ulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
58057763|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
58057764|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
58066554|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
57707130|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
57707131|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
57707132|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
57707133|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
57909143|NCT03812393|DRUG|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
57909144|NCT05497401|BIOLOGICAL|MesenCure|Enhanced mesenchymal cell-based product
57909145|NCT05497401|OTHER|Placebo|Saline
57707134|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
57707135|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
57909146|NCT02469272|DRUG|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
57909147|NCT00522873|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
57909148|NCT00522873|DRUG|0.5mg NETA / 1.0mg E2 (Activella)|One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
57909149|NCT00461032|DRUG|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
57909150|NCT00461032|DRUG|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
57909151|NCT06212401|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr
57909152|NCT06212401|DRUG|Ketofole|Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
57909153|NCT03192657|DRUG|Basiliximab|The first administration should be within 8 weeks after disease onset.
57909154|NCT03192657|DRUG|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
57909155|NCT03192657|DRUG|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
58066555|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
58066556|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
58066557|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
58066558|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
57909156|NCT05921825|DIAGNOSTIC_TEST|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
58057765|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
58057766|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
58057767|NCT02627196|DEVICE|BAROSTIM NEO® System|
58057768|NCT02627196|DRUG|Medical Management|
58057769|NCT00367627|DRUG|Albendazole|
58057770|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
58057771|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
58057772|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
58057773|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
58057774|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
58057775|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
58057776|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
58057777|NCT00249522|BEHAVIORAL|Contingency management|
58257612|NCT02901743|OTHER|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
58257613|NCT00905281|OTHER|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
58257614|NCT00905281|OTHER|Standard care|No specific intervention
58257615|NCT00370318|BIOLOGICAL|10 valent pneumococcal conjugate vaccine|
58257616|NCT00370318|BIOLOGICAL|Infanrix Hexa|
58257617|NCT00370318|BIOLOGICAL|Rotarix|
58257618|NCT00370318|DRUG|Paracetamol|
58257619|NCT04042766|PROCEDURE|laser vaginal treatment|Er:YAG laser
58257620|NCT05610384|DRUG|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
58257621|NCT05610384|DRUG|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
57909157|NCT05921825|DIAGNOSTIC_TEST|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
58257622|NCT05108740|DRUG|everolimus|Self-administered as a daily dose of 10mg orally
58257623|NCT06617221|BIOLOGICAL|Composite graft plug|after tooth extraction the socket was grafted with a composite graft plug
58257624|NCT06617221|BIOLOGICAL|Allograft|after tooth extraction the socket was grafted with allograft
58257625|NCT01751334|DEVICE|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
58257626|NCT01751334|DEVICE|total knee arthroplasty|Fixed Total Knee Arthroplasty
57909158|NCT01165931|DRUG|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
57909159|NCT00231946|DRUG|VP4896|
58066559|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
58066560|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
58257627|NCT05700812|PROCEDURE|Sound sparing levonorgestrel 52 mg IUD placement|"In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance."
58257628|NCT00991757|DRUG|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
58257629|NCT04194762|OTHER|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
57707136|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
57707137|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
57707138|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
57707139|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
57707140|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
57707141|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
57707142|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
57707143|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
57707144|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
57707145|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
57707146|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
57707147|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
57707148|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
58257630|NCT05409001|DIAGNOSTIC_TEST|tomography pan scan|This is a retrospective chart review
58257631|NCT02379351|DEVICE|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
57707149|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
58257632|NCT03340220|DRUG|XPF-008|Capsule filled with XEN1101
58257633|NCT03340220|DRUG|Microcrystalline Cellulose|Placebo capsule
58257634|NCT03340220|DRUG|XPF-010|Capsule filled with XEN1101
58257635|NCT03340220|DRUG|Itraconazole 400mg|Oral
58257636|NCT03831412|BEHAVIORAL|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
58257637|NCT03831412|BEHAVIORAL|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
58257638|NCT02748135|DRUG|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
58257639|NCT02748135|DRUG|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
58257640|NCT02748135|DRUG|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
58257641|NCT02748135|DRUG|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
58257642|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
57707150|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
57707151|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
57707152|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
57707153|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
58066561|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
58257643|NCT00650117|DRUG|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
58257644|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
58257645|NCT00650117|DRUG|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
58257646|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
58257647|NCT00650117|DRUG|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
58257648|NCT06067399|DIAGNOSTIC_TEST|Glycated hemoglobin (HbA1C)|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
57909160|NCT01850277|DRUG|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
58257649|NCT06067399|DIAGNOSTIC_TEST|RDW|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
58257650|NCT06067399|DIAGNOSTIC_TEST|Lipid profile|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
58257651|NCT04054973|DRUG|L-arginine|6000mg of L-arginine daily for 14 days
58257652|NCT04054973|DRUG|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
58257653|NCT02848365|DEVICE|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
58257654|NCT03976687|DRUG|EYP001a|Oral tablets
58257655|NCT00065104|DRUG|DHEA|
58257656|NCT00596128|BEHAVIORAL|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
58257657|NCT04084730|RADIATION|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
58257658|NCT02413385|BEHAVIORAL|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
58257659|NCT05178303|DRUG|SB-1121(1)|The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
58257660|NCT05178303|DRUG|SB-1121(2)|The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
58257661|NCT04868604|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
58257662|NCT04868604|DRUG|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
58257663|NCT06514040|DRUG|Precedex|Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to anaesthesia and surgical procedure.
58257664|NCT06514040|DRUG|Sumatriptan 25 mg|Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain (as substance -p), nausea, and other symptoms of migraine
58257665|NCT06499233|DRUG|Trimethoprim/Sulfamethoxazole|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
58257666|NCT00981045|DRUG|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
58257667|NCT00981045|DRUG|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
57909161|NCT01850277|PROCEDURE|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
57909162|NCT01850277|DRUG|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% \>95%
58257668|NCT04916743|OTHER|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
58257669|NCT01192529|DIETARY_SUPPLEMENT|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
58380625|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
58380626|NCT04292197|DRUG|18-MC Compound|18-MC
58380627|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
58380628|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
58380629|NCT00132990|DEVICE|Deep brain stimulation|
57707154|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
57707155|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
57707156|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
57707157|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
57707158|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
57707159|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
57707160|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
57707161|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
57707162|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
57707163|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
57707164|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
57707165|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
57707166|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
57909163|NCT01850277|PROCEDURE|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
57909164|NCT03061071|DEVICE|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
57909165|NCT03061071|DEVICE|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
57909166|NCT03251391|OTHER|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
57909167|NCT03251391|OTHER|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
57909168|NCT04369716|OTHER|Whole oranges|Navel oranges (227 g total)
57909169|NCT04369716|OTHER|Whole Apples|Red Delicious apple with skin (230 g)
57909170|NCT04369716|OTHER|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
57909171|NCT04369716|OTHER|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
57707167|NCT02014675|DEVICE|SD01 ICD lead|
57909172|NCT04369716|OTHER|Orange juice|Orange Juice (250 g)
57909173|NCT04369716|OTHER|Apple juice|Apple Juice (235 g)
57909174|NCT01671254|DIETARY_SUPPLEMENT|FishOil|
57909175|NCT01671254|DIETARY_SUPPLEMENT|CBE75|
57909176|NCT01671254|DIETARY_SUPPLEMENT|CBE150|
57909177|NCT01671254|DIETARY_SUPPLEMENT|placebo|
57909178|NCT02197559|PROCEDURE|DES group|all the participants in this group will be performed with drug -eluting stents
57909179|NCT02197559|PROCEDURE|BMS group|all the participants in this group will be performed with bare-metal stents
57909180|NCT02769403|DEVICE|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
57909181|NCT02769403|OTHER|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
57909182|NCT02769403|OTHER|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
57909183|NCT02769403|OTHER|Sick Days|Sick days during the 12 week study period will be collected
58066562|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
58066563|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
58066564|NCT04419558|DRUG|Placebo|Sterile solution for injection
58380630|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
58380631|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
58057778|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
58057779|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
58257670|NCT01192529|DIETARY_SUPPLEMENT|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
58257671|NCT00032188|BIOLOGICAL|aldesleukin|Given subcutaneously
58257672|NCT00032188|DRUG|bryostatin 1|Given IV
58257673|NCT00032188|OTHER|laboratory biomarker analysis|Correlative studies
57707168|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
58057780|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
58057781|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
58057782|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
58257674|NCT03898479|DRUG|CTP-543|Twice daily dosing
58257675|NCT00124007|BIOLOGICAL|VRC-HIVADV014-00-VP|
58257676|NCT00124007|BIOLOGICAL|VRC-HIVDNA016-00-VP|
58257677|NCT00824382|DRUG|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
57707169|NCT05305599|DRUG|Placebo|Placebo
57707170|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
57707171|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
57909184|NCT02769403|OTHER|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
57909185|NCT05515003|OTHER|Individualized patient education|"In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes."
58257678|NCT00824382|DRUG|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
58257679|NCT00824382|DRUG|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
58257680|NCT00824382|DRUG|Placebo|2 puffs delivered by the RespimatÂ® inhaler
58380632|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
58380633|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
58380634|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
58257681|NCT04775901|OTHER|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
58257682|NCT04775901|DEVICE|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
58257683|NCT02437500|BIOLOGICAL|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
58257684|NCT06094413|BEHAVIORAL|Multicomponent Training Intervention|The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
58257685|NCT06051123|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day.
58257686|NCT06051123|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
58257687|NCT04537910|DRUG|LY3819253|Administered SC.
58257688|NCT04537910|DRUG|Placebo|Administered SC.
58257689|NCT02874079|OTHER|Blood sample and cotton skin swabs|
58257690|NCT01905553|DRUG|SSP-004184SS|Disodium salt
58257691|NCT02958280|BEHAVIORAL|Fit&Sober App|Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
58257692|NCT02958280|BEHAVIORAL|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
58257693|NCT03975556|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
58257694|NCT03975556|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
58257695|NCT05730244|DRUG|Cassia alata extract|1 ml Cassia alata extract
58257696|NCT05730244|DRUG|Placebo|1 ml placebo solution
58257697|NCT00614120|DRUG|liraglutide|0.6 mg/day, s.c. (under the skin) injection
58257698|NCT00614120|DRUG|placebo|Glimepiride placebo, capsules
58057783|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
58257699|NCT00614120|DRUG|liraglutide|1.2 mg/day, s.c. (under the skin) injection
58257700|NCT00614120|DRUG|liraglutide|1.8 mg/day, s.c. (under the skin) injection
58257701|NCT00614120|DRUG|glimepiride|Capsules, 4.0 mg/day
58257702|NCT00614120|DRUG|metformin|Tablets, 1.5-2.0 g/day
58257703|NCT00614120|DRUG|placebo|Liraglutide placebo, s.c. (under the skin) injection
58380635|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
58380636|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
58257704|NCT05748158|BEHAVIORAL|Weight loss|"A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 37 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks."
58257705|NCT05140629|OTHER|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
57707172|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
57707173|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
58257706|NCT05140629|OTHER|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
58257707|NCT01296542|DRUG|Moxifloxacin Ophthalmic|
58257708|NCT01296542|DRUG|Besifloxacin Ophthalmic|
58257709|NCT01233960|DRUG|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
58257710|NCT04725942|DRUG|Oral Posaconazole tablets|Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.
57707174|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
57909186|NCT01135537|BIOLOGICAL|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
57909187|NCT02390245|OTHER|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
57909188|NCT02390245|OTHER|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
57909189|NCT02390245|OTHER|Usual Care|This group will receive ophthalmic referral.
57909190|NCT05397834|DRUG|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
58057784|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
58057785|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
58057786|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
57707175|NCT03454555|BEHAVIORAL|Shared Decision Making|"The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality's SHARE: Seek, Help, Assess, Reach, Evaluate Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient. Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice."
57707176|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
57909191|NCT05397834|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
58257711|NCT03539770|PROCEDURE|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
58257712|NCT03628989|BEHAVIORAL|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
58257713|NCT00831974|DRUG|masitinib (AB1010)|3 mg/kg/day
58257714|NCT00831974|DRUG|masitinib (AB1010)|6 mg/kg/day
58257715|NCT05839782|PROCEDURE|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
58257716|NCT05839782|PROCEDURE|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
58257717|NCT02092480|BEHAVIORAL|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
58257718|NCT06642155|BEHAVIORAL|RESPONSIBLEPLAY© MTM-Based Intervention|Participants in this group will receive a theory-based intervention using the Multi-theory Model (MTM) of health behavior change. The intervention includes participatory dialogue, behavioral confidence-building, and strategies to modify the physical and social environments. It also incorporates emotional transformation and practice for change. Sessions will be delivered in-person over three weeks, focusing on promoting responsible gambling behaviors.
58257719|NCT06642155|BEHAVIORAL|Knowledge-Based Intervention|Participants in this group will receive a knowledge-based intervention that provides information on gambling risks and responsible gambling strategies. The intervention consists of lectures and reading materials delivered in-person over three weeks. It focuses on raising awareness of gambling risks but does not include the behavioral change strategies used in the MTM-based intervention.
58257720|NCT03762239|OTHER|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
58257721|NCT03762239|OTHER|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
57909192|NCT06078865|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
57909193|NCT06121167|DIAGNOSTIC_TEST|urinary partial oxygen pressure|arterial blood gas
57909194|NCT03876860|DEVICE|Silicone Dilator|Addition of silicone band to standard vaginal dilator
57909195|NCT03876860|DEVICE|Standard Dilator|Standard vaginal dilator
57909196|NCT03590405|PROCEDURE|uterus transplantation surgery and IVF|IVF before surgery living donor uterus transplantation ET
57909197|NCT02699086|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
57909198|NCT05675787|DRUG|Medroxyprogesterone acetate + Atorvastatin|MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
57909199|NCT05342506|DRUG|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
57909200|NCT03599973|OTHER|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
58257722|NCT02262689|DRUG|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
58257723|NCT02262689|DRUG|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
58257724|NCT06178653|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
58380637|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
57707177|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
57909201|NCT01819259|DRUG|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
57909202|NCT01819259|DRUG|Placebo|
57909203|NCT00560066|BIOLOGICAL|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
57707178|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
57909204|NCT00560066|BIOLOGICAL|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
57909205|NCT01732159|OTHER|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
58257725|NCT06178653|OTHER|Trunk Control Training|Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
58257726|NCT05537441|BEHAVIORAL|Text messaging|Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
58380638|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
57707179|NCT06125821|OTHER|questionnaire|questionnaire
57707180|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
57707181|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
57909206|NCT04132531|PROCEDURE|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
57909207|NCT01245985|RADIATION|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
57909208|NCT00194987|DRUG|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
57909209|NCT00194987|DRUG|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
58057787|NCT06142162|DIAGNOSTIC_TEST|flow cytometry|Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils
58057788|NCT06142162|DIAGNOSTIC_TEST|ELISA|estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum
58057789|NCT06142162|DIAGNOSTIC_TEST|RFLP|assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique
58257727|NCT05221346|DIETARY_SUPPLEMENT|Plant food supplement|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
58380639|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
58380640|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
57707182|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
57707183|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
57707184|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
57707185|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
57707186|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
57707187|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
57707188|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
58057790|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
57707189|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
57707190|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
57707191|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
57707192|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
57707193|NCT02269891|OTHER|Placebo|
57707194|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
58057791|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
58057792|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
58257728|NCT05221346|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
58257729|NCT02683044|PROCEDURE|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
58257730|NCT02845960|BEHAVIORAL|rapid recovery|rapid recovery
57707195|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
57707196|NCT03196752|OTHER|simple palpation|conventional
58057793|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
58057794|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
58057795|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
58057796|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
58257731|NCT03046901|DRUG|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
58057797|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
58057798|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
58257732|NCT03355157|DRUG|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
58257733|NCT06052423|DRUG|HS-20093|HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
57707197|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
57707198|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
57707199|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
57707200|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
57707201|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
58057799|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
58257734|NCT05546346|DEVICE|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
58257735|NCT06304883|DRUG|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally.
57707202|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
57707203|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
57707204|NCT01849588|DRUG|Sorafenib|
57707205|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
58257736|NCT00639574|DRUG|Néfopam|"There are two groups :~* a group N : néfopam~* a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
58257737|NCT04014166|OTHER|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
58257738|NCT03075345|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
58257739|NCT03075345|BEHAVIORAL|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
57707206|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
57707207|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
57707208|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
57707209|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
57707210|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
58257740|NCT03991169|DRUG|Ferrous Sulfate|Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
58257741|NCT01383629|BEHAVIORAL|Counselling|Preoperative counselling
58257742|NCT00754208|DRUG|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
57707211|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
57707212|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
58257743|NCT03385304|DRUG|10% povidone-iodine (1% free iodine) in purified water|Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
58257744|NCT03385304|DRUG|4% chlorhexidine gluconate (CHG) in purified water|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
58257745|NCT01597388|DRUG|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
58380641|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
58257746|NCT01597388|DRUG|Fulvestrant|IM monthly after loading dose
58380642|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
58380643|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
58380644|NCT02945163|DRUG|Lamivudine|Lamivudine
58380645|NCT02945163|DRUG|Efavirenz|Efavirenz
58380646|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
58380647|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
58380648|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
58380649|NCT03204877|DRUG|Melatonin|Oral capsules
58380650|NCT03204877|OTHER|Placebo|Oral capsules
58380651|NCT05821452|DRUG|Camrelizumab|200mgQ3w
58380652|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
58380653|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
58380654|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
58380655|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
58380656|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
58380657|NCT00076089|DRUG|Roflumilast|
57707213|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
57707214|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
57707215|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
57707216|NCT01812928|DRUG|Diclofenac|
57707217|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
57707218|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
57707219|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
57707220|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
57707221|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
57707222|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
57707223|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
57707224|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
58380658|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
57707225|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
57707226|NCT01573780|OTHER|pharmacological study|Correlative studies
57707227|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
57707228|NCT05466578|DRUG|abrocitinib|
57707229|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
57707230|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
57707231|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
57707232|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
57707233|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
57707234|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
57707235|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
57707236|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
57707237|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
57707238|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
57707239|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
57707240|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
58057800|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
57707241|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
58257747|NCT06202664|PROCEDURE|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
58257748|NCT06202664|DRUG|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
58257749|NCT06036043|DRUG|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~1. 100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~2. 100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
58257750|NCT03896711|BEHAVIORAL|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
58257751|NCT03896711|OTHER|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
58257752|NCT01051544|DRUG|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
58257753|NCT01051544|DRUG|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
58257754|NCT00301496|DEVICE|Coban 2 Layer Compression System|
58380659|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
57707242|NCT00038922|DRUG|rhIL-11|
58057801|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
58057802|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
57707243|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
57707244|NCT02886052|OTHER|Active control|
57707245|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
58057803|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
58257755|NCT05732142|OTHER|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
58257756|NCT00217776|BEHAVIORAL|Open Airways Educational Intervention|
58380660|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
58380661|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
58057804|NCT05538585|DRUG|Galicaftor|Oral
58257757|NCT00217776|BEHAVIORAL|Peer Asthma Action Educational Intervention|
58257758|NCT03319264|OTHER|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
58257759|NCT03319264|OTHER|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
58257760|NCT03319264|RADIATION|DXA measurement|DXA measurement will be performed to assess patient's body composition
58380662|NCT02242058|OTHER|Quantitative sensory testing|
58257761|NCT03319264|OTHER|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
58057805|NCT05538585|DRUG|Navocaftor|Oral
58057806|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
58380663|NCT02177630|OTHER|Endomyocardial Biopsy|
58380664|NCT02056028|PROCEDURE|Hepatic resection|
58380665|NCT00060671|DRUG|rituximab|
58380666|NCT00060671|DRUG|Pixantrone (BBR 2778)|
58380667|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
58380668|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
58380669|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
58380670|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
58257762|NCT03319264|BEHAVIORAL|Life habits Questionnaire|Life habits Questionnaire
58257763|NCT06408545|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
58257764|NCT04053140|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
58257765|NCT04053140|DEVICE|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
58257766|NCT04053140|DRUG|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
58257767|NCT04053140|DRUG|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
58257768|NCT04053140|DRUG|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
58257769|NCT01118260|PROCEDURE|total intravenous anaesthesia|propofol and remifentanil
58257770|NCT01118260|PROCEDURE|spinal anaesthesia|bupivacaine and fentanyl
58257771|NCT05753891|DEVICE|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
58257772|NCT00893165|BEHAVIORAL|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
58257773|NCT02101931|DRUG|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
58257774|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of liquid biopsy.
58257775|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of tissue biopsy.
58257776|NCT05032092|GENETIC|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
58257777|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at high intensity (HI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 85% of the one-repetition maximum per exercise (high load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
58257778|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate-high intensity (MHI-bands)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
58380671|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
58380672|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
58380673|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
58380674|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
58380675|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
58380676|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
58380677|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
57909210|NCT03787056|OTHER|Blood draws|"Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort"
58057807|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
58057808|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
58057809|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
58057810|NCT02089178|DRUG|propofol-remifentanil|
58057811|NCT02089178|DRUG|sevoflurane-remifentanil|
58057812|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
58057813|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
58057814|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
58057815|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
58057816|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
58057817|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
58380678|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
58380679|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
57707246|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
57707247|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
58057818|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
58057819|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
58057820|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
58057821|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
57909211|NCT00081627|DRUG|CoFactor and 5FU|
58057822|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
58057823|NCT02367859|DRUG|Dabrafenib|Given PO
57909212|NCT04829500|BEHAVIORAL|Montessori Approaches to Person-Centered Care (MAP-VA)|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities. Staff are also introduced to concrete strategies that improve dignity, control, and independence. MAP-VA is based on the work of Maria Montessori who demonstrated that a structured, supportive environment and meaningful, active roles in the classroom enabled children to fulfill their greatest potential physically, mentally, and emotionally. Montessori principles have been applied to dementia care for more than 20 years to promote functional independence, meaningful engagement, and dignity.
57909213|NCT01029951|PROCEDURE|manipulation|
57909214|NCT01029951|PROCEDURE|Mobilisation|
58057824|NCT02367859|DRUG|Trametinib|Given PO
58057825|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
58380680|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
58380681|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
58380682|NCT00659841|DRUG|Placebo|placebo
57909215|NCT01029951|DEVICE|Activator instrument|
57909216|NCT01970631|BEHAVIORAL|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
57909217|NCT01970631|OTHER|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
57909218|NCT00244686|DRUG|Mepolizumab|open label investigational product
57909219|NCT04550533|OTHER|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
57909220|NCT02843893|DEVICE|Measure the minimum intensity of a painful stimulation|With Neurolight device.
58057826|NCT04919694|PROCEDURE|orbital compression|orbital compression
58057827|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
58057828|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
58057829|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
58057830|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
58380683|NCT02678754|OTHER|No intervention required, purely observational|
58380684|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
58380685|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
58380686|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
57909221|NCT03028038|DRUG|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
57909222|NCT03028038|DRUG|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
57909223|NCT04672226|DIETARY_SUPPLEMENT|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
57909224|NCT06609915|DEVICE|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany)|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany). Initially FiO2 at 1.0, reduced to 0.3 during laser interventions. Frequency and pressure set according to the local standards
58057831|NCT00826787|DRUG|Levetiracetam|750 mg tablet
58057832|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
58057833|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
58057834|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
58057835|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
58057836|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
58380687|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
58380688|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
58380689|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
58380690|NCT04316559|OTHER|Placebo|Placebo capsule
58380691|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
58257779|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate intensity (MI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 65-70% of the one-repetition maximum per exercise (moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
57909225|NCT06609915|DEVICE|High-flow nasal supplemental oxygen via nasal cannula with the Optiflow (Fisher & Paykel, Auckland, New Zealand)|up to 70 L/min FiO2 1.0 high flow oxygen via nasal cannula with the Optiflow (Fisher \& Paykel, Auckland, New Zealand) initially. Reduced FiO2 to 0.3 during laser intervention.
58257780|NCT06618469|BEHAVIORAL|Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic tubes equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase)
58257781|NCT06618469|BEHAVIORAL|Water-based resistance training program at moderate intensity (WMI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
58257782|NCT06619977|DEVICE|Analgesia nociception monitoring (ANI)|Analgesia nociception index (ANI; MetroDoloris Medical Systems, Lille, France) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, in particular - the parasympathetic nervous system. The ANI algorithm uses data from one lead ECG trace. Heart rate variability, or the beat-to-beat alterations in heart rate, is a well-known and recognised noninvasive indicator of autonomic nervous system activity.
57909226|NCT02022189|PROCEDURE|Renal Biopsy|
58057837|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
58257783|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
58257784|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
58257785|NCT04529252|OTHER|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
57909227|NCT00200993|BEHAVIORAL|physical activity|
57909228|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
57909229|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
57909230|NCT04133051|DRUG|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
58057838|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
58057839|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
58057840|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
58257786|NCT04739722|DIAGNOSTIC_TEST|ColoSense|"ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals."
57909231|NCT04133051|DRUG|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
58057841|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
58057842|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
58057843|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
58057844|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
58257787|NCT06136182|PROCEDURE|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
58257788|NCT03060343|BIOLOGICAL|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10\^5 cells/kg, Dose Level Two: 1.0×10\^6 cells/kg, Dose Level Three: 1.0×10\^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
57909232|NCT02980731|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
57909233|NCT02866136|DRUG|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
57909234|NCT02866136|DRUG|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
57909235|NCT02866136|DRUG|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
58057845|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
58057846|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
58057847|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
57909236|NCT02866136|DRUG|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
57909237|NCT02866136|DEVICE|Laser (local treatment)|
57909238|NCT02866136|DEVICE|cryoapplication (local treatment)|
57909239|NCT02866136|RADIATION|I125 radioactive plaques (local treatment)|
57909240|NCT02866136|DRUG|intravitreal Melphalan (local treatment)|
57909241|NCT02689518|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
58057848|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
58057849|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
58057850|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
58257789|NCT04652908|BIOLOGICAL|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
58257790|NCT04652908|OTHER|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
58257791|NCT03329170|BEHAVIORAL|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
58380692|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
58257792|NCT06388200|GENETIC|Sub-Retinal Administration of OCU400-301|Sub-Retinal Administration of OCU400-301
58380693|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
57909242|NCT05900700|BEHAVIORAL|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
57909243|NCT00795613|DRUG|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN\>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
58257793|NCT04203992|BEHAVIORAL|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
58257794|NCT04203992|BEHAVIORAL|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
58380694|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
58380695|NCT05575700|DRUG|Placebo|tablet three times daily
58380696|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
58380697|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
58380698|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
58057851|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
58257795|NCT03016481|BEHAVIORAL|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
58257796|NCT03016481|BEHAVIORAL|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
58257797|NCT04711174|BEHAVIORAL|LMA removal|the timing when conducting LMA removal
58257798|NCT02496351|DEVICE|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
58257799|NCT01576445|PROCEDURE|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
58257800|NCT01576445|PROCEDURE|medial parapatellar approach|medial parapatellar approach
57707248|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
57707249|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
57707250|NCT04970758|OTHER||no intervention
57707251|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
57707252|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
57909244|NCT00795613|DRUG|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
57909245|NCT02073747|DRUG|Normal Saline|One hour inhaled normal saline
58057852|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
58257801|NCT02668809|OTHER|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
58257802|NCT02668809|OTHER|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
58257803|NCT02668809|OTHER|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
58257804|NCT02668809|OTHER|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
58257805|NCT02668809|OTHER|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
58257806|NCT02668809|OTHER|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
58257807|NCT02668809|OTHER|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
58257808|NCT02668809|OTHER|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
58257809|NCT03843632|BIOLOGICAL|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
58257810|NCT03290755|BEHAVIORAL|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
58257811|NCT06257342|PROCEDURE|6 minutes walk|A 6 minutes walk test
58257812|NCT05413018|DRUG|CC-486|Specified dose on specified days
58257813|NCT05413018|OTHER|Placebo|Specified dose on specified days
58257814|NCT01684098|DRUG|Tc 99m EC20|
58057853|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
58057854|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
58257815|NCT03928808|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
58257816|NCT05916456|DIAGNOSTIC_TEST|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
57909246|NCT02073747|DRUG|Albuterol|One hour inhaled ten milligrams of albuterol
57909247|NCT02677480|DIETARY_SUPPLEMENT|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
58380699|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
58380700|NCT02879513|DRUG|Paclitaxel|
57909248|NCT02677480|DIETARY_SUPPLEMENT|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
57909249|NCT05636423|OTHER|Survey|Online survey via a questionnaire composed of 28 questions.
57909250|NCT04914299|BEHAVIORAL|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
57909251|NCT04914299|BEHAVIORAL|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
57909252|NCT00551265|DRUG|Cyclophosphamide|Given IV
58257817|NCT05916456|DIAGNOSTIC_TEST|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
58257818|NCT05916456|DIAGNOSTIC_TEST|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
58257819|NCT01123941|BIOLOGICAL|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
58257820|NCT01123941|BIOLOGICAL|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
58057855|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
57909253|NCT00551265|PROCEDURE|Laboratory Biomarker Analysis|Correlative studies
57909254|NCT00551265|BIOLOGICAL|Oregovomab|Given IV
58057856|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
58057857|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
58257821|NCT02231879|DRUG|Plerixafor|Twice daily low dose injection for 14 months.
58257822|NCT02231879|DRUG|G-CSF|Twice daily low dose injection for 14 months.
58380701|NCT02879513|DRUG|Cisplatin|
58380702|NCT02879513|DRUG|Epirubicin|
58380703|NCT02879513|DRUG|Cyclophosphamide|
58380704|NCT02879513|DRUG|5-fluoruracil|
58380705|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
58380706|NCT00243139|DEVICE|Mandibular advancement device (activator)|
58380707|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
57707253|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
58257823|NCT03624062|DRUG|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
57707254|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
57707255|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
57707256|NCT02812667|DRUG|Nivolumab + Plinabulin|
57707257|NCT01926795|PROCEDURE|Short leg cast|
57707258|NCT01926795|PROCEDURE|No Immobilization|
57707259|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
57909255|NCT00294203|DRUG|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
57909256|NCT00294203|OTHER|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
57909257|NCT00244816|DRUG|Taxoprexin|
58057858|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
58057859|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
58257824|NCT05701072|PROCEDURE|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
58257825|NCT05701072|PROCEDURE|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
58257826|NCT03104062|DIAGNOSTIC_TEST|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
58257827|NCT03104062|DIAGNOSTIC_TEST|Platelet Aggregability|Obtained using Multiplate Analyzer
58257828|NCT03104062|DIAGNOSTIC_TEST|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
57707260|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
57707261|NCT01653522|DRUG|Triptan|
57707262|NCT01653522|DRUG|Doxycycline|
57707263|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
57707264|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
58380708|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
57707265|NCT04573036|DRUG|HRS4800 tablets|single oral administration
57707266|NCT04573036|DRUG|Placebo tablets|single oral administration
57707267|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
57707268|NCT00632697|DRUG|placebo|
57707269|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
57707270|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
57707271|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
57707272|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
57707273|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
57707274|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
57707275|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
57707276|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
58057860|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
58057861|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
58257829|NCT04025775|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data."
58257830|NCT04025775|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
58257831|NCT03876366|OTHER|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
58257832|NCT03876366|OTHER|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
57707277|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
57707278|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
58057862|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
58057863|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
58257833|NCT03375671|DRUG|Ketalar|single administration of 5 mg/kg, IM
57707279|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
57707280|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
58057864|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
58057865|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
58057866|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
58057867|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
58257834|NCT03375671|DRUG|Midazolam injection|single administration of 5 mg, IM
58380709|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
58380710|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
58380711|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
57707281|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
57707282|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
58057868|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
58057869|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
58057870|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
58257835|NCT03375671|DRUG|Haloperidol|single administration of 5 mg, IM
58257836|NCT02316899|DRUG|linaclotide|Oral administration once daily
58380712|NCT03759600|DRUG|Niraparib|Niraparib capsule
58380713|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
57707283|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
57707284|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
57707285|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
57707286|NCT01971658|DRUG|Thalidomide®|
57707287|NCT01971658|DRUG|Cyclophosphamide|
57707288|NCT01971658|DRUG|Velcade®|
57707289|NCT01971658|DRUG|Dexaméthasone|
58257837|NCT02316899|DRUG|Placebo|Oral administration once daily
58257838|NCT01864070|OTHER|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
58257839|NCT01864070|DRUG|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
58380714|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
57707290|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
57707291|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
57707292|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
57707293|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
57707294|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
57707295|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
58057871|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
58057872|NCT01962116|DRUG|Citrate 4%|
58057873|NCT01962116|DRUG|unfractionated heparin|
58057874|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
58057875|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
58057876|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
58057877|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
58257840|NCT01864070|OTHER|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
58380715|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
58380716|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
57707296|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
58257841|NCT05243485|DIAGNOSTIC_TEST|PreHEART|"The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes."
58257842|NCT03425578|DIETARY_SUPPLEMENT|MSG|150 mg/kg body mass monosodium glutamate (MSG).
58257843|NCT03425578|DIETARY_SUPPLEMENT|CHO|75g CHO (i.e. dextrose)
58257844|NCT03425578|DIETARY_SUPPLEMENT|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
58257845|NCT03425578|DIETARY_SUPPLEMENT|Placebo B|A non-caloric placebo composed of flavoured water.
57707297|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
58257846|NCT01846481|DRUG|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
58257847|NCT01846481|DRUG|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
58257848|NCT01846481|DRUG|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
58257849|NCT01846481|DRUG|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
58257850|NCT03352193|DIETARY_SUPPLEMENT|Wheat spaghetti|Wheat oral immunotherapy
58257851|NCT06490380|DRUG|PARPi|Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
58257852|NCT00449085|PROCEDURE|Electrophysiology|
57707298|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
57707299|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
57707300|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
57707301|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
57707302|NCT04619706|DRUG|FSD201|Tablets for oral administration.
57707303|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
57707304|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
58057878|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
58257853|NCT00449085|DEVICE|CARTO™ XP EP Navigation System V9|
58257854|NCT05784753|BEHAVIORAL|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
58257855|NCT05784753|BEHAVIORAL|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
58257856|NCT04988971|DRUG|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
57707305|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
58057879|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
58057880|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
58257857|NCT04988971|DRUG|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
58257858|NCT02926586|DRUG|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
58257859|NCT02926586|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
58257860|NCT03768011|COMBINATION_PRODUCT|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
58257861|NCT00558662|DEVICE|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
58380717|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
57707306|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
58057881|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
58057882|NCT01914510|DRUG|ENMD-2076|
58057883|NCT00003687|DRUG|dextromethorphan hydrobromide|
58057884|NCT00003687|DRUG|morphine sulfate|
58057885|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
58257862|NCT00558662|DEVICE|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
58257863|NCT02312596|DEVICE|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
57707307|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
58057886|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
57909258|NCT03948165|PROCEDURE|Distal Transradial Access|The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
57909259|NCT02954965|BEHAVIORAL|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
57909260|NCT02954965|BEHAVIORAL|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
57909261|NCT05378230|DIETARY_SUPPLEMENT|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
58057887|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
58057888|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
58057889|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
58057890|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
58057891|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
58257864|NCT02312596|OTHER|Usual and Customary Practice|Usual and customary care for non-healing wounds
58257865|NCT06292598|OTHER|Blood sample|Sample taken to test plasma permeability markers
58057892|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
58057893|NCT01786499|BEHAVIORAL|Relaxation Response Training|
58257866|NCT06292598|OTHER|Stool sample|Sample taken to test microbial diversity and composition
58257867|NCT06292598|OTHER|CSF sample|Sample taken to test orexin level
58257868|NCT05454969|BEHAVIORAL|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
58257869|NCT05454969|BEHAVIORAL|Control|Patients will receive standard of care.
58257870|NCT04634240|PROCEDURE|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
58257871|NCT00431028|DEVICE|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
58257872|NCT01185743|DRUG|olanzapine|olanzapine 10mg od + placebo od
58257873|NCT01185743|DRUG|ziprasidone|ziprasidone 40mg td
58057894|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
58057895|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
58057896|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
58257874|NCT01185743|DRUG|placebo|placebo td
58257875|NCT06375616|DRUG|Nafamostat Mesylate|During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
58257876|NCT06375616|DRUG|Unfractionated Heparin|During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
58257877|NCT00452673|DRUG|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
58257878|NCT00452673|DRUG|Capecitabine|Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
58257879|NCT06623864|OTHER|meaningful activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
58257880|NCT06623864|OTHER|other activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
58257881|NCT03020199|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
58257882|NCT03020199|RADIATION|nb-UVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
58257883|NCT06124755|DEVICE|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
58257884|NCT06124755|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
58257885|NCT04310709|DRUG|Regorafenib/Nivolumab|Combination of regorafenib and nivolumab
58257886|NCT06437821|DIAGNOSTIC_TEST|Petrissage|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
58257887|NCT06437821|OTHER|Graston Technique|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
58257888|NCT05156554|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
58380718|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
58380719|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
58380720|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
58380721|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
58380722|NCT04436445|OTHER|Life style modification|Life style modification
57909262|NCT04659577|BEHAVIORAL|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
58257889|NCT05156554|DRUG|rhG-CSF|rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil\>0.5×10\^9 /L.
58257890|NCT03555565|DRUG|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
58380723|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
58380724|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
58380725|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
58380726|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
58380727|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
58380728|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
58257891|NCT01739218|DRUG|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
58257892|NCT01739218|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
58257893|NCT01739218|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
58257894|NCT01098656|DRUG|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
58257895|NCT06619197|OTHER|Global reflexology|The EMC method is a global reflexology technique inspired by the work of the American naturopath Stanley Burrough (Vitaflex, 1976). It is a method of reflexology on the whole body, of acupressure massages (rhythmic and targeted movements) on so-called \&#34;reflex\&#34; zones which is practiced on different areas of the body (feet, hands, arms, legs, collarbone, ear) and allows the stimulation of all systems.
58257896|NCT05680051|DEVICE|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
58257897|NCT05680051|DEVICE|Drug-eluting stent|Drug eluting stent was used in the control group
58257898|NCT06442098|BEHAVIORAL|CAMP SMART Literacy Summer Camp|Multimodal approach to reading intervention
58257899|NCT06094283|DRUG|YCT-529|Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
58257900|NCT06094283|DRUG|YCT-529 Placebo|YCT-529 Placebo
58257901|NCT00563810|DRUG|MYO-029|
57707308|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
58257902|NCT05346211|DIETARY_SUPPLEMENT|Curcumin|Curcumin Supplementation
58257903|NCT06304792|PROCEDURE|Immediate FET in a stimulated or programmed cycle|Patients will undergo FET in the cycle immediately following oocyte retrieval and a failed fresh embryo transfer or freeze all.
58257904|NCT06299111|DRUG|REGN9933|Intravenous (IV) single dose administered
57707309|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
57909263|NCT02133118|DRUG|individual SUs, insulin, pioglitazone|
58257905|NCT06299111|DRUG|REGN7508|IV single dose administered
58257906|NCT06299111|DRUG|Placebo|IV single dose administered
58257907|NCT06608875|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
58257908|NCT06608875|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
58257909|NCT06608875|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
58257910|NCT02478034|OTHER|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
58257911|NCT05069545|DRUG|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
58257912|NCT05069545|DRUG|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
58380729|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
57707310|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
57707311|NCT00165971|PROCEDURE|BIS monitoring|
57909264|NCT04762121|PROCEDURE|Peripheral IV|Insertion of peripheral intravenous catheter
57909265|NCT00243048|DIETARY_SUPPLEMENT|soy protein isolate|
57909266|NCT00243048|RADIATION|radiation therapy|
57909267|NCT00226837|DRUG|Nitrous oxide|nitrous oxide by inhalation during induction
57909268|NCT02760277|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
57909269|NCT02760277|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
57909270|NCT02760277|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
57909271|NCT02760277|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
57909272|NCT03620331|PROCEDURE|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
58257913|NCT04196413|DRUG|GD2 CAR T cells|Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
58257914|NCT04196413|DRUG|Fludarabine|Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
58257915|NCT04196413|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
58257916|NCT01789411|OTHER|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
58380730|NCT02537730|DEVICE|comfilcon A|contact lens
57707312|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
57707313|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
57707314|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
57707315|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
57707316|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
57707317|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
57707318|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
57707319|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
57707320|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
57707321|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
57707322|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
57707323|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
57707324|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and Day 1 of cycle 2, 3, 4 and 5 (priming phase). Boost vaccinations: every 3 cycles beginning C6D1. For Cohort A-(Initial) only: Patients with FLC cancer with no prior checkpoint inhibitor therapy treatment.~2. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~   * Cohort A-(Expansion): Patients with FLC cancer with no prior checkpoint inhibitor treatment.~  * Cohort B: Patients with FLC cancer with prior checkpoint inhibitor treatment.~  * Cohort C: Patients with non-FLC cancer (solid tumors) with prior checkpoint inhibitor treatment eligible.~3. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
57707325|NCT04248569|DRUG|Nivolumab|"1. Cohort A (Initial): Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 2-5 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 6.~2. Cohort A (Expansion), B and C: Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~3. Drug: 3mg/kg and 480mg IV"
57707326|NCT04248569|DRUG|Ipilimumab|"1. Cohort A (Initial): Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 2, 3, 4 and 5 of the study, every 3 weeks of the priming phase.~2. Cohort A (Expansion), B and C: Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~3. Drug: 1mg/kg IV"
57707327|NCT03325166|DRUG|Ferumoxytol|Given IV
57707328|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
57707329|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57707330|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
57707331|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
58057897|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
58057898|NCT00000244|DRUG|Dynorphin 1 - 13|
58057899|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
57707332|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
58257917|NCT01789411|DEVICE|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
58257918|NCT01789411|DEVICE|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
58257919|NCT06181292|BIOLOGICAL|PHH-1V81|booster of PHH-1V81
58257920|NCT06181292|BIOLOGICAL|Comirnaty Omicron XBB1.5|booster of Comirnaty Omicron XBB1.5
58257921|NCT02861326|DEVICE|Gracey Curettes|
58257922|NCT00697086|DRUG|Dronedarone (SR33589)|
58257923|NCT00697086|DRUG|Placebo|
57909273|NCT03620331|PROCEDURE|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
57909274|NCT04895137|DRUG|mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
57909275|NCT00841555|DRUG|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
57909276|NCT00841555|RADIATION|Hypofractionated radiation therapy|Patients will undergo HIMRT
57909277|NCT00841555|RADIATION|Intensity-modulated radiation therapy|Patients undergo HIMRT
57909278|NCT04642872|OTHER|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
57909279|NCT04642872|OTHER|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
58380731|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
57707333|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
57909280|NCT04642872|OTHER|Conventional therapy|Following the usual therapy in the baby.
57909281|NCT04642872|OTHER|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
58257924|NCT02644629|DRUG|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
58257925|NCT02644629|DRUG|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
58257926|NCT02644629|DRUG|Ketamine (2st phase)|Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
58257927|NCT05019196|DEVICE|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
58257928|NCT06420934|OTHER|Drying procedure after surgical handwashing|Participants will dry their hands with one surgical towel
58257929|NCT06433622|DIAGNOSTIC_TEST|Repeat Thromboelastography with Platelet Mapping|Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
58257930|NCT01063270|DRUG|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
58257931|NCT01063270|PROCEDURE|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
58380732|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
58380733|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
58380734|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
58380735|NCT02067143|DRUG|Prephase PDN + CY|
58380736|NCT02067143|DRUG|Cycle 1 Induction|
58380737|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
58380738|NCT02067143|DRUG|Cycle 3 Early consolidation|
58257932|NCT06624176|DEVICE|Bionix ShotBlocker|This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.
58257933|NCT06624176|OTHER|Swaddling|Standard of care swaddling
58257934|NCT06624176|OTHER|Sucrose administration|Standard of care sucrose administration
58257935|NCT06624176|OTHER|Masimo Rad-97 Oximeter probe|Oximeter probe
58257936|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
58257937|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
58257938|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
58257939|NCT05554536|PROCEDURE|PEEP titration trial|PEEP trial, starting from clinical PEEP 16 cmH2O and ending at PEEP 6 cmH2O. The PEEP trial will be stopped for haemodynamic instability (defined as arterial pressure \< 80 mmHg and /or heart rate \> 150 bpm) or desaturation (defined as SpO2 \< 92%).
58257940|NCT04623879|DRUG|Lumacaftor, Ivacaftor Drug Combination|
58257941|NCT04541108|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
58257942|NCT04541108|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
58257943|NCT04541108|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
58257944|NCT04541108|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
57707334|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
57707335|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
58257945|NCT06200311|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)
58257946|NCT06200311|DRUG|Pharmacological rhythm management|1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
58257947|NCT04463056|BIOLOGICAL|Elizaria®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
57707336|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
58257948|NCT04463056|BIOLOGICAL|Soliris®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
58257949|NCT02621489|DRUG|Bydureon|2 mg Once Weekly
58257950|NCT02621489|DRUG|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
58257951|NCT02621489|DRUG|Metformin|Metformin 1g BID
58257952|NCT06617845|DEVICE|Stimulation Set A and B|Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
57707337|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
57707338|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
57909282|NCT01777451|OTHER|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
57909283|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
58257953|NCT06093646|BEHAVIORAL|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
58257954|NCT00778284|DRUG|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
58380739|NCT02067143|DRUG|Cycle 4 Consolidation|
58380740|NCT02067143|DRUG|Cycle 5 Consolidation|
58380741|NCT02067143|DRUG|Cycle 6 Consolidation|
58380742|NCT02067143|DRUG|Cycle 7 Consolidation|
58380743|NCT02067143|DRUG|Cycle 8 Reinduction|
57707339|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
57707340|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
57707341|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
57707342|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
57707343|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
57707344|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
57909284|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
57707345|NCT01032135|DRUG|medication management|Prescription for naltrexone
57707346|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
57909285|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
57909286|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
57909287|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
57909288|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
57909289|NCT01262677|DRUG|placebo|matched to the active drug
58380744|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
58380745|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
58057900|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
58057901|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
58257955|NCT02286570|DEVICE|Glidescope|videolaryngoscope used for endotracheal intubation
58257956|NCT02286570|DEVICE|Airtraq|videolaryngoscope used for endotracheal intubation
58257957|NCT02286570|DEVICE|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
58257958|NCT01958216|OTHER|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
58257959|NCT05969392|DEVICE|Intradiscal Gelified Ethanol|Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
58257960|NCT06620484|DEVICE|Musculoskeletal Ultrasound with elastography|Musculoskeletal Ultrasound with elastography
58380746|NCT01541488|DRUG|BI 1021958|tablet
58380747|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
58380748|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
58380749|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
58380750|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
58380751|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
58257961|NCT06356844|DIETARY_SUPPLEMENT|Resolvin supplement|Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
58257962|NCT04807309|DRUG|Danazol Pill|Danazol 200 mg orally twice a day
58257963|NCT04807309|DRUG|Placebo|Placebo twice a day
58257964|NCT05179018|DIAGNOSTIC_TEST|Ribosomal p2 Autoantibodies as a Serum marker|Using serum marker
58257965|NCT04178824|BEHAVIORAL|Discount Intervention|15% or 30% discount on fruits and vegetables
58257966|NCT00507078|PROCEDURE|Surgical treatment for OSA|
58257967|NCT04266886|OTHER|Best Practice|Receive usual care
58380752|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
58380753|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
58380754|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
58380755|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
58380756|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
58380757|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
58380758|NCT01725802|DRUG|Placebo|
58380759|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
57909290|NCT01249989|BEHAVIORAL|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
58057902|NCT02194192|DRUG|Placebo|Normal saline 10 ml
58057903|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
58257968|NCT04266886|PROCEDURE|Hypnotherapy|Receive self-hypnosis guided relaxation
58257969|NCT04266886|OTHER|Quality-of-Life Assessment|Ancillary studies
58257970|NCT04266886|OTHER|Questionnaire Administration|Ancillary studies
58380760|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
58380761|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
58380762|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
58380763|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
58057904|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
58380764|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
58380765|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
58380766|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
58380767|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
58380768|NCT03449849|OTHER|Base Diet|Base Diet
58380769|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
58257971|NCT03178240|BEHAVIORAL|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
58257972|NCT02763982|OTHER|Physical evaluation|
58257973|NCT01565668|DRUG|AC220|oral
58257974|NCT05905666|BEHAVIORAL|health education and counseling|In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
58257975|NCT01904292|DRUG|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
58257976|NCT06009107|BIOLOGICAL|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
58257977|NCT06009107|DRUG|Cyclophosphamide|Administered intravenously.
58257978|NCT06009107|DRUG|Fludarabine Phosphate|Administered intravenously.
58257979|NCT03156842|DRUG|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
58057905|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
58057906|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
58057907|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
58380770|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
58057908|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
58057909|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
58257980|NCT03156842|DRUG|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
58257981|NCT03156842|DRUG|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
58257982|NCT03316469|DRUG|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
58057910|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
58057911|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
58057912|NCT03381703|DRUG|YH12852|YH12852 administration
58057913|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
58257983|NCT03316469|DIAGNOSTIC_TEST|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
58257984|NCT00669643|DRUG|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
58257985|NCT00669643|DRUG|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
57707347|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
57909291|NCT01249989|BEHAVIORAL|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
58057914|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
58257986|NCT00669643|DRUG|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
58257987|NCT00669643|DRUG|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
58380771|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
57707348|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
57707349|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
57707350|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
57707351|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
58257988|NCT04141891|BEHAVIORAL|Driving Decision Aid|Healthwise DDA
58257989|NCT04141891|BEHAVIORAL|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
58257990|NCT04946942|BEHAVIORAL|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
58257991|NCT04946942|BEHAVIORAL|Usual Care|Attendance at primary care appointments as usual.
58257992|NCT03097367|DIAGNOSTIC_TEST|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at \<2 cm below SMSP, and Level -2: bladder neck at \>2 cm below SMSP.
58257993|NCT00923182|DRUG|alemtuzumab|
58257994|NCT06411951|OTHER|Participation in the INTUK care offer at Klinik Zugersee|Person-centered treatment and care tailored to the individual patients needs by a team consisting of a senior physician, a nurse, social workers and peers.
58257995|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
58057915|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
58057916|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
58057917|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
58057918|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
58057919|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
58057920|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
58057921|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
58057922|NCT05076552|DRUG|TACH101|Orally via capsules
58057923|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
58057924|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
58057925|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
58057926|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
58057927|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
58057928|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
58057929|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
58057930|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
58057931|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
58057932|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
57707352|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
57707353|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
58057933|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
58057934|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
58057935|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
58057936|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
58057937|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
58057938|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
57707354|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
57707355|NCT00111228|DEVICE|Guardian RT|
57707356|NCT00111228|DEVICE|SMBG only|SMBG only
57707357|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
57707358|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
57707359|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
57707360|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
58257996|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
57707361|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
58257997|NCT02123615|DRUG|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
58257998|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
58257999|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
58258000|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
58258001|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
57707362|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
57707363|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
57707364|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
57707365|NCT01371656|DRUG|levofloxacin|Given PO or IV
57707366|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
57707367|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
57707368|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
57909292|NCT01249989|BEHAVIORAL|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
57909293|NCT01976117|DEVICE|enose|
57909294|NCT00480376|DRUG|ofloxacin|
57909295|NCT00480376|DRUG|gentamicin|
58258002|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
57707369|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
57909296|NCT03037073|DRUG|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
57909297|NCT03037073|DRUG|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
58258003|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
58258004|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
58258005|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
58258006|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
58258007|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
58258008|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
58258009|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
58258010|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
58258011|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
58380772|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
58380773|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
58380774|NCT00642707|DRUG|Placebo Comparator|
58258012|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
58258013|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
58258014|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
58258015|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
58057939|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
58057940|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
58258016|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
58258017|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
58057941|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
58258018|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
58258019|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
58258020|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
58057942|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
58057943|NCT02079506|DRUG|Candesartan|
58258021|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
58258022|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
58258023|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
58057944|NCT02079506|DRUG|Rosuvastatin|
58057945|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
57909298|NCT02341131|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
58057946|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
58258024|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
58258025|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
58258026|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
57909299|NCT02341131|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
58057947|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
58057948|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
58057949|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
58258027|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
57909300|NCT01015859|DEVICE|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
58057950|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
58258028|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
58258029|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
58258030|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
58380775|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
58057951|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
58057952|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
58057953|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
58057954|NCT00003465|DRUG|temozolomide|
58057955|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
58057956|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
58057957|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
58258031|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
57909301|NCT00847925|DRUG|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
57909302|NCT00376831|DRUG|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
58066565|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
58258032|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
58258033|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
58258034|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
58258035|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
58258036|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
57707370|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
57707371|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
57707372|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
57909303|NCT00376831|DRUG|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
57909304|NCT04049734|DRUG|oral losatan|50 mg of oral losartan one hour before the ERCP once
57909305|NCT02093559|BEHAVIORAL|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
58258037|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
58258038|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
58258039|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
58258040|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
58258041|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
58258042|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
58258043|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
58258044|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
57909306|NCT04498338|OTHER|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
58258045|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
58258046|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
58258047|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
58258048|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
58380776|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
58380777|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
58380778|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
58380779|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
58380780|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
58380781|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
58258049|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
58258050|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
57707373|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
57707374|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
57707375|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
57707376|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
57909307|NCT04498338|OTHER|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
57909308|NCT00950326|PROCEDURE|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
58258051|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
58258052|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
57909309|NCT00950326|PROCEDURE|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
58258053|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
57909310|NCT00950326|PROCEDURE|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
57909311|NCT00994682|DRUG|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
58380782|NCT00255905|BEHAVIORAL|Clinician monitoring|
58380783|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
58380784|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
58380785|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
58380786|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
58380787|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
58380788|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
57909312|NCT00994682|DRUG|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
57909313|NCT00994682|DRUG|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
57909314|NCT00434213|DRUG|Daytrana|Methylphenidate Transdermal System (MTS)
57909315|NCT00339456|DRUG|HAART|
58057958|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
58380789|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
58380790|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
58380791|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
57707377|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
57707378|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
57707379|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
57707380|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
57707381|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
57707382|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
57707383|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
57707384|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
57707385|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
57707386|NCT01197469|DRUG|Placebo|
57707387|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
57707388|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
57707389|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
57707390|NCT02567396|OTHER|Pharmacological Study|Correlative studies
57707391|NCT02567396|DRUG|Talazoparib|Given PO
57707392|NCT00062582|DRUG|Roflumilast|
57707393|NCT03431116|RADIATION|ultrasound|to detect the placental site
57707394|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
57707395|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
57909316|NCT05664867|OTHER|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
57909317|NCT05664867|OTHER|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
57909318|NCT00236093|DRUG|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
57707396|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
57707397|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
57707398|NCT04185168|OTHER|control|2 tablets of placebo
57707399|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
57909319|NCT00903682|DRUG|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
57909320|NCT00903682|DRUG|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
58057959|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
58057960|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
58057961|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
58380792|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
58258054|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
58258055|NCT05311228|DRUG|Azithromycin Powder|Azithromicyn intravena for 14 days
58258056|NCT06029933|BIOLOGICAL|Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)|Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
57707400|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
58258057|NCT06029933|BIOLOGICAL|High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)|Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
58258058|NCT01990196|DRUG|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
58057962|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
58057963|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
58057964|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
58258059|NCT01990196|DRUG|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
58380793|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
58380794|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
58380795|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
58380796|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
57707401|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
57707402|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
57707403|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
57909321|NCT04535804|DRUG|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
57909322|NCT03368638|OTHER|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
57909323|NCT06459739|PROCEDURE|sacral ESPB|sacral ESPB
57909324|NCT00825825|DRUG|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
58057965|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
57707404|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
57707405|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
57707406|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
57707407|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
57707408|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
57909325|NCT00825825|DRUG|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
57909326|NCT00825825|DRUG|Placebo|Two weeks of placebo taken orally.
57909327|NCT02046889|BEHAVIORAL|Bicycle Training Intervention|
57909328|NCT05839392|BIOLOGICAL|Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal
57909329|NCT00191178|DRUG|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
57909330|NCT00191178|DRUG|insulin glargine|
58057966|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
58258060|NCT01990196|DRUG|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
58258061|NCT01990196|DRUG|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
58258062|NCT04984863|DEVICE|Magnetically controlled capsule endoscopy|Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
57707409|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
57707410|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
57707411|NCT04074317|DRUG|PRAM9|SC injection
57707412|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
57707413|NCT04074317|DRUG|Regular Insulin|SC injection
57707414|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
57909331|NCT05729971|PROCEDURE|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
57909332|NCT02167737|BEHAVIORAL|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
58057967|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
58057968|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
58057969|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
58380797|NCT01718522|DEVICE|sensor augmented pump (SAP)|
58380798|NCT01810900|DEVICE|Protescal|
58380799|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
57707415|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
57707416|NCT04089540|PROCEDURE|New intubation method|
57707417|NCT04089540|PROCEDURE|Conventional intubation method|
57707418|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
58380800|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
57707419|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
58380801|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
57707420|NCT00448422|DRUG|prulifloxacin|Tablet
57707421|NCT00275158|DRUG|L-Arginine Supplementation|
57707422|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
57707423|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
57707424|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
57707425|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
57707426|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
57707427|NCT01013233|OTHER|control group|no intervention
57707428|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
57707429|NCT02386943|DRUG|Sitagliptin|100mg po once.
57707430|NCT02386943|DRUG|Saxagliptin|5mg po once.
57707431|NCT02386943|DRUG|Blank control|No medication is taken.
57707432|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
57707433|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
57707434|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
57707435|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
57707436|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
57707437|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
57707438|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
57707439|NCT02693574|DRUG|Clarithromycin|
57707440|NCT02693574|DRUG|Levofloxacin|
57707441|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
57707442|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
57707443|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
57707444|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
57707445|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
57707446|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
57707447|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
57707448|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
58057970|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
58057971|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
57909333|NCT02167737|BEHAVIORAL|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
57909334|NCT05011773|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
57909335|NCT01119105|DRUG|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
57909336|NCT01119105|DRUG|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
57909337|NCT01119105|DRUG|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
57909338|NCT01940185|DEVICE|LINX device|
57707449|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
58057972|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
58057973|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
58057974|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
57707450|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
57909339|NCT04925687|BIOLOGICAL|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
58057975|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
58258063|NCT05661981|DEVICE|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
57707451|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
57707452|NCT00003002|BIOLOGICAL|sargramostim|
57909340|NCT04458129|DRUG|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
58258064|NCT04765657|DRUG|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
58258065|NCT04765657|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
58258066|NCT01712165|DIETARY_SUPPLEMENT|ANMUM Materna|
58258067|NCT01712165|DIETARY_SUPPLEMENT|Control (milk powder)|
58258068|NCT03414996|OTHER|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
58258069|NCT00878566|OTHER|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
58258070|NCT00878566|OTHER|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
57909341|NCT05802225|DRUG|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
58258071|NCT04464720|BEHAVIORAL|Cooking Ventilation Intervention|An educational video presentation for the families regarding the importance of ventilation use during and after cooking, and strategies for improving the ventilation during cooking, has been created by Dr. Holm, with input from Youth Research Assistants (YRAs) The youth involvement will help to ensure that the information is presented in a way that will resonate with the local community and will also provide the youth with exposure to developing health education tools. The educational video will be shown to families at the time of the intervention visit and they will receive printed reminder materials of what they have learned.
57707453|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
57707454|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
58057976|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
57707455|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
57707456|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
57707457|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
57909342|NCT05802225|DRUG|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
57909343|NCT02491515|DRUG|Denosumab|every 6 month injection
57909344|NCT04715243|DEVICE|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
58057977|NCT00366444|DRUG|Placebo|Placebo every 6 hours
58057978|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
58057979|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
58057980|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
57707458|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
58057981|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
58057982|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
58057983|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
57707459|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
57707460|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
57707461|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
57707462|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
57707463|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
57707464|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
57707465|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
57707466|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
57909345|NCT04715243|DEVICE|Helmet NIV|NIV interface
58057984|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
58057985|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
58057986|NCT04844970|DRUG|Placebo|Anamorelin placebo
58057987|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
58057988|NCT01881724|BEHAVIORAL|Sleep education|
58057989|NCT01289028|DRUG|Nilotinib|
57707467|NCT00417443|DRUG|Clonidine|
57707468|NCT04709575|DRUG|REGN5713|Administered subcutaneously
57707469|NCT04709575|DRUG|REGN5714|Administered subcutaneously
57707470|NCT04709575|DRUG|REGN5715|Administered subcutaneously
57909346|NCT04715243|DEVICE|Face-mask NIV|NIV interface
57909347|NCT05144126|OTHER|CT radioraphic assessment|CT radioraphic assessment
57909348|NCT03568396|DEVICE|Pupillometer|Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
57909349|NCT03576170|OTHER|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
57707471|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
57707472|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
57707473|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
57707474|NCT00481442|DRUG|Phenylephrine|
57707475|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
57707476|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
57707477|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
57707478|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
57707479|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
57707480|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
57909350|NCT05769569|BIOLOGICAL|VRC07-523LS|VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
57909351|NCT05769569|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
57909352|NCT05769569|BIOLOGICAL|N-803|N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
57909353|NCT05769569|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
57909354|NCT05769569|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
58258072|NCT05414396|BEHAVIORAL|Behavioral Intervention|Attend EML program sessions
58380802|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
57707481|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
57707482|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
57707483|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
57707484|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
57707485|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
58258073|NCT05414396|OTHER|Questionnaire Administration|Ancillary studies
58258074|NCT01050010|OTHER|MRI|dedicated extremity MRI
57707486|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
57707487|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
57707488|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
57707489|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
57707490|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
57707491|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
57707492|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
57707493|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
57707494|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
57707495|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
57707496|NCT00654381|DRUG|BI 1356|5 mg/daily
58057990|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
58057991|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
57707497|NCT00654381|DRUG|BI 1356|10 mg/daily
57707498|NCT00654381|DRUG|voglibose placebo|three times daily
57707499|NCT00654381|DRUG|BI 1356 placebo|once daily
57707500|NCT00654381|DRUG|voglibose|0.6 mg/daily
57707501|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
57707502|NCT02254707|DRUG|BILB 1941 ZW|
57707503|NCT02254707|DRUG|Placebo|
57707504|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
58057992|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
58057993|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
58057994|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
58057995|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
58057996|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
58258075|NCT06623890|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
58258076|NCT06341907|BIOLOGICAL|Neoantigen polypeptide vaccine|Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)
58258077|NCT06620952|PROCEDURE|O-ring technique|"O-ring technique. consists on a different arrangement of fibrin-glue on a polymethilmetacrylate cranioplasty, with the aim to create a gasket to prevent CSF leakage"
58258078|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 1 (less than 40 IU per dL)|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1 (less than 40 IU per dL).
58258079|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 1 (less than 50 IU per dL)|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1(less than 50 IU per dL).
58258080|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 2 and Type 3|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2 and Type 3.
58258081|NCT03241628|DEVICE|Dressing Glove|Viscose dressing glove
58258082|NCT05928884|OTHER|There is no intervention. It is a phenotyping study only|See above, this is only a phenotyping study but NIH required us to register it as a trial.
58258083|NCT05883774|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
58380803|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
58380804|NCT06319404|OTHER||
58380805|NCT02492243|DEVICE|PCI|
57909355|NCT05769569|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
57909356|NCT05769569|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
57707505|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
57707506|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
57909357|NCT05769569|COMBINATION_PRODUCT|Antiretroviral Therapy (ART)|This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
58057997|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
57707507|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
58258084|NCT05883774|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
58258085|NCT05314842|DRUG|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
58258086|NCT05314842|DRUG|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
57909358|NCT02728869|BIOLOGICAL|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
58258087|NCT05705492|DRUG|Olanzapine|Given PO
58258088|NCT05705492|DRUG|Placebo Administration|Given PO
58258089|NCT05705492|OTHER|Questionnaire Administration|Ancillary studies
58258090|NCT04183738|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
58258091|NCT04183738|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
58258092|NCT04183738|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
58258093|NCT04183738|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
58258094|NCT00877409|DRUG|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
57707508|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
57909359|NCT02728869|BIOLOGICAL|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
57909360|NCT02728869|BIOLOGICAL|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
57909361|NCT05479201|DIAGNOSTIC_TEST|Home based sleep test|Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
57909362|NCT04025346|OTHER|Capsimax|1 capsule to be taken before breakfast.
57909363|NCT04025346|OTHER|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
57909364|NCT00014807|BEHAVIORAL|Reducing Pesticide Exposure in Minority Families|
57909365|NCT00351520|DRUG|Miltefose|
57909366|NCT06079125|PROCEDURE|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
58066566|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
58066567|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
58066568|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
58258095|NCT00877409|DRUG|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
58258096|NCT04490642|OTHER|Questionnaire|Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
58258097|NCT02622763|BIOLOGICAL|Tolerogenic Dendritic Cells|Intralesional administration
58258098|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
58258099|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
58258100|NCT04487483|BEHAVIORAL|Sleep App|A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
58258101|NCT04281901|DRUG|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
58258102|NCT04281901|DRUG|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
58258103|NCT03614078|DRUG|PRCL-02|Oral tablets
58258104|NCT03614078|DRUG|Placebo|Oral tablets
58258105|NCT03429751|DRUG|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
57707509|NCT01442363|DRUG|placebo|topical ointment
57707510|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
57707511|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
57909367|NCT06079125|PROCEDURE|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
57909368|NCT05800418|DRUG|Ramucirumab Injection|Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
58258106|NCT03429751|DRUG|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
58258107|NCT04694365|DRUG|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
58380806|NCT02492243|DEVICE|ILR implantation|
58380807|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
57909369|NCT05800418|DRUG|Ramucirumab Injection [Cyramza]|Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
58258108|NCT00639444|DIETARY_SUPPLEMENT|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
58258109|NCT05427760|DRUG|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
57909370|NCT02641574|OTHER|compare complication|
57909371|NCT06609317|DEVICE|Digital therapeutic motion-based device|This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training
57909372|NCT05163782|DEVICE|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
57909373|NCT05163782|DEVICE|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
57909374|NCT05163782|DEVICE|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
57909375|NCT05163782|DEVICE|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
58380808|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
57909376|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
57707512|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
58066569|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
58066570|NCT03602209|PROCEDURE|Removal of infected implant|
58066571|NCT03602209|DRUG|Antibiotic durations|
58258110|NCT05097092|PROCEDURE|Orthopedic immobilization|Orthopedic immobilization will be performed with a sling and swathe.
58258111|NCT05097092|OTHER|Unilateral resistance training|Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
58380809|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
58066572|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
58258112|NCT05097092|OTHER|Bilateral resistance training|Bilateral resistance training will be performed by both arms in both groups during Phase 2.
58258113|NCT05617040|BIOLOGICAL|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
58380810|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
58380811|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
58380812|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
58380813|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
58380814|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
58380815|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
58380816|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
58258114|NCT05617040|BIOLOGICAL|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
57707513|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
57707514|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
57707515|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
57707516|NCT01401933|DRUG|Rifampin|QD on Days 5-16
57707517|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
57707518|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
57707519|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
57707520|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
57707521|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
57909377|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
58057998|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
58057999|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
58058000|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
58058001|NCT00000641|DRUG|Ethambutol hydrochloride|
58058002|NCT00000641|DRUG|Amikacin sulfate|
58058003|NCT00000641|DRUG|Azithromycin|
58058004|NCT00000641|DRUG|Rifampin|
58058005|NCT00000641|DRUG|Clofazimine|
58066573|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
57707522|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
57707523|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
57707524|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
57707525|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
57707526|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
57707527|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
58066574|NCT05233319|OTHER|There is no intervention|There is no intervention
57707528|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
57707529|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
57707530|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
58066575|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
57909378|NCT04835077|OTHER|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
58066576|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
57707531|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
57707532|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
57707533|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
57909379|NCT04835077|OTHER|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
57909380|NCT06301425|OTHER|Intervention group|"Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7."
58258115|NCT05952700|DEVICE|inContAlert|InContAlert is a non-invasive sensor technology to measure the bladder filling level for incontinence patients. The device is fixed about 2cm above the pubic bone using a patch or strap and does not require surgery. The data collected from the patient is analyzed using deep learning algorithms. The bladder filling level determined in this way is then displayed on an app.
58258116|NCT02155673|DRUG|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
58066577|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
58258117|NCT03554863|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
58258118|NCT03554863|DEVICE|Facial Mask|Preoxygenation with facial mask
58258119|NCT03150654|DEVICE|Laser pan-retinal photocoagulation|Green laser photocoagulator
58258120|NCT03467217|DRUG|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
58380817|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
57707534|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
58066578|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
58258121|NCT03467217|DRUG|Placebo losartan capsule|Matching placebo losartan oral capsule
58258122|NCT04894149|OTHER|Physiotherapy|Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
58380818|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
58380819|NCT01138085|DRUG|GSK1120212|MEK inhibitor
58380820|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
57707535|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
58380821|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
58380822|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
58380823|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
57707536|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
57707537|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
57707538|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
57707539|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
57707540|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
57707541|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
57909381|NCT06301425|OTHER|Control group|Receive allo-HSCT directly without the second consolidation chemotherapy.
57909382|NCT00828477|DRUG|Xibrom|Xibrom: two times a day for seven days in the first eye.
57909383|NCT00828477|DRUG|Nevanac|Nevanac: three times a day for seven days in the second eye.
57909384|NCT03694275|DRUG|Soticlestat|TAK-935 tablets
57909385|NCT06610149|DIETARY_SUPPLEMENT|Probiotic mixture|8 weeks treatment with Probiotic mixture
57909386|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under popliteal sciatic nerve
57909387|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under an ankle block
57707542|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
57707543|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
57707544|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
57707545|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
57707546|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
58258123|NCT05879406|DIETARY_SUPPLEMENT|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
58258124|NCT05879406|OTHER|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
57707547|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
57909388|NCT05749484|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
57909389|NCT00760773|DRUG|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
57909390|NCT00760773|DRUG|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
58258125|NCT06076018|DRUG|Group morphine|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
58066579|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
58258126|NCT06076018|OTHER|Group placebo|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
58258127|NCT05885035|DRUG|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
57707548|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
57707549|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
57707550|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
57707551|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
57707552|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
57707553|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
57707554|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
57707555|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
57707556|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
57707557|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
57707558|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
57707559|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
57707560|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
57707561|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
57707562|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
57707563|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
57909391|NCT00760773|DRUG|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
57909392|NCT05817552|DIAGNOSTIC_TEST|Geomagic Control X|3D Surface matching and compare
57909393|NCT04073459|BIOLOGICAL|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
57909394|NCT04073459|BIOLOGICAL|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
57909395|NCT04918446|OTHER|T-POSE|Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.
57909396|NCT04918446|OTHER|Usual Care|Printed instruction sheets on prescribed opioid.
57909397|NCT00876577|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
57909398|NCT03592810|OTHER|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
58058006|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
58058007|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
58066580|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
58258128|NCT05233150|BEHAVIORAL|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
58258129|NCT05682378|DRUG|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution administered subcutaneously in pre-filled syringe
58258130|NCT04015076|DRUG|Inzomelid|Active Drug
58258131|NCT04015076|DRUG|Placebo|Placebo to Match
58258132|NCT02076503|PROCEDURE|PET-MR 18f-FACBC|
57707564|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
57707565|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
57707566|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
57707567|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
58258133|NCT02076503|PROCEDURE|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
57707568|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
57707569|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
57707570|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
57707571|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
57909399|NCT03831373|OTHER|Physical exercise|Three physical exercise programs, two of resistance training with elastic bands and one of stretching exercises, all performed in a sitting position.
57909400|NCT04988867|DRUG|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
57909401|NCT06083779|GENETIC|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
57909402|NCT00808054|DRUG|EMLA|0.5g topical EMLA
58258134|NCT05896501|DEVICE|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
58258135|NCT00619567|BEHAVIORAL|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
58258136|NCT02253316|BIOLOGICAL|Ixazomib|
58258137|NCT02253316|DRUG|Lenalidomide|
58258138|NCT02253316|DRUG|Dexamethasone|
58258139|NCT00792688|DRUG|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
58258140|NCT00792688|DRUG|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
58258141|NCT00792688|DRUG|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
58258142|NCT02188472|DRUG|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
58258143|NCT02188472|DRUG|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
58258144|NCT02188472|DRUG|Placebo|Placebo: 2 tablets should be taken twice daily
58258145|NCT00020943|BIOLOGICAL|filgrastim|5 ug/kg subQ daily day 4 until ANC \>10,000 (or ANC\> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
58258146|NCT00020943|BIOLOGICAL|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5
57707572|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
57707573|NCT00368589|DRUG|atorvastatin|
58058008|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
58258147|NCT00020943|DRUG|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
58258148|NCT00020943|DRUG|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
58258149|NCT00020943|DRUG|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
58258150|NCT00020943|DRUG|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1\& 2
58258151|NCT00020943|DRUG|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
58258152|NCT00020943|DRUG|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
58258153|NCT00020943|DRUG|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
58258154|NCT00020943|DRUG|prednisone|100 mg/sq m PO Days 3-7, Tx 1 \& 2
58258155|NCT00020943|DRUG|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 \& 2
58258156|NCT00020943|PROCEDURE|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
58258157|NCT03152331|BEHAVIORAL|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
58258158|NCT02155517|DRUG|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
58258159|NCT02155517|DRUG|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
57707574|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
57707575|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
57707576|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
58258160|NCT05803096|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
58258161|NCT05803096|OTHER|Oxygen|Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
57909403|NCT02884895|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
57909404|NCT02884895|DEVICE|Direct Laryngoscopy|Direct Laryngoscopy
58058009|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
58258162|NCT01075230|PROCEDURE|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
58258163|NCT00675168|RADIATION|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
58258164|NCT06011395|DEVICE|Smartwatch|Activity tracker (step count, calories burned), heart rate monitor
58258165|NCT06011395|DEVICE|Imperial Healthy Hearts app|Digital cardiac rehabilitation smartphone application. Represents smart watch data and source of educational materials for cardiac rehabilitiation programme.
58258166|NCT01376921|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
58258167|NCT02354755|DEVICE|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
58258168|NCT05113641|DIETARY_SUPPLEMENT|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
58258169|NCT05113641|DRUG|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
58258170|NCT04132453|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
58258171|NCT04132453|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
58258172|NCT04132453|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
58258173|NCT05401110|DRUG|Osimertinib|Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
58258174|NCT05401110|DRUG|Carotuximab|Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
58258175|NCT04624958|DRUG|Zanubrutinib and Rituximab|Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
58258176|NCT04624958|DRUG|R-DHAOx|Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
57909405|NCT00659178|DRUG|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
57909406|NCT04874285|DIETARY_SUPPLEMENT|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
57909407|NCT02790944|GENETIC|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
57909408|NCT04571359|OTHER|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
57909409|NCT01157676|PROCEDURE|Open radical cystectomy|Standard of care removal of urinary bladder.
57909410|NCT01157676|PROCEDURE|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
57909411|NCT01157676|DEVICE|DaVinci robot|DaVinci robotic surgical system.
57909412|NCT03517033|DRUG|Torrent's Nebivolol Tablets|
58058010|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
58066581|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
58066582|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
58258177|NCT04624958|DRUG|Zanubrutinib Maintenance|Zanubrutinb 160mg PO BID.
58258178|NCT03700333|DRUG|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
58258179|NCT03700333|DRUG|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
58258180|NCT01996865|DRUG|Lenalidomide|
58258181|NCT01996865|DRUG|Rituximab|
57707577|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
58380824|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
57707578|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
57707579|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
57707580|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
57707581|NCT03872180|DRUG|Bendamustine|Given IV
57909413|NCT03517033|DRUG|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
57909414|NCT02388854|GENETIC|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
56136615|NCT06728397|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
58258182|NCT05081843|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
58258183|NCT05081843|BEHAVIORAL|Usual health education curriculum|The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
58258184|NCT06622980|OTHER|Education|"The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice."
58380825|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
58380826|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
58380827|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
57909415|NCT05973695|OTHER|clamshell exercise|For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
57909416|NCT05973695|OTHER|Gluteal Bridge exercises|Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
58380828|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
58380829|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
58380830|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
57707582|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
57707583|NCT03872180|DRUG|Venetoclax|Given PO
57707584|NCT02099214|DEVICE|3Tesla cardiac MRI|
57707585|NCT02099214|DEVICE|Electrocardiogram (EKG)|
57707586|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
57707587|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
57707588|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
57707589|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
57707590|NCT02099214|DEVICE|3Tesla abdominal MRI|
57909417|NCT02112747|OTHER|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
57707591|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
57707592|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
57707593|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
57707594|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
57909418|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
58258185|NCT06522555|DRUG|polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide|"Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
58258186|NCT06522555|DRUG|zanubrutinib, rituximab and lenalidomide|"Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
58258187|NCT04697004|DEVICE|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
58258188|NCT04697004|DEVICE|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
58258189|NCT05059041|DEVICE|Dilated Refraction|The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.
58258190|NCT05059041|DEVICE|Non-Dilated Refraction|The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
58258191|NCT03599856|OTHER|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
58258192|NCT06620120|DEVICE|Insoles|"At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
58258193|NCT06620120|OTHER|Without insoles|"At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
58258194|NCT02720744|DRUG|FT218|
58258195|NCT02720744|DRUG|Placebo|
58258196|NCT00831545|DRUG|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
58258197|NCT05742139|OTHER|Non intervention|Non intervention
57909419|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
57909420|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
57909421|NCT06079541|DRUG|Placebo in Cohorts 1 to 7|oral once
57909422|NCT06079541|DRUG|Placebo in 3 Cohorts|oral once
57909423|NCT01900197|DRUG|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
57909424|NCT00155974|BIOLOGICAL|Community-based vaccine outreach intervention|
57909425|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
57909426|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
57909427|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
57909428|NCT05823831|DIAGNOSTIC_TEST|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
58258198|NCT03970148|PROCEDURE|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
58258199|NCT01437709|BIOLOGICAL|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
58258200|NCT01437709|OTHER|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
58380831|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
58380832|NCT00104338|DRUG|FK778|
58380833|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
58380834|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
58380835|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
58380836|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
58380837|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
57909429|NCT05823831|DIAGNOSTIC_TEST|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
57909430|NCT05823831|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
57909431|NCT05823831|DIAGNOSTIC_TEST|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
57909432|NCT04417322|OTHER|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
57909433|NCT01678105|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
57909434|NCT01277900|PROCEDURE|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
57909435|NCT04729686|OTHER|Pericapsular Nerve Block|Per Standard Institutional Practice
57909436|NCT04729686|OTHER|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
57909437|NCT02145234|DRUG|BMS-986089|
57909438|NCT02145234|DRUG|Placebo matching with BMS-986089|
57909439|NCT05131568|DEVICE|Layered thermal insulation system|No other intervention
57909440|NCT03699826|DEVICE|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
57909441|NCT06046950|OTHER|Treatment target DAS28CRP-LDA|Aiming for DAS28CRP-low disease activity
57909442|NCT06046950|OTHER|Treatment target SDAI-remission|Aiming for SDAI-remission
57909443|NCT04392401|BIOLOGICAL|Collection of blood samples in order to create a biocollection|Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
57909444|NCT04635592|DIAGNOSTIC_TEST|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
57909445|NCT03298243|BEHAVIORAL|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
57909446|NCT01263665|DEVICE|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
58380838|NCT02377024|DIETARY_SUPPLEMENT|placebo|
57909447|NCT05151705|DRUG|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
57909448|NCT05151705|DRUG|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
57909449|NCT05151705|DRUG|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
57909450|NCT00803751|DEVICE|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
57909451|NCT00803751|DEVICE|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
57909452|NCT02325479|DRUG|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
57909453|NCT02325479|DRUG|tissue culture media|intrauterine administration after oocyte pickup as placebo
57909454|NCT05373823|OTHER|MySmartSkin enhancement|Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
57909455|NCT05373823|OTHER|Educational webpage on Skin Self-Examination|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
57909456|NCT05373823|OTHER|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
57909457|NCT06487611|BEHAVIORAL|A humanoid social robot|A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
57909458|NCT05421611|BIOLOGICAL|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
58380839|NCT00432068|DRUG|Octreotide pamoate|
57909459|NCT05421611|BIOLOGICAL|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
58380840|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
58380841|NCT01968538|RADIATION|Radiation Therapy|
58380842|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
58380843|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
58380844|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
58380845|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
57909460|NCT00230087|PROCEDURE|blood donation|phlebotomy until iron depleted
57909461|NCT05332145|BEHAVIORAL|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
57909462|NCT01741896|PROCEDURE|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
57909463|NCT02076438|DIETARY_SUPPLEMENT|Probiotics|Randomized to receive probiotics or placebo
57909464|NCT02880384|OTHER|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
57909465|NCT04004936|OTHER|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
58380846|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
58380847|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
58380848|NCT02484443|OTHER|Pharmacological Study|Correlative studies
58380849|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
58380850|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57707595|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
57707596|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
57707597|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
57707598|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
58258201|NCT00885742|BIOLOGICAL|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
58380851|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
57707599|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
57707600|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
57707601|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
57707602|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
57707603|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
57707604|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
57707605|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
57707606|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
58066583|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
57707607|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
57707608|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
57707609|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
57707610|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
57707611|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
58258202|NCT05234086|COMBINATION_PRODUCT|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
58258203|NCT05234086|PROCEDURE|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
58258204|NCT06622174|RADIATION|Pulse radiotherapy|Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
58258205|NCT06621147|PROCEDURE|Surgery|Surgery
58258206|NCT03605862|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
58258207|NCT03605862|DRUG|Placebo|Placebo administered orally twice daily for five days
58258208|NCT03931473|OTHER|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
58258209|NCT03776110|DRUG|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
58258210|NCT03776110|DRUG|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
58380852|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
58380853|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
58380854|NCT04571060|DRUG|Placebo|One dose of matching placebo
58066584|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
58258211|NCT05310786|OTHER|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
58258212|NCT05104801|DRUG|sitravatinib|sitravatinib 100mg QD PO
58258213|NCT05104801|DRUG|tislelizumab|tislelizumab 200mg Q3W IV
58258214|NCT00545246|DRUG|aflibercept (AVE0005)|intravenous infusion
58258215|NCT00545246|DRUG|docetaxel|intravenous infusion
58258216|NCT06138743|DRUG|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
58258217|NCT06138743|DRUG|Placebo|calculated volume to match active treatment by IV infusion
58258218|NCT02523066|DEVICE|Magna Ease|This study is non-intervention
58258219|NCT03477747|DEVICE|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
58258220|NCT02964754|DEVICE|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
58258221|NCT02964754|PROCEDURE|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
58380855|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
58380856|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
57707612|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
58066585|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
58258222|NCT01909323|OTHER|maltitol 85% / FOS15%|
58380857|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
58380858|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
58380859|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
58380860|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
58380861|NCT00002343|DRUG|Ethambutol hydrochloride|
58066586|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
58066587|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
58258223|NCT01909323|OTHER|maltitol alone|
58258224|NCT01909323|OTHER|maltitol 68% / FOS 32%|
58258225|NCT01909323|OTHER|maltitol 50% / FOS 50%|
58258226|NCT01909323|OTHER|FOS alone|
58380862|NCT00002343|DRUG|Rifabutin|
58258227|NCT01909323|OTHER|Placebo|
58258228|NCT02289287|BEHAVIORAL|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
58058011|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
58058012|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
58380863|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
58058013|NCT01832051|DRUG|89Zr-trastuzumab injection|
58058014|NCT03626389|OTHER|Physiotherapy|
58058015|NCT05120375|DRUG|BAT6021|Ⅳ infusions
58058016|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
58058017|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
58258229|NCT02289287|BEHAVIORAL|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
58258230|NCT04483817|DEVICE|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
58258231|NCT04483817|DEVICE|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
58258232|NCT04532190|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS)
58258233|NCT04102254|PROCEDURE|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
58258234|NCT06137573|DRUG|[14C]TNP-2198|600mg suspension containing 150μCi of \[14C\] TNP-2198
58258235|NCT06090903|PROCEDURE|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
58258236|NCT06090903|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
58258237|NCT06090903|OTHER|Medical Chart Review|Review Medical Chart
58380864|NCT03270059|DRUG|Ferumoxytol|Given IV
58058018|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
58058019|NCT05661838|PROCEDURE|transfusion|transfusion
58058020|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
58058021|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
58258238|NCT05933200|DRUG|Triheptanoin|Liquid for oral (PO) or enteral feeding tube administration
58258239|NCT05933200|DIETARY_SUPPLEMENT|MCT Oil|Liquid for oral (PO) or enteral feeding tube administration
58258240|NCT05555524|OTHER|Baby oil|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
58258241|NCT05555524|OTHER|Placebo|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
58380865|NCT03270059|DRUG|Gadolinium|Given IV
58380866|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58258242|NCT06521645|OTHER|transcutaneous electrical stimulation|electrical stimulation is given through electrodes attached to the skin
58380867|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
58380868|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
58380869|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
58380870|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
58380871|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
58380872|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
58258243|NCT06521645|OTHER|electrodes attachment|electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
58258244|NCT03955081|DEVICE|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
58258245|NCT06593886|DEVICE|BabyG|This involves wearing a harness connected to the overhead device while in a 10 X 10 play area filled with toys and equipment commonly used for infants to promote mobility skills (e.g. crawling and walking). Families can choose to come for 3 30-minute or 2 45-minute sessions per week. Half of the children will participate in the training immediately after enrollment in the study, the others will wait for 12 weeks before starting training. All will receive a comprehensive assessment at 0, 12 and 24 weeks, with additional developmental assessments at 6 and 18 weeks
58258246|NCT02341495|DRUG|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
58258247|NCT02341495|DRUG|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
58258248|NCT02341495|DRUG|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
58258249|NCT00447031|DRUG|intravitreal bevacizumab and triamcinolone acetonide|
58258250|NCT06422104|DEVICE|Repetitive transcranial magnetic stimulation|10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
58380873|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
58258251|NCT04998279|DRUG|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
58258252|NCT04998279|OTHER|placebo|mock test without injection of G-CSF
58258253|NCT04025931|DRUG|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
58258254|NCT00041106|DRUG|gemcitabine hydrochloride|Given IV
58058022|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
58058023|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
58258255|NCT00041106|DRUG|cisplatin|Given IV
58258256|NCT00041106|DRUG|gefitinib|Given PO
58258257|NCT00041106|OTHER|laboratory biomarker analysis|Correlative studies
58258258|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
58058024|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
58258259|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
58258260|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
58258261|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
58258262|NCT02269410|DIETARY_SUPPLEMENT|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
58258263|NCT02269410|DIETARY_SUPPLEMENT|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
58258264|NCT02269410|DIETARY_SUPPLEMENT|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
58258265|NCT02269410|DIETARY_SUPPLEMENT|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
58258266|NCT06622616|DIETARY_SUPPLEMENT|EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS|"The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated."
58380874|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
58380875|NCT01899781|DRUG|Antibiotic-Cefamezin|
58380876|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
58380877|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
58380878|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
58380879|NCT03161210|OTHER|Saline|Saline is a control group
58380880|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
58380881|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
58380882|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
58380883|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
58380884|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
58380885|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
58380886|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
58058025|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
58058026|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
58058027|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
58058028|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
58258267|NCT06540079|DEVICE|Solia CSP S lead|The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.
58258268|NCT06648070|PROCEDURE|Neuromuscular reeducation technique|"5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds."
58258269|NCT06648070|PROCEDURE|Post Facilitation Stretch|3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
58258270|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
58380887|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
58380888|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
58380889|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
58380890|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
58380891|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
58380892|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
58380893|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
58380894|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
58380895|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
58380896|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
57707613|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
58058029|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
58058030|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
58380897|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
58380898|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
58380899|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
58380900|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
57707614|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
58380901|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
57707615|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
57707616|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
57707617|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
57707618|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
58058031|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
58058032|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
58058033|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
58058034|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
58058035|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
58258271|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
58380902|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
57707619|NCT05908279|OTHER|Walking test|Walk with and without a metronome
58258272|NCT03937908|DRUG|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
58258273|NCT03937908|DRUG|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
58380903|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
57707620|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
57707621|NCT00276718|BIOLOGICAL|bleomycin sulfate|
57707622|NCT00276718|DRUG|carboplatin|
57707623|NCT00276718|DRUG|etoposide|
57707624|NCT00276718|PROCEDURE|conventional surgery|
57707625|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
57707626|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
58058036|NCT03742271|DEVICE|senofilcon A|TEST Lens
58058037|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
58058038|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
58058039|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
57707627|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
58258274|NCT04747613|DRUG|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
58258275|NCT02889198|BEHAVIORAL|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
58258276|NCT00790231|DEVICE|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
58258277|NCT00308087|DRUG|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
58258278|NCT00308087|DRUG|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
58258279|NCT02935504|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
58258280|NCT02935504|BEHAVIORAL|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
58258281|NCT03627338|DIAGNOSTIC_TEST|questionaire, interview|questionaire, interview
58258282|NCT05343364|DRUG|Vonoprazan|Oral Tablet
57707628|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
57707629|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
57707630|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
57909466|NCT04004936|OTHER|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
57909467|NCT04311528|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV vaccine
57909468|NCT04326595|PROCEDURE|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
57909469|NCT02609347|OTHER|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
57909470|NCT02609347|OTHER|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
58258283|NCT06370871|DRUG|Brigimadlin|Brigimadlin
58258284|NCT06370871|DRUG|Ezabenlimab|Ezabenlimab
58258285|NCT06370871|DRUG|Gemcitabine|Solution for infusion
58258286|NCT06370871|DRUG|Docetaxel|Solution for infusion
58258287|NCT06618716|BIOLOGICAL|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|Intravenous administration of endotoxin (0.8 ng/kg body weight)
57707631|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
57707632|NCT02262481|DRUG|dydrogesterone|
57909471|NCT02733055|OTHER|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
57909472|NCT02234648|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
57909473|NCT02234648|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
57909474|NCT04307771|BEHAVIORAL|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
57909475|NCT05966597|BEHAVIORAL|Written persuasive leaflet|Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.
57909476|NCT05966597|BEHAVIORAL|Standard referral leaflet|Standard referral leaflet provided at the end of the home-based health screening.
58258288|NCT06618716|OTHER|Placcebo|Placebo injection of 0.9% NaCl
57707633|NCT02262481|DRUG|placebo|
57707634|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
57707635|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
58258289|NCT03087097|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
57909477|NCT01299870|DRUG|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
58258290|NCT06158997|DEVICE|EyePeace|EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.
58258291|NCT06158997|DEVICE|Heated Eye Mask|Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
58258292|NCT06410703|DRUG|CAN1012|CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
58258293|NCT05994521|PROCEDURE|ERCP alone|"ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed"
58258294|NCT05994521|PROCEDURE|ERCP +ProEUS-GE|ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
58258295|NCT04671381|BEHAVIORAL|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
58258296|NCT04671381|DEVICE|Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation|Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.
58258297|NCT04671381|BEHAVIORAL|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
58258298|NCT04671381|DEVICE|Provision of Over-the-Counter Hearing Aids|Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
58258299|NCT04109287|DEVICE|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
58258300|NCT03655912|DEVICE|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
58258301|NCT03655912|DEVICE|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
57909478|NCT01299870|DRUG|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
57909479|NCT02786550|DRUG|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
57909480|NCT02786550|OTHER|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
57909481|NCT04109924|DRUG|Irinotecan|Given IV
57909482|NCT04109924|BIOLOGICAL|Bevacizumab|Given IV
57909483|NCT04109924|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
57909484|NCT04334200|BEHAVIORAL|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
57909485|NCT05378971|DRUG|Pomalidomide|Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
58058040|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
58058041|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
58258302|NCT03655912|DEVICE|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
58258303|NCT03852628|DRUG|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
58258304|NCT03852628|DRUG|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
58258305|NCT02689869|DRUG|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
58258306|NCT02689869|DRUG|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
58258307|NCT05229523|OTHER|repeated assessments|validity and reliability of the Modified Four Square Step Test (mFSST) in children with cerebral palsy with the tests of Pediatric Berg Balance Scale (PBSS), Timed Up and Go Test (TUG), Pediatric Functional Reaching Test (PFUT)
58258308|NCT01038401|PROCEDURE|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
58258309|NCT01038401|BIOLOGICAL|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
58258310|NCT05075824|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
58258311|NCT05075824|DRUG|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
57707636|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
57707637|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
57707638|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
57707639|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
57909486|NCT00979810|DRUG|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
57909487|NCT06392074|DRUG|MB04|Subcutaneous injection
57707640|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
57909488|NCT06392074|DRUG|US License Enbrel|Subcutaneous injection
57909489|NCT06392074|DRUG|EU Source Enbrel|Subcutaneous injection
58058042|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
58058043|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
58058044|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
58058045|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
58058046|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
58058047|NCT02826083|DIETARY_SUPPLEMENT|XXS|
58058048|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
58058049|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
58058050|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
58258312|NCT00576160|BEHAVIORAL|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
58258313|NCT03189667|DEVICE|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon."
58258314|NCT03189667|DEVICE|Plain balloon angioplasty|"Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon."
58258315|NCT03189667|DEVICE|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion."
58380904|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
58380905|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
58380906|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
57909490|NCT06016959|OTHER|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition \& also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
57909491|NCT06016959|OTHER|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton \& Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
58258316|NCT01604863|DRUG|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
58380907|NCT02015481|DRUG|Cabaletta|
58380908|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
57909492|NCT04021550|DEVICE|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
57909493|NCT04021550|DRUG|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
57909494|NCT04021550|DIETARY_SUPPLEMENT|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
58058051|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
58258317|NCT01604863|DRUG|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
58258318|NCT01604863|DRUG|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
58258319|NCT02222311|OTHER|Blood Samples|
58258320|NCT06665828|DRUG|REGN9533|Administered per the protocol
58258321|NCT06665828|DRUG|Matching Placebo|Administered per the protocol.
58258322|NCT01053962|DRUG|SP-304 0.3 mg|SP-304 0.3 mg
58258323|NCT01053962|DRUG|SP-304 1.0 mg|SP-304 1.0 mg
58258324|NCT01053962|DRUG|SP-304 3.0 mg|SP-304 3.0 mg
58258325|NCT01053962|DRUG|SP-304 9.0 mg|SP-304 9.0 mg
58380909|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
58380910|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
58058052|NCT02180191|OTHER|Comparison of the gut microbiota composition|
58258326|NCT01053962|DRUG|Placebo|Placebo
58258327|NCT04112602|OTHER|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
58258328|NCT04112602|OTHER|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
58258329|NCT02735525|DEVICE|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
58258330|NCT03592537|DRUG|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
58258331|NCT03592537|DRUG|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
58380911|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
58380912|NCT02573571|OTHER|Development of biomarkers|Blood sampling
58380913|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
58380914|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
57909495|NCT04021550|OTHER|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
58058053|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
58258332|NCT03592537|DRUG|Bupivacaine Hydrochloride|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
58258333|NCT01351480|BIOLOGICAL|abatacept|Abatacept administered SC weekly at 125 mg dose
58258334|NCT03421314|DIETARY_SUPPLEMENT|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
58258335|NCT03075891|DRUG|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
58258336|NCT03075891|DRUG|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
58258337|NCT03075891|OTHER|Oral placebo capsules|1 Capsule once-daily for 12 weeks
58258338|NCT05253716|OTHER|ONS|Immunonutritional supplement
58258339|NCT02991729|OTHER|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
58380915|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
58380916|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
58380917|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
58258340|NCT02991729|OTHER|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
58380918|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
58380919|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
58380920|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58380921|NCT01918865|DRUG|ISIS-PTP1BRx|
58058054|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
58058055|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
58380922|NCT01918865|DRUG|Placebo|
58380923|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
58380924|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
58380925|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
58380926|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
58380927|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
58380928|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
58380929|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
58380930|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
58380931|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
58058056|NCT00253422|DRUG|anastrozole|
58380932|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
58258341|NCT05016141|BEHAVIORAL|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
58258342|NCT05981703|DRUG|BGB-26808|Planned doses administered orally as a tablet daily.
58380933|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
57707641|NCT03548584|DRUG|Brexpiprazole|Oral tablets
57707642|NCT03548584|OTHER|Placebo|Oral tablets
57707643|NCT00675116|DRUG|GW823296|
58058057|NCT00253422|DRUG|exemestane|
58058058|NCT00253422|DRUG|fulvestrant|
58258343|NCT05981703|DRUG|Tislelizumab|Planned doses administered by intravenous infusion.
58380934|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
58058059|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
58058060|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
58058061|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
57707644|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
57707645|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
58058062|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
58058063|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
58058064|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
58058065|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
58058066|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
58058067|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
58258344|NCT06271668|OTHER|Naloxone Co-prescribing Clinical Decision Support (CDS)|Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
58058068|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
58380935|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
58058069|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
58058070|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
58058071|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
58066588|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
58258345|NCT04787471|COMBINATION_PRODUCT|30 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
58258346|NCT04787471|COMBINATION_PRODUCT|10 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
58258347|NCT05010512|DEVICE|Delefilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
58258348|NCT05010512|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
58258349|NCT05943288|DEVICE|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
58380936|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
58380937|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
58058072|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
58058073|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
58066589|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
58258350|NCT06032052|DRUG|Single drug chemotherapy plus immunotherapy|The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
58258351|NCT01542723|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
58258352|NCT01491204|DRUG|Paclitaxel+HM30181|oral, 3times for 4weeks
58258353|NCT00003779|BIOLOGICAL|Connaught|Compare two strains of BCG
58258354|NCT00003779|BIOLOGICAL|Tice|Compare two strains of BCG
58258355|NCT00539149|DRUG|Amoxycillin|50 mg/kg/day twice daily
58258356|NCT00539149|DRUG|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
58258357|NCT03731559|DRUG|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
58258358|NCT03731559|DRUG|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
58258359|NCT02184585|DRUG|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
58258360|NCT02184585|DRUG|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
58258361|NCT02184585|DRUG|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
58258362|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
58258363|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
58258364|NCT00648622|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
58258365|NCT00648622|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
58258366|NCT02190032|DEVICE|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
58258367|NCT02190032|DEVICE|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
58258368|NCT04510246|BEHAVIORAL|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
58258369|NCT01645878|BEHAVIORAL|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
58258370|NCT01645878|BEHAVIORAL|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
58258371|NCT01645878|BEHAVIORAL|routin breast feeding education|
58258372|NCT06342999|PROCEDURE|Fetal Aortic Valvuloplasty Procedure|Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.
58258373|NCT06342999|DEVICE|Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter|Balloon Catheter
58258374|NCT06342999|DEVICE|Trek RX and Mini Trek RX Coronary Dilatation Catheter|Coronary Dilation Catheter
58258375|NCT00137007|DRUG|Azithromycin|
58258376|NCT00137007|DRUG|Ampicillin/sulbactam|
58258377|NCT05930795|PROCEDURE|pectopexy|pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
58258378|NCT05930795|PROCEDURE|lateral suspension|lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
58258379|NCT06231693|DRUG|Trastuzumab deruxtecan|Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
58258380|NCT01275755|DRUG|Placebo|
58258381|NCT01275755|DRUG|ADL5945 0.25 mg|
58258382|NCT01524939|DRUG|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
58058074|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
58258383|NCT06344026|BIOLOGICAL|ANPD001|Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
58258384|NCT06344026|DEVICE|Custom Device|A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
58258385|NCT04183153|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
58258386|NCT06368830|DIAGNOSTIC_TEST|3-ounce water swallow test|Bedside water swallow dysphagia screen where vocal quality of the participant is assessed before and after swallowing 3 ounces of water
58258387|NCT06368830|DIAGNOSTIC_TEST|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Scored assessment of the lymph nodes, lips, tongue, tissue inside of cheek, floor and roof of mouth, gums between teeth and/or under artificial teeth, saliva, condition of natural/artificial teeth, chewing position of teeth, and oral cleanliness
58258388|NCT06368830|DIAGNOSTIC_TEST|Tongue pressure|"Maximum isometric lingual pressure at the front and back of tongue will be measured by placing an air-filled pressure bulb on the surface of the oral tongue and having participants press the bulb as hard as possible against the hard palate"
58258389|NCT06368830|DIAGNOSTIC_TEST|Test of Masticating and Swallowing Solids (TOMASS)|Measurement of bites, masticatory cycles, swallows, and time taken to consume a cracker
58258390|NCT06368830|DIAGNOSTIC_TEST|Respiratory function tests|Participants will take a maximum inhalation and forcefully exhale into a spirometer to measure maximum expiratory pressure (MEP), fully exhale their air and take a maximal inhalation into the spirometer to measure maximum inspiratory pressure (MIP), and produce a single strong cough into to spirometer to measure peak expiratory flow (PEF) and forced expiratory volume (FEV1)
58258391|NCT01871181|PROCEDURE|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
58058075|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
58258392|NCT01871181|PROCEDURE|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
58258393|NCT06517888|COMBINATION_PRODUCT|AAVAnc80-antiVEGF via Akouos Delivery Device|AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
58258394|NCT04068129|DEVICE|photoscreen|Determine amblyopia risk factors
58258395|NCT05800197|DRUG|Tamoxifen 20mg|Selective estrogen receptor modulator
58258396|NCT05800197|DRUG|Anastrozole 1mg|Aromatase Inhibitor
58058076|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
58058077|NCT02249351|DRUG|Talsaclidine|
58058078|NCT02249351|DRUG|Placebo|
58058079|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
58258397|NCT05800197|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
58258398|NCT05800197|DRUG|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
58258399|NCT05800197|DRUG|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
58058080|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
58058081|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
58058082|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
58058083|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
58058084|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
58258400|NCT04170348|DRUG|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
58258401|NCT04170348|DRUG|Bolus oral vitamin D3, 100,000 IU|Bolus oral vitamin D3, 100,000 IU, will be administered monthly.
58258402|NCT04170348|DRUG|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
58258403|NCT06544707|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
58258404|NCT01790828|DRUG|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
58258405|NCT02348346|OTHER|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
58258406|NCT02394340|DRUG|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
58258407|NCT02394340|DRUG|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
58258408|NCT04865601|OTHER|resectomy of the colon|The patient scheduled for colon resectomy are included in the study
58380938|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
58380939|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
58380940|NCT04335448|OTHER|No intervention is planed|No intervention is planed
58380941|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
57909496|NCT03972085|OTHER|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
57909497|NCT03972085|OTHER|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
58258409|NCT05113888|DRUG|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
58258410|NCT05113888|DRUG|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
58258411|NCT05113888|DRUG|Placebo|take orally before meals, 1 bag each time, 3 times a day.
58258412|NCT04912440|DEVICE|MSE-ERCP|No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
58258413|NCT05416515|DRUG|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
58258414|NCT06491394|DRUG|Lactoferrin|an iron-binding protein
58258415|NCT06491394|DIAGNOSTIC_TEST|iron|Iron in kidney and heart tissues
58258416|NCT06491394|DIAGNOSTIC_TEST|MDA, TAC, and GSH|Oxidative stress levels in kidney and heart tissues
58380942|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
58380943|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
57909498|NCT04495101|BIOLOGICAL|Prolastin|Intravenous infusion 120 mg/kg
57909499|NCT04495101|DRUG|Standard Medical Treatment|Standard medical treatment per local policies or guidelines
58058085|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
58258417|NCT06491394|DIAGNOSTIC_TEST|Nrf2|Nrf2 expression in kidney and heart tissues
58258418|NCT06491394|DIAGNOSTIC_TEST|AMPK|AMPK levels in heart and kidney tissues
57909500|NCT05146180|DEVICE|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
57909501|NCT03394001|PROCEDURE|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
57909502|NCT03394001|DRUG|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
57909503|NCT03394001|DRUG|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
58258419|NCT06491394|DIAGNOSTIC_TEST|HO-1|HO-1 levels in kidney and heart tissues
58258420|NCT06491394|DRUG|glycerin|GLY intramuscular injection for rhabdomyolysis induction
58258421|NCT06618625|PROCEDURE|nasotracheal intubation|"For nasotracheal intubation, the nasal RAE tube will be inserted with it rotated by 90 degrees in counter-clockwise direction for patients in the 'Rotation' arm.~For nasotracheal intubation, the nasal RAE tube will be inserted without tube rotation for patients in the 'Neutral' arm."
58258422|NCT04804748|OTHER|No intervention|no intervention
58258423|NCT04907669|OTHER|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
58258424|NCT05566834|DRUG|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
58258425|NCT04973631|GENETIC|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
58258426|NCT05697237|DRUG|Carrelizumab|Carrelizumab 200mg/3 weeks
58380944|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
57909504|NCT05110027|DRUG|Enpatoran|Participants will receive single oral dose of enpatoran tablet on Day 1
57909505|NCT05110027|DRUG|[14C]enpatoran microtracer|Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.
57909506|NCT05110027|DRUG|[14C]enpatoran microdose|Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
58258427|NCT05697237|DRUG|Solfantinib|Solfantinib 300mg/d
58380945|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
58380946|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
58380947|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
58380948|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
57909507|NCT03042897|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo DASH diet
58258428|NCT02774122|DEVICE|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
58380949|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
58380950|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
58066590|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
58380951|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
58380952|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
58380953|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
58258429|NCT02774122|DEVICE|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
58380954|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
58380955|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
58380956|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
58258430|NCT02511314|DEVICE|TENA Identifi|TENA Identifi
57707646|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
57909508|NCT03042897|BEHAVIORAL|Exercise Intervention|Undergo in aerobic exercise
57909509|NCT03042897|OTHER|Laboratory Biomarker Analysis|Correlative studies
57909510|NCT03042897|OTHER|Quality-of-Life Assessment|Ancillary studies
58258431|NCT05675527|BIOLOGICAL|Low-dose PRP|Injection
58258432|NCT05675527|BIOLOGICAL|High-dose PRP|Injection
58258433|NCT05675527|OTHER|Saline|Injection
58380957|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
58380958|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
58380959|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
58380960|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
57909511|NCT04897750|COMBINATION_PRODUCT|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
58380961|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
58380962|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
58380963|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
58258434|NCT05789589|DRUG|Azeliragon|"Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)"
57909512|NCT06476613|OTHER|Permissive Hypotension|Patients will be randomized in 1:1 fashion to either a) Permissive Hypotension (MAP target \> 60mmHg) or b) Usual Care. The duration of the intervention will extend until the patient no longer needs vasopressors to maintain prespecified MAP.
57909513|NCT00687687|DRUG|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
58258435|NCT05789589|RADIATION|Stereotactic radiosurgery|Patients will undergo standard of care SRS as per the treating facility's policies.
58258436|NCT05789589|DRUG|Corticosteroid|"Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT)."
58258437|NCT00858312|OTHER|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
58258438|NCT00858312|OTHER|Low Dairy|less than 1 serving of dairy foods per day.
58380964|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
58380965|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
58380966|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
58380967|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
57909514|NCT00687687|DRUG|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
58066591|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
58258439|NCT00688935|BIOLOGICAL|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
58258440|NCT05887843|DRUG|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
58066592|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
58066593|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
58258441|NCT05887843|DRUG|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
58258442|NCT05887843|DRUG|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
58258443|NCT01369108|DEVICE|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
57909515|NCT00687687|DRUG|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
57909516|NCT00218660|DRUG|Naltrexone|150mg/day Naltrexone
57909517|NCT00218660|BEHAVIORAL|BRENDA|Psychosocial Treatment
57909518|NCT00218660|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
57909519|NCT00218660|DRUG|Placebo|
57909520|NCT05294601|OTHER|High-Intensity Interval Training|high intensity exercise with games
57909521|NCT05294601|OTHER|Medium-Intensity Interval Training|medium intensity exercise with games
57909522|NCT02478710|DRUG|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
57909523|NCT02478710|DRUG|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
58258444|NCT01369108|DEVICE|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
58258445|NCT04409457|OTHER|fasting state|16 hours of fasting
58258446|NCT04409457|OTHER|fed state|fed a standardized meal
58258447|NCT04409457|OTHER|magnetic resonance imaging|neuroimaging with computational modeling
58258448|NCT03858803|BEHAVIORAL|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
58258449|NCT03858803|BEHAVIORAL|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
58258450|NCT03823079|DRUG|rhTPO|rhTPO 300u/kg, subcutaneous injection, qd
57909524|NCT00117923|DRUG|Resiquimod|
58066594|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
58258451|NCT03823079|DRUG|irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
58258452|NCT03823079|DRUG|Raltitrexed|3mg/m2 q3w
58258453|NCT03823079|RADIATION|radiotherapy|in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
58258454|NCT03823079|DRUG|rhIL-11|rhIL-11 50ug/kg, subcutaneous injection, qd
58258455|NCT01936181|DRUG|Remicade (infliximab)|
58258456|NCT01936181|DRUG|SB2 (proposed biosimilar to infliximab)|
58258457|NCT06514053|PROCEDURE|Full pulpotomy|A full pulpotomy will be performed by removing the entire roof of the pulp chamber and the remaining pulp tissue will be covered by Biodentine.
58258458|NCT06514053|PROCEDURE|Root canal treatment|The regular procedure of root canal treatment will be performed on teeth with irreversible pulpitis
58258459|NCT06617182|DRUG|Thalidomide|Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
58258460|NCT06617182|DRUG|Glutamine|In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
58258461|NCT06617182|DRUG|Thalidomide+Glutamine|Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.
58258462|NCT00330330|DRUG|ISIS 113715|
58258463|NCT04390425|DEVICE|Experimental - Limb Occlusion pressure|This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
58258464|NCT01307137|BEHAVIORAL|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~* Weight management success is defined as a loss of at least 5% of the weight since enrollment~* Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
57909525|NCT05372952|DEVICE|Dynetic-35 Peripheral Balloon-Expandable Stent System|Stenotic iliac lesions will be treated with the Dynetic 35 stent via a radial access
57909526|NCT03750045|DIAGNOSTIC_TEST|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
58258465|NCT01307137|BEHAVIORAL|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
58258466|NCT06243601|BIOLOGICAL|Aloe vera Gel|A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
58258467|NCT04172012|BIOLOGICAL|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
58258468|NCT04172012|OTHER|Placebo|Placebo mixture
58258469|NCT00703794|DEVICE|The AXIUM Progressive Coil System|Embolization of aneurysm
58258470|NCT00694252|DRUG|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
58258471|NCT03495739|DRUG|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
58258472|NCT03495739|DRUG|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
58258473|NCT06667869|DRUG|Sedative|Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
58258474|NCT02772874|OTHER|No intervention|No intervention
58258475|NCT05129137|DRUG|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
58258476|NCT05129137|DRUG|paracetamol 500 mg X2|paracetamol 500 mg X2
58258477|NCT05129137|DRUG|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
58258478|NCT03247465|OTHER|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
58380968|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
58380969|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
57707647|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
57909527|NCT03750045|DIAGNOSTIC_TEST|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
57909528|NCT03750045|OTHER|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
57909529|NCT06610123|DIETARY_SUPPLEMENT|Caffeine and Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
57909530|NCT06610123|DIETARY_SUPPLEMENT|Placebo and Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
57909531|NCT03356626|DEVICE|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
57909532|NCT03356626|DEVICE|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
57909533|NCT03356626|DEVICE|Thunderbeat|to use Thunderbeat when performing gastrectomy
58058086|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
58380970|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
57909534|NCT04444544|OTHER|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
57909535|NCT05688345|DRUG|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
58058087|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
58380971|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
58380972|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
57909536|NCT05688345|DRUG|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
57909537|NCT05688345|DRUG|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
57909538|NCT00369473|DRUG|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
57909539|NCT00369473|DRUG|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
57909540|NCT03271554|DRUG|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
57909541|NCT04733521|DRUG|SC-43|SC-43 oral, every day of 21-day cycle
57909542|NCT04733521|DRUG|Cisplatin|cisplatin 75mg/m2 on day 1 of 21-day cycle
57909543|NCT02984293|DRUG|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
57909544|NCT02984293|DRUG|Placebo|Placebo once daily for 28 days.
57909545|NCT00146120|DRUG|Idarubicin|
58380973|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
58380974|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
58380975|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
57707648|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
57707649|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
57909546|NCT00146120|DRUG|Cytosin-Arabinosid|
57909547|NCT00146120|DRUG|Etoposide|
57909548|NCT00146120|DRUG|All-trans Retinoid acid|
57909549|NCT05690724|DIETARY_SUPPLEMENT|Mitocholine™ or Placebo|Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
57909550|NCT02383056|DEVICE|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
57909551|NCT02383056|DEVICE|Omnilux Sham|Sham light instead of phototherapy from the same light device
57909552|NCT03350373|DRUG|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
58258479|NCT05296954|PROCEDURE|high resolution cartography|High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
58258480|NCT02830958|DEVICE|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
58258481|NCT02830958|OTHER|No intervention|No intervention. Uses of an ordinary tape
58258482|NCT04362540|DIAGNOSTIC_TEST|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
58058088|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
58258483|NCT06066346|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression
58258484|NCT05387460|DIAGNOSTIC_TEST|radiomics|Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
58258485|NCT04763655|DIAGNOSTIC_TEST|clinical and neuropsychological testing|Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
58258486|NCT06498466|OTHER|myofascial release|Myofascial release therapy (MRT) is a manual therapy technique that involves gradual stretching by a therapist or the individual, acting on the muscles and surrounding fascia. Its effects include increasing joint range of motion and mobility of soft tissues, eliminating imbalances in muscle tone, reducing muscle pain, reducing stress on joints, and increasing neuromuscular efficiency.
58258487|NCT05551520|DEVICE|Normative|ImPACT will be administered at baseline testing
58380976|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
57707650|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
57707651|NCT00565279|DRUG|ASF1057|Twice daily, topical
57707652|NCT00565279|DRUG|ASF1057|Twice daily, Topical
57707653|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
57909553|NCT00556387|DRUG|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
57909554|NCT00556387|DRUG|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
58058089|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
58058090|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
58258488|NCT05551520|DEVICE|Reliability|ImPACT will be administered again within 60 days of baseline test
58258489|NCT02012738|BEHAVIORAL|FORNET|"8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook"
58258490|NCT02012738|BEHAVIORAL|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
58258491|NCT02012738|OTHER|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
58258492|NCT02012738|OTHER|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
58380977|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
57909555|NCT04695912|DEVICE|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
58058091|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
58058092|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
58058093|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
58058094|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
58058095|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
58258493|NCT05329584|DEVICE|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
58258494|NCT03640975|OTHER|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
58258495|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
58258496|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
58258497|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
58258498|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
58258499|NCT03028857|DRUG|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
58258500|NCT03028857|DRUG|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
58258501|NCT01253174|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
58258502|NCT01253174|DRUG|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
58258503|NCT01253174|DRUG|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
58258504|NCT04085172|DRUG|Guanfacine hydrochloride (TAK-503)|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.
58258505|NCT04085172|DRUG|Atomoxetine hydrochloride|Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.
58258506|NCT04085172|OTHER|Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
58258507|NCT06647706|DEVICE|Transthoracic echocardiography|MPNs patients who have echocardiographic probability of PH
58380978|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
58258508|NCT00815815|BEHAVIORAL|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
58380979|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
58258509|NCT03531528|OTHER|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
57909556|NCT02781844|DRUG|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
57909557|NCT02781844|DRUG|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
58258510|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
58258511|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
58258512|NCT00425061|OTHER|placebo|placebo
57909558|NCT02781844|DRUG|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
58380980|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
58380981|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
58380982|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
58380983|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
58380984|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
58380985|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
57707654|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
57707655|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
57707656|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
57707657|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
57707658|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
57707659|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
57707660|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
57707661|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
57707662|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
57707663|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
57707664|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
57707665|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
57909559|NCT04201782|DRUG|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
57909560|NCT06434896|OTHER|ctDNA analysis after surgery|ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
57707666|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
57909561|NCT02592408|DRUG|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
58258513|NCT02544425|DRUG|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
58258514|NCT02544425|DRUG|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
58380986|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
58380987|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
57707667|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
57707668|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
57707669|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
57707670|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
57909562|NCT02592408|DRUG|SDPQ|single dose primaquine on day 2
57909563|NCT02592408|DRUG|14DPQ|14 day primaquine starting on day 2
57909564|NCT02592408|DRUG|14DPQ on Day 42|14 day primaquine starting on day 42
57909565|NCT00189488|DRUG|Palifermin|Administered as an intravenous (IV) bolus.
57909566|NCT00189488|DRUG|Placebo|Administered as an intravenous (IV) bolus.
58258515|NCT02544425|DRUG|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
58258516|NCT02544425|DRUG|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
58258517|NCT02544425|DRUG|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
58380988|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
58380989|NCT02903693|OTHER|cross sectional|
57909567|NCT00189488|OTHER|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])"
58380990|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
57909568|NCT00189488|PROCEDURE|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
57909569|NCT00189488|DRUG|Methotrexate|
57909570|NCT00366002|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
58058096|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
57909571|NCT01849627|BEHAVIORAL|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
57909572|NCT01849627|BEHAVIORAL|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
57909573|NCT06179784|BEHAVIORAL|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
57909574|NCT00381277|DRUG|Gatorade|
57909575|NCT00381277|DRUG|Performance|
57909576|NCT04158232|OTHER|Method|treatment of mature teeth with apical periodontitis
58058097|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
58058098|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
58380991|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
58058099|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
58258518|NCT02544425|DRUG|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
58258519|NCT00776113|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
58380992|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
58380993|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
57909577|NCT00730275|DRUG|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
57909578|NCT00730275|DRUG|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
58058100|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
58380994|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
58380995|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
57909579|NCT04019223|DIAGNOSTIC_TEST|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
58380996|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
58380997|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
58380998|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
58380999|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
58381000|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
57909580|NCT04019223|DIAGNOSTIC_TEST|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
57909581|NCT03690232|DRUG|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
57909582|NCT03690232|DRUG|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
57909583|NCT05486962|BEHAVIORAL|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
58066595|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
58258520|NCT05843058|BEHAVIORAL|laughter yoga|The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
58258521|NCT04776018|DRUG|TAK-981|TAK-981 IV infusion.
58258522|NCT04776018|DRUG|Mezagitamab|Mezagitamab SC injection.
58258523|NCT04776018|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
58258524|NCT03385044|PROCEDURE|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
58381001|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
58381002|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
58381003|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
58381004|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
57909584|NCT03995693|DIETARY_SUPPLEMENT|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
57909585|NCT03995693|BEHAVIORAL|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
57909586|NCT03995693|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
57909587|NCT03995693|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
57909588|NCT03995693|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
57909589|NCT03995693|BEHAVIORAL|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
57909590|NCT03995693|DIAGNOSTIC_TEST|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
57909591|NCT03995693|DIAGNOSTIC_TEST|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
57909592|NCT03995693|DIAGNOSTIC_TEST|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
58058101|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
58058102|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
58058103|NCT02110550|OTHER|IPS.emmax endocrown|
58058104|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
58058105|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
58058106|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
58058107|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
58058108|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
58058109|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
58058110|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
58058111|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
58058112|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
58058113|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
58058114|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
58258525|NCT03385044|PROCEDURE|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
58258526|NCT06276777|PROCEDURE|Tooth varnish (PRG Barrier Coat from Shofu)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
58258527|NCT06276777|PROCEDURE|Tooth varnish (Clinpro white varnish 3M)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
58258528|NCT04756583|OTHER|Notification system|Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
58258529|NCT04136977|DEVICE|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
58258530|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
58258531|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
58258532|NCT03188068|DRUG|Sirolimus|Oral administration
58381005|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
58058115|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
58058116|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
58058117|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
58058118|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
58058119|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
58058120|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
58058121|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
58058122|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
58058123|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
58058124|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
58058125|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
58058126|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
58058127|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
58058128|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
58058129|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
58058130|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
58058131|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
58058132|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
58058133|NCT01265173|DRUG|Cefotaxime|3 g
58058134|NCT01265173|DRUG|Ceftriaxone|2 g
58058135|NCT01265173|DRUG|Ciprofloxacin|400 mg
58058136|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
58058137|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
58058138|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
58058139|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
58058140|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
58058141|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
58058142|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
58058143|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
58258533|NCT03188068|DRUG|Prednisolone|Oral administered with sirolimus
58258534|NCT06621017|DRUG|ROSE-010 99 mcg|Sub-cutaneous injection of ROSE-010 solution
58258535|NCT06621017|DRUG|Placebo|Sub-cutaneous injection of saline solution
58258536|NCT06621017|DRUG|ROSE-010 150 mcg|Sub-cutaneous injection of ROSE-010 solution
58258537|NCT05069259|OTHER|Stool sample collection|collection for measuring calprotectin levels
58381006|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
58381007|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
58381008|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
57707671|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
57909593|NCT03995693|PROCEDURE|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
57909594|NCT02881580|OTHER|No intervention : descriptive study|
57909595|NCT04054700|DEVICE|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
57909596|NCT04054700|DEVICE|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
57909597|NCT03623373|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
57909598|NCT03623373|DRUG|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m\^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
57909599|NCT03623373|DRUG|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
57909600|NCT03623373|DRUG|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
57909601|NCT03623373|PROCEDURE|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
57909602|NCT03623373|PROCEDURE|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
58058144|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
57909603|NCT03623373|PROCEDURE|Oral rinse|-Baseline
57909604|NCT03623373|PROCEDURE|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
57909605|NCT04096053|OTHER|TEACHH|See arm/group description.
58258538|NCT05929196|DIAGNOSTIC_TEST|In vitro full blood diagnostic test.|Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
58258539|NCT05210465|OTHER|speckle tracking mode of the stress ECHO test with dobutamine|speckle tracking mode of the stress ECHO test with dobutamine
58258540|NCT00343785|DRUG|cyclophosphamide|Given IV
58258541|NCT00343785|BIOLOGICAL|anti-thymocyte globulin|Given IV
57707672|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
57909606|NCT01756768|RADIATION|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
57909607|NCT05857982|DRUG|Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
57909608|NCT03103451|DRUG|BCD-121|
57707673|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
57707674|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
57707675|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
57909609|NCT03103451|OTHER|Placebo|
57909610|NCT00824447|DRUG|Oralgen|allergen solution sublingually
57909611|NCT00824447|OTHER|placebo|placebo control
57909612|NCT05339984|PROCEDURE|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
57909613|NCT05339984|PROCEDURE|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
57909614|NCT05339984|PROCEDURE|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
57909615|NCT02619981|PROCEDURE|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
57909616|NCT02619981|DRUG|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
58058145|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
58058146|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
58058147|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
58058148|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
58258542|NCT00343785|DRUG|cyclosporine|Given IV or PO
58258543|NCT00343785|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
57909617|NCT04064593|DIAGNOSTIC_TEST|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
58058149|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
57707676|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
57707677|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
57707678|NCT02888327|DRUG|AL-794|
57707679|NCT02888327|DRUG|Oseltamivir|
57707680|NCT02888327|DRUG|Digoxin|
57707681|NCT02888327|DRUG|Midazolam|
57707682|NCT02888327|DRUG|Pitavastatin|
58258544|NCT00343785|DRUG|methotrexate|Given IV
58258545|NCT00343785|GENETIC|DNA analysis|Correlative studies
58258546|NCT00343785|OTHER|flow cytometry|Correlative studies
58381009|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
58381010|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
58381011|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
58381012|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
57707683|NCT02888327|DRUG|JNJ-63623872|
57707684|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
57707685|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
57909618|NCT01234077|DEVICE|CPC M1|CPC M1
58058150|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
58381013|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
58381014|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
57707686|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
57707687|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
58058151|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
58058152|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
58058153|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
58058154|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
58058155|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
58258547|NCT00343785|GENETIC|polymorphism analysis|Correlative studies
58258548|NCT00343785|OTHER|laboratory biomarker analysis|Correlative studies
58258549|NCT06083727|OTHER|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
58258550|NCT03828110|DEVICE|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
58381015|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
58258551|NCT03828110|PROCEDURE|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
58258552|NCT03455010|OTHER|Increased load|Participants walk with 120% body weight achieved with a weight vest
58381016|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
58381017|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
58381018|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
58058156|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
58058157|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
58058158|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
58058159|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
58058160|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
58058161|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
58058162|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
58258553|NCT03455010|OTHER|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
58258554|NCT06569667|BEHAVIORAL|PRC supported text + AI driven SDH-enhanced text|This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
58258555|NCT06569667|BEHAVIORAL|AI driven SDH-enhanced text only|This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
58258556|NCT06569667|BEHAVIORAL|Treatment as Usual (TAU)|Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
58258557|NCT02220179|BEHAVIORAL|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
58381019|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
58381020|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
58381021|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
58381022|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
58381023|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
58381024|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
58381025|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
58381026|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
58381027|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
58381028|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
58058163|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
58058164|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
58058165|NCT03371394|OTHER|no intervention|no intervention
58058166|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
58058167|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
58058168|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
58381029|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
58258558|NCT01405417|PROCEDURE|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
58258559|NCT00262470|DRUG|Acetazolamide|250 mg PO x 1
58258560|NCT00262470|DRUG|Atomoxetine|10-40 mg PO x 1 dose
58258561|NCT00262470|OTHER|NO Drug|No intervention - just monitoring
58258562|NCT00262470|DRUG|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
58258563|NCT00262470|DRUG|Entacapone|Entacapone 200-400 mg PO x 1 dose
58258564|NCT00262470|DRUG|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
58258565|NCT00262470|DRUG|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
58381030|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
58381031|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
58058169|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
58058170|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
58058171|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
58258566|NCT00262470|DRUG|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
58258567|NCT00262470|DRUG|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
58258568|NCT00262470|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
58258569|NCT00262470|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg PO x 1 dose
58258570|NCT00262470|DRUG|Midodrine|midodrine 2.5-10 mg PO x 1 dose
58258571|NCT00262470|DRUG|Modafinil|modafinil 100-200 mg PO x 1 dose
58258572|NCT00262470|DRUG|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
58258573|NCT00262470|RADIATION|Placebo|lactose tablet x 1 pill
58258574|NCT00262470|DRUG|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
58258575|NCT00262470|DRUG|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
58258576|NCT00262470|DRUG|Sertraline|sertraline 25-50 mg PO x 1 dose
58258577|NCT00262470|PROCEDURE|IV Saline|1 liter IV over 2 hours
58258578|NCT00262470|OTHER|Drinking Water|16 fluid ounces
58258579|NCT00262470|DEVICE|Breathing Device|Breathing through a dead space tube
58258580|NCT00262470|DRUG|memantine|memantine 5-20 mg PO x 1 dose
58258581|NCT00262470|DEVICE|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
58258582|NCT00489905|DRUG|Zolderonic acid (Zometa)|
58381032|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
58381033|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
58381034|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
57707688|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
57707689|NCT01782781|DRUG|Placebo|Placebo group
58258583|NCT02339116|DRUG|fluoruracil|
58258584|NCT02339116|DRUG|Oxaliplatin|
58258585|NCT02339116|DRUG|Irinotecan|
58258586|NCT02339116|DRUG|Bevacizumab|
58258587|NCT02572596|DRUG|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
58258588|NCT02572596|DRUG|CTX|CTX 2.5/m2 for 2 days.
58258589|NCT02572596|DRUG|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
58258590|NCT03439540|DIETARY_SUPPLEMENT|Plantago major|Individuals receive Plantago major daily, for 12 weeks
58258591|NCT03439540|DIETARY_SUPPLEMENT|Placebo|Individuals receive placebo daily, for 12 weeks
58258592|NCT04029363|DEVICE|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
58258593|NCT02141815|DIETARY_SUPPLEMENT|Arabinoxylan-oligosaccharides|
58258594|NCT02141815|DIETARY_SUPPLEMENT|Maltodextrine|
58258595|NCT04627532|DRUG|PF-07304814|Participants will receive PF-07304814
58258596|NCT04627532|DRUG|Placebo|Participants will recieve placebo
58258597|NCT02441270|DRUG|Cyclophosphamide|
58258598|NCT02441270|RADIATION|Stereotactic body radiotherapy|
58258599|NCT04675515|BEHAVIORAL|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
58258600|NCT05770102|DRUG|Atezolizumab|"Adult participants will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric participants will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
57909619|NCT05660460|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
57909620|NCT06610916|OTHER|Reinforced Communautary Support Program (PARC)|"Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \&amp;#34;before\&amp;#34;. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\&amp;#34;after\&amp;#34;) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\&amp;#39; course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach"
57909621|NCT01963923|BEHAVIORAL|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
57909622|NCT04238273|DIAGNOSTIC_TEST|Functional Echocardiography|Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
58058172|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
58258601|NCT04778059|DRUG|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
57909623|NCT03638973|PROCEDURE|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
58258602|NCT04778059|DRUG|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
58258603|NCT06061081|DRUG|VH3739937|VH3739937 will be administered.
57909624|NCT00192647|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
57909625|NCT00192647|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
57909626|NCT01405326|BIOLOGICAL|adalimumab|40mg sc. every two weeks for six months
57909627|NCT00820196|DRUG|Nexagon®|
57909628|NCT00820196|DRUG|Nexagon® vehicle|
57909629|NCT03838887|DEVICE|ultrasound machine|Ultrasound machine with a vocal software
57909630|NCT01164904|DRUG|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
57909631|NCT05601154|DRUG|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
57909632|NCT05601154|DRUG|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
57909633|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
57909634|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
57909635|NCT03410368|BIOLOGICAL|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
57909636|NCT00819390|DRUG|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
57909637|NCT00819390|DRUG|Placebo|Taken orally, once daily for 12 weeks.
58058173|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
58058174|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
58058175|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
58058176|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
58058177|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
58058178|NCT02050672|OTHER|untreated|
58381035|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
57707690|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
57707691|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
57707692|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
57707693|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
57707694|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
57707695|NCT02773043|DEVICE|CZT SPECT camera|
57707696|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
57707697|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
57707698|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
57707699|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
57707700|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
57707701|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
57707702|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
58058179|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
57707703|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
58381036|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
57707704|NCT01664143|DRUG|Placebo|Multiple doses of placebo
58058180|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
58058181|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
58058182|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
58058183|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
58258604|NCT06061081|DRUG|Placebo|Placebo will be administered.
58258605|NCT04567368|DIAGNOSTIC_TEST|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
58381037|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
57707705|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
57707706|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
57707707|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
57707708|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
57707709|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
57707710|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
57707711|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
58381038|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
57707712|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
57707713|NCT00127140|DRUG|vorinostat|
57707714|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
57707715|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
57909638|NCT06532370|BEHAVIORAL|Contingency Managment|"If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. great job!). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
58381039|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
57707716|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
57707717|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
57909639|NCT03258684|DRUG|Hydrocortisone, Vitamin C, and Thiamine|Intervention
57909640|NCT03258684|OTHER|Normal saline|Placebo
57909641|NCT00061984|BIOLOGICAL|pegfilgrastim|
57909642|NCT00061984|DRUG|doxorubicin hydrochloride|
57909643|NCT00061984|DRUG|ifosfamide|
57909644|NCT00061984|PROCEDURE|multimodality therapy|
57909645|NCT04324203|OTHER|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
57909646|NCT00768079|OTHER|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
58258606|NCT06000501|DRUG|Serdexmethylphenidate/dexmethylphenidate|Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
58258607|NCT04446650|DRUG|Fedratinib|Oral
57707718|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
57707719|NCT00482755|DRUG|sunitinib malate|
57707720|NCT00482755|OTHER|immunohistochemistry staining method|
57707721|NCT00482755|OTHER|laboratory biomarker analysis|
57707722|NCT00482755|OTHER|pharmacological study|
57707723|NCT00482755|PROCEDURE|needle biopsy|
57707724|NCT00482755|PROCEDURE|neoadjuvant therapy|
57707725|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
57707726|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
57707727|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
57909647|NCT00768079|BIOLOGICAL|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
58381040|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58381041|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58381042|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
57707728|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
57707729|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
57707730|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
57707731|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
57707732|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
57707733|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
57707734|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
57707735|NCT00968591|DRUG|Everolimus|
57707736|NCT00969553|DRUG|BI 6727|Dose level 1
57707737|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
57707738|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
57707739|NCT02129075|DRUG|Poly ICLC|Given SC
57707740|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
57707741|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
57707742|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
57707743|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
57707744|NCT00324779|BIOLOGICAL|rituximab|
58058184|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
58058185|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
58058186|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
58058187|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
58058188|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
57909648|NCT02461043|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
57909649|NCT02461043|RADIATION|radiation|radiation
58058189|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
57707745|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
57707746|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
57707747|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
57707748|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
57707749|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
57707750|NCT03254134|DRUG|Warfarin|patients treated with warfarin
57707751|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
57707752|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
57707753|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
57707754|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
57707755|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
57707756|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
57707757|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
57707758|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
57707759|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
57707760|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
58058190|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
57707761|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
57707762|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
57707763|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
57707764|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
57707765|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
57707766|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
57707767|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
57707768|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
57707769|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
57707770|NCT00223106|DEVICE|Vaginal Sling|
57707771|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
57707772|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
57707773|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
57707774|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
57707775|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
57707776|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
57707777|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
57707778|NCT03702478|OTHER|Questionnaire|No intervention only observational
57707779|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
57707780|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
57707781|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
57707782|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
57909650|NCT01809496|BEHAVIORAL|Informational Counseling|
57909651|NCT01809496|BEHAVIORAL|Patient Centered Counseling|
57909652|NCT02782546|PROCEDURE|Graft cell infusion|-Day 0
57909653|NCT02782546|DRUG|Tacrolimus|-GVHD prophylaxis
57909654|NCT02782546|DRUG|Mycophenolate mofetil|-GVHD prophylaxis
57909655|NCT02782546|DRUG|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
57909656|NCT02782546|PROCEDURE|CIML NK cell infusion|-Day +7
57909657|NCT02782546|DRUG|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
57909658|NCT02782546|PROCEDURE|Leukapheresis|-Day +6
57909659|NCT04858087|OTHER|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
57909660|NCT04688502|OTHER|High intensity interval training|High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
57909661|NCT04688502|OTHER|Continuous exercise training|5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
57909662|NCT03404687|RADIATION|ultrasound|for assessment of adnexal masses size and pattern
57909663|NCT03404687|DIAGNOSTIC_TEST|cancer antigen 125 level|for prediction of malignancy
57909664|NCT03404687|RADIATION|Doppler|for detection of blood flow
57909665|NCT02374671|DEVICE|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
57909666|NCT00267904|OTHER|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
57909667|NCT00267904|OTHER|Banana|Banana ingestion
57909668|NCT00267904|OTHER|Olives|Olives ingestion
57909669|NCT00267904|OTHER|Temp. manip.|Manipulate temperature at skin of the back
57909670|NCT02730637|OTHER|Early nephrologist consultation|
57909671|NCT05320432|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
57909672|NCT05320432|DEVICE|Sham|No current applied through pads.
57909673|NCT02130921|BEHAVIORAL|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
57909674|NCT02097901|PROCEDURE|Microfracture|Rotator Cuff Repair AND Microfracture
57909675|NCT02097901|PROCEDURE|NO microfracture|Rotator Cuff Repair without microfracture
57909676|NCT06441500|OTHER|Daily tooth brushing programme|Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
57707783|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
57707784|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
57707785|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
57707786|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
57707787|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
57707788|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
57909677|NCT02388243|BEHAVIORAL|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
58058191|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
58058192|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
58058193|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
58258608|NCT01645891|DEVICE|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
58258609|NCT01645891|DEVICE|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
58258610|NCT05073328|OTHER|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
58258611|NCT00904865|PROCEDURE|SPA cholecystectomy|SPA cholecystectomy
58258612|NCT00904865|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
58258613|NCT04811053|DRUG|HR021618|Treatment group A: HR021618 injection
58258614|NCT04811053|DRUG|Placebo|Treatment group B: Saline injection
58258615|NCT01583075|PROCEDURE|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
58258616|NCT01583075|PROCEDURE|single ring pulmonary vein ablation|single ring pulmonary vein ablation
58258617|NCT03440307|BEHAVIORAL|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
58058194|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
58258618|NCT03440307|BEHAVIORAL|Email Only|Participants received health and fitness education.
58258619|NCT01613222|DEVICE|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
58258620|NCT05093985|OTHER|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
58258621|NCT06263998|DRUG|NCP112|NCP112 topical ophthalmic solution
57707789|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
58258622|NCT06263998|DRUG|NCP112 Placebo|Placebo comparator
58258623|NCT01928342|DRUG|Coenzyme A|Coenzyme A 400mg per day
57707790|NCT02805335|DEVICE|KTFIX PLUS|
57707791|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
58058195|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
58058196|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
58258624|NCT01928342|DRUG|Placebo|Capsule without coenzyme A.
58258625|NCT05360446|DRUG|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
57707792|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
57707793|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
57707794|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
57707795|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
57707796|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
57707797|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
57707798|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
57707799|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
57707800|NCT04569045|DEVICE|HA+Lidocaine|20 mg
57707801|NCT04569045|DEVICE|HA|20 mg
57707802|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
57707803|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
57707804|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
57707805|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
57707806|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
57707807|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
58258626|NCT05360446|DRUG|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
57707808|NCT04199429|BEHAVIORAL|Relationship-Based Care|
57707809|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
57707810|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
57707811|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
57707812|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
57707813|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
57707814|NCT00004028|DRUG|carmustine|
57707815|NCT00004028|PROCEDURE|conventional surgery|
58058197|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
58058198|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
58058199|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
58258627|NCT05030194|OTHER|Electronic Cigarette|Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
58258628|NCT05030194|OTHER|Oral Nicotine Pouch|Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
58258629|NCT05893147|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
58258630|NCT05893147|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
57707816|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
57909678|NCT02388243|BEHAVIORAL|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
58381043|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
57909679|NCT02388243|BEHAVIORAL|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
57909680|NCT02388243|BEHAVIORAL|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
57909681|NCT02876276|PROCEDURE|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
57909682|NCT05849831|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
58258631|NCT05893147|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
58258632|NCT05893147|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
58381044|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
58381045|NCT01408277|PROCEDURE|Control|Standard Care
58381046|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
58381047|NCT06457477|DRUG|NAs|tablets
58381048|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
58381049|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
58381050|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
58381051|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
58058200|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
58058201|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
57707817|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
57909683|NCT01261637|DRUG|Saline placebo|20ml saline
57909684|NCT01261637|DRUG|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
57707818|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
57707819|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
57707820|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
57909685|NCT01810601|DRUG|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
57909686|NCT06208098|DIAGNOSTIC_TEST|Salivary cortisol dosage|saliva sample at 8 - 9h \& at T30
57909687|NCT02547259|PROCEDURE|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
57909688|NCT02547259|PROCEDURE|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
57909689|NCT01330173|DRUG|Vismodegib|Given PO
57909690|NCT01330173|OTHER|Pharmacological Study|Correlative studies
57909691|NCT01330173|OTHER|Laboratory Biomarker Analysis|Correlative studies
57909692|NCT05841732|OTHER|Usual Care|Education; Pain Medication, imaging, referrals to other health services, other health care appointments
57707821|NCT00019474|BIOLOGICAL|filgrastim|
58066596|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
58066597|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
58258633|NCT05893147|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
57707822|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
57707823|NCT00019474|DRUG|fluorouracil|
57909693|NCT05841732|OTHER|MyBack Program|A tailored exercise and behavioural change program
57909694|NCT02652923|DRUG|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
57909695|NCT04619940|DIAGNOSTIC_TEST|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
57909696|NCT04619940|DIAGNOSTIC_TEST|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
58066598|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
58066599|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
57707824|NCT00019474|DRUG|hydroxyurea|
57707825|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
57707826|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
57909697|NCT06116864|DEVICE|Endocuff and GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
57909698|NCT06116864|DEVICE|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
58258634|NCT05531578|DEVICE|INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)|Transfemoral implantation of the INOVARE® transcatheter valve
58258635|NCT03192618|PROCEDURE|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
58381052|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
58066600|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
58381053|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
58381054|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
58381055|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
58381056|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
58381057|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
58381058|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
58381059|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
58381060|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
58381061|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
58381062|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
58381063|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
58381064|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
58381065|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
58381066|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
58381067|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
58381068|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
58381069|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
57909699|NCT03068065|DRUG|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
57909700|NCT03068065|DRUG|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
58066601|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
58258636|NCT03192618|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
57707827|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
57707828|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
57707829|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
57707830|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
57707831|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
57707832|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
57707833|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
57707834|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
57707835|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
57707836|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
57707837|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
57707838|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
57707839|NCT02674412|DRUG|Buspirone|
57707840|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
57707841|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
57707842|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
57909701|NCT03068065|DRUG|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
58381070|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
57909702|NCT01830959|DRUG|Roflumilast|Roflumilast
57909703|NCT01830959|DRUG|Placebo|Placebo one a day
57909704|NCT06372873|OTHER|re-evaluate by two senior radiologists in our medical center|The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
57909705|NCT00398554|DRUG|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
57909706|NCT00398554|DRUG|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
57909707|NCT00398554|DRUG|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
57909708|NCT00398554|DRUG|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
57909709|NCT00398554|DRUG|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
57909710|NCT00398554|DRUG|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
57909711|NCT00398554|RADIATION|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
57909712|NCT00262951|BIOLOGICAL|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
57909713|NCT00262951|DRUG|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
57707843|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
57707844|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
57909714|NCT00262951|DRUG|fluorouracil|administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
57909715|NCT00262951|RADIATION|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
57909716|NCT00262951|PROCEDURE|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
57909717|NCT01627977|OTHER|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
58381071|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
58381072|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
57909718|NCT02440451|DEVICE|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
57909719|NCT06243393|DRUG|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG)
58066602|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
57707845|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
57707846|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
57707847|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
57707848|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
57707849|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
57707850|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
57707851|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
57707852|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
57707853|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
57707854|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
57707855|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
57707856|NCT01826162|OTHER|acetate or placebo infusion|
57909720|NCT06243393|DRUG|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
57909721|NCT01182467|RADIATION|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
58258637|NCT04629781|DRUG|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
58258638|NCT06268405|GENETIC|Liquid Biopsy|Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
58258639|NCT06268405|DEVICE|Positron Emission Mammography (PEM)|PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
58258640|NCT03839875|DRUG|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
58258641|NCT01040195|DRUG|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
58258642|NCT01040195|DRUG|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
58258643|NCT05484154|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
58258644|NCT05484154|OTHER|Placebo|Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
57707857|NCT00431171|DRUG|Lithium carbonate|
57707858|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
57909722|NCT05277103|BEHAVIORAL|Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD|The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
57909723|NCT01030406|DRUG|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
58258645|NCT05571644|DRUG|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
58258646|NCT05571644|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
58258647|NCT05571644|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
58258648|NCT05527093|RADIATION|MRI 3T and MRI 7T|MRI 3T and MRI 7T before and post epilepsy surgery
58381073|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
57707859|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
57707860|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
57707861|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
57707862|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
57707863|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
57707864|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
57707865|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
57707866|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
57707867|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
57707868|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
57707869|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
57707870|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
57707871|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
57707872|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
57707873|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
57909724|NCT01030406|DRUG|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
57909725|NCT01030406|DRUG|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
57707874|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
57909726|NCT01030406|DRUG|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
57909727|NCT01030406|DRUG|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
57909728|NCT00468104|DRUG|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
57909729|NCT00468104|DRUG|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
57909730|NCT03058029|DEVICE|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
57909731|NCT03058029|DEVICE|Placebo|Subject would take placebo capsules 2 times per day.
57909732|NCT03925545|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
57909733|NCT03925545|DEVICE|AcrySof IQ monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
57909734|NCT03925545|PROCEDURE|Cataract surgery|Standard cataract extraction with phacoemulsification
57909735|NCT03075410|DRUG|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
57909736|NCT03075410|DRUG|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
57909737|NCT01049932|DRUG|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
57909738|NCT00116883|DRUG|GW685698X aqueous nasal spray|
57707875|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
57707876|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
58258649|NCT04892693|DRUG|Talazoparib Oral Capsule|- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
58258650|NCT02533102|DRUG|E7050|100 mg tablet administered orally
58258651|NCT04660500|OTHER|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
57707877|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
57707878|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
57707879|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
57707880|NCT00274599|DRUG|Telmisartan|
57707881|NCT00274599|DRUG|Ramipril|
57707882|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
58258652|NCT01950104|OTHER|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
58258653|NCT01950104|OTHER|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
58258654|NCT05652179|DRUG|Stellate ganglion block|After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.
58258655|NCT05390528|DRUG|HLX301|HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
57707883|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
57707884|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
57707885|NCT00989833|DRUG|budesonide|400 yg x 1
57707886|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
57707887|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
58258656|NCT04995653|DRUG|Vancomycin Pre-Treatment|Four times daily dosing with Vancomycin
58258657|NCT04995653|DRUG|Vancomycin Placebo|Four times daily dosing with Vancomycin Placebo
58258658|NCT04995653|DRUG|SER-155|Once daily dosing with SER-155
58258659|NCT04995653|DRUG|SER-155 Placebo|Once daily dosing with SER-155 placebo
58258660|NCT02832375|DRUG|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
58258661|NCT02832375|DRUG|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
58258662|NCT06291922|BEHAVIORAL|Exercise Intervention|See arm description.
58258663|NCT06291922|BEHAVIORAL|Usual Care|See arm description.
58258664|NCT02956369|DIETARY_SUPPLEMENT|Control|Control granulates (maize starch and long-chain fatty acids) with powder
58258665|NCT02956369|DIETARY_SUPPLEMENT|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
58258666|NCT05157542|DRUG|Durvalumab|Day 1 and 22, 1500mg
58258667|NCT05157542|DRUG|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
57707888|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
57707889|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
57707890|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
57707891|NCT06108817|OTHER|No Intervention|These practices do not receive information material
57707892|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
57707893|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
57707894|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
57707895|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
57909739|NCT06231654|DEVICE|Remote photoplethysmography for physiological parameters|"Patients participating in the study will be recruited from our emergency department.~The child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient. The whole device is connected to our standard device. Once the child is immobile and ready, the Caducy® application is launched. At the same time, our standard device is activated. After 30 seconds, we will collect the HR and FR values revealed by the Caducy® application via the non-contact plethysmography method. On the other hand, it will collect the HR and FR values revealed by our standard device (Mindray® scope)."
57909740|NCT02686684|DRUG|Dimethyl fumarate|
57909741|NCT00003890|DRUG|MG 98|
57909742|NCT01417650|RADIATION|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
57909743|NCT01417650|RADIATION|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
58258668|NCT05157542|RADIATION|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
57707896|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
57707897|NCT02089061|DRUG|BMS-919373|
57707898|NCT02089061|DRUG|Rosuvastatin|
57707899|NCT02089061|DRUG|Atorvastatin|
57909744|NCT06610552|BEHAVIORAL|Powerly|Powerly is a mental well-being mobile app, in which pregnant women can track their mood and level of stress, and receive personalized psychological modules to increase their mental health and well-being. By integrating evidence-based content and cognitive behavioral techniques with insights from pregnant and postpartum individuals and health professionals, Powerly offers a comprehensive psychological support including reappraisal, mental imagery, gratitude, mindfulness, self-efficacy and behavioral activation exercises.
57909745|NCT03916939|OTHER|osteopathy|osteopathy treatment
57909746|NCT03916939|OTHER|simulated osteopathy|simulated osteopathic sessions
58258669|NCT03754855|BEHAVIORAL|Questionnaire|Questionnaire
58258670|NCT02181322|DRUG|Meloxicam - low dose|
58258671|NCT02181322|DRUG|Meloxicam - medium dose|
58258672|NCT02181322|DRUG|Meloxicam - high dose|
57707900|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
57707901|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
57909747|NCT02570685|BEHAVIORAL|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for.....
58381074|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
58381075|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
57909748|NCT02570685|BEHAVIORAL|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
57909749|NCT02570685|BEHAVIORAL|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
57909750|NCT03141723|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
58381076|NCT01022970|DRUG|QAX576 placebo|
57909751|NCT03141723|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
57909752|NCT03141723|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
57909753|NCT03141723|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\]
57909754|NCT06068595|OTHER|musculoskeletal ultrasound|After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
58066603|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
58066604|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
58066605|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
58381077|NCT01022970|DRUG|QAX576|
58381078|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
58381079|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
58381080|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
58381081|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
58381082|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
58381083|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
57707902|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
57707903|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
57707904|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
57707905|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
57707906|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
57707907|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
57707908|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
57707909|NCT04212468|OTHER|no intervention|no intervention
57707910|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
57707911|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
57909755|NCT04772482|DIAGNOSTIC_TEST|Sensitivity Patch Testing|Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
57909756|NCT01467726|DRUG|Velusetrag|Capsules
57909757|NCT01467726|DRUG|Velusetrag|Capsules
57909758|NCT01467726|DRUG|Placebo|Capsules
57909759|NCT01018303|DIETARY_SUPPLEMENT|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
57909760|NCT01744392|BEHAVIORAL|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
58058202|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
58381084|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
58381085|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
58381086|NCT00283543|DRUG|Gliadel Wafer|
58381087|NCT00283543|DRUG|Temozolomide|
57707912|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
57707913|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
57707914|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
57909761|NCT02850484|DRUG|Budesonide|Inhaled corticosteroid
57909762|NCT02850484|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
57909763|NCT04664543|OTHER|Free diet|To follow the regular dietary habits with no restriction nor modification.
57909764|NCT04664543|OTHER|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
57909765|NCT02825862|BEHAVIORAL|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
58066606|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
58381088|NCT00283543|PROCEDURE|Limited field radiation|
58258673|NCT04546009|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
58258674|NCT04546009|DRUG|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
58058203|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
58258675|NCT04546009|DRUG|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
58258676|NCT04546009|DRUG|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
58258677|NCT04546009|DRUG|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
58258678|NCT04546009|DRUG|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
58258679|NCT04649736|OTHER|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
58258680|NCT02031640|DRUG|Beclomethasone dipropionate|
58258681|NCT02031640|DRUG|Placebo|
58258682|NCT02031640|DRUG|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
58258683|NCT04566978|DRUG|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
58258684|NCT04566978|DIAGNOSTIC_TEST|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~* Within one to four hours following injection of tracer on Day 1~* 24-72 hours post-injection (Day 2-4)~* 20-168 hours post-injection (once during days 5-7)"
58258685|NCT02487771|DRUG|DHA|600 mg DHA capsule
58258686|NCT02487771|DRUG|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
58258687|NCT02247635|BEHAVIORAL|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
58066607|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
58258688|NCT00501124|DRUG|Clevudine|
58258689|NCT00501124|BIOLOGICAL|Purified hepatitis B surface antigen|
58258690|NCT03285503|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
58258691|NCT00559403|BEHAVIORAL|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
58381089|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
58381090|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
57707915|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
57707916|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
58381091|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
57707917|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
57707918|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
58381092|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
58381093|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
57707919|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
57707920|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
57707921|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
57707922|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
57707923|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
57707924|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
57707925|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
58258692|NCT00559403|BEHAVIORAL|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
58258693|NCT06648876|DRUG|YG1699|10mg qd for 8 days
58258694|NCT06648876|DRUG|Placebo|10mg qd for 8 days
58381094|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
58381095|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
58381096|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
57707926|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
57707927|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
57707928|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
58381097|NCT01745653|DEVICE|Low level laser therapy|
57707929|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
58058204|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
58058205|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
58258695|NCT06410495|BEHAVIORAL|NiteCAPP SINCC|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
58381098|NCT01745653|PROCEDURE|sham procedure|
57707930|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
57707931|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
57707932|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
57707933|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
57707934|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
58258696|NCT04502147|PROCEDURE|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
58258697|NCT06621589|BEHAVIORAL|Nutritional Counseling|The intervention involves nutritional counseling aimed at improving dietary habits and overall health to participants. During the 2-month period, participants will receive guidance on nutrition, diet planning, and lifestyle changes tailored to their needs. Assessments of knowledge, attitudes, and health metrics will be conducted before and after the counseling sessions to measure the effectiveness of the intervention
57707935|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
57707936|NCT00330291|DRUG|Xyrem|
58058206|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
57707937|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
58258698|NCT06142942|OTHER|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
57707938|NCT01791361|OTHER|Other|No intervention other than routine medical care
57707939|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
57707940|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
57707941|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
57707942|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
58258699|NCT03800836|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
57707943|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
57707944|NCT06323642|OTHER|placebo|milk as placebo
57707945|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
58058207|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
58058208|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
58058209|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
58258700|NCT03800836|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
58258701|NCT03800836|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
58258702|NCT03800836|DRUG|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of each 28 day cycle.
58258703|NCT03800836|DRUG|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
58381099|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
58258704|NCT04886089|DEVICE|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
57707946|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
58058210|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
58058211|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
58258705|NCT00720512|BIOLOGICAL|bevacizumab|Given IV
57707947|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
57707948|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
57707949|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
57909766|NCT02825862|BEHAVIORAL|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
58258706|NCT00720512|DRUG|fluorouracil|Given IV
58258707|NCT00720512|DRUG|irinotecan hydrochloride|Given IV
58258708|NCT00720512|DRUG|leucovorin calcium|Given IV
58258709|NCT00720512|DRUG|oxaliplatin|Given IV
58258710|NCT03946683|RADIATION|Cyberknife for Early Stage Breast Cancer|Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
58258711|NCT05896462|OTHER|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
58258712|NCT06667895|OTHER|respiratory gated taVNS|Electrical stimulation will be delivered in bursts during expiration
58381100|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
58381101|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
58258713|NCT06667895|OTHER|random burst stimulation|Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle
57707950|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
57707951|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
57707952|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
57707953|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
57707954|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
57707955|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
57707956|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
57909767|NCT00061139|BEHAVIORAL|Pediatric Constraint-Induced Movement therapy|
58258714|NCT06667895|OTHER|continuous stimulation|Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.
58258715|NCT06667895|OTHER|Sham stimulation|Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
58258716|NCT06619262|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
58258717|NCT06619262|DEVICE|Neuromuscular and Muscular Electrical Stimulation|Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
58258718|NCT06619262|OTHER|Exercise program|Specific exercise program for patients with lower extremity hemiparesis after stroke
58258719|NCT04748458|DEVICE|Conical tapered stem|Implantation of conical tapered stem
58381102|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
58381103|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
57707957|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
57707958|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
57707959|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
57707960|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
57707961|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
57909768|NCT00061139|BEHAVIORAL|Conventional pediatric motor rehabilitation therapy|
57909769|NCT04193124|DIAGNOSTIC_TEST|transcranial doppler.|Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
58258720|NCT06620796|DRUG|Arm 1|Ivonescimab combined with Cadonilimab plus EC
58258721|NCT06620796|DRUG|second-line group|AK112+AK104+paclitaxel
58258722|NCT04679636|BEHAVIORAL|heart rate variability biofeedback|receive biofeedback training for heart rate variability for eight weeks
58258723|NCT05220462|DRUG|Remimazolam|As per Remimazolam arm
58258724|NCT05220462|DRUG|Midazolam|As per Midazolam arm
58258725|NCT05761210|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
58381104|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
57707962|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
57707963|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
57707964|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
57707965|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
57707966|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
57707967|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
57707968|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
58066608|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
58258726|NCT06537076|DRUG|AR1005|AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
57707969|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
57707970|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
57707971|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
57707972|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
57707973|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
57707974|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
57707975|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
58258727|NCT06537076|DRUG|Placebo|Matching placebo for AR1005 to be administered BID for 20 weeks
57909770|NCT04029194|BEHAVIORAL|Assistance with old age pension application|The intervention will offer elderly assistance in applying for the old age pension.
57707976|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
57707977|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
58258728|NCT06537076|DRUG|Rivastigmine 3 mg|3mg Rivastigmine will be administered BID for both active and placebo groups
57707978|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
57707979|NCT02410720|OTHER|Picoprep solution|
58066609|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
58066610|NCT00000894|DRUG|Cidofovir|
58066611|NCT00000894|DRUG|Probenecid|
58066612|NCT00000894|DRUG|Ganciclovir|
57707980|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
57707981|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
58058212|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
58058213|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
57707982|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
58058214|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
58058215|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
58058216|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
58258729|NCT01785719|BEHAVIORAL|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
57707983|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
57707984|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
57707985|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
57707986|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
57707987|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
58058217|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
58058218|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
58058219|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
58058220|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
58058221|NCT01893879|DRUG|placebo for study drug|Given PO
58058222|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
57707988|NCT03458130|DRUG|AG10|TTR stabilizer
57707989|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
57707990|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
57707991|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
57707992|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
57707993|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
57707994|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
57707995|NCT03470337|OTHER|Placebo|
57909771|NCT00619333|DRUG|follitropin and lutropin|follitropin and lutropin
58058223|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
58066613|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
58258730|NCT06265701|BEHAVIORAL|Derailment-Focused Reflective Journaling|Experimental group aimed at decreasing anxiety symptoms
58258731|NCT06265701|OTHER|Everyday Tasks Reflective Journaling|Control group
58258732|NCT06647719|OTHER|Educational Videos|Subjects in the experimental group will be provided with 3 links to videos to be watched after CTR surgery. These videos will be available through YouTube, Twitter, Facebook, Instagram, TikTok, or MyChart. Videos will be available to watch multiple times at the subjects choice.
58258733|NCT05367284|DRUG|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
58258734|NCT03891862|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
58258735|NCT03891862|DRUG|Placebo oral capsule|non-active dosage form
58258736|NCT02210247|DRUG|EXPAREL|
58258737|NCT05892718|DRUG|HCB101|HCB101 administered via. intravenous (IV) infusion.
58258738|NCT01775358|DRUG|ALRN-5281 0.015 mg/kg|
58258739|NCT01775358|DRUG|ALRN-5281 0.05 mg/kg|
58258740|NCT01775358|DRUG|ALRN-5281 0.15 mg/kg|
58258741|NCT01775358|DRUG|Placebo 0.015 mg/kg|
58258742|NCT01775358|DRUG|Placebo 0.05mg/kg|
58258743|NCT01775358|DRUG|Placebo 0.15mg/kg|
58258744|NCT05749770|OTHER|blood testing|blood testing for basal hormones and markers of inflammation
58258745|NCT03108170|OTHER|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
58258746|NCT03108170|OTHER|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
57707996|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
58066614|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
58066615|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
58066616|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
58258747|NCT03108170|OTHER|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
58258748|NCT03403751|DRUG|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
58258749|NCT03403751|DRUG|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
58258750|NCT00046852|BIOLOGICAL|filgrastim|
58258751|NCT00046852|BIOLOGICAL|pneumococcal polyvalent vaccine|
58258752|NCT00046852|BIOLOGICAL|therapeutic autologous lymphocytes|
58258753|NCT00046852|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58381105|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
58381106|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
57707997|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
57707998|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
57707999|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
57909772|NCT02845362|OTHER|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
57909773|NCT06062290|DEVICE|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
58258754|NCT00046852|DRUG|carmustine|
58258755|NCT00046852|DRUG|cyclophosphamide|
58258756|NCT00046852|DRUG|melphalan|
57909774|NCT06062290|DEVICE|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
58258757|NCT00046852|PROCEDURE|bone marrow ablation with stem cell support|
58258758|NCT00046852|PROCEDURE|peripheral blood stem cell transplantation|
58258759|NCT01328899|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
58258760|NCT03706885|DRUG|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
58258761|NCT00375050|DRUG|Riluzole|
58258762|NCT00375050|DRUG|Placebo|placebo
58258763|NCT00311519|DRUG|Hylenex|
58258764|NCT02704520|DIAGNOSTIC_TEST|High resolution MRI scan|MRI reporting of tumour but not mrTRG in the control arm = standard of care
58258765|NCT02704520|DIAGNOSTIC_TEST|mrTRG assessment|Watch and wait offered for good responders Consider further treatment for poor responders
58258766|NCT03902717|PROCEDURE|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
58258767|NCT01426464|DRUG|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
58258768|NCT01685489|DRUG|Docetaxel, PSK®|
58258769|NCT01685489|DRUG|Docetaxel, Placebo|
58258770|NCT04495504|DRUG|Ropivacaine|Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
57708000|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
58258771|NCT02721524|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
58258772|NCT04186702|PROCEDURE|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
58258773|NCT00129727|DRUG|Paclitaxel|Given intravenously
58258774|NCT00129727|DRUG|Carboplatin|Given intravenously
58258775|NCT00129727|DRUG|Bevacizumab|Given intravenously
58258776|NCT00372723|DRUG|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
58258777|NCT06358209|PROCEDURE|Ventricular irrigation|Dual-catheter ventricular irrigation, with the lavage catheter placed in the frontal horn of lateral ventricle, and the drainage catheter placed through another burr hole in the ipsilateral occipital horn or in the contralateral ventricle. Lavage is performed twice daily, with each time 500ml of saline over a duration of one hour. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open.
58258778|NCT06622759|PROCEDURE|CTG|Connective Tissue Graft has been widely used around implants to increase either the thickness of the soft tissues or the width of keratinized tissues. It is considered the gold standard for soft tissue grafting. The main drawbacks are the donor morbidity and the limit amount of intraoral donor sites. In this study it will be used in the test 1 group in order to compare its clinical results with the other groups.
58258779|NCT06622759|PROCEDURE|Collagen Matrix|Collagen matrix has been used in several studies in order to evaluate its clinical properties over the last years. In this study, the graft will be placed buccally at the time of implant placement in the aesthetic zone in order to assess its clinical and radiographic properties in terms of buccal bone resorption and soft tissue augmentation. Histological assessment and Patient Reported outcomes will also be evaluated.
57708001|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
57708002|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
58058224|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
58058225|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
58258780|NCT06622759|PROCEDURE|Control group|In the control group, the implant will be placed without any kind of soft tissue graft in order to compare this treatment modality that many clinicians apply at the clinical practice.
58258781|NCT01603745|DRUG|Zoely|1 pill every day
58258782|NCT01603745|DRUG|Yasmin|1 pill every day
58258783|NCT01647516|DRUG|Ozanimod|Ozanimod capsules by mouth daily.
58258784|NCT01647516|DRUG|Placebo|
58258785|NCT04939012|BEHAVIORAL|MyPath Intervention|MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
58258786|NCT04939012|BEHAVIORAL|Usual care|Standard of Care
58258787|NCT06345157|DRUG|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
58258788|NCT00542906|OTHER|localization|localization of the several types of somatosensory stimuli
57708003|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
58258789|NCT06621173|DRUG|HNF4α srRNA|HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
58381107|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
58258790|NCT03855020|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
58381108|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
57708004|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
57708005|NCT02131480|DRUG|Doxorubicin|60 mg/m²
57708006|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
58258791|NCT03579186|DEVICE|OKS|Optokinetic stimulation
57708007|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
58058226|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
58258792|NCT03996174|OTHER|Interview|Interview bases on the use of an interview guide, during one hour maximum
58258793|NCT03425682|OTHER|ViBone|Viable Bone Allograft
58258794|NCT00154804|DRUG|Paclitaxel, Cisplatin,Surgery, CCRT|
58258795|NCT02205008|PROCEDURE|surgery|Total or subtotal gastrectomy with D2
57708008|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
57708009|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
57708010|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
57708011|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
57708012|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
57708013|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
57708014|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
57708015|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
57708016|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
57708017|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
57708018|NCT02244203|DRUG|BI 60732|
57708019|NCT02244203|DRUG|Placebo|
57708020|NCT03791866|OTHER|Nutrition|Enteral nutrition
57708021|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
57708022|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
58258796|NCT02205008|DRUG|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
58258797|NCT02205008|DRUG|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
58258798|NCT01953874|DEVICE|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
58258799|NCT01953874|DRUG|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
58258800|NCT04231877|DRUG|Polatuzumab Vedotin|Given IV
57708023|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
57708024|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
57708025|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
57708026|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
57708027|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
58058227|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
58258801|NCT04231877|BIOLOGICAL|Rituximab|Given IV
58258802|NCT04231877|DRUG|Prednisone|Given PO
58258803|NCT04231877|DRUG|Etoposide|Given IV
58258804|NCT04231877|DRUG|Doxorubicin|Given IV
58258805|NCT04231877|DRUG|Cyclophosphamide|Given IV
57708028|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
58058228|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
58258806|NCT04231877|BIOLOGICAL|Glofitamab|Given IV
58258807|NCT04231877|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
57708029|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
58258808|NCT04231877|PROCEDURE|Echocardiography|Undergo echocardiography
58258809|NCT04231877|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET scan
57708030|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
57909775|NCT05939141|DEVICE|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
58258810|NCT04231877|PROCEDURE|Computed Tomography|Undergo CT scan
58258811|NCT04231877|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58258812|NCT04231877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58258813|NCT04231877|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58258814|NCT04322019|OTHER|Data record|Data record
58258815|NCT06622746|PROCEDURE|Endoscopic Hand Suturing|Endoscopic Hand Suturing is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
58258816|NCT02963558|DEVICE|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
57909776|NCT04995939|PROCEDURE|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
57909777|NCT00184665|DRUG|insulin detemir|
57909778|NCT00184665|DRUG|insulin NPH|
57708031|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
57909779|NCT00184665|DRUG|insulin aspart|
58058229|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
58258817|NCT03580408|DRUG|Nivolumab|240 mg
58258818|NCT03580408|DRUG|Vinblastin|6mg/m²
58258819|NCT04981834|OTHER|Quality-of-Life Assessment|Ancillary studies
58258820|NCT04981834|OTHER|Questionnaire Administration|Ancillary studies
58258821|NCT04981834|PROCEDURE|Radical Prostatectomy|Undergo RARP
58258822|NCT04981834|PROCEDURE|Vesicopexy|Undergo vesicopexy
58258823|NCT01968707|DRUG|ChloraPrep Hi-Lite Orange|Apply topically.
58258824|NCT01968707|DRUG|Normal saline|Apply topically.
58258825|NCT01968707|DRUG|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
58258826|NCT01968707|DRUG|3M CHG/IPA Prep Tint 26-mL|Apply topically
58258827|NCT02985606|OTHER|Caffeine powder -60|
58258828|NCT02985606|OTHER|Caffeine powder -30|
58258829|NCT02985606|OTHER|Caffeine powder 0|
58258830|NCT02985606|OTHER|Placebo powder -60|
57708032|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
58258831|NCT02985606|OTHER|Placebo powder -30|
58381109|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
57708033|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
57708034|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
58258832|NCT02985606|OTHER|Placebo powder 0|
57708035|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
58058230|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
58258833|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
58258834|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
58258835|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
58258836|NCT02637895|DRUG|Placebo|Placebo pill matching Vortioxetine.
58258837|NCT02637895|DRUG|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
58258838|NCT03298945|DRUG|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
58381110|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
58381111|NCT00915889|OTHER|counseling intervention|counseling and communications studies
58381112|NCT00915889|OTHER|questionnaire administration|Ancillary studies
58381113|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
58058231|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
58058232|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
58058233|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
57708036|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
57708037|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
57708038|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
57708039|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
58066617|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
58258839|NCT03298945|DRUG|Golytely|4-L split dose Golytely is the current standard prep at the VA
58258840|NCT03814512|BEHAVIORAL|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
58258841|NCT01684982|DEVICE|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
58258842|NCT01684982|DEVICE|sirolimus eluting stent|control arm of a comparison between drug eluting stents
58258843|NCT06354361|BEHAVIORAL|Trauma-Informed Goal Management Training (TI-GMT)|"Trauma Informed-Goal Management Training (TI-GMT) is a modified version of Goal Management Training (GMT), a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours. TI-GMT enhances the standard GMT protocol with the addition of several trauma-informed adaptations and content that is sensitive and specific to public safety personnel with PTSD.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
57708040|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
57708041|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
58381114|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
57909780|NCT03170349|DEVICE|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
58058234|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
58258844|NCT06354361|BEHAVIORAL|Goal Management Training (GMT)|"Goal Management Training (GMT) is a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
58258845|NCT06510556|DEVICE|Ablation Treatment|Subjects scheduled to undergo endocardial mapping and ablation therapy in the treatment of persistent atrial fibrillation. Ablation of the pulmonary veins and left atrial posterior wall will be performed; ablation of the cavo-tricuspid isthmus (CTI) is at the discretion of the investigator.
57708042|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
57708043|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
57708044|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
57708045|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
57909781|NCT00714545|RADIATION|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
57909782|NCT05979350|DIAGNOSTIC_TEST|Metagenomic next-generation sequencing|Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
58058235|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
58058236|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
57909783|NCT05979350|DIAGNOSTIC_TEST|Standard work-up for pneumonia|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
58058237|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
58258846|NCT03589976|DRUG|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
57708046|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
57708047|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
58258847|NCT03589976|OTHER|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
58258848|NCT02988440|DRUG|PDR001|PDR001 will be administered intravenously
57708048|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
57708049|NCT01103934|DRUG|Placebo|Placebo taken once daily
58258849|NCT02988440|DRUG|Sorafenib|Sorafenib is formulated as a tablet.
58258850|NCT06619613|BIOLOGICAL|Alzheimer Disease (AD)|CM383 injection
58258851|NCT06619613|OTHER|Placebo|Matched placebo
58258852|NCT02856607|OTHER|determine the prognosis of threated patients according to the clinical care pathway.|
58258853|NCT05299944|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in opioid consumption, opioid craving, pain, peripheral markers of inflammation, and anxiety, as well as changes in sleep, AEA, and cognition.
58258854|NCT05299944|DRUG|Placebo|Placebo arm
58258855|NCT05483101|OTHER|Alternative birth units|"Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room."
58258856|NCT00226668|DRUG|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
58258857|NCT00226668|DRUG|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
58258858|NCT01054300|DRUG|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
58258859|NCT01054300|DRUG|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
58258860|NCT01054300|DRUG|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
57708050|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
58258861|NCT01054300|DRUG|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
58258862|NCT01054300|DRUG|Placebo|Placebo to ertugliflozin administered as a single dose
58058238|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
58058239|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
58058240|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
57708051|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
57708052|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
57708053|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
57708054|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
57708055|NCT01703793|DRUG|Test Product 49778|
57708056|NCT01703793|DRUG|Test Product 10156|
57708057|NCT01703793|DRUG|Vehicle (placebo)|
57708058|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
58058241|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
58058242|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
58058243|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
58058244|NCT03858855|OTHER|Subject Diary|Complete journal
58058245|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
58258863|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
58258864|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
58258865|NCT06221592|DEVICE|defocus spectacle lenses|To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
57708059|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
57708060|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
57909784|NCT06322979|PROCEDURE|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
58058246|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
57708061|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
57909785|NCT06322979|PROCEDURE|Premixed Bioceramic Putty|Apexification treatment was done with Premixed Bioceramic Putty (Well-Root™ PT)
58258866|NCT01393509|DRUG|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
57909786|NCT01358487|BEHAVIORAL|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
57909787|NCT01358487|BEHAVIORAL|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
57909788|NCT05503472|OTHER|observational|observational
58258867|NCT02698202|DEVICE|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
58258868|NCT06622629|OTHER|Nature based Therapy (NbT): Planned therapeutic techniques performed in natural settings and based on nature-human active participation and connection|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application App, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
58258869|NCT06622629|OTHER|Nature based Therapy (NbT)|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application MyCap app, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
58258870|NCT03581734|BIOLOGICAL|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
58258871|NCT03581734|BIOLOGICAL|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
57708062|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
57708063|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
57708064|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
57708065|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
57708066|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
57909789|NCT01225419|DRUG|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
57909790|NCT01119599|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
57909791|NCT01119599|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
57909792|NCT01119599|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57909793|NCT01119599|OTHER|Laboratory Biomarker Analysis|Correlative studies
57909794|NCT01119599|OTHER|Pharmacological Study|Correlative studies
58058247|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
58258872|NCT01171781|DRUG|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
58258873|NCT01171781|DRUG|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
58258874|NCT03122743|PROCEDURE|Biospecimen Collection|Undergo collection of serum samples
58258875|NCT03122743|OTHER|Laboratory Biomarker Analysis|Correlative studies
58258876|NCT03122743|OTHER|Questionnaire Administration|Ancillary studies
58258877|NCT00564837|PROCEDURE|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
58258878|NCT00564837|PROCEDURE|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
58258879|NCT05204160|BIOLOGICAL|Pembrolizumab|Given IV
58258880|NCT01537874|BEHAVIORAL|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
58258881|NCT01537874|BEHAVIORAL|Usual best practices|Standard care delivered using informational materials
57909795|NCT01119599|DRUG|Temozolomide|Given PO
57909796|NCT01119599|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57909797|NCT03861208|OTHER|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
57909798|NCT03861208|OTHER|usual diet|foods representing the usually provided foods at childcare are offered
57909799|NCT02703051|DRUG|GMI-1271|
57909800|NCT02703051|DRUG|Filgrastim|
57909801|NCT02703051|DRUG|Placebo Injection|
57909802|NCT02703051|DRUG|Placebo Infusion|
57909803|NCT02439047|PROCEDURE|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction"
57909804|NCT03715179|DEVICE|Ostomy Pouching System|An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder), specifically from a stoma. No intervention is administered during the course of this study.
57909805|NCT03188393|PROCEDURE|Biopsy of Breast|Undergo stereotactic biopsy
57909806|NCT01475279|DRUG|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
57909807|NCT04504604|DIAGNOSTIC_TEST|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
58058248|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
58258882|NCT01628796|OTHER|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
58258883|NCT03138252|DRUG|Oxytocin|
58258884|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
58258885|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
58258886|NCT00380081|DRUG|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
58258887|NCT06618872|DIAGNOSTIC_TEST|PET/CT with RO958 (experimental)|the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)
58258888|NCT00658775|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
58258889|NCT00658775|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
58258890|NCT06245525|OTHER|This is not an interventional study|This is not an interventional study
58258891|NCT06206551|OTHER|Spiritual Needs Questionnaire|This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
58258892|NCT01463592|BIOLOGICAL|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
58258893|NCT01463592|DRUG|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
57708067|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
57708068|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
58258894|NCT01463592|BIOLOGICAL|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
58258895|NCT02836236|DRUG|TAF|TAF 25 mg tablet administered orally once daily
58258896|NCT02836236|DRUG|TDF|TDF 300 mg tablet administered orally once daily
58258897|NCT02836236|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
57708069|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
57708070|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
57708071|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
58258898|NCT02836236|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
58258899|NCT05035667|OTHER|Questionnaire Administration|Complete questionnaires
58258900|NCT04631484|DRUG|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
58258901|NCT04631484|DRUG|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
58258902|NCT06621134|OTHER|AI Chatbot|Participants will be required to provide consent for randomization when they first access our system. Users can ask questions covered by the question bank, as well as specific questions not covered by the bank, through an AI chatbox. The aim is to understand the significant difference between using AI chatbots and telephone hotlines to assist parents, as well as the effectiveness of AI chatbots compared to telephone hotlines.
57708072|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
57708073|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
57708074|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
57708075|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
57708076|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
57708077|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
57708078|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
57909808|NCT04463316|DIAGNOSTIC_TEST|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
57909809|NCT00950586|DRUG|GSK1043702|Oral dose in liquid or tablet formulation
58258903|NCT06621134|OTHER|Telephone hotline|Participants will be asked to consent to randomization on their first access to our system. Users ask questions covered by the question bank and specific questions not covered by the question through a telephone hotline.
58258904|NCT04773184|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
58258905|NCT04773184|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
58258906|NCT04773184|PROCEDURE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
58258907|NCT04773184|PROCEDURE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
57708079|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
58258908|NCT04773184|PROCEDURE|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
58381115|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
57909810|NCT00950586|DRUG|Dextromethorphan|30mg Oral dose
58258909|NCT04773184|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
57909811|NCT00950586|DRUG|Placebo|To match GSK1034702
58258910|NCT04773184|OTHER|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
58258911|NCT04456868|BEHAVIORAL|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
58258912|NCT04456868|BEHAVIORAL|walking test|8-Meter walking test will be done for gait parameter assessment
58381116|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
58381117|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
58258913|NCT04456868|BEHAVIORAL|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
58381118|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
58381119|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
58381120|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
57909812|NCT04866251|DIAGNOSTIC_TEST|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
58381121|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
57909813|NCT03268525|DRUG|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
57909814|NCT03268525|DRUG|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
58258914|NCT04456868|PROCEDURE|Position emission tomography|Position emission tomography will be done for
57909815|NCT03756129|DRUG|MIJ821|Different dosages and different regimen for MIJ821
57909816|NCT03756129|DRUG|Placebo|Infusion
57909817|NCT03756129|DRUG|Ketamine|Infusion
57909818|NCT04463966|DRUG|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
57909819|NCT02355080|BEHAVIORAL|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
57909820|NCT02355080|BEHAVIORAL|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
58258915|NCT01700075|DRUG|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
58258916|NCT01700075|DIETARY_SUPPLEMENT|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
58258917|NCT01176695|DRUG|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
57909821|NCT02734927|OTHER|realization of computerized exercises|
57909822|NCT04971681|DEVICE|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
58058249|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
58058250|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
58058251|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
58058252|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
58258918|NCT01176695|DRUG|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
58258919|NCT02449317|OTHER|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr"
58258920|NCT02449317|OTHER|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
58258921|NCT04360174|DRUG|OTX-TIC|OTX-TIC implant is injection in the anterior chamber of the eye
58258922|NCT03219359|PROCEDURE|Autologous stem cell transplant|Hematopoietic stem cell transplantation
58381122|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
58381123|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
58381124|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
58381125|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
57909823|NCT04971681|DEVICE|Sham|The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
57909824|NCT06235944|PROCEDURE|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
57909825|NCT06235944|PROCEDURE|Sacral erector spinae block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
58258923|NCT03219359|DRUG|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
58258924|NCT03219359|DRUG|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
58258925|NCT03219359|DRUG|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
58258926|NCT03219359|DRUG|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
58258927|NCT03219359|DRUG|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
58258928|NCT03692975|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
58258929|NCT03692975|OTHER|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
58058253|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
58258930|NCT03692975|OTHER|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
58258931|NCT03692975|DEVICE|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
58381126|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
58381127|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
58381128|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
58381129|NCT00080574|PROCEDURE|Skin Biopsy|
57909826|NCT04108052|RADIATION|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
58058254|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
58258932|NCT06219291|OTHER|Observational|Observation of the natural course of the disease
57909827|NCT04108052|RADIATION|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index\>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
58058255|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
58058256|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
58058257|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
58258933|NCT06647563|BIOLOGICAL|Toripalimab|Specified dose on specified days
58258934|NCT06647563|BIOLOGICAL|Cetuximab|Specified dose on specified days
58258935|NCT06647563|DRUG|Albumin-Bound Paclitaxel|Specified dose on specified days
58058258|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
58058259|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
58058260|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
58058261|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
58058262|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
58058263|NCT02839655|DEVICE|Da Vinci Xi|
58058264|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
58058265|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
58058266|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
58066618|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
58258936|NCT06647563|DRUG|Carboplatin|Specified dose on specified days
58381130|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
58381131|NCT01673659|DRUG|Mometasone furoate|
58066619|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
58381132|NCT01673659|DRUG|Nasonex Nasal Spray|
58381133|NCT01673659|DRUG|Placebo nasal spray|
58381134|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
58258937|NCT06647563|DRUG|Cisplatin|Specified dose on specified days
58258938|NCT06647563|RADIATION|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
58258939|NCT06647563|RADIATION|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
58258940|NCT06647563|RADIATION|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
58258941|NCT05764733|DRUG|Bisphosphonate|Medicine used to treat bone problems, called osteopenia or osteoporosis.
58066620|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
58258942|NCT05764733|BEHAVIORAL|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
57909828|NCT02849522|PROCEDURE|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
58066621|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
58258943|NCT05764733|OTHER|Placebo|Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
58258944|NCT00725608|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
58258945|NCT06618989|OTHER|Blood sampling and follow-up call|An additional 1.5 mL of blood will be collected at the time of the child care in the pediatric emergency department. In addition, a telephone call for patient follow-up (unless still hospitalized) will be done.
58258946|NCT02541669|DRUG|TAK-491|TAK-491 tablets
58258947|NCT02541669|DRUG|TAK-491 placebo|TAK-491 placebo-matching tablets
58258948|NCT06307496|OTHER|Smoking cessation intervention|Receive links to smoking cessation videos
58258949|NCT06307496|OTHER|Informational intervention|"Receive NCI's Clearing the Air booklet"
58258950|NCT05341206|DRUG|Herbal gargle|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
58258951|NCT05341206|OTHER|Normal saline|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
58258952|NCT06619353|DIAGNOSTIC_TEST|Blood Sample|Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.
58258953|NCT06619353|OTHER|DICOM Dataset|Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.
58258954|NCT01048060|PROCEDURE|Bone marrow specimen banking|
58258955|NCT02111746|DRUG|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
58258956|NCT02111746|DRUG|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
58258957|NCT02111746|DRUG|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
58258958|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix|The 25g MCT-based nutrient mix will be consumed two hours after breakfast.
58258959|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix + cofactors|The 25g MCT-based nutrient mix + cofactors will be consumed two hours after breakfast.
58258960|NCT06511206|DIETARY_SUPPLEMENT|non-ketogenic control|The non-ketogenic control will be consumed two hours after breakfast.
58058267|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
58258961|NCT01298726|OTHER|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
58258962|NCT01298726|OTHER|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
58381135|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
58381136|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
58381137|NCT00259844|BIOLOGICAL|TroVax|
58381138|NCT06512779|OTHER|Control Group|sleep hygiene education
58381139|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
58381140|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
58381141|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
58381142|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
58381143|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
57708080|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
57708081|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
58058268|NCT05143645|OTHER|Plasma vancoymcin measurements|
58058269|NCT00485121|DRUG|Ezetimibe|
58058270|NCT06410729|OTHER|Observational study, no intervention|
58258963|NCT06617611|PROCEDURE|Surgical intervention and anesthesia|Any surgical procedure
58258964|NCT04805697|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
58258965|NCT04805697|DIETARY_SUPPLEMENT|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
58258966|NCT00282906|DEVICE|hybrid PET-CT imaging system|15 mCi of FDG
58381144|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
58258967|NCT05846399|DRUG|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
58258968|NCT05846399|DRUG|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
57708082|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
58381145|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
58381146|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
58381147|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
58381148|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
58381149|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
58381150|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
57708083|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
57708084|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
57909829|NCT02849522|PROCEDURE|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
57909830|NCT02849522|PROCEDURE|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
57909831|NCT02849522|PROCEDURE|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
57909832|NCT03129139|DRUG|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
58058271|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
58058272|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
58058273|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
58058274|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
58381151|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
57909833|NCT01375231|PROCEDURE|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
57909834|NCT01375231|PROCEDURE|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
57909835|NCT06611319|DRUG|Prevention of Venous Thromboembolism|Direct oral anticoagulant
57909836|NCT06611319|DRUG|Placebo Oral Tablet|Placebo
58258969|NCT05846399|DRUG|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
58258970|NCT05846399|OTHER|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
58258971|NCT05846399|PROCEDURE|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
58381152|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
57909837|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
57909838|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
57909839|NCT05216887|BIOLOGICAL|Aducanumab|Administered as specified in the treatment arm.
57909840|NCT05330312|DEVICE|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
57909841|NCT01498029|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
58258972|NCT04305249|DRUG|ATG-017|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
58258973|NCT04305249|DRUG|ATG-017+Nivolumab|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
58258974|NCT01389479|BIOLOGICAL|Fluviral™|Intramuscular, single dose
58258975|NCT01389479|BIOLOGICAL|Fluzone®|Intramuscular, single dose
57708085|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
57708086|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
57909842|NCT01498029|DEVICE|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
57909843|NCT00646633|PROCEDURE|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
58058275|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
58058276|NCT02607865|DRUG|semaglutide|Oral administration once-daily
58058277|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
58058278|NCT02607865|DRUG|placebo|Oral administration once-daily
58058279|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
58258976|NCT04042922|DEVICE|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
58258977|NCT04042922|DEVICE|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
58381153|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
57708087|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
57708088|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
57708089|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
57708090|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
57708091|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
57708092|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
57708093|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
57708094|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
57708095|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
57708096|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
57708097|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
57708098|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
57708099|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
58058280|NCT02499172|BIOLOGICAL|Shanchol|
58058281|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
58058282|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
58058283|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
58058284|NCT01369667|OTHER|Placebo|
58058285|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
58058286|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
58058287|NCT04607291|OTHER|Survey Administration|Ancillary studies
58258978|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
58258979|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
58058288|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
58058289|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
58058290|NCT01173328|BEHAVIORAL|Normal Breathing|
58058291|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
58381154|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
57909844|NCT06202586|PROCEDURE|low FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
57909845|NCT06202586|PROCEDURE|high FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
57909846|NCT00130624|PROCEDURE|Multidisciplinary intervention: primary or secondary care|
57909847|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
57909848|NCT00000145|DIETARY_SUPPLEMENT|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
58058292|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
58058293|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
58058294|NCT02169466|DRUG|Placebo|PLC, Placebo
58058295|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
58058296|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
58058297|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
58381155|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
57708100|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
58058298|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
58258980|NCT04653337|COMBINATION_PRODUCT|Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
58258981|NCT03361865|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
58258982|NCT03361865|DRUG|Epacadostat|Epacadostat administered orally twice daily.
58381156|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
58381157|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
58381158|NCT00661830|DRUG|Placebo|Placebo
58381159|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
58381160|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
57909849|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
58058299|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
58258983|NCT03361865|DRUG|Placebo|Matching placebo administered orally twice daily.
58258984|NCT06618222|DEVICE|Wingspan stent system|All patients had received Percutaneous transluminal angioplasty and stenting with Wingspan stent system.
58258985|NCT06605222|DRUG|SHR-7787 injection|Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
58258986|NCT00841347|BEHAVIORAL|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
58258987|NCT00841347|BEHAVIORAL|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
58258988|NCT05273060|PROCEDURE|3D Nasal Reconstruction Planning|3D molds or models to use in the reconstruction of nasal cartilage
58258989|NCT05481723|DRUG|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
58258990|NCT05481723|PROCEDURE|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
58258991|NCT04070690|PROCEDURE|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
57708101|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
57708102|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
57708103|NCT01586468|DRUG|NaCl Solution|NaCl Solution
57909850|NCT00972205|DRUG|paclitaxel|Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
57909851|NCT00972205|DRUG|CBT-1(Registered Trademark)|CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
58258992|NCT02780024|DRUG|Metformin|Metformin,
58258993|NCT06646328|PROCEDURE|Central venous access|Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
58258994|NCT06646328|DEVICE|Pump-assisted circuit|The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
58381161|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
57708104|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
57708105|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
57708106|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
57708107|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
57708108|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
57708109|NCT00052728|DRUG|tamoxifen citrate|
58058300|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
58058301|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
58058302|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
58058303|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
58058304|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
58058305|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
58058306|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
58058307|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
58258995|NCT06646328|DRUG|Heparin sodium|Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
58258996|NCT06646328|OTHER|Regional citrate anticoagulation|Regional citrate anticoagulation will be used in the other arm with an initial dose of 3 mmol/L and with a calcium reinfusion solution at an initial dose of 2 mmol/L, with adaptation of both infusions to the patient ionic calcium levels.
58258997|NCT06646328|PROCEDURE|Blood and ultrafiltrate samples|"Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein."
58258998|NCT04760041|DRUG|Midazolam nebulized|midazolam nebulized
58258999|NCT04760041|DRUG|Midazolam oral solution|midazolam given oral
58381162|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
58381163|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
58381164|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
58381165|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
57708110|NCT00052728|DRUG|tipifarnib|
58058308|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
58058309|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
58058310|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58058311|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
58259000|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
58259001|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
58259002|NCT03141229|BEHAVIORAL|Mindfulness based stress reduction|
57909852|NCT00972205|RADIATION|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
57909853|NCT04982237|BIOLOGICAL|AK104|IV infusion
57909854|NCT04982237|DRUG|paclitaxel|IV infusion
57909855|NCT04982237|DRUG|carboplatin|iv infusion
57909856|NCT04982237|DRUG|cisplatin|iv infusion
57909857|NCT04982237|DRUG|bevacizumab|iv infusion
57909858|NCT04982237|DRUG|Placebo|iv infusion
58259003|NCT04536857|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
58259004|NCT06649422|DRUG|Blinatumomab|The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
58381166|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
58381167|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
57708111|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
57708112|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
58381168|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
57708113|NCT00113737|DRUG|fluoxetine|
57708114|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
57708115|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
57909859|NCT06196632|DRUG|Peginterferon-α; Nucleoside analogs|Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
57909860|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
57909861|NCT00790816|DRUG|Lapatinib|Lapatinib monotherapy
57909862|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
57909863|NCT04130763|BIOLOGICAL|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
57909864|NCT02617303|PROCEDURE|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
57909865|NCT02617303|PROCEDURE|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
57909866|NCT05180929|DEVICE|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
57909867|NCT05180929|DEVICE|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
58058312|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
58058313|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
58058314|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
58259005|NCT03694418|BEHAVIORAL|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.
58259006|NCT04323306|DRUG|MMV688533|Investigational medicinal product
58259007|NCT01609439|DRUG|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
58259008|NCT01609439|DRUG|Placebo|Placebo
58259009|NCT03755869|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
58259010|NCT02892604|DEVICE|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
58259011|NCT05279729|OTHER|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
57909868|NCT05180929|DEVICE|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
57909869|NCT06399133|OTHER|Warm water intake|Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.
58259012|NCT06002529|OTHER|HFR|patient received HFR treatment
57708116|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
57708117|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
57909870|NCT06399133|OTHER|High-fiber diet|After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
57909871|NCT06399133|OTHER|Abdominal massage|Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
57909872|NCT04500795|PROCEDURE|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
57909873|NCT00090077|DRUG|GW695634|
57909874|NCT05074797|DIAGNOSTIC_TEST|laboratory|laboratory data
57909875|NCT00106418|DRUG|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
57909876|NCT02170818|OTHER|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
57909877|NCT02170818|OTHER|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
57909878|NCT01659853|DRUG|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
57909879|NCT01659853|DRUG|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
57909880|NCT00759018|BIOLOGICAL|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10\^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
58058315|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
58058316|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
58058317|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
58058318|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
58259013|NCT03747068|DRUG|Anti-TNF Drug|
58259014|NCT06624163|BEHAVIORAL|OHWL Clinic Activities (Standard of Care)|Following a directed history and physical at the initial visit, the OHWL Care provider (OCP) develops a medical and weight management plan, which includes laboratory testing (such as for Hemoglobin A1C (HbA1c), consultant referrals (e.g. sleep, heart failure clinics) and referral to nutritionists and physical therapy (PT). The OCP begins the process of establishing patient goals, which will be followed up by the coach. The OCP reviews patient progress with the goals during face-to-face visits (some by telehealth) at two, four and six months. As part of the standard initial clinic evaluation, a medical assistant evaluates grip strength (using a hand dynamometer) the timed up and go mobility test; these are repeated at the 6-month visit.
58381169|NCT00315510|DRUG|Rosuvastatin|
58381170|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
58381171|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
58381172|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
58381173|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
58381174|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
58381175|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
58381176|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
58259015|NCT06624163|BEHAVIORAL|Coach Activities|A patient coach follows patients outside of clinic to ensure adherence with referral appointments and use of recommended community services. The coach assesses the participant at baseline, 3 months, and 6 months using the Patient-Specific Functional Scale and follows up with patients via phone over 6 months. The coach utilizes S.M.A.R.T. (Specific, Measurable, Achievable, Relevant, Time-bound) goals to facilitate, for example, transportation, barriers to scheduling, etc. The coach follows up on specialist referral recommendations, physical therapy, and nutrition program, as well as social work recommendations. Barriers and facilitators to program adherence are identified and addressed.
58259016|NCT03917472|DRUG|Brolucizumab|Intravitreal injection
58259017|NCT03917472|DRUG|Aflibercept|Intravitreal injection
58259018|NCT02872610|BEHAVIORAL|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
58259019|NCT06252701|BEHAVIORAL|Reduction of Ultra-processed foods|Reduction of Ultra-processed foods for four weeks.
58259020|NCT06621303|BIOLOGICAL|Diabetic foot ulcer treatment|The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.
58259021|NCT02870816|PROCEDURE|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
58381177|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
58381178|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
58381179|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
58381180|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
57708118|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
57909881|NCT04490590|DRUG|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
58259022|NCT02870816|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
58259023|NCT02870816|PROCEDURE|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
58381181|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
58381182|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
58381183|NCT01194245|DRUG|Insulin lispro|
58381184|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
58381185|NCT01194245|DRUG|Insulin aspart|
58381186|NCT01194245|DRUG|Insulin glulisine|
58381187|NCT01194245|DRUG|Insulin glargine|
58381188|NCT00400855|DRUG|Fluticasone propionate|Study drug
58381189|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
58381190|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
58381191|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
57708119|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
58259024|NCT02792114|DRUG|Cyclophosphamide|
57909882|NCT03312452|DEVICE|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
58259025|NCT02792114|BIOLOGICAL|Mesothelin-targeted T cells|
58259026|NCT02792114|DRUG|AP1903|
58381192|NCT03448016|RADIATION|[C-11]|Radiolabel
58381193|NCT03448016|DRUG|NOP-1A|Tracer
58381194|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
58259027|NCT05780970|OTHER|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
57909883|NCT03312452|DEVICE|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
57909884|NCT03471351|DRUG|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
57909885|NCT03471351|BIOLOGICAL|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
57909886|NCT04727268|OTHER|No intervention|No interventions present in this study.
57909887|NCT05299294|OTHER|Data collection|Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain
57909888|NCT01952353|PROCEDURE|Preoprative TACE|
57909889|NCT01952353|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
57909890|NCT02679508|DRUG|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
57909891|NCT02679508|DRUG|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
57909892|NCT01001559|DRUG|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
57909893|NCT01001559|DRUG|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
57909894|NCT01001559|DRUG|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
57909895|NCT02947087|DRUG|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
57909896|NCT02947087|DRUG|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
58259028|NCT02196376|OTHER|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
58259029|NCT02196376|OTHER|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
58259030|NCT02196376|OTHER|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
57909897|NCT01781507|DRUG|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
57909898|NCT01781507|DRUG|Placebo|This placebo ( sugar pill) will provide the negative control for this study
57909899|NCT03476707|OTHER|Anemia|Hematocrit less than 0.39
57909900|NCT00492362|BEHAVIORAL|ergometer exercise during hemodialysis|
57909901|NCT00492362|BEHAVIORAL|pedometer activity outside of hemodialysis|
57909902|NCT01049295|DIETARY_SUPPLEMENT|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
57909903|NCT01049295|OTHER|corn oil pearls|corn oil pearls 3 times a day
57909904|NCT00195091|DRUG|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
57909905|NCT02289092|BEHAVIORAL|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
57909906|NCT00560118|DRUG|fotemustine|
57909907|NCT00560118|GENETIC|gene expression analysis|
57909908|NCT00560118|GENETIC|polymerase chain reaction|
57909909|NCT01683656|DRUG|niacin/laropiprant|
57909910|NCT01683656|DRUG|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
57909911|NCT03012698|DEVICE|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
57909912|NCT01581138|DRUG|VX-222|400 mg tablets twice daily for oral administration
57909913|NCT01581138|DRUG|telaprevir|1125 mg tablets twice daily for oral administration
57909914|NCT01581138|DRUG|ribavirin|1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
57708120|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
57708121|NCT03607916|DRUG|Morphine|100µg morphine
57708122|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
57708123|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
57708124|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
57708125|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
57708126|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
57708127|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
57708128|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
57708129|NCT02997033|OTHER|No intervention|No intervention
57708130|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
57708131|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
57708132|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
57708133|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
57909915|NCT03891693|DEVICE|Passeo-18 Lux and SUPERA® stent|Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
57909916|NCT04826861|BEHAVIORAL|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
57909917|NCT02059785|DRUG|Pinocembrin for Injection|
57708134|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
57909918|NCT01611805|DRUG|GSK1605786|Opaque Swedish orange body and cap.
57909919|NCT01611805|DRUG|GSK1605786 Placebo|Opaque Swedish orange body and cap.
57708135|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
57708136|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
57909920|NCT03009552|PROCEDURE|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
57909921|NCT01775150|OTHER|health education|Health education via text messaging
57708137|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
57708138|NCT01148004|DRUG|Fenofibrate|
57708139|NCT01148004|DRUG|Ritonavir|
57708140|NCT01148004|DRUG|Lopinavir/Ritonavir|
57708141|NCT01726010|DEVICE|22-G Procore Needle|
57708142|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
57708143|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
57708144|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
57909922|NCT05803031|DRUG|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
57708145|NCT01368575|PROCEDURE|CABG|CABG
57708146|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
57708147|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
57708148|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
57708149|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
57708150|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
57909923|NCT05803031|PROCEDURE|Non-surgical periodontal debridement|Scaling and root surface debridement
58259031|NCT02196376|BEHAVIORAL|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
58259032|NCT01486472|DRUG|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
58259033|NCT04050124|DEVICE|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
58259034|NCT04050124|DEVICE|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
58259035|NCT05820711|DRUG|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)"
57909924|NCT00518466|DRUG|topiramate|25 mg modified-release capsules
58259036|NCT04998721|BEHAVIORAL|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
58259037|NCT04998721|BEHAVIORAL|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
58259038|NCT00996411|DRUG|Salvinorin A|This is an initial dose ranging study
58259039|NCT05684510|DEVICE|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
58259040|NCT05684510|DEVICE|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
57909925|NCT00518466|DRUG|phentermine|7.5 mg immediate-release capsules
57909926|NCT00518466|DRUG|topiramate|100 and 25 mg immediate-release tablets
57909927|NCT00518466|DRUG|phentermine|37.5 and 7.5 mg immediate-release tablets
57909928|NCT02838927|OTHER|No intervention|No intervention
57909929|NCT00039312|OTHER|Papanicolaou test|
57909930|NCT00039312|OTHER|cytology specimen collection procedure|
57909931|NCT00039312|PROCEDURE|annual screening|
57909932|NCT00039312|PROCEDURE|colposcopic biopsy|
57909933|NCT00039312|PROCEDURE|comparison of screening methods|
57909934|NCT04242953|DRUG|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
57909935|NCT04242953|DRUG|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
57909936|NCT04284215|DRUG|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
57909937|NCT03603249|DRUG|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
57909938|NCT04618445|BEHAVIORAL|some risk factors that might be correlated with TMD|Fonesca questionnaire
57909939|NCT02747641|PROCEDURE|Pixel CO2 Laser System|
57909940|NCT04738227|RADIATION|Low-Level Laser Therapy|Low level laser will be applied and post laser results will be seen to assess any improvements.
57909941|NCT00178126|DEVICE|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
57909942|NCT00178126|DEVICE|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
57909943|NCT03745261|DRUG|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
58259041|NCT05397067|BEHAVIORAL|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
58259042|NCT02370628|PROCEDURE|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~* Step 1: facet block~* Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
58381195|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
58259043|NCT02370628|PROCEDURE|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
58259044|NCT00791661|DRUG|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
57708151|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
57708152|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
57909944|NCT03745261|DRUG|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
57909945|NCT03745261|DRUG|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
57909946|NCT03745261|DRUG|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
57909947|NCT03745261|DRUG|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
57909948|NCT04092361|DEVICE|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
57708153|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
57708154|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
57708155|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
57909949|NCT03254485|DRUG|IW-1973|Oral Tablet
57909950|NCT03254485|DRUG|Placebo Oral Tablet|Oral Tablet
57909951|NCT04748874|PROCEDURE|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
57909952|NCT03695237|DRUG|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
57909953|NCT01681888|DEVICE|Sanger EMG Biofeedback Device|
57909954|NCT04157374|OTHER|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
57909955|NCT04157374|OTHER|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
58259045|NCT00791661|DRUG|Placebo|Matching placebo to MK-1006 in a single oral dose
58259046|NCT04157114|DRUG|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
58259047|NCT04157114|DRUG|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
57708156|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
57708157|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
58259048|NCT04157114|BEHAVIORAL|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
58259049|NCT04725812|DRUG|Eculizumab|Eculizumab Intravenous Solution
57708158|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
58058319|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
58259050|NCT06620809|DRUG|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）
58381196|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
58381197|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
58381198|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
58381199|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
58381200|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
57909956|NCT02004353|DEVICE|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
57909957|NCT01847300|BEHAVIORAL|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
57909958|NCT00667771|DRUG|Naltrexone|
57909959|NCT02414932|DRUG|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
58058320|NCT03928509|OTHER|No intervention|No intervention
58058321|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
58058322|NCT00172003|DRUG|Zoledronic acid|
58381201|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
58058323|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
58259051|NCT06620809|DRUG|A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles placebo(5×10\^9 particles）
58259052|NCT06545916|DRUG|Sunobinop|1 tablet taken orally at bedtime
58381202|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
58381203|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
58381204|NCT01825330|DEVICE|sham|
57708159|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
57708160|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
57909960|NCT02414932|DRUG|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
57909961|NCT04950829|DEVICE|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
57909962|NCT04950829|DEVICE|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
57909963|NCT04950829|PROCEDURE|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
57909964|NCT03545503|DRUG|Etomidate|Etomidate will be administered as the sedative for RSI on even days
57909965|NCT03545503|DRUG|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
58058324|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
58058325|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
58058326|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
58259053|NCT06545916|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
58381205|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
58381206|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
58381207|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
58381208|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
58381209|NCT03768089|DRUG|IVA|Tablet for oral administration.
58381210|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
58381211|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
58381212|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
58381213|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
58381214|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
58381215|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
58381216|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
58259054|NCT06353126|PROCEDURE|DEB-TACE|"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."
58259055|NCT04504825|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
58381217|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
57909966|NCT02670759|DRUG|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
57909967|NCT02670759|DRUG|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
57909968|NCT04556721|DRUG|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
57909969|NCT04073251|DIETARY_SUPPLEMENT|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
57909970|NCT04073251|DIETARY_SUPPLEMENT|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
58058327|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
58058328|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
57909971|NCT04610541|DRUG|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
58058329|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
58381218|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
58381219|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
58381220|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
58381221|NCT04244071|OTHER|routine hospital care|routine hospital care
57909972|NCT04877730|DEVICE|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
57909973|NCT04877730|DEVICE|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
57909974|NCT04877730|DEVICE|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
57909975|NCT05576753|PROCEDURE|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
58058330|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
58381222|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
58381223|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
58381224|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
57708161|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
57909976|NCT02244645|BEHAVIORAL|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
57909977|NCT02244645|BEHAVIORAL|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
57909978|NCT06262074|OTHER|Structured Exercise Program|30 minutes of structured exercise programs
57909979|NCT06262074|OTHER|Non structured exercise program|Non structured exercises
58058331|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
58058332|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
58058333|NCT01807676|DEVICE|ET View Double Lumen Tube|
58058334|NCT01807676|DEVICE|conventional Double Lumen Tube|
58058335|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
58058336|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
58058337|NCT04958551|OTHER|No intervention|No intervention
58058338|NCT00517725|DRUG|carvedilol|
58058339|NCT00517725|DRUG|bisoprolol|
58058340|NCT00517725|DRUG|Nebivolol|
58058341|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
58058342|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
58058343|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
58058344|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
58058345|NCT03611946|BIOLOGICAL|Placebo|Administered by subcutaneous injection.
58058346|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
58058347|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
58058348|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
58259056|NCT04504825|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
58259057|NCT04504825|DRUG|cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen|According to institutional standard of care.
58259058|NCT04332341|DRUG|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
58259059|NCT04205409|BIOLOGICAL|Nivolumab|Given IV
58259060|NCT03863171|DIAGNOSTIC_TEST|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
58259061|NCT03863171|DIAGNOSTIC_TEST|Fundus fluorescein angiography|Fundus fluorescein angiography test
57909980|NCT02442336|BEHAVIORAL|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
58058349|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
58058350|NCT02347202|OTHER|Telephone support as needed|
58058351|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
58058352|NCT00221689|DRUG|baclofen (drug)|
58058353|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
58058354|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
58259062|NCT05888441|OTHER|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
57909981|NCT04218045|PROCEDURE|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
57909982|NCT04218045|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
58058355|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
58259063|NCT05330702|DEVICE|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation|Fibro-gide is the VCMX
58259064|NCT05330702|PROCEDURE|Tuberosity Connective Tissue Graft (CTG)|CTG will be taken from the patient's own mouth
58259065|NCT06618937|OTHER|Treatment medication withdrawal strategy|The study aims to compare early biomarkers-guided versus conventional unguided drugs withdrawal strategy.
58058356|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
58058357|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
58058358|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
58058359|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
58058360|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
58381225|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
58259066|NCT04603768|OTHER|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
58259067|NCT04603768|OTHER|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
58381226|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
58381227|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
57708162|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
58381228|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58381229|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
58381230|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
57909983|NCT00480129|BEHAVIORAL|Probiotic or placebo yogurt consumed daily|
57909984|NCT00480129|DEVICE|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
58381231|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
57909985|NCT00480129|PROCEDURE|Blood sample|
57909986|NCT00480129|PROCEDURE|Nasal lavage|
57909987|NCT05004571|DRUG|EQU-001|EQU-001 in 10 and 20 mg capsules
57909988|NCT05004571|DRUG|Placebo|Matched placebo
57909989|NCT03581825|DEVICE|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
57909990|NCT03581825|DEVICE|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
57909991|NCT03581825|DEVICE|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
58381232|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
58381233|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
58381234|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
58381235|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
58381236|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
58381237|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
58381238|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
58381239|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
58381240|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
58381241|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
58381242|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
58381243|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
57909992|NCT03581825|DEVICE|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
57909993|NCT05576259|OTHER|oVRcome phone app with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
57909994|NCT02575859|DRUG|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
58259068|NCT04603768|OTHER|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
58259069|NCT03699462|DRUG|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
58259070|NCT03699462|DRUG|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
58259071|NCT04264390|BEHAVIORAL|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
58259072|NCT01413789|DRUG|Dermatix|1 application of Dermatix
57909995|NCT02575859|PROCEDURE|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
57909996|NCT03573583|BEHAVIORAL|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
58058361|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
58259073|NCT01413789|DRUG|Kelocote|1 application of Kelocote
58259074|NCT01413789|DRUG|BAP scar gel|1 application of BAP scar gel
58381244|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
58259075|NCT01413789|DRUG|Alhydran|1 application of Alhydran
58259076|NCT01413789|DRUG|Bap Scar Care T|1 application of BAP Scar Care T
58259077|NCT01413789|DRUG|Bap Scar Care S|1 Application of Bap Scar Care S
58259078|NCT01413789|DRUG|Mepiform|1 application of Mepiform
58259079|NCT01413789|DRUG|Scar Ban Elastic|1 application of Scar Ban Elastic
58259080|NCT05911828|DRUG|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
58259081|NCT05911828|DRUG|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
57909997|NCT03573583|BEHAVIORAL|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
57909998|NCT05161728|DIAGNOSTIC_TEST|PSMA-PET/CT|PSMA-PET/CT
58381245|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
58058362|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
58259082|NCT06418477|DRUG|Dara-CyBorD|"Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis."
58381246|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
58381247|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
57909999|NCT02279628|DRUG|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
57910000|NCT02279628|DRUG|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
58058363|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
58058364|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
58058365|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
58058366|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
58259083|NCT05731037|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
58259084|NCT02107105|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
58259085|NCT02107105|OTHER|Questionnaire Administration|Complete quality of life questionnaire
58259086|NCT03070340|DIAGNOSTIC_TEST|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
58259087|NCT03070340|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
58259088|NCT01181544|PROCEDURE|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
58259089|NCT03806699|BIOLOGICAL|Placebo|Sterile normal saline
58259090|NCT03806699|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
58259091|NCT00532194|DRUG|cediranib|Once-daily oral tablet starting dose 20mg
58259092|NCT06621095|DRUG|anlotinib + benmelstobart + nab-paclitaxel + gemcitabine|"1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
58259093|NCT06621095|DRUG|nab-paclitaxel + gemcitabine|"1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
58259094|NCT00567489|DRUG|Physioneal|Physioneal 40 or Physioneal 35
58259095|NCT00567489|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
57910001|NCT00629733|DRUG|RO-14|
58058367|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
58259096|NCT00567489|DRUG|Extraneal|7.5% Icodextrin
58259097|NCT00567489|DRUG|Nutrineal|Amino Acids 1.1%
58058368|NCT04011137|OTHER|Exercise|Arm-cranking exercise
58259098|NCT01088880|DRUG|Canakinumab|
58259099|NCT01486901|DRUG|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
58259100|NCT05672017|BEHAVIORAL|Dietary Instructions|Dietary Instructions
58259101|NCT04662528|DRUG|Placebo|4 x 1g capsules/day
58259102|NCT04662528|DRUG|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
58259103|NCT03696108|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID
58259104|NCT03696108|DRUG|Placebo|Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
58259105|NCT04497870|DRUG|Peppermint oil|Administration of peppermint oil at one of two daily doses.
58381248|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
58381249|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
58381250|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
58381251|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
58381252|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
58381253|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
58381254|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
58381255|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
58381256|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
58381257|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
58259106|NCT01868698|OTHER|high-voltage electrical stimulation|
58259107|NCT01868698|OTHER|Kinesiotherapy|
58259108|NCT01868698|OTHER|shortwave diathermy|
58259109|NCT03287284|DEVICE|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
58259110|NCT03287284|BEHAVIORAL|Resistance Training|Resistance Training
58259111|NCT03287284|DEVICE|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
58259112|NCT04792593|BIOLOGICAL|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
58259113|NCT04017832|DRUG|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
58259114|NCT04017832|DRUG|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
58259115|NCT04017832|DRUG|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
58259116|NCT04017832|DRUG|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
58259117|NCT04197674|OTHER|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
57708163|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
58259118|NCT02234596|DRUG|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
58259119|NCT00401713|PROCEDURE|Transplantation of autologous RPE|RPE cell suspension
58259120|NCT00401713|PROCEDURE|Translocation of autologous RPE and Choroid|RPE patch
58381258|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
58381259|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
58381260|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
58381261|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
58259121|NCT02002039|DRUG|Erythropoietin|500 units /kg /day every other day for 5 doses
58259122|NCT05108077|BIOLOGICAL|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
58259123|NCT05108077|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
58259124|NCT06619873|DRUG|HRS-8080|"Medication regimen A~Drug:~600mg, Old process tablets，NPO~Medication regimen B~Drug:~600mg, New process tablets，NPO~Medication regimen C~Drug:~600mg, New process tablets，PC.，low-fat diet~Medication regimen D~Drug:~600mg, New process tablets，PC.，high-fat diet"
58259125|NCT04804267|DRUG|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
58259126|NCT04804267|DRUG|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
58259127|NCT04804267|DRUG|Placebo|Drug: Placebo orally once daily
58259128|NCT03409107|DRUG|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
58381262|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
58259129|NCT03409107|DRUG|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
58259130|NCT03409107|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
58259131|NCT04715542|DRUG|Stibium metallicum praeparatum 6x|Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
58259132|NCT04715542|DRUG|Placebo|Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
58259133|NCT01701193|DRUG|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
58259134|NCT01701193|DRUG|Physiologic saline|Placebo
58259135|NCT05613998|OTHER|GPR Group|"6-week treatment using the GPR method. 1 weekly session (45 min) with frog on the ground and sitting postures + daily home self-postures (10 min)"
58381263|NCT01842373|DRUG|LMX4|
58381264|NCT01842373|DRUG|BLT|
58381265|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
58381266|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
58259136|NCT05613998|OTHER|Aerobic Exercice Group|6-week nonspecific aerobic exercise treatment. Participants will take a daily walk (20 min)
58381267|NCT00003846|BIOLOGICAL|filgrastim|
58381268|NCT00003846|DRUG|carboplatin|
58259137|NCT00797628|BEHAVIORAL|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
58259138|NCT00797628|BEHAVIORAL|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
58259139|NCT06321068|DRUG|carboplatin|the usage and dosage should be determined by the investigator
58381269|NCT00003846|DRUG|cyclophosphamide|
58381270|NCT00003846|DRUG|thiotepa|
58381271|NCT00003846|DRUG|vincristine sulfate|
58381272|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
58381273|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
58381274|NCT00003846|RADIATION|radiation therapy|
58259140|NCT06321068|DRUG|Paclitaxel|the usage and dosage should be determined by the investigator
58259141|NCT06321068|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
58259142|NCT01005940|DEVICE|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
58259143|NCT01064258|DEVICE|CPAP|CPAP at 4 cm H2O
58259144|NCT01064258|DEVICE|autoCPAP|autoCPAP working between 4 and 15 cm H2O
58381275|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
58381276|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
58381277|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
58381278|NCT00364650|OTHER|Placebo|placebo
58259145|NCT06201975|OTHER|Thyme honey|Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
58259146|NCT03018496|DIETARY_SUPPLEMENT|Beta-Hydroxy-Beta-Methylbutyrate|
58259147|NCT03018496|OTHER|Placebo|
58259148|NCT05591066|BEHAVIORAL|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
58259149|NCT05591066|BEHAVIORAL|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
58259150|NCT02100670|DRUG|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
58259151|NCT02100670|DRUG|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
58259152|NCT02100670|DRUG|3% menthol|To be applied four times daily for 10 days.
58381279|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
58381280|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
58381281|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
58381282|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
58381283|NCT02682459|DRUG|Lisinopril|
58381284|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
58259153|NCT02100670|DRUG|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
58381285|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
58381286|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
58381287|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
58381288|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd)|Sixty % of the energy content is based on fat.
58259154|NCT04159415|DRUG|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
58259155|NCT04159415|DRUG|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
57910002|NCT02585232|BEHAVIORAL|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
58259156|NCT04159415|DRUG|High-dose REGN4461|IV infusion loading dose or SC injection QW.
58259157|NCT03697759|OTHER|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
58259158|NCT02070731|DEVICE|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
58259159|NCT05503602|OTHER|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
58381289|NCT02088853|DIETARY_SUPPLEMENT|high carb diet|Sixty % of the energy content is based on carbohydrates.
58381290|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
58381291|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
58381292|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
58381293|NCT05679349|OTHER|Survey Administration|Complete survey
58381294|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
58381295|NCT05679349|OTHER|Survey Administration|Complete survey
58381296|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
58381297|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
58381298|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
58381299|NCT05679349|OTHER|Survey Administration|Complete survey
58381300|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
58381301|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
58381302|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
58381303|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
58381304|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
58058369|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
58058370|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
58058371|NCT02565576|DRUG|Placebo|
58058372|NCT02565576|DRUG|CFZ533|
58058373|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
58259160|NCT05503602|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
58259161|NCT05503602|OTHER|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
58259162|NCT01943968|OTHER|Blood test|
57910003|NCT02585232|BEHAVIORAL|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
57910004|NCT03756987|DRUG|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
57910005|NCT03756987|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane.
57910006|NCT00574756|DRUG|ranolazine|extended release 500 mg twice a day for two weeks
57910007|NCT05102721|DRUG|Avelumab and Pepinemab|IV Infusions every two weeks.
57910008|NCT04336787|OTHER|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
57910009|NCT01638234|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
57910010|NCT01638234|DIETARY_SUPPLEMENT|Placebo|starch pill
57910011|NCT05201118|DRUG|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
57910012|NCT05201118|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
57910013|NCT04896151|DIAGNOSTIC_TEST|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath \& Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
57910014|NCT03118986|DRUG|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
58058374|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
58058375|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
58058376|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
58381305|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
58381306|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
57910015|NCT03118986|DRUG|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
57910016|NCT00283218|DRUG|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
57910017|NCT00551590|DRUG|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
57910018|NCT00551590|DRUG|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
57910019|NCT00551590|DRUG|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
57910020|NCT00551590|DRUG|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
57910021|NCT00543712|DRUG|PRO95780|Intravenous repeating dose
57910022|NCT01379378|DEVICE|Artificial urinary sphincter|Standard of care
57910023|NCT01379378|DEVICE|InVance Sling|Standard of care
57910024|NCT01379378|DEVICE|AdVance Sling|Standard of care
58381307|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
58381308|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
57708164|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
57708165|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
57708166|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
57708167|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
57708168|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
57708169|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
57708170|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
57708171|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
57708172|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
57910025|NCT01379378|DEVICE|Virtue Sling|Standard of care
57910026|NCT01379378|DRUG|Contigen|2.5-10 cc
57910027|NCT00982995|DRUG|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
57910028|NCT04441060|OTHER|Distress intervention (CBT & Mindfulness-based program)|Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
58058377|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
58381309|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
58381310|NCT01352208|DRUG|ASP9521|oral
57708173|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
57708174|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
57708175|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
57708176|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
57708177|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
57708178|NCT00846118|DRUG|Pitavastatin|1-4mg/day
57708179|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
57708180|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
57708181|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
57708182|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
57708183|NCT01686646|DRUG|paracetamol|paracetamol
57708184|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
57708185|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
57708186|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
57708187|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
57708188|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
57708189|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
57708190|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
58058378|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
58259163|NCT03073694|DRUG|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
58259164|NCT03073694|DRUG|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
58259165|NCT04792840|DRUG|Femara Pill|study effect on bone
58259166|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming|Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.
58259167|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback|Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.
58259168|NCT03596606|PROCEDURE|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
58259169|NCT03596606|PROCEDURE|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
58259170|NCT05759520|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
58259171|NCT05759520|BIOLOGICAL|Prevenar 13|the 2-month-old control group received the active control vaccine
58259172|NCT05662059|DEVICE|RAVANS|Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation
58259173|NCT05662059|DEVICE|RAVANS-sham|RAVANS sham device
58259174|NCT06547424|DRUG|Chondroitin sulfate|Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
58259175|NCT03096769|OTHER|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
58259176|NCT02951221|DRUG|BIIB074 Treatment A|Lower dose RCF fasted
58259177|NCT02951221|DRUG|BIIB074 Treatment B|Lower dose DCF fasted
58259178|NCT02951221|DRUG|BIIB074 Treatment C|Higher dose DCF fasted
58259179|NCT02951221|DRUG|BIIB074 Treatment D|Higher dose DCF fed
57708191|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
58259180|NCT02290236|DEVICE|Pulseoximetry|Peripheral saturation will be recorded continuously
58259181|NCT05401448|BIOLOGICAL|Influenza|Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
58259182|NCT05401448|BIOLOGICAL|MMR vaccines|MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
58259183|NCT05401448|OTHER|Placebo|Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
58259184|NCT05013879|DEVICE|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
58259185|NCT01457586|BIOLOGICAL|Blood transfusion|Blood transfusion in perioperative period.
58058379|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
58058380|NCT01644812|BEHAVIORAL|Aerobic exercise|
58259186|NCT01457586|BIOLOGICAL|No blood transfusion|No transfusion in the perioperative period.
57708192|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
57708193|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
58058381|NCT01644812|BEHAVIORAL|Stretching|
58058382|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
58058383|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
58259187|NCT05103904|OTHER|Laboratory Biomarker Analysis|Correlative studies
58259188|NCT05103904|DRUG|Lenvatinib|Given PO
58259189|NCT03357133|DRUG|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
58259190|NCT03357133|DRUG|Alteplase|Only alteplase intravenous thrombolysis
58381311|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
58259191|NCT04569422|DRUG|Benoxyl|reduce pain
58259192|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
58259193|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
58259194|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
58259195|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
58259196|NCT04842188|PROCEDURE|L-PRF with aPDT|surgical open flap debridement followed by L-PRF with aPDT
58259197|NCT04842188|PROCEDURE|L-PRF|surgical open flap debridement followed by L-PRF alone
58259198|NCT04079257|OTHER|Blood collection for measurement of eculizumab peak concentrations|collection of blood
58259199|NCT00655148|BIOLOGICAL|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
58259200|NCT00655148|BIOLOGICAL|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
58259201|NCT02756780|OTHER|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
58259202|NCT06648057|DRUG|lenvatinib plus pembrolizumab|"* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens)."
58259203|NCT02527759|BEHAVIORAL|Survey|
58259204|NCT06461715|OTHER|Machine learning with artificial intelligence software program|This is a retrospective observational study using cardiac MRI, cardiac CT and x-ray fluoroscopy images to develop a 3D hybrid guidance system with the use of deep learning methods.
58259205|NCT00522691|PROCEDURE|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
58259206|NCT06623604|BEHAVIORAL|Experimental: Physical activity program|"In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity."
58259207|NCT05642429|BIOLOGICAL|AV-1959D|Three doses of AV-1959D administered as a sterile suspension via intradermal injection
57708194|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
57708195|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
58259208|NCT05642429|BIOLOGICAL|Placebo|Three doses of Placebo administered as a sterile suspension via intradermal injection
58381312|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
57708196|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
57708197|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
58058384|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
58058385|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
58381313|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
58381314|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
57910029|NCT06037473|DRUG|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
58259209|NCT06391541|PROCEDURE|modified thoracolumbar interfacial plan block (mTLIP)|Injecting local anesthetic at L3 vertebral level between the longisimus and iliocostalis muscles within the erector spinae muscles.
58259210|NCT06391541|PROCEDURE|Intertransverse process block (ITP)|injection of local anesthetic on the superior costotransverse ligament between the transverse process and the pleura.
58259211|NCT06621030|DEVICE|MIB Breath Analyzer|Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC IMS and the MIBs (investigational devices). Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices) Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).
58259212|NCT06126835|DRUG|Ozanimod|Women with UC exposed to ozanimod during pregnancy
58259213|NCT06126835|DRUG|Conventional therapy|Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
58259214|NCT06126835|DRUG|Advanced therapy|Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
58381315|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
58381316|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
58381317|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
58381318|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
58381319|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
58381320|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
58381321|NCT01786681|PROCEDURE|Positive pressure|
57708198|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
57708199|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
57708200|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
57910030|NCT04902508|BEHAVIORAL|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
58381322|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
58381323|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
58381324|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
58381325|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
57708201|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
57708202|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
57708203|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
57910031|NCT04902508|BEHAVIORAL|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
57910032|NCT03361280|DRUG|Beta blocker|Beta blockers are administered as described in arms.
57910033|NCT03318042|OTHER|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
58259215|NCT03523143|OTHER|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
58381326|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
57910034|NCT03318042|OTHER|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
58381327|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
58381328|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
58381329|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
58381330|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
57708204|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
57708205|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
57708206|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
57708207|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
57708208|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
58381331|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
58381332|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
58381333|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
57910035|NCT02978573|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
57910036|NCT00785993|OTHER|Vitrification of oocytes for IVF treatment|
58381334|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
58381335|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
58381336|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
58381337|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
58381338|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
58381339|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
57708209|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
57910037|NCT00785993|OTHER|Protocolary IVF treatment with fresh donor oocytes|
57708210|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
57708211|NCT00193401|DRUG|Topotecan|
57910038|NCT04837820|PROCEDURE|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
57910039|NCT04837820|PROCEDURE|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
58058386|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
58058387|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
58058388|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
58058389|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
58058390|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
58058391|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
57910040|NCT04837820|OTHER|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
58058392|NCT02316379|DEVICE|MRI|
58058393|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
58259216|NCT03523143|OTHER|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
58259217|NCT00922467|DRUG|NaCl 9/00|Same volume as in the esmolol group
58259218|NCT00922467|DRUG|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
58259219|NCT06313086|DRUG|DP303c|intravenous injection
58259220|NCT06313086|DRUG|trastuzumab emtansine|intravenous injection
58259221|NCT02046083|DRUG|arachid|
58259222|NCT03671564|DRUG|Milademetan|Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
58259223|NCT03134846|DRUG|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
58259224|NCT03470558|OTHER|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
58259225|NCT05251363|DEVICE|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
58259226|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
58259227|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension Placebo|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
58259228|NCT06209398|BIOLOGICAL|Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )|Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
58259229|NCT06209398|BIOLOGICAL|Recombinant Hepatitis B Vaccine|Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
57708212|NCT03825289|DRUG|Hydroxychloroquine|Given PO
57708213|NCT03825289|DRUG|Trametinib|Given PO
57708214|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
57708215|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
57708216|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
57708217|NCT00112203|DRUG|Itopride|
57910041|NCT04837820|OTHER|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
58058394|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
58381340|NCT02553928|DRUG|Memantine (once daily)|
58381341|NCT02553928|DRUG|Memantine (twice daily)|
58381342|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
58259230|NCT06209398|BIOLOGICAL|Group A meningococcal polysaccharide vaccine|This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
58259231|NCT06414824|DEVICE|Intermittently Scanned Continuous Glucose Monitoring|FreeStyle Libre, 4 weeks
58259232|NCT06414824|DEVICE|Standard Blood Glucose Monitoring|Standard blood glucose monitoring with glucose meters
57910042|NCT01026285|DRUG|Risperidone Long-Acting injectable or oral antipsychotics|According to label
57910043|NCT04133506|DRUG|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
58058395|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
58259233|NCT05225675|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
58259234|NCT05225675|OTHER|Placebo|Intravenous administration of placebo
58259235|NCT06027554|DRUG|Mitoquinone Mesylate|MitoQ given 20 mg per day for 12 weeks.
58259236|NCT06027554|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule taken every day for 12 weeks.
58259237|NCT00786331|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
58259238|NCT00786331|DRUG|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
58259239|NCT06012656|DEVICE|MiniMAX|Total or Partial Hip Arthroplasty
57708218|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
58259240|NCT06619379|OTHER|retention time of speculum|"according to the randomization, the speculum can be extracted :~1. just after the transfer catheter is withdrawn~2. 60 seconds after the transfer catheter is withdrawn~3. 420 second (7 minutes) after the catheter is withdrawn"
58259241|NCT01543763|DRUG|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
58259242|NCT00964938|DEVICE|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
58259243|NCT02279745|DRUG|Ralinepag|Active
58259244|NCT05259150|BEHAVIORAL|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
58259245|NCT05259150|BEHAVIORAL|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
58259246|NCT05259150|BEHAVIORAL|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
58259247|NCT05259150|OTHER|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
58259248|NCT00251303|DRUG|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
58259249|NCT00251303|DRUG|Placebo|Capsules matched active drug in appearance.
58259250|NCT03376971|PROCEDURE|Biopsy|Undergo lung biopsy
58259251|NCT03376971|OTHER|Laboratory Biomarker Analysis|Correlative studies
58259252|NCT04810494|DRUG|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
58259253|NCT04810494|DRUG|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
58259254|NCT03360409|PROCEDURE|ACD|Undertake anterior cervical discectomy without fusion
58259255|NCT03360409|PROCEDURE|ACDF|anterior cervical discectomy with fusion
58259256|NCT03360409|PROCEDURE|ACDA|anterior cervical discectomy with arthroplasty
58259257|NCT02197832|PROCEDURE|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
58259258|NCT02197832|PROCEDURE|control procedure|Using pipelle catheter without entering the uterine cavity.
58259259|NCT02197832|DEVICE|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
58259260|NCT05002959|DEVICE|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
58259261|NCT05002959|DEVICE|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
58259262|NCT04613193|OTHER|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
58259263|NCT06408220|PROCEDURE|Biopsy|Undergo tissue biopsy
58259264|NCT06408220|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58259265|NCT06408220|PROCEDURE|Breath Test|Undergo H. pylori breath test
58259266|NCT06408220|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
58259267|NCT06408220|OTHER|Questionnaire Administration|Complete questionnaires
58259268|NCT06615258|BEHAVIORAL|Dynamic Neuromuscular Stabilization based breathing training and pelvic floor muscle training|"DNS-based breathing exercises will be taught to the women in this group using tactile biofeedback. To create tactile stimulation, one of the hard sponges placed within a belt will be positioned anteriorly in the inguinal region, and the other posteriorly in the Grynfeltt-Lesshaft triangle region. Breathing training will be provided in 3 different positions: sitting, crawling, and happy baby pose.~Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises.~Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position."
58259269|NCT06615258|BEHAVIORAL|Pelvic floor muscle training|Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises. Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position.
58259270|NCT01787487|DRUG|Azacitidine|Given SC or IV
58259271|NCT01787487|OTHER|Laboratory Biomarker Analysis|Correlative studies
58259272|NCT01787487|DRUG|Ruxolitinib Phosphate|Given PO
58259273|NCT01725932|BEHAVIORAL|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
57708219|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
57708220|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
58058396|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
58058397|NCT01081951|DRUG|olaparib|Tablets Oral BID
58058398|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
58058399|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
58058400|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
58058401|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
58259274|NCT02389790|DRUG|MT-1303|
58259275|NCT05433909|DIAGNOSTIC_TEST|Blood, fecal, vaginal and endometrial liquid samples|"During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling."
58259276|NCT02677038|DRUG|Olaparib|Given PO
58259277|NCT03991897|DIETARY_SUPPLEMENT|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
58058402|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
58058403|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
58058404|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
58259278|NCT03991897|DIETARY_SUPPLEMENT|Isocaloric diet|Patients will follow an isocaloric diet
58259279|NCT06471946|DRUG|Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT|"Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9"
57708221|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
58058405|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
58058406|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
58058407|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
58058408|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
58058409|NCT00005623|DRUG|cyproterone acetate|
58058410|NCT00005623|PROCEDURE|quality-of-life assessment|
58259280|NCT04376086|PROCEDURE|Epidural anesthesia|Segmental epidural analgesia
58259281|NCT04376086|PROCEDURE|general anesthesia|general anesthesia
58259282|NCT00743730|OTHER|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
58259283|NCT00743730|OTHER|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
58381343|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
58381344|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
58259284|NCT00743730|OTHER|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
58381345|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
58381346|NCT01302327|DRUG|Exenatide|Exenatide
57708222|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
57708223|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
57708224|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
57708225|NCT01072201|DRUG|Fluoride|Brush twice daily
57708226|NCT05393375|OTHER|No intervention|No intervention
57708227|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
57708228|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
57708229|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
58381347|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
57708230|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
57708231|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
57708232|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
57708233|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
57708234|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
58259285|NCT02197286|DRUG|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
58259286|NCT02197286|DRUG|Placebo|Daily dose of a single gelatin placebo capsule.
58259287|NCT05705154|BEHAVIORAL|Psychology interventions|"Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~* Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~* Identifying the connections between body and mind to address anxiety and breathlessness~* Coping skills for managing anxiety using principles from narrative therapy and mindfulness~* Online materials to improve self-efficacy with home practice~* Social connection with other CYP for peer support, and resource sharing~* Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
58381348|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
58381349|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
58381350|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
58381351|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
58381352|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
58259288|NCT06622564|DRUG|Before CPB Tranexamic Acid|Tranexamic acid 1 to 10 g (10 to 100 mL) administered intravenously as per standard care at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB).
58259289|NCT06622564|DRUG|After CPB Tranexamic Acid|Tranexamic acid 5 g (50 mL) administered after heparin reversal (i.e., after CPB).
58259290|NCT06622564|DRUG|Before CPB Placebo|Placebo (10 to 100 mL saline) administered intravenously at the induction of anesthesia as a bolus and/or continuous infusion.
58259291|NCT06622564|DRUG|After CPB Placebo|Placebo (50 mL saline) administered after heparin reversal.
58259292|NCT00752258|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
58259293|NCT03397329|DRUG|AG-348 Sequence A|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
58259294|NCT03397329|DRUG|AG-348 Sequence B|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
58259295|NCT06407661|OTHER|"Disaster Nursing course/education"|"In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level."
58259296|NCT05709353|BEHAVIORAL|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist."
58259297|NCT05709353|DRUG|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
58259298|NCT05709353|DRUG|Niacin|Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
58259299|NCT04606992|PROCEDURE|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
58259300|NCT01791946|PROCEDURE|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
58259301|NCT01791946|PROCEDURE|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
58259302|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 1|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
58259303|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 1|Preparation of PRP Concentrate via sterile Terumo-Harvest System
58259304|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 2|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
58259305|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 2|Preparation of PRP Concentrate via sterile Terumo-Harvest System
57708235|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
58259306|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 2|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
58259307|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 3|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
58259308|NCT04238143|DRUG|Sterile Normal Saline (IV Solution)|Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
58259309|NCT05492006|BEHAVIORAL|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
58259310|NCT05492006|BEHAVIORAL|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
58259311|NCT03133273|OTHER|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
58259312|NCT02822573|DRUG|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
58259313|NCT02822573|DRUG|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
58259314|NCT06288399|OTHER|No treatment given|No treatment given
58259315|NCT03921970|OTHER|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
58259316|NCT03727152|DRUG|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
58259317|NCT06648811|DEVICE|Pain management after surgery|Kinesio tapes will be applied to the patients in the study group after gynecological laparoscopic operations. The routine pain management will also be provided in these patients in addition to the kinesio tapes. Only postoperative pain management will be provided to the patients in the control group. The patients will be consisted of only the patients who will be operated laparoscopically for gynecological diseases.
58259318|NCT06322576|DRUG|177Lu-PNT2002|"10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires."
58259319|NCT02580669|OTHER|Neuropsychological assessment|A neuropsychological assessment is done
58259320|NCT02580669|OTHER|Neurologic consultation|A neurologic consultation is done
57708236|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
58259321|NCT02580669|OTHER|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
58259322|NCT01321138|PROCEDURE|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
58259323|NCT01321138|PROCEDURE|PCA morphine|Postoperative analgesia with self-administration iv morphine
58259324|NCT06317714|OTHER|questionnaires|"o Quality of life questionnaires EORTC QLQC-30 and EQ-5D-5L~° questionnaires NCI- PRO-CTCAE"
58259325|NCT03148457|DRUG|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
58381353|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
58381354|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
58381355|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
58381356|NCT04475107|DRUG|Placebo|Placebo
58381357|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
58381358|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
58381359|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
58381360|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
58381361|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
58381362|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
58381363|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
58381364|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
58381365|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
58381366|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
58381367|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
58381368|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
58381369|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
58259326|NCT03148457|DRUG|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
58259327|NCT04669951|OTHER|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
58259328|NCT01167049|DRUG|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
58381370|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
58381371|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
57708237|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
58381372|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
58381373|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
58381374|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
58381375|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
58381376|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
58381377|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
58381378|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
58381379|NCT02276430|OTHER|Vena punction|Once 90 ml
58381380|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
58381381|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
58381382|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
58381383|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
58381384|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
58381385|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
58381386|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
58381387|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
57708238|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
57708239|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
57708240|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
58259329|NCT04873102|DRUG|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
58259330|NCT06617156|OTHER|RSBI Value Evaluation|"Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance."
58259331|NCT03665922|DIETARY_SUPPLEMENT|BroccoMax®|Nutraceutical neoadjuvant
58259332|NCT03665922|OTHER|Placebo|control
58259333|NCT01435096|DRUG|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
58259334|NCT06070857|DRUG|LV232|Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
58259335|NCT06070857|DRUG|Placebo|Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
58259336|NCT06564506|DEVICE|Disposable acupuncture needles (0.30 × 75 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
58259337|NCT06564506|DEVICE|Placebo needles (0.30 × 25 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.
58259338|NCT06564506|DEVICE|SDZ-V electroacupuncture devices|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
57708241|NCT00353678|DRUG|YM150|
57708242|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
57708243|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
57708244|NCT04566328|DRUG|Bortezomib|Given SC
57708245|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
57708246|NCT04566328|DRUG|Dexamethasone|Given PO
57708247|NCT04566328|DRUG|Lenalidomide|Given PO
57708248|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
57708249|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
57708250|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
57708251|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
57708252|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
57910044|NCT05026346|DIAGNOSTIC_TEST|Pathologic Exercise|"1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
57910045|NCT06446622|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
58259339|NCT03928756|BEHAVIORAL|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
58259340|NCT03928756|BEHAVIORAL|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
58259341|NCT03928756|BEHAVIORAL|No Push Notifications|Participants will not receive a push notification.
58259342|NCT00614523|DRUG|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
58259343|NCT00614523|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
58259344|NCT04123106|PROCEDURE|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
58259345|NCT04123106|PROCEDURE|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
58259346|NCT06190730|OTHER|Voice-Assisted Remote Symptom Monitoring System (VARSMS)|Installed on Amazon Echo Dot, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
58259347|NCT03494062|BEHAVIORAL|Exercise|Home-based exercise training
58259348|NCT03308136|PROCEDURE|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
58259349|NCT03308136|PROCEDURE|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.
58259350|NCT03308136|DRUG|1% Lidocaine|1% Lidocaine
58259351|NCT05723328|BEHAVIORAL|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
58259352|NCT04119076|OTHER|Classroom-based physical activity|
58259353|NCT04119076|OTHER|Control Group|
58259354|NCT05121051|PROCEDURE|Biospecimen Collection|Undergo collection of blood, buccal cell, and nasal epithelial cell samples
58259355|NCT05121051|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
57910046|NCT00363870|BIOLOGICAL|Fluarix vaccine|
57910047|NCT04569643|DIAGNOSTIC_TEST|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
58259356|NCT05121051|DRUG|Placebo Administration|Given PO
58259357|NCT05121051|OTHER|Questionnaire Administration|Ancillary studies
58259358|NCT06619041|BEHAVIORAL|HealthyTogether|HealthyTogether is a brief (8-session), virtual, dyadic weight management intervention.
58259359|NCT06618079|DRUG|HUC2-565-A, HUC2-565-A and HUC2-565-B|Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.
58259360|NCT06618079|DRUG|HUC2-565-B, HUC2-565-A and HUC2-565-B|Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
58259361|NCT05180019|DEVICE|SMD ( Self Monitoring Device)|Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
58259362|NCT05448365|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
58259363|NCT05448365|DIETARY_SUPPLEMENT|Placebo|Maltodextrines
58259364|NCT04530058|DRUG|Metformin|Metformin 500 mg twice a day, administered orally or via gastric tube.
58259365|NCT04530058|DRUG|Placebos|Placebo twice a day, administered orally or via gastric tube.
58259366|NCT00200109|DEVICE|Occipital Nerve Stimulation|Each group had a different plan
58259367|NCT02996552|PROCEDURE|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
58259368|NCT02996552|PROCEDURE|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
58259369|NCT01028638|OTHER|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
58259370|NCT03228524|DRUG|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
58259371|NCT03228524|BEHAVIORAL|Therapeutic exercise|Standard physiotherapy
58259372|NCT03228524|DRUG|Placebo Oral Tablet|Placebo
58259373|NCT04861285|DEVICE|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
58259374|NCT04861285|DEVICE|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
58381388|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
58381389|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
57708253|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
57708254|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
57708255|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
57910048|NCT04569643|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
57910049|NCT04569643|DIAGNOSTIC_TEST|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
57910050|NCT04569643|OTHER|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
57910051|NCT04569643|OTHER|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
58381390|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
58381391|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
58381392|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
57910052|NCT01518933|DRUG|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
57708256|NCT04999631|DRUG|Ethanol Solution|Control
57708257|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
57708258|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
57708259|NCT00003217|BIOLOGICAL|filgrastim|
57708260|NCT00003217|DRUG|cyclophosphamide|
58381393|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
58381394|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
57708261|NCT00003217|DRUG|cytarabine|
57910053|NCT01518933|DRUG|Saline|Placebo
58259375|NCT04861285|DEVICE|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
58259376|NCT01839617|DIETARY_SUPPLEMENT|Early parenteral nutrition|
58259377|NCT01839617|DIETARY_SUPPLEMENT|Late parenteral nutrition|
57708262|NCT00003217|DRUG|dexamethasone|
57708263|NCT00003217|DRUG|doxorubicin hydrochloride|
57708264|NCT00003217|DRUG|methotrexate|
58259378|NCT03922737|PROCEDURE|In-person office visit|Post-operative visit to occur in-person with provider
58259379|NCT03922737|PROCEDURE|Teleheath visit|Post-operative visit to occur via telehealth software platform with provider
58381395|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
58381396|NCT00129285|DRUG|Placebo|placebo 400 mg/day
57708265|NCT00003217|DRUG|vincristine sulfate|
57708266|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
57708267|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
58259380|NCT05554913|DRUG|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
58259381|NCT05554913|DRUG|Placebo|Placebo comparator
58259382|NCT03648437|DRUG|Paracetamol 10Mg/mL|Experimental drug
58259383|NCT03648437|DRUG|0.45% Sodium Chloride|Placebo comparator
58259384|NCT03648437|DRUG|Ibuprofen|Standard therapy
57708268|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
57708269|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
57708270|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
57708271|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
58259385|NCT03648437|DRUG|Indomethacin|Standard therapy
58259386|NCT03107689|OTHER|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
58259387|NCT06322095|DRUG|PD-1|Previous PD-1
58259388|NCT06322095|DRUG|MET inhibitor|Previous MET inhibitor
58259389|NCT06322095|DRUG|ALK inhibitor|Previous ALK inhibitor
58259390|NCT06322095|DRUG|BRAF Inhibito|Previous BRAF inhibitor
58259391|NCT06322095|DRUG|EGFR Monoclonal antibody|Previous EGFR Monoclonal antibody
58259392|NCT06322095|DRUG|GH21|Oral, 15mg BIW or 6mg QD
58259393|NCT06322095|DRUG|MEK Inhibitor|Previous MEK Inhibitor
58259394|NCT05667974|BIOLOGICAL|PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried|PIKA rabies vaccine
57708272|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
57708273|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
57708274|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
57708275|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
58259395|NCT05667974|BIOLOGICAL|Chirorab|Active Comparator
57708276|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
57708277|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
57708278|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
57708279|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
57708280|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
58259396|NCT06386068|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for chronic Whiplash-Associated Disorder (WAD). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants' lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
57910054|NCT00536302|DIETARY_SUPPLEMENT|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
57910055|NCT00536302|DIETARY_SUPPLEMENT|Placebo|Matching placebo solution per day by mouth for 48 weeks.
58259397|NCT04513080|BEHAVIORAL|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
58259398|NCT04513080|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
58259399|NCT04513080|BEHAVIORAL|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
58259400|NCT04513080|BEHAVIORAL|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
58259401|NCT02613039|DRUG|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
58259402|NCT03868748|DIETARY_SUPPLEMENT|Beta-arbutin|Beta-arbutin capsules
58259403|NCT03868748|OTHER|Placebo|Placebo capsules containing non-medicinal ingredients
58259404|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support before the introduction of systemic oncology treatment
58259405|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
58381397|NCT00187304|DEVICE|Aortic valve replacement|
58381398|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
58381399|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
58259406|NCT05623670|PROCEDURE|minimally invasive cardiac surgery using a VJI cannula.|Observation of postinterventional internal jugular vein thrombus after minimally invasive cardiac surgery using VJI cannulation to achieve complete CPB.
58259407|NCT04881032|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
58259408|NCT04881032|RADIATION|radiotherapy|60 Gy in 6 weeks
58381400|NCT00937495|DRUG|vorinostat|400 mg given PO
58381401|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
58381402|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
58381403|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
58381404|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
58381405|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
57708281|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
58259409|NCT04881032|DRUG|Temozolomide|"Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
58259410|NCT01000220|DRUG|Omeprazole|
58259411|NCT01000220|DRUG|Placebo|
58259412|NCT05963633|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
58259413|NCT05963633|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
58259414|NCT06620744|DEVICE|Sponsor MCG deivce|Unshielded device measuring cardiac magnetic fields.
58381406|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
58381407|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
58381408|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
58381409|NCT03228784|PROCEDURE|LASIK|
58381410|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
58381411|NCT04226625|DRUG|Propofol|Intravenous administration
58381412|NCT04226625|DRUG|Desflurane|Volatile administration
58381413|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
58381414|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
58381415|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
58259415|NCT01113645|PROCEDURE|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
58259416|NCT04446845|DRUG|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
58259417|NCT04446845|DRUG|Conventional Stimulation (Elonva+rFSH) in follicular phase|From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
58259418|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.1%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
58259419|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|IVW-1001 Ophthalmic Eyelid Wipe 0.2%
58381416|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
58381417|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
58381418|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
58381419|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
58381420|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
58381421|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
58381422|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
58381423|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
57708282|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
57708283|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
57708284|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
57708285|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
57708286|NCT00861211|DRUG|Placebo|Placebo comparator
57708287|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
58259420|NCT06400459|DRUG|IVW-1001 Placebo|IVW-1001 Placebo
58259421|NCT01047826|PROCEDURE|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
58259422|NCT01047826|PROCEDURE|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
58259423|NCT05748392|DEVICE|Wound and per-wound assessments While using Device|3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
58259424|NCT00348790|DRUG|vatalanib|
58381424|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
58381425|NCT02041299|DRUG|Deferiprone|
58381426|NCT02041299|DRUG|Deferoxamine|
58381427|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
58381428|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
58381429|NCT05608954|OTHER|Pediasuit|Pediasuit
58381430|NCT05608954|OTHER|Locomotor training|Locomotor training
58381431|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
58381432|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
58259425|NCT01446133|DRUG|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
58259426|NCT01446133|DRUG|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
58259427|NCT01103453|BEHAVIORAL|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
58259428|NCT00071656|BEHAVIORAL|Psychosocial (behavioral) Intervention|
58259429|NCT06347900|DIAGNOSTIC_TEST|Pentacam (corneal topographic changes detection), Polysymnography|Pentacam for recording corneal parameters in different stages of OSA patients. Polysymnography for for detction of hyponea, oxygen saturation and desaturation and staging of OSA in different patients.
58259430|NCT06252142|OTHER|Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose|Short Course radiotherapy followed by eighteen weeks of chemotherapy in between sandwich brachy therapy followed by observation.
58259431|NCT02656290|DEVICE|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
58259432|NCT01614782|DRUG|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
58259433|NCT01614782|OTHER|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
58259434|NCT03845361|PROCEDURE|Radial artery cannulation|Radial artery cannulation
58259435|NCT02589249|DIETARY_SUPPLEMENT|AyuFlex|Active product
58259436|NCT02589249|DIETARY_SUPPLEMENT|Placebo|Placebo
58259437|NCT02712762|OTHER|Cross-sectional study|
58259438|NCT05831696|OTHER|Powered Microprocessor-controlled Knee (PMPK)|A microprocessor-controlled Knee with standardized commercial prosthetic foot
58259439|NCT00782184|DRUG|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
58381433|NCT05608954|OTHER|Virtual reality|Virtual reality
58381434|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
58381435|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
58259440|NCT00782184|DRUG|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
58259441|NCT00782184|DRUG|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
58259442|NCT03207542|DRUG|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
58259443|NCT05445232|DRUG|LY3437943|Administered SC.
58259444|NCT05445232|DRUG|Midazolam|Administered orally.
58259445|NCT05445232|DRUG|Warfarin|Administered orally.
58259446|NCT05445232|DRUG|Caffeine|Administered orally.
58259447|NCT06482723|DEVICE|mGlobal L+AS|The investigated dermal filler mGlobal L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
58259448|NCT03479359|BEHAVIORAL|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
58259449|NCT04448132|BIOLOGICAL|IPV-Al|adjuvanted reduced dose inactivated polio vaccine
58259450|NCT00045370|BIOLOGICAL|recombinant interferon alfa|
58259451|NCT00045370|DRUG|temsirolimus|
58381436|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
58259452|NCT05845567|DRUG|Givinostat|ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
58259453|NCT05845567|DRUG|Clarithromycin|Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
58259454|NCT06393257|DEVICE|Oscillation and Lung Expansion|A novel airway clearance technology
58259455|NCT06393257|BEHAVIORAL|Postural drainage|A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.
58259456|NCT06393257|DRUG|Anti-infective therapy|Antibiotics were used in these patients.
58259457|NCT06393257|DRUG|Mucolytic|Mucolytics were used in these patients.
58259458|NCT01128218|DRUG|Tumor fluorescence|"Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2"
58259459|NCT02879656|PROCEDURE|non-operative treatment|conservative treatment with 5 weeks cast immobilization
58259460|NCT02879656|PROCEDURE|operative treatment|surgery with volar locking plate with modified Henry's volar approach
58259461|NCT06560229|OTHER|Grocery gift card|Monthly $100 grocery gift cards for 12 months
58259462|NCT05045027|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
58259463|NCT05045027|PROCEDURE|Diagnostic Imaging|Undergo multinuclear metabolic imaging
58259464|NCT05045027|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58259465|NCT06163742|DEVICE|Product X|The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
58259466|NCT06163742|DEVICE|Standard-of-Care|The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
58259467|NCT01070667|DRUG|Dronedarone|400mg orally once per day for 3 months
57910056|NCT04628351|BEHAVIORAL|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
58259468|NCT01070667|DRUG|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
58259469|NCT06623812|OTHER|Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake|Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
58259470|NCT04737395|DEVICE|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
58259471|NCT04676958|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
58259472|NCT04676958|DIETARY_SUPPLEMENT|Micro-crystalline cellulose|Micro-crystalline cellulose
58259473|NCT06041308|OTHER|valve|bioprothetic valve versus mechanical valve
58259474|NCT06018558|GENETIC|OCU410|Subretinal administration of OCU410
58259475|NCT06090409|OTHER|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
58259476|NCT01232881|PROCEDURE|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
58259477|NCT01232881|PROCEDURE|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
58259478|NCT06622447|DIETARY_SUPPLEMENT|βGluCnCs intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
58259479|NCT06622447|DIETARY_SUPPLEMENT|Placebo intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
58259480|NCT04993508|DIAGNOSTIC_TEST|PSA test|testing for blood levels of PSA
58259481|NCT04993508|DEVICE|multiparametric prostate Magnetic Resonance Imaging (mpMRI)|mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD \> 0.15 will considered suspicious for csPCa.
57910057|NCT05526079|OTHER|Watchfuf waiting|Careful review of patient response with the hope of avoiding radical surgery.
57910058|NCT03341689|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
57910059|NCT03341689|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
57910060|NCT03341689|DRUG|Placebo|microcrystalline cellulose capsule
57910061|NCT03398213|OTHER|Acupuncture|Acupuncture
57910062|NCT03398213|OTHER|Sham procedure|Ear stimulation with plaster
58259482|NCT04993508|PROCEDURE|targeted MRI/US fusion-guided biopsy|Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
58259483|NCT04993508|PROCEDURE|combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)|The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
58259484|NCT04993508|PROCEDURE|MRI inbore biopsy|MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
58259485|NCT05370586|OTHER|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
58259486|NCT05370586|OTHER|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
58259487|NCT05685134|DEVICE|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
58259488|NCT05685134|DEVICE|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
58259489|NCT05367271|DRUG|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
58259490|NCT05367271|DRUG|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
58259491|NCT01500187|DEVICE|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
58259492|NCT01500187|DEVICE|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
58259493|NCT02289781|DEVICE|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
58259494|NCT02289508|DEVICE|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
58259495|NCT02289508|DEVICE|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
58259496|NCT06324071|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
58259497|NCT06324071|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
58259498|NCT05969223|DRUG|Risankizumab|Subcutaneous injection
58259499|NCT05969223|DRUG|Placebo for Risankizumab|Subcutaneous injection
58259500|NCT00109681|DRUG|Iloprost Inhalation Solution (Ventavis)|
58259501|NCT05068778|BEHAVIORAL|Artificial Intelligence Application|AI application through smart phone
58259502|NCT04270864|DRUG|Ipilimumab|20mg (4mL) IT
58259503|NCT04270864|DRUG|Nivolumab|360mg IV then 480mg IV
58259504|NCT04270864|DRUG|Tilsotolimod|8 mg (2mL) IT
58259505|NCT01138358|OTHER|medical chart review|
58381437|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
58259506|NCT01138358|OTHER|study of socioeconomic and demographic variables|
58259507|NCT01138358|OTHER|survey administration|
58259508|NCT01138358|PROCEDURE|quality-of-life assessment|
58259509|NCT05959096|DRUG|LY3437943|Administered SC
58259510|NCT05959096|DRUG|LY3437943|Administered IV
58259511|NCT01531530|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
58259512|NCT01531530|OTHER|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
58259513|NCT02643849|DEVICE|The Spanner Temporary Prostatic Stent|
58259514|NCT02247596|DRUG|Resveratrol|1g tds 2 weeks
58259515|NCT02247596|DRUG|Placebo|Sugar pill 1g tds for 2 weeks
58259516|NCT02370589|BIOLOGICAL|Base Dose EBOV GP Vaccine|
58259517|NCT02370589|BIOLOGICAL|2x Base Dose EBOV GP Vaccine|
58259518|NCT02370589|BIOLOGICAL|4x Base Dose EBOV GP Vaccine|
58259519|NCT02370589|BIOLOGICAL|8x Base Dose EBOV GP Vaccine|
58259520|NCT02370589|BIOLOGICAL|Placebo|
58259521|NCT02370589|BIOLOGICAL|Matrix-M Adjuvant|
58259522|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation alone|Ablation of the pulmonary veins for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
58259523|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation|Ablation of the pulmonary veins and the left atrium posterior wall for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
58259524|NCT06621940|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
58381438|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
58259525|NCT06621940|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
58381439|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
58381440|NCT00002798|DRUG|asparaginase|
58381441|NCT00002798|DRUG|daunorubicin hydrochloride|
58058411|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
58058412|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
58259526|NCT04018456|OTHER|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
58259527|NCT04018456|OTHER|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
58259528|NCT05299931|DRUG|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
57910063|NCT01493232|OTHER|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
58058413|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
57910064|NCT01975870|OTHER|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
58058414|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
58259529|NCT02153671|BIOLOGICAL|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
58259530|NCT02153671|BIOLOGICAL|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
58259531|NCT05970588|BEHAVIORAL|Standing Promotion Intervention|Participants will be provided with a standing desk converter to set on top of their existing desk for 4 weeks.
57708288|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
57708289|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
58058415|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
58058416|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
58259532|NCT06620991|DRUG|Phentolamine|A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml
58381442|NCT00002798|DRUG|fludarabine phosphate|
58381443|NCT00002798|DRUG|therapeutic hydrocortisone|
58381444|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
58381445|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
58381446|NCT00002798|BIOLOGICAL|filgrastim|Given SC
58381447|NCT00002798|DRUG|cytarabine|Given IV or IT
58381448|NCT00002798|DRUG|idarubicin|Given IV
58381449|NCT00002798|DRUG|dexamethasone|Given PO
58381450|NCT00002798|DRUG|thioguanine|Given PO
58381451|NCT00002798|DRUG|etoposide|Given IV
57708290|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
58381452|NCT00002798|DRUG|methotrexate|Given IT
57910065|NCT01244854|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
58259533|NCT06620991|DRUG|Esmolol|A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml
58259534|NCT00026442|DRUG|capecitabine|
58259535|NCT06350318|DRUG|Zanubrutinib|Zanubrutinib is an anti-cancer medication administered orally.
58259536|NCT06350318|DRUG|Rituximab|Rituximab is a biologic medication administered intravenously or subcutaneously.
58259537|NCT06602427|OTHER|Shoulder proprioception measurement using isokinetic dynamometer|A Cybex brand isokinetic dynamometer \[Cybex NORM®, Humac, CA, USA\] was used for shoulder proprioception assessment. Active Joint Position Sensation (AJPS) was evaluated to examine proprioception. AJPS was measured in the sitting position. The target angle was 30° external and 30° internal rotation. The participant was positioned with the elbow in 90° flexion and the wrist in the neutral position. The dynamometer was fixed at 0° to ensure the same starting position for each participant during trials and evaluations. Before starting the test, 3 trials were performed and then the participants were asked to find the target angle 3 times. The amount of error between the target angle and the angle found by the participant was used to describe the accuracy of the AJPS. The arithmetic mean of the result of the 3 tests was recorded for use.
58259538|NCT04441684|DIAGNOSTIC_TEST|Blood sample for serological test|"Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
58259539|NCT04216589|DRUG|Semaglutide|Administered subcutaneously
58259540|NCT05540158|OTHER|Mobile Integrated Health Intervention|"Subjects will have access to on-demand mobile integrated health program for acute symptoms. Subjects will be educated on the nature and capabilities of the MIH community paramedics and will be able to call a hotline for unscheduled visits 24 hours a day, 7 days a week if they wish to be evaluated for acute symptoms or changes in their condition. All visits entail focused history and physical exam with community paramedic, portable diagnostics as indicated, and telehealth visit with a physician"
58259541|NCT00070382|DRUG|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
58259542|NCT00070382|DRUG|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
58259543|NCT05176483|DRUG|Zanzalintinib|Zanzalintinib orally once daily (qd)
58259544|NCT05176483|DRUG|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
58259545|NCT05176483|DRUG|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
57708291|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
57708292|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
57708293|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
57708294|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
58259546|NCT05176483|DRUG|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
58259547|NCT05176483|DRUG|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
58259548|NCT05176483|DRUG|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
58381453|NCT00002798|DRUG|cyclophosphamide|Given IV
58381454|NCT00002798|BIOLOGICAL|aldesleukin|
58259549|NCT00382590|DRUG|5-Azacytidine|75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.
58259550|NCT00382590|DRUG|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
58259551|NCT00382590|DRUG|Valproic Acid (VPA)|50 mg/m\^2 orally daily days 1-7.
58381455|NCT00002798|DRUG|busulfan|
58381456|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
58381457|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
58381458|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
58381459|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
58381460|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
58381461|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
58259552|NCT06039371|PROCEDURE|Biopsy|Undergo a biopsy
58259553|NCT06039371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58381462|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
58381463|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
58381464|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
58381465|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
58381466|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
58259554|NCT06039371|PROCEDURE|Bone Scan|Undergo bone scan
58259555|NCT06039371|DRUG|Carboplatin|Given IV
58381467|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
58381468|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
57910066|NCT04298021|DRUG|AZD6738|"* In AZD6738+Durvalumab cohort~  - AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"
57910067|NCT04298021|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
58259556|NCT06039371|PROCEDURE|Computed Tomography|Undergo CT
57910068|NCT04298021|DRUG|Olaparib|Olaparib 300 mg bid on D1-28 Every 4 weeks
58259557|NCT06039371|DRUG|Etoposide|Given PO
58259558|NCT06039371|OTHER|Quality-of-Life Assessment|Ancillary studies
58259559|NCT06039371|OTHER|Questionnaire Administration|Ancillary studies
58259560|NCT06039371|DRUG|Testosterone Cypionate|Given IM
58259561|NCT05797415|PROCEDURE|Sentinel Lymph Node Biopsy|"* Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
58259562|NCT04725058|OTHER|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
58259563|NCT04725058|OTHER|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
58259564|NCT01521156|OTHER|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
58381469|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
58381470|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
58381471|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
58381472|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
57910069|NCT05202639|OTHER|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
57910070|NCT01474434|DRUG|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
57910071|NCT01474434|DRUG|Placebo|matching placebo tablets
57910072|NCT00456677|DRUG|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
58259565|NCT01521156|OTHER|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
58259566|NCT00864825|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
58259567|NCT06473597|DRUG|Rimegepant|NURTEC ODT 75 mg orally disintegrating tablets
58259568|NCT06473597|DRUG|Rizatriptan Benzoate|Rizatriptan ODT 10mg orally disintegrating tablets
58259569|NCT00875199|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
58259570|NCT00875199|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
58259571|NCT03249597|DIAGNOSTIC_TEST|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
58259572|NCT06255522|PROCEDURE|Fully guided implant placement|Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
58259573|NCT06522282|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
57910073|NCT00456677|DRUG|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
58259574|NCT06522282|COMBINATION_PRODUCT|Standard stroke unit|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
58259575|NCT06431399|DRUG|JLP-2004 qd|Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
58259576|NCT04725318|OTHER|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
58259577|NCT04616573|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
57708295|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
57708296|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
57708297|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
57708298|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
57708299|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
57708300|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
57708301|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
57708302|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
57708303|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
57910074|NCT06067061|COMBINATION_PRODUCT|Atezolizumab + RP1|Patients will be treated in a window period (ie 3 treatment cycles). After evaluation, patients that had no increase in ctDNA after 3 cycles (see Definition of ctDNA status) will continue on the same treatment (intratumoral injections of RP1 in combination with Atezolizumab) for a total of 10 treatment cycles prior to surgery.
57910075|NCT02891408|DRUG|Firsocostat|Capsule(s) administered orally on Day 1
57910076|NCT02891408|DRUG|Fenofibrate|Tablet administered orally on Day 1
57910077|NCT03524053|OTHER|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
57910078|NCT03524053|OTHER|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
57910079|NCT04955444|OTHER|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
57910080|NCT03417895|DRUG|SHR-1210|A humanized anti-PD-1 monoclonal antibody
58259578|NCT04616573|DEVICE|iStent inject|Trabecular meshwork implantation
58259579|NCT02078895|DRUG|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
58259580|NCT05803070|DRUG|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
58259581|NCT05803070|DRUG|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
58259582|NCT06423963|BEHAVIORAL|Physical Activity|Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.
58259583|NCT06423963|BEHAVIORAL|Nutrition Counseling|Participants will receive nutritional counseling with a registered dietician.
58259584|NCT06423963|BEHAVIORAL|Resistance Training|Participants will engage in progressive, full-body resistance training based on American College of Sports Medicine (ACSM) guidelines.
58259585|NCT00302484|DRUG|Zoledronate|
58259586|NCT06320015|BEHAVIORAL|Substance Misuse Assistance Response Team (SMART)|The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.
58259587|NCT06320015|OTHER|Usual Care Group|Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
58259588|NCT03632629|OTHER|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
58259589|NCT05989711|DRUG|Pemvidutide|Administered by subcutaneous injection
58259590|NCT05989711|DRUG|Placebo|Administered by subcutaneous injection
58259591|NCT03003039|BIOLOGICAL|GB241|Single intravenous infusion (IV) 375 mg/m2
58259592|NCT03003039|BIOLOGICAL|Rituximab|Single intravenous infusion (IV) 375 mg/m2
58259593|NCT04353167|OTHER|observational evaluation|Patients will be evaluated only observationally without intervention
58259594|NCT05587829|OTHER|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
58259595|NCT05587829|OTHER|basic breathing technique|Deep Breathing for 15 minutes
58259596|NCT06623825|DEVICE|teleconsultation by Augmented Reality smart glasses|The device operated on Android 9.0 and it connected to 5G connection with a bandwidth speed 30-mbps delivering a very low latency. The device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. Physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. The features facilitate healthcare providers at SRRSH and medical personnel in the HAG2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient.
58259597|NCT06623825|DEVICE|teleconsultation by two-way radio connection.|adhering to the standard conventional triage process without the AR tool, only using a two-way radio connection.
58381473|NCT04295837|OTHER|Usual Care|Standard occupational therapy
58381474|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
57910081|NCT03417895|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
58259598|NCT04184362|DEVICE|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
58259599|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|phase 3 tablets
58259600|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|registration tablets
58259601|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment C)|registration tablets
58259602|NCT02573766|PROCEDURE|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
58259603|NCT02573766|PROCEDURE|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
58259604|NCT02573766|BEHAVIORAL|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
58381475|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
58259605|NCT02573766|BEHAVIORAL|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
58381476|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
58381477|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
58381478|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
58381479|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
58259606|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
58259607|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
58259608|NCT02530411|DRUG|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
57910082|NCT00294918|DRUG|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
57910083|NCT02677454|DEVICE|Flash Glucose Monitor|
57910084|NCT02907645|BEHAVIORAL|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
57910085|NCT02907645|BEHAVIORAL|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
57910086|NCT06137326|DEVICE|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
57910087|NCT06137326|DEVICE|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
57910088|NCT01660581|BIOLOGICAL|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
57910089|NCT01660581|BIOLOGICAL|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
57910090|NCT02486276|DRUG|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
57910091|NCT02486276|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
57910092|NCT02486276|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
57910093|NCT03397732|PROCEDURE|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
58259609|NCT02530411|DRUG|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
58058417|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
58259610|NCT06622603|DRUG|Febuxostat|The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
58259611|NCT03221426|BIOLOGICAL|Pembrolizumab|IV infusion
58259612|NCT03221426|DRUG|Placebo|IV infusion
58259613|NCT03221426|DRUG|Cisplatin|IV infusion
58259614|NCT03221426|DRUG|Capecitabine|Oral tablets
58259615|NCT03221426|DRUG|5-fluorouracil|IV infusion
58259616|NCT03221426|DRUG|Docetaxel|IV infusion
58259617|NCT03221426|DRUG|Oxaliplatin|IV infusion
58259618|NCT03221426|DRUG|Leucovorin|IV infusion
58259619|NCT05784974|DRUG|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
58259620|NCT06621563|DRUG|HS-20117 combined HS-20093|HS-20117 + HS-20093
58259621|NCT06621563|DRUG|HS-20117 combined Platinum-containing chemotherapy|HS-20117 + cisplatin/carboplatin + pemetrexed
58259622|NCT06621563|DRUG|HS-20117 combined HS-20093 and 5-FU|HS-20117 + HS-20093 + 5-FU
58259623|NCT06053398|DRUG|Phenylephrine|Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) \> 65 mm Hg.
58259624|NCT06053398|DRUG|Norepinephrine|Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
58259625|NCT04284930|DRUG|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
58259626|NCT04284930|DRUG|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
58259627|NCT04284930|DRUG|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
58259628|NCT02402023|BEHAVIORAL|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
58381480|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
57708304|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
57910094|NCT06054282|BEHAVIORAL|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
57910095|NCT04949347|BIOLOGICAL|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
57910096|NCT02721667|DEVICE|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
57910097|NCT02721667|OTHER|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
57910098|NCT03386825|DRUG|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
57910099|NCT02341027|DEVICE|Jadelle|within 5 days of delivery and before discharge from hospital
57910100|NCT02341027|DEVICE|Jadelle|6-8 weeks (42-56 days) postpartum
58259629|NCT02402023|BEHAVIORAL|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
57910101|NCT04852367|DEVICE|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
58259630|NCT06620497|PROCEDURE|stress free implant bar|SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
57708305|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
57708306|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
57910102|NCT04852367|DRUG|Doxorubicin|Doxorubicin infusion
58259631|NCT06620497|PROCEDURE|milled bar|bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
58381481|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
58381482|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
58381483|NCT02909088|DRUG|Ecopipam 50mg|
57910103|NCT04852367|DRUG|ThermoDox|ThermoDox infusion
57910104|NCT02513719|DEVICE|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
57910105|NCT00559611|PROCEDURE|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
58259632|NCT05629234|DRUG|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
58259633|NCT02179606|DEVICE|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
58259634|NCT02179606|DEVICE|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
58259635|NCT03343717|OTHER|Rehabilitation|physical therapy exercise
58259636|NCT03343717|OTHER|Chest physical therapy|chest physical therapy exercise
58381484|NCT02909088|DRUG|Ecopipam 100mg|
58259637|NCT04648982|OTHER|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
58259638|NCT01878812|BIOLOGICAL|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
58259639|NCT00559624|DRUG|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
58259640|NCT06419686|OTHER|Placebo (saline)|Intravenous saline during experimental days.
58259641|NCT06419686|DRUG|GIP|Intravenous GIP administration during experimental days.
58259642|NCT06419686|DRUG|Alanine|Intravenous alanine administration during experimental days.
58259643|NCT06419686|DRUG|GIP + alanine|Intravenous administration of GIP and alanine during experimental days.
58259644|NCT03326349|OTHER|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
58259645|NCT03326349|OTHER|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
58259646|NCT06141616|OTHER|Asthma Rehabilitation Program|The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.
58259647|NCT01513109|BIOLOGICAL|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
58259648|NCT06564519|DEVICE|Posture Biofeedback Device|Participants will wear a commercially available posture training device for a two-week tracking period and a two-week training period while performing laparoscopic procedures.
58381485|NCT00042237|BEHAVIORAL|Schema Therapy|
58381486|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
58381487|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
58381488|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
58381489|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
58381490|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
58381491|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
58381492|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
58381493|NCT01872975|RADIATION|regional nodal XRT|
58381494|NCT01872975|RADIATION|chestwall XRT|
58381495|NCT01872975|RADIATION|WBI|
58381496|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
58381497|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
57910106|NCT00559611|PROCEDURE|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
57910107|NCT05251701|DEVICE|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
57910108|NCT00802698|DEVICE|Transcorneal electric stimulation|central artery occlusion
57910109|NCT00802698|DEVICE|Transcorneal stimulation|new waveform
57910110|NCT00802698|DEVICE|transcorneal electric stimulation|Novel waveform central artery occlusion
58259649|NCT00110227|BEHAVIORAL|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
58381498|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
58381499|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
58381500|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
58381501|NCT01847092|DRUG|AZD1722|
58381502|NCT01847092|DRUG|Placebo|Placebo for AZD1722
58381503|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
58381504|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
58381505|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
58058418|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
58259650|NCT00110227|BEHAVIORAL|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
58259651|NCT02968433|DRUG|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
58259652|NCT03824132|BEHAVIORAL|Improvisational comedy classes|6 consecutive improvisational comedy classes
58058419|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
58058420|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
58381506|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
58381507|NCT00003262|BIOLOGICAL|bleomycin sulfate|
58381508|NCT00003262|BIOLOGICAL|filgrastim|
58381509|NCT00003262|DRUG|Stanford V regimen|
58381510|NCT00003262|DRUG|doxorubicin hydrochloride|
58381511|NCT00003262|DRUG|epirubicin hydrochloride|
58381512|NCT00003262|DRUG|etoposide|
58381513|NCT00003262|DRUG|mechlorethamine hydrochloride|
58381514|NCT00003262|DRUG|prednisone|
58381515|NCT00003262|DRUG|vinblastine sulfate|
58259653|NCT03824132|BEHAVIORAL|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
58259654|NCT03832790|OTHER|observation|observation
58259655|NCT00995046|DRUG|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
58259656|NCT00995046|DRUG|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
58259657|NCT06597617|BEHAVIORAL|Adapted physical activity with aerobic training [GEA]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions."
58381516|NCT00003262|DRUG|vincristine sulfate|
58381517|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
58381518|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
58381519|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
58381520|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
58381521|NCT03951610|DEVICE|Test lens|contact lens
58381522|NCT03951610|DEVICE|Control lens|contact lens
58259658|NCT06597617|BEHAVIORAL|Adapted physical activity with strength training [GRM]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity."
58259659|NCT03452046|OTHER|IVC diametres|
58259660|NCT04116827|DRUG|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
58381523|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
57910111|NCT05757284|DIAGNOSTIC_TEST|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
57910112|NCT01321385|OTHER|laboratory biomarker analysis|
57910113|NCT01321385|OTHER|study of socioeconomic and demographic variables|
57910114|NCT00756691|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
57910115|NCT06074029|DRUG|Immune Checkpoint Inhibitors|Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
57910116|NCT02859324|DRUG|CC-122|
57910117|NCT02859324|DRUG|Nivolumab|
57910118|NCT06145191|DRUG|Tranexamic acid|Prophylactic topical application (1x) of tranexamic acid (100mg, 2ml, room temperature) before sampling
57910119|NCT06145191|DRUG|Adrenaline|Prophylactic topical application (1x) of adrenaline (1:10.000, 2ml, room temperature) before sampling
57910120|NCT06145191|DRUG|Placebo|Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
57910121|NCT06576661|DEVICE|INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™.
58058421|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
58259661|NCT04990323|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)
58259662|NCT06596460|DIAGNOSTIC_TEST|TAVI planning CT (adapted)|TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
58259663|NCT06648564|PROCEDURE|Bone regenerative surgery with a bone graft substitute and a resorbable membrane|Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
58259664|NCT01570270|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
58259665|NCT05889585|OTHER|quality of life questionnaire|EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
58259666|NCT04654754|DEVICE|high-flow high humidity oxygen device with tracheostomy adapter|This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
58259667|NCT02144480|BEHAVIORAL|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
58259668|NCT02144480|BEHAVIORAL|traditional training|usual care: conventional rehabilitation
58259669|NCT06623708|DEVICE|SMARTCLOTH|The intervention consists of using SMARTCLOTH. This device makes it possible to monitor dietary intake throughout the day and record it in a database that, through a website, allows to track it. SMARTCLOTH is a digital tablecloth consisting of a scale, several buttons and a screen. The device allows weighing the food to be consumed and recording its nutritional value (macronutrients in grams, macronutrient servings and kilocalories). The latter is achieved because SMARTCLOTH allows the patient to select to which food group the food being weighed belongs, increasing the accuracy of the nutritional estimation.
58259670|NCT04064242|DRUG|CMK389|single i.v. dose every 4 weeks
58259671|NCT04064242|DRUG|Placebo|single i.v. dose every 4 weeks
58259672|NCT05356533|BEHAVIORAL|Drinking to Cope CBT skills|Young adults who drink to cope with negative affect will receive 8 web-based modules with cognitive behavioral skills
58259673|NCT04424212|BEHAVIORAL|Intervention group CoronaCope|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
58259674|NCT05340933|OTHER|Voice registration|Voice registration
58259675|NCT03140072|DRUG|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
57910122|NCT02215382|DRUG|sugammadex|sugammadex 2 mg/kg
57708307|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
58259676|NCT03140072|DRUG|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
58259677|NCT02218736|DRUG|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
58259678|NCT02218736|DRUG|placebo|oral dosing of 10 mg placebo daily for 8 weeks
58259679|NCT01654653|DRUG|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
58259680|NCT01654653|DRUG|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
58259681|NCT01803503|DRUG|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
58259682|NCT01803503|DRUG|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
58259683|NCT01254318|OTHER|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
57708308|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
57910123|NCT02215382|DRUG|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
57910124|NCT01313247|DRUG|paracetamol|1000 mg 4 times daily
57910125|NCT01313247|DRUG|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
57910126|NCT04924842|OTHER|Review of medical file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
57910127|NCT04924842|OTHER|Phone call interview|less than 15 minutes phone call
58058422|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
58259684|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Dietary supplement I (WPowDSI)|The WPowDSI group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding supplementation, participants were randomly assigned to receive their daily dose.
58259685|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Placebo (WPowPl)|The WPowCr group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding placebo, participants were randomly assigned to receive their daily dose.
58381524|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
57910128|NCT04889105|BEHAVIORAL|Smart MOVE!|"Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring"
57910129|NCT04889105|BEHAVIORAL|General walking advice|Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
58058423|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
58058424|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
58381525|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
58259686|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Dietary supplement I (EBPowDSI)|The EBPowDSI group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
58381526|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
58259687|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Placebo (EBPowPl)|The EBPotPl group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition,) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
58259688|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)|The EBEccDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
58381527|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
58381528|NCT04861779|DRUG|HSK29116|Oral HSK29116
58381529|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
58381530|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
58381531|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
58381532|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
58381533|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
58381534|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
58381535|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
58381536|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
58381537|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
58381538|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
58381539|NCT06288204|DIETARY_SUPPLEMENT|Propolis + Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
58381540|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
58058425|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
58058426|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
58058427|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
58259689|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Placebo (EBEccPl)|The EBEccPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding placebo, participants were randomly assigned to receive their daily dose.
58058428|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
58058429|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
58259690|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)|The EBMaxDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
58381541|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
58058430|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
57708309|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
58058431|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
58058432|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
58058433|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
58058434|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
58058435|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
58058436|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
58058437|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
58058438|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
58058439|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
58259691|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Placebo (EBMaxPl)|The EBMaxPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
58259692|NCT06620666|DIETARY_SUPPLEMENT|Control + Placebo (CPl)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding placebo, participants were randomly assigned to receive their daily dose.
58259693|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement I (CDSI)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
58058440|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
58058441|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
58058442|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
58058443|NCT00381472|DRUG|Ropinirole|
58058444|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
58381542|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
58381543|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
58381544|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
58381545|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
58381546|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
58381547|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
58058445|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
58058446|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
57708310|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
58259694|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement (CDSII)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
58381548|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
57708311|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
58259695|NCT06620666|DIETARY_SUPPLEMENT|Active Comparator: Aerobic training + Placebo (AerPl)|The group will perform aerobic exercise for 20-40 minutes with easy execution exercise. Regarding placebo, participants were randomly assigned to receive their daily dose.
58259696|NCT04722367|BEHAVIORAL|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
58259697|NCT02686866|DEVICE|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
57910130|NCT04889105|BEHAVIORAL|Performance evaluation|"Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2) N-of-1 trials to refine the intervention"
57910131|NCT02250092|DEVICE|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
57910132|NCT02250092|DEVICE|Placebo Comparator|
58058447|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
58259698|NCT02686866|DEVICE|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
58259699|NCT02686866|DEVICE|hand grip strength|
58381549|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
58381550|NCT01999686|DRUG|DLBS3233|
57708312|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
57708313|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
57910133|NCT04002401|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of CAR-transduced autologous T cells administered intravenously
57910134|NCT04002401|DRUG|Rituximab|Administered intravenously
58058448|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
58058449|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
58058450|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
58259700|NCT05026905|DRUG|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
58259701|NCT05026905|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
58381551|NCT01999686|DRUG|Metformin XR|
58381552|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
58381553|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
58381554|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
57708314|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
57708315|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
57708316|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
57910135|NCT04002401|DRUG|Fludarabine|Administered according to package insert
57910136|NCT04002401|DRUG|Cyclophosphamide|Administered according to package insert
57910137|NCT04028089|BEHAVIORAL|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
57910138|NCT04028089|OTHER|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
57910139|NCT00485901|DRUG|Olanzapine Hydrochloride|
57708317|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
57708318|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
58259702|NCT05026905|DRUG|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day"
57708319|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
57708320|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
57708321|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
57708322|NCT01790464|DRUG|placebo|
57708323|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
57708324|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
57708325|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
58058451|NCT00779818|DEVICE|Laser|Treatment by laser
58259703|NCT05026905|DRUG|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
58259704|NCT05026905|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
58259705|NCT03185715|BEHAVIORAL|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
58259706|NCT06247384|DEVICE|Hypotension Prediction Index Hemodynamic Monitoring|The application of the perioperative hemodynamic management according to the hypotension prediction index algorithm.
58381555|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
58381556|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
58381557|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
57708326|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
57708327|NCT00413725|OTHER|Placebo|Placebo
57708328|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
57708329|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
57708330|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
57708331|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
57708332|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
57708333|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
57708334|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
57708335|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
57708336|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
57708337|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
57910140|NCT00485901|DRUG|Haloperidol|
58259707|NCT00000161|DRUG|Aspirin|
58259708|NCT00000161|DRUG|Beta-Carotene|
58259709|NCT00000161|DRUG|Vitamin C|
58259710|NCT00000161|DRUG|Vitamin E|
58259711|NCT02331550|PROCEDURE|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
58259712|NCT02331550|PROCEDURE|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
58259713|NCT04822194|BEHAVIORAL|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
58259714|NCT06066723|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
57708338|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
58259715|NCT06623747|BEHAVIORAL|Diet|15 kcal per kg fat-free mass
58259716|NCT06623747|BEHAVIORAL|Diet|45 kcal per kg fat-free mass
57708339|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
57708340|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
58058452|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
58058453|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
58259717|NCT06618742|PROCEDURE|Cryotherapy|Focal cryoballoon ablation, 1-3 treatments with an interval of 1-3 weeks
57708341|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
57708342|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
58058454|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
58058455|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
57708343|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
57708344|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
58058456|NCT04322266|DRUG|HGP0904|Amlodipine
58058457|NCT04322266|DRUG|HGP0608|Losartan potassium
58259718|NCT06157164|OTHER|UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)|Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
58259719|NCT06620965|PROCEDURE|Mulligan Mobilization Technique|NAGs (Natural Apophyseal Glides) involve passive oscillatory movements of a spinal facet joint in an anterocranial direction, performed with the patient seated. SNAGs (Sustained Natural Apophyseal Glides) maintain facet glides during active movements, aiming to reach the joint\&#39;s end range. In SNAGs, the patient actively participates, and overpressure is applied at the end of movements to enhance the range of motion. Techniques include increasing rotation, lateral flexion, flexion, and extension. These were applied by a certified physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain.
57910141|NCT05619029|RADIATION|X-ray|Chest radiographs
57910142|NCT04011943|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
57910143|NCT02819362|DEVICE|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
57910144|NCT03177499|PROCEDURE|Invasive PPG|Invasive PPG obtained by means of catheterization.
58058458|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
58381558|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
57910145|NCT00057629|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
57910146|NCT00057629|BEHAVIORAL|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
57910147|NCT00057629|BEHAVIORAL|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
57910148|NCT03117231|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
57910149|NCT03117231|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
57910150|NCT01993173|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
57910151|NCT01993173|BIOLOGICAL|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
58058459|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
58058460|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
58058461|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
58058462|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
58058463|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
58058464|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
58058465|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
58259720|NCT06620965|PROCEDURE|Proprioceptive Neuromuscular Facilitation (PNF) Technique|"Proprioceptive Neuromuscular Facilitation (PNF) Technique: PNF consists of four movement patterns in two diagonals:~Flexion-left rotation and extension-right rotation Flexion-right rotation and extension-left rotation 3 PNF techniques were applied.~Combined Isotonic Contractions: This technique involves concentric, eccentric, and stabilizing contractions of a muscle group (agonist). The goal is to increase active range of motion (ROM), strength, and improve control and coordination.~Dynamic Stabilization (Stabilizing Reversal): This involves applying resistance in various directions to prevent movement, aiming to enhance dynamic stability, strength, and agonist-antagonist coordination.~Hold-Relax Technique: This relaxation method involves isometric contractions against maximum resistance without movement to increase passive ROM and reduce pain. These were applied by physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain."
58259721|NCT00455559|DRUG|Perifosine|
58259722|NCT00455559|DRUG|Imatinib Mesylate|
58259723|NCT05398952|DIAGNOSTIC_TEST|Laboratory investigations|Laboratory investigations correlated with symptoms and imaging results
58259724|NCT00604942|PROCEDURE|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
57910152|NCT01993173|BIOLOGICAL|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
58058466|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
58058467|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
58058468|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
58058469|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
58058470|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58058471|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
58058472|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
58259725|NCT00604942|PROCEDURE|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
58259726|NCT00604942|DRUG|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
58259727|NCT00604942|DRUG|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
57910153|NCT02807103|DRUG|Rituximab|1 g intravenous pulse at day1 and day15
57910154|NCT02807103|DRUG|Placebo-rituximab|intravenous pulses at day1 and day15
57910155|NCT02807103|DRUG|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
58058473|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
57910156|NCT02807103|DRUG|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
57910157|NCT00417105|PROCEDURE|hemodialysis|group 1: twice weekly, four hours
57910158|NCT00417105|PROCEDURE|hemodialysis|group 2: twice weekly, eight hours
58259728|NCT04453072|OTHER|Interview|Participate in interviews
58259729|NCT04453072|OTHER|Media Intervention|Receive iPhone with W8Loss2Go app
58259730|NCT04453072|OTHER|Questionnaire Administration|Complete questionnaires
58259731|NCT04453072|OTHER|Scale Device|Receive body scale and food scale
58259732|NCT04453072|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
58259733|NCT04453072|OTHER|Text Message|Receive text message
58259734|NCT01170026|BEHAVIORAL|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion \& Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
57910159|NCT00417105|PROCEDURE|hemodialysis|group 3: every other day, eight hours
58259735|NCT01170026|BEHAVIORAL|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
57910160|NCT00417105|PROCEDURE|hemodialysis|group 4: six days a week, eight hours
57910161|NCT06419478|OTHER|postoperative symptoms|Observational study, focusing solely on symptom surveys of patients.
57910162|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
57910163|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
57910164|NCT02190045|OTHER|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
57910165|NCT02190045|OTHER|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
57910166|NCT01276938|RADIATION|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
58058474|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
58058475|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
57910167|NCT01276938|RADIATION|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
57910168|NCT04251507|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
57910169|NCT04812275|PROCEDURE|Skin closure|Skin closure
57910170|NCT00911937|DRUG|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
58058476|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
58058477|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
58058478|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
58058479|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
57910171|NCT00911937|DRUG|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
58058480|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
57910172|NCT05631470|DIAGNOSTIC_TEST|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
58058481|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
58058482|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
58058483|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
57910173|NCT01546636|OTHER|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
58058484|NCT01738594|DRUG|carfilzomib|Given IV
58058485|NCT01738594|DRUG|romidepsin|Given IV
58259736|NCT05460221|DIETARY_SUPPLEMENT|Optimized oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
58259737|NCT05460221|DIETARY_SUPPLEMENT|Functional oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
58259738|NCT05460221|DIETARY_SUPPLEMENT|Control group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
58259739|NCT02389569|PROCEDURE|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
57910174|NCT01546636|OTHER|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
57910175|NCT01048554|DRUG|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
57910176|NCT01048554|DRUG|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
57910177|NCT01959997|PROCEDURE|Redo PVI|
57910178|NCT01959997|PROCEDURE|PVI + RDN|
57910179|NCT00416832|DRUG|cyclophosphamide|
57910180|NCT00416832|DRUG|dacarbazine|
57910181|NCT00416832|DRUG|doxorubicin hydrochloride|
57910182|NCT00416832|DRUG|etoposide|
58259740|NCT02389569|PROCEDURE|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
57910183|NCT00416832|DRUG|prednisone|
57910184|NCT00416832|DRUG|procarbazine hydrochloride|
57910185|NCT00416832|DRUG|vincristine sulfate|
57910186|NCT00416832|RADIATION|radiation therapy|
57910187|NCT02217124|OTHER|dried apples|120 calories
57910188|NCT02217124|OTHER|muffin|120 calories
57910189|NCT04054518|DRUG|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
57910190|NCT06605495|COMBINATION_PRODUCT|fumigation with Chinese medicine|Eye fumigation with the Eyesight Eye Therapy,10 minutes once daily for 6 weeks.
57910191|NCT06605495|DRUG|Oral herbal medicine|Patients were identified into the appropriate group according to the individual evidence profile, and the herbal formula under the corresponding evidence profile was taken orally as one dose of 150 ml of water twice a day for 6 weeks.
57910192|NCT06605495|DRUG|Modern Western Medicine|Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
57910193|NCT05790577|DRUG|Metformin and Nicotinamide vs Kligman Formula|Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
57910194|NCT05462886|DEVICE|Masimo INVSENSOR00057|Noninvasive wearable health monitoring device
57910195|NCT03420170|OTHER|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
57910196|NCT03420170|OTHER|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
57910197|NCT00670345|DRUG|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
57910198|NCT00670345|DRUG|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
57910199|NCT05868902|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
57910200|NCT00974376|DRUG|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
58058486|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
58058487|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
57910201|NCT00974376|DRUG|Placebo|1200mg/day of placebo for 12 weeks
58058488|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
58058489|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
58058490|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
57708345|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
57708346|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
57708347|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
57708348|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
57708349|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
57910202|NCT00974376|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
57910203|NCT01458431|DRUG|Levobupivacaine|continuous levobupivacaine subfascial infusion
57910204|NCT01458431|DRUG|NaCl|continuous NaCl subfascial infusion
57910205|NCT00950794|DRUG|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
58259741|NCT01472653|DRUG|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
58259742|NCT01472653|RADIATION|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
57708350|NCT00898703|OTHER|flow cytometry|
57708351|NCT00898703|OTHER|immunoenzyme technique|
57708352|NCT00898703|OTHER|laboratory biomarker analysis|
57708353|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
57708354|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
57910206|NCT00950794|DRUG|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
57910207|NCT00159133|DRUG|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
57910208|NCT03732404|DRUG|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
57910209|NCT03732404|DRUG|Placebo|The control group will receive plain water with the same volume and timing of treatment.
57910210|NCT01415362|DEVICE|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
57910211|NCT00370682|BIOLOGICAL|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
57910212|NCT00370682|BIOLOGICAL|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
58259743|NCT01472653|DRUG|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
57708355|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
57708356|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
57708357|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
57708358|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
57708359|NCT02790346|PROCEDURE|arthrodesis talonavicular|
57708360|NCT02790346|PROCEDURE|tendon gestures|
58058491|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
58259744|NCT00539162|BEHAVIORAL|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
58259745|NCT06506045|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of known non-functional and functional implanted shunts will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
58259746|NCT02063945|DRUG|Methylphenidate|As stated in arm/group
57910213|NCT00370682|OTHER|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
57910214|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg with phytase supplement 176mg (800FTU)|zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day
57910215|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg|zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.
57910216|NCT05670015|DRUG|Low dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
57910217|NCT05670015|DRUG|High dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
57910218|NCT06495372|DRUG|Experimenta group (standard of care + Methoxyflurane).|standard of care + Methoxyflurane
57910219|NCT06495372|DRUG|control group (standard of care + placebo).|standard of care + placebo
57910220|NCT02047331|PROCEDURE|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
57910221|NCT02047331|PROCEDURE|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
57910222|NCT04181684|DEVICE|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
57910223|NCT04181684|RADIATION|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
58259747|NCT02063945|DRUG|Risperidone|As stated in arm/group
58259748|NCT02347891|DRUG|Belimumab|Randomized phase: Week 0 - Week 40
58259749|NCT02347891|DRUG|Placebo|Randomized phase: Week 0 - Week 40
57910224|NCT01962415|DRUG|Hydroxyurea|Oral administration at 30 mg/kg/day.
57910225|NCT01962415|DRUG|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only."
57910226|NCT01962415|DRUG|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
57910227|NCT01962415|DRUG|Melphalan|IV administration at 70 mg/m2/dose.
58259750|NCT01056991|OTHER|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
58259751|NCT01056991|OTHER|warming blanket|
58259752|NCT06169137|BEHAVIORAL|Early Time-Restricted Eating|Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
57910228|NCT01962415|DRUG|Thiotepa|IV administration at 200 mg/m2/dose
58259753|NCT06169137|BEHAVIORAL|Conventional dietary regimen (12-hr, 9:30a-9:30p)|Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
58259754|NCT06610045|OTHER|No intervention|No specific intervention is assess in this study.
57910229|NCT05916339|DRUG|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
57910230|NCT05916339|DRUG|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
57910231|NCT04482686|DRUG|Ivermectin|Treatment days 1, 4, and 8
57910232|NCT04482686|DRUG|Doxycycline Hcl|10 day treatment
57910233|NCT04482686|DIETARY_SUPPLEMENT|Zinc|10 Day treatment
58259755|NCT06570343|DRUG|Fentanyl-Morphine|Intrathecal injection of bupivacaine, fentanyl and morphine
58259756|NCT06570343|DRUG|Morphine|Intrathecal injection of bupivacaine and morphine
58259757|NCT00174967|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
58259758|NCT00174967|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
58259759|NCT00174967|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
58259760|NCT00174967|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
58259761|NCT01460654|DRUG|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
58259762|NCT01460654|DRUG|Alendronate|Alendronate (Fosamax) 70mg every week.
58259763|NCT01460654|DRUG|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
58259764|NCT01460654|DRUG|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
57910234|NCT04482686|DIETARY_SUPPLEMENT|Vitamin D3|10 day treatment
57910235|NCT04482686|DIETARY_SUPPLEMENT|Vitamin C|10 day treatment
58058492|NCT02783651|OTHER|Other|No intervention other than routine medical care
58058493|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
58058494|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
58058495|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
57910236|NCT04602273|DRUG|Azacitidine Injection [Vidaza]|
57910237|NCT02614417|OTHER|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
57910238|NCT00297336|DRUG|Topiramate|80 patients with diagnosed with migraine
57910239|NCT05816265|DRUG|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
57910240|NCT00148512|DRUG|1. Tesofensine (NS 2330)|
58058496|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
58058497|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
58058498|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
58058499|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
58259765|NCT04779580|PROCEDURE|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
58259766|NCT04779580|PROCEDURE|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
58058500|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
58259767|NCT01689246|DRUG|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
58058501|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
58259768|NCT01689246|DRUG|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
58259769|NCT01689246|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
58259770|NCT05681468|OTHER|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
58259771|NCT05681468|OTHER|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
58259772|NCT05681468|OTHER|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
57910241|NCT05318547|OTHER|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
57910242|NCT05318547|OTHER|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
57910243|NCT02857569|DRUG|Ipilimumab IT|
57910244|NCT02857569|DRUG|Ipilimumab IV|
57910245|NCT02857569|DRUG|Nivolumab IV|
57910246|NCT05074927|DIAGNOSTIC_TEST|diaphragm ultrasonography|For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
57910247|NCT00366808|PROCEDURE|LASIK surgery|
58058502|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
58058503|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
58058504|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
58058505|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
58058506|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
58259773|NCT00525811|OTHER|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
58259774|NCT00525811|OTHER|patient information|Information on acute low back pain, information on depression
57910248|NCT02192125|DEVICE|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database"
57910249|NCT06233825|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Essential Amino Acids|Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
57910250|NCT06233825|DIETARY_SUPPLEMENT|Safflower Oil and Non-Essential Amino Acids|Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.
57910251|NCT02802254|BEHAVIORAL|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
57910252|NCT02802254|DEVICE|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
57910253|NCT01134120|DRUG|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
57910254|NCT03518827|OTHER|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
57910255|NCT03095001|DRUG|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
58058507|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
58058508|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
58058509|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
58058510|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
58058511|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
58259775|NCT04306744|DEVICE|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
57910256|NCT03095001|DRUG|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
57708361|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
58058512|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
58058513|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
58058514|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
58259776|NCT04306744|DEVICE|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
58259777|NCT04852679|DRUG|Lanreotide autogel|Administered as deep subcutaneous (SC) injections
58259778|NCT02855359|DRUG|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
58259779|NCT02855359|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
58259780|NCT02855359|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
58381559|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
58381560|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
58381561|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
58381562|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
57910257|NCT03095001|DRUG|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
57910258|NCT00095420|BEHAVIORAL|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
57910259|NCT00095420|BEHAVIORAL|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
58058515|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
58058516|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
58058517|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
58058518|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
58058519|NCT00004147|DRUG|incyclinide|
58259781|NCT02855359|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
58058520|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
58259782|NCT02855359|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
58259783|NCT02855359|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
58259784|NCT04402996|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
58259785|NCT04402996|OTHER|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
58259786|NCT00177281|DRUG|S CKD602|
58259787|NCT02642003|DRUG|Granulocyte Colony Stimulating Factor|
58259788|NCT06144606|DRUG|Tecartus|Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
58259789|NCT02409745|PROCEDURE|endometrial scratch|local injury to the endometrium by Pipelle
58259790|NCT04931485|OTHER|Fluid management according to the REDUCE Fluid Protocol|Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
58259791|NCT04931485|OTHER|Standard of care|Fluid resuscitation and de-resuscitation will be managed according to the standard of care
58381563|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
58381564|NCT02232971|OTHER|Isotonic saline solution|Placebo
58381565|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
58381566|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
58381567|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
57910260|NCT00095420|BEHAVIORAL|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
57910261|NCT00095420|BEHAVIORAL|Usual training|Participants will receive the usual training offered in their local school districts.
57910262|NCT03196154|DIAGNOSTIC_TEST|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
57910263|NCT03196154|DIAGNOSTIC_TEST|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
57910264|NCT01134536|DRUG|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight \<20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight \>=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
58259792|NCT06272136|DEVICE|Clinical Demo 2.0|During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
58259793|NCT04032106|OTHER|Best Practice|Receive standard information about HPV and HPV vaccine
58259794|NCT04032106|OTHER|Informational Intervention|Receive Outsmart HPV intervention
58259795|NCT04032106|OTHER|Questionnaire Administration|Ancillary studies
58381568|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
57910265|NCT02121301|DRUG|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
57910266|NCT02121301|DRUG|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
57910267|NCT02121301|DRUG|Placebo (Vehicle) opthalmic solution|eyedrops
57910268|NCT01587391|DRUG|Placebo to BI 163538 XX|1 single dose per subject as oral solution
57910269|NCT01587391|DRUG|BI 163538 XX|1 single dose per subject as oral solution
57910270|NCT05042232|OTHER|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
57910271|NCT05042232|OTHER|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
57910272|NCT06475261|DEVICE|Tissue Oximetry with ForeSight|Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer
58058521|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
57910273|NCT04393753|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
57910274|NCT00621361|DRUG|AZD2171|Oral
57910275|NCT00621361|DRUG|Etoposide|Intravenous
57910276|NCT00621361|DRUG|Cisplatin|Intravenous
57910277|NCT05773144|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
57910278|NCT05773144|BEHAVIORAL|Progressive stretching|Static stretching of eight major muscle groups
58381569|NCT00702832|OTHER|standard treatment|treatment as usual
57910279|NCT06124911|OTHER|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
58058522|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
57910280|NCT06124911|OTHER|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
57910281|NCT06414837|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
58058523|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
58058524|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
58058525|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
58058526|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
58259796|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
58259797|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive interactive text message vaccine reminders
58259798|NCT06420492|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.
58381570|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
58381571|NCT02973997|DRUG|Lenvatinib|Given PO
58381572|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
58058527|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
58259799|NCT04926103|OTHER|Fecal Microbiota transplant (FMT)|Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
58259800|NCT04967547|OTHER|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
58259801|NCT04967547|OTHER|Education|Education on renal replacement therapy and dialysis
58259802|NCT04318522|DEVICE|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
58259803|NCT05285995|OTHER|Music Intervention|Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.
58259804|NCT05285995|OTHER|The animation intervention|Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
58058528|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
58259805|NCT06614465|OTHER|Multimodal Rehabilitation|The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
58259806|NCT06649253|OTHER|Sampling bone tissue and blood|Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
58259807|NCT06076304|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
58259808|NCT06076304|DRUG|Placebo antibiotic|Placebo antibiotic, oral, twice daily for 7 days
58058529|NCT02132169|DRUG|Drug: AC-170 0.24%|
58058530|NCT02132169|DRUG|AC-170 0%|
58058531|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
58058532|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
57708362|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
57708363|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
57708364|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
57708365|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
57708366|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
57910282|NCT06414837|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
57910283|NCT02717351|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
57910284|NCT03029221|OTHER|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
57910285|NCT03029221|OTHER|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
57910286|NCT03029221|OTHER|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
57910287|NCT00440999|DRUG|Pyronaridine artesunate|
57910288|NCT00440999|DRUG|Chloroquine|
58259809|NCT06076304|DRUG|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
58259810|NCT06076304|OTHER|C-reactive protein|Measurement of C-reactive protein level in capillary blood
58259811|NCT06076304|OTHER|Mid-turbinate swab (optional)|Optional collection of mid-turbinate nasal swab sample
57910289|NCT05812833|BEHAVIORAL|Education|Pregnant women will be given online baby care training
57910290|NCT03913780|OTHER|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
58058533|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
58058534|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
58259812|NCT01891565|BEHAVIORAL|Feedback|
58259813|NCT05293873|BIOLOGICAL|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
58259814|NCT05293873|OTHER|Rehabilitation therapy|Rehabilitation therapy
57910291|NCT02805881|DEVICE|Neurolief system|Non-invasive cephalic neurostimulation device
57910292|NCT02116673|OTHER|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
58259815|NCT05743101|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
58259816|NCT05743101|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
57910293|NCT02116673|OTHER|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
57910294|NCT01028027|DRUG|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
57910295|NCT01028027|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
57910296|NCT01957449|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
57910297|NCT01957449|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
58058535|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
58058536|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
58259817|NCT02089958|PROCEDURE|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
58381573|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
58381574|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
58381575|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
58259818|NCT01946893|BEHAVIORAL|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
57708367|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
57708368|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
57708369|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
57708370|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
57910298|NCT01390077|DRUG|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
57910299|NCT00653666|OTHER|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is \< 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
57910300|NCT02381600|DRUG|Vitamin D|"Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
57910301|NCT02847247|DRUG|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
57910302|NCT02645227|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
57910303|NCT02645227|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
58259819|NCT01946893|BEHAVIORAL|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
58259820|NCT00003134|DRUG|irinotecan hydrochloride|
58259821|NCT02899559|BEHAVIORAL|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
58259822|NCT03598920|DEVICE|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
58259823|NCT03598920|OTHER|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
58259824|NCT00209963|DRUG|Gaboxadol|
57708371|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
57708372|NCT04683185|DRUG|E6742|E6742 tablets.
57910304|NCT02645227|PROCEDURE|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
58259825|NCT05172973|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
57708373|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
57708374|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
57708375|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
57708376|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
57708377|NCT00569686|DRUG|placebo|placebo
57910305|NCT06219369|PROCEDURE|Group T|"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."
57910306|NCT02731183|PROCEDURE|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
57910307|NCT05976893|DRUG|Evolocumab|Evolocuma:420 mg every 4 weeks
57910308|NCT05976893|DRUG|Statin|The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
58058537|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
57708378|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
57708379|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
57708380|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
57708381|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
58259826|NCT01943851|DRUG|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
58259827|NCT05050734|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)|Behavioral treatment for persistent tic disorders.
57910309|NCT02319759|DRUG|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
58058538|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
58058539|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
58058540|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
58058541|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
58058542|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
58381576|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
58381577|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
58381578|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
58381579|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
57910310|NCT02319759|DRUG|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
57910311|NCT02319759|DRUG|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
57910312|NCT04290936|DRUG|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
57910313|NCT04290936|DRUG|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
57910314|NCT02793076|OTHER|Bollywood Dance|8 week Bollywood Dance Program
57910315|NCT06231446|OTHER|No intervention|This was an observational cohort study with no intervention for all enrolled patients.
58058543|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
58381580|NCT03127696|PROCEDURE|Sham|Sham
58381581|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
58381582|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
58381583|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
58381584|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
57910316|NCT05722574|BEHAVIORAL|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
57910317|NCT05722574|BEHAVIORAL|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
57910318|NCT03562650|BEHAVIORAL|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
57910319|NCT03562650|BEHAVIORAL|Present Centered|Participants are asked to try to increase their focus on the present.
57910320|NCT04100577|OTHER|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
58259828|NCT02662764|DRUG|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
58259829|NCT06483815|DIAGNOSTIC_TEST|Culture, İsolation|Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
58381585|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
58381586|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
58381587|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
58381588|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
58381589|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
58381590|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
58381591|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
58381592|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
58259830|NCT05599984|DRUG|ABBV-706|Intravenous (IV) Infusion
57910321|NCT00892073|DRUG|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
58058544|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
58259831|NCT05599984|DRUG|Cisplatin|Intravenous infusion
58259832|NCT05599984|DRUG|Budigalimab|IV Infusion
58259833|NCT05599984|DRUG|Carboplatin|Intravenous infusion
58259834|NCT04756154|DRUG|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
58259835|NCT04756154|DRUG|Normal saline|Apply topically to the inguinal region for 2 minutes
58259836|NCT06316193|OTHER|Diary|The diary is the tool through which the experiences and experiences of the parents of infants admitted to Neonatal Pathology and included in the study and the health care personnel who decide to participate will be collected and analyzed. This tool is given to the parents of infants included in the study in the first few days of the infant's stay (by the third day after admission), subject to the parents' written consent, accompanied by a brief letter of introduction to the diary itself, written by the nurses on the ward. This tool has been part of current clinical practice since January 2023.
58259837|NCT03348475|BEHAVIORAL|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
58259838|NCT06648538|DEVICE|Phonix Care|Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
58259839|NCT05740683|DIAGNOSTIC_TEST|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
58259840|NCT06621888|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
58259841|NCT06115044|PROCEDURE|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
58259842|NCT06115044|PROCEDURE|Continuous|Calculated daily nutritional requirement given over 24 hours
58259843|NCT05774795|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
58381593|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
58381594|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
58259844|NCT05774795|PROCEDURE|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
57910322|NCT00892073|DRUG|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
57910323|NCT00153881|DRUG|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
57910324|NCT03770533|OTHER|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
57910325|NCT02590705|DRUG|Lidocaine|surface anesthesia with lidocaine
58058545|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
58058546|NCT00519571|DEVICE|ImplantLock device|dental implant
58259845|NCT06267976|DEVICE|ProSomnus RPMO2|The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
58259846|NCT03442478|OTHER|2D/3D Tomosynthesis|
58259847|NCT02928783|BEHAVIORAL|Home-based cardiac rehabilitation|
57910326|NCT03323073|OTHER|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
57910327|NCT01183234|DRUG|SPD544|two 30mg capsules, single oral dose
58259848|NCT02826668|OTHER|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
57910328|NCT01183234|DRUG|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
57910329|NCT03531385|DIAGNOSTIC_TEST|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
57910330|NCT03531385|DIAGNOSTIC_TEST|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
58259849|NCT06466590|DIAGNOSTIC_TEST|Use of Measurement Instrument|Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions. The results from both sessions will be compared to assess the instrument's consistency and accuracy
58259850|NCT02648477|DRUG|Anastrozole|Given PO
58259851|NCT02648477|DRUG|Doxorubicin Hydrochloride|Given IV
58259852|NCT02648477|DRUG|Exemestane|Given PO
58259853|NCT02648477|OTHER|Laboratory Biomarker Analysis|Correlative studies
58259854|NCT02648477|DRUG|Letrozole|Given PO
57910331|NCT03531385|OTHER|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
57910332|NCT03531385|OTHER|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
58259855|NCT02648477|BIOLOGICAL|Pembrolizumab|Given IV
58259856|NCT03896529|BEHAVIORAL|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
58259857|NCT03575299|BIOLOGICAL|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
58259858|NCT03575299|OTHER|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
58259859|NCT03575299|DRUG|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
58259860|NCT01335074|DRUG|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
58259861|NCT02588651|DRUG|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
58259862|NCT00245297|DRUG|Kogenate FS, reconstituted in a suspension of liposomes|
58259863|NCT06614998|DRUG|Patients diagnosed with HLH-94 should be treated as soon as possible|For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
57910333|NCT06476756|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUE|Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.
57910334|NCT06476756|OTHER|Buteyko techniques|Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1.
57910335|NCT05354765|OTHER|blood sample|lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression
57910336|NCT05354765|OTHER|blood sample|lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment
57910337|NCT03262324|OTHER|VAS-FA Turkish version|Self-reported outcome questionnaires
57910338|NCT05617482|OTHER|General anesthesia|All patients undergoing ceaserian section under general anesthesia
58259864|NCT05580978|BEHAVIORAL|GEM|The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
58259865|NCT05580978|OTHER|Routine Care|Participant's current prediabetes treatment.
58259866|NCT05670236|DRUG|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
58259867|NCT01508052|DEVICE|sequential compression device|applying sequential compression device during the surgery
58259868|NCT01508052|DEVICE|elastic stockings|applying elastic stockings during the surgery
58259869|NCT05218356|DRUG|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
57708382|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
57708383|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
57708384|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
57708385|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
57708386|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
57910339|NCT05617482|OTHER|Ilioinguinal, iliohypogastric nerve blocks|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
58259870|NCT05218356|DIAGNOSTIC_TEST|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
58259871|NCT05218356|DIAGNOSTIC_TEST|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
58259872|NCT05218356|DIAGNOSTIC_TEST|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
58259873|NCT05218356|DIAGNOSTIC_TEST|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
58259874|NCT05218356|OTHER|NEWS-2 score|assessment of the participant by the NEWS-2 score.
58259875|NCT05218356|OTHER|WHO score|assessment of the participant by the score of the World Health Organization.
58259876|NCT05218356|OTHER|Physical examination|evaluation by the principal investigator or assistant physician
58259877|NCT05218356|OTHER|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
57708387|NCT01828034|DRUG|Gemcitabine|
57708388|NCT01828034|DRUG|Cisplatin|
57708389|NCT01828034|DRUG|MEK162|
57708390|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
57708391|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
57708392|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
57708393|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
57708394|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
57708395|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
58259878|NCT02068781|DIETARY_SUPPLEMENT|Low-sodium diet|50 mmol NaCl per 24h
58259879|NCT02068781|DIETARY_SUPPLEMENT|High-sodium diet|250 mmol NaCl per 24h
58259880|NCT02829723|DRUG|BLZ945|"BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days."
58259881|NCT02829723|DRUG|PDR001|PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
58259882|NCT00528060|DRUG|Atazanavir|2pills/day
58259883|NCT00528060|DRUG|Ritonavir|1 pill/day
58259884|NCT00528060|DRUG|Tenofovir/emtricitabine|1 pill/day
57708396|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
57708397|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
57708398|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
57910340|NCT05617482|OTHER|TAP block|In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.
57708399|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
57708400|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
57708401|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
57708402|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
58259885|NCT02062944|DRUG|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
57708403|NCT00638703|DRUG|Placebo|placebo
57708404|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
58259886|NCT02714088|OTHER|Novel high-intensity interval training|
57910341|NCT05617482|OTHER|Quadratus lumborum block|For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
57910342|NCT05451914|OTHER|My Diabetes Care|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
57910343|NCT02891837|DRUG|L-citrulline|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
58259887|NCT02368379|OTHER|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
58259888|NCT02368379|OTHER|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
58259889|NCT03053063|DRUG|SEL|Tablets administered orally once daily
58259890|NCT03053063|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
58259891|NCT03053063|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
58259892|NCT05098210|BIOLOGICAL|Neoantigen Peptide Vaccine|Given IM
58259893|NCT05098210|BIOLOGICAL|Nivolumab|Given IV
58259894|NCT05098210|DRUG|Poly ICLC|Given IM
58259895|NCT05098210|PROCEDURE|Echocardiography|Undergo ECHO
58259896|NCT05098210|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58259897|NCT05098210|PROCEDURE|Biopsy|Undergo tumor biopsy
58259898|NCT05098210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58259899|NCT05098210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58259900|NCT05098210|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58259901|NCT05098210|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
58259902|NCT01673412|OTHER|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
58259903|NCT03568682|BEHAVIORAL|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
58259904|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
58259905|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
57708405|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
57708406|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
57708407|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
57708408|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
57708409|NCT00607763|DRUG|Micafungin (Mycamine)|IV
57708410|NCT05828017|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
57708411|NCT05828017|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
57910344|NCT02891837|OTHER|Placebo|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
58259906|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
58259907|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
58259908|NCT06619600|DRUG|Dapagliflozin|Dapagliflozin 10 mg qd
58259909|NCT06619600|DRUG|Placebo|Matched placebo qd
58259910|NCT02952131|PROCEDURE|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
57708412|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
57708413|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
57708414|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
57708415|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
57708416|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
57708417|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
57708418|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
57708419|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
57708420|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
57708421|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
57708422|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
57708423|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
57708424|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
57708425|NCT02171598|DRUG|Clopidogrel|
57708426|NCT02171598|DRUG|Dabigatran high dose|
57708427|NCT02171598|DRUG|Dabigatran low dose|
57910345|NCT04595318|DRUG|Standard clinical care first, followed by standard clinical care and varenicline|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
57910346|NCT04595318|DRUG|Standard clinical care and varenicline first, followed by standard clinical care|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
57910347|NCT03138772|OTHER|This is an observational study, no intervention used.|No intervention is being used in this study.
57910348|NCT06610058|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
57910349|NCT06610058|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
57910350|NCT01453829|PROCEDURE|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
57910351|NCT03606668|DEVICE|HTC Vive Virtual Reality (VR) system|VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
57910352|NCT05612152|OTHER|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
57910353|NCT05612152|OTHER|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
58259911|NCT02952131|PROCEDURE|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
58259912|NCT02952131|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
58259913|NCT01084200|DRUG|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
58259914|NCT01084200|DRUG|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
58259915|NCT01084200|DRUG|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
58259916|NCT06068829|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
58259917|NCT06068829|DRUG|Rituximab(RTX)|RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
58259918|NCT02071862|DRUG|CB-839|CB-839 monotherapy
58259919|NCT02071862|DRUG|Pac-CB|CB-839 in combination with standard dose paclitaxel
58259920|NCT02071862|DRUG|CBE|CB-839 in combination with standard dose everolimus
58259921|NCT02071862|DRUG|CB-Erl|CB-839 in combination with standard dose erlotnib
58259922|NCT02071862|DRUG|CBD|CB-839 in combination with standard dose docetaxel
58259923|NCT02071862|DRUG|CB-Cabo|CB-839 in combination with standard dose cabozantinib
58381595|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
58381596|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
58381597|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
57708428|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
57708429|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
58259924|NCT05031650|PROCEDURE|openCPAP|Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
58259925|NCT05031650|PROCEDURE|standardCPAP|Randomized to : Standard level CPAP between 6-8 cmH2O pressure
58381598|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
58381599|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
58381600|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
57708430|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
58381601|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
58381602|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
57708431|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
57708432|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
57708433|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
57708434|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
58259926|NCT06481891|DRUG|Sotagliflozin|Sotagliflozin will be administered as a tablet(s), orally once daily.
58259927|NCT06481891|DRUG|Placebo|Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
58259928|NCT01992653|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
58259929|NCT01992653|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
58259930|NCT01992653|DRUG|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
58259931|NCT01992653|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
58259932|NCT01992653|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
58259933|NCT01992653|DRUG|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
58259934|NCT01992653|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
58058547|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
58058548|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
58259935|NCT04497376|PROCEDURE|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
57910354|NCT02291081|OTHER|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~* Anamnesis with the participants~* File recherche,Physical examination~* Documentation of the cardiovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Exercise Montreal Cognitive Assessment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
57910355|NCT01981473|OTHER|no intervention|
57910356|NCT01981473|OTHER|no intervention|
57910357|NCT01981473|OTHER|no intervention|
57910358|NCT04658238|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
57910359|NCT04658238|OTHER|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
57910360|NCT06248333|DEVICE|STN-DBS ON|Stimulation ON
57910361|NCT06248333|DEVICE|STN-DBS OFF|Stimulation OFF
57910362|NCT00670839|BIOLOGICAL|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
57910363|NCT00670839|BIOLOGICAL|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
57910364|NCT03062579|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
57910365|NCT02351518|OTHER|No intervention|There will be no interventions in this study
57910366|NCT04814641|BIOLOGICAL|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
57910367|NCT01052103|DRUG|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
57910368|NCT01052103|DRUG|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
57910369|NCT01052103|DRUG|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
57910370|NCT01391039|DRUG|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
57910371|NCT02632162|OTHER|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
57910372|NCT03801473|OTHER|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
57910373|NCT03801473|OTHER|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
58058549|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
58058550|NCT06439342|DRUG|Maribavir|Maribavir tablets
58058551|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
58058552|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
58058553|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
58058554|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
58058555|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
58058556|NCT02150291|DRUG|Neurobion|
58058557|NCT02150291|DRUG|placebo|
57910374|NCT02743026|BEHAVIORAL|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
58259936|NCT04497376|PROCEDURE|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
57910375|NCT03444350|DEVICE|Gaseous ozone|SRP plus gaseous ozone
57910376|NCT03444350|DEVICE|SRP plus placebo|only SRP
57910377|NCT01675479|DEVICE|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
57910378|NCT02084173|BEHAVIORAL|MET + CRA|
57910379|NCT01075802|DRUG|Tamoxifen|Dose escalation
57910380|NCT02369640|PROCEDURE|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
58259937|NCT05581641|BIOLOGICAL|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection
58259938|NCT05581641|OTHER|Placebo|Placebo
58259939|NCT04289207|DRUG|Romiplostim and danazol|Treatment with romiplostim and danazol
58259940|NCT04531254|BEHAVIORAL|Wearing a face mask at all times|Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
58259941|NCT04086212|DRUG|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
58259942|NCT04086212|DRUG|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
58259943|NCT00493662|DRUG|Polyethylene Glycol 400 0.4%|
58259944|NCT00493662|DRUG|Propylene Glycol 0.3%|
58259945|NCT00493662|DRUG|0.15% sodium Hyaluronate|
58259946|NCT00493662|DRUG|sodium chloride|
58259947|NCT00493662|DRUG|sodium phosphate monobasic|
58259948|NCT04413552|DRUG|INDV-2000|INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
58259949|NCT04413552|DRUG|Placebo|Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
58259950|NCT00271011|DRUG|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
57910381|NCT05569772|DRUG|Semaglutide Pen Injector|maintenance dose of 1mg SC once weekly
57910382|NCT05569772|DRUG|Semaglutide placebo|maintenance dose of 1mg SC once weekly
57910383|NCT03618368|DEVICE|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
57910384|NCT03618368|DEVICE|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
58259951|NCT00271011|DRUG|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
58259952|NCT00271011|DRUG|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2.
58259953|NCT02777970|DRUG|Tramadol Hydrochloride/Dexketoprofen Trometamol|
58259954|NCT02777970|DRUG|Tramadol Hydrochloride/Paracetamol|
58259955|NCT02777970|DRUG|Placebo|
58259956|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
58259957|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
58259958|NCT00793624|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
58259959|NCT00793624|DRUG|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
58259960|NCT00793624|DRUG|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
57708435|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
58259961|NCT03322774|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
58259962|NCT03322774|BEHAVIORAL|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
58058558|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
58259963|NCT03322774|BEHAVIORAL|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
58058559|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
58058560|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
58058561|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
58058562|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
58058563|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
58058564|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
58259964|NCT06534255|BIOLOGICAL|MegaLT injection|"Three dose groups were set: 1×10\^6/kg, 5×10\^6/kg, and 1×10\^7/kg. The dose escalation was carried out in ascending order using a 3+3 design. To ensure participant safety, enrollment followed a 1+2 rule. Specifically, the first participant in each dose group received the cell infusion and was observed for 14 days. If no dose-limiting toxicity (DLT) was observed, the remaining two participants could then be enrolled and receive cell therapy at the same dose level."
58259965|NCT05525442|PROCEDURE|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
58259966|NCT03093649|OTHER|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
58259967|NCT03093649|OTHER|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
57708436|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
58259968|NCT02428049|RADIATION|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
58259969|NCT03048695|BEHAVIORAL|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
58381603|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
58381604|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
58381605|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
58381606|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
58381607|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
58381608|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
58381609|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
58381610|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
58381611|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
58381612|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
58381613|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
58381614|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
58381615|NCT01890265|DRUG|Placebo|Solution for infusion
57708437|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
58259970|NCT03911661|OTHER|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
58259971|NCT03911661|OTHER|Usual care|Historical management of warfarin by patient's usual care providers
58259972|NCT05136339|BEHAVIORAL|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
58259973|NCT01077739|DRUG|fluorouracil (5FU)|standard FOLFOX regimen
58259974|NCT01077739|DRUG|leucovorin|standard FOLFOX regimen
58259975|NCT01077739|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
58259976|NCT01077739|DRUG|capecitabine [Xeloda]|standard XELOX regimen
58259977|NCT01077739|DRUG|oxaliplatin|standard XELOX or FOLFOX regimen
58259978|NCT02589236|DRUG|Cavosonstat|GSNOR inhibitor
58259979|NCT02589236|DRUG|Placebo|Control sample with only capsule excipients and fillers
58259980|NCT06646159|BEHAVIORAL|REThink Intervention|"At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention."
58259981|NCT01328106|DRUG|GSK1120212|Repeating oral dose
58259982|NCT06329687|DRUG|Tyrvaya Nasal Pump|Tyrvaya Nasal Pump with Silicone Lubricant
58259983|NCT00006398|DRUG|Timolol Maleate|
58381616|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
58381617|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
58381618|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
58259984|NCT00006398|DRUG|Placebo|
58259985|NCT03886779|DRUG|Bromfenac|0.7 MG/ML \[Prolensa\]
58259986|NCT03886779|DRUG|Nepafenac|3 MG/ML \[Ilevro\]
57708438|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
58259987|NCT02468154|DEVICE|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
58381619|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
57708439|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
57708440|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
57708441|NCT04124172|DEVICE|Sham rTMS|See arm description
58259988|NCT02468154|OTHER|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
57708442|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
57708443|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
57708444|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
58259989|NCT03809468|OTHER|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
58259990|NCT06618820|DRUG|Tranexamic acid|One dose consists of three 650 milligram (mg) capsules, to be taken orally.
57708445|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
57708446|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
57708447|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
57708448|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
57708449|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
57708450|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
58058565|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
58259991|NCT06618820|DRUG|Placebo|One dose consists of three microcrystalline cellulose capsules.
58259992|NCT03716843|OTHER|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
58259993|NCT03290547|DEVICE|Cutera enLighten laser|Subjects will receive laser treatments.
58259994|NCT05969314|DRUG|Cannabis capsules|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
58381620|NCT02453893|DRUG|Iloperidone|
58381621|NCT02453893|DRUG|Risperidone|
58381622|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
58381623|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
58381624|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
57708451|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
57708452|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
57708453|NCT02665871|BIOLOGICAL|placebo|
57708454|NCT02665871|BIOLOGICAL|placebo|
57708455|NCT00000102|DRUG|Nifedipine|
57708456|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
57708457|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
58381625|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
58381626|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
58381627|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
57708458|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
57708459|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
57708460|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
57708461|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
57708462|NCT01485861|DRUG|Abiraterone|Orally once daily
57708463|NCT01485861|DRUG|Apitolisib|Orally once daily
57708464|NCT01485861|DRUG|Ipatasertib|Orally once daily
57708465|NCT01485861|DRUG|Placebo|Orally once daily
58259995|NCT06620705|DEVICE|Left bundle branch area pacing|Pacing of the left bundle branch area using a transvenous pacemaker lead
57708466|NCT01485861|DRUG|Prednisone|Orally bid
58381628|NCT02789085|DEVICE|ULF TENS stimulation|
57708467|NCT01485861|DRUG|Prednisolone|Orally bid
57708468|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
58259996|NCT06620705|DEVICE|Biventricular pacing|Pacing of the right and left ventricle using transvenous pacemaker leads
58259997|NCT03026140|DRUG|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
58259998|NCT03026140|DRUG|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
58259999|NCT03026140|DRUG|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
58381629|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
58381630|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
58381631|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
57708469|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
57708470|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
57708471|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
58058566|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
57708472|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
57708473|NCT04688164|DRUG|REL-1017|REL-1017 tablet
57708474|NCT04688164|DRUG|Placebo|Placebo tablet
58058567|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
58058568|NCT00150514|DRUG|Oralgen|
58058569|NCT00150514|PROCEDURE|Nasal biopsy|
57708475|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
57708476|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
57708477|NCT02159547|OTHER|Normal Saline|50 ml normal saline
57708478|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
57708479|NCT03627728|OTHER|placebo|regorafenib/placebo
57708480|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
57708481|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
57708482|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
57708483|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
58058570|NCT00150514|PROCEDURE|Nasal washing|
58058571|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
58260000|NCT03026140|DRUG|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
58260001|NCT03026140|DRUG|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29
58260002|NCT00055770|DRUG|erlotinib hydrochloride|Given orally
58260003|NCT00055770|DRUG|docetaxel|Given IV
58260004|NCT00055770|OTHER|laboratory biomarker analysis|Correlative studies
58260005|NCT00055770|OTHER|pharmacological study|Correlative studies
58260006|NCT02267772|DRUG|IV Acetaminophen|IV Acetaminophen
58260007|NCT02267772|DRUG|IV Morphine|IV Morphine
58260008|NCT02773212|DRUG|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
58260009|NCT02773212|BEHAVIORAL|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
58260010|NCT02773212|DRUG|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
58260011|NCT03914261|DRUG|Risankizumab|Tablet
58381632|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
58381633|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
58393687|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
58260012|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in DDP
58260013|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in HT
58260014|NCT03546972|OTHER|Questionnaire Administration|Ancillary studies
58260015|NCT06451835|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
58381634|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
58381635|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
58381636|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
58381637|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
58381638|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
58381639|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
58381640|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
58381641|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
58381642|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
58381643|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
58381644|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
58381645|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
58381646|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
58381647|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
58381648|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
58381649|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
58381650|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
58381651|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
58381652|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
58058572|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
58381653|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
58381654|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
58058573|NCT00544193|DRUG|gemcitabine hydrochloride|
58058574|NCT00544193|GENETIC|polymerase chain reaction|
58058575|NCT00544193|OTHER|immunohistochemistry staining method|
58260016|NCT03465774|DRUG|Doxycycline|Receive via IPC
58260017|NCT03465774|DEVICE|Indwelling Catheter|Receive IPC
58381655|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
58381656|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
58381657|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
58058576|NCT00544193|PROCEDURE|conventional surgery|
58058577|NCT00544193|RADIATION|intraoperative radiation therapy|
58260018|NCT03465774|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
58260019|NCT03465774|OTHER|Questionnaire Administration|Ancillary studies
58260020|NCT03465774|OTHER|Survey Administration|Ancillary studies
58260021|NCT02140216|BIOLOGICAL|No blood transfusion|No blood transfusion
58260022|NCT02140216|BIOLOGICAL|Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
58260023|NCT02140216|BIOLOGICAL|Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
58381658|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
58381659|NCT00754689|DRUG|Metformin|Tablet, oral administration
58381660|NCT00754689|DRUG|placebo|Tablet, oral administration
58381661|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
57708484|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
57708485|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
57708486|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
57708487|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
57708488|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
57708489|NCT00286416|DRUG|omalizumab (Xolair)|
57708490|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
57708491|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
58058578|NCT00544193|RADIATION|radiation therapy|
58058579|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
58260024|NCT03078179|DIETARY_SUPPLEMENT|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
58260025|NCT03078179|DIETARY_SUPPLEMENT|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
58260026|NCT06090643|OTHER|Best Practice|Receive CRC screening usual care
58260027|NCT06090643|OTHER|Consultation|Receive consultation with clinic staff
58260028|NCT06090643|OTHER|Educational Intervention|Receive education and training on CRC screening
58260029|NCT06090643|OTHER|Electronic Health Record Review|Ancillary studies
58260030|NCT06090643|OTHER|Fecal Immunochemical Test|Receive FIT kit with culturally tailored instructions
58260031|NCT06090643|BEHAVIORAL|Feedback|Receive feedback on CRC screening
58260032|NCT06090643|BEHAVIORAL|Health Education|Receive CRC screening recommendations
57708492|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
57708493|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
57708494|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
57708495|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
57708496|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
57708497|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
57708498|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
57708499|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
57708500|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
58058580|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
58058581|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
58260033|NCT06090643|OTHER|Support Education Activity|Utilize clinical decision support tool
58260034|NCT06090643|OTHER|Text Message-Based Navigation Intervention|Receive text message reminders
58260035|NCT04791319|DRUG|Placebo|Placebo will be administered subcutaneously.
58260036|NCT04791319|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
58260037|NCT04791319|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
58260038|NCT01729000|OTHER|Gloves|All staff must wear gloves for subjects that are in the experimental group.
58260039|NCT00095641|DRUG|capecitabine|
58260040|NCT00095641|PROCEDURE|adjuvant therapy|
58260041|NCT00095641|PROCEDURE|chemotherapy|
57910385|NCT06610877|DEVICE|Focused Ultrasound Neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
58260042|NCT06284395|DRUG|Bortezomib|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
57708501|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
57708502|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
57708503|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
57708504|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
57910386|NCT06610877|DEVICE|Focused ultrasound neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
58260043|NCT04143594|DRUG|Oral Lenacapavir|Tablets administered without regard to food
57708505|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
57708506|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
57708507|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
57708508|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
57708509|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
57708510|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
58381662|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
57708511|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
57708512|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
57708513|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
57910387|NCT04973904|DRUG|Toripalimab|IV infusion
57910388|NCT04973904|DRUG|Paclitaxel|IV infusion
57910389|NCT04973904|DRUG|Cisplatin|IV infusion
57910390|NCT04973904|DRUG|Bevacizumab|IV infusion
58058582|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
58058583|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
58260044|NCT04143594|DRUG|F/TAF|Tablets administered without regard to food
58260045|NCT04143594|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
58260046|NCT04143594|DRUG|TAF|Tablets administered without regard to food
58260047|NCT04143594|DRUG|BIC|Tablets administered without regard to food
58260048|NCT04143594|DRUG|B/F/TAF|Tablets administered without regard to food
58381663|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
58381664|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
58381665|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
58381666|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
58381667|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
58381668|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
58381669|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
58260049|NCT02876991|PROCEDURE|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
58260050|NCT05224960|BIOLOGICAL|UC-MSCs|3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
58260051|NCT05224960|BIOLOGICAL|Placebo(solution without UC-MSCs)|3 doses of placebo intravenously at day 1, day 8, day 15.
58381670|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
58381671|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
58381672|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
58381673|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
58381674|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
58381675|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
58381676|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
58381677|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
58260052|NCT00387751|BIOLOGICAL|Bevacizumab|Given IV
58381678|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
58381679|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
58381680|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
58381681|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
58381682|NCT02994966|DEVICE|Surrosense|
58381683|NCT02994966|OTHER|Standard care|
58393688|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
58260053|NCT00387751|OTHER|Laboratory Biomarker Analysis|Correlative studies
57708514|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
58260054|NCT00387751|OTHER|Pharmacological Study|Correlative studies
58260055|NCT00387751|DRUG|Sorafenib Tosylate|Given orally
58260056|NCT00992628|DEVICE|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
58260057|NCT00992628|DEVICE|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
58260058|NCT01639547|DRUG|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
57708515|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
57708516|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
57708517|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
57708518|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
57708519|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
57708520|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
57910391|NCT00538200|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
57910392|NCT00538200|OTHER|Dietary Advice|Standard dietary advice
57910393|NCT05574491|BEHAVIORAL|Super Skills for Life: traditional version|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández."
57910394|NCT05574491|BEHAVIORAL|Super Skills for Life: computerized version|Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
57910395|NCT05511961|BEHAVIORAL|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
57708521|NCT04306510|PROCEDURE|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
57708522|NCT04306510|PROCEDURE|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
58260059|NCT03451916|DRUG|PLX-PAD|PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
58260060|NCT03451916|DRUG|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
58260061|NCT05633979|DRUG|Trastuzumab deruxtecan|Given by IV (vein)
58260062|NCT05633979|DRUG|Valemetostat|Given by PO
58260063|NCT03004170|BEHAVIORAL|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
58260064|NCT03004170|BEHAVIORAL|Telephone-Administered Coping Effectiveness Training|
58260065|NCT04197102|DRUG|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
58260066|NCT04197102|OTHER|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
58260067|NCT04197102|OTHER|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
58381684|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
58393689|NCT05734443|BEHAVIORAL|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
57708523|NCT04306510|PROCEDURE|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
57708524|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
57708525|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
57708526|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
57708527|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
57708528|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
57708529|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
57910396|NCT04042493|BEHAVIORAL|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
57910397|NCT01039792|DRUG|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
57910398|NCT01039792|DIETARY_SUPPLEMENT|Placebo|placebo
58058584|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
57910399|NCT01414504|BIOLOGICAL|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
57910400|NCT01414504|BIOLOGICAL|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
57910401|NCT01414504|BIOLOGICAL|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
57910402|NCT01414504|BIOLOGICAL|Control|control, 0.1mL Pneumovax at 3-5yrs
57910403|NCT04884412|PROCEDURE|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
57910404|NCT04884412|PROCEDURE|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
57910405|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
57910406|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Test product 20 ml
58058585|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
58260068|NCT05674916|DIAGNOSTIC_TEST|Point-of-care ultrasound-driven diagnostic pathway|Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
58058586|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
58058587|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
58058588|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
58058589|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
58058590|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
58058591|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
58260069|NCT03484936|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
58260070|NCT03484936|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
57708530|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
57708531|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
57708532|NCT01876264|PROCEDURE|Extended resection|
57708533|NCT01876264|PROCEDURE|Conventional resection|
57708534|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
57708535|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
57708536|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
57910407|NCT02372136|DIETARY_SUPPLEMENT|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
57910408|NCT02372136|DIETARY_SUPPLEMENT|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
57910409|NCT02317133|BIOLOGICAL|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
58260071|NCT05260385|DRUG|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
58260072|NCT03275259|DEVICE|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
58260073|NCT06540664|OTHER|Auricular Acupuncture needles|Auricular Acupuncture needles 5 days in 2 weeks
57708537|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
57708538|NCT00004804|DRUG|interferon alfa|
58260074|NCT06540664|OTHER|Sham Auricular Acupuncture needles|Sham Auricular Acupuncture needles 5 days in 2 weeks
58260075|NCT01512069|BEHAVIORAL|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
58260076|NCT01512069|BEHAVIORAL|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
58260077|NCT04310631|DRUG|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
58260078|NCT03142152|DEVICE|Carillon Mitral Contour System|The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
57708539|NCT00660062|DRUG|escitalopram|10 mg daily
57708540|NCT00660062|DRUG|escitalopram|20 mg daily dosage
58260079|NCT03142152|OTHER|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
58260080|NCT00286923|DRUG|Topiramate|
58260081|NCT04831697|BEHAVIORAL|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
58260082|NCT04831697|BEHAVIORAL|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
58260083|NCT06623461|DRUG|Standard of Care Immune Checkpoint Blockade|Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
57708541|NCT00660062|DRUG|escitalopram|30 mg daily dosage
57708542|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
58260084|NCT06623461|DRUG|LND101|Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
58260085|NCT03819322|DRUG|sofosbuvir/velpatasvir|12 week, oral, fixed dose
58260086|NCT02866149|BIOLOGICAL|Blood sampling|Up to 5 blood samplings can be performed at different time points
58260087|NCT02866149|PROCEDURE|Tumor sampling|One tumor sampling can be performed, if applicable
58260088|NCT02866149|OTHER|Stool sampling|Up to 5 blood samplings can be performed at different time points
58260089|NCT00308594|DRUG|Dexamethasone|
58260090|NCT02194712|OTHER|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
57708543|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
57708544|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
57910410|NCT02317133|BIOLOGICAL|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
58260091|NCT02141568|OTHER|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
58260092|NCT06619522|DRUG|Ruxolitinib|Given orally
58260093|NCT06619522|DRUG|INCB57643|Given orally
58260094|NCT03183713|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
58260095|NCT03183713|BEHAVIORAL|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
58260096|NCT06073054|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
57708545|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
57708546|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
57708547|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
57708548|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
57708549|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
57708550|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
57708551|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
57708552|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
57708553|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
57708554|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
57708555|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
57708556|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
57708557|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
57708558|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
57708559|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
58058592|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
58260097|NCT02327338|DEVICE|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
58260098|NCT02327338|DRUG|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
58260099|NCT05353582|DRUG|Preoperative systematic therapy|6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.
58260100|NCT05353582|PROCEDURE|CRS+HIPEC|CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.
58260101|NCT05353582|DRUG|Postoperative chemotherapy|6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
58260102|NCT05353582|DRUG|Postoperative chemotherapy|12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
58260103|NCT00850304|DRUG|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
58260104|NCT00850304|DRUG|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
58393690|NCT05734443|BEHAVIORAL|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
58393691|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
58260105|NCT06618911|OTHER|5 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 5 Hz"
58260106|NCT06618911|OTHER|Sham electroacupuncture|Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce \&#34;deqi.\&#34; A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm serves as a placebo control to evaluate the true effect of electroacupuncture.
58381685|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
58381686|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
57708560|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
58260107|NCT06618911|OTHER|100 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 100 Hz"
57708561|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
57708562|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
57910411|NCT04262752|DEVICE|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
57910412|NCT04230603|PROCEDURE|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
57910413|NCT04230603|DIAGNOSTIC_TEST|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
57910414|NCT04230603|DIAGNOSTIC_TEST|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
57910415|NCT04204603|DRUG|CKD-506|Tablets for oral administration
58260108|NCT06502964|DRUG|ALTO-101|4.5 mg ALTO-101 patches
58260109|NCT06502964|DEVICE|ALTO-101 Transdermal Delivery System|4.5 mg ALTO-101 transdermal delivery system
58381687|NCT00344175|DRUG|pitavastatin|
58381688|NCT00344175|DRUG|simvastatin|
58381689|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
57910416|NCT04204603|DRUG|Placebo|Tablets for oral administration
57910417|NCT00525382|DRUG|levocetirizine dihydrochloride|
58381690|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
58381691|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
58393692|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
57910418|NCT01854853|BEHAVIORAL|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
58058593|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
58058594|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
58058595|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
58058596|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
58058597|NCT00740194|DRUG|Aromatase inhibition|Letrozole
58058598|NCT00740194|DRUG|Estradiol|Dermestril
57708563|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
57708564|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
57910419|NCT01854853|BEHAVIORAL|Health Promotion|Health promotion intervention
57910420|NCT01079663|DRUG|Chlorhexidine 2.5 mg|
58058599|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
58058600|NCT00002494|DRUG|cyclophosphamide|
57910421|NCT01079663|DRUG|Placebo chip|
57910422|NCT05368467|COMBINATION_PRODUCT|The clinical course and disease management|The clinical course and disease management of pulmonary hypertension patients
58058601|NCT00002494|DRUG|cytarabine|
58260110|NCT06502964|DRUG|Placebo|Inactive placebo patches
58260111|NCT06502964|DEVICE|Placebo Transdermal Delivery System|Placebo transdermal delivery system
58260112|NCT02590575|DEVICE|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"1. With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
58260113|NCT00224939|DRUG|Potassium Chloride|
58260114|NCT06649266|DRUG|RBD1016|RBD1016, active drug.
58260115|NCT06649266|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
58260116|NCT05303194|BEHAVIORAL|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
58260117|NCT05303194|BEHAVIORAL|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
58260118|NCT06618417|DEVICE|sleep apnea home-evaluation|Participants will receive a home-monitoring device by mail to test for sleep apnea at home
58260119|NCT05954845|OTHER|biopsies|Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
58260120|NCT06644469|DEVICE|Dynatronics VF5 Model vibration platform|The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.
58260121|NCT06644469|DEVICE|Placebo Dynatronics VF5 Model vibration platform|Placebo intensity with vertical vibration of 0.2 mm
58260122|NCT02999230|OTHER|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
57910423|NCT02876822|DIETARY_SUPPLEMENT|Vitamin D|
58058602|NCT00002494|DRUG|dexamethasone|
58058603|NCT00002494|DRUG|doxorubicin hydrochloride|
58058604|NCT00002494|DRUG|etoposide|
58058605|NCT00002494|DRUG|ifosfamide|
58058606|NCT00002494|DRUG|leucovorin calcium|
58058607|NCT00002494|DRUG|mesna|
58058608|NCT00002494|DRUG|methotrexate|
58058609|NCT00002494|DRUG|prednisone|
58058610|NCT00002494|DRUG|therapeutic hydrocortisone|
58058611|NCT00002494|DRUG|vincristine sulfate|
58058612|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
58058613|NCT00002494|RADIATION|low-LET photon therapy|
58058614|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
58058615|NCT02476903|DRUG|Monovisc|
58058616|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
58058617|NCT02149628|DRUG|propofol|
58058618|NCT02149628|DRUG|Desflurane|
58058619|NCT02299128|OTHER|Physical Therapy Treatment|
58058620|NCT05905601|BEHAVIORAL|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
58381692|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
58381693|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
58381694|NCT04987827|OTHER|No intervention|No intervention
58381695|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
57708565|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
57910424|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
58381696|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
58381697|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
58381698|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
58260123|NCT02999230|OTHER|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
58260124|NCT02999230|OTHER|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
58260125|NCT02999230|OTHER|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
58381699|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
58381700|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
57910425|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
58381701|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
58381702|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
58381703|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
58381704|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
58381705|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
58381706|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
57910426|NCT02368678|PROCEDURE|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
57910427|NCT02368678|PROCEDURE|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
58381707|NCT00483678|OTHER|counseling intervention|
58381708|NCT00483678|OTHER|questionnaire administration|
57910428|NCT04401501|OTHER|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
58381709|NCT00483678|PROCEDURE|psychosocial assessment and care|
58381710|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
58381711|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
58381712|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
58381713|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
58393693|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
57708566|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
58260126|NCT00990392|DRUG|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
58260127|NCT00990392|OTHER|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
58260128|NCT06215183|OTHER|Music therapy|Women applying for IUD application will receive music therapy for 5 minutes before the procedure, during the IUD application, and for 5 minutes after the procedure.
58260129|NCT06142877|BEHAVIORAL|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
58381714|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
58381715|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
58381716|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
58381717|NCT04762836|DRUG|Placebo|Placebo control in oral form
58381718|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
58381719|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
57910429|NCT04401501|OTHER|Exercise|Exercises for cervicogenic headache
57910430|NCT05410431|OTHER|clinical and radiologic manifestations of rare presentations of Dermoid cyst|
58381720|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
57910431|NCT03404453|DIAGNOSTIC_TEST|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
57910432|NCT03294148|OTHER|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
57910433|NCT03294148|BEHAVIORAL|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
57910434|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
57910435|NCT01946438|BIOLOGICAL|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
57910436|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
57910437|NCT01946438|BIOLOGICAL|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
57910438|NCT00566878|BIOLOGICAL|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
57910439|NCT02436590|DEVICE|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
58260130|NCT01978470|DEVICE|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
58260131|NCT06144736|PROCEDURE|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
58260132|NCT06144736|DRUG|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
58381721|NCT02100930|DRUG|oral isotretinoin|
58381722|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
58381723|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
58381724|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
58381725|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
57910440|NCT04292184|DRUG|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
57910441|NCT03367390|DEVICE|AID System|AID system
57910442|NCT03367390|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
57910443|NCT02418676|DRUG|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
58058621|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
58058622|NCT00075413|DRUG|arsenic trioxide|
58260133|NCT03062527|OTHER|Dietary Intervention: Low vs. moderate glycemic index|
58260134|NCT03933670|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
58260135|NCT03933670|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
58260136|NCT03933670|PROCEDURE|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
58260137|NCT06621706|DEVICE|Gastric ultrasonography|"Women will be requested to fast 2 hours for clear drinks, 6 hours for a light meal, and 8 hours for a meal high in fried or fatty content prior to their next antenatal clinic visit.~On the day of assessment, fasting and dietary compliance will be confirmed individually with each woman and Gastric ultrasonography will be performed after sex and eight hours of fasting food.~Women will be first scanned in a semi-recumbent (45 degrees head up) supine position, followed by a semi-recumbent (45 degrees head up) right lateral position (RLP). In both positions the gastric antrum will be identified in the sagittal plane with its internal anatomical landmarks identified, i.e. the left lobe of the liver anteriorly and the abdominal aorta posteriorly."
58260138|NCT03005223|DRUG|Co-administration of DWC20155/DWC20156|
58381726|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
58381727|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
58381728|NCT04750863|OTHER|diagnosis criteria performance|
58381729|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
57910444|NCT02418676|DRUG|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
57910445|NCT02418676|DRUG|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
57910446|NCT05319301|DIETARY_SUPPLEMENT|Melatonin|A single dose of melatonin (1.9 mg)
58260139|NCT03005223|DRUG|DWC20163|
58260140|NCT02103959|DRUG|CMX-2043|Slow bolus IV administration of CMX-2043
58260141|NCT02103959|DRUG|Placebo comparator|Slow bolus IV administration of PBS
58381730|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
58381731|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
58381732|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
57910447|NCT03402815|DRUG|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
57910448|NCT05370001|OTHER|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
57910449|NCT02143752|BEHAVIORAL|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
57910450|NCT02143752|BEHAVIORAL|Quit Line|see arm
58260142|NCT06462482|DRUG|Nandrolone Decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
58260143|NCT06462482|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
58260144|NCT06189157|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
58260145|NCT04726644|PROCEDURE|hernia repair|different methods for hernia repair
58260146|NCT06616051|OTHER|mHealth referral reminder to identified visually impaired school children|Intervention consists of a Multi-component health message which was framed with assistance from a panel of public health consultant and research supervisors. WHO health promotion and prevention messages library from has also been utilized. Two parts make up the computerized text message reminder system: an SMS application for text messaging that is sent automatically and a web-based application for child registration and automated reminder scheduling. The parents will get text messages written in Urdu, the native language, as part of the intervention. Mothers will receive instruction on how to access and interpret SMS text messages upon enrollment. The message consists of four parts and will be sent as an SMS: Health promotion message, visual depiction of a child vision, a customized action plan with details on how to get to the hospital including the location and a snapshot of the key location, how much money is needed.
58381733|NCT03475069|OTHER|Custom Designed Exercises|
58260147|NCT00306358|DRUG|Vitamin B12 (Cyanocobalamin)|
58260148|NCT04888429|DRUG|Camrelizumab|Patients received camrelizumab 200 mg every 3 weeks
58260149|NCT04888429|DRUG|Famitinib|Patients received Famitinib 20 mg once per day
58381734|NCT03475069|OTHER|Plates Exercises|
58381735|NCT03475069|OTHER|Calisthenics Exercises|
58381736|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
58381737|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
58381738|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
58381739|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
58381740|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
58381741|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
58260150|NCT00020046|DRUG|docetaxel|
58260151|NCT00020046|DRUG|thalidomide|
58260152|NCT02520427|DRUG|AMG 330|0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.
58260153|NCT06021951|DRUG|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
58260154|NCT06021951|DRUG|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
58260155|NCT04173728|OTHER|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
58260156|NCT06640985|DEVICE|EDX110 wound dressing system|EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
57910451|NCT03316300|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
57910452|NCT03316300|PROCEDURE|Sham Procedure|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
57910453|NCT04910607|OTHER|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
58260157|NCT05523232|OTHER|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
58260158|NCT05523232|OTHER|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
58260159|NCT03492398|DRUG|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
58381742|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
58381743|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
58381744|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
58381745|NCT03814356|DRUG|Methylphenidate|IV MPH
58381746|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
57910454|NCT04910607|OTHER|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
57910455|NCT05244915|OTHER|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
57910456|NCT05244915|OTHER|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
57910457|NCT05244915|OTHER|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
57910458|NCT04705207|PROCEDURE|reflexology massage|the patient receive only foot reflexology massage
57910459|NCT04705207|PROCEDURE|sham massage|the patient receive only foot traditional massage
57910460|NCT00936741|DRUG|mifepristone|Mifepristone 300 mg to 1200 mg once daily
57910461|NCT01633918|BEHAVIORAL|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
57910462|NCT01633918|BEHAVIORAL|Usual health education|Usual health education lessons
57910463|NCT01739816|BEHAVIORAL|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
57910464|NCT04735380|DEVICE|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
57910465|NCT05900362|DEVICE|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
57910466|NCT02272088|BEHAVIORAL|physical activity-moderate|cross -over of moderate and intense physical activity
57910467|NCT02272088|BEHAVIORAL|Intense physical activity|cross -over of moderate and intense physical activity
57910468|NCT05871567|PROCEDURE|colorectal resection|potential resective surgery
57910469|NCT03671694|PROCEDURE|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
57910470|NCT03482401|DIETARY_SUPPLEMENT|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
57910471|NCT04317677|OTHER|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
57910472|NCT06611124|PROCEDURE|k -wires fixation for metacarpals fractures|reduction and fixation of metacarpal fracture with k-wire
57910473|NCT03898232|RADIATION|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
57910474|NCT06205537|OTHER|Control Liquid Supplement|Ready to drink supplement.
57910475|NCT06205537|OTHER|Experimental Liquid Supplement|Ready to drink supplement.
57910476|NCT03888989|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
57910477|NCT06302517|DEVICE|BIS-guided|underwent intraoperative monitoring of BIS anesthesia depth
57910478|NCT06387368|DRUG|Huaier Granule|Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
57910479|NCT06387368|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
57910480|NCT00327496|BIOLOGICAL|DC vaccine|
57910481|NCT00893984|DRUG|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
57910482|NCT02704468|OTHER|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
58381747|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
58381748|NCT02250469|DEVICE|Treatment with the Axium SCS system|
57910483|NCT00743301|OTHER|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
57910484|NCT01981772|DRUG|4% lidocaine with 1:100,000 epinephrine|see arm/group description
57910485|NCT01981772|DRUG|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
57910486|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 100 days
57910487|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 200 days
57910488|NCT06180018|OTHER|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
57910489|NCT03910686|COMBINATION_PRODUCT|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
57910490|NCT03354091|DEVICE|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
57910491|NCT02873091|PROCEDURE|Epidural analgesia|
57910492|NCT02873091|PROCEDURE|Continuous epidural infusion|
58381749|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
58393694|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
58393695|NCT02066831|BEHAVIORAL|Telemedical coaching|
58393696|NCT02066831|OTHER|Telemedicine|
57910493|NCT02873091|PROCEDURE|Intermittent epidural bolus|
57910494|NCT02873091|DRUG|ropivacaine|
57910495|NCT02873091|DRUG|sufentanil|
57910496|NCT01128816|DEVICE|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
57910497|NCT06378268|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
57910498|NCT06378268|DRUG|Cetrorelix 0.25 mg|Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
57910499|NCT02824081|BIOLOGICAL|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
57910500|NCT03191500|DEVICE|steerable catheter|peripheral vascular disease
57910501|NCT00190749|DRUG|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
57910502|NCT00190749|DRUG|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
57910503|NCT05609110|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
57910504|NCT05609110|DEVICE|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
58260160|NCT06449001|DRUG|Danicopan|Participants will receive danicopan on a weight-based dosing regimen.
58260161|NCT00496275|DRUG|Zactima (ZD6474)|
58260162|NCT00496275|DRUG|Vinorelbine plus cisplatin|
58381750|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
58381751|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
58381752|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
58381753|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
57910505|NCT02938026|PROCEDURE|Bariatric surgery|
58058623|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
57910506|NCT02938026|BEHAVIORAL|Telephone Intensive Lifestyle Counselling|
58260163|NCT00496275|DRUG|Gemcitabine plus cisplatin|
57910507|NCT00446992|DRUG|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
57910508|NCT03216421|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
57910509|NCT02799901|BIOLOGICAL|Nivolumab|Injection of nivolumab
58260164|NCT00293124|DRUG|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
58260165|NCT03227172|PROCEDURE|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
58260166|NCT04507802|DEVICE|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
58260167|NCT03440762|BEHAVIORAL|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
58260168|NCT03555864|DEVICE|infrared transluminescent device|use of infra red for venous access for second intravenous access
58260169|NCT05109442|DRUG|AFM24|intravenous infusion
58260170|NCT05109442|DRUG|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
58260171|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
58260172|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 0.25 mg/kg
58260173|NCT00754520|DEVICE|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
57910510|NCT02799901|RADIATION|hypofractionned radiotherapy|radiation
57910511|NCT02328339|OTHER|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
57910512|NCT02328339|OTHER|Placebo|Placebo matched to tea with respect to taste and appearance
57910513|NCT03834038|DRUG|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
57910514|NCT02700477|DIETARY_SUPPLEMENT|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
57910515|NCT02700477|OTHER|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
57910516|NCT00350480|DRUG|Provera|
57910517|NCT00350480|DRUG|Combination Birth Control pills|
57910518|NCT00725933|DRUG|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
57910519|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish sauce|
57910520|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish/liver sauce|
57910521|NCT01724073|DIETARY_SUPPLEMENT|Misola|
57910522|NCT06216873|OTHER|multiple trauma|Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
57910523|NCT05765162|BEHAVIORAL|Patient reported ourcomes|Full screening for the perioperative periode
57910524|NCT02108990|DRUG|Acetaminophen|
58381754|NCT02508545|OTHER|Parabolic flight|
58058624|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
58058625|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
58058626|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
58058627|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
58058628|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
57910525|NCT04593927|DRUG|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
57910526|NCT01177982|BEHAVIORAL|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
58058629|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
58058630|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
57708567|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
57708568|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
57708569|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
57708570|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
57708571|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
57910527|NCT01177982|BEHAVIORAL|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
57910528|NCT01177982|BEHAVIORAL|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
57910529|NCT01177982|BEHAVIORAL|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
57910530|NCT01177982|BEHAVIORAL|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
58058631|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
58058632|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
58058633|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
58058634|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
57708572|NCT00397995|PROCEDURE|above- or under elbow cast|
57708573|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
57708574|NCT02800148|DRUG|Azelaic acid foam|
58058635|NCT00010244|RADIATION|radiation therapy|
58058636|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
58058637|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
57708575|NCT02800148|DRUG|Azelaic acid foam|
57708576|NCT02800148|DRUG|Azelaic acid foam - Placebo|
57708577|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
57708578|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
57708579|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
57708580|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
57708581|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
58260174|NCT00754520|DEVICE|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
58260175|NCT01305889|BEHAVIORAL|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
58260176|NCT01305889|DRUG|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
57708582|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
58058638|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
58058639|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
58381755|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
58381756|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
58381757|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
58381758|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
58381759|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
58381760|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
58381761|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
57708583|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
57708584|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
57708585|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
57708586|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
58058640|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
58058641|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
58381762|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
58058642|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
57708587|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
57708588|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
57708589|NCT00020670|BIOLOGICAL|CD 40|
58058643|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
58058644|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
58260177|NCT04483492|DRUG|Caffeine citrate|diaphragm contractility after administration
58260178|NCT06433661|DRUG|Etavopivat|Participants will receive single dose of oral Etavopivat in each treatment period.
57708590|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
58260179|NCT06622395|DIAGNOSTIC_TEST|Remote diagnosys|Remote Diagnostic Arm (Teleconsultation): First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability). Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction.
58260180|NCT03367052|PROCEDURE|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
58260181|NCT03367052|PROCEDURE|Hybrid|The hybrid method will be used in one group of patients.
58381763|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
58381764|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
58381765|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
58381766|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
58381767|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
58381768|NCT02419378|DRUG|Alemtuzumab|
58381769|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
58381770|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
58260182|NCT02183259|DRUG|ESR 1150 CL, Capsule, oral|
58260183|NCT02183259|DRUG|ESR 1150 CL, solution, intravenous|
58260184|NCT06618170|DIAGNOSTIC_TEST|Tissue surface analysis with the device|Usage of the device to analyse the presence or absence of tumoral membrane marker at the surface of the removed tumoral specimen
58260185|NCT02510105|DEVICE|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
58260186|NCT02510105|DEVICE|CT scan|
58260187|NCT02510105|DEVICE|Servo-i|
58260188|NCT02510105|DEVICE|- Intubation|
58260189|NCT02510105|DEVICE|Ventilation ( with an ICU conventional ventilator)|
58260190|NCT05161455|BIOLOGICAL|platelet rich fibrin|we would like to measure the effect of PRF on soft and hard tissue healing
58260191|NCT04685460|OTHER|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
58260192|NCT05724628|PROCEDURE|Laparoscopic appendectomy|Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
57708591|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
58260193|NCT05724628|DRUG|Antibiotics (IV transitioned to oral)|"Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin"
58381771|NCT02971319|DEVICE|F-18 FDG PET|
58260194|NCT01747889|DEVICE|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
58260195|NCT05990348|OTHER|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
58381772|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
58381773|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
58381774|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
58381775|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
58381776|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
58381777|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
58381778|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
58381779|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
58381780|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
58260196|NCT01335217|PROCEDURE|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
58260197|NCT00536549|DEVICE|Guardian RT|
58260198|NCT00536549|BEHAVIORAL|Education about the self monitoring blood glucose|
58260199|NCT03721952|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
58260200|NCT06622200|BEHAVIORAL|Mindfulness-based Intervention|"In the present research, the standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study.~Participants in the experimental group completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing and delivering MBIs."
58260201|NCT05249322|OTHER|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~* An usual in-hospital consult of about 1h30 with paramedical and medical consult."
58381781|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
58381782|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
58381783|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
58381784|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
58381785|NCT05340530|DRUG|Placebo|It is a placebo.
58381786|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
58381787|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
57708592|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
58381788|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
58381789|NCT02791347|OTHER|Nutrition Intervention|
58381790|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
57910531|NCT01177982|BEHAVIORAL|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
58381791|NCT04704713|DRUG|Afamelanotide|
58381792|NCT04704713|DRUG|Placebo|
58381793|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
58381794|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
58381795|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
58381796|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
58381797|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
57708593|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
57708594|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
57910532|NCT01177982|BEHAVIORAL|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
57910533|NCT01177982|BEHAVIORAL|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
57910534|NCT05907109|BEHAVIORAL|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"* Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic."
57910535|NCT02030301|BIOLOGICAL|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
58260202|NCT00485043|BEHAVIORAL|Modified T'ai Chi: T'ai Chi for Arthritis|
58260203|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
58260204|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
58260205|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
58260206|NCT05356364|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
58260207|NCT05356364|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
58381798|NCT00356070|DRUG|Strattera|
58381799|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
57910536|NCT02030301|BIOLOGICAL|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
58260208|NCT04558775|OTHER|Observational|no intervention
58260209|NCT03805217|DEVICE|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
58260210|NCT03663465|OTHER|Hawthorn|Hawthorn tablet
58381800|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
58381801|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
58381802|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
58381803|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
58381804|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
57910537|NCT02030301|BIOLOGICAL|PBS|Phosphate-buffered saline
57910538|NCT00851838|DRUG|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
58260211|NCT03663465|DRUG|SGAs|SGAs tablet
58260212|NCT06186830|OTHER|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
58260213|NCT03454828|DIETARY_SUPPLEMENT|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
58260214|NCT03454828|DIETARY_SUPPLEMENT|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
58260215|NCT06620900|OTHER|Integrated Model of Care|The Integrated Model of Care was developed and piloted by the study team provide support for individuals seeking care in an interdisciplinary intensive outpatient program for mild traumatic brain injury to receive support for co-occurring substance use-related needs.
58260216|NCT05205343|OTHER|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
58381805|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
58381806|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
57910539|NCT03770910|OTHER|GIP receptor antagonist|GIP receptor antagonist
57910540|NCT03770910|OTHER|GIP receptor agonist|GIP(1-42)
57910541|NCT03770910|OTHER|Saline|Placebo (vehicle for infusions)
57910542|NCT01535560|DRUG|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
57910543|NCT01535560|DRUG|AL-60371 Vehicle|Inactive ingredients used as placebo
57910544|NCT00002987|BIOLOGICAL|bleomycin sulfate|
57910545|NCT00002987|DRUG|cyclophosphamide|
57910546|NCT00002987|DRUG|doxorubicin hydrochloride|
57910547|NCT00002987|DRUG|etoposide|
57910548|NCT00002987|DRUG|prednisolone|
58260217|NCT05205343|OTHER|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
58260218|NCT05117554|DRUG|casdatifan|Capsule
58381807|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
58381808|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
58381809|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
58381810|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
58381811|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
58381812|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
58381813|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
58381814|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
58381815|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
58260219|NCT05117554|DRUG|Placebo|Capsule
58260220|NCT05117554|DRUG|Midazolam|Syrup solution
58260221|NCT03030144|OTHER|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
58260222|NCT01567566|OTHER|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
58260223|NCT06665295|BEHAVIORAL|THRIVE-CAR-T|The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
58260224|NCT04233047|DRUG|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
58260225|NCT05893004|DIAGNOSTIC_TEST|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
58260226|NCT05248113|DEVICE|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
57910549|NCT00002987|DRUG|vincristine sulfate|
58260227|NCT03425266|OTHER|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
58381816|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
58381817|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
58381818|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
58381819|NCT02986633|OTHER|Echocardiography|
58381820|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
57708595|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
57910550|NCT00002987|RADIATION|radiation therapy|
58381821|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
58381822|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
58381823|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
58381824|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
58381825|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
58381826|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
58381827|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
58260228|NCT00727844|DRUG|Immediate Start Linezolid|
58260229|NCT00727844|DRUG|Delayed Start Linezolid|
58381828|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
58381829|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
58381830|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
58381831|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
58381832|NCT00269607|DRUG|Implantation of naltrexone implants|
58381833|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
58381834|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
58381835|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58381836|NCT03381664|DRUG|AVP-923|capsule
58381837|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
57708596|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
58260230|NCT02535130|DEVICE|Positive expiratory pressure|
58260231|NCT02535130|DRUG|amikacine nebulization|
58381838|NCT00348946|OTHER|placebo|an inactive substance
58381839|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
58381840|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
58381841|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
58381842|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
58381843|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
58393697|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
58260232|NCT00418366|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
58260233|NCT03309657|DRUG|Ceftolozane/tazobactam|This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
58260234|NCT05449535|DRUG|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
58260235|NCT05449535|DRUG|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
58260236|NCT05449535|DRUG|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
58260237|NCT03326128|DRUG|Bupropion Hydrochloride|Antidepressant that is also effective in smoking cessation
58260238|NCT03277053|DEVICE|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
58260239|NCT03277053|OTHER|Control.|Patient receive an ipad with no application.
58260240|NCT03471728|DRUG|linaclotide|Oral
58260241|NCT02381301|BIOLOGICAL|Venous blood sampling prior to CCTA.|
57708597|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
57708598|NCT02109328|DRUG|Placebo|Placebo oral tablets
57708599|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
57708600|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
57708601|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
57708602|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
57708603|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
57708604|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
58058645|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
58260242|NCT06074809|DRUG|Modified Guizhi Fuling granules|Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
58260243|NCT06074809|OTHER|Placebo|Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
58260244|NCT06667648|PROCEDURE|cupping session|Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
58260245|NCT02568228|DIETARY_SUPPLEMENT|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
58260246|NCT02568228|OTHER|Lean and fatty fish|The fish group will be open labeled.
57708605|NCT02719158|OTHER|Sham|
57708606|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
57708607|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
57708608|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
57708609|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
57708610|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
57708611|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
57708612|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
57708613|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
57708614|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
57708615|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
57708616|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
57708617|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
57708618|NCT06388551|DRUG|LY03017|single dose, administered orally
57708619|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
57708620|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
57708621|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
57708622|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
58058646|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
58381844|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter...). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
58393698|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
58260247|NCT02568228|DIETARY_SUPPLEMENT|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
58058647|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
58260248|NCT03676114|DRUG|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
58260249|NCT03676114|DRUG|Normal saline|Same volume of normal saline will be administrated
58260250|NCT05123092|OTHER|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
58260251|NCT05123092|OTHER|Intrathecal Morphine injection|Injecting intrathecal morphine
58260252|NCT02438605|DEVICE|Nellix|
58260253|NCT06647784|OTHER|pulmonary aeration in supine and ventral decubitus|The addition of repeated periods of 30 minutes of lateralization of 30° amplitude in dorsal decubitus and in ventral decubitus in patients with moderate to severe ARDS. Included patients will benefit from sessions of lateral decubitus for 30 minutes on each side (with an inclination of 30°) with alternation12 right/left, repeatedly for 6 hours. During this period, the upper part of the bed will be inclined by 30°. Patients will then be positioned in strict prone position for a period of 6 hours after which, the same pattern of alternating lateral decubitus will be applied for 12 hours while the patient is still in the prone position. After reversal in supine position, an observation period of 1 hour will be respected before carrying out the last measurements. The total duration of the intervention will be 25 hours.
58260254|NCT05250531|BEHAVIORAL|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
58260255|NCT02520882|DRUG|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
58260256|NCT02520882|DEVICE|PET/CT|
57708623|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
57708624|NCT01589432|DRUG|Placebo|2 placebo capsules
57910551|NCT00618982|DRUG|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
58058648|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
58058649|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
57708625|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
57708626|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
58058650|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
58260257|NCT05509569|DRUG|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
58260258|NCT04809857|OTHER|Exercise|
58260259|NCT00102648|DRUG|Lonafarnib|Given PO
58260260|NCT00102648|DRUG|Temozolomide|Given PO
58260261|NCT02760212|DEVICE|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
58260262|NCT02760212|OTHER|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
58260263|NCT06621693|DEVICE|Transcutaneous electrical diaphragmatic stimulation intervention|It will be applied on diaphragm, 30 min per session ,3 days/week for 4 weeks at a stimulation frequency of 30 Hz, pulse width of 400 μs, the intensity was gradually increased until visible muscle contraction was observed.
58260264|NCT06621693|OTHER|traditional physiotherapy program|The participants will receive traditional physiotherapy ( postural drainage, percussion , diaphragmatic breathing, phase 1 cardiac Rehabilitation and balance training ) three times per week for 4 weeks
58260265|NCT02280616|DRUG|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
58260266|NCT02280616|DRUG|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
58260267|NCT02280616|DRUG|high dose budesonide suspension|placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily
58381845|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
58260268|NCT02280616|DRUG|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
58260269|NCT00927511|DRUG|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
58381846|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
58058651|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
58381847|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
58381848|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
58381849|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
58381850|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
58381851|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
57708627|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
58058652|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
58058653|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
58058654|NCT00184366|DRUG|efalizumab|efalizumab
58058655|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
58058656|NCT00703781|DRUG|placebo|sterile ophthalmic solution
58058657|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
58381852|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
58381853|NCT05528406|DRUG|HLX208|900mg bid po
58381854|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
58381855|NCT00297739|DRUG|Risperidone|
58381856|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
58381857|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
58058658|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
58260270|NCT05766488|DEVICE|Continuous glucose monitor|A continuous glucose monitor will be provided in the experimental arm of this study for 6 months. This monitor will be a Freestyle Libre 2 device.
58260271|NCT05766488|DEVICE|Traditional glucometer|A traditional glucometer device will be assigned in the standard of care arm of this study for 6 months.
58260272|NCT05249114|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
58381858|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
58381859|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
58393699|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
58260273|NCT05249114|DRUG|Lu-177|Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
58260274|NCT04521621|BIOLOGICAL|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
58260275|NCT04521621|DRUG|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
58260276|NCT06617884|OTHER|Gait and balance training|The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
58260277|NCT01734915|DEVICE|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
58381860|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
57910552|NCT02948023|BIOLOGICAL|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
57910553|NCT03727438|BEHAVIORAL|Tele-Self CBTI|The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
58260278|NCT02656134|PROCEDURE|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
58260279|NCT02656134|GENETIC|Molecular analysis.|DNA analysis
58260280|NCT05178641|DEVICE|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
58260281|NCT05178641|OTHER|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
57910554|NCT03727438|OTHER|Health Education Control|The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
58260282|NCT01915667|DRUG|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
57910555|NCT06246266|PROCEDURE|Helfer Skin Tap Technique group|During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
57910556|NCT06246266|PROCEDURE|ShotBlocker Technique group|"The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain."
58260283|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
58260284|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
58260285|NCT04790162|BEHAVIORAL|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
58260286|NCT04199767|DRUG|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
58260287|NCT04199767|DRUG|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
58381861|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
58260288|NCT05496413|DEVICE|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
58260289|NCT06101017|DIAGNOSTIC_TEST|Optical Coherence Tomography|Non-invasive imaging test that use light waves to take cross-section pictures of the eye.
58381862|NCT01393899|DRUG|Placebo|oral tablets twice daily
58381863|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
58381864|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
58381865|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
58381866|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
58260290|NCT04357912|BEHAVIORAL|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
58381867|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
58381868|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
58381869|NCT05208008|OTHER|With service dog|No intervention
58260291|NCT04357912|BEHAVIORAL|Standard of Care Group|Participants will receive standard of care exercise education.
58260292|NCT06426472|OTHER|Web-based support program|Web-based support program for infertile women with failed IVF experience
58260293|NCT03201874|BEHAVIORAL|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
58260294|NCT03201874|BEHAVIORAL|Education|Education about sickle cell disease to increase disease knowledge
58260295|NCT06513962|OTHER|Best Practice|Receive standard chemotherapy
58260296|NCT06513962|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58260297|NCT06513962|OTHER|Electronic Health Record Review|Ancillary studies
58260298|NCT06513962|OTHER|Survey Administration|Ancillary studies
58260299|NCT06513962|DRUG|Triptorelin Pamoate|Given IM
57910557|NCT01915472|DRUG|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
57910558|NCT01621737|DRUG|Oxytocin|42 IU BID for six weeks
57910559|NCT01621737|DRUG|Oxytocin|84 IU BID for six weeks
57910560|NCT01621737|DRUG|Placebo|Vehicle placebo
58260300|NCT06279533|DRUG|LV232/Placebo|"Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 25mg Group:~6 subjects will receive LV232 25mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally."
58260301|NCT06279533|DRUG|LV232|"Drug: LV232 15mg Group:~12 subjects will receive LV232 15mg, orally~Drug: LV232 25mg Group:~12 subjects will receive LV232 25mg, orally"
57910561|NCT03954795|PROCEDURE|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
57910562|NCT03954795|PROCEDURE|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
57910563|NCT04694443|PROCEDURE|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
58260302|NCT01582178|PROCEDURE|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
58260303|NCT01582178|PROCEDURE|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
58381870|NCT00190333|DRUG|escitalopram|escitalopram
58381871|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
58381872|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
58381873|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
58381874|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
58381875|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
58381876|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
58381877|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
57910564|NCT04694443|OTHER|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
57910565|NCT00539565|DRUG|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
57910566|NCT00539565|DRUG|placebo|
57910567|NCT03887078|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
57910568|NCT03614637|OTHER|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
58260304|NCT06498622|DRUG|Donafenib + Envafolimab|"Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI"
57910569|NCT02261259|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
58260305|NCT01740271|DRUG|Epirubicin|
57910570|NCT01337583|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
57910571|NCT01337583|OTHER|Placebo|Vaginal Ring containing no drug substance
57910572|NCT01337583|DRUG|Dapivirine|
58260306|NCT01021761|DRUG|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
58260307|NCT01021761|DRUG|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
58260308|NCT01021761|DRUG|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
58260309|NCT01759849|OTHER|Allergen|Allergen extract is administered by inhalation.
58260310|NCT00893997|BIOLOGICAL|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
58260311|NCT01780402|BEHAVIORAL|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
58260312|NCT04638881|DRUG|Magnesium sulfate|Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
58260313|NCT04638881|DRUG|Normal Saline|Placebo. Bolus and infusion administered similarly under general anesthesia.
58260314|NCT06547086|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
58260315|NCT02733185|DRUG|disodium EDTA|IV Disodium Ethylene diamine tetra acetic acid in 500 cc
58381878|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
58381879|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
57910573|NCT04406090|OTHER|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
57910574|NCT03217682|OTHER|Music Therapy|Music therapy sessions
57910575|NCT03217682|OTHER|Massage Therapy|Massage therapy sessions
57910576|NCT02869854|BEHAVIORAL|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
58058659|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
58058660|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
58260316|NCT02733185|DIETARY_SUPPLEMENT|Oral Multi Vitamins/Minerals (OMVM)|6 tablets of Multi-vitamin/Multimineral daily
58260317|NCT02733185|DRUG|Placebo disodium EDTA|IV Placebo comparator- 500 normal saline
58260318|NCT02733185|DIETARY_SUPPLEMENT|Placebo Oral Multi Vitamins/Minerals (OMVM)|6 tablets of a placebo Multi-vitamin/Multimineral daily
58260319|NCT05636787|DRUG|Treosulfan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
58260320|NCT05636787|DRUG|Melphalan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
58260321|NCT01945437|DRUG|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
58260322|NCT00748189|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
58260323|NCT00748189|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
58381880|NCT02994745|DRUG|Fimasartan, Atorvastatin|
57910577|NCT02869854|BEHAVIORAL|PAP|Physical Activity on Prescription, after 3 months a new prescription
57910578|NCT05233332|DRUG|HL-085|12mg BID HL-085
57910579|NCT05233332|DRUG|Vemurafenib|720mg BID Vemurafenib
58260324|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
58381881|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
57708628|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
57708629|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
57708630|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
57708631|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
57708632|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
57708633|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
57708634|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
57708635|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
58260325|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
58260326|NCT05207917|PROCEDURE|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
58260327|NCT05207917|PROCEDURE|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
58260328|NCT05207917|PROCEDURE|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
58260329|NCT06605430|DRUG|Medical Cannabis|The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.
58260330|NCT03007290|OTHER|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
58260331|NCT04255732|DEVICE|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
58260332|NCT04255732|DEVICE|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
58260333|NCT00321880|PROCEDURE|therapeutic touch|administration of healing touch in 30 minute sessions
58260334|NCT06202625|DRUG|avatrombopag|The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
58393700|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
57708636|NCT01020019|DRUG|Placebo|Placebo control
57708637|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
57708638|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
57708639|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
58260335|NCT06202625|DRUG|Placebo|The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
57708640|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
57708641|NCT01395940|DRUG|KLH-2109|
57708642|NCT01395940|DRUG|KLH-2109|
57708643|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
58260336|NCT04827082|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
58260337|NCT03751800|DRUG|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
58381882|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
58381883|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
57910580|NCT04288609|OTHER|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
57708644|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
57708645|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
57708646|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
58058661|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
57708647|NCT04902495|OTHER|MTA Pro Root|pulp therapy
57708648|NCT04902495|OTHER|MTA HP Repair|pulp therapy
57708649|NCT04902495|OTHER|Biodentine|pulp therapy
57708650|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
57708651|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
57708652|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
57708653|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
57708654|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
57910581|NCT04288609|OTHER|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
58260338|NCT05525988|PROCEDURE|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
58058662|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
58058663|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
58260339|NCT00742872|DRUG|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
58260340|NCT00742872|DRUG|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
58381884|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
58381885|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
58260341|NCT06618703|RADIATION|Blood sample, urine sample, osteodensitometry|Blood sample, urine sample, osteodensitometry
58260342|NCT06374277|OTHER|Med AAAction intervention|The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
58260343|NCT02947204|OTHER|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
58260344|NCT02947204|OTHER|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
58260345|NCT05971602|DRUG|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
58381886|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
58381887|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
58058664|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
58260346|NCT05971602|DRUG|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
58260347|NCT05971602|DRUG|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
58381888|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
58260348|NCT05971602|DRUG|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
57708655|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
58058665|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
58260349|NCT05971602|DRUG|Isoniazid and Rifampicin (HR)|Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
57708656|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
57708657|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
57708658|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
57708659|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
57708660|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
57708661|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
57708662|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
58058666|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
58058667|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
58058668|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
58260350|NCT03948035|DRUG|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
58260351|NCT03948035|DRUG|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
58260352|NCT03948035|DRUG|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
58260353|NCT03948035|DRUG|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
58260354|NCT03948035|OTHER|autologous stem cell transplant|autologous stem cell transplant
58260355|NCT06523881|PROCEDURE|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.
58260356|NCT06523881|PROCEDURE|Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)|Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
58260357|NCT04421560|DRUG|Ibrutinib|Capsule, taken by mouth daily
57708663|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
57708664|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
57708665|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
57708666|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
58058669|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
58058670|NCT00000231|DRUG|Buprenorphine|
58058671|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
58260358|NCT04421560|DRUG|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
58260359|NCT04421560|DRUG|Rituximab|Given as infusion into a vein (intravenous, IV)
57708667|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
58260360|NCT05129475|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
57708668|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
57708669|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
58381889|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
58381890|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
57708670|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
58058672|NCT03508973|OTHER|Sculpta|
58260361|NCT05129475|DRUG|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
58260362|NCT05331248|BEHAVIORAL|Leaders in Action: Household Treatment|The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.
58381891|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
58381892|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
58381893|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
58381894|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
57708671|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
57708672|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
57708673|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58058673|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
58058674|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
58058675|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
58058676|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
58058677|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
58058678|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
57708674|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
58381895|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
58381896|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
58381897|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
58381898|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
58381899|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
58381900|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
57910582|NCT04467528|DEVICE|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
58260363|NCT05331248|BEHAVIORAL|Leaders in Action: Group Treatment|The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.
58381901|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
58381902|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
58381903|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
58381904|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
58381905|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
58381906|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
58381907|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
58381908|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
58381909|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
58381910|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
58381911|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
58381912|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
58381913|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
57910583|NCT04467528|DRUG|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
57910584|NCT00345293|BIOLOGICAL|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
57910585|NCT02533531|DEVICE|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
57910586|NCT01254240|DEVICE|UVA / UVB phototherapy|UVA / UVB phototherapy
57910587|NCT01254240|DEVICE|UVB phototherapy|UVB phototherapy
57910588|NCT06611371|BIOLOGICAL|IVT GBS-06|Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.
57910589|NCT06611371|BIOLOGICAL|Placebo|0.9% sodium chloride
58260364|NCT05053048|DEVICE|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
57910590|NCT05253820|PROCEDURE|distal radial approach|coronary diagnosis and intervention via distal vs conventional radial approach
57910591|NCT05253820|PROCEDURE|conventional radial access|conventional radial access
58058679|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
58058680|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
58058681|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
58058682|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
58381914|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
58058683|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
58058684|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
58058685|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
58058686|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
58260365|NCT06553729|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
58260366|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
57910592|NCT03946579|OTHER|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
57910593|NCT05087979|DEVICE|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
57910594|NCT06147050|DRUG|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
58260367|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo.
58260368|NCT06553729|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
58260369|NCT06305676|DIAGNOSTIC_TEST|combined HPV 16 DNA and host gene methylation oral biomarker panel|DNA Methylation Profiling
58260370|NCT04570852|OTHER|LiDCO|"We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,"
58260371|NCT02977325|OTHER|water cure|
58260372|NCT05186636|OTHER|KPI reports|Quarterly
57910595|NCT06147050|OTHER|Placebo|Patients will receive matching placebo control twice daily.
57910596|NCT01939665|DEVICE|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
57910597|NCT00682773|OTHER|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
58260373|NCT05186636|OTHER|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
57910598|NCT05145309|DRUG|KMgCit|Supplement that provide K, Mg, and citrate
57910599|NCT05145309|DRUG|Placebo|Power with identical appearance to KMgCit
57910600|NCT03553680|BEHAVIORAL|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
58260374|NCT03936465|DRUG|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
58260375|NCT03936465|DRUG|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
58381915|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
58260376|NCT06464848|OTHER|Narrative identity task|All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).
58260377|NCT00394836|DRUG|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
57708675|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
57910601|NCT05416190|DIAGNOSTIC_TEST|Lupus anticoagulant testing|The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
57910602|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 3|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves
57910603|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 4|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
57910604|NCT01893294|DRUG|gemcitabine hydrochloride|Given IT
57910605|NCT01893294|DRUG|fluorouracil|Given IV
57910606|NCT01893294|RADIATION|radiation therapy|Undergo radiation therapy
57910607|NCT01893294|OTHER|laboratory biomarker analysis|Correlative studies
57910608|NCT05600296|DRUG|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
57910609|NCT05600296|PROCEDURE|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
57910610|NCT05600296|PROCEDURE|IINB+ Spermatic cord block|IINB+ Spermatic cord block
57910611|NCT02711969|DRUG|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
58260378|NCT00394836|DRUG|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
58260379|NCT06080594|BEHAVIORAL|High-intensity exercise training|Eight sessions of high-intensity interval exercise using a single-leg cycle ergometer are conducted on separate days over a 2-week period.
58260380|NCT04425473|DRUG|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
58260381|NCT04425473|DRUG|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
58260382|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on deepLive™ LC-OCT device|Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
58260383|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on skin biopsy|Control Arm: Standard management with an initial diagnosis based on skin biopsy
58381916|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
58381917|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
58381918|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
57910612|NCT06293703|PROCEDURE|Surgery|Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
57910613|NCT04362384|DRUG|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
57910614|NCT04362384|DRUG|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
57910615|NCT05073666|OTHER|NO INTERVENTION|NO INTERVENTION
57910616|NCT04897906|BEHAVIORAL|Education Group|Mother care, newborn care and breastfeeding education will be provided to pregnant women in the third trimester of pregnancy.
57708676|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
57708677|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
57708678|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
58058687|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
58260384|NCT05350332|DEVICE|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
58260385|NCT05350332|DEVICE|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test evaluating lung function, consisting of two parts: spirometry and body plethysmography. In spirometry, participants breathe through a mouthpiece that measures airflow and volume to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants enter in an enclosed chamber where they breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing are used to calculate the volume of air that remains in the lung after expiration. A MiniBox+ device may be used. The MiniBox+ device derives total lung capacity (TLC) during tidal breathing by the analysis of gas pressures and airflows immediately preceding and immediately following airway occlusions to calculate the same measures as conventional PFT analysis.
58381919|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
58381920|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
58381921|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
58058688|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
58260386|NCT05350332|DEVICE|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed transcutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS8R Bipolar Constant Current Stimulator). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
58381922|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
58260387|NCT00163982|DRUG|Norfloxacin|
58260388|NCT00790998|DRUG|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
58260389|NCT00790998|DRUG|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
58260390|NCT05831839|DEVICE|RehaCom|computerized cognitive training
58260391|NCT00588211|BEHAVIORAL|Interviews|45-minute individual interviews after the conclusion of their dental appointment
58260392|NCT00588211|BEHAVIORAL|focus group|A focus group of the preliminary cancer-related risk perception item pool.
58260393|NCT00588211|BEHAVIORAL|Survey|Quantitative item analysis of the final item pool.
58260394|NCT00588211|BEHAVIORAL|Survey|A second confirmatory factor analysis.
58260395|NCT05839405|OTHER|None - Cross Sectional.|There is no intervention, this is cross-sectional only.
58260396|NCT04404920|OTHER|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
58260397|NCT05629494|DRUG|Ibuprofen 400 mg, TID|Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
58260398|NCT05629494|DIAGNOSTIC_TEST|PSA test|PSA test will be repeated in 6 weeks
58260399|NCT04805580|PROCEDURE|unilateral intrathecal block|Quadratus lunborum block
58260400|NCT06375746|OTHER|Personalized video|After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
58260401|NCT05963386|DRUG|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
58260402|NCT01008956|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
57708679|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
57708680|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
58260403|NCT01785511|RADIATION|UVA Radiation|UVA radiation exposure for 20 minutes
58260404|NCT05740189|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
58260405|NCT02128347|OTHER|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
57708681|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
57708682|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
57708683|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
57708684|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
57708685|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
58381923|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
57708686|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
57708687|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
57708688|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
57708689|NCT02677090|DRUG|Placebo (including Maltodextrin)|
57708690|NCT02677090|DRUG|Dose 1 - Promitor®|
57708691|NCT02677090|DRUG|Dose 2 - Promitor®|
57708692|NCT02677090|DRUG|Dose 3 - Promitor®|
57708693|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
57708694|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
57708695|NCT03906318|DRUG|Iticitinib|
57708696|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
57708697|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
57708698|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
57708699|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
57708700|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
57708701|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
57708702|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
57708703|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
58260406|NCT05634954|DRUG|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
58381924|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
58381925|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
58381926|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
57708704|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
57708705|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
57708706|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
57708707|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
57708708|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
57708709|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
57708710|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
57708711|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
57708712|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
57708713|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
58260407|NCT05634954|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
58260408|NCT05634954|DIAGNOSTIC_TEST|Static - PET/CT Scan|Group 2: Static whole-body scans
58381927|NCT04738175|DRUG|Placebo|Diluent solution
58381928|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
58381929|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
58381930|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
58381931|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
58381932|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
58381933|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
58381934|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
58381935|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
58381936|NCT02590536|DRUG|placebo|
58381937|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
57708714|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
57708715|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
57708716|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
57708717|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
57708718|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
57708719|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
57708720|NCT04181346|DRUG|Pregabalin|antipsychotic
57708721|NCT04181346|DRUG|Placebo|Placebo
58260409|NCT01684579|BEHAVIORAL|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
58381938|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
57708722|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
57910617|NCT02109315|DRUG|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
57910618|NCT02109315|DRUG|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
57910619|NCT02391779|DIETARY_SUPPLEMENT|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
57910620|NCT02391779|BEHAVIORAL|Walking training|30-60 minutes walking training, 5 days/week.
57910621|NCT02391779|BEHAVIORAL|Flexibility training|5 days/week; e.g. stretching training at home
57910622|NCT02391779|DIETARY_SUPPLEMENT|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
57910623|NCT02391779|BEHAVIORAL|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
58260410|NCT01684579|BEHAVIORAL|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
58260411|NCT01684579|BEHAVIORAL|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
58260412|NCT00468442|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
58260413|NCT00468442|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
58381939|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
58381940|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
58260414|NCT00468442|BIOLOGICAL|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
58260415|NCT00468442|BIOLOGICAL|Rituximab|Depletes transient B-cells
58381941|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
58381942|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
58381943|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
58381944|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
58381945|NCT02655718|DEVICE|MRI|
57910624|NCT00514891|BIOLOGICAL|Vitamin A|The effect of vitamin A given with different vaccines will be studied
57910625|NCT02866500|BEHAVIORAL|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
57910626|NCT02647567|OTHER|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
58260416|NCT00468442|DRUG|Sirolimus|Maintenance immunosuppressive therapy
58260417|NCT06463652|PROCEDURE|Cervical cerclage|Cervical cerclage using the McDonald technique under anaesthesia.
58260418|NCT06463652|DRUG|Vaginal progesterone|Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
58381946|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
58381947|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
58381948|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
58381949|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
58381950|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
58381951|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
58381952|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
58381953|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
57910627|NCT02647567|OTHER|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
57910628|NCT03592901|DRUG|brachial plexus anesthesia|Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
57910629|NCT02343874|OTHER|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
57910630|NCT03677765|PROCEDURE|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
57910631|NCT01545323|GENETIC|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
57910632|NCT04393337|OTHER|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
57910633|NCT04393337|OTHER|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
57910634|NCT01778257|DIETARY_SUPPLEMENT|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
57910635|NCT01778257|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Mate extracts.
57910636|NCT06283368|PROCEDURE|Thyroidectomy, Bilaterally Total|Thyroidectomy, Bilaterally Total
57910637|NCT06283368|PROCEDURE|Thyroidectomy, Unilaterally Total|Thyroidectomy, Unilaterally Total
57910638|NCT06283368|PROCEDURE|Thyroidectomy, Complementary|Thyroidectomy, Complementary
58260419|NCT06648720|DRUG|DAPT de-escalation|Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
58260420|NCT06328010|BIOLOGICAL|Advanced Treatment Modalities for wound and injuries|Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts
58381954|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
57910639|NCT06283368|PROCEDURE|Thyroidectomy, Near Total|Thyroidectomy, Near Total
57910640|NCT00419510|BEHAVIORAL|Culturally Tailored Genetic Counseling|
57910641|NCT02164123|OTHER|Spinal mobilization|Experimental group
57910642|NCT02164123|OTHER|Spinal Mobilization II|Active comparator group
57910643|NCT02164123|OTHER|Placebo|Placebo group
57910644|NCT03561831|DRUG|Propofol|propofol based anesthesia
58381955|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
57910645|NCT03561831|DRUG|Sevoflurane|sevoflurane based anesthesia
57910646|NCT02865980|OTHER|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
57910647|NCT02865980|OTHER|Betadine|in control group, will be washed the Catheter with Betadine
57910648|NCT01946763|BEHAVIORAL|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
58260421|NCT06328010|BIOLOGICAL|Standard of care|Standard of care without use of grafts or scaffolded grafts
58260422|NCT06328010|OTHER|Retrospective wound treatment data collection|Completed wound care treatment regardless of modality.
58260423|NCT06567613|DIAGNOSTIC_TEST|Speech test|The hearing screening ensures normal hearing before enrollment. The speech reception threshold for swiss german mono- and bisyllable words is determined in an adaptive procedure.
58260424|NCT05856994|DRUG|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
58260425|NCT04288141|OTHER|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
58260426|NCT05942105|PROCEDURE|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
58381956|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
57910649|NCT01946763|BEHAVIORAL|pre operative education|
57910650|NCT02372500|DIETARY_SUPPLEMENT|Chewing gum|Sugar free chewing gum
57910651|NCT03383926|PROCEDURE|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
57910652|NCT03383926|PROCEDURE|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
57910653|NCT01893125|DRUG|CNV2197944|
57910654|NCT01893125|DRUG|Placebo|
57910655|NCT02341859|DEVICE|stenfilcon A|contact lens
57910656|NCT02341859|DEVICE|delefilcon A|contact lens
57910657|NCT02341859|DEVICE|narafilcon A|contact lens
57910658|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"* 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment"
57910659|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
57910660|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
58381957|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
58381958|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
58381959|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
58381960|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
57708723|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
57708724|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
57708725|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
57708726|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
58260427|NCT03805451|BEHAVIORAL|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
58260428|NCT06249854|DRUG|Bojungikki-tang(BJIKT)|"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects"
58260429|NCT06249854|DRUG|Pembrolizumab|It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
58260430|NCT06215560|OTHER|PDMP Check CDS|Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
58260431|NCT06618443|OTHER|Scapular mobilization with movement|The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
58260432|NCT04376125|OTHER|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
58260433|NCT03713008|DIAGNOSTIC_TEST|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
58260434|NCT06642519|OTHER|Brain Stimulation|Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
58260435|NCT04887090|DEVICE|Acupuncture and Drug Compound Technology|Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.
58381961|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
58381962|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
57708727|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
58381963|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
57708728|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
58381964|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
58381965|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
57708729|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
57708730|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
57708731|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
57910661|NCT05249439|OTHER|I-SatPro weight loss programme|I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing
57910662|NCT05712473|DIAGNOSTIC_TEST|PYLARIFY|PYLARIFY PET
57910663|NCT03929172|BIOLOGICAL|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
57910664|NCT03929172|DRUG|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
57910665|NCT02447172|DRUG|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
57910666|NCT02447172|OTHER|Placebo|Matching placebo sponge
57910667|NCT00434005|DRUG|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
57910668|NCT00434005|DRUG|Placebo|matched appearance to acetylcysteine and ascorbate intervention
57910669|NCT03273361|BEHAVIORAL|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
57910670|NCT05924308|OTHER|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
57910671|NCT05924308|OTHER|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
58260436|NCT04887090|OTHER|Routine perioperative management|Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.
58381966|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
58381967|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
58381968|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
57910672|NCT00188786|PROCEDURE|daily Cone Beam CT for imaging guidance for radiotherapy|
57910673|NCT04839874|OTHER|No intervention|Semi-structured qualitative interviews
57708732|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
57708733|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
57708734|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
57910674|NCT03362047|DRUG|Riciguat Group|Patients will be administered 12 weeks Riciguat
57910675|NCT03362047|DRUG|Macitentan Group|Patients will be administered 12 weeks Macitentan
57910676|NCT00081497|BIOLOGICAL|agalsidase beta|1.0 mg/kg every 2 weeks
57910677|NCT04353973|OTHER|Pre-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
57910678|NCT04353973|OTHER|Standard of Care|Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
58058689|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
57910679|NCT04353973|OTHER|Post-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
57910680|NCT02257567|DRUG|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
57910681|NCT02257567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
57910682|NCT02257567|DRUG|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
57910683|NCT02257567|DRUG|Rituximab|Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
57910684|NCT02257567|DRUG|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
57910685|NCT00699894|DRUG|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
57910686|NCT00699894|DRUG|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
57910687|NCT02232607|DRUG|Lacidipine, low dose|
57910688|NCT02232607|DRUG|Lacidipine, medium dose|
57910689|NCT02232607|DRUG|Lacidipine, high dose|
57910690|NCT02232607|DRUG|Placebo|
57910691|NCT04806217|OTHER|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
57910692|NCT06609564|DEVICE|inspiratory muscle training|Inspiratory muscle training with a pressure-adjustable device
57910693|NCT06609564|OTHER|Convantional chest physiotherapy|Chest physiotherapy
57910694|NCT00628576|DRUG|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
57910695|NCT00628576|DRUG|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
57910696|NCT03368339|DRUG|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
57910697|NCT03368339|DRUG|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
57910698|NCT03368339|DRUG|Vehicle|Vehicle
57910699|NCT01880528|DRUG|lisinopril|Given PO
58260437|NCT03492671|DRUG|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
58260438|NCT03492671|DRUG|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
57910700|NCT01880528|DRUG|placebo|Given PO
57910701|NCT06116955|DRUG|Midazolam and sufentanil|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
57910702|NCT06116955|DRUG|Midazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
57910703|NCT06116955|DRUG|Remazolam and sufentanil.|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
57910704|NCT06116955|DRUG|Remazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
57910705|NCT03860285|OTHER|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
57910706|NCT04232059|DEVICE|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
57910707|NCT01096654|OTHER|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
57910708|NCT04899141|DEVICE|Percutaneous Coronary Intervention|stenting with the ihtDEStiny® sirolimus eluting stent
57910709|NCT03226951|DEVICE|Subthreshold 532nm laser|Subthershold 532nm laser
57910710|NCT02704663|PROCEDURE|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
57910711|NCT02704663|PROCEDURE|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
58260439|NCT03492671|RADIATION|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
58260440|NCT04161079|DEVICE|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
57910712|NCT00910689|DRUG|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
57910713|NCT00910689|DRUG|Placebo control|Placebo
58058690|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
58260441|NCT03895606|OTHER|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
58260442|NCT04316039|DRUG|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
58260443|NCT04316039|RADIATION|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
58260444|NCT04058535|BIOLOGICAL|Eylea|Aflibercept
58260445|NCT04058535|BIOLOGICAL|ALT-L9|Aflibercept biosimilar
58260446|NCT03490461|DRUG|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
58260447|NCT00702442|DRUG|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
58260448|NCT00702442|DRUG|Saline solution|Saline solution administrated i.v 30 min prior surgery
58393701|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
58260449|NCT05214586|PROCEDURE|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
58260450|NCT06204094|RADIATION|node-sparing short-course radiotherapy|5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
58260451|NCT06204094|DRUG|Sintilimab|200mg intravenous infusion d1 of each cycle\*8cycles
58393702|NCT02483793|DRUG|Tamsulosin|
58058691|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
58058692|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
58260452|NCT06204094|DRUG|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
58260453|NCT06204094|DRUG|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle\*8cycles
58260454|NCT06204094|PROCEDURE|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
58260455|NCT06204094|PROCEDURE|watch and wait|WW for cCR patients
58260456|NCT05496283|OTHER|denture adhesive|After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
58260457|NCT04036305|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
58260458|NCT04036305|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
58260459|NCT04036305|DRUG|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
58260460|NCT02600845|DEVICE|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
58381969|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
58381970|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
58381971|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
58381972|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
58381973|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
57708735|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
58260461|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
58260462|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
58381974|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
58381975|NCT02172391|DRUG|Placebo inhalation powder capsules|
58260463|NCT06622187|DRUG|Desmopressin (DDAVP)|Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
58260464|NCT06622187|DRUG|Sodium Chloride|Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
58260465|NCT01594892|RADIATION|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
58260466|NCT05146986|DEVICE|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
58260467|NCT04403503|DRUG|Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
58381976|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
57910714|NCT00910689|BEHAVIORAL|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
58058693|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
58058694|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
58260468|NCT04403503|DRUG|Cyanoacrylate, Isobutyl|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
58260469|NCT06105749|DEVICE|contrast-enhanced mammography|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
58260470|NCT00319384|DEVICE|Ultrafiltration therapy|
58381977|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
58381978|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
58381979|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
58381980|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
58381981|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
58381982|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
58260471|NCT05274581|OTHER|A new type of ultrasound course|All participants will receive the educational intervention. The educations intervention consists of three teaching seminars over three months, a curriculum of 10 point-of-care ultrasound applications, an online learning platform providing educational support before, during and after the teaching sessions.
58260472|NCT00382525|DEVICE|Cardiac Rhythm Management device|
58260473|NCT06621108|OTHER|Focus group session|Participants will take part in a focus group, which includes sharing their experience of the four-week feeling tone mindfulness course in an online group session. The focus group session will be led by trained moderator, and attended by several other course participants who completed the four-week feeling tone mindfulness course. The session will be audio-recorded as the research team will analyze the qualitative feedback offered by participants.
58260474|NCT04651049|DRUG|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
58260475|NCT04651049|DEVICE||
58260476|NCT05496959|DRUG|Lutetium Lu-177 PNT2002|Given IV
57708736|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
57708737|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
57708738|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
57708739|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
57708740|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
57708741|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
57708742|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
57708743|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
57708744|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
57708745|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
57708746|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
57708747|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
57708748|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
57708749|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
57708750|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
57708751|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
57708752|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
58058695|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
58058696|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
58058697|NCT02685839|OTHER|general physical therapy|
58058698|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
58058699|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
58260477|NCT05496959|OTHER|Quality-of-Life Assessment|Ancillary studies
57708753|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
57708754|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
57708755|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
57708756|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
57708757|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
57708758|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
57708759|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
57708760|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
57708761|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
57708762|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
57708763|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
57708764|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
57708765|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
57708766|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
57708767|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
57708768|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
57708769|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
57708770|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
58058700|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
58058701|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
58058702|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
58058703|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
58058704|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
58058705|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
58260478|NCT05496959|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58260479|NCT06461247|OTHER|Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals|Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
58260480|NCT06461247|OTHER|Standard Care Group|Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
57910715|NCT00910689|DRUG|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
57910716|NCT02220231|PROCEDURE|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
57910717|NCT01759576|DRUG|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
58260481|NCT02900105|DRUG|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
58260482|NCT01223469|DEVICE|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
58260483|NCT06144320|OTHER|Acupuncture|Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
58260484|NCT05856149|BEHAVIORAL|Mobile Diabetes Prevention Program|The intervention is a mobile, web-based diabetes prevention program that participants will have access to for a total of 12 weeks. The intervention is a behavioral intervention aimed at increasing the knowledge and skills of participants to reduce type 2 diabetes risk behaviors.
58260485|NCT02781753|BIOLOGICAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
58260486|NCT02781753|BIOLOGICAL|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
58260487|NCT03096678|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
58260488|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline to index surgery|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Powered Systems, Instruments, and Imaging device(s)
57708771|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
57708772|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
58260489|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline to discharge|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Advanced Energy device(s)
58260490|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to index surgery for those receiving eligible Medtronic Robotics and Navigation, Rods and Screws, Interbodies and Biologics, Spinal Tethers, and Other Spinal Hardware device(s)
58260491|NCT00312481|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
57708773|NCT00503386|DRUG|Palonosetron|
58058706|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
58058707|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
58058708|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
58260492|NCT00312481|DRUG|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
57708774|NCT00503386|DRUG|Granisetron|
57708775|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
58393703|NCT02483793|DRUG|Oxybutynin|
57708776|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
57708777|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
57708778|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
57708779|NCT01753635|DEVICE|supraglottic airway placement and use|
57708780|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
57708781|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
57708782|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
57708783|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
57708784|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
57708785|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
57708786|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
57708787|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
58058709|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
58260493|NCT06648967|DIETARY_SUPPLEMENT|Supplementation with a multi-ingredient whey supplement|Malabsorption of two different fructose boluses at baseline and after 3 and 5 weeks of multi-ingredient whey supplementation.
57708788|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
57910718|NCT05198011|PROCEDURE|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
58260494|NCT06643416|DRUG|Timolol 0.5% eye drops and betamethasone valerate 0.1% cream|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
57708789|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
57910719|NCT05198011|PROCEDURE|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
57910720|NCT02349373|BEHAVIORAL|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
57910721|NCT02349373|BEHAVIORAL|16 week training period|Receipt of a weekly running schedule through an online training diary.
57910722|NCT01321320|OTHER|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
57910723|NCT05391737|DIAGNOSTIC_TEST|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
58058710|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
57910724|NCT05391737|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
58260495|NCT06643416|DRUG|Betamethasone valerate 0.1% cream|The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
58260496|NCT05672407|DRUG|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
58260497|NCT05672407|DRUG|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
58260498|NCT05880082|DRUG|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
57708790|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
57708791|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
57910725|NCT05391737|DIAGNOSTIC_TEST|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
57910726|NCT02863497|BEHAVIORAL|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
57910727|NCT05560347|OTHER|Hot water application|Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
57910728|NCT05468359|DRUG|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
57910729|NCT05468359|DRUG|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
57910730|NCT05468359|DRUG|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
58260499|NCT03820817|DRUG|Rifaximin|Given PO
58260500|NCT03683186|DRUG|Ralinepag|Active
58260501|NCT01778738|PROCEDURE|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
58260502|NCT01778738|PROCEDURE|Sleeve gastrecomy|Vertical sleeve gastrectomy
58260503|NCT01778738|PROCEDURE|Bastric bypass|Gastric bypass surgery
58260504|NCT05481593|BEHAVIORAL|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
58260505|NCT05481593|BEHAVIORAL|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
58260506|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
58260507|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
58260508|NCT05715489|PROCEDURE|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
57910731|NCT05468359|DRUG|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
57910732|NCT00329511|DRUG|methyldopa vs. clonidine|Comparison of compliance
57910733|NCT00329511|DRUG|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
57708792|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
57708793|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
57708794|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
57708795|NCT00006125|DRUG|doxorubicin hydrochloride|
57708796|NCT00006125|DRUG|topotecan hydrochloride|
57708797|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
57708798|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
58260509|NCT05715489|PROCEDURE|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
58260510|NCT02584998|OTHER|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
58260511|NCT02584998|OTHER|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
58260512|NCT02883075|OTHER|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
58260513|NCT02883075|OTHER|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
58381983|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
57708799|NCT02493634|DEVICE|MRWire|
57708800|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
57708801|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
57708802|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
57708803|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
57708804|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
58260514|NCT02883075|OTHER|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
58260515|NCT00438243|DRUG|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
58260516|NCT00438243|DRUG|Refresh Plus|1 drop in the affected eye twice daily
58393704|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
58260517|NCT04207931|DRUG|Topical steroid class I-II|applied once daily - 18 month duration of the study
58393705|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
57708805|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
57708806|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
57708807|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
57708808|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
58393706|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
58393707|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
57708809|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
57708810|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
57708811|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
57708812|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
57708813|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
57708814|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
57708815|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
57708816|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
57708817|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
58393708|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
57708818|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
57708819|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
58058711|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
57708820|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
57708821|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
57708822|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
58058712|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58260518|NCT04207931|DRUG|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
58260519|NCT04207931|DRUG|Doxycyline|oral antibiotic twice daily for 6 months
57708823|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
57708824|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
57708825|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
57708826|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
58058713|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
58260520|NCT04207931|DRUG|Minoxidil|5% solution or foam started after month 8
58260521|NCT05088590|DIETARY_SUPPLEMENT|Enfagrow® Neuropro Toddler Nutritional Drink|Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
57708827|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
57708828|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
57708829|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
57708830|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
57708831|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
58260522|NCT05088590|DIETARY_SUPPLEMENT|Pediasure® Grow & Gain Protein Shake for Kids|Pediasure® Grow \& Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
58260523|NCT04294706|DIETARY_SUPPLEMENT|Hemp arm|Hemp oil
58260524|NCT00432276|DRUG|Alogliptin|Alogliptin tablets.
57708832|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
57708833|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
57708834|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
57708835|NCT00743912|DRUG|rifaximin|550 mg TID
57708836|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
57708837|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
58058714|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
58260525|NCT00432276|DRUG|Pioglitazone|Pioglitazone tablets.
58260526|NCT00432276|DRUG|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
57708838|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
57708839|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
57708840|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
57910734|NCT04703738|PROCEDURE|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
58058715|NCT00320632|DRUG|Desipramine|
58058716|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
58260527|NCT00432276|DRUG|Placebo|Matching placebo tablets.
57708841|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
57708842|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
57708843|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
58058717|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
58260528|NCT00665587|PROCEDURE|Cox-MAZE III|Maze procedure according to standards of the department
58260529|NCT03430401|BEHAVIORAL|Perceptual-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
58260530|NCT03430401|BEHAVIORAL|Semantic-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
58260531|NCT03430401|BEHAVIORAL|Cognitive stimulation|The frequency, duration and the number of sessions will be consistent with the experimental interventions.
58260532|NCT02484651|DRUG|Sugammadex|Reversal of deep neuromuscular block
58260533|NCT02484651|DRUG|Rocuronium|Maintenance of deep neuromuscular block
58260534|NCT03597009|DRUG|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
58260535|NCT03597009|DRUG|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
58393709|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
58260536|NCT05200013|BIOLOGICAL|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
58260537|NCT06621628|OTHER|stretching, strengthening exercises and active exercises|Bioptron light therapy device, resisted exercises and stretching exercises
58381984|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
58381985|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
57708844|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
58058718|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
58260538|NCT01875627|DIETARY_SUPPLEMENT|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
58260539|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate and Konjac Noodles|
58260540|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate noodles|
58260541|NCT01120080|BEHAVIORAL|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
58260542|NCT01120080|BEHAVIORAL|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
58381986|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
57910735|NCT04703738|DEVICE|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
57910736|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
57910737|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
58381987|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
58381988|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
58381989|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
58381990|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
58381991|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
58381992|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
58381993|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
57708845|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
57910738|NCT00159276|PROCEDURE|Induced Sputum|
58058719|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
57708846|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
57708847|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
57708848|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
57708849|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
57708850|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
57708851|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
57708852|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
57708853|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
57708854|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
58381994|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
58381995|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
58381996|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
58381997|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
57708855|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
57708856|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
57708857|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
57708858|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
57708859|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
57708860|NCT00240370|DRUG|Muraglitazar|
57708861|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
58381998|NCT00654225|DRUG|Rosuvastatin|
58381999|NCT00654225|DRUG|Atorvastatin|
58382000|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
58058720|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
58058721|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
58058722|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
58058723|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
58058724|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
58058725|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
58382001|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
57708862|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
57708863|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
57708864|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
57708865|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
57708866|NCT04545515|DRUG|IVA|Tablet for oral administration.
57708867|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
57708868|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
57708869|NCT02667938|DRUG|HGP1201|
57708870|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
57708871|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
57708872|NCT02667938|DRUG|HGP1201 placebo|
57708873|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
57708874|NCT02254538|DRUG|BILR 355 BS|
57708875|NCT02254538|DRUG|PEG 400|
57708876|NCT00895180|BIOLOGICAL|olaratumab|Given IV
57708877|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
57708878|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
57708879|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
57708880|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
57708881|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
57708882|NCT02133729|OTHER|Blood sampling and OGTT|
57708883|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
57708884|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
57708885|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
57708886|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
57708887|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
57708888|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
57708889|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
57708890|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
57708891|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
57708892|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
57708893|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
57708894|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
57708895|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
58382002|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
57708896|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
57708897|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
57708898|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
57708899|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
57708900|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
57910739|NCT00201721|DRUG|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
58382003|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
58382004|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
58382005|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
57708901|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
57708902|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
58382006|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
58382007|NCT05267535|DRUG|Placebo|Tablets
57708903|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
57708904|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
57708905|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
57708906|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
57708907|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
57708908|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
57708909|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
57708910|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
57708911|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
57708912|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
57708913|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
57708914|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
57708915|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
57708916|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
57708917|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
57708918|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
57708919|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
57708920|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
57708921|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
57708922|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
57708923|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
57708924|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
57708925|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
57708926|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
57708927|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
57708928|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
57708929|NCT06371222|DRUG|Beta blocker|controlled group
57708930|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
57708931|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
57708932|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
57708933|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
57708934|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
57708935|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
58382008|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
58382009|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
58382010|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
57910740|NCT00201721|DRUG|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
57910741|NCT00201721|DRUG|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
57910742|NCT01347801|DRUG|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
57910743|NCT01347801|DRUG|Placebo (Saline)|Normal saline (NaCl 0,9%)
57910744|NCT01347801|DRUG|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
57910745|NCT01347801|OTHER|OGTT|Oral glucose tolerance test with 75 g glucose
57910746|NCT01347801|OTHER|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
57910747|NCT01181323|OTHER|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
57910748|NCT01181323|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
57910749|NCT01181323|OTHER|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
57910750|NCT01181323|BIOLOGICAL|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
57910751|NCT03594604|DRUG|Norethindrone|Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
57910752|NCT03594604|DRUG|oral contraceptive pill|Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
57910753|NCT06609447|DIETARY_SUPPLEMENT|VSL#3|VSL#3 450 billion CFU/sachet
57910754|NCT06609447|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
58058726|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
58058727|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
58058728|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
58382011|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
58382012|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
58382013|NCT01078792|OTHER|CT pulmonary angio, blood tests|
58382014|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
58382015|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
57910755|NCT06609447|DRUG|Vedolizumab|Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
57910756|NCT01912560|DRUG|CAT-2003|
58382016|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
57910757|NCT01912560|DRUG|Placebo|
57910758|NCT01912560|DRUG|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
57910759|NCT04750785|OTHER|No Intervention|Administered as specified in the treatment arm.
57910760|NCT06078137|OTHER|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
57910761|NCT00134745|DRUG|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
57910762|NCT03102645|DRUG|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
57910763|NCT03102645|DRUG|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
57910764|NCT05223777|DEVICE|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
57910765|NCT05223777|DEVICE|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
57910766|NCT02946190|BIOLOGICAL|Pertagen® aP + Td-pur®|see arm/group descriptions
57910767|NCT02946190|BIOLOGICAL|Boostrix® dTpa|see arm/group descriptions
57910768|NCT04802616|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
58058729|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
58058730|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
58382017|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
58058731|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
58058732|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
58260543|NCT04954742|DRUG|Riociguat|Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
58382018|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
58382019|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
58382020|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
58382021|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
58382022|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
58382023|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
58382024|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
58382025|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
57910769|NCT04802616|DRUG|Placebo|Matched tablets without any active substance.
57910770|NCT03212989|DRUG|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
58393710|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
58058733|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
58058734|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
58058735|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
58058736|NCT00003716|BIOLOGICAL|rituximab|
58058737|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
58058738|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
58058739|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
58058740|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
58058741|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
58058742|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
58058743|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
57708936|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
57708937|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
57708938|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
57708939|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
57708940|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
57708941|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
57708942|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
57708943|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
57708944|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
57708945|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
57708946|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
57708947|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
57708948|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
57708949|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
58058744|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
57910771|NCT03212989|BIOLOGICAL|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
58058745|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
58058746|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
58058747|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
58058748|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
58058749|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
58058750|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
58058751|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
58260544|NCT06621901|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
58058752|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
58058753|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
58058754|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
58260545|NCT06621901|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
58382026|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
58393711|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
57708950|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
57708951|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
57708952|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
57708953|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
58260546|NCT06333574|OTHER|Family weight self-measurement and remote follow-up management based on wechat.|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
57708954|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
57910772|NCT05367115|OTHER|longitudinal observational study|longitudinal observational study
58058755|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
58058756|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
58382027|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
57708955|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
57708956|NCT05431062|DRUG|Bupivacain|%0.25
57708957|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
57708958|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
57708959|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
57708960|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
58058757|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
58058758|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
58058759|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
58058760|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
58058761|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
58260547|NCT06333574|OTHER|Routine care|The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
58260548|NCT02358525|BEHAVIORAL|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
57910773|NCT05999695|OTHER|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
58260549|NCT05521334|DEVICE|micropulse transscleral cyclophotocoagulation|glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
58058762|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
58058763|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
58058764|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
58058765|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
58058766|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
58058767|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
58260550|NCT05756790|BEHAVIORAL|Motivational Interviewing|Counseling
58260551|NCT05756790|BEHAVIORAL|Motivational Interviewing plus Breathalyzer|Counseling plus mobile breathalyzer/ app
58260552|NCT01092819|OTHER|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
58260553|NCT00970632|DRUG|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
58260554|NCT00970632|DRUG|Placebo tablet|Placebo tablet po QD for 12 weeks
58260555|NCT00970632|DRUG|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
58260556|NCT00970632|DRUG|Placebo capsule|Placebo capsule po QD for 12 weeks
58058768|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
58058769|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
58260557|NCT05803447|OTHER|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
58260558|NCT05803447|DIAGNOSTIC_TEST|biochemical parameters|"The concentrations of the following parameters were determined from the:~* blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~* plasma: metabolites of the oxidative stress"
58382028|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
58382029|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
57910774|NCT05999695|OTHER|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
57910775|NCT02851641|PROCEDURE|"pushed mono-canaliculonasal intubation"|
57910776|NCT00201890|PROCEDURE|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
57910777|NCT00618618|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
58260559|NCT05803447|DIAGNOSTIC_TEST|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
58260560|NCT06647901|DRUG|ICG (Indocyanine Green)|Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
58260561|NCT05093959|DRUG|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
58260562|NCT05093959|DRUG|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
58260563|NCT06620029|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.
58260564|NCT06620029|DRUG|Paclitaxel (Taxol)|Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
57708961|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
57910778|NCT00618618|DRUG|Placebo|
57910779|NCT00136981|DRUG|torcetrapib/atorvastatin|
57910780|NCT00136981|DRUG|atorvastatin|
58260565|NCT02275780|DRUG|Doravirine|Doravirine 100 mg tablet administered p.o. q.d.
58260566|NCT02275780|DRUG|Darunavir|Darunavir 800 mg tablet administered p.o. q.d.
58260567|NCT02275780|DRUG|Ritonavir|Ritonavir 100 mg tablet administered p.o. q.d.
58260568|NCT02275780|DRUG|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
58382030|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
58382031|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
58382032|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
58382033|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
58382034|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
57708962|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
57910781|NCT01791036|PROCEDURE|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
58058770|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
58382035|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
58382036|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
58382037|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
58382038|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
58382039|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
58260569|NCT03358771|OTHER|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
57708963|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
57708964|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
57708965|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
57708966|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
57708967|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
57708968|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
57708969|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
58260570|NCT03358771|OTHER|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
58260571|NCT06295991|DEVICE|Lycra garment|Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
58260572|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
58260573|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
58260574|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
58260575|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
58260576|NCT05511207|DEVICE|RECOM - hBCI training|The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
58382040|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
58393712|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
58393713|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
57708970|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
57708971|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
57708972|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
57708973|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
57708974|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
57708975|NCT02170610|DRUG|BIBR 1048 MS|
57708976|NCT02170610|DRUG|Pantoprazole|
57708977|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
57708978|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
57708979|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
57708980|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
57708981|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
57708982|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
57910782|NCT01791036|PROCEDURE|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
57910783|NCT00513604|BIOLOGICAL|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
57910784|NCT00513604|BIOLOGICAL|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
58260577|NCT05511207|OTHER|CTRL - upper limb training with FES|An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
58260578|NCT01071486|DRUG|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
58260579|NCT05835362|BEHAVIORAL|Question prompt list|A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.
58393714|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
57708983|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
57708984|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
57708985|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
57708986|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
58058771|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
58058772|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
58393715|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
57708987|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
57708988|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
57708989|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
57708990|NCT00072865|DRUG|Pemetrexed|
57708991|NCT00072865|DRUG|Carboplatin|
57708992|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
57708993|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
57708994|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
57708995|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
57708996|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
57708997|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
57708998|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
57708999|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
57709000|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
57709001|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
57709002|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
57709003|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
57910785|NCT00513604|DRUG|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
57910786|NCT00513604|DRUG|Fludarabine phosphate|Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
57910787|NCT00513604|RADIATION|Total body irradiation|600 cGy
57910788|NCT01771640|BIOLOGICAL|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
57910789|NCT03429231|DIETARY_SUPPLEMENT|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
57910790|NCT02510209|BEHAVIORAL|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
57910791|NCT04845243|BEHAVIORAL|Emotionen Verstehen und Ausdrücken (E.V.A.)|The online training is focused on the strengthening of socioemotional competences and consists of different training tasks (up to 3 million) presented to the participant as mini games. These training tasks are specifically designed according to empirical findings to match the socio-emotional recognition needs of people with ASD. During these games, an adapted Elo-Algorithm allows to automatically evaluate the participants' performance and adapts the difficulty levels throughout the users' progress in the training.
57910792|NCT01493843|DRUG|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
57910793|NCT01493843|DRUG|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
57910794|NCT01493843|DRUG|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
57910795|NCT01493843|DRUG|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
57910796|NCT01493843|DRUG|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
57910797|NCT02262091|DIETARY_SUPPLEMENT|Food fibers|
57910798|NCT02262091|DIETARY_SUPPLEMENT|Maltodextrin|
57910799|NCT02262091|BIOLOGICAL|Influenza vaccine (incl. criterion)|
58260580|NCT05835362|BEHAVIORAL|Pre-visit video|The 11-minute video has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD.
58260581|NCT05835362|BEHAVIORAL|Combined question prompt list/video|"A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.~And the video is an 11-minute video that has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD."
58260582|NCT00759785|DRUG|dalotuzumab (MK0646)|Single intravenous infusion
58260583|NCT04393064|DEVICE|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera \& light source \& video recording system will be used. Procedure will be done without anesthesia~."
58260584|NCT00979589|DRUG|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
58260585|NCT00979589|DRUG|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
58260586|NCT05043012|DEVICE|flexible AIR coil|mpMRI scan
58393716|NCT05081518|DRUG|Placebo|Placebo - capsule
58393717|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
58393718|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
57910800|NCT05164029|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
57910801|NCT03947190|BIOLOGICAL|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
57910802|NCT03947190|BIOLOGICAL|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
57910803|NCT03947190|BIOLOGICAL|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
57910804|NCT01296789|OTHER|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
57910805|NCT01296789|OTHER|Usual Care|Usual Care
58058773|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
58058774|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
58260587|NCT05043012|DEVICE|endorectal coi|mpMRI scan
57910806|NCT05342025|OTHER|PNF|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. Breathing PNF patterns, pressure, and stretches will be applied inward and upwards into the rib cage so that they do not cause pain. Diaphragmatic stimulation will be performed on both sides with repeated contractions, hand contacts, and stabilization techniques. Facilitation techniques will be used to stimulate the intrinsic respiratory muscles. Again, with respect to inspiration, the patterns will be studied in neck extension, upper and lower trunk extension, and upper extremities flexion patterns. Neck flexion, upper and lower trunk flexion, and extension patterns of the upper extremities will be applied in relation to expiration. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases.
58260588|NCT00516191|DRUG|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
58260589|NCT06621212|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day 1, every 4 weeks
58382041|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
58382042|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
58382043|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
58382044|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
58382045|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
58382046|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
58382047|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
58382048|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
58260590|NCT06621212|DRUG|Cytarabine|Cytarabine (100 mg/m\^2 ) on day 1-7, every 4 weeks
58382049|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
58382050|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
58382051|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
57709004|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
57910807|NCT05342025|OTHER|Breathing exercises|Breathing exercises: diaphragmatic breathing, thoracic expansion, pursed-lip breathing and respiratory control for 15 minutes a day, every day of the week.
58260591|NCT06621212|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
58260592|NCT03203408|DEVICE|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
58260593|NCT03203408|DEVICE|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
58260594|NCT03177434|DRUG|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
58393719|NCT05271253|DRUG|normal Saline|injection of normal Saline
58260595|NCT03177434|DRUG|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
58260596|NCT00569647|DEVICE|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
58260597|NCT00569647|DEVICE|Placebo|no use of device
58260598|NCT02624245|OTHER|Conventional Physical Therapy|
57709005|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
57709006|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
57709007|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
58260599|NCT04958681|OTHER|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
58260600|NCT03175692|DIAGNOSTIC_TEST|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
57910808|NCT06406842|OTHER|Cerebral oxygenation index guided hemodynamics management|In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
57910809|NCT01460173|OTHER|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
58260601|NCT05212701|DRUG|Reparixin|The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
57709008|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
57910810|NCT01380015|OTHER|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
57910811|NCT01380015|OTHER|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
57709009|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
58260602|NCT05212701|DRUG|Placebo|The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
58260603|NCT06621992|OTHER|Skills to Enhance Positivity|
58260604|NCT06621992|OTHER|Treatment as Usual|Participants received treatment as usual
57910812|NCT06093776|DEVICE|ioveraº system|the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold
58260605|NCT06622837|PROCEDURE|implant overdenture|With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.
58260606|NCT02131818|DRUG|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
58260607|NCT02131818|DRUG|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
57709010|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
57709011|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
57709012|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
57709013|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
57709014|NCT02496780|DRUG|levemir insulin|basal insulin once a day
57709015|NCT02496780|DRUG|placebo|once or 3x daily
57709016|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
57709017|NCT01417403|DRUG|hydroxychloroquine|Given PO
57709018|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
57709019|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
58260608|NCT04258254|BEHAVIORAL|Multimodal|Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.
58260609|NCT04258254|BEHAVIORAL|General|The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.
58260610|NCT04258254|BEHAVIORAL|Standard of Care|The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
58260611|NCT04117672|DIETARY_SUPPLEMENT|Salovum|Active egg yolk powder
58260612|NCT04117672|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Normal egg yolk powder
58260613|NCT05469269|BEHAVIORAL|Passive Education|Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
58260614|NCT05469269|BEHAVIORAL|Education by Community Navigator|A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
58260615|NCT05469269|BEHAVIORAL|Education at Community Outreach Screening Event|The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
58260616|NCT02086084|DEVICE|NIV|Standard care
58260617|NCT02086084|DEVICE|ECCO2R|Application of ECCO2R in addition to NIV
58260618|NCT03265821|PROCEDURE|Healing after treatment|
58260619|NCT03380702|PROCEDURE|whitening photoactivation gel|35 subjects in active comparator group
58260620|NCT03380702|PROCEDURE|placebo|35 subjects in placebo comparator group
58260621|NCT02809105|DRUG|linaclotide|Oral administration once daily
58260622|NCT02809105|DRUG|Placebo|Oral administration once daily
57709020|NCT02995252|OTHER|Blood draws|
58058775|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
58058776|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
58260623|NCT06452199|DIETARY_SUPPLEMENT|B. infantis|1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.
58260624|NCT06452199|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
58260625|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
58260626|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
58260627|NCT06523907|OTHER|Intervention Basic Nursing skills|Evaluating the effectiveness of the education program in improving paramedics' knowledge of essential nursing care principles, such as hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
58260628|NCT06523907|OTHER|Control Present Knowledge about basic nursing skill|Assess the current and baseline knowledge status of the participants about the hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
57709021|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
57709022|NCT02995252|OTHER|Knowledge Index Questionnaire|
57709023|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
58260629|NCT06613854|DRUG|Oral semaglutide|Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
57709024|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
57709025|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
57709026|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
57709027|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
57910813|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
57910814|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
58260630|NCT06613854|DRUG|Empagliflozin 10 mg|Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
58260631|NCT06350461|OTHER|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.
57709028|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
57709029|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
57709030|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
57709031|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
57910815|NCT02501915|DEVICE|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
58260632|NCT06350461|OTHER|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
57910816|NCT00300521|GENETIC|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
57910817|NCT03435354|BEHAVIORAL|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
57910818|NCT01051830|OTHER|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
57910819|NCT01575028|DRUG|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
57910820|NCT01575028|DRUG|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
57910821|NCT01841931|DRUG|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
58058777|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
58260633|NCT05729399|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
58260634|NCT03535454|OTHER|working hours|weekly working hours
58260635|NCT02908672|DRUG|Atezolizumab|Will be administered as per the schedule described in individual arm.
58260636|NCT02908672|DRUG|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
58260637|NCT02908672|DRUG|Cobimetinib|Will be administered as per the schedule described in individual arm.
58260638|NCT02908672|DRUG|Vemurafenib|Will be administered as per the schedule described in individual arm.
58260639|NCT02908672|DRUG|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
58260640|NCT06623513|DRUG|Parecoxib Sodium|Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.
58260641|NCT06623513|DRUG|Indomethacin suppository|Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
58260642|NCT01858779|BEHAVIORAL|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
58260643|NCT01858779|DEVICE|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
58260644|NCT06581809|OTHER|Algosteril|hemostatic dressing
58260645|NCT06581809|OTHER|Other Dressings: interface, hydrocellular, hydrofiber|Non-haemostatic dressing
58260646|NCT00712881|DRUG|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
58260647|NCT00712881|DRUG|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
58260648|NCT00712881|DRUG|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
58382052|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
58382053|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
58382054|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
58382055|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
58382056|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
58382057|NCT00216918|DRUG|Atomoxetine Hydrochloride|
58382058|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
58382059|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
57910822|NCT04952454|PROCEDURE|External Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.
57910823|NCT04952454|PROCEDURE|Endonasal Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.
58058778|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
58058779|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
58260649|NCT00712881|DRUG|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
58260650|NCT00712881|DRUG|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
58260651|NCT06624215|PROCEDURE|Appendectomy|Robotic-assisted or laparoscopic appendectomy for acute appendicitis.
58260652|NCT03164473|DRUG|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
58260653|NCT03164473|DRUG|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
58260654|NCT03164473|DRUG|Placebo-rituximab|4 infusions for 18 months
58260655|NCT03164473|DRUG|Placebo-azathioprine|oral tablets for 24 months
58260656|NCT05960227|DRUG|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
58260657|NCT05960227|DRUG|Placebo|250ml of saline 0,9% for 4 hours insusion.
58260658|NCT02809859|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
58260659|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
58382060|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
58260660|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
58260661|NCT00707278|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
58260662|NCT00707278|DRUG|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
58260663|NCT00707278|DRUG|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
58260664|NCT03273465|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
58260665|NCT02417922|OTHER|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
58260666|NCT02417922|OTHER|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
58382061|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
58382062|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
58382063|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
58382064|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
57910824|NCT04952454|PROCEDURE|Transcanalicular Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.
57910825|NCT02300441|OTHER|ECG, blood pressure and oximetry|
57910826|NCT05415943|DEVICE|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
58260667|NCT04892628|OTHER|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
57910827|NCT05813639|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
57910828|NCT05813639|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
57910829|NCT05813639|PROCEDURE|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
57910830|NCT00658684|DRUG|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
57910831|NCT02822144|DRUG|Etomidate|
57910832|NCT02822144|DRUG|Succinylcholine|
57910833|NCT02822144|DRUG|Propofol|
57910834|NCT02822144|DRUG|Remifentanil|
57910835|NCT02822144|DRUG|Lidocaine|
57910836|NCT01524601|DRUG|Rosuvastatin|20 mg rosuvastatin for 4 weeks
57910837|NCT02570932|BIOLOGICAL|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
57910838|NCT03383315|DRUG|Tramadol|One dose of intravenous tramadol 50mg
57910839|NCT03383315|DRUG|Metoclopramide|One dose of intravenous metoclopramide 10mg
57910840|NCT03383315|DRUG|Placebo|Sodium chloride 0.9%
57910841|NCT00539773|DRUG|BCG, Interferon|Chemotherapy
58058780|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
58058781|NCT02465541|OTHER|questionnaire administration|Ancillary studies
58260668|NCT04892628|OTHER|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
58260669|NCT00895128|DRUG|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
58260670|NCT00895128|DRUG|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
58260671|NCT05177354|DEVICE|Inceptiv|Implantable Neurostimulator with Neuro Sense
58382065|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
58382066|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
58382067|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
57709032|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
58058782|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
58058783|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
58058784|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
58058785|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
58058786|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
58058787|NCT01660529|BIOLOGICAL|hTERT|
58058788|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
58058789|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
58260672|NCT00690196|BEHAVIORAL|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
58260673|NCT00690196|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
58260674|NCT00039494|DRUG|erlotinib hydrochloride|Given orally
58260675|NCT00039494|RADIATION|3-dimensional conformal radiation therapy|
58260676|NCT00039494|DRUG|temozolomide|Given orally
58260677|NCT03441971|DEVICE|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
58260678|NCT06602856|OTHER|Point-of-care ultrasound examination|We are investigating the extent to which pre-hospital point-of-care ultrasound examination influences the further deployment tactics, medical treatment and choice of destination hospital for patients.
58260679|NCT06622135|DEVICE|Tasso Lancet Device|blood samples will be obtained from all participants using Tasso device
58260680|NCT01202370|DRUG|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
57709033|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
57709034|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
58058790|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
58058791|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
58058792|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
58058793|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
58260681|NCT04569747|COMBINATION_PRODUCT|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
58260682|NCT04569747|DRUG|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
58382068|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
58382069|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
57910842|NCT03207009|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
57910843|NCT02112032|DRUG|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
58058794|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
58260683|NCT00866086|OTHER|questionnaire administration|
57910844|NCT02112032|DRUG|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
58260684|NCT00866086|PROCEDURE|computed tomography|
58260685|NCT00866086|RADIATION|radiation therapy treatment planning/simulation|
58260686|NCT06623318|DEVICE|Remote therapeutic monitoring device|IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.
58260687|NCT05996107|DRUG|Ribociclib|400 mg daily with a possibly dose reduction to 200 mg daily if required
58260688|NCT05996107|RADIATION|Postoperative Radiation Therapy|50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
58260689|NCT05763875|DRUG|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
58260690|NCT05763875|DRUG|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
57709035|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
57910845|NCT00057174|DRUG|Disease management of gastroesophageal reflux disease|
57910846|NCT01474928|BEHAVIORAL|patient role played community video|Group two viewed the patient role played community video
58058795|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
58058796|NCT00742391|DRUG|Vehicle gel|two day treatment
58058797|NCT05141565|OTHER|No intervention|No intervention
58260691|NCT05763875|DRUG|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
58260692|NCT05763875|DRUG|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
58260693|NCT06299904|BEHAVIORAL|Modified Air-pulse Stimulation|Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)
58382070|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
58382071|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
58382072|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
58382073|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
58382074|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
58260694|NCT06299904|BEHAVIORAL|Conventional air-pulse stimulation|The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
58260695|NCT01921244|OTHER|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
58260696|NCT00868725|OTHER|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
58260697|NCT01916603|BEHAVIORAL|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
58260698|NCT06054243|BEHAVIORAL|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
58260699|NCT06054243|BEHAVIORAL|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
58260700|NCT00874835|DEVICE|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
58260701|NCT06648590|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
58260702|NCT06648590|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
58260703|NCT03272659|DRUG|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
58260704|NCT02558621|DEVICE|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
58260705|NCT00656487|DRUG|rimonabant|double blind, placebo controlled, single 90 mg dose
57709036|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
57709037|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
57709038|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
57910847|NCT01474928|BEHAVIORAL|both videos group|Group three viewed both the knowledge and community videos
57910848|NCT01474928|BEHAVIORAL|Pamphlet group|Group four read an educational pamphlet only
57910849|NCT01474928|BEHAVIORAL|physician-led knowledge video|Group one viewed a physician-led knowledge video
58260706|NCT00656487|DRUG|placebo|matched placebo
57910850|NCT01474928|BEHAVIORAL|Community video group|Group two viewed the patient role played community video
58260707|NCT00033176|DRUG|Alpha Lipoic Acid|
58260708|NCT06157801|BEHAVIORAL|Interview Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
58382075|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
58382076|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
58382077|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
58382078|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
58382079|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
58382080|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
58382081|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
57910851|NCT01474928|BEHAVIORAL|knowledge video|Group one viewed a physician-led knowledge video
57910852|NCT05564416|BIOLOGICAL|Atezolizumab|Given IV
58260709|NCT06157801|BEHAVIORAL|Survey Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
58382082|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
58382083|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
57910853|NCT05564416|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57910854|NCT05564416|PROCEDURE|Biospecimen Collection|Correlative studies
57910855|NCT05564416|PROCEDURE|Computed Tomography|Undergo CT
58260710|NCT06618209|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH
58260711|NCT06618209|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase
58382084|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
57910856|NCT05564416|PROCEDURE|Cystoscopy|Undergo cystoscopy
58382085|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
58382086|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
58382087|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
58382088|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
58382089|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
58382090|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
58260712|NCT06618209|DIAGNOSTIC_TEST|Oral Findings|DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion
58260713|NCT06618209|DIAGNOSTIC_TEST|Pediatric Oral Health Quality of Life|The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.
57910857|NCT05564416|DRUG|Erdafitinib|Given PO
57910858|NCT05564416|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57910859|NCT03085615|OTHER|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
57910860|NCT04617977|BEHAVIORAL|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
57910861|NCT04617977|BEHAVIORAL|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
57910862|NCT04447846|DRUG|Cannabidiol|Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
58260714|NCT06154395|PROCEDURE|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
58382091|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
58382092|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
57709039|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
57910863|NCT00968227|BIOLOGICAL|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
57910864|NCT05727345|PROCEDURE|Interscalene brachial plexus block|Preoperative ultrasound-guided interscalene brachial plexus block application
57910865|NCT05727345|PROCEDURE|Shoulder anterior capsular block|Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
57910866|NCT00346671|OTHER|Rest|30 min supine rest
57910867|NCT00346671|OTHER|Sham|30 min session with Sham practitioner
57910868|NCT00346671|OTHER|Reiki|30 min session with Reiki practitioner
58058798|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
58260715|NCT06154395|PROCEDURE|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
58260716|NCT06154395|PROCEDURE|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
57910869|NCT05126082|BEHAVIORAL|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
58260717|NCT02113995|OTHER|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
58260718|NCT01735344|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
58260719|NCT01735344|DRUG|Lisinopril|40 mg tablet once a day
58382093|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
58382094|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
58382095|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
57910870|NCT02105922|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
57910871|NCT02105922|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
57910872|NCT02105922|PROCEDURE|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
57910873|NCT00731809|RADIATION|FDG PET CT|FDG PET CT
57910874|NCT00112047|DRUG|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
57910875|NCT00112047|DRUG|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
57709040|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
57709041|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
57709042|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
57709043|NCT03181828|OTHER|No treatment|No treatment
57709044|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
57910876|NCT00112047|DRUG|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
57910877|NCT00112047|DRUG|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
57910878|NCT00112047|DRUG|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
57910879|NCT00112047|DRUG|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
57910880|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
58058799|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
58058800|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
57910881|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
57910882|NCT06401239|OTHER|Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
57910883|NCT06401239|OTHER|Self-efficacy|Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.
57910884|NCT06401239|OTHER|Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
57910885|NCT01149109|DRUG|Temozolomide and lomustine|
58260720|NCT03540004|DEVICE|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
58260721|NCT00483197|DEVICE|VentrAssistTM Left Ventricular Assist Device|
58260722|NCT01932736|OTHER|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
57910886|NCT01149109|DRUG|Temozolomide|
58260723|NCT03573960|DRUG|Lenvatinib|Lenvatinib capsules.
58260724|NCT02212990|OTHER|Acetaminophen Arm|Blinded Therapy
58260725|NCT02212990|OTHER|Placebo Arm|Blinded Therapy
58260726|NCT02212990|OTHER|Ibuprofen Arm|Open Label Therapy
58260727|NCT05923775|PROCEDURE|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
58260728|NCT05277142|OTHER|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
57910887|NCT00577356|DRUG|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
57910888|NCT00577356|BIOLOGICAL|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
57910889|NCT00767468|DRUG|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
58260729|NCT05277142|DEVICE|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
58260730|NCT05382793|DIETARY_SUPPLEMENT|Control|No iodine
58382096|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
58382097|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
57910890|NCT04939961|DIETARY_SUPPLEMENT|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
57910891|NCT04939961|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
57910892|NCT05681923|OTHER|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
57910893|NCT05681923|OTHER|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
57910894|NCT05681923|OTHER|Neurodevelopmental assessment visit|"Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, between 60 and 66 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment."
57910895|NCT05681923|OTHER|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
58260731|NCT05382793|DIETARY_SUPPLEMENT|Iodide (150 μg/day)|A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
58260732|NCT05382793|DIETARY_SUPPLEMENT|Iodine (300 μg/day)|Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
58260733|NCT04988022|DRUG|Dupilumab|300 mg prefilled syringe
58260734|NCT04988022|DRUG|Placebo|Matching placebo
58260735|NCT04074746|BIOLOGICAL|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
58260736|NCT04074746|DRUG|Cyclophosphamide|Given IV
58260737|NCT04074746|DRUG|Fludarabine|Given IV
58260738|NCT04074746|DRUG|Fludarabine Phosphate|Given IV
58382098|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
58382099|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
58382100|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
58382101|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
58382102|NCT05243979|RADIATION|DEXA scan|bone study
58382103|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
57910896|NCT04614454|DEVICE|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
58260739|NCT04074746|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
58260740|NCT01795092|OTHER|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
58260741|NCT01785225|DEVICE|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
58260742|NCT06648343|OTHER|Intensive cognitive and physical training|The cognitive and physical training program consists of 25-35 minutes of cognitive training (memory, attention, visuospatial orientation) and 10-15 minutes of physical training (stretching, strength training, coordination, and aerobic exercise). Additionally, participants will be instructed to perform 30-40 minutes of aerobic exercise 3-4 times per week
58260743|NCT06416787|DRUG|placebo|IBI355 7.5mg/kg Q4W
58260744|NCT06416787|DRUG|IBI355|IBI355 1mg/kg Q4W
58382104|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
58382105|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
58382106|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
57910897|NCT04614454|DEVICE|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
57910898|NCT01776801|OTHER|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
57910899|NCT01853774|BEHAVIORAL|Tailored navigation|
57910900|NCT01413854|DRUG|sugar pill|One tablet two times daily during four weeks
57910901|NCT01413854|DRUG|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
57910902|NCT00735020|BIOLOGICAL|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
57910903|NCT00735020|BIOLOGICAL|Influenza Vaccine|1 dose of Influenza Vaccine
57910904|NCT03733041|DEVICE|rTMS|This group will receive rTMS treatment
57910905|NCT03733041|DEVICE|Sham|This group will receive sham treatment
57910906|NCT03733041|OTHER|No intervention|This group will receive no intervention
57910907|NCT03805620|OTHER|Combined physical-cognitive training|combined physical-cognitive training
57910908|NCT03805620|OTHER|Physical training|Multi-component physical exercise
58382107|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
58382108|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
58382109|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
58382110|NCT02547103|OTHER|Normal saline|
57910909|NCT03805620|OTHER|Cognitive training|cognitive training
57910910|NCT05747300|OTHER|Premixed bioceramic paste wellroot PT|Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
57910911|NCT04621773|PROCEDURE|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
57910912|NCT00632437|PROCEDURE|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
57910913|NCT04771754|DRUG|Dolutegravir|50 mg once daily orally
57910914|NCT01723254|BIOLOGICAL|IGE-1|Intramuscular, multiple dose
57910915|NCT01723254|BIOLOGICAL|IGE-2|Intramuscular, multiple dose
57910916|NCT01723254|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
57910917|NCT02691533|DRUG|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
57910918|NCT02691533|DRUG|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
57910919|NCT02691533|DRUG|No Lipid Emulsion/Placebo|
57910920|NCT04007341|DRUG|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
57910921|NCT05396482|DIAGNOSTIC_TEST|Pure tone audiometer|Pure tone audiometer
57910922|NCT02764216|RADIATION|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
57910923|NCT02951364|DRUG|LDV/SOF|90/400 mg tablet administered orally once daily
57910924|NCT03074890|DEVICE|Application Protocol|Application lMassive Transfusion Protocol
57910925|NCT04793841|OTHER|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
58260745|NCT06649136|DRUG|Methotrexate|comparison between oral and subcutaneous methotrexate dosis of 25mg
58260746|NCT05209126|DIETARY_SUPPLEMENT|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
58260747|NCT03565029|DRUG|XELOX|Capecitabine and Oxaliplatin (4x cycles)
58260748|NCT03565029|RADIATION|Radiotherapy|Pelvic radiotherapy
58260749|NCT03885180|DRUG|Warfarin Sodium|Extending warfarin anticoagulation
58382111|NCT02547103|OTHER|mupirocin ointment|
58382112|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
58382113|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
57910926|NCT04095481|DEVICE|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
57910927|NCT06610409|DIAGNOSTIC_TEST|blood sampling|Blood sample for CXCL5 Level
57910928|NCT01274845|OTHER|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
57910929|NCT04630392|OTHER|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
57910930|NCT04630392|OTHER|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
58058801|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
58260750|NCT00670293|RADIATION|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
58260751|NCT00670293|DRUG|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
58382114|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
58382115|NCT05975346|DRUG|Ketamine|description
57910931|NCT05522621|DRUG|TJAOA102|Once enrolled, participants will be administrated TJAOA102
58058802|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
58260752|NCT00670293|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
58260753|NCT00001029|DRUG|Zidovudine|
58260754|NCT00001029|DRUG|Zalcitabine|
58260755|NCT00001029|DRUG|Didanosine|
58260756|NCT05887570|BEHAVIORAL|Educational intervention|intervention through extra education, modules, instruction on models
58260757|NCT05887570|OTHER|Control - Regular Instruction|participants receive usual training
58260758|NCT03074435|DEVICE|Indoor residual sprayings|Houses will be spayed with this formulation containing Pyrimiphos methyl.
58382116|NCT05975346|OTHER|saline nebulization|description
58382117|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
58382118|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
58382119|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
57910932|NCT01736865|DRUG|Cholecalciferol|
57910933|NCT01736865|DRUG|Placebo|
57910934|NCT01864954|BEHAVIORAL|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
57910935|NCT05615493|DEVICE|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
57910936|NCT05615493|DEVICE|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), \& frequency 4 Hz every week for one month without operating the machine .
57910937|NCT00472160|PROCEDURE|Non Invasive Ventilation|Non Invasive Ventilation
57910938|NCT00558259|DRUG|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
57910939|NCT00558259|DRUG|matching placebo twice daily (BID)|Matching placebo BID
57910940|NCT05442996|DRUG|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
57910941|NCT05442996|DRUG|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
57910942|NCT02013960|DRUG|Cytotec|Cytotec medication compared with cytotec and laminaria
57910943|NCT06545838|OTHER|Analysis of plasma renin concentration|The concentration of plasma renin in patients will be assessed using the immunochemiluminescent method
57910944|NCT00371332|DRUG|Minocycline HCL Microspheres|
57910945|NCT01015560|DRUG|anti-CCR2 monoclonal antibody MLN1202|
58058803|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
58058804|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
58260759|NCT03074435|DEVICE|Larvicide|Larval breeding sites will be treated with larvicide
58260760|NCT03074435|BEHAVIORAL|BCC|
58260761|NCT03074435|BIOLOGICAL|Ivermectin|
58260762|NCT04636385|OTHER|Observational study no intervention|No intervention
57910946|NCT01015560|GENETIC|polymorphism analysis|
58058805|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
57709045|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
58058806|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
58382120|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
58260763|NCT03664310|OTHER|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
58260764|NCT03664310|OTHER|Control|Physical health control
58382121|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
58382122|NCT06371157|DRUG|AK104|intravenous
58382123|NCT06371157|DRUG|Lenvatinib|oral
58382124|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
58382125|NCT06371157|OTHER|Placebo for AK104|intravenous
58382126|NCT06371157|OTHER|Placebo for Lenvatinib|oral
58382127|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
58382128|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
58382129|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
58382130|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
58382131|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
58382132|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
58382133|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
58382134|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
57910947|NCT01015560|OTHER|laboratory biomarker analysis|
57910948|NCT03915704|DEVICE|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
57910949|NCT03915704|PROCEDURE|Control|No intervention was made in the children.
57709046|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
57910950|NCT03915704|DEVICE|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
57910951|NCT03450187|DRUG|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
57910952|NCT04463368|PROCEDURE|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
57910953|NCT04463368|DRUG|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
57910954|NCT04463368|DRUG|Nivolumab|4 courses of nivolumab 1mg/kg every third week
58058807|NCT02543801|DRUG|Ropivacaine|Periarticular injection
58058808|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
58058809|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
58058810|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
58058811|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
58260765|NCT00915486|PROCEDURE|Good Standard of Care (GSoC)|Procedural treatment twice per week
58260766|NCT00915486|BIOLOGICAL|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
58260767|NCT00915486|BIOLOGICAL|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
58260768|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
57709047|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
57709048|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
57709049|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
57910955|NCT02713282|DRUG|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
57910956|NCT01532895|DRUG|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
57910957|NCT00232674|DRUG|Pulmicort (budesonide) Turbuhaler|
58058812|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
58058813|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
58058814|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
58058815|NCT01156012|DRUG|T2345|One drop of T2345
58058816|NCT01156012|DRUG|Prostaglandin|One drop
58382135|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
58058817|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
58382136|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
58382137|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
58382138|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
58058818|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
58382139|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
58382140|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
57910958|NCT00002291|DRUG|Pentamidine isethionate|
57910959|NCT03283072|DEVICE|Intervention 1|15 bouts of 2mins:1min hypoxia:hyperoxia
57910960|NCT03283072|DEVICE|Intervention 2|15 bouts of 1mins:1min hypoxia:hyperoxia
57910961|NCT03283072|DEVICE|Intervention 3|8 bouts of 2mins:1min hypoxia:hyperoxia
57910962|NCT03283072|DEVICE|Intervention 4 (sham)|15 bouts of 1min:1min normoxia
58058819|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
58058820|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
58382141|NCT00807183|OTHER|Active air filter|air filter units correctly operating
58382142|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
57709050|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
58382143|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
58382144|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
58382145|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
57709051|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
57709052|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
57709053|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
57709054|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
57709055|NCT00025285|DRUG|carboplatin|
57709056|NCT00025285|DRUG|irinotecan hydrochloride|
57709057|NCT00025285|DRUG|thalidomide|
57709058|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
58058821|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
58058822|NCT02442765|DRUG|AVP-786|
58260769|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
58260770|NCT05566873|BEHAVIORAL|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
58260771|NCT05566873|BEHAVIORAL|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
58260772|NCT06060613|BIOLOGICAL|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide."
58260773|NCT04212208|DEVICE|IV cannulation|IV cannulation in the preoperative period
58260774|NCT02767492|DEVICE|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
58260775|NCT02767492|DRUG|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
58260776|NCT06148428|PROCEDURE|Laser in situ keratomileusis (LASIK)|"Patients were planned to undergo laser in situ keratomileusis. Local anesthesia was achieved by preservative-free oxybuprocaine hydrochloride 0.4% drops (a commonly used topical anesthetic due to its effectiveness in alleviating pain and ocular surface discomfort during the procedure). During surgery, the lights of the operating room were dimmed as much as possible and the surgeons spoke to the patients in a calm voice and explained what was happening. They also reassured the patients that the surgery was going as planned and would be over soon.~For patients undergoing (Microkeratome) MK-LASIK, a Moria 2 Microkeratome (Moria SA, Antony, France) was used to create the flap. For patients undergoing Femtosecond LASIK (FS-LASIK), the Allegretto Wave Light FS-200 femtosecond Laser (Alcon labs, Fort Worth, TX, USA) was used for flap creation.~Laser ablation was performed using WaveLight EX500 Excimer Laser (Alcon labs, Fort Worth, TX, USA) with a planned post-operative emmetropia."
58260777|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
58260778|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
58260779|NCT04271319|DEVICE|BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device|"Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
58260780|NCT04271319|DEVICE|Sham PRO-SPORT Ultra® Device|"Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications."
58260781|NCT03196427|DRUG|Vedolizumab|Vedolizumab intravenous infusion
58260782|NCT03140332|OTHER|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
58260783|NCT02836964|DEVICE|Crown placement|Dental implant
58260784|NCT01601327|DRUG|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
58058823|NCT02442765|DRUG|Placebo|
58260785|NCT01601327|DRUG|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
58260786|NCT01601327|DRUG|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
58260787|NCT01277653|DEVICE|tumor maker interval shortly|tumor maker interval every 3 month
58260788|NCT05141916|PROCEDURE|Endoscopic Retrograde Cholagiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
58260789|NCT06519344|BIOLOGICAL|anti-CD20/CD30-CAR-T Cells|Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
57709059|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
58260790|NCT02946073|DRUG|buprenorphine|
58260791|NCT02946073|OTHER|Placebo|
57709060|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
58058824|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
58260792|NCT04245215|DRUG|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
58260793|NCT05568615|DRUG|MT-1186|Suspension
58260794|NCT05691608|BIOLOGICAL|Solid tumor and CT DNA|Biopsy and blood sample
58058825|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
58260795|NCT05326308|DRUG|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
58260796|NCT05326308|DRUG|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
58260797|NCT03289325|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
58260798|NCT03289325|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation."
58260799|NCT05477212|DIETARY_SUPPLEMENT|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
58260800|NCT01437917|OTHER|20% amylose bread|20% amylose bread
58382146|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
58058826|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
58058827|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
58058828|NCT04048876|DRUG|CC-90001|oral
58058829|NCT04048876|DRUG|Placebo|oral
58058830|NCT00058448|DRUG|docetaxel|
58058831|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
58058832|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
58260801|NCT01437917|DIETARY_SUPPLEMENT|10% amylose bread|10% amylose bread
58260802|NCT01437917|DIETARY_SUPPLEMENT|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
58260803|NCT04546529|DEVICE|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
58260804|NCT04546529|DEVICE|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
58260805|NCT05249127|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
58058833|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
58058834|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
58058835|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
58260806|NCT00832442|DRUG|Beta blocker|as determined by individual study
58260807|NCT00832442|OTHER|Placebo|in addition to usual care
58260808|NCT05856539|PROCEDURE|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
58260809|NCT05685004|BIOLOGICAL|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
58260810|NCT05685004|PROCEDURE|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
58260811|NCT05685004|RADIATION|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
58260812|NCT05685004|DRUG|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
58260813|NCT05466994|OTHER|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
58382147|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
58382148|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
58382149|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
58382150|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
57709061|NCT00753207|DRUG|epirubicin hydrochloride|
57709062|NCT00753207|DRUG|lapatinib ditosylate|
57709063|NCT00753207|OTHER|biomarker analysis|
57709064|NCT00753207|OTHER|immunohistochemistry staining method|
58260814|NCT05466994|OTHER|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
58260815|NCT06350526|DIAGNOSTIC_TEST|Complete Blood Count|blood sample
58260816|NCT06350526|DIAGNOSTIC_TEST|C-reactive protein|serum sample
58382151|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
58382152|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
58382153|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
58382154|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
58382155|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
58382156|NCT06425510|BEHAVIORAL|Viviendo las Ventajas de la Asistencia Tecnológica|It comprises 2-hours small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected ATDs. The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals, providing information on ATDs, resources, and services, reflection on the advantages and disadvantages of using these ATDs, hands-on practice with selected ATDs, goal setting, and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
58382157|NCT06425510|OTHER|Attention calls|Ten minutes attention calls, once a week for six weeks to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
58382158|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
58382159|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
58382160|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
58382161|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
58382162|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
58382163|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
58382164|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
58382165|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
58260817|NCT06350526|DIAGNOSTIC_TEST|O2 saturation|blood sample
58260818|NCT06350526|DIAGNOSTIC_TEST|Serum ferritin and D-dimer|Blood sample
58058836|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
58260819|NCT06350526|DIAGNOSTIC_TEST|Liver and renal function tests|Blood sample
58260820|NCT06350526|DIAGNOSTIC_TEST|Lactate dehydrogenase|Blood sample
58260821|NCT06350526|DIAGNOSTIC_TEST|coronavirus (SARS-CoV-2) swab|Throat swab
58260822|NCT06350526|RADIATION|CT chest|Radiation
58260823|NCT06590389|OTHER|mandala activity|A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
58260824|NCT06497764|DEVICE|Vibrational Anesthesia (VA) Device|The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.
58260825|NCT06497764|PROCEDURE|PRP Treatment|PRP (a needle-related procedure) will be delivered per routine standard of care.
58260826|NCT06643364|OTHER|Vision Training Program|Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.
58260827|NCT06643364|OTHER|Routine Training Program|All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
58260828|NCT05383092|OTHER|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
57709065|NCT00753207|OTHER|liquid chromatography|
58260829|NCT05002998|DRUG|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
58260830|NCT05002998|DRUG|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
58260831|NCT00477750|DRUG|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
58260832|NCT00477750|DRUG|melphalan|"Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression"
58260833|NCT00477750|DRUG|prednisone|60mg/m\^2, orally days 1-4 every 28 days until progression
58260834|NCT01447446|DRUG|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
58260835|NCT01447446|DRUG|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
58260836|NCT01447446|DRUG|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
58058837|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
58260837|NCT01447446|DRUG|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
58260838|NCT01447446|DRUG|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
58260839|NCT06620510|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
58260840|NCT06620510|BIOLOGICAL|No Interventions|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
57709066|NCT00753207|OTHER|mass spectrometry|
57709067|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
57709068|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
57709069|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
58260841|NCT00065637|DRUG|Teriparatide|Synthetic human parathyroid hormone
58260842|NCT00065637|DRUG|Placebo teriparatide|Placebo injections
57709070|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
58260843|NCT06581003|DRUG|Oxygen 99.7 %|The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
58058838|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
58058839|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
58058840|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
58058841|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
58260844|NCT06581003|DRUG|Oxygen 21 %|The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
58260845|NCT05966506|BEHAVIORAL|Dyad-based Zoom health coaching|This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 \&11) for 45 minutes
58260846|NCT05966506|BEHAVIORAL|Fitbit activity monitor|"Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep."
58260847|NCT05966506|OTHER|Electronic newsletters|Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
58260848|NCT02351908|DRUG|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
58260849|NCT02351908|DRUG|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
58382166|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
58382167|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
58058842|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
58058843|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
58058844|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
58058845|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
58058846|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
58260850|NCT02351908|DRUG|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
58260851|NCT02557204|PROCEDURE|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
58260852|NCT02557204|PROCEDURE|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
58382168|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
58382169|NCT02840253|DEVICE|NIRS|
58382170|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
58382171|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
58382172|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
57709071|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
57709072|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
58260853|NCT02557204|PROCEDURE|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
58260854|NCT02557204|PROCEDURE|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
58260855|NCT00725790|DRUG|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
58260856|NCT00725790|DRUG|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
58260857|NCT02977611|DRUG|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
58260858|NCT03946878|DRUG|Acalabrutinib|Given PO
58260859|NCT03946878|DRUG|Venetoclax|Given PO
58260860|NCT06482125|DRUG|Total Intravenous Dexmedetomidine|Intervention group will receive Total Intravenous Dexmedetomidine as their anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour continued as the sole anesthetic maintenance agent, thereafter.
58260861|NCT06482125|DRUG|Inhalation Sevoflurane|Inhalation Sevoflurane will be administered as an anesthetic maintenance agent. Sevoflurane at 2 - 2.5 Vol% will be administered throughout the operative procedure.
58260862|NCT02550392|BEHAVIORAL|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
58260863|NCT04010929|PROCEDURE|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
58260864|NCT04010929|PROCEDURE|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
58260865|NCT05980923|OTHER|Performing blood thyroid test (TSH, FT4, FT3)|Blood test as above
57709073|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
57709074|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
58382173|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
57709075|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
57709076|NCT02243150|DRUG|Placebo|
57910963|NCT05325801|BIOLOGICAL|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
58260866|NCT03465501|RADIATION|Brachytherapy|Brachytherapy
58260867|NCT04083469|BEHAVIORAL|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
58260868|NCT04083469|BEHAVIORAL|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
58260869|NCT04083469|BEHAVIORAL|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
58260870|NCT02010658|OTHER|Cognitive Aid|
57910964|NCT03289429|DRUG|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
57910965|NCT03289429|DRUG|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
57910966|NCT03289429|OTHER|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
57910967|NCT03289429|OTHER|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
58260871|NCT06623760|DEVICE|Desk and chair adaptation interventions|Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
58260872|NCT02781857|OTHER|No intervention|
58260873|NCT05069142|OTHER|Rehabilitation|Pre- and post-operative exercise and education.
58260874|NCT05137847|DRUG|Remitoro|Intravenous infusion.
58260875|NCT06519643|BEHAVIORAL|career planning application|"Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app."
58382174|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
58058847|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
58058848|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
58382175|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
58382176|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
58382177|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
58382178|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
58382179|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
57709077|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
57910968|NCT03108456|DEVICE|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
58058849|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
58058850|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
58260876|NCT05564026|OTHER|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
58260877|NCT05564026|OTHER|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
58260878|NCT05564026|OTHER|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
58382180|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
58382181|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
58382182|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
58382183|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
58382184|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
57709078|NCT05545670|DRUG|Placebo|not containing drugs
57709079|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
57910969|NCT03108456|DEVICE|Balloon|Vessel preparation with conventional and/or specialty balloons
57910970|NCT04663724|BEHAVIORAL|Computer-Based Treatment|A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
58382185|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
58382186|NCT01797757|DRUG|Orlistat|
58382187|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
58382188|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
58382189|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
58382190|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
58260879|NCT05564026|PROCEDURE|Blood Sample Collection|Collection and storing of serum/plasma
58260880|NCT01679067|PROCEDURE|colonoscopy with endoscopic biopsies|
58260881|NCT04325698|DRUG|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
58260882|NCT04325698|DRUG|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
58260883|NCT04325698|DRUG|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
58260884|NCT04325698|DRUG|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
58260885|NCT05546723|BIOLOGICAL|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
58260886|NCT05149352|BEHAVIORAL|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
58382191|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
57709080|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
57709081|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
57709082|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
57709083|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
57709084|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
58058851|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
58260887|NCT05149352|BEHAVIORAL|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
58382192|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
57709085|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
57709086|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
57709087|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
57709088|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
58058852|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
58058853|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
58382193|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
58382194|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
57709089|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
57709090|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
57709091|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
58058854|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
58058855|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
58382195|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
57709092|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
57709093|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
58058856|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
58058857|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
57709094|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
58260888|NCT04669964|PROCEDURE|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
58260889|NCT05189093|DRUG|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
58260890|NCT01154088|BIOLOGICAL|Mencevax ACWY|One dose, Subcutaneous injection
58260891|NCT01154088|BIOLOGICAL|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
58260892|NCT05795140|DRUG|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
58260893|NCT00006617|DRUG|Abacavir sulfate|
58260894|NCT00006617|DRUG|Amprenavir|
58260895|NCT00006617|DRUG|Lamivudine|
58260896|NCT00006617|DRUG|Zidovudine|
58260897|NCT03535740|DRUG|Brigatinib|Brigatinib Tablets
58260898|NCT04506905|DRUG|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
58260899|NCT04506905|DRUG|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
58260900|NCT04738422|DRUG|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
58260901|NCT06621550|OTHER|High Intensity Interval Training|Participants will receive a single session of HIIT, which last for 19 minutes in duration. During the HIIT session, participants will complete 2 minutes stretching warm-up exercise, followed by a video of exercises which will be projected on the screen to facilitate the participants to follow. The exercise in the video involves various combinations of aerobic and core resistance exercise such as squat jump, jump lunge, push up, burpee, mountain climber etc. The exercise involved bodyweight or minimal basic equipment only, the workout to rest ratio is 45 secs: 15 secs. Participants' heart rate will be kept surveillance and to maintain their respective heart rate attained 85% of aged predicted maximal heart rate during the workout period.
58260902|NCT04430842|DRUG|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
58260903|NCT05514587|BEHAVIORAL|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
58260904|NCT06341543|DIAGNOSTIC_TEST|Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).|The QF-CMV will be performed in all participants.
58260905|NCT06341543|OTHER|Communication of the result of the QF-CMV to the clinician in charge|"The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge."
58260906|NCT04446195|BEHAVIORAL|Individualized Intervention|In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index \> 25 kg / m2, age \> 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
57709095|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
58260907|NCT00984139|BIOLOGICAL|Engerix™-B Kinder|Intramuscular, one dose.
58260908|NCT02658734|DRUG|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
58260909|NCT06617988|OTHER|Not applicable- observational study|Not applicable- observational study
58260910|NCT02662400|BIOLOGICAL|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
58260911|NCT06620380|DEVICE|Pharmacoscopy 1.0|Pharmacoscopy is currently an academically developed platform. The study is designed to investigate the clinical performance of this academic platform. In the interventional arm, the best candidate agent defined by pharmascopy will be considered to guide the therapeutic decision for each patient.
58260912|NCT06620380|OTHER|Control|The next systemic treatment after surgery will be discussed, with the investigator and at the tumor board, considering also standard histopathological and molecular analysis, including next generation sequencing, molecular profiling analysis and previous treatments received
57709096|NCT00347295|DRUG|Brotizolam|
57709097|NCT00347295|DRUG|Estazolam|
57709098|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
57709099|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
57709100|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
57709101|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
57709102|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
57709103|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
58260913|NCT03740529|DRUG|Pirtobrutinib|Oral
57709104|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
57709105|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
57709106|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
58058858|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
58260914|NCT03740529|DRUG|Venetoclax|Oral
58260915|NCT03740529|DRUG|Rituximab|IV
58260916|NCT03624543|DRUG|CFI-400945|32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
58260917|NCT01759810|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
58058859|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
58058860|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
58260918|NCT01759810|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
58260919|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
58382196|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
57709107|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
57709108|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
58058861|NCT01594749|DRUG|Fosaprepitant dimeglumine|
57709109|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
57910971|NCT06140654|DIAGNOSTIC_TEST|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
58260920|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
58260921|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
58260922|NCT03898362|OTHER|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
58260923|NCT03898362|DEVICE|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
58382197|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
57709110|NCT00139568|DRUG|Tegaserod|
57709111|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
57709112|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
57709113|NCT04722640|DRUG|SKYRIZI|SKYRIZI
57910972|NCT06140654|DIAGNOSTIC_TEST|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
57910973|NCT03422523|DRUG|Atezolizumab|Intravenous drip
57910974|NCT03422523|DRUG|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
57910975|NCT03422523|DRUG|Gemcitabine 1000 mg|intravenous drip
58058862|NCT01594749|DRUG|Fosaprepitant Placebo|
58058863|NCT01594749|DRUG|Dexamethasone|
58058864|NCT01594749|DRUG|Ondansetron|
58382198|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
58382199|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
58382200|NCT02621437|OTHER|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
58382201|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
58382202|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
58382203|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
58382204|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
58382205|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
58382206|NCT02065349|DRUG|ASP8477|oral
57709114|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
57709115|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
57709116|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
57709117|NCT00895739|BIOLOGICAL|alemtuzumab|
57709118|NCT00895739|DRUG|cyclosporine|
58260924|NCT06477068|COMBINATION_PRODUCT|Mobile medical reminder application|"Experimental group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department, in addition to being supported through the telemedicine medication reminder app on smartphones.~Control group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department."
58260925|NCT06621316|DRUG|HRS-7535 Tablet|at multiple dose levels
58260926|NCT06621316|DRUG|Placebo|at multiple dose levels (matching active arm HRS-7535 Tablet)
58260927|NCT02744664|PROCEDURE|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
58260928|NCT02744664|DRUG|Icotinib|After Cryotherapy, subjects begin Icotinib administration
58260929|NCT00207792|DRUG|filgrastim|
58260930|NCT06035861|DRUG|XBD173|Participants will be treated with XBD173 90mg twice daily for 6 weeks
58260931|NCT04142320|DEVICE|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
58260932|NCT04142320|DEVICE|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
58260933|NCT04142320|DEVICE|sham rTMS|Delivers placebo magnetic stimulation
58260934|NCT06649396|DIAGNOSTIC_TEST|Dried Blood Spot|Comparing analysis results between dried blood spot and plasma
58260935|NCT06649396|DIAGNOSTIC_TEST|Analysis on plasma|Analysis on plasma
58260936|NCT06243952|DEVICE|ARC-BSI Lumbar system|Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
58260937|NCT05589155|OTHER|Mobile health application|Intervention will be with mobile health application
58260938|NCT06618768|DIETARY_SUPPLEMENT|Consumption of an aronia-mixture to prevent Urinary Tract Infections in female patients|The present pilot study will assess the feasibility of methods and procedures to be used in a larger study and contribute to establish power calculations required to conduct a randomised clinical trial which will examine whether consumption of 1 dL aronia-mixture/day for six months will reduce prevalence of symptomativ UTi episodes among adult women with a recent history of uncomplicated, recurrent UTIs.
58260939|NCT05160038|DEVICE|Embodied virtual reality|An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
58260940|NCT02584127|BEHAVIORAL|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
58260941|NCT02584127|BEHAVIORAL|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
58260942|NCT06617936|DRUG|neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)
58260943|NCT06617936|PROCEDURE|surgery|Patients who are discussed by the MDT panel to evaluate surgical resection will undergo surgery.Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
58260944|NCT06617936|DRUG|Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.
58260945|NCT06617936|OTHER|Standard Treatment|Patients assessed by the MDT panel as inoperable for surgical treatment will be selected by the investigator for a standard treatment protocol determined by the MDT discussion
58260946|NCT01867294|DRUG|Doxycycline|Given PO
58260947|NCT01867294|PROCEDURE|Management of Therapy Complications|Moisturizer given topically
58260948|NCT01867294|OTHER|Placebo|Given topically
58382207|NCT02065349|DRUG|Placebo|oral
58058865|NCT01594749|DRUG|Dexamethasone Placebo|
58260949|NCT01867294|OTHER|Questionnaire Administration|Ancillary studies
58260950|NCT01867294|DRUG|Spironolactone|Given topically
58260951|NCT01867294|DRUG|Sunscreen|Given topically
58260952|NCT01867294|DRUG|Therapeutic Hydrocortisone|Given topically
58260953|NCT02036658|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
58382208|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
58382209|NCT01738633|BEHAVIORAL|nutritional counseling|
58058866|NCT01594749|DRUG|Ondansetron Placebo|
58058867|NCT01594749|DRUG|Rescue Therapy|
58260954|NCT02036658|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
58260955|NCT02517242|DEVICE|Pens Device|
58260956|NCT02517242|DEVICE|Syringe|
58260957|NCT02517242|OTHER|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
58382210|NCT01738633|BEHAVIORAL|respirology counseling|
58382211|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
58260958|NCT03961386|BEHAVIORAL|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
58260959|NCT03961386|BEHAVIORAL|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
58260960|NCT02339129|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
58058868|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
58260961|NCT02339129|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
58260962|NCT02027597|OTHER|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
58260963|NCT02027597|OTHER|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
58260964|NCT02027597|OTHER|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
58382212|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
57910976|NCT03422523|DRUG|Oxaliplatin 100 MG|intravenous drip
57910977|NCT03191773|COMBINATION_PRODUCT|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
57910978|NCT05264389|DEVICE|Poly-Tape|Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
58260965|NCT06260943|BEHAVIORAL|Target Navigation Pilot Program|Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.
58260966|NCT06117709|BEHAVIORAL|I-STAMP|A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
58260967|NCT06438133|OTHER|CIMON|The sensor assess changes in the circumference of the limb and will be applied to the lower limb before compression bandaging is applied.
58260968|NCT06438133|OTHER|Sens Motion|The sensor assess physical activity and the amount of time spent at rest, standing, walking, running and count steps.
58260969|NCT04668638|OTHER|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
58260970|NCT06624202|BEHAVIORAL|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) includes use of practice plans and a resource booklet aligned with the National Federation for High School guidelines for contact in practice. Coaches will also attend a pre-season coaches' clinic and be paired with a peer mentor during the season.
58260971|NCT05015140|OTHER|musıc therapy|calm music with nature sounds set by the music therapist
58058869|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
58260972|NCT00402532|DRUG|Everolimus|Initial dosage 2 x 0.75 mg/d
58260973|NCT00402532|DRUG|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
58260974|NCT04887935|DRUG|Dapagliflozin|-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
57910979|NCT04091048|DEVICE|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
58260975|NCT06648239|OTHER|Usual Care|In the usual care group, patients will proceed directly to ICA following referral from community cardiology, as is the current standard of care. Research staff will screen participants in this group for significant CAD using the decision support tool; however, the tool's recommendations will not affect their care, as all patients in this group will invariably receive ICA.
58260976|NCT06648239|OTHER|Centralized triage with risk score-based screening for obstructive CAD|Patients randomized to the intervention will have selected features of their medical history, recorded on their referral form, entered into a decision support tool by research personnel to generate a recommendation of whether they should proceed directly to ICA or whether they should receive CCTA. Patients with recommendations for ICA will proceed directly to ICA. Patients with recommendations for CCTA will be referred to CCTA. Based on the results of the CCTA, recommendations for medical management versus referral for ICA will be made.
58260977|NCT06622382|PROCEDURE|Bariatric endoscopic antral myotomy|A mucosal incision is performed using a triangle-tip knife J at the level of the incisura along the level of the greater curvature. Submucosal tunneling is then performed and stopped immediately proximal to the pylorus. Two parallel lines of partial thickness myotomy are then performed from the distal to proximal antrum using the same endoscopic knife. The myotomy is stopped approximately 2 cm distal to the mucosal incision site. Finally, the mucosal incision is closed using endoclips after haemostasis is confirmed.
58260978|NCT03578458|OTHER|subjects will install a mobile app for use|novel mobile application
58260979|NCT06618482|PROCEDURE|Kinesiotaping|Low back kinesiotaping
58260980|NCT06618482|PROCEDURE|Kinesiotaping|Transversus abdominis kinesiotaping
57910980|NCT03302351|DRUG|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
57910981|NCT03302351|DRUG|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
57910982|NCT03302351|DRUG|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
57910983|NCT02194673|OTHER|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
57910984|NCT02194673|OTHER|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
57910985|NCT02194673|OTHER|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
58058870|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
58058871|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
58260981|NCT04391738|OTHER|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
58260982|NCT06648577|PROCEDURE|Ultrasound imaging|The participants are scanned with an ultrasound scanner
58260983|NCT00654875|DRUG|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
58260984|NCT00654875|DRUG|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
58260985|NCT06212271|DRUG|Colchicine|See arm description.
58260986|NCT06212271|DRUG|Placebo|See arm description.
57910986|NCT03933904|DRUG|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
57910987|NCT01789736|DRUG|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
57910988|NCT01789736|DRUG|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
57910989|NCT01789736|DRUG|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
57910990|NCT05331677|PROCEDURE|correction of deformities around the knee with external fixator|minimally invasive surgery
58058872|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
58058873|NCT05466240|DRUG|AT-752|AT-752 for 5 days
57910991|NCT04326517|PROCEDURE|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
57910992|NCT02033161|BEHAVIORAL|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
57910993|NCT01681173|DIETARY_SUPPLEMENT|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
57910994|NCT01681173|DIETARY_SUPPLEMENT|Placebo|200ml Placebo, BID, over 24 months
58058874|NCT05466240|DRUG|Placebo|Placebo for 5 days
58260987|NCT04558567|DRUG|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
58260988|NCT04760509|OTHER|In this study, the short-term follow-up of patients with neural tube defects in the neonatal intensive care unit will be evaluated retrospectively.|there is no intervention. It is retrospective study.
58382213|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
58382214|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
58382215|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
58382216|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
58382217|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
58382218|NCT04284501|BEHAVIORAL|Non|questionnaire
58382219|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
58382220|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
58382221|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
57910995|NCT04370548|DRUG|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
57910996|NCT02245737|DRUG|Lanabecestat|Administered orally
57910997|NCT02245737|DRUG|Placebo|Administered orally
58058875|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
58058876|NCT04335357|DRUG|Placebo|Placebo
58260989|NCT04606485|OTHER|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
58260990|NCT01758107|OTHER|Withdraw cyclosporine|
58382222|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
57910998|NCT00324675|DRUG|Rosiglitazone|4 mg tablets, bid, 12 months
57910999|NCT00324675|DRUG|Placebo|2 tablets per day
57911000|NCT01081054|OTHER|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
57911001|NCT01080833|DEVICE|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
58058877|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
58260991|NCT02290834|OTHER|Cognitive, functional and subjective assessments|Cognitive and functional assessments
58260992|NCT02290834|DEVICE|MRI|Magnetic Resonance Imaging (MRI) Scan
58260993|NCT02290834|RADIATION|PET Scan|Positron Emission Tomography (PET) Scan
58260994|NCT06540651|OTHER|use of Luminettes ® with active light emission|Spectrum of 400 \< X \< 750 nm assumed active
58260995|NCT06540651|OTHER|use of Luminettes ® with a light emission presumed to have no therapeutic effect|Modification of spectrum parameters for wavelengths covered, with light emission in a spectrum of 560 \< X \< 650 nm assumed to have no therapeutic effect
58260996|NCT02853669|PROCEDURE|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
57911002|NCT05961904|OTHER|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
57911003|NCT00140985|DRUG|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
58260997|NCT02853669|PROCEDURE|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
58260998|NCT03692325|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
58260999|NCT06455319|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
58261000|NCT06455319|DRUG|verapamil extended release capsule|Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
58261001|NCT06455319|DRUG|Placebo|I.V. Saline
58261002|NCT06084715|OTHER|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
58261003|NCT04101916|DEVICE|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
58261004|NCT04101916|DEVICE|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
58261005|NCT02410421|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
58261006|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
58261007|NCT01639066|DRUG|Entecavir|Entecavir 1 mg daily Oral
58382223|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
58382224|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
57709119|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
58261008|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
58382225|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
57709120|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
57709121|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
57911004|NCT00140985|DRUG|Comparator: amlodipine / Duration of Treatment: 20 weeks|
57911005|NCT02822313|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76_V27-006)
57911006|NCT00740987|DEVICE|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
57911007|NCT02923687|DRUG|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
57911008|NCT02923687|DRUG|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
58261009|NCT04277650|OTHER|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
58261010|NCT05883293|DRUG|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
57709122|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
57911009|NCT01425424|OTHER|Vitamin D supplementation|Vitamin D
57911010|NCT01788787|BEHAVIORAL|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
58058878|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
58261011|NCT05913206|BEHAVIORAL|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
58261012|NCT05913206|BEHAVIORAL|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
58261013|NCT05913206|BEHAVIORAL|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
58382226|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
57911011|NCT01788787|BEHAVIORAL|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
57911012|NCT01788787|BEHAVIORAL|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
58058879|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
58058880|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
58261014|NCT05913206|BEHAVIORAL|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
58261015|NCT02289547|DRUG|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
58261016|NCT03721835|DEVICE|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
58261017|NCT03087422|BEHAVIORAL|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
58261018|NCT03825835|DRUG|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
58382227|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
58382228|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
57709123|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
58058881|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
58058882|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
58261019|NCT03825835|DRUG|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
58261020|NCT04514744|PROCEDURE|Knee bracing|Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
57709124|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
58058883|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
58058884|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
58058885|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
58058886|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
57911013|NCT01788787|BEHAVIORAL|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
58261021|NCT04514744|OTHER|Unilateral Resistance Exercise Training|Participants will perform resistance training on 4 occasions throughout an 8 day time period.
58382229|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
58382230|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
58382231|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
58382232|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
58382233|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
58382234|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
58382235|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
58382236|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
58382237|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
58382238|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58382239|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
58382240|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
58382241|NCT01004536|OTHER|no treatment|left untreated during the study period
58382242|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
57911014|NCT01735851|DRUG|Thoracic epidural analgesia|
58382243|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
58382244|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
58382245|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
58382246|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
58382247|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
58382248|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
58382249|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
58382250|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
58382251|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
58382252|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
58382253|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
58382254|NCT02843438|OTHER|Fluorescein angiography|
58382255|NCT02843438|OTHER|Dilated fundus examination|
58382256|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
58382257|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
58382258|NCT02843438|DRUG|Anti-inflammatory treatments|
58382259|NCT02843438|OTHER|Puncture in anterior chamber|
58382260|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
57911015|NCT01735851|PROCEDURE|Bilateral Paravertebral block|
58058887|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
58261022|NCT05100953|BEHAVIORAL|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
57709125|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
58261023|NCT06624033|OTHER|amino acids kinetics|"After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured."
58261024|NCT06292858|DRUG|IMB071703 injection|Intratumoral injection
58261025|NCT05190211|OTHER|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
58261026|NCT05190211|OTHER|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
57911016|NCT05375851|OTHER|Digital Interventions|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management."
58058888|NCT02678156|DEVICE|Lyoplant Onlay|
58058889|NCT04476706|DRUG|canakinumab|canakinumab
58261027|NCT04183140|PROCEDURE|primary percutaneous coronary intervention|primary percutaneous coronary intervention via transulnar or transradial access
58261028|NCT03676296|DRUG|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
58261029|NCT03676296|DRUG|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
58261030|NCT03811288|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
58261031|NCT00032136|DRUG|exemestane|
58261032|NCT00032136|DRUG|tamoxifen citrate|
58261033|NCT00032136|PROCEDURE|adjuvant therapy|
58261034|NCT06577519|DRUG|Vicagrel|Vicagrel loading followed by Maintenance dose
58058890|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
58058891|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
58058892|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
58261035|NCT06577519|DRUG|Clopidogrel|Clopidogrel loading followed by Maintenance dose
58261036|NCT01438294|OTHER|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
58261037|NCT01438294|OTHER|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
58261038|NCT00546117|DRUG|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
58261039|NCT00546117|DRUG|placebo|Placebo Solutab in 15 and 30 mg dosages.
58261040|NCT06622421|DEVICE|Piezoelectric surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
58261041|NCT06622421|PROCEDURE|Conventional surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
58261042|NCT06619249|DIETARY_SUPPLEMENT|CoQ10 supplementation|Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.
58261043|NCT06619249|DIETARY_SUPPLEMENT|Placebo supplementation|Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
58382261|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
58382262|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
58261044|NCT01798407|DEVICE|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
58261045|NCT01798407|OTHER|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
58261046|NCT02012933|DRUG|3,4-diaminopyridine|10mg tablets for up to 100mg per day
58261047|NCT05575752|OTHER|high temperature (32℃) group|The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
58261048|NCT05575752|OTHER|moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
58261049|NCT06649097|DEVICE|IRRAflow® CNS (Active Fluid Exchange) System|The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
58261050|NCT06124521|BEHAVIORAL|ComBaT Glaucoma|ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
58382263|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
58382264|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
58382265|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
58382266|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
58382267|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
58261051|NCT00887523|BEHAVIORAL|radiation in prone position|radiation in prone position
58382268|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
58058893|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
58261052|NCT00887523|BEHAVIORAL|radiation in supine position|radiation in supine position
58261053|NCT00474786|DRUG|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
58261054|NCT00474786|DRUG|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
58261055|NCT06622993|OTHER|Psychotherapy|The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.
58261056|NCT06452849|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
58261057|NCT05172869|PROCEDURE|Suprainguinal Performed FICB|Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
58382269|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
58382270|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
58382271|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
58261058|NCT05172869|PROCEDURE|Infrainguinal Performed FICB|Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
58261059|NCT05028075|BEHAVIORAL|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
58261060|NCT02094222|DRUG|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
57911017|NCT05375851|DRUG|Treatment as Usual|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
58261061|NCT06618573|DRUG|Isoniazid/Pyridoxine|Treatment group received isoniazid 300mg and pyridoxine 10mg/day
57911018|NCT05270174|OTHER|no intervention|no intervention
58261062|NCT06618573|DRUG|Saccharum Lactis|Control group received placebo
58261063|NCT02860000|DRUG|Alisertib|Given PO
58382272|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
58261064|NCT02860000|DRUG|Fulvestrant|Given IM
58261065|NCT02860000|OTHER|Laboratory Biomarker Analysis|Correlative studies
58261066|NCT05116202|DRUG|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
58261067|NCT05116202|DRUG|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
58261068|NCT05116202|DRUG|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
58382273|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
58382274|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
58382275|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
57911019|NCT03110185|DEVICE|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
58058894|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
58261069|NCT05116202|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
58261070|NCT05116202|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
58261071|NCT05116202|DRUG|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
57911020|NCT03110185|DEVICE|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
57709126|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
57709127|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
57709128|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
57709129|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
57911021|NCT03110185|DEVICE|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
57911022|NCT05774743|OTHER|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
57911023|NCT03862001|BEHAVIORAL|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
57911024|NCT00211185|DRUG|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
57911025|NCT00211185|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
57911026|NCT00211185|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
58261072|NCT05613608|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
58261073|NCT05613608|DRUG|Placebo|Placebo arm.
58261074|NCT02183805|DRUG|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
58382276|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
57709130|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
57709131|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
57709132|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
57709133|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
57709134|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
57911027|NCT00211185|DRUG|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
57911028|NCT00211185|DRUG|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
58058895|NCT00269685|DRUG|vasopressin|
58261075|NCT04220021|DRUG|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
58261076|NCT00630175|DRUG|zolpidem-MR (modified release)|
57709135|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
57709136|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
57709137|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
57709138|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
57709139|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
57709140|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
57709141|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
57709142|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
57911029|NCT00211185|OTHER|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
58261077|NCT00630175|DRUG|zolpidem (SL800750)|
58382277|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
58382278|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
58261078|NCT00630175|DRUG|placebo|
58261079|NCT01022294|DRUG|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
58382279|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
58382280|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
58382281|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
58382282|NCT01284959|DRUG|placebo|lactose PO, 3times
58382283|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
58382284|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
57709143|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
57709144|NCT03242499|DRUG|Placebo|placebo for 48 weeks
57709145|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
57911030|NCT04307420|PROCEDURE|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
57911031|NCT04307420|PROCEDURE|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
58261080|NCT01022294|DRUG|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
58261081|NCT03248310|BEHAVIORAL|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
58382285|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
58382286|NCT00003631|BIOLOGICAL|filgrastim|
58261082|NCT03443310|PROCEDURE|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
58382287|NCT00003631|DRUG|carboplatin|
58382288|NCT00003631|DRUG|carmustine|
58382289|NCT00003631|DRUG|cyclophosphamide|
58382290|NCT00003631|DRUG|cytarabine|
58382291|NCT00003631|DRUG|etoposide|
58382292|NCT00003631|DRUG|ifosfamide|
58382293|NCT00003631|DRUG|melphalan|
58382294|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
58382295|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
58382296|NCT00003631|RADIATION|radiation therapy|
58058896|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
58261083|NCT00989456|BEHAVIORAL|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
58261084|NCT00989456|BEHAVIORAL|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
58382297|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
58382298|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
58382299|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
58382300|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
58382301|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
58382302|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
58382303|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
58382304|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
58382305|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
58382306|NCT00405249|DRUG|elvucitabine|
58382307|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
58382308|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
58382309|NCT02056444|DRUG|Tranexamic Acid|
58382310|NCT06172816|OTHER|SARS-CoV-2|a virus infection
58382311|NCT04451408|DRUG|LY3372993|Administered IV or SC.
58382312|NCT04451408|DRUG|Placebo|Administered IV or SC.
58382313|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
58261085|NCT04114357|DRUG|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
58261086|NCT02719912|DEVICE|mitral valve replacement|transcatheter mitral valve replacement
58261087|NCT03256240|OTHER|side-to-side functional end anastomosis|type of anastomosis
58261088|NCT03256240|OTHER|Kono-S analstomosis|antimesenteric anastomosis
58261089|NCT04972968|DRUG|ABBV-154|Subcutaneous Injection
58261090|NCT04972968|DRUG|Placebo|Subcutaneous Injection
58261091|NCT04972968|DRUG|Glucocorticoid|Oral Tablet
58261092|NCT06443398|OTHER|There is no intervention in the study|There is no intervention in the study
58382314|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
58382315|NCT05424835|DRUG|SHR-A1811|SHR-A1811
58058897|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
58382316|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
58382317|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
58382318|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
58382319|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
58382320|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
58382321|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
58382322|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
58382323|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
58382324|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
57709146|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
57709147|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
57709148|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
57709149|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
57709150|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
58058898|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
57709151|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
57709152|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
57709153|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
57709154|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
57709155|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
57709156|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
58058899|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
58382325|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
57709157|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
57709158|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
57709159|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
57709160|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
57709161|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
57709162|NCT06101264|DEVICE|Virtual Reality Intervention|Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
57709163|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
57709164|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
57709165|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
57709166|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
57709167|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
57709168|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
57709169|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
57709170|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
58058900|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
58058901|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
58058902|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
58382326|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
58058903|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
58261093|NCT06316739|BEHAVIORAL|Ganchero intervention|"The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services."
58261094|NCT05282446|DRUG|INV-202|tablet
58058904|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
58261095|NCT05282446|DRUG|Placebo|matching tablet
58261096|NCT05847257|DRUG|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
58382327|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
58058905|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
58058906|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
58058907|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
58382328|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
58382329|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
58058908|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
58058909|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
58382330|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
58382331|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
57709171|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
57709172|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
58058910|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
58058911|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
58058912|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
58058913|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
58058914|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
58261097|NCT05847257|DIETARY_SUPPLEMENT|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
58261098|NCT06563544|DEVICE|FCV|90 minutes of FCV
58261099|NCT02589522|DRUG|Berzosertib|Given IV
58261100|NCT02589522|OTHER|Quality-of-Life Assessment|Ancillary studies
58261101|NCT02589522|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58261102|NCT02589522|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
58261103|NCT03944759|PROCEDURE|serratus anterior plan block|serratus anterior plan block
58261104|NCT02396303|DRUG|Carbetocin|
58261105|NCT04889196|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
58261106|NCT04889196|DEVICE|hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
58261107|NCT00003764|DRUG|cyclophosphamide|
58261108|NCT00003764|DRUG|fludarabine phosphate|
58261109|NCT00000864|DRUG|Abacavir sulfate|
58261110|NCT00000864|DRUG|Zidovudine|
58382332|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
58382333|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
58382334|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
58382335|NCT00002493|DRUG|cisplatin|
58382336|NCT00002493|DRUG|doxorubicin hydrochloride|
58382337|NCT00002493|RADIATION|low-LET photon therapy|
58382338|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
58382339|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
58382340|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
58382341|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
58382342|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
58382343|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
58382344|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
58382345|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
58382346|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
58382347|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
58382348|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
58261111|NCT05341336|PROCEDURE|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
58261112|NCT06511596|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
58261113|NCT06511596|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
58261114|NCT05798741|PROCEDURE|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
58261115|NCT06329960|OTHER|Ultrasound-guided injection combined with needle release|Ultrasound-guided PIT using D5W HD for dorsal scapular nerve combined with needle release of major and minor rhomboideus
58261116|NCT06478849|OTHER|QUESTIONNAIRES|QUESTINNAIRES / WEBINARS
58261117|NCT06320431|DRUG|Tenecteplase|Thrombolytic
58382349|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
58382350|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
58261118|NCT04514640|BEHAVIORAL|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
58261119|NCT04150484|OTHER|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
58261120|NCT00704444|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets
58261121|NCT00704444|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
58382351|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
58382352|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
57709173|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
58058915|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
58058916|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
58058917|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
58058918|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
58261122|NCT06620978|PROCEDURE|Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..|"Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..~Operative hysteroscopy without anesthesia using normal Saline as medium with different pressure according to the arm allocated. The procedure is done for endometrial polyp removal, retained products of conception removal, intrauterine adhesyolisis and intrauterine device removal."
58261123|NCT06620978|PROCEDURE|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium in High pressure.|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium at high pressure.
58261124|NCT03841968|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
58261125|NCT03841968|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
58261126|NCT01000350|DRUG|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
58261127|NCT01000350|OTHER|Placebo|Placebo x1 lactose tablet
58261128|NCT06078709|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58261129|NCT06078709|PROCEDURE|Computed Tomography|Undergo CT and PET/CT scan
58261130|NCT06078709|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
58261131|NCT06078709|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
58261132|NCT06078709|DRUG|Fluorouracil|Given IV
58261133|NCT06078709|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58261134|NCT06078709|DRUG|Leucovorin Calcium|Given IV
58261135|NCT06078709|DRUG|Oxaliplatin|Given IV
58261136|NCT06078709|PROCEDURE|Positron Emission Tomography|Undergo PET and PET/CT scan
58382353|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
58382354|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
58382355|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
58382356|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
58382357|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
58058919|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
58261137|NCT06078709|OTHER|Survey Administration|Ancillary studies
58261138|NCT06078709|DRUG|Docetaxel|Given IV
58261139|NCT03602391|BEHAVIORAL|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
58261140|NCT06580600|DIAGNOSTIC_TEST|Point of care respiratory virus testing|"Patients to be randomised to receive OCS based on the the result of the RSV results within their respiratory virus test. This test will be performed as a point of care (POC) test in ED.~This intervention will stratify the randomisation in a 1:1 ratio, to receive OCS or not.~NB) Whilst the respiratory pathogen test is not routine care to determine the OCS prescription, it is frequently used within this setting. Additionally both the receipt (or not the receipt) of OCS is within standard care pathway. For the purpose of the trial OCS = Dexamethasone, which is delivered as oral suspension 300mcg/kg as per standard practice within the local Trust."
58261141|NCT05002894|OTHER|Pilates exercises|Pilates exercises for flexibility and stability
58261142|NCT05002894|DIETARY_SUPPLEMENT|medical standard care for fatigue|supplements and medical care
58261143|NCT06516055|DRUG|S1B-408|Medication with multiple monoamine activities
58261144|NCT05071040|BEHAVIORAL|Home-based physical activity|Participants will follow a strength exercise program
58261145|NCT01921192|DRUG|Folic Acid, vit B6 and B12|
58261146|NCT01921192|DRUG|Placebo|
58261147|NCT03001349|PROCEDURE|Computed Tomography|Undergo PET/CT
58261148|NCT03001349|DRUG|Gallium Ga 68-Edotreotide|Given IV
58261149|NCT03001349|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58261150|NCT03698838|DEVICE|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
58261151|NCT01624857|DRUG|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
58382358|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
58382359|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
58382360|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
58261152|NCT01624857|DRUG|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
58382361|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
58382362|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
58382363|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
58382364|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
58382365|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
58382366|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
58382367|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
58382368|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
58382369|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
58382370|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
58382371|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
58382372|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
58382373|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
58382374|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
58382375|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
57709174|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
58382376|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
58382377|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
58382378|NCT02385903|OTHER|Flammacerium|
57709175|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
58382379|NCT02385903|OTHER|Standard dressing procedure|
58261153|NCT06619327|BEHAVIORAL|Resilient Together for Dementia|RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.
58261154|NCT06619327|BEHAVIORAL|MEUC|The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.
58382380|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
58382381|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
58382382|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
58382383|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
57911032|NCT00464009|BEHAVIORAL|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
57911033|NCT04020354|BEHAVIORAL|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
58058920|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
58058921|NCT01979328|DEVICE|geko|
58058922|NCT01979328|DEVICE|Plaster cast|
58058923|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
58261155|NCT04188431|DRUG|Dexamethasone|Is usually commercialized as dexamethasone phosphate as solution for injection
58261156|NCT04188431|DRUG|Sodium chloride|prepared in the same intravenous volume to mimic experimental arm
58261157|NCT03335423|DRUG|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
57709176|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
57911034|NCT04020354|BEHAVIORAL|Usual Care|Usual customary care
58058924|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
58058925|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
57911035|NCT03034538|DRUG|Zonegran|100mg
57911036|NCT03034538|DRUG|Zonegran|200mg
58058926|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
58058927|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
58058928|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
58058929|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
58058930|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
58058931|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
58058932|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
58058933|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
58058934|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
58058935|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
58058936|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
58058937|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
58058938|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
58058939|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
58058940|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
58058941|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
58058942|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
58261158|NCT03335423|DRUG|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
58261159|NCT03335423|DRUG|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
58261160|NCT03335423|DRUG|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
58382384|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
58382385|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
58382386|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
58382387|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
57709177|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
58261161|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength VitaJoy (ES/VJ)|Extra Strength VitaJoy Capsule, 2 capsules in the morning
58261162|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength Vita Calm (ES/VC)|Extra Strength Vita Calm Capsule, 2 capsules in the evening
58261163|NCT06579183|DIETARY_SUPPLEMENT|Placebo|Placebo Capsule, 4 capsules in the morning and evening respectively
58261164|NCT01730534|DRUG|Dapagliflozin 10 mg|Oral dose (od)
58261165|NCT01730534|DRUG|Placebo tablet|Oral dose (od)
58261166|NCT00602290|DRUG|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.
58261167|NCT00602290|DRUG|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
58382388|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
58382389|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
58382390|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
58261168|NCT00602290|DRUG|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
58261169|NCT05545631|OTHER|no intervention|no intervention in this study
58382391|NCT01433406|DRUG|TAK-875|
58382392|NCT01433406|DRUG|TAK-875|
58382393|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
58382394|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
57709178|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
57709179|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
57709180|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
58058943|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
58058944|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
58058945|NCT00685828|DRUG|imatinib mesylate|By mouth
58382395|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
58382396|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
58382397|NCT06549465|BIOLOGICAL|45 KBq/kg Ac-225 rosopatamab tetraxetan|45 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
58382398|NCT06549465|BIOLOGICAL|55 KBq/kg Ac-225 rosopatamab tetraxetan|55 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
58382399|NCT06549465|BIOLOGICAL|60 KBq/kg Ac-225 rosopatamab tetraxetan|60 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
58382400|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
58382401|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
57709181|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
57709182|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
57709183|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
57709184|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
57709185|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
57709186|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
57709187|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
57709188|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
57709189|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
58058946|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
58058947|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
58261170|NCT03998163|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
58382402|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
58382403|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
57709190|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
57709191|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
57709192|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
57709193|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
58058948|NCT00421616|BEHAVIORAL|High protein diet study|
58058949|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
58261171|NCT06514716|PROCEDURE|Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI)|Participants will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). This combination aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
58261172|NCT06514716|PROCEDURE|Geniculate Artery Embolization alone (GAE alone)|Participants will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This procedure aims to serve as a control to evaluate the effectiveness and safety of GAE with IACI in comparison.
58382404|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
58382405|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
58382406|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
57709194|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
58261173|NCT01104246|DRUG|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
58261174|NCT01264237|DRUG|Etoricoxib|90mg Tablet QD at 10:00a.m.
57709195|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
58261175|NCT01264237|DRUG|Placebo|One tablet QD at 10:00a.m.
58261176|NCT06259695|DEVICE|Adjustable Aquatic Therapy Prosthesis|We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
57911037|NCT03699085|BEHAVIORAL|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
58058950|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
58058951|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
58058952|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
58382407|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
58382408|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
58261177|NCT01550705|DRUG|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
58261178|NCT05895890|GENETIC|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
58382409|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
58382410|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
57911038|NCT02867878|DRUG|Adenosine|
57911039|NCT02867878|DRUG|Saline solution|
58058953|NCT00040066|PROCEDURE|Cocaine (IV)|
58058954|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
58261179|NCT05397171|DRUG|AZD8853|Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
58382411|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
58382412|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
57709196|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
57709197|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
58058955|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
58058956|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
58058957|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
58261180|NCT05397171|DRUG|Zirconium-89 crefmirlimab berdoxam|CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
57709198|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
58058958|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
58058959|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
58058960|NCT04802928|DRUG|Placebo|Placebo
58382413|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
58382414|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
58382415|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
58382416|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
58382417|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
57709199|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
57709200|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
57709201|NCT00745914|DRUG|Placebo comparator|Placebo comparator
57709202|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
57709203|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
57709204|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
57709205|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
58058961|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
58058962|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
57709206|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
57709207|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
57709208|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
58261181|NCT06621615|BIOLOGICAL|CVL006 Injection|CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
57709209|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
57709210|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
57709211|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
57709212|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
57709213|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
57709214|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
57709215|NCT01340976|DRUG|LY2787106|Administered IV.
57709216|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
57709217|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
57709218|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
57709219|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
57709220|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
58261182|NCT06275711|BEHAVIORAL|Therapeutic communication methods|Drawing pictures, story completion, breathing and relaxation exercises
58261183|NCT02573558|DRUG|Dexmedetomidine|
58261184|NCT02573558|DRUG|Propofol|
58382418|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
58382419|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
57709221|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
57709222|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
57709223|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
57709224|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
57709225|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
57709226|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
58058963|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
58058964|NCT00122824|DRUG|duloxetine hydrochloride|
58058965|NCT00122824|DRUG|placebo|
57709227|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
57709228|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
57709229|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
57709230|NCT01723228|DRUG|Rasagiline|
57709231|NCT01723228|DRUG|Placebo|
57709232|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
57709233|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
57709234|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
57709235|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
57709236|NCT04237961|PROCEDURE|Injection|Fat injection and botox
57709237|NCT04237961|PROCEDURE|Suture|Suspension suture
57709238|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
57709239|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
57709240|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
57709241|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
57709242|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
57911040|NCT01372098|BEHAVIORAL|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
57911041|NCT02047864|DIETARY_SUPPLEMENT|Creatine monohydrate|
57911042|NCT04702542|DRUG|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
57911043|NCT02366468|DRUG|ranibizumab 0.5 mg|intravitreal injection
58382420|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
57911044|NCT01764685|DRUG|Topiramate|Max therapeutic dose of 150mg/day
58058966|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
58382421|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
58382422|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
58261185|NCT02521558|BEHAVIORAL|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
57709243|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
57709244|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
57709245|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
57709246|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
57709247|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
57709248|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
57709249|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
57709250|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
57911045|NCT01764685|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
57911046|NCT01764685|DRUG|Placebo|Placebo
57911047|NCT01258413|PROCEDURE|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
57911048|NCT01258413|PROCEDURE|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
57911049|NCT00987454|DRUG|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
58382423|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
58382424|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
57709251|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
57911050|NCT00987454|DRUG|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
57911051|NCT05425628|DEVICE|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
57911052|NCT00705861|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
57911053|NCT00705861|DRUG|SK3530|SK3530 100mg
57911054|NCT02926404|DEVICE|UNiD Rods|Spinal osteosynthesis
57911055|NCT00316160|DRUG|Bupropion Hydrochloride Extended-release|
57911056|NCT00316160|DRUG|Extended-release Venlafaxine|
57911057|NCT01632982|BEHAVIORAL|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
57911058|NCT01632982|BEHAVIORAL|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
57911059|NCT01632982|BEHAVIORAL|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
58382425|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
57911060|NCT04967560|DEVICE|deep brain stimulation|Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
58058967|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
58058968|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
58058969|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
58058970|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
58261186|NCT02521558|BEHAVIORAL|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
58382426|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
58382427|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
57911061|NCT05130047|DRUG|Aldafermin|1 mg solution
58058971|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
57911062|NCT05130047|DRUG|Placebo|Aldafermin placebo solution
58058972|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
58058973|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
58058974|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
58058975|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
58261187|NCT06315478|DRUG|Omeprazole 20 MG Oral Tablet|standard triple therapy for 14 days Bid for each drug
58261188|NCT06315478|DRUG|Amoxicillin 500Mg Tab|Quadruple regimen for 14 days Bid for each drug
57911063|NCT04418570|BEHAVIORAL|cognitive remediation|
57911064|NCT04418570|OTHER|attendance to an Early Intervention Service for Psychosis|
57911065|NCT02502123|OTHER|No Intervention|No intervention was administered in this study.
57911066|NCT05865015|OTHER||
57911067|NCT05712122|PROCEDURE|stellate block|stellate blockade effect on Ventricular arrytmia
58058976|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
58261189|NCT06315478|DRUG|Clarithromycin 500Mg Tab|Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
57709252|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
57911068|NCT01047293|DRUG|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
57911069|NCT01047293|DRUG|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
57911070|NCT01047293|DRUG|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
57911071|NCT03768583|OTHER|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
57911072|NCT03768583|OTHER|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
57911073|NCT03768583|OTHER|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
57911074|NCT03768583|OTHER|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
57911075|NCT05235230|DRUG|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
57911076|NCT05235230|DRUG|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
57911077|NCT01959334|DRUG|Nasal Glucagon (NG)|
58261190|NCT01300299|RADIATION|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (\> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
58261191|NCT00519233|DRUG|AGS-1C4D4|IV
57709253|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
57709254|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
57911078|NCT01959334|DRUG|Glucagon IM|
57911079|NCT02830971|PROCEDURE|Doing Different ICU techniques and skills|
57911080|NCT05060978|BEHAVIORAL|Watch your Weight During the Holidays Program|Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
57911081|NCT05060978|OTHER|Relative 5:2 Fasting|Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
57911082|NCT05060978|OTHER|Control Group|Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
57911083|NCT02977637|PROCEDURE|Feraheme MRI/MRA|
58261192|NCT05630521|BEHAVIORAL|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
58261193|NCT04722991|DRUG|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
58261194|NCT04722991|OTHER|Placebo|Oral dose of matching placebo
57911084|NCT00588653|DEVICE|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
57709255|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
57709256|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
58261195|NCT04491747|DIAGNOSTIC_TEST|functional capacity|Six minute walk test used assessment of functional capacity.
58382428|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
57709257|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
57709258|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
57709259|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
57709260|NCT00003724|PROCEDURE|surgical procedure|
57709261|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
57709262|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
57911085|NCT02369146|DRUG|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
57911086|NCT04867928|DRUG|Venetoclax+azacitidine|subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
57911087|NCT04452760|OTHER|Physical exercise|Physical exercise intervention
57911088|NCT04452760|OTHER|Testing sessions|Testing sessions
58058977|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
58058978|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
58058979|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
58261196|NCT03544931|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
57911089|NCT05246280|DRUG|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
58261197|NCT03544931|DEVICE|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
58261198|NCT06648122|OTHER|laboratory results|evaluation of laboratory results (hemogram results:WBC, RBC, Hematocrit, Monocyte count, Neutrophil count, Lymphocyte count, Platelet count, PDW, MPV, MLR, NLR, NMR, PLR, PMR, PNR, PWR, SII)
57911090|NCT04027192|DRUG|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
57911091|NCT04027192|DRUG|BAY2328065 tablet|50 mg tablet, orally
57911092|NCT04027192|DRUG|Placebo LSF|Matching Placebo LSF, orally
57911093|NCT04027192|DRUG|Placebo tablet|Matching Placebo tablet, orally
57911094|NCT04027192|DRUG|Midazolam|1 mg per day, orally
57911095|NCT00801931|DRUG|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
57911096|NCT00801931|RADIATION|Total Body Irradiation|
57911097|NCT00801931|DRUG|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
57911098|NCT00801931|DRUG|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
58058980|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
57911099|NCT00801931|DRUG|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
57911100|NCT00801931|DRUG|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
57911101|NCT00801931|DRUG|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
57911102|NCT00801931|DRUG|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG \[horse\]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
57911103|NCT00801931|DRUG|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
57911104|NCT00801931|DRUG|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
57911105|NCT05334251|OTHER|combined spinal-epidural anesthesia|Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
57911106|NCT00616057|DIETARY_SUPPLEMENT|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
57911107|NCT00616057|DIETARY_SUPPLEMENT|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
58261199|NCT02499146|DRUG|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
58261200|NCT02499146|DRUG|Letrozole|2.5 mg , orally once daily (continuously)
57709263|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
57709264|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
57709265|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
58382429|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
57709266|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
57911108|NCT02455154|DRUG|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
58058981|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
58058982|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
58058983|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
58261201|NCT02728583|DIETARY_SUPPLEMENT|Margarine enriched with plant sterols and fish oil|
58261202|NCT02728583|DIETARY_SUPPLEMENT|Placebo margarine|
58261203|NCT03144843|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
57709267|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
57709268|NCT00017758|DRUG|Pravastatin sodium|
57709269|NCT00017758|DRUG|Simvastatin|
57709270|NCT00017758|DRUG|Atorvastatin calcium|
57709271|NCT00017758|DRUG|Nelfinavir mesylate|
58261204|NCT03144843|DRUG|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
58261205|NCT00867828|DIETARY_SUPPLEMENT|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
58261206|NCT00867828|DIETARY_SUPPLEMENT|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
58261207|NCT00867828|DIETARY_SUPPLEMENT|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
57709272|NCT00017758|DRUG|Efavirenz|
57709273|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
57911109|NCT02455154|DRUG|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
57911110|NCT02455154|DRUG|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
58261208|NCT03994770|DIAGNOSTIC_TEST|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
58382430|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
58382431|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
58382432|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
58382433|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
58261209|NCT04450134|OTHER|Lactose|Placebo: Lactose capsules
58382434|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
58382435|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
58261210|NCT04450134|DRUG|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
58261211|NCT04450134|DRUG|Famotidine|H2 receptor antagonist: 40 mg Famotidine
58261212|NCT04450134|OTHER|High-intensity interval training (HIIT)|6 weeks HIIT
58382436|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
58382437|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
58382438|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
58382439|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
58382440|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
58382441|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
58382442|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
58382443|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
58058984|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
58261213|NCT06483048|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
58261214|NCT06483048|DRUG|Bendamustine|Given IV
58261215|NCT06483048|PROCEDURE|Biospecimen Collection|Undergo blood and possible ascites sample collection
58261216|NCT06483048|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58261217|NCT06483048|DRUG|Cyclophosphamide|Given IV
58261218|NCT06483048|PROCEDURE|Echocardiography|Undergo ECHO
58261219|NCT06483048|PROCEDURE|Leukapheresis|Undergo leukapheresis
58261220|NCT06483048|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58261221|NCT06483048|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58261222|NCT06483048|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58261223|NCT02266290|PROCEDURE|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
58261224|NCT02266290|DEVICE|Sport tex® kinesiotape|
58261225|NCT02266290|DEVICE|Pretape Cramer®|
58261226|NCT02375555|DRUG|Lenalidomide|
58382444|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
58382445|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
58382446|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
58382447|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
58382448|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
58382449|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
58382450|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
58382451|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
58382452|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
58382453|NCT03843151|DRUG|BI 1358894|tablet
58382454|NCT03843151|DRUG|Itraconazole|oral solution
58382455|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
58382456|NCT02135627|OTHER|Current standard therapy|
57709274|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
57709275|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
57709276|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
57709277|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
58058985|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
58261227|NCT02375555|DRUG|Elotuzumab|
58261228|NCT02375555|DRUG|Bortezomib|
58261229|NCT02375555|DRUG|Dexamethasone|
58261230|NCT02375555|PROCEDURE|Stem Cell Mobilization|
58261231|NCT05644821|OTHER|complex intervention|"The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist."
58261232|NCT05644821|OTHER|current clinical practice|current clinical practice
58261233|NCT06620094|OTHER|diabetes education videos|In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
58261234|NCT04653753|DEVICE|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
58261235|NCT05570851|BEHAVIORAL|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
58261236|NCT05570851|BEHAVIORAL|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
58261237|NCT06629298|OTHER|5Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 5 Hz."
58382457|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
57709278|NCT04497987|DRUG|Bamlanivimab|Administered IV.
57709279|NCT04497987|DRUG|Placebo|Administered IV.
57709280|NCT04497987|DRUG|Etesevimab|Administered IV.
58058986|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
57709281|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
57709282|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
58058987|NCT05825365|DRUG|Selumetinib|Selumetinib
58058988|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
58261238|NCT06629298|OTHER|2 Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 2 Hz."
58261239|NCT02340442|OTHER|Obstetrical care parameters|
58261240|NCT02340442|OTHER|DVA measurements|
58261241|NCT02340442|OTHER|Fundus photographs|
58261242|NCT02407457|DEVICE|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
58261243|NCT02407457|DEVICE|FDA Approved EVAR AAA Graft Systems|
58261244|NCT06649123|DIAGNOSTIC_TEST|Oricol Test|Assessment of diagnostic accuracy of Oricol Sampling device for triage in patients with suspected lower gastrointestinal cancer
58261245|NCT04598451|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
58261246|NCT04598451|OTHER|Placebo|Subcutaneous injection of placebo
58261247|NCT04598451|DRUG|prednisone|Oral prednisone tablets
58261248|NCT05306782|DEVICE|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
58261249|NCT05306782|BEHAVIORAL|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
58261250|NCT04955665|PROCEDURE|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
58261251|NCT04955665|PROCEDURE|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
58261252|NCT03942068|DRUG|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
58261253|NCT03942068|DRUG|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
58261254|NCT05622929|BEHAVIORAL|Digitally-enabled Multifaceted Quality Improvement Intervention|"Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~* Knowledge of effective lipid lowering therapies~* Clinical decision support~* Audit and feedback on adherence to optimal clinical management~* Audit and feedback on LDL-C control"
58261255|NCT05622929|BEHAVIORAL|Usual care|Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
58261256|NCT06413056|DRUG|Micafungin|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
58261257|NCT06413056|DRUG|Amphotericin B|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
58261258|NCT06620913|OTHER|Description of clinical, immunological and tumor features of patients harboring CV2 Abs|This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
58261259|NCT06260267|DRUG|Microbiota suspension|Microbiota suspension
58261260|NCT06260267|DRUG|Microbiota capsule|Microbiota capsule
58261261|NCT06260267|DRUG|Placebo suspension|Placebo suspension
57709283|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
58058989|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
58261262|NCT06260267|DRUG|Placebo capsule|Placebo capsule
57709284|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
57709285|NCT00033384|DRUG|CI-1040|
57709286|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
58261263|NCT04766957|DEVICE|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
58058990|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
58058991|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
58058992|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
58058993|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
58058994|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
58058995|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
58058996|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
58058997|NCT05673785|DRUG|Prednisone|Prednisone tablets
57709287|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
57709288|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
58058998|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
58058999|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
58059000|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
58059001|NCT00396344|OTHER|Çontrol|Intravenous saline
58059002|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
58059003|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
58059004|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
58059005|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
58059006|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
58059007|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
58059008|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
58059009|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
58261264|NCT01885286|PROCEDURE|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
58261265|NCT05860439|PROCEDURE|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
58261266|NCT06424275|DIAGNOSTIC_TEST|Risk-based screening algorithm|Risk-based screening algorithm
58261267|NCT06618430|OTHER|None (Observational Study)|None (Observational Study)
58261268|NCT01752881|BIOLOGICAL|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
58261269|NCT01752881|BIOLOGICAL|AdimFlu-S|
58261270|NCT00036491|DRUG|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
58261271|NCT03783130|BIOLOGICAL|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
58261272|NCT03783130|OTHER|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
58059010|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
58059011|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
58261273|NCT06342011|BEHAVIORAL|Anti-inflammatory diet group|"Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later."
58261274|NCT00514904|BIOLOGICAL|Nimenrix|Single dose, intramuscular injection
58261275|NCT00514904|BIOLOGICAL|Mencevax|Single dose, subcutaneous injection
58261276|NCT02193139|DRUG|WL8713, 6 mg|
57911111|NCT02901782|PROCEDURE|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
58382458|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
57911112|NCT06602089|DEVICE|Arterial pressure monitoring|We will record intraarterial arterial pressure, finger-sensor arterial pressure and oscillometric arterial pressure in all included patients.
58261277|NCT02193139|DRUG|WL8713, 12 mg|
58261278|NCT02193139|DRUG|WL8713, 18 mg|
58261279|NCT02193139|DRUG|WL8713, 24 mg|
58382459|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
58382460|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
57911113|NCT05764941|DRUG|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
57911114|NCT05764941|DRUG|Pyrotinib|400mg, oral, every day.
57911115|NCT05764941|DRUG|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
58059012|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
58059013|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
58059014|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
58059015|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
58059016|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
58059017|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
58261280|NCT02193139|DRUG|Placebo|
58261281|NCT06620770|OTHER|questionnaires|Morisky and SF12 Questionnaires delivery at inclusion, 6, 12 and 18 months
58261282|NCT00878150|BEHAVIORAL|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
58261283|NCT00878150|BEHAVIORAL|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
58382461|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
58382462|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
58382463|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
58261284|NCT00510016|DRUG|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
58261285|NCT06623617|BEHAVIORAL|Three-dimensional breathing training|Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
58382464|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
58382465|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
58382466|NCT00994825|DRUG|Levosimendan|
58382467|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
58382468|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
58382469|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
58382470|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
58261286|NCT06623617|BEHAVIORAL|control group：Health education|Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
58261287|NCT05670223|OTHER|Fit&Strong Exercise Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
58261288|NCT01129349|DRUG|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
57911116|NCT02950064|DRUG|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
58261289|NCT02027662|DRUG|Osvaren Granules|
58261290|NCT02027662|DRUG|Osvaren film-coated tablets|
58261291|NCT02545361|DRUG|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
58261292|NCT06622057|DRUG|D07001-Softgel Capsules|D07001-softgel capsule is an oral gemcitabine.
58261293|NCT06622057|DRUG|Placebo|Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
58261294|NCT06622057|COMBINATION_PRODUCT|Capecitabine|Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.
58261295|NCT05854303|BEHAVIORAL|Opioid cessation|opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
58261296|NCT05854303|OTHER|No opioid cessation|Subjects will not stop taking opioids
58261297|NCT02757937|BEHAVIORAL|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
58059018|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
58261298|NCT02757937|OTHER|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
58261299|NCT06620276|BEHAVIORAL|Acceptance and Commitment Therapy|8 sessions of one hour of Acceptance and Commitment Therapy delivered one on one by a licensed psychologist with experience and training in this intervention.
58261300|NCT06620887|OTHER|Evaluate the impact of HEMAGO program on maternal morbidity and mortality in sickle cell disease patients during their pregnancies.|"HEMAGO pregnancy monitoring is a joint consultation program between the sickle cell disease hematologist and an obstetrician. This program was implemented in April 2016 at the Croix-Rousse maternity Hospital. This program offers close, complete and personalized pregnancy monitoring for each patient with major sickle cell syndrome.~These are follow-up consultations once a month until 24 weeks then every 15 days until delivery. At each consultation, doctors evaluate a general and obstetric clinical examination. The team establishes a precise schedule adapted to each patient for pregnancy monitoring : monthly blood tests, monthly ultrasounds with maternal and fetal Doppler, adaptation of basic treatment, transfusion exchange program according to eligibility criteria, and organization of childbirth."
58261301|NCT05840315|DIETARY_SUPPLEMENT|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
58382471|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
57911117|NCT04866446|DEVICE|endotracheal intubation and laringeal mask airway insertion|endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
58059019|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
58059020|NCT05021666|DRUG|Placebo|matching placebo
58059021|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
58261302|NCT05840315|PROCEDURE|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
58261303|NCT05840315|PROCEDURE|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
58261304|NCT05840315|PROCEDURE|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trials 1 and 2, progressive strength training of the gluteal muscles is carried out in the form of hip abduction from a sitting position, using a hip abduction machine, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press."
58261305|NCT00166257|DEVICE|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
58059022|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
58059023|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
58059024|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
58059025|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
58261306|NCT00166257|DRUG|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
58382472|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
58059026|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
58382473|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
58382474|NCT04294225|DRUG|Anastrozole|Given PO
58059027|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
58382475|NCT04294225|DRUG|Letrozole|Given PO
58382476|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
58382477|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
58261307|NCT06597565|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.
58261308|NCT06597565|DRUG|ACR-368|ACR-368 is an experimental drug.
58261309|NCT06545656|DRUG|Doxycycline|Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.
58261310|NCT06616025|COMBINATION_PRODUCT|NTX-001 (PEG-Fusion)|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
58261311|NCT03912714|PROCEDURE|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (\>20).
58261312|NCT03912714|PROCEDURE|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
58261313|NCT06194747|OTHER|Quality improvement bundle|(1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams
58261314|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles with central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.
58261315|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles without central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.
58261316|NCT06295627|OTHER|There were no interventions in retrospective analysis|A retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. A single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.
58261317|NCT03625635|OTHER|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
57911118|NCT05769283|OTHER|Platelet Rich Plasma|Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
57911119|NCT05769283|OTHER|Saline|Normal Saline to be injected into the anterior vaginal wall and periclitoral area
58261318|NCT00562289|DRUG|aspirin|during the follow up
58261319|NCT00562289|DRUG|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
58261320|NCT00562289|DEVICE|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
57911120|NCT05610332|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
57911121|NCT05610332|DRUG|Albumin Taxol|Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle
57911122|NCT05610332|DRUG|FLOT scheme|"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"
58059028|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
58261321|NCT00632684|BEHAVIORAL|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
58261322|NCT00632684|BEHAVIORAL|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
58261323|NCT02453217|BEHAVIORAL|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
57709289|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
57911123|NCT04735328|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
58261324|NCT02453217|OTHER|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
58261325|NCT01917812|DEVICE|Digital Activity Tracker|
58261326|NCT01917812|OTHER|Smart Text Messaging|
58261327|NCT06293118|DEVICE|Ischemic conditioning group|The ischemic conditioning protocol will consist of a period of 12 weeks (24 sessions) with a frequency of 2 weekly sessions lasting between 15 and 20 minutes each. Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) with customized ischemia programs, partially restricting blood flow through special pressure cuffs that are internally valved, providing greater comfort and safety for these patients who typically have stiffness in the affected limb and localized muscle pain. In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
58261328|NCT06293118|DEVICE|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer
58261329|NCT05504486|DRUG|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
58261330|NCT04390672|DEVICE|SUPRAFLEX Cruz|Percutaneous Coronary Intervention for multivessel disease
58261331|NCT04390672|DEVICE|SYNERGY|Percutaneous Coronary Intervention for multivessel disease
58261332|NCT03091881|DRUG|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
58261333|NCT03091881|DRUG|Placebos|Placebos will be given 10 min before spinal block
58261334|NCT00792376|DRUG|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
58382478|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
58382479|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
58261335|NCT00792376|DRUG|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
58261336|NCT02703272|DRUG|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
57911124|NCT04735328|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
58382480|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
58382481|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
58382482|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
58382483|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
57709290|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
57709291|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
57709292|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
57911125|NCT04735328|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
57911126|NCT03070951|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
58261337|NCT02703272|DRUG|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
58261338|NCT02703272|DRUG|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
58261339|NCT02703272|DRUG|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
58261340|NCT02703272|DRUG|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
58261341|NCT02703272|DRUG|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
58261342|NCT02703272|DRUG|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
58261343|NCT02703272|DRUG|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
58261344|NCT02863107|PROCEDURE|Biospecimen Collection|Undergo collection of blood or saliva samples
58261345|NCT02863107|OTHER|Medical Chart Review|Review of medical charts
58261346|NCT02863107|OTHER|Quality-of-Life Assessment|Ancillary studies
58382484|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
58382485|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
58382486|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
58382487|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
58382488|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
58382489|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
58261347|NCT02863107|OTHER|Questionnaire Administration|Complete questionnaires
58261348|NCT06124248|BEHAVIORAL|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention."
58261349|NCT05923242|BEHAVIORAL|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
58261350|NCT00199797|DRUG|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
58261351|NCT00199797|DRUG|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
58261352|NCT00199797|DRUG|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
58382490|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
58382491|NCT01662739|BEHAVIORAL|Questionnaire|
58382492|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
58382493|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
58382494|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
58382495|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
58382496|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
58382497|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
58382498|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
58261353|NCT00199797|DRUG|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
58382499|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
58261354|NCT04962724|DRUG|Radiolabelled Xevinapant 200 mg (Oral Solution)|\[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.
57709293|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
58261355|NCT04962724|DRUG|Radiolabelled Xevinapant 100 μg (IV Solution)|100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].
57911127|NCT03070951|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
57911128|NCT03070951|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
58261356|NCT04962724|DRUG|Xevinapant 200 mg (Oral Solution)|Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
57911129|NCT03070951|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
57911130|NCT05559931|DRUG|N,N-Dimethyltryptamine|IV infusion over 6 hours
58382500|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
58382501|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
58382502|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
58382503|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
58382504|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
57709294|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
58261357|NCT00534079|DRUG|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
58261358|NCT00534079|DRUG|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
58261359|NCT06591884|DRUG|Tacrolimus modified-release|0.08% tacrolimus nanoencapsulated aqueous solution spray
58261360|NCT06591884|DRUG|tacrolimus ointment 0.1%|0.1% free tacrolimus commercial ointment
58261361|NCT00006024|DRUG|lomustine|
58382505|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
58382506|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
58382507|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
58382508|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
57709295|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
57709296|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
57709297|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
57911131|NCT05559931|DRUG|Placebo|Placebo infusion over 6 hours
57911132|NCT00269347|PROCEDURE|Chiropractic Spinal Manipulation|
57911133|NCT00269347|PROCEDURE|Exercise|
57911134|NCT00269347|BEHAVIORAL|Self-care|
57911135|NCT00602563|BEHAVIORAL|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
57911136|NCT00602563|BEHAVIORAL|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
58261362|NCT00006024|DRUG|temozolomide|
58261363|NCT02726438|DRUG|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
57709298|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
57911137|NCT00602563|BEHAVIORAL|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
57911138|NCT00602563|BEHAVIORAL|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
57911139|NCT05653570|DIAGNOSTIC_TEST|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
57911140|NCT05653570|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
57911141|NCT01227382|PROCEDURE|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
57911142|NCT00432666|DRUG|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
57911143|NCT00432666|DRUG|Placebo|Placebo
57911144|NCT03774485|DEVICE|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
58261364|NCT06622811|OTHER|Students' Knowledge about Virtual Reality Questionnaire|"Part I: Personal Characteristics of Nursing Students:~It covers; age and gender.~Part II: Students' Knowledge about Virtual Reality Questionnaire:~This part will used to assess students' knowledge related to virtual reality that includes a definition of virtual reality, history of virtual reality, advantages and disadvantages of virtual reality on nursing education and equipment used for virtual reality and the effect virtual reality on future of education~Scoring system:~Respondents' answers will be scored (0) for incorrect answers, and (1) for correct answers. The overall items scores will be summed up and categorized according to the total percentages of unsatisfactory (\<60%) and satisfactory (≥60%)."
58382509|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
58382510|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
58382511|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
58382512|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
58382513|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
57911145|NCT02939612|BEHAVIORAL|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
57911146|NCT03650309|DEVICE|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
57911147|NCT04696380|DRUG|Nicotine|Participants will sample high vs low nicotine.
57911148|NCT04696380|DEVICE|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
57911149|NCT06474728|OTHER|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
57911150|NCT02413333|DEVICE|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
57911151|NCT02413333|DEVICE|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
57911152|NCT02413333|DEVICE|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
57911153|NCT05918237|OTHER|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
58382514|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
58382515|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
58382516|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
58382517|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
57709299|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
57709300|NCT00077168|DRUG|anastrozole|
57709301|NCT00077168|DRUG|tamoxifen citrate|
57911154|NCT02211885|DRUG|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
57911155|NCT02173847|PROCEDURE|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
57911156|NCT02173847|DEVICE|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
58059029|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
58059030|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
58059031|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
58261365|NCT06622811|OTHER|California Critical Thinking Disposition Inventory (CCTDI)|"It will consist of 24 items classify into 7 dimensions grouped as follows; truth-seeking (3 items); open-mindedness (4 items); analyticity (3 items); systematicity (4 items); critical thinking self-confidence (4 items); inquisitiveness (3 items); and cognitive maturity (3 items).~Scoring system:~Students asked to respond to all items with six points Likert scale as follows; strongly disagree = 1, disagree= 2, neutral = 3, sometimes agree = 4, agree = 5, and strongly agree= 6. The overall items scores will be summed up and categorized according to the total percentages of satisfactory critical thinking (≥75%) and unsatisfactory critical thinking (\<75%)."
58261366|NCT03815591|DEVICE|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
58382518|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
58382519|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
57709302|NCT00077168|PROCEDURE|adjuvant therapy|
57911157|NCT02173847|DEVICE|Diode laser|Low power, near infrared diode laser for welding the surgical wound
57911158|NCT01322802|BIOLOGICAL|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
58382520|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
57709303|NCT00077168|RADIATION|radiation therapy|
57709304|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
57709305|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
57911159|NCT01322802|OTHER|laboratory biomarker analysis|Correlative studies
58059032|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
58261367|NCT06619158|PROCEDURE|Crown modification|Zirconia glaze removal and polish after crown removal to reduce roughness and prohibit plaque adhesion
58382521|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
58382522|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
57709306|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
57709307|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
57709308|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
57709309|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
57709310|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
57911160|NCT02376374|OTHER|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
57911161|NCT04973644|DEVICE|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
57911162|NCT04954404|DEVICE|transcatheter mitral valve repair/transcatheter mitral valve replacement|transcatheter mitral valve repair/transcatheter mitral valve replacement
57911163|NCT04465747|OTHER|Publications|Reviewing published evidence
57911164|NCT01789151|DEVICE|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
58382523|NCT00348998|BIOLOGICAL|bevacizumab|
57911165|NCT01423032|DRUG|bendamustine|100 mg/m² iv, day 1+2, q4w
58382524|NCT00348998|DRUG|bicalutamide|
58382525|NCT00348998|DRUG|goserelin acetate|
58382526|NCT00348998|RADIATION|radiation therapy|
58066622|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
58261368|NCT01179841|BEHAVIORAL|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
58261369|NCT01179841|BEHAVIORAL|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
58261370|NCT01179841|BEHAVIORAL|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
58261371|NCT01125670|DRUG|YM150|oral
58261372|NCT03360006|DRUG|ABBV-744|Tablet, oral
58261373|NCT04484636|DIAGNOSTIC_TEST|FoundationOne®CDx and FoundationOne®Liquid|FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient's cancer. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. FoundationOne®Liquid is a liquid biopsy test for solid tumors that analyzes circulating tumor DNA (ctDNA) in blood.
58261374|NCT01961895|PROCEDURE|Continuous lumbar plexus (LP) block analgesia|
58261375|NCT01961895|DRUG|Intravenous patient-controlled analgesia|
58261376|NCT06618950|BEHAVIORAL|physical activity|The key factor that distinguishes this study from others is its comprehensive examination of the effects of regular physical activity on late adolescents, not only in terms of physical health but also regarding healthy lifestyle behaviors, self-esteem, and psychological well-being. While other studies typically focus on the benefits of physical activity for physical health, this research considers the broader psychological and social development of adolescents, offering a wider perspective. Additionally, its emphasis on the sustainability of a planned and structured physical activity regimen, along with its approach to transforming physical activity into a lifestyle, represents a significant difference.
58261377|NCT00043030|PROCEDURE|psychosocial assessment and care|
58261378|NCT02175134|OTHER|Blood and Ascites ELISPOT|
58261379|NCT02018172|DRUG|somatropin|
58261380|NCT04889157|DRUG|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
58261381|NCT04889157|DRUG|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
58261382|NCT00346047|DRUG|Placebo|Corresponding placebo is applied for 12weeks
58261383|NCT00346047|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
58261384|NCT01490606|OTHER|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
58066623|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
58261385|NCT01490606|OTHER|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
58261386|NCT01864876|BIOLOGICAL|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
58261387|NCT01864876|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
58261388|NCT01864876|BIOLOGICAL|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
58261389|NCT04505722|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.
58261390|NCT04505722|OTHER|Placebo|Participants will receive Placebo.
57911166|NCT01423032|DRUG|Fludarabine|25 mg/m² iv, days 1-5, q4w
58261391|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
58261392|NCT05919472|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
58261393|NCT05919472|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
58261394|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
58261395|NCT05919472|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
58382527|NCT00267306|DRUG|Visilizumab|
57911167|NCT00326833|DRUG|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
58261396|NCT02202044|DEVICE|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
58261397|NCT00169715|PROCEDURE|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
58261398|NCT03101826|BEHAVIORAL|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
58261399|NCT06499610|DRUG|Irinotecan Hydrochloride Liposome Injection|At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
58261400|NCT06645353|DEVICE|MSOT Multispectral Optoacoustic Tomography|MSOT Multispectral Optoacoustic Tomography, single-wavelength, HbT, Hb, HbO2, collagen and mSO2 (700-1.100 nm wavelength range, in 10 nm increments) in the tibialis anterior and flexor hallucis brevis, at multiple time-points before, during and after interventional LER Lower Extremity Revascularization .
58261401|NCT06267560|DRUG|TQJ230|TQJ230 80mg QM s.c.
58261402|NCT06267560|DRUG|Placebo|matching placebo
58261403|NCT05838339|BEHAVIORAL|Healthy Sleep Intervention|The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
58261404|NCT01084317|OTHER|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
58261405|NCT05562765|OTHER|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
58261406|NCT04754438|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy
58261407|NCT04754438|BEHAVIORAL|Mental Health Coaching|Electronically delivered mental health coaching
58261408|NCT06216535|DRUG|Escitalopram|Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
57709311|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
57709312|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
57709313|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
57709314|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
57709315|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
57709316|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
57709317|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
57911168|NCT00092352|DRUG|MK0966, rofecoxib|
58261409|NCT06216535|DRUG|Placebo|Inactive placebo comparator
57911169|NCT00092352|DRUG|Comparator: celecoxib, placebo|
57709318|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
57709319|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
57911170|NCT01116102|DRUG|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
57911171|NCT00591370|DRUG|Temozolomide (TMZ)|One group treatment study
58261410|NCT02638571|OTHER|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
58382528|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
58382529|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
57911172|NCT03857074|DEVICE|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
58261411|NCT00272207|DRUG|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
58261412|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
58382530|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
58382531|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
58382532|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
58382533|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
58382534|NCT00088270|DRUG|OSI-7904L|
58382535|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
58382536|NCT02963883|OTHER|SVO2 group / control group|
58382537|NCT00225862|DRUG|ropinirole|
58382538|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
58382539|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
58382540|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
58382541|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
58382542|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
58382543|NCT03299478|OTHER|Will look for immune infiltration|
58382544|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
58261413|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
58382545|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
58261414|NCT00251082|DRUG|Placebo|Placebo
58382546|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
58382547|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
57709320|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
58261415|NCT03886961|DEVICE|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
58382548|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
58382549|NCT02453698|OTHER|Placebo|Lactose Placebo
58382550|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
57709321|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
58261416|NCT00002104|DRUG|Thalidomide|
58261417|NCT01046279|DRUG|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
58382551|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
58382552|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
58261418|NCT06016569|DIAGNOSTIC_TEST|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
58261419|NCT06016569|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
58261420|NCT06016569|PROCEDURE|LDCT|LDCT scan will be performed.
58261421|NCT06016569|DIAGNOSTIC_TEST|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
57709322|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
58261422|NCT06016569|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed.
58261423|NCT04393220|DRUG|Bevacizumab Injection|15mg/kg (Q3W)
58261424|NCT04393220|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
58261425|NCT00546676|DRUG|Telithromycin|
58261426|NCT02852200|OTHER|SEGAm|
58261427|NCT04115917|DEVICE|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
58261428|NCT04115917|DEVICE|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
58261429|NCT05798013|BEHAVIORAL|Digital health management|The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
57709323|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
57709324|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
58261430|NCT00368693|DEVICE|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
58261431|NCT02405169|DEVICE|4 vs 6 implant treatment in the maxilla|
58261432|NCT01940315|BIOLOGICAL|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
58261433|NCT01940315|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
57709325|NCT01973101|RADIATION|Radiotherapy|45 Gy
58261434|NCT03603951|DRUG|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
58261435|NCT05026580|BEHAVIORAL|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
58261436|NCT06501820|DEVICE|Transcranial direct current stimulation|2mA transcranial direct current stimulation, applied bilaterally on the scalp, over the brain vestibular cortex
57709326|NCT01973101|RADIATION|Brachytherapy|80 Gy
57709327|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
57709328|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
57709329|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
57709330|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
57709331|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
57709332|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
57709333|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
57709334|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
57709335|NCT01086592|OTHER|No intervention|Daily life activities
57709336|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
57709337|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
57709338|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
58261437|NCT05659862|BEHAVIORAL|Digitally assisted behavioral physical activity intervention|"Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward"
58382553|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
58382554|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
58382555|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
58382556|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
58382557|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
58382558|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
58382559|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
58382560|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
58382561|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
58382562|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
58382563|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
58382564|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
58382565|NCT02148263|DEVICE|senofilcon A|
58382566|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
58382567|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
58059033|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
58382568|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
58382569|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
58382570|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
58382571|NCT00001964|DRUG|ATG|ATG
57709339|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
58382572|NCT00001964|DRUG|MMF|MMF
58382573|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
58382574|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
58382575|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
58382576|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
58382577|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
58382578|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
58382579|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
58382580|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
58382581|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
58382582|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
58261438|NCT05659862|BEHAVIORAL|Education|"Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website."
58261439|NCT05168332|BEHAVIORAL|patellar taping combined with isometric strength training|patellar taping combined with isometric strength training
58261440|NCT05168332|BEHAVIORAL|sham patellar taping combined with isometric strength training|sham patellar taping combined with isometric strength training
58261441|NCT01845168|OTHER|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
58261442|NCT01845168|DEVICE|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
58382583|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
58382584|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
58382585|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
58382586|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
58261443|NCT01845168|DEVICE|Computer-alert|
58261444|NCT00003913|BIOLOGICAL|anti-thymocyte globulin|
58261445|NCT00003913|BIOLOGICAL|filgrastim|
57709340|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
58261446|NCT00003913|DRUG|busulfan|
58261447|NCT00003913|DRUG|cyclophosphamide|
58261448|NCT00003913|DRUG|methylprednisolone|
58261449|NCT00003913|PROCEDURE|umbilical cord blood transplantation|
58261450|NCT00003913|RADIATION|radiation therapy|
58261451|NCT01607229|OTHER|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
58261452|NCT06621381|BEHAVIORAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
58261453|NCT05565040|PROCEDURE|Circumcision in concealed penis|comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
57911173|NCT03620370|DRUG|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
58261454|NCT04641260|DRUG|Fezolinetant|Oral
58261455|NCT01362244|DRUG|Mepolizumab|750 mg of mepolizumab by IV infusion
58261456|NCT01362244|DRUG|Placebo|Placebo by IV infusion
58261457|NCT01362244|DRUG|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
57911174|NCT02043964|PROCEDURE|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
57911175|NCT00016939|DRUG|alvocidib|
58261458|NCT00000238|DRUG|Buprenorphine|
58261459|NCT01844180|DRUG|ONO-2952|
58382587|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
58382588|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
58261460|NCT01844180|DRUG|ONO-2952 Matching Placebo|
58261461|NCT06114875|BEHAVIORAL|Peer support intervention|"Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress."
58382589|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
58382590|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
57911176|NCT06448832|DIAGNOSTIC_TEST|Ultrasound|An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
58382591|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
58382592|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
58382593|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
57911177|NCT01466933|BEHAVIORAL|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
57911178|NCT01466933|BEHAVIORAL|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
57911179|NCT00832182|DRUG|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
58382594|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
58382595|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
58261462|NCT01389570|PROCEDURE|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
58261463|NCT00336024|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
57709341|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
58059034|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
58261464|NCT00336024|DRUG|Carboplatin|Given IV
58261465|NCT00336024|DRUG|Cisplatin|Given IV
58261466|NCT00336024|DRUG|Cyclophosphamide|Given IV
58261467|NCT00336024|DRUG|Etoposide|Given IV
58261468|NCT00336024|BIOLOGICAL|Filgrastim|Given IV or SC
58261469|NCT00336024|OTHER|Laboratory Biomarker Analysis|Correlative studies
58261470|NCT00336024|DRUG|Leucovorin Calcium|Given IV or orally
58261471|NCT00336024|DRUG|Methotrexate|Given IV
58261472|NCT00336024|OTHER|Quality-of-Life Assessment|Ancillary studies
58261473|NCT00336024|DRUG|Thiotepa|Given IV
58261474|NCT00336024|DRUG|Vincristine Sulfate|Given IV
58261475|NCT03761758|DEVICE|Spectacle lenses|Spectacle lenses with clear central apertures
58261476|NCT00006013|DRUG|semaxanib|
57709342|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
57709343|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
58261477|NCT05132712|DRUG|Losartan Potassium|ACE inhibitor
58261478|NCT05132712|DRUG|multi-vitamins|placebo drug
58261479|NCT05393115|OTHER|Square wave breathing|difference in time to failure from the two breathing modes
58261480|NCT06006494|OTHER|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
58261481|NCT06006494|OTHER|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
58261482|NCT06006494|OTHER|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
58261483|NCT02464761|DRUG|Visudyne|
58261484|NCT05081700|DRUG|All patients in the study will be treated with ocrelizumab|300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
58261485|NCT06649058|OTHER|Systemic Therapy|Participants will receive systemic therapy as a standard of care therapeutic option
58261486|NCT06649058|RADIATION|Stereotactic Radiosurgery|Participants will receive systemic therapy as a standard of care therapeutic option
58261487|NCT06630078|DEVICE|Wevosys acoustic analysis|Recording of voice signal of subjects enrolled
58261488|NCT04760288|DRUG|Pralsetinib|Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
58261489|NCT04760288|DRUG|Cabozantinib|Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
58261490|NCT04760288|DRUG|Vandetanib|Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
57911180|NCT00832182|DRUG|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
57911181|NCT05004896|DRUG|Ketamine Hydrochloride|50 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
57911182|NCT05004896|DRUG|Midazolam Hydrochloride|50 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
57911183|NCT04059653|DEVICE|Electrical stimulation|Electrical stimulation device
57911184|NCT04059653|OTHER|Treatment as usual|GP treatment as usual
57911185|NCT00423930|BIOLOGICAL|bevacizumab|
57911186|NCT00423930|DRUG|cisplatin|
57911187|NCT00423930|PROCEDURE|conventional surgery|
58261491|NCT05918991|BEHAVIORAL|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
58382596|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
57709344|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
57709345|NCT02584309|DRUG|Dexrazoxane|
57709346|NCT02584309|DRUG|Doxorubicin|
57709347|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
57911188|NCT00423930|RADIATION|intensity-modulated radiation therapy|
57911189|NCT02199704|OTHER|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study."
57911190|NCT05963139|DRUG|Bupivacaine|US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
57911191|NCT05963139|DRUG|Morphine Sulfate|In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
58059035|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
58059036|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
57709348|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
57911192|NCT00625248|DRUG|Antithrombotics|With or without or discontinuted use of Antithrombotics
57911193|NCT01885520|DIETARY_SUPPLEMENT|fasting condition|eperisone SR tablet 75mg administrated under fasting
57911194|NCT01885520|DIETARY_SUPPLEMENT|fed condition|eperisone SR tablet 75mg administrated fed condition
57709349|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
57709350|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
57911195|NCT05599503|BEHAVIORAL|Behavioral Interventions|Traditional SimpleC Wellness
57911196|NCT05599503|BEHAVIORAL|Robot Interventions|Robot interventions
57911197|NCT05444959|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
57911198|NCT05444959|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
57911199|NCT03494478|OTHER|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
57911200|NCT03494478|OTHER|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
57911201|NCT03494478|OTHER|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
57911202|NCT02877329|BEHAVIORAL|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
58059037|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
58059038|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
58059039|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
58382597|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
58059040|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
58059041|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
58059042|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
58059043|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
58059044|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
58059045|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
58059046|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
58059047|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
58261492|NCT05918991|OTHER|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
58261493|NCT03150992|DIETARY_SUPPLEMENT|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars \& sweeteners.
58261494|NCT00515359|PROCEDURE|Intermittent Propofol Sedation|Intermittent versus continuous dosage
58382598|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
58261495|NCT00515359|PROCEDURE|Continuous Propofol Sedation|intermittent vs continuous dosage
58261496|NCT03813186|DRUG|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
58382599|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
57709351|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
57911203|NCT05344781|OTHER|Questionnaire|Questionnaire regarding relationship and sexual satisfaction
57911204|NCT01832285|DRUG|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
57911205|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
57911206|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
57911207|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
57911208|NCT00969709|DRUG|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
57911209|NCT02415673|DEVICE|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
58382600|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
57911210|NCT03516929|DIAGNOSTIC_TEST|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
57911211|NCT00623402|DRUG|Sorafenib|2x 400 mg orally per day (4 tablets)
57911212|NCT00623402|DRUG|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
58059048|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
58059049|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
58059050|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
58059051|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
57709352|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
57709353|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
57709354|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
57709355|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
57911213|NCT03912246|BIOLOGICAL|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
57911214|NCT03912246|PROCEDURE|lumbar puncture|collection of cerebrospinal fluid
58261497|NCT03813186|DRUG|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
58261498|NCT06145581|BEHAVIORAL|Supportive Care (home-based physical activity)|Receive health coaching
58382601|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
57911215|NCT03718130|COMBINATION_PRODUCT|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
57911216|NCT03718130|COMBINATION_PRODUCT|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
57911217|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
57911218|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
58059052|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
57709356|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
57709357|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
57709358|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
58059053|NCT04493229|DRUG|Oxytocin|IM Oxytocin
58261499|NCT06145581|OTHER|Exercise Intervention|Participate in home-based physical activity
58261500|NCT06145581|OTHER|telephone interview|Participate in a telephone interview
58261501|NCT06145581|OTHER|Remote Monitoring|Undergo remote monitoring
58261502|NCT06145581|PROCEDURE|Patient Monitoring|Monitor physical activity
58261503|NCT06145581|OTHER|Questionnaire Administration|Ancillary studies
58261504|NCT06145581|OTHER|Electronic Health Record Review|Ancillary studies
58261505|NCT06624098|PROCEDURE|Early TIPS|TIPS was performed within 72 hours after the endoscopic hemostasis.
58382602|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
57709359|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
57709360|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
58059054|NCT04493229|DRUG|Placebo|Placebo IM
58059055|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
58261506|NCT00538044|DRUG|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
58261507|NCT02632240|OTHER|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
58261508|NCT01295463|OTHER|questionnaire administration|
58261509|NCT01295463|OTHER|study of socioeconomic and demographic variables|
58261510|NCT01295463|PROCEDURE|assessment of therapy complications|
58261511|NCT01295463|PROCEDURE|fertility assessment and management|
58261512|NCT01295463|PROCEDURE|psychosocial assessment and care|
58261513|NCT01295463|PROCEDURE|quality-of-life assessment|
58261514|NCT04878432|DRUG|MBG453|Solution for intravenous infusion
58261515|NCT04878432|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
58261516|NCT04878432|DRUG|Decitabine|Solution for intravenous infusion
58261517|NCT04878432|DRUG|INQOVI (oral decitabine)|Tablet for oral administration
58261518|NCT02085616|BEHAVIORAL|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
58261519|NCT02085616|BEHAVIORAL|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
58261520|NCT06648083|OTHER|Food autonomy|Determine the age of acquisition of full oral feeding in extremely premature infants hospitalised in a neonatal unit where that applies a strategy of specific and individualized stimulation of orality.
58261521|NCT00478010|OTHER|counseling intervention|
58261522|NCT00478010|OTHER|study of socioeconomic and demographic variables|
58261523|NCT00478010|PROCEDURE|psychosocial assessment and care|
58261524|NCT00478010|PROCEDURE|quality-of-life assessment|
58382603|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
57709361|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
57709362|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
58382604|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
58382605|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
58382606|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
58382607|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
58382608|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
58382609|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
57709363|NCT05770037|DRUG|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
57709364|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
57709365|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
57709366|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
57709367|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
57709368|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
57709369|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
57709370|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
57709371|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
57709372|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
57709373|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
57709374|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
57709375|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
58059056|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
57709376|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
57709377|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
57709378|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
57709379|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
57709380|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
57709381|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
57709382|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
57709383|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
58261525|NCT04919824|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
58382610|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
58382611|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
58261526|NCT04919824|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
58261527|NCT06643767|DEVICE|Bexa and focus ultrasound|The Bexa exam uses pressure elastography to produce a map of the breast tissue's elasticity to identify any masses. Focused ultrasound is then used to further classify the mass into a BIRADS category.
58382612|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
58382613|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
57709384|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
58261528|NCT06624280|PROCEDURE|single-event multilevel surgery|surgical orthopedic approach where multiple deformities are corrected in one solution, often involving both lower limbs, to improve walking performance
58059057|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
58261529|NCT03475199|DEVICE|FabLife|"* A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility."
58261530|NCT06642389|OTHER|Sonoanatomical Structure Identification|ChatGPT-4 will analyze the ultrasound images to identify key anatomical landmarks such as nerves, muscles, blood vessels, and fascial planes that are critical for successful regional anesthesia. These structures will be labeled and compared to the expert anesthesiologist's assessment to determine accuracy.
58261531|NCT06642389|OTHER|Block Type Prediction|Based on the ultrasound images and the position of the probe, ChatGPT-4 will predict the type of regional anesthesia block being performed (e.g., supraclavicular block, femoral nerve block). These predictions will be compared to the actual block performed to evaluate the AI's accuracy.
58382614|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
57709385|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
58059058|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
58059059|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
58382615|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
58382616|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
58382617|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
58382618|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
58382619|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
58382620|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
58382621|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
57709386|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
57709387|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
57709388|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
57911219|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
58059060|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
58059061|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
58059062|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
58059063|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
58261532|NCT06642389|OTHER|Block Success Assessment|After analyzing the ultrasound images from the block application, ChatGPT-4 will assess whether the block was successfully administered. This assessment will be based on the correct placement of the needle, the spread of the anesthetic, and proximity to target structures. The AI's evaluation of block success will be compared to the expert anesthesiologist's judgment.
58261533|NCT01748617|OTHER|Controlled diet|1 week of controlled diet
58261534|NCT03722745|BEHAVIORAL|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
58261535|NCT03722745|BEHAVIORAL|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
58261536|NCT04987099|DIETARY_SUPPLEMENT|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
58261537|NCT04987099|DIETARY_SUPPLEMENT|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
58261538|NCT06620419|DEVICE|Perineal-applied electrical stimulation|Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
58261539|NCT06078449|DEVICE|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of \>20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves \& to reduce friction.
58382622|NCT00618735|DRUG|BIIB021|Twice daily dosing
58382623|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
58382624|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
58382625|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
58382626|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
58382627|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
57911220|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
58066624|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
58261540|NCT06078449|DRUG|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
58261541|NCT04638894|PROCEDURE|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
58382628|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
58382629|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
58382630|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
58382631|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
58382632|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
58382633|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
58382634|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
58382635|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
58382636|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
58382637|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
58382638|NCT00457678|DRUG|Visudyne|
58382639|NCT00457678|DRUG|Lucentis|
58382640|NCT00457678|DRUG|Dexamethasone|
58382641|NCT03691298|DEVICE|Suturefix Ultra and Suturefix Curved Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip
58382642|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
58382643|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
58382644|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
58382645|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
58382646|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
58382647|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
58382648|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
58382649|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
58382650|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
58382651|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
58382652|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
58382653|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
58382654|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
58382655|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
58382656|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
58382657|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
57911221|NCT03801915|DRUG|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
57911222|NCT03801915|PROCEDURE|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
58382658|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
58382659|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
58382660|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
58382661|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
58382662|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
58382663|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
58382664|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
58382665|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
58382666|NCT02454530|BIOLOGICAL|Nivestim®|
58382667|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
58382668|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
58382669|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
58382670|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
58382671|NCT01994746|DRUG|Nasal Glucagon|
58382672|NCT01994746|DRUG|Intramuscular Glucagon|
58382673|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
58382674|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
58382675|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
58261542|NCT05115422|BEHAVIORAL|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
58261543|NCT02688998|DEVICE|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
58261544|NCT05839652|DRUG|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
58261545|NCT04775342|DEVICE|smartphone|modern technology
58382676|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
58382677|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
58382678|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
58382679|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
58382680|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
58382681|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
58382682|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
58382683|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
58382684|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
58382685|NCT01580410|DRUG|mitomycin C|Given by HIPEC
58382686|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
58382687|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58382688|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
58382689|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
58382690|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
58382691|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
58066625|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
57911223|NCT02104050|DRUG|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
58066626|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
58261546|NCT04381507|DEVICE|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
58261547|NCT01506765|DRUG|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
58261548|NCT06459505|OTHER|Routine or standard Physical Therapy|Participants will undergo physical therapy to stop abnormal movement patterns and restore control over output in the developmental sequence. Therapists will provide cues to elicit basic posture and movement patterns, inhibiting aberrant patterns. The therapy aims to promote normal posture and movement patterns, incorporating the hemiplegic side for symmetry and functional use. Active usage and targeted strengthening activities will be emphasized, with motor performance practice included.
58382692|NCT00017069|DRUG|arsenic trioxide|
58382693|NCT00017069|DRUG|dexamethasone|
58382694|NCT02534883|DRUG|Misoprostol|To be place vaginally
58382695|NCT02534883|DRUG|Placebo|To be placed vaginally
58382696|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
58382697|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
58261549|NCT06459505|OTHER|Adapted Physical Activity|For Upper extremities, Manual Ability Classification Scale (MACS) is a tool designed to support individuals with hemiplegic cerebral palsy by providing structured support through activities focusing on strength, flexibility, balance, and coordination. Participants at different MACS levels receive tailored treatments, including adaptive tools, task-specific training, assistive gadgets, and functional training. For lower extremities, the therapy will begin on stable support surfaces before progressing to more challenging surfaces such as inflatable cushions, foam pads, or balance discs, focusing on slow and controlled motions for improved body alignment and coordination.
58261550|NCT03091192|DRUG|Savolitinib|600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
58261551|NCT03091192|DRUG|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
57911224|NCT02104050|DRUG|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
57911225|NCT00462332|DRUG|Fludarabine|Induction therapy
58261552|NCT05234879|OTHER|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
58261553|NCT02686242|PROCEDURE|spinal anesthesia|bupivacaine injected by spinal puncture
58382698|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
57911226|NCT00462332|DRUG|Campath|Induction therapy
57911227|NCT00462332|PROCEDURE|Transplant|Post-induction therapy
57911228|NCT00462332|DRUG|Campath|Post-induction therapy
57911229|NCT00462332|DRUG|Fludarabine|Induction therapy
57911230|NCT00462332|DRUG|Campath|Induction therapy
57911231|NCT00462332|DRUG|Campath|Post-induction therapy
57911232|NCT04540250|OTHER|questionnaire|conventional intra-oral examination and questionnaire
57911233|NCT01340638|DEVICE|cookgas mask|This group will be assigned to use cookgas mask
57911234|NCT01340638|DEVICE|LMA mask|LMA mask
58261554|NCT02686242|PROCEDURE|general anesthesia|general anesthesia with intubation
58261555|NCT02459847|BEHAVIORAL|Mindfulness Training|
58261556|NCT02459847|BEHAVIORAL|Sonographic Biofeedback|
58261557|NCT02459847|OTHER|Standard Care|
58261558|NCT00000861|DRUG|Indinavir sulfate|
58261559|NCT02553499|BIOLOGICAL|MK-1248|IV infusion
58261560|NCT02553499|BIOLOGICAL|pembrolizumab|IV infusion
58261561|NCT05425043|BIOLOGICAL|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
58261562|NCT03212092|DIETARY_SUPPLEMENT|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
57911235|NCT05557227|OTHER|1-hour cycling|60 % VO2 max
57911236|NCT05347043|OTHER|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
57911237|NCT04971278|BEHAVIORAL|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
57911238|NCT02503189|DRUG|KCT-0809 ophthalmic solution|
57911239|NCT02503189|DRUG|Placebo|
58261563|NCT03212092|DIETARY_SUPPLEMENT|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
57709389|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
57709390|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
58059064|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
58059065|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
58059066|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
58059067|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
58059068|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
58059069|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
58261564|NCT05958771|DRUG|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
58261565|NCT05958771|DRUG|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
58261566|NCT03991013|DRUG|Dolutegravir 50 mg|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
58261567|NCT03991013|DRUG|Placebo|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
58261568|NCT03580434|DEVICE|V-STRUT|Minimally invasive implantation of V-STRUT
58261569|NCT03081806|DRUG|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
58261570|NCT00697736|PROCEDURE|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
57709391|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
57709392|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
58261571|NCT03163056|BEHAVIORAL|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
57911240|NCT05497973|BEHAVIORAL|E-health ecosystem of stepped psychosocial care|"1. Screening and monitoring: weekly administration of an emotional state thermometer. If the score is \>5, participants are asked to complete the HADS. If HADS' score \>10, step 2 is assigned. The same procedure is followed for steps 3 \& 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~2. Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~3. Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q\&As.~4. Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
58261572|NCT03163056|BEHAVIORAL|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
58382699|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
58382700|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
58382701|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
58382702|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
58382703|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
58382704|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
58382705|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
57911241|NCT05497973|BEHAVIORAL|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
57911242|NCT01280162|DRUG|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
58059070|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
57709393|NCT00133081|DRUG|All registered antiepileptic drugs|
57709394|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
57709395|NCT00085943|DRUG|LEXIVA (GW433908)|
58382706|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
58382707|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
57709396|NCT00085943|DRUG|Ritonavir|
57709397|NCT00085943|DRUG|KALETRA|
57709398|NCT00085943|DRUG|EPIVIR|
57709399|NCT00085943|DRUG|Ziagen|
57709400|NCT00085943|DRUG|Abacavir/Lamivudine|
57709401|NCT00085943|DRUG|Fosamprenavir|
58059071|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
58059072|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
58059073|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
58059074|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
58261573|NCT03163056|BEHAVIORAL|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
58261574|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
58261575|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
58059075|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
58261576|NCT05709119|DIAGNOSTIC_TEST|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
58261577|NCT00356252|DRUG|mixed carotenoids|
58261578|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
58261579|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
58261580|NCT02091596|DRUG|PluroGel N|Study Drug
58261581|NCT02091596|DRUG|PluroGel|PluroGel Vehicle Placebo Comparator
58059076|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
58059077|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
58059078|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
58261582|NCT03198832|PROCEDURE|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
58059079|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
58059080|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
58059081|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
58059082|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
58059083|NCT02865681|DRUG|Menopur|Nasal versus injectable
58261583|NCT01318590|DRUG|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
58261584|NCT01318590|OTHER|EUS procedure|EUS procedure without any drug injection
58261585|NCT03369067|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
58261586|NCT03369067|DEVICE|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
58261587|NCT03369067|DEVICE|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
58261588|NCT03657524|OTHER|echocardiography|Speckle tracking echocardiography
58261589|NCT05709444|DRUG|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
58261590|NCT05709444|DRUG|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
58382708|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
58059084|NCT02865681|DRUG|Synarel|nasal
58059085|NCT02865681|DRUG|HCG trigger|injectable
58059086|NCT02865681|DRUG|Clomiphene citrate|oral
58059087|NCT02865681|DRUG|Letrozole|Oral
58059088|NCT00199368|DRUG|Istradefylline ( KW-6002)|
58059089|NCT00078455|DRUG|ILX651|
58059090|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
58382709|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
58382710|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
58382711|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
58261591|NCT04696861|BEHAVIORAL|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
58382712|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
58382713|NCT03218280|DRUG|Vitamin C|
58261592|NCT04696861|BEHAVIORAL|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
58261593|NCT04228757|DIETARY_SUPPLEMENT|phytoestrogen herbal blend|phytoestrogen herbal blend
58261594|NCT04228757|OTHER|Placebo|Tablet without active ingredients
58261595|NCT01953432|DRUG|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
58261596|NCT01953432|DRUG|Placebo|Matched placebo daily dosing
58261597|NCT06434220|DIAGNOSTIC_TEST|Baseline model|Model prediction of patient disposition including feature importance scores driving prediction.
58261598|NCT06434220|DIAGNOSTIC_TEST|Fairness-aware model|Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
58261599|NCT06475729|DRUG|Citrate-Free Mirikizumab|Administered SC
58382714|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
58382715|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
58382716|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
58382717|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
58261600|NCT06617975|OTHER|Balneotherapy program in rheumatology indication|"At least 4 balneotherapy sessions per day, 6 days a week during 3 consecutive weeks that may include: 1 whirlpool bath per day, 1 poultice application per day, 1 bath with immersion showers in a pool per day, a local jet shower every other day, a penetrating shower every other day.~Alternative treatments may replace penetrating shower or local jet shower, or other care, e.g., collective jet shower or steam bath. 10-minute air diffusion baths are taken in individual tubs at 37°C. Mud is applied 10 minutes as a poultice to both knees (minimum 2 per knee, 52°C), if necessary, to other painful osteoarthritis areas. 10-minute collective pool bathing takes place in a thermal pool equipped with jet stations immersed in water at 32°C. 3-minute local jet shower is applied to the predefined area using thermal water at 37°C. 10-minute penetrating showers are delivered by an affusion ramp on the patient lying down and directed on the area defined, using thermal water at 37°C."
58382718|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
58382719|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
58382720|NCT05892419|OTHER|No intervention|There is no intervention
58382721|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
58382722|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
58382723|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
58382724|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
58059091|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
58059092|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
58382725|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
58382726|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
58261601|NCT06604234|DIETARY_SUPPLEMENT|Probiotic|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule
58261602|NCT06604234|OTHER|Placebo|Placebo comparator containing maltodextrin
58261603|NCT03627416|DEVICE|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
58261604|NCT04115995|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
58261605|NCT02609100|PROCEDURE|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
58261606|NCT02609100|PROCEDURE|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
58261607|NCT02609100|DEVICE|1.0 X 2.5 cm 'pill' containing a camera|
58261608|NCT02599597|BEHAVIORAL|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
58382727|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
58059093|NCT02884440|DRUG|TAP block ropivacaine|
58261609|NCT02599597|BEHAVIORAL|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
58261610|NCT01187498|BEHAVIORAL|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
58382728|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
58382729|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
58059094|NCT02884440|DRUG|TAP block placebo|
58261611|NCT01187498|DRUG|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
58261612|NCT01044290|OTHER|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
58261613|NCT01044290|OTHER|Attention Control|Subjects listened to a non-guided relaxation CD
58059095|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
58059096|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
58059097|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
58261614|NCT05022524|DIETARY_SUPPLEMENT|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
58261615|NCT04285424|BIOLOGICAL|Fecal Microbiota Transplantation|The fecal collection produced from a single healthy donor, unrelated to the patients
58261616|NCT04946032|OTHER|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
58261617|NCT06444763|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
57911243|NCT06433960|DIAGNOSTIC_TEST|Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~Instruct the patient to clench their wrist while the examiner occlude with three fingers the patients ulnar and radial arteries; instruct the patient to unclench their wrist; release the ulnar artery. The MAT result is negative or positive considering in how long the palm flushes:~≤5 seconds: negative MAT; good collateral hand circulation (suggesting harvestable radial artery).~greater than 5 seconds: positive MAT; poor collateral hand circulation (suggesting not-harvestable radial artery)."
57911244|NCT06433960|DIAGNOSTIC_TEST|Pulse-oximetry guided Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~A pulse-oximetry probe is positioned on the patients index finger; both radial and ulnar arteries are occluded by the examiner (with three fingers) until flattening of pulse waveform is obtained. Pressure on the ulnar artery is released and the result of the assessment is calculated considering in how long the pulse waveform returns to baseline:~≤5 seconds: negative result (suggesting harvestable radial artery). greater than 5 seconds: positive result (suggesting not harvestable radial artery).~(Busti and Kellogg, 2015)"
58261618|NCT06444763|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
58261619|NCT00372710|DRUG|Zoledronic acid|
58261620|NCT04994912|DRUG|EI-001|EI-001 IV infusion
58261621|NCT04994912|OTHER|Placebo|Placebo IV infusion
57911245|NCT06433960|DIAGNOSTIC_TEST|Barbeau Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 2 minutes.~A pulse-oximetry probe is positioned on the patients thumb; the radial artery is then compressed by the examiner, and the pulse waveform is analysed for up to 120 seconds, providing four result patterns of ulno-palmar patency:~1. No damping of the pulse tracing immediately after compression (suggesting harvestable radial artery)~2. Damping of the pulse tracing (suggesting harvestable radial artery)~3. Loss of the pulse tracing, followed by recovery within 120 sec (suggesting harvestable radial artery)~4. Loss of the pulse tracing, without recovery within 120 sec (suggesting not harvestable radial artery).~(Zalocar et al., 2020)"
58059098|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
58059099|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
58059100|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
58261622|NCT04983667|DIETARY_SUPPLEMENT|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
58261623|NCT06473025|BEHAVIORAL|Information on Relative Nutritional Status|The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards
58261624|NCT06473025|BEHAVIORAL|Information on Returns to Child Nutrition|The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
58261625|NCT05948566|BIOLOGICAL|TS23|Monoclonal antibody
58261626|NCT06621069|DRUG|Bisphosphonates|Alendronate Sodium or Zoledronic acid
58261627|NCT06621069|OTHER|Control|control without BP
58261628|NCT02345889|DEVICE|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
58261629|NCT02345889|DEVICE|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
57911246|NCT06433960|DIAGNOSTIC_TEST|Ultrasound examination of the forearm arteries|"Pre-operative intervention aimed at evaluating morphological characteristics (diameter, presence of calcifications) of the radial and ulnar arteries. Duration: 5 minutes.~The radial artery is surgically exposed (negative result) when the following apply:~1. ulnar artery inner diameter ≥2 mm~2. radial artery inner diameter ≥2 mm~3. absence of radial artery intraluminal calcifications and plaques.~(Vukovic et al., 2017)"
58059101|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
58059102|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
58059103|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
58059104|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
58059105|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
58059106|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
58059107|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
58261630|NCT02345889|DEVICE|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
58261631|NCT02345889|DEVICE|Standard Colonoscopy|Current standard of care colonoscopy
58261632|NCT04768127|OTHER|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
58261633|NCT04768127|OTHER|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
58261634|NCT06623136|DRUG|ES102|ES102 is administered via intravenous infusion, once every 21 days.
58261635|NCT06623136|DRUG|Toripalimab|Toripalimab is administered via intravenous infusion, once every 21 days.
58261636|NCT02347215|OTHER|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
58261637|NCT02347215|PROCEDURE|Stress imaging|Stress imaging
58261638|NCT03551951|DIAGNOSTIC_TEST|Test for circulating tumor cells, DNA alterations|
58261639|NCT05640297|BEHAVIORAL|KMC with Massage therapy|investigator will provide tactile and kinesthetic massage
58261640|NCT06621641|BEHAVIORAL|The new HFNC weaning protocol|Patients will be randomly assigned to two groups: one following the new HFNC weaning protocol and another using the standard care protocol. The new protocol includes stepwise flow reduction based on the patient's clinical stability and uses the Respiratory Assessment Scale (RAS) to monitor weaning progress. The protocol emphasizes a multidisciplinary approach involving pediatricians, nurses, and respiratory therapists, with consistent training and application of weaning criteria
58261641|NCT05720494|DRUG|JZP441|Oral study drug administered for up to 4 weeks
58261642|NCT05720494|DRUG|Placebo|Oral placebo administered for up to 4 weeks
58059108|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
58059109|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
58059110|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
58059111|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
58059112|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
58261643|NCT05885295|DIAGNOSTIC_TEST|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
58059113|NCT02125812|OTHER|scaling and root planing|scaling and root planing
58261644|NCT02375490|BEHAVIORAL|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
58261645|NCT00001044|BIOLOGICAL|Aluminum hydroxide|
58261646|NCT00001044|BIOLOGICAL|QS-21|
58261647|NCT00001044|BIOLOGICAL|rgp120/HIV-1MN|
58261648|NCT01444729|DRUG|Xiapex|Xiapex administration will follow SMPC
58261649|NCT01444729|PROCEDURE|surgery|Non-pharmacological treatment
58261650|NCT05170100|BEHAVIORAL|NUIG OAB App|An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
57709402|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
57709403|NCT02498093|BEHAVIORAL|Maximal strength training|
57709404|NCT02498093|BEHAVIORAL|conventional rehabilitation|
57709405|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
57709406|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
57709407|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
57709408|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
57709409|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
57709410|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
57709411|NCT02059148|DRUG|LY2835219|Administered orally.
57709412|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
57709413|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
58059114|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
58059115|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
58059116|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
58261651|NCT06166043|BEHAVIORAL|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
58261652|NCT01757912|PROCEDURE|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
58059117|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
58059118|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
57709414|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
57911247|NCT06433960|DIAGNOSTIC_TEST|Measurement of oxygen saturation|"Intra-operative intervention aimed at evaluating the blood oxygen level in the hand if the radial artery was harvested. Duration: 1 minute.~The radial artery is surgically harvested when the oxygen saturation reading (SpO2) from the thumb through pulse-oximetry remains at 95% or above when an occlusive atraumatic clamp is applied on the mobilised radial artery."
57911248|NCT06433960|OTHER|Radial Artery Quality Evaluation Survey|"Intra-operative intervention (validated structured questionnaire) aimed at evaluating anatomical and physiological characteristics of the radial artery and suitability for coronary graft implantation.~The radial artery is surgically harvested when its morphology and pathology (diameter, calcifications, presence of pulsatile flow), quality of harvesting technique and surgical accessibility are considered satisfactory, good or optimal.~The Radial Artery Quality Evaluation Survey is completed by surgical care practitioners."
57911249|NCT06433960|OTHER|Follow-up Radial Artery Harvesting Scale|"Postoperative intervention (ordinal symptoms scale) aimed at evaluating patients finger movements, cold tolerance sensitivity and tactile/touch perception at post-operative day 2 to 5 and at follow-up appointment (3-6 weeks after surgery). Bilateral comparison between hands and forearms is undertaken. Tactile perception is assessed through monofilaments (single touch). Cold sensitivity is assessed through the use of ice-pack.~The Follow-up Radial Artery Harvesting Scale was developed from a verbal rating scale (VRS) questionnaire documented in the literature. The VRS questionnaire was re-adapted to appreciate people postoperative experience with their finger movements, cold sensitivity and tactile/touch perception of their forearm."
58059119|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
58059120|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
58059121|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
57709415|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
57709416|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
58059122|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
58059123|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
58261653|NCT05565443|DEVICE|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
58261654|NCT05177926|DRUG|antiviral prophylaxis with Tenofovir Alafenamide Fumarate|All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
57709417|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
57709418|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
57709419|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
57709420|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
57709421|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
57709422|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
57709423|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
57709424|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
57709425|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
57709426|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
57709427|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
57709428|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
57709429|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
57911250|NCT00919347|OTHER|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~1. RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~2. LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~3. SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~* Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa \< 0.1 bpm2.~* Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa \< 0.5 bpm2 or 0.1 \< RFa \< 0.5 bpm2.~* Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
57911251|NCT00986973|DRUG|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
57911252|NCT03009760|DRUG|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
57911253|NCT03009760|DRUG|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
57911254|NCT03009760|DRUG|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
57911255|NCT03009760|DRUG|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
57911256|NCT06126731|DRUG|Enzalutamide 40mg|Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
57911257|NCT06126731|DRUG|Amoxicillin 500mg|"Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder"
57911258|NCT06126731|DRUG|Metronidazole 400mg|"Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other"
57911259|NCT06126731|DRUG|Vancomycin 125mg|"Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass"
57911260|NCT06126731|DRUG|Ciprofloxacin 500g|"White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side"
57911261|NCT05216432|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
57709430|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
57709431|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
57911262|NCT05216432|DRUG|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
57911263|NCT05216432|DRUG|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
57911264|NCT05216432|DRUG|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
57911265|NCT05216432|DRUG|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
57911266|NCT05018221|DRUG|Vitamin K1|Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
57911267|NCT05018221|DRUG|Magnesium citrate|Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
57911268|NCT05018221|DRUG|Sodium Thiosulfate|Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
57911269|NCT05018221|DEVICE|High Flux Dialyser|Hemodialysis using a high flux dialyser.
57911270|NCT05018221|DEVICE|Medium Cut-off Dialyser|Hemodialysis using a medium cut-off dialyser.
58261655|NCT05616117|OTHER|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
57911271|NCT05018221|DRUG|Placebo injection (normal saline)|Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
57911272|NCT05018221|DRUG|Placebo capsule (Vitamin K1)|Placebo to be administered 3 times per week following the subject's hemodialysis session.
57911273|NCT05018221|DRUG|Placebo tablet (Magnesium citrate)|Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
58059124|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
58059125|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
58059126|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
58261656|NCT05616117|OTHER|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
58261657|NCT01217385|PROCEDURE|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
57911274|NCT04431700|OTHER|Anti-inflammatory diet|Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.
57911275|NCT04431700|OTHER|Regular diet|Focus on food journal and recording all food intake.
57911276|NCT05303220|DRUG|Branebrutinib|Specified dose on specified days
57911277|NCT05303220|DRUG|Placebo|Specified Dose on specified days
57911278|NCT04025567|DRUG|vancomycin|1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
57911279|NCT05366790|BEHAVIORAL|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
57911280|NCT02598024|BEHAVIORAL|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
57911281|NCT02598024|BEHAVIORAL|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
57911282|NCT02957526|BEHAVIORAL|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
57911283|NCT02957526|BEHAVIORAL|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
58059127|NCT02994927|DRUG|Azathioprine|Orally administered
58059128|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
58059129|NCT00129376|DRUG|Doxorubicin|
58059130|NCT00129376|DRUG|Cyclophosphamide|
58261658|NCT03195647|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
58261659|NCT02814227|DEVICE|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
58059131|NCT00129376|DRUG|Docetaxel|
57911284|NCT02097082|DEVICE|STANZA Drug-eluting resorbable Scaffold|
57911285|NCT06169683|DEVICE|Lyric4|Lyric4 Hearing instrument use
57911286|NCT02673515|BEHAVIORAL|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
57911287|NCT04702529|DEVICE|Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)|Administration of 3 Rapid Acoustic Pulse (RAP) treatments
57911288|NCT02992821|PROCEDURE|Bed-side pocket size ultrasound imaging|
58261660|NCT03862430|DRUG|NanO2TM|0.1 mL/kg NanO2 infusion
57911289|NCT02992821|PROCEDURE|High frame rate tracking doppler|
58059132|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
58059133|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
58059134|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
58059135|NCT00457093|DRUG|glargine|
58261661|NCT03862430|DRUG|Placebo Saline Infusion|Saline Infusion
58261662|NCT03706859|PROCEDURE|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
57709432|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
57911290|NCT06334484|DEVICE|Advanced hybrid closed loop systems|Collect data from advanced hybrid closed loop users
58261663|NCT01222754|DRUG|Lenalidomide|"1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
58261664|NCT01222754|RADIATION|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
57911291|NCT02496689|BIOLOGICAL|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
57911292|NCT04331496|OTHER|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
58059136|NCT00457093|DRUG|detemir|
58059137|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
58059138|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
58261665|NCT04930042|DRUG|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
58261666|NCT04930042|DRUG|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
58261667|NCT05745207|DRUG|E2086|E2086 tablets.
58261668|NCT05745207|DRUG|Placebo|E2086 matched placebo tablets.
58261669|NCT06514755|PROCEDURE|GNA followed by GAE|Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.
58261670|NCT06514755|PROCEDURE|GAE alone|Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
58261671|NCT03737500|DEVICE|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
57709433|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
57709434|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
58261672|NCT03737500|DEVICE|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
57709435|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
58059139|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
58261673|NCT06607835|BEHAVIORAL|Mindful- compassion|Online mindful-compassion weekly for four weeks
58261674|NCT06607835|BEHAVIORAL|Mindful-compassion and cannabis suppositories|Cannabis suppositories and online mindful-compassion for vaginal pain
58261675|NCT03916367|RADIATION|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
58382730|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
58059140|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
58382731|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
58382732|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
58059141|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
58261676|NCT06509750|OTHER|Carob-meal|A meal with carob-beverage
58261677|NCT06509750|OTHER|Non-carob-meal|A meal with orange-beverage
58382733|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
58382734|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
58382735|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
57709436|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
58261678|NCT03796819|PROCEDURE|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
58261679|NCT05212688|OTHER|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 \& GV24 midline.
58261680|NCT05212688|OTHER|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
58261681|NCT06619925|BEHAVIORAL|after-school extended sports service|Impact of voluntary participation in different types (e.g. outdoor physical activities, indoor physical activities, ball games, calisthenics, etc.), intensity and duration of after-school extended physical education services on children\&#39;s myopia and other physical and psychological well-being
58261682|NCT06619925|BEHAVIORAL|non-after school extended sports service|Students in the same grade as the exposure group but participating in after-school non-physical education extended services (e.g., homework help, static activities such as calligraphy, chess, etc.) served as a control group, aiming to maximise the control of the influence of potential factors other than physical activity on the results of the study.
57709437|NCT06075485|OTHER|Ketocal|ketogene diet
57709438|NCT01700179|DRUG|ACH-0143102|
58261683|NCT00290134|DRUG|Fispemifene once daily for 4 weeks|
58261684|NCT05930028|DRUG|Fimasartan|Subjects take the investigational products once a day for 8 weeks.
58261685|NCT05930028|DRUG|Ezetimibe/Atorvastatin|Subjects take the investigational products once a day for 8 weeks.
57911293|NCT04331496|OTHER|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
57911294|NCT06187194|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
58261686|NCT05930028|DRUG|Fimasartan Placebo|Subjects take the investigational products once a day for 8 weeks.
58261687|NCT05930028|DRUG|Ezetimibe/Atorvastatin Placebo|Subjects take the investigational products once a day for 8 weeks.
58261688|NCT00260598|PROCEDURE|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
58261689|NCT06424990|OTHER|balance training with TENS|children will receive Biodex balance training with TENS for 30 minutes a day, 5 days per week for 4 weeks
58382736|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
58382737|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
57911295|NCT01697215|OTHER|AirWave|
57911296|NCT06277310|OTHER|3 Wishes Project|palliative care initiative in which clinicians elicits and implements small acts of kindness for dying patients and their families
57911297|NCT02686047|DEVICE|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
58261690|NCT06424990|OTHER|Balance training with placebo TENS|children will receive Biodex balance training with placebo TENS for the same period.
58261691|NCT05540041|OTHER|Bubble breathing play therapy group|The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.
58261692|NCT05540041|OTHER|Tell-show-do play therapy group|The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.
58261693|NCT05540041|OTHER|No intervention|Routine nursing care
58261694|NCT02224027|DEVICE|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
57911298|NCT02686047|DEVICE|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
58059142|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
58382738|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
58059143|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
58382739|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
57709439|NCT01700179|DRUG|Ribavirin|
58059144|NCT02422160|OTHER|No interventions are planned|No interventions are planned
58059145|NCT03089008|OTHER|Eccentric exercises|
58261695|NCT02224027|DEVICE|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
58261696|NCT02224027|DEVICE|i-gel|In i-gel group, i-gel is inserted by novices.
58261697|NCT06620718|PROCEDURE|coronectomy|The inferior alveolar nerve and buccal nerve were blocked with maxicaine anaesthetic solution (articaine hydrochloride 40 mg, epinephrine hydrochloride 0.006 mg). Incisions were applied uniformly across all patients, and a triangular flap technique was employed. After elevating the flap and exposing the bone, the bone overlying the crown of the tooth was removed using a bone round bur to fully visualize the tooth\&#39;s crown. Once the crown was fully exposed, the crown preparation was initiated at the enamel-dentin junction using a fissure bur. The crown preparation was completed without leaving any sharp edges, and the crown was extracted. Then, the exposed pulp was washed with sterile serum without any further intervention. The surgical area was sutured using 5/0 silk. Analgesic (25 mg of dexketoprofen trometamol twice a day) and antibiotic (125 mg clavulanic acid, 875 mg amoxicilin twice a day) drugs were described.
58382740|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
58382741|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
57709440|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
57709441|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
57709442|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
58382742|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
58382743|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
58382744|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
58382745|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
58382746|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
58382747|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
57709443|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
57709444|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
57709445|NCT02259933|DRUG|KUC 7483 CL|
57911299|NCT02015182|OTHER|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
57911300|NCT06437587|OTHER|Home-based rehabilitation appropriate technology (S-HRAT) training|The S-HRAT training instruction consists of two phases: in-hospital training and post-discharge remote home training. Based on the S-HRAT list, we select individualized home rehabilitation training exercises for the participants and conduct five offline training instruction sessions one week before discharge to ensure that the participants master the correct method for each exercise and clarify precautions. At discharge, participants will receive an S-HRAT brochures, which will include detailed text, pictures and video demonstrations of exercises, to visualize the rehabilitation instructions and make them easy to understand. Participants learn how to use the S-HRAT booklet and follow a daily training program to complete the prescribed content. They will be asked to record a video of their training and send it to the researcher via WeChat for monitoring purposes and feedback.
57911301|NCT00227474|DRUG|recombinant modified vaccinia Ankara-5T4 vaccine|
57709446|NCT02259933|DRUG|Placebo|
57709447|NCT02351869|DRUG|Nitrous Oxide|
57709448|NCT02351869|DRUG|Midazolam|
57709449|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
57709450|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
57709451|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
57709452|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
57709453|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
57709454|NCT02684227|DRUG|Carboplatin|Given IV
57911302|NCT00227474|PROCEDURE|adjuvant therapy|
58059146|NCT03089008|OTHER|Stretching exercises|
58261698|NCT00288600|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin
58382748|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
58382749|NCT00167375|DRUG|eszopiclone 3 mg qHS|
57911303|NCT00227474|PROCEDURE|recombinant viral vaccine therapy|
57911304|NCT01607632|BEHAVIORAL|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
58059147|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
58059148|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
58059149|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
58059150|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
58059151|NCT00027404|DRUG|Fluoxetine|
58059152|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
58059153|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
58382750|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
57911305|NCT04771728|DRUG|Metronidazole vaginal suppositories|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
58059154|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
58059155|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
58059156|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
58059157|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
58059158|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
58261699|NCT00288600|DRUG|Normal saline solution|Normal saline solution 10 ml/Kg
58261700|NCT05637775|OTHER|EEG-based BCI system for (hands) Motor Imagery training|For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
58059159|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
58059160|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
58059161|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
57709455|NCT02684227|DRUG|Enzalutamide|Given PO
57709456|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
57911306|NCT04771728|DRUG|Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
57911307|NCT03657654|OTHER|No intervention: observational only|No intervention: observational only
57911308|NCT02029846|DRUG|Standard Treatment|traditional drugs only
57911309|NCT02029846|DRUG|Incretin-Based Treatment|incretin-based drugs
58059162|NCT00073515|DRUG|Alfimeprase|
58382751|NCT00055926|DRUG|CP-724,714|
58382752|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
58382753|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
58382754|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
57911310|NCT03780075|DRUG|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
57911311|NCT03780075|DRUG|2.00 GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
58382755|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
58382756|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
58382757|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
58382758|NCT00899418|GENETIC|gene expression analysis|
58261701|NCT05637775|OTHER|Control - MI intervention|Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
58261702|NCT06514703|PROCEDURE|CT-Guided Genicular Nerve Ablation|This procedure involves using computed tomography (CT) imaging to guide the precise placement of a needle for the ablation of genicular nerves in the knee. The goal is to disrupt the pain signals caused by osteoarthritis, providing long-term pain relief. The intervention is performed under local anesthesia and is aimed at patients who have not responded adequately to conservative pain management strategies.
58261703|NCT06514703|PROCEDURE|Fluoroscopic-Guided Genicular Nerve Ablation|This procedure utilizes fluoroscopy to accurately guide the needle placement for the ablation of genicular nerves associated with osteoarthritis knee pain. The technique focuses on minimizing pain and improving functional mobility by disrupting nerve pathways that transmit pain signals. Like the CT-guided approach, it is intended for use in patients whose symptoms have not been sufficiently managed with non-invasive treatments.
58261704|NCT06665217|DRUG|Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
57911312|NCT03780075|DRUG|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
58261705|NCT06648044|OTHER|Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie|
58382759|NCT00899418|GENETIC|polymerase chain reaction|
58382760|NCT00899418|GENETIC|polymorphism analysis|
58382761|NCT00899418|OTHER|immunohistochemistry staining method|
58382762|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
58059163|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
58261706|NCT05769868|DRUG|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
58382763|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
58382764|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
58382765|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
58382766|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
57911313|NCT04577547|OTHER|DGA diet WL & exercise|Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise
58382767|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
58382768|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
58382769|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
58382770|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
58382771|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
57911314|NCT04577547|OTHER|DGA diet WL & no exercise|Intake of DGA weight loss 8 day rotating menu \& no exercise
57911315|NCT04577547|OTHER|DGA diet WM & exercise|Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise
57911316|NCT04577547|OTHER|DGA diet WM & no exercise|Intake of DGA weight maintenance 8 day rotating menu \& no exercise
58261707|NCT06405789|OTHER|yoga practice|The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
58261708|NCT06506019|DRUG|Psilocybin|25 mg psilocybin
58261709|NCT06506019|DEVICE|Functional MRI|The fMRI involving resting state measures and a facial affect task will be conducted one-day and one-month after the dosing session.
58261710|NCT01239212|DRUG|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
58261711|NCT04319627|DRUG|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
58261712|NCT04319627|DRUG|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
57202736|NCT05861024|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
58261713|NCT02888392|OTHER|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
58261714|NCT02888392|DIETARY_SUPPLEMENT|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
58261715|NCT06538740|PROCEDURE|Ventilating the patient with 70% (instead of standardized 100%) oxygen concentration during the wash out phase, before extubation.|The investigated intervention is the application of 70% inspired oxygen compared to 100% inspired oxygen during the anesthetic washout, right before extubation of the patient. Before and after the intervention EIT measurements are performed at designated time points to assess lung aeration and calculate the center of ventilation. This information allows assumptions on atelectasis formation in the patients' lung.
58261716|NCT01311518|DRUG|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
58261717|NCT01311518|DRUG|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
58261718|NCT05923866|DRUG|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
58261719|NCT05923866|DRUG|Placebo|Oral administration of placebo once a daily for 24 weeks
58261720|NCT05874375|DEVICE|Urge stimulation|Participants will receive stimulation for 60 seconds, when they feel an urgency.
58059164|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
58261721|NCT05874375|DEVICE|Time limited stimulation|Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
58261722|NCT06624124|BEHAVIORAL|Gamified Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a video game-based training platform
58261723|NCT06624124|BEHAVIORAL|Traditional Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a traditional text-based training platform
57709457|NCT02684227|DRUG|Paclitaxel|Given IV
58261724|NCT03729570|OTHER|ePrEP|Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
58261725|NCT04553640|OTHER|Group A/Intervention Curriculum|Virtual patient cases and feedback
58261726|NCT04553640|OTHER|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
58261727|NCT06649513|DIAGNOSTIC_TEST|eye drops (Tropicamid)|Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
57709458|NCT02684227|OTHER|Pharmacological Study|Correlative studies
57709459|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
57709460|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
57709461|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
57709462|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
57709463|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
58261728|NCT03768440|PROCEDURE|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
58261729|NCT03768440|PROCEDURE|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
57911317|NCT04577547|OTHER|Western diet WL & exercise|Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise
57911318|NCT04577547|OTHER|Western diet WL & no exercise|Intake of Western-type weight loss 8 day rotating menu \& no exercise
58261730|NCT03768440|DRUG|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
57911319|NCT04577547|OTHER|Western diet WM & exercise|Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise
58382772|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
58382773|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
57911320|NCT04577547|OTHER|Western diet WM & no exercise|Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
57911321|NCT03031860|OTHER|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
58382774|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
58382775|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
58382776|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
57911322|NCT00417261|DRUG|ATF936|
57911323|NCT00417261|DRUG|AXT914|
57911324|NCT01410123|OTHER|Integrated Stepped Care (ISC)|"1. At risk drinking:~   Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~2. Alcohol abuse/dependence:~   Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~3. Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
58382777|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
57911325|NCT01410123|OTHER|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
57911326|NCT00235482|DRUG|Coxsackievirus A21|
57911327|NCT02253901|DRUG|BILR 355 BS|
57911328|NCT02253901|DRUG|Ritonavir|
58059165|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
58382778|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
57911329|NCT02253901|DRUG|TRUVADA|
57911330|NCT04039477|DRUG|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
57911331|NCT04428073|BIOLOGICAL|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
57911332|NCT01666457|OTHER|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
57911333|NCT01015339|DRUG|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
57911334|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
57911335|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
57911336|NCT01015339|DRUG|cisplatin|80mg/m2, day 1 of every 3 weeks
58059166|NCT00003899|BIOLOGICAL|filgrastim|
58059167|NCT00003899|DRUG|cyclophosphamide|
57709464|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
57709465|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
58261731|NCT06648187|OTHER|Early motor-cognitive integrative training (e-MCIT)|Early motor-cognitive integrative training (e-MCIT) is an approach where motor and cognitive training are conducted simultaneously. The intervention consists of 30-minute sessions, conducted 4-5 times per week, until discharging from the hospital. Both motor and cognitive training have five stages each, and their progression is independent, meaning that during training, a participant might be in the fourth stage of motor training and the second stage of cognitive training. According to hospital's policy, occupational therapy and speech therapy will be provided in schedule if needed. Motor training is derived from a previous protocol of early mobilization intervention applied to a population with SAH, which based on the ICU Mobility Scale. The activities of cognitive training target areas such as attention, orientation, language ability, memory, calculation, judgment, working memory, executive function, and daily living functions.
58261732|NCT05245721|DRUG|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
58261733|NCT05245721|DRUG|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
58261734|NCT06179017|OTHER|Experimental group:Intervention Group|Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
58261735|NCT06179017|OTHER|Control group:best medical treatment|Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
57709466|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
57709467|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
57709468|NCT02187302|DRUG|CRLX101|
57709469|NCT02187302|DRUG|Bevacizumab|
57709470|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
57709471|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
57709472|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
57709473|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
58261736|NCT04943302|DRUG|Bendamustine Hydrochloride|To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
58261737|NCT04943302|DRUG|Isatuximab|To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
58261738|NCT04511962|OTHER|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
58261739|NCT06619054|DRUG|KP-001|Oral single dose 50mg.
58382779|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
57709474|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
58059168|NCT00003899|DRUG|melphalan|
58059169|NCT00003899|DRUG|paclitaxel|
58059170|NCT00003899|DRUG|thiotepa|
58059171|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
58059172|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
58059173|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
58059174|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
58059175|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
58059176|NCT00898690|GENETIC|cytogenetic analysis|
58261740|NCT05963516|OTHER|LIVEBORN: A Mobile Health Application (app) for Newborn Resuscitation|LIVEBORN is a mobile health application designed to help providers learn from their clinical practice during newborn resuscitation through real-time guidance and debriefing. Using LIVEBORN, an observer can document events during a resuscitation such as the actions of the provider and when the baby cries. A battery-operated heart rate meter, NeoBeat, measures and sends the newborn's heart rate to the LIVEBORN app via Bluetooth. LIVEBORN integrates data from the observer and NeoBeat to provide audio-visual real-time guidance to the provider during a resuscitation. Following the resuscitation, providers can also debrief using LIVEBORN. The app operates on the Android system and is functional off-line, except for the need for an internet connection to upload data to the cloud for research.
57709475|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
57709476|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
57709477|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
57709478|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
57709479|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
58059177|NCT00898690|GENETIC|gene expression analysis|
58059178|NCT00898690|GENETIC|microarray analysis|
58059179|NCT00898690|GENETIC|mutation analysis|
58059180|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
57709480|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
57911337|NCT02437071|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
58059181|NCT00898690|OTHER|immunohistochemistry staining method|
58059182|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
58059183|NCT01468844|DRUG|Placebo|Placebo
58382780|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
57709481|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
57911338|NCT02437071|RADIATION|Radiotherapy|
57911339|NCT02437071|PROCEDURE|Radiofrequency ablation|
57911340|NCT00645866|DRUG|capecitabine|
57911341|NCT00645866|DRUG|docetaxel|
58382781|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
57911342|NCT00645866|DRUG|epirubicin hydrochloride|
57911343|NCT00645866|OTHER|laboratory biomarker analysis|
57911344|NCT00645866|OTHER|pharmacogenomic studies|
57911345|NCT00645866|PROCEDURE|biopsy|
57911346|NCT00645866|PROCEDURE|neoadjuvant therapy|
58059184|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
58059185|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
58059186|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
58059187|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
58059188|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
58059189|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
58059190|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
57709482|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
57911347|NCT00645866|PROCEDURE|therapeutic surgical procedure|
58382782|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
57709483|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
58382783|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
57911348|NCT03866161|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment
57911349|NCT06056167|DRUG|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
58059191|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
58261741|NCT05963516|DEVICE|NeoBeat: Heart Rate Meter for Newborn Resuscitation|NeoBeat is a low-cost device for the measurement of newborn heart rate (HR) that was developed by Laerdal Global Health for use in low-resource settings. It is applied by placing the device around the torso of the newborn. It detects HR accurately, quickly (\<5 sec), is reusable and can be easily disinfected. NeoBeat's dry electrodes detect HR which is digitally displayed and recorded. It uses an impedance system to sense skin contact and motion detection to validate signal quality. It does not require the use of buttons, adhesive, gel or cables and has no disposable parts. A single birth attendant can apply NeoBeat in 2-3 seconds.
58382784|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
58382785|NCT02168062|OTHER|Educational Intervention|Review educational modules
58382786|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
58382787|NCT02168062|DRUG|Goserelin Acetate|Given SC
58382788|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
58382789|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
57709484|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
58382790|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
57709485|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
58382791|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
58382792|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
58059192|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
58382793|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
57911350|NCT05045508|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
57911351|NCT05045508|DRUG|Placebo (vehicle) Nasal Spray|Placebo (vehicle) nasal spray \[control\]
58059193|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
58059194|NCT01873196|BEHAVIORAL|Receive extra oil|
58059195|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
58382794|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
58382795|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
58382796|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
58382797|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
58382798|NCT01619761|DRUG|Cyclophosphamide|Given IV
58382799|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
58382800|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
58382801|NCT01619761|DRUG|Lenalidomide|Given PO
58261742|NCT06630585|DRUG|Tirzepatide|"Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks."
58261743|NCT06263153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58261744|NCT06263153|PROCEDURE|Computed Tomography|Undergo CT
58382802|NCT01619761|DRUG|Melphalan|Given IV
58059196|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
58059197|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
58382803|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
58382804|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
58382805|NCT01619761|BIOLOGICAL|Rituximab|Given IV
58382806|NCT01619761|DRUG|Tacrolimus|Given IV or PO
58066627|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
58261745|NCT06263153|BIOLOGICAL|Durvalumab|Given IV
58261746|NCT06263153|DRUG|Futibatinib|Given PO
58261747|NCT06263153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58261748|NCT06263153|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
58261749|NCT03420807|DEVICE|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
58261750|NCT01942044|DEVICE|Promus element, Xience prime, and Nobori|
58261751|NCT01118624|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
58261752|NCT01118624|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
57709486|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
58261753|NCT01118624|DIETARY_SUPPLEMENT|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
58261754|NCT05977127|BIOLOGICAL|Comirnaty|Administration of Comirnaty vaccine
58382807|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
58382808|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
58382809|NCT01759342|BEHAVIORAL|Aerobic exercise|
58382810|NCT01759342|BEHAVIORAL|Resistance exercise|
58382811|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
58382812|NCT01759342|BEHAVIORAL|Balance exercise|
58382813|NCT02449811|DRUG|Perindopril|
58382814|NCT02449811|DRUG|Olmesartan|
58382815|NCT02449811|DRUG|Amlodipine|
58382816|NCT02449811|DRUG|Hydrochlorothiazide|
58382817|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
58382818|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
58382819|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
58382820|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
58382821|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
58382822|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
58382823|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
58382824|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
58382825|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
58059198|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
58059199|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
58059200|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
58059201|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
58261755|NCT03205761|DRUG|Olaparib|Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
58261756|NCT03426865|DRUG|Axumin PET scan|PET scan prior to RPLND
58261757|NCT05994118|OTHER|NaCl 0.9% (normal saline)|Subcutaneous normal saline injection
58261758|NCT05994118|OTHER|Magnetized Normal Saline|Magnetized Normal Saline
57709487|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
58059202|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
58059203|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
58059204|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
58261759|NCT02835651|DIETARY_SUPPLEMENT|Palmitic acid|Experimental products are enriched with C16:0
58261760|NCT02835651|DIETARY_SUPPLEMENT|Stearic acid|Experimental products are enriched with C18:0
58261761|NCT03247491|BEHAVIORAL|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
58261762|NCT05728853|RADIATION|Assessment of body composition|Assessment of body composition using BIA and DXA
58261763|NCT05773651|OTHER|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
58261764|NCT01899716|OTHER|Exercise|
58261765|NCT00810446|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
58261766|NCT01828541|BEHAVIORAL|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
58261767|NCT01828541|OTHER|Standard of Care|
58059205|NCT00071604|BEHAVIORAL|Friendly Support Group|
57709488|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
58059206|NCT00215228|DRUG|duloxetine vs. escitalopram|
58059207|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
58059208|NCT02670187|BIOLOGICAL|GLS-5300|
58059209|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
57709489|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
57709490|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
57709491|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
57709492|NCT01387607|DRUG|placebo|Placebo, twice daily
58059210|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
58059211|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
58059212|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
58059213|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
58059214|NCT03944811|PROCEDURE|Summers technique|Summers technique
58261768|NCT06008197|DRUG|Finerenone|Oral finerenone
58261769|NCT06008197|DRUG|Placebo|Matching oral placebo
58261770|NCT01461720|OTHER|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
58261771|NCT01461720|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
58261772|NCT05497388|OTHER|Serious Game|using Serious Game for HCV education
58261773|NCT01993589|DRUG|comparison of pain relievers during curattage|
58261774|NCT01993589|DRUG|comparison of pain relievers|
58261775|NCT01993589|DRUG|comparison of pain relievers during curattage|
58261776|NCT01993589|DRUG|comparison of pain relievers during curattage|
58261777|NCT01993589|DRUG|comparison of pain relievers during curattage|
58261778|NCT03912532|BIOLOGICAL|NGM282|NGM282
58261779|NCT03912532|OTHER|Placebo|Placebo for NGM282
58261780|NCT04103827|OTHER|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
58261781|NCT03770416|DRUG|Ibrutinib|Given PO
58261782|NCT03770416|BIOLOGICAL|Nivolumab|Given IV
58261783|NCT03350061|DEVICE|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
58261784|NCT02149823|DRUG|Syntocinon 24 Intranasal Units (IU)|
58261785|NCT02149823|DRUG|Syntocinon 40 Intranasal Units (IU)|
58261786|NCT02149823|DRUG|Intranasal Placebo|
58261787|NCT06622369|OTHER|Virtual Reality-Game group|Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use
58261788|NCT06622369|OTHER|Virtual Reality-Cartoon-video group|Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
58261789|NCT01945801|DRUG|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
58261790|NCT01945801|OTHER|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
58261791|NCT01945801|DRUG|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
58382826|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
58059215|NCT03432208|PROCEDURE|GI consult|
57911352|NCT03104491|DRUG|Inotuzumab Ozogamicin|"Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)"
58261792|NCT04604275|DRUG|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
58261793|NCT04604275|OTHER|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
58261794|NCT05314140|DIAGNOSTIC_TEST|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
58059216|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
58261795|NCT05930145|DEVICE|Double stentriever|Double stentriever technique
58261796|NCT05930145|DEVICE|Single stentriever|Single stentriever technique
58261797|NCT04153890|BEHAVIORAL|FamPALcare|"Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines."
58261798|NCT01424514|DRUG|SB-705498|12mg intra nasal
57911353|NCT01332773|PROCEDURE|Artery first procedure|early identification of SMA to evaluate infiltration
58059217|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
57709493|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
58261799|NCT01424514|DRUG|Placebo|Placebo intra nasal
58261800|NCT06602349|DRUG|Lidocaine 10 MG/ML|administration of lidocaine in posterior perineal block infiltration
58261801|NCT06602349|DRUG|Saline|administration of salin solution in posterior perineal block infiltration
58261802|NCT02889835|DEVICE|Supreme Universal Restorative|
58261803|NCT02889835|DEVICE|Supreme Flowable Restorative|
58261804|NCT02889835|DEVICE|Bulk Fill Flowable Restorative|
58261805|NCT06511570|DRUG|sabirnetug (ACU193)|sabirnetug by intravenous infusion
58261806|NCT06511570|COMBINATION_PRODUCT|Sabirnetug + rHuPH20|sabirnetug + rHuPH20 by subcutaneous injection
58261807|NCT01984892|DRUG|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
57709494|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
57709495|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
57911354|NCT01332773|PROCEDURE|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
57911355|NCT02682745|DRUG|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
57911356|NCT02682745|DRUG|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
57911357|NCT02183844|BEHAVIORAL|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
57911358|NCT01567904|DRUG|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
57911359|NCT02867579|BEHAVIORAL|"evaluation of the child quality attachment (Strange situation)"|
57911360|NCT04834453|DIAGNOSTIC_TEST|transcranial ultrasound|- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
58261808|NCT04933084|BEHAVIORAL|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
58261809|NCT05288595|DEVICE|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
58261810|NCT02137109|DRUG|natalizumab|Administered as specified in the treatment arm.
58382827|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
58382828|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
58261811|NCT05918419|DRUG|Serplulimab|PD-1 antibody
58261812|NCT00855205|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
58261813|NCT05806567|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
58261814|NCT05806567|DRUG|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
58261815|NCT05806567|DRUG|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
58261816|NCT05806567|DRUG|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
58261817|NCT03933644|DEVICE|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
58261818|NCT03933644|DEVICE|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
58261819|NCT06138002|DEVICE|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
58261820|NCT06138002|PROCEDURE|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
58261821|NCT01136889|OTHER|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
58261822|NCT01276522|DRUG|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
58261823|NCT06385340|OTHER|Lipikar Baume AP+M|• Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
58261824|NCT05814536|DRUG|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
58261825|NCT04867993|DRUG|Amikacin|15 mg/kg/36h
58261826|NCT02893553|DRUG|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
58261827|NCT02893553|DRUG|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
57709496|NCT00002082|DRUG|Azithromycin|
58261828|NCT02893553|DRUG|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
58261829|NCT02893553|OTHER|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
58261830|NCT00525941|DRUG|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
58261831|NCT02838836|PROCEDURE|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
58261832|NCT03937401|DRUG|Oxytocin|Oxytocin infusion during MRI-HIFU treatment
58261833|NCT00664859|DRUG|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
58261834|NCT03687372|DRUG|A-101|hydrogen peroxide topical solution 45%
58261835|NCT03687372|OTHER|vehicle|vehicle as a topical solution
58261836|NCT02536118|DEVICE|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
58261837|NCT00503958|GENETIC|DNA methylation analysis|
58261838|NCT00503958|GENETIC|DNA stability analysis|
58261839|NCT00503958|GENETIC|gene expression analysis|
58261840|NCT00503958|OTHER|epidemiologic study|
58261841|NCT00503958|OTHER|study of socioeconomic and demographic variables|
58261842|NCT00503958|PROCEDURE|biopsy|
58382829|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
58059218|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
58261843|NCT00503958|PROCEDURE|evaluation of cancer risk factors|
58261844|NCT00503958|PROCEDURE|study of high risk factors|
58261845|NCT06043479|OTHER|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
58261846|NCT04482660|PROCEDURE|Positron emission tomography with 18F-RO6958948|tau PET ()
58261847|NCT00059878|BIOLOGICAL|recombinant interferon gamma|
58261848|NCT00059878|DRUG|voriconazole|
58261849|NCT03576755|DRUG|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
58261850|NCT03576755|DRUG|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
58261851|NCT02715700|DRUG|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
58261852|NCT02715700|DRUG|Doravirine|Doravirine 100 mg oral tablet once per day.
58261853|NCT06648733|OTHER|Structured pharmaceutical discharge management|These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
58261854|NCT03887507|OTHER|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
58261855|NCT03887507|OTHER|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
58261856|NCT03376451|OTHER|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
58059219|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
58059220|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
58059221|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
58059222|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
58059223|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
58261857|NCT03476174|DRUG|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
58261858|NCT03476174|DRUG|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
58261859|NCT05052606|OTHER|No intervention|This study is an observational study without treatment intervention.
58261860|NCT06421675|DRUG|Elranatamab injection|Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
58261861|NCT06623929|DRUG|Etofenamat|E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
58261862|NCT06623929|DRUG|Diclofenac|Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
58261863|NCT01292421|BIOLOGICAL|hepatitis B antigen peptide|Given PO
58261864|NCT01292421|OTHER|placebo|Given orally (PO)
58261865|NCT01292421|OTHER|immunoenzyme technique|Correlative studies
58261866|NCT04761549|PROCEDURE|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
58261867|NCT02581475|PROCEDURE|Extending withdrawal time in the proximal colon|
58261868|NCT02581475|PROCEDURE|Segmental examination twice of the proximal colon|
58261869|NCT06528535|OTHER|Health promotion intervention|Health promotion activities on nutrition with distribution of baskets of fresh fruits and vegetables
58261870|NCT01007136|DEVICE|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
58261871|NCT01007136|DEVICE|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
58261872|NCT06622213|OTHER|mucoadhesive film with Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
58261873|NCT06622213|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Apply ¼ inch on ulcer 3 times per day (after meals)
58261874|NCT06622213|OTHER|mucoadhesive film without Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
58261875|NCT02043951|DEVICE|Lutonix Drug Coated Balloon Catheter|
58261876|NCT03655678|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
58261877|NCT05870449|DEVICE|tunneled PICC|Tunneled PICC is a type of PICC catheterization technique that involves establishing a subcutaneous tunnel to keep the outlet of the catheter away from the puncture site
58261878|NCT05870449|DEVICE|routine PICC|Peripherally inserted central venous catheterization is a technique that involves inserting PICC through the peripheral vein and infusing drugs into the central vein through a catheter.
58261879|NCT00800306|DRUG|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
58261880|NCT00800306|DRUG|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
58261881|NCT02620384|DRUG|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
58382830|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
58382831|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
58382832|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
58382833|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
57709497|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
57911361|NCT03543657|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
57911362|NCT03543657|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
57709498|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
57709499|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
57709500|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
57911363|NCT03543657|DRUG|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
58059224|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
58382834|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
58382835|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
57709501|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
57709502|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
57709503|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
57911364|NCT03543657|DRUG|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
57911365|NCT00269360|PROCEDURE|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
58059225|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
58261882|NCT02620384|DRUG|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
58261883|NCT04096443|BIOLOGICAL|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
58261884|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
58261885|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
58261886|NCT04892212|DRUG|Sirolimus|The daily dose of sirolimus is divided twice.
58261887|NCT02224820|BIOLOGICAL|IdeS|Doses are administered in ascending doses
58261888|NCT02796859|DRUG|Siltuximab|Investigational agent
58382836|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
58382837|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
58382838|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
58382839|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
58261889|NCT02796859|DRUG|normal saline|Placebo
58382840|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
58382841|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
58382842|NCT01738685|OTHER|Nutritional Education.|
58382843|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
58382844|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
58382845|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
58382846|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
58382847|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
57709504|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
57709505|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
58059226|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
58059227|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
58059228|NCT02358928|OTHER|Diet Intervention|
58261890|NCT06623851|OTHER|Intraoral scanner|"* The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages"
58261891|NCT06623851|OTHER|Alginate impression|Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
58261892|NCT06444464|OTHER|Aerobic exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
58261893|NCT06444464|OTHER|Isometric exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
58382848|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
58382849|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
58059229|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
58059230|NCT03983304|DEVICE|The ZELTIQ System|The EMS device will be used to perform the treatments.
58059231|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
58059232|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
58059233|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
57709506|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
58261894|NCT04537117|OTHER|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
58382850|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
58261895|NCT06328244|BEHAVIORAL|Simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
58382851|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
58382852|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
58382853|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
57709507|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
57709508|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
57709509|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
57709510|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
57709511|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
58382854|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
58382855|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
58382856|NCT02822742|DRUG|DE-117 ophthalmic solution|
57709512|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
57911366|NCT00269360|PROCEDURE|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
57911367|NCT00269360|BEHAVIORAL|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
58382857|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
58382858|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
58382859|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
58382860|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
58382861|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
58382862|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
57911368|NCT06300450|BEHAVIORAL|Computer Alert|On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
58382863|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
57911369|NCT03616977|DRUG|LY900014 U-200|Administered SC
57911370|NCT03616977|DRUG|LY900014 U-100|Administered SC
58261896|NCT06621225|DEVICE|Artificial Intelligence|Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
58261897|NCT06621225|DEVICE|Mucosal Exposure Device|The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
57911371|NCT06354231|DRUG|DV|2.0 mg/kg, intravenously administered every 2 weeks
58261898|NCT05567432|PROCEDURE|thyroidectomy|use diathermy or ligasure for homeostatic during thyroidectomy
58261899|NCT05420857|OTHER|Overground Visual Biofeeback|Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
57911372|NCT06354231|DRUG|Toripalimab|3.0mg/kg, intravenously administered every 2 weeks
57911373|NCT06354231|PROCEDURE|Laser surgery|Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
58261900|NCT00449943|PROCEDURE|Computed Tomographic Angiography|CT scan
58261901|NCT00449943|PROCEDURE|Myocardial Perfusion Imaging Scan|SPECT
58261902|NCT02947256|PROCEDURE|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
58261903|NCT02947256|PROCEDURE|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
58261904|NCT06622863|BEHAVIORAL|Standard oral hygiene instructions will be given verbally by the periodontics resident|Standard oral hygiene instructions will be given verbally by the periodontics resident
58382864|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
57911374|NCT02907515|DEVICE|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
57911375|NCT02907515|DEVICE|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
57911376|NCT03629639|DRUG|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
57911377|NCT00660543|DRUG|Gadolinium|Given IV
57911378|NCT00660543|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
57911379|NCT00660543|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
57911380|NCT00660543|OTHER|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
57911381|NCT00660543|OTHER|Diffusion Weighted Imaging|Undergo DWI
58059234|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
57709513|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
58261905|NCT06622863|BEHAVIORAL|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
57911382|NCT00660543|OTHER|MRI-Based Angiogram|Undergo TOF MR angiography
58059235|NCT00003736|DRUG|motexafin gadolinium|
58261906|NCT06621797|DIETARY_SUPPLEMENT|Intervention 1: Dietary Supplement - Caffeine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) taken orally 45 minutes before performance testing. No additional interventions will be administered.
58261907|NCT06621797|DIETARY_SUPPLEMENT|Intervention 2: Dietary Supplement - Caffeine + L-Theanine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) along with L-theanine in a 1:2 ratio taken orally 45 minutes before performance testing.
57709514|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
57709515|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
57709516|NCT00004031|DRUG|CHOP regimen|
57709517|NCT00004031|DRUG|carmustine|
57709518|NCT00004031|DRUG|cyclophosphamide|
57709519|NCT00004031|DRUG|doxorubicin hydrochloride|
57709520|NCT00004031|DRUG|etoposide|
57709521|NCT00004031|DRUG|prednisone|
57709522|NCT00004031|DRUG|vincristine sulfate|
57709523|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
57709524|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
57709525|NCT00004031|RADIATION|radiation therapy|
57709526|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
57709527|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
58059236|NCT00003736|PROCEDURE|biopsy|
58059237|NCT00003736|PROCEDURE|breast imaging study|
58059238|NCT00003736|PROCEDURE|comparison of screening methods|
58261908|NCT06621797|BEHAVIORAL|Intervention 3: Dietary Supplement - Caffeine Supplement + Diaphragmatic Breathing Exercises|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) 45 minutes before performance testing, followed by a 10-minute session of diaphragmatic breathing exercises.
58261909|NCT03813147|DRUG|Azacitidine|Given IV
58261910|NCT03813147|DRUG|Cytarabine|Given intrathecally and IV
58261911|NCT03813147|DRUG|Fludarabine Phosphate|Given IV
58261912|NCT03813147|DRUG|Methotrexate|Given intrathecally
58261913|NCT03813147|DRUG|Pevonedistat|Given IV
58261914|NCT03813147|DRUG|Therapeutic Hydrocortisone|Given intrathecally
57709528|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
58261915|NCT06136481|OTHER|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT). CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. Prior to engaging in therapy, one session will be devoted to gathering information regarding psychosocial history, trauma, and current functioning. The following sessions will follow the standard outpatient CPT protocol. The standard outpatient CPT consists of 12 one-hour sessions conducted over a 6- to 12-week period. An additional 3 weeks will be provided in case of participant and therapist vacation and/or sick days. CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
58261916|NCT02261662|DRUG|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
58261917|NCT02261662|DRUG|Betamethasone|Topical Steroids alone will be used; Betamethasone
57709529|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
58261918|NCT05871398|DRUG|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
58261919|NCT05871398|DRUG|Placebo|Placebo
58261920|NCT05817383|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
57709530|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
57709531|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
58382865|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
57709532|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
57709533|NCT01782313|DRUG|tivozanib|Given PO
58261921|NCT05817383|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
58261922|NCT06618261|DIETARY_SUPPLEMENT|Caffeine + Resistance exercise|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
58261923|NCT06618261|DIETARY_SUPPLEMENT|Placebo + Resistance exercise|Acute placeb intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
58261924|NCT06153186|DRUG|Flunarizine Hydrochloride|Flunarizine tablet
57709534|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
57709535|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
57709536|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
57709537|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
58059239|NCT00003736|PROCEDURE|magnetic resonance imaging|
58059240|NCT00003736|PROCEDURE|study of high risk factors|
58261925|NCT06606574|OTHER|Titration protocol|A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
58261926|NCT03500458|BEHAVIORAL|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
58261927|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 1
58261928|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 2
58261929|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 3
58261930|NCT01367496|DRUG|IV Methylnaltrexone (MNTX)|
58261931|NCT05418894|DEVICE|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
58261932|NCT03760367|OTHER|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
58261933|NCT03760367|OTHER|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
58261934|NCT03410472|BEHAVIORAL|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
58261935|NCT03651687|OTHER||
58261936|NCT06620562|DRUG|Naltrexone/Bupropion|Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.
58261937|NCT06620562|DRUG|Placebo|Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.
58261938|NCT02128425|DRUG|FOLFOXIRI|"irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients"
58382866|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
58382867|NCT02529111|DEVICE|"Echonavigator software"|
58382868|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
58382869|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
58382870|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
57709538|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
58261939|NCT02128425|DRUG|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
58261940|NCT02961322|OTHER|lobo-isthmectomy assisted robot|
58261941|NCT04865549|PROCEDURE|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
58261942|NCT04884113|DEVICE|Motorized Spiral enteroscopy|Small-bowel enteroscopy for diagnosis and intervention
58382871|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
58382872|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
58382873|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
58382874|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
58382875|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
58382876|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
58059241|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
58382877|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
58382878|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
58382879|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
58382880|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
58382881|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
58059242|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
58059243|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
58059244|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
58059245|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
58059246|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
58382882|NCT05174338|OTHER|Registry|Observational, data collection
58382883|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
58382884|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
58382885|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
58382886|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
58382887|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
58382888|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
58382889|NCT00331916|DRUG|quinolone|
58382890|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
58382891|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
58382892|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
58382893|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
58382894|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
58382895|NCT01741493|DRUG|Tofacitinib|Oral administration
58382896|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
58261943|NCT06374225|DEVICE|Automated Titration (O2matic)|The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.
58382897|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
58382898|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
58382899|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
58382900|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
58382901|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
58382902|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
58382903|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
58382904|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
58382905|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
58382906|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
58382907|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
58382908|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
58382909|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
58382910|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
58382911|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
58382912|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
58382913|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
58382914|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
58382915|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
58382916|NCT04855240|DRUG|Placebo|Oral dose of placebo
58382917|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
57709539|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
57709540|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
57709541|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
57709542|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
58382918|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
57709543|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
57709544|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
57709545|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
57709546|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
57709547|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
57709548|NCT02431858|DEVICE|E-Catheter (Pajunk)|
57709549|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
58261944|NCT06302296|DEVICE|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
58382919|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
58382920|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
58382921|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
58382922|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
58382923|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
58382924|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
58261945|NCT06302296|BEHAVIORAL|Placebo injection|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
58261946|NCT00138073|DEVICE|Web-based waveform interpretation guide|Use of an educational website.
58382925|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
58382926|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
58382927|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
58382928|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
58382929|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
58059247|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
58059248|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
58059249|NCT02171806|DRUG|BI 1744 CL|
58059250|NCT02171806|DRUG|Placebo|
58059251|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
58059252|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
58059253|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
58059254|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
58261947|NCT03616444|DRUG|Shenbai Granules|In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
58382930|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
58382931|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
58382932|NCT03008070|DRUG|IVA337|1200mg
58382933|NCT03008070|DRUG|IVA337|800mg
58382934|NCT03008070|DRUG|Placebo|Placebo to match
58382935|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
58382936|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
58382937|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
58382938|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
58382939|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
57709550|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
58382940|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
58382941|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
58382942|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
58382943|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
57709551|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
57709552|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
58261948|NCT06648434|DRUG|Zunsemetinib|Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.
57709553|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
58261949|NCT06648434|DRUG|mFOLFIRINOX|Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
58261950|NCT06237244|DIAGNOSTIC_TEST|triglyceride to glucose ratio|Ratio of triglyceride level to glucose
58261951|NCT06237244|DIAGNOSTIC_TEST|triglycerdie to HDL ratio|Ratio of triglyceride to HDL cholesterol
58261952|NCT06622915|DEVICE|Tissue Doppler imaging and Conventional Echocardiography|non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum
58261953|NCT06618963|DRUG|Omalizumab Injection|Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.
58382944|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
57911383|NCT06609382|OTHER|Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)|Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
57911384|NCT01733173|PROCEDURE|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
57911385|NCT04646954|DIAGNOSTIC_TEST|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
58261954|NCT01013844|BEHAVIORAL|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
58261955|NCT06618365|DRUG|Vitamin D Deficiency|"The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each."
58261956|NCT00481052|DRUG|Nilotinib|
58261957|NCT02999529|OTHER|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
58261958|NCT01310556|OTHER|ogtt for patients with coronary artery disease|75 g OGTT
58261959|NCT05573490|DEVICE|Cognitive Training|Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
58261960|NCT05573490|BEHAVIORAL|Tai Chi- Qi Gong|Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
58261961|NCT05573490|DEVICE|Brain Games|Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
58261962|NCT05573490|BEHAVIORAL|Stretching|Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
58382945|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
57911386|NCT04646954|DIAGNOSTIC_TEST|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
58261963|NCT03359486|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
58261964|NCT03359486|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
58261965|NCT03185806|DEVICE|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
58382946|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
58382947|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
58382948|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
57911387|NCT04641871|DRUG|Sym021|IV infusion over 30 minutes on day 1 and 15 of each cycle.
57911388|NCT04641871|DRUG|Sym022|IV infusion over 30 minutes on day 1 and 15 of each cycle.
57911389|NCT04641871|DRUG|Sym023|IV infusion over 30 minutes on day 1 and 15 of each cycle.
57911390|NCT04641871|DRUG|Irinotecan Hydrochloride|IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
57911391|NCT05879549|OTHER|Closed Chain Exercise Group|Closed Chain Exercise Group
57911392|NCT05879549|OTHER|Proprioceptive Exercise Group|Proprioceptive Exercise Group
57911393|NCT02539147|BIOLOGICAL|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
58059255|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
58382949|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
58261966|NCT06588907|DRUG|Bupivacaine Hydrochloride|After preparing the infraclavicular block site, a 22-gauge needle, guided by ultrasound, will be placed in the 6-7 o'clock position in the same plane as the ultrasound probe. Subsequently, lateral, medial, and posterior cords described as hypoechoic nerve fascicles within hyperechoic structures will be identified. Initially, 2 mL of saline will be administered to confirm proper spread. Once confirmed, 20 mL of 0.25% bupivacaine (prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline) will be injected in fractional doses with intermittent negative aspiration. Fifteen minutes after this procedure, anesthesia depth will be assessed using a cold-hot test, followed by reduction and application of the cast.
58261967|NCT06588907|DRUG|Ketamine|Until the recovery period, patients will be closely monitored by an experienced doctor or nurse during sedation. Emergency equipment will be readily available in case of any complications. The following protocol will be used for procedural sedation-analgesia (PSA): Ketamine will be administered intravenously at a dose of 0.5-1 mg/kg. Patients with Numeric Rating Scale (NRS) scores above 5 may receive additional doses of 0.25-1 mg/kg, repeated every 5 to 10 minutes as needed.
58261968|NCT04101929|DRUG|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
58261969|NCT04101929|DRUG|S-1 capsule|Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
58261970|NCT04101929|DRUG|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
58261971|NCT03839771|DRUG|AG-120|250mg tablets
58261972|NCT03839771|DRUG|Placebo for AG-120|250mg tablets
58261973|NCT03839771|DRUG|AG-221|100mg tablets
58261974|NCT03839771|DRUG|Placebo for AG-221|100mg tablets
58382950|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
57709554|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
57709555|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
57709556|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
57709557|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
57709558|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
57911394|NCT05887115|BEHAVIORAL|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
58261975|NCT05721846|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
58261976|NCT05721846|DRUG|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
58261977|NCT05721846|RADIATION|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
58261978|NCT05721846|BIOLOGICAL|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
58382951|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
58382952|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
58382953|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
58382954|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
57709559|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
57911395|NCT02055781|DRUG|Pacritinib|
57911396|NCT02055781|DRUG|Best Available Therapy|
58382955|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
57911397|NCT01805401|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
58261979|NCT03415789|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
58261980|NCT03415789|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
58261981|NCT03415789|DIAGNOSTIC_TEST|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
58261982|NCT03415789|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
58261983|NCT03698994|OTHER|Pharmacokinetic Study|Ancillary studies
58261984|NCT03698994|DRUG|Ulixertinib|Given PO
57911398|NCT00386373|DRUG|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
58261985|NCT06488209|DRUG|LAD191|LAD191 SC injection.
58261986|NCT06488209|OTHER|Placebo|Matching placebo SC injection.
58261987|NCT02326922|DEVICE|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
58382956|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
57911399|NCT01859273|BEHAVIORAL|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
58261988|NCT04476342|DEVICE|minimal invasive cardiopulmonary bypass (MICPB) system|The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
58261989|NCT06649409|DRUG|Vamorolone|vamorolone 20 mg/kg single dose on Day 2
58261990|NCT06649409|DRUG|Eplerenone|Eplerenone 200 mg single dose on Day 2
57911400|NCT01201265|DRUG|Bevacizumab|15 mg/kg iv every 3 weeks
57911401|NCT01201265|DRUG|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
57911402|NCT01201265|DRUG|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
57911403|NCT03341767|DRUG|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
57911404|NCT03341767|DRUG|Placebo|Oil-wax in gelatin capsule
58059256|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
58382957|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
58382958|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
58382959|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
58382960|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
58382961|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
58382962|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
58382963|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
58382964|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
57911405|NCT03306459|DIAGNOSTIC_TEST|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
58382965|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
58382966|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
58382967|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
58382968|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
58382969|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
57911406|NCT00267839|BEHAVIORAL|physical exercise, wellness|
58261991|NCT06649409|DRUG|Fludrocortisone|"Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm."
58382970|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
58382971|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
58382972|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
58382973|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
58382974|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
58382975|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
57911407|NCT04682444|DRUG|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
58261992|NCT04682652|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
58261993|NCT06007963|PROCEDURE|Treatment with impella device.|Impella percutaneous mechanical supported patients will be included after revision to support.
58261994|NCT01649648|BIOLOGICAL|Autologous cord blood|Baby's own umbilical cord blood
58261995|NCT06217783|DEVICE|Introcan Safety IV Catheter|Given by IV
58261996|NCT01294007|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
58261997|NCT01294007|PROCEDURE|Autograft bone|Iliac Crest and Local Autograft Bone
58261998|NCT00370981|DRUG|pagoclone|
58261999|NCT02396017|DEVICE|Capsule endoscopy|Endoscopic device
58262000|NCT02396017|DRUG|Polyethylene Glycol|Bowel purgative
58262001|NCT06620874|BIOLOGICAL|STABHA Injection|Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval
58262002|NCT06620874|OTHER|High-Concentration Glucose Water Injection|Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval
58262003|NCT06620874|OTHER|Saline Injection|Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval
58262004|NCT05100368|OTHER|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
58382976|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
58382977|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
57911408|NCT04682444|DRUG|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
57911409|NCT02436473|DRUG|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
58262005|NCT01740128|DEVICE|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
58262006|NCT01740128|OTHER|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
57911410|NCT02436473|OTHER|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
57911411|NCT02436473|DRUG|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
57911412|NCT02436473|DRUG|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
58262007|NCT06161831|BEHAVIORAL|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
58262008|NCT02893176|DRUG|macitentan|
58262009|NCT02893176|DRUG|placebo (for macitentan)|
58262010|NCT06620081|OTHER|Performance Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
58262011|NCT06620081|OTHER|Functional Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
58262012|NCT04664946|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
58262013|NCT04504266|BEHAVIORAL|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
58262014|NCT04982692|DRUG|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
58382978|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
58382979|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
58262015|NCT04982692|DRUG|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
58382980|NCT00334568|DRUG|Placebo|Placebo
58382981|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
58382982|NCT00088491|DRUG|Oral Olanzapine|
58382983|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
58382984|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
58382985|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
58382986|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
58382987|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
58382988|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
58382989|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
58382990|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
58382991|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
58382992|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
58382993|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
58382994|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
58382995|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
58262016|NCT01308112|DIETARY_SUPPLEMENT|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
58382996|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
58262017|NCT04378959|DRUG|Lidocaine patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
58262018|NCT04378959|DRUG|Placebo patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
58262019|NCT02123836|BIOLOGICAL|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
58262020|NCT03673748|DRUG|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
58262021|NCT03673748|DRUG|Placebo|Endovenous injection of saline solution without cells
58382997|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
58382998|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
58382999|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
58383000|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
58383001|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
58383002|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
58383003|NCT05789459|DEVICE|Stapler|Stapler
58383004|NCT05789459|OTHER|Suture|Suture
58262022|NCT02168374|OTHER|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
57911413|NCT02252380|DEVICE|Transcranial ExAblate System|MR Guided Focused Ultrasound
57911414|NCT02747199|DEVICE|SYNERGY stent|
58262023|NCT05856344|DEVICE|Spherical tip noncompliant balloon|The main difference of this experimental balloon is the spherical tip, other parameters are consistent with regular noncompliant balloons.
58262024|NCT05856344|DEVICE|Regular noncompliant balloon|The balloon is designed as tapered-tip.
57911415|NCT02747199|DEVICE|BVS ABSORB scaffold|
58059257|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
58262025|NCT05288387|PROCEDURE|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
58262026|NCT05563012|DRUG|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
58262027|NCT05319743|OTHER|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
58262028|NCT06617910|RADIATION|SBRT by Cyberknife|The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife.
58262029|NCT06461143|DRUG|%4 articaine with 1:200 000 adrenaline|For intraosseous anesthesia SleeperOne5 device is going to be used.
58383005|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
58383006|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
58383007|NCT02593903|DRUG|Septra|
57911416|NCT01796015|OTHER|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
58262030|NCT05958316|BEHAVIORAL|Computerized Symptom Capture Tool (C-SCAT) Intervention|"The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs)."
58262031|NCT05958316|BEHAVIORAL|Usual Care Control|Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
58262032|NCT06624150|DEVICE|Active tDCS sessions, StarStim device|10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
58262033|NCT06624150|DEVICE|Sham (fake) tDCS sessions|10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
58262034|NCT05789784|OTHER|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
58262035|NCT05789784|OTHER|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
58262036|NCT02433925|DIETARY_SUPPLEMENT|Resveratrol|
58262037|NCT02433925|DIETARY_SUPPLEMENT|Placebo|
58262038|NCT04630249|BEHAVIORAL|Listening to Women and Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
58262039|NCT05965635|OTHER|Ixodus scapularis nymphs|Tick challenge
58262040|NCT02585817|DEVICE|Remote CIED Management|Information Technology
58262041|NCT03470012|DEVICE|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
58262042|NCT03760406|PROCEDURE|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
58262043|NCT03250091|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
58262044|NCT03250091|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
58383008|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
58383009|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
58262045|NCT03250091|PROCEDURE|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
58262046|NCT03250091|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
58262047|NCT04066296|DRUG|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
58262048|NCT02344290|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
58262049|NCT02344290|DRUG|Placebo|One tablet taken once daily, orally with or without food
58262050|NCT02235051|BEHAVIORAL|exercise intervention|Undergo Curves exercise program
58262051|NCT02235051|OTHER|laboratory biomarker analysis|Correlative studies
58262052|NCT02235051|OTHER|questionnaire administration|Ancillary studies
58262053|NCT02235051|OTHER|quality-of-life assessment|Ancillary studies
58262054|NCT02062424|OTHER|DIPI|
58262055|NCT02085668|DEVICE|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
58262056|NCT00834639|DRUG|divalproex sodium|delayed-release 500 mg tablet
58262057|NCT00834639|DRUG|Depakote®|delayed-release 500 mg tablet
58262058|NCT06648252|BEHAVIORAL|Healing Minds Biofeedback and Breathing Practices Intervention|The study participant will attend ten weekly Healing Minds sessions at the Hoskinson Health and Wellness Clinic. The parent (s) or guardian will accompany the study participant and follow along with the cues during the weekly session. Each session will be approximately 60 minutes. The principal investigator/pediatrician or trained and certified health care or research staff member will deliver the intervention. Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
58262059|NCT06056882|OTHER|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
58059258|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
58262060|NCT01370824|PROCEDURE|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
58262061|NCT01370824|PROCEDURE|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
58262062|NCT05718427|BEHAVIORAL|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
58262063|NCT00002701|DRUG|busulfan|
57911417|NCT02234687|DRUG|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
57709560|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
57911418|NCT02234687|DRUG|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
57911419|NCT02234687|DRUG|Placebo|Placebo, one dose, one time
57911420|NCT05216497|DRUG|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
57911421|NCT05216497|DRUG|Placebo|1-2 capsules for 7 days on top of standard therapy
58262064|NCT00002701|DRUG|cyclophosphamide|
58262065|NCT00002701|DRUG|cytarabine|
58262066|NCT00002701|DRUG|etoposide|
58262067|NCT00002701|DRUG|idarubicin|
58262068|NCT00002701|DRUG|mercaptopurine|
57911422|NCT00178100|BEHAVIORAL|Interpersonal Psychotherapy|
57911423|NCT00178100|DRUG|paroxetine|
57911424|NCT01536015|DRUG|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
57709561|NCT02117037|OTHER|blood sample|
57709562|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
57911425|NCT01536015|DRUG|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
57911426|NCT05909111|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI weekly during the radiation treatment course (5 RMI added to the standard care)
57911427|NCT04361682|PROCEDURE|Surgical Drain Management|
57911428|NCT00002674|BIOLOGICAL|filgrastim|
57911429|NCT00002674|DRUG|cytarabine|
57911430|NCT00002674|DRUG|etoposide|
57911431|NCT00002674|DRUG|hydroxyurea|
57911432|NCT00002674|DRUG|mitoxantrone hydrochloride|
57911433|NCT00002674|PROCEDURE|peripheral blood stem cell transplantation|
57911434|NCT00157560|DRUG|Chemotherapy, multiple agents|
57911435|NCT02996331|OTHER|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
57911436|NCT02996331|OTHER|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
58262069|NCT00002701|DRUG|methotrexate|
58262070|NCT00002701|DRUG|mitoxantrone hydrochloride|
58262071|NCT00002701|DRUG|thioguanine|
58262072|NCT00002701|DRUG|tretinoin|
58262073|NCT00002701|PROCEDURE|allogeneic bone marrow transplantation|
58262074|NCT00002701|PROCEDURE|autologous bone marrow transplantation|
58262075|NCT00002701|RADIATION|radiation therapy|
58262076|NCT05592561|OTHER|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (\~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was \~10 min.
58262077|NCT01014897|DEVICE|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
58262078|NCT04439019|OTHER|Lifestyle and dietary modification program|"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown."
58262079|NCT01093326|DRUG|Ponesimod 10 mg|Ponesimod 10 mg oral use
58262080|NCT01093326|DRUG|Ponesimod 20 mg|Ponesimod 20 mg oral use
58262081|NCT01093326|DRUG|Ponesimod 40 mg|Ponesimod 40 mg oral use
58383010|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
58383011|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
58383012|NCT00270751|PROCEDURE|1 apical pleurectomy|
58383013|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
58383014|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
57709563|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
58262082|NCT04501783|DRUG|Favipiravir|TL-FVP-t will be administered orally
58262083|NCT04501783|DRUG|Standard of care (SOC)|SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
58262084|NCT04501783|DRUG|standard concomitant therapy|Standard of care according to MoH of Russian Federation recomendation for COVID-19
58262085|NCT01037127|DRUG|GSK1120212|Daily oral dosing
58262086|NCT06620848|DRUG|HRS-4642 monotherapy|HRS-4642 will be administrated per dose level in which the patients are assigned.
58383015|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
57709564|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
57709565|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
58262087|NCT06620848|DRUG|HRS-4642 and adebrelimab combination therapy|HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
58262088|NCT03249246|OTHER|No intervention|
58262089|NCT05735262|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58262090|NCT05735262|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58262091|NCT01852552|DEVICE|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
58262092|NCT01852552|PROCEDURE|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
58262093|NCT06603961|DEVICE|CPG-EB group|Customized-pressure guided elastic bandage group
58383016|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
58262094|NCT00904202|DRUG|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
58262095|NCT00904202|DRUG|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
58262096|NCT00904202|DRUG|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
58262097|NCT00904202|DRUG|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
58383017|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
58383018|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
58383019|NCT01783197|DRUG|Paclitaxel|
58383020|NCT01783197|DRUG|Carboplatin|
58383021|NCT01783197|DRUG|Selumetinib|
57709566|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
58383022|NCT01783197|DRUG|Pemetrexed|
58383023|NCT01783197|DRUG|Cisplatin|
58383024|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
57709567|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
58262098|NCT00904202|DRUG|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
58262099|NCT00904202|DRUG|Gabapentin 1800 mg/day + Lidoderm patch|
58383025|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
58383026|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
58383027|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
57709568|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
57709569|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
57709570|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
57709571|NCT02287896|DRUG|ROLEDUMAB|See Arm description
58059259|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
58059260|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
58383028|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
58059261|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
58059262|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
58383029|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
58383030|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
57709572|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
58059263|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
58059264|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
58059265|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
58059266|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
58059267|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
58059268|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
58059269|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
58262100|NCT02434172|OTHER|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
58262101|NCT00504491|DRUG|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
58262102|NCT05432947|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
58262103|NCT05432947|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
58262104|NCT04023552|DRUG|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
58262105|NCT04023552|DRUG|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
58262106|NCT02691936|DEVICE|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
58262107|NCT02691936|DRUG|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
58383031|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
58383032|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
58262108|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
58262109|NCT02447497|OTHER|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
58383033|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
58383034|NCT02962245|DRUG|berberine|
58383035|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
58383036|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
58383037|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
58383038|NCT00044369|PROCEDURE|Varicocele repair|
58383039|NCT00060710|DRUG|CP-461|
58383040|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
58383041|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
58383042|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
58383043|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
58383044|NCT01034501|DEVICE|sham procedure|non activated laser tip
58383045|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
57709573|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
58262110|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
58262111|NCT02447497|OTHER|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
58262112|NCT06228924|GENETIC|TN-401|TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
58262113|NCT06648005|PROCEDURE|the spinal manipulative therapy combined brace|Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.
58262114|NCT06648005|OTHER|brace|Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
58262115|NCT06503406|DEVICE|SupraSDRM®|SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.
58262116|NCT06503406|DEVICE|NovoSorb® BTM|NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
58262117|NCT06599099|DEVICE|Medtronic Percept RC System|"Medtronic Percept RC System includes:~Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module"
58262118|NCT06599099|BEHAVIORAL|One Month Blinded Discontinuation Period|The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
58262119|NCT01869621|DRUG|Metformin|6 days treatment with metformin to steady-state
58262120|NCT05669898|BEHAVIORAL|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
58262121|NCT05669898|OTHER|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
58262122|NCT05669898|BEHAVIORAL|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
58262123|NCT00522535|PROCEDURE|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
58262124|NCT00522535|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
58262125|NCT00662662|BEHAVIORAL|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
58262126|NCT01972451|PROCEDURE|Colonoscopy with enhanced dye|
58262127|NCT06648629|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a trans-diagnostic treatment that targets experiential avoidance as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms via improved psychological acceptance.
58262128|NCT06648629|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention (BI) is a standard intervention for reducing alcohol use in PWH. The BI includes the creation of a drinking agreement, self-monitoring via drinking diary cards, discussion of risky moods/situation, and strategies for managing these moods/situations.
57709574|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
57709575|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
57709576|NCT06382987|DRUG|Deucravacitinib|According to the product label
57709577|NCT06382987|DRUG|Apremilast|According to the product label
57709578|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
57709579|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
57709580|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
57709581|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
57709582|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
57709583|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
58262129|NCT04525079|DRUG|CT-P59|CT-P59 will be administered
58262130|NCT04525079|DRUG|Placebo|Placebo-matching CT-P59
58262131|NCT03673345|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
57709584|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
57709585|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
58262132|NCT06421545|BEHAVIORAL|Resilient Together for Dementia|A novel live video dyadic resiliency intervention
57709586|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
57709587|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
57709588|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
57709589|NCT00956410|BIOLOGICAL|CAD106|
57709590|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
58262133|NCT02428803|OTHER|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
58262134|NCT02491372|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
58383046|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
57709591|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
57709592|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
57709593|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
57709594|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
57709595|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
57911437|NCT02996331|OTHER|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
57709596|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
57709597|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
57709598|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
57709599|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
57709600|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
57709601|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
57709602|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
57709603|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
57709604|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
57709605|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
57709606|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
57709607|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
57709608|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
57709609|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
57709610|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
58262135|NCT05307016|DIAGNOSTIC_TEST|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
58262136|NCT00636194|DEVICE|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
58262137|NCT00636194|DEVICE|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
57709611|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
57709612|NCT01454726|OTHER|drug|the Western medical treatment alone.
57709613|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
58262138|NCT00707876|DRUG|ferumoxytol|Dose 1 versus non-contrast MRA
58262139|NCT00707876|DRUG|ferumoxytol|Dose 2 versus non-contrast MRA
58262140|NCT00707876|DRUG|ferumoxytol|Dose 3 versus non-contrast MRA
57709614|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
58262141|NCT01088243|DRUG|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
57709615|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
57709616|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
57709617|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
57709618|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
57709619|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
57709620|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
57709621|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
57709622|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
57709623|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
57911438|NCT04838951|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
58059270|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
58059271|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
57709624|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
58262142|NCT01088243|DRUG|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
58262143|NCT06620575|PROCEDURE|Atrial fibrillation ablation|Persistent atrial fibrillation ablation
58262144|NCT04108494|PROCEDURE|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
58262145|NCT03808350|PROCEDURE|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
58262146|NCT03808350|OTHER|Placebo/Control|Family members will not be invited to remain in the ICU room
58262147|NCT04346212|DIAGNOSTIC_TEST|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
58262148|NCT04546321|OTHER|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
58262149|NCT03338803|DRUG|Linagliptin|drug
58383047|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
58383048|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
58262150|NCT03439215|DRUG|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
58262151|NCT06620289|BEHAVIORAL|Dental Desensitization Clinic|The goal of offering desensitization visits is to reduce the dental anxiety and distress of patients and enhance their cooperation during future appointments. The specifics of the desensitization are individualized to meet the unique needs of each patient based on information provided by the parent/caregiver. A standard desensitization visit involves providing the patient the opportunity to sit in the exam chair; touch the toothbrush and rubber prophy cup, mouth mirror, fluoride applicator brush, air-water syringe tip and saliva ejector tip; gain exposure to the dental lights and sounds commonly experienced in the dental visit; practice opening their mouth; and tolerate toothbrush and rubber prophy cup, mirror, explorer, fluoride applicator brush, air-water syringe, and salvia ejector in the mouth. If the child is unable or unwilling to participate, these activities are modeled on the parent or by the CCLS.
58383049|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
58383050|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
58383051|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
57709625|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
57709626|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
58059272|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
58059273|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
58262152|NCT03852368|OTHER|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
58262153|NCT04202913|BEHAVIORAL|Coaching|Child will receive 1:1 coaching with health coach.
58262154|NCT03068819|DRUG|CIML NK Cell Infusion|-Day 0
58262155|NCT03068819|PROCEDURE|CD3+ T Cell Product Infusion|-Day -1
58059274|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
57709627|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
57709628|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
58262156|NCT05836974|PROCEDURE|Ex-utero cord blood collection|SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
58262157|NCT05836974|PROCEDURE|In-utero cord blood collection|The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
58262158|NCT05526807|DRUG|Ursodeoxycholic acid|Oral
58262159|NCT02156895|DRUG|Axitinib|based on Axitinib approval
58383052|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
58383053|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
58383054|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
58383055|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
58383056|NCT01308359|DRUG|saline|saline
58383057|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
58383058|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
58383059|NCT02596139|OTHER|No Interventions|
57709629|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
57911439|NCT02498431|PROCEDURE|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
58262160|NCT04530266|DIAGNOSTIC_TEST|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
58262161|NCT01608815|BIOLOGICAL|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
57709630|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
57709631|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
57709632|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
57709633|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
57709634|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
57709635|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
57709636|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
57709637|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
57709638|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
57709639|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
57911440|NCT02498431|PROCEDURE|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
57911441|NCT02498431|DEVICE|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
57911442|NCT01996189|DEVICE|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
57709640|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
57709641|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
58262162|NCT02915536|OTHER|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
57709642|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
57911443|NCT01996189|DEVICE|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
57911444|NCT03383120|DEVICE|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
57709643|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
57709644|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
57911445|NCT03383120|PROCEDURE|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
57911446|NCT05420844|OTHER|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
57911447|NCT03374527|OTHER|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
57911448|NCT03374527|PROCEDURE|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
57911449|NCT05174455|DRUG|Niraparib Tosylate Monohydrate|Given PO
57911450|NCT02818959|DEVICE|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
57911451|NCT03402490|BEHAVIORAL|Motivational interviewing|
57911452|NCT03723616|BEHAVIORAL|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
58262163|NCT00775840|DRUG|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
58262164|NCT00775840|DRUG|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
58262165|NCT00359736|DRUG|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
57911453|NCT03723616|BEHAVIORAL|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
57911454|NCT03723616|BEHAVIORAL|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
58383060|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
58383061|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
57911455|NCT04596943|DIAGNOSTIC_TEST|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), \[68Ga\]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
58059275|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
58059276|NCT01110889|DRUG|Agomelatine (AGO178C)|
58059277|NCT01110889|DRUG|Agomelatine (AGO178C)|
58262166|NCT03560726|BEHAVIORAL|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
58059278|NCT01110889|DRUG|Placebo|
58059279|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
58059280|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
58059281|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
58262167|NCT03246165|PROCEDURE|Cardiac surgery|Coronary bypass, heart valve replacement
58262168|NCT05960448|OTHER|Transcutaneous Spinal Cord Stimulation (TSCS)|This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
58262169|NCT05960448|OTHER|Sham Transcutaneous Spinal Cord Stimulation|This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
58262170|NCT00003829|DRUG|cyclophosphamide|
58383062|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
58383063|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
58383064|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
58059282|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
58262171|NCT00003829|DRUG|fludarabine phosphate|
58383065|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
58383066|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
58262172|NCT00591617|OTHER|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
58262173|NCT03780465|DRUG|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
58262174|NCT03780465|DRUG|NOX66 (A)|Idronoxil formulated in suppository base A
58262175|NCT03780465|DRUG|NOX66 (B)|Idronoxil formulated in suppository base B
57911456|NCT01534377|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
57911457|NCT01534377|BEHAVIORAL|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
57911458|NCT01383460|DRUG|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
57911459|NCT01383460|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
57911460|NCT02648490|DRUG|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
58383067|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
58383068|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
58383069|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
57709645|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
57709646|NCT00366392|DEVICE|Optical Aids|
57709647|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
57709648|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
57709649|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
57709650|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
57911461|NCT02648490|DRUG|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
57911462|NCT02648490|DRUG|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
57911463|NCT02648490|DRUG|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
57911464|NCT02648490|DRUG|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
58262176|NCT02533557|DEVICE|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
58383070|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
58383071|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
57709651|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
57709652|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
57709653|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
57911465|NCT00697333|PROCEDURE|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
57911466|NCT04709315|DRUG|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
58262177|NCT02533557|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
57911467|NCT04709315|DRUG|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
57911468|NCT05983224|DIETARY_SUPPLEMENT|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
57911469|NCT05983224|OTHER|Placebo|The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
57911470|NCT00691327|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
57911471|NCT05300347|DIAGNOSTIC_TEST|adenosine deaminase enzyme deficiency test|adenosine deaminase enzyme deficiency
57911472|NCT00710853|OTHER|YiRen Qi gong|One hour weekly class for 8 week duration
57911473|NCT00710853|OTHER|Tai Chi|One hour weekly class for 8 week duration
58383072|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
58383073|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
58383074|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
58262178|NCT04448067|BEHAVIORAL|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
58262179|NCT04448067|BEHAVIORAL|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
58262180|NCT06362018|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
57709654|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
57709655|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
58262181|NCT04001894|DRUG|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
57709656|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
57709657|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
57911474|NCT00710853|OTHER|Hatha yoga|One hour weekly class for 8 week duration
57911475|NCT03143621|DIETARY_SUPPLEMENT|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
57911476|NCT03143621|OTHER|Water|Tap water heated to same temperature as coffee
57911477|NCT01236534|DRUG|Lubiprostone|24 mcg twice daily for 21 days.
58262182|NCT04001894|DRUG|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
57911478|NCT01236534|DRUG|Placebo|matching placebo twice daily for 21 days.
57911479|NCT05629754|DIAGNOSTIC_TEST|MRI, radiological assessment|MRI and radiological assessment of the involved knee
57911480|NCT03468231|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
57911481|NCT03468231|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
57911482|NCT03468231|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
57911483|NCT01710891|PROCEDURE|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
57911484|NCT01710891|PROCEDURE|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
57911485|NCT01220518|DRUG|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
57911486|NCT00497185|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
57911487|NCT04678115|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.
58262183|NCT05617638|BEHAVIORAL|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
58262184|NCT03543098|PROCEDURE|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
58262185|NCT03543098|PROCEDURE|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
58262186|NCT03543098|PROCEDURE|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
58262187|NCT03543098|PROCEDURE|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
58262188|NCT06619548|OTHER|Auricular magnet with a magnetic strength of 1800 Gauss|Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.
58262189|NCT06619548|OTHER|Auricular magnet with no magnetic strength|Auricular magnets with no magnetic strength are used as placebo control.
57709658|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
57911488|NCT04678115|DEVICE|Kinesiotape Frontalis Sling (KTFS)|Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
57911489|NCT01581359|DRUG|Triptorelin acetate|"* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
58262190|NCT05332990|DIAGNOSTIC_TEST|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
58262191|NCT04571970|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
58262192|NCT00916968|DEVICE|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
58262193|NCT00916968|DEVICE|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
57709659|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
57911490|NCT04869228|DRUG|GT0918 tablets or placebo|GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
58059283|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
58262194|NCT04291664|DRUG|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
58262195|NCT04291664|DRUG|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
58262196|NCT04291664|DRUG|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
58262197|NCT05294159|OTHER|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
58262198|NCT03756727|DRUG|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
58262199|NCT03756727|DRUG|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
58262200|NCT04432090|DRUG|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
57709660|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
57709661|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
58262201|NCT04432090|DRUG|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
58262202|NCT04432090|OTHER|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
57709662|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
57709663|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
57709664|NCT00004066|BIOLOGICAL|filgrastim|
57709665|NCT00004066|DRUG|docetaxel|
57709666|NCT00004066|DRUG|gemcitabine hydrochloride|
57709667|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
57709668|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
57911491|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|"The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
58059284|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
58262203|NCT00591058|DRUG|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
58059285|NCT00131131|BEHAVIORAL|Exercise|
58059286|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
58059287|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
58059288|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
58262204|NCT06619145|DRUG|Low dose Oliceridine|Low dose Oliceridine
57709669|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
57709670|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
57709671|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
57709672|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
57709673|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
57709674|NCT05224492|OTHER|Placebo|Placebo
57709675|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
58059289|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
58059290|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
58262205|NCT06619145|DRUG|High dose Oliceridine|High dose Oliceridine
58262206|NCT04535050|DEVICE|Renal denervation|Renal Denervation: DENEX system
58262207|NCT04535050|PROCEDURE|Renal angiography|Renal angiography
58262208|NCT03363451|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
58262209|NCT05957536|BIOLOGICAL|D3L-001|Intravenous administration
58262210|NCT04999306|BEHAVIORAL|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
58262211|NCT04999306|BEHAVIORAL|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
58262212|NCT04694950|PROCEDURE|Usual care|Intravenous morphine according to clinician´s discretion.
58262213|NCT05093530|DRUG|Neumifil|Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
57911492|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle|"The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
57911493|NCT02594605|DEVICE|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
57911494|NCT02594605|DEVICE|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
57911495|NCT00704379|DRUG|Placebo|an inactive substance
57911496|NCT00704379|DRUG|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
58262214|NCT05093530|DRUG|Placebo|Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
58383075|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
58383076|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
58383077|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
58383078|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
58383079|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
57709676|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
57709677|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
57709678|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
57911497|NCT05466409|OTHER|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
57911498|NCT05466409|OTHER|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
57911499|NCT05466409|OTHER|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
57911500|NCT05466409|OTHER|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
58383080|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
57709679|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
57911501|NCT05466409|OTHER|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
58262215|NCT02223650|DEVICE|Overminus treatment|2.50D overminus spectacles
58262216|NCT02223650|DEVICE|Non-overminus treatment|spectacles without overminus or no spectacles
58262217|NCT06512935|OTHER|Increase in the PEEP followed by decrease in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
58262218|NCT06512935|OTHER|Decrease in the PEEP followed by increase in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
58262219|NCT05001295|PROCEDURE|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
58262220|NCT03126006|PROCEDURE|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
58383081|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
58383082|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
57911502|NCT05466409|OTHER|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
57911503|NCT05466409|OTHER|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
57911504|NCT05466409|OTHER|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
57911505|NCT05466409|OTHER|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
57911506|NCT05466409|OTHER|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
57911507|NCT05324397|DEVICE|NEUROMARK System|The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
57911508|NCT01322997|DEVICE|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
57911509|NCT01322997|BEHAVIORAL|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
57911510|NCT01322997|DEVICE|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
57911511|NCT03768804|OTHER|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
57911512|NCT03768804|OTHER|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
57911513|NCT02982460|OTHER|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
58262221|NCT03126006|OTHER|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
57911514|NCT02982460|OTHER|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
57911515|NCT03723876|BEHAVIORAL|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
57911516|NCT00996476|DRUG|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
57911517|NCT00996476|DRUG|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
57911518|NCT00996476|DRUG|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
57911519|NCT02706899|DRUG|vadastuximab talirine|Intravenous (IV) push every 4 weeks
57911520|NCT02706899|DRUG|Azacitidine|75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks
57911521|NCT02706899|DRUG|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
58262222|NCT01196689|DRUG|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
58262223|NCT00410020|BEHAVIORAL|Alpha-linolenic enriched diet|
58262224|NCT05170503|DRUG|Sintilimab|Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
57911522|NCT00911287|DRUG|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
58262225|NCT01032421|PROCEDURE|IVF procedure|
58262226|NCT02819245|PROCEDURE|posterior correction and fusion|
58262227|NCT03126019|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food
58383083|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
57911523|NCT02274974|DRUG|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
57911524|NCT02274974|DRUG|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
58383084|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
58383085|NCT04907253|DRUG|Quercetin|500 mg twice daily
58383086|NCT04907253|DRUG|Placebo|twice daily
58383087|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
57911525|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.
57911526|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.
58262228|NCT05220566|BEHAVIORAL|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
58383088|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
58383089|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
58383090|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
58383091|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
58383092|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
58383093|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
58383094|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
58383095|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
58383096|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
57911527|NCT05952687|DRUG|Selinexor|Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
57911528|NCT00832234|DRUG|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
57911529|NCT01206036|DRUG|Docetaxel|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
57911530|NCT01206036|DRUG|Temsirolimus|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
58383097|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
58383098|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
58383099|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
58383100|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
58383101|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
58383102|NCT00373048|DRUG|mefloquine|tablet, once weekly
58383103|NCT00373048|DRUG|placebo|tablet, once weekly
58383104|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
58383105|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
58383106|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
57911531|NCT00940732|OTHER|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
57911532|NCT00940732|OTHER|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
57911533|NCT00940732|OTHER|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
57911534|NCT02675127|DRUG|Daktavira|1 tablet contains 60 mg Daclatasvir
57911535|NCT02675127|DRUG|Daklinza|1 tablet contains 60 mg Daclatasvir
58059291|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
58059292|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
58059293|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
58059294|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
58059295|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
58059296|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
58059297|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
58059298|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
58059299|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
58059300|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
58059301|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
58059302|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
57911536|NCT05358106|BIOLOGICAL|AntiBKV|AntiBKV neutralising antibody
58059303|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
58059304|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
58059305|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
58059306|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
58059307|NCT01172054|BIOLOGICAL|VAX128|one IM injection
58383107|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
58059308|NCT01172054|BIOLOGICAL|Placebo|One IM injection
58059309|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
58059310|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
58059311|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
58059312|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
58059313|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
58059314|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
58059315|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
57911537|NCT05358106|BIOLOGICAL|Placebo|Solution with no active ingredients
57911538|NCT03047304|DIAGNOSTIC_TEST|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
57911539|NCT00352911|DRUG|VGX-410 (Mifepristone)|
58059316|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
58262229|NCT06621355|OTHER|Physical fitness test: Progressive intervalic test|"An incremental interval test of 4\&#39; of work for 1\&#39; of rest will be performed at an individual intensity below the aerobic threshold. At the end of the rest minute, the load shall be increased slightly. In order to be as adjusted and individualised as possible, the subjective physical condition level stated by the patient during the sociodemographic data collection shall be taken as a reference for the establishment of the initial load, being a value of power (W) in cycle ergometer and speed (km/h) in treadmill. Never less than 50W or 6 km/h, respectively.~The minimum incremental values will be 25W or 0.5km/h until you are unable to complete a full interval. An incomplete interval shall also be recorded and analysed.~During the one minute rest period, as will have been well emphasised during the explanation of the test, no part of the body may be moved at all, so at the end of the 4 minutes of work, the evaluator will count down for the patient to get ready and remain stil"
58262230|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
58262231|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
57709680|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
57709681|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
57911540|NCT00352911|DRUG|Placebo for VGX-410 (Mifepristone)|
58059317|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
58059318|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
58262232|NCT04689048|DRUG|18F fluciclovine|Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
58059319|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
58262233|NCT05275868|DRUG|MGY825|investigational drug
58262234|NCT02953587|PROCEDURE|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
58262235|NCT02953587|DRUG|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
58262236|NCT02953587|DRUG|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
58262237|NCT05948124|DRUG|L-carnitine|L-carnitine supplementation
58262238|NCT05948124|OTHER|isotonic saline|Intravenous 5 ml of isotonic saline
58262239|NCT01230424|DRUG|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
58262240|NCT01230424|DRUG|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
58262241|NCT06648278|BEHAVIORAL|Patient Navigation Program|Online health tool
58262242|NCT06648278|OTHER|Quality-of-Life (QOL) Assessment|Online surveys to assess QOL
58262243|NCT06648278|OTHER|Survey Administration|Ancillary studies
58262244|NCT04723953|DIAGNOSTIC_TEST|68Ga-FAPI PET/MRI|PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.
58262245|NCT03764540|DRUG|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
58059320|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
58059321|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
58059322|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
58383108|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
57911541|NCT04780477|DIETARY_SUPPLEMENT|High Fiber Diet Featuring Legumes (HLD)|The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (\~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. \~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
57911542|NCT04780477|DIETARY_SUPPLEMENT|Healthy American Diet|The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
57911543|NCT03500913|DRUG|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
57911544|NCT02032979|BEHAVIORAL|Psychiatric test|
57911545|NCT02213341|PROCEDURE|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
57911546|NCT02213341|PROCEDURE|Blood draw|
58262246|NCT03764540|DRUG|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
58262247|NCT02994459|OTHER|Weight Loss|Diet-induced weight loss (obese only)
58262248|NCT03180658|PROCEDURE|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
58262249|NCT03180658|PROCEDURE|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
58262250|NCT03622398|PROCEDURE|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
58262251|NCT03622398|PROCEDURE|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
58262252|NCT00520481|DRUG|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
58262253|NCT01783639|PROCEDURE|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
58262254|NCT05081180|DRUG|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
58059323|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
57911547|NCT06408974|DRUG|Ketamine|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition
57911548|NCT06408974|DRUG|dexamethasone|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
57911549|NCT00023894|DRUG|alvocidib|
57911550|NCT00918580|BIOLOGICAL|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
57911551|NCT03816267|DEVICE|Nebulizer|Nebulization via mask
57911552|NCT03816267|DRUG|Salbutamol|Delivery of appropriate dose according to weight
57911553|NCT03816267|DEVICE|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
57911554|NCT05307211|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
57911555|NCT05307211|OTHER|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
58262255|NCT05081180|DRUG|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
58262256|NCT02226705|PROCEDURE|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
58262257|NCT02559791|BIOLOGICAL|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
58262258|NCT02559791|DRUG|Placebo|Matching placebo once monthly for 2 months
58262259|NCT00095186|DRUG|Recombinant Human Lactoferrin|
58383109|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
58383110|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
58383111|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
58383112|NCT02538536|DRUG|PBI4050|
57911556|NCT05307211|OTHER|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
58059324|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
58059325|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
58059326|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
58059327|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
58262260|NCT01770366|DEVICE|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
58262261|NCT01770366|DEVICE|Usual Care|
58383113|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
58383114|NCT02446821|DEVICE|VeraCept|IUD placement of VeraCept
58383115|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
58383116|NCT02359032|DRUG|ASP6858|Oral tablets
58383117|NCT02359032|DRUG|Placebo|Oral tablets
57911557|NCT00842985|DRUG|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
57911558|NCT01480219|DRUG|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
57911559|NCT01480219|OTHER|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
57911560|NCT02244021|DRUG|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
57911561|NCT00636311|DRUG|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
57911562|NCT00636311|DRUG|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
57911563|NCT00206661|DRUG|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
57911564|NCT00206661|DRUG|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
58262262|NCT06505135|BIOLOGICAL|Stem-cell treatment|"In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe."
58262263|NCT06505135|OTHER|Standard care|Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
58262264|NCT05164640|OTHER|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
58262265|NCT03499691|DEVICE|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
58262266|NCT03499691|DEVICE|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
58262267|NCT06512454|OTHER|No Intervention|This is a non-interventional study.
58262268|NCT06579937|DRUG|Esketamine hydrochloride|During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
58262269|NCT06579937|DRUG|normal saline|During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
57911565|NCT02434068|OTHER|CT|followup
57911566|NCT03411447|OTHER|Parenteral nutrition|
57911567|NCT03411447|OTHER|Enteral nutrition|
57911568|NCT02819830|BEHAVIORAL|Exercise Intervention|Combined strength and aerobic exercise
58262270|NCT00427206|DRUG|acetaminophen (4g/day)|
58262271|NCT00427206|DRUG|placebo|
58262272|NCT01983072|DIETARY_SUPPLEMENT|Infant formula|
58383118|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
57911569|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
57911570|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
57911571|NCT01632670|OTHER|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
57911572|NCT02412410|BEHAVIORAL|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
57911573|NCT02918227|PROCEDURE|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
57911574|NCT05097222|DEVICE|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
57911575|NCT05097222|DEVICE|Sham device|Control
57911576|NCT00950274|DRUG|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
57911577|NCT00950274|DRUG|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
57911578|NCT02708264|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
57911579|NCT05550701|OTHER|lymph node yield|We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer
58262273|NCT01983072|OTHER|Breastfeeding|Breastfeeding
58383119|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
57911580|NCT06414707|DRUG|Vonoprazan, Amoxicillin and Levofloxacin|Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
58262274|NCT05482321|DRUG|Definity Suspension for Injection|"* DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided)."
57709682|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
58383120|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
57911581|NCT06414707|DRUG|Pantoprazole 40mg, Amoxicillin and Levofloxacin|Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
57911582|NCT05239637|OTHER|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
57911583|NCT05239637|OTHER|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
57911584|NCT02617680|DRUG|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
57911585|NCT02617680|DRUG|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
58383121|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
58383122|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
57911586|NCT05744752|OTHER|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
57911587|NCT05744752|DIETARY_SUPPLEMENT|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
58262275|NCT01968356|DRUG|3M CHG/IPA Prep Colorless|Apply topically.
58262276|NCT01968356|DRUG|3M CHG/IPA Prep Tint|Apply topically.
58262277|NCT01968356|DRUG|ChloraPrep|Apply topically.
58262278|NCT01968356|DRUG|Saline|Apply topically.
58262279|NCT06475885|OTHER|Infant Massage Program|The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
58262280|NCT02580474|DRUG|Daclatasvir plus Asunaprevir|
58262281|NCT06618586|BEHAVIORAL|TodaysBaby|The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .
58383123|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
58383124|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
58383125|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
58383126|NCT00173017|DEVICE|wearing N95 masks|
58383127|NCT00442923|DRUG|Coreg|
57709683|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
57709684|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
57709685|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
58059328|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
58059329|NCT00000756|DRUG|Lymphocytes, Activated|
58383128|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
57709686|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
57709687|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
57709688|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
57911588|NCT05744752|DIETARY_SUPPLEMENT|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
57911589|NCT05744752|OTHER|Placebo|1ml NaCl 0.9% daily for 12 weeks
57911590|NCT01593332|DRUG|Rituximab|two 500 mg rituximab infusions 2 weeks apart
58059330|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
58059331|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
57709689|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
57911591|NCT01593332|DRUG|Rituximab|500mg,two times with two weeks interval
57911592|NCT06470061|DRUG|Resveratrol, Quercetin, and Curcumin (RQC)|"2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)"
57911593|NCT06470061|DRUG|Curcumin|2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
58059332|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
58059333|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
58262282|NCT05755607|PROCEDURE|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
58262283|NCT05755607|PROCEDURE|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
58383129|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
57709690|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
58059334|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
58059335|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
58262284|NCT03270475|OTHER|exercise training|subjects complete 4-5 weeks of training
58059336|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
58059337|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
58059338|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
58059339|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
58059340|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
58059341|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
58262285|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
58262286|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
58262287|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
57911594|NCT04261998|OTHER|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
57911595|NCT03552432|DRUG|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
57911596|NCT04579822|BIOLOGICAL|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
57911597|NCT05338489|DRUG|Selpercatinib|Administered orally.
57911598|NCT05338489|DRUG|Itraconazole|Administered orally.
57911599|NCT05338489|DRUG|Rifampin|Administered orally.
57911600|NCT02638480|DEVICE|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
58059342|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
58262288|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
58262289|NCT01670734|DRUG|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
58262290|NCT04482595|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
57911601|NCT04694209|PROCEDURE|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
58262291|NCT04482595|DRUG|Placebo|Matched placebo for BIO 300 Oral Suspension
58262292|NCT02784626|DRUG|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
58262293|NCT02784626|DRUG|Propofol|Intraoperative sedation using propofol
58262294|NCT03430661|DRUG|ACT-246475|Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
57911602|NCT04694209|PROCEDURE|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
57911603|NCT02428361|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
57911604|NCT00005829|DRUG|gemcitabine hydrochloride|
57911605|NCT03988920|DRUG|Tenapanor|NHE3 Inhibitor
57911606|NCT03988920|DRUG|Sevelamer Carbonate|Phosphate binder
58059343|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
58059344|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
58059345|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
58059346|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
58059347|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
58059348|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
58059349|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
58059350|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
58059351|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
58262295|NCT03430661|DRUG|Clopidogrel|Tablet for oral administration (300 or 600 mg)
58262296|NCT03430661|DRUG|Prasugrel|Tablet for oral administration (60 mg)
58262297|NCT03430661|DRUG|Placebo|Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
58262298|NCT03430661|DRUG|Ticagrelor|Tablet for oral administration (180 mg)
58383130|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
58383131|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
58383132|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
58383133|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
57911607|NCT00080132|DRUG|implitapide|
58383134|NCT06169618|OTHER|normal group|this group will have normal subjects
58383135|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
58383136|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
58383137|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
58383138|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
58383139|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
58383140|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
58383141|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
58059352|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
58059353|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
58059354|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
58059355|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
58059356|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
58059357|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
58059358|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
58383142|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
58383143|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
58383144|NCT01484496|BIOLOGICAL|Placebo|Placebo
58383145|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
58262299|NCT02017912|BIOLOGICAL|Nurown MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
58262300|NCT02017912|BIOLOGICAL|Placebo|Excipient administration by combined intramuscular and intrathecal administration
58262301|NCT05047731|DRUG|Antihypertensive medication|Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
58262302|NCT05109637|DEVICE|Konectom NMD Application|Administered as specified in the treatment arm.
58383146|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
58383147|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
58383148|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
58383149|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
58383150|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
58383151|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
58383152|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
57911608|NCT01323647|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration
57911609|NCT01323647|BIOLOGICAL|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
57911610|NCT00379041|BIOLOGICAL|bleomycin sulfate|
57911611|NCT00379041|DRUG|doxorubicin hydrochloride|
58059359|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
58383153|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
58383154|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
58383155|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
58383156|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
58383157|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
58383158|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
58383159|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
58383160|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
58262303|NCT02049840|DEVICE|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
58262304|NCT05524818|DIAGNOSTIC_TEST|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
58262305|NCT03042169|DRUG|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
58262306|NCT03042169|PROCEDURE|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
58262307|NCT03042169|DRUG|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
58262308|NCT04902703|DRUG|Sargramostim|Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
58262309|NCT04902703|DRUG|Saline - placebo comparator|Saline will be administered subcutaneously, 5 days/week, for 24 weeks
58262310|NCT04766489|PROCEDURE|Complete Decongtestive Therapy|Patients will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise, for 5 days a week and for a mean of 20 sessions. Each session will be of 1 hour duration for compressive therapies(Short stretch bandages will be left on for 23 hours a day), 30 minutes of manual lymphatic drainage, and decongestive exercises 3 times a day for 15 minutes each time.
58383161|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
57709691|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
57709692|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
57911612|NCT00379041|DRUG|mechlorethamine hydrochloride|
57911613|NCT00379041|DRUG|prednisone|
57911614|NCT00379041|DRUG|procarbazine hydrochloride|
57911615|NCT00379041|DRUG|vinblastine sulfate|
57911616|NCT00379041|DRUG|vincristine sulfate|
57911617|NCT00379041|RADIATION|radiation therapy|
58262311|NCT00181350|DEVICE|Relocatable fixation system|
58262312|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
58262313|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
58383162|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
58383163|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
58383164|NCT02859831|OTHER|water samples|
58383165|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
58059360|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
58262314|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
57709693|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
58262315|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
58262316|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
57709694|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
57911618|NCT00004204|DRUG|temozolomide|
57911619|NCT04805229|OTHER|Retrospective analysis of opioid use after surgery|Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
57911620|NCT06095700|PROCEDURE|first rib resection|standard first rib resection
57911621|NCT06095700|PROCEDURE|First rib avulsion|As the active treatment, just instead of resectioning the first rib, we will do an avulsion of the first rib through the same incision
57911622|NCT03180177|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.
58262317|NCT06298474|BEHAVIORAL|The BRAIN App|The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
58262318|NCT05136313|BEHAVIORAL|Time-restricted eating|16 weeks of TRE consisting of an 8-hour eating window.
58262319|NCT06618495|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.
58262320|NCT00536224|BEHAVIORAL|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
58262321|NCT00536224|BEHAVIORAL|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
58262322|NCT03932149|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
58262323|NCT03932149|DEVICE|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
58383166|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
58383167|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
58383168|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
57911623|NCT03180177|PROCEDURE|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
57911624|NCT03180177|DRUG|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
57911625|NCT03180177|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
57911626|NCT03439423|RADIATION|CT with contrast agent|
58059361|NCT05569356|OTHER|Retrospective|None (only data collection)
58059362|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
58059363|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
58262324|NCT06618248|COMBINATION_PRODUCT|Sirolimus coated balloon angioplasty|This study involves the use of a Sirolimus-Coated Balloon (SCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The SCB is coated with sirolimus, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
58262325|NCT06618248|COMBINATION_PRODUCT|Paclitaxel coated balloon angioplasty|This study involves the use of a Paclitaxel-Coated Balloon (PCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The PCB is coated with paclitaxel, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
58262326|NCT02362776|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
58262327|NCT05499260|DRUG|CB03-154|CB03-154 tablet once daily.
58383169|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
58383170|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
58383171|NCT02705612|DRUG|Cisplatin|
57709695|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
57709696|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
57911627|NCT03439423|DIAGNOSTIC_TEST|MR without contrast agent|"on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)"
58262328|NCT05499260|DRUG|Placebo|Placebo tablet once daily.
58262329|NCT02897726|DRUG|NVP-1402|Oral
58262330|NCT02897726|DRUG|NVP-1402R|Oral
58262331|NCT05019846|DRUG|Triptorelin Embonate|single administration before SRT starting
57709697|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
57709698|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
58262332|NCT05019846|DRUG|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
58383172|NCT02705612|RADIATION|External Beam Radiation Therapy|
57709699|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
57709700|NCT02009033|DRUG|Hydroxyethylstarch|
57911628|NCT03439423|DIAGNOSTIC_TEST|Color-Doppler Ultrasound|
57911629|NCT03439423|OTHER|Questionnaire|regarding their perception of examinations
57911630|NCT03686631|BEHAVIORAL|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
57911631|NCT02666469|OTHER|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
58262333|NCT01226368|OTHER|Biological Sample collection|Cervix cells
58262334|NCT03344575|PROCEDURE|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
58262335|NCT03344575|PROCEDURE|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
58262336|NCT02410083|DRUG|Clopirin 1|
58383173|NCT02705612|RADIATION|Internal Radiation Therapy|
58383174|NCT02705612|DRUG|nimotuzumab|
57709701|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
57709702|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
57709703|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
57709704|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
58262337|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 1|
58262338|NCT02410083|DRUG|Clopirin 2|
58262339|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 2|
58262340|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|"Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)"
58262341|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
57911632|NCT02666469|OTHER|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
57911633|NCT02666469|DEVICE|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
57911634|NCT01473446|PROCEDURE|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV\> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding \>1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
57911635|NCT00527592|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
58262342|NCT00169728|BIOLOGICAL|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
58262343|NCT00169728|BIOLOGICAL|heptavalent pneumococcal conjugate vaccine, Prevenar|
58262344|NCT03710070|DEVICE|Amplatzer vascular plug 4|See above
58262345|NCT03710070|OTHER|Sham Control|Angiography of the IMA without occlusion
58262346|NCT06620601|DIAGNOSTIC_TEST|Portable Polysomnography|Research assistants set up the portable polysomnography (Prodigy) for the overnight sleep study.
58262347|NCT06620601|DEVICE|Treatment|Based on the decision aid, patient preference, and CADTH recommendations, the sleep physicians will recommend the participant to use Auto-CPAP or MAD for six months.
58262348|NCT06620601|OTHER|Questionnaires|Participants will complete eleven questionnaires: Stop-Bang, Insomnia severity index, Epworth sleepiness score (ESS), quality of life (FOSQ-10), Beck Depression Inventory (BDI), Chalder Fatigue Scale (CFQ), primary care post-traumatic stress disorder (PTSD) scale (PC-PTSD-5), Asthma control questionnaire (ACQ), OHIP-14, and Participant demographics. The RA will help the participants complete the questionnaires (\~one and a half hours in total).
58262349|NCT01483482|PROCEDURE|Conservative Treatment|Simple Sling
58262350|NCT01483482|PROCEDURE|Surgical treatment|Superior Locking plate
58262351|NCT01250132|OTHER|Biological and behavioral explorations|"Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
58262352|NCT02106416|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
58262353|NCT00236158|DEVICE|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
58262354|NCT04291482|BEHAVIORAL|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
57911636|NCT00527592|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
58262355|NCT04291482|BEHAVIORAL|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
58262356|NCT06369519|PROCEDURE|Surgery treatment or local tumor destruction.|Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
58262357|NCT05940493|DRUG|Abemaciclib|Tablet
58262358|NCT05940493|DRUG|Placebo|Tablet
58262359|NCT01317797|DRUG|namilumab (MT203)|administered three times, subcutaneous in the abdomen
58383175|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
58383176|NCT00820144|BIOLOGICAL|CTB by nasal way|
58262360|NCT01317797|DRUG|Placebo|administered three times, subcutaneous in the abdomen
58262361|NCT00396552|DEVICE|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
58383177|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
58383178|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
58383179|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
57911637|NCT02772419|DRUG|benralizumab|SC administration
57911638|NCT02772419|DRUG|benralizumab|SC administration
57911639|NCT02772419|DRUG|Placebo|SC administration
57709705|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
57709706|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
57911640|NCT02128542|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
58059364|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
58059365|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
57709707|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
57709708|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
57709709|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
57911641|NCT02128542|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
57911642|NCT06312228|OTHER|Helfer Skin Tap|Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
57709710|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
57709711|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
57709712|NCT00006219|DRUG|clarithromycin|
58059366|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
58059367|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
58059368|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
57709713|NCT00006219|DRUG|prasterone|
58059369|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
58383180|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
57709714|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
57709715|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
57709716|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
58059370|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
58059371|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
58383181|NCT02811120|OTHER|venepuncture only|single venepuncture
58059372|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
58059373|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
58059374|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
58059375|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
58383182|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
58383183|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
57709717|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
57709718|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
57784714|NCT06014567|PROCEDURE|Magnetic Resonance Imaging|"1. A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~2. A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2\*, perfusion imaging and cine imaging to assess the heart dynamically."
58059376|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
58059377|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
58059378|NCT03681808|DEVICE|Control|Contact Lens
58059379|NCT03681808|DEVICE|Test|Soft Contact Lens
58059380|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
58059381|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
58059382|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
58059383|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
58059384|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
57784715|NCT02381860|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
57784716|NCT02381860|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
58383184|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
57784717|NCT03788148|DEVICE|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
57784718|NCT03046303|PROCEDURE|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
57784719|NCT01150851|OTHER|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
57784720|NCT01150851|OTHER|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
58059385|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
57784721|NCT05900453|OTHER|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
58059386|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
58262362|NCT00396552|DEVICE|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
58262363|NCT01451138|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
58262364|NCT04056273|OTHER|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
58262365|NCT04056273|OTHER|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
57709719|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
57709720|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
57709721|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
57911643|NCT06312228|OTHER|Buzzy|The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
58262366|NCT05030909|BEHAVIORAL|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
58262367|NCT00756392|PROCEDURE|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
57709722|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
57709723|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
57709724|NCT01041716|OTHER|None - Observational study|None - Observational study
57709725|NCT01719692|DRUG|Rituximab|
58383185|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
57709726|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
57709727|NCT00001720|DRUG|Alendronate|
57709728|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
57709729|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
57709730|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
57709731|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
57709732|NCT02183441|DRUG|BI 1356|
57709733|NCT02183441|DRUG|Ritonavir|
57911644|NCT06265870|DRUG|Albendazole|Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
57709734|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
57709735|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
57709736|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
57911645|NCT06265870|DRUG|Ivermectin or albendazole|Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
57709737|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
57709738|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
57709739|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
57911646|NCT02910739|DRUG|MK-8931|MK-8931 40 mg
57911647|NCT06306339|DRUG|Burfiralimab|Humanized monoclonal antibody.
57911648|NCT06306339|DRUG|SOC (Standard of care)|"The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)"
57911649|NCT06306339|DRUG|Placebo|The placebo for Burfiralimab (hzVSF-v13)
57911650|NCT00662233|DRUG|cyclophosphamide|
57911651|NCT00662233|DRUG|doxorubicin hydrochloride|
57911652|NCT00662233|DRUG|etoposide|
57911653|NCT00662233|DRUG|ifosfamide|
57709740|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
57709741|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
58262368|NCT03805373|OTHER|Diet Assessment Survey|Participants will complete 2 different diet assessment tools separated by at least 1 week.
58262369|NCT05161520|PROCEDURE|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
58262370|NCT05161520|PROCEDURE|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
58262371|NCT03281187|DRUG|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
57709742|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
57709743|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
57709744|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
58262372|NCT03281187|DRUG|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
58262373|NCT03281187|OTHER|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
58262374|NCT03281187|OTHER|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
58262375|NCT06387667|DIAGNOSTIC_TEST|Complete blood count|blood sample
57709745|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
57709746|NCT00003255|DRUG|carboplatin|
57709747|NCT00003255|DRUG|topotecan hydrochloride|
57709748|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
57709749|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
57709750|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
57709751|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
57709752|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
57709753|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
57709754|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
57709755|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
57709756|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
57709757|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
57709758|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
57709759|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
58262376|NCT06387667|DIAGNOSTIC_TEST|C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)|serum sample
58262377|NCT06387667|RADIATION|CT chest|Computed tomography of the chest
58262378|NCT06387667|DIAGNOSTIC_TEST|Microscopic examination|sputum and bronchoalveolar lavage (BAL)
58262379|NCT06387667|DIAGNOSTIC_TEST|culture and sensitivity|for bacterial and fungal
58262380|NCT05225415|DRUG|CT1812|Orally administered CT1812
58262381|NCT00224458|DRUG|Truvada|
58262382|NCT00224458|DRUG|efavirenz|
58262383|NCT03748576|BEHAVIORAL|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
58262384|NCT04891406|OTHER|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
58262385|NCT04891406|OTHER|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
58262386|NCT04891406|OTHER|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
58262387|NCT04891406|OTHER|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
58262388|NCT04891406|OTHER|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
57911654|NCT00662233|DRUG|vincristine sulfate|
58262389|NCT02952625|OTHER|Imaging|Single arm Imaging (PET/MR) study
58383186|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
58383187|NCT05433701|PROCEDURE|Radiofrequency Ablation|- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
57709760|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
57709761|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
57709762|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
57709763|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
57709764|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
57709765|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
57911655|NCT00662233|PROCEDURE|adjuvant therapy|
57911656|NCT00662233|PROCEDURE|neoadjuvant therapy|
57911657|NCT00662233|PROCEDURE|therapeutic conventional surgery|
57911658|NCT00662233|RADIATION|brachytherapy|
57911659|NCT00662233|RADIATION|intraoperative radiation therapy|
57911660|NCT00662233|RADIATION|radiation therapy|
57911661|NCT01585987|BIOLOGICAL|Ipilimumab|
57911662|NCT01585987|OTHER|Best Supportive care (BSC)|
58262390|NCT04803422|DRUG|Antibiotic|The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
58262391|NCT03962543|DRUG|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
58262392|NCT00001111|DRUG|Nevirapine|
58262393|NCT00001111|DRUG|Zidovudine|
58262394|NCT06636084|PROCEDURE|Guided bone regeneration (GBR)|A composite graft composed of a 50:50 proportion of autogenous bone and a demineralized bone mineral will be positioned around the bony defect or placed in the membrane, depending on the group randomization. The selected membrane will then be secured with screws to ensure a complete and stable coverage of the grafted area.
58262395|NCT02129790|BEHAVIORAL|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
58262396|NCT06620692|DRUG|5% GM-XANTHO [GM-XAN003]|5% GM-XANTHO \[GM-XAN003\]
58262397|NCT06620692|DRUG|Placebo|The placebo
58262398|NCT06647732|DRUG|Zanubrutinib|160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
58262399|NCT06647732|DRUG|Rituximab|375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
58262400|NCT04557462|DRUG|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
58262401|NCT03108599|OTHER|Enhanced Cab|The enhanced cab intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep program.
58262402|NCT03108599|BEHAVIORAL|Fit4Sleep|The behavioral sleep program includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The behavioral sleep program includes an optional body weight management component. The intervention arm will receive the behavioral sleep program in combination with the enhanced cab intervention.
58262403|NCT04006262|DRUG|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
58262404|NCT04006262|DRUG|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
58262405|NCT02985073|DEVICE|Veritas®|Biologic mesh
58262406|NCT02985073|DEVICE|TIGR®|Non biologic mesh
58262407|NCT01849068|DRUG|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
58262408|NCT01849068|DRUG|Placebo|Placebo for 12 weeks
58383188|NCT02805959|DEVICE|MTS2|
58383189|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
57709766|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
57709767|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
57709768|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
57709769|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
57709770|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
58383190|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
57709771|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
57709772|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
57709773|NCT00499135|OTHER|Computed Tomography|Correlative studies
57709774|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
57709775|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
57709776|NCT00499135|OTHER|Pharmacological Study|Correlative studies
57709777|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
57709778|NCT00499135|DRUG|Sunitinib Malate|Given PO
58262409|NCT04175782|PROCEDURE|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
58262410|NCT00230022|BEHAVIORAL|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
58262411|NCT01430780|DRUG|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
58262412|NCT01430780|DRUG|control group|placebo
58262413|NCT02097251|DRUG|UX003|Open Label
57709779|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
57709780|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
57709781|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
57709782|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
57709783|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
57709784|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
57709785|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
57709786|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
57709787|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
57709788|NCT03536039|DRUG|Prednisone|75 mg
57709789|NCT06249308|OTHER|Blood collection|Blood sample will be collected
57709790|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
57709791|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
57709792|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
57911663|NCT03254446|DRUG|TRC150094|TRC150094 Tablet 45 mg
57709793|NCT02142452|OTHER|Usual Prenatal Care|
57709794|NCT02534792|OTHER|Revalvulation|
57709795|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
57709796|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
57709797|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
57709798|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
57911664|NCT03254446|DRUG|Placebo|Matching Placebo Tablet
57911665|NCT01680484|DIETARY_SUPPLEMENT|Bitter chocolate|
58262414|NCT03018366|DRUG|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
57709799|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
57709800|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
57709801|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
58262415|NCT03018366|DRUG|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
58262416|NCT03018366|DRUG|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
58383191|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
58383192|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
58383193|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
58383194|NCT05182450|OTHER|Placebo capsule|Single dose
57709802|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
57709803|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
58262417|NCT03018366|DRUG|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
57709804|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
57709805|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
57709806|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
57911666|NCT01680484|DIETARY_SUPPLEMENT|Orange juice|
58262418|NCT02930746|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
58383195|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
57709807|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
57911667|NCT04059003|DRUG|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
58262419|NCT02284659|DEVICE|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
58262420|NCT02284659|DEVICE|FES- Sham|
58383196|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
58383197|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
58383198|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
57709808|NCT03022617|DRUG|Apremilast|
57709809|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
57709810|NCT01221259|DRUG|placebo|a single dose of matching placebo
57709811|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
57709812|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
57709813|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
57709814|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
58383199|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
58383200|NCT05641012|OTHER|data collection|helioderma evaluation
58383201|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
58383202|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
58262421|NCT04938219|OTHER|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
57709815|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
57709816|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
57709817|NCT00028756|DRUG|vinblastine sulfate|Given IV
57709818|NCT00028756|DRUG|methotrexate|Given IV
58383203|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
58383204|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
58383205|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
58383206|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
58383207|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
58383208|NCT00618007|DRUG|Placebo|Placebo
58383209|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
58383210|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
57709819|NCT00028756|DRUG|cisplatin|Given IV
57709820|NCT00028756|BIOLOGICAL|filgrastim|Given SC
57709821|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
57709822|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
57911668|NCT04496492|DRUG|Tocotrienol|Tocotrienol 200 mg orally twice a day
57911669|NCT03854773|OTHER|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
58383211|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
58383212|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
58262422|NCT06647615|DEVICE|VR headset|The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
57709823|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
57709824|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
57709825|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
57709826|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
58262423|NCT03110861|DEVICE|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
57709827|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
57709828|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
57709829|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
57911670|NCT03854773|OTHER|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
57911671|NCT03854773|OTHER|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
57911672|NCT04687280|OTHER|non interventional|non interventional, study on data
57911673|NCT03373201|DRUG|Tasimelteon|Oral capsule
57911674|NCT03373201|DRUG|Placebo|Oral capsule
58262424|NCT06260033|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58262425|NCT06260033|PROCEDURE|Bone Scan|Undergo bone scan
57911675|NCT00827320|DRUG|Levetiracetam|1000 mg tablet
57911676|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
57911677|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
57911678|NCT05015933|PROCEDURE|Pump refill procedure at home|Implantable pump refill is performed at home
58262426|NCT06260033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
58262427|NCT06260033|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
58262428|NCT06260033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
58262429|NCT06260033|OTHER|Questionnaire Administration|Ancillary studies
58262430|NCT06260033|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58262431|NCT06648109|DEVICE|Electric Blanket|Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
57911679|NCT01619397|DEVICE|Test condom with new Xanthan gum condom coating|
57911680|NCT00002332|DRUG|Thymopentin|
57911681|NCT03284047|DRUG|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
57911682|NCT04320706|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
57911683|NCT04320706|DRUG|Oral Placebo|Administration of placebo orally
58262432|NCT01091545|RADIATION|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
58262433|NCT02026817|DRUG|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
58262434|NCT02026817|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
58262435|NCT02026817|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
58262436|NCT06072677|BEHAVIORAL|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
58262437|NCT00595517|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
58262438|NCT03809377|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
58262439|NCT02892513|DEVICE|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.
58262440|NCT02892513|DEVICE|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
58262441|NCT03530787|OTHER|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
58383213|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
58383214|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
58383215|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
58383216|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
58383217|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
58383218|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
58383219|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
58383220|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
58383221|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
58383222|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
58383223|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
58383224|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
58383225|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
57911684|NCT00359216|DRUG|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
57911685|NCT00359216|DRUG|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
58262442|NCT03530787|OTHER|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
58262443|NCT05666128|DRUG|HD-6277|HD-6277 100mg
58262444|NCT05666128|DRUG|HD-6277|HD-6277 50mg
58262445|NCT05666128|DRUG|Placebo|Placebo
58383226|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
58383227|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
58383228|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
58383229|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
58383230|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
58383231|NCT04887194|DRUG|Digoxin|P-gp probe substrate
58383232|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
58383233|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
57709830|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
57709831|NCT02827058|DEVICE|G25 pencil point needle|
58262446|NCT00862342|DRUG|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
57709832|NCT02827058|DEVICE|G27 pencil point needle|
57709833|NCT00049062|DRUG|anastrozole|
58059387|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
58059388|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
58059389|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
58059390|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
58059391|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
58059392|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
58262447|NCT05386277|DEVICE|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
58262448|NCT00005046|DRUG|chemotherapy|
58262449|NCT00005046|DRUG|paclitaxel|
58262450|NCT06629233|PROCEDURE|Tumor resection|As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
57709834|NCT00049062|DRUG|gefitinib|
57709835|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
57709836|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
57709837|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
58262451|NCT00687349|BEHAVIORAL|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
57709838|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
58262452|NCT06624241|PROCEDURE|Lipo-Curcumin gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.
58262453|NCT06624241|PROCEDURE|Lipo gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.
58262454|NCT06624241|PROCEDURE|Discharged Gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.
58262455|NCT06624241|PROCEDURE|SRP alone|The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
58262456|NCT04794205|DRUG|Low Dose Beta-Caryophyllene|5 mg BCP
58262457|NCT04794205|DRUG|Medium Dose Beta-Caryophyllene|30 mg BCP
58262458|NCT04794205|DRUG|High Dose Beta-Caryophyllene|150 mg BCP
58262459|NCT04794205|DRUG|Placebo|Placebo drug.
58262460|NCT06612463|DIETARY_SUPPLEMENT|Caffeine 6mg/kg|In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day
58262461|NCT06612463|DIETARY_SUPPLEMENT|Placebo|In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
58262462|NCT05389657|BEHAVIORAL|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
58262463|NCT05389657|BEHAVIORAL|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
57709839|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
58262464|NCT05248295|BEHAVIORAL|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
58262465|NCT05399017|DEVICE|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
58262466|NCT03023111|DRUG|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
58262467|NCT03023111|DRUG|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
58262468|NCT03023111|DRUG|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
58262469|NCT05283382|DRUG|Cannabidiol Oral Product|Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
58262470|NCT05283382|OTHER|Placebo|Participants will receive a one-time dose of placebo capsules in the form of six capsules.
58262471|NCT05051605|BIOLOGICAL|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
58262472|NCT05501015|OTHER|Ice chips|Consuming small amounts of ice chips with supervision
58262473|NCT00334633|DRUG|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
58262474|NCT01918150|DEVICE|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
57709840|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
57709841|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
57709842|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
58262475|NCT01918150|DEVICE|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
58262476|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.
58262477|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.
58262478|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.
58262479|NCT01950559|OTHER|Oral food challenge|Oral food challenge to determine allergy to soy
58262480|NCT06615713|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
58262481|NCT03841539|BEHAVIORAL|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
58262482|NCT03841539|DIETARY_SUPPLEMENT|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
58262483|NCT03841539|BEHAVIORAL|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
57709843|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
58262484|NCT04197921|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
57709844|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
58262485|NCT01333358|DRUG|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
57709845|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
57709846|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
58262486|NCT06621823|PROCEDURE|image-guided surgery technique|The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
57709847|NCT02837432|DRUG|Hydrocortisone acetate|
57709848|NCT02837432|DRUG|Placebo|
57911686|NCT05528029|DEVICE|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
57911687|NCT04068766|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
58262487|NCT06186817|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
58262488|NCT06186817|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
58262489|NCT06186817|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
58262490|NCT06186817|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
58262491|NCT04500600|OTHER|Quality-of-Life Assessment|Ancillary studies
58262492|NCT04500600|OTHER|Questionnaire Administration|Complete questionnaire
57709849|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
57709850|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
57709851|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
57709852|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
57709853|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
57709854|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
57709855|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
57709856|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
57709857|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
57911688|NCT04068766|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
58262493|NCT06460844|GENETIC|RTx-015|Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
58262494|NCT03097055|PROCEDURE|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
58383234|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
58383235|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
58383236|NCT02432937|DRUG|Corever|Corever
58383237|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
58383238|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
58383239|NCT00219596|DRUG|Xalacom|
58383240|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
58262495|NCT03097055|PROCEDURE|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
58262496|NCT04902313|BEHAVIORAL|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
58383241|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
58383242|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
58383243|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
58383244|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
58262497|NCT02587572|BIOLOGICAL|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
58383245|NCT00628498|DRUG|Defibrotide|
58383246|NCT00288548|DRUG|Metoprolol|
57911689|NCT04068766|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
57911690|NCT03704246|DRUG|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
57911691|NCT01065844|DRUG|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
57911692|NCT00662506|DRUG|Cediranib Maleate|Given PO
57911693|NCT00662506|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
58262498|NCT03586674|DRUG|Lipanthyl|Tablet
58262499|NCT03586674|DRUG|Ursogal|suspension
58262500|NCT02609724|OTHER|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
58262501|NCT02609724|OTHER|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
58262502|NCT02609724|OTHER|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
58383247|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
58383248|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
58383249|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
58383250|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
58383251|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
57911694|NCT00662506|PROCEDURE|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
57911695|NCT00662506|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
57911696|NCT00662506|RADIATION|Fludeoxyglucose F-18|Undergo 18 FDG PET
57911697|NCT00662506|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58262503|NCT02609724|OTHER|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
58262504|NCT02609724|OTHER|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
58262505|NCT02609724|OTHER|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
58262506|NCT06530758|OTHER|Altered ASRS format, without shading and with grouping|Participants will be asked to complete the ASRS form without shading and with grouping.
58262507|NCT06530758|OTHER|Altered ASRS format, with shading and without grouping|Participants will be asked to complete the ASRS form with shading and without grouping.
58262508|NCT06530758|OTHER|Altered ASRS format, without shading and without grouping|Participants will be asked to complete the ASRS form without shading and without grouping.
58262509|NCT02454712|DRUG|PF614|PF614 is an oxycodone prodrug
58262510|NCT02454712|DRUG|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
58262511|NCT02454712|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
58383252|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
58383253|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
58059393|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
58262512|NCT05775003|DIETARY_SUPPLEMENT|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
58262513|NCT04932824|BIOLOGICAL|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
58262514|NCT04761120|DEVICE|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
58262515|NCT04761120|DEVICE|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
58262516|NCT04761120|DEVICE|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
58383254|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
58383255|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
58383256|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
57911698|NCT00662506|OTHER|Laboratory Biomarker Analysis|Correlative studies
57911699|NCT00662506|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo PWI
57911700|NCT00662506|PROCEDURE|Positron Emission Tomography|Undergo 18 F FDG-PET
57911701|NCT00662506|DRUG|Temozolomide|Given PO
57911702|NCT00203762|BEHAVIORAL|Public sector antiretroviral treatment programmes|
57911703|NCT00518492|PROCEDURE|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
57911704|NCT01183260|DEVICE|Trabecular Metal Revision Cup|Revision of the acetabular cup
57911705|NCT01183260|DEVICE|Trabecular Metal Modular Cup|Revision of the acetabular cup
57911706|NCT02668484|DEVICE|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
57911707|NCT02668484|DEVICE|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
57911708|NCT00901823|DRUG|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
58383257|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
58383258|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
58383259|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
58383260|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
58383261|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
57709858|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
57709859|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
57709860|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
58059394|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
58059395|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
58262517|NCT04761120|DEVICE|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
58059396|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
58262518|NCT02543892|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
58262519|NCT02543892|BIOLOGICAL|Placebo|Normal Saline
58262520|NCT05144503|DEVICE|SpherePVI™ Catheter|SpherePVI™ Catheter with the Affera Mapping and Ablation System
58262521|NCT06649539|DRUG|Collagenase Clostridium Histolyticum|"4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL"
58262522|NCT06649539|DEVICE|RestoreX|Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.
58059397|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
58059398|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
58262523|NCT06649539|DRUG|Sildenafil|Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
58262524|NCT03064100|OTHER|Observational Study|Exclusion from the study
57709861|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
57709862|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
58262525|NCT01944618|DRUG|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
58262526|NCT03982446|GENETIC|Mutations|
58262527|NCT00937040|DRUG|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
58262528|NCT00937040|DRUG|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
58262529|NCT00937040|DRUG|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
58262530|NCT00937040|DRUG|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
58383262|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
57709863|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
57709864|NCT02170246|DRUG|Telmisartan|
57709865|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
58262531|NCT00598546|BEHAVIORAL|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
58262532|NCT01952119|OTHER|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
58262533|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
57709866|NCT00279565|DRUG|buprenorphine|
57709867|NCT00279565|DRUG|methadone|
57911709|NCT00901823|DRUG|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
57911710|NCT01376427|DRUG|Dexamethasone|Dexamethasone
58262534|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase cognitive flexibility|Increase the intervention dose of cognitive flexibility in Mindfulness Intervention for Emotional Distress (MIED). For example, including more cognitive reappraisal practice, psychoeducational content and practice about regarding thoughts just as thoughts.
58262535|NCT05517824|PROCEDURE|microinsulated needle radiofrequency|A single treatment using a microinsulated needle radiofrequency device
58262536|NCT05251948|DRUG|Atezolizumab|Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
58262537|NCT05251948|DRUG|Capecitabine|Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
58262538|NCT05251948|DRUG|Oxaliplatin|Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
58262539|NCT05251948|DRUG|Tiragolumab|Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
58262540|NCT03105986|DRUG|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
58262541|NCT03105986|DRUG|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
57709868|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
58059399|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
58059400|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
58059401|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
58059402|NCT00439309|DEVICE|VascuSeal|VascuSeal
58262542|NCT02010281|DEVICE|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
58383263|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
57709869|NCT00501202|DRUG|placebo|twice daily for 4 weeks
57709870|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
57709871|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
57911711|NCT01376427|DRUG|Methotrexate|Methotrexate
57911712|NCT01376427|DRUG|Vincristine|Vincristine
57911713|NCT02516020|DRUG|Global|Embryos are cultured in single step culture from day 1 to day 5
57911714|NCT02516020|DRUG|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
57911715|NCT06140706|BEHAVIORAL|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
58262543|NCT05670314|DIETARY_SUPPLEMENT|Inulin Fibre supplement|20g/ day. Inulin is easily dissolvable in liquid and can be incorporated into the usual diet - by adding to water, juice, smoothies, cereal, yogurt etc.
58262544|NCT05670314|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10g/ day which can be consumed by adding to breakfast cereal/ smoothie/ yogurt or drink of choice
58262545|NCT05670314|BEHAVIORAL|Exercise|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises.
58262546|NCT05304949|OTHER|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription will be enrolled.
57911716|NCT04138693|DEVICE|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
57911717|NCT04138693|DEVICE|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
57911718|NCT04138693|DEVICE|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
57911719|NCT03580005|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
58262547|NCT03203226|OTHER|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
58262548|NCT06622252|OTHER|13-week session program|The newly designed intervention was split into three major components - Healthy Literacy, Caregiver Wellness, and Culturally Competent Care and is delivered throughout a 13-session program delivered via Zoom. Sessions are guided by a psychologist, nutritionist, spirituality specialist, social worker, case coordinator, oncologist and traditional Chinese medicine practitioner. Sessions are intended for caregivers specifically, however, other members of the family may join if they choose to.
58262549|NCT03259828|RADIATION|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
57911720|NCT03580005|DRUG|Placebo|Placebo to Match Quillichew ERCT
57911721|NCT05258045|RADIATION|F18 FDG|Radioactive material
58383264|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
57911722|NCT00757341|DRUG|SKI-606|
58262550|NCT06620263|OTHER|Pre-education period (PreEd)|No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
57709872|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
57709873|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
57911723|NCT06072508|BIOLOGICAL|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
58262551|NCT06620263|OTHER|Post-education period (PostEd)|In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
58262552|NCT05264792|OTHER|Enhanced Implementation Support|"This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines."
58262553|NCT05264792|OTHER|Routine Implementation Support|This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
58262554|NCT04450407|DRUG|LY3209590|Administered SC
58262555|NCT04450407|DRUG|Insulin Degludec|Administered SC
58262556|NCT04097158|OTHER|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
58262557|NCT06057493|OTHER|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
58262558|NCT04889521|OTHER|No intervention|No intervention. Study is cross-sectional observational.
58262559|NCT06622538|DEVICE|Orotracheal intubation|Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
57911724|NCT06444230|OTHER|Routine Physical therapy with Neurodevelopmental technique|participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks
57911725|NCT06444230|OTHER|Routine Physical therapy|participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo
58262560|NCT01985438|PROCEDURE|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
58383265|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
58383266|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
57709874|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
57911726|NCT06292962|DEVICE|non-invasive transcutaneous vagal nerve stimulation (tVNS)|The device is used stimulate the vagus nerve
57709875|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
58059403|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
57709876|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
57709877|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
57709878|NCT00004436|DRUG|leuprolide|
57709879|NCT00004436|DRUG|prednisone|
57709880|NCT02473068|DEVICE|CPAP|
57709881|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
57709882|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
57911727|NCT06292962|DEVICE|Sham device|Sham device that does not stimulate the vagus nerve
57709883|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
57709884|NCT02920268|OTHER|Dance and yoga intervention|
57709885|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
57709886|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
57709887|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
57709888|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
57709889|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
57709890|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
57709891|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
58059404|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
57709892|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
57709893|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
57709894|NCT06442501|OTHER|routine care|routine care
57709895|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
58059405|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
58059406|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
57709896|NCT01430065|DRUG|ASP015K|oral
57709897|NCT01430065|DRUG|Tacrolimus|oral
58383267|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
58383268|NCT06114940|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
57709898|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
57709899|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
58262561|NCT01985438|PROCEDURE|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
58262562|NCT03192995|DRUG|lorcaserin|lorcaserin 20 mg tablet
58262563|NCT03192995|DRUG|Placebo Oral Tablet|placebo 20 mg. tablet
58262564|NCT03192995|BEHAVIORAL|Substance use counseling|Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
58262565|NCT03192995|BEHAVIORAL|ACASI|Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
58262566|NCT03192995|DIAGNOSTIC_TEST|Cocaine metabolites|Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
58383269|NCT06114940|DRUG|Lenvatinib|18 mg by mouth once each day for 12 weeks prior to nephrectomy
58383270|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
58262567|NCT03192995|BEHAVIORAL|Ecological Momentary Assessment (EMA)|EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
57709900|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
58262568|NCT03192995|BEHAVIORAL|Balloon Analogue Risk Task (BART)|BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
58059407|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
58262569|NCT03192995|BEHAVIORAL|Qualitative Exit Interview|The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
58262570|NCT06622590|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
58262571|NCT06622590|BIOLOGICAL|QIV control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
58262572|NCT00201240|BIOLOGICAL|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
58262573|NCT01772186|DEVICE|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
58262574|NCT05809258|PROCEDURE|Supraclavicular block|brachial plexus nerve block by supraclavicular route
58383271|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
57911728|NCT02383004|OTHER|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
58262575|NCT05809258|PROCEDURE|Axillary block|brachial plexus nerve block by axillary route
58262576|NCT02525601|DEVICE|Triathlon CR cemented|Implantation of Knee Prosthesis
58262577|NCT02525601|DEVICE|Triathlon CR uncemented|Implantation of Knee Prosthesis
58262578|NCT02244346|DRUG|Secotex®|
58262579|NCT05545345|PROCEDURE|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
58383272|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
58383273|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
58383274|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
58383275|NCT02931838|DRUG|BMS-986165|
58383276|NCT02931838|DRUG|Placebo for BMS-986165|
58383277|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
58383278|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
58383279|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
58383280|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
57709901|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
57709902|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
57911729|NCT04684407|PROCEDURE|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
57911730|NCT06178081|OTHER|Periodontal Healthy|Non surgical periodontal therapy
58262580|NCT05545345|PROCEDURE|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
58262581|NCT00743015|DRUG|BI 44370 TA tablet|
58262582|NCT04046848|DRUG|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
58262583|NCT04743804|BIOLOGICAL|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
58262584|NCT04743804|OTHER|Placebo|Matching placebo
58262585|NCT04743804|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
58262586|NCT06046001|DEVICE|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
58262587|NCT04190498|DIAGNOSTIC_TEST|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
58383281|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
58383282|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
58383283|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
57911731|NCT03605173|DIAGNOSTIC_TEST|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
57911732|NCT03605173|DIAGNOSTIC_TEST|total vitamin d|routinely measured from serum
58262588|NCT02852668|OTHER|Power Training|This experimental groups underwent an intervention period of power training
58262589|NCT02852668|OTHER|Strength Training|This experimental groups underwent an intervention period of strength training
58262590|NCT01854879|DEVICE|Nucleus 6 sound processor|
58262591|NCT06041425|DRUG|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
58262592|NCT06041425|DRUG|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
58262593|NCT04824391|BIOLOGICAL|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
58383284|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
58383285|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
58383286|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
58383287|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
58383288|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
58383289|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
58383290|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
58383291|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
58383292|NCT02474303|DRUG|Truvada|Demonstration Study
58383293|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
58383294|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
57709903|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
57911733|NCT00484458|DEVICE|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
58059408|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
58059409|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
58059410|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
57911734|NCT00484458|DEVICE|Total Disc Replacement|Total disc
57911735|NCT05105451|OTHER|Collecting clinical data, EGG，arterial blood gas data and venous blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），arterial blood gas data(before induction of anesthesia and first day after surgery) and venous blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
58262594|NCT04824391|BIOLOGICAL|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
58262595|NCT04824391|OTHER|Placebo|Two IM applications on Days 1 and 28
58262596|NCT04984473|DEVICE|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
58383295|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
58383296|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
58383297|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
58383298|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
57911736|NCT06594783|OTHER|Carvedilol plus endoscopic variceal ligation|Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
57911737|NCT06594783|DRUG|Carvedilol alone|Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
57911738|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
58383299|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
58383300|NCT00153595|DRUG|EWO1|
57709904|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
57709905|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
57709906|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
58383301|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
58383302|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
57709907|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
57911739|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
58059411|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
58059412|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
58262597|NCT03652636|DRUG|Sulfur Hexafluoride Microspheres|2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
58383303|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
57709908|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
57911740|NCT01553773|DRUG|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
57911741|NCT01553773|DRUG|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
57911742|NCT02592993|DEVICE|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
58383304|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
58383305|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
58383306|NCT01316458|DRUG|STI571 (Glivec®)|
58059413|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
58059414|NCT02967172|DRUG|Ropivacaine|
57709909|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
57709910|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
57709911|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
57709912|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
57709913|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
57911743|NCT04268290|COMBINATION_PRODUCT|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
58262598|NCT06130891|OTHER|Cognitive sensory motor relearning|"Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
58262599|NCT06130891|OTHER|Sensory motor relearning|"Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
58262600|NCT06130891|OTHER|Motor Relearning|"Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
58262601|NCT01087840|DRUG|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
58262602|NCT00443664|DEVICE|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
57709914|NCT05979103|BEHAVIORAL|Listening to Nature Sounds|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to nature sounds over the 4 weeks. Each day, we will send them a playlist to listen to.
57709915|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
57709916|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
57709917|NCT06357988|PROCEDURE|Biopsy|Undergo tumor biopsy
57709918|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57709919|NCT06357988|PROCEDURE|Echocardiography|Undergo echocardiography
57709920|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
57911744|NCT03866291|OTHER|No intervention, observational|See above
58059415|NCT02967172|DRUG|Epinephrine|
58383307|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
58383308|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
57709921|NCT06357988|DRUG|Vismodegib|Given PO
57709922|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
57709923|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
57709924|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
57709925|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
57709926|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
57709927|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
57709928|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
57709929|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
57709930|NCT05176093|OTHER|Placebo|Injectable Liquid
57709931|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
57709932|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
58262603|NCT03164655|DRUG|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
57709933|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
58262604|NCT03165760|PROCEDURE|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
58262605|NCT00258349|DRUG|vorinostat|Given orally
58262606|NCT00258349|DRUG|trastuzumab|Given IV
58262607|NCT05463237|DIAGNOSTIC_TEST|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
57709934|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
57709935|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
57709936|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
58262608|NCT05463237|DIAGNOSTIC_TEST|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
58262609|NCT03966937|OTHER|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
58262610|NCT03966937|OTHER|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
57709937|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
57709938|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
57911745|NCT02641496|BEHAVIORAL|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
57709939|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
57709940|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
57709941|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
57709942|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
57709943|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
58262611|NCT03784794|DIAGNOSTIC_TEST|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
58262612|NCT03784794|DIAGNOSTIC_TEST|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
58262613|NCT03784794|DRUG|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 \< 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
58262614|NCT03784794|DRUG|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT \> 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
58262615|NCT03784794|OTHER|Platelets|PLATELETS EXTEM A5 \< 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 \< 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 \< 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT \< 100/µL PLT \< 100/µL → 1 PLATELET POOL OR APHERESIS; PLT \> 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT \> 100/µL
58262616|NCT03784794|OTHER|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels \< 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb \> 7.5 G/DL"
58262617|NCT03784794|OTHER|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR \< 2.0
58262618|NCT03784794|OTHER|cryoprecipitates|FIBRINOGEN (CLAUSS) \< 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB \< 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB \> 250 MG/DL
58262619|NCT01287091|DRUG|GDC-0980|Oral tablet dose
58262620|NCT01287091|DRUG|GDC-0980|Oral capsule dose
58262621|NCT01287091|DRUG|GDC-0980|Oral tablet dose in fed state
58262622|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fasting state
58262623|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fed state
57709944|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
57911746|NCT02641496|BEHAVIORAL|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
58262624|NCT01287091|DRUG|GDC-0980|Oral tablet in a fasting state
58262625|NCT01287091|DRUG|rabeprazole|Oral repeating dose
57911747|NCT04637854|PROCEDURE|Operating microscope|Third molar extraction using microscope
58059416|NCT02967172|DRUG|Morphine|
57911748|NCT04637854|PROCEDURE|Surgical loupes|Third molar extraction using loupes with co-axial illumination
58059417|NCT02967172|DRUG|0.9% sodium chloride solution|
58262626|NCT01130519|DRUG|Bevacizumab|Commercially available. Administered by intravenous infusion.
58262627|NCT01130519|DRUG|Erlotinib|Commercially available. Administered orally.
58262628|NCT06622772|DEVICE|Valsalva assist device|A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.
58059418|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
58262629|NCT06622772|OTHER|standard Valsalva manoeuvre|The Valsalva manoeuvre is carried out without any device.
58383309|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
58383310|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
58383311|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
58383312|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
57911749|NCT04637854|PROCEDURE|Naked eyes|Third molar extraction using naked eyes
57911750|NCT03219515|DRUG|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
57911751|NCT03219515|DRUG|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
57911752|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
57911753|NCT01198756|BIOLOGICAL|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
58059419|NCT01773616|DRUG|Oral prednisolone|
58059420|NCT01773616|DRUG|Rituximab|
58059421|NCT01773616|DRUG|Mycophenolate mofetil|
58059422|NCT01773616|DRUG|Methyl prednisolone|
58059423|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
58059424|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
58262630|NCT04747067|DEVICE|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
58262631|NCT06373458|DRUG|Ritlecitinib|Ritlecitinib 50mg QD for 36 weeks starting at Day 1
58262632|NCT00180492|DEVICE|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
57911754|NCT01198756|BIOLOGICAL|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
57709945|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
57709946|NCT03128697|BEHAVIORAL|Satiating diet|
57709947|NCT03128697|BEHAVIORAL|Control diet|
57709948|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
57709949|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
57709950|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
57709951|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
57709952|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
57709953|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
57709954|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
57709955|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
57709956|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
57709957|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
57709958|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
57911755|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
57709959|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
57911756|NCT03143946|DIETARY_SUPPLEMENT|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
57911757|NCT03143946|OTHER|Diet advice|
57911758|NCT01085266|DRUG|Dimebon (latrepirdine)|
57911759|NCT03510585|OTHER|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
57911760|NCT03510585|OTHER|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
57911761|NCT01893931|BEHAVIORAL|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
57911762|NCT01893931|BEHAVIORAL|Placebo Comparator|
57911763|NCT00196976|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
57911764|NCT00196976|BIOLOGICAL|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
57911765|NCT00196976|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
57911766|NCT00196976|BIOLOGICAL|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
57911767|NCT00196976|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
57911768|NCT04206033|OTHER|Observational study|Observational study
57911769|NCT05977504|OTHER|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
57709960|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
57709961|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
57709962|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
57709963|NCT01971138|OTHER|this is a survey|
57709964|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
57709965|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
57709966|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
57709967|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
57911770|NCT05893628|OTHER|muscle length and muscle endurance assessment|Pectoralis Minor Length and muscle endurance evaluation
57911771|NCT00641329|DRUG|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
57911772|NCT00641329|DRUG|Placebo|Matching placebo tablets
58059425|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
58059426|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
58059427|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
58383313|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
58383314|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
58383315|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
58383316|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
58383317|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
58383318|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
58383319|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
58383320|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
58383321|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
58383322|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
58383323|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
58383324|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
58383325|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
58383326|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
58383327|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
58059428|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
57911773|NCT01074216|DRUG|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
57911774|NCT00605215|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
58059429|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
58059430|NCT01984359|OTHER|Obtaining Human tissue|
58383328|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
58383329|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
58383330|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
58383331|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
58383332|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
58383333|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
58383334|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
58383335|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
58383336|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
58383337|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
58383338|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
57911775|NCT00605215|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
57911776|NCT00605215|DRUG|Avonex®|Avonex® will be administered per dose and schedule specified in the arm description.
57911777|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
57911778|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
58383339|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
58383340|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
58383341|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
57709968|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
58262633|NCT04569968|OTHER|Expiratory muscle training|For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
57709969|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
58262634|NCT04748601|DRUG|Qudexy XR|Extended-Release Capsule
58262635|NCT04748601|DRUG|Placebo|Qudexy XR Matching capsules
58262636|NCT06621199|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 24 mg/m\^2 on day 1, every 4 weeks
58262637|NCT06621199|DRUG|Cytarabine|Cytarabine 100 mg/m\^2 on day 1-5, every 4 weeks
58262638|NCT06621199|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
58262639|NCT02614222|DEVICE|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
58262640|NCT02467257|DIETARY_SUPPLEMENT|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
57709970|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
57709971|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
57709972|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
58262641|NCT04106050|DRUG|BIIB095|Administered as specified in the treatment arm.
58262642|NCT04106050|DRUG|BIIB074|Administered as specified in the treatment arm.
57709973|NCT02559388|DRUG|Montelukast|
57709974|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
57709975|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
58262643|NCT04106050|DRUG|Placebo|Administered as specified in the treatment arm.
58262644|NCT04106050|DRUG|Lidocaine|Administered as specified in the treatment arm.
58262645|NCT04733937|OTHER|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
58262646|NCT04733937|OTHER|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
57911779|NCT05357430|DRUG|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
57709976|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
57911780|NCT01870232|PROCEDURE|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
57911781|NCT01039623|BIOLOGICAL|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
57911782|NCT02274532|DEVICE|SoftHand|Biomechanical, ADL, and functional testing.
57911783|NCT00574613|DRUG|P144|Cream 0,3 ml once a day (3 months)
57911784|NCT00574613|DRUG|placebo|Cream 0,3 ml once a day (3 months)
57911785|NCT04893265|BEHAVIORAL|Text Messaging Only|Active Comparator
57911786|NCT04893265|BEHAVIORAL|INFORMED|Experimental
57911787|NCT02932566|DRUG|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
57911788|NCT02932566|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
57911789|NCT02947893|DRUG|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
57911790|NCT02947893|DRUG|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
57911791|NCT00000241|DRUG|Flupenthixol|
58059431|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
58383342|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
58262647|NCT00585013|DRUG|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
58262648|NCT05896722|OTHER|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
58262649|NCT05896722|OTHER|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
58262650|NCT05896722|OTHER|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
58262651|NCT05896722|OTHER|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
58262652|NCT05896722|OTHER|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
58262653|NCT05651919|BIOLOGICAL|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
58383343|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
58383344|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
58383345|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
58383346|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
58383347|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
58383348|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
58383349|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
58383350|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
58383351|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
58383352|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
58383353|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
58383354|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
58383355|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
58383356|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
58383357|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
58383358|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
58262654|NCT05651919|BEHAVIORAL|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
58383359|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
58383360|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383361|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383362|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383363|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383364|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383365|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383366|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383367|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
58383368|NCT02342353|DRUG|Pacritinib|
58383369|NCT02342353|DRUG|Erlotinib|
58383370|NCT02904369|DRUG|Emtricitabine|
58383371|NCT02904369|DRUG|Tenofovir alafenamide|
58383372|NCT02904369|DRUG|Tenofovir disoproxil|
57709977|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
57709978|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
58059432|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
58262655|NCT05651919|BEHAVIORAL|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
58262656|NCT02071706|DEVICE|PET/MRI system|Enrolled subject undergoes PET/MR scan
58262657|NCT03521297|DRUG|Probiotic|UDCA combined probiotic
58383373|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
58262658|NCT03521297|DIETARY_SUPPLEMENT|Placebo|UDCA combined placebo
58262659|NCT02990585|OTHER|Back school|
58262660|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat drug screen|Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
58262661|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat laboratory analysis|Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
58059433|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
58059434|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
58262662|NCT04611867|OTHER|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
58262663|NCT05979935|DIAGNOSTIC_TEST|tongue diagnosis|The tongue image of participants will be collected via camera and professional tongue diagnosis report will be provided to pariticipants.
58262664|NCT03080766|DRUG|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
58262665|NCT03244670|OTHER|Observation study only, no specific intervention|Observation study only, no specific intervention
58059435|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
58059436|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
58383374|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
58059437|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
58262666|NCT00865917|DRUG|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
58262667|NCT00865917|DRUG|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
58262668|NCT00865917|DRUG|Placebo|matching appearance
58262669|NCT06612099|OTHER|Aerobic Exercise|Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
58262670|NCT06612099|OTHER|Mat Pilates Exercise|Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
57709979|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
57709980|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
57709981|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
57709982|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
57709983|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
57709984|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
57709985|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
57911792|NCT00351663|DRUG|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day"
57911793|NCT06417567|DRUG|NEPA|NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
57911794|NCT02641860|BIOLOGICAL|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
57911795|NCT02740374|DEVICE|ROTEM|ROTEM coagulation assessment and guided transfusion management.
58383375|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
58383376|NCT05270018|OTHER|normal saline|14.0ml once a day
58383377|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
58383378|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
58383379|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
58383380|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
57911796|NCT02740374|OTHER|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
57911797|NCT02706132|BIOLOGICAL|Mesenchymal Stem Cells(MSCs)|Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
58059438|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
58262671|NCT03382301|DRUG|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
57911798|NCT05834777|DRUG|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
57911799|NCT05834777|DRUG|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
58262672|NCT03382301|DRUG|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
58262673|NCT03440294|DIAGNOSTIC_TEST|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
58262674|NCT03440294|DIAGNOSTIC_TEST|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
58262675|NCT02429388|DRUG|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
58262676|NCT03785912|BEHAVIORAL|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
58262677|NCT06174376|DEVICE|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
58262678|NCT05284929|GENETIC|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
58262679|NCT00858299|DRUG|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
58262680|NCT06614296|PROCEDURE|Crenel Lateral Interbody Fusion|The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.
58262681|NCT06614296|PROCEDURE|Crenel lateral interbody fusion plus second stage surgery|The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
58262682|NCT00738881|DRUG|Erlotinib Hydrochloride|Given PO
58262683|NCT00738881|DRUG|Pemetrexed Disodium|Given IV
57911800|NCT05932745|OTHER|E-liquid coolant (No WS-3) for non-menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
57911801|NCT05932745|OTHER|E-liquid coolant (No WS-3) for low menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
57911802|NCT05932745|OTHER|E-liquid coolant (No WS-3) for high menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
57911803|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for non-menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
57911804|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for low menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
57911805|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for high menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
57911806|NCT05932745|OTHER|E-liquid coolant (High WS-3) for non-menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
57911807|NCT05932745|OTHER|E-liquid coolant (High WS-3) for low menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
57911808|NCT05932745|OTHER|E-liquid coolant (High WS-3) for high menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
57911809|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for non-menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
57911810|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for low menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
58262684|NCT00916344|DEVICE|EVIA Pacemaker|patient has standard indication for pacemaker therapy
58262685|NCT06342219|BEHAVIORAL|Neurofeedback Mindfulness|The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.
58262686|NCT06342219|BEHAVIORAL|Attention Task|The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
57911811|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for high menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
57911812|NCT05932745|OTHER|E-liquid coolant (High WS-23) for non-menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
57911813|NCT05932745|OTHER|E-liquid coolant (High WS-23) for low menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
57911814|NCT05932745|OTHER|E-liquid coolant (High WS-23) for high menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
58383381|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
57911815|NCT00589589|DEVICE|Endo Tool|Computer tool to help achieve glucose control
58059439|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
58059440|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
57709986|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
57911816|NCT01928251|BEHAVIORAL|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
58059441|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
58059442|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
58059443|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
58059444|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
58059445|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
58059446|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
58059447|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
58059448|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
58059449|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
58059450|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
58059451|NCT01633372|DRUG|itacitinib|
58059452|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
58059453|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
58059454|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
58059455|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
58059456|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
58059457|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
58059458|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
57709987|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
58262687|NCT06333275|BIOLOGICAL|Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles|"First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative"
58262688|NCT03824886|OTHER|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
58262689|NCT06620354|DRUG|Selumetinib|Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)
58262690|NCT04412200|DEVICE|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
58262691|NCT00765895|DRUG|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
58262692|NCT00765895|DRUG|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
58262693|NCT06215924|OTHER|Reverse Kegel exercise|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
58262694|NCT06215924|OTHER|Postisometric Relaxation Technique|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
58262695|NCT00086112|DRUG|risperidone oral tablets|
58262696|NCT06031935|BEHAVIORAL|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
58262697|NCT03193801|DEVICE|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
58262698|NCT00705718|DEVICE|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
58383382|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
58383383|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
58059459|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
58059460|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
58059461|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
58262699|NCT03839290|PROCEDURE|Early neonatal cheiloplasty|
58383384|NCT04532125|OTHER|Placebo|Subjects treated with placebo
58383385|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
58383386|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
58383387|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
58383388|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
58383389|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
58383390|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
58383391|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
58059462|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
58383392|NCT01162473|OTHER|Food Challenge|
58383393|NCT00529438|DRUG|Bardoxolone methyl|
58383394|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
58383395|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
58383396|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
58383397|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
58383398|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
58383399|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
58383400|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
58059463|NCT00002986|DRUG|carmustine|
58059464|NCT00002986|DRUG|topotecan hydrochloride|
58059465|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
58059466|NCT00004885|DRUG|FOLFIRI regimen|
58059467|NCT00004885|DRUG|fluorouracil|
58059468|NCT00004885|DRUG|irinotecan hydrochloride|
57709988|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
58059469|NCT00004885|DRUG|leucovorin calcium|
58262700|NCT04283682|BEHAVIORAL|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
58262701|NCT01764789|OTHER|questionnaire administration|Ancillary studies
58262702|NCT01764789|PROCEDURE|quality-of-life assessment|Patients will participate in a quality life assessment.
58262703|NCT01764789|PROCEDURE|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
58262704|NCT01764789|BEHAVIORAL|behavioral intervention|Participate in multi-component biobehavioral intervention
58262705|NCT01764789|OTHER|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
58262706|NCT01764789|OTHER|educational intervention|Participate in multi-component biobehavioral intervention
58262707|NCT00029536|BIOLOGICAL|Progesterone Lozenges|200mg Progesterone Lozenges
58383401|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
58262708|NCT00029536|OTHER|Matched Placebo Lozenges|Matched Placebo Lozenges
58383402|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
58383403|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
58383404|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
57709989|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
58059470|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
58059471|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
57709990|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
58059472|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
58059473|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
58059474|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
58059475|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
58059476|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
58059477|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
58059478|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
58262709|NCT05462223|COMBINATION_PRODUCT|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~1. VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~2. VRS Light Fiber~3. VRS Light Source"
58262710|NCT06620146|OTHER|mechanical bathing|Providing mechanical bathing (MB) is a commonly used strategy to maintain cleanness and comfort in patients with terminally illness. The electric medical bathtub (ARJO, Rhapsody) provides functions such as showering, bathing, and water massage. The MB will be operated by 2-3 nursing staff, trained hospice volunteers, or researchers. Each patient\&amp;#39;s MB process lasts about 20 minutes, including washing the hair and body with a handheld showerhead, followed by soaking in warm water for about 5-10 minutes. Based on the patient preference, the water temperature is adjusted between 38 to 40 degrees Celsius.
58262711|NCT00428051|OTHER|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
58383405|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
58383406|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
58383407|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
58383408|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
58383409|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
58383410|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
58383411|NCT02059564|DRUG|Placebo|Normal saline solution
58383412|NCT02059564|DRUG|Victoza|doses of 1.8 mg
57709991|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
57709992|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
57709993|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
57709994|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
57709995|NCT04707534|DRUG|Dexamethasone|Dexamethasone
57709996|NCT00006484|DRUG|carboplatin|
57709997|NCT00006484|DRUG|paclitaxel|
57709998|NCT00006484|DRUG|tirapazamine|
57709999|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
57710000|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
57710001|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
57710002|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
57710003|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
57710004|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
57710005|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
57710006|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
57710007|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
57710008|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
57710009|NCT05956769|DRUG|Placebo|Normal saline injection
58059479|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
58059480|NCT06191991|DRUG|Atorvastatin|40 mg
57710010|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
57710011|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
57911817|NCT01928251|BEHAVIORAL|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
58059481|NCT06191991|DRUG|ALG-055009|0.9 mg
58059482|NCT06191991|DRUG|Rosuvastatin|10 mg
58059483|NCT00006463|DRUG|ECTEINASCIDIN 743|
58059484|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
58059485|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
58059486|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
57710012|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
57710013|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
57710014|NCT04476030|DRUG|SAGE-217|Oral capsules
57710015|NCT04476030|DRUG|Matching Placebo|Oral capsules
57710016|NCT04476030|DRUG|Sertraline|Oral tablets
57710017|NCT04476030|DRUG|Escitalopram|Oral tablets
57710018|NCT04476030|DRUG|Citalopram|Oral tablets
57710019|NCT04476030|DRUG|Duloxetine|Oral capsules
57710020|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
57710021|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
57710022|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
57710023|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
57710024|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
57710025|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
57710026|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
57710027|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
58383413|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
58383414|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
57710028|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
57710029|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
57710030|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
57710031|NCT01437228|DRUG|placebo|NO İNTERVENTİON
57710032|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
57710033|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
57710034|NCT02041130|DEVICE|Renal Denervation|
57710035|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
57710036|NCT01670929|DRUG|Progesterone|
58059487|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
58383415|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
58059488|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
58059489|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
58059490|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
58383416|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
58383417|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
58383418|NCT02776683|DRUG|BI 695502|
58383419|NCT02776683|DRUG|Avastin|
57710037|NCT01670929|OTHER|Placebo|
57710038|NCT03638986|OTHER|No intervention planned|No Intervention planned.
57710039|NCT01399359|BEHAVIORAL|Counseling session|
57710040|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
57710041|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
57710042|NCT01399359|OTHER|online questionnaire|
57710043|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
57710044|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
57911818|NCT04085965|BEHAVIORAL|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
57911819|NCT00283127|PROCEDURE|Home sampling (urine test) for uro-genital C.trachomatis.|
58383420|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
57911820|NCT03168607|DRUG|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
58383421|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
58383422|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
58383423|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
57710045|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
57710046|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
57911821|NCT06234878|DEVICE|REEV SENSE|Gait analysis with an Inertial Measurement Unit (IMU) sensor
58383424|NCT02013349|DEVICE|coronary intervention|
57911822|NCT06234878|DEVICE|Motion capture system|Gait analysis with reflective markers and pressure sensors
58059491|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
57710047|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
57710048|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
57710049|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
57710050|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
57911823|NCT05839015|BEHAVIORAL|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
57911824|NCT02290132|DRUG|Rabbit Anti-human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
58059492|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
58059493|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
58262712|NCT00641576|DEVICE|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
58262713|NCT02737631|DEVICE|"Chameleon Personal Lubricant"|
58262714|NCT03450785|OTHER|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
58262715|NCT03660475|DRUG|Naltrexone|naltrexone formulated as ophthalmic solution
58262716|NCT03660475|DRUG|Placebos|Placebo ophthalmic solution
58262717|NCT03652233|DRUG|Nivolumab|Given by vein every 14 days for up to 12 months
58262718|NCT03652233|DRUG|Afatinib|Taken by mouth daily for up to 12 months
58262719|NCT06515483|DEVICE|Brushing and Flossing of teeth|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects in the experimental group will brush and floss with the provided stretchable loop floss at least twice a day. To assess compliance, each subject will be asked to fill out a diary every time they brush/floss. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
57911825|NCT03231631|BEHAVIORAL|Education plan and adherence to exercise|"* Send text messages with motivational sense at any time of the day, every 3 or 4 days.~* They will be given the option of performing directed exercise at the cardiac rehabilitation center.~* It will be recorded in an Excel table every time that text is sent to the patient.~* At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
57911826|NCT03053154|OTHER|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
57911827|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
57911828|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
57911829|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
57911830|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
58262720|NCT06515483|OTHER|Brushing Only|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects assigned to the control group will brush their teeth at least twice a day only. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
58262721|NCT03831334|DRUG|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
58262722|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
58262723|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
58262724|NCT01652326|DRUG|Diazepam|
58262725|NCT01156649|DEVICE|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
58383425|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
57911831|NCT02275832|DRUG|3 % Minoxidil lotion|
57911832|NCT02275832|DRUG|Placebo|
58059494|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
57710051|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
58262726|NCT01156649|DEVICE|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
57911833|NCT03454698|OTHER|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
57911834|NCT04351737|DRUG|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
57911835|NCT04351737|DRUG|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
57911836|NCT04793659|DRUG|Oral Fasudil 90 mg/day|Oral tablet
57911837|NCT04793659|DRUG|Oral Fasudil 180 mg/day|Oral tablet
57911838|NCT04793659|DRUG|Oral Placebo|Oral tablet
58262727|NCT05351827|OTHER|Mild Intermittent Hypoxia|Participants will breathe 8% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. 100% oxygen and carbon dioxide are titrated into the system to ensure the appropriate hypoxic and hypercapnic stimulus is delivered. The investigators will lower oxygen to 55-60 mmHg and maintain end-tidal carbon dioxide 1-3 mmHg above individual baseline values. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
58262728|NCT05351827|OTHER|Sham|Participants will breathe 21% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. No supplemental oxygen or carbon dioxide will be used during the sham protocol. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
58262729|NCT04236518|BEHAVIORAL|Diets with either predominantly animal protein sources.|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
58262730|NCT04236518|BEHAVIORAL|Diets with predominantly plant protein sources|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
58262731|NCT02070627|DRUG|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
58262732|NCT02070627|DEVICE|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
58262733|NCT01210677|DRUG|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
57710052|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
57911839|NCT04486326|DRUG|Crofelemer|Crofelemer
57911840|NCT04486326|DRUG|Placebo|placebo
57911841|NCT00353769|PROCEDURE|Hair Apposition Technique|
57911842|NCT04041674|BIOLOGICAL|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
57911843|NCT04041674|BIOLOGICAL|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
57911844|NCT04041674|BIOLOGICAL|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
57911845|NCT04041674|BIOLOGICAL|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
57911846|NCT04041674|BIOLOGICAL|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
57911847|NCT05569031|DRUG|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
57710053|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
57710054|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
57911848|NCT05569031|DRUG|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
57911849|NCT06203015|DIAGNOSTIC_TEST|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
57911850|NCT06203015|DIAGNOSTIC_TEST|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
57911851|NCT06203015|DIAGNOSTIC_TEST|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
57911852|NCT06203015|DIAGNOSTIC_TEST|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
57710055|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
57710056|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
57710057|NCT06178874|DRUG|Insulin regular|hyperglycemic control
57710058|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
57710059|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
57710060|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
57911853|NCT06203015|OTHER|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
57911854|NCT02516475|DIETARY_SUPPLEMENT|zinc sulfate|1 zinc sulfate capsule for 15 weeks
57911855|NCT02516475|OTHER|corn starch|1 corn starch capsule for 15 weeks
57911856|NCT05720845|PROCEDURE|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
57911857|NCT05720845|PROCEDURE|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
57911858|NCT02072915|PROCEDURE|Suction|
57911859|NCT05402930|DIAGNOSTIC_TEST|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
58059495|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
58059496|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
58059497|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
58262734|NCT01099501|DIETARY_SUPPLEMENT|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
58383426|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
58059498|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
58383427|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
58262735|NCT01099501|DIETARY_SUPPLEMENT|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
58262736|NCT01099501|DIETARY_SUPPLEMENT|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
58383428|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
57710061|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
57710062|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
57710063|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
57710064|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
57710065|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
57710066|NCT00000707|DRUG|Pentamidine isethionate|
58262737|NCT01446276|DIETARY_SUPPLEMENT|Resveratrol|500 mg 3 times daily for six month
57710067|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
57710068|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
57710069|NCT00224211|BEHAVIORAL|Music|
57710070|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
57710071|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
57710072|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
57710073|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
57710074|NCT02470728|OTHER|New Clinical Pathway|
57710075|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
57710076|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
57710077|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
57710078|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
58262738|NCT01446276|OTHER|Placebo|1 placebo tablet 3 times daily for six month
58383429|NCT01431898|DRUG|GS-9669 tablets|
58383430|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
57784722|NCT00773071|DEVICE|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
58059499|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
58262739|NCT04248504|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
58262740|NCT02047994|DRUG|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days"
58383431|NCT00293930|DRUG|Tacrolimus|
58383432|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
58383433|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
58383434|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
58383435|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
58383436|NCT02069977|DRUG|Aripiprazole|
58383437|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
58383438|NCT02462187|DRUG|NVN1000 16%|once daily
58383439|NCT02462187|DRUG|Vehicle|placebo comparator
58383440|NCT02462187|DRUG|NVN1000 24%|once daily
58383441|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
58383442|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
58383443|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
58383444|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
57784723|NCT04012814|DEVICE|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
57784724|NCT05465421|OTHER|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
57784725|NCT01375894|DEVICE|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
57784726|NCT02478359|BEHAVIORAL|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
57784727|NCT02328456|OTHER|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
57784728|NCT03406234|OTHER|No intervention.|Cross-sectional observation without interventions.
57784729|NCT02900911|OTHER|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
57784730|NCT02900911|OTHER|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
57784731|NCT01058863|DRUG|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
57784732|NCT01058863|DRUG|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
57784733|NCT01058863|OTHER|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
57784734|NCT06307938|DIAGNOSTIC_TEST|liquid biopsy|based on a panel of circulating tumor DNA markers
57784735|NCT02839681|DRUG|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
57784736|NCT02839681|DEVICE|Blood test|Research blood test for eligibility
58059500|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
58059501|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
58059502|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
58059503|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
58059504|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
58059505|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
58059506|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
58059507|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
58059508|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
58059509|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
58059510|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
58262741|NCT04336449|DRUG|Eptinezumab|Eptinezumab - single intravenous infusion
58262742|NCT04336449|DRUG|Placebo|Placebo - single intravenous infusion
58262743|NCT03367546|PROCEDURE|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
58262744|NCT04062032|DRUG|Aspirin 81 mg|ASA 81mg taken daily
58262745|NCT04062032|DRUG|Aspirin 325mg|ASA 325mg taken daily
58262746|NCT06426862|OTHER|Otago Exercise Program|"Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing"
57784737|NCT05248464|OTHER|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
57784738|NCT05248464|OTHER|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
57784739|NCT01071265|PROCEDURE|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
57784740|NCT01071265|PROCEDURE|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
57784741|NCT02689856|DRUG|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
57784742|NCT02689856|DRUG|Placebo control|Vehicle cream alone
57784743|NCT02689856|DRUG|Hydrocortisone acetate|hydrocortisone alone
57784744|NCT02689856|DRUG|Lidocaine hydrochloride|lidocaine alone
57784745|NCT00432861|DRUG|PANCRECARB® (pancrelipase)|Capsules
57784746|NCT00432861|DRUG|Placebo|Capsules
57784747|NCT03094897|DRUG|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
57784748|NCT03094897|DEVICE|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
57784749|NCT05994599|COMBINATION_PRODUCT|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
57784750|NCT05994599|COMBINATION_PRODUCT|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
57784751|NCT03557983|DRUG|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
57784752|NCT03557983|DRUG|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
57784753|NCT01888562|DRUG|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
57784754|NCT06117475|PROCEDURE|Posterior corpectomy|Removal of posterior portion of vertebrae by posterior approach
57784755|NCT02694614|BEHAVIORAL|smartphone-assisted dietary coaching|
57784756|NCT05466474|BIOLOGICAL|Tislelizumab Injection|Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
57784757|NCT01833117|OTHER|FID 119515A|topical ocular drops
57784758|NCT01833117|OTHER|Blink® Tears|topical ocular drops
57784759|NCT00150410|DRUG|Inhaled insulin|
57784760|NCT00388362|DRUG|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
57784761|NCT00388362|DRUG|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
58059511|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
58059512|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
57710079|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
57710080|NCT05957068|BEHAVIORAL|Control|Usual care group.
58262747|NCT06426862|OTHER|Control Group|Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
58262748|NCT03472300|OTHER|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
58262749|NCT05398185|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
58262750|NCT02416531|DRUG|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
58383445|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
57911860|NCT02593266|BEHAVIORAL|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up"
58059513|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
58059514|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
57710081|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
58059515|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
58059516|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
58059517|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
58059518|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
57710082|NCT03982329|PROCEDURE|physical therapy|
57710083|NCT02753647|DRUG|Rituximab|
57710084|NCT02753647|DRUG|Cyclophosphamide|
58262751|NCT02416531|RADIATION|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
58262752|NCT02416531|RADIATION|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
58262753|NCT01007331|BEHAVIORAL|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10\^10 colony forming units pr day of probiotics
58262754|NCT02967913|PROCEDURE|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
58262755|NCT05195684|OTHER|imaginal probe|trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
58262756|NCT00381238|DRUG|rosiglitazone|Extended Release Tablets
58262757|NCT01714843|DRUG|linaclotide|oral
58262758|NCT01714843|DRUG|placebo|oral
58262759|NCT01253668|DRUG|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
58262760|NCT01253668|GENETIC|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
58262761|NCT01253668|OTHER|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
58262762|NCT01253668|PROCEDURE|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
58262763|NCT01253668|GENETIC|Protein expression analysis|Correlative studies
58262764|NCT01253668|OTHER|Immunohistochemistry|correlative studies
58383446|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
58383447|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
58383448|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
58383449|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
58383450|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
57911861|NCT04375761|PROCEDURE|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
57911862|NCT04375761|PROCEDURE|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
57911863|NCT04253080|BIOLOGICAL|Blood sample|Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.
57911864|NCT04253080|BIOLOGICAL|Cutaneous melanoma biopsy|Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
58059519|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
58262765|NCT05526378|BEHAVIORAL|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
58262766|NCT02317835|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
58262767|NCT06647979|BIOLOGICAL|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein
58262768|NCT06647979|DEVICE|Sequencing Assay for Variant rs114518452|Device used to carry out the diagnostic testing for exclusion criteria number 12
58383451|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
58383452|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
58383453|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
58383454|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
58383455|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
58383456|NCT04871828|OTHER|Placebo|Placebo
58383457|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
58383458|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
58383459|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
58383460|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
58383461|NCT06493045|DRUG|IRL757|IRL757 capsule
58383462|NCT06493045|DRUG|Placebo|Placebo capsule
58383463|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
57710085|NCT02753647|DRUG|Doxorubicin|
57710086|NCT02753647|DRUG|Vincristine|
57911865|NCT02632032|DRUG|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice"
57911866|NCT02944591|DEVICE|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
58383464|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
58383465|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
57710087|NCT02753647|DRUG|Prednisone|
57710088|NCT02753647|DRUG|Chidamide|
58262769|NCT05484076|OTHER|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
58262770|NCT00811317|DEVICE|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
58262771|NCT02074969|DEVICE|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
58262772|NCT02074969|DEVICE|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
57710089|NCT00676442|DRUG|PN400|naproxen/esomeprazole
57710090|NCT01306617|DRUG|ABT-450|tablets
57710091|NCT01306617|DRUG|ABT-333|tablets
57710092|NCT01306617|DRUG|ribavirin|tablets
57710093|NCT01306617|DRUG|ritonavir|capsules
57710094|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
57710095|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
57710096|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
58262773|NCT01173055|DRUG|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
58262774|NCT01173055|DRUG|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
58262775|NCT04913350|OTHER|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
57710097|NCT00437034|BIOLOGICAL|aflibercept|Given IV
57710098|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
57710099|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
57710100|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
57710101|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
58262776|NCT04913350|DEVICE|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
58262777|NCT03817411|DRUG|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
58262778|NCT03817411|DRUG|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
57710102|NCT01002144|OTHER|blood sampling|
57911867|NCT00201227|OTHER|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
57911868|NCT06108960|OTHER|Proprioceptive neuromuscular facilitation|Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
58262779|NCT03817411|DRUG|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
58262780|NCT03817411|DRUG|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
58262781|NCT02034396|PROCEDURE|Blood Draw|One blood draw at enrollment
57911869|NCT06108960|OTHER|Pelvic stabilization exercises|"Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks."
57911870|NCT01545154|DEVICE|Transperineal Ultrasound|
57911871|NCT05442905|DRUG|propofol|Anesthesia will be induced with propofol 2-3mg/kg
58059520|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
58262782|NCT05665166|GENETIC|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
58262783|NCT04621526|DRUG|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
57911872|NCT05442905|DRUG|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
57911873|NCT05442905|DRUG|sevoflurane|sevoflurane(1%-2%) used during anesthesia
57911874|NCT05422664|DRUG|Lacosamide|Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
57911875|NCT04665999|DEVICE|Continuous Glucose Monitor|Data collection only
57911876|NCT03143166|DRUG|Dabigatran Etexilate|Tablet, film coated
58059521|NCT03309722|OTHER|biomarker study|
58059522|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
58262784|NCT04621526|DRUG|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
58262785|NCT06098872|DRUG|Trametinib tablet|Drug is supplied in 2mg and 0.5 mg tablets
58262786|NCT05814900|DEVICE|Two photon microscopy imaging|Excised tissues will be imaged with two photon microscopy
57710103|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
57710104|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
57710105|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
57710106|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
57710107|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
58383466|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
57710108|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
57911877|NCT03143166|DRUG|Rabeprazol sodium|Tablet
58262787|NCT04290988|DEVICE|EEG Neurofeedback|Active EEG neurofeedback
58262788|NCT04290988|DEVICE|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
58262789|NCT02056106|DRUG|antidepressant therapy|
58262790|NCT05720026|DRUG|SYSA1901|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
58262791|NCT05720026|DRUG|Pertuzumab|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
58262792|NCT05720026|DRUG|Trastuzumab|loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
58262793|NCT05720026|DRUG|Docetaxel|75 mg/m\^2 IV, q3w/cycle, total 4cycle
58383467|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
58383468|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
58262794|NCT05032274|OTHER|Home-based Exercise Program|The exercise program will include chink tuck and shoulder retraction exercises. The chin tuck exercise will be performed in standing position. The shoulder retraction exercise includes activation and strengthening components. The activation component will be performed in standing position and strengthening component will be performed in prone position.
57710109|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
57710110|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
57911878|NCT03674593|PROCEDURE|Mitral valve chordae prosthesis|"The method consists of five stages:~1. Measure the required length of the chords~2. Forming loops~3. Fixation of the loop group to the papillary muscles~4. Fixation of chordal loops to the free edge of the valve~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
58262795|NCT05406505|DRUG|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
58262796|NCT05406505|OTHER|Placebo|patients will receive placebo and standard care.
58262797|NCT00710684|DRUG|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
58262798|NCT00710684|DRUG|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
58262799|NCT00710684|DRUG|Placebo|Placebo added to existing donepezil
58262800|NCT00710684|DRUG|donepezil 5-10mg|existing donepezil treatment
58383469|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
58383470|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
58262801|NCT05060146|OTHER|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
58383471|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
58262802|NCT02548000|OTHER|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
58383472|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
58383473|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
58383474|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
58262803|NCT02548000|OTHER|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
58262804|NCT03260517|DEVICE|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
58383475|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
58383476|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
58383477|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
58383478|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
57911879|NCT03674593|PROCEDURE|Mitral valve chordae translocation|"The method consists essentially of three stages:~1. Selection of the secondary chord.~2. Fixation of secondary chords to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
58262805|NCT05385952|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
58262806|NCT05385952|DRUG|TachoSil|"TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical."
58262807|NCT00278148|DRUG|carboplatin|AUC2 weekly x 3 weeks
58262808|NCT00278148|DRUG|Erlotinib|Daily
58262809|NCT00278148|DRUG|paclitaxel|50mg/m2/weekly x 3 weeks
58383479|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
58383480|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
58262810|NCT00278148|PROCEDURE|conventional surgery|conventional surgery
58262811|NCT00278148|RADIATION|radiation therapy|150 cGy bid
58262812|NCT05811585|DEVICE|ADEPT|Adhesion Reduction Solution (4% icodextrin solution)
58383481|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
58383482|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
58383483|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
58383484|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
58383485|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
57911880|NCT04470232|OTHER|Self-assessment questionnaires|"120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
57911881|NCT01571401|BEHAVIORAL|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
57911882|NCT06526013|OTHER|Cholesterol self-measurement|Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
57911883|NCT00350116|DRUG|topical vitamin B12|
57911884|NCT06243861|BEHAVIORAL|Mother-child bond|assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
57911885|NCT05306405|DRUG|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
58383486|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
58383487|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
58383488|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
58383489|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
58383490|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
58383491|NCT00856635|DRUG|placebo|injected daily subcutaneously
58383492|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
58383493|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
58383494|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383495|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383496|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383497|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383498|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383499|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
58383500|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
58383501|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
58383502|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
58383503|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
58383504|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
58383505|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
58383506|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
58262813|NCT03634033|BEHAVIORAL|MiCAP with IF (Main Study)|"Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
58262814|NCT03634033|BEHAVIORAL|MiCAP with IF and EF (Main Study)|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
58262815|NCT03634033|BEHAVIORAL|MiCAP with IF and Caregiver Engagement (Administrative Supplement)|A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
58383507|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
57710111|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
57710112|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
58262816|NCT03081559|BEHAVIORAL|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
58262817|NCT03499457|DRUG|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
57710113|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
57710114|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
57710115|NCT05074433|DRUG|Placebo|Administered SC
57710116|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
58262818|NCT00972816|BIOLOGICAL|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
58262819|NCT04824235|OTHER|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
58262820|NCT04824235|OTHER|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
58383508|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
58383509|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
58262821|NCT03792529|OTHER|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
58383510|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
58383511|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
58383512|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
58383513|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
58383514|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
58383515|NCT03456700|DRUG|Auranofin|Given PO
58383516|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
58383517|NCT03456700|DRUG|Sirolimus|Given PO
58383518|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
58383519|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
58383520|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
58383521|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
58262822|NCT06016088|DRUG|RSP-1502|RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
58262823|NCT06016088|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
58262824|NCT06619340|DRUG|Exparel|20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.
58262825|NCT05448326|OTHER|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
58262826|NCT05448326|OTHER|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
58262827|NCT05448326|BIOLOGICAL|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
58262828|NCT04690790|PROCEDURE|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
58262829|NCT05368402|DRUG|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) will be administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules will be swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
58383522|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
58383523|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
58383524|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
58383525|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
58383526|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
58262830|NCT05368402|OTHER|Placebo|Placebo will be administered with the same ladarixin schedule.
58262831|NCT00570544|DRUG|tiotropium|18ug capsule daily for 30 days
58262832|NCT04157127|BIOLOGICAL|Autologous DC vaccine|Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
58262833|NCT03320850|DRUG|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
58262834|NCT03320850|DRUG|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
58262835|NCT05163821|DIAGNOSTIC_TEST|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
58262836|NCT05163821|DIAGNOSTIC_TEST|ACE-III Somali Translation|Cognitive screen for dementia
58262837|NCT03647735|OTHER|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
58262838|NCT00153127|DRUG|polyethyleneglycol3350|
58383527|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
58262839|NCT05632198|OTHER|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
58262840|NCT06623916|DEVICE|Endometrial Cancer Survivors|strain sonoelastograghy method has not been studied before in endometrial cancer as a prognostic factor. we compared well known pathologic prognostic factors with elastographic methods.
58262841|NCT04283292|DRUG|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
58383528|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
58383529|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
57911886|NCT06151223|OTHER|Bio-specimen Collection: Blood|At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.
58383530|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
58383531|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
58383532|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
58262842|NCT04283292|DRUG|Placebo|Placebo cream that is applied once topically
58383533|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
58383534|NCT00039039|DRUG|carboplatin|
58383535|NCT00039039|DRUG|chemotherapy|
58383536|NCT00039039|DRUG|cisplatin|
58383537|NCT00039039|DRUG|paclitaxel|
58383538|NCT00039039|RADIATION|radiation therapy|
57911887|NCT06151223|OTHER|Bio-specimen Collection: Pancreatic Juice|This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.
57911888|NCT06151223|DIAGNOSTIC_TEST|MRI|"A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia/anxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.~Clinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.~If a clinical MRI/MRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI/MRCP could be used to obtain baseline imaging data."
58262843|NCT06620783|BEHAVIORAL|exercise|Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
58262844|NCT06620783|BEHAVIORAL|yoga|The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
57911889|NCT03606434|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia
58059523|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
58059524|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
58059525|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
58059526|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
58262845|NCT06620783|BEHAVIORAL|active self-care|The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
58262846|NCT04561102|DIAGNOSTIC_TEST|Diagnostic test for detection of SARS-CoV-2|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
58262847|NCT00559780|BEHAVIORAL|Resistance training|12 weeks of resistance training (3/week)
58262848|NCT00559780|BEHAVIORAL|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
58262849|NCT00559780|BEHAVIORAL|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
58262850|NCT01765244|DRUG|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
58262851|NCT01765244|OTHER|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
58262852|NCT02631460|DRUG|S1 80-120 mg/d|d1, every 3 weeks
58262853|NCT02631460|DRUG|pemetrexed 500 mg/m2|d1, every 3 weeks
58262854|NCT02631460|DRUG|carboplatin AUC=5|d1, every 3 weeks
58262855|NCT02563262|OTHER|body angles measurements during weightlessness|
58059527|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
58262856|NCT01825356|PROCEDURE|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
57911890|NCT00681460|DRUG|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
57911891|NCT00681460|DRUG|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
57911892|NCT03266705|DRUG|tafamidis|bioequivalence study
58262857|NCT01825356|PROCEDURE|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
58262858|NCT06648369|OTHER|MAX-ICH care bundle|The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.
58383539|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
58383540|NCT05429580|OTHER|5% Dextrose|given placebo.
58383541|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
58383542|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
58383543|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
58262859|NCT06648369|OTHER|Standard of care|The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
58383544|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
58383545|NCT03645278|DRUG|Placebo|Ascending dose oral administration
57911893|NCT02146326|BEHAVIORAL|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
57911894|NCT02146326|BEHAVIORAL|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
57911895|NCT01477554|OTHER|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
58383546|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
57911896|NCT06315504|OTHER|Observation|Observation
57911897|NCT05100082|DRUG|Cabozantinib|Cabozantinib tablets
57911898|NCT03496831|DRUG|Biologic Agents|
58262860|NCT05714046|BEHAVIORAL|Control|An informative presentation
58262861|NCT05714046|BEHAVIORAL|Yoga training|Yoga exercise training
58262862|NCT02395640|DRUG|Epirubicin|50mg/m2 ivgtt d1
58262863|NCT02395640|DRUG|Oxaliplatin|
58262864|NCT02395640|DRUG|Capecitabine|1000mg/m2 po d1-14
58262865|NCT01528397|PROCEDURE|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
57911899|NCT03237637|DRUG|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
57911900|NCT03237637|DRUG|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
57911901|NCT01853644|DRUG|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
57911902|NCT02657512|DRUG|rivaroxaban|rivaroxaban 40 mg/day (1 day)
57911903|NCT02657512|DRUG|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
57911904|NCT00177034|DRUG|Narrow Band UVB Treatment|
58059528|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
58059529|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
58262866|NCT04258969|BEHAVIORAL|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
58262867|NCT05555225|OTHER|Methylome|Epigenetic study : analysis of DNA methylation
58383547|NCT03310359|OTHER|Placebo|Matching placebo pill
58262868|NCT05866562|DRUG|Dupilumab|Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;
58262869|NCT05866562|DRUG|Placebo|Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
58262870|NCT06365008|DRUG|Sintilimab+irinotecan+leucovorin folinate+fluorouracil|sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
58262871|NCT04030962|DRUG|AGN-242428|Ophthalmic solution administered as a topical eye drop
58262872|NCT04030962|DRUG|AGN-231868|Ophthalmic solution administered as a topical eye drop
58262873|NCT04030962|OTHER|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
58262874|NCT04030962|OTHER|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
58262875|NCT04030962|DRUG|Lifitegrast|Ophthalmic solution administered as a topical eye drop
58262876|NCT05392439|DEVICE|taVNS|transcutaneous auricular vagal nerve stimulation
58262877|NCT05392439|DEVICE|sham-taVNS|transcutaneous stimulation at the elbow area
58262878|NCT02433041|DRUG|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
58262879|NCT02433041|DRUG|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
58262880|NCT02433041|DRUG|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
58262881|NCT02433041|DRUG|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
58262882|NCT03736330|BIOLOGICAL|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck \& Co., Inc.） and were transferred to participants via intravenous infusion .
58262883|NCT06137703|DRUG|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
58262884|NCT06137703|DRUG|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
58262885|NCT06137703|DRUG|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
58262886|NCT06137703|DRUG|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
58262887|NCT01805076|PROCEDURE|Breast surgery|
58262888|NCT01805076|PROCEDURE|Magnetic resonance imaging|
58262889|NCT01805076|PROCEDURE|Mammography|
58262890|NCT01552915|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
58262891|NCT01552915|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
58262892|NCT01552915|DRUG|Placebo|Daily oral dosing in the AM for 8 weeks
57710117|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
57710118|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
57710119|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
57710120|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
57710121|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
57710122|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
57911905|NCT05955794|OTHER|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\]."
57911906|NCT05209763|PROCEDURE|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
57911907|NCT05209763|DIETARY_SUPPLEMENT|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses"
58262893|NCT03875092|BIOLOGICAL|Pembrolizumab|IV infusion
58262894|NCT03875092|DRUG|Paclitaxel|IV infusion
58262895|NCT03875092|DRUG|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
58262896|NCT03875092|DRUG|Saline placebo for pembrolizumab|IV infusion
58262897|NCT04789291|DRUG|BI 1595043|Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
58262898|NCT00635453|BEHAVIORAL|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
58262899|NCT02625441|DRUG|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
58262900|NCT02625441|DRUG|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
58262901|NCT06113341|DRUG|IDegLira|Pre-filled pen injection.
58262902|NCT06618131|OTHER|Exercise|Exercise program with virtual reality applications for lower extremities
57911908|NCT02956785|DRUG|10 mg Dinoprostone; CTS, UK|
57911909|NCT02956785|DRUG|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
57911910|NCT02956785|DRUG|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
57911911|NCT04415723|OTHER|supportive care management programme|nurse-led management programme
57911912|NCT01990118|DRUG|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
58262903|NCT01892085|BEHAVIORAL|Early initiation|Initiation of breast milk expression \<1 hour following delivery.
58262904|NCT01892085|BEHAVIORAL|Intermediate expression|Initiation of milk expression 1-\<3 hours following delivery.
58262905|NCT01892085|BEHAVIORAL|Late initiation|Initiation of milk expression \>3-6 hours following delivery.
58262906|NCT03820219|DEVICE|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
58262907|NCT03820219|OTHER|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
58262908|NCT00875433|DRUG|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
57710123|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
57710124|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
57911913|NCT01990118|DRUG|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
57911914|NCT01560468|DRUG|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
57911915|NCT01629602|PROCEDURE|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
57911916|NCT06279026|BIOLOGICAL|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
57911917|NCT05414487|DRUG|Ofatumumab|There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
57911918|NCT01543932|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
57911919|NCT01543932|DRUG|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
57911920|NCT01543932|DRUG|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
57911921|NCT03044925|PROCEDURE|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
57911922|NCT03044925|PROCEDURE|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
57911923|NCT03580668|DRUG|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
57911924|NCT04281446|DEVICE|Photobiomodulation|Application of light at specific wavelength for interaction with biological tissue
57911925|NCT04303767|DRUG|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
57911926|NCT04303767|PROCEDURE|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
57911927|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the morning|The patients in this group underwent impacted tooth surgery at 08:30 in the morning.
57911928|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the afternoon|Impacted tooth surgery was performed on the patients in this group at 15:30.
57911929|NCT05820477|BEHAVIORAL|FAMS-T1D|Behavioral FAMS-T1D FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.
57911930|NCT05820477|BEHAVIORAL|Digital resources for diabetes|Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
57911931|NCT03598010|DEVICE|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
57911932|NCT03598010|DEVICE|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
58262909|NCT01312233|OTHER|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
57710125|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
57710126|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
57911933|NCT03147404|DRUG|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
57911934|NCT03460691|PROCEDURE|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
57710127|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
57710128|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
57911935|NCT03536143|BIOLOGICAL|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
57911936|NCT03536143|BIOLOGICAL|Placebo gel|Placebo gel
57911937|NCT03997084|OTHER|phone interviews|phone interviews
57911938|NCT00822211|DRUG|Vildagliptin 50 mg bid|
57911939|NCT00822211|DRUG|Vildagliptin 50 mg qd|
57911940|NCT00822211|DRUG|Placebo|
57911941|NCT00513513|DRUG|TMC114 (darunavir) / ritonavir|
57911942|NCT05505331|RADIATION|three-Dimensional ultrasonography|transadominal and transvaginal examination
57911943|NCT05505331|RADIATION|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
57911944|NCT05505331|PROCEDURE|myomectomy|myoma excision
57911945|NCT02854969|BEHAVIORAL|Device: Anapphylaxis|
57710129|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
57710130|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
57911946|NCT06223854|DIETARY_SUPPLEMENT|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
57911947|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
57911948|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
57911949|NCT00790751|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
57911950|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
57911951|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
57911952|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
57911953|NCT01046773|DRUG|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
57911954|NCT01046773|DRUG|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
57911955|NCT00080457|DRUG|sitaxsentan sodium|
57911956|NCT03029351|DRUG|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
58262910|NCT01312233|OTHER|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
58262911|NCT01312233|OTHER|Shared Care|Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
58262912|NCT05704335|OTHER|Questionnaire administration|A trained physician will administer a structured questionnaire
58262913|NCT06622018|PROCEDURE|Seashell Nanoparticles and Gluma Desensitizer|Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
58262914|NCT02211690|DRUG|dolutegravir 50 mg (one tablet daily)|
57710131|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
57710132|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
57911957|NCT03029351|DRUG|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
57911958|NCT01326754|DRUG|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
57911959|NCT01326754|DRUG|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
57911960|NCT01326754|DRUG|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
58262915|NCT02211690|DRUG|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
58262916|NCT04457375|DIAGNOSTIC_TEST|TDC|measurements
58262917|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
58262918|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
58262919|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
58262920|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
58262921|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
58262922|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
58262923|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
58262924|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
58262925|NCT06149065|DRUG|Testosterone|Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
58262926|NCT03268824|DEVICE|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
58262927|NCT03268824|DEVICE|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
57710133|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
57911961|NCT02040584|DRUG|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
57911962|NCT02040584|DRUG|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
57911963|NCT03100643|OTHER|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
58059530|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
58059531|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
58262928|NCT03268824|OTHER|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
58262929|NCT04154462|OTHER|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
58262930|NCT05261334|PROCEDURE|contour augmentation|early implant placement with contour bone augmentation
58262931|NCT00750841|DRUG|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
58262932|NCT04299139|OTHER|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
58262933|NCT01756105|DRUG|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
58262934|NCT01756105|DRUG|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
58262935|NCT05537792|DEVICE|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
58262936|NCT04616560|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
58262937|NCT00463762|DRUG|CP-75385-02 Cefoperazone/sulbactam|
58383548|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
58383549|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
57710134|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
57710135|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
57710136|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
57710137|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
58262938|NCT04047134|OTHER|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
58383550|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
58383551|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
58383552|NCT02872870|BEHAVIORAL|auditory lexical decision task|
58383553|NCT02872870|DEVICE|electroencephalogram|
58383554|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
57710138|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
58383555|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
58383556|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
58262939|NCT04047134|OTHER|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
58262940|NCT04112160|DRUG|Ketorolac|IM injection of either normal saline or Ketorolac
58262941|NCT04112160|DRUG|normal saline|normal saline
58262942|NCT04878445|PROCEDURE|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
58262943|NCT00033202|DRUG|Gimatecan® (ST-1481)|
58262944|NCT01185223|DRUG|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
58262945|NCT01185223|DRUG|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
58262946|NCT02793401|DEVICE|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
58262947|NCT02793401|DEVICE|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
58262948|NCT02793401|DEVICE|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
58262949|NCT02793401|DEVICE|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
58262950|NCT02793401|OTHER|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
58262951|NCT02793401|OTHER|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
58262952|NCT04188015|BIOLOGICAL|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
58262953|NCT04188015|BIOLOGICAL|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
58262954|NCT04188015|OTHER|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
58262955|NCT01882881|OTHER|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
58262956|NCT01882881|OTHER|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).
58262957|NCT01882881|OTHER|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
58262958|NCT01882881|OTHER|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
58262959|NCT01258179|OTHER|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
58262960|NCT02584894|DEVICE|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
57710139|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
57710140|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
57710141|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
58262961|NCT02584894|DEVICE|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
58262962|NCT02584894|BEHAVIORAL|psychoneurological assessment|psychoneurological assessment
58262963|NCT02584894|DEVICE|conductivity meter|electrodermal conductance measure
58383557|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
57710142|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
57710143|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
57710144|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
57710145|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
57710146|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
57710147|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
57710148|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
57710149|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
57710150|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
57710151|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
57710152|NCT00006475|DRUG|imatinib mesylate|
57710153|NCT02165111|DRUG|Onabotulinumtoxin A|
57710154|NCT02165111|DRUG|sterile saline solution|
58262964|NCT02584894|DEVICE|electrocardiogram|heart rate measure
58262965|NCT04040634|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
58262966|NCT04040634|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
57710155|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
58262967|NCT06645054|BEHAVIORAL|Standard rehabilitation|The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).
57710156|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
57710157|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
57710158|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
57710159|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
57710160|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
57710161|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
58262968|NCT06645054|DEVICE|Lower-limb prosthesis|The patients from the LLL group will be fitted with an appropriate lower-limb prosthesis.
58262969|NCT06645054|DEVICE|Lower-limb orthosis|The patients from the LLO group will be fitted with an appropriate lower-limb orthosis.
58262970|NCT00504725|DRUG|Ketamine|Interventional
58383558|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
58383559|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
57710162|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
58262971|NCT00504725|DRUG|0.9% saline|placebo
58262972|NCT06050655|DEVICE|Lingual aligners|orthodontic treatment with lingual aligners
57710163|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
58262973|NCT06025253|DEVICE|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
58262974|NCT06025253|DEVICE|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
58262975|NCT06104761|OTHER|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
58262976|NCT06104761|OTHER|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
58262977|NCT00697034|DRUG|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
57710164|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
58262978|NCT03826810|RADIATION|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
58262979|NCT03826810|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
58262980|NCT02987517|OTHER|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
58262981|NCT02987517|OTHER|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
58383560|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
58262982|NCT02987517|OTHER|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
58262983|NCT03122613|DIETARY_SUPPLEMENT|Curcumin|3g of Curcumin per day
58262984|NCT03122613|DRUG|Placebo|3g of Curcumin Placebo per day
57710165|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
57710166|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
57710167|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
58262985|NCT06628752|DEVICE|Deep brain stimulation|Stimulation through a device implanted bilaterally into deep brain structures.
58262986|NCT02052596|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
58262987|NCT02052596|BIOLOGICAL|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
58383561|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
58383562|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
58383563|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
58383564|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
58383565|NCT00000277|DRUG|Mazindol|
58383566|NCT00004891|DRUG|chemotherapy|
58383567|NCT00004891|PROCEDURE|computed tomography|
58383568|NCT00004891|PROCEDURE|conventional surgery|
58383569|NCT00004891|PROCEDURE|neoadjuvant therapy|
58383570|NCT00004891|PROCEDURE|positron emission tomography|
58383571|NCT00004891|PROCEDURE|radionuclide imaging|
58262988|NCT03187067|DEVICE|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
58383572|NCT00004891|RADIATION|fludeoxyglucose F 18|
58383573|NCT00004891|RADIATION|radiation therapy|
58383574|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
58383575|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
58383576|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
58262989|NCT02889705|OTHER|Ultrasonographic examination|
58262990|NCT01665846|DRUG|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
58262991|NCT05890690|DIAGNOSTIC_TEST|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
58262992|NCT05890690|DIAGNOSTIC_TEST|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
58262993|NCT01797081|BIOLOGICAL|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
58383577|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
57710168|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
57710169|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
57710170|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
57710171|NCT03620318|DRUG|Crenolanib besylate|
57710172|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
57710173|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
58262994|NCT01797081|BIOLOGICAL|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
57710174|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
57710175|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
58262995|NCT01797081|OTHER|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
58262996|NCT06619405|DIAGNOSTIC_TEST|Streetlab VR|Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.
58262997|NCT00182728|PROCEDURE|surgery|conventional
58262998|NCT00182728|PROCEDURE|therapy|neoadjuvant
58262999|NCT00182728|RADIATION|radiation therapy|intraoperative radiation therapy
58263000|NCT00422344|DRUG|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
58383578|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
58383579|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
57710176|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
57710177|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
57710178|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
57784836|NCT04793464|BEHAVIORAL|Promotores de Salud|The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
58263001|NCT05269420|PROCEDURE|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
58263002|NCT00854425|DRUG|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
58263003|NCT00716352|BEHAVIORAL|Educational intervention programme|
58263004|NCT01796197|DRUG|Trastuzumab|
58263005|NCT01796197|DRUG|Pertuzumab|
58263006|NCT01796197|DRUG|Paclitaxel|
58263007|NCT01796197|DRUG|Doxorubicin|
58263008|NCT01796197|DRUG|Cyclophosphamide|
58263009|NCT01796197|PROCEDURE|Mastectomy|
58263010|NCT01796197|RADIATION|Radiation Therapy|
58263011|NCT02449135|PROCEDURE|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
58263012|NCT06042569|DRUG|Cyclophosphamide|Given IV
58263013|NCT06042569|DRUG|Docetaxel|Given IV
58263014|NCT06042569|OTHER|Medical Chart Review|Ancillary studies
58263015|NCT06042569|OTHER|Questionnaire Administration|Ancillary studies
58263016|NCT00962364|BIOLOGICAL|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
58263017|NCT05853367|DRUG|MK-0472|Oral Administration
58263018|NCT05853367|BIOLOGICAL|Pembrolizumab|IV infusion
58263019|NCT05853367|DRUG|MK-1084|Oral Administration
58263020|NCT02651415|DRUG|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories."
58263021|NCT02651415|DRUG|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
58263022|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Intranasal insulin will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
58263023|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Placebo spray will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over ten minutes starting at time point -15 minutes on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
58263024|NCT05315700|DRUG|ORIC-114|ORIC-114 oral daily
58263025|NCT05315700|DRUG|Chemotherapy drug|21 days for up to 4 cycles
58383580|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
58383581|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
58383582|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
58263026|NCT02831985|PROCEDURE|general practice follow-up|Post-surgery follow-up by general practitioner
58263027|NCT02831985|PROCEDURE|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
58263028|NCT02032381|OTHER|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
58263029|NCT05778032|OTHER|Multidisciplinary metabolic rehabilitation program|Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks
58263030|NCT02658006|PROCEDURE|Cardiac surgery|All cardiac surgery procedures
58263031|NCT02416648|BEHAVIORAL|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
58263032|NCT06316154|PROCEDURE|Echinococcectomy|Echinococcectomy with subsequent pathomorphological analysis of liver parenchyma next to and in the thickness of the fibrous capsule
58263033|NCT00348595|DRUG|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
58263034|NCT06620003|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
58263035|NCT06620003|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
57784837|NCT04793464|BEHAVIORAL|Services as usual|Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
57784838|NCT04562506|DEVICE|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
58263036|NCT05174858|DEVICE|Hemostatic dressing ETIK COLLAGENE|The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
58263037|NCT05174858|OTHER|Comparator|The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
58263038|NCT03929159|PROCEDURE|Biospecimen Collection|Undergo blood biospecimen collection
58263039|NCT02350946|DRUG|Oxytocin|
58263040|NCT02350946|DRUG|Placebo|
58263041|NCT02564640|DEVICE|videolaryngoscope|patients intubated by using the videolaryngoscope
58263042|NCT02564640|DEVICE|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
58263043|NCT01815606|PROCEDURE|biopsy with 19 gauge needle|biopsy with 19 gauge needle
57710179|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
57784839|NCT04562506|DEVICE|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
58263044|NCT01815606|PROCEDURE|biopsy with 25 gauge needle|biopsy with 25 gauge needle
58263045|NCT05359549|DEVICE|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
58263046|NCT03275675|DRUG|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
58263047|NCT01021475|PROCEDURE|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
58383583|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
58263048|NCT01021475|DRUG|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
58263049|NCT00059605|GENETIC|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
58263050|NCT00189306|DRUG|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
58263051|NCT00388336|DRUG|Epoetin Alfa|
58263052|NCT06647992|BEHAVIORAL|Nurse Navigation Program|"It is planned to provide Cervical Cancer Education and Counseling to women in the experimental group about cervical cancer. Training and counseling is planned to be implemented face to face. An information booklet will be given to the experimental group. After 30 and 60 days after the training and counseling given to the experimental and control groups, it was planned to provide online (WhatApp) training and counseling to the patients in the experimental group:~Participants will be given a contact number that they can reach during the day when they want to receive counseling about HPV-DNA or Pap smear. Interviews will be scheduled between 08.00-20.00.~Individuals who are not screened will receive a reminder message by phone on the 45th and 75th day. Transtheoretical Model In the study, interventions will be planned for the experimental group according to the stages of the transtheoretical model.~The researcher will conduct motivational interviews with the individuals."
58263053|NCT02815124|OTHER|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
58383584|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
58383585|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
58383586|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
58383587|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
58263054|NCT02815124|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
58263055|NCT03061656|DRUG|Cyclophosphamide|1st HDCT
58263056|NCT03061656|DRUG|Carboplatin|1st HDCT
58383588|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
58383589|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
58383590|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
58383591|NCT01360814|OTHER|questionnaire administration|Ancillary studies
58263057|NCT03061656|DRUG|Etoposide|1st HDCT
58263058|NCT03061656|RADIATION|131I-MIBG|2nd HDCT
58263059|NCT03061656|DRUG|Thiotepa|2nd HDCT
58263060|NCT03061656|DRUG|Melphalan|2nd HDCT
58383592|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
58263061|NCT01424046|DRUG|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
58263062|NCT01424046|DRUG|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
58263063|NCT01881997|DRUG|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
58263064|NCT01881997|DRUG|Normal Saline|IM normal saline
58263065|NCT05481229|OTHER|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
58263066|NCT06618378|BEHAVIORAL|Biofeedback exercise combined with breathing exercise|Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.
58263067|NCT06618378|BEHAVIORAL|urotherapy educational group|"1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity."
58263068|NCT06395298|OTHER|Experimental group PIOMI|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI
58263069|NCT06395298|OTHER|Control group NIDCAP|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
58263070|NCT01553240|DEVICE|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
58263071|NCT04604418|OTHER|No intervention. It is observational|No intervention. It is observational
58263072|NCT04399408|DEVICE|Obstetrics Ultrasound (non invasive)|Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
58263073|NCT06648304|DRUG|TTYP01 tablets|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
58263074|NCT06648304|DRUG|Placebo (Simulant TTYP01 Tablets)|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
58263075|NCT05000203|BEHAVIORAL|Online prenatal specific education|"The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants."
58383593|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
58383594|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
58383595|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
58383596|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
58383597|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
58383598|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
57784840|NCT01762163|DRUG|Qizhitongluo Capsule|
58263076|NCT05000203|BEHAVIORAL|Intrapartum specific support|"At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard"
58263077|NCT05000203|BEHAVIORAL|Prenatal usual education|The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
58383599|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
58383600|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
58383601|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
58383602|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
58059532|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
58383603|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
58383604|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
58383605|NCT00178074|BEHAVIORAL|total sleep deprivation|
58383606|NCT00178074|PROCEDURE|PET imaging|
58059533|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
58059534|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
57784841|NCT01762163|DRUG|Naoxintong Capsule|
57784842|NCT01762163|DRUG|Aspirin Enteric-coated Tablets|
57784843|NCT01762163|BEHAVIORAL|the routine recovery training|
58059535|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
57784844|NCT01762163|DRUG|placebo|
58059536|NCT02444689|BEHAVIORAL|Standard of care education|
58059537|NCT00439699|DRUG|Memantine|Mematine administration
58263078|NCT05000203|BEHAVIORAL|Intrapartum usual support|A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
58263079|NCT03588078|DRUG|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
58383607|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
57784845|NCT00035958|DRUG|Prednisone|
57784846|NCT00035958|DRUG|Methotrexate|
58383608|NCT00881530|DRUG|Metformin|open label comparator
58383609|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
58383610|NCT00881530|DRUG|Sitagliptin|open label comparator
57911964|NCT01283477|DEVICE|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
58263080|NCT03588078|DRUG|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
58263081|NCT02998385|DRUG|Cisplatin|intravenous, concomitant to irradiation
58263082|NCT02998385|RADIATION|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
58263083|NCT04451616|DIAGNOSTIC_TEST|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
58263084|NCT04451616|DIAGNOSTIC_TEST|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
58263085|NCT04451616|DIAGNOSTIC_TEST|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
58263086|NCT04451616|DIAGNOSTIC_TEST|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
58263087|NCT04451616|DIAGNOSTIC_TEST|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
58263088|NCT04451616|DIAGNOSTIC_TEST|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
58263089|NCT04898543|BIOLOGICAL|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)|M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
58383611|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
58383612|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
57784847|NCT00035958|DRUG|Etanercept|
57784848|NCT02435511|OTHER|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
57784849|NCT05721339|BEHAVIORAL|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
57784850|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
57784851|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
57784852|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
57784853|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
57784854|NCT04378634|BEHAVIORAL|Exercise|Sub-maximal exercise test
57784855|NCT04378634|OTHER|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
57784856|NCT03717675|DEVICE|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
57784857|NCT03434535|DEVICE|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
57784858|NCT02959138|DRUG|Lanraplenib.|20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
57911965|NCT01283477|DEVICE|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
58263090|NCT04898543|BIOLOGICAL|N-803 (Cohort 2 part B)|N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
57710180|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
57710181|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
58263091|NCT04898543|OTHER|Apheresis collection of MNCs (part A)|Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
58263092|NCT02493010|DEVICE|Arousal-based biofeedback system|
58263093|NCT06648902|DRUG|meldonium|500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6
58263094|NCT05288894|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
58383613|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
58263095|NCT06060990|OTHER|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
58263096|NCT05477485|BEHAVIORAL|Experimental: AIMS program - patient|Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.
58059538|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
58059539|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
58059540|NCT00807989|DRUG|Carbamazepine|
58059541|NCT00807989|DRUG|Lamotrigine/Valproate|
58263097|NCT05477485|OTHER|No Intervention/Usual care|Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
58263098|NCT03603470|OTHER|EOS imagery|Whole body EOS imaging in seated and standing position
58383614|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
58383615|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
58383616|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
58383617|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
58059542|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58263099|NCT00074997|OTHER|Placebo|Single intravenous infusion of placebo.
58263100|NCT00074997|GENETIC|OZ1|Single intravenous infusion of OZ1.
58263101|NCT00074997|GENETIC|CD34+ cells|Autologous CD34+ cells.
58263102|NCT00533689|PROCEDURE|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
58263103|NCT02916394|RADIATION|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
58263104|NCT04586218|BEHAVIORAL|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure \> 65mmHg
58263105|NCT04586218|BEHAVIORAL|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
58263106|NCT06649526|OTHER|endotracheal intubation with videolaryngoscope|The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
58383618|NCT00486356|DRUG|capecitabine|
58383619|NCT00486356|DRUG|carboplatin|
58383620|NCT00486356|DRUG|epirubicin hydrochloride|
58383621|NCT00486356|GENETIC|microarray analysis|
58383622|NCT00486356|GENETIC|polymorphism analysis|
58383623|NCT00486356|OTHER|pharmacological study|
58059543|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
58263107|NCT03969303|DEVICE|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
58263108|NCT04781829|DIAGNOSTIC_TEST|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
57710182|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
57710183|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
57710184|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
57710185|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
57710186|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
58059544|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
58059545|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
58059546|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
58059547|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
58059548|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
58059549|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
58263109|NCT05333939|DIETARY_SUPPLEMENT|Moringa leaf powder|capsule ingestion
58263110|NCT05333939|OTHER|Placebo|capsule ingestion
58383624|NCT03411018|OTHER|Mechanical ventilation exposure|
58059550|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
58263111|NCT00403650|DRUG|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
58263112|NCT03231540|DIETARY_SUPPLEMENT|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
58263113|NCT05817487|BEHAVIORAL|high-intensity interval training (HIIT)|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
58263114|NCT05817487|BEHAVIORAL|crossover point(COP) exercise training|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
58383625|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
58383626|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
58383627|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
57710187|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
58263115|NCT03369028|OTHER|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
58263116|NCT06003907|OTHER|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
58263117|NCT06003907|OTHER|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
58263118|NCT06648512|OTHER|No Interventions|No Intervention
58263119|NCT06028958|OTHER|Neck Isometrics Exercises|Isometric exercises are tightening (contractions) of a specific muscle or group of muscles. During isometric exercises, the muscle doesn't noticeably change length. The affected joint also doesn't move. Isometric exercises help maintain strength.
58263120|NCT06028958|OTHER|Global Posture Re-Education|Global postural rehabilitation (GPR) is an approach that considers the body in its overall aspect. This technique aims to relax the envelope of the muscles (fascia) while relaxing the muscle chains to reduce the strain on the joints. The end result is a more suitable posture and less pain.
58263121|NCT04927377|BEHAVIORAL|AI4DM|Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor
58263122|NCT04927377|BEHAVIORAL|Attention-control|Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.
58263123|NCT05824052|OTHER|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
58263124|NCT06620549|DIAGNOSTIC_TEST|gastric ultrasonograppy|Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (\>1,5ml/Kg) and the last option is solid food in one or both positions.
58263125|NCT02004821|DIETARY_SUPPLEMENT|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
58263126|NCT02262000|RADIATION|Image Guided Stereotactic Ablative Radiotherapy|
58263127|NCT06619223|DIAGNOSTIC_TEST|Duplex Ultrasound|The primary intervention in this study is the use of ankle Doppler waveform assessment for post-revascularisation surveillance in patients with Peripheral Arterial Disease (PAD). This technique utilises continuous-wave Doppler (CWD) and pulsed-wave Doppler (PWD) to assess the blood flow in the key ankle arteries, including the dorsalis pedis artery (DPA) and posterior tibial artery (PTA).
58263128|NCT06349512|PROCEDURE|68Ga-FAPI-46 PET/CT imaging|The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
58263129|NCT01702675|DRUG|ACH15 50 mg|ACH15 50mg capsule
58263130|NCT01702675|DRUG|ACH15 250 mg|ACH15 250mg capsule
58263131|NCT01702675|DRUG|ACH15 500mg|ACH15 500 mg capsule
58263132|NCT01702675|DRUG|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
58263133|NCT01702675|DRUG|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
58263134|NCT01702675|DRUG|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
57710188|NCT05927233|DRUG|Saline|30 ml Normal saline
57710189|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
57710190|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
58059551|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
58059552|NCT01196091|DRUG|Standard of Care|
58059553|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
58059554|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
58059555|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
58263135|NCT01702675|DRUG|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
58263136|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
58263137|NCT01702675|DRUG|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
58263138|NCT01702675|DRUG|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
58263139|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
58263140|NCT04346901|DRUG|Thiamazol|All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
57710191|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
58383628|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
58383629|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
58383630|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
58383631|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
58383632|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
58383633|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
58383634|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
58383635|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
58383636|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
57710192|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
57710193|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
57710194|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
57710195|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
57710196|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
58383637|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
58383638|NCT01485276|PROCEDURE|DBS Surgery|
58383639|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
58263141|NCT00783315|BEHAVIORAL|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
58383640|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
57710197|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
57710198|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
57911966|NCT03099746|BEHAVIORAL|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
58059556|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
58263142|NCT00783315|BEHAVIORAL|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
58059557|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
58263143|NCT00783315|BEHAVIORAL|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
57710199|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
57710200|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57710201|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
57710202|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
57710203|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
57710204|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57710205|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
57911967|NCT03099746|BEHAVIORAL|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
57911968|NCT03099746|BEHAVIORAL|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
58263144|NCT03743103|DRUG|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
58263145|NCT03743103|DRUG|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
57710206|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
57710207|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
57710208|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
57710209|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
57710210|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
57710211|NCT02149433|DRUG|Placebo|
57710212|NCT02420496|DRUG|Enteral fish oil|
58059558|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
58059559|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
58059560|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
58263146|NCT05961410|DRUG|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
57710213|NCT02420496|DRUG|Ursodeoxycholic Acid|
57710214|NCT02420496|DRUG|Placebo|
57710215|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
57710216|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
57710217|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
57911969|NCT04968808|PROCEDURE|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
58059561|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
58059562|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
58263147|NCT04643418|DRUG|MPB-1734|Administered once daily in a 21-day cycle
58263148|NCT06620224|DEVICE|Virtual Reality|we only use single group in this study, before the acupuncture treatment, let the participant wear the virtual reality to realize the course of the acupuncture treatment
58383641|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
58059563|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
58263149|NCT01726387|BEHAVIORAL|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
58263150|NCT01726387|BEHAVIORAL|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
58263151|NCT01668524|DRUG|ATS907|Single dose of each of three increasing concentrations
58383642|NCT05071612|DRUG|AD109|Oral administration at bedtime
58383643|NCT05071612|DRUG|AD504|Oral administration at bedtime
58263152|NCT01609634|OTHER|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
58263153|NCT01609634|OTHER|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
58263154|NCT01609634|OTHER|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
58263155|NCT06252051|DRUG|Trivalent Influenza Vaccine|We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
58263156|NCT00773578|DEVICE|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
58263157|NCT00773578|DEVICE|Measurement of biomarkers of nasal inflammation|Nasal lavage
58263158|NCT05603195|DRUG|REGN7508 (IV)|Administered sequential, ascending single intravenous (IV) dose
58383644|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
58383645|NCT05071612|DRUG|Placebo|Oral administration at bedtime
58383646|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
58383647|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
58059564|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
58059565|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
58059566|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
58059567|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
58059568|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
58059569|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
58059570|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
58059571|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
58059572|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
58059573|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
58059574|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
58059575|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
58059576|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
58059577|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
58059578|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
58059579|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
58059580|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
58059581|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
57911970|NCT04968808|PROCEDURE|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
57911971|NCT01152632|OTHER|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
57911972|NCT00212160|PROCEDURE|omentectomy|RYGB with omentectomy
58059582|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
58059583|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
58059584|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
58263159|NCT05603195|DRUG|REGN7508 (SC)|Administered sequential, ascending single subcutaneous (SC) dose
57710218|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
57710219|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
57710220|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
57911973|NCT00597246|DRUG|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
57911974|NCT00597246|OTHER|PET Scan|GE Advance PET scanner for sequential body imaging
57911975|NCT02434497|DRUG|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
57911976|NCT02174042|DRUG|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
57911977|NCT03309462|DEVICE|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
58263160|NCT05603195|DRUG|Matching Placebo (IV)|Administered sequential, ascending single intravenous (IV) dose
58263161|NCT05603195|DRUG|Matching Placebo (SC)|Administered sequential, ascending single subcutaneous (SC) dose
58263162|NCT03398512|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
58263163|NCT03398512|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
58383648|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
57710221|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
57710222|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
57710223|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
57710224|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
57911978|NCT01495832|OTHER|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
57911979|NCT01495832|OTHER|Control Group|The control group will consume comparator foods for 12 weeks.
57911980|NCT05615545|PROCEDURE|Cryoablation|Cryoablation of selected tumor lesions
57911981|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
57911982|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
57911983|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
57911984|NCT03952325|DRUG|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
57911985|NCT03952325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
57911986|NCT03952325|DRUG|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
57911987|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
58263164|NCT03398512|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
58263165|NCT06647745|DRUG|THP-00101|Dapagliflozin 10 mg
58263166|NCT06647745|DRUG|THP-00102|Telmisartan 80 mg
58263167|NCT06647745|DRUG|THP-00103|Telmisartan 40 mg
58263168|NCT06647745|DRUG|THP-00104|Placebo of Dapagliflozin 10mg
58263169|NCT06647745|DRUG|THP-00105|Placebo of Telmisartan 80mg
58263170|NCT06647745|DRUG|THP-00106|Placebo of Telmisartan 40mg
58263171|NCT02076737|DEVICE|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
58383649|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
57710225|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
57710226|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
58263172|NCT04235374|BEHAVIORAL|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
58263173|NCT05996640|OTHER|This is study does not use an intervention|This is study does not use an intervention. A survey will be used to collected data on patients' experiences and preferences about waiting list for heart surgery.
58383650|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
58383651|NCT02284256|DRUG|Fibrocaps|
58383652|NCT02284256|DRUG|TachoSil|
58383653|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
58383654|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
58383655|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
58383656|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
58383657|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
58383658|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
57911988|NCT03971630|OTHER|Telemedicine|Patients will be followed up using the MyVENT System and APP
58059585|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
57710227|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
57710228|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
57784859|NCT04997967|DRUG|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
58059586|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
58059587|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
58383659|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
58383660|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
57784860|NCT04997967|DRUG|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
57784861|NCT03088137|DRUG|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
57784862|NCT03088137|DRUG|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
57784863|NCT02342587|DRUG|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
57710229|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
57710230|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
57710231|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
58263174|NCT05176548|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy|Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
58263175|NCT05700916|DRUG|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
58263176|NCT05700916|DIETARY_SUPPLEMENT|Dairy Powder|Effects of dairy control powder
57710232|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
58263177|NCT04442451|OTHER|Control Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
58263178|NCT04442451|OTHER|Blood Flow Restriction Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
58263179|NCT04599725|DRUG|medical abortion|medical abortion
58263180|NCT01300338|DEVICE|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
58263181|NCT01300338|DEVICE|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
58263182|NCT04087629|DEVICE|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
58383661|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
58383662|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
58263183|NCT06622876|DIAGNOSTIC_TEST|Computed tomography exam of the chest|Computed tomography exam of the chest done for other indications other than pulmonary emboli, in which incidental pulmonary embolism was detected.
57710233|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
57710234|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
57710235|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
57710236|NCT02244333|DRUG|ALNA®|
57710237|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
57784864|NCT05174650|DRUG|Atezolizumab|Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 20 cycles in total
57784865|NCT05174650|DRUG|Derazantinib|Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 20 cycles in total
57911989|NCT04822493|OTHER|Counseling Aid|Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
57710238|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
57911990|NCT03619070|OTHER|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
57911991|NCT03619070|OTHER|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
57911992|NCT03619070|OTHER|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
57911993|NCT03619070|OTHER|Control group, CG|The CG groups do not will performed the exercise.
57911994|NCT02373943|OTHER|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
58059588|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
58059589|NCT02278159|PROCEDURE|Peritoneal dialysis|
58383663|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
58383664|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
58383665|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
58383666|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
58383667|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
58383668|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
57911995|NCT02373943|OTHER|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
57911996|NCT02373943|OTHER|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
58059590|NCT02278159|PROCEDURE|Home hemodialysis|
58059591|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
58059592|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
58059593|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
58059594|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
57911997|NCT00626132|DIETARY_SUPPLEMENT|Eucommia|two capsules three times a day orally for 2 weeks
57911998|NCT04669353|DRUG|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
58059595|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
58059596|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
58059597|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
58059598|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
58059599|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
58383669|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
58383670|NCT00095472|DRUG|L-NMMA|
58383671|NCT00095472|DRUG|Sodium Nitrite|
58383672|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
58059600|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
58059601|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
58263184|NCT02546791|DRUG|Dasatinib|
58263185|NCT04229602|DRUG|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
57710239|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
57911999|NCT03451760|DRUG|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
57912000|NCT03451760|OTHER|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
58263186|NCT04229602|DRUG|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
58263187|NCT06617728|PROCEDURE|Intervention 1: Regional Analgesia|Regional analgesia techniques like epidural or peripheral nerve blocks.
58263188|NCT06617728|DRUG|Intervention 2: Intravenous (IV) Analgesia|IV medications used for pain control, including opioids and non-opioid analgesics.
58263189|NCT06177769|DEVICE|LMA classic|Airway is secured with LMA clasic
58383673|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
58383674|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
58383675|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
58383676|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
58263190|NCT06177769|DEVICE|LMA Proseal|Airway is secured with LMA proseal
58383677|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
58383678|NCT00343499|DRUG|valsartan|
58383679|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
58383680|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
57710240|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
57912001|NCT04850794|BEHAVIORAL|Decision Support Tool|The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
58263191|NCT06177769|DEVICE|I-gel|Airway is secured with I-gel
58263192|NCT04230512|OTHER|Pump prototype|Effects of pump function on gait
58263193|NCT06648018|BEHAVIORAL|Nutritional information|Written nutritional information about food with high content of iron.
58383681|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
58383682|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
58383683|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
58383684|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
58383685|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
58383686|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
58383687|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
58383688|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|
58383689|NCT00236964|DRUG|Ferrous Sulfate + Erythropoietin|
58383690|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
58383691|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
57710241|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
57710242|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
58263194|NCT06648018|DIETARY_SUPPLEMENT|Iron-succinate|100 mg of Iron-succinate per day.
58263195|NCT06376136|DRUG|BAT8010 for Injection|Intravenous
58263196|NCT06376136|DRUG|BAT1006 for Injection|Intravenous
57912002|NCT01207297|DRUG|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
57912003|NCT01207297|DRUG|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
58059602|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
58263197|NCT05994911|BEHAVIORAL|Mindfulness Training|"The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness."
57912004|NCT05384405|DEVICE|Active iTBS|MagPro X100
58059603|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
58263198|NCT05025358|DRUG|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
58263199|NCT01282164|PROCEDURE|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
58263200|NCT01282164|PROCEDURE|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
58263201|NCT03139006|DEVICE|Dual-layer spectral detector CT|A dual energy CT approach
58263202|NCT01766752|DEVICE|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
58263203|NCT01735968|DRUG|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
58263204|NCT06051435|OTHER|lumbar proprioception training|"a) Sensorimotor training: Sensorimotor training and reconditioning of proprioceptive senses have recently been found to be helpful in increasing motor performance and coordination, muscle strength, sensorimotor abilities, increasing intermuscular control, and improving one's response to sensory information and muscle tone. Reconditioning of proprioceptive senses and sensorimotor training increases one's muscle adjustment ability, maximizes the sensory input in different parts of the body and aids in improving one's motor adjustment ability (Hwang et al ., 2013).~Position Exercise methods as Hollowing exercise: Participants will be asked to contract the abdominal muscles, raising the center of movement toward the navel in a quadruped position."
58263205|NCT06051435|OTHER|Hot packs|hot application in the form of hot packs on the lower abdomen and lower back for a total duration of 30 minutes, once per day, during the first two days of menstruation
58263206|NCT06051435|OTHER|Pelvic rocking exercise|Pelvic rocking exercise
58383692|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
57710243|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
57912005|NCT05384405|DEVICE|Sham iTBS|MagPro X100
58059604|NCT00369564|OTHER|placebo|Given orally 3 times daily
57710244|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
57710245|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
57710246|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
57710247|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
57912006|NCT06271460|OTHER|Traditional physiotherapy|All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.
58263207|NCT04430023|OTHER|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
58263208|NCT04699201|PROCEDURE|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
58263209|NCT04699201|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
58263210|NCT04699201|DIAGNOSTIC_TEST|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
58263211|NCT06417177|DRUG|Placebo|Participants will receive a placebo in pill form.
58383693|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
58383694|NCT04878107|RADIATION|LDRT|low dose radation therapy
58383695|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
58383696|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
58383697|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
58383698|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
58383699|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
58383700|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
58383701|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
58383702|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
58383703|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
57710248|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
57710249|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
57912007|NCT01683929|OTHER|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
58059605|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
58059606|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
58059607|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
58059608|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
58263212|NCT06417177|DRUG|Propranolol|Participants will receive oral propranolol (1 mg/kg).
58263213|NCT06417177|DRUG|Gemtesa|Participants will receive oral gemtesa (75 mg).
58263214|NCT02319967|BEHAVIORAL|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
58263215|NCT02319967|BEHAVIORAL|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
58263216|NCT03266458|PROCEDURE|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
58263217|NCT03108404|OTHER|Validation of a diagnostic test|Validation of a diagnostic test
57912008|NCT01683929|OTHER|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
58263218|NCT00826592|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
58263219|NCT00791362|OTHER|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
58263220|NCT04055311|BEHAVIORAL|Cancer Resource Information Support (CRIS)|Intervention support is patient initiated and accessed as needed
58263221|NCT04055311|BEHAVIORAL|Usual Care Enhanced|Usual care is enhanced with the addition of the NCI Facing Forward brochure
58263222|NCT00508287|DRUG|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
58263223|NCT00508287|DRUG|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
58263224|NCT00508287|DRUG|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
57912009|NCT03878251|DEVICE|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
57710250|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
57710251|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
57912010|NCT05271552|DRUG|BXCL501|Sublingual Film
57912011|NCT05271552|DRUG|Matching Placebo|Sublingual Placebo Film
57912012|NCT00531102|OTHER|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
57912013|NCT00531102|OTHER|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
57912014|NCT00737373|DRUG|Docetaxel|50mg/m2 qd15
57912015|NCT00737373|DRUG|5-Fluorouracil|2600mg/m2 qd15
58383704|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
58383705|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
57912016|NCT00737373|DRUG|Oxaliplatin|85mg/m2 qd15
57912017|NCT00737373|DRUG|folinic acid|200mg/m2 qd15
57912018|NCT01442831|DRUG|Human ADME|Oral single dose
57912019|NCT02877966|DIETARY_SUPPLEMENT|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
58263225|NCT02333721|PROCEDURE|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
58263226|NCT02333721|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
58263227|NCT00154050|DRUG|candesartan (drug) or quinapril (drug)|
58263228|NCT06618677|OTHER|LOW FODMAPs Diet|patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
57912020|NCT02877966|OTHER|Placebo|
57912021|NCT02120742|BEHAVIORAL|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
57912022|NCT02697994|OTHER|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
57912023|NCT02697994|OTHER|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
57912024|NCT02898415|PROCEDURE|Liver transplantation|
58263229|NCT02228304|DRUG|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
58263230|NCT02228304|DRUG|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
58059609|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
58059610|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
58059611|NCT00040911|PROCEDURE|electroacupuncture therapy|
58059612|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
58059613|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
58059614|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
58263231|NCT01063920|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
58263232|NCT01063920|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
58263233|NCT06618027|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D was adapted from Learning to BREATHE, a group mindfulness-based intervention for teens. It teaches mindfulness strategies adapted to be specific and relatable to, teens with T1D to improves symptoms of depression and anxiety as well as diabetes self-management.
58383706|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
58383707|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
58383708|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
58383709|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
58059615|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
58059616|NCT00001925|DRUG|Alcohol|
58059617|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
58059618|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
58263234|NCT06618027|BEHAVIORAL|HealthEd-T1D|HealthEd-T1D is a 6 week, virtual, group based diabetes education group.
58263235|NCT01046851|DRUG|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
58383710|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
58383711|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
58383712|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
58383713|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
58383714|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
58383715|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
58383716|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
58383717|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
58059619|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
58059620|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
58059621|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
58059622|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
58059623|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
57912025|NCT03231501|DRUG|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
58059624|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
58263236|NCT01046851|DRUG|Placebo|Placebo in a manner similar to the active comparator
58263237|NCT06222060|OTHER|Questionnaire about Shaken Baby Syndrome|Knowledge assessment questionnaire completed in the maternity ward by both parents
58263238|NCT06623565|PROCEDURE|Multimodal image-guided resection|Supramarginal resection using combination of ADC MRI and FET PET
57912026|NCT00964587|BEHAVIORAL|Education + Problem-Solving Training Self-Study|"* Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
58263239|NCT03867149|OTHER|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
58263240|NCT03867149|OTHER|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
58383718|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
58383719|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
58383720|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
57912027|NCT00964587|BEHAVIORAL|Education + Group Problem-Solving Training|"* Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions"
58059625|NCT04052594|DRUG|LY3475766 - IV|Administered IV
58059626|NCT04052594|DRUG|LY3475766 - SC|Administered SC
58263241|NCT00900549|DEVICE|CRT on|12 months
58263242|NCT00900549|DEVICE|CRT off|12-month
58263243|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Adductor Canal Block|0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block
58383721|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
58383722|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
58383723|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
57710252|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
57710253|NCT00104533|DEVICE|Magnets|
57710254|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
57912028|NCT00964587|BEHAVIORAL|Education + Individual Problem-Solving Training|"* Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)"
57912029|NCT00964587|BEHAVIORAL|Usual Care|"* Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
57912030|NCT06271629|DIAGNOSTIC_TEST|Insomnia severity index|"The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties."
58059627|NCT04052594|DRUG|Placebo - IV|Administered IV
58059628|NCT04052594|DRUG|Placebo - SC|Administered SC
58059629|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
58059630|NCT04091451|DRUG|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
58059631|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
58263244|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block|10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
58263245|NCT05367817|OTHER|Neuromuscular exercise therapy|Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
58263246|NCT05367817|OTHER|Training program|Participants perform range of motion exercises for the wrist.
58263247|NCT06017089|DEVICE|AI-based Advisor system|Tandem t:slim X2 with Control-IQ and t:connect mobile application and Dexcom G6 or G7 system, connected to UVA cloud-based Physician Dashboard with insulin pump parameters driven by an AI-based Advisor system.
58263248|NCT05642260|OTHER|fall prevention programe|Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
58383724|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
58383725|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
58383726|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
58383727|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
58383728|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
58383729|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
57912031|NCT06015828|DIETARY_SUPPLEMENT|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
57912032|NCT00363909|DRUG|citalopram hydrobromide|
57912033|NCT00363909|OTHER|placebo|
57912034|NCT01078454|DRUG|melphalan|Given PO
57912035|NCT01078454|DRUG|dexamethasone|Given PO
58263249|NCT04724902|OTHER|Elastic bandage compression|The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
58263250|NCT05142150|OTHER|Questionaire|"Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying."
58263251|NCT04939246|RADIATION|Stereotactic ablative body radiation therapy|Single-fraction of stereotactic ablative body radiation (SABR) therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian Linac). The prescription dose is dependent on the anatomic location of the lesion and based on previously published safety data.
58263252|NCT04326296|DRUG|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
58263253|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
58263254|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
58263255|NCT05195918|COMBINATION_PRODUCT|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
57912036|NCT01078454|DRUG|bortezomib|Given IV
57912037|NCT05031663|DIETARY_SUPPLEMENT|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
57912038|NCT05031663|DIETARY_SUPPLEMENT|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
58263256|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
58263257|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
58263258|NCT05195918|COMBINATION_PRODUCT|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
58383730|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
57912039|NCT00650351|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
57912040|NCT00650351|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
58059632|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
58059633|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
58383731|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
58383732|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
58383733|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
57710255|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
57710256|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
57912041|NCT04940026|DRUG|amcenestrant|Tablet Oral
57912042|NCT04940026|DRUG|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
57912043|NCT04940026|DRUG|[14C]-SAR439859|Powder for oral solution Oral
57912044|NCT00798915|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
57912045|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
57912046|NCT00798915|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
57912047|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
57912048|NCT05790330|DRUG|Methotrexate|As per usual standard of care
57912049|NCT05790330|DRUG|Dupilumab|As per usual standard of care
57912050|NCT01921010|DRUG|Niaspan|See Arm Description
57912051|NCT01921010|DRUG|Placebo|See Arm Description
57912052|NCT03813420|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
58263259|NCT05431946|BEHAVIORAL|Advance Care Planning and the consequent actions|"The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities"
58263260|NCT04186806|DEVICE|3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray|20 ml bottle
58263261|NCT04186806|DEVICE|Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray|44.3 ml bottle
58383734|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
58383735|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
57912053|NCT03813420|BEHAVIORAL|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
58263262|NCT02215863|BIOLOGICAL|Fluad and Prevenar13|
58263263|NCT02215863|BIOLOGICAL|Fluad|
58263264|NCT02215863|BIOLOGICAL|Prevenar13|
58263265|NCT06564948|OTHER|Treatment as usual (TAU)|"TAU patients will be identified using targeted limited chart review methods used in our prior studies, scraping clinical notes in the EHR for criminal justice involvement. Initial Identification terms, police, arrest, court, summons, jail, and crime will be used to identify candidates for police involvement, downloading the sentence in which the keyword appeared and the sentence before and after. Next, an iterative process of editing of the search terms will be conducted to remove patients with negation of the keyword (did not commit a crime), and other sentence characteristics that generate false positives (cardiac arrest). Samples of the resulting dataset will be taken, accuracy assessed by examining the surrounding sentences, leading to further iterations and repetition of the process until a high level of accuracy is achieved."
58263266|NCT06564948|OTHER|Family and Social Justice|Documentation and follow-up by the Cambridge Police Department (CPD) for all mental health-related police calls, including involuntary and voluntary Emergency Department admissions; Established partnerships with city departments, healthcare systems, clergy, courts, businesses, and mental health advocates to ensure timely engagement in mental health treatment and community-based services; Required 40 hours of officer crisis intervention training (CIT), and additional sessions on trauma- informed policing, mental health, procedural justice, race, and crisis negotiation; and Staffing of sworn and civilian staff including specially-trained officers designated to work with individuals living with mental illness, homelessness, and substance abuse.
58263267|NCT06564948|OTHER|Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention|"The FSJS+Navigator intervention adds an Emergency Department (ED)-based Systems Navigator, a community health worker with lived experience (as family member or patient) with criminal justice and mental health systems, to the FSJS. This navigator will enhance communication between Cambridge Police Department (CPD), Cambridge Health Alliance (CHA), and community agencies by being the needed point person within the healthcare system (the FSJS intervention only has a CPD-based social worker) to maintain communication to improve mental health services and prevent deeper justice involvement. The Navigator engages with the FSJS process in step i) of the above sequence, engaging the patient in the CHA ED and obtaining consent. The Navigator then discusses the case with the presenting CPD officer, and relays critical information about the context of the service call to ED staff. Next, the Navigator will administer the baseline CAT-MH/SS and assess additional needs (employment, housing, food)."
58263268|NCT05882838|OTHER|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
58383736|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
58383737|NCT00360178|DRUG|Amlodipine|
58383738|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
58383739|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
58383740|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
58383741|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
58383742|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
57710257|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
57710258|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
57710259|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
57710260|NCT01868633|DRUG|Dexamethasone|
57710261|NCT01868633|DRUG|Placebo|
57710262|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
57710263|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
57710264|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
57710265|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
57710266|NCT02595736|DRUG|Placebo (SC)|Administered SC
57710267|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
57710268|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
57710269|NCT02595736|DRUG|Placebo (IV)|Administered IV
57710270|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
57710271|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
57710272|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
57710273|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
57912054|NCT03813420|BEHAVIORAL|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
57912055|NCT05500443|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone-7)|Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
57912056|NCT00029133|PROCEDURE|mild intraoperative hypothermia (33 degrees Celsius)|
58263269|NCT03958214|BEHAVIORAL|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
58383743|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
57912057|NCT02176213|DRUG|Pomalidomide|4 mg PO x 21 days
57912058|NCT02176213|DRUG|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
57912059|NCT02176213|DRUG|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
57912060|NCT04025112|DEVICE|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
58383744|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
58383745|NCT02501681|OTHER|priming solution during cardiovascular surgery|
57710274|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
57710275|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
57710276|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
57710277|NCT00305617|OTHER|antitumor drug screening assay|
57710278|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
57710279|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
57710280|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
57710281|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
57710282|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
57710283|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
57710284|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
57710285|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
57710286|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
57710287|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
57710288|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
57710289|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
57710290|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
57710291|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
57710292|NCT02729649|DEVICE|ArmAssist robotic training|
57710293|NCT02729649|OTHER|Conventional therapy|
57710294|NCT02729649|OTHER|Extended conventional therapy|
57710295|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
57710296|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
57710297|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
57710298|NCT03087201|DRUG|placebo|analogous to experimental intervention
57710299|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
57710300|NCT01493271|DRUG|Placebo|Placebo to RO5093151
57710301|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
57912061|NCT04025112|OTHER|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
57912062|NCT05730062|DRUG|Oxycodone Hydrochloride|Oxycodone 10 mg IR
57912063|NCT05730062|DRUG|Placebo|placebo comparator
57912064|NCT06610708|OTHER|Cardiac Prehabilitation Program|Patients begin with a one-on-one assessment by a program cardiologist and a CR nurse, followed by a symptom-limited cardiopulmonary exercise test (CPET) to tailor their exercise regimen. The exercise program, based on the FITT (frequency, intensity, time, and type) principle, includes biweekly sessions either at home or at a commercial gym, with ongoing oversight by SJHC CRSP rehabilitation trainers. Additionally, participants have access to dietary counseling to optimize heart-healthy nutrition.
57912065|NCT04906408|DEVICE|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
57912066|NCT04906408|DEVICE|Prineo|Incisions will be dressed with Prineo
57912067|NCT04906408|DRUG|Traditional|Incisions will be dressed with bacitracin/xeroform
57710302|NCT02093572|OTHER|3 standard meals/day|
57912068|NCT00411853|DRUG|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
57912069|NCT06414473|DRUG|Cannabidiol (CBD) Extract|Administered thrice daily (with food) using a sublingual route of administration
57912070|NCT06414473|DRUG|Placebo|Administered thrice daily (with food) using a sublingual route of administration
57912071|NCT01714531|BEHAVIORAL|Telephone-Based Goal Management Training|
58263270|NCT03958214|BEHAVIORAL|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
57710303|NCT02093572|OTHER|2 meals/day (omit breakfast)|
57710304|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
57710305|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
57710306|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
57710307|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
57710308|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
57710309|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
57710310|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
57912072|NCT01714531|BEHAVIORAL|Telephone-Based Attention-Control|
57912073|NCT02518737|OTHER|Meal Test|
57912074|NCT01303731|DRUG|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
57912075|NCT01303731|DRUG|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
57912076|NCT04037267|PROCEDURE|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
57912077|NCT00249002|DRUG|ABI-007|
58059634|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
58263271|NCT06505915|DIETARY_SUPPLEMENT|Pre op Carbohydrate drink|Lemon flavoured clear carbohydrate drink
57710311|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
57912078|NCT02142140|BEHAVIORAL|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
57912079|NCT02142140|BEHAVIORAL|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
58059635|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
58059636|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
58059637|NCT02773849|BIOLOGICAL|ADSTILADRIN|
58059638|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
58059639|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
58263272|NCT06505915|OTHER|Clear fluid as per sip til send policy|clear fluid such as water
57710312|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
57710313|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
57710314|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
57784866|NCT04647019|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
57784867|NCT04647019|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
57784868|NCT02873299|OTHER|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
57784869|NCT02873299|OTHER|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
57784870|NCT03823976|OTHER|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
57784871|NCT00884286|DRUG|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
58059640|NCT01271049|OTHER|Control Food Product|Control food product
58059641|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
58059642|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
58263273|NCT01275651|OTHER|laboratory biomarker analysis|Correlative studies
58263274|NCT00247169|DRUG|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
58263275|NCT00962975|DRUG|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
58263276|NCT01612637|BEHAVIORAL|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
57912080|NCT02142140|BEHAVIORAL|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
57912081|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
58263277|NCT01612637|BEHAVIORAL|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
58263278|NCT05012904|BEHAVIORAL|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
58383746|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
57710315|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
57912082|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
58263279|NCT01191775|DRUG|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
58263280|NCT02615015|OTHER|Blood draw|
58263281|NCT00090987|DRUG|imatinib mesylate|400 mg orally once a day for up to 6 months.
58263282|NCT04567927|OTHER|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
58263283|NCT02161003|PROCEDURE|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
58263284|NCT02161003|PROCEDURE|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
58263285|NCT05189067|DRUG|Paclitaxel|i.v. 80mg/m\^2
58383747|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
58383748|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
58383749|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
58383750|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
58383751|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
58383752|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
58383753|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
58383754|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
58263286|NCT05189067|DRUG|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
58263287|NCT05189067|DRUG|Docetaxel|i.v. 100mg/m2
58263288|NCT05455359|DRUG|Prucalopride|Prucalopride 0.04 mg/kg/day
58263289|NCT05455359|DRUG|Famotidine|Famotidine 0.4 mg/kg/day
58383755|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
58263290|NCT04247464|PROCEDURE|Fasting|Food intake restriction
58383756|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
58383757|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
58383758|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
58383759|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
58383760|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
58383761|NCT04755764|DRUG|Labetalol|Beta blocker
58383762|NCT04755764|DRUG|Atenolol|Beta blocker
58383763|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
58383764|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
57912083|NCT02727062|DEVICE|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
58263291|NCT02742116|GENETIC|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
57912084|NCT02727062|DEVICE|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
57912085|NCT03170037|PROCEDURE|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
57912086|NCT03170037|PROCEDURE|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
57912087|NCT04675151|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
57710316|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
57710317|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
57710318|NCT02694224|DRUG|vismodegib|Smo inhibitor
57710319|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
57710320|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
57710321|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
57710322|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
57710323|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
57710324|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
57710325|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
57710326|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
57912088|NCT04675151|DRUG|Pilocarpine|Pilocarpine ophthalmic solution
57912089|NCT04675151|OTHER|Placebo|Topical sterile ophthalmic solution
57912090|NCT03228602|OTHER|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
57710327|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
57710328|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
57710329|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
57710330|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
57710331|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
57710332|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
58263292|NCT00534885|BIOLOGICAL|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
58263293|NCT00534885|BIOLOGICAL|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
57710333|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
57710334|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
57710335|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
57710336|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
57912091|NCT04326166|DRUG|Evogliptin|Evogliptin
57912092|NCT04326166|DRUG|Evogliptin|Evogliptin
57912093|NCT04326166|DRUG|Metformin and Evogliptin|Metformin and Evogliptin
57710337|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
57710338|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
57710339|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
57912094|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Single dose
57912095|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Multiple dose
57912096|NCT04137094|BEHAVIORAL|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
57912097|NCT00647491|BIOLOGICAL|adalimumab|20 mg sc eow
57912098|NCT00647491|BIOLOGICAL|adalimumab|40 mg sc eow
57912099|NCT00647491|BIOLOGICAL|adalimumab|80 mg sc eow
57912100|NCT00647491|BIOLOGICAL|placebo|placebo sc eow
57912101|NCT02674815|OTHER|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
57912102|NCT06594744|PROCEDURE|Endoscopic variceal ligation|EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.
57912103|NCT06594744|DRUG|Carvedilol|The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
58383765|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
57912104|NCT01009580|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
57912105|NCT01009580|DRUG|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
57912106|NCT02878902|OTHER|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
58383766|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
58383767|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
57912107|NCT00998998|BEHAVIORAL|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
57912108|NCT00998998|BEHAVIORAL|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
57912109|NCT00998998|DIETARY_SUPPLEMENT|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
57912110|NCT03809559|DEVICE|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
58383768|NCT02725476|BIOLOGICAL|XmAb5871|
58383769|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
58383770|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
57710340|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
57710341|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
57912111|NCT00912301|DRUG|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
57912112|NCT00912301|OTHER|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
57912113|NCT05941728|OTHER|Avocado|The intervention treatment will contain avocado
57912114|NCT05941728|OTHER|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
57912115|NCT05941728|OTHER|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
57912116|NCT02508246|DRUG|Cisplatin|Given IV
58263294|NCT00534885|BIOLOGICAL|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
57710342|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
57710343|NCT02293785|DRUG|Oxycodone-Naloxone|
57912117|NCT02508246|DRUG|Docetaxel|Given IV
57912118|NCT02508246|OTHER|Laboratory Biomarker Analysis|Correlative studies
57912119|NCT02508246|OTHER|Pharmacological Study|Correlative studies
57912120|NCT02508246|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57912121|NCT02508246|DRUG|WEE1 Inhibitor AZD1775|Given PO
57912122|NCT06132243|DRUG|Jaktinib Hydrochloride Tablets|Orally, one tablet at a time
57912123|NCT04538690|OTHER|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
57912124|NCT04538690|OTHER|Electrotherapy|TENS, US
58383771|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
58383772|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
58383773|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
58383774|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
58383775|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
58383776|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
58383777|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
58383778|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
58383779|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
58383780|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
57912125|NCT06596447|DEVICE|Deep Brain Stimulation|While most patients with obsessive compulsive disorder (OCD) eventually respond to treatment with medication and/or behavioral therapy, a small minority do not improve following all conventional treatments. Obsessive-compulsive disorder (OCD) can sometimes be difficult to treat with medication and psychotherapy. For these patients, in this study, we employ deep brain stimulation (DBS), an advanced surgical treatment that uses electrical impulses.
57912126|NCT04613349|OTHER|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~1. New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~2. Gold standard: Intraoperative examination."
57912127|NCT04684394|BIOLOGICAL|GEM103|GEM103 500 mcg/50 mcL intravitreal injection
57912128|NCT04684394|DRUG|Aflibercept|"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
58059643|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
58383781|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
58383782|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
58383783|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
58383784|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
58383785|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
58383786|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
58383787|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
58383788|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
57912129|NCT04684394|DRUG|Sham|Sham intravitreal injection
57912130|NCT06023563|DEVICE|Virtual reality active video gaming using Nintendo switch sports|Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
58059644|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
58059645|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
58263295|NCT00534885|BIOLOGICAL|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
58263296|NCT01662921|DRUG|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
58383789|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
58383790|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
58383791|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
58383792|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
58383793|NCT02733822|DRUG|Naloxone|
58383794|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
58383795|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
58383796|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
58383797|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
58383798|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
58383799|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
58383800|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
58383801|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
58383802|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
58383803|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
58263297|NCT01662921|DRUG|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
58263298|NCT01662921|DRUG|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
58263299|NCT06648174|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear."
58263300|NCT06648174|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.
58263301|NCT06648174|OTHER|Blood glucose meters (BGM)|Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.
58263302|NCT05330273|DRUG|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
58263303|NCT05330273|COMBINATION_PRODUCT|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
58383804|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
58383805|NCT02039765|DRUG|Brimonidine tartrate|
58383806|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
57912131|NCT06023563|BEHAVIORAL|Standard physical therapy balance exercises|Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
58263304|NCT05330273|DRUG|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
58383807|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
58383808|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
58263305|NCT00090701|DRUG|AG2037|
58383809|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
58383810|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
58383811|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
58383812|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
58383813|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
58383814|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
58383815|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
58383816|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
58383817|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
58383818|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
58383819|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
58383820|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
57912132|NCT02279394|DRUG|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8
57912133|NCT02279394|DRUG|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
57912134|NCT02279394|DRUG|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
58059646|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
58059647|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
58059648|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
57912135|NCT06335602|DEVICE|LASER acupuncture|Low level LASER therapy
57912136|NCT00689585|DRUG|Placebo|250mg matching placebo capsules
58059649|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
58059650|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
58059651|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
58059652|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
58059653|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
58059654|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
58059655|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
58383821|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
58383822|NCT01715363|DRUG|Oxaliplatin|
57912137|NCT00689585|DRUG|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
58059656|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
58383823|NCT01715363|DRUG|Folinic Acid|
58383824|NCT01715363|DRUG|Fluorouracile|
58059657|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
58059658|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
58059659|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
58059660|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
58059661|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
58059662|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
58383825|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
58383826|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
57912138|NCT00432146|DRUG|lugol's solution|
57912139|NCT04078633|BEHAVIORAL|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
57912140|NCT04498091|BIOLOGICAL|Biological data|Biological data
57912141|NCT04498091|OTHER|Clinical data|Clinical data
57912142|NCT05014646|DRUG|Cholestyramine|Given PO
57912143|NCT05014646|DRUG|Leflunomide|Given PO
57912144|NCT04234854|DIAGNOSTIC_TEST|Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent|IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
57912145|NCT02588300|PROCEDURE|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
57912146|NCT03439254|DRUG|Obeticholic acid (10 mg)|Tablets administered orally once daily.
57912147|NCT03439254|DRUG|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
57912148|NCT03439254|DRUG|Placebo|Tablets administered orally once daily.
57912149|NCT00007449|DRUG|DPC 083|
58263306|NCT00176644|DRUG|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
58059663|NCT00171327|DRUG|valsartan, fluvastatin|
58383827|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
58383828|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
58383829|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
58383830|NCT02855879|OTHER|Collection of biological data|
58383831|NCT02855879|OTHER|Collection of clinical data|
57710344|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
58059664|NCT04775485|DRUG|DAY101|DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
58059665|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
58059666|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
58059667|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
58059668|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
58383832|NCT06128850|OTHER|disease|compare to diseases
58383833|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
58263307|NCT05581498|BEHAVIORAL|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
58263308|NCT03585153|OTHER|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
58263309|NCT00004087|BIOLOGICAL|filgrastim|as prescribed by physician
58263310|NCT00004087|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
58059669|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
58263311|NCT00004087|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
58263312|NCT00004087|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
58263313|NCT00004087|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
58383834|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
58383835|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
58383836|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
58383837|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
58383838|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
58383839|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
57912150|NCT05959954|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
57912151|NCT03224351|DRUG|VX-659|Tablet for oral administration.
57912152|NCT03224351|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
57912153|NCT03224351|DRUG|IVA|Tablet for oral administration.
57912154|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
57912155|NCT03224351|DRUG|TEZ|Tablet for oral administration.
57912156|NCT03224351|DRUG|VX-561|Tablet for oral administration.
57912157|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
58059670|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
58059671|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
58059672|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
58059673|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
58059674|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
58059675|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
58263314|NCT04888403|DRUG|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
58263315|NCT00978939|OTHER|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
58263316|NCT00978939|OTHER|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
58263317|NCT06311435|DIAGNOSTIC_TEST|RNA Biomarker Blood Test|Blood will be collected into a PaxGene Blood tube for processing by sponsor
58263318|NCT03558152|DRUG|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
58383840|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
58383841|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
58383842|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
58383843|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
58383844|NCT02070328|OTHER|Registry|
58383845|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
57912158|NCT03112564|OTHER|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
58383846|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
58383847|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
58383848|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
58383849|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
57912159|NCT03112564|DRUG|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
58059676|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
58059677|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
58263319|NCT03558152|DRUG|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
58263320|NCT03558152|DRUG|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
58263321|NCT03558152|DRUG|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
58263322|NCT01301781|DRUG|BLI801|BLI801 laxative - oral solution
58263323|NCT01301781|DRUG|Placebo|BLI801 placebo - oral solution
58383850|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
58383851|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
58383852|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
58383853|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
58383854|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
58383855|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
58383856|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
57912160|NCT02813629|DEVICE|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
57912161|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
57912162|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
57912163|NCT00825916|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
58059678|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
58059679|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
58263324|NCT06492265|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
58263325|NCT06492265|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
57912164|NCT06143436|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
58059680|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
58059681|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
58263326|NCT00784238|DRUG|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
58263327|NCT00567385|DRUG|somatropin|
58263328|NCT05320718|DRUG|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
58263329|NCT05821296|DEVICE|Crystal Peel|3 applications performed by a dermatologist.
58263330|NCT03061201|BIOLOGICAL|SB-525 (PF-07055480)|Single dose of investigational product SB-525 (PF-07055480)
58263331|NCT06623838|DIAGNOSTIC_TEST|Evolutionarily informed case conceptualization|Case conceptualization of personality functioning of a few transcripts of initial sessions and report of psychometric measures of patients diagnosed with personality disorder.
58383857|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
57912165|NCT04374851|DEVICE|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
58263332|NCT00869284|DRUG|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
58263333|NCT00869284|PROCEDURE|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
58383858|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
58383859|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
58383860|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
58383861|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
58383862|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
57912166|NCT04374851|DEVICE|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
57912167|NCT02258308|BEHAVIORAL|CHW intervention|Home education and support for asthma self management
57912168|NCT02003573|DRUG|decitabine iv|decitabine iv fixed dose
57912169|NCT02003573|DRUG|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
57912170|NCT03339700|DRUG|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
57912171|NCT03339700|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
57912172|NCT03339700|DRUG|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
58383863|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
57912173|NCT03339700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
57912174|NCT04802798|DIETARY_SUPPLEMENT|Fibre 1|Food derived fibre presented as a white powder
58383864|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
58383865|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
58383866|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
58383867|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
58383868|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
58383869|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
57912175|NCT04802798|DIETARY_SUPPLEMENT|Fibre 2|Food derived fibre presented as a white powder
57912176|NCT04802798|DIETARY_SUPPLEMENT|Placebo|Simple sugar, presented as a white powder
57912177|NCT05829356|BIOLOGICAL|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
57912178|NCT05829356|BIOLOGICAL|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
58383870|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
57912179|NCT06183957|OTHER|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
57912180|NCT03058835|DRUG|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
57912181|NCT05900687|BEHAVIORAL|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
57912182|NCT03710031|OTHER|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
57912183|NCT04399070|DRUG|S-ketamine|The depression patients received propofol and S-ketamine before ECT
57912184|NCT04399070|DRUG|ketamine|The depression patients received propofol and ketamine before ECT
58263334|NCT04178642|DRUG|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
57912185|NCT04399070|DRUG|saline|The depression patients received propofol and saline before ECT
57912186|NCT01178385|BEHAVIORAL|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
58263335|NCT04178642|PROCEDURE|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
58263336|NCT03775122|DEVICE|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
58263337|NCT05973019|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
58059682|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
57912187|NCT01178385|BEHAVIORAL|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
57912188|NCT01449136|OTHER|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
58059683|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
58059684|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
58059685|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
58059686|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
58059687|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
58059688|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
58059689|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
58059690|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
58059691|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
58059692|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
58263338|NCT03384784|DRUG|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
58263339|NCT03384784|DRUG|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
58263340|NCT00220324|DRUG|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
58263341|NCT03020875|DRUG|Ofirmev|Intravenously administered acetaminophen.
58263342|NCT03020875|DRUG|Per Os Acetaminophen|Orally administered acetaminophen.
58263343|NCT03653351|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
58383871|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
58383872|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
57912189|NCT04580342|DRUG|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
57912190|NCT04580342|DRUG|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
58383873|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
57912191|NCT06610812|BEHAVIORAL|KETOGENIC MEDITERRANEAN diet|"each patient in group A was instructed briefly about the nature of the treatment regimen to gain the patient's confidence and cooperation. the patient will receive ketogenic Mediterranean diet with aerobic training program. The diet will contain approximately 9300 kJ accordingly, 37% as total fat, 18% as monounsaturated and 9% as saturated, and 33 g of fiber per day for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.~This procedure performed by using the components of ketogenic Mediterranean diet:~* Protein source: fatty fish, seafood, poultry, and eggs.~* Fats and oils: olive oil, avocado oil, and MCT oil (medium-chain triglycerides oil).~* Low carb vegetables: leafy greens, cruciferous vegetables, and other low carb veggies.~* Low carb fruits: avocados, olives, and tomato.~* Flavourings: paprika, cumin, cinnamon, coriander, anise, lemon or lime juice , mint , parsley and garlic ."
57912192|NCT06610812|BEHAVIORAL|hypo-caloric diet:|"Group (b) received low caloric balanced diet regimen with aerobic exercise for 3 months in the form of moderate aerobic exercises in the form of walking for 30 to 45 minutes a day, 3 times per week for 3 months. This group received a diet of 1800 calories or lower accordingly including a combination of two or more of the following in each meal: Non starchy vegetable: spinach, broccoli, cauliflower, peppers, mushrooms, tomatoes, etc.~Fruits: berries, apples bears, citrus fruits, melon, grapes bananas, etc. Starchy vegetables: potatoes peas, sweet potatoes etc. Fish and shellfish: salmon, clams, Trouts, oysters, etc. Eggs: whole eggs are more nutrient dense than white eggs. Poultry and meat: chicken turkey, beef, lamb, etc. Whole grains: oats, brown rice, farro etc. Legumes: chickpeas, kidney beans, lentils etc. Healthy fats: avocados, olive oil, unsweetened coconut, avocado oil. Dairy products: full-fat or reduced fat plain yogurt kefir and full-fat cheese."
57912193|NCT06610812|BEHAVIORAL|moderate aerobic exercises|moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
57912194|NCT03116737|DRUG|Benzocaine Otic Solution|
57912195|NCT03116737|DRUG|Placebo|
58059693|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
58059694|NCT00003958|DRUG|vincristine sulfate|Given IV
58059695|NCT00003958|DRUG|cyclophosphamide|Given IV
58059696|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58059697|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
58059698|NCT00003958|DRUG|topotecan hydrochloride|Given IV
58059699|NCT00003958|BIOLOGICAL|filgrastim|Given SC
58059700|NCT00003958|BIOLOGICAL|sargramostim|Given SC
58263344|NCT03653351|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
58263345|NCT04384861|BEHAVIORAL|Mayo Clinic SMART program (Stress Management and Resilience Training)|The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
58383874|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
58383875|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
58059701|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
58059702|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
58059703|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
58059704|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
58059705|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
58059706|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
58383876|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
58383877|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
58383878|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
58383879|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
57912196|NCT00309296|BEHAVIORAL|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
57912197|NCT00212420|PROCEDURE|parenteral nutrition; enteral nutrition|
57912198|NCT04903587|DEVICE|Ultrasonography and MRI|Abdominal Ultrasonography and axial MRI
57912199|NCT03896204|BEHAVIORAL|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
57912200|NCT03896204|BEHAVIORAL|joint protection technique training|Training will be given to individuals about joint protection technique
58059707|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
58059708|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
58059709|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
58059710|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
58383880|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
57912201|NCT06610500|OTHER|Questionnaires|Questionnaires investigating the prescription and dispensing of clozapine.
58059711|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
58059712|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
57912202|NCT04974242|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
57912203|NCT00653445|DRUG|Rosuvastatin|40mg
57912204|NCT00653445|DRUG|Ezetimibe|10mg
57912205|NCT05057845|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
57912206|NCT05057845|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
57912207|NCT05057845|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
58059713|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
58059714|NCT02438670|DEVICE|PID control algorithm|
58059715|NCT02438670|DEVICE|MPC control algorithm|
58059716|NCT00605228|DRUG|MOVIPREP|2L Drug
58383881|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
58383882|NCT05519111|DRUG|Placebo|placebo equivalent
57912208|NCT03725085|DRUG|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
57912209|NCT00271518|DRUG|growth hormone (somatropin)|dosing regimen is weight based.
57912210|NCT04894110|BIOLOGICAL|EO2002|EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
57912211|NCT04894110|BIOLOGICAL|EO2002 low dose|Low dose of EO2002 (magnetic human corneal endothelial cells)
57912212|NCT04894110|BIOLOGICAL|EO2002 mid dose|Mid dose of EO2002 (magnetic human corneal endothelial cells)
57912213|NCT04894110|BIOLOGICAL|EO2002 high dose|High dose of EO2002 (magnetic human corneal endothelial cells)
58383883|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
58263346|NCT01668966|DRUG|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
58263347|NCT05028413|BEHAVIORAL|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
58059717|NCT00605228|DRUG|COLOPEG|4L Drug
58059718|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
58059719|NCT02085486|OTHER|Standard|Standard inspection, palpation.
58059720|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
58263348|NCT06620328|PROCEDURE|endoscopic ultrasonography-guided biliary drainage|"Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover"
58263349|NCT05153148|DRUG|NDI-034858|NDI-034858 oral capsule
58383884|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
58383885|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
58383886|NCT02228044|BEHAVIORAL|Prevention program|
58383887|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
58383888|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
58383889|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
58383890|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
58383891|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
58383892|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
58383893|NCT02869542|OTHER|Data collection|
57912214|NCT02892786|OTHER|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
58059721|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
58059722|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
58263350|NCT05153148|OTHER|Placebo|NDI-034858-matching oral placebo capsule
58383894|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
58383895|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
58383896|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
57912215|NCT01877473|PROCEDURE|Ablation|
58059723|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
58059724|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
57710345|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
57710346|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
57710347|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
57710348|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
57710349|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
57710350|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
57710351|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
57710352|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
57710353|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
57710354|NCT01910064|DRUG|GK530G|
57912216|NCT02439073|BEHAVIORAL|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
58059725|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
58059726|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
57710355|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
57710356|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
57710357|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
57710358|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
58059727|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
58059728|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
58059729|NCT02006394|OTHER|Market variety bread products|placebo bread products
58059730|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
58059731|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
58383897|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
58383898|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
58383899|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
58383900|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
58383901|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
58383902|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
57710359|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
57710360|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
58059732|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
58059733|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
58059734|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
58263351|NCT05342922|PROCEDURE|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
58263352|NCT05342922|PROCEDURE|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
58263353|NCT00459706|DEVICE|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
58263354|NCT00459706|DEVICE|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
58263355|NCT01993498|PROCEDURE|blood sampling|blood samples collection
58263356|NCT03777813|DRUG|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
58263357|NCT03777813|COMBINATION_PRODUCT|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
58263358|NCT00732758|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
58263359|NCT00732758|DIETARY_SUPPLEMENT|Placebo Tablet|Placebo Tablet once daily for 6 months
58263360|NCT00514826|OTHER|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
58263361|NCT06622694|BIOLOGICAL|RD13-02|"Before cell infusion (Day 0), subjects will undergo a lymphodepleting chemotherapy based on the Fludarabine + Cyclophosphamide (FC regimen). Prior to the lymphodepleting chemotherapy, subjects must undergo an assessment, and only those meeting the criteria will be eligible for the lymphodepleting chemotherapy. The CAR T infusion should be performed at least 48 hours after the completion of the lymphodepleting chemotherapy. The infusion will be administered intravenously as a single dose. It should be completed within 30 minutes, with continuous cardiac monitoring during the infusion to observe heart rate (HR), blood pressure (BP), respiratory rate (R), and peripheral oxygen saturation (SpO2) for up to 2 hours post-infusion."
58263362|NCT05922319|OTHER|Computerized cognitive training with different training doses|The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
58059735|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
58059736|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
58263363|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
58383903|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
58383904|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
58383905|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
58263364|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
58263365|NCT05662293|OTHER|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
58263366|NCT05662293|OTHER|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
58263367|NCT05662293|OTHER|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
58263368|NCT05662293|OTHER|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
58263369|NCT01995175|PROCEDURE|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
58263370|NCT01995175|PROCEDURE|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
58263371|NCT01995175|OTHER|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
57912217|NCT05010837|OTHER|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
58263372|NCT02413242|OTHER|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
58263373|NCT02983435|OTHER|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
58263374|NCT02983435|OTHER|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
58263375|NCT01828333|OTHER|No intervention|No intervention
58383906|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
58383907|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
57912218|NCT05010837|OTHER|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
58059737|NCT01881906|OTHER|Usual care|
58263376|NCT05588869|OTHER|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
58263377|NCT00645281|DRUG|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
58263378|NCT04833725|DEVICE|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
58383908|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
58383909|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
58059738|NCT01881906|OTHER|Exercise|
58383910|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
58383911|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
57912219|NCT00000739|DRUG|Dapsone|
57912220|NCT04357197|DEVICE|Closed-loop|The system will be tested to see if it can avoid hypotension
57912221|NCT00297596|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
58059739|NCT02616328|OTHER|No intervention|No intervention administered in this study
58263379|NCT03242174|OTHER|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
58263380|NCT02461524|DEVICE|Endurant Evo AAA Stent Graft System|
58263381|NCT02461524|PROCEDURE|Endovascular aneurysm repair (EVAR)|
58263382|NCT05297084|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
58263383|NCT00881439|DRUG|Aliskiren|Oral, 300 mg, once daily, 6 months
58263384|NCT00881439|DRUG|Placebo|Matching Placebo once daily, 6 months
58263385|NCT06598384|DRUG|Venetoclax combined with Azacytidine|"Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5."
58263386|NCT03136341|DRUG|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
58383912|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
57912222|NCT00297596|DRUG|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
57912223|NCT02844725|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
57912224|NCT02844725|DRUG|Placebo|water for injection
58263387|NCT03136341|OTHER|Placebo|Dosing will be determined at each study visit based upon muscles involved
58263388|NCT05454384|OTHER|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
58263389|NCT01451944|BEHAVIORAL|education|home asthma case management and education
58263390|NCT03166540|OTHER|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
58263391|NCT03166540|OTHER|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
58263392|NCT01644526|DEVICE|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
57912225|NCT02596438|OTHER|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
57912226|NCT01873066|DEVICE|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
57912227|NCT01873066|DEVICE|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
57912228|NCT01455493|DRUG|GDC-0980|Oral daily dose
57912229|NCT00086333|DRUG|SGN-15, Docetaxel|
57912230|NCT06012253|OTHER|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
57912231|NCT05104281|DRUG|osimertinib oral and bevazizumab intravenously|osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
57912232|NCT02359682|OTHER|No intervention|No Intervention
57912233|NCT03624348|BEHAVIORAL|meditation|10 minute per day, 8 week digital meditation
58263393|NCT04691817|DRUG|Atezolizumab|1200mg infusion
58263394|NCT04691817|DRUG|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
58383913|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
58383914|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
58383915|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
58383916|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
58383917|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
58383918|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
58383919|NCT01596855|DRUG|Epoetin Alfa|TIW
58263395|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
58263396|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
58263397|NCT00811824|BEHAVIORAL|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
57922917|NCT04382274|PROCEDURE|Quadratus Lumborum Block|transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
58263398|NCT06559384|OTHER|Interviews|semi-structured individual interviews
58263399|NCT04458025|OTHER|Standard rehabilitation program|Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
58263400|NCT04458025|OTHER|Early rehabilitation program|Early rehabilitation program will start 2 weeks
58263401|NCT01381991|DEVICE|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
58263402|NCT03347734|BEHAVIORAL|Eye exercises group|"* 20 times hot water, 20 times cold water washing face in the morning and evening.~* Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~* 20 blinks~* Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
58263403|NCT03347734|BEHAVIORAL|Convergence exercise group|"* Close eyes for 15 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 20 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Blink for 5 s,~* Close eyes for 5 s."
58263404|NCT03347734|BEHAVIORAL|Oculomotor Exercise Group (OMEG)|"* The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~* The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~* The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~* The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
58383920|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
58383921|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
58059740|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
58059741|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
58059742|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
58059743|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
58263405|NCT04631328|OTHER|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
58263406|NCT04605380|OTHER|Virtual reality online world|Virtual patient with open fracture inside a virtual world
57710361|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
57710362|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
57710363|NCT02191189|DRUG|Nevirapine suspension|
57710364|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
58263407|NCT02918903|PROCEDURE|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
58263408|NCT02918903|PROCEDURE|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
58263409|NCT01203826|BIOLOGICAL|Asfotase Alfa|
58263410|NCT02089334|DRUG|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
57710365|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
57710366|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
58263411|NCT00065650|DRUG|Vedic Medicine|
58263412|NCT00065650|BEHAVIORAL|Vedic Medicine|
58383922|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
57710367|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
57710368|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
57710369|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
57710370|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
57710371|NCT00514267|DRUG|YM 155|IV
57710372|NCT00514267|DRUG|Docetaxel|IV
58383923|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
58383924|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
58383925|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
58383926|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
57710373|NCT00514267|DRUG|Prednisone|Oral
57710374|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
57710375|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
57710376|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
57710377|NCT01099085|DRUG|Placebo|Placebo
57710378|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
57710379|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
57710380|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
57710381|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
57710382|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
57710383|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
57912234|NCT06519487|BEHAVIORAL|Cyberball|"Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars."
58383927|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
57710384|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.
57912235|NCT01837784|OTHER|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
57912236|NCT05908045|OTHER|KAP Survey|This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
57912237|NCT06380855|PROCEDURE|Flexible colonoscope assisted hybrid transanal total mesorectal resection|Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
57912238|NCT02757027|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
57912239|NCT02757027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
57912240|NCT05727969|DRUG|Dexmedetomidine|Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
57912241|NCT05727969|DRUG|Lactated Ringer|Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
57912242|NCT05727969|PROCEDURE|Hypospadias|Children who will undergone hypospadias surgery
57912243|NCT05727969|DEVICE|Surgical pleth index|The SPI value will be measured using Datex-Ohmeda (GE Healthcare,Madison,WI 53707-7550 USA) monitoring system.
57912244|NCT02769559|PROCEDURE|Reduction mammaplasty|Surgical removal of excess breast tissue
57912245|NCT05597462|DRUG|Minocycline hydrochloride capsules|Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
57912246|NCT05597462|OTHER|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
57912247|NCT02775695|DRUG|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
57912248|NCT04647643|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
57912249|NCT01851954|DRUG|Clarithromycin|IV clarithromycin infusion
57912250|NCT03071367|OTHER|Clinical Simulation|
57912251|NCT05616520|DEVICE|drug-coated balloon|The intervention relates to a drug-coated balloon catheter includes a balloon and cover the drug-coated balloon surface.
57912252|NCT00149760|BEHAVIORAL|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
57912253|NCT00149760|BEHAVIORAL|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
57912254|NCT01564628|DEVICE|CADScor1|Acoustic recording
57912255|NCT05731453|GENETIC|Polygenetic risk score|Polygenetic risk score assessment for breast cancer
57912256|NCT00541398|BEHAVIORAL|Implementation of guideline|Outreach visits with interactive education for health staff
58059744|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
57912257|NCT00585195|DRUG|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
57912258|NCT00585195|DRUG|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
58059745|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
58059746|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
58383928|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
58383929|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
58263413|NCT05492487|DRUG|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
58383930|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
57710385|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
57710386|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
57710387|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
57710388|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
57710389|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
57912259|NCT00585195|DRUG|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
57912260|NCT01389427|DRUG|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912261|NCT01389427|DRUG|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912262|NCT01389427|DRUG|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912263|NCT01389427|DRUG|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912264|NCT01389427|DRUG|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912265|NCT01389427|DRUG|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912266|NCT01389427|DRUG|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
58059747|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
58383931|NCT03073863|DRUG|Atorvastatin|Analysis
58383932|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
58383933|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
58383934|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
58383935|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
58383936|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
58383937|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
58383938|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
58383939|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
57710390|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
57710391|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
57710392|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
57710393|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
57710394|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
57710395|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
58263414|NCT05492487|DRUG|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
58383940|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
58383941|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
58263415|NCT06649461|PROCEDURE|ozone injections|Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).
58263416|NCT06649461|OTHER|Splint|hand splint for night
58383942|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
57710396|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
57912267|NCT01389427|DRUG|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
58383943|NCT05536882|DRUG|Benzoyl peroxide|See arm description
58383944|NCT05536882|DRUG|Adapalene Gel|See arm description
58383945|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
57912268|NCT01389427|DRUG|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912269|NCT01389427|DRUG|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
58263417|NCT03364764|DRUG|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
58263418|NCT06213896|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
58383946|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
58383947|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
58383948|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
57912270|NCT01389427|DRUG|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912271|NCT01389427|DRUG|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
57912272|NCT03051243|DRUG|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
57912273|NCT03051243|DRUG|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
58059748|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
58263419|NCT06213896|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
58263420|NCT06213896|DEVICE|EyeCheckup v2.0|Screening for existence of eye diseases
58263421|NCT01862939|DRUG|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
58059749|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
58059750|NCT02161224|DRUG|FG-4592|Oral
58263422|NCT01862939|DRUG|placebo|placebo to match part 2 DS-7309
58383949|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
58383950|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
58383951|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
58383952|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
57912274|NCT04182945|OTHER|Data collection for algorithm development|50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
57912275|NCT04987736|DIAGNOSTIC_TEST|RT-PCR|COVID 19 diagonostic test
57912276|NCT02561065|BEHAVIORAL|Lifestyle intervention|"1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
57912277|NCT01953653|BEHAVIORAL|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
58059751|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
58059752|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
58059753|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
58059754|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
58059755|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
58059756|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
58059757|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
58059758|NCT00021281|DRUG|FOLFIRI regimen|
58383953|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
58383954|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
57912278|NCT01478139|PROCEDURE|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
57912279|NCT01478139|PROCEDURE|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
58059759|NCT00021281|DRUG|fluorouracil|
58059760|NCT00021281|DRUG|irinotecan hydrochloride|
58059761|NCT00021281|DRUG|leucovorin calcium|
58059762|NCT00021281|DRUG|semaxanib|
58059763|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
58263423|NCT06618508|PROCEDURE|Manual debridement|Traditional technique which consists of scraping off the irregular epithelium to allow a new layer to form.
58263424|NCT06618508|PROCEDURE|Phototherapeutic keratectomy|New technique which has been increasingly used and which consists of a 193nm excimer laser that breaks molecular bonds between cells on the epithelial surface.
58383955|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
58383956|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
58383957|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
58383958|NCT00945373|DRUG|calcium dobesilate|2.5% gel
58383959|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
58383960|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
58383961|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
58383962|NCT05424965|OTHER|no intervention|no intervention
58383963|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
58263425|NCT01373112|PROCEDURE|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
58263426|NCT01373112|PROCEDURE|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
57912280|NCT02013518|BEHAVIORAL|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
58263427|NCT02817516|DRUG|TAK-828|TAK-828 solution.
58263428|NCT02817516|DRUG|Placebo|TAK-828 placebo-matching solution.
58263429|NCT04159649|DRUG|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
58263430|NCT04159649|DRUG|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
58383964|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
58383965|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
58383966|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
58383967|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
58383968|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
58383969|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
58383970|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
57912281|NCT00816400|DRUG|MEDI-575|MEDI-575 as an IV infusion
57912282|NCT02863471|DRUG|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
57912283|NCT01489891|DRUG|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
57912284|NCT01489891|DRUG|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
58383971|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
58383972|NCT02134301|DRUG|Oritavancin|
57912285|NCT04940000|OTHER|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
57912286|NCT01668667|DRUG|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
57912287|NCT01668667|DRUG|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
57912288|NCT01668667|DRUG|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
57912289|NCT01668667|DRUG|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
57912290|NCT00038909|DRUG|BDDrFVII|
58383973|NCT04326010|DEVICE|Surgery|THA surgery
58383974|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
58383975|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
58383976|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
58263431|NCT04159649|PROCEDURE|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
58263432|NCT06622733|BEHAVIORAL|Questionnaire|Attitude towards the concept of CS on demand
58263433|NCT06302842|DIETARY_SUPPLEMENT|Bioritmon Immuno Defend|Bioritmon Immuno Defend daily oral preparation for 24 days.
57912291|NCT05127252|DIAGNOSTIC_TEST|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
57912292|NCT06261164|DEVICE|Cytosorb® and Oxiris® adsorbents|The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
57912293|NCT01492465|DRUG|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
57912294|NCT01468467|DRUG|AC220|Oral Liquid
57912295|NCT06227143|PROCEDURE|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
57912296|NCT06025760|OTHER|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
58263434|NCT05435625|PROCEDURE|FCO2|Fractional Carbon dioxide laser
58263435|NCT05435625|PROCEDURE|FRF|Fractional Microneedling Radiofrequency
58263436|NCT03136458|PROCEDURE|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
58263437|NCT03136458|DRUG|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
58263438|NCT04342741|DEVICE|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
58263439|NCT05427318|BEHAVIORAL|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
58263440|NCT00827749|DEVICE|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
58383977|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
58383978|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
58059764|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
58059765|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
58059766|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
58263441|NCT05614778|OTHER|Zoledronic Acid injection, 5mg/100mL|Zoledronic Acid injection, 5mg/100mL
58263442|NCT06195631|BEHAVIORAL|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
58383979|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
58383980|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
58263443|NCT06298695|BEHAVIORAL|Individual Schema Therapy|"Schema therapy focuses on adapting maladaptive schemas (i.e., core representations of oneself, others or the world) and dysfunctional personality traits, while also incorporating exposure therapy. It consists of a maximum of 40 sessions within one year."
58263444|NCT06298695|OTHER|TAU|Treatment As Usual according to the Dutch Multidisciplinary Guidelines Anxiety Disorders and the Dutch Quality Standard for Anxiety Disorders. TAU often consists of a continuation of Cognitive Behavioral Therapy (CBT) and (different) medications, sometimes in a more treatment-intensive format. There are no restrictions to TAU, except that it may not be schema therapy. The actual content of TAU will be tracked.
58263445|NCT04085224|DRUG|Somatropin|LG Somatropin
57710397|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
57710398|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
57912297|NCT03751566|OTHER|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
57912298|NCT03751566|DRUG|Standard supportive therapy|Standard supportive therapy
57912299|NCT05551533|OTHER|Kampung Care App|Please refer to the previous session
57912300|NCT05054153|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
57912301|NCT05054153|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
57912302|NCT05054153|OTHER|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
57912303|NCT06163911|DEVICE|ECG|Routine care 12-lead electrocardiogram
58263446|NCT06098417|DIAGNOSTIC_TEST|Plasma Test|IGF-2 (insulin-like growth factor 2)
58263447|NCT06098417|DIAGNOSTIC_TEST|Plasma test|SPARC (secreted protein acidic and rich in cysteine)
58263448|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EPICAN (heparan sulfate proteoglycan)
58263449|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EGFR (epidermal growth factor receptor)
58263450|NCT06098417|DIAGNOSTIC_TEST|Liver biopsy|Fibrosis and steatosis grade according to Brunt-Kleiner classification
58263451|NCT06098417|DIAGNOSTIC_TEST|Visceral adipose tissue biopsy|Presence of inflammation
58263452|NCT06098417|DIAGNOSTIC_TEST|Liver elastography|Grade of fibrosis according to Hamaguchi score
58263453|NCT06098417|DIAGNOSTIC_TEST|Blood test|Determination of surrogate based diagnostic tests/scores for liver fibrosis
58263454|NCT05072964|DEVICE|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
58263455|NCT02987972|BIOLOGICAL|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
58263456|NCT02987972|BIOLOGICAL|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
58263457|NCT02987972|BIOLOGICAL|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
58263458|NCT02706886|DRUG|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
58263459|NCT02706886|DRUG|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
58263460|NCT04612881|DRUG|fitostimoline vaginal pessaries|vaginal pessaries
58263461|NCT04612881|OTHER|standard of care|standard of care
58263462|NCT01893580|BEHAVIORAL|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
58263463|NCT01893580|BEHAVIORAL|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
58263464|NCT01893580|BEHAVIORAL|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
58263465|NCT01893580|BEHAVIORAL|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
58263466|NCT05995886|BEHAVIORAL|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
58263467|NCT06622460|OTHER|Hand Dexterity Assessment|to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
58383981|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
58383982|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
58383983|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
58383984|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
57912304|NCT06163911|DEVICE|Echocardiography|Routine care echocardiography
57710399|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
57710400|NCT00000436|PROCEDURE|High-intensity strength training|
57912305|NCT01648686|PROCEDURE|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
57912306|NCT03010176|DRUG|Ulevostinag|IT injection
57912307|NCT03010176|BIOLOGICAL|Pembrolizumab|IV infusion
57912308|NCT02768311|PROCEDURE|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
58263468|NCT00124202|BEHAVIORAL|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
58383985|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
58383986|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
58383987|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
58383988|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
58383989|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
58059767|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
58059768|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
58263469|NCT05093426|OTHER|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
58263470|NCT03031574|DRUG|SUVN-D4010|Tablets
58263471|NCT05818358|DIETARY_SUPPLEMENT|black beans|¾ cup of cooked black beans
58383990|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
58383991|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
58263472|NCT05818358|DIETARY_SUPPLEMENT|wheat berries|¾ cup of cooked whole wheat grain
58383992|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
58059769|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
58059770|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
58059771|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
58059772|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
58059773|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
58059774|NCT00545740|DRUG|Placebo|QD orally
58059775|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
58059776|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
58059777|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
58263473|NCT05818358|DIETARY_SUPPLEMENT|white rice|¾ cup of cooked white rice
58263474|NCT03584464|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
58263475|NCT05976685|PROCEDURE|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
58263476|NCT05976685|DRUG|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
58263477|NCT00897962|OTHER|Healthy Controls|One blood draw (2 teaspoons)
58263478|NCT00897962|OTHER|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
58263479|NCT00897962|OTHER|Non-cancer medical illness|One blood draw (2 teaspoons)
58263480|NCT02973334|OTHER|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
58263481|NCT02973334|OTHER|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
58383993|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
58383994|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
58383995|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
58383996|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
58383997|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
58383998|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
58383999|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
58384000|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
58384001|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
58059778|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
58059779|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
58384002|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
58384003|NCT05247684|DRUG|AK112|IV infusion
58384004|NCT05247684|DRUG|Carboplatin|IV infusion
58384005|NCT05247684|DRUG|Cisplatin|IV infusion
57912309|NCT02768311|PROCEDURE|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
57912310|NCT02768311|PROCEDURE|hand files k-files|Procedure: hand files k-files
57912311|NCT02503878|DEVICE|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
57912312|NCT05156684|DRUG|Placebo|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
57912313|NCT05156684|DRUG|Pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
57912314|NCT05156684|DRUG|zinc|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
57912315|NCT05156684|DRUG|zinc + pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
57912316|NCT06307899|OTHER|Unilateral Corner Stretch|Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
58059780|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
58263482|NCT02973334|OTHER|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
58263483|NCT05108142|OTHER|Dietary intervention|fresh, hot pasta and re-heated pasta
58263484|NCT02222363|DRUG|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
58263485|NCT00006066|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
58263486|NCT00006066|BIOLOGICAL|Diphtheria and Tetanus Toxoids Adsorbed|
58263487|NCT00006066|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|
58263488|NCT00006066|DRUG|Bacteriophage phi X 174|
58384006|NCT05247684|DRUG|Paclitaxel|IV infusion
58384007|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
58384008|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
58384009|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
58384010|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
58384011|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
58384012|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
58384013|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
58384014|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
58384015|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
58263489|NCT00006066|DRUG|Aldesleukin|
58263490|NCT01328548|DRUG|Zostavax|
58384016|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
58384017|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
58263491|NCT06621043|DRUG|NTI164|Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
58263492|NCT03238885|DIAGNOSTIC_TEST|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
58263493|NCT05070429|OTHER|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
58384018|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
58384019|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
58384020|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
58384021|NCT02872597|DRUG|Ipratropium|
58384022|NCT02872597|DRUG|0.9% Sodium Chloride|
58384023|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
58384024|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
58384025|NCT00039169|DRUG|ortataxel|
58384026|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
58384027|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
58384028|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
58384029|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
58384030|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
58384031|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
58384032|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
58384033|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
58384034|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
58384035|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
58384036|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
58384037|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
58384038|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
57710401|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
57912317|NCT06307899|OTHER|Manual Stretching|Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
58263494|NCT05070429|OTHER|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
58384039|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
58384040|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
58384041|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
58263495|NCT06389149|OTHER|LEAP therapy|Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting
58263496|NCT06389149|OTHER|no LEAP therapy|2.5 hours of uninterrupted prolonged sitting (no movement)
58384042|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
58384043|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
58384044|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
58384045|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
58384046|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
58384047|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
57912318|NCT06307899|OTHER|PNF Stretching|Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
57912319|NCT01954966|DRUG|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
57912320|NCT01954966|DRUG|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
58263497|NCT04712591|DIAGNOSTIC_TEST|Auditory stimuli|Auditory stimuli (passive, active perturbations)
58263498|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
58263499|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
58263500|NCT01468753|PROCEDURE|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
58384048|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
58384049|NCT00002124|DRUG|Delavirdine mesylate|
58384050|NCT00002124|DRUG|Lamivudine|
58384051|NCT00002124|DRUG|Zidovudine|
58384052|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
58384053|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
58384054|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
58384055|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
58384056|NCT05246878|DRUG|EDP-235|Oral administration
58384057|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
58384058|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
58384059|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
58384060|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
58263501|NCT06163040|DRUG|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
58263502|NCT06163040|DRUG|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
58263503|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification and autotransplantation of anterior lens capsule|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification with autotransplantation of anterior lens capsule.
58263504|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification alone.
57710402|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
58263505|NCT00805870|DRUG|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
58263506|NCT00805870|DRUG|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
58263507|NCT00156039|BEHAVIORAL|Follow-up Strategy for Breast Cancer|
58263508|NCT05811052|OTHER|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
58263509|NCT05811052|OTHER|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
58263510|NCT00689624|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
58384061|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
57710403|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
58263511|NCT00689624|DRUG|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
58263512|NCT00689624|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
58384062|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
57710404|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
57710405|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
58263513|NCT00689624|DRUG|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
58263514|NCT00689624|DRUG|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
58263515|NCT03627377|BEHAVIORAL|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
58263516|NCT00801697|BIOLOGICAL|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
58263517|NCT00801697|BIOLOGICAL|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
58263518|NCT00801697|BIOLOGICAL|rAd35|VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL
58263519|NCT00801697|BIOLOGICAL|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
58384063|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
58384064|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
58384065|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
58263520|NCT00801697|BIOLOGICAL|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
58263521|NCT00801697|BIOLOGICAL|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
58384066|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
58263522|NCT03104400|DRUG|Adalimumab|Administered by subcutaneous injection
58263523|NCT03104400|DRUG|Upadacitinib|Oral tablet
58263524|NCT03104400|DRUG|Placebo to Upadacitinib|Oral tablet
58263525|NCT03104400|DRUG|Placebo to Adalimumab|Administered by subcutaneous injection
58263526|NCT01443494|OTHER|NE|norepinephine
58263527|NCT00451295|DRUG|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
58263528|NCT00451295|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
58263529|NCT01385488|BEHAVIORAL|self-monitor arm volume|bioelectrical impedance
58384067|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
58263530|NCT03702114|DEVICE|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
58384068|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
58263531|NCT01048112|BIOLOGICAL|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
58263532|NCT04985175|BEHAVIORAL|Question prompt list|The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
58384069|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
58384070|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
58384071|NCT03462641|DRUG|Placebo|10 cc normal saline
58384072|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
58384073|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
57912321|NCT05323760|DEVICE|Cardiopulmonary exercise test (CPET)|A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
58059781|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
58384074|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
58384075|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
58384076|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
58384077|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
58384078|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
58384079|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
58384080|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
57912322|NCT03782077|PROCEDURE|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
57912323|NCT02335528|BEHAVIORAL|SimCoach|
57912324|NCT01232179|PROCEDURE|conventional prp|pan retinal photocoagulation
57912325|NCT01232179|PROCEDURE|targeted prp|1200-1600 spot in far periphery retin, anterior equator
58059782|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
58059783|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
58059784|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
58263533|NCT00621595|DIETARY_SUPPLEMENT|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
58263534|NCT02144207|DEVICE|Glidescope|
58263535|NCT05236972|DRUG|Sintilimab|Sintilimab 200mg iv drip Q3W
58263536|NCT05236972|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
58263537|NCT05236972|DRUG|capecitabine|1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
58263538|NCT05454046|OTHER|Food intake among women and men in fertility treatment|Filling in an FFQ
58263539|NCT04142164|OTHER|MacInfo presentation|Presentation about intravitreal drug injection
58263540|NCT04142164|OTHER|Placebo presentation|Placebo presentation
58263541|NCT06620315|COMBINATION_PRODUCT|RBM|Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability
58263542|NCT06620315|COMBINATION_PRODUCT|sand blasted implant|sand blasted implant
58384081|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
58384082|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
58384083|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
58384084|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
58384085|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
58384086|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
58384087|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
57710406|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
57710407|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
57710408|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
57710409|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
57710410|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
57710411|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
58059785|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
58263543|NCT00645125|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
58263544|NCT00645125|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
58384088|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
58384089|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
58384090|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
58384091|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
58384092|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
58384093|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
58384094|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
58384095|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
58384096|NCT02974829|OTHER|follow-up|
58384097|NCT00358033|BEHAVIORAL|Counseling|
58384098|NCT00358033|BEHAVIORAL|Interactive Education|
58384099|NCT00358033|BEHAVIORAL|Group Support|
58384100|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
58384101|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
58384102|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
58384103|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
58384104|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
58384105|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
57710412|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
57710413|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
57710414|NCT02691767|DRUG|pazopanib|
57710415|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
58263545|NCT01011166|DRUG|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
58263546|NCT01011166|DRUG|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
58263547|NCT01011166|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
58384106|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
58059786|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
58263548|NCT01011166|DRUG|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
58263549|NCT06011161|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
57912326|NCT06301984|DEVICE|Insight GS|"The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.~The Andromeda Insight Growing System consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. The implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. The components are implanted from a posterior approach and are made from Titanium alloy (Ti6AL-4V-ELI), and High Density Polyethylene (HDPE)."
58263550|NCT05428163|OTHER|Biological sampling|3ml of blood
58263551|NCT04658524|DIAGNOSTIC_TEST|Thyroid function|laboratorial thyroid tests
58263552|NCT02317770|DRUG|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
58263553|NCT02317770|DRUG|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
58263554|NCT02750475|DRUG|Sunscreen Sport Lotion (BAY987516)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
58263555|NCT02750475|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
58263556|NCT06142175|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
58263557|NCT06485349|DIETARY_SUPPLEMENT|Olive Leaf Extract (OLE)|Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.
58263558|NCT06485349|OTHER|Placebo|100mg microcrystalline cellulose
57912327|NCT00553072|DRUG|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
57912328|NCT00553072|DRUG|Normal saline|1 ml/kg/dose
57912329|NCT02880891|PROCEDURE|prothetic procedure|splinted crown
57912330|NCT02988622|DEVICE|Fraxel Laser|One half of the scar is treated with Fraxel Laser
57912331|NCT02988622|DEVICE|CO2 Laser|One half of the scar is treated with CO2 Laser.
57912332|NCT01762319|DRUG|Misoprostol|
57912333|NCT01762319|DRUG|Vitamin B6|
57912334|NCT04985968|DRUG|Cobitolimod 250 mg|Rectal administration
57912335|NCT04985968|DRUG|Cobitolimod 500 mg|Rectal administration
57912336|NCT04985968|DRUG|Placebo|Rectal administration
57912337|NCT03260257|OTHER|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
57912338|NCT05644860|COMBINATION_PRODUCT|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
58263559|NCT05541978|OTHER|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
58263560|NCT04980651|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
58263561|NCT04980651|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
58263562|NCT00793546|DRUG|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
58263563|NCT00793546|DRUG|exemestane|25 mg tablet once daily
58263564|NCT00793546|DRUG|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
58263565|NCT01783600|DEVICE|NanoCross .014 balloon catheter|
58263566|NCT05085106|DRUG|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
58263567|NCT05085106|DRUG|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
58263568|NCT06184113|PROCEDURE|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
58263569|NCT06184113|DIAGNOSTIC_TEST|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
58263570|NCT06184113|DIAGNOSTIC_TEST|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
58263571|NCT04658706|OTHER|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
58263572|NCT04658706|OTHER|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
58263573|NCT03594019|PROCEDURE|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
57710416|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
57710417|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
58263574|NCT03594019|PROCEDURE|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
57710418|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
58384107|NCT04088799|OTHER|No intervention|No intervention
57912339|NCT05644860|COMBINATION_PRODUCT|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
57912340|NCT03452579|DRUG|Nivolumab|240mg
57912341|NCT03452579|DRUG|Standard Dose Bevacizumab|10mg/kg
57912342|NCT03452579|DRUG|Low Dose Bevacizumab|3mg/kg
57912343|NCT05596058|OTHER|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
57912344|NCT05596058|OTHER|active exercise|Physical activity and motor task only
57912345|NCT05596058|OTHER|cognitive task only|cognitive exercise in executive functions
57912346|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
58059787|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
58059788|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
58263575|NCT03594019|PROCEDURE|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
58263576|NCT01329926|PROCEDURE|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
58263577|NCT06648460|OTHER|Effort-based Decision-Making Task|"Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive."
58263578|NCT03375879|DEVICE|Bandage contact lens|Bandage contact lens
58263579|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
58263580|NCT00721344|DRUG|Moxifloxacin|Tablets 400mg
58263581|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
58384108|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
58384109|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
58384110|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
58384111|NCT01594840|DEVICE|Changing chat|Diapers with tips
58263582|NCT00721344|DRUG|Placebo|Placebo cartridges
58263583|NCT02474589|DRUG|tecovirimat|Study is based on Animal Regulatory Rule
58263584|NCT02474589|OTHER|Placebo|Does not apply
58263585|NCT01897662|DIETARY_SUPPLEMENT|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
58263586|NCT01897662|DIETARY_SUPPLEMENT|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
58263587|NCT02140528|BIOLOGICAL|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
58263588|NCT02140528|BIOLOGICAL|Placebo|
58263589|NCT03411694|OTHER|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
58263590|NCT03871738|OTHER|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
58263591|NCT00005711|BEHAVIORAL|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
58263592|NCT00222482|DRUG|Depakote ER|
58263593|NCT06158659|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
58384112|NCT00243867|DRUG|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
58384113|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
58384114|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
58384115|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
57710419|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
57710420|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
58384116|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
58384117|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
58384118|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
57710421|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
57710422|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
57710423|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
57710424|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
57710425|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
57710426|NCT03364049|DRUG|MK-7162|oral tablets
57710427|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
58263594|NCT06158659|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
58263595|NCT06158659|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
58384119|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
58384120|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
58384121|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
58384122|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
58384123|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
58384124|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
58384125|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
58384126|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
57912347|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
58263596|NCT04564469|DRUG|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration \&( F - 15)protocol in which furosemide is administered 15 min before tracer administration
57912348|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
58059789|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
58263597|NCT00005941|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58263598|NCT00005941|DRUG|cyclosporine|
58263599|NCT00005941|DRUG|fludarabine phosphate|
58263600|NCT00005941|DRUG|mycophenolate mofetil|
57710428|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
57912349|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
57912350|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
57912351|NCT06384573|DRUG|lecanemab|Administered intravenously
58059790|NCT04473495|DEVICE|educational video|educational video before intervention
58263601|NCT00005941|PROCEDURE|peripheral blood stem cell transplantation|
58059791|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
58059792|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
58059793|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
58059794|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
58263602|NCT00005941|RADIATION|radiation therapy|
58263603|NCT05676099|PROCEDURE|Phlebotomy|Participants may elect to submit a blood sample to the Biosample Repository.
58263604|NCT05676099|PROCEDURE|Buccal (cheek) swab|Participants may elect to submit a buccal swab sample to the Biosample Repository.
58263605|NCT05676099|GENETIC|Genetic Testing|Biosamples may be processed and analyzed for genetic variants using whole genome sequencing (WGS) or other sequencing methods. Participants whose samples are processed in this manner may be contacted and provided the option to receive TSC1 or TSC2 genetic variant results by opting in using Consent to Return of Genetic Results Form. Participants will be offered a one-time genetic counseling session to review their results, free of charge. CLIA-certified, TSC1 or TSC2 genetic variant results will be returned to participants who opt in to receive such results. Additionally, negative results and results not able to be clinically certified will also be offered to participants with a one-time genetic counseling session to review their results, free of charge using the Return of Genetic Research Results Template Letter. CSS will be responsible for informing clinic participants that their samples have been sequenced and offer to connect participant to the TSC Alliance for further information.
57710429|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
57710430|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
58263606|NCT05676099|OTHER|Tissue donation after routine clinical procedure|Participants may elect to submit a tissue sample to the Biosample Repository following a medical procedure.
58263607|NCT06183203|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
58263608|NCT06183203|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
58263609|NCT05497336|DRUG|IBI351|IBI351 is administered orally
58263610|NCT05497336|DRUG|Cetuximab|Cetuximab is administered intravenously
57912352|NCT04714476|DEVICE|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
57912353|NCT02379104|DEVICE|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
57912354|NCT02999126|DRUG|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
57912355|NCT02999126|DRUG|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
58263611|NCT00524004|BIOLOGICAL|Anti-CsbD Bovine IgG|Three times a day for seven days
58263612|NCT00524004|OTHER|Placebo|Three times a day for seven days
58263613|NCT00524004|BIOLOGICAL|Anti-CS17 Bovin IgG|Three times a day for seven days
58263614|NCT06390774|DRUG|SSGJ-705|anti-PD-1 and anti-HER2 bispecific antibody
58263615|NCT04412837|DRUG|Topical CBD Patch|35 mg CBD patch
58263616|NCT04412837|OTHER|Placebo Patch|Identical patch without active ingredient.
57912356|NCT06608173|BEHAVIORAL|radKIDS2.0 Safety and Empowerment Education Program|radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
57912357|NCT05923671|DIAGNOSTIC_TEST|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
57912358|NCT05923671|DIAGNOSTIC_TEST|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
57912359|NCT03860701|PROCEDURE|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
57912360|NCT00002331|DRUG|Ethambutol hydrochloride|
57912361|NCT00002331|DRUG|Clarithromycin|
57912362|NCT00002331|DRUG|Clofazimine|
57912363|NCT01084837|DRUG|velcade|"INDUCTIoN (Cycles 1-4)~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~* Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~* Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
57912364|NCT00001573|DRUG|SU101|
57912365|NCT03307759|DRUG|Pembrolizumab|Pembrolizumab
57912366|NCT03307759|RADIATION|Radiotherapy (SABR)|Radiotherapy
57912367|NCT06609967|PROCEDURE|application of PRF|PRF will be randomly administered into one group of patients undergoing any extractions group A (Right after the extraction) Group B will be a control group in which extraction sockets will be left to heal with the natural blood clot. Consenting patients will be assigned into groups randomly and not informed which group they were placed into. The PRF will be administered obtained from a tube of 10 ml blood and no material will be placed in the control group. The progress of healing and post-operative complications will be tracked over a period of 7 days with patients being called for follow-up on days 3, 5 and 7
57912368|NCT06609967|PROCEDURE|application of conventional surgicel|it will be a control group in which extraction sockets will be left to heal with the natural blood clot.
57912369|NCT00444171|PROCEDURE|insulin infusion rate controled by computer algorithm|
57912370|NCT00444171|PROCEDURE|insulin infusion rate guided by in-house glucose management protocol|
57912371|NCT02364843|DIETARY_SUPPLEMENT|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
57912372|NCT02776384|OTHER|Observational study|
57912373|NCT00939666|PROCEDURE|Wait&see or TEM with intensive follow-up|Wait\&see or TEM with intensive follow-up
57912374|NCT02849717|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
57912375|NCT01236365|DRUG|Atorvastatin|10 or 20 mg daily
57912376|NCT01236365|DRUG|Atorvastatin Placebo|10 or 20 mg daily
57710431|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
57710432|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
57710433|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
57912377|NCT05925361|PROCEDURE|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
58263617|NCT01488669|PROCEDURE|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
57710434|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
57710435|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
57710436|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
57710437|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
57912378|NCT02115516|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
57912379|NCT02115516|BIOLOGICAL|0.9% Sodium Chloride (Placebo)|
57912380|NCT00252577|DRUG|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
57912381|NCT02634489|DRUG|Tamsulosin HCl|Oral
57912382|NCT02634489|DRUG|Solifenacin Succinate|Oral
57912383|NCT02634489|DRUG|EC905|Oral
57912384|NCT03241225|BEHAVIORAL|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
57912385|NCT03241225|BEHAVIORAL|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
57912386|NCT05336812|DRUG|Acalabrutinib|Given PO
57912387|NCT05336812|BIOLOGICAL|Obinutuzumab|Given IV
57912388|NCT05336812|DRUG|Venetoclax|Given PO
57912389|NCT02002650|DRUG|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
58059795|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
57912390|NCT02002650|DRUG|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
57912391|NCT05352568|BEHAVIORAL|Cognitive Training|Computer-Based Cognitive Training from BrainHQ (Posit Science)
57912392|NCT05379504|BEHAVIORAL|Standard Health Education|Participants randomized to the standard health education arm will receive the intervention at month 1 and then months 3, 6, 9, and 12 (coinciding with the quarterly interviews). The participant will use the tablet and telehealth platform to complete the interview and education session with research staff. The content of these sessions will be focused on helping the participant (and family member/caregiver as appropriate) understand their health data, assisting them with any technology issues and providing the participant with education on their condition(s) and any requested resources. Research staff will will also provide any additional health education if there are changes to conditions or new diagnoses after an outside provider visit.
57912393|NCT05379504|BEHAVIORAL|Self Management|"The self-management intervention will be delivered over the course of a year. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN and SW) for 12 visits per participant. The team (OT, RN and SW) will meet twice during the first 2 months to determine a lead interventionist based on the participant's SMART goals and areas of concern. The lead interventionist will have three additional sessions with the participant and will be the point-person for sensor system alerts and messages. Goal Attainment Scaling \[83\] will be administered during the quarterly interview to assess participant progress on SMART goals. This measure is administered collectively with the participant, provides further accountability, offers opportunities to the participant for reflection on progress, and is a concrete measure of success of the self-management intervention."
57710438|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
57912394|NCT01336803|DRUG|Feraheme|5 mg/kg by intravenous (IV) administration
57912395|NCT01336803|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
58059796|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
58263618|NCT01488669|PROCEDURE|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
58263619|NCT05877417|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
58263620|NCT05877417|DEVICE|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
58263621|NCT05877417|OTHER|Exercise|Participants will exercise
58263622|NCT05451433|DRUG|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
58263623|NCT05451433|DRUG|Placebo|Placebo capsule twice a day
58263624|NCT04299048|DRUG|PF-06946860|subcutaneous injection
58263625|NCT01506154|DRUG|MRX-7EAT|Once daily application of a patch for 14 days
58263626|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 2 stages|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
58263627|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 1 stage|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
58263628|NCT04172402|DRUG|TS-1|Intervention is administered to patients in this Arm.
58263629|NCT04172402|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
58263630|NCT04172402|DRUG|Nivolumab|Intervention is administered to patients in this Arm.
58263631|NCT05619718|BEHAVIORAL|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
58263632|NCT05619718|OTHER|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
58263633|NCT01619644|DRUG|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
58263634|NCT01619644|DRUG|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
57710439|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
57710440|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
57710441|NCT05555433|OTHER|NO INTERVENTION|no intervention
57710442|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
57710443|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
57710444|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
57710445|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
58059797|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
57710446|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
57710447|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
58263635|NCT02083055|DRUG|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
58263636|NCT02083055|DRUG|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
58263637|NCT02975245|PROCEDURE|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
58384127|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
58384128|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
58384129|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
57710448|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
57710449|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
57710450|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
57710451|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
57710452|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
57710453|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
57710454|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
57710455|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
57912396|NCT01014533|DRUG|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
58059798|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
58059799|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
58263638|NCT04683939|DRUG|BNT141|Intravenous (IV)
58263639|NCT04683939|DRUG|Nab-paclitaxel|IV
58263640|NCT04683939|DRUG|Gemcitabine|IV
58384130|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
58384131|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
58384132|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
57710456|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
57710457|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
58263641|NCT01953835|DRUG|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
57710458|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
57710459|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
57710460|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
57710461|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
57710462|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
57912397|NCT01014533|DRUG|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
57912398|NCT06374173|DRUG|TGI-6 Injection|TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
57912399|NCT00000201|DRUG|Selegiline|
57912400|NCT02952378|DRUG|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
58384133|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
58384134|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
58384135|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
57912401|NCT02708914|BIOLOGICAL|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
57912402|NCT02708914|BIOLOGICAL|Eprex|Eprex® is chosen as the comparator.
57710463|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
57710464|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
57710465|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57710466|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
57912403|NCT04162613|OTHER|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
57912404|NCT01129466|DIETARY_SUPPLEMENT|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
57912405|NCT01129466|DIETARY_SUPPLEMENT|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
57912406|NCT05885087|DEVICE|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
57912407|NCT03107234|OTHER|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
57912408|NCT02792673|OTHER|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
57912409|NCT02792673|OTHER|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
57912410|NCT02792673|OTHER|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
57912411|NCT02792673|DEVICE|Labotect embryo transfer catheter|
57912412|NCT04580576|PROCEDURE|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
58384136|NCT01333722|DRUG|Placebo|Placebo tablet
58384137|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
57710467|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
57710468|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
57912413|NCT00901433|DEVICE|Personal WheezoMeter|pulmonary sounds analyzer
58384138|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
58384139|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
58384140|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
58384141|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
57912414|NCT00357851|DRUG|Aprotinin|
58384142|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
58384143|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
58384144|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
58263642|NCT01953835|DRUG|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
58263643|NCT01953835|DRUG|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
58263644|NCT01953835|DRUG|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
58263645|NCT06624293|DIAGNOSTIC_TEST|BNP|Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
58263646|NCT05990192|DRUG|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
58263647|NCT05990192|RADIATION|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
58263648|NCT05203549|PROCEDURE|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
58263649|NCT02863510|DEVICE|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
58384145|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
58384146|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
58384147|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
57710469|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
57912415|NCT02371213|OTHER|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
57912416|NCT03471260|DRUG|Azacitidine|Given IV or SC
58263650|NCT05768750|OTHER|Rehabilitation|X
58263651|NCT01097421|DRUG|Pramipexole Extended Release|
58263652|NCT03373058|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.
58263653|NCT03373058|PROCEDURE|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
58384148|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
58384149|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
58384150|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
58384151|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
58384152|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
58384153|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
57710470|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
57710471|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
57912417|NCT03471260|DRUG|Ivosidenib|Given PO
57912418|NCT03471260|DRUG|Venetoclax|Given PO
57912419|NCT01295762|OTHER|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
58384154|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
58384155|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
58384156|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
58384157|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
57912420|NCT02293304|OTHER|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
58263654|NCT03373058|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
58384158|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
57912421|NCT02293304|OTHER|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
57912422|NCT02924064|DRUG|Teneligliptin 20mg|
57912423|NCT02924064|DRUG|Placebo|
57912424|NCT02924064|DRUG|Metformin ≥ 1000 mg|
57912425|NCT02724059|PROCEDURE|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
57912426|NCT02851485|DRUG|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
58263655|NCT04481893|BEHAVIORAL|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~* The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~* The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
58384159|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
58384160|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
57710472|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
58384161|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
58384162|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
58384163|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
58384164|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
58384165|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
58384166|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
58384167|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
58384168|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
57912427|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
58263656|NCT05708677|BIOLOGICAL|EB-101|This is non-interventional and follows patients treated with EB-101
58263657|NCT02444364|DRUG|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
57912428|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
57912429|NCT05015907|DRUG|Ropivacaine|The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
57912430|NCT05015907|OTHER|Control (without intervention)|No intervention
57912431|NCT03017300|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
57912432|NCT03017300|DEVICE|PFLEX®|A device used to offer resisive to inspiratory muscle
57912433|NCT01719354|OTHER|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
58263658|NCT05124080|DRUG|Deucravacitinib|All participants will receive 6 mg of Deucravacitinib daily.
58384169|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
58384170|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
58384171|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
58384172|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
58384173|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
58384174|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
58384175|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
58263659|NCT02046005|BEHAVIORAL|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
57912434|NCT01719354|OTHER|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
58263660|NCT02046005|BEHAVIORAL|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
58263661|NCT02046005|BEHAVIORAL|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
58263662|NCT00227630|DRUG|cisplatin|
58263663|NCT00227630|DRUG|pemetrexed disodium|
58263664|NCT00227630|PROCEDURE|adjuvant therapy|
58384176|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
58384177|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
58384178|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
58384179|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
58384180|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
58384181|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
58059800|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
58059801|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
58384182|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
57710473|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
58059802|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
58059803|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
58263665|NCT00227630|PROCEDURE|conventional surgery|
58263666|NCT00227630|PROCEDURE|neoadjuvant therapy|
58263667|NCT00227630|RADIATION|radiation therapy|
58263668|NCT02312453|PROCEDURE|Posterior approach|We adopted the technique as described by Hebbard et al.
58263669|NCT01446237|OTHER|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
58263670|NCT04169672|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
58263671|NCT04169672|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
58263672|NCT04105946|DRUG|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
58263673|NCT04105946|DRUG|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
58263674|NCT01661933|BIOLOGICAL|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
58384183|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
58384184|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
58384185|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
58384186|NCT02076854|BEHAVIORAL|Text-Message Intervention|
58384187|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
58384188|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
58384189|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
58384190|NCT02216916|DRUG|HM781-36B|
58384191|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
58263675|NCT01661933|BIOLOGICAL|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
58384192|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
58384193|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
58384194|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
58384195|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
58384196|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
58384197|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
58384198|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
58059804|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
58059805|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
58059806|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
58059807|NCT03261739|BIOLOGICAL|Placebo|Placebo
58059808|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
58059809|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
58059810|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
58263676|NCT06649565|OTHER|no intervention|no intervention
58384199|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
58384200|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
58384201|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
58384202|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
58384203|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
58263677|NCT01632904|DRUG|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
57710474|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
57710475|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
57710476|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
58263678|NCT01632904|DRUG|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
58263679|NCT01632904|DRUG|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
58263680|NCT01632904|DRUG|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
58263681|NCT06406075|DEVICE|Lab demo 1.0|During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
58059811|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
58263682|NCT01746498|PROCEDURE|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
58059812|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
58059813|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
58059814|NCT00142818|DRUG|Modafinil|400 mg daily
58059815|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
58059816|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
58059817|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
58059818|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
58059819|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
58059820|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
58059821|NCT02583828|DRUG|Cyclophosphamide 50mg|
58059822|NCT02583828|DRUG|Letrozole 2.5 mg|
58059823|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
58059824|NCT00236574|DRUG|Galantamine hydrobromide|
58059825|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
58059826|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
58059827|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
58059828|NCT05512195|RADIATION|New delineation approach|New delineation approach
58263683|NCT01746498|PROCEDURE|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
58263684|NCT01746498|PROCEDURE|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
58263685|NCT04076423|DRUG|Dual Therapy|DTG + 3TC
57710477|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
57710478|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
57710479|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
57710480|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
57710481|NCT00268138|DRUG|elmex gel|elmex gel once a week
57912435|NCT00702351|DRUG|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
58059829|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
58384204|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
58059830|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
58059831|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
58263686|NCT04076423|DRUG|Triple therapy|BIC / FTC / TAF
58384205|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
58384206|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
58384207|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
57710482|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
57710483|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
57710484|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
58059832|NCT00633425|DRUG|GLIMEPIRIDE|
58263687|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
57710485|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
57710486|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
57710487|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
57710488|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
57710489|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
57912436|NCT01465347|DRUG|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
58059833|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
58059834|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
58263688|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
58263689|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
58263690|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
58263691|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
58384208|NCT06075134|PROCEDURE|Botox injection|Botox injection
58384209|NCT06075134|DEVICE|EMG|Quantitative Electromyography
58384210|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
58384211|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
58384212|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
58384213|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
58384214|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
58263692|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
58384215|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
58384216|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
58384217|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
58384218|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
58384219|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
57710490|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
57710491|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
57710492|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
57710493|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
57710494|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
58263693|NCT06307691|PROCEDURE|Conventional drilling|Atraumatic extraction, followed by sequential drilling using conventional drills
58263694|NCT06307691|PROCEDURE|Osseodensification drilling|Atraumatic extraction, followed by osteotomy prepared using densah bur (sequential drilling)
58384220|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
57710495|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
58263695|NCT01729052|DEVICE|Acupuncture|
58263696|NCT01566942|DRUG|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
58384221|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
58384222|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
57710496|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
57710497|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
57710498|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
57710499|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
57710500|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
57710501|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
57710502|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
57710503|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
58059835|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
58059836|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
58059837|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
58059838|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
58059839|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
57710504|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
57710505|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
57710506|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
57710507|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
57912437|NCT05094505|OTHER|Exercise in normoxia|Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
57912438|NCT05094505|OTHER|Control diet|Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
58059840|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
57912439|NCT05094505|OTHER|Exercise in hypoxia|Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
58059841|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
58059842|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
58059843|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
58059844|NCT02020564|BEHAVIORAL|Speed of Processing Training|
58059845|NCT02020564|BEHAVIORAL|Placebo Control|
58059846|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
58059847|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
58059848|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
58059849|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
58059850|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
58263697|NCT01566942|DRUG|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
58384223|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
58384224|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
57710508|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
57710509|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
57912440|NCT05094505|OTHER|Low carbohydrate diet|Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
57912441|NCT03063801|OTHER|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
57912442|NCT01103362|DRUG|flibanserin|all patients will receive open-label flibanserin 100mg
57912443|NCT00289497|DEVICE|TempTouch®|
58059851|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
58059852|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
58059853|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
58263698|NCT00412217|DRUG|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
58263699|NCT00412217|DRUG|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
58263700|NCT00412217|OTHER|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
57912444|NCT05696301|DEVICE|Winback® on|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated."
58263701|NCT01266785|DRUG|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
58263702|NCT06269263|BEHAVIORAL|Home-based cardiac rehabilitation|Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
58263703|NCT02195310|DEVICE|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
58263704|NCT02195310|DEVICE|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
58263705|NCT00492596|DEVICE|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
58263706|NCT00492596|PROCEDURE|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
58263707|NCT04656197|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
58384225|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
58384226|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
58384227|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
58384228|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
58384229|NCT00183144|BEHAVIORAL|Contingency management|
57710510|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
57710511|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
58059854|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
58263708|NCT04873453|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
58263709|NCT04873453|DRUG|Placebo|Placebo arm
58263710|NCT06622512|DEVICE|Radial Pressure Wave Therapy|Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
58263711|NCT05619536|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
58263712|NCT05619536|DRUG|Saline placebo|Sterile normal saline for injection
58384230|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
58384231|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
58384232|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
58384233|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
58384234|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
58384235|NCT00149539|DRUG|Buprenorphine/naloxone|
57710512|NCT00153491|DRUG|artemether-lumefantrine|
58059855|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
58059856|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
58263713|NCT03445234|DIETARY_SUPPLEMENT|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
58263714|NCT03445234|DIETARY_SUPPLEMENT|Placebo|Placebo powder
58263715|NCT03445234|DIETARY_SUPPLEMENT|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
58263716|NCT03445234|DIETARY_SUPPLEMENT|No banana|water only
58263717|NCT06439589|DRUG|HRS2398|HRS2398: Tablets, 40mg/tablet, oral
58263718|NCT06439589|DRUG|Adebrelimab|Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion
58263719|NCT03863457|DRUG|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
58384236|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
58384237|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
58384238|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
58263720|NCT03593421|DRUG|synthetic PreImplantation Factor|peptide
58263721|NCT06620653|OTHER|Telemonitoring|Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.
58263722|NCT06620653|OTHER|Standard Care|patients with a recent admission for heart failureare seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines with face-to-face follow up at 6 and 12 weeks.
58263723|NCT00058968|DRUG|Duloxetine hydrochloride|
58263724|NCT00058968|DRUG|placebo|
58263725|NCT03467763|DRUG|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
58263726|NCT03467763|DRUG|Placebo oral capsule|Placebo capsule
58263727|NCT06350695|DEVICE|low grade compression stockings (10-15 mmHg)|Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
58263728|NCT06350695|DEVICE|high grade compression stockings (20-30 mmHg)|Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
58263729|NCT04751773|BEHAVIORAL|Exercise training|Perioperative exercise training
58263730|NCT05366985|PROCEDURE|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
58263731|NCT03837964|DRUG|BI 1291583|Tablet
58263732|NCT02170090|DRUG|Gemcitabine|Gemcitabine 1000mg/m2
58263733|NCT02170090|DRUG|Cisplatin|Cisplatin 25mg/m2
58263734|NCT02170090|DRUG|Capecitabine|Capecitabine 1250mg/m2
58263735|NCT02634034|DRUG|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
57710513|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
57710514|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
58263736|NCT02634034|DRUG|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
58384239|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
58059857|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
58263737|NCT02634034|DRUG|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
58263738|NCT05977075|OTHER|ApisMela protocol|The activities and games proposed by this protocol are offered in a sequence characterized by increasing complexity. The same function is stimulated with varied tasks because the repetitiveness of the same task negatively affects skill generalization. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Language plays a crucial role, participants are encouraged to use speech as a tool for attention regulation and cognitive processing. It's divided into 20 sessions: a weekly group meeting of one hour and thirty.
58263739|NCT05977075|OTHER|"Unstuck and on Target protocol"|The protocol teaches people to be more flexible, skillful in planning and goal-oriented. It is useful for moving more easily from one topic to another and from one task to another, considering new ideas or another person's point of view, generalizing skills learned across contexts so that teachers, parents and therapists can focus more on educational aspects and less on behavioral management. It is divided into 20 sessions: a weekly group meeting of one hour and thirty minutes. A homework sheet is provided for each session to consolidate the skill learned and generalize it outside the work setting. Parents have an active role in performing the task.
58263740|NCT03959826|BEHAVIORAL|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
58263741|NCT03959826|BEHAVIORAL|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
58263742|NCT03613558|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
58263743|NCT03613558|DRUG|Placebo|saline solution
58263744|NCT03616067|DRUG|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
58263745|NCT03616067|DRUG|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
58263746|NCT04367493|DIETARY_SUPPLEMENT|Chocolate|25 g of chocolate by day for 4 weeks
58263747|NCT03694444|DRUG|AMY-101|C3 complement inhibitor
58384240|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
58384241|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
58384242|NCT01694433|DRUG|Calcipotriene|1g daily BID
58384243|NCT01694433|DRUG|Placebo|1g daily BID
58384244|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
58384245|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
58384246|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
58384247|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
58384248|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
58384249|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
58384250|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
57710515|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
57710516|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
57710517|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
57710518|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
57710519|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
58384251|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
57710520|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
58263748|NCT03694444|OTHER|Water for injection|Placebo
58384252|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
58384253|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
58384254|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
58263749|NCT05801510|BEHAVIORAL|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
58263750|NCT00574210|DRUG|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
58263751|NCT00574210|DRUG|Placebo|Placebo Tablets administered twice per day
58263752|NCT06618404|OTHER|No intervention - cross-sectional cohort analysis|Observational
58263753|NCT02375880|DRUG|DKN-01|Administration by intravenous (IV) infusion.
57710521|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
58263754|NCT02375880|DRUG|gemcitabine|Administered by IV infusion.
58263755|NCT02375880|DRUG|cisplatin|Administered by IV infusion
58263756|NCT04558606|DEVICE|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
57912445|NCT05696301|DEVICE|Winback® off|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated."
57912446|NCT05696301|BEHAVIORAL|self-massage of the scar|The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
57912447|NCT06609772|OTHER|Individualised Pain Education|Individualised Pain Education
58059858|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
58059859|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
58059860|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
58384255|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
58384256|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
58384257|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
58384258|NCT04951219|DRUG|Resmetirom|Tablet
58059861|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
58059862|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
58059863|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
58059864|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
58059865|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
58384259|NCT02656394|DRUG|GL101|Topical Gel
57710522|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
57710523|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
58059866|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
58059867|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
58059868|NCT03000413|DRUG|Ketamine|Active treatment
58059869|NCT03000413|DRUG|Fentanyl|
58384260|NCT02656394|DRUG|Placebo|Placebo topical gel
58384261|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
58384262|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
58384263|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
57710524|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
58263757|NCT04558606|DEVICE|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
57710525|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
58263758|NCT04253405|DEVICE|High Flow Nasal Catheter|"HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2"
58384264|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
58384265|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
57912448|NCT02422862|OTHER|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
57912449|NCT01696838|OTHER|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
57912450|NCT01696838|OTHER|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
57710526|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
57710527|NCT04596540|OTHER|Placebo|Normal saline
57710528|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
57710529|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
57710530|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
57710531|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
57710532|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
57912451|NCT02709213|DIAGNOSTIC_TEST|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
57912452|NCT06336733|DRUG|ANAKINRA|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
57912453|NCT04377750|DRUG|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
57912454|NCT04959448|DRUG|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
57912455|NCT02698085|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
58263759|NCT04253405|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
58263760|NCT00640653|BEHAVIORAL|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
58263761|NCT00640653|BEHAVIORAL|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
58384266|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
57710533|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
57710534|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
57710535|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
57710536|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
57710537|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
57912456|NCT02698085|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
57912457|NCT00096343|DRUG|carboplatin|
58263762|NCT00640653|BEHAVIORAL|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
58384267|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
58263763|NCT00640653|BEHAVIORAL|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
57710538|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
57710539|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
58384268|NCT01480726|PROCEDURE|Surgery|
58384269|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
57710540|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
57710541|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
57710542|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
57710543|NCT02260427|DEVICE|Insertion of the air-Q sp|
57710544|NCT00126295|DEVICE|'What you need to know about stroke' education package|
57710545|NCT04122833|OTHER|Next generation sequencing|observational study
57710546|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
57710547|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
57710548|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
57912458|NCT00096343|DRUG|paclitaxel|
57912459|NCT02367820|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
57912460|NCT05077085|DRUG|Bezlotoxumab|single intravenous infusion of bezlotoxumab 10 mg/kg
58384270|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
57710549|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
57710550|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
57710551|NCT00215826|DRUG|Alferon LDO|
57912461|NCT05077085|PROCEDURE|Fecal Microbiota Transplantation (FMT)|single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
57912462|NCT05077085|DRUG|Vancomycin oral|14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
57912463|NCT04591431|DRUG|Erlotinib|TT arm
57912464|NCT04591431|DRUG|Trastuzumab|TT arm
57710552|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
58384271|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
57912465|NCT04591431|DRUG|Trastuzumab emtansine|TT arm
57912466|NCT04591431|DRUG|Pertuzumab|TT arm
57912467|NCT04591431|DRUG|Lapatinib|TT arm
58263764|NCT00640653|BEHAVIORAL|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
57912468|NCT04591431|DRUG|Everolimus|TT arm
58263765|NCT05331768|COMBINATION_PRODUCT|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
57912469|NCT04591431|DRUG|Vemurafenib|TT arm
58059870|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
58384272|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
58384273|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
58059871|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
58384274|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
57710553|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
57912470|NCT04591431|DRUG|Cobimetinib|TT arm
58059872|NCT05487092|OTHER|Placebo|Placebo
57912471|NCT04591431|DRUG|Alectinib|TT arm
57912472|NCT04591431|DRUG|Brigatinib|TT arm
58059873|NCT01845766|OTHER|exercise rehabilitation|
58263766|NCT05970770|DEVICE|Hypotension Prediction Index|in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index \>85
58384275|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
58384276|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
58384277|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
57912473|NCT04591431|DRUG|Palbociclib|TT arm
58384278|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
57912474|NCT04591431|DRUG|Ponatinib|TT arm
57912475|NCT04591431|DRUG|Vismogedib|TT arm
57912476|NCT04591431|DRUG|Itacitinib|TT arm
57912477|NCT04591431|DRUG|Ipatasertib|TT arm
58263767|NCT05970770|DRUG|Norepinephrine|Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
58263768|NCT06192992|OTHER|Peripheral heating of 2 feet|Heating of both feet
58263769|NCT06192992|OTHER|Sham|No heating
57710554|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
57912478|NCT04591431|DRUG|Entrectinib|TT arm
57912479|NCT04591431|DRUG|Atezolizumab|TT arm
57912480|NCT04591431|DRUG|Nivolumab|TT arm
57912481|NCT04591431|DRUG|Ipilimumab|TT arm
57912482|NCT04591431|DRUG|Pemigatinib|TT arm
57912483|NCT04591431|DRUG|Oncology Drugs|Standard of Care Arm
57912484|NCT04591431|DRUG|Pralsetinib|TT arm
57912485|NCT04591431|DRUG|Selpercatinib|TT arm
57912486|NCT04591431|DRUG|Talazoparib|TT arm
57912487|NCT04591431|DRUG|Tepotinib|TT arm
57912488|NCT04591431|DRUG|Alpelisib|TT arm
57912489|NCT00837798|DEVICE|CRM Device|Pacemaker, ICD, or CRT device
57912490|NCT00391131|DRUG|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
57912491|NCT02110719|DRUG|Celebrex|
57912492|NCT02110719|DRUG|Gabapentin|
57912493|NCT02110719|DRUG|IV acetaminophen|
57912494|NCT02110719|DRUG|oral acetaminophen|
57912495|NCT02110719|DRUG|oral ibuprofen|
57912496|NCT02110719|DRUG|percocet|
58059874|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
58059875|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
58263770|NCT05222022|DEVICE|Retitrack|Retitrack device measures and analyzes eye movement
58384279|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
57912497|NCT02110719|DRUG|vicodin|
57912498|NCT02110719|DRUG|Oxycodone|
57912499|NCT02110719|DRUG|dilaudid|
58263771|NCT00355706|PROCEDURE|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
58384280|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
58384281|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
58384282|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
58384283|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
58384284|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
58384285|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
58384286|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
57912500|NCT02110719|DRUG|Dexamethasone|
57912501|NCT02110719|DRUG|zofran|
57912502|NCT05490719|DRUG|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
57912503|NCT04369482|DEVICE|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
57912504|NCT04369482|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
57912505|NCT03154073|BEHAVIORAL|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
57912506|NCT03154073|BEHAVIORAL|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
57912507|NCT05189873|DRUG|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
57912508|NCT05189873|DRUG|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
57912509|NCT03557580|DRUG|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
58059876|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
58059877|NCT02282774|DRUG|Sham subtenon block|
58059878|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
58059879|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
58059880|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
58263772|NCT02008747|DRUG|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
58384287|NCT03700164|OTHER|Temperature|Water-perfused suit.
58384288|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
58384289|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
58384290|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
58384291|NCT04342676|DEVICE|k ras|K ras
58384292|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
58384293|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
58384294|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
58384295|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
58384296|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
57710555|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
57912510|NCT03557580|DRUG|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
57912511|NCT03557580|DRUG|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
58059881|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
57912512|NCT01642251|DRUG|Cisplatin|Given IV
58059882|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
58059883|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
57912513|NCT01642251|DRUG|Etoposide|Given IV
57912514|NCT01642251|DRUG|Veliparib|Given PO
57912515|NCT01642251|DRUG|Placebo|placebo of Veliparib
57912516|NCT01947972|DIETARY_SUPPLEMENT|Tailored protein fortification|4-4.5g of protein/kg/d
57912517|NCT05692479|OTHER|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
57912518|NCT05308238|BEHAVIORAL|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
57912519|NCT05308238|BEHAVIORAL|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
57912520|NCT01076426|DRUG|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
57912521|NCT01076426|DIETARY_SUPPLEMENT|Oligosaccharide|oligosaccharide one pack per day
58059884|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
58059885|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
58059886|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
58384297|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
58384298|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
57710556|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
57912522|NCT01856777|DEVICE|Semi-quantitative panel test|
57912523|NCT01856777|DEVICE|High sensitivity urine pregnancy test|
57912524|NCT06453785|DEVICE|Promaxo portable MRI|"The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel truly open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies."
57912525|NCT06130761|PROCEDURE|Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block|"For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane."
58059887|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
57710557|NCT01701661|OTHER|conservative treatment|Compression stockings class II
57710558|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
57710559|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
57912526|NCT06130761|PROCEDURE|trans muscular quadratus lumborum block|With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
57912527|NCT05288153|DRUG|Metformin|Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
57912528|NCT05288153|DRUG|Folate|Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
57912529|NCT01457989|DRUG|retigabine/ezogabine|dose range up to 1200 mg/day
57912530|NCT01485081|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
57912531|NCT01704638|DRUG|fluvoxamine|
57912532|NCT01704638|DRUG|Digoxin|
57912533|NCT01181388|PROCEDURE|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
57912534|NCT01181388|PROCEDURE|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
58059888|NCT02417935|DRUG|Duloxetine|Administered orally
58059889|NCT02417935|DRUG|Pregabalin|Administered orally
58059890|NCT02417935|DRUG|Placebo|Administered orally
58263773|NCT05692531|BEHAVIORAL|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
58263774|NCT03644836|DRUG|Amino Acids|Sweet taste cocoa flavored drink
58263775|NCT03644836|DRUG|Placebos|Sweet taste cocoa flavored drink
58059891|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
58059892|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
58059893|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
58059894|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
58059895|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
57912535|NCT02647216|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
57912536|NCT02647216|BEHAVIORAL|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
57912537|NCT03078426|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
57912538|NCT03078426|OTHER|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
57912539|NCT04556292|DRUG|SC10914|SC10914 400mg tid
57912540|NCT00408252|OTHER|biopsies|No intervention, only biopsy for translational project
57912541|NCT00408252|DRUG|SU011248|no intervention
57912542|NCT00879866|BIOLOGICAL|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
58059896|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
57912543|NCT05639660|OTHER|non-interventional|The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
57912544|NCT05069103|DEVICE|Intervention|"Similar to the original TWIST trial , patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s)."
57912545|NCT04754204|DEVICE|Arrhythmia Management System (AMS)|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
57912546|NCT01582685|BEHAVIORAL|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
58059897|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
58059898|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
58059899|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
58059900|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
58384299|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
57912547|NCT06608316|DEVICE|Intermittent Theta Burst Stimulation|A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.
58263776|NCT05686161|BIOLOGICAL|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
58263777|NCT05686161|BIOLOGICAL|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
58263778|NCT05686161|BIOLOGICAL|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
58263779|NCT00878969|DRUG|valsartan (ARB)|
57710560|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
58263780|NCT00878969|DRUG|ramipril (ACE inhibitor)|
58263781|NCT00878969|DRUG|Placebo|
57912548|NCT06112990|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
57912549|NCT06112990|OTHER|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
58263782|NCT05269888|OTHER|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
58263783|NCT05269888|OTHER|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
58263784|NCT03085992|DRUG|FOLFOXIRI plus Bevacizumab|"* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
58263785|NCT03085992|OTHER|Chemoradiotherapy plus Bevacizumab|"* FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
58059901|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
57710561|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
57710562|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
58384300|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
58384301|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
58384302|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
57710563|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
57912550|NCT06112990|BEHAVIORAL|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
57710564|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
57710565|NCT05685797|PROCEDURE|trigminal nerve block with RFT|trigminal nerve block with RFT
57710566|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
57710567|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
58263786|NCT05550987|OTHER|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy|The Vibramoov device (Techno Concept, France) will be used in the rehabilitation program. Before starting the training session, each subject will undergo a diagnosis in order to qualify for the use of Functional Proprioceptive Vibration. Before starting the therapy, pads are placed on the patient's body to fix the vibrating modules in the places to be treated (lower limbs, left upper limb or right upper limb). Then the vibrating modules are attached to the supports. The therapy carried out with the use of the Vibramoov device consists in the targeted and individualized stimulation of the nervous system, as in the course of natural movements of the upper or lower limbs with the use of visual biofeedback. Therapy with the use of the Vibramoov device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
58263787|NCT05550987|OTHER|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy|The Ekso GT ™ exoskeleton (Ekso Bionics, Inc. Richmond, CA, USA) used in the rehabilitation program has been approved by the Food and Drug Administration (FDA). Before starting the training session, each subject will undergo a thorough diagnosis to individually adjust the bionic skeleton. After entering the patient's data into the device's software, the physiotherapist selects the optimal training parameters. As the patient progresses during the training unit, the therapist will update the exoskeleton settings on an ongoing basis, so that the training is best suited to the current capabilities of the subject. Therapy with the use of the exoskeleton device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
58263788|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.|The RoboGait stationary robot (Bama technologist, Turkey) will be used in the rehabilitation program. Before starting the training session, each subject will undergo detailed diagnostics in order to individually adjust the orthoses. The next step will be to put on a vest and inguinal straps on a wheelchair or standing, and then lift it up with the device, then attach it to the Robogait orthoses. After entering the patient's data into the software of the device, the physiotherapist selects the optimal training parameters. During the session, biofeedback is also displayed informing the patient and the therapist about the patient's activity level in the transfer phase and the support during walking for both lower limbs. Therapy with the use of the RoboGait device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
58263789|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy|The Zebris FDM-T treadmill will be used in the rehabilitation program for gait analysis. Before each session, patients will be equipped with a harness for safety reasons. The need for a handrail will be assessed prior to each session and patients will be encouraged to support their hands as little as possible. Before starting the training session, each subject will undergo a thorough diagnosis in order to individually adjust the training parameters. Therapy with the use of the Zebris FDM-T treadmill will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
58384303|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
58384304|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
58384305|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
58384306|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
58384307|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
58384308|NCT03288454|DRUG|Placebo|Saline for injection
58384309|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
58384310|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
58059902|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
58059903|NCT00149006|PROCEDURE|Cell therapy|
58059904|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
58059905|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
58384311|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
58384312|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
58384313|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
58384314|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
58384315|NCT03440567|DRUG|Avelumab|Given IV
58384316|NCT03440567|DRUG|Carboplatin|Given IV
57710568|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
57710569|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
57710570|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
57710571|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
57710572|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
57710573|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
57710574|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
57710575|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
57710576|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
57710577|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
57710578|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
57710579|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
57710580|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
57710581|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
57710582|NCT06184334|DRUG|Solfenacin|pills taken once day
57710583|NCT06184334|DRUG|Mirabegron|pills taken once day
57710584|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
57710585|NCT00460941|DRUG|Placebo|sc weekly
57710586|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
57710587|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
57710588|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
57710589|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
57710590|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
57710591|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
57710592|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
58059906|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
58059907|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
58059908|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
58059909|NCT05659459|DRUG|KIN001|Oral tablet
58384317|NCT03440567|DRUG|Etoposide Phosphate|Given IV
58384318|NCT03440567|DRUG|Ibrutinib|Given PO
58384319|NCT03440567|DRUG|Ifosfamide|Given IV
58384320|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
58384321|NCT03440567|BIOLOGICAL|Rituximab|Given IV
58384322|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
58384323|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
58263790|NCT05550987|OTHER|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy|The Pablo (Tyromotion) device will be used in the rehabilitation program. Before the start of the training session, each subject will undergo detailed diagnostics assessing the range of mobility in the shoulder, radiocarpal (frontal and sagittal plane), elbow (sagittal plane), and explosive strength of the cylindrical, pinch and lateral and three-point grip. The Force Control Index will also be designated. The next stage will be training on the Pablo device using visual and auditory biofeedback. The physiotherapist selects the optimal training parameters (type of pad, type of game, level of the game). Each training session will be stored in the software and recorded in the patient's medical records. Therapy with the use of the Pablo device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
58263791|NCT05550987|OTHER|Control Group|In control Group the rehabilitation program will be carried out for a period of 4 weeks. In each of the studied groups, the rehabilitation program will include conventional physiotherapy sessions performed 5 times a week, consisting of 50 minutes a day of individual physiotherapy and 50 minutes a day of standing upright.
58263792|NCT00177307|DRUG|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
58263793|NCT00177307|DRUG|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
58263794|NCT00177307|DRUG|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
58263795|NCT05725265|DEVICE|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
58263796|NCT05725265|DEVICE|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
58263797|NCT04662788|DRUG|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
58263798|NCT02650947|DIETARY_SUPPLEMENT|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
58384324|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
58384325|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
58384326|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
57710593|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
57710594|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
57710595|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
57710596|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
58384327|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
58384328|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
57710597|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
57912551|NCT06154109|DRUG|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
57912552|NCT06154109|DRUG|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
57912553|NCT06154109|DRUG|Placebo|The placebo does not contain any active pharmaceutical ingredients .
57912554|NCT01823692|OTHER|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
58059910|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
58384329|NCT03620032|DRUG|Vinorelbine|Chemotherapy
58263799|NCT02650947|DIETARY_SUPPLEMENT|Placebo|Consumption of empty capsule everyday for 4 weeks
58263800|NCT03202537|DRUG|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
58263801|NCT05716906|DIETARY_SUPPLEMENT|Melatonin|5mg gummy 30 min before bedtime for 2 consecutive nights
58263802|NCT02684409|DRUG|PROT-CL-NP101-015.01|
58263803|NCT04058106|PROCEDURE|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
58263804|NCT01575275|DRUG|aminolevulinic acid|Given PO
58263805|NCT01575275|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58384330|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
58384331|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
58384332|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
58384333|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
58384334|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
58384335|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
58384336|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
58384337|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
58384338|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
58384339|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
58384340|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
58384341|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
58384342|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
58384343|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
58384344|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
58384345|NCT03974932|DRUG|Ibuprofen|NSAID.
58384346|NCT03974932|DRUG|Acetaminophen|Analgesic.
58384347|NCT03974932|DRUG|Celecoxib|NSAID.
58384348|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
58384349|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
58384350|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
58384351|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
58384352|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
58384353|NCT01206140|DRUG|Selumetinib|Given PO
58384354|NCT01206140|DRUG|Temsirolimus|Given IV
58384355|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
58384356|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
58263806|NCT05574803|DEVICE|Active-tDCS|Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.
58263807|NCT05574803|DEVICE|Sham-tDCS|Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
58263808|NCT02863081|OTHER|Survey|Administered to healthcare providers
58263809|NCT02863081|OTHER|interview|Administered to patients and LAR (i.e., interviews)
58384357|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
58384358|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
58384359|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
58384360|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
58384361|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
57710598|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
57710599|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
57710600|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
58059911|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
58059912|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
58059913|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
58263810|NCT04761081|BEHAVIORAL|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
58263811|NCT02618694|PROCEDURE|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
58263812|NCT02618694|PROCEDURE|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
58263813|NCT04055376|DEVICE|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
58263814|NCT04055376|DEVICE|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
58059914|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
58059915|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
58059916|NCT00517634|DRUG|Placebo|Matching Placebo
57710601|NCT01769885|DRUG|tivozanib|Given PO
57710602|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
58059917|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
57710603|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
57912555|NCT02536807|DRUG|Hyaluronan|HA gel injection
57710604|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
57710605|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
57710606|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
57710607|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
57710608|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
57710609|NCT02907359|DRUG|Guadecitabine|
58059918|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
58263815|NCT03200847|DRUG|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
58263816|NCT05213793|DIAGNOSTIC_TEST|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
58263817|NCT02409381|DRUG|Motore|250 mg
58263818|NCT02409381|DRUG|Alivium|600 mg
58263819|NCT01730651|RADIATION|Tomotherapy|"IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
57710610|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
57710611|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
57710612|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
57710613|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
57710614|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
57710615|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
57710616|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
57710617|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
57710618|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
58263820|NCT00968058|PROCEDURE|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
58263821|NCT03051698|DRUG|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
58059919|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
58059920|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
58059921|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
58263822|NCT03051698|OTHER|Saline|0.9% NaCl
58263823|NCT03051698|DRUG|Antibiotics|vancomycin, ciprofloxacin, metronidazole
58263824|NCT06619288|DRUG|B/F/TAF|Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
58263825|NCT06619288|DRUG|TDF+3TC+EFV|Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
58263826|NCT06619288|DRUG|DTG/3TC|Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
58263827|NCT05336292|BEHAVIORAL|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
58263828|NCT05336292|BEHAVIORAL|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
58263829|NCT05336292|BEHAVIORAL|Control Group|This group does not do any intervention
58263830|NCT05615870|OTHER|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
58263831|NCT04002999|DEVICE|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, \[24\] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
58263832|NCT04002999|DEVICE|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
58263833|NCT04002999|DEVICE|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
58263834|NCT00274079|DRUG|SPIRIVA|
58263835|NCT06042361|BEHAVIORAL|Smokefree Implementation Framework and Toolkit|"Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities."
58384362|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
58384363|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
58384364|NCT00752921|DRUG|etoricoxib|120 mg
58384365|NCT00752921|DRUG|placebo|placebo
58384366|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
58384367|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
57710619|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
57912556|NCT02335177|BEHAVIORAL|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
57912557|NCT00978627|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
58059922|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
58263836|NCT00297531|DEVICE|PerioWave|
58263837|NCT00297531|PROCEDURE|Scaling and Root Planing|
58263838|NCT02119221|DRUG|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]
58263839|NCT05721248|OTHER|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
58263840|NCT06376422|PROCEDURE|Spongioflex®|partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.
58263841|NCT06376422|OTHER|non-operated|no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
58384368|NCT01393795|DRUG|Qutenza|8% patch
58384369|NCT01393795|DRUG|Tegaderm|No active drug
58384370|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
58384371|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
58384372|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
58384373|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
57710620|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
57710621|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
57710622|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
57710623|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
57710624|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
57710625|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
58059923|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
58263842|NCT01841450|DEVICE|iStent|Implantation of one iStent in conjunction with cataract surgery
58384374|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
57710626|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
57710627|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
57710628|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
57710629|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
57710630|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
57710631|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
57710632|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
58263843|NCT01841450|PROCEDURE|Cataract surgery|Cataract surgery alone
58263844|NCT00655733|DRUG|HMPL-004|HMPL-004 1200 mg/d
58263845|NCT00655733|DRUG|Placebo|Placebo 1200 mg/d
57710633|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
57710634|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
58263846|NCT03431662|PROCEDURE|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
57912558|NCT00978627|DRUG|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
58263847|NCT03431662|PROCEDURE|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
58263848|NCT02253771|DEVICE|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
57912559|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
58263849|NCT02253771|DEVICE|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
58263850|NCT05512806|DRUG|AZD5462|Participants will receive AZD5462 orally.
58263851|NCT06137287|DRUG|BOTOX|Intramuscular Injection
57912560|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
57912561|NCT02279225|RADIATION|Group Phototherapy|
57912562|NCT02279225|RADIATION|Phototherapy + Physical activity|
57912563|NCT02279225|OTHER|Physical activity|
58263852|NCT06137287|DRUG|Placebo for BOTOX|Intramuscular Injection
58263853|NCT05724459|OTHER|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
58263854|NCT01741792|DRUG|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
57912564|NCT02279225|OTHER|Placebo|
57912565|NCT05416060|BEHAVIORAL|Dulce Digital Text-Based Education|Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
58263855|NCT00723190|DRUG|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
58059924|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
58263856|NCT03861312|BEHAVIORAL|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
58263857|NCT03861312|BEHAVIORAL|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
58263858|NCT01820507|DEVICE|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
58263859|NCT01820507|DEVICE|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
58263860|NCT06073275|DIETARY_SUPPLEMENT|Beetroot juice ingestion|Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
58263861|NCT06073275|DIETARY_SUPPLEMENT|Placebo ingestion|Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
58263862|NCT05487378|DIETARY_SUPPLEMENT|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
58263863|NCT03195023|DRUG|Lisinopril|
58263864|NCT03195023|DRUG|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
58263865|NCT06461065|DEVICE|AIDS|mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by by Ypsomed, Dexcom G6 blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)
58263866|NCT06461065|OTHER|Brain MRI|To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject
58263867|NCT01756781|DRUG|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
58263868|NCT01756781|DRUG|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
58263869|NCT01756781|DRUG|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
58263870|NCT01756781|DRUG|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
58263871|NCT02585271|DEVICE|Transanal decompression tube|22 Fr transanal decompression tube
58263872|NCT02585271|DEVICE|Stent|self-expandable colorectal nitinol alloys stent
58263873|NCT00079586|DRUG|Heparin|Unfractionated Heparin per institutional practice
58263874|NCT00079586|DRUG|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
58263875|NCT03128320|DRUG|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
58059925|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
58059926|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
58263876|NCT03128320|DRUG|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
58059927|NCT03376776|PROCEDURE|Vitrectomy|
58059928|NCT02133144|BEHAVIORAL|overeating fat|
58059929|NCT02133144|BEHAVIORAL|overeating carbohydrate|
58059930|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
57912566|NCT05416060|BEHAVIORAL|Project Dulce Telehealth|Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
57912567|NCT05416060|BEHAVIORAL|Project Dulce Live|Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
57912568|NCT04541784|OTHER|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
58059931|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
58059932|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
58059933|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
58059934|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
58059935|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
58263877|NCT03128320|DRUG|Placebo|Single dose of placebo given in the fasted state
58263878|NCT01759316|OTHER|heliox|heliox or oxygen is used in the two groups respectively
58263879|NCT00731757|DRUG|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
58263880|NCT03203759|OTHER|Home hospitalization|See above
58263881|NCT03203759|OTHER|Traditional inpatient hospitalization|See above
58263882|NCT01609309|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
57912569|NCT04541784|OTHER|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
57912570|NCT02220673|DRUG|BHT 0.1%|
57912571|NCT02220673|DRUG|BHT 0.5%|
57912572|NCT02220673|DRUG|Placebo for RMT-B|
57912573|NCT02220673|DRUG|Placebo for HFA-MDI|
58059936|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
58059937|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
58059938|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
58059939|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
58059940|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
58059941|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
58059942|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
58059943|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
58059944|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
58059945|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
58263883|NCT01609309|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
58263884|NCT04385290|DRUG|MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO|"Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7"
57710635|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
58059946|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
58059947|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
58059948|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
58059949|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
58059950|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
58059951|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
58059952|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
58059953|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
58059954|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
58059955|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
58059956|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
58059957|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
58059958|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
58059959|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
58059960|NCT03001726|DRUG|S1|S1 40mg/m2
58059961|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
58059962|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
58059963|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
58059964|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
58059965|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
58059966|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
58059967|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
58059968|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
58059969|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
58059970|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
58059971|NCT02113644|OTHER|Lifestyle intervention|
58059972|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
58059973|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
58059974|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
58059975|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
58059976|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
58059977|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
57912574|NCT00742053|DEVICE|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
57912575|NCT00095732|DRUG|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
58263885|NCT04385290|DRUG|MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
58263886|NCT04385290|DRUG|MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO|"GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
58263887|NCT04385290|DRUG|MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
58384375|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
58384376|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
58384377|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
58384378|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
58384379|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
58384380|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
58384381|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
58384382|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
57912576|NCT00095732|DRUG|Placebo|Administered orally in either Size 2 or Size 5 capsules
57912577|NCT01003678|DRUG|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
57912578|NCT05939531|BEHAVIORAL|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
58384383|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
58059978|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
58059979|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
58059980|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
58059981|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
58263888|NCT04385290|DRUG|MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
58263889|NCT02083185|DRUG|Relugolix|Relugolix tablets
58263890|NCT02083185|DRUG|Leuprorelin|Leuprorelin subcutaneous injection
58263891|NCT01293513|OTHER|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
58263892|NCT00307632|DRUG|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
58263893|NCT02236806|DRUG|Bisoprolol|5 mg daily
58263894|NCT02236806|DRUG|Ramipril|5 mg daily
58263895|NCT02236806|DRUG|Placebo|1 capsule daily
58263896|NCT01112410|OTHER|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
58263897|NCT01112410|OTHER|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
58263898|NCT04848792|DIETARY_SUPPLEMENT|Sulforaphane|Myrosinase-active whole broccoli sprout material
57912579|NCT05939531|BEHAVIORAL|Standard Care|Standard post-stroke care
57912580|NCT01096485|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
57912581|NCT01096485|DRUG|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
58263899|NCT04848792|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
57912582|NCT02729285|DRUG|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
57912583|NCT02729285|DRUG|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
58263900|NCT03641534|PROCEDURE|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
58263901|NCT03641534|PROCEDURE|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
58263902|NCT03641534|PROCEDURE|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
58263903|NCT03641534|PROCEDURE|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
58263904|NCT03641534|PROCEDURE|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
57912584|NCT02729285|PROCEDURE|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
58263905|NCT03641534|PROCEDURE|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
58263906|NCT03641534|PROCEDURE|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
58263907|NCT03641534|PROCEDURE|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
58263908|NCT03641534|PROCEDURE|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
58263909|NCT03641534|PROCEDURE|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
58263910|NCT06406634|DRUG|Cadonilimab|Injectable solution
58263911|NCT06406634|DRUG|Lenvatinib|capsule
58263912|NCT05443438|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
58263913|NCT05443438|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
58263914|NCT05443438|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
58263915|NCT02133794|DEVICE|Tomosynthesis|
57912585|NCT00836420|PROCEDURE|no intervention|the value of the clinical use of microdialysis monitoring of the brain
57912586|NCT02163564|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
57912587|NCT01439152|DRUG|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
57912588|NCT01439152|DRUG|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
57912589|NCT01439152|DRUG|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
58263916|NCT06622265|DEVICE|Electrocardiogram recording|ECG recording with investigational device
58263917|NCT00100113|DRUG|GBR 12909|
58263918|NCT06017817|DEVICE|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
57912590|NCT01439152|DRUG|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
58059982|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
58059983|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
58059984|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
58263919|NCT06017817|PROCEDURE|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
58059985|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
58263920|NCT06017817|PROCEDURE|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
58059986|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
58059987|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
58059988|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
58059989|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
58059990|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
58059991|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
58059992|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
58263921|NCT06017817|PROCEDURE|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
58263922|NCT00774527|DRUG|Cyclophosphamide-fludarabine-anti thymocyte globulin|"* Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
58263923|NCT00004638|PROCEDURE|pathogenesis study|
58263924|NCT05668143|BEHAVIORAL|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
58384384|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
58384385|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
57710636|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
58263925|NCT02426749|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
58384386|NCT00161915|DRUG|Fibrin Sealant|
58384387|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
58384388|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
58384389|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
57710637|NCT00222495|DRUG|quetiapine|
57710638|NCT00222495|DRUG|olanzapine|
57710639|NCT00222495|DRUG|risperidone|
58059993|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
58059994|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
58384390|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
57710640|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
57912591|NCT05293951|DEVICE|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
58384391|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
58384392|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
58384393|NCT01795976|GENETIC|NY-ESO-1 T cells|
57710641|NCT00394797|PROCEDURE|mitral valve annuloplasty|
57710642|NCT02142530|DRUG|Carfilzomib|
57912592|NCT05293951|DEVICE|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
57710643|NCT02142530|DRUG|Belinostat|
58384394|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
58384395|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
57710644|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
57710645|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
57912593|NCT02879474|BEHAVIORAL|Melanoma scale questionnair|
57912594|NCT05353946|DEVICE|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
57912595|NCT00003849|BIOLOGICAL|rituximab|
58384396|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
58384397|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
58384398|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
58384399|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
58384400|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
58384401|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
58384402|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
58384403|NCT02345616|DRUG|Nitric oxide|
57710646|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
57912596|NCT04161625|BEHAVIORAL|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)"
57912597|NCT02973711|DRUG|Nilotinib|Nilotinib 300 mg BID
57912598|NCT02973711|DRUG|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
57912599|NCT06359691|BEHAVIORAL|Patient-focused strategies|"Patient-focused strategies to increase HTN management practices:~1. Hypertension registry: notify patients of their status, target education and resources to patients~2. Home BP monitoring: provide BP monitors, encourage reporting of home BP readings~3. Enhance standardization of home and office BP readings: patients trained by care staff, posters in clinics on how to measure BP correctly~4. Nurse-directed BP medication titration with CHW/Health Educator reinforcement: self-directed referrals to nurse-directed clinics and CHW/health educators~5. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: tailored educational materials offered to patients in clinic, via text and the patient portal.~6. Social needs screening and linkage to community resources: awareness of and self-referrals to community resources~7. Behavioral science intervention messaging: posters in clinic waiting rooms, scripts for RN/PCP, texts to patients"
58059995|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
57710647|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
57710648|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
58263926|NCT02426749|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
58384404|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
57710649|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
57710650|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
57710651|NCT02399150|OTHER|No intervention as observational study|
57710652|NCT00646204|DRUG|Memantine|10 mg bid
57710653|NCT00646204|DRUG|placebo|2 tabs bid
57710654|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
57710655|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
57710656|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
57710657|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
57710658|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
57912600|NCT06359691|BEHAVIORAL|Provider-focused strategies|"Provider-focused strategies to increase HTN management practices:~1. Hypertension registry: identify patients with uncontrolled BP, notify care team~2. Home BP monitoring: provide home BP monitors, encourage reporting of BP readings~3. Enhance standardization of home/office BP readings: staff training, posters in clinic~4. Simplify treatment protocols using fixed-dose combo meds: education on fixed-dose combo meds~5. Nurse-directed BP med titration w/ CHW/Health Educator support: system for team-based care, referral to nurse-directed clinics \& CHWs/health educators~6. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: Increased availability of tailored materials~7. Social needs screening and linkage to community resources: referral system to resources~8. CHW assigned to patients with complex medical and social needs: referral of complex patients to CHWs~9. Behavioral science messaging: posters in charting rooms, scripts for RNs"
57912601|NCT06359691|BEHAVIORAL|Patient- and provider-focused strategies|A combination of the 7 patient-focused strategies (see patient-focused strategies outlined above) and 9 provider-focused strategies (see provider-focused strategies outlined above) implemented simultaneously.
57912602|NCT01426867|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
57912603|NCT01426867|DRUG|Brinzolamide ophthalmic suspension, 1%|
58384405|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
58384406|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
57710659|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
58384407|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
58384408|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
58384409|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
57710660|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
57710661|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
57710662|NCT01826500|OTHER|blood test|blood test
57710663|NCT00226616|DRUG|Zinc|
57710664|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
57912604|NCT01426867|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
57912605|NCT01630746|DRUG|TAK-438|
57912606|NCT01630746|DRUG|TAK-438|
58059996|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
58059997|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
58059998|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
58263927|NCT01335880|BEHAVIORAL|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
58384410|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
57710665|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
57710666|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
57710667|NCT01420081|DRUG|PF-05212384|154mg IV weekly
57710668|NCT01420081|DRUG|PF-05212384|154mg IV weekly
57710669|NCT01420081|DRUG|PF-05212384|154mg IV weekly
58263928|NCT01335880|BEHAVIORAL|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
57710670|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
57710671|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
57710672|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
58263929|NCT06042049|DRUG|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
58263930|NCT05447767|DEVICE|KIT BMAC AND at-SVF FIDIA|intra-articular infiltration or intra-articular and intra-osseous infiltration
58263931|NCT03279796|BIOLOGICAL|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
58263932|NCT03279796|DRUG|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
58263933|NCT00108511|DRUG|Gemfibrozil|
58263934|NCT04909749|GENETIC|Oneome RightMEd Pharmacogenomic testing Kit|The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively
58263935|NCT06394856|PROCEDURE|Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques|rotator cuff tears with modified versus classic double row suture bridge
58263936|NCT01325116|BEHAVIORAL|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
58384411|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
58384412|NCT02103062|DRUG|ABI-007|
57710673|NCT03707288|OTHER|Spine Exercise Program|Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
57710674|NCT00132340|DEVICE|Electrodes|
57710675|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
57710676|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
58384413|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
58384414|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
57710677|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
57710678|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
58384415|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
58384416|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
58384417|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
58384418|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
58384419|NCT02727816|DEVICE|ocufilcon D|test lens
57710679|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
57710680|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
57710681|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
57710682|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
57710683|NCT05521204|DRUG|Olverembatinib|Given PO
57710684|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
57710685|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
57710686|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
57710687|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
57710688|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
57710689|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
57710690|NCT03904459|OTHER|no intervention|
57710691|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
57710692|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
57710693|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
57912607|NCT01703650|DRUG|iopromide|"1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤."
57912608|NCT01703650|PROCEDURE|CT|"1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
57912609|NCT02902874|OTHER|Blood sample|
57710694|NCT01860417|DRUG|Mepivacaine|
57710695|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
57912610|NCT01170611|DEVICE|PACEMAKER SYMPHONY 2550|
57912611|NCT06258226|DRUG|Conventional dosage reduction|The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
58263937|NCT01565369|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
58263938|NCT00312065|DEVICE|Application of reflective heat shield to thermistor probe|
58263939|NCT04754620|OTHER|real time online video visit|Participants have received an online visit by a smartphone application
58384420|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
58384421|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
58384422|NCT02727816|DEVICE|somofilcon A|test lens
58384423|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
58384424|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
58384425|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
57710696|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
57710697|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
57710698|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
57710699|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
57710700|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
57710701|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
57710702|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
57912612|NCT06258226|PROCEDURE|Auricular acupressure|Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.
57912613|NCT06258226|PROCEDURE|Sham auricular acupressure|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
58263940|NCT01513811|DRUG|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
58263941|NCT01513811|DRUG|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
58263942|NCT01513811|DRUG|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
58263943|NCT03812562|BIOLOGICAL|Nivolumab|Given IV
58263944|NCT03812562|RADIATION|Yttrium Y 90 Glass Microspheres|Given IV
58263945|NCT03763461|DEVICE|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
57710703|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
57710704|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
58263946|NCT03763461|DEVICE|Oxygen Mask|Application of oxygen during conscious sedation
58263947|NCT03412188|DRUG|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
58263948|NCT03412188|DRUG|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
58384426|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
58384427|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
57710705|NCT02292628|OTHER|Infusion of placebo|
57710706|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
57710707|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
57710708|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
57912614|NCT05148143|DRUG|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
58263949|NCT06619418|DEVICE|TENS device|will be using an FDA- cleared TENS device for electrical stimulation (TENS 7000, Compass Health Brands) in combination with commercially-available headphones for acoustic stimulation (AKG 845 BT).Will be shown how to use the device, trained on the multimodal stimulation procedure, and sent home with the device for 12 weeks.
58263950|NCT06619418|BEHAVIORAL|Integrative health modalities|will be instructed on the integrative health modalities for this study. They will be given a tablet that includes the videos for the visually guided deep breathing. They will also receive the reflective journal and be set up for health coaching visits. At the end of the 12 weeks, this group of participants will return to the U of M campus and complete an interview about satisfaction and usability of the IH modalities.
58263951|NCT06619119|OTHER|Excape room simulation|"Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time."
58263952|NCT01696149|DEVICE|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
58263953|NCT02619396|PROCEDURE|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
58263954|NCT02619396|PROCEDURE|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
58263955|NCT02619396|PROCEDURE|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
58263956|NCT02619396|PROCEDURE|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
58263957|NCT06619106|OTHER|Cognitive test|Cognitive test based on building blocks
58263958|NCT06616714|OTHER|Observtional Study|Observtional Study
58263959|NCT05657600|BEHAVIORAL|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
58263960|NCT05657600|OTHER|Video-based yoga|Video-based yoga
58263961|NCT05657600|OTHER|Face-to-face yoga|Face-to-face yoga
57912615|NCT04910789|PROCEDURE|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
57912616|NCT04910789|PROCEDURE|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
58263962|NCT05657600|OTHER|physical exercise|physical exercise
58384428|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
58384429|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
58384430|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
58384431|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
58384432|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
57710709|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
57710710|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
57912617|NCT05367154|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
57710711|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
57710712|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
57710713|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
57710714|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
57710715|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
57710716|NCT00073671|OTHER|Usual care|Participants receive usual care
57912618|NCT04304573|DIAGNOSTIC_TEST|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
58263963|NCT03976167|DEVICE|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
58263964|NCT03976167|DEVICE|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
57912619|NCT04913454|OTHER|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
57912620|NCT04913454|OTHER|Cognitive training|Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
57912621|NCT05361525|PROCEDURE|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
58263965|NCT01500408|DRUG|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
58263966|NCT01500408|DRUG|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
58263967|NCT02634268|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
58384433|NCT01899638|DRUG|VI 25 mcg|LABA mono
57710717|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
57710718|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
57710719|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
57710720|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
57710721|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
58263968|NCT05426213|DEVICE|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
57710722|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
57710723|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
57710724|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
57710725|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
57710726|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
58263969|NCT05760742|DIETARY_SUPPLEMENT|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
58384434|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
58384435|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
57912622|NCT05361525|PROCEDURE|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
57912623|NCT02861547|OTHER|death|
57912624|NCT01096277|DRUG|Sitagliptin|oral tablets 100 mg per day for two weeks
57912625|NCT01096277|DRUG|Placebo|oral tablet, one per day for two weeks
57912626|NCT01096277|OTHER|Control|no intervention
57710727|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
57710728|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
57710729|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
57710730|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
57912627|NCT03573726|OTHER|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
58263970|NCT05760742|DIETARY_SUPPLEMENT|Placebo|2 months of supplementation with a placebo (Maltodextrin)
58263971|NCT06318052|DEVICE|The FemTouch delivery system|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology
58263972|NCT06318052|DRUG|Gynomunal gel treatment|hormone/free, vaginal moisturizing gel for women with vaginal dryness
58384436|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
58059999|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
58384437|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
58384438|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
58384439|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
58384440|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
58384441|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
58384442|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
58060000|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
58060001|NCT00192712|DRUG|irinotecan, gemcitabine|
58384443|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
58384444|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
58384445|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
57710731|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
57912628|NCT05450094|BEHAVIORAL|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
58384446|NCT00004744|DRUG|immune globulin|
58384447|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
58384448|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
58384449|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
58384450|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
58384451|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
58384452|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
58384453|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
58384454|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
57710732|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
57710733|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
57710734|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
58384455|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
57710735|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
57710736|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
57710737|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
58263973|NCT01152359|BEHAVIORAL|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
58384456|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
58384457|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
58384458|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
58384459|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
58384460|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
58384461|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
58384462|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
58384463|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
57710738|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
57710739|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
57912629|NCT05450094|BEHAVIORAL|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically supported enhancements: 1) Voluntary school teams will review screening and service receipt data disaggregated by racial/ethnic subgroups to identify and problem solve inequities. 2) Unintentional bias training for voluntary school teams, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 3) Mental Health Literacy training for voluntary school teams in awareness and understanding of students' mental health well-being and need for intervention.
58060002|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
58384464|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
58384465|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
58384466|NCT00343005|BIOLOGICAL|AMA1-C1|
58384467|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
57710740|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
57710741|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
57710742|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
57710743|NCT04441294|BEHAVIORAL|ACE-Plus|
57912630|NCT00950222|DRUG|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
57710744|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
57710745|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
57710746|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
57710747|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
57710748|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
57710749|NCT04090567|DRUG|Cediranib|Given PO
57710750|NCT04090567|DRUG|Ceralasertib|Given PO
57710751|NCT04090567|DRUG|Olaparib|Given PO
57710752|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
57710753|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
57710754|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
57912631|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
57912632|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
57912633|NCT06021171|DIETARY_SUPPLEMENT|Maltodextrin|5 g Maltodextrin
57912634|NCT00334854|DRUG|doxorubicin hydrochloride|
57912635|NCT00334854|DRUG|ifosfamide|
57912636|NCT00334854|PROCEDURE|adjuvant therapy|
57912637|NCT00334854|PROCEDURE|conventional surgery|
58263974|NCT01152359|BEHAVIORAL|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
57912638|NCT00334854|PROCEDURE|neoadjuvant therapy|
57912639|NCT00334854|RADIATION|radiation therapy|
57912640|NCT05480410|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
58263975|NCT00132938|DRUG|telithromycin|
57912641|NCT03787927|DRUG|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
57912642|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
58263976|NCT02101372|BEHAVIORAL|treatment as usual|case management
58263977|NCT02101372|BEHAVIORAL|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
58263978|NCT00327743|DRUG|larotaxel|IV infusion on Day 1 of a 21-day cycle
58263979|NCT00327743|DRUG|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
58263980|NCT04913727|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging before the procedure|CMR image acquisition with previously mentioned analysis
58263981|NCT04913727|PROCEDURE|Transcatheter mitral edge-to-edge repair.|Included patients will undergo Transcatheter mitral edge-to-edge repair.
58263982|NCT06215469|DEVICE|Amma Portable Scalp Cooling System (PSCS)|The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.
58263983|NCT06215469|OTHER|Questionnaires|Quality of Life (QoL) and device usage questionnaires
58384468|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
58384469|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
58384470|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
57710755|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
58263984|NCT04826887|OTHER|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
58384471|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
58384472|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
58384473|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
58384474|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
58384475|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
58263985|NCT04826887|OTHER|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
58384476|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
57912643|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
57912644|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
57912645|NCT03787927|DRUG|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
58263986|NCT03566875|PROCEDURE|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
58263987|NCT03566875|PROCEDURE|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
58263988|NCT06304805|DRUG|cycle 1: treatment drug|for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
58263989|NCT06304805|DRUG|cycle 1: reference drug|for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
58263990|NCT06304805|BEHAVIORAL|cycle 1: fasted|for cycle 1 treatment: participants are asked to take the drug fasted
57710756|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
57710757|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
57710758|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
57710759|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
57710760|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
57710761|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
57710762|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
57710763|NCT02044536|OTHER|No intervention|retrospective data review
57710764|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
57710765|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
57710766|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
57710767|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
57710768|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
57710769|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
57710770|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
57710771|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
57710772|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
57710773|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
57912646|NCT03787927|DRUG|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
57912647|NCT03519906|DRUG|Metoprolol|Patients are tested for their normal prescription metaprolol medication
57912648|NCT06609694|DEVICE|Portable oxygen concentrator Inogen G5 model|The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
58060003|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
57710774|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
57710775|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
57710776|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
57710777|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
58060004|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
58060005|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
58060006|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
58060007|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
58060008|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
58060009|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
57710778|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
58060010|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
58060011|NCT03481634|DRUG|Aflibercept|Intravitreal injection
58060012|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
58060013|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
58060014|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
58263991|NCT06304805|BEHAVIORAL|cycle 1: food|for cycle 1 treatment: participants are asked to take the drug after food intake
57710779|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
57710780|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
57710781|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
57710782|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
58060015|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
58263992|NCT06304805|DRUG|cycle 2: treatment drug|for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
58263993|NCT06304805|DRUG|cycle 2: reference drug|for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
58263994|NCT06304805|BEHAVIORAL|cycle 2: fasted|for cycle 2 treatment: participants are asked to take the drug fasted
58263995|NCT06304805|BEHAVIORAL|cycle 2: food|for cycle 2 treatment: participants are asked to take the drug after food intake
58384477|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
58384478|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
58384479|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
58384480|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
57710783|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
57710784|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
57710785|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
57710786|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
57710787|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
58263996|NCT06304805|DRUG|cycle 3: treatment drug|for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
58263997|NCT06304805|DRUG|cycle 3: reference drug|for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
58263998|NCT06304805|BEHAVIORAL|cycle 3: fasted|for cycle 3 treatment: participants are asked to take the drug fasted
58263999|NCT06304805|BEHAVIORAL|cycle 3: food|for cycle 3 treatment: participants are asked to take the drug after food intake
58264000|NCT02393924|OTHER|No intervention|
58264001|NCT04973059|DEVICE|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
58264002|NCT04973059|DEVICE|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
58264003|NCT00131365|DEVICE|ExAblate 2000|
57710788|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
57710789|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
57710790|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
57710791|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
57710792|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
58384481|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
57710793|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
57710794|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
58384482|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
57710795|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
57710796|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
57710797|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
57710798|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
57710799|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
57710800|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
57710801|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
57710802|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
57710803|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
57710804|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
57710805|NCT00333112|DRUG|solifenacin succinate|Oral
57710806|NCT00333112|DRUG|tamsulosin|oral
58384483|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
58384484|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
58384485|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
57710807|NCT00333112|DRUG|placebo|oral
57710808|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
57710809|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
57710810|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
58060016|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
58264004|NCT01618851|RADIATION|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
58384486|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
58384487|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
57710811|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
58060017|NCT00499161|BEHAVIORAL|New model of nursing care|
57710812|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
58060018|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
58060019|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
58060020|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
57710813|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
57710814|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
57710815|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
57710816|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
57710817|NCT05891236|OTHER|Control|No drug or placebo will be administered.
58264005|NCT03843424|BEHAVIORAL|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
58264006|NCT03843424|BEHAVIORAL|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
57710818|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
57710819|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
57710820|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
57710821|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
57710822|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
57710823|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
57710824|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
57710825|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
57710826|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
57710827|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
57710828|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
58060021|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
58384488|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
57710829|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
57710830|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
57710831|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
58060022|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
58060023|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
58060024|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
58264007|NCT05272696|DRUG|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
58264008|NCT05272696|PROCEDURE|surgery|Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.
58264009|NCT05272696|RADIATION|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
58264010|NCT05272696|DRUG|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
57710832|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
57710833|NCT01178970|BEHAVIORAL|Resistance training|
57710834|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
57710835|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
58384489|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
58384490|NCT05568563|OTHER|Honey|Honey is a natural dietary product
58384491|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
57710836|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
57710837|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
57710838|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
57710839|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
58264011|NCT02440542|OTHER|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
57912649|NCT04200976|BEHAVIORAL|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
57912650|NCT04200976|BEHAVIORAL|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
58060025|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
58060026|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
58060027|NCT04526444|OTHER|Online training|Les Mills On Demand
58060028|NCT04526444|OTHER|Peer support via social media|Facebook group
58060029|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
58060030|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
58060031|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
58264012|NCT05491525|DRUG|Vibegron|Participants will be administered Vibegron orally, once daily (QD)
58264013|NCT05620992|DEVICE|Echocardiography|Echocardiography 3 and 6 months post operative
58060032|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
58060033|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
58060034|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
58264014|NCT04933916|DRUG|EMB-001|Combination product metyrapone and oxazepam
58264015|NCT05119868|OTHER|Nutritional intervention based on Mediterranean Diet|A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
58264016|NCT04395092|BIOLOGICAL|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
58060035|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
58264017|NCT04395092|PROCEDURE|Conditioning Regimen|"From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3."
58060036|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
58264018|NCT04395092|PROCEDURE|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
58264019|NCT00347919|DRUG|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
58384492|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
58384493|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
58384494|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
58384495|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
58384496|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
58384497|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
57710840|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
57710841|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
58264020|NCT00347919|DRUG|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
58264021|NCT00347919|DRUG|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
57912651|NCT03106597|DRUG|Manidipine 20mg|"After a 1\~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
57912652|NCT03106597|DRUG|Amlodipine 10mg|"After a 1\~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
57912653|NCT02054611|OTHER|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
57912654|NCT02054611|OTHER|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
57912655|NCT04224571|DRUG|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
57912656|NCT04224571|DRUG|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
58264022|NCT00347919|DRUG|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
57912657|NCT00662935|PROCEDURE|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
57912658|NCT02531347|BEHAVIORAL|Telemedical home blood pressure measurements|
58264023|NCT05822362|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
58264024|NCT05822362|OTHER|Placebo|Placebo arm.
58264025|NCT01877356|PROCEDURE|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
58264026|NCT01877356|PROCEDURE|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
58264027|NCT02560324|DRUG|Ramelteon|
58264028|NCT02560324|DRUG|Placebo|
58264029|NCT05520970|BIOLOGICAL|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
58264030|NCT00920127|DIETARY_SUPPLEMENT|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
57710842|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
57912659|NCT02531347|BEHAVIORAL|Conventional blood pressure monitoring|
57912660|NCT00207610|BEHAVIORAL|Daily iron supplements of 65 mg a day for 3 months|
58264031|NCT02951845|DRUG|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
58264032|NCT02951845|DRUG|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
58264033|NCT02951845|DRUG|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
58264034|NCT06494332|OTHER|Exercise and stretching programe|It consists in: a serie of mobility exercises, which were used as warp-up; the mobility of the elbow, forearm, wrist and fingers of both upper limbs was worked on; and, exercises were performed to strengthen the muscles of both forearms.
58264035|NCT06649071|OTHER|Naturalistic observation|Naturalistic observation
58384498|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
57912661|NCT00207610|BEHAVIORAL|Universal anemia screening and treatment|
58264036|NCT03573219|RADIATION|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
58384499|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
58384500|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
58264037|NCT01621451|DRUG|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
58264038|NCT01621451|DRUG|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
58264039|NCT00819780|DRUG|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
58264040|NCT00819780|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
58264041|NCT00819780|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
57710843|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
58264042|NCT00043667|DRUG|Daclizumab|
58264043|NCT01835275|BEHAVIORAL|Enhanced Audio|
57710844|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
57710845|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
57710846|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
57912662|NCT00207610|BEHAVIORAL|Selective anemia screening and treatment|
57912663|NCT01845909|OTHER|ECG and survey screening|
57912664|NCT05083000|DRUG|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
58264044|NCT01835275|BEHAVIORAL|Audio|
58264045|NCT05785013|DIETARY_SUPPLEMENT|Zinc|Zinc Supplementation
58384501|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
58384502|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
58384503|NCT01489709|DRUG|Vesicare|oral
57710847|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
57710848|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
57912665|NCT01153958|DRUG|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
57912666|NCT01153958|DRUG|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
57912667|NCT00414037|DRUG|Eszopiclone|
58264046|NCT03441607|DRUG|mHACMb|Active ingredient
58264047|NCT03441607|OTHER|placebo|inactive ingredient
58264048|NCT06620367|PROCEDURE|conventional guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks
58384504|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
58384505|NCT00004215|BIOLOGICAL|filgrastim|
58384506|NCT00004215|BIOLOGICAL|leridistim|
58384507|NCT00004215|DRUG|cytarabine|
58384508|NCT00004215|DRUG|daunorubicin hydrochloride|
58384509|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
57912668|NCT00414037|DRUG|Placebo|Placebo-treatment
57912669|NCT05448612|OTHER|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
57912670|NCT03542461|DRUG|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
58264049|NCT06620367|PROCEDURE|digital guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
58264050|NCT01447927|DRUG|metformin hydrochloride|Given PO QD and BID
58264051|NCT01447927|OTHER|placebo|Given PO QD and BID
58264052|NCT01459718|DRUG|Deferasirox|20-40 mg/kg/day orally, once daily
58264053|NCT01459718|DRUG|Deferoxamine (DFO)|40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
58264054|NCT02066818|DRUG|Lidocaine/tetracaine patch|
58264055|NCT02066818|DRUG|1% lidocaine|
58264056|NCT04246138|PROCEDURE|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
58264057|NCT04206176|DRUG|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
58264058|NCT03258970|OTHER|Observational cohort study|taking vitamin supplements
58264059|NCT00093847|DRUG|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
58264060|NCT00093847|DRUG|Placebo|Placebo to be taken daily for 6 weeks
58264061|NCT02718183|OTHER|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
58264062|NCT02718183|OTHER|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
58384510|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
58384511|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
58384512|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
58384513|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
58384514|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
58384515|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
58384516|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
58384517|NCT00002811|DRUG|liposomal T4N5 lotion|
58384518|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
58384519|NCT01527045|DRUG|Cyclosporine|Given PO
58384520|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
58384521|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
58384522|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
58384523|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
58384524|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
58384525|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
58384526|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
58384527|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
57912671|NCT03542461|OTHER|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
58384528|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
58384529|NCT02423525|DRUG|Afatinib|
57710849|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
58384530|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
58384531|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
58264063|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
58384532|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
58384533|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
58384534|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
58384535|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
58384536|NCT03186092|OTHER|sham muscle training|sham comparator
58384537|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
57912672|NCT03735212|BEHAVIORAL|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
57912673|NCT02409069|DEVICE|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
57912674|NCT02409069|DEVICE|Sham stimulation (Nemos®, Cerbomed GmbH)|
58264064|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
58264065|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
58264066|NCT00971035|DRUG|placebo|Subcutaneous repeating dose
58264067|NCT01004224|DRUG|BGJ398|
58264068|NCT02775877|DRUG|Letrozole|
57710850|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
58384538|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
58384539|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
58384540|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
58384541|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
58384542|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
58384543|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
58384544|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
58384545|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
58384546|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
57710851|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
57710852|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
57710853|NCT00178438|DEVICE|Capsule Endoscopy|
57710854|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
58264069|NCT02775877|DRUG|clomiphene|
58384547|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
58384548|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
58384549|NCT02089932|DRUG|Placebo|
58384550|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
58384551|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
58384552|NCT02122497|PROCEDURE|abdominal aortic surgery|
58264070|NCT02775877|DRUG|HMG|
58264071|NCT05190822|OTHER|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
58264072|NCT02252900|OTHER|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
58384553|NCT03162133|OTHER|Baduanjin exercise|
58384554|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
58384555|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
58384556|NCT00050830|DRUG|CI 1033|
58384557|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
58384558|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
58384559|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
58384560|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
57710855|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
57710856|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
57710857|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
57710858|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
57710859|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
57710860|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
57912675|NCT05399420|DIAGNOSTIC_TEST|Blood sampling|One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
57912676|NCT01738425|DRUG|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
57912677|NCT01738425|DRUG|GIC-1001 matching placebo|"Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]"
57912678|NCT00004404|DRUG|clotrimazole|
57912679|NCT00004404|DRUG|hydroxyurea|
57710861|NCT00591448|OTHER|Virtual Reality (VR)|See above
57912680|NCT02350608|DEVICE|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
58060037|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
57710862|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
57710863|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
57912681|NCT05178667|DIETARY_SUPPLEMENT|High dose|Food supplements are consumed during 3 months by healthy volunteers.
57912682|NCT05178667|DIETARY_SUPPLEMENT|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
57912683|NCT05178667|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
57710864|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
57710865|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
57710866|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
57710867|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
57710868|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
57710869|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
57710870|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
57710871|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
57710872|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
57710873|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
57710874|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
57912684|NCT00729872|BIOLOGICAL|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
57912685|NCT00729872|OTHER|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
57912686|NCT01657851|DRUG|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
58384561|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58264073|NCT04496505|DEVICE|Device|is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
58264074|NCT04496505|DEVICE|Sham Device|The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
58264075|NCT03211923|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
58264076|NCT04007107|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
58264077|NCT04007107|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
57912687|NCT01657851|DRUG|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
57912688|NCT01657851|DRUG|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
57710875|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
57912689|NCT00921596|PROCEDURE|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
57710876|NCT04152447|DEVICE|VR device|Patients use a VR device
58264078|NCT05176626|BEHAVIORAL|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
58384562|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
57912690|NCT05657717|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
57912691|NCT04129697|DRUG|Dexamethasone or Methylprednisolone|steroids
58384563|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58384564|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58384565|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58384566|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58384567|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
58384568|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
57912692|NCT03170999|OTHER|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
57912693|NCT03170999|OTHER|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
57912694|NCT03170999|OTHER|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
58264079|NCT05176626|DRUG|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
58060038|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
58060039|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
58060040|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
58060041|NCT03196206|DRUG|BMS-986177|Oral Suspension
58264080|NCT04306159|PROCEDURE|Subcostal TAP|Subcostal transversus abdominis plane block
58264081|NCT04306159|PROCEDURE|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
58264082|NCT04306159|OTHER|General anesthesia|Traditional general anesthesia management
58264083|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
58264084|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
58264085|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
58264086|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
58264087|NCT00102141|DRUG|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
58264088|NCT01518231|PROCEDURE|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
57710877|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
57710878|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
57710879|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
57710880|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
57912695|NCT00638781|DRUG|Desmoteplase|Desmoteplase 62.5 µg/kg BW
57912696|NCT00638781|DRUG|Desmoteplase|Desmoteplase 90 µg/kg BW
57912697|NCT00638781|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW
57912698|NCT00638781|DRUG|Placebo|Placebo
57912699|NCT04580329|PROCEDURE|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(\>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
57912700|NCT04580329|PROCEDURE|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
57912701|NCT03929757|BIOLOGICAL|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
57912702|NCT03929757|BIOLOGICAL|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
57912703|NCT03929757|BIOLOGICAL|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
58264089|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
58264090|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
58264091|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
58264092|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt.
58264093|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
58264094|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
57710881|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
58384569|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
57710882|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
57710883|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
57710884|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
57710885|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
57710886|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
57710887|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
57710888|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
57710889|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
58384570|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
57710890|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
57710891|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
57710892|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
57710893|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
57710894|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
57710895|NCT04535128|OTHER|No intervention|No intervention
57710896|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
58264095|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
58384571|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
58384572|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
57710897|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
57710898|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
57710899|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
57710900|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
57710901|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
57710902|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
57710903|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
57710904|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
57710905|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
57710906|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
57710907|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
57710908|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
57710909|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
57710910|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
57710911|NCT00909636|DRUG|ABT-333|See arm description for more information
57710912|NCT00909636|DRUG|Placebo|See arm description for more information
57710913|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
57912704|NCT02778854|GENETIC|detection of driver mutation|participants are received gene detection via the liquid biopsy
57710914|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
57710915|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
57710916|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
57710917|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
57710918|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
57710919|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
57912705|NCT01066520|DRUG|Traumeel S ointment|2 g, 3 times daily topical during 14 days
57912706|NCT01066520|DRUG|Traumeel S gel|2 g, 3 times daily topical during 14 days
57912707|NCT01066520|DRUG|Diclofenac gel|2 g, 3 times daily topical during 14 days
57912708|NCT00840151|BEHAVIORAL|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
57710920|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
57710921|NCT00354224|DRUG|capecitabine|
57710922|NCT00354224|DRUG|oxaliplatin|
57710923|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
57710924|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
57710925|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
57710926|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
57710927|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
57710928|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
57912709|NCT06605664|DIAGNOSTIC_TEST|Hyperpolarized 13C pyruvate MRI|The subject enrolled in this trial will receive DNP-MRI scanning for two times through hyperpolarized \[1-13C\]pyruvate injection (\~250 mM, 0.43 mL/Kg) before and 2-5 weeks after radiotherapy.
57710929|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
57912710|NCT02791074|OTHER|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
57912711|NCT02791074|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
57912712|NCT02791074|OTHER|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
57912713|NCT05514782|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
57912714|NCT05514782|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
57912715|NCT05514782|OTHER|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
57912716|NCT05657015|DRUG|Lepidium Sativum|2 ml of LS in situ gel at baseline
57912717|NCT05657015|DRUG|Simvastatin|1.2% of SMV in situ gel at baseline
57912718|NCT06226740|OTHER|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
57912719|NCT03099499|DRUG|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
57710930|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
58384573|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
57710931|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
57710932|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
57710933|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
57710934|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
57710935|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
57710936|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
57710937|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
57912720|NCT04004247|DEVICE|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
57710938|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
57710939|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
57912721|NCT04991532|OTHER||
57912722|NCT01588431|DRUG|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
58384574|NCT00390897|DRUG|Glivec|
58384575|NCT00390897|DRUG|Interferon|
57710940|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
58384576|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
57710941|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
57710942|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
57912723|NCT03187574|DEVICE|Elevate Ant™|Surgery with Elevate Ant™
57912724|NCT03187574|DEVICE|Perigee™|Surgery with Perigee™
57912725|NCT01688687|PROCEDURE|Endoscopic submucosal dissection|
57912726|NCT06477822|PROCEDURE|Sequence of manual therapy techniques|Receive a sequence of manual therapy techniques composed by: suboccipital decompression technique, suboccipital release technique, fourth ventricle compression technique, vagus nerve neurodynamic technique
57912727|NCT06477822|PROCEDURE|Simulated manual therapy techniques|Receive a sequence of simulated manual therapy techniques composed by four maneuvers without effect on autonomic nervous system
57912728|NCT02021097|DRUG|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
57912729|NCT02021097|DRUG|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
57912730|NCT03476213|PROCEDURE|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
57912731|NCT03476213|PROCEDURE|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
57912732|NCT03235284|OTHER|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
58264096|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt
58264097|NCT02260869|PROCEDURE|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
58264098|NCT02260869|DEVICE|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
58264099|NCT00769067|DRUG|Erlotinib|Continuous oral dosing at 150 mg daily.
58264100|NCT00769067|DRUG|PF-00299804|Continuous oral dosing at 45mg daily
58264101|NCT04868851|BEHAVIORAL|Here for Health Only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
58384577|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
58384578|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
58264102|NCT04868851|BEHAVIORAL|mHealth technology assisted exercise counselling|Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
58264103|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
58264104|NCT02048917|DRUG|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
58384579|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
58384580|NCT01928290|DRUG|Irinotecan|
58384581|NCT01928290|DRUG|Trastuzumab|
58384582|NCT01928290|DRUG|Oxaliplatin|
58384583|NCT01928290|DRUG|Leucovorin|
58384584|NCT01928290|DRUG|Fluorouracil|
58384585|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
57710943|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
57710944|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
57710945|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
57710946|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
57710947|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
57710948|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
57710949|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
57912733|NCT03235284|OTHER|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
57912734|NCT03235284|OTHER|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
57710950|NCT06048484|DRUG|Quemliclustat|100 mg IV
57710951|NCT06048484|DRUG|Etrumadenant|150 mg orally
57912735|NCT00306670|DRUG|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
57912736|NCT00306670|DRUG|prednisone|\<30 mg/day
57912737|NCT05420285|DRUG|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
57912738|NCT03801122|DRUG|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
57710952|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
57912739|NCT00541021|DRUG|gemcitabine hydrochloride|
57912740|NCT00541021|DRUG|sorafenib tosylate|
58060042|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
57710953|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
57710954|NCT01486017|DRUG|ASP015K|oral
57710955|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
57710956|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
57710957|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
57710958|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
57710959|NCT01947400|OTHER|Hospitalists|AIDET Training
57710960|NCT02537418|DRUG|durvalumab|
57710961|NCT02537418|DRUG|tremelimumab|
57710962|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
57710963|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
57912741|NCT02305836|PROCEDURE|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
57912742|NCT02305836|DRUG|donepezil|cholinesterase inhibitors (ChE-Is)
57912743|NCT05033873|OTHER|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
58264105|NCT02048917|DRUG|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
57912744|NCT05033873|OTHER|Sling Exercise Therapt (SET)|"1. The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~2. In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~3. The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~4. Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
58264106|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
58264107|NCT02048917|DRUG|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
58264108|NCT02048917|DRUG|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
58384586|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
57912745|NCT05033873|OTHER|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~* Active and passive joint movement~* Muscle strength training~* Bridging exercises~* Balance training in sitting and standing positions, according to the patients' functional state.~* Weight bearing exercises on affected Limbs"
58060043|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
58264109|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
58060044|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
58264110|NCT02048917|DRUG|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
58264111|NCT02048917|DRUG|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
58264112|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
58264113|NCT02048917|DRUG|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
58264114|NCT02048917|DRUG|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
58264115|NCT00960349|DRUG|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
58264116|NCT00960349|DRUG|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
58264117|NCT00960349|DRUG|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
58264118|NCT00960349|DRUG|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
58264119|NCT00960349|DRUG|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
58264120|NCT00000592|PROCEDURE|blood transfusion|
58264121|NCT03090724|DRUG|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
57710964|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
57710965|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
57710966|NCT03112161|OTHER|Eucaloric Feeding Period|
58384587|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
57710967|NCT03112161|OTHER|Overfeeding Feeding Period|
57710968|NCT03112161|OTHER|Underfeeding Feeding Period|
57912746|NCT03322072|DEVICE|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
58264122|NCT03156179|DIAGNOSTIC_TEST|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
58384588|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
58384589|NCT00776542|DRUG|Minocycline 100mg Tablets|
58384590|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
58384591|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
58384592|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
57710969|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
57710970|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
57710971|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
57710972|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
57710973|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
57710974|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
57710975|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
57710976|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
57710977|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
57710978|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
58264123|NCT03276468|DRUG|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
57710979|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
57710980|NCT02932891|DRUG|DSXS topical|topical treatment
57710981|NCT03052582|OTHER|Milk type|
57710982|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
57912747|NCT04822597|DRUG|Lidocaine patch|Lidocaine is a local anesthetic.
58264124|NCT03276468|DRUG|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
57710983|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
57710984|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
57710985|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
57710986|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
57710987|NCT02358746|OTHER|combined endo/epicardial approach|
57710988|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
57710989|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
57710990|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
57710991|NCT00004448|DRUG|omega-3 fatty acids|
57710992|NCT00004448|DRUG|prednisone|
57710993|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
57710994|NCT03662100|DRUG|LY3074828|Administered SC
57710995|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
57710996|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
57710997|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
57710998|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
57710999|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
57711000|NCT03746522|DRUG|Placebo|SC injection of placebo
57711001|NCT01049724|OTHER|Tear collection|Tear collection
57711002|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
58264125|NCT03276468|DRUG|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
58264126|NCT02758444|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
58264127|NCT02758444|DIETARY_SUPPLEMENT|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
58264128|NCT02758444|DIETARY_SUPPLEMENT|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
58264129|NCT02758444|DIETARY_SUPPLEMENT|MNP without Zn|Same as above except MNP will not contain Zn
57711003|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
57711004|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
57711005|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
57711006|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
57711007|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
57711008|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
57711009|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
57711010|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
57711011|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
57711012|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
57711013|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
57711014|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
57912748|NCT04822597|DEVICE|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
57912749|NCT04822597|OTHER|Ice pack|Ice cools the skin and can provide some numbing for pain.
57912750|NCT01583153|OTHER|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
58264130|NCT05754580|RADIATION|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
58264131|NCT05754580|RADIATION|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
58264132|NCT04908215|DRUG|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
58264133|NCT04908215|DRUG|Vehicle Cream|topical cream base for dermal application containing no active agent
58264134|NCT06162845|BEHAVIORAL|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
58384593|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
58384594|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
58264135|NCT06162845|BEHAVIORAL|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
58264136|NCT00279617|DRUG|levetiracetam|open label levetricetam
58264137|NCT06624189|OTHER|Auto-pended bot liver ultrasound order|This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
58264138|NCT05561946|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
58264139|NCT05278338|DRUG|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
58264140|NCT05278338|DRUG|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
58264141|NCT05278338|DRUG|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
58264142|NCT04355429|DRUG|captopril 25mg|Drug administration
57711015|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
57711016|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
57711017|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
57711018|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
57711019|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
58264143|NCT02673801|OTHER|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
57711020|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
58264144|NCT00801281|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
58264145|NCT00801281|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
58264146|NCT00801281|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
57711021|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
57711022|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
57711023|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
57711024|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
57711025|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
57711026|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
57711027|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
57711028|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
57711029|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
58264147|NCT00801281|DRUG|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
58264148|NCT00801281|DRUG|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
58264149|NCT00801281|DRUG|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
58264150|NCT00108485|DRUG|Extended release niacin|Extended release niacin 1500-2000mg once daily
58264151|NCT00108485|OTHER|Placebo|Placebo tablets
58264152|NCT05685862|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
57711030|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
57711031|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
57711032|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
58264153|NCT02879994|OTHER|Laboratory Biomarker Analysis|Correlative studies
58264154|NCT02879994|BIOLOGICAL|Pembrolizumab|Given IV
58264155|NCT05759429|OTHER|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
58264156|NCT05759429|OTHER|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
58264157|NCT04417972|DRUG|SHR7280|treatment
58264158|NCT04417972|DRUG|Placebo oral tablet|blank control
58264159|NCT04792671|BEHAVIORAL|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
57711033|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
57711034|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
57912751|NCT01583153|OTHER|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
57912752|NCT00181064|BEHAVIORAL|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
57912753|NCT04355247|DRUG|MethylPREDNISolone 80 Mg/mL Injectable Suspension|"* Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
57912754|NCT00588185|DRUG|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
57912755|NCT02644486|DRUG|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
57912756|NCT02644486|DRUG|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
57912757|NCT02644486|DRUG|Irbesartan|Irbesartan 300mg/d
57912758|NCT03096704|DIAGNOSTIC_TEST|vitamine d dosage|dosage of vitamine D in slow transit time constipation
57912759|NCT06238518|PROCEDURE|Intravascular Lithotripsy|The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.
58264160|NCT04792671|BEHAVIORAL|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
57912760|NCT06238518|PROCEDURE|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
57912761|NCT06159153|DIAGNOSTIC_TEST|Dynamic Ultrasonography assessment|Ultrasound evaluation that will be compared with an MRI.
57912762|NCT02388685|OTHER|Exercise|Home exercise therapy
57711035|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
57711036|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
57711037|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
57711038|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
58264161|NCT04792671|BEHAVIORAL|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
57711039|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
57711040|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
57711041|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
57711042|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
57711043|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
57711044|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
57711045|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
57711046|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
57711047|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
57711048|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
57711049|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
57711050|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
57711051|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
57711052|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
57912763|NCT02909530|DEVICE|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
57912764|NCT02909530|DEVICE|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
57912765|NCT02703090|DRUG|Remifentanil|
57912766|NCT02703090|DRUG|Normal saline|
57711053|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
57711054|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
57912767|NCT03999996|BIOLOGICAL|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
57711055|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
57711056|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
57912768|NCT03999996|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
57912769|NCT03239613|OTHER|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
57912770|NCT04275089|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
58384595|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
57711057|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
57711058|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
57912771|NCT04280341|BIOLOGICAL|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
58384596|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
57912772|NCT04307251|DEVICE|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
57912773|NCT04307251|DEVICE|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
58060045|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
58264162|NCT04792671|BEHAVIORAL|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
58060046|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
58060047|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
58060048|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
58060049|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
58060050|NCT01890733|DEVICE|InSpace™ system|
58060051|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
58264163|NCT02603068|DRUG|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
58384597|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
58060052|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
58060053|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
58060054|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
58264164|NCT02042300|DEVICE|XIENCE Xpedition/Alpine/Sierra|
58264165|NCT03170466|BEHAVIORAL|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
58264166|NCT03337581|DRUG|Dexmedetomidine|see arms
58264167|NCT01283334|DRUG|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
58384598|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
58384599|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
57711059|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
57711060|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
58264168|NCT01283334|DRUG|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
58264169|NCT01283334|DRUG|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
58384600|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
58060055|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
58060056|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
58384601|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
58384602|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
58384603|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
58384604|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
58384605|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
58384606|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
58384607|NCT00235222|DRUG|stavudine|
57711061|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
57711062|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
58060057|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
58060058|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
58264170|NCT04428242|DEVICE|RHMS-RTM|Assessment of retinal thickness.
58264171|NCT04428242|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure.
58264172|NCT06648330|PROCEDURE|Paraaortic retroperitoneal lymph node dissection|The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
58264173|NCT02407054|DRUG|LY3023414|Administered orally
58264174|NCT02407054|DRUG|Enzalutamide|Administered orally
58384608|NCT02270658|DEVICE|CPAP|
58384609|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
58384610|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
58384611|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
58384612|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
58384613|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
57912774|NCT01351831|OTHER|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
58060059|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
58264175|NCT02407054|DRUG|Placebo|Administered orally
58264176|NCT04678427|OTHER|6 Minute Walk Functional Test|Complete 6-minute walk test
58264177|NCT04678427|BEHAVIORAL|Behavioral Intervention|Participate in walking and other activities
58264178|NCT04678427|OTHER|Survey Administration|Complete survey
58264179|NCT04678427|BEHAVIORAL|Timed Get Up and Go Test|Complete timed get up and go test
58264180|NCT05795920|DRUG|Utidelone injection in combination with gemcitabine|Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
58264181|NCT04958148|DIETARY_SUPPLEMENT|Salt pills|Subjects will supplement salt pills with meals.
58264182|NCT04958148|DIETARY_SUPPLEMENT|Placebo pills|Subjects will supplement placebo pills with meals.
58264183|NCT02971475|PROCEDURE|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
58264184|NCT02971475|PROCEDURE|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
58384614|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
58384615|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
58384616|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
57711063|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
57711064|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
57711065|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
57711066|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
57711067|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
57711068|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
57912775|NCT01351831|OTHER|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
57912776|NCT04806542|BEHAVIORAL|TMR-group|A mindfulness-based 8 week program.
57912777|NCT04806542|BEHAVIORAL|Treatment as usual|Individual counselling.
58060060|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
58060061|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
58264185|NCT02971475|DRUG|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
58264186|NCT02909829|DEVICE|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
58264187|NCT02909829|DEVICE|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
58264188|NCT02909829|DEVICE|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
58264189|NCT05428202|DRUG|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
58264190|NCT05428202|DRUG|Placebo|Placebo cream containing base without active ingredients
58264191|NCT03205735|DIAGNOSTIC_TEST|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
58264192|NCT00276185|DRUG|Time delay treatment of botulinum toxin|
58264193|NCT02564445|BEHAVIORAL|Gamification|All participants will be entered with their teammate into a game that includes points and levels
58264194|NCT02564445|BEHAVIORAL|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
58264195|NCT02564445|BEHAVIORAL|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
58264196|NCT02564445|BEHAVIORAL|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
58264197|NCT00449228|PROCEDURE|-preoperative education and total hip replacement|-preoperative education and total hip replacement
58384617|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
58384618|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
58384619|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
58384620|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
58384621|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
58384622|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
58384623|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
58384624|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
58384625|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
58264198|NCT01004406|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
58264199|NCT01004406|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
58264200|NCT02004899|DRUG|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
58264201|NCT05002517|DRUG|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
58264202|NCT05002517|DRUG|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
58264203|NCT04655248|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
58264204|NCT01883947|PROCEDURE|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
58264205|NCT01883947|OTHER|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
58264206|NCT00231439|DRUG|IvIg|
58384626|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
58264207|NCT01439022|BEHAVIORAL|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
58264208|NCT01439022|BEHAVIORAL|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
58264209|NCT00215527|DRUG|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
58384627|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
58384628|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
58384629|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
58384630|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
58384631|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
57711069|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
57711070|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
58384632|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
58384633|NCT02955888|DRUG|Placebo|Comparator
58384634|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
58384635|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
58384636|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
58384637|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
57912778|NCT01248546|PROCEDURE|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
57912779|NCT03367650|DIETARY_SUPPLEMENT|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
58060062|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
58384638|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
57711071|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
57711072|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
57711073|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
57711074|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
57711075|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
58060063|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
58060064|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
58060065|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
58060066|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
58264210|NCT03785509|DRUG|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
58384639|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
57912780|NCT06463561|DEVICE|Continuous positive airway pressure|Treatment will start with an empirical pressure of 8 cmH2O and, within a maximum of 3 weeks, the pressure will be adjusted by means of automatic titration, establishing the pressure corresponding to the 95th percentile.
57711076|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
57711077|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
57711078|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
57711079|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
57711080|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
57711081|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
57912781|NCT06463561|OTHER|Hygienic-dietary recommendations and daily physical activity promotion|Hygienic-dietary recommendations on sleep and intervention for the promotion of daily physical activity, establishing walking as a goal 10,000 steps per day. To do this, they will be provided with a pedometer and asked to fill out a form with the steps walked each day. At each visit, the distance walked will be reviewed and the goal set will be reiterated.
57711082|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
57711083|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
57912782|NCT05963373|DIAGNOSTIC_TEST|Urine analysis|Diagnostic test
57912783|NCT00297687|BIOLOGICAL|MnB rLP2086|
57711084|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
57711085|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
57912784|NCT00520169|DRUG|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
57912785|NCT00095498|DRUG|placebo|placebo subcutaneous injection
57711086|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
57912786|NCT00095498|DRUG|denosumab|For subcutaneous injection
57912787|NCT03983629|OTHER|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
58060067|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
58060068|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
58060069|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
58060070|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
58060071|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
58264211|NCT06638385|PROCEDURE|DCE + SPACE SHIELD|Patients receive a DCE with implantation of a space-expanding shield.
58060072|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
58264212|NCT06638385|PROCEDURE|DCE + CP|Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
58384640|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
57711087|NCT00243516|DEVICE|PREtest Consult|
57711088|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
57711089|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
57711090|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
57711091|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
57711092|NCT02517905|DRUG|Bupivacaine liposome|Local administration
57711093|NCT02517905|DRUG|Placebo|Local administration
57711094|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
58060073|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
58060074|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
58060075|NCT01225211|DRUG|Lumacaftor|Tablet
58264213|NCT03338543|DEVICE|PENS|percutaneous electrical nerve stimulation
58264214|NCT03338543|DEVICE|TENS|transcutaneous electrical nerve stimulation
58264215|NCT05970016|DRUG|TCC1727 tablet|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
57711095|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
57912788|NCT05421507|RADIATION|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
58060076|NCT01225211|DRUG|Ivacaftor|Tablet.
58264216|NCT00072436|DRUG|gemcitabine hydrochloride|Given IV
58264217|NCT00072436|DRUG|alvocidib|Given IV
58264218|NCT00072436|OTHER|pharmacological study|Correlative studies
57711096|NCT02111252|DRUG|TAK-850|TAK-850 injection
57711097|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
57912789|NCT04533568|DRUG|Ibuprofen 400 mg|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
57912790|NCT04533568|DRUG|Dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
58060077|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
58060078|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
58060079|NCT02227433|DRUG|Brentuximab Vedotin|
58060080|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
58060081|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
58264219|NCT05839106|DRUG|PM1032 injection|Subjects will receive PM1032 by intravenous administration.
58264220|NCT06618833|OTHER|Collection of medical data|Collection of medical data focused on the history of atrial fibrillation by the principal investigator
58264221|NCT06618833|BEHAVIORAL|Collection of global health elements|Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient
58264222|NCT06618833|BEHAVIORAL|PROMIS global questionnaire|"The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense"
58264223|NCT06618833|BEHAVIORAL|Collection of sociological data|Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
58264224|NCT03576534|OTHER|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
58264225|NCT06623253|OTHER|not aplicable|no intervention
58264226|NCT02455609|PROCEDURE|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
58264227|NCT02455609|DRUG|Dexmedetomidine|
58264228|NCT02455609|DRUG|ketamine|
58264229|NCT02455609|DRUG|Bupivacaine|
58264230|NCT06623110|BIOLOGICAL|RP2 Injection|Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
57711098|NCT01856543|OTHER|Eucerin|
57711099|NCT01856543|OTHER|Mometasone Furoate 0.1%|
58384641|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
57912791|NCT03639467|DRUG|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
58060082|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
58060083|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
58060084|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
58060085|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
57711100|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
57711101|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
57711102|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
57711103|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
57711104|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
57711105|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
57711106|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
57711107|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
57711108|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
57711109|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
57711110|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
58264231|NCT00688233|DEVICE|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
57711111|NCT04340882|DRUG|Docetaxel|Given IV
58264232|NCT02381938|BEHAVIORAL|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
57711112|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
58264233|NCT02381938|OTHER|Healthy Finances|6-month intervention to educate and improve financial health
58264234|NCT01942317|OTHER|Balneotherapy|
58384642|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
58384643|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
58384644|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
58384645|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
58384646|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
58264235|NCT01563367|DRUG|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
58384647|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
57711113|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
58264236|NCT01563367|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
58264237|NCT02794701|OTHER|People with silicosis|
58384648|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
58384649|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
58384650|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
58384651|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
58384652|NCT05490316|DRUG|placebo|placebo
58384653|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
58384654|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
57711114|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
57711115|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
57711116|NCT00231608|DRUG|topiramate|
57711117|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
57711118|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
57711119|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
58060086|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
57711120|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
57912792|NCT06255327|OTHER|I COUGH care program|"The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees."
57912793|NCT05614154|OTHER|hypochlorous active substance|Poviodin iyot
58060087|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
58060088|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
58060089|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
58060090|NCT00337740|PROCEDURE|endoscopic variceal banding|
58384655|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
58384656|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
58384657|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
58384658|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
57711121|NCT05178849|OTHER|Hypnosis|Hypnosis
57912794|NCT05621577|DEVICE|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
57912795|NCT05166187|OTHER|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
57912796|NCT00781287|DRUG|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
57912797|NCT00781287|DRUG|Raltegravir|400 mg BID PO
58060091|NCT00337740|DRUG|propranolol|
58060092|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
58060093|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
58060094|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
58060095|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
58060096|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
58060097|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
58060098|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
58060099|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
58384659|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
58384660|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
58384661|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
58384662|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
58384663|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
58384664|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
58384665|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
58060100|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
58060101|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
58060102|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
58060103|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
58060104|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
58060105|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
58060106|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
58060107|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
58060108|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
58060109|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
58384666|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
58384667|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
58384668|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
57711122|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
58264238|NCT06382441|BEHAVIORAL|tele-exercise|It is a prospective and pilot study of RCT. It will be a pilot to test acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
58384669|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
58384670|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
57912798|NCT00521066|DEVICE|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
57912799|NCT03856554|PROCEDURE|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
58060110|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
58060111|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
58060112|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
58060113|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
58384671|NCT01030120|DRUG|placebo|placebo
57711123|NCT01689896|DRUG|Testosterone Gel|
57711124|NCT01689896|DRUG|Placebo Gel|
58060114|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
58264239|NCT02021136|DEVICE|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
58384672|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
57711125|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
58384673|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
58384674|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
57912800|NCT03856554|PROCEDURE|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
57912801|NCT03786523|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
57711126|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
57711127|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
57711128|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
57912802|NCT03786523|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
57912803|NCT04665570|DRUG|BAY81-9783 (Acarbose/Metformin)|Tablet (FDC of 25/50mg acarbose + 500mg metformin), three times daily
57912804|NCT03193359|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
57711129|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
57711130|NCT03865290|DRUG|Placebo|Oral matched placebo
57711131|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
57711132|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
57711133|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
57711134|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
57711135|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
57711136|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
57711137|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
57711138|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
57711139|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
57711140|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
57711141|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
57711142|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
57711143|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
57711144|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
57711145|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
58060115|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
58060116|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
57711146|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
57711147|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
57711148|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
57711149|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
57711150|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
58060117|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
58060118|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
58060119|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
58060120|NCT02362256|DRUG|Naltrexone|
58060121|NCT02362256|DRUG|Clonidine|
58060122|NCT02362256|DRUG|Lorazepam|
58264240|NCT02021136|OTHER|Control|Usual antalgic treatment + physical exercises recommendations
58264241|NCT05410041|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.
58264242|NCT01588457|DRUG|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
58264243|NCT01588457|DRUG|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
58060123|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
58060124|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
58060125|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
58060126|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
58060127|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
58060128|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
58060129|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
58060130|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
58264244|NCT01588457|DRUG|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
58264245|NCT01588457|DRUG|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
58060131|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
58264246|NCT03289598|BEHAVIORAL|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
58060132|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
58264247|NCT05168878|BEHAVIORAL|30-second BeSMART video|30 second video focused on education about child gun deaths and responsible gun storage
58264248|NCT05168878|BEHAVIORAL|3-minute BeSMART video|3-minute video focused on education about child gun deaths and responsible gun storage
58264249|NCT02594189|OTHER|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
58264250|NCT06157112|OTHER|Lifestyle behaviour (exposure in a observational study)|Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
58264251|NCT05849922|DRUG|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
58264252|NCT05849922|DRUG|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
58264253|NCT04291105|BIOLOGICAL|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
58060133|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
58060134|NCT01431456|DRUG|Dabigatran|Dabigatran
58060135|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
58060136|NCT01431456|DRUG|Nadroparin|Nadroparin
58060137|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
58264254|NCT04291105|BIOLOGICAL|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
58264255|NCT02012465|BIOLOGICAL|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~* Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~* The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
58264256|NCT06466876|BEHAVIORAL|retrieval-based word learning|Word learning intervention that compares two strategies for teaching novel words
58264257|NCT02620241|OTHER|sitting position|
58264258|NCT04799548|DRUG|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
58264259|NCT04799548|DRUG|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
58264260|NCT03506568|DEVICE|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
57711151|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
57711152|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
57711153|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
57912805|NCT04140019|DIAGNOSTIC_TEST|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
57912806|NCT00001396|DEVICE|Paragon Pacemaker|
57912807|NCT03447808|BIOLOGICAL|Daratumumab|Given IV
57912808|NCT03447808|DRUG|Ibrutinib|Given PO
57912809|NCT03447808|OTHER|Laboratory Biomarker Analysis|Correlative studies
58264261|NCT06188702|DRUG|S095035|S095035 will be taken orally once daily in 28-day cycle.
58384675|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
58384676|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
58384677|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
58384678|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
57711154|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
57912810|NCT03447808|OTHER|Pharmacological Study|Correlative studies
57912811|NCT02337751|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
57912812|NCT03857620|OTHER|Best Practice|Receive usual care
57912813|NCT03857620|OTHER|Informational Intervention|Receive OPTI-Surg program materials
57912814|NCT03857620|OTHER|Questionnaire Administration|Ancillary studies
57912815|NCT03857620|OTHER|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
57912816|NCT03451617|DEVICE|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
57912817|NCT03451617|DEVICE|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
57912818|NCT05381610|DEVICE|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
58060138|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
58060139|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
58060140|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
58060141|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
58060142|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
58060143|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
58060144|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
58264262|NCT03257878|OTHER|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
57711155|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
57912819|NCT05782023|BEHAVIORAL|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
57912820|NCT04634929|PROCEDURE|bariatric surgery|bariatric surgery
57912821|NCT04634929|DIETARY_SUPPLEMENT|conservative diet|conservative diet
57912822|NCT04496531|DEVICE|Portable Neuromodulation Stimulator|
57912823|NCT01465529|DRUG|OligoG CF-5/20|6% OligoG CF-5/20 in water
57912824|NCT01465529|DRUG|Saline|0.9% NaCl in water
57912825|NCT03970070|OTHER|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
57912826|NCT03970070|OTHER|Quality-of-Life Assessment|Ancillary studies
57912827|NCT03970070|OTHER|Questionnaire Administration|Ancillary studies
58060145|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
58264263|NCT06118814|OTHER|Body Awareness Therapy Exercise|Body awareness therapy exercises were applied to the subjects in this group.
58264264|NCT06118814|OTHER|Virtual Reality Exercise|Virtual reality exercises were applied to the subjects in this group.
58264265|NCT06118814|OTHER|Core Stability Exercise|Core stabilization exercises were applied to the subjects in this group.
58384679|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
57711156|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
57711157|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
57711158|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
57711159|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
57711160|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
58060146|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
57912828|NCT03970070|OTHER|Survey Administration|Ancillary studies
58060147|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
57912829|NCT01315353|PROCEDURE|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
57912830|NCT01315353|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
57912831|NCT05830045|DRUG|QLP2117|Specified dose on specified days
57912832|NCT03736473|DRUG|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
57912833|NCT01685671|DRUG|NESP 60μg|Administrated NESP 60μg once subcutaneously
57912834|NCT01685671|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
57912835|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
57912836|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
57912837|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
57912838|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
58384680|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
58384681|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
57912839|NCT00284817|DRUG|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
58264266|NCT06118814|OTHER|Home Exercise|Subjects in this group implemented a home exercise program.
57912840|NCT05025046|DIAGNOSTIC_TEST|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
57711161|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
57912841|NCT04524325|OTHER|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
57912842|NCT04460885|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
57912843|NCT04460885|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
57912844|NCT04041531|OTHER|blood sampling|venous blood sampling for oxygen affinity in-vitro test
58264267|NCT00274313|DRUG|552-02|
58264268|NCT04982068|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
58264269|NCT04982068|BIOLOGICAL|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
58264270|NCT04982068|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
58264271|NCT04982068|OTHER|Placebo|Normal saline solution
58264272|NCT00643461|DEVICE|Adhesive A|Applied per manufacturer's instructions.
58384682|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
58384683|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
57711162|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
57711163|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
57711164|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
57711165|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
57711166|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
57912845|NCT01496482|OTHER|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
57912846|NCT02375178|DRUG|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
57912847|NCT02375178|DRUG|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
57912848|NCT02375178|DRUG|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
57912849|NCT05747053|DIAGNOSTIC_TEST|AlloSure|AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
57912850|NCT05747053|DIAGNOSTIC_TEST|PAXGene|1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
58264273|NCT00643461|DEVICE|Adhesive B|Applied per manufacturer's instructions.
58264274|NCT00643461|DEVICE|Adhesive C|Applied per manufacturer's instructions.
58264275|NCT03707119|OTHER|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
58264276|NCT00212472|DRUG|Factor VIII concentrates|To be determined at the discretion of the investigator.
58264277|NCT00212472|OTHER|Low-dose treatment|50 FVIII u/kg three times a week.
58264278|NCT00212472|OTHER|High-dose treatment|200 FVIII u/kg per day.
58264279|NCT03435224|DEVICE|INVSENSOR00012|Noninvasive pulse oximeter sensor
58264280|NCT03203928|BEHAVIORAL|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
58264281|NCT06107946|OTHER|USD questionnaire|After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
58264282|NCT05107791|DRUG|Stulln Eyedrops|Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
58264283|NCT05107791|DRUG|Thera Tears|The eyedrops will be used in the identical manner as Stulln eyedrops.
58264284|NCT02945397|BEHAVIORAL|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
58264285|NCT02945397|BEHAVIORAL|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
58264286|NCT02920541|DRUG|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
58264287|NCT06648941|PROCEDURE|Muscle release|supraspinatus muscle release
58264288|NCT02824016|BIOLOGICAL|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
58264289|NCT02824016|RADIATION|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
58264290|NCT06250907|PROCEDURE|The guidance of dynamic navigation|Osteotomy and implant placement with the guidance of dynamic navigation
58384684|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
57711167|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
57711168|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
57711169|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
57711170|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
57711171|NCT02188368|DRUG|POM|
57711172|NCT02188368|DRUG|Steroids|
57711173|NCT02188368|DRUG|PLD|
58264291|NCT06250907|PROCEDURE|The guidance of static template|Osteotomy and implant placement with the guidance of static template
58264292|NCT02607852|DEVICE|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
58264293|NCT00182598|PROCEDURE|computer-based psychoeducational intervention|
58264294|NCT00182598|PROCEDURE|community-based substance abuse counseling|
58264295|NCT06158815|OTHER|proprioceptive neuromuscular facilitation exercise|The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
58264296|NCT04990349|DRUG|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
58264297|NCT00082017|DRUG|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days."
58264298|NCT05400733|DIETARY_SUPPLEMENT|Total Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
58264299|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
58264300|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
58384685|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
58384686|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
58384687|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
58384688|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
58384689|NCT01930604|DRUG|NaCl (placebo)|
58384690|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
58384691|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
57711174|NCT02188368|DRUG|CFZ|
57711175|NCT02188368|DRUG|BTZ|
57711176|NCT02188368|DRUG|CLA|
57711177|NCT02188368|DRUG|CY|
57912851|NCT05778669|OTHER|Monitoring of medical, health and psychosocial conditions|"Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system."
57912852|NCT05184023|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
57912853|NCT05184023|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
57912854|NCT03299868|DEVICE|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
57711178|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
57711179|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
57711180|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
57912855|NCT03125720|OTHER|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
57711181|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
57711182|NCT05418556|DRUG|aspirin|DAPT strategy
57711183|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
57711184|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
57912856|NCT05682391|OTHER|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
58264301|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Leucine|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
58264302|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids High|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
58264303|NCT05400733|DIETARY_SUPPLEMENT|Placebo Water|Water
58264304|NCT02611505|DRUG|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
58264305|NCT00771251|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
58384692|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
58384693|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
58384694|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
58384695|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
58384696|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
58384697|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
58384698|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
58384699|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
58384700|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
58384701|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
57912857|NCT03639831|DIETARY_SUPPLEMENT|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
58264306|NCT00771251|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
58264307|NCT01279070|BEHAVIORAL|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
57711185|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
57711186|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
57711187|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
58384702|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
58384703|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
58384704|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
58384705|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
58384706|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
58384707|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
58384708|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
57912858|NCT03639831|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|2 capsules/ day providing no active component
58264308|NCT01470781|BEHAVIORAL|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
58264309|NCT01470781|BEHAVIORAL|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
58264310|NCT00022243|DRUG|batabulin sodium|
58264311|NCT04250350|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
58384709|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
58384710|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
58384711|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
58384712|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
58384713|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
58384714|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
57912859|NCT00700973|BEHAVIORAL|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
57912860|NCT00700973|OTHER|Usual care|Substance use disorder usual care
57912861|NCT02611791|DEVICE|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
58264312|NCT01241877|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin
58384715|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
58384716|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
58384717|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
58384718|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
58384719|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
58384720|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
58384721|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
58264313|NCT01241877|DIETARY_SUPPLEMENT|placebo|placebo
58264314|NCT00028899|DRUG|asparaginase|
58264315|NCT00028899|DRUG|cytarabine|
58384722|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
57711188|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
57711189|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
57711190|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
57711191|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
57711192|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
57711193|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
57711194|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
57912862|NCT02611791|DEVICE|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
58060148|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
58264316|NCT00028899|DRUG|gemtuzumab ozogamicin|
58264317|NCT00028899|DRUG|mitoxantrone hydrochloride|
58264318|NCT01122407|DRUG|L-NMMA|L-NMMA 250 ug/Kg/min
58264319|NCT01122407|DRUG|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
58384723|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
57711195|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
57711196|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
57711197|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
57711198|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
57912863|NCT04979650|DRUG|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
57912864|NCT04979650|DRUG|Normal saline|500 g of normal saline without methylprednisolone succinate
58384724|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
58384725|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
58384726|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
57912865|NCT00277576|BIOLOGICAL|ppdpSC18 administered by PMED|
57912866|NCT04980443|DIAGNOSTIC_TEST|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
57912867|NCT03623854|BIOLOGICAL|Nivolumab|Given IV
57912868|NCT03623854|BIOLOGICAL|Relatlimab|Given via infusion
58060149|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
58060150|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
58060151|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
58264320|NCT06619301|DRUG|Insulin glargine|Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
58264321|NCT06619301|DRUG|insulin NPH|Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
58384727|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
58384728|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
57912869|NCT06087926|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
57711199|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
57711200|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
57711201|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
57711202|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
57711203|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
57711204|NCT02128295|DEVICE|Electric breast pump - A|
57711205|NCT02128295|DEVICE|Electric breast pump - B|
57711206|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
57711207|NCT02107703|DRUG|Abemaciclib|Administered Orally
57711208|NCT02107703|DRUG|Fulvestrant|Administered IM
57912870|NCT03389906|OTHER|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
57912871|NCT02667197|OTHER|Algorithm to determine overdose from opioid abuse|
58060152|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
58384729|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
58384730|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
58384731|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
58384732|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
57711209|NCT02107703|DRUG|Placebo|Administered Orally
58060153|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
58384733|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
58384734|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
58384735|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
58384736|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
58384737|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
58384738|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
58384739|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
58384740|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
58384741|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
58384742|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
58384743|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
57711210|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
58264322|NCT02273271|OTHER|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
58384744|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
58384745|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
57711211|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
57711212|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
57711213|NCT00284531|DRUG|Daclizumab|
57711214|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
58384746|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
58384747|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
58384748|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
58384749|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
57711215|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
57711216|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
58384750|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
58384751|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
57711217|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
57711218|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
57711219|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
58264323|NCT06258928|DIAGNOSTIC_TEST|Functional examination|Compared to nonoperated limb, after 6 months of early rehabilitation.
58264324|NCT05481528|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
58264325|NCT05481528|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant
58264326|NCT05481528|DRUG|Placebo|Single oral dose of placebo
57711220|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
57711221|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
57711222|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
57912872|NCT06168552|DIAGNOSTIC_TEST|Injection of fluorescent developer (anti-EGFR-IR800CW)|The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
58264327|NCT01609166|DRUG|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
58264328|NCT01609166|DRUG|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
58384752|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
57711223|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
57711224|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
57711225|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
57711226|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
57711227|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
57711228|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
57711229|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
57711230|NCT01158625|OTHER|Change of time of administration|Change of time of administration
57711231|NCT02189187|BEHAVIORAL|Mindfulness|
57711232|NCT02189187|BEHAVIORAL|Psychoeducation|
57711233|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
57912873|NCT00978796|DRUG|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
58060154|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
58060155|NCT01996228|DEVICE|Stem Cell Educator|
58060156|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
58060157|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
58264329|NCT02312869|OTHER|No intervention|not applicable, observational study
58264330|NCT06620835|BIOLOGICAL|Blood samples for Hematology|Complete blood count will include erythrocytes, neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, leukocytes, hemoglobin, hematocrit.
58264331|NCT06620835|BIOLOGICAL|Blood samples for Chemistry|Clinical chemistry will include serum electrolytes (sodium, potassium, calcium, corrected calcium for hypoalbuminemia), creatinine, CrCl with local formula, and fasting blood glucose.
58264332|NCT06620835|BIOLOGICAL|Blood sample for liver function tests|Laboratory tests to assess liver function will include Aminotransferase Alanine (ALAT), Aminotransferase Aspartate (ASAT), Phosphatase Alkaline (ALP), Gamma-glutamyl Transferase (GGT), total and conjugated bilirubin.
58384753|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
58384754|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
58384755|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
58384756|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
58384757|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
58384758|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
58384759|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
57711234|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
58384760|NCT01435694|BEHAVIORAL|Conventional Therapy|
57711235|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
57711236|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
57711237|NCT00179413|DRUG|PEG -Intron|
57711238|NCT00179413|DRUG|Colchicine|0.6mg twice a day
57711239|NCT00803127|DEVICE|vs-sense|detection swab
57711240|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
57711241|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
58060158|NCT01228084|OTHER|Pharmacological study|Correlative studies
58060159|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
58060160|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
58060161|NCT02306291|DRUG|Etoposide|induction chemotherapy
58060162|NCT02306291|DRUG|Cytarabine|induction chemotherapy
58060163|NCT02306291|DRUG|Idarubicin|induction chemotherapy
58060164|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
58384761|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
58384762|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
57711242|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
57711243|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
57711244|NCT05571059|DRUG|Placebo|Matching oral placebo
57711245|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
58060165|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
58264333|NCT06620835|BIOLOGICAL|Pregnancy test|Pregnancy test will be performed in women of childbearing potential, including women who have had a tubal ligation. Childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy or not being postmenopausal (≥12 months of amenorrhea). Urine pregnancy tests will be based on the measurement of β-Human Chorionic Gonadotropin (HCG). If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed at screening.
58264334|NCT06620835|PROCEDURE|Tumour assessment|Tumor assessment according to the RECIST v1.1 include the following radiological evaluation: thoracic CT scan, brain MRI or CT scan (MRI is preferred), abdominopelvic scan, PET-CT scan mandatory and at the Investigator's discretion, if needed bone scintigraphy and chest X-ray.
58264335|NCT06620835|PROCEDURE|Local Ablative Therapy (LAT)|Local Ablative Treatment (LAT) (stereotactic body radiotherapy, surgery, thermal ablation)
58264336|NCT05320107|DRUG|Ketamine|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
58264337|NCT05320107|DRUG|Placebo|0.9% NaCl
58264338|NCT00902343|PROCEDURE|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
58264339|NCT00902343|PROCEDURE|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
58264340|NCT03147131|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
58264341|NCT00493233|DRUG|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
58264342|NCT00493233|DRUG|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
57711246|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
57711247|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
57711248|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
58060166|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
57711249|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
57711250|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
57711251|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
57711252|NCT01849705|OTHER|No intervention|
57711253|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
57711254|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
57711255|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
57711256|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
57711257|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
57711258|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
58060167|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
58384763|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
58264343|NCT06255379|DRUG|Fuquinitinib+Tegafur Gimeracil Oteracil|Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
58264344|NCT00373958|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
57912874|NCT00978796|DRUG|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
58264345|NCT00373958|BIOLOGICAL|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
58060168|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
58384764|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
58060169|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
57711259|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
58060170|NCT00645736|OTHER|No intervention|No intervention
58264346|NCT01650545|DRUG|Liposomal aerosol cyclosporine|inhaled form of immune suppression
58264347|NCT01650545|OTHER|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
58264348|NCT06622473|DEVICE|hand dexterity assessement|Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
58264349|NCT00240955|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
58264350|NCT01984489|DRUG|Placebo|
58264351|NCT01984489|DRUG|SHR117887|
57912875|NCT06422468|DEVICE|FibriCheck recordings|PPG, ACC, GYR, ECG and sound measurements
57912876|NCT05055505|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
58384765|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
58384766|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
58384767|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
58384768|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
57912877|NCT01666379|DRUG|Fentanyl|
57912878|NCT03824639|BEHAVIORAL|Structured exercise|Exercise instruction and encouragement
58384769|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
57711260|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
57711261|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
57711262|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
57711263|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
57711264|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
57711265|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
57711266|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
57912879|NCT03824639|BEHAVIORAL|Health Education|Provision of general information about a variety of health topics
57711267|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
57912880|NCT04908397|DIETARY_SUPPLEMENT|L-carnitine|supplement provided twice a day for 2 weeks
57912881|NCT02844647|OTHER|Hyperpolarized Pyruvate (13C)|MRI contrast agent
57912882|NCT05810454|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
57912883|NCT05810454|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
57912884|NCT01945060|DEVICE|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server."
57912885|NCT01945060|OTHER|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
57912886|NCT06257524|OTHER|Education and training|Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
57711268|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
57711269|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
57912887|NCT04338087|OTHER|Questionnaire and personal interviews.|Questionnaire and personal interviews.
57912888|NCT02621320|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
57711270|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
57711271|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
57711272|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
57711273|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
57711274|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
57711275|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
57912889|NCT02621320|DIETARY_SUPPLEMENT|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
57912890|NCT02020382|DEVICE|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
57912891|NCT04304521|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
58384770|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
58384771|NCT01194219|DRUG|Apremilast|
58384772|NCT01194219|DRUG|Placebo|Identical matching placebo
58384773|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
57912892|NCT03045068|BIOLOGICAL|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient"
58264352|NCT02481271|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
58264353|NCT02481271|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
58264354|NCT01871402|DRUG|000-0551 Lotion|
58264355|NCT01871402|DRUG|Vehicle Lotion|
58384774|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
58264356|NCT06622681|OTHER|No intervention|No intervention
58384775|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
58384776|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
58384777|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
58060171|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
58060172|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
58264357|NCT01482962|DRUG|Alisertib|Alisertib enteric coated tablets
58264358|NCT01482962|DRUG|Pralatrexate|Pralatrexate IV infusion
58384778|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
58264359|NCT01482962|DRUG|Gemcitabine|Gemcitabine IV infusion
58264360|NCT01482962|DRUG|Romidepsin|Romidepsin IV infusion
58264361|NCT01789580|OTHER|Gambling moderator|
58264362|NCT04827966|OTHER|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
58264363|NCT04827966|OTHER|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
58384779|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
58384780|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
58384781|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
58384782|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
58384783|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
58384784|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
58384785|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
58264364|NCT04827966|OTHER|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
58264365|NCT04827966|OTHER|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
58264366|NCT04827966|OTHER|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
58264367|NCT00355225|PROCEDURE|ITN distribution channel|
58264368|NCT05742893|DIAGNOSTIC_TEST|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
58384786|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
58384787|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
58384788|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
58384789|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
58384790|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
58384791|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
58384792|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
58384793|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
58384794|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
58384795|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
58384796|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
58384797|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
58060173|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
58060174|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
58060175|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
58264369|NCT00003910|DRUG|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
58264370|NCT00003910|DRUG|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
58264371|NCT00003910|DRUG|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
58264372|NCT04028973|OTHER|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
58264373|NCT04028973|OTHER|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
58384798|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
58384799|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
58384800|NCT01060748|BIOLOGICAL|Placebo|Placebo
58384801|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
58384802|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
58384803|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
58384804|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
58384805|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
58384806|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
58384807|NCT01642056|DRUG|Placebo|
58384808|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
58384809|NCT01840813|DRUG|Normal saline|It is a placebo group
58384810|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
58384811|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
58384812|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
58384813|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
58060176|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
58060177|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
58060178|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
58060179|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
58060180|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
58060181|NCT00362141|DRUG|levetiracetam (add-on)|
57711276|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
57711277|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
57711278|NCT00431249|DRUG|Cilostazol|
57711279|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
57711280|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
57711281|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
57711282|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
57711283|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
58264374|NCT05286359|DIAGNOSTIC_TEST|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
58264375|NCT05556850|BEHAVIORAL|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
58264376|NCT04579445|OTHER|Education on tailored Quality Improvement measures|Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
58264377|NCT05490602|PROCEDURE|Running subcutaneous sutures technique|The Running subcutaneous sutures consist of running sutures in the profound and superficial dermis without knotting the thread (suture).
58264378|NCT05490602|PROCEDURE|Classical closures|Classical closures
58264379|NCT03796442|DEVICE|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
58264380|NCT03796442|DEVICE|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
58264381|NCT03419598|PROCEDURE|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
58264382|NCT03419598|DEVICE|Personalised subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
58264383|NCT03419598|DEVICE|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
58264384|NCT01573767|DRUG|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
58264385|NCT01573767|DRUG|Placebo|Placebo inhalation powder during treatment period
58264386|NCT01573767|DRUG|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
58264387|NCT03794661|DEVICE|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
58060182|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
58060183|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
58060184|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
58060185|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
58060186|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
58060187|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
58060188|NCT02029365|OTHER|semi-structured interview|phone interview
58060189|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
58060190|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
58060191|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
58060192|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
58060193|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
58060194|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
58060195|NCT02878135|PROCEDURE|fast application|
58060196|NCT02878135|PROCEDURE|slow application|
57912893|NCT03045068|BIOLOGICAL|FFP and Cryoprecipitate|"1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed"
57912894|NCT03045068|BIOLOGICAL|PRBC and cell saver Transfusion|1. Transfuse for target Hematocrit \> 40 in neonates with SV physiology; Transfuse for Hematocrit\> 33 for 2-Ventricle physiology
57912895|NCT03045068|BIOLOGICAL|Factor Concentrate (Bebulin)|1. Based on clinical bleeding and achievement of hemostasis
58060197|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
58060198|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
58060199|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
58060200|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
58060201|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
58060202|NCT02335567|OTHER|there is no intervention|
58060203|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
58060204|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
58060205|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
57711284|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
57912896|NCT02117947|BEHAVIORAL|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
57912897|NCT02117947|BEHAVIORAL|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
58060206|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
58060207|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
58060208|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
58060209|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
58060210|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
58060211|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
58060212|NCT00002024|DRUG|Ganciclovir|
58060213|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
58060214|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
58060215|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
58060216|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
58264388|NCT02142361|DEVICE|enfilcon A|Silicone hydrogel toric lenses.
58264389|NCT05387681|DRUG|Envafolimab|short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
58264390|NCT01829178|DRUG|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
58264391|NCT01829178|DRUG|Placebo|placebo tablets: 420 mg in 3 divided dose
58264392|NCT01829178|DRUG|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
58264393|NCT01903785|DRUG|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
58264394|NCT01903785|DRUG|Placebo|
58264395|NCT00801437|DRUG|Xalacom|Xalacom 1 drop into the affected eye daily
58264396|NCT00565916|DRUG|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
57711285|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
57711286|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
57711287|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
57711288|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
57711289|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
57711290|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
57912898|NCT01319630|DEVICE|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
57912899|NCT01319630|DEVICE|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
57912900|NCT00652210|OTHER|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
57912901|NCT02853747|BEHAVIORAL|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
57912902|NCT04555980|DEVICE|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
57912903|NCT04555980|DEVICE|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
58264397|NCT00565916|DRUG|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
58264398|NCT00565916|DRUG|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
58264399|NCT02522013|DRUG|Aminophylline|
58264400|NCT02522013|DRUG|isotonic saline|
58264401|NCT05648175|BEHAVIORAL|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
58264402|NCT05648175|BEHAVIORAL|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
57912904|NCT05986747|BEHAVIORAL|Video-based CBT guided self-help Interventions|"Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments."
57912905|NCT02293564|DRUG|gevokizumab|Solution for subcutaneous injection
57912906|NCT02744378|DRUG|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
57912907|NCT02744378|DRUG|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
57912908|NCT01246739|PROCEDURE|Adrenalectomy|Adrenalectomy (open or laparoscopic)
57912909|NCT05475652|OTHER|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
57912910|NCT05475652|OTHER|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
57912911|NCT03375528|DEVICE|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
57912912|NCT00807287|PROCEDURE|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
57912913|NCT00807287|PROCEDURE|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
58060217|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
58060218|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
57711291|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
57711292|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
57711293|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
57711294|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
57912914|NCT03701529|DRUG|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
58060219|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
58060220|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
57711295|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
58060221|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
58060222|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
58060223|NCT00216086|PROCEDURE|EUS|biopsy per EUS
58060224|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
58060225|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
58060226|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
58060227|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
58060228|NCT00000952|DRUG|Ritonavir|
58060229|NCT00000952|DRUG|Lamivudine|
57711296|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
57711297|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
57711298|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
57912915|NCT03701529|DRUG|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
57912916|NCT00292721|DRUG|Celecoxib|celecoxib: loading and maintenance for 6 months
58264403|NCT05648175|BEHAVIORAL|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
57711299|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
57711300|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
57711301|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
57912917|NCT02006953|PROCEDURE|Bolus feeding schedule following gastrostomy tube placement|
57912918|NCT02006953|PROCEDURE|Continuous chimney feeds following gastrostomy tube placement|
57912919|NCT02472197|PROCEDURE|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
58264404|NCT06272045|BEHAVIORAL|ENRICH|In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.
58264405|NCT06272045|BEHAVIORAL|Usual Home Visiting|Usual home visiting without cardiovascular health promotion content
58264406|NCT05454540|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
58264407|NCT04516382|DRUG|PTG-300|Active drug
58264408|NCT01595958|DRUG|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
58264409|NCT01595958|PROCEDURE|cardio-pulmonary resuscitation|usual care of cardiac arrest
58264410|NCT03035435|OTHER|fast-track rehabilitation|
58264411|NCT03035435|OTHER|standard care rehabilitation|
58264412|NCT03912818|DRUG|Carboplatin|Given IV
58264413|NCT03912818|DRUG|Cisplatin|Given IV
58264414|NCT03912818|PROCEDURE|Cystectomy|Undergo cystectomy
58264415|NCT03912818|DRUG|Doxorubicin|Given IV
58264416|NCT03912818|BIOLOGICAL|Durvalumab|Given IV
57711302|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
57711303|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
57711304|NCT00211471|DRUG|anecortave acetate|
57912920|NCT02472197|PROCEDURE|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
57912921|NCT03810131|OTHER|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
57912922|NCT06181331|BEHAVIORAL|eConquerFear|The key goals of this e-intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
57912923|NCT06181331|BEHAVIORAL|eHealthMaintenance|eHealthMaintenance is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
58264417|NCT03912818|DRUG|Gemcitabine|Given IV
58264418|NCT03912818|DRUG|Methotrexate|Given IV
58264419|NCT03912818|DRUG|Vinblastine|Given IV
58264420|NCT00560287|DEVICE|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
57912924|NCT06181331|BEHAVIORAL|ConquerFear|ConquerFear is an intensive version of eConquerFear, which consists of 6 face-to-face therapist-led sessions.
57912925|NCT06181331|BEHAVIORAL|eConquerFear+eHealthMaintenance|The combination of eConquerFear and eHealthMaintenance interventions, that consists of 10 weekly online modules.
57912926|NCT05403112|PROCEDURE|Bone ring with open sinus lifting|All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
58264421|NCT00560287|DEVICE|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
58264422|NCT02044874|DRUG|APD356-lorcaserin hydrochloride|
57711305|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
58264423|NCT02044874|DRUG|Placebo|
58264424|NCT00638742|DRUG|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
58264425|NCT02267135|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
58264426|NCT02267135|BIOLOGICAL|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
58264427|NCT04709419|DEVICE|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
58264428|NCT04709419|DEVICE|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
58264429|NCT05912231|RADIATION|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
58264430|NCT05912231|RADIATION|Accelerated Photon Radiation Therapy (XRT)|per protocol
58264431|NCT03114501|BEHAVIORAL|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
58264432|NCT03114501|BEHAVIORAL|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
58264433|NCT03114501|BEHAVIORAL|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
57711306|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
57711307|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
57711308|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
57711309|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
57711310|NCT01862172|OTHER|Additional MRI|
57711311|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
57711312|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
57711313|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
57711314|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
57711315|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
57711316|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
57711317|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
57711318|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
57711319|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
58060230|NCT00000952|DRUG|Zidovudine|
58060231|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
58264434|NCT04875988|PROCEDURE|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
58264435|NCT04875988|PROCEDURE|Traditional|ultrasound will not be used in the traditional IV placement group
58264436|NCT01596153|DIETARY_SUPPLEMENT|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
58264437|NCT06623500|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
58264438|NCT06623500|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
58384814|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
58384815|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
58384816|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
58384817|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
58384818|NCT02229786|DRUG|Buscopan® plus|
58384819|NCT02229786|DRUG|Buscopan®|
58384820|NCT02229786|DRUG|Paracetamol|
58384821|NCT02229786|DRUG|Placebo|
58384822|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
58384823|NCT05042401|DRUG|placebo|placebo low dose
57711320|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
57711321|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
58264439|NCT00228319|DIETARY_SUPPLEMENT|Oral Ascorbic Acid|4 grams per day for 12 months
57711322|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
58264440|NCT00228319|DRUG|Paclitaxel|Six cycles
58264441|NCT00228319|DRUG|Carboplatin|Six cycles
58264442|NCT00228319|DRUG|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
57711323|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
57711324|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
58264443|NCT00228319|DIETARY_SUPPLEMENT|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
58384824|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
57711325|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
57711326|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
57912927|NCT03324191|DIETARY_SUPPLEMENT|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
57912928|NCT03324191|DIETARY_SUPPLEMENT|Tea beverage|Tea beverage
57912929|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
57711327|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
58264444|NCT00228319|DIETARY_SUPPLEMENT|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
58264445|NCT00435435|DRUG|Disulfiram|
58264446|NCT00435435|DRUG|Acamprosate|
58264447|NCT00435435|DRUG|Naltexone|
58264448|NCT06621056|OTHER|not applicable for observational research|This is an observational research and has no intervention
58264449|NCT02743390|BIOLOGICAL|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
58264450|NCT02743390|OTHER|Saline|Saline for 2 hours (250mL)
58384825|NCT05042401|DRUG|placebo|placebo high dose
58384826|NCT02785783|DEVICE|Standard colonoscopy|
58384827|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
58384828|NCT04954300|OTHER|no intervention|No intervention
58384829|NCT04587206|DRUG|CKD-348|QD, PO
58384830|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
58384831|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
58384832|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
58384833|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
58384834|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
58384835|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
58384836|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
58264451|NCT00006357|DRUG|imatinib mesylate|
58264452|NCT05663944|DRUG|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
58264453|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
58264454|NCT05663944|PROCEDURE|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
58264455|NCT05663944|DRUG|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
58264456|NCT05663944|DIAGNOSTIC_TEST|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
58264457|NCT05663944|DIAGNOSTIC_TEST|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
58264458|NCT05663944|DIAGNOSTIC_TEST|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
58264459|NCT05663944|OTHER|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
58264460|NCT05663944|DIAGNOSTIC_TEST|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
58264461|NCT05663944|OTHER|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
58384837|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
58384838|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
58384839|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
57912930|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
58060232|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
58060233|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
58060234|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
58060235|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
58060236|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
58060237|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
58264462|NCT05663944|DIAGNOSTIC_TEST|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
58264463|NCT05663944|OTHER|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
58264464|NCT05663944|DIAGNOSTIC_TEST|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
58264465|NCT05663944|PROCEDURE|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
58384840|NCT02565693|DRUG|Apixaban|
57711328|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
57912931|NCT03324191|OTHER|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
57912932|NCT01435616|DRUG|Glargine|
57912933|NCT01435616|DRUG|LY2605541|
57912934|NCT02811731|DRUG|CKD-330 16/5mg - B|
57912935|NCT02811731|DRUG|Candesartan 16mg and Amlodipine 5mg|
57912936|NCT01854723|DRUG|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
57912937|NCT01854723|DRUG|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
57912938|NCT05551312|OTHER|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
57912939|NCT04405349|BIOLOGICAL|VB10.16|Vaccination
57912940|NCT04405349|BIOLOGICAL|Atezolizumab|Intravenously infusion
57912941|NCT05838144|DEVICE|Acapella device|Group A. Will use Acapella device.
57912942|NCT05838144|OTHER|Only routine chest physical therapy program|Group B. Will take medications and perform routine chest physical therapy program.
58060238|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
58060239|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
58060240|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
57912943|NCT03805347|DRUG|Helminthostachys zeylanica(L.)Hook|Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
57912944|NCT03805347|DRUG|Starch|Starch in capsule, 1gm/time, 3 times daily
58060241|NCT00256204|OTHER|Placebo|Placebo
57912945|NCT01992393|BEHAVIORAL|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
57912946|NCT02199743|DRUG|Lurasidone|Compare to haloperidol and perphenazine
57912947|NCT02199743|DRUG|Haloperidol|Compare to lurasidone
58060242|NCT00527046|DRUG|CP-424,391|
58060243|NCT00051194|DRUG|Combination IOP Lowering Therapy|
58060244|NCT03323385|DRUG|N1539|Once Daily
58060245|NCT03323385|DRUG|Placebo|Once Daily
58060246|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
58060247|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
58384841|NCT02565693|DRUG|Aspirin|
58384842|NCT02565693|DRUG|Carbasalate calcium|
58384843|NCT02565693|DRUG|Clopidogrel|
58384844|NCT02565693|DRUG|Dipyridamole|
58384845|NCT02565693|OTHER|No antithrombotic treatment|
58384846|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
57711329|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
57912948|NCT02199743|DRUG|Perphenazine|Compare to lurasidone
57912949|NCT04235179|RADIATION|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
57912950|NCT04199897|DIETARY_SUPPLEMENT|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
57912951|NCT04199897|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
58264466|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
58264467|NCT01765777|PROCEDURE|Osteopathic Manipulative Medicine|
58384847|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
57711330|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
57711331|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
57711332|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
57912952|NCT04199897|OTHER|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
57912953|NCT04199897|OTHER|Placebo tablets|Placebo lozenges 2 times a day for 35 days
57912954|NCT01404195|DIETARY_SUPPLEMENT|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
58264468|NCT01765777|PROCEDURE|Phototherapy|
58264469|NCT01432561|DRUG|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
58264470|NCT00828724|DRUG|Lorcaserin 10mg|
57711333|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
58264471|NCT04145375|DRUG|ZEN003694|Up to 120mg
58264472|NCT04145375|DRUG|Enzalutamide|160mg
58264473|NCT02641886|DRUG|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
58264474|NCT02641886|OTHER|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
58264475|NCT05593536|BEHAVIORAL|Breastfeeding Education|Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
58264476|NCT04852796|OTHER|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
58384848|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
58384849|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
57912955|NCT03505541|BIOLOGICAL|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
57912956|NCT02031692|DRUG|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
58060248|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
58384850|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
58060249|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
58264477|NCT03438461|DRUG|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
58264478|NCT03438461|DRUG|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
58264479|NCT00224146|DRUG|oxybutynin transdermal delivery system (Oxytrol(r))|
57711334|NCT00427635|DRUG|Esomeprazole|
57711335|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
57711336|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58060250|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
58060251|NCT01430910|DRUG|CAZ104|IV infusion
58060252|NCT01430910|DRUG|Avibactam|IV infusion
58264480|NCT06618885|BIOLOGICAL|SUM-101|Three immunizations every 4 weeks for 3 months (total 3 immunizations)
58264481|NCT00084318|BIOLOGICAL|cetuximab|400 mg/m\^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m\^2 intravenously over 60 minutes in weeks 2 through 7.
58264482|NCT00084318|DRUG|cisplatin|30 mg/m\^2 intravenously infused over over 60 minutes in weeks 2 through 7.
58264483|NCT00084318|DRUG|docetaxel|15 mg/m\^2 intravenously infused over 30 minutes in weeks 2 through 7.
58264484|NCT00084318|RADIATION|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
58264485|NCT00497770|DRUG|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
58264486|NCT04416737|DRUG|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
58264487|NCT05930834|BEHAVIORAL|exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
57711337|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
58264488|NCT03618563|OTHER|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
58264489|NCT02200237|BIOLOGICAL|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
58384851|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
57711338|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
57711339|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
57711340|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
58060253|NCT01430910|DRUG|Ceftazidime|IV infusion
58060254|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
58264490|NCT02200237|BIOLOGICAL|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
58264491|NCT02944500|DRUG|liraglutide|
58264492|NCT02944500|OTHER|Placebo|
58264493|NCT03600012|OTHER|Cycling Functional Electrical Stimulation|
58384852|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
58384853|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
58384854|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58384855|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
58384856|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
58384857|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
58384858|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
57711341|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
57711342|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
57711343|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
57711344|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
58060255|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
58060256|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
58264494|NCT03600012|OTHER|Physiotherapy|
58384859|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
58384860|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
58384861|NCT05123339|OTHER|Questionnaire|Questionnaire
58384862|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
58384863|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
57711345|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
57711346|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
58264495|NCT06621433|OTHER|T-PRF with CAF|Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.
58264496|NCT06621433|OTHER|SECTG with CAF|Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.
58264497|NCT06448533|OTHER|No intervention|No intervention
58060257|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
58384864|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
58384865|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
58264498|NCT05740176|DEVICE|Anterior Cervical Discectomy and Fusion|Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
58264499|NCT06207240|DEVICE|NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve|Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
57711347|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
57711348|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
58264500|NCT06623331|OTHER|AI-ehnanced endoscopy training|Endosopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.
58384866|NCT03806530|DRUG|Gabapentin|100 mg capsule
58384867|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
58384868|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
57711349|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
57711350|NCT05256017|DRUG|Acoziborole|Acoziborole tablets
58264501|NCT06623331|OTHER|Conventional endoscopy training|Endoscopists trained conventionally
58264502|NCT05632315|DRUG|PMT|Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
58384869|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
58384870|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
58384871|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
58384872|NCT00290719|DRUG|cisplatin|
58384873|NCT00290719|DRUG|gefitinib|
58384874|NCT00290719|DRUG|irinotecan hydrochloride|
57711351|NCT05256017|DRUG|Placebo|matching placebo of acoziborole tablets
57711352|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
58060258|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
58060259|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
58264503|NCT06554990|OTHER|physical therapy excersies|1- selected physical therapy exercises
58264504|NCT06554990|OTHER|sensory perceptual motor exercises|selected sensory perceptual motor exercises
58264505|NCT06160284|DRUG|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
57711353|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
58060260|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
58060261|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
58264506|NCT05654428|OTHER|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
58384875|NCT00290719|PROCEDURE|conventional surgery|
58384876|NCT00290719|PROCEDURE|neoadjuvant therapy|
58384877|NCT00290719|RADIATION|radiation therapy|
57711354|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
57711355|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
58384878|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
58060262|NCT02223949|DEVICE|Cook double balloon catheter|
58060263|NCT02223949|DRUG|PGE1 tablet|
58060264|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
58060265|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
58060266|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
58060267|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
58384879|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
58384880|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
58384881|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
58060268|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
58060269|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
57711356|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
57711357|NCT00470288|PROCEDURE|bladder flap during cesarean section|
57711358|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
58060270|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
58060271|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
58264507|NCT05654428|OTHER|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
58264508|NCT04181437|DRUG|NVP-1203-R1|1 tablet, Single oral dosing
58264509|NCT04181437|DRUG|NVP-1203-R2|1 tablet, Single oral dosing
58264510|NCT04181437|DRUG|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
58264511|NCT06575660|BEHAVIORAL|Mental health support session|a single AI-VR mental health support session using the XAIA application
58264512|NCT02395237|DRUG|: Amaryl® M IR 2/1000|
58264513|NCT00707902|DRUG|chlorhexidine/lidocaine|
58264514|NCT00707902|DRUG|echinacea/sage|
57711359|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
57912957|NCT03481192|BEHAVIORAL|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
57711360|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
57711361|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
57711362|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
57711363|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
57711364|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
57711365|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
57711366|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
57711367|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
57711368|NCT00770120|DRUG|everolimus|
57711369|NCT01825369|DRUG|IV L-carnitine|See arm description
57711370|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
57711371|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
57711372|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
57711373|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
57711374|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
57711375|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
57711376|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
57711377|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
58060272|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
57711378|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
57711379|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
57711380|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
57711381|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
57711382|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
58384882|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
58384883|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
57711383|NCT02808845|OTHER|microalbuminuria|
57711384|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
57711385|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
58264515|NCT06647680|DRUG|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
58264516|NCT05152654|DEVICE|Tacker|metallic staples used to fix the mesh
58264517|NCT01622270|OTHER|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
58264518|NCT02573831|DRUG|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
57912958|NCT03507660|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
57912959|NCT03484845|DRUG|Lactoferrin and ferrous fumarate|"* Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
57912960|NCT00976612|DRUG|Nilotinib|Nilotinib 400mg bid daily
58060273|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
57912961|NCT03588286|PROCEDURE|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
57912962|NCT03588286|OTHER|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
58264519|NCT02573831|DRUG|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
57912963|NCT03588286|PROCEDURE|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
57912964|NCT03558373|DRUG|Immunosuppressive|Immunosuppressive therapies
58060274|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
58060275|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
57711386|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
58264520|NCT06623552|OTHER|Neck Pain and Disability Scale (NPDS)|"The Turkish version of the Neck Pain and Disability Scale (NPDS), developed by Wheeler et al., was used for individuals with neck pain. The severity of neck pain is evaluated on a 5-point Likert scale; where 0 indicates no pain and 4 indicates very severe pain. The score is higher in those with upper extremity symptoms.The cut-off value of this scale was set to 15 to detect disability-related neck pain.The cut-off value is mandatory to evaluate a patient or a particular group of patients for clinically significant neck pain by distinguishing it from insignificant pain"
58264521|NCT06623552|OTHER|Fonseca Anamnestic Index (FAI)|It is a questionnaire consisting of 10 questions, including pain during the period, parafunctional habits, movement restriction, clicking, malocclusion, emotional stress.In this study, clinical signs relevant to each severity category of Fonseca's anamnestic index were used to detect the frequency of symptoms and to characterize the symptoms and clinical findings of TMD.The Turkish version of Fonseca's Anamnestic Index (FAI) questionnaire was used to assess the symptom severity.
58384884|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
58264522|NCT06623552|OTHER|Evaluation of Jaw Functional Limitation|The Jaw Functional Limitation Scale (JFLS) was developed as an 8-item scale for general functional limitation in the jaw. In the light of the obtained items and supporting psychometric data, it has been expanded and re-developed to include the verbal and non-verbal communication limitations that occur in a 20-item tool16 JFLS-20 is a tool with three structure contents (chewing, vertical mobility of jaw state and emotional and verbal statement) to evaluate functional state.Difficulty performing a determined task is graded from 0 (without limitation) to 10 (severe limitation). Higher scores are a more serious sign of functional limitation.
58264523|NCT06622551|DIETARY_SUPPLEMENT|Iron-folic acid supplement|The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.
58264524|NCT01892709|DRUG|Hydromorphone|
58384885|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
58264525|NCT03191864|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
57711387|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
57711388|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
57711389|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
58060276|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
58060277|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
58264526|NCT03191864|DRUG|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
58264527|NCT06619678|DRUG|MK-8507|Oral administration
58264528|NCT06619678|DRUG|Islatravir|Oral administration
57711390|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
57711391|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
57711392|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
57711393|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
57912965|NCT04314804|COMBINATION_PRODUCT|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
57912966|NCT04314804|COMBINATION_PRODUCT|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
57912967|NCT02831387|DRUG|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
58060278|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
58060279|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
58060280|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
58264529|NCT06628778|DRUG|Dalteparin|Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
58264530|NCT06234696|OTHER|entrepreneurial intervention|The experimental group will be given psychoeducation for 4 weeks.
58264531|NCT04285515|DRUG|Lumateperone|Lumateperone 42mg oral capsule
58264532|NCT04285515|DRUG|Placebos|Placebo oral capsule
58264533|NCT04324736|OTHER|no interventional study|no interventional study
58384886|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
57711394|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
57912968|NCT02831387|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
58264534|NCT05328596|BEHAVIORAL|CBT treatment|CBT-treatment
58264535|NCT05328596|BEHAVIORAL|Wait list control|No intervention
58264536|NCT01647919|DIETARY_SUPPLEMENT|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
58264537|NCT01647919|DIETARY_SUPPLEMENT|Placebo|4 capsules of placebo identical to cogniVida™ once a day
58264538|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space isolated corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
58264539|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
58264540|NCT06493656|DRUG|1mL of Triamcinolone (40mg/1mL) Injectable Solution|1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
57912969|NCT06472193|PROCEDURE|Shanfield implantation technique in Mitroffanof procedure|a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
57912970|NCT03081052|DRUG|iNO|Subject will receive inhaled Nitric Oxide in this intervention
58060281|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
58060282|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
58264541|NCT06493656|DRUG|4mL of Lidocaine 1% Solution Injectable Solution|4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
58264542|NCT06493656|DRUG|15mL of Normal Saline|15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
57912971|NCT03081052|DRUG|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
57912972|NCT02761876|BEHAVIORAL|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
57912973|NCT02761876|BEHAVIORAL|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
57912974|NCT02761876|BEHAVIORAL|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
58060283|NCT03062605|DRUG|Iodine (Betadine)|
58060284|NCT03062605|BIOLOGICAL|NaOCL|
58060285|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
58264543|NCT01671072|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
57711395|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
57912975|NCT02515877|RADIATION|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
58060286|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
58060287|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
58060288|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
58264544|NCT01671072|DRUG|Normal Saline|Sodium chloride 0.9%, 3.5ml
58264545|NCT02742454|PROCEDURE|Standard 30-60 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, the cord is clamped at 30 seconds. If the baby is breathing well, the cord is clamped at 60 seconds. Ventilatory assistance is given after cord clamping.
58264546|NCT02742454|PROCEDURE|VentFirst 120 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, PPV by face mask is given starting at 30 seconds. If the baby is breathing well, CPAP is given starting at 30 seconds. The cord is clamped at 120 seconds.
58264547|NCT03664830|DRUG|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
58264548|NCT06592755|PROCEDURE|single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection|The included patients chose to undergo single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach based on patients preference.
58264549|NCT06592755|PROCEDURE|conventional open surgery|These patients chose to undergo total thyroidectomy with central compartment neck dissection via conventional open surgery based on patients preference.
58384887|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
57912976|NCT02515877|DRUG|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
58384888|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
58384889|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
58384890|NCT01470131|DRUG|Placebo|Matching placebo
58384891|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
58384892|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
57912977|NCT02515877|DRUG|Carboplatin|AUC= 2,5 (Calvert formula)
57912978|NCT01143779|DRUG|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
58060289|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
58384893|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
58384894|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
58384895|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
58384896|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
58384897|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
58384898|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
58060290|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
58384899|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
58384900|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
58384901|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
58384902|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
57912979|NCT06171347|OTHER|Oral cold spray (tap water)|Oral cold spray (tap water)
57912980|NCT02438501|RADIATION|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
57912981|NCT02438501|RADIATION|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
58060291|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
58060292|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
58060293|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
58384903|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
58384904|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
58384905|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
58384906|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
58384907|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
58384908|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
58384909|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
58060294|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
58060295|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
58060296|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
58060297|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
58060298|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
58060299|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
58060300|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
58060301|NCT04974944|DRUG|Camrelizumab|IV injection
58060302|NCT04974944|DRUG|Apatinib|Oral
58060303|NCT04974944|DRUG|Paclitaxel|IV injection
58060304|NCT04974944|DRUG|Cisplatin|IV infusion
58060305|NCT04974944|DRUG|Carboplatin|IV infusion
58060306|NCT04974944|DRUG|Bevacizumab|IV infusion
58060307|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
58060308|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
58060309|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
58060310|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
58264550|NCT06443801|OTHER|THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY|"The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria."
58264551|NCT03518970|OTHER|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
57711396|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
58060311|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
58060312|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
58060313|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
58060314|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
58060315|NCT04229082|OTHER|observational|
58060316|NCT04479306|DRUG|Alisertib|Given PO
58060317|NCT04479306|DRUG|Osimertinib|Given PO
58060318|NCT04479306|DRUG|Sapanisertib|Given PO
58264552|NCT00483106|DRUG|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
58264553|NCT00483106|DRUG|Placebo|taken orally twice a day for 7 consecutive days
57711397|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
57711398|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
57711399|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
58060319|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
58060320|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
58060321|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
58264554|NCT06483243|DRUG|Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG|At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
58384910|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
58384911|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
58384912|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
58384913|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
58384914|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
58060322|NCT00681902|DRUG|Placebo|Jet saline
58384915|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
57711400|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
57711401|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
57711402|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
58264555|NCT06517901|PROCEDURE|Software fusion prostate biopsy|Software fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
58264556|NCT06517901|PROCEDURE|Cognitive fusion prostate biopsy|Cognitive fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using visual estimation and/or measurements of lesion. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
57711403|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
58384916|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
57711404|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
57711405|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
58264557|NCT04110561|DEVICE|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
57711406|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
57912982|NCT04032054|DEVICE|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
57711407|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
58384917|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
58384918|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
57711408|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
57711409|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
58384919|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
57711410|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
57711411|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
57711412|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
57711413|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
57711414|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
57711415|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
57711416|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
57711417|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
58384920|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
58384921|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
58384922|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
57711418|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
57912983|NCT02276183|DIETARY_SUPPLEMENT|Nutrition intervention, test formula|
58264558|NCT05985473|OTHER|audiological measurements|audiological measurements
58264559|NCT05985473|OTHER|Objective and subjective audiological measurements|Objective and subjective audiological measurements
58264560|NCT05985473|OTHER|Evaluation of the denoising methods REFINED|Evaluation of the denoising methods REFINED
58264561|NCT02180997|DRUG|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
58264562|NCT02180997|DRUG|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
58264563|NCT02180997|DRUG|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
58384923|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
57711419|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
57711420|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
58264564|NCT05097547|BEHAVIORAL|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
58264565|NCT06204406|OTHER|Observational|This is a prospective observational study with observation only and no intervention
58264566|NCT04481035|DRUG|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
58384924|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
58384925|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
57711421|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
57711422|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
57711423|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
57711424|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
57711425|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
57711426|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
57912984|NCT02276183|BEHAVIORAL|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
57711427|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
57711428|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
57912985|NCT04114630|DRUG|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
57711429|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
57711430|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
57711431|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
57711432|NCT01912248|OTHER|strength training|strength training, lower limb.
57912986|NCT03002753|BEHAVIORAL|detached mindfulness|Please see detailed study description.
57912987|NCT03002753|BEHAVIORAL|cognitive restructuring|Please see detailed study description.
57912988|NCT00291850|DRUG|Paclitaxel, Cisplatin, Pegfilgrastim|
57912989|NCT05867628|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
58060323|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
58384926|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
58384927|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
58384928|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
58384929|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
57912990|NCT05309915|DRUG|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
57912991|NCT01280110|DRUG|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
57912992|NCT01280110|DRUG|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
57912993|NCT00731120|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
57912994|NCT00731120|DRUG|Placebo|Vortioxetine placebo-matching capsules
58264567|NCT04481035|OTHER|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
57711433|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
58264568|NCT04409535|OTHER|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
58264569|NCT01067625|DEVICE|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
58264570|NCT02079142|BEHAVIORAL|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
58264571|NCT02079142|BEHAVIORAL|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
58384930|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
58384931|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
58384932|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
58384933|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
58384934|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
57711434|NCT00072345|DRUG|lomustine|
57711435|NCT00072345|DRUG|temozolomide|
57711436|NCT00072345|DRUG|thalidomide|
57711437|NCT02020668|OTHER|Physiotherapy|
57912995|NCT03206762|DEVICE|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
57711438|NCT02020668|OTHER|Wait list control|
57711439|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
58264572|NCT02387528|BEHAVIORAL|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
58264573|NCT02387528|BEHAVIORAL|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
58264574|NCT02387528|OTHER|3- Wait List Control Group|No intervention
57711440|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
57711441|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
57711442|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
57711443|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
57711444|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
57711445|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
57711446|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
57912996|NCT03969381|RADIATION|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
57912997|NCT05998473|DIAGNOSTIC_TEST|Dynamic stability measurement|The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.
58264575|NCT06356974|DRUG|Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)|Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
57711447|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
57912998|NCT02729753|DEVICE|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
57912999|NCT02729753|DEVICE|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
57711448|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
57913000|NCT04110977|DEVICE|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
58384935|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
57913001|NCT01091077|DIETARY_SUPPLEMENT|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
57913002|NCT05724589|DRUG|Epidermal Growth Factor|Apply facial twice daily.
57913003|NCT02729662|DRUG|Tolvaptan|"* Before administration of tolvaptan~  * TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~ * 24-hour urine collection・Hematology/urinalysis: Once/year~ * Physical findings: Blood pressure and medical interview at ambulatory visit~* Hospitalization for education and examination at the start of tolvaptan administration~  * 24-hour urine collection・Hematology/urinalysis・Inulin clearance~ * Physical findings: Body weight, blood pressure~ * Adverse Events~* After administration of tolvaptan~  * TKV・Liver capacity・inulin clearance: Once/year~ * 24-hour urine collection: Once/6 months~ * Hematology/urinalysis: Once/month in principle~ * Physical findings: Blood pressure and medical interview at ambulatory visit~ * Adverse Events"
57913004|NCT05688982|BEHAVIORAL|General information provision|Patients will receive information with general oral health and aSDoH resources.
57913005|NCT05688982|BEHAVIORAL|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
57913006|NCT05688982|BEHAVIORAL|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
57913007|NCT02400294|OTHER|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
57913008|NCT00311727|BIOLOGICAL|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
58060324|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
58264576|NCT05716854|DRUG|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
58264577|NCT05716854|DRUG|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
58264578|NCT05716854|DRUG|Placebo (Part 1)|Subjects receive matching placebo for treatments.
58264579|NCT05716854|DRUG|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
58264580|NCT05716854|DRUG|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
58264581|NCT05716854|DRUG|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
58264582|NCT05716854|DRUG|Placebo (Part 2)|Subjects receive matching placebo for treatments.
58264583|NCT04128722|DRUG|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
58264584|NCT05866367|DRUG|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
58264585|NCT05866367|DRUG|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
58264586|NCT05296902|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
58264587|NCT05735314|OTHER|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
58264588|NCT05735314|OTHER|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
58264589|NCT04181515|DRUG|Placebo oral tablet|placebo stressor
58384936|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
57711449|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
58264590|NCT04181515|DRUG|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
57711450|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
58060325|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
58060326|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
58264591|NCT04181515|DEVICE|sham rTMS|sham rTMS (inactive coil)
58264592|NCT04181515|DEVICE|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
57711451|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
58264593|NCT03873415|DRUG|BMS-986165|Oral administration
58264594|NCT06457360|DRUG|tranexamic acid|Application of sterile gauze after extraction for hemostasis
58264595|NCT06457360|DRUG|Ankaferd Blood Stopper|Application of sterile gauze after extraction for hemostasis
58384937|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
57711452|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
57711453|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
57711454|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
57711455|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
57711456|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
57711457|NCT03362515|DRUG|Furosemide|furosemide
58264596|NCT06457360|DRUG|Chitosan|Application of sterile gauze after extraction for hemostasis
58384938|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
58384939|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
58384940|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
58384941|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
58384942|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
58384943|NCT00002395|DRUG|Topotecan|
58264597|NCT02613429|BEHAVIORAL|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
58384944|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
58264598|NCT02613429|BEHAVIORAL|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
58264599|NCT04395391|DIAGNOSTIC_TEST|SARS-CoV-2|Determine usability of study materials and kit
57711458|NCT03362515|DRUG|Placebo|placebo
57711459|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
58264600|NCT06649084|BEHAVIORAL|Multicomponent Lexical Retrieval Training (Multi-LRT)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing names of personally relevant target in multiple communication modalities. Treatment focuses on the use of strategies which capitalize on residual linguistic ability and autobiographical memory to support word retrieval. The participant completes two one-hour-long sessions per week plus daily homework. The participant also meets 4 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
58384945|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
58384946|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
58384947|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
58384948|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
58384949|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
58384950|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
58264601|NCT06649084|BEHAVIORAL|Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing personally relevant scripts of 3-5 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician are held which target clear and accurate script production, script memorization, and conversational usage of the script and multimodal communication. The participant also meets 6 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
58264602|NCT06649084|BEHAVIORAL|Multicomponent Communication Partner Training (Multi-CPT)|In person or via teletherapy: A multi-component treatment incorporating elements of compensatory and care-partner focused interventions. Biweekly (one hour each) sessions with a clinician are held which target use of communication strategies including multimodal communication for the participant and study partner (e.g., spouse). The participant also completes regular assignments meant to increase generalization of communication strategies and progress on personal goals.
57711460|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
57711461|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
57711462|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
57711463|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
57711464|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
57711465|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
57711466|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
57711467|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
57711468|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
57711469|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
57711470|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
57711471|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
57711472|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
57711473|NCT03032003|OTHER|Placebo|2 BID for 15 days
57711474|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
58060327|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
58060328|NCT02089191|DEVICE|Nelfilcon A contact lenses|
58060329|NCT02089191|DEVICE|Stenfilcon A contact lenses|
58060330|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
58060331|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
58060332|NCT02061540|DRUG|LUM001|LUM001 oral dose
58060333|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
58060334|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
58060335|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
58060336|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
58060337|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
58060338|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
58060339|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
58060340|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
58060341|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
58060342|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
58060343|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
57711475|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
57711476|NCT00317681|DRUG|Tacrolimus ointment|
57711477|NCT01898793|DRUG|Fludarabine|
57711478|NCT01898793|DRUG|Cyclophosphamide|
57711479|NCT01898793|PROCEDURE|Leukapheresis|
57711480|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
57711481|NCT01898793|BIOLOGICAL|IL-2|
57711482|NCT01898793|DRUG|ALT-803|
57711483|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
57711484|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
57711485|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
57711486|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
57711487|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
57711488|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
57711489|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
57711490|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
57711491|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
57913009|NCT02730598|DEVICE|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
57913010|NCT02730598|DEVICE|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
57913011|NCT04998760|DRUG|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
57913012|NCT04998760|DRUG|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
57913013|NCT01742611|DRUG|ASP1585|oral
57913014|NCT00757588|DRUG|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
57913015|NCT00757588|DRUG|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
57913016|NCT02580643|BIOLOGICAL|APS|intra-articular injection
57913017|NCT03531944|OTHER|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
57913018|NCT03531944|OTHER|Usual care|Usual care with physician and as needed visit to the nurse
57913019|NCT05601687|PROCEDURE|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
58060344|NCT02850276|DRUG|Pyridostigmine|
58060345|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
57711492|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
57711493|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
58060346|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
58060347|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
58060348|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
58060349|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
57711494|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
58264603|NCT03310658|DEVICE|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
57711495|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
57711496|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
57711497|NCT03945877|OTHER|No interventions|No interventions
57711498|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
57711499|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
57711500|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
57711501|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
57711502|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
57711503|NCT06413810|OTHER|Calmarell|Food ingredient
57711504|NCT06413810|OTHER|Placebo|Blinded placebo
57711505|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
57711506|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
57711507|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
57711508|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
58264604|NCT03772977|BEHAVIORAL|Brain Health Champion|A health coach embedded within an existing clinical care team
57711509|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
57711510|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
57711511|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
57711512|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
57711513|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
57711514|NCT02168166|BEHAVIORAL|Executive Function Training|
57711515|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
57711516|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
58060350|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
58060351|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
58060352|NCT03494946|PROCEDURE|Liver transplantation|
58060353|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
58384951|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
57711517|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
57711518|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
57711519|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
58060354|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
58060355|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
58060356|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
57711520|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
57711521|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
57711522|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
58264605|NCT05328375|BEHAVIORAL|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
58264606|NCT05328375|BEHAVIORAL|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
58264607|NCT05913635|BEHAVIORAL|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
58384952|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
58384953|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
58384954|NCT04082650|DRUG|vitamin D|4000IU per day
58384955|NCT04082650|OTHER|Placebo|The same doses with vitamin D
58060357|NCT00033293|OTHER|Clinical Observation|Undergo observation
57711523|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
57711524|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
57711525|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
58384956|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
58384957|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
57711526|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
57711527|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
57711528|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
57711529|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
57711530|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
58060358|NCT00033293|DRUG|Cyclophosphamide|Given IV
58060359|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
58060360|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
58060361|NCT00033293|DRUG|Prednisone|Given orally
58060362|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
58060363|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
58060364|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
58060365|NCT00826540|DRUG|sorafenib tosylate|Given orally
57711531|NCT00700791|OTHER|Placebo|Oral Placebo
57711532|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
57711533|NCT04921358|DRUG|Tislelizumab|administered intravenously
57711534|NCT04921358|DRUG|Docetaxel|administered intravenously
57711535|NCT04921358|DRUG|Sitravatinib|administered orally
57711536|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
58264608|NCT05913635|BEHAVIORAL|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
57711537|NCT02208791|DRUG|No intervention|
57711538|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
57913020|NCT05601687|PROCEDURE|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
58060366|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
58264609|NCT00894790|DRUG|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
58264610|NCT00894790|DRUG|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
58264611|NCT01793688|DRUG|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
57711539|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
57711540|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
57711541|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
57711542|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
57711543|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
57711544|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
58264612|NCT06244498|DRUG|Tranexamic acid injection|Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
58264613|NCT05292417|RADIATION|hypofractionation Radiotherapy|Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
58060367|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
57711545|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
57711546|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
57711547|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
57711548|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
57711549|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
57711550|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
57711551|NCT01745029|DEVICE|Motilis-3D-transit|
57711552|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
58264614|NCT05292417|DRUG|sintilimab|200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
57711553|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
57711554|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
58060368|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
57711555|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
58060369|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
57711556|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
57711557|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
57711558|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
57711559|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
58060370|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
58060371|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
58384958|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
58060372|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
58060373|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
58060374|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
58264615|NCT05292417|DRUG|GM-CSF|200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
58264616|NCT05292417|DRUG|Fruquintinib|Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
58060375|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
57711560|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
57711561|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
57711562|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
57711563|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
57711564|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
57711565|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
58264617|NCT06559189|BIOLOGICAL|CD19x22 CAR T|The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
57711566|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
57913021|NCT06323512|DEVICE|Pulmonary artery denervation (PADN)|Combining invasive angiography with pulmonary artery CTA is frequently employed to determine the final size of the PADN catheter, aiming for an expected ratio of distal ring/vessel diameter between 1.1 and 1.2. The PADN system comprises a radiofrequency generator, connecting tubing and control handle, and the PADN catheter. The main interface of the radiofrequency generator offers multiple language options and displays parameters such as temperature, impedance, energy, and ablation time. The generator features three control modes: temperature control, power control, and a combination of both.
57913022|NCT01304433|DRUG|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
57913023|NCT01455857|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
58060376|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
58060377|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
58264618|NCT01306045|DRUG|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
57711567|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
57711568|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
57711569|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
58060378|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
58060379|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
58264619|NCT01306045|DRUG|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
58264620|NCT01306045|DRUG|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
58264621|NCT01306045|DRUG|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
58264622|NCT01306045|DRUG|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
58264623|NCT01306045|PROCEDURE|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
58264624|NCT01615211|DRUG|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
58264625|NCT01615211|DRUG|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
58264626|NCT01570634|DRUG|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
58264627|NCT04278235|DRUG|Elezanumab|Solution for intravenous (IV) infusion
58384959|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
58384960|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
58384961|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
58384962|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
58384963|NCT00414323|DRUG|Duloxetine|
58384964|NCT00414323|DRUG|Escitalopram|
58384965|NCT00414323|DRUG|Placebo|
58384966|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
58384967|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
58384968|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
57711570|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
57711571|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
57711572|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
57711573|NCT00678691|DRUG|armodafinil|50-250mg/d
57711574|NCT00678691|DRUG|placebo|matching placebo
57913024|NCT01455857|OTHER|ITCA placebo|Formulation in DUROS (no exenatide)
57913025|NCT00208780|DRUG|Tetrahydrobiopterin|
57913026|NCT00208780|DRUG|Tetrahydrobiopterin|
58264628|NCT00094536|DEVICE|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
58264629|NCT05878821|DEVICE|Shockwave|Shockwave therapy session once a week for month 1000shock per session
58264630|NCT04264117|PROCEDURE|FlexAbility (Mesh-like irrigated tip catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
57711575|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
57711576|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
57711577|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
57711578|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
57711579|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
57711580|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
57711581|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
57711582|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
57711583|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
57711584|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
57711585|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
57711586|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
57711587|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
57711588|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
57711589|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
57711590|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
57711591|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
57711592|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
58264631|NCT04264117|PROCEDURE|TactiCath (Contract force monitoring catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. contact force \>10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
57711593|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
57711594|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
57711595|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
57711596|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
57711597|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
57711598|NCT00065533|DRUG|pemetrexed|
57711599|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
57711600|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
57711601|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
58264632|NCT02763397|DEVICE|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
57711602|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
58264633|NCT02763397|DEVICE|DBS|DBS will be switched off
58384969|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
58264634|NCT03407703|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|HCV treatment
58264635|NCT03370575|DRUG|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
57711603|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
57711604|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
57711605|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
57711606|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
57711607|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
57711608|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
57711609|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
57711610|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
57711611|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
57711612|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
57711613|NCT02962037|OTHER|Melatonin and light therapy|
58264636|NCT03370575|DRUG|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
58264637|NCT06572423|PROCEDURE|Personalized ultrafractionated stereotactic adaptive radiotherapy|PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
58264638|NCT06572423|RADIATION|Volume Modulated Arc Therapy|Use HyperArc technology
58264639|NCT06572423|PROCEDURE|Computed Tomography|Undergo CT simulation for radiation planning
58264640|NCT06572423|PROCEDURE|Positron Emission Tomography|Undergo PET
58264641|NCT06572423|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58264642|NCT06572423|OTHER|Best Practice|Undergo standard of care
58264643|NCT06572423|BEHAVIORAL|University of Washington Quality of Life Scale, Version 4|Complete questionnaire
57711614|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
57711615|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
57711616|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
57711617|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
57711618|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
57711619|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
57711620|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
57711621|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
57711622|NCT00040040|DRUG|Bupropion|
58264644|NCT06572423|BEHAVIORAL|Functional Assessment of Cancer Therapy-Head & Neck|Complete questionnaire
58264645|NCT01471717|DRUG|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
57711623|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
58264646|NCT01471717|DRUG|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
57711624|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
57711625|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
58264647|NCT01471717|DRUG|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
58264648|NCT01471717|DRUG|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
58264649|NCT01471717|DRUG|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
57711626|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
57711627|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
57711628|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
57711629|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
57711630|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
57711631|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
57711632|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
58264650|NCT01471717|DRUG|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
58264651|NCT00985517|BIOLOGICAL|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
58264652|NCT00985517|PROCEDURE|Sham Surgery|
58264653|NCT01286168|DEVICE|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
58264654|NCT01286168|DEVICE|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
58264655|NCT01286168|PROCEDURE|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
57711633|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
57711634|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
57711635|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
58264656|NCT01286168|DEVICE|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
58264657|NCT06621524|DEVICE|EucaLimus coronary stent system|The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
58264658|NCT00880581|DRUG|PF-3512676|18 mg injection
58264659|NCT00880581|RADIATION|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
58264660|NCT06312111|BEHAVIORAL|recommendation to increase physical activity|education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
58264661|NCT00739505|BIOLOGICAL|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
57711636|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
57711637|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
57711638|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
57711639|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
57711640|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
57711641|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
57711642|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
57711643|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
57711644|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
57711645|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
57711646|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
57711647|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
57711648|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
57711649|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
57711650|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
57711651|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
57711652|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
57711653|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
57711654|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
57711655|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
57711656|NCT02199418|DRUG|Paclitaxel|
57711657|NCT02199418|DRUG|Cisplatin|
57711658|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
57711659|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
57711660|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
57711661|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
57711662|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
57711663|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
57711664|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
57711665|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
57711666|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
58264662|NCT00739505|BIOLOGICAL|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
58264663|NCT05039567|BEHAVIORAL|optimal heart team protocol|Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.
57711667|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
57711668|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
57711669|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
57711670|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
57711671|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
57711672|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
57711673|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
57711674|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
57711675|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
57711676|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
57711677|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
58384970|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
58384971|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
57711678|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
57711679|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
57711680|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
57711681|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
57711682|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
57711683|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
58384972|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
57711684|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
57711685|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
57913027|NCT05806307|DRUG|Misoprostol|(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
58384973|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
58384974|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
58384975|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
58384976|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
58384977|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
58384978|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
58384979|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
57711686|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
57711687|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
57913028|NCT05806307|DEVICE|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
58384980|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
58384981|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
58384982|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
57711688|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
57711689|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
57711690|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
57913029|NCT05806307|DRUG|Carbetocin|(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
57711691|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
57711692|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
57711693|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
57711694|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
58264664|NCT06051474|DRUG|Nicotine Replacement Product|Adults will receive a 2-week supply of nicotine patches to place on skin (14mg or 21mg; dosing depending on tobacco use per package insert) and oral nicotine mini-lozenges (2mg, 4mg, dosing depending on tobacco use per package insert). All participants will also receive a single smoking cessation counseling session with a physician. Surveys will be completed pre-intervention, within 24 hours of hospital discharge, and 2-weeks after hospital discharge.
58264665|NCT02289846|DRUG|IW-9179|
58264666|NCT02289846|DRUG|Matching Placebo|
58384983|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
58384984|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
58384985|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
58384986|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
58384987|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
57711695|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
57711696|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
57711697|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
57711698|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
58264667|NCT03295552|DRUG|Decitabine|decitabine 7mg/m2, d1-d5, q3w
58264668|NCT03295552|DRUG|Carboplatin|carboplatin AUC = 6, d6, q3w
58264669|NCT01685957|BEHAVIORAL|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
58384988|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
58384989|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
57711699|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
57711700|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
57711701|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
57711702|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
57711703|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
57711704|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
57711705|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
57711706|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
57711707|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
57711708|NCT01947504|BEHAVIORAL|education and support intervention|
57711709|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
57711710|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
57711711|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
57711712|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
57711713|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
57711714|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
57711715|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
57711716|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
57711717|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
57711718|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
57711719|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
57711720|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
57711721|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
57711722|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
57711723|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
57711724|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
58264670|NCT01685957|BEHAVIORAL|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
58264671|NCT01685957|BEHAVIORAL|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
58384990|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
58384991|NCT03238703|DRUG|Anastrozole|Given PO
57711725|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
57711726|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
57711727|NCT00065884|DRUG|Valproate|
57711728|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
57711729|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
57711730|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
58384992|NCT03238703|DRUG|Exemestane|Given PO
58384993|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
58384994|NCT03238703|DRUG|Letrozole|Given PO
58384995|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
58384996|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
58384997|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
58384998|NCT03238703|DRUG|Toremifene Citrate|Given PO
57711731|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
57711732|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
57711733|NCT06663605|DRUG|PALI-2108|Oral dose
57711734|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
57711735|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
57711736|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
57711737|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
57711738|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
57711739|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
57711740|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
57711741|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
57711742|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
57711743|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
58264672|NCT03911986|DEVICE|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
58264673|NCT04964297|DEVICE|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
58264674|NCT00475345|BEHAVIORAL|Bedtime snacks|
58384999|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
58385000|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
58385001|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
58385002|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
57711744|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
58264675|NCT00291772|DRUG|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
58264676|NCT03186534|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
58264677|NCT03186534|BEHAVIORAL|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
58385003|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
58385004|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
58385005|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
58385006|NCT01805687|DRUG|Zileuton extended release|
58385007|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
58264678|NCT02813005|PROCEDURE|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
57711745|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
57711746|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
57711747|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
57711748|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
57711749|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
57711750|NCT01573624|DRUG|FF/GSK573719|100/15.6
57711751|NCT01573624|DRUG|FF/GSK573719|100/31.25
57711752|NCT01573624|DRUG|FF/GSK573719|100/62.5
57711753|NCT01573624|DRUG|FF/GSK573719|100/125
57711754|NCT01573624|DRUG|FF/GSK573719|100/250
57711755|NCT01573624|DRUG|FF|100
57711756|NCT01573624|DRUG|FF/VI|100/25
57711757|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
57711758|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
57711759|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
57711760|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
57711761|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
57711762|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
57711763|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
57711764|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
57711765|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
57711766|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
57711767|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
57711768|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
57711769|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
57711770|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
57711771|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
57711772|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
57711773|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
57711774|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
57711775|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
57711776|NCT00141063|DRUG|Focalin XR|
57711777|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
57711778|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
57711779|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
58060380|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
57711780|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
57711781|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
57711782|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
58264679|NCT02813005|PROCEDURE|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
58264680|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
58264681|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
58264682|NCT00570349|DRUG|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
57711783|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
57711784|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
57711785|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
57711786|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
57711787|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
57711788|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
57711789|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
57711790|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
57711791|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
57711792|NCT03285321|DRUG|Nivolumab|480mg
57711793|NCT03285321|DRUG|Nivolumab|240mg
57711794|NCT03285321|DRUG|Ipilimumab|1mg/kg
58060381|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
58060382|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
58060383|NCT02088736|DEVICE|Intraosseous|
58385008|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
58385009|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
57711795|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
57711796|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
57711797|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
57711798|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
58060384|NCT02088736|DEVICE|Intravenous|
58060385|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
58060386|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
58060387|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
58060388|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
58060389|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
58060390|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
58060391|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
58060392|NCT06447935|OTHER|No intervention|not applicable - no intervention required
58385010|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
58385011|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
58385012|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
58385013|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
58385014|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
58385015|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
58385016|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
57711799|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
57711800|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
57711801|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
58385017|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
58385018|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
58385019|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
58385020|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
58385021|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
57711802|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
57711803|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
57711804|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
57711805|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
57711806|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
57711807|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
57711808|NCT00006482|DRUG|cisplatin|
57711809|NCT00006482|DRUG|gemcitabine hydrochloride|
57711810|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
57711811|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
57711812|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
57711813|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
58060393|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
58060394|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
58060395|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
58060396|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
57711814|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
57711815|NCT02489227|DRUG|CHS-1420|
57711816|NCT02489227|DRUG|Adalimumab|
57711817|NCT01464320|DRUG|ABT-614|Active
57711818|NCT01464320|DRUG|Placebo Comparator|Placebo
57913030|NCT05806307|DRUG|Oxytocin|(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
57913031|NCT05806307|DRUG|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
58060397|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
58060398|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
58385022|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
57711819|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
57711820|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
57913032|NCT05806307|DRUG|Vasopressin|15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
57913033|NCT05806307|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine|15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
57913034|NCT02457559|DRUG|Tirabrutinib|Tablets or capsules administered orally
58060399|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
58060400|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
58060401|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
58060402|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
58060403|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
57711821|NCT02710604|DRUG|CMX157|tablet
57711822|NCT02710604|DRUG|TDF|300mg tablet
57711823|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
57711824|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
58060404|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
58060405|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
58060406|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
58060407|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
58060408|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
57711825|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
57711826|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
58264683|NCT05928559|OTHER|OMRON BF511 Body Composition Monitor|The OMRON BF511 Body Composition Monitor is a digital scale and participants' body compositions will be evaluated with this device. The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test and the maximum oxygen consumption levels will be calculated with the help of the formula with the data obtained from this test. The trunk extensor muscle endurance of the participants will be evaluated with the Biering-Sorensen Test and the trunk flexor endurance will be evaluated with the Kraus-Weber Test. Participants' M. Quadriceps, M. Hamstring, M. Biceps Brachii and M. Triceps Brachii muscle strengths will be evaluated with MicroFET® 2 hand dynamometer.
58264684|NCT06559852|BEHAVIORAL|Yoga|Participants will engage in a 12-week virtual yoga course to assess impact on endometriosis-related pain
58264685|NCT02210286|DIETARY_SUPPLEMENT|Magtein|
58264686|NCT03852927|PROCEDURE|Computer guided contouring|Using virtual planing and rapid prototyping a surgical guide will be fabricated, and will be used for bone contouring of the bone lesion.
58264687|NCT00735137|DEVICE|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
58264688|NCT00002063|DRUG|Zidovudine|
58264689|NCT05102825|DIAGNOSTIC_TEST|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
58264690|NCT05237284|DRUG|SAR443820|Tablet oral
58264691|NCT05237284|DRUG|Placebo|Tablet
58264692|NCT00232596|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
58264693|NCT00232596|DRUG|Placebo|Oral tablet.
58264694|NCT06631482|DEVICE|Maintain HPI < 85|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
58385023|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
58385024|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
58264695|NCT06631482|DRUG|Maintain MAP>=73|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
58264696|NCT03156907|DRUG|Buprenorphine|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
58264697|NCT02957058|PROCEDURE|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
58264698|NCT04420585|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
58264699|NCT06618846|PROCEDURE|laparoscopic sleeve gastric bypass|This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
58264700|NCT04875390|OTHER|Erector spina plane block|After the surgery is completed, intraoperative Erector spina plane block will be performed
58264701|NCT04875390|OTHER|local infiltration|After the surgery is completed, intraoperative local infiltration will be performed
58264702|NCT05528913|DRUG|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
58264703|NCT05528913|OTHER|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
58385025|NCT02866162|GENETIC|High-throughput exome sequencing|
58385026|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
58385027|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
58264704|NCT04242446|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
58264705|NCT04242446|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
58385028|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
58385029|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
58385030|NCT03114111|DRUG|aminolevulinic acid (ALA)|
58264706|NCT06582407|OTHER|Mathematical Prediction of unforseen patient reorientation|The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
58264707|NCT03366324|GENETIC|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
58264708|NCT03366324|PROCEDURE|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
58264709|NCT04531618|BEHAVIORAL|Emotional Exchange (EE)|These sessions, conducted by a trained study staff member through Zoom, will involve storytelling and discussing emotional experiences with the baby, with prompts like sharing about the pregnancy or reactions to the baby's smiles.
58385031|NCT03114111|DRUG|Placebo|
58385032|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
57913035|NCT00926497|OTHER|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
57913036|NCT04750525|DEVICE|BreEStim|120 BreEStim stimuli will applied for about 10 minutes.
57913037|NCT04750525|DEVICE|EStim|120 EStim stimuli will applied for about 10 minutes.
57913038|NCT00305240|PROCEDURE|T Wave Alternans Test|
57913039|NCT02868385|DRUG|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
57913040|NCT02868385|DRUG|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
57913041|NCT02633579|DRUG|erythromycin lactobionate|intravenous administration of erythromycin
57913042|NCT02633579|DRUG|Atropine|intravenous administration of atropine
57913043|NCT02633579|DRUG|Erythromycin with atropine|intravenous administration of erythromycin with saline
57913044|NCT02633579|DRUG|Saline|intravenous administration of saline
58060409|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
58060410|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
58060411|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
58060412|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
58060413|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
58385033|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
58385034|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
58385035|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
58385036|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
58385037|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
57913045|NCT05057299|OTHER|retrospective data analysis|chart review, analysis and reporting outcomes
58385038|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
58385039|NCT03056235|DEVICE|Saline|Saline control
58385040|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
58385041|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
57913046|NCT03394729|DRUG|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
57913047|NCT03394729|DRUG|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
57913048|NCT01531010|DEVICE|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
57913049|NCT03366623|BEHAVIORAL|Hospital clown|Presence of the hospital clown
57913050|NCT03366623|BEHAVIORAL|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
58060414|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
57913051|NCT03922646|BEHAVIORAL|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
57913052|NCT03922646|BEHAVIORAL|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
58060415|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
58264710|NCT04531618|OTHER|Newborn Care (NC)|Newborn Care (NC) is a teaching curriculum designed to provide mothers with developmentally appropriate information about newborn care. The curriculum is adapted from previously studied literature that increased maternal knowledge about both medical and developmental concerns.
58264711|NCT02847923|OTHER|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
58385042|NCT02253095|DRUG|Albendazole|
58264712|NCT02847923|OTHER|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
58264713|NCT02847923|OTHER|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
57913053|NCT03737474|DRUG|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
57913054|NCT04323631|DRUG|Hydroxychloroquine|Oral
57913055|NCT04323631|OTHER|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
57913056|NCT05483634|DRUG|Vaginal estrogen supplement|Daily vaginal estrogen supplement, then twice per week. Continue for three months.
57913057|NCT05483634|PROCEDURE|Platelet-rich plasma injection|Monthly platelet-rich plasma injection for three months
57913058|NCT00287495|DRUG|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
58060416|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
58060417|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
58060418|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
58060419|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
58060420|NCT00039546|DRUG|cyclophosphamide|
58385043|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
58385044|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
58060421|NCT00039546|DRUG|epirubicin hydrochloride|
58060422|NCT00039546|DRUG|gemcitabine hydrochloride|
58060423|NCT00039546|DRUG|paclitaxel|
58060424|NCT00039546|PROCEDURE|adjuvant therapy|
58060425|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
58060426|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
58264714|NCT02847923|OTHER|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
58385045|NCT02253095|DRUG|Placebo|
58385046|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
58385047|NCT02372695|DRUG|Paricalcitol|
58385048|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
58385049|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
58385050|NCT01253369|DRUG|Pazopanib|
57711827|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
57711828|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
57711829|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
57711830|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
57711831|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
57711832|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
57711833|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
57711834|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
57711835|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
57711836|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
57711837|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
57711838|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
57711839|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
57711840|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
57711841|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
57711842|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
57711843|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
57711844|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
57913059|NCT03643393|PROCEDURE|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
57913060|NCT04552977|DRUG|fluzoparil|a PARP1 inhibitor
58385051|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
58385052|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
58385053|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
58385054|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
57913061|NCT04552977|DRUG|temozolomide|an alkylating chemotherapeutic agent
58060427|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
57711845|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
57711846|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
58385055|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
57711847|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
57711848|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
57711849|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
57711850|NCT03592641|DRUG|Savolitinib|Given PO
57711851|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
57711852|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
57711853|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
57711854|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
57711855|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
57711856|NCT00392613|PROCEDURE|Strict versus lenient rate control|
57711857|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
57711858|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
57913062|NCT02469389|BEHAVIORAL|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
57913063|NCT02469389|BEHAVIORAL|Health & Wellness (H&W)|"Health \& Wellness (H\&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
58060428|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
57711859|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
57711860|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
57913064|NCT00557934|OTHER|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
57913065|NCT00730457|BIOLOGICAL|VAX125|Single intramuscular dose
57913066|NCT02912676|DRUG|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
58060429|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
58060430|NCT03538899|DRUG|AProArt|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
57711861|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
57711862|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
57711863|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
57711864|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
57711865|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
58385056|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
57913067|NCT02533570|DRUG|Brentuximab vedotin|
57913068|NCT02533570|DRUG|Placebo|
57913069|NCT00158860|DRUG|Valaciclovir|1g once daily
58385057|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
58385058|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
57711866|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
57711867|NCT02384603|OTHER|Global postural reeducation|
57711868|NCT02384603|OTHER|Segmental muscle stretching exercises|
57913070|NCT00158860|DRUG|Placebo|placebo
57913071|NCT04000360|OTHER|High-Intensity Aerobic Exercise|The home-based exercise group will receive a Peloton indoor cycle delivered to their home and a heart rate monitor strap. Participants will be asked to cycle 3x/week for 12 months on their bike with their heart rate monitor at an aerobic intensity between 60-80% of heart rate reserve with a target cadence between 80-90 revolutions per minute (RPMs). Additionally, participants (both groups) will receive activity monitors to monitor their daily activity levels.
57913072|NCT01372423|DRUG|Lubiprostone|24 mcg capsules
58264715|NCT04593095|OTHER|NeuroN-QI|SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
57913073|NCT01372423|DRUG|Placebo|24 mcg capsules
58385059|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
58385060|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
58385061|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
58385062|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
57913074|NCT01290315|DRUG|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
58385063|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
58385064|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
57711869|NCT02384603|OTHER|Cognitive behavioral therapy|
57913075|NCT01290315|DRUG|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
58060431|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
57711870|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
57711871|NCT01823029|DRUG|erythropoietin|
57711872|NCT01823029|DRUG|enteral nutrition.|
57913076|NCT00408239|DRUG|YM150|Oral
58264716|NCT04887636|OTHER||
57913077|NCT00408239|DRUG|enoxaparin|Sub cutaneous
57913078|NCT01090427|DRUG|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
58385065|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
57711873|NCT01823029|DRUG|injection of iron|
57711874|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
57711875|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
57711876|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
57711877|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
57711878|NCT00333229|DRUG|Placebo|Matching Placebo
57711879|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
57711880|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
57711881|NCT00466960|BIOLOGICAL|sargramostim|Given SC
57913079|NCT01090427|DRUG|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
57913080|NCT01090427|OTHER|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
57913081|NCT03782220|OTHER|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
57913082|NCT03782220|OTHER|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
58385066|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
58385067|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
58385068|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
58385069|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
58385070|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
58385071|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
58385072|NCT05005273|OTHER|Placebo|Specified dose on specified days
58385073|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
58385074|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
57711882|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
57711883|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
57711884|NCT00466960|OTHER|immunologic technique|Correlative studies
57711885|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
57711886|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
57711887|NCT02966171|DRUG|HMPL-453|oral administration
57711888|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
57711889|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
57711890|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
57711891|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
57913083|NCT04217629|DRUG|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
57913084|NCT02977585|DEVICE|10 cmH2O peep|positive end expiratory pressure
57913085|NCT01869582|DEVICE|Fetoscope, Fetal heart rate|
57913086|NCT01869582|DEVICE|Upright Resuscitator, Resuscitation|
57913087|NCT01869582|DEVICE|Doppler, Fetal heart rate|
57913088|NCT01869582|DEVICE|Standard Resuscitator, Resuscitation|
57913089|NCT05665465|DRUG|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
57913090|NCT05665465|DRUG|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
57913091|NCT02087709|OTHER|Low-calorie diet|
58385075|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
57913092|NCT01241175|DRUG|Magnesium Sulfate|
57913093|NCT01241175|DRUG|normal saline|
57913094|NCT04161495|BIOLOGICAL|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV injection
57913095|NCT00622258|DRUG|Everolmus|
57913096|NCT03525431|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
58060432|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
58060433|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
58060434|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
58060435|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
58060436|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
58060437|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
58060438|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
58060439|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
58060440|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
58060441|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
58060442|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
58060443|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
58060444|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
58060445|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
58385076|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
58385077|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
58060446|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
58060447|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
58060448|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
58060449|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
58060450|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
57913097|NCT01559753|DRUG|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
58264717|NCT00566956|PROCEDURE|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
58264718|NCT06359314|BEHAVIORAL|ALDER|The ALDER skills are delivered over approximately 5 weeks. A week consists of learning at least one skill and then applying that skill(s) in daily home practice throughout the week. Skill lessons and daily home practice exercises are housed on the ALDER website. Participants have the option to share their home practice responses with fellow participants by posting them to the discussion board, where they can like and comment on each other's posts.
58264719|NCT05265091|DRUG|KL590586 Capsule|Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
58060451|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
58264720|NCT02779335|OTHER|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
58264721|NCT03714646|DIETARY_SUPPLEMENT|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
58264722|NCT03714646|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before the CID
58264723|NCT03714646|DIETARY_SUPPLEMENT|beta gluten|12 g beta gluten there day before the CID
58264724|NCT03048123|PROCEDURE|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
58264725|NCT03048123|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
58264726|NCT03048123|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
58264727|NCT03048123|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
58264728|NCT05212220|BEHAVIORAL|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
58264729|NCT05212220|BEHAVIORAL|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
58264730|NCT02925715|PROCEDURE|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
58264731|NCT00005072|BIOLOGICAL|Leuvectin|1000 ug of Leuvectin injected intratumorally
58264732|NCT02174913|DEVICE|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
58264733|NCT02174913|DRUG|Target controlled infusion of propofol|TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
58385078|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
58264734|NCT02174913|DRUG|Fentanyl|Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
58264735|NCT02174913|DRUG|Atracurium|Atracurium 0.6 mg/kg is used for endotracheal intubation
58385079|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
58264736|NCT01342250|BIOLOGICAL|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
58060452|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
57711892|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
58264737|NCT01342250|BIOLOGICAL|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
58264738|NCT01342250|BIOLOGICAL|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
58264739|NCT02035748|DRUG|Ocriplasmin|0.5 mg/0.2 mL solution for injection
58264740|NCT03240523|DRUG|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
58264741|NCT01189734|PROCEDURE|laparoscopic common bile duct exploration|
58264742|NCT01189734|PROCEDURE|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
58264743|NCT05413343|DRUG|Ceftazidime-avibactam|Patients with severe sepsis and treatment with Ceftazidime-Avibactam will be enrolled. Blood samples at 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of Ceftazidime-avibactam.
58264744|NCT05519137|DEVICE|Active lighting intervention|Lighting intervention designed to impact the circadian system
58264745|NCT05519137|DEVICE|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
58385080|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
58385081|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
58264746|NCT03043157|DRUG|rocuronium|intravenous rocuronium infusion
58264747|NCT00385775|DRUG|AEG35156|weekly IV solution infused over 2 hrs
58264748|NCT04695951|DIETARY_SUPPLEMENT|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
58385082|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
58385083|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
58264749|NCT04695951|OTHER|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
58385084|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
58385085|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
57711893|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
58060453|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
58060454|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
58060455|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
58060456|NCT02108795|DRUG|Placebo|
58264750|NCT06649474|BIOLOGICAL|assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy|assess the serum HMGB1 concentrations
58060457|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
58264751|NCT05908331|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
58264752|NCT05908331|DEVICE|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
58264753|NCT06648551|DIAGNOSTIC_TEST|CONUT|It is a scale that uses albumin, lymphocytes, and cholesterol for the diagnosis of malnutrition
58264754|NCT06645912|DIETARY_SUPPLEMENT|oral nutritional supplement|The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
58264755|NCT04808232|BEHAVIORAL|progressive muscle relaxation exercise|"We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body."
58264756|NCT05470010|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
58385086|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
58385087|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
58385088|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
58385089|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
58385090|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
58385091|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
58385092|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
58385093|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
58385094|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
58385095|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
58385096|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
58264757|NCT06612437|DEVICE|Theta burst stimulation (TBS)|Device: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. The stimulation will be delivered with an intensity of 70% individual resting motor threshold .
58385097|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
58060458|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
58060459|NCT00114257|DRUG|decitabine|
58060460|NCT00114257|DRUG|romidepsin|
58060461|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
58060462|NCT02220660|DRUG|BI 1744 CL|
58060463|NCT02220660|DRUG|BI 54903 XX|
58060464|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
58060465|NCT02220660|DRUG|Placebo|
58060466|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
58060467|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
58060468|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
57711894|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
57711895|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
57711896|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
58060469|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
58060470|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
58060471|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
58060472|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
58060473|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
58385098|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
57711897|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
58060474|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
58060475|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
58060476|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
58060477|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
58060478|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
58060479|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
58060480|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
58060481|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
58060482|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
58385099|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
58385100|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
58385101|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
58385102|NCT04774068|DRUG|Parsaclisib|Given PO
58385103|NCT04774068|DRUG|Romidepsin|Given IV
58385104|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
58060483|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
58060484|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
58060485|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
58060486|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
58385105|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
58060487|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
58060488|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
58060489|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
58060490|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
58060491|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
58385106|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
57711898|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
57913098|NCT01559753|DRUG|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
57913099|NCT05808881|DRUG|Nalmefene Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
57913100|NCT05808881|DRUG|Naloxone Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
57913101|NCT02518321|DEVICE|Technology-Assisted Toileting|
57913102|NCT00946101|BIOLOGICAL|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
58060492|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
58060493|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
58060494|NCT01551381|DRUG|EV-077|twice daily oral administration
58060495|NCT01551381|DRUG|Placebo|twice daily oral administration
58060496|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
58060497|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
58060498|NCT00519558|DRUG|somatropin|
58060499|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
58060500|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
58060501|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
58060502|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
58060503|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
58060504|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
57913103|NCT00946101|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
57913104|NCT01786473|DRUG|Testogel 1%|
57913105|NCT01786473|DRUG|Placebo|
57913106|NCT02551406|DEVICE|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
58060505|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
58060506|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
58060507|NCT01293214|PROCEDURE|Limb transplantation|
57711899|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
57711900|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
58060508|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
58060509|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
58060510|NCT02477800|DRUG|Placebo|Placebo
58060511|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
58060512|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
58060513|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
58060514|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
58060515|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
58060516|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
58060517|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
58060518|NCT04804072|OTHER|Primary care|Primary care
58060519|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
58060520|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
58060521|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
58264758|NCT06612437|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device.
58264759|NCT02982616|DIETARY_SUPPLEMENT|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
58264760|NCT02982616|BEHAVIORAL|Positive emotion|Positive emotion induced by facial expressions and classic music.
58264761|NCT02982616|DIETARY_SUPPLEMENT|saline|saline
58385107|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
58385108|NCT00000763|DRUG|TNP-470|
58385109|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
57913107|NCT04331145|DRUG|Ticagrelor 60mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
57913108|NCT01576250|OTHER|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
57711901|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
57711902|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
57711903|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
57711904|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
57913109|NCT05557357|PROCEDURE|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
57913110|NCT05557357|PROCEDURE|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
58060522|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
58264762|NCT02982616|BEHAVIORAL|neutral emotion|Neutral emotion induced by facial expressions and classic music.
58264763|NCT04546516|DEVICE|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
57711905|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
57711906|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
58060523|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
58264764|NCT06293040|DRUG|Cannabis|Cannabis will be vaporized using the Mighty Medic
58264765|NCT06293040|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
58264766|NCT06293040|DRUG|Placebo Cannabis|Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
58264767|NCT06293040|DRUG|Placebo Alcohol|A non-alcoholic, placebo, flavored drink will be orally ingested.
58264768|NCT04086589|OTHER|Observational study without intervention|Observational study without intervention
58264769|NCT02147951|DRUG|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
58385110|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
58385111|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
58060524|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
58060525|NCT06045936|DRUG|Placebo|Saline injection
58060526|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
58060527|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
58060528|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
57711907|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
57711908|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
57711909|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
57711910|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
58060529|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
58060530|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
58060531|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
58060532|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
58060533|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
58060534|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
57711911|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
57711912|NCT01043965|DRUG|Metformin|Metformin 850mg
57711913|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
57711914|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
57711915|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
57711916|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
57711917|NCT00548860|DRUG|Ferric Carboxymaltose|
57711918|NCT00548860|DRUG|Standard Medical Care (SMC)|
57711919|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
57711920|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
57711921|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
57711922|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
57711923|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
57711924|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
57913111|NCT05557357|OTHER|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
58060535|NCT02198313|DRUG|BIIX 1 XX - D1|
58060536|NCT02198313|DRUG|BIIX 1 XX - D2|
58060537|NCT02198313|DRUG|BIIX 1 XX - D3|
58060538|NCT02198313|DRUG|Placebo|
58060539|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
58060540|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
58060541|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
58060542|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
58060543|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
58060544|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
58060545|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
58060546|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
58385112|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
58385113|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
58385114|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
58385115|NCT00005987|DRUG|carmustine|
58385116|NCT00005987|DRUG|cyclophosphamide|
58385117|NCT00005987|DRUG|dexamethasone|
58385118|NCT00005987|DRUG|etoposide|
57711925|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
58060547|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
58060548|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
58264770|NCT04612777|BEHAVIORAL|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
58264771|NCT04612777|BEHAVIORAL|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
58385119|NCT00005987|DRUG|filgrastim|
58385120|NCT00005987|DRUG|mitoxantrone hydrochloride|
58385121|NCT00005987|DRUG|recombinant interferon alfa|
58385122|NCT00005987|DRUG|sargramostim|
58385123|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
58385124|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
58385125|NCT00005987|PROCEDURE|radiation therapy|
58385126|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
58060549|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
58060550|NCT01364948|OTHER|No oil application|Oil application was not done
58385127|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
58385128|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
58385129|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
58060551|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
58060552|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
58385130|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
58385131|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
57711926|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
57711927|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
57711928|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
57711929|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
57711930|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
58385132|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
58385133|NCT02012855|BEHAVIORAL|Exercise|
58385134|NCT02012855|OTHER|Diet (meal type)|
58264772|NCT04612777|BEHAVIORAL|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
58385135|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
58385136|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
58385137|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
57711931|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
57913112|NCT05618834|BEHAVIORAL|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
57711932|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
58385138|NCT01283438|DEVICE|Barricaid|Annular closure device
58385139|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
57913113|NCT05618834|BEHAVIORAL|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
57913114|NCT04800432|BEHAVIORAL|ADAPT+|ADAPT+ is designed as an 6-week intervention. For each session, children and parents participate in separate 1.5-hour group meetings, followed by a joint goal setting session. Practical strategies related to improving diet and physical activity as well as the role of dealing with parent stress-related factors related to making long-lasting behavioral changes in the family are addressed.
57913115|NCT04800432|BEHAVIORAL|EUC|Enhanced Usual Care is an abbreviated version of the full ADAPT+ intervention in which parents are engaged in a one-time, two hour information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
57913116|NCT05537831|DEVICE|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
58060553|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
58060554|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
58385140|NCT02497222|DRUG|RNS60|
58385141|NCT02497222|DRUG|Normal Saline|
58385142|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
58060555|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
58385143|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
58385144|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
58385145|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
58385146|NCT01941654|RADIATION|preemptive local ablative therapy|
58385147|NCT01941654|DRUG|Oral TKI|
58385148|NCT05592990|DRUG|NGI226|NGI226 MP
58385149|NCT05592990|DRUG|Placebo|Placebo MP
58385150|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
58385151|NCT02663427|DEVICE|serological examination and gastroscope|
58385152|NCT00161044|DRUG|Galantamine|
58385153|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
58385154|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
58385155|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
58385156|NCT00440492|DRUG|PLA-695|
58060556|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
57913117|NCT03082404|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
58060557|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
58060558|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
58060559|NCT00258596|DEVICE|sirolimus-eluting stent|
58060560|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
58264773|NCT04000698|DRUG|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
58385157|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
58385158|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
58385159|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
58385160|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
58385161|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
57913118|NCT00090129|DRUG|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
57913119|NCT00090129|DRUG|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
58060561|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
58060562|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
58060563|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
58060564|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
58060565|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
58264774|NCT05622045|BEHAVIORAL|Voice data|Recorded response to a question about their participation in a weight loss study.
58060566|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
58060567|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
58060568|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
58060569|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
58060570|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
58060571|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
58264775|NCT05538767|DRUG|Emodepside|Treatment with Emodepside 30 mg
58264776|NCT05538767|DRUG|Albendazole 400mg|Treatment with Albendazole 400 mg
58264777|NCT02829827|DRUG|Radiprodil|Radiprodil at individualized doses.
58385162|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
58385163|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
58385164|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
58385165|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
58385166|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
58264778|NCT01768975|DRUG|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
58264779|NCT01768975|OTHER|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
58264780|NCT02079636|DRUG|Abemaciclib|Administered orally
58264781|NCT02079636|DRUG|Pemetrexed|Administered IV
58264782|NCT02079636|DRUG|Gemcitabine|Administered IV
58264783|NCT02079636|DRUG|Ramucirumab|Administered IV
58264784|NCT02079636|DRUG|LY3023414|Administered orally
58264785|NCT02079636|DRUG|Pembrolizumab|Administered IV
57913120|NCT06043583|PROCEDURE|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
57913121|NCT06043583|PROCEDURE|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
57913122|NCT03592550|DEVICE|Ultrasound imaging|Abdominal ultrasound imaging of the liver
57913123|NCT04603638|DRUG|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
57913124|NCT04603638|DRUG|Isotonic|100 ml
57913125|NCT02716818|DRUG|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
57913126|NCT02716818|DRUG|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
57913127|NCT00599911|DRUG|Lu AA24530|per oral, once daily for 6 weeks
57913128|NCT00599911|DRUG|Duloxetine|per oral, once daily for 6 weeks
57913129|NCT00599911|DRUG|Placebo|per oral, once daily for 6 weeks
57913130|NCT02656823|DEVICE|ANKYLOS C/X implant A 6.6|Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
57913131|NCT00025103|BIOLOGICAL|dactinomycin|
57913132|NCT00025103|DRUG|carboplatin|
57913133|NCT00025103|DRUG|cyclophosphamide|
57913134|NCT00025103|DRUG|doxorubicin hydrochloride|
57913135|NCT00025103|DRUG|etoposide|
57913136|NCT00025103|DRUG|melphalan|
57913137|NCT00025103|DRUG|vincristine sulfate|
57913138|NCT00025103|PROCEDURE|autologous bone marrow transplantation|
57913139|NCT00025103|PROCEDURE|conventional surgery|
57913140|NCT00025103|PROCEDURE|peripheral blood stem cell transplantation|
57913141|NCT00025103|RADIATION|radiation therapy|
57913142|NCT06308003|PROCEDURE|Anterior hip arthroplasty|Anterior hip arthroplasty
57913143|NCT05963490|DRUG|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
57913144|NCT05963490|DRUG|Toripalimab|240 mg intravenously every 3 weeks
57913145|NCT05963490|RADIATION|Radiotherapy|hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).
57913146|NCT05963490|DRUG|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
57913147|NCT02119845|DEVICE|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
57913148|NCT00679393|PROCEDURE|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
57913149|NCT00679393|PROCEDURE|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
57913150|NCT01462123|OTHER|endoscopic assessment of colonic polyps|
57913151|NCT00307502|DRUG|Nevirapine|tablets 200 mg, 400 mg/day
57913152|NCT00307502|DRUG|Efavirenz|tablets 600 mg, 600 mg/day
57913153|NCT00307502|DRUG|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
57913154|NCT00307502|DRUG|Nelfinavir|tablets 250 mg, 2500 mg/day
57913155|NCT00307502|DRUG|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
57913156|NCT00307502|DRUG|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
57913157|NCT00307502|DRUG|Atazanavir|capsules 200 mg, 400 mg/day
57913158|NCT00307502|DRUG|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
57913159|NCT00307502|DRUG|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
57913160|NCT00307502|DRUG|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
57913161|NCT00307502|DRUG|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
57913162|NCT01690598|DRUG|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
57913163|NCT01690598|DRUG|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
57913164|NCT03998982|DRUG|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
57913165|NCT03998982|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
58264786|NCT02823392|OTHER|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 \< 95%).
58385167|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
58385168|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
58264787|NCT04505384|PROCEDURE|left bundle branch pacing|left bundle branch pacing
58264788|NCT04505384|PROCEDURE|biventricular pacing|biventricular pacing
58264789|NCT03228316|PROCEDURE|superior hypogastric plexus block|nerve plexus block
58385169|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
58385170|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
58385171|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
58385172|NCT03462758|DEVICE|IUD|Postpartum IUD placement
58385173|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
58385174|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
58385175|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
58060572|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
58385176|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
58385177|NCT04812535|DRUG|IFX-1|IFX-1 Monotherapy
58385178|NCT04812535|DRUG|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
58385179|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
58385180|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
58385181|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
58060573|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
58385182|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
57913166|NCT04725786|OTHER|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
58264790|NCT03228316|RADIATION|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
58264791|NCT04374682|OTHER|exercises|stretching exercises - physiotherapy modalities - self care instructions
58264792|NCT00000865|DRUG|Abacavir sulfate|
58264793|NCT00000865|DRUG|Lamivudine|
58264794|NCT00000865|DRUG|Stavudine|
58264795|NCT00000865|DRUG|Zidovudine|
58264796|NCT00000865|DRUG|Didanosine|
58264797|NCT01115556|DRUG|Ranibizumab|2.0 mg
58264798|NCT01115556|DRUG|Ranibizumab|0.5 mg
58264799|NCT01576276|RADIATION|Integrated MR-PET scan|Integrated MR-PET scan using \[11C\]diprenorphine
58264800|NCT01576276|DRUG|Ketorolac|3 administrations of ketorolac over course of study
58385183|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
58385184|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
58060574|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
58060575|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
58060576|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
57913167|NCT04201964|DRUG|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
57913168|NCT00065377|DRUG|Glucosamine Hydrochloride|
57913169|NCT01237587|DRUG|Duloxetine|Administered orally
57913170|NCT01237587|DRUG|Placebo|Administered orally
57913171|NCT04637178|BEHAVIORAL|Resistance training|Resistance training sessions twice a week for ten weeks
57913172|NCT04637178|BEHAVIORAL|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
57913173|NCT00349674|DRUG|Azathioprine: 2 mg/kg/day|
57913174|NCT00349674|DRUG|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
57913175|NCT01251250|OTHER|laboratory biomarker analysis|Correlative studies
57913176|NCT01251250|GENETIC|western blotting|Correlative studies
57913177|NCT01251250|GENETIC|gene expression analysis|Correlative studies
58060577|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
58060578|NCT02029885|DEVICE|Sham Control|
58060579|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
58060580|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
58060581|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
58060582|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
58060583|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
57913178|NCT01251250|OTHER|pharmacological study|Correlative studies
57913179|NCT01251250|OTHER|flow cytometry|Correlative studies
57913180|NCT01251250|GENETIC|fluorescence in situ hybridization|Correlative studies
57913181|NCT01251250|BIOLOGICAL|azadirachta indica|Given orally
57913182|NCT01251250|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
57913183|NCT00320125|DIETARY_SUPPLEMENT|Orange juice plus calcium|\> 1,200mg Ca (four glasses of orange juice plus calcium)per day
57913184|NCT00320125|DIETARY_SUPPLEMENT|Dairy products|\> 1,200mg Ca (by consuming milk, yogurt, and cheese)
58060584|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
58060585|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
58060586|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
58060587|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
58060588|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
58060589|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
58060590|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
58060591|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
58060592|NCT05192044|OTHER|Conventional Care|Conventional Care
57913185|NCT06058754|BEHAVIORAL|The ADAPT Program|The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0
57913186|NCT06058754|BEHAVIORAL|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
57913187|NCT06211881|DRUG|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
57913188|NCT06152809|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
58385185|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
58385186|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
57913189|NCT06152809|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.
57913190|NCT06152809|DRUG|Venetoclax|Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
58385187|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
58385188|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
57913191|NCT00066313|DRUG|vandetanib|
58060593|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
58264801|NCT04742660|DRUG|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
58385189|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
58385190|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
58385191|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
58385192|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
58060594|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
58385193|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
58060595|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
58060596|NCT04547127|DRUG|Standard Medical Treatment|SMT
58060597|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
58264802|NCT00781170|PROCEDURE|allogeneic hematopoietic SCT|
58264803|NCT06197503|PROCEDURE|Conduction system pacing|Left bundle branch pacing or His bundle branch pacing
58264804|NCT06197503|PROCEDURE|Right ventricular pacing|Conventional pacing
58264805|NCT02494375|OTHER|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
58264806|NCT02873572|BEHAVIORAL|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
58385194|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
57711933|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
57913192|NCT00066313|PROCEDURE|adjuvant therapy|
57913193|NCT02816242|OTHER|concept map teaching|teaching anatomy using concept map to improve critical thinking
58385195|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
58385196|NCT00890435|OTHER|questionnaire administration|
57913194|NCT02816242|OTHER|traditional teaching|teaching anatomy using lecture
57913195|NCT03272126|DRUG|Vitamin D|vitamin D given as bolus versus daily dosing
57913196|NCT03272126|DRUG|Placebo|identical looking as vitamin D
57913197|NCT00804089|PROCEDURE|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
57913198|NCT00804089|PROCEDURE|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
58385197|NCT00890435|PROCEDURE|psychosocial assessment and care|
58385198|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
58385199|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
58385200|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
58385201|NCT00852579|DRUG|Placebo|Placebo
58385202|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
58385203|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
58385204|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
58264807|NCT02873572|BEHAVIORAL|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~* psychiatric assesment and~* registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
58264808|NCT03129282|OTHER|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
58264809|NCT02719938|BEHAVIORAL|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
58264810|NCT04935840|DIETARY_SUPPLEMENT|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
58264811|NCT04935840|OTHER|Control|400 mcg of folic acid
58385205|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
57913199|NCT00804089|PROCEDURE|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
58060598|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
58060599|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
58060600|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
58264812|NCT03962231|OTHER|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
58264813|NCT03962231|OTHER|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
58264814|NCT03711149|OTHER|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
58264815|NCT05959408|PROCEDURE|Collection of throat swab|Introduction of a cotton swab for self-collection
58264816|NCT05959408|PROCEDURE|Collection of anal swab|Introduction of a cotton swab for self-collection
58264817|NCT05959408|PROCEDURE|Collection of first void urine|first void urine collected on urine pot
58385206|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
58385207|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
58385208|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
57711934|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
57711935|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
57913200|NCT01406964|OTHER|CAT test|A CAT test is performed in order to diagnose tubal factor causes
57913201|NCT01406964|OTHER|Histerosalpingography|A Histerosalpingography is performed.
57913202|NCT04185454|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daily intake of Jarlsberg cheese
58385209|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
58385210|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
58385211|NCT00000325|BEHAVIORAL|Gonadorelin|
58060601|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
58264818|NCT03480698|DRUG|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
58264819|NCT05048212|DRUG|Nivolumab|Given by IV
58264820|NCT05048212|DRUG|Ipilimumab|Given by IV
58385212|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
58060602|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
58264821|NCT05048212|DRUG|Cabozantinib|Given by IV
58264822|NCT02351193|OTHER|transvaginal Ultrasound|
58385213|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
58385214|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
58385215|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
58060603|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
58060604|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
58264823|NCT04329091|DRUG|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
58264824|NCT05678244|DRUG|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
58385216|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
58385217|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
58385218|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
58385219|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
58264825|NCT05678244|DRUG|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
58385220|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
58385221|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
58060605|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
58060606|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
58060607|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
58060608|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
58060609|NCT00761033|BEHAVIORAL|music|
58264826|NCT04282291|PROCEDURE|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
58385222|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
57913203|NCT03636282|BEHAVIORAL|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
57913204|NCT01013454|DRUG|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
57913205|NCT02443974|DEVICE|Brace (Fisiotensor®)|
57913206|NCT02443974|DEVICE|Sleeve (Fisiotensor®)|
57913207|NCT00883051|DRUG|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
58060610|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
58060611|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
58060612|NCT03460665|PROCEDURE|Arteriography|knee arteriography
58264827|NCT04282291|DRUG|Morphine|The continuous (basal) dose
58264828|NCT04282291|DEVICE|PCA CADD Smith Medical pumps|perfusion
58385223|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
57913208|NCT00883051|DRUG|Placebo|Placebo
58060613|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
58060614|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
58060615|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
58060616|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
58264829|NCT00260312|BIOLOGICAL|Inactivated Polio Vaccine given at an accelerated schedule|
58264830|NCT06100692|DRUG|Vitamin D|the patients will receive a 30 pts a combination of oral vit D and zinc
58264831|NCT03720145|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
58264832|NCT00437827|OTHER|Star*D algorithm|Standard of care based upon the therapies selected in the Star\*D study.
57711936|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
57711937|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
57711938|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
57913209|NCT04557943|DRUG|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
58264833|NCT00437827|OTHER|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
58264834|NCT00389298|DRUG|VCH-759 (BCH-27759)|
58264835|NCT04250233|DEVICE|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
58264836|NCT05274542|OTHER|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
58385224|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
58385225|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
58385226|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
57711939|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
57711940|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
57711941|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
57711942|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
57711943|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
57711944|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
57711945|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
57711946|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
57711947|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
58385227|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
58385228|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
57711948|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
57711949|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
58264837|NCT05274542|OTHER|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
58385229|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
57711950|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
58264838|NCT06623045|OTHER|Pelvic floor muscle training intervention|"The training program consisted of 12 weeks of PFM exercises, 3 times per week, with each session lasting between 10 and 15 minutes. The program followed different stages through the weeks: (1) proprioception of pelvic floor muscles activation and integration with diaphragmatic breathing, (2) stabilization and strengthening of the pelvic floor musculature through progressive overloading, and (3) transference of these exercises to FFT practice. During the 12 weeks, short contractions (2) were combined with longer ones (5 to 10), carrying out the progressive overload by increasing the number of contractions, the duration of the contraction, or by evolving the execution position towards more upright postures and sporting movements."
58264839|NCT05832918|OTHER|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
58264840|NCT04080674|OTHER|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
58385230|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
58385231|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
58264841|NCT05631106|BEHAVIORAL|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
58264842|NCT05631106|BEHAVIORAL|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
58264843|NCT03118141|PROCEDURE|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
58264844|NCT03118141|PROCEDURE|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
58264845|NCT03118141|PROCEDURE|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
58264846|NCT06648616|OTHER|EBT|Elastic Band Resistance Training
58385232|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
57711951|NCT00263523|DRUG|[11C] (-)-RWAY|
57711952|NCT02130401|DEVICE|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
57711953|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
58060617|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
58060618|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
58264847|NCT03667872|PROCEDURE|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
58264848|NCT02170467|OTHER|assessment of the intestinal permeability|
57913210|NCT04557943|DRUG|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
57913211|NCT00484133|DRUG|Dopamine|
57913212|NCT00484133|DRUG|dobutamine|
57913213|NCT00484133|DRUG|enoximone|
58060619|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
58060620|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
58060621|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
58060622|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
58060623|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
58385233|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
58385234|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
58385235|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
58060624|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
58385236|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
58385237|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
58385238|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
58385239|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
58385240|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
58385241|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
57913214|NCT00484133|DRUG|nitroglycerine|
57913215|NCT00484133|DRUG|noradrenaline|
57913216|NCT06327308|DIAGNOSTIC_TEST|MRI|The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination.
57913217|NCT06327308|BIOLOGICAL|Blood sampling|Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
57913218|NCT02732977|OTHER|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
57913219|NCT02125747|OTHER|No Respiratory Therapy|Patients received conventional treatment.
58060625|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
58060626|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
58264849|NCT04574934|OTHER|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
58264850|NCT01949441|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
58264851|NCT01949441|BIOLOGICAL|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
58264852|NCT04791540|DIAGNOSTIC_TEST|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
58264853|NCT04791540|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
58385242|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
58385243|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
57711954|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
57711955|NCT06182267|DRUG|L Arginine|toothpaste
58385244|NCT03544593|DEVICE|Revolve System|Fat grafting system
58385245|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
58385246|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
58385247|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
58385248|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
58385249|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
58385250|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
58385251|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
58385252|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
58385253|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
58385254|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
57711956|NCT06182267|DRUG|Sodium Fluoride|toothpaste
57711957|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
57711958|NCT03906669|DRUG|Letrozole|PO daily for 14 days
57711959|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
57711960|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
58264854|NCT04791540|DIAGNOSTIC_TEST|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
57913220|NCT02125747|OTHER|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
57913221|NCT05982132|OTHER|anthropometric measurement|Measurement of weight and other anthropometrics data
57913222|NCT05296018|OTHER|Mandala coloring page|Mandala program will be applied three days a week (30 minutes) for 8 weeks.
58264855|NCT04791540|DIAGNOSTIC_TEST|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
58385255|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
58385256|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
58385257|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
58385258|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
57913223|NCT02825030|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation-SR15-78_Y73-167).
58385259|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
58385260|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
58385261|NCT00481455|DRUG|Temozolomide|Fixed dose
58385262|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
58385263|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
58385264|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
58385265|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
58385266|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
58385267|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
58385268|NCT01627626|DRUG|saline|0.9% saline solution
58385269|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
58060627|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
58060628|NCT00003684|DRUG|theophylline|
58060629|NCT00003684|PROCEDURE|quality-of-life assessment|
58264856|NCT04791540|BIOLOGICAL|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
58264857|NCT04791540|BIOLOGICAL|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
58264858|NCT04791540|OTHER|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
58264859|NCT00821223|PROCEDURE|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
58264860|NCT00821223|PROCEDURE|manual small incision surgery|
58264861|NCT00821223|PROCEDURE|phacoemulsification|cataract surgery
58264862|NCT06361303|DEVICE|SNOO Bassinet|This is a non-interventional, prospective observational and descriptive active surveillance study of a cohort of individuals who have purchased or rented a SNOO for use with their infant.
58264863|NCT00876226|DRUG|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
58264864|NCT01721915|DRUG|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
57913224|NCT04568694|PROCEDURE|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
57913225|NCT04568694|PROCEDURE|Conventional Lung Transplantation|Reference Therapy
57913226|NCT04226885|DRUG|fentanyl|nebulized fentanyl 2μg/kg body weigh
57913227|NCT04226885|DRUG|midazolam|nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
58060630|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
58060631|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
58060632|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
58060633|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
58060634|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
58060635|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
58060636|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
58264865|NCT01721915|DRUG|Placebo|
58264866|NCT00383695|BIOLOGICAL|cetuximab|
58264867|NCT00383695|DRUG|capecitabine|
58264868|NCT00383695|DRUG|oxaliplatin|
58060637|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
58060638|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
57913228|NCT04226885|DRUG|dexmedetomidine|nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
57913229|NCT00479492|DRUG|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
58060639|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
58060640|NCT01924260|DRUG|alisertib|Given PO
58060641|NCT01924260|DRUG|gemcitabine|Given IV
58060642|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
58060643|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
57913230|NCT00479492|DRUG|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
57913231|NCT00479492|DRUG|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
57913232|NCT00479492|DRUG|placebo|placebo administered QD for 84 days
57913233|NCT01871701|DRUG|Escitalopram|Escitalopram
58060644|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
58060645|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
58060646|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
58060647|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
58060648|NCT00498927|DRUG|temozolomide|
58264869|NCT00383695|PROCEDURE|adjuvant therapy|
58264870|NCT00383695|PROCEDURE|conventional surgery|
58264871|NCT00383695|PROCEDURE|neoadjuvant therapy|
58264872|NCT00383695|RADIATION|radiation therapy|
58264873|NCT03613883|PROCEDURE|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
58264874|NCT01947426|DIETARY_SUPPLEMENT|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
58264875|NCT01947426|DIETARY_SUPPLEMENT|Control (milk without DHA)|mothers consuming placebo product and their neonates
58264876|NCT05621005|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
58264877|NCT06648291|DEVICE|QOCA EKG Device|The investigators scheduled telephone interviews every three days to encourage and monitor the development of good self-health care behaviors by: (1) asking about daily blood pressure, weight, and lower extremity edema; (2) providing medication counseling, as well as exercise and dietary hygiene recommendations; (3) offering wound care guidance; (4) advising on the proper use of wounds; (5) advising on avoiding cardiac risk factors such as smoking and secondhand smoke; and (6) following up on physical status at outpatient clinics and assisting with referrals to relevant clinics, such as nutrition or rehabilitation, based on the patient's condition. A QOCA portable electrocardiogram (ECG) measurement device will be provided for patients to use at home. In the event of abnormal physiological values, the investigator will contact the patient to assess his or her medical status and provide 24-hour online counseling.
58264878|NCT06648291|OTHER|Usual Care|Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
58264879|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
57913234|NCT01871701|DRUG|Quetiapine|Quetiapine
57913235|NCT01871701|DRUG|Moxifloxacin|Moxifloxacin
57913236|NCT01871701|OTHER|Placebo|Placebo
57913237|NCT03211754|DIETARY_SUPPLEMENT|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
58264880|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
58264881|NCT02062710|DRUG|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
58264882|NCT02062710|DRUG|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
58264883|NCT02062710|DRUG|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
58264884|NCT02062710|DRUG|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
58264885|NCT01605032|DRUG|Busulfan|Given IV
58264886|NCT01605032|DRUG|Melphalan|Given IV
58264887|NCT01605032|DRUG|Bortezomib|Given IV
58264888|NCT01605032|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
58264889|NCT01605032|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
58264890|NCT02222597|DEVICE|infrascanner|
58385270|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
58385271|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
58060649|NCT00498927|GENETIC|protein expression analysis|
58060650|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
58060651|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
58060652|NCT00498927|OTHER|immunoenzyme technique|
58264891|NCT03633149|BEHAVIORAL|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
58264892|NCT03633149|BEHAVIORAL|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
58385272|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
58060653|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
58264893|NCT03633149|BEHAVIORAL|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
58264894|NCT04965441|PROCEDURE|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness\<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
58264895|NCT00083941|BIOLOGICAL|TroVax|1ml intramuscular injection
58264896|NCT00083941|BIOLOGICAL|Interleukin-2|Intravenous IL-2
58264897|NCT05501327|DRUG|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
57913238|NCT04345757|BEHAVIORAL|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
57913239|NCT05443646|DRUG|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
57913240|NCT05443646|RADIATION|hypofractionated radiotherapy|45Gy/3Gy/3week
58060654|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
58060655|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
58060656|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
57913241|NCT05443646|RADIATION|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
58060657|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
57913242|NCT05703997|DIETARY_SUPPLEMENT|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
57913243|NCT05703997|DRUG|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
57913244|NCT04824053|DIETARY_SUPPLEMENT|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
57913245|NCT04824053|DIETARY_SUPPLEMENT|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
57913246|NCT04824053|DIETARY_SUPPLEMENT|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
57913247|NCT04824053|DIETARY_SUPPLEMENT|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
57913248|NCT04824053|DIETARY_SUPPLEMENT|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
57913249|NCT04824053|DIETARY_SUPPLEMENT|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
57913250|NCT05441241|DEVICE|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
58060658|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
57913251|NCT05441241|OTHER|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
57913252|NCT00081042|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
57913253|NCT04497922|DEVICE|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
57913254|NCT04497922|BEHAVIORAL|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
57913255|NCT02457169|BEHAVIORAL|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
57913256|NCT02457169|BEHAVIORAL|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
58264898|NCT02222675|PROCEDURE|Sonography assisted breast surgery|
58264899|NCT02222675|PROCEDURE|Conventional breast surgery|
57913257|NCT02962960|DRUG|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
58264900|NCT01254838|BIOLOGICAL|HLA-A02 restricted HIG2|
58264901|NCT00295035|DRUG|CELECOXIB|
57913258|NCT02962960|DRUG|Placebo|subcutaneous administration every two weeks from week 0 to week 50
57913259|NCT04098757|DIETARY_SUPPLEMENT|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
57913260|NCT03117322|BIOLOGICAL|agave inulin|Duration: four weeks Dosage: powder 4 g/d
58060659|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
58060660|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
57913261|NCT03117322|BIOLOGICAL|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
58060661|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
58060662|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
58060663|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
58060664|NCT00276224|DRUG|ferrous sulphate (drug)|
58060665|NCT01118039|DRUG|sunitinib malate|
58060666|NCT01118039|OTHER|immunohistochemistry staining method|
58060667|NCT01118039|OTHER|laboratory biomarker analysis|
58060668|NCT01118039|OTHER|pharmacological study|
58264902|NCT00295035|DRUG|CURCUMIN|
58264903|NCT05295979|DRUG|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
57913262|NCT03117322|OTHER|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
58060669|NCT01118039|PROCEDURE|quality-of-life assessment|
58060670|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
58060671|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
58264904|NCT05295979|DRUG|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
58264905|NCT03147859|BIOLOGICAL|Vedolizumab (brand name Entyvio)|IV infusion
58264906|NCT02850016|DRUG|3BNC117|Intravenous Infusion of 3BNC117
58264907|NCT02850016|DRUG|Romidepsin|Intravenous Infusion of Romidepsin
58264908|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
58264909|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
58264910|NCT04455698|BEHAVIORAL|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
58264911|NCT06463483|DEVICE|Medtronic 780G System|Automated insulin delivery using Medtronic 780G system
58264912|NCT06463483|DEVICE|Continuous Glucose Monitoring|Usual care with continuous glucose monitoring
58264913|NCT03679338|DEVICE|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
58264914|NCT03168737|PROCEDURE|Computed Tomography|Undergo PET-CT scan
58264915|NCT03168737|RADIATION|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
58264916|NCT03168737|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
58264917|NCT04727034|DRUG|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
58264918|NCT04727034|DRUG|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
58264919|NCT04024267|OTHER|Eurythmy therapy|Mind-body therapy
58264920|NCT04024267|OTHER|CoordiFit|Fitness training
58385273|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
58385274|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
58385275|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
57913263|NCT03117322|OTHER|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
58385276|NCT02620033|BEHAVIORAL|Yoga therapy|
58385277|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
58385278|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
57913264|NCT00445354|DRUG|cinnamon|
58385279|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
58385280|NCT00302354|DRUG|OROS methylphenidate HCl|
58385281|NCT00302354|DRUG|SODAS methylphenidate HCl|
58385282|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
57913265|NCT05363371|BEHAVIORAL|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
57913266|NCT05363371|BEHAVIORAL|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
57913267|NCT02914977|DRUG|Daunorubicin|"* Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle"
57913268|NCT03235960|DEVICE|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
57913269|NCT00545051|DRUG|Placebo|po monthly for 12 months
57913270|NCT00545051|DRUG|ibandronate|150mg po monthly for 12 months
58264921|NCT00467961|COMBINATION_PRODUCT|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
58264922|NCT04869319|BEHAVIORAL|MyChart message|Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
58264923|NCT04690725|DRUG|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
58264924|NCT06620445|BEHAVIORAL|Interventiion or CBT Group|This RCT aims to evaluate the effect of Cognitive Behavioral Therapy (CBT) compared to usual care (UC) in pediatric oncology patients. We hypothesize that those receiving CBT will report lower depression and anxiety and improved QoL six months post-enrollment.
58264925|NCT02285543|DRUG|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
58264926|NCT02285543|PROCEDURE|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
58264927|NCT02285543|RADIATION|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
58264928|NCT02378415|DRUG|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
58264929|NCT02378415|DRUG|Placebo|Normal Saline Infusion
58264930|NCT01633008|BEHAVIORAL|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
58264931|NCT04651946|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
58264932|NCT01896947|DIAGNOSTIC_TEST|MRI|evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
58264933|NCT00955968|DRUG|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
58264934|NCT03508752|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery dose is based on the largest tumor size
58264935|NCT00919997|GENETIC|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
58264936|NCT00919997|GENETIC|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
58264937|NCT00919997|OTHER|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
58264938|NCT00919997|OTHER|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
58264939|NCT00919997|OTHER|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
58264940|NCT00919997|PROCEDURE|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
58264941|NCT00900757|DRUG|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
58264942|NCT02284568|DRUG|Placebo|Placebo
57913271|NCT04901260|DEVICE|AMAZE™ Disease Management Platform|The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
57913272|NCT00267085|BIOLOGICAL|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
58264943|NCT02284568|DRUG|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
58264944|NCT02284568|DRUG|Placebo|Placebo capsules
57913273|NCT04640077|OTHER|No Intervention|No intervention
57913274|NCT04640077|DRUG|donanemab|Administered IV
58264945|NCT00459004|DRUG|rimonabant (SR141716)|
58264946|NCT06011356|DEVICE|Smartwatch|Activity tracker (step count, calories burned), measures heart rate, heart variability and other physiological variables.
58264947|NCT01647984|DIETARY_SUPPLEMENT|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
58264948|NCT01647984|DIETARY_SUPPLEMENT|placebo|
58264949|NCT03721042|DEVICE|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
58264950|NCT06002139|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
58264951|NCT06002139|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~* Two hours of kinesiotherapy (120 minutes, including gait training).~* Thirty minutes of ergotherapy.~* Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
58264952|NCT06590025|BEHAVIORAL|INtegral Cognitive REMediation program|This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.
58385283|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
58385284|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
58264953|NCT06590025|BEHAVIORAL|Psychoeducation for depression|Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
58264954|NCT05222152|DRUG|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
58264955|NCT05222152|DRUG|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
58264956|NCT04253782|OTHER|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
58264957|NCT04512599|OTHER|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
58385285|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
58385286|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
58385287|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
57913275|NCT05405452|DEVICE|Vibration Anesthesia Device by Blaine Labs|Device which vibrates on top of skin
57913276|NCT05405452|DRUG|Gebauers Ethyl Chloride 100% Topical Spray|Sterile ethyl chloride spray
57913277|NCT05195502|DIAGNOSTIC_TEST|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
57913278|NCT05428930|DRUG|CKDB-501B|Intramuscular injection CKDB-501B
58264958|NCT00197002|BIOLOGICAL|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
58264959|NCT00197002|BIOLOGICAL|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
58264960|NCT06079307|OTHER|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
58264961|NCT06079307|OTHER|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
58385288|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
58385289|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
58385290|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
58385291|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
58385292|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
58385293|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
57711961|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
57711962|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
57711963|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
57711964|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
57711965|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
57711966|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
57711967|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
57711968|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
57711969|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
57711970|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
57913279|NCT05428930|DRUG|Botox®50U|Intramuscular injection Botox®50U
57913280|NCT04192903|DRUG|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
57913281|NCT03821753|OTHER|Case|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
57913282|NCT03821753|OTHER|Control|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
57913283|NCT02922309|BEHAVIORAL|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
57913284|NCT02922309|BEHAVIORAL|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
57913285|NCT04552483|DRUG|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
57913286|NCT04552483|DRUG|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
57913287|NCT04459013|OTHER|Salivary samples|The salivary samples will be collected at 5 defined times
57913288|NCT02542774|OTHER|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
57913289|NCT00901654|BIOLOGICAL|ACE527 vaccine|"First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21"
58264962|NCT03160222|OTHER|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
58264963|NCT05487885|DEVICE|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
58264964|NCT05487885|BEHAVIORAL|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
58264965|NCT05487885|DRUG|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
58385294|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
57913290|NCT00901654|BIOLOGICAL|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
57913291|NCT00406523|DEVICE|JANUS Stent|
57913292|NCT02839759|OTHER|TELLYHealth|Educational videos and questions.
57913293|NCT03842722|DEVICE|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
58264966|NCT03714334|DRUG|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
58264967|NCT05073029|OTHER|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
58264968|NCT05073029|DIETARY_SUPPLEMENT|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
58264969|NCT05073029|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
58264970|NCT04645602|DRUG|Lenvatinib|Pill taken by mouth, once daily.
57913294|NCT00424385|DRUG|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
57913295|NCT01825928|DRUG|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
57913296|NCT01825928|DRUG|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
57913297|NCT03390647|DRUG|E6130|Oral dose
57913298|NCT03390647|DRUG|Placebo|E6130-matched placebo
58264971|NCT04645602|DRUG|Pembrolizumab|Intravenous injection through a vein (IV).
58264972|NCT03940274|BEHAVIORAL|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
58264973|NCT02651805|DEVICE|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
58264974|NCT02651805|OTHER|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
58385295|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
58385296|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
58385297|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
58264975|NCT04647656|DEVICE|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
58264976|NCT04647656|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
58264977|NCT05080283|DEVICE|CP1110 Sound Processor System|Sound Processor
58385298|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
57711971|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
57913299|NCT00827866|OTHER|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
57913300|NCT00827866|OTHER|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
57913301|NCT03866707|OTHER|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
58385299|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
57711972|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
57711973|NCT00668681|DEVICE|EndoRefix|
57711974|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
58264978|NCT05080283|DEVICE|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
58264979|NCT05129293|BEHAVIORAL|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
58264980|NCT05129293|BEHAVIORAL|Educational|Psychoeducation
58264981|NCT02231281|DRUG|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
58264982|NCT02231281|PROCEDURE|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
58385300|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
58385301|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
58385302|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
58385303|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
58385304|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
58385305|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
58385306|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
57711975|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
57711976|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
58264983|NCT01658592|OTHER|Deep brain stimulation|Stimulator setting is ON
58385307|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
58385308|NCT06526312|BEHAVIORAL|Fidelity Monitoring System (Lyssn)|Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists,
57913302|NCT03866707|OTHER|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
57913303|NCT03866707|OTHER|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
57913304|NCT05467423|DIETARY_SUPPLEMENT|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
58264984|NCT01658592|OTHER|Placebo|Stimulator setting is OFF
58264985|NCT02054910|PROCEDURE|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
58385309|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
58385310|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
58264986|NCT02054910|PROCEDURE|Sham|Patients will not receive celiac plexus block during endoscopy.
58264987|NCT03359798|BEHAVIORAL|Narcotic counseling script|Script regarding post-cesarean section narcotic use
57913305|NCT00000473|BEHAVIORAL|dietary supplements|
57913306|NCT00000473|DRUG|fatty acids, omega-3|
57913307|NCT00000473|BEHAVIORAL|diet, fat-restricted|
57913308|NCT01240226|DRUG|GDC-0941|Oral repeating dose
57913309|NCT01240226|DRUG|GDC-0941|Oral repeating dose
57913310|NCT01240226|DRUG|ketoconazole|Oral repeating dose
57913311|NCT01211288|DEVICE|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
57913312|NCT03337451|DRUG|OPN-305|Patients will receive study drug every 4 weeks
58264988|NCT03359798|BEHAVIORAL|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
58264989|NCT00932698|DRUG|Ixazomib|Ixazomib capsules
58264990|NCT00318851|DEVICE|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
58264991|NCT01930344|DEVICE|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
58264992|NCT01930344|DEVICE|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
58264993|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
58264994|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
58264995|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
58264996|NCT01096589|DEVICE|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
58264997|NCT04000737|DRUG|YIV-906+Sorafenib|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
58385311|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
58385312|NCT02298309|OTHER|Test-and-Treat TB|
58385313|NCT00550186|OTHER|placebo|
58385314|NCT00550186|DRUG|Ringers Lactate|
58385315|NCT00550186|DRUG|HaemoHES 6%|
58264998|NCT04000737|DRUG|Placebo+Sorafenib|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
58264999|NCT00460265|DRUG|ARM 2|Subjects will receive Cisplatin plus 5FU
58265000|NCT00460265|DRUG|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
58265001|NCT00535847|DRUG|Telaprevir|Tablet
58265002|NCT00535847|DRUG|Ribavirin|Tablet
58265003|NCT00535847|DRUG|Pegylated interferon alfa 2a|Solution for Injection
58265004|NCT06619665|DRUG|MK-6552|MK-6552 gelatin coated capsules taken orally two times 8 hours apart
58265005|NCT06619665|DRUG|MK-6552 placebo|MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
58265006|NCT06619665|DRUG|Modafinil|Modafinil tablet taken once orally
58265007|NCT06619665|DRUG|Modafinil placebo|Modafinil placebo tablet taken once orally
58385316|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
58385317|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
58385318|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
58385319|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
57711977|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
58265008|NCT00108342|DRUG|Nicotine gum - 2 mg and 4 mg|
57711978|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
58265009|NCT00108342|DRUG|Nicotine lozenges - 2 mg and 4 mg|
58265010|NCT00108342|DRUG|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
58265011|NCT00108342|OTHER|Computer learning|
58265012|NCT05909813|BEHAVIORAL|Individualized Piano Keyboard Instruction|"During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson."
58265013|NCT00358956|DRUG|ZD6474 (vandetanib)|100 mg once daily oral tablet
58265014|NCT02638675|BEHAVIORAL|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
58265015|NCT02638675|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
58265016|NCT02638675|BEHAVIORAL|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
58265017|NCT04008706|DRUG|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
58265018|NCT06618781|PROCEDURE|Sedation|Preoperatively, 2 mg intravenous midazolam was administered to the patients. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and when the Vizel analog score was \>4, intravenous 0.1-1 mcg/kg remifentanil was administered.
58265019|NCT06618781|PROCEDURE|Sedation + Quadratus Lumborum Block|Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \>4.
58265020|NCT06619431|DEVICE|Mobile Application|"Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies."
58385320|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
57711979|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
57711980|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
57711981|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
57711982|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
57711983|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
57711984|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
57711985|NCT02290587|DEVICE|MRI|
57711986|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
57711987|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
58265021|NCT06642311|PROCEDURE|Empty bladder group|Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty. All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
58265022|NCT06642311|PROCEDURE|Bladder distension group|Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended . All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
58265023|NCT04437875|BIOLOGICAL|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
58265024|NCT02523235|DRUG|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
58265025|NCT00157911|DRUG|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
57711988|NCT04024475|OTHER|Observation|
58265026|NCT00157911|DRUG|Comparator: simvastatin / Duration of Treatment: 12 weeks|
58265027|NCT04684758|OTHER|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
58265028|NCT05577910|DEVICE|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
57711989|NCT06444477|OTHER|ITP and cancer|ITP and cancer
57913313|NCT04288999|DRUG|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
57711990|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
57711991|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
57711992|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
57711993|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
57711994|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
57711995|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
57711996|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
57711997|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
57711998|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
57711999|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
57712000|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
57712001|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
57712002|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
57712003|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
57913314|NCT04288999|RADIATION|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
57913315|NCT04288999|OTHER|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
58385321|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
58385322|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music...).
58385323|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
58385324|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
58385325|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
57712004|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
57913316|NCT02826915|DEVICE|Near Infra Red Spectroscopy (NIRS)|
57913317|NCT02826915|DEVICE|Electroencephalogram (EEG)|
58060672|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
58385326|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
58385327|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
58385328|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
58385329|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
58385330|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
58385331|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
58385332|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
57712005|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
57712006|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
57712007|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
57712008|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
57712009|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
57712010|NCT01159301|DRUG|entinostat|Given orally (PO)
57712011|NCT01159301|DRUG|sorafenib tosylate|Given PO
57712012|NCT01159301|OTHER|pharmacological study|Correlative studies
57712013|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
57712014|NCT06663176|DRUG|RESP302|Nitric Oxide agent
57712015|NCT06663176|DRUG|RESP303|Nitric Oxide agent
57712016|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
57712017|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
57712018|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
58385333|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
58385334|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
58385335|NCT02018029|OTHER|cardiac resynchronisation therapy|
58385336|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
57712019|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
57712020|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
57712021|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
57712022|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
57712023|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
57913318|NCT01522469|DRUG|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
57913319|NCT03720873|DRUG|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
57913320|NCT03720873|DRUG|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
58385337|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
58385338|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
57712024|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
57712025|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
57712026|NCT00004923|DRUG|docetaxel|
57712027|NCT00004923|DRUG|irinotecan hydrochloride|
57712028|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
57712029|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
57712030|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
57712031|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
57712032|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
57913321|NCT03028220|DEVICE|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
57913322|NCT03028220|DEVICE|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
57913323|NCT00003382|BIOLOGICAL|filgrastim|
57913324|NCT00003382|DRUG|gemcitabine hydrochloride|
57913325|NCT00003382|DRUG|topotecan hydrochloride|
58385339|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
58385340|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
58385341|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
58385342|NCT00143624|DRUG|Placebo|See detailed description.
58385343|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
58385344|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
58385345|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
58385346|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
58385347|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
58385348|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
57712033|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
57913326|NCT01771107|DRUG|Brentuximab Vedotin|Given IV
58060673|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
58060674|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
58385349|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
57913327|NCT01771107|DRUG|Dacarbazine|Given IV
57913328|NCT01771107|DRUG|Doxorubicin Hydrochloride|Given IV
57913329|NCT01771107|OTHER|Pharmacological Study|Correlative studies
57913330|NCT01771107|DRUG|Vinblastine|Given IV
57913331|NCT01184261|BEHAVIORAL|behavioral intervention|8 session behavioral intervention.
58060675|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
58060676|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
58060677|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
58060678|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
57712034|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
57913332|NCT05896878|DIETARY_SUPPLEMENT|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
57913333|NCT01122160|DRUG|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
57913334|NCT01122160|DRUG|placebo|Placebo with berries (blackberries + strawberries)
57913335|NCT02635568|OTHER|Cannabis Use|Observational Study
57913336|NCT00561132|DIETARY_SUPPLEMENT|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
58060679|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
58385350|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
58385351|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
57913337|NCT00561132|OTHER|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
57913338|NCT03932669|DRUG|Nilotinib|150-300mg daily dose of nilotinib
58060680|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
57712035|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
57712036|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
57913339|NCT02822586|RADIATION|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
57913340|NCT02822586|DRUG|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
57913341|NCT06244420|OTHER|Clinical data review|review the medical records, radiological imaging, and histological data of these patients
57913342|NCT04775771|BEHAVIORAL|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
57913343|NCT05985421|OTHER|Fecal collection|approximate volume of 2 ml
57913344|NCT05985421|OTHER|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
57913345|NCT05985421|OTHER|Polysomnography|Polysomnography
57913346|NCT05985421|OTHER|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
58385352|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
57913347|NCT00709852|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
57913348|NCT00709852|DRUG|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
58385353|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
57712037|NCT05756764|DRUG|Semaglutide|Medication for weight loss
57913349|NCT03107338|DRUG|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
57913350|NCT03107338|OTHER|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
57913351|NCT02937233|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine|
57913352|NCT02937233|OTHER|Placebo|
57913353|NCT01849159|BIOLOGICAL|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
58385354|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
58385355|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
58385356|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
57712038|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
57712039|NCT05756764|DRUG|Phentermine|Medication for weight loss
57712040|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
57712041|NCT05756764|DRUG|Topiramate|Medication for weight loss
57712042|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
57712043|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
57712044|NCT05756764|DRUG|Liraglutide|Medication for weight loss
57913354|NCT01849159|OTHER|Reference therapy: 400 mL of 0.9% NaCl solution|
57913355|NCT05023421|OTHER|no intervention|no intervention
57913356|NCT03795597|DRUG|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
57913357|NCT03795597|DRUG|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
57913358|NCT03795597|DRUG|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
57913359|NCT06006559|DRUG|EYU688|EYU688 administered by oral route
57913360|NCT06006559|DRUG|Placebo|Matching placebo administered orally as capsules
57913361|NCT00154765|DEVICE|sling suspension exercises|
57913362|NCT06124781|PROCEDURE|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
57913363|NCT06124781|PROCEDURE|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
58060681|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
58385357|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
58385358|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
58385359|NCT00003776|BIOLOGICAL|filgrastim|
57712045|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
57913364|NCT06124781|PROCEDURE|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
57913365|NCT03186131|DRUG|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
57913366|NCT03186131|DRUG|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
57913367|NCT04487912|DRUG|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
57913368|NCT04487912|DRUG|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
58060682|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
58060683|NCT00325949|DRUG|placebo|2 tablets BID
58060684|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
58060685|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
58385360|NCT00003776|DRUG|cisplatin|
58385361|NCT00003776|DRUG|doxorubicin hydrochloride|
58385362|NCT00003776|DRUG|ifosfamide|
58385363|NCT00003776|DRUG|leucovorin calcium|
58385364|NCT00003776|DRUG|methotrexate|
58385365|NCT00003776|DRUG|trimetrexate glucuronate|
58385366|NCT00003776|PROCEDURE|surgical procedure|
58385367|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
58385368|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
58385369|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
58385370|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
58385371|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
58385372|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
57712046|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
57712047|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
57712048|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
57712049|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
57712050|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
57712051|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
57712052|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
57712053|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
57712054|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
57913369|NCT05064683|OTHER|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
57913370|NCT00568035|DRUG|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
57913371|NCT01670955|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
57913372|NCT01670955|DRUG|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
58385373|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
58385374|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
58385375|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
57913373|NCT03461276|BIOLOGICAL|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.
57913374|NCT03461276|BIOLOGICAL|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
58385376|NCT00080834|DRUG|DJ-927|
58385377|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
58385378|NCT03235921|OTHER|placebo|no drug given to the control group
58385379|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
58385380|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
58385381|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
58385382|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
58385383|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58385384|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
58385385|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
58385386|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
58385387|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
58385388|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
58385389|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
58385390|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
58385391|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
58385392|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
58385393|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
58385394|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
58385395|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
58385396|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
58385397|NCT00156104|DRUG|Asenapine|5 mg BID
58385398|NCT00156104|DRUG|Asenapine|10 mg BID
58385399|NCT00156104|DRUG|Haloperidol|4 mg BID
58385400|NCT00156104|OTHER|Placebo arm|
58385401|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
58385402|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
58385403|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
58385404|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
58385405|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
58385406|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
58385407|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
58385408|NCT01558284|DRUG|Placebo|Placebo
58385409|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
58385410|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
58385411|NCT04194944|DRUG|Selpercatinib|Administered orally
58385412|NCT04194944|DRUG|Carboplatin|Administered IV
58385413|NCT04194944|DRUG|Cisplatin|Administered IV
58385414|NCT04194944|DRUG|Pemetrexed|Administered IV
58385415|NCT04194944|DRUG|Pembrolizumab|Administered IV
58385416|NCT01294137|DEVICE|ventilatory polygraphy|
58385417|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
58385418|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
58385419|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
58385420|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
58265029|NCT05577910|DEVICE|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
58265030|NCT05577910|BEHAVIORAL|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
58265031|NCT05577910|DRUG|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
58265032|NCT05366309|OTHER|Tailored education|Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
58265033|NCT05366309|OTHER|Standard care education|Participants randomised to this group will receive usual care in terms of their education.
58385421|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
57712055|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
57712056|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
57712057|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
57913375|NCT06014840|OTHER|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
57913376|NCT00335647|DRUG|fluphenazine hydrochloride|
57913377|NCT06372678|BIOLOGICAL|CM326|CM326 injection
57913378|NCT06372678|DRUG|Placebo|Placebo
57913379|NCT04837898|DIETARY_SUPPLEMENT|Haskapa|Haskapa Ltd, Oxford, UK
57913380|NCT04837898|DIETARY_SUPPLEMENT|Placebo|isocaloric to the haskap powder
58265034|NCT00034619|DRUG|ALIMTA|
58265035|NCT00034619|DRUG|Oxaliplatin|
58265036|NCT03181503|DRUG|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
58265037|NCT03181503|DRUG|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
58265038|NCT04257162|OTHER|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
58385422|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
58385423|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
58385424|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
57712058|NCT04953767|OTHER|White light|White light is used as sham control.
57712059|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
57712060|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
57712061|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
57913381|NCT03429829|DEVICE|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
57913382|NCT00985153|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
57913383|NCT00985153|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
57913384|NCT00985153|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
58265039|NCT05262712|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
58265040|NCT05262712|OTHER|Placebo Control|Devices mounted, no stimulation
58265041|NCT05984264|DRUG|lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
58265042|NCT04836364|OTHER|No Intervention|There is no intervention; observation only.
58265043|NCT06098703|BEHAVIORAL|CARD (Comfort Ask Relax Distract)|CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
58265044|NCT04182568|DRUG|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
58265045|NCT04182568|DRUG|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
58265046|NCT02847143|DRUG|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
58265047|NCT02847143|DEVICE|fMRI|FMRI during emotional image visualization
58265048|NCT02847143|BEHAVIORAL|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
58385425|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
58385426|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
57913385|NCT04280068|BEHAVIORAL|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
57913386|NCT04280068|BEHAVIORAL|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
57913387|NCT00677326|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
57913388|NCT05569720|DRUG|ApTOLL|"ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
57913389|NCT04725474|BIOLOGICAL|visugromab (CTL-002)|monoclonal antibody
57913390|NCT01398995|OTHER|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
57913391|NCT02188420|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
57913392|NCT02576301|DRUG|Phase 1 - OXi4503|Determination of MTD of OXi4503
58385427|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
57913393|NCT02576301|DRUG|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
57913394|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
57913395|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
57913396|NCT00058760|BEHAVIORAL|NIA intervention (after school health promotion didactic program)|
58265049|NCT02847143|BEHAVIORAL|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
58265050|NCT04106089|BEHAVIORAL|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
58265051|NCT01264666|DIETARY_SUPPLEMENT|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
58265052|NCT01264666|DIETARY_SUPPLEMENT|Chinese Meijiao liquor|
58265053|NCT01264666|DIETARY_SUPPLEMENT|Water control|
58385428|NCT00470002|DRUG|Somatropin|
58385429|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
58385430|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
58385431|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
58385432|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
58385433|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
58385434|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
58385435|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
58385436|NCT00091741|DRUG|Etanercept (Enbrel)|
57712062|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
57712063|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
58265054|NCT06649188|DEVICE|Magnesium Sulphate Iontophoresis|"Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity."
58265055|NCT06649188|OTHER|traditional physical therapy program|Deep friction massage, stretching and pressure therapy.
58385437|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
58385438|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
58385439|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
58385440|NCT02261064|OTHER|Japanese meal|
58385441|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
58385442|NCT02628405|DRUG|Carboplatin|Given IV
58385443|NCT02628405|DRUG|Etoposide|Given IV
58385444|NCT02628405|DRUG|Ifosfamide|Given IV
58385445|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
58385446|NCT02628405|DRUG|Lenalidomide|Given PO
58385447|NCT02628405|BIOLOGICAL|Rituximab|Given IV
58385448|NCT02508363|BEHAVIORAL|questionnaires|
57712064|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
58385449|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
58385450|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
58385451|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
58385452|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
58385453|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
58385454|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
58385455|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
58385456|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
58385457|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
58385458|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
58385459|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
58385460|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
58385461|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
58385462|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
58265056|NCT00526903|BEHAVIORAL|Elimination Diet|Daily diet change for 8 days.
58265057|NCT02691429|OTHER|Acai dye 10%|dye to be used during chromovitrectomy in humans
58265058|NCT00063791|DRUG|Bortezomib|
58265059|NCT05475587|OTHER|Routine care|Both two groups received the same routine care.
58265060|NCT01886586|BEHAVIORAL|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
58265061|NCT01886586|BEHAVIORAL|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
58265062|NCT01886586|OTHER|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
57712065|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
58265063|NCT01179737|DRUG|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
58265064|NCT01179737|DRUG|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
58265065|NCT00431665|DRUG|NG-monomethyl-L-Arginine (L-NMMA)|
58265066|NCT00431665|DRUG|triglycerides (Intralipid 20%)|
58265067|NCT00431665|DRUG|heparin|
58265068|NCT00431665|DRUG|somatostatin|
58265069|NCT00431665|DRUG|insulin|
58265070|NCT00431665|DRUG|glucose|
58265071|NCT00431665|DRUG|inulin|
58265072|NCT00431665|DRUG|paraamino hippurate (PAH)|
58265073|NCT01794793|DRUG|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
58265074|NCT01794793|DRUG|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
57712066|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
58265075|NCT01794793|DRUG|Pasireotide LAR|Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
57712067|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
58265076|NCT04108221|PROCEDURE|laparoscopy or laparotomy withTransversusAbdominis Plane Block|"The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance."
58265077|NCT00972634|OTHER|computer-assisted intervention|symptom assessment
58265078|NCT00972634|OTHER|questionnaire administration|Symptom assessment
58265079|NCT00972634|PROCEDURE|assessment of therapy complications|Symptom assessment
58265080|NCT00972634|PROCEDURE|quality-of-life assessment|Symptom assessment
58265081|NCT06459570|BEHAVIORAL|Virtual reality based exercises|one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.
58265082|NCT06459570|OTHER|standard physical therapy|"Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes."
58265083|NCT01917344|OTHER|MRI|
58265084|NCT02954653|BIOLOGICAL|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
58265085|NCT02954653|DRUG|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
58265086|NCT02954653|DRUG|Daunorubicin|60-90 mg/m2 daily for 3 days
58265087|NCT02954653|DRUG|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
58385463|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
58265088|NCT02954653|DRUG|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
58265089|NCT03250481|DRUG|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
58265090|NCT05169112|DRUG|Lupron Depot|Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
58265091|NCT03274557|PROCEDURE|RFM|
58265092|NCT02681757|DEVICE|triple antibiotic ointment dressing|used for control group under soft cast
58265093|NCT02681757|DEVICE|Mepitel Ag|used for variable/experimental group under soft cast
58265094|NCT01843114|DEVICE|FDOCT|Measurement of retinal blood velocities
58265095|NCT01843114|OTHER|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
58265096|NCT05972291|DIETARY_SUPPLEMENT|Oral Glutamine|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
58265097|NCT05972291|OTHER|Control Arm|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
58265098|NCT05565001|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
58265099|NCT01537627|OTHER|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
58265100|NCT01537627|OTHER|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
58265101|NCT05814042|DRUG|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
58265102|NCT05814042|DRUG|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
58265103|NCT03499405|BEHAVIORAL|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
58265104|NCT03740321|DEVICE|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
58265105|NCT02788370|DEVICE|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
58385464|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
57913397|NCT04383808|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
58385465|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
57913398|NCT04383808|DIAGNOSTIC_TEST|Pre-injected group with PET insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
58385466|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
58385467|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
58385468|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
57913399|NCT04258501|OTHER|Mulberry fruit|
57913400|NCT04258501|OTHER|Mulberry leaf|
58265106|NCT02788370|OTHER|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)"
58265107|NCT02411604|DRUG|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
58265108|NCT04765995|DRUG|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
58385469|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
58385470|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
58385471|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
58385472|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
58265109|NCT04765995|DRUG|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
58265110|NCT04765995|DRUG|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
58385473|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
57712068|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
57913401|NCT04258501|OTHER|White bean|
57913402|NCT04258501|OTHER|Apple|
57913403|NCT04258501|OTHER|Elderberry|
57913404|NCT04258501|OTHER|Turmeric|
58265111|NCT04765995|DRUG|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
58265112|NCT04765995|DRUG|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
58265113|NCT04765995|DRUG|Placebo|Matching placebo will be administered intramuscularly.
57913405|NCT04258501|OTHER|Rice porridge|
58265114|NCT01967641|DRUG|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
58265115|NCT03221140|DRUG|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
58265116|NCT01889121|BEHAVIORAL|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
57913406|NCT00452426|DEVICE|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
57913407|NCT00452426|OTHER|benzodiazepines and opioid sedation|per site's current standard of care
57913408|NCT05217498|DRUG|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
57913409|NCT05217498|DEVICE|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
57913410|NCT01877772|PROCEDURE|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
57913411|NCT01877772|PROCEDURE|Control|The control group will undergo standard rotator cuff repair.
57913412|NCT05934786|BEHAVIORAL|Cognitive rehabilitation|Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
57913413|NCT01449149|RADIATION|Proton Therapy|
57913414|NCT06122480|PROCEDURE|Surgery|All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
57913415|NCT02785471|BEHAVIORAL|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
57913416|NCT02785471|BEHAVIORAL|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
57913417|NCT05356104|DRUG|Exenatide extended release|2mg once weekly via subcutaneous injection
57913418|NCT04621318|DRUG|Denosumab|60 mg, single-dose
58265117|NCT00477997|DEVICE|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
58265118|NCT00979524|BEHAVIORAL|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
58265119|NCT03229148|PROCEDURE|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
58385474|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
57913419|NCT02824419|DRUG|Methionine|Subject undergoes imaging studies with FDG and with methionine.
58385475|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
57913420|NCT02824419|DRUG|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
57913421|NCT04318067|DRUG|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
57913422|NCT02784054|DRUG|Carboplatin|
58385476|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
57913423|NCT02784054|DRUG|Etoposide|
57913424|NCT02784054|DRUG|Cyclophosphamide|
57913425|NCT02784054|DRUG|Bleomycin|
57913426|NCT02784054|DRUG|Thiotepa|
57913427|NCT02784054|DRUG|Melphalan|
57913428|NCT02784054|RADIATION|Reduced dose radiotherapy|
57913429|NCT05606731|BEHAVIORAL|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
57913430|NCT00577837|DRUG|risedronate|tablet, 5 mg risedronate daily for 6 months
57913431|NCT00577837|DRUG|risedronate|tablet, 100 mg risedronate monthly for 6 months
57913432|NCT00577837|DRUG|risedronate|tablet, 150 mg risedronate monthly for 6 months
57913433|NCT00577837|DRUG|experimental|tablet, 200 mg risedronate monthly for 6 months
57913434|NCT02717572|RADIATION|Fludeoxyglucose F 18|
57913435|NCT02717572|DEVICE|Positron Emission Tomography|
57913436|NCT02717572|DEVICE|Computerized Tomography|
57913437|NCT02717572|DEVICE|Magnetic Resonance Imaging|
57913438|NCT04600492|DRUG|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
57913439|NCT01209780|BIOLOGICAL|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
57913440|NCT01209780|BIOLOGICAL|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
57913441|NCT01209780|BIOLOGICAL|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
57913442|NCT04602416|BEHAVIORAL|Training sessions|
57913443|NCT00666601|DRUG|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
57913444|NCT00666601|DRUG|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
58265120|NCT03229148|PROCEDURE|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
58385477|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
57913445|NCT03252847|GENETIC|AAV2/5-RPGR|Single, subretinal administration of AAV2/5-RPGR
57913446|NCT00055601|DRUG|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
57913447|NCT00055601|DRUG|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
57913448|NCT00055601|DRUG|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
57913449|NCT00055601|RADIATION|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
57913450|NCT00055601|DRUG|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
57913451|NCT00055601|PROCEDURE|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
57913452|NCT05598671|PROCEDURE|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
57913453|NCT02112331|OTHER|Raw human milk|
57913454|NCT02112331|OTHER|Pasteurized human milk|
57913455|NCT02112331|OTHER|Pasteurized-homogenized human milk|
57913456|NCT02112331|OTHER|Gastric samples|
58060686|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
58265121|NCT04606823|PROCEDURE|Minimally invasive surgery|The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
57913457|NCT05576038|DRUG|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
58385478|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
58385479|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
58385480|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
58385481|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
58385482|NCT02226588|DRUG|Misoprostol|
58385483|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
58385484|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
58385485|NCT04615624|OTHER|Placebo|Normal saline
58385486|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
58385487|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
58385488|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
57913458|NCT05576038|DRUG|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
57913459|NCT00848926|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
57913460|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
58265122|NCT04606823|OTHER|Glasgow Benefit Inventory (GBI)|A quality of life-questionnaire is to be completed by the subjects at one occasion.
58265123|NCT04606823|OTHER|Additional follow-up visits after surgery|There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
58265124|NCT04300452|DRUG|Carbetocin|Administration of Carbetocin after placental detachment
58265125|NCT04300452|DRUG|Ergometrine Maleate|Administration of ergometrin after placental detachment
58385489|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
58385490|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
58385491|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
58265126|NCT05451875|DEVICE|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
58265127|NCT04216446|BEHAVIORAL|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
58385492|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
58385493|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
58385494|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
58385495|NCT00005844|DRUG|oxaliplatin|
58385496|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
58385497|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
57712069|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
57712070|NCT00219128|DRUG|aliskiren|
57712071|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
57712072|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
58265128|NCT04316442|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
58265129|NCT02678585|DRUG|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
58385498|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
58385499|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
58385500|NCT00613548|PROCEDURE|CABG alone|CABG alone
58385501|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
58385502|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
58385503|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
58385504|NCT05231759|DEVICE|L'DISQ|
57712073|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
58265130|NCT02678585|DRUG|Lidocaine|53 patients received intravenous regional lidocaine
58265131|NCT00787098|OTHER|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
58265132|NCT03722940|DRUG|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
58265133|NCT03722940|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
58265134|NCT06344533|DRUG|JMKX003142 Injection|JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
58385505|NCT02254044|DRUG|bivatuzumab mertansine|
58385506|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
58385507|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
58385508|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
58385509|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
58385510|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
58385511|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
58385512|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
57712074|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
57712075|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
57712076|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
57712077|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
57712078|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
57712079|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
57712080|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
57712081|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
57712082|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
57712083|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
57712084|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
57712085|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
57712086|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
57913461|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
57913462|NCT02224976|BEHAVIORAL|Intensified Training|Volunteers will increase exercise training by 30% from baseline
57913463|NCT02596165|DEVICE|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
57913464|NCT01775280|RADIATION|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
57913465|NCT02463110|DRUG|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
57913466|NCT02463110|DRUG|No treatment|
57913467|NCT02463110|DRUG|Placebo|
57913468|NCT05877313|OTHER|Sterile water foot bath|Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
57913469|NCT05877313|DRUG|Nitric Oxide|Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
58385513|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
57913470|NCT05753371|DRUG|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
57913471|NCT06106529|DRUG|Oxybutynin|Oxybutynin 5 mg twice per day for 6 weeks
57913472|NCT06106529|DRUG|Venlafaxine|Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
58060687|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
58265135|NCT06344533|DRUG|Placebo|Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
58265136|NCT00984061|DRUG|colchicine|0.6mg tablet administered at 9am on Day 1
57712087|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
57712088|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
57712089|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
57712090|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
57712091|NCT05592015|DRUG|Ruxolitinib|Given PO
57913473|NCT03169101|DRUG|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
57913474|NCT03169101|BEHAVIORAL|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
57913475|NCT01773291|OTHER|acupuncture|acupuncture on GV26 and 12 Well points
57913476|NCT01773291|OTHER|laser acupuncture|laser acupuncture on GV26 and 12 Well points
57913477|NCT01773291|OTHER|control|sham laser acupuncture
57913478|NCT00460226|DRUG|lamotrigine|lamotrigine treatment for 12weeks
57913479|NCT03488641|DIAGNOSTIC_TEST|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
58265137|NCT00984061|DRUG|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
58265138|NCT00984061|DRUG|colchicine|0.6 mg tablet administered at 9am on Day 29
58265139|NCT04855617|DRUG|Ocrelizumab|"Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion"
58385514|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
58385515|NCT00993863|DRUG|Placebo|single dose
58385516|NCT00993863|DRUG|ADL5859 30 mg|single dose
57712092|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
57712093|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
57712094|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
57712095|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
57712096|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
57712097|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
57712098|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
57712099|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
57913480|NCT04097392|OTHER|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
57913481|NCT04097392|OTHER|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
57913482|NCT04688073|BEHAVIORAL|Exercise|Running
58385517|NCT00993863|DRUG|ADL5859 100 mg|single dose
58385518|NCT00993863|DRUG|ADL5859 200 mg|single dose
58385519|NCT00993863|DRUG|ibuprofen 400 mg|single dose
58385520|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
57712100|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
57712101|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
57712102|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
57913483|NCT04688073|BEHAVIORAL|Rest|sit and rest
58265140|NCT00366119|DRUG|Ramipril|
58265141|NCT06371729|PROCEDURE|DEEP mapping|"The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
58385521|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
58385522|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
58265142|NCT06371729|PROCEDURE|Activation Mapping|"VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
58265143|NCT06245447|OTHER|Retrospective evaluation of specific brain MRI features|"* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
57712103|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
57712104|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
58265144|NCT06056804|DRUG|capecitabine|825-1000mg/m2,po,bid
58265145|NCT06056804|DRUG|tislelizumab|200mg,iv.gtt,q3w
58265146|NCT06056804|DRUG|thymalfasin|4.8mg,sc,biw
58265147|NCT06056804|RADIATION|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
58265148|NCT02395263|DRUG|Yuxintine|
58265149|NCT03889470|DRUG|NTG 1 MG/ML Injectable Solution|administered after sheath placement
58385523|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
58385524|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
58385525|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
57712105|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
57712106|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
58385526|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
58385527|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
58385528|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
58385529|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
58385530|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
58385531|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
58385532|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
57712107|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
58265150|NCT06400706|PROCEDURE|EEG guided general anesthesia|EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
58385533|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
58385534|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
58385535|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
58385536|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
58385537|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
57712108|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
57712109|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
57712110|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
57712111|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
57712112|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
57913484|NCT02292654|DRUG|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
57913485|NCT04937803|DEVICE|Drug-coated balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
57913486|NCT04937803|DEVICE|Zotarolimus-Eluting Coronary Stent|Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
57913487|NCT03017534|PROCEDURE|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
58265151|NCT02550600|PROCEDURE|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
58265152|NCT02550600|PROCEDURE|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
58265153|NCT04185935|OTHER|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
58265154|NCT04185935|OTHER|Questionnaire Administration|Ancillary studies
58385538|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
58385539|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
58385540|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
58385541|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
57712113|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
57712114|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
57913488|NCT02844426|DRUG|bifid triple viable capsule and pectin|
57913489|NCT02844426|DRUG|maltodextrin|
57913490|NCT03573349|DRUG|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
57712115|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
57913491|NCT00348023|DRUG|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
58060688|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
57913492|NCT03224754|BEHAVIORAL|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
58265155|NCT01623973|OTHER|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
57913493|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
57913494|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58265156|NCT03410732|BIOLOGICAL|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
58265157|NCT03410732|PROCEDURE|radical surgery only|Only radical surgery is given to the control group
58265158|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
58265159|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
57712116|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
57712117|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
57712118|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
57913495|NCT05130853|BEHAVIORAL|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
58060689|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
58385542|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
58385543|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
58385544|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
58385545|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
57712119|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
58265160|NCT04587349|OTHER|Physiotherapy|Physiotherapy 2-years-long (3/week)
58265161|NCT01647191|BEHAVIORAL|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
58265162|NCT01647191|BEHAVIORAL|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
58385546|NCT02134561|BEHAVIORAL|psychological interview|
58385547|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
58385548|NCT02134561|OTHER|cognitive tests|
58385549|NCT02134561|OTHER|neurological tests|
58385550|NCT04444271|DRUG|Mesenchymal stem cells|1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
58385551|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
58385552|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
58265163|NCT06387706|OTHER|Gamified web-based pain management Program|"Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform."
58265164|NCT04620590|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
57913496|NCT05130853|OTHER|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
58265165|NCT01729520|OTHER|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
58265166|NCT01433068|DEVICE|NBTXR3|One intratumor implantation by injection
58265167|NCT04890977|BEHAVIORAL|Talking Story|A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
58385553|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
57712120|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
58265168|NCT00713661|DRUG|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
58265169|NCT02994758|OTHER|Personalised treatment|Treatment based on NGS or DSRT
58265170|NCT02308813|OTHER|Braking and functionality|
57913497|NCT04051736|BIOLOGICAL|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
58265171|NCT00387010|DRUG|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
58265172|NCT02529904|BIOLOGICAL|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
58265173|NCT04221620|DEVICE|Zengar Electroencephalogram (EEG) Neurofeedback device|Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
58265174|NCT00877955|DRUG|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
58265175|NCT00877955|DRUG|alprazolam sublingual tablet test|0.5 mg tablet, single dose
58265176|NCT00380666|PROCEDURE|PET/CT scan|
58265177|NCT02737228|DRUG|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
57913498|NCT03562247|OTHER|Usual Care of IPF|standard of care given to patients with IPF
58265178|NCT02737228|DRUG|Gemcitabine|1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
58265179|NCT02737228|DRUG|Erlotinib|100 mg per oral daily per cycle (4 weeks)
58265180|NCT05637970|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
57913499|NCT03562247|OTHER|Telenursing|scheduled phone calls with the patient and care giver
58265181|NCT05637970|DEVICE|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
58265182|NCT02286648|DRUG|Formocresol|pulpotomy with formocresol
58265183|NCT02286648|DRUG|Mineral Trioxide Aggregate|pulpotomy with MTA
57913500|NCT03562247|OTHER|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
57913501|NCT02139293|DEVICE|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
57913502|NCT06115447|PROCEDURE|lung suturing with polyglactin|lung suturing with polyglactin
57913503|NCT06115447|PROCEDURE|ung suturing with polypropylene|ung suturing with polypropylene
57913504|NCT00502086|DIETARY_SUPPLEMENT|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
57913505|NCT00502086|OTHER|Placebo|Placebo three sachets daily during 96 weeks
58385554|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
58385555|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
58385556|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
58385557|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
58385558|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
58385559|NCT03292003|DEVICE|Journey II BCS Total Knee System|
57913506|NCT03587051|DIETARY_SUPPLEMENT|Low glycemic index post-exercise diet|Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
58265184|NCT05519488|BEHAVIORAL|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
58265185|NCT05519488|BEHAVIORAL|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
58265186|NCT00616980|BIOLOGICAL|CD34-positive cells|
58265187|NCT00616980|BIOLOGICAL|CD34-positive cells|
58385560|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
58385561|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
58385562|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
57913507|NCT03587051|DIETARY_SUPPLEMENT|High glycemic index post-exercise diet|Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
58265188|NCT00616980|BIOLOGICAL|Saline and 5% autologous plasma|
58265189|NCT02400567|DRUG|Fluorouracile|
58265190|NCT02400567|DRUG|Epirubicin|
57913508|NCT02708654|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
57913509|NCT02708654|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
57913510|NCT02708654|BEHAVIORAL|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
57913511|NCT02708654|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
58265191|NCT02400567|DRUG|Cyclophosphamide|
58265192|NCT02400567|DRUG|Letrozole|
58265193|NCT02400567|DRUG|Palbociclib|
58265194|NCT03863704|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
58265195|NCT02928770|DEVICE|Nastent|Use of the device while at home and in the sleep lab
58265196|NCT05818241|PROCEDURE|Treatment of fracture by forearm cast|Patient that are not surgically treated for DRF
58265197|NCT05818241|PROCEDURE|Surgical treatment of fracture|Patients that are surgically treated for DRF
57712121|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
58265198|NCT04053985|COMBINATION_PRODUCT|TAI combine lenvatinib|TAI combine lenvatinib
58265199|NCT04053985|DRUG|Lenvatinib|lenvatinib only
58265200|NCT06305312|BEHAVIORAL|Community Service Navigation|Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.
58265201|NCT06305312|OTHER|Usual Care|Standard referral to community resources.
58265202|NCT00509379|DRUG|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
58265203|NCT00509379|DRUG|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
58265204|NCT04801472|OTHER|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
58265205|NCT00204282|BEHAVIORAL|Educational presentation, group discussion, questionnaires|
58265206|NCT05288296|DEVICE|dynamic taping|"1. The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~2. By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
58265207|NCT02122770|DRUG|MLN4924|MLN4924 intravenous solution.
58265208|NCT02122770|DRUG|Fluconazole|Fluconazole tablets.
58385563|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
58385564|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
58385565|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
57712122|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
58385566|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
57712123|NCT00079274|DRUG|oxaliplatin|Given IV
57712124|NCT00079274|DRUG|leucovorin calcium|Given IV
58265209|NCT02122770|DRUG|Itraconazole|Itraconazole oral solution.
58265210|NCT02122770|DRUG|Docetaxel|Docetaxel intravenous solution.
58265211|NCT02122770|DRUG|Carboplatin|Carboplatin intravenous solution.
58265212|NCT02122770|DRUG|Paclitaxel|Paclitaxel intravenous solution.
58265213|NCT01382225|DRUG|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
58265214|NCT01382225|OTHER|Vehicle|Inactive ingredients used as run-in and placebo comparator
58265215|NCT06608186|DRUG|Cetrorelix drug|a drug injection daily sc. from day 5 of stimulation till hCG trigger day
58265216|NCT06608186|DRUG|Drospirenone drug|A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
58385567|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
58385568|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
58385569|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
57712125|NCT00079274|DRUG|fluorouracil|Given IV
57712126|NCT00079274|BIOLOGICAL|cetuximab|Given IV
57712127|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
57913512|NCT00000731|DRUG|Zidovudine|
57913513|NCT00000731|DRUG|Acetaminophen|
58265217|NCT03750747|DEVICE|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing \>10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
58265218|NCT06451328|DRUG|Lignosus rhinoceros TM02®|Lignosus rhinoceros TM02®
58265219|NCT06027034|BEHAVIORAL|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
58265220|NCT02402634|OTHER|Mechanical ventilatory lung care|
58265221|NCT05766345|BIOLOGICAL|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
58265222|NCT05766345|BIOLOGICAL|Placebo|Nothing to add
58385570|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
57712128|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
57712129|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
58265223|NCT00633776|DRUG|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
58265224|NCT05141643|DIAGNOSTIC_TEST|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
58265225|NCT03053648|OTHER|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
58265226|NCT03053648|OTHER|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
58385571|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
58385572|NCT00001901|DRUG|Etanercept|
58385573|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
58385574|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
58385575|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
58265227|NCT06622967|DIAGNOSTIC_TEST|CadAI-B|"The ultrasound is performed following the usual process. If there are any lesions or areas of concern identified by the patient, a more detailed analysis is conducted on the affected area.~When a lesion is confirmed, the examiner verifies the results through the frozen image, while also securing the results displayed on CadAI-B.~The examiner uses the analysis from CadAI-B as a reference to make the final BI-RADS classification.~Static images and cine clips are captured from the most suspicious areas."
58265228|NCT05614180|PROCEDURE|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
58385576|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
58385577|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
58385578|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
57712130|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
57712131|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
57913514|NCT03019731|BEHAVIORAL|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
57913515|NCT03019731|BEHAVIORAL|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
58265229|NCT04473820|DRUG|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
58265230|NCT04473820|DRUG|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
58385579|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
58385580|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
58385581|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
58385582|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
58385583|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
58385584|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
58385585|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
57712132|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
57712133|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
57712134|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
57712135|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
57712136|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
57712137|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
58265231|NCT04447677|OTHER||
58265232|NCT00951834|DRUG|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
57712138|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
57712139|NCT02316717|OTHER|Placebo|Matched placebo
57712140|NCT02310542|DEVICE|MARS albumin dialysis system|
58265233|NCT00951834|DRUG|Placebo|Placebo
58385586|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
58385587|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
58385588|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
58385589|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
58385590|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
57712141|NCT02310542|DEVICE|SPAD albumin dialysis system|
57712142|NCT04906434|DRUG|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
58265234|NCT01616849|DRUG|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
57712143|NCT04906434|DRUG|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
57712144|NCT04906434|DRUG|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
58265235|NCT03848806|DRUG|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
58265236|NCT03848806|DRUG|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
58265237|NCT00386425|DRUG|Drotrecogin alfa (activated)|intravenous
58265238|NCT04864158|PROCEDURE|TSA-group|Reverse total shoulder arthroplasty followed by standard rehabilitation.
58265239|NCT04864158|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
58265240|NCT02978391|DEVICE|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
58265241|NCT02978391|DRUG|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
58265242|NCT04254107|DRUG|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
58265243|NCT04254107|DRUG|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
58265244|NCT04254107|DRUG|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
57712145|NCT04906434|DRUG|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
57712146|NCT04906434|DRUG|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
57712147|NCT04906434|DRUG|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
57712148|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
57712149|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
58265245|NCT06646510|OTHER|traditional exercises|strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand
58265246|NCT06646510|OTHER|sensory electrical stimulation|The stimulated muscles included the flexor carpi radialis (FCR), extensor carpi radialis (ECR), and flexor carpi ulnaris (FCU). Rectangular surface electrodes (Ag/AgCl; 50mm _ 50mm size) were attached on the motor point of each muscle, i.e., at four fingerbreadths from biceps tendon of FCR, at two fingerbreadths distal from lateral epicondyle for the ECR, at two fingerbreadths volar to ulna at the junction of the upper and middle thirds of the forearm for FCU.14 Portable stimulators will use with the following stimulation settings: constant current (0.2 mA step), 100 Hz stimulation frequency, biphasic pulse, and 300 _s pulsewidth.
58265247|NCT05015621|DRUG|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
58265248|NCT05015621|DRUG|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
58265249|NCT04430231|OTHER|Wait list time|
58265250|NCT02521779|OTHER|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
58265251|NCT02521779|OTHER|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
58265252|NCT02521779|OTHER|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
58385591|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
58385592|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
58385593|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
58385594|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
58385595|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
58385596|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
58385597|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
58385598|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
58385599|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
58060690|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
58385600|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
58385601|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
57712150|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
57712151|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
57712152|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
57712153|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
57712154|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
57712155|NCT00084695|DRUG|busulfan|Given orally
57712156|NCT00084695|DRUG|cyclophosphamide|Given IV
57712157|NCT00084695|DRUG|fludarabine phosphate|Given IV
57712158|NCT00084695|DRUG|melphalan|Given IV
58060691|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
58265253|NCT02521779|OTHER|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
58265254|NCT02873637|DEVICE|under sartorial catheter|
57712159|NCT00084695|DRUG|methylprednisolone|Given IV
57712160|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
58265255|NCT02873637|DEVICE|femoral catheter|
58385602|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
58385603|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
58385604|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
58385605|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
58385606|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
57712161|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
57712162|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
57712163|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
57712164|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
57712165|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
57712166|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
57913516|NCT03743467|DIAGNOSTIC_TEST|Clinical evaluation of vision and eye tests|"* VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
58265256|NCT03931317|DRUG|Latanoprostene bunod 0.024% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
58265257|NCT03931317|DRUG|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
58385607|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
58385608|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
58385609|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
58385610|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
58385611|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
58385612|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
58385613|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
58385614|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
58265258|NCT05976308|DRUG|Bushen Huatan Decoction|The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
58265259|NCT05976308|DRUG|Placebo|The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
58265260|NCT06264752|OTHER|Level A|Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
58265261|NCT06264752|OTHER|Level B|The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
58265262|NCT06264752|OTHER|Passive Alert|Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
58265263|NCT03817957|DRUG|Polyglucoferron|intravenous administration
58265264|NCT03817957|DRUG|Ferric carboxymaltose|intravenous administration
58265265|NCT03817957|DRUG|Ferrous Sulfate|oral administration
58060692|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
58265266|NCT00900731|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
57712167|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
57712168|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
57712169|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
57712170|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
57913517|NCT03897764|PROCEDURE|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
58060693|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
58265267|NCT00900731|DRUG|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
58265268|NCT00900731|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
58265269|NCT00900731|DRUG|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
58265270|NCT02895724|DRUG|Medical Oxygen|Hyperbaric oxygen therapy
58265271|NCT04624776|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
58265272|NCT04624776|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
58265273|NCT03254212|DEVICE|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to \> 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to \< 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
58265274|NCT04195555|DRUG|Ivosidenib|Given PO
58265275|NCT03379844|DEVICE|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
57712171|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
57712172|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
57712173|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
57712174|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
57712175|NCT03912233|DRUG|VX-121|Tablets for oral administration.
57712176|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
57712177|NCT03912233|DRUG|VX-561|Tablets for oral administration.
57712178|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
57712179|NCT03912233|DRUG|IVA|Tablets for oral administration.
57712180|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
57712181|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
57712182|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
57712183|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
57712184|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
57712185|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
57712186|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
57712187|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
57712188|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
58060694|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
57712189|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
57712190|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
57712191|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
57712192|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
57712193|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
57712194|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
57712195|NCT04925297|OTHER|No intervention|No intervention will be given
57712196|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
58265276|NCT02063178|BEHAVIORAL|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
58265277|NCT02063178|BEHAVIORAL|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
57712197|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
57712198|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
57712199|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
58385615|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
58385616|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
57712200|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
57913518|NCT00636077|DEVICE|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
57913519|NCT00636077|DEVICE|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
58060695|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
58060696|NCT01157585|DRUG|paliperidone ER|8 week prospective study
58060697|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
57712201|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
57712202|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
57712203|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
57712204|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
58060698|NCT00281528|DRUG|bevacizumab|infusions
57712205|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
57712206|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
57712207|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
57712208|NCT02561507|BEHAVIORAL|Survey|
57913520|NCT00636077|DEVICE|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
57913521|NCT00636077|DEVICE|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
57913522|NCT03106909|RADIATION|pulmonary computed tomography (CT)|Pulmonary CT imaging
57712209|NCT00028028|DRUG|temsirolimus|Given IV
57712210|NCT00028028|OTHER|pharmacological study|Correlative studies
57712211|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
57913523|NCT04801810|OTHER|Normobaric hypoxia|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
57913524|NCT04801810|OTHER|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
57913525|NCT03865264|OTHER|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
58060699|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
58060700|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
58060701|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
58060702|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
58060703|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
58060704|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
58265278|NCT02063178|BEHAVIORAL|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
58060705|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
58060706|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
58060707|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
58060708|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
58385617|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
58385618|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
58385619|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
58385620|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
58385621|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
58060709|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
57712212|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
57712213|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
58265279|NCT02063178|BEHAVIORAL|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
57712214|NCT00011804|DRUG|Topiramate|
58060710|NCT02002637|DEVICE|Latella Knee Implant System|
58265280|NCT02063178|BEHAVIORAL|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
58265281|NCT02063178|BEHAVIORAL|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
58265282|NCT02063178|BEHAVIORAL|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
57712215|NCT01797536|DRUG|Elbasvir|
58060711|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
58265283|NCT02063178|BEHAVIORAL|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
58265284|NCT02063178|BEHAVIORAL|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
58265285|NCT02063178|BEHAVIORAL|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
58265286|NCT02063178|BEHAVIORAL|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
58265287|NCT03559868|DRUG|Digoxin|Participants will receive 3 mcg/Kg/day doses of oral digoxin
58265288|NCT03559868|OTHER|Placebo|Oral placebo
58265289|NCT03559868|DRUG|Digoxin|Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
58265290|NCT00760370|DRUG|Zoledronic Acid|4 mg intravenous (iv), one treatment
58265291|NCT05845450|DRUG|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
58265292|NCT05845450|DRUG|Durvalumab|durvalumab 1500 mg IV on day 1
58265293|NCT05845450|DRUG|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
58265294|NCT05845450|DRUG|Botensilimab|botensilimab 1 mg/kg on day 1
58265295|NCT05845450|DRUG|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
58265296|NCT05845450|DRUG|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
58265297|NCT02718248|DEVICE|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
58265298|NCT02718248|BEHAVIORAL|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
57913526|NCT06203366|PROCEDURE|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
58385622|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
57913527|NCT05613374|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
57913528|NCT05613374|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~* Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~* Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
57913529|NCT00140751|DRUG|Lopinavir/ritonavir (drug)|
57913530|NCT00964093|DEVICE|Silver Alginate|(Algidex ™)
57913531|NCT00014651|DRUG|vapreotide|
57913532|NCT00014651|PROCEDURE|conventional surgery|
58060712|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
58265299|NCT03098056|OTHER|PROG2|"Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food"
58265300|NCT00697541|DRUG|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
58265301|NCT00697541|DRUG|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
58265302|NCT00697541|DRUG|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
58265303|NCT00697541|DRUG|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
58265304|NCT02120820|BEHAVIORAL|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
58265305|NCT02120820|BEHAVIORAL|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
58265306|NCT02120820|OTHER|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
58265307|NCT02120820|BEHAVIORAL|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
58265308|NCT04064021|PROCEDURE|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
58265309|NCT05205148|DEVICE|Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz|Patients treated with ultrathin coronary stents (namely stents with strut thickness \< 70 um) for specific coronary disease scenarios: unprotected left main stenosis; Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm); Chronic total coronary occlusion; In-stent restenosis
57913533|NCT02217332|DRUG|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
57913534|NCT05062187|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
57913535|NCT02377115|OTHER|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
58060713|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
58060714|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
57913536|NCT02105584|DEVICE|Implantation of LAA closure device|
58060715|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
58060716|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
58385623|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
58385624|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
58385625|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
58385626|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
58385627|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
58385628|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
58385629|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
58385630|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
58385631|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
58385632|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
58385633|NCT02277574|OTHER|Placebo|Placebo
58385634|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
58385635|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
58385636|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
58385637|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
58385638|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
58385639|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
58265310|NCT03811327|BEHAVIORAL|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
58265311|NCT04988477|BEHAVIORAL|Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
57913537|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
58385640|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
58385641|NCT00187538|BEHAVIORAL|Dietary|dietary
58385642|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
58060717|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
58385643|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
58385644|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
58385645|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
58385646|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
58385647|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
57913538|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
57913539|NCT01170559|DEVICE|Implantable Loop Recorder|
58060718|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
58385648|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
57712216|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
57712217|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
57712218|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
57712219|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
57712220|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
57712221|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
57712222|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
57712223|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
57913540|NCT01877837|DRUG|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued \>48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
57913541|NCT01877837|DRUG|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
57913542|NCT01877837|DRUG|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
57913543|NCT01877837|PROCEDURE|Stem Cells|Infusion of Hematopoietic Stem Cells
57913544|NCT03470246|BEHAVIORAL|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
58060719|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
58060720|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
58060721|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
58060722|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
58060723|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
58060724|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
58060725|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
58060726|NCT02462200|OTHER|Indocyanine green|
57712224|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
58060727|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
58385649|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
57712225|NCT03128879|DRUG|Ibrutinib|Given PO
57712226|NCT03128879|DRUG|Venetoclax|Given PO
57712227|NCT03128879|DRUG|Acalabrutinib|Given BID
57712228|NCT02753894|DRUG|ASP1585|Oral
57712229|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
57712230|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
58060728|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
58060729|NCT02143336|PROCEDURE|subcuticular suture|
58060730|NCT02143336|PROCEDURE|Skin staples|
58060731|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
58385650|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
57712231|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
57712232|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
58385651|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
58385652|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
57712233|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
57712234|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
57712235|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
57712236|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
57712237|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
57712238|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
57712239|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
57712240|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
57712241|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
58060732|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
58385653|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
58060733|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
58060734|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
58385654|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
57712242|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
57712243|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
58385655|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
57712244|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
57712245|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
58060735|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
58060736|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
58060737|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
58385656|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
58385657|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
58385658|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
58385659|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
58385660|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
58385661|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
58385662|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
58385663|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
58385664|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
58385665|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
58385666|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
57712246|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
57712247|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
58265312|NCT01992315|DEVICE|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
58265313|NCT01237249|DRUG|Melphalan|
58265314|NCT01237249|DRUG|Prednisone|
58265315|NCT01237249|DRUG|Velcade|
57712248|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
58265316|NCT01237249|DRUG|Revlimid|
58265317|NCT01237249|DRUG|Dexamethasone|
58265318|NCT06050720|DEVICE|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
58265319|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
58265320|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
58265321|NCT06649227|DRUG|CAR-T cell therapy|cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
58265322|NCT06498089|DRUG|Prednisone|This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.
58265323|NCT06498089|DRUG|Methotrexate|This drug will be used in the traditional arm. A dose of 15mg per week will be used.
57712249|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
57712250|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
57712251|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
57712252|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
57712253|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
57712254|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
57712255|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
57712256|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
57712257|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
57712258|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
57712259|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
58265324|NCT06498089|DRUG|Tocilizumab|This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).
58265325|NCT06498089|DRUG|Tofacitinib|This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).
58265326|NCT06498089|DRUG|Adalimumab|This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
58265327|NCT00274443|DRUG|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
58265328|NCT04912219|DEVICE|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
58265329|NCT02472743|DEVICE|Custom-built phototherapy lamp|Described in the arm description
58265330|NCT05351541|DRUG|Psilocybin therapy with Zolpidem and Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
58265331|NCT05351541|DRUG|Psilocybin therapy with Zolpidem|1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
58265332|NCT05351541|DRUG|Psilocybin therapy with Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
58265333|NCT05351541|DRUG|Psilocybin therapy with Placebo|1-30 mg (oral administration), and placebo (oral administration)
58265334|NCT04527211|DRUG|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
58265335|NCT02211963|DRUG|BI 44847|
58265336|NCT02211963|DRUG|Placebo|
58265337|NCT05914038|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
58265338|NCT03846115|BEHAVIORAL|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
58265339|NCT03846115|BEHAVIORAL|Control app|This app offers the Seeking Safety content but without the enhanced features
57712260|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
57712261|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
57712262|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
57712263|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
58265340|NCT04094272|DIAGNOSTIC_TEST|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
58265341|NCT06021756|DRUG|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
58265342|NCT06618612|OTHER|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
57712264|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
57712265|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
58265343|NCT06618612|DEVICE|PuraPly AM|PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
58265344|NCT06618612|DEVICE|PuraPly XT|PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
58060738|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
57712266|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
57712267|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
57712268|NCT02538926|DRUG|Asparaginase|Given IM or IV
57913545|NCT03470246|BEHAVIORAL|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
57913546|NCT03470246|BEHAVIORAL|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
57913547|NCT06425874|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery
57913548|NCT06425874|PROCEDURE|Mastectomy|Mastectomy without reconstruction
57712269|NCT02538926|DRUG|Cyclophosphamide|Given IV
57913549|NCT06425874|PROCEDURE|Mastectomy with reconstruction|Any type of reconstruction(include implant and autologous)
57913550|NCT00470340|DRUG|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
58060739|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
58060740|NCT03272009|DRUG|Entecavir|Tablets administered orally
58060741|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
58060742|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
58060743|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
58265345|NCT01873300|PROCEDURE|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
57712270|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
58265346|NCT02763332|OTHER|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
57712271|NCT02538926|DRUG|Etoposide|Given IV
57712272|NCT02538926|DRUG|Imatinib Mesylate|Given PO
57712273|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
57712274|NCT02538926|DRUG|Prednisone|Given PO
57712275|NCT02538926|BIOLOGICAL|Rituximab|Given IV
57712276|NCT02538926|DRUG|Vincristine Sulfate|Given IV
57712277|NCT05942248|OTHER|No Intervention|No Intervention
57712278|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
57712279|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
57712280|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
58060744|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
58060745|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
58060746|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
58060747|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
58060748|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
58060749|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
58265347|NCT02763332|OTHER|Global trunk group (GTG)|This bandage was placed globally along the back
58265348|NCT01870674|DRUG|YH12852|
58265349|NCT01870674|DRUG|Prucalopride|
58265350|NCT01870674|DRUG|Placebo|
58265351|NCT03266692|BIOLOGICAL|ACTR087|Autologous T cell product
58265352|NCT03266692|BIOLOGICAL|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
58265353|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
57913551|NCT05451498|DIETARY_SUPPLEMENT|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
58060750|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
58060751|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
58265354|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
57712281|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
57913552|NCT05451498|DIETARY_SUPPLEMENT|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
58060752|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
58060753|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
58265355|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
58385667|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
58385668|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
57712282|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
58060754|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
58060755|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
58265356|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
58265357|NCT00044707|DRUG|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
58265358|NCT00317200|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
58265359|NCT00317200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
58385669|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
58385670|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
58385671|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
58385672|NCT00413673|PROCEDURE|PRK|PRK
57712283|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
58265360|NCT04326868|DRUG|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
58265361|NCT06483061|DRUG|Ferumoxytol|Ferumoxytol will be injected to enhance MRI images
57712284|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
57712285|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
57913553|NCT01813929|DRUG|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
58265362|NCT02630849|PROCEDURE|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
58265363|NCT02630849|PROCEDURE|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
58265364|NCT02968667|BEHAVIORAL|Empowerment|6 weeks of empowerment program and supported face to face discussion
58265365|NCT05483894|DRUG|Atorvastatin 10mg|Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
58265366|NCT05483894|DRUG|Placebo|Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
58265367|NCT04197895|PROCEDURE|Socket preservation with APRF|Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
58385673|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
57712286|NCT02984397|DRUG|Placebo|
57913554|NCT01813929|DRUG|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
58265368|NCT04197895|PROCEDURE|natural healing|after atraumatic extraction , the socket will be left for natural healing after suturing
58265369|NCT04167124|BEHAVIORAL|multi-sensor lifestyle intervention|
58265370|NCT06230666|RADIATION|SBRT|Stereotactic Body Radiation Therapy
58265371|NCT00705458|PROCEDURE|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
58265372|NCT00705458|PROCEDURE|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
58265373|NCT04220333|BEHAVIORAL|Mandalas of Emotions|Application of mandalas during 15 minutes
58265374|NCT04220333|BEHAVIORAL|Control|"Participants were requested to lie down, relax and pay attention to your breath."
58385674|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
58385675|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
57712287|NCT02984397|OTHER|Standard of Care|
57712288|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
57712289|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
57712290|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
57712291|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
57712292|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
57712293|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
57712294|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
57712295|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
57712296|NCT00304785|DRUG|latanoprost 0.005%|
57712297|NCT00304785|DRUG|Fotil|
57712298|NCT00304785|DRUG|placebo|
57712299|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
58385676|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
58385677|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
58385678|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
58385679|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
58385680|NCT03121300|OTHER|Lung CT|CT lung ventilation
58385681|NCT03121300|OTHER|MRI|DCE MRI
58385682|NCT03121300|OTHER|Walk Test|6 minute hall walk test
58385683|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
58385684|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
58385685|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
58385686|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
58385687|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
58385688|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
58265375|NCT00750412|BEHAVIORAL|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
58265376|NCT06037694|PROCEDURE|Conventional Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.
58385689|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
58385690|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
58385691|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
58385692|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
58385693|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
58265377|NCT06037694|PROCEDURE|'Mesh Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
58265378|NCT04819503|DRUG|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
58385694|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
58385695|NCT02244307|DRUG|alpha-adrenergic blocker|
58385696|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
58385697|NCT03925272|GENETIC|Genetic determinants analysis|
58385698|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
58385699|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
58385700|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
58385701|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
58385702|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
58385703|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
58385704|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
58265379|NCT04819503|DEVICE|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
57712300|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
57712301|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
57712302|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
57712303|NCT02399085|DRUG|Tafasitamab|12 mg/kg
57712304|NCT02399085|DRUG|Lenalidomide|25 mg
58385705|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
57712305|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
57712306|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
57712307|NCT03780179|BIOLOGICAL|Placebo|Placebo
57913555|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
58265380|NCT05640284|DIAGNOSTIC_TEST|Nuclear Factor-Kappa B Ligand (RANKL) analysis|samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
58265381|NCT05640284|DIAGNOSTIC_TEST|Osteoprotegerin (OPG) analysis|samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
58265382|NCT05640284|DIAGNOSTIC_TEST|Tumor Necrosis Factor Alpha (TNF-α) analysis|samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
58385706|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
58385707|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
58385708|NCT01094977|DRUG|Saline Placebo|
58385709|NCT05195086|DRUG|endoxan|Immunosuppressant
57712308|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
57712309|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
58265383|NCT05640284|DIAGNOSTIC_TEST|MicroRNA-223 analysis|samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
58265384|NCT05640284|DIAGNOSTIC_TEST|Microrna-27a analysis|samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
58265385|NCT06556277|DRUG|Metyrapone And Hydrocortisone|"Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7"
58385710|NCT05195086|DRUG|cellcept|Immunosuppressant
58385711|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
57712310|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
57913556|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
57913557|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
57913558|NCT04360317|DRUG|Combination of SH003 and Docetaxel|Combination of SH003 and Docetaxel
57913559|NCT00284687|DRUG|Artesunate|PO Artesunate
58060756|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
58060757|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
58060758|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
58060759|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
57913560|NCT03046654|DIAGNOSTIC_TEST|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
57913561|NCT03046654|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
58060760|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
58060761|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
58060762|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
58265386|NCT06556277|DRUG|Placebo|"Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7"
58265387|NCT03926390|DIETARY_SUPPLEMENT|Bovine colostrum|bovine colostrum for first 2 weeks
58385712|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
58265388|NCT05587868|BIOLOGICAL|COVID-19 Vaccine|Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
58265389|NCT02425722|DRUG|ASP0456|oral
58265390|NCT02425722|DRUG|Placebo|oral
58265391|NCT03653949|OTHER|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
58265392|NCT03653949|OTHER|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
58265393|NCT06389487|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1;
58265394|NCT01243502|DRUG|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
58265395|NCT01243502|DRUG|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
58265396|NCT06260046|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
58265397|NCT06260046|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
58265398|NCT00270231|DRUG|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
58265399|NCT00270231|DRUG|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
58385713|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
58385714|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
58385715|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
58385716|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
58385717|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
57712311|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
57712312|NCT06387303|DRUG|Methadone|Intravenous Methadone
58060763|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
58265400|NCT02733341|DRUG|Cangrelor|
58265401|NCT02733341|DRUG|Ticagrelor|
58265402|NCT05465616|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
58265403|NCT06622577|DIETARY_SUPPLEMENT|Cysteine|Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
57712313|NCT06387303|DRUG|Morphine|Intrathecal Morphine
57712314|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
57712315|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
58265404|NCT05906186|BEHAVIORAL|kiwifruit|eating two kiwifruits a day
58265405|NCT02590874|DRUG|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
58265406|NCT02590874|DRUG|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
58265407|NCT05157620|OTHER|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
58385718|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
58385719|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
58385720|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
58385721|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
58385722|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
58385723|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
58385724|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
58385725|NCT00191399|DRUG|Olanzapine|
58385726|NCT00191399|DRUG|Fluoxetine|
58385727|NCT00370266|DRUG|Triamcinolone|
58385728|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
58385729|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
58060764|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
58060765|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
58060766|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
58060767|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
58060768|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
58265408|NCT05157620|OTHER|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
58265409|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the participant will be able to troubleshoot any technical difficulties and ask any questions about the material being taught in the intervention."
58265410|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention without phone coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week."
58385730|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
58385731|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
58385732|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
58385733|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
58385734|NCT02386462|DRUG|Propofol|
58385735|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
58385736|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
58385737|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
58385738|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
58385739|NCT00833469|DRUG|Escitalopram|Once daily by mouth
58385740|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
58385741|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
58060769|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
58060770|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
58060771|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
57712316|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
57712317|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
58265411|NCT02978859|DRUG|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
58265412|NCT02998476|DRUG|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
58265413|NCT03204487|DRUG|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
58265414|NCT03589339|DRUG|NBTXR3|Single intra Tumoral injection
58385742|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
57913562|NCT03046654|DIAGNOSTIC_TEST|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
57913563|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
57913564|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
57913565|NCT00705679|DRUG|Tenofovir disoproxil fumarate|300 mg tablet
57913566|NCT00705679|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet
57913567|NCT00705679|DRUG|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
57913568|NCT00705679|DRUG|Tenofovir placebo|placebo gel
57913569|NCT05027997|DRUG|Dipraglurant|Oral tablet
57913570|NCT05027997|DRUG|Placebo|Oral matching placebo tablet
57913571|NCT05506579|OTHER|Exercises for knees, lower back, hip/groin and pelvic floor muscles in an expanded warm up program|Rhythmic gymnastics clubs allocated to the intervention group will be visited by a physiotherapist (the PhD candidate), which will perform thorough teaching of coaches and gymnasts on how to perform the exercises in the expanded warm up program. During the same visit, before commencing PFMT, the gymnasts will have an individual session were a portable 2D ultrasound machine (GE Healthcare -Logiq e R7, GE\>12L-RS - 5-13 MHz Wideband Linear Probe) will be used to teach and assess ability to perform a correct PFM contraction. The probe is placed suprapubically and provides concurrent visible biofeedback of the PFM contraction. Adherence to the intervention will be registered weekly by the coach in a training diary and asked for as an additional question in the monthly OSTRC-H2 sent to the gymnasts. Reminders will be sent by phone to the coaches every week. To assure proper execution and motivation, the PhD candidate will perform one extra visit midterm.
57913572|NCT04479631|DRUG|BRII-196|BRII-196 given intravenously
57913573|NCT04479631|DRUG|Placebo|Placebo given intravenously
58265415|NCT03589339|RADIATION|SABR|Radiotherapy given as a definite number of fractions at the dose defined for each radiation field
58385743|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
58385744|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
57913574|NCT00486629|BEHAVIORAL|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
57913575|NCT05937334|DIAGNOSTIC_TEST|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
57913576|NCT01354561|PROCEDURE|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
57913577|NCT06000137|DRUG|Dezocine|dezocine for patient-controlled analgesia
57913578|NCT06000137|DRUG|Sufentanil injection|sufentanil for patient-controlled analgesia
57913579|NCT06000137|DRUG|Flurbiprofen|Flurbiprofen for patient-controlled analgesia
58265416|NCT03589339|DRUG|Nivolumab|Anti-PD-1 monotherapy
58265417|NCT03589339|DRUG|Pembrolizumab|Anti-PD-1 monotherapy
58265418|NCT04735770|PROCEDURE|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
58265419|NCT00115245|DRUG|Telbivudine (LdT)|
58265420|NCT00115245|DRUG|Adefovir Dipivoxil|
58265421|NCT03668717|DEVICE|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
58265422|NCT01876537|DEVICE|Hardware wound healing|
58265423|NCT01876537|DEVICE|Usual Surgery|
58265424|NCT02002533|BEHAVIORAL|Brief Behavioral Therapy|Undergo BBT intervention
58265425|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo BBT intervention
58265426|NCT02002533|OTHER|Educational Intervention|Undergo HEAL
58265427|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo HEAL
58265428|NCT00192101|DRUG|gemcitabine|
58265429|NCT00192101|DRUG|cisplatin|
58265430|NCT01103947|DEVICE|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
58265431|NCT01103947|DEVICE|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
58265432|NCT01103947|DEVICE|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
57712318|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
57712319|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
57712320|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
57712321|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
57712322|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
57712323|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
58060772|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
58060773|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
58265433|NCT01103947|DEVICE|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
57712324|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
58265434|NCT02346110|DRUG|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
58265435|NCT02346110|DRUG|Dexamethasone|4 mg
58385745|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
57712325|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
57712326|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
57712327|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
57712328|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
57712329|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
58265436|NCT02346110|OTHER|Sodium chloride|1 mL of sodium chloride solution as placebo
58265437|NCT00293371|DRUG|docetaxel|
57712330|NCT00434096|DRUG|placebo|oral administration once daily
57712331|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
57913580|NCT06000137|DRUG|Granisetron Injection|granisetron has antiemetic function.
57913581|NCT00485498|DRUG|Olanzapine Hydrochloride|
57913582|NCT00485498|DRUG|Risperidone|
57913583|NCT02880345|DRUG|PEMBROLIZUMAB|
58265438|NCT00293371|DRUG|prednisone|
58265439|NCT00293371|DRUG|vatalanib|
58265440|NCT06181305|DRUG|estradiol valerate and letrozole|hormone replacement therapy by estradiol valerate plus letrozole incorporation .
58265441|NCT06181305|DRUG|letrozole 2,5 mg tablet|mild ovarian stimulation
58265442|NCT05137535|OTHER|Questionnaire|Family-based questionnaire
58265443|NCT01825174|BEHAVIORAL|Ball games program|twice a week different ball games 90min
58265444|NCT01825174|BEHAVIORAL|Nutrition counseling|9 units of 90min each of nutrition counseling
58265445|NCT00150124|DRUG|MTZ+LT4|
58265446|NCT00150124|DRUG|Methimazole|
58385746|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
58385747|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
58385748|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
57913584|NCT02880345|RADIATION|hypofractionated radiation|
57913585|NCT06226090|DRUG|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
58385749|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
58385750|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
57712332|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
58265447|NCT04649918|OTHER|pulmonary rehabilitation|COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
58265448|NCT05631522|OTHER|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
58385751|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
58385752|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
58385753|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
57712333|NCT00203450|DRUG|Zonegran|zonisamide
57712334|NCT00203450|DRUG|Placebo|Placebo pill
57712335|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
57712336|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
57712337|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
57712338|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
57712339|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
58265449|NCT03785613|DRUG|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
58385754|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
58385755|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
58385756|NCT00439595|DEVICE|Copack HBCS|
58385757|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
57712340|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
57712341|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
57712342|NCT00197379|DRUG|roxithromycin|
58265450|NCT03785613|DRUG|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
58385758|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
58385759|NCT00530634|DRUG|cisplatin|
57712343|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
58385760|NCT00530634|DRUG|gemcitabine hydrochloride|
57712344|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
57712345|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
58385761|NCT00530634|GENETIC|gene expression analysis|
58385762|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
58385763|NCT00530634|OTHER|immunohistochemistry staining method|
58385764|NCT00530634|PROCEDURE|adjuvant therapy|
58385765|NCT00530634|PROCEDURE|conventional surgery|
57712346|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
57712347|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
57712348|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
57712349|NCT00325806|DRUG|Ramipril|
57712350|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
57712351|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
57712352|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
58385766|NCT00530634|RADIATION|radiation therapy|
58385767|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
58385768|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
58385769|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
58385770|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
58385771|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
58385772|NCT00961740|OTHER|Waitlist condition|See Summary
57913586|NCT06226090|DRUG|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
57913587|NCT06226090|DRUG|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
57913588|NCT06226090|DRUG|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
57913589|NCT06226090|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
57712353|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
57913590|NCT06226090|DRUG|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
57913591|NCT02407990|BIOLOGICAL|BGB-A317|In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
57913592|NCT02407990|BIOLOGICAL|BGB-A317|Participants were assigned to different groups based on their tumor types
57913593|NCT00661479|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
58265451|NCT03785613|DRUG|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
58265452|NCT03785613|DRUG|Matching placebo patch to T1|Placebo patch to T1.
58385773|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
57712354|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
57712355|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
58385774|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
57913594|NCT00661479|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
57913595|NCT00661479|DRUG|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
57913596|NCT00661479|OTHER|Sham (no implant)|Sham in the fellow eye on Day 1.
57913597|NCT06124287|DIAGNOSTIC_TEST|MR Enterography (MRE)|MRI scan
57913598|NCT00990977|BEHAVIORAL|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
57913599|NCT04310384|DEVICE|ShuttleScope|Alternative intervention
57913600|NCT04310384|DEVICE|MacIntosh Laryngoscope|Gold Standart
57913601|NCT03218345|PROCEDURE|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
57913602|NCT00569556|OTHER|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
58265453|NCT03785613|DRUG|Matching placebo patch to T2|Placebo patch to T2.
58265454|NCT03785613|DRUG|Matching placebo patch to R|Placebo patch to R.
58265455|NCT06623578|PROCEDURE|robotic-assisted surgery|robotic-assisted surgery via single-incision transaxillary approach
58265456|NCT06623578|PROCEDURE|Open Surgery|conventional open surgery
58385775|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
57712356|NCT00002335|DRUG|Emtricitabine|
57712357|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
57712358|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
57712359|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
57913603|NCT04962243|PROCEDURE|Repair surgery for Achilles tendon rupture|Repair surgery for Achilles tendon rupture
57913604|NCT02288247|DRUG|Enzalutamide|Oral
57913605|NCT02288247|DRUG|Docetaxel|intravenous infusion
57913606|NCT02288247|DRUG|Prednisolone|Oral
57913607|NCT02288247|DRUG|Placebo|Oral
57913608|NCT02627729|DEVICE|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
57913609|NCT02627729|DEVICE|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
58385776|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
58385777|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
58385778|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
58385779|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
58385780|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
58385781|NCT01740258|RADIATION|Radiation Therapy|
58385782|NCT01740258|DRUG|Temozolomide|
58385783|NCT01740258|DRUG|Bevacizumab|
58385784|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
58265457|NCT04045132|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
58385785|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
58385786|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
58265458|NCT04045132|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
58265459|NCT03525028|DRUG|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
58265460|NCT03525028|DRUG|Placebo|The investigators use placebo in the control group.
58265461|NCT06389292|DRUG|Lisaftoclax (APG-2575)|QD, oral administration, every 28 days for a dosing cycle.
58265462|NCT06389292|OTHER|Placebo|QD, oral administration, every 28 days for a dosing cycle.
58385787|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
58385788|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
58385789|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
58385790|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
58385791|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
58385792|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
58385793|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
58385794|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
58265463|NCT06389292|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
57712360|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
57712361|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
57712362|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
57712363|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
57712364|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
57712365|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
57712366|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
57712367|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
57712368|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
57712369|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
57712370|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
57712371|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
57712372|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
57712373|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
57712374|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
58060774|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
58265464|NCT03085238|DEVICE|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
58265465|NCT01378975|DRUG|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
58265466|NCT02895308|BEHAVIORAL|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
57712375|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
57712376|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
57712377|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
57712378|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
57712379|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
57712380|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
57712381|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
57712382|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
57712383|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
57712384|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
58060775|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
58060776|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
57712385|NCT05112497|OTHER|No intervention procedure|No intervention procedure
57712386|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
57712387|NCT04613180|DRUG|Placebo|placebo containing no active substance
57712388|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
57712389|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
57712390|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
57712391|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
57712392|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
57712393|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
58265467|NCT02895308|BEHAVIORAL|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
58265468|NCT04807504|DRUG|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
58265469|NCT03376347|DEVICE|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
57712394|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
57712395|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
57712396|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
57712397|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
57712398|NCT01678534|DRUG|Placebo|
57712399|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
57712400|NCT02886585|DRUG|Pembrolizumab|
57712401|NCT02886585|RADIATION|MRI|
57712402|NCT02886585|RADIATION|PET/CT|
57712403|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
57712404|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
57712405|NCT06572657|OTHER|physical exercise|physical exercise
57712406|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
57913610|NCT05878301|OTHER|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
57913611|NCT00482560|DRUG|Sucrose solution 30%1 ml|
57913612|NCT00482560|BEHAVIORAL|Breastfeeding|
58060777|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
58265470|NCT00148577|DEVICE|Transcutaneous Electrical Nerve Stimulation|
58265471|NCT02288078|OTHER|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
58265472|NCT02288078|OTHER|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
58265473|NCT02288078|OTHER|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
58265474|NCT02288078|OTHER|Clinical findings|"* Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis"
58265475|NCT02288078|OTHER|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
58265476|NCT02288078|OTHER|Coagulation and fibrinolysis system|international normalized ratio (INR)
58265477|NCT02288078|OTHER|Urinalysis|Proteinuria (qualitative)
58265478|NCT02288078|OTHER|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
58265479|NCT02288078|OTHER|Adverse event|CTCAE ver.4.0
58265480|NCT02288078|OTHER|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
57913613|NCT02750982|OTHER|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
58060778|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
58265481|NCT02288078|OTHER|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
58265482|NCT02288078|OTHER|Brain MRI|If any symptom of brain metastasis is suspected
58265483|NCT02288078|DRUG|Dexamethasone|Capsule filled with dexamethasone and lactose
58385795|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
58385796|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
58060779|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
58265484|NCT02288078|DRUG|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
58265485|NCT02288078|DRUG|Placebo|Capsule filled with lactose
58265486|NCT02288078|DRUG|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
58265487|NCT06649448|DRUG|Efbemalenograstim alfa Injection|This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
58265488|NCT06649448|DRUG|carboplatin/cisplatin-etoposide|one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
58265489|NCT06649448|DRUG|Carboplatin plus Paclitaxel|"For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W)."
58265490|NCT06649448|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|"For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W)."
58265491|NCT06649448|DRUG|TP regimen|"The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W)."
58265492|NCT03219606|OTHER|Organized education course of Modified Rodnan Skin Scoring|"1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
58060780|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
58265493|NCT00278226|BEHAVIORAL|smoking cessation intervention|
58265494|NCT00278226|OTHER|educational intervention|
58060781|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
58060782|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
58060783|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
58385797|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
57712407|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
57712408|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
57712409|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
57913614|NCT00318071|DEVICE|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
57913615|NCT05416073|DRUG|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
57913616|NCT05416073|DRUG|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
57913617|NCT03635593|DRUG|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
57913618|NCT03635593|DRUG|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
57913619|NCT03635593|OTHER|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
57913620|NCT03730480|DEVICE|Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes|Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
57913621|NCT03436251|DEVICE|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
57913622|NCT03436251|DEVICE|LEEP or cold knife|For patients with HPV+ / CIN-2
57913623|NCT03436251|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
57913624|NCT06610786|PROCEDURE|foldable capsular scleral buckling|Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity
57913625|NCT06610786|PROCEDURE|vitrectomy|Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
58060784|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
57712410|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
57712411|NCT02059928|DEVICE|Intraosseous Device|
57913626|NCT01765166|BEHAVIORAL|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
58265495|NCT06060106|PROCEDURE|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
58265496|NCT06060106|PROCEDURE|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
57913627|NCT05587439|GENETIC|Data and Specimen Collection|"* Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members"
57913628|NCT05132192|PROCEDURE|living donor liver transplantation|Living donor liver transplantation
58060785|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
58060786|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
58265497|NCT06009016|DIAGNOSTIC_TEST|Inflammatory factors and coagulation factors level in cerebrospinal fluid after subarachnoid hemorrhage|Inflammatory factors and coagulation factors level in cerebrospinal fluid will be tested by ELISA kits.
58265498|NCT02468128|DRUG|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
58265499|NCT02468128|DRUG|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
58385798|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
58385799|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
58385800|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
58385801|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
58060787|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
58265500|NCT00239213|DRUG|catechin extracts (health food)|
58385802|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
57913629|NCT05132192|PROCEDURE|Thrombectomy or interposition graft|Portal flow restoration due to PVT in any manner
57913630|NCT01274832|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
57913631|NCT00475397|DRUG|Duloxetine|
57913632|NCT00475397|DRUG|Placebo|
57913633|NCT02896049|DEVICE|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
58060788|NCT04835389|DRUG|Placebo|0.9% normal saline
58060789|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
58060790|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
58060791|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
58265501|NCT02231593|OTHER|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
58265502|NCT03521817|OTHER|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
58265503|NCT03521817|OTHER|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
58060792|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
57712412|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
57712413|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
57712414|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
57712415|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
58060793|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
58060794|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
58265504|NCT04395612|DRUG|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
58265505|NCT04395612|DRUG|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
58265506|NCT05487287|DEVICE|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~1. Finger extension~2. Wrist extension~3. Finger separation~4. Finger clamp"
58265507|NCT05373992|BEHAVIORAL|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
58265508|NCT05373992|BEHAVIORAL|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
58265509|NCT05373992|BEHAVIORAL|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
58060795|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
58265510|NCT05373992|BEHAVIORAL|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
58265511|NCT00810017|DRUG|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
58265512|NCT00810017|DRUG|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
58265513|NCT06439628|DRUG|Rimegepant|patients take rimegepant to treat migraine attack as needed
58265514|NCT00955045|DRUG|istradefylline|
58385803|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
58385804|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
58385805|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
58385806|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
58385807|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
58385808|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
58265515|NCT05756127|OTHER|Observational - no intervention given|Observational - no intervention given
58265516|NCT01560533|BEHAVIORAL|Interviews|Interviews will be done with patients
58265517|NCT03042871|DRUG|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
58265518|NCT04053010|BIOLOGICAL|Sabin-IPV and DTaP|Sabin-IPV +DTaP at the age of 3/4/5 months old respectively
58265519|NCT04053010|BIOLOGICAL|Sabin-IPV|Sabin-IPV only at the age of 3/4/5 months old respectively
58265520|NCT04053010|BIOLOGICAL|DTaP|DTaP only at the age of 3/4/5 months old respectively
58265521|NCT03336268|BEHAVIORAL|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
58265522|NCT00962091|DRUG|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
58385809|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
58385810|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
58385811|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
58385812|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
58265523|NCT01440140|OTHER|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
58265524|NCT01440140|OTHER|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
58265525|NCT04388904|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
58265526|NCT03703908|DRUG|CCX140-B|Orally administered tablet
58385813|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
58385814|NCT00536718|GENETIC|gene expression analysis|
58385815|NCT00536718|GENETIC|molecular diagnostic method|
58385816|NCT00536718|GENETIC|polymorphism analysis|
58385817|NCT00536718|GENETIC|protein expression analysis|
58385818|NCT00536718|OTHER|medical chart review|
58385819|NCT00536718|OTHER|questionnaire administration|
58385820|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
58385821|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
58385822|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
58385823|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
58385824|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
58385825|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
58385826|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
58385827|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
58385828|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
58385829|NCT01739608|OTHER|Invitation to screening|Invitation to screening
58385830|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
58385831|NCT00040742|OTHER|placebo|Given orally
58385832|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
58385833|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
58385834|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
58385835|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
58385836|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
58385837|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
57712416|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
57712417|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
57913634|NCT05919862|PROCEDURE|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
57913635|NCT05919862|PROCEDURE|Freehand surgery|Freehand implant placement by experienced surgeon.
58385838|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
58385839|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
58385840|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
58385841|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
57712418|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
57712419|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
57712420|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
57913636|NCT06300385|DEVICE|Electromyostimulation|Electromyostimulation (EMS), a low-frequency current, will be used for electrical stimulation of the wrist flexor muscle group. Stimulation frequency will be applied as 25 Hertz. Care will be taken to ensure that the current intensity does not cause pain in the patient. The size of the EMS electrodes is 2 cm2 and they will be placed in the form of 4 electrodes on the wrist flexor muscles (inner wrist area) with a distance of 1 cm between them. Each strengthening session will be 15 minutes for 6 weeks, 3 days a week, for a total of 18 sessions. EMS application will be carried out together with strengthening exercises. Laica MD6078 branded device belonging to the researchers will be used.
57913637|NCT06300385|OTHER|Strengthening exercises|All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.
57913638|NCT04838600|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
58385842|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
58385843|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
58385844|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
58385845|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
57712421|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
57712422|NCT04515186|DRUG|Miltefosine|50 mg capsule
57712423|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
57712424|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
57913639|NCT05462301|OTHER||Neonatal bedside echocardiography was performed by a trained neonatologist or sonographer
58060796|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
58060797|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
58385846|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
58385847|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
58385848|NCT06469190|DRUG|KN5501|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
58385849|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
58385850|NCT00181818|DRUG|bupropion SR (sustained-release)|
57712425|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
57712426|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
57913640|NCT04213950|OTHER|Rabies PEP quality improvement bundle|The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
57913641|NCT03085030|DRUG|Antioxidant Formula|Antioxidant tablet will be taken by the patients
57913642|NCT03085030|DRUG|Placebo|The placebo will be taken by the patients
57913643|NCT01296347|DRUG|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
57913644|NCT03990831|DIAGNOSTIC_TEST|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
57913645|NCT04367012|OTHER|Abdominal Ultrasound|patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
57913646|NCT03002831|BIOLOGICAL|Cytokine-induced Killer Cells|
58265527|NCT01811862|PROCEDURE|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
58265528|NCT01811862|PROCEDURE|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
57913647|NCT03002831|DRUG|Tegafur-Gimeracil-Oteracil Potassium|
58265529|NCT05107466|DIAGNOSTIC_TEST|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
58265530|NCT00560586|DRUG|Budesonide|1 puff each nostril (32 micrograms) at bedtime
57913648|NCT02816944|PROCEDURE|EUS-guided laser ablation for refractory neoplasms|
57712427|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
57712428|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
57913649|NCT03866499|DRUG|BPI-7711|180 mg, oral, QD
57913650|NCT03866499|DRUG|Gefitinib|250 mg, oral, QD
57913651|NCT03866499|DRUG|Placebo Tablet|250 mg gefitinib placebo tablet, QD
58265531|NCT00560586|DRUG|placebo|1 puff each nostril at bedtime
57913652|NCT03866499|DRUG|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
57913653|NCT03897686|DEVICE|"hydrous biopolymer with silver ions Argiform"|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
57913654|NCT03897686|DEVICE|saline solution|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
57913655|NCT05577884|DIAGNOSTIC_TEST|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
57913656|NCT00806572|DRUG|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
57913657|NCT03933527|BEHAVIORAL|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
58060798|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
58060799|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
57712429|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
57712430|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
57712431|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
57712432|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
57712433|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
58060800|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
58265532|NCT00526565|BEHAVIORAL|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
58265533|NCT00526565|BEHAVIORAL|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
58265534|NCT02567409|DRUG|Berzosertib|Given IV
58385851|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
58385852|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
58060801|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
58385853|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
57712434|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
58385854|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
58385855|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
58385856|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
58385857|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
57712435|NCT00002275|DRUG|Fat Emulsion 2%|
57712436|NCT00002275|DRUG|Fat Emulsion 20%|
57712437|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
57712438|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
57712439|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
57712440|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
57712441|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
57712442|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
57712443|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
58265535|NCT02567409|DRUG|Cisplatin|Given IV
58265536|NCT02567409|DRUG|Gemcitabine Hydrochloride|Given IV
58385858|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
58265537|NCT01027728|DRUG|CCX 354-C|"* Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
57913658|NCT04924933|DIAGNOSTIC_TEST|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
58060802|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
58265538|NCT04982458|DIAGNOSTIC_TEST|68Ga-FAPI|68Ga-FAPI injection is a radiopharmaceutical used for positron emission tomography (PET) diagnosis. This product is used for PET, qualitative and localized diagnosis and evaluation of abnormal expression of fibroblast-activated protein in focus-associated fibroblasts.
58265539|NCT02332239|BEHAVIORAL|iDOVE Intervention (ED+text)|"1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program"
58265540|NCT02332239|BEHAVIORAL|Control (EUC)|"1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program"
58265541|NCT03071731|DRUG|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
58265542|NCT03071731|DRUG|Placebos|Administration of a nebulized placebo before the administration of a functional test
57712444|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
58265543|NCT04231396|OTHER|Audiobooks for hearing loss App|Same as Arm 1
58265544|NCT00735293|DEVICE|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
58265545|NCT02900495|DEVICE|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
58265546|NCT02255318|DEVICE|Taurolock|
58385859|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
58385860|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
57712445|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
57712446|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
58265547|NCT02255318|DRUG|Placebo|
58385861|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
57712447|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
57712448|NCT01852890|RADIATION|Radiation therapy|
57712449|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
57712450|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
57712451|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
57712452|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57712453|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
57712454|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
57712455|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
58265548|NCT01655849|DRUG|z160|
58265549|NCT01655849|DRUG|Placebo|
58385862|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
58385863|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
58385864|NCT02100423|DRUG|curcumin|Given PO
58385865|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
58385866|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
58385867|NCT02100423|OTHER|pharmacological study|Correlative studies
58385868|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
58385869|NCT00358319|DRUG|Karenitecin|
58385870|NCT00358319|DRUG|Valproic Acid|
57913659|NCT00036959|DRUG|ABT-751|
58060803|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
58265550|NCT01534208|DRUG|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
58265551|NCT01443091|OTHER|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
57712456|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
57913660|NCT02783664|OTHER|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
58060804|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
58060805|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
57913661|NCT01168323|BEHAVIORAL|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
57913662|NCT01094860|DRUG|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
57913663|NCT04160520|DRUG|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
57913664|NCT04160520|DRUG|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
58060806|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
58265552|NCT01443091|OTHER|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
58265553|NCT04341831|DRUG|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
58265554|NCT06619938|BEHAVIORAL|Mindfulness With Biofeedback|The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.
57712457|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
57712458|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57712459|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
57712460|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57712461|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
57712462|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
57712463|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
58060807|NCT04383743|DRUG|Cisplatin|Given IV
58060808|NCT04383743|DRUG|Doxorubicin|Given IV
58060809|NCT04383743|DRUG|Methotrexate|Given IV
58060810|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
57712464|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
57712465|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57712466|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
57712467|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
57712468|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
57712469|NCT03244228|DRUG|HTL0016878|Oral solution
57712470|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
57712471|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
57712472|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
58060811|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
58060812|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
58060813|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
57712473|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
57913665|NCT04160520|DRUG|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
57913666|NCT04209959|DRUG|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
57913667|NCT02715791|BEHAVIORAL|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
57913668|NCT02715791|OTHER|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
57913669|NCT02754986|OTHER|Analysis of the holter electrocardiogram|
57913670|NCT02756273|DEVICE|bridge device|
57913671|NCT02756273|DEVICE|no bridge device|
57913672|NCT00657202|DRUG|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
57913673|NCT02270918|DRUG|Kcentra|IV infusion
57913674|NCT02270918|DRUG|Apixaban|
58060814|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
58060815|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
57712474|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
57913675|NCT02270918|DRUG|Placebo|
58060816|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
58060817|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
58060818|NCT00025090|DRUG|cisplatin|
58060819|NCT00025090|DRUG|fluorouracil|
58060820|NCT00025090|DRUG|mitomycin C|
58060821|NCT00025090|RADIATION|radiation therapy|
58060822|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
58060823|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
58060824|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
58060825|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
58060826|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
58060827|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
58060828|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
58060829|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
58265555|NCT06619938|BEHAVIORAL|Mindfulness Without Biofeedback|The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
58265556|NCT01149421|DRUG|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
57712475|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
58265557|NCT01149421|DRUG|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
58265558|NCT05821972|DRUG|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
58265559|NCT05821972|DRUG|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
58265560|NCT02956447|DRUG|Kisspeptin 112-121|0.313 ug/kg - 2 ug/kg IV or SC
58265561|NCT02956447|DRUG|GnRH|0.075 ug/kg IV
58265562|NCT06390007|DEVICE|Sham press needle|The plester used is a round plaster that resembles the shape of an acupuncture press needle.
58265563|NCT06390007|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
58265564|NCT00556634|DRUG|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
58265565|NCT01881880|DEVICE|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
58265566|NCT00070018|BIOLOGICAL|rituximab|250 mg/m\^2, as part of Zevalin regimen
58265567|NCT00070018|DRUG|Cyclophosphamide|750 mg/m\^2
58265568|NCT00070018|DRUG|doxorubicin hydrochloride|50 mg/m\^2
58265569|NCT00070018|DRUG|prednisone|100 mg
58265570|NCT00070018|DRUG|vincristine sulfate|1.4 mg/m\^2
58385871|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
57712476|NCT01108575|OTHER|IMST|inspiratory muscle strength training
57712477|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
57712478|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
57712479|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
57712480|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
58265571|NCT00070018|RADIATION|radiation therapy|4000-5000 cGy total
58265572|NCT00070018|BIOLOGICAL|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
58265573|NCT00070018|BIOLOGICAL|Indium-111 ibritumomab tiuxetan|5 mCi
58265574|NCT00292110|DRUG|Methadone|100 mg/day orally
58265575|NCT00292110|BEHAVIORAL|Contingency Management|Incentives given for cocaine abstinence
58265576|NCT00292110|DRUG|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
58265577|NCT00292110|BEHAVIORAL|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
58265578|NCT02528890|OTHER|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
58265579|NCT01695330|DRUG|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
58265580|NCT05950581|DEVICE|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
58265581|NCT05950581|DEVICE|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
58060830|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
58385872|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
58385873|NCT02779777|DRUG|Tipifarnib|Oral tablet
58060831|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
58060832|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
58385874|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
58060833|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
58385875|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
58385876|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
58385877|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
58385878|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
58385879|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
58385880|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
58385881|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
58385882|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
58385883|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
58385884|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
58385885|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
58385886|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
58060834|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
58060835|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
58060836|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
58060837|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
58060838|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
58060839|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
58060840|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
58385887|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
58385888|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
58385889|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
58060841|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
57712481|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
57712482|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
57712483|NCT01172548|DRUG|imatinib mesylate|
57913676|NCT03525951|BEHAVIORAL|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
58060842|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
58060843|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
58060844|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
58060845|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
58265582|NCT04340258|DEVICE|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
58385890|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
57712484|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
58060846|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
58060847|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
57913677|NCT03525951|OTHER|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
57913678|NCT06253091|PROCEDURE|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist laparoscopic radical cystectomy was performed extraperitoneal
57913679|NCT00045513|DRUG|7-hydroxystaurosporine|
58060848|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
58060849|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
58060850|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
58060851|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
58060852|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
58265583|NCT04340258|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
58265584|NCT02013661|PROCEDURE|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
58265585|NCT01425970|DRUG|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
58265586|NCT01425970|DRUG|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
58265587|NCT01425970|DRUG|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
58265588|NCT01425970|DRUG|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
58265589|NCT01425970|BIOLOGICAL|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
58265590|NCT01425970|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
58060853|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
58060854|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
58385891|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
58385892|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
58385893|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
58385894|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
57712485|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
57712486|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
57712487|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
57712488|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
57913680|NCT00045513|DRUG|fludarabine phosphate|
58060855|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
58060856|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
58060857|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
58060858|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
57712489|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
57712490|NCT02224872|RADIATION|TBI|200 cGy on day -1
57913681|NCT05678751|DIAGNOSTIC_TEST|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
57913682|NCT04328883|DRUG|Aspirin|Oral and inhaled ASA formulations
58060859|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
58265591|NCT01425970|DRUG|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
58385895|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
58385896|NCT00094562|DRUG|Fish oil supplement|
58385897|NCT01104545|DRUG|MK-3614|
58385898|NCT01104545|DRUG|Comparator: Placebo|
58385899|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
58385900|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
58385901|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
58385902|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
58385903|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
58385904|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
57712491|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
57712492|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
57712493|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
58060860|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
58060861|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
58060862|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
58060863|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
58060864|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
58265592|NCT01425970|DRUG|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
58265593|NCT03488849|DEVICE|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
58265594|NCT03488849|OTHER|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
58385905|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
58385906|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
58385907|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
58385908|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
58385909|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
58385910|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
58265595|NCT00689559|DRUG|AZD3480|AZD3480 capsules qd, oral, 22 days
58385911|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
58385912|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
58385913|NCT01005641|DRUG|exemestane|25 mg daily
58385914|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
58385915|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
57712494|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
58265596|NCT00689559|DRUG|Placebo|Placebo qd, 12 days
58265597|NCT00689559|DRUG|Aripiprazole|single dose on day 5
58265598|NCT03925584|OTHER|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
58060865|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
58265599|NCT02255136|OTHER|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
57712495|NCT00772096|DRUG|n-3 fatty acids|
57913683|NCT06206252|OTHER|Medical Cannabis|Participants will be restricted to specific medical cannabis products from Ethos Dispensary. They will be randomized to one medical cannabis formulation (tincture or vaporization) for the duration of the study. Each month for three months, they will purchase a different composition (predominantly THC, predominantly CBD, or balanced products) of their designated formulation. The order of compositions will be randomized and double-blinded, so participants and the research team will not know which compositions of medical cannabis they are using each month.
57913684|NCT04379726|BEHAVIORAL|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
58385916|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
57913685|NCT05444049|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
57913686|NCT06347887|DIAGNOSTIC_TEST|ColonAiQ test and Colonoscopy|Diagnostic Test
57913687|NCT02794753|BEHAVIORAL|Working memory training|
57913688|NCT02794753|BEHAVIORAL|Game|
57913689|NCT01526031|PROCEDURE|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
57913690|NCT01526031|PROCEDURE|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
58265600|NCT02255136|OTHER|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
58385917|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
57712496|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
57913691|NCT01526031|PROCEDURE|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
57913692|NCT01526031|PROCEDURE|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program"
58060866|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
58265601|NCT00621465|BEHAVIORAL|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
58265602|NCT00621465|BEHAVIORAL|Usual care|Usual care will include the standard aftercare and community care services.
58385918|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
57712497|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
57913693|NCT03390218|BEHAVIORAL|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
57913694|NCT03390218|BEHAVIORAL|Treatment as usual|Individual and group therapy, generic in nature
58060867|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
58060868|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
58060869|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
58060870|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
58265603|NCT03375515|DRUG|Hydromorphone|"1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
58265604|NCT03375515|DEVICE|PCA pump|"1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
58385919|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
58385920|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
58060871|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
58385921|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
58385922|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
58385923|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
58385924|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
58385925|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
58385926|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
58385927|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
58385928|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
58385929|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
58385930|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
58385931|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
58385932|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
58385933|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
58385934|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
58385935|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
58385936|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
58060872|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
58265605|NCT00784550|DRUG|Tiotropium Bromide|Long-acting muscarinic antagonist
58265606|NCT00784550|DRUG|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
57913695|NCT00591721|BEHAVIORAL|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
57913696|NCT06342271|OTHER|Nordic walking training|Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.
57913697|NCT06342271|OTHER|Free Walking training|Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
57913698|NCT00379743|BEHAVIORAL|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
57913699|NCT00379743|BEHAVIORAL|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
57913700|NCT00836095|DEVICE|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
57913701|NCT00836095|DEVICE|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
57913702|NCT02610127|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
57913703|NCT04555031|DEVICE|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
57913704|NCT04555031|DEVICE|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
57913705|NCT04555031|DEVICE|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
57913706|NCT04555031|DEVICE|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
57913707|NCT04810143|DEVICE|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
57913708|NCT05396677|DRUG|Acetaminophen|2 x 500 mg acetaminophen (one time)
57913709|NCT05396677|OTHER|Placebo|2 x 500 mg microcrystalline cellulose (one time)
57913710|NCT06609720|PROCEDURE|(guided tissue regeneration)|Randomized clinical and radiographic trial
57913711|NCT05029180|OTHER|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
57913712|NCT06442033|OTHER|High intensity stationary cycling|All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
57913713|NCT05998538|PROCEDURE|Knee Replacement|Total vs Partial Knee Replacement
57913714|NCT02299154|BEHAVIORAL|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
57913715|NCT00626301|DRUG|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
57913716|NCT06266715|DRUG|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
57913717|NCT06266715|DRUG|Placebo Group|Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
58385937|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
57913718|NCT04169230|DRUG|Citalopram|Single dose administration of citalopram (20mg)
57913719|NCT04169230|DRUG|Placebo oral tablet|Single dose administration lactose placebo tablet
57913720|NCT03864822|DEVICE|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
58060873|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
58265607|NCT06623188|OTHER|Auricular neuromodulation|3 neuromodulation sessions over 12 weeks
58265608|NCT06623188|OTHER|Sham auricular neuromodulation|3 neuromodulation sessions over 12 weeks
58265609|NCT02685501|OTHER|no intervention|
58265610|NCT00105287|DRUG|OraVescent fentanyl (OVF)|
57712498|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
58265611|NCT03546010|BEHAVIORAL|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
58385938|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
58385939|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
57712499|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
57712500|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
57712501|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
57712502|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
57712503|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
57712504|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
57712505|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
57712506|NCT01872572|DRUG|Placebo|Placebo
57712507|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
57913721|NCT03902925|PROCEDURE|Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
57913722|NCT03902925|PROCEDURE|Peribulbar injection|Peribulbar injection of 4-6 ml of ropivacaine 10%
58265612|NCT03546010|BEHAVIORAL|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
58385940|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
58385941|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
58385942|NCT03835481|DRUG|BI 730357|Film-coated tablet
58385943|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
58385944|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
57712508|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
57913723|NCT03567434|OTHER|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
57913724|NCT06064175|DRUG|Ibuprofen 400 mg|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
57913725|NCT06064175|DRUG|Ibuprofen 800 mg|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
58265613|NCT06211933|PROCEDURE|HIFU intervention|HIFU intervention on non resectable pancreatic lesions at day 0 for each patient included
58265614|NCT04750733|OTHER|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
57913726|NCT02192879|DEVICE|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
58265615|NCT02719353|DEVICE|comfilcon A Extended Range test lens|contact lens
58265616|NCT02719353|DEVICE|comfilcon A control lens|contact lens
58265617|NCT05400889|DRUG|tofacitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
57913727|NCT02192879|DEVICE|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
57913728|NCT02192879|DRUG|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
57913729|NCT06066450|DEVICE|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
57913730|NCT04589949|BIOLOGICAL|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
58265618|NCT01527487|DRUG|Eribulin|1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
58265619|NCT01527487|DRUG|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
58265620|NCT01527487|DRUG|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
58265621|NCT03132870|OTHER|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
58265622|NCT02403349|DRUG|Fimasartan|
58265623|NCT02403349|DRUG|Valsartan|
58265624|NCT02403349|DRUG|Atenolol|
58265625|NCT06211738|OTHER|no intervention|no intervention
58265626|NCT04495816|DRUG|Omega-3 Fatty Acid Supplement|Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
58265627|NCT04495816|DRUG|Placebo/Control|Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
57913731|NCT04589949|BIOLOGICAL|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
57712509|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
57712510|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
57913732|NCT06507202|DRUG|Remimazolam|General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.
57913733|NCT06507202|DRUG|Propofol|General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
57913734|NCT05464797|PROCEDURE|Pulp therapy|partial or complete removal of inflamed pulp tissue
57913735|NCT05464797|DIAGNOSTIC_TEST|Cytokines level in pulpal blood.|Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
57913736|NCT01022060|DIETARY_SUPPLEMENT|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
57913737|NCT01022060|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
58060874|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
58060875|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
58060876|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
58060877|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
58060878|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
58265628|NCT02939027|DEVICE|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
58385945|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
58265629|NCT02939027|DEVICE|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
58265630|NCT06430502|BIOLOGICAL|Tumor Treatment Vaccine; PD-1/L1 inhibitors|Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
58385946|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
58060879|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
58060880|NCT01987609|DRUG|Hylenex|
57913738|NCT00986674|BIOLOGICAL|cixutumumab|Given IV
57913739|NCT00986674|DRUG|carboplatin|Given IV
58060881|NCT01987609|DRUG|Normal Saline|
58265631|NCT01664949|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
58385947|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
58385948|NCT01971671|OTHER|no intervention.|
58385949|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
58385950|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
58385951|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
58265632|NCT01664949|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
58385952|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
57913740|NCT00986674|DRUG|paclitaxel|Given IV
58265633|NCT02416050|PROCEDURE|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
57913741|NCT00986674|BIOLOGICAL|cetuximab|Given IV
57913742|NCT04574050|OTHER|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
57913743|NCT05590884|DRUG|Gadopiclenol|Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
57913744|NCT04308161|DRUG|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
57913745|NCT04308161|DRUG|Miconazole Topical Gel|topical anti fungal agent
58265634|NCT03149289|DRUG|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
58385953|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
58385954|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
58385955|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
57712511|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
57913746|NCT04308161|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
57913747|NCT04308161|DRUG|Oracure gel|Topical analgesic gel
57913748|NCT04308161|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
57913749|NCT03635073|DRUG|Soticlestat|Soticlestat tablets or mini-tablets.
57913750|NCT03707197|BEHAVIORAL|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
57913751|NCT05208177|DRUG|SHR-1802＋camrelizumab + famitinib|SHR-1802 for injection，q3w； Camrelizumab for injection, q3w; Famitinib malate capsules, qd.
57913752|NCT05173740|OTHER|Individually tailored rehabilitation intervention|Individually tailored rehabilitation intervention
57913753|NCT05173740|OTHER|Usual care|Usual care
57913754|NCT01485055|DRUG|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
57913755|NCT00898183|GENETIC|gene expression analysis|
57913756|NCT00898183|GENETIC|polymorphism analysis|
58060882|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
58265635|NCT04072991|OTHER|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
58265636|NCT01688778|BEHAVIORAL|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
58265637|NCT03117894|DRUG|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
57913757|NCT02684851|DRUG|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
57913758|NCT02684851|DRUG|Placebo|Placebo
57913759|NCT00537693|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
57913760|NCT04538443|OTHER|functional capacity|impact of hemodialysis on functional capacity in children with CKD
57913761|NCT04538443|OTHER|muscle strength|impact of hemodialysis on muscle strength in children with CKD
57913762|NCT04538443|OTHER|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
57913763|NCT04538443|OTHER|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
57913764|NCT05196568|DIETARY_SUPPLEMENT|Fasting mimicking diet|Women will be given three administrations of fasting mimicking diet once a month
58385956|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
58385957|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
58385958|NCT02076529|DRUG|Ramosetron 0.3mg|
58385959|NCT02076529|DRUG|Ramosetron 0.45mg|
58385960|NCT02076529|DRUG|Ramosetron 0.6mg|
57712512|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
57913765|NCT04456569|DEVICE|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
58265638|NCT03117894|DRUG|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
58265639|NCT03117894|DRUG|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
58385961|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
58385962|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
58385963|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
58385964|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
58385965|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
58385966|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
58385967|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
57913766|NCT03520946|DRUG|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
57913767|NCT03520946|DRUG|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
58060883|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
58265640|NCT03117894|DRUG|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
58385968|NCT00290992|DRUG|rasburicase (SR29142)|
58385969|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
58385970|NCT04649216|DRUG|PCO371|PCO371 Capsule
58385971|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
57913768|NCT02486744|DRUG|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
58265641|NCT03117894|DRUG|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
58265642|NCT03117894|DRUG|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
58385972|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
58385973|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
58385974|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
58385975|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
58385976|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
58385977|NCT03276832|DRUG|Imiquimod|Applied cutaneously
58385978|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
58385979|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
58385980|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58385981|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58385982|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58385983|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
58385984|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
58385985|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
57712513|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
57712514|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
57712515|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
57913769|NCT02687893|BEHAVIORAL|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
57712516|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
57913770|NCT02687893|BEHAVIORAL|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
57712517|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
58265643|NCT03117894|DRUG|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
58265644|NCT03117894|DRUG|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
58385986|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
58385987|NCT03045614|OTHER|No intervention|No intervention
58385988|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
58385989|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
58385990|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
58385991|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
57712518|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
57712519|NCT00599937|DRUG|ATRA|early introduction of ATRA
57712520|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
58265645|NCT04109937|RADIATION|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
58265646|NCT04318171|DEVICE|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~* Plaque volume where detectable.~* Max area stenosis.~* Volumetric stenosis.~* Measured length.~* 3D GSM. The entire assessment should not take more than 45 minutes."
58385992|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
58385993|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
57712521|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
57712522|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
57712523|NCT04556305|BEHAVIORAL|Mind|See arm description.
57712524|NCT04556305|BEHAVIORAL|Move|See arm description.
57712525|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
57712526|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
58265647|NCT01768845|GENETIC|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
57712527|NCT03860896|DRUG|GB004|GB0004 high dose
57712528|NCT03860896|DRUG|Placebo|Placebo
57712529|NCT03860896|DRUG|GB004|GB004 low dose
57712530|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
57712531|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
57712532|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
57712533|NCT02353481|OTHER|Heart Failure Management|
58385994|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
58385995|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
58385996|NCT00117780|DRUG|insulin detemir|
57712534|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|Curcumin is a bioactive compound found in turmeric (Curcuma longa), known for its potent anti-inflammatory, antioxidant, and antimicrobial properties. Its therapeutic effects are primarily attributed to its ability to modulate various molecular targets and signaling pathways within the body
57712535|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Epigallocatechin gallate (EGCG) is a type of catechin, a natural phenol, and antioxidant found predominantly in green tea. EGCG is known for its potent health-promoting properties, including strong antioxidant, anti-inflammatory, and anti-carcinogenic effects.
57712536|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
57913771|NCT02479048|DIETARY_SUPPLEMENT|Test meal 1|High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
57913772|NCT02479048|DIETARY_SUPPLEMENT|Test meal 2|High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.
57913773|NCT02479048|DIETARY_SUPPLEMENT|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
58265648|NCT00847782|PROCEDURE|Blood draw|1 day
58265649|NCT01152216|DRUG|Dimebon|20 mg orally three times daily
58385997|NCT00117780|DRUG|insulin aspart|
58385998|NCT02443337|DRUG|LY3023414|Administered orally
58385999|NCT02443337|DRUG|Necitumumab|Administered IV
58386000|NCT00125814|DRUG|Interferon alfa-2b|
58386001|NCT00125814|PROCEDURE|Structured treatment interruptions|
58386002|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
58386003|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
58386004|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
58386005|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
57913774|NCT03069001|DRUG|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
58265650|NCT03485937|BEHAVIORAL|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
58265651|NCT03485937|BEHAVIORAL|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
58386006|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
58386007|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
57913775|NCT03069001|DRUG|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
57712537|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
57712538|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
57712539|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
57712540|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
57712541|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
57712542|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
57712543|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
58265652|NCT03485937|BEHAVIORAL|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
58386008|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
57712544|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
57913776|NCT06084091|DEVICE|Myocardial spectrometric measurement|Myocardial spectrometric measurement during open-heart Surgery
57913777|NCT00645554|DRUG|Galantamine oral solution|
57913778|NCT02637570|DIETARY_SUPPLEMENT|Hibiscus tea|
57913779|NCT02637570|DIETARY_SUPPLEMENT|green tea|
57913780|NCT02637570|DIETARY_SUPPLEMENT|placebo (dextrose)|
58265653|NCT02091375|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
58265654|NCT02091375|DRUG|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
57712545|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
58386009|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
58386010|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
57913781|NCT05518682|DEVICE|Lenire bimodal stimulation device|The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
58060884|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
58060885|NCT01641029|OTHER|No intervention|There is no intervention
58265655|NCT00690300|DRUG|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
58265656|NCT00690300|DRUG|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
58265657|NCT06309420|DEVICE|Cryogenic treatment of warts (Pixie CO2)|Treatment of common and plantar warts by cryotherapy treatment.
58265658|NCT06309420|DEVICE|Cryogenic treatment of warts (Wortie®)|Treatment of common and plantar warts by cryotherapy treatment.
58386011|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
58265659|NCT02061683|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
58265660|NCT02250066|OTHER|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
58386012|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
57712546|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
57712547|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
58386013|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
58386014|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
58386015|NCT01597648|DRUG|Maraviroc|300 mg
58386016|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
58386017|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
58386018|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
58386019|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
58386020|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
58386021|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
57712548|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
57712549|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
57712550|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
58386022|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
57712551|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
58386023|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
58386024|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
58386025|NCT03741907|PROCEDURE|MLC|Gold standard
58386026|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
58386027|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
58386028|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
58386029|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
58386030|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
57712552|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
57712553|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
57712554|NCT01035879|DRUG|placebo|tablets and capsule once daily
58386031|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
58386032|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
58386033|NCT00000696|DRUG|Interferon alfa-2a|
58386034|NCT00000696|DRUG|Zidovudine|
58386035|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
58386036|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
58386037|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
57712555|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
57712556|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
57712557|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
57712558|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
57712559|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
58265661|NCT03634436|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
58265662|NCT03634436|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
58265663|NCT03795025|OTHER|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
58265664|NCT03795025|OTHER|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
58386038|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
57712560|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
57712561|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
57712562|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
58265665|NCT03795025|OTHER|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
58265666|NCT02679833|DIETARY_SUPPLEMENT|Placebo|Toothpaste not containing the vitamin.
58265667|NCT02679833|DIETARY_SUPPLEMENT|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
58386039|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
57712563|NCT00567775|DRUG|human insulin|
57712564|NCT00567775|DRUG|inhaled human insulin|
58265668|NCT01520142|DRUG|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
58265669|NCT01520142|DRUG|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
57712565|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
57712566|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
58386040|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
58386041|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
58386042|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
58386043|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
57712567|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
57712568|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
57712569|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
58060886|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
58265670|NCT05200117|DEVICE|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
58265671|NCT06624254|OTHER|lung mechanics, respiratory drive and effort|Patient lung mechanics and respiratory drive and effort will be measured
58265672|NCT05412225|DIAGNOSTIC_TEST|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
57712570|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
58265673|NCT05412225|RADIATION|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
58265674|NCT05412225|PROCEDURE|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
58265675|NCT05402124|DRUG|acetylsalicylic acid delayed release tablets, 81mg|acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
58265676|NCT01763723|DEVICE|IPL-home use device|A light based home use device for hair removal
57712571|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
57712572|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
57712573|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
57712574|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
58265677|NCT00369200|DRUG|AFP464|Given IV
58265678|NCT00369200|OTHER|laboratory biomarker analysis|Correlative study
58265679|NCT00369200|OTHER|pharmacological study|Correlative study
58386044|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
58386045|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
58386046|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
57712575|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
57712576|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
57712577|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
57712578|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
58386047|NCT00093262|DRUG|clevidipine|
58386048|NCT00093262|DRUG|placebo|
58386049|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
57712579|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
57712580|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
58265680|NCT06200415|DRUG|Glucosamine Sulfate|Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
58265681|NCT06200415|DRUG|Ginger Oil|Ginger (Zingiber officinale Roscoe) has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities.
58265682|NCT00390442|DEVICE|continuous positive airway pressure|
57712581|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
57712582|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
57712583|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
57712584|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
57712585|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
57712586|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
57712587|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
57712588|NCT00098839|DRUG|L-asparaginase|Given IM
57712589|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
57712590|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
57712591|NCT00098839|DRUG|vincristine sulfate|Given IV
57712592|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
57712593|NCT00098839|DRUG|cytarabine|Given IT
57712594|NCT00098839|DRUG|prednisone|Given orally
57712595|NCT00098839|DRUG|pegaspargase|Given IM
57712596|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
58265683|NCT01451632|DRUG|MM-121|escalating doses MM-121 IV QW
57712597|NCT00098839|DRUG|methotrexate|Given IT
57712598|NCT00098839|DRUG|etoposide|Given IV
57712599|NCT00098839|DRUG|cyclophosphamide|Given IV
58265684|NCT01451632|DRUG|Irinotecan|180 mg/m2 IV Q2W
58265685|NCT01451632|DRUG|Cetuximab|escalating doses cetuximab IV QW
58265686|NCT01577849|DRUG|Vitamin D3|administration of Vitamin D3 24,000 IU
58265687|NCT01577849|DRUG|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
58265688|NCT06372275|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts related to physical activity once a day over four weeks.
58265689|NCT06372275|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the control group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to physical activity.
58386050|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
58386051|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
58386052|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
58386053|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
57712600|NCT00098839|DRUG|leucovorin calcium|Given IV
58265690|NCT03395717|DEVICE|Exoskeleton-Assisted Gait Training|
58265691|NCT03817034|DRUG|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
58265692|NCT04038177|BEHAVIORAL|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
57712601|NCT00098839|BIOLOGICAL|filgrastim|Given SC
57712602|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
57712603|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
58060887|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
58060888|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
58265693|NCT04038177|BEHAVIORAL|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
58265694|NCT05964517|OTHER|Fascial Distortion Model|Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
58265695|NCT01001598|DRUG|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
58265696|NCT02250261|BEHAVIORAL|KÄPY|
58265697|NCT00103922|DRUG|cilomilast|
58265698|NCT04146675|DEVICE|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
58265699|NCT04146675|DEVICE|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
58265700|NCT04713436|DRUG|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
58265701|NCT00134641|DRUG|gemcitabine|
58265702|NCT00134641|DRUG|vinorelbine|
58265703|NCT02556619|BEHAVIORAL|Early Palliative Care/Symptom Control|"1. Establish palliative care goals~   1. Determination of Medical Power of Attorney~  2. Discuss/plan code status/advance directives~  3. Document palliative care goals~2. Symptom Assessment and Control~   1. Pain-treatment with opioid and non-opioid medications~  2. Itching-H2 blockers, steroids~  3. Nutrition-appetite stimulated with Megace, review low sodium diet~  4. Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~  5. Nausea- treated with anti-emetics~  6. Jaundice and Body Image- counselling regarding symptoms~3. End-of-Life Care~   1. Discuss religious preferences~  2. Assess for distress- ensure interaction with Cancer Resource Center~  3. Hospice- charity Hospice options for select patients."
58265704|NCT02952989|DRUG|SGN-2FF|SGN-2FF oral daily dosing.
58265705|NCT02952989|DRUG|pembrolizumab|200 mg every 3 weeks by IV infusion
57712604|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
57712605|NCT02321865|DRUG|NPC-02|
58265706|NCT06158568|OTHER|Percutaneous Electrical Nerve Stimulation|Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
58265707|NCT06158568|OTHER|Placebo Percutaneous Electrical Nerve Stimulation|Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
58265708|NCT06158568|OTHER|Exercise|Application of three weeks of progressive exercises targeting the shoulder musculature
58386054|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
57712606|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
57712607|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
57712608|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
57712609|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
57712610|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
57712611|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
57712612|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
58265709|NCT02255552|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
58386055|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
58386056|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
57712613|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
58386057|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
57712614|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
57712615|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
57712616|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
57712617|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
57712618|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
57712619|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
58060889|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
58060890|NCT02814799|OTHER|bone removal|
58265710|NCT03903003|DEVICE|high flow nasal oxygen device (POİNT)|With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
58386058|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
58386059|NCT01331746|DRUG|Placebo|qds for 7 days
58386060|NCT00394758|PROCEDURE|CO2 laser surgery|
58386061|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
58386062|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
57712620|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
57712621|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
57712622|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
57712623|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
57712624|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
57712625|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
57712626|NCT03916627|DRUG|fianlimab|Administered IV
57712627|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
57712628|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
58265711|NCT03903003|DEVICE|Face mask|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
58265712|NCT00583882|OTHER|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
58265713|NCT01332279|DRUG|everolimus|Given PO
58386063|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
58386064|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
58386065|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
58386066|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
57712629|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
57712630|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
58060891|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
58265714|NCT01332279|DRUG|erlotinib hydrochloride|Given PO
58265715|NCT01332279|PROCEDURE|biopsy|Correlative studies
58386067|NCT06005012|DRUG|Placebo|Placebo
58386068|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
58386069|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
58386070|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
58386071|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
58386072|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
58386073|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
57712631|NCT04537806|DRUG|Placebo|Administered as IV infusion.
57712632|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
57712633|NCT03748940|DRUG|LY3074828|Administered SC
58060892|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
57712634|NCT03748940|DRUG|Placebo|Administered SC
57712635|NCT03748940|DRUG|LY900021|Administered SC
57712636|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
57712637|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
57712638|NCT06277934|DRUG|RGT001-075|Administered orally
57712639|NCT06277934|DRUG|Placebo|Administered orally
57712640|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
57712641|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
57712642|NCT00191893|DRUG|teriparatide|
57712643|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
57712644|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
57712645|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
58060893|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
58060894|NCT05960656|OTHER|Placebo|Inert tablet
58060895|NCT05960656|DRUG|Pioglitazone 30mg|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
58265716|NCT01332279|OTHER|laboratory biomarker analysis|Correlative studies
58265717|NCT01332279|OTHER|immunohistochemistry staining method|Correlative studies
58265718|NCT01332279|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
58265719|NCT01332279|OTHER|pharmacological study|Correlative studies
58265720|NCT01332279|RADIATION|external beam radiation therapy|Undergo EBRT
58265721|NCT01332279|GENETIC|microarray analysis|Correlative studies
58265722|NCT03794102|OTHER|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
58265723|NCT03794102|OTHER|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
58265724|NCT01497886|BEHAVIORAL|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
58386074|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
57712646|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
57712647|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
58265725|NCT01497886|BEHAVIORAL|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
58386075|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
58386076|NCT01673854|DRUG|Ipilimumab|
58386077|NCT01673854|BIOLOGICAL|Vemurafenib|
57712648|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
57712649|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
58265726|NCT05953480|BIOLOGICAL|Redasemtide|Lyophilized white powder reconstituted in 0.9% saline for injection
58265727|NCT05953480|DRUG|Placebo|Lyophilized white powder reconstituted in 0.9% saline for injection
58265728|NCT03260426|DIETARY_SUPPLEMENT|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
58265729|NCT03260426|DIETARY_SUPPLEMENT|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
58265730|NCT03260426|DEVICE|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
58265731|NCT01241617|DEVICE|Duet TRS|Endo GIA stapler with integrated Duet TRS
58265732|NCT01241617|DEVICE|Endo GIA|Endo GIA stapler with Single Use Loading Units
58265733|NCT00945204|OTHER|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
57712650|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
57712651|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
58265734|NCT01783821|DRUG|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
58386078|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
58386079|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
58386080|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
58386081|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
57712652|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
57712653|NCT00588913|BIOLOGICAL|aldesleukin|
57712654|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
57712655|NCT00588913|DRUG|zoledronic acid|
57712656|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
57712657|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
58386082|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
58386083|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58386084|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
58386085|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
58386086|NCT00124969|DRUG|Amlodipine|10mg
58386087|NCT00124969|DRUG|Placebo|10mg
57712658|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
57712659|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
58386088|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
58386089|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
57712660|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
57712661|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
58265735|NCT01783821|DRUG|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
58386090|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
58386091|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
58386092|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
58386093|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
58386094|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
58386095|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
58386096|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
58386097|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
58386098|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
58386099|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
58386100|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
57712662|NCT00002794|DRUG|carboplatin|
57712663|NCT00002794|DRUG|vincristine sulfate|
57712664|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
58060896|NCT05960656|DRUG|Pioglitazone 30mg + Empagliflozin (25 mg)|Combination of two medications used in the management and treatment of type 2 diabetes mellitus in the thiazolidinedione and sodium-glucose co-transporter (SGLT-2) class of medications, respectively.
58265736|NCT01783821|DRUG|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
58265737|NCT02760030|DRUG|Fulvestrant|Given IM
58265738|NCT02760030|OTHER|Laboratory Biomarker Analysis|Correlative studies
58265739|NCT02760030|DRUG|Palbociclib|Given PO
58265740|NCT02760030|OTHER|Questionnaire Administration|Correlative studies
58265741|NCT02760030|DRUG|Aromatase Inhibitors|Given PO
58265742|NCT05520021|DRUG|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
58265743|NCT05520021|DRUG|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
58265744|NCT02918552|DRUG|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
58265745|NCT02918552|DRUG|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
58386101|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
58386102|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
58386103|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
58386104|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
58386105|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
58386106|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
58386107|NCT00301145|BEHAVIORAL|smoking cessation intervention|
57913782|NCT04816331|OTHER|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
58265746|NCT00732979|PROCEDURE|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
57913783|NCT04878354|DRUG|SQ tree SLIT-tablet|Sublingual allergy immunotherapy tablets
58265747|NCT00732979|PROCEDURE|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
58265748|NCT03611231|DRUG|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
57913784|NCT04878354|DRUG|Placebo|Placebo
57913785|NCT05182697|DRUG|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
58265749|NCT03495154|DEVICE|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
58265750|NCT00477607|DRUG|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
58265751|NCT00477607|BEHAVIORAL|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
58265752|NCT00477607|BIOLOGICAL|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
58265753|NCT00477607|DRUG|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
58386108|NCT00301145|DRUG|varenicline|
58386109|NCT00301145|OTHER|counseling intervention|
58386110|NCT00301145|OTHER|internet-based intervention|
58386111|NCT00048945|DRUG|PEGASYS|
58386112|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
57913786|NCT05182697|DRUG|Oral CBD oil|CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
57913787|NCT06081504|OTHER|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
58386113|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
57712665|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
58386114|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
57712666|NCT02880566|PROCEDURE|Scalp block|Full scalp block
57712667|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
57712668|NCT02285985|DRUG|Placebo|Tablets: 5mg
57712669|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
58386115|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
58386116|NCT04037891|DRUG|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
58386117|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
58386118|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
58386119|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
58386120|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
58386121|NCT00977639|PROCEDURE|Pathwork TOO test|
57712670|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
57712671|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
58386122|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
58386123|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
57712672|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
57712673|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
58386124|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
57712674|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
57712675|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
57712676|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
57712677|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
57712678|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
57712679|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
58386125|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
57712680|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
57712681|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
57712682|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
57712683|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
58386126|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
58386127|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
58386128|NCT01582009|DRUG|panobinostat|Given orally
58386129|NCT01582009|DRUG|everolimus|Given orally
58386130|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
57712684|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
57712685|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
57913788|NCT06081504|OTHER|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
58060897|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
58386131|NCT01582009|OTHER|pharmacological study|Correlative studies
58386132|NCT01582009|OTHER|liquid chromatography|Correlative studies
58386133|NCT01582009|OTHER|mass spectrometry|Correlative studies
58386134|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58386135|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
58386136|NCT00014274|DRUG|carboplatin|
58386137|NCT00014274|DRUG|gemcitabine hydrochloride|
58386138|NCT00014274|DRUG|methotrexate|
58386139|NCT00014274|DRUG|vinblastine sulfate|
58386140|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
58386141|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
58386142|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
57712686|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
57712687|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
57712688|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
58265754|NCT03438734|DEVICE|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
58265755|NCT03438734|DEVICE|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
58265756|NCT02039973|BEHAVIORAL|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
58265757|NCT02039973|BEHAVIORAL|Enhanced standard of care|
58265758|NCT03578016|OTHER|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
58386143|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
58386144|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
57712689|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
57712690|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
57712691|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
57712692|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
58265759|NCT03578016|OTHER|Treatment as Usual|TAU consists of clinical assessment and treatment.
58265760|NCT02991417|BIOLOGICAL|CDVAX|
58265761|NCT04991363|PROCEDURE|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
58265762|NCT02170896|DRUG|BIBR 1048 MS Capsule A|
58386145|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
58386146|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
58386147|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
58060898|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
58265763|NCT02170896|DRUG|BIBR 1048 MS Capsule B|
57712693|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
57712694|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
57712695|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
57712696|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
58060899|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
58265764|NCT02170896|DRUG|BIBR 1048 MS Capsule C|
58265765|NCT02170896|DRUG|BIBR 1048 MS Capsule D|
58386148|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
58265766|NCT02170896|DRUG|BIBR 1048 MS tartaric acid solution|
58265767|NCT02170896|DRUG|Pantoprazole|
58265768|NCT04840420|OTHER|social prescribing|as above
58265769|NCT04840420|OTHER|usual care|as above
58265770|NCT03542331|DRUG|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
57712697|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
57712698|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
58265771|NCT03542331|DEVICE|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
58265772|NCT00001656|DRUG|Olanzapine|tablet; 5-20mg/day; 8 weeks
58265773|NCT00001656|DRUG|Clozapine|tablet; 12.5-900mg/day; 8 weeks
58265774|NCT01659346|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
57712699|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
57712700|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
57712701|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
58265775|NCT01659346|DRUG|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
58265776|NCT04620954|DRUG|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
58265777|NCT04620954|DRUG|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
58265778|NCT04620954|DRUG|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
58265779|NCT04824755|PROCEDURE|Yune Zhao|Yune Zhao did congenital cataract surgeries
58265780|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
58386149|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
58386150|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
58265781|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
58265782|NCT05473741|DRUG|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
58386151|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
58386152|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
58386153|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
58386154|NCT03269539|OTHER|MRI Imaging|
58265783|NCT00813670|DRUG|XPF-001|Single oral dose, or 6 days of repeated oral doses.
57913789|NCT06081504|OTHER|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
58265784|NCT05062330|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
58265785|NCT05062330|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
58386155|NCT02001324|OTHER|Web-based data collection|
58386156|NCT02001324|OTHER|Paper-based data collection|
58386157|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
57913790|NCT04229992|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
57913791|NCT04229992|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
57913792|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
58386158|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
58386159|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
58386160|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
58386161|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
58386162|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
58386163|NCT02977364|DRUG|HS-10241|
58386164|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
58386165|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
58386166|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
58386167|NCT04267887|DRUG|Abiraterone Acetate|Given PO
58386168|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
58386169|NCT04267887|DRUG|Apalutamide|Given PO
58386170|NCT04267887|DRUG|Prednisone|Given PO
58386171|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
58386172|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
58386173|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58386174|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
57712702|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
57913793|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
57913794|NCT03083353|DRUG|Isradipine|Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
57913795|NCT03083353|BEHAVIORAL|Cue Exposure|Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
58265786|NCT03308318|PROCEDURE|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
58265787|NCT06648525|DRUG|Adebrelimab|Adebrelimab, IV
57913796|NCT05172427|BEHAVIORAL|14 days of EMI|Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
57913797|NCT05172427|BEHAVIORAL|Uncertainty reappraisal training|CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
57913798|NCT04394208|DRUG|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
57913799|NCT04394208|DRUG|Placebo|Placebo comparator
58060900|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
58265788|NCT06648525|DRUG|Irinotecan liposomes|Irinotecan liposomes, IV
57712703|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
57712704|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
57712705|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
57712706|NCT01135810|BEHAVIORAL|Hypnosis|
57712707|NCT01135810|BEHAVIORAL|Meditation|
57712708|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
57712709|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
58386175|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
58386176|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
57712710|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
57712711|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
57712712|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
57712713|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
57913800|NCT02389608|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
57913801|NCT02389608|DEVICE|Functional electrical stimulation (FES)|
58265789|NCT06648525|DRUG|Lenvatinib|Lenvatinib, po
58265790|NCT06648525|DRUG|5-Fluorouracil (5-FU)|5-Fluorouracil (5-FU), IV
58265791|NCT06648525|DRUG|Calcium Folinate|Calcium folinate, IV
58265792|NCT00026429|BIOLOGICAL|denileukin diftitox|
58265793|NCT05136144|DRUG|SM-020|Topical Akt Inhibitor SM-020 Gel
58265794|NCT04777669|OTHER|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
58386177|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
58386178|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
57712714|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
57712715|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
57712716|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
57712717|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
57712718|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
57913802|NCT02389608|DEVICE|Sham stimulation|
57913803|NCT04463173|DRUG|Anaprazole|single dose, oral administration 30 minutes after breakfast with high fat food.
58265795|NCT00777322|PROCEDURE|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
58265796|NCT05742568|DRUG|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
58265797|NCT05742568|DRUG|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
58265798|NCT05742568|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
58265799|NCT05742568|DRUG|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
58265800|NCT05742568|DRUG|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
58265801|NCT05742568|DRUG|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
58386179|NCT02016495|DRUG|Placebo|
58386180|NCT04308655|OTHER|Interview|Semi-structured interviews
57913804|NCT04463173|DRUG|Anaprazole|single dose, oral administration before breakfast.
58060901|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
58060902|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
58386181|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
58386182|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
57913805|NCT01481220|DRUG|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
57913806|NCT06132126|DRUG|LY3938577|Administered SC.
57712719|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
58265802|NCT01067261|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
57712720|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
57913807|NCT06132126|DRUG|Placebo|Administered SC.
57913808|NCT06132126|DRUG|Insulin degludec|Administered SC.
57913809|NCT04684251|PROCEDURE|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
57913810|NCT04722939|DIAGNOSTIC_TEST|Cerebral oxygenation|Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
57913811|NCT00444899|BEHAVIORAL|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
58265803|NCT01067261|OTHER|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
58265804|NCT02549976|PROCEDURE|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
58265805|NCT02549976|PROCEDURE|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
58265806|NCT02549976|PROCEDURE|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
58265807|NCT02549976|PROCEDURE|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
58265808|NCT00549913|BIOLOGICAL|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
58265809|NCT00549913|PROCEDURE|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
58265810|NCT04761991|DIAGNOSTIC_TEST|CMR and CTCA with CT-FFR|multi-parametric CMR assessment and CT coronary angiography with FFR assessment
58265811|NCT04608344|DRUG|Atorvastatin|Administered as single dose tablet orally.
58265812|NCT04608344|DRUG|Pravastatin|Administered as single dose tablet orally.
57913812|NCT00444899|OTHER|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
57913813|NCT05714748|BIOLOGICAL|EBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
57913814|NCT03486847|PROCEDURE|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
57913815|NCT03486847|PROCEDURE|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
58265813|NCT04608344|DRUG|Rosuvastatin|Administered as single dose tablet orally.
58265814|NCT04608344|DRUG|Filgotinib|Administered as tablet orally once daily for 11 days.
58265815|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
57913816|NCT01452659|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
57913817|NCT01452659|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
57913818|NCT01452659|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
57913819|NCT01452659|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
57913820|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
58265816|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
58265817|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
58265818|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of placebo in each eye.
58265819|NCT04476121|PROCEDURE|PRF application|PRF application into post-operative wound.
58265820|NCT04476121|DRUG|Nipas application|Nipas application into post-operative wound.
58265821|NCT00136435|DRUG|prednisone|Induction Phase: Given orally on days 1-28
58265822|NCT00136435|DRUG|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
57712721|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
57712722|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
57712723|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
57712724|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
57712725|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
57712726|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
57712727|NCT03031288|DEVICE|A|standard bottle
57712728|NCT03031288|DEVICE|B|vented base bottle
57712729|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
57712730|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
57712731|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
57712732|NCT04380207|DRUG|QPX7728|antibiotic
57913821|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
57913822|NCT05187468|DEVICE|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
57913823|NCT05234229|OTHER|Survey|Collection of immunization status by questionnaire
57913824|NCT05342909|OTHER|5x a week BFR training group|This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
58386183|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
58386184|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
57712733|NCT04380207|DRUG|Placebo|Placebo comparator
57712734|NCT04380207|DRUG|QPX2014|antibiotic
57712735|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
57712736|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
57712737|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
57712738|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
57712739|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
57712740|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
57712741|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
57712742|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
57913825|NCT05342909|OTHER|2x a week BFR training group|This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
57913826|NCT05505110|PROCEDURE|Vaginal Seeding|Following delivery by C-section, participating infants randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
57913827|NCT05505110|PROCEDURE|Sterile Swab|Following delivery by C-section, participating infants randomized to the control group will have their nasal cavity swabbed with a sterile swab.
57913828|NCT00289432|BEHAVIORAL|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
57913829|NCT00289432|OTHER|Support group|Standard Hospital follow-up support group
57913830|NCT05077644|DEVICE|Stella (TM) Mobile Application|Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
57913831|NCT02181387|DRUG|Acetaminophen|administered every 6 hours by mouth up to 4 doses
57913832|NCT02181387|DRUG|Placebo|
58386185|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
58265823|NCT00136435|DRUG|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
58386186|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
58386187|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
58386188|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
58386189|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
58386190|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
58386191|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
58386192|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
58386193|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
57913833|NCT00383136|DRUG|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
58386194|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
58386195|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
58386196|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
58386197|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
57913834|NCT00383136|DRUG|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
58386198|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
58386199|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
57913835|NCT03656237|OTHER|Usual Training|Training in a classroom setting of health care providers
58265824|NCT00136435|DRUG|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
58265825|NCT00136435|DRUG|asparaginase|Induction: Given into the muscle on day 5
58265826|NCT00136435|DRUG|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
58386200|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
58386201|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
58386202|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
58386203|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
58386204|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
58386205|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
58386206|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
58386207|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
57913836|NCT03656237|OTHER|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
58265827|NCT00136435|RADIATION|cranial radiation|Given in 10 daily treatments during CNS therapy phase
58265828|NCT00136435|DRUG|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
58265829|NCT00136435|DRUG|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
58386208|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
58386209|NCT04373148|OTHER|There is no intervention|There is no intervention
58386210|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
57913837|NCT00265421|PROCEDURE|Suture technique for perineal repair after delivery|
58265830|NCT00136435|DRUG|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
58265831|NCT00136435|DRUG|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
58386211|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
57712743|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
57712744|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
57712745|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
57712746|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
57712747|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
57712748|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
57712749|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
57712750|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
57913838|NCT02464150|DIETARY_SUPPLEMENT|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
58265832|NCT00136435|DRUG|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
58265833|NCT02790359|OTHER|Air|Group of patients who would receive air insufflation
58265834|NCT02790359|OTHER|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
58386212|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
58386213|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
58386214|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
58386215|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
58386216|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
58386217|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
57712751|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
57712752|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
57712753|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
57712754|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
57712755|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
57712756|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
57712757|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
57913839|NCT00050037|PROCEDURE|CBT|
57913840|NCT03944473|DRUG|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
58386218|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
58386219|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
58386220|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
58386221|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
58386222|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
57712758|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
57913841|NCT03944473|DRUG|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
57913842|NCT04684602|BIOLOGICAL|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
57712759|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
57712760|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
57913843|NCT04643522|OTHER|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
57913844|NCT00006260|DRUG|cisplatin|cisplatin IV over 30 minutes on days 1-3.
57913845|NCT00006260|DRUG|etoposide|etoposide IV over 60-90 minutes on days 1-3.
57913846|NCT00006260|DRUG|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
57913847|NCT00006260|DRUG|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
57913848|NCT00509808|DEVICE|Electrostimulation|"1. 1st month GN wearing (activated or sham mode)~2. 2nd month wearing (opposite mode)~3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
57913849|NCT01201733|OTHER|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
58265835|NCT06623370|DRUG|methylprednisolone|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
58265836|NCT06623370|OTHER|Saline (NaCl 0,9 %) (placebo)|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
58265837|NCT01732471|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
58386223|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
58386224|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
58386225|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
57712761|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
57712762|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
57712763|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
57712764|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
57712765|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
57712766|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
57913850|NCT01201733|OTHER|Ultrasound therapy and hot pack|
57913851|NCT05333679|DEVICE|UTRA|Collect urine on intervention participants and screen for presence of TFV.
57913852|NCT05333679|BEHAVIORAL|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
57913853|NCT02572882|DIETARY_SUPPLEMENT|p-inulin|12 week self-administered treatment phase
58386226|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
58386227|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
57913854|NCT05182281|DEVICE|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
58386228|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
57712767|NCT00128180|DRUG|Placebo|Placebo
57913855|NCT05182281|DEVICE|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
57913856|NCT05182281|OTHER|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
57913857|NCT02534454|BEHAVIORAL|Active Retraining|
58265838|NCT01404208|DRUG|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
58265839|NCT01404208|DRUG|Placebo|Sugar pill
58265840|NCT05186038|DIAGNOSTIC_TEST|iVYCHECK GIP Urine|To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).
58265841|NCT05186038|DIAGNOSTIC_TEST|CeliacDetect|To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
58265842|NCT04117074|DRUG|Liposomal bupivacaine|Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
58265843|NCT04117074|OTHER|Thoracic epidural analgesia (bupivacaine)|Perioperative bupivacaine based thoracic epidural placed preoperatively.
58265844|NCT01537068|DRUG|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
58265845|NCT01537068|DRUG|Placebo|Matching placebo pills
58265846|NCT02691728|DRUG|LDV/SOF FDC|
58386229|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
58386230|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
58386231|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
58386232|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
57712768|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
57712769|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
57913858|NCT02534454|BEHAVIORAL|Sham Retraining|
57913859|NCT02534454|DEVICE|Active transcranial direct current stimulation (TDCS)|
57913860|NCT02534454|DEVICE|Sham transcranial direct current stimulation (TDCS)|
57913861|NCT02534454|DRUG|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
57913862|NCT05536752|DRUG|QA102/Placebo|Capsules
57913863|NCT05536752|DRUG|QA102|Capsules
57913864|NCT05536752|DRUG|Placebo|Capsules
57913865|NCT03197779|DRUG|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
57913866|NCT03197779|DRUG|Aspirin|Oral administration
57913867|NCT03197779|OTHER|Placebo|Oral administration
57913868|NCT05026333|OTHER|Cognitive Stress Testing|Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
57913869|NCT02277002|DEVICE|Cabin Air Filtration|
57913870|NCT02277002|OTHER|Placebo|No Cabin Air Filtration
58265847|NCT03026530|PROCEDURE|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
58265848|NCT03026530|PROCEDURE|Laparoscopic bariatric surgery|
58265849|NCT03026530|DEVICE|Ventilator|
58265850|NCT05432323|BEHAVIORAL|Multi-family therapy|8 sessions of Multi-family therapy of 3 hours each during 24 weeks
58265851|NCT02152553|DRUG|Hydrocortisone|
58265852|NCT02152553|DRUG|Placebo|
57712770|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
57712771|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
58265853|NCT06437275|OTHER|Questionnaire for the degree of knowledge and attitude|Questionnaire for the degree of knowledge and attitude of Egyptian physicians regarding emergency treatment of traumatic dental injuries.
58265854|NCT00956631|PROCEDURE|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
58386233|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
58386234|NCT00821158|OTHER|Placebo|Placebo tablet and iv
58386235|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
58386236|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
58386237|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
58386238|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
57712772|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
57712773|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
58060903|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
58265855|NCT00162994|PROCEDURE|adenoidectomy and tymapanostomy|
57712774|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
57712775|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
58265856|NCT05418972|DRUG|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
58265857|NCT00174226|DRUG|Atomoxetine|
58265858|NCT00174226|DRUG|Buspirone|
58265859|NCT04003545|RADIATION|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
58386239|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
58386240|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
58386241|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
58386242|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
57712776|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
57712777|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
57712778|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
57712779|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
57913871|NCT04267302|OTHER|Baby Bouncer|Fischer Price baby bouncer.
58060904|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
58060905|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
58265860|NCT04003545|OTHER|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
58265861|NCT05221268|OTHER|Level walking exercise|treadmill exercise with 0 inclination
58265862|NCT05221268|OTHER|Downhill exercise|treadmill exercise with -20 inclination
58265863|NCT02574702|PROCEDURE|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
58265864|NCT06465134|OTHER|No intervention|There is no intervention
58265865|NCT05528198|DRUG|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
58265866|NCT05528198|DRUG|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
58265867|NCT05528198|DRUG|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
58265868|NCT01472965|DRUG|ethanol|70% ethanol catheter lock therapy
58265869|NCT01472965|DRUG|heparin-saline placebo|heparin-saline placebo catheter lock therapy
58386243|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
57712780|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
57712781|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
57913872|NCT04267302|OTHER|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
57913873|NCT04267302|OTHER|Baby Carrier|Ergobaby Baby carrier.
58060906|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
58060907|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
58060908|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
58265870|NCT04829331|DEVICE|Restrata|Restrata is a sterile, single use device intended for use in local management of wounds
58386244|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
58386245|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
57712782|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
57913874|NCT02761161|DRUG|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
57913875|NCT02761161|BEHAVIORAL|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
57913876|NCT02315352|DRUG|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
57913877|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
57913878|NCT02315352|DRUG|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
57913879|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
58386246|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
57712783|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
57712784|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
57712785|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
57712786|NCT01611571|DRUG|Risedronate|weekly risedronate
58060909|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
57712787|NCT01611571|DRUG|Teriparatide|daily teriparatide
57712788|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
58060910|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
58060911|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
57712789|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
57712790|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
57712791|NCT00273403|BEHAVIORAL|Access to Care Services|
57712792|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
57712793|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
57712794|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
57712795|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
58060912|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
57712796|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
57712797|NCT00359450|DRUG|BMS-275183 (oral taxane)|
57712798|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
58265871|NCT01058486|BEHAVIORAL|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
58265872|NCT05040620|DRUG|Olive Oil Topical Oil|the effect of olive oil local application in decreasing orthodontic alighment phase
57913880|NCT02315352|DRUG|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
57913881|NCT03541174|DRUG|Aprocitentan 12.5 mg|Tablet, oral use
58265873|NCT00389051|DRUG|bendamustine hydrochloride|1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)
57712799|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
57712800|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
57913882|NCT03541174|DRUG|Aprocitentan 25 mg|Tablet, oral use
57913883|NCT03541174|DRUG|Placebo|Matching placebo tablet
58265874|NCT01374932|DEVICE|CPAP|Continuous positive airways pressure (CPAP)
58265875|NCT03367559|BIOLOGICAL|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
58265876|NCT04566133|DRUG|Trametinib|orally 2 mg once a day
58265877|NCT04566133|DRUG|Hydroxychloroquine|orally 600 mg twice a day-1,200 mg total dose
58265878|NCT00553852|DRUG|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
58265879|NCT04111718|BIOLOGICAL|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
58265880|NCT04111718|BEHAVIORAL|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
58265881|NCT02103335|DRUG|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
57712801|NCT00006279|DRUG|Nevirapine|
57712802|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
57712803|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
57712804|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
58265882|NCT02103335|DRUG|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
58265883|NCT02103335|DRUG|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
58265884|NCT00038623|DRUG|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
57712805|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
57913884|NCT00056485|BEHAVIORAL|Pleasant Events-Based Behavioral Intervention|
57913885|NCT00585416|DRUG|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
57913886|NCT02560714|DEVICE|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
57913887|NCT05801744|BEHAVIORAL|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
57913888|NCT04283331|DRUG|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
57913889|NCT01530451|DRUG|Desmopressin|120mg OD
57913890|NCT01530451|DRUG|Placebo|one tab OD
57913891|NCT00549783|BIOLOGICAL|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
57913892|NCT00549783|BIOLOGICAL|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
57913893|NCT02690922|DRUG|Dasatinib|100mg (d1-d84)
57913894|NCT02690922|DRUG|prednisone|60mg/m2 d1-24
58265885|NCT00038623|DRUG|Rituximab|250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
58265886|NCT03298256|RADIATION|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
58265887|NCT02741791|DRUG|AXS-05|AXS-05 taken daily for 6 weeks.
58265888|NCT02741791|DRUG|Bupropion|Buproprion taken daily for 6 weeks.
58265889|NCT01789671|BEHAVIORAL|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
58265890|NCT00411073|DRUG|Darapladib|
58265891|NCT06621082|DRUG|Selumetinib|After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
57712806|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
57712807|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
57712808|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
57913895|NCT02690922|DRUG|dexamethasone|10mg/d 3-7days
57913896|NCT02690922|DRUG|methotrexate|3g/m2 1day
57913897|NCT02721173|DRUG|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
57913898|NCT02721173|DRUG|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
57913899|NCT00003232|DRUG|clodronate disodium|
57913900|NCT00003232|DRUG|mitoxantrone hydrochloride|
57913901|NCT00003232|DRUG|prednisone|
57913902|NCT00003232|PROCEDURE|quality-of-life assessment|
57913903|NCT01321151|DRUG|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
57712809|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
57712810|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
57712811|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
57913904|NCT01321151|DRUG|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
57913905|NCT04002193|OTHER|volume expansion|To assess fluid responsiveness
58265892|NCT05057897|BIOLOGICAL|AZD1222|10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
58265893|NCT00155766|BIOLOGICAL|HPV16 E7 peptide-pulsed autologous DCs|
58265894|NCT00203944|BEHAVIORAL|Behavioral, Development|
58060913|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
58386247|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
58386248|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
58060914|NCT02570581|OTHER|Jelly with Furosemide|
58060915|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
58386249|NCT01088295|DRUG|Telmisartan|
58386250|NCT00255723|DRUG|carboplatin|Given IV
58386251|NCT00255723|DRUG|etoposide|Given IV
58386252|NCT00255723|DRUG|ifosfamide|Given IV
58386253|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
58386254|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
58386255|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
58386256|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
57712812|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
57712813|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
57913906|NCT05839496|OTHER|Cervical stabilization exercises|Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
58060916|NCT02570581|OTHER|Jelly with Memantine|
58060917|NCT02570581|OTHER|Jelly with Zopiclone|
57913907|NCT00003424|DRUG|tamoxifen citrate|
58060918|NCT02570581|OTHER|Jelly with Alprazolam|
58060919|NCT02570581|OTHER|Jelly with Oxazepam|
58060920|NCT02570581|OTHER|Jelly with Donepezil|
58060921|NCT02570581|OTHER|Jelly with Clopidogrel|
58386257|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
58386258|NCT00003322|DRUG|cisplatin|
58386259|NCT00003322|DRUG|paclitaxel|
58386260|NCT00003322|PROCEDURE|quality-of-life assessment|
57913908|NCT03566654|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
58060922|NCT02570581|OTHER|Jelly with Ramipril|
57913909|NCT03566654|DEVICE|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
57712814|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
58060923|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
57712815|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
57712816|NCT06161792|DRUG|0.8 mg RCN3028|Oral
57712817|NCT06161792|DRUG|Placebo|Oral
57712818|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
57712819|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
58060924|NCT02570581|OTHER|Plain jelly control|
58060925|NCT02570581|OTHER|Apple compote Paracetamol|
58060926|NCT02570581|OTHER|Apple compote Furosemide|
58060927|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
58060928|NCT02570581|OTHER|Apple compote Memantine|
58060929|NCT02570581|OTHER|Apple compote Zopiclone|
58265895|NCT06617351|DIETARY_SUPPLEMENT|Melatonin|Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.
58265896|NCT06617351|DIETARY_SUPPLEMENT|Placebo|Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
58265897|NCT01528657|OTHER|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
58265898|NCT01528657|OTHER|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
58265899|NCT03944369|OTHER|KB109|KB109 is a novel glycan
58265900|NCT03944369|OTHER|No intervention|No intervention
58265901|NCT03936335|DRUG|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
58265902|NCT06649500|OTHER|Treadmill|The Walker View system is a treadmill equipped with a loaded cell sensor belt and a 3D camera that allows you to detect every single angular movement of the subject. Furthermore, thanks to the two optics, a classic one for 2D shooting in high resolution, and a revolutionary one for infrared rays, it is possible to reconstruct the position of the subject in space in three-dimensional mode and in real time. The reflected image reconstructed by the system helps to improve movement through the \&#34;continuous feedback system\&#34; method.
58265903|NCT06649500|OTHER|conventional therapy|Conventional therapy intervention will follow the usual treatment according to current clinical practice. This treatment will be delivered to patients in a group session in order the balance disorders.
57712820|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
57712821|NCT04983394|OTHER|Aerobic exercises|cycling activity
57712822|NCT04983394|OTHER|conventional exercises|stretching, strengthening and endurance exercises
57712823|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
57712824|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
58060930|NCT02570581|OTHER|Apple compote Alprazolam|
58060931|NCT02570581|OTHER|Apple compote Oxazepam|
58060932|NCT02570581|OTHER|Apple compote Donepezil|
58060933|NCT02570581|OTHER|Apple compote Clopidogrel|
58060934|NCT02570581|OTHER|Apple compote Ramipril|
58060935|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
58060936|NCT02570581|OTHER|Plain apple compote control|
58060937|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
58060938|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
58060939|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
58060940|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
58060941|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
58060942|NCT00062842|DRUG|Irinotecan|
58060943|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
58265904|NCT05269212|OTHER|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
58265905|NCT05269212|OTHER|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
58265906|NCT00063479|DRUG|Zoledronic Acid|
58265907|NCT05236231|DRUG|Macitentan 10 mg|Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
58265908|NCT05236231|DRUG|Tadalafil 20 mg|Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
58386261|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
57712825|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
58265909|NCT05236231|DRUG|Macitentan 10 mg/Tadalafil 20mg FDC|FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
57712826|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
57712827|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
58060944|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
58060945|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
58386262|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
58386263|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
57712828|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
58060946|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
58060947|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
58060948|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
58060949|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
58060950|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
58060951|NCT02993289|OTHER|Different well-known treatments|
58060952|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
58060953|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
58060954|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
58060955|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
58060956|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
58060957|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
58060958|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
58265910|NCT03301740|OTHER|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
58265911|NCT03301740|OTHER|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
58386264|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
58386265|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
58386266|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
58386267|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
58386268|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
58386269|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
58386270|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
58386271|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
57913910|NCT03566654|DEVICE|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
58265912|NCT04298450|BEHAVIORAL|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
58060959|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
58265913|NCT04298450|BEHAVIORAL|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
58265914|NCT01707251|DRUG|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
58265915|NCT01707251|DRUG|Saline|Placebo control
58265916|NCT03540303|DRUG|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
58265917|NCT05738876|PROCEDURE|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
58265918|NCT03149120|BIOLOGICAL|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
58265919|NCT03149120|DRUG|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
58265920|NCT05455190|BEHAVIORAL|Fit Together|Fit Together intervention follows a clinic and community partnership model for childhood obesity treatment. Children with obesity will receive standard of care obesity treatment from their usual provider and will also receive a referral to an activity program run out of the local community center. Each session delivers a combination of high-intensity individual exercises, sports and games, and unstructured playtime to help children reach the US Physical Activity guidelines of 60min moderate-to-vigorous physical activity daily. There will also be a nutrition activity session offered regularly.
58265921|NCT05455190|BEHAVIORAL|Educational materials|Participants will receive a child-friendly cooking magazine mailed quarterly and a local Parks and Recreation program guide.
58265922|NCT00122122|BEHAVIORAL|Enhanced Pharmacy Care|
58060960|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
58265923|NCT01185509|DRUG|trastuzumab|
58386272|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
57712829|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
58265924|NCT01185509|DRUG|vinorelbine|
58265925|NCT04944810|PROCEDURE|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
58265926|NCT04944810|PROCEDURE|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
58386273|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
58386274|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
58386275|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
58386276|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
58386277|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
58386278|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
57712830|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
57712831|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
57913911|NCT06109025|COMBINATION_PRODUCT|FESIA GRASP|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
57712832|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
58265927|NCT04944810|PROCEDURE|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
57913912|NCT06109025|COMBINATION_PRODUCT|VIRTUAL REHAB|VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.
57913913|NCT06109025|COMBINATION_PRODUCT|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
58386279|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
58386280|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
58386281|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
58386282|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
58386283|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
58386284|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
58386285|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
57712833|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
58386286|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
58386287|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
58386288|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
58386289|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
58386290|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
58386291|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
58386292|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
57712834|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
57712835|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
57712836|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
57913914|NCT00126373|DRUG|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
57913915|NCT02679573|DRUG|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
57913916|NCT02679573|DRUG|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
57913917|NCT02679573|DRUG|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
57913918|NCT03575988|OTHER|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
57913919|NCT01195051|OTHER|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
58386293|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
58386294|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
58386295|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
58386296|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
58386297|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
58386298|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
58386299|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
58386300|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
58265928|NCT04944810|PROCEDURE|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
58265929|NCT04944810|PROCEDURE|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
58265930|NCT06273475|OTHER|Robot-assisted Training|Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.
58386301|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
58386302|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
58386303|NCT05340478|BEHAVIORAL|Intensive Transdiagnostic Cognitive Behavioral Therapy|cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
58386304|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
58386305|NCT02213497|DRUG|Carboplatin|
58386306|NCT02213497|DRUG|Paclitaxel|
58386307|NCT03017339|OTHER|Functional Exercise|
58386308|NCT03017339|RADIATION|Low Level Laser Therapy|
58386309|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
58386310|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
58386311|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
58386312|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
57913920|NCT00321373|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
58060961|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
58265931|NCT06273475|OTHER|Standard Training|Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
58265932|NCT03426436|DIAGNOSTIC_TEST|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
58265933|NCT03547362|DIETARY_SUPPLEMENT|Casein|See arm description
58265934|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 1|See arm description
58265935|NCT03547362|DIETARY_SUPPLEMENT|Whey protein|See arm description
58060962|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
58265936|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 2|See arm description
58060963|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
58265937|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 3|See arm description
58265938|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 4|See arm description
57712837|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
57913921|NCT00321373|BIOLOGICAL|FluarixTM|Single dose, Intramuscular injection
58060964|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
58265939|NCT03595813|PROCEDURE|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
58265940|NCT03595813|PROCEDURE|Biopsy collection|Optional biopsy collection at baseline and progression
58386313|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
58386314|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
58386315|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
58386316|NCT01844297|DRUG|TDF+3TC+EFV|
58386317|NCT00100958|DRUG|indole-3-carbinol|
58265941|NCT03141775|OTHER|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
58265942|NCT05750732|BEHAVIORAL|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
58265943|NCT02579343|DEVICE|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
58265944|NCT02579343|DRUG|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
58265945|NCT01841567|DEVICE|Mepilex border post. op|
58265946|NCT01841567|DEVICE|Mepilex border post op|
58386318|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
57712838|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
57712839|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
57712840|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
57712841|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
57712842|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
57712843|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
57712844|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
57712845|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
57712846|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
57712847|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
58060965|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
58265947|NCT01914575|DEVICE|Mapping with the Acutus Medical System followed by Ablation|
58265948|NCT02429310|DEVICE|Revitive IX|This is a neuromuscular electrical stimulation device
58265949|NCT01908933|DEVICE|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
58265950|NCT04794413|DRUG|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
58265951|NCT00900640|PROCEDURE|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
58386319|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
57712848|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
57712849|NCT00619697|DRUG|biphasic insulin aspart|
57712850|NCT00619697|DRUG|insulin glargine|
57712851|NCT00619697|DRUG|metformin|
57712852|NCT00619697|DRUG|glimepiride|
58265952|NCT05609942|DRUG|BLU-263|BLU-263 Oral Tablets
58060966|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
58060967|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
58060968|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
58265953|NCT05609942|DRUG|Azacitidine|Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
58265954|NCT00157820|DEVICE|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
58386320|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
58386321|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
58386322|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
57712853|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
57712854|NCT01929668|DRUG|polyethylene glycol|
57712855|NCT01929668|DRUG|Ascorbic Acid|
57712856|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
58265955|NCT00157820|DEVICE|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF \& GemIII AT as DC ICDs (DC true and SC sim arms)
58265956|NCT04972370|OTHER|Patients with Unilateral Cleft Lip with or without Cleft Palate|2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
58265957|NCT02744482|DRUG|risedronate|risedrante tablet (75 mg)
58386323|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
58386324|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
58386325|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
58386326|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
57712857|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
57712858|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
57712859|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
57712860|NCT02054364|BEHAVIORAL|FBT and CRT|
57712861|NCT02054364|BEHAVIORAL|FBT and art therapy|
57712862|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
58060969|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
58265958|NCT02744482|DRUG|placebo|risedrante placebo tablet (75 mg)
58265959|NCT02789956|DEVICE|Internal vs. external cad cam co/cr framework|
58265960|NCT00373009|BEHAVIORAL|Traditional Army training|As usual training for Soldiers
58265961|NCT00373009|BEHAVIORAL|Core stabilization exercise only|Core stabilization exercise
58265962|NCT00373009|BEHAVIORAL|Psychosocial education class only|Psychosocial education class
58265963|NCT00373009|BEHAVIORAL|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
58386327|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
58265964|NCT00416689|PROCEDURE|assessment of therapy complications|
58265965|NCT00416689|PROCEDURE|quality-of-life assessment|
58265966|NCT04234295|PROCEDURE|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
58265967|NCT02762552|DEVICE|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
58265968|NCT03780803|OTHER|home cardiac rehabilitation and respiratory rehabilitation|
58265969|NCT01491750|BEHAVIORAL|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
58265970|NCT01491750|BEHAVIORAL|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
58265971|NCT06128291|PROCEDURE|posterior colporrhaphy|posterior colporrhaphy for rectocele.
58265972|NCT02634372|BEHAVIORAL|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
58265973|NCT02634372|BEHAVIORAL|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
58265974|NCT01236781|DEVICE|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
58265975|NCT01236781|DEVICE|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
57712863|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
58265976|NCT00093418|DRUG|tipifarnib|Given orally
58265977|NCT03332628|DEVICE|Microneedle patch|Each patch contains 50 microneedles.
58265978|NCT00481260|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
58265979|NCT00264160|DRUG|AMN107|
58265980|NCT05940129|BEHAVIORAL|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
58265981|NCT05869279|BIOLOGICAL|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
58265982|NCT00923663|DRUG|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
58265983|NCT04642677|OTHER|healthcare provider's recommended communication with sympathy and printed paper|"Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation."
58265984|NCT00715728|DEVICE|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
58386328|NCT03367403|DRUG|Donanemab|Administered IV
58386329|NCT03367403|DRUG|Placebo|Administered IV
58386330|NCT03367403|DRUG|LY3202626|Administered orally
58386331|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
58386332|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
57712864|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
57712865|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
58265985|NCT00715728|DEVICE|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
58386333|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
58386334|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
58386335|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
58386336|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
58265986|NCT06205173|OTHER|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
58060970|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
58265987|NCT06205173|OTHER|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
58265988|NCT05680831|BIOLOGICAL|0.070 ppm ozone concentration|The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
58265989|NCT05680831|BIOLOGICAL|Clean air (0.0 ppm ozone)|Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
58265990|NCT00714753|RADIATION|brachytherapy|
58265991|NCT00714753|RADIATION|hypofractionated radiation therapy|
58265992|NCT00714753|RADIATION|image-guided radiation therapy|
58265993|NCT00714753|RADIATION|intensity-modulated radiation therapy|
58265994|NCT05213013|OTHER|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
58265995|NCT05228925|OTHER|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
58265996|NCT00857597|PROCEDURE|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
58265997|NCT00857597|DRUG|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
58265998|NCT04323865|DIAGNOSTIC_TEST|fetal heart rate variability|No direct intervention, as the study is observational.
58265999|NCT05062824|BEHAVIORAL|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. \[Parental FFQ portal\]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age \[Clinician Portal\]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component \[Parent's Portal\].
58266000|NCT02237209|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
58266001|NCT02237209|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
58386337|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
58386338|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
58386339|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
58386340|NCT05388227|OTHER|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
58386341|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
58386342|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
57712866|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
58266002|NCT06620211|PROCEDURE|promontofixation, prolapse cure|Patient who underwent surgery to place the Sacromesh® medical device (promontofixation) for a prolapse cure, between 2009 and 2018
58266003|NCT02013856|DIETARY_SUPPLEMENT|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
58266004|NCT02013856|DIETARY_SUPPLEMENT|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
58266005|NCT02013856|DIETARY_SUPPLEMENT|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
58266006|NCT02013856|DIETARY_SUPPLEMENT|Placebo|Placebo control once daily for 28 days
58266007|NCT00259974|DRUG|Rituximab|Rituximab
58266008|NCT05405894|DRUG|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
58266009|NCT01228110|DRUG|Hydrocortison|
58266010|NCT01228110|DRUG|Saline Solution|
58266011|NCT03984227|GENETIC|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
58266012|NCT05542797|DRUG|Duphastone|dydrogesterone hormone
58266013|NCT03399903|DRUG|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
58266014|NCT02784522|DEVICE|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
58266015|NCT02784522|DEVICE|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
58266016|NCT01338961|PROCEDURE|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
58266017|NCT00383175|OTHER|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
58386343|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
57712867|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
57712868|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
57913922|NCT05811923|OTHER|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
58060971|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
58266018|NCT06237413|DRUG|ZG2001 Tosilate Tablets|ZG2001 will be administered orally once or twice daily in a continuous regimen
58266019|NCT05992259|DEVICE|TENS|TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
58266020|NCT05737017|DEVICE|ClearCoajet|The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.
58266021|NCT03462459|DRUG|Vancomycin|Vancomycin capsule, 125 mg
58266022|NCT03462459|DRUG|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
58386344|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
58386345|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
58386346|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
58060972|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
58060973|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
58266023|NCT03102697|DEVICE|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
58266024|NCT00860249|BEHAVIORAL|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
58266025|NCT00860249|BEHAVIORAL|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
58266026|NCT04777448|PROCEDURE|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
58266027|NCT03112668|BEHAVIORAL|Cognitive Behavior Therapy|Undergo ACT
57913923|NCT05811923|OTHER|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
57913924|NCT05811923|OTHER|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
57913925|NCT05811923|OTHER|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
57913926|NCT00142077|DEVICE|Electronic health record and messaging system|
57913927|NCT02323282|DRUG|ropivacaine|
57913928|NCT04061447|DRUG|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
57913929|NCT04061447|DRUG|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
57913930|NCT01762501|DRUG|Azilsartan|Azilsartan 20mg/day
57913931|NCT01762501|DRUG|Amlodipine|Amlodipine 5mg/day
57913932|NCT00038168|DRUG|Estramustine|Intravenous dose
58060974|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
58060975|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
58060976|NCT04778644|DRUG|CBD|Oral gel capsule CBD
58060977|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
58060978|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
58266028|NCT03112668|OTHER|Quality-of-Life Assessment|Ancillary studies
58266029|NCT03112668|OTHER|Questionnaire Administration|Ancillary studies
57913933|NCT00038168|DRUG|Taxol|Intravenous dose
58266030|NCT03112668|OTHER|Survey Administration|Ancillary studies
57913934|NCT01795027|DRUG|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
57913935|NCT01795027|DRUG|S-1 single|16 courses S-1 single after d D2 resection
57913936|NCT02729831|BEHAVIORAL|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
58266031|NCT01297166|DRUG|LEO 27989 ointment|once daily application, 3weeks
58266032|NCT01297166|DRUG|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
58266033|NCT01297166|DRUG|Calcipotriol ointment|once daily application, 3weeks
58266034|NCT01297166|DRUG|Vehicle ointment|once daily application, 3weeks
58266035|NCT06077552|OTHER|pyramidal training by treadmill|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
58266036|NCT01194934|DRUG|NOX-A12|4 mg/kg daily IV for 5 days
57712869|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
57712870|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
57712871|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
58266037|NCT01194934|DRUG|NOX-A12|2 mg/kg daily IV for 5 days
58266038|NCT01194934|DRUG|Filgrastim|5 µg/kg SC daily for 5 days
58266039|NCT01194934|DRUG|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
57712872|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57712873|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
57913937|NCT02729831|BEHAVIORAL|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
57913938|NCT02729831|BEHAVIORAL|Provider Report|A short report that includes the patients' goals and treatment preferences
57913939|NCT01513577|OTHER|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
57913940|NCT01513577|OTHER|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
57913941|NCT04729998|DRUG|Rivaroxaban film-coated tablet 20 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
58266040|NCT06623279|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
58266041|NCT06621953|DEVICE|BFR|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to either 80% or 40% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum in Week 1, 25% in Week 2 and 30% in Week 3.
58266042|NCT06621953|OTHER|control group|Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
58266043|NCT05569928|OTHER|Administration of deuterated compounds for kinetic study|Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
58266044|NCT04376333|BEHAVIORAL|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
58266045|NCT04376333|BEHAVIORAL|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
57913942|NCT04729998|DRUG|Xarelto® film-coated tablet 20 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
57913943|NCT04706767|DRUG|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
57913944|NCT04706767|DRUG|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
57913945|NCT04706767|DRUG|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
57913946|NCT04706767|DRUG|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
58060979|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
58060980|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
58266046|NCT04376333|OTHER|Standard Conservative Care|Standard conservative dental care for orofacial pain
58266047|NCT03333902|PROCEDURE|QLB|QLB, quadratus lumborum block.
58266048|NCT03333902|PROCEDURE|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
58266049|NCT06055244|DRUG|Amantadine|Subjects will be give amantadine 100 mg twice daily.
58266050|NCT02119832|DEVICE|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
58386347|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
58266051|NCT01334580|BEHAVIORAL|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
58266052|NCT01334580|BEHAVIORAL|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
58266053|NCT00175032|DRUG|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
58266054|NCT00175032|DRUG|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
58266055|NCT01292343|OTHER|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
58266056|NCT01292343|OTHER|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
58266057|NCT04351906|DEVICE|ECCO2R|ECCO2R integrated into the multiFiltrate device
58266058|NCT03179293|DRUG|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
58266059|NCT03179293|DRUG|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
58266060|NCT03410082|DEVICE|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
58266061|NCT03410082|DIAGNOSTIC_TEST|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
58266062|NCT01979471|OTHER|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
58266063|NCT01041976|BEHAVIORAL|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
58060981|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
58060982|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
58266064|NCT01041976|BEHAVIORAL|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
58266065|NCT01319851|DRUG|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
58266066|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
58266067|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
58266068|NCT01489124|DRUG|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
58266069|NCT05625191|DIAGNOSTIC_TEST|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
58266070|NCT05625191|DIAGNOSTIC_TEST|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
58266071|NCT04519788|DRUG|AT-301B|Nasal Spray
58266072|NCT04519788|DRUG|AT-301A|Nasal Spray
57712874|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
57712875|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
57913947|NCT00640133|DEVICE|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
57913948|NCT00640133|DEVICE|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
57712876|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
57712877|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
57712878|NCT06574230|OTHER|TRAINING PROGRAM|Each training session included a structured set of exercises aimed at enhancing these skills. For example, participants practiced precision drills to target specific areas of the dartboard, endurance drills to build stamina for longer games, and competitive exercises to simulate real-game conditions. This combination of theoretical knowledge, practical skill development, and strategic gameplay was designed to comprehensively improve the participants\&#39; dart-throwing abilities over the course of the program. A 12-week dart training program, with sessions conducted three times per week, each lasting 90 minutes. In the first week, participants received comprehensive theoretical and practical instruction covering the rules of the game, proper breathing techniques, and throwing mechanics. This initial phase was designed to ensure a solid understanding of the fundamentals before progressing to more advanced training.
57712879|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
57712880|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
57712881|NCT05142358|OTHER|Free Breath|Regular breathing
57913949|NCT00563888|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
57913950|NCT02877238|DRUG|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
57913951|NCT02877238|DRUG|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
57913952|NCT00407576|DRUG|[11C]MeS-IMPY|
57913953|NCT00954486|DRUG|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
57913954|NCT02857166|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
57712882|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
57712883|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
57712884|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
57712885|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
57712886|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
57913955|NCT06370533|BEHAVIORAL|behavioral interventions|The investigators set diet, physical activity, and weight goals for each participant. During the lifestyle intervention period, the participants need to complete weekly self-monitoring of weight, weekly recording of diet behavioral goals, timely exercise logging, online health education course learning by using the WeChat public account. They will receive corresponding timely reminder and tailored feedback in the form of graphical illustration and text according to diet, physical activity, and weight data collected by WeChat public account and Huawei Wristband. They will receive individual face to face or telephone sessions every 2 weeks to complete health education, goal review, motivational interview as well as collecting adverse events.
57913956|NCT04001231|DRUG|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
57913957|NCT04184739|OTHER|My Braces App|An App designed to support patients undertaking orthodontic treatment.
57913958|NCT06415565|OTHER|conventional physiotherapy|Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.
58060983|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
58060984|NCT02802735|DRUG|Apremilast|Tablet for oral administration
58060985|NCT02802735|DRUG|Placebo|Tablet for oral administration
57913959|NCT06415565|OTHER|thoracic mobilization methods|Methods applied as conventional physiotherapy methods: hotpack, Transcutaneous electrical nerve stimulation and ultrasound applications will be applied. Also within the scope of thoracic mobilization: thoracic region extension stretching in the kneeling position, thoracic flexion in the crawling position, halo exercise, thoracic rotation exercises in the crawling position, thoracic rotation in the side lying position. , quadruped extension and rotation exercises will be applied. Patients will be informed that these exercises can also be done as home exercises and they will be asked to practice for 8 weeks.
57913960|NCT01000285|DRUG|Bortezomib|
58386348|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
58386349|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
58060986|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
58386350|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
58386351|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
58386352|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
58386353|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
57913961|NCT01000285|DRUG|Etoposide|
57913962|NCT01000285|DRUG|Vincristine|
57913963|NCT01000285|DRUG|Doxorubicin|
57913964|NCT01000285|DRUG|Prednisone|
57913965|NCT01000285|DRUG|Cyclophosphamide|
57913966|NCT01000285|DRUG|Raltegravir|
58060987|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
58060988|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
58386354|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
58386355|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
58386356|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
58060989|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
57913967|NCT02938260|DRUG|Metoprolol vs Diltiazem|
57913968|NCT06106932|DRUG|Leuprolide Acetate|Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
57913969|NCT04020627|OTHER|BiPAP Group|"BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
57913970|NCT04020627|OTHER|CPAP Group|"CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
57913971|NCT00109382|DRUG|Aspirin|
57913972|NCT00109382|DRUG|Clopidogrel|
57913973|NCT00109382|DRUG|Simvastatin|
57913974|NCT05143983|BEHAVIORAL|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
57913975|NCT05143983|BEHAVIORAL|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
58060990|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
58060991|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
58060992|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
58266073|NCT05908435|BEHAVIORAL|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
58266074|NCT00441818|DRUG|TNX-650|
58266075|NCT02815813|BEHAVIORAL|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
58386357|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
58386358|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
57913976|NCT05088018|OTHER|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
57913977|NCT05088018|OTHER|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
57913978|NCT01798251|DRUG|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
57913979|NCT01798251|DRUG|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
57913980|NCT03773315|DIETARY_SUPPLEMENT|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
58060993|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
58060994|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
58060995|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
58060996|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
58060997|NCT00304421|DRUG|rabeprazole|
58060998|NCT00304421|DRUG|pantoprazole|
58060999|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
58061000|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
57913981|NCT03773315|DIETARY_SUPPLEMENT|Placebo|Starch placebo 500 mg/day for 12 weeks
57712887|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
57712888|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
57712889|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
57913982|NCT04727892|PROCEDURE|epilepsy surgery|Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
57913983|NCT05235204|PROCEDURE|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
57913984|NCT05690113|PROCEDURE|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
57913985|NCT03607422|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
57913986|NCT03607422|DRUG|Upadacitinib|Tablets taken orally once a day
57913987|NCT05319782|OTHER|Urethral stenosis assesment|Auto-questionnaires + Clinical examination + Flow metry and post-mictional residue
57913988|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
57913989|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
57913990|NCT03765099|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
57913991|NCT00122915|DEVICE|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
57712890|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
57712891|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
57913992|NCT04705129|DRUG|Zanubrutinib|160mg Bid, D1-21, po
57913993|NCT04705129|DRUG|Tislelizumab|200mg, D1, ivgtt
58266076|NCT02815813|BEHAVIORAL|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
58266077|NCT00691899|DRUG|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
57712892|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
57712893|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
57913994|NCT01365832|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
57913995|NCT04049799|OTHER|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
57913996|NCT04049799|OTHER|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
57913997|NCT04049799|BEHAVIORAL|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
57913998|NCT03910751|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
57913999|NCT04147078|BIOLOGICAL|DC vaccine subcutaneous administration|subcutaneous administration
57914000|NCT01598311|DRUG|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
57914001|NCT01598311|DRUG|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
57914002|NCT01598311|DRUG|Placebo|Placebo size 00 opaque hard gelatin capsules.
57914003|NCT01874431|DRUG|Finerenone (BAY94-8862)|
57914004|NCT01874431|DRUG|Placebo|
57914005|NCT00672893|OTHER|Vibration Response Imaging|12 seconds of recording lung sounds
57914006|NCT02330146|DRUG|RCT-01|
57914007|NCT02330146|DRUG|Placebo|
57914008|NCT05129553|DEVICE|Béa Applicator and Béa Cervical Cap Device|Single-use of the investigational device
57914009|NCT03293641|DIETARY_SUPPLEMENT|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
57914010|NCT03293641|DRUG|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
57914011|NCT01998087|BEHAVIORAL|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
57914012|NCT04886895|OTHER|Let's Move|Motor intervention
57914013|NCT02797574|PROCEDURE|Punch Biopsy at a Lesional Site|
57712894|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
57914014|NCT02797574|PROCEDURE|Punch Biopsy at a Non- Lesional site|
57914015|NCT01970345|DRUG|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
58061001|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
58061002|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
58061003|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
57712895|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
58061004|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
58061005|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
58061006|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
58061007|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
58266078|NCT00691899|DRUG|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
57914016|NCT01970345|DRUG|Placebo/saline|Placebo
57914017|NCT00467168|BEHAVIORAL|Diet|
57914018|NCT06153927|DIAGNOSTIC_TEST|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
57914019|NCT01561404|DRUG|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
57914020|NCT00201994|DRUG|Tolvaptan|
57914021|NCT01345773|PROCEDURE|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
57914022|NCT03868605|DEVICE|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
58061008|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
58061009|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
58061010|NCT02709889|DRUG|Rovalpituzumab tesirine|
58061011|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
58061012|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
57914023|NCT03868605|DEVICE|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
58386359|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
58386360|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
58386361|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
58386362|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
58386363|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
58386364|NCT02365610|DRUG|GWP42006|
58386365|NCT02365610|DRUG|Placebo Control|
58386366|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
58386367|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
58386368|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
57914024|NCT06502912|OTHER|no intervention|no intervention
58061013|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
58061014|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
58061015|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
58061016|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
58061017|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
58266079|NCT06090097|DEVICE|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
58386369|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
58386370|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
58386371|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
58386372|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
58386373|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
58386374|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
58386375|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
58386376|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
58386377|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
58386378|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
58386379|NCT01833494|DRUG|PA21|
58386380|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
58386381|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
58386382|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
58061018|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
58061019|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
58061020|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
58061021|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
58061022|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
58266080|NCT06090097|OTHER|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
58266081|NCT05862883|DRUG|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
58266082|NCT05862883|OTHER|Control group|Taking basic therapy without Rutan
58266083|NCT05900089|DRUG|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
58266084|NCT03357575|BIOLOGICAL|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
58266085|NCT03357575|BIOLOGICAL|Hyaluronic Acid|inject hyaluronic acid
58266086|NCT04204928|DRUG|pralsetinib (BLU-667)|Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
58266087|NCT00648934|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
58266088|NCT00648934|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
58061023|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
58266089|NCT00379808|DRUG|montelukast|10 mg tablet (masked by capsule) daily for 1 month
58266090|NCT00379808|DRUG|Placebo|1 lactose-containing capsule daily for 1 month
58266091|NCT01834716|BEHAVIORAL|Aerobic vs. Non-Aerobic exercise|
58266092|NCT02071810|DRUG|BIA 9-1067|
58266093|NCT02071810|DRUG|Placebo|
58266094|NCT05375344|BEHAVIORAL|Exercise Group|Home-based exercise group intervention
58266095|NCT04814316|DIAGNOSTIC_TEST|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
58266096|NCT03124121|DRUG|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
58266097|NCT05680506|PROCEDURE|Pain neuroscience education|Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.
58266098|NCT05680506|PROCEDURE|Standard Therapy|Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
58266099|NCT05210101|DRUG|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
58266100|NCT03409900|OTHER|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
58266101|NCT03409900|OTHER|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
58266102|NCT03840148|DRUG|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
58266103|NCT03840148|DRUG|Meropenem|Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
58061024|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
58061025|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
58061026|NCT00979862|DRUG|Cediranib Maleate|Given PO
58061027|NCT00979862|DRUG|Cilengitide|Given IV
58061028|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
58061029|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
58266104|NCT03265548|DEVICE|Video Laryngoscope|The use of video laryngoscopy
58266105|NCT00980174|DRUG|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
58266106|NCT00980174|OTHER|Placebo|Placebo for denosumab (SC injection every 6 months)
58266107|NCT05596500|DIETARY_SUPPLEMENT|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
58266108|NCT05596500|DIETARY_SUPPLEMENT|Blueberry gel|Sport gel with blueberry extract only.
58266109|NCT05596500|DIETARY_SUPPLEMENT|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
58266110|NCT04932746|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
58266111|NCT04932746|DRUG|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
58266112|NCT00497848|BEHAVIORAL|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
57914025|NCT02504515|OTHER|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
58061030|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
58266113|NCT00497848|OTHER|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
58266114|NCT02319720|BIOLOGICAL|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
58266115|NCT02319720|BIOLOGICAL|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
58266116|NCT02319720|PROCEDURE|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
58266117|NCT05449938|PROCEDURE|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
58266118|NCT01200732|DRUG|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
58266119|NCT01966419|DRUG|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
58266120|NCT01966419|DRUG|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
58266121|NCT01103102|DRUG|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
58266122|NCT01103102|DRUG|Placebo|Placebo
58266123|NCT06402591|DRUG|Cefazolin|cefazolin extended prophylaxis 5 days (15 doses)
58266124|NCT00718380|DRUG|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
58266125|NCT01819753|PROCEDURE|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
58266126|NCT06119334|BEHAVIORAL|Online intervention|Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
58266127|NCT03344965|DRUG|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
58266128|NCT00751257|DRUG|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
58266129|NCT00751257|DRUG|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
58266130|NCT01942499|OTHER|Community-based exercise program|
58266131|NCT01343667|DEVICE|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
58266132|NCT01343667|DEVICE|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
58266133|NCT06622096|DIAGNOSTIC_TEST|Evaluation of laboratory exams prescription|Evaluation of laboratory exams prescription
58266134|NCT00334191|DRUG|Sodium Bicarbonate|
58266135|NCT00334191|DRUG|Placebo|
58266136|NCT01060605|DRUG|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
58386383|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
58386384|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
57914026|NCT03224923|DRUG|Ticagrelor 60mg|twice daily
57914027|NCT03224923|DRUG|Clopidogrel 75mg|once daily
57914028|NCT03224923|DRUG|Aspirin 81 mg|once daily
58061031|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
58061032|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
58061033|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
58061034|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
58386385|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
58266137|NCT04810247|BEHAVIORAL|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
58266138|NCT01367600|DRUG|SC Methylnaltrexone (MNTX)|
58266139|NCT06166537|OTHER|Graduated compression stockings|Graduated compression stockings are standard care (control)
58266140|NCT06166537|OTHER|No Graduated compression stockings|No Graduated compression stockings is the intervention
58266141|NCT04530591|OTHER|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
58266142|NCT04530591|OTHER|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
58266143|NCT02542241|DRUG|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
58266144|NCT02542241|DRUG|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
58266145|NCT04605393|DRUG|Cannabidiol|CBD
58266146|NCT04605393|DRUG|Placebo|Placebo
58266147|NCT04605393|DRUG|Delta-9-THC|THC
58266148|NCT02895646|OTHER|Collection of blood sample|
58266149|NCT01848743|DRUG|Tenofovir|
58266150|NCT01848743|DRUG|lamivudine|
58386386|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
58386387|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
58266151|NCT04144036|BIOLOGICAL|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
58266152|NCT04144036|DRUG|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
58266153|NCT04144036|DRUG|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
57914029|NCT05636605|DIAGNOSTIC_TEST|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
58266154|NCT04144036|DRUG|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
58266155|NCT03482076|DIAGNOSTIC_TEST|transferrin receptor concentration|Sandwich radio-imunoassay
58266156|NCT06649032|OTHER|No intervention|no difference: both cohorts are followed in the same way
58386388|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
58386389|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
57914030|NCT05071196|OTHER|Facilitated Vegan Diet|Vegan boxed meal kits
57914031|NCT05071196|OTHER|Omnivorous Diet|Non-vegan boxed meal kits
58266157|NCT04443621|BEHAVIORAL|questionnaire|Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
58266158|NCT04443621|BEHAVIORAL|in-depth interview|Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
58266159|NCT06477835|BIOLOGICAL|SIM0718 Injection|Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
58386390|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
57712896|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
58386391|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
57712897|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
57712898|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
57712899|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
57712900|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
57712901|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
57712902|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
57712903|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
57712904|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
57712905|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
58386392|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
57712906|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
57712907|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
57712908|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
57712909|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
57712910|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
57712911|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
57712912|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
58386393|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
57712913|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
57712914|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
57712915|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
57712916|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
57712917|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
58386394|NCT02655952|DRUG|Foxy-5|
58386395|NCT01949766|DRUG|Glycerol phenylbutyrate|
57712918|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
57712919|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
57712920|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
57712921|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
57712922|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
57712923|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
57712924|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
57712925|NCT00000735|DRUG|Ampligen|
57712926|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
58386396|NCT04311112|DRUG|Placebos|Placebo
58386397|NCT04311112|DRUG|ZA Low dose|ZA low dose
58386398|NCT04311112|DRUG|ZA high dose|ZA high dose
58386399|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
58386400|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
58386401|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
58386402|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
58266160|NCT04875312|DEVICE|Ultrasound cavitation in group A|"Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
58266161|NCT04875312|DEVICE|Electro acupuncture in group B|"Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
58266162|NCT06648954|DEVICE|multisite HD-tDCS|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
57712927|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
58266163|NCT06648954|DEVICE|Conventional tDCS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
58266164|NCT06648954|DEVICE|Sham stimulation|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
58266165|NCT00284427|DRUG|vitamin C|IV Vitamin C given 2-3 times a week
58266166|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
58266167|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
58266168|NCT04211974|DIAGNOSTIC_TEST|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
58386403|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
58386404|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
57712928|NCT03497559|OTHER|Music|Classical music
57712929|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
57712930|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
57712931|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
58266169|NCT00655473|DRUG|Dalcetrapib (RO4607381)|600mg po daily for 24 months
58266170|NCT00655473|DRUG|Placebo|po daily for 24 months
58266171|NCT03273400|OTHER|Lumbar Mobilisations|Please see arm (intervention) description
58266172|NCT05250687|PROCEDURE|MR- High intensity focused ultrasound|The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
58266173|NCT05250687|RADIATION|External beam radiotherapy|Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
58266174|NCT06505161|OTHER|Dry needling|It consists in application of dry needling on active and/or latent TPs in low back multifidus muscles
58266175|NCT06505161|OTHER|Percutaneous electrolysis|It consists in the application of intratissue percutaneous electrolysis with galvanic current as a cathodic flow electrode in the low back multifidus muscles. The intervention will be guided by ultrasound equipment medically certified.
58266176|NCT05952804|BIOLOGICAL|Immune Globulin Infusion (Human), 10% Solution|Given IV
58266177|NCT05952804|BIOLOGICAL|Anti-CD19 CAR T Cells Preparation|Given CAR-T treatment
58266178|NCT05952804|OTHER|Saline|Given IV
58266179|NCT05952804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58266180|NCT05952804|OTHER|Survey Administration|Ancillary studies
58266181|NCT05952804|OTHER|Electronic Health Record Review|Ancillary studies
57712932|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
57712933|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
57914032|NCT05191992|OTHER|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
57914033|NCT01934361|DRUG|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
57914034|NCT01934361|DRUG|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
57914035|NCT01934361|DRUG|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
57914036|NCT01934361|DRUG|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
57914037|NCT00626678|DRUG|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
57914038|NCT00626678|DRUG|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
58266182|NCT05591612|BEHAVIORAL|Salt replacement seasoning (50% salt and 50% MSG) mix|Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.
58266183|NCT05591612|BEHAVIORAL|Salt replacement seasoning (70% salt and 30% MSG) mix|Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.
58386405|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
58386406|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
58386407|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
57914039|NCT00626678|DRUG|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
57914040|NCT00372229|DRUG|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
57914041|NCT00372229|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
57914042|NCT00372229|DRUG|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
58061035|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
58266184|NCT05591612|BEHAVIORAL|NaCl (sodium chloride/table salt)|Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
58266185|NCT05307185|DIETARY_SUPPLEMENT|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
58266186|NCT03701698|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.
58266187|NCT03701698|DRUG|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
58386408|NCT04719481|DRUG|Placebo|daily oral administration
58386409|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
58386410|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
58386411|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
58386412|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
57914043|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
57914044|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance|Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.
58061036|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
58061037|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
58061038|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
58061039|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
58061040|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
58061041|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
58061042|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
58061043|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
58061044|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
58061045|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
58061046|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
58061047|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
58061048|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
58061049|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
58061050|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
58061051|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
58061052|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
58061053|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
58061054|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
58386413|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
58061055|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
58061056|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
58061057|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
58061058|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
58061059|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
58061060|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
58061061|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
58061062|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
58386414|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
58386415|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
58061063|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
58061064|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
58061065|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
58061066|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
58266188|NCT02624388|DRUG|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
57712934|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
57712935|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
57712936|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
57712937|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
57712938|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
57712939|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
57712940|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
57712941|NCT06013371|DRUG|Placebo Ointment|matching placebo
57712942|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
57712943|NCT00596011|DRUG|Placebo|Matching placebo BID
57712944|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
57712945|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
57712946|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
57712947|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
57712948|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
58061067|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
58061068|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
58061069|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
58266189|NCT02624388|DRUG|Placebo|Pill that contains no medicine
58386416|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
58386417|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
57712949|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
58061070|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
58061071|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
58061072|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
58061073|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
58266190|NCT01971762|BEHAVIORAL|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
58386418|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
58386419|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
57712950|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
57712951|NCT01785602|DRUG|QAW039|Capsules
57712952|NCT01785602|DRUG|Placebo|Capsules
57712953|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
57712954|NCT00003589|DRUG|cisplatin|
57712955|NCT00003589|DRUG|gemcitabine hydrochloride|
57712956|NCT00003589|DRUG|paclitaxel|
58266191|NCT01971762|BEHAVIORAL|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
58266192|NCT03194711|DEVICE|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
58266193|NCT04380012|DRUG|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
58386420|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
58386421|NCT00109252|DRUG|Raptiva (efalizumab)|
57712957|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
57712958|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
57712959|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
58386422|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
57712960|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
58386423|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
58386424|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
58386425|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
58386426|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
58386427|NCT00033046|DRUG|Modafinil|
58061074|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
58061075|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
58061076|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
58386428|NCT02463396|BEHAVIORAL|MBCT for ADHD|
57712961|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
57712962|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
57712963|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
57712964|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
57712965|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
58061077|NCT02730546|DRUG|Carboplatin|Given IV
58061078|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
57712966|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
57712967|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
57712968|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
57712969|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
58061079|NCT02730546|DRUG|Fluorouracil|Given IV
58061080|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
58061081|NCT02730546|DRUG|Leucovorin Calcium|Given IV
58061082|NCT02730546|DRUG|Oxaliplatin|Given IV
58061083|NCT02730546|DRUG|Paclitaxel|Given IV
58061084|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
58061085|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
58061086|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
58061087|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
58061088|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
58061089|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
58061090|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
58386429|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
58386430|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
58386431|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
58386432|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
58386433|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
58386434|NCT00075764|DRUG|anastrozole|Given orally
58386435|NCT00075764|DRUG|fulvestrant|Given intramuscularly
57914045|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance|Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
57914046|NCT04694430|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
57914047|NCT04694430|OTHER|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool."
58266194|NCT04380012|DRUG|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
58266195|NCT04789928|DRUG|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
58266196|NCT04104217|BEHAVIORAL|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
58266197|NCT04104217|BEHAVIORAL|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
58266198|NCT05493813|BEHAVIORAL|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
58266199|NCT05493813|BEHAVIORAL|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
58266200|NCT05621369|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
58266201|NCT05621369|BEHAVIORAL|Psoriasis Draw|Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
58266202|NCT05621369|BEHAVIORAL|Psoriasis Area Photo|Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
58266203|NCT05621369|BEHAVIORAL|Finger and Toe Photos|Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
58266204|NCT05621369|BEHAVIORAL|Digital Jar Open|Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
58266205|NCT05621369|BEHAVIORAL|30 Second Walk|Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
58266206|NCT05621369|OTHER|Psorcast mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
58266207|NCT01838434|DRUG|lenalidomide|given PO
57914048|NCT04694430|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
57914049|NCT00067509|DRUG|emergency contraception (estrogen/progesterone)|
57914050|NCT00140192|DRUG|creatine|
58061091|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
58061092|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
58266208|NCT01838434|DRUG|idelalisib|given PO
58266209|NCT03293082|DEVICE|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
58266210|NCT03293082|DEVICE|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
58266211|NCT00454818|GENETIC|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
58266212|NCT00454818|PROCEDURE|Placebo Infusion|Saline; epicardial coronary artery infusion
57914051|NCT04600154|DRUG|MS-20|Specific fraction from fermented soy milk
57914052|NCT04600154|OTHER|Placebo|Fermented soy milk without active component
57914053|NCT04558749|OTHER|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
58061093|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
57712970|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
57712971|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
57712972|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
57712973|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
57712974|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
57712975|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
57712976|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
57712977|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
57712978|NCT05526872|OTHER|Best Practice|Receive usual care
57712979|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
57712980|NCT05526872|OTHER|Interview|Ancillary studies
57712981|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
57914054|NCT04558749|OTHER|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
57914055|NCT02390050|DRUG|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
58061094|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
58061095|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
57712982|NCT05526872|OTHER|Survey Administration|Ancillary studies
57712983|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
57712984|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
57712985|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
57712986|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
57712987|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
57712988|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
57712989|NCT00000327|DRUG|Heroin Dependence|
57712990|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
57712991|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
57712992|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
57712993|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
57712994|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
57712995|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
57712996|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
57712997|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
58061096|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
58061097|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
58061098|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
58061099|NCT03056209|DRUG|Placebo|oral administration, placebo
58266213|NCT00454818|GENETIC|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
58266214|NCT03738800|DRUG|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
58266215|NCT03738800|DRUG|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
58266216|NCT03738800|DRUG|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
58266217|NCT03356899|DRUG|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
58266218|NCT03356899|DRUG|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
58266219|NCT03870776|DRUG|MAP4343|Daily oral administration of MAP4343
57914056|NCT02390050|DRUG|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
58266220|NCT03870776|DRUG|Placebo|Daily oral administration of Placebo
58266221|NCT04659629|DRUG|NL-201|NL-201 is a de novo protein therapeutic.
58266222|NCT04659629|DRUG|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
58266223|NCT01712893|DRUG|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
58266224|NCT01734252|DRUG|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
58266225|NCT04134065|DRUG|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration \<75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
58266226|NCT04134065|DRUG|Placebo oral capsule|the capsule contain nothing
58266227|NCT04403659|DEVICE|Telemedicine/telemonitoring (TM) suite|"The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured."
58266228|NCT00492882|DRUG|usual administration of exogenous recombinant FSH|
58266229|NCT02941796|DRUG|HCP1105|
57712998|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
57712999|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
57914057|NCT05025202|OTHER|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
58266230|NCT02941796|DRUG|HCP0918|
57713000|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
58266231|NCT02941796|DRUG|HCP0816|
58266232|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
58266233|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
58266234|NCT01582659|OTHER|Telephone counseling|2 planned telephone counseling sessions are conducted.
58266235|NCT01582659|OTHER|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
58266236|NCT05056792|OTHER|Isometric strength training for 8 week|Plyometric training for 8 week
58266237|NCT05056792|OTHER|Conventional training|Conventional training for 8 week
58266238|NCT05583500|OTHER|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
58266239|NCT06618521|DRUG|Anti-hypertensive drug (Methyldopa 250 mg)|Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.
58266240|NCT06618521|OTHER|Pilates exercise|Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.
58266241|NCT06618521|OTHER|Circuit exercise training|Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.
58266242|NCT00503451|DRUG|LBH589|
57713001|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
57713002|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
57713003|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
57914058|NCT01207037|PROCEDURE|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
57914059|NCT03533985|BEHAVIORAL|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
57914060|NCT03533985|OTHER|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
57914061|NCT03533985|OTHER|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
58266243|NCT02062996|DRUG|Oxymetazoline|
58266244|NCT06451289|DIAGNOSTIC_TEST|Head computered tomography|Retrospective data collecting from medical records
58266245|NCT01523210|OTHER|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
58266246|NCT02651519|DRUG|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
58266247|NCT02651519|DRUG|saline|stellate-ganglion block with saline
58266248|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
58266249|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
58266250|NCT02669082|DRUG|Ramelteon|Ramelteon tablets
58266251|NCT04660708|BEHAVIORAL|manual physical therapy|Previously described in the arm description
57914062|NCT03533985|OTHER|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
57914063|NCT03533985|OTHER|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
58266252|NCT03447652|OTHER|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
58266253|NCT03447652|OTHER|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
58266254|NCT03447652|OTHER|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
58266255|NCT05659511|DIAGNOSTIC_TEST|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
58266256|NCT06649279|DEVICE|Oxygen reserve index|Measuring oxygen reserve index during preoxygenation and under general anesthesia
58266257|NCT01238718|DRUG|Lidocaine|lidocaine 1.5 mg/kg intravenously
58266258|NCT01238718|DRUG|Placebo|normal saline
58266259|NCT02781181|DEVICE|CAS with CPD|using a neuroprotection device
58266260|NCT02781181|OTHER|CAS without CPD|No Neuroprotection
58266261|NCT03283059|DRUG|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
58266262|NCT03283059|DRUG|Aricept|Aricept 5mg/day, P.O.
58266263|NCT03283059|DRUG|Placebos|Placebo Tablet: P.O. tid
58266264|NCT02839564|PROCEDURE|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
58386436|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
58386437|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
57914064|NCT03533985|OTHER|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
57914065|NCT04578782|DRUG|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
58266265|NCT02839564|PROCEDURE|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
58266266|NCT00622336|DRUG|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
57914066|NCT05180188|BEHAVIORAL|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
57914067|NCT05589168|BEHAVIORAL|Triage nurse|Triage nurse joins 911 call
57914068|NCT05589168|BEHAVIORAL|No triage nurse|Triage nurse does not join 911 call (business as usual)
57914069|NCT04695743|OTHER|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
57914070|NCT03384901|PROCEDURE|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
58386438|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
57914071|NCT02482077|DRUG|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
57914072|NCT02482077|DRUG|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
57914073|NCT02482077|DRUG|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
57914074|NCT00002448|DRUG|Ritonavir|
57914075|NCT00002448|DRUG|Efavirenz|
57914076|NCT00002448|DRUG|Saquinavir|
57914077|NCT01148914|OTHER|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
58266267|NCT00622336|DRUG|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
58386439|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
58386440|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
57914078|NCT03939091|DIAGNOSTIC_TEST|Ultrasonography|Renal Ultrasonography
58266268|NCT05695105|DEVICE|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
58386441|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
58386442|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
58386443|NCT00725946|DRUG|Iodine-124|
57914079|NCT02269332|OTHER|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
57914080|NCT06118996|DEVICE|3D Ultrasound Image Acquisition|A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
57914081|NCT04196101|DRUG|EDP-938|Four tablets daily for 5 days
57914082|NCT04196101|DRUG|Placebo|Four tablets daily for 5 days
58266269|NCT05695105|DEVICE|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
58266270|NCT00046917|DRUG|alvocidib|Given IV
58266271|NCT00046917|DRUG|irinotecan hydrochloride|Given IV
58266272|NCT00046917|DRUG|cisplatin|Given IV
58266273|NCT05807997|OTHER|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
58266274|NCT03788668|PROCEDURE|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
58266275|NCT00199329|DRUG|ondansetron adding in PCA|
58266276|NCT03466125|PROCEDURE|Cardiac surgery|Retrospective cohort study
58266277|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
58266278|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
58386444|NCT00725946|RADIATION|PET/CT with Iodine-124|
58386445|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
58386446|NCT00002081|DRUG|Zidovudine|
58386447|NCT00002081|DRUG|Zalcitabine|
58386448|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
58386449|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
58386450|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
58266279|NCT01718834|BIOLOGICAL|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
58266280|NCT01718834|BIOLOGICAL|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
58266281|NCT01801358|DRUG|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
58266282|NCT01801358|DRUG|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
58266283|NCT03552224|PROCEDURE|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
57713004|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
57713005|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
57713006|NCT00095784|DRUG|Decitabine|Given SC
57713007|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
57914083|NCT05346133|BEHAVIORAL|Suicide Prevention Intervention for Adolescents|Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
58266284|NCT02611128|OTHER|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
58061100|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
57914084|NCT00504660|DRUG|Capecitabine|Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
57914085|NCT00504660|DRUG|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
58386451|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
58266285|NCT02068170|DRUG|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
58266286|NCT02638259|DRUG|GP2015|Enbrel comparator
58266287|NCT01157650|OTHER|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
58386452|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
58386453|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
58386454|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
58386455|NCT00022295|DRUG|idronoxil|
58386456|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
58386457|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
58386458|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
58386459|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
57713008|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
58061101|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
58061102|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
58061103|NCT03479541|BEHAVIORAL|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
57914086|NCT00504660|DRUG|Temozolomide|Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.
57914087|NCT00504660|DRUG|Lomustine|Arms 2,3 = 100 mg/m\^2 PO on Day 4.
58061104|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
58061105|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
58061106|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
57914088|NCT00504660|DRUG|6-Thioguanine|Arms 1,2,3 = 80 mg/m\^2 PO Every 6 Hours on Day 1-3.
58061107|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
58061108|NCT00207636|BEHAVIORAL|Computer-based prostate cancer screening decision aid|
57914089|NCT00126893|DRUG|CC-401|
57914090|NCT02034370|DEVICE|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
58061109|NCT00601510|DRUG|capecitabine|
58061110|NCT00601510|DRUG|cisplatin|
58061111|NCT00601510|DRUG|imatinib mesylate|
58266288|NCT01461252|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
58266289|NCT01461252|PROCEDURE|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
58266290|NCT02115074|DRUG|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
57914091|NCT02034370|DEVICE|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
57914092|NCT05778344|BEHAVIORAL|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
57914093|NCT05367232|DRUG|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
57914094|NCT01783847|DRUG|Recombinant human erythropoietin (EPO)|4000 units per vial
57914095|NCT01783847|OTHER|Observation|Just observation
57914096|NCT01783847|DRUG|Methyl prednisolone|250 mg every 6 hours for 3 days.
57914097|NCT00584649|PROCEDURE|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
57914098|NCT03141385|OTHER|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
57914099|NCT03141385|OTHER|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
58061112|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
58061113|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
58061114|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
58061115|NCT00004728|DRUG|Warfarin|
58061116|NCT00004728|DRUG|Aspirin|
58061117|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
58061118|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
58061119|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
57914100|NCT01775267|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy|
57914101|NCT01775267|PROCEDURE|Portal vein embolization or ligation|
57914102|NCT02630693|DRUG|Palbociclib 100mg|100mg PO daily
57914103|NCT02630693|DRUG|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
57914104|NCT02630693|DRUG|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
58266291|NCT02115074|DRUG|Celebrex|"Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
57914105|NCT01871753|OTHER|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
57914106|NCT04619901|OTHER|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
58266292|NCT06295887|OTHER|Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation|Simulation program using VR or simulator that mimics patient's desaturation
58061120|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
58061121|NCT00000642|DRUG|CD4-IgG|
58266293|NCT05267925|DIETARY_SUPPLEMENT|CuraLin|"CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour"
58266294|NCT05137340|OTHER|Nasal continuous positive airway pressure and Non-invasive positive pressure ventilation|After transfer to NICU ward, infants were randomly assigned to NCPAP group and NIPPV group. Patients diagnosed with NRDS on non-invasive respiratory support (NIPPV or NCPAP) were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth.
58266295|NCT02203851|DRUG|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
58266296|NCT00874328|DRUG|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
58061122|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
58266297|NCT00874328|DRUG|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
58386460|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
58386461|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
58386462|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
58061123|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
58061124|NCT01741584|BEHAVIORAL|stationary bike exercise|
58386463|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
58386464|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
58386465|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
58386466|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
58386467|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
58386468|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
58386469|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
58386470|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
58386471|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
58386472|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
58386473|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
58061125|NCT01741584|BEHAVIORAL|aerobic|
58061126|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
58061127|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
58061128|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
58061129|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
58061130|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
58266298|NCT00874328|DRUG|TS-1 (S-1)|TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
58386474|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
58386475|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
58386476|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
58386477|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
58386478|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
58386479|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
58386480|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
58386481|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
58386482|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
58386483|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
58386484|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
58386485|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
58386486|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
58386487|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
58386488|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
58386489|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
58386490|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
58386491|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
58386492|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
58266299|NCT05939115|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
58266300|NCT00001047|DRUG|Ethambutol hydrochloride|
58266301|NCT00001047|DRUG|Clarithromycin|
58266302|NCT00001047|DRUG|Clofazimine|
58266303|NCT00001047|DRUG|Rifabutin|
58266304|NCT06143254|BEHAVIORAL|Infant sign training|Training session 1: Information is given about what infant signs are, how they originated, how speech and (gestural) language develop in young children with CP ± L, the possible advantages of using infant signs and tips for success. Twelve signs are chosen to start with: six narrative signs (mostly object concepts) and six steering signs (mostly non-object concepts). Training session 2: Experiences with using infant signs at home are shared, repetition of the 12 infant signs and tips for success are discussed. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Reading aloud while using infant signs is shown and practiced.
58266305|NCT06143254|BEHAVIORAL|Verbal training|Training session 1: Information is given about how speech and language develop in young children with CP ± L and how caregivers can support their child during this development Tips for success and suggestions on how to use these supportive verbal techniques at home are discussed. Training session 2: Experiences with using supportive verbal techniques at home are shared and supportive verbal techniques repeated. Information is provided about how children learn new words and tips for success are expanded. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Additionally, advances of reading aloud are discussed and reading aloud is practiced.
58266306|NCT04100915|OTHER|No Intervention|There is no intervention for this study
58266307|NCT01902758|DRUG|ambrisentan and theophylline|
58266308|NCT01902758|DRUG|placebo|placebo for comparison group
58266309|NCT05999838|DIAGNOSTIC_TEST|HRCT chest visual scoring|"CT-based semi-quantitative scoring will be calculated according to number of lung segments affected on both sides.~The finding on each segment will be given a score from 1 to 4 as follows:~1. for ground glass opacities.~2. for reticulations and fibrotic changes.~3. for bronchiectatic changes.~4. for honeycombing and sub-pleural cysts."
58266310|NCT00733083|DRUG|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
58266311|NCT00733083|DRUG|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
58266312|NCT00733083|DRUG|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
58266313|NCT00733083|DRUG|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
58266314|NCT05729542|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
58266315|NCT05729542|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
58266316|NCT01905501|DRUG|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
57713009|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
57713010|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
57713011|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
57914107|NCT04619901|OTHER|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
57914108|NCT04619901|OTHER|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
57914109|NCT06290674|OTHER|Extracorporeal Shockwave therapy|2000 shots, 120mJ pulse energy setting, 3 bar pressure, and 15 Hz for 15 minute per session.
57914110|NCT06290674|OTHER|Balanced low-calorie diet|1500 k/cal for 6 weeks
57914111|NCT03265938|DEVICE|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
57914112|NCT00538915|BIOLOGICAL|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
57914113|NCT00219804|DRUG|tetrabenazine or placebo|
58061131|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
57914114|NCT06357013|PROCEDURE|Bilateral Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.
58061132|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
58266317|NCT01905501|DRUG|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
58266318|NCT04462523|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
58061133|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
58061134|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
58266319|NCT04462523|DRUG|Topical Prednisolone|Standard of care topical drop treatment
58266320|NCT00421824|DRUG|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
58266321|NCT00421824|DRUG|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
58386493|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
58386494|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
58386495|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
58386496|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
58386497|NCT00385385|DRUG|Rifalazil|
58386498|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
58386499|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
58386500|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
58386501|NCT02786212|DRUG|Dexmedetomidine|
58386502|NCT02786212|DRUG|Normal Saline|
58386503|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
58386504|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
58386505|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
58386506|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
58386507|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
58386508|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
58386509|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
58386510|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
58386511|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
58386512|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
58386513|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
58386514|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
57914115|NCT06357013|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
58386515|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
58386516|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
58386517|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
58386518|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
58386519|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
58386520|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
58386521|NCT02078024|DRUG|IVM plus ALB|
58386522|NCT02078024|DRUG|IVM|
58386523|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
58386524|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
58386525|NCT05689918|OTHER|No intervention|No intervention
58386526|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
58266322|NCT03866733|OTHER|continous erector spinea block|Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
58266323|NCT03866733|DRUG|intravenous narcotics|intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
58266324|NCT06440733|OTHER|Multicomponent exercise program focused in elderly.|"Each of these sessions will be carried out taking into account the main physiotherapy objectives, such as gaining strength in both upper and lower limbs, as well as proprioception, balance, and promoting a pleasant and safe social environment where these older people feel valid.~All sessions will begin with a 5-minutes. It will begin with a general warm-up based on general joint mobility of the head and neck, shoulders, trunk, elbows, hands, wrists, hips, knees and ankles to begin to accustom the body to the physical work environment. And at the end of the sessions, a stretching program will be carried out, and it will end with a return to calm with a respiratory training program, in which you will be instructed to take in air through the nose and release it through the mouth, while the room is silent, and thus promote self-awareness."
58266325|NCT00027677|DRUG|halofuginone hydrobromide|
58266326|NCT02687906|DRUG|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
58266327|NCT02322502|DRUG|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
58266328|NCT02322502|DRUG|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
58266329|NCT02322502|DRUG|propofol|intravenous injection to maintain anaesthesia
58266330|NCT02823834|DEVICE|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
58266331|NCT06197412|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
58266332|NCT02189018|OTHER|Active Exercise|Active exercise on a treadmill
58266333|NCT02189018|OTHER|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
58266334|NCT02189018|OTHER|Weight loss and active exercise|Weight loss and active exercise on a treadmill
58266335|NCT02189018|OTHER|Ad lib activity at home|Ad lib activity at home
58266336|NCT06532136|DRUG|Deucravacitinib|Deucravacitinib 6 mg orally once daily.
58266337|NCT06532136|DRUG|Placebo|Matching placebo orally once daily.
58266338|NCT02811588|DEVICE|Non-invasive ventilation|
58386527|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
57713012|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
57713013|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
58266339|NCT02428374|DRUG|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
58266340|NCT02428374|DRUG|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
58266341|NCT02428374|DRUG|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
58266342|NCT02428374|DRUG|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
58266343|NCT05217511|BEHAVIORAL|Neuromuscular Electrical Stimulation|NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
58266344|NCT04303754|OTHER|Diabetes-Specific Formula|Other: Diabetes Specific Formula
58266345|NCT04303754|OTHER|Bread with Spread|Other: White Bread with Spread
58266346|NCT04303754|OTHER|Rice Porridge|Other: Rice Porridge
58266347|NCT01350440|BIOLOGICAL|IVIG|Intravenous Immune Globulin
58266348|NCT05509764|DIAGNOSTIC_TEST|lung ultrasound score|determination of atelectasis by lung ultrasound score
58266349|NCT04469673|BIOLOGICAL|Biological：JS002|Administered by subcutaneous injection
58266350|NCT04469673|BIOLOGICAL|Placebo|Administered by subcutaneous injection
58266351|NCT02014220|OTHER|dietary treatment|
58266352|NCT04482244|DRUG|Cannabidiol|Liquid taken orally
58266353|NCT04482244|OTHER|Placebo|Liquid taken orally
58266354|NCT06228079|DRUG|Immunotherapy,Toripalimab Injection|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
57914116|NCT02990312|DRUG|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
57914117|NCT00506987|DRUG|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
57914118|NCT00506987|DRUG|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
58386528|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
57914119|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
57914120|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
57914121|NCT00081107|DRUG|epothilone D|
57914122|NCT06227078|DEVICE|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
58386529|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
58386530|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
57914123|NCT01018147|PROCEDURE|4-dimensional computed tomography|Undergo 4-D CT imaging
57914124|NCT04123574|DRUG|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
57914125|NCT03207100|COMBINATION_PRODUCT|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
57914126|NCT03207100|COMBINATION_PRODUCT|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
57914127|NCT00851448|DIETARY_SUPPLEMENT|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
57914128|NCT00547820|OTHER|placebo|
57914129|NCT00547820|DEVICE|Urinary sensor|
57914130|NCT00220467|BEHAVIORAL|Aerobic exercise|
57914131|NCT01739491|DRUG|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
57914132|NCT00111215|DRUG|Tranexamic Acid|
57914133|NCT00111215|DRUG|Desmopressin Acetate|
57914134|NCT03966807|BEHAVIORAL|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
58061135|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
58061136|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
58061137|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
58061138|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
58061139|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
58386531|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
58386532|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
58386533|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
58386534|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
58386535|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
58386536|NCT00229697|DRUG|Gefitinib|
58386537|NCT00229697|DRUG|Tamoxifen|
57914135|NCT03966807|BEHAVIORAL|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
57914136|NCT04728412|DEVICE|High Flow Oxygen Therapy (HFOT)|HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
57914137|NCT06270472|PROCEDURE|hernioplasty|"The polysome repair was carried out as described by pelisse . In the case of a lateral hernia, the spermatic cord was mobilised and the cremasteric fibers were separated (in men). The hernia sac was dissected from the cord structures and reduced in the preperitoneal space through the internal ring. A dissection gauze was inserted through the internal ring to create the preperitoneal space. The medial border of the internal ring and the epigastric vessels were lifted with a refractor and blunt digital dissection was carried out in the preperitoneal space in all directions. A pocket was created to allow a complete expansion of the mesh. The conventional mesh was introduced with blunt forceps and, after the gauze has been removed, positioned in the preperitoneal space .~In the case of a medial hernia, the preperitoneal space was reached by incising the transversalis fascia around the base of the sac. Completion of the repair is the same as the lateral hernia procedure."
57914138|NCT00486460|DRUG|Gemcitabine|
57914139|NCT00486460|DRUG|Curcumin|
57914140|NCT00486460|DRUG|Celebrex|
57914141|NCT03190447|DEVICE|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
57914142|NCT03190447|DEVICE|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
57914143|NCT03190447|DEVICE|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
57914144|NCT03190447|DEVICE|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
57914145|NCT03190447|DEVICE|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
57914146|NCT05096585|BEHAVIORAL|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
58061140|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
58386538|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
58061141|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
58061142|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
58386539|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
58386540|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
58386541|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
57914147|NCT05096585|BEHAVIORAL|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
58386542|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
58386543|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
57713014|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
57713015|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
57713016|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
58266355|NCT06228079|DRUG|Chemotherapy,Gemcitabine based regimen|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
58266356|NCT02026336|OTHER|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
58266357|NCT04198285|PROCEDURE|Retrograde bladder filling|The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
58266358|NCT03229629|BEHAVIORAL|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
58266359|NCT03229629|OTHER|Food Voucher (Monetary)|Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
58266360|NCT04907331|BIOLOGICAL|Vaxzevria|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
58266361|NCT04907331|BIOLOGICAL|Comirnaty|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
58386544|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
58386545|NCT02713334|BEHAVIORAL|survey|
58386546|NCT02713334|BEHAVIORAL|semi-structured interview|
58386547|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
58386548|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
57713017|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
57713018|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
58266362|NCT03509870|BIOLOGICAL|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
58386549|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
58386550|NCT01894724|DEVICE|NeuroSave device|
58386551|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
58386552|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
58386553|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
58386554|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
57713019|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
57713020|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
57914148|NCT06046963|DRUG|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
58061143|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
58266363|NCT02747797|DRUG|Lucitanib|10 mg orally daily
58266364|NCT04682262|PROCEDURE|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
58266365|NCT03408249|DIAGNOSTIC_TEST|IBDoc calprotectin test|Patients are asked to perform a single IBDoc calprotectin home test.
58266366|NCT03408249|OTHER|questionnaire|Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
58266367|NCT06621498|PROCEDURE|Ridge preservation technique|Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
58266368|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
58266369|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, full-thickness graft harversting and socket sealing with it.
58266370|NCT02407132|BEHAVIORAL|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
58266371|NCT02407132|BEHAVIORAL|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
58266372|NCT04429204|PROCEDURE|Biospecimen Collection|Undergo collection of tissue
58266373|NCT04429204|PROCEDURE|Cryosurgery|Undergo cryoablation
58266374|NCT00426140|DRUG|Patupilone|
58266375|NCT04738136|DRUG|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
58266376|NCT01726036|DEVICE|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
58386555|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
58386556|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
58386557|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
57713021|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
57713022|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
58266377|NCT01726036|DEVICE|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
58386558|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
58386559|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
57713023|NCT05044234|DRUG|Cedirogant|Capsule, Oral
57713024|NCT05044234|DRUG|Placebo|Capsule, Oral
57713025|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
58266378|NCT03251794|DIAGNOSTIC_TEST|three dimensional ultrasound|evaluation of the suprarenal glands
58266379|NCT03251794|DIAGNOSTIC_TEST|color Doppler|Doppler evaluation of the suprarenal artery
58386560|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
58386561|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
58386562|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
58386563|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
57713026|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
57713027|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
57713028|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
57713029|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
57713030|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
57713031|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
57713032|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
57914149|NCT06046963|OTHER|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
58266380|NCT04463732|OTHER|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
58266381|NCT01928797|DEVICE|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
58266382|NCT01980810|DRUG|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
58386564|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
57713033|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
57713034|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
57713035|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
57713036|NCT01228240|DRUG|Metformin|
57713037|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
57713038|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
57713039|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
57914150|NCT00183001|DRUG|Vitamin K|
57914151|NCT00897312|BIOLOGICAL|infliximab|
57914152|NCT00897312|BIOLOGICAL|pegylated interferon alfa|
57914153|NCT00897312|BIOLOGICAL|ticilimumab|
57914154|NCT00897312|DRUG|ribavirin|
57914155|NCT00897312|OTHER|high performance liquid chromatography|
57914156|NCT00897312|OTHER|laboratory biomarker analysis|
57914157|NCT01011387|PROCEDURE|NPWT System|Dressing change 3 times per week
57914158|NCT01011387|DEVICE|NPWT system|3 dressing changes/week for maximum 4 weeks.
58061144|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
58061145|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
57713040|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
57914159|NCT03310905|PROCEDURE|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
58061146|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
58061147|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
58061148|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
57914160|NCT03310905|PROCEDURE|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
57914161|NCT05584787|PROCEDURE|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
58061149|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
58061150|NCT01563224|DRUG|placebo|placebo
58061151|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
58061152|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
58386565|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
57914162|NCT04539782|OTHER|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
57914163|NCT00234767|DEVICE|Pulmonary Artery Catheter|
57914164|NCT00234767|BEHAVIORAL|Protocolized Fluid Management|
57914165|NCT02202382|DRUG|Korean Red Ginseng, Varicocelectomy|
57914166|NCT02202382|DRUG|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
57914167|NCT02202382|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
57914168|NCT01377753|DEVICE|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
57914169|NCT00834145|DEVICE|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
57914170|NCT01088828|OTHER|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
57914171|NCT05680038|DRUG|Penpulimab|Penpulimab is a modified PD1 inhibitor, which innovated the use of IgG1 subtype. On the basis of ensuring the stability of the antibody, it eliminated ADCC, ADCP, CDC and other effects that were not conducive to the efficacy of T cells and reduced the effect of ADCR by modifying the Fc segment
58061153|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
58061154|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
58061155|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
58061156|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
58061157|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
58061158|NCT01676649|DRUG|Carboplatin|AUC = 6
58061159|NCT01676649|DRUG|Paclitaxel|175 mg/m2
58061160|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
58061161|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
58061162|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
58061163|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
58061164|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
58061165|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
58061166|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
58061167|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
58061168|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
58061169|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
58061170|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
57713041|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
57713042|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
58061171|NCT00089505|DRUG|Nevirapine|200 mg taken orally
58061172|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
58061173|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
57914172|NCT04870684|OTHER|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
58266383|NCT01980810|DRUG|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
58386566|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
58386567|NCT00626886|DRUG|placebo collagen sponge|collagen
57914173|NCT01653067|DRUG|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
57914174|NCT00398645|DRUG|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
57914175|NCT03924908|BEHAVIORAL|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
58061174|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
58061175|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
58061176|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
58061177|NCT00065221|DRUG|Ginger|
58061178|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
58061179|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
58386568|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
57914176|NCT03924908|BEHAVIORAL|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
57914177|NCT02667587|DRUG|Nivolumab|
57914178|NCT02667587|DRUG|Temozolomide|
57914179|NCT02667587|RADIATION|Radiotherapy|
57914180|NCT02667587|OTHER|Nivolumab Placebo|
57914181|NCT04592042|BEHAVIORAL|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
57914182|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
57914183|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
57914184|NCT00153062|DRUG|Clopidogrel placebo|placebo
57914185|NCT00153062|DRUG|Clopidogrel placebo|placebo
57914186|NCT00153062|DRUG|Micardis|80 mg micardis
57914187|NCT00153062|DRUG|Micardis|80 mg micardis
57914188|NCT00153062|DRUG|Aggrenox placebo|placebo
57914189|NCT00153062|DRUG|Aggrenox placebo|placebo
57914190|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
57914191|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
57914192|NCT00153062|DRUG|Micardis placebo|placebo
57914193|NCT00153062|DRUG|Micardis placebo|placebo
57914194|NCT02810548|PROCEDURE|OFD alone|Periodontal surgical cleaning procedure
57914195|NCT02810548|DRUG|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
57914196|NCT02810548|DRUG|Nanohydroxyapatite|Synthetic bone graft
57914197|NCT00505284|DRUG|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
57914198|NCT00505284|DRUG|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
57914199|NCT00505284|DRUG|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
58061180|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
58061181|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
58061182|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
58061183|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
58061184|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
58061185|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
58061186|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
58061187|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
58266384|NCT00393263|DRUG|pimecrolimus and clobetasol|
58266385|NCT00393263|DRUG|clobetasol 0.05% cream|twice daily for three months
57713043|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
57713044|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
57713045|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
57713046|NCT01166594|DRUG|Bevacizumab|Intrableb injection
57713047|NCT01166594|DRUG|Control|intrableb BSS injection
57713048|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
57713049|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as stand-alone therapy and another minimum of approximately 15 patients (maximum of 20) will receive ECCO2R using PrismaLung+ in combination with CRRT.
57713050|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
57914200|NCT00505284|DRUG|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
57914201|NCT00505284|DRUG|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
58266386|NCT06619028|DEVICE|Weighted vest|During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
58266387|NCT04948554|BIOLOGICAL|MK-2225|Administered Subcutaneously (SC)
58266388|NCT04948554|BIOLOGICAL|Placebo|Administered SC
58266389|NCT00204503|DRUG|Depakote ER|
58266390|NCT01846221|DRUG|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
58266391|NCT01846221|DRUG|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
58266392|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
58266393|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
57914202|NCT01731509|OTHER|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
57914203|NCT02335710|DEVICE|Journey II BCS TKA|
58266394|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
57914204|NCT06006689|DRUG|Qishen Yiqi Dripping Pills placebo 3 bags|Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
57914205|NCT06006689|DRUG|Low dose Qishen Yiqi Dripping Pills 3 bags|Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
57914206|NCT06006689|DRUG|High dose Qishen Yiqi Dripping Pills 3 bags|High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
57914207|NCT02501798|DRUG|Methylphenidate|Drug: Methylphenidate
57914208|NCT02501798|DRUG|Placebo|Drug: Placebo
57914209|NCT01248780|DRUG|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
57914210|NCT01248780|DRUG|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
58266395|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
57914211|NCT01248780|DRUG|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
58061188|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
58266396|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
58266397|NCT01168310|DRUG|Formoterol Fumarate|Inhalation Solution
58266398|NCT01168310|DRUG|Placebo|Inhalation Solution
58266399|NCT06404060|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
58266400|NCT06404060|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
58266401|NCT03688958|DRUG|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
58266402|NCT03688958|DRUG|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
57713051|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
57914212|NCT06171581|OTHER|stress ball|In the study, the experimental group was given a round, compressible ball for stress ball application and it was planned to squeeze this ball in their hands as often as they wanted during anaesthesia and endometrial biopsy application. The endometrial biopsy procedure is a procedure that usually takes between 8-10 minutes. The results will be evaluated considering these average times. As it is foreseen that individuals may experience the most intense anxiety and stress during anaesthesia and biopsy, it was preferred to cover this time period.
57914213|NCT06171581|OTHER|control|In the study, the no intervention group ( control group) will receive no intervention and blood pressure and stress measurements will be made with routine care and nursing interventions.
57914214|NCT02112838|DRUG|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
57914215|NCT02112838|DRUG|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
58386569|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
57914216|NCT02112838|DRUG|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
57914217|NCT04690868|DRUG|AD-213-A|1 tablet administered before the breakfast during 5 days
57914218|NCT04690868|DRUG|AD-2131|1 tablet administered before the breakfast during 5 days
57914219|NCT00933855|BEHAVIORAL|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
57914220|NCT05023603|DIAGNOSTIC_TEST|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
58386570|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
57914221|NCT00999674|OTHER|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
57914222|NCT02671370|OTHER|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
57914223|NCT00901186|DRUG|RFB002|0.5 mg
57914224|NCT00901186|PROCEDURE|Laser photocoagulation|
57914225|NCT01506609|DRUG|Placebo|
57914226|NCT01506609|DRUG|Veliparib|
57914227|NCT01506609|DRUG|Carboplatin|
57914228|NCT01506609|DRUG|Temozolomide|
57914229|NCT01506609|DRUG|Paclitaxel|
57914230|NCT02789046|PROCEDURE|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
57914231|NCT04961658|BIOLOGICAL|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
57914232|NCT01828788|DRUG|Ropivacaine|
57914233|NCT01828788|DRUG|placebo|
58386571|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
57713052|NCT01848990|DRUG|Insulin lispro|
57713053|NCT01848990|DRUG|Insulin aspart|
57713054|NCT01848990|DRUG|Insulin glulisine|
57713055|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
57713056|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
57713057|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
57713058|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
57713059|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
57713060|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
57914234|NCT04932668|OTHER|Feasibility and Impact of Home-based Electrical Stimulation Program|"Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion."
57914235|NCT02550470|DEVICE|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
57914236|NCT02550470|DEVICE|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
57914237|NCT02550470|DRUG|Sevoflurane|
57914238|NCT00459615|DRUG|Artesunate for Injection|
57914239|NCT00528645|DRUG|saracatinib|Given orally
58386572|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
58386573|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
58061189|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
58386574|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
57713061|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
57713062|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
57713063|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
57914240|NCT00435591|DRUG|Conivaptan|ampoule or premix bag
58061190|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
58061191|NCT02355860|BEHAVIORAL|assessment|assessment
58386575|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
58386576|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
58386577|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
57713064|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
57713065|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
57713066|NCT02919670|OTHER|Standard Supportive Care|
57713067|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
57713068|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
57713069|NCT03069027|DRUG|saline adrenaline|
57713070|NCT03069027|DRUG|Xylocaine, adrenaline|
57713071|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
57713072|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
57914241|NCT00435591|DRUG|placebo|ampoule or premix bag
57914242|NCT02561754|DIETARY_SUPPLEMENT|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
58061192|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
57914243|NCT02561754|DIETARY_SUPPLEMENT|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
57914244|NCT02561754|BEHAVIORAL|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
58386578|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
58386579|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
58386580|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
58386581|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
58386582|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
58386583|NCT00755963|DRUG|placebo|maltodextrin
58386584|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
58386585|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
58386586|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
58386587|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
57713073|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
57713074|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
57713075|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
57713076|NCT02483234|DRUG|secukinumab|
57713077|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
57914245|NCT02561754|BEHAVIORAL|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
57914246|NCT02561754|OTHER|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
57914247|NCT02951767|DRUG|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
57914248|NCT06328751|DEVICE|Case group|Meditation will be taught through a video played on a Samsung® gear VR virtual reality glasses with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
57914249|NCT06328751|BEHAVIORAL|Active control group|Meditation will be taught through a video played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
57914250|NCT06328751|BEHAVIORAL|Passive control group|Meditation will be taught through a audio played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
57914251|NCT00559702|DRUG|natalizumab|natalizumab
57914252|NCT00559702|OTHER|standard of care|standard of care as determined by the Investigator and Treating Neurologist
58061193|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
58061194|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
58061195|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
57713078|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
57713079|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
57713080|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
57713081|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
57713082|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
57713083|NCT00029731|DRUG|Arginine hydrochloride|
57713084|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
57713085|NCT02360618|DRUG|Metformin|See Group Description
57713086|NCT02360618|DRUG|Simvastatin|See Group Description
57713087|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
57713088|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
57713089|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
57713090|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
57713091|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
57914253|NCT05316415|OTHER|Acemaşiran Music Group|Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
57914254|NCT02075541|BIOLOGICAL|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
57914255|NCT02075541|DRUG|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
57914256|NCT01948726|RADIATION|Hypofractionation with simultaneous integrated boost|
57914257|NCT05502549|DRUG|CB03-154|CB03-154 tablet once daily.
57914258|NCT05502549|DRUG|Placebo|Placebo tablet once daily.
57914259|NCT06258460|OTHER|psychotherapy training program intervention|The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
57914260|NCT06258460|OTHER|the wail-list control intervention|The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
58061196|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
58061197|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
58061198|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
58061199|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
58061200|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
57713092|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
57713093|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
57713094|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
57713095|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
57713096|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
57713097|NCT02433834|DRUG|Serevent Diskus 50 μg|
57713098|NCT02433834|DRUG|Placebo|
57713099|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
57713100|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
57713101|NCT00225355|DRUG|Rosiglitazone|
58266403|NCT03688958|DRUG|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
58061201|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
58386588|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
57713102|NCT02679586|DEVICE|Diffusion weighted MRI|
57914261|NCT04878653|DEVICE|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
57914262|NCT01650246|DRUG|lesinurad|Tablets, 400 mg QD
58061202|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
58266404|NCT03688958|DRUG|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
58266405|NCT01656278|PROCEDURE|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)"
58386589|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
57914263|NCT01586637|OTHER|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
58386590|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
58386591|NCT04187248|DRUG|Asparaginase|
57914264|NCT01586637|OTHER|Walking|The group walked twice a week during one hour.
57914265|NCT04842097|BEHAVIORAL|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
57914266|NCT02936128|OTHER|TruSkin|
58386592|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
58386593|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
58061203|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
58266406|NCT01656278|OTHER|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2"
58386594|NCT00243945|DRUG|Rotigotine|
58386595|NCT01525862|DEVICE|Balloon sinus dilation|
58386596|NCT01654874|DRUG|99mTc-MIP-1404|
58386597|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
58386598|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
58386599|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
58386600|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
58386601|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
58386602|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
58386603|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
58386604|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
58386605|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
58386606|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
58386607|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
58386608|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
58386609|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
58386610|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
58386611|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
58386612|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
58386613|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
57713103|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
57713104|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
57713105|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
57713106|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
58266407|NCT06623773|DRUG|Chondroitin sulfate|Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.
57713107|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
57713108|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
57713109|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
57914267|NCT02936128|OTHER|Wound Cover|
57914268|NCT00371228|PROCEDURE|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
57914269|NCT02584803|RADIATION|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~1. Patient Acceptability of procedure~2. Patient Comfort:~3. Ease of exam for the examiner"
57914270|NCT06096987|OTHER|Electronic medical record portal videos|Teen to teen videos reviewing information about electronic medical record portals and information shared in electronic medical record portals.
57914271|NCT06096987|OTHER|General adolescent health videos|Teen to teen videos reviewing information about general adolescent health issues.
57914272|NCT01800084|DEVICE|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
57914273|NCT03120247|DRUG|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
57914274|NCT03120247|DRUG|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
57914275|NCT03120247|DRUG|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
57914276|NCT00612469|DRUG|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
58061204|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
57713110|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
57713111|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
57713112|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
57713113|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
57914277|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
57914278|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
57914279|NCT00612469|DRUG|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
57914280|NCT05191277|DRUG|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
57914281|NCT05191277|DRUG|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
57914282|NCT05191277|BEHAVIORAL|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
57713114|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
57914283|NCT05191277|BEHAVIORAL|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
58061205|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58386614|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
58386615|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
58386616|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
57713115|NCT02089750|OTHER|Orthotics|
57914284|NCT02157922|DRUG|alginate oligosaccharide|Inhalation
57914285|NCT01617304|OTHER|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
58061206|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
58266408|NCT01653860|BEHAVIORAL|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
58061207|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
58386617|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
58386618|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
58386619|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
58386620|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
58386621|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
58386622|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
58386623|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
58386624|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
58386625|NCT01901614|DRUG|Topical Anesthesia|
58061208|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
58266409|NCT01653860|BEHAVIORAL|Ordinary group treatment|group treatment 8 weeks (16 hours)
58266410|NCT03101722|DRUG|BTHE and Huperzine A|huperzine A intervention
58266411|NCT03101722|OTHER|BETH|basic treatment and health education
58266412|NCT05755386|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
58061209|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
58266413|NCT05755386|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
58266414|NCT04891211|DIETARY_SUPPLEMENT|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
58266415|NCT00160225|DRUG|Daglutril|
58266416|NCT00101075|DRUG|Capecitabine|
58266417|NCT00101075|DRUG|Oxaliplatin|
58266418|NCT00663897|DRUG|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
58266419|NCT00663897|DRUG|mosapride|mosapride, 5 mg, thrice daily for 14 days
58266420|NCT00245076|BEHAVIORAL|smoking cessation intervention|
58266421|NCT00245076|OTHER|internet-based intervention|
58266422|NCT02657577|OTHER|There is no intervention|There is no intervention
58266423|NCT01312714|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
58266424|NCT01312714|DRUG|Placebo|3 tablets of 1000 IU daily for 26 weeks
58266425|NCT05545020|DRUG|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
57713116|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
57713117|NCT02089750|OTHER|Wait List|
57713118|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
57713119|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
57713120|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
57713121|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
57713122|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
57713123|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
57713124|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
57914286|NCT05780320|OTHER|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
57914287|NCT01656382|DRUG|ABLC|
57914288|NCT04048954|DEVICE|Applitabac|Smartphone application in screening on tabagism complications
58266426|NCT02090621|PROCEDURE|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
58386626|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
58386627|NCT00003730|DRUG|fluorouracil|
58386628|NCT00003730|DRUG|vinorelbine tartrate|
57713125|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
57914289|NCT00151151|BEHAVIORAL|Computer-Assisted Motivational Intervention|
57914290|NCT00151151|BEHAVIORAL|Didactic Educational Counseling|
57914291|NCT05902312|DEVICE|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
57914292|NCT02641678|DEVICE|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
57914293|NCT02843477|DEVICE|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
57713126|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
57713127|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
58266427|NCT06647082|DEVICE|Pediatric Knee Exoskeleton|The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
58266428|NCT03444051|PROCEDURE|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
58266429|NCT03444051|PROCEDURE|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
57713128|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
58386629|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
58386630|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
58061210|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
57713129|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
58061211|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
58061212|NCT00143728|DRUG|Lamivudine|See Detailed Description.
58266430|NCT03449992|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
58266431|NCT03449992|DIETARY_SUPPLEMENT|Placebo|Placebo drink
58266432|NCT05148403|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
58061213|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
58061214|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
58061215|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
58061216|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
58061217|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
58061218|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
58061219|NCT04411472|OTHER|Placebo|Placebo
58061220|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
58061221|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
58061222|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
58061223|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
58061224|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
58061225|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
58266433|NCT00091637|DRUG|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
58266434|NCT00091637|DRUG|Placebo infusion|bolus infusion over a 10 minute period once
58266435|NCT02953106|DRUG|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
58266436|NCT02953106|DRUG|Placebos|Placebo nasal spray
58266437|NCT02610829|DIETARY_SUPPLEMENT|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
58386631|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
58386632|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
58386633|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
58266438|NCT04045184|OTHER|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
57713130|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
57713131|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
57713132|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
57713133|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
57713134|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
57713135|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
57713136|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
57713137|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
57713138|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
58266439|NCT01044511|BEHAVIORAL|Home visits|home visits by specialist nurse 2 times and 1 phonecall
58266440|NCT01044511|BEHAVIORAL|standard|hotline
57713139|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
57713140|NCT03643822|OTHER|Saline|Control/Placebo intervention
58266441|NCT00126100|DRUG|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
57713141|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
58266442|NCT00126100|OTHER|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
58266443|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|Subconjunctival daily or bid
58386634|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
57713142|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
57713143|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
57713144|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
57713145|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
58386635|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
57713146|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
57713147|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
57713148|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
58266444|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical and systemic
58266445|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical systemic
58266446|NCT06355167|DIETARY_SUPPLEMENT|Bacopa monnieri|Daily oral intake of Bacopa monnieri during 6 weeks
58266447|NCT00196339|DRUG|Cyproterone acetate 5|Cyproterone acetate 5 mg
58266448|NCT00196339|DRUG|Placebo|Matching placebo
58266449|NCT00196339|DRUG|Cyproterone acetate 15|Cyproterone acetate 15 mg
58266450|NCT00196339|DRUG|Cyproterone acetate 25|Cyproterone acetate 25 mg
58266451|NCT03104426|DRUG|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
58266452|NCT05356962|BEHAVIORAL|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
57713149|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
57713150|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
57713151|NCT01433263|DRUG|BYM338 active drug|
57713152|NCT01433263|DRUG|Placebo|
57713153|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
57713154|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
58266453|NCT02342548|DRUG|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
57713155|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
57713156|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
57713157|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
57713158|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
58266454|NCT02232854|BEHAVIORAL|Depression training/supervision program|"The intervention will be composed of:~* Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~* After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~* Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~* Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
57713159|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
57713160|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
57713161|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
57713162|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
57713163|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
57713164|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
57713165|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
58266455|NCT03541954|OTHER|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
58386636|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
58061226|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
58061227|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
58061228|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
57713166|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
57713167|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
57713168|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
58061229|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
58266456|NCT03541954|OTHER|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
57713169|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
57713170|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
58061230|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
58061231|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
58061232|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
58061233|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
58061234|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
58061235|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
58061236|NCT01128855|OTHER|Placebo|Weekly Placebo
58386637|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
58386638|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
58386639|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
58386640|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
58386641|NCT00302744|OTHER|Niacin|Active Placebo
58386642|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
58386643|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
58386644|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
58386645|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
58386646|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
58386647|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
58386648|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
58386649|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
58386650|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
57713171|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
58061237|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
58386651|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
58386652|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
58386653|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
58386654|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
58386655|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
58061238|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
58061239|NCT00174876|DRUG|Drug Abilify|
58061240|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
58266457|NCT03541954|OTHER|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
58266458|NCT03541954|OTHER|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
58386656|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
58386657|NCT00395499|DRUG|Risperidone|
58386658|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
58386659|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
58386660|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
58386661|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
58386662|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
58386663|NCT00480831|DRUG|placebo|Intravenous repeating dose
58386664|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
58386665|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
58266459|NCT01632150|BIOLOGICAL|Elotuzumab|Powder for solution, 400-mg vials, for infusion
57713172|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
58061241|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
58266460|NCT01632150|BIOLOGICAL|Thalidomide|50-mg capsules administered orally
58266461|NCT01632150|BIOLOGICAL|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
58266462|NCT01632150|BIOLOGICAL|Cyclophosphamide|50-mg tablets administered orally
58266463|NCT04909268|DIAGNOSTIC_TEST|HIV testing|serology for HIV testing
58266464|NCT00139100|DRUG|antimicrobial agent in soap|
58266465|NCT02603562|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
58266466|NCT05738122|OTHER|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
58386666|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
58386667|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
58061242|NCT00779233|DRUG|Zidovudine tablets 300 mg|
58061243|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
58061244|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
58266467|NCT05249283|OTHER|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
58266468|NCT05836857|BEHAVIORAL|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
58266469|NCT05836857|BEHAVIORAL|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
58266470|NCT02660606|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
57713173|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
57713174|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
58061245|NCT01371799|DRUG|Drug|Placebo
58061246|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
58061247|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
58061248|NCT02005718|DRUG|Cholecalciferol|
58266471|NCT01484093|OTHER|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
58266472|NCT00558896|DRUG|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
58266473|NCT00558896|DRUG|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
58266474|NCT02132975|DEVICE|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
58266475|NCT02132975|PROCEDURE|Biopsies using UroStation® (image fusion)|
58386668|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
58061249|NCT01021553|DRUG|GSK557296|50 mg GSK557296
58061250|NCT01021553|DRUG|GSK557296|150 mg GSK557296
58061251|NCT01021553|DRUG|placebo|placebo
58061252|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
58061253|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
58061254|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
58061255|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
58061256|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
58061257|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
58386669|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
58386670|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
58386671|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
58386672|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
57914294|NCT03871842|DEVICE|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
58266476|NCT05731869|OTHER|epicondylitis band|An off-the-shelf lateral epicondylitis tape in S-M-L dimensions was used distal to the lateral epicondylitis.
58266477|NCT05731869|OTHER|wrist orhosis|Wrist orthosis of the shelf was used in sizes S-M-L, covering the hand and wrist.
58061258|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
58061259|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
58266478|NCT04064164|BEHAVIORAL|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
57713175|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
58266479|NCT03067675|DEVICE|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
58266480|NCT05308602|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
58266481|NCT05308602|BIOLOGICAL|SCTV01C|Day 28; intramuscular injection
58266482|NCT05308602|BIOLOGICAL|SCTV01C|Day 180; intramuscular injection
57713176|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
57713177|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
57713178|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
57713179|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
57914295|NCT03871842|DEVICE|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
57914296|NCT02780154|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
58061260|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
58061261|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
58061262|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
58061263|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
58266483|NCT05308602|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
58266484|NCT05308602|BIOLOGICAL|SCTV01E|Day 28; intramuscular injection
58266485|NCT05308602|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
58266486|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 0; intramuscular injection
58266487|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 28; intramuscular injection
58266488|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 180; intramuscular injection
58266489|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
58266490|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 28; intramuscular injection
58266491|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 180; intramuscular injection
58266492|NCT02913027|OTHER|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
58266493|NCT02913027|OTHER|Bimanual Exam|
58266494|NCT02913027|OTHER|Speculum Exam|
58266495|NCT01222377|PROCEDURE|endoscopic surgery|Undergo endoscopic breast surgery
58266496|NCT01222377|PROCEDURE|quality-of-life assessment|Ancillary studies
57914297|NCT02780154|BIOLOGICAL|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
58061264|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
58266497|NCT04160572|BEHAVIORAL|Morning sleep schedule|sleep right after night shifts
58266498|NCT04160572|BEHAVIORAL|Evening sleep schedule|sleep before night shifts
58266499|NCT02361554|DEVICE|Medtronic Percept with SensSight Deep Brain Stimulation System|Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
58386673|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
57914298|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
57914299|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
57914300|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
57914301|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
57914302|NCT04433546|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
58386674|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
57914303|NCT04433546|DRUG|Low Dose (10 mg) Control|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
57914304|NCT03549533|OTHER|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
57914305|NCT05496946|OTHER|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
57914306|NCT00475930|DRUG|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
57914307|NCT00475930|DRUG|Comfort Bath cloths (placebo cloths)|self applied three times weekly
57914308|NCT05951296|DRUG|Leramistat|Drug: Leramistat
57914309|NCT05951296|DRUG|Placebo|Placebo comparator
58061265|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
58061266|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
58061267|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
58061268|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
58061269|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
58266500|NCT00985959|DRUG|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
58266501|NCT00985959|DRUG|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
58386675|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
58386676|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
57914310|NCT01013597|DRUG|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
57914311|NCT04540393|BIOLOGICAL|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
57914312|NCT03819738|DIAGNOSTIC_TEST|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
57914313|NCT04281550|OTHER|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
58061270|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
57914314|NCT01844947|DRUG|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance \>60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
58061271|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
58061272|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
58061273|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
58061274|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
58061275|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
58061276|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
58061277|NCT02897011|DRUG|Methotrexate|
58061278|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
58061279|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
58061280|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
58061281|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
58061282|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
58061283|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
58061284|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
58061285|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
58061286|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
58061287|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
58061288|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
58061289|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
58266502|NCT00985959|DRUG|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
58061290|NCT03449186|OTHER|Saliva collection|
58061291|NCT03449186|OTHER|GCF collection|
58061292|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
58061293|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
58061294|NCT00641979|DRUG|budesonide|Current product
58061295|NCT00641979|DEVICE|Budesonide|New type device
58061296|NCT00641979|DRUG|Placebo|
58061297|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
58061298|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
58061299|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
58061300|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
58061301|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
58061302|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
58061303|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
58061304|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
58061305|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
58061306|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
58061307|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
57914315|NCT01844947|DRUG|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
57914316|NCT02582567|OTHER|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
58061308|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
58061309|NCT00004166|DRUG|amifostine trihydrate|
58061310|NCT00004166|PROCEDURE|quality-of-life assessment|
58061311|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
58061312|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
58061313|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
57713180|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
57713181|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
58061314|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
58061315|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
58061316|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
58266503|NCT00985959|DRUG|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
58266504|NCT00985959|DRUG|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
57713182|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
57713183|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
57713184|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
57713185|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
58061317|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
58061318|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
58061319|NCT00983944|BIOLOGICAL|rituximab|Given IV
58061320|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
58061321|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
58061322|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
57914317|NCT01822301|PROCEDURE|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
58061323|NCT00983944|DRUG|etoposide|Given IV or orally
58061324|NCT00983944|DRUG|prednisone|Given IV or orally
58061325|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
58061326|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
58061327|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
58266505|NCT05968027|OTHER|"Nouveal numeric application Onco'nect"|A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
58386677|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
58386678|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
58386679|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
57914318|NCT01012713|DRUG|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
57914319|NCT01012713|DRUG|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
57914320|NCT01012713|PROCEDURE|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
58061328|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
58061329|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
58061330|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
58061331|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
58061332|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
58061333|NCT01943136|DRUG|papaya 1% extract ointment|
58386680|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
58386681|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
57713186|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
57914321|NCT02364791|DEVICE|standard techniques used to achieve air leak control|
57914322|NCT02364791|DEVICE|Hemopatch|
58061334|NCT01943136|DRUG|mupirocin 2% ointment|
58061335|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
58061336|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
58061337|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
57713187|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
57713188|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
57713189|NCT01844635|DRUG|Thymoglobulin|
57914323|NCT01958307|BEHAVIORAL|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
57713190|NCT00225706|DRUG|Caldolor|
57914324|NCT01006473|OTHER|Exercise training|
58061338|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
58061339|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
58061340|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
58061341|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
58061342|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
58061343|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
58061344|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
57914325|NCT06299085|OTHER|50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
58061345|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
58061346|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
58061347|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
58061348|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
57713191|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
57914326|NCT04388397|PROCEDURE|Arteriovenous Grafts|Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
58061349|NCT01022918|DRUG|Temodal/radiotherapy|
58061350|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
58061351|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
58061352|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
58061353|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
58386682|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
57914327|NCT03536299|OTHER|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
57914328|NCT03536299|OTHER|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
57914329|NCT04537182|PROCEDURE|Lung volume reduction surgery|Lung volume reduction by surgery
57914330|NCT04537182|PROCEDURE|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
57914331|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
57914332|NCT01613560|DRUG|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
57914333|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
57914334|NCT02768870|DEVICE|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
58266506|NCT03994614|OTHER|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
57713192|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
57914335|NCT05788211|OTHER|standard of care|retrospective study: standard of care
57914336|NCT00104663|DRUG|Quinacrine|
57914337|NCT00705354|DRUG|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
57914338|NCT00705354|PROCEDURE|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
57914339|NCT04694404|DRUG|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
57914340|NCT06199674|DEVICE|photobiomodulation therapy|Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
57914341|NCT06199674|OTHER|orthodontic fixed-appliance|All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
57914342|NCT05162989|DEVICE|iCare HOME2 vs iCare IC200|Measurement of IOP with iCare HOME2 compared with iCare IC200.
57914343|NCT00903630|DRUG|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
57914344|NCT00903630|DRUG|liposomal doxorubicin|administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
57914345|NCT06244485|DRUG|Valemetostat tosylate|Administered orally once daily
57914346|NCT06244485|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
57914347|NCT06244485|DRUG|Dato-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle.
58266507|NCT02872857|DRUG|Placebo|Placebo will match drug capsules.
58266508|NCT02872857|DRUG|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
58266509|NCT02872857|DRUG|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
58061354|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
58061355|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
58061356|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
58061357|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
58061358|NCT01681537|DRUG|Lenalidomide|
57713193|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
58061359|NCT01681537|DRUG|Mitoxantrone|
58061360|NCT01681537|DRUG|Etoposide|
58061361|NCT01681537|DRUG|Cytarabine|
58061362|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
58061363|NCT02182856|DRUG|Ipratropium 500 µg|
58061364|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
58061365|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
58266510|NCT03619759|DRUG|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
58266511|NCT02835950|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
57914348|NCT03213860|OTHER|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
57914349|NCT03869151|DIAGNOSTIC_TEST|CBC|lymphocyte and monocyte count
57914350|NCT01670760|DEVICE|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
57914351|NCT02036879|DRUG|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
57914352|NCT04690530|PROCEDURE|mechanical ventilation|mechanical vantilation will be performed
57914353|NCT04690530|DRUG|Sedation|sedation wil be performed
57914354|NCT02628782|DEVICE|InSeal's Vascular Closure Device|Intravascular closure device
57914355|NCT04789772|DEVICE|Laser acupuncture|The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
57914356|NCT01206543|OTHER|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
57914357|NCT01362257|DRUG|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
57914358|NCT01362257|DRUG|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
57914359|NCT02926144|DEVICE|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
57914360|NCT02926144|DEVICE|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
57914361|NCT03868072|DRUG|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
57914362|NCT03868072|DRUG|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
57914363|NCT00784693|BIOLOGICAL|Tanezumab|15 mg IV single dose
57914364|NCT00784693|DRUG|Placebo|Placebo IV single dose
57914365|NCT05846347|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
57914366|NCT01821287|OTHER|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
57914367|NCT00168623|DRUG|Vitamin A|
57914368|NCT02502799|BEHAVIORAL|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
57914369|NCT02502799|BEHAVIORAL|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
57914370|NCT02502799|DRUG|Methylphenidate|Adolescents will receive methylphenidate.
58386683|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
57914371|NCT05259020|COMBINATION_PRODUCT|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
57914372|NCT05259020|COMBINATION_PRODUCT|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
57914373|NCT02725801|DEVICE|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
57914374|NCT02725801|DEVICE|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
57914375|NCT06284720|DEVICE|Gamma tACS (40 Hz) over the precuneus|5 sessions of gamma tACS (40 Hz) over the precuneus
57914376|NCT06284720|DEVICE|Sham tACS over the precuneus|5 sessions of sham tACS over the precuneus
57914377|NCT01523925|BEHAVIORAL|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
57914378|NCT01523925|BEHAVIORAL|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
57713194|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
57914379|NCT01523925|BEHAVIORAL|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
57914380|NCT01523925|BEHAVIORAL|Functional electrical stimulation|
57914381|NCT00447811|DRUG|MOA-728|
57914382|NCT05660486|OTHER|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
58386684|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
57914383|NCT05660486|OTHER|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
57914384|NCT04908462|DRUG|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
57914385|NCT04908462|DRUG|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
57914386|NCT02650882|PROCEDURE|Device POWERbreathe|
57914387|NCT03139110|BEHAVIORAL|Presence of a mediator in the emergency departments|"The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
57914388|NCT02111187|DRUG|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
57914389|NCT03561012|BEHAVIORAL|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
57914390|NCT03561012|OTHER|Control Condition|Standard of care
57914391|NCT06063811|OTHER|Ablation|VT ablation
58061366|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
58386685|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
58386686|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
58386687|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
58266512|NCT04543318|PROCEDURE|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
58386688|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
58386689|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
58386690|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.
58386691|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.
58386692|NCT05989672|BIOLOGICAL|Placebo|This intervention will be administered intramuscular as 2 doses to Placebo group.
58386693|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
58386694|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
57914392|NCT03759951|BEHAVIORAL|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
58266513|NCT04543318|PROCEDURE|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
58386695|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
58386696|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
58386697|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
58386698|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
58386699|NCT03233139|DRUG|Fianlimab|To be administered per protocol
58386700|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
57713195|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
57713196|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
57914393|NCT03759951|BEHAVIORAL|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
57914394|NCT03759951|BEHAVIORAL|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
57914395|NCT03759951|BEHAVIORAL|Control|No training will be performed during a 1-year period. Participation only in measurements.
57914396|NCT01639781|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
57914397|NCT01639781|DIETARY_SUPPLEMENT|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
58266514|NCT04104932|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation
58266515|NCT05135884|BEHAVIORAL|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
58266516|NCT00150397|DRUG|Tofimilast|
58266517|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
58266518|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
58386701|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
58386702|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
58386703|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
58386704|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
58386705|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
57914398|NCT06610136|DIETARY_SUPPLEMENT|Caffeine plus Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
57914399|NCT06610136|OTHER|Placebo + Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
57914400|NCT05994404|PROCEDURE|ACDF|
57914401|NCT05994404|PROCEDURE|Posterior Cervical Fusion|
57914402|NCT05994404|PROCEDURE|Cervical Laminoplasty|
57914403|NCT04074863|PROCEDURE|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
57914404|NCT04074863|PROCEDURE|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
57914405|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
57914406|NCT01502020|DRUG|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
57914407|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
57914408|NCT02301260|BEHAVIORAL|Speed of Processing Training (SPT)|
57914409|NCT02301260|BEHAVIORAL|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
57914410|NCT04949360|BEHAVIORAL|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
57914411|NCT04949360|BEHAVIORAL|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
57914412|NCT04949360|BEHAVIORAL|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by regular mail and email.
57914413|NCT04296253|GENETIC|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
57914414|NCT05221671|OTHER|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
57914415|NCT01300962|DRUG|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
57914416|NCT01300962|DRUG|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
57914417|NCT01300962|DRUG|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
57914418|NCT01300962|DRUG|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
57914419|NCT01300962|DRUG|Lapatinib|lapatinib daily for 21 days in each cycle.
57914420|NCT04918667|COMBINATION_PRODUCT|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
57914421|NCT04918667|DIETARY_SUPPLEMENT|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
57914422|NCT01248065|DRUG|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
57914423|NCT01248065|DRUG|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
57914424|NCT00511901|DRUG|placebo|
58061367|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
57914425|NCT00511901|DRUG|epoetin alpha|
57914426|NCT00511901|DRUG|Niferex|
57914427|NCT06407596|DEVICE|high intensity laser|3 times per week, for 9 sessions
57914428|NCT06407596|DEVICE|tens+us|5 times per week, total 15 sessions for 3 weeks
57914429|NCT00150865|DRUG|ropivacaine|
57914430|NCT05813977|DEVICE|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
57914431|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
57914432|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58061368|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
58061369|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
57713197|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
57914433|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
57914434|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
57914435|NCT00386269|DRUG|Codeine Phosphate Analgesia|
57914436|NCT02331251|DRUG|Pembrolizumab|
57914437|NCT02331251|DRUG|Gemcitabine|
57914438|NCT02331251|DRUG|Docetaxel|
57713198|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
57914439|NCT02331251|DRUG|Nab-paclitaxel|
57914440|NCT02331251|DRUG|Vinorelbine|
58061370|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
58266519|NCT00655681|DRUG|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
58266520|NCT00655681|OTHER|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
58061371|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
58061372|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
58061373|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
58266521|NCT00691873|DRUG|Placebo|placebo
58266522|NCT00691873|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
58386706|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
58386707|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
58386708|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
58386709|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
57713199|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
57713200|NCT01985737|OTHER|Sample collection|
57914441|NCT02331251|DRUG|Irinotecan|
57914442|NCT02331251|DRUG|Liposomal Doxorubicin|
57914443|NCT06598722|DRUG|BCL-2 inhibitors combined with the HyperCVAD regimen|BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
57914444|NCT06598722|OTHER|Propensity score matching historical data|Propensity score matching was conducted with historical data (matching factors included age, gender, initial LDH levels, and the presence or absence of a large mediastinal mass at diagnosis) to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols.
57914445|NCT02389920|DRUG|Nilotinib|
57914446|NCT01991054|DIETARY_SUPPLEMENT|vitamin D3|
57914447|NCT01323634|DRUG|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
57914448|NCT01323634|DRUG|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
57914449|NCT04788511|DRUG|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
57914450|NCT04788511|DRUG|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
57914451|NCT01807013|PROCEDURE|ultrasound, liver elastometry, minilaparoscopy|"* conventional high-end ultrasound technique,~* small access laparoscopy with fine laparoscopes~* Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
57914452|NCT06183749|OTHER|hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit|diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment
57914453|NCT01618604|PROCEDURE|Quantitative Sensory Testing|following the standardized protocol of DFNS
57914454|NCT01618604|PROCEDURE|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
57914455|NCT01618604|PROCEDURE|Repetition of four QST parameters|"* warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)"
57914456|NCT04543487|OTHER|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
57713201|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
57713202|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
57914457|NCT04681599|DEVICE|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
57914458|NCT04681599|DEVICE|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
57914459|NCT05601947|OTHER|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
57914460|NCT05601947|OTHER|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
58266523|NCT05744037|BIOLOGICAL|regimen with BTK inhibitor +Anti-CD19 CAR T cells|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
57914461|NCT04803331|DIAGNOSTIC_TEST|SPIO-enhanced MRI|SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
57914462|NCT04293445|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
57914463|NCT04150601|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
57914464|NCT04150601|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
57914465|NCT04150601|OTHER|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
57914466|NCT00287066|DRUG|Inhaled Human Insulin|
57914467|NCT00287066|DRUG|Regular Human Insulin|
57914468|NCT00346632|DRUG|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
57914469|NCT00956748|DRUG|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
57914470|NCT00956748|DRUG|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
57914471|NCT04329507|DIAGNOSTIC_TEST|Breath test|collection of an exhaled breath sample
57914472|NCT05748691|DIAGNOSTIC_TEST|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
57914473|NCT04555382|DIAGNOSTIC_TEST|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
57914474|NCT04026880|DRUG|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
57914475|NCT04026880|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
58266524|NCT04481191|BIOLOGICAL|RotaTeq (V260)|Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
58266525|NCT04481191|BIOLOGICAL|IPV|0.5 mL dose IPV (Sabin strain based), administered via IM injection
58386710|NCT00002108|DRUG|Lamivudine|
57914476|NCT00862147|BEHAVIORAL|ICDP|Parent training group
57914477|NCT00862147|BEHAVIORAL|Treatment as usual|Parent and/or child focused interventions
57914478|NCT00005597|DRUG|temozolomide|200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
57914479|NCT02165254|BEHAVIORAL|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
57914480|NCT02165254|BEHAVIORAL|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
57914481|NCT01054170|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
57914482|NCT01054170|DRUG|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
57914483|NCT03173677|DIETARY_SUPPLEMENT|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
57914484|NCT03173677|DIETARY_SUPPLEMENT|Glucose intake|300 calories of glucose
57914485|NCT03173677|DIETARY_SUPPLEMENT|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
57914486|NCT02183051|DRUG|Meloxicam 7.5 mg|
57914487|NCT02183051|DRUG|Meloxicam 3.75 mg|
57914488|NCT02183051|DRUG|Meloxicam 1.875 mg|
57914489|NCT02183051|DRUG|Ibuprofen 200 mg|
57914490|NCT02183051|DRUG|Placebo|
57914491|NCT02183051|DRUG|Meloxicam 15 mg|
57914492|NCT02183051|DRUG|Ibuprofen 400 mg|
57914493|NCT03845569|OTHER|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
57914494|NCT03845569|OTHER|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
57914495|NCT04987086|DIAGNOSTIC_TEST|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
58386711|NCT00002108|DRUG|Zidovudine|
57914496|NCT03655821|DRUG|Pemetrexed|Dosing is either based on BSA or renal function
57914497|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
57914498|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
57914499|NCT00757783|DRUG|darunavir|800 mg tablet once daily for 48 weeks
57914500|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
58266526|NCT06622707|OTHER|kinesio taping|Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.
58266527|NCT06622707|OTHER|Routine clinical care|As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
58266528|NCT03769675|DEVICE|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
58266529|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (RhinAdvil(R))
58266530|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (BI product)
58266531|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (BI product)
58266532|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
58266533|NCT04398654|DEVICE|CardioMEMSTM HF sensor - pulmonary artery pressure measurement|CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
58386712|NCT01680354|PROCEDURE|ReLEx|
58386713|NCT01680354|PROCEDURE|LASIK|
58386714|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
58386715|NCT00154817|PROCEDURE|radiotherapy|
58386716|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
57914501|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
57914502|NCT00757783|DRUG|atazanavir|300 mg capsule once daily for 48 weeks
57914503|NCT02736305|DRUG|Regorafenib|Once a day for 21 days in a 28 days cycle
57914504|NCT01177579|DIETARY_SUPPLEMENT|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
57914505|NCT04532203|DRUG|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
57914506|NCT04532203|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
57914507|NCT02953860|DRUG|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
57914508|NCT01633983|DRUG|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
57914509|NCT01633983|DRUG|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
57914510|NCT00073866|DRUG|celecoxib|
57914511|NCT00073866|DRUG|docetaxel|
57914512|NCT00073866|DRUG|irinotecan hydrochloride|
57914513|NCT04703231|DIAGNOSTIC_TEST|measurement of macular thickness, corneal thickness and lens opacities|The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
57914514|NCT01688830|DRUG|Dabigatran|
57914515|NCT01688830|DRUG|BI 655075|
57914516|NCT01688830|DRUG|Placebo|
57914517|NCT01762891|DRUG|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
57914518|NCT01762891|DRUG|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
57914519|NCT01762891|DRUG|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
57914520|NCT01762891|DRUG|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
57914521|NCT01414140|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
57914522|NCT02558504|PROCEDURE|Oesophagectomy|
57914523|NCT02558504|DEVICE|Radiofrequency ablation|
57914524|NCT03418831|DRUG|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
57914525|NCT03418831|OTHER|Placebo|1 tablet daily for 12 weeks
57914526|NCT00818649|DRUG|bortezomib|1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
57914527|NCT00818649|DRUG|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
57914528|NCT01895283|BEHAVIORAL|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
57914529|NCT01408615|DRUG|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
58061374|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
58061375|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
58061376|NCT00039104|DRUG|rebimastat|Given PO
58061377|NCT00039104|DRUG|zoledronic acid|Given IV
57713203|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
57713204|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
57713205|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
57914530|NCT01648881|RADIATION|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
57914531|NCT01948908|DRUG|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
57914532|NCT02830945|BEHAVIORAL|Motivational Interviewing Intervention Arm|
58061378|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
58061379|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
58061380|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
57713206|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
57713207|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
57713208|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
57713209|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
58061381|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
58061382|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
58061383|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
58061384|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
57713210|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
57713211|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
57713212|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
57713213|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
57713214|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
57713215|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
57713216|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
57713217|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
57713218|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
57914533|NCT02830945|OTHER|Control Brochure Arm|
57914534|NCT00655291|DRUG|XP20B|
57914535|NCT00655291|DRUG|Placebo|
57914536|NCT04572113|DEVICE|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
57914537|NCT02032277|DRUG|Cyclophosphamide|Cyclophosphamide
57914538|NCT02032277|DRUG|Placebo|Placebo for Carboplatin
57914539|NCT02032277|DRUG|Doxorubicin|Doxorubicin
57914540|NCT02032277|DRUG|Paclitaxel|Paclitaxel
57914541|NCT02032277|DRUG|Carboplatin|Carboplatin
57914542|NCT02032277|DRUG|Veliparib|Veliparib
57914543|NCT02032277|DRUG|Placebo|Placebo for Veliparib
57914544|NCT00784355|PROCEDURE|Laparoscopic cholecystectomy|Surgery
57914545|NCT03715439|DEVICE|Dental implant|A single dental implant was inserted 3 months after tooth extraction
57914546|NCT04680754|OTHER|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
58061385|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
58061386|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
58061387|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
58061388|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
57914547|NCT00841880|DRUG|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
57914548|NCT00841880|DRUG|Ramipril|10 mg once a day
58061389|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
58061390|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
58386717|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
58061391|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
58061392|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
58061393|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
58061394|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
58061395|NCT01813149|OTHER|punch biopsy|
58061396|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
58061397|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
58061398|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
57713219|NCT00259558|DRUG|retarded release phosphatidylcholine|
57914549|NCT00841880|DRUG|Ramipril|5mg once a day
57914550|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
57914551|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
57914552|NCT03700073|OTHER|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
58061399|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
57914553|NCT03700073|OTHER|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
57914554|NCT03794687|PROCEDURE|Left heart catheterization|Catheterization via the distal radial artery
57914555|NCT05137015|OTHER|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~1. Balance~2. Core stability~3. Hamstring eccentrics~4. Glute activation~5. Plyometrics~6. Running~7. Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
57914556|NCT05379660|DEVICE|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 \~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
58061400|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
58061401|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
58061402|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
58061403|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
58061404|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
58061405|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
58061406|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
58061407|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
58061408|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
58061409|NCT03615690|OTHER|Regular Diet|Regular Diet
58061410|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
58061411|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
58061412|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
57713220|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
57713221|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
57713222|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
57713223|NCT04614766|DRUG|Lutathera|intravenous administration
57713224|NCT04614766|DRUG|Azedra|intravenous administration
57713225|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
57713226|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
57713227|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
57914557|NCT01657513|DRUG|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
57914558|NCT05351684|DRUG|Dolutegravir 50 MG|already included in arm/group descriptions.
57914559|NCT05074485|DRUG|anakinra|intravenous injection of 100 milligrams anakinra
57914560|NCT05074485|DRUG|Placebo|intravenous injection of 1 milliliter normal saline
57914561|NCT05074485|OTHER|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
57914562|NCT05134441|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
57914563|NCT05134441|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
57914564|NCT05358028|OTHER|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
57914565|NCT05358028|OTHER|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
57914566|NCT04854668|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
57914567|NCT04854668|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
57914568|NCT04854668|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
57914569|NCT04854668|DRUG|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
57914570|NCT01789645|OTHER|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
57914571|NCT01789645|PROCEDURE|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
57914572|NCT04666402|OTHER|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
57914573|NCT04666402|DIAGNOSTIC_TEST|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
57914574|NCT04666402|DIAGNOSTIC_TEST|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
58061413|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
58386718|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
57914575|NCT04617561|DRUG|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
57914576|NCT04617561|DRUG|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
57914577|NCT04219397|OTHER|Medication take back|Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
58386719|NCT04965792|OTHER|Screening|Blood test
58386720|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
57914578|NCT04219397|OTHER|Medication home disposal|Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
57914579|NCT05234112|BEHAVIORAL|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
57914580|NCT05234112|DIAGNOSTIC_TEST|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
57713228|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
57914581|NCT05234112|BEHAVIORAL|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
57914582|NCT05234112|DIAGNOSTIC_TEST|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
57914583|NCT05234112|PROCEDURE|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
57914584|NCT05234112|DIAGNOSTIC_TEST|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
57914585|NCT00619203|DRUG|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
58061414|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
58061415|NCT03008928|BEHAVIORAL|Alcooquizz|
58386721|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
58386722|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
57713229|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
57713230|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
57914586|NCT00619203|DRUG|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
57914587|NCT00619203|DRUG|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
57914588|NCT00619203|DRUG|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
57914589|NCT00619203|DRUG|Placebo|2 placebos, one po, one suppository
58266534|NCT00800813|BEHAVIORAL|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
58266535|NCT02707471|BEHAVIORAL|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
58266536|NCT02707471|BEHAVIORAL|general health education|general health education intervention that focuses on improving overall health.
58266537|NCT00846703|DRUG|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
57914590|NCT00619203|DRUG|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
57914591|NCT00619203|DRUG|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
57914592|NCT04067375|OTHER|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
57914593|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
57914594|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
57914595|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
57914596|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
58266538|NCT00846703|DRUG|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
57914597|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
57914598|NCT02796625|OTHER|Painful Stimuli|warm or painful heat administration
57914599|NCT00032526|DRUG|Corticosteroids|
58061416|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
58266539|NCT00250458|DRUG|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
58266540|NCT00250458|DRUG|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
57914600|NCT00032526|BEHAVIORAL|Classical conditioning to corticosteroid|
57914601|NCT03881618|PROCEDURE|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
57914602|NCT00239343|DRUG|gefitinib|
58266541|NCT04494763|DRUG|Propanolol|Non-selective Beta-blocker
57914603|NCT04650308|DIAGNOSTIC_TEST|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
57914604|NCT00414284|DRUG|Increased dose of Kaletra|
57914605|NCT04419883|DEVICE|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
57914606|NCT01721460|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
58061417|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
58061418|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
58061419|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
58266542|NCT04494763|OTHER|Placebo|Inactive drug
58386723|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
57713231|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
58386724|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
58386725|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
57713232|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
57713233|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
58386726|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
57713234|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
57713235|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
57713236|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
58061420|NCT02357524|DRUG|Oritavancin|
58061421|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
58061422|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
58266543|NCT03639805|OTHER|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
58266544|NCT03639805|OTHER|standard care of vaso-occlusive crises|administration of standard care only
58266545|NCT06011460|DRUG|Clozapine|"Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old."
58386727|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
58386728|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
58386729|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
58386730|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
57713237|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
57713238|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
57713239|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
57713240|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
57713241|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
57713242|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
57713243|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
57713244|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
57713245|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
57713246|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
57713247|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
57713248|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
57713249|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
57713250|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
58061423|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
58061424|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
58061425|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
58266546|NCT04303936|DEVICE|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
58266547|NCT06526650|OTHER|'Ai Pono|"Hands-on Cooking and Cultural Lessons These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare."
58266548|NCT05997823|OTHER|kinesiotape|The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension
58266549|NCT05997823|OTHER|home exercises|home exercises
58266550|NCT06620822|DRUG|IBI363|IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.
58266551|NCT06620822|DRUG|LM-108+Sintilimab|LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.
58266552|NCT06620822|DRUG|IBI310+Sintilimab|The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.
58386731|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
58386732|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
58061426|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
58061427|NCT03040479|DRUG|lasmiditan 200 mg|single dose
58061428|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
57713251|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
57713252|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
57713253|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
57713254|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
57713255|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
57713256|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
57713257|NCT02359292|DRUG|Placebo pMDI|
57713258|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
57713259|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
57713260|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
57713261|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
57713262|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
57713263|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
58386733|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
58386734|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
58386735|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
58266553|NCT06620822|DRUG|Sintilimab|Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
58386736|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
58386737|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
58386738|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
58386739|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
57713264|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
57713265|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
58386740|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
58386741|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
57713266|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
57713267|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
57713268|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
58266554|NCT05884424|BEHAVIORAL|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
58266555|NCT03243344|DEVICE|Surgiflo|using device during the endonasal surgery.
57713269|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
57713270|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
58386742|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
58386743|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
58386744|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
58386745|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
57713271|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
57713272|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
57713273|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
58266556|NCT03243344|DEVICE|Floseal|using device during the endonasal surgery.
58266557|NCT03243344|DEVICE|Algosteril|using device during the endonasal surgery.
58266558|NCT02495194|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
58266559|NCT03916731|DEVICE|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
57713274|NCT05676034|DRUG|AMX0035|AMX0035
57713275|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
57713276|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
57713277|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
57713278|NCT05784701|DRUG|Placebo|Placebo
57713279|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
57713280|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
57713281|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
57713282|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
57713283|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
57713284|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
57713285|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
57713286|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
57713287|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
57713288|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
58386746|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
58386747|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
58386748|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
58386749|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
58386750|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
58061429|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
57914607|NCT04563286|OTHER|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
57914608|NCT04015999|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
58061430|NCT02186340|PROCEDURE|Inspiratory muscle training|
58061431|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
58061432|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
58061433|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
58061434|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
58061435|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
58061436|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
58061437|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
58061438|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
58061439|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
58061440|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
58061441|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
58061442|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
58061443|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
58061444|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
58061445|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
58386751|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
58061446|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
58061447|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
58061448|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
58061449|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
57713289|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
58061450|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
58061451|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
58061452|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
58061453|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
58386752|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
57914609|NCT04015999|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
58061454|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
58266560|NCT03916731|DEVICE|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
58266561|NCT04692766|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
58386753|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
58386754|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
58386755|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
58386756|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
58386757|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
58386758|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
58386759|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
58266562|NCT04692766|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
58266563|NCT01346540|DRUG|BIBF 1120|VEGF inhibitor
58266564|NCT01346540|DRUG|Placebo|BIBF 1120 placebo
57914610|NCT00320827|DRUG|CS-1008 (humanized anti-DR5 antibody)|
57914611|NCT06138054|BEHAVIORAL|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
58061455|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
58266565|NCT05850390|OTHER|Respiratory-Responsive Vocal Biomarker application|"A smartphone app that allows participants to receive a respiratory-responsive vocal biomarker (RRVB) score by recording a 6-second held ahh vowel elicitation. The applications returns the RRVB score which has previously been validated to correspond to the likelihood that the user's voice is similar to those of people diagnosed with asthma. This study will examine if the RRVB scores correlate with respiratory function and symptoms in asthma patients."
58266566|NCT06416020|BEHAVIORAL|HC-MOUD Only|MOUD with buprenorphine provided in a hub buprenorphine clinic
57713290|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
57713291|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
57713292|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
57713293|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
57713294|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
57713295|NCT00667238|BEHAVIORAL|Questionnaire|
57713296|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
57713297|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
57713298|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
57713299|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
57713300|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
57713301|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
57713302|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
57713303|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
57713304|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
57713305|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
57713306|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
57713307|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
57713308|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
58061456|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
58061457|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
57713309|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
57713310|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
57713311|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
58061458|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
57713312|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
57713313|NCT02386202|OTHER|No intervention|No interventions
57914612|NCT06138054|BEHAVIORAL|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
58061459|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
58061460|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
58061461|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
58061462|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
58061463|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
58061464|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
58061465|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
58061466|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
58061467|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
58061468|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
58061469|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
58061470|NCT01433328|DRUG|Lidocaine|Lidocaine
58266567|NCT06416020|BEHAVIORAL|BT-MOUD with Buprenorphine|MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
58266568|NCT00000207|DRUG|Buprenorphine|
58266569|NCT03633799|DRUG|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
58266570|NCT02559726|PROCEDURE|Echocardiography (TEE)|
58266571|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) with gadolinium enhancement|
58266572|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) without gadolinium enhancement|
58266573|NCT02559726|PROCEDURE|3D electrocardiographic mapping (ECM)|
58266574|NCT01131884|DRUG|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
58266575|NCT01131884|DRUG|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
58266576|NCT00250536|DRUG|nandrolone decanoate|
58266577|NCT00250536|BEHAVIORAL|resistance exercise training|
58061471|NCT01433328|DRUG|Placebo|Placebo
58061472|NCT02324049|DRUG|SBC-103|
58266578|NCT06287866|PROCEDURE|Pinch Graft|In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
57914613|NCT04451174|DRUG|Prednisone|Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
57914614|NCT02218294|DRUG|BCX4161|
58266579|NCT01455246|DRUG|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of \> 30 ml/min and \< 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
58386760|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
58061473|NCT02256150|DRUG|Mizoribine (MZR)|
58061474|NCT02256150|DRUG|Cyclophosphamide (CTX)|
58061475|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
58061476|NCT02180464|DRUG|LAS41004|
58061477|NCT02180464|DRUG|control|
58061478|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
58061479|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
58061480|NCT03200418|OTHER|P-4|This patch is made of new adhesive
58061481|NCT03200418|OTHER|P-15|This patch is made of new adhesive
58061482|NCT03200418|OTHER|P-16|This patch is made of new adhesive
58061483|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
57713314|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
58061484|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
58061485|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
58061486|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
58386761|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
58386762|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
58386763|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
57713315|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
57914615|NCT02377141|PROCEDURE|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
57914616|NCT02377141|PROCEDURE|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
58266580|NCT01455246|DRUG|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
58266581|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR and SMV|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV
58266582|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
58266583|NCT01626625|DRUG|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
58266584|NCT01626625|OTHER|autograft taken from iliac crest|patient will be transplanted with autograft
58266585|NCT05409079|DEVICE|Abilitech Assist|The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
57713316|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
57713317|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
57914617|NCT01651442|BEHAVIORAL|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
57914618|NCT01651442|DRUG|Zolpidem|5mg or 10mg
57914619|NCT01651442|DRUG|Trazodone|50mg to 150mg
57914620|NCT01651442|BEHAVIORAL|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
57914621|NCT05463692|BEHAVIORAL|Camelia Cohort|Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
57914622|NCT02197767|DRUG|rituximab|1000 mg infusion
57914623|NCT02571049|DRUG|DFN-11|Sumatriptan 3 mg versus 6 mg
57914624|NCT01304238|DRUG|lepirudin|lepirudin
57914625|NCT01304238|DRUG|danaparoid|danaparoid
58266586|NCT02948010|DEVICE|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device
58266587|NCT02948010|DEVICE|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
58266588|NCT02948010|DEVICE|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
58266589|NCT02948010|DEVICE|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
58266590|NCT02948010|DEVICE|CPAP with comfort feature A|CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
58386764|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
57713318|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
57713319|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
57713320|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
58061487|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
58266591|NCT02948010|DEVICE|CPAP with comfort feature B|CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
58266592|NCT02948010|DEVICE|CPAP with no comfort feature|CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
58266593|NCT02948010|DEVICE|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
58266594|NCT02948010|DEVICE|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
58266595|NCT04518969|DEVICE|CytoSorb|"CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
58266596|NCT01981343|DIETARY_SUPPLEMENT|A-F Betafood|
58266597|NCT01981343|OTHER|Placebo|
58266598|NCT05591924|PROCEDURE|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
58386765|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
58386766|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
58386767|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
58386768|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
57713321|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
57713322|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
57713323|NCT01867034|OTHER|Bare Metal Stent|
57713324|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
57914626|NCT01304238|DRUG|argatroban|argatroban
57914627|NCT01304238|DRUG|fondaparinux|fondaparinux
58061488|NCT05753124|OTHER|Observational|This is an observational study
58061489|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
58061490|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
58061491|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
58061492|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
58386769|NCT03556670|OTHER|Control|Usual practice control
57713325|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
57713326|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
57713327|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
57713328|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
57713329|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
57713330|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
57713331|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
58061493|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
58266599|NCT05591924|PROCEDURE|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
58266600|NCT05591924|PROCEDURE|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
58386770|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
57713332|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
57713333|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
57914628|NCT03341208|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
57914629|NCT00552877|DEVICE|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
57914630|NCT04125732|BIOLOGICAL|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
58061494|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
58061495|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
58061496|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
58061497|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
58061498|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
58061499|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
58061500|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
58061501|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
58061502|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
58266601|NCT05591924|PROCEDURE|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
58266602|NCT01907061|DRUG|N-acetylcysteine|drug will be administered via IV,NG
58266603|NCT01907061|DRUG|Placebo|placebo or NAC will be given
58266604|NCT01976468|OTHER|SCC metastasis|occurrence of SCC metastasis
58266605|NCT02827643|DRUG|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
57713334|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
58061503|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
58061504|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
58061505|NCT01768039|DRUG|Vitamin D|
58061506|NCT01768039|DRUG|Placebo|
58061507|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
58061508|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
58266606|NCT02827643|OTHER|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
58266607|NCT02544295|BEHAVIORAL|Clinical interview|
58266608|NCT02544295|BEHAVIORAL|Virtual reality task|
58266609|NCT03714854|DEVICE|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
58266610|NCT03058224|DRUG|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
58266611|NCT03058224|DRUG|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
58266612|NCT04492605|DIETARY_SUPPLEMENT|Placebo|consume 1 capsule per day for 2 months
57713335|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
58266613|NCT04492605|DIETARY_SUPPLEMENT|TCI378 Probiotics|consume 1 capsule per day for 2 months
58266614|NCT04492605|DIETARY_SUPPLEMENT|TCI507 Probiotics|consume 1 capsule per day for 2 months
58266615|NCT00843037|DRUG|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
58266616|NCT01546168|DEVICE|esophageal deviation with IDE device|esophageal deviation during AF ablation
58386771|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
58386772|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
57713336|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
57713337|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
57713338|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
57713339|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
57713340|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
57713341|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
58061509|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
58061510|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
58061511|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
58386773|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
58061512|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
58061513|NCT00279266|DRUG|Thiamine|
58386774|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
58386775|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
58266617|NCT06532604|DEVICE|Electroretinography (ERG)|ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
58266618|NCT01877382|DRUG|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
58266619|NCT01877382|DRUG|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
58266620|NCT00176436|BEHAVIORAL|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
58266621|NCT00176436|BEHAVIORAL|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
58266622|NCT06622954|OTHER|Protein- and Calorie restriction|The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
58266623|NCT02143791|PROCEDURE|Burst and Tonic stimulation|
58266624|NCT03604770|OTHER|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
58266625|NCT00993759|DRUG|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
58266626|NCT01528943|DRUG|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
58266627|NCT01528943|DRUG|Isotonic saline|same volume as the group that are allocated to prostacycline
58266628|NCT01252862|DEVICE|iStent|Implantation of two iStents through a small temporal clear corneal incision
58266629|NCT01886742|DRUG|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
58266630|NCT01886742|DRUG|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
58266631|NCT04139837|BEHAVIORAL|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
58266632|NCT02678000|DRUG|LHW090|LHW090 is orally administered
58266633|NCT02678000|DRUG|Placebo|Matching placebo of LHW090
58266634|NCT04132089|BEHAVIORAL|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
58266635|NCT03931408|DRUG|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
57713342|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
58061514|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
58266636|NCT03931408|OTHER|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
58266637|NCT03931408|OTHER|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
58266638|NCT05146063|DIAGNOSTIC_TEST|Take the patient's subcutaneous fat tissue to detect the expression of LNK|Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
58266639|NCT01432821|OTHER|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2"
58266640|NCT04489381|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
58266641|NCT04489381|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
58061515|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
57713343|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
57713344|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
57713345|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
57713346|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
57713347|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
57713348|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
57713349|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
57713350|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
57713351|NCT01281488|DRUG|indocyanine green|Given IV
57713352|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
57713353|NCT00651482|DRUG|Everolimus|
58061516|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
58061517|NCT03720067|DRUG|Rosuvastatin|20mg / day
58061518|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
58061519|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
58061520|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
57713354|NCT00651482|DRUG|Bevacizumab|
57713355|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
57713356|NCT04414384|OTHER|Step Counter|step counter to track steps
57713357|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
57713358|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
57713359|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
57713360|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
57713361|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
57713362|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
57713363|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
58061521|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
57713364|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
57713365|NCT00117091|DRUG|Anakinra (Kineret®)|
57713366|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
57713367|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
57713368|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
58061522|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
58061523|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
58061524|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
58061525|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
58061526|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
58061527|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
58061528|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
58061529|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
58061530|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
58061531|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
58061532|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
58061533|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
58061534|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
58061535|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
57914631|NCT01176279|PROCEDURE|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
58061536|NCT00006037|DRUG|fluorouracil|
58061537|NCT00006037|DRUG|irinotecan hydrochloride|
58266642|NCT04489381|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
58266643|NCT00688311|DIETARY_SUPPLEMENT|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).
58061538|NCT00006037|DRUG|oglufanide disodium|
58266644|NCT00688311|DIETARY_SUPPLEMENT|Placebo|Placebo
58266645|NCT06619470|OTHER|binaural beats|binaural beats
58266646|NCT04787796|DEVICE|a 28-channel ECG (MECG) system|To test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms.
58266647|NCT06647875|BEHAVIORAL|Complementary Feeding Education|"This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet."
58266648|NCT04323267|DEVICE|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
57713369|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
57713370|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
57713371|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
58266649|NCT04323267|BEHAVIORAL|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
57713372|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
57713373|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
57713374|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
57713375|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
57713376|NCT03081416|DRUG|Normal saline|
57713377|NCT03081416|DRUG|Metoclopramide|Standard therapy
57713378|NCT03081416|DRUG|Ketorolac|standard therapy
57713379|NCT03081416|DRUG|Dexamethasone|Standard therapy
57713380|NCT03081416|DRUG|Benadryl|Standard therapy
57713381|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
57713382|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
58386776|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
58386777|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
58386778|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
58386779|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
57713383|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
57713384|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
57713385|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
57713386|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
57713387|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
57713388|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
57713389|NCT00062426|BIOLOGICAL|bevacizumab|
57713390|NCT00062426|DRUG|capecitabine|
57713391|NCT00062426|DRUG|fluorouracil|
57713392|NCT00062426|DRUG|leucovorin calcium|
57713393|NCT00062426|DRUG|oxaliplatin|
58266650|NCT06391593|DRUG|ALTO-203 25 μg|Active, ALTO-203 25 μg
58266651|NCT06391593|DRUG|ALTO-203 75 μg|Active, ALTO-203 75 μg
58266652|NCT06391593|DRUG|Placebo|Comparator, Placebo-to-match
58266653|NCT01572467|GENETIC|RNA analysis|
58266654|NCT01572467|GENETIC|gene expression analysis|
58266655|NCT01572467|GENETIC|mutation analysis|
58266656|NCT01572467|GENETIC|reverse transcriptase-polymerase chain reaction|
58266657|NCT01572467|OTHER|laboratory biomarker analysis|
58266658|NCT01572467|OTHER|medical chart review|
58266659|NCT01763138|BEHAVIORAL|oral health education|oral health education in the form of a pictorial pamphlet.
58266660|NCT01763138|BEHAVIORAL|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
58266661|NCT05273775|DRUG|HRS5091 Tablets|HRS5091 Tablets once daily
58266662|NCT05273775|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
58266663|NCT05273775|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
58386780|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
58386781|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
58386782|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
58386783|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
58386784|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
58386785|NCT02748252|OTHER|stroke center referral|
58386786|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
57914632|NCT01176279|PROCEDURE|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
57914633|NCT03664089|BEHAVIORAL|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
57914634|NCT03664089|BEHAVIORAL|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
57914635|NCT01662726|DRUG|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
57914636|NCT04100668|DEVICE|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
58061539|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
58061540|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
58061541|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
58061542|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
58061543|NCT01207921|DRUG|Lenalidomide|
58061544|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
58061545|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
58386787|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
58386788|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
57914637|NCT04100668|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
57914638|NCT04100668|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
57914639|NCT01879215|PROCEDURE|Intramedullary nailing of the tibia|Standard care surgery
57914640|NCT03824782|DEVICE|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
57914641|NCT02171416|DRUG|Rilonacept|
57914642|NCT02171416|DRUG|Placebo|
57914643|NCT05453123|BEHAVIORAL|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
58061546|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
58061547|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
58061548|NCT02478658|OTHER|exercise training|high-intensity resistance training
58061549|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
58061550|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
58061551|NCT00304681|DRUG|OROS*-Methylphenidate|
58266664|NCT05273775|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
58266665|NCT05273775|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
58266666|NCT05273775|DRUG|Digoxin Tablets|Digoxin Tablets single dose
58266667|NCT05273775|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin Calcium Tablets single dose
58266668|NCT02570139|DEVICE|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
57713394|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
58386789|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
57713395|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
57713396|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
57713397|NCT00192452|DRUG|MEDI-507|
57713398|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
57713399|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
57713400|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
58266669|NCT02570139|DEVICE|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
57713401|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
57713402|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
57713403|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
57713404|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
57713405|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
57713406|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
57713407|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
57713408|NCT04257578|DRUG|Acalabrutinib|Given PO
57914644|NCT01795482|DEVICE|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
57713409|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
57713410|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
57713411|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
57713412|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
57713413|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
57713414|NCT00343187|DRUG|Vehicle Control|
57713415|NCT04266457|OTHER|No Intervention|No Intervention
57713416|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
57713417|NCT01403103|PROCEDURE|biopsy|Correlative studies
58266670|NCT02292186|DRUG|Revusiran (ALN-TTRSC)|
57914645|NCT00225966|DEVICE|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
58266671|NCT03145662|DEVICE|high pressure balloon|high pressure balloon will be used to treat stenosis
58266672|NCT03145662|DEVICE|cutting balloon|cutting balloon will be used to treat stenosis
58266673|NCT00659698|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
58266674|NCT06619795|DEVICE|Anodal tDCS|In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
57713418|NCT01403103|GENETIC|protein expression analysis|Correlative studies
57713419|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
57713420|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
57713421|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
57713422|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
57713423|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
57713424|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
57713425|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
57713426|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
57713427|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
57713428|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
58061552|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
58266675|NCT06619795|DEVICE|Sham tDCS|In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
58266676|NCT01777295|BIOLOGICAL|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
57713429|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
57713430|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
57713431|NCT06654726|DRUG|aldafermin|aldafermin
57713432|NCT06654726|DRUG|Placebo|placebo
58266677|NCT01777295|BIOLOGICAL|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
58266678|NCT01777295|BIOLOGICAL|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
57713433|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
57713434|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
57713435|NCT01061749|OTHER|Pharmacological Study|Correlative studies
57713436|NCT01061749|DRUG|Selumetinib|Given PO
57713437|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
57713438|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
57713439|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
57713440|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
57713441|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
58266679|NCT02847182|BIOLOGICAL|Cord Blood Infusion|
57713442|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
57713443|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
57713444|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
57713445|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
57713446|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
57713447|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
57713448|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
58266680|NCT02847182|BIOLOGICAL|Placebo|
58266681|NCT01764997|DRUG|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
57713449|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
57713450|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
57713451|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
58061553|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
58061554|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
58386790|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
58386791|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
58386792|NCT00272831|DRUG|Placebo|1 tablet twice daily
58386793|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
58386794|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
58386795|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
58386796|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
58386797|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
58386798|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
58386799|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
58386800|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
58386801|NCT03226249|DRUG|Dacarbazine|Given IV
58386802|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
57713452|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
57713453|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
57713454|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
57713455|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
58061555|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
58266682|NCT01764997|DRUG|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
58386803|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
58386804|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
58386805|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
58386806|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
58386807|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
58386808|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
58386809|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
58386810|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
58386811|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
57914646|NCT03377309|DRUG|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
57914647|NCT01748877|DRUG|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
58061556|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
58266683|NCT01764997|DRUG|Methotrexate|Dispensed according to local practice.
58266684|NCT01764997|DRUG|Placebo (for sarilumab)|
58266685|NCT01764997|DRUG|Placebo (for etanercept)|
57914648|NCT01748877|DRUG|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
58266686|NCT01764997|DRUG|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
58266687|NCT01100892|DRUG|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
58266688|NCT06623305|DEVICE|Photobiomodulation|Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
58266689|NCT00767039|DRUG|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
58386812|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
58386813|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
58386814|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
58386815|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
58386816|NCT03098433|DRUG|Liothyronine|Single dose
58386817|NCT03098433|DRUG|Levothyroxine|Active comparator
58386818|NCT03098433|DRUG|Placebos|Placebo
57914649|NCT00370331|DRUG|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
57914650|NCT00370331|DRUG|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
57914651|NCT02035644|DRUG|Jinlida granules|
57914652|NCT02035644|DRUG|placebo granules|
58386819|NCT02649920|DEVICE|Cervical ripening balloon|
58386820|NCT02649920|DRUG|Dinoprostone|
58386821|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
58386822|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
58386823|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
58386824|NCT01390298|OTHER|Observational|Observational study only
58386825|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
58386826|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
58386827|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
58386828|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
57713456|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
57713457|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
57713458|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
57713459|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
57713460|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
57713461|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
57713462|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
57713463|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
57713464|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
57713465|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
58266690|NCT00767039|DRUG|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
57713466|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
58061557|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
58061558|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
58061559|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
58386829|NCT04738994|OTHER|Control group|Standard hospital diet
58061560|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
58061561|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
58061562|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
58266691|NCT05194267|DEVICE|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
58266692|NCT03816644|OTHER|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
58386830|NCT00220155|DRUG|Gemcitabine|
58386831|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
58386832|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
58386833|NCT03715140|DRUG|Placebo|Placebo
58386834|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
58386835|NCT03271216|DEVICE|No intervention|no intervention
58386836|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
58061563|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
58061564|NCT00002852|DRUG|paclitaxel|Given IV
58386837|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
58386838|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
58061565|NCT00002852|DRUG|carboplatin|Given IV
58266693|NCT03816644|OTHER|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
58266694|NCT03968224|DRUG|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
58266695|NCT03968224|DRUG|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
58266696|NCT04533191|PROCEDURE|LAL IOL lens|Standard of care Cataract surgery with IOL placement
58266697|NCT01729533|OTHER|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
58266698|NCT01729533|OTHER|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
58061566|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58061567|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
58061568|NCT00242814|DRUG|Micardis|
58061569|NCT00242814|DRUG|Amlodipine|
58266699|NCT04268498|DRUG|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
58266700|NCT04268498|DRUG|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
58386839|NCT05205616|DEVICE|Reciprocating saw|See above description
58386840|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
57713467|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
57713468|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
57713469|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
57713470|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
57713471|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
57713472|NCT00796965|DRUG|Placebo|
57713473|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
57713474|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
57713475|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
57713476|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
57713477|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
57713478|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
58061570|NCT00242814|PROCEDURE|Abdominal biopsy|
58266701|NCT04268498|DRUG|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
57713479|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
57713480|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
57713481|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
57713482|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
57713483|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
57713484|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
57713485|NCT01878604|GENETIC|Gene analysis|Gene analysis
57713486|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
57713487|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
57713488|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
57713489|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
57713490|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
57713491|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
57713492|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
57713493|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
57713494|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
57713495|NCT06309875|OTHER|Conventional care|Description Conventional care
57713496|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
57713497|NCT03235024|BIOLOGICAL|B244|B244 suspension
57713498|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
58061571|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
58061572|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
58061573|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
58266702|NCT04268498|DRUG|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
58266703|NCT04268498|DRUG|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
58266704|NCT04268498|DRUG|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
58266705|NCT04268498|DRUG|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
58266706|NCT04268498|DRUG|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
58266707|NCT04268498|BIOLOGICAL|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
58266708|NCT05821790|OTHER|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
58266709|NCT00743938|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
58266710|NCT00743938|DRUG|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
58266711|NCT04612413|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
58266712|NCT04612413|OTHER|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
58386841|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
58386842|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
58386843|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
58386844|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
58386845|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
58386846|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
58386847|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
58061574|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
58061575|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
58266713|NCT03108937|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
58266714|NCT03108937|DRUG|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
58386848|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
58386849|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
57713499|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
57713500|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
57713501|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
57713502|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
57713503|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
57713504|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
58061576|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
58386850|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
57713505|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
57713506|NCT02978690|DRUG|Spesolimab|Solution for infusion
57713507|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
58061577|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
58386851|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
58386852|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
58386853|NCT00196690|DRUG|Donepezil|
58386854|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
58386855|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
58386856|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
58386857|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
58386858|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
58061578|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
58386859|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
58386860|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
58386861|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
58386862|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
57713508|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
57713509|NCT06333938|DEVICE|Bridge|Percutaneous Nerve Field Stimulation using a disposable battery operated and device, approved by the FDA for the treatment of clinical symptoms related to opioid withdrawal.
57713510|NCT06333938|DEVICE|BFA|BFA is an auricular acupuncture technique (developed within the VA/ DoD health systems) delivered by providers using 1mm acupuncture needles.
57713511|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
57713512|NCT03376997|DRUG|Perampanel|IV infusion
57713513|NCT03376997|DRUG|Perampanel|Oral tablet
58061579|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
58061580|NCT01017640|DRUG|Mitomycin|Given IV
58061581|NCT01017640|DRUG|Veliparib|Given PO
57713514|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
57713515|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
57713516|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
57713517|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
57713518|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
57713519|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
57713520|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
57713521|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
57713522|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
57713523|NCT02690961|DRUG|placebo multiple doses|
57713524|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
57713525|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
58266715|NCT06225154|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
58266716|NCT02938949|DRUG|alirocumab|
58386863|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
58266717|NCT02938949|DRUG|placebo|
58266718|NCT05599672|BEHAVIORAL|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
58386864|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
58386865|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
58386866|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
58386867|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
57713526|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
57713527|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
57713528|NCT00000826|DRUG|Clarithromycin|
57713529|NCT00000826|DRUG|Rifabutin|
57713530|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
57713531|NCT00000826|DRUG|Dapsone|
57713532|NCT00000826|DRUG|Fluconazole|
57713533|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
57713534|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
57713535|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
58061582|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
58266719|NCT05599672|BEHAVIORAL|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
58266720|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
58266721|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
58386868|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
58386869|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
58386870|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
58386871|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
58386872|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
58386873|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
57713536|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
58386874|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
57713537|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
57713538|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
57713539|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
57713540|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
57713541|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
57914653|NCT00361660|BEHAVIORAL|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
58061583|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
58061584|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
58061585|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
58061586|NCT02367196|DRUG|CC-90002|
58061587|NCT02367196|DRUG|Rituximab|
57713542|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
57914654|NCT00361660|BEHAVIORAL|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
58386875|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
58386876|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
58386877|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
58386878|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
58386879|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
57713543|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
57713544|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
57713545|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
57713546|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
57713547|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
57713548|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
57713549|NCT00191997|DRUG|Olanzapine|
57713550|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
57713551|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
57713552|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
57713553|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
57713554|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
57914655|NCT03715582|DRUG|trimetazidine|Pills of masking drug - trimetazidine
58061588|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
58061589|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
57713555|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
57914656|NCT03715582|DRUG|Placebo Oral Tablet|Pills of masking drug - placebo
57914657|NCT01025401|DEVICE|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
57713556|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
57713557|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
57713558|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
57713559|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
57713560|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
57713561|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
57713562|NCT03828305|OTHER|Control Group|No intervention
57713563|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
57713564|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
57713565|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
57713566|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
57713567|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
57713568|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
57713569|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
57713570|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
57713571|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
57713572|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
57713573|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
57713574|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
57713575|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
57914658|NCT00416143|PROCEDURE|bed rest|
58266722|NCT03705000|DEVICE|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
58266723|NCT03705000|DEVICE|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
58266724|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Sucrosomial® B12
58266725|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|B-SUB® B12
58266726|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Mecogen SL® B12
58266727|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Evermin® B12
58266728|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Neuromax® B12
58266729|NCT00146900|PROCEDURE|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
58266730|NCT00146900|PROCEDURE|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
58386880|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
58386881|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
58386882|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
58386883|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
57713576|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
57713577|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
57713578|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
57713579|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
57713580|NCT00296556|DRUG|Rivenprost (drug)|
57713581|NCT01581203|DRUG|Asunaprevir (ASV)|
57713582|NCT01581203|DRUG|Daclatasvir (DCV)|
57713583|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
57713584|NCT01581203|DRUG|Ribavirin (RBV)|
57713585|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
57914659|NCT00416143|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
58266731|NCT00146900|DRUG|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
57914660|NCT05946057|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
58266732|NCT00146900|OTHER|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
58266733|NCT00371644|BEHAVIORAL|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
58266734|NCT00371644|BEHAVIORAL|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
58266735|NCT01733043|DRUG|Dexmedetomidine|
58386884|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
58386885|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
57713586|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
57713587|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
57713588|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
57713589|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
57713590|NCT01038778|DRUG|Entinostat|Given PO
57713591|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
57713592|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
57713593|NCT01038778|OTHER|Pharmacological Study|Correlative studies
57713594|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
57713595|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
57914661|NCT02041520|DRUG|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
57914662|NCT02041520|OTHER|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
57914663|NCT03775889|BEHAVIORAL|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
58266736|NCT01733043|DRUG|Placebo|
58266737|NCT00005817|DRUG|becatecarin|Given IV
58266738|NCT00005817|OTHER|laboratory biomarker analysis|Correlative studies
58266739|NCT01455181|DRUG|NPSP558|50, 75, 100 μg
58266740|NCT02060266|DRUG|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
58266741|NCT03212066|BEHAVIORAL|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
58266742|NCT03321461|DRUG|TMTP1|Fluorescent sites will be removed
58266743|NCT03321461|DRUG|ICG|Fluorescent sites will be removed
58266744|NCT01498705|OTHER|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
57713596|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
58266745|NCT03011983|DEVICE|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
58266746|NCT03011983|DEVICE|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
57713597|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
57713598|NCT05550129|DRUG|AMG 510|Oral tablet
57713599|NCT05550129|DRUG|Metformin|Oral tablet
57713600|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
57713601|NCT02338947|PROCEDURE|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
57713602|NCT02338947|PROCEDURE|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
57713603|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
57713604|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
57713605|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
57713606|NCT02953834|DRUG|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
57713607|NCT02953834|OTHER|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
58386886|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
57713608|NCT02953834|OTHER|Placebo|Receive IV fluids for up to 16 hours that do not contain any study drug
57713609|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
57713610|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
58266747|NCT03011983|BEHAVIORAL|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
58386887|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
58386888|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
58386889|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
58386890|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
58386891|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
58386892|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
58386893|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
57713611|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
57713612|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
57713613|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
57713614|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
57713615|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
57713616|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
57713617|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
57713618|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
57713619|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
58266748|NCT00946894|PROCEDURE|Total thyroidectomy|Total thyroidectomy
58386894|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
58266749|NCT00946894|PROCEDURE|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
58386895|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
57914664|NCT04881981|RADIATION|SCART radiation therapy|We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
57914665|NCT04951154|OTHER|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
58266750|NCT00946894|PROCEDURE|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
58266751|NCT04147624|DRUG|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
57914666|NCT04951154|OTHER|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
57914667|NCT04828200|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|The ultrasonographic assesment will be used to examine the rectus femoris, gastrocnemius medailalis and rectus abdominis subcutaneous and muscle thickness. Additionally, fascicle length and pennation angle were measured between the two parallel aponeuroses of the gastrocnemius muscle (bulkiest part of medial head) in the longitudinal view when subjects were in prone position with their ankles at 90°.
57914668|NCT04828200|DIAGNOSTIC_TEST|Dual-X-ray absorptiometry|The muscle masses of the patients were evaluated by measuring the fat mass (Fat Mass-FM), fat mass index (FMI), lean body mass (LBM) and skeletal muscle index (SMI) calculated by DEXA. Appendicular muscle mass (ASM) is calculated by summing the lean soft tissue of the two upper limbs and the two lower limbs. Skeletal muscle mass index is calculated by dividing the appendicular lean mass by the square of the neck height \[SMI = ASM / height2 (kg / m2)\].
57914669|NCT04828200|DIAGNOSTIC_TEST|Isokinetic dynamometer|Quadriceps-hamstring Peak Torque (PT) values and the ratio of PT values to body weight (PT / VA) (at 60 and 180 ° / sec speeds) were evaluated with an isokinetic dynamometer
57914670|NCT05276297|DRUG|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
57914671|NCT05276297|BIOLOGICAL|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~* 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~* 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~* 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
57914672|NCT05276297|DRUG|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
57914673|NCT00010985|PROCEDURE|Acupuncture|
57914674|NCT00010985|PROCEDURE|Chiropractic|
58266752|NCT04147624|OTHER|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
58266753|NCT03362138|DEVICE|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
58266754|NCT06507631|BEHAVIORAL|Blended care pirate group|During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
57713620|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
57713621|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
57713622|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
57713623|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
57713624|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
58266755|NCT00868491|DRUG|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
58266756|NCT00868491|RADIATION|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
58266757|NCT00868491|DRUG|cetuximab, cisplatin|"* cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
58266758|NCT04561024|DIAGNOSTIC_TEST|AI model|Deep Learning CNN model
58266759|NCT01619540|OTHER|Valsalva maneuver|
58266760|NCT05415371|BEHAVIORAL|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
58386896|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
58386897|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
58266761|NCT05415371|OTHER|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
58266762|NCT06452745|PROCEDURE|Colonoscopy|Colonoscopy performed as a regular practice during colorectal cancer screening.
57713625|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
57713626|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
57713627|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
57713628|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
57713629|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
57713630|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
57713631|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
57713632|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
57713633|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
57713634|NCT05226650|OTHER|Regular meal pattern|6 meals every day
57713635|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
57713636|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
57713637|NCT05932290|DRUG|Standard of care|Standard of care
57713638|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
57914675|NCT00010985|PROCEDURE|massage|
57914676|NCT05611437|OTHER|Ultrafast ultrasonography|Ultrasonography of the neck, patient in supine position, neck hyper-extended. Three different scanning planes containing several landmarks. Carried out in the 12h prior extubation.
57914677|NCT00250939|BIOLOGICAL|Myozyme|20 mg/kg qow
57914678|NCT02423928|BIOLOGICAL|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
57914679|NCT02423928|DRUG|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
57914680|NCT02423928|DRUG|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
57914681|NCT01639495|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
57713639|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
57713640|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
57713641|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
57914682|NCT01664598|DRUG|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
57914683|NCT05630482|BEHAVIORAL|Healthy Family Foundations|Healthy Family Foundations Curriculum
57914684|NCT05630482|OTHER|Standard of Care|Standard of Care
57914685|NCT04248660|OTHER|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
57914686|NCT04421183|DIAGNOSTIC_TEST|draw blood|draw blood from the all of patients
57914687|NCT05114239|DRUG|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
57914688|NCT05114239|OTHER|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
58061590|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
58061591|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
57713642|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
57713643|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
57713644|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
57713645|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
57713646|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
57713647|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
57713648|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
57713649|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
57713650|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
57713651|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
57713652|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
57713653|NCT04865835|DRUG|placebo|single dose of placebo
58266763|NCT06452745|OTHER|Urine and FOBT collection|After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
58266764|NCT06441760|OTHER|Video teleconsultation|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while PEM physicians will provide medical direction remotely using video to communicate with EMS personnel via tablet devices.
57713654|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
58386898|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
57713655|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
57713656|NCT00004091|OTHER|Papanicolaou test|
57713657|NCT00004091|OTHER|cytology specimen collection procedure|
58061592|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
58061593|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
58266765|NCT06441760|OTHER|Audio support|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while EM physicians will provide medical direction remotely using audio to communicate with EMS personnel via tablet devices.
58266766|NCT03035006|DRUG|Lipotecan|Lipotecan based concurrent chemoradiotherapy
58266767|NCT00241124|DRUG|valsartan|
58386899|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
58386900|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
57713658|NCT00004091|OTHER|fluorescent antibody technique|
57713659|NCT00004091|PROCEDURE|colposcopic biopsy|
57713660|NCT00004091|PROCEDURE|study of high risk factors|
57713661|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
57713662|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
58266768|NCT00241124|DRUG|lisinopril|
58266769|NCT02059434|DRUG|LAS190792 Dose 1|
58266770|NCT02059434|DRUG|LAS190792 Dose 2|
58266771|NCT02059434|DRUG|LAS190792 Dose 3|
58266772|NCT02059434|DRUG|LAS190792 Dose 4|
58266773|NCT02059434|DRUG|LAS190792 Dose 5|
58266774|NCT02059434|DRUG|LAS190792 Dose 6|
57713663|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
57713664|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
57713665|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
57713666|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
57713667|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
57713668|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
57713669|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
58061594|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
58266775|NCT02059434|DRUG|LAS190792 Dose 1 (Part 2)|
58266776|NCT02059434|DRUG|LAS190792 Dose 2 (Part 2)|
58266777|NCT02059434|DRUG|Tiotropium 18 μg|
58266778|NCT02059434|DRUG|Indacaterol 150 μg|
58266779|NCT02059434|DRUG|Placebo|
58266780|NCT03407183|PROCEDURE|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
58266781|NCT06079762|BEHAVIORAL|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
58266782|NCT01503398|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
58266783|NCT06521580|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
58266784|NCT00000710|DRUG|Didanosine|
58266785|NCT05125952|DEVICE|Viasys Avea Ventilator|Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.
58386901|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
58061595|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
58266786|NCT05125952|DEVICE|Philips Respironics NM3 device|Measuring static airway driving pressure during pressure support breath
58266787|NCT05125952|DEVICE|Servo U ventilator|Measuring static airway driving pressure and p0.1 during pressure support breath.
58266788|NCT05125952|DEVICE|Vyaire SmartCath adult nasogastric tube with Esophageal balloon|Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
58266789|NCT06623669|BEHAVIORAL|MORPH|A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.
58266790|NCT06623669|BEHAVIORAL|Measurement Only|This intervention entails receipt of a body weight scale and wearable activity monitor.
58266791|NCT03168919|RADIATION|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
57713670|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
57713671|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
57713672|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
57713673|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
57713674|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
57713675|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
58061596|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
57713676|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
57713677|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
57713678|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
57713679|NCT02111486|OTHER|breakfast|
57914689|NCT03843931|BEHAVIORAL|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
58061597|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
57713680|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
57713681|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
57713682|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
57713683|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
57713684|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
57713685|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
57713686|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
57713687|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
58061598|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
57713688|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
57713689|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
57713690|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
57713691|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
57713692|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
58061599|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
57713693|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
57914690|NCT03843931|DRUG|Intra-articular saline injection|"Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
58266792|NCT03168919|DRUG|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
58266793|NCT03168919|DEVICE|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
58266794|NCT05131087|DEVICE|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
58266795|NCT03803228|DRUG|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
58386902|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
58386903|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
58386904|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
58386905|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
58386906|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
58386907|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
58386908|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
58386909|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
58386910|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
57914691|NCT00563485|DRUG|Doxazosin GITS (Cardura XL)|
58386911|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
57713694|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
57713695|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
57713696|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
57713697|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
57713698|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
57713699|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
58061600|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
58061601|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
58061602|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
58061603|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
58266796|NCT03803228|DRUG|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
58386912|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
58386913|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
58386914|NCT05034042|DRUG|Fezolinetant|oral
58386915|NCT05034042|DRUG|Placebo|oral
58266797|NCT00497978|DIETARY_SUPPLEMENT|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
58386916|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
57713700|NCT00794872|OTHER|blood sampling|
57713701|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
57713702|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
57914692|NCT00563485|DRUG|Terazosin (Hytrin)|
57713703|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
57713704|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
57713705|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
57713706|NCT05492084|OTHER|without Intervention|without Intervention
57713707|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
57713708|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
57713709|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
57713710|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
57713711|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
58386917|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
58386918|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
57914693|NCT04398407|BEHAVIORAL|Coaching and Advancement for Peer Providers (CAPP)|The CAPP intervention will combine executive coaching approaches and techniques with the specific needs and environmental demands of individuals working as PSS. A person who has been a PSS and trainer of PSS nationally has developed the CAPP intervention using the expertise of Center staff, the Harvard Institute of Coaching (IOC) and our Peer Advisory Group. Individuals randomized to the experimental condition will receive 16 individual coaching sessions tailored to the specific job stressors they are experiencing. CAPP is designed to address the following issues: role confusion, lack of clarity about job tasks, conflict with other providers, burnout, lack of organizational commitment and job satisfaction.
57914694|NCT05323396|DRUG|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls."
58266798|NCT00497978|DIETARY_SUPPLEMENT|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
57713712|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
57713713|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
57713714|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
57713715|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
57713716|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
57914695|NCT00557180|DRUG|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
58061604|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
58266799|NCT00339196|DRUG|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
58266800|NCT01818206|OTHER|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
57713717|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
57713718|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
58266801|NCT03425357|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
57713719|NCT00177424|DRUG|Placebo|matching placebo tablets
57713720|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
57713721|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
57713722|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
57713723|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
57914696|NCT00557180|DRUG|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
57914697|NCT00557180|DRUG|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
57914698|NCT05337358|PROCEDURE|endocrown|endocrown
57914699|NCT01941719|BEHAVIORAL|Enhanced foot care education|In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
58061605|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
58061606|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
58266802|NCT04237558|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
57713724|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
57713725|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
57713726|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
57713727|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
57713728|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
57713729|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
57713730|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
57713731|NCT01769157|DRUG|L-carnitine|
57713732|NCT01769157|DRUG|Placebo|
57713733|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
58266803|NCT04237558|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
58266804|NCT01045083|DRUG|RO4917523|Oral single dose
57713734|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
58266805|NCT01045083|DRUG|escitalopram|Oral single dose
58266806|NCT01045083|DRUG|methylphenidate|Oral single dose
58266807|NCT01045083|DRUG|placebo|Oral single dose
57713735|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
57713736|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
57713737|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
58061607|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
58061608|NCT02382276|DRUG|Nalmefene hydrochloride|
58266808|NCT05105828|DIAGNOSTIC_TEST|Share wave fibro scan|Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
58266809|NCT04489875|BEHAVIORAL|Chewing Gum|The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
58266810|NCT01157000|DRUG|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
58386919|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
57713738|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
58266811|NCT06385691|OTHER|myDIET software tool|"The tool is based on self-questionnaires completed by the patient. They are mainly filled in using visual analogue scales (from 0-10) or grades of symptoms/toxicities (Grades 0 to 4), based on the CTCAE V5. These scales will cover the following themes: food intake, weight changes, digestive symptoms, taste disorders, pain and fatigue. The system will be able to monitor data changes and the response given will be adapted according to the severity of symptoms:~* No signs of seriousness: general prevention or treatment documents/advice: toxicity management, nutritional advices targeted on symptoms, on digestive problems, on appropriate physical activity.~* Presence of signs of seriousness: action to be taken and alert to the coordinating nurse, oncologist or dietician.~In case of an alert, the coordinating nurse will call the patient back and either manage the symptom, schedule a nutritional consultation to initiate nutritional management, or refer the patient to the oncologist."
58266812|NCT04116723|DEVICE|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
58266813|NCT02262598|DRUG|Telmisartan|
58266814|NCT02262598|DRUG|Hydrochlorthiazide (HCTZ)|
58266815|NCT02262598|DRUG|Telmisartan/HCTZ fixed dose|
58061609|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
58061610|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
58061611|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
58061612|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
58061613|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
57713739|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
57713740|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
57713741|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
57713742|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
57713743|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
57713744|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
57713745|NCT05867394|OTHER|Stress ball|Stress ball squeeze
58266816|NCT04543097|BEHAVIORAL|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
58266817|NCT06230029|OTHER|Music listening|Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.
58266818|NCT06083688|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
58266819|NCT06083688|DRUG|Chloroquine|Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.
58266820|NCT06083688|DRUG|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 2 (females less than 13 years old and all males).
58266821|NCT05519059|DRUG|Pelareorep|Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
58266822|NCT03717051|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
58266823|NCT03717051|BEHAVIORAL|Medication counseling|Medication counseling
58386920|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
57713746|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
57713747|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
57713748|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
57713749|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
57713750|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
57713751|NCT00732121|DRUG|Placebo|Placebo
57713752|NCT05421078|DRUG|Obicetrapib|tablet
57713753|NCT05421078|DRUG|Placebo|No active ingredient
57713754|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
57713755|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
58266824|NCT02535351|DRUG|sunitinib or pazopanib|First-line treatment
58266825|NCT02535351|PROCEDURE|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
58266826|NCT06270017|DRUG|Chemotherapy drug|rsponse evaluation in zebrafish embryo model
58386921|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
58266827|NCT00825526|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
58061614|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
58061615|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
58386922|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
58386923|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
58386924|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
58386925|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
57713756|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
57713757|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
57713758|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
57713759|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
57713760|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
57713761|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
57713762|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
57713763|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
57713764|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
58386926|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
58386927|NCT04248712|DRUG|Placebo|Contains no active ingredient
58386928|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
58386929|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
57713765|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
57713766|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
58386930|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
58386931|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
58386932|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
57713767|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
58061616|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
58386933|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
58386934|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
58386935|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
58386936|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
57713768|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
58386937|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
57713769|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
58386938|NCT02079909|DRUG|Placebo|Placebo
57713770|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
57713771|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
57713772|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
57713773|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
57713774|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
58061617|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
58266828|NCT04622761|DRUG|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)"
58266829|NCT00648505|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
58266830|NCT00648505|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
58266831|NCT02018354|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
58266832|NCT02018354|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
57713775|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
58386939|NCT01281384|OTHER|Advanced Imaging|
58061618|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
58061619|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
58061620|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
58061621|NCT02241356|DEVICE|single vision glasses|single vision glasses
58061622|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
58266833|NCT02696447|BIOLOGICAL|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
58266834|NCT02106702|BEHAVIORAL|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
58386940|NCT01281384|OTHER|Standard Imaging|
58386941|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
58266835|NCT02106702|BEHAVIORAL|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
58266836|NCT04908904|DIETARY_SUPPLEMENT|Cafestol|Capsule with 12 mg cafestol
58266837|NCT04908904|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
58266838|NCT06128785|DEVICE|Electroacupuncture group|Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal exhaust or until the fourth day.
58266839|NCT06128785|OTHER|Sham EA group|Sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output.
58266840|NCT03256292|DRUG|Testosterone replacement|Testosterone replacement therapy
58266841|NCT03256292|BEHAVIORAL|lifestyle|lifestyle intervention consisting of diet and increased physical activity
58266842|NCT00081731|DRUG|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
58266843|NCT00081731|PROCEDURE|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
58266844|NCT02631746|OTHER|Laboratory Biomarker Analysis|Correlative studies
58266845|NCT02631746|BIOLOGICAL|Nivolumab|Given IV
58266846|NCT02631746|OTHER|Pharmacogenomic Study|Correlative studies
57713776|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
58266847|NCT01904318|DRUG|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
58266848|NCT01904318|DRUG|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
58266849|NCT01904318|DRUG|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
58266850|NCT01904318|DRUG|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
58386942|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
58386943|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
58386944|NCT02782234|BEHAVIORAL|Contract management|
57713777|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
57713778|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
57713779|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
58061623|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
58061624|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
58266851|NCT01904318|DRUG|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
58266852|NCT01904318|DRUG|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
58266853|NCT01904318|DRUG|Placebo|Placebo single dose administration
58266854|NCT03207074|DIAGNOSTIC_TEST|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
58266855|NCT04660318|DEVICE|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
58266856|NCT04660318|DEVICE|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
58266857|NCT01272141|DRUG|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
58266858|NCT05542667|COMBINATION_PRODUCT|Giomer varnish|* After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
58266859|NCT05542667|COMBINATION_PRODUCT|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
57713780|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
57914700|NCT01941719|BEHAVIORAL|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
57914701|NCT00477334|DRUG|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
57914702|NCT00477334|DRUG|Placebo|oral; two tablets twice a day; single day treatment
57914703|NCT01873222|DEVICE|OFDI-guided PCI & IVUS|"* Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up"
58266860|NCT05044949|OTHER|Probiotic|The study product is a probiotic strain
58266861|NCT05044949|OTHER|Placebo|The study product is a placebo to the probiotic strain
58266862|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
58266863|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
58266864|NCT03273725|OTHER|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
58266865|NCT02386930|BEHAVIORAL|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
58266866|NCT02622841|PROCEDURE|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
58266867|NCT01058759|DRUG|Enoxaparin|
58266868|NCT01058759|OTHER|No Enoxaparin|
58266869|NCT02340611|DRUG|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
58266870|NCT02340611|DRUG|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
58266871|NCT01454843|PROCEDURE|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
58266872|NCT01454843|PROCEDURE|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
58266873|NCT03161249|BEHAVIORAL|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
58266874|NCT03161249|OTHER|Control group|Group that does not receive any treatment added to its usual treatment
57713781|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
57713782|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
57713783|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
57713784|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
57713785|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
57914704|NCT01873222|DEVICE|IVUS-guided PCI & OFDI|"* Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up"
57914705|NCT05444569|DRUG|LY3537021|Administered SC.
57914706|NCT05444569|DRUG|Liraglutide|Administered SC.
57914707|NCT05444569|DRUG|Placebo|Administered SC.
57914708|NCT04183309|OTHER|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
58266875|NCT01192113|DRUG|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
58266876|NCT01192113|DRUG|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
58266877|NCT01192113|DRUG|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
58266878|NCT01060878|DRUG|PYM50028|IMP
58266879|NCT01060878|DRUG|Placebo|Matching placebo comprising identical vehicle to active doses
58266880|NCT01952080|DRUG|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
58266881|NCT01200459|BEHAVIORAL|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
58266882|NCT02124759|DRUG|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
58266883|NCT02124759|DRUG|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
57914709|NCT01598623|DRUG|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
57914710|NCT01598623|BEHAVIORAL|Social Skills Training|three times a week for three weeks.
58266884|NCT02124759|DRUG|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
58266885|NCT02124759|OTHER|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
58266886|NCT02124759|OTHER|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
58266887|NCT01018381|PROCEDURE|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
58266888|NCT01018381|PROCEDURE|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
58266889|NCT01018381|PROCEDURE|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
58266890|NCT01018381|PROCEDURE|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
58266891|NCT01018381|DIETARY_SUPPLEMENT|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
58266892|NCT01018381|DRUG|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
58266893|NCT02278367|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
58266894|NCT02278367|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
57713786|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
57713787|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
57713788|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
57713789|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
58266895|NCT04875026|DRUG|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
58266896|NCT04875026|DEVICE|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
57713790|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
57713791|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
58061625|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
58266897|NCT01135069|DRUG|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
58266898|NCT01135069|DRUG|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
58266899|NCT01135069|DRUG|placebo microsphere gel|treatment of acne vulgaris
57713792|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
57713793|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
57713794|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
58061626|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
58266900|NCT00756600|DRUG|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
58061627|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
57713795|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
57713796|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
58061628|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
58266901|NCT00756600|DRUG|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
58266902|NCT05882695|DRUG|SPG302|synthetic small molecule
58266903|NCT05882695|DRUG|Placebo|Placebo
58266904|NCT01472757|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
58266905|NCT01472757|DRUG|Placebo|Placebo delivered via a new dry powder inhaler
58266906|NCT02934087|PROCEDURE|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
58266907|NCT00703287|OTHER|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
57713797|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
58266908|NCT00703287|OTHER|Physiotherapy|Generic physiotherapy
58266909|NCT03417024|DEVICE|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
58266910|NCT03417024|DEVICE|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
58386945|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
58386946|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
57713798|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
57713799|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
57713800|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
58266911|NCT04747951|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
58266912|NCT04747951|PROCEDURE|TME|Total mesorectal excision
58386947|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
58061629|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
58386948|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
57713801|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
58266913|NCT04747951|DRUG|consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
58266914|NCT04747951|DRUG|adjuvant chemotherapy|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
58266915|NCT01942031|BEHAVIORAL|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
58266916|NCT04568525|DIAGNOSTIC_TEST|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
58266917|NCT05382195|OTHER|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
58386949|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
58386950|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
58386951|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
58386952|NCT00148486|DRUG|NS 2330|
57713802|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
57713803|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
57914711|NCT01598623|BEHAVIORAL|Placebo + Non Specific Counselling|
57914712|NCT05915650|BEHAVIORAL|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
58266918|NCT03757637|OTHER|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
58386953|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
57713804|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
57713805|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
57914713|NCT05915650|BEHAVIORAL|Routine Education|Carry out routine education intervention for TKA patients
57914714|NCT04080921|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
57914715|NCT03133052|BEHAVIORAL|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
57914716|NCT03133052|BEHAVIORAL|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
58386954|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
58386955|NCT00454740|DRUG|solifenacin succinate|Oral
57914717|NCT00006342|GENETIC|chromosomal translocation analysis|
57914718|NCT00006342|GENETIC|gene rearrangement analysis|
57914719|NCT00006342|GENETIC|mutation analysis|
57914720|NCT03080012|OTHER|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
57914721|NCT03080012|OTHER|Plasma/serum sampling|Simultaneously with saliva sampling.
57914722|NCT01528176|DRUG|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
57914723|NCT01173406|BEHAVIORAL|CPAP education|Standard CPAP education plus an session and one telephone follow up
57914724|NCT00226031|PROCEDURE|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
57914725|NCT02519400|DRUG|Amitriptyline|Single oral dosing
57914726|NCT02485782|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
57914727|NCT02485782|DEVICE|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
58266919|NCT03757637|OTHER|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
58266920|NCT06618807|DEVICE|Active tPBM device|The Neuro RX Gamma (version 2) delivers a synchronized pulse frequency of 40 Hz from all LED clusters. The gamma pulse frequency of 40 Hz has been demonstrated to attenuate amyloid beta proteins production in the hippocampus and modulate microglial activity resulting in increased scavenging of amyloid beta which may lead to improving cognition in MCI. Finally, the Vielight Neuro RX Gamma (version 2) has been designed to target the delivery of NIR energy to particular brain regions; specifically the default mode network (DMN). The active intervention device proceeds to deliver light to each LED at 40 Hz with a 50% duty cycle for 20 minutes and stops automatically. During the 20 minute treatment the power indicator LED on the controller flashes green at 40 Hz. The operator is notified that the treatment is finished when the power indicator LED on the controller stops flashing and the device beeps 2 times.
58266921|NCT06618807|DEVICE|Sham device|The sham device delivers infrared light for only a few seconds before stopping. The controller will still show a green light to maintain the study\&#39;s blinding. If the headset is removed, the device will emit a beep and cease functioning.
57713806|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
57713807|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
57713808|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
57713809|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
57713810|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
58266922|NCT00329641|DRUG|carboplatin|Given IV
58266923|NCT00329641|DRUG|paclitaxel|Given IV
57713811|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
57713812|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
57713813|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
57713814|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
57713815|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
58266924|NCT00329641|DRUG|sorafenib tosylate|Given orally
58266925|NCT04437472|OTHER|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
58266926|NCT06424600|OTHER|Gingival Index|The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.
58266927|NCT03024528|BEHAVIORAL|CPOT assessment|Polish version of Critical care pain observation tool validation.
58266928|NCT02744027|OTHER|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
58386956|NCT01696799|DRUG|Econazole Nitrate|
58386957|NCT01696799|DRUG|placebo|
58386958|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
57914728|NCT02485782|DEVICE|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
58266929|NCT02744027|OTHER|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
58266930|NCT02744027|OTHER|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
58266931|NCT00653302|DRUG|Lantus (insulin glargine) + Glucophage (Metformin)|
58266932|NCT03111199|OTHER|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
58266933|NCT03111199|OTHER|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
58266934|NCT03111199|OTHER|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
57713816|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
57713817|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
57713818|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
57713819|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
57713820|NCT05875038|OTHER|Tele-alarm|Tele-alarm
57713821|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
57713822|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
57914729|NCT02853838|OTHER|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
58386959|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
58386960|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
58386961|NCT03102515|DRUG|USG-TAP block|
58386962|NCT03102515|DRUG|CIC|
58386963|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
58266935|NCT03111199|OTHER|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
58266936|NCT01465633|DRUG|levothyroxine|
58266937|NCT01465633|DRUG|levothyroxine|
58266938|NCT00606840|BEHAVIORAL|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
58266939|NCT00606840|BEHAVIORAL|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
58266940|NCT01550016|OTHER|Observation|Clinical follow-up and laboratory investigations.
58266941|NCT04448600|OTHER|MRI|"The patients included in the study will all have a cerebral MRI as part of the cholesteatoma follow-up or for the assessment of cerebral or inner ear pathology.~- ENT evaluation"
58266942|NCT06648161|OTHER|Labor Mirror|The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
58266943|NCT00929474|DEVICE|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
58266944|NCT00929474|DEVICE|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
58266945|NCT06500923|OTHER|Oral rehabilitation by means of implant-supported single unit crowns|Surgery: Implant placement; Prothetic rehabilitation: single unit crown
58266946|NCT04561297|DIAGNOSTIC_TEST|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
58266947|NCT01897610|DRUG|Immuncell-LC|intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
58266948|NCT01617772|DRUG|Atorvastatin|Atorvastatin 20 mg
58266949|NCT01617772|DRUG|L-Carnitine|1000mg L-carnitine
58266950|NCT01617772|DRUG|Placebo|Identically looking placebo
57713823|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
58266951|NCT01117675|OTHER|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
58266952|NCT01117675|OTHER|Standard of Care|Standard of Care
58266953|NCT03248518|BEHAVIORAL|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
58266954|NCT03248518|BEHAVIORAL|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
58266955|NCT03248518|BEHAVIORAL|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
58266956|NCT05500482|BIOLOGICAL|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
58266957|NCT04676685|DRUG|E2730|E2730 capsules.
58266958|NCT04676685|DRUG|E2730-matched placebo|E2730-matched placebo capsules.
58266959|NCT03157739|BEHAVIORAL|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
58266960|NCT00585715|DEVICE|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
58266961|NCT05447676|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
58061630|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
58061631|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
58061632|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
58061633|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
58266962|NCT05447676|OTHER|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
57914730|NCT02853838|OTHER|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
57914731|NCT02853838|OTHER|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
57914732|NCT01413776|DIETARY_SUPPLEMENT|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
57914733|NCT04646538|OTHER|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
57914734|NCT03259360|BEHAVIORAL|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
58061634|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
58061635|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
58061636|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
58061637|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
58061638|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
58061639|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
58061640|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
58061641|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
58061642|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
58061643|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
58061644|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
58061645|NCT00372944|DRUG|AZD6244|oral capsule
58061646|NCT00372944|DRUG|capecitabine|oral tablet
58061647|NCT00002625|DRUG|topotecan hydrochloride|
58061648|NCT00002625|RADIATION|low-LET electron therapy|
58061649|NCT00002625|RADIATION|low-LET photon therapy|
58061650|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
58061651|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
58061652|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
57914735|NCT03259360|BEHAVIORAL|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
57914736|NCT02873143|OTHER|No intervention|No intervention
58266963|NCT05447676|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
58266964|NCT05447676|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
58266965|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
58266966|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
58266967|NCT01087580|DRUG|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
58266968|NCT00322361|BIOLOGICAL|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
58266969|NCT00322361|BIOLOGICAL|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
58266970|NCT03449394|OTHER|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
58266971|NCT03556293|BEHAVIORAL|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
58266972|NCT03556293|BEHAVIORAL|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
58266973|NCT03556293|BEHAVIORAL|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
58266974|NCT03556293|BEHAVIORAL|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
58266975|NCT06461351|OTHER|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection
58266976|NCT05595564|DEVICE|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
58266977|NCT01627301|DEVICE|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
58266978|NCT01627301|DEVICE|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
58266979|NCT01627301|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
58266980|NCT01627301|DEVICE|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
57914737|NCT03019796|DRUG|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
57914738|NCT01942265|DRUG|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
57914739|NCT01942265|DRUG|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
57914740|NCT01942265|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
58061653|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
58061654|NCT01078974|DRUG|pomalidomide|Taken orally once a day
58061655|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
58386964|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
58266981|NCT00115037|DRUG|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
57914741|NCT06056193|PROCEDURE|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
57914742|NCT00777946|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
58266982|NCT00115037|DRUG|placebo|placebo comparer for 16 weeks in phase 2.
58266983|NCT00115037|BEHAVIORAL|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
58266984|NCT00115037|BEHAVIORAL|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
58266985|NCT00115037|BEHAVIORAL|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
58266986|NCT02163616|DRUG|Misoprostol|800 mcg of sublingual misoprostol
58266987|NCT02268747|DRUG|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction."
58266988|NCT06223321|DIAGNOSTIC_TEST|Computed Tomography in congenital heart diseases|"● CT examination will be done by~* 160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~* We used the following parameters during cardiac CT scanning:~  * Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~ * The radiation dose set to 80-100 kvp.~ * Tube current from 10 to 40 mA/kg.~ * The gantry rotation speed at 0.35-.4 sec.~ * ECG gated Retrospective With MA modulation.~ * Wide FOV.~* A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~* Scanning begins when contrast filled the LV by bolus tracking.~* All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
58266989|NCT05936216|BIOLOGICAL|TVI-Brain 1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
58266990|NCT03125187|BIOLOGICAL|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
58386965|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
58386966|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
58386967|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
58386968|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
58386969|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
58386970|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
58386971|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
57914743|NCT00777946|DRUG|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
57914744|NCT00777946|DRUG|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
57914745|NCT00777946|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
57914746|NCT00777946|DRUG|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
57914747|NCT02935933|DRUG|bupivicaine|Paravertebral block
57914748|NCT02935933|DRUG|morphine|
57914749|NCT02935933|DRUG|Dexmedetomidine|
58061656|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
57914750|NCT03221192|OTHER|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.
58061657|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
57713824|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
58266991|NCT03125187|BIOLOGICAL|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
58266992|NCT02212548|DEVICE|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
58266993|NCT00334802|DRUG|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
58266994|NCT00334802|DRUG|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
58266995|NCT04893356|GENETIC|O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients|"Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent."
58266996|NCT02870842|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
58266997|NCT02870842|OTHER|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
58266998|NCT06090617|PROCEDURE|Skin Biopsy|Skin biopsies were obtained in all recruited patients.
58386972|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
57713825|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
57713826|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
57713827|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
57713828|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
57713829|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
58266999|NCT06090617|PROCEDURE|Video-laparoscopic adrenalectomy|Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
58267000|NCT02903524|DRUG|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
58267001|NCT02903524|DRUG|pirarubicin and cyclophosphamide|
58267002|NCT03008993|BEHAVIORAL|HQIS implementation|
58267003|NCT03415659|DRUG|HWH340 tablet|"1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
58386973|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
58386974|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
57713830|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
57713831|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
58061658|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
58061659|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
58267004|NCT05636007|DEVICE|Huawei Watch|pulse rate variability measured by a smartwatch
58267005|NCT03838406|GENETIC|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
58267006|NCT03838406|DRUG|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
58267007|NCT03957811|OTHER|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
57713832|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
57713833|NCT00277602|DRUG|Riluzole|
58267008|NCT04954716|OTHER|Deep Neck Flexor Massage|Deep friction massage is a specific connective tissue massage that was given across the affected fibers.The therapist's fingers and patient's skin must move as one, otherwise moving subcutaneous fascia against muscle or ligament could lead to blister formation or subcutaneous bruising.The friction massage must have sufficient sweep and be deep enough.
57713834|NCT01707004|DRUG|decitabine|Given IV
58267009|NCT04954716|OTHER|Post-Isometric Relaxation Technique|The PIR technique is performed as follows.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted.A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction . The patient should inhale during this effort.After the isometric contraction the patient is asked to relax and exhale while doing so.Following this a gentle stretch is applied to take up the slack till the new barrier.Starting from this new barrier, the procedure is repeated two or three times.
57713835|NCT01707004|DRUG|fludarabine phosphate|Given IV
57713836|NCT01707004|DRUG|busulfan|Given IV
57914751|NCT03221192|OTHER|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
57914752|NCT03221192|OTHER|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
57914753|NCT03087019|RADIATION|Radiation|Standard use of radiation is administered
57914754|NCT03087019|DRUG|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
57914755|NCT04407585|DIAGNOSTIC_TEST|Covid-19 swab PCR test|Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
57914756|NCT04315051|DRUG|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
57914757|NCT04315051|OTHER|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
57914758|NCT06524206|BEHAVIORAL|The Awareness, Courage and Love Intervention|Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
57914759|NCT05939973|DEVICE|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
57914760|NCT04412291|DRUG|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
57914761|NCT04412291|DRUG|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
57914762|NCT04412291|DRUG|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
57914763|NCT05469750|DRUG|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
57914764|NCT05795244|DRUG|Nivolumab|- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
58267010|NCT00847392|PROCEDURE|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
58267011|NCT01498224|DEVICE|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
58267012|NCT01498224|PROCEDURE|Sutures|
58386975|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
57713837|NCT01707004|DRUG|cyclophosphamide|Given IV
57914765|NCT06156618|DIETARY_SUPPLEMENT|Nitrate|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
57713838|NCT01707004|DRUG|tacrolimus|Given PO or IV
57713839|NCT01707004|DRUG|mycophenolate mofetil|Given PO
58061660|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
57713840|NCT01707004|BIOLOGICAL|filgrastim|Given SC
57713841|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
57713842|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
57713843|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
57713844|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
57713845|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
57914766|NCT03012607|DRUG|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
58267013|NCT05192408|BEHAVIORAL|Multi-component intervention|"Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
57914767|NCT03945682|OTHER|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
58267014|NCT05192408|OTHER|Usual Care|Patient Education Materials
58267015|NCT02707588|DRUG|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
58267016|NCT02707588|DRUG|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
58267017|NCT02707588|RADIATION|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
58267018|NCT06098963|DEVICE|sacral neuromodulation|sacra neuromodulator implantation outcomes
58267019|NCT00319033|DRUG|bosentan|
58267020|NCT05074446|OTHER|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information."
58386976|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
58386977|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
58386978|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
57914768|NCT01822509|BIOLOGICAL|Ipilimumab|Given IV
58267021|NCT03675295|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
58267022|NCT03675295|DRUG|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
58267023|NCT05572177|DEVICE|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
57914769|NCT01822509|OTHER|Laboratory Biomarker Analysis|Correlative studies
57914770|NCT01822509|BIOLOGICAL|Nivolumab|Given IV
57914771|NCT04218149|DRUG|Bupivacaine Injection|Block with bupivacaine
58267024|NCT04709705|BIOLOGICAL|Human platelets|Platelets given to control bleeding
58267025|NCT06107270|DEVICE|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
58267026|NCT06107270|DEVICE|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
58267027|NCT06107270|DEVICE|infra red radiation|(R 125, 250watt, Philips)
57914772|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
57914773|NCT00983931|DRUG|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
57914774|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
57914775|NCT01520220|DRUG|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
57914776|NCT02518490|DEVICE|Sapphire Lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
58267028|NCT06107270|OTHER|post isometric relaxation|sustained contraction followed by relaxation
58386979|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
58386980|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
57914777|NCT02518490|DEVICE|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
58061661|NCT02415582|OTHER|Control|45 minutes resting sitting
57914778|NCT00394082|DRUG|ABI-007|125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
57914779|NCT00394082|DRUG|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
57914780|NCT02881905|DEVICE|ball attachment|it is attachment part that connects the overdenture to the implant
58061662|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
57914781|NCT02881905|DEVICE|cm loc attachment|It is a new attachment made of peek material
58061663|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
58061664|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
58061665|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
58061666|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
58267029|NCT04543721|DEVICE|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
57914782|NCT03060460|DIAGNOSTIC_TEST|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
58061667|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
58061668|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
58061669|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
58061670|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
58061671|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
58061672|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
58061673|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
58061674|NCT04214470|OTHER|No intervention|There is no intervention for this study
58061675|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
58061676|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
58061677|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
58061678|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
58061679|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
57914783|NCT04395027|DEVICE|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
57914784|NCT03187691|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
57914785|NCT01411839|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
57914786|NCT03080428|DIAGNOSTIC_TEST|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
58061680|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
58061681|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
58061682|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
58061683|NCT05421416|DRUG|Placebo|Placebo sugar pill
58061684|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
58061685|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
58267030|NCT03089671|OTHER|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
58267031|NCT03089671|OTHER|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
58267032|NCT00715104|BIOLOGICAL|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
58267033|NCT00715104|BIOLOGICAL|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
58267034|NCT00779688|DEVICE|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
58267035|NCT00210600|DRUG|PROCRIT (Epoetin alfa)|
58267036|NCT03247764|OTHER||observational study
58267037|NCT02089100|RADIATION|stereotactic body radiation therapy|
58267038|NCT02089100|RADIATION|Systemic treatment|
58267039|NCT01366859|DIETARY_SUPPLEMENT|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
58267040|NCT01366859|DIETARY_SUPPLEMENT|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
58267041|NCT02666898|DRUG|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD \>10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
58267042|NCT02666898|DRUG|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~* patients in CR with BM MRD \< 10-4 : Ibrutinib alone 420mg daily~* patients with BM MRD \>10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
58267043|NCT02666898|DRUG|Cyclophosphamide|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
58267044|NCT02666898|DRUG|Fludarabine|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
58267045|NCT00642109|PROCEDURE|midurethral sling procedure|quality of life, voiding dysfunction
58267046|NCT03244618|DEVICE|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
58267047|NCT03244618|DEVICE|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
58267048|NCT01625208|PROCEDURE|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
58267049|NCT01625208|PROCEDURE|Supraclavicular block|Standard supraclavicular brachial plexus block
58267050|NCT04331067|DRUG|Paclitaxel|-Given standard of care
58386981|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
57713846|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
58061686|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
58061687|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
57713847|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
58267051|NCT04331067|DRUG|Carboplatin|-Given standard of care
58267052|NCT04331067|BIOLOGICAL|Nivolumab|-Given standard of care
58267053|NCT04331067|BIOLOGICAL|Cabiralizumab|-Will be provided by Bristol Myers Squibb
58267054|NCT04331067|PROCEDURE|Tumor biopsy|-Baseline, week 5, surgery, and at time of relapse (optional)
58267055|NCT04331067|PROCEDURE|Bone marrow|-Time of port placement (baseline), time of surgery, and time of recurrence (optional)
58267056|NCT04331067|PROCEDURE|Blood draw|-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
58267057|NCT00415597|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
58386982|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
58386983|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
58386984|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
58386985|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
58386986|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
58386987|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
58386988|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
57914787|NCT01676181|PROCEDURE|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
58061688|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
58061689|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
58061690|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
58061691|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
57914788|NCT01676181|PROCEDURE|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
57914789|NCT05521945|BEHAVIORAL|Intermittent Fasting|16 hours fasting and 8 hours eating window
57914790|NCT05521945|BEHAVIORAL|Calorie Restricted Diet|The customized diet plan will be given to the participants according to their calorie intake requirements
57914791|NCT05521945|BEHAVIORAL|Normal dietary intake|normal diet without any customization
57914792|NCT00617253|DRUG|recombinant interleukin-21|3 mcg/kg, s.c. injection
57914793|NCT00617253|DRUG|sunitinib|Hard gelatine capsules, 12.5 mg
57914794|NCT00617253|DRUG|recombinant interleukin-21|10 mcg/kg, s.c. injection
57914795|NCT00617253|DRUG|recombinant interleukin-21|30 mcg/kg, s.c. injection
58386989|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
58386990|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
57914796|NCT00617253|DRUG|recombinant interleukin-21|100 mcg/kg, s.c. injection
57914797|NCT05714098|BEHAVIORAL|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
57914798|NCT03407664|OTHER|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
57914799|NCT02783768|DEVICE|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
58061692|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
57914800|NCT02783768|OTHER|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
58061693|NCT01729806|BIOLOGICAL|Rituximab|Given IV
58061694|NCT00984919|OTHER|high performance liquid chromatography|
58061695|NCT00984919|OTHER|laboratory biomarker analysis|
58061696|NCT00984919|OTHER|mass spectrometry|
58061697|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
58061698|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
58061699|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
58061700|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
58061701|NCT00090246|DRUG|MK0869, aprepitant|
58061702|NCT00090246|DRUG|Comparator: ondansetron IV|
58061703|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
58386991|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
58386992|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
58267058|NCT05661630|OTHER|EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL|"In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended."
58267059|NCT02169206|RADIATION|Bilateral shoulder anteroposterior radiography|"1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction."
58061704|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
58267060|NCT02191176|DRUG|Dextromethorphan syrup - low dose|
58267061|NCT02191176|DRUG|Dextromethorphan syrup - high dose|
58267062|NCT02191176|DRUG|Placebo|
58386993|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, ...). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
58386994|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
58386995|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
58386996|NCT01095991|DRUG|AZD1656|Oral tablet bd,
58386997|NCT01095991|DRUG|Sitagliptin|Oral tablet od
57914801|NCT02783768|DRUG|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
58061705|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
58061706|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
58061707|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
58061708|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
58061709|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
58061710|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
58061711|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
58061712|NCT01970124|DRUG|KPS-0373, High dose|
58061713|NCT01970124|DRUG|KPS-0373, Low dose|
58061714|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
58386998|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
58386999|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
58387000|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
58387001|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
58387002|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
58061715|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
58061716|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
58267063|NCT01323153|DRUG|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
58267064|NCT01323153|DRUG|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
58387003|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
58387004|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
58267065|NCT06621264|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\&#39;s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.
57713848|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
57713849|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
58267066|NCT06621264|OTHER|Control (Standard treatment)|Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices
58267067|NCT05656703|DEVICE|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
58267068|NCT05656703|OTHER|Standard of Care|Anesthesia is administered as usual
58267069|NCT05749068|DEVICE|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
58387005|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
58387006|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
57713850|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
57713851|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
57713852|NCT01850004|DRUG|Dasatinib|
57713853|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
57713854|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
57914802|NCT02783768|DRUG|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
57914803|NCT03840915|DRUG|Cisplatin|Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
57914804|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
57914805|NCT03840915|DRUG|Pemetrexed|Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
58387007|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
58387008|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
58387009|NCT00001033|DRUG|Ethambutol hydrochloride|
58387010|NCT00001033|DRUG|Isoniazid|
58387011|NCT00001033|DRUG|Pyrazinamide|
58387012|NCT00001033|DRUG|Pyridoxine hydrochloride|
58387013|NCT00001033|DRUG|Levofloxacin|
58387014|NCT00001033|DRUG|Rifampin|
58061717|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
58061718|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
57914806|NCT03840915|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
58061719|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
58061720|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
58061721|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
58061722|NCT00069251|DRUG|Bupropion|
58061723|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
58061724|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
58061725|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
58061726|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
58061727|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
58061728|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
58267070|NCT06154642|DIAGNOSTIC_TEST|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
58061729|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
58061730|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
58267071|NCT06154642|DIAGNOSTIC_TEST|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
58267072|NCT06154642|DIAGNOSTIC_TEST|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
58267073|NCT06154642|DIAGNOSTIC_TEST|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
58267074|NCT06154642|DIAGNOSTIC_TEST|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
58267075|NCT06154642|DIAGNOSTIC_TEST|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
58267076|NCT06154642|PROCEDURE|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
58267077|NCT00783224|DRUG|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
58267078|NCT00783224|DRUG|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
58387015|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
58387016|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
58387017|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
57914807|NCT03840915|DRUG|Gemcitabine|Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
57914808|NCT03840915|DRUG|Docetaxel|Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
57914809|NCT03840915|DRUG|M7824|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
58061731|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
58061732|NCT00712764|DRUG|Adenosine|
58061733|NCT00712764|DRUG|Placebo|
58061734|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
58267079|NCT00783224|DRUG|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
58267080|NCT00783224|DRUG|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
58267081|NCT01914159|DRUG|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
58387018|NCT04362800|OTHER|MRI|MRI at baseline and J90
58387019|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
58387020|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
58061735|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
58061736|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
58387021|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
58387022|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
58387023|NCT00212875|DRUG|epoetin alfa|
58387024|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
58387025|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
58387026|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
58387027|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
58387028|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
58387029|NCT03663569|DRUG|Spiolto® Respimat®|Drug
58387030|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
58387031|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
58387032|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
58387033|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
58267082|NCT06052540|DIETARY_SUPPLEMENT|Probiotic supplement|"* Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~* Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
58267083|NCT06052540|DIETARY_SUPPLEMENT|Placebo|"* Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~* Stick: Maltodextrin."
58267084|NCT02930161|DRUG|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
58267085|NCT02930161|OTHER|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
58267086|NCT03305900|OTHER|No Intervention|Cross-sectional study requiring a single serum sample
58267087|NCT05548998|OTHER|General anesthesia with low fresh gas flow|General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia
58267088|NCT05548998|OTHER|General anesthesia with high fresh gas flow|General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia
58267089|NCT05548998|DIAGNOSTIC_TEST|Mini mental state examination|6 category and 30-point test to inquire patient's cognitive function
58267090|NCT05548998|DIAGNOSTIC_TEST|Visual Analogue Scale|The patient's self-reported pain intensity according to a visual scale between 0 and 100
58267091|NCT00147784|DRUG|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
58267092|NCT00147784|DRUG|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
58267093|NCT06010420|DEVICE|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
58267094|NCT04571801|DIAGNOSTIC_TEST|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
57713855|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
57914810|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
58267095|NCT04571801|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
58267096|NCT01524783|DRUG|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
58267097|NCT01524783|DRUG|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
58267098|NCT01524783|OTHER|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
58387034|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
58387035|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
58387036|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
57914811|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
57914812|NCT03840915|DRUG|Bintrafusp alfa|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
57914813|NCT03840915|DRUG|Paclitaxel|Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
57914814|NCT02114710|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
57914815|NCT00114413|DRUG|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
57914816|NCT00114413|PROCEDURE|eNO measurement|measured by Aerocrine® NIOX device
58267099|NCT03160001|DRUG|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
58267100|NCT03160001|DRUG|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
58267101|NCT03160001|DRUG|Etanercept|Etanercept 50mg weekly
58267102|NCT06623877|DIAGNOSTIC_TEST|renal shear wave elastography|"Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups"
58267103|NCT05177900|DEVICE|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
57713856|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
57713857|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
57713858|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
58267104|NCT05726942|OTHER|Healthi|Healthi refers to the Healthi app, which is a mobile application for weight loss
57713859|NCT00001839|DRUG|Antithymocyte globulin|
57713860|NCT00001839|DRUG|Cyclosporine|
57713861|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
57713862|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
57713863|NCT05650879|DRUG|ELVN-002|capsule
58387037|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
58387038|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
58387039|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
57713864|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
57713865|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
57713866|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
57713867|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
57713868|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
57713869|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
57713870|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
57713871|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
57713872|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
57713873|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
57713874|NCT03152786|OTHER|Survey Administration|Ancillary studies
57713875|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
57713876|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
57713877|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
57713878|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
57713879|NCT03436472|DRUG|placebo|normal saline infusion
57713880|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
57713881|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
58267105|NCT04208321|OTHER|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
58267106|NCT04208321|DRUG|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
58387040|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
58061737|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
58061738|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
58061739|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
58267107|NCT00850096|OTHER|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
58267108|NCT00850096|DRUG|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
58267109|NCT04319081|DRUG|PCSK9 inhibitor|Patients are included after PCSK9 inhibitors prescription , at the first dispensation
58387041|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
58387042|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
58387043|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
58387044|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
58387045|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
58061740|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
58061741|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
58061742|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
58267110|NCT04927871|BEHAVIORAL|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
58267111|NCT04927871|BEHAVIORAL|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
58267112|NCT04927871|BEHAVIORAL|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
58387046|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
58387047|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
58387048|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
58387049|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
58387050|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
58061743|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
58267113|NCT04927871|BEHAVIORAL|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
58387051|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
58387052|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
58267114|NCT01916161|OTHER|Questionnaire|
58267115|NCT05450926|PROCEDURE|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
58267116|NCT05359770|DEVICE|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
58267117|NCT05359770|DEVICE|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
58267118|NCT00123617|PROCEDURE|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
58267119|NCT05471570|DEVICE|tDCS stimulation|The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
57713882|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
57713883|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
57713884|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
57713885|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
57713886|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
57713887|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
57713888|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
57713889|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
57713890|NCT02502786|DRUG|GM-CSF|
57713891|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
57713892|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
57713893|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
58267120|NCT04529512|DRUG|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
58267121|NCT05290480|OTHER|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
58267122|NCT05290480|DEVICE|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
57713894|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
57713895|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
57914817|NCT06119672|DRUG|Probiotic Blend Oral capsules|probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
58267123|NCT02482064|OTHER|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
58267124|NCT01690910|DEVICE|Rifton Gait Trainer|
58267125|NCT01690910|DEVICE|Front Wheeled Walker|
58267126|NCT03047096|DRUG|hyaluronic acid|intra-Articular injection
57713896|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
58267127|NCT03047096|DRUG|hyaluronic acid and corticosteroids|intra-Articular injection
58267128|NCT00517894|DRUG|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
58387053|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
58387054|NCT00389376|DRUG|Placebo|Placebo
58387055|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
58387056|NCT00389376|DRUG|Silymarin|280 mg single dose
58387057|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
58387058|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
58387059|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
57713897|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
57713898|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
58387060|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
57713899|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
57713900|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
57713901|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
57713902|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
57713903|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
57713904|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
57713905|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
57713906|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
58267129|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
58267130|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
58267131|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
58387061|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
58387062|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
58387063|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
58387064|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
58387065|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
58387066|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
58387067|NCT00828958|DRUG|Risperidone long-acting injectable|
57914818|NCT06119672|DRUG|Corticosteroids for Local Oral Treatment|topical clobetasol probionate in orabase application 4 times daily
57914819|NCT01970722|DRUG|Carboplatin|Given IP or IV
57914820|NCT01970722|DRUG|Cisplatin|Given IP
58267132|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
57914821|NCT01970722|DRUG|Gemcitabine Hydrochloride|Given IP or IV
58267133|NCT02909881|BEHAVIORAL|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
58267134|NCT00624559|DRUG|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
58267135|NCT00624559|OTHER|Placebo|Placebo pill taken twice per day on each day of the diet
58267136|NCT06620341|BEHAVIORAL|drug education|"* Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably."
58267137|NCT03376217|OTHER|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
58267138|NCT05818410|DEVICE|Prosthetic device (Lunaris)|Participants with an amputation will conduct experiments with the prosthetic device
58267139|NCT05818410|OTHER|No prosthetic device|Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation
58267140|NCT05818410|DEVICE|Prosthetic device (Sach foot)|Participants with an amputation will conduct experiments with the prosthetic device
58387068|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
58387069|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
58387070|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
57713907|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
57914822|NCT01970722|OTHER|Laboratory Biomarker Analysis|Correlative studies
57914823|NCT01970722|DRUG|Paclitaxel|Given IP or IV
57914824|NCT01970722|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
57914825|NCT01970722|OTHER|Quality-of-Life Assessment|Ancillary studies
57914826|NCT01970722|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57914827|NCT01999270|DRUG|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
58061744|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
57713908|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
57914828|NCT01999270|DRUG|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
57914829|NCT01999270|DEVICE|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
57914830|NCT01886612|DEVICE|Duo-STIM neuromuscular electrical stimulator|
57914831|NCT01886612|DEVICE|AV Impulse System Model 6000|
57914832|NCT02979392|DRUG|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
57914833|NCT01288521|DRUG|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
57914834|NCT01288521|DRUG|Tacrolimus alone, Then Tacrolimus + Ketoconazole|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
57914835|NCT00593294|BEHAVIORAL|Physical exercise|45 minutes each day for three times/week for 6 months
57914836|NCT00593294|DRUG|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
57914837|NCT00593294|DIETARY_SUPPLEMENT|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
57914838|NCT03465098|OTHER|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
58267141|NCT03258008|DRUG|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
58267142|NCT03258008|BIOLOGICAL|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
58267143|NCT05468749|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
58267144|NCT01537016|DEVICE|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
58387071|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
58387072|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
58387073|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
58387074|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
58387075|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
58267145|NCT01537016|DEVICE|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
58267146|NCT00600405|DRUG|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
58267147|NCT00600405|DRUG|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
58267148|NCT03176615|DIETARY_SUPPLEMENT|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
57713909|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
57713910|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
57713911|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
57713912|NCT04047017|DRUG|Apatinib|250mg, po, qd
57713913|NCT04047017|DRUG|Camrelizumab|200mg, q2w
57713914|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
58267149|NCT04520334|OTHER|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
58267150|NCT03264378|BEHAVIORAL|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
58267151|NCT00104065|DRUG|CG53135-05, velafermin|
58267152|NCT05084365|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
58267153|NCT05084365|DRUG|Placebo|Placebo
58267154|NCT00772122|DRUG|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
58387076|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
57713915|NCT00020111|DRUG|arsenic trioxide|
57713916|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
57713917|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
57713918|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
57713919|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
57713920|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
58387077|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
58387078|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
58387079|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
58387080|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
57713921|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
57713922|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
57914839|NCT05566977|OTHER|autologous adoptive T regulatory cell transfer.|Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
57914840|NCT02688907|DRUG|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
57914841|NCT03128008|DRUG|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
57914842|NCT03128008|DRUG|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
58267155|NCT00772122|DRUG|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
58267156|NCT05548868|DEVICE|E4W mobile app|Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
58267157|NCT05548868|BEHAVIORAL|Standard Care|Patients will receive standard dietary counselling as part of the weight management program.
57914843|NCT03128008|RADIATION|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
57914844|NCT02534298|OTHER|functional magnetic resonance imaging|functional magnetic resonance imaging
58267158|NCT06499012|DIETARY_SUPPLEMENT|All-plant Protein Booster Product Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
58267159|NCT06499012|DIETARY_SUPPLEMENT|Placebo Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
58267160|NCT00526331|DEVICE|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
58267161|NCT00526331|DEVICE|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
58267162|NCT02750605|DEVICE|DEB|Intervention with drug eluting balloon.
58267163|NCT02750605|DEVICE|POBA|Intervention with old technology as comparison
58267164|NCT02680184|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
58267165|NCT02680184|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
57713923|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
57914845|NCT04059419|BEHAVIORAL|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
57914846|NCT04059419|BEHAVIORAL|Geriatric Care|Remain under geriatric care as usual
57914847|NCT02817022|OTHER|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
57914848|NCT03587077|DRUG|Misoprostol|vaginal application
57914849|NCT03587077|DRUG|Placebos|vaginal application
57914850|NCT03587077|DRUG|isosorbide mononitrate|vaginal application
57914851|NCT05833633|DIAGNOSTIC_TEST|MUSCLE MAGNETIC RESONANCE IMAGING (MRI)|To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
57914852|NCT04894760|DIAGNOSTIC_TEST|Rapid Antigen Test (PanBio Ag test)|Rapid Antigen Test (PanBio Ag test)
57914853|NCT02009761|DRUG|BI 655064|subcutaneous injection
58267166|NCT06648980|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
58267167|NCT06648980|DIETARY_SUPPLEMENT|Phytoglycogen|Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
57914854|NCT02907164|BEHAVIORAL|Email invitation|Receive emails encouraging them to sign up
58061745|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
58061746|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
58267168|NCT04588727|DRUG|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
58061747|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
58061748|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
58061749|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
58061750|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
58267169|NCT04588727|DRUG|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
58267170|NCT04588727|DRUG|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
58387081|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
58387082|NCT02695017|DEVICE|Iso inertial|
58387083|NCT02695017|DEVICE|Conventional machine|
58387084|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
57914855|NCT02907164|BEHAVIORAL|Social norm|Receive information about how many people have signed up
57914856|NCT02907164|BEHAVIORAL|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
57914857|NCT02907164|BEHAVIORAL|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
57914858|NCT01878214|BEHAVIORAL|Targeted messaging|6 targeted mailed messages and 6 booster text messages
57914859|NCT01878214|BEHAVIORAL|Standard messaging|1 informational letter
57914860|NCT03742284|DEVICE|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
58061751|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
58267171|NCT04588727|DRUG|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
58267172|NCT04586335|DRUG|CYH33|Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
58267173|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
58267174|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
58267175|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
58267176|NCT02360475|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
58387085|NCT01328028|OTHER|Data collection|Log sheet
58387086|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
58267177|NCT06074887|BEHAVIORAL|transtheoretical model-based intervention|"Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, the patient will be visited at home and final tests will be collected."
58267178|NCT00112281|DRUG|Tilarginine Acetate Injection intravenous infusion|
58267179|NCT06527222|DRUG|Ranolazine|500mg twice daily
58267180|NCT06527222|DRUG|Ranolazine|1000 mg twice daily
58267181|NCT06527222|DRUG|Placebo|Ranolazine placebo twice daily
58387087|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
58387088|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
58387089|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
58387090|NCT01957293|DRUG|Placebo|single oral administration
58387091|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
58267182|NCT05400031|BIOLOGICAL|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
58267183|NCT05400031|BIOLOGICAL|Placebo|Placebo
58267184|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
58267185|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
58267186|NCT00719914|DRUG|normal saline|Intra-coronary injection, weight based, of normal saline.
58267187|NCT02271711|OTHER|Laboratory Biomarker Analysis|Correlative studies
58267188|NCT02271711|BIOLOGICAL|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
58267189|NCT06077149|BIOLOGICAL|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
58267190|NCT04295057|OTHER|Non-intervention|Non-intervention
58267191|NCT05602129|DRUG|HSK36273|HSK36273
58061752|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
58267192|NCT05602129|DRUG|Heparin sodium|Heparin sodium
58061753|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
58267193|NCT05582369|BEHAVIORAL|Affective Rewards Messages|Messages about the affective rewards of exercise
58267194|NCT00001043|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
58267195|NCT00001783|DRUG|0-15 Water|
58267196|NCT01479192|DRUG|Fenretinide|100mg (2cps/day) for 5 years
58387092|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
58387093|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
58387094|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
58061754|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
58387095|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
57713924|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
58061755|NCT00477867|PROCEDURE|quality-of-life assessment|
58061756|NCT02136264|OTHER|PCFA interventional dietary counselling|
58061757|NCT02136264|OTHER|conventional DASH diet counselling|
58267197|NCT01479192|OTHER|Placebo|2 cpr/day of matched placebo for 5 years
58267198|NCT02110940|OTHER|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
58267199|NCT02110940|OTHER|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
58267200|NCT01519297|DRUG|Irbesartan|150mg orally for one dose
58267201|NCT03685292|BEHAVIORAL|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
58267202|NCT03685292|DRUG|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
58267203|NCT03685292|DEVICE|Behavioral Division|This study is relative to minimal contact control (MCC).
58267204|NCT03909854|PROCEDURE|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
58387096|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
58387097|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
58387098|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
58061758|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
58061759|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
58267205|NCT05600283|DIAGNOSTIC_TEST|Swab kit (COBAS HPV 4800 Assay -Evalyn brush)|Patient self-sampling swab kit to collect a vaginal sample for HPV testing
58267206|NCT05600283|DIAGNOSTIC_TEST|Clinician-collection of cervical sample for HPV testing|Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing (Evalyn brush)
58387099|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
57713925|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
57713926|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
57713927|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
57713928|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
57713929|NCT04089267|DRUG|TPO|
58267207|NCT02028403|DRUG|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
57713930|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
57713931|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
58267208|NCT02028403|DRUG|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
58387100|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
58387101|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
57713932|NCT00000781|DRUG|Nevirapine|
57713933|NCT00000781|DRUG|Zidovudine|
57713934|NCT00000781|DRUG|Zalcitabine|
57713935|NCT00000781|DRUG|Didanosine|
58061760|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
58061761|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
58061762|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
57713936|NCT02082717|DRUG|potassium chloride replacement|
58061763|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
58387102|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
58061764|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
58061765|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
58061766|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
58387103|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
58387104|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
57713937|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
57713938|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
57713939|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
58061767|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
58061768|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
58061769|NCT00056628|DEVICE|The COGNIShunt® System|
58267209|NCT03929250|DRUG|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
57713940|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
58267210|NCT03929250|DRUG|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
58387105|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
57713941|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
57713942|NCT04953923|DRUG|Placebo|Capsule for oral administration
57713943|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
57713944|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
57713945|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
57713946|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
57713947|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
57713948|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
57713949|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
57713950|NCT01438541|DEVICE|Window|Dressing
57713951|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57713952|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
57713953|NCT04817241|DRUG|Cytarabine|Given IV
57713954|NCT04817241|DRUG|Daunorubicin|Given IV
57713955|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
58061770|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
57713956|NCT04817241|DRUG|Venetoclax|Given PO
58061771|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
58061772|NCT00018694|DRUG|Chenodeoxycholic Acid|
58061773|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
58267211|NCT01736605|PROCEDURE|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
58267212|NCT01736605|PROCEDURE|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
58267213|NCT02660879|OTHER|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
58267214|NCT02660879|OTHER|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
58387106|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
57713957|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
57713958|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
57713959|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
57713960|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
57713961|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
57713962|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
57713963|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
57713964|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
57713965|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
57713966|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
57713967|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
57713968|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
57713969|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
57713970|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
57713971|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
57713972|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
57914861|NCT05085236|PROCEDURE|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
57914862|NCT05085236|PROCEDURE|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
57713973|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
57713974|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
57713975|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
57713976|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
57914863|NCT00580645|DRUG|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
57914864|NCT00580645|DRUG|placebo|placebo
58267215|NCT01752153|DRUG|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
58267216|NCT01752153|DRUG|Silymarin (Legalon)|
58267217|NCT00574795|BIOLOGICAL|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
58267218|NCT03679286|DEVICE|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
57713977|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
58267219|NCT05524220|DEVICE|Standard care with a facemask.|The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
57713978|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
57713979|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
57914865|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Aerobic Walking Exercise Training|"This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance."
57914866|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Stretching and Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
58267220|NCT05524220|DEVICE|SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)|The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
57914867|NCT01340651|DRUG|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
57914868|NCT00819962|DRUG|Bupivacaine|Local anesthetic
57914869|NCT00819962|OTHER|TAP|
58061774|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
58061775|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
58061776|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
58061777|NCT03313752|OTHER|Placebo|placebo
57914870|NCT02487732|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
57914871|NCT02487732|DRUG|Prasugrel|Prasugrel 10mg once daily for 5 weeks
57914872|NCT02850367|DIETARY_SUPPLEMENT|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
57914873|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
57914874|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
58061778|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
57914875|NCT02850367|DIETARY_SUPPLEMENT|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
57914876|NCT02850367|BIOLOGICAL|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
57914877|NCT02850367|BIOLOGICAL|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
57914878|NCT01401582|OTHER|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
58267221|NCT05366413|OTHER|Early Referral|Directing a patient for a pain specialist consult earlier than standardly occurs.
57713980|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
57713981|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
57914879|NCT04782401|OTHER|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
57914880|NCT04782401|DEVICE|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
57914881|NCT00294853|PROCEDURE|MDCT calcium score|
57914882|NCT06336720|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The active PoNS device delivers amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes.
58267222|NCT05366413|OTHER|Pain Management Strategies|Specialized plan with procedures to ease pain
57914883|NCT05444153|DRUG|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
58387107|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
58387108|NCT00521209|OTHER|Stand procedures, no intervention|
58387109|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
58387110|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
58387111|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
57914884|NCT05444153|DRUG|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
57914885|NCT02743156|PROCEDURE|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
58267223|NCT00005604|BIOLOGICAL|recombinant interleukin-12|Given IV
58267224|NCT00005604|BIOLOGICAL|aldesleukin|Given SC
58387112|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
58387113|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
58267225|NCT00005604|OTHER|laboratory biomarker analysis|Correlative studies
58267226|NCT03897933|PROCEDURE|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
58267227|NCT03897933|PROCEDURE|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
58267228|NCT01667939|BEHAVIORAL|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
58267229|NCT00943670|BIOLOGICAL|pertuzumab|Intravenous repeating dose
58267230|NCT00943670|BIOLOGICAL|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
58387114|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
57713982|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
57713983|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
57713984|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
57713985|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
57713986|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
57713987|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
57914886|NCT02743156|PROCEDURE|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
57914887|NCT01285609|DRUG|Ipilimumab|
57914888|NCT01285609|DRUG|Placebo|
57914889|NCT01285609|DRUG|Paclitaxel|
57914890|NCT01285609|DRUG|Carboplatin|
57914891|NCT05142384|BEHAVIORAL|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
57914892|NCT05142384|COMBINATION_PRODUCT|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
57713988|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
57914893|NCT06191653|BEHAVIORAL|Mindfulness and Self-Compassion for Caregivers working in Youth Detention Centres|The adapted form of the MSC is a 12-session structured program, delivered on a weekly basis in group. It intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind and courageous way. Each session lasts about 2 hours. Each session has the following structure: Grounding exercise; sharing individual insights about the weekly practice; Reviewing the previous session and link for the session theme; coffee break; soft landing exercise; Formal/Informal practice(s); Session summary and challenges to be applied during the week; Session evaluation and take-off. Each participant receives a manual with the contents shared in each session as well as some space for individual reflections. On the day after each session, a summary email is sent to the participants, resuming the contents and with records of the (in)formal practices delivered. All the sessions will be delivered in a space on each YDC.
57914894|NCT05309343|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
57914895|NCT01295177|DRUG|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
57914896|NCT04020705|DEVICE|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
57914897|NCT04020705|OTHER|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
57914898|NCT01724853|PROCEDURE|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
57914899|NCT01724853|OTHER|Conservative|Injection
57914900|NCT00690560|BIOLOGICAL|rituximab|
57914901|NCT00690560|DRUG|cyclophosphamide|
57914902|NCT00690560|DRUG|doxorubicin hydrochloride|
57914903|NCT00690560|DRUG|prednisone|
58061779|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
57914904|NCT00690560|DRUG|vincristine sulfate|
57914905|NCT00690560|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
57914906|NCT02869100|OTHER|Blood sample|
57914907|NCT02869100|PROCEDURE|Sodium fluoride Positron Emission Tomography|
57914908|NCT02869100|OTHER|Magnetic Resonance Imaging|
57914909|NCT02869100|OTHER|Radiography|
57914910|NCT01182701|BEHAVIORAL|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
57914911|NCT02940405|DRUG|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
57914912|NCT02940405|DRUG|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
57914913|NCT02927600|OTHER|Low GI Breakfast|Intake of low GI breakfast
58387115|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
58387116|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
57713989|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
57713990|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
57713991|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
57914914|NCT02927600|OTHER|High GI Breakfast|Intake of high GI breakfast
57914915|NCT02927600|OTHER|Low GI Dinner|Intake of Low GI dinner
57914916|NCT02927600|OTHER|High GI Dinner|Intake of high GI dinner
57914917|NCT02238574|PROCEDURE|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
57713992|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
57713993|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
57713994|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
57713995|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
57713996|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
57713997|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
57713998|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
57713999|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
57714000|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
57714001|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
57914918|NCT02238574|OTHER|follow up|Intensified outpatient follow up (16 visits in 5 years)
57914919|NCT01893437|DRUG|RO6799477|Single doses of RO6799477
57914920|NCT04771949|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
57914921|NCT04771949|OTHER|Questionnaires|"After the periodontal chart, patients will be administered the italian version of 4 questionnaires regarding:~1. Adherence to Mediterranean Diet (Gnagnarella et al. 2018);~2. International Physical Activity Questionnaire (IPAQ) (Mannocci et al. 2010);~3. Pittsburgh Sleep Quality Index (PSQI) (Curcio et al. 2013);~4. Italian Perceived Stress Scale (Fossati, 2010)."
57914922|NCT03814187|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
57914923|NCT04310891|RADIATION|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
57914924|NCT03327337|PROCEDURE|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
57914925|NCT03830749|DRUG|Eltrombopag|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
57914926|NCT00251823|DRUG|Eptifibatide facilitated PCI|
57714002|NCT00253565|DRUG|capecitabine|
57714003|NCT00253565|DRUG|imatinib mesylate|
57714004|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
57714005|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
57714006|NCT01978431|DRUG|cocaine hydrochloride|
57914927|NCT00559858|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|
57914928|NCT00559858|OTHER|placebo|
57914929|NCT00559858|PROCEDURE|quality-of-life assessment|
58061780|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
58387117|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
57714007|NCT01978431|DRUG|methylphenidate|
57914930|NCT02058654|DRUG|Creatine|Creatine powder (5 g)
57914931|NCT02058654|DRUG|Placebo|Bulking agent powder (5 g)
57914932|NCT04633798|PROCEDURE|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
57914933|NCT04633798|PROCEDURE|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
57914934|NCT04178044|BIOLOGICAL|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
57914935|NCT04178044|BIOLOGICAL|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
57914936|NCT04178044|BIOLOGICAL|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
57914937|NCT04178044|BIOLOGICAL|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
57914938|NCT04178044|BIOLOGICAL|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
57914939|NCT04585776|DRUG|LY900014|Administered SC
58267231|NCT06454422|OTHER|wu qinxi|"Wuqinxi, also known as the Hundred-step Sweating Exercise, is one of the most emblematic Health qigong exercises. Huatuo, guided by the principle, formulated the 'Wuqinxi':  Running water is never stale and a door-hinge is never gets worm-eaten, and sums up the experiences of the fitness activities of Huatuo's predecessors that imitate the movements of tigers, deer, bears, apes, birds, and other animals, and are associated with human organs, meridians, and 'qi'"
58387118|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
57914940|NCT04585776|DRUG|Insulin Degludec|Administered SC
57914941|NCT03717129|DRUG|Genvoya Oral dose|Single Genvoya oral dose directly observed
57914942|NCT03717129|DRUG|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
58387119|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
57914943|NCT04708925|OTHER|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
57914944|NCT01116882|PROCEDURE|PCI|
57914945|NCT03270397|BEHAVIORAL|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
57914946|NCT00416234|PROCEDURE|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
57914947|NCT00416234|PROCEDURE|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
57914948|NCT02749240|OTHER|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
57914949|NCT02020759|DEVICE|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
57914950|NCT02041234|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
58267232|NCT00038896|DRUG|Venlafaxine ER|
58267233|NCT02670733|PROCEDURE|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
58387120|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
58387121|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
58387122|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
57914951|NCT02041234|DRUG|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
57914952|NCT02041234|DRUG|Xenical|Xenical: Up to 120 mg tds
57914953|NCT02041234|DRUG|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
57914954|NCT02041234|DRUG|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
57914955|NCT01904123|OTHER|Laboratory Biomarker Analysis|Correlative studies
57914956|NCT01904123|OTHER|Pharmacological Study|Correlative studies
57914957|NCT01904123|DRUG|STAT3 Inhibitor WP1066|Given PO
58267234|NCT02865603|BEHAVIORAL|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
57714008|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
57914958|NCT02189720|DRUG|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients \> 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age \< 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
57914959|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
57914960|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 100mcg
58061781|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
58061782|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
58061783|NCT02746991|DRUG|Sham Injection|Placebo
58267235|NCT02898324|OTHER|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
58267236|NCT03147300|BEHAVIORAL|Current routine practice|Current routine practice for the primary care management of LBP
58267237|NCT03147300|BEHAVIORAL|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
58267238|NCT00727090|DRUG|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
58267239|NCT00335959|DRUG|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
58267240|NCT00335959|DRUG|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
58267241|NCT00335959|PROCEDURE|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
58267242|NCT00335959|RADIATION|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
58267243|NCT04576065|OTHER|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
58267244|NCT01044953|OTHER|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
57714009|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
57714010|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
57714011|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
57714012|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
58267245|NCT02806544|DRUG|Tamoxifen|Tamoxifen 20mg by mouth daily
57714013|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
57714014|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
57714015|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
57714016|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
57714017|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
57714018|NCT03752723|DRUG|GX-I7|i.m.
57714019|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
57714020|NCT03752723|DRUG|Cyclophosphamide|i.v.
58267246|NCT02210169|DRUG|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
58267247|NCT05236894|BEHAVIORAL|Cigarette Smoking|Smoke preferred brand of cigarette
58267248|NCT05236894|DRUG|Nicotine Oral Pouch|Given lower dose nicotine pouch
58267249|NCT05236894|DRUG|Nicotine Oral Pouch|Given higher dose nicotine pouch
57714021|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
57714022|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
57914961|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
57714023|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
57914962|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 500mcg
58267250|NCT05236894|OTHER|Questionnaire Administration|Ancillary studies
58267251|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
57714024|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
57714025|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
57714026|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
57714027|NCT03178656|PROCEDURE|surgery|curative resection
57714028|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
57714029|NCT03998124|OTHER|Usual care|Staff-led social activity
57714030|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
58267252|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
58267253|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
58267254|NCT05123469|DEVICE|Electroencephalography|Simultaneous recording of electroencephalogram by conventional EEG device and the Zeto EEG device
58267255|NCT05730153|BIOLOGICAL|advanced PRF|advanced PRF+ surgery
58267256|NCT06507904|DRUG|Osivelotor|A medicine to treat sickle cell disease.
58267257|NCT06507904|OTHER|Famotidine|Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
58267258|NCT00126269|DRUG|cisplatin|
58267259|NCT00126269|DRUG|gemcitabine|
58267260|NCT03410810|DIAGNOSTIC_TEST|MRI|MRI analysis
58387123|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
57714031|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
57714032|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
57714033|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
57714034|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
57714035|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
57714036|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
57714037|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
57714038|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
57714039|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
57914963|NCT00715962|BEHAVIORAL|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
57914964|NCT00715962|OTHER|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
58267261|NCT03410810|DIAGNOSTIC_TEST|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
58387124|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
57714040|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
57714041|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
57914965|NCT00715962|OTHER|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
57914966|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
58387125|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
57914967|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
57914968|NCT03531970|DRUG|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
57914969|NCT03531970|DRUG|Dexamethasone|Corticostroide
57914970|NCT03531970|DRUG|Placebo|Placebo
57914971|NCT05128994|DEVICE|User-controlled FES system|Wearable FES sleeve with non-invasive user controls
58061784|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
58061785|NCT00126386|DRUG|Zoledronic acid (Zometa)|
58061786|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
58061787|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
58387126|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
57714042|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
57714043|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
57914972|NCT03508037|OTHER|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
58387127|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
57914973|NCT04719884|PROCEDURE|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) \>10% and SI and CI \>10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of \>10% and the SVV still \>10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI \<10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
57914974|NCT05909995|DRUG|INCB 99280 with Ipilimumab|Dose Escalation and expansion of INCB 99280 with Ipilimumab
57914975|NCT06318715|PROCEDURE|modified deep extubation (mDE)|The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.
57914976|NCT06318715|PROCEDURE|standard awake extubation|awake extubation (AE) is still considered the standard practice.
57714044|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
57714045|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
57914977|NCT04176146|BEHAVIORAL|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
57914978|NCT04708210|DRUG|IBI319|Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
58267262|NCT00958607|BEHAVIORAL|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
57914979|NCT02905071|OTHER|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
57914980|NCT02905071|OTHER|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
57914981|NCT02905071|OTHER|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
58267263|NCT00958607|BEHAVIORAL|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
57914982|NCT03018951|OTHER|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
57914983|NCT03018951|OTHER|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
58267264|NCT06184139|DRUG|Misoprostol|Oral misoprostol for induction of labor in late term pregnancies
58267265|NCT02515994|DEVICE|senofilcon C|Investigational contact lens
58267266|NCT02515994|DEVICE|comfilcon A|Marketed Monthly Replacement Lens (Control)
58267267|NCT01549041|DRUG|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
58267268|NCT01549041|DRUG|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
57714046|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
57714047|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
57714048|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
57714049|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
57714050|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
57714051|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
57714052|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
57714053|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
57714054|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
57714055|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
57714056|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
57714057|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
57714058|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
57714059|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
57714060|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
57714061|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
57714062|NCT06414499|DRUG|rhTNK-tPA|0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.
57714063|NCT06414499|DRUG|Control group|Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
57714064|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
57714065|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
57714066|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
57714067|NCT03273036|DRUG|Placebos|no injected agent
57714068|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
58267269|NCT05787366|OTHER|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
58387128|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
58387129|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
58387130|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
57714069|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
57714070|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
57914984|NCT03018951|OTHER|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
58061788|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
58061789|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
58267270|NCT05787366|OTHER|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
58267271|NCT01384019|DEVICE|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
58267272|NCT01384019|PROCEDURE|c-PCI|conventional PCI without Guard wire
58267273|NCT02745912|DRUG|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
58387131|NCT02846792|DRUG|Plinabulin|Given IV
58387132|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
58387133|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
58061790|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
58061791|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
58387134|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
57714071|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
57714072|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
58061792|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
58061793|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
58061794|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
58267274|NCT02745912|DRUG|Metformin|Metformin immediate-release tablet.
58387135|NCT00335738|DRUG|carboplatin|Given IV
58267275|NCT01280682|DRUG|rituximab|anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
58267276|NCT06519409|PROCEDURE|Open flap debridement and photodynamic therapy|
58267277|NCT06214702|DIAGNOSTIC_TEST|ELISA|ELISA estimation of PLGF, sFlt-1 and Serpin C
58387136|NCT00335738|DRUG|etoposide|Given IV
58387137|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
58387138|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
57714073|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
57714074|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
57714075|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
57714076|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
58387139|NCT02036580|OTHER|Placebo|
58387140|NCT00057759|DRUG|sildenafil citrate|
58387141|NCT00057759|OTHER|Placebo|Placebo
58387142|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
58387143|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
58387144|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
58387145|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
58387146|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
58387147|NCT02997696|DRUG|ONO-4474|
58387148|NCT02997696|DRUG|Placebo matching ONO-4474|
58387149|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
57914985|NCT06108882|OTHER|Experimental: Manual Ischemic Compression with Strain Counter Strain technique|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
58061795|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
58061796|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
57914986|NCT06108882|OTHER|Active Comparator: Manual Ischemic Compression|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
58061797|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
57714077|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
57714078|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
57914987|NCT05827432|DEVICE|Field-cycling imaging (FCI)|FCI scan
57914988|NCT02143557|OTHER|Fat-Modified Breast Milk|
57914989|NCT02143557|OTHER|MCT formula|
57914990|NCT02798965|BIOLOGICAL|serodiagnosis|
58061798|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
58387150|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
57914991|NCT01335087|OTHER|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
57914992|NCT01335087|DEVICE|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
57914993|NCT04070443|DRUG|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
57914994|NCT04070443|DRUG|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
58387151|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
57714079|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
57914995|NCT03312283|DRUG|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
57914996|NCT03312283|DRUG|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
57914997|NCT00737971|DRUG|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
57914998|NCT00737971|DRUG|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
57914999|NCT00737971|DRUG|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
57915000|NCT01550445|DRUG|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
57915001|NCT00989131|DRUG|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
57915002|NCT00989131|DRUG|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
57915003|NCT02850120|PROCEDURE|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
57915004|NCT02850120|PROCEDURE|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
58061799|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
58061800|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
58061801|NCT00501930|DRUG|GSK189075|
57915005|NCT02850120|PROCEDURE|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
58061802|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
58061803|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
58387152|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
58387153|NCT01934907|OTHER|Washing of packed RBC by normal saline|
58387154|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
57714080|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
57714081|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
57714082|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
57714083|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
57714084|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
57714085|NCT01560624|DRUG|Treprostinil Diolamine|Active
57714086|NCT01560624|DRUG|Placebo|Placebo
57714087|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
57714088|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
57714089|NCT01985984|RADIATION|Radiation alone|Radiation alone
58061804|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
57714090|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
57915006|NCT03741452|OTHER|transversalis fascia plane block|patient controlled analgesia devices with tramadol
57915007|NCT02050711|BEHAVIORAL|Pulmonary rehabilitation|
57915008|NCT02050711|OTHER|Usual care|
57915009|NCT00687973|DRUG|Valsartan/amlodipine 80/5 mg tablets|
58061805|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
58061806|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
58061807|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
58061808|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
58061809|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
58061810|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
57714091|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
57714092|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
57714093|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
58061811|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
58061812|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
58061813|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
58061814|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
58061815|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
58061816|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
58061817|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
58267278|NCT04441476|OTHER|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~* The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~* At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
58267279|NCT04441476|OTHER|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
58267280|NCT03647774|DRUG|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
57714094|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
57714095|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
57915010|NCT00687973|DRUG|Amlodipine 5 mg capsules|
57915011|NCT00687973|DRUG|Amlodipine 10 mg capsules|
57714096|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
57714097|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
57714098|NCT01588002|DRUG|danoprevir|multiple oral doses
57714099|NCT01588002|DRUG|efavirenz|multiple oral doses
57915012|NCT00687973|DRUG|Atenolol 50 mg tablets|
58267281|NCT06451796|DEVICE|Obtinu|Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter
58267282|NCT05514210|BEHAVIORAL|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
58267283|NCT05734950|OTHER|Translational study|Non-interventional, translational study
58267284|NCT05827575|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
57714100|NCT01588002|DRUG|ritonavir|multiple oral doses
58267285|NCT01807416|PROCEDURE|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
58267286|NCT03034473|OTHER|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\]."
57915013|NCT00687973|DRUG|Atenolol 100 mg tablets|
57714101|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
57714102|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
57714103|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
57915014|NCT00913315|DRUG|tolterodine|4 mg of tolterodine ER
57915015|NCT00913315|DRUG|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
57915016|NCT00913315|DRUG|placebo|placebo once a day for 8 weeks
57915017|NCT01094379|PROCEDURE|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
57915018|NCT01094379|PROCEDURE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
57915019|NCT06398977|DRUG|Dapagliflozin|Dapagliflozin10MG, PO once daily
57915020|NCT05007808|DRUG|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
57915021|NCT05007808|DRUG|Vehicle|Vehicle Gel for topical administration
58061818|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
58061819|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
58061820|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
58267287|NCT01801280|DRUG|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
57915022|NCT00508703|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
57915023|NCT00508703|PROCEDURE|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
57915024|NCT01820013|DEVICE|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
57915025|NCT01820013|DEVICE|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
57915026|NCT05222724|DRUG|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
57915027|NCT05222724|DRUG|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
57714104|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
57714105|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
57714106|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
57714107|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
57714108|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
57714109|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
57714110|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
58267288|NCT01801280|DRUG|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
57714111|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
57915028|NCT05275725|DRUG|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
57915029|NCT04058366|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
57915030|NCT04058366|DRUG|IVA|Tablet for oral administration.
57915031|NCT01007643|OTHER|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
57915032|NCT01007643|OTHER|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
57714112|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
57714113|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
57714114|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
57714115|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
57714116|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
57915033|NCT01210664|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
57915034|NCT02440009|DRUG|Itraconazole|Oral itraconazole 200 mg BD for 6 months
57915035|NCT02440009|DRUG|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
57915036|NCT02311868|DIETARY_SUPPLEMENT|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
58267289|NCT01801280|DRUG|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
58267290|NCT02680613|BEHAVIORAL|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
58267291|NCT02680613|BEHAVIORAL|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
57714117|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
57714118|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
58267292|NCT03721588|OTHER|Clinical interviews, psychometric scales were applied.|
57714119|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
57714120|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
57714121|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
57714122|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
57714123|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
57714124|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
57915037|NCT02311868|DIETARY_SUPPLEMENT|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
58061821|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
58061822|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain \~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill \~70% of the RNI of vitamin A for children aged 7-11 years old.
58061823|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
58061824|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
58061825|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
58061826|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
58061827|NCT01162967|DRUG|Benznidazole|Standard dosage
58061828|NCT01162967|DRUG|Posaconazole|
58061829|NCT02967965|OTHER|Imagery|MRI at year 3
58061830|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
58061831|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
58267293|NCT05563402|DEVICE|Atalante|Atalante Gait training: Using the Atalante System (self-reliant walking system), participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute).
57714125|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
57714126|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
57714127|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
57915038|NCT02304796|BEHAVIORAL|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
57915039|NCT02304796|BEHAVIORAL|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
57915040|NCT04622774|DRUG|IMGC936|Antibody Drug Conjugate
57915041|NCT01227577|DRUG|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
57714128|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
57915042|NCT03271021|DRUG|FMX101|FMX101, 4% minocycline foam
57714129|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
57714130|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
57714131|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
57714132|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
57915043|NCT03271021|DRUG|Vehicle Foam|Vehicle Foam
58061832|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
58267294|NCT01573416|OTHER|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
57714133|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
58061833|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
57714134|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
57714135|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
57714136|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
57714137|NCT05679791|DEVICE|Dynamometer|to assses hand grip
57714138|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
57714139|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
57714140|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
57714141|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
57714142|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
57714143|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
57915044|NCT04782466|BEHAVIORAL|Physical Activity (PA) Intervention|The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
58061834|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
58061835|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
58267295|NCT01573416|OTHER|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
58267296|NCT05715047|BEHAVIORAL|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
58267297|NCT05715047|BEHAVIORAL|Usual Care|Standard transplant care.
58267298|NCT02557373|DIETARY_SUPPLEMENT|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
58267299|NCT02557373|DIETARY_SUPPLEMENT|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
58267300|NCT02608255|OTHER|blood samples|
58267301|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
58267302|NCT01314105|DRUG|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
57714144|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
57714145|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
57714146|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
58267303|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
58267304|NCT03605940|COMBINATION_PRODUCT|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
57714147|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
58267305|NCT03605940|DRUG|Corticosteroids|2 mg/kg/day
58267306|NCT01939626|DEVICE|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
58267307|NCT01939626|DEVICE|Standard culture medium|This culture system needs media change on day 3 of culture.
58267308|NCT05783024|OTHER|Data collection|retrospective data collection
58267309|NCT04836481|OTHER|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
58267310|NCT00771511|DRUG|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
57714148|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
58061836|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
58267311|NCT00771511|DRUG|Placebo|Only lidocaine gel will be appled to the cervix
58267312|NCT02172586|DRUG|Telmisartan|
57915045|NCT04782466|BEHAVIORAL|Waitlist attention-control|For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
57915046|NCT00763737|PROCEDURE|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
57915047|NCT02662101|DEVICE|Exsalt SD7, Exsalt T7 Wound Dressing|
57915048|NCT01882933|DRUG|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
57915049|NCT01882933|PROCEDURE|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
58061837|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
58387155|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
57915050|NCT02445001|PROCEDURE|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
58061838|NCT00688194|DRUG|fulvestrant|Given intramuscularly
58061839|NCT00688194|DRUG|lapatinib ditosylate|Given orally
58061840|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
58061841|NCT00688194|OTHER|placebo|Given orally
58061842|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
58267313|NCT02172586|DRUG|Losartan|
58267314|NCT02172586|DRUG|Hydrochlorothiazide|
58387156|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
58267315|NCT04764084|DRUG|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
57915051|NCT00405691|DEVICE|"TOPS System - Total Posterior Arthroplasty Implant"|
58387157|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
58387158|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
58387159|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
58267316|NCT04764084|DRUG|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
58267317|NCT05299372|OTHER|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
58387160|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
58387161|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
58387162|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
57714149|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
57915052|NCT05373160|OTHER|Assessment study|Assessment of functional tests with and without dual tasks
57915053|NCT01105754|BEHAVIORAL|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
57915054|NCT01508715|OTHER|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
58267318|NCT02195427|DEVICE|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
58267319|NCT02195427|DEVICE|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
58267320|NCT05814692|DIAGNOSTIC_TEST|blood and urine samples|blood and urine samples
58387163|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
57714150|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
57714151|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
57714152|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
57714153|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
57714154|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
57714155|NCT03199703|DEVICE|Baylis transseptal system group|
57714156|NCT03199703|DEVICE|Standard conventional transseptal group|
57915055|NCT01243632|DRUG|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
57915056|NCT01952054|DRUG|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
58387164|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
57915057|NCT00279786|PROCEDURE|Blood draw|blood drawn
58061843|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
57714157|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
57714158|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
57714159|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
57714160|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
57714161|NCT06615570|DRUG|VX-973|Suspension for oral administration.
57714162|NCT06615570|DRUG|Placebo|Suspension for oral administration.
57915058|NCT01677897|DRUG|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
57915059|NCT00760006|DRUG|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
57915060|NCT00760006|OTHER|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
58061844|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
58061845|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
57714163|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
57714164|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
57714165|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
57714166|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
57714167|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
58061846|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
57714168|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
57714169|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
57714170|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
57714171|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
58061847|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
57714172|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
58387165|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
57714173|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
57714174|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
57714175|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
57714176|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
57714177|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
57714178|NCT03325413|DEVICE|Temperature management|Perioperative warming
58267321|NCT04375904|RADIATION|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
58267322|NCT02697565|BEHAVIORAL|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
57714179|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
57714180|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
57714181|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
57714182|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
57714183|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
57714184|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
57714185|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
57714186|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
58061848|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
58267323|NCT02697565|BEHAVIORAL|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
58267324|NCT00672841|DRUG|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
57714187|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
57714188|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
57915061|NCT02589860|OTHER|Melphalan kinetic study|Concentration of Melphalan in plasma samples
57915062|NCT02589860|GENETIC|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
57915063|NCT02589860|GENETIC|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
58061849|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
57915064|NCT03277573|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
57915065|NCT03277573|DRUG|Placebo|Inactive ingredient
57915066|NCT03787082|DRUG|Nitrates|1,000 mg/11.18 mmol, oral
58267325|NCT00672841|DRUG|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
57915067|NCT03787082|DRUG|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
57915068|NCT03787082|DRUG|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
57915069|NCT01115751|DRUG|LY2780301|"Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
58061850|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
58267326|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
58267327|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
58267328|NCT03486002|DEVICE|Cleansweep|The Cleansweep closed suction system
58267329|NCT03486002|DEVICE|Halyard|Halyard Closed Suction System
57915070|NCT04260880|OTHER|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
58267330|NCT01572311|BEHAVIORAL|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
58267331|NCT01572311|BEHAVIORAL|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
58267332|NCT01070836|DRUG|natalizumab|Administered as specified in the treatment arm
57915071|NCT04260880|OTHER|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
57915072|NCT04260880|OTHER|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
57915073|NCT01944371|DRUG|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
57915074|NCT03534323|DRUG|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
57915075|NCT03534323|DRUG|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
57915076|NCT02649946|DEVICE|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
58267333|NCT02333383|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
57915077|NCT02649946|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
57915078|NCT03946150|DIAGNOSTIC_TEST|P/FP Ratio|PaO2/Fio2 X PEEP
57915079|NCT03059069|DRUG|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
57915080|NCT03059069|DRUG|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
58267334|NCT01959698|DRUG|Carboplatin|Given IV
58267335|NCT01959698|DRUG|Carfilzomib|Given IV
58267336|NCT01959698|DRUG|Etoposide|Given IV
58267337|NCT01959698|DRUG|Ifosfamide|Given IV
58387166|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
57714189|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
57714190|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
57915081|NCT01452321|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
57915082|NCT04928430|DRUG|XAV-19|150 mg of XAV-19 single IV perfusion
57915083|NCT04928430|DRUG|Placebo|Single IV infusion
57915084|NCT02970474|DEVICE|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
57915085|NCT02970474|DEVICE|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
57915086|NCT02091648|BEHAVIORAL|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
58267338|NCT01959698|OTHER|Laboratory Biomarker Analysis|Correlative studies
58387167|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
58387168|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
58387169|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
57714191|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
57714192|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
57714193|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
58387170|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
58387171|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
57915087|NCT02091648|BEHAVIORAL|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
57915088|NCT02872831|DEVICE|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
58267339|NCT01959698|OTHER|Pharmacological Study|Correlative studies
58267340|NCT01959698|BIOLOGICAL|Rituximab|Given IV
58267341|NCT06288269|OTHER|Severity of Stroke and 1 year survival|Evaluated from NIHSS and clinical outcome 1 year survival death
58267342|NCT03391804|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
58387172|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
58387173|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
58267343|NCT04407429|DIAGNOSTIC_TEST|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
58387174|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
58387175|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
58387176|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
57915089|NCT02872831|DEVICE|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
57915090|NCT01312012|DRUG|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
57915091|NCT03466801|DRUG|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
57915092|NCT03466801|DRUG|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
57915093|NCT01827618|DRUG|Rapamycin|
57915094|NCT01667211|DRUG|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
57915095|NCT00987246|DRUG|Placebo Gel|Topical
57915096|NCT00987246|DRUG|LAS41005|Topical
57915097|NCT00987246|DRUG|LAS106521|Topical
57915098|NCT02639598|DRUG|Flunarizine|"as in arm descriptions"
57915099|NCT02639598|DRUG|Topiramate|"as in arm descriptions"
58387177|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
58387178|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
57915100|NCT02594761|BIOLOGICAL|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
57915101|NCT02594761|BIOLOGICAL|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
57915102|NCT02594761|BIOLOGICAL|Herceptin US|Intravenous Infusion, 440 mg/vial
57915103|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
57915104|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
57915105|NCT03536754|OTHER|Placebo|Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
58061851|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
57915106|NCT03536754|DRUG|CCX140-B|One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
57915107|NCT03536754|DRUG|CCX140-B|Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
57915108|NCT03536754|DRUG|CCX140-B|Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
58267344|NCT04122664|DEVICE|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
57915109|NCT00377091|DRUG|Fondaparinux|
58387179|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
57915110|NCT06164392|DRUG|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
58267345|NCT04122664|DEVICE|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
58267346|NCT04453800|DRUG|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
58267347|NCT04453800|DRUG|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
58387180|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
57714194|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
57714195|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
57714196|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
57714197|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
57714198|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
57714199|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
57714200|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
57714201|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
57915111|NCT02245906|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
57915112|NCT02245906|DIETARY_SUPPLEMENT|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
57915113|NCT02245906|DIETARY_SUPPLEMENT|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
57915114|NCT05345808|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
57915115|NCT00002301|DRUG|Foscarnet sodium|
57915116|NCT01955889|BEHAVIORAL|Mobile Health Technology|
57915117|NCT01955889|BEHAVIORAL|Stretching & Strengthening Exercises|
57915118|NCT01955889|BEHAVIORAL|Walking with Pedometer|
57915119|NCT01149356|DRUG|Exemestane|Given orally
57915120|NCT01149356|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
57915121|NCT01149356|DRUG|Goserelin Acetate|Given subcutaneously to premenopausal patients
57915122|NCT05374161|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.
57915123|NCT05374161|OTHER|Waitlist Control Group|Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
57915124|NCT00414687|DRUG|Ventavis (Iloprost, BAYQ6256)|
57915125|NCT04257591|OTHER|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
57915126|NCT05187182|DRUG|CA-4948|Provided by Curis, Inc.
57915127|NCT05187182|BIOLOGICAL|Nivolumab|240 mg IV on Day 1 of each cycle
57915128|NCT05187182|BIOLOGICAL|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,...) and dosing may continue for a max of 2 years
57915129|NCT05187182|DRUG|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
57915130|NCT05187182|DRUG|mFOLFOX7|Standard of care
58267348|NCT04453800|DRUG|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
57714202|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
57714203|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
57714204|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
57714205|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
57714206|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
57915131|NCT00413972|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
57915132|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
57915133|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
57915134|NCT00413972|DRUG|Placebo|Placebo once daily for a total of eight weeks
58267349|NCT04453800|OTHER|placebo|Saline was administered intravenously
57714207|NCT00002010|DRUG|Fluconazole|
57714208|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
57714209|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
57714210|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
57714211|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
57714212|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
57714213|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
57714214|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
57714215|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
57714216|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
57714217|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
57714218|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
57714219|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
57714220|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
57714221|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
57714222|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
57915135|NCT02789254|BIOLOGICAL|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA\* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~\* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
58267350|NCT03309826|DEVICE|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
57915136|NCT05523999|OTHER|Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA|Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.
57915137|NCT05040984|DRUG|Solifenacin Oral Tablet|Solifenacin 1 tablet per day
57915138|NCT05040984|DRUG|Mirabegron 25mg|Mirabegron 1 tablet per day
58061852|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
58061853|NCT01682759|DRUG|Omarigliptin|
58267351|NCT03309826|DEVICE|Nasal Dilator Strip|Nightly use of nasal dilator strip
58387181|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
58387182|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
57714223|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
57915139|NCT05609201|DIAGNOSTIC_TEST|HRCT Thorax|HRCT Thorax at 0, 6 and 12 months
57915140|NCT05609201|DEVICE|Glycocheck Endothelial Glycocalyx Assessment|Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months
58061854|NCT01682759|DRUG|Placebo to Omarigliptin|
57714224|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
57714225|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
57714226|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
57714227|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
58267352|NCT00840242|DRUG|Nicotine gum|8-12 pieces per day, maximum 24 daily
58267353|NCT00840242|DRUG|Placebo gum|8-12 pieces per day, maximum 24 daily
58267354|NCT00840242|DRUG|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
58267355|NCT00840242|DRUG|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
58267356|NCT01704001|DRUG|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
58267357|NCT05961475|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snacks with original level of sugar
58267358|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
58267359|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 3|Fruit snacks with reduced level of sugar
58387183|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
58387184|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
57714228|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
57714229|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
58061855|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
57714230|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
57714231|NCT01873989|DRUG|Testosterone replacement|
57714232|NCT01873989|OTHER|Waitlist control|
57714233|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
58267360|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 4|Fruit snacks with zero added sugar
57714234|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
57714235|NCT02121340|BEHAVIORAL|Behavioral Activation|
57714236|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
57915141|NCT05609201|DIAGNOSTIC_TEST|Blood biomarkers|Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months
58061856|NCT01682759|DRUG|Glimepiride Placebo|
58387185|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
58387186|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
57714237|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
58061857|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
58267361|NCT05961475|DIETARY_SUPPLEMENT|White Bread|White bread with matched carbohydrate as control
58267362|NCT02898558|BEHAVIORAL|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
58267363|NCT02898558|DEVICE|magnifying lenses|
58387187|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
58387188|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
58387189|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
57714238|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
58061858|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
58387190|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
58061859|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
58061860|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
58061861|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
58267364|NCT04390763|BIOLOGICAL|NIS793|anti-TGFb antibody
58267365|NCT04390763|BIOLOGICAL|Spartalizumab|anti-PD-1 antibody
57714239|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
57714240|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
58061862|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
58267366|NCT04390763|DRUG|gemcitabine|SOC chemotherapy
58267367|NCT04390763|DRUG|nab-paclitaxel|SOC chemotherapy
58267368|NCT01944670|DEVICE|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
58267369|NCT03774225|OTHER|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
57714241|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
57714242|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
58267370|NCT03774225|OTHER|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
58061863|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
58267371|NCT03774225|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
58061864|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
57714243|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
57714244|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
57714245|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
58267372|NCT00803205|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
58387191|NCT02318368|DRUG|Ficlatuzumab|
58387192|NCT02318368|DRUG|Erlotinib|
58387193|NCT02318368|DRUG|placebo|
58387194|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
58387195|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
57714246|NCT02201797|OTHER|DCE MRI|
57714247|NCT02317302|DEVICE|FDG-PET/MR|
57714248|NCT02317302|DEVICE|FDG-PET/CT|
57714249|NCT02176733|DRUG|cyclosporine|
58061865|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
58061866|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
58061867|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
58061868|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
58061869|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
58267373|NCT00803205|DRUG|Placebo|Placebo matching to ataluren will be provided.
57714250|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
58267374|NCT03423966|DEVICE|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
58267375|NCT05248334|DRUG|Ranibizumab Injection|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
58267376|NCT05248334|PROCEDURE|PPV|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
58387196|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
58387197|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
57714251|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
57714252|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
57714253|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
57714254|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
57714255|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
57714256|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
57714257|NCT06659445|OTHER|Sham|Sham injection
57714258|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
57714259|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
58061870|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
57714260|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
57714261|NCT04139590|DEVICE|Panda|
57714262|NCT04139590|DEVICE|Visual Analogue Scale - Original|
57714263|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
58061871|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
58387198|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
58387199|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
58387200|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
57714264|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
57714265|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
57714266|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
57714267|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
58061872|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
58387201|NCT00287001|DEVICE|Cold air cooling|
58387202|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
58387203|NCT01882712|DRUG|CD07805/47 Gel Placebo|
57714268|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
57714269|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
57714270|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
57714271|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
57714272|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
57714273|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
57714274|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
57714275|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
57714276|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
57714277|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
57714278|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
57714279|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
57714280|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
57714281|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
57714282|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
57714283|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
57714284|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
57714285|NCT01720095|DRUG|Niaspan|
57714286|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
57714287|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
57915142|NCT05609201|DIAGNOSTIC_TEST|Peripheral leucocyte telomere length|HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months
58061873|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
57714288|NCT04935697|OTHER|SOC|Standard of care patient management.
58061874|NCT00001302|DRUG|PSC 833|
58387204|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
58061875|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
57714289|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
57714290|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
58061876|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
58061877|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
58387205|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
58387206|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
58387207|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
58387208|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
57714291|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
58061878|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
58387209|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
58387210|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
58387211|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
58267377|NCT05583279|BEHAVIORAL|Dialetical Behavioral Therapy for Adolescents|DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
57714292|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
57714293|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
58387212|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
58267378|NCT00623597|DRUG|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
58267379|NCT00623597|DRUG|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
58267380|NCT00344591|BEHAVIORAL|Structured Ecosystems Therapy (SET)|
58267381|NCT00344591|BEHAVIORAL|Individually tailored intervention|
58267382|NCT00018291|DRUG|Risperidone|
58267383|NCT00018291|DRUG|Gabapentin|
58267384|NCT01300208|DRUG|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
58267385|NCT01300208|OTHER|Placebo|
58387213|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
57714294|NCT00647192|DRUG|Eplerenone|50 mg per day
57714295|NCT00647192|DRUG|Placebo|50 mg per day
57714296|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
57714297|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
57714298|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
57714299|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
57714300|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
58387214|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
57714301|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
57714302|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
58061879|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
58061880|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
58267386|NCT02014922|DRUG|TheraTears® Lubricant Eye Drop|
57714303|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
57714304|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
57714305|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
58267387|NCT02014922|DRUG|TheraTears® preservative-free single-use containers|
58267388|NCT02014922|DIETARY_SUPPLEMENT|TheraTears® Nutrition|
58267389|NCT02014922|OTHER|TheraTears® TheraLid® Eyelid Cleanser|
57714306|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
57714307|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
57714308|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
57714309|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
58267390|NCT02252471|BEHAVIORAL|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
58267391|NCT03786692|DRUG|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
58267392|NCT03786692|DRUG|Arm B|Carboplatin + Pemetrexed + Bevacizumab
58267393|NCT03799406|DRUG|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
58267394|NCT03799406|OTHER|Placebo|Placebo supplementation during acute episode of bronchiolitis
58387215|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
58387216|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
58387217|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
58387218|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
58387219|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
58387220|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
58387221|NCT02448992|RADIATION|hippocampal-sparing WBRT|
57714310|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
57714311|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
58061881|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
58387222|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
58387223|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
57714312|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
57714313|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
57714314|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
57714315|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
57714316|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
57714317|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57714318|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57714319|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
57915143|NCT05609201|DIAGNOSTIC_TEST|Pulmonary function testing|Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months
57915144|NCT05609201|DIAGNOSTIC_TEST|Patient reported outcome measures|Electronic collection of patient reported outcome measures
57915145|NCT02118558|DEVICE|Negative Pressure Wound Therapy (NPWT)|
57915146|NCT02118558|DRUG|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
57915147|NCT03430531|DRUG|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
57915148|NCT04033185|OTHER|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
57915149|NCT04033185|OTHER|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
58061882|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
58061883|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
58061884|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
58061885|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
58061886|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
58061887|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
58061888|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
57915150|NCT04822831|BEHAVIORAL|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
57915151|NCT04822831|BEHAVIORAL|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
57915152|NCT02723526|OTHER|Blood drawing|
57915153|NCT00004051|DRUG|irinotecan hydrochloride|
58061889|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
58387224|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
58387225|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
57915154|NCT02684253|DRUG|Nivolumab|
58387226|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
57915155|NCT02684253|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
57915156|NCT04900987|DEVICE|Steri-strips|Pneumatic TR band compression with use of steri-strips
58061890|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
58061891|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
57714320|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
57915157|NCT01478529|DRUG|mirabegron OCAS|oral administration
57915158|NCT01478529|DRUG|mirabegron|iv administration
57915159|NCT02450799|DEVICE|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
57915160|NCT02450799|DEVICE|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
57915161|NCT02450799|DEVICE|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
58387227|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
58387228|NCT02229825|DRUG|Duloxetine|Capsule
57915162|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
57915163|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
57915164|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
57915165|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
57915166|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
57915167|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
58387229|NCT02229825|DRUG|Placebo|Capsule
58387230|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
58387231|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
58387232|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
58387233|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
58387234|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
58387235|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
58387236|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
58387237|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
58387238|NCT00037440|GENETIC|Polymorphisms measured|
58387239|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
57915168|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
58387240|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
58387241|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58387242|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57915169|NCT01365949|GENETIC|microarray analysis|
57915170|NCT01365949|GENETIC|protein analysis|
57915171|NCT01365949|OTHER|immunohistochemistry staining method|
57915172|NCT01365949|OTHER|laboratory biomarker analysis|
57915173|NCT04097301|DRUG|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
57915174|NCT02996565|OTHER|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~1. Improved recognition of uncontrolled BP at primary care encounters,~2. Therapeutic action to address uncontrolled BP at primary care encounters,~3. Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
57915175|NCT02996565|OTHER|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~1. Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~2. Systematic home BP telemonitoring with data transmitted into patient medical record~3. Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
57915176|NCT01043393|DRUG|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
57915177|NCT05314790|OTHER|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
58387243|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
58387244|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57714321|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
57915178|NCT05003440|DRUG|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
58387245|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
58387246|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
58387247|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
58387248|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
58387249|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
57714322|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
57714323|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
57714324|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
57714325|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
57714326|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
57714327|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
58387250|NCT00511628|DRUG|Risperidone|As prescribed
58061892|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
58061893|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
58387251|NCT02227030|DRUG|BIIB 722 CL solution|
58387252|NCT02227030|DRUG|BIIB 722 CL tablet|
58387253|NCT02227030|DRUG|Placebo solution|
58387254|NCT02227030|DRUG|Placebo tablet|
58387255|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
58387256|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
58387257|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
58387258|NCT01211977|DRUG|XOMA 052|
58387259|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
58061894|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
58061895|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
57714328|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
58387260|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
58387261|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
58387262|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
58387263|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
58387264|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
57714329|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
57915179|NCT05003440|DRUG|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
57915180|NCT05117164|OTHER|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
57915181|NCT03305731|BEHAVIORAL|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
58061896|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
57915182|NCT00390585|DRUG|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
58061897|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
58061898|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
58061899|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
58061900|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
58061901|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
58061902|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
58061903|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
58061904|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
58387265|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
58387266|NCT02533544|DRUG|tenofovir disoproxil fumarate|
58387267|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
57714330|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
57714331|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
57714332|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
57915183|NCT00390585|DRUG|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
57915184|NCT01873820|DIETARY_SUPPLEMENT|Calcium ascorbate|
57915185|NCT01873820|DIETARY_SUPPLEMENT|Ascorbic acid|
57714333|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
57714334|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
57714335|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
57915186|NCT02475239|BEHAVIORAL|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
57915187|NCT02475239|BEHAVIORAL|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
57915188|NCT02084056|DRUG|Linagliptin|Linagliptin
58387268|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points."
58387269|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
57714336|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
57714337|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
57714338|NCT02095184|DRUG|Anastrozole|1 mg daily
57714339|NCT02095184|DRUG|Letrozole|2.5 mg daily
57915189|NCT02084056|DRUG|Metformin|Metformin
57915190|NCT02084056|DRUG|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
57915191|NCT00291590|BEHAVIORAL|DHEP|
57915192|NCT04584775|OTHER|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
57915193|NCT04584775|OTHER|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
57714340|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
57714341|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
57714342|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
57714343|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
57714344|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
57915194|NCT02483585|DRUG|Erenumab|Administered once a month by subcutaneous injection
57915195|NCT02483585|DRUG|Placebo|Administered once a month by subcutaneous injection
58061905|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
58267395|NCT03347344|DRUG|Riluzole|50 mg will be administered (per os) twice a day
58267396|NCT03347344|DRUG|Placebo|50 mg will be administered (per os) twice a day
58267397|NCT05990959|OTHER|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
58267398|NCT00550862|DRUG|INT-747|Once a day (QD) by mouth (PO)
57915196|NCT03938545|DRUG|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
58061906|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
58267399|NCT00550862|DRUG|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
58267400|NCT00550862|DRUG|Placebo|Placebo
58267401|NCT03479593|DIAGNOSTIC_TEST|CMR and OCT in NSTEMI patients with MVD|Lesions \>50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
58267402|NCT05173818|DRUG|Hyperbaric oxygen at 1.5 ATA|Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
58267403|NCT05173818|DRUG|Sham treatment|"Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent"
58267404|NCT05922527|PROCEDURE|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
58267405|NCT05922527|PROCEDURE|Open flap debridement|Open flap debridement
58267406|NCT01671566|BEHAVIORAL|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
58267407|NCT00699231|BIOLOGICAL|HBV-MPL vaccine 208129|IM injection
58267408|NCT00699231|BIOLOGICAL|Engerix™-B|IM injection
58267409|NCT00140530|DEVICE|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
58267410|NCT00140530|DEVICE|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
58267411|NCT04723563|DRUG|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
58267412|NCT04723563|DRUG|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
58267413|NCT04791605|OTHER|Gait analysis|Kinematic and kinetic analysis
58267414|NCT02663752|PROCEDURE|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
58267415|NCT02663752|DRUG|Deferasirox|Patients are already on commercial deferasirox before entering the study.
58267416|NCT05890430|BIOLOGICAL|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
58267417|NCT04481113|DRUG|Abemaciclib|Given PO
58267418|NCT04481113|DRUG|Niraparib Tosylate Monohydrate|Given PO
58387270|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
58267419|NCT02205905|DRUG|14C PER977|Open-label, single dose
57915197|NCT03938545|OTHER|Placebo (Administered via subcutaneous injection)|Placebo
57915198|NCT02924428|DEVICE|Venus Versa|
58267420|NCT04240860|BIOLOGICAL|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
58267421|NCT04240860|PROCEDURE|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
58267422|NCT04191941|BIOLOGICAL|Novel CAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
58267423|NCT05356975|BEHAVIORAL|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~1. One leg squat, side plank, and push up.~2. Deadlift, lumbar extension stretch, and row.~3. Glute bridge, crunches, and front raise."
58387271|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
58267424|NCT05356975|BEHAVIORAL|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
58387272|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
58387273|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
58387274|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
58387275|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
58387276|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
58387277|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
58387278|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
58387279|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
58061907|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
58267425|NCT05220059|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
58387280|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
58387281|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
57714345|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
58387282|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
58387283|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
58387284|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
58387285|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
58387286|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
58061908|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
58267426|NCT05220059|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58387287|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
58387288|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
58387289|NCT00955643|OTHER|oxygen|
58387290|NCT00955643|OTHER|other|
57714346|NCT03559660|DRUG|Certolizumab Pegol|
57714347|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
58061909|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
58061910|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
58061911|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
58061912|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
58061913|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
58061914|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
58061915|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
58061916|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
58061917|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
58061918|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
58061919|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
58061920|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
58061921|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
58061922|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
58061923|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
58267427|NCT02947542|DEVICE|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
58387291|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
58387292|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
57714348|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
58061924|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
58061925|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
58061926|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
58061927|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
58061928|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
58061929|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
58061930|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
58061931|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
58061932|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
58061933|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
58061934|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
58061935|NCT04025749|OTHER|Care as usual|Care as usual
58061936|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
58061937|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
58061938|NCT00006493|DRUG|Rosiglitazone|
58061939|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
58267428|NCT02947542|DEVICE|Standard catheter|Coronary angiography will be performed using a standard catheter.
58267429|NCT00698074|DEVICE|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
58267430|NCT02382796|DRUG|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
58267431|NCT00401544|DRUG|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
58061940|NCT04352049|PROCEDURE|Preoxygenation|
58061941|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
58267432|NCT00401544|DRUG|IV iron dextran|Administered by intravenous (IV) injection.
57714349|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
57915199|NCT05973435|OTHER|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
57915200|NCT00373477|PROCEDURE|Generalist Care Manager vs Usual Care|
57915201|NCT03634020|DEVICE|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
58267433|NCT01833936|DEVICE|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
58267434|NCT01833936|DEVICE|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
58267435|NCT03619551|DRUG|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
58267436|NCT03619551|DEVICE|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
58267437|NCT01777568|DRUG|30% oxygen|Inspired oxygen will be maintained at 30%.
57915202|NCT02216474|OTHER|Transcranial direct current stimulation|
57915203|NCT01347762|DRUG|Nabilone|nabilone titrated to 1 mg by mouth twice daily
57915204|NCT01347762|DRUG|Placebo|one placebo capsule by mouth twice daily
57915205|NCT04248231|OTHER|CINSARC signature|CINSARC molecular signature analysis
57915206|NCT02482337|PROCEDURE|POEM|POEM procedure in the OR
57915207|NCT02090959|DRUG|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
58267438|NCT01777568|DRUG|80% oxygen|Inspired oxygen will be maintained at 30%.
58267439|NCT00324142|DRUG|Oral tinidazole|
58267440|NCT01471509|OTHER|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
58267441|NCT02713438|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
58387293|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
57714350|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
57714351|NCT00667342|DRUG|Cisplatin|Given IV.
58387294|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
58387295|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
57714352|NCT00667342|DRUG|Doxorubicin|Given IV.
57714353|NCT00667342|DRUG|Methotrexate|Given IV.
57714354|NCT00667342|DRUG|Ifosfamide|Given IV.
57714355|NCT00667342|DRUG|etoposide|Given IV.
57714356|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
57714357|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
57915208|NCT01130233|PROCEDURE|robotic assisted rectal resection|robotic assisted rectal resection
57915209|NCT01130233|PROCEDURE|laparoscopic rectal resection|laparoscopic rectal resection
57915210|NCT03620916|PROCEDURE|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days
57915211|NCT03620916|PROCEDURE|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days in the postoperative period
57915212|NCT00950950|DRUG|Romosozumab|Administered by subcutaneous injection
57915213|NCT00950950|DRUG|Placebo|Administered by subcutaneous injection
57915214|NCT00006373|DRUG|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
57915215|NCT00006373|DRUG|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
57915216|NCT00006373|DRUG|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
57915217|NCT00006373|PROCEDURE|autologous bone marrow transplantation|
58061942|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
58387296|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
57714358|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
57714359|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
57714360|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
57714361|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
57915218|NCT00006373|DRUG|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
57915219|NCT00783900|OTHER|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
57915220|NCT05706753|DRUG|Milvexian|Milvexian will be administered orally.
57915221|NCT05706753|DRUG|Midazolam|Midazolam will be administered orally.
57915222|NCT05706753|DRUG|Ethinylestradiol|Ethinylestradiol will be administered orally.
57915223|NCT05706753|DRUG|Drospirenone|Drospirenone will be administered orally.
57915224|NCT02819466|DEVICE|3D echography|ultrasound visualization of the stomach in fasting patients.
57915225|NCT01620112|DRUG|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
57915226|NCT01620112|DRUG|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
57915227|NCT01620112|DRUG|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
57915228|NCT01620112|DRUG|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
58061943|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
57714362|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
57714363|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
57714364|NCT00054613|DRUG|Methoxsalen|
57714365|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
57915229|NCT03020654|OTHER|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
57915230|NCT03020654|OTHER|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
57915231|NCT05247554|DRUG|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
58387297|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
58387298|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
58387299|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
58061944|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
57714366|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
57915232|NCT05247554|DRUG|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
57915233|NCT00038974|DRUG|peginterferon alfa-2a|
57915234|NCT00038974|DRUG|Ribavirin|
58061945|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
58061946|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
58061947|NCT00510406|DRUG|Placebo|Placebo
58061948|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
58061949|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
58061950|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
58061951|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
58061952|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
58061953|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
58387300|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
58387301|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
58387302|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
57915235|NCT02344563|DRUG|Meropem|
57915236|NCT02344563|DRUG|Mepem|
58061954|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
58061955|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
58061956|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
58061957|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
58267442|NCT02713438|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
58387303|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
58387304|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
58387305|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
58387306|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
58387307|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
58061958|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
58061959|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
58061960|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
58061961|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
58061962|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
58387308|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
58387309|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
58387310|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
58387311|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
58061963|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
58061964|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
58061965|NCT00539825|DRUG|GSK704838|
58061966|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
58387312|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
58387313|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
58387314|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
58387315|NCT00861692|DRUG|argatroban|
58387316|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
58387317|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
58061967|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
58061968|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
58061969|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
58061970|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
58061971|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
58061972|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
58061973|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
58387318|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
58387319|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
58387320|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
58387321|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
58387322|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
58387323|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
58267443|NCT02713438|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
58061974|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
57714367|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
57714368|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
57714369|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
57714370|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
57714371|NCT04715984|PROCEDURE|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
58061975|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
58061976|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
58061977|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
58061978|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
58061979|NCT00311012|DRUG|Aliskiren|
58061980|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
58061981|NCT00278044|PROCEDURE|blood sampling and medical records|
58061982|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
58061983|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
58061984|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
58061985|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
58061986|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
58061987|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
58061988|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
58061989|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
58061990|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
58061991|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
57915237|NCT03687047|DEVICE|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
58061992|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
58061993|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
58061994|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
58061995|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
58061996|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
58061997|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
58061998|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
58061999|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
58062000|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
58062001|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
58062002|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
57714372|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
57714373|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
57714374|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
57714375|NCT01157481|DRUG|Conventional therapy|Conventional therapy
57714376|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
57714377|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
57714378|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
57714379|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
57714380|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
57714381|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
57714382|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
57714383|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
57714384|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
57714385|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
57714386|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
57915238|NCT04664439|DIAGNOSTIC_TEST|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
57915239|NCT04322838|DIAGNOSTIC_TEST|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
57915240|NCT04322838|DIAGNOSTIC_TEST|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
57915241|NCT04322838|DIAGNOSTIC_TEST|Skin Prick Test|Diagnostic skin test for sensitization to allergens
57915242|NCT04322838|DIAGNOSTIC_TEST|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
57915243|NCT04322838|DIAGNOSTIC_TEST|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
57915244|NCT04322838|DIAGNOSTIC_TEST|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
57915245|NCT04937712|OTHER|RT-PCR SARS-COV2 in urine|proteinuria/renal phosphate leak/uricosuria/glycosuria/ aminoaciduria)
57915246|NCT01990560|DRUG|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
57915247|NCT05907278|BEHAVIORAL|Advanced Cooking Education|"Participants attend the ACE Program for 12 weeks after school.~On one assigned day of the week, participants attend ACE virtually. The session will begin with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes).~On any day during the week, the students will make a dish using groceries they received (1 hour)."
57915248|NCT03597074|DIAGNOSTIC_TEST|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
57714387|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
57714388|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
57915249|NCT01350310|PROCEDURE|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
57915250|NCT01350310|PROCEDURE|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
57915251|NCT01350310|PROCEDURE|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
57915252|NCT01154010|DEVICE|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
57915253|NCT01154010|DEVICE|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
58062003|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
58267444|NCT02713438|BEHAVIORAL|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
57915254|NCT01932567|OTHER|Physiotherapy|
57915255|NCT01932567|PROCEDURE|Electrical impedance tomography|
57915256|NCT00758277|DRUG|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
57915257|NCT00758277|DRUG|Placebo|Sugar Pill
58062004|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
58267445|NCT02637713|DEVICE|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
58267446|NCT02637713|PROCEDURE|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
57714389|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
57915258|NCT00994084|BEHAVIORAL|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
57915259|NCT00994084|BEHAVIORAL|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
57915260|NCT04443101|OTHER|different types of intracular lens|different types of intracular lens
57915261|NCT01362777|BEHAVIORAL|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~* 15' start warming up muscles~* 30' muscle strengthening exercise for arms and abdominal muscles~* 45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~* 15' stretching~* 15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
57915262|NCT01362777|BEHAVIORAL|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~* Physiological mechanisms of apneas/hypopneas~* Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~* Beneficials effects of CPAP and/or advanced mandibular orthosis~* Description of sleep stages and physiological roles of sleep~* Known effects of exercise on sleep and metabolism~* Importance of good nutritional status and sleep hygiene on quality of life~* How to apply theses lessons of rehabilitation in daily life"
57714390|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
58387324|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
57714391|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
57714392|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
57714393|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
57714394|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
57714395|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
57915263|NCT02720367|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
58062005|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
58062006|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
58062007|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
58062008|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
58387325|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
58387326|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
57714396|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
57714397|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
57714398|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
57714399|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
57714400|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
57714401|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
58387327|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
58387328|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
57714402|NCT02803710|OTHER|Microbiological study|
57714403|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
57915264|NCT05158998|DRUG|propofol infusion|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
58062009|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
58062010|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
58387329|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
58387330|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
58387331|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
57714404|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
57714405|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
57714406|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
57714407|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
57714408|NCT02247349|BIOLOGICAL|Nivolumab|
57714409|NCT00199745|DRUG|atorvastatin|
57714410|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
57915265|NCT05158998|DRUG|sevoflurane inhalation|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
57915266|NCT00079989|DRUG|tigecycline|
57915267|NCT04960189|PROCEDURE|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
57915268|NCT02292927|BEHAVIORAL|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
58062011|NCT02485431|DRUG|Deflazacort|
58062012|NCT02785861|BEHAVIORAL|supervision of physical activity|
58062013|NCT02785861|BEHAVIORAL|distance supervised physical activity|
58062014|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
58062015|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
58062016|NCT02146885|OTHER|Weight Control|Weight Control
58062017|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
58062018|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
58062019|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
58062020|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
58062021|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
58062022|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
58062023|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
58062024|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
58062025|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
58062026|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
58062027|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
58062028|NCT01930396|DRUG|Tinzaparin|
58062029|NCT01930396|DRUG|Unfractionated Heparin|
58387332|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
57714411|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
58267447|NCT02222831|PROCEDURE|Day 0 denudation and time lapse culture on IVF-oocytes.|
57714412|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
57714413|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
57714414|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
57714415|NCT06285539|DRUG|Filgotinib|Filgotinib
57714416|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
58267448|NCT02581228|DEVICE|ML-PrediCare|
58267449|NCT06619002|PROCEDURE|Sentinel lymph node sampling|video analysis
58267450|NCT01871766|DRUG|Vincristine|"Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants."
58387333|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
58387334|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
57714417|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
57714418|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
57714419|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
57714420|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
57714421|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
57714422|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
58387335|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
58387336|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
58387337|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
58387338|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
58387339|NCT00074139|DRUG|cyclophosphamide|
58062030|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
58062031|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
58387340|NCT00074139|DRUG|docetaxel|
58387341|NCT00074139|DRUG|doxorubicin hydrochloride|
58267451|NCT01871766|DRUG|Dactinomycin|"Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
58267452|NCT01871766|DRUG|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)"
58387342|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
58387343|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
57714423|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
58062032|NCT00653198|OTHER|No intervention|
58387344|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
58387345|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
58062033|NCT00305773|DRUG|vorinostat|Given orally once daily
58062034|NCT00305773|DRUG|vorinostat|Given orally three times daily
58267453|NCT01871766|PROCEDURE|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
57714424|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
57714425|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
57714426|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
57714427|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
57915269|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
57915270|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
57915271|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
57915272|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
57915273|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
57915274|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
57915275|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
57915276|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
58267454|NCT01871766|PROCEDURE|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
58267455|NCT01871766|DRUG|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
57915277|NCT02608593|PROCEDURE|Strattice|Implant based reconstruction with strattice cover of part or all of implant
57915278|NCT02870335|OTHER|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
58062035|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
58062036|NCT01997333|DRUG|CDX-011|
58062037|NCT01997333|DRUG|Capecitabine|
58062038|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
58062039|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
58267456|NCT01871766|DRUG|Sorafenib|Dosage and route of administration: 90 mg/m\^2/dose twice daily.
58062040|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
58062041|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
58062042|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
58062043|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
58062044|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
58062045|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
58062046|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
58062047|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
58062048|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
58062049|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
57714428|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
58062050|NCT00404326|DRUG|Hydralazine and magnesium valproate|
57714429|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
57714430|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
57714431|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
57915279|NCT02870335|OTHER|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
57915280|NCT03622619|OTHER|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
58062051|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
58062052|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
58062053|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
58062054|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
58062055|NCT00238160|DRUG|cisplatin|
57714432|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
58062056|NCT00238160|DRUG|fluorouracil|
57714433|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
57714434|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
57714435|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
57915281|NCT03622619|OTHER|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
57915282|NCT00003657|BIOLOGICAL|filgrastim|
58062057|NCT00238160|PROCEDURE|adjuvant therapy|
58062058|NCT00238160|PROCEDURE|chemotherapy|
58062059|NCT00238160|PROCEDURE|conventional surgery|
58062060|NCT00238160|PROCEDURE|hepatic arterial infusion|
58062061|NCT00238160|PROCEDURE|surgery|
57915283|NCT00003657|DRUG|Amifostine|
57915284|NCT00003657|DRUG|Carboplatin|
57915285|NCT00003657|DRUG|Etoposide|
57915286|NCT00003657|DRUG|Ifosfamide|
57915287|NCT00003657|PROCEDURE|peripheral blood stem cell transplantation|
58062062|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
58062063|NCT00170846|DRUG|Everolimus (RAD001)|
58062064|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
58062065|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
58062066|NCT00170846|DRUG|Steroids|
58062067|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
58062068|NCT00062972|DRUG|donepezil|
58062069|NCT00062972|DRUG|glucose|
58267457|NCT01871766|DRUG|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
58387346|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
58387347|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
58387348|NCT02509364|OTHER|No intervention|
57714436|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
57714437|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
57714438|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
57714439|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
57714440|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
57714441|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
57714442|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
57714443|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
57915288|NCT04249154|DRUG|Eligard|Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
57714444|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
57714445|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
58387349|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
58387350|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
57915289|NCT05365048|OTHER|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
58267458|NCT01871766|PROCEDURE|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
58387351|NCT00757952|OTHER|chromatography|
58387352|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
58387353|NCT00757952|OTHER|questionnaire administration|
58387354|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
58387355|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
58387356|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
58387357|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
57714446|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
58062070|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
58267459|NCT01871766|DRUG|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
58267460|NCT01871766|DRUG|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
58267461|NCT01871766|DRUG|Etoposide|"Dosage and Route of Administration:~Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis"
58267462|NCT01871766|DRUG|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
58387358|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
58387359|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
58387360|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
57915290|NCT05365048|OTHER|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
57915291|NCT04661956|PROCEDURE|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
57915292|NCT04401852|DRUG|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
57915293|NCT04401852|DRUG|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
57915294|NCT04061538|DIETARY_SUPPLEMENT|zinc sulfate|zinc 20mg tablets
57915295|NCT04061538|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
57915296|NCT05163171|OTHER|questionnaire|questionnaire for conjugal violence prevalence
57915297|NCT00642772|OTHER|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
57915298|NCT01092741|DRUG|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
57915299|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
57915300|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
57915301|NCT02492022|OTHER|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
57915302|NCT06265064|DIAGNOSTIC_TEST|STOP-Bang score >= 3 with factors predicting difficult intubation|patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm
57915303|NCT00728585|DRUG|Palifermin|Given IV
57915304|NCT00728585|OTHER|Placebo|Given IV
57915305|NCT02725346|PROCEDURE|Acromioplasty with planning|
57915306|NCT02725346|PROCEDURE|Acromioplasty without planning|
57915307|NCT06492122|DRUG|[225Ac]Ac-FL-020|\[225Ac\]Ac-FL-020 injected intravenously
57915308|NCT06492122|DRUG|Blood samples for PK|Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
58267463|NCT01871766|DRUG|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
58267464|NCT01871766|DRUG|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
58267465|NCT01871766|DRUG|^1^1C-methionine|Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
58267466|NCT01765829|DRUG|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
58387361|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
57915309|NCT06492122|DRUG|[111In]In-FL-020|A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
57915310|NCT06492122|PROCEDURE|Blood and urine samples collection|For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
57915311|NCT06492122|PROCEDURE|SPECT/CT images|For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
57915312|NCT02542111|DRUG|Bortezomib|Bortezomib IV
57915313|NCT02542111|DRUG|Gemcitabine|Gemcitabine IV
58387362|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
57714447|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
57915314|NCT02542111|DRUG|Dexamethasone|Dexamethasone IV
57915315|NCT02542111|DRUG|Cisplatin|Cisplatin IV
57915316|NCT04103060|DRUG|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
57915317|NCT04103060|DRUG|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
58062071|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
58062072|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
58267467|NCT01765829|DRUG|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
57714448|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
57714449|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
57714450|NCT05755373|OTHER|No treatment given|No treatment given
57714451|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
57714452|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
57915318|NCT01471496|PROCEDURE|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
57915319|NCT05945797|DRUG|Dexamethasone 4mg|An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
58062073|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
57714453|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
57714454|NCT01540370|OTHER|No Treatment|No treatment
57714455|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
57714456|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
57714457|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
57714458|NCT00058331|BIOLOGICAL|epoetin alfa|
57714459|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
57714460|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
57714461|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
57714462|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
57714463|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
57714464|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
57714465|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
57714466|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
57714467|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
57714468|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
57915320|NCT01795573|BIOLOGICAL|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
57915321|NCT03329560|BIOLOGICAL|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
57915322|NCT03834051|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Rectal Administration Open Label
58062074|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
58387363|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
58267468|NCT03364517|OTHER|Predictor score of the imminence of a childbirth (SPIA)|The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
58267469|NCT05838950|OTHER|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
58267470|NCT04423627|DRUG|Clonidine|Clonidine 0.2 mg/day oral tablet
58387364|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
57714469|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
57714470|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
57714471|NCT04834011|RADIATION|3D CT angiography|
57714472|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
57714473|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
57714474|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
57714475|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
57714476|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
57714477|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
57714478|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
57714479|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
57714480|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
57714481|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
57915323|NCT03855423|DIETARY_SUPPLEMENT|Tocotrienol-rich Fraction (TRF)|TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
57915324|NCT03060668|OTHER|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
57915325|NCT03060668|OTHER|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
58267471|NCT04423627|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 37.5 mg/day oral tablet
58267472|NCT04423627|DRUG|Placebo|Placebo
58267473|NCT03787303|DRUG|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
58387365|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
58387366|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
58387367|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
57915326|NCT01401907|OTHER|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
57915327|NCT00928447|DRUG|rHuPH20|0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
58267474|NCT06253741|PROCEDURE|PARAVERTEBRAL BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes
58387368|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
57714482|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
57714483|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
57714484|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
57714485|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
57714486|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
57714487|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
57915328|NCT00928447|DRUG|Placebo|0.25 mL ID syringe push bolus injection of placebo control
57915329|NCT02042222|DRUG|Hydroxyurea|
57915330|NCT03432715|BEHAVIORAL|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
58062075|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
58062076|NCT02940353|DEVICE|TREFOIL concept|
58062077|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
58062078|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
58062079|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
58387369|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
57714488|NCT05846009|DRUG|SAR442501|Subcutaneous injection
57714489|NCT05846009|DRUG|Placebo|Subcutaneous injection
57714490|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
57714491|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
58387370|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
58387371|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
58387372|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
57714492|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
57714493|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
57714494|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
57714495|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
57714496|NCT00360776|DRUG|tipifarnib|Given orally
57714497|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
57714498|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
57915331|NCT03432715|BEHAVIORAL|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
57915332|NCT02731573|DRUG|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
57915333|NCT02731573|PROCEDURE|Open heart surgery|Subject will undergo open heart surgery according to standard of care
57915334|NCT02860494|DRUG|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
58062080|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
58267475|NCT06253741|PROCEDURE|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
58267476|NCT06253741|PROCEDURE|PLACEBO|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
57915335|NCT02860494|DRUG|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
58062081|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
58062082|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
58062083|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
58267477|NCT01741506|DRUG|Dalteparin (Fragmin®)|
57714499|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
58387373|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
57714500|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
57714501|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
58267478|NCT04861116|BEHAVIORAL|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
58267479|NCT06521255|DRUG|Tafasitamab|Tafasitmab was infused intravenously
58387374|NCT02229981|DRUG|ABC294640|
57714502|NCT05351008|OTHER|Exercise program:|Core strengthening program
57714503|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
57714504|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
57714505|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
57714506|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
57714507|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
58387375|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
58387376|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
58062084|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
58267480|NCT06521255|DRUG|Lenalidomide|Lenalidomide orally
58387377|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
57714508|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
57714509|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
57915336|NCT05636722|BEHAVIORAL|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
57915337|NCT02539953|DEVICE|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
57915338|NCT01711723|DRUG|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
57714510|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
57915339|NCT00861523|DRUG|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
57915340|NCT03743285|DEVICE|AID System|AID system
58062085|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
58062086|NCT02853318|DRUG|Cyclophosphamide|Given PO
58267481|NCT06521255|DRUG|Gemcitabine|Gemcitabine was infused intravenously
58267482|NCT06521255|DRUG|Oxaliplatin|Oxaliplatin was infused intravenously
58267483|NCT06521255|DRUG|Rituximab|Rituximab was infused intravenously.
58267484|NCT06298513|OTHER|Cardiac rehabilitation|Six weeks of cardiac rehabilitation with physical training
58267485|NCT02167815|DEVICE|Mepilex XT|Experimental arm
58267486|NCT02167815|OTHER|standard care|
58267487|NCT00291161|BEHAVIORAL|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
58267488|NCT02553434|DEVICE|Pigtail catheter|Insertion of pigtail catheter
58267489|NCT00331513|DRUG|vorinostat|Given orally
58267490|NCT00331513|DRUG|idarubicin|Given IV
58267491|NCT00331513|OTHER|laboratory biomarker analysis|Correlative studies
58267492|NCT00331513|OTHER|pharmacological study|Correlative studies
58267493|NCT04385875|BIOLOGICAL|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
58267494|NCT04385875|OTHER|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI_extension trial, ATI will be extended for 48 weeks.
58267495|NCT04948034|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
58267496|NCT04948034|DRUG|Fruquintinib|Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.
57714511|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
58267497|NCT04948034|DRUG|Tislelizumab|Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
58267498|NCT04291456|DRUG|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
58267499|NCT02602613|DEVICE|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
58267500|NCT05776316|BEHAVIORAL|Integrated Harm Reduction Intervention (IHRI)|8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.
58267501|NCT06595459|DRUG|Nicotine Pouches|3mg or 6mg nicotine pouches
58267502|NCT06595459|DRUG|Mini Nicotine lozenges|2mg to 4mg mini lozenges
58267503|NCT05872100|BEHAVIORAL|MINDFULNESS BASED APPLICATION|"* The effectiveness of mindfulness practices in the field of health~* Breathing exercise~* Discussing and sharing about exercise~* Introduction of informal and formal mindfulness practices~* Communication exercise with conscious awareness~* Sounds and thoughts meditation~* The concept of compassion~* Biological foundations of compassion~* Self-compassion~* Barriers to compassion~* Coping with compelling emotions~* Coping with the intensity of compassion~* Compassionate mindfulness attitudes~* Admission stages and improving acceptance~* Compassion Meditation~* Courtesy Meditation~* My partner activity~* Body Scan~* Mindfulness Sitting Meditation~* Receiving feedback on the development of mindfulness skills and the content of the training program~* Integration of conscious awareness exercises in daily life for the future"
58267504|NCT01758978|DRUG|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
58267505|NCT00420277|DRUG|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
58267506|NCT00420277|DRUG|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
58267507|NCT00326781|DRUG|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
58267508|NCT00326781|DRUG|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
58267509|NCT02703506|OTHER|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
58267510|NCT02703506|OTHER|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
58267511|NCT05809024|DRUG|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
58267512|NCT02653170|OTHER|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services."
57714512|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
58062087|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
58267513|NCT02653170|OTHER|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~1. Contact list of care team members.~2. Access to hospital patient portal.~3. Stroke education materials, resources, and guidelines.~4. Access to Michigan 2-1-1 services.~5. Medication information and adherence tools.~6. Patient and Caregiver support networks."
58267514|NCT00556205|DRUG|Sunitinib|Sunitinib orally once daily
58267515|NCT00556205|DRUG|Bevacizumab|Intravenously every 14 days
58267516|NCT02672007|DEVICE|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
58267517|NCT01577615|BEHAVIORAL|Patterned Experience|"* The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age."
58387378|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
58387379|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
58387380|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
57714513|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
57915341|NCT03743285|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
57915342|NCT06004011|OTHER|ARROW strategies|ARROW strategies are peer-to-peer support at the patient, provider and health system levels
58062088|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
58267518|NCT04288336|OTHER|Food Diary|Ancillary studies
58267519|NCT04288336|OTHER|Preventative Dietary Intervention|Follow intermittent fasting
57714514|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
57714515|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
58387381|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
58387382|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
57714516|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
57714517|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
57714518|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
57714519|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
57714520|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
57915343|NCT06004011|OTHER|One-time education|The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
57915344|NCT02039453|DRUG|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
57915345|NCT02039453|DRUG|pethidine dose|pethidine dose 50mg, IV bolus (25mg if \< 50kg or \>70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
58267520|NCT04288336|OTHER|Questionnaire Administration|Ancillary studies
58267521|NCT00326170|DRUG|5-Azacytidine (5-aza)|Start at 75 mg/m\^2 subcutaneously daily for 7 days.
58267522|NCT00326170|DRUG|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
58267523|NCT00326170|DRUG|All-Trans Retinoic Acid (ATRA)|45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
58267524|NCT05939791|OTHER|Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518|The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
58267525|NCT05939791|OTHER|Physical exercise|The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
58267526|NCT00347594|DEVICE|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
58267527|NCT00347594|DEVICE|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
58267528|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
58267529|NCT00947024|DRUG|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
58267530|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
58267531|NCT02768441|DRUG|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
58267532|NCT00454467|PROCEDURE|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
58387383|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
58387384|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
57714521|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
57915346|NCT00008073|DRUG|doxorubicin hydrochloride|
58267533|NCT00454467|PROCEDURE|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
58267534|NCT00454467|PROCEDURE|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
58267535|NCT00454467|PROCEDURE|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
57915347|NCT00008073|DRUG|octreotide acetate|
57915348|NCT03241303|DRUG|Acarbose|Glucobay tablets on experimental day.
57915349|NCT03241303|DRUG|Placebo Oral Tablet|Placebo tablets on experimental day.
57915350|NCT03241303|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
57915351|NCT03241303|DRUG|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
58267536|NCT00454467|PROCEDURE|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
58267537|NCT00454467|PROCEDURE|Cost Data|Cost Data will be collected via hospital billing databases.
58267538|NCT00454467|PROCEDURE|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
58267539|NCT05259410|BEHAVIORAL|TRE|All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
58267540|NCT05259410|BEHAVIORAL|MedTRE|A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
58267541|NCT02101359|DRUG|T2380|200 microlitres of T2380 will be administrated intracamerally
58267542|NCT02101359|DRUG|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
58267543|NCT02101359|DRUG|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
58387385|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
58387386|NCT00887159|DRUG|Cisplatin|Given IV
58387387|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
58387388|NCT00887159|DRUG|Etoposide|Given IV
58387389|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
58387390|NCT00887159|DRUG|Vismodegib|Given PO
58387391|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
58387392|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
58387393|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
58387394|NCT00851890|DRUG|ABT-333|50 mg capsules
58387395|NCT00851890|OTHER|Placebo for ABT-333|Capsule
58387396|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
58387397|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
58387398|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
58387399|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
58387400|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
58387401|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
57714522|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
57714523|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
57714524|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
57714525|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
57714526|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
57714527|NCT01270945|PROCEDURE|Standard of Care|
57714528|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
57714529|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
57714530|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
57714531|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
57714532|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
57714533|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
57714534|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
57714535|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
57915352|NCT05972031|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
57915353|NCT02875977|OTHER|Educational video|A 4-minute educational video describing PFPT
57915354|NCT02875977|OTHER|Educational handout|A 2-page educational handout describing PFPT
57915355|NCT01439360|BIOLOGICAL|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
57915356|NCT01439360|BIOLOGICAL|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
57915357|NCT01439360|BIOLOGICAL|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
57915358|NCT01439360|BIOLOGICAL|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
57915359|NCT01439360|BIOLOGICAL|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
57915360|NCT01827293|DRUG|Promethazine|
57915361|NCT01827293|DRUG|Lorazepam|
57915362|NCT02277041|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
57915363|NCT02277041|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
57915364|NCT04340323|OTHER|Pelvic Floor Muscle Training (PFMT)|The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
57915365|NCT02814201|BEHAVIORAL|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
57915366|NCT03068533|OTHER|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
57915367|NCT03068533|OTHER|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
57915368|NCT00728611|BIOLOGICAL|PRGF|intra auricular injection 6mg
57915369|NCT00728611|DRUG|hyaluronic acid|20 mg / 2 ml
57714536|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
58387402|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
57915370|NCT00728611|DRUG|placebo|physiological water 3cc + lidocain 3cc
57915371|NCT05999097|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
57915372|NCT05999097|DIETARY_SUPPLEMENT|Placebo Group|This group will receive 12 g of corn starch as a control group.
57915373|NCT04601701|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
57915374|NCT04601701|DRUG|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
57915375|NCT03336567|OTHER|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
57915376|NCT02319577|DRUG|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
58062089|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
58062090|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
58062091|NCT02067546|DEVICE|Experimental toilet seat|
58062092|NCT02067546|DEVICE|Standard toilet seat|
58387403|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
57915377|NCT02319577|DRUG|Gefitinib|EGFR tyrosine kinase inhibitor
57915378|NCT05341596|PROCEDURE|repeat endotracheal intubation|repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
58062093|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
58062094|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
58387404|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
57915379|NCT02394951|DRUG|Pregabalin|Anticonvulsant
57915380|NCT02394951|DRUG|Placebo|Identical, matching inactive substance
57915381|NCT04869631|OTHER|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
57915382|NCT02968082|DRUG|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
58062095|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
58062096|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
58062097|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
58062098|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
58062099|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
58062100|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
58062101|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
58062102|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
58062103|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
57714537|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
57714538|NCT03212677|OTHER|Placebo|Cornstarch
57714539|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
57714540|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
57714541|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
57714542|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
57714543|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
57714544|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
57714545|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
58062104|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
58062105|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
58062106|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
58062107|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
58387405|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
58387406|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
58387407|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
58387408|NCT03774771|DRUG|Placebo|Capsules for oral administration
58387409|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
58387410|NCT00002509|BIOLOGICAL|filgrastim|
57714546|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
57714547|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
57714548|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
58387411|NCT00002509|DRUG|carboplatin|
57714549|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
57714550|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
57714551|NCT02327208|DIETARY_SUPPLEMENT|Control|
58387412|NCT00002509|DRUG|cyclophosphamide|
58387413|NCT00002509|DRUG|etoposide|
58387414|NCT00002509|DRUG|mesna|
58387415|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
58387416|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
58387417|NCT03240861|OTHER|18F-FHBG|Given IV
58387418|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
57714552|NCT02327208|DIETARY_SUPPLEMENT|Protein|
57714553|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
57714554|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
57714555|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
57714556|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
57915383|NCT02968082|DRUG|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
57915384|NCT02877914|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
57915385|NCT03343301|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
57915386|NCT03343301|DRUG|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
57915387|NCT05974215|DEVICE|assessment of change in bone height by cone beam computed tomography|bone height was measured at 1 ,30 ,90 days after denture insertion
57915388|NCT02162589|PROCEDURE|POEM|Per oral endoscopic myotomy
57915389|NCT00898898|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
57915390|NCT00995969|DRUG|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
58267544|NCT02387775|DEVICE|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
58267545|NCT00800956|DRUG|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
58267546|NCT01043562|DIAGNOSTIC_TEST|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
58387419|NCT03240861|DRUG|Busulfan|Given IV
57915391|NCT00995969|DRUG|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
58387420|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
57714557|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
57714558|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
57714559|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
57714560|NCT00529386|DRUG|Botox|300 units
57714561|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
57714562|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
57714563|NCT02665728|DRUG|BLI400 Laxative|
58267547|NCT01043562|OTHER|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole \>4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a \>10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
58267548|NCT01786824|DRUG|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
58267549|NCT01786824|DRUG|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
58267550|NCT01786824|DRUG|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
58267551|NCT01786824|PROCEDURE|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
58267552|NCT02526875|DRUG|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
58267553|NCT00977704|DEVICE|Restylane and Perlane|
58267554|NCT00657306|DRUG|hydrocortisone|50 mg/6 h per day
58267555|NCT00657306|DRUG|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
58267556|NCT01758198|BIOLOGICAL|Abatacept|
58267557|NCT01758198|DRUG|Placebo matching with Abatacept|
58267558|NCT01758198|DRUG|Methotrexate|
58267559|NCT01505738|OTHER|bacterial samples|bacterial samples taken
58267560|NCT03326284|OTHER|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
58267561|NCT03326284|OTHER|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
58267562|NCT03326284|OTHER|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
58267563|NCT03326284|OTHER|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
58267564|NCT00771329|DRUG|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
58267565|NCT00771329|OTHER|Placebo (sterile normal saline)|Single IV dose of Placebo
58267566|NCT03216148|DIAGNOSTIC_TEST|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
57915392|NCT04500431|BIOLOGICAL|Targeting CD269 chimeric antigen receptor engineered T cells|Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
58267567|NCT03981965|OTHER|Physical activity|Physical activity as described previously.
58267568|NCT05112289|DIAGNOSTIC_TEST|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
58267569|NCT01090154|DRUG|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
58267570|NCT05304689|DIAGNOSTIC_TEST|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
58267571|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for breast cancer per local standard.
58267572|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
58267573|NCT00785434|DRUG|escitalopram|Dose ranging up to 50mg
58267574|NCT00435019|DRUG|insulin detemir|s.c. injection, once or twice daily.
58267575|NCT00435019|DRUG|insulin NPH|s.c. injection, once or twice daily.
58267576|NCT00435019|DRUG|insulin aspart|s.c. injection, at main meals.
58267577|NCT03616561|DRUG|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
58267578|NCT00835679|BIOLOGICAL|cetuximab|Given IV
58267579|NCT00835679|DRUG|dasatinib|Given orally
58267580|NCT00835679|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58267581|NCT00835679|OTHER|laboratory biomarker analysis|Correlative studies
58267582|NCT03825068|PROCEDURE|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
57714564|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
57714565|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
57915393|NCT00812331|DRUG|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
57915394|NCT03430206|DEVICE|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
58387421|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
58062108|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
58062109|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
58062110|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
58062111|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
58062112|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
58062113|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
58062114|NCT00642122|DRUG|Budesonide|0.5mg once daily
58062115|NCT00642122|DRUG|Budesonide|1mg once daily
58387422|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
58387423|NCT03240861|DRUG|Fludarabine|Given IV
57714566|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
57714567|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
57714568|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
58062116|NCT00642122|DRUG|Budesonide|1mg twice daily
58062117|NCT00642122|DRUG|Budesonide|2mg once daily
58062118|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
58062119|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
58062120|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
58062121|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
58267583|NCT03825068|DRUG|general anesthetic|patient receive general anaesthetic only
57714569|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
57714570|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
57714571|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
57714572|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
58267584|NCT04611737|BEHAVIORAL|Interviewing|Self-Determination Theory within motivational interviewing
58387424|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
58387425|NCT03240861|DRUG|Plerixafor|Given SC
58387426|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58387427|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
58387428|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
58387429|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
58387430|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
58387431|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
58387432|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
58062122|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
58062123|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
58267585|NCT02187575|DRUG|UHAC 62 XX tablet|
58267586|NCT02187575|DRUG|UHAC 62 XX capsule|
58267587|NCT00527644|DEVICE|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
58267588|NCT03586479|BEHAVIORAL|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
58267589|NCT03541330|OTHER|semi-directive interview|semi-structured interview conducted by a clinical psychologist
58267590|NCT03133091|DRUG|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
58267591|NCT03133091|DRUG|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
58267592|NCT00842075|DRUG|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
58267593|NCT02777944|BEHAVIORAL|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
58267594|NCT04984317|DRUG|onabotulinumtoxin A|One-time injection of 100U BOTOX
58267595|NCT02425761|PROCEDURE|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
58267596|NCT01258075|DRUG|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
57915395|NCT01162317|OTHER|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
58062124|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
58267597|NCT01258075|DRUG|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
57915396|NCT01162317|OTHER|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
58267598|NCT04104113|OTHER|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
58267599|NCT04104113|OTHER|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
58267600|NCT03909113|DIETARY_SUPPLEMENT|amino acid based formula|amino acid based formula
58267601|NCT03059706|DEVICE|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
58267602|NCT03059706|OTHER|saline|intra-articular injection of saline after arthroscopic surgery
58267603|NCT02795520|DRUG|OTS167IV|
58267604|NCT02811497|DRUG|Azacitidine|
58267605|NCT02811497|DRUG|Durvalumab|
58267606|NCT05467618|PROCEDURE|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
58267607|NCT04721704|DRUG|Clarithromycin+ Amoxicillin + Omeprazole|In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
57714573|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
57714574|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
57915397|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
58267608|NCT04721704|DRUG|Metronidazole +Amoxicillin + Omeprazole|Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
58267609|NCT01825083|DRUG|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
58267610|NCT01825083|DRUG|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
58267611|NCT02604550|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
58267612|NCT02604550|DRUG|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
57915398|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
57915399|NCT04510831|OTHER|Refined maize with extrinsic addition of labelled FeSO4|Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
57915400|NCT04510831|OTHER|T.molitor native chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
57915401|NCT04510831|OTHER|T molitor reduced chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
57915402|NCT02670031|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
57915403|NCT02670031|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
57915404|NCT02670031|OTHER|Electrocardiogram|To examine specific function of the heart.
57915405|NCT02670031|DEVICE|Ambulatory Blood Pressure Monitoring|A 24-hour test.
57915406|NCT02670031|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
57915407|NCT05897450|OTHER|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
57915408|NCT02481947|DRUG|BLI400 Laxative|21 gm BLI400 powder
57915409|NCT02481947|DRUG|Lubiprostone|24 mcg capsule bid
57915410|NCT04999098|DRUG|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
57915411|NCT04999098|DRUG|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
57915412|NCT04999098|DRUG|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
58267613|NCT02604550|DRUG|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
58267614|NCT02910570|DRUG|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
58267615|NCT02910570|DRUG|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
58267616|NCT03416634|BEHAVIORAL|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
58267617|NCT03416634|BEHAVIORAL|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
57714575|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
57714576|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
57714577|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
57714578|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
57714579|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
57714580|NCT03056690|DRUG|ASP0819|Oral capsule
57714581|NCT03056690|DRUG|Placebo|Oral capsule
57714582|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
57714583|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
57714584|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
57714585|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
57915413|NCT01028937|DEVICE|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
57714586|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
57714587|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
57714588|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
57714589|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
57714590|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
57714591|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
57714592|NCT00682019|DRUG|Placebo|matching placebo
57714593|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
57714594|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
57714595|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
57714596|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
57714597|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
57915414|NCT03948555|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)|All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
58387433|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
57714598|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
57714599|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
57714600|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
57714601|NCT00218062|DRUG|D-Amphetamine 30mg|
57714602|NCT00218062|DRUG|D-Amphetamine 60mg|
57714603|NCT00218062|DRUG|Modafinil 200mg|
57714604|NCT00218062|DRUG|Modafinil 400mg|
57714605|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
57714606|NCT00218062|DRUG|Placebo|
57915415|NCT02666846|DRUG|Ibuprofen|
57915416|NCT02666846|DRUG|Diclofenac|
57915417|NCT02666846|DRUG|Methyl-salicylate / Menthol|
57915418|NCT02666846|DRUG|Placebo|
57915419|NCT02442492|DRUG|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
57714607|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
57714608|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
57714609|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
57714610|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
57714611|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
57714612|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
58062125|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
57714613|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
57714614|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
57714615|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
57714616|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
57714617|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
57915420|NCT02442492|DRUG|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
58062126|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
57714618|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
57714619|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
57915421|NCT00628264|DRUG|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
57915422|NCT00628264|DRUG|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
57915423|NCT00257062|DRUG|Levofloxacin|
57915424|NCT00024986|DRUG|Tenofovir DF|
58062127|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
58062128|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
58267618|NCT03416634|BEHAVIORAL|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
58267619|NCT03416634|BEHAVIORAL|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
58267620|NCT05900817|OTHER|antivet|A material used for micro abrasion of teeth
58267621|NCT05900817|OTHER|Oplsture|A material used for micro abrasion of teeth
58267622|NCT02851056|BIOLOGICAL|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered."
57714620|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
58267623|NCT02851056|PROCEDURE|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
58267624|NCT02851056|BIOLOGICAL|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
57714621|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
57714622|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
57714623|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
57915425|NCT05035784|DRUG|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
57915426|NCT05035784|DRUG|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
57915427|NCT06139016|DEVICE|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
57915428|NCT02628496|DRUG|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
57915429|NCT02628496|DEVICE|Confocal laser microlaryngoscopy|
57915430|NCT02628496|PROCEDURE|Biopsy (standard of care)|
57915431|NCT02628496|PROCEDURE|KTP laser photoablation (standard of care)|
58062129|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
57714624|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
57714625|NCT00004357|DRUG|Methylprednisolone|IV
57714626|NCT00004357|DRUG|Prednisolone|Oral
57915432|NCT02293148|DRUG|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
57915433|NCT02293148|DRUG|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
57915434|NCT02293148|DRUG|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
57915435|NCT02293148|DRUG|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
57915436|NCT02293148|DRUG|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
57915437|NCT03644407|OTHER|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
57915438|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
58062130|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
58062131|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
58062132|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
58062133|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
58267625|NCT02851056|DRUG|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
58267626|NCT00416676|DRUG|carboplatin|
58267627|NCT00416676|DRUG|cisplatin|
58267628|NCT00416676|DRUG|cyclophosphamide|
58267629|NCT00416676|DRUG|etoposide|
58267630|NCT00416676|DRUG|vincristine sulfate|
58267631|NCT00416676|PROCEDURE|adjuvant therapy|
58267632|NCT00416676|PROCEDURE|conventional surgery|
58267633|NCT00416676|PROCEDURE|neoadjuvant therapy|
58267634|NCT00416676|RADIATION|radiation therapy|
57714627|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
57714628|NCT03858075|DRUG|BLU-782|oral capsules
57714629|NCT03858075|DRUG|Placebo|oral capsules
58267635|NCT01569750|DRUG|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
58267636|NCT01569750|DRUG|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
58267637|NCT01569750|DRUG|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
58267638|NCT01569750|DRUG|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
58267639|NCT01569750|DRUG|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
58267640|NCT03956615|OTHER|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
58267641|NCT00745511|DRUG|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
57714630|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
57714631|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
57915439|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
58062134|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
57915440|NCT01548378|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
57915441|NCT01548378|GENETIC|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
58062135|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
58062136|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
58267642|NCT00745511|DRUG|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
58062137|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
58267643|NCT05189496|BEHAVIORAL|hyperbaric oxygen therapy|hyperbaric oxygen therapy
58267644|NCT04428203|DRUG|Epidiolex Oral Liquid Product|patients with rising PSA after failure of localized therapy will receive Epidiolex PO once daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients receive an Epidiolex taper for 7-10 days after withdrawing from study for any reason or completion of the study period.
57714632|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
57714633|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
57714634|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
57714635|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
57714636|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
57714637|NCT01632579|DRUG|LY3023703|Administered orally
57714638|NCT01632579|DRUG|Placebo|Administered orally
57714639|NCT01632579|DRUG|Celecoxib|Administered orally
57714640|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
57714641|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
57714642|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
57714643|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
57714644|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
57714645|NCT00024518|DRUG|30,000 units hrINF-alpha|
57714646|NCT00024518|DRUG|5,000 hrINF-alpha|
58062138|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
58062139|NCT00151528|DRUG|Pregabalin|
58062140|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
58387434|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
58062141|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
58387435|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
58387436|NCT05844735|DRUG|SAR441566|Tablet
58387437|NCT05844735|DRUG|Placebo|Tablet
57714647|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
57714648|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
58267645|NCT04844905|DRUG|Ivermectin|Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.
58267646|NCT04844905|DRUG|Placebo|Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
57915442|NCT01548378|GENETIC|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
58062142|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
58062143|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
58267647|NCT04844905|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
58062144|NCT03761628|DEVICE|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of VVC
58062145|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
58267648|NCT01623037|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
57714649|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
57714650|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
57714651|NCT00536367|OTHER|No intervention - observational study only|
57714652|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
57714653|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
58267649|NCT00189852|DEVICE|Chronic heart failure monitoring system|
58267650|NCT00189852|DEVICE|Lifestyle monitoring system|
58267651|NCT03672448|OTHER|Naturalistic observation|Naturalistic observation
58267652|NCT05673161|OTHER|iron|iron treatment
58267653|NCT00802061|BEHAVIORAL|Sleeping position in glaucoma patient|
58267654|NCT01058902|DRUG|Aspirin 75 mg|Aspirin 75 mg
58267655|NCT01058902|OTHER|no aspirin|nothing
58267656|NCT03652948|BEHAVIORAL|Meru Health Ascend Program|Cognitive-behavioral skills, mindfulness
58267657|NCT04907227|BIOLOGICAL|Pembrolizumab|IV infusion
58267658|NCT04907227|DRUG|Docetaxel|IV infusion
58267659|NCT04907227|DRUG|Prednisone|Oral tablets
57714654|NCT00434668|DRUG|cisplatin/docetaxel|
57915443|NCT01548378|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
58267660|NCT04907227|DRUG|Placebo|IV infusion
58267661|NCT04907227|DRUG|Dexamethasone|Oral tablets
58267662|NCT05578105|OTHER|no intervention|No intervention, only observation
57714655|NCT00434668|DRUG|cisplatin/vinorelbine|
57915444|NCT02075268|DRUG|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
57915445|NCT00648154|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
57915446|NCT00648154|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fed
58062146|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
58062147|NCT05647928|OTHER|no intervention|no intervention
57915447|NCT01124032|DRUG|methylphenidate|a capsule containing 20 mg
57915448|NCT01638494|DIETARY_SUPPLEMENT|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
57915449|NCT01774487|DRUG|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
57915450|NCT04262817|DRUG|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
57915451|NCT04262817|OTHER|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
57915452|NCT03660800|DRUG|CTAP101 Capsules|Calcifediol Extended-Release Capsules
57915453|NCT02344004|DRUG|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
57915454|NCT02274818|BEHAVIORAL|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
58062148|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
58062149|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
58062150|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
57915455|NCT00669994|DRUG|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
57915456|NCT03898401|COMBINATION_PRODUCT|Platelet rich plasma|After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
57915457|NCT04330131|BEHAVIORAL|3Ts - Newborn|A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
57915458|NCT04330131|BEHAVIORAL|3Ts - Well Baby|Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
58062151|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
58062152|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
58062153|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
58062154|NCT01177826|PROCEDURE|Sample collection|Stool sample
58267663|NCT04210375|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
58267664|NCT04210375|DRUG|Matching Placebo|Vehicle control
57714656|NCT00169637|DRUG|rhGH|
57714657|NCT06265220|DRUG|AB-101|NK Cell Therapy
57915459|NCT04330131|BEHAVIORAL|3Ts - Let's Talk!|A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
57714658|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
58387438|NCT05844735|DRUG|Ciprofloxacin|Tablet
58387439|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
57714659|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
57714660|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
57915460|NCT04697771|OTHER|Fine Motor Skills Training|The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani \& Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith \& O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
57915461|NCT06610110|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
58062155|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
58062156|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
58062157|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
58267665|NCT04489849|DRUG|Apixaban 2.5 MG|apixaban 2.5mg BID for 3 months in experimental group
58267666|NCT04489849|OTHER|Active Control|Medication other than anticoagulation
58267667|NCT03871816|OTHER|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
58267668|NCT05409313|BEHAVIORAL|EBP training|The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
58267669|NCT05409313|BEHAVIORAL|SDM training|A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
58387440|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
58387441|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
58387442|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
58387443|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
57714661|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
57714662|NCT03895853|OTHER|Best Practice|Receive standard of care
58387444|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
58387445|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
58387446|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
58387447|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
58387448|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
58387449|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
58387450|NCT00092820|DRUG|MK0653, ezetimibe|
58387451|NCT00092820|DRUG|Comparator: placebo|
57714663|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
57714664|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
57714665|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
58387452|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
58387453|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
57915462|NCT06610110|DIETARY_SUPPLEMENT|Placebo|Placebo (3 mg/kg maltodextrin)
58062158|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
58387454|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
57714666|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
57714667|NCT03970434|OTHER|Venous blood collection|Venous blood collection
57714668|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
57714669|NCT00384137|DRUG|Tacrolimus|Immunosuppression
58062159|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
58062160|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
58387455|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
58387456|NCT00408265|BEHAVIORAL|Contingency Management|
58387457|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
57714670|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
57714671|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
57714672|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
57714673|NCT00121771|BIOLOGICAL|FP9 CS|
57714674|NCT00121771|BIOLOGICAL|MVA CS|
57714675|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
57714676|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
57714677|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
57714678|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
57915463|NCT02757391|BIOLOGICAL|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
57915464|NCT02757391|BIOLOGICAL|Aldesleukin|Given SC
57915465|NCT02757391|DRUG|Cyclophosphamide|Given IV
57915466|NCT02757391|OTHER|Laboratory Biomarker Analysis|Correlative studies
57915467|NCT02757391|BIOLOGICAL|Pembrolizumab|Given IV
57915468|NCT03038230|DRUG|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
57915469|NCT02876198|DEVICE|Gonioscopy|Study of the trabecular structure by gonioscopy
57915470|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
58062161|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
57714679|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
57714680|NCT00797667|DRUG|Telcagepant 140 mg|
57714681|NCT00797667|DRUG|Telcagepant 280 mg|
57714682|NCT00797667|DRUG|140 mg telcagepant placebo|
57714683|NCT00797667|DRUG|280 mg telcagepant placebo|
57915471|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
57915472|NCT04471623|BEHAVIORAL|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
57915473|NCT04046718|DEVICE|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
57915474|NCT04762823|DEVICE|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
57915475|NCT04762823|DEVICE|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
58267670|NCT04198584|BEHAVIORAL|VC-CBCS|A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
58267671|NCT00711828|DRUG|Bortezomib|Given IV
58267672|NCT00711828|BIOLOGICAL|Rituximab|Given IV
58387458|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
58387459|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
58387460|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
58387461|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
58387462|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
57714684|NCT01980849|DRUG|Nadroparin, long term|
58267673|NCT00711828|DRUG|Cyclophosphamide|Given PO
58267674|NCT00711828|DRUG|Dexamethasone|Given PO
58387463|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
58387464|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
58387465|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
58387466|NCT03320837|OTHER|Breast milk|Breast milk
58387467|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
57714685|NCT01980849|DRUG|Nadroparin: short-term|
57714686|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
57714687|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
57714688|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
57714689|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
57714690|NCT00349492|DRUG|IP|irinotecan+cisplatin
57915476|NCT01636960|BIOLOGICAL|PegIFN alfa-2b|
57915477|NCT02037633|DRUG|Fentanyl|Fentanyl IV
57915478|NCT02037633|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
57915479|NCT02037633|DRUG|ropivacaine|
57915480|NCT02866084|DEVICE|Device|"The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
57915481|NCT02618915|GENETIC|DTX101|solution for IV infusion
58267675|NCT00711828|OTHER|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
58267676|NCT00711828|OTHER|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
58387468|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
58387469|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
58387470|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
57714691|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
57714692|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
57714693|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
57714694|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
57714695|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
57714696|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
58267677|NCT06510387|DEVICE|Ultrasound using suprasternal method|"The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan."
58267678|NCT06510387|DEVICE|Ultrasound using subxiphoid method|Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.
58267679|NCT00600990|DRUG|GW597599|
58267680|NCT01329718|OTHER|Blood Sample|Blood sample collection
58267681|NCT05523141|DRUG|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
58387471|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
58387472|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
58387473|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
58387474|NCT00496977|PROCEDURE|annual CT screening|
58387475|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
58387476|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
58267682|NCT05523141|DRUG|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
58387477|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
58387478|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
58387479|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
58267683|NCT00871442|OTHER|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
58267684|NCT00871442|OTHER|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
58387480|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
58387481|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
58387482|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
58387483|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
58387484|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
58387485|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
58387486|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
58387487|NCT02198859|DRUG|Lithium Carbonate|
58387488|NCT03644498|OTHER|Non-Interventional|Non-Interventional
58387489|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
58267685|NCT00871442|DRUG|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
58267686|NCT03211143|DRUG|CKD-381|Test drug: CKD-381
58267687|NCT03211143|DRUG|Nexium|Reference drug: Nexium
58387490|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
58387491|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
58387492|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
58387493|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
58387494|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
58387495|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
58387496|NCT02967419|OTHER|No Intervention|
58267688|NCT03621540|DEVICE|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
58267689|NCT03621540|DEVICE|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
58387497|NCT00375505|DRUG|Zoledronic acid|
58387498|NCT00375505|DRUG|Placebo|Placebo
58387499|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
58387500|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
58387501|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
58267690|NCT03621540|BEHAVIORAL|Adaptive working memory training|Adaptive spatial n-back training.
58267691|NCT05448287|BEHAVIORAL|Health and family planning|Promotion of health and family planning behaviors
58267692|NCT05448287|BEHAVIORAL|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
58267693|NCT05448287|BEHAVIORAL|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
58267694|NCT05448287|BEHAVIORAL|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
58267695|NCT05207618|DIETARY_SUPPLEMENT|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
58267696|NCT05907161|DEVICE|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
58267697|NCT05907161|DEVICE|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
58387502|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
58387503|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
58387504|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
58387505|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
57714697|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
57714698|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
57714699|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
57714700|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
58062162|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
57714701|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
57714702|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
58062163|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
57714703|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
57714704|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
58062164|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
58062165|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
58062166|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
58267698|NCT05907161|DEVICE|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
58267699|NCT05660824|DEVICE|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
57714705|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
58062167|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
58062168|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
58062169|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
58062170|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
58062171|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
58062172|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
58062173|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
58062174|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
57714706|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
57714707|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
57714708|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
57714709|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
57714710|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
57915482|NCT05513924|DRUG|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
58387506|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
58387507|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
58387508|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
57915483|NCT05513924|DRUG|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
58387509|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
58387510|NCT02026947|DRUG|Placebo|
58387511|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
58387512|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
57915484|NCT01398722|OTHER|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
58267700|NCT05660824|PROCEDURE|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 5000 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
58267701|NCT00065767|DRUG|Raloxifene|
58267702|NCT05771818|OTHER|Falls Prevention Program|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
58267703|NCT03469180|OTHER|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
58267704|NCT03469180|OTHER|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
58267705|NCT00058084|DRUG|ixabepilone|Given IV
58267706|NCT00058084|DRUG|mitoxantrone hydrochloride|Given IV
58387513|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
58387514|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
58062175|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
58062176|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
58267707|NCT00058084|DRUG|prednisone|Given orally
58267708|NCT00248976|BEHAVIORAL|Net-present value of individual health behaviors in years|
58267709|NCT04445506|DRUG|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
58387515|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
58267710|NCT05525234|DRUG|Thalidomide|Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
58387516|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
58387517|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
58387518|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
58387519|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
58387520|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
58387521|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
58387522|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
57915485|NCT01398722|OTHER|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
58267711|NCT05525234|DRUG|Placebo|Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
58387523|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
58387524|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
58387525|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
58387526|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
58267712|NCT01658449|OTHER|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
58387527|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
57714711|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
57714712|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
58062177|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
58267713|NCT01658449|OTHER|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
58267714|NCT02268370|DRUG|Dasatinib|
58267715|NCT03398863|PROCEDURE|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
58267716|NCT04237129|DRUG|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
58267717|NCT02848989|OTHER|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
58267718|NCT00272870|DRUG|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
58387528|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
58387529|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
58387530|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
58387531|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
58387532|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
58062178|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
58267719|NCT00272870|GENETIC|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
58267720|NCT00272870|DEVICE|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
58267721|NCT02833935|BEHAVIORAL|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
58267722|NCT05046431|DRUG|BAT2506|50mg/0.5mL
58267723|NCT05046431|DRUG|EU Simponi|50mg/0.5mL
58267724|NCT04169438|OTHER|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
58387533|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
57714713|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
57714714|NCT02545907|DRUG|Thalidomide|50mg capsule.
57714715|NCT02545907|DRUG|Dexamethasone|2mg tablet.
57714716|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
57714717|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
58062179|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
58267725|NCT04169438|OTHER|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
58267726|NCT01428687|BEHAVIORAL|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
58267727|NCT01428687|BEHAVIORAL|No change in sleep|This group is taught to maintain their current sleep habits.
57915486|NCT00570050|DRUG|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
58267728|NCT02370667|OTHER|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
58267729|NCT02370667|OTHER|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
58267730|NCT02370667|OTHER|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
58267731|NCT01279564|DEVICE|ETview TVT endotracheal tube|intubation
58267732|NCT01279564|DEVICE|Endotracheal tube|Intubation
58267733|NCT02519634|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
57915487|NCT00570050|DRUG|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
57915488|NCT06391060|PROCEDURE|Impact of Gender on Davinci rectal surgery|gender-specific considerations in the surgical management and post-operative care of rectal cancer patients undergoing robotic surgery
57915489|NCT02601664|PROCEDURE|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
57915490|NCT02601664|PROCEDURE|Conventional PCI|Conventional PCI
57915491|NCT04574752|DIAGNOSTIC_TEST|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
57915492|NCT04171453|DRUG|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
57915493|NCT01196273|OTHER|Comprehensive non invasive cardiovascular examination|"The examination includes:~* Anamnesis incl. admission form~* Physical examination~* Documentation of the medical therapy (incl. HAART)~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* 6 minute walk test~* Blood collection~* Questionnaire to quality of life and health economics"
57915494|NCT02769377|DEVICE|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
57915495|NCT02769377|DEVICE|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
57915496|NCT02679352|DEVICE|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
57915497|NCT05208671|OTHER|NOURISH Food Box|Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
57915498|NCT03291587|OTHER|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
57915499|NCT00716508|PROCEDURE|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
58267734|NCT02519634|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
58267735|NCT04218292|DEVICE|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
57915500|NCT00716508|PROCEDURE|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
57915501|NCT00753051|DRUG|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
57915502|NCT00753051|DRUG|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
57915503|NCT02545023|OTHER|Quality-of-Life Assessment|Complete an in-person one-on-one interview
57915504|NCT02545023|OTHER|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
57915505|NCT02954068|DRUG|IV Oxytocin + IM placebo|
57915506|NCT02954068|DRUG|IM Oxytocin + IV placebo|
58267736|NCT01844206|DRUG|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
58267737|NCT01844206|DRUG|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
58267738|NCT00854919|DRUG|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
58267739|NCT00854919|BEHAVIORAL|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
58062180|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
58387534|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
58062181|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
58062182|NCT05330429|DRUG|Magrolimab|Administered intravenously
58267740|NCT02237924|DRUG|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
58387535|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
57714718|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
57714719|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
58267741|NCT02237924|DRUG|DDP|DDP:100mg/m2 for 2-3 cycles
58387536|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
57714720|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
57915507|NCT05455515|PROCEDURE|IVL procedures|Intravascular Lithotripsy (IVL)
58062183|NCT05330429|DRUG|Bevacizumab|Administered intravenously
57714721|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
57714722|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
58062184|NCT05330429|DRUG|Irinotecan|Administered intravenously
58062185|NCT05330429|DRUG|Fluorouracil|Administered intravenously
57714723|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
57915508|NCT02729428|DEVICE|MRI|Participants will undergo an MRI scan
58267742|NCT02237924|RADIATION|IMRT|IMRT:70-74Gy for 2-3 cycles
58387537|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
58387538|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
58387539|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
57714724|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
57714725|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
57714726|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
57714727|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
58062186|NCT05330429|DRUG|Leucovorin|Administered intravenously
58062187|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
58062188|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
58267743|NCT00357136|BEHAVIORAL|password usage|
58267744|NCT02186847|RADIATION|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
57714728|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
57915509|NCT03523429|DRUG|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
58267745|NCT02186847|DRUG|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
58387540|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
57714729|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
57714730|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
57915510|NCT03038438|DEVICE|Abre venous self-expanding stent system|venous stent
57915511|NCT05365217|DRUG|Nonacog beta pegol|Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
57915512|NCT02624310|DRUG|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
57915513|NCT02624310|DRUG|Placebo|
58387541|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
57714731|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
57714732|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
57714733|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
57714734|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
57714735|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
57915514|NCT04984525|DRUG|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
57915515|NCT04984525|DRUG|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
57915516|NCT02314845|OTHER|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
57714736|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
57714737|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
57714738|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
57915517|NCT02314845|OTHER|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
57915518|NCT05056987|DEVICE|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
58062189|NCT03018028|DRUG|Semaglutide|Oral administration once daily
58062190|NCT03018028|DRUG|Placebo|Oral administration once daily
58062191|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
58267746|NCT02186847|DRUG|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
58062192|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
58062193|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
58062194|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
58062195|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
58062196|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
58062197|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
58267747|NCT02186847|DRUG|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
58267748|NCT00004809|PROCEDURE|gene therapy|
58267749|NCT06339216|DRUG|Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)|"Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes."
58267750|NCT03055468|BEHAVIORAL|Peer support|Peer support and antidepressant medications
58267751|NCT01738841|BIOLOGICAL|Priorix-Tetra™|Single dose, subcutaneous injection
58267752|NCT01738841|OTHER|Safety data collection|Recording of adverse events, using diary cards
58267753|NCT03635905|DRUG|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
57915519|NCT05056987|DEVICE|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
57915520|NCT05056987|DEVICE|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
58062198|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
58062199|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
58062200|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
58062201|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
58062202|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
58062203|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
58062204|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
58062205|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
58062206|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
58062207|NCT04319835|DEVICE|OnZurf Probe|
58267754|NCT03635905|DRUG|Placebo|Methylcellulose placebo capsule
58267755|NCT00438802|DRUG|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
58267756|NCT04507893|OTHER|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
58387542|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
58387543|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
57915521|NCT00001718|DEVICE|Electropalatography|
57915522|NCT01822288|DRUG|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
57915523|NCT01822288|DRUG|Estradiol & medroxyprogesterone acetate|Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
57915524|NCT02918578|OTHER|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
58062208|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
58062209|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
58062210|NCT02327182|DRUG|MT-4666|
58062211|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
58062212|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
58062213|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
58267757|NCT00928941|BEHAVIORAL|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
58387544|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
58387545|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
58387546|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
58267758|NCT00928941|BEHAVIORAL|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
58387547|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
58387548|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
58387549|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
58267759|NCT05347875|OTHER|ICanWALK© App.|"App containing educational and instructional videos on crutch fitting and walking with key components of these skills highlighted. App video records individual using the taught skills to enable them and their care providers to review their usage of the walking aids."
58387550|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
57714739|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
57714740|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
57915525|NCT02918578|OTHER|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
57915526|NCT02918578|OTHER|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
57915527|NCT02819206|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
57915528|NCT03297723|OTHER|Therapeutic education Programm|"Intervention will include:~* an identification of educational needs and expectations,~* a bilateral agreement between patient and medical staff on the priority skills acquirement,~* a structured educational activities tailored to the patient's need.~* the making of an educational record."
58387551|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
57915529|NCT06191497|PROCEDURE|non surgical periodontal therapy|NSPT based on Guided biofilm therapy principle (EMS Dental, Switzerland)
58267760|NCT06533852|DRUG|Fecal Microbiome Transplantation (FMT)|"Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months."
58267761|NCT06533852|OTHER|FMT Placebo|"Two doses:~First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months."
58267762|NCT01264354|DRUG|Clevudine 30mg|Clevudine 30mg
58267763|NCT01264354|DRUG|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
58267764|NCT01264354|DRUG|Clevudine 20mg|Clevudine 20mg
58387552|NCT02944708|DRUG|Conventional chemotherapy|
58387553|NCT02944708|DRUG|Maintenance chemotherapy 1|
58387554|NCT02944708|DRUG|Maintenance chemotherapy 2|
57714741|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
57714742|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
57915530|NCT06191497|DRUG|Chlorhexidine mouthwash|0.12% chlorhexidine based mouthwash used twice a day for 15 days after therapy
57915531|NCT00125502|BIOLOGICAL|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
58267765|NCT00001569|DRUG|Cisplatin|
58267766|NCT00001569|DRUG|Paclitaxel|
58387555|NCT01689987|DRUG|Cyclophosphamide|Given IV
58387556|NCT01689987|DRUG|Dexamethasone|Given PO
58387557|NCT01689987|DRUG|Hydroxychloroquine|Given PO
58387558|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
57714743|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
57714744|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57714745|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
57714746|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
57714747|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
57714748|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
57915532|NCT00125502|DRUG|MF59 adjuvant|Oil-in-water emulsion
57915533|NCT00125502|DRUG|Placebo|Normal saline solution
58267767|NCT00001569|DRUG|5-FU|
58267768|NCT05998434|BEHAVIORAL|Improving Low Back Pain Through Motor Control Training|In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.
58267769|NCT00936130|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
58267770|NCT00936130|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
58387559|NCT01689987|OTHER|Pharmacological Study|Correlative studies
58387560|NCT01689987|DRUG|Sirolimus|Given PO
58387561|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
58387562|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
58387563|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
58387564|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
58267771|NCT00936130|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
58267772|NCT00936130|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet Program
58267773|NCT05112094|DEVICE|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
58387565|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
58387566|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
58387567|NCT03275090|DRUG|Smoflipid ®|
58387568|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
58387569|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
58387570|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
57915534|NCT04831294|DRUG|Cannabidiol|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
57915535|NCT04831294|DRUG|Placebo|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
57915536|NCT02701140|PROCEDURE|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
57915537|NCT02701140|PROCEDURE|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
58267774|NCT05112094|OTHER|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
58267775|NCT02503072|BEHAVIORAL|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
58267776|NCT02503072|BEHAVIORAL|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
58267777|NCT05612802|DIAGNOSTIC_TEST|IGF-1|We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
58267778|NCT00576810|DRUG|sodium picosulphate|
58387571|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
58387572|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
58387573|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
58387574|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
58387575|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
58387576|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
57915538|NCT02701140|PROCEDURE|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
57915539|NCT02701140|PROCEDURE|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
57714749|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
57915540|NCT02701140|PROCEDURE|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
57915541|NCT06215027|OTHER|Dance|Dance protocol
58062214|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
58062215|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
57714750|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
57714751|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
57714752|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
58387577|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
58387578|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
57714753|NCT00000415|PROCEDURE|Physical activity|
57915542|NCT05138367|PROCEDURE|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
57915543|NCT03293693|OTHER|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
57915544|NCT03293693|OTHER|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
57915545|NCT03293693|OTHER|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
58387579|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
58387580|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
58387581|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
58387582|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
58387583|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
58387584|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
57714754|NCT00000415|DRUG|Calcium supplement|
57714755|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
57714756|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
57714757|NCT02803697|OTHER|Patients|
57714758|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
57714759|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
57714760|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
57714761|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
57915546|NCT01853137|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
57915547|NCT00565539|DRUG|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
58387585|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
58387586|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
57915548|NCT03217643|DRUG|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
57915549|NCT03676231|DRUG|SGM-1019|Active
58387587|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
58387588|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
57714762|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
57714763|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
57714764|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
57714765|NCT01974050|BEHAVIORAL|Text message surveillance|
57915550|NCT03676231|DRUG|Placebo|Inactive
58062216|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
58387589|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
58387590|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
57714766|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
57915551|NCT02202954|OTHER|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
58387591|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
58387592|NCT00460655|DRUG|Placebo|Placebo
58387593|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
58062217|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
58267779|NCT01907217|DEVICE|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
58267780|NCT01907217|DRUG|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
58267781|NCT01907217|DRUG|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
58267782|NCT00460707|DRUG|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
58267783|NCT00460707|DRUG|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
58267784|NCT00460707|DRUG|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
58267785|NCT00460707|DRUG|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
58267786|NCT00460707|DRUG|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
58267787|NCT03494972|DRUG|Tetracyclin ointment|During 3rd molar surgery
58267788|NCT03284645|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
58267789|NCT03284645|DRUG|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
58387594|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
58387595|NCT02552095|DEVICE|Triathlon PKR|
58387596|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
58387597|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
57714767|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
57714768|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
57714769|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
58267790|NCT03284645|DRUG|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
57714770|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
57714771|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
57714772|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
57714773|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
57714774|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
58267791|NCT05565144|OTHER|None, pure observational study|None, pure observational study
58267792|NCT02432859|PROCEDURE|Electrical Stimulation|Direct current with sensory intensity for one hour
58267793|NCT02432859|PROCEDURE|Placebo|Direct current with zero intensity for one hour
58267794|NCT04339803|OTHER|rehabilitation intervention|we use lower limb mirror therapy after stroke for two weeks
58267795|NCT06408064|OTHER|Music therapy|Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.
57714775|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
57714776|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
57714777|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
57915552|NCT01424904|DIETARY_SUPPLEMENT|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
57915553|NCT05130242|PROCEDURE|Cement-augmented Pedicle Screws (CPS)|Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
58267796|NCT06298357|BEHAVIORAL|Immediate Start - Virtual Reality|Participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness. They will start using the headsets in the hospital and then will continue to do so for 8 weeks after hospital discharge.
58267797|NCT06298357|BEHAVIORAL|Delayed Start - Virtual Reality|Participants will receive usual care in the hospital and outside of the hospital for 8 weeks. After the 8 week post-discharge period, participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness for an 8 week period.
58267798|NCT01255410|BIOLOGICAL|10^6 PFU rHMPV-Pa vaccine|Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally
58267799|NCT01255410|BIOLOGICAL|10^5 PFU rHMPV-Pa vaccine|Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally
57714778|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
57714779|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
57714780|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
57714781|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
57714782|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
57714783|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
58267800|NCT01255410|BIOLOGICAL|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
58267801|NCT02870205|DRUG|GSP 301 NS|2 spray in each nostril twice daily for 14 days
58267802|NCT02870205|DRUG|GOM-NS|2 spray in each nostril twice daily for 14 days
58267803|NCT02870205|DRUG|GMM-2 NS|2 spray in each nostril twice daily for 14 days
58267804|NCT02870205|DRUG|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
58267805|NCT02570672|DRUG|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
58267806|NCT02570672|DRUG|Placebo|Subjects will randomized to placebo will receive placebo
58267807|NCT05995405|DRUG|GTX-104|Nimodipine IV infusion
57714784|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
57915554|NCT05130242|PROCEDURE|Hybrid Construct (HC)|Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
57915555|NCT01771120|OTHER|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
57915556|NCT01251731|DRUG|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
58062218|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
58062219|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
58062220|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
58062221|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
58062222|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
58062223|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
58062224|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
58062225|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
58062226|NCT04247724|BEHAVIORAL|Recreational handball|
57714785|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
57915557|NCT01251731|DRUG|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
57915558|NCT01251731|DRUG|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
57915559|NCT01251731|DRUG|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
57915560|NCT05203354|RADIATION|Narrowband Ultraviolet B|patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
57915561|NCT05203354|DRUG|Acitretin|patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
57915562|NCT01178554|BEHAVIORAL|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
57915563|NCT01178554|BEHAVIORAL|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
57915564|NCT01178554|BEHAVIORAL|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita \& Weisz, 2004)
58062227|NCT04247724|BEHAVIORAL|Control|
58062228|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
58387598|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
57714786|NCT00228527|DRUG|Esomeprazole (Nexium)|
57714787|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
57915565|NCT06025162|DRUG|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
57915566|NCT04308343|DRUG|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
57915567|NCT04308343|DRUG|Letrozole|Drugs to treat undisturbed ectopic pregnancies
57915568|NCT04308343|DRUG|cetrotide|Drugs to treat undisturbed ectopic pregnancies
57915569|NCT05000073|OTHER|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
58062229|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
58062230|NCT02036476|DRUG|Cabozantinib|oral administration
58062231|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
58062232|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
58062233|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
58062234|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
58062235|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
58387599|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
58387600|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
58387601|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
57915570|NCT05000073|OTHER|dialysis|dialysis
58062236|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
58062237|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
58267808|NCT05995405|DRUG|Nimotop 30 MG Oral Capsule|Oral nimodipine capsules
58267809|NCT06486649|DIAGNOSTIC_TEST|Multimodal Large Language Model Diagnosis|Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.
58267810|NCT06486649|DIAGNOSTIC_TEST|Routine diagnostic and therapeutic procedure|Routine diagnostic and therapeutic procedure
58267811|NCT02105714|PROCEDURE|Stool culturing for pathogenic bacteria|
58267812|NCT02105714|PROCEDURE|Kato-Katz technique|
58267813|NCT02105714|PROCEDURE|Baermann technique|
58267814|NCT02105714|DEVICE|Mini-FLOTAC|
57915571|NCT03054402|DRUG|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
57915572|NCT03054402|DRUG|Placebo|Single dose of placebo
57915573|NCT03990493|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
57915574|NCT03990493|BIOLOGICAL|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
57915575|NCT02825784|DIETARY_SUPPLEMENT|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
57915576|NCT00944177|DRUG|Metformin HCl|
57915577|NCT03457363|DEVICE|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
57915578|NCT00744523|DEVICE|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
58267815|NCT02105714|DEVICE|Crypto/Giardia Duo Strip|
58267816|NCT02105714|PROCEDURE|Formalin-ether concentration technique|
58267817|NCT02105714|DEVICE|CCA RDT|
58267818|NCT02105714|PROCEDURE|Koga agar plate culture|
58267819|NCT02105714|PROCEDURE|Kinyoun staining|
58387602|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
57915579|NCT02110615|OTHER|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
57915580|NCT04667078|DRUG|Cangrelor|administration of cangrolor by iv befor thrombectomy
57915581|NCT04667078|OTHER|best medical management|used yhe best medical management
58267820|NCT02105714|DEVICE|Multiplex PCR|
58267821|NCT02105714|PROCEDURE|Metagenomics analysis|
58267822|NCT01686698|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
58267823|NCT01686698|OTHER|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
58267824|NCT01447875|OTHER|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
58267825|NCT01447875|DRUG|propofol or mexmedetomidine|
58267826|NCT02897427|OTHER|Biomarker Analysis|Complete HPV testing
58267827|NCT02897427|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral gargle samples
58267828|NCT02897427|PROCEDURE|Ultrasonography|Undergo transcervical ultrasonography
58387603|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
58387604|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
58267829|NCT04984759|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
57714788|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
57714789|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
57714790|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
57714791|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
57714792|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
57714793|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
57714794|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
57714795|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
57714796|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
57714797|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
57714798|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
57714799|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
57714800|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
57714801|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
57915582|NCT02879422|GENETIC|genetic analysis|
57915583|NCT01783041|DRUG|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
57915584|NCT01783041|DRUG|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
57714802|NCT00218192|BEHAVIORAL|Behavior Therapy|
57714803|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
57714804|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
57714805|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
57714806|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
57714807|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
57714808|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
58387605|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
58387606|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
58387607|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
58387608|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
57714809|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
58267830|NCT04984759|DRUG|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
58267831|NCT01860742|DRUG|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
58267832|NCT01860742|DRUG|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
58267833|NCT05940896|DRUG|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
57714810|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
58267834|NCT04477044|OTHER|Study Group|GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
58267835|NCT00597506|DRUG|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
57714811|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
57714812|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
57714813|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
58062238|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
58267836|NCT00597506|DRUG|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
58267837|NCT04857918|BEHAVIORAL|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
58267838|NCT04857918|BEHAVIORAL|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
58267839|NCT05021289|BEHAVIORAL|guided imagery|guided imagery
57915585|NCT04882995|DIETARY_SUPPLEMENT|Psyillium fiber|Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
58267840|NCT02149316|PROCEDURE|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
58267841|NCT02149316|PROCEDURE|control|a deflated cuff placed on the right upper arm
58387609|NCT02998671|BIOLOGICAL|CJM112|
58387610|NCT02998671|OTHER|Placebo|
58062239|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
57714814|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
57915586|NCT00759915|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
58062240|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
58062241|NCT00216346|DRUG|Paromomycin sulfate|
58062242|NCT00216346|DRUG|Amphotericin B|
58062243|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
58062244|NCT00409149|BEHAVIORAL|CALM Approache|
58062245|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
58062246|NCT02777008|DRUG|CTP-543|
58062247|NCT02777008|DRUG|Placebo for CTP-543|
58062248|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
58387611|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
58062249|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
58062250|NCT00425594|DRUG|NuLYTELY|
58062251|NCT02219516|DRUG|RDEA3170|
58062252|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
58387612|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
58387613|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
57714815|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
57714816|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
57714817|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
57915587|NCT00759915|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
57915588|NCT05485467|DIAGNOSTIC_TEST|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
57915589|NCT03994289|BEHAVIORAL|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
58062253|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
58062254|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
58062255|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
58062256|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
58062257|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
58062258|NCT00323479|DRUG|Anastrozole|1mg/Day oral
58062259|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
58062260|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
58062261|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
58062262|NCT06083428|DRUG|Control Test|Only spinal anesthesia
58062263|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
58062264|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
58062265|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
58062266|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
58062267|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
58062268|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
58387614|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
58062269|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
58062270|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
58062271|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
58062272|NCT04598100|BEHAVIORAL|FOCUS-EC|
58062273|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
58062274|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
58062275|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
58062276|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
58062277|NCT02079701|BIOLOGICAL|Placebo|
58062278|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
58062279|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
58062280|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
58267842|NCT03657940|BEHAVIORAL|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
58267843|NCT04220749|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
58062281|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
58267844|NCT04220749|PROCEDURE|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
58387615|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
58387616|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
58387617|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
58387618|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
58387619|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
58267845|NCT06618053|OTHER|cost-effectiveness and audiometry outcomes|Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
58267846|NCT06501495|OTHER|video polysomnography|video polysomnography during 2 nights
58267847|NCT06501495|OTHER|Attention task|Attention task : SART Test (Sustained Attention to Response Task)
58387620|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
58267848|NCT00742508|DRUG|SK&F-105517-D 10 mg capsule|1 capsule once a day
58387621|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
58387622|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
58387623|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
58387624|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
58387625|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
58387626|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
58387627|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
58387628|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
58062282|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
58062283|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
58062284|NCT00068549|DRUG|Cisplatin|Given IV
58062285|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
58267849|NCT00742508|DRUG|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
58062286|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
58267850|NCT00742508|DRUG|SK&F-105517-D 20 mg capsule|1 capsule once a day
58062287|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
58062288|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
58062289|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
58062290|NCT02405091|DRUG|NBI-98854|
58267851|NCT00742508|DRUG|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
58267852|NCT00742508|DRUG|Carvedilol-IR 10 mg tablet|1 tablet twice a day
58267853|NCT00888602|DIETARY_SUPPLEMENT|3.4 g psyllium|3.4 g psyllium served with meal
58267854|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium served with a meal
58267855|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium
58267856|NCT00888602|OTHER|Meal|meal
58267857|NCT00598611|DRUG|desloratadine|singel dose, oral, 20 mg
58267858|NCT00598611|DRUG|desloratadine|single dose, oral, 5 mg
58267859|NCT02071082|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
58267860|NCT03863327|OTHER|No intervention|There will be no intervention as a part of this protocol.
58387629|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
58387630|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
58387631|NCT03012828|OTHER|Placebo|
58387632|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
58387633|NCT02317601|DRUG|placebo saline|
58387634|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
58387635|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
58387636|NCT06102512|DRUG|LOXO-783|Administered orally
58387637|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
58387638|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
58387639|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
57714818|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
57714819|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
57714820|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
57714821|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
57714822|NCT00027430|DRUG|TheraDerm|
57714823|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
57714824|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
57714825|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
57714826|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
58062291|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
58387640|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
58387641|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
58387642|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
58387643|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
58387644|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
57714827|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
57714828|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
57714829|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
57714830|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
57714831|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
58062292|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
58062293|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
58062294|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
58062295|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
57714832|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
57714833|NCT03348761|DEVICE|rTMS group|
57714834|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
57714835|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
57714836|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
57714837|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
57714838|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
57714839|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
57714840|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
58062296|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
58062297|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
58387645|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
58387646|NCT01288170|DRUG|Nebcinal Tobi|
58387647|NCT01288170|DRUG|Tobi Nebcinal|
58387648|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
58387649|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
58387650|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
58387651|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
58387652|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
58387653|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
58387654|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
58387655|NCT05541822|DRUG|ABN401|"Tablets~Route of Administration: Oral"
58387656|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
58387657|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
58387658|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
58267861|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
57714841|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
57714842|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
57714843|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
57714844|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
57714845|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
58062298|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
58062299|NCT01758367|DRUG|Deciatbine(DAC)|
58062300|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
58267862|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
58267863|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
58267864|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
58267865|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
58267866|NCT00006033|BIOLOGICAL|gene therapy|
58267867|NCT00006033|BIOLOGICAL|interleukin-2 gene|
58387659|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
58267868|NCT00006033|DRUG|methotrexate|
58267869|NCT00361920|DRUG|prednisone|
58267870|NCT03161002|GENETIC|detection of genotype|detection of genotype by next generation sequencing
58267871|NCT00990665|DEVICE|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
58267872|NCT01702194|DRUG|TD-1211 IV [C14]|
58267873|NCT01702194|DRUG|TD-1211 PO [C14]|
58267874|NCT01376466|OTHER|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
57714846|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
57714847|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
57714848|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
57714849|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
57714850|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
58267875|NCT05992961|DIAGNOSTIC_TEST|Troponin I|"Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists."
58267876|NCT02554318|DRUG|Rifampicin|
58267877|NCT02554318|DRUG|Isoniazid|
58062301|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
58267878|NCT02554318|DRUG|Pyrazinamide|
58267879|NCT02554318|DRUG|Ethambutol|
58267880|NCT02554318|DIETARY_SUPPLEMENT|Fermented soybean|
58062302|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
58062303|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
58267881|NCT04382144|DRUG|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
58267882|NCT03040427|DRUG|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
58267883|NCT05098067|DRUG|Capsaicin Topical Cream|5g 0.075% applied once
58267884|NCT05098067|DRUG|Metoclopramide|10mg IV once
58267885|NCT05098067|DRUG|Ondansetron|8mg IV once if needed
58267886|NCT05098067|DRUG|Lactated Ringers, Intravenous|1000cc once
58267887|NCT03808025|BEHAVIORAL|opioid education|see arm/group descriptions
58267888|NCT02225327|BIOLOGICAL|Fluad alone|Fluad
58267889|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the different arms|Fluad and Prodiax
58267890|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the same arm|Fluad and Prodiax
58267891|NCT02225327|BIOLOGICAL|PPV23 alone|Prodiax
58267892|NCT04486170|OTHER|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
58387660|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
58267893|NCT06730906|DEVICE|PACTAID App|The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
58267894|NCT02782299|OTHER|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
58387661|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
58387662|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
58267895|NCT05766618|PROCEDURE|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~* Space closure will be done on a 17x25 stainless steel wire~* Both molars will be indirectly anchored to the miniscrew~* Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~* Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~* The First injection will be 3 weeks before extraction~* By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~* At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~* follow up every month and injection will be repeated month after month with an observational period of 5 months."
58267896|NCT01914211|DRUG|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
58267897|NCT01914211|PROCEDURE|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)
58267898|NCT04978805|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
58267899|NCT04398186|DIAGNOSTIC_TEST|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
58267900|NCT05654272|DIAGNOSTIC_TEST|MRI|Cardiac MRI
58267901|NCT05168384|COMBINATION_PRODUCT|Extracorporeal Photopheresis|"ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks)."
58267902|NCT05168384|COMBINATION_PRODUCT|MS standard of care|Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
58267903|NCT02635542|DRUG|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
58062304|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
58062305|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
58062306|NCT02425813|DRUG|Budesonide|Given PO
58062307|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
58062308|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
58062309|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
58062310|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
58062311|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
58062312|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
58062313|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
58062314|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
58062315|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
58267904|NCT02635542|DRUG|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
58267905|NCT05353972|DRUG|IMG-007 or placebo|intravenously administered
58267906|NCT02607306|DRUG|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
58267907|NCT02607306|DRUG|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
58267908|NCT02607306|DRUG|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
58267909|NCT06384456|DRUG|Topical TRanexamic Acid|10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
58267910|NCT06384456|DRUG|Placebo|10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
58267911|NCT00835627|DRUG|sertraline|flexible dose sertraline
58267912|NCT00835627|BEHAVIORAL|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
58267913|NCT00835627|OTHER|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
58267914|NCT00835627|OTHER|Standard Care|community care, treatment as usual: routine follow up with existing providers
57714851|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
57714852|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
57714853|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
58062316|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
58062317|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
58062318|NCT03874208|OTHER|MRI|MRI exam
58062319|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
58062320|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
58062321|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
58062322|NCT03686579|RADIATION|chest trauma|clinical and radiological study
58062323|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
58062324|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
58062325|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
58062326|NCT00090324|DRUG|quetiapine fumarate tablets|
58267915|NCT00311103|PROCEDURE|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
58387663|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
57714854|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
57714855|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
57714856|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
57714857|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
57714858|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
57915590|NCT03994289|BEHAVIORAL|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
57915591|NCT01927926|DIETARY_SUPPLEMENT|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
57915592|NCT01927926|DIETARY_SUPPLEMENT|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
58387664|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
58387665|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
57915593|NCT03173573|DRUG|FDL176|CFTR modulator
58062327|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
58062328|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
58062329|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
58062330|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
58062331|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
58062332|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
58062333|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
58062334|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
58387666|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
57714859|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
57714860|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
57714861|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
57714862|NCT04856176|DRUG|pemetrexed|500mg/m2
57714863|NCT04856176|DRUG|Paclitaxel|200mg/m2
57714864|NCT04856176|DRUG|Carboplatin|AUC 5/6
57714865|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
57714866|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
57714867|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
57915594|NCT03173573|DRUG|Placebo|Placebo for FDL176
57915595|NCT05717231|BEHAVIORAL|laughter yoga|laughter yoga
58267916|NCT01099774|DRUG|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
58267917|NCT01099774|DRUG|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
58267918|NCT03054064|DEVICE|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
58267919|NCT06455124|RADIATION|Radiation|Shor-course radiotherapy: 25Gy/5Fx
58267920|NCT06455124|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
58267921|NCT06455124|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
58267922|NCT06455124|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
58267923|NCT00480493|BEHAVIORAL|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
57915596|NCT01257425|DRUG|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
57915597|NCT05314920|BEHAVIORAL|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
57915598|NCT05314920|BEHAVIORAL|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
58387667|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
58387668|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
58062335|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
58062336|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
58267924|NCT02990351|PROCEDURE|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
58267925|NCT02454075|DRUG|YF476|Gastrin receptor antagonist
58387669|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
58387670|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
57915599|NCT04881604|DEVICE|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
58062337|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
58387671|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
58062338|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
58062339|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
58062340|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
58062341|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
58267926|NCT00501059|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
58387672|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
58267927|NCT00501059|DRUG|Placebo|Placebo, taken daily
58267928|NCT05810506|OTHER|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
58387673|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
58387674|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
58267929|NCT05721677|DEVICE|2-octyl cyanoacrylate based topical skin adhesive|Tissue adhesive on CVL exit-site
58267930|NCT01031745|BEHAVIORAL|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
58387675|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
58387676|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
58387677|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
58387678|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
58387679|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
58387680|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
58387681|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
57915600|NCT04881604|DEVICE|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
57915601|NCT05008861|PROCEDURE|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
57915602|NCT05008861|DRUG|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
57915603|NCT05008861|DRUG|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
57915604|NCT04375020|DRUG|GABA|GABA nutritional supplement 750mg per day for 6 months
57915605|NCT00776126|DEVICE|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
57915606|NCT00648817|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
57915607|NCT00648817|DRUG|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
57915608|NCT03259451|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
58062342|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
57915609|NCT00088686|DRUG|Capsaicin (Intramucosal Injection)|
58062343|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
58062344|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
58062345|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
58267931|NCT01031745|OTHER|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
58267932|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
58267933|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
58267934|NCT00785213|DRUG|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
58267935|NCT04355806|DRUG|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
57915610|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
57915611|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
57915612|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
57915613|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
57915614|NCT01108107|BIOLOGICAL|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
57915615|NCT03263286|DEVICE|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
57915616|NCT03339570|PROCEDURE|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
57915617|NCT04943367|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
57915618|NCT03198182|DRUG|Placebo|Specified dose on specified days
57915619|NCT03198182|DRUG|BMS-986036|Specified dose on specified days
57915620|NCT03069612|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
57915621|NCT05488015|OTHER|Global Postural Re-education (GPR)|GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
57915622|NCT05488015|OTHER|Lifestyle habits|No change in lifestyle habits during the 8-week trial.
57915623|NCT02175251|PROCEDURE|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
57915624|NCT02175251|PROCEDURE|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
57915625|NCT02175251|PROCEDURE|Sham Comparator|10 session in 5 days with sham-controlled
57915626|NCT02083484|BIOLOGICAL|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
57915627|NCT00484107|DRUG|Conjugated Estrogen Cream (Premarin®)|
57915628|NCT01516242|OTHER|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
58267936|NCT04355806|BIOLOGICAL|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
58267937|NCT02174705|DRUG|Sucrose|Sucrose 24% orally prior to vaccine injections
58267938|NCT02174705|DRUG|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
58267939|NCT02134353|DRUG|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
58267940|NCT02134353|DRUG|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
58387682|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
58387683|NCT00189579|DRUG|Herceptin|
57714868|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
57714869|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
57714870|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
57714871|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
57714872|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
58267941|NCT06339203|DEVICE|Irrisept|450ml low concentration (0.05%) Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water
58267942|NCT06339203|DRUG|Normal Saline|450mL
58267943|NCT02464891|DRUG|CCX168|
58387684|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
57714873|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
57714874|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
57714875|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
57714876|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
57714877|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
58062346|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
58062347|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
58267944|NCT02456038|DRUG|Asfotase Alfa (ALXN1215)|
58267945|NCT06215300|GENETIC|coronary artery bypass grafting|coronary artery bypass grafting
58267946|NCT00130429|DRUG|PYM50028|
58267947|NCT00994695|BIOLOGICAL|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
58267948|NCT06172348|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
58267949|NCT05308784|OTHER|Cellworks Singula and Ventura reports|Personalized drug match reports based on patients' genomic aberration.
58267950|NCT01284387|BIOLOGICAL|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
58267951|NCT01397786|DRUG|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
58267952|NCT03119623|DRUG|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
58267953|NCT03119623|DRUG|Enalapril|enalapril 5mg, titrated up to 10mg po BID
57714878|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
58062348|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
58062349|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
58062350|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
58062351|NCT05189535|DRUG|Placebo|placebo
58267954|NCT03806231|DRUG|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
58267955|NCT03806231|DRUG|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
58387685|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
58387686|NCT03533699|DRUG|Propranolol|
57714879|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
58062352|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
57714880|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
57714881|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
57714882|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
57915629|NCT02669511|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
57915630|NCT02870166|OTHER|blood sample|
57915631|NCT00129597|DRUG|ketalar|
58062353|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
58062354|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
58062355|NCT00397527|DRUG|lactoserum|
58062356|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
58387687|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
58387688|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
57915632|NCT00164931|DRUG|Intravenous omeprazole infusion|
57915633|NCT00164931|PROCEDURE|Scheduled second endoscopy|
58062357|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
58062358|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
58387689|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
58387690|NCT00193011|DRUG|Docetaxel|Docetaxel
58387691|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
58387692|NCT00193011|DRUG|Methotrexate|Methotrexate
58387693|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
58387694|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
57714883|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
57714884|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
57714885|NCT01915277|DRUG|Dexmedetomidine|
57714886|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
57714887|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
57714888|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
57915634|NCT05493215|DRUG|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
57915635|NCT06355193|DRUG|Langenlianqiao|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
57714889|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
57915636|NCT06355193|DRUG|LianhuaQingWen|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
57915637|NCT06355193|OTHER|placebo control group|placebo control group
57915638|NCT04847726|DIAGNOSTIC_TEST|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
57915639|NCT04847726|DIAGNOSTIC_TEST|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
57915640|NCT04847726|DIAGNOSTIC_TEST|Liver MRI|Participants underwent liver MRI for hepatic lesion
58267956|NCT06620523|DRUG|CoQ10 1200 mg orally with Glutathione 1000 mg orally|This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
57915641|NCT02878681|DRUG|Ranibizumab|0.5 mg intravitreal injections
57915642|NCT02878681|DRUG|Aflibercept|2 mg intravitreal injections
57915643|NCT02675504|OTHER|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
57915644|NCT01240031|OTHER|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~* Thorough sensory and nutrition assessment (questionnaire).~* Nutrition plan adjusted daily according to the assessment.~* Serving appetising, energy- and protein-dense meals, snacks and drinks."
57915645|NCT01240031|OTHER|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
57915646|NCT04843553|DRUG|Oral Nicotinamide|
58267957|NCT06620523|DRUG|Group B: Placebo CoQ10 orally and Placebo Glutathione orally|A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
58267958|NCT04007224|DRUG|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
58267959|NCT04007224|BIOLOGICAL|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
58267960|NCT05678400|BEHAVIORAL|Hypopressive abdominal techniques|Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.
58267961|NCT05678400|BEHAVIORAL|Stretching of proprioceptive neuromuscular facilitation|Stretching of proprioceptive neuromuscular facilitation
57714890|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
57714891|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
57915647|NCT01315496|DRUG|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
57915648|NCT00557648|BEHAVIORAL|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
58267962|NCT06441032|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
58267963|NCT02970019|DRUG|K0706|Once a day administration after fast
58267964|NCT02970019|DRUG|Placebo|Once a day administration after fast
58267965|NCT05651308|BEHAVIORAL|Care coordination delivered based on perceived need|If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
58267966|NCT05651308|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
58267967|NCT05901350|DRUG|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
58267968|NCT03499275|DEVICE|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
58267969|NCT03499275|DEVICE|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
58267970|NCT03499275|OTHER|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
58267971|NCT03499275|OTHER|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
57714892|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
57714893|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
58267972|NCT01629823|DEVICE|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
58267973|NCT05049928|OTHER|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects"
58267974|NCT02787733|DIETARY_SUPPLEMENT|Citrus flavonoid|Daily dose of 500mg divided over two capsules
57714894|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
57714895|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
57714896|NCT02387021|PROCEDURE|Continuous femoral nerve block|
57714897|NCT02387021|PROCEDURE|Continuous adductor canal block|
57714898|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
57714899|NCT02387021|DRUG|Ropivacaine 0.2%|
57714900|NCT02387021|DRUG|Saline|
57714901|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
57714902|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
57714903|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
57714904|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
57714905|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
57714906|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
57714907|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
58267975|NCT02787733|DIETARY_SUPPLEMENT|Placebo|Daily dose of 500mg divided over two capsules
58267976|NCT03399682|DIAGNOSTIC_TEST|cystography|observationnal study
58267977|NCT03762928|DRUG|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
58267978|NCT03762928|DRUG|midazolam|single administration of midazolam 2 mg oral solution
58267979|NCT03762928|DRUG|efavirenz|single administration of efavirenz 50 mg capsule
58267980|NCT03964467|DEVICE|transcranial direct current stimulation|see arm/group descriptions
58267981|NCT01029171|BEHAVIORAL|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
58267982|NCT01029171|BEHAVIORAL|control; usual care|Usual care as prescribed by geriatrician.
58267983|NCT01501773|BIOLOGICAL|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
57714908|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
58267984|NCT00072540|DRUG|celecoxib|
58387695|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
57714909|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
57714910|NCT02114970|OTHER|Randomized- paper consent|
57714911|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
58062359|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
58062360|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
58062361|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
58267985|NCT00072540|PROCEDURE|anti-cytokine therapy|
58267986|NCT00072540|PROCEDURE|antiangiogenesis therapy|
58267987|NCT00072540|PROCEDURE|biological therapy|
58267988|NCT00072540|PROCEDURE|cancer prevention intervention|
58267989|NCT00072540|PROCEDURE|chemoprevention of cancer|
58267990|NCT00072540|PROCEDURE|enzyme inhibitor therapy|
58267991|NCT00072540|PROCEDURE|growth factor antagonist therapy|
58387696|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
58387697|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
58387698|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
58387699|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
58062362|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
58062363|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
58062364|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
58062365|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
58062366|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
58062367|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
58062368|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
57915649|NCT00557648|BEHAVIORAL|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
57915650|NCT06483529|DIAGNOSTIC_TEST|compliance measurement|compliance can be measured by analyzing pressure volume curves generated through different methods
57915651|NCT04925973|DRUG|Tofacitinib 10 MG [Xeljanz]|Tofacitinib 10mg PO BID
57915652|NCT06084156|DRUG|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
57915653|NCT06084156|DRUG|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
57915654|NCT02518126|OTHER|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
57915655|NCT02942238|PROCEDURE|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
57915656|NCT02942238|PROCEDURE|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
58062369|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
58062370|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
57714912|NCT02114970|OTHER|Focus Group- paper and tablet consent|
57714913|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
57714914|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
57915657|NCT04710160|DRUG|Novel fast-setting calcium silicate cement (Protooth)|In form of power and liquid to be mixed together to form a paste.
58062371|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
58062372|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
58062373|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
58062374|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
58062375|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
58062376|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
58062377|NCT01852591|BIOLOGICAL|PCV 13|
58062378|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
58062379|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
58062380|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
58267992|NCT01254851|BEHAVIORAL|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
58267993|NCT05309473|DEVICE|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
58267994|NCT05309473|DEVICE|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
58267995|NCT03873909|OTHER|Fruit Smoothie|Fruit Smoothie with 150-200 g mamey sapote fruit
58267996|NCT03873909|OTHER|Matrix-Free Shake|Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
58267997|NCT00129181|DRUG|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
58267998|NCT00129181|DRUG|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
58267999|NCT00129181|PROCEDURE|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
57714915|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
58062381|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
58062382|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
58268000|NCT05964114|DRUG|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
58268001|NCT03640481|DRUG|Belumosudil (KD025)|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
58268002|NCT01925235|PROCEDURE|remote ischemic preconditioning|
58268003|NCT00628095|DRUG|CE-224,535|500 mg po BID
58268004|NCT00628095|DRUG|Placebo|no active ingredient
58268005|NCT02307084|PROCEDURE|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
58062383|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
58268006|NCT04554212|DEVICE|Blood Flow Restriction Training|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
58268007|NCT04554212|DEVICE|Sham Blood Flow Restriction Training|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
58268008|NCT05103839|BEHAVIORAL|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
58268009|NCT01194635|GENETIC|fluorescence in situ hybridization|
58268010|NCT01194635|GENETIC|gene expression analysis|
58268011|NCT01194635|GENETIC|polymerase chain reaction|
58268012|NCT01194635|GENETIC|protein analysis|
58268013|NCT01194635|GENETIC|protein expression analysis|
58268014|NCT01194635|OTHER|enzyme-linked immunosorbent assay|
58268015|NCT01194635|OTHER|immunohistochemistry staining method|
58268016|NCT01194635|OTHER|laboratory biomarker analysis|
58268017|NCT02105389|BEHAVIORAL|Individualized Yoga Intervention|
58268018|NCT06448858|DIAGNOSTIC_TEST|serum Mn, Se, iron, Cu & Zn levels|Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.
58268019|NCT04616105|DRUG|REGN6490|Single dose of REGN6490
58268020|NCT04616105|DRUG|Placebo|Placebo matching single dose of REGN6490
58268021|NCT01210495|DRUG|Axitinib (AG-013736)|Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
58387700|NCT00880269|DRUG|Panobinostat/LBH589|
58062384|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
58062385|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
57714916|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
58062386|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
58062387|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
58062388|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
58062389|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
58062390|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
58062391|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
58268022|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
58268023|NCT01210495|DRUG|Placebo|Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
58268024|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
58387701|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
58268025|NCT03343249|BEHAVIORAL|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
58387702|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
58062392|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
58268026|NCT04470284|OTHER|Mobile Application|SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
58268027|NCT04470284|OTHER|Standard SMBP|Standard treatment (SMBP-alone)
58268028|NCT01273740|PROCEDURE|External support|Bypass surgery with externally supported graft
58387703|NCT02204046|DRUG|BIWA 4|
58387704|NCT02020798|OTHER|Dietary Intervention|
58387705|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
58387706|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
58387707|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
57714917|NCT01182077|DRUG|ASP015K|Oral
57714918|NCT01182077|DRUG|Midazolam|Oral
57714919|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
58062393|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
58062394|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
58062395|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
58062396|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
58062397|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
58062398|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
58268029|NCT06302088|OTHER|SAINTS program|A brief descriptive name used to refer to the intervention(s) studied in each arm of the clinical study. A non-proprietary name of the intervention must be used, if available. If a non-proprietary name is not available, a brief descriptive name or identifier must be used.
58268030|NCT03013296|OTHER|GIP-A|GIP-A
58268031|NCT03013296|OTHER|Placebo|Placebo
58268032|NCT03013296|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
58268033|NCT03013296|OTHER|GIP-A + Exendin[9-39]|GIP-A + Exendin\[9-39\]
58387708|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
58387709|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
57915658|NCT03993821|DRUG|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
57915659|NCT01814202|OTHER|PTM202|
58268034|NCT03199612|DRUG|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
58268035|NCT03199612|DRUG|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
58268036|NCT05956353|BEHAVIORAL|Digital Storytelling Intervention|Culturally tailored narrative-based videos created by individuals to promote colorectal, breast and cervical cancer screening among eligible participants in a primary care practice.
58268037|NCT00047216|DRUG|tipifarnib|
58387710|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
58387711|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
58387712|NCT04089527|DRUG|CC-95775|CC-95775
58387713|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
58387714|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
57714920|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
57714921|NCT00003380|DRUG|etoposide|
57714922|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
57714923|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
57915660|NCT01814202|OTHER|Placebo|
57915661|NCT04564651|OTHER|platelet transfusion|when the ADP inhibition \>70%, give one unit platelet tansfusion
57915662|NCT01590017|DRUG|cisplatin|
57714924|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
57714925|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
57915663|NCT01590017|RADIATION|external beam radiation therapy|
57915664|NCT00732225|DEVICE|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
57915665|NCT00732225|DEVICE|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
57915666|NCT00732225|DEVICE|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
57915667|NCT00732225|DEVICE|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
57915668|NCT00732225|DEVICE|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
57915669|NCT00285220|PROCEDURE|Laparoscopic Truncal Vagotomy|
57915670|NCT00541060|GENETIC|mutation|a mutation of a gene coding
58268038|NCT05167175|DRUG|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
58268039|NCT05167175|DRUG|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
58268040|NCT05167175|DRUG|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
58268041|NCT06258187|DEVICE|Pedi-Cap|The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
58268042|NCT00581542|DRUG|moxifloxacin|1-2 drops three times a day for 8-10 days.
58268043|NCT00581542|DRUG|polytrim|1-2 drops four times a day for 8-10 days.
58268044|NCT01406184|OTHER|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
58268045|NCT03796338|DEVICE|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
58268046|NCT03066245|BIOLOGICAL|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
58268047|NCT04417140|BIOLOGICAL|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
58387715|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
58387716|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
58387717|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
58387718|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
58387719|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
58387720|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
58062399|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
58062400|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
58062401|NCT02992054|OTHER|stimulating activities|
58062402|NCT00191438|DRUG|gemcitabine|
58387721|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
58062403|NCT00191438|DRUG|capecitabine|
58062404|NCT00191438|DRUG|docetaxel|
57915671|NCT00831337|DIETARY_SUPPLEMENT|VSL3|2 times daily 450 billion live bacteria (in each saschet)
57915672|NCT04384315|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
58062405|NCT01706744|OTHER|Intermediate care unit|
58062406|NCT01706744|OTHER|Local health care 1|
58062407|NCT01706744|OTHER|Local health care 2|
58062408|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
58062409|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
57915673|NCT05396469|DIAGNOSTIC_TEST|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
57915674|NCT03536260|DEVICE|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
58062410|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
58062411|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
58062412|NCT00207493|PROCEDURE|patient referral versus contract referral|
58062413|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
58062414|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
58062415|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
58062416|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
58062417|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
58062418|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
58062419|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
58062420|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
58062421|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
58268048|NCT03533881|DIETARY_SUPPLEMENT|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
58387722|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
58387723|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
58387724|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
57915675|NCT03536260|DEVICE|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
57915676|NCT00680784|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
57915677|NCT00680784|OTHER|Placebo Patch|Placebo Patch
57915678|NCT02334501|DRUG|Lansoprazole|
57915679|NCT02334501|DRUG|Neratinib|
57915680|NCT01515397|DRUG|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
57915681|NCT01515397|DRUG|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
58268049|NCT03533881|BEHAVIORAL|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
58268050|NCT01813513|DRUG|IDX719|50 mg tablet for oral administration
58268051|NCT01813513|DRUG|Simeprevir|150 mg capsule for oral administration
58268052|NCT02750007|DRUG|HS-20004|
58268053|NCT03794505|DRUG|Methylprednisolone Acetate|depo-medrol 40 mg
58268054|NCT03794505|DRUG|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
58268055|NCT03794505|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
58268056|NCT05294991|BEHAVIORAL|Wellness app intervention #1|This is the active intervention group.
58387725|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
58387726|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
58387727|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
58387728|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
58387729|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
58387730|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
58387731|NCT00631813|DRUG|Prucalopride|0.5 mg bid
58387732|NCT00631813|DRUG|Prucalopride|1 mg bid
58268057|NCT05294991|BEHAVIORAL|Wellness app intervention #2|This is the active comparator/control group.
58268058|NCT01485445|DRUG|Fluticasone Furoate (200mcg unit strength)|inhalation powder
58268059|NCT01485445|DRUG|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
58268060|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
58268061|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
58268062|NCT02326298|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
58268063|NCT02326298|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
58268064|NCT04773652|DIAGNOSTIC_TEST|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
58387733|NCT00631813|DRUG|Prucalopride|2 mg bid
58387734|NCT00631813|DRUG|Placebo|bid
58387735|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
58387736|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
58387737|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
58387738|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
58268065|NCT04505605|OTHER|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
58268066|NCT02134002|DRUG|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
58268067|NCT02134002|DRUG|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
58268068|NCT02521532|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
58268069|NCT02521532|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
58387739|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
58387740|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
58387741|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
58062422|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
58268070|NCT06366139|PROCEDURE|Radiofrequency thermocoagulation of the trigeminal ganglion|The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.
58387742|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
58387743|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
57714926|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
57915682|NCT01558011|DRUG|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
57915683|NCT03275129|DIAGNOSTIC_TEST|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
58062423|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
58062424|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
58062425|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
58062426|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
58062427|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
58062428|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
58062429|NCT03453593|OTHER|No intervention|No intervention
58387744|NCT00769223|OTHER|medical chart review|
58387745|NCT00769223|OTHER|questionnaire administration|
58387746|NCT00769223|PROCEDURE|quality-of-life assessment|
58062430|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
58387747|NCT00769223|RADIATION|brachytherapy|
57714927|NCT00602303|DRUG|Torsemide|
57915684|NCT01744223|BIOLOGICAL|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
58062431|NCT04686539|DRUG|Placebo|Placebo Oil
58387748|NCT00769223|RADIATION|radiation therapy|
58387749|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
58387750|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
58387751|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
58387752|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
58387753|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
58387754|NCT00140153|DRUG|testosterone gel (Androgel)|
58387755|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
58387756|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
57714928|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
57714929|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
57915685|NCT01744223|DRUG|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
58062432|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
58062433|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
58062434|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
58062435|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
58062436|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
58062437|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
58387757|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
58387758|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
58387759|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
58268071|NCT06366139|PROCEDURE|Maxillary/Mandibular nerve pulsed radiofrequency|The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
57714930|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
57714931|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
57714932|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
57714933|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
57714934|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
57714935|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
57714936|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
57714937|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
57714938|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
57714939|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
57714940|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
57714941|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
57714942|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
57915686|NCT01744223|BIOLOGICAL|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
57714943|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
57714944|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
57714945|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
58062438|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
57714946|NCT00088296|PROCEDURE|Blood Draw|
57714947|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
57714948|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
57714949|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
57714950|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
57714951|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
57714952|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
57714953|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
57714954|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
57714955|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
57714956|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
58062439|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
57714957|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
57714958|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
57714959|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
57915687|NCT01744223|BIOLOGICAL|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
58062440|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
58268072|NCT02971540|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
58268073|NCT02971540|DRUG|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
57915688|NCT01744223|BIOLOGICAL|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
57915689|NCT01744223|PROCEDURE|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
57915690|NCT03634696|OTHER|mPCL|Smart phone application to support palliative care among late-stage cancer patients
57915691|NCT03634696|OTHER|Usual Care|Usual care through OCRI palliative care clinic
57915692|NCT04483505|DRUG|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
57915693|NCT03446729|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
57915694|NCT05566496|DIAGNOSTIC_TEST|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
57915695|NCT00465920|BEHAVIORAL|modified cognitive behavioural therapy (mCBT)|
57915696|NCT02574156|DRUG|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
57915697|NCT03422588|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
57915698|NCT05213897|DEVICE|SARS-CoV-2 Antigen Assay|To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
57915699|NCT04252768|DRUG|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
57915700|NCT04252768|DRUG|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
57915701|NCT02314182|PROCEDURE|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~* Within 3 weeks after randomization~* Immunonutrition given 7 days prior to PT resection~* Mechanical bowel preparation performed before surgery according to the local practices~* Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~* Must be performed within 4 weeks after surgery~* CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~* Within 4 weeks after the surgery~* Chemotherapy administered according to the usual scheme for the chosen protocol~* All validated and/or registered perioperative rectal cancer treatments authorized~* The duration of one treatment cycle depending on the type of treatment administered~* Radiotherapy is allowed after randomization if indicated"
57915702|NCT02314182|DRUG|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
57915703|NCT04633486|DIAGNOSTIC_TEST|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
57915704|NCT04200885|DRUG|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
57915705|NCT04200885|DRUG|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
58062441|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
58062442|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
58268074|NCT02971540|DRUG|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
58268075|NCT02971540|DRUG|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
58268076|NCT02971540|OTHER|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
58268077|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Tablet|1.5 grams/day
57714960|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
57714961|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
57714962|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
57714963|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
57714964|NCT04314193|DRUG|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
58268078|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Placebo|2 tablets
58268079|NCT04303533|DEVICE|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
58268080|NCT01458717|DRUG|Neoadjuvant chemoradiation|"* Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
57714965|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
57714966|NCT02310659|OTHER|No intervention|No intervention
57714967|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
57915706|NCT04200885|DEVICE|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
58062443|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
57915707|NCT01528501|DRUG|Panobinostat (LBH589)|
57915708|NCT03404141|OTHER|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
58062444|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
58062445|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
58062446|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
58062447|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
58062448|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
58268081|NCT01458717|PROCEDURE|Upfront surgery|"* Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
58062449|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
58062450|NCT01485185|DRUG|Donepezil|Repeat, oral dose
58062451|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
58268082|NCT01637766|DRUG|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
57714968|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
57915709|NCT03404141|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
57915710|NCT04732494|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
57915711|NCT04732494|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
57915712|NCT04732494|DRUG|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
57915713|NCT00932113|DRUG|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
57915714|NCT00932113|DRUG|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
58062452|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
58062453|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
58062454|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
58062455|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
58062456|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58062457|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58062458|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58268083|NCT06287775|BIOLOGICAL|Atezolizumab|Given IV
58268084|NCT06287775|PROCEDURE|Biopsy|Undergo optional tumor biopsy
58268085|NCT06287775|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
58268086|NCT06287775|PROCEDURE|Computed Tomography|Undergo CT scan
58268087|NCT06287775|BIOLOGICAL|Durvalumab|Given IV
58268088|NCT06287775|PROCEDURE|Echocardiography|Undergo ECHO
58268089|NCT06287775|DRUG|Iadademstat|Given PO
58268090|NCT06287775|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58268091|NCT06287775|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57714969|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
57714970|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
57714971|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
57714972|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
57714973|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
57714974|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
57714975|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
57714976|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
57714977|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
57714978|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
57714979|NCT00233025|DRUG|Duloxetine|
57714980|NCT00233025|DRUG|Placebo|
58268092|NCT04803591|DRUG|Tranexamic Acid|Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
58268093|NCT01585324|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
58268094|NCT01585324|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
58268095|NCT03652116|DRUG|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
58268096|NCT03652116|DRUG|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
57714981|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
57915715|NCT05273697|PROCEDURE|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
58268097|NCT02877719|OTHER|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
58268098|NCT03176667|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
58268099|NCT03176667|PROCEDURE|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
57714982|NCT02097134|DRUG|Melphalan|Given IA
57714983|NCT00963729|DRUG|cyclophosphamide|Given IV
57714984|NCT00963729|DRUG|docetaxel|Given IV
57714985|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
57714986|NCT00963729|DRUG|fluorouracil|Given IV
57714987|NCT00963729|DRUG|letrozole|Given orally
57714988|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
57714989|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
57714990|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
57714991|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
57714992|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
57714993|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
57714994|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
57714995|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
57714996|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
57714997|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
57714998|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
57714999|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
57715000|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
57715001|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
58268100|NCT00313365|PROCEDURE|Surgical Lavage (Arthrotomy)|
57715002|NCT04685135|DRUG|MRTX849|21 day cycles
57715003|NCT04685135|DRUG|Docetaxel|21 day cycles
57715004|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
57715005|NCT03393221|BEHAVIORAL|SBWC|
57715006|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
57715007|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
57715008|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
57715009|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
57715010|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
57715011|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
57715012|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
57715013|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
57715014|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
57715015|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
57915716|NCT05273697|PROCEDURE|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
57915717|NCT03080831|DRUG|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
58268101|NCT00313365|PROCEDURE|Arthrocentesis (Serial needle aspiration)|
57915718|NCT03080831|DRUG|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
58268102|NCT02595281|OTHER|Experimental arm|"Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy"
57715016|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
57715017|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
57915719|NCT04778241|PROCEDURE|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
58268103|NCT02035774|PROCEDURE|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
58268104|NCT04601103|DRUG|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
58268105|NCT04601103|DRUG|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
58268106|NCT04601103|DRUG|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
58268107|NCT04601103|DEVICE|Anti-plaque|Rinse prevents bacterial adherence to teeth
57715018|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
57715019|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
57915720|NCT05248074|OTHER|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
57915721|NCT05248074|DRUG|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
57915722|NCT01011426|DRUG|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
57915723|NCT01011426|DRUG|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
57915724|NCT02088437|OTHER|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
57915725|NCT02088437|OTHER|Usual Care|once daily physiotherapy whilst acute hospital inpatient
57915726|NCT00437723|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
57915727|NCT01095107|DIETARY_SUPPLEMENT|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
57915728|NCT01095107|DIETARY_SUPPLEMENT|Increased fat intake|increased fat intake : Intake \> 50 grams of fat per day between meals and snacks
57915729|NCT02368496|DEVICE|HR-pQCT|
57915730|NCT00414713|PROCEDURE|red blood cell transfusion|red blood cell transfusion
58268108|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58268109|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58268110|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
57915731|NCT03751579|PROCEDURE|coelioscopic surgery|observational study based on the computation of respiratory quotient in patient cohort treated by routine coelioscopic surgery
57915732|NCT04302441|DRUG|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
57915733|NCT04302441|DRUG|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
57915734|NCT01971710|BEHAVIORAL|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
57915735|NCT01971710|BEHAVIORAL|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
57915736|NCT01971710|BEHAVIORAL|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
58268111|NCT01985139|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
58268112|NCT01985139|BIOLOGICAL|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
58268113|NCT03014713|DRUG|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
58268114|NCT03014713|DRUG|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
58268115|NCT03014713|DRUG|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
57715020|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
57715021|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
57715022|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
57715023|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
57715024|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
57715025|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
57715026|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
57715027|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
57715028|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
57715029|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
57915737|NCT01203280|OTHER|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
57915738|NCT02212210|DRUG|Methylprednisolone|
57915739|NCT02212210|DRUG|Normal saline|
57915740|NCT01835938|DRUG|1- Erlotinib|"* Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,"
57915741|NCT01835938|DRUG|placebo|"* Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,"
57915742|NCT00390910|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
57715030|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
57915743|NCT00390910|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
57915744|NCT02463565|OTHER|no intervention|
57915745|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
57915746|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
57915747|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
57715031|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
57915748|NCT00691405|DRUG|Placebo|Placebo inhalation solution BID
57915749|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
57915750|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
57915751|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
57915752|NCT00691405|DRUG|Placebo|Placebo inhalation solution QD
57915753|NCT02567500|BEHAVIORAL|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
57915754|NCT02567500|BEHAVIORAL|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
57915755|NCT03253965|OTHER|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
57915756|NCT03253965|OTHER|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
57915757|NCT03253965|OTHER|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
57715032|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
57715033|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
57715034|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
57715035|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
57715036|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
57715037|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
57715038|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
57715039|NCT05430516|OTHER|No intervention|No intervention
57715040|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
57715041|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
57715042|NCT05822011|PROCEDURE|Thoraccic Epidural analgesia|Neuroaxial block
57715043|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
57915758|NCT03253965|OTHER|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
57915759|NCT03253965|OTHER|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
58062459|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
58268116|NCT05276622|OTHER|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
58268117|NCT05276622|OTHER|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
58268118|NCT05276622|OTHER|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
58268119|NCT06269016|OTHER|expremental pre and post test|effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
58268120|NCT01289756|DRUG|Clomiphene|clomiphene once 100 mg oral
58268121|NCT01289756|DRUG|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
58268122|NCT01289756|DRUG|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
57715044|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
57715045|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
57715046|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
57715047|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
57715048|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
57915760|NCT03253965|OTHER|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
57915761|NCT03253965|OTHER|No Auditory cueing|Steps are not timed with any auditory cue.
58268123|NCT03269084|OTHER|No intervention. DIPP is an observational study.|
57915762|NCT03542370|OTHER|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
58268124|NCT04205149|OTHER|ERAS post-operative pathway|ERAS Pathway
58268125|NCT04005144|DRUG|Binimetinib|Given PO
58268126|NCT04005144|DRUG|Brigatinib|Given PO
58387760|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
58268127|NCT02160847|BEHAVIORAL|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
58387761|NCT00770562|DRUG|rituximab|
58387762|NCT00770562|DRUG|Dexamethasone|
58387763|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
58387764|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
58387765|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
58387766|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
58387767|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
58387768|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
57715049|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
58062460|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
57715050|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
57715051|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
57715052|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
58062461|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
58062462|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
58268128|NCT02106663|PROCEDURE|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
58268129|NCT02106663|PROCEDURE|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
58268130|NCT01593280|DEVICE|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
58062463|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
58062464|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
58268131|NCT01593280|DRUG|intrathecal morphine|0.3 mg
58268132|NCT01013623|PROCEDURE|Surgery|surgical resection to remove all known disease
58387769|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
58387770|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
58387771|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
58387772|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
58387773|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
58387774|NCT05535023|DRUG|SAR444245|Given by vein (IV)
58387775|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
58387776|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
58387777|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
57715053|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
57715054|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
57715055|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
57715056|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
57715057|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
57715058|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
57715059|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
57915763|NCT02288533|DEVICE|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
58387778|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
58387779|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
58268133|NCT01013623|PROCEDURE|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
58268134|NCT01013623|OTHER|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
58268135|NCT05697250|OTHER|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
57715060|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
58268136|NCT05285722|BEHAVIORAL|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
57715061|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
58387780|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
57715062|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
58387781|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
58387782|NCT00075855|DRUG|therapeutic testosterone|
57915764|NCT02742636|DEVICE|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
57915765|NCT00690118|DRUG|pioglitazone|45 mg/day, 18 months
57915766|NCT00690118|DRUG|placebo|once daily, 18 months
57915767|NCT01270971|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
57915768|NCT01270971|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
58387783|NCT00075855|OTHER|placebo|
57715063|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
58062465|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
58062466|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
58062467|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
58062468|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
58062469|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
57715064|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
57915769|NCT00515632|DRUG|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
57915770|NCT02925013|PROCEDURE|Blood sampling|Blood sampling for lipid profile
57915771|NCT02925013|OTHER|Dietary- Normal western diet|Normal western diet
57915772|NCT05526066|BIOLOGICAL|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).
57915773|NCT05526066|OTHER|Placebo|Normal Saline
57915774|NCT01802567|DEVICE|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
57915775|NCT02134977|DRUG|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
57915776|NCT03956485|OTHER|Type of center|Tertiary versus non-tertiary
57915777|NCT02050152|BEHAVIORAL|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
58062470|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
58062471|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
58062472|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
58062473|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
58062474|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
58062475|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
57915778|NCT02050152|DRUG|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
58062476|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
58268137|NCT04747873|BEHAVIORAL|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
58268138|NCT04747873|BEHAVIORAL|Stepped Care|Stepped care procedure (see arm/group descriptions).
58268139|NCT01701297|DRUG|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
58268140|NCT01701297|DRUG|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
57915779|NCT01242358|DEVICE|Capnography|Capnographic monitoring
58387784|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
57715065|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
58268141|NCT01701297|DRUG|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
57915780|NCT01242358|DEVICE|Standard monitoring|Standard monitoring
57915781|NCT00153504|BEHAVIORAL|Housing and Health Study housing rental assistance|
57915782|NCT00153504|BEHAVIORAL|Standard local practice housing assistance|
58062477|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
58062478|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
58062479|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
58387785|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
58387786|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
58387787|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
58387788|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
57915783|NCT00122460|DRUG|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
57915784|NCT00122460|DRUG|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
57915785|NCT01546350|GENETIC|PGD|array CGH after blastocyst biopsy
57915786|NCT01546350|PROCEDURE|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
57915787|NCT00156819|DRUG|fluticasone|fluticasone (100 microgram twice daily) treatment
57915788|NCT00156819|DRUG|montelukast|Montelukast (5 or 10 mg each night).
57915789|NCT00156819|DRUG|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
57915790|NCT02426346|BEHAVIORAL|Behavioral weight control|Prescription of diet \& physical activity and behavioral strategies for weight control
58062480|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
58062481|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
58062482|NCT02581098|OTHER|No interventions|No interventions
58062483|NCT00343161|DRUG|esomeprazole|
58268142|NCT03041103|OTHER|Food Product 1|50 grams of fortified nutritious product from legumes
58268143|NCT06245967|DEVICE|Frequency specific microcurrent therapy|Concussion protocol
58268144|NCT06245967|DEVICE|Sham Frequency specific microcurrent therapy|Shan concussion protocol
58387789|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
57915791|NCT02426346|BEHAVIORAL|Group-based physical activity|Teens exercise for 60 minutes with their group
57915792|NCT02426346|BEHAVIORAL|Group-based incentives|Adolescents earn reinforcements within group
57915793|NCT02426346|BEHAVIORAL|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
57915794|NCT05134077|PROCEDURE|CT scan with contrast|CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
57915795|NCT05134077|RADIATION|Nephroscintigraphy|Nephroscintigraphy is necessary to determine the renal function
57915796|NCT04600193|OTHER|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
58062484|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
58062485|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
57915797|NCT04600193|OTHER|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
58387790|NCT00641355|PROCEDURE|No intervention|No intervention
58387791|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
58387792|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
57915798|NCT06241768|OTHER|mPATH-CRC Web app|Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening
58387793|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
57915799|NCT05384444|OTHER|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
57915800|NCT00723021|DRUG|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
58387794|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
58387795|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
57915801|NCT00723021|DRUG|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
57915802|NCT00723021|DRUG|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
58062486|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
58062487|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
58387796|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
58387797|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
58387798|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
58387799|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
58387800|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
58387801|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
57915803|NCT00723021|DRUG|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
57915804|NCT00723021|DRUG|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
57915805|NCT01730781|RADIATION|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
57915806|NCT03995667|OTHER|Questionnaire Administration|Ancillary studies
57915807|NCT03995667|DEVICE|Tumor Treating Fields Therapy|Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
57915808|NCT06486038|DIAGNOSTIC_TEST|MRI standard and qMRI|Non-contrast cervical spine MRI including morphological and quantitative MRI sequences on a 3 Tesla scanner. MRI examination includes conventional and experimental sequences
57915809|NCT06486038|OTHER|MEPs and SSEPs|Neurophysiological examination by motor and somatosensorial evocked potential using transcranial magnetic stimulation and electrical stimulation to the peripheral nerve
58062488|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
57915810|NCT06486038|OTHER|Neuromotor assessment|Upper and Lower limb assessment: Purdue Pegboard Test (PTT), Box and Block test (BBT), Nine Hole Peg Test (NHPT), gait analysis and 30 seconds sit to stand test (30CST)
57915811|NCT06486038|PROCEDURE|Anterior cervical discectomy and fusion|If applicable: Anterior cervical discectomy and fusion surgery using PEEK or modern carbon fiber material
58062489|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
58062490|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
58062491|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
58062492|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
58062493|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
58062494|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
57715066|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
57915812|NCT03272581|OTHER|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
57915813|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
58062495|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
58062496|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
58062497|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
58062498|NCT02055872|DRUG|Intravenous albumin|
58062499|NCT02055872|DRUG|Normal saline|
57915814|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
57915815|NCT00550875|BIOLOGICAL|placebo|Sublingual. 2 drops/daily 2 years
58062500|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
57915816|NCT02963610|DRUG|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
58062501|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
58062502|NCT00089206|BIOLOGICAL|sargramostim|
58062503|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
58062504|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
58062505|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
58062506|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
58062507|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
58062508|NCT02367157|PROCEDURE|Kenzo Kase Method|
58062509|NCT02367157|DEVICE|Kinesio Taping|
58062510|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
58387802|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
58387803|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
58387804|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
58387805|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
58387806|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
58387807|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
57715067|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
57915817|NCT02963610|DRUG|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
58387808|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
58387809|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
57915818|NCT05030545|DRUG|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
57915819|NCT01994668|DRUG|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
57915820|NCT01994668|DRUG|Placebo|A single intravenous administration of 0.9% saline over 1 minute
57915821|NCT01776541|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
57915822|NCT01964885|DIETARY_SUPPLEMENT|IQP-AS-105|
57915823|NCT01964885|DIETARY_SUPPLEMENT|Placebo|
57915824|NCT02782689|DEVICE|Kit Biflex|Two-layer reusable compression system
57915825|NCT02782689|DEVICE|Profore|Four-layer compression system
57915826|NCT06276907|BIOLOGICAL|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
58387810|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
58387811|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
57915827|NCT06276907|OTHER|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
57915828|NCT02349646|DEVICE|Implantation with the commercially available Axium neurostimulator|
57915829|NCT05012891|OTHER|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
58387812|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
58387813|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
58387814|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
58387815|NCT00981162|DRUG|sorafenib tosylate|Given PO
58387816|NCT00981162|DRUG|everolimus|Given PO
58387817|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
58387818|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
58387819|NCT00981162|OTHER|pharmacological study|Correlative study
58387820|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
58387821|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
58062511|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
58062512|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
58387822|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
58387823|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
58387824|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
58387825|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
58387826|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
58387827|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
58387828|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
57915830|NCT01600820|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
57915831|NCT01600820|OTHER|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
58062513|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
58062514|NCT00000576|DRUG|beclomethasone|
58062515|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
58062516|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
58062517|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
58062518|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
58062519|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
58062520|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
58387829|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
58387830|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
58387831|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
58387832|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
58387833|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
57915832|NCT01600820|OTHER|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
57915833|NCT02608320|DRUG|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
57915834|NCT02608320|DRUG|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
57915835|NCT02608320|DRUG|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
57715068|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
57715069|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
57715070|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
57715071|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
57715072|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
57715073|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
57715074|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
57715075|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
57715076|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
57715077|NCT02251665|OTHER|No intervention|a single-center prospective observational study
58268145|NCT03141983|DRUG|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
58062521|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
58062522|NCT00072098|BIOLOGICAL|adenovirus vector|
58062523|NCT00072098|BIOLOGICAL|interleukin-12 gene|
58268146|NCT03141983|DRUG|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
58387834|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
58387835|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
58387836|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
58387837|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
58387838|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
58387839|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
58387840|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
57715078|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
57715079|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
57715080|NCT00550836|BIOLOGICAL|panitumumab|Given IV
57715081|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
58062524|NCT03830463|DRUG|CTP-692|Single oral dose
57715082|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
57715083|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
57715084|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
57715085|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
57715086|NCT05002946|DRUG|SP-104|single oral dose
57715087|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
57715088|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
58387841|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
57715089|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
57715090|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
57715091|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
57715092|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
57715093|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
57715094|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
57715095|NCT04711304|OTHER|Saline|Intraarticular injection
58062525|NCT03830463|DRUG|Placebo|Single oral dose
58062526|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
58062527|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
58062528|NCT00005838|OTHER|placebo|Given orally
58062529|NCT00005838|DRUG|cisplatin|Given IV
58387842|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
58387843|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
58387844|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
58387845|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
58062530|NCT00005838|DRUG|vinorelbine tartrate|Given IV
58062531|NCT00005838|DRUG|carboplatin|Given IV
58062532|NCT00005838|DRUG|paclitaxel|Given IV
58062533|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
58062534|NCT00120029|BEHAVIORAL|weight loss counseling|
58387846|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
58387847|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
58387848|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
58387849|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
58387850|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
58387851|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
58387852|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
57715096|NCT06165744|DEVICE|UNITY VCS|Investigational device used during anterior and posterior segment ophthalmic surgery.
57715097|NCT06165744|PROCEDURE|Eye surgery|Eye surgery performed with UNITY VCS
57715098|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
57715099|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
57715100|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
57715101|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
58062535|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
58062536|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
58062537|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
57715102|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
57915836|NCT02608320|DRUG|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
57915837|NCT02608320|DRUG|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
57915838|NCT02608320|DRUG|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
57915839|NCT02966951|BIOLOGICAL|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
57915840|NCT05185583|DRUG|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
57915841|NCT05185583|DRUG|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
57915842|NCT06109675|BEHAVIORAL|Nutrition Education|All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
58062538|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
58062539|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
58062540|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
58062541|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
58062542|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
57715103|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
57915843|NCT06208319|OTHER|data collection|data collection from the patient's medical record. The data will be that of routine care, with no procedures added by the research.
58062543|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
58062544|NCT02487901|DEVICE|drill|making gutter with drill
58062545|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
58062546|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
58062547|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
58062548|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
58062549|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
58268147|NCT05311566|COMBINATION_PRODUCT|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
58268148|NCT04113408|OTHER|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
57715104|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
57915844|NCT03905161|OTHER|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
57915845|NCT01080495|PROCEDURE|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
57715105|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
57715106|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
57715107|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
57715108|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
57715109|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
57715110|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
57715111|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
57715112|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
57715113|NCT01728155|DRUG|chemotherapy|
57715114|NCT02258282|DRUG|Etanercept|
57715115|NCT02258282|DRUG|Control|
57715116|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
57715117|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
57915846|NCT02684357|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
58268149|NCT01211483|DRUG|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
57915847|NCT02684357|DRUG|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
58062550|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
58387853|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
58387854|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
58387855|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
58387856|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
58268150|NCT01211483|DRUG|Erlotinib|Tablet 150 mg for oral administration
58268151|NCT01211483|DRUG|Placebo|Placebo liquid matching U3-1287 for IV infusion
58268152|NCT03713840|BEHAVIORAL|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
58268153|NCT05220345|DEVICE|colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)|All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
58387857|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
58387858|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
57915848|NCT02684357|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
58387859|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
58387860|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
58387861|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
58387862|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
58387863|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
57915849|NCT02684357|DRUG|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
57915850|NCT03975595|BEHAVIORAL|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
57915851|NCT03975595|BEHAVIORAL|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
57915852|NCT02868866|BEHAVIORAL|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
57915853|NCT02354508|DRUG|Pasireotide LAR|Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
57715118|NCT00116389|DRUG|talabostat mesylate tablets|
58268154|NCT05432050|DEVICE|Bispectral index and Patient state index monitoring|The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
58387864|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
58387865|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
58387866|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
57715119|NCT00116389|DRUG|gemcitabine|
57915854|NCT00004145|BIOLOGICAL|anti-thymocyte globulin|
57915855|NCT00004145|DRUG|cyclophosphamide|
57915856|NCT00004145|DRUG|fludarabine phosphate|
58268155|NCT03635385|PROCEDURE|Apheresis technics|Blood draw will be performed for anti bodies dosages
57915857|NCT00004145|PROCEDURE|peripheral blood stem cell transplantation|
57915858|NCT01730794|OTHER|NAVA ventilation|Neurally adjusted ventilatory assist
57915859|NCT01730794|OTHER|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
58062551|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
58062552|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
58268156|NCT05263765|PROCEDURE|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
58268157|NCT05615610|DEVICE|spine TENS|The participants in Group A will receive TENS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
57915860|NCT04912271|DRUG|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
57915861|NCT04912271|DRUG|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
57915862|NCT04912271|DRUG|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
57915863|NCT04912271|DRUG|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
57915864|NCT04912271|DRUG|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
57915865|NCT00241852|BEHAVIORAL|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
57915866|NCT00241852|BEHAVIORAL|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
57915867|NCT02350777|PROCEDURE|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
57915868|NCT02350777|DEVICE|CliniMACS Cell Selection System|
57915869|NCT02739295|DRUG|recombinant granulocyte - colony stimulating factor|
57915870|NCT02739295|DRUG|NaCl 0.9%|
58062553|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
58062554|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
58062555|NCT01888367|DRUG|DFA-02 Placebo Gel|
58062556|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
58062557|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
57715120|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
57715121|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
57715122|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
57715123|NCT01947530|PROCEDURE|Standard Bronchoscopy|
57715124|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
57715125|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
57715126|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
57915871|NCT05386797|PROCEDURE|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
57915872|NCT02418221|DIETARY_SUPPLEMENT|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
57915873|NCT02418221|PROCEDURE|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure \& pulse
57915874|NCT06328907|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
57715127|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
57715128|NCT00237952|DRUG|EDTA chelating agents|
57715129|NCT02647034|OTHER|no intervention|no intervention
57715130|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
57715131|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
57715132|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
57715133|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
57715134|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
57715135|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
57715136|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
57715137|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
57715138|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
57915875|NCT06328907|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58387867|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
57715139|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
57715140|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
57715141|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
57715142|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
57715143|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
57715144|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
57715145|NCT00099775|DRUG|Caspofungin|
58387868|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
58387869|NCT00244725|DRUG|Odiparcil|
58387870|NCT00244725|DRUG|Warfarin|
58387871|NCT00244725|DRUG|Coumadin|
57715146|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
57715147|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
57715148|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
57715149|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
57715150|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
57915876|NCT06328907|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
57915877|NCT00969527|DIETARY_SUPPLEMENT|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
57915878|NCT00969527|DIETARY_SUPPLEMENT|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
58062558|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
58062559|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
58062560|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
58062561|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
58268158|NCT05615610|DEVICE|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
57715151|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
57715152|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
58387872|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
57915879|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
57915880|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
58062562|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
58062563|NCT00086164|DRUG|edifoligide (E2F Decoy)|
58062564|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
58387873|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
58387874|NCT01736423|DRUG|YM060|oral
57715153|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
57715154|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
57915881|NCT02706912|BEHAVIORAL|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
57915882|NCT03433053|BEHAVIORAL|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
57915883|NCT03433053|BEHAVIORAL|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
58387875|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
58387876|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
58387877|NCT01780844|DRUG|ASKP1240|intravenous infusion
58387878|NCT01780844|DRUG|Tacrolimus|intravenous or oral
58387879|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
58387880|NCT01780844|DRUG|Basiliximab|intravenous
58387881|NCT01780844|DRUG|Methylprednisone|Intravenous
58387882|NCT01780844|DRUG|Prednisone|Oral
58387883|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
58387884|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
57715155|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
57915884|NCT01060540|GENETIC|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
58268159|NCT05615610|DEVICE|Control|The participants in Group C will receive placebo tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
58387885|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
57715156|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
57715157|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
57915885|NCT01060540|BEHAVIORAL|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
57915886|NCT01060540|BEHAVIORAL|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
57715158|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
57715159|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
57915887|NCT01218893|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
57915888|NCT01218893|BIOLOGICAL|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
57915889|NCT01218893|BIOLOGICAL|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
57915890|NCT01218893|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
57915891|NCT06231342|DEVICE|Direct Laryngoscope (DL)|DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
58062565|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
58062566|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
58062567|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
58268160|NCT01113138|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
58268161|NCT01113138|DRUG|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
58268162|NCT06622525|DRUG|Sodium bicarbonate|This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
58268163|NCT06622525|OTHER|No intervention|The usual management for heat stroke will be given to this group
58268164|NCT02505451|DRUG|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
58268165|NCT05149378|DRUG|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
58268166|NCT01551719|BEHAVIORAL|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
58268167|NCT00948506|DRUG|1% topical cidofovir|1% topical cidofovir
58268168|NCT00948506|DRUG|3% topical cidofovir|3% topical cidofovir
58268169|NCT00948506|DRUG|Placebo|topical placebo
58268170|NCT03284372|BEHAVIORAL|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
57715160|NCT00079105|DRUG|cyclophosphamide|Treatment
57715161|NCT00079105|DRUG|etoposide|Treatment
57715162|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
57715163|NCT00079105|DRUG|prednisolone|Treatment
57715164|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
57715165|NCT00079105|DRUG|vinblastine sulfate|Treatment
57915892|NCT06231342|DEVICE|Video laryngoscope (VL)|VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
57915893|NCT06231342|PROCEDURE|Endotracheal Tube (ETT) 180|A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
58268171|NCT03284372|BEHAVIORAL|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
57715166|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
57715167|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
57715168|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
57715169|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
57715170|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
57715171|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
58268172|NCT03754634|DRUG|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
57715172|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
57715173|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
57715174|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
57715175|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
57715176|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
57715177|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
57715178|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
57715179|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
57715180|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
57715181|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
58268173|NCT04837599|DEVICE|Discovery TM of Pentax medical on/off in colonoscopy|on the monitor artificial integlligence Discovery can be switched on or off.
57715182|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
57715183|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
58268174|NCT01885715|DRUG|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
57715184|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
57715185|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
57715186|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
57715187|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
57715188|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
57715189|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
57915894|NCT01506453|DRUG|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
57915895|NCT01506453|DRUG|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
57715190|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
57715191|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
57715192|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
57715193|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
57715194|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
57715195|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
57715196|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
57915896|NCT05658237|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
58062568|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
58062569|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
58268175|NCT00463216|BEHAVIORAL|A multidisciplinary diagnostic evaluation|
58268176|NCT01601457|DRUG|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
58387886|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
57715197|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
57715198|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
57715199|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
57715200|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
57715201|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
57715202|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
57715203|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
57715204|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
57715205|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
57715206|NCT02132000|DRUG|toremifene or tamoxifen|
57715207|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
57715208|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
57715209|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
57715210|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
57715211|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
57715212|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
57715213|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
57715214|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
57715215|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
57915897|NCT02479321|OTHER|GDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
57915898|NCT02479321|DEVICE|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
57915899|NCT04723420|OTHER|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
57915900|NCT04723420|OTHER|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
57915901|NCT06367673|BIOLOGICAL|iPSC-NK cells|iPSC-NK cells
57915902|NCT00002209|DRUG|CPI-1189|
58062570|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
57715216|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
57715217|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
57715218|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
57715219|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
57715220|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
57715221|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
57715222|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
57715223|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
57715224|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
57715225|NCT02246504|DEVICE|HIFU treatment|
57715226|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
57715227|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
58268177|NCT01601457|DRUG|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
58268178|NCT03075202|DEVICE|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
58268179|NCT04812340|OTHER|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
58268180|NCT04812340|OTHER|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
58268181|NCT03968250|BEHAVIORAL|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
58268182|NCT02063048|BEHAVIORAL|Text Message Based Weight Loss Support|
58268183|NCT03118791|DIETARY_SUPPLEMENT|anthocyanins|Acute intake of capsules
58268184|NCT00664794|PROCEDURE|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
58268185|NCT00664794|PROCEDURE|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
57715228|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
57715229|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
57715230|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
57715231|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
57915903|NCT02511912|PROCEDURE|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
57915904|NCT05874154|PROCEDURE|Tibial nerve selective neurotomy|Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
57915905|NCT05874154|DRUG|Botulinum toxin injection|Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
57915906|NCT00250926|DRUG|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
57915907|NCT00250926|DRUG|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
57915908|NCT00250926|DRUG|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
57915909|NCT01704768|BEHAVIORAL|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
57915910|NCT01704768|BEHAVIORAL|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
57715232|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
57915911|NCT02435758|PROCEDURE|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
58062571|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
58062572|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
58062573|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
58268186|NCT01436331|OTHER|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
58387887|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
58387888|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
58062574|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
58387889|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
58387890|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
58268187|NCT01436331|BEHAVIORAL|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
58268188|NCT04251962|DRUG|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
57715233|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
57715234|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
58268189|NCT04251962|DRUG|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
58268190|NCT00407927|DRUG|Epinastine Nasal Spray|
58268191|NCT05199896|BEHAVIORAL|Behavioral protocol|A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
58268192|NCT05199896|DEVICE|EEG protocol|"The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch.~Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products)."
58268193|NCT05199896|DEVICE|fMRI protocol|"The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant.~During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position."
58268194|NCT02939976|DEVICE|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
58387891|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
58387892|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
57715235|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
58387893|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
58387894|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
58387895|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
57715236|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
58387896|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
57715237|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
57715238|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
57715239|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
57715240|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
57715241|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
58387897|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
58387898|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
58387899|NCT03024112|OTHER|Standard oxygen therapy|
57715242|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
57715243|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
57715244|NCT06464939|DRUG|Placebo|Applications of water for injection
57715245|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
57715246|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
57715247|NCT02206113|BEHAVIORAL|Standing workstation|
57715248|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
57715249|NCT04902105|DRUG|ecopipam HCL|oral tablets
57715250|NCT04902105|DRUG|Mefenamic acid|oral capsules
57915912|NCT06168097|PROCEDURE|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
57915913|NCT06168097|PROCEDURE|women with intraoperative and / or histopathology findings suggestive of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
58062575|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
58268195|NCT02939976|PROCEDURE|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
57715251|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
57715252|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
58268196|NCT02939976|PROCEDURE|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
57715253|NCT00399334|DRUG|antipsychotic medications|as prescribed
58387900|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
57715254|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
57715255|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
57715256|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
57715257|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
58268197|NCT02939976|DEVICE|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
58387901|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
57715258|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
57715259|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
57715260|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
57715261|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
57715262|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
57715263|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
57715264|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
57915914|NCT04566926|DRUG|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
57915915|NCT04566926|DRUG|Placebo|Participant will receive matching placebo.
57915916|NCT05786430|DRUG|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
58387902|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
58387903|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
58268198|NCT02939976|DEVICE|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
58387904|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
58387905|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
57715265|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
57715266|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
57715267|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
57715268|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
57715269|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
57715270|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
57715271|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
57715272|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
57715273|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
57715274|NCT00309933|PROCEDURE|cognitive assessment|
57715275|NCT00309933|PROCEDURE|psychosocial assessment and care|
57715276|NCT00309933|PROCEDURE|quality-of-life assessment|
57715277|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
57715278|NCT02157324|DRUG|acalabrutinib|
57715279|NCT02157324|DRUG|ACP-319|
57715280|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
57715281|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
57715282|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
57915917|NCT01453803|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
57915918|NCT05276609|DRUG|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
57915919|NCT05276609|DRUG|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
57915920|NCT01477320|DRUG|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
57715283|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
57715284|NCT01978184|DRUG|gemcitabine|
57715285|NCT01978184|DRUG|abraxane|
57715286|NCT01978184|DRUG|hydroxychloroquine|
57715287|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
57715288|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
57715289|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
57715290|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
57715291|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
57715292|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
57715293|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
57715294|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
57715295|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
57715296|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
57715297|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
57715298|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
57715299|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
57715300|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
57715301|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
57715302|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
57715303|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
57715304|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
57715305|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
57715306|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
57715307|NCT05060419|DRUG|Saline|180min
57715308|NCT05060419|DRUG|Saline|30min
57715309|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
57715310|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
57715311|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
57915921|NCT01477320|OTHER|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
57915922|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
58268199|NCT02939976|DEVICE|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
58268200|NCT02939976|DEVICE|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
58268201|NCT03042416|DRUG|18F-DOPA|18F-DOPA intravenous injection single dose
58268202|NCT02306694|DRUG|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
58268203|NCT04984681|BEHAVIORAL|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
58268204|NCT04984681|OTHER|Usual Care|The control condition will continue receiving usual care or standard of care.
58268205|NCT04151238|BEHAVIORAL|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
58268206|NCT00079300|DRUG|imiquimod|
58268207|NCT00079300|PROCEDURE|conventional surgery|
58268208|NCT01540136|DRUG|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
58268209|NCT01540136|DRUG|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
58268210|NCT01778699|DIETARY_SUPPLEMENT|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
58268211|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
58268212|NCT02258334|BIOLOGICAL|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
58268213|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
58268214|NCT02258334|BIOLOGICAL|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
58268215|NCT06478602|BIOLOGICAL|Fecal microbiota transplantation|Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
58268216|NCT02277158|DRUG|Chemoradiotherapy|S-1 CCRT
58268217|NCT02440321|BEHAVIORAL|Parent-child interactive program|
58268218|NCT02440321|OTHER|written materials|
57715312|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
57715313|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
57715314|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
57715315|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
57915923|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
57915924|NCT02564874|OTHER|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
58268219|NCT02490748|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
57715316|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
57715317|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
57715318|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
57715319|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
57715320|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
57715321|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
57715322|NCT00036920|DRUG|canfosfamide hydrochloride|
57715323|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
57715324|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
57715325|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
57715326|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
57715327|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
57915925|NCT05638997|OTHER|Instrument assisted manipulation + Core exercises|The effect of Instrument assisted manipulation on chronic non-spesific low back pain
57915926|NCT05638997|OTHER|Mulligan mobilization with movement + Core exercises|The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
57915927|NCT05638997|OTHER|Core exercises|The effect of core exercises on chronic non-spesific low back pain
58268220|NCT02490748|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
58268221|NCT01131065|DRUG|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
58268222|NCT00360815|BEHAVIORAL|Insulin|
58268223|NCT03526926|DRUG|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
58387906|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
57915928|NCT06347406|OTHER|Blood flow restriction combined with physiotherapy and education|Blood flow restriction Physiotherapy exercises Education
58062576|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
57715328|NCT05479175|DRUG|Ibuprofen|Ibuprofen
57715329|NCT05479175|DEVICE|Diode laser|Diode laser
57715330|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
57715331|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
58062577|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
58268224|NCT04447495|DIAGNOSTIC_TEST|iAMP test|The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
57715332|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
58268225|NCT02538692|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
58268226|NCT02538692|DRUG|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
58268227|NCT06266156|BEHAVIORAL|Score of anxiety questionnaire|All participants were answered the dental anxiety questionnaire.
58268228|NCT06266156|DIAGNOSTIC_TEST|Heart rate|All participants heart rate were measured with finger type pulse oxymeter.
58268229|NCT06266156|DIAGNOSTIC_TEST|Oxygen saturation|All participants oxygen saturation were measured with finger type pulse oxymeter.
58268230|NCT04497350|DEVICE|Transcranial Magnetic Stimulation|5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
58268231|NCT04497350|DEVICE|Theta Burst Stimulation|One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
58268232|NCT00103493|BEHAVIORAL|Motivational interviewing|
58268233|NCT00103493|BEHAVIORAL|Targeted DVD-based educational program|
57715333|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
58268234|NCT04978428|DRUG|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
58268235|NCT06496022|DIAGNOSTIC_TEST|Frail scale|FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).
58268236|NCT06496022|DIAGNOSTIC_TEST|Barthel scale|The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.
58268237|NCT06496022|DIAGNOSTIC_TEST|SARC-F|The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).
57715334|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
57715335|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
57715336|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
57715337|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
57915929|NCT05344482|OTHER|Secukinumab|Included all the patients treated with secukinumab
57915930|NCT05232994|DRUG|Esomeprazole 20mg|Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
57915931|NCT01432717|BIOLOGICAL|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
57715338|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
57715339|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
57715340|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
57715341|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
57715342|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
58387907|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
58387908|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
57715343|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
57715344|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
57715345|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
58387909|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
57715346|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
57715347|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
58387910|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
58387911|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
58387912|NCT05116397|OTHER|Inspired gas|Inspired gas content
58387913|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
58387914|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
57715348|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
57715349|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
57715350|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
57715351|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
57715352|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
57715353|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
57715354|NCT06028022|DRUG|Placebo Administration|Given PO
57715355|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
57715356|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
57715357|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
57715358|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
57715359|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
57715360|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
57715361|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
58268238|NCT06496022|DIAGNOSTIC_TEST|FRAX|FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72
58268239|NCT06496022|DIAGNOSTIC_TEST|Mini-Cog scale|The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).
58268240|NCT06496022|DIAGNOSTIC_TEST|dynamometry|carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
58268241|NCT06472102|PROCEDURE|Cardioneuroablation|Endocardial radio-frequency ablation of areas of ganglionated plexi in the left and the right atrium
57715362|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
58268242|NCT05421052|OTHER|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
57715363|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
57715364|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
57715365|NCT05879146|DRUG|Nirogacestat|Given by PO
57715366|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
58268243|NCT06620250|COMBINATION_PRODUCT|Digital Prevention and control of myopia|The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
58268244|NCT05864053|DRUG|Ketamine|Ketamine will be administered over a 45-minute period.
58268245|NCT05864053|DRUG|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
57715367|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
57715368|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
57715369|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
58268246|NCT05864053|DRUG|Saline|Saline will be administered over a 45-minute period.
57715370|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
57715371|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
57715372|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
57715373|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
57715374|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
57715375|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
57915932|NCT01432717|OTHER|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
57915933|NCT06164080|OTHER|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
57915934|NCT03244085|DRUG|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
57915935|NCT06098456|DRUG|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
57715376|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
57715377|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
57715378|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
57715379|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
57715380|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
57715381|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
57715382|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
57915936|NCT02198079|BIOLOGICAL|Sputum|
58268247|NCT05479591|DRUG|IDegLira|Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
58268248|NCT01116713|DRUG|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
58268249|NCT01116713|DRUG|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
58387915|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
58387916|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
58387917|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
58387918|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
58387919|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
58387920|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
58387921|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
58387922|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
58387923|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
58387924|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
58387925|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
58387926|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
58387927|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
58387928|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
58387929|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
58387930|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
58387931|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
58268250|NCT03873441|OTHER|Computer Games-Aided Balance Training Protocol|"1) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities."
58268251|NCT03873441|OTHER|Conventional Balance Training Protocol|"The following is a summary of the conventional physical therapy balance training protocol:~1. Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~2. Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~3. Weight transfer exercises with multi-directional reach outs and~4. Stepping exercises in different directions on variety of surfaces."
58268252|NCT06071182|DEVICE|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
58387932|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
57715383|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
57715384|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
57715385|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
57715386|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
57915937|NCT02731794|DEVICE|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
58387933|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
58387934|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
58387935|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
58387936|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
58387937|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
58387938|NCT01963793|DRUG|Placebo|gel without active component
58387939|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
58387940|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
57715387|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
57715388|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
57715389|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
57715390|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
57715391|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
57715392|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
57715393|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
57715394|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
57715395|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
57715396|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
57715397|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
57715398|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
57715399|NCT00563797|DRUG|Placebo|Placebo pill
57715400|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
57715401|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
57715402|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
57715403|NCT04141462|GENETIC|blood sample|blood test
57715404|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
57715405|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
57715406|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
57715407|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
57715408|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
57715409|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
57915938|NCT02731794|PROCEDURE|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
57715410|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
57715411|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
57715412|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
57715413|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
57715414|NCT02311049|RADIATION|Hypofractionation|
57915939|NCT01864057|DRUG|thiamine hydrochloride 100 mg|
57915940|NCT02070003|BEHAVIORAL|Motivational Interviewing and Physician Guided Opioid Weaning|
57915941|NCT01115660|BEHAVIORAL|stroke education|call by medication coach 2 weeks after hospital discharge
57915942|NCT01621113|DRUG|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
57915943|NCT01621113|DRUG|Placebo|Placebo tablet, twice daily, for 10 weeks.
57915944|NCT01498367|PROCEDURE|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
58268253|NCT06071182|OTHER|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
57715415|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
57915945|NCT02625727|OTHER|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
58268254|NCT03126565|OTHER|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
58268255|NCT00508937|OTHER|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
58268256|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
58387941|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
57715416|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
57715417|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
57715418|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
57715419|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
57915946|NCT02625727|OTHER|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
57915947|NCT03154060|DEVICE|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
58268257|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
57915948|NCT03566446|BIOLOGICAL|CALRLong36 peptide|200 ug CALRLong36 peptide in water mixed with 500ul montanide
58268258|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
58268259|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
58268260|NCT03330067|DEVICE|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
58268261|NCT03330067|DEVICE|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
58387942|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
58387943|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
58387944|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
58387945|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
58387946|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
58387947|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
58387948|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
57715420|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
57715421|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
57715422|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
57715423|NCT02791334|DRUG|LY3300054|Administered IV
57715424|NCT02791334|DRUG|Ramucirumab|Administered IV
57715425|NCT02791334|DRUG|Abemaciclib|Administered orally
57715426|NCT02791334|DRUG|Merestinib|Administered orally
57715427|NCT02791334|DRUG|LY3321367|Administered IV
57715428|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
57715429|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
57715430|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
57715431|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
57715432|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
57715433|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
57715434|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
57715435|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
58062578|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
58387949|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
58387950|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
58387951|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
58387952|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
58387953|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
58387954|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
57915949|NCT05491304|DRUG|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
57915950|NCT05491304|DRUG|Etoposide|Used in severe group combined with etoposide.
57715436|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
57715437|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
57715438|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
57715439|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
57715440|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
57715441|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
57715442|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
57715443|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
58062579|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
58062580|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
58268262|NCT04236167|DEVICE|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
58268263|NCT01139099|BEHAVIORAL|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
58268264|NCT03079037|DEVICE|Stimulation|Traditional deep brain stimulation
58268265|NCT02167048|DRUG|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
57715444|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
57715445|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
57715446|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
57715447|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
57715448|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
57715449|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
57715450|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
57715451|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
57715452|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
57715453|NCT00054561|DRUG|isotretinoin|
57715454|NCT00054561|PROCEDURE|adjuvant therapy|
57715455|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
58268266|NCT04989972|DRUG|PSIL428|1 mg of psilocybin
58268267|NCT04989972|DIETARY_SUPPLEMENT|Oyster mushroom|1 mg of oyster mushroom
58268268|NCT04989972|DRUG|PSIL428|1 mg psilocybin
58268269|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of ropivacapine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side
57915951|NCT05491304|DRUG|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
57915952|NCT02470910|DEVICE|Magnetic Resonance Imaging|
57715456|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
58387955|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
57715457|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
57715458|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
57715459|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
57715460|NCT02258152|DRUG|Placebo|Placebo QD
57715461|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
57715462|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
57715463|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
58062581|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
58387956|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
58387957|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
58387958|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
58387959|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
58387960|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
58387961|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
58387962|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
58387963|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
57715464|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
57715465|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
57715466|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
57715467|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
57715468|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
57715469|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
57715470|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
57715471|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
57715472|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
57715473|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
57715474|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57715475|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
57715476|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57715477|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
57715478|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
57715479|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
57715480|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
57715481|NCT01809626|DRUG|Zolpidem|
57715482|NCT01809626|OTHER|Placebo|
57715483|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
58268270|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaïne 3,75 mg/ml/side
57715484|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
57715485|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
57715486|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
57715487|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
57715488|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
58268271|NCT03801824|OTHER|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
58268272|NCT03801824|OTHER|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
58268273|NCT00758147|DEVICE|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
57715489|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
58268274|NCT00757029|GENETIC|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
58268275|NCT05437588|GENETIC|Genetic testing|Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
58268276|NCT04101032|BEHAVIORAL|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
58268277|NCT00503997|DRUG|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
58387964|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
58387965|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
58387966|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
57715490|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
57715491|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
57715492|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
57715493|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
57715494|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
58387967|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
57715495|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
57915953|NCT01668511|BIOLOGICAL|ABT-981|Injection
58268278|NCT00503997|DRUG|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
58268279|NCT03944733|DIETARY_SUPPLEMENT|Iron|65 mg of iron (ferrous sulfate)
58062582|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
57915954|NCT01668511|BIOLOGICAL|Placebo|Placebo Injection
57915955|NCT01048671|DRUG|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
57915956|NCT01048671|DRUG|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
57915957|NCT03972254|BEHAVIORAL|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
58062583|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
58062584|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
58062585|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
58062586|NCT02306928|OTHER|Blood draw|
58062587|NCT02367690|DRUG|Selinexor|Topical gel
58062588|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
58062589|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
58062590|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
58062591|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
58062592|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
58062593|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
58062594|NCT04145310|DRUG|Placebo + SCO|sublingual drops
58268280|NCT03944733|DIETARY_SUPPLEMENT|Gelatin|600 mg gelatin
58387968|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
58062595|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
58268281|NCT02405975|OTHER|SCRIPT|An online tool designed to train doctors in all areas of prescribing
58387969|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
58387970|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
58387971|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
58387972|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
57915958|NCT04219579|DRUG|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
57915959|NCT04219579|DRUG|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
57915960|NCT06159322|DRUG|Olanzapine|Antipsychotic medication
57915961|NCT06159322|DRUG|Clozapine|Antipsychotic medication
57915962|NCT03672656|DEVICE|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
57915963|NCT03672656|DEVICE|conventional laser|conventional laser multiple-session treatment
58062596|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
58062597|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
58062598|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
58062599|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
58268282|NCT04402281|DIAGNOSTIC_TEST|suPAR algoritm|All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR \> 6 ng/mL) the Intervention will be carried out
58387973|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
58387974|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
57915964|NCT02541123|OTHER|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
57915965|NCT05229731|PROCEDURE|Neurovisual evaluation|Standardized tests and scales classically used during a neurovisual evaluation,
57915966|NCT05229731|PROCEDURE|Cerebral MRI|"Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir"
58268283|NCT02906033|OTHER|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
58268284|NCT06328504|COMBINATION_PRODUCT|Cashew immunotherapy|Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
57715496|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
58268285|NCT05362240|PROCEDURE|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
58268286|NCT05362240|PROCEDURE|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
57915967|NCT06336954|DRUG|Adibelimab|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)
58268287|NCT00940680|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
58268288|NCT00940680|DRUG|Losartan|losartan 100mg q.d.
58268289|NCT03567512|BEHAVIORAL|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
57915968|NCT04511182|BEHAVIORAL|Exercise-based cardiac rehabilitation|"Exercise program is based on aerobic exercise and supplemented by strength training following the principle of gradual improvement. The type of exercise, such as walking, jogging, cycling, and the intensity of exercise which is recommended to use a cardiotach or pedometer to detect, are both defined by the results of CPET, such as METs value. Participators must be prepared for about 5-10 minutes to warm up and recover before and after exercise. 30-50 minutes a day, 5 days a week, with a total exercise time of not less than 150 minutes per week. It can be carried out in different stages according to the physical condition. After 1-3 months, the exercise prescription will be re-adjusted according to the results of reexamination.~All patients will undergo Cardiopulmonary Exercise Test, SF-36, echocardiography and laboratory examination prior to initiation of the trial, and which will be checked again after 3 months, and 6 months."
57915969|NCT00546130|DRUG|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
57915970|NCT00546130|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
57915971|NCT00546130|DRUG|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
57915972|NCT01088373|DRUG|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
57715497|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
57715498|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
57715499|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
57715500|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
57915973|NCT00617474|DRUG|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
57915974|NCT00617474|DRUG|Placebo|placebo
58062600|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
58062601|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
57915975|NCT03226210|DRUG|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
57915976|NCT03733639|DRUG|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
57915977|NCT03733639|DEVICE|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
58062602|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
58062603|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
57915978|NCT02442154|PROCEDURE|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
57915979|NCT03802084|DRUG|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
57915980|NCT00682890|DRUG|placebo|placebo birth control pill daily
57915981|NCT00682890|DRUG|metformin|2000 mg per day for 3 months daily birth control pill
58062604|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
58062605|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
58062606|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
58062607|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
58062608|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
58062609|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
58062610|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
58062611|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
58062612|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
58062613|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
57915982|NCT04417296|DIAGNOSTIC_TEST|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
57915983|NCT03456284|DEVICE|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
58062614|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
57915984|NCT06153225|DIETARY_SUPPLEMENT|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
57915985|NCT04734093|DIAGNOSTIC_TEST|Evaluation of sonographic signs of gouty arthritis|the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
58062615|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
58062616|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
58062617|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
58268290|NCT03567512|BEHAVIORAL|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes)."
58268291|NCT05062252|DEVICE|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
57915986|NCT01645293|GENETIC|Genetically modified T cells # 1138|
57915987|NCT04754308|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
58268292|NCT05062252|DEVICE|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
57915988|NCT03037931|DRUG|Ferric Carboxymaltose|Intravenous Iron
57915989|NCT03037931|DRUG|Placebo|Normal Saline Solution
57915990|NCT00648830|PROCEDURE|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
57915991|NCT00648830|DRUG|Clarithromycin|single-dose 250 mg immediate-release oral tablets
57915992|NCT00410085|DRUG|L-NMMA (N-mono.methyl-L-arginine)|
57915993|NCT05321147|BIOLOGICAL|lacutamab|Patients will receive a fixed dose of 750mg as 1-hour IV infusion
57915994|NCT04210869|DIETARY_SUPPLEMENT|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
57915995|NCT03781999|DIETARY_SUPPLEMENT|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
57915996|NCT03781999|OTHER|Placebo|Maltodextrin
57915997|NCT06385431|OTHER|observational study|obeservational study with none intervention
57915998|NCT02116101|DIETARY_SUPPLEMENT|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
57915999|NCT02116101|DIETARY_SUPPLEMENT|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
57916000|NCT00054054|DRUG|cisplatin|
58062618|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
58062619|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
58062620|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
58062621|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
58268293|NCT06331195|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol.
58268294|NCT06331195|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil.
57916001|NCT00054054|DRUG|docetaxel|
57916002|NCT00054054|DRUG|fluorouracil|
57916003|NCT00054054|RADIATION|radiation therapy|
57916004|NCT01328717|DEVICE|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
57916005|NCT04112121|BEHAVIORAL|Meeting with a Chaplain coupled with Biblical Readings|
57916006|NCT02738736|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
57916007|NCT04389736|BEHAVIORAL|Sitting|Participants sat in a chair with back, arms and legs supported.
57916008|NCT04389736|BEHAVIORAL|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
57916009|NCT04389736|BEHAVIORAL|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
58062622|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
58062623|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
58268295|NCT06331195|DIETARY_SUPPLEMENT|Phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
58268296|NCT06331195|DIETARY_SUPPLEMENT|Krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
58268297|NCT00142259|DEVICE|Deep brain stimulation of the internal globus pallidus|
57916010|NCT06254768|DEVICE|Continuous glucose monitor|its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
57916011|NCT04956172|DEVICE|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
57916012|NCT05629403|OTHER|observe|no intervention
58062624|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
58062625|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
58268298|NCT02427438|OTHER|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
58268299|NCT02427438|OTHER|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
58268300|NCT02300350|DRUG|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
58268301|NCT02300350|DRUG|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
58268302|NCT02300350|DRUG|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
57916013|NCT05918250|BIOLOGICAL|mRNA-2736|mRNA-2736 will be administered IV.
58062626|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
58268303|NCT03890627|DEVICE|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
58268304|NCT00362713|DRUG|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
58268305|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
58268306|NCT01397539|DRUG|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
58268307|NCT01397539|OTHER|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
58268308|NCT03978013|OTHER|Pomegranate juice|Pomegranate juice
58268309|NCT03978013|OTHER|Apple juice|Apple juice
58268310|NCT03784118|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
57916014|NCT03987178|BEHAVIORAL|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
57916015|NCT03987178|OTHER|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
57916016|NCT00906945|DRUG|G-CSF|
57916017|NCT00906945|DRUG|Plerixafor|
57916018|NCT00906945|DRUG|Mitoxantrone|
57916019|NCT00906945|DRUG|Etoposide|
57916020|NCT00906945|DRUG|Cytarabine|
57916021|NCT04017676|OTHER|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
57916022|NCT01786187|BEHAVIORAL|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
57916023|NCT01786187|OTHER|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
57916024|NCT02216305|PROCEDURE|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
57916025|NCT02216305|PROCEDURE|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
58268311|NCT03784118|DIAGNOSTIC_TEST|perfusion index|measurement of perfusion index immediately after arterial catheterization until surgery end, in arterial catheterization site and contralateral site.
58268312|NCT01361269|DRUG|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
57916026|NCT00596427|DRUG|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
57916027|NCT00596427|DRUG|Placebo|Placebo tablets: 3 tablets twice per day
57916028|NCT04714931|DIAGNOSTIC_TEST|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
57916029|NCT03452358|PROCEDURE|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
57916030|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
57916031|NCT05359497|DEVICE|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
57916032|NCT05359497|DEVICE|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
58062627|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
58062628|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
58268313|NCT00256321|DRUG|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
57916033|NCT05359497|DIAGNOSTIC_TEST|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
57916034|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
57916035|NCT05359497|DEVICE|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
57916036|NCT05359497|DEVICE|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
57916037|NCT01440712|DRUG|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
57916038|NCT01440712|DRUG|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
57916039|NCT00369720|PROCEDURE|Titration of oxygen in delivery room|
57715501|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
57916040|NCT00645307|DRUG|Extended Release OROS® Paliperidone|
57916041|NCT01696942|DRUG|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
57916042|NCT01696942|DRUG|Mesalamine|mesalamine 800 mg orally three times daily
57916043|NCT04253067|DEVICE|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
57916044|NCT04253067|DEVICE|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
57916045|NCT03174912|PROCEDURE|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
57916046|NCT04413773|OTHER|Treatment as usual + Video|Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
57916047|NCT04413773|OTHER|Treatment as usual|Explanation of standard procedures before, during and after surgery by nurse
57916048|NCT05677152|DRUG|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
57916049|NCT04262947|DEVICE|Near Infrared Vein Imaging|Use of NI vein imaging device for visualization of veins during peripheral IV placement
58062629|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
58268314|NCT00256321|DRUG|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
58268315|NCT00256321|DRUG|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
58268316|NCT03524352|OTHER|fecal microbiota|fecal microbiota in suspension
58268317|NCT03524352|OTHER|Placebo|sterile saline
58268318|NCT02466217|OTHER|1: AID groups|Clinical and Biological investigations
58268319|NCT02466217|OTHER|2: Control groups|Clinical and Biological investigations
58268320|NCT01915654|PROCEDURE|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
57916050|NCT04262947|OTHER|Conventional IV placement|IV placement utilizing conventional methods
57916051|NCT01279512|DRUG|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
57916052|NCT01279512|DRUG|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
57916053|NCT00640081|BIOLOGICAL|cetuximab|
57916054|NCT00640081|DRUG|capecitabine|
57715502|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
57715503|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
57916055|NCT00640081|DRUG|fluorouracil|
58268321|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
58268322|NCT04108988|BEHAVIORAL|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
58268323|NCT04108988|OTHER|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
58268324|NCT03165474|OTHER|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
57916056|NCT00640081|DRUG|leucovorin calcium|
57916057|NCT00640081|DRUG|oxaliplatin|
57916058|NCT00640081|OTHER|immunohistochemistry staining method|
57916059|NCT00640081|OTHER|laboratory biomarker analysis|
58062630|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
58062631|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
58062632|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
58268325|NCT03165474|OTHER|Didactic health information|Didactic health information and resources by email and/or text
57916060|NCT03172676|DRUG|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
57916061|NCT03172676|DRUG|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
57916062|NCT03172676|DRUG|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
57916063|NCT00368160|DRUG|Eszopiclone|eszopiclone 3 mg
57916064|NCT00368160|DRUG|Placebo|Placebo tablet
57916065|NCT02703493|RADIATION|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
57916066|NCT03006731|BEHAVIORAL|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
57916067|NCT03006731|BEHAVIORAL|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
57916068|NCT03296033|DRUG|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
57916069|NCT03296033|DRUG|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
57916070|NCT02072161|DRUG|ETC-1002|ETC-1002 capsules, taken once daily oral
57916071|NCT02072161|DRUG|Placebo|Placebo capsules, taken once daily oral
57916072|NCT02072161|DRUG|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
58268326|NCT06618040|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for Caregivers (BTS-C)|The BTS-C includes 6 educational modules on different topics related to sleep health: principles of healthy sleep practices include sleep routines, the sleep environment, considerations for screen time, timing of sleep and activities surrounding sleep, expectations for healthy sleep and sleep duration. Caregivers will also receive a combination of tailored messages or prompts to explore progress, identify strategies for change, and goal setting.
58268327|NCT04491305|PROCEDURE|Surgically treated women with endometriosis and confirmed diagnosis|Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
58268328|NCT02505334|DRUG|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
58268329|NCT05919914|OTHER|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
58268330|NCT05919914|OTHER|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
57715504|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
57916073|NCT05347420|DIAGNOSTIC_TEST|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
57916074|NCT03182452|OTHER|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
58276705|NCT05867693|DIETARY_SUPPLEMENT|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
57715505|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
57916075|NCT03862846|DRUG|REN001|Once daily
57916076|NCT05140941|DRUG|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
57916077|NCT03234985|BIOLOGICAL|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
57916078|NCT06218147|BEHAVIORAL|Nutrition-behavior lifestyle program|The 15 participants randomized to the intervention group will complete the activities described in the arm/group description.
57916079|NCT02953405|DRUG|Clopidogrel|
57916080|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
58268331|NCT06263270|BIOLOGICAL|CYT-108, a recombinant protease inhibitor|"CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the bait region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA."
57916081|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
58268332|NCT06263270|OTHER|Phosphate Buffered Saline (PBS)|Phosphate Buffered Saline (PBS)
58268333|NCT04587739|COMBINATION_PRODUCT|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
58268334|NCT02712021|OTHER|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
58268335|NCT02712021|OTHER|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
58268336|NCT04051099|PROCEDURE|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
58268337|NCT04051099|DRUG|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
58268338|NCT04051099|PROCEDURE|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
58268339|NCT04051099|PROCEDURE|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
58268340|NCT04599933|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
58268341|NCT04599933|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
57715506|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
57916082|NCT00665158|BEHAVIORAL|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
58268342|NCT04940520|BIOLOGICAL|Drug recommended by the Brazilian Society of Dermatology|Using a drug recommended by the Brazilian Society of Dermatology, twice a day.
57715507|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
57715508|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
57715509|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
57916083|NCT00665158|BEHAVIORAL|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
57916084|NCT00966277|DRUG|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
57916085|NCT04323774|BEHAVIORAL|AYA-RISE Adolescents and Young Adults Risk Information and Screening Education|A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.
58062633|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
57916086|NCT04323774|BEHAVIORAL|Standard clinical visit for genetic counseling|Standard clinical visit for genetic counseling and follow up
57916087|NCT06446960|DRUG|Lidocaine 20mg/ml|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
58062634|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
58062635|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
58062636|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
57715510|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
57916088|NCT06446960|DRUG|Levobupivacaine Hydrochloride 1.25 MG/ML|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
57916089|NCT06446960|DRUG|Sodium Chloride 0.9% Inj|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
57916090|NCT03650517|PROCEDURE|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
58062637|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
58062638|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
58062639|NCT02023892|DRUG|atorvastatin|
58062640|NCT02023892|DRUG|placebo|
58062641|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
58268343|NCT04940520|COMBINATION_PRODUCT|Alpha bisabolol product and laser|Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.
57916091|NCT03650517|PROCEDURE|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
57916092|NCT03650517|PROCEDURE|Robotic Surgery|Procedure is performed using robotic instruments
57916093|NCT03650517|PROCEDURE|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
57916094|NCT06112561|DEVICE|CO/CI/SVR|fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
57916095|NCT00603720|DRUG|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
57916096|NCT00603720|DRUG|L-Arginine|aids in nitric oxide production
57916097|NCT00603720|DRUG|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
57916098|NCT03214094|DRUG|Vonoprazan|Vonoprazan tablets
57916099|NCT04647812|BEHAVIORAL|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
57916100|NCT04647812|BEHAVIORAL|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
57916101|NCT00259584|BEHAVIORAL|Management and Outcome of SVCO|
57916102|NCT04076748|DRUG|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
57916103|NCT04076748|DRUG|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
57916104|NCT06020742|PROCEDURE|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
58268344|NCT04940520|BIOLOGICAL|Alpha bisabolol product|Using alpha bisabolol-based product twice a day
57916105|NCT01978522|OTHER|Randomisation of questionnaire receipt.|"1. The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~2. Self-completion questionnaire handed to participants immediately after completing the CAPI."
57916106|NCT04983641|OTHER|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
57916107|NCT05320549|BEHAVIORAL|Community Programme|Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
57916108|NCT04310033|OTHER|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
57916109|NCT04869943|DRUG|Enobosarm|Oral Enobosarm 9mg per day
57916110|NCT04869943|DRUG|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
57916111|NCT03487354|DRUG|Misoprostol|Misoprostol
57916112|NCT02529631|DRUG|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
57916113|NCT02529631|DEVICE|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
57916114|NCT04439682|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
57916115|NCT03475615|DRUG|Oxaliplatin|130mg/m2, d1, q3w
57916116|NCT03475615|DRUG|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
57916117|NCT03475615|DRUG|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
57916118|NCT05273593|DEVICE|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
57916119|NCT00975767|DRUG|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
57916120|NCT00975767|DRUG|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
57916121|NCT00000823|DRUG|Zidovudine|
57916122|NCT00000823|DRUG|Didanosine|
57916123|NCT02579499|DRUG|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
58062642|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
58062643|NCT02411994|DRUG|Pyronaridine-artesunate|
58276706|NCT05867693|DIETARY_SUPPLEMENT|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
58276707|NCT00576004|PROCEDURE|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
58387975|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
58387976|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
58387977|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
58387978|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
58387979|NCT06032559|OTHER|TAU|TAU only
58387980|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
58387981|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
58387982|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
58387983|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
57916124|NCT02579499|DRUG|targeted LDL-C goal statin|"1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
57916125|NCT03464799|OTHER|immunohistochemical staining|immunohistochemical staining
57916126|NCT05175638|GENETIC|Gene Expression|the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.
57916127|NCT01959022|DRUG|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
57916128|NCT04953325|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
57916129|NCT04953325|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
57916130|NCT04953325|BIOLOGICAL|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
57916131|NCT05067465|DIETARY_SUPPLEMENT|Selected food groups|"Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)"
57916132|NCT03668184|OTHER|preeclampsia|occurrence of pre-eclampsia
58062644|NCT02411994|DRUG|Artemether-lumefantrine combination|
58062645|NCT00424736|PROCEDURE|whole body CT scan|
58062646|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
58062647|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
58268345|NCT04788225|OTHER|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
58387984|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
58268346|NCT04788225|OTHER|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
58387985|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
56858563|NCT06692907|OTHER|B7A (ETEC challenge strain)|A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.
58062648|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
58268347|NCT04788225|OTHER|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
58268348|NCT04788225|OTHER|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
58268349|NCT06277154|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.
58268350|NCT06277154|DRUG|Doxorubicin|Commercially approved for cancer treatment
58268351|NCT06277154|DRUG|Ifosfamide|Commercially approved for cancer treatment
58268352|NCT02332564|OTHER|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
58268353|NCT05988905|OTHER|robot assited gati training|SUBAR® (CRETEM, Korea) is a exoskeletal-robot with a footplate that assists gait movements. The patient's thigh length and lower leg length were measured before training, so that the SUBAR® can be adjusted to patient's size to ensure accurate training. During training, the therapist facilitated the treatment and stood by the patients' side to adjust the direction and speed. RAGT is programmed automatically, and it can be performed regularly over a long period. The patients received 30 min of robot-assisted training using SUBAR® once a day for 5 days a week for 8 weeks. Each training session lasted up to 40 min.
58268354|NCT05988905|OTHER|conventional traiing|Patients also received conventional exercise rehabilitation with the same duration and frequency. Conventional rehabilitation therapy, which consisted of active assistive knee exercises, knee stretching, patellar mobilization exercises, and quadriceps setting exercises, was performed every day throughout the rehabilitation period.
56858564|NCT06692907|BIOLOGICAL|CssBA|A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.
58268355|NCT04120454|BIOLOGICAL|Pembrolizumab|Given IV
56858565|NCT06692907|BIOLOGICAL|dmLT|An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.
56858566|NCT06692907|OTHER|Placebo|Placebo
57916133|NCT05199194|DRUG|Tenecteplase|Intravenous thrombolysis with tenecteplase 0.25mg/kg
57916134|NCT05199194|DRUG|Placebo|Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
57916135|NCT05764928|DRUG|BLEX 404|BLEX 404 Oral Liquid, PO, BID
57916136|NCT03796260|DRUG|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
57916137|NCT03796260|DRUG|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
57916138|NCT02749435|OTHER|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
57916139|NCT00118755|DRUG|capecitabine|850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
58268356|NCT04120454|BIOLOGICAL|Ramucirumab|Given IV
58268357|NCT05265156|OTHER|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
57916140|NCT00118755|DRUG|Oxaliplatin|130 mg/m\^2 IV on Day 1 of each 3-week cycle
57916141|NCT00118755|DRUG|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
57916142|NCT00118755|DRUG|capecitabine|1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
58268358|NCT01511718|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
58268359|NCT01511718|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
58268360|NCT04251728|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
58268361|NCT04251728|OTHER|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
58268362|NCT04251728|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
58268363|NCT06621667|OTHER|diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis|diaphragmatic myofascial release
57916143|NCT00118755|DRUG|Oxaliplatin|85 mg/m\^2 IV on Day 1 of each 2-week cycle
57916144|NCT00118755|DRUG|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
57916145|NCT04384185|OTHER|Exercise protocol|"Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation"
57916146|NCT04384185|OTHER|Manual therapy|"1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles."
57916147|NCT01210261|DEVICE|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
58062649|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
58268364|NCT06621667|OTHER|traditional physical therapy exercises for hyperkyphosis|traditional physical therapy exercises for hyperkyphosis
58268365|NCT04586634|DEVICE|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
58268366|NCT05615805|OTHER|OSDI questionnaire|Ocular Surface Disease Index
58268367|NCT05615805|OTHER|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
57916148|NCT01210261|DEVICE|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
57916149|NCT01685164|OTHER|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
57916150|NCT01853982|DRUG|Ceftolozane/Tazobactam|
57916151|NCT01853982|DRUG|Piperacillin/Tazobactam|
57916152|NCT00343252|DRUG|teriparatide|20 ug/day, subcutaneous, 18 months
58062650|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
58387986|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
57916153|NCT00343252|DRUG|risedronate|35 mg/once weekly, oral, 18 months
57916154|NCT00343252|DRUG|placebo|once weekly, oral, 18 months
57916155|NCT00343252|DRUG|placebo|daily, subcutaneous, 18 months
57916156|NCT00519038|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
57916157|NCT00519038|OTHER|Usual Care|Usual care is the current practice actually performed in the hospital
57916158|NCT06069674|DIAGNOSTIC_TEST|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
57916159|NCT04157231|OTHER|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
57916160|NCT01468831|DRUG|Minocycline|100 mg of minocycline in a pink opaque capsule
57916161|NCT01468831|OTHER|Placebo|Pill with inactive ingredients in a pink opaque capsule
57916162|NCT01468831|DRUG|Bevacizumab|1.25 mg bevacizumab injection
58062651|NCT01256957|DEVICE|HEPA filter|
57916163|NCT04236115|DRUG|Articaine 4%|Articaine 4% is dental local anaesthetic agent
57916164|NCT04236115|DRUG|Prilocain 3%|prilocaine is dental local anaesthetic agent
58062652|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
58062653|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
58062654|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
58062655|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
57916165|NCT04236115|DRUG|Adrenalin|adrenaline is a vasoconstrictor
57916166|NCT04236115|DRUG|Felypressin|Felypressin is a vasoconstrictor
58387987|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
58387988|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
58387989|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
57916167|NCT03887390|BEHAVIORAL|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
57916168|NCT02871856|DIAGNOSTIC_TEST|Low dose CT|low-dose screening CT of chest for lung cancer detection
57715511|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
57715512|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
57916169|NCT00601419|DRUG|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
57715513|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
57715514|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
57715515|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
57916170|NCT01386073|DRUG|FreshKote|Three times a day for three months
57916171|NCT01386073|DRUG|Systane|three times a day for three months
58062656|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
58268368|NCT00880386|DRUG|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
58268369|NCT01890226|BEHAVIORAL|Mobile Personal Health Record App.|
58268370|NCT05876793|DRUG|Remimazolam tosilate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
58268371|NCT03138694|OTHER|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
58268372|NCT06250634|DRUG|esomeprazole + amoxicillin|esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
58276708|NCT01361867|DEVICE|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
58387990|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
58387991|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
58387992|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
58387993|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
58387994|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
58387995|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
57715516|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
57916172|NCT02084745|PROCEDURE|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
58387996|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
58268373|NCT06250634|DRUG|esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent|20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
58387997|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
58387998|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
58387999|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
57916173|NCT02084745|PROCEDURE|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
57916174|NCT05103293|DIAGNOSTIC_TEST|patient-derived tumor-like cell clusters drug sensitivity test|Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
58268374|NCT06250634|DRUG|Vonoprazan + amoxicillin|20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
58268375|NCT06250634|DRUG|Vonoprazan + amoxicillin + clarithromycin|20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
58268376|NCT05236101|BEHAVIORAL|survey research|Children with dental treatment were asked to draw pictures.
58268377|NCT03112733|DIAGNOSTIC_TEST|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
58268378|NCT02209805|DRUG|BIRB 796 BS, low dose|
58268379|NCT02209805|DRUG|BIRB 796 BS, high dose|
58268380|NCT02209805|DRUG|Placebo|
58268381|NCT00104819|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
58268382|NCT00104819|BIOLOGICAL|sargramostim|
58268383|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus Anodic transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Anodal tDCS over DLPFC (20 min) daily for 1 month
58268384|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus sham transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Sham tDCS over DLPFC (20 min) daily for 1 month
58268385|NCT03461016|BEHAVIORAL|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure \[is\] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
58388000|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
58388001|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
57916175|NCT03800615|PROCEDURE|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
58268386|NCT01844505|BIOLOGICAL|Nivolumab|
58268387|NCT01844505|BIOLOGICAL|Ipilimumab|
58268388|NCT01844505|BIOLOGICAL|Placebo for Nivolumab|
58268389|NCT01844505|BIOLOGICAL|Placebo for Ipilimumab|
58268390|NCT00574223|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
58268391|NCT00574223|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
58268392|NCT04498416|DIAGNOSTIC_TEST|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
58268393|NCT05914675|DRUG|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
58268394|NCT00866333|DRUG|Entinostat|Entinostat tablets
58268395|NCT03294291|PROCEDURE|Quadratus lumborum block|Postoperative pain procedure
57715517|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
57715518|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
58062657|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
57715519|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
57715520|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
57715521|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
57715522|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
57715523|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
58062658|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
58062659|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
58062660|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
58062661|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
58062662|NCT00045006|DRUG|vorinostat|
58062663|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
58062664|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
58062665|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
58062666|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
57715524|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
57715525|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
57715526|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
57715527|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
57715528|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
57715529|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
57715530|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
57715531|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
57715532|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
57715533|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57715534|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57715535|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57715536|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
58388002|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
58388003|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
58388004|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
57715537|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
57715538|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
57715539|NCT02726763|BEHAVIORAL|Questionnaires|
57715540|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
57715541|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
57715542|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
57715543|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
57715544|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
57715545|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
57916176|NCT02429674|BEHAVIORAL|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
57916177|NCT04312893|OTHER|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
57916178|NCT04312893|OTHER|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
58062667|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
58062668|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
58062669|NCT00000151|DRUG|Aspirin|
57715546|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
57715547|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
57715548|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
57715549|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
57715550|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
57715551|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
57916179|NCT05657886|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
58062670|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
58268396|NCT03294291|PROCEDURE|Caudal block|Postoperative pain procedure
58268397|NCT00391157|DRUG|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
58062671|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
58062672|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
58062673|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
57715552|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
57916180|NCT05657886|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
57916181|NCT01580969|DRUG|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
57916182|NCT01580969|DRUG|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
57916183|NCT01580969|RADIATION|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
57916184|NCT05068245|BEHAVIORAL|Preselected classical music|Preselected classical music
57916185|NCT06147284|BEHAVIORAL|Preventive interventions|Parallel randomized controlled trial
57916186|NCT02775799|OTHER|Registration|Registration according to approved data sets
57916187|NCT01635920|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
58062674|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
58062675|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
58062676|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
58062677|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
58062678|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
58062679|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
57916188|NCT01635920|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
57916189|NCT05150951|BEHAVIORAL|Novel Exploration|Exploration of a novel 3D-environment in virtual reality.
57916190|NCT05150951|BEHAVIORAL|Threat conditioning|Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.
57916191|NCT05150951|BEHAVIORAL|Extinction|Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.
57916192|NCT05150951|BEHAVIORAL|Reinstatement|Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.
57916193|NCT05150951|BEHAVIORAL|Visual attention control task|Session 2. A visual attention task used as a control task instead of novel exploration.
58062680|NCT01901809|DRUG|Furosemide|
58062681|NCT01901809|DRUG|Dopamine|
58062682|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
58062683|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
57715553|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
57715554|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
57715555|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
57715556|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
57715557|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
57916194|NCT05660239|OTHER|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
57916195|NCT01104116|RADIATION|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
57916196|NCT05066737|PROCEDURE|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
57916197|NCT05532982|OTHER|Interviews and Surveys|Qualitative interviews and surveys
57916198|NCT04646915|OTHER|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
57916199|NCT05636956|OTHER|Education and Counseling Program|Researches created an education and counseling program. In this context, patients receive an one hour education. Education program consist of face-to-face informing and teach-back method. At the end of the face-to-face informing, researchers give a comicbook about instructions of living with CIEDs as a written material. After discharge, researches follow-up patients with phone calls. In the context of phone calls researches continue to informing patients, remind related instructions for that time and answer questions of patients. Patients are allowed to reach reserarches any time if they have any concern or question. This program lasts for six months.
57916200|NCT05316701|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
57916201|NCT05316701|BIOLOGICAL|Standard-of-Care|unmanipulated donor allograft
57916202|NCT02927860|OTHER|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
57916203|NCT01195285|PROCEDURE|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
57916204|NCT01195285|PROCEDURE|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
57916205|NCT00062049|BIOLOGICAL|recombinant interleukin-7|
57916206|NCT05969743|DRUG|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
57916207|NCT02067117|DRUG|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
58062684|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
58062685|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
57916208|NCT03829293|DEVICE|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
57916209|NCT03234101|BEHAVIORAL|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1) Healthy body weight (Minimum: BMI \<30kg/m2 or WC of \<88 in females or \<92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits \& vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation \>12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (\>6 hours)"
57916210|NCT00458887|PROCEDURE|management of therapy complications|Undergo hearing tests
58268398|NCT03138746|PROCEDURE|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
58268399|NCT03138746|PROCEDURE|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
58268400|NCT03564080|OTHER|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
57916211|NCT00457808|DRUG|Rapamycin, sirolimus|
57916212|NCT03297931|DIETARY_SUPPLEMENT|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
57916213|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + hummus|Novel pulse chip + pulse spread
57916214|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
57916215|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
57916216|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
57916217|NCT03297931|DIETARY_SUPPLEMENT|Corn chips + hummus|Non-pulse chip + pulse spread
57916218|NCT00601094|BIOLOGICAL|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
58062686|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
58268401|NCT01643733|DEVICE|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
58268402|NCT00117624|DRUG|darbepoetin alfa|
58268403|NCT01934075|BEHAVIORAL|Mental health treatment|6 sessions of individual mental health counseling.
57715558|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
57916219|NCT02391454|DEVICE|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
57916220|NCT02391454|OTHER|Usual care|
57916221|NCT01377597|DRUG|ranibizumab|
58388005|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
58388006|NCT02651324|DRUG|Ketamine|
57916222|NCT03435523|PROCEDURE|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
57916223|NCT05540288|DRUG|Nalmefene|"Week 1: 18 mg/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~2. In the presence of grade 3 ARs, 18 mg/d~3. In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
57916224|NCT05540288|DRUG|Placebo|"Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
58268404|NCT01642485|DRUG|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
58268405|NCT01642485|OTHER|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
58268406|NCT01642485|OTHER|Continental breakfast|High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
58388007|NCT02651324|OTHER|Placebo|
58388008|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
58388009|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
58388010|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
57715559|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
57715560|NCT00544596|DRUG|cisplatin|Given IV
57715561|NCT00544596|DRUG|etoposide|Given IV
57715562|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
58062687|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
58268407|NCT01642485|DRUG|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
57916225|NCT03815786|DIETARY_SUPPLEMENT|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
57916226|NCT03815786|DIETARY_SUPPLEMENT|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
57916227|NCT00400348|DRUG|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
57916228|NCT02860780|DRUG|prexasertib|Administered IV
57916229|NCT02860780|DRUG|ralimetinib|Administered orally
57916230|NCT04497454|OTHER|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O
57916231|NCT04497454|OTHER|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
57916232|NCT01580423|DRUG|aprepitant|125 mg capsule
58388011|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
57715563|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
57916233|NCT01580423|DRUG|placebo|capsule identical to aprepitant
57916234|NCT06195254|RADIATION|Stereotactic body radiotherapy (SBRT)|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.
57916235|NCT06195254|DRUG|PD-1 blocking antibody|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
57916236|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
57916237|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
57916238|NCT00238524|DRUG|SPM 927|
57916239|NCT02889003|DRUG|Pioglitazone + TKI|
57916240|NCT04420715|OTHER|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
57916241|NCT00451880|DRUG|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
57916242|NCT00451880|DRUG|famotidine|single dose, supplied as 20-mg or 40-mg tablets
57916243|NCT05586074|DRUG|Clifutinib|tablet, oral
58062688|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
58062689|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
58062690|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
58268408|NCT01642485|PROCEDURE|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
57916244|NCT05586074|DRUG|LoDAC|subcutaneous (SC) or intravenous (IV) injection
57916245|NCT05586074|DRUG|Azacitidine|SC or IV
57916246|NCT05586074|DRUG|Decitabine|IV
57916247|NCT05586074|DRUG|Ara-C±IDA|SC and IV
57916248|NCT05586074|DRUG|FLAG-IDA|SC and IV
58268409|NCT01642485|DRUG|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
58268410|NCT01143064|DRUG|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
57715564|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
58268411|NCT01143064|DRUG|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
57715565|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
58268412|NCT05150782|DIETARY_SUPPLEMENT|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
58268413|NCT04744259|BEHAVIORAL|Behavioural Activation|A psychological intervention which aims to increase activity and reduce depressive symptoms.
58268414|NCT05109871|OTHER|KForce Link|Traction (pull-type) dynamometer
57715566|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
57715567|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
57715568|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
57715569|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
57715570|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
57715571|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
57715572|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
57715573|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
57715574|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
57715575|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
57715576|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
57715577|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
57715578|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
57715579|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
57715580|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
57715581|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
57715582|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
57715583|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
57715584|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
57715585|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
57715586|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
57715587|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
57715588|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
58268415|NCT04270227|OTHER|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
57715589|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
57715590|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
57916249|NCT02107053|DIETARY_SUPPLEMENT|PJ|
57916250|NCT02107053|DRUG|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
57916251|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
57916252|NCT01236339|PROCEDURE|LVP|Large Volume Paracentesis
57916253|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
57916254|NCT05171023|DEVICE|ROTEM and standard coagulation tests|ROTEM and standard coagulation tests assessment
57916255|NCT00425984|PROCEDURE|Adult male circumcision|
57916256|NCT02880631|DEVICE|BAROSTIM NEO™ System|
57916257|NCT00336895|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
58268416|NCT01232621|OTHER|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
58062691|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
58062692|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
58062693|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
58062694|NCT05071794|DRUG|saline 0.9%|Placebo
57916258|NCT03368469|DEVICE|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
58062695|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
58062696|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
58062697|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
58062698|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
58062699|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
58062700|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
58062701|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
57715591|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
57916259|NCT05933408|DIAGNOSTIC_TEST|TREM-1|The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
57916260|NCT00162357|DRUG|Technetium Tc99m Sestamibi|
58062702|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
58062703|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
58062704|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
58062705|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
58268417|NCT02330757|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
58276709|NCT01487213|OTHER|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
57916261|NCT05958641|OTHER|Questionnaires|Participants will be asked to complete the questionnaire including general demographic information, the cognition, resistance and use of NPS as well as the behavioral expression of addiction susceptibility genes and adverse childhood experience.
57916262|NCT00873314|BEHAVIORAL|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
57916263|NCT00873314|BEHAVIORAL|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
58062706|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
58062707|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
58062708|NCT01968629|DRUG|Eovist|
57715592|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
58268418|NCT02330757|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
58268419|NCT01920867|PROCEDURE|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
58268420|NCT01920867|PROCEDURE|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
58268421|NCT01920867|PROCEDURE|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
58268422|NCT01920867|PROCEDURE|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
58268423|NCT01920867|PROCEDURE|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
58268424|NCT04240275|DEVICE|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
58268425|NCT01432964|PROCEDURE|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
58268426|NCT00431873|DRUG|MGCD0103|MGCD0103 Administered orally three times per week.
58268427|NCT03094676|OTHER|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
58268428|NCT03094676|OTHER|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
58268429|NCT04439305|DRUG|Dasatinib|Given PO
58268430|NCT05267990|DIAGNOSTIC_TEST|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
58268431|NCT06363526|OTHER|Digital respiratory intervention program|"A 4 times a week for a period of 5 weeks will be done, for a duration of 55-60 minutes (20 sessions), with an intensity adapted to the characteristics of each participant. Moreover, an intervention program will be used based on respiratory muscle training exercises, upper limb strength work, yoga, diaphragmatic awareness exercises, always trying to do them through the use of games, and even try to include exercises that use motor imagery.~The intervention program is carried out and stimulated through videos and therapeutic teaching to the caregivers in the first evaluation session, as well as as well as with a weekly follow-up using WhatsApp or Zoom as forms of communication, or a telephone call to ensure correct follow-up of the intervention program. Moreover, YouTube videos, own videos prepared by the physiotherapy will be used to help optimally resolve doubts that arise when carrying out the program by video call."
58268432|NCT00992134|DRUG|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
58268433|NCT01904903|DRUG|Trastuzumab|HER2 therapy
58388012|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
57715593|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
57715594|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
57715595|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
57715596|NCT00024362|DRUG|BBR 3464|
58268434|NCT01904903|DRUG|Pertuzumab|HER2 therapy
58268435|NCT01904903|DRUG|Ado Trastuzumab Emtansine|HER2 therapy
58268436|NCT03286933|BEHAVIORAL|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
58268437|NCT06482177|DRUG|Cyclosporine ophthalmic solution|Cyclosporine BID in the study eye
57715597|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
57715598|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
57715599|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
58268438|NCT01195844|BIOLOGICAL|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
58268439|NCT01005888|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
58268440|NCT01005888|DRUG|Placebo (saline)|
58268441|NCT02243046|DRUG|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
58268442|NCT02243046|DRUG|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
58268443|NCT02243046|DRUG|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
58268444|NCT04554992|BIOLOGICAL|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
58268445|NCT05963828|BEHAVIORAL|Post-hospital management based on WeChat applet|The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.
57715600|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
57715601|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
57715602|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
58062709|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
58062710|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
58062711|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
58062712|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
58268446|NCT05963828|BEHAVIORAL|Routine post-hospital follow-up management|The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
58268447|NCT02733198|OTHER|Prognosis-guided therapy|
58268448|NCT00948415|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
58268449|NCT03558841|OTHER|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
58268450|NCT03558841|OTHER|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
58268451|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Nut|
58268452|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Sup|
58268453|NCT06528795|OTHER|Scenario-based high-reality hybrid simulation method|"Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario."
58268454|NCT02553707|DRUG|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
58268455|NCT05105906|DIAGNOSTIC_TEST|cognitive tests performed|cognitive tests performed
58268456|NCT01671150|DRUG|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
58268457|NCT04318639|COMBINATION_PRODUCT|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
58268458|NCT03218319|BIOLOGICAL|Renin measurement|patients will have a blood sample for measuring renin activity
58268459|NCT02739308|OTHER|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
58268460|NCT02739308|OTHER|Control Group|The control group will not make the intervention and will continue with usual training fencing.
58268461|NCT03240224|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
58268462|NCT03240224|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
57916264|NCT05353933|OTHER|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
57916265|NCT05353933|DRUG|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
57916266|NCT04825483|OTHER|Weight loss|"Participants will receive resources to support the weight loss program including a recipe book, activities book and how-to guide. The diet program comprises two phases: 1) intensive weight loss through a ketogenic Very Low Calorie Diet (VLCD), including meal replacements for two meals/day, and 2) transition from ketogenic VLCD onto a longer-term eating plan for weight maintenance. Meal replacements will be provided free of charge for up to 6 months. Participants will be encouraged to lose at least 10% body weight."
57916267|NCT04825483|OTHER|Exercise|"Participants will receive resources to facilitate the physiotherapy management plan, including information about the video-conference platform, osteoarthritis information, an exercise plan/log book and a booklet of possible exercises. The physiotherapist consultations include a structured, progressive exercise and physical activity plan. Participants will be given exercise resistance bands and a ankle weight for home exercises.~Physiotherapists will choose from a list of exercises, aiming to prescribe 5-6 at once. Intensity is determined using a modified Rating of Perceived Exertion (RPE) scale, where it should feel hard to very hard to perform a full set of each exercises. Participants are encouraged to complete exercises three times per week. Physiotherapists encourage the participant to increase their general and incidental levels of physical/aerobic activity based on their individual needs and goals, as well as their current level of activity."
57916268|NCT03468738|OTHER|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
57916269|NCT01248091|PROCEDURE|Nitroprusside Gel|10 cc nitroprusside gel
57916270|NCT01248091|PROCEDURE|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
57916271|NCT03392545|COMBINATION_PRODUCT|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
57916272|NCT00833131|RADIATION|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
58062713|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
58268463|NCT01902212|OTHER|Oral Nutritional Supplement|
58268464|NCT00842998|DRUG|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
58062714|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
58268465|NCT03456999|BIOLOGICAL|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
58268466|NCT03456999|BIOLOGICAL|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
58268467|NCT05735990|DEVICE|Intraocular lens|Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
58268468|NCT02933905|DRUG|Intravitreal Ranibizumab injection|
58062715|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
58062716|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
58062717|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
58062718|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
58062719|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
58062720|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
58062721|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
58388013|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
58062722|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
58268469|NCT03183934|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
58268470|NCT00237471|DRUG|Insulin (tight blood glucose control)|
58268471|NCT01079754|DRUG|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
58388014|NCT01034982|DRUG|AZD9668|20 mg
58388015|NCT01034982|DRUG|AZD9668|60 mg
58388016|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
58388017|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
57916273|NCT00833131|RADIATION|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
57916274|NCT03344653|DEVICE|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
57916275|NCT03344653|DEVICE|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
57916276|NCT03876782|DIAGNOSTIC_TEST|IOLMaster|IOL power calculation will be done with IOLMaster
58062723|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
58062724|NCT02155712|DEVICE|Triathlon Knee|Cemented
58062725|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
58062726|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
58062727|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
58268472|NCT01079754|DRUG|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
57715603|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
57715604|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
57715605|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
57715606|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
57916277|NCT03876782|DIAGNOSTIC_TEST|Verion|IOL power calculation will be done with Verion
57916278|NCT04662541|OTHER|Mobile Integrated Health (MIH)|MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
57715607|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
58268473|NCT03180515|DEVICE|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
58268474|NCT00001076|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
57916279|NCT04662541|OTHER|Transitions of care coordinator (TOCC)|The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
57916280|NCT00568802|DRUG|Hydroxyurea|
57916281|NCT00568802|DRUG|Placebo to match hydroxyurea|
58062728|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
58062729|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
58268475|NCT00001076|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
58268476|NCT00001076|BIOLOGICAL|rgp120/HIV-1 SF-2|
58268477|NCT04590677|OTHER|Samples required from group 1 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
58268478|NCT04590677|OTHER|Samples required from group 2 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs"
58268479|NCT06648694|PROCEDURE|Abdominoplasty surgery|Correlation between IAP and Diaphragmatic Mobility
58268480|NCT06648694|PROCEDURE|Abdominoplasty|For the practice of the surgical procedure, the region to be operated on was marked using a surgical marking pen (Textel®). With the patient in the orthostatic position, a median line was drawn from the xiphoid appendix to the pubic symphysis, reaching the anterior vulvar commissure. Then, with the patient in the dorsal position, a transverse line was drawn 6 cm above the vulvar commissure and elongated to the iliac spine on each side. From there, the lateral skin surplus was estimated by means of bidigital clamping. The excess tissue was marked in a triangular shape, with a slight arching up to the xiphoid appendix. To determine the horizontal skin surplus, marking was performed, similar to that performed in classic abdominoplasty described in the literature(AMORIM FILHO; AMORIM, 2012). In this study, an anchor incision was recommended for all volunteers. All patients underwent intravenous sedation followed by spinal anesthesia.
58268481|NCT03973333|DRUG|IMC-C103C|Weekly IV infusions
58268482|NCT03973333|DRUG|Atezolizumab|IV infusions every 3 weeks
58268483|NCT03973333|DRUG|IMC-C103C|Weekly subcutaneous Injection
58268484|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
58268485|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
58268486|NCT01876979|DEVICE|IMF Screws|stainless steel screws placed in bone
58268487|NCT01876979|DEVICE|Erich Arch Bars|Surgical braces wired around teeth
58268488|NCT04761406|DIETARY_SUPPLEMENT|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
58268489|NCT04761406|DIETARY_SUPPLEMENT|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
58268490|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
58268491|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
58268492|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
58268493|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
58388018|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
58268494|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
58268495|NCT04272827|PROCEDURE|Liposuction|"Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions."
58268496|NCT00328159|DRUG|Oil special 107 and MYGLIOL 810|
58268497|NCT04308980|DIETARY_SUPPLEMENT|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
58268498|NCT04308980|BEHAVIORAL|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
58268499|NCT00162175|DRUG|Muraglitazar|
58388019|NCT04420832|PROCEDURE|Surgical treatment|Se above
58388020|NCT04420832|OTHER|Non-surgical treatment|See above
58388021|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
58388022|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
58388023|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
58268500|NCT05302024|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
58388024|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
57715608|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
58062730|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
58062731|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
58062732|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
58062733|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
58062734|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
58268501|NCT03066219|DRUG|BRM421|A topical solution of BRIM421 ophthalmic drops
58388025|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
57715609|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
57715610|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
58062735|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
58062736|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
58388026|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
58388027|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
58062737|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
58268502|NCT03066219|DRUG|Placebo|vehicle ophthalmic drops
58268503|NCT01685853|DRUG|Bisacodyl plus PEG-CS|"* the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
58388028|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
57715611|NCT02138318|OTHER|High definition (HD) endoscopy|
58062738|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
58062739|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
58062740|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
58062741|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
58062742|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
58062743|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
58062744|NCT03161015|DRUG|GBT440|Oral
58062745|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
58062746|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
58062747|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
58268504|NCT01685853|DRUG|PEG 4 litres split|"* the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
58268505|NCT00432315|DRUG|Docetaxel + CDDP|"* 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel"
58268506|NCT00432315|DRUG|docetaxel + CDDP|"* 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel"
58268507|NCT03994744|DRUG|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
57715612|NCT02138318|OTHER|chromoendoscopy|
58062748|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
58062749|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
58388029|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
58388030|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
58388031|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
57715613|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
57715614|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
58062750|NCT00953784|PROCEDURE|standard operating management|As previously described
58062751|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
58062752|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
58268508|NCT03994744|DRUG|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
58268509|NCT03990935|OTHER|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
57715615|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
57715616|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
57715617|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
58268510|NCT02086825|DRUG|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
58268511|NCT02086825|DRUG|Lactulose|20g dose titrated
58268512|NCT06137534|OTHER|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
58268513|NCT05011890|DEVICE|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
58268514|NCT06107907|DEVICE|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
58268515|NCT01236950|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
58268516|NCT01236950|DRUG|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
58268517|NCT02034812|OTHER|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
57715618|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
57715619|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
57715620|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
58268518|NCT03515629|DRUG|REGN2810/ipi|REGN2810 plus ipilimumab
57916282|NCT05699954|DIAGNOSTIC_TEST|Presence of Blink impression features for cancer in colorectal polyps|"1. 20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~2. A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~3. The survey asks for demographics of the participant endosopists (experience, country where they work).~4. The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~   * Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~  * If yes, why do you think that? (Free comment box)~  * What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~5. Study will be closed after 2 weeks.~6. Data analysis"
57916283|NCT03378505|BEHAVIORAL|Mobile App|Purposeful Living Mobile App JOOL to be used daily
58388032|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
58388033|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
58388034|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
58388035|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
57715621|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
57715622|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
57715623|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
57715624|NCT01983800|DRUG|Isoflurane|
57916284|NCT03378505|BEHAVIORAL|Reflection|Bi-weekly online reflection question
57916285|NCT00008489|DRUG|Didanosine|
58388036|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
58388037|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
57916286|NCT05169138|OTHER|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
58388038|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
57916287|NCT05169138|OTHER|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
57916288|NCT02947269|DRUG|Prucalopride|Prucalopride 2mg capsule
57916289|NCT02947269|DRUG|Placebo Oral Capsule|Placebo capsule
58388039|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
58388040|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
57715625|NCT01983800|DRUG|Propofol/midazolam|
57715626|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
57715627|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
57715628|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
57916290|NCT01436851|BIOLOGICAL|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
58062753|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
58388041|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
58268519|NCT03515629|DRUG|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
58268520|NCT03515629|DRUG|Pembrolizumab|Reference drug administered IV infusion
57715629|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
57916291|NCT01927029|DRUG|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
57916292|NCT01927029|DRUG|Placebo|
57916293|NCT01055379|DRUG|Rasagiline|1 mg/day for 12 weeks; orally
58268521|NCT02553785|DEVICE|Revivent TC|
58268522|NCT05767242|OTHER|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
58268523|NCT05767242|BEHAVIORAL|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
58268524|NCT04234269|OTHER|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
57715630|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
57916294|NCT01055379|DRUG|Placebo|Once daily for 12 weeks; orally
57916295|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
57916296|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & CS|Test meal consumed with the control supplement
57916297|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
58062754|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
58062755|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
57916298|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & CS|Test drink consumed with the control supplement
57916299|NCT04844801|PROCEDURE|Risk control strategy|"* Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance \>30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
57916300|NCT04844801|PROCEDURE|Rate control strategy:|"* Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
58062756|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
58062757|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
58268525|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
58268526|NCT02222441|DRUG|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
58268527|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
58268528|NCT02222441|DRUG|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
58268529|NCT00669552|PROCEDURE|Percutaneous coronary intervention|PCI previously electively scheduled.
58268530|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
58268531|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
58268532|NCT00650416|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
58268533|NCT00650416|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
58268534|NCT00111371|DRUG|Levodopa|
58268535|NCT02119975|BEHAVIORAL|Working memory training|
58268536|NCT02119975|BEHAVIORAL|Placebo training|
58268537|NCT01055405|DRUG|Sildenafil|Sildenafil 20mg TID orally
58268538|NCT01055405|OTHER|Placebo|Placebo TID orally
58268539|NCT01162148|BEHAVIORAL|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
58268540|NCT01162148|DEVICE|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
58268541|NCT01162148|DEVICE|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
58268542|NCT01162148|DEVICE|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
58062758|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
58062759|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
58268543|NCT04615806|DRUG|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
57715631|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
58062760|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
58062761|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
58062762|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
58268544|NCT06088251|BEHAVIORAL|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
58268545|NCT06088251|BEHAVIORAL|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
58268546|NCT06287710|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output)."
58268547|NCT06095635|OTHER|Placebo Protocol|ingestion of 500 mg of starch following 30 minutes of exercise (treadmill)
58268548|NCT06095635|OTHER|Protocol Beet|ingestion of 500 mg of beet extect following 30 minutes of exercise (treadmill)
58268549|NCT06095635|OTHER|Protocol Resveratrol|ingestion of 500 mg of resveratrol following 30 minutes of exercise (treadmill)
58268550|NCT06095635|OTHER|Protocol Beet and Resveratrol|ingestion 500 mg of beet extect and 500 mg of resveratrol following 30 minutes of exercise (treadmill)
58268551|NCT00181129|BEHAVIORAL|home based self paced walking program|
58268552|NCT04734275|DRUG|AZD5718|Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
58062763|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
58062764|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
58268553|NCT02568618|GENETIC|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
58388042|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
57715632|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
57715633|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
58388043|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
57715634|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
57715635|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
57715636|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
57715637|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
57715638|NCT01304888|OTHER|Control|No benefits were provided
57715639|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
57715640|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
57715641|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
58062765|NCT00267267|DRUG|torcetrapib/atorvastatin|
58062766|NCT00267267|DRUG|ezetimibe/simvastatin|
58388044|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
58062767|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
58276710|NCT02289105|BEHAVIORAL|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
58388045|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
58388046|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
58388047|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
58388048|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
58388049|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
58388050|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
58388051|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
58388052|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
57715642|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
57715643|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
57715644|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
57715645|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
57715646|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
57715647|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
57715648|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
57715649|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
57715650|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
57715651|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
57715652|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
58268554|NCT03879057|DRUG|Surufatinib/humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
58388053|NCT02110186|DEVICE|Dynamic Stabilization|
57715653|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
57916301|NCT04844801|PROCEDURE|Rhythm control strategy:|"* Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses \> 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus."
57916302|NCT00753272|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
57916303|NCT00753272|BIOLOGICAL|Fluarix TM|IM administration, two times one annual dose
58268555|NCT04939675|DRUG|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
57916304|NCT01635400|DRUG|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
58388054|NCT02110186|PROCEDURE|Discectomy|
57916305|NCT04270201|OTHER|Saliva collection|Saliva collection
58388055|NCT02110186|DEVICE|Instrumentation and fusion|
57916306|NCT01183078|PROCEDURE|free-hand|Free-hand technique utilizes x-rays to find screw holes.
58268556|NCT04939675|DRUG|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
58268557|NCT04939675|DRUG|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
58268558|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D2|Ergocalciferol vitamin D2
57715654|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
57715655|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
57715656|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
57715657|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
57715658|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
58062768|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
58268559|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol vitamin D2
58268560|NCT05717764|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
58268561|NCT05717764|DRUG|Capecitabine|Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
58268562|NCT00615979|DEVICE|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
57715659|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
57715660|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
57715661|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
57715662|NCT01938534|DRUG|Helicobacter pylori eradication|
57715663|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
57715664|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
57715665|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
57715666|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
57715667|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
57715668|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
57715669|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
57715670|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
57715671|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
57715672|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
57715673|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
57715674|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
57715675|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
57715676|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
57715677|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
57715678|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
57715679|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
57715680|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
57715681|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
57916307|NCT01183078|PROCEDURE|Wand technique|Wand technique is utilized to find screw holes.
57916308|NCT03133754|PROCEDURE|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
57916309|NCT03133754|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
57916310|NCT00437736|DRUG|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
57916311|NCT00160043|DRUG|SH T00268C|1250 mg experimental drug od
57916312|NCT00160043|DRUG|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
57916313|NCT04916080|DRUG|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
57916314|NCT01411215|DRUG|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
57715682|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
57715683|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
57715684|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
57715685|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
57715686|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
57715687|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
57715688|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
57715689|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
57715690|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
57715691|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
58268563|NCT01022775|PROCEDURE|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
57715692|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
57715693|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
57715694|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
57916315|NCT05787028|DRUG|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
57916316|NCT05787028|DRUG|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
58268564|NCT01022775|PROCEDURE|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
58268565|NCT01546597|DRUG|Metformin|"* Metformin 500 mg bid on Days 1-5~* Metformin 850 mg bid on Days 6-10~* Metformin 500 mg bid on Days 11-15~* Metformin 850 mg bid on Days 16-20"
58268566|NCT01546597|DRUG|Ranolazine|"* Ranolazine 1000 mg bid on Days 11-15~* Ranolazine 1000 mg bid on Days 16-20"
58268567|NCT02294175|DEVICE|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
58268568|NCT02294175|PROCEDURE|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
57715695|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
57715696|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
57715697|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
57916317|NCT02708719|PROCEDURE|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
57916318|NCT01538927|DRUG|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
57916319|NCT01538927|DRUG|Suture|Black silk 000
57916320|NCT00971243|DRUG|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
57916321|NCT00971243|DRUG|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
57916322|NCT00971243|DRUG|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
57916323|NCT00971243|DRUG|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
58268569|NCT05619406|DEVICE|Riskometer Application|The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.
57715698|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
58268570|NCT05619406|BEHAVIORAL|Routine Clinic Therapy|After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
58268571|NCT04912388|OTHER|Lumbal stabilization excercises|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
58268572|NCT04912388|OTHER|Conventional exercises|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
58268573|NCT06072404|BIOLOGICAL|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
58268574|NCT02097797|OTHER|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
58268575|NCT02097797|OTHER|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
58268576|NCT02631278|DEVICE|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
58268577|NCT00040235|PROCEDURE|magnesium|
58268578|NCT02274064|BEHAVIORAL|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
58268579|NCT02939716|OTHER|Rhubarb|300gm rhubarb
58268580|NCT02939716|OTHER|Bread|2 slices bread
58268581|NCT02939716|OTHER|Lettuce|300g lettuce
58268582|NCT01779167|DRUG|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)
58268583|NCT01779167|DRUG|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.
58268584|NCT01779167|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
58268585|NCT04094831|OTHER|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
58268586|NCT00365209|OTHER|laboratory biomarker analysis|Correlative studies
58062769|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
58062770|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
58062771|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
58062772|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
58062773|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
58062774|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
58062775|NCT02253173|DRUG|Estradiol|
57715699|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
57916324|NCT00971243|DRUG|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
58062776|NCT02253173|DRUG|Placebo|
58062777|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
58268587|NCT00365209|OTHER|pharmacological study|Correlative studies
58268588|NCT00365209|DRUG|curcumin|Given orally
57715700|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
57916325|NCT02949466|DRUG|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
58268589|NCT00002369|DRUG|Indinavir sulfate|
58268590|NCT00002369|DRUG|Lamivudine|
58268591|NCT00002369|DRUG|Stavudine|
58268592|NCT00002369|DRUG|Zidovudine|
57715701|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
57715702|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
58062778|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
58268593|NCT02073565|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
57715703|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
57715704|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
58388056|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
57916326|NCT02949466|DEVICE|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
58062779|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
58062780|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
58062781|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
58268594|NCT02073565|DEVICE|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
58268595|NCT00367484|BIOLOGICAL|Rebif® (clone 484-39)|s.c. administered Rebif®
58268596|NCT03374670|DRUG|Zimura|Zimura in combination with Eylea
58268597|NCT03374670|DRUG|Eylea|Zimura in combination with Eylea
57715705|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
57916327|NCT02752074|DRUG|pembrolizumab + epacadostat|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
58062782|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
58062783|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
58062784|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
58268598|NCT01206413|DIETARY_SUPPLEMENT|Low glycemic index diet|
58388057|NCT03427593|GENETIC|FACS analyses|FACS analyses
57916328|NCT02752074|DRUG|pembrolizumab + placebo|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)"
58062785|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
58268599|NCT01206413|DIETARY_SUPPLEMENT|High glycemic index diet|
58268600|NCT01206413|OTHER|Home-based exercise intervention|
58268601|NCT01206413|OTHER|Non-exercisers|
58268602|NCT03161626|DRUG|Coagadex|Plasma-driven blood coagulation factor X concentration
58268603|NCT03070405|DRUG|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
58268604|NCT03070405|DRUG|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
58268605|NCT03005431|BEHAVIORAL|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
58268606|NCT02900417|DRUG|Sitagliptin|All the patients will receive sitagliptin 100mg daily
58388058|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
58388059|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
57916329|NCT00183365|BEHAVIORAL|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
57916330|NCT00183365|BEHAVIORAL|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
58268607|NCT06509971|DRUG|QL1706|"The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab."
57715706|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
57715707|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
57715708|NCT00134368|DRUG|Etanercept|
57715709|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
57715710|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
58268608|NCT04363918|DEVICE|bioelectric stimulation|bioelectric stimulation
58268609|NCT04861194|RADIATION|Neurovascular-sparing|Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT
58388060|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
58388061|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
58388062|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
58388063|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
57916331|NCT06225011|DRUG|Fluoxetine|Receive PO
57916332|NCT01277367|BEHAVIORAL|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
57916333|NCT01277367|BEHAVIORAL|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
57916334|NCT01277367|BEHAVIORAL|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
58388064|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
58388065|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
58388066|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
57715711|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
57715712|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
57715713|NCT00240422|DRUG|Telmisartan|
57715714|NCT00240422|DRUG|Ramipril|
57715715|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
57715716|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
57715717|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
57715718|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
58062786|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
58268610|NCT02057913|DRUG|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
57715719|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
57715720|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
57715721|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
57715722|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
57715723|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
57715724|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
57715725|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
57715726|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
57715727|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
57715728|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
57916335|NCT01277367|BEHAVIORAL|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
57715729|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
58268611|NCT06363032|DIAGNOSTIC_TEST|elastography|When routine renal ultrasound is arranged, patients will be invited to receive elastography at the same time.
58268612|NCT02690519|DRUG|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
58268613|NCT02690519|DRUG|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
58268614|NCT05256875|OTHER|chemical adherence test, medication adherence questionnaire, pharmacy refill rate|Urine/blood samples will be collected from participants, also they will be asked to complete a medication adherence questionnaire, medication records will also be examined to determine the pharmacy refill rate.
58276711|NCT03257969|BEHAVIORAL|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
58388067|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
58388068|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
58388069|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
58388070|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
58388071|NCT02342847|OTHER|N/A (non-interventional study)|
57715730|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
57715731|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
57916336|NCT01277367|BEHAVIORAL|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
57916337|NCT01277367|BEHAVIORAL|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
57715732|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
57715733|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
57715734|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
58062787|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
58388072|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
57715735|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
57715736|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
57715737|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
57715738|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
57715739|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
57715740|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
57715741|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
57715742|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
57715743|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
57715744|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
57715745|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
57715746|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
57715747|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
57715748|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
57916338|NCT05780892|BEHAVIORAL|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
57916339|NCT05780892|BEHAVIORAL|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
58062788|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
58062789|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
58276712|NCT03257969|BEHAVIORAL|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
58276713|NCT02552888|DRUG|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
58276714|NCT02552888|DIETARY_SUPPLEMENT|Isoquercetin|Isoquercetin 225 mg by mouth once per day
57715749|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
57715750|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
57715751|NCT05294263|DRUG|Placebo|Matching, inactive medication
57715752|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
58062790|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
58276715|NCT02552888|OTHER|placebos|placebos
57715753|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
57715754|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
57715755|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
57916340|NCT05780892|BEHAVIORAL|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
57916341|NCT05780892|BEHAVIORAL|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
57916342|NCT00004468|DRUG|calcitriol|
57916343|NCT00971932|DRUG|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.
57916344|NCT00971932|DRUG|Cisplatin/Carboplatin|Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
58062791|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
58388073|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
57715756|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
58062792|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
58062793|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
57715757|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
57916345|NCT00971932|DRUG|5-Fluorouracil|Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
57916346|NCT01459419|DRUG|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
58062794|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
58062795|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
58062796|NCT00679354|DRUG|cilengitide|Given IV
58062797|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
58062798|NCT00679354|OTHER|pharmacological study|Correlative studies
58062799|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
58062800|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
58062801|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
58388074|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
58388075|NCT00601614|DRUG|temozolomide|
58388076|NCT00601614|DRUG|vandetanib|
58388077|NCT00601614|OTHER|immunoenzyme technique|
58388078|NCT00601614|OTHER|laboratory biomarker analysis|
57715758|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
57715759|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
57715760|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
57715761|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
57715762|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
57715763|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
57715764|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
57715765|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
57715766|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
57715767|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
58062802|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
57715768|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
57715769|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
57715770|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
57715771|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
57715772|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
57715773|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
57715774|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
58062803|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
58276716|NCT05462275|DEVICE|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
58276717|NCT03994406|DRUG|CLM2 topical gel|Active topical gel for forehead dermal application
57715775|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
57715776|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
57715777|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
57715778|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
57715779|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
57715780|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
57715781|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
57715782|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
57715783|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
57715784|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
57715785|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
57715786|NCT02927691|DEVICE|EMST|
57715787|NCT02927691|BEHAVIORAL|smTAP|
58276718|NCT03994406|DRUG|Placebo topical gel|Placebo topical gel for forehead dermal application
57715788|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
57715789|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
57715790|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
57715791|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
58276719|NCT00211627|DEVICE|KEEPASLEEP enhanced breathing device|
58276720|NCT01777737|DRUG|Cotrimoxazole|24 weeks of treatment
57715792|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
57715793|NCT00895219|OTHER|Breathing re-training|Breathing re-training
57715794|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
57715795|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
57715796|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
57715797|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
58062804|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
58276721|NCT01777737|DRUG|Placebo|Identical capsules to cotrimoxazole
57916347|NCT01459419|DRUG|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
57715798|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
57715799|NCT02962895|BIOLOGICAL|VAY736|VAY736
57916348|NCT05620368|BEHAVIORAL|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
57916349|NCT05620368|BEHAVIORAL|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
57916350|NCT05788393|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
57916351|NCT05788393|DRUG|Lidocaine IV|lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
57916352|NCT06161168|DEVICE|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
57916353|NCT01213160|DRUG|AZD4547|film coated tablet, PO, twice daily
57916354|NCT02866539|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
58062805|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
58062806|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
58062807|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
58062808|NCT00073541|DRUG|EMD 72000|
58388079|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
58388080|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
57715800|NCT02962895|OTHER|Placebo|Placebo control
57916355|NCT02866539|DRUG|Placebo|Similar looking inactive powder
57916356|NCT01856556|DRUG|NRX-1074|Single IV or PO administration
57916357|NCT01856556|DRUG|Placebo|Single IV or PO placebo administration
58062809|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
58062810|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
58062811|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
58268615|NCT04685668|BEHAVIORAL|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
57916358|NCT03738345|OTHER|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
58268616|NCT02849392|OTHER|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
58388081|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
58388082|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
58388083|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
58388084|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
58388085|NCT00232323|BEHAVIORAL|simulation training|
58388086|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
58388087|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
58388088|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
57715801|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
57715802|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
57715803|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
57715804|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
58276722|NCT05658952|OTHER|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
58388089|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
57715805|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
57715806|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
57715807|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
57715808|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
57715809|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
57715810|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
57916359|NCT04043689|DEVICE|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
58062812|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
58388090|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
58388091|NCT04177004|DRUG|Cyclophosphamide|Given IV
58388092|NCT04177004|DRUG|Etoposide|Given IV
57715811|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
57715812|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
57715813|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
57715814|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
57715815|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
57715816|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
57715817|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
57715818|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
57715819|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
57916360|NCT01589237|DRUG|LCQ908|
58388093|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
58388094|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
58268617|NCT05270915|BEHAVIORAL|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
58268618|NCT04936698|DRUG|PTU 50 MG Oral Tablet|to treat if the patient has hyperthyroidism
58268619|NCT04936698|DRUG|Levothyroxin|to treat if the patient has hypothyroidism
58268620|NCT02433067|OTHER|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
58268621|NCT02433067|OTHER|Control Group|standard oncologic care
58268622|NCT00766467|DRUG|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
58268623|NCT00766467|OTHER|Placebo|Placebo taken once a day in the morning
57715820|NCT06573866|BEHAVIORAL|Participatory workplace intervention|The Participatory Workplace Intervention (PWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. Subsequently, the implementation (process) of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
57715821|NCT00191061|DRUG|duloxetine hydrochloride|
57715822|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
57715823|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
57715824|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
57715825|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
57715826|NCT04394416|DRUG|Imatinib|Therapeutic
57715827|NCT04394416|DRUG|Placebo oral tablet|Placebo
57715828|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
57715829|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
57715830|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
57715831|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
57715832|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
57715833|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
57715834|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
57715835|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
57715836|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
57715837|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
58268624|NCT06729892|DRUG|Esketamine at low dose|Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
58268625|NCT06729892|DEVICE|new BIS baseline|Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.
58268626|NCT06729892|DRUG|an equivalent dose of saline|An equivalent dose of saline was given and closed-loop control stared.
58268627|NCT06729892|DEVICE|original BIS baseline|Drug dosage was adjused under close-loop control based on original BIS baseline.
58268628|NCT04493151|DRUG|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
57715838|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
57715839|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
57715840|NCT00151359|DEVICE|SoleSensor|
57715841|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
57715842|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
57715843|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
57715844|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
57916361|NCT02838771|OTHER|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
57916362|NCT02838771|OTHER|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
57916363|NCT01513980|PROCEDURE|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
57916364|NCT01513980|PROCEDURE|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
57916365|NCT00770341|DRUG|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
57916366|NCT00770341|DRUG|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
57916367|NCT00770341|DRUG|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
57916368|NCT05077657|DEVICE|Early Bird® Bleed Monitoring System|The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
58388095|NCT04177004|BIOLOGICAL|Palifermin|Given IV
58388096|NCT04177004|DRUG|Sirolimus|Given PO
58388097|NCT04177004|DRUG|Tacrolimus|Given IV and PO
57916369|NCT05077657|DEVICE|Impella®|Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
57916370|NCT04719325|OTHER|Herbert screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
58268629|NCT04511195|DIETARY_SUPPLEMENT|Standardized extract of Sphaeralcea angustifolia|Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin
58268630|NCT04511195|DRUG|Diclofenac Sodium Gel|Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
58268631|NCT01398189|DRUG|clozapine|C-11 clozapine
58268632|NCT06511323|DIAGNOSTIC_TEST|dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases|at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
58268633|NCT03646305|BEHAVIORAL|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
57715845|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
58276723|NCT05658952|OTHER|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
58276724|NCT05658952|OTHER|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
57715846|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
57916371|NCT04719325|OTHER|Lag screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
57715847|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
58388098|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
57916372|NCT06067568|DRUG|Lutikizumab Dose A|Injection; subcutaneous (SC)
57916373|NCT06067568|DRUG|Lutikizumab Dose B|Injection; subcutaneous (SC)
58388099|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
58268634|NCT05313282|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
58268635|NCT05313282|COMBINATION_PRODUCT|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
58268636|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
58268637|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
58268638|NCT04687748|DEVICE|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
58268639|NCT04687748|OTHER|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
58276725|NCT02927002|DEVICE|Noninvasive brain stimulation|
58388100|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
58388101|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
58388102|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
58388103|NCT02869581|OTHER|Data collection|
57715848|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
57916374|NCT01548560|DRUG|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
57916375|NCT01548560|DRUG|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
57916376|NCT00888004|DRUG|AFQ056|
57916377|NCT00888004|DRUG|Placebo|
57916378|NCT05202548|OTHER|Immuno-histochemical staining|blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
57916379|NCT00000301|DRUG|Amantadine|
58388104|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
58388105|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
58388106|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
58388107|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
57715849|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
57715850|NCT00079352|DRUG|alvocidib|Given IV
57715851|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
57715852|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
57715853|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
57715854|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
57916380|NCT02285465|DRUG|ASP3700|Oral
57916381|NCT02285465|DRUG|Placebo|Oral
57916382|NCT04499820|DIETARY_SUPPLEMENT|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
58268640|NCT03974841|PROCEDURE|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
57916383|NCT04499820|DIETARY_SUPPLEMENT|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
57916384|NCT05448781|DRUG|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
58388108|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
58388109|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
57715855|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
57715856|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
57916385|NCT05350631|OTHER|OnKO-Tips&Tricks digital phone application|Using daily OnKO-Tips\&Tricks digital phone application
57916386|NCT06414187|DEVICE|Intra-Aortic Balloon Pump|Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
58388110|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
58388111|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
57715857|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
57916387|NCT04950504|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
57916388|NCT04950504|DRUG|Placebo|CNP-201 Placebo
57916389|NCT04390022|DRUG|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
57916390|NCT04390022|DRUG|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
57916391|NCT02637973|DRUG|Empagliflozin|25 mg once daily
57916392|NCT02637973|DRUG|Placebo|once daily
57916393|NCT06050187|PROCEDURE|implant casts fabrication|four implant casts fabricated
57916394|NCT06382025|OTHER|showing cartoons -storybook|A goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period
57916395|NCT06382025|OTHER|showing cartoons - standard|standard
57916396|NCT02443090|DRUG|fispemifene|
58268641|NCT06731218|BIOLOGICAL|RGB-5088|Transplantation under the anterior rectus sheath
58268642|NCT02917824|DEVICE|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
57715858|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
57715859|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
57715860|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
57715861|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
57916397|NCT02443090|OTHER|Placebo|
57916398|NCT03371381|BIOLOGICAL|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
58268643|NCT02917824|DEVICE|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
57715862|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
57715863|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
58268644|NCT03860714|DIAGNOSTIC_TEST|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
58276726|NCT02194764|DRUG|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
57715864|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
57715865|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
57916399|NCT03371381|DRUG|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
58062813|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
58062814|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
58062815|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
58062816|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
58062817|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
57715866|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
57715867|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
57715868|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
57715869|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
57715870|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
57916400|NCT00023296|DRUG|Nitric Oxide|
57916401|NCT00023296|DEVICE|INO Pulse - NO Delivery System|
58062818|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
58062819|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
58062820|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
58062821|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
58062822|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
57916402|NCT02011087|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
57916403|NCT00536783|DRUG|Quetiapine|
57916404|NCT02667977|OTHER|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
57916405|NCT02667977|OTHER|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
57916406|NCT02770456|DIETARY_SUPPLEMENT|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
57916407|NCT02770456|DIETARY_SUPPLEMENT|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
58062823|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
57715871|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be perfomed during each cardio-oncologic evaluation.
57715872|NCT06664528|DIAGNOSTIC_TEST|ELETTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
57916408|NCT02770456|DIETARY_SUPPLEMENT|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
58062824|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
58062825|NCT01520675|PROCEDURE|surgery|Drainage procedure
58062826|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
58062827|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
58268645|NCT04823793|DIAGNOSTIC_TEST|Stool DNA methylation detection|Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
58268646|NCT03767556|PROCEDURE|Inspiratory muscle training|Powerbreathe® K5
58268647|NCT03672461|OTHER|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
58268648|NCT03672461|OTHER|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
58268649|NCT06730009|BIOLOGICAL|SLOG + Allogeneic NK cell|"Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD."
58388112|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
58388113|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
57715873|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
57715874|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
57916409|NCT04954261|DIAGNOSTIC_TEST|CAPD|CAPD evaluation every day per 12hours during their stay in PICU
58062828|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
58062829|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
58062830|NCT00003368|DRUG|irinotecan hydrochloride|
58062831|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
58062832|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
58062833|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
57715875|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
57715876|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
58062834|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
57715877|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
57715878|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
57715879|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
57715880|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
57715881|NCT02675452|DRUG|AMG 176|Study Drug
57715882|NCT02675452|DRUG|Azacitidine|Non-investigational product
57715883|NCT02675452|DRUG|Itraconazole|Non-investigational product
57715884|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
57715885|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
57916410|NCT00513643|DRUG|insulin aspart|6, 12, 24 U s.c.
57916411|NCT00513643|DRUG|human regular insulin|6, 12 and 24 IU sc
58062835|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
58062836|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
58062837|NCT02698917|OTHER|High normal PaO2|20-25 kPa
58062838|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
58062839|NCT02698917|OTHER|High normal MAP|80-100 mmHg
58062840|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
58062841|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
58388114|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
58388115|NCT00452075|DRUG|erlotinib|150mg daily
58388116|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
58388117|NCT05070312|DRUG|Placebo|Placebo
58388118|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
58388119|NCT00070109|DRUG|trabectedin|Given IV
57715886|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
57715887|NCT02358824|DRUG|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
57715888|NCT02358824|DRUG|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
57715889|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
57715890|NCT04693364|PROCEDURE|Discussion|Participate in consultation
57715891|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
57715892|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
57715893|NCT01599650|DRUG|Ranibizumab|
57715894|NCT01599650|PROCEDURE|Laser|laser photocoagulation
57715895|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
57715896|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
58062842|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
58062843|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
58268650|NCT06730009|DRUG|SLOG chemotherapy|Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
57715897|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
57715898|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
57715899|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
57715900|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
57715901|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
57715902|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
57715903|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
58268651|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
57715904|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
57715905|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
58062844|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
58268652|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
58268653|NCT06016439|PROCEDURE|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
57715906|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
57916412|NCT05960617|DRUG|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count \> 1.0 × 10\^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
57916413|NCT00890487|OTHER|hyaluronic acid pill|pill, 220 mg, once a day, three months
57916414|NCT02192021|DRUG|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
58062845|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
58062846|NCT05949528|OTHER|no intervention|no intervention
58062847|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
58062848|NCT00079157|BIOLOGICAL|sargramostim|
58062849|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
58062850|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
58062851|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
58062852|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
58062853|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
58268654|NCT06016439|DEVICE|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
58268655|NCT01028248|DRUG|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
58268656|NCT00933582|DRUG|JNJ-39439335; Placebo; Naproxen|
58268657|NCT02865590|DEVICE|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
58268658|NCT02865590|DEVICE|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
58268659|NCT00289406|DRUG|S-amlodipine gentisate|
58268660|NCT00289406|DRUG|Amlodipine besylate|
57715907|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
58062854|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
58268661|NCT00844480|DRUG|zoledronic acid|zoledronic acid, 5mg, iv
57715908|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
57715909|NCT00718172|PROCEDURE|Liver Biopsy|
57715910|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
57715911|NCT00718172|DRUG|Pre-treatment Ribavirin|
57715912|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
57715913|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
58268662|NCT00844480|DRUG|placebo|iv
58268663|NCT00725101|DRUG|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
58268664|NCT03325894|DRUG|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
57715914|NCT00643955|OTHER|muscle strength|muscle strength
58268665|NCT04687020|DRUG|Viltolarsen|Received during weekly intravenous infusions
58268666|NCT02174003|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
58268667|NCT03625310|DRUG|Sodium Fluoride|
58268668|NCT03625310|DRUG|Sodium Fluoride with TCP|
58268669|NCT03625310|DRUG|Sodium Fluoride with CXP|
58268670|NCT03625310|DRUG|Sodium Fluoride with CPP-ACP|
58268671|NCT06109376|PROCEDURE|hypothermia|In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
58268672|NCT06109376|PROCEDURE|thrombectomy|Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
57715915|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
57715916|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
57715917|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
57715918|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
57916415|NCT05302388|DRUG|SIBP-R002|SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
57916416|NCT05302388|DRUG|Dexamethasone or Methyl prednisolone|Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
58062855|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
58268673|NCT05489640|OTHER|No Intervention|No Intervention will be administered in this study.
58268674|NCT06708949|DRUG|Drugs Nivolumab|Given by IV Infusion
58268675|NCT06708949|DRUG|Ipilimumab|Given by IV Infusion
58268676|NCT06708949|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV Infusion
58268677|NCT02984267|DEVICE|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
58268678|NCT02984267|OTHER|Palpation|Using palpation only to evaluate the spine prior to epidural placement
58268679|NCT02510313|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
58268680|NCT02991716|OTHER|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
58268681|NCT04529304|DEVICE|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
58268682|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
57715919|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
57715920|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
57715921|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
58268683|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
58388120|NCT00070109|OTHER|pharmacological study|Correlative studies
57715922|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
57715923|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
57715924|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
57715925|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
57715926|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
57715927|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
57715928|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
57715929|NCT00214994|DRUG|Gabitril|
57715930|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
57715931|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
57715932|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
57715933|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
57916417|NCT05302388|DRUG|Diphenhydramine|10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
57916418|NCT05302388|DRUG|Placebo|The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
57715934|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
57715935|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
57715936|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
57715937|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
57715938|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
57916419|NCT03160508|PROCEDURE|Fracture fixation with the TFNA|Fracture fixation with the TFNA
57916420|NCT06319456|DRUG|Lisaftoclax (APG-2575)|QD, oral administration, every 28 days for a dosing cycle.
57916421|NCT06319456|DRUG|Acalabrutinib|BID, oral administration, every 28 days for a dosing cycle.
57916422|NCT06319456|DRUG|Fludarabine|Every 28 days for a treatment cycle, administration of 6 cycles.
58062856|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
58062857|NCT01927276|OTHER|Gluten Free Flour|
58062858|NCT01927276|OTHER|Wheat Flour|
58062859|NCT01886144|DEVICE|Knee OA Brace|
58062860|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
57715939|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
57715940|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
57715941|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
57715942|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
57916423|NCT06319456|DRUG|Cyclophosphamide，CTX|Every 28 days for a treatment cycle, administration of 6 cycles.
57916424|NCT06319456|DRUG|Rituximab|Every 28 days for a treatment cycle, administration of 6 cycles.
57916425|NCT06319456|DRUG|Chlorambucil|Every 28 days for a treatment cycle, administration of 6 cycles.
57916426|NCT04320394|DIAGNOSTIC_TEST|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
57916427|NCT01597453|BEHAVIORAL|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
57916428|NCT02637960|DRUG|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
57916429|NCT02637960|DRUG|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
58062861|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
58062862|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
58268684|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
57715943|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
57916430|NCT05441709|BEHAVIORAL|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
58268685|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
58268686|NCT06022354|DRUG|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
58268687|NCT00034346|DRUG|ABX-EGF|
57916431|NCT02305537|BEHAVIORAL|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
58062863|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
58268688|NCT00034346|DRUG|paclitaxel|
58268689|NCT00034346|DRUG|carboplatin|
58268690|NCT01371877|DRUG|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
58268691|NCT01371877|DRUG|Low Dose Vitamin D3|Vitamin D 600 IU per day
58268692|NCT05391581|OTHER|GIPR antagonist / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
58268693|NCT05391581|OTHER|GLP-2R antagonist / study tool|Selective antagonist of the GLP-2R, GLP-2(3-33)
58268694|NCT05391581|OTHER|Placebo|Saline
58268695|NCT03725501|DRUG|ALS-L1023|ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
58268696|NCT03725501|DRUG|Ranibizumab|LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
57715944|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
57916432|NCT00207701|DRUG|infliximab|
57916433|NCT01919814|DIETARY_SUPPLEMENT|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
58062864|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
58062865|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
58268697|NCT03725501|OTHER|Placebo|Control group for comparison with oral administration of ALS-L1023
58268698|NCT00160134|DRUG|SLV320|
58268699|NCT01801241|DEVICE|Anatomic TSA using IRI Instrumentation|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
58268700|NCT01801241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
58268701|NCT03679169|PROCEDURE|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
58268702|NCT00191425|DRUG|Teriparatide|
58268703|NCT00191425|DRUG|Raloxifene|
58268704|NCT00112021|DRUG|pramlintide acetate|
58268705|NCT04655040|DRUG|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
58268706|NCT04655040|OTHER|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
58268707|NCT03673501|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
58268708|NCT03673501|DRUG|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
58268709|NCT06147960|DIAGNOSTIC_TEST|Immunohistochemistry|Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.
58268710|NCT00541008|DRUG|sunitinib malate|
58268711|NCT00759057|DEVICE|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
57916434|NCT01919814|OTHER|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
57715945|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
57715946|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
57715947|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
57715948|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
57715949|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
57715950|NCT00023816|DRUG|carbendazim|
57715951|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
57715952|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
57715953|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
57715954|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
57715955|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
58268712|NCT03408444|DEVICE|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
58268713|NCT03408444|DEVICE|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
57715956|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
57715957|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
57715958|NCT05428969|DRUG|Bexmarilimab|Intravenous
57715959|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
57715960|NCT05428969|DRUG|Venetoclax|Oral
57715961|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
57715962|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
57715963|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
57715964|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
57916435|NCT02293915|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
57715965|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
57916436|NCT02293915|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
58268714|NCT03408444|DEVICE|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
57715966|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
57715967|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
57715968|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
57715969|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
57715970|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
57916437|NCT00810394|DRUG|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
58062866|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
57715971|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
57715972|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
57715973|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
57715974|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
57715975|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
57715976|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
57715977|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
57715978|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
58062867|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
58062868|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
58062869|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
58268715|NCT03408444|DEVICE|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
57715979|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
58268716|NCT04536870|DIAGNOSTIC_TEST|Echocardiography|Ultrasound of heart
57715980|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
57715981|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
57715982|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
57715983|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
57916438|NCT01251185|DEVICE|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
57916439|NCT05469984|DRUG|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
57916440|NCT05469984|DRUG|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
57916441|NCT01111747|PROCEDURE|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
58062870|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
58062871|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
58268717|NCT04536870|DIAGNOSTIC_TEST|ECG screening|Single lead ECG screening twice daily for two weeks
58268718|NCT04536870|DIAGNOSTIC_TEST|ECG Screening|12-lead ECG screening
58268719|NCT02826265|DEVICE|multiple breath washout test (MBW)|
58268720|NCT02826265|DEVICE|impulse oscillometry (IOS)|
58268721|NCT02826265|DEVICE|body plethysmography (BP)|
58268722|NCT02826265|DEVICE|quantitative computed tomography (qCT)|ultra-low-dose qCT
58268723|NCT02887222|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
58268724|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method A
58268725|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method B
58268726|NCT01507402|DRUG|Placebo|(inactive substance)
58268727|NCT02982044|OTHER|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
57715984|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
57715985|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
57715986|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
57715987|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
58268728|NCT02982044|OTHER|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
57715988|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
57715989|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
57715990|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
57916442|NCT01111747|PROCEDURE|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
57916443|NCT04644562|OTHER|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
57916444|NCT05004051|DEVICE|ViTAA Analysis|Imaging Analysis Software
57916445|NCT05507905|BEHAVIORAL|Music|Music associated with dance forms in dance classes.
57916446|NCT05507905|BEHAVIORAL|Dance Classes|Four Different dance forms taught for 6 weeks each
57916447|NCT04773197|BEHAVIORAL|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
57916448|NCT04773197|BEHAVIORAL|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
58268729|NCT02982044|OTHER|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
58268730|NCT04578093|BEHAVIORAL|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
58268731|NCT05007041|BIOLOGICAL|FLUAD® Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
58268732|NCT05007041|BIOLOGICAL|Fluzone® High-Dose Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
58268733|NCT05007041|BIOLOGICAL|SHINGRIX®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
58268734|NCT02397824|OTHER|Salivary and blood samples|
58268735|NCT05616429|DIETARY_SUPPLEMENT|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
58268736|NCT05616429|DIETARY_SUPPLEMENT|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
58268737|NCT05616429|OTHER|usual care|usual care
58268738|NCT00094549|DRUG|olanzapine|
58268739|NCT00094549|DRUG|divalproex sodium|
58388121|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
57715991|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
57715992|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
57715993|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
57715994|NCT00000601|DRUG|estrogen replacement therapy|
57715995|NCT00000601|DRUG|estrogens|
57715996|NCT00000601|DRUG|progesterone|
57715997|NCT00000601|DRUG|hormone replacement therapy|
57715998|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
57715999|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
57916449|NCT04773197|BEHAVIORAL|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
58062872|NCT02334813|DRUG|Prednisone|Continuous daily therapy
58268740|NCT00094549|DRUG|placebo|
58388122|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
57716000|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
57716001|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
57716002|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
58268741|NCT04102865|DEVICE|Negative-Pressure Wound Therapy (NPWT)|Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
58388123|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
57716003|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
57716004|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
57716005|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
57716006|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
57716007|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
57716008|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
58388124|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
58388125|NCT02225704|DRUG|Radium-223 and enzalutamide|
58388126|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
58388127|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
57716009|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
57716010|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
57716011|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
57716012|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
57716013|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
57716014|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
57716015|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
57716016|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
57716017|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
57716018|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
57716019|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
58062873|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
58062874|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
58268742|NCT04820231|OTHER|intra-articular PRP injection|
58268743|NCT01592292|DRUG|Rituximab|Rituximab as per physician's discretion.
58268744|NCT01592292|DRUG|Adalimumab|Adalimumab as per physician's discretion.
58268745|NCT01592292|DRUG|Etanercept|Etanercept as per physician's discretion.
57716020|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
57716021|NCT00456092|DRUG|Apremilast|Capsules for oral administration
57716022|NCT00456092|DRUG|Placebo|Capsules for oral administration
57716023|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
57716024|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
57716025|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
57716026|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
57916450|NCT01443715|BEHAVIORAL|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
57916451|NCT01443715|BEHAVIORAL|Treatment as Usual|Standard treatment in the community
57916452|NCT02695303|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
57916453|NCT02345785|OTHER|urologic surgery and caudal block|
57916454|NCT00681785|DRUG|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
58268746|NCT01592292|DRUG|Infliximab|Infliximab as per physician's discretion.
58388128|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
57916455|NCT03334136|DRUG|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
57916456|NCT03334136|DRUG|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
57916457|NCT00886496|BIOLOGICAL|recombinant human mannose-binding lectin|
57916458|NCT06248385|DEVICE|2D ultrasound|2D TVUS
57916459|NCT03527368|BEHAVIORAL|Time-restricted feeding|Participants consume food earlier in the day
57916460|NCT03527368|BEHAVIORAL|Usual feeding pattern|Participants consume food later in the day
58268747|NCT01299415|DRUG|Vadimezan™|
58268748|NCT00911209|BEHAVIORAL|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
58268749|NCT06525636|DRUG|KK8123|Subcutaneous administration
57916461|NCT05810987|OTHER|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]"
57916462|NCT05810987|BEHAVIORAL|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
57916463|NCT05220384|BEHAVIORAL|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
57916464|NCT05220384|BEHAVIORAL|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
58062875|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
58268750|NCT06504667|DEVICE|Point Mini|The Point Mini finger prosthetic system consists of 1-4 ratcheting mechanical digits and mounting brackets
58268751|NCT04970017|RADIATION|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
58268752|NCT06514378|BIOLOGICAL|Mesenchymal stem cells|Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
58268753|NCT02865811|DRUG|Pembrolizumab|"Please see Arms for description."
58268754|NCT02865811|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
58268755|NCT06135025|OTHER|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
58268756|NCT00013000|BEHAVIORAL|Test strategy for implementation guideline|
58388129|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
58388130|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
57716027|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
57716028|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
57716029|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
58388131|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
57716030|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
57716031|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
57716032|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
57716033|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
57716034|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
57716035|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
58388132|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
58388133|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
58388134|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
57716036|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
57716037|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
57716038|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
57916465|NCT04463017|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
58388135|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
58388136|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
58388137|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
58388138|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
58388139|NCT00003566|PROCEDURE|videothoracoscopy|
58388140|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
58388141|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
58388142|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
58388143|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
58388144|NCT02322580|DRUG|etanercept|
58388145|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
58388146|NCT01798901|DRUG|decitabine|Given IV
58388147|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
58388148|NCT01798901|OTHER|pharmacological study|Correlative studies
58388149|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
58388150|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
57716039|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
57716040|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
57716041|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
57716042|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
57716043|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
57716044|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
57716045|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
57716046|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
58062876|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
57716047|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
57716048|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
57716049|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
57716050|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
57716051|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
57716052|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
57716053|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
58268757|NCT06731634|DEVICE|Hand grip strength dynamometer, pinch strength dynamometer|Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer
58268758|NCT06731634|DIAGNOSTIC_TEST|Finkelstein test|Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
57716054|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
57716055|NCT05647512|DRUG|LM-305|Administered intravenously
57716056|NCT05647512|DRUG|Dexamethasone|Administered orally
57716057|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
57916466|NCT05125666|OTHER|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
58062877|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
58062878|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
57716058|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
57716059|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
57716060|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
57916467|NCT05125666|OTHER|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
58062879|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
58062880|NCT03436992|OTHER|Placebo|placebo
57716061|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
57716062|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
57716063|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
57716064|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
57716065|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
57716066|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
57716067|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
57716068|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
57716069|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
57716070|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
57716071|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
57716072|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
57716073|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57716074|NCT00585754|DRUG|Guanfacine|1.5mg BID
57916468|NCT04407871|OTHER|Acupuncture and Chinese Herbal Medicine|1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
57916469|NCT03546322|OTHER|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
57916470|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
58062881|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
58062882|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
58062883|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
57916471|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
58062884|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
57716075|NCT00585754|DRUG|Placebo|placebo
57716076|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
57716077|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
57916472|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
57916473|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
57916474|NCT00552240|DRUG|Nevirapine 200 mg BID|200 mg BID
57916475|NCT00552240|DRUG|Atazanavir 300 mg|300 mg QD
57916476|NCT00552240|DRUG|Ritonavir 100 mg|100 mg QD
57916477|NCT03433079|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
57716078|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
57716079|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
57716080|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
57916478|NCT03433079|DIAGNOSTIC_TEST|Arterial lactate|Arterial lactate level was assessed in all patients.
58268759|NCT00266591|DRUG|topiramate|
58268760|NCT05245734|DRUG|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
58388151|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
57916479|NCT03433079|DIAGNOSTIC_TEST|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
58268761|NCT04446351|DRUG|GSK6097608|GSK6097608 will be administered as an IV infusion.
58388152|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
57916480|NCT03433079|DIAGNOSTIC_TEST|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
58268762|NCT04446351|DRUG|Dostarlimab|Dostarlimab will be administered as an IV infusion.
58268763|NCT04446351|DRUG|Cobolimab|Cobolimab will be administered as an IV infusion.
58268764|NCT04446351|DRUG|Belrestotug|Belrestotug will be administered as an IV infusion.
58268765|NCT01237093|OTHER|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
58268766|NCT01237093|OTHER|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
58268767|NCT01237093|OTHER|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
58268768|NCT01237093|OTHER|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
58268769|NCT01237093|OTHER|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
58268770|NCT01237093|OTHER|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
58388153|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
58388154|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
58388155|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
58388156|NCT00335283|DRUG|lansoprazole|40mg bid
57916481|NCT03433079|DIAGNOSTIC_TEST|Myoglobin|The level of myoglobin was assessed in all patients.
57916482|NCT03243877|OTHER|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
57916483|NCT00561054|DRUG|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
57916484|NCT00190411|DRUG|celiprolol|celiprolol
57916485|NCT00190411|DRUG|Control|Untreated controls excluding betablockers
57916486|NCT01952223|DRUG|Cabazitaxel|Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
58268771|NCT01237093|OTHER|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
57916487|NCT01952223|RADIATION|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
57916488|NCT01952223|RADIATION|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
57916489|NCT02851927|PROCEDURE|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
57916490|NCT02851927|PROCEDURE|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
58268772|NCT01237093|OTHER|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
58268773|NCT05940025|DEVICE|MORT-LBP|The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
58268774|NCT05940025|OTHER|treatment as usual (TAU)|In the control group, education and physiotherapy is delivered and self-exercise is recommended.
58268775|NCT02672358|DRUG|Dabrafenib|Oral Dabrafenib 150 mg BID
58268776|NCT02672358|DRUG|Trametinib|Oral Trametinib 2 mg QD
58268777|NCT02311556|DEVICE|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
58268778|NCT03851146|BIOLOGICAL|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
58268779|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
58268780|NCT05564650|DRUG|Venetoclax|Given PO
58268781|NCT05564650|DRUG|Decitabine|Given IV
58268782|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58268783|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58268784|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
58268785|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
58268786|NCT04629924|DEVICE|sleeper one|anesthesic injection with sleeper one device
58268787|NCT04629924|DEVICE|conventional technis|anesthesic injection with the conventional technic
58268788|NCT05910060|DIAGNOSTIC_TEST|OTTAWA ANKLE RULES|count the ottawa score and do an x-ray if the score is greater than or equal to 1
58388157|NCT00335283|DRUG|placebo|one tablet bid
58388158|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
58388159|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
58388160|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
58388161|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
58388162|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
58062885|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
58062886|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
58268789|NCT00629876|DRUG|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
58268790|NCT00248833|BIOLOGICAL|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
58268791|NCT00248833|BIOLOGICAL|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
58268792|NCT00002266|DRUG|AS-101|
58268793|NCT02460523|PROCEDURE|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
58268794|NCT02460523|PROCEDURE|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
58268795|NCT05735912|PROCEDURE|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
58268796|NCT05735912|PROCEDURE|Surgery|Surgical resection of pancreatic insulinoma
58062887|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
57916491|NCT00110110|BIOLOGICAL|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
58062888|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
58062889|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
58268797|NCT05307796|BEHAVIORAL|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
58062890|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
58062891|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
58268798|NCT03180424|DRUG|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
58268799|NCT03180424|BEHAVIORAL|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
58268800|NCT03180424|DRUG|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
58268801|NCT03180424|BEHAVIORAL|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
58268802|NCT02707315|DRUG|Gemcitabine|
58268803|NCT02707315|RADIATION|Stereotactic Radiosurgery|
58268804|NCT03678896|BEHAVIORAL|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
58388163|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
58388164|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
58388165|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
58388166|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
57916492|NCT00110110|DRUG|Carboplatin|Given at 28 mg/kg/dose.
58062892|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
58062893|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
58062894|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
58062895|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
57916493|NCT00110110|DRUG|Cyclosporine|Given at 33 mg/kg/dose
57916494|NCT00110110|DRUG|Etoposide|Given at 12 mg/kg/dose
58268805|NCT03678896|BEHAVIORAL|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
58268806|NCT05941741|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.
58268807|NCT05941741|DRUG|Chemotherapy|Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles
58268808|NCT05941741|BIOLOGICAL|Immune checkpoint inhibitor|Cadonilimab: 10mg/kg, Q3W, 3 cycles
58268809|NCT05941741|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy will be performed to study group, with the use of IMRT.
58268810|NCT04604405|RADIATION|photobiomodulation|650nm low energy red light eye irradiation
58268811|NCT06133946|GENETIC|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
57916495|NCT00110110|DRUG|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
57916496|NCT00110110|PROCEDURE|cryosurgery|Local application of extreme cold to destroy residual tumor.
57916497|NCT00110110|PROCEDURE|laser therapy|Local and precise application of laser beams to destroy residual tumor.
58268812|NCT03897114|DIETARY_SUPPLEMENT|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
58268813|NCT03897114|DIETARY_SUPPLEMENT|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
58268814|NCT00564044|PROCEDURE|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
58268815|NCT01821209|PROCEDURE|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
57716081|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
57716082|NCT03930316|DEVICE|NOX T3|portable sleep study device
57716083|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
57716084|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
58268816|NCT04850573|OTHER|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
57716085|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
57716086|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
57716087|NCT01343706|DRUG|Placebo|Solution for oral administration
57716088|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
57716089|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
57716090|NCT01343706|DRUG|BI 409306|solution for oral administration
57716091|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
58268817|NCT00432796|DRUG|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
58268818|NCT00432796|OTHER|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
57716092|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
58062896|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
58268819|NCT05526222|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
58268820|NCT03662113|DRUG|Domperidone|5ml Domperidone prior to VCE
58268821|NCT03662113|DIETARY_SUPPLEMENT|water|5ml water prior to VCE
58268822|NCT04934176|OTHER|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
58388167|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
57916498|NCT04265313|OTHER|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
57716093|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
58062897|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
58268823|NCT04934176|OTHER|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
58388168|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
58388169|NCT00069875|DRUG|Gemcitabine|
58268824|NCT04673656|DIETARY_SUPPLEMENT|BKR-017|Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
58268825|NCT02569086|OTHER|Blood draw|
58268826|NCT00970099|BEHAVIORAL|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
58268827|NCT00970099|BEHAVIORAL|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
58268828|NCT03729414|PROCEDURE|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
58388170|NCT00069875|DRUG|LY293111|
58388171|NCT00069875|DRUG|cisplatin|
58388172|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
58062898|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
58268829|NCT03729414|PROCEDURE|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
58268830|NCT06254508|BEHAVIORAL|Online program that includes exercise guided by the FITT-VP principle and dietary advice|"1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance."
58268831|NCT06254508|BEHAVIORAL|Conventional in-clinic nutrition and exercise advice and self-control|Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
58268832|NCT01786538|DRUG|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
58388173|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
58388174|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
57716094|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
57716095|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
58268833|NCT01786538|DRUG|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
58268834|NCT06730477|OTHER|observational study|Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
58388175|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
57716096|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
57716097|NCT00315276|DRUG|Modafinil|
57716098|NCT02699905|OTHER|phlebotomy|phlebotomy
57716099|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
57716100|NCT04111497|DRUG|Glasdegib|Given PO
57716101|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
57716102|NCT00005638|DRUG|cisplatin|
57716103|NCT00005638|DRUG|irinotecan hydrochloride|
57716104|NCT00005638|RADIATION|radiation therapy|
57716105|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
57716106|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
57716107|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
57716108|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
58062899|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
58062900|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
57716109|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
57716110|NCT02506114|DRUG|Ipilimumab|
57716111|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
57916499|NCT00815685|DRUG|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
57916500|NCT01372865|DRUG|Mometasone furoate|
57916501|NCT01372865|DRUG|Mometasone furoate|
57916502|NCT04830397|DRUG|QLS-101|Ophthalmic solution 1x daily
57916503|NCT04830397|DRUG|Timolol Maleate|Ophthalmic solution 1x daily
57916504|NCT03945825|DRUG|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
57916505|NCT03945825|BIOLOGICAL|Delta Inulin-CpG55.2|A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
57916506|NCT03945825|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
57916507|NCT03945825|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
57916508|NCT00969410|BIOLOGICAL|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
57916509|NCT02936167|BIOLOGICAL|Ringer Lactate|
58268835|NCT05900336|DRUG|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
58268836|NCT05900336|DRUG|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
58268837|NCT06173804|OTHER|Adapted Look Ahead Lifestyle Intervention|Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
58268838|NCT00505661|DRUG|Letrozole|2.5 mg PO Once Daily
57716112|NCT01328002|DRUG|Placebo|matching placebo tablets daily
57916510|NCT02936167|BIOLOGICAL|Plasmalyte|
57916511|NCT00452062|DRUG|Dexamethasone|
57916512|NCT04451538|DIETARY_SUPPLEMENT|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoons, 440 kcal\]/day, twice a day).
57916513|NCT04451538|DIETARY_SUPPLEMENT|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
57916514|NCT06057675|DRUG|Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.
57916515|NCT06057675|DRUG|Control (1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
57916516|NCT04361942|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
57916517|NCT04361942|OTHER|Placebo|Intravenous injection of 100 ml physiological saline solution containing no cells
57916518|NCT01517646|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
58268839|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
58388176|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
58388177|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
58388178|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
57716113|NCT05735080|DRUG|INX-315|Oral administration
57716114|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
57716115|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
57716116|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
57916519|NCT02238353|DRUG|azelastine + fluticasone|
57916520|NCT02238353|DRUG|Placebo|
58268840|NCT06057714|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
58268841|NCT04093791|BEHAVIORAL|"Collective Intervention G"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
58388179|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
57716117|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
57716118|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
57716119|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
57716120|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
57716121|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
57916521|NCT03970460|DEVICE|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
57916522|NCT03970460|DEVICE|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
57916523|NCT02268474|DEVICE|532nm KTP Laser vs 595nm Pulse Dye Laser|Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
57916524|NCT01548079|DRUG|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
57916525|NCT02526147|OTHER|Cash|
57916526|NCT02526147|OTHER|Voucher|
57716122|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
58062901|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
58062902|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
58062903|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
58268842|NCT04093791|BEHAVIORAL|"Individual Intervention I"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
58388180|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
58388181|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
58388182|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
58388183|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
57916527|NCT02526147|OTHER|Food|
57916528|NCT03742921|DRUG|Istodax|Istodax
57916529|NCT02790268|PROCEDURE|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
58268843|NCT05240469|DEVICE|Automated sperm selection software|"The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters."
58268844|NCT05267223|OTHER|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
58268845|NCT06620185|BIOLOGICAL|FLUENZ|LAIV (Intranasal Influenza Vaccine)
58268846|NCT06620185|BIOLOGICAL|Influenza challenge virus|Influenza challenge virus (H3N2 strain)
58268847|NCT00061373|DRUG|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
58268848|NCT00061373|DRUG|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
58388184|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
58388185|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
58388186|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
58388187|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
58388188|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
58062904|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
58268849|NCT00061373|DRUG|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
57916530|NCT04885452|OTHER|biobank|"* Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
57916531|NCT04698642|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
58268850|NCT03667417|OTHER|Questionnaires|standardized data collection and 10-year prospective follow-up
58268851|NCT00311636|DRUG|cyclophosphamide|
57916532|NCT01466634|PROCEDURE|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
57916533|NCT01052922|OTHER|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
57916534|NCT01052922|OTHER|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
57916535|NCT01052922|OTHER|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
58268852|NCT00311636|DRUG|docetaxel|
58268853|NCT00311636|DRUG|doxorubicin hydrochloride|
58268854|NCT00311636|DRUG|epirubicin hydrochloride|
58388189|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
57916536|NCT02202005|DRUG|Nevirapine|Nevirapine 400mg PR tablet
57916537|NCT02202005|DRUG|Viramune®|Viramune® 400 mg Retardtabletten
57916538|NCT01822236|OTHER|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
57916539|NCT01822236|OTHER|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
57916540|NCT05285930|COMBINATION_PRODUCT|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
57916541|NCT05285930|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
57916542|NCT00936546|DRUG|Rituximab|Mabthera, Rituximab 1000 mg I.V.
58062905|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
58268855|NCT00311636|DRUG|fluorouracil|
58268856|NCT00311636|DRUG|methotrexate|
58268857|NCT00311636|DRUG|paclitaxel|
58268858|NCT00311636|DRUG|triptorelin|
58268859|NCT00311636|PROCEDURE|adjuvant therapy|
58268860|NCT01663194|PROCEDURE|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
58268861|NCT04973241|RADIATION|OPG & CBCT|panoramic images , cone beam computed tomography
58268862|NCT04779606|DRUG|Ocular gel|3 drops instilled in the right eye
58388190|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
58388191|NCT05802472|OTHER|Placebo|During Visit 2. 250 ml of single potable water was administered orally.
58388192|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
57716123|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
57716124|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
57716125|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
57716126|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
58062906|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
58062907|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
58062908|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
58062909|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
58062910|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
58062911|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
58276727|NCT02194764|DRUG|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
58388193|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
58388194|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
57716127|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
57716128|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
57916543|NCT05943223|DRUG|Piperacillin/tazobactam|Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)
58388195|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
58388196|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
57916544|NCT05943223|DRUG|Normal saline|Post-operative normal saline 50 mL once daily
58388197|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
58268863|NCT01474031|OTHER|Biomechanics|"* Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)"
58062912|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
58268864|NCT05110521|BEHAVIORAL|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
58268865|NCT05110521|BEHAVIORAL|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
58268866|NCT01071239|DEVICE|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
58268867|NCT01071239|DRUG|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
58268868|NCT01071239|DRUG|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
58268869|NCT01071239|DRUG|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
58268870|NCT01071239|DRUG|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
58388198|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
58388199|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
57716129|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
57716130|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
58388200|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
58062913|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
58062914|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
58268871|NCT02893904|DEVICE|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
58268872|NCT02893904|DEVICE|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
57716131|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
57916545|NCT05943223|DRUG|CefTRIAXone Injection|Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)
58062915|NCT02557633|BIOLOGICAL|Placebo|
58062916|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
58062917|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
58388201|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
58388202|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
58062918|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
58062919|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
58268873|NCT03013764|BEHAVIORAL|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
58268874|NCT03013764|BEHAVIORAL|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
58268875|NCT00631085|DRUG|gamma tocopherol|Maxi Gamma softgels 1200mg QD
58268876|NCT01298141|BIOLOGICAL|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
58268877|NCT02961062|DRUG|SAF312|
58268878|NCT02961062|DRUG|Placebo|
58276728|NCT02515084|DEVICE|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
58276729|NCT02515084|DEVICE|MRI imaging|
58388203|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
58388204|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
58388205|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
58388206|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
57716132|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
57716133|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
58268879|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
58268880|NCT04605432|DRUG|PEG-FFI|"Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher."
58268881|NCT04605432|DRUG|PEG-nonFFI|"All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse."
58268882|NCT05024981|BEHAVIORAL|Videographic feedback|Twice a week during his classic re-education sessions, the patient will be filmed for 1 minute. After transferring the video to a tablet, he will watch the video once and decide what he wants to correct. During the second viewing, he will analyse his walk, the therapist being present to provide additional information. Finally, the patient will apply his analysis while being filmed and will compare the possible differences between the 2 videos. Depending on the time available, the patient may have to repeat the recordings, analyses and exercises.
58268883|NCT05024981|BEHAVIORAL|Classic reeducation|The patient will benefit twice a day for 30 minutes from re-education sessions.
58268884|NCT00081796|DRUG|larotaxel (RPR109881, XRP9881)|
58268885|NCT00081796|DRUG|capecitabine|
58268886|NCT02290600|DEVICE|Continuous Glucose Monitor|CGM sensor calibration individualization
58388207|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
57716134|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
57716135|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
58268887|NCT00299559|DRUG|smart textiles containing menthol, camphor, cineol|application to skin
58268888|NCT02824536|DRUG|3BNC117|Intravenous Infusion of 3BNC117
58268889|NCT02824536|DRUG|10-1074|Intravenous Infusion of 10-1074
57916546|NCT05943223|DRUG|Metronidazole Injection|Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
58268890|NCT02824536|DRUG|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
57916547|NCT00775463|DRUG|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
57916548|NCT00775463|DRUG|placebo|
58268891|NCT02406300|PROCEDURE|Subarachnoid Anesthesia|
58268892|NCT02406300|PROCEDURE|PNB/GA|
58268893|NCT02406300|DRUG|ropivacaine|
58268894|NCT02406300|DRUG|sevoflurane or desflurane|
58268895|NCT02406300|DRUG|bupivacaine or levobupivacaine|
58268896|NCT00426777|DRUG|risedronate|risedronate 35mg tablet, weekly for 12 months
58268897|NCT00426777|DRUG|risedronate|35mg weekly
58268898|NCT00426777|DRUG|Control|risedronate-matched placebo weekly
57716136|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
58268899|NCT02096068|DRUG|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
58268900|NCT02096068|DRUG|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
58268901|NCT06730867|BEHAVIORAL|EMDR Therapy Protocol|The intervention involves an eight-week program that details a specific EMDR protocol and questionnaire for people living with HIV. The EMDR sessions occur once a week for eight weeks under the supervision of the investigator.
58268902|NCT03152825|PROCEDURE|PCI|percutaneous coronary intervention attempt
58268903|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
58268904|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
58268905|NCT00067769|BEHAVIORAL|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
58268906|NCT00067769|BEHAVIORAL|treatment as usual|Routine clinical care.
58268907|NCT00481767|BIOLOGICAL|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
57716137|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
57716138|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
57716139|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
58062920|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
58268908|NCT00481767|DRUG|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
58268909|NCT03600246|DEVICE|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
58268910|NCT04375813|DRUG|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
57716140|NCT01086553|DRUG|budesonide|9mg budesonide OD
57716141|NCT01086553|DRUG|budesonide|3mg budesonide TID
57716142|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
57716143|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
57716144|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
58268911|NCT04375813|DRUG|Placebos|placebo capsules visually identical to eRapa oral capsules
58268912|NCT03242187|PROCEDURE|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
58268913|NCT03242187|PROCEDURE|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
58268914|NCT00273468|DRUG|Granisetron|
58268915|NCT01589107|BEHAVIORAL|video decision aid|video decision aid
58268916|NCT05576441|PROCEDURE|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
58268917|NCT05576441|PROCEDURE|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
57716145|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
57716146|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
57716147|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
57716148|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
58268918|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
58268919|NCT06531772|DRUG|Antitubercular Agents|Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
58268920|NCT01890616|DEVICE|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
58268921|NCT06726837|OTHER|Postoperative pain - 6th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 6th hour.
58268922|NCT06726837|OTHER|Postoperative pain - 24th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 24th hour.
58268923|NCT06726837|OTHER|Postoperative pain - 48th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 48th hour.
58268924|NCT06726837|OTHER|Postoperative pain - 72nd hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 72nd hour.
58268925|NCT06726837|OTHER|Postoperative pain - 7 day|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 7 day.
58388208|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
57716149|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
57716150|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
57716151|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
58268926|NCT06619886|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R248Q|TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
58268927|NCT06730256|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion chimeric antigen receptor T cells
58268928|NCT05873335|COMBINATION_PRODUCT|Mixtures of nitrogen, air, and carbon dioxide|Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
58268929|NCT06451549|DEVICE|Syndi recommender system for mental health apps|Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
58268930|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
58268931|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
58268932|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
58268933|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
58268934|NCT00004759|DRUG|methylprednisolone|
58268935|NCT00004759|DRUG|tirilazad|
58268936|NCT02180802|BEHAVIORAL|motivational interviewing|
58268937|NCT02180802|BEHAVIORAL|motivational interviewing with parental involvement|
58268938|NCT02180802|BEHAVIORAL|Control group|
58268939|NCT01432275|DEVICE|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
58388209|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
58388210|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
58388211|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
58388212|NCT00056173|DRUG|GTI-2040|
58062921|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
58062922|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
58268940|NCT01432275|DEVICE|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
58268941|NCT01432275|DEVICE|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
58268942|NCT05795205|BEHAVIORAL|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
58268943|NCT05795205|BEHAVIORAL|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
58268944|NCT05795205|BEHAVIORAL|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
58268945|NCT02818621|DRUG|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
58268946|NCT02535234|DEVICE|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
58268947|NCT02535234|DEVICE|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
58268948|NCT00561470|DRUG|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
58268949|NCT00561470|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
58268950|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
58268951|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
58268952|NCT00322127|DRUG|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
58268953|NCT04012281|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
58388213|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
57716152|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
58062923|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
58062924|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
58062925|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
58062926|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
58268954|NCT02671734|BEHAVIORAL|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
58388214|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
58062927|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
58062928|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
58062929|NCT03020797|DRUG|Perampanel|
58388215|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
58388216|NCT06365255|OTHER|questionnaires|filling in questionnaires
58388217|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
58062930|NCT03020797|DRUG|Placebo Oral Tablet|
58062931|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
58062932|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
58062933|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
58268955|NCT04405284|OTHER|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
58268956|NCT03182634|DRUG|Fulvestrant|
58268957|NCT03182634|DRUG|Neratinib|
58062934|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
58062935|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
58062936|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
58062937|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
58062938|NCT03076411|DRUG|Pepsin|
58268958|NCT03182634|DRUG|AZD5363|
58268959|NCT03182634|DRUG|Olaparib|
57716153|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
58062939|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
58062940|NCT00219310|DRUG|Famciclovir|
58062941|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
58062942|NCT02409251|BEHAVIORAL|Education and feedback|
58062943|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
58062944|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
58062945|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
58062946|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
58062947|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
58062948|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
58062949|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
58268960|NCT03182634|DRUG|AZD6738|
58268961|NCT00877149|DRUG|telbivudine/LDT600|
58268962|NCT01764724|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
58268963|NCT03525782|BIOLOGICAL|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
58268964|NCT03525782|COMBINATION_PRODUCT|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
58268965|NCT03525782|BIOLOGICAL|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
58268966|NCT03525782|DRUG|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
58268967|NCT03525782|OTHER|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
58268968|NCT00000298|DRUG|Buprenorphine/naloxone|
58268969|NCT05069311|DRUG|Multimodal analgesia|"Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
58268970|NCT05069311|DRUG|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
58268971|NCT02882880|DEVICE|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
57916549|NCT01707225|DRUG|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
57916550|NCT04433273|DEVICE|Electrical vestibular nerve stimulation|Electrical vestibular nerve stimulation using a headset device
57916551|NCT00233870|DRUG|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
58268972|NCT06509893|DRUG|aspirin 80 mg and clopidogrel 75 mg daily|post PCI patients received these two drugs as dual antiplatelet regimen
58268973|NCT06509893|DRUG|Ticagrelor 90 MG|Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
58268974|NCT00070213|DRUG|FOLFOX regimen|
57716154|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
57916552|NCT00596778|OTHER|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
57916553|NCT03407443|OTHER|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
57916554|NCT03407443|OTHER|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
57916555|NCT06044974|DEVICE|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
57916556|NCT06044974|DRUG|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
57916557|NCT06415006|PROCEDURE|Measurement of hemodynamic parameters.|The measurement and recording of Heart Rate (HR), Systolic Arterial Blood Pressure (ABPsys), Diastolic Arterial Blood Pressure (ABPdias), Mean Arterial Blood Pressure (ABPmean), and age parameters.
57916558|NCT04466826|OTHER|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
58268975|NCT00070213|DRUG|capecitabine|
58268976|NCT00070213|DRUG|fluorouracil|
58268977|NCT00070213|DRUG|leucovorin calcium|
58268978|NCT00070213|DRUG|oxaliplatin|
58268979|NCT00070213|PROCEDURE|quality-of-life assessment|
57916559|NCT04466826|DRUG|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
58268980|NCT05207904|DRUG|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
58268981|NCT02470819|GENETIC|Genetic profiling|genetic profiling
58268982|NCT02747849|DEVICE|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
58268983|NCT06006013|BIOLOGICAL|Atezolizumab|Given IV
58268984|NCT06006013|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58268985|NCT06006013|DRUG|Cabozantinib S-malate|Given PO
57716155|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
58062950|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
58062951|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
58268986|NCT06006013|PROCEDURE|Computed Tomography|Undergo CT
58268987|NCT06006013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58268988|NCT04587401|PROCEDURE|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
58268989|NCT04587401|PROCEDURE|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
58268990|NCT04587401|PROCEDURE|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
58268991|NCT01004601|DRUG|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
58268992|NCT01004601|DRUG|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
58268993|NCT00083668|DRUG|Paliperidone ER|
58268994|NCT01473394|DRUG|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
58268995|NCT01473394|DRUG|Vilazodone|Vilazodone was supplied as tablets.
58268996|NCT06730750|DRUG|BMS-986490|Specified dose on specified days.
58268997|NCT06730750|DRUG|Bevacizumab|Specified dose on specified days.
58268998|NCT00787917|DRUG|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
58268999|NCT00787917|DRUG|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
57716156|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
57716157|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
57716158|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
57716159|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
57716160|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
57716161|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
57716162|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
57716163|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
57716164|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
57716165|NCT04857866|DRUG|Placebo|Single dose of placebo
57716166|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
57716167|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
57716168|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
58062952|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
58062953|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
58388218|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
58062954|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
58388219|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
57716169|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
57716170|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
57716171|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
57716172|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
57716173|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
57916560|NCT04466826|DEVICE|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
57916561|NCT06001931|OTHER|handgrip force and bioimpedance values in healthy Turkish children.|Demographic characteristics, calf circumference , Hand grip strength , TANITA BIA analysis
57716174|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
57716175|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
57716176|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
57716177|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
57716178|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
57716179|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
57716180|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
57716181|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
57716182|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
57716183|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
57716184|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
57716185|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
57716186|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
57716187|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
57716188|NCT02912481|PROCEDURE|posterior tibial artery|
57916562|NCT01719926|DRUG|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
57916563|NCT01767805|PROCEDURE|Standard incubator|
57916564|NCT01767805|PROCEDURE|Mini incubator|
58062955|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
58062956|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
58062957|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
57716189|NCT02912481|PROCEDURE|radial artery|
58062958|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
57716190|NCT02912481|PROCEDURE|dorsalis pedis artery|
57716191|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
57716192|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
57716193|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
58062959|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
58062960|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
58062961|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
58062962|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
58269000|NCT00787917|DRUG|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
58269001|NCT03502018|DRUG|Bupivacaine liposome|A long-acting liposomal bupivacaine
57716194|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
57916565|NCT01767805|PROCEDURE|5% oxygen|
57916566|NCT01767805|PROCEDURE|20% oxygen|
57916567|NCT06071260|DRUG|0.01% atropine eye drop|One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.
57916568|NCT00669526|BEHAVIORAL|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
57916569|NCT00669526|BEHAVIORAL|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
57916570|NCT02763787|DRUG|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
57916571|NCT02763787|DRUG|Placebo|Identical placebo
57916572|NCT02636179|OTHER|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
57916573|NCT04623970|PROCEDURE|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
57916574|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
58269002|NCT03502018|DRUG|Saline|Saline injection used as control
58269003|NCT04940715|OTHER|Passive joint mobilization|Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (\>50% of maximum therapist strength), according to patient's irritability and severity.
57716195|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
57716196|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
58269004|NCT04940715|OTHER|Mobilization with movement|Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
58269005|NCT06126094|DIETARY_SUPPLEMENT|Myrkl|The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg
58269006|NCT06126094|DIETARY_SUPPLEMENT|dextrin|The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
57716197|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
58269007|NCT04472026|BEHAVIORAL|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
58269008|NCT01477294|DRUG|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
58269009|NCT01477294|DRUG|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
58269010|NCT05425680|OTHER|Core muscle training|Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
58269011|NCT05608278|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
58269012|NCT05608278|BEHAVIORAL|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
57716198|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
57716199|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
57716200|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
57716201|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
57716202|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
57916575|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
58269013|NCT05556564|DRUG|observational study|No intervention, observational study
58269014|NCT02432391|BEHAVIORAL|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
58269015|NCT04305106|DRUG|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
58269016|NCT04305106|OTHER|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
58269017|NCT04305106|OTHER|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
58269018|NCT04326439|DRUG|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
58269019|NCT04326439|DRUG|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
58269020|NCT04326439|DRUG|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
58269021|NCT04326439|DRUG|Etoposide|150 mg/m²/dose IV Days 1-5
57716203|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
58269022|NCT04326439|DRUG|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
58269023|NCT04326439|PROCEDURE|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
58269024|NCT04326439|DRUG|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
58388220|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
58388221|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
58388222|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
58388223|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
58388224|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
58388225|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
58388226|NCT00110435|DRUG|Comparator: atorvastatin|
58269025|NCT05714475|PROCEDURE|Pancreas surgery|"Criteria~Inclusion Criteria:~* Isolated pancreatic metastases from Colorectal cancer~* Previous surgery for colorectal cancer~* Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
58269026|NCT00987402|OTHER|Plain soap and water (PSW)|Presence or absence of infection
58388227|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
58388228|NCT04625101|DRUG|Placebo|Non-active dosage form.
57716204|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
57716205|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
57916576|NCT06204874|PROCEDURE|Pulsed radiofrequency ablation|See left.
57716206|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
57916577|NCT06204874|PROCEDURE|Sham ablation|See left.
58388229|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
58388230|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
58388231|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
58388232|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
58388233|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
57916578|NCT01189084|BIOLOGICAL|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
58388234|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
58388235|NCT03442556|DRUG|Carboplatin|Given IV
58388236|NCT03442556|DRUG|Docetaxel|Given IV
58388237|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
58388238|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
57716207|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
57716208|NCT04865094|OTHER|placebo|placebo
57716209|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
57716210|NCT02970968|OTHER|Placebo|placebo oral
57716211|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
57716212|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
57716213|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
58388239|NCT03442556|DRUG|Rucaparib|Given PO
58388240|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
58388241|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
58388242|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
57916579|NCT01210118|BEHAVIORAL|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
57916580|NCT01210118|BEHAVIORAL|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
58269027|NCT00987402|OTHER|Alcohol-based hand rub (ABHR)|Presence or absence of infection
58269028|NCT00146913|DRUG|Imatinib mesylate 600mg/day|
58388243|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
58388244|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
58269029|NCT00146913|DRUG|Peg-Interféron at 90 microg/week|
58388245|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
57716214|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
58269030|NCT02484638|DRUG|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
57716215|NCT06498973|DRUG|Azacitidine|Given IV
57716216|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58269031|NCT02484638|DRUG|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
58388246|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
58388247|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
58388248|NCT01942824|BEHAVIORAL|Text Messages|
58388249|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
58388250|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
58388251|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
57716217|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
57716218|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
57716219|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
57716220|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
58062963|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
58269032|NCT00287391|DRUG|Rabeprazole|
58269033|NCT03669718|BIOLOGICAL|ISA101b|Every 3 weeks for a total of 3 times
57716221|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
57716222|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
57716223|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
57716224|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
58062964|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
58269034|NCT03669718|DRUG|Cemiplimab|Every 3 weeks for up to 24 months
58269035|NCT03669718|OTHER|Placebo|Every 3 weeks for a total of 3 times
57716225|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
57716226|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
57716227|NCT01976416|DRUG|Hydroxyurea|
57716228|NCT01976416|DRUG|Placebo|
57716229|NCT00058240|DRUG|alvocidib|Given IV
58269036|NCT06013202|OTHER|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
58269037|NCT06013202|OTHER|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
58269038|NCT01869569|DRUG|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
58388252|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
58388253|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
58388254|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
58388255|NCT00000407|BEHAVIORAL|Reading materials for control participants|
57716230|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
57716231|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
57716232|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
57716233|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
57716234|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
57716235|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
57716236|NCT05257265|OTHER|Placebo|Capsule
57716237|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
57716238|NCT02046434|DRUG|Glycerol Phenylbutyrate|
58388256|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
57716239|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
57716240|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
57716241|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
57716242|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
57716243|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
57716244|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
57716245|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
57716246|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
57716247|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
58269039|NCT01869569|DRUG|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
57716248|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
57716249|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
57716250|NCT03996928|OTHER|Exercise|
57716251|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
57716252|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
57916581|NCT00738582|DRUG|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
57716253|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
57916582|NCT00738582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
58269040|NCT01313494|DRUG|Roflumilast|Roflumilast tablets
58269041|NCT01313494|DRUG|Placebo|Placebo tablets
58388257|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
58388258|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
58388259|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
58388260|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
58388261|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
58388262|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
58388263|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
58388264|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
58388265|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
57716254|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
57716255|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
57716256|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
57716257|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
57716258|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
57716259|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
57716260|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
57716261|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
57716262|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
58269042|NCT01313494|DRUG|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
58269043|NCT00894244|DEVICE|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
58269044|NCT01683422|RADIATION|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
58269045|NCT01683422|RADIATION|Proton Radiation|
58269046|NCT00410618|PROCEDURE|cognitive assessment|
58269047|NCT00410618|PROCEDURE|magnetic resonance imaging|
58269048|NCT00410618|PROCEDURE|management of therapy complications|
58269049|NCT04028622|OTHER|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
58269050|NCT01348113|OTHER|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
58269051|NCT03978247|DIAGNOSTIC_TEST|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
58269052|NCT04888715|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
58269053|NCT04888715|DRUG|Pirfenidone|Pirfenidone
58269054|NCT04888715|DRUG|Nintedanib|Nintedanib
58269055|NCT06292793|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
57716263|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
57716264|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
57716265|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
57916583|NCT00738582|DRUG|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
58062965|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
58062966|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
58062967|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
58269056|NCT06292793|BEHAVIORAL|Cyclical Sighing|A 4-minute audio recording consisting of a 1-minute introduction to cyclical sighing followed by a 3-minute cyclical sighing practice.
58269057|NCT01085136|DRUG|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
58269058|NCT01085136|DRUG|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
58269059|NCT00328094|DRUG|continuous intravenous insulin infusion|Tight glucose control versus standard of care
58269060|NCT00674856|DRUG|naproxcinod|750mg
57916584|NCT00418626|DRUG|Nilotinib|
57716266|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
58269061|NCT02921750|DEVICE|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
58388266|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
57716267|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
57716268|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
57716269|NCT01068327|DRUG|leucovorin calcium|Given IV
57716270|NCT01068327|DRUG|fluorouracil|Given IV
57716271|NCT01068327|DRUG|nelfinavir mesylate|Given PO
57716272|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
57716273|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
57716274|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
57716275|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
57716276|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
57716277|NCT01914432|DRUG|YH16410|
57716278|NCT01914432|DRUG|Rosuvastatin|
58062968|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
58269062|NCT02921750|DEVICE|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
57716279|NCT01914432|DRUG|Telmisartan|
57716280|NCT01914432|DRUG|YH16410 placebo|
57716281|NCT01914432|DRUG|Rosuvastatin placebo|
57716282|NCT01914432|DRUG|Telmisartan placebo|
57716283|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
58269063|NCT01920256|OTHER|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
57716284|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
57716285|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
57716286|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
57716287|NCT05850871|OTHER|Conventional treatment|Conventional treatment
57716288|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
58269064|NCT01920256|OTHER|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
58388267|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
58388268|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
58388269|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
57716289|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
57716290|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
57716291|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
57716292|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
57716293|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
57716294|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
57716295|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
57716296|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
57716297|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
57716298|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
58388270|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
58269065|NCT05247892|PROCEDURE|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
58388271|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
57716299|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
58062969|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
58062970|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
58269066|NCT05247892|PROCEDURE|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
58269067|NCT06308757|DIETARY_SUPPLEMENT|Very-low-calorie ketogenic diet (VLCKD) with meal replacements|The VLCKD study arm will receive an experimental diet therapy with very-low-calorie ketogenic meal replacements (VLCKD) consisting of 5 successive phases (600 - 1500 kcal/day).
58269068|NCT06308757|DIETARY_SUPPLEMENT|Mediterranean low-calorie diet (LCD)|The Control arm LCD will receive standard Mediterranean type low-calorie diet (LCD) therapy by the most recent guidelines on MAFLD/NAFLD (1200-1500 kcal/day).
58388272|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
57716300|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
57716301|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
57716302|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
58062971|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
57716303|NCT02291627|DEVICE|MAC|direct laryngoscopy
57716304|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
57716305|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
57716306|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
57716307|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
57716308|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
58388273|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388274|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388275|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388276|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388277|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388278|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388279|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388280|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
58388281|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
58388282|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
58388283|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
58388284|NCT00192920|BEHAVIORAL|Transfusion practice|
58388285|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
58388286|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
58388287|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
58388288|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
58388289|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
58388290|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
58388291|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
58388292|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
57916585|NCT04278157|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
58388293|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
58388294|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
58388295|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
58388296|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
58388297|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
58388298|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
58388299|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
57916586|NCT04278157|BEHAVIORAL|Treatment as Usual|Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
58388300|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
58062972|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
57716309|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
57716310|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
57716311|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
57716312|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
57716313|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
57716314|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
57916587|NCT03300115|DRUG|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
57916588|NCT02777723|DRUG|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
57916589|NCT02777723|DRUG|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
58276730|NCT06408597|PROCEDURE|Nitroglycerin Infusion|"Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU."
58388301|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
57916590|NCT00900744|DRUG|Tamoxifen|20 mg daily
57916591|NCT02027220|DRUG|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
57916592|NCT02027220|DRUG|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
57916593|NCT02027220|DRUG|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
57916594|NCT02027220|DRUG|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
57916595|NCT02049164|DRUG|AR08|
58388302|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
58388303|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
58388304|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
58388305|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
58388306|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
57916596|NCT02049164|DRUG|Placebo|
57916597|NCT00074971|DRUG|Fabrazyme (agalsidase beta)|
57916598|NCT03131583|DRUG|Colchicine|Day-14\~Day16 qd
57916599|NCT03131583|DRUG|Febuxostat|Day1 and Day8 qd
57916600|NCT03131583|DRUG|SHR4640|Day3\~Day8 qd
58062973|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
58062974|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
58062975|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
57716315|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
57716316|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
57716317|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
57716318|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
57716319|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
57716320|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
57716321|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
57716322|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
58269069|NCT04045080|DEVICE|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
58269070|NCT04045080|OTHER|Training|training
57916601|NCT03790319|BEHAVIORAL|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
58062976|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
58062977|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
58062978|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
58269071|NCT04045080|OTHER|OT Training|training
58269072|NCT04217005|DEVICE|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
58269073|NCT01319240|DRUG|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
57716323|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
57716324|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
57716325|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
57716326|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
57916602|NCT03790319|BEHAVIORAL|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
57916603|NCT01990209|DRUG|Orteronel|
57916604|NCT04256577|DIAGNOSTIC_TEST|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
57916605|NCT05127629|PROCEDURE|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
58269074|NCT01319240|DRUG|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
57916606|NCT05127629|PROCEDURE|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
57916607|NCT05127629|PROCEDURE|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
58269075|NCT01319240|DRUG|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
58388307|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
58388308|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
57916608|NCT05127629|PROCEDURE|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
57916609|NCT05423886|OTHER|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
58388309|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
58388310|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
57916610|NCT00722930|DRUG|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
58269076|NCT03578146|COMBINATION_PRODUCT|PRT064445/Rivaroxaban|
58269077|NCT03578146|COMBINATION_PRODUCT|Placebo/Rivaroxaban|
58388311|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
58269078|NCT03578146|DRUG|Placebo|
58388312|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
58388313|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
57716327|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
57716328|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
57716329|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
57716330|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
57716331|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
57716332|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
57716333|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
57716334|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
57716335|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
57716336|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
57716337|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
57716338|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
57716339|NCT03943810|OTHER|No intervention|There is no intervention
58388314|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
57716340|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
57716341|NCT02420860|DRUG|Lenalidomide|Given PO
58388315|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
58388316|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
57716342|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
57716343|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
57716344|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
57716345|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
57716346|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
57716347|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
57716348|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
57716349|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
57716350|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
57716351|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
57716352|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
57716353|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
57716354|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
57716355|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
57716356|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
57716357|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
57716358|NCT02090907|DRUG|Levothyroxine|
57716359|NCT02090907|DRUG|Placebo|
57716360|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
57716361|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
57716362|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
57716363|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
57716364|NCT02422381|DRUG|MK-3475|Investigational drug.
57716365|NCT02422381|DRUG|Gemcitabine|Standard care drug.
57716366|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
57716367|NCT01507428|DRUG|Carboplatin|Given IV
57716368|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
57716369|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
57716370|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
57916611|NCT05249829|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
57916612|NCT05249829|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
58269079|NCT02621658|OTHER|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
58269080|NCT02621658|OTHER|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
58269081|NCT04885894|DRUG|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
58269082|NCT00394771|DRUG|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
58269083|NCT00394771|DRUG|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
58269084|NCT00394771|DRUG|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
58269085|NCT00919906|DEVICE|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
58269086|NCT03215719|RADIATION|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.
58388317|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
58388318|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
58388319|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
57716371|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
57716372|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
57716373|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
57716374|NCT01507428|DRUG|Paclitaxel|Given IV
57716375|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
57716376|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
57716377|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
57716378|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
57716379|NCT00004917|BIOLOGICAL|epoetin alfa|
57716380|NCT00004917|DRUG|cisplatin|
57716381|NCT00004917|RADIATION|radiation therapy|
57716382|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
57716383|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
57716384|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
57716385|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
57716386|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
57716387|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
57716388|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
57716389|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
57716390|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
57916613|NCT05249829|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
57916614|NCT02995577|OTHER|Feeding tolerant|
57916615|NCT02995577|OTHER|Feeding intolerant|
57916616|NCT02995577|OTHER|Necrotizing enterocolitis|
58388320|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
57716391|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
57716392|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
57716393|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
57716394|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
57716395|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
57716396|NCT04031885|DRUG|Abemaciclib|Administered orally
57716397|NCT04031885|DRUG|Fulvestrant|Administered IM
58388321|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
57716398|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
57916617|NCT01768117|BIOLOGICAL|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
57916618|NCT01097382|DRUG|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
57916619|NCT05764993|BIOLOGICAL|CUVITRU - Ig subcutaneous human 20%|Subcutaneous Immunoglobin Replacement Therapy, SCigR
58388322|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
58388323|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
57716399|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
57716400|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
57716401|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
57716402|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
57716403|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
57716404|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
57916620|NCT05764993|OTHER|Standard Medical Therapy|Standard Medical Therapy
57916621|NCT00002570|DRUG|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
57916622|NCT00002570|DRUG|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
57916623|NCT02619149|DRUG|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
58388324|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
58388325|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
58388326|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
57916624|NCT02619149|DRUG|Saline solution|Saline iv as placebo control
57916625|NCT02976701|DRUG|DLBS1033|
57916626|NCT02976701|DRUG|Placebo|
57916627|NCT02976701|DRUG|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
57916628|NCT06107725|DRUG|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
58388327|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
58388328|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
58388329|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
58388330|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
58388331|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
57716405|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
57716406|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
57716407|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
57716408|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
57716409|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
57716410|NCT01960231|OTHER|OGTT|
57716411|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
57716412|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
58269087|NCT03215719|RADIATION|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
58269088|NCT03215719|DRUG|Cisplatinum|Standard of care chemotherapy
58388332|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
58388333|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
57716413|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
57716414|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
57716415|NCT00075868|DRUG|octreotide acetate|
57716416|NCT00075868|OTHER|Placebo|
57916629|NCT01362660|OTHER|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
57916630|NCT01007448|DRUG|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
58269089|NCT00316862|DRUG|cisplatin|Given IV
58269090|NCT00316862|DRUG|irinotecan hydrochloride|Given IV
58269091|NCT00316862|PROCEDURE|therapeutic conventional surgery|Undergo Surgery
58269092|NCT00316862|RADIATION|radiation therapy|Undergo radiation
58269093|NCT04486469|OTHER|Physical Therapy Group|"1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
58269094|NCT01291134|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
58388334|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
58388335|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
58388336|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
57716417|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
57716418|NCT05397379|DRUG|HEC96719|Oral tablets
57716419|NCT05397379|DRUG|Placebo|Comparator
57716420|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
58269095|NCT05883059|DEVICE|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
58269096|NCT05883059|OTHER|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
58269097|NCT06730386|DRUG|AK138D1|Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
58388337|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
57716421|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
57716422|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
57716423|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
57716424|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
57716425|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
57716426|NCT00568308|DRUG|placebo|matched placebo
57716427|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
57716428|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
57716429|NCT00002181|DRUG|Cidofovir|
58062979|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
57716430|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
57716431|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
57716432|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
57716433|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
57716434|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
57716435|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
57716436|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
57716437|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
57716438|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
57716439|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
57716440|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
57716441|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
57716442|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
57716443|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
57716444|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
57916631|NCT03720743|OTHER|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
57916632|NCT00912691|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
57916633|NCT02520284|BIOLOGICAL|Andecaliximab|Andecaliximab 150 mg administered via SC injection
57916634|NCT02520284|BIOLOGICAL|Placebo|Placebo matched to andecaliximab administered via SC injection
57916635|NCT06382454|DEVICE|Assist-On Arm Robot Group|30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
58062980|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
58062981|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
58062982|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
58062983|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
58062984|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
58062985|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
57716445|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
57716446|NCT02053727|DRUG|Placebo|
57716447|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
57716448|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
57716449|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
57716450|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
57716451|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
57716452|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
57716453|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
57716454|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
57716455|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
57716456|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
58388338|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
57716457|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
57716458|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
57716459|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
57716460|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
57716461|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
57716462|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
57716463|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
57716464|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
57716465|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
57716466|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
57716467|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
57716468|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
57716469|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
57716470|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
57716471|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
57716472|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
57716473|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
57716474|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
57716475|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
57716476|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
57716477|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
58062986|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
58062987|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
58062988|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
58062989|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
58388339|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
58388340|NCT01239277|OTHER|protein|20g protein
58388341|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
58388342|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
58388343|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
57716478|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
57716479|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
57716480|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
57716481|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
57716482|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
57716483|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
57716484|NCT03384446|OTHER|Implant-specific treatment|Implant brush
57716485|NCT00265811|DRUG|Folfox|
57716486|NCT00265811|DRUG|Cetuximab|
57716487|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
57716488|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
57716489|NCT03979716|DEVICE|fMRI|fMRI examination
57716490|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
57716491|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
57716492|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
57716493|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
57716494|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
57916636|NCT06382454|OTHER|Control Group|For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
57916637|NCT02717403|BEHAVIORAL|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
57916638|NCT02717403|BEHAVIORAL|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
57716495|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
57716496|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
57716497|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
57716498|NCT02287415|DRUG|BIA 2-093|
57716499|NCT02287415|DRUG|Warfarin|
57716500|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
57716501|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
57716502|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
57716503|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
57916639|NCT02717403|BEHAVIORAL|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
58388344|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
57916640|NCT02717403|BEHAVIORAL|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
57916641|NCT01847469|BEHAVIORAL|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
57916642|NCT01847469|DRUG|Zonisamide|
57916643|NCT01847469|DRUG|Placebo|
58388345|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
58388346|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
57716504|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
57716505|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
57716506|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
57716507|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
57716508|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
57716509|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
57716510|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
57716511|NCT02422030|DRUG|Lipitor Tab. 40mg|
57716512|NCT02422030|DRUG|Trilipix 135mg|
57716513|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
58388347|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
57716514|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
57716515|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
57716516|NCT04666038|DRUG|LOXO-305|Oral LOXO-305
57716517|NCT04666038|DRUG|Idelalisib|Oral
57716518|NCT04666038|DRUG|Bendamustine|IV
58388348|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
58388349|NCT01048242|DRUG|Placebo|placebo
58388350|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
57716519|NCT04666038|DRUG|Rituximab|IV
57716520|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
57716521|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
57716522|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
57716523|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
57716524|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
57716525|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
57716526|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
57716527|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
57716528|NCT06035926|OTHER|questionnaire|questionnaire
57716529|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
57716530|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
57716531|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
57716532|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
57716533|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
57716534|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
57716535|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
57716536|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
57716537|NCT05898399|DRUG|Niraparib|Niraparib will be given orally.
57716538|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
57716539|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
57716540|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
57716541|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
57716542|NCT00355446|DRUG|Bimatoprost 0.03%|
58269098|NCT00637806|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
58269099|NCT00637806|DRUG|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
57716543|NCT04584567|DRUG|Doxycyclin|daily (100mg)
57916644|NCT06352164|OTHER|Acupuncture treatment|The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
57916645|NCT05898256|DRUG|Cadonilimab|10mg/kg administered intravenously (IV)
57916646|NCT05898256|DRUG|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
57916647|NCT05898256|DRUG|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
57916648|NCT03963531|OTHER|chemotherapy, surgery, radiotherapy, interventional radiology.|
58062990|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
57716544|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
57716545|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
57716546|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
57716547|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
57716548|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
57716549|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
58062991|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
58269100|NCT00637806|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
58269101|NCT01416155|DRUG|natalizumab|
58269102|NCT00162227|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
57716550|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
57916649|NCT03720054|BEHAVIORAL|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
57916650|NCT03720054|BEHAVIORAL|Fitbit|Fitbit Only
57916651|NCT00680680|DRUG|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
57916652|NCT01597141|BEHAVIORAL|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
57916653|NCT01597141|BEHAVIORAL|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
57916654|NCT00666523|DIETARY_SUPPLEMENT|phytalgic|3/day
58269103|NCT01329588|DRUG|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
58269104|NCT01329588|DRUG|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
58269105|NCT00000213|DRUG|Fluoxetine|
58269106|NCT06108739|DRUG|Cyclophosphamid|A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
58269107|NCT06108739|DRUG|ATG|A total of 10mg/kg ATG was administered.
58269108|NCT03098017|OTHER|Short pasta (dry)|50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
58269109|NCT03098017|OTHER|Long pasta (dry)|50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
58269110|NCT03098017|OTHER|Couscous|50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water
58269111|NCT03098017|OTHER|Glucose|50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
58269112|NCT04336813|OTHER|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
58269113|NCT06731478|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
58269114|NCT06731478|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg IV Q3W
57916655|NCT00666523|DIETARY_SUPPLEMENT|placebo|3/Day
57916656|NCT05039528|BEHAVIORAL|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
58269115|NCT06731478|DRUG|Trastuzumab|Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W
58269116|NCT06731478|DRUG|Chemotherapy|"For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered."
58269117|NCT02636556|RADIATION|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
57716551|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
57716552|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
57716553|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
57716554|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
57716555|NCT06576765|DRUG|AZD0780|Dose 1
57716556|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
57716557|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
57716558|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
57716559|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
57716560|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
57716561|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
57716562|NCT02894203|BEHAVIORAL|Mindfulness|
57716563|NCT02894203|BEHAVIORAL|Yoga|
57716564|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
57716565|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
57716566|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
57716567|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
57716568|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
57716569|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
57716570|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
58269118|NCT04650906|BEHAVIORAL|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
58269119|NCT04564924|RADIATION|DXA|Bone mineral density was examined in all cases and controls
57716571|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
57716572|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
57716573|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
58062992|NCT02736149|DRUG|ubenimex|
58269120|NCT00247988|DRUG|Weekly Taxotere with weekly carboplatin|
57716574|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
57716575|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
57716576|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
57716577|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
57716578|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
57716579|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
57716580|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
57716581|NCT00002604|DRUG|chemosensitization/potentiation therapy|
57716582|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
57916657|NCT05039528|OTHER|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
57916658|NCT02301715|DRUG|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
57916659|NCT02301715|DRUG|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
57916660|NCT03854045|OTHER|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
58269121|NCT06731426|BEHAVIORAL|CBM-TAF|CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.
57716583|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
57716584|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
57716585|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
57916661|NCT01605292|PROCEDURE|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
57916662|NCT01605292|PROCEDURE|Palpation|Manual palpation for localizing radial artery for inserting needle.
57916663|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses with Molded Mark|
57916664|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses|
57916665|NCT04513184|DRUG|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
57916666|NCT04513184|DRUG|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
57916667|NCT04062968|OTHER|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
57716586|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
57716587|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
57716588|NCT00068055|DRUG|Placebo|Normal Saline.
57716589|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
57716590|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
57716591|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
57716592|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
57716593|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
57716594|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
57716595|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
57716596|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
57716597|NCT06556368|DRUG|Aflibercept|Intravitreal injection
57716598|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
57716599|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
57916668|NCT04503343|OTHER|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
57916669|NCT02941250|DEVICE|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
57916670|NCT03200015|DRUG|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
57916671|NCT06158685|OTHER|Study Group|"Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks"
57916672|NCT06158685|OTHER|Control Group|"Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15"
58062993|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
58062994|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
57716600|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
57716601|NCT06571279|OTHER|Plant-based diet|"Participants will follow one week Western diet run-in where participants will consume a diet high in processed foods (e.g., fast food, chips, soda). Following the run-in phase, participants will consume plant-based meals and snacks for 5 weeks, which will be delivered directly to their homes or provided directly by the study team. Participants will be permitted to consume one cheat meal of up to 500kcal per week, which will all be reported to the study team."
57716602|NCT01831375|BEHAVIORAL|Speak Up|Intervention group_treatment group
57716603|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
57716604|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
57716605|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
58269122|NCT06731426|BEHAVIORAL|CBM-SMP|CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
58388351|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
58388352|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
58388353|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
58388354|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
57716606|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
57916673|NCT05812287|OTHER|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
57716607|NCT04007536|OTHER|No Intervention|No Intervention
57916674|NCT04220697|OTHER|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
57916675|NCT04220697|OTHER|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
58062995|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
58388355|NCT01098331|PROCEDURE|Radical Prostatectomy|
58388356|NCT01098331|PROCEDURE|Brachytherapy|
58388357|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
57716608|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
57716609|NCT03726112|DEVICE|Sham Specs|Sham device
57716610|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
57716611|NCT06661980|OTHER|Placebo|Normal Saline IV.
57916676|NCT04220697|OTHER|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
57916677|NCT04220697|OTHER|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
57916678|NCT06443554|PROCEDURE|Health Management Intervention Program|This study implemented a 12-week eye health management intervention program based on the Protection Motivation Theory (PMT). The intervention included eye health interventions conducted twice weekly at community health service locations.During the health management process, specialist doctors from higher-level comprehensive hospitals provided professional guidance, while community general practitioners took on a leading role. They provided personalized eye health management for patients under the guidance of the PMT theory. The intervention content included group education, individual guidance, experience sharing meetings, and traditional Chinese medicine appropriate technology, among other aspects.
57916679|NCT06443554|PROCEDURE|Standard Treatment|Each week, patients were subjected to standard treatment and follow-up procedures, including basic interventions, medication, and routine follow-up via phone or WeChat, during which general conditions were assessed.
57916680|NCT02680002|BIOLOGICAL|7.5 mcg H5N1 (stored as monobulk)|
57916681|NCT02680002|BIOLOGICAL|15 mcg H5N1 (stored as monobulk)|
57916682|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored as monobulk)|
58062996|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
58062997|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
57716612|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
58269123|NCT06018506|DRUG|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
58269124|NCT00002615|DRUG|cisplatin|
58269125|NCT00002615|DRUG|epirubicin hydrochloride|
57716613|NCT00244244|DRUG|arimoclomol|
58269126|NCT00002615|DRUG|fluorouracil|
57716614|NCT02120339|DRUG|Carvedilol|
57716615|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
57716616|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
57716617|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
58269127|NCT00002615|PROCEDURE|conventional surgery|
58269128|NCT01664832|DEVICE|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
58269129|NCT06012955|DEVICE|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
58269130|NCT06061172|OTHER|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
58269131|NCT00180427|DEVICE|ICD|
58269132|NCT01023841|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
58269133|NCT01023841|DRUG|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
58269134|NCT05706038|DRUG|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
57716618|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
58269135|NCT05159102|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
58269136|NCT05159102|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
58269137|NCT02670382|DIETARY_SUPPLEMENT|EPA|10 week supplementation
58269138|NCT02670382|DIETARY_SUPPLEMENT|DHA|10 week supplementation
58269139|NCT02670382|DIETARY_SUPPLEMENT|sunflower oil|4-week lead-in
57716619|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
57716620|NCT03747484|DRUG|Avelumab|Given IV
57716621|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
57716622|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
57716623|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
57916683|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored in vials)|
58269140|NCT03005457|BEHAVIORAL|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
57716624|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
57716625|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
57716626|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
57716627|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
57716628|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
57716629|NCT06664281|BEHAVIORAL|SIT|sprint interval training
57716630|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
58062998|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
58269141|NCT02787018|DRUG|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
58269142|NCT02787018|DRUG|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
58269143|NCT02787018|DRUG|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
58269144|NCT00476892|PROCEDURE|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
58269145|NCT01681316|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
58269146|NCT01681316|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
58269147|NCT01681316|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
58388358|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
58388359|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
57716631|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
57716632|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
57716633|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
57716634|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
57716635|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
58062999|NCT05761769|OTHER|no intervention|no intervention
58063000|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
58388360|NCT02506855|DRUG|Ropivacaine|
57716636|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
57716637|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
57716638|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
58388361|NCT02506855|OTHER|Placebo|
58388362|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
58388363|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
58388364|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
58388365|NCT03782259|OTHER|Placebo|Placebo
58388366|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
57716639|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
57716640|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
57716641|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
57716642|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
57716643|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
58388367|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
58388368|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
58388369|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
58388370|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
58388371|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
57716644|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
57916684|NCT02680002|OTHER|MF59|
57916685|NCT02680002|OTHER|MF59 (stored as monobulk)|
58063001|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
58063002|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
58063003|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
58063004|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
58063005|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
57716645|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
57716646|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
57716647|NCT03808610|DRUG|Cyclophosphamide|Given IV
57716648|NCT03808610|DRUG|Cytarabine|Given IV
57716649|NCT03808610|DRUG|Dexamethasone|Given IV or PO
57916686|NCT04208945|DRUG|Colistin|500000 units of inhaled colistin three times daily for 10 days
58269148|NCT00898599|DIETARY_SUPPLEMENT|Prebiotic|Inulin type fructooligosaccharides
58269149|NCT00898599|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
58269150|NCT02940093|OTHER|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
57716650|NCT03808610|DRUG|Methotrexate|Given IV
57716651|NCT03808610|DRUG|Nelarabine|Given IV
57716652|NCT03808610|DRUG|Pegaspargase|Given IV
57916687|NCT01202214|DRUG|1440115|
57916688|NCT01202214|DRUG|Placebo|matching placebo
57916689|NCT05559008|DRUG|Azacitidine Injection|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
57916690|NCT05559008|DRUG|Dasatinib|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
57916691|NCT05559008|DRUG|Linperlisib|Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
58063006|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
58063007|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
58063008|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
58063009|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
58269151|NCT00034944|DRUG|MK0869, aprepitant|
58269152|NCT00034944|DRUG|Comparator: placebo|
58269153|NCT00456508|DRUG|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
58269154|NCT01625689|BIOLOGICAL|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
58269155|NCT01625689|BIOLOGICAL|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
58269156|NCT00757185|DRUG|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
57716653|NCT03808610|DRUG|Prednisone|Given PO
57716654|NCT03808610|BIOLOGICAL|Rituximab|Given IV
57716655|NCT03808610|DRUG|Venetoclax|Given PO
57716656|NCT03808610|DRUG|Vincristine|Given IV
57716657|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
57916692|NCT05559008|DRUG|Tucidinostat|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
58269157|NCT00757185|DRUG|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
58269158|NCT02344797|PROCEDURE|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures \>185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
58269159|NCT00533052|BEHAVIORAL|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
57716658|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
57716659|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
57716660|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
57716661|NCT02489981|DRUG|Spiriva|60 puffs
57716662|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
57716663|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
57716664|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
57716665|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
57916693|NCT05559008|DRUG|SHR2554|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
57916694|NCT05559008|DRUG|Camrelizumab|Camrelizumab and Apatinib will be administered in T3.2 subtypes
57916695|NCT05559008|DRUG|Apatinib|Camrelizumab and Apatinib will be administered in T3.2 subtypes
57916696|NCT05125705|BIOLOGICAL|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
57916697|NCT05125705|OTHER|Saline injection|Saline injection
57916698|NCT05631431|DIETARY_SUPPLEMENT|Curalin|Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
58269160|NCT02958358|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
58388372|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
57716666|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
57916699|NCT04121195|DRUG|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
57916700|NCT04639141|COMBINATION_PRODUCT|Synbiotic|Prebiotic + Probiotic
57916701|NCT04639141|BEHAVIORAL|Gut-directed Hypnotherapy|Psychotherapy sessions
57916702|NCT01543529|DRUG|RO4917838|Single dose of RO4917838
57916703|NCT01543529|DRUG|Placebo to RO4917838|Single dose of placebo to RO4917838
57916704|NCT01543529|OTHER|Alcohol|Standard alcoholic drink
58269161|NCT02973113|BIOLOGICAL|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
58269162|NCT02973113|BIOLOGICAL|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
58388373|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
58388374|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
58269163|NCT04703361|BIOLOGICAL|Placebo NaCl|Placebo
57916705|NCT05822219|BEHAVIORAL|COVID-19 vaccine and booster training, and importance|COVID-19 vaccine and booster information training
57916706|NCT01874301|OTHER|High quantity probiotic|The intervention type is food product
57916707|NCT01874301|OTHER|Low quantity probiotic|The intervention type is food product
57916708|NCT01874301|OTHER|placebo|
57916709|NCT05807737|DEVICE|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
57916710|NCT03542773|DRUG|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
57916711|NCT04967534|BEHAVIORAL|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
58388375|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
58388376|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
58388377|NCT03391830|DRUG|Placebo|Placebo
57916712|NCT04967534|BEHAVIORAL|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
57716667|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
57916713|NCT00001032|DRUG|Zidovudine|
57916714|NCT00001032|DRUG|Zalcitabine|
58269164|NCT04703361|BIOLOGICAL|Niacin|B3 vitamin, Niacin
58269165|NCT04703361|BIOLOGICAL|Na-3-OHB|Na-3-OHB
58269166|NCT02908074|DRUG|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
57916715|NCT05727787|RADIATION|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
57916716|NCT00645047|BEHAVIORAL|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
58269167|NCT04258540|BEHAVIORAL|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
58269168|NCT04258540|BEHAVIORAL|yoga course|yoga course
58269169|NCT00002048|DRUG|Zidovudine|
58269170|NCT03760328|DEVICE|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
58269171|NCT00771264|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
58269172|NCT06267521|OTHER|Healthy Minds Program|Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.
58388378|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
58388379|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
58388380|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
58388381|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
57716668|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
57716669|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
57716670|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
57716671|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
57716672|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
57716673|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
57716674|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
57716675|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
57716676|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
57716677|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
57916717|NCT00645047|BEHAVIORAL|In-Person CBT|In-Person Provision Of Cognitive Therapy
57916718|NCT05149911|BEHAVIORAL|Life Coaching|Sessions with a professional life coach.
57916719|NCT01275131|DRUG|Insulin aspart|
57916720|NCT01275131|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
57916721|NCT03372707|DIAGNOSTIC_TEST|Cuff Leak Test|The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
57916722|NCT04685057|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo for 6 months
57916723|NCT04685057|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic for 6 months
57916724|NCT04685057|DIETARY_SUPPLEMENT|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
57916725|NCT04805190|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
57916726|NCT04805190|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
57916727|NCT00839657|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
57916728|NCT00839657|BEHAVIORAL|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
58063010|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
58388382|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
58063011|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
58388383|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
57716678|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
57716679|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
57716680|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
57716681|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
57716682|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
57716683|NCT00309998|BIOLOGICAL|bevacizumab|
57716684|NCT00309998|DRUG|vinorelbine tartrate|
57716685|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
57716686|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
57916729|NCT01070030|DRUG|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
57916730|NCT06337526|DEVICE|Apple Watch v8|Apple Watch used for data collection only
58269173|NCT06267521|OTHER|Sham Meditation Didactic Material|Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.
58269174|NCT06267521|DEVICE|Sham Stimulation in Lab|On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night
57916731|NCT02504944|DRUG|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
57916732|NCT02748720|OTHER|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
58269175|NCT06267521|DEVICE|Stimulation in Lab|Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
58269176|NCT06267521|DEVICE|MRI Scanner|Imaging protocol will include: structural T1-weighted and T2-weighted images, resting-state functional MRI, task-based functional MRI, and multi-shell diffusion weighted MRI, total scan time will be approximately 2 hours
58269177|NCT05125913|DIAGNOSTIC_TEST|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
58269178|NCT05125913|DIAGNOSTIC_TEST|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
57716687|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
58063012|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
58063013|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
58063014|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
58269179|NCT05125913|DIAGNOSTIC_TEST|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
58276731|NCT06408597|PROCEDURE|Mannitol Infusion|"Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes."
57716688|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
57716689|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
57716690|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
57716691|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
57716692|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
57716693|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
57716694|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
58063015|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
58063016|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
58269180|NCT05125913|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
58276732|NCT06408597|PROCEDURE|Fluid Regimen|"Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status."
58388384|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
58388385|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
58388386|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
58388387|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
57916733|NCT06280625|OTHER|Replacement of wheat flour by soyflour|The intervention consist in replacing a fraction of wheat flour by soyflour
58388388|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
58388389|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
58388390|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
57916734|NCT00865969|DRUG|Belinostat|
57916735|NCT00831285|DIETARY_SUPPLEMENT|food product|food product given at one of six visits
57916736|NCT02445950|BEHAVIORAL|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
57916737|NCT02445950|BEHAVIORAL|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
57916738|NCT04928001|OTHER|internet based iCBT program, Youth Thrive|iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
57916739|NCT05227105|BEHAVIORAL|Physical Activity|Physical activity will be encouraged up to an amount of 150 minutes per week.
58388391|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
57916740|NCT05227105|BEHAVIORAL|Delayed intervention|Physical activity will be encouraged at the end of the trial.
57916741|NCT03522480|DEVICE|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
57916742|NCT03522480|OTHER|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
57916743|NCT01729143|OTHER|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
57916744|NCT00978653|DRUG|allopurinol|150 mg once a day
57916745|NCT01596621|DRUG|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
57916746|NCT00495586|DRUG|Placebo|One pill to be taken every eight hours for 8 days
57916747|NCT00495586|DRUG|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
57916748|NCT00898027|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
57916749|NCT01793311|OTHER|decaffeinated coffee|contains caffeine 0.5-2 mg
57916750|NCT01793311|OTHER|regular dose coffee|contains 91.8 mg of caffeine
57916751|NCT01793311|OTHER|high dose coffee|contains 144 mg of caffeine
57916752|NCT04758689|COMBINATION_PRODUCT|Laser, exercise, and methotrexate|Laser therapy at acupuncture points, aerobic exercise, and methotrexate
57916753|NCT04758689|COMBINATION_PRODUCT|Exercise, and methotrexate|Aerobic exercise, and methotrexate
57916754|NCT04634825|BIOLOGICAL|Enoblituzumab|Anti-B7-H3 antibody
58269181|NCT05125913|DIAGNOSTIC_TEST|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
57916755|NCT04634825|BIOLOGICAL|Retifanlimab|Anti-PD-1 antibody
57916756|NCT04634825|BIOLOGICAL|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
57916757|NCT05576194|DEVICE|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
57916758|NCT05576194|DEVICE|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
57916759|NCT05576194|DRUG|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
57916760|NCT03276325|DRUG|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
57916761|NCT03276325|DRUG|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
57916762|NCT00657670|DEVICE|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
58276733|NCT04294251|DRUG|DWP450|Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
58063017|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
58269182|NCT05125913|DIAGNOSTIC_TEST|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
58269183|NCT05125913|OTHER|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
58388392|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
57916763|NCT00657670|DEVICE|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
57916764|NCT03013660|OTHER|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
57916765|NCT03076333|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
57916766|NCT01374373|BIOLOGICAL|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
57916767|NCT05037877|DIETARY_SUPPLEMENT|HUM supplement|HUM supplement - 1 capsule per day
57916768|NCT05037877|DIETARY_SUPPLEMENT|Placebo|Placebo supplement - 1 capsule per day
57916769|NCT00551941|PROCEDURE|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
57916770|NCT00551941|PROCEDURE|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
57916771|NCT05751772|OTHER|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;~2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
57916772|NCT03513588|DRUG|Placebo|tablet, 0 mg, 14 days, every 12 hours
57916773|NCT03513588|DRUG|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
58063018|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
58063019|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
58063020|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
58063021|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
58063022|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
58269184|NCT06428721|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
58269185|NCT03589963|BEHAVIORAL|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
58269186|NCT04960852|OTHER|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
58269187|NCT04377464|OTHER|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
58269188|NCT04895813|BEHAVIORAL|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
58388393|NCT02038946|DRUG|Nivolumab|
58388394|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
58388395|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
58388396|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
57716695|NCT06653894|PROCEDURE|patients undergoing hip replacement surgery|Hip surgery typically involves procedures aimed at repairing or replacing damaged hip joints to alleviate pain and restore mobility. Common types of hip surgery include total hip replacement, partial hip replacement, and hip arthroscopy. Total hip replacement involves removing the damaged joint and replacing it with an artificial implant, while partial hip replacement focuses on replacing only the damaged parts of the joint. Hip arthroscopy is a minimally invasive procedure used to diagnose and treat hip joint issues using small incisions and specialized instruments. Recovery from hip surgery can vary, but many patients experience significant improvement in pain levels and mobility with proper rehabilitation and physical therapy.
57916774|NCT03513588|DRUG|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
58063023|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
58269189|NCT05604794|COMBINATION_PRODUCT|Ketamine-Assisted Psychotherapy (KAP)|KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
58269190|NCT00741091|DEVICE|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
58269191|NCT00741091|DEVICE|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
58269192|NCT04981093|DRUG|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
58269193|NCT04981093|DRUG|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
58269194|NCT06394466|OTHER|Non Applicable|Non Applicable
58269195|NCT02506127|DEVICE|Neuronetics XPLOR system|Transcranial magnetic stimulation system
58269196|NCT02436031|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
58388397|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
57716696|NCT05770544|DRUG|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
57716697|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
57716698|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
57716699|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
57916775|NCT01442818|DRUG|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
57916776|NCT01442818|DRUG|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
57916777|NCT02621125|DIETARY_SUPPLEMENT|Fertilix|daily supplementation
57916778|NCT02621125|OTHER|Placebo|Placebo
57916779|NCT05949112|DEVICE|soft bristle toothbrush|manual toothbrushes
57916780|NCT05949112|DEVICE|mechanical toothbrush|sonic toothbrush
57916781|NCT01947985|DRUG|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
57916782|NCT01947985|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
57916783|NCT04206930|OTHER|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
57916784|NCT00552487|DRUG|synacthen|1 µg synacthen in the vein
57916785|NCT03322748|OTHER|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
57916786|NCT03322748|OTHER|Usual physical therapy|Usual physical therapy
58063024|NCT00000980|DRUG|Spiramycin|
58063025|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
58063026|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
58063027|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
58269197|NCT02436031|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
58269198|NCT06293105|OTHER|Qualitative interview, participant observation|Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
58269199|NCT03383575|DRUG|Azacitidine|Given IV or SC
58269200|NCT03383575|DRUG|Enasidenib|Given PO
58269201|NCT03383575|OTHER|Quality-of-Life Assessment|Ancillary studies
58269202|NCT05401214|DRUG|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
58269203|NCT05401214|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
57916787|NCT02299492|OTHER|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
58269204|NCT01622725|PROCEDURE|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
57916788|NCT04923074|OTHER|diffusion tensor imaging(DTI) evaluation|DTI is a new kind of MRI technique to evaluate peripheral neuropathy
57916789|NCT00611312|BEHAVIORAL|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
57916790|NCT04438577|DRUG|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
57916791|NCT03948724|BEHAVIORAL|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
58063028|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
57716700|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
58063029|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
58063030|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
58063031|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
58063032|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
58269205|NCT01622725|PROCEDURE|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
58269206|NCT05521841|PROCEDURE|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
58276734|NCT04294251|DRUG|Placebo|Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
58388398|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
58063033|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
58063034|NCT04772651|OTHER|dietary coaching|dietary coaching
58063035|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
58063036|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
57916792|NCT03948724|BEHAVIORAL|Usual Information|Patient receive usual informations
58269207|NCT05521841|PROCEDURE|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
58269208|NCT00207727|DRUG|CNTO 1275|
58269209|NCT04512313|DRUG|Rocuronium 0,3mg/kg|Rocuronium 0,3mg/kg at induction
57716701|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
57916793|NCT03568331|DRUG|Tradipitant|Oral Capsule
57916794|NCT03568331|DRUG|Placebo|Oral Capsule
57916795|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
57916796|NCT01436188|PROCEDURE|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
57916797|NCT01436188|PROCEDURE|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
57916798|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
57916799|NCT01436188|PROCEDURE|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
57916800|NCT06207331|DRUG|Dexmedetomidine 0.5 μg/kg|Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
57916801|NCT06207331|DRUG|Dexmedetomidine 1 μg/kg|Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
57916802|NCT06207331|DRUG|Saline|Participants inhale atomized 2 ml 0.9% saline.
58063037|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
58063038|NCT00672139|DRUG|Methylnaltrexone bromide|
58269210|NCT04512313|DRUG|Rocuronium 0,9mg/kg|Rocuronium 0,9mg/kg at induction
58269211|NCT00430352|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
58269212|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
58269213|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58269214|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
58063039|NCT00298285|DRUG|enoxaparin|
58388399|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
57716702|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
57716703|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
58063040|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
58063041|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
58063042|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
58063043|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
58269215|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
57716704|NCT06663579|OTHER|Fathers who not practicing kangaroo care|The control group (n=28) It consists of fathers of babies practicing Kangaroo Care with their mothers in the neonatal intensive care unit.
57916803|NCT00253994|PROCEDURE|Acupuncture|
57916804|NCT00680589|BIOLOGICAL|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
57916805|NCT01574391|DEVICE|Epidrum|Epidrum is used
57916806|NCT00665912|PROCEDURE|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
57916807|NCT00665912|PROCEDURE|Standard post-lobectomy wound care|Standard post-lobectomy wound care
57916808|NCT02678247|DEVICE|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
57916809|NCT02678247|DEVICE|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
57916810|NCT00202293|DRUG|Olanzapine|
57916811|NCT00202293|DRUG|Lithium|
57916812|NCT00202293|DRUG|Chlorpromazine|
58063044|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
58063045|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
58269216|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
58269217|NCT06343376|DRUG|Cyclophosphamide|Given IV
58269218|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
58269219|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
58269220|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
58269221|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
58269222|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58269223|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
58269224|NCT03790449|BEHAVIORAL|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
58269225|NCT03790449|BEHAVIORAL|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
58269226|NCT05297929|DRUG|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
58269227|NCT01197170|DRUG|Anastrozole|1 mg by mouth daily of a 28 day cycle.
58269228|NCT01197170|DRUG|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
58269229|NCT01197170|DRUG|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
58269230|NCT01197170|DRUG|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
58269231|NCT01197170|DRUG|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
58269232|NCT03403946|DEVICE|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
58269233|NCT03403946|DEVICE|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
58269234|NCT03403946|DEVICE|Intubation|Intubation with C-MAC PM in combination with D-Blade
58269235|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
58269236|NCT00223964|DRUG|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
57716705|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
58063046|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
58063047|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
58063048|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
58269237|NCT01046032|DRUG|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
58269238|NCT01046032|DRUG|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
58269239|NCT01124292|PROCEDURE|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
58269240|NCT01124292|DEVICE|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
58269241|NCT01510535|DRUG|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
58388400|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
58388401|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
58388402|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
58269242|NCT01510535|DRUG|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
58269243|NCT01510535|DRUG|LBSA0103|at third week LBSA0103(60mg) once in experimental group
58269244|NCT06463418|DEVICE|Ekoskeleton (Intervention)|Exoskeleton walking three times per week for 12 weeks.
58269245|NCT06463418|OTHER|Relaxation (Comparator)|Relaxation three times per week for 12 weeks.
58269246|NCT02951572|DEVICE|NIV|
58269247|NCT02594774|OTHER|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
58269248|NCT06730503|DRUG|Immune checkpoint inhibitor|Observe a situation before and after immunotherapy
58269249|NCT00055861|BIOLOGICAL|bevacizumab|Given IV
58269250|NCT00055861|DRUG|docetaxel|Given IV
58269251|NCT00055861|OTHER|laboratory biomarker analysis|Correlative studies
58269252|NCT00955981|DRUG|RDEA594|Uricosuric agent for the treatment of gout
58269253|NCT00955981|DRUG|Placebo|Matching placebo
58269254|NCT02870127|OTHER|blood sample|
58269255|NCT05171244|BEHAVIORAL|virtual reality training|training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care
58388403|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
58388404|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
58388405|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
58388406|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
58063049|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
58269256|NCT05171244|BEHAVIORAL|usual care|usual program of interventions in usual care
58388407|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
58388408|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
58388409|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
58388410|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
58388411|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
58388412|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
58388413|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
58269257|NCT00651534|DRUG|Ronacaleret|
58269258|NCT05532176|OTHER|Posture standards|Dynamic and static Postural measurements according to four types of tests
58269259|NCT01935700|DRUG|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
58269260|NCT06320041|DRUG|Low dose oxelidine group|Analgesic dose
58269261|NCT06320041|DRUG|High dose oxelidine group|Analgesic dose
58269262|NCT06320041|DRUG|Hydromorphone group|Analgesic dose
58269263|NCT03334318|OTHER|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269264|NCT03334318|OTHER|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269265|NCT03334318|OTHER|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269266|NCT03334318|OTHER|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
57716706|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
57716707|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
58388414|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
58388415|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
58388416|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
58388417|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
58388418|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
57716708|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
57716709|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
57716710|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
57716711|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
57716712|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
58063050|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
58269267|NCT03334318|OTHER|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269268|NCT03334318|OTHER|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58388419|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
58388420|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
58388421|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
58388422|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
57716713|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
57716714|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
57716715|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
57716716|NCT01383681|OTHER|No treatment|There was no treatment in this study.
57716717|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
57916813|NCT01140711|PROCEDURE|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
58269269|NCT03334318|OTHER|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269270|NCT03334318|OTHER|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269271|NCT03334318|OTHER|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
58269272|NCT03334318|DRUG|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
58269273|NCT03334318|DRUG|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
57916814|NCT05279001|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
58269274|NCT05029193|BEHAVIORAL|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
58269275|NCT03039491|BIOLOGICAL|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
58269276|NCT03039491|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
58269277|NCT01700738|PROCEDURE|gastric ring surgery|
58269278|NCT01700738|OTHER|nutritional help|
58269279|NCT02293759|PROCEDURE|HoLEP|Holmium laser enucleation of the prsotate
58269280|NCT02293759|PROCEDURE|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
58269281|NCT01084395|BEHAVIORAL|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
58269282|NCT01084395|BEHAVIORAL|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
57916815|NCT02270515|OTHER|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
58269283|NCT01084395|OTHER|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
58269284|NCT01084395|OTHER|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
58269285|NCT01863498|OTHER|Epidural|Patients will have an epidural for pain control
58269286|NCT01863498|OTHER|PCA|Patients will have PCA for pain control
57916816|NCT04871854|DRUG|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
58388423|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
58388424|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
58388425|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
58388426|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
58388427|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
58388428|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
58388429|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
58388430|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
58388431|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
58063051|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
58063052|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
58063053|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
58063054|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
58063055|NCT00000970|DRUG|Foscarnet sodium|
58063056|NCT00000970|DRUG|Ganciclovir|
58063057|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
58063058|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
58063059|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
58063060|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
58063061|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
58063062|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
58063063|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
58063064|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
58063065|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
57716718|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
58063066|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
58063067|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
58063068|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
58388432|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
58388433|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
58388434|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
57916817|NCT04871854|DRUG|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
58063069|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
58269287|NCT06505551|BIOLOGICAL|SCG142|Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
58269288|NCT06505551|DRUG|Cyclophosphamide|for 3 consecutive days
58269289|NCT06505551|DRUG|Fludarabine|for 3 consecutive days
58269290|NCT05363163|DEVICE|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
58269291|NCT06375096|OTHER|evaluate bone mineral density|observation effect of graves' in bone mineral density in children
58269292|NCT04872556|DEVICE|Laser acupuncture device|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
58269293|NCT04872556|DEVICE|Pseudo-laser acupuncture|The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
58269294|NCT05646758|DRUG|TQB2934 injection|TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
58269295|NCT02716493|BEHAVIORAL|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
57716719|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
57716720|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
57916818|NCT02309255|OTHER|no intervention|
57916819|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
57916820|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
57916821|NCT01689337|DRUG|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
57916822|NCT04991792|OTHER|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
57916823|NCT04991792|OTHER|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
57916824|NCT04991792|OTHER|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
57916825|NCT02080741|OTHER|Blood sample of 12 ml|
57916826|NCT05742022|DRUG|"Phospholipovit"|500 mg orally 2 times a day, for 12 weeks
57916827|NCT05742022|DRUG|Placebo|500 mg orally 2 times a day, for 12 weeks
58063070|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
58063071|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
58063072|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
58063073|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
58063074|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
58063075|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
58269296|NCT05008809|DRUG|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
58269297|NCT05008809|DRUG|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
58269298|NCT05008809|DRUG|FOLFIRI|Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.
58269299|NCT05008809|DRUG|CAPOX|Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
58269300|NCT01859052|OTHER|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
58269301|NCT01859052|OTHER|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
58269302|NCT01859052|OTHER|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
58269303|NCT06037525|DEVICE|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
58269304|NCT04170907|OTHER|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
58269305|NCT05481918|PROCEDURE|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
58269306|NCT05481918|PROCEDURE|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
58269307|NCT04858594|OTHER|Planned Chemotherapy|standard oncologic supportive care including antibiotic prophylaxis
58269308|NCT00937248|DEVICE|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
58269309|NCT00937248|DEVICE|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
58269310|NCT06726902|DEVICE|GBT and SI with erythritol powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy~   * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system.~  * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only."
58269311|NCT06726902|OTHER|GBT and SI with glycine powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder.~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
58388435|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
58388436|NCT03687242|DRUG|SPR001|Open label SPR001
58388437|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
58388438|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
58388439|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
58388440|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
58388441|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
57716721|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
57716722|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
57716723|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
57716724|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
57716725|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
57916828|NCT05049954|OTHER|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
58388442|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
58063076|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
58063077|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
58063078|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
58388443|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
58388444|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
58388445|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
58388446|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
58388447|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
58388448|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
58388449|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
58388450|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
58388451|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
58388452|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
58388453|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
58388454|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
58388455|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
58388456|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
58063079|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
57916829|NCT05049954|OTHER|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
57916830|NCT00411346|PROCEDURE|Nurse-led telemonitoring|
57916831|NCT04256629|DRUG|Verinurad|Randomized subjects will receive oral dose of verinurad
57916832|NCT04256629|DRUG|Placebo|Randomized subjects will receive oral dose of placebo
57916833|NCT04256629|DRUG|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
57916834|NCT00182299|PROCEDURE|porcine small intestine submucosa (SIS)|
58063080|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
58063081|NCT02192190|OTHER|Placebo- oral|Administered orally
58388457|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
58388458|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
58388459|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
58388460|NCT02342782|DRUG|Carmustine|Given IV
58388461|NCT02342782|DRUG|Etoposide|Given IV
58388462|NCT02342782|DRUG|Cytarabine|Given IV
57916835|NCT00334035|DRUG|Quetiapine|
57916836|NCT02831803|DIETARY_SUPPLEMENT|Walnuts|28 gm/day in single-serve package
57916837|NCT02831803|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
57916838|NCT03991819|DRUG|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
58063082|NCT02192190|OTHER|Placebo - SC|Administered SC
58388463|NCT02342782|DRUG|Melphalan|Given IV
58063083|NCT02192190|DRUG|Celecoxib|Administered orally
58063084|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
58063085|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
58388464|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
58388465|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
58388466|NCT02342782|OTHER|Pharmacological Study|Correlative studies
58388467|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
58388468|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
58269312|NCT06726902|OTHER|GBT and SI with trehalose powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
57716726|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
58269313|NCT06726902|OTHER|SRP and SI|conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed
58269314|NCT05068492|DIAGNOSTIC_TEST|CT|enhanced CT with standard procedure
58269315|NCT05068492|DIAGNOSTIC_TEST|MRI|enhanced MRI with standard procedure
58269316|NCT05068492|DIAGNOSTIC_TEST|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
58269317|NCT05068492|DIAGNOSTIC_TEST|Ultrasound|Digestive ultrasound with standard procedure
57716727|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
57716728|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
58269318|NCT03457805|DEVICE|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
58269319|NCT06625593|DRUG|BG-C137|Administered intravenously
58269320|NCT04268654|PROCEDURE|Preoperative Arterial Embolization|"PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized."
58269321|NCT04962828|OTHER|Vocabulary based intervention- Non Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP
58269322|NCT04962828|OTHER|Vocabulary based intervention - Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
58269323|NCT03603977|DRUG|Lpv/r+3TC|It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
58269324|NCT04502238|OTHER|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
57716729|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
58269325|NCT02457832|BEHAVIORAL|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
58269326|NCT02457832|BEHAVIORAL|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
58269327|NCT02352987|DRUG|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
58388469|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
57716730|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
57716731|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
58388470|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
58269328|NCT02352987|DRUG|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
58388471|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
58269329|NCT03570554|DRUG|Naproxen Sodium (Aleve, BAY117031)|660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
58269330|NCT03570554|DRUG|Acetaminophen ER|3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
58269331|NCT03570554|DRUG|Celecoxib|200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
58269332|NCT03570554|DRUG|Placebo|Over-encapsulation capsule, 4 days, oral (Treatment D)
58269333|NCT06342583|OTHER|Advanced social relations training with technical device|15 participants from the experimental group will undergo a first part in which they will be guided through social stories to construct an appropriate conversation repertoire. In the first phase the participants will see 8 social stories with scenes from everyday life and after learning the correct mode of interaction and communication they will be asked to interact in the group by playing the roles previously seen in the social stories. These will be shown on a technological device. Participants will have the opportunity to choose the correct mode of interaction by selecting it directly on the technological device. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media. Slides will be shown to explain risks and correct use and the operator will show on the technological device (Smartphone) all the practical steps to be taken (e.g. privacy settings).
58276735|NCT05087121|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
57916839|NCT03991819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
57916840|NCT02823366|DRUG|Fenofibrate|
57916841|NCT02823366|DRUG|UDCA|
57916842|NCT01614197|DRUG|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
57916843|NCT01614197|DRUG|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
57916844|NCT01614197|DRUG|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
58063086|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
58063087|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
58388472|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
58388473|NCT01059045|OTHER|Control|No intervention
58388474|NCT00407615|DEVICE|Flex Pad/Static Magnet|
58388475|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
58388476|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
58388477|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
58388478|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
58388479|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
58063088|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
57716732|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
58063089|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
58063090|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
58063091|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
58063092|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
58063093|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
58063094|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
58063095|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
58063096|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
58063097|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
58063098|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
58063099|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
58063100|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
58063101|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
58063102|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
58063103|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
58269334|NCT06342583|OTHER|Advanced social relations training without technical device|15 participants from the control group will undergo a first part in which they will be guided through social stories to build an appropriate conversation repertoire. In the first phase, the participants will see eight social stories illustrating scenes from everyday life and, after learning the correct modes of interaction and communication, they will be invited to interact in the group by playing the roles previously seen in the social stories. These will be shown in traditional mode (flashcards). Participants will have the opportunity to choose the correct mode of interaction by touching the card showing the appropriate mode. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media (facebook, instagram, TikTok, Whatsapp, YouTube). The trainer will show images on paper related to risks and correct use of social media.
58269335|NCT05021458|OTHER|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
58269336|NCT05021458|OTHER|SNAG|: Ten patients will be treated with SNAGs
58269337|NCT00525902|DRUG|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
58269338|NCT01040936|DRUG|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
58269339|NCT01040936|DRUG|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
58063104|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
58063105|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
58269340|NCT04585620|DRUG|Onabotulinum Toxin A|Series of subcutaneous injections
58269341|NCT04585620|DRUG|Normal saline|Series of subcutaneous injections
58269342|NCT02271399|DRUG|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
58269343|NCT02271399|DRUG|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
58269344|NCT04748172|BIOLOGICAL|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
58269345|NCT04748172|DIAGNOSTIC_TEST|AMH sampling|Blood sample for AMH on recruitment and after three months
58269346|NCT04748172|DIAGNOSTIC_TEST|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
58063106|NCT00391820|DRUG|TD-5108|
58063107|NCT00000529|DRUG|tamoxifen|
58063108|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
58063109|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
58063110|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
58063111|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
58063112|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
58269347|NCT00782600|DRUG|suspension IR|50 mg IR suspension once daily for one day
58269348|NCT00782600|DRUG|CR 1|50 mg shorter release CR once daily for one day
58269349|NCT00782600|DRUG|CR 2|50 mg medium release CR once daily for one day
58269350|NCT00782600|DRUG|CR 3|longer release SR formulation once daily for one day
58269351|NCT05718323|DRUG|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
58269352|NCT01214252|DEVICE|Permacol Surgical Implant|Permacol Surgical Implant
58269353|NCT03150394|DIETARY_SUPPLEMENT|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
58269354|NCT03150394|OTHER|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
58269355|NCT02720900|DIETARY_SUPPLEMENT|B-GOS|1.8 g/day for 6 weeks
58269356|NCT02720900|DIETARY_SUPPLEMENT|Maltodextrin|1.8 g/day for 6 weeks
58269357|NCT05442606|OTHER|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
58269358|NCT05442606|OTHER|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
58269359|NCT05442606|OTHER|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
58269360|NCT05481268|OTHER|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
57716733|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
58063113|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
58063114|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
58063115|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
58063116|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
58063117|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
58063118|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
58063119|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
58063120|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
57716734|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
58063121|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
58063122|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
58063123|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
58269361|NCT05481268|OTHER|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
58269362|NCT05481268|OTHER|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
58269363|NCT06529172|OTHER|Resistance training|RG performed RT with an elastic band (yellow, force of 9-11 pounds when stretched twice the original length). They performed eight movements. Each movement was performed for 3-5 sets at 8 times/sets with 30 s of rest between groups. The movements included upright rows, reverse curls, standing shoulder rotations, neck-elbow extensions, elbow bends, downward lunges, standing leg lifts, side lifts and standing back kicks. All participants completed the RT movements according to the regular rhythm (1-2-1) provided by the experimenter, which ensured that all participants had similar movements completion rates.
58388480|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
57716735|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
58063124|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
58063125|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
58063126|NCT01326481|DRUG|TRC105|IV
58063127|NCT01326481|DRUG|Capecitabine|oral
57716736|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
58063128|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
58063129|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
58063130|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
58063131|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
58388481|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
58388482|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
57716737|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
57716738|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
57916845|NCT01614197|DRUG|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
57916846|NCT01614197|DRUG|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
58388483|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
58269364|NCT06529172|OTHER|Yijinjing|YG performed 12 movements . These movements included extending the hands upwards and slowly lowering them; extending the torso by stretching the hands straight up and bending the body to the left or right; squatting with the hands on the knees and standing up slowly; bending the body to the left or right side, extending the arms and waist; getting down on the knees, leaning forward, extending the hands forward and slowly pulling them back; bending forward, placing the hands around the knees and standing up slowly; placing the hands on the hips; and leaning back to stretch the back and waist.
58388484|NCT02082444|OTHER|Skipping lunch|
58388485|NCT06407453|OTHER|control|There will be no interference ergonomics training
58388486|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
58388487|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
58388488|NCT00003923|DRUG|porfimer sodium|
58388489|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
58388490|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
58388491|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
58388492|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
58388493|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
58388494|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
58388495|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
57716739|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
57716740|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
57916847|NCT01614197|DRUG|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age"
58063132|NCT03820518|DRUG|Calcitriol|
58388496|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
58269365|NCT06529172|OTHER|Baduanjing|BG performed eight movements . These movements included holding the hands straight up, slowly bringing the hands down and turning the waist while in a standing position; bending the body to the left or right side and extending the arms; extending one hand straight up, placing the other hand on the waist, then switching arms and repeating the movement; tilting the head back and looking back while stretching the neck and back; squatting the body, swinging the head and hips from side to side and moving the spine and waist; bending the body forward, touching the hands to the toes and standing up slowly; making fists with the hands and moving the arms and shoulders; and gently bouncing the body to relax the whole body in a standing position.
58269366|NCT06529172|OTHER|Control|The CG group maintained their original lifestyle without engaging in regular exercise
58269367|NCT05547061|DRUG|Lu-177-DGUL|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
58269368|NCT05547061|DRUG|Ga-68-NGUL|Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
58269369|NCT05344690|GENETIC|SLMAP and EPO genetic polymorphism|Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
58269370|NCT03906292|DRUG|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
58269371|NCT03906292|DRUG|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
58269372|NCT03906292|DRUG|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
58269373|NCT03906292|DRUG|Asciminib|Asciminib 80 mg QD Monotherapy
58269374|NCT06517173|DRUG|Y-3 for injection|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
58269375|NCT06517173|DRUG|Placebo control group|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
58269376|NCT02713854|PROCEDURE|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
58269377|NCT01668953|OTHER|Platelet Rich Plasma (PRP) Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
58269378|NCT01668953|OTHER|Whole Blood Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
58269379|NCT01668953|OTHER|Dry Needle Fenestration|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
58269380|NCT01668953|OTHER|Sham Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
58269381|NCT02935582|DRUG|Enstilar® aerosol foam|Treatment according to local labelling
58269382|NCT02935582|DRUG|Other topical|Treatment according to local practise
57916848|NCT06016673|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
58269383|NCT03782974|DIETARY_SUPPLEMENT|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
58388497|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
57916849|NCT05325580|DRUG|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
57916850|NCT04984954|DRUG|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
57916851|NCT01798121|BIOLOGICAL|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
57916852|NCT01798121|BIOLOGICAL|Reference standard|Response of reference standard material compared to Aplisol@.
58269384|NCT06011304|DRUG|[18F]Florastamin Injection|"The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection."
58269385|NCT02470403|DRUG|LIK066|LIK066 25 mg tablets
58269386|NCT02470403|DRUG|Placebo|Matching placebo tablets
58388498|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
57916853|NCT04141969|DIETARY_SUPPLEMENT|RLP|RLP nutraceutical
58269387|NCT04840459|BIOLOGICAL|BAMLANIVIMAB|n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
58269388|NCT04840459|BIOLOGICAL|CASIRIVIMAB|CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
58269389|NCT04840459|BIOLOGICAL|IMDEVIMAB|IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
58269390|NCT04655144|DRUG|Dexamethasone|Dexamethasone delivered to the uterine arterial bed, prior to embolization.
58269391|NCT04655144|DRUG|Saline|Saline delivered to the uterine arterial bed, prior to embolization.
58269392|NCT03042754|DIAGNOSTIC_TEST|XpertMTB/RIF|
58269393|NCT00189319|DRUG|Flecainide controlled release|
58269394|NCT04508114|BEHAVIORAL|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
58269395|NCT02962323|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
58388499|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
58388500|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
58388501|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
58388502|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
58388503|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
58388504|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
57916854|NCT04141969|OTHER|Placebo|Inert brown powder
57916855|NCT00003025|BIOLOGICAL|vitespen|
57916856|NCT02077569|DRUG|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
57916857|NCT06414694|PROCEDURE|Direct Oral Challenge|Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose
58063133|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
58269396|NCT02962323|DRUG|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
58269397|NCT00079872|DRUG|Pemetrexed|
58269398|NCT03589118|OTHER|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
58269399|NCT05099107|DRUG|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
58269400|NCT05099107|DRUG|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
58269401|NCT04568291|OTHER|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
58269402|NCT04568291|OTHER|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
58269403|NCT02368743|DRUG|mesalazine|
57916858|NCT01809002|BIOLOGICAL|Processed Nerve Allograft (human)|
57916859|NCT01809002|DEVICE|Collagen Nerve Cuff|Bovine collagen based nerve cuff
58063134|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
58269404|NCT01072513|OTHER|Semen analysis|Semen analysis before and after proton radiation therapy.
58269405|NCT03437876|OTHER|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
58269406|NCT02147522|BEHAVIORAL|Self-care management|AHH behavioral intervention is provided by promotoras
58269407|NCT03534115|DIETARY_SUPPLEMENT|NAC|solution containing NAC
58269408|NCT03534115|DIETARY_SUPPLEMENT|Placebo|Placebo
58269409|NCT04936659|OTHER|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
58269410|NCT02201095|DEVICE|Forced air warming|
58269411|NCT02201095|DEVICE|Conduction warming mattress|
58269412|NCT02698644|DRUG|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
58269413|NCT05100498|DEVICE|Web-based oncofertility support tool|The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
58269414|NCT04205461|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
58269415|NCT05051800|BEHAVIORAL|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
58269416|NCT01425567|DRUG|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
58269417|NCT03764228|BIOLOGICAL|hAECs|Human amniotic epithelial cells（hAECs）
58269418|NCT05117398|DRUG|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
58388505|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
58388506|NCT01823198|DRUG|Busulfan|Given IV
58388507|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
58388508|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
58388509|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
58388510|NCT01823198|OTHER|Pharmacological Study|Correlative studies
57916860|NCT02913417|DEVICE|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
58269419|NCT05117398|DRUG|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
58269420|NCT00718796|OTHER|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
58269421|NCT00718796|OTHER|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
58269422|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
58269423|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
58388511|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
58388512|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
58388513|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
57916861|NCT02913417|DRUG|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
57916862|NCT02913417|DRUG|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
58063135|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
58063136|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
58388514|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
58388515|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
58063137|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
58063138|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
58063139|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
58388516|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
58269424|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
58269425|NCT03356119|DEVICE|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
58063140|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
58063141|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
58063142|NCT01662752|DRUG|Indocyanine green|Please see arm description
58063143|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
58269426|NCT01706575|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
58269427|NCT01706575|DRUG|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
58269428|NCT04982016|OTHER|crystal therapy|Infusion of 250ml crystal solution before anesthesia induction
58269429|NCT04982016|OTHER|colloid therapy|Infusion of 250ml colloid solution before anesthesia induction
58388517|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
58388518|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
58388519|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
58388520|NCT02173639|DRUG|BI 1356|
58388521|NCT02173639|DRUG|Metformin|
58388522|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
58388523|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
58388524|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
58388525|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
58388526|NCT06094244|OTHER|No drugs|No drugs
58388527|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
58388528|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
58063144|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
58269430|NCT01619020|DIETARY_SUPPLEMENT|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
58269431|NCT00073892|DRUG|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
58269432|NCT02645552|DRUG|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
58269433|NCT02645552|OTHER|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
58269434|NCT05405660|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
58269435|NCT05405660|DRUG|Matching Placebo|Subcutaneous Administration
58269436|NCT06408311|COMBINATION_PRODUCT|ENC-201-CED hPI|macro-encapsulated human primary islets
58269437|NCT00088959|DRUG|erlotinib hydrochloride|Given orally
58269438|NCT00088959|DRUG|celecoxib|Given orally
58388529|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
58388530|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
58388531|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
58388532|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
58388533|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
58388534|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
58388535|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
58388536|NCT02816268|OTHER|Pulmonary vein isolation|
58063145|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
58269439|NCT00088959|OTHER|laboratory biomarker analysis|Correlative studies
58269440|NCT03477994|DRUG|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
58269441|NCT03477994|DRUG|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
58269442|NCT01676506|DRUG|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
58269443|NCT01676506|PROCEDURE|Ranibizumab Injection|
58388537|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
58388538|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
58388539|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
58388540|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
58388541|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
58388542|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
58388543|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
58388544|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
58388545|NCT01441947|DRUG|Cabozantinib|Part of combination arm
58388546|NCT01441947|DRUG|Fulvestrant|part of combination arm
58388547|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
58388548|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
57716741|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
57916863|NCT03257020|DIAGNOSTIC_TEST|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
58269444|NCT03650725|OTHER|Mandatory Split bowel preparation|Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
58269445|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
58388549|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
58388550|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
58388551|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
58063146|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
58063147|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
58269446|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
58269447|NCT00924391|DIETARY_SUPPLEMENT|phytosterol enhanced soy based beverage|
58269448|NCT00924391|DIETARY_SUPPLEMENT|1% milk|
58388552|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
57716742|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
58063148|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
58269449|NCT01886781|DRUG|Lactobacillus plantarum 299v|two capsules of 5 X 10 \^9 c.f.u each
58269450|NCT01886781|DRUG|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
58269451|NCT01886781|OTHER|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
58269452|NCT01886781|OTHER|Wash - out period|Wash - out period following treatment phase of eight weeks
58269453|NCT01591551|DRUG|Natalizumab (Tysabri)|300 mg IV every 4 weeks
58388553|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
58388554|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
58388555|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
57916864|NCT05493241|BEHAVIORAL|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
58388556|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
58388557|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
57716743|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
57716744|NCT00059904|BIOLOGICAL|aldesleukin|
57716745|NCT00059904|BIOLOGICAL|rituximab|
57716746|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
57716747|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
57716748|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
57716749|NCT00188526|DEVICE|lung biopsy|
58269454|NCT03442166|RADIATION|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
58269455|NCT03442166|RADIATION|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
58269456|NCT02223819|DRUG|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
58388558|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
58388559|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
58388560|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
58388561|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
58388562|NCT00282633|DEVICE|Dermabond|
58388563|NCT00140179|DRUG|valnoctamide|
58388564|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
58388565|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
57716750|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
57716751|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
57716752|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
58063149|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
57716753|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
58388566|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
58388567|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
58388568|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
58388569|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
58388570|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
58388571|NCT00000870|DRUG|Indinavir sulfate|
58388572|NCT00000870|DRUG|Lamivudine|
58388573|NCT00000870|DRUG|Stavudine|
58388574|NCT00000870|DRUG|Zidovudine|
58388575|NCT00000870|DRUG|Didanosine|
58388576|NCT00000870|DRUG|Aldesleukin|
58269457|NCT03482791|RADIATION|Proton beam therapy|"* The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used."
58269458|NCT03482791|OTHER|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
58388577|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
58388578|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
58388579|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
57716754|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
57916865|NCT05493241|BEHAVIORAL|Attention control|An attention control (AC) group will be used to control for the social interaction and educational aspects of ACTIVaTE. The AC arm will consist of 6 weekly one-hour VVC-delivered sessions including friendly social conversation plus education on remaining active within the physical, cognitive, and social domains during older adulthood. During each session, the interventionist will review a relevant handout or other educational materials with the participant. AC interventionists will not be trained in the ACTIVaTE intervention, and the investigators will assess whether any key features of ACTIVaTE (activity monitoring/planning, values exploration, problem-solving) are incidentally incorporated into this arm during fidelity assessment.
58269459|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
58269460|NCT06598371|DRUG|Cyclophosphamide|Given by IV
58269461|NCT06598371|DRUG|Fludarabine|Given by IV
58269462|NCT06598371|DRUG|KSQ-004EX|Given by IV
58269463|NCT06598371|DRUG|Interleukin-2|Given by IV
58269464|NCT03896672|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
58269465|NCT03458923|DRUG|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
58388580|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
58388581|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
58388582|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
58388583|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
58388584|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
58388585|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
57716755|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
57716756|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
57716757|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
57716758|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
57716759|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
57716760|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
57716761|NCT02139163|OTHER|Cohort Study|
58269466|NCT03458923|DRUG|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
58063150|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
58063151|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
58269467|NCT06027502|BEHAVIORAL|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
58269468|NCT06181630|DIAGNOSTIC_TEST|Breast milk, plasma, and blood samples|Although this study is non- interventional regarding treatment with ozanimod, the study is considered interventional due to the collection of breast milk and plasma from the lactating women and blood samples from their breastfed infants and the additional diagnostic and monitoring procedures required for the study.
58269469|NCT03860116|BEHAVIORAL|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
58269470|NCT03860116|BEHAVIORAL|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
58063152|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
58063153|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
58063154|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
58063155|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
58063156|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
58269471|NCT03025568|OTHER|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
58269472|NCT03025568|OTHER|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
58269473|NCT03824821|OTHER|No intervention|No intervention
58063157|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
57716762|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
57716763|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
57716764|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
57716765|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
57716766|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
57716767|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
58063158|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
58269474|NCT00100191|PROCEDURE|uterine artery embolization|
58269475|NCT00100191|PROCEDURE|hysterectomy|
58269476|NCT02938624|DRUG|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
57716768|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
57716769|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
58269477|NCT02938624|DRUG|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
58269478|NCT02938624|DRUG|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
58269479|NCT02938624|DRUG|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
58269480|NCT02938624|PROCEDURE|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
58269481|NCT01007292|DRUG|YM155|intravenous infusion
58269482|NCT01007292|BIOLOGICAL|Rituximab|intravenous infusion
58269483|NCT03376191|DRUG|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
58269484|NCT05846217|DEVICE|Multiwave Locked System|Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
58269485|NCT03870529|DRUG|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
57716770|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
57716771|NCT00295672|DRUG|Vinorelbine|
57716772|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
57716773|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
57916866|NCT04987437|DEVICE|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
57916867|NCT01729325|BEHAVIORAL|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
58269486|NCT03870529|PROCEDURE|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
58269487|NCT02453854|BEHAVIORAL|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
58269488|NCT00693602|DRUG|Erwinase|Chemotherapy
58269489|NCT00975858|PROCEDURE|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
58269490|NCT05409430|DEVICE|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
58269491|NCT00583375|DEVICE|Augment® Bone Graft|Augment® Bone Graft
58269492|NCT00583375|PROCEDURE|Standard of Care|Autologous Bone Graft
58269493|NCT03847415|DIAGNOSTIC_TEST|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
58269494|NCT05365269|BEHAVIORAL|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
58269495|NCT04064541|OTHER|Virtual Visit|Virtual Visit
57716774|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
57716775|NCT01064921|DRUG|cisplatin|Given IV
57716776|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
57716777|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
58269496|NCT03121924|PROCEDURE|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
58269497|NCT00035295|DRUG|MK0869, aprepitant|
58269498|NCT00035295|DRUG|Comparator: placebo|
57716778|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
57716779|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
57716780|NCT02233049|DRUG|Erlotinib|
57716781|NCT02233049|DRUG|Everolimus|
57716782|NCT02233049|DRUG|Dasatinib|
57716783|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
57716784|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
57716785|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
58269499|NCT01538992|DEVICE|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
58269500|NCT00776802|DRUG|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
58269501|NCT00776802|DRUG|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
58269502|NCT02036671|DEVICE|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
58269503|NCT01552148|OTHER|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
58269504|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
58269505|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
58269506|NCT02753387|DRUG|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
58269507|NCT02753387|DEVICE|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
58269508|NCT05805085|DEVICE|Lens A|Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
58269509|NCT05805085|DEVICE|Lens B|Silicone Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
58269510|NCT00805077|PROCEDURE|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
58269511|NCT00805077|OTHER|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
57716786|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
57716787|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
57716788|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
57716789|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
57716790|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
57716791|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
57716792|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
57716793|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
58063159|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
57716794|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
57716795|NCT01922596|DRUG|Ropivacaine|
57716796|NCT01922596|DRUG|Placebo|
57716797|NCT03569644|OTHER|qualitative study|Interviews
58269512|NCT04826133|DRUG|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
57716798|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
57716799|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
57716800|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
57716801|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
57716802|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
57716803|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
57716804|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
57716805|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
57716806|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
58063160|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
58269513|NCT04826133|OTHER|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
58269514|NCT05674877|DRUG|Opioid-based group (OB) (placebo/saline)|Patients in the opioid-based group will receive placebo boluses and infusions of saline.
58269515|NCT05674877|DRUG|"Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)"|"Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine."
57716807|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
57716808|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
57716809|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
57716810|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
57716811|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
57716812|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
57716813|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
58063161|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
58276736|NCT05087121|DEVICE|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
58276737|NCT05203198|BEHAVIORAL|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
58063162|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
57716814|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
57716815|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
57716816|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
57716817|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
58063163|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
58063164|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
58063165|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
57716818|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
57716819|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
57716820|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
57716821|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
57716822|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
57716823|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
57716824|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
57716825|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
57716826|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
57716827|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
57716828|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
58063166|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
57716829|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
57716830|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
57716831|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
57716832|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
57716833|NCT02209324|DRUG|ASP2151|
57716834|NCT04776148|DRUG|pembrolizumab|IV infusion
57716835|NCT04776148|DRUG|lenvatinib|oral capsule
57916868|NCT03149718|BEHAVIORAL|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
57916869|NCT03149718|BEHAVIORAL|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
58269516|NCT05531448|OTHER|two way texting|"Automated 2WT-based adherence support messages combined with scheduled visit reminders focus on preventing visit default will be implemented. One-way blast motivational support messages will be sent to all new ART patients who opt-into 2WT. ART visit reminders 3- and 1- day before visits will ask clients to respond with 1=attend and 0=no, triggering 2wT responses to clients to reschedule visits, record transfers, etc. 2WT clerks proactively communicate with clients before a visit to prevent default or ascertain true outcomes for those who don't return. Those who miss visits receive additional 2wT reminders. On day 14 post visit, 2wT patients who missed visits, did not respond to text or did not have outcomes updated (transfer, stop, etc.), are identified by the 2WT system and referred to B2C for tracing, days or months earlier than routine B2C. The 2wT-generated tracing list is more timely and accurate, reducing workload and increasing B2C effectiveness"
58269517|NCT00290381|PROCEDURE|Oxagen OC000459|
58269518|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
58269519|NCT02098616|DRUG|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
58269520|NCT02098616|DRUG|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
57716836|NCT04776148|DRUG|regorafenib|oral tablet
57716837|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
57916870|NCT02166125|PROCEDURE|Endosuturing|Endoscopic suturing
57916871|NCT00549614|DRUG|acipimox|capsule, 250 mg, 4 times daily for 28 days
57916872|NCT00549614|DRUG|placebo|capsule, 250 mg, 4 times daily for 28 days
57916873|NCT03059225|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
57916874|NCT03059225|DEVICE|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
57916875|NCT04061395|BIOLOGICAL|Guselkumab|See study arm description.
57716838|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
57716839|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
57716840|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
57716841|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
57716842|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
57716843|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
57716844|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
57716845|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
57916876|NCT03251781|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
57916877|NCT04606043|PROCEDURE|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
58269521|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
58269522|NCT01821950|BEHAVIORAL|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
58269523|NCT00033657|DRUG|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
58269524|NCT00033657|DRUG|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
57916878|NCT04606043|PROCEDURE|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
58063167|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
58063168|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
58269525|NCT00033657|DRUG|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
57716846|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
57716847|NCT03251924|DRUG|BMS-986226|specified dose on specified days
58063169|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
58063170|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
58063171|NCT00095134|DRUG|risperidone|
58063172|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
58063173|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
58063174|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
58063175|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
57716848|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
57716849|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
57716850|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
57916879|NCT03543501|DEVICE|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
57916880|NCT03543501|DEVICE|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
58269526|NCT00033657|PROCEDURE|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
58269527|NCT00033657|RADIATION|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
58388586|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
58388587|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
57716851|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
58388588|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
57716852|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
57716853|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
57716854|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
57716855|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
57716856|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
57716857|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
57716858|NCT03948685|DRUG|Placebo|Placebo
57716859|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
57716860|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
57716861|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
57716862|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
57716863|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
57716864|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
57716865|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57916881|NCT05737537|DIAGNOSTIC_TEST|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
57916882|NCT00775320|PROCEDURE|FLT-PET scan|Imaging test
57916883|NCT04618328|DRUG|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
57916884|NCT05623722|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
57916885|NCT00685633|DRUG|bicalutamide|Given orally
57916886|NCT00685633|DRUG|enzastaurin hydrochloride|Given orally
57916887|NCT05060068|DRUG|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
57916888|NCT05060068|DRUG|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
57916889|NCT05060068|DRUG|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
57916890|NCT00433459|DRUG|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
57916891|NCT00433459|DRUG|dacarbazine|drug is used in first line treatment in combination (COPDAC)
57916892|NCT00433459|DRUG|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
57916893|NCT00433459|DRUG|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
57916894|NCT00433459|DRUG|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
57716866|NCT04550481|DRUG|Lisinopril|Given PO
57716867|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
57716868|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
57716869|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
57716870|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
57716871|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
57716872|NCT02744846|DRUG|Antibiotics exposure|
57716873|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
57716874|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
57916895|NCT00433459|DRUG|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
58269528|NCT06583447|BEHAVIORAL|Calorie-restricted diet (CRD)|"Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week."
58269529|NCT06583447|BEHAVIORAL|Time-restricted eating (TRE)|Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
57916896|NCT00433459|RADIATION|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
57916897|NCT00433459|RADIATION|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
57916898|NCT00116337|PROCEDURE|Spinal Cord Stimulation to restore cough|Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
58063176|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
58063177|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
58063178|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
57716875|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
57716876|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
57716877|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
57716878|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
57716879|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
57716880|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
57716881|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
57716882|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58063179|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
57716883|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
57716884|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
57716885|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
57716886|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
57716887|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
57716888|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
57716889|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
57716890|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
57716891|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
57716892|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
57716893|NCT01696630|DRUG|Xenon|
58269530|NCT02109016|DRUG|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
57716894|NCT01696630|DRUG|Desflurane|
58269531|NCT02418585|DRUG|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
58269532|NCT02418585|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
57716895|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
57716896|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
57716897|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
57716898|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
57716899|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
57716900|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
57716901|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
57716902|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
57716903|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
57916899|NCT00116337|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
57916900|NCT02076178|DRUG|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
57916901|NCT02076178|DRUG|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
57916902|NCT02076178|DRUG|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
57716904|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
57716905|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
57716906|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
57716907|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
57716908|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
57716909|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
57716910|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
57716911|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
57916903|NCT02076178|DRUG|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
57916904|NCT02892084|DEVICE|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
57916905|NCT02892084|DEVICE|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
57916906|NCT03095690|OTHER|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
57916907|NCT03022279|PROCEDURE|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
57916908|NCT03022279|PROCEDURE|local wound infiltration|local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
57916909|NCT05406076|BEHAVIORAL|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
57916910|NCT05406076|BEHAVIORAL|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
57916911|NCT00176397|PROCEDURE|Percutaneous coronary intervention (left main)|
58269533|NCT02418585|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
57916912|NCT04331223|OTHER|Observation|observational
57916913|NCT01839487|DRUG|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
58269534|NCT02418585|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
58269535|NCT02418585|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
57716912|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
57716913|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
57716914|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
57716915|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
57716916|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
57716917|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
57716918|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
57716919|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
57716920|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
57716921|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
57716922|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
57716923|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
57716924|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
57716925|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
57716926|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
57716927|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
57716928|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
57716929|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
57916914|NCT01839487|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
57916915|NCT01839487|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
57916916|NCT01839487|DRUG|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
57916917|NCT01839487|DRUG|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
57716930|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
57716931|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
57716932|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
57716933|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
57716934|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
57716935|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
57716936|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
57716937|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
57716938|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
57716939|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
57716940|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
57716941|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
57716942|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
57716943|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
57716944|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
57716945|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
57716946|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
57716947|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
57716948|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
57716949|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
57716950|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
57716951|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
57716952|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
57716953|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
57716954|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
57716955|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
58063180|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
58388589|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
58388590|NCT00497419|PROCEDURE|fast track|
57716956|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
57716957|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
57716958|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
57716959|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
57716960|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
57716961|NCT06142201|DRUG|JT001|oral administration
57716962|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
57716963|NCT01131481|DEVICE|Intraocular lens|
57716964|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
58269536|NCT02418585|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
57716965|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
57716966|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
57716967|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
57716968|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
57716969|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
57716970|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
57716971|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
57716972|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
57716973|NCT02811198|OTHER|No intervention|
57716974|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
57716975|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
57716976|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
57716977|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
57716978|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
57716979|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
57716980|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
58269537|NCT05915676|DIAGNOSTIC_TEST|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
57716981|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
58063181|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
58269538|NCT01010958|DRUG|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
58063182|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
58269539|NCT03318679|OTHER|No intervention is planned.|None is planned
58269540|NCT05642624|DRUG|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
58269541|NCT04281316|DEVICE|Nasal High Flow installation|"Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface"
58269542|NCT04281316|DEVICE|Non Invasive Ventilation|Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.
57716982|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
58063183|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
58063184|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
58269543|NCT04281316|OTHER|Training session|The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital
58269544|NCT04281316|OTHER|Education session|Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
58388591|NCT05523557|BEHAVIORAL|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
58388592|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
58388593|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
58388594|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
57916918|NCT06065969|RADIATION|Photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session.
57916919|NCT03453320|DRUG|Albumin solution|Infusion rate and effects
57916920|NCT06015178|OTHER|Intelligent Language Model|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
57916921|NCT06015178|OTHER|control|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
57916922|NCT01319188|DRUG|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
57916923|NCT01319188|PROCEDURE|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
57916924|NCT01319188|OTHER|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
57916925|NCT01135407|OTHER|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
58388595|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
58063185|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
57716983|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
57716984|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
57716985|NCT06481150|OTHER|Placebo|Placebo
57916926|NCT01135407|OTHER|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
57916927|NCT01135407|OTHER|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
57916928|NCT05685927|DRUG|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
57916929|NCT05685927|PROCEDURE|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
57916930|NCT04175626|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
57916931|NCT03030170|DEVICE|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
58269545|NCT06173739|PROCEDURE|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
58269546|NCT02107287|RADIATION|IMRT Technique|
58269547|NCT03196375|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
58269548|NCT03196375|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
57716986|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
57716987|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
57716988|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
57716989|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
58269549|NCT06278727|DRUG|angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor|Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
58388596|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
58269550|NCT06278727|OTHER|The development of the prediction model|The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
58269551|NCT03933722|DEVICE|Caretaker|Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
58269552|NCT04747444|OTHER|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
58269553|NCT02889250|DEVICE|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
57716990|NCT00175474|PROCEDURE|knee surgery|
57716991|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
57716992|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
57716993|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
57716994|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
57716995|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
57916932|NCT03030170|DEVICE|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
58388597|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
57916933|NCT04421833|BEHAVIORAL|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
57916934|NCT04421833|BEHAVIORAL|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
57916935|NCT04815967|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
57916936|NCT04815967|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
58063186|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
58063187|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
58063188|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
58063189|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
58388598|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
58388599|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
58388600|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
57716996|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
57716997|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
57716998|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
57716999|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
57717000|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
58063190|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
58063191|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
58063192|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
58063193|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
58063194|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
58269554|NCT04706806|DIETARY_SUPPLEMENT|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
58269555|NCT04706806|DIETARY_SUPPLEMENT|vinegar pill|one pill taken daily
58388601|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
57717001|NCT03197220|OTHER|fish|300 gr/week fish
57717002|NCT03197220|OTHER|walnut|18 walnut per week
57717003|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
57717004|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
57717005|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
57916937|NCT04815967|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
57916938|NCT04815967|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
57717006|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
57717007|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
57717008|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
57717009|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
57717010|NCT06167096|OTHER|Water|Water
57717011|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
57717012|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
57717013|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
57717014|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
57717015|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
57717016|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
57717017|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
57717018|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
57717019|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
57717020|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
57717021|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
57717022|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
57916939|NCT04815967|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
58269556|NCT04276610|BEHAVIORAL|Low Vision Reading Rehabilitation|Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
58269557|NCT00003418|DRUG|exemestane|
57717023|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
58388602|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
57717024|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
57717025|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
57916940|NCT01556477|DRUG|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
58063195|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
57717026|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
58063196|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
58063197|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
58388603|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
58388604|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
58388605|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
57717027|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
57717028|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
57717029|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
57717030|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
57717031|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
58063198|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
58063199|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
58063200|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
58063201|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
58063202|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
58063203|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
58269558|NCT00003418|DRUG|tamoxifen citrate|
58269559|NCT02484300|DIETARY_SUPPLEMENT|Melatonin|
58269560|NCT02484300|OTHER|Placebo|
58388606|NCT01861691|PROCEDURE|Open surgery|Conventional technique
58388607|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
58388608|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
58388609|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
58388610|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
58388611|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
58388612|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
57717032|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
57717033|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
58269561|NCT03768700|OTHER|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
58269562|NCT04733716|PROCEDURE|Using Tourniquet|The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
57717034|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
57916941|NCT01556477|DRUG|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
57916942|NCT00819520|DRUG|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
57916943|NCT00819520|DRUG|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
57916944|NCT02178670|BIOLOGICAL|CSC-DC|
58269563|NCT00270283|DRUG|epoetin alfa|
58269564|NCT02358980|DEVICE|KIDNEY therapy|
57717035|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
57717036|NCT06053658|DRUG|Tivozanib|Given by PO
58269565|NCT05489991|BIOLOGICAL|TmPSMA-02|Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
58269566|NCT00616603|DRUG|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
57717037|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
57717038|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
57717039|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
57717040|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
57916945|NCT05389085|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids|In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
57916946|NCT02240693|DRUG|BI 409306|
57916947|NCT02240693|DRUG|Placebo|
57916948|NCT02240693|DRUG|BI 409306|
58269567|NCT00616603|DRUG|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
58269568|NCT00616603|DRUG|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
58388613|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
57916949|NCT02240693|DRUG|Placebo|
57916950|NCT02240693|DRUG|Placebo|
58269569|NCT00616603|DRUG|Normal Saline|2ml of normal saline given once intravenously.
58269570|NCT05530200|RADIATION|Hypofractionated radiotherapy|24Gy/8Gy/3f
57916951|NCT02240693|DRUG|BI 409306|
57916952|NCT02240693|DRUG|BI 409306|
57916953|NCT02240693|DRUG|Placebo|
58269571|NCT05530200|DRUG|PD-L1 inhibitor|q3w
58269572|NCT05530200|DRUG|GM-CSF|200μg, D1-D7
58269573|NCT05530200|DRUG|IL-2|at a dose of 2 million IU, D8-D14
58269574|NCT05426824|DRUG|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
57916954|NCT02240693|DRUG|Placebo|
58269575|NCT05426824|DRUG|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
58269576|NCT02672332|DRUG|SB204 4%|Once daily
58269577|NCT02672332|DRUG|Vehicle Gel|Placebo comparator
58269578|NCT05848882|DEVICE|Elastodontic Device|Removable device that embraces two dental archs
58388614|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
57916955|NCT02796157|DEVICE|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
58269579|NCT01420679|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
58269580|NCT04018040|OTHER|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
58269581|NCT06420375|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
58269582|NCT06420375|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
58269583|NCT01236326|PROCEDURE|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
58269584|NCT01236326|PROCEDURE|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
58269585|NCT02745691|OTHER|Surgery|Thoracic surgery for lung cancer
58269586|NCT02745691|OTHER|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
58269587|NCT02745691|OTHER|Targeted therapy|New targeted therapies for lung cancer
58269588|NCT02745691|OTHER|Immunotherapy|New immunotherapies for lung cancer
58269589|NCT04621838|OTHER|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
58269590|NCT00691639|OTHER|Blood Collection Only|Blood Collection Only
57717041|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
57916956|NCT02796157|DEVICE|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
57916957|NCT00201747|DRUG|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
58269591|NCT02491801|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
58269592|NCT02041650|DRUG|Ticagrelor|
58388615|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
58388616|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
57717042|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
57717043|NCT01527916|DRUG|placebo|Placebo Comparator
57717044|NCT01527916|DRUG|donepezil|Active Comparator
57717045|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
57717046|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
57717047|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
57717048|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
57717049|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
57717050|NCT03011814|DRUG|Lenalidomide|Given PO
58269593|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
58269594|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
58269595|NCT03153267|DRUG|Controls without a history of lyme disease.|No intervention.
58269596|NCT06618144|OTHER|Texting platform|Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
58269597|NCT06579404|DEVICE|CamAPS HX|"The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm"
57717051|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
58269598|NCT06579404|OTHER|Standard insulin therapy with glucose sensor|Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
58269599|NCT04731025|DRUG|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
58269600|NCT04731025|OTHER|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
58269601|NCT00109876|PROCEDURE|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
58269602|NCT05949541|DRUG|Everolimus 10 mg|Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
58269603|NCT05949541|DRUG|CDK4/6 Inhibitor SHR6390|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
58388617|NCT06390046|PROCEDURE|Intubation|Comparing videao laryngospy with traditional laryngoscopy
57717052|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
57717053|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
57717054|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
57717055|NCT04746937|DRUG|Norfloxacin|Standard therapy
57717056|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
57717057|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
57717058|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
57717059|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
57717060|NCT05669092|RADIATION|SCRT|25Gy/5fx
58269604|NCT05949541|DRUG|Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
58269605|NCT03393429|OTHER|DAVID assisted training|DAVID device assisted training under supervision
58269606|NCT03393429|OTHER|training recommendation|"training recommendation to stay active"
58388618|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
57717061|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
57717062|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
57717063|NCT00568984|DRUG|repaglinide|
57717064|NCT00568984|DRUG|metformin|
57717065|NCT00568984|DRUG|glicazide|
57717066|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
57717067|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
57717068|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
58269607|NCT05014581|DRUG|Noradrenaline|Pre-emptive continuous infusion of noradrenaline during the peri-intubation period
57717069|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
58063204|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
58269608|NCT03057223|DEVICE|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
58063205|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
58063206|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
58388619|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
58388620|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
58388621|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
58063207|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
58063208|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
57717070|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
58063209|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
58063210|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
58063211|NCT00155246|DRUG|pentoxifylline (drug)|
58269609|NCT03473613|DRUG|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
58269610|NCT03473613|DRUG|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
58269611|NCT03493750|OTHER|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
58269612|NCT05201040|DEVICE|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
58269613|NCT05201040|DEVICE|Normal saline|2mL of normal saline
57916958|NCT00201747|DRUG|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
58063212|NCT02624661|DRUG|Glycerol|
58269614|NCT04392167|DEVICE|a/LCI-OCT imaging probe|a/LCI and OCT imaging measurements of several locations in the esophagus
58269615|NCT04392167|PROCEDURE|esophageal biopsy|biopsies of esophageal tissue imaged by a/LCI-OCT probe
58269616|NCT01866267|DRUG|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
58269617|NCT02596217|DRUG|ABBV-066|SC injection
58388622|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
58388623|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
58388624|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
58388625|NCT00935493|DRUG|Placebo|Placebo po qhs
58388626|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
58388627|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
58388628|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
58388629|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
58388630|NCT00269113|DRUG|Standard chemotherapy|As prescribed
58269618|NCT02596217|DRUG|ABBV-066|IV infusion
58269619|NCT02596217|DRUG|Placebo|SC injection (stage 1)
58388631|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
57717071|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
57717072|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
58388632|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
58388633|NCT03409081|DRUG|gilteritinib|oral
58388634|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
58388635|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
58388636|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
57717073|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
57916959|NCT03482583|DRUG|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
57916960|NCT03482583|OTHER|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
58063213|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
58269620|NCT02596217|DRUG|Placebo|IV infusion (stage 2)
57717074|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
58269621|NCT01270386|DRUG|apatinib|Apatinib 750 mg p.o. once daily
58269622|NCT01270386|DRUG|placebo|placebo p.o. once daily
58269623|NCT01539395|OTHER|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
58388637|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
58388638|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
57717075|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
57717076|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
57717077|NCT02047604|DRUG|Placebo|
57717078|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
57717079|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
57717080|NCT03296696|DRUG|AMG 596|Drug
58269624|NCT03698968|DEVICE|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
58269625|NCT00908076|DRUG|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
58269626|NCT02537834|DRUG|Tofogliflozin|
58269627|NCT02537834|DRUG|GLP-1 analogue|
58388639|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
58388640|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
58388641|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
57717081|NCT03296696|DRUG|AMG 404|Drug
57717082|NCT02950636|OTHER|Yoga|Restorative Yoga
57717083|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
57717084|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
58063214|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
58269628|NCT02235441|OTHER|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
58269629|NCT04919876|DIETARY_SUPPLEMENT|fruit/vegetable supplement (FVS)|The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
58269630|NCT04919876|DIETARY_SUPPLEMENT|Placebo|The product does not contain nutrients present in the FVS.
58269631|NCT05650346|OTHER|Deep Cervical Training|The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
57717085|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
57717086|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
57717087|NCT02520024|BEHAVIORAL|self-directed care|
57916961|NCT05368051|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
57916962|NCT05169320|DEVICE|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
57916963|NCT05169320|PROCEDURE|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
58063215|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
58388642|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
58388643|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
58388644|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
58388645|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
58388646|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
57717088|NCT00374777|DRUG|zolpidem MR|oral
58388647|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
58063216|NCT02561273|DRUG|Cyclophosphamide|Given IV
57717089|NCT00374777|DRUG|nitrazepam|oral
57717090|NCT00374777|DRUG|placebo|oral
57717091|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
57717092|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
58063217|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
58063218|NCT02561273|DRUG|Etoposide|Given IV
58388648|NCT04051294|OTHER|Control: Water|Tap water
58388649|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
58388650|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
57717093|NCT01636141|DRUG|Placebo gel|
57717094|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
57717095|NCT02877706|OTHER|no specific intervention|
57717096|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
57717097|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
57717098|NCT04319315|OTHER|survey|online survey
58063219|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
58063220|NCT02561273|DRUG|Lenalidomide|Given PO
58063221|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
58063222|NCT02561273|DRUG|Prednisone|Given PO
58063223|NCT02561273|DRUG|Vincristine Sulfate|Given IV
58388651|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
58388652|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
58388653|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
58388654|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
58388655|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
58388656|NCT01735734|DEVICE|Air cooling to CM site|
58388657|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
58388658|NCT01564212|OTHER|laminar airflow with surgical drapes|
58388659|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
58388660|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
58269632|NCT05650346|OTHER|Deep cervical training + Upper cervical mobilization group|"1. the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~2. The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk."
58269633|NCT05650346|OTHER|Deep cervical training + Upper thoracic mobilization group|"1. The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~2. The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2)."
58269634|NCT03901053|DEVICE|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
58388661|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
58388662|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
58388663|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
57717099|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
58063224|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
58388664|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
58388665|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
58388666|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
58388667|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
58388668|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
58388669|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
58063225|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
58063226|NCT01416259|DRUG|Withdraw treatment|
58063227|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
58269635|NCT03901053|DEVICE|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
58269636|NCT02335749|DEVICE|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
58269637|NCT06625398|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
57717100|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
57717101|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
57717102|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
57717103|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
57717104|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
57717105|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
58269638|NCT06625398|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
58269639|NCT03643367|DRUG|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
58388670|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
58388671|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
57717106|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
57717107|NCT00144118|DRUG|sevoflurane or isoflurane|
57717108|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
57717109|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
57717110|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
57717111|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
58063228|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
58269640|NCT03643367|DRUG|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
58269641|NCT03536949|DRUG|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
58269642|NCT03536949|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
58388672|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
58388673|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
58388674|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
58388675|NCT00644072|DRUG|SNX-5422|
57717112|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
57717113|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
57717114|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
57717115|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
57717116|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
57717117|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
58269643|NCT04813913|DRUG|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
57717118|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
57717119|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
57717120|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
57717121|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
57717122|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
57717123|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
57717124|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
57717125|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
57717126|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
57717127|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
58063229|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
58063230|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
57717128|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
57717129|NCT00130767|DRUG|finasteride|
57717130|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
57717131|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
57717132|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
57717133|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
58063231|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
58063232|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
58063233|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
58063234|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
58269644|NCT01306435|OTHER|Laser|3-week treatment with three Laser sessions per week
58388676|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
58388677|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
58063235|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
57717134|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
57717135|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
57717136|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
57717137|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
58063236|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
57717138|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
57717139|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
57717140|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
57717141|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
57717142|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
57717143|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
57717144|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
57717145|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
57717146|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
58063237|NCT00004844|PROCEDURE|tissue implantation|
58063238|NCT00313742|DRUG|insulin detemir|
58063239|NCT00313742|DRUG|insulin glargine|
58063240|NCT00313742|DRUG|insulin NPH|
58063241|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
58063242|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
58063243|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
58269645|NCT01306435|OTHER|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
58063244|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
58269646|NCT06051331|BEHAVIORAL|simulation-based breast health education|The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
58269647|NCT04679051|BEHAVIORAL|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
58269648|NCT00495599|PROCEDURE|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
58063245|NCT00264628|DRUG|GW679769|
58063246|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
58269649|NCT02359799|DEVICE|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
58269650|NCT04785040|OTHER|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
58269651|NCT00731718|DEVICE|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
57717147|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
57717148|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
57717149|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
58269652|NCT00032422|PROCEDURE|Acupuncture|
58269653|NCT00756197|DEVICE|Cryo Spray Ablation Group 1|Cryo Spray Ablation
58269654|NCT00756197|DEVICE|Cryo Spray Ablation Group 2|cryo spray ablation
58269655|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement
57717150|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
58269656|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement
57717151|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
58269657|NCT05583643|OTHER|Scaling and debridement only|Scaling and debridement only
57717152|NCT06466395|DRUG|Venetoclax|Given by PO
57717153|NCT06466395|DRUG|Hyper-CVAD|Given by IV
58063247|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
58063248|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
58063249|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
58063250|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
58063251|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
58269658|NCT00365001|DRUG|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
58269659|NCT00365001|DRUG|Methotrexate|10-25mg po/week
58269660|NCT00365001|DRUG|Simvastatin|40mg po on days 1, 15 and 43
58269661|NCT05111392|BIOLOGICAL|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
58269662|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
58269663|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
58269664|NCT03211442|RADIATION|Radiotherapy|Breast cancer patients treated with radiotherapy
58269665|NCT01464801|DIETARY_SUPPLEMENT|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
58269666|NCT01464801|DIETARY_SUPPLEMENT|Placebo|Tablet Placebo 3 times daily for 6 months
58269667|NCT02946814|DRUG|essential oils|
58269668|NCT02946814|DRUG|essential oils without mouthwash|
58269669|NCT02946814|DRUG|sterile water|
58269670|NCT00337324|DEVICE|Frequency-modulated electromagnetic neural stimulation|
58269671|NCT05531305|DEVICE|Muscle ultrasound|Standardized ultrasonographic measurement of quadriceps muscle layer thickness.
58269672|NCT05531305|DEVICE|Indirect calorimetry|Non-invasive measurement of resting energy expenditure using the Q-NRG metabolic monitor with hood and canopy.
58269673|NCT05531305|DIAGNOSTIC_TEST|Hand dynamometry|Assessment of handgrip strength using hand dynamometry.
57717154|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
58269674|NCT05531305|DIAGNOSTIC_TEST|MRC Sum Score|Assessment of muscle function/limb strength using the Medical Research Council sum score (12-60 points).
57717155|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
58063252|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
58063253|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
58063254|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
58063255|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
58063256|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
58063257|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
58063258|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
58269675|NCT04805359|BEHAVIORAL|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
58269676|NCT04805359|BEHAVIORAL|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
58269677|NCT00772824|DIETARY_SUPPLEMENT|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
57717156|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
58063259|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
58063260|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
58063261|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
58063262|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
58063263|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
58063264|NCT05455723|PROCEDURE|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
58063265|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
58063266|NCT04146870|OTHER|not have|not have
58063267|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
58063268|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
58063269|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
58063270|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
58063271|NCT03968523|PROCEDURE|TAP block|TAP block technique
58063272|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
58063273|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
58269678|NCT00772824|DIETARY_SUPPLEMENT|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
58269679|NCT04192058|DEVICE|Sham transcranial direct current stimulation (tDCS)|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
58388678|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
58388679|NCT02125838|DEVICE|Endotracheal Tube|ETT
58063274|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
58269680|NCT04192058|DEVICE|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
58269681|NCT02314754|DRUG|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
58269682|NCT04969380|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
58269683|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
58269684|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
58388680|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
58388681|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
58063275|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
58388682|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
57717157|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
57717158|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
57717159|NCT00388518|DRUG|Actos|45mg po daily
58063276|NCT04880642|DRUG|C21|C21
57717160|NCT00388518|DRUG|Placebo|po daily
57717161|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
57717162|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
57717163|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
57717164|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
58063277|NCT04880642|DRUG|Placebo|Placebo
58063278|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
58063279|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
58063280|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
58063281|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
58063282|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
58063283|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
58063284|NCT00848172|DRUG|Octanoic Acid|4mg/kg
58063285|NCT00848172|DRUG|Placebo|identical capsules
58063286|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
58063287|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
58063288|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
58269685|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
58269686|NCT02727426|OTHER|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
58269687|NCT02727426|OTHER|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
58269688|NCT05821075|DRUG|Prednisolone|prednisolone 60mg tablet once daily for 5 days then tapering dose
58269689|NCT05821075|DRUG|Cerebrolysin|intramuscular Cerebrolysin 10 mg daily for 3 weeks
58269690|NCT03744845|OTHER|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
58063289|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
58063290|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
58063291|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
58063292|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
58063293|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
58063294|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
58269691|NCT03974022|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
58269692|NCT05368415|DRUG|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
58063295|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
58269693|NCT01752894|DEVICE|Angio-guided PCI with EES or BES|Angio-guided intervention
58269694|NCT01752894|DEVICE|OCT-guided PCI with EES or BES|OCT-guided intervention
58269695|NCT01752894|DEVICE|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
58269696|NCT01752894|DEVICE|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
58269697|NCT01752894|DRUG|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.
57717165|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
57717166|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
57717167|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
58063296|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
58063297|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
58063298|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
58269698|NCT01752894|DRUG|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
58269699|NCT05461456|DRUG|Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)|"Intervention:~The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.~Comment:~The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation."
58269700|NCT02144636|DIETARY_SUPPLEMENT|herbalife protein shake|
58269701|NCT05233384|BIOLOGICAL|Blood test|"For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation)."
58269702|NCT03861871|DRUG|Fenfluramine Hydrochloride|Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
58269703|NCT05597579|DIAGNOSTIC_TEST|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
58269704|NCT01899807|DEVICE|OssDsign AB|
58269705|NCT03324828|DRUG|Hydroxyzine|Hydroxyzine solution
58269706|NCT03324828|OTHER|Clowns intervention|Clowns intervention
58269707|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
58388683|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
57717168|NCT01312467|DRUG|metformin hydrochloride|
58269708|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
58269709|NCT03644056|DRUG|IMC-001|Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
58388684|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
58388685|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
57916964|NCT05169320|PROCEDURE|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~1. Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~2. Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity \[≤5 mm\] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
57916965|NCT02862834|GENETIC|High-throughput exome sequencing|
57916966|NCT03784560|OTHER|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
57916967|NCT03784560|OTHER|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
57717169|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
58063299|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
58063300|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
58063301|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
58063302|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
57717170|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
57717171|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
57717172|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
57717173|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
57717174|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
58063303|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
58063304|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
58063305|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
58063306|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
58063307|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
58388686|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
57717175|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
57717176|NCT01961830|DRUG|ME1100 inhalation solution|
57717177|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
57717178|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
57717179|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
57717180|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
57717181|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
57717182|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
57717183|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
57717184|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
57717185|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
57717186|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
57717187|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
57717188|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
57717189|NCT01723891|DRUG|Surfolase capsule|
57717190|NCT01723891|DRUG|HT-002-01|
57717191|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
57717192|NCT01697384|DRUG|histrelin acetate|52 week implant
57717193|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
57717194|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
57717195|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
57717196|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
58063308|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
58269710|NCT05571202|PROCEDURE|General anesthesia plus local infiltration|The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.
57717197|NCT00999349|DRUG|Placebo|
57717198|NCT06360588|PROCEDURE|Biopsy|Undergo tumor biopsy
57717199|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58388687|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
57717200|NCT06360588|DRUG|Copanlisib|Given IV
57717201|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
57717202|NCT00764348|OTHER|no treatment|
57717203|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
57717204|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
57717205|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
57717206|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
57717207|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
57717208|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
57717209|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
58063309|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
58269711|NCT05571202|PROCEDURE|Spinal anesthesia|The eligible patients underwent anorectal surgery under spinal anesthesia alone.
58269712|NCT04506398|PROCEDURE|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
58269713|NCT04506398|DIAGNOSTIC_TEST|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
58269714|NCT04506398|DIAGNOSTIC_TEST|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
57717210|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
57717211|NCT05660616|OTHER|supportive care|supportive care
58269715|NCT00191659|DRUG|Atomoxetine Hydrochloride|
57717212|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
57717213|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
57916968|NCT03784560|OTHER|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (\<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
58269716|NCT03274258|BIOLOGICAL|Ipilimumab|Given IV
58269717|NCT03274258|BIOLOGICAL|Nivolumab|Given IV
58269718|NCT01122940|DRUG|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
58269719|NCT01122940|DRUG|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
57717214|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
57916969|NCT03784560|OTHER|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington \& Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
57916970|NCT05880615|OTHER|collection of datas|"collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery"
57916971|NCT04960735|OTHER|VOICE intervention|"The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Model construction: Based on the process mapping and on root cause analysis, the multidisciplinary team designs the new care pathway. Professionals are trained in those tasks allocated according to the new care process."
58269720|NCT01240928|DRUG|MSK-2206|Level 1: MK-2206 135mg weekly
58269721|NCT01240928|DRUG|Exemestane|Level 1: Exemestane - 25mg daily
58269722|NCT01240928|DRUG|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
58269723|NCT06461416|BEHAVIORAL|ActiveHeal|Participants will have 6 group activity sessions and six individualized sessions from home, all focused on optimizing persistence in performance of specific selected activities.
58269724|NCT02320227|DEVICE|Miami w/o frag Personal lubricant|
58269725|NCT04600362|DRUG|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
58269726|NCT06066541|BEHAVIORAL|Scorecard|"Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score."
58269727|NCT06066541|BEHAVIORAL|Social norms|Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).
58269728|NCT06066541|BEHAVIORAL|Messenger effects|Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.
58269729|NCT06066541|BEHAVIORAL|Processing fluency|"Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring."
58269730|NCT04327661|DRUG|Tradipitant|Oral Capsule
58269731|NCT04327661|DRUG|Placebo|Oral Capsule
58269732|NCT03479944|PROCEDURE|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
58269733|NCT03479944|PROCEDURE|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
57717215|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
57717216|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
57717217|NCT01532687|DRUG|Gemcitabine|Given IV
57717218|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
57717219|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
57916972|NCT02943226|DEVICE|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
57916973|NCT02943226|DEVICE|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
58269734|NCT03479944|DEVICE|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
58269735|NCT03479944|DEVICE|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
58388688|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
57717220|NCT01532687|DRUG|Pazopanib|Given PO
57717221|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
57717222|NCT01532687|OTHER|Placebo Administration|Given PO
57717223|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
57717224|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
57717225|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
57717226|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
57717227|NCT00824317|DRUG|Placebo|
57717228|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
57717229|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
57717230|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
57717231|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
57916974|NCT03809429|DRUG|FE 999049 + GnRH agonist (GONAPEPTYL)|Pre-filled injection pen
57916975|NCT03809429|DRUG|FE 999049 + GnRH antagonist (CETROTIDE)|Powder and solvent for solution for injection
57916976|NCT02038491|PROCEDURE|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
57916977|NCT03008707|PROCEDURE|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
57916978|NCT04461483|DRUG|TAK-935|TAK-935 Tablets
58388689|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
58388690|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
58269736|NCT03921359|BEHAVIORAL|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
57916979|NCT04461483|DRUG|Placebo|TAK-935 placebo-matching tablets
57717232|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
57916980|NCT04153123|DRUG|Epinephrine|
58269737|NCT03921359|BEHAVIORAL|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
58269738|NCT05896683|DRUG|Lazertinib|Lazertinib will be administered orally.
58269739|NCT01590732|DRUG|Carboplatin|Given IV
58269740|NCT01590732|DRUG|Etoposide|Given IV
58269741|NCT01590732|DRUG|Ifosfamide|Given IV
58269742|NCT01590732|DRUG|Romidepsin|Given IV
58269743|NCT05347134|DRUG|SKB264|"SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
58269744|NCT02614131|DRUG|LY2599666|Administered SC
57916981|NCT02207881|DRUG|VDO gel|VDO gel
58269745|NCT02614131|DRUG|Solanezumab|Administered IV
58269746|NCT02614131|DRUG|Placebo SC|Administered SC
58269747|NCT02614131|DRUG|Placebo IV|Administered IV
58269748|NCT04527913|BEHAVIORAL|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
58269749|NCT04527913|PROCEDURE|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
58269750|NCT04527913|PROCEDURE|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
58269751|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
58269752|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
58269753|NCT00779532|DRUG|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
58269754|NCT00779532|DRUG|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
57916982|NCT02207881|DRUG|placebo|matching placebo gel
57916983|NCT04818333|DRUG|SHR-A1811|Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
58063310|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
58063311|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
58063312|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
57717233|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
57916984|NCT06409520|DIAGNOSTIC_TEST|thyroid function tests|(TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.
57916985|NCT06409520|DIAGNOSTIC_TEST|cardiac enzymes|troponine
57916986|NCT06409520|DIAGNOSTIC_TEST|ECG|Electrocardiogram
57717234|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
58063313|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
58388691|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
58269755|NCT00779532|DRUG|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
58269756|NCT00779532|DRUG|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
58269757|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
58269758|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
57717235|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
57717236|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
57717237|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
57717238|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
58063314|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
58063315|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
58269759|NCT05553470|DRUG|Miricorilant|600 mg miricorilant
58269760|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
58269761|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with an arcuate cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
58269762|NCT01925157|BIOLOGICAL|LY3090106 - SQ|Administered SQ.
58269763|NCT01925157|BIOLOGICAL|LY3090106 - IV|Administered IV.
58388692|NCT03080571|OTHER|standard care|
57717239|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
57717240|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
58269764|NCT01925157|BIOLOGICAL|Placebo - SQ|Administered SQ.
58269765|NCT04511949|DIAGNOSTIC_TEST|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"* The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
58269766|NCT00800605|BIOLOGICAL|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
58269767|NCT00800605|BIOLOGICAL|Placebo: Phosphate-buffered saline|Single intramuscular injection
58388693|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
58388694|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
58388695|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
58388696|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
58388697|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
58388698|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
57717241|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
57717242|NCT00485875|DRUG|Atomoxetine Hydrochloride|
57717243|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
57717244|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
57717245|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
57717246|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
58269768|NCT04469959|DRUG|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
58269769|NCT04469959|DRUG|Placebo|Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
58269770|NCT00909714|DEVICE|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
58269771|NCT00909714|DEVICE|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
58269772|NCT03070041|OTHER|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
58269773|NCT05262868|DEVICE|rTMS|The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
58388699|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
58388700|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
58388701|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58388702|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
58388703|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
58388704|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
58388705|NCT02298868|DRUG|Baclofen|
58388706|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
58388707|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
58388708|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
57717247|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
57916987|NCT05555056|DEVICE|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
58269774|NCT00101036|DRUG|lapatinib ditosylate|Given PO
58269775|NCT00101036|OTHER|laboratory biomarker analysis|Correlative studies
58269776|NCT02783456|PROCEDURE|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
58269777|NCT02783456|PROCEDURE|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
58269778|NCT00774007|DRUG|mesalazine|
58269779|NCT00774007|DRUG|placebo|
58388709|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
57717248|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
57717249|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
57717250|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
57916988|NCT05555056|DEVICE|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
57916989|NCT06524752|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
57916990|NCT06524752|OTHER|Non-existence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
57916991|NCT04883437|DRUG|Acalabrutinib|Given PO
58269780|NCT02479971|DRUG|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
58269781|NCT02479971|DRUG|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
58269782|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
58269783|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
58269784|NCT05324280|PROCEDURE|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
58269785|NCT00219570|DRUG|clindamycin|
57717251|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
58388710|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
57717252|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
57717253|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
57717254|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
57717255|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
58269786|NCT00219570|DRUG|nadifloxacin|
58269787|NCT03504306|OTHER|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
58269788|NCT04989634|BEHAVIORAL|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
58269789|NCT04989634|BEHAVIORAL|Standard care|Standard prenatal education on diet, nutrition and physical activity
58269790|NCT01718145|DRUG|Daclatasvir|
58269791|NCT01718145|DRUG|Asunaprevir|
58388711|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
58388712|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
58388713|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
58269792|NCT01718145|DRUG|Ribavirin|
58269793|NCT01718145|BIOLOGICAL|pegIFNα-2b|
58269794|NCT01718145|DRUG|Telaprevir|
58269795|NCT00769535|GENETIC|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
58269796|NCT02013570|DRUG|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
58388714|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
58388715|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
57717256|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57717257|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
57717258|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
57717259|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
57717260|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
57717261|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
57717262|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
57916992|NCT04883437|BIOLOGICAL|Obinutuzumab|Given IV
57916993|NCT04883437|OTHER|Quality-of-Life Assessment|Ancillary studies
57916994|NCT04883437|OTHER|Questionnaire Administration|Ancillary studies
58269797|NCT06304558|DEVICE|Non-Invasive Neuromodulation (NESA)|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
58388716|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
58388717|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
58388718|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
58388719|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
58269798|NCT02253121|DRUG|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
58269799|NCT02253121|DRUG|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
58388720|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
58388721|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
58388722|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
58388723|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
58388724|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
58388725|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
58388726|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
58388727|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
58388728|NCT01897727|DRUG|Spironolactone|
58269800|NCT00834730|DRUG|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
58269801|NCT05581433|OTHER|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
58269802|NCT05581433|OTHER|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
58269803|NCT03203460|BEHAVIORAL|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
58269804|NCT02061449|DRUG|Romidepsin|
58388729|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
58388730|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
58388731|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
58388732|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
58388733|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
57717263|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
58269805|NCT02061449|DRUG|Poly ICLC|
58269806|NCT02061449|RADIATION|Focal lesional radiation|
58269807|NCT06431685|RADIATION|Whole Brain Low Dose Radiotherapy|Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).
58269808|NCT06431685|DRUG|Pemetrexed|Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total
58269809|NCT06431685|DRUG|Sintilimab|PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total
58269810|NCT06431685|DRUG|Chemotherapy|Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
58269811|NCT03794934|BEHAVIORAL|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
58269812|NCT02827435|DRUG|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
58388734|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
58388735|NCT00164840|DRUG|Esomeprazole|
58388736|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
58388737|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
57717264|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
57717265|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
57717266|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
57717267|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
57717268|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
57717269|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
57717270|NCT00881309|DRUG|Tripterygium|TW 90mg/d
57717271|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
57717272|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
57717273|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
57916995|NCT05979454|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
57916996|NCT03111251|BEHAVIORAL|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
58269813|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (330mg)|High dose capsules
58269814|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (165mg)|Low dose capsules
58269815|NCT03058367|DIETARY_SUPPLEMENT|Placebo|Placebo identical to verum capsules
57717274|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
57717275|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
57717276|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
57717277|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
57717278|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
58269816|NCT04766255|PROCEDURE|Soft Tissue graft augmentation|"Donor site:~SCTG group: The SCTG will be harvested in the palat,In order to extract the same thickness in each grafts a double-bladed knife (separated by 1,5mm) will be used. The donor area will be sutured.~Recipient site:~SCTG group: the connective tissue graft will be trimmed to the correct dimensions (10mm height, 12mm length and 1,5mm thick) and placed and secured at the recipient site with a resorbable 5-0 suture CM group: The CM graft (Geistlich Fibro-gide) will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture PADM Group: the ADM (NovoMatrix, Biohorizons, Birmingham AL) graft will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture"
57717279|NCT06005259|DRUG|Placebo|Placebo capsule
57717280|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
57717281|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
57717282|NCT02444650|DEVICE|tonometer|
57717283|NCT03745703|BEHAVIORAL|MOCHA|(see above)
57916997|NCT03111251|BEHAVIORAL|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
58269817|NCT04766255|PROCEDURE|Implant Placement|A crestal incision will be made in the implant reception area, extending from the distal of the most mesial tooth to the mesial of the most distal tooth. A mucoperiosteal flap will be elevated in the most crestal part of the ridge. The receptor bed will be prepared following the established drilling protocol for the placement of a BioHorizons Tapered Pro Implant (Biohorizons, Birmingham AL). The diameter and length of the implant will be previously established during the implant study. Later a healing abutment will be placed.
58269818|NCT02710344|BEHAVIORAL|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
58269819|NCT03704948|BEHAVIORAL|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
57717284|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
57717285|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
57717286|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
57717287|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
57717288|NCT02340559|BEHAVIORAL|Psychoeducational group|
57717289|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
57916998|NCT03111251|BEHAVIORAL|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
57916999|NCT03111251|BEHAVIORAL|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
57917000|NCT03111251|BEHAVIORAL|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
57917001|NCT04160767|DRUG|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
57917002|NCT04160767|BEHAVIORAL|Gluten free diet|Gluten free diet will be encouraged in both arms
57917003|NCT04160767|OTHER|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
57917004|NCT05882097|OTHER|Transform program|International Care Ministries' (ICM) Transform is a 15-lesson, 15-week long values, health, and livelihood program that targets some of the poorest households in Uganda. The health dimension focuses on increasing health knowledge and behaviours on a range of health topics such as malnutrition, respiratory infection, lifestyle, sanitations, family planning and infant care. The livelihood dimension focuses on increasing the amount and sources of household income. Participants will learn about business ideas and farming techniques to diversify their income sources. Additionally, a savings group will be formed at the end of Transform to promote a sustainable strategy to reduce poverty among the participants. The values dimension will focus on relationships, personal character and decision making aspects of an individual.
58269820|NCT03704948|BEHAVIORAL|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
58269821|NCT03704948|BEHAVIORAL|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
58269822|NCT02258269|OTHER|SQ|
57717290|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
57717291|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
57717292|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
57717293|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
57717294|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
57717295|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
57717296|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
57917005|NCT03794167|DRUG|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
57917006|NCT03794167|DRUG|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
57917007|NCT03794167|DRUG|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
57917008|NCT03794167|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
57917009|NCT00420433|PROCEDURE|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
57917010|NCT00420433|PROCEDURE|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
57917011|NCT00420433|PROCEDURE|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
57917012|NCT03363763|DRUG|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
57917013|NCT03363763|DRUG|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
57917014|NCT03363763|DRUG|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
58269823|NCT02258269|OTHER|Control|
58269824|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
58269825|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
58269826|NCT00634595|DRUG|E10A|E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
58269827|NCT00634595|DRUG|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
58269828|NCT00634595|DRUG|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
58269829|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
57717297|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show PVP presence in histiocytes of injecting drug users compared to controls
57717298|NCT06573671|DIAGNOSTIC_TEST|X-ray spectromicroscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
57717299|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
57717300|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of PVP-exposed in vitro histiocytes of injecting drug users compared to control samples
57717301|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
58269830|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
57717302|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
57717303|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
57717304|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
57717305|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
57717306|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
57717307|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
57717308|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
57717309|NCT00984841|OTHER|Tailored letter|
57717310|NCT01433224|GENETIC|DNA methylation analysis|
57717311|NCT01433224|GENETIC|RNA analysis|
57717312|NCT01433224|GENETIC|mutation analysis|
57717313|NCT01433224|GENETIC|nucleic acid sequencing|
57717314|NCT01433224|GENETIC|polymerase chain reaction|
57717315|NCT01433224|GENETIC|polymorphism analysis|
57717316|NCT01433224|OTHER|laboratory biomarker analysis|
57717317|NCT01433224|OTHER|medical chart review|
58269831|NCT00000774|BIOLOGICAL|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
58269832|NCT00000774|BIOLOGICAL|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
57717318|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
57717319|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
57717320|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
57717321|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
57717322|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
57717323|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
58269833|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
58269834|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
58269835|NCT03989934|BEHAVIORAL|The Mind in Action|Mindfulness program for adolescents
58269836|NCT03989934|BEHAVIORAL|Healthy Topics|Health education program for adolescents
58269837|NCT01047332|DEVICE|Partially Covered Wallstent|Partially covered wallstent
58269838|NCT01047332|DEVICE|Uncovered Wallstent|Uncovered wallstent
58269839|NCT04336462|DEVICE|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
58269840|NCT04336462|DEVICE|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
58269841|NCT05899075|OTHER|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
58269842|NCT05899075|OTHER|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
58269843|NCT03309696|DEVICE|sham tDCS and sham rTMS|Both combinations of tDCS and rTMS in this intervention are sham.
58269844|NCT03309696|DEVICE|sham tDCS and active rTMS|tDCS in this intervention is sham and rTMS is active
58269845|NCT03309696|DEVICE|active tDCS and active rTMS|Both combinations of tDCS and rTMS in this intervention are active
57717324|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
57717325|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
58269846|NCT02283736|OTHER|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
58269847|NCT02283736|OTHER|Talc powder|Tablet containing talc powder
58269848|NCT02283736|PROCEDURE|Periodontal treatment|Scaling and root planning
58269849|NCT00737893|DRUG|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
58269850|NCT00737893|DRUG|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
58269851|NCT00671827|BEHAVIORAL|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
58269852|NCT04560621|BEHAVIORAL|Managed Problem Solving (MAPS)|MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
58269853|NCT03186859|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
58269854|NCT03186859|PROCEDURE|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
58269855|NCT03259672|DRUG|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
57717326|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
57717327|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
57717328|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
57717329|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
57717330|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
57717331|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
57717332|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
57717333|NCT00159523|BIOLOGICAL|placebo|
58269856|NCT03259672|DRUG|Desflurane|Desflurane was used as a maintenance anesthetic agent.
57717334|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
57717335|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
57717336|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
57717337|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
57717338|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
57717339|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
57717340|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
57717341|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
57717342|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
57717343|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
58269857|NCT06730802|DRUG|PCSK9 inhibitor|the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
58269858|NCT06730802|DRUG|Statin|the control group will receive standard statin therapy.
58269859|NCT01746238|DRUG|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
58269860|NCT01746238|DRUG|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
58269861|NCT01746238|RADIATION|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
58269862|NCT01094652|DIETARY_SUPPLEMENT|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
57717344|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
58063316|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
58269863|NCT01094652|DIETARY_SUPPLEMENT|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
57717345|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
57717346|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
57717347|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
58269864|NCT05865275|DEVICE|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
58269865|NCT05865275|OTHER|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
58388738|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
58388739|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
58388740|NCT00000673|DRUG|Ganciclovir|
58388741|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
58388742|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
58269866|NCT01585610|BEHAVIORAL|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (\< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
58269867|NCT01585610|BEHAVIORAL|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (\< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
58269868|NCT01569256|DRUG|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
58269869|NCT03572400|DRUG|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
58269870|NCT03572400|DRUG|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
58269871|NCT00041665|DRUG|Recombinant Human Keratinocyte Growth Factor|
57717348|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
58269872|NCT04151485|BEHAVIORAL|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
58269873|NCT04151485|BEHAVIORAL|Fertility Support Program|see Arm Description
58269874|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
58269875|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
58269876|NCT02919267|DEVICE|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
58269877|NCT02919267|DEVICE|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
58269878|NCT06613360|DRUG|CLN-978|Specified dose on specified days
58269879|NCT01870804|DRUG|Rosuvastatin|
58269880|NCT01870804|DRUG|Atorvastatin|
58388743|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
58269881|NCT05588245|BEHAVIORAL|Standard of Care|Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
58269882|NCT05588245|BEHAVIORAL|Community-based prenatal/perinatal/postpartum patient navigator|Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
58269883|NCT01201174|OTHER|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
58269884|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
58269885|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
58269886|NCT01267201|DRUG|methylprednisolone|tablet 32 mg single dose
58269887|NCT00571571|BEHAVIORAL|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
58063317|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
58269888|NCT00571571|BEHAVIORAL|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
58269889|NCT01420562|PROCEDURE|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
58269890|NCT05284734|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
58269891|NCT02437032|DRUG|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
58269892|NCT02437032|DRUG|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
57917015|NCT04464954|DEVICE|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
58063318|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
58269893|NCT02437032|DRUG|hMG|Controlled ovarian stimulation with 150-300 UI hMG
58269894|NCT05123391|RADIATION|External beam image guided radiotherapy|Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
58269895|NCT00128804|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
58269896|NCT00473785|BEHAVIORAL|Group-based motivational interviewing|
58269897|NCT00473785|BEHAVIORAL|Individual CVD-risk factor feedback|
58269898|NCT00473785|BEHAVIORAL|Education for protective health behavior change|
58269899|NCT03631719|BIOLOGICAL|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
57917016|NCT04464954|DEVICE|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
57917017|NCT04464954|DEVICE|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
57917018|NCT04398953|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
58269900|NCT00334295|DRUG|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
58269901|NCT06034925|DRUG|Maribavir|maribavir 400mg twice daily
58269902|NCT06034925|DRUG|Valganciclovir|valganciclovir 900mg once daily
58269903|NCT02491125|DIETARY_SUPPLEMENT|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
58269904|NCT02491125|DIETARY_SUPPLEMENT|Placebo|12 weeks daily intake of 15g of maltodextrin
58388744|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
58388745|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
58388746|NCT00568594|DRUG|APL180|
58388747|NCT00568594|DRUG|Placebo|
58388748|NCT00708136|BEHAVIORAL|water based training program to improve balance|
58388749|NCT00296049|DRUG|daptomycin|
58388750|NCT00296049|DRUG|vancomycin|
58388751|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
57717349|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
57717350|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
57717351|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
57717352|NCT01970202|OTHER|Control|no treatment
57717353|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
57717354|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
57717355|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
58063319|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
58063320|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
58063321|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
58388752|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
57717356|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
57717357|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
57717358|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
57717359|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
58063322|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
58063323|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
58388753|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
58388754|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
58388755|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
58388756|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
58388757|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
58388758|NCT00918606|DRUG|LIPO-102|LIPO-102
58388759|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
58388760|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
58388761|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
57717360|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
58063324|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
58063325|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
58269905|NCT03218267|OTHER|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
58388762|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
58388763|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
58388764|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
57717361|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
57717362|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
57717363|NCT02738775|DRUG|Placebo|
58063326|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
58388765|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
58388766|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
58388767|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
58388768|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
58388769|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
58388770|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
58388771|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
57717364|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
58269906|NCT03218267|OTHER|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
57717365|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
57717366|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
57717367|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
57717368|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
57717369|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
57717370|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
57917019|NCT00582686|PROCEDURE|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
58269907|NCT02240069|BEHAVIORAL|Education (Tx1)|Education on best burn practices
58269908|NCT02240069|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
58269909|NCT02240069|DEVICE|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
58269910|NCT02380495|OTHER|Data Collection|
58269911|NCT00376272|DRUG|Valsartan|
58269912|NCT00376272|DRUG|Placebo|
58269913|NCT01895348|DRUG|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
58269914|NCT01895348|DRUG|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
58269915|NCT01895348|DRUG|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
58269916|NCT03838237|DIAGNOSTIC_TEST|Cardiological evaluation|"Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
58269917|NCT02947906|OTHER|No intervention|No intervention
58269918|NCT06540417|DEVICE|External trigeminal nerve stimulation|The stimulation parameters were set to 120Hz, 250μs, 30s ON-30s OFF, with the intensity adjusted for patient comfort.
58269919|NCT00676572|OTHER|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
58269920|NCT05901584|DRUG|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
58269921|NCT01366794|OTHER|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
57717371|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
57717372|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
57717373|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
57717374|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
57717375|NCT02331446|BEHAVIORAL|Physical exercise intervention|
57717376|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
57717377|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
57917020|NCT00582686|PROCEDURE|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
57917021|NCT04261491|PROCEDURE|scaling and root planing|scaling and root planing
57917022|NCT05165797|BIOLOGICAL|platelet activation factors|platelet activation factors of subject blood
58063327|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
58269922|NCT01541839|DEVICE|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
58269923|NCT06431113|COMBINATION_PRODUCT|Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )|treatment for 4 months and then cross over to the other therapy
58269924|NCT04220086|PROCEDURE|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
58269925|NCT04220086|PROCEDURE|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
58269926|NCT04220086|OTHER|No intervention|No intervention for healthy controls
58269927|NCT00005005|DRUG|PTH|
58269928|NCT00005005|DRUG|Alendronate|
57717378|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
58269929|NCT00874562|DRUG|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
58269930|NCT00874562|DRUG|Rapamycin|Taken orally mixed with water or orange juice
58269931|NCT06016985|DIETARY_SUPPLEMENT|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
58269932|NCT02165475|BEHAVIORAL|Biofeedback|
58388772|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
58388773|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
58388774|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
58388775|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
57717379|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
58269933|NCT02165475|DRUG|Loperamide|
58388776|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
57717380|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
57717381|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
57717382|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
57717383|NCT00000189|DRUG|Gepirone|
57717384|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
57717385|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
57717386|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
57717387|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
57917023|NCT06090877|DEVICE|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
58269934|NCT02165475|DRUG|Stool bulking agent (stericulia or isphagula husk)|
58269935|NCT02165475|OTHER|Combination of biofeedback and medical treatment|
58269936|NCT01291576|PROCEDURE|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
58269937|NCT01291576|PROCEDURE|Rectal nodule excision|Either full thickness excision or rectal shaving
58269938|NCT06558188|DRUG|Romosozumab|romosozumab 210 milligrams monthly
58269939|NCT06558188|DRUG|Teriparatide|teriparatide 20 micrograms daily
58269940|NCT00709007|BEHAVIORAL|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
58269941|NCT00709007|BEHAVIORAL|SAT|Participants take their HIV medications by themselves.
58269942|NCT00077441|DRUG|bortezomib|Given IV
58269943|NCT00077441|OTHER|laboratory biomarker analysis|Correlative studies
58388777|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
58388778|NCT00371202|PROCEDURE|keratoplasty|
58388779|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
58388780|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
58388781|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
58388782|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
58388783|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
58388784|NCT04856605|PROCEDURE|surgery|regular surgery
58388785|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
58388786|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
58388787|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
58388788|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
58269944|NCT05248724|COMBINATION_PRODUCT|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
58269945|NCT05248724|DRUG|placebo|50 ml of 0.9 saline
57717388|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
57717389|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
57717390|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
57717391|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
57717392|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
57717393|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
57717394|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
57717395|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
57717396|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
57717397|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
57717398|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
57717399|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
57717400|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
58269946|NCT05212324|PROCEDURE|widening of first web space|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
58269947|NCT01651338|PROCEDURE|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
58269948|NCT00778102|DRUG|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
58269949|NCT00778102|DRUG|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
57717401|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
58269950|NCT00778102|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
58269951|NCT00778102|DRUG|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
58269952|NCT00778102|DRUG|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
58269953|NCT00778102|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
58269954|NCT00778102|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
58269955|NCT00778102|DRUG|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
57717402|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
57717403|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
57717404|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
57717405|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
57917024|NCT02057523|DRUG|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
58063328|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
57917025|NCT02683005|DRUG|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
58063329|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
57917026|NCT05065333|OTHER|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
57917027|NCT05065333|OTHER|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
57917028|NCT00284986|DRUG|Prochymal®|Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
58063330|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
58269956|NCT05329051|BIOLOGICAL|SCTV01E|intramuscular injection
58269957|NCT05329051|BIOLOGICAL|Comirnaty|intramuscular injection
58269958|NCT05679817|OTHER|Dose-graded aerobic exercises|The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes
57717406|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
57717407|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
57717408|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
57717409|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
58269959|NCT05679817|OTHER|Traditional physical rehabilitation|The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
58269960|NCT00551161|DRUG|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
58388789|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
58388790|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
58388791|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
58388792|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
57917029|NCT00235547|BEHAVIORAL|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
57917030|NCT03200379|OTHER|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
57917031|NCT05102604|OTHER|Avocado|Subjects will eat one avocado in addition to their usual diet
57917032|NCT05102604|OTHER|Habitual diet|Subjects will eat their usual diet
57917033|NCT00947557|DRUG|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
57917034|NCT00947557|DRUG|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
57917035|NCT02801968|PROCEDURE|Tap block|
57917036|NCT02801968|OTHER|intravenous analgesia|
57917037|NCT03457038|BIOLOGICAL|Blood Test|"Addition to the current care but during the normal follow-up visit :~* At the entrance to the service: search for bacterial 16S RNA in the blood~* Additional blood tests (4) at T6-12-18 and 36h~* At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~* 1 time per day: Assay of CRP and PCT from samples taken in common practice~* J30: Assessment of the vital status of the patient"
58063331|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
58063332|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
58269961|NCT04898972|BEHAVIORAL|Mindfulness-based stress reduction intervention|The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months. Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week. For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice. During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants. This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel. The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
58269962|NCT04898972|BEHAVIORAL|Information on stress reduction|"COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet Coping with your chronic disease, targeting COPD patients, to teach them how to manage stress. This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress."
58269963|NCT02033200|DRUG|Stendra 200 mg|
58269964|NCT02033200|DRUG|Placebo|
58269965|NCT01108419|OTHER|Fermented dairy product|
58269966|NCT01108419|OTHER|milk-based non-fermented dairy product|
58269967|NCT03197870|DRUG|AKB-9778|Subcutaneous AKB-9778 15mg
58269968|NCT03197870|DRUG|Placebo|Subcutaneous Placebo
58269969|NCT03345888|OTHER|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
58063333|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
58269970|NCT05510219|DRUG|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
58269971|NCT04796883|DEVICE|Hanita Glaucoma shunt Ver.3.2|The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
58269972|NCT04694768|BEHAVIORAL|Rehabilitation|Rehabilitation program
58269973|NCT01678885|BEHAVIORAL|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
58269974|NCT01678885|OTHER|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
58269975|NCT01678885|DEVICE|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
58388793|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
58388794|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
58269976|NCT01678885|BEHAVIORAL|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
58269977|NCT01678885|DEVICE|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
58388795|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
58388796|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
58388797|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
58388798|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
58388799|NCT02266147|DRUG|SD-101|
58063334|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
58063335|NCT05248776|DRUG|Placebo|Matching placebo tablet.
58063336|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
58063337|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
58063338|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
58063339|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
58269978|NCT01678885|DEVICE|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
58269979|NCT03530813|OTHER|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
58269980|NCT03530813|OTHER|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
58269981|NCT05919095|DRUG|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
58388800|NCT02266147|RADIATION|Radiation therapy|
58388801|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
58388802|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
58388803|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
58388804|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
57717410|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
57717411|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
58269982|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
58269983|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
58388805|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
58388806|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
58388807|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
58388808|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
57717412|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
57717413|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
58388809|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
58388810|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
58388811|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
58388812|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
58388813|NCT02919891|OTHER|Questionnaire|Questionnaires
58388814|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
57717414|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
57717415|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
57717416|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
57717417|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
57717418|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
57717419|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
57717420|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
57717421|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
58269984|NCT02315872|DRUG|ACTH|ACTH injections twice weekly for 28 weeks.
58269985|NCT02315872|DRUG|Placebo|Placebo injections twice weekly for 28 weeks.
58269986|NCT00618709|DRUG|ATX-101|ATX-101 single dose
58269987|NCT02107573|PROCEDURE|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
58269988|NCT02107573|PROCEDURE|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
58269989|NCT02956057|DRUG|Polyethylene Glycols|
58269990|NCT02956057|DRUG|Natrium picosulfate / Magnesium citrate|
58269991|NCT02956057|DRUG|Polyethylene glycol / Ascorbic acid|
57717422|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
58269992|NCT05160194|BEHAVIORAL|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
57717423|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
57717424|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
57917038|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
57917039|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
57917040|NCT05872360|DIETARY_SUPPLEMENT|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
57917041|NCT05872360|DIETARY_SUPPLEMENT|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
57917042|NCT04876677|DRUG|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
57917043|NCT02874339|DEVICE|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
57917044|NCT02874339|DEVICE|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
57917045|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
57917046|NCT01401192|DRUG|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks
58063340|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
58063341|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
58063342|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
57717425|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
58063343|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
58063344|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
58063345|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
58063346|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
57717426|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
57717427|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
57717428|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
58063347|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
57717429|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
57717430|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
57717431|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
58269993|NCT04800874|DRUG|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
57717432|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
58269994|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
58269995|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
58269996|NCT04580537|DRUG|Enstilar|Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
58269997|NCT04580537|DEVICE|Ablative fractional laser|Pre-treatment of affected fingers (nail plates, nail folds)
58269998|NCT06386692|BEHAVIORAL|FCHVs-led community based educational physical activity intervention|This intervention will be designed to promote physical activity among adults
58269999|NCT01542034|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
58270000|NCT01542034|DRUG|Placebo|Phosphate buffered saline placebo for injection
58270001|NCT01851187|BEHAVIORAL|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
58388815|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
57717433|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
57917047|NCT01401192|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks
57917048|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
58270002|NCT01851187|BEHAVIORAL|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
57717434|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
58270003|NCT04523870|DIETARY_SUPPLEMENT|Botanical extract|One capsule
58270004|NCT04523870|DIETARY_SUPPLEMENT|Main compound of the botanical extract|one capsule
57917049|NCT00627211|PROCEDURE|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
58270005|NCT04523870|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, one capsule
57717435|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
57917050|NCT02466633|OTHER|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
57917051|NCT02874274|BEHAVIORAL|Standard of Care|
57717436|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
57717437|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
57717438|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
58270006|NCT03452241|OTHER|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
57717439|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
57717440|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
57717441|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
57717442|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
58270007|NCT03452241|OTHER|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
57717443|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
57717444|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
57717445|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
58063348|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
58270008|NCT01884012|PROCEDURE|long term oxygen therapy|
58270009|NCT05479838|PROCEDURE|Percutaneous coronary intervention|Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
58388816|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
58388817|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
58388818|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
57717446|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
57717447|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
57717448|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
58270010|NCT01286194|DRUG|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
58270011|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
58270012|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac)|MRI without contrast
58270013|NCT03532815|BEHAVIORAL|Lifestyle Modification|
58270014|NCT01570569|DRUG|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
58270015|NCT01570569|DRUG|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
57717449|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
58270016|NCT01570569|DRUG|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
58270017|NCT01570569|DRUG|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
58388819|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
57717450|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
57717451|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
58388820|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
57717452|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
57717453|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
57717454|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
57917052|NCT02874274|BEHAVIORAL|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
57917053|NCT05132283|DEVICE|3D Slicer|Navigational device used during surgery to locate abnormal lymph nodes.
57917054|NCT05132283|DEVICE|Monaco|Navigational device used during surgery to locate abnormal lymph nodes.
57917055|NCT00887432|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
57917056|NCT00887432|OTHER|Laboratory Biomarker Analysis|Correlative studies
57917057|NCT00887432|OTHER|Patient Observation|
58063349|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
58270018|NCT01570569|DRUG|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
58270019|NCT01570569|DRUG|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
58270020|NCT02358785|DEVICE|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
58270021|NCT03619824|DRUG|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
57717455|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
58270022|NCT03619824|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
58270023|NCT03619824|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
58270024|NCT03619824|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
57717456|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
57717457|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
57717458|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
57717459|NCT01014494|DEVICE|Adaprev|Class III Medical Device
57717460|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
57717461|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
57917058|NCT00887432|DRUG|Placebo Administration|Given PO
57917059|NCT00887432|OTHER|Quality-of-Life Assessment|Ancillary studies
57917060|NCT00887432|OTHER|Questionnaire Administration|Ancillary studies
57917061|NCT00002996|DRUG|flecainide acetate|
57917062|NCT01576653|OTHER|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
58270025|NCT00574249|BIOLOGICAL|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
58270026|NCT00574249|DRUG|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
58270027|NCT00574249|DRUG|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
58270028|NCT02846870|OTHER|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
58270029|NCT02846870|OTHER|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
58270030|NCT01451242|OTHER|no intervention is made|no intervention is made
58270031|NCT04182438|DIETARY_SUPPLEMENT|Low potassium content vegetables|use low-potassium content vegetables
58270032|NCT05571176|DRUG|S-ketamine|S-ketamine infusion 0.29 mg/kg/h for 4 hours
58270033|NCT04068740|PROCEDURE|Surgical treatment of valvular heart disease|Valve replacement or repair
58270034|NCT04068740|DIAGNOSTIC_TEST|Virtual treatment|Virtual valve replacement or repair surgery
58270035|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
58270036|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
57717462|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
57717463|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
57717464|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
57717465|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
57717466|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
58270037|NCT05280899|OTHER|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
58270038|NCT05280899|OTHER|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
58270039|NCT00110916|DRUG|Intra-articular metHuIL-1ra (anakinra)|anakinra
57717467|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
57717468|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
57717469|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
57717470|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
57717471|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
57917063|NCT06301282|BEHAVIORAL|assessment during the transition between OFF-levodopa (i.e. withdrawal of levodopa phase) and ON-levodopa (i.e. effect of Levodopa phase)states|Electroencephalographic measurements are taken during both motor and non-motor assessments while the transition between the OFF-levodopa and ON-levodopa states occurs
57917064|NCT00304525|DRUG|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
57917065|NCT04156854|DIAGNOSTIC_TEST|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
57917066|NCT02995954|DRUG|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
58270040|NCT00110916|DRUG|placebo|placebo
58270041|NCT03077659|DRUG|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
58388821|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
57717472|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
57717473|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
57717474|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
57717475|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
57717476|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
57717477|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
57717478|NCT00950638|DRUG|ARC1905|intravitreal injection
57717479|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
57917067|NCT00679237|BEHAVIORAL|smoking cessation|NRT and varenicline
57917068|NCT00679237|DRUG|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
57917069|NCT00679237|DRUG|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
57917070|NCT00679237|BEHAVIORAL|training|daily walking
57917071|NCT00679237|BIOLOGICAL|influenza vaccine|vaccine (FLuarix, Influvac etc)
57717480|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
57717481|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
57717482|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
57717483|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
57917072|NCT00679237|DRUG|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
57917073|NCT00679237|BEHAVIORAL|weight reduction|diet tips
57917074|NCT06063785|DIAGNOSTIC_TEST|Acoustic Radiation Forced Impulse Imaging|Measurement of Liver stiffness
57917075|NCT06063785|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|Measurement of optoacoustic spectra in liver and gastrointestinal tract
57917076|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
57717484|NCT02096055|DRUG|Cladribine|Given IV
57717485|NCT02096055|DRUG|Guadecitabine|Given SC
57717486|NCT02096055|DRUG|Idarubicin|Given IV
57717487|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
57717488|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
57717489|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
57717490|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
57917077|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
57917078|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
57917079|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
57917080|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
57917081|NCT02920619|DEVICE|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
57917082|NCT01131234|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
57917083|NCT01131234|DRUG|Cediranib Maleate|Given PO
57917084|NCT01131234|OTHER|Pharmacological Study|Correlative studies
57917085|NCT01131234|OTHER|Laboratory Biomarker Analysis|Correlative studies
58270042|NCT05745467|DRUG|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
57917086|NCT04780347|DRUG|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
57917087|NCT04780347|DRUG|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
57917088|NCT06223204|OTHER|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
57917089|NCT02607696|DRUG|Zolpidem Hemitartarate|
57917090|NCT02932007|DRUG|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
58388822|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
57917091|NCT01209143|DRUG|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
57917092|NCT01209143|DRUG|Rosiglitazone|Rosiglitazone was supplied in tablets.
58270043|NCT01436864|BIOLOGICAL|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
57917093|NCT01209143|DRUG|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
57917094|NCT03890718|PROCEDURE|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
57917095|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Manioc powder (placebo) 60 g/day
57917096|NCT00502021|DIETARY_SUPPLEMENT|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
57917097|NCT00502021|DIETARY_SUPPLEMENT|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
58270044|NCT03579628|DRUG|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
58388823|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
57717491|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
57717492|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
57917098|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Safflower oil 30 ml/day
58270045|NCT02860117|DEVICE|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
58388824|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
58270046|NCT02860117|DRUG|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
58270047|NCT06731465|DEVICE|Clear aligner therapy|Participants in this group will receive clear aligners (EON Aligner, Minneapolis), designed and customized based on a digital model of each patient's dental structure. Aligners will be worn for at least 22 hours daily, and patients will change to a new aligner depending on treatment progress.
58388825|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
58388826|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
57717493|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
57717494|NCT03167294|DEVICE|AquaBeam System|Aquablation
57717495|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
58270048|NCT06731465|DEVICE|Fixed pre-adjusted edgewise orthodontic appliance|Participants in this group will be treated with pre-adjusted fixed orthodontic appliances (Master Series®, American Orthodontics™, WI, USA). This system includes fixed brackets bonded on the labial surface of teeth and a sequence of progressively larger arch wires aimed at achieving alignment over time.
57717496|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
58388827|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
58388828|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
58388829|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
58388830|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
57917099|NCT06137014|DRUG|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
57917100|NCT06137014|DIETARY_SUPPLEMENT|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
57917101|NCT04617210|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
57917102|NCT01468129|OTHER|Cell Saver|
57917103|NCT04997759|DRUG|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
57917104|NCT05740735|OTHER|"Use of expressive sounds"|"Use of expressive sounds, that is to say the own first name pronounced by the voice of the relative to generate the P300 and a sound with an approaching character of the subject to generate the MMN.~The investigators will thus be able to compare:~* MMN: present/absent for each modality (neutral vs approaching sounds)~* Wave P3a: latencies and amplitudes for each modality (own first name voice of the near vs unfamiliar)."
58388831|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
58388832|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
57917105|NCT05740735|OTHER|Having benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)|"Retrospective inclusion Have already had an assessment with event related potentials without emotional modalities (VF and similar sounds) as part of their care between April 2022 and December 2022 in intensive care at Cochin hospital."
57917106|NCT01684332|OTHER|Strawberry Jam|
57917107|NCT03797261|DRUG|Venetoclax|tablet, oral
57717497|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
57717498|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
57917108|NCT03797261|DRUG|AMG 176|solution, intravenous
57917109|NCT01079741|BIOLOGICAL|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
57917110|NCT04107376|DIAGNOSTIC_TEST|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
57917111|NCT03701815|BEHAVIORAL|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
57917112|NCT03309306|OTHER|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
57917113|NCT03309306|BEHAVIORAL|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns"
58270049|NCT05057572|DRUG|Carvedilol|- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
58270050|NCT05057572|DRUG|Standard Medical Treatment|"* Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
58270051|NCT03724266|DRUG|Chitosan|chitosan will be used as intracanal medication
58270052|NCT03724266|DRUG|Calcium Hydroxide|intracanal medication
57717499|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
57717500|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
57717501|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
57917114|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
58270053|NCT03677934|DRUG|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
57917115|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
57917116|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
57917117|NCT04188691|BIOLOGICAL|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
57917118|NCT04188691|BIOLOGICAL|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
57917119|NCT04448197|OTHER|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
57917120|NCT04491669|DIAGNOSTIC_TEST|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~* Stage1 in which GFR\>90 mil/min but evidence of kidney damage.~* Stage 2 GFR 60-89 mil/min.~* Stage 3 GFR 30-95 mil/min.~* Stage 4 GFR 15-29 mil/min.~* Stage 5 GFR\<15 mil/min."
58063350|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
58270054|NCT03677934|DRUG|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
58270055|NCT04460534|DIAGNOSTIC_TEST|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
58270056|NCT04459598|DRUG|Efavirenz|Single oral dose, 600-mg tablet
58270057|NCT04459598|DRUG|Quizartinib|Single oral dose, 60 mg (2 x 30 mg) tablets
58270058|NCT01987232|DRUG|Carfilzomib|Administered by intravenous infusion.
58388833|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
58063351|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
58270059|NCT01987232|DRUG|Carboplatin|Administered by intravenous infusion.
57717502|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
57717503|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
57917121|NCT01676909|BEHAVIORAL|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
57917122|NCT01676909|BEHAVIORAL|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
58270060|NCT01987232|DRUG|Etoposide|Administered by intravenous infusion.
58270061|NCT06611397|DEVICE|Discogen Low pulsed ultrasound treatment|"The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.~The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.~The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge"
57717504|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
57717505|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
57717506|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
57717507|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
57717508|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
57717509|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
57717510|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
57717511|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
57917123|NCT05517837|DRUG|BMS-986421|Specified dose on specified days
57717512|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
57917124|NCT05517837|OTHER|Placebo|Specified dose on specified days
57917125|NCT00095654|DRUG|Ramipril|
57917126|NCT00095654|DRUG|Rosiglitazone|
57917127|NCT02480153|BIOLOGICAL|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
57917128|NCT02480153|BIOLOGICAL|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
58270062|NCT06611397|DEVICE|Discogen Sham Treatment|The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week
57917129|NCT04989413|DRUG|Placebo oral drops|use of placebo for 12 weeks
57917130|NCT04989413|DRUG|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|use of cannabidiol + canabigerol + thc for 12 weeks
57917131|NCT00447304|DRUG|moxifloxacin|
57917132|NCT00447304|PROCEDURE|cholecystectomy|
58270063|NCT05005689|DRUG|Fluoride mouthwash (0.05%; 225ppm).|Mouthwash
58270064|NCT05005689|DRUG|Tooth Mousse Plus|Tooth Mousse
57917133|NCT05681858|DIAGNOSTIC_TEST|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
58270065|NCT06339359|OTHER|Exmainations including clinical measurement, kinetic and kinematic measurmetns. Behavioral assessments|Collection of clinical data including K-Bayley Scales of Infant and Toddler Development Third Edition (K-BSID-Ⅲ), , Beery-Buktenica Visual-Motor Integration, Sixth Edition (VMI-6) and clinical measurement. motor analysis and eye tracking
57717513|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
57717514|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
57717515|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
57717516|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
57717517|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
57717518|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
57717519|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
57717520|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
57717521|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
57717522|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
57717523|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
57917134|NCT03426254|BIOLOGICAL|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
57917135|NCT03426254|DRUG|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
58270066|NCT02363985|DIETARY_SUPPLEMENT|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
57717524|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
57717525|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
57717526|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
57717527|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
57717528|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
57717529|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
58270067|NCT04911335|COMBINATION_PRODUCT|Faringel plus and oral hygiene|The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
57717530|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
57717531|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
58270068|NCT06083844|DRUG|Pembrolizumab|Given by IV (vein)
58270069|NCT06083844|DRUG|Bevacizumab|Given by IV (vein)
58270070|NCT06083844|DRUG|Cyclophosphamide|Given by mouth
58270071|NCT05030675|DRUG|Fostamatinib|Given PO
58270072|NCT06355089|DIETARY_SUPPLEMENT|Placebo Comparator|Low-protein milk product
58270073|NCT06355089|DIETARY_SUPPLEMENT|Whey protein hydrolysate milk product|Milk product with whey protein hydrolysate
58270074|NCT06355089|DIETARY_SUPPLEMENT|Postbiotic and whey protein hydrolysate milk product|Milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
58270075|NCT05165199|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
58270076|NCT01448603|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
58270077|NCT01448603|BIOLOGICAL|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
57717532|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
57717533|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
57717534|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
57717535|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
57717536|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
57717537|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
58270078|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
58270079|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
58270080|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
58270081|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
58270082|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
58270083|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
58270084|NCT03422159|DRUG|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
58270085|NCT03422159|DRUG|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
58270086|NCT03422159|DRUG|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
58270087|NCT03422159|DRUG|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
57717538|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
57917136|NCT03775070|DRUG|Simvastatin|"* Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
57917137|NCT00252733|DRUG|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
57917138|NCT03314597|OTHER|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
57917139|NCT03314597|OTHER|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
57917140|NCT01166867|DEVICE|Photo-plethysmography monitoring|monitoring vital sign in infant
58063352|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
58063353|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
58063354|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
58063355|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
58063356|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
58063357|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
58270088|NCT05980143|OTHER|Metacognitive Therapy|The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
58270089|NCT05854615|BIOLOGICAL|Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
57917141|NCT01680068|PROCEDURE|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
58063358|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
58063359|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
58270090|NCT03380104|DEVICE|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
57717539|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
57917142|NCT03450967|DRUG|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
57917143|NCT03489473|DIAGNOSTIC_TEST|18F-FES PET CT scan|PET CT scan with estrogen tracer
57917144|NCT00187967|DEVICE|pumps used for cardiopulmonary bypass|
58063360|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
57917145|NCT00167960|DRUG|Piperacillin/tazobactam and other β-lactam/β-lactamase|
57917146|NCT02739373|DRUG|BMS-986189|
57917147|NCT02739373|OTHER|Placebo|
57917148|NCT02312388|OTHER|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
58063361|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
58063362|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
58063363|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
58063364|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
58063365|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
58063366|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
58063367|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
57917149|NCT02312388|OTHER|Thin-wall needle technique|using 18 - 21 G introducer needle
57917150|NCT04386187|OTHER|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
57917151|NCT04386187|OTHER|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
57917152|NCT04386187|OTHER|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
58063368|NCT00316212|DRUG|INS50589 Intravenous Infusion|
58063369|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
58063370|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
58063371|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
58270091|NCT03380104|BEHAVIORAL|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
58270092|NCT03003000|DRUG|ibuprofen|
57917153|NCT00006165|BEHAVIORAL|'Ohana (Family) Support Lifestyle Intervention|
58270093|NCT03003000|DRUG|caffeine|
58270094|NCT03003000|DRUG|placebo|
57917154|NCT03626519|OTHER|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
57917155|NCT03626519|OTHER|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
58270095|NCT02735707|DRUG|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
57717540|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
57717541|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg.
57717542|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
57717543|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
57717544|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
57717545|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
57717546|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57717547|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57717548|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
58270096|NCT02735707|DRUG|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
58270097|NCT02735707|DRUG|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
58270098|NCT02735707|DRUG|Ceftaroline|"The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Note: this intervention is now closed."
58270099|NCT02735707|DRUG|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
58270100|NCT02735707|DRUG|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
57717549|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57717550|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
57717551|NCT00253526|DRUG|bevacizumab|
57717552|NCT00253526|DRUG|gemcitabine hydrochloride|
57717553|NCT00253526|PROCEDURE|adjuvant therapy|
57717554|NCT00253526|PROCEDURE|anti-cytokine therapy|
57717555|NCT00253526|PROCEDURE|antiangiogenesis therapy|
57717556|NCT00253526|PROCEDURE|antibody therapy|
57717557|NCT00253526|PROCEDURE|biological therapy|
57717558|NCT00253526|PROCEDURE|chemotherapy|
57717559|NCT00253526|PROCEDURE|conventional surgery|
58388834|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
57717560|NCT00253526|PROCEDURE|growth factor antagonist therapy|
58388835|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
57717561|NCT00253526|PROCEDURE|monoclonal antibody therapy|
57717562|NCT00253526|PROCEDURE|surgery|
57717563|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
57717564|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
57917156|NCT03450512|OTHER|prospective study on digestive affections in an homogeneous cohort of hematological patients|"Systematic realization during the induction and/or every consolidation of a CTscan with injection, at the same time as the thoracic CTscan (to research an invasive fungal bronchopulmonary infection), in front of a febrile neutropenia with persistent fever after 5 days of antibiotics and presence of digestive signs.~Statement of the information characterizing the digestive affection: clinical symptoms, microbiological, characteristic, realized additional explorations, infectious complications and specific therapeutics.~The abdominal scanner will be repeated in case of suspicion of complication or clinical worsening. In case of EC, the abdominal scanner will be realized before beginning the next cycle of AML treatment to evaluate digestive remission. Finally, a CT scan, will be performed when digestive disease, digestive neoplasia or digestive symptoms are noted at AML diagnosis."
57917157|NCT05925179|PROCEDURE|Surgical crown lengthening|Surgical clinical crown lengthening with bone excision
57917158|NCT05925179|DRUG|Augmentin|Pre-operative antibiotic prophylaxis (2 g Augmentin)
57917159|NCT04361188|PROCEDURE|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
58388836|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
58388837|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
58388838|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
57717565|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
57717566|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
58388839|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
57717567|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
57717568|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
57717569|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
57917160|NCT04361188|PROCEDURE|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
57917161|NCT00061529|DRUG|Brimonidine Tartrate Ophthalmic Solution|
57917162|NCT05397184|BIOLOGICAL|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
58063372|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
58388840|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
58063373|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
58063374|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
58388841|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
58388842|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
57917163|NCT02647294|DIETARY_SUPPLEMENT|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
57917164|NCT02647294|OTHER|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
57917165|NCT02754817|DRUG|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
57917166|NCT01718353|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
57917167|NCT01718353|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
57917168|NCT01718353|DRUG|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
57917169|NCT02409368|DRUG|Nivolumab|
58388843|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
58388844|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
58388845|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
58388846|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
58388847|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
58388848|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
58270101|NCT02735707|DRUG|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
58270102|NCT02735707|OTHER|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
58388849|NCT04166773|DRUG|Tirzepatide|Administered SC
58388850|NCT04166773|DRUG|Placebo|Administered SC
58388851|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
57717570|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
58388852|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
58388853|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
58270103|NCT02735707|DRUG|Fixed-duration Hydrocortisone|"50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed."
58388854|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
58388855|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
58388856|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
58388857|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
58270104|NCT02735707|DRUG|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
58270105|NCT02735707|DRUG|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
58388858|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
58388859|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
58388860|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
58388861|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
58388862|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
58388863|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
58388864|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
58388865|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
58270106|NCT02735707|OTHER|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
58270107|NCT02735707|DRUG|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
58270108|NCT02735707|DRUG|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
58270109|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
58388866|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
58270110|NCT02735707|DRUG|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
57717571|NCT05458349|DEVICE|acellular dermis|
57717572|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
58270111|NCT02735707|DRUG|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
57717573|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
57717574|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
57717575|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
57717576|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
57717577|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
57717578|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
58270112|NCT02735707|DRUG|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
58270113|NCT02735707|DRUG|Ivermectin|"Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.~Note: this intervention is now closed."
58270114|NCT02735707|OTHER|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
57717579|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
57717580|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
57917170|NCT02303522|OTHER|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
58270115|NCT02735707|DRUG|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
58270116|NCT02735707|DRUG|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
58270117|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.~Note: this intervention is now closed."
57717581|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
57717582|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
57717583|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
57717584|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
57717585|NCT00125554|DRUG|Metyrapone|
57717586|NCT00733824|DRUG|AMD3100|
57917171|NCT03414489|DRUG|ABC294640|
57917172|NCT03753659|DRUG|Pembrolizumab|IV infusion
57717587|NCT00733824|DRUG|G-CSF|
57717588|NCT00733824|PROCEDURE|Apheresis|
57917173|NCT03753659|PROCEDURE|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
57917174|NCT03753659|PROCEDURE|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
57917175|NCT03753659|RADIATION|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
57717589|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
57717590|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
57917176|NCT03753659|DRUG|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
57917177|NCT04291820|PROCEDURE|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
57717591|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
57717592|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
57717593|NCT00949780|DRUG|Chloral Hydrate|
57917178|NCT04291820|PROCEDURE|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
57917179|NCT01907360|DRUG|HLD200 (methylphenidate hydrochloride)|
57917180|NCT03897244|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
57917181|NCT03897244|DRUG|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
57917182|NCT03897244|DRUG|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
57917183|NCT05353673|DRUG|Sitagliptin|Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
57917184|NCT05353673|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
58270118|NCT02735707|DRUG|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
57917185|NCT00605644|DRUG|MOA-728|Oral Capsules
57917186|NCT00605644|DRUG|Placebo|Placebo
58270119|NCT02735707|DRUG|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270120|NCT02735707|DRUG|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
58388867|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
58388868|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
57917187|NCT05219474|DIAGNOSTIC_TEST|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
58388869|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
57917188|NCT06294054|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
58388870|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
58388871|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
58388872|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
58388873|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
58270121|NCT02735707|DRUG|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
57717594|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
57717595|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
57717596|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
57717597|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
57717598|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
57717599|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
57717600|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
57717601|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
57717602|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
57717603|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
57717604|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
57717605|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
57717606|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
57717607|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
57717608|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
58270122|NCT02735707|DRUG|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
58270123|NCT02735707|DRUG|Continuation of therapeutic dose anticoagulation|"Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270124|NCT02735707|OTHER|No immunoglobulin|No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
57717609|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
57717610|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
57717611|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
57717612|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
58388874|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
58388875|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
57717613|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
57717614|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
57717615|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
57717616|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
57717617|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
57717618|NCT04485481|DRUG|Placebo|Matching single dose placebo
57917189|NCT05172349|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
58270125|NCT02735707|BIOLOGICAL|Convalescent plasma|Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
58270126|NCT02735707|BIOLOGICAL|Delayed administration of convalescent plasma|Note: this intervention is now closed.
58388876|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
58388877|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
57917190|NCT03686748|BEHAVIORAL|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
57917191|NCT03686748|BEHAVIORAL|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
57917192|NCT02569203|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition
58270127|NCT02735707|OTHER|No vitamin C|"No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed."
58270128|NCT02735707|DRUG|Vitamin C|"Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed."
58270129|NCT02735707|OTHER|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
58270130|NCT02735707|DRUG|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270131|NCT02735707|DRUG|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270132|NCT02735707|OTHER|No simvastatin|"No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed."
58388878|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
57717619|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
57717620|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
57717621|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
57917193|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
57917194|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
58388879|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
58388880|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
58388881|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
58388882|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
58388883|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
58388884|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
57717622|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
57717623|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
57717624|NCT02985736|DRUG|Topicort Topical Spray|
57717625|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
57917195|NCT01669876|DIETARY_SUPPLEMENT|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
58270133|NCT02735707|DRUG|Simvastatin|"Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed."
58388885|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
58388886|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
58388887|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
58388888|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
58388889|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
58388890|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
58388891|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
58388892|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
58388893|NCT02147197|DRUG|Placebo|Matching placebo tablet.
57717626|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
57717627|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
57717628|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
57717629|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
57917196|NCT01669876|DIETARY_SUPPLEMENT|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
57917197|NCT06340399|DIETARY_SUPPLEMENT|BCAA|patients administering BCAA
57917198|NCT06340399|OTHER|patient not administered BCAA|patients not administered BCAA
57917199|NCT03215810|PROCEDURE|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
58388894|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
57917200|NCT03215810|DRUG|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
58388895|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
58388896|NCT05937386|DRUG|AGMB-129|Oral capsule
58388897|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
58388898|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
58388899|NCT02933879|DRUG|NVXT topical|topical treatment
58388900|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
57717630|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
58388901|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
57717631|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
57717632|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
57717633|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
57717634|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
57717635|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
57717636|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
57717637|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
58388902|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
58388903|NCT02791035|DRUG|Oral administration of Ipragliflozin|
58388904|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
57717638|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
57717639|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
57717640|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
57917201|NCT03215810|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
57917202|NCT03215810|DRUG|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
57917203|NCT03215810|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
57917204|NCT03215810|DRUG|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
57917205|NCT00407277|DRUG|Nicotine patch|21 mg of nicotine via a dermal patch
57917206|NCT00407277|OTHER|placebo|placebo via a dermal patch
58388905|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
58388906|NCT01786382|DRUG|PPI-668|
58388907|NCT01786382|DRUG|Midazolam|
58388908|NCT01786382|DRUG|Omeprazole|
58388909|NCT01786382|DRUG|Telaprevir|
58388910|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
58388911|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
58388912|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
58388913|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
58388914|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
58388915|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
58388916|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
58388917|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
57717641|NCT05895006|DEVICE|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
57717642|NCT05895006|DEVICE|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
57717643|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
57717644|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
57717645|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
57717646|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
57717647|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
57717648|NCT00298896|DRUG|SNS-595|
58388918|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
58270134|NCT02735707|DRUG|Eritoran|"Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed."
58270135|NCT02735707|DRUG|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58388919|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
58388920|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
57717649|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
57717650|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
57717651|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
57717652|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
57717653|NCT01070810|DRUG|D5W|Dextrose 5%
57717654|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
58388921|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
58388922|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
58388923|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
58388924|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
57717655|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
57717656|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
57717657|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
58270136|NCT02735707|PROCEDURE|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
57717658|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
57717659|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
57717660|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
57717661|NCT03861000|DRUG|BPN14770|selective compound
58388925|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
58388926|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
58388927|NCT00090961|OTHER|educational intervention|
57717662|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
57717663|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
57717664|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
57717665|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
57717666|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
57917207|NCT00407277|BEHAVIORAL|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
58063375|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
58270137|NCT02735707|PROCEDURE|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
58388928|NCT00090961|OTHER|supervised exercise program|
57717667|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
57917208|NCT05021094|DRUG|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
58063376|NCT01697371|RADIATION|Proton Radiation|
58270138|NCT02735707|OTHER|No renin-angiotensin system inhibitor|"No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed."
57717668|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
57717669|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
57717670|NCT00213174|BEHAVIORAL|school playgrounds|
57717671|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
57717672|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
57717673|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
58063377|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
58063378|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
58063379|NCT02161614|DRUG|Estradiol valerate|
58063380|NCT02161614|DRUG|Placebo|
58270139|NCT02735707|DRUG|Angiotensin converting enzyme inhibitor|"Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270140|NCT02735707|DRUG|Angiotensin Receptor Blockers|"Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
57717674|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
57717675|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
57917209|NCT05021094|DRUG|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
58388929|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
57917210|NCT00920049|BEHAVIORAL|Persuasion|
57917211|NCT04009915|PROCEDURE|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
57917212|NCT04009915|PROCEDURE|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
57917213|NCT01911065|BIOLOGICAL|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
57917214|NCT02641223|DEVICE|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
57917215|NCT06043167|DIAGNOSTIC_TEST|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
58063381|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
58063382|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
58063383|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
58063384|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
58063385|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
58388930|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
58388931|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
58388932|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
58388933|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
58388934|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
57717676|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
57717677|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
57717678|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
58270141|NCT02735707|DRUG|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed."
58270142|NCT02735707|OTHER|No cysteamine|"No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed."
58270143|NCT02735707|DRUG|Cysteamine|"Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
58270144|NCT02735707|DRUG|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
58270145|NCT02735707|DRUG|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
58270146|NCT02735707|DRUG|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
58270147|NCT02735707|DRUG|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
58270148|NCT02735707|OTHER|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
57717679|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
57717680|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
57917216|NCT02835326|BEHAVIORAL|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
58270149|NCT02735707|DRUG|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
58270150|NCT02735707|OTHER|No Immune Modulator for Influenza|No immune modulating agent intended to be active against influenza is to be administered.
57717681|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
57717682|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
58063386|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
58270151|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
58270152|NCT02735707|DRUG|Baricitinib|Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
58270153|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
58270154|NCT02735707|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
58270155|NCT02735707|DRUG|Remdesivir|Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
58063387|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
57717683|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
57717684|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
57717685|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
57717686|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
57717687|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
57717688|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
57717689|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
57717690|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
57917217|NCT02835326|BEHAVIORAL|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
58270156|NCT02735707|DRUG|Nirmatrelvir/ritonavir + remdesivir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
58270157|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
58388935|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
58388936|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
58063388|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
58063389|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
57717691|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
58270158|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
58270159|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
57917218|NCT01313689|DRUG|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
58063390|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
58270160|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
58270161|NCT05537623|BEHAVIORAL|Safe Alternatives for Teens and Youths (SAFETY)|Please see description of experimental arm (arm one)
58270162|NCT05537623|BEHAVIORAL|Supportive Therapy|Please see description of active comparator arm (arm two)
58270163|NCT05180370|OTHER|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
58388937|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
58388938|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
58388939|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
58388940|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
58388941|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
58388942|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
58388943|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
58063391|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
58063392|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
58063393|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
58063394|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
58270164|NCT02110030|DEVICE|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
58388944|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
57917219|NCT01313689|DRUG|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
57917220|NCT00330265|DEVICE|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
57917221|NCT00330265|OTHER|Conventional Wound Therapy|Normal Saline Dressings
57917222|NCT06333262|DRUG|Pirtobrutinib|"Initial treatment:~- Pirtobrutinib 200 mg by mouth (PO) daily from Cycle 1 Day 1 until the end of Cycle 12. Each cycle is 28 days.~Re-treatment:~-Pirtobrutinib 200 mg PO daily continuously"
58063395|NCT02181335|DRUG|Respimat® Budesonide low dose|
57917223|NCT06333262|DRUG|Obinutuzumab|"Obinutuzumab is given intravenously from Cycle 7 to Cycle 12, for total 6 cycles during initial treatment only.~Initial treatment:~- Obinutuzumab intravenous (IV) following the standard schedule from Cycle 6 through Cycle 12 (total 6 cycles: 100 mg on Cycle 6 Day 1, 900 mg on Cycle 6 Day 2, 1000 mg on Cycle 6 Day 8 and Cycle 6 Day 15, 1000 mg on Day 1 of Cycle 7 through Cycle 12)."
57917224|NCT00186394|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
57917225|NCT06086925|DRUG|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
57917226|NCT03975738|OTHER|To be part of a blog|To be part of a blog - to respond to questions and free to comment on other participants comments
57917227|NCT05536011|DRUG|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
58063396|NCT02181335|DRUG|Respimat® Budesonide high dose|
58063397|NCT02181335|DRUG|Turbohaler® Budesonide|
58063398|NCT02181335|DRUG|Placebo|
58063399|NCT01969565|DRUG|Carfilzomib|
58063400|NCT01969565|DRUG|Dexamethasone|
58063401|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
57917228|NCT05536011|DRUG|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
57917229|NCT02661087|PROCEDURE|Hysteroscopic resection with bipolar energy|Hysteroscopic resection with bipolar energy
57917230|NCT02661087|PROCEDURE|Hysteroscopic resection with monopolar energy|Hysteroscopic resection with monopolar energy
57917231|NCT02675868|DRUG|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
57917232|NCT02675868|DRUG|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
57917233|NCT02675868|DRUG|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
57917234|NCT02675868|DRUG|Placebo|NaCl 0.9% infusion
57917235|NCT00286260|DRUG|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
57917236|NCT02054988|OTHER|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake."
57917237|NCT02054988|OTHER|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
58063402|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
58063403|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
58063404|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
58063405|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
58063406|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
58063407|NCT06323863|RADIATION|ultra high resolution CT|imaging study
58063408|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
58063409|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
58063410|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
58063411|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
58063412|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
58063413|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
58063414|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
58063415|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
57717692|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
57717693|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
57717694|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
57717695|NCT04678414|OTHER|Survey Administration|Complete survey
57717696|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
57717697|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
57717698|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
57717699|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
57717700|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
57917238|NCT05251467|OTHER|Focus group|Focus group to confirm PROM conceptual framework
57917239|NCT05251467|OTHER|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
57717701|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
57917240|NCT05251467|OTHER|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
57917241|NCT05251467|DEVICE|Testing of the pilot PROM in a smartphone app (n = 150)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
58063416|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
58388945|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
57717702|NCT02749903|DRUG|enzalutamide|oral
57717703|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
57717704|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
57717705|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
57717706|NCT02665481|BEHAVIORAL|MBSR|
57717707|NCT02665481|BEHAVIORAL|Exercise|
57717708|NCT02665481|BEHAVIORAL|Health Education|
57717709|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
57717710|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
57717711|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
57717712|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
57717713|NCT04560504|OTHER|Control Group|Leisure activities
57717714|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
57717715|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
57717716|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
57717717|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
57717718|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
57717719|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
57717720|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
57717721|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
57717722|NCT06662682|OTHER|Control Condition|Non-intervention control condition
57717723|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
57717724|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
57917242|NCT00323856|DRUG|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
57917243|NCT01937156|DRUG|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
58063417|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
58063418|NCT05516316|DRUG|EP395|Capsule for oral use
57717725|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
57717726|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
57717727|NCT00900484|OTHER|biologic sample preservation procedure|
57717728|NCT00900484|OTHER|immunohistochemistry staining method|
57717729|NCT00900484|OTHER|laboratory biomarker analysis|
57717730|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
57717731|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
57717732|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
57717733|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
57717734|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
57717735|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
57717736|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
57717737|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
57717738|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
57717739|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
57717740|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
57717741|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
57717742|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
57717743|NCT02261116|DRUG|Telmisartan|
57717744|NCT02261116|DRUG|Candesartan|
57717745|NCT02261116|DRUG|Placebo|
57917244|NCT01937156|DRUG|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
57917245|NCT03326453|DEVICE|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
57917246|NCT04832282|DEVICE|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
57917247|NCT04832282|OTHER|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
57917248|NCT04480125|DRUG|Azacitidine|100mg D1-7
57917249|NCT04480125|DRUG|Chidamide|30mg BIW PO
57917250|NCT03466996|BEHAVIORAL|Intervention group|More frequent follow up with face to face interaction.
57717746|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
57717747|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
57717748|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
57717749|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
57717750|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
57917251|NCT03466996|BEHAVIORAL|Standard of care group|Transition goal setting during annual follow up.
57917252|NCT00319839|DRUG|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
57717751|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
57717752|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
57717753|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
57717754|NCT06205290|DRUG|Rituximab|Specified dose on specified days
57717755|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
57717756|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
57917253|NCT00319839|DRUG|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
57917254|NCT00580346|DEVICE|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
57917255|NCT02216045|DRUG|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
57917256|NCT02216045|DRUG|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
57917257|NCT01355653|DEVICE|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
57917258|NCT01355653|DEVICE|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
58063419|NCT05516316|DRUG|Placebo|Capsule for oral use
57717757|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
58063420|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
58270165|NCT02110030|DEVICE|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
57717758|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
57717759|NCT00393549|DEVICE|NeuroPath|
57717760|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
57717761|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
57717762|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
57717763|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
57717764|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
57717765|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
57717766|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
57717767|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
57717768|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
57717769|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
57717770|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
57717771|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
58063421|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
58063422|NCT01412333|DRUG|Interferon beta-1a|
58063423|NCT01412333|DRUG|Ocrelizumab-matching placebo|
58063424|NCT01412333|DRUG|Ocrelizumab|
58063425|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
58063426|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
58270166|NCT01996657|DRUG|Warfarin|
58270167|NCT03837119|OTHER|pregnancy outcome|descriptive statistics of variables
58270168|NCT00980018|DRUG|Nilotinib|Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
57717772|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
58270169|NCT05026047|OTHER|HPV self-sampling|HPV self-sampling in HIV-positive women
57717773|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
57717774|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
57717775|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
57717776|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
57717777|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
57917259|NCT01234753|OTHER|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
57917260|NCT00234806|OTHER|Health-e-Access|telemedicine intervention
57917261|NCT05252650|BEHAVIORAL|pain|postoperative pain
57917262|NCT01130584|OTHER|Pyruvate kinase isoform M2|
58063427|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
58063428|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
58270170|NCT06300476|GENETIC|JWK006|Subretinal administration of gene therapy vector JWK006 to one eye.
58270171|NCT03557476|DIETARY_SUPPLEMENT|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
58270172|NCT03557476|DIETARY_SUPPLEMENT|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
58270173|NCT01273714|PROCEDURE|thyroid resection|bilateral subtotal versus total thyroidectomy
58270174|NCT05032742|BEHAVIORAL|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
58270175|NCT00310076|DRUG|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
57717778|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
57717779|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
57717780|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
57717781|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception and psychosocial factors|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
57717782|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
58270176|NCT00310076|PROCEDURE|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
58270177|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
57717783|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
57917263|NCT00014326|RADIATION|radiation therapy|
57917264|NCT00530907|DRUG|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
57917265|NCT00530907|DRUG|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
57917266|NCT01127269|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
58270178|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
58270179|NCT06596317|PROCEDURE|Chromoendoscopy|Patients will undergo chromoendoscopy with spraying indigo carmine.
58270180|NCT06596317|PROCEDURE|Conventional colonoscopy|Patients will undergo conventional colonoscopy.
58270181|NCT04364113|OTHER|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
57717784|NCT01159067|DRUG|deferasirox|Given orally
57717785|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
57917267|NCT05938374|DRUG|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
57917268|NCT05938374|RADIATION|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
57917269|NCT03172182|BEHAVIORAL|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
57917270|NCT04514666|OTHER|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
57917271|NCT05871177|DEVICE|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight \[32 mg (HHA) + 32 mg (LHA) / 2 ml\]
58063429|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
58063430|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
58063431|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
58063432|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
58270182|NCT04364113|OTHER|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
58270183|NCT04364113|OTHER|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
58270184|NCT04364113|DRUG|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
58063433|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
58063434|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
58270185|NCT04364113|DRUG|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
58270186|NCT03235115|DEVICE|Methafilcon A IV|Contact Lens
58270187|NCT03235115|DEVICE|Ocufilcon B|Contact Lens
58063435|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
58063436|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
58270188|NCT03235115|DEVICE|Omafilcon A|Contact Lens
57717786|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
57717787|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
58063437|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
58063438|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
58063439|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
58063440|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
58270189|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
57917272|NCT05241457|DEVICE|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
57917273|NCT05241457|PROCEDURE|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
57917274|NCT02121834|DRUG|LY3050258|
58270190|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
58270191|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
58270192|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
58270193|NCT06385197|DEVICE|App randomizing dosing regimen|patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.
58270194|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
58270195|NCT03059121|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|
58270196|NCT03884816|OTHER|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
58270197|NCT01036659|DRUG|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
58388946|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
57917275|NCT02121834|DRUG|Placebo|
57917276|NCT01672723|DRUG|Naltrexone|
57917277|NCT00014131|BIOLOGICAL|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
58270198|NCT02771600|DEVICE|Buzzy|See arm description
58270199|NCT02771600|DRUG|Topical anaesthetic cream|See arm description
58270200|NCT06182046|PROCEDURE|Complete decongestive treatment program|It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
58388947|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
57917278|NCT04707651|DIETARY_SUPPLEMENT|Formula diet|Formula diet for 12 weeks
57917279|NCT03706313|DRUG|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
57917280|NCT03706313|PROCEDURE|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
58388948|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
58388949|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
58388950|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
58270201|NCT06182046|PROCEDURE|Balance exercises|These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
57917281|NCT03706313|DRUG|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
57917282|NCT06011174|OTHER|survey application|Participants will only be asked to fill out the questionnaires.
57917283|NCT01945541|DEVICE|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
57917284|NCT02372656|DRUG|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
57917285|NCT02372656|DRUG|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
57917286|NCT02372656|DRUG|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
58270202|NCT04958902|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
58270203|NCT04306250|PROCEDURE|Apical prolapse fixation - anterior access|The surgery is done in anterior access
58388951|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
58388952|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
58388953|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
57917287|NCT04890925|BEHAVIORAL|Community Support Network (CSN) intervention|The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.
57917288|NCT04890925|BEHAVIORAL|Usual care|Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
57917289|NCT05236478|OTHER|CoviMouv' program|"* An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
57917290|NCT05236478|OTHER|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
57917291|NCT05635981|OTHER|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
58063441|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
58063442|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
58063443|NCT04852809|OTHER|No intervention|This is an observational study
58388954|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
58388955|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
58063444|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
58388956|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
58270204|NCT04306250|PROCEDURE|Apical prolapse fixation - posterior access|The surgery is done in posterior access
58270205|NCT03684824|DRUG|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
57917292|NCT05629481|PROCEDURE|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
57917293|NCT05629481|PROCEDURE|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
57917294|NCT03866304|DEVICE|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
57917295|NCT03050255|OTHER|Medical air|
57917296|NCT03050255|OTHER|Oxygen (2Liter/min)|
57917297|NCT03050255|OTHER|Oxygen (4Liter/min)|
58270206|NCT03684824|DRUG|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
58270207|NCT05794009|OTHER|Immersive Virtual Reality Exercise (IVRE)|The IVRE program will include aerobic exercise, muscle strengthening exercise, balance and flexibility exercise.
58388957|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
58063445|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
58063446|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
58270208|NCT05794009|OTHER|Home Exercise|Aerobic exercise, muscle strengthening exercise, balance and flexibility exercise at home.
58063447|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
58270209|NCT04705519|DRUG|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
58270210|NCT04068688|BEHAVIORAL|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
58388958|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
58388959|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
58388960|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
58270211|NCT04068688|BEHAVIORAL|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
58270212|NCT05191667|DRUG|AN0025|250 mg or 500 mg Q.D., oral administration
58270213|NCT04505449|DIAGNOSTIC_TEST|Left heart catheterization|Patients who underwent left heart catheterization
58270214|NCT04063657|PROCEDURE|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
58388961|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
58270215|NCT04063657|PROCEDURE|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
58270216|NCT01751581|BEHAVIORAL|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
58270217|NCT01751581|BEHAVIORAL|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
58388962|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
58388963|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
58388964|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
58270218|NCT01800019|DRUG|Nicotine Replacement Therapy (NRT)|
58270219|NCT01800019|DRUG|Varenicline|
58270220|NCT01800019|BEHAVIORAL|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
58270221|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
58270222|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
58270223|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
58270224|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
58270225|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
58270226|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
58270227|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
58270228|NCT05923411|DRUG|Single dose of PF-07220060 as third tablet formulation|A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
58388965|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
58388966|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
58270229|NCT03802565|DRUG|Tolperisone|TID
58270230|NCT03802565|DRUG|Placebo|Placebo
58270231|NCT00050817|DRUG|clopidogrel (SR25990)|
58388967|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
58388968|NCT01823107|DEVICE|Meso BioMatrix Device|
58388969|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
58388970|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
58388971|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
58388972|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
58388973|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
57717788|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
57717789|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
57717790|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
57717791|NCT04560712|OTHER|Best Practice|Undergo usual care
57717792|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
57717793|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
57717794|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
57717795|NCT00130962|DRUG|ALGRX 4975|
57717796|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
57717797|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
57717798|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
57717799|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
57717800|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
57717801|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
57717802|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
57717803|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
57717804|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
57717805|NCT00491790|OTHER|Sterile water|Sterile water
57717806|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
57717807|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
58270232|NCT03542591|OTHER|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
58270233|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Tilting|Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.
58388974|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
57717808|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
58063448|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
58388975|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
58388976|NCT00575107|OTHER|Exercise|Standard training of leg extension
58388977|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
57717809|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
57717810|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
57717811|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
57917298|NCT05432726|OTHER|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
57917299|NCT02086123|PROCEDURE|Epidural Analgesia|Bupivacaine + Fentanyl
57917300|NCT02086123|PROCEDURE|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
58388978|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
58388979|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
58388980|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
57917301|NCT02631512|DEVICE|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
57917302|NCT02631512|DEVICE|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
57917303|NCT00390182|DRUG|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study."
57917304|NCT05745831|OTHER|Therapeutic decision tool|A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
57917305|NCT03107104|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
57917306|NCT03107104|DEVICE|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
57917307|NCT03785171|PROCEDURE|surgical revascularization|Indirect revascularization procedure
57917308|NCT04595383|DEVICE|ti.care|Electronic platform for doctor-patient communication
58063449|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
57717812|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
58388981|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
58388982|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
58388983|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
58388984|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
58388985|NCT01903122|DRUG|Cevimeline|
58388986|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
58388987|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
58388988|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
58388989|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
58388990|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
58388991|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
58388992|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
58388993|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
57717813|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
58388994|NCT01018173|DRUG|placebo|sc weekly
58388995|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
58388996|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
58388997|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
58388998|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
58388999|NCT00666653|DRUG|pramipexole|
57717814|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
57717815|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
58389000|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
58389001|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
58389002|NCT03349138|DEVICE|Conventional Therapy|
58389003|NCT03349138|DEVICE|Robotic Glove|
57717816|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
57717817|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
58389004|NCT03349138|DEVICE|Electrical Stimulation|
57717818|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
57717819|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
57717820|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
58389005|NCT00230776|DRUG|pregabalin|
58389006|NCT00230776|DRUG|placebo|
58270234|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure|The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.
58389007|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
57717821|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
57717822|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
58270235|NCT04505202|DRUG|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
57717823|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
58270236|NCT04505202|DRUG|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
58389008|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
58270237|NCT00696202|DRUG|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
58270238|NCT01649310|OTHER|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
58389009|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
58389010|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
58389011|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
58389012|NCT03704844|OTHER|non applicable|non applicable
58389013|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
57717824|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
57717825|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
57717826|NCT01786408|DEVICE|TAP20-C|
57717827|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
57717828|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
57717829|NCT04453852|BIOLOGICAL|Saline|Saline control
57717830|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
57717831|NCT04543422|OTHER|Placebo|Placebo containing inert material.
57717832|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
58389014|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
57717833|NCT04558476|OTHER|Standard of Care|Gold Standards
58270239|NCT05040334|DRUG|Group 1: Antibiotic receiving group|Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
58270240|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
58270241|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
57717834|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
57717835|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
57717836|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
57717837|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
57717838|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
57717839|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
58270242|NCT06731140|DRUG|Retinoic Acid|Retinoic acid 20mg tid, p.o.
58270243|NCT06731140|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
57717840|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
57717841|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
58270244|NCT00478114|DRUG|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
58270245|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
58270246|NCT02841566|OTHER|questionnaire|
58389015|NCT00332579|DRUG|Naltrexone|daily
58389016|NCT00332579|DRUG|Placebo|daily
58389017|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
58389018|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
58389019|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
58389020|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
58389021|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
58389022|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
58389023|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
58389024|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
58063450|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
58270247|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
58270248|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
58270249|NCT01186380|DEVICE|PET-512MC|Transesophageal Transducer
58270250|NCT02686658|DRUG|Zimura|Zimura 20 mg/mL solution for intravitreal (IVT) injection
58270251|NCT02686658|OTHER|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
58270252|NCT03295123|OTHER|phone interview with the mother|it's a telephone survey about children's health
58389025|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
58389026|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
58389027|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
58389028|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
58389029|NCT03665766|DRUG|Cycloserine,Tacrolimus|
58389030|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
58389031|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
58389032|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
58389033|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
58389034|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
57717842|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
58270253|NCT06045442|BEHAVIORAL|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
58270254|NCT06045442|BEHAVIORAL|Control|Usual care
58270255|NCT03219151|DEVICE|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
57717843|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
57717844|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
58063451|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
58063452|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
58063453|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
58063454|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
58063455|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
58063456|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
58063457|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
58063458|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
58063459|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
58063460|NCT00946829|DRUG|telmisartan|
58063461|NCT02008461|PROCEDURE|radiofrequency ablation|
58063462|NCT02008461|DRUG|botulinum toxin injection|
58270256|NCT03219151|OTHER|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
58270257|NCT06019962|DEVICE|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
58270258|NCT01542905|DIETARY_SUPPLEMENT|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
58270259|NCT01542905|OTHER|Placebo|Placebo Capsule (1g/day) for 8 Weeks
58270260|NCT06242418|DRUG|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
58270261|NCT06242418|DRUG|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
57717845|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
57717846|NCT00003341|BIOLOGICAL|epoetin alfa|
57717847|NCT00003341|PROCEDURE|quality-of-life assessment|
57717848|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
57717849|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
58063463|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
58063464|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
58063465|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
58063466|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
58063467|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
58063468|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
58270262|NCT00722566|DRUG|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
58270263|NCT00722566|DRUG|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
58270264|NCT04800614|DRUG|sitravatinib|100 mg sitravatinib on Day 1 of each of 3 periods
58270265|NCT06133413|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
57717850|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
58063469|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
58063470|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
58270266|NCT06133413|OTHER|Alert generation by remote plateform|Alert will be generated from weight regain \> 5% of baseline weight
58270267|NCT06536088|OTHER|Walking assesment|Spatiotemporal walking assessments are performed using the Gait Analyzer app (version 0.9.95.0) on a smartphone. Participants who can walk independently without assistance walk a 25-meter path at their normal speed, with the smartphone securely attached to their body above the third lumbar vertebra using a belt. The app records gait velocity, cadence, step time, step length, and vertical center of mass for all participants.
57717851|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
57717852|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
57717853|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
57717854|NCT02863354|DRUG|Aflibercept|Intravitreal injection
57717855|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
57717856|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
57717857|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
57717858|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
57717859|NCT01903447|DRUG|SSRI|
57717860|NCT01903447|BEHAVIORAL|CBT|
57917309|NCT04288765|DRUG|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
57917310|NCT00889668|DEVICE|GlucoTrack|comparison of different glucose monitoring devices
57917311|NCT06327932|PROCEDURE|TURBT|Transurethral Resection of Bladder Tumors
58063471|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
58063472|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
58270268|NCT01463267|DEVICE|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
58270269|NCT01463267|BEHAVIORAL|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
58063473|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
58063474|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
58270270|NCT05106920|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
58389035|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
57917312|NCT06327932|PROCEDURE|HIVEC|Hyperthermic Intravesical Chemotherapy with Gemcitabine (3g/150ml NS) at 45 °C for 60 minutes. Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
57917313|NCT06327932|PROCEDURE|Intravesical Chemotherapy|Intravesical Chemotherapy with Gemcitabine (3g/150ml NS). Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
57917314|NCT06327932|DRUG|Gemcitabine|Gemcitabine (3g/150ml NS).
57917315|NCT01848951|DRUG|Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
57917316|NCT01848951|DRUG|TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
57917317|NCT01750203|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
57917318|NCT03178539|DRUG|diclofenac|non steroidal anti-inflammatory drug
57917319|NCT03178539|DRUG|ketorolac|non steroidal anti-inflammatory drug
57917320|NCT00348855|OTHER|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
57917321|NCT00348855|BEHAVIORAL|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
57917322|NCT00348855|BEHAVIORAL|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
57917323|NCT00348855|BEHAVIORAL|Stop Smoking|Minimal intervention
57917324|NCT00348855|BEHAVIORAL|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
57917325|NCT00348855|OTHER|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
57917326|NCT02068209|DRUG|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
57917327|NCT02068209|DRUG|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
57917328|NCT00139191|PROCEDURE|C-11 acetate PET scan|
57917329|NCT00063154|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
57917330|NCT02314767|BEHAVIORAL|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
58063475|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
57917331|NCT02314767|BEHAVIORAL|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
57917332|NCT05466773|BEHAVIORAL|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
57917333|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
57917334|NCT01193920|OTHER|Saline solution|Subjects received two injection of saline solution.
57917335|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
57917336|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
57917337|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
57917338|NCT01193920|OTHER|saline solution|Subjects received one injection of saline solution.
58063476|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
58063477|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
58063478|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
58063479|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
58063480|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
58063481|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
58063482|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
58063483|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
58063484|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
58270271|NCT03914027|BEHAVIORAL|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
58389036|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
57917339|NCT00562133|DRUG|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
57917340|NCT00562133|DRUG|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
57917341|NCT04342793|DRUG|Placebo oral tablet|Placebo
57917342|NCT04342793|DRUG|ALS-L1023 1,200mg|ALS-L1023
57917343|NCT04342793|DRUG|ALS-L1023 1,800mg|ALS-L1023
57917344|NCT06349928|OTHER|Focus group or interview|Focus groups and qualitative interview will be conducted with dancers investigating thoughts, beliefs and behaviors related to injury. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
57917345|NCT03160651|DRUG|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
57917346|NCT05052554|DRUG|QR-504a|Intravitreal (IVT) injection
57917347|NCT02091453|BEHAVIORAL|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
57917348|NCT02091453|BEHAVIORAL|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
57917349|NCT05954520|DEVICE|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
57917350|NCT04784260|OTHER|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
58063485|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
58063486|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
58063487|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
58063488|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
58063489|NCT01869686|BIOLOGICAL|Denosumab|60 mg
58063490|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
58063491|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
58063492|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
58063493|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
58063494|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
58063495|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
58389037|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
58389038|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
58270272|NCT02418741|OTHER|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
58389039|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
58389040|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
58270273|NCT03702712|BEHAVIORAL|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
58389041|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
58389042|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
58389043|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
58389044|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
58063496|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
58389045|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
58389046|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
58389047|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
58389048|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
58389049|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
58389050|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
58389051|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
58063497|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
58063498|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
58270274|NCT03702712|BEHAVIORAL|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
58270275|NCT03702712|BEHAVIORAL|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
58270276|NCT03919500|DRUG|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
58270277|NCT03919500|DRUG|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
58389052|NCT02735057|DRUG|Carboplatin|
58389053|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
58389054|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
58389055|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
58389056|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
58389057|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
58389058|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
58389059|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
58389060|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
58389061|NCT05653245|DRUG|RGD Peptide|adhesion molecules
57717861|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
57917351|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
58063499|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
58270278|NCT01561599|DRUG|BB3|Daily intravenous administration of 2mg/kg for 4 days
58270279|NCT01561599|DRUG|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
58270280|NCT01217125|DRUG|Sirolimus|plasma levels between 4 and 8
58270281|NCT00475514|DRUG|Frovatriptan 2.5mg QD|
58270282|NCT00475514|DRUG|Frovatriptan 2.5 mg BID|
58270283|NCT00475514|DRUG|placebo|
58270284|NCT04600063|PROCEDURE|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
58270285|NCT04600063|PROCEDURE|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
58270286|NCT05106751|DEVICE|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
58270287|NCT04517045|DRUG|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
58270288|NCT04517045|DRUG|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
58270289|NCT04517045|OTHER|Conventional treatment|Conventional treatment
58270290|NCT03725033|DRUG|Subetta|Oral administration.
58270291|NCT03725033|DRUG|Placebo|Oral administration.
58270292|NCT02163642|DEVICE|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
58270293|NCT05244434|OTHER|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
58270294|NCT05244434|PROCEDURE|Biopsy|Undergo biopsy of tumor tissue
58270295|NCT05244434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58389062|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
58389063|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
58389064|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
58389065|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
58389066|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
58270296|NCT05244434|OTHER|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
58270297|NCT01679912|OTHER|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
58389067|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
58389068|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
58270298|NCT01680653|DRUG|Mini-glucagon|Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age
58270299|NCT01680653|DEVICE|Remote monitoring|Provides real-time continuous glucose monitoring
58270300|NCT01680653|DIETARY_SUPPLEMENT|Carbohydrates|16 grams of carbohydrate
58270301|NCT04128891|DRUG|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
58270302|NCT02930525|OTHER|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
58270303|NCT02930525|OTHER|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
58270304|NCT04787328|DRUG|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
58270305|NCT00162149|DRUG|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
58270306|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
58270307|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
58270308|NCT00162149|DRUG|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
58270309|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
58270310|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
58270311|NCT00005601|BIOLOGICAL|rituximab|
58270312|NCT00005601|DRUG|cisplatin|
58389069|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
57917352|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
57917353|NCT04268524|COMBINATION_PRODUCT|drug: miltefosine with thermotherapy|see previous
58270313|NCT00005601|DRUG|cytarabine|
58389070|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
57917354|NCT02960854|BIOLOGICAL|Nivolumab|Specified dose on specified days
58389071|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
58270314|NCT00005601|DRUG|dexamethasone|
58270315|NCT00005601|DRUG|sargramostim|
58270316|NCT03104218|OTHER|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
58270317|NCT03104218|OTHER|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
58270318|NCT00423397|BIOLOGICAL|PEG-interferon alfa-2a|
58270319|NCT00423397|DRUG|gefitinib|
58270320|NCT04302480|OTHER|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
58270321|NCT04302480|OTHER|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
58270322|NCT04302480|OTHER|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
57917355|NCT05611008|DEVICE|CDSS|A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.
57917356|NCT05611008|DEVICE|Patient Portal|A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
57917357|NCT04409353|DEVICE|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
57917358|NCT00828880|DEVICE|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
57917359|NCT04345835|PROCEDURE|Percutanous nephrolithotomy (PCNL)|different procedure positioning
58270323|NCT04302480|OTHER|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
58270324|NCT02633566|DEVICE|Plantar orthoses|
58270325|NCT06301009|DIAGNOSTIC_TEST|AI-CAC score|Deep-learning based prediction of the coronary artery calcium score with a plain chest x-ray
58270326|NCT01500967|OTHER|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
58270327|NCT01500967|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
58270328|NCT02673268|PROCEDURE|Mastectomy|
58270329|NCT02673268|DEVICE|Da Vinci Robot Xi|
57917360|NCT01414374|DRUG|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
57917361|NCT01414374|DRUG|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
57917362|NCT04879771|PROCEDURE|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
57917363|NCT03868488|BEHAVIORAL|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
57917364|NCT04217733|DRUG|pentoxyifylline|Pentoxyifylline two times daily for 3 months
58270330|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
57717862|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
57717863|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
57717864|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
57717865|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
57717866|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
57717867|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
57717868|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
57717869|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
57717870|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
57717871|NCT02116322|DEVICE|Expect 19 G Flex needle|
57717872|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
57717873|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
57717874|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
57717875|NCT00546143|DRUG|Omalizumab|
57717876|NCT00546143|DRUG|Omalizumab|
57917365|NCT04217733|DRUG|Mebeverine|Mebeverine 3 times for 3 months
57717877|NCT00546143|DRUG|Omalizumab|
57917366|NCT04217733|DRUG|ethosuximide|ethosuximide 3 times for 3 months
57917367|NCT01588496|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
57717878|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
57717879|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
58270331|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
57717880|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
58270332|NCT01982838|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
58270333|NCT01982838|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
58270334|NCT04202315|OTHER|Virtual Reality|Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
58270335|NCT03955965|OTHER|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
58270336|NCT06429137|DRUG|BI 3731579|BI 3731579
58270337|NCT06429137|DRUG|Matching placebo to BI 3731579|Matching placebo to BI 3731579
58270338|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
57717881|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
57717882|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
57717883|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
57717884|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
57717885|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
57917368|NCT01588496|DRUG|Placebo|Administered by subcutaneous injection
57917369|NCT03747198|DIETARY_SUPPLEMENT|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
57917370|NCT03747198|OTHER|Placebo|Subjects will be given 2 g/day placebo (rice flour).
58270339|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
57917371|NCT02952287|DEVICE|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
57917372|NCT05884151|DRUG|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
58270340|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
58270341|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
58270342|NCT02507843|DRUG|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
58270343|NCT02507843|DRUG|Placebo|Placebo will be administered in placebo group monthly for 6 months.
58270344|NCT02394236|OTHER|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
57717886|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
57717887|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
57717888|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
57717889|NCT00018109|DRUG|glutamine|
57717890|NCT00018109|DRUG|creatine monohydrate|
57717891|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
57917373|NCT05884151|DRUG|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
57717892|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
57717893|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
57717894|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
57717895|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
57717896|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
57717897|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
57717898|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
57717899|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
58063500|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
58270345|NCT02671019|BEHAVIORAL|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
58270346|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
58270347|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
58270348|NCT02334176|DRUG|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
58270349|NCT00971061|DEVICE|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
57717900|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
57717901|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
57717902|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
57717903|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
57717904|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
57717905|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
57717906|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
57717907|NCT01827904|DEVICE|Transcranial ExAblate|
57717908|NCT01827904|DEVICE|Sham Transcranial ExAblate|
57717909|NCT02285751|DRUG|acetylsalicylic acid|
57717910|NCT02285751|DRUG|clopidogrel|
57717911|NCT02285751|DRUG|prasugrel|
57717912|NCT02285751|DRUG|ticagrelor|
57717913|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
58270350|NCT00971061|DEVICE|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
57717914|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
57717915|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
57717916|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
57717917|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
57717918|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
57717919|NCT02010424|OTHER|control group|standard IVF protocol
57717920|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
57717921|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
57717922|NCT00042328|DRUG|Valacyclovir|
57717923|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
57717924|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
57717925|NCT04145791|OTHER|Ice|ice packs
57717926|NCT03709550|DRUG|Decitabine|Given IV
57717927|NCT03709550|DRUG|Enzalutamide|Given PO
57717928|NCT01618539|DRUG|propofol|varying intravenous dosages
57717929|NCT00113113|DRUG|Rubitecan|
57717930|NCT00949013|OTHER|immunohistochemistry staining method|
57717931|NCT00949013|OTHER|laboratory biomarker analysis|
58270351|NCT03514706|DIAGNOSTIC_TEST|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
57717932|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
57717933|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
58270352|NCT03514706|DIAGNOSTIC_TEST|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
57717934|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
57717935|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
57717936|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
57717937|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
57717938|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
57717939|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
57717940|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
57717941|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
58270353|NCT06029153|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
58270354|NCT00565669|DRUG|Cyclosporin A Restasis®|
58270355|NCT00565669|DRUG|Blink tears|blink tears to be used twice a day
58270356|NCT00565669|DRUG|Systane|systane to be used twice a day
58270357|NCT02707042|DRUG|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
57717942|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
57717943|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
57717944|NCT02039427|DRUG|Placebo|Normal saline 2 ml
57717945|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
57717946|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
57917374|NCT05323201|BIOLOGICAL|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.
57917375|NCT05323201|DRUG|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)
57917376|NCT05323201|DRUG|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
57917377|NCT02714387|OTHER|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
57917378|NCT02325427|DEVICE|tDCS|tDCS could deliver either real or sham stimulation.
58063501|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
58063502|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
58270358|NCT02707042|DRUG|Azithromycin|5-day oral course of once-daily azithromycin
58270359|NCT02707042|OTHER|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
58270360|NCT06289686|PROCEDURE|Rotator cuff repairs with BioEnthesis augmentation|Rotator cuff repair using BioEnthesis allograft patch
57917379|NCT02705287|OTHER|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
57917380|NCT02705287|OTHER|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
57917381|NCT03109145|OTHER|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
57917382|NCT03618654|DRUG|Metformin|Given PO
57917383|NCT03618654|BIOLOGICAL|Durvalumab|Given IV
57917384|NCT04509115|DRUG|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
57917385|NCT03437343|PROCEDURE|Hip arthroplasty|
57917386|NCT00606957|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
57917387|NCT02941562|RADIATION|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
57917388|NCT02941562|DRUG|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
57917389|NCT02941562|RADIATION|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
57917390|NCT02941562|DRUG|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
57917391|NCT02941562|PROCEDURE|Radical rectal cancer resection|Radical rectal cancer resection
57717947|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
57917392|NCT02941562|DRUG|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
58063503|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
58063504|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
58063505|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
58063506|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
58270361|NCT06289686|PROCEDURE|Rotator cuff repairs without BioEnthesis augmentation|Rotator cuff repair using standard of care sutures and anchors
58270362|NCT03632226|DRUG|18F-OGA-1|
58270363|NCT03528057|DEVICE|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
58270364|NCT00546455|DRUG|Fenretinide|200 mg/day
58270365|NCT00546455|DRUG|Placebo|2 capsules/day
58270366|NCT01848509|DEVICE|With teletransmission|Teletransmission of alerts
57717948|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
57717949|NCT05897216|DRUG|CKD-383|QD, PO
57717950|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
57717951|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
57717952|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
57917393|NCT03188757|OTHER|hyperglycaemic clamp|2h hyperglyceamic clamp
57917394|NCT00002521|DRUG|cisplatin|
57917395|NCT00002521|DRUG|cyclophosphamide|
57917396|NCT00002521|DRUG|etoposide|
57917397|NCT00002521|PROCEDURE|autologous bone marrow transplantation|
57917398|NCT00002521|PROCEDURE|bone marrow ablation with stem cell support|
57917399|NCT00002521|PROCEDURE|peripheral blood stem cell transplantation|
57917400|NCT00002521|PROCEDURE|syngeneic bone marrow transplantation|
57917401|NCT00002521|RADIATION|radiation therapy|
58270367|NCT00114738|DRUG|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
58270368|NCT00114738|BIOLOGICAL|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
58270369|NCT00114738|DRUG|Bortezomib (B)|Bortezomib is given alone for one cycle.
58270370|NCT00114738|DRUG|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
58270371|NCT00114738|DRUG|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
58270372|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
58270373|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
57717953|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
57717954|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717955|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717956|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717957|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717958|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717959|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717960|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717961|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
57717962|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
57717963|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
57717964|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
58063507|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
58063508|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
57717965|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
57717966|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
57717967|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
57717968|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
57717969|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES)|DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
57717970|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment with Coach-Assisted Support (DECIDES + coach)|Live support in the form of a coach is provided to support navigation of DECIDES and promote involvement in decision-making. DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
57717971|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
57717972|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
57717973|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
57717974|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
57917402|NCT05134350|DRUG|LOXO-305|Oral LOXO-305
57917403|NCT05134350|DRUG|Omeprazole|Oral omeprazole
57917404|NCT02707237|OTHER|Verbal counseling|Verbal counseling done by physician
57917405|NCT02707237|OTHER|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
57917406|NCT01706887|OTHER|Diet Amiloride|only arm of the trial
57917407|NCT00645801|DRUG|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
57917408|NCT00645801|DRUG|Placebo|Amitiza Placebo
57917409|NCT00562705|BEHAVIORAL|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
57917410|NCT00562705|BEHAVIORAL|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
57917411|NCT01768520|DRUG|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg"
57917412|NCT01768520|DRUG|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
57917413|NCT01768520|DRUG|Placebo|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
57917414|NCT01658722|DRUG|Bapineuzumab|
57917415|NCT02787889|OTHER|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.
57917416|NCT02787889|OTHER|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
57917417|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
57717975|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
57717976|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
57717977|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
57717978|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
57717979|NCT03610490|DRUG|Cyclophosphamide|Given IV
57717980|NCT03610490|DRUG|Fludarabine|Given IV
57717981|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
57717982|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
57717983|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
57717984|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
57917418|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
58063509|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
58063510|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
57717985|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
57717986|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
57717987|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
57717988|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
57717989|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
57717990|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
57917419|NCT04176302|DEVICE|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
58063511|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
58063512|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
58063513|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
57717991|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
57717992|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
57717993|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
57717994|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
57717995|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
57717996|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
57717997|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
57717998|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
57717999|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
57718000|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
57718001|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
57718002|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
57718003|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
57718004|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
57718005|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
57718006|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
57718007|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
57718008|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
57718009|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
57718010|NCT03120624|OTHER|Pharmacological Study|Correlative studies
57718011|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
57718012|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
57718013|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
57718014|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
57718015|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
57718016|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
57718017|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
57718018|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
57718019|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
57718020|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
57718021|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
57718022|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
57917420|NCT04176302|DIAGNOSTIC_TEST|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
57718023|NCT02453451|OTHER|Walking Test|for 6 minutes
57718024|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
57718025|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
57718026|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
57718027|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
57718028|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
58063514|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
58270374|NCT04775576|OTHER|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
58270375|NCT04775576|OTHER|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
58270376|NCT04775576|OTHER|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
58063515|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
58063516|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
58063517|NCT02382887|DEVICE|Airtraq|
58270377|NCT05878665|DIAGNOSTIC_TEST|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
58063518|NCT02382887|DEVICE|fiberscope|
58063519|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
58270378|NCT02086448|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
57718029|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
57718030|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
57718031|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
57718032|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
57718033|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
57718034|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
57917421|NCT04176302|OTHER|Traditional clinical practice|The neurologists will receive the patient \& caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
58270379|NCT02086448|DEVICE|sham-CPAP|
58270380|NCT02086448|OTHER|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
57718035|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
57718036|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
57718037|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
57718038|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
57718039|NCT04816357|OTHER|Questionaire|only questionaire
57917422|NCT05063825|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
58270381|NCT05083676|BEHAVIORAL|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
58270382|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
58270383|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
58270384|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
57718040|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
57718041|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
57718042|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
57718043|NCT01612546|OTHER|Pharmacological studies|Correlative studies
57917423|NCT05063825|BEHAVIORAL|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
57917424|NCT03879837|DRUG|Fluticasone propionate pressurized metered dose inhaler|110 mcg per actuation
57917425|NCT03879837|DRUG|Flovent HFA pressurized metered dose inhaler|110 mcg per actuation
58270385|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
58270386|NCT03084068|OTHER|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
58270387|NCT03084068|OTHER|Placebo|Open rotator cuff surgery with standard suture repair
57718044|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
57718045|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
57718046|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
57917426|NCT03879837|DRUG|Placebo pressurized metered dose inhaler|no active content
57917427|NCT03753620|DEVICE|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
57917428|NCT03753620|DEVICE|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
57917429|NCT02687022|DEVICE|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
57917430|NCT02687022|DEVICE|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
57917431|NCT03501641|OTHER|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
57917432|NCT03501641|OTHER|video-based learning|voice of the staffs and standard patients.
57917433|NCT02835833|DRUG|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
57917434|NCT02835833|DRUG|Bevacizumab|Bevacizumab will be given at 15 mg/kg
58063520|NCT01784900|DRUG|Catumaxomab 100µg|
58063521|NCT01784900|DRUG|Catumaxomab 140µg|
57917435|NCT00852540|DRUG|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
58063522|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
58063523|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
57917436|NCT00852540|DRUG|Linezolid|Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
57917437|NCT02856828|DEVICE|DIE|digital image enhancement
57917438|NCT02206594|PROCEDURE|Descemetorhexis|
58063524|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
58063525|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
58063526|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
58063527|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
58063528|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
58063529|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
58063530|NCT01531244|DRUG|melphalan|Given via ILI
57718047|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
57718048|NCT05115994|DEVICE|Continous positive airway pressure|
57718049|NCT05174767|DEVICE|AMDS|AMDS Implantation
57718050|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
58270388|NCT00792506|DRUG|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
58270389|NCT03285659|OTHER|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
57718051|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
57718052|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
57718053|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
57718054|NCT02279641|DRUG|RDEA3170 10 mg|
57718055|NCT02279641|DRUG|allopurinol 300 mg|
57718056|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
57718057|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
57718058|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
57718059|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
57718060|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
57718061|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
58063531|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
58063532|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
58063533|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
58270390|NCT01315041|DRUG|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
58270391|NCT01315041|DRUG|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
58270392|NCT01007760|OTHER|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
58270393|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
58270394|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
58270395|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
58389072|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
58063534|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
58063535|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
58270396|NCT05559424|DIAGNOSTIC_TEST|OCT|OCT will be used to assess results after intervention
58389073|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
58270397|NCT06731595|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
57718062|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
57718063|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
57718064|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
57718065|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
57718066|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
58270398|NCT00424021|DRUG|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
58270399|NCT02259634|BEHAVIORAL|Patient Navigation|Motivational Interviewing
58270400|NCT02093390|DRUG|TAK-385|TAK-385 tablets
58270401|NCT02093390|DRUG|Fluconazole|Fluconazole tablets
58270402|NCT02093390|DRUG|Atorvastatin|Atorvastatin tablets
58270403|NCT05061017|DRUG|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
58270404|NCT05061017|DRUG|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
58270405|NCT05061017|DRUG|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
58270406|NCT02467894|OTHER|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
58270407|NCT05196906|PROCEDURE|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
58270408|NCT01549262|DEVICE|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
58389074|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
58389075|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
58389076|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
58389077|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
58389078|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
58389079|NCT04300504|OTHER|observational study|observational study
57718067|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
57718068|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
57718069|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
57718070|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
58063536|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
58063537|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
58063538|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
58389080|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
57718071|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
57718072|NCT03603964|DRUG|Guadecitabine|Guadecitabine
58063539|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
58063540|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
58270409|NCT01549262|DEVICE|Observe embryo development|Observe embryo development in the traditional manner
58389081|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
58389082|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
58389083|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
57718073|NCT02505516|OTHER|metformin|
57718074|NCT05690958|OTHER|Survey|Filling in a survey
57718075|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
57718076|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
57718077|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
57718078|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
57718079|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
58270410|NCT06424587|BEHAVIORAL|Music intervention|: In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
58389084|NCT02821065|DEVICE|Remote Patient Monitoring|
58389085|NCT00333411|DRUG|BIRT 2584 XX|
58389086|NCT00333411|DRUG|Placebo|
57718080|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
57718081|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
57718082|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
57718083|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
57718084|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
57718085|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
57718086|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
57718087|NCT02334748|DRUG|canakinumab|canakinumab
57718088|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
57718089|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
57718090|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
57718091|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
57718092|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
57718093|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
57718094|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
57718095|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
57718096|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
57718097|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
57718098|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
58063541|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
57718099|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
57718100|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
57718101|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
57718102|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
58270411|NCT03161886|DEVICE|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
58270412|NCT03598582|DRUG|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
58270413|NCT02920814|OTHER|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
57718103|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
57718104|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
57917439|NCT05304468|RADIATION|IMRT|Patients in experimental group received reduced dose IMRT
57917440|NCT05304468|DRUG|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
57917441|NCT05304468|DRUG|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
57917442|NCT00194519|DRUG|Generic acyclovir|400 mg twice-daily oral
58063542|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
58063543|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
58063544|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
58063545|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
58270414|NCT02182466|DEVICE|Colon capsule endoscopy|
58270415|NCT02974205|PROCEDURE|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
58270416|NCT02974205|DEVICE|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
58389087|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
57917443|NCT00194519|DRUG|Placebo|twice-daily oral
57917444|NCT04374344|OTHER|Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements|Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
57917445|NCT01124409|RADIATION|EPID Verification|Set up error verification and correction by EPID
58063546|NCT02939326|DRUG|EB-001 injection|
58063547|NCT02939326|DRUG|Placebo injection|
58270417|NCT02974205|DEVICE|össur brace|Rehabilitation after acute isolated PCL rupture
57718105|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
57917446|NCT01124409|RADIATION|CBCT verification|Setup error verification and correction by CBCT
57917447|NCT05916573|DRUG|HSK16149|single oral adminiatration, 20mg
57917448|NCT06322953|DRUG|Direct-Acting Oral Anticoagulants (used as per local standard practice)|Direct-acting oral anticoagulants to be prescribed as per local standard practice at either 1 or 4 weeks.
57917449|NCT03942809|DEVICE|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
57917450|NCT05624320|DRUG|AGN-190584|miotic for treatment of presbyopia
57917451|NCT04115085|PROCEDURE|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
57917452|NCT04115085|PROCEDURE|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
58270418|NCT04066777|PROCEDURE|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
58270419|NCT05655468|DRUG|Dronedarone|oral administration fed conditions
58270420|NCT05655468|DRUG|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
58270421|NCT02764567|OTHER|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
58270422|NCT05904080|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58270423|NCT05904080|DRUG|Cabozantinib S-malate|Given PO
58270424|NCT05904080|PROCEDURE|Computed Tomography|Undergo CT scan
58270425|NCT05904080|BIOLOGICAL|Ipilimumab|Given IV
58270426|NCT05904080|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57917453|NCT04115085|PROCEDURE|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
57917454|NCT04115085|PROCEDURE|Sham ultrasound group (18 treatments)|Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
57917455|NCT00824356|DRUG|GSK1004723 (200mg)|Intranasal antihistamine.
57917456|NCT00824356|OTHER|Placebo|Equivalent to GSK1004723 in presentation etc.
57917457|NCT00824356|DRUG|GSK1004723 (1000mg)|Intranasal antihistamine.
57917458|NCT04833699|OTHER|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
58389088|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
57718106|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
57917459|NCT00591045|DRUG|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
57917460|NCT03290209|PROCEDURE|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
57917461|NCT03290209|PROCEDURE|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
57917462|NCT04236505|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
57917463|NCT04236505|BEHAVIORAL|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
57917464|NCT04236505|BEHAVIORAL|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
57917465|NCT00584597|DRUG|Saline|Saline Control
57917466|NCT00584597|DRUG|Traumeel S|Traumeel S 1 mL
57917467|NCT00584597|DRUG|Traumeel S|Traumeel S 2mL
58063548|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
58063549|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
58063550|NCT03006276|DRUG|DFN-15 Active|
57917468|NCT00584597|DRUG|Traumeel S|Traumeel S 3mL
57917469|NCT00923533|DRUG|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
57917470|NCT00923533|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
57917471|NCT03034304|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
57917472|NCT03034304|DRUG|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
57917473|NCT03034304|DRUG|PD1 antibody|200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
57917474|NCT03034304|DRUG|Adriamycin|60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
57917475|NCT03034304|DRUG|Gemcitabine|1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
57917476|NCT03034304|DRUG|Cisplatin|70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
57718107|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
57718108|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
57718109|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
57917477|NCT03034304|DRUG|Carboplatin|5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
57917478|NCT01001832|DRUG|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
57917479|NCT01001832|DRUG|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
57917480|NCT05438017|DEVICE|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
57917481|NCT05534256|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
57917482|NCT05441254|DRUG|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
57917483|NCT00515320|DRUG|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
57917484|NCT00515320|DRUG|Placebo|Oral dispersible tablet placebo
57917485|NCT04429997|PROCEDURE|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
57917486|NCT04429997|PROCEDURE|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
57917487|NCT01924520|DRUG|FK949E|Oral
57917488|NCT06164067|OTHER|abortus within 24 hours or 24-48 hours|second trimester medical termination
57917489|NCT04552756|DIAGNOSTIC_TEST|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
58063551|NCT03006276|OTHER|DFN-15 Placebo|
58270427|NCT05904080|BIOLOGICAL|Nivolumab|Given IV
57718110|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
57917490|NCT03410615|RADIATION|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
57917491|NCT03410615|DRUG|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
57917492|NCT03410615|DRUG|Durvalumab|Given in concurrent and adjuvant phase
57917493|NCT03410615|DRUG|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
57917494|NCT04115553|DIAGNOSTIC_TEST|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
57917495|NCT04115553|DIAGNOSTIC_TEST|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
57917496|NCT04553198|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
58063552|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
58270428|NCT06066528|DRUG|Survodutide|once weekly subcutaneous injection
58270429|NCT06066528|DRUG|Placebo|once weekly subcutaneous injection
57718111|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
57718112|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
57718113|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
57718114|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
57718115|NCT06364826|RADIATION|IMRT|IMRT
57718116|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
57718117|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
57718118|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
57718119|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
57718120|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
57718121|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
57718122|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
58389089|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
57718123|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
57718124|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
57718125|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
58389090|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
57718126|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
58270430|NCT04309565|BEHAVIORAL|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
58389091|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
58389092|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
58389093|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
58389094|NCT01667497|DRUG|Fampridine SR|
58389095|NCT01667497|DRUG|Placebo|
58389096|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
58389097|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
58389098|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
58389099|NCT01956747|PROCEDURE|venapunction|
58389100|NCT01956747|PROCEDURE|bone marrow punction|
58270431|NCT04309565|BEHAVIORAL|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
58389101|NCT02181946|DRUG|Fluconazole|
58389102|NCT02181946|DRUG|Nevirapine|
57718127|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
57718128|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
57718129|NCT05686408|DRUG|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
57718130|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
57917497|NCT02035592|OTHER|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
58389103|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
58063553|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
58270432|NCT02999724|DRUG|Gabapentin|Gabapentin 300-600 mg 1 hour preop
58270433|NCT02999724|OTHER|placebo|placebo capsule(s) 1 hour preop
58270434|NCT03654131|DEVICE|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
58270435|NCT03654131|RADIATION|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
58270436|NCT02923245|OTHER|point-of-care ultrasound|
58270437|NCT01472939|DRUG|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
57718131|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
57718132|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
58270438|NCT01472939|DRUG|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
58389104|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
57718133|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
57718134|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
57718135|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
57718136|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
57718137|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
58270439|NCT01472939|DRUG|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
58270440|NCT01472939|DRUG|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
58270441|NCT05958745|BEHAVIORAL|Aerobic Exercise|Aerobic exercise training Program
58389105|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
58389106|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
58389107|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
57718138|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
57718139|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
57718140|NCT00003545|DRUG|nelarabine|
57718141|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
58270442|NCT05958745|BEHAVIORAL|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
58270443|NCT00603382|DRUG|GW685698X|GW685698X
58270444|NCT00603382|DRUG|Placebo|placebo comparator
58270445|NCT05769634|BEHAVIORAL|Stereoelectroencephalography|Three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
57718142|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
57917498|NCT02035592|OTHER|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
58063554|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
58063555|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
58063556|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
58063557|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
58063558|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
57718143|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
57718144|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
58063559|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
58063560|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
57718145|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
57718146|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
58063561|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
58063562|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
57718147|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
57917499|NCT02035592|OTHER|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
57917500|NCT04054752|BIOLOGICAL|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
57917501|NCT04054752|BIOLOGICAL|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
57718148|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
57917502|NCT04054752|BIOLOGICAL|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
57917503|NCT04025580|BIOLOGICAL|Flucelvax|Seasonal influenza vaccine
57917504|NCT04025580|BIOLOGICAL|Fluvirin|Seasonal influenza vaccine
57917505|NCT04025580|BIOLOGICAL|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
57917506|NCT02009254|OTHER|Dietary treatment|
57917507|NCT04119258|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
57917508|NCT00842270|DRUG|AB1010|3 mg/kg/day
57917509|NCT00842270|DRUG|AB1010|4,5 mg/kg/day
57917510|NCT00842270|DRUG|AB1010|6 mg/kg/day
57917511|NCT00842270|DRUG|placebo|matching placebo to AB1010 dosages
57718149|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
57718150|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
57718151|NCT05351606|DRUG|Bupropion|Given orally
57718152|NCT05351606|DRUG|Nicotine patch|Given transdermally
57718153|NCT05351606|DRUG|Nicotine lozenge|Given orally
57718154|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
57718155|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
57718156|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
57718157|NCT02233231|DRUG|Placebo|similar tabl
57718158|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
57718159|NCT00002312|DRUG|Delavirdine mesylate|
57718160|NCT00002312|DRUG|Zidovudine|
57718161|NCT06574373|OTHER|Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention|Blood will be collected from patients with indolent IPMN, invasive IPMN, and IPMN associated with pancreatic cancer, depending on their clinical course. Patients with indolent IPMN will be monitored by the gastroenterology units of their respective institutions, which will inform the patient. Patients with invasive IPMN and/or associated with cancer will undergo surgical resection as part of their standard clinical care, and blood will be collected after informed consent is obtained by the surgical teams at each institution.
57718162|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
58270446|NCT03080480|DRUG|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
58270447|NCT02060864|DIETARY_SUPPLEMENT|AN-PEP|Two pills are consumed in the morning with a breakfast
57917512|NCT03073265|DEVICE|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
58063563|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
58063564|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
57718163|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
57718164|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
57917513|NCT03231930|DEVICE|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
58063565|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
58270448|NCT02060864|DIETARY_SUPPLEMENT|Placebo|
57718165|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
58063566|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
58063567|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
58270449|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
58270450|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
57718166|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
57718167|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
57718168|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
57718169|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
57718170|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
57718171|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
57718172|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
57718173|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
57718174|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
57718175|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
57718176|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
57917514|NCT03231930|DEVICE|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
58063568|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
58063569|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
58270451|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
58270452|NCT06731361|COMBINATION_PRODUCT|Systematic multidisciplinary medication review + ACP (SMMR+)|"The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components:~1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy)~2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations.~Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned."
58270453|NCT01861873|OTHER|measuring liver function by 18-FDGal PET/CT|
57718177|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
57718178|NCT06381986|DRUG|SHJ002|Topical ophthalmic
57718179|NCT06381986|OTHER|Vehicle|Topical ophthalmic
57917515|NCT01217957|DRUG|Ixazomib|Ixazomib capsules
57917516|NCT01217957|DRUG|Lenalidomide|Lenalidomide capsules
57917517|NCT01217957|DRUG|Dexamethasone|Dexamethasone tablets
57718180|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
57718181|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
57718182|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
57718183|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
58389108|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
57718184|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
58389109|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
57917518|NCT01813370|OTHER|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
57917519|NCT02105623|BEHAVIORAL|Standard Therapy|Risk factor control Diet Exercise for 24months
57917520|NCT02105623|DRUG|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
58063570|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
58389110|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
57718185|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
57718186|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
57718187|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
57718188|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
57917521|NCT04822285|BEHAVIORAL|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
57917522|NCT04822285|BEHAVIORAL|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
57917523|NCT00000263|DRUG|30% Nitrous oxide|
57917524|NCT00000263|OTHER|0.25 g/Kg ethanol|
57917525|NCT00000263|OTHER|0.5 g/KG ethanol|
57917526|NCT00000263|OTHER|0 g/Kg ethanol|
57917527|NCT02436785|OTHER|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
57917528|NCT02436785|OTHER|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
57917529|NCT04834349|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
58063571|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
58063572|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
58063573|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
58063574|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
57718189|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
57718190|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
57718191|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
57718192|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57718193|NCT03096782|DRUG|Busulfan|Given IV
57718194|NCT03096782|DRUG|Clofarabine|Given IV
57718195|NCT03096782|DRUG|Cyclophosphamide|Given IV
57718196|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
57718197|NCT03096782|DRUG|Fludarabine|Given IV
57718198|NCT03096782|DRUG|Melphalan|Given IV
57718199|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
57718200|NCT03096782|BIOLOGICAL|Rituximab|Given IV
57718201|NCT03096782|DRUG|Tacrolimus|Given IV
57718202|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
57718203|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
57718204|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
57718205|NCT01713777|DRUG|"Lamotrigine Generic A"|
57917530|NCT04834349|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
57917531|NCT04834349|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57917532|NCT04834349|BIOLOGICAL|Pembrolizumab|Given IV
57917533|NCT04834349|OTHER|Quality-of-Life Assessment|Ancillary studies
58063575|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
57718206|NCT01713777|DRUG|"Lamotrigine generic B"|
57718207|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
57718208|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
57917534|NCT04834349|OTHER|Questionnaire Administration|Ancillary studies
57917535|NCT04834349|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57917536|NCT00333385|DRUG|ceftazidime|
57917537|NCT03129880|BEHAVIORAL|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
57917538|NCT03129880|BEHAVIORAL|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
58063576|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
57718209|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
57718210|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
57718211|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
57718212|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
57917539|NCT01190137|DIETARY_SUPPLEMENT|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
57917540|NCT05663437|OTHER|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
57917541|NCT05663437|OTHER|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
57917542|NCT01341756|RADIATION|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
57917543|NCT01111474|OTHER|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
58270454|NCT03724240|BIOLOGICAL|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
58270455|NCT03724240|BIOLOGICAL|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
58389111|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
58389112|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
57917544|NCT01111474|RADIATION|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
58063577|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
58270456|NCT06730945|DRUG|Oral isosorbide mononitrate 4+ amlodipine|Oral isosorbide mononitrate 40mg (if unable to tolerate, 20mg) once daily + amlodipine 5mg (if unable to tolerate, 2.5mg) once daily for 24 weeks after CABG
57917545|NCT03422354|PROCEDURE|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
57917546|NCT03422354|DEVICE|Ultrasound|Ultrasound
58063578|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
58063579|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
58063580|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
58063581|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
58063582|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
58389113|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
58389114|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
58389115|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
58389116|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
58389117|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
58389118|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
57917547|NCT03422354|DRUG|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
57917548|NCT03422354|DRUG|General Aneasthesia|General Aneasthesia
57917549|NCT04894487|BEHAVIORAL|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
58063583|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
58063584|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
58270457|NCT04246645|OTHER|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
58389119|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
58389120|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
58389121|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
58389122|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
58389123|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
58389124|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
58389125|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
58389126|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
58389127|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
58389128|NCT03958864|DRUG|CC-90001|CC-90001
58389129|NCT01858441|DRUG|Abiraterone Acetate|
58389130|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
58389131|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
58389132|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
58389133|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
58389134|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
58389135|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
57917550|NCT06436027|DIAGNOSTIC_TEST|Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling|Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.
57917551|NCT01801735|DRUG|Meloxicam Test Capsules|
57917552|NCT02052830|BEHAVIORAL|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
57917553|NCT06004947|DRUG|CCX168|Administered orally.
57917554|NCT06004947|DRUG|Midazolam|Administered orally.
57917555|NCT06004947|DRUG|Celecoxib|Administered orally.
57917556|NCT06004947|DRUG|Itraconazole|Administered orally.
57917557|NCT06004947|DRUG|Rifampicin|Administered orally.
57917558|NCT02391272|DRUG|rhTPO|
58389136|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
58389137|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
58389138|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
58389139|NCT00002028|DRUG|Didanosine|
58389140|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
58389141|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
58389142|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
58389143|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
57718213|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
57718214|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
57718215|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
57718216|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
57718217|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
57718218|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
57718219|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
57718220|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
57718221|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
57718222|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
57718223|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
57718224|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
57718225|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
57718226|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
57718227|NCT06207682|DRUG|Avacopan|Orally via capsules
57718228|NCT06207682|DRUG|Simvastatin|Orally via tablets
57718229|NCT02067403|OTHER|Pressure-support Eadi optimization|
57917559|NCT05272956|PROCEDURE|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
58389144|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
58389145|NCT05245682|DRUG|Tolinapant|Given PO
58389146|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
58389147|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
58389148|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
57718230|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
57718231|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
57917560|NCT06181474|OTHER|ESAS|Observation of symptoms
58063585|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
58270458|NCT01239836|BEHAVIORAL|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
58389149|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
58389150|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
58389151|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
58389152|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
58389153|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
58389154|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
57718232|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
57718233|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
57718234|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
57718235|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
57718236|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
57718237|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
57718238|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
57718239|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
57718240|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
57917561|NCT05532943|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
57917562|NCT05532943|BIOLOGICAL|Control group|Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
57917563|NCT04080908|DRUG|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
58063586|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
58063587|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
58270459|NCT01239836|BEHAVIORAL|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
58389155|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
58389156|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
58389157|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
58389158|NCT00086983|DRUG|becatecarin|Given IV
58389159|NCT00086983|DRUG|oxaliplatin|Given IV
58389160|NCT00086983|OTHER|pharmacological study|Correlative studies
58389161|NCT04736290|OTHER|NLR|Calculation of NLR
58389162|NCT04736290|OTHER|PLR|Calculation of PLR
58270460|NCT01239836|BEHAVIORAL|General health lecture|Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
58270461|NCT01811836|DIETARY_SUPPLEMENT|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
58270462|NCT03348098|DRUG|Apatinib|500 mg, po, qd. 12weeks
58270463|NCT03348098|DRUG|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
58270464|NCT00989859|DEVICE|Plethysmographic monitoring|Plethysmographic monitoring
58270465|NCT00236275|DRUG|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
58270466|NCT05530980|BEHAVIORAL|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
57917564|NCT04840641|DRUG|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
57917565|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
58063588|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
58270467|NCT00314132|BIOLOGICAL|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
58270468|NCT00314132|BIOLOGICAL|0.9% Saline|0.5 mL, Subcutaneous
58270469|NCT04130048|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
57917566|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
57917567|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
58063589|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
57917568|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
57917569|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
57917570|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
57917571|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
58063590|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
57917572|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
57917573|NCT03788083|DRUG|Trimix|Intratumoral TriMix injection
58063591|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
58389163|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
58389164|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
57917574|NCT03788083|DRUG|Placebo|Intratumoral placebo injection
57917575|NCT02919904|DEVICE|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~* NREM and REM sleep frequency and duration~* Duration and number of arousal~* Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~* Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~* Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~* Apnea/hypopnea index and respiratory disturbance index"
57917576|NCT03356457|DRUG|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
57917577|NCT03356457|DRUG|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
57917578|NCT02772406|DEVICE|Linked Color Imaging|
57917579|NCT02772406|DEVICE|white light imaging|
57917580|NCT04651517|DEVICE|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
57718241|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
57917581|NCT00272922|DEVICE|hernia repair|
58063592|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
58063593|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
58063594|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
58389165|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
57718242|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
57718243|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
57917582|NCT01491672|DRUG|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
57917583|NCT00960531|BIOLOGICAL|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
57917584|NCT00960531|BIOLOGICAL|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
57917585|NCT00960531|BIOLOGICAL|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
57917586|NCT05486650|DRUG|PD-1 inhibitor|After receiving PD-1 inhibitor treatment in the first three cycles, patients with locally advanced or advanced NSCLC whose curative effect is evaluated as stable disease receive SBRT combined with PD-1 inhibitor treatment
58063595|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
58063596|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
58063597|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
58063598|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
58063599|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
58063600|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
58063601|NCT03087474|OTHER|Non-Interventional|Non-Interventional
58063602|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
58063603|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
58063604|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
58063605|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
58063606|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
58389166|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
58389167|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
57917587|NCT03722147|BIOLOGICAL|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
58063607|NCT06376942|OTHER|Saline|0.9% saline 2 ml
58063608|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
58270470|NCT05885633|PROCEDURE|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
58389168|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
58389169|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
57718244|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
57718245|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
57718246|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
57718247|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
57718248|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
57718249|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
57718250|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
58389170|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
57917588|NCT00610467|DEVICE|Disease Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
58063609|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
58063610|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
58063611|NCT04746729|OTHER|No intervention|No intervention
58063612|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
58063613|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
57718251|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
57917589|NCT00610467|DEVICE|Control Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
57917590|NCT05333770|DEVICE|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
58063614|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
57917591|NCT03107897|OTHER|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
57917592|NCT02054741|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
58063615|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
58063616|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
58063617|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
58063618|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
58063619|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
58389171|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
58389172|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
57917593|NCT02054741|OTHER|Quality-of-Life Assessment|Ancillary studies
57917594|NCT02054741|OTHER|Survey Administration|Ancillary studies
57917595|NCT00220753|DEVICE|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
58063620|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
58063621|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
57917596|NCT02966301|DRUG|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
58270471|NCT01878734|DIETARY_SUPPLEMENT|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
58270472|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
57718252|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
57917597|NCT01063660|DRUG|Treosulfan|14 g/m²/d day -6 to -4
57917598|NCT04250441|DEVICE|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
57917599|NCT04593316|OTHER|Saliva collection|A saliva sample will be collected before physical exercise.
57917600|NCT04593316|BEHAVIORAL|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
58270473|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
58270474|NCT04577534|DRUG|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
58270475|NCT02861417|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
58270476|NCT02861417|DRUG|Busulfan|Given IV
58270477|NCT02861417|DRUG|Cyclophosphamide|Given IV
58270478|NCT02861417|DRUG|Fludarabine|Given IV
58270479|NCT02861417|DRUG|Fludarabine Phosphate|Given IV
58270480|NCT02861417|OTHER|Laboratory Biomarker Analysis|Correlative studies
58270481|NCT02861417|DRUG|Mycophenolate Mofetil|Given PO
58270482|NCT02861417|OTHER|Pharmacological Study|Correlative studies
58270483|NCT02861417|DRUG|Tacrolimus|Given IV or PO
58270484|NCT02861417|DRUG|Thiotepa|Given IV
58270485|NCT02631070|DRUG|Luspatercept|
58270486|NCT02631070|OTHER|Placebo|
57718253|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
58389173|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
58270487|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
57718254|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
57718255|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
58270488|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
58270489|NCT03628248|PROCEDURE|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
58270490|NCT03628248|PROCEDURE|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
58270491|NCT00672399|DRUG|exenatide|Subcutaneously injected, 10 mcg, single doses
58270492|NCT00672399|DRUG|Moxifloxacin|oral, 400 mg tablet, single doses
58389174|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
58389175|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
58389176|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
58389177|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
57718256|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
58270493|NCT00672399|DRUG|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
58270494|NCT04515641|DRUG|Islatravir|Two ISL 30 mg capsules taken by mouth.
58389178|NCT02720523|DRUG|Placebo|Tablet; Oral
58389179|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
58389180|NCT00009880|BIOLOGICAL|filgrastim|
58389181|NCT00009880|DRUG|cisplatin|
58389182|NCT00009880|DRUG|fluorouracil|
58389183|NCT00009880|DRUG|paclitaxel|
58270495|NCT02532114|DRUG|Enzalutamide|Given PO
58270496|NCT02532114|OTHER|Laboratory Biomarker Analysis|Correlative studies
58389184|NCT00009880|RADIATION|radiation therapy|
58389185|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
58389186|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
58389187|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
58389188|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
58389189|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
57718257|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
57718258|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
58389190|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
58389191|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
57917601|NCT04593316|OTHER|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
57917602|NCT04593316|OTHER|Physical exercise|The participant will perform a walk/run test.
57917603|NCT04593316|OTHER|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
57917604|NCT04593316|OTHER|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
58389192|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
57718259|NCT02442921|DRUG|Placebo|Daily placebo
57718260|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
57718261|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
57718262|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
57917605|NCT00346268|DRUG|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
57917606|NCT00346268|DRUG|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
57917607|NCT01501760|DRUG|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
57917608|NCT01501760|DRUG|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
58063622|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
58389193|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
58389194|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
58389195|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
57917609|NCT02943486|OTHER|dac-MSCs|Cell-free therapy
57917610|NCT02943486|OTHER|MSCs|Cell-based therapy
57917611|NCT02943486|DRUG|Fitostimoline|Triticum vulgare
57917612|NCT04721028|DEVICE|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
57917613|NCT05515380|OTHER|8-stage model based exercise program|The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.
57917614|NCT05515380|OTHER|Conventional exercise program|The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
57917615|NCT03275844|PROCEDURE|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
58270497|NCT02532114|DRUG|Niclosamide|Given PO
58270498|NCT02532114|OTHER|Pharmacological Study|Correlative studies
57917616|NCT04229251|BEHAVIORAL|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
58389196|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
58389197|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
57917617|NCT04229251|BEHAVIORAL|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
57917618|NCT00315900|DRUG|Depakote ER|depakote ER
57917619|NCT00315900|DRUG|Seroquel|seroquel
58063623|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
58063624|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
58063625|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
58063626|NCT02548091|PROCEDURE|Non invasive ventilation|
58389198|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
58063627|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
58063628|NCT02548091|PROCEDURE|Computed tomography (CT)|
58063629|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
58063630|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
58063631|NCT02522091|DEVICE|functional brain MRI|
58063632|NCT02522091|OTHER|Neuropsychology tests|
58063633|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
58063634|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
58063635|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
58063636|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
58063637|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
58063638|NCT03531918|DRUG|Cladribine|Given IV
58063639|NCT03531918|DRUG|Cytarabine|Given IV
58063640|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
58063641|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
58063642|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
58063643|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
58063644|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
58270499|NCT06730620|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
58389199|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
58389200|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
58270500|NCT06730620|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）|Cholinergic agonists
58270501|NCT00423189|DRUG|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
58270502|NCT00423189|DRUG|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
58270503|NCT05581992|DRUG|AMG 510|Oral Tablet
58270504|NCT05581992|DRUG|Omeprazole|Capsule
58270505|NCT05451615|DRUG|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
58270506|NCT05451615|DRUG|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
58270507|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
58270508|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
58270509|NCT05648240|OTHER|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
58389201|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
58389202|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
58270510|NCT01430624|BEHAVIORAL|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
58270511|NCT01430624|BEHAVIORAL|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
58270512|NCT03526198|DEVICE|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
58270513|NCT05828212|DRUG|CD19 CAR-T cells injection|CD19 CAR-T cells in the treatment of R/R neuromyelitis optica
58389203|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
58389204|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
58389205|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
57917620|NCT03527173|BIOLOGICAL|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
58270514|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
57917621|NCT03527173|DRUG|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
57917622|NCT03527173|BIOLOGICAL|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
57917623|NCT02499770|DRUG|Carboplatin|
57917624|NCT02499770|DRUG|Placebo|
57917625|NCT02499770|DRUG|Trilaciclib|
58270515|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
58389206|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
58389207|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
58389208|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
58389209|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
58389210|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
58389211|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
58389212|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
58389213|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
58389214|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
58389215|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
57917626|NCT02499770|DRUG|Etoposide|
57917627|NCT02094755|OTHER|Blood draw only|Blood draw only
57917628|NCT01122862|DRUG|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
57718263|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
57917629|NCT01122862|OTHER|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
57917630|NCT01122862|OTHER|Sterile water|Sterile water
58270516|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
58270517|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
58270518|NCT00588081|BEHAVIORAL|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
58270519|NCT05215379|DRUG|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
58270520|NCT05215379|OTHER|Control|neoadjuvant chemoradiation therapy
58270521|NCT01836991|PROCEDURE|surgery|
58270522|NCT05995457|OTHER|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques"
58270523|NCT05995457|OTHER|Intramuscular injection of Haloperidol decanoate using standard techniques|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
58270524|NCT03484221|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
58270525|NCT03484221|RADIATION|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.
58270526|NCT03484221|DRUG|XELOX|OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
58270527|NCT05259384|PROCEDURE|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
58270528|NCT05259384|PROCEDURE|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
58389216|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
57917631|NCT03086525|OTHER|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
57917632|NCT02154789|DRUG|polidocanol|
57917633|NCT02154789|PROCEDURE|infra-red coagulation|
57917634|NCT02154789|PROCEDURE|cryotherapy|
57917635|NCT00569595|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
58270529|NCT05259384|PROCEDURE|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
58270530|NCT05259384|PROCEDURE|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
57718264|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
58270531|NCT00624650|DRUG|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
58389217|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
58389218|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
58389219|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
58389220|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
57718265|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
57718266|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
57718267|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
57718268|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
57917636|NCT00569595|BEHAVIORAL|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
57718269|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
57718270|NCT05195996|DRUG|Saline|intravenous saline for placebo
57917637|NCT04371653|DRUG|PRIM-DJ2727|administration orally
57917638|NCT04371653|DRUG|Placebo|administration orally placebo
57917639|NCT04612374|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
57917640|NCT04612374|BEHAVIORAL|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
57917641|NCT02434939|DRUG|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
57917642|NCT02434939|DRUG|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
57917643|NCT00355199|DRUG|Rituximab-HDS|Rituximab-HDS
57917644|NCT00355199|DRUG|Rituximab-CHOP|Rituximab-CHOP
57917645|NCT01795664|RADIATION|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
57917646|NCT01795664|DRUG|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
58270532|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP\<8 or measured PaOP \<12mmHg in addition to concurrent urine output of \<0.5 ml/kg/hr
58270533|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases \> 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map \< 60 or who are on vasopressors that also have a measured GEDI less than goal"
57917647|NCT01795664|DRUG|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
57917648|NCT01795664|DRUG|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
57917649|NCT01795664|DRUG|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
57917650|NCT02648165|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
57917651|NCT02648165|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
57917652|NCT02648165|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
57917653|NCT06107608|PROCEDURE|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
58270534|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
58270535|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60"
58270536|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5"
58389221|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
57718271|NCT03376204|OTHER|No intervention|No intervention
57917654|NCT04752982|BEHAVIORAL|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
57917655|NCT04752982|BEHAVIORAL|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
57917656|NCT04700020|DIAGNOSTIC_TEST|ITT|In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
57917657|NCT03418948|DEVICE|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
57917658|NCT03418948|DEVICE|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
57917659|NCT03418948|DEVICE|2x EC|EC = endocuff assisted colonoscopy
57917660|NCT03418948|DEVICE|2x CC|CC = conventional colonoscopy
58063645|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
57718272|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
57718273|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
57718274|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
57917661|NCT02273817|DRUG|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
57917662|NCT03503344|DRUG|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
57917663|NCT03503344|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57917664|NCT00446667|DRUG|mannitol|400mg BD for 2 days
58270537|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
58270538|NCT00624650|OTHER|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP \> 60 and off vasopressors for \>12 hours, as well as patients with a measured cardiac index \>2.5 that also have a measured GEDI \> goal."
58270539|NCT00624650|DRUG|Diuresis (furosemide) part II|"Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period"
57917665|NCT05186194|DRUG|Vitamin D, Calcium|Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
57917666|NCT05186194|DRUG|Placebo|Placebo
57917667|NCT05674331|PROCEDURE|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
57718275|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
57718276|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
57718277|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
57718278|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
57718279|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
57718280|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
57917668|NCT05674331|DEVICE|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
57917669|NCT05674331|PROCEDURE|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
57917670|NCT03373695|DEVICE|Dissolve™|Dissolve™ are to be used in the trial
57917671|NCT03373695|DEVICE|SeQuent®Please|SeQuent®Please are to be used in the trial
58270540|NCT00624650|PROCEDURE|Dialysis|"1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
58270541|NCT02583867|BEHAVIORAL|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
58270542|NCT01744002|OTHER|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
58270543|NCT01744002|OTHER|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
58270544|NCT06385522|BIOLOGICAL|BITR2101|TNFR2 monoclonal antibody
58270545|NCT06730542|DRUG|Zanubrutinib|Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.
58270546|NCT06730542|DRUG|Methotrexate|Participants will receive Methotrexate as per standard of care (SOC).
58270547|NCT06730542|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin as per standard of care (SOC).
58270548|NCT06730542|DRUG|Rituximab|Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
58270549|NCT06730542|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
58270550|NCT06730542|DRUG|Doxorubicin|Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
58270551|NCT06730542|DRUG|Prednisone|Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
58270552|NCT03881891|BEHAVIORAL|Follow-app intervention arm|The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
58270553|NCT06712186|DRUG|Dexmedetomidine Group / Group D|In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.
58270554|NCT06712186|OTHER|Normal Saline (Placebo)|The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
58270555|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
58270556|NCT03404349|BEHAVIORAL|Mindfulness for Adolescence Course|There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
58270557|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
58270558|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
58270559|NCT02100137|OTHER|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
58270560|NCT01303640|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent
58270561|NCT01303640|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
58270562|NCT04427137|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
58270563|NCT05473689|DEVICE|Continuous positive airway pressure (CPAP) therapy|Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
58270564|NCT05191368|OTHER|No intervention|No intervention
58270565|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
58270566|NCT04022239|DRUG|Bendamustine|Given IV
58270567|NCT04022239|DRUG|Cyclophosphamide|Given IV
58270568|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
58270569|NCT04022239|DRUG|Fludarabine|Given IV
58270570|NCT04022239|DRUG|Melphalan|Given IV
58270571|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
58270572|NCT04022239|BIOLOGICAL|Rituximab|Given IV
58270573|NCT04022239|DRUG|Tacrolimus|Given IV and PO
58270574|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
58063646|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
58063647|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
58063648|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
58063649|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
58063650|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
58063651|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
58063652|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
58063653|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
58063654|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
58063655|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
58063656|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
58063657|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
58063658|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
58063659|NCT06477523|DRUG|AK104|IV infusion
58063660|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
58063661|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
58063662|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
58063663|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
58063664|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
58063665|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
58063666|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
58270575|NCT04742309|DRUG|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
58389222|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
58389223|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
58389224|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
57718281|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
57718282|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
57718283|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
57917672|NCT05810337|DIETARY_SUPPLEMENT|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
57917673|NCT05810337|DIETARY_SUPPLEMENT|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
57917674|NCT05810337|DIETARY_SUPPLEMENT|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
57917675|NCT03714425|DEVICE|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
57917676|NCT03324451|BEHAVIORAL|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
58063667|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
58063668|NCT02447393|DRUG|levocetirizine|levocetirizine
58063669|NCT02447393|DRUG|cetirizine|cetiridine
58063670|NCT02447393|DRUG|placebo|placebo
58063671|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
58063672|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
58270576|NCT04742309|DRUG|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
57917677|NCT03324451|BEHAVIORAL|Usual care|Regular patient education on insulin injection at the control arm hospital.
58063673|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
58063674|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
58063675|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
58063676|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
58063677|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
58063678|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
58063679|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
58063680|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
58270577|NCT02065414|OTHER|Listerine Advance Gum Defense|
58270578|NCT02065414|OTHER|Mouth rinse containing Chlorhexidine|
58270579|NCT02065414|OTHER|Mouth rinse containing 5% Hydroalcohol|
57917678|NCT01558895|RADIATION|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
58063681|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
58063682|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
58389225|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
58389226|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
57917679|NCT01558895|OTHER|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
57917680|NCT00879112|DRUG|MB07811|Oral
57917681|NCT00879112|DRUG|Placebo|Oral
57917682|NCT02710903|PROCEDURE|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
57917683|NCT00512317|DRUG|ganaxolone|liquid suspension dosed tid
58063683|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
58063684|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
58063685|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
58063686|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
58063687|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
58063688|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
58063689|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
57718284|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
57718285|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
57718286|NCT00142909|DRUG|Placebo|Lofexidine Placebo
57718287|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
57718288|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
58270580|NCT03976414|OTHER|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
58270581|NCT00388297|DRUG|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
58270582|NCT00388297|DRUG|Placebo for Levothyroxine|
58389227|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
58270583|NCT04815499|DIETARY_SUPPLEMENT|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
58270584|NCT04815499|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
58270585|NCT04294433|BIOLOGICAL|Infanrix-hexa, Twinrix-Junior|Vaccines administrated according to product monographs' recommendations
57718289|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
57718290|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
57718291|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
57718292|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
58270586|NCT00798018|DRUG|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
58270587|NCT00798018|DRUG|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
58389228|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
58389229|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
58270588|NCT00798018|DRUG|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
58270589|NCT00798018|DRUG|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
58270590|NCT01174810|DRUG|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
57917684|NCT03434782|DRUG|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
57917685|NCT03434782|DRUG|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
57917686|NCT03434782|DRUG|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
58270591|NCT06272006|PROCEDURE|Coronally Positioned Flap with Connective Tissue Graft|his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.
58389230|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
58389231|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
58389232|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
57917687|NCT05508620|DRUG|Sirolimus for Injection (Albumin-bound)|Intravenous infusion
57917688|NCT03507465|DRUG|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
58270592|NCT06272006|PROCEDURE|Modified Coronally Advanced Tunnel with Connective Tissue Graft|This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
58389233|NCT02289196|DRUG|Vx-006: 0,5mg|
57718293|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
57917689|NCT03507465|DRUG|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
57917690|NCT03390374|DRUG|Nystatin Oral|Nystatin oral suspension
57917691|NCT00655863|DRUG|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
57917692|NCT00655863|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
58270593|NCT01720329|DIETARY_SUPPLEMENT|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
58270594|NCT01720329|OTHER|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
58270595|NCT01361113|DRUG|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
58270596|NCT06515210|DIETARY_SUPPLEMENT|Acacia Gum|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
58270597|NCT06515210|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
58389234|NCT02289196|DRUG|Vx-006: 1mg|
57718294|NCT02037503|DRUG|Ketamine|
57718295|NCT02037503|DRUG|Saline|
57917693|NCT00655863|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
57917694|NCT02791945|BEHAVIORAL|Medical Management Counseling|Brief alcohol counseling
57917695|NCT02791945|DRUG|N-acetylcysteine|Experimental supplement
57917696|NCT02791945|DRUG|Placebo|Placebo comparator
57917697|NCT05748496|BEHAVIORAL|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
57917698|NCT04975477|PROCEDURE|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
57917699|NCT04975477|PROCEDURE|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
58063690|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
58270598|NCT06515210|DIETARY_SUPPLEMENT|Placebo|Participants (n=23) incorporate the placebo into their usual diet daily.
58389235|NCT02289196|DRUG|Vx-006: 5mg|
58063691|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
58270599|NCT02991014|BEHAVIORAL|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
58270600|NCT02991014|BEHAVIORAL|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
58270601|NCT02991014|BEHAVIORAL|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
58270602|NCT05690165|BEHAVIORAL|Walking Exercise|Heart rate controlled walking exercise
58270603|NCT03328494|DRUG|BOS172722|Oral capsules
58270604|NCT03328494|DRUG|Paclitaxel|IV infusion
58270605|NCT00401960|DRUG|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
58270606|NCT06514456|OTHER|no intervention|no intervention
58270607|NCT06731686|OTHER|Retrospective study|Collection of children's datas
57718296|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
57718297|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
57718298|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
57718299|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
57718300|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
57718301|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
57718302|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
58270608|NCT01945294|DRUG|Boceprevir|800 mg three times daily orally
58270609|NCT01945294|BIOLOGICAL|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
58270610|NCT01945294|DRUG|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
58270611|NCT04533243|DRUG|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
58270612|NCT04533243|DRUG|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
58270613|NCT03927027|DRUG|Isosulfan Blue|Given SC
58270614|NCT03927027|PROCEDURE|Axillary Lymph Node Dissection|Undergo ALND
58270615|NCT03927027|PROCEDURE|Mapping|Undergo ARM
57718303|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
58270616|NCT03927027|OTHER|Quality-of-Life Assessment|Ancillary studies
58270617|NCT03927027|OTHER|Questionnaire Administration|Ancillary studies
58270618|NCT02623842|DEVICE|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
58270619|NCT03690973|DRUG|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
58270620|NCT03690973|DEVICE|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
58270621|NCT03690973|DEVICE|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
58270622|NCT03690973|DRUG|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
58270623|NCT03349905|PROCEDURE|fresh transfer|"Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved"
58270624|NCT03349905|PROCEDURE|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
58270625|NCT03969264|OTHER|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
58270626|NCT04115410|DRUG|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
58270627|NCT04115410|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
58270628|NCT00081926|DRUG|Gleevec|
58270629|NCT02570334|OTHER|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
58270630|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
58270631|NCT05921149|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
58270632|NCT05921149|DRUG|Carboplatin|Given IV
57917700|NCT04869423|BEHAVIORAL|Dog-Assisted Therapy|During seven weeks patients will assist one time per week (1 hour). The therapy will be conducted by an expert psychologist. The intervention will consist of 7 weeks conducted once a week (50 minutes each session). It will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to say goodbye to the dogs.
58270633|NCT05921149|DRUG|Paclitaxel|Given IV
58270634|NCT05921149|DIETARY_SUPPLEMENT|Standard diet|Normal diet
58270635|NCT05615233|BEHAVIORAL|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~1. 2 sub-ethnic specific social media sites;~2. interactive online educational modules;~3. online resources; and~4. a VR component based on A Walk Through Dementia (WTD)"
58270636|NCT05615233|BEHAVIORAL|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
58270637|NCT06426160|DRUG|Tocilizumab 20 MG/ML [Actemra]|Tocilizumab 8 mg/kg every four weeks for 24 weeks.
58270638|NCT06426160|DRUG|Sodium Chloride 0.9% Inj|Placebo (Sodium chloride) every four weeks for 24 weeks.
58389236|NCT02289196|DRUG|Vx-006: 10mg|
58389237|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
58389238|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
57718304|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
57917701|NCT03170453|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
58270639|NCT03257241|DRUG|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
58389239|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
58389240|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
58389241|NCT00392587|DRUG|GW856553|
58389242|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
58389243|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
58389244|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
58270640|NCT03257241|DRUG|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
58270641|NCT03257241|DRUG|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
57917702|NCT03170453|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
58389245|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
57718305|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
57718306|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
57718307|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
57718308|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
57718309|NCT02381535|DRUG|Cisplatin|Given IV
57718310|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57718311|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
57718312|NCT02381535|DRUG|Onalespib|Given IV
57718313|NCT02381535|OTHER|Pharmacological Study|Correlative studies
57718314|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
57917703|NCT02937454|DRUG|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
57917704|NCT02937454|OTHER|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
57917705|NCT04581954|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
57718315|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
57917706|NCT04581954|DRUG|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
57718316|NCT00054002|DRUG|porfimer sodium|iv
57718317|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
57718318|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
57718319|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
57718320|NCT02758236|OTHER|No Intervention|No Intervention
57718321|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
57718322|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
57718323|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
57718324|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
57718325|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
57718326|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
57718327|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
57718328|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
58270642|NCT03257241|DRUG|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
58389246|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
58389247|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
58389248|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
58389249|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
58389250|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
57718329|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57718330|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57718331|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57718332|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57718333|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57917707|NCT04581954|OTHER|Standard of care|Standard of care treatment as per site-level policies and guidelines.
57917708|NCT02730741|DRUG|Lcr restituo® sachet|symptomatic treatment of diarrhoea
57917709|NCT02730741|DRUG|Placebo|
57917710|NCT02574754|DRUG|warfarin|warfarin 10 mg PO x 1
57917711|NCT00271960|BEHAVIORAL|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
58270643|NCT01342172|DRUG|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
58063692|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
58270644|NCT02046772|DRUG|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
58270645|NCT02046772|DRUG|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
58270646|NCT02046772|DRUG|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
58270647|NCT01606748|BIOLOGICAL|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
58270648|NCT01606748|DRUG|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
58063693|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
58270649|NCT01606748|DRUG|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
58270650|NCT02117713|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
58270651|NCT00851773|DRUG|semaglutide|0.1 mg once weekly, s.c. injection
58270652|NCT00851773|DRUG|semaglutide|0.2 mg once weekly, s.c. injection
58270653|NCT00851773|DRUG|semaglutide|0.4 mg once weekly, s.c. injection
58270654|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
58389251|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
58063694|NCT00997906|DRUG|carboplatin,|Given IV
58063695|NCT00997906|DRUG|cisplatin|Given IV
58270655|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
58389252|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
58389253|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
58389254|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
58389255|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
58389256|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
58063696|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
58063697|NCT00997906|DRUG|paclitaxel|Given IV
58063698|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
58063699|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
58270656|NCT00851773|DRUG|placebo|0.1 mg once weekly, s.c. injection
58270657|NCT00851773|DRUG|placebo|0.2 mg once weekly, s.c. injection
58270658|NCT00851773|DRUG|placebo|0.4 mg once weekly, s.c. injection
58270659|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
58270660|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
58270661|NCT00732680|DRUG|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
58270662|NCT00032721|PROCEDURE|Reiki; Subtle energy therapy|
58270663|NCT00483210|DRUG|Fenofibrate|
58270664|NCT03040505|OTHER|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
58270665|NCT03387345|OTHER|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
58270666|NCT03387345|OTHER|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
58270667|NCT03387345|OTHER|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
58063700|NCT02908841|DEVICE|Surgicel Snow|
58063701|NCT02908841|OTHER|Standard of Care|
58063702|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
58063703|NCT02841254|OTHER|Non interventional study|
58063704|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
58063705|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
58389257|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
58389258|NCT01999244|BEHAVIORAL|Self-monitoring skills|
58389259|NCT01999244|BEHAVIORAL|Technology|
58389260|NCT01999244|BEHAVIORAL|Interventionist Contact|
58389261|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
58389262|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
58389263|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
58389264|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
58389265|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
58389266|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
58389267|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
58389268|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
58270668|NCT03387345|OTHER|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
58270669|NCT03387345|OTHER|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
58270670|NCT03387345|OTHER|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
58270671|NCT04312841|DRUG|Letermovir|Given PO
58389269|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
58389270|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
58389271|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
58389272|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
58389273|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
58389274|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
58389275|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
58389276|NCT03163134|DEVICE|Lumbar Drain|
58389277|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
58389278|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
58389279|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
58389280|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
58389281|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
58389282|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
58389283|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
58389284|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
58389285|NCT00851552|BIOLOGICAL|rituximab|Given IV
58063706|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
58063707|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
58389286|NCT00851552|DRUG|bortezomib|Given IV
58389287|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
58389288|NCT00851552|GENETIC|gene expression analysis|Correlative Study
58389289|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
58389290|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
58389291|NCT00851552|GENETIC|proteomic profiling|Correlative Study
58389292|NCT00851552|OTHER|flow cytometry|Correlative Study
58389293|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
58389294|NCT00003421|BIOLOGICAL|bleomycin sulfate|
58389295|NCT00003421|DRUG|ABVD regimen|
58389296|NCT00003421|DRUG|chlorambucil|
58389297|NCT00003421|DRUG|dacarbazine|
58389298|NCT00003421|DRUG|doxorubicin hydrochloride|
58389299|NCT00003421|DRUG|etoposide|
58389300|NCT00003421|DRUG|prednisolone|
58389301|NCT00003421|DRUG|procarbazine hydrochloride|
58389302|NCT00003421|DRUG|vinblastine sulfate|
58389303|NCT00003421|DRUG|vincristine sulfate|
58270672|NCT06731153|DRUG|Ivarmacitinib|a selective Janus kinase 1 inhibitor
58389304|NCT00003421|RADIATION|radiation therapy|
58270673|NCT06731153|DRUG|Camrelizumab (SHR-1210)|a humanised anti-programmed death-1 (anti PD-1) antibody
58270674|NCT06731153|DRUG|Eribulin|Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
58389305|NCT01848067|DRUG|Alisertib|Given PO
58389306|NCT01848067|DRUG|Abiraterone acetate|Given PO
58389307|NCT01848067|DRUG|Prednisone|Given PO
58389308|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
58389309|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
58389310|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
58389311|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
58270675|NCT00522704|OTHER|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
58270676|NCT03647605|BEHAVIORAL|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
58270677|NCT00179205|DRUG|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
58270678|NCT00179205|DRUG|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
58270679|NCT06215755|DRUG|VRG50635|"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."
58270680|NCT05414266|DRUG|Placebo|Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
58270681|NCT05414266|DRUG|SADBE 5%|SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
58389312|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
58270682|NCT02539654|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
58270683|NCT02539654|PROCEDURE|Tympanostomy Tube Insertion|
58389313|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
58389314|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
58389315|NCT00006459|DRUG|gemcitabine hydrochloride|
58389316|NCT00006459|DRUG|paclitaxel|
58389317|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
58389318|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
58389319|NCT00191568|DRUG|Gemcitabine|
58389320|NCT00191568|DRUG|Oxaliplatin|
58389321|NCT00191568|PROCEDURE|Radiotherapy|
58389322|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
58389323|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
58389324|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
58389325|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
58389326|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
58389327|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
58389328|NCT02291783|DRUG|HTL0009936|Single dose
58389329|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
58389330|NCT00322413|DRUG|Epoetin|
58389331|NCT01236261|OTHER|Non intervention|Non interventional study
58389332|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
58389333|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
58389334|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
58389335|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
58389336|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
58389337|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
58389338|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
58270684|NCT02949908|DRUG|Rebif|Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
58389339|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
58389340|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
58389341|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
58389342|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
58270685|NCT04929158|PROCEDURE|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
58270686|NCT04076371|DRUG|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
58389343|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
58389344|NCT02534012|PROCEDURE|Major abdominal surgery|
58063708|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
58063709|NCT02288416|OTHER|questionnaire administration|Ancillary studies
58270687|NCT04076371|DRUG|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
58270688|NCT04076371|DRUG|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
58270689|NCT04076371|DRUG|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
58389345|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
58063710|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
58063711|NCT02288416|OTHER|Best Practice|
58063712|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
58389346|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
58389347|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
58389348|NCT00864175|DRUG|INCB007839|100 mg BID
58063713|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
58063714|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
58063715|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
58063716|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
58063717|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
58063718|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
58389349|NCT00864175|DRUG|INCB007839|200 mg BID
58389350|NCT00864175|DRUG|INCB007839|300 mg BID
58389351|NCT00864175|DRUG|INCB007839|300 mg BID
57718334|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
57718335|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
58063719|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
58270690|NCT04076371|DRUG|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
58270691|NCT04076371|DRUG|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
58270692|NCT04076371|DRUG|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
57718336|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
57718337|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
57718338|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
57718339|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
57718340|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
57917712|NCT00271960|BEHAVIORAL|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
58270693|NCT04076371|DRUG|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
58270694|NCT06047600|OTHER|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
58270695|NCT05104879|OTHER|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
58389352|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
58389353|NCT00864175|DRUG|Docetaxel|
58270696|NCT02376296|DRUG|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
57917713|NCT00271960|BEHAVIORAL|Usual care|Participants will receive usual prenatal care.
58270697|NCT02376296|OTHER|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
58270698|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
58270699|NCT04609241|DRUG|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
58270700|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
58270701|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
58270702|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
58270703|NCT05470075|DRUG|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
58270704|NCT05470075|DRUG|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
58270705|NCT04105894|DEVICE|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
58389354|NCT01995526|DRUG|Insulin Peglispro|
58389355|NCT01740921|DRUG|Liraglutide|Administered once daily
58389356|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
58389357|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
58389358|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
57917714|NCT01614743|DRUG|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
58270706|NCT04105894|DIAGNOSTIC_TEST|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
58270707|NCT04105894|DRUG|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
58270708|NCT00849134|DRUG|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
58270709|NCT00568360|DEVICE|Oximeter|
58270710|NCT00914706|OTHER|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
58270711|NCT02683148|DRUG|DHEA|
58270712|NCT02683148|OTHER|FACT-67 validated survey|"* Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much."
58270713|NCT04724577|RADIATION|carbon ion radiotherapy|dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
58270714|NCT01523015|OTHER|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
58389359|NCT00960791|DEVICE|AZD1656|Oral single dose
58389360|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
58389361|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
57917715|NCT01614743|DRUG|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
57917716|NCT03617341|PROCEDURE|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
57917717|NCT00577473|DRUG|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
58389362|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
58389363|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
57917718|NCT00577473|DRUG|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
57917719|NCT05837494|DRUG|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
58389364|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
58389365|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
58389366|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
57917720|NCT05837494|DRUG|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
58063720|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
58270715|NCT01523015|PROCEDURE|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
58270716|NCT00908427|PROCEDURE|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
58270717|NCT00908427|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
58270718|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
58270719|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
58270720|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
58270721|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
58389367|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
58389368|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
58389369|NCT04734483|RADIATION|MRI and CT|MRI and CT
58389370|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
58389371|NCT04734483|OTHER|electromyography|electromyography
58063721|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
58270722|NCT01021488|DRUG|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
58270723|NCT01021488|DRUG|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
58270724|NCT04308915|BEHAVIORAL|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
58270725|NCT00259285|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
57917721|NCT04581668|OTHER|Neurally adjusted ventilatory assist first|Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
57917722|NCT04581668|OTHER|Conventional ventilation first|Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
58063722|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
58063723|NCT02401945|DRUG|DE-120|
58063724|NCT02401945|DRUG|Aflibercept|
58063725|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
58270726|NCT00259285|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
58270727|NCT06002776|OTHER|a retrospective study|a retrospective study
58270728|NCT01343992|BEHAVIORAL|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
58270729|NCT01343992|BEHAVIORAL|No bedrest|Patients will not rest in bed after the embryo transfer.
57718341|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
57718342|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
57718343|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
57718344|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
57718345|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
57718346|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
57718347|NCT06573320|OTHER|physical exercise|physical exercise
57718348|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
58063726|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
57718349|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
57718350|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
57718351|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
57718352|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
58270730|NCT04424511|DRUG|Placebo|Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
58270731|NCT04424511|DRUG|Azithromycin|Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
58270732|NCT04764786|OTHER|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
58270733|NCT04764786|OTHER|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
58063727|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
58063728|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
58270734|NCT00199576|DRUG|Methylprednisolone|
57718353|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
58063729|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
58063730|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
58063731|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
58063732|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
58063733|NCT00145379|DRUG|Tablet Metformin 500 mg|
57718354|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
57718355|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
57718356|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
58063734|NCT00145379|DRUG|Placebo|
58063735|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
58063736|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
58270735|NCT04167930|OTHER|electronic medical record(EMR) Data and patient survey|"1. Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~2. Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
58270736|NCT03759366|DRUG|Eculizumab|Eculizumab will be administered by IV infusion.
58270737|NCT00807391|PROCEDURE|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
57718357|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
57718358|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
57917723|NCT02664727|BEHAVIORAL|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
57917724|NCT02664727|BEHAVIORAL|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
57917725|NCT05237661|DIETARY_SUPPLEMENT|Moon Balance|Moon Balance is a blend of 6 food ingredients
57917726|NCT02593409|DRUG|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
58063737|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
58063738|NCT00779181|DRUG|Placebo|Placebo taken three times a day
58389372|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
57917727|NCT02258165|DEVICE|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
57917728|NCT04485182|OTHER|Underwater jet massage (Tangentor)|"Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks."
57917729|NCT03756246|BIOLOGICAL|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
57917730|NCT06105268|OTHER|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
57917731|NCT05709015|OTHER|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
57917732|NCT05709015|DRUG|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
58063739|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
58063740|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
58063741|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
58063742|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
58270738|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
58389373|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
58389374|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
58389375|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
58389376|NCT04474197|DRUG|VX-864|Tablets for oral administration.
58389377|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
57917733|NCT05709015|DRUG|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
57917734|NCT05997368|OTHER|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
57917735|NCT05997368|OTHER|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
58389378|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
58389379|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
58270739|NCT00568256|BEHAVIORAL|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
57718359|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
57718360|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
57718361|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
57718362|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
57718363|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
57917736|NCT05997368|OTHER|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
57917737|NCT00763867|DRUG|Placebo|
57917738|NCT00763867|DRUG|Sildenafil|
57917739|NCT03295110|OTHER|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
57917740|NCT03295110|OTHER|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
58063743|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
58270740|NCT02284763|OTHER|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
58270741|NCT00770133|DRUG|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
58270742|NCT00770133|DRUG|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
58270743|NCT00770133|DRUG|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
58270744|NCT00770133|DRUG|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
58270745|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
58270746|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
58270747|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
58270748|NCT04324866|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
58270749|NCT05209841|DRUG|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
58270750|NCT05209841|DRUG|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
58270751|NCT00553982|PROCEDURE|Patellar component|Resurfacing with onlay technique
58389380|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
58389381|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
58270752|NCT00553982|PROCEDURE|No patellar component|Trimming of osteophytes when appropriate
58389382|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
58389383|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
58389384|NCT02890745|DRUG|Empagliflozin|
58389385|NCT02890745|DRUG|Placebo|
58389386|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
57718364|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
57718365|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
57718366|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
57718367|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
57718368|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
57718369|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
57718370|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
57718371|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
57718372|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
57718373|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
58270753|NCT03013608|PROCEDURE|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
58270754|NCT02176460|DRUG|Colchicine|0.5mg twice daily for 16 weeks
58270755|NCT02176460|DRUG|Placebo|1 tablet twice daily
58389387|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
57718374|NCT00051116|DRUG|CC-5013|
57718375|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
57718376|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
57718377|NCT00021307|DRUG|carboplatin|
57718378|NCT00021307|DRUG|temozolomide|
57718379|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
57718380|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
58063744|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
58063745|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
58270756|NCT06441617|DEVICE|Online Therapy for Fatigue|An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
57917741|NCT00190567|DRUG|duloxetine|
58270757|NCT04027075|BEHAVIORAL|Qlarity app users|Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
58270758|NCT04846816|COMBINATION_PRODUCT|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
58270759|NCT00504959|DRUG|ranibizumab|
58270760|NCT00552032|DRUG|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
57917742|NCT00190567|DRUG|Placebo|
58270761|NCT00552032|DRUG|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
57718381|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
57718382|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
57718383|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
58063746|NCT04874129|DRUG|YYC506 (phase 1)|Test
58063747|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
58063748|NCT04874129|DRUG|YYC506 (phase 2)|Test
58063749|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
58270762|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
58270763|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
58270764|NCT03785899|DEVICE|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
58270765|NCT03785899|DEVICE|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
58389388|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
57718384|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
57718385|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
58270766|NCT03785899|DEVICE|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
58389389|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
58389390|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
58389391|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
58389392|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
58389393|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
58389394|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
58389395|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
58389396|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
58389397|NCT02317198|DRUG|Clopidogrel|
58389398|NCT02317198|DRUG|Ticagrelor or Prasugrel|
58389399|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
57718386|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
57718387|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
57718388|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
57718389|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
57718390|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
57718391|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
57718392|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
58270767|NCT03785899|DEVICE|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
58270768|NCT05705115|DRUG|Ringer acetate|Ringer acetate 5 ml/kg.
58270769|NCT05705115|OTHER|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
58270770|NCT06710899|DRUG|Methenamine Hippurate 1g BD|Methenamine Hippurate 1g BD for 6 months
58270771|NCT06710899|DRUG|Methenamine Hippurate 1g BD + Vitamin C 1g BD|Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
58270772|NCT06336148|DRUG|ACTM-838|Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
58270773|NCT01733485|DRUG|Aspirin|500 mg/8 h for 5 days
58270774|NCT01733485|DRUG|Indomethacin|25 mg/8 h for 5 days
58270775|NCT04753268|BEHAVIORAL|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
58270776|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
58389400|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
58389401|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
58389402|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
58389403|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
58389404|NCT02400970|OTHER|malignant cells|
58389405|NCT00408707|PROCEDURE|local infiltration analgesia|
58389406|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
58389407|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
57718393|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
57718394|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
58270777|NCT05009407|BIOLOGICAL|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
57718395|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
57718396|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
57718397|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
57718398|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
57718399|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
57718400|NCT02367313|DRUG|Placebo|Placebo twice daily
58063750|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
58063751|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
57718401|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
57718402|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
57718403|NCT00507052|DRUG|N-acetylcysteine|
57718404|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
57718405|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
57718406|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
57917743|NCT05160792|DEVICE|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
57917744|NCT00292162|PROCEDURE|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
58270778|NCT06318819|DEVICE|Dental Floss Holders|Dental Floss Holders for flossing purposes
58270779|NCT00563160|DRUG|gemcitabine, carboplatin|
57917745|NCT00292162|DRUG|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
57917746|NCT00292162|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
57917747|NCT00292162|DRUG|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
57718407|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
57718408|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
57917748|NCT04759664|DRUG|LUT014 Gel (Dose 1)|Topical gel
57917749|NCT04759664|DRUG|LUT014 Gel (Dose 2)|Topical gel
57917750|NCT04759664|DRUG|Placebo|LUT014 matching placebo topical gel
57917751|NCT03325920|DEVICE|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
57917752|NCT02097641|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
57917753|NCT02097641|BIOLOGICAL|Plasma-Lyte A|Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
57917754|NCT03401229|BIOLOGICAL|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
58270780|NCT00563160|PROCEDURE|surgery|
58270781|NCT04291677|OTHER|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
58270782|NCT04291677|OTHER|Without intervention musical|Control group with standard treatment without musical intervention.
58270783|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
58270784|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
58270785|NCT05503875|BIOLOGICAL|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
57718409|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
57718410|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
57718411|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
57718412|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
57718413|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
57718414|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
57718415|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
57718416|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
57718417|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
57718418|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
57718419|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
57718420|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
57718421|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
57718422|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
57718423|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
57718424|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
57917755|NCT03401229|BIOLOGICAL|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
57917756|NCT03435757|PROCEDURE|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
57917757|NCT03435757|PROCEDURE|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
57917758|NCT06305377|DEVICE|Tandem Control IQ|Use of Tandem control IQ in a group of diabetic adolescents in not good glicaemic control
57917759|NCT00882154|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
57917760|NCT00882154|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
58063752|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
58270786|NCT03196037|BEHAVIORAL|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
58389408|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
58389409|NCT02183493|DRUG|BI 1356|
58270787|NCT00325624|DEVICE|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
57718425|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
57718426|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
57718427|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
57718428|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
57718429|NCT00030589|DRUG|bexarotene|
57718430|NCT00030589|DRUG|methoxsalen|
57718431|NCT00030589|PROCEDURE|UV light therapy|
57718432|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
57718433|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
57718434|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
57718435|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
57718436|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
57718437|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
57718438|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
57718439|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
57718440|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
57718441|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
58063753|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
58063754|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
57718442|NCT00274716|DRUG|MK0736|
58063755|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
58063756|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
58063757|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
58063758|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
58063759|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
58063760|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
58063761|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
58063762|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
58063763|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
58063764|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
58063765|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
58063766|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
58063767|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
57718443|NCT00274716|DRUG|MK0916|
57718444|NCT00274716|DRUG|Placebo|
57718445|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
57718446|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
57718447|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
57718448|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
57718449|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
57718450|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
57718451|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
57718452|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
57718453|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
57718454|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
57718455|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
57718456|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
57718457|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
58389410|NCT01017224|OTHER|18F-FAZA|PET scan
57718458|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
58389411|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
58389412|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
58389413|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
58389414|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
57718459|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
57718460|NCT00453765|DRUG|placebo|placebo
57718461|NCT00178958|DEVICE|Holter Monitor|
58389415|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
58389416|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
58389417|NCT04762992|OTHER|standard of care|Obsteric standard of care.
58389418|NCT01802580|BEHAVIORAL|Internet Survey|
58389419|NCT01802580|DRUG|fluocinonide 0.05% ointment|
58389420|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
58389421|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
58389422|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
58389423|NCT02793973|DEVICE|shoe lifts|
58389424|NCT01761006|DEVICE|NIOX MINO®|
58389425|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
58389426|NCT03346421|BEHAVIORAL|diet and physical activity|
58389427|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
57718462|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
57718463|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
57718464|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
57718465|NCT00804297|DRUG|Octreotide (drug)|
57718466|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
57718467|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
57718468|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
57718469|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
57718470|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
57718471|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
57718472|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
57718473|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
57718474|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
57718475|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
57718476|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
57718477|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
57718478|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
57718479|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
57718480|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
58389428|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
57718481|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
57718482|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
57718483|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
58389429|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
57718484|NCT03202316|DRUG|Atezolizumab|Given IV
58389430|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
58389431|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
58389432|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
58389433|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
58389434|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
57718485|NCT03202316|DRUG|Cobimetinib|Given PO
57718486|NCT03202316|DRUG|Eribulin|Given IV
57718487|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
57718488|NCT03202316|OTHER|Pharmacological Study|Correlative studies
57718489|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
57718490|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
58063768|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
58063769|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
58270788|NCT01382316|BEHAVIORAL|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
57718491|NCT00009230|DRUG|Celecoxib|
57718492|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
57718493|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
57718494|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
57718495|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
57718496|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
57718497|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
57718498|NCT05468840|DRUG|Normal saline|see study arm description
58270789|NCT01382316|BEHAVIORAL|Usual care|Group format, six weekly education sessions about alcohol and drugs
58270790|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
57718499|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
57718500|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
57718501|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
57718502|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
57718503|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
57718504|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
57718505|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
57718506|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
57718507|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
58270791|NCT04272606|DRUG|Saline Solution|Placebo
58270792|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
58270793|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
58270794|NCT00345878|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
58389435|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
57718508|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
57718509|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
57718510|NCT00690638|DRUG|PHX1149T|200 mg
57718511|NCT00690638|DRUG|PHX1149T|400 mg
57718512|NCT00690638|DRUG|Placebo|Placebo
57718513|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
57718514|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
57718515|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
57718516|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
57718517|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
57718518|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
57718519|NCT01696032|DRUG|SGI-110|
57718520|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
57718521|NCT01696032|DRUG|Carboplatin|
58063770|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
58063771|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
58389436|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
58389437|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
58389438|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
57718522|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
57718523|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
58063772|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
57718524|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
57917761|NCT04290169|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
58063773|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
58270795|NCT00345878|BIOLOGICAL|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
58270796|NCT03755518|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
58270797|NCT02983916|PROCEDURE|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
58270798|NCT04351126|DRUG|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
58270799|NCT04351126|DRUG|Bromocriptine|2.5 mg prescribed Vaginally twice daily
58389439|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
58389440|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
58389441|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
57718525|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
57718526|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
57718527|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
57718528|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
57718529|NCT02659865|DRUG|Placebo|Administered orally
57718530|NCT02659865|DRUG|LY3039478 original formulation|Administered orally
58063774|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
58270800|NCT06731348|DRUG|restricted opioid prescribing|Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
58270801|NCT06731348|DRUG|standard opioid prescribing|Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
58270802|NCT02077413|PROCEDURE|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
58270803|NCT02077413|PROCEDURE|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes."
58270804|NCT02077413|PROCEDURE|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
58270805|NCT02077413|PROCEDURE|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
58270806|NCT00436098|BEHAVIORAL|Motorpedagogic exercise|physical training
58270807|NCT06731543|OTHER|No interventions will be made|
57718531|NCT02659865|DRUG|LY3039478 new formulation|Administered orally
58389442|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
58389443|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
57718532|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
57917762|NCT04290169|DEVICE|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
58063775|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
58389444|NCT00531440|DRUG|Everolimus (RAD001)|
57917763|NCT02635360|DRUG|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
57917764|NCT02635360|RADIATION|Brachytherapy|Radiation is done for standard clinical care purposes.
57917765|NCT02635360|DRUG|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
57917766|NCT02617849|DRUG|Pembrolizumab|200 mg IV every 3 weeks
57917767|NCT02617849|DRUG|Carboplatin|AUC=6, every 3 weeks x 4
57917768|NCT02617849|DRUG|Paclitaxel|175 mg/m2, every 3 weeks x 4
57917769|NCT06153953|DEVICE|vacuum device|use of vacuum device in dressing of diabetic wounds
58063776|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
58063777|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
58063778|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
58063779|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
58063780|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
58389445|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
57917770|NCT06153953|OTHER|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
57917771|NCT01313637|DRUG|GSK573719/GW642444 125/25mcg|125/25mcg
57917772|NCT01313637|DRUG|GSK573719 125mcg|125mcg
57917773|NCT01313637|DRUG|GW642444 25mcg|25mcg
57917774|NCT01313637|DRUG|Placebo only|Placebo
57917775|NCT06244446|OTHER|No intervention|No intervention. It is an observational study
57917776|NCT00044031|BIOLOGICAL|G17DT Immunogen|
57917777|NCT02991131|DRUG|Tedizolid (Sivextro, BAY1192631)|Antibiotic
57917778|NCT02991131|DRUG|Linezolid|Antibiotic
57917779|NCT03511313|DEVICE|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
57917780|NCT03511313|DIAGNOSTIC_TEST|Renal angiography|A renal angiography according to standard procedure.
57917781|NCT04040816|DRUG|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
57917782|NCT03769012|DIETARY_SUPPLEMENT|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
57917783|NCT03769012|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
57917784|NCT02541760|DRUG|Monteleukast|4 ml monteleukast daily for one month
57917785|NCT02541760|DRUG|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
57917786|NCT02132013|BEHAVIORAL|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
58063781|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
58063782|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
58063783|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
57917787|NCT02026310|DRUG|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
57917788|NCT02026310|DRUG|glargine and metformin|
57917789|NCT00116727|DRUG|ENBREL®|50 mg/wk SC
57917790|NCT02237313|BEHAVIORAL|psychological support and therapeutic education program|
57917791|NCT04312217|BEHAVIORAL|Medical clowning|Medical clowning
57917792|NCT01098097|BIOLOGICAL|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
57917793|NCT01098097|DRUG|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
57917794|NCT01722110|DRUG|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
57917795|NCT01722110|DRUG|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
57917796|NCT01777269|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
57917797|NCT01777269|DRUG|Placebo|Take one capsule daily
57917798|NCT04781088|DRUG|Lenvatinib|Given PO
57917799|NCT04781088|DRUG|Paclitaxel|Given IV
57917800|NCT04781088|BIOLOGICAL|Pembrolizumab|Given IV
57917801|NCT02968732|PROCEDURE|Radical Cystectomy|
57917802|NCT06266884|OTHER|Kangaroo care|Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
58063784|NCT00000175|DRUG|Estrogen|
58063785|NCT00000175|DRUG|Testosterone|
58063786|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
58063787|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
58063788|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
57718533|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
57718534|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
57718535|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
57718536|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
57917803|NCT04790019|BEHAVIORAL|Low energy availability|Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
57917804|NCT04790019|BEHAVIORAL|High impact jumping|Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
57917805|NCT03453437|BEHAVIORAL|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
57917806|NCT01600521|DRUG|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
57917807|NCT02132546|DRUG|Chlorhexidine|
57917808|NCT02066285|DRUG|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
57917809|NCT02225951|DIETARY_SUPPLEMENT|Nutritional product|
57917810|NCT02225951|OTHER|Standard breakfast according to ADA recommendations|
57917811|NCT05535933|DRUG|HMPL-523(300mg PO QD)|No more than two doses will be explored
57917812|NCT05535933|DRUG|Placebo|Placebo
57917813|NCT00005652|DRUG|rituximab|
57917814|NCT05506657|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
57917815|NCT05506657|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
57917816|NCT00585377|DRUG|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
57917817|NCT00433524|PROCEDURE|computed tomography|
57917818|NCT05663879|DRUG|ID120040002|Drug: ID120040002
57917819|NCT05663879|DRUG|Compound-X|Drug: Compound-X
57917820|NCT05663879|DRUG|Placebo comparator|Placebo comparator
57917821|NCT03637985|DEVICE|resistive exercise|resistive exercise by elastic band for 12 weeks
58389446|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
58389447|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
58389448|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
58389449|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
58389450|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
58389451|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
58389452|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
58389453|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
58389454|NCT00034671|DRUG|Posaconazole oral suspension|
58063789|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
58063790|NCT05458674|DRUG|Tucatinib|taken orally
57718537|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
57718538|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
57917822|NCT03637985|DEVICE|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
57917823|NCT03237351|DEVICE|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
57917824|NCT00894153|DRUG|chemotherapy plus p53|chemotherapy plus p53
57917825|NCT00894153|DRUG|chemotherapy|chemotherapy
58063791|NCT05458674|DRUG|Eribulin|taknen intravenously
58063792|NCT05458674|DRUG|Trastuzumab|taken intravenously
58063793|NCT00015015|DRUG|Dichloroacetate|
58063794|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
58063795|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
58389455|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
58389456|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
58389457|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
58389458|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
58389459|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
58389460|NCT03611816|GENETIC|Blood taken|Collection of DNA
57917826|NCT00894153|RADIATION|radiotherapy|radiotherapy
58389461|NCT03611816|GENETIC|Blood taken|Collection of plasma
57917827|NCT04246567|PROCEDURE|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
57917828|NCT04246567|DRUG|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
58063796|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
58389462|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
58389463|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
57917829|NCT00816348|DRUG|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
57917830|NCT02647229|OTHER|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
57917831|NCT02647229|OTHER|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
57917832|NCT01577745|BIOLOGICAL|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
57917833|NCT02738944|BEHAVIORAL|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
57917834|NCT02738944|BEHAVIORAL|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
58270808|NCT04524585|DRUG|Neuromuscular blockade|Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
58270809|NCT06422936|DRUG|BO-112|Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
58270810|NCT05710679|BIOLOGICAL|Blood sample|"The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the potentiated radiotherapy in case of incomplete response (PET-CT)"
58270811|NCT02689882|DIETARY_SUPPLEMENT|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
58270812|NCT01712308|BIOLOGICAL|Sotatercept|Given SC
58270813|NCT01712308|DRUG|Ruxolitinib|
58270814|NCT05292976|OTHER|Methacholine Chloride|Serial Methacholine dilutions
57718539|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
58270815|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
58270816|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
57718540|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
57718541|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
57718542|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
57718543|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
57718544|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
57718545|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
58270817|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
58389464|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
58389465|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
58270818|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
58270819|NCT05292976|DRUG|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
58270820|NCT00693342|BIOLOGICAL|immunological adjuvant OPT-821|Given subcutaneously
58270821|NCT00693342|BIOLOGICAL|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
58389466|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
58389467|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
57718546|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
57718547|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
57917835|NCT02911415|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
58063797|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
58063798|NCT00003016|DRUG|tamoxifen citrate|
58270822|NCT00842400|DRUG|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~* metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~* sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~* VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~* 2 g (four 500 mg) probenecid tablets on Day 29."
57718548|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
57718549|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
57718550|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
57718551|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
57718552|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
57718553|NCT01717573|PROCEDURE|Deferred stenting|
57917836|NCT02893930|DRUG|Sapanisertib|Given PO
58063799|NCT00003016|PROCEDURE|adjuvant therapy|
58063800|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
58063801|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
58063802|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
58063803|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
58389468|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
58270823|NCT03017027|BEHAVIORAL|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
58389469|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
58389470|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
58389471|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
58389472|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
58389473|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
58389474|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
58389475|NCT03953248|DRUG|L-Carnitine|
57718554|NCT01717573|PROCEDURE|Conventional treatment|
57718555|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
58063804|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
58389476|NCT02859285|OTHER|Placebo vulvar cream|
58389477|NCT02859285|OTHER|Estradiol vulvar cream|
58389478|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
58063805|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
58063806|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
58270824|NCT03017027|BEHAVIORAL|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
58063807|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
58063808|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
57718556|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
57718557|NCT06563089|OTHER|blood sampling|Albumin level in blood
57718558|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
58270825|NCT03489941|DRUG|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
58270826|NCT03489941|DRUG|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
58389479|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
58389480|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
57718559|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
57718560|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
57718561|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
57718562|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
57718563|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
57718564|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
57718565|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
58270827|NCT03489941|DRUG|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
58270828|NCT06381154|PROCEDURE|Biopsy|Undergo biopsy
58270829|NCT06381154|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58270830|NCT06381154|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58270831|NCT06381154|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
58270832|NCT06381154|DRUG|Fluorouracil|Given IV
58270833|NCT06381154|DRUG|Irinotecan|Given IV
58270834|NCT06381154|DRUG|Leucovorin|Given IV
58270835|NCT06381154|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
58270836|NCT06381154|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58389481|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
58389482|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
58063809|NCT00809627|DRUG|saline|Normal saline
58270837|NCT06381154|DRUG|Oxaliplatin|Given IV
58270838|NCT06381154|BIOLOGICAL|Pembrolizumab|Given IV
58270839|NCT06381154|DRUG|Photodynamic Therapy|Undergo intratumoral photoradiation
58389483|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
58389484|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
58270840|NCT06381154|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and PET/MRI
58270841|NCT06381154|OTHER|Questionnaire Administration|Ancillary studies
58270842|NCT06381154|DRUG|Verteporfin|Given IV
58270843|NCT00943176|DRUG|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
58389485|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
57718566|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
57718567|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
57718568|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
57718569|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
57718570|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
57718571|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
58270844|NCT04202289|DEVICE|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
58270845|NCT04202289|DRUG|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
57917837|NCT05401760|PROCEDURE|Group A :combined phacoaspiration and angle surgery|"* Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture."
58270846|NCT06730633|BEHAVIORAL|Heart Matters|Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.
58389486|NCT00133159|BIOLOGICAL|Grass MATAMPL|
58270847|NCT04965103|PROCEDURE|SCR|Superior Capsule reconstruction
57718572|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
57917838|NCT05401760|PROCEDURE|Group B : phacoaspiration only|"* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture."
57917839|NCT01014260|DRUG|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
58063810|NCT02292615|OTHER|Medical Imaging|
58270848|NCT04965103|PROCEDURE|Bridging|Tendon repair with graft interposition
57718573|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
57718574|NCT02637934|DRUG|[18F]FluorThanatrace|
57718575|NCT02637934|RADIATION|PET/CT imaging sessions|
57718576|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
57718577|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
57718578|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
57718579|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
57718580|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
57718581|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
57917840|NCT01014260|DRUG|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
57917841|NCT01759368|DEVICE|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
58270849|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
58270850|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
58270851|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
58270852|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
58270853|NCT06325670|BEHAVIORAL|BED treatment|A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.
57718582|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
57718583|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
57718584|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
57718585|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
57718586|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
57718587|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
57718588|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
57718589|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
57718590|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
58063811|NCT01512849|DRUG|TA-7284 Low|Low
58063812|NCT01512849|DRUG|TA-7284 High|High
58270854|NCT06325670|OTHER|Waitlist|A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.
58389487|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
58063813|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
57718591|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
57718592|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
57718593|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
57718594|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
57718595|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
57718596|NCT02708745|BEHAVIORAL|Intervention Survey|
57718597|NCT02708745|BEHAVIORAL|Placebo Survey|
57718598|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
57718599|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
57718600|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
57718601|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
57718602|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
58063814|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
58063815|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
58063816|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
58063817|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
58063818|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
58063819|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
57718603|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
57718604|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
57718605|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
57718606|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
58063820|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
58063821|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
57718607|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
57718608|NCT00258986|PROCEDURE|Living donornephrectomy|
58063822|NCT02650804|DRUG|Gemcitabine|
58063823|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
58063824|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
58063825|NCT00005066|DRUG|O6-benzylguanine|
58063826|NCT00005066|DRUG|carmustine|
58063827|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
57718609|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
57718610|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
57718611|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
57718612|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
57718613|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
57718614|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
58270855|NCT03813134|PROCEDURE|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
58270856|NCT03813134|OTHER|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure \>75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
57718615|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
57718616|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
57718617|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
57718618|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
57718619|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
58063828|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
58270857|NCT03813134|DEVICE|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
58270858|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
58270859|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
58270860|NCT01934127|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
58270861|NCT00061022|DRUG|NXY-059|
58270862|NCT03660150|OTHER|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
58270863|NCT00998348|BEHAVIORAL|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
58270864|NCT03035734|DRUG|BMS-986141 Form A Tablet|tablet
58270865|NCT03035734|DRUG|BMS-986141 Form B tablet (low dose)|tablet
57718620|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
57718621|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
58270866|NCT03035734|DRUG|BMS-986141 Form B tablet (high dose)|tablet
57718622|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
57718623|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
57718624|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
57718625|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
58270867|NCT05171634|DEVICE|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
58270868|NCT05171634|DEVICE|iSCAN|Virtual colonoscopy assisted by iSCAN
58063829|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
58063830|NCT02987166|DRUG|Pembrolizumab|200 mg
57718626|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
58063831|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
58063832|NCT01694966|DRUG|Methylene Blue MMX®|
58063833|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
58270869|NCT00392470|BIOLOGICAL|cetuximab|
57718627|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
57718628|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
57718629|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
57718630|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
57718631|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
57718632|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
57718633|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
57718634|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
57718635|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
57718636|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
58063834|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
58063835|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
58063836|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
58063837|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
57718637|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
57718638|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
57718639|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
57718640|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
57718641|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
57718642|NCT02629146|DRUG|Midazolam|
57718643|NCT02629146|DRUG|Fentanyl|
57718644|NCT02629146|DRUG|Isotonic saline|
57718645|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
57718646|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
58270870|NCT00392470|DRUG|irinotecan hydrochloride|
58270871|NCT00392470|PROCEDURE|conventional surgery|
58270872|NCT00392470|PROCEDURE|neoadjuvant therapy|
58270873|NCT00392470|RADIATION|3-dimensional conformal radiation therapy|
58270874|NCT00392470|RADIATION|intensity-modulated radiation therapy|
58270875|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
57718647|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
58063838|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
58063839|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
58063840|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
58270876|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
58270877|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
58270878|NCT02696954|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
58270879|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
58063841|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
58063842|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
58063843|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
58063844|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
58063845|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
58063846|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
58389488|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
57917842|NCT06294132|PROCEDURE|Lumbar Manipulation|"The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed to the level to be manipulated, and the left foot is placed behind the right lower leg. The caregiver introduces rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver then rolls the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. If a cavitation pop is not heard the first time, a second attempt is made. The procedure is repeated on the opposite side."
58063847|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
58063848|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
58063849|NCT00003572|DRUG|mycophenolate mofetil|
58063850|NCT00003572|DRUG|tacrolimus|
58063851|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
58063852|NCT00003572|RADIATION|radiation therapy|
58063853|NCT04829591|OTHER|observational|Heart failure, non interventional
58063854|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
58063855|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
58063856|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
58063857|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
58063858|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
58063859|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
58063860|NCT04804111|DRUG|arm 0|placebo group
58063861|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
58063862|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
58063863|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
58063864|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
58063865|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
58063866|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
58063867|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
58063868|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
58063869|NCT01979003|DRUG|Fluorescein|
58063870|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
58063871|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
58063872|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
58063873|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
58063874|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
58063875|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
58389489|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
57917843|NCT06294132|PROCEDURE|Sham Lumbar Manipulation|The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed SLIGHTLY, and the left foot is placed behind the right lower leg. The caregiver DOES NOT introduce rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver DOES NOT roll the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. NO ROTATION OCCURS IN THE SPINE. The procedure is repeated on the opposite side.
57917844|NCT02175004|DRUG|Inotersen|Inotersen SC
57917845|NCT01444573|DEVICE|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
57917846|NCT05694104|OTHER|Malnutrition|For the diagnosis of malnutrition, we adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
57917847|NCT06284148|DIAGNOSTIC_TEST|Screening for intimate partner violence|confidential screening using exam computer
57917848|NCT06284148|OTHER|Assessment and referral|confidential assessment and referral of high-risk patients using decision-support templates
57917849|NCT00174512|DRUG|GTN|
57917850|NCT00174512|DRUG|Moxifloxacin|
57917851|NCT05134870|BEHAVIORAL|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
57917852|NCT02700763|OTHER|[18F]dabrafenib molecular imaging|A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
57917853|NCT05469399|OTHER|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
57917854|NCT05469399|OTHER|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
58270880|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
58270881|NCT02696954|DRUG|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
57917855|NCT00169052|BEHAVIORAL|Health Care Management and Supported Rehabilitation|
58270882|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
58270883|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
57917856|NCT00512460|DRUG|RTA 744|4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
58270884|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
58270885|NCT01167634|BEHAVIORAL|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
58389490|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
58063876|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
58270886|NCT01167634|BEHAVIORAL|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
58270887|NCT01167634|BEHAVIORAL|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
58270888|NCT01205074|DEVICE|13C Methacetin Breath Test|
58270889|NCT01205074|DIETARY_SUPPLEMENT|Grape fruit juice|
58270890|NCT01205074|DRUG|Non selective beta blocker - Propranolol|
58270891|NCT01205074|DIETARY_SUPPLEMENT|Ethanol|
58270892|NCT03536052|DEVICE|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
58270893|NCT01192035|DRUG|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count \>250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
58270894|NCT01192035|DRUG|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
58270895|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
58270896|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
58389491|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
58270897|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
58270898|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
58270899|NCT01224652|DRUG|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
58270900|NCT01224652|DRUG|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
58270901|NCT03906721|DRUG|Placebo|Sugar pill used to condition patients.
58270902|NCT03906721|DRUG|Oxycodone|An opioid used for analgesia.
58270903|NCT03906721|OTHER|Essential Oil|An aromatic oil used for conditioning.
57917857|NCT02973048|DRUG|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
58063877|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
58063878|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
58270904|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
58270905|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
58389492|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
57917858|NCT02973048|DRUG|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
57917859|NCT02958267|BIOLOGICAL|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
57917860|NCT02958267|BIOLOGICAL|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
57917861|NCT02958267|DEVICE|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution \[10 mg/mL\], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
57917862|NCT02464033|DRUG|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
57917863|NCT02464033|DRUG|Vitamin D|
57917864|NCT02464033|DRUG|Etanercept|
57917865|NCT03306836|DRUG|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
57917866|NCT03306836|DRUG|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
57917867|NCT02673840|DRUG|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
57917868|NCT02673840|DRUG|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
57917869|NCT03572478|DRUG|Rucaparib|600 mg taken by mouth twice daily.
57917870|NCT03572478|DRUG|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
57917871|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 80mg|The patient received one treatment of RC18 80mg in the test group
58270906|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
58270907|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
58270908|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
58389493|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
58389494|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
57917872|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 160mg|The patient received one treatment of RC18 160mg in the test group
57917873|NCT04235933|BIOLOGICAL|RC18 240mg|The patient received one treatment of RC18 240mg in the test group
58063879|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
58063880|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
58063881|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
58063882|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
58063883|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
58270909|NCT04876976|DRUG|Cyanoacrylate, Isobutyl|using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
57917874|NCT00164645|BEHAVIORAL|Problem Solving intervention|
57917875|NCT01201317|DRUG|AZD2423|20 mg tablet
57917876|NCT01201317|DRUG|AZD2423|150 mg tablet
57917877|NCT01201317|DRUG|Placebo|Placebo
57917878|NCT05391477|DEVICE|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
57917879|NCT04067648|DRUG|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
57917880|NCT01532726|DRUG|ESL|ESL 400/800/1200 mg tablets once daily
57917881|NCT06250556|DIETARY_SUPPLEMENT|creatine|creatine supplementation (Creapure)
57917882|NCT00959647|DRUG|Vismodegib|Vismodegib was supplied in capsules.
57917883|NCT00959647|DRUG|FOLFOX|FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
58270910|NCT04876976|PROCEDURE|Classic surgical repair|classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
58270911|NCT03907020|DIETARY_SUPPLEMENT|Barley|Assessing the metabolic availability of lysine in barley.
58270912|NCT04786093|RADIATION|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
58389495|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
58389496|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
58270913|NCT04786093|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
57718648|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
57718649|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
57718650|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
58063884|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
57718651|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
57718652|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
57718653|NCT02780349|DEVICE|WIRION|Embolic Protection System
57718654|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
58063885|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
58063886|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
58063887|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
58270914|NCT02655419|DRUG|ATM-AVI|"Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
58270915|NCT02655419|DRUG|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
58270916|NCT01323816|OTHER|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
58270917|NCT03490396|DEVICE|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
58270918|NCT03490396|COMBINATION_PRODUCT|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
58270919|NCT05590117|DRUG|Pentoxifylline|Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily
58270920|NCT05590117|DRUG|Placebo|placebo tablets
58270921|NCT05590117|DRUG|FOLFOX-6 regimen|12 cycles of FOLFOX-6 regimen
58270922|NCT02954185|OTHER|WellClub|
58389497|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
58389498|NCT02180685|OTHER|Anchor fixation|
58389499|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
57718655|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
57718656|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
57718657|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
58270923|NCT02954185|BEHAVIORAL|Standard Therapy|
58270924|NCT05725213|DRUG|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
58389500|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
58389501|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
58389502|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
58389503|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
58270925|NCT00941694|BEHAVIORAL|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
58389504|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
58389505|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
58389506|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
58270926|NCT00941694|BEHAVIORAL|placebo group|3 phone calls not related to asthma self-management
58270927|NCT01894659|OTHER|24% oral sucrose|
58389507|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
58389508|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
58063888|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
58063889|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
58270928|NCT01894659|OTHER|30% oral glucose|
58270929|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
58389509|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
58389510|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
58389511|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
58063890|NCT01901679|DRUG|Celebrex|200 mg PO BID
58270930|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
58389512|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
58389513|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
58389514|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
58389515|NCT04600726|OTHER|no intervention|no interventioni
58389516|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
58389517|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
58389518|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
58389519|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
58389520|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
57718658|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
57917884|NCT00959647|DRUG|FOLFIRI|FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
58063891|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
58389521|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
58389522|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
58389523|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
57917885|NCT00959647|DRUG|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
57917886|NCT04568460|OTHER|Intervention Group Sessions|Participants will undergo a multi-session group intervention over the course of six months.
57917887|NCT00947674|DEVICE|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
57917888|NCT00001267|DRUG|zidovudine|
57917889|NCT00001267|DRUG|2',3'-dideoxyinosine|
57917890|NCT05969925|DIAGNOSTIC_TEST|new biomarkers for heart failure|assess efficacy of new biomarkers for heart failure
58063892|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
58270931|NCT03652649|OTHER|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
58270932|NCT00860041|BEHAVIORAL|pain questionnaires|
58389524|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
57917891|NCT03133546|DRUG|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
58389525|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
58389526|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
58389527|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
57718659|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
57718660|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
57718661|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
57718662|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
57718663|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
57718664|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
57917892|NCT03133546|DRUG|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
57917893|NCT03584568|BEHAVIORAL|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
58270933|NCT05764746|DRUG|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
58270934|NCT05764746|DRUG|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
58270935|NCT05764746|DRUG|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
58270936|NCT00398437|BIOLOGICAL|trastuzumab|
58270937|NCT00398437|DRUG|chemotherapy|
58270938|NCT00398437|PROCEDURE|magnetic resonance imaging|
58270939|NCT03310294|DIETARY_SUPPLEMENT|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
58270940|NCT03310294|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
58270941|NCT05669469|PROCEDURE|Bariatric surgery|1) gastric pouch creation, 2) creation of biliopancreatic limb, 3) jejunojejunostomy creation, and 4) creation of gastrojejunostomy.
58389528|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
58389529|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
57718665|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
57718666|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
57718667|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
58389530|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
58389531|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
58389532|NCT00600275|DRUG|BGT226|
58389533|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
58389534|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
58389535|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
57718668|NCT02760238|OTHER|Observational|
57718669|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
57718670|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
57718671|NCT01701466|OTHER|Aveeno cream|Twice a day
57718672|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
57718673|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
57718674|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
57917894|NCT03584568|OTHER|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
58063893|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
58063894|NCT01450566|DRUG|Lidocaine|Use of lidocaine
58063895|NCT01450566|DRUG|Saline|Saline
57718675|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
57718676|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
57718677|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
57718678|NCT06023095|DRUG|LY3502970|Administered orally.
57718679|NCT06023095|DRUG|Placebo|Administered orally.
57718680|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
58063896|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
58063897|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
58063898|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
57917895|NCT04354896|DRUG|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
58270942|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
58270943|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
58389536|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
58389537|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
58389538|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
58389539|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
58389540|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
58389541|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
58389542|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
57718681|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
57917896|NCT04354896|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
58063899|NCT03793010|DRUG|FX006|Single Intra-articular injection
58270944|NCT03872258|BEHAVIORAL|Control|Counseling on physical activity
58270945|NCT03872258|BEHAVIORAL|Intervention group|Program of combined exercise and a Smartband for 6 months.
58063900|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
58063901|NCT04907942|DEVICE|EMA + Automated Text Message Intervention|Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.
58270946|NCT01433744|PROCEDURE|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
58389543|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
58270947|NCT04295343|DIAGNOSTIC_TEST|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
57917897|NCT04076839|BEHAVIORAL|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
57917898|NCT00000550|BEHAVIORAL|health education|
57917899|NCT01759407|DRUG|Ropivicaine|
57917900|NCT01759407|DRUG|Epinephrine|
57917901|NCT04460274|OTHER|Model Building|Model building
57917902|NCT04460274|OTHER|Model validation|Model validation
57917903|NCT02709096|DRUG|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
57917904|NCT02709096|DRUG|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
57917905|NCT02236104|DEVICE|Plethysmography opto electronic|
57917906|NCT02236104|PROCEDURE|respiratory parameters|
57917907|NCT05218187|DEVICE|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
57917908|NCT05218187|OTHER|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
58063902|NCT04907942|BEHAVIORAL|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
58063903|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
58270948|NCT04295343|DIAGNOSTIC_TEST|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
58270949|NCT06730763|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.
57917909|NCT03958786|OTHER|Simplified Geriatric Evaluation|"* Questionnaires~* Self assessment questionnaires~* Mobility and balance tests"
57917910|NCT03958786|OTHER|Sampling|- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
57917911|NCT00343447|BIOLOGICAL|autologous tumor cell vaccine|
57917912|NCT00343447|BIOLOGICAL|rituximab|
57917913|NCT00343447|DRUG|cyclophosphamide|
57917914|NCT04612959|OTHER|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
58063904|NCT01296464|DRUG|Carbidopa|Capsules
58063905|NCT00000515|BEHAVIORAL|diet, reducing|
58063906|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
58063907|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
57917915|NCT06088212|OTHER|Disease management program|"The components of our DMP include:~1. Intensive post-discharge education~2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~4. Exercise program delivered by an exercise physiologist~5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly."
57917916|NCT06035679|DRUG|Pyrotinib and Trastuzumab|Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
58063908|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
58063909|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
58063910|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
58063911|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
58270950|NCT06730763|OTHER|Exercise|selected traditional physical therapy program for improve balance and decrease risk of falling
58270951|NCT00766285|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
58270952|NCT00766285|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
58270953|NCT05158686|DEVICE|Paclitaxel-coated Balloon dilation angioplasty|Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
58270954|NCT05158686|DEVICE|Non-coated Balloon dilation angioplasty|Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
58270955|NCT00113191|DRUG|Veronate|
58389544|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
58389545|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
58389546|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
58389547|NCT00954564|OTHER|medical chart review|Observational only
58389548|NCT00954564|OTHER|questionnaire administration|Observational only
58389549|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
58389550|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
58389551|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
57718682|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
57718683|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
57917917|NCT05914441|OTHER|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
57917918|NCT04446533|DRUG|Hydrogen Peroxide and Hyaluronic acid filming formulation|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
57917919|NCT04446533|DRUG|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
58063912|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
58063913|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
58270956|NCT03217019|PROCEDURE|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
58270957|NCT03217019|PROCEDURE|Direct|catheter insertion without guidewire assist(catheter over needle)
58270958|NCT05724485|DRUG|Branched-chain Amino Acid|12.45 grams of BCAA orally per day before bedtime
58270959|NCT05724485|DRUG|Placebo|12.45 grams of Maltodextrin orally per day before bedtime
58270960|NCT00394433|DRUG|Bevacizumab|
58270961|NCT00394433|DRUG|Docetaxel|
58270962|NCT00394433|DRUG|Cisplatin|
58270963|NCT00394433|DRUG|Irinotecan|
58389552|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
58389553|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
58389554|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
58389555|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
58270964|NCT06032520|BEHAVIORAL|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
58270965|NCT06354205|DIAGNOSTIC_TEST|Sliva Procalcitonin|Sliva Procalcitonin vs Blood procalcitonin
57718684|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
58270966|NCT05489419|BEHAVIORAL|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
57718685|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
57917920|NCT04446533|DRUG|Placebo|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
58270967|NCT01110668|DRUG|Nilotinib|
57917921|NCT04084470|DIETARY_SUPPLEMENT|Different types of bread|Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
57917922|NCT00639353|DEVICE|senofilcon A toric soft contact lens|contact lens
57917923|NCT00639353|DEVICE|senofilcon A sphere soft contact lens|contact lens
57917924|NCT01592500|DRUG|MOD-4023|Once weekly subcutaneous injection
57917925|NCT01592500|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin
57917926|NCT05380778|DRUG|Deep anesthesia|"Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45"
57917927|NCT05380778|DRUG|Shallow anesthesia|"Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45"
57917928|NCT01847053|OTHER|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
57917929|NCT01847053|OTHER|Oatmeal|Oatmeal control, around 70g; without cinnamon
57917930|NCT05782452|PROCEDURE|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
58270968|NCT03597022|DRUG|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
58270969|NCT00796744|DRUG|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
58270970|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
58270971|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
58270972|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
58270973|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
58270974|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
58270975|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
57718686|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
57917931|NCT05782452|GENETIC|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
58270976|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
58270977|NCT03781583|DEVICE|SmartHMD version 1|First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.
58270978|NCT03781583|DEVICE|SmartHMD version 2|Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.
58270979|NCT03781583|DEVICE|SmartHMD version 3|Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.
58270980|NCT03781583|DEVICE|SmartHMD version 4|Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
58270981|NCT05937607|BEHAVIORAL|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
58270982|NCT00097305|BEHAVIORAL|Body-Oriented Therapy|
58270983|NCT00097305|BEHAVIORAL|Standardized Massage Therapy|
58270984|NCT00263055|DRUG|oxaliplatin|
57718687|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
57718688|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
57718689|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
57718690|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
58270985|NCT05738837|BEHAVIORAL|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships\&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
58389556|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
58063914|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
57718691|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
57718692|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
57718693|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
57718694|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
58270986|NCT05738837|BEHAVIORAL|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
58063915|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
58270987|NCT03761173|DEVICE|FlowTriever System|Thrombectomy
58270988|NCT03761173|DRUG|Anticoagulation Agents|Anticoagulation medication
58270989|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
58270990|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
58270991|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
58270992|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
58270993|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
58270994|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
58270995|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
58270996|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
58270997|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
58270998|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
58270999|NCT04312594|DRUG|Placebo|Patients were administered Placebo taken orally as tablets twice daily
58271000|NCT05031637|BEHAVIORAL|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
58271001|NCT05031637|BEHAVIORAL|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
58271002|NCT06490172|DEVICE|Shock wave therapy|Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
58271003|NCT03728998|OTHER|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~* 1. Starting in semi-succumbed position (45 degree head-up)~* 2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
58271004|NCT03728998|OTHER|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
58063916|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
57718695|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
58271005|NCT00939471|DEVICE|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
58271006|NCT02014051|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
58271007|NCT06236724|DRUG|Asciminib|Given by PO
58271008|NCT06730893|OTHER|share decision aids|card news and videos related to general knowledge and treatment of low-risk thyroid cancer
58271009|NCT03081143|DRUG|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
58271010|NCT03081143|DRUG|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
57718696|NCT00403455|DRUG|Paroxetine|SSRI
58271011|NCT03081143|DRUG|Paclitaxel|80 mg/m2 on day 1, 8, 15
58271012|NCT04343053|OTHER|SARS-Cov-2 infection|blood sample withdrawal
58271013|NCT03696485|BIOLOGICAL|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
58271014|NCT04832750|DEVICE|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
58271015|NCT01484860|DRUG|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
58271016|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
58271017|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
58271018|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
58271019|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
58063917|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
58063918|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
58063919|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
58063920|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
58271020|NCT03600155|BIOLOGICAL|Ipilimumab|Given IV
58271021|NCT03600155|BIOLOGICAL|Nivolumab|Given IV
58271022|NCT05949424|DRUG|Olaparib|Starting dose of 200mg 2dd.
58271023|NCT05949424|DRUG|Lenvatinib|Starting dose of 10mg 1dd.
58271024|NCT05949424|DRUG|Sunitinib|Starting dose of 25mg 1dd 28/42 days.
58271025|NCT05949424|DRUG|Palbociclib|Starting dose of 75mg 1dd 21/28 days.
58271026|NCT05949424|DRUG|Pazopanib|Starting dose of 200mg 1dd.
58271027|NCT05949424|DRUG|Olaparib|Starting dose of 300mg 2dd.
58063921|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
58063922|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
58063923|NCT00271076|PROCEDURE|IVUS|
58063924|NCT00271076|DEVICE|CAS|
58063925|NCT00271076|PROCEDURE|CEA|
58063926|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
58063927|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
58063928|NCT02523742|DEVICE|IMRf|
58063929|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
58271028|NCT05949424|DRUG|Lenvatinib|Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.
58271029|NCT05949424|DRUG|Sunitinib|Starting dose of 50mg 1dd 28/42 days.
58271030|NCT05949424|DRUG|Palbociclib|Starting dose of 125mg 1dd 21/28 days.
58271031|NCT05949424|DRUG|Pazopanib|Starting dose of 800mg 1dd.
58271032|NCT03859791|OTHER|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
58271033|NCT02452840|OTHER|No Intervention|No Intervention
58271034|NCT04633603|DEVICE|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
58271035|NCT03114657|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
58271036|NCT03114657|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
58271037|NCT00630747|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
58271038|NCT06718387|OTHER|PsychoEducation Program|6 sessions of PsychoEducational Program
58271039|NCT06717854|OTHER|transanal irrigation|The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
58389557|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
58389558|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
58389559|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
57718697|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
58063930|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
58063931|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
58271040|NCT06717854|OTHER|antegrade enema|The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
57718698|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
58271041|NCT01325259|OTHER|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
58271042|NCT01325259|RADIATION|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of \[18F\]AV-45
58271043|NCT01325259|RADIATION|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
58271044|NCT01325259|OTHER|MRI|Magnetic Resonance Imaging
58271045|NCT05801900|DRUG|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
58389560|NCT02515968|DRUG|Propofol|
58389561|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
57718699|NCT01978405|DRUG|Alpha lipoic acid|
58063932|NCT05588076|OTHER|no intervention|no intervention
58063933|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
58271046|NCT05801900|DRUG|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
57718700|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
57718701|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
57718702|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
57718703|NCT00260052|DRUG|Erythropoietin administration|
57718704|NCT03367533|DRUG|Ketamine|Intravenous ketamine
57718705|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
57718706|NCT03367533|DRUG|Placebo|Oral placebo
58063934|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
58063935|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
58063936|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
58271047|NCT04886206|BIOLOGICAL|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
58271048|NCT05555316|DRUG|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
58389562|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
58389563|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
58389564|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
58389565|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
57718707|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
58063937|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
57718708|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
57718709|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
57718710|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
57718711|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
57718712|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
58271049|NCT06104280|OTHER|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
57718713|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
57718714|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
58271050|NCT06104280|OTHER|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
58271051|NCT06104280|OTHER|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
58063938|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
58271052|NCT06104280|BEHAVIORAL|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
58271053|NCT06104280|DEVICE|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
58271054|NCT06104280|OTHER|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
58271055|NCT06104280|OTHER|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
58271056|NCT00429845|BEHAVIORAL|Nutritional|
58271057|NCT05691491|PROCEDURE|Biopsy|Undergo biopsy
58271058|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58389566|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
58389567|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
58389568|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
58389569|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
58389570|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
57718715|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
58271059|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
58271060|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58271061|NCT05691491|DRUG|Temozolomide|Given orally (PO)
58271062|NCT05691491|DRUG|Tuvusertib|Given PO
58271063|NCT06380803|OTHER|A educational program|A educational program using cadaver or porcine models for robotic brest surgery
58271064|NCT02508571|OTHER|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
58271065|NCT02508571|OTHER|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
58271066|NCT02508571|OTHER|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
58271067|NCT02129634|DEVICE|CB-PTA|
57718716|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
57718717|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
57718718|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
58271068|NCT02129634|DEVICE|DEB-PTA|
58271069|NCT06210373|DEVICE|Myrialen Gel|Myrialen Gel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment.
58271070|NCT06210373|DEVICE|Recugel|"Recugel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.~In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment."
57718719|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
57718720|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
57718721|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
58271071|NCT06436755|PROCEDURE|no intervention,this is a observational studies|no intervention,this is a observational studies
58271072|NCT02951039|DRUG|Edoxaban|Prescribed according to approved label
58271073|NCT00622596|OTHER|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
58271074|NCT04106362|BIOLOGICAL|Cetuximab|Given IV
58271075|NCT04106362|DRUG|Cisplatin|Given IV
58271076|NCT04106362|OTHER|Quality-of-Life Assessment|Ancillary studies
58271077|NCT04106362|OTHER|Questionnaire Administration|Ancillary studies
57718722|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
57917932|NCT03821441|BIOLOGICAL|bOPV(Candy)|"A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
58271078|NCT04106362|RADIATION|Radiation Therapy|Undergo radiation therapy
58271079|NCT00848978|BEHAVIORAL|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
58271080|NCT00662558|DRUG|celecoxib|200 mg capsules BID for 6 weeks
57917933|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
57917934|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
57917935|NCT04969978|BEHAVIORAL|Enhanced Academic Detailing|"* Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~* Follow-up booster sessions~* Monthly performance audit and feedback"
57917936|NCT04969978|OTHER|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
57917937|NCT00610103|DRUG|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
57917938|NCT04660604|DEVICE|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
57917939|NCT02534038|DRUG|AVP-786|d6-DM/Q
57917940|NCT02534038|DRUG|Placebo|matching placebo
57917941|NCT03377426|DRUG|LYS228|LYS228 IV infusion
57917942|NCT03377426|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
57917943|NCT02102477|PROCEDURE|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
57917944|NCT02102477|OTHER|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
58271081|NCT00662558|DRUG|tramadol HCL|50 mg capsules QID for 6 weeks
58271082|NCT06719219|BIOLOGICAL|LTB-SA7|LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.
57718723|NCT05905185|DRUG|Placebo|50mg of Placebo
57718724|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
57917945|NCT03601988|RADIATION|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
58271083|NCT06719219|BIOLOGICAL|Placebo|Sodium Phosphate with Sodium Chloride
58271084|NCT04397471|PROCEDURE|Bone Marrow Harvest|Healthy volunteer bone marrow harvest
57718725|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
57718726|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
57718727|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
57917946|NCT03601988|DRUG|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
57917947|NCT01966471|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
57917948|NCT01966471|DRUG|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
57917949|NCT01966471|DRUG|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
57917950|NCT01966471|DRUG|Paclitaxel|IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
58271085|NCT03299894|PROCEDURE|systematic calculation of qSOFA|calculation of qSOFA for each patient
58271086|NCT00100841|BIOLOGICAL|cetuximab|Given IV
58271087|NCT00100841|BIOLOGICAL|bevacizumab|Given IV
58271088|NCT00100841|DRUG|oxaliplatin|Given IV
58271089|NCT00100841|DRUG|leucovorin calcium|Given IV
58271090|NCT00100841|DRUG|fluorouracil|Given IV
58271091|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
57917951|NCT01966471|DRUG|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
57917952|NCT01966471|DRUG|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
57917953|NCT01966471|DRUG|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
57917954|NCT01966471|DRUG|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
58271092|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
57917955|NCT01966471|DRUG|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
57917956|NCT04088487|BEHAVIORAL|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
57917957|NCT01442779|DRUG|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
57917958|NCT04295876|BEHAVIORAL|The BRIDGES Project Intervention|The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
57917959|NCT00669448|BEHAVIORAL|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
57917960|NCT02665637|DRUG|Trastuzumab|Each patient may receive single dose by intravenous infusion
57917961|NCT04300686|BIOLOGICAL|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
58271093|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
58271094|NCT05849584|OTHER|Transperineal ultrasound|A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
57917962|NCT04300686|BIOLOGICAL|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
57917963|NCT02939547|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
57917964|NCT00633724|BIOLOGICAL|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
57917965|NCT00040677|DRUG|Low Dose ICA-17043|Low dose arm
57917966|NCT00040677|DRUG|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
57917967|NCT00040677|DRUG|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
57917968|NCT02145247|DRUG|hCG|"3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
57917969|NCT01740141|PROCEDURE|Plexus brachialis block|
57917970|NCT04924543|OTHER|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
57917971|NCT04924543|OTHER|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
57917972|NCT00343954|DRUG|L-citrulline tablets, 1000 mg|
58271095|NCT05230615|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
57917973|NCT01419457|DRUG|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
57917974|NCT01419457|DRUG|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
57917975|NCT01419457|DRUG|Favipiravir|800 mg Single Dose
58389571|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
58389572|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
58389573|NCT01670279|DRUG|Placebo|
58389574|NCT02880228|DRUG|Dexamethasone|Given PO
58389575|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
58389576|NCT02880228|DRUG|Lenalidomide|Given PO
57917976|NCT00862628|DRUG|Rebamipide|100mg tid, 4 or 8 weeks
57917977|NCT00428623|PROCEDURE|wound dressing|
57917978|NCT02416804|DRUG|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr
57917979|NCT02416804|DRUG|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
57917980|NCT00123552|DRUG|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
57917981|NCT00123552|DRUG|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
57917982|NCT00123552|DRUG|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
57917983|NCT00549133|DRUG|Irbesartan|
57917984|NCT01145755|DRUG|AZD2066|18 mg once daily
57917985|NCT01145755|DRUG|Placebo|
57917986|NCT01145755|DRUG|Duloxetine|60 mg once daily
57917987|NCT03336996|BIOLOGICAL|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
57917988|NCT03336996|PROCEDURE|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
57917989|NCT00171600|DRUG|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
57917990|NCT05354180|OTHER|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
57917991|NCT05354180|OTHER|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
57917992|NCT05354180|OTHER|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
58389577|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
58271096|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
58389578|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
58389579|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
58389580|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
58389581|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
58389582|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
58389583|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
58389584|NCT06345261|DRUG|Saline|injection of saline
57718728|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
57917993|NCT05300360|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase enzyme deficiency test
57917994|NCT02867319|BIOLOGICAL|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
57917995|NCT04810754|DRUG|Daratumumab Injection|1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
57917996|NCT04891432|PROCEDURE|Lateral lumbar interbody fusion|oblique lumbar interbody fusion or direct lateral interbody fusion
57917997|NCT02722733|DRUG|G-CSF (filgrastim)|
58389585|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
58389586|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
58389587|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
58389588|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
58389589|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
58389590|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
57917998|NCT02722733|DRUG|Cytosine arabinoside with G-CSF (filgrastim)|
57917999|NCT04305938|DIAGNOSTIC_TEST|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
57918000|NCT02486133|DRUG|Prezista|once daily
57918001|NCT02486133|DRUG|Norvir|once daily
57918002|NCT02486133|DRUG|Tivicay|once daily
57918003|NCT02486133|DRUG|Truvada|once daily
57918004|NCT02486133|DRUG|Kivexa|once daily
57918005|NCT02486133|DRUG|Descovy|once daily
57918006|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight sleep and morning wake|Overnight period and morning period device measurements
58389591|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
58389592|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
57718729|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
57918007|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight wake and morning sleep|Overnight period and morning period device measurements
58271097|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
58271098|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
58389593|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
57718730|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
57718731|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
57718732|NCT02039531|DRUG|Hyaluronic Acid|
57718733|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
57718734|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
57718735|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
57718736|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
57718737|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
57718738|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
57718739|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
57718740|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
57718741|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
57718742|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
58271099|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
58271100|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
58271101|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
57718743|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
58271102|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
58271103|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
58271104|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
58271105|NCT02153229|RADIATION|Photodynamic Therapy|
57718744|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
58271106|NCT02153229|PROCEDURE|Radical Pleurectomy|
58271107|NCT02153229|RADIATION|Chemotherapy|
58271108|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
58271109|NCT05241600|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
58271110|NCT05241600|BEHAVIORAL|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
58271111|NCT01744171|BIOLOGICAL|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
58271112|NCT01744171|OTHER|Laboratory Biomarker Analysis|Correlative studies
58389594|NCT01633255|DRUG|18F-Fluciclatide|
58389595|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
58389596|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
58389597|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
57718745|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
57718746|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
57718747|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
57718748|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
57718749|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
57918008|NCT05261048|OTHER|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
57918009|NCT05261048|OTHER|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
57718750|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
57918010|NCT00104559|BEHAVIORAL|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
58389598|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
58389599|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
58389600|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
57718751|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
57718752|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
57718753|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
57718754|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
57718755|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
58063939|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
57718756|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
58271113|NCT06338215|BEHAVIORAL|Moderate Alcohol Drinking Pattern|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake."
57718757|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
57718758|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
57718759|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
57718760|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
57718761|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
58271114|NCT06338215|BEHAVIORAL|Abstention|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol."
58271115|NCT06469385|BIOLOGICAL|ENS-002|"Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria.~Low Dose ENS-002 High Dose ENS-002"
58271116|NCT04038619|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
58271117|NCT04038619|DRUG|Loperamide|Given PO
58271118|NCT04399603|OTHER|no intervention-mechanistic study|no intervention-mechanistic study
58271119|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation A (light)|Omega-3 monoglyceride based serum and cream of lighter formulation
58271120|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation B (rich)|Omega-3 monoglyceride based serum and cream with a richer formulation
58271121|NCT05198154|DIAGNOSTIC_TEST|ctDNA detection|High-depth sequencing method is used to detecting ctDNA.
58271122|NCT04662294|BIOLOGICAL|CD70 CAR T-cells|Each subject receive CD70 CAR T-cells by intravenous infusion
58271123|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
58271124|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
58389601|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
58389602|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
57718762|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
57718763|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
57718764|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
57718765|NCT01132079|DRUG|cream treatment|
57718766|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
57718767|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
58063940|NCT06292429|OTHER|Control Group|No intervention given
58271125|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management|The children will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.
57918011|NCT00104559|BEHAVIORAL|Standard paper consent form|Standard paper consent form
57918012|NCT03525288|RADIATION|PSMA -PET/CT simulation|"* PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
57918013|NCT03525288|RADIATION|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
57918014|NCT05981599|OTHER|There is no intervention|There is no intervention. Only retrieving clinical, biological and epidemiological data from patient files
57918015|NCT04538456|OTHER|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
57918016|NCT03618121|DEVICE|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
57918017|NCT03618121|DEVICE|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax \& Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
58271126|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management + short peptide ONS|"During the study period, an additional 3 months of short peptide ONS enteral nutrition intervention is expected to be performed in children enrolled from Dec 1, 2024 to Feb 28, 2025 to explore the improvement of the nutritional status of the children. Short peptide type ONS 30ml/(kg.d) will be taken orally for children under 3 years old, and 20ml/(kg.d) for children over 3 years old. Due to conditional restrictions, standardized nutritional management + short peptide ONS intervention is only carried out in this subgroup.~Inclusion criteria for short peptide ONS enteral nutrition intervention:~1. Male and female, age 1-10 years old~2. Pathological diagnosis is malignant solid tumor with untreated initial onset~3. It is expected to receive enteral nutrition intervention for 3 months~4. Clear consciousness, willing to cooperate, no serious dysfunction of major organ functions"
58271127|NCT05600062|DRUG|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
58271128|NCT05600062|DRUG|Placebo|Placebo capsule
58271129|NCT01259375|DRUG|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
58271130|NCT01969084|DRUG|Linagliptin|
58271131|NCT01969084|DRUG|Placebo|
58271132|NCT01969084|OTHER|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
58271133|NCT01969084|OTHER|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
58271134|NCT01969084|OTHER|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
57918018|NCT03618121|BEHAVIORAL|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
57918019|NCT03618121|BEHAVIORAL|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
57918020|NCT03730857|DRUG|Olanzapine|olanzapine tablet
57918021|NCT03730857|DRUG|risperidone|risperidone tablet
57918022|NCT03730857|DRUG|Paliperidone|paliperidone tablet
57918023|NCT02457208|DRUG|Isoniazid (H)|
57918024|NCT02457208|DRUG|Rifampicin (R)|
57918025|NCT02457208|DRUG|Pyrazinamide (Z)|
57918026|NCT02457208|DRUG|Ethambutol (E)|
57718768|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
57718769|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
57718770|NCT00131781|BEHAVIORAL|Cognitive Therapy|
57718771|NCT00131781|BEHAVIORAL|Supportive Therapy|
57718772|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
57918027|NCT02952807|DRUG|Misoprostol|vaginal Misoprostol Plus Foley Catheter
58389603|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
58389604|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
58389605|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
57718773|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
57918028|NCT02952807|DEVICE|Foley Catheter|
57918029|NCT01786733|BEHAVIORAL|Behavioral Activation|
58389606|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
58389607|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
58389608|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
58389609|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
58389610|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
58389611|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
58389612|NCT03180333|DRUG|PNA|
58389613|NCT03180333|DRUG|PNA placebo|
57718774|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
57718775|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
57718776|NCT00928148|DRUG|Placebo|Once daily for 7 days
57718777|NCT02928341|OTHER|Improved water supply|
57918030|NCT01786733|BEHAVIORAL|Supportive Therapy|
57918031|NCT02295657|DEVICE|standard double-lumen tube|intubation using standard double-lumen tube
57918032|NCT02295657|DEVICE|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
57918033|NCT04265833|OTHER|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
58063941|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
57718778|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
57718779|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
57718780|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
57718781|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
57718782|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
57718783|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
57718784|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
57718785|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
57718786|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
57718787|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
58063942|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
58063943|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
58063944|NCT00266149|DRUG|Oral contraception|
58063945|NCT00266149|DRUG|Lamotrigine|
58389614|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
57718788|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
57718789|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
57718790|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
57718791|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
58063946|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
58063947|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
58063948|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
58063949|NCT00117520|DRUG|Caffeine|
58063950|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
58063951|NCT01729481|DRUG|Erlotinib|100mg, once per day
58063952|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
58063953|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
58063954|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
58063955|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
57718792|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
57918034|NCT04265833|OTHER|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
57718793|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
57718794|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
57718795|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
57718796|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
57718797|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
57718798|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
57718799|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
57718800|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
57718801|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
57718802|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
57918035|NCT04265833|OTHER|Calcium hydroxide|Calcium hydroxide (Ca\[OH\]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
57918036|NCT03426267|DRUG|SDN-037|twice daily
57918037|NCT03426267|DRUG|Placebo|twice daily
57718803|NCT00821691|DRUG|Amantadin|Amantadin caps
57918038|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
57918039|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
57718804|NCT00821691|DRUG|Placebo|Placebo caps
57718805|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
57918040|NCT01892826|DRUG|hCG|5000IU
57918041|NCT06282614|DEVICE|Mucogyne Ovule|At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
58389615|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
58389616|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
58389617|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
57718806|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
57918042|NCT04565379|DRUG|NuSepin® 0.1 mg|NuSepin® 0.1 mg
57918043|NCT04565379|DRUG|NuSepin® 0.2 mg|NuSepin® 0.2 mg
58389618|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
57718807|NCT02772068|OTHER|Exercise|
57918044|NCT04565379|DRUG|Placebo|Normal Saline
57918045|NCT06328803|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
57918046|NCT06328803|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
57918047|NCT01249274|DRUG|Progesterone|100mgs progesterone twice daily
57918048|NCT01249274|OTHER|Placebo|Matched placebo pills to be taken twice daily
58389619|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
58389620|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
57718808|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
57718809|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
57718810|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
57718811|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
57918049|NCT01079338|OTHER|caffeine|
57918050|NCT01498679|DRUG|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
57918051|NCT01498679|DRUG|Placebo|Placebo administered once daily in the evening via a NDPI
57918052|NCT01586000|DRUG|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
57918053|NCT01586000|DRUG|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
57918054|NCT01586000|DRUG|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
57918055|NCT00229411|BEHAVIORAL|simulation training|
57918056|NCT02833532|DEVICE|Volus/Powerfill|Maximum: 22ml
57918057|NCT05971667|DRUG|tadalafil|tadalafil 10 mg one tablet daily
57918058|NCT05971667|DRUG|Sildenafil|sildenafil 20 mg two tablets daily
57918059|NCT05971667|DRUG|pentoxifylline|pentoxifylline 400 mg two tabs daily
57918060|NCT04330885|OTHER|Supervised abdominal exercises and stationary biking|Explain pain to the patients in order to minimize fear of movement
57918061|NCT02737839|OTHER|Stepping On Education Program|
58389621|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
58389622|NCT01995500|DEVICE|BioNIR|drug-eluting stent
58389623|NCT01995500|DEVICE|Resolute|drug-eluting stent
58389624|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
57918062|NCT02737839|OTHER|Home visit|
58389625|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
57718812|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
57718813|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
57718814|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
57918063|NCT02737839|OTHER|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
57918064|NCT02737839|OTHER|Mini-Balance Evaluation Systems Test|"* The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes."
58063956|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
58271135|NCT00737334|DEVICE|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
58389626|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
58389627|NCT02520388|DRUG|Placebo|
58389628|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
58389629|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
58389630|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
58389631|NCT01864148|DRUG|BIIB033|
58389632|NCT01864148|OTHER|Placebo|
58389633|NCT01864148|DRUG|Avonex|
58389634|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
58389635|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
58389636|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
58389637|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
58389638|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
58389639|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
57918065|NCT02737839|OTHER|GAITRite|"* Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
57918066|NCT02737839|OTHER|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
58389640|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
58389641|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
58389642|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
58389643|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
58389644|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
58389645|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
58389646|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
58063957|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
58063958|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
58063959|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
58063960|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
58063961|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
58063962|NCT03742258|DRUG|Cyclophosphamide|Given IV
58063963|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
58063964|NCT03742258|DRUG|Prednisone|Given PO
58063965|NCT03742258|BIOLOGICAL|Rituximab|Given IV
58063966|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
58389647|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
58389648|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
58063967|NCT03742258|DRUG|Vincristine Sulfate|Given IV
58063968|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
58063969|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
57718815|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
58389649|NCT01014936|DRUG|MSC2156119J|
58389650|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
57718816|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
57718817|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
57718818|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
58063970|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
58063971|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
58063972|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
58063973|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
58063974|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
57718819|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
57718820|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
57718821|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
58063975|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
58389651|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
57718822|NCT02155439|DRUG|Triamcinolone|
58063976|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
58063977|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
58389652|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
58389653|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
58389654|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
58389655|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
58063978|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
57718823|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
57718824|NCT06237426|DRUG|Methylone|"A course of methylone treatment includes weekly oral methylone administrations for up to 4 weeks.~Participants may be eligible to receive up to two courses of methylone treatment in this study. After a course of methylone treatment is complete, participants will return to observational study visits."
58271136|NCT05210153|DRUG|Sertraline|"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."
58389656|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
57718825|NCT05007873|DRUG|Dasatinib|Given PO
57718826|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
57718827|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
58063979|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
58063980|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
58063981|NCT00585104|DRUG|levosimendan|10-minute infusion
58063982|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
58063983|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
58063984|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
58271137|NCT05605639|DRUG|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
58389657|NCT02160249|OTHER|Facility based care|
58389658|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
58389659|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
58389660|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
57718828|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
57718829|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
57718830|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
57718831|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
57718832|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
57718833|NCT00538005|BIOLOGICAL|bevacizumab|
57718834|NCT00538005|DRUG|oxaliplatin|
57718835|NCT00538005|DRUG|sorafenib tosylate|
57718836|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
57718837|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
57718838|NCT04143347|OTHER|No Intervention|
57718839|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
57718840|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
57718841|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
57718842|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
57918067|NCT04223427|PROCEDURE|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
57918068|NCT05539274|DIAGNOSTIC_TEST|human papilloma virus testing and genotyping in cervical cancer cases|an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
57918069|NCT03353831|DRUG|Bevacizumab|Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
57918070|NCT03353831|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
57918071|NCT03353831|DRUG|Chemotherapy|Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
57918072|NCT03353831|DRUG|Placebos|Placebo will be administered by intravenous route q14 during the treatment period
57918073|NCT00407212|DRUG|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
58063985|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
58063986|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
58063987|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
58063988|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
58063989|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
58271138|NCT05605639|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
58271139|NCT05988710|DRUG|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
58271140|NCT05988710|DRUG|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
58271141|NCT05988710|DRUG|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
58389661|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
57718843|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
58389662|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
57718844|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
58271142|NCT05988710|DRUG|Buccal Placebo|Placebo for buccal administration
58271143|NCT05988710|DRUG|Oral Placebo|Placebo for oral administration
58271144|NCT05988710|DRUG|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
57718845|NCT01653431|DEVICE|Transcranial direct current stimulation|
57718846|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
57718847|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
57718848|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
57718849|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
58271145|NCT05988710|DRUG|Buccal Buprenorphine 450mcg|buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
58271146|NCT01131039|DRUG|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression"
58271147|NCT02897388|OTHER|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
58271148|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
57718850|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
57718851|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
58389663|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
58389664|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
58389665|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
57918074|NCT00690443|DRUG|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
57918075|NCT00690443|DRUG|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
57918076|NCT06185361|DRUG|Fluoxetine 20 MG|fluoxetine
58389666|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
57918077|NCT06185361|DRUG|Desmopressin|desmopressin
58389667|NCT00479570|DRUG|PF-00446687|Single 200mg dose
57718852|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
57718853|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
58389668|NCT00479570|DRUG|Placebo|
57718854|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
57918078|NCT04113083|OTHER|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
58389669|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
57918079|NCT06001086|DRUG|Disitamb Vedotin ,pyrotinib|Disitamb Vedotin combined with pyrotinib
57918080|NCT03089151|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
58063990|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
58063991|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
58063992|NCT05978804|OTHER|Computerized Cognitive Training via BrainHQ|Computerized Cognitive training (BrainHQ)
58389670|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
58389671|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
58389672|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
58271149|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
58271150|NCT01420016|OTHER|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR \>= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
58271151|NCT04030260|DRUG|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
58271152|NCT04030260|RADIATION|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
58271153|NCT03032601|DIETARY_SUPPLEMENT|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
58271154|NCT03005613|PROCEDURE|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
58271155|NCT03005613|PROCEDURE|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
58271156|NCT01537978|OTHER|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
58271157|NCT04427488|OTHER|Morning Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
58271158|NCT04427488|OTHER|Evening Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
58271159|NCT06436391|OTHER|Kinesio taping|Kinesio taping will be applied to the lateral part of the baby's heel to increase blood flow. Blood collection will always be performed by the same nurse
58271160|NCT06436391|OTHER|ShotBlocker|Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal pressure.
58271161|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
58271162|NCT01534364|OTHER|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
58271163|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
58271164|NCT06720077|OTHER|Acupressure|"It will be applied for the experimental group only. Before starting the first treatment session, the participants will be instructed briefly about the nature of the treatment to gain their confidence and cooperation. Each participant in this group will be asked to lie in supine position and the acupressure will be applied by using the therapist's fingers on the following acupoints (san jio 6/ spleen 15/ stomach 25/ joining vally  intestine 4) 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week for 6 weeks."
58389673|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
58389674|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
58389675|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
57718855|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
57718856|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
57718857|NCT06238505|OTHER|biodex|application will be made with biodex device
58389676|NCT01734798|RADIATION|Radiation|
58389677|NCT01734798|DRUG|gemcitabine and cisplatin|
58389678|NCT01734798|OTHER|Radiotherapy and Drug|
58389679|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
58389680|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
58389681|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
57718858|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
57718859|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
57718860|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
57718861|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
58389682|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
58271165|NCT06720077|OTHER|Diaphragmatic breathing exercises|A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
58389683|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
58389684|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
58389685|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
58389686|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
58389687|NCT03520686|DRUG|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])"
58389688|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
58389689|NCT03520686|DRUG|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
58389690|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
58389691|NCT03520686|DRUG|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
58389692|NCT03520686|DRUG|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
58389693|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab|The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
57718862|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
57718863|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
57718864|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
57718865|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
58271166|NCT06720077|OTHER|General bowel care advise|All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
58271167|NCT00071968|DRUG|temsirolimus|
58271168|NCT00071968|PROCEDURE|conventional surgery|
58271169|NCT00071968|PROCEDURE|neoadjuvant therapy|
58389694|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
58389695|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
58389696|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
58271170|NCT00822575|DEVICE|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
58271171|NCT02732327|DRUG|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
57718866|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
58271172|NCT02732327|DRUG|Vancomycin|15 mg/kg
58271173|NCT02732327|DRUG|Linezolid|600 mg
58389697|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
58063993|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
58271174|NCT02732327|DRUG|Cefepime|2 g
58271175|NCT02732327|DRUG|Meropenem|1 g
58271176|NCT02732327|DRUG|Piperacillin/tazobactam|4.5 g
58271177|NCT04296786|DRUG|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
58271178|NCT04296786|DRUG|Chidamide|20mg po per week continuously
58271179|NCT06028334|BEHAVIORAL|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
58271180|NCT06028334|BEHAVIORAL|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
58271181|NCT01534806|DRUG|Ketorolac|Ketorolac(0.5mg/kg) IV push
58271182|NCT01534806|DRUG|Placebo|Sodium Chloride 0.9% - 10 mL IV push
58271183|NCT02232152|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
58271184|NCT02232152|DRUG|fluorouracil|Given IV
58271185|NCT02232152|OTHER|pharmacological study|Correlative studies
58271186|NCT02232152|OTHER|laboratory biomarker analysis|Correlative studies
58271187|NCT01859962|DRUG|PPI-668|
58271188|NCT01859962|DRUG|BI 207127 Dose 1|
58271189|NCT01859962|DRUG|BI 207127 Dose 2|
57718867|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
57718868|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
57718869|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
57718870|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
58271190|NCT01859962|DRUG|Faldaprevir|
58271191|NCT01859962|DRUG|Ribavirin|
58389698|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
58389699|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
58389700|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
58389701|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
58389702|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
58389703|NCT00245388|DRUG|Muraglitazar|
57718871|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
57718872|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
57718873|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
57718874|NCT00760279|DRUG|Azithromycin|
58271192|NCT01859962|DRUG|BI 207127 Placebo|
58271193|NCT05027048|DRUG|Calcium chloride|See arm description above
58389704|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
58389705|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
57718875|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
57718876|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
57718877|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
57718878|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
57918081|NCT00807261|DRUG|Gemcitabine and Docetaxel|"Drug and schedule~* Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~* Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~* Treatment should be delayed if the ANC\<1,500/ mm3, or if the platelet count \<75,000/mm3 on the first day of the next cycle.~* Gemcitabine \& docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
58271194|NCT05027048|DRUG|Saline placebo|see arm description above
58271195|NCT06181786|DRUG|IMB-101|Intravenous administration.
58271196|NCT06181786|DRUG|Placebo|Matching-placebo intravenous administration.
58271197|NCT02929966|OTHER|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
58271198|NCT02929966|OTHER|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
58389706|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
58389707|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
58389708|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
58389709|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
58389710|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
58389711|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
58389712|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
58271199|NCT04944303|DRUG|Sugammadex|Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
58271200|NCT04944303|DRUG|Normal saline|Equal doseage of normal saline was injected to reverse the NMB.
58271201|NCT06254235|DRUG|The test octreotide microsphere|A single intramuscular dose of the test octreotide microsphere 30mg,
58271202|NCT06254235|DRUG|The reference octreotide microsphere|A single intramuscular dose of the reference octreotide microsphere 30mg
58271203|NCT03219905|DEVICE|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
58271204|NCT03219905|DEVICE|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
58271205|NCT06433505|DRUG|BMS-986365|Specified dose on specified days
58271206|NCT06433505|DRUG|[14C] BMS-986365|Specified dose on specified days.
57718879|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
58271207|NCT06433505|DRUG|[14C] BMS-986409 + BMS-986410|Specified dose on specified days
58271208|NCT06433505|DRUG|[14C] BMS-986410 + BMS-986409|Specified dose on specified days
58271209|NCT06264674|DRUG|CHF5993 200/6/12.5 μg pMDI HFA-152a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
58271210|NCT06264674|DRUG|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
58271211|NCT05264103|DEVICE|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
58271212|NCT05570370|OTHER|This is an observational study|This is an observational study
58271213|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
58271214|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
58389713|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
58389714|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
58271215|NCT04364464|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
58271216|NCT03383900|DEVICE|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
58389715|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
58389716|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
58389717|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
58389718|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
58271217|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
58389719|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
58389720|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
58389721|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
58389722|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
58389723|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
58063994|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
58063995|NCT01766401|DRUG|Placebo|
57918082|NCT01379391|DRUG|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
57918083|NCT00589238|DRUG|carboplatin|
57918084|NCT00589238|DRUG|cyclophosphamide|
58063996|NCT01766401|DRUG|Vilazadone|Viibryd
58063997|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
58063998|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
58063999|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
58389724|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
58389725|NCT03435120|OTHER|No intervention|No intervention
58389726|NCT03272386|OTHER|Observational study|Completing a questionnaire
58389727|NCT02259725|DRUG|regorafenib|Given PO
57718880|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
57718881|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
57718882|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
57718883|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
57718884|NCT06535256|DRUG|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
57718885|NCT06535256|DRUG|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
57718886|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
57718887|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
57718888|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
57918085|NCT00589238|DRUG|doxorubicin hydrochloride|
57918086|NCT00589238|DRUG|paclitaxel|
57918087|NCT02424188|OTHER|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
57918088|NCT06036303|DEVICE|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
57918089|NCT06036303|DEVICE|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
57918090|NCT05437185|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
57918091|NCT05437185|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
57918092|NCT02949258|DRUG|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
57918093|NCT02949258|DRUG|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
57918094|NCT02949258|DRUG|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
58064000|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
58389728|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
57718889|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
57718890|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
57718891|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
58271218|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
58271219|NCT02978885|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
58271220|NCT02978885|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
58271221|NCT02978885|PROCEDURE|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
58271222|NCT02978885|PROCEDURE|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
58271223|NCT04036097|OTHER|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
58271224|NCT04036097|OTHER|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
58271225|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
58271226|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System with In-office Follow-up|
58271227|NCT01101659|DRUG|JNJ-40411813|500 mg as 20 mL of oral suspension
58271228|NCT01101659|DRUG|normal saline|single dose
58271229|NCT01101659|DRUG|ketamine|20 mL of oral suspension
58271230|NCT01101659|DRUG|Placebo|single dose
58271231|NCT01279174|OTHER|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
57718892|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
57718893|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
57718894|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
57718895|NCT00491686|DRUG|AZD6765|intravenous infusion
57718896|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
58271232|NCT05763368|DIAGNOSTIC_TEST|Clinical tests and proprioception evaluation|Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
58271233|NCT02847338|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
58271234|NCT02847338|DRUG|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
58271235|NCT02847338|DRUG|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
58271236|NCT02847338|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
58271237|NCT02636101|DRUG|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
58389729|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
57718897|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
57718898|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
57718899|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
57718900|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
57718901|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
57918095|NCT02949258|DRUG|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
57718902|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
57918096|NCT00521560|DRUG|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
57918097|NCT03226821|DRUG|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
57918098|NCT03287531|OTHER|conventional therapy|Exercise therapeutic Ultrasound
57918099|NCT03287531|OTHER|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
57718903|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
58064001|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
58064002|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
58064003|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
58064004|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
58064005|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
58064006|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
58064007|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
58064008|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
58064009|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
58064010|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
57918100|NCT00136539|DRUG|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
57918101|NCT00136539|DRUG|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
57918102|NCT00136539|DRUG|Adriamycin|Given every three weeks for 12 weeks after surgery.
57918103|NCT00136539|DRUG|Cytoxan|Given every three weeks for 12 weeks after surgery.
57918104|NCT04094246|PROCEDURE|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
57918105|NCT04094246|PROCEDURE|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
57918106|NCT05406830|DEVICE|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
57918107|NCT05406830|BEHAVIORAL|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
57718904|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
57718905|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
57718906|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
57718907|NCT02192684|DRUG|placebo|Compare with pioglitazone
57718908|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
57718909|NCT04861623|OTHER|Placebo juice (Fanta)|Fanta will be purchased commercially.
57718910|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
57718911|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
57718912|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
57718913|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
57718914|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
57718915|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
57718916|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
57918108|NCT05406830|DEVICE|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
57918109|NCT04651075|OTHER|music listening|The music selected by the participants was played to the music listening group.
58064011|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
58064012|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
57718917|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
57718918|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
57718919|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
57718920|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
57718921|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
57718922|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
57718923|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
57718924|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
57718925|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
57718926|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
57718927|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
57718928|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
57718929|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
57718930|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
57718931|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
57718932|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
57718933|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
57718934|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
58271238|NCT03878875|DIAGNOSTIC_TEST|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test (Around 35 minutes with breaks if required)~* Extended Frequency Audiometry (\~ 8 min), 0.25-16 kHz: Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~* DPOAE (\~ 5 min), 0.5-10 kHz: A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~* MEMR (\~ 8 min), 4 kHz: A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~* Speech-in-Noise Test (\~ 5 min): Participants asked to repeat back a list of words as best as they can.~* Tinnitus: Participants were also asked if they experience any tinnitus i.e. bilateral, lasting \> 5 minutes. This was reported as Y/N."
58389730|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
57718935|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
57718936|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
57718937|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
57718938|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
57718939|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
57718940|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
57718941|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
57718942|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
57718943|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
57718944|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
57718945|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
58389731|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
58389732|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
58389733|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
58389734|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
58389735|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
58389736|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
58389737|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
58389738|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
58389739|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
58389740|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
58389741|NCT02202915|BEHAVIORAL|Behavioral Checklist|
58389742|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
58389743|NCT00349349|DRUG|ofatumumab|Intravenous infusion
58389744|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
58389745|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
58389746|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
58389747|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
58389748|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
58389749|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
58389750|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
58271239|NCT03878875|DIAGNOSTIC_TEST|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital or sound level meter applications to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
58271240|NCT03878875|DIAGNOSTIC_TEST|Session Three Test Battery|1 week later (recovery): Repeat test battery.
58271241|NCT01973335|DRUG|Combination therapy with acetazolamide and low-dose loop diuretics|"* Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
58271242|NCT01973335|DRUG|High-dose loop diuretics|"* Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
58271243|NCT01973335|DRUG|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
58271244|NCT00003045|DEVICE|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
58271245|NCT00003045|RADIATION|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
58271246|NCT00990067|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
58271247|NCT00990067|DRUG|Duloxetine|120 mg two doses 12h and 2h before MDMA
57918110|NCT04651075|OTHER|individual training|Individual training group was trained on coronary angiography.
58271248|NCT00990067|DRUG|Placebo|capsules identical to MDMA or duloxetine
57718946|NCT06573749|DIETARY_SUPPLEMENT|Pea-based protein supplement|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
57918111|NCT03369990|DRUG|Botulinum toxin type A|Botulinum toxin type A(DWP450)
58271249|NCT06545344|OTHER|Best Practice|Receive usual care
58271250|NCT06545344|PROCEDURE|Palliative Care Consultation|Attend a palliative care visit
58271251|NCT06545344|OTHER|Survey Administration|Ancillary studies
58271252|NCT06545344|OTHER|Tumor Board Review|Undergo evaluation by tumor board
57718947|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
58271253|NCT05078749|OTHER|Exercise training group|A regular advanced exercise program will be given and followed.
58271254|NCT05078749|OTHER|Control training group|Basic exercises will be given at the beginning and will do the same exercises
57718948|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
57718949|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
57718950|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
57718951|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
57718952|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
57918112|NCT03369990|DRUG|Placebos|Normal Saline
57918113|NCT04017039|OTHER|Targeted Sleep Intervention|
57918114|NCT03965611|PROCEDURE|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
57918115|NCT03965611|PROCEDURE|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
57918116|NCT03965611|PROCEDURE|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
57918117|NCT00075647|DRUG|temsirolimus|Given IV
57918118|NCT00075647|OTHER|laboratory biomarker analysis|Correlative studies
57918119|NCT03501160|OTHER|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
57918120|NCT06486207|COMBINATION_PRODUCT|Gong's mobilization|increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula
57918121|NCT06486207|OTHER|Kendall Exercise|The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
57918122|NCT05318079|BEHAVIORAL|Virtual Reality Gaming|Peer-to-peer gaming.
58271255|NCT03434249|DIETARY_SUPPLEMENT|Bifidobacterium, BB-12® (Bifidolactis Infant)|
58271256|NCT03434249|DIETARY_SUPPLEMENT|Bifidolactis Infant Placebo|
57718953|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
58271257|NCT05524844|OTHER|Sample Collection|Saliva, gastric aspirate, and esophageal brushings and biopsies.
57918123|NCT00001457|DRUG|Lamivudine|
57918124|NCT02447367|DRUG|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
57918125|NCT02447367|DRUG|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
57918126|NCT04259515|DRUG|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
57918127|NCT04259515|DRUG|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
58271258|NCT05524844|OTHER|Endoscopy results|Results from standard of care endoscopy (scheduled separate of study)
58271259|NCT05524844|OTHER|Dietary questionnaire|Diet History Questionnaire (II)
58271260|NCT04701918|DRUG|Pembrolizumab|Intravenous injection through a vein (IV) every 3 weeks
58271261|NCT04701918|PROCEDURE|Cryoablation|Needle inserted through the skin and into the tumor using CT guidance
58064013|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
57918128|NCT03905954|OTHER|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
57918129|NCT04227964|DEVICE|Enamel matrix derivative, bone replacement graft, barrier membrane|
57918130|NCT04227964|PROCEDURE|Tooth extraction and replacement|
57918131|NCT04679688|OTHER|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
57918132|NCT02054520|DRUG|HyperAcute®-Melanoma (HAM) Immunotherapy|
58064014|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
58064015|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
58271262|NCT04701918|DRUG|Avelumab|Intravenous injection through a vein (IV) every 2 weeks
58389751|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
58389752|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
58389753|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
58389754|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
58389755|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
57718954|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
57718955|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
57918133|NCT02054520|DRUG|Ipilimumab|
57918134|NCT02054520|DRUG|Pembrolizumab|
58064016|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
58064017|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
58064018|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
58064019|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
58064020|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
58064021|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
58064022|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
58064023|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
58064024|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
58064025|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
58064026|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
58389756|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
58389757|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
58389758|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
58389759|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
58389760|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
57718956|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
57718957|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
57718958|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
57718959|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
57918135|NCT02054520|DRUG|Nivolumab|
57918136|NCT00519311|BEHAVIORAL|Health Intervention Package|CHAP and Ask Diary
57918137|NCT01313117|DRUG|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
57918138|NCT02913729|RADIATION|partial breast irradiation|irradiation
58389761|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
58389762|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
57718960|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
57718961|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
57718962|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
57718963|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
57918139|NCT03745482|OTHER|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
57918140|NCT02737709|DRUG|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
57918141|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
57918142|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
58271263|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
58271264|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
58271265|NCT03053427|DRUG|Placebo|Oral administration
58271266|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
58271267|NCT04565899|OTHER|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
58271268|NCT04306887|DRUG|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
58271269|NCT04097197|BEHAVIORAL|Brief educational intervention|same as before
58271270|NCT02073656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
58271271|NCT02073656|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58271272|NCT03634683|BIOLOGICAL|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
58271273|NCT05496608|PROCEDURE|L-PRF|a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
58389763|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
58389764|NCT03377595|DRUG|Exparel|Wound infiltration
58389765|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
57718964|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
57718965|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
58271274|NCT05496608|PROCEDURE|OFD|Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
58271275|NCT05496608|PROCEDURE|CM|Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
58271276|NCT05048589|DRUG|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
58271277|NCT05048589|DRUG|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
58271278|NCT06730776|OTHER|Topical medication|It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
58389766|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
58389767|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
58389768|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
58389769|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
58389770|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
58389771|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
57718966|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
58271279|NCT06730776|OTHER|Transcutaneous electrical acupoint stimulation|This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
58389772|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
57718967|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
57718968|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
57718969|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
58064027|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
58064028|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
58389773|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
58389774|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
57718970|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
57718971|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
57718972|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
57718973|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
57718974|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
57718975|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
57718976|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
57718977|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
58064029|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
58064030|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
57718978|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
57718979|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
58064031|NCT00162799|DRUG|Triflusal (DCI)|
58271280|NCT05866549|OTHER|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
58271281|NCT04352218|DEVICE|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
58271282|NCT04352218|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
58271283|NCT04722952|DRUG|Visilizumab|Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) \> 5X109／L or white blood cell（WBC）\> 20X109／L.
58271284|NCT02957045|PROCEDURE|Cough pressure measurement|
58271285|NCT02957045|DEVICE|Pcough|
58271286|NCT00265525|BEHAVIORAL|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
58271287|NCT04742166|PROCEDURE|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
58271288|NCT01554176|DRUG|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
58271289|NCT01554176|DRUG|Placebo|Placebo, one tablet, orally, once daily at bedtime
58271290|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
58271291|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
58271292|NCT01185262|DRUG|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
58271293|NCT05143008|BEHAVIORAL|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
58271294|NCT04939753|DRUG|Sevoflurane|Sevoflurane administration to sedate the patient
58271295|NCT06658886|OTHER|No intervention|No intervention
58271296|NCT00198913|BEHAVIORAL|lower fat food supplied and education|
58271297|NCT00198913|BEHAVIORAL|gift cards for grocery foods and written education|
58271298|NCT04809948|BIOLOGICAL|viral vector vaccine|AstraZeneca vaccine
58271299|NCT02959515|PROCEDURE|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
58271300|NCT02959515|PROCEDURE|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
58271301|NCT06671587|DRUG|iGlarLixi (insulin glargine/lixisenatide)|"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~- iGlarLixi must not be mixed with other insulins nor diluted."
57718980|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
58271302|NCT06671587|DRUG|Gla-100 (insulin glargine)|Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
58271303|NCT04662255|DRUG|Pirtobrutinib|Oral
58271304|NCT04662255|DRUG|Ibrutinib|Oral
58271305|NCT04662255|DRUG|Acalabrutinib|Oral
58271306|NCT04662255|DRUG|Zanubrutinib|Oral
58271307|NCT00324389|DRUG|Interferon alpha|
58271308|NCT00775554|OTHER|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
58271309|NCT00775554|OTHER|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
57918143|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
57918144|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
58271310|NCT01890213|BIOLOGICAL|AVX701|
58271311|NCT01941836|DRUG|ETC-1002|Patients receive ETC-1002
58271312|NCT01941836|DRUG|Ezetimibe|Patients receive ezetimibe
58271313|NCT05385224|DIAGNOSTIC_TEST|PillSense|The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
57918145|NCT00448123|DRUG|Tamsulosin|Study Drug
57918146|NCT00448123|DRUG|Placebo|Placebo
58271314|NCT06073743|OTHER|Conventional Physiotherapy|The conventional physiotherapy program will be applied 2 days a week, 60 minutes a day for 10 weeks and consist of weight bearing on the upper and lower extremities, strengthening, functional stretching exercises, walking training and balance exercises.
58271315|NCT06073743|OTHER|Video Game Based Exercise Training|In the Video Game Based Exercise Training program, in addition to the same conventional physiotherapy application for 30 minutes a day, 2 days a week for 10 weeks, 30 minutes of Microsoft Xbox Kinect video games such as reflex ridge and rallyball are used.
58271316|NCT00087126|DRUG|topotecan hydrochloride|
58389775|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
58389776|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
58389777|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
58389778|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
58389779|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
58389780|NCT03489772|DRUG|ITI-214|Oral
57918147|NCT05729178|OTHER|observational study|analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
57918148|NCT02705560|OTHER|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
58389781|NCT03489772|DRUG|Placebo|Oral
58389782|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
58389783|NCT01506635|DRUG|Timolol|
58389784|NCT01506635|DRUG|Placebo|artificial tear twice a day
58389785|NCT02755662|DEVICE|Mandibular Retention Device|
57918149|NCT02705560|OTHER|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
57918150|NCT02705560|OTHER|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
57918151|NCT00867282|DRUG|Treatment A|PF-00241939 750ug using inhaler A
57918152|NCT00867282|DRUG|Treatment B|PF-00241939 750ug using inhaler B
57918153|NCT03728777|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
58271317|NCT03903367|DRUG|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
58271318|NCT04963959|DEVICE|Peripheral blood mononuclear cell apheresis|mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
58271319|NCT01827215|BEHAVIORAL|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
58271320|NCT03078127|OTHER|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
58271321|NCT03078127|DEVICE|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
58271322|NCT03078127|DEVICE|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
58271323|NCT03078127|DEVICE|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
58271324|NCT02555124|DRUG|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
58271325|NCT02555124|DRUG|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
58271326|NCT02555124|DRUG|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
58389786|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
58389787|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
58271327|NCT02555124|DRUG|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
58271328|NCT02721303|DIETARY_SUPPLEMENT|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
58389788|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
58389789|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
58389790|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
58389791|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
57918154|NCT00690820|DRUG|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
57918155|NCT00690820|DRUG|Placebo Comparator|Placebo
58064032|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
58064033|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
58064034|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
58389792|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
57718981|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
57718982|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
57918156|NCT02926625|BEHAVIORAL|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~* Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~* Children who are getting worse should come back immediately or at any time for a re-assessment~* All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~* HEW should fill out a loose child assessment form~* If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
58064035|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
58271329|NCT02721303|PROCEDURE|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
58271330|NCT02721303|PROCEDURE|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
58271331|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
58271332|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
58271333|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
58271334|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
58271335|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
58271336|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
58271337|NCT01546038|DRUG|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
58271338|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
58271339|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
58271340|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
57718983|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
57718984|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
57718985|NCT03388073|OTHER|Placebo|Placebo
57718986|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
57718987|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
57718988|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
57718989|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
57718990|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
57718991|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
57718992|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
58271341|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
58271342|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
58271343|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
58271344|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
58271345|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
58271346|NCT06588634|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
58271347|NCT06588634|PROCEDURE|Standard of Care|Standard of care treatment for pulmonary embolism
58271348|NCT04736173|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
57918157|NCT02926625|BEHAVIORAL|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
58064036|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
57718993|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
57718994|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
57918158|NCT02802826|BEHAVIORAL|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
58064037|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
58064038|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
58064039|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
58271349|NCT04736173|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
57718995|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
57718996|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
57718997|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
57918159|NCT02697292|DRUG|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
58064040|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
58064041|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
58064042|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
58064043|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
58064044|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
58064045|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
58271350|NCT04736173|DRUG|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
58271351|NCT04736173|DRUG|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
57718998|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
58271352|NCT04736173|DRUG|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
58271353|NCT04736173|DRUG|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
58064046|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
58271354|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
58064047|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
58271355|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
58271356|NCT03051516|OTHER|Laboratory Biomarker Analysis|Correlative studies
58271357|NCT03051516|OTHER|Placebo Administration|Given IM
58271358|NCT03051516|OTHER|Questionnaire Administration|Ancillary studies
58271359|NCT03051516|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
58271360|NCT06176313|OTHER|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~* Two days before the intervention day, students will be contacted and invited to participate in the study.~* Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~* After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
58271361|NCT06176313|OTHER|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~* One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
58271362|NCT06176313|OTHER|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~* At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~* Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~* On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
58271363|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
58271364|NCT05760222|OTHER|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
58389793|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
57718999|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
58389794|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
58389795|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
58064048|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58389796|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
58064049|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58389797|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
57719000|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
57719001|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
58271365|NCT05758272|BEHAVIORAL|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
58271366|NCT05758272|BEHAVIORAL|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
58271367|NCT04432116|BEHAVIORAL|virtual reality 1|the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible
58271368|NCT04432116|BEHAVIORAL|virtual reality 2|Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
58271369|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
58271370|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
58271371|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
58271372|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
58271373|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
58271374|NCT02009059|DEVICE|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
58271375|NCT06448195|DRUG|Polyethylene Glycol Somatropin (rDNA origin) Injection|Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
58271376|NCT03738449|DRUG|CKD-387|Test drug
57719002|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
58064050|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58271377|NCT03738449|DRUG|D484|reference drug
58271378|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
58271379|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
57918160|NCT02697292|DRUG|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.
58271380|NCT05801419|DEVICE|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
58064051|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58064052|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58271381|NCT05801419|DEVICE|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
58271382|NCT05801419|DEVICE|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
58271383|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
58271384|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
58271385|NCT00930631|DRUG|[3H] BMS747158|Single bolus intravenous injection of \[3H\] BMS747158
58271386|NCT01229033|PROCEDURE|Ablation|Ablation of atrial tachycardia
58271387|NCT01229033|PROCEDURE|Cardioversion|Cardioversion of atrial tachycardia
58271388|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.
58271389|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
58271390|NCT06247553|OTHER|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
57918161|NCT02697292|DRUG|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
58064053|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
58271391|NCT06247553|OTHER|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
57918162|NCT06046768|OTHER|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
58064054|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
58064055|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
58064056|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
58064057|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
58064058|NCT02987205|DEVICE|Restylane|NLF Correction
57719003|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
58064059|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
58271392|NCT01362517|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
58271393|NCT06408142|DIAGNOSTIC_TEST|HIV testing|Point of Care HIV testing universally regardless of risk factors
58064060|NCT02763605|OTHER|no intervention|
58271394|NCT03630913|PROCEDURE|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
58271395|NCT02561741|DRUG|COV155|COV155 tablets
58271396|NCT00006994|DIETARY_SUPPLEMENT|glutamine|20 cc three times daily for 60 days
58271397|NCT00006994|RADIATION|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
58271398|NCT00006994|DRUG|l-glutamine placebo|20 cc three times daily for 60 days
58271399|NCT06729970|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
58271400|NCT06729970|DRUG|Lithium|Specified dose on specified days
58271401|NCT06729970|DRUG|Valproic Acid|Specified dose on specified days
57719004|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
58064061|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
58271402|NCT06665971|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
58271403|NCT01255462|BIOLOGICAL|LFG316|
58271404|NCT01255462|BIOLOGICAL|LFG316|
58271405|NCT01255462|BIOLOGICAL|LFG316|
57719005|NCT00334659|DRUG|apricitabine|
57719006|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
57719007|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
57719008|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
57719009|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
58271406|NCT01255462|BIOLOGICAL|LFG316|
58271407|NCT03572361|BIOLOGICAL|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
57719010|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
57719011|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
57719012|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
58271408|NCT03059199|BEHAVIORAL|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
58271409|NCT01038414|BEHAVIORAL|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
58271410|NCT05148845|BIOLOGICAL|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
58271411|NCT01772680|DIETARY_SUPPLEMENT|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
57918163|NCT03253874|BEHAVIORAL|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
58389798|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
58389799|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
58389800|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
58389801|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
57918164|NCT05898243|PROCEDURE|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
58389802|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
57719013|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
57719014|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
57719015|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
58064062|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
58389803|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
57719016|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
57719017|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
58064063|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
58389804|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
58389805|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
57719018|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
57719019|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
57719020|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
57719021|NCT04726982|DRUG|Acetazolamide|250 mg once daily
57719022|NCT04726982|DRUG|Acetazolamide|500 mg once daily
57719023|NCT04726982|OTHER|Placebo|Once daily
57719024|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
57918165|NCT02824666|DRUG|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
58064064|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
58064065|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
58271412|NCT03406000|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
58389806|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
58389807|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
58389808|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
58389809|NCT02504398|OTHER|Fast injection speed by immunizer|
58389810|NCT02504398|OTHER|Slow injection speed by immunizer|
58389811|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
58389812|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
58389813|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
57719025|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
57719026|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
57719027|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
57719028|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
57719029|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
57719030|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
58389814|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
58389815|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
58389816|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
58389817|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
58389818|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
58389819|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
58389820|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
57719031|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
57719032|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
58271413|NCT01577719|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
58271414|NCT01577719|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
58271415|NCT03215407|DRUG|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
58271416|NCT03215407|DRUG|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
58271417|NCT06534086|DEVICE|Virtual reality (VR) guided meditation therapy|Tripp application on Meta Quest 3 VR headset
58271418|NCT06534086|OTHER|Treatment as usual|No VR, local anesthetic only
58271419|NCT06244459|OTHER|VR Assessment Tool|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
58271420|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|"DETECT is an elder mistreatment (EM) screening tool created for medics in the Fort Worth Texas area to use when responding to the homes of older adults, enabling them to screen for signs of elder mistreatment. DETECT-RPC is the adapted version of this tool designed specifically for use by home-based primary care (HBPC) clinicians.~The DETECT-RPC tool is designed to:~1. Be brief and easy to use.~2. Focus on the clinician's direct observations of the older adult and their physical and social environment.~3. Provide clear guidance on reporting suspected EM.~4. Integrate seamlessly into existing procedures and medical charting systems."
58271421|NCT03424629|BIOLOGICAL|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
58271422|NCT03424629|BIOLOGICAL|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
57719033|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
57719034|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
57719035|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
58271423|NCT03424629|DRUG|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
58271424|NCT03654105|DRUG|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
58271425|NCT03654105|DRUG|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
58271426|NCT03654105|OTHER|Diet Modification and Physical Activity Increase|"It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results."
58271427|NCT03654105|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
58271428|NCT03654105|DIAGNOSTIC_TEST|spirometry with CO test|spirometry with CO test
58271429|NCT03654105|OTHER|anthropometic data collection|anthropometic data collection
58271430|NCT03654105|OTHER|blood test|blood test to assess the metabolic and inflammatory profile
58389821|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
58389822|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
57719036|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
57719037|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
57719038|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
57719039|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
57719040|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
57719041|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
57719042|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
57719043|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
58389823|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
57719044|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
57719045|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
57719046|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
57719047|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
57719048|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
57719049|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
58271431|NCT03349281|DRUG|Pevonedistat|Administered each cycle on days 1, 3 and 5.
57719050|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
57719051|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
57719052|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
57719053|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
57918166|NCT02824666|RADIATION|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
58271432|NCT03349281|DRUG|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
58271433|NCT03349281|DRUG|Dexamethasone|Taken orally each cycle on days 2 through 15.
58271434|NCT03349281|DRUG|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
58271435|NCT03349281|DRUG|Doxorubicin|Administered via IV each cycle on day 2.
58271436|NCT03349281|DRUG|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
58271437|NCT03349281|DRUG|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
58271438|NCT03349281|DRUG|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
58271439|NCT03894215|DRUG|AGEN2034|PD-1 antibody
58271440|NCT03894215|DRUG|AGEN1884|CTLA-4 antibody
58389824|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
58389825|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
58389826|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
58389827|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
58389828|NCT03375489|OTHER|Telehealth|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
58389829|NCT03375489|OTHER|In-person PC|"In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
58389830|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
58389831|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
58389832|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
58389833|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
58389834|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
58389835|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
58389836|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
58389837|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
58389838|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
58064066|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
58389839|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
58389840|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
58389841|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
58389842|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
58389843|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
58389844|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
58389845|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
58389846|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
58389847|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
58389848|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
58389849|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
58389850|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
57719054|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
57719055|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
58271441|NCT03674697|DEVICE|Green LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
58271442|NCT03674697|DEVICE|White LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
58271443|NCT06695247|OTHER|Exercise Training|Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
58271444|NCT05331781|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
58271445|NCT05331781|DRUG|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
57719056|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
58271446|NCT03391232|BIOLOGICAL|PolyPEPI1018 CRC Vaccine|Colorectal Cancer Vaccine
57719057|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
57719058|NCT02242877|DRUG|Telmisartan|
57719059|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
57719060|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
58271447|NCT00383682|DRUG|morphine and mexiletine|
58271448|NCT03410212|DRUG|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
57719061|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
57719062|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
57719063|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
57719064|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
57719065|NCT03766009|OTHER|Usual Care|Usual Care
57719066|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
57918167|NCT02926976|DRUG|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
57918168|NCT02926976|DRUG|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
58389851|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
58271449|NCT03410212|BEHAVIORAL|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
58271450|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
58271451|NCT05673096|BEHAVIORAL|MAU|Management as usual
58271452|NCT03050112|OTHER|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
58271453|NCT00572052|DEVICE|NovoFine® needle 6 mm|
58271454|NCT00572052|DEVICE|Ultra-Fine needle 12.7 mm|
57918169|NCT02926976|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
58271455|NCT06557733|PROCEDURE|Biopsy|Undergo biopsy
58271456|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58271457|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
58271458|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
58271459|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
58271460|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
58271461|NCT06588166|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
58389852|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
58389853|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
58271462|NCT01861418|OTHER|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
58271463|NCT01861418|OTHER|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
57918170|NCT02926976|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
57918171|NCT02926976|DEVICE|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
58271464|NCT06271278|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
58271465|NCT03595358|DIAGNOSTIC_TEST|Ellume Home Flu Test|The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
58271466|NCT03595358|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
58271467|NCT03595358|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
58271468|NCT03595358|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
58271469|NCT03768024|DRUG|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
58271470|NCT03768024|DRUG|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
58271471|NCT03768024|DRUG|Matching placebo|Matching placebo
57918172|NCT02926976|DEVICE|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
58064067|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
58064068|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
58271472|NCT01772849|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
58271473|NCT03511716|DEVICE|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
58271474|NCT02993354|DEVICE|The EUM300 (electrical uterine myography)|This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
58271475|NCT05651438|OTHER|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
58271476|NCT05019885|DRUG|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
58271477|NCT04977362|OTHER|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
58271478|NCT04977362|OTHER|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
58271479|NCT04686266|BEHAVIORAL|Health Information + Health Coaching|Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
58389854|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
58389855|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
58064069|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
58271480|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
58271481|NCT00215371|DRUG|Formoterol Fumarate|
58271482|NCT06446336|OTHER|HASS Score|Creation of a pre-operative score
58271483|NCT04045899|DEVICE|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
58271484|NCT04045899|DEVICE|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
58271485|NCT04045899|DEVICE|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
58271486|NCT04996511|DEVICE|PulseOn|Postoperative HRV measurement
58271487|NCT06255717|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58389856|NCT04506593|OTHER|no intervention|
58389857|NCT01918605|DEVICE|Diluted spacer|
58389858|NCT01918605|DEVICE|Non-diluted spacer|
58389859|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
58389860|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
58389861|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
58389862|NCT00002552|BIOLOGICAL|filgrastim|
58389863|NCT00002552|BIOLOGICAL|sargramostim|
58389864|NCT00002552|DRUG|carmustine|
58389865|NCT00002552|DRUG|cyclophosphamide|
58389866|NCT00002552|DRUG|cytarabine|
58389867|NCT00002552|DRUG|etoposide|
57918173|NCT02343055|OTHER|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
58271488|NCT06255717|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
58271489|NCT05413122|DRUG|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
58389868|NCT00002552|DRUG|leucovorin calcium|
58389869|NCT00002552|DRUG|methotrexate|
58389870|NCT00002552|DRUG|perfosfamide|
57918174|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
57918175|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
58064070|NCT04770701|DRUG|Ahah Drug|"- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
58389871|NCT00002552|DRUG|therapeutic hydrocortisone|
58389872|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
58389873|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
58389874|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
58389875|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
58389876|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
58389877|NCT00002552|RADIATION|radiation therapy|
58389878|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
58389879|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
58389880|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
58389881|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
58389882|NCT05006989|OTHER|Blueberry Powder|Administered 10 grams/day
58389883|NCT05006989|OTHER|Placebo Powder|Administered 10 grams/day
58389884|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
58389885|NCT04764097|DRUG|Placebo|Placebo
58389886|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
58389887|NCT00140296|BEHAVIORAL|Contraceptive counseling|
58389888|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
58389889|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
58389890|NCT00315952|DRUG|Exubera|
58389891|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
57918176|NCT04628819|DIETARY_SUPPLEMENT|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
57918177|NCT01324440|BIOLOGICAL|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
57918178|NCT01324440|BIOLOGICAL|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
57918179|NCT00007345|DRUG|Romidepsin|
57918180|NCT01214265|DEVICE|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
57918181|NCT02709915|OTHER|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
57918182|NCT02709915|OTHER|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
57918183|NCT01045395|DIETARY_SUPPLEMENT|Corn starch|90mg/d
57918184|NCT01045395|DIETARY_SUPPLEMENT|Unique Marine Algae Concentrate (UMAC)|90mg/d
57918185|NCT01045395|DIETARY_SUPPLEMENT|Golden brown algae|90mg/d
58064071|NCT04770701|DEVICE|Ahah Placebo|"- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
58271490|NCT05413122|DRUG|Nicotine patch|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
58271491|NCT05413122|DRUG|Nicotine gum|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
58271492|NCT05413122|BEHAVIORAL|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
58271493|NCT05413122|BEHAVIORAL|Peer Counselling|Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
58271494|NCT05601297|OTHER|questationair|acceptability of women to partner violance
58271495|NCT02927041|DEVICE|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
58271496|NCT03233204|DRUG|Olaparib|Given PO
57918186|NCT00264927|DRUG|SR121463B|
57918187|NCT01137968|DRUG|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
57918188|NCT01137968|DRUG|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
57918189|NCT04211428|OTHER|No intervention|There is no intervention for this study
57918190|NCT03230526|DRUG|[18F]DPA-714 PET scan|"One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24"
57918191|NCT00907790|BEHAVIORAL|Usual Care (Control Group)|
58064072|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
58064073|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
58064074|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
58271497|NCT02567864|OTHER|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
58271498|NCT02567864|OTHER|control|participants maintain their daily activities.
58389892|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
58389893|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
58389894|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
58389895|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
58389896|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
58389897|NCT06271681|DRUG|15-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
58389898|NCT06271681|DRUG|23-valent pneumococcal polysaccharide vaccine|23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
58389899|NCT05202899|DRUG|sugammadex|The use of sugammadex
57719067|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
57918192|NCT00907790|BEHAVIORAL|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
57918193|NCT04733742|DRUG|rhTNK-tPA|intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
57918194|NCT04733742|OTHER|Endovascular treatment|endovascular treatment
58271499|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
57918195|NCT00004815|DRUG|growth hormone|
57918196|NCT01959516|DRUG|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
57918197|NCT01959516|DRUG|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
57918198|NCT01959516|DRUG|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
57918199|NCT01959516|DRUG|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
58271500|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
58271501|NCT06494306|BEHAVIORAL|European Test of Olfactory Capabilities (ETOC)|Investigators will collect the ETOC score in patient of both arms
58271502|NCT06494306|BEHAVIORAL|Standardized Hedonicity Test|To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))
58271503|NCT06494306|BEHAVIORAL|Questionnaires|Patients with PTSD will have the following questionnaires : PTSD Checklist for Diagnostic and Statistical Manual (DSM)-V (PCL-5), Peri-trauma Dissociation Experience Questionnaire (PDEQ), Patient Health Questionnaire-9 (PHQ9), Snaith-Hamilton Pleasure Scale (SHAPS), Childhood Trauma Questionnaire (CTQ) and Apathy Evaluation Scale (AES)
57918200|NCT00406653|DRUG|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
58389900|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
58389901|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
58389902|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
58389903|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
58389904|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
58389905|NCT02905539|DRUG|Iron Isomaltoside 1000|
58389906|NCT02905539|DRUG|Ferric Carboxymaltose|
58389907|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
58389908|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
57918201|NCT00406653|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
57918202|NCT00406653|DRUG|abatacept|"\~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
57918203|NCT03183700|DEVICE|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
57918204|NCT03183700|OTHER|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
57918205|NCT02578862|DRUG|Propofol|
58064075|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
57719068|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
58389909|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
58389910|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
57719069|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
57719070|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
57719071|NCT06573528|DRUG|CS060380|Tablets administered orally
57719072|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
57719073|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
57719074|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
57918206|NCT02578862|DRUG|Sevoflurane|
57918207|NCT02733393|PROCEDURE|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
57918208|NCT02733393|DRUG|lidocaine|
57918209|NCT02912325|DIETARY_SUPPLEMENT|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
57918210|NCT05001594|DEVICE|Active vibratory knee device|The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
58064076|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
58064077|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
58064078|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
58064079|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
58064080|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
57918211|NCT01520493|OTHER|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
57918212|NCT04641494|DIETARY_SUPPLEMENT|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
58064081|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
58064082|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
58064083|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
58064084|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
58064085|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
58064086|NCT04657003|DRUG|Tirzepatide|Administered SC
58064087|NCT04657003|OTHER|Placebo|Administered SC
57719075|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
57719076|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
57719077|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
57918213|NCT04641494|DIETARY_SUPPLEMENT|High oleic acid safflower oil capsules|
57918214|NCT02057978|PROCEDURE|EXCEL DES implatation|Implant DES for CAD cases
58064088|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
58064089|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
58064090|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
58064091|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
58064092|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
57918215|NCT02057978|PROCEDURE|EXCEL-II DES implantation|Implant DES for CAD cases
57918216|NCT02660463|OTHER|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
57918217|NCT03682549|DIAGNOSTIC_TEST|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
57918218|NCT04100642|DRUG|Hemay808|topical apply
58064093|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
58271504|NCT06494306|BEHAVIORAL|Odor / trauma association questionnaire|Patients with PTSD will have Odor / trauma association questionnaire
58271505|NCT01826370|DRUG|Linagliptin|tablet
58271506|NCT03237780|DRUG|Atezolizumab|Given IV
58271507|NCT03237780|PROCEDURE|Biopsy|Undergo biopsy
58271508|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58271509|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
58271510|NCT03237780|DRUG|Eribulin Mesylate|Given IV
58271511|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
57918219|NCT04100642|DRUG|Placebo|topical apply
57918220|NCT00594360|BEHAVIORAL|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
57918221|NCT01047423|DRUG|Simvastatin|40mg encapsulated once daily for 12 weeks
57719078|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
57719079|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
57719080|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
58064094|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
58389911|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
57918222|NCT01047423|DRUG|Placebo|Encapsulated oral once daily for 12 weeks
57918223|NCT05560971|DIETARY_SUPPLEMENT|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
58389912|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
58389913|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
58389914|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
58389915|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
58389916|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
57719081|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
57719082|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
57719083|NCT00935103|BEHAVIORAL|Psychoeducation|
57918224|NCT05560971|OTHER|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
57918225|NCT04990479|BIOLOGICAL|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
57918226|NCT04990479|BIOLOGICAL|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
58064095|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
58064096|NCT00075634|DRUG|decitabine|Given IV
58064097|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
58064098|NCT00075634|DRUG|cyclophosphamide|Given IV
58389917|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
58389918|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
58389919|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
58389920|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
58389921|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
58389922|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
57719084|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
57719085|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
57719086|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
57719087|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
57719088|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
57719089|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
57719090|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
57719091|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
57719092|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
57719093|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
57719094|NCT05615467|DRUG|LY3556050|Administered orally.
57719095|NCT05615467|DRUG|Metformin|Administered orally.
57719096|NCT05615467|DRUG|Iohexol|Administered IV.
57719097|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
57719098|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
57719099|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
57719100|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
57719101|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
57719102|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
57719103|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
57719104|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
57719105|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
57719106|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
57719107|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
57719108|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
57719109|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
57719110|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
57719111|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
57719112|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
57719113|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
57719114|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
57918227|NCT00322673|DRUG|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
57918228|NCT04309136|DRUG|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
57918229|NCT04309136|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
57918230|NCT04309136|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
57918231|NCT02417402|OTHER|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
58064099|NCT00075634|BIOLOGICAL|filgrastim|Given SC
58064100|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
58271512|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
58271513|NCT06629584|DRUG|Asciminib|Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
58271514|NCT04240964|OTHER||
58271515|NCT02360202|PROCEDURE|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
58064101|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
58271516|NCT02360202|DRUG|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
58389923|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
58389924|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
58389925|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
58389926|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
58389927|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
58389928|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
58389929|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
58389930|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
58389931|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
58389932|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
58389933|NCT03001193|DRUG|DF 01|
58389934|NCT03001193|DRUG|Oxytocin|
58271517|NCT06731764|DRUG|Levothyroxine|"Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily."
58271518|NCT06731764|DRUG|Levothyroxine/Liothyronine once daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
58271519|NCT06731764|DRUG|Levothyroxine/Liothyronine twice daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
58271520|NCT05688254|BEHAVIORAL|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
58271521|NCT01676818|DRUG|eribulin mesylate|Given IV
58389935|NCT03001193|DRUG|Placebo|
58389936|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
58389937|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
58389938|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
58389939|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
58389940|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
58389941|NCT02209792|DRUG|Placebo|
58064102|NCT00075634|OTHER|pharmacological study|Correlative studies
58271522|NCT05704777|BEHAVIORAL|Exercise|A 24-weeks concurrent exercise training program
58271523|NCT05704777|OTHER|Control|Usual care
58271524|NCT03491631|DRUG|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
58271525|NCT03491631|DRUG|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
58271526|NCT02987569|BEHAVIORAL|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
58389942|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
58389943|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
58389944|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
58389945|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
58271527|NCT02987569|BEHAVIORAL|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
58064103|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
58271528|NCT03541109|DRUG|Polypill|fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
58271529|NCT02400866|DRUG|Olanzapine|
58271530|NCT00622804|PROCEDURE|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
58271531|NCT00622804|PROCEDURE|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
58271532|NCT00622804|PROCEDURE|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
58271533|NCT01562249|OTHER|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
58271534|NCT01562249|OTHER|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
58389946|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
58389947|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
58389948|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
58389949|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
58389950|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
58389951|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
58389952|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
58389953|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
58389954|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
58389955|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
58064104|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
58064105|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
58064106|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
58064107|NCT01223560|OTHER|Exercise|Exercise on tread mill
58064108|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
58389956|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
58389957|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
58389958|NCT01501890|DRUG|Placebo|0.9% NaCl
58389959|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
58389960|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
58389961|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
58389962|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
58389963|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
58389964|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
58389965|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
58389966|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
58389967|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
58389968|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
58389969|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
58389970|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
58389971|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
58389972|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
58389973|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
58389974|NCT00310336|DRUG|S-adenosyl-L-methionine|
58389975|NCT00310336|DRUG|betaine|
58389976|NCT00310336|DRUG|pegylated interferon alpha2b|
58389977|NCT00310336|DRUG|ribavirin|
58389978|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
58389979|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
58389980|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
58389981|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
58389982|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
58389983|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
58389984|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
58389985|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
58389986|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
58064109|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
58389987|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
58389988|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
58389989|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
58389990|NCT00727545|OTHER|iron bisglycine chelate|
58389991|NCT00727545|OTHER|placebo|
57719115|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
57719116|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
57719117|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
57719118|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
58271535|NCT01562249|OTHER|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
58271536|NCT04233671|BEHAVIORAL|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
58271537|NCT04242992|BEHAVIORAL|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
58271538|NCT04242992|OTHER|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
58389992|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
57719119|NCT02838017|DEVICE|Tissue Adhesive|
57719120|NCT02838017|DEVICE|Sterile strips|
57719121|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
58064110|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
58064111|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
58271539|NCT01855282|BEHAVIORAL|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
58271540|NCT04060459|DRUG|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
58064112|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
58271541|NCT03451110|DRUG|lemborexant|oral tablet
58271542|NCT03451110|DRUG|Loestrin|oral tablet
58271543|NCT03451110|DRUG|famotidine|oral tablet
58271544|NCT03451110|DRUG|fluconazole|oral tablet
58271545|NCT04074382|OTHER|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
58271546|NCT04074382|OTHER|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
58389993|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
58389994|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
58389995|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
57719122|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
57719123|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
57719124|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
57918232|NCT02417402|OTHER|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
58271547|NCT05029804|OTHER|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
58271548|NCT05020418|OTHER|Chart Review|Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
58271549|NCT06432309|DRUG|Opicapone 50 mg|Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
58271550|NCT06432309|DRUG|Duodopa|Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
58271551|NCT01500213|DRUG|Rolapitant|200 mg PO
58271552|NCT01500213|DRUG|Granisetron|10 mcg/kg IV
58389996|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
58389997|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
57719125|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
57719126|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
57719127|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
57719128|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
58271553|NCT01500213|DRUG|Dexamethasone|20 mg PO and 8 mg PO
58271554|NCT01500213|DRUG|Placebo|(4 X 0 mg capsules) o mg PO
58271555|NCT03840551|OTHER|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
58271556|NCT06347445|OTHER|There is no intervention.|There is no intervention.
58271557|NCT04134520|DEVICE|ProLung System|Non-invasive bioconductance measurements
58271558|NCT02160522|DEVICE|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
58271559|NCT00641875|PROCEDURE|Nocturnal Hemodialysis|
58389998|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
58389999|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
57918233|NCT00282204|BEHAVIORAL|antenatal hypnosis + audio compact disc on hypnosis|
57918234|NCT00282204|BEHAVIORAL|Audio compact disc on hypnosis|
57918235|NCT05695937|DIETARY_SUPPLEMENT|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
57918236|NCT05695937|DIETARY_SUPPLEMENT|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
58271560|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
58271561|NCT04015518|DRUG|Placebo|Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
58271562|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
58271563|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
58271564|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
58271565|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
57719129|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
57719130|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
58064113|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
58064114|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
57719131|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
57719132|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
57719133|NCT00497120|DRUG|acetazolamide|
57719134|NCT00497120|DRUG|placebo|
57719135|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
57719136|NCT00013897|DRUG|Atazanavir|
57719137|NCT00013897|DRUG|Lamivudine/Zidovudine|
57719138|NCT00013897|DRUG|Efavirenz|
57719139|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
57719140|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
58064115|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
57719141|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
57719142|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
57719143|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
57719144|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
57719145|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
58064116|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
58064117|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
58064118|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
58271566|NCT03871725|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
58271567|NCT05450185|PROCEDURE|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
57719146|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
57719147|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
57719148|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
58271568|NCT00829816|DRUG|Dimebon|
57719149|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
57918237|NCT05695937|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
57918238|NCT05695937|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
57918239|NCT04385420|DRUG|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
57918240|NCT04385420|DRUG|Placebo oral tablet|Placebo film-coated tablet administered via oral route
58064119|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
58064120|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
58064121|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
58064122|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
58271569|NCT00829816|DRUG|Placebo|
58271570|NCT05037539|DRUG|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
58390000|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
58390001|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
57719150|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
57719151|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
57918241|NCT01393327|BEHAVIORAL|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
57918242|NCT00091169|DIETARY_SUPPLEMENT|levocarnitine|Given orally
57918243|NCT00091169|OTHER|placebo|Given orally
57918244|NCT02618954|OTHER|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
57918245|NCT02070588|DEVICE|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
57918246|NCT04196153|PROCEDURE|Pedicle screws instrumentation|The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
57918247|NCT02522351|OTHER|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
58064123|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
58271571|NCT05037539|DRUG|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
58271572|NCT03448939|DRUG|S5G4T-1|Once a day topical cream
58271573|NCT03448939|DRUG|S5G4T-2|Once a day topical cream
58271574|NCT02798120|DRUG|SB204 4%|Open label, topical SB204 4%
58271575|NCT03910530|DRUG|Retifanlimab|Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
58271576|NCT03910530|DRUG|INCB001158|Part 1: INCB001158 75 or 100 mg twice daily administered orally.
58271577|NCT03910530|DRUG|Retifanlimab + INCB001158|Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
58271578|NCT01576003|DRUG|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
58271579|NCT01576003|DIETARY_SUPPLEMENT|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
58271580|NCT01440569|DRUG|COBI|150 mg tablet administered orally with food once daily
58271581|NCT01440569|DRUG|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
57719152|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
57719153|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
57719154|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
57719155|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
57719156|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
57719157|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
57719158|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
57719159|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
57719160|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
57719161|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
57719162|NCT06573554|OTHER|Total Contact Cast|TCC will be applied to the Charcot patients
57719163|NCT06573554|OTHER|Posterior Slab|Posterior Slab will be applied to the Charcot patients
57918248|NCT02522351|OTHER|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
57918249|NCT02522351|OTHER|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
57918250|NCT02522351|OTHER|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
57918251|NCT02522351|OTHER|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
57719164|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
58271582|NCT01440569|DRUG|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
58271583|NCT01323036|DIETARY_SUPPLEMENT|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
58064124|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
58064125|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
58271584|NCT01323036|DIETARY_SUPPLEMENT|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
58271585|NCT01839305|OTHER|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
57719165|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
57719166|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
57719167|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
57719168|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
57719169|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
57719170|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
57719171|NCT05981651|OTHER|non-intervention|non-intervention
57719172|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
57719173|NCT02478892|OTHER|surveillance endoscopic ultrasound or MRI of the abdomen|The patients will be followed up clinically with routine surveillance endoscopic ultrasound or MRI surveillance every 12 months for a duration of 10 years
57918252|NCT02522351|OTHER|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
57918253|NCT05155163|BEHAVIORAL|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
57918254|NCT04465760|DRUG|Xisomab 3G3|Given IV or via catheter
58064126|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
58064127|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
58064128|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
58064129|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
58271586|NCT03289806|PROCEDURE|Samples of fibroblasts from Tenon's capsule|
58271587|NCT03858894|DRUG|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
57719174|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
58271588|NCT03858894|DRUG|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
57719175|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
57719176|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
57719177|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
57719178|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
57719179|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
57918255|NCT01525719|DRUG|Everolimus|10 mg everolimus
57918256|NCT05227885|OTHER|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
57918257|NCT04681547|PROCEDURE|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
57918258|NCT04681547|PROCEDURE|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
57918259|NCT00461136|DRUG|Aliskiren|
57918260|NCT00505817|DRUG|Cetrorelix and Leuprolide|
58064130|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
58064131|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
58271589|NCT04332731|DEVICE|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
58271590|NCT04332731|DIAGNOSTIC_TEST|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
58271591|NCT02811380|DEVICE|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
58271592|NCT02811380|DEVICE|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
58271593|NCT03317457|BIOLOGICAL|Durvalumab and Tremelimumab|immun checkpoint inhibitor
58271594|NCT03317457|DRUG|Doxorubicin|Anthracycline
58271595|NCT01923844|DRUG|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
57719180|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
57719181|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
57918261|NCT04984733|DRUG|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
57918262|NCT04984733|DRUG|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
57918263|NCT04984733|DRUG|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
57918264|NCT04984733|DRUG|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
57918265|NCT02743377|OTHER|Brain PET Imaging with 11C Rolipram|Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
57918266|NCT02743377|DRUG|Whole Body PET Baseline with 11C Rolipram|Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
57918267|NCT02743377|DRUG|Whole Body PET Blocked with Roflumilast|Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
57918268|NCT04986995|DRUG|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
57918269|NCT01491893|BIOLOGICAL|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
57918270|NCT01600573|DRUG|pazopanib in combination with weekly topotecan|"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
57918271|NCT04328636|DRUG|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
57918272|NCT04328636|DRUG|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
58271596|NCT05268354|OTHER|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
58271597|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
58271598|NCT01770067|DRUG|CITA-RNPT|
58271599|NCT01770067|PROCEDURE|Extraction of infected CIED|
58271600|NCT04549376|DRUG|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
58271601|NCT04549376|DRUG|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
57918273|NCT02182557|DRUG|WAL 801 CL Dry Syrup|
57918274|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup|
58271602|NCT04549376|DRUG|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
57918275|NCT02182557|DRUG|WAL 801 CL Dry Syrup placebo|
57918276|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup placebo|
57918277|NCT05050994|PROCEDURE|Microwave ablation|Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
58271603|NCT04549376|DRUG|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
58271604|NCT04549376|DRUG|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
57918278|NCT06081023|BEHAVIORAL|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
58271605|NCT04549376|OTHER|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
58271606|NCT04549376|OTHER|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
58271607|NCT02176083|BEHAVIORAL|Text message management prompts|
58271608|NCT03433313|DRUG|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
58271609|NCT03433313|DRUG|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
58271610|NCT03761225|DRUG|Masitinib|
58271611|NCT03761225|DRUG|Docetaxel|
58271612|NCT03761225|DRUG|Prednisone|
58271613|NCT03761225|DRUG|Placebo|
58271614|NCT04150302|OTHER|Exploratory interviews|Exploratory interviews to generate an interview guide
58271615|NCT04150302|OTHER|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
58271616|NCT04150302|OTHER|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
58271617|NCT04150302|OTHER|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
58271618|NCT04150302|OTHER|Psychometric validation|Psychometric properties study
58390002|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
58390003|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
58064132|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
58064133|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
58390004|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
58390005|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
58390006|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
58390007|NCT02173483|PROCEDURE|Quadriceps graft|
58390008|NCT02583633|DRUG|Transdermal nitroglycerin|
58390009|NCT02583633|DRUG|nifedipine|
57918279|NCT02618031|PROCEDURE|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.
58064134|NCT06160531|DRUG|Placebo|Matching placebo
58064135|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
58390010|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
58064136|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
58390011|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
58064137|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
58064138|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
58064139|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
58271619|NCT01100216|OTHER|Nicotine Lozenge|4 mg for 12 days
58271620|NCT01100216|OTHER|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
58271621|NCT01100216|OTHER|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
58271622|NCT01100216|OTHER|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
58390012|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
58390013|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
58390014|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
58390015|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
58271623|NCT02248974|OTHER|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
57918280|NCT00332189|DRUG|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
57918281|NCT04778423|OTHER|Avatar Therapy|In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
57918282|NCT03686319|OTHER|Reflexology|Reflexology: foot massage
57918283|NCT04671134|OTHER|Biomimetic remineralizing agent|Self-assempling peptide
57918284|NCT04671134|OTHER|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
57918285|NCT00938860|DRUG|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
57918286|NCT00938860|DRUG|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
57918287|NCT03399487|DRUG|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
57918288|NCT04187989|BEHAVIORAL|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
57918289|NCT05436080|DEVICE|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
57918290|NCT03005964|DRUG|AM001 Cream, 7.5%|Active Cream
57918291|NCT03005964|DRUG|Vehicle Cream|Placebo
57918292|NCT02470156|BEHAVIORAL|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
57918293|NCT02470156|BEHAVIORAL|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
57918294|NCT05311891|DIAGNOSTIC_TEST|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
57918295|NCT02584582|DRUG|Liraglutide|
58064140|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
57918296|NCT02584582|DRUG|Exenatide|
57918297|NCT02584582|PROCEDURE|Liquid meal test|
57918298|NCT02584582|OTHER|No drug (Baseline day)|
58271624|NCT05279768|BIOLOGICAL|UC-MSCs|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
58064141|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
58271625|NCT05279768|BIOLOGICAL|Secretomes|Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
58271626|NCT05279768|BIOLOGICAL|UC-MSCs and Secretomes|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
58064142|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
58064143|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
58390016|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
58390017|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
57719182|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
57719183|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
57719184|NCT02897843|DEVICE|sham tDCS|sham tDCS
57719185|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
57719186|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
57719187|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
57719188|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
58064144|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
58271627|NCT05279768|BIOLOGICAL|Control|Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
58390018|NCT05723692|OTHER|Placebo|formulation buffer
58390019|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
58390020|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
57719189|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
57719190|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
57719191|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
57918299|NCT03130803|BEHAVIORAL|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
58064145|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
58271628|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
58271629|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
58064146|NCT02842333|OTHER|Additional biological samples|Blood samples
58064147|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
58271630|NCT02791438|DRUG|Azilsartan|Azilsartan granules and tablets
58390021|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
58390022|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
58390023|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
58390024|NCT00068315|DRUG|bortezomib|Given IV
58390025|NCT00068315|DRUG|fludarabine phosphate|Given IV
58390026|NCT00068315|BIOLOGICAL|rituximab|Given IV
58390027|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
58390028|NCT01812213|DRUG|[18F]NAV4694|
58390029|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
57719192|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
58271631|NCT02791438|DRUG|Placebo|Placebo-matching azilsartan granules and tablets
57719193|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
57719194|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
57918300|NCT00640887|DRUG|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
57918301|NCT00640887|DRUG|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
57918302|NCT00640887|DRUG|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
57918303|NCT00221741|DRUG|Fresh Frozen Plasma (blood product)|
58271632|NCT01759836|DRUG|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
58271633|NCT05958719|DRUG|Chidamide|chidamide 30mg biw, p.o, 28 days for a cycle.
58271634|NCT05958719|DRUG|Azacitidine|75mg/m2, continuous i.h. on day 1-7，28 days for a cycle.
58271635|NCT03488225|DRUG|Cyclophosphamide|Given IV
58271636|NCT03488225|DRUG|Cytarabine|Given IT or IV
58271637|NCT03488225|DRUG|Dexamethasone|Given IV or PO
58271638|NCT03488225|DRUG|Doxorubicin Hydrochloride|Given IV
58271639|NCT03488225|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
57918304|NCT02963103|DRUG|Tacrolimus|Oral
57918305|NCT05880394|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
57918306|NCT05880394|DRUG|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
58271640|NCT03488225|OTHER|Laboratory Biomarker Analysis|Correlative studies
58271641|NCT03488225|DRUG|Leucovorin Calcium|Given IV
57918307|NCT02788903|OTHER|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
57918308|NCT00098852|DRUG|rosiglitazone maleate|
57918309|NCT04589429|DRUG|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
57918310|NCT04589429|DRUG|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
57918311|NCT04871100|BEHAVIORAL|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
57918312|NCT04871100|BEHAVIORAL|Problem Solving therapy|Skills based approach for managing negative moods and stress.
57918313|NCT02709824|DRUG|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
57918314|NCT02709824|DRUG|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
57918315|NCT03940053|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
58271642|NCT03488225|DRUG|Mercaptopurine|Given PO
58271643|NCT03488225|DRUG|Methotrexate|Given IT, IV or PO
58271644|NCT03488225|BIOLOGICAL|Ofatumumab|Given IV
57918316|NCT00507364|DRUG|Local injection of activated macrophages to anal fissure|
58271645|NCT03488225|DRUG|Prednisone|Given PO
58271646|NCT03488225|BIOLOGICAL|Rituximab|Given IV
58271647|NCT03488225|DRUG|Vincristine Sulfate|Given IV
58271648|NCT05073354|DEVICE|Full SWOT Model|Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
58271649|NCT06730516|DRUG|Latanoprost (Xalatan)|latanoprost 0.005
58271650|NCT06730516|DRUG|Brimonidine 0.2 %|Brimonidine0.2
58271651|NCT01797159|RADIATION|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
58271652|NCT05502991|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
58271653|NCT03447600|BEHAVIORAL|Alternate Day Fasting|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
58271654|NCT03447600|BEHAVIORAL|Continuous dietary restriction|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
58271655|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
58390030|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
58390031|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
58390032|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
57719195|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
57719196|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
57719197|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
57719198|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
57719199|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
57719200|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
58271656|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
57719201|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
57719202|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
58271657|NCT00022880|DRUG|Iodine-131 Anti-B1 Antibody|
58271658|NCT00367419|DRUG|Erythromycin|
58390033|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
58390034|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
58390035|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
58390036|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
58390037|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
58390038|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
58390039|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
58390040|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
57719203|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
57719204|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
57719205|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
57719206|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
57719207|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
57719208|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
58271659|NCT06030830|BEHAVIORAL|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
58271660|NCT04047849|DRUG|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
57918317|NCT01414985|BIOLOGICAL|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
58271661|NCT06729983|PROCEDURE|Prophylactic Conjoint Tendon Lengthening|During a standard reverse shoulder arthroplasty procedure, the conjoint tendon will be incised and lengthened prophylactically
58271662|NCT06729983|PROCEDURE|Standard Reverse Shoulder Arthroplasty|A standard reverse shoulder arthroplasty procedure will be performed
58271663|NCT01267084|DRUG|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
58271664|NCT01267084|DRUG|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
58271665|NCT01267084|DRUG|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
58271666|NCT01810705|DRUG|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
58271667|NCT03219086|PROCEDURE|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
58271668|NCT03219086|DRUG|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
58271669|NCT03219086|DRUG|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
58271670|NCT03922204|DRUG|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
58271671|NCT03922204|DRUG|Pembrolizumab (Keytruda)|Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
58271672|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
57719209|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
57719210|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
57719211|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
57719212|NCT03160430|DRUG|Placebos|matching placebo capsule
57719213|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
57719214|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
57719215|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
57719216|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
57719217|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
57719218|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
57719219|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
57719220|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
57719221|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
58271673|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
58271674|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
58271675|NCT05929079|DRUG|Retatrutide|Administered SC
58271676|NCT05929079|DRUG|Placebo|Administered SC
58271677|NCT02849067|OTHER|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
57719222|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they transition from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~As a result of the California Healthy Youth Act, which mandates sexual health education (SHE) in public schools, most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
57719223|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
58271678|NCT02849067|OTHER|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
58271679|NCT03693469|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
58271680|NCT06676735|DEVICE|Inflatable warming system|Inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient\&#39;s temperature is normal, it can be adjusted back to 38 ℃.
58271681|NCT06676735|DIAGNOSTIC_TEST|Prediction of intraoperative hypothermia risk|According to the Intelligent Care For The Elderly (ICE, an optimized model based on the existing prediction model of our research group after dynamic incremental training), patients are divided into intraoperative hypothermia lowrisk group and intraoperative hypothermia high risk group.
58271682|NCT06676735|OTHER|The difference between axillary temperatature and core temperature in elderly patients|Previous studies have shown that the difference and standard deviation between esophageal temperature and axillary temperature are core 0.05 ℃ and 0.26 ℃, respectively. In light of 10% dropout rate, a integer sample size of 400 achieves 95% power to detect a mean of paired differences of 0.05 with an estimated standard deviation of paired differences of 0.26 and with a significance level (alpha) of 0.05 using a two-sided paired t-test. So 400 patients in the Model optimization group need to undergo core temperature (esophageal temperature or nasopharyngeal temperature).
58271683|NCT06676735|OTHER|Measurement of tympanic membrane temperature|As a intraoperative core temperature reference (measure every 15 minutes) for patients without esophageal temperature or nasopharyngeal temperature monitoring.
58271684|NCT04159168|BEHAVIORAL|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
58271685|NCT04159168|BEHAVIORAL|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
58271686|NCT05904119|DRUG|Lomustine|Oral administration of Lomustine
57719224|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
57719225|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
58271687|NCT05904119|RADIATION|Reirradiation|Given at least 6 months after the end of prior radiotherapy
58271688|NCT02804906|BEHAVIORAL|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
58390041|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
57719226|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
57719227|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
57719228|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
57719229|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
57719230|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
57719231|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
57719232|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
57719233|NCT00001100|DRUG|ganciclovir|
57719234|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
57719235|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
57719236|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
57719237|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
57719238|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
58064148|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
58390042|NCT00000788|DRUG|Methadone hydrochloride|
57719239|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
57719240|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
57719241|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
57918318|NCT02325167|BEHAVIORAL|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
58390043|NCT00000788|DRUG|Fluconazole|
58390044|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
58390045|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
58390046|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
58390047|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
58390048|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
58390049|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
57719242|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
58390050|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
58390051|NCT00681395|DRUG|ABT-143|once daily for 6 days
58390052|NCT00681395|DRUG|ABT-335|once daily for six days
58271689|NCT02804906|BEHAVIORAL|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
58390053|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
58390054|NCT05628285|DEVICE|Sentio 1|Sound processor
58390055|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
58271690|NCT02303990|DRUG|Pembrolizumab|
58390056|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
58390057|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
57719243|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
57719244|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
58271691|NCT02303990|RADIATION|Radiotherapy|
58271692|NCT03337035|DRUG|intranasal oxytocin|4-24 IU per day, dosage gradually increases
58271693|NCT03337035|DIETARY_SUPPLEMENT|oral probiotics|200 million cfu per day
58271694|NCT03337035|DIETARY_SUPPLEMENT|oral placebo|2 pills per day
58390058|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
58390059|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
58390060|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
57719245|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
57719246|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
57719247|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
57719248|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
57719249|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
58271695|NCT00237250|DRUG|vildagliptin|
57719250|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
57719251|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
57719252|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
58271696|NCT01889355|DEVICE|AgaMatrix Blood Glucose Monitor|
58390061|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
58390062|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
58390063|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
57719253|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
57719254|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
57719255|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
57719256|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
57719257|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
57719258|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
57719259|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
57918319|NCT02325167|BEHAVIORAL|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
58064149|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
58271697|NCT05580328|DRUG|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
58390064|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
58390065|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
57719260|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
57719261|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
57719262|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
58064150|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
57719263|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
57719264|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
57719265|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
57719266|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
57918320|NCT03748407|OTHER|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
57918321|NCT05864261|DRUG|JT1801 60ug|JT1801, 60ug, IV injection
57918322|NCT05864261|DRUG|NESP 60ug|NESP, 60ug, IV injection
58064151|NCT02554916|DEVICE|Dual-Belt Treadmill|
58271698|NCT05942924|PROCEDURE|Repeated tactile stimulation|See arm
58271699|NCT05942924|PROCEDURE|Selective tactile stimulation|See arm
58271700|NCT02707406|OTHER|NEOX®CORD 1K|use of human tissue product wound covering
58271701|NCT02707406|OTHER|standard of care|standard wound coverings
58271702|NCT03563664|PROCEDURE|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
57918323|NCT02789527|DRUG|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
57918324|NCT02789527|GENETIC|Genotyping|DNA sampling from a saliva sample
58271703|NCT03563664|DRUG|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
58271704|NCT03563664|PROCEDURE|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
58271705|NCT05861102|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
58271706|NCT05861102|DRUG|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
58271707|NCT02454374|PROCEDURE|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
58271708|NCT02454374|PROCEDURE|Routine Physiotherapy Care|Routine Physiotherapy Care
58271709|NCT04895995|BEHAVIORAL|Daylight dCBT Application|Participants will complete up to four modules of digital intervention delivered in a self-paced format.
58271710|NCT00785902|DEVICE|AtriCure Bipolar System|
58271711|NCT06368882|DRUG|Peg-Interferon α|Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
58390066|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
57918325|NCT06254547|OTHER|Daily updated ranking on leaderboard|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service and view a daily updated leaderboard ranking.~Leaderboards will demonstrate participant's ranking in their respective group, participant's (anonymized) name, cumulative point total, total case amount, and current level. Participant ranking will be based on the cumulative point total. All groups will have continual access to their personal score.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
57918326|NCT06254547|OTHER|Daily motivational message|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service encouraging training.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
57918327|NCT01531647|DRUG|danoprevir|100 mg q12h Days 8-21
57918328|NCT01531647|DRUG|raltegravir|400 mg q12h Days 1-4 and 18-21
57918329|NCT01531647|DRUG|ritonavir|100 mg q12h Days 8-21
57918330|NCT04191018|DIAGNOSTIC_TEST|Liver elastography|Liver stiffness measurement
57918331|NCT04191018|DIAGNOSTIC_TEST|Splenic elastography|Splenic stiffness measurement
57918332|NCT04191018|DIAGNOSTIC_TEST|Gastrointestinal endoscopy|Gastrointestinal endoscopy
57918333|NCT00290108|DRUG|Propofol|
57918334|NCT01747525|DEVICE|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
58271712|NCT00003734|DRUG|flutamide|
58271713|NCT00003734|DRUG|triptorelin|
58271714|NCT00003734|RADIATION|radiation therapy|
58271715|NCT04020081|OTHER|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
58271716|NCT05143216|OTHER|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
58271717|NCT05143216|OTHER|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
58271718|NCT06372418|OTHER|Breastfeeding peer support intervention|In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, care givers will receive a homebased individualized face to face support provided by breastfeeding peer supporters and phone call support upto 7 weeks post hospital discharge.
58271719|NCT06372418|OTHER|Standard Care|Caregivers will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines.
57918335|NCT04525872|OTHER|Full parenteral nutrition light protection of the bag, tubing and lipids|Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
57918336|NCT02010008|BEHAVIORAL|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
57918337|NCT00953407|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57918338|NCT00953407|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57918339|NCT00953407|DEVICE|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57918340|NCT00953407|DEVICE|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57918341|NCT00953407|DEVICE|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57918342|NCT04490187|BEHAVIORAL|Motor Learning|"Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995)."
57918343|NCT05504863|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
57918344|NCT05504863|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
57918345|NCT05504863|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
57918346|NCT04970030|PROCEDURE|ML lithotripsy|we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
57918347|NCT04970030|PROCEDURE|EHL lithotripsy|after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
57918348|NCT01599715|BEHAVIORAL|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
57719267|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
57719268|NCT04900974|DRUG|Doravirine|100mg
57719269|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
57719270|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
57719271|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
57918349|NCT01599715|BEHAVIORAL|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
57918350|NCT05784220|BEHAVIORAL|DPP Curriculum for Lifestyle Intervention|See arms.
57918351|NCT04848870|OTHER|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
57918352|NCT04259645|DRUG|Drug: Bupivacaine 0.375% 20 mL|20 mL 0.375% Bupivacaine
57918353|NCT04259645|DRUG|Drug: Bupivacaine 0.375% diluted to 0.1875%|Each block of 0.375% Bupivacaine x 20 ml mixed (diluted) with Normal Saline Solution 20 mL (total 40 mL)
57918354|NCT03165929|DRUG|Flurbiprofen|oral flurbiprofen spray
57918355|NCT03165929|DRUG|placebo|oral placebo spray
57918356|NCT00282282|DRUG|tacrolimus|Given orally just prior to and following stem cell transplant
57918357|NCT00282282|DRUG|sirolimus|Given orally just prior to and following stem cell transplant
57918358|NCT00282282|DRUG|fludarabine|Given once daily over 30 minutes for 4 days
57918359|NCT00282282|DRUG|busulfex|Given intravenously over 3 hours for 4 days
58390067|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
57918360|NCT01403610|DRUG|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
58271720|NCT00556738|PROCEDURE|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
58271721|NCT00556738|PROCEDURE|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
58271722|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
57918361|NCT01403610|DRUG|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
57918362|NCT01403610|DRUG|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
57918363|NCT02731053|BEHAVIORAL|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
58271723|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
58271724|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
58271725|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
58271726|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
57918364|NCT03936582|BEHAVIORAL|Treatment|information already included in arm/group descriptions
57918365|NCT03435497|BEHAVIORAL|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
57918366|NCT00547365|BIOLOGICAL|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
57918367|NCT03975205|DRUG|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
57918368|NCT04891822|PROCEDURE|ERAS protocol|E: ERAS protocol C: control
58271727|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
58271728|NCT05903313|DRUG|Chang Gung ECG Abnormality Detection Software|This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
58271729|NCT00717275|DRUG|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
58271730|NCT05693545|DRUG|phenoxymethyl penicillin|Prophylaxis
58271731|NCT05693545|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
58271732|NCT04947995|DEVICE|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
58271733|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
58271734|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
58271735|NCT02298413|DEVICE|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
58271736|NCT03193658|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
58271737|NCT03193658|DRUG|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
58271738|NCT01399970|OTHER|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
58271739|NCT01399970|OTHER|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
58390068|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
58390069|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
58064152|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
58271740|NCT00240825|DRUG|Ibuprofen|
58271741|NCT00240825|DRUG|Placebo|
58271742|NCT00240825|DRUG|Acetaminophen|
58271743|NCT05792995|DRUG|Sindillimab|Any treatment regimen that includes immunotherapy.
58271744|NCT00623051|PROCEDURE|Male Circumcision|
58271745|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
58271746|NCT01805973|BEHAVIORAL|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
58390070|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
58390071|NCT02561481|DRUG|Sulforaphane|See under active arm description
58390072|NCT02561481|DRUG|Placebo|See under placebo arm description
58390073|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
58390074|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
58390075|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
58271747|NCT01606202|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
58271748|NCT01606202|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
58271749|NCT06730295|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 39-42Gy/3 fractions, administered once daily. FBCT and 4DCT will be acquired.
58271750|NCT02340312|PROCEDURE|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
58271751|NCT02340312|OTHER|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
58271752|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
58271753|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
58271754|NCT03241537|RADIATION|Intensity modulated radiotherapy|
58271755|NCT03862768|PROCEDURE|surgery|Surgery requires at least removal of all drug-resistant lesions.
58271756|NCT03862768|DRUG|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
58271757|NCT03862768|DRUG|Imatinib escalation|Imatinib 600 MG/d
58271758|NCT03862768|DRUG|Sunitinib|Sunitinib 37.5 MG/d
58271759|NCT04666844|OTHER|no intervention|Observational Study
58271760|NCT06505083|OTHER|modified stepping trainings|step-up on box texture difference
58271761|NCT00410059|DRUG|Erlotinib|150 mg by mouth daily x 28 days
58271762|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
58271763|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
58271764|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
58271765|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
58271766|NCT01541670|DRUG|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
58271767|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
58271768|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
58271769|NCT04312282|DRUG|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
58271770|NCT04312282|DRUG|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
58271771|NCT02322450|DRUG|QGC001|
58390076|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
58390077|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
58390078|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
58390079|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
58390080|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
58271772|NCT02322450|DRUG|Placebo|
58390081|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
58390082|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
58271773|NCT03933020|DEVICE|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
58271774|NCT03933020|BEHAVIORAL|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
57918369|NCT04862871|BEHAVIORAL|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
57918370|NCT04253574|DIAGNOSTIC_TEST|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
57918371|NCT00095069|DRUG|MK0928, gaboxadol / Duration of Treatment - 1 year|
57918372|NCT00095069|DRUG|Comparator: placebo / Duration of Treatment -1 year|
57918373|NCT01222273|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
57918374|NCT04398420|DEVICE|TVERP|Transurethral Vapor Enucleation Resection of the prostate
57918375|NCT04398420|DEVICE|TURis|Transurethral Vapor Enucleation Resection of the prostate
57918376|NCT04398420|DEVICE|HoLEP|Transurethral Vapor Enucleation Resection of the prostate
57918377|NCT02668185|DRUG|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
57918378|NCT02668185|DRUG|Placebo|Placebo
57918379|NCT01530165|BEHAVIORAL|Life style intervention|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
57918380|NCT05919160|DEVICE|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
57918381|NCT01542931|DRUG|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
57918382|NCT02012114|OTHER|Cysteamine bitartrate|No intervention
57918383|NCT04450160|DRUG|Anhydrous Enol-Oxaloacetate (AEO)|Oral supplementation with AEO along with the Standard of Care (Temozolomide)
57918384|NCT04450160|OTHER|Standard of Care|Standard of Care Temozolomide
57918385|NCT02935452|BEHAVIORAL|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
57918386|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
57918387|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
58390083|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
58390084|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
58390085|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
57918388|NCT05955287|BEHAVIORAL|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
58390086|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
58271775|NCT03933020|BEHAVIORAL|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
58390087|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
58390088|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
58390089|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
57918389|NCT05955287|BEHAVIORAL|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
58390090|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
57918390|NCT05955287|BEHAVIORAL|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
58064153|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
58271776|NCT06238713|PROCEDURE|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
58271777|NCT06238713|PROCEDURE|Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
58271778|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
58271779|NCT02858180|DRUG|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
58271780|NCT03099772|BEHAVIORAL|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
58271781|NCT00001863|DRUG|Leflunomide|
58271782|NCT06344325|DRUG|fospropofol|The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.
58271783|NCT03697564|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
58271784|NCT03697564|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
58271785|NCT03697564|DRUG|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
58390091|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
57918391|NCT05955287|BEHAVIORAL|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
57918392|NCT01898923|DRUG|ON101 Cream|
57918393|NCT01898923|OTHER|Aquacel® Hydrofiber® dressing|
58271786|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice with 12% ethanol|
58271787|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice|
58271788|NCT04263636|PROCEDURE|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
58390092|NCT02944721|GENETIC|Genetical analyses|
58390093|NCT02944721|OTHER|Chronic pain identification questionnaires|
58271789|NCT01281267|PROCEDURE|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
58271790|NCT03327961|DEVICE|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
58271791|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
58271792|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
58271793|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
58271794|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
58390094|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
58390095|NCT02944721|OTHER|Quality of life questionnaires|
58390096|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
58390097|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
58390098|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
57719272|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
57719273|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
57719274|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
57918394|NCT05190718|DEVICE|Pharyngeal electrostimulation|"Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential."
57918395|NCT02652871|DRUG|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
57918396|NCT02652871|DRUG|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
58064154|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
58271795|NCT03811210|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
58271796|NCT02397291|DRUG|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
58271797|NCT02397291|DRUG|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
58064155|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
58064156|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
58064157|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
57719275|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
57719276|NCT02906007|DRUG|Bedaquiline|100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
57719277|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
57719278|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
57719279|NCT02682420|DEVICE|everlinQ endoAVF System|
57719280|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
57719281|NCT01699425|DEVICE|Ajust sling|
57719282|NCT01699425|DEVICE|Classical transobturator sling|Control group
57918397|NCT02652871|DRUG|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
57918398|NCT00454129|PROCEDURE|cholangiography via double-balloon enteroscopy|
58271798|NCT02397291|DRUG|Placebo|placebo
58271799|NCT00619164|DRUG|E5555|E5555, 50 mg (tablet), taken orally, once a day.
57918399|NCT00454129|PROCEDURE|MR cholangiography|
57918400|NCT04459247|DRUG|Vit D|Oral liquid formulation of 60000 IU
58271800|NCT00619164|DRUG|E5555|E5555, 100 mg (tablet), taken orally, once a day.
58271801|NCT00619164|DRUG|E5555|E5555, 200 mg (tablet), taken orally, once a day.
57918401|NCT04594447|DEVICE|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
57918402|NCT04594447|DEVICE|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
57918403|NCT03849001|BEHAVIORAL|Exercise Conditions|Light Exercise
57918404|NCT03849001|BEHAVIORAL|Exercise Conditions|Moderate Exercise
58064158|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
58064159|NCT00374764|DRUG|Risperidone|
58064160|NCT00374764|BEHAVIORAL|ABA|
57719283|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
57719284|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
57719285|NCT03249038|OTHER|Measurement of external blood loss|
57719286|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
57719287|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
57719288|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
57719289|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
57719290|NCT05089734|DRUG|Docetaxel|Administered intravenously
57719291|NCT03405467|OTHER|general and specific data|General and specific data collected
57719292|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
57719293|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
58064161|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
58064162|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
57719294|NCT01603550|OTHER|Energy Restriction|Energy Restriction
57918405|NCT03849001|BEHAVIORAL|Exercise Conditions|Vigorous Exercise
57918406|NCT03849001|BEHAVIORAL|Exercise Conditions|Seated Rest
57918407|NCT06445426|DEVICE|Cystometry|The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure. The investigational device is inserted into a 12F single-use hydrophilic catheter. After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter. The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder. The investigational device is connected to a data logger. In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate. The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder. The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
58064163|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
58064164|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
58064165|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
57719295|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
57719296|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
57719297|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
57719298|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
57719299|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
57719300|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
57918408|NCT02764294|OTHER|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
57918409|NCT02764294|OTHER|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
57719301|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
57719302|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
57719303|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
57719304|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
57719305|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
57719306|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
57719307|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
57719308|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
57918410|NCT02764294|OTHER|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
57918411|NCT03841682|BEHAVIORAL|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
57918412|NCT02859363|GENETIC|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
58064166|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
58064167|NCT05231291|OTHER|hand grip strength|Observational study
57918413|NCT00678184|DRUG|Atorvastatin|80 mg atorvastatin on two following days each
58064168|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
58064169|NCT00537251|DRUG|Insulin glargine|
58064170|NCT00212667|DRUG|ONO-5920|
58064171|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
58064172|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
58271802|NCT00619164|DRUG|Placebo|Placebo tablet taken orally, once a day.
58064173|NCT00034697|DRUG|temozolomide|
58064174|NCT00006242|DRUG|BMS-214662|Given IV
58064175|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
58064176|NCT00006242|OTHER|pharmacological study|Correlative studies
58271803|NCT00051441|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|
58064177|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
58064178|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
58271804|NCT05848596|OTHER|hand hygiene theoretical training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,"
58271805|NCT05848596|OTHER|hand hygiene theoretical + simulation training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,~Hand hygiene simulation training will be carried out by the researcher in an environment with a sink.~* Simulation-based training on standard patients,~* Hand hygiene application and important points to be considered during the application will be emphasized."
58271806|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
58390099|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
58390100|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
58390101|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
58390102|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
58390103|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
58390104|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
58390105|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
58390106|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
58390107|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
58390108|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
58390109|NCT00003065|BIOLOGICAL|filgrastim|
58390110|NCT00003065|DRUG|paclitaxel|
58390111|NCT00003065|DRUG|topotecan hydrochloride|
57719309|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
58271807|NCT00287677|BIOLOGICAL|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
58271808|NCT00287677|BIOLOGICAL|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
58390112|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
58390113|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
58390114|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
58390115|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
58390116|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
58390117|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
58390118|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
58390119|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
57918414|NCT06353893|DEVICE|Anika Integrity Implant System|The implant is a porous, flexible construct knitted using HYAFF® fibers and designed to support cell infiltration and regenerative healing. HYAFF is Anika's proven and proprietary esterified HA technology that resorbs over time as tissue remodels. Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a truly unique and differentiated solution for shoulder surgeons to treat rotator cuff tears.
58271809|NCT00287677|DRUG|HAART|HAART all over the trial
58390120|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
58390121|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
57719310|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
57918415|NCT02411357|BEHAVIORAL|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
57918416|NCT02411357|BEHAVIORAL|WHO contraception protocol|World Health Organization's contraception protocol
57918417|NCT02411357|BEHAVIORAL|Incentives|Financial incentives contingent on follow-up visit attendance
57918418|NCT01659619|DRUG|Erythromycin|125mg in normal saline single use infusion for 5 min.
57918419|NCT03111121|DRUG|Sugammadex|receive reversal with sugammadex 4mg/kg
58064179|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
58064180|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
58064181|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
58064182|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
58390122|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
57918420|NCT03111121|DRUG|neostigmine|receive reversal with neostigmine 0.04 mg/kg
57918421|NCT03111121|DRUG|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
57719311|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
57719312|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
57719313|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
57719314|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
57719315|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
57719316|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
57719317|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
57719318|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
57918422|NCT01619150|DRUG|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
58390123|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
57719319|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
57719320|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
57719321|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
57719322|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
57719323|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
57719324|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
57719325|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
57719326|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
57719327|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
57719328|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
58064183|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
57719329|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
57719330|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
57719331|NCT04231435|DRUG|Fedratinib|Oral
58064184|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
58064185|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
58390124|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
57719332|NCT04231435|DRUG|Digoxin|Oral
57719333|NCT04231435|DRUG|Rosuvastatin|Oral
57719334|NCT04231435|DRUG|Metformin|Oral
57719335|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
57719336|NCT01626976|DRUG|Placebo|Solution, single dose
57719337|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
57719338|NCT01626976|DRUG|Placebo|suspension, single dose
57719339|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
57719340|NCT01626976|DRUG|Placebo|suspension, single dose
58064186|NCT03466528|DRUG|Pabrinex|standard treatment
58064187|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
58064188|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
57719341|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
57719342|NCT01626976|DRUG|Placebo|suspension, single dose
57719343|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
57719344|NCT01626976|DRUG|Placebo|suspension, single dose
57719345|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
57719346|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
57719347|NCT01421875|GENETIC|DNA methylation analysis|
57719348|NCT01421875|GENETIC|RNA analysis|
57719349|NCT01421875|GENETIC|gene expression analysis|
57918423|NCT01619150|DRUG|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
57719350|NCT01421875|GENETIC|microarray analysis|
57719351|NCT01421875|GENETIC|nucleic acid sequencing|
57719352|NCT01421875|OTHER|laboratory biomarker analysis|
57719353|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
57719354|NCT02690246|OTHER|questionnaire|a questionnaire based study
57719355|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
57719356|NCT00439400|DRUG|doxycycline|
57719357|NCT00439400|DRUG|placebo|
57719358|NCT01187589|DEVICE|Pulsehaler|
57719359|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
57918424|NCT03203395|BEHAVIORAL|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
57918425|NCT01012739|DRUG|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
57918426|NCT01012739|DRUG|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
57918427|NCT01012739|DRUG|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
57918428|NCT01012739|DRUG|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
57918429|NCT05612763|DEVICE|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
58390125|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
58390126|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
58064189|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
58064190|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
58064191|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
58064192|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
58064193|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
58390127|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
57719360|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
57719361|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
57918430|NCT06375707|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS|"Docetaxel: 100mg/m2 IV every 21 days Paclitaxel: 175mg/m2 every 21 days, IV drip Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week.~Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral"
58271810|NCT04769505|BEHAVIORAL|digital mindfulness-based intervention (MBI)|The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.
58271811|NCT06730971|PROCEDURE|Total thyroidectomy|Post operative specimen after total thyroidectomy
57918431|NCT06375707|DRUG|Ribociclib combined with NSAI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral
57918432|NCT00368992|BIOLOGICAL|cetuximab|Given IV
57918433|NCT00368992|DRUG|paclitaxel|Given IV
57918434|NCT00368992|BIOLOGICAL|bevacizumab|Given IV
57918435|NCT03982615|DEVICE|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
57918436|NCT03982615|DEVICE|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
57918437|NCT04278040|DRUG|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
57918438|NCT04293380|PROCEDURE|amniosyntesis|
57918439|NCT02619487|OTHER|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
57918440|NCT02619487|OTHER|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
57918441|NCT01426763|BIOLOGICAL|CINRYZE with rHuPH20|
57918442|NCT04988815|DRUG|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
58390128|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
58271812|NCT06730971|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
58390129|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
58390130|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
58390131|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
58271813|NCT04477733|DRUG|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
58390132|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
58390133|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
58390134|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
58390135|NCT04461873|OTHER|Reiki|Reiki by touching
57719362|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
57719363|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
57719364|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
57918443|NCT06378489|DRUG|Etonogestrel implant|The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management
57918444|NCT02348762|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
57918445|NCT06424626|DRUG|AK104+Axitinib|Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
57918446|NCT06424626|DRUG|AK112+Axitinib|Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
57918447|NCT00549809|PROCEDURE|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
57918448|NCT04997473|BEHAVIORAL|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
57918449|NCT01800825|DRUG|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
57918450|NCT01800825|DRUG|Placebo|This will be an identical placebo comparator made of starch.
58064194|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
58271814|NCT04477733|DRUG|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
58271815|NCT05079776|OTHER|Physical length measurement|Physical length will be measured and images will be collected for AI to estimate the length
58271816|NCT05815485|DRUG|Azeliragon|30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
58271817|NCT05815485|DRUG|Placebo|Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
58276738|NCT04733222|OTHER|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
58390136|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
58390137|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
58390138|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
58064195|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
58390139|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
58390140|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
58390141|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
58271818|NCT05155449|DIETARY_SUPPLEMENT|Probiotics|Capsule
57719365|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
57719366|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
57719367|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
57719368|NCT04982029|DRUG|Placebo|Matching placebo
57719369|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
57719370|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
58064196|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
58064197|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
58271819|NCT05155449|DIETARY_SUPPLEMENT|Placebo|Capsule
58271820|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
57719371|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
57719372|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
57719373|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
57719374|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
57719375|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
57719376|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
57719377|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
57719378|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
57719379|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
57719380|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
57719381|NCT03431194|DRUG|Placebo|
57719382|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
58064198|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
58064199|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
58271821|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
57918451|NCT04283721|OTHER|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
57719383|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
57719384|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
57918452|NCT00914264|DEVICE|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 \& 12 months
58064200|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
58064201|NCT02744963|OTHER|Free and convenient medicine access|
58064202|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
58064203|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
58064204|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
58064205|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
58064206|NCT02381795|DRUG|Nasal Carbon Dioxide|
58271822|NCT04407416|PROCEDURE|Breath sampling|The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
58271823|NCT03827902|DEVICE|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
58271824|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
58271825|NCT02073318|OTHER|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
58271826|NCT02073318|OTHER|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
58276739|NCT04733222|OTHER|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
57918453|NCT04927182|OTHER|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
57918454|NCT04927182|OTHER|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
57918455|NCT04927182|OTHER|Moderate Exercise Training (Age Group 3; Above 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
58271827|NCT03890614|OTHER|Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
58271828|NCT00962936|DRUG|CT-011|CT-011
58271829|NCT04930614|OTHER|Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour|Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
58271830|NCT05242133|DRUG|Pegylated interferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
58271831|NCT05242133|DRUG|Interferon Beta-1A Prefilled Syringe|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
58271832|NCT00957749|DRUG|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
58271833|NCT04756128|DRUG|Colchicine 0.6 mg|"Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)"
58271834|NCT04756128|DRUG|Naltrexone|"Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension."
58271835|NCT00169624|DRUG|Metformin|
58271836|NCT00169624|DRUG|Gliclazide|
58271837|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
58271838|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
58271839|NCT03027206|OTHER|Vibration technique|Comparison of different technique
58271840|NCT03027206|OTHER|Acceleration of expiratory flow|Comparison of different technique
58271841|NCT04982172|DRUG|Infliximab|Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
58271842|NCT04982172|DRUG|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
58271843|NCT03704116|BEHAVIORAL|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
58271844|NCT06523543|PROCEDURE|Inclusion (Visit 1 - Week 7-16)|Extraction of cervico-vaginal sampling
58271845|NCT06523543|DIAGNOSTIC_TEST|Second semester of pregnancy (Visit 2 - Week 20-24)|Ultrasound examination (determination of chromosomal sex)
58271846|NCT06523543|DIAGNOSTIC_TEST|Third semester of pregnancy (Visit 3- Week 34)|Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
58271847|NCT05674318|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
57719385|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
58271848|NCT00310466|BIOLOGICAL|Sublingual immunotherapy|once daily intake of sublingual drops
57719386|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
57719387|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
57918456|NCT03846141|OTHER|Placebo|Inhalation of room air for 20 min per day during 7 days
57918457|NCT03846141|OTHER|Hydrogen|Inhalation of 4% hydrogen for 20 min per day during 7 days
58271849|NCT00310466|BIOLOGICAL|Placebo|once daily intake of sublingual drops
58271850|NCT02920177|DRUG|platelet-rich plasma injection|platelet-rich plasma injection
58271851|NCT02920177|DRUG|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
58271852|NCT00659542|PROCEDURE|cyanoacrylate glue|1 ml glue
58271853|NCT01785849|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
58271854|NCT01785849|DRUG|Placebo|Administered intravenously (IV) three times per week.
58271855|NCT03046992|DRUG|YH25448|"* Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448"
58271856|NCT05071716|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
58271857|NCT05071716|DRUG|Placebo|Placebo Twice Daily
58271858|NCT04633239|DRUG|Abemaciclib|Given PO
58271859|NCT04633239|PROCEDURE|Biopsy|Undergo tumor biopsy
58271860|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58271861|NCT04633239|DRUG|Olaparib|Given PO
58271862|NCT03146871|DRUG|Azacitidine|Given IV or SC
58271863|NCT03146871|DRUG|Decitabine|Given IV
58271864|NCT03146871|OTHER|Laboratory Biomarker Analysis|Correlative studies
57918458|NCT04895683|BEHAVIORAL|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
58271865|NCT03146871|OTHER|Pharmacological Study|Correlative studies
58271866|NCT03146871|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
58271867|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
58271868|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
58271869|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
58271870|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
58271871|NCT06520514|DRUG|Spesolimab|Spesolimab
58271872|NCT06511362|PROCEDURE|Functional stabilization training|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
58271873|NCT06511362|PROCEDURE|perturbation exercises|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
58271874|NCT05654090|DRUG|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
57719388|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
58271875|NCT02444975|DIETARY_SUPPLEMENT|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
57719389|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
57719390|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
57719391|NCT06534294|OTHER|standard care|standard medical care no other treatment
57719392|NCT06532227|OTHER|No intervention|No intervention excepted data collection
58271876|NCT02444975|OTHER|Coaching program|Coaching program to support increased water intake
58271877|NCT02444975|OTHER|No intervention|No intervention
58271878|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
58271879|NCT02379273|DEVICE|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
58390142|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
57719393|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
57719394|NCT05403827|DRUG|Placebo|Vehicle Solution
57918459|NCT05822778|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
57918460|NCT05822778|DEVICE|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
57918461|NCT04945915|OTHER|blood sampling|There was no intervention because this reasearch is observational study.
57918462|NCT05319275|DRUG|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
57918463|NCT05319275|DRUG|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
57918464|NCT02645188|OTHER|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
57918465|NCT00421044|DRUG|Patupilone/EPO906|
57918466|NCT04553250|PROCEDURE|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
57918467|NCT06093854|RADIATION|Intraoperative radiotherapy (IORT)|Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)
58271880|NCT00901784|DRUG|Topiramate|25mg Tablets
58271881|NCT05541900|BEHAVIORAL|TEC-Sacredness|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a self-related word paired with a life-related stimulus, a sacredness of life-related stimulus paired with a pleasant stimulus, and a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
58271882|NCT05541900|BEHAVIORAL|TEC-Control|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
57719395|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
57719396|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
57719397|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
57719398|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
57719399|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
57719400|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
57719401|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
57719402|NCT00035906|DRUG|DEX PS DDS®|
57719403|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
57719404|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
57719405|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
57719406|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
57719407|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
57719408|NCT00004026|DRUG|CT-2584|
58271883|NCT04746261|BEHAVIORAL|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
57719409|NCT00004026|DRUG|chemotherapy|
57918468|NCT06093854|RADIATION|Stereotactic body radiotherapy (SBRT)|postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
58390143|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
57918469|NCT00100581|DRUG|Efavirenz|
57918470|NCT00100581|DRUG|Lamivudine|
58390144|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
57918471|NCT00100581|DRUG|Lopinavir/ritonavir|
57918472|NCT00100581|DRUG|Pegylated interferon alfa-2a|
57918473|NCT00100581|DRUG|Ribavirin|
57918474|NCT00100581|DRUG|Tenofovir disoproxil fumarate|
57918475|NCT04721535|DRUG|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
57918476|NCT04721535|DRUG|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
57918477|NCT05584267|RADIATION|radiotherapy|Different cohorts received different doses of radiotherapy
57918478|NCT05584267|DRUG|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
57918479|NCT04822974|OTHER|blood collection|longitudinally collection of blood samples for each patient included.
57918480|NCT00502957|BEHAVIORAL|Biofeedback|
57918481|NCT06463925|OTHER|acneic participants group|Application of Effaclar Duo+M to the face and trunk twice daily (morning and evening) after washing with the cleansing gel.
57918482|NCT03013582|BIOLOGICAL|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
57918483|NCT03013582|PROCEDURE|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
57918484|NCT00290043|DRUG|Insulin glulisine|
57719410|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
57719411|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
57719412|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
57719413|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
57719414|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
57719415|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
57719416|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
57719417|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
57719418|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
57918485|NCT02679131|DRUG|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
57719419|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
57719420|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
57719421|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
57719422|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
57719423|NCT02885363|OTHER|Clinical examination|
58390145|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
57719424|NCT02885363|OTHER|Blood sample|
57719425|NCT02885363|PROCEDURE|Echocardiography|
57918486|NCT03931031|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
57918487|NCT02074553|DRUG|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
57918488|NCT02074553|DRUG|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
57918489|NCT02074553|DRUG|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
57918490|NCT02074553|DRUG|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
57918491|NCT05552885|OTHER|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
57918492|NCT00448279|DRUG|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
57918493|NCT00448279|DRUG|Chemotherapy|Schedule and dose at the investigator's discretion
57918494|NCT02767128|DRUG|Triferic|
57918495|NCT02767128|DRUG|Fer-In-Sol|
58390146|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
57719426|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
57719427|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
57719428|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
58271884|NCT04746261|OTHER|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
58271885|NCT01276691|DRUG|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
58271886|NCT05136534|PROCEDURE|spinal anesthesia|subarachnoid anesthesia with 2% hyperbaric pilicaine
57918496|NCT02767128|DRUG|Shohl's solution|
58490343|NCT05680688|OTHER|Manual Therapy|"* Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
57719429|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
57719430|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
57719431|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
57719432|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
57719433|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
57719434|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
57918497|NCT00277706|PROCEDURE|Periodontal surgery|
57918498|NCT00277706|DRUG|FORTEO|parathyroid hormone; self-administration for 6 weeks
57918499|NCT00277706|DRUG|Placebo|placebo; self administration for 6 weeks
57918500|NCT00277706|DIETARY_SUPPLEMENT|Vitamin D and Calcium|PO, QD, for six weeks
57918501|NCT00445900|DRUG|cyclophosphamide|
57918502|NCT00445900|DRUG|prednisone|
57918503|NCT00445900|DRUG|thalidomide|
57918504|NCT00445900|OTHER|immunohistochemistry staining method|
57918505|NCT00445900|OTHER|laboratory biomarker analysis|
57918506|NCT00445900|PROCEDURE|biopsy|
57918507|NCT00831831|BEHAVIORAL|Safety planning|See detailed description
58271887|NCT05136534|PROCEDURE|local anesthesia|(Mepivacaine 2%) performed by the surgeon before skin incision
58271888|NCT02938234|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
58271889|NCT03172364|OTHER|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
57719435|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
57918508|NCT00658099|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
57918509|NCT00658099|DRUG|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
58390147|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
58064207|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
58064208|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
58064209|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
58064210|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
58390148|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
58064211|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
58271890|NCT03172364|OTHER|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
58271891|NCT00772005|DRUG|armodafinil|150 mg/day armodafinil
58271892|NCT00772005|DRUG|placebo|placebo
58271893|NCT00772005|DRUG|armodafinil|200 mg/day armodafinil
58271894|NCT00772005|DRUG|armodafinil|250 mg/day armodafinil
57719436|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
57918510|NCT02294227|BIOLOGICAL|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
57918511|NCT02294227|OTHER|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
57918512|NCT02325557|DRUG|ADXS31-142|ADXS31-142 IV infusion
57918513|NCT02325557|DRUG|Pembrolizumab|Pembrolizumab IV infusion
58271895|NCT02832141|PROCEDURE|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
57719437|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
57719438|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
58064212|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
58064213|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
58064214|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
58064215|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
58064216|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
58064217|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
58271896|NCT02832141|PROCEDURE|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
58271897|NCT06241924|PROCEDURE|High Resolution Electroencephalogram (EEG-HR)|Local field potentials (LFP) recording using EEG-HR
58271898|NCT06241924|PROCEDURE|Stereo-electro-encephalography (SEEG)|Local field potentials (LFP) recording using sEEG
58271899|NCT01578954|DRUG|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
57719439|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
57719440|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
57719441|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
58064218|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
58064219|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
58064220|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
58064221|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
58064222|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
58064223|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
58271900|NCT05366218|BIOLOGICAL|Tafasitamab|Antibody vaccination
58271901|NCT01921738|DRUG|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
58390149|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
58064224|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
58064225|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
57719442|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
57719443|NCT03615651|OTHER|Placebo|Placebo intervention.
57719444|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
57719445|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
58064226|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
58064227|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
58064228|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
58064229|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
58064230|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
58064231|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
58064232|NCT03068182|OTHER|Exercise|
57719446|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
57719447|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
58271902|NCT01921738|DRUG|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
58271903|NCT01921738|DRUG|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
58271904|NCT01921738|DRUG|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
58271905|NCT05482165|BEHAVIORAL|Multi-faceted health promotion programme|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses"
58271906|NCT05209711|PROCEDURE|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
58390150|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
58390151|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
58276740|NCT03066037|PROCEDURE|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
58276741|NCT00002379|DRUG|Indinavir sulfate|
58390152|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
58390153|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
58390154|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
58390155|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
58390156|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
58390157|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
58390158|NCT05606211|OTHER|No intervention|Observational, no intervention
58390159|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
58490344|NCT03283514|OTHER|Complete denture|questionnaire
57719448|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
57719449|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
57719450|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
57719451|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
57719452|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
57719453|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
58064233|NCT00001658|DRUG|Amoxicillin|
57719454|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
57719455|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
58271907|NCT05209711|PROCEDURE|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
58390160|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
58390161|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
58390162|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
58390163|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
57719456|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
57719457|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
57719458|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
57719459|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
57719460|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
57719461|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
57719462|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
57719463|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
57719464|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
57719465|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
57719466|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
57719467|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
58271908|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
58271909|NCT05470816|DRUG|Placebo|Normal saline
58271910|NCT00684632|DRUG|Placebo|Placebo
58271911|NCT00684632|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
58271912|NCT03368404|DEVICE|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
58276742|NCT00002379|DRUG|Levocarnitine|
58390164|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
58064234|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
57719468|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
58271913|NCT03368404|DEVICE|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
57719469|NCT02279810|BEHAVIORAL|survey|Survey
57719470|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
57719471|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
57719472|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
57719473|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
57719474|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
57719475|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
57719476|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
58271914|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
58271915|NCT02509975|DEVICE|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
58271916|NCT06068283|BEHAVIORAL|LOTUS mHealth Intervention Group|A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
57719477|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
57719478|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
57719479|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
57719480|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
58271917|NCT06068283|BEHAVIORAL|LOTUS Control Group|Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
58271918|NCT05118061|DIAGNOSTIC_TEST|Ketone|compare diagnostic tests to reference methods
57719481|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
57719482|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
57719483|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
58064235|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
58271919|NCT01675154|DRUG|SLx-4090 placebo|Given for 4 weeks
58271920|NCT01675154|DRUG|Orlistat Placebo|Given for 4 weeks
58271921|NCT01675154|DRUG|Orlistat|Given for 4 weeks
58271922|NCT01675154|DRUG|Slx-4090|Given for 4 weeks
58271923|NCT06401343|DRUG|Empagliflozin 10 MG|Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
58271924|NCT00409851|DRUG|valsartan+amlodipine|
58271925|NCT06435806|OTHER|Medical Illustration design|We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
58390165|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
57719484|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
57719485|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
57719486|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
57719487|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
57719488|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
57719489|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
58064236|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
58064237|NCT01909635|BEHAVIORAL|Food Feelings|
58064238|NCT01909635|BEHAVIORAL|Other Feelings|
58271926|NCT06528145|OTHER|Evalation|Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
57719490|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
57719491|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
57719492|NCT02098343|DRUG|APR-246|Intravenous infusion.
57719493|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
58271927|NCT02667626|OTHER|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
57719494|NCT06022159|PROCEDURE|Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.|"Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~Post-operative follow-up: post-operative complications will be followed at 3 and 6 weeks post-surgery.~A visit at 6 months post-surgery will also be carried out to evaluate post-operative complications and late adverse effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
57719495|NCT06022159|PROCEDURE|Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).|"Post-operative follow-up: postoperative complications will be followed at 3 and 6 weeks post-surgery (before the start of irradiation). Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~A 6-month post-surgery check-up will also be carried out to assess post-operative complications and acute side effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
57719496|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
57719497|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
58390166|NCT06299865|OTHER|Ungrouped|Ungrouped
58271928|NCT02667626|OTHER|Control|Web-based resource lists and text-based study adherence reminders
58390167|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
57719498|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
57719499|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
57719500|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
57719501|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
57719502|NCT00550784|BIOLOGICAL|filgrastim|
57719503|NCT00550784|DRUG|cisplatin|
57719504|NCT00550784|DRUG|cyclophosphamide|
57719505|NCT00550784|DRUG|melphalan|
57719506|NCT00550784|DRUG|paclitaxel|
58064239|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
58390168|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
58390169|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
58390170|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
58390171|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
58390172|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
58390173|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
57719507|NCT00550784|DRUG|topotecan hydrochloride|
57719508|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
57719509|NCT00550784|GENETIC|gene expression analysis|
57719510|NCT00550784|OTHER|immunohistochemistry staining method|
57719511|NCT00550784|OTHER|pharmacological study|
58271929|NCT01962545|DRUG|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
58271930|NCT06730698|OTHER|No intervention|No intervention
58271931|NCT04531982|DRUG|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
58271932|NCT04531982|DRUG|Placebo|Placebo, taken as two blinded tablets once daily by mouth
58271933|NCT04205344|DRUG|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
57719512|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
57719513|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
58276743|NCT00002379|DRUG|Adefovir dipivoxil|
58390174|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
58390175|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
58390176|NCT02096250|OTHER|NaFeEDTA|
58390177|NCT02096250|OTHER|Ferrous fumarate|
58390178|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
58390179|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
57719514|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
57719515|NCT05383170|DRUG|CyPep-1|Intratumoral injection
57719516|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
57719517|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
57719518|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
57719519|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
57719520|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
57719521|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
57719522|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
57719523|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
57719524|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
57719525|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
57719526|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
58271934|NCT04205344|DRUG|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
57719527|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
58271935|NCT04940416|DEVICE|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
58271936|NCT03213197|OTHER|CPR video|Patient watches a short CPR video
58271937|NCT00673426|BIOLOGICAL|Enoxaparin sodic|
57719528|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
58064240|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
58064241|NCT02940158|OTHER|1/4 cup- Small red lentil|
58064242|NCT02940158|OTHER|1/4 cup- Small green lentil|
58271938|NCT03277716|PROCEDURE|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
58064243|NCT02940158|OTHER|1/4 cup- corn|
58271939|NCT03277716|PROCEDURE|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
58271940|NCT03277716|DEVICE|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
58271941|NCT03277716|DRUG|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
58271942|NCT06052306|DRUG|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
58390180|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
57719529|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
58064244|NCT02940158|OTHER|1/4 cup- macaroni|
58064245|NCT02940158|OTHER|1/4 cup- white potato|
58064246|NCT02940158|OTHER|1/4 cup- white rice|
58064247|NCT02940158|OTHER|1/2 cup- small red lentil|
58064248|NCT02940158|OTHER|1/2 cup- small green lentil|
58064249|NCT02940158|OTHER|1/2 cup- corn|
58064250|NCT02940158|OTHER|1/2 cup- macaroni|
57719530|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
57719531|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
57719532|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
58064251|NCT02940158|OTHER|1/2 cup- white potato|
58271943|NCT04408508|DRUG|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
58271944|NCT06091592|OTHER|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
58271945|NCT03195972|OTHER|Drug diary filling|patient will fill every day a drug diary
58271946|NCT04575259|DRUG|ANAVEX2-73|Oral capsules
58271947|NCT04122755|DRUG|ALA-1000|Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
58271948|NCT04122755|DRUG|buprenorphine sublingual film|ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
58271949|NCT00382902|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
58271950|NCT06109272|DRUG|Livmoniplimab|Intravenous (IV) Solution
58271951|NCT06109272|DRUG|Budigalimab|Intravenous (IV) Solution
58390181|NCT02212366|DEVICE|Active TDCS|Active Stimulation
58390182|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
58390183|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
57719533|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
58064252|NCT02940158|OTHER|1/2 cup- white rice|
58390184|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
58390185|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
58390186|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
58390187|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
58064253|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
58064254|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
58064255|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
58064256|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
58064257|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
58390188|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
58064258|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
58064259|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
58064260|NCT02086760|RADIATION|Scintigraphy|
58064261|NCT06356649|PROCEDURE|extubation|Complications after extubation
58271952|NCT06109272|DRUG|Durvalumab|Intravenous (IV) Solution
58271953|NCT06109272|DRUG|Atezolizumab|Intravenous (IV) Solution
58271954|NCT06109272|DRUG|Bevacizumab|Intravenous (IV) Solution
58271955|NCT06109272|DRUG|Tremelimumab|Intravenous (IV) Solution
58271956|NCT02461797|OTHER|healthy controls|biopsy of nasal mucosa for healthy controls
58390189|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
58490345|NCT05846737|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
57719534|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
57719535|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
58271957|NCT02461797|OTHER|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
58271958|NCT02461797|OTHER|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
58271959|NCT04010864|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
58271960|NCT03383692|DRUG|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
58271961|NCT03383692|DRUG|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
58271962|NCT03383692|DRUG|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
58276744|NCT00002379|DRUG|Lamivudine|
58276745|NCT00002379|DRUG|Stavudine|
57719536|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
57719537|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
58064262|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
58271963|NCT05123976|DRUG|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
58271964|NCT05123976|DRUG|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
58271965|NCT02446262|BEHAVIORAL|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
58271966|NCT02446262|BEHAVIORAL|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
58271967|NCT02446262|BEHAVIORAL|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
58271968|NCT02446262|BEHAVIORAL|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
58271969|NCT02879708|OTHER|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
58271970|NCT02879708|OTHER|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
58271971|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
58271972|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
58271973|NCT05189522|DEVICE|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
58276746|NCT00002379|DRUG|Zidovudine|
58490346|NCT03062540|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
58490347|NCT03062540|DRUG|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
58490348|NCT00280748|DRUG|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
58490349|NCT00280748|RADIATION|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
58490350|NCT03254511|DRUG|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
58490351|NCT03254511|RADIATION|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
58490352|NCT03254511|DRUG|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
58490353|NCT04096599|OTHER|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
58490354|NCT04096599|OTHER|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
58490355|NCT04756908|DEVICE|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
57918514|NCT04841356|PROCEDURE|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
57918515|NCT02395874|PROCEDURE|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
58064263|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
58064264|NCT00840684|DRUG|amsacrine|
58271974|NCT05189522|OTHER|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
58271975|NCT01916902|DRUG|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
58064265|NCT00840684|DRUG|busulfan|
58064266|NCT00840684|DRUG|cytarabine|
58271976|NCT01916902|DRUG|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
58271977|NCT01916902|PROCEDURE|Optical Coherence Tomography|
58271978|NCT06534385|DEVICE|Air purifier|Winix HEPA air purifier
58271979|NCT03605849|DRUG|Centanafadine SR|200mg, BID, oral tablets
58271980|NCT06731517|PROCEDURE|intubation|Double-Lumen Tube Intubation
58271981|NCT03802435|PROCEDURE|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
58271982|NCT03802435|PROCEDURE|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
58271983|NCT03802435|PROCEDURE|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
58271984|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
58271985|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
58271986|NCT03232164|DRUG|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
58271987|NCT06349005|OTHER|Tracheal intubation using Storz VL|Video-assisted intubation technique using Storz VL
58271988|NCT06349005|OTHER|Tracheal intubation using Macintosh laryngoscopy|Traditional intubation technique using Macintosh laryngoscopy
58271989|NCT06349005|OTHER|Tracheal intubation using MacGrath VL|Video-assisted intubation technique using MacGrath VL
58271990|NCT06349005|OTHER|Tracheal intubation using EzVision VL|Video-assisted intubation technique using EzVision VL
58271991|NCT00925652|DRUG|Bevacizumab|
58271992|NCT00925652|DRUG|Cyclophosphamide|
58271993|NCT00925652|DRUG|Methotrexate|
58064267|NCT00840684|DRUG|daunorubicin hydrochloride|
58064268|NCT00840684|DRUG|laromustine|
58064269|NCT00840684|DRUG|melphalan|
58064270|NCT00840684|DRUG|mitoxantrone hydrochloride|
58064271|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58064272|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
58271994|NCT00925652|BEHAVIORAL|Lifestyle: Diet|
58271995|NCT00925652|BEHAVIORAL|Lifestyle: Diet+Exercise|
58271996|NCT00078949|BIOLOGICAL|rituximab|Given IV
58271997|NCT00078949|DRUG|cisplatin|Given IV
58271998|NCT00078949|DRUG|cytarabine|Given IV
58271999|NCT00078949|DRUG|dexamethasone|Given IV
58272000|NCT00078949|DRUG|gemcitabine hydrochloride|Given IV
58272001|NCT04761159|DRUG|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
57719538|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
57719539|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
57719540|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
57918516|NCT00639210|OTHER|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
57918517|NCT05772494|OTHER|Assessment of activity limitations, SDO and DOA|The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
57918518|NCT05772494|OTHER|Control group|All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
58064273|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
58064274|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
58064275|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
58064276|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
58064277|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
58064278|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
58064279|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
58064280|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
58272002|NCT03362801|DIAGNOSTIC_TEST|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
58272003|NCT05920135|DRUG|BBT-207|BBT-207 given orally alone
58272004|NCT06235697|RADIATION|Radiation|"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate~+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"
58272005|NCT06235697|RADIATION|Radiation SBRT only|25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT)
58272006|NCT06235697|DRUG|ADT|Assigned at enrollment
58390190|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
58064281|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
57719541|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
58064282|NCT01833299|PROCEDURE|TACE|
57719542|NCT02855502|DRUG|Prednisolone|
58064283|NCT00297284|DRUG|Modafinil|
58064284|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
58064285|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
58064286|NCT04084444|DRUG|Placebo|Blank control.
58064287|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
58272007|NCT03988673|OTHER|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
58272008|NCT03988673|OTHER|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
58272009|NCT01864213|DRUG|Ametop cream|
58390191|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
58390192|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
57719543|NCT02855502|DRUG|Placebo|
57719544|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
57719545|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
57719546|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
57719547|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
57719548|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
57719549|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
57719550|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
57719551|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
57719552|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
58272010|NCT00572975|OTHER|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
57719553|NCT00136708|PROCEDURE|Neonatal Resuscitation|
57719554|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
58272011|NCT04877444|DEVICE|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
58272012|NCT04877444|BEHAVIORAL|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
58390193|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
58390194|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
58390195|NCT02853396|OTHER|Cognitive Behaviour Therapy|
57719555|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
58272013|NCT04877444|BEHAVIORAL|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
58272014|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
58272015|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
58272016|NCT04032951|OTHER|Fine Needle Tissue Acquisition|diagnostic
58272017|NCT03025347|OTHER|Control|Participants complete a resting control condition instead of a run.
58272018|NCT03025347|OTHER|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
58390196|NCT02853396|OTHER|Psychoeducation|
58390197|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
58390198|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
58390199|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
58390200|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
57719556|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
57918519|NCT00706199|PROCEDURE|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
57918520|NCT04716491|DEVICE|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
57918521|NCT02872883|PROCEDURE|Expectant management|
58064288|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
58064289|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
58272019|NCT01078298|DRUG|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
58390201|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
58390202|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
57918522|NCT02872883|PROCEDURE|Minimal Vaginal examinations (only when necessary)|
58064290|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
58064291|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
58272020|NCT01078298|DRUG|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
58272021|NCT06255028|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
58272022|NCT06255028|BIOLOGICAL|IL-2|IL-2 subcutaneous (SC) injection
58272023|NCT06255028|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
58272024|NCT02370069|BIOLOGICAL|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
58272025|NCT00194194|BEHAVIORAL|moderate|moderate behavioral management with RD
58272026|NCT00194194|DEVICE|Resting Metablic Rate measurements|intensive behavior management
58272027|NCT04798872|OTHER|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
58272028|NCT04645134|BEHAVIORAL|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
58272029|NCT05147701|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58390203|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
57719557|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
57719558|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
57719559|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
57719560|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
57719561|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
57918523|NCT02872883|PROCEDURE|Active management|
57918524|NCT02872883|PROCEDURE|Routine vaginal examinations|
57918525|NCT02490202|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
57918526|NCT02490202|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
57918527|NCT02238665|DEVICE|Endomicroscopy|
57918528|NCT00409214|DRUG|LS11 (talaporfin sodium)|
58390204|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
58390205|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
58390206|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
58390207|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
58390208|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
58272030|NCT06730308|RADIATION|Radiotherapy|Hypofractionated radiotherapy
58272031|NCT06730308|DRUG|Concurrent chemotherapy|weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
57719562|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
57719563|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
57918529|NCT00409214|DEVICE|Light source (interstitial light emitting diodes)|
57918530|NCT00409214|PROCEDURE|Intraoperative placement of device in glioma|
57918531|NCT02525757|DRUG|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
57918532|NCT02525757|DRUG|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
57918533|NCT02525757|DRUG|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
57918534|NCT02525757|RADIATION|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
57918535|NCT03495570|DIAGNOSTIC_TEST|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
57918536|NCT04432246|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
57918537|NCT00180570|DEVICE|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
57918538|NCT04281004|BIOLOGICAL|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
57918539|NCT04281004|OTHER|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
57918540|NCT01553123|DRUG|Ulipristal Acetate|once daily, oral
57918541|NCT01553123|DRUG|Iron|once daily, dried ferrous sulfate
58272032|NCT06730308|DRUG|Methylprednisolone|Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
57918542|NCT03720197|OTHER|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
57918543|NCT03720197|OTHER|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
57918544|NCT03720197|OTHER|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
57918545|NCT03720197|OTHER|Food questionnaire|24-hour food recall questionnaire
57918546|NCT03720197|OTHER|Pedometer|Participants will wear a podometer for 14 consecutives days
57918547|NCT03720197|OTHER|Waist circumference|Participants will be asked to measure their waist circumference
57918548|NCT03720197|OTHER|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
57918549|NCT03720197|OTHER|List of medications|Participants will be invited to send us their list of medications
58272033|NCT03662815|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
57719564|NCT02460640|DRUG|Morphine|
57719565|NCT02460640|DRUG|Ropivacaine|
57918550|NCT03720197|OTHER|Continuous glucose monitor|Participants will be invited to send us the latest report of their continuous glucose monitor
57918551|NCT06436157|OTHER|Enhanced education|"In addition to the education conducted as part of usual care, the nurse will: 1) provide basic education on GCT; and 2) if the patient is eligible and agreeable to GCT, place a referral to GCT (if not already ordered).~Patients will also be provided with written materials reinforcing the key messages of GCT education, designed to be understandable to individuals without a medical background. Nurses will also conduct a follow-up nudge by sending an in basket message via electronic medical record to ensure that the referrals are processed by the referral coordinators."
58272034|NCT03662815|OTHER|GM-CSF|immune adjuvant
58272035|NCT01126866|DRUG|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
58272036|NCT01512459|DRUG|Venlafaxine|Venlafaxine MR Capsules 150 mg
57719566|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
57719567|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
57719568|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
57719569|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
57719570|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
57719571|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
57918552|NCT06436157|OTHER|Usual care education|"A brief introduction to GCT will be provided in accordance with the information covered in the chemo education binder, which is the current standard of care at Enloe Regional Cancer Center. As per the usual care, referrals for genetic testing will be clinician-initiated without the proactive involvement of the RN."
58064292|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
58272037|NCT04128124|OTHER|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
58390209|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
58064293|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
57918553|NCT04016467|OTHER|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
57918554|NCT04016467|OTHER|Sham thoracic treatment|Hand placement on thorax without thrust.
57918555|NCT03674567|DRUG|FLX475|tablet
57918556|NCT03674567|DRUG|pembrolizumab (KEYTRUDA®)|IV infusion
57918557|NCT00581815|DEVICE|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
57918558|NCT00581815|DEVICE|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
57918559|NCT06459466|PROCEDURE|kinesiotherapy exercises with cervical mobilization|Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction
58064294|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
58064295|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
58272038|NCT01630356|BEHAVIORAL|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
58272039|NCT01630356|DEVICE|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
58272040|NCT01630356|BEHAVIORAL|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
58272041|NCT01630356|BEHAVIORAL|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
58272042|NCT03667027|DEVICE|Respiratory support|Mechanical ventilation or extracorporeal life support
58390210|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
58390211|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
57719572|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
57719573|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
57719574|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
57918560|NCT06459466|PROCEDURE|cervical Mobilization|This includes Cervical lateral glide mobilization
57918561|NCT01824160|DEVICE|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
57918562|NCT00561951|DRUG|fesoterodine fumarate|8mg tablets OD for 12 weeks
57918563|NCT00561951|DRUG|Placebo|Corresponding placebo tablets OD for 12 weeks
57918564|NCT00561951|DRUG|fesoterodine fumarate|4mg tablets OD for 12 weeks
58064296|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
58064297|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
58272043|NCT03818776|DRUG|Durvalumab|Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
58272044|NCT03818776|RADIATION|Proton beam therapy RT|Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
58272045|NCT04935008|DIAGNOSTIC_TEST|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
58272046|NCT02869841|DRUG|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
57719575|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
57719576|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
58390212|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
58390213|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
58390214|NCT02137447|DEVICE|Negative Pressure treatment|
58390215|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
57719577|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
57719578|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
58272047|NCT02869841|DRUG|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
58272048|NCT02869841|DRUG|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
58272049|NCT02869841|OTHER|Placebo|No rectus sheath analgesia
57719579|NCT05798507|DRUG|Avutometinib|Given PO
58390216|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
58390217|NCT05965583|DRUG|BI 1815368|BI 1815368
58390218|NCT05965583|DRUG|Itraconazole|Itraconazole
58390219|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
58390220|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
57719580|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
57719581|NCT05798507|DRUG|Defactinib|Given PO
58272050|NCT05212480|DIETARY_SUPPLEMENT|Zinc|For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
58272051|NCT05212480|DIETARY_SUPPLEMENT|Placebo|For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
58390221|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
58390222|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
58390223|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
57719582|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
58390224|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
58390225|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
58390226|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
58390227|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
58390228|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
58390229|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
58390230|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
57719583|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
57719584|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
57918565|NCT05560100|OTHER|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
57918566|NCT03714932|DIAGNOSTIC_TEST|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
58272052|NCT06333405|DRUG|Fecal Microbiota Transplantation|"Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI"
58272053|NCT02214862|DRUG|[F18]-FDDNP|radiopharmaceutical tracer
58272054|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
58272055|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
58272056|NCT04532411|OTHER|Personal Protective Testing Booth|Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
58390231|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
58390232|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
58272057|NCT00005762|DRUG|Indinavir sulfate|
58272058|NCT00005762|DRUG|Ritonavir|
58272059|NCT00005762|DRUG|Amprenavir|
58272060|NCT00005762|DRUG|Nelfinavir mesylate|
58272061|NCT00005762|DRUG|Efavirenz|
58272062|NCT00005762|DRUG|Saquinavir|
58272063|NCT03268018|DEVICE|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
58272064|NCT00146666|DEVICE|Intermittent compression|
58272065|NCT01967095|DRUG|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
58272066|NCT05637112|OTHER|None (Observational study)|Not Applicable since Observational Study
58272067|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
58272068|NCT04189133|DRUG|Lutropin alfa|daily increasing dosages of lutropin alfa
58272069|NCT04189133|DRUG|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
58272070|NCT06285734|DIAGNOSTIC_TEST|Breath test|The concentration of methane and hydrogen in the exhaled gas of patients with Abdominal distention is measured by a breath test to determine the presence of SIBO and abnormal OCTT.
58272071|NCT06731387|OTHER|Pharmaceutical technical assistants supported medication dispensation on the hospital ward|Pharmaceutical technical assistants (PTAs) visit the hospital ward for two hours in the morning or afternoon to dispense medications for admitted patients for the following day. Night nurses then complete any final additions or adjustments as needed.
58272072|NCT00399295|DRUG|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
58272073|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
57719585|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
58272074|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
58272075|NCT05495217|DEVICE|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
58272076|NCT05495217|DEVICE|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
58272077|NCT00655603|OTHER|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
58272078|NCT00597012|PROCEDURE|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
58272079|NCT00597012|OTHER|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
58272080|NCT00597012|OTHER|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
58272081|NCT04842591|DIAGNOSTIC_TEST|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
58272082|NCT06433934|DEVICE|Oxy2mask|Open design oxygen mask
58272083|NCT03832504|OTHER|No intervention|The participant will rest in a seated position.
58272084|NCT03832504|OTHER|Fan|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
58272085|NCT03832504|OTHER|Skin Wetting|Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
58272086|NCT03832504|OTHER|Fan + Skin wetting|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
58272087|NCT02450552|DRUG|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
58272088|NCT02450552|DRUG|Placebo|Matched placebo
58272089|NCT05691764|DRUG|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
58272090|NCT05691764|PROCEDURE|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
58272091|NCT05691764|DRUG|Placebo|Intravenous placebo
57918567|NCT01610141|OTHER|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
57918568|NCT01610141|OTHER|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
57918569|NCT02279069|DEVICE|4-roll canne|
58272092|NCT01634659|DEVICE|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
58272093|NCT01634659|DEVICE|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
57719586|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
57719587|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
57719588|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
57719589|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
58272094|NCT03727295|DRUG|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
58272095|NCT04594941|DRUG|Flurpiridaz (18F) Injection|All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
58272096|NCT02381769|DIETARY_SUPPLEMENT|Soybean based lipid emulsion|
58272097|NCT05548491|DRUG|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
58272098|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
58272099|NCT05629091|DEVICE|Epicite hydro|Wound dressing
58272100|NCT05629091|DEVICE|Epiprotect|Wound dressing
58272101|NCT05437237|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
58272102|NCT02603926|DRUG|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
58272103|NCT03066856|OTHER|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products."
57719590|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
57719591|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
57719592|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
57719593|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
58064298|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
58272104|NCT05225571|OTHER|no intervention|there is no any intervention in this study. it is an observational and cross-sectional study.
58272105|NCT03091075|DRUG|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
58272106|NCT03091075|DRUG|Placebo|Placebo group will receive placebo for 12 weeks postoperative
58272107|NCT01492725|DEVICE|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
58272108|NCT01492725|GENETIC|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
58272109|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
58272110|NCT05721638|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
58272111|NCT04504175|DRUG|Ketamine|ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
58390233|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
57719594|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
57719595|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
57719596|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
57719597|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
57719598|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
57719599|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
57719600|NCT02097875|DRUG|BLZ-100|
57719601|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
57719602|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
57719603|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
57719604|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
58064299|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
58064300|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
58064301|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
58064302|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
58390234|NCT00285155|DRUG|Bupropion|
58272112|NCT05842005|DEVICE|Mesh-reduced Sling|In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
57719605|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
58390235|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
57719606|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
57719607|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
57719608|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
57719609|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
57719610|NCT02066558|OTHER|Placebo|
57719611|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
57719612|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
57719613|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
57719614|NCT02162628|DEVICE|Exair Prolapse Repair System|
57719615|NCT02162628|PROCEDURE|Total Native Tissue Repair|
57719616|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
57719617|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
57719618|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
57719619|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
57719620|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
57719621|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
57719622|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
58272113|NCT06294665|DRUG|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed ,the patient is placed in the supine position , the procedural leg is slightly abducted, the curvilinear low-frequency ultrasound probe will be placed over the line parallel to the inguinal ligament. It will subsequently rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration, by one of the two syringes each one has a serial number corresponding to each group.
58390236|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
58390237|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
57719623|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
58272114|NCT01903681|DRUG|Circadin 2 mg|First arm lower dose
58390238|NCT01297608|DRUG|coated suppository|coated suppository with placebo
58390239|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
58390240|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
57719624|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
57719625|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
57719626|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
57719627|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
57719628|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
57719629|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
57719630|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
57719631|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
57719632|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
57719633|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
57719634|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
57719635|NCT00077259|DRUG|epothilone D|
57719636|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
57719637|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
57719638|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
57719639|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
57719640|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
57719641|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
58064303|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
58064304|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
58064305|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
57719642|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
57719643|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
57719644|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
57719645|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
57719646|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
57719647|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
57719648|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
57719649|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
57719650|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
57719651|NCT01984723|DRUG|Experimental: EVP-6124|
58272115|NCT01903681|DRUG|Circadin 10 mg|Second arm higher dose
58272116|NCT04484155|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
57719652|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
57719653|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
57719654|NCT00440271|DRUG|tipranavir|
57719655|NCT00440271|DRUG|ritonavir|
57719656|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
57719657|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
58064306|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
58064307|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
58064308|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
58272117|NCT04717388|OTHER|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory"
57719658|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
57719659|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
57719660|NCT00865527|OTHER|Fecal occult blood test|FOBT
57918570|NCT05260515|BEHAVIORAL|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
57918571|NCT01405586|DRUG|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
57918572|NCT01405586|DRUG|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
57918573|NCT01405586|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
57918574|NCT04343638|DEVICE|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
57918575|NCT04343638|DEVICE|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
57918576|NCT04690842|DIAGNOSTIC_TEST|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
58272118|NCT04717388|RADIATION|MRI|Anatomical and functional MRI at V2
58272119|NCT02384109|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
58272120|NCT02384109|OTHER|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
58272121|NCT00087425|BIOLOGICAL|rituximab|
58272122|NCT00087425|DRUG|bryostatin 1|
58272123|NCT02356510|PROCEDURE|Primary PCI|
58272124|NCT06283680|PROCEDURE|Lung transplantation|Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.
58272125|NCT05299619|DEVICE|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
58272126|NCT02758873|GENETIC|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
57719661|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
57719662|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
57719663|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
57719664|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
57719665|NCT02239458|DRUG|Saxagliptin|
58272127|NCT02758873|GENETIC|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
58272128|NCT02758873|OTHER|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
57719666|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
57918577|NCT04470167|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
57918578|NCT04470167|OTHER|Placebo|Ultrasound-guided intratendinous placebo injection
57918579|NCT00027781|DRUG|sabarubicin|
57918580|NCT02832154|OTHER|Internet-Based Intervention|Complete online PA program
57918581|NCT02832154|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
57918582|NCT02832154|OTHER|Questionnaire Administration|Ancillary studies
57918583|NCT01340820|DRUG|AERAS-422|rBCG
57918584|NCT01340820|DRUG|BCG Tice|1-8 x 10\^5 CFU
58272129|NCT00214734|DRUG|rAHF-PFM|
58390241|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
57719667|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
57719668|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
57719669|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
57719670|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
58390242|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
57918585|NCT05316194|OTHER|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
57918586|NCT01551212|DRUG|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
57918587|NCT01551212|DRUG|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
58390243|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
58390244|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
58390245|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
58390246|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
58390247|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
57719671|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
58390248|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
57719672|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
57719673|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
57719674|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
57918588|NCT01551212|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
58390249|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
57719675|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
57719676|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
57719677|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
57719678|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
57719679|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
57719680|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
57719681|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
57719682|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
57719683|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
57719684|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
57719685|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
58064309|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
58064310|NCT05278611|DRUG|placebo|placebo
58064311|NCT03708029|OTHER|Revita Allograft|Human placental allograft
58064312|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
58272130|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
57719686|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
57719687|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
57719688|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
57719689|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
57719690|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
57719691|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
58064313|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
58064314|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
58064315|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
58064316|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
58064317|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
58064318|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
58064319|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
58064320|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
58064321|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
58272131|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
58272132|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
58272133|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
58272134|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
58272135|NCT06304922|BEHAVIORAL|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
58272136|NCT05433480|DRUG|BPI-16350|BPI-16350 400 mg, orally once daily
58272137|NCT05433480|DRUG|placebo|Placebo 400 mg, orally once daily
58272138|NCT05433480|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
58272139|NCT00507351|BEHAVIORAL|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
57719692|NCT02720484|DRUG|Nivolumab|Given IV
57719693|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
57719694|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
57719695|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
57719696|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
58064322|NCT00497744|DRUG|Intraperitoneal Cefepime|
58064323|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
57918589|NCT04520360|DRUG|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
57918590|NCT01604707|OTHER|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
57719697|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
57719698|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
57918591|NCT00062894|DRUG|Iodine I 131 Tositumomab|
58064324|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
58064325|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
57719699|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
57719700|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
57719701|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
57719702|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
57719703|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
57719704|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
58064326|NCT00837889|DRUG|diuretics, inotropica|
57719705|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
57719706|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
57719707|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
57719708|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
57719709|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
57719710|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
57918592|NCT03558594|BEHAVIORAL|Hypnosis|Behavioral Condition
57918593|NCT03558594|BEHAVIORAL|Mindfulness|Behavioral Condition
57918594|NCT03680404|DRUG|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
57918595|NCT03680404|DRUG|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
57918596|NCT03680404|DRUG|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
57918597|NCT03680404|DRUG|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
57918598|NCT00899548|GENETIC|DNA methylation analysis|laboratory analysis
57918599|NCT00899548|GENETIC|microarray analysis|laboratory analysis
58272140|NCT03084757|DIAGNOSTIC_TEST|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
57719711|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
57719712|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
57719713|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
57719714|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
57719715|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
57719716|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
57719717|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
57719718|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
57719719|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
57719720|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
57719721|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
57719722|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57918600|NCT00899548|GENETIC|polymerase chain reaction|laboratory analysis
57918601|NCT00899548|OTHER|laboratory biomarker analysis|laboratory analysis
57918602|NCT02201589|DEVICE|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
57918603|NCT00504881|DRUG|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
57918604|NCT00504881|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
57918605|NCT01966380|DEVICE|Leia|
57918606|NCT02179320|PROCEDURE|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
57918607|NCT02179320|DEVICE|acupuncture needle 0,25 x 40mm|
57918608|NCT06033651|RADIATION|x-ray|A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.
57918609|NCT02318797|BEHAVIORAL|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
57918610|NCT02318797|BEHAVIORAL|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
57918611|NCT01097785|DRUG|Simvastatin|40 mg, P.O.,daily for 30 days
57918612|NCT01097785|DRUG|Placebo|1 capsule daily for 30 days
58064327|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
58272141|NCT05149573|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
57719723|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57918613|NCT04260425|OTHER|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
57918614|NCT04260425|OTHER|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
57918615|NCT06373029|OTHER|Ultrasound examination|The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
58272142|NCT05149573|DEVICE|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
57918616|NCT00160784|PROCEDURE|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
57719724|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57719725|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57719726|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57719727|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
57719728|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
57719729|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
57918617|NCT00160784|PROCEDURE|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
57918618|NCT00160784|OTHER|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
57918619|NCT02148549|DRUG|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
58390250|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
57918620|NCT01975974|DEVICE|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
58272143|NCT05957224|OTHER|Shake 1 then Shake 2|Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
58272144|NCT05957224|OTHER|Shake 2 then Shake 1|Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
58272145|NCT00361166|DRUG|ACP-103|
58272146|NCT04529850|DRUG|Drug: GC4419|GC4419 60 Minute Infusion
58390251|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
57918621|NCT04748900|DIAGNOSTIC_TEST|spirometer|different values are measured on the spirometer after training in respiratory physiotherapy.
57918622|NCT02652403|DEVICE|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
57719730|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
57719731|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
57719732|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
57719733|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
57719734|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
57719735|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
57719736|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
57719737|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
57719738|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
57719739|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
58390252|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
58390253|NCT01091038|OTHER|Routine Care|Routine Care
58390254|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
58390255|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
58390256|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
58390257|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
58390258|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
58390259|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
58390260|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
58390261|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
58390262|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
57719740|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
57719741|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
57719742|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
57719743|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
57719744|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
57719745|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
57719746|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
57719747|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
57719748|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
57719749|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
57719750|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
57719751|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
57719752|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
58390263|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
57719753|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
57719754|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
57719755|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
57719756|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
58272147|NCT04529850|RADIATION|Intensity-modulated radiation therapy (IMRT)|2.0 to 2.2 Gy daily over 7 weeks
57719757|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
57719758|NCT05634681|RADIATION|Standard plan|One treatment plan
57719759|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
57719760|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
57719761|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
57719762|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
57719763|NCT02265705|DRUG|Baricitinib|Administered orally
57719764|NCT02265705|DRUG|Placebo|Administered orally
57719765|NCT00141960|DRUG|Famotidine|
57719766|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
57918623|NCT02652403|DEVICE|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
57719767|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
57719768|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
58064328|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
58272148|NCT04529850|DRUG|Cisplatin|100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
58272149|NCT00412594|DRUG|Cladribine|Given IV
57918624|NCT06421610|DRUG|PITAC|Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
57918625|NCT00905112|OTHER|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
57918626|NCT00905112|OTHER|Standard OB Care|Receive standard obstetrical care
57918627|NCT04044274|DEVICE|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
57918628|NCT04044274|DEVICE|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
58390264|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
57918629|NCT04032587|BEHAVIORAL|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
57918630|NCT04032587|BEHAVIORAL|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
57918631|NCT02711111|DEVICE|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
57918632|NCT02711111|DEVICE|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
58272150|NCT00412594|OTHER|Laboratory Biomarker Analysis|Correlative studies
58272151|NCT00412594|BIOLOGICAL|Rituximab|Given IV
58390265|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
58272152|NCT02476370|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
58390266|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
57918633|NCT04455438|RADIATION|SBRT dose escalation|Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
58272153|NCT02476370|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
58272154|NCT04353388|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
58272155|NCT04643964|BEHAVIORAL|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
57918634|NCT05033171|DIAGNOSTIC_TEST|3D Scanning|3D scanning of the rod using Artec Eva Spider type manual 3D scanner
57719769|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
57719770|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
57719771|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
57719772|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
57719773|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
57719774|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
57918635|NCT05033171|DIAGNOSTIC_TEST|EOS 2D/3D scanning|EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
57918636|NCT01175447|DRUG|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
57918637|NCT06143306|DRUG|bupivacaine.|an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
57918638|NCT06143306|DRUG|Saline|an ultrasound guided pectoserratus block with 25 mL of saline
57918639|NCT00494481|DRUG|Vandetanib (ZD6474)|once daily oral dose
57918640|NCT00494481|DRUG|Docetaxel|intravenous infusion
57719775|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
58390267|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
58390268|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
58390269|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
57719776|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
57719777|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
57918641|NCT05126433|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
57918642|NCT00824161|DRUG|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
57918643|NCT00647725|PROCEDURE|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
57918644|NCT00647725|PROCEDURE|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
57918645|NCT01502631|DRUG|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
57918646|NCT01502631|DRUG|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
57918647|NCT04310423|DRUG|Placebo|Matched to endotoxin
57918648|NCT04310423|BIOLOGICAL|Endotoxin|Bolus dose of 0.8 ng/kg
57918649|NCT06186570|BEHAVIORAL|Online-Based Self-Help Intervention|See the description above.
57918650|NCT02766894|DEVICE|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
57918651|NCT03875846|DIAGNOSTIC_TEST|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
57719778|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
57719779|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
58064329|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
57719780|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
57719781|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
57719782|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
57719783|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
57719784|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
57918652|NCT03875846|DIAGNOSTIC_TEST|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
58064330|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
58390270|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
58272156|NCT04643964|BEHAVIORAL|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
58390271|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
58064331|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
58064332|NCT01521494|DRUG|PA21|
58490356|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix with collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane"
57719785|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
57719786|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
57719787|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
57719788|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
57719789|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
57719790|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
57719791|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
57719792|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
57719793|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
57719794|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
57719795|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
57719796|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
58272157|NCT04643964|BEHAVIORAL|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
57719797|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
57719798|NCT04908813|DRUG|HLX22|IV Q3W D1
57719799|NCT04908813|DRUG|Placebo|IV Q3W D1
57719800|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
57719801|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
57719802|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
57719803|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
57719804|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
57719805|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
57719806|NCT05797805|DRUG|Pembrolizumab|"In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle"
57719807|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
58064333|NCT01521494|DRUG|PA21|
58064334|NCT01521494|DRUG|PA21|
57719808|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
57719809|NCT02804607|OTHER|questionnaire|
57719810|NCT05889858|OTHER|Data collection|Data collection
57719811|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
57719812|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
57719813|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
57719814|NCT00928317|DRUG|Placebo|Placebo s.c.
58064335|NCT01521494|DRUG|PA21|
58064336|NCT01521494|DRUG|Placebo|
58064337|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
58064338|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
58064339|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
58064340|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
58064341|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
58272158|NCT04643964|BEHAVIORAL|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
58272159|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
58390272|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
58390273|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
57719815|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
57719816|NCT05280574|DEVICE|GE Portrait Monitor|All patients will be monitored
57719817|NCT05280574|DEVICE|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
57719818|NCT05280574|DEVICE|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
58272160|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
58390274|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
58390275|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
58390276|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
58390277|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
58390278|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
58390279|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
57719819|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
57719820|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
57719821|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
57719822|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
57719823|NCT01650389|BIOLOGICAL|MVA85A|
57719824|NCT01650389|BIOLOGICAL|Candin|
57719825|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
57719826|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
57719827|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
57719828|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
58272161|NCT03304184|DEVICE|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
58272162|NCT03304184|DEVICE|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
58272163|NCT03745040|DRUG|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
57719829|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
58064342|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
58390280|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
58064343|NCT04346368|BIOLOGICAL|Placebo|Placebo
58064344|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
58064345|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
58064346|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
58064347|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
58272164|NCT05347290|DEVICE|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
57719830|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
57719831|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
57719832|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
58064348|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
58064349|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
57719833|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
58064350|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
58064351|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
58064352|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
58064353|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
58064354|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
58064355|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
57719834|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
58064356|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
58064357|NCT00124384|BEHAVIORAL|CBT-I|
58064358|NCT00124384|DRUG|modafinil|
58064359|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
58064360|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
58064361|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
58064362|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
58064363|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
57719835|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
57719836|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
57719837|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
57719838|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
57719839|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
57719840|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
57719841|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
57719842|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
57719843|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
57719844|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
57719845|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
57719846|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
57719847|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
57719848|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
58390281|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
57719849|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
57719850|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
58064364|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
58064365|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
58272165|NCT05347290|DEVICE|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
58064366|NCT01322711|DRUG|Placebo|Diet
58272166|NCT05347290|DEVICE|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
58272167|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
57719851|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
57719852|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
57719853|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
57719854|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
57719855|NCT01903694|DRUG|Sorafenib + Pravastatin|
57719856|NCT01903694|DRUG|Sorafenib|
58064367|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
58064368|NCT02738073|DRUG|Control: Saline|
58064369|NCT02738073|DRUG|Tranexamic Acid|
58064370|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
58064371|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
58064372|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
58064373|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
58064374|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
58064375|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
58064376|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
58272168|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
58390282|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
57719857|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
57719858|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
57719859|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
57719860|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
57719861|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
57719862|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
57719863|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
57719864|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
57719865|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
57719866|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
58272169|NCT00904839|DRUG|mFolfox|standard i.v chemotherapy
57719867|NCT04830826|PROCEDURE|Surgeries|Surgeries
57719868|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
57719869|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
57719870|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
57719871|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
57719872|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
57719873|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
57719874|NCT05409924|DRUG|ATR-258|Single Ascending Dose
57719875|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
57719876|NCT05409924|DRUG|ATR-258|Repeat Dose
57719877|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
58390283|NCT01208324|DRUG|Placebo Patch|placebo
58390284|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
58390285|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
57719878|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
57719879|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
57719880|NCT02366572|OTHER|Control|Non pulse extruded cereal
57719881|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
58272170|NCT00904839|DRUG|Bevacizumab|100 mg/Kg solution , IV infusion
58272171|NCT00904839|DRUG|mFolfox 6|IV standard chemotherapy
58272172|NCT00904839|DRUG|bevacizumab|100 mg/4 ml solution
58272173|NCT05657457|DRUG|Tenecteplase|intra-arterial tenecteplase
58272174|NCT00003028|DRUG|sabarubicin|
58272175|NCT03138200|BIOLOGICAL|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
58390286|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
58390287|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
58390288|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
58390289|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
57719882|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
57719883|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
57719884|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
57719885|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
57719886|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
57918653|NCT03616197|PROCEDURE|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
57918654|NCT03105622|BEHAVIORAL|TV and music|Watching TV or listening to music while running on a treadmill
57918655|NCT01943409|DRUG|Intralipid|soybean oil-based lipid emulsion
57918656|NCT01943409|DRUG|ClinOleic|olive oil-based lipid emulsion
57918657|NCT06085001|DIAGNOSTIC_TEST|Lumella finger prick blood test|Finger prick blood test
57918658|NCT05034120|DRUG|XZP-3621|Administer a single dose of XZP-3621 tablet after a low-fat meal.
57918659|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
57918660|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
57918661|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
57918662|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
57918663|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
57918664|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
57918665|NCT00464607|DRUG|hMG-IBSA|
57918666|NCT00464607|PROCEDURE|Ovarian stimulation|
58064377|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
58064378|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
58064379|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
58064380|NCT02196389|DEVICE|Nasal dilator Nozovent|
58064381|NCT02196389|DEVICE|Nasal dilator Breath Right|
57719887|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
57719888|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
57719889|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
57719890|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
57719891|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
57719892|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
57719893|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
57719894|NCT06571461|DRUG|S-1|S-1: Oral
57719895|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
57719896|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
57719897|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
58064382|NCT02196389|DEVICE|Nasal dilator Airmax|
58064383|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
57719898|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
58272176|NCT00540904|DRUG|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
58272177|NCT00540904|DRUG|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
58272178|NCT05353634|DIAGNOSTIC_TEST|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
57719899|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
58272179|NCT03102307|OTHER|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
58272180|NCT03102307|PROCEDURE|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
57719900|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
57719901|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
57719902|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
57719903|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
57719904|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
57918667|NCT06189560|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
58064384|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
58272181|NCT06712615|BIOLOGICAL|PG-102|PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.
57719905|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
58064385|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
58064386|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
58064387|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
58064388|NCT01985152|DRUG|Placebo|
58272182|NCT06712615|OTHER|Placebo|vehicle-based formulation for PG-102
58272183|NCT02679989|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
58272184|NCT02679989|BEHAVIORAL|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
58272185|NCT06472999|PROCEDURE|Nephroprotective measures|Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
57719906|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
57719907|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
57719908|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
57719909|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
57719910|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
57918668|NCT06189560|DRUG|SGB|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
57918669|NCT05163587|COMBINATION_PRODUCT|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
57918670|NCT02634957|BEHAVIORAL|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
57918671|NCT03048643|BEHAVIORAL|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
57918672|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
58064389|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
58064390|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
58390290|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
58390291|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
57719911|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
57719912|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
57719913|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
57918673|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
57918674|NCT03774966|PROCEDURE|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter \& IPACK block
57918675|NCT03774966|PROCEDURE|Adductor canal block + catheter|Adductor canal block + catheter
57918676|NCT05647915|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
57719914|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
58272186|NCT04373798|DIAGNOSTIC_TEST|C-reactive protein|Measurement of CRP value from blood sample taken at covid19 check point (baseline).
58390292|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
58390293|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
57719915|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
57719916|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
57719917|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
57719918|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
58064391|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
58272187|NCT05359510|PROCEDURE|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
58272188|NCT05947227|OTHER|Buteyko breathing technique|Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise
58390294|NCT01756573|DRUG|Dexamthsone|
58272189|NCT05947227|OTHER|Diaphragmatic breathing technique.|Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
58390295|NCT01756573|DRUG|Bupivacaine|
57719919|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
57719920|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
57719921|NCT02308202|DRUG|doxazosin|
57719922|NCT02308202|DRUG|Perindopril|
57719923|NCT02308202|DRUG|Placebo|
57719924|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
57719925|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
57918677|NCT05647915|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
58064392|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
58064393|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
58272190|NCT05272826|DRUG|Iberdomide|Available as formulated capsules and administered as oral medication
58272191|NCT05272826|DRUG|Bortezomib|Administered as subcutaneous injection
58272192|NCT05272826|DRUG|Dexamethasone|Administered as oral medication
58272193|NCT05272826|DRUG|Isatuximab|Administered as subcutaneous injection
58390296|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
58390297|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
58390298|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
58390299|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
58390300|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
58390301|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
58272194|NCT04226495|DRUG|Sufentanil Infusion|Intra-operative sufentanil infusion
58272195|NCT04226495|DRUG|Sufentanil Bolus|Intra-operative sufentanil bolus
58272196|NCT05104424|DRUG|Insulin aspart|intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
58272197|NCT06625411|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
58272198|NCT06625411|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
58390302|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
58390303|NCT00033423|BIOLOGICAL|rituximab|
58390304|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
58390305|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
57719926|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
57719927|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
57719928|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
57918678|NCT03169504|OTHER|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.
57918679|NCT03169504|DRUG|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
57918680|NCT03169504|OTHER|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
58272199|NCT05260424|OTHER|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
58272200|NCT01238094|DRUG|Simvastatin|simvastatin 40 mg qd daily until disease progression
58272201|NCT04181268|DEVICE|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
58272202|NCT04840524|PROCEDURE|Laminate veneers preparation|facial laminate veneers teeth preparation
58272203|NCT01792323|DRUG|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
58390306|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
58390307|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
58390308|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
58390309|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
57918681|NCT01244776|DEVICE|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
58390310|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
57719929|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
57719930|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
57918682|NCT04634656|DRUG|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
57918683|NCT04634656|DRUG|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
57918684|NCT06432608|DIETARY_SUPPLEMENT|fermented milk, Yakult|Study subjects will be provided with a product based on fermented milk, Yakult (80mL) daily for four weeks in order to know the effects of clinical manifestation of functional constipation and short-fatty acids in the Mexican population
58272204|NCT01230684|PROCEDURE|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
58272205|NCT02271724|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
58272206|NCT02271724|PROCEDURE|Blood sample|Blood sample
58272207|NCT05830669|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
58272208|NCT05830669|PROCEDURE|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
58272209|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
58272210|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
58272211|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
58390311|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
58390312|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
57719931|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
57719932|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
58064394|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
58064395|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
58064396|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
58272212|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
58272213|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
58272214|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
58272215|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
58272216|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
58064397|NCT01853397|DEVICE|Liposonix System (Model 2)|
58272217|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
58272218|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
58272219|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
58272220|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
58272221|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
58272222|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
58390313|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
57719933|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
57719934|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
58064398|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
58064399|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
58272223|NCT03407547|DIAGNOSTIC_TEST|Electroencephalography|EEG is a device to measure brain activity via surface electrodes
58272224|NCT00825656|DRUG|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
58272225|NCT05537649|DIETARY_SUPPLEMENT|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
58272226|NCT05652400|OTHER|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
58272227|NCT02647255|PROCEDURE|Plasma Exchange (PE)|PE treatment\>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
58272228|NCT02647255|DRUG|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
58272229|NCT00649233|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
58272230|NCT00649233|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
58272231|NCT00303212|OTHER|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
58272232|NCT02564406|DEVICE|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
58272233|NCT01032070|DRUG|erlotinib|oral
58272234|NCT01032070|DRUG|etoposide|oral
58272235|NCT03844594|DRUG|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
58272236|NCT02966119|DRUG|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
58390314|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
58272237|NCT01195181|DRUG|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
58272238|NCT01395173|PROCEDURE|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
58390315|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
58390316|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
58390317|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
58390318|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
58390319|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
58390320|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
57719935|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
57918685|NCT06429475|DRUG|Budesonide/formoterol|"The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years."
57918686|NCT06429475|DRUG|standard of care|Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
57918687|NCT03802942|DIETARY_SUPPLEMENT|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
57918688|NCT06423209|OTHER|Strength training program|Strength training program to be developed during 16 weeks. There will be 3 exercise sessions per week and those participants who perform at least 2 sessions during the program will be considered for the statistical analysis.
58390321|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
58390322|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
58390323|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
58390324|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
58272239|NCT01395173|PROCEDURE|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
58390325|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
58390326|NCT03370419|BEHAVIORAL|Usual care|Usual care
58390327|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
58390328|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
58390329|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
58390330|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
57719936|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
57719937|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
57719938|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
57719939|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
58272240|NCT02339155|BIOLOGICAL|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
58272241|NCT02339155|BIOLOGICAL|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
58272242|NCT02339155|DRUG|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
58272243|NCT06731712|OTHER|Physical Function Exercises|Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
58272244|NCT04394793|RADIATION|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
57918689|NCT01470313|DRUG|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
58390331|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
58390332|NCT06129591|DRUG|Lazarus Naturals THC-Free CBD Tincture (flavorless) + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessment will be done over a period of 6 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale. Statistical analysis will assess whether CBD oil improves short-term and long-term scar appearances."
58390333|NCT06129591|DRUG|Silicone patch|A non-treatment group is included in this study to comply with the standard of care, as to treat post-operative wounds with silicone patches to improve final scar outcomes.
57719940|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
57719941|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
57719942|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 4 months
57918690|NCT01470313|DRUG|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
57918691|NCT05493085|PROCEDURE|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
57918692|NCT05493085|PROCEDURE|Caudal epidural injection|Single Caudal epidural injection
58064400|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
58272245|NCT03127813|OTHER|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
57918693|NCT05430360|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
57918694|NCT04094792|DEVICE|Happify Breather App|Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
58272246|NCT01857700|OTHER|Compensation for transport cost|
58272247|NCT01857700|OTHER|Compensation for lost wages|
58272248|NCT01857700|OTHER|Compensation for transport cost and lost wages|
58272249|NCT01857700|OTHER|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
58272250|NCT00346736|PROCEDURE|Acupuncture (Procedure)|
58390334|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
58390335|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
58390336|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
58390337|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
57719943|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
57719944|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
58272251|NCT02631902|BEHAVIORAL|Exercise|Community-based exercise program with 3 weekly exercise sessions
58390338|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
58390339|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
58390340|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
58390341|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
58390342|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
58390343|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
58390344|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
57719945|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
57719946|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
57719947|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
57719948|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
57719949|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
57719950|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
57719951|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
57918695|NCT05057923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
57918696|NCT01119482|BIOLOGICAL|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
57918697|NCT00419133|BIOLOGICAL|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
57918698|NCT00419133|BIOLOGICAL|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
57719952|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
57719953|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
57719954|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
57918699|NCT00959166|OTHER|PET scan|PET brain scan
57918700|NCT04200157|OTHER|Online survey|Subjects will complete a single survey that takes 5-10 minutes to complete
57719955|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
57918701|NCT01146626|DRUG|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
57918702|NCT01146626|DRUG|Peg+ Ribavirine|Peg+ Ribavirine
57918703|NCT03701867|OTHER|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
58064401|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
58390345|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
58390346|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
58390347|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
58390348|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
58390349|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
58390350|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
58390351|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
58390352|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
58390353|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
58390354|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
58390355|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
57719956|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
57918704|NCT02019927|DEVICE|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
58272252|NCT02631902|BEHAVIORAL|Dietary intervention|Community-based dietary intervention program
58272253|NCT06731075|DRUG|ORMD-0801 8 mg|1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
58272254|NCT06731075|OTHER|Placebo capsule|Placebo capsule
58390356|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
58390357|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
58390358|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
58390359|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
58390360|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
58390361|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
58390362|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
58272255|NCT06731075|DRUG|ORMD-0801 16 mg|2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
58390363|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
58390364|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
58390365|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
58390366|NCT05523830|OTHER|No Intervention|No intervention
58390367|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
58390368|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
58390369|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
57918705|NCT02019927|DEVICE|Sham|Sham
57918706|NCT00599885|DRUG|telmisartan|telmisartan 40-80mg once per day for 8 months
58272256|NCT06730178|BEHAVIORAL|relaxation training|The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
58390370|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
58390371|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
58390372|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
58390373|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
58390374|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
58390375|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
58390376|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
58390377|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
58390378|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
58390379|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
57918707|NCT00599885|DRUG|valsartan|valsartan 80-160mg once per day for 8 months
57918708|NCT01657955|DRUG|Bendamustine Hydrochloride Injection|
57918709|NCT01657955|DRUG|Chlorambucil|
58272257|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
58272258|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
58272259|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
58272260|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
58390380|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
58390381|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
58390382|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
58390383|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
58390384|NCT02469701|DRUG|nivolumab and ablation|
58390385|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
58390386|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
58390387|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
58390388|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
58390389|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
58390390|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
57918710|NCT03587974|BEHAVIORAL|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
57918711|NCT01745848|DRUG|Roflumilast|
57918712|NCT05159869|BEHAVIORAL|User-Led Meaningful Activity Plan|The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
57918713|NCT06082583|DEVICE|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
58272261|NCT05605509|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
58272262|NCT01249833|DRUG|Oseltamivir|Oseltamivir 75mg BID for 5 days
58272263|NCT02007044|DRUG|Ibrutinib|Given PO
58272264|NCT02007044|OTHER|Quality-of-Life Assessment|Ancillary studies
58272265|NCT02007044|OTHER|Questionnaire Administration|Ancillary studies
58390391|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
58390392|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
58064402|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
58064403|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
58272266|NCT02007044|BIOLOGICAL|Rituximab|Given IV
58272267|NCT06731114|PROCEDURE|Suboccipital muscle release|"Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total"
58272268|NCT06731114|PROCEDURE|Conventional physical therapy|TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks
58390393|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
58064404|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
58064405|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
58064406|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
58272269|NCT06731114|PROCEDURE|Sternocleidomastoid release|Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
58272270|NCT01440387|BIOLOGICAL|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
58272271|NCT05161078|DEVICE|CARPEDIEM|CARPEDIEM treatment as per local standard of care
58272272|NCT00156000|DEVICE|Fetal Fibronectin|fFN test done during pregnancy
58272273|NCT00156000|DEVICE|Salivary Estriol|Salivary Estriol done during pregnancy
58390394|NCT00004573|DRUG|ganciclovir|
58390395|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
58390396|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
58390397|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
58390398|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
58390399|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
58390400|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
58390401|NCT01221753|DRUG|docetaxel|
58390402|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
58390403|NCT01221753|DRUG|5-FU|
58390404|NCT01221753|RADIATION|IMRT|
58390405|NCT01221753|DRUG|cetuximab|
58390406|NCT01221753|DRUG|carboplatin|
58390407|NCT05262777|DEVICE|GP0112|Injectable gel
58390408|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
58390409|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
58390410|NCT00056576|DRUG|Zonisamide|
58390411|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
58390412|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
58390413|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
58390414|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
58390415|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
58390416|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
57918714|NCT06082583|DRUG|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
57918715|NCT02770573|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
57918716|NCT02770573|OTHER|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
57918717|NCT02770573|OTHER|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
57918718|NCT05540054|OTHER|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
57918719|NCT05540054|OTHER|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
58390417|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
58390418|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
58390419|NCT06200597|DRUG|LAD603|LAD603 SC injection.
58390420|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
58390421|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
58390422|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
58390423|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
58390424|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
58390425|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
57918720|NCT06081582|DRUG|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
57918721|NCT01235104|PROCEDURE|Total nephrectomy|Total nephrectomy
57918722|NCT03883425|OTHER|interRAI-HC assessments|Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses
58272274|NCT04747990|PROCEDURE|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
57918723|NCT00066989|DRUG|Staphylococcus aureus Immune Globulin (Human) 5%|
58064407|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
58064408|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
58064409|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
58064410|NCT01602627|OTHER|pharmacological study|Correlative studies
58272275|NCT05245045|PROCEDURE|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
58390426|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
58390427|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
58390428|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
58390429|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
58390430|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
58390431|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
58390432|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
58390433|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
58272276|NCT05245045|PROCEDURE|Red light|Red light
58272277|NCT03062995|OTHER|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
58272278|NCT03062995|OTHER|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
58272279|NCT01451554|BEHAVIORAL|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
58272280|NCT01451554|BEHAVIORAL|Usual Care|self-help booklets
58272281|NCT03907930|PROCEDURE|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
58272282|NCT03986554|PROCEDURE|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
57918724|NCT05960253|PROCEDURE|Pericapsular Nerve Group Block|1st group to be applied PENG block
57918725|NCT05960253|PROCEDURE|Lumber Erector Spinae Plane Block|2nd group to be applied Lumber ESP block
58064411|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
58064412|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
58272283|NCT03986554|PROCEDURE|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (\< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
58390434|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
58390435|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
58390436|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
58390437|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
58390438|NCT05778864|DRUG|LY3473329|Administered orally.
58390439|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
58390440|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
57719957|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
57719958|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
57918726|NCT02587468|DIETARY_SUPPLEMENT|Juice Plus+(R)|before-after comparison of plasma phenolics
58064413|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
58272284|NCT05740345|DRUG|Metformin|Metformin
58272285|NCT03386604|DIETARY_SUPPLEMENT|Whey protein|whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
58272286|NCT03386604|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin energy value 160 kcal.
58272287|NCT02219776|DRUG|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
58390441|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
58390442|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
58390443|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
57719959|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
57719960|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
57719961|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
57719962|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
57719963|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
58064414|NCT02963194|DRUG|Oxytocin|
58064415|NCT02963194|DRUG|Placebo|
58064416|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
57918727|NCT05399043|OTHER|Multidisciplinary Conventional Neuromotor Rehabilitation|Patients will receive conventional treatment consisting of two daily one-hour session (4 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
58272288|NCT02219776|OTHER|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
57918728|NCT05399043|DEVICE|Technology-based Rehabilitation|"According to their individualized rehabilitation project, patients will undergo RAT or non-immersive VR-based rehabilitation.~RAT will consist of three times a week one-hour session (4 weeks) and will be conducted by the implementation of an exoskeleton device for the upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™).~VR-based rehabilitation will consist of one daily one-hour session (4 weeks) and will be conducted by the implementation of a single non-immersive VR device among the Riablo™ (Corehab, Italy), the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), the Walker View™ (TechnoBody SRL, Italy).~Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants."
57918729|NCT00000837|BIOLOGICAL|Varicella Virus Vaccine (Live)|
57918730|NCT06432894|COMBINATION_PRODUCT|Analgesia Nociception Index, remimazolam|"The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam.~During this study, remimazolam infusion rate is determined by the pharmacopoeia.~Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model.~ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery."
57918731|NCT03063112|DEVICE|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
57918732|NCT03063112|DRUG|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
57918733|NCT03063112|DEVICE|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
57918734|NCT03063112|DRUG|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
57918735|NCT01098565|DEVICE|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
58272289|NCT03568032|DIAGNOSTIC_TEST|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
58390444|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
58390445|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
57918736|NCT05786989|DRUG|selinexor|Given PO
57918737|NCT03589092|GENETIC|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
57918738|NCT05603130|OTHER|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
57918739|NCT06351527|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol
57918740|NCT00440258|DRUG|Cabergoline|
57918741|NCT00440258|PROCEDURE|MR|
58272290|NCT03568032|DIAGNOSTIC_TEST|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
58272291|NCT03568032|DIAGNOSTIC_TEST|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
58272292|NCT03568032|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Cognitive assessment
58272293|NCT03568032|OTHER|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
57918742|NCT00440258|PROCEDURE|Ultrasound|
57918743|NCT00440258|PROCEDURE|Blood Analysis|
58272294|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
58272295|NCT06378632|DEVICE|Hearo App|No intervention - only data collection
58272296|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
58272297|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
58272298|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
58272299|NCT06730347|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
58272300|NCT02539134|DRUG|TAK-935|TAK-935 oral solution
58272301|NCT02539134|DRUG|Placebo|TAK-935 placebo-matching oral solution
58390446|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
57719964|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
57918744|NCT05581667|OTHER|post isometric relaxation|PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
57918745|NCT05581667|OTHER|Swedish Massage|classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
57918746|NCT05511792|PROCEDURE|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
57918747|NCT05511792|PROCEDURE|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
57918748|NCT05782426|DRUG|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
57918749|NCT03952494|GENETIC|Genomind®Professional PGx Express TM|The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
57918750|NCT02440230|DRUG|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
57918751|NCT02440230|DRUG|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
57918752|NCT01030198|DEVICE|RevLite (Laser Treatment)|
57918753|NCT02301598|PROCEDURE|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
57918754|NCT04271501|PROCEDURE|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
58272302|NCT01159288|BIOLOGICAL|Dex2|"* Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~* Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~* Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
57918755|NCT04271501|DEVICE|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
57918756|NCT04271501|DEVICE|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
57918757|NCT04271501|DEVICE|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
57918758|NCT00140309|DRUG|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
57918759|NCT03346161|OTHER|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
57918760|NCT03346161|OTHER|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
58064417|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
58390447|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
58390448|NCT01958580|DRUG|Docetaxel|Given IV
58272303|NCT06710457|OTHER|ESP|Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.
58390449|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
58390450|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58390451|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
58390452|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
58390453|NCT06215820|DRUG|MR-107A-02|tablet
58390454|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
58390455|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
58390456|NCT01454609|DRUG|0.9% Normal saline|Saline
58390457|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
57719965|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
58272304|NCT06710457|OTHER|No ESP|Patients will receive standard medical treatment to prevent PONV and postoperative pain.
57719966|NCT00036166|DRUG|FK463|
57719967|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
57719968|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
57719969|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
57719970|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
58272305|NCT06055998|DEVICE|MRI|MRI SPINE
58390458|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
57719971|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
57719972|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
57719973|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
58272306|NCT01323504|OTHER|Music|Patient are listen music during their local care
58272307|NCT01323504|OTHER|no music|There are no music during the local care
58272308|NCT06718036|OTHER|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
58272309|NCT04512365|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
58272310|NCT04512365|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
58272311|NCT05922813|BIOLOGICAL|BMI2004|hyaluronidase, recombinant
58272312|NCT05922813|OTHER|0.9% NaCl|Normal Saline
58272313|NCT04544943|DRUG|BioLexa- Cohort 1|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
58390459|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
58390460|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
58390461|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
58390462|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
58390463|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
58390464|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
58390465|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
58390466|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
58490357|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix (MPM) without collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM."
58272314|NCT04544943|DRUG|BioLexa- Cohort 2|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
58390467|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
57719974|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
57719975|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
57719976|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
57719977|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
57719978|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
57719979|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
57719980|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
57719981|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
57719982|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
58272315|NCT04544943|DRUG|Placebo|Twice daily (BID) application of placebo for 14 days
58272316|NCT04544943|DRUG|Gentamicin|Twice daily (BID) application of Gentamicin for 14 days
57719983|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
57719984|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
57719985|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
57719986|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
58272317|NCT05604326|BEHAVIORAL|Pathways Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.
58272318|NCT05604326|BEHAVIORAL|Parent Education Intervention (PEI)|Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
58272319|NCT04072731|OTHER|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
58272320|NCT01643798|PROCEDURE|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
58272321|NCT01643798|PROCEDURE|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
58272322|NCT06132113|DRUG|BI 764532|BI 764532
58272323|NCT06132113|DRUG|Carboplatin|Standard of care
58272324|NCT06132113|DRUG|Etoposide|Standard of care
58272325|NCT06132113|DRUG|Cisplatin|Standard of care
58272326|NCT06291740|DEVICE|continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
58272327|NCT06291740|DEVICE|Intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
58272328|NCT02607280|DRUG|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
57719987|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
58390468|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
58390469|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
58390470|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
58390471|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
57719988|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
57719989|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57719990|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
57918761|NCT03346161|OTHER|Usual Care Group - Outcome Measures|"* Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
57918762|NCT03346161|OTHER|Decision Group - Outcome Measures|"* Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
58272329|NCT05703464|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
58272330|NCT04693468|DRUG|Axitinib|Given PO
58272331|NCT04693468|DRUG|Crizotinib|Given PO
58272332|NCT04693468|DRUG|Palbociclib Isethionate|Given PO
58272333|NCT04693468|DRUG|Talazoparib Tosylate|Given PO
58272334|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
58272335|NCT01656187|DRUG|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
58272336|NCT01656187|DRUG|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
58390472|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
58390473|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
58390474|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
58390475|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
58390476|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
58390477|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
58390478|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
58390479|NCT02243319|DRUG|HGP1201|
58390480|NCT02243319|DRUG|HGP0904|
58390481|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
58490358|NCT04321707|RADIATION|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
57719991|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
57719992|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
57719993|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic.
57719994|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
57719995|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
57719996|NCT01867684|OTHER|Psychotherapy|
57719997|NCT03853707|DRUG|Atezolizumab|Given IV
57719998|NCT03853707|DRUG|Capecitabine|Given PO
57719999|NCT03853707|DRUG|Carboplatin|Given IV
57720000|NCT03853707|DRUG|Ipatasertib|Given PO
57720001|NCT03853707|DRUG|Paclitaxel|Given IV
57720002|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
57720003|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
57720004|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
57720005|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
58272337|NCT03743480|OTHER|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
58272338|NCT00694720|DRUG|AVE0657|capsules once a day at bedtime
58272339|NCT00694720|DRUG|placebo|capsules once a day at bedtime
57720006|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
57720007|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
57720008|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
57720009|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
58390482|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
58390483|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
57720010|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
58390484|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
58390485|NCT00763191|OTHER|examination of ocular movements|
58390486|NCT00763191|OTHER|MATTIS test|
57720011|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
57720012|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
57720013|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
58272340|NCT03398239|DEVICE|Noninvasive mechanical ventilation|
58272341|NCT03284112|BEHAVIORAL|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
58272342|NCT03284112|BEHAVIORAL|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
58272343|NCT04267159|OTHER|Acute cardioversion|Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
58272344|NCT04267159|OTHER|Delayed cardioversion|Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
58390487|NCT00763191|OTHER|UPDRS test|
58390488|NCT00763191|OTHER|CRST test|
57918763|NCT03346161|OTHER|Demographic and Background Questions|"* Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
58064418|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
58064419|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
58064420|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
58064421|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
58064422|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
58064423|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
58390489|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
57720014|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
58064424|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
58064425|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
58064426|NCT02220608|BIOLOGICAL|Bortezomib|
58064427|NCT02220608|DRUG|G-CSF|
58064428|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
58272345|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
58390490|NCT01876303|OTHER|questionnaire administration|Ancillary studies
57720015|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
57720016|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
57918764|NCT06074965|DEVICE|Medtronic Extended Infusion Set|Each subject will be given 2 types of infusion sets to wear and change sets per label use (3 days for Medtronic Quick-set™ and 7 days for Medtronic Extended).
57918765|NCT04789278|OTHER|Notification|Notification of coronary calcium to the patient and their clinician
58064429|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
58064430|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
58064431|NCT02438111|GENETIC|metagenome|metagenome
58064432|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
57918766|NCT04483245|BIOLOGICAL|Blood sampling|Blood sampling
57918767|NCT01046890|DRUG|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
58064433|NCT02429076|DRUG|Placebo|normal saline
58064434|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
58064435|NCT02429076|DRUG|Propofol|IV anesthetic
58064436|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
58064437|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
58390491|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
58390492|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
58064438|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
58390493|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
58390494|NCT00025792|DRUG|Pramipexole|
57918768|NCT06033014|OTHER|PM HeartIHD prediction|The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.
57918769|NCT00500162|BEHAVIORAL|Tri-Luma Maintenance regimen|
58064439|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
58064440|NCT00752518|DRUG|bortezomib|
58064441|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
58064442|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
58064443|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
58064444|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
58064445|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
58064446|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
58064447|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
58064448|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
58064449|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
58272346|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
58390495|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
58390496|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
58272347|NCT06721637|COMBINATION_PRODUCT|Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.|Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds
58064450|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
57918770|NCT03609684|OTHER|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
57918771|NCT03609684|OTHER|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
57918772|NCT03609684|OTHER|Sedentary Group|People who are not interested in any sports and don't do any exercises
57918773|NCT04094025|DRUG|dATS|d-Amphetamine Transdermal System
58064451|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
58064452|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
58390497|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
58390498|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
58390499|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
57720017|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
57720018|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
57720019|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
58272348|NCT06721637|DEVICE|Group B (n = 20): received whole body vibration trained three times a week for 8 weeks|The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
58272349|NCT06446349|OTHER|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
58272350|NCT00829829|OTHER|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
58390500|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
58390501|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
58390502|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
57720020|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
57720021|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
57720022|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
57720023|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
57918774|NCT00799513|DRUG|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
57918775|NCT04125030|OTHER|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
57918776|NCT00703898|DRUG|nevirapine|200 mg/day twice a day
58390503|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
57918777|NCT01852474|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
57918778|NCT04805775|DRUG|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
57918779|NCT05293210|DRUG|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
57918780|NCT01190982|DRUG|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
58390504|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
58390505|NCT02398136|DRUG|Ketamine|
58390506|NCT02398136|DRUG|Midazolam|
58390507|NCT05962151|DRUG|Nalbuphine ER|Oral tablets
58390508|NCT05962151|DRUG|Placebo|Oral tablets
57918781|NCT00200434|DRUG|Nebivolol|
58390509|NCT01732029|OTHER|Normobaric hypoxia chamber|
58390510|NCT00192764|DRUG|high-dose cyclophosphamide|
58390511|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
57918782|NCT03488433|DEVICE|Abduction brace|Donjoy Ultrasling IV
57918783|NCT03488433|DEVICE|Antirotation sling|Donjoy shoulder immobilizer
57918784|NCT00622349|DRUG|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
57918785|NCT00622349|DRUG|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
57918786|NCT00622349|DRUG|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
57918787|NCT02303691|BEHAVIORAL|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
58390512|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
58390513|NCT04153981|DRUG|Insulin Glargine|Administered SC
57918788|NCT02303691|BEHAVIORAL|Neutral Training|A control version of computerized attention training.
57918789|NCT05776212|RADIATION|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
58272351|NCT00829829|DRUG|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
58390514|NCT02901249|DRUG|sertraline|
58390515|NCT02901249|DRUG|Nortriptyline|
58390516|NCT02901249|DRUG|Lithium|
58390517|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
58390518|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
58390519|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
58390520|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
58490359|NCT04396561|DRUG|Paravertebral group (group P):|"In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels."
57720024|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
57720025|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
57720026|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
57720027|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
57720028|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
57720029|NCT00007800|BEHAVIORAL|Motivational Interviewing|
57720030|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
57918790|NCT02528383|BEHAVIORAL|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life"
57918791|NCT05857631|RADIATION|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
57918792|NCT05857631|DRUG|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
58272352|NCT00829829|DRUG|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
57918793|NCT05857631|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
58272353|NCT03734900|OTHER|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
58390521|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
57720031|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
57918794|NCT00078611|DRUG|natalizumab|
58390522|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
58490360|NCT00405600|PROCEDURE|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
57720032|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
57720033|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
57918795|NCT02573220|BIOLOGICAL|Cetuximab|Given IV
57918796|NCT02573220|DRUG|Fluorouracil|Given IV
57918797|NCT02573220|DRUG|Irinotecan Hydrochloride|Given IV
57918798|NCT02573220|DRUG|Leucovorin Calcium|Given IV
57918799|NCT05390411|BEHAVIORAL|SOCIAL HF|participate in SOCIAL HF training
57918800|NCT00180323|DEVICE|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
57918801|NCT01535755|DEVICE|protocol|In this group, the patients were weaned as the protocol.
57918802|NCT01535755|OTHER|physician's orders|In this group, the patients were weaned as the clinicians' order.
57918803|NCT02877563|OTHER|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
58272354|NCT03734900|BIOLOGICAL|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
58272355|NCT03734900|BIOLOGICAL|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
57720034|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
57720035|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
57720036|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
57720037|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
57720038|NCT02928692|DRUG|Minocycline|
57720039|NCT02928692|DRUG|Placebo|
57720040|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
57720041|NCT03639155|DRUG|vadadustat test tablets|oral tablet
58064453|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
58490361|NCT01458041|DRUG|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
58490362|NCT01429740|DRUG|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
57720042|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
57720043|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
57720044|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
57720045|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
57720046|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
57720047|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
57720048|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
58272356|NCT05844150|DRUG|PM8002|IV infusion
58490363|NCT01429740|DRUG|Placebo|Placebo oral solution or capsules
58490364|NCT02670239|PROCEDURE|normothermic ex vivo lung perfusion|
58272357|NCT05844150|DRUG|Platinum|IV infusion
58272358|NCT05844150|DRUG|Atezolizumab|IV infusion
58272359|NCT05844150|DRUG|Etoposide|IV infusion
58272360|NCT05961345|OTHER|late mobilization|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
58272361|NCT06111872|DRUG|Ketamine|Administration described in arm/ group description
58272362|NCT06111872|DRUG|Midazolam|Administration described in arm/ group description
57720049|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
57720050|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
57720051|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
57720052|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
57720053|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
57720054|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
57720055|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
57720056|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
57720057|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
57720058|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
57720059|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
57720060|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
57720061|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
57720062|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
58272363|NCT06111872|DRUG|Pethidin|Administration described in arm/ group description
58272364|NCT00370097|DRUG|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
57720063|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
57918804|NCT05963529|OTHER|Humidity-ramp protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
57918805|NCT05963529|OTHER|Above-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
57918806|NCT05963529|OTHER|Below-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
57918807|NCT05963529|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
57918808|NCT04151797|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician"
57918809|NCT04698941|DRUG|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.
57918810|NCT04698941|DRUG|Simvastatin|20mg daily oral tablet taken.
57918811|NCT00251420|PROCEDURE|writing about disease|writing about physical or emotional consequences of pulmonary disease
57918812|NCT06262685|OTHER|Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines|"Atorvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
57918813|NCT06262685|OTHER|Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines|"Simvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
58064454|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
58064455|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
58064456|NCT00028015|DRUG|SarCNU|
58064457|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
58064458|NCT02798159|DRUG|TD0025|
58064459|NCT02798159|DRUG|Sildenafil Citrate 50mg|
57720064|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
58064460|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
58064461|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
58064462|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
58064463|NCT03010358|DRUG|Entospletinib|Given PO
58490365|NCT06210321|OTHER|Prescription of escitalopram using pharmacogenetic testing|Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
57720065|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
57720066|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
57720067|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
57720068|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
57720069|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
58064464|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
58064465|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
58064466|NCT03010358|OTHER|Pharmacological Study|Correlative studies
58064467|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
58490366|NCT00063843|BIOLOGICAL|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
58490367|NCT01780220|DRUG|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
58490368|NCT00004669|DRUG|hydrocortisone|
57720070|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
58272365|NCT00370097|DRUG|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
57720071|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
57720072|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
57720073|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
57720074|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
57720075|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
57720076|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
57918814|NCT06262685|OTHER|Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines|"Pitavastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
58064468|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
57918815|NCT06262685|OTHER|Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines|"Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
58272366|NCT01756508|DRUG|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
57918816|NCT06262685|OTHER|Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines|"Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
58064469|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
58064470|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
58064471|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
58064472|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
58064473|NCT01196065|DRUG|RO5313534|single oral dose
58064474|NCT01196065|DRUG|memantine|multiple doses to steady state
58064475|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
58064476|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
58064477|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
58272367|NCT04291495|DIAGNOSTIC_TEST|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
58272368|NCT06147089|BEHAVIORAL|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
58490369|NCT00152919|DRUG|Meloxicam|
58490370|NCT00080899|DRUG|fenretinide|Given orally
58490371|NCT00080899|OTHER|laboratory biomarker analysis|Correlative studies
58490372|NCT06133062|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
57720077|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
58064478|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
58064479|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
57720078|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
57918817|NCT06262685|OTHER|Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines|"Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
57918818|NCT06262685|OTHER|Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines|"Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
58064480|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
58272369|NCT06147089|BEHAVIORAL|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
57918819|NCT06262685|OTHER|Standard of Care (SoC) dosing of atorvastatin|Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
58272370|NCT03174288|OTHER|Exercise|24 weeks of exercise treatment
58272371|NCT03174288|DRUG|Spironolactone|24 weeks of spironolactone
58390523|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
57720079|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
57720080|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
57720081|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
57720082|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
57720083|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
57720084|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
57918820|NCT06262685|OTHER|Standard of Care (SoC) dosing of simvastatin|Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
58064481|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
58064482|NCT02204267|DEVICE|ECG|
58064483|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
58064484|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
58064485|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
58064486|NCT02576951|DRUG|Galcanezumab|Administered SC
58064487|NCT02576951|DRUG|Placebo|Administered SC
58064488|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
58064489|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
58272372|NCT01349933|DRUG|Akt inhibitor MK2206|Given PO
58272373|NCT00792116|BEHAVIORAL|Gum Chewing|
58272374|NCT04108949|BEHAVIORAL|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
57720085|NCT00003945|DRUG|cisplatin|
58064490|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
57720086|NCT00003945|DRUG|topotecan hydrochloride|
57720087|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
58272375|NCT04108949|BEHAVIORAL|Treatment as usual|See description included in arm/Group description.
58272376|NCT01160835|PROCEDURE|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
58272377|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
58272378|NCT00524173|DRUG|Tenofovir & Emtricitabine|
58272379|NCT00524173|DRUG|Tenofovir|
58272380|NCT04156945|BEHAVIORAL|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
58272381|NCT04156945|DIAGNOSTIC_TEST|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
58272382|NCT05008393|DRUG|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
57720088|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
57918821|NCT06262685|OTHER|Standard of Care (SoC) dosing of pitavastatin|Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
57918822|NCT06262685|OTHER|Standard of Care (SoC) dosing of rosuvastatin|Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
57918823|NCT06262685|OTHER|Standard of Care (SoC) dosing of prasavastatin|Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
58064491|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
58272383|NCT05008393|DRUG|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
58272384|NCT05008393|DRUG|Placebo|Patients will receive placebo daily for 10 days.
58272385|NCT00235781|DRUG|Thymoglobulin|
58272386|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
58272387|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
58272388|NCT02893111|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
58272389|NCT02706171|RADIATION|CyberKnife|
58272390|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
58272391|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
58272392|NCT00394134|BEHAVIORAL|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
58272393|NCT01881087|DRUG|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
57720089|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
58272394|NCT00555126|DEVICE|Forced Air Warming|Warming after Randomization
58272395|NCT00555126|DEVICE|Warming with endovascular catheter + forced air warming|Warming after Randomization
58390524|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
58272396|NCT03601572|OTHER|No intervention|No intervention
58272397|NCT00711607|DRUG|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
58272398|NCT06075810|DRUG|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
58390525|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
57720090|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
58064492|NCT01825759|DRUG|danshen dripping pill|
57720091|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
58272399|NCT01724801|RADIATION|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
58272400|NCT01724801|DRUG|Icotinib|administered orally at a dose of 125 mg 3 times daily
58272401|NCT03006068|DRUG|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
58272402|NCT03006068|DRUG|Placebo|Placebo will be administered orally.
57918824|NCT06262685|OTHER|Standard of Care (SoC) dosing of lovastatin|Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
58272403|NCT00667186|OTHER|Targeted Screening|Selection method for screening is based on risk
58272404|NCT00667186|OTHER|Routine Screening|Selection method for screening is not based on risk
58390526|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
58064493|NCT05327309|DRUG|Bleomycin|
58064494|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
58272405|NCT00752869|DRUG|dutasteride|0.5mg by mouth one time per day for 1 year
58272406|NCT00752869|DRUG|placebo|one tablet per day for 1 year
58272407|NCT06731166|BEHAVIORAL|self-care|Videomonitoring provide by cardiovascular nurses
58272408|NCT04652700|DRUG|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
58390527|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
58064495|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
58064496|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
58272409|NCT04652700|DRUG|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
58272410|NCT04652700|DRUG|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
58272411|NCT04652700|DRUG|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
58272412|NCT04652700|DRUG|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
58272413|NCT04652700|DRUG|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
58272414|NCT00077116|DRUG|busulfan|
58272415|NCT00077116|DRUG|cyclophosphamide|
58272416|NCT00077116|DRUG|cytarabine|
58272417|NCT00077116|DRUG|gemtuzumab ozogamicin|
58272418|NCT00077116|DRUG|idarubicin|
58272419|NCT00077116|PROCEDURE|allogeneic bone marrow transplantation|
58272420|NCT00077116|PROCEDURE|peripheral blood stem cell transplantation|
57918825|NCT06262685|OTHER|Standard of Care (SoC) dosing of fluvastatin|Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
57918826|NCT00260663|PROCEDURE|Group hearing aid fittings|
57918827|NCT00260663|PROCEDURE|Group hearing aid follow-up|
57918828|NCT00589654|OTHER|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
58064497|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
58064498|NCT02150785|DRUG|Streptokinase|
58272421|NCT00077116|RADIATION|radiation therapy|
58272422|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
58272423|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
58272424|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
58272425|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
58272426|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
58272427|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
58272428|NCT05853211|COMBINATION_PRODUCT|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
58272429|NCT05216458|BEHAVIORAL|Emails and letter intervention|Emails and letters for households assigned to the treatment group
58272430|NCT05216458|BEHAVIORAL|Control group|No outreach during the intervention period.
58272431|NCT04853108|OTHER|Remote Monitoring of COVID-19|Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
58272432|NCT00112255|BEHAVIORAL|Practice nurse-led partner notification|
58272433|NCT00112255|BEHAVIORAL|Referral to specialist genitourinary clinic|
58272434|NCT00893906|BIOLOGICAL|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
58272435|NCT00893906|BIOLOGICAL|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
58272436|NCT06731621|DRUG|Psilocybin|"2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021)."
58272437|NCT06221813|BIOLOGICAL|PHV02|Nipah virus vaccine
58272438|NCT06221813|BIOLOGICAL|Lactated Ringer's|Placebo
58272439|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
58272440|NCT06358430|DRUG|Cyclophosphamide|Given by IV
58272441|NCT06358430|DRUG|Cetuximab|Given by IV
58272442|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
58272443|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
58272444|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
58272445|NCT03383952|BIOLOGICAL|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
58272446|NCT03790605|DRUG|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
58272447|NCT03790605|OTHER|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
58272448|NCT03790605|PROCEDURE|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
58272449|NCT05677230|PROCEDURE|Balloon occluded/plug assisted retrograde transvenous obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
58272450|NCT05677230|PROCEDURE|Endoscopic Variceal Obturation|Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
58272451|NCT03715231|OTHER|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
58272452|NCT03715231|OTHER|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
57918829|NCT01005433|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
58272453|NCT02671825|DRUG|PUR0200|PUR0200 dry powder inhalation
58272454|NCT02671825|DRUG|Reference Product|Dry Powder Inhalation Reference Product
58272455|NCT03442374|OTHER|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
58272456|NCT01093651|DRUG|Sitagliptin|100 mg sitagliptin daily for 4-6 months
58272457|NCT01093651|DRUG|Placebo|Daily placebo for 4-6 months
58272458|NCT06241066|OTHER|no-Intervention|no-Intervention
58272459|NCT06731296|OTHER|Presence of a risk factor|Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
58272460|NCT01507714|PROCEDURE|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
58272461|NCT03946228|BEHAVIORAL|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
58272462|NCT04266704|BEHAVIORAL|Sharing Intervention|intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
58272463|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
58272464|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Boost motivation and self-efficacy|"In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!."
58272465|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Future-selves and implementation intentions|"In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker."
58390528|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
58390529|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
57918830|NCT01005433|DRUG|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
57918831|NCT00484731|PROCEDURE|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
57918832|NCT00484731|PROCEDURE|Infiltration with Bupivacaine|
58390530|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
57918833|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.
57918834|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
57918835|NCT02210234|DIETARY_SUPPLEMENT|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
58064499|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
58064500|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
58064501|NCT06464276|OTHER|No intervention|No intervention
58390531|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
57720092|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
57720093|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
57720094|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
58064502|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
58390532|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
58390533|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
58390534|NCT02952313|DEVICE|Nasal Implant|
57720095|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
58390535|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
57720096|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
58390536|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
57720097|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
57720098|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
57918836|NCT02210234|DIETARY_SUPPLEMENT|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
57918837|NCT06178406|BEHAVIORAL|dysmenorrhea|Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.
57918838|NCT06176677|DEVICE|Videolaryngoscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
58390537|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
58390538|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
58390539|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
58390540|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
57720099|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
58390541|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
57720100|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
57720101|NCT01470027|DRUG|Placebo|effervescent tablets
57720102|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
57720103|NCT04067141|DEVICE|somofilcon A|Contact Lens
57720104|NCT04067141|DEVICE|nelfilcon A|Contact Lens
57720105|NCT00151801|DRUG|estroprogestins|
58390542|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
57720106|NCT00151801|DRUG|interferon-beta 1a|
58390543|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
57720107|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
57720108|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
57720109|NCT02174094|DRUG|Clobazam|
57720110|NCT02174094|DRUG|Placebo|
57720111|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
57720112|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
57720113|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
57720114|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
57918839|NCT06176677|DEVICE|Boroscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
58390544|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
58390545|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
58390546|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
57720115|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
57720116|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
57720117|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
57720118|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
57918840|NCT02736773|OTHER|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
57918841|NCT01306097|DRUG|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
57918842|NCT05752539|DEVICE|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
57918843|NCT03328403|DEVICE|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
58390547|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
58390548|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
58390549|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
58390550|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
58390551|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
57720119|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
57720120|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
57720121|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
57918844|NCT03328403|DEVICE|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
58064503|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
58064504|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
58276747|NCT01819844|DEVICE|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose \> 2 u/kg).
58390552|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
58390553|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
57720122|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
58390554|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
58390555|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
57720123|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
57918845|NCT02853357|OTHER|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
58390556|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
58390557|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
58390558|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
57720124|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
57720125|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
57720126|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
57720127|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
57720128|NCT01717417|DEVICE|miniscrew|
57720129|NCT01717417|DEVICE|TPA|
57720130|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
58390559|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
58390560|NCT03989349|DRUG|Placebo|Placebo
58390561|NCT03989349|DRUG|Nemolizumab|Nemolizumab
58390562|NCT04333979|OTHER|Drainage|Using drain after operation
58390563|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
58390564|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
58390565|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
57720131|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
58390566|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
58390567|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
58390568|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
57720132|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
57720133|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
57720134|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
57720135|NCT01569334|BIOLOGICAL|blood samples|
57720136|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
57720137|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
57720138|NCT05352074|PROCEDURE|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
57918846|NCT02853357|OTHER|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
58390569|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
58390570|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
58390571|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
58390572|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
58390573|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
58390574|NCT04701853|OTHER|Usual care|Care according to each center.
58390575|NCT00062855|PROCEDURE|Skin Biopsy|
58272466|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Identity-related positive self-talk|"In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud.."
58272467|NCT05654545|BEHAVIORAL|Attention control dialog: neutral topic|"The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!)."
58272468|NCT04151745|PROCEDURE|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
58390576|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
57720139|NCT05352074|PROCEDURE|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
57720140|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
58064505|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
58064506|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
58064507|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
57720141|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
58064508|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
58272469|NCT06221098|PROCEDURE|bilateral medial rectus recession|release muuscle from its original insertion and backword inserted in sclera
58272470|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
58272471|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
58390577|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
58390578|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
57720142|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
58064509|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
58064510|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
57720143|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
57720144|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
57720145|NCT00194012|DRUG|Placebo|Addressed in arm description.
57720146|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
57720147|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
57720148|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
58272472|NCT06099431|PROCEDURE|Mandibular marginal resection and reconstruction|Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
57720149|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
57720150|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
57720151|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
57720152|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
57720153|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
58272473|NCT06099431|DEVICE|mandibular osteosynthesis a 2.3mm reconstruction bone plate|a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
58272474|NCT02616718|RADIATION|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
58272475|NCT02736591|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
58272476|NCT02736591|DRUG|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
58272477|NCT02736591|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
58272478|NCT02736591|DRUG|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
58272479|NCT02612350|GENETIC|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
57720154|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
58272480|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
57720155|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
57720156|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
57720157|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
57720158|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
58064511|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
58064512|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
58272481|NCT06390761|PROCEDURE|Acupuncture|All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.
57720159|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
57720160|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
58064513|NCT03965234|DRUG|Cisplatin|Given via infusion
58272482|NCT05920785|DIAGNOSTIC_TEST|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~* general blood test, general urine test,~* biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~* hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~* glycated hemoglobin,~* - glucose tolerance test,~* ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~* blood pressure monitoring.~Special laboratory methods:~* Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~* analysis of feces for microbiota by MALDI-TOF mass spectrometry,~* bioimpedance measurement."
58272483|NCT03784859|DEVICE|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
58272484|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
58272485|NCT06602167|COMBINATION_PRODUCT|True electroacupuncture + True self-administered acupressure|"True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes."
58272486|NCT06602167|DRUG|Doctor-prescribed treatment|Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
58390579|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
58390580|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
58390581|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
58390582|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
58390583|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
58276748|NCT05487053|PROCEDURE|Single-shot adductor canal block|Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
58390584|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
58390585|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
58390586|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
58390587|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
58390588|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
58390589|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
58390590|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
58390591|NCT00332085|DRUG|Chromium Picolinate|
58390592|NCT02667041|DEVICE|NeuroQore rTMS Device|
58390593|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
57720161|NCT00863538|DRUG|KPS-0373|
57720162|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
57720163|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
58064514|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
58064515|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
58064516|NCT00114400|DRUG|folic acid|
58064517|NCT00114400|DRUG|vitamin B12|
58064518|NCT00114400|DRUG|vitamin B6|
58064519|NCT02400281|DRUG|Crenolanib besylate|
58064520|NCT02400281|DRUG|Idarubicin|
57720164|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
57720165|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
57918847|NCT02853357|OTHER|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
58064521|NCT02400281|DRUG|Cytarabine|
58064522|NCT02400281|DRUG|Azacytidine|
58064523|NCT02400281|DRUG|Mitoxantrone|
58064524|NCT02400281|DRUG|Etoposide|
58272487|NCT06602167|COMBINATION_PRODUCT|Sham electroacupuncture + Sham self-administered acupressure|"Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
58272488|NCT00738062|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
58390594|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
58390595|NCT03107052|DRUG|Fremanezumab|Fremanezumab
58390596|NCT03154515|DRUG|Ingavirin|
57720166|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
57720167|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
57720168|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
58390597|NCT03154515|DRUG|Placebo|
57720169|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
57918848|NCT03267160|DIAGNOSTIC_TEST|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
57918849|NCT00421707|DRUG|GW876008|
57918850|NCT00421707|OTHER|Placebo|
57918851|NCT01710332|DRUG|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
57918852|NCT06207513|PROCEDURE|Suction Circuit Flushing with Chlorhexidine|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
57918853|NCT02159430|OTHER|Clinical and psychopathological assessment of HAE patients|
57918854|NCT03032393|OTHER|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
58064525|NCT02400281|DRUG|Fludarabine|
58064526|NCT02400281|DRUG|G-CSF|
57918855|NCT03032393|OTHER|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
58064527|NCT05482958|DEVICE|HOP watch|Prospective observational study
57720170|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
57720171|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
57720172|NCT00575588|DRUG|Metformin|open-label metformin
57720173|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
57720174|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
57720175|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
57720176|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
57720177|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
57720178|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
57720179|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
57720180|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
57720181|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
57720182|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
57720183|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
58272489|NCT00738062|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
58272490|NCT03342131|OTHER|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
57720184|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
57720185|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
57720186|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
57720187|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
57720188|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
57918856|NCT04977141|OTHER|Decisional Conflict Scale|Decisional Conflict Scale
58272491|NCT05936541|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium Bifidum PRL2010|Probiotic supplement
58272492|NCT05936541|OTHER|Control group|No probiotic supplementation
58272493|NCT02817698|DRUG|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
58272494|NCT00005624|DRUG|CI-994|CI-994 as outlined in treatment arm.
58272495|NCT06061211|OTHER|TREADMILL(SIDEA-Germany treadmill ) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
57720189|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
57720190|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
57720191|NCT05831852|OTHER|no intervention|no intervention
57918857|NCT03280667|DRUG|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
57918858|NCT02156128|BEHAVIORAL|Cogmed working memory training|
58272496|NCT06514521|OTHER|Lutetium vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
57918859|NCT02156128|BEHAVIORAL|Control group|
57918860|NCT00122694|DRUG|carbon monoxide|
57918861|NCT00160862|DRUG|SLV317|
57918862|NCT02042612|DRUG|Sedation with sevoflurane during 48-hr in ICU|
57918863|NCT02767713|DRUG|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
58272497|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
58272498|NCT02035397|DRUG|Botulinum Toxin Type A|
58272499|NCT02035397|DRUG|Saline solution|
58390598|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
58390599|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
57720192|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
57720193|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
57918864|NCT02767713|OTHER|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
57918865|NCT03268122|OTHER|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
57918866|NCT03268122|OTHER|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
58390600|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
58390601|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
57918867|NCT01377051|DRUG|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
57918868|NCT01377051|DRUG|Placebo|Dry powered, same to study drug, only one inhalation
57918869|NCT00790608|DRUG|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
57918870|NCT04819984|DEVICE|TCM5 device (Radiometer) for PtC02 continuous measurement|Evaluation of PtC02 variation as a reflect of PaC02 during 30 minutes of weaning proof for mechanical ventilation (spontaneous ventilation on T-piece)
57918871|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Single dose of theobromine
58272500|NCT00532272|DRUG|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
58272501|NCT02425033|PROCEDURE|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
58272502|NCT03009383|DEVICE|A bedside portable endoscopy|
58390602|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
58390603|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
58390604|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
57720194|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
57720195|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
57720196|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
57918872|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Multiple doses of theobromine
57918873|NCT01544829|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
57918874|NCT04771468|DEVICE|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
57918875|NCT04771468|DEVICE|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
57918876|NCT03718533|DRUG|Eltrombopag|Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
57918877|NCT02271477|DEVICE|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
58390605|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
57918878|NCT03439176|OTHER|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
58390606|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
57720197|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
57720198|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
57720199|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
57720200|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
57918879|NCT03439176|OTHER|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
57918880|NCT03439176|OTHER|PL4|This strip contains a new adhesive
57918881|NCT03439176|OTHER|PL16-L|This strip contains a new adhesive
57918882|NCT01988623|BEHAVIORAL|Pivotal Response Treatment (PRT)|
57918883|NCT05634525|DRUG|MRTX849|Given By PO
57918884|NCT05029479|OTHER|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
57918885|NCT04292678|BEHAVIORAL|Progressive muscle relaxation|The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
57918886|NCT04292678|OTHER|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
57918887|NCT03054896|DRUG|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
57918888|NCT03054896|OTHER|DA-EPOCH-R|Intensive chemotherapy regiment
57918889|NCT03054896|OTHER|R-CHOP|Intensive chemotherapy regiment
58390607|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
58390608|NCT03371576|DEVICE|intraocular lenses|
58390609|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
57720201|NCT00434720|DEVICE|GlideScope Specific Stylet|
57720202|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
57720203|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
57720204|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
57720205|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
57720206|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
58390610|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
57720207|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
57720208|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
57918890|NCT01166321|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
57918891|NCT02334774|PROCEDURE|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
57918892|NCT01616056|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Wear bandage lenses
57918893|NCT01616056|OTHER|questionnaire administration|Ancillary studies
58064528|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
58272503|NCT04724031|DRUG|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
58272504|NCT06725667|OTHER|Transversalis fascia plane block|Patients will receive transversalis fascia plane block after the induction of general anesthesia.
58272505|NCT06725667|OTHER|Caudal block|Patients will receive caudal block after the induction of general anesthesia.
58272506|NCT04583358|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
58272507|NCT04583358|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
58272508|NCT00902980|OTHER|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
57720209|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
57720210|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
57720211|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
57720212|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
58272509|NCT00235066|DEVICE|PCI|PCI with Cypher Sirolimus-Eluting Stent
57918894|NCT01616056|PROCEDURE|optical coherence tomography|Optional ancillary studies
58064529|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
57720213|NCT01384539|DRUG|Cholecalciferol|
57720214|NCT01384539|DRUG|Calcitriol|
57720215|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
57918895|NCT01704924|DEVICE|Prevena|Device will be applied at end of procedure over closed incision
57918896|NCT01704924|PROCEDURE|Standard of Care Dressing|Dressing applied as Standard of Care
57918897|NCT00666809|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
58064530|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
58064531|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
58064532|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
58064533|NCT02795182|DRUG|Zanubrutinib|
58064534|NCT02795182|DRUG|Tislelizumab|
58272510|NCT04698421|BIOLOGICAL|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
58272511|NCT01380691|DRUG|LY2216684|Administered orally
58272512|NCT01380691|DRUG|Placebo-matching LY2216684|Administered orally
58272513|NCT01380691|DRUG|Placebo-matching alcoholic beverage|Administered orally
58272514|NCT01380691|DRUG|Alcoholic beverage|Administered orally
58272515|NCT01948583|DRUG|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
58272516|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
58272517|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
58272518|NCT05777941|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
58272519|NCT01442727|DRUG|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
58272520|NCT01442727|DRUG|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
58272521|NCT05141006|DRUG|BOTOX|Injection into the bladder
58272522|NCT05141006|DRUG|Placebo for BOTOX|Injection into the bladder
58272523|NCT05753501|DRUG|ABBV-101|Oral:Tablet
57918898|NCT00666809|DRUG|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
57720216|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
57720217|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
57720218|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
57720219|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
57720220|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
57720221|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
57720222|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
57720223|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
58272524|NCT04245202|DEVICE|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
58272525|NCT04245202|OTHER|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
58272526|NCT03023540|DRUG|PXT3003|Liquid oral solution, twice 5 mL (Dose 1) bid
58272527|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
57720224|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
57720225|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
57720226|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
57720227|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
57720228|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
57720229|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
57720230|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
57720231|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
57720232|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
57720233|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
57918899|NCT06042010|DRUG|Oral zinc supplement|patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
58272528|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
58272529|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
58272530|NCT06718673|OTHER|virtual delivery room visit|The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)
57720234|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
57720235|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
57720236|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
57720237|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
57720238|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
57720239|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
58064535|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
57720240|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
57720241|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
57720242|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
57720243|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
57720244|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
57720245|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
57720246|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
57720247|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
58064536|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
58272531|NCT06718673|OTHER|standart of care|Pregnant women in the control group did not receive any intervention other than routine care and counselling.
58272532|NCT04907500|DEVICE|Intraocular lens|Cataract surgery
58272533|NCT00379431|DRUG|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
58272534|NCT02799173|BIOLOGICAL|RANKL/OPG ratio|
58064537|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
58064538|NCT00115622|DRUG|fluticasone furoate|
57720248|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
57720249|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
58064539|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
58064540|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
57720250|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
58272535|NCT02799173|DEVICE|bone densitometry|
58272536|NCT02799173|DEVICE|fan beam CT scan|
58272537|NCT02799173|DEVICE|Doppler ultrasound|
57720251|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
57720252|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
57720253|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
57918900|NCT06042010|DRUG|triamcinolone acetonide Oral paste|patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
58064541|NCT02609529|OTHER|Placebo|
58272538|NCT06531629|PROCEDURE|Surgery, radiation therapy and chemotherapy|Surgery, radiation therapy and chemotherapy
58276749|NCT05487053|PROCEDURE|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
58064542|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
58272539|NCT05260216|COMBINATION_PRODUCT|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
58390611|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
58390612|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
57720254|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
57720255|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
57720256|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
57720257|NCT00685815|DRUG|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
58272540|NCT05260216|COMBINATION_PRODUCT|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
58272541|NCT01538849|DRUG|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
58390613|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
57720258|NCT01736852|DEVICE|CRB|Labor induction using the CRB
57720259|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
57720260|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
58064543|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
58390614|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
58390615|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
57720261|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
57720262|NCT02732847|DRUG|Usual Dated|
57720263|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
57720264|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
57720265|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
58272542|NCT01538849|DRUG|YH4808 A mg|1 tablet = YH4808 A mg
58272543|NCT01538849|DRUG|YH4808 B mg|1 tablet = YH4808 B mg
58272544|NCT01538849|DRUG|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
58272545|NCT03280225|OTHER|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
58272546|NCT03725774|OTHER|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
58272547|NCT00986986|DRUG|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
58390616|NCT01130909|DRUG|AZD6765|75 mg
58390617|NCT01130909|DRUG|AZD6765|150 mg
58390618|NCT01130909|DRUG|Ketamine|0.5 mg/kg
57720266|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
57720267|NCT00023673|DRUG|carboplatin|
57720268|NCT00023673|DRUG|paclitaxel|
57720269|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
57720270|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
57720271|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
57720272|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
57720273|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
57918901|NCT05365477|BEHAVIORAL|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day
57918902|NCT05365477|DRUG|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
58272548|NCT03707834|BEHAVIORAL|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
58390619|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
57720274|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
57720275|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
57720276|NCT03732248|DRUG|Placebo|Inert drug
57720277|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
57720278|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
57720279|NCT00130884|DRUG|levosimendan|
57720280|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
58064544|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
58390620|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
58390621|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
58390622|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
57720281|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
57720282|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
57720283|NCT02770391|PROCEDURE|Radical prostatectomy|
57720284|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
57720285|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
57720286|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
57720287|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
57720288|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
57720289|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
57720290|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
58390623|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
58390624|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
58390625|NCT00368680|DEVICE|Early Bubble CPAP|
58390626|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
58390627|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
58064545|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
58064546|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
58390628|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
58390629|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
57720291|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
57720292|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
57720293|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
57720294|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
57918903|NCT05365477|BEHAVIORAL|Selective Therapy: Diet|"Diet:~Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements~Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d~Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium \>150mmol Reduce sodium intake to \<2000mg/d~Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
57918904|NCT05365477|DRUG|Selective Therapy: Drug|"Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
57918905|NCT04333927|DRUG|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
57720295|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
57918906|NCT04333927|OTHER|Observation|Patients in observation group will not receive any anti-cancer therapy.
57918907|NCT04333927|PROCEDURE|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
57918908|NCT04333927|RADIATION|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
57918909|NCT00947739|DRUG|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
57918910|NCT02640157|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
57918911|NCT02640157|DRUG|Sofosbuvir|Tablet
57918912|NCT02640157|DRUG|Daclatasvir|Tablet
57918913|NCT03127254|BEHAVIORAL|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
58390630|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
57720296|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
57918914|NCT03127254|BEHAVIORAL|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
57918915|NCT03127254|BEHAVIORAL|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
58064547|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
58064548|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
58064549|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
58064550|NCT01986049|DRUG|Bupivicaine|
58390631|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
58390632|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
57720297|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
57720298|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
57720299|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
57720300|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
57720301|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
57720302|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
57720303|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
57918916|NCT03127254|BEHAVIORAL|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
57918917|NCT03127254|BEHAVIORAL|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
57918918|NCT04773496|DIAGNOSTIC_TEST|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
58064551|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
58272549|NCT04848259|DRUG|Normal saline|Saline will be applied after surgery
58064552|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
58272550|NCT04848259|DRUG|Dexamethasone|Dexamethason will be given IV before surgery
58272551|NCT04848259|DRUG|Honey|Honey will be applied locally after surgery
58272552|NCT04848259|DRUG|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
58272553|NCT00104468|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
58272554|NCT04946552|DIAGNOSTIC_TEST|PET Scan|Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
58272555|NCT04946552|DIETARY_SUPPLEMENT|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
58272556|NCT04946552|DIAGNOSTIC_TEST|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
58390633|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
58390634|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
58390635|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
58390636|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
58390637|NCT00475085|DRUG|aprepitant|Given orally or IV
58390638|NCT00475085|DRUG|dexamethasone|Given orally or IV
58390639|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
58390640|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
58390641|NCT00475085|DRUG|prochlorperazine|Given orally or IV
58390642|NCT00475085|DRUG|placebo|Given orally
58390643|NCT00021567|DRUG|Interferon Gamma for Aerosol|
58390644|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
57720304|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
58272557|NCT04946552|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
57720305|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
57720306|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
57720307|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
57720308|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
57720309|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
57720310|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
57720311|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
57720312|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
57720313|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
57720314|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
57720315|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
58064553|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
58064554|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
58390645|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
58390646|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
58390647|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
57720316|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
57720317|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
57720318|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
58064555|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
57720319|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
57720320|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
57720321|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
57720322|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
57720323|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
57720324|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
57720325|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
57720326|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
57720327|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
57720328|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
58064556|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
58272558|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
58272559|NCT04946552|DIAGNOSTIC_TEST|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.
58390648|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
58390649|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
58390650|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
58390651|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
58390652|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
58390653|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
58390654|NCT03456349|DRUG|HTL0018318|HTL0018318
58390655|NCT03456349|DRUG|Placebo|Placebo
58390656|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
58390657|NCT06547333|DRUG|Placebo|Placebo
58390658|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
57720329|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
57720330|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
58064557|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
57720331|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
57720332|NCT00000571|DEVICE|ventilators, negative pressure|
57720333|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
57720334|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
57720335|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
57720336|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
58272560|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
58272561|NCT00001502|DRUG|RMP-7 and carboplatin|
58272562|NCT06730880|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (abbreviated PCR) is a laboratory technique for rapidly producing (amplifying) millions to billions of copies of a specific segment of DNA, which can then be studied in greater detail.
57720337|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
58272563|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
58272564|NCT06545942|DRUG|Olaparib|Olaparib administered orally
58272565|NCT03410901|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
58064558|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
58064559|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
58064560|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
58272566|NCT03410901|OTHER|Laboratory Biomarker Analysis|Correlative studies
58272567|NCT03410901|RADIATION|Radiation Therapy|Undergo radiation therapy
58272568|NCT03410901|DRUG|TLR9 Agonist SD-101|Given intratumorally
58272569|NCT04728373|PROCEDURE|surgery|the need for surgery after aircraft accidents
58272570|NCT04172428|DIAGNOSTIC_TEST|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
58272571|NCT01199822|BIOLOGICAL|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
58272572|NCT04297475|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
58272573|NCT00051181|DRUG|Travoprost (0.004%)|
58272574|NCT00051181|DRUG|Latanoprost (0.005%)|
58272575|NCT02600767|DRUG|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
58272576|NCT01324570|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
58272577|NCT01573754|DRUG|Hydroxychloroquine|100 mg by mouth twice weekly
57720338|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
58064561|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
58064562|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
58064563|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
58064564|NCT00381810|DRUG|Methylprednisolone|
58272578|NCT01573754|PROCEDURE|Phlebotomy|450 mL every 2 weeks
58272579|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
58272580|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
58272581|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
58272582|NCT01167556|BEHAVIORAL|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
58272583|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
58272584|NCT02230540|DEVICE|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
58272585|NCT02230540|DEVICE|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
58272586|NCT02230540|DEVICE|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
58272587|NCT06731738|DRUG|Gadoteric acid|A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.
57720339|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
58272588|NCT06731738|DRUG|Mangafodipir trisodium injection|Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
58272589|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
58272590|NCT04108780|DEVICE|T-tube|T shaped tube used as stent after CBD exploration
58272591|NCT06730022|DRUG|MTX-001 (Dermacyte Liquid)|Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
57720340|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
57720341|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
58064565|NCT00381810|DRUG|Acetaminophen|
58064566|NCT00381810|DRUG|Diphenhydramine|
58390659|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
58390660|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
58390661|NCT02934841|DRUG|Conbercept|
58064567|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
58272592|NCT04056000|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine, 60 minutes before exercise
58272593|NCT04056000|DIETARY_SUPPLEMENT|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
58272594|NCT04056000|BEHAVIORAL|60-minutes of steady state exercise|See intervention name
58272595|NCT04927494|BEHAVIORAL|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
58272596|NCT00392522|DRUG|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
58390662|NCT02934841|DRUG|sham|
58272597|NCT05367882|DIAGNOSTIC_TEST|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
58390663|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
58390664|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
58390665|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
58390666|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
57720342|NCT02663128|DRUG|Lanabecestat|Administered orally
58390667|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
57720343|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
58064568|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
58064569|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
58064570|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
58064571|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
58064572|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
58064573|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
58064574|NCT00286234|DRUG|extended release niacin|2 g qpm
58390668|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
58390669|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
58272598|NCT06239779|OTHER|Education|The education intervention involves a brief PowerPoint presentation delivered by a physician, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
58272599|NCT04592627|OTHER|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
58272600|NCT06731088|DRUG|Midazolam|Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
58390670|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
58390671|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
58390672|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
58390673|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
58390674|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
58390675|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
58272601|NCT06731088|DRUG|Remazolam besylate|Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
58390676|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
58390677|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
58390678|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
58390679|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
58390680|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
57720344|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
57720345|NCT00151645|DRUG|activated lymphocytes|
58390681|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
57720346|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
58064575|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
58064576|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
58064577|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
58272602|NCT00655512|DRUG|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
58272603|NCT00655512|DRUG|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
58272604|NCT00655512|DRUG|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
58390682|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
58390683|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
58390684|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
57720347|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
57720348|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
57720349|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
57720350|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
58272605|NCT00655512|DRUG|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
58272606|NCT00655512|DRUG|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
58272607|NCT01635907|DRUG|Dovitinib|
58272608|NCT06464926|DEVICE|Enterra Therapy System|"The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options."
58272609|NCT05572372|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
58272610|NCT04140240|BEHAVIORAL|intervention group|Parallel Assignment a experimental design with pre test and post test
58272611|NCT00677573|DRUG|Fostimon|450 IU for 4 days then adjusted
58272612|NCT02608008|DEVICE|Data analysis|data parameters Analysis
57720351|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
57720352|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
57720353|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
57720354|NCT04670679|DRUG|ERAS-601|Administered orally
57720355|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
57720356|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
57720357|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
57720358|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
57720359|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
57720360|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
57720361|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
57720362|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
57720363|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
57720364|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
58064578|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
58272613|NCT01110213|BEHAVIORAL|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
58272614|NCT01110213|BEHAVIORAL|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
58272615|NCT00092339|DRUG|MK0966, rofecoxib|
58272616|NCT00092339|DRUG|Comparator: valdecoxib, placebo|
58272617|NCT01931241|DRUG|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
58272618|NCT05166720|BEHAVIORAL|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
58272619|NCT00678470|DRUG|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
58272620|NCT02535169|BEHAVIORAL|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
58272621|NCT02535169|BEHAVIORAL|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
58272622|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
58272623|NCT05854043|OTHER|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)\>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
57918919|NCT01146054|DEVICE|CyberKnife based stereotactic radiotherapy|"1. Initial orthogonal images will be obtained to confirm location of fiducial seeds.~2. Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~3. Quality assurance will be performed as per standard practice at each participating institution."
58272624|NCT05854043|OTHER|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
57918920|NCT01146054|DRUG|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
58272625|NCT01891318|RADIATION|radiosurgery|Undergo radiosurgery
58272626|NCT01891318|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
58272627|NCT01891318|PROCEDURE|quality-of-life assessment|Ancillary studies
58272628|NCT04910672|OTHER|Control Group|"Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression."
58272629|NCT04910672|OTHER|Experimental Group|"Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion."
58272630|NCT06220409|OTHER|Dance classes|A 12-week dance class training program two times a week for 3 months
58272631|NCT05342428|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
58272632|NCT04736732|OTHER|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
58272633|NCT05800496|DIETARY_SUPPLEMENT|SesZen-Bio™|mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
58272634|NCT05800496|OTHER|Placebo|Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
58276750|NCT05604872|PROCEDURE|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
57720365|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
57918921|NCT01146054|DRUG|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
58272635|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
58272636|NCT03769597|DRUG|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
58272637|NCT03418194|PROCEDURE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
58272638|NCT03418194|PROCEDURE|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
58272639|NCT06528509|BEHAVIORAL|AI-Generated Informative Videos|"Participants in the experimental arm will receive an AI-generated video designed to provide comprehensive information about cataract surgery. The video will cover key aspects of the procedure, including the nature of the surgery, potential risks, benefits, and postoperative care. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.~The video will be delivered to participants via a secure link sent to their mobile devices or email. Patients can watch the video at their convenience, and they are encouraged to view it as many times as necessary to fully understand the information provided. The video link will be provided once after the initial clinic appointment, but patients can access and watch the video multiple times.~The videos will be created using the Synthesia platform, which uses artificial intelligence to generate realistic, photo-realistic digital avatars that deliver the information in a personalized and engaging manner."
58272640|NCT06528509|BEHAVIORAL|Standard Written Information Brochures|Participants in the control arm will receive traditional written information brochures about cataract surgery. These brochures are designed to deliver detailed and essential information in a clear and understandable format. The brochures will be handed to participants during their face-to-face clinic appointment. Patients can read the material at their convenience and keep it for future reference. These brochures follow standardized guidelines and recommendations to ensure that all relevant information is included and presented in an accessible manner. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
58272641|NCT03745105|DRUG|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
57720366|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
58272642|NCT03745105|DRUG|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
58272643|NCT03745105|DRUG|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
58272644|NCT05729581|BEHAVIORAL|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
58272645|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
58272646|NCT01074723|DIETARY_SUPPLEMENT|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
58272647|NCT05438966|OTHER|No intervention|No intervention
57918922|NCT05350579|OTHER|Yogurt Intervention|"Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract."
57918923|NCT03726710|BEHAVIORAL|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
57720367|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
57720368|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
57720369|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
58272648|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
58272649|NCT02065063|DRUG|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
58272650|NCT02065063|DRUG|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
58272651|NCT03938688|PROCEDURE|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
58272652|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
58272653|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
58272654|NCT05133414|OTHER|Selective left subclavian ansae stimulation|Percutaneous, transarterial approach for target stimulation
58272655|NCT03875976|PROCEDURE|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
58272656|NCT03875976|PROCEDURE|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
58272657|NCT01393132|DRUG|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
58272658|NCT01393132|DRUG|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
58272659|NCT03643913|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
58272660|NCT03643913|PROCEDURE|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
58390685|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
57720370|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
58272661|NCT03643913|DRUG|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
57720371|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
57720372|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
57720373|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
57720374|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
57720375|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
57720376|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
57720377|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
57720378|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
57720379|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
58390686|NCT00162591|DRUG|remifentanyl|
57918924|NCT06018181|DRUG|Shuxuetong Injection|According to clinical real treatment records
58272662|NCT02795845|DIETARY_SUPPLEMENT|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
58272663|NCT02795845|OTHER|Placebo|capsule without active ingredient
58272664|NCT05297110|DRUG|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
58272665|NCT02320682|DEVICE|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
57720380|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
57918925|NCT02336750|DRUG|Aprepitant|125mg D1, 80mg D2-3
57918926|NCT02336750|DRUG|Mirtazapine|15mg D2-4
58272666|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
58272667|NCT06712901|BEHAVIORAL|Median Ranked Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
58390687|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
58272668|NCT06712901|BEHAVIORAL|Overall Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
58272669|NCT06712901|BEHAVIORAL|Black American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
58272670|NCT06712901|BEHAVIORAL|White American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
58272671|NCT06712901|BEHAVIORAL|Control|There will be no message content of cancer screening and sharing intentions in this arm.
58272672|NCT03606694|DRUG|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
58272673|NCT03606694|DRUG|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
58272674|NCT04339010|OTHER|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
58390688|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
57720381|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
57720382|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
57720383|NCT06085417|DRUG|bupivacaine|bupivacaine
58390689|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
58390690|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
57720384|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
57720385|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
57720386|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
57720387|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
57720388|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
57720389|NCT02369133|DRUG|Placebo|
57720390|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
57720391|NCT00189085|DRUG|simvastatin and ezetimibe|
57918927|NCT03322787|DEVICE|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
58064579|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
58272675|NCT04339010|OTHER|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
58272676|NCT05628298|DEVICE|Soovu Pain Relief System|The Soovu Pain Relief system uses pulses of heat to block the TRPV-1 calcium channel on peripheral pain nerves. The study will determine if the FDA cleared device significantly reduces the subject's pregnancy related pain.
58272677|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
58272678|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
58272679|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
58272680|NCT05679180|DEVICE|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
58272681|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
58272682|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
58272683|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
58272684|NCT06098716|BEHAVIORAL|Self Regulation|How to plan for Family PA
58272685|NCT06098716|BEHAVIORAL|Identity & Family functioning|Increasing self-identity to increase parental support of child PA \& family functioning
58390691|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
58390692|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
57720392|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
57720393|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
57720394|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
57720395|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
57720396|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
58272686|NCT04310475|OTHER|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
57720397|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
57720398|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
57720399|NCT00664144|DRUG|Rasburicase (SR29142)|
58272687|NCT02722161|DRUG|[14C]BI 1482694|
58272688|NCT03279354|BEHAVIORAL|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
58390693|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
58390694|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
58390695|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
58390696|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
58390697|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
57720400|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
57720401|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
57720402|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
57720403|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
57720404|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
57720405|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
57720406|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
57720407|NCT06508554|OTHER|Haptonomy|5. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
57918928|NCT05768633|BEHAVIORAL|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
58272689|NCT03279354|BEHAVIORAL|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
58272690|NCT05615636|DRUG|Mosunetuzumab|Given by IV (vein)
58272691|NCT05615636|DRUG|Polatuzumab vedotin|Given by IV (vein)
58272692|NCT05615636|DRUG|Tafasitamab|Given by IV (vein)
58272693|NCT05615636|DRUG|Lenalidomide|Given by PO
58272694|NCT01449513|DRUG|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
57720408|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
57720409|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
57720410|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
58272695|NCT01449513|DRUG|Placebo Gel|Gel vehicle of PEP005
58272696|NCT00090584|DRUG|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
58272697|NCT00090584|BEHAVIORAL|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
58272698|NCT02972749|BEHAVIORAL|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
58272699|NCT06276452|BEHAVIORAL|Psychoeducation|Psychoeducation is the therapeutic management of illness through the increase of related knowledge, skills, and motivation.
58272700|NCT04129528|DRUG|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
58272701|NCT04129528|OTHER|Placebo|Placebo for active drug
58272702|NCT03759145|OTHER|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
58272703|NCT03759145|OTHER|usual care|participants continued their planned rehabilitation sessions
58272704|NCT00213577|DRUG|type A botulinum toxin|
57720411|NCT02320019|DRUG|Placebo|Placebo matching YH14618
57720412|NCT02320019|DRUG|YH14618|
57720413|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
57720414|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
58272705|NCT05477628|OTHER|Childcare Navigator|"Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record."
58390698|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
58390699|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
57720415|NCT00506935|DRUG|GVG|5 grams GVG
57720416|NCT00506935|DRUG|placebo|placebo
57720417|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
57720418|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
57720419|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
57720420|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
57720421|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
57720422|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
57720423|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
58272706|NCT05477628|OTHER|Lactation Consultant|"Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare."
58272707|NCT05477628|OTHER|Lactation Consultant Support and Childcare Navigator Support|This intervention is a combination of the two interventions described above.
57720424|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
57720425|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
57720426|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
57720427|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
58064580|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
58064581|NCT02215915|PROCEDURE|DES implantation|
58064582|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
58064583|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
58272708|NCT05477628|OTHER|Control Group|All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
58390700|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
58390701|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
57720428|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
57720429|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
57720430|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
57720431|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
57720432|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
57720433|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
57720434|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
58064584|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
57720435|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
57720436|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
57720437|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
57720438|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
57720439|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
58064585|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
58064586|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
57720440|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
57720441|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
57720442|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
57720443|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
57720444|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
57720445|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
58064587|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
58064588|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
58064589|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
58272709|NCT05497232|PROCEDURE|simultaneous pancreas-kidney transplantation|"Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases."
57720446|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
58272710|NCT06621576|DRUG|HM2002 injection|Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
57720447|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
57720448|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
57720449|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
57720450|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
57720451|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
57720452|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
57720453|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
57720454|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
58272711|NCT01733459|DRUG|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
58390702|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
58390703|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
58390704|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
58390705|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
58390706|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
58390707|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
58390708|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
58390709|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
57720455|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
57720456|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
57720457|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
57720458|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
57720459|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
57720460|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
57720461|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
57720462|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
58064590|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
57720463|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
57720464|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
58064591|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
58272712|NCT01733459|DRUG|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
58272713|NCT01733459|DRUG|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
58272714|NCT01733459|DRUG|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
58272715|NCT03918278|BIOLOGICAL|MK-0482|IV infusion
58272716|NCT03918278|BIOLOGICAL|pembrolizumab|IV infusion
58390710|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
58390711|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
58390712|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
57720465|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
57720466|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
57720467|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
58272717|NCT03918278|DRUG|Paclitaxel|IV infusion
57720468|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
58272718|NCT03918278|DRUG|Nab-paclitaxel|IV infusion
58272719|NCT03918278|DRUG|Gemcitabine|IV infusion
58390713|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
57720469|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
58272720|NCT03918278|DRUG|Carboplatin|IV infusion
58272721|NCT03918278|DRUG|Pemetrexed|IV infusion
58272722|NCT04002778|DIAGNOSTIC_TEST|Fine needle aspiration|
58272723|NCT04002778|DIAGNOSTIC_TEST|Rapid on-site evaluation|
58272724|NCT00853515|OTHER|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
58272725|NCT06731413|DRUG|Reduced Dose of Chemotherapy and Immunotherapy|Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
57720470|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
57720471|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
57720472|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
58272726|NCT01935245|DEVICE|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
57720473|NCT00472914|DEVICE|portable surface electromyography|
57720474|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
57720475|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
58272727|NCT01935245|DEVICE|Conventional extracorporeal circulation|
58272728|NCT03050541|DRUG|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
58272729|NCT03050541|DRUG|Placebo|
58390714|NCT05849675|DRUG|Placebo|Single dose placebo
58390715|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
58272730|NCT04400981|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
58272731|NCT04400981|OTHER|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
57720476|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
57720477|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
57720478|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
57720479|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
57720480|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
57720481|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
57720482|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
57720483|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
57720484|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
57720485|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
57720486|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
57720487|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
57720488|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
57720489|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
57720490|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
57720491|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
57720492|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
57918929|NCT05992402|BEHAVIORAL|ReBOOT program|This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
58272732|NCT06070753|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
58272733|NCT00933114|PROCEDURE|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
58272734|NCT03108872|DEVICE|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
58390716|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
58390717|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
58390718|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
58390719|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
58390720|NCT05073484|DRUG|BAT6021|Ⅳ infusions
58390721|NCT05073484|DRUG|BAT1308|Ⅳ infusions
58390722|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
57720493|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
57720494|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
57720495|NCT00298038|DRUG|Rifaximin|Oral
57720496|NCT00298038|DRUG|Placebo|Oral
57720497|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
57720498|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
57720499|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
57720500|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
57720501|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
57720502|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
57720503|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
57720504|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
57720505|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
57720506|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
57720507|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
57720508|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
57720509|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
57918930|NCT05003960|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57918931|NCT00952172|BEHAVIORAL|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
57918932|NCT03068663|OTHER|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
57918933|NCT03170154|DEVICE|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
57720510|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
57918934|NCT02245672|DRUG|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
58390723|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
58390724|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
58390725|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
58390726|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
57720511|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
57720512|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
58390727|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
57720513|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
57720514|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
57720515|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
57720516|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
57720517|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
57720518|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
58064592|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
57720519|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
57720520|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
57918935|NCT02245672|DRUG|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
58064593|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
57918936|NCT02245672|DRUG|Placebo|Placebo administered via the CRC749 and Diskus devices
57918937|NCT01493011|DEVICE|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
58064594|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
58064595|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
58272735|NCT03108872|DRUG|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
58272736|NCT03152994|OTHER|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
57720521|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
57720522|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
57720523|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
57720524|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
57918938|NCT02774161|OTHER|Ultrasound Tomography|Undergo B-mode ultrasound imaging
57918939|NCT03467503|DIETARY_SUPPLEMENT|Blueberry + soluble fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
57918940|NCT01386788|OTHER|There is no intervention planned (observational)|No intervention foreseen
57918941|NCT05901662|OTHER|Competence training program|A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
57918942|NCT05901662|OTHER|Control|This group provided their routine services at senior activity centers.
57918943|NCT01133951|DRUG|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
57918944|NCT01133951|DRUG|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
57918945|NCT04242563|OTHER|VIRTUAL REALITY|Patient equipped with virtual reality in transfer room
58064596|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
58064597|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
58064598|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
58064599|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
58064600|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
57720525|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
57720526|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
57720527|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
57918946|NCT02841930|OTHER|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
57918947|NCT00495287|DRUG|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
57918948|NCT03731507|DEVICE|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
58064601|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
58064602|NCT03613766|OTHER|Physical activity program|
58272737|NCT04877158|BEHAVIORAL|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
58272738|NCT02368210|DRUG|122-0551 Foam|Topical Foam
58272739|NCT02368210|DRUG|Vehicle Foam|Topical Foam
58272740|NCT06392386|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injections
58272741|NCT06308588|DRUG|Blinatumomab|Given by Infusion
58272742|NCT06308588|DRUG|Asciminib|Given by PO
58272743|NCT05822206|BEHAVIORAL|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
58272744|NCT05822206|BEHAVIORAL|Life Steps and Sexual Decision-Making|
58272745|NCT06719232|DEVICE|Catheter-Free Intravesical Instillation with a special syringe adapter|The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
58272746|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
57918949|NCT02370082|DEVICE|Localization of breast lesion|localization of breast lesion for removal
57720528|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
58064603|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
58064604|NCT05818215|OTHER|NO intervention|NO intervention
58272747|NCT03538067|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
58272748|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
58272749|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
58272750|NCT03592498|DRUG|Sulfadiazine, Silver|Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
58390728|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
58390729|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
57720529|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
57720530|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
57720531|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
57720532|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
57720533|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
57720534|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
57720535|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
57720536|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
57720537|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
57720538|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
57720539|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
58064605|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
58064606|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
58064607|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
58272751|NCT03592498|DEVICE|Skin of Nile tilapia|Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
58272752|NCT02397434|RADIATION|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
58272753|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
58272754|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
58272755|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
58272756|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
58272757|NCT04673435|DEVICE|PermeaDerm for temporary coverage|See above
57720540|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
57720541|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
57720542|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
58064608|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
58272758|NCT04673435|DEVICE|FHCA for temporary coverage|See above
58272759|NCT04673435|DEVICE|PermeaDerm over autograft|See above
58272760|NCT04673435|DEVICE|FHCA over autograft|see above
57720543|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
57720544|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
57720545|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
57720546|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
57720547|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
57720548|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
57918950|NCT04875676|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
58064609|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
58272761|NCT02954822|DRUG|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
58272762|NCT02954822|DRUG|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
58272763|NCT03535532|PROCEDURE|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
58272764|NCT03535532|DRUG|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
58272765|NCT05575336|OTHER|ADLIFE intervention|"The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study (a year). If the proposed sample size is not reached by the start date (Dec. 2022), the recruitment period could be expanded to a maximum of three additional months. Patient's follow-up may range between 9 (March-Nov. 2023) and 12 (Dec. 2022 - Nov. 2023) months."
57918951|NCT02688959|BEHAVIORAL|Tai Chi|
57918952|NCT02688959|BEHAVIORAL|Exercise|
57918953|NCT00629330|BEHAVIORAL|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
58064610|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
57720549|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
58390730|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
58390731|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
58390732|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
58390733|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
58390734|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
58272766|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
58272767|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
58272768|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
58272769|NCT02774005|DRUG|Idebenone|
58390735|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
58390736|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
58390737|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
58390738|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
57720550|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
58064611|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
58272770|NCT01120132|DRUG|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
58272771|NCT01120132|DRUG|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
58272772|NCT01120132|DRUG|PA|Suspension of Prednisolone Acetate administered during 28 days
58272773|NCT01120132|DRUG|Placebo|Placebo solution administered during 28 days
58390739|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
58390740|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
58390741|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
58390742|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
57720551|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
58272774|NCT03148717|DRUG|Misoprostol|Cytotec
58272775|NCT03148717|OTHER|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
58272776|NCT04320953|DEVICE|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
58272777|NCT06505278|DRUG|Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
58272778|NCT05096572|DEVICE|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
58272779|NCT05096572|DEVICE|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
58272780|NCT05096572|DEVICE|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
58272781|NCT06314451|OTHER|Cognitive Interview|"The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles."
58272782|NCT04311281|BIOLOGICAL|[F-18]FDDNP-PET|\[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
58272783|NCT02664922|DRUG|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
58272784|NCT02664922|DRUG|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
58272785|NCT02664922|DRUG|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
58272786|NCT02664922|DRUG|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
58272787|NCT05040100|OTHER|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
57918954|NCT03730636|PROCEDURE|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
58272788|NCT02064465|DRUG|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
58272789|NCT02064465|DRUG|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
58272790|NCT05201066|DRUG|decitabine|Solution for intravenous infusion
58272791|NCT05201066|DRUG|spartalizumab|Solution for intravenous infusion
58272792|NCT05201066|DRUG|sabatolimab|Solution for intravenous infusion
58272793|NCT05201066|DRUG|azacitidine|Solution for subcutaneous injection or intravenous infusion
58272794|NCT05201066|DRUG|venetoclax|Tablet for oral administration
58272795|NCT05201066|DRUG|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
58272796|NCT05075044|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
58272797|NCT04636294|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
58390743|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
57918955|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
58272798|NCT03093051|DEVICE|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
58272799|NCT01037816|DRUG|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
58272800|NCT01037816|OTHER|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
57918956|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
58064612|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
58272801|NCT04777656|DIETARY_SUPPLEMENT|Phase1 : CDED/Modulen™IBD® + Maintenance therapy|from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
58272802|NCT04777656|DIETARY_SUPPLEMENT|Phase2 and 3 :|from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
58390744|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
58390745|NCT04036201|DRUG|Bupivacaine|peribulbar block
58272803|NCT00348036|BEHAVIORAL|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
57720552|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
57720553|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
57918957|NCT03742167|OTHER|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
58272804|NCT00348036|OTHER|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
58064613|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
58272805|NCT02772276|DRUG|MB-102-- single dose of 4 µmol/kg|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
58272806|NCT02772276|DRUG|MB-102-- single dose of 130 mg|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
57720554|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
57720555|NCT01970332|PROCEDURE|Revascularization Surgery|
57720556|NCT01970332|OTHER|Supervised exercise therapy|
57720557|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
57720558|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
57720559|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
57720560|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
57720561|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
57720562|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
57720563|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
57720564|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
57720565|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
57720566|NCT02360540|OTHER|Gestalt estimation|
57720567|NCT03208972|DRUG|low dose hCG|
57720568|NCT03208972|DRUG|hp-FSH|
57720569|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
57918958|NCT01079130|DRUG|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
58272807|NCT02772276|DRUG|MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
58272808|NCT02772276|DRUG|MB-102-- two doses of 130 mg 24 hours apart|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
57720570|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
57720571|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
57720572|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
57720573|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
57720574|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
57720575|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
57720576|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
57918959|NCT01079130|DRUG|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
57918960|NCT01079130|DRUG|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
58272809|NCT02772276|DRUG|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
58272810|NCT02772276|DEVICE|QuantumLeap|Optical Renal Function Monitor (ORFM)
58272811|NCT02772276|DEVICE|Radiance|Optical Renal Function Monitor (ORFM)
58272812|NCT02772276|DEVICE|Brilliance (1 or 2 sensors)|Optical Renal Function Monitor (ORFM)
58272813|NCT02772276|DEVICE|Brilliance (2-part sensor)|Optical Renal Function Monitor (ORFM)
58272814|NCT06055023|DRUG|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272815|NCT06055023|DRUG|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272816|NCT06055023|DRUG|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272817|NCT06055023|DRUG|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272818|NCT06055023|DRUG|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272819|NCT06055023|DRUG|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
57720577|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
57720578|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
57720579|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
57720580|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
57720581|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
57720582|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
57720583|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
57720584|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
58272820|NCT06055023|DRUG|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272821|NCT06055023|DRUG|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
58272822|NCT01500044|PROCEDURE|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
58272823|NCT01500044|PROCEDURE|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
58272824|NCT03742856|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
58272825|NCT00154401|DRUG|liraglutide|
58272826|NCT04280458|BEHAVIORAL|Intentive rehabilitation|"Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months."
58272827|NCT04280458|BEHAVIORAL|Routine care|"Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months."
58272828|NCT03858283|BEHAVIORAL|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
58272829|NCT05039320|DIETARY_SUPPLEMENT|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
58272830|NCT05039320|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
58272831|NCT06517550|OTHER|positive end-expiratory pressure while mechanical ventilation|a parameter in ventilator
58272832|NCT01853696|DRUG|loteprednol etabonate|
58272833|NCT01853696|DRUG|prednisolone acetate 1%|
58272834|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
58272835|NCT06292013|DRUG|Placebo|Administered SC
58272836|NCT01254721|DRUG|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
58272837|NCT01254721|DRUG|lithium|300mg tablet, oral
58272838|NCT05840328|DRUG|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
58272839|NCT05840328|DRUG|Bupivacaine Injection|intervention drug will be administred epidurally
58272840|NCT01490697|DRUG|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
58064614|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
58272841|NCT01490697|DRUG|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
58272842|NCT01490697|DRUG|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
58272843|NCT01490697|DRUG|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
57720585|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
57720586|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
57720587|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
57720588|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
57720589|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
57720590|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
57720591|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
57720592|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
58390746|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
57720593|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
58272844|NCT01288092|DRUG|BEZ235|
58272845|NCT06044272|OTHER|Factors associated|Factors associated with the type of resistance by microorganisms.
58272846|NCT03684551|OTHER|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
58390747|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
58272847|NCT03684551|OTHER|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
57720594|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
57720595|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
57918961|NCT01079130|DRUG|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
58272848|NCT03684551|OTHER|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
57918962|NCT02727465|OTHER|Meningitis cases|None - blood draw only
58272849|NCT05306236|OTHER|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
58272850|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
58272851|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
58272852|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
57720596|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
57720597|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
57720598|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
57784598|NCT03510858|OTHER|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
57918963|NCT04789512|OTHER|Respiratory functions|Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
57918964|NCT02875093|DRUG|ADI-PEG 20|Investigational Medicine
57918965|NCT02875093|DRUG|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
57918966|NCT04851340|OTHER|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
57918967|NCT04851340|OTHER|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
57918968|NCT01516593|DRUG|Induction Phase|"* dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
57918969|NCT01516593|DRUG|Consolidation Phase (on day +50)|"* dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection."
57918970|NCT01516593|DRUG|Intensification phase|"1. One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~2. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~3. AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
58064615|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
57720599|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
57720600|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
57720601|NCT06024746|DRUG|Finerenone|Oral finerenone.
57720602|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
58272853|NCT05796648|BEHAVIORAL|RN-CHeFRx|The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
58272854|NCT04520139|DRUG|N-Acetyl-Cysteine|Given PO
57720603|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
57720604|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
57720605|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
57720606|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
57720607|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
57720608|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
57720609|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
58272855|NCT04520139|OTHER|Placebo|Given PO
58272856|NCT06730581|DRUG|Utidelone Capsule 60mg/m2/d|60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
58272857|NCT06730581|DRUG|Utidelone capsule 75mg/m2|75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
58272858|NCT06730581|DRUG|Utidelone Capsule|Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
58272859|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
58272860|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
58272861|NCT01429064|DRUG|ODM-201|ODM-201 administered orally daily
58272862|NCT00583102|DRUG|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
58272863|NCT00583102|DRUG|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
57720610|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
57720611|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
57720612|NCT04878705|DRUG|placebo|a single subcutaneous injection
57720613|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
57720614|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
57720615|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
58064616|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
58064617|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
58064618|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
57720616|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
57720617|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
57720618|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
57720619|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
57720620|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
57720621|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
57720622|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
57720623|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
57720624|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
57720625|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
57720626|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
57720627|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
57918971|NCT01516593|DRUG|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
57918972|NCT01516593|RADIATION|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
57918973|NCT05392153|OTHER|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
57918974|NCT03497754|DEVICE|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
58064619|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
58064620|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
58064621|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
58064622|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
57720628|NCT00185133|DRUG|Olmesartan medoxomil|
57720629|NCT00185133|DRUG|Amlodipine|
57720630|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
57918975|NCT04270630|BEHAVIORAL|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
57720631|NCT03938701|DEVICE|Fluorescence Imaging|"Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
57720632|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
57918976|NCT02066428|BIOLOGICAL|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
57720633|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
57720634|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
57720635|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
57720636|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
57720637|NCT05739500|OTHER||no intervention, just observation
57720638|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
57720639|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
57720640|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
57720641|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
57720642|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
57720643|NCT03403634|DRUG|Celecoxib|Given PO
57720644|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
57918977|NCT02066428|BIOLOGICAL|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
57918978|NCT02641600|DEVICE|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
57720645|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
57720646|NCT03403634|DRUG|Rintatolimod|Given IV
57720647|NCT01884350|DRUG|Apixaban|
57720648|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
57720649|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
57720650|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
57720651|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
57720652|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
57720653|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
57720654|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
57720655|NCT00844441|OTHER|medical chart review|
57720656|NCT00844441|OTHER|questionnaire administration|
58272864|NCT05416645|PROCEDURE|patients with GERD after LSG|patients with GERD after LSG
58272865|NCT06401044|DRUG|AMG 732|SC injection
57720657|NCT00844441|PROCEDURE|quality-of-life assessment|
57720658|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
58272866|NCT06401044|OTHER|Placebo|SC injection
58272867|NCT00323037|DRUG|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
58272868|NCT00323037|DRUG|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
58272869|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
57720659|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
58272870|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
57720660|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
57720661|NCT00982319|DRUG|Mango juice|150 mL of mango juice
57918979|NCT02641600|DEVICE|Placebo stockings|Placebo stocking with pressure applied to the legs
57918980|NCT00602394|DRUG|Lithium|
57918981|NCT03818685|DRUG|Nivolumab|Radiotherapy will be maintained in each Arm.
57918982|NCT03818685|DRUG|Ipilimumab|Radiotherapy will be maintained in each Arm.
58272871|NCT00425893|BEHAVIORAL|hand hygiene|alcohol-based hand wash
57720662|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
57720663|NCT02934139|OTHER|Placebo|Matched placebo
57720664|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
57720665|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
57720666|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
57720667|NCT05277467|OTHER|no intervention|no intervention
57720668|NCT02251535|DEVICE|ATTUNE® Knee System|
57720669|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
57918983|NCT03818685|DRUG|Capecitabine|Radiotherapy will be maintained in each Arm.
57918984|NCT04223869|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
58272872|NCT00425893|OTHER|health education|Proper nutrition, etc.
58272873|NCT00425893|DEVICE|face masks|face masks
58272874|NCT05611996|BEHAVIORAL|Peers plus|Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texting to older adults with depression.
58272875|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
58272876|NCT05995249|DRUG|TAK-279|TAK-279 capsules
58272877|NCT05995249|DRUG|Erythromycin|Erythromycin tablets
58272878|NCT05995249|DRUG|Phenytoin|Phenytoin capsules
58272879|NCT05995249|DRUG|Efavirenz|Efavirenz tablets
57918985|NCT05831930|DRUG|Nituozumab|Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
57918986|NCT04756388|OTHER|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
58272880|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
58390748|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
58390749|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
58390750|NCT03545087|DRUG|Lanabecestat|Administered orally
57918987|NCT04756388|OTHER|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
57918988|NCT01816854|DEVICE|Stenting|
58064623|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
58064624|NCT00106496|DRUG|Protopic|topical
58272881|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
58064625|NCT00106496|DRUG|Corticosteroid|topical
58272882|NCT03514979|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
58272883|NCT01190111|BIOLOGICAL|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
58390751|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
58064626|NCT00106496|DRUG|placebo|topical
58064627|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
58064628|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
58390752|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
58390753|NCT01532921|PROCEDURE|Tricuspid valve repair|
58390754|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
58390755|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
57918989|NCT05418023|OTHER|Salivary Collection|Collection of saliva via swab for miRNA processing
57918990|NCT05418023|OTHER|Adaptive Assessment|Includes Vineland Adaptive Behavior Scale or equivalent
57918991|NCT05418023|OTHER|Medical and Demographic questionnaire|Survey that collects basic medical and demographic information
58064629|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
57720670|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
57720671|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
57720672|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
57720673|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
57918992|NCT05418023|OTHER|Autism Assessment|Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
57918993|NCT05418023|OTHER|Intellectual Development Assessment|Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
58064630|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
58272884|NCT00437372|DRUG|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
58272885|NCT00437372|RADIATION|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
57918994|NCT01720173|BIOLOGICAL|Dalantercept|Given SC
57918995|NCT01720173|OTHER|Laboratory Biomarker Analysis|Correlative studies
57918996|NCT05407922|PROCEDURE|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
57918997|NCT03171077|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
58064631|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
58064632|NCT00151723|PROCEDURE|treatment with 131I|
58064633|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
58272886|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
57720674|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
57720675|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
57720676|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
57720677|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
57720678|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
57720679|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
57720680|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
58390756|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
58390757|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
57720681|NCT00499369|DRUG|leucovorin calcium|Given IV
57720682|NCT00499369|DRUG|fluorouracil|Given IV
57720683|NCT00499369|BIOLOGICAL|cetuximab|Given IV
57720684|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
57720685|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
57720686|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
57720687|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
57720688|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
57720689|NCT05212259|DRUG|Placebo|4 capsules per day
57720690|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
57720691|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
57720692|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
57720693|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
58064634|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
58390758|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
57720694|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
57720695|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
57720696|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
57720697|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
57720698|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
57720699|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
57720700|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
57720701|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
57720702|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
57918998|NCT03171077|OTHER|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
57918999|NCT03171077|OTHER|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
57919000|NCT00888446|BIOLOGICAL|tgAAC09|
57919001|NCT00888446|BIOLOGICAL|tgAAC09|
57919002|NCT00888446|BIOLOGICAL|tgAAC09|
57919003|NCT00888446|OTHER|Formulation buffer|Sterile isotonic buffered salt solution
58064635|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
58064636|NCT02475564|DRUG|Placebo|40mg of starch
58064637|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
58064638|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
58064639|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
58272887|NCT06731439|OTHER|Starting feeds within 6 hours of life|Starting feeds within 6 hours of life
58272888|NCT06731439|OTHER|Standard feeding protocol|Starting feeds based on standard protocol as per primary team
58390759|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
57720703|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
57720704|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
57720705|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
57720706|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
57919004|NCT03695666|OTHER|Clerical policy|Clerical policy introduction
57919005|NCT04010825|OTHER|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
57919006|NCT05830838|PROCEDURE|Computed Tomography|Undergo PET/CT
57919007|NCT05830838|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
57919008|NCT05830838|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57919009|NCT05830838|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58390760|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
58390761|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
57919010|NCT05830838|OTHER|Questionnaire Administration|Ancillary studies
57919011|NCT05830838|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57919012|NCT04929548|DRUG|Pyrotinib Maleate Tablets|Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
58064640|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
58064641|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
58064642|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
58064643|NCT01813630|DRUG|DA-3002|
57919013|NCT05916118|OTHER|Aerobic Exercise|Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
57919014|NCT02925637|OTHER|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
57919015|NCT00295594|DRUG|tacrolimus|Immunosuppression
57919016|NCT03904355|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
57919017|NCT03904355|DRUG|human chorionic gonadotropin|HCG triggering of ovulation
57919018|NCT03904355|PROCEDURE|Ovum pick up|34 to 36 hours after oocyte retrieval
57919019|NCT03904355|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
58064644|NCT01813630|DRUG|Genotropin®|
58272889|NCT05671419|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
58272890|NCT04480567|DRUG|BMN 307|AAV Gene Therapy Infusion
58272891|NCT01097070|DRUG|Bevirimat|
57919020|NCT04704011|OTHER|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
57919021|NCT04704011|OTHER|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
58064645|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
58272892|NCT05666921|OTHER|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
58272893|NCT05563506|BEHAVIORAL|Healthy Kids +|Three times a week for 30 weeks.
58272894|NCT00673725|DRUG|Locobase® REPAIR|emollient
58390762|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
58390763|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
58390764|NCT02472587|OTHER|Questionnaire|
58390765|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
58390766|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
58390767|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
58390768|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
58390769|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
58272895|NCT03493022|OTHER|Test Granola|50.5 Test Granola
58272896|NCT03493022|OTHER|Control Granola|54.3 Control Granola
57919022|NCT04704011|OTHER|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
58064646|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
58064647|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
58064648|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
58064649|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
58064650|NCT03044730|DRUG|Capecitabine|Given PO
58064651|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
58064652|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
58064653|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc...
58272897|NCT06731660|OTHER|Education with personalized performance feedback|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email
58272898|NCT06731660|DEVICE|Use of digital otoscope|Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
58272899|NCT00096993|DRUG|Placebo|Placebo was provided as a single-use formulation for infusion.
58272900|NCT00096993|DRUG|Gemcitabine|Gemcitabine was provided as a solution for infusion.
58272901|NCT00096993|DRUG|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
58272902|NCT03330366|DIETARY_SUPPLEMENT|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
58272903|NCT03330366|DIETARY_SUPPLEMENT|Placebo|take two capsules per day
58272904|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
58390770|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
57720707|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
57720708|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
57919023|NCT04704011|OTHER|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
57919024|NCT04704011|OTHER|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
58064654|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
58390771|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
58390772|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
57720709|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
58390773|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
58390774|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
58272905|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
58390775|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
58390776|NCT00505973|DRUG|SCA-136|
58390777|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
58390778|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
58390779|NCT02579421|DRUG|Progesterone|generic progesterone
58390780|NCT02579421|DRUG|placebo|placebo
58390781|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
58272906|NCT06465914|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
58272907|NCT06465914|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
58272908|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
58390782|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
58390783|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
58390784|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
58390785|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
58390786|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
58390787|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
57919025|NCT04751656|BEHAVIORAL|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
57919026|NCT00567710|DRUG|BL - 1020|10 mg/day
58272909|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
58272910|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
57919027|NCT00567710|DRUG|BL - 1020|BL 1020 20-30 mg/day
58272911|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58272912|NCT06729541|OTHER|Multigenetic Pharmacogenomics-Guided Treatment (MPGT)|In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
57919028|NCT00567710|DRUG|Placebo|Capsules
57919029|NCT00567710|DRUG|Risperidone|Capsules
57720710|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
57720711|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
57720712|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
57720713|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
57720714|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
58272913|NCT02155075|DEVICE|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
58272914|NCT01329432|PROCEDURE|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
58272915|NCT01329432|PROCEDURE|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
58272916|NCT04365478|PROCEDURE|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
58272917|NCT04365478|PROCEDURE|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
58272918|NCT01618110|DEVICE|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
58272919|NCT01618110|OTHER|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
58272920|NCT03370523|OTHER|No intervention is planned in our study|No intervention is planned in our study
58272921|NCT03557684|DIETARY_SUPPLEMENT|leucine|amino acid leucine in powder
58272922|NCT03557684|OTHER|PO placebo|maltodextrin
58272923|NCT03557684|BIOLOGICAL|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
58272924|NCT03557684|OTHER|IV placebo|0.9% saline
58272925|NCT01443325|DRUG|lidocaine patch|1 patch for 12 hours within each 24 hours period
58272926|NCT01900431|DRUG|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
58272927|NCT01900431|DRUG|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
58272928|NCT01900431|DRUG|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
58272929|NCT01900431|DRUG|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
58390788|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
57720715|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
57720716|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
57720717|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
57720718|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
57919030|NCT03556241|DEVICE|Case management|Case management consists keeping patient's current pacemaker mode during surgery
57919031|NCT00061451|DRUG|Pemetrexed|
57919032|NCT00061451|DRUG|Gemcitabine|
58272930|NCT01900431|OTHER|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
58272931|NCT01192724|DRUG|Cilostazol|100 mg BID, for 3 months
58272932|NCT01192724|DRUG|Aspirin|Aspirin 100 mg QD, for 1 year
58272933|NCT01192724|DRUG|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
58272934|NCT06020196|PROCEDURE|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
58272935|NCT06020196|PROCEDURE|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
58272936|NCT01917357|BIOLOGICAL|Quinvaxem in Uniject|
58272937|NCT01917357|BIOLOGICAL|Quinvaxem in single dose vials|
58272938|NCT06199349|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
58390789|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
58390790|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
58064655|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
58064656|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
58064657|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
58272939|NCT06199349|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
58272940|NCT00001736|DRUG|Cysteamine|
58272941|NCT01618019|DIETARY_SUPPLEMENT|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
58272942|NCT01618019|DIETARY_SUPPLEMENT|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
58272943|NCT04247568|OTHER|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
57720719|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
58272944|NCT03427268|DRUG|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
58272945|NCT02348359|DRUG|X-82|
57720720|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
58064658|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
58272946|NCT02348359|DRUG|Anti-VEGF|
58272947|NCT02348359|DRUG|Placebo|
57720721|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
58064659|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
58272948|NCT01831323|DIETARY_SUPPLEMENT|VSL#3|VSL#3
58272949|NCT01831323|DRUG|Rifaximin|Rifaximin
57720722|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
57720723|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
57720724|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
58272950|NCT01831323|DRUG|Mesalazine|Mesalazine
58272951|NCT01831323|DIETARY_SUPPLEMENT|Psyllium|psyllium
58272952|NCT04026932|OTHER|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
58272953|NCT04026932|OTHER|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
58272954|NCT03248414|DIETARY_SUPPLEMENT|Lactobacillus sakei|1 pack contained 5 x 109 cfu
58272955|NCT04369235|DEVICE|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
58272956|NCT04369235|DEVICE|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
58272957|NCT02921633|OTHER|Intervention letter|
58272958|NCT05343104|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
58272959|NCT05705271|DRUG|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
58272960|NCT04592289|PROCEDURE|Full bowel preparation|MBP+OA
58272961|NCT04592289|PROCEDURE|Mechanical bowel preparation only|MBP
58272962|NCT00257205|DRUG|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
58272963|NCT00257205|DRUG|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
58272964|NCT00257205|DRUG|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
57720725|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
58064660|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
58064661|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
58064662|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
58064663|NCT01520727|DRUG|Placebo|single-dose
58272965|NCT06731101|DEVICE|Stellate ganglion block|Sonar guided block of Stellate Ganglion By Local anathetics
58390791|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after PRK
58390792|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
58390793|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
57720726|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
58064664|NCT06333535|OTHER|foot massage|foot massage
58064665|NCT06333535|OTHER|abdominal massage|abdominal massage
58064666|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
58272966|NCT06731101|DRUG|Anticholinergic and Antidepressant Drugs|Tryptizole Librax
58390794|NCT00540241|DRUG|Pemetrexed|in-label use
58390795|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
58390796|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
58390797|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
58390798|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
58390799|NCT02293967|DRUG|MT-1303|
58390800|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
57720727|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
57720728|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
57720729|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
57720730|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
58064667|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
58064668|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
58064669|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
58064670|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
58272967|NCT03889119|RADIATION|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
58272968|NCT06718270|DRUG|CAR-T cells Infusion|chimeric antigen receptor T cells
58272969|NCT01752634|DRUG|Secukinumab (AIN457)|Secukinumab (AIN457)
58272970|NCT01752634|DRUG|Placebo|Placebo PFS for s.c. administration.
57720731|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
57720732|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
57720733|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
57720734|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
58390801|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
58064671|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
58390802|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
58390803|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
58390804|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
58390805|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
58390806|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
58390807|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
58390808|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
58390809|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
58390810|NCT02013778|DRUG|HCQ|
58390811|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
58390812|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
58390813|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
58390814|NCT02319460|BIOLOGICAL|Plasma|
58390815|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
58390816|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
58390817|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
58064672|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
58064673|NCT01808911|DRUG|Steroid + cyclophosphamide|
58064674|NCT01808911|DRUG|Steroid + rituximab|
58064675|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
58064676|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
58272971|NCT05167279|BIOLOGICAL|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
58064677|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
58064678|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
58272972|NCT05167279|BIOLOGICAL|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
58272973|NCT03959696|BEHAVIORAL|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
58272974|NCT03959696|BEHAVIORAL|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
58390818|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
58390819|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
58390820|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
58064679|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
57720735|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
58064680|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
58064681|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
58272975|NCT03950141|DRUG|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
57720736|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
58064682|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
58064683|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
58064684|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
58064685|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
58064686|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
58064687|NCT03976882|DRUG|Hetrombopag|Hetrombopag
58064688|NCT03976882|DRUG|Placebo|Placebo
58064689|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
58064690|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
58064691|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
58064692|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
58064693|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
58064694|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
58064695|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
58064696|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
58064697|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
58064698|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
58272976|NCT06379568|OTHER|No intervention|No intervention
58272977|NCT03796715|DIAGNOSTIC_TEST|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
58390821|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
58390822|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
58390823|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
58390824|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
57919033|NCT05337852|OTHER|Emotional Freedom Technique|"To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
57919034|NCT00015041|DRUG|Buprenorphine|
57919035|NCT00972452|BEHAVIORAL|Exercise|short period of exercise training (5-10 days)
57919036|NCT06324565|DIAGNOSTIC_TEST|D-Dimer test|All patients in whom preoperative diagnostics have not been able to exclude a surgical pathology and who are candidates for diagnostic-therapeutic surgery will be referred for minimally invasive abdominal exploration in the real suspicion of ovarian torsion. During the pre-operative phase, blood exams will be performed including coagulation which will be integrated with the D-dimer values. In addition, as usual, the clinical examination of the patients will be performed integrated with the various diagnostic image tools generally used in this category of patients (abdomen ultrasound +/- magnetic resonance in urgency).
57919037|NCT05874115|OTHER|liquid biopsy|liquid biopsy
57919038|NCT00709696|DRUG|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
57919039|NCT00709696|DRUG|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
57720737|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
57919040|NCT03211910|DEVICE|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
57919041|NCT03211910|OTHER|Standard Care of Treatment|Standard Care of Treatment
57919042|NCT00258063|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
57919043|NCT04621591|DEVICE|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
58064699|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
58390825|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
57919044|NCT00945126|OTHER|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
57919045|NCT00609765|DRUG|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
57919046|NCT00609765|DRUG|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
57919047|NCT00609765|DRUG|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
57919048|NCT00609765|DRUG|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
57919049|NCT00609765|DRUG|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
57919050|NCT00609765|DRUG|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
57919051|NCT03924739|BEHAVIORAL|Nurse-coordinated integrated care model for AF|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
58064700|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
58064701|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
58064702|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
58064703|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
58272978|NCT03796715|DIAGNOSTIC_TEST|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
58272979|NCT06426134|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)|1x50g ingestion of pure dGK
58390826|NCT01731340|OTHER|Low Dietary Calcium|450 mg
58390827|NCT01731340|OTHER|High Dietary Calcium|1200 mg
58390828|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
58390829|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
58390830|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
57720738|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
57919052|NCT06249373|DEVICE|Low intensity pulse ultrasound （LIPUS） intervention for arteriovenous fistula anastomosis|The LIPUS intervention group for arteriovenous fistula should receive forearm wearable portable low-intensity pulse ultrasound （LIPUS） intervention at the anastomotic site no more than 3 days after suture removal two weeks after the fistula surgery. If the ultrasound examination indicates the presence of stenosis in the outflow tract, the intervention should also be performed at the same time. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
57919053|NCT04589208|DRUG|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
57919054|NCT05331963|OTHER|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
57919055|NCT00675090|DRUG|GSK239512|GSK239512 oral tablets once a day
57919056|NCT00675090|DRUG|Placebo|Placebo tablets to match once a day
57919057|NCT05695625|OTHER|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
58272980|NCT06426134|OTHER|Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride|Isocaloric carbohydrate control (active control)
58272981|NCT00083720|BIOLOGICAL|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
58272982|NCT01068626|DRUG|Rosuvastatin|10 mg once daily
58272983|NCT01068626|DRUG|Placebo for rosuvastatin|once daily
58390831|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
58390832|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
58390833|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
58390834|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
58390835|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
57720739|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
57720740|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
57720741|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
57720742|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
58272984|NCT01897766|DRUG|Somatropin|0.23 mg to 0.48 mg/kg/week
58272985|NCT03168490|DIETARY_SUPPLEMENT|Gluten Friendly bread|parallel study
58272986|NCT02778841|OTHER|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
58272987|NCT03601273|PROCEDURE|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
58272988|NCT05103436|OTHER|TENS|Electrical nerve stimulation
58390836|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
58390837|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
58390838|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
58390839|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
58390840|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
58390841|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
58390842|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
58272989|NCT05032456|DEVICE|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
58064704|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
58390843|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
58390844|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
58390845|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
58390846|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
57720743|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
57720744|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
57720745|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
57720746|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
57720747|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
57720748|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
57720749|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
57919058|NCT05695625|OTHER|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
57919059|NCT00925431|BEHAVIORAL|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
57919060|NCT00925431|BEHAVIORAL|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
57919061|NCT03029312|DEVICE|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
57919062|NCT04633551|DIETARY_SUPPLEMENT|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
57919063|NCT01093521|DRUG|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
58064705|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
58272990|NCT05459194|DEVICE|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
57720750|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
57720751|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
57720752|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
58272991|NCT03945994|OTHER|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
58272992|NCT06467994|OTHER|Cashew oral immunotherapy|Cashew Flour (boiled/ roasted) that is prepared under food manufacturing regulations
58390847|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
57720753|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
57720754|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
58272993|NCT06467994|OTHER|Placebo oral immunotherapy|Placebo oral immunotherapy consists of corn flour with food colouring that has similar appearance, taste and smell to the active product
58272994|NCT02939482|DRUG|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
58390848|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
58390849|NCT00150215|DRUG|PF-00184562|
58390850|NCT00150215|DRUG|Olanzapine|
58390851|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
58390852|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
58390853|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
58390854|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
58390855|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
58390856|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
58390857|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
58390858|NCT01419496|GENETIC|protein expression analysis|
58390859|NCT01419496|OTHER|flow cytometry|
58272995|NCT02732405|DRUG|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
58390860|NCT01419496|OTHER|laboratory biomarker analysis|
58390861|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
57919064|NCT01093521|DRUG|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
58064706|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
58272996|NCT02466607|DEVICE|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
58390862|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
58390863|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
58390864|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
58390865|NCT00305903|DRUG|Rivastigmine, memantine|
58390866|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
58390867|NCT00232999|DRUG|Nebulized IVX-0142|
58390868|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
58390869|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
58390870|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
58390871|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
58390872|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
58390873|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
58390874|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
57919065|NCT02113930|BIOLOGICAL|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
58272997|NCT02466607|DEVICE|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
58272998|NCT02466607|OTHER|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
58272999|NCT05289024|BEHAVIORAL|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
58273000|NCT01902355|PROCEDURE|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
58273001|NCT01902355|PROCEDURE|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
58273002|NCT04291326|DIAGNOSTIC_TEST|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
58273003|NCT00775853|DRUG|6-[18F]Fluorodopamine|
58273004|NCT00775853|DRUG|6-[18F]Fluorodopa|
58273005|NCT00775853|DRUG|13N-Ammonia|
58273006|NCT00306787|DRUG|Famciclovir|Famciclovir 500 mg tablet
58390875|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
58390876|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58390877|NCT01270880|GENETIC|RNA analysis|Correlative studies
57919066|NCT02113930|GENETIC|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
58273007|NCT00306787|DRUG|Valacyclovir|Valacyclovir 500 mg capsule
58273008|NCT00306787|DRUG|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
58273009|NCT00306787|DRUG|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
58273010|NCT06509672|OTHER|Combined Plyometric and Endurance Training|this include Combined Plyometric and Endurance Training for 12 weeks
58273011|NCT06509672|OTHER|Plyometric Training|this include Plyometric Training for 12 weeks
58390878|NCT01270880|OTHER|spectrophotometry|Correlative studies
58390879|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
58390880|NCT01270880|GENETIC|gene expression analysis|Correlative studies
58273012|NCT06509672|OTHER|Endurance training|this include Endurance Training for 12 weeks
58273013|NCT01623024|DRUG|Vitamin D|20.000 UI/week for 96 weeks
58273014|NCT01623024|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling for 96 weeks
58273015|NCT00416429|BIOLOGICAL|aldesleukin|
58273016|NCT00416429|BIOLOGICAL|recombinant interferon alpha-2a|
58273017|NCT00416429|DRUG|medroxyprogesterone|
58273018|NCT00405743|DRUG|CP-4055|CP-4055 Continuous IV infusion
58273019|NCT00405743|DRUG|CP-4055|CP4055 2 and 4 hour IV infusion
58390881|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
58390882|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
58390883|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
58390884|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
58390885|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
58390886|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
58390887|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
58390888|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
58273020|NCT03350308|OTHER|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
57720755|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
57720756|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
57720757|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
58390889|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
58390890|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
58390891|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
58273021|NCT06519097|DRUG|Vitamin E Delta Tocotrienol|"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"
58273022|NCT06519097|OTHER|Placebo|"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"
58390892|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
58390893|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
58390894|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
58390895|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
58390896|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
57720758|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
57720759|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
57720760|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
57720761|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
58273023|NCT05454254|OTHER|Individualised muscle strengthening exercise training protocol.|Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
58273024|NCT00089700|DRUG|TNX-355|
58390897|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
58390898|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
58390899|NCT00118248|DRUG|tanespimycin|Given IV
57720762|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
58390900|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
58390901|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
58390902|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
58390903|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
58390904|NCT01212887|BIOLOGICAL|aldesleukin|
57720763|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
57720764|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
57720765|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
57720766|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
57720767|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
57720768|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
58273025|NCT05635097|BEHAVIORAL|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
58273026|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation|Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. No adjunctive therapies were applied in this group.
58273027|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and chlorhexidine irrigation|The participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were irrigated with 0.2% chlorhexidine digluconate solution for 1 minute.
58273028|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and ozone application|The participants in the mechanical instrumentation with ozone (MO) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, gaseous ozone was applied to the peri-implant pockets using an ozone-generating device and a specialized glass fiber probe. The ozone gas was delivered to four sites (mesial, distal, buccal, and lingual) for 15 seconds per site, resulting in a total application time of 1 minute per implant. The device operated at a power of 3 watts and 80% oxygen concentration, as recommended by the manufacturer.
58276751|NCT03899207|OTHER|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
58390905|NCT01212887|DRUG|cyclophosphamide|
57720769|NCT01849341|DRUG|Roflumilast 500 mcg per day|
58390906|NCT01212887|DRUG|fludarabine phosphate|
57720770|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
57720771|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
57919067|NCT04095741|DIAGNOSTIC_TEST|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
57720772|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
58273029|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and air abrasion|The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were treated with glycine powder-based air abrasion using an air-abrasion device (AIR-FLOW® handy 3.0 PERIO HANDPIECE, EMS, Nyon, Switzerland) and a flexible Perio-Flow® nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant.
57720773|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
58390907|NCT01212887|OTHER|laboratory biomarker analysis|
57720774|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
57720775|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
57720776|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
58273030|NCT06730568|PROCEDURE|Air abrasion monotherapy|The participants in the glycine powder air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion. Local anesthesia was applied before the procedure. The peri-implant pockets were instrumented with an air-abrasion device using glycine powder and a flexible nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant. .
58390908|NCT01212887|OTHER|pharmacological study|
58390909|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
58390910|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
57720777|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
57720778|NCT01813019|DRUG|Placebo|Matched placebo
57720779|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
57720780|NCT03598998|DRUG|Pralatrexate|Given IV
58273031|NCT03218605|OTHER|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
58273032|NCT00670605|OTHER|medical chart review|
58273033|NCT00670605|OTHER|study of socioeconomic and demographic variables|
58273034|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58273035|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58390911|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
58273036|NCT05590533|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
58273037|NCT04003454|OTHER|HCV Screening|The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
58273038|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
57720781|NCT05141682|DRUG|Oral Azacitidine|Given PO
57720782|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
57720783|NCT00039767|DRUG|Lepirudin|
57720784|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
57720785|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
57720786|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
57720787|NCT02376413|RADIATION|Radiation therapy|
57720788|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
57720789|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
57720790|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
57720791|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
58273039|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
58273040|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
58273041|NCT00864136|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
58273042|NCT00864136|DRUG|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
58273043|NCT00864136|DRUG|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
58273044|NCT01822951|DRUG|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
58273045|NCT01822951|DRUG|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
58390912|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
58390913|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
57720792|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
57720793|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
57720794|NCT00029835|DRUG|Rimonabant (SR141716)|
57720795|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
57720796|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
57720797|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
57720798|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
57720799|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
57720800|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
57720801|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
57720802|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
57720803|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
58273046|NCT04760379|OTHER|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
58273047|NCT04760379|OTHER|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
58273048|NCT03776071|DRUG|Enzastaurin Hydrochloride|mg
58273049|NCT03776071|OTHER|Placebo|mg
58273050|NCT03776071|DRUG|Temozolomide|mg/m\^2
58273051|NCT03776071|RADIATION|Radiotherapy|Gy
57720804|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
58273052|NCT05948839|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
58273053|NCT05948839|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
58273054|NCT06729931|DIAGNOSTIC_TEST|Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement|The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
58390914|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
58390915|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
58390916|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
58390917|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
57720805|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
57720806|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
57919068|NCT03274960|COMBINATION_PRODUCT|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
58390918|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
58390919|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
57720807|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
57720808|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
57919069|NCT00430261|DRUG|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
58390920|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
58390921|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
58390922|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
58390923|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
58390924|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
58390925|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
58390926|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
58390927|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
58064707|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
58390928|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
58390929|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
58390930|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
58390931|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
58390932|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
58390933|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
58390934|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
57720809|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
57720810|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
57720811|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
57720812|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
57720813|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
57720814|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
58064708|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
58273055|NCT00586287|OTHER|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
58390935|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
58390936|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
58390937|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
58390938|NCT06659042|DRUG|Cisplatin|administered via IV infusion
58390939|NCT06659042|DRUG|Carboplatin|administered via IV infusion
58390940|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
58390941|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
58390942|NCT00429676|DRUG|Haloperidol|
57720815|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
57720816|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
57720817|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
57720818|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
58390943|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
58390944|NCT02752919|DRUG|Galunisertib|Administered orally
58390945|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
58390946|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
58390947|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
58390948|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
58390949|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
58390950|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
58390951|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
58390952|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
58390953|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
58390954|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
58390955|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
58390956|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
58390957|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
58390958|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
58390959|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
58390960|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
58390961|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
58390962|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
58390963|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
58390964|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
58390965|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
58390966|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
58390967|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
57720819|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
57720820|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
57720821|NCT02129179|DRUG|Glucagon-Like Peptide 1|
58064709|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
57720822|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
58064710|NCT00124696|DRUG|Cocaethylene|
58064711|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
58064712|NCT02183792|DRUG|Tolvaptan|
58064713|NCT02183792|DRUG|Furosemide|
58064714|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
58064715|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
58064716|NCT04005885|DEVICE|comfilcon A|Contact Lens
58390968|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
58390969|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
58390970|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
58390971|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
58390972|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
57720823|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
57919070|NCT00210470|BIOLOGICAL|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
58064717|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
58064718|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
58390973|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
58390974|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
58390975|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
58390976|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
58390977|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
57720824|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
57720825|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
57720826|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
57720827|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
57720828|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
57720829|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
57720830|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
57720831|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
57720832|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
57720833|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
57720834|NCT05825287|OTHER|Management training|Management training
57720835|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
58390978|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
57919071|NCT00210470|DRUG|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
57919072|NCT00210470|DRUG|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
57919073|NCT00210470|DRUG|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
58064719|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
58064720|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
58064721|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
58390979|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
58390980|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
57720836|NCT02144675|DRUG|idarubicin|Given IV
57720837|NCT02144675|DRUG|cytarabine|Given IV
57720838|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
57720839|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
57919074|NCT00210470|DRUG|Omeprazole|21 days of 20 mg. orally
57919075|NCT04397341|DRUG|docetaxel, cisplatin, fluorouracil|Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
57919076|NCT01203748|PROCEDURE|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
57919077|NCT01203748|PROCEDURE|PVI|Pulmonary vein antrum isolation
57919078|NCT01203748|PROCEDURE|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
58064722|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
58064723|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
58064724|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
58064725|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
58064726|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
58064727|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
58064728|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
58064729|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
58064730|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
58064731|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
58064732|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
58064733|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
58064734|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
58273056|NCT00586287|OTHER|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
58273057|NCT00586287|DRUG|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
58390981|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
57919079|NCT03646201|BEHAVIORAL|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
57919080|NCT02430688|PROCEDURE|Irreversible electroporation (IRE)|
57919081|NCT02430688|DEVICE|NanoKnife|
57919082|NCT01258335|DIETARY_SUPPLEMENT|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
57919083|NCT01258335|OTHER|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
57919084|NCT01640275|DRUG|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
57919085|NCT01640275|DRUG|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
57919086|NCT00889317|DEVICE|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
58064735|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
58064736|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
58064737|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
58064738|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
58064739|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
58064740|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
58064741|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
58064742|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
58064743|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
58064744|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
58064745|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
58064746|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
58390982|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
58390983|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
57720840|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
57919087|NCT05061784|PROCEDURE|Routine thymectomy, which has been performed|There is no intervention
57919088|NCT05507931|DIETARY_SUPPLEMENT|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
57919089|NCT05507931|DIETARY_SUPPLEMENT|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
58273058|NCT01237327|DRUG|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
58273059|NCT01237327|DRUG|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
58273060|NCT05362695|DRUG|IW-3300|A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
58273061|NCT05362695|DRUG|Placebo|A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
58273062|NCT02189655|PROCEDURE|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
58273063|NCT04603794|DRUG|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
58273064|NCT04603794|DRUG|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
58273065|NCT04603794|DRUG|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
58273066|NCT04603794|DRUG|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
58273067|NCT03202069|OTHER|Even protein|Intake of even protein 5 day rotating menu
58273068|NCT03202069|OTHER|Skewed protein|Intake of skewed protein 5 day rotating menu
57720841|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
57720842|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
57720843|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
57720844|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
58273069|NCT05400395|DRUG|GNX80|GNX80 oral intake(BID) for 24 weeks
57720845|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
57720846|NCT03827798|DRUG|CFZ533|s.c.
57720847|NCT03827798|DRUG|Placebo to CFZ533|s.c.
57720848|NCT03827798|DRUG|LYS006|p.o.
57720849|NCT03827798|DRUG|Placebo to LYS006|p.o.
57720850|NCT03827798|DRUG|MAS825|s.c.
58064747|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
58064748|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
58064749|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
58273070|NCT05400395|DRUG|Placebo|Placebo oral intake(BID) for 24 weeks
57720851|NCT03827798|DRUG|Placebo to MAS825|s.c.
57720852|NCT03827798|DRUG|LOU064 25mg|p.o.
57720853|NCT03827798|DRUG|LOU064 100mg|p.o.
57720854|NCT03827798|DRUG|Placebo to LOU064|p.o.
57720855|NCT03827798|DRUG|VAY736|s.c.
57720856|NCT03827798|DRUG|Placebo to VAY736|s.c.
57720857|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
57720858|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
58273071|NCT01438372|DRUG|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
58273072|NCT01438372|DRUG|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
57720859|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
57720860|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
57919090|NCT04528927|DRUG|HCQ|600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
57919091|NCT04528927|DRUG|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
57919092|NCT04528927|DRUG|Doxycycline|200 mg per day for 10 days
57919093|NCT04528927|DIETARY_SUPPLEMENT|Zinc|220 mg per day for 10 days
57919094|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
58273073|NCT01534780|PROCEDURE|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
58273074|NCT01534780|DEVICE|Protack|fixation of mesh with protack
58273075|NCT01534780|DEVICE|Securestrap|fixation of mesh with Securestrap
58273076|NCT01534780|DEVICE|Glubran|fixation of mesh with Glubran
58273077|NCT03059251|BIOLOGICAL|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
58273078|NCT05055934|DRUG|SHR-1314 injection|SHR-1314 injection
58273079|NCT05055934|DRUG|placebo|placebo
57720861|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
57919095|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
57919096|NCT03434678|PROCEDURE|Open Pancreaticoduodenectomy|Whipple' Procedure
57919097|NCT03481023|DEVICE|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
57919098|NCT03481023|PROCEDURE|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
57919099|NCT04395898|PROCEDURE|pancreaticoduodenectomy|Whipple's procedure
57919100|NCT05657483|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
58390984|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
57720862|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
57720863|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
57919101|NCT05657483|OTHER|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
57919102|NCT03548246|DRUG|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
57919103|NCT03548246|DRUG|Placebo|Daily placebo for 2 years.
57919104|NCT03548246|DRUG|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
57919105|NCT03548246|DRUG|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
57919106|NCT05344729|DRUG|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
57919107|NCT01614535|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
57919108|NCT00517582|DRUG|HOE-140|Subcutaneous at time 0 and 6 hours
58273080|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
58273081|NCT01836809|DRUG|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
58390985|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
58273082|NCT01836809|DRUG|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
58273083|NCT00932451|DRUG|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
57919109|NCT00517582|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
57919110|NCT02408276|OTHER|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
57720864|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
57720865|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
57720866|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
57720867|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
57720868|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
57919111|NCT04481477|OTHER|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
58064750|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
58064751|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
58064752|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
58064753|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
58064754|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
58064755|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
58064756|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
58064757|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
58064758|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
58273084|NCT01057797|BEHAVIORAL|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
58390986|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
57720869|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
57720870|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
57720871|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
58064759|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
58064760|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
58064761|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
58064762|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
58064763|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
58064764|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
58064765|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
58064766|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
58064767|NCT00208572|DRUG|Citalopram|
58064768|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
58064769|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
57720872|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
57720873|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
57720874|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
57720875|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
58064770|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
58064771|NCT00025194|DRUG|estramustine phosphate sodium|
58064772|NCT00025194|DRUG|ixabepilone|
58273085|NCT01057797|BEHAVIORAL|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
58390987|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
58390988|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
58390989|NCT02840318|OTHER|Compassion Intervention|See arm description
58390990|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
57720876|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
57720877|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
57720878|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
58064773|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
58273086|NCT01057797|BEHAVIORAL|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
58390991|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
58390992|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
58390993|NCT03955783|DRUG|Venetoclax|Given by mouth
58390994|NCT03955783|DRUG|Selinexor|Given by mouth
58390995|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
58390996|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
58390997|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
58390998|NCT01927523|OTHER|Match|An intensive math tutoring program.
58390999|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
58391000|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
58391001|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
57720879|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
57720880|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
58273087|NCT06258317|PROCEDURE|fixation of conventional polypropylene mesh|"By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh."
58273088|NCT02612610|DRUG|Gefapixant|Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
58273089|NCT02612610|DRUG|Placebo (for gefapixant)|
58273090|NCT04684875|DEVICE|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
58273091|NCT03493581|PROCEDURE|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
58273092|NCT03493581|DIAGNOSTIC_TEST|blood-sampled|"* after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~* after 6 weeks (V2),~* after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~* - after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~* after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~* after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
58273093|NCT03493581|OTHER|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
58273094|NCT03441282|DRUG|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
58273095|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
58273096|NCT05017025|DRUG|Osimertinib|Given PO
58391002|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
57720881|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
57720882|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
58273097|NCT04482166|OTHER|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
58273098|NCT04482166|DEVICE|supraglottic airway device|supraglottic airway device
58273099|NCT03031041|PROCEDURE|Ultrasound-guided short-axis hydrodissection with 5cc normal saline|Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
58273100|NCT03031041|PROCEDURE|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
58273101|NCT05370508|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
58273102|NCT05716217|OTHER|Arm training|Daily arm training program
58273103|NCT01880567|DRUG|Ibrutinib|Given PO
58273104|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
58273105|NCT01880567|BIOLOGICAL|Rituximab|Given IV
58273106|NCT01923337|DRUG|irinotecan hydrochloride|Given IV
58273107|NCT01923337|DRUG|alisertib|Given PO
58273108|NCT05428384|DEVICE|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
58273109|NCT05735275|DRUG|SHR-A2102|All participants receive SHR-A2102 alone.
58273110|NCT02380118|DRUG|Olanzapine|Intramuscular injection
57720883|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
58273111|NCT02380118|DRUG|Haloperidol|Intramuscular injection
58273112|NCT02380118|DRUG|Midazolam|Intramuscular injection
58391003|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
58391004|NCT00211796|DRUG|Divalproex Sodium ER|
57720884|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
57720885|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
57720886|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
57720887|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
57720888|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
58273113|NCT05812092|DEVICE|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
58273114|NCT03105921|DEVICE|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
58273115|NCT05191589|OTHER|Haptic|Trainees are randomized in this group to use the haptic device.
58273116|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
58391005|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
58273117|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
58273118|NCT06481488|DRUG|E2086|E2086 tablets.
58391006|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
58391007|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
58391008|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
58391009|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
58391010|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
58391011|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
57720889|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
57720890|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
57720891|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
58391012|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
58391013|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
58391014|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
58391015|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
58391016|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
58391017|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
58391018|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
58391019|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
58391020|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
58391021|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
57720892|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
57720893|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
57720894|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
57720895|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
58064774|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
58064775|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
58064776|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
58064777|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
58064778|NCT02599740|OTHER|Placebo|Rice only
58064779|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
58273119|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
57720896|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
57720897|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
57720898|NCT01802411|DRUG|EXPAREL 266 mg|
57720899|NCT01802411|DRUG|Placebo|
58273120|NCT04392830|DRUG|ALZ002 DS|Administered orally
58273121|NCT04392830|DRUG|Placebo|Administered orally
58273122|NCT05439928|DEVICE|DEXCOM G6 CGM|Continuous glucose monitoring
58273123|NCT01075399|DRUG|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
58273124|NCT03065036|DRUG|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
58273125|NCT01172964|DRUG|flucytosine|Given orally
58273126|NCT01172964|OTHER|polymerase chain reaction|Correlative studies
58273127|NCT01172964|OTHER|immunohistochemistry staining method|Correlative studies
58391022|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
58273128|NCT01172964|BIOLOGICAL|gene therapy|Injected at the time of the surgery to resect the tumor
58391023|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
58391024|NCT03999099|DRUG|Placebo oral tablet|Placebo
58391025|NCT00002134|DRUG|Ganciclovir|
58391026|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
58391027|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
58273129|NCT01172964|OTHER|pharmacological study|Correlative studies
58273130|NCT01172964|OTHER|3-Tesla magnetic resonance imaging|Correlative studies
58273131|NCT01172964|OTHER|laboratory biomarker analysis|Correlative studies
58273132|NCT01172964|PROCEDURE|therapeutic conventional surgery|Surgery to resect the tumor
58273133|NCT01172964|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
58273134|NCT02200991|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
58273135|NCT02200991|DRUG|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
58273136|NCT02200991|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
58273137|NCT04688398|DIETARY_SUPPLEMENT|Seal oil|Consumption of seal oil once per day (at breakfast)
58273138|NCT04688398|DIETARY_SUPPLEMENT|Control|Consumption of vegetable oil once per day (at breakfast)
58391028|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
58391029|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
58391030|NCT00159679|DRUG|Pregabalin|
58391031|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
58273139|NCT01277809|BEHAVIORAL|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
58273140|NCT01277809|BEHAVIORAL|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
58273141|NCT01702532|DRUG|Nicotine|Comparison of different dosage forms of nicotine
58273142|NCT02766452|BEHAVIORAL|"You and your child in the recovery room DVD"|
58273143|NCT02766452|BEHAVIORAL|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
58273144|NCT04952207|DRUG|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
58273145|NCT00150306|DRUG|Zoloft (Sertraline)|
58273146|NCT02604355|OTHER|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
58273147|NCT02604355|DRUG|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
58391032|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
58391033|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
58391034|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
58391035|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
58391036|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
58391037|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
58391038|NCT01001767|DRUG|Placebo|Placebo
58391039|NCT00000333|DRUG|Benztropine|
58391040|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
58391041|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
58273148|NCT03318081|BEHAVIORAL|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
58273149|NCT00431067|DRUG|BIBW 2992|
58273150|NCT04148963|DRUG|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
58273151|NCT04148963|DRUG|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
57720900|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
58273152|NCT02262156|OTHER|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
58273153|NCT02262156|DRUG|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
58391042|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
58391043|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
58391044|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
57720901|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
57720902|NCT01920295|DEVICE|Cryoballoon ablation|
57720903|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
57919112|NCT00917605|OTHER|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
57720904|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
57720905|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
57919113|NCT06476886|BEHAVIORAL|Intensive Crisis Intervention (ICI)|"The Pilot Phase will consist of 20 youth admitted to YCSU and their parents receiving ICI.~In the randomized control trial (RCT), 60 youth will be randomized in a 1:1 ratio to YCSU (n=30) or APIU (n=30)."
58273154|NCT06050330|DIAGNOSTIC_TEST|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
58391045|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
58391046|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
58391047|NCT00111449|DRUG|Etanercept|
58391048|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
58391049|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
57720906|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
57720907|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
57720908|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
57720909|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
57919114|NCT06476886|BEHAVIORAL|Adolescent Psychiatric Inpatient Unit (APIU)|In the randomized control trial (RCT), 60 youth will be randomized in a 1:1 ratio to YCSU (n=30) or APIU (n=30).
57919115|NCT02673424|PROCEDURE|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
58273155|NCT06406413|DIAGNOSTIC_TEST|micro-movement; electroencephalogram; MRI|micro-movement; electroencephalogram; MRI
58273156|NCT03765424|DIAGNOSTIC_TEST|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
58273157|NCT05627752|DRUG|Enzalutamide 40 MG|Adding Enzalutamide to Docetaxel chemotherapy
58273158|NCT05627752|DRUG|Docetaxel injection|Docetaxel chemotherapy
58391050|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
58273159|NCT06710860|BEHAVIORAL|ScreenTalk AI-based tailored communication intervention|Participants in intervention group will receive the ScreenTalk AI-based intervention consisting of 3 sessions: (1) tailored messages: to provide CRC risk and screening recommendation based on family history and health belief assessment; (2) open dialogue: to communicate with users asking questions related to CRC risk and screening information, underpinned based on professional knowledge database and Large language models; (3) summary session: to provide a picture overview for easy review. The primary outcome (uptake of colonoscopy) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), and 12 months post-intervention (T3).
57720910|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
58273160|NCT03765112|DEVICE|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
58273161|NCT00387049|BEHAVIORAL|Anxiety Sensitivity Program for Smoking Cessation|
58273162|NCT06731816|OTHER|Neck and stabilization exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. In addition to neck stretching, range of motion, and isometric exercises applied in the neck exercise group, they will also apply spinal and cervical region stabilization exercises.
58273163|NCT06731816|OTHER|Neck exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. They will perform neck stretching, range of motion and isometric exercises.
58273164|NCT04261127|GENETIC|Genetic diagnosis (PMDA panel)|Blood samples for DNA study
58273165|NCT04261127|DIAGNOSTIC_TEST|Use of RADIAL algorithm|RADIAL card filling (contains clinical and biological data)
58273166|NCT06504888|DRUG|Penicillin|Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
58273167|NCT01116076|BEHAVIORAL|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
58273168|NCT01522235|DRUG|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
58391051|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
58391052|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
58391053|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
57720911|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
58273169|NCT01522235|OTHER|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
58273170|NCT01522235|OTHER|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
58273171|NCT05775328|OTHER|Intense pulsed light|Already described in the arm/group description
58273172|NCT02716766|DRUG|Sorafenib|PO
58391054|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
57720912|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
57720913|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
57720914|NCT00726115|DRUG|SAM-531|
57720915|NCT00726115|DRUG|placebo|
58273173|NCT02716766|DRUG|Capecitabine|PO
58273174|NCT02716766|DRUG|Oxaliplatin|IV
58273175|NCT05808816|DRUG|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
58273176|NCT02370030|DIETARY_SUPPLEMENT|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
58273177|NCT06730243|PROCEDURE|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"
58273178|NCT06730243|PROCEDURE|Standard Robot-Assisted Radical Prostatectomy|Standard Robot-Assisted Radical Prostatectomy
58391055|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
58391056|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
58391057|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
58273179|NCT06730243|PROCEDURE|Laparoscopic Radical Prostatectomy|Laparoscopic Radical Prostatectomy
57720916|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
58273180|NCT05859022|OTHER|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
58273181|NCT05859022|OTHER|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
58273182|NCT02175381|DRUG|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
58273183|NCT02175381|DRUG|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
58273184|NCT05627726|DEVICE|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
57720917|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58064780|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
58273185|NCT05627726|OTHER|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
58273186|NCT02140983|DRUG|Liraglutide|90 days of liraglutide up to 1.8mg/day.
58273187|NCT02140983|DRUG|Placebo|Placebo medication
58273188|NCT01901861|DRUG|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
58273189|NCT01901861|DRUG|Placebo|Placebo is given before meal ingestion
58273190|NCT06107153|DRUG|Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
58273191|NCT06107153|DRUG|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
58273192|NCT06107153|DRUG|Pioglitazone 30mg|Pioglitazone 30mg
58273193|NCT01860144|DRUG|Bevacizumab|
57720918|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57720919|NCT06572618|DRUG|Nemtabrutinib|Given PO
57720920|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
57720921|NCT06572618|BIOLOGICAL|Rituximab|Given IV
57720922|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
57720923|NCT00400413|PROCEDURE|fMRI|
57720924|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
57720925|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
57720926|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
57720927|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
57720928|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
57720929|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
58273194|NCT03026933|DRUG|KI1107 4 Capsules, QD|KI1107 4 Capsules
58273195|NCT03026933|DRUG|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
57720930|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
57720931|NCT02977949|DRUG|Raloxifene|
57720932|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
57720933|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
57720934|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
57720935|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
57720936|NCT03258476|DRUG|Placebo|Placebo oral capsule
57720937|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
58273196|NCT03979183|BEHAVIORAL|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
58273197|NCT00311454|DRUG|T.R.U.E.Test|
58273198|NCT04953507|PROCEDURE|Thermal Radiofrequency|Radiofrequency lesioning at level of T2, T3 using 80°c for 60-90 seconds
58273199|NCT04953507|PROCEDURE|Chemical Neurolysis|injection of 2 to 3 ml of the chemical neurolytic agent (phenol in glycerin 6%)
58273200|NCT05114980|PROCEDURE|Parathyroid Allotransplant|Patients that meet inclusion criteria and are enrolled in the trial will undergo parathyroid allotransplantation
57720938|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
57720939|NCT01835782|DRUG|L-Serine|
57720940|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
57720941|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
57720942|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
57720943|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
57720944|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
57720945|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
57720946|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
57720947|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
57720948|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
57720949|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
57720950|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
57720951|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
57720952|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
57720953|NCT00268125|DEVICE|Acupression's bracelet|
57720954|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
57720955|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
58273201|NCT03197194|DRUG|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
58391058|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
58391059|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
58391060|NCT06221761|DRUG|not using antibiotic|no antibiotic application
58391061|NCT06221761|DRUG|using antibiotic|antibiotic application
58391062|NCT02441907|DRUG|aflibercept|
58391063|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
58391064|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
57919116|NCT02673424|PROCEDURE|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)"
57919117|NCT03490526|DEVICE|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
57919118|NCT03490526|DEVICE|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
58064781|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
58064782|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
58064783|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
58273202|NCT03197194|DRUG|acetylsalicylic acid|one tablet of aspirin 300 mg
58273203|NCT03197194|DRUG|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
58273204|NCT03197194|DRUG|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
58273205|NCT01180556|DIETARY_SUPPLEMENT|Probiotics|Daily oral supplementation for four weeks
58273206|NCT01180556|DIETARY_SUPPLEMENT|Placebo|Placebo administration
58273207|NCT03865589|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
58273208|NCT04663087|DEVICE|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
58273209|NCT04663087|OTHER|Standard of Care|As currently provided by EMS services
58273210|NCT00441532|DRUG|Lidocaine|
58273211|NCT05527847|BEHAVIORAL|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
58391065|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
58273212|NCT05527847|BEHAVIORAL|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
58273213|NCT01036633|DEVICE|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
58391066|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
58391067|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
58391068|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
58391069|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
58391070|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
58391071|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
58391072|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
58064784|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
58391073|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
58391074|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
57919119|NCT04776785|DEVICE|Curodont™ Repair|"It is a product used in biomimetic remineralization of initial carious lesions. The product consists of smart P11-4 peptide molecules (CUROLOX® TECHNOLOGY) that within the lesion the molecules self-assemble to a 3D matrix. This bio-matrix enables the regeneration of the tooth tissue.~Test 1 lesions will be cleaned with a prophylaxis paste and isolated with cotton rolls. Then, the pellicle will be removed using 2% sodium hypochlorite (20 sec) and the inorganic deposits will be removed using 35% phosphoric acid (20 sec). The tooth surface will be rinsed with water and dried. Thereafter, Curodont™ Repair will be applied in compliance with the manufacturers' instructions and left for 5 minutes."
57919120|NCT04776785|DEVICE|MI Varnish™|"MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
57919121|NCT04776785|DEVICE|Profluorid® Varnish|"Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
57919122|NCT04961723|DIAGNOSTIC_TEST|(OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
58064785|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
58064786|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
58064787|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
58064788|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
58064789|NCT04335552|OTHER|Standard of care|Standard of care
58064790|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
58064791|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
58064792|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
58064793|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
58064794|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
58064795|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
58391075|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
58273214|NCT03336723|DEVICE|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
58391076|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
58273215|NCT04547231|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|"1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
58273216|NCT02211092|BEHAVIORAL|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
58273217|NCT02211092|OTHER|Usual care|Access to usual community resources but no active lifestyle coaching.
58273218|NCT04916314|BEHAVIORAL|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
58273219|NCT05202275|DRUG|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
58273220|NCT04312945|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
58273221|NCT04312945|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
58273222|NCT01819948|DIETARY_SUPPLEMENT|PhytoMed™|
58273223|NCT06412458|BIOLOGICAL|IM83 CAR-T Cells|IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
58273224|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
58273225|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
58273226|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
58273227|NCT03751436|DRUG|Enzalutamide|Given PO
58273228|NCT03751436|DRUG|Venetoclax|Given PO
58273229|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
58273230|NCT06712849|DEVICE|Sham Transcranial Random Noise Stimulation|Sham transcranial random noise stimulation will be applied over the primary visual cortex (area V1) with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2.0 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 40 minutes.
58273231|NCT06712849|DEVICE|High Frequency Transcranial Random Noise Stimulation|Non-invasive brain stimulation will involve the use of high-frequency transcranial random noise stimulation (100-640 Hz) to apply a 2.0 milliamp current over the primary visual cortex (area V1) for approximately 40 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
58273232|NCT02519816|OTHER|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
58273233|NCT05710094|DRUG|SoftOx Biofilm Eradicator (Groups 1 to 7)|SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
57919123|NCT05837715|DEVICE|Chattanooga Stabilizer pressure biofeedback|"Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error."
57919124|NCT05837715|DEVICE|VibraSens - Focal Vibration Therapy (TechnoConcept - France)|"Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation."
58064796|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
58064797|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
58273234|NCT05710094|DEVICE|Sterile isotonic saline (Groups 1 to 4)|Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
58273235|NCT04984278|DRUG|Nabiximols|oromucosal spray
58273236|NCT04984278|DRUG|Placebo|oromucosal spray
58273237|NCT06731855|PROCEDURE|Abdominal Surgery for congenital gut malformation in the first 5 days of life.|Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.
58273238|NCT02172040|DRUG|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
58273239|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
58273240|NCT02172040|DRUG|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
58273241|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
57720956|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
57919125|NCT05837715|OTHER|Telerehabilitation|Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
57919126|NCT03407820|PROCEDURE|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
57919127|NCT03407820|PROCEDURE|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
57919128|NCT05621603|BEHAVIORAL|Training|"The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session"
57919129|NCT00240045|DRUG|Midodrine, albumin, octreotide LAR|
58273242|NCT03729323|BEHAVIORAL|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
58273243|NCT03729323|BEHAVIORAL|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
58391077|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
57919130|NCT00240045|DRUG|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
57919131|NCT03728413|BIOLOGICAL|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
57919132|NCT05268874|OTHER|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
58391078|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
57919133|NCT01906554|OTHER|Egg Dose|Different quantities of eggs
57720957|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
57720958|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
57720959|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
58391079|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
58391080|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
58391081|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
58391082|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
57720960|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
57720961|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
57720962|NCT05363891|DRUG|Placebo|Placebo
57720963|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
57720964|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
57720965|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
57919134|NCT03166826|OTHER|Modified Apgar Scoring System|Modified APGAR scoring system
57919135|NCT04780022|OTHER|Clinical events at last follow-up|Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
57919136|NCT00207805|PROCEDURE|autologous PBSC transplant|optimal timining of a second autologous transplant
57720966|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
57720967|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
58273244|NCT05665140|DRUG|Isatuximab|i.v. Induction Phase (Arm A and B): Induction Cycle 1 10 mg/kg D 1, 8, 15, 22, 29. Induction Cycle 2-3 10 mg/kg D 1, 15, 29 Consolidation Phase (Arm B): Consolidation Cycle 1-3 10 mg/kg D 1, 15, 29 Maintenance Phase (Arm A and B): Maintenance Cycle 1 and subsequent cycles 10 mg/kg D 1, 15, 29
58273245|NCT05665140|DRUG|Lenalidomide|hard capsule for oral use. Induction Phase (Arm A and B): Induction Cycle 1-3 25 mg D1-14, 20-35. Consolidation Phase (Arm B): Consolidation Cycle 1-3 25 mg D1-14, 20-35. Maintenance Phase (Arm A and B): Maintenance Cycle 1-2 10 mg D1-28. Maintenance Cycle 3 and subsequent cycles 15 mg D1-28 if tolerable
58391083|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
58391084|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
58391085|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
58391086|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
58391087|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
58391088|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
58391089|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
57720968|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
57720969|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
57919137|NCT02719587|PROCEDURE|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
57919138|NCT02719587|PROCEDURE|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
58273246|NCT05665140|DRUG|Bortezomib|s.c. injection. Induction Phase (Arm A and B): Induction Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32. Consolidation Phase (Arm B): Consolidation Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32
58391090|NCT06400589|DRUG|tanfanercept|TNF inhibitor
58391091|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
57720970|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
57720971|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
57720972|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
57720973|NCT06338995|DRUG|LY3650150|Administered SC.
57919139|NCT02719587|PROCEDURE|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
58273247|NCT05665140|DRUG|Dexamethasone|orally and i.v. Induction Phase (Arm A and B): Induction Cycle 1 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 8, 15, 22 and 29. Induction Cycles 2 and 3 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 15 and 29. Consolidation Phase (Arm B): Consolidation Cycle 1-3 20 mg p.o. on D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. on D1, 15 and 29
58273248|NCT05665140|OTHER|autologous stem cell transplant|autologous stem cell transplant
58391092|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
58391093|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
58391094|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
58391095|NCT03851627|DRUG|Placebo|Placebo Arm
58391096|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
58391097|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
57720974|NCT06338995|DRUG|Placebo|Administered SC.
57919140|NCT04085406|DEVICE|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
57919141|NCT01757808|DRUG|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
57720975|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
57919142|NCT01757808|DRUG|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
57919143|NCT04436939|DEVICE|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
57919144|NCT04168684|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
58391098|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
58391099|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
57720976|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
57720977|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
58273249|NCT05065736|DRUG|18F-Clofarabine|The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
58273250|NCT06731244|OTHER|Usual Care Group|Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.
58391100|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
58391101|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
58391102|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
58391103|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
58391104|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
58391105|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
58391106|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
58391107|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
58391108|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
58391109|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
58391110|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
57720978|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
57720979|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
57720980|NCT02605590|DRUG|AIR DNase|
57720981|NCT02605590|DRUG|Placebo|
57720982|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
57720983|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
57720984|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
57720985|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
57720986|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
57720987|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
57720988|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
57720989|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
57720990|NCT02823925|DRUG|Pamidronate or Zoledronate|
57720991|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
57720992|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
57720993|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
57720994|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
57720995|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
57720996|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
57919145|NCT04168684|BEHAVIORAL|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
57919146|NCT06164509|DRUG|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
58391111|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
58391112|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
57720997|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
57720998|NCT02978144|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
57720999|NCT02978144|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
57721000|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
57721001|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
57721002|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
57721003|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
57721004|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
57721005|NCT02211989|DRUG|BI 14332 CL|
57721006|NCT02211989|DRUG|Placebo|
57721007|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
57721008|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
57721009|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
57721010|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
57721011|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
57919147|NCT00196404|DRUG|DR-3001a|4mg daily vaginally
57919148|NCT00196404|DRUG|DR-3001b|6 mg vaginally daily
57919149|NCT00196404|OTHER|Placebo|Administered vaginally to match experimental arms
57919150|NCT00985946|DRUG|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
57919151|NCT04121494|BIOLOGICAL|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
58273251|NCT06731244|OTHER|shared decision-making process|"The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).~The shared decision-making process will be conducted as follows:~* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;~* Step 2: Communicating risks, benefits and consequences to the patient;~* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed."
57721012|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
57721013|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
57721014|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
57721015|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
57721016|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
57721017|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
57721018|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
57721019|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
57721020|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
57721021|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
57721022|NCT03770468|PROCEDURE|Blood drawl|
57721023|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
57721024|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
57721025|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
57721026|NCT01700946|DRUG|dexamethasone|given intravenously or orally
57721027|NCT01700946|DRUG|vincristine sulfate|given intravenously
57721028|NCT01700946|BIOLOGICAL|rituximab|given intravenously
57721029|NCT01700946|DRUG|clofarabine|given intravenously
57721030|NCT01700946|DRUG|cyclophosphamide|given intravenously
57721031|NCT01700946|DRUG|etoposide|given intravenously
57721032|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
58273252|NCT00002756|BIOLOGICAL|filgrastim|
57721033|NCT01700946|DRUG|pegaspargase|given intravenously
57721034|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
58273253|NCT00002756|DRUG|asparaginase|
58273254|NCT00002756|DRUG|cyclophosphamide|
58273255|NCT00002756|DRUG|cytarabine|
57721035|NCT01700946|DRUG|mercaptopurine|given orally
57721036|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
57721037|NCT01700946|DRUG|mitoxantrone|given intravenously
57721038|NCT01700946|DRUG|teniposide|given intravenously
57721039|NCT01700946|DRUG|vinblastine|given intravenously
57721040|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
57721041|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
57721042|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
57721043|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
57721044|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
57919152|NCT04121494|BIOLOGICAL|ChadOx1 85A - IM|Intramuscular administration
58273256|NCT00002756|DRUG|daunorubicin hydrochloride|
58273257|NCT00002756|DRUG|etoposide|
58273258|NCT00002756|DRUG|leucovorin calcium|
58273259|NCT00002756|DRUG|mercaptopurine|
58273260|NCT00002756|DRUG|methotrexate|
57721045|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
57721046|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
57721047|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
57919153|NCT05927857|DRUG|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
58273261|NCT00002756|DRUG|prednisone|
58273262|NCT00002756|DRUG|therapeutic hydrocortisone|
58391113|NCT02314156|OTHER|Placebo|Given PO
57721048|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
57721049|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
57721050|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
57721051|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
57721052|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
57721053|NCT06464055|DRUG|Dose Escalation|GQ1010
57721054|NCT06464055|DRUG|Dose Expansion1|GQ1010 dose1
57721055|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose2
57721056|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
57721057|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
57721058|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
57721059|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive a 60-minute IV infusion of BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
58273263|NCT00002756|DRUG|vincristine sulfate|
58273264|NCT02160028|OTHER|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
58273265|NCT02160028|OTHER|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
58273266|NCT03774134|PROCEDURE|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
57919154|NCT05927857|DRUG|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
57919155|NCT05927857|DRUG|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
57919156|NCT04309344|DEVICE|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
57919157|NCT04309344|PROCEDURE|control|mechanical debridement
58273267|NCT03774134|PROCEDURE|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
58273268|NCT01877551|DRUG|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
58273269|NCT01877551|OTHER|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
58273270|NCT01178814|DRUG|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
58391114|NCT02314156|DRUG|Telapristone Acetate|Given PO
57721060|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
57721061|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
57721062|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
57721063|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
57721064|NCT01124890|DEVICE|early percutaneous coronary intervention|
57721065|NCT01124890|DEVICE|late percutaneous coronary intervention|
58276752|NCT03899207|OTHER|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
57721066|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
57721067|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
57721068|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
57721069|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
57721070|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
57721071|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
57721072|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
57721073|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
57721074|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
57721075|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
57721076|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
57721077|NCT00971971|PROCEDURE|Standard SLED|
57721078|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
57721079|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
57721080|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
57721081|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
57721082|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
58273271|NCT06201455|PROCEDURE|PEI+GT|After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
58273272|NCT06201455|PROCEDURE|PEI+MED|Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
58276753|NCT01243294|DEVICE|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
57721083|NCT00003326|DRUG|paclitaxel|
57721084|NCT03286140|PROCEDURE|Early endovenous ablation|
57721085|NCT03286140|PROCEDURE|Delayed endovenous intervention|
58391115|NCT02314156|OTHER|Placebo|Given transdermally
58391116|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
57721086|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
57721087|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
57721088|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
57721089|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
57721090|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
57721091|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
57721092|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
57721093|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
57721094|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
57721095|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
57721096|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
57919158|NCT05253677|DEVICE|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
57919159|NCT05253677|DEVICE|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
57919160|NCT04556461|DRUG|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
57919161|NCT00671944|OTHER|Low protein diet|Low protein diet for 6.5 weeks
57919162|NCT00163306|DRUG|Pantoprazole|
57919163|NCT03565120|RADIATION|Aggressive Thoracic Radiotherapy|The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
58064798|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
58064799|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
58064800|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
57919164|NCT03034629|BEHAVIORAL|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
57919165|NCT01751074|DRUG|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
58273273|NCT04405622|DRUG|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
58273274|NCT01714609|DRUG|Placebo|Placebo Comparator: Placebo
58273275|NCT01714609|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
58391117|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
58391118|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
57919166|NCT01751074|DRUG|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
57919167|NCT03752918|DRUG|MDMA|A single dose of 1.5mg/kg will be administered once orally.
57919168|NCT03752918|DRUG|Niacin|A single dose of 250mg will be administered once orally.
57919169|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
57919170|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
57919171|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
57919172|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
57919173|NCT01435330|DRUG|BVS857|
57919174|NCT01435330|DRUG|Placebo|
58064801|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
58064802|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
58064803|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
57919175|NCT00837551|DRUG|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
57919176|NCT03364712|OTHER|routine medical care, venipuncture|
57919177|NCT05199220|OTHER|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
58064804|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
57919178|NCT05494177|DIAGNOSTIC_TEST|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART)."
57919179|NCT05494177|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
58064805|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
58276754|NCT01243294|DEVICE|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
58064806|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
58064807|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
58064808|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
58064809|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
58064810|NCT04373616|BIOLOGICAL|ACI-24|injections
57919180|NCT04258436|PROCEDURE|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
57919181|NCT04832425|DRUG|PRAX-114|40 mg once daily
57919182|NCT04832425|DRUG|Placebo|Placebo once daily
57919183|NCT00866853|DRUG|TMC435|
57919184|NCT01765465|DRUG|Rowachol|
57919185|NCT01765465|DRUG|Placebo|
57919186|NCT03772444|DIETARY_SUPPLEMENT|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
57919187|NCT03772444|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
58273276|NCT05633277|PROCEDURE|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
57721097|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
57721098|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
57721099|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
57721100|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
57721101|NCT01085318|DRUG|Rebif|44 mcg tiw
57721102|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
57721103|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
57721104|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
57721105|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
57721106|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
57721107|NCT03352115|DRUG|Placebos|Placebo syrup
57721108|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
57721109|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
57721110|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
58391119|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
57721111|NCT00471601|BEHAVIORAL|counseling intervention|
57721112|NCT00471601|BEHAVIORAL|questionnaire administration|
57721113|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
57721114|NCT00471601|BEHAVIORAL|quality-of-life assessment|
57721115|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
57721116|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
57721117|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
57721118|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
57721119|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
57721120|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
57721121|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
57721122|NCT02041455|DRUG|Melatonin and Placebo|
57721123|NCT02041455|DRUG|Amitriptyline and Placebo|
57721124|NCT02041455|DRUG|Melatonin and Amitriptylin|
57721125|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
57721126|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
57721127|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
57721128|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
58273277|NCT01483989|OTHER|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
58273278|NCT04862663|DRUG|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
58064811|NCT04373616|BIOLOGICAL|Placebo|injections
58391120|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
58391121|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
58391122|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
58064812|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
58391123|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
58391124|NCT01375816|DRUG|fluorouracil|
58273279|NCT04862663|DRUG|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
58273280|NCT04862663|DRUG|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
58273281|NCT04862663|DRUG|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
58273282|NCT04862663|DRUG|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
58391125|NCT01375816|DRUG|irinotecan hydrochloride|
58273283|NCT00833118|PROCEDURE|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
58273284|NCT03707366|BEHAVIORAL|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
58273285|NCT04164823|DEVICE|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
58391126|NCT01375816|DRUG|leucovorin calcium|
58391127|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
58391128|NCT01375816|DRUG|Bevacizumab|
58391129|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
58064813|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
58064814|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
58064815|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
58064816|NCT04840914|DRUG|LY3461767|Administered SC.
58273286|NCT04164823|DRUG|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
58273287|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
58273288|NCT01909726|OTHER|ScreenPlay|Interactive technology
58273289|NCT05587426|DIETARY_SUPPLEMENT|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
58391130|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
58391131|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
58391132|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
58391133|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
57721129|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
57721130|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
57721131|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
57721132|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
57721133|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
57721134|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
58064817|NCT04840914|DRUG|Placebo|Administered SC.
58064818|NCT02182505|DRUG|Berodual® Respimat®, low dose|
58391134|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
58391135|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
57919188|NCT03772444|DIETARY_SUPPLEMENT|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
57919189|NCT00354458|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
57721135|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
57919190|NCT00354458|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
58064819|NCT02182505|DRUG|Berodual® Respimat®, high dose|
58064820|NCT02182505|DRUG|Berodual® MDI|
58273290|NCT05587426|DIETARY_SUPPLEMENT|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
58273291|NCT05587426|DIETARY_SUPPLEMENT|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
58273292|NCT05587426|DIETARY_SUPPLEMENT|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
58273293|NCT05984693|BEHAVIORAL|Video Assisted Instruction|Video Assisted Instruction
58273294|NCT02779660|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
58273295|NCT02779660|PROCEDURE|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
58273296|NCT04288817|BIOLOGICAL|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
58273297|NCT02598011|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
57721136|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
57721137|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
58273298|NCT02598011|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
58273299|NCT06731790|OTHER|Blood sampling for inflammatory phenotype analysis|Blood sampling for basal and post-stimulation inflammatory phenotype analysis
58273300|NCT06731790|GENETIC|Blood sampling for genetic analysis|Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.
58273301|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
58273302|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
58273303|NCT03973255|BEHAVIORAL|Rehabilitation|Posturography, Whole body vibration
57919191|NCT02314910|OTHER|Sample histology|
57919192|NCT03279263|DRUG|MLR-1023|MLR-1023 Tablets
57919193|NCT03279263|OTHER|Placebo|Matching Placebo Tablets
57919194|NCT05220254|BEHAVIORAL|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
57919195|NCT00340691|DRUG|Doxycycline|
57919196|NCT06001489|BEHAVIORAL|360-degree Virtual Reality Patient Tour|A 360-degree video that encompasses the entire clinical pathway. Patients are able to familiarize themselves with the hospital settings (nursery ward, operating room, intensive care unit).
57919197|NCT06001489|DIAGNOSTIC_TEST|State Trait Anxiety Inventory|Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
58064821|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
58064822|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
58064823|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
58273304|NCT06247072|DEVICE|Tonometer|measures IOP
58273305|NCT05007574|DEVICE|Microphone MI-305|Remote data collection
58273306|NCT03212391|BEHAVIORAL|Diet|52 weeks of Diet supervised by a dietician
58273307|NCT03212391|BEHAVIORAL|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
58273308|NCT03212391|BEHAVIORAL|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
58273309|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
58273310|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
58276755|NCT01466517|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
58276756|NCT01466517|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
58064824|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
58064825|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
58064826|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
58064827|NCT03091920|DRUG|IW-1973|Oral Tablet
58064828|NCT03091920|DRUG|Placebo|Oral Tablet
58064829|NCT05275140|OTHER|Physical activity|Combat sports and exercise
58064830|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
58064831|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
57919198|NCT06001489|DIAGNOSTIC_TEST|Amsterdam Preoperative Anxiety and Information Scale|This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
57919199|NCT00598143|BEHAVIORAL|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
57919200|NCT00598143|BEHAVIORAL|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
57919201|NCT04681027|DRUG|Oxymorphone hydrochloride (HCl)|Opioid
57919202|NCT02148614|DRUG|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
57919203|NCT02148614|DRUG|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
58064832|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
58064833|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
58064834|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
58391136|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
57721138|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
57721139|NCT02773979|OTHER|Placebo|Placebo
57721140|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
57919204|NCT00458991|DRUG|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
57919205|NCT03532087|DRUG|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
57721141|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
57919206|NCT03532087|DRUG|Denosumab 60 mg|Denosumab 60 mg every 6 months.
57919207|NCT02208999|DEVICE|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
57919208|NCT03240874|BEHAVIORAL|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
58064835|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
58064836|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
58064837|NCT00529646|DRUG|APD791|
58064838|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
58064839|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
58064840|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
58064841|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
58064842|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
58064843|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
58064844|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
58064845|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
58064846|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
58276757|NCT04505618|DEVICE|Swept-Source (SS) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
58276758|NCT04505618|DEVICE|Spectral-Domain (SD) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
57721142|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
57721143|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
57721144|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
57721145|NCT01313559|DRUG|Pasireotide|Given IM
57721146|NCT01313559|DRUG|Everolimus|Given PO
57721147|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
57721148|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
57721149|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
57919209|NCT03240874|BEHAVIORAL|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
57919210|NCT03240874|BEHAVIORAL|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
57919211|NCT00101881|DEVICE|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
57919212|NCT02970331|DRUG|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
58064847|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
58064848|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
58273311|NCT06098144|DRUG|Nicoderm C-Q Gum|"Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
58273312|NCT06098144|BEHAVIORAL|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
58273313|NCT06098144|BEHAVIORAL|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
58276759|NCT04505618|DEVICE|Fundus Imaging|Non-invasive, minimal risk, ocular imaging study
58391137|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
57721150|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
57721151|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
57721152|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
57721153|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
57721154|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
57721155|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
57721156|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
57721157|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
57721158|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
57721159|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
58391138|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
58273314|NCT06098144|BEHAVIORAL|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
58273315|NCT00455520|DRUG|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
58273316|NCT00455520|DRUG|placebo|matching placebo twice daily for 12 weeks
58391139|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
58391140|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
58391141|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
58391142|NCT02924441|OTHER|Lidocaine|Applied to breast skin
58391143|NCT02924441|OTHER|Calming Music|Played during mammography
58391144|NCT02924441|OTHER|No Music|No music played during mammography
58391145|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
58064849|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
58064850|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
58064851|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
58064852|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
58273317|NCT06730646|BEHAVIORAL|Health effects|Participants in this arm will watch 3 short videos about the smoking-related diseases during the survey data collection.
58273318|NCT06730646|BEHAVIORAL|Tobacco industry manipulation|Participants in this arm will watch 3 short videos about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults during the survey data collection.
58273319|NCT06730646|BEHAVIORAL|Secondhand smoke|Participants in this arm will watch 3 short videos about the risks of secondhand smoke exposure during the survey data collection.
58273320|NCT06730646|BEHAVIORAL|Mentral health|Participants in this arm will watch 3 short videos about the effects of smoking on mental health during the survey data collection.
58273321|NCT06730646|BEHAVIORAL|Social acceptability|Participants in this arm will watch 3 short videos about how smoking is socially unacceptable in China during the survey data collection.
58273322|NCT06730646|BEHAVIORAL|Control|Participants in this arm will watch 3 short videos about drinking bottled water during the survey data collection. These messages display specific water products and describe hydration as a healthy activity.
58273323|NCT01768091|PROCEDURE|POEM|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~4. Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia... Endoscopy 2010; 42: 265-271)"
58391146|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
58391147|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
58391148|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
57721160|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
57721161|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
57721162|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
57721163|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
57721164|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
57721165|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
57721166|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
57721167|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
58273324|NCT01768091|PROCEDURE|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
58273325|NCT06730100|PROCEDURE|Biopsy|Undergo biopsy
58273326|NCT06730100|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58273327|NCT06730100|PROCEDURE|Computed Tomography|Undergo CT scan
58273328|NCT06730100|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57721168|NCT02522897|DRUG|Ranibizumab|
58273329|NCT06730100|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
58391149|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
57721169|NCT02522897|DEVICE|Laser|
57721170|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
57721171|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
57721172|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
57721173|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
57919213|NCT05106829|OTHER|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
57919214|NCT05106829|OTHER|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
57919215|NCT03709420|DRUG|Placebo|Placebo capsule to match active drug
57919216|NCT03709420|DRUG|FOR-6219|FOR-6219 capsule
57919217|NCT05603091|PROCEDURE|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
57721174|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
57919218|NCT02238522|DRUG|ZEN003365|
57919219|NCT06450938|DEVICE|AI guidance for finding radiographic features|A secured website was made for the trial in which each student could log in using the assigned number. All the image datasets were uploaded to this website. The students will be randomly assigned to the experiment and control group. Both students were asked to segment the features associated with the quality of root canal treatment and predict the prognosis of treatment while the experiment group had access to AI guidance and the control group didn't.
57919220|NCT05144633|DEVICE|Auscultation|This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
58273330|NCT06730100|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
58391150|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
57919221|NCT02283554|PROCEDURE|open flap debridement (OFD)|
57919222|NCT02283554|OTHER|Platelet rich fibrin (PRF)|
57919223|NCT02283554|DRUG|Metformin|
58273331|NCT03617861|DRUG|Human Secretin|Injected once over one minute
58273332|NCT03617861|DRUG|Placebo|Injected once over one minute
58273333|NCT06286475|DRUG|VRG50635|Specified dose on specified days
58273334|NCT06286475|DRUG|Placebo|Specified dose on specified days
58273335|NCT06152744|OTHER|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
58273336|NCT02638129|DRUG|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
58064853|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
58064854|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
58273337|NCT02638129|DRUG|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
57919224|NCT04953715|OTHER|collection of body microbioma|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
58273338|NCT03924505|OTHER|Organize and Mobilize for Implementation Effectiveness|Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs
58273339|NCT03924505|OTHER|Dissemination|Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
58273340|NCT04896437|PROCEDURE|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
58273341|NCT01537276|PROCEDURE|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
58273342|NCT06080906|BIOLOGICAL|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
57721175|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
57919225|NCT05724160|OTHER|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
57919226|NCT05724160|OTHER|Physiotherapy Protocol|Routine physiotherapy protocol
57919227|NCT03467243|BEHAVIORAL|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
58064855|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
58064856|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
58064857|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
58273343|NCT06080906|BIOLOGICAL|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
58273344|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
58273345|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
58273346|NCT00382395|DEVICE|SOLX Gold Shunt GMS-plus|Single use implant
58273347|NCT00382395|DEVICE|Ahmed FP7 Glaucoma Valve|Single use implant
58273348|NCT02918643|OTHER|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
57919228|NCT03467243|BEHAVIORAL|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
57919229|NCT03467243|BEHAVIORAL|Treatment as usual|TAU is when Veterans continue to receive their usual care.
57919230|NCT00896051|DRUG|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
57919231|NCT00896051|DRUG|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
58273349|NCT04279782|OTHER|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
58273350|NCT04022356|DEVICE|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
58273351|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
58273352|NCT03211429|BEHAVIORAL|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
57919232|NCT00896051|DRUG|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
57919233|NCT00896051|DRUG|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
57919234|NCT00896051|DRUG|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
57919235|NCT00896051|DRUG|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
57919236|NCT02216357|DRUG|Ifetroban, Oral Capsule|
57919237|NCT02216357|DRUG|Placebo, Oral Capsule|
57919238|NCT05682157|OTHER|Paula Method of muscle exercises|12 weekly sessions of Paula Method of exercise
57919239|NCT04428125|DIAGNOSTIC_TEST|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
57919240|NCT04428125|DIAGNOSTIC_TEST|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
57919241|NCT01008293|DRUG|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
57919242|NCT01008293|DRUG|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
57919243|NCT05271292|DRUG|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
57919244|NCT05008835|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
57919245|NCT05008835|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
57919246|NCT05008835|DRUG|Placebo|Placebo
57919247|NCT02940821|OTHER|Toothbrushing|Mechanical plaque removal
57919248|NCT02940821|OTHER|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
57919249|NCT02940821|OTHER|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
57919250|NCT02940821|OTHER|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
57919251|NCT02940821|OTHER|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
57919252|NCT03794570|DEVICE|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
57919253|NCT03794570|DEVICE|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
58273353|NCT03211429|OTHER|Tai chi|Tai Chi training in the Yang style of 24 movement
58273354|NCT03211429|OTHER|Postural control exercise|Individually adjusted progressive and specific postural control training,
58273355|NCT02071602|DRUG|CD-NP|Randomized 1:1:1
58273356|NCT00001300|DRUG|doxorubicin|
57919254|NCT04977726|BEHAVIORAL|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
57919255|NCT00699920|DRUG|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
57919256|NCT00699920|DRUG|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
57919257|NCT03333239|BEHAVIORAL|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)
58273357|NCT00001300|DRUG|ifosfamide|
58273358|NCT00001300|DRUG|mesna|
58273359|NCT00217737|BIOLOGICAL|Bevacizumab|Given IV
58273360|NCT00217737|DRUG|Fluorouracil|Given IV
58273361|NCT00217737|OTHER|Laboratory Biomarker Analysis|Correlative studies
58273362|NCT00217737|DRUG|Leucovorin Calcium|Given IV
58273363|NCT00217737|DRUG|Oxaliplatin|Given IV
57721176|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
57721177|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
57721178|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
57721179|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
57721180|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
57721181|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
57721182|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
57721183|NCT02488044|DRUG|AEB1102|modified human arginase I
57721184|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
57721185|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
57721186|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
57721187|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
57721188|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
57721189|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately half an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
57721190|NCT06573658|BEHAVIORAL|Active control (control)|It will be a two-session training with each session lasting for approximately half an hour. The same training duration and format will be used as the PBT group, except no perturbations will be induced during the treadmill walking.
57721191|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
58273364|NCT06709014|DRUG|buntanetap/posiphen|30mg capsule by mouth once daily for 18 months
58273365|NCT06709014|DRUG|Placebo|Placebo capsule by mouth once daily for 18 months
58273366|NCT01731769|PROCEDURE|vacuum assisted closure in experimental arm|
57721192|NCT00821626|OTHER|Control|No rapid flu test
57721193|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
57721194|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
57721195|NCT00191321|DRUG|Teriparatide|
57721196|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
57721197|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
57721198|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
58273367|NCT01731769|PROCEDURE|Axillary dissection|
58273368|NCT05702411|OTHER|Air Stacking Technique|Air Stacking lung reexpansion technique after aspiration with expiratory pause in a closed system.
58273369|NCT05702411|OTHER|No Air Stacking Technique|Aspiration technique in a closed system of aspiration with an expiratory pause of 10 seconds.
58273370|NCT03404258|OTHER|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
58391151|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
57721199|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
58391152|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
58391153|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
57721200|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
57721201|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
57721202|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
58064858|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
58273371|NCT04559035|OTHER|Nasal lavage|Twice daily nasal lavage.
58273372|NCT04812795|OTHER|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
58391154|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
58391155|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
58391156|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
58391157|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
58391158|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
58391159|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
58391160|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
58391161|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
58273373|NCT04812795|OTHER|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
58273374|NCT01902875|DRUG|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
58273375|NCT01902875|BIOLOGICAL|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
58391162|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
58391163|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
58273376|NCT02295761|BEHAVIORAL|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
58273377|NCT02295761|BEHAVIORAL|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
58273378|NCT05273489|PROCEDURE|Hepatectomy|Neoadjuvant treatment
57721203|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
57721204|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
57721205|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
57721206|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
58273379|NCT02195726|PROCEDURE|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
58391164|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
57721207|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
57919258|NCT03333239|BEHAVIORAL|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)
57721208|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
57721209|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
57919259|NCT03333239|BEHAVIORAL|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
58273380|NCT02195726|PROCEDURE|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
58273381|NCT04128488|OTHER|Abdominal MR Imaging|Imaging to evaluate visceral adipose tissue and hepatic lipid content
58273382|NCT04128488|OTHER|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
58273383|NCT04128488|OTHER|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
58273384|NCT04128488|OTHER|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
58273385|NCT05903040|DRUG|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
57919260|NCT02739360|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
57919261|NCT02669420|PROCEDURE|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
57919262|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
57919263|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
58273386|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
58391165|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
58391166|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
58391167|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
58391168|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
58391169|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
57721210|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
57721211|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
57721212|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
57721213|NCT00426478|DRUG|Amlodipine (5mg)|
57721214|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
57721215|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
57919264|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
57919265|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
57919266|NCT02796560|DRUG|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
57919267|NCT02796560|DRUG|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
58273387|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
58273388|NCT06018545|OTHER|Ground truthing|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration.
58276760|NCT04505618|DEVICE|Axial Length Measurement Device|Non-invasive, minimal risk, ocular imaging study
58391170|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
58391171|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
58391172|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
58391173|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
58391174|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
57721216|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
57919268|NCT04647630|DIAGNOSTIC_TEST|urine test|test for pneumococcal antigen in urine
57721217|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
57721218|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
57721219|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
57721220|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
57721221|NCT02864017|PROCEDURE|Enteral nutrition|
57721222|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
57721223|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
57721224|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
57721225|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
57919269|NCT00518791|OTHER|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
57919270|NCT00518791|OTHER|Usual Care|No altered organisation of care
57919271|NCT03153137|DRUG|Macitentan 10 mg|film-coated tablet; oral use
58273389|NCT06018545|OTHER|Reading|All 30 readers will review all 150 cases, in each of two study phases. The readers will provide their opinion on the presence or absence of some acute abnormalities, including intracranial haemorrhage, infarct, midline shift and fracture. They will provide a confidence in their diagnosis (10-point visual analogue scale), and a single click point to mark the location of each abnormality that they consider as being present. The time taken for each scan will be automatically recorded.
57721226|NCT02875119|DRUG|Placebo Gel|Placebo Gel
57721227|NCT01840592|DRUG|Sorafenib|
57721228|NCT01840592|DRUG|Doxorubicin|
57721229|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
57721230|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
57721231|NCT02104557|OTHER|Non intervention|Non intervention
57721232|NCT02104557|OTHER|Non intervention|Non intervention
57721233|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
57721234|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
57721235|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
57721236|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
57721237|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
57721238|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
57919272|NCT03153137|DRUG|Placebo|film-coated tablet; oral use
57919273|NCT05428761|OTHER|TP1|Participants will receive TP1 during one experimental visit.
57919274|NCT05428761|OTHER|TP2|Participants will receive TP2 during one experimental visit.
57919275|NCT05428761|OTHER|Placebo|Participants will receive placebo during one experimental visit.
58273390|NCT05808790|PROCEDURE|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
58273391|NCT05808790|RADIATION|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
58273392|NCT01179789|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
58273393|NCT01179789|DIETARY_SUPPLEMENT|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
58273394|NCT01179789|DIETARY_SUPPLEMENT|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
58273395|NCT01179789|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water
57919276|NCT03692260|PROCEDURE|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
57919277|NCT04506268|BEHAVIORAL|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
57919278|NCT04506268|BEHAVIORAL|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
57919279|NCT04787250|BIOLOGICAL|Phage Therapy|Phage will be administered based on patient's matching results.
58273396|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
57919280|NCT04787250|PROCEDURE|Two-Stage Exchange Arthroplasty|Performed per the study center's standard of care. No investigational products are used.
57919281|NCT00790764|BIOLOGICAL|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
57919282|NCT00790764|OTHER|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
58064859|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
58064860|NCT00495508|DRUG|Quinine|
58064861|NCT00495508|DRUG|artemether / lumefantrine|
58064862|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
57721239|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
57721240|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
57721241|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
57721242|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
57721243|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
57721244|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
57721245|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
57721246|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
57721247|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
57721248|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
57919283|NCT06494891|DRUG|Intravenous Alcohol|Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an alcohol challenge. During the challenge, participants will be administered alcohol designed to reach target BrACs of 20, 40, and 60 mg%, each over 15 min. After reaching the last target BrAC (0.06 g/dl) participants will complete a self-administration (SA) paradigm. Participants will be invited to work (button press) for alcohol according to a log-linear progressive ratio schedule.
57919284|NCT04168853|DIAGNOSTIC_TEST|vascular reactivity of internal thoracic arteries|"1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis"
57919285|NCT00460200|GENETIC|polymorphism analysis|
57919286|NCT00460200|OTHER|laboratory biomarker analysis|
57919287|NCT00460200|OTHER|physiologic testing|
58064863|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
58391175|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
58391176|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
58391177|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
58064864|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
58064865|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
58064866|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
58273397|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
58273398|NCT06004492|BEHAVIORAL|blended learning program|blended learning program: 8 hours of workshops and four months of practical learning on technology platforms.
58273399|NCT01823172|PROCEDURE|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
57721249|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
57721250|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
58273400|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
57721251|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
57721252|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
57919288|NCT00460200|OTHER|questionnaire administration|
57919289|NCT00460200|PROCEDURE|conventional surgery|
57919290|NCT00460200|PROCEDURE|fatigue assessment and management|
57919291|NCT00460200|PROCEDURE|psychosocial assessment and care|
58064867|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
58064868|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
58273401|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
58391178|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
58064869|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
58064870|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
58391179|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
58391180|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
58391181|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
57721253|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
57721254|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
57919292|NCT00055523|DRUG|Adalimumab (D2E7)|
57919293|NCT00141726|DRUG|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
58391182|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
58391183|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
57721255|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
57919294|NCT04386811|DRUG|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
57919295|NCT04386811|OTHER|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
57919296|NCT03390920|OTHER|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
57919297|NCT03159533|BEHAVIORAL|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
57919298|NCT03159533|BEHAVIORAL|Wait List Control Group|4 education sessions beginning 6-12 months later.
57919299|NCT02139787|OTHER|Radio Story|
57919300|NCT02139787|OTHER|Control -listened to a brochure|
58064871|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
58391184|NCT01581528|GENETIC|gene expression analysis|
58391185|NCT01581528|OTHER|cell culture procedure|
57721256|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
57721257|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
57721258|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
58064872|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
58064873|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
58273402|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
57721259|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
58391186|NCT01581528|OTHER|flow cytometry|
57721260|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
57721261|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
57919301|NCT01049971|DEVICE|wound protector|after minilaparotomy, the wound protector is applied
57919302|NCT01049971|DEVICE|no wound protector|use of woven drape instead of wound protector
57919303|NCT02826330|OTHER|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
58391187|NCT01581528|OTHER|laboratory biomarker analysis|
58391188|NCT01581528|OTHER|metabolic assessment|
58391189|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
58391190|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
58391191|NCT02574078|DRUG|Nivolumab|
58391192|NCT02574078|DRUG|Bevacizumab|
58391193|NCT02574078|DRUG|Pemetrexed|
58391194|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
58391195|NCT02574078|DRUG|nab-Paclitaxel|
58391196|NCT02574078|DRUG|Paclitaxel|
58391197|NCT02574078|DRUG|Docetaxel|
58391198|NCT02574078|DRUG|Gemcitabine|
58391199|NCT02574078|DRUG|Erlotinib|
58391200|NCT02574078|DRUG|Crizotinib|
58391201|NCT02574078|DRUG|Carboplatin|
58273403|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
58273404|NCT00095589|GENETIC|loss of heterozygosity analysis|
58273405|NCT00095589|GENETIC|microarray analysis|
58273406|NCT00095589|GENETIC|microsatellite instability analysis|
58273407|NCT00095589|OTHER|cytology specimen collection procedure|
58273408|NCT00095589|OTHER|laboratory biomarker analysis|
58273409|NCT00095589|PROCEDURE|computed tomography|
58273410|NCT00095589|PROCEDURE|cystoscopy|
58273411|NCT00206089|DRUG|EXANTA|
57721262|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
58064874|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
58064875|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
58064876|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
58273412|NCT03255252|DRUG|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
58273413|NCT03255252|COMBINATION_PRODUCT|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
58273414|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
58273415|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
58273416|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
57721263|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
57721264|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
57721265|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
57721266|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
58273417|NCT06368323|BEHAVIORAL|Choir singing|The 12-week intervention will consist of 12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master in addition to home training (3 x 30-minutes-sessions/week, total 18h). In total, participants will undergo the intervention for 3 hours/week for 12 weeks (i.e., 36 hours).
58273418|NCT06368323|OTHER|Usual care|Rehabilitation services received by patients and social activities will be monitored and documented.
58273419|NCT04775498|BEHAVIORAL|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
58273420|NCT04775498|BEHAVIORAL|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
58273421|NCT04201678|PROCEDURE|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
58276761|NCT05846113|DIAGNOSTIC_TEST|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
57721267|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
57919304|NCT05877378|DEVICE|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
58064877|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
58064878|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
58276762|NCT03000530|DRUG|SAGE-217|
58276763|NCT03000530|DRUG|Placebo|
57721268|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
57721269|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
57721270|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
57721271|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
57721272|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
57721273|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
57721274|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
57721275|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
58064879|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
58064880|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
58064881|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
58064882|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
58276764|NCT00938587|DRUG|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
58276765|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
58276766|NCT00938587|DRUG|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
57721276|NCT02936076|OTHER|Exercise intervention|
57721277|NCT02936076|OTHER|Delayed exercise intervention|
57721278|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
57721279|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
57721280|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
57721281|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
58064883|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
58391202|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
57919305|NCT00526487|DEVICE|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
57919306|NCT00526487|DEVICE|Endovascular Repair|Endovascular Repair
58391203|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
58391204|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
58391205|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
58391206|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
57721282|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
57919307|NCT05198908|OTHER|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
57919308|NCT05198908|OTHER|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
57919309|NCT00796120|DRUG|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
57919310|NCT00796120|DRUG|Doxorubicin|Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
57919311|NCT00796120|DRUG|Ifosfamide|Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
57919312|NCT03444753|DRUG|BMS-986299|Specified dose on specified day
57919313|NCT03444753|BIOLOGICAL|Nivolumab|Specified dose on specified day
57919314|NCT03444753|BIOLOGICAL|Ipilimumab|Specified dose on specified day
58064884|NCT00915226|PROCEDURE|Squatting|Squatting
58064885|NCT00154895|DRUG|intrapleural minocycline instillation|
58064886|NCT00352833|DRUG|catumaxomab|
58064887|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
58391207|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
58391208|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
58391209|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
58391210|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
57919315|NCT01454518|PROCEDURE|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
57721283|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
58064888|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
58064889|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
57721284|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
57721285|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
57721286|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
57721287|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
58064890|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
58064891|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
58391211|NCT01301287|DRUG|Chlorella|
58391212|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
58391213|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
57919316|NCT01454518|PROCEDURE|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
57919317|NCT04778956|DRUG|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
58064892|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
58391214|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
58391215|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
58391216|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
58391217|NCT00070928|DRUG|valerian|
58391218|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
57721288|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
57721289|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
57919318|NCT04778956|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
57919319|NCT00884494|DRUG|Ghrelin infusion to assess effects on insulin sensitivity|
57919320|NCT03316625|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone Densitometry and measurement of body composition
57919321|NCT00821574|DRUG|Fluvastatin|Fluvastatin: daily 80 mg, oral
58391219|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
57919322|NCT00821574|DRUG|Valsartan|Valsartan: daily 160 mg, oral
57919323|NCT00821574|DRUG|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
58391220|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
58391221|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
57919324|NCT02349360|BIOLOGICAL|L. johnsonii N6.2|L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
57919325|NCT02349360|BIOLOGICAL|Placebo|Encapsulated starch placebo administered for 8 weeks
57919326|NCT06193460|DEVICE|low-level laser therapy|photobiomodulation mode of diode laser (low-level laser therapy).
57919327|NCT05510752|BEHAVIORAL|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
57721290|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
57919328|NCT05510752|BEHAVIORAL|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
57919329|NCT00977054|DRUG|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
58391222|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
57721291|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
57721292|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
57721293|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
57919330|NCT00977054|DRUG|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
57919331|NCT03541382|DEVICE|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
57919332|NCT00690235|DRUG|Pramlintide|180mg subcutaneous injections, twice daily
57919333|NCT00690235|DRUG|Placebo|180mg subcutaneous injections, twice daily
57919334|NCT01647269|PROCEDURE|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
57919335|NCT01560689|DRUG|Budesonide/formoterol|800 µg/j twice a day, every day
57919336|NCT01560689|DRUG|Placebo|Twice a day, every day
57919337|NCT02471833|DRUG|Telmisartan 20mg|Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
57919338|NCT02471833|DRUG|Telmisartan 40mg|Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
57919339|NCT02471833|DRUG|Placebo|Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
57919340|NCT03294746|OTHER|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
57919341|NCT03294746|OTHER|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
57919342|NCT04320797|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
57919343|NCT04047589|BEHAVIORAL|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
58276767|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
58276768|NCT00938587|DRUG|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
58391223|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
58391224|NCT00164008|DRUG|zoledronic acid vs pamidronate|
57919344|NCT04047589|BEHAVIORAL|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
57919345|NCT05350384|DRUG|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
57919346|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care|"Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio."
57919347|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning|The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
57919348|NCT02784197|DEVICE|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
57919349|NCT05680064|BEHAVIORAL|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
57919350|NCT01828073|DRUG|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
57919351|NCT02795429|DRUG|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
57919352|NCT02795429|DRUG|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
57919353|NCT00901277|BEHAVIORAL|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
57919354|NCT00901277|BEHAVIORAL|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
57919355|NCT05334745|OTHER|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
57919356|NCT01832233|PROCEDURE|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
57919357|NCT01416415|OTHER|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
58064893|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
57919358|NCT01416415|OTHER|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
57919359|NCT03187340|BEHAVIORAL|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
57919360|NCT03187340|BEHAVIORAL|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
57919361|NCT05555407|DIAGNOSTIC_TEST|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
57919362|NCT05555407|DEVICE|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
57919363|NCT06161935|OTHER|no intervention|no intervention, it is a retrospective study .
57919364|NCT01487408|DRUG|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
57919365|NCT04725396|DEVICE|Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).|PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
57919366|NCT04725396|DEVICE|Conventional Mandibular Reconstruction (MR without PVP)|Conventional Mandibular Reconstruction
58064894|NCT04330794|OTHER|NMFACT|caries index
58064895|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
58064896|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
58064897|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
58064898|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
58064899|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
58064900|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
58064901|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
58064902|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
58064903|NCT00327834|DRUG|atomoxetine|
58064904|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
58064905|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
58064906|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
58064907|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
57721294|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
57721295|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
57721296|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
57721297|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
57919367|NCT02527343|DRUG|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
58064908|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
57721298|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
57721299|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
57721300|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
57919368|NCT02527343|DRUG|Placebo|Volanesorsen-matching placebo administered SC injection.
57919369|NCT00722852|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
57919370|NCT00722852|DRUG|Placebo|100 mg (b.i.d.)
57919371|NCT03353350|DRUG|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
57919372|NCT03353350|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
57919373|NCT01137526|DRUG|ABT-384|Subjects will take study drug once daily for 12 weeks
58064909|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
58064910|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
58064911|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
58064912|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
58064913|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
58064914|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
58064915|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
58064916|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
58064917|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
58064918|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
58276769|NCT00938587|OTHER|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
58276770|NCT00938587|OTHER|Placebo|Placebo tablet every day for 14 days
57721301|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
58273422|NCT04201678|PROCEDURE|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
58273423|NCT04201678|PROCEDURE|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
57721302|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
58273424|NCT00478699|DRUG|Docetaxel/Cisplatin control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
58273425|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
58273426|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
58273427|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
57721303|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
57721304|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
58273428|NCT04350814|BEHAVIORAL|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
58273429|NCT04350814|BEHAVIORAL|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
58273430|NCT00055679|DRUG|cyclophosphamide|
57721305|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
57721306|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
57721307|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
57721308|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
58064919|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
58273431|NCT00055679|DRUG|epirubicin hydrochloride|
58064920|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
58273432|NCT00055679|DRUG|fluorouracil|
58273433|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
58273434|NCT03283917|DRUG|Dexamethasone|Given IV or PO
58273435|NCT03283917|DRUG|Ixazomib|Given PO
58273436|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
58273437|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
58273438|NCT03345628|DRUG|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
58273439|NCT05220748|COMBINATION_PRODUCT|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
58276771|NCT00938587|OTHER|Placebo for PF-04171327|Placebo tablet every day for 14 days
57721309|NCT00002526|BIOLOGICAL|filgrastim|
57721310|NCT00002526|DRUG|doxorubicin hydrochloride|
57721311|NCT00002526|DRUG|ifosfamide|
57721312|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
57721313|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
58276772|NCT03482895|BIOLOGICAL|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
58064921|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
57721314|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
57919374|NCT01137526|DRUG|donepezil|Subjects will take study drug once daily for 12 weeks.
58064922|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
58273440|NCT05220748|BIOLOGICAL|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
57721315|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
57919375|NCT01137526|DRUG|placebo|Subjects will take study drug once daily for 12 weeks
57919376|NCT00509678|DRUG|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
57919377|NCT04751708|PROCEDURE|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
57919378|NCT04751708|OTHER|best medical management|best medical management
57919379|NCT02960841|OTHER|Intracavitary Manual Lymphatic Drainage|
57919380|NCT02960841|OTHER|Conventional treatment|
57919381|NCT06135675|DRUG|TNP-2092 capsules|TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
57919382|NCT06135675|DRUG|TNP-2092 capsules Placebo|TNP-2092 capsules Placebo will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
57919383|NCT02699983|BEHAVIORAL|Behavioral Dietary Intervention|Use SparkPeople web-based program
57919384|NCT02699983|BEHAVIORAL|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
57919385|NCT02699983|DEVICE|Activity Monitoring Device|Wear Fitbit activity monitoring device
57919386|NCT05242185|OTHER|Observational study|- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
58064923|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
57919387|NCT00517907|DRUG|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
57919388|NCT03931720|BIOLOGICAL|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
58064924|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
58064925|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
58064926|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
58273441|NCT06730217|DEVICE|Intervention : mechanical insufflator|Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).
58273442|NCT06730217|OTHER|Control : standard care|Participants randomized to the control group will receive standard care
58276773|NCT03482895|BIOLOGICAL|Feces sampling|Intestinal absorption assessment
57721316|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
57919389|NCT04942834|DRUG|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
57919390|NCT04942834|DEVICE|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
57919391|NCT03482154|PROCEDURE|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
57919392|NCT04166890|DRUG|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
57919393|NCT01174160|DRUG|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
58064927|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
58273443|NCT06730841|DEVICE|Dose-Optimized and Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
58273444|NCT06730841|DEVICE|Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
58276774|NCT05612464|OTHER|No intervention|No intervention
58391225|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
57919394|NCT01174160|DRUG|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
57919395|NCT04626492|DIAGNOSTIC_TEST|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
57919396|NCT06266819|OTHER|chewing gum|In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
57919397|NCT02284451|OTHER|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
57919398|NCT05077865|DRUG|MYMD-1|150 mg capsule
58273445|NCT06730841|DEVICE|Sham Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
58273446|NCT05676476|DRUG|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
58273447|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
58273448|NCT05983575|DEVICE|Placebo|Placebo
58391226|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
58391227|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
58391228|NCT02570724|BIOLOGICAL|blood patch|
58391229|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
58273449|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
58273450|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
58391230|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
58391231|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
58391232|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
58391233|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
58391234|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
57919399|NCT05077865|DRUG|Placebo|Matching in appearance to MyMD-1 150mg capsule
58064928|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
58064929|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
57721317|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
57919400|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
57919401|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
57919402|NCT01280812|BEHAVIORAL|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
57919403|NCT04254302|OTHER|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
57919404|NCT00448409|BIOLOGICAL|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
57919405|NCT00448409|DRUG|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
58064930|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
58064931|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
58064932|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
58064933|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
58064934|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
58064935|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
58064936|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
57919406|NCT05786833|DRUG|Dexmedetomedine|Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
57919407|NCT05786833|DRUG|Ketofol|Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.
57919408|NCT05786833|DRUG|isotonic saline 0.9%|Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
57919409|NCT06267586|DIETARY_SUPPLEMENT|PeptiSleep|Plant protein hydrolysate
57919410|NCT06267586|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
57919411|NCT03642951|DEVICE|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
58064937|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
58064938|NCT01422395|PROCEDURE|Freezing|Vitrification
58064939|NCT02058186|DRUG|oral vitamin D|
58064940|NCT02058186|DRUG|Placebo|
58064941|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
58064942|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
57721318|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
57721319|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
57721320|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
57721321|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
57721322|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
57721323|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
57721324|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
57721325|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
57721326|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
57721327|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
57721328|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
57721329|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
57721330|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
57721331|NCT00646958|DRUG|Radezolid|450mg PO QD
57721332|NCT00646958|DRUG|Radezolid|450mg PO BID
57721333|NCT00646958|DRUG|Linezolid|600mg PO BID
57919412|NCT03642951|DEVICE|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
58391235|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate...), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
58391236|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
57721334|NCT03788889|DRUG|Ketamine|Ketamine infusion
57721335|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
57721336|NCT03788889|DRUG|Lorazepam|Standard of Care
57919413|NCT04267783|DIAGNOSTIC_TEST|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
57919414|NCT00182403|DRUG|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
58391237|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
58391238|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
58391239|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
58391240|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
57721337|NCT03788889|DRUG|Placebo A|Placebo injection
57721338|NCT03788889|DRUG|Placebo B|Placebo infusion
57721339|NCT05826821|DRUG|Pirfenidone|Intervention drug
57721340|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
57721341|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
57721342|NCT05809453|DRUG|Cocaine|Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
57721343|NCT05809453|DRUG|Lidocaine|Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
57721344|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
57721345|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
57721346|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721347|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721348|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721349|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721350|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
57721351|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
57721352|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
57721353|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
57721354|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
57721355|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
57721356|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
57721357|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
57721358|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
57721359|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
57721360|NCT00249145|DRUG|risperidone|
57721361|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
57721362|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
57721363|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
57721364|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
57721365|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
57721366|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
57721367|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
57721368|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
57721369|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
58273451|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
58273452|NCT00782691|OTHER|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
58273453|NCT05119569|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
58273454|NCT05119569|DRUG|Placebo|Placebo will be administered orally.
58273455|NCT04140916|DEVICE|Midline catheter|Peripherally inserted short intravenous catheter
58273456|NCT04140916|DEVICE|PICC-line catheter|Peripherally inserted long intravenous catheter
58273457|NCT00919542|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
57919415|NCT02159560|DEVICE|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
58391241|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
58391242|NCT00100074|DRUG|Lobeline|
58391243|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
57721370|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
57721371|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
57721372|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
57721373|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
57721374|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
57721375|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
57721376|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
57721377|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
57721378|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
57721379|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
57721380|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
57721381|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
57721382|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
57721383|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
57919416|NCT01241097|DRUG|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
58064943|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
58273458|NCT00919542|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
58273459|NCT03934359|DRUG|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
58273460|NCT02984514|RADIATION|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
58273461|NCT06730191|PROCEDURE|soft tissue graft covering immediate dental implant|soft tissue graft covering immediate dental implant
58391244|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
58391245|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
58391246|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
58391247|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
58391248|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
58391249|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
58391250|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
58391251|NCT05064501|OTHER|Asthma control test|Asthma control test
58391252|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
57721384|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
57721385|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
58273462|NCT03385369|DRUG|MEDI0382|Single dose of MEDI0382
58273463|NCT03385369|DRUG|Placebo|Single dose of placebo
58273464|NCT00688922|DRUG|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
58273465|NCT03365453|OTHER|frailty evaluation|frailty and comorbidity scores
58273466|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
58273467|NCT04856631|DRUG|Toripalimab Injection|240mg once per 3 weeks
58273468|NCT04856631|DRUG|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
58273469|NCT02818426|DRUG|UCPVax|
58273470|NCT03661216|DIETARY_SUPPLEMENT|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
58273471|NCT03661216|OTHER|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
58273472|NCT00858715|DRUG|aspirin|100 mg aspirin
58273473|NCT00858715|DRUG|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
58273474|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
58273475|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
58273476|NCT06731036|BIOLOGICAL|CD34+ cell enriched stem cell graft|Patients will receive a peripheral blood stem cell graft that has been CD34+ cell enriched using the Miltenyi CliniMACS Prodigy® system.
58273477|NCT04667533|DRUG|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg"
58273478|NCT03953625|OTHER|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
58273479|NCT02604173|DRUG|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
58273480|NCT02604173|DRUG|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
58273481|NCT02604173|DRUG|Placebo|Placebo pill and sham inhaler
58273482|NCT06731270|BIOLOGICAL|Atezolizumab|Given atezolizumab
58273483|NCT06731270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58273484|NCT06731270|BIOLOGICAL|Cemiplimab|Given cemiplimab
58273485|NCT06731270|PROCEDURE|Computed Tomography|Undergo CT
58273486|NCT06731270|DRUG|Diclofenac Potassium|Given PO
58273487|NCT06731270|OTHER|Electronic Health Record Review|Ancillary studies
58273488|NCT06731270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58273489|NCT06731270|BIOLOGICAL|Nivolumab|Given nivolumab
58273490|NCT06731270|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
58273491|NCT06731270|PROCEDURE|Positron Emission Tomography|Undergo PET
58273492|NCT05170230|DRUG|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
58273493|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
58391253|NCT00019968|DRUG|melphalan|
58391254|NCT00019968|DRUG|tumor necrosis factor|
58391255|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
58391256|NCT00399217|DEVICE|ICD|
58391257|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
58391258|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
58391259|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
58391260|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
58391261|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
58391262|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
58391263|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
58273494|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
57721386|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
58273495|NCT04893460|BEHAVIORAL|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
57721387|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
58273496|NCT04126642|BEHAVIORAL|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
58273497|NCT04126642|BEHAVIORAL|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
58273498|NCT05393934|OTHER|High dense nutrients formula|High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
58273499|NCT05393934|OTHER|Pediatric Nutrition Care (PNC)|Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
58273500|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
58273501|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
58273502|NCT06730230|BEHAVIORAL|Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support|CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
58273503|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
58273504|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
58273505|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
58273506|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
58273507|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
58273508|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
58273509|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
58273510|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
58273511|NCT06308536|PROCEDURE|bone powder + collagen membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.
58273512|NCT06308536|PROCEDURE|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
58273513|NCT06308536|PROCEDURE|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
58273514|NCT06308536|PROCEDURE|bone powder + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
58273515|NCT01531595|DRUG|Bevacizumab plus alternating XELOX/XELIRI|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
58273516|NCT02658383|OTHER|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
58273517|NCT02658383|OTHER|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
58273518|NCT04492072|DRUG|Oxytocin|Intervention
58273519|NCT04492072|DRUG|Misoprostol|Control
58273520|NCT06124586|PROCEDURE|Percutaneous transluminal angioplasty|Percutaneous transluminal angioplasty of the leg
58273521|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
58273522|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
58273523|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
58273524|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
58273525|NCT03409445|OTHER|no intervention|no intervention (observational study)
58273526|NCT02826577|DRUG|Pregnenolone 175mg|Single Dose 175mg
58273527|NCT02826577|DRUG|Pregnenolone 400mg|Single Dose 400mg
57721388|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
58273528|NCT02826577|DRUG|Placebo|Single Dose
58273529|NCT06731335|DRUG|Psilocybin|PSILOCYBIN (PEX010) 25 mg PO single dose
58273530|NCT06731335|DRUG|Active Placebo|Dextromethorphan 400 mg PO single dose
58273531|NCT04057664|BEHAVIORAL|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
58273532|NCT00763516|RADIATION|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
58273533|NCT02777281|BEHAVIORAL|Shoulder pain and SCI|Shoulder pain and SCI
57721389|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
57721390|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
57721391|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
58273534|NCT02777281|BEHAVIORAL|Shoulder pain and able bodies|
58273535|NCT06729957|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients engage in substance use treatment by increasing motivation and reducing barriers to accessing treatment. The care navigator helps the patient engage in the treatment plan established by the mental health care coordinator.
58273536|NCT02472626|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
57721392|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
57919417|NCT05050916|DIETARY_SUPPLEMENT|Vitamin D|"This is a Phase II randomized, dose-ranging clinical trial including 1) a within-woman comparison of hormones pre-and post-supplementation and 2) a comparison across women on a Vitamin D and a placebo. After recruitment, there will be two phases: Phase 1 will follow all women for one menstrual cycle prior to supplementation; blood will be assayed for 25OHD. Phase 2 includes only: 1) women with less than 20 ng/ml 25OHD (deficient) OR 2) a sample of women with \>20 ng/ml 25OHD (sufficient) as the placebo group. During Phase 2, deficient women will be assigned to receive a blinded dose of 50,000 IU of vitamin D supplementation per week and followed for three more menstrual cycles. Hormone levels will be compared between the pre-and post-supplementation cycles as the primary analysis. The primary aim will test: if mid-luteal progesterone, rate of estrogen rise and pre-ovulatory LH are higher in vitamin D supplemented cycles."
58273537|NCT02472626|DRUG|Cytarabine|Given IV
58273538|NCT02472626|DRUG|Daunorubicin Hydrochloride|Given IV
58273539|NCT00167401|DRUG|docetaxel|
58273540|NCT00167401|DRUG|cisplatin|
58273541|NCT00167401|PROCEDURE|radiation treatment|
58273542|NCT02245113|OTHER|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
58273543|NCT06654297|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
58273544|NCT06654297|DRUG|Palbociclib(100mg)|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
58273545|NCT06654297|DRUG|Palbociclib(125mg)|Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
58273546|NCT06035939|BEHAVIORAL|Voice Crisis Alert V2|The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
57919418|NCT00241605|DRUG|rosiglitazone/metformin|
57919419|NCT05455138|PROCEDURE|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
57919420|NCT03082742|DRUG|Hydrochlorothiazide|
57919421|NCT03082742|DRUG|Furosemide|
57919422|NCT05849948|BEHAVIORAL|choronobiological nutrition|Providing infant nutrition in accordance with crinobiological nutrition
57919423|NCT02808637|OTHER|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
57919424|NCT02808637|OTHER|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
58273547|NCT06035939|BEHAVIORAL|Electronic educational materials|The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
58273548|NCT03913104|DRUG|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
58273549|NCT06663163|OTHER|Observation|This study was an observational study without intervention
58273550|NCT02615392|BEHAVIORAL|Park Prescription|Please refer to the information included in the arm description.
57721393|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
58273551|NCT04129840|OTHER|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
58273552|NCT04129840|OTHER|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
58273553|NCT04129840|OTHER|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
57721394|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
57721395|NCT00014144|DRUG|gefitinib|
57721396|NCT00054899|BIOLOGICAL|EP2101|
57721397|NCT02192268|OTHER|PEP|
57721398|NCT02192268|OTHER|HFOO|
57721399|NCT02192268|OTHER|Assisted Coughing|
57721400|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
58273554|NCT01915524|BIOLOGICAL|CV9202|Intradermal injection of CV9202
57721401|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
57721402|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
57721403|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
57721404|NCT00304070|DRUG|Cisplatin|Given IV
57721405|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
57721406|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
58273555|NCT01915524|RADIATION|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
58273556|NCT04612972|BIOLOGICAL|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
58391264|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
58391265|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
57721407|NCT00304070|DRUG|Etoposide|Given IV
57721408|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
57721409|NCT00304070|DRUG|Mitotane|Given orally
57721410|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
57721411|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
57721412|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
57721413|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
57721414|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
57721415|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
57721416|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
57721417|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
57721418|NCT00126048|DRUG|Atorvastatin|40mg tablet
57721419|NCT00126048|DRUG|Placebo|Placebo tablet
57919425|NCT02808637|OTHER|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
58064944|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
57721420|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
57721421|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
57721422|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
57721423|NCT02284828|DRUG|BIA 2-093|
57721424|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
57721425|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
57721426|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
57919426|NCT02808637|OTHER|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
57919427|NCT01809223|DRUG|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
57919428|NCT01809223|DRUG|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
57919429|NCT01809223|OTHER|sham injection|sham intravitreal injection per month, fixed injection
57919430|NCT04779372|BEHAVIORAL|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
57919431|NCT04779372|BEHAVIORAL|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
58064945|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
57721427|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
57721428|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
57721429|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
57721430|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
57721431|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
58064946|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
57721432|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
57721433|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
57721434|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
57721435|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
57721436|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
57721437|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
57721438|NCT02486406|DRUG|Ribavirin solution|Oral solution
57721439|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
57721440|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
57721441|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
58064947|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
57721442|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
57721443|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
57721444|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
57721445|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
57721446|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
57721447|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
57721448|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
57721449|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
57721450|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
57721451|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
57919432|NCT01337115|PROCEDURE|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
57721452|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
57721453|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
57721454|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
57721455|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
57721456|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
57721457|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
57721458|NCT02617589|DRUG|Nivolumab|
58391266|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
57919433|NCT01337115|PROCEDURE|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
57721459|NCT02617589|DRUG|Temozolomide|
57721460|NCT02617589|RADIATION|Radiotherapy|
57721461|NCT00796029|DRUG|14C-paliperidone|
57721462|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
57721463|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
57721464|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
58064948|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
58064949|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
58064950|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
58391267|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
57721465|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
57721466|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
57721467|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
57721468|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
57721469|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
57721470|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
57721471|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
58391268|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
57721472|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
57721473|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
57721474|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
57721475|NCT02172313|DRUG|semaglutide|For oral administration.
57919434|NCT00655694|PROCEDURE|sputum, blood, urine, exhaled breath, lung function|
57919435|NCT02396043|DRUG|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
57919436|NCT02396043|DRUG|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
58064951|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
58064952|NCT01048164|PROCEDURE|Massage|Chair Massage
58064953|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
57721476|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
57721477|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
57721478|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
57721479|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
57721480|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
57721481|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
57721482|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721483|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721484|NCT06030193|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
57721485|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
57721486|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
57721487|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
57721488|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
57721489|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
57721490|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
57721491|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
57721492|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
57721493|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
57721494|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
57919437|NCT02396043|DRUG|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
57919438|NCT02396043|DRUG|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
57919439|NCT02396043|DRUG|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
58064954|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
58064955|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
58064956|NCT03055806|DRUG|Placebo|Placebo caplet(s)
58064957|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
58064958|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
57919440|NCT02396043|DRUG|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
57919441|NCT02396043|DRUG|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
57919442|NCT00029172|OTHER|case management|
57919443|NCT05694572|DEVICE|Implantation of a CIED|Implantation of a CIED
57919444|NCT05344820|BEHAVIORAL|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
57919445|NCT03902223|DIAGNOSTIC_TEST|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
57919446|NCT03902223|DIAGNOSTIC_TEST|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
57919447|NCT03498482|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
57919448|NCT04364009|DRUG|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
57919449|NCT04364009|DRUG|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
57919450|NCT01553305|OTHER|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
57919451|NCT01553305|OTHER|Exercise programme|Supervised exercise programme
57919452|NCT02577731|OTHER|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
57919453|NCT02577731|OTHER|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
58064959|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
58064960|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
58064961|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
58064962|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
57919454|NCT02577731|OTHER|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
58064963|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
57919455|NCT02822638|OTHER|STEMI PATIENT Cohort|PCI
57919456|NCT02794168|DRUG|VAS203|Treatment
58064964|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
58064965|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
58064966|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
58064967|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
57919457|NCT02794168|DRUG|Saline|Placebo
57919458|NCT03413657|PROCEDURE|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
58064968|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
58064969|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
58064970|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
58064971|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
57919459|NCT01018121|BEHAVIORAL|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
57919460|NCT01018121|OTHER|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
57919461|NCT02621671|BEHAVIORAL|Cognitive interview|
57919462|NCT02621671|OTHER|Survey|
57919463|NCT02293031|DEVICE|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
57919464|NCT05939466|DRUG|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
57919465|NCT02044211|BEHAVIORAL|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
57919466|NCT02044211|BEHAVIORAL|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
57919467|NCT03126708|DRUG|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
57919468|NCT03126708|DRUG|cisplatin plus paclitaxel|Chemotherapy
57919469|NCT00259987|DRUG|Lapatinib (GW572016) oral tablets|
57919470|NCT02253108|DEVICE|Everolimus eluting bioresorbable polymer stent|
57919471|NCT02253108|DEVICE|Biolimus eluting bioresorbable polymer stent|
57919472|NCT05635539|DIETARY_SUPPLEMENT|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
58064972|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
58064973|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
58064974|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
58064975|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
58064976|NCT00462657|GENETIC|polymerase chain reaction|
58273557|NCT05675514|OTHER|Myofascial Release Therapy|The increasing number of basketball players also increases the risk of sports-related injuries. Basketball has the highest injury risk of all sports because the game is so powerful and fast moving. Myofascial release therapy; ıt is a form of manual therapy applied on the muscle fascia complex to restore optimal length, reduce pain and improve functions. It is known to be effective in providing rapid relief of pain and tissue sensitivity. By restoring the length and health of the restricted connective tissue with the myofascial release therapy, it aims to relieve pressure on pain sensitive structures such as nerves and blood vessels, as well as improves sports performance.
58273558|NCT03486119|OTHER|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
58273559|NCT00776620|DRUG|Glimepiride 1mg Tablets|
57919473|NCT01506141|DRUG|Idursulfase-IT|Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
57919474|NCT01506141|DRUG|Elaprase|Participants will receive weekly IV infusions of commercially available Elaprase.
57919475|NCT02038543|DRUG|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
57919476|NCT02934425|OTHER|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
57919477|NCT02934425|OTHER|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
58064977|NCT00462657|OTHER|bronchoalveolar lavage|
58064978|NCT00462657|OTHER|immunoenzyme technique|
58273560|NCT04587024|OTHER|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
57721495|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
57919478|NCT02783521|BEHAVIORAL|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
58273561|NCT04587024|OTHER|standard of care|Subjects will receive standard of care observation for 12 weeks
58273562|NCT03963180|OTHER|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
57721496|NCT02477384|PROCEDURE|8mm-TIPS|
57919479|NCT02783521|BEHAVIORAL|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
57919480|NCT02498496|DRUG|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
57919481|NCT02498496|DRUG|Placebo|Administration of 100 mL of Normal Saline
57919482|NCT05139433|BEHAVIORAL|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
58064979|NCT00462657|OTHER|laboratory biomarker analysis|
58064980|NCT00462657|PROCEDURE|bronchoscopy|
58064981|NCT00462657|PROCEDURE|management of therapy complications|
58064982|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
58064983|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
58064984|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
58273563|NCT05731167|BEHAVIORAL|Multidomain frailty prevention method|We use the nutrition, physical training, medication consultation, cognition training to prevent the occurrence of frailty or other adverse outcome.
58273564|NCT05731167|OTHER|Regular follow up|Subjects will receive regular follow up and suggestion in outpatient department.
58273565|NCT05640661|DEVICE|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
58391269|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
58273566|NCT05640661|DEVICE|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
58391270|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
57721497|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
57721498|NCT02477384|DRUG|Propranolol|
57721499|NCT02477384|DEVICE|8mm ePTFE-covered stent|
58064985|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
58064986|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
57721500|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
57721501|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
58273567|NCT02226926|DRUG|Aggrenox|
57721502|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
58273568|NCT02226926|DRUG|Persantin Retard|
58273569|NCT02226926|DRUG|Acetylsalicylic acid|
58273570|NCT03069456|DEVICE|BIS|
58273571|NCT03069456|DEVICE|ADMS|
58273572|NCT04412642|DRUG|Methoxyflurane, MEOF|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
58391271|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
57721503|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
57721504|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
57721505|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
57721506|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
57721507|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
57721508|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
58273573|NCT00865267|DRUG|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
58273574|NCT06729996|DRUG|Pioglitazone (PIO)|Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
58273575|NCT06729996|DRUG|Empagliflozin (EMPA)|Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
58273576|NCT02428894|DEVICE|LVAD|
58273577|NCT00417638|DEVICE|Endovascular cooling by the Celsius Control System|
58273578|NCT00417638|OTHER|Standard of care|
58273579|NCT01564641|DEVICE|iDuo G2|single comparator
58391272|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
57721509|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
57721510|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
57721511|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
58273580|NCT00931827|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
58273581|NCT00931827|DRUG|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
58273582|NCT05857670|BEHAVIORAL|Genetic predisposition to breast cancer|Guilt feelings about procreating
57721512|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
57721513|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
57721514|NCT06573086|OTHER|Resistance Training|12-week resistance training
57721515|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
57721516|NCT06567808|DRUG|Cefazolin|administration as outlined
57721517|NCT06567808|DRUG|Vancomycin|administered as outlined
57721518|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
58391273|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
58391274|NCT00104728|DRUG|ZD1839|
58391275|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
57919483|NCT05139433|BEHAVIORAL|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
57919484|NCT00208923|DRUG|Busulfan, Cyclophosphamide and Fludarabine|"* Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
57919485|NCT03341351|OTHER|Instructional video|Instructional video using the modified beef tongue model
57919486|NCT03341351|OTHER|Instructional workshop|Instructional workshop using the modified beef tongue model.
57919487|NCT02261051|OTHER|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
57919488|NCT05708404|BEHAVIORAL|Outpatient treatment of severe and enduring anorexia nervosa|A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm
57919489|NCT04035174|DIAGNOSTIC_TEST|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
57919490|NCT04035174|DIAGNOSTIC_TEST|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
57919491|NCT03343457|BEHAVIORAL|Cognitive therapy|
57721519|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
57721520|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
57721521|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
57721522|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
57721523|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
57721524|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
57721525|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
57919492|NCT00326469|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
58391276|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
58391277|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
57721526|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
57721527|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
57721528|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
57721529|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
57721530|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
57721531|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
57721532|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
57721533|NCT00452504|DRUG|SRA-444|
57919493|NCT00096811|DRUG|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
57919494|NCT06027164|DEVICE|Portable Ultrasound System|EchoNous KOSMOS
57919495|NCT04454177|DEVICE|HUAWEI watch|HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
57919496|NCT00454766|BEHAVIORAL|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
57919497|NCT00491777|DEVICE|Noninvasive Hemodynamic Patient Monitor|
58273583|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
58273584|NCT04477694|PROCEDURE|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
57721534|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
57721535|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
57721536|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
57721537|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
57721538|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
57721539|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
57721540|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
57721541|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
57721542|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
57919498|NCT04431401|DEVICE|Magstim rTMS|The device is made in London,UK
58273585|NCT06721221|DEVICE|Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software|PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
57721543|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
57721544|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
57919499|NCT01944813|BEHAVIORAL|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
57919500|NCT04053530|OTHER|restorative materials|glass ionomer and bulk fill flowable composite
58273586|NCT03121573|DRUG|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
57721545|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
57721546|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
57721547|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
57721548|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
57721549|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
57721550|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
57721551|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
57721552|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
57721553|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
57721554|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
57721555|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
57721556|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
57721557|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
57721558|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
57919501|NCT03861117|PROCEDURE|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
58273587|NCT00958412|DRUG|Proellex®|one (1) 25 mg capsule daily
58273588|NCT04978077|OTHER|Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)|After a night fast participants will drink the test meal
58273589|NCT06232434|DRUG|Prospidelong|Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
58273590|NCT06232434|PROCEDURE|chemotherapy|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1"
58273591|NCT04498598|DEVICE|A/Z Supraglottic airway|Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
58273592|NCT04474613|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
57721559|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
57721560|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
57721561|NCT04313153|DRUG|Vadadustat|oral tablets
57721562|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
57721563|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
57721564|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
57721565|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
57721566|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
57721567|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
57721568|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
57721569|NCT04166318|DRUG|Capecitabine|Given PO
57721570|NCT04166318|DRUG|Fluorouracil|Given IV
57721571|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57721572|NCT04166318|DRUG|Mitomycin|Given IV
57721573|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
57919502|NCT03861117|PROCEDURE|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
57919503|NCT02949505|BEHAVIORAL|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
58273593|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
58273594|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
57721574|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
57721575|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
57721576|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
57721577|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
57721578|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
57721579|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
57721580|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
57721581|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
57721582|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
57919504|NCT04499274|DRUG|0 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron
58273595|NCT06319872|DRUG|Oral disulfiram|250 mg/day
58273596|NCT03357900|DEVICE|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
57919505|NCT04499274|DRUG|0.2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron
57919506|NCT04499274|DRUG|2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron
57919507|NCT04499274|DRUG|20 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
57919508|NCT00491829|DRUG|50 mg qhs|flibanserin 50 mg
57919509|NCT00491829|DRUG|100 mg|flibanserin 100mg
57919510|NCT00491829|DRUG|placebo|placebo
58273597|NCT01846806|OTHER|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
58273598|NCT06725680|OTHER|Retrolaminar block|Patients will receive retrolaminar block after the induction of general anesthesia.
58273599|NCT06725680|OTHER|Erector spinae plane block|Patients will receive erector spinae plane block after the induction of general anesthesia.
58273600|NCT03205098|BIOLOGICAL|Blood analysis|Blood test of biological markers of mesenteric ischemia
58273601|NCT01687387|DRUG|IPH2102 at 0.1 mg/kg|every 3 months
58273602|NCT01687387|DRUG|IPH2102 at 1 mg/kg|every 4 weeks
58273603|NCT01687387|DRUG|Placebo (normal saline solution)|every 4 weeks
58273604|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
58273605|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
58273606|NCT02897063|DRUG|Placebo|sugar pill
58391278|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
57721583|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
57721584|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
57721585|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
57721586|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
57721587|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
57919511|NCT00461487|BEHAVIORAL|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
57919512|NCT00461487|BEHAVIORAL|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
57919513|NCT01422226|DRUG|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
57919514|NCT01422226|OTHER|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
57919515|NCT05692297|DRUG|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
57919516|NCT05692297|DRUG|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
57919517|NCT05749289|DRUG|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
58273607|NCT03623633|DRUG|denosumab|denosumab 60 milligrams subcutaneously every 6 months
58391279|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
58391280|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
57721588|NCT02736162|OTHER|No treatment (intervention) was administered|
58273608|NCT03623633|DRUG|alendronate|alendronate 70 milligrams weekly
58273609|NCT03623633|DRUG|raloxifene|raloxifene 60 milligrams daily
57721589|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
57919518|NCT00001563|BIOLOGICAL|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
58273610|NCT05292482|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
58273611|NCT05292482|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
57721590|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
57919519|NCT00001563|BIOLOGICAL|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
57919520|NCT00001563|DRUG|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
57919521|NCT05251662|DRUG|Sintilimab|200mg IV d1 Q3W
57919522|NCT05251662|DRUG|IBI305|7.5mg/kg IV d1 Q3W
57919523|NCT05251662|DRUG|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
58273612|NCT05328388|DIETARY_SUPPLEMENT|Lycomato|Lycomato sof gels
58273613|NCT03535194|DRUG|Mirikizumab|Administered SC
58273614|NCT03535194|DRUG|Placebo|Administered SC
58273615|NCT03535194|DRUG|Secukinumab|Administered SC
58273616|NCT02295267|OTHER|walnut allergy provocation|double blind placebo controlled food challenge
58273617|NCT06731309|PROCEDURE|Punch Debridement|A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.
58391281|NCT03136224|DEVICE|Thermocautery|
58391282|NCT03136224|DEVICE|Plastic Clamping|
58391283|NCT03136224|DEVICE|Surgical Circumcision|
58391284|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
58391285|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
58391286|NCT00107900|DRUG|DU-176b|
58064987|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
57721591|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
57721592|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
57721593|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
57721594|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
57721595|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
57721596|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
57721597|NCT04401124|OTHER|no intervention|no intervention
57721598|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
57721599|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
57721600|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
57919524|NCT05624294|DRUG|CS0159|Tablets administered orally
57919525|NCT05624294|DRUG|Placebo|Tablets administered orally
57919526|NCT04012996|DEVICE|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
57919527|NCT04012996|DEVICE|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
58064988|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
58064989|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
58273618|NCT06731309|PROCEDURE|Incision and Drainage|Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
57721601|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
57919528|NCT04144504|DEVICE|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
58273619|NCT06730048|OTHER|Experimental Group|An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
58273620|NCT06730048|OTHER|Control group (placebo)|After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
58273621|NCT01094782|OTHER|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
57919529|NCT04144504|DEVICE|Plastic stenting|Use of plastic stents
57721602|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
57721603|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
57721604|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
57721605|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
57721606|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
57721607|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
57721608|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
57721609|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
57721610|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
57721611|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
57721612|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
57721613|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
57721614|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
57721615|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
57721616|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
57721617|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
57721618|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
57721619|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
57721620|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
57721621|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
57721622|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
58064990|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
58064991|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
58064992|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
58064993|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
58391287|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
58391288|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
58391289|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
57721623|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
57721624|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
57721625|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
57721626|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
57721627|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
57721628|NCT00204191|DRUG|tacrolimus|
57721629|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
57721630|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
57721631|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
57721632|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
57721633|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
57721634|NCT00393445|DRUG|saline control|intravenous infusion of saline
57721635|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
57721636|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
57721637|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
57721638|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
57721639|NCT03136068|DRUG|Placebo|Trans-abdominal injection
57721640|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
57721641|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
58273622|NCT01094782|OTHER|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
58273623|NCT04454710|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
58273624|NCT06323317|BEHAVIORAL|Multi-component exercise programme|Each exercise session will start with a warm-up, followed by core exercise training and ending with a cool-down period. A series of flexibility training and stretching exercises will be performed during the warm-up and cool-down phases (10 minutes in total). The core exercise session will comprise aerobic (10 minutes), resistance (20 minutes), and balance (20 minutes) training, where resistance and balance exercises constitute the major components, as they are particularly effective in strengthening functional capacity, muscle strength, and balance function for mobility in frail patients.
58273625|NCT06323317|OTHER|Attention Placebo|The control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
58273626|NCT06323317|BEHAVIORAL|Structured preoperative education|The prehabilitation programme will begin with a 60-minute (group- or individual-based) structured education session at the centre. The content will cover frailty, its impacts on postoperative recovery, cardiovascular and overall health, and functional well-being. The importance of nutrition and exercise on their recovery potential and postoperative functional capacity will be elaborated. Their commitment to intervention engagement will be highlighted as the key to success. This session will also cover the principles of exercise, its progression, and exercise safety.
58273627|NCT06323317|BEHAVIORAL|Nutritional optimization|The Malnutrition Universal Screening Tool (MUST) will be used for a nutritional screening to determine the risk of malnutrition (low, medium, or high). The nurse will evaluate the dietary patterns of each participant, and provide tailored nutritional advice on daily protein intake according to a protein supplementation protocol. The participants and their caregivers will be provided with plenty of suggestions for high-quality protein foods according to patients' preferences. The nurse will follow-up with the participants to identify any barriers they encountered in real-world settings when they attend the exercise sessions. She will reinforce the advice and provide suggestions to overcome barriers according to the preference and lifestyle of the participants.
58273628|NCT06323317|BEHAVIORAL|Stress management|Relaxation techniques to reduce tense arousal, including guide imagery and breathing techniques, will be taught. Guided imagery makes use of attention-focus to target mental arousal, whereas deep and diaphragmatic breathing is a fundamental relaxation method for various stress relieving techniques. Both techniques are designed to reduce sympathetic arousal, which is particularly beneficial to cardiac patients. Participants will be encouraged to self-practice on a daily basis, and a sound track will be provided to guide their practice.
58273629|NCT06219018|OTHER|Medical grade honey formulation (MGH) (L-Mesitran®)|daily application of 5 grams (with applicator)
58273630|NCT04670380|OTHER|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
58273631|NCT05499078|DEVICE|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
58273632|NCT01678703|DEVICE|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
58273633|NCT01678703|DRUG|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
58273634|NCT01580176|DEVICE|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
58273635|NCT04517578|OTHER|Survey|Participants will be asked to fill in an online survey that will be anonimized.
58273636|NCT06731829|DRUG|HRS-9231|HRS-9231
58273637|NCT06731829|DRUG|Gadobutrol|Gadobutrol
57919530|NCT01096134|BIOLOGICAL|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
57919531|NCT01216033|DRUG|111-In-ABY-025|Intravenous injection of the agent
57919532|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
57919533|NCT01321346|DRUG|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
57919534|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
58064994|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
58064995|NCT02216539|PROCEDURE|Lung transplantation|
58064996|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
58064997|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
58273638|NCT02415062|DRUG|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
58273639|NCT02636439|BEHAVIORAL|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
58273640|NCT02636439|BEHAVIORAL|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
58273641|NCT05490433|PROCEDURE|robot assisted nipple sparing mastectomy(RNSM)|"Patients receiving RNSM and IBR are enrolled in this group. The RNSM is performed using a robotic surgical system.~The robotic surgical system includes da Vinci S, Si, X, Xi, and SP Systems. An armpit or lateral chest incision is used in this surgical procedure. A lateral chest incision is used. Posterior flow tissue collection is recommended for frozen segment biopsy during surgery. If a suspected lesion is observed on the superficial or posterior interface during surgery, a frozen section for that lesion. Biopsy is recommended. For NAC, superficial edges, and/or posterior edges in frozen intercept biopsy, If tumor invasion is identified, additional resection or postoperative radiotherapy, including skin and NAC, should be considered do. In IBR, tissue extensor insertion, prosthesis insertion, photolateral sheath, transverse abdominal rectangular sheath, or deep lower abdominal perforated vessels. The skin plate is applicable."
58273642|NCT05490433|PROCEDURE|Conventional nipple sparing mastectomy(CNSM)|"Patients who receive CNSM and IBR are enrolled in this group. CNSM uses a robot or endoscopic surgical system Do not travel. All kinds of skin incisions can be performed in this technique. It is recommended to collect posterior mammary gland tissue for frozen segment biopsy during surgery. If a lesion suspected of tumor invasion is observed at the edge of the surface or posterior edge during surgery, a freeze-intercept biopsy is recommended for that lesion.~If a frozen segment biopsy identifies invasion of tumors on NAC, superficial edges, and/or posterior edges, further resection or postoperative radiotherapy, including skin and NAC, is considered.~In IBR, tissue extensor insertion, prosthesis insertion, photomultiplier sheath, transverse rectangular sheath, or deep lower abdominal perforated vessels.~It includes a sheath. It is excluded if there is no IBR."
58273643|NCT04910243|OTHER|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
58273644|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
58273645|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
58273646|NCT06150768|DEVICE|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
57919535|NCT02898844|BEHAVIORAL|Mixed Diet Condition|One roommate dieted and the other ate normally.
57919536|NCT02898844|BEHAVIORAL|Both Diet Condition|Both roommates dieted.
57919537|NCT03503253|DEVICE|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
57919538|NCT03503253|DEVICE|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
57919539|NCT03503253|DEVICE|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
58064998|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
58064999|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
58065000|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
58391290|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
58065001|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
58391291|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
58065002|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
58391292|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
58391293|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
58391294|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
58391295|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
57721642|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
57721643|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
57721644|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
57721645|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
58391296|NCT02283905|DRUG|amphotericin-B|continuously infused
58391297|NCT02283905|DRUG|voriconazole|intravenously or orally administered
58391298|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
58391299|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
58391300|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
58065003|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
58065004|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
58391301|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
58391302|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
58391303|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
58391304|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
58391305|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
58391306|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
58391307|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
58391308|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
58391309|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
58391310|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
58391311|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
58391312|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
58391313|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
58391314|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
58391315|NCT01819207|OTHER|blood test by thromboelastography|
58391316|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
58391317|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
58391318|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
57721646|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
57919540|NCT05808504|OTHER|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
57919541|NCT05808504|OTHER|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
58391319|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
58391320|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
58391321|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
57721647|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
57721648|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
57721649|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
57919542|NCT05808504|OTHER|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
57919543|NCT05808504|PROCEDURE|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
58065005|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
58065006|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
58065007|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
58065008|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
57721650|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
57721651|NCT04280211|OTHER|Balance Assessment|Postural stability
57721652|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
57721653|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
58065009|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
58065010|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
57721654|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
57721655|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
58065011|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
58065012|NCT01888380|PROCEDURE|Conventional autopsy|
57721656|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
57721657|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
57721658|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
58065013|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
58065014|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
58065015|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
58065016|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
57919544|NCT05808504|PROCEDURE|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
57919545|NCT00188175|RADIATION|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
57919546|NCT02475902|BEHAVIORAL|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
57919547|NCT02475902|BEHAVIORAL|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
57919548|NCT03433911|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
57919549|NCT03433911|PROCEDURE|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
57919550|NCT03019185|DRUG|Placebo Oral Capsule|Capsule containing an inert placebo
57919551|NCT03019185|DRUG|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
57919552|NCT06341348|OTHER|Case management|Case Management (CM) is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone. All interventions were delivered by a nursing case manager who had over 5 years of nursing experience and received more than 20 hours of CM training.
57919553|NCT02388867|PROCEDURE|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
57919554|NCT02388867|PROCEDURE|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
57919555|NCT03021954|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
57919556|NCT02846753|PROCEDURE|trans catheter heart valve replacement|trans catheter heart valve replacement
57919557|NCT00413296|DRUG|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
57919558|NCT00413296|DRUG|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
58391322|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
57919559|NCT00413296|DRUG|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
57919560|NCT04693494|OTHER|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
57919561|NCT00081406|BEHAVIORAL|Individual Child CBT|
57919562|NCT00081406|BEHAVIORAL|Family CBT|
57919563|NCT00081406|BEHAVIORAL|Education/Support/Attention|
57919564|NCT01492530|BEHAVIORAL|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
57919565|NCT01492530|BEHAVIORAL|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
57919566|NCT05205915|DEVICE|tDCS intervention applied by Starstim device|Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
57919567|NCT03628898|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
57919568|NCT01620255|DRUG|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
58065017|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
57919569|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
57919570|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
58065018|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
57721659|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
57721660|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
57721661|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
57721662|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
58273647|NCT06150768|DEVICE|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
58273648|NCT06150768|DEVICE|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
58391323|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
58391324|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
58391325|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
58391326|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
58391327|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
58391328|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
58391329|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
58391330|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
58391331|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
58391332|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
58391333|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
58391334|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
57721663|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
57721664|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
57721665|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
57919571|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
57919572|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
58273649|NCT02945254|DEVICE|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
58273650|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
58273651|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
58273652|NCT02223364|DRUG|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
58273653|NCT02223364|DRUG|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
58273654|NCT02223364|DRUG|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
57919573|NCT04648735|OTHER|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
57919574|NCT06335043|GENETIC|Pharmacogenetics Testing|Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
57919575|NCT00250679|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
58273655|NCT04373850|BEHAVIORAL|Home Visit|Physical exam, medication dose titration
58273656|NCT03871959|DRUG|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
58273657|NCT03871959|DRUG|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
58391335|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
58391336|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
57919576|NCT00250679|DRUG|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
57919577|NCT00250679|DRUG|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
57919578|NCT00250679|DRUG|Placebo|Placebo nebule or placebo aerolizer
57919579|NCT00312143|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
57919580|NCT01048580|DRUG|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
57721666|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
57721667|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
57721668|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
57721669|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
57721670|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
57919581|NCT01048580|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
57919582|NCT05714631|OTHER|Placebo Patch|Transdermal placebo patch
57919583|NCT05714631|DRUG|4% Lidocaine Patch|Transdermal patch
57919584|NCT01395979|BEHAVIORAL|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
57919585|NCT01395979|BEHAVIORAL|Supportive Psychotherapy|Eight weekly sessions
57919586|NCT01395979|BEHAVIORAL|Sexual Risk Reduction Intervention|Two weekly sessions.
57721671|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
57721672|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
57721673|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
57721674|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
57919587|NCT01246934|OTHER|ASR METHOD|
58065019|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
58391337|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
58391338|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
58391339|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
58391340|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
57721675|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
57721676|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
57721677|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
57721678|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
57721679|NCT00701389|DRUG|sumatriptan placebo|single oral dose
57721680|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
57919588|NCT02799953|DEVICE|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
57919589|NCT01821716|BIOLOGICAL|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
57919590|NCT05423626|DEVICE|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
57919591|NCT05423626|DEVICE|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers."
57721681|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
57721682|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
57919592|NCT05048433|BEHAVIORAL|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
57919593|NCT05048433|BEHAVIORAL|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
58391341|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
58391342|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
57721683|NCT02972697|RADIATION|11C-acetate ligand|
57721684|NCT02972697|RADIATION|FDG ligand|
57721685|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
57721686|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
58391343|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
58391344|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
58391345|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
58391346|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
58391347|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
58391348|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
57721687|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
57721688|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
57721689|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
57721690|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
57721691|NCT00621439|DRUG|Placebo|Patients will receive placebo.
58391349|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
58391350|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
57721692|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
57721693|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
58273658|NCT02851979|OTHER|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
58273659|NCT02638051|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
58273660|NCT02638051|DIETARY_SUPPLEMENT|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
58273661|NCT02638051|DRUG|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
58273662|NCT00019630|DRUG|doxorubicin HCl liposome|
58273663|NCT01520194|OTHER|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
58273664|NCT01520194|OTHER|medical records|medical chart review of patients assisted January 2009 to December 2010
58273665|NCT05015543|OTHER|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
58273666|NCT01731470|BIOLOGICAL|Liposomes|Intravesical instillation of liposomes.
58273667|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
57919594|NCT03991104|DRUG|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
58273668|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
58273669|NCT06622291|DRUG|Nitric Oxide|Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
58273670|NCT06622291|OTHER|Placebo|This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
58273671|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
58391351|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
57721694|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
58273672|NCT03729622|OTHER|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
58273673|NCT06721559|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
58273674|NCT06721559|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
57919595|NCT03991104|DRUG|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
57919596|NCT03991104|RADIATION|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
57919597|NCT01327859|DRUG|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
57919598|NCT01327859|DRUG|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
57919599|NCT01327859|DRUG|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
57919600|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
57919601|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
57721695|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
57721696|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
57721697|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
57721698|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
57721699|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
57721700|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
57721701|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
58273675|NCT06719869|DEVICE|Midline intravenous catheter|Patients in the intervention group receive a 10 cm PowerGlide Pro™ Midline Catheter (Becton Dickinson). Catheters are inserted with ultrasound-guidance by an anesthesiologist using sterile gloves, mask, and large drape. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. All catheters are secured with using a StatLock™ Stabilization device (Becton Dickinson), and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. Choice of insertion site on arm below or above the elbow avoiding catheter across joints and at the clinician's discretion.
58273676|NCT06719869|DEVICE|Central Venous Catheter (CVC):|Patients in the control group receive a Celsite 320 or 315 (B. Braun) or Pressure Injectable Arrowg+ard Blue Plus+ (Arrow). Catheters are inserted with ultrasound-guidance by an anesthesiologist with maximal sterile precautions (cap, mask, gown, gloves, and large drape) using the Seldinger technique. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. Catheters are secured with monofilament sutures, and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. The choice of insertion site is at the clinician's discretion
58273677|NCT04885400|BEHAVIORAL|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
58273678|NCT03012763|DRUG|Paracetamol|Oral administration of 250 mg paracetamol
58273679|NCT03012763|DRUG|Sulfasalazine|Oral administration of 50 mg sulfasalazine
57721702|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
57721703|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
57721704|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
58273680|NCT03012763|DRUG|Fexofenadine|Oral administration of 120 mg fexofenadine
58273681|NCT03012763|DRUG|Valsartan|Oral administration of 40 mg valsartan
58273682|NCT03012763|DEVICE|non-caloric water|Oral administration of 240 ml non-caloric water
58273683|NCT03012763|DEVICE|caloric drink|Oral administration of 240 ml caloric drink
58273684|NCT03012763|DEVICE|grapefruit juice|Oral administration of 240 ml grapefruit juice
58273685|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
58273686|NCT05207722|BIOLOGICAL|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
58273687|NCT05207722|DRUG|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
58273688|NCT05207722|DRUG|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
57721705|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
57721706|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
57721707|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
57721708|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
57919602|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
58273689|NCT05207722|DRUG|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
57721709|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
57721710|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
57919603|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
57919604|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
57919605|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
57919606|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
57919607|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
57919608|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
57919609|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
57919610|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
57919611|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
57919612|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
57919613|NCT05720988|DRUG|Azacitidine|Given SC
57919614|NCT05720988|BIOLOGICAL|Tagraxofusp-erzs|Given IV
57919615|NCT01935180|DEVICE|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
57919616|NCT02307760|OTHER|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
57919617|NCT02307760|OTHER|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
57919618|NCT00134433|GENETIC|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
57919619|NCT00134433|DRUG|oral L-arginine supplementation (at a dose of 6 g/day)|
57919620|NCT03523260|DEVICE|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
57919621|NCT03143816|DRUG|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
57919622|NCT02688673|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
57919623|NCT03438786|PROCEDURE|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
57919624|NCT03438786|PROCEDURE|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
57919625|NCT04997733|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit)."
57919626|NCT04997733|DRUG|Sham-transplantation (placebo)|"The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo)."
58065020|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
57919627|NCT00396500|DRUG|Albendazole (400 mg) and/or Vitamin a|
58065021|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
58065022|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
58065023|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
58273690|NCT05207722|DRUG|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
57721711|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
58391352|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
57721712|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
57721713|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
57721714|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
57721715|NCT05257538|OTHER|placebo enema|colored water enema
57721716|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
57721717|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
57721718|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
57721719|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
57721720|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
57721721|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
57721722|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
57721723|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
57721724|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
57721725|NCT00228449|DRUG|peginesatide|
57721726|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
58391353|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
57721727|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
57919628|NCT04541537|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
57721728|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
57721729|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
57721730|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
57721731|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
58391354|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
57721732|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
57721733|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
57721734|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
58391355|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
57721735|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
57721736|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
57919629|NCT04541537|DIAGNOSTIC_TEST|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
57919630|NCT01139060|BEHAVIORAL|organized care program for chronic or recurrent depression|
57919631|NCT05030987|PROCEDURE|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
57919632|NCT05030987|PROCEDURE|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
58273691|NCT05207722|DRUG|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
57721737|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
57721738|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
57721739|NCT03103529|OTHER|Active Rehabilitation|
57919633|NCT01490671|DRUG|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
57919634|NCT01490671|DRUG|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
57919635|NCT00562211|DRUG|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
57919636|NCT00562211|DRUG|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
57919637|NCT01110876|DRUG|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
57919638|NCT01110876|DRUG|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
57919639|NCT01110876|DRUG|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
57919640|NCT03286322|OTHER|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
57919641|NCT03286322|OTHER|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
57919642|NCT01431222|DEVICE|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
57919643|NCT03728322|BIOLOGICAL|iHSCs treatment group|iHSCs intravenous injection
57919644|NCT03251196|OTHER|No Intervention, and Observational Study|Observational Study
57919645|NCT03030703|DIETARY_SUPPLEMENT|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
57919646|NCT04942730|DRUG|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
57919647|NCT04942730|DRUG|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
57919648|NCT04942730|DRUG|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
57919649|NCT04942730|DRUG|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
57721740|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
57721741|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
57919650|NCT04942730|DRUG|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
58065024|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
58065025|NCT01952041|BEHAVIORAL|Device: Smartphone|
57721742|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
57721743|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
57721744|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
57721745|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
57721746|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
57721747|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
57721748|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
57919651|NCT04942730|DRUG|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
57919652|NCT04424797|OTHER|Prone Positioning|Intervention is patient in prone positioning
57919653|NCT04424797|OTHER|Supine Positioning|Intervention is patient in supine positioning
57919654|NCT01485354|DEVICE|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
57919655|NCT00666679|DRUG|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
57919656|NCT00666679|DRUG|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
58065026|NCT01952041|BEHAVIORAL|Treatment as usual|
58065027|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
58065028|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
58065029|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
58391356|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
58391357|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
58273692|NCT05207722|DRUG|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
58273693|NCT02103257|DRUG|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
58273694|NCT02103257|DRUG|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
58273695|NCT05869110|OTHER|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
58273696|NCT06444828|PROCEDURE|Non-operative|Non-operative treatment versus operative treatment (surgery)
58273697|NCT03004924|DRUG|SHP640|Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
58273698|NCT03004924|DRUG|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
58273699|NCT03004924|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
58273700|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
58273701|NCT02371564|DEVICE|High flow humidified oxygen|
58391358|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
58391359|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
57721749|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
57721750|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
58065030|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
58065031|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
58391360|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
57721751|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
57721752|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
57721753|NCT03963518|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor
57721754|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
58273702|NCT02371564|DEVICE|Standard flow humidified oxygen|
58273703|NCT05228886|BEHAVIORAL|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
58273704|NCT05228886|BEHAVIORAL|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
58273705|NCT05228886|OTHER|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
58273706|NCT04616001|DRUG|IVIG|Patients will receive IVIG daily for four days.
58273707|NCT00701480|OTHER|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
58391361|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
58391362|NCT00213941|DEVICE|Echocardiography|
58391363|NCT00899821|BIOLOGICAL|aldesleukin|
58391364|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
58391365|NCT00899821|BIOLOGICAL|sargramostim|
57721755|NCT02929576|DRUG|Placebo|
57721756|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
57721757|NCT02530619|DRUG|Alisertib|Given PO
58391366|NCT00899821|OTHER|immunologic technique|
58391367|NCT00899821|PROCEDURE|biopsy|
58391368|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
58273708|NCT00701480|OTHER|marketed skin cleanser|face washing 2-3 times/day
58273709|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
58273710|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
58273711|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
58273712|NCT04698174|PROCEDURE|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
58391369|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
58391370|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
58391371|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
58391372|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
58273713|NCT00190372|BEHAVIORAL|Controlled diet|Controlled diet
58273714|NCT00190372|BEHAVIORAL|Self-hypnotic relaxation|Self-hypnotic relaxation
58391373|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
58391374|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
58391375|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
57721758|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
58273715|NCT06730165|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation of the vagus nerve through the tragus and concha in the ear
57721759|NCT02530619|OTHER|Pharmacological Study|Correlative studies
58273716|NCT06730165|DEVICE|Transcutaneous Auricular Trigeminal Nerve Stimulation|Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
58273717|NCT00312572|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
58273718|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
58273719|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
58273720|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
58273721|NCT05039801|DRUG|Capivasertib|Given by PO
58273722|NCT06436833|DRUG|2-Liter polyethylene glycol plus elobixibat|Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
58273723|NCT06436833|DRUG|4-Liter polyethylene glycol|Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
58273724|NCT00618241|DRUG|lamotrigine|100 mg
58273725|NCT00618241|DRUG|Raltegravir|400 mg BD
58273726|NCT01069315|PROCEDURE|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
58273727|NCT01069315|PROCEDURE|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
58273728|NCT05156645|DRUG|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
58273729|NCT05156645|DRUG|Placebo|Diluted by 0.9% normal saline
58273730|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
58273731|NCT02722837|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
58273732|NCT00073502|DRUG|OSI-7904L|
58391376|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
58391377|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
58391378|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
58273733|NCT03623971|DEVICE|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
58273734|NCT00934856|DRUG|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
58273735|NCT00934856|DRUG|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
57721760|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
57721761|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
57721762|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
57721763|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
57721764|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
57721765|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
57721766|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
57721767|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
57721768|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
57721769|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
57721770|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
57721771|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
57721772|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
57721773|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
57721774|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
57721775|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
57721776|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
57721777|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
57721778|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
58273736|NCT00934856|DRUG|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
58273737|NCT05269589|OTHER|Thermoneutral water|Participants will immerse their feet in a foot bath that contains thermoneutral water
58273738|NCT05269589|OTHER|Hot water|Participants will immerse their feet in a foot bath that contains hot water
57721779|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
57721780|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
58273739|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
58273740|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
58273741|NCT05226286|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Stimulation of the tibial nerve using Medtronic's tibial neuromodulation device.
57721781|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
57721782|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
57721783|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
57721784|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
57721785|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
57721786|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
58391379|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
58065032|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
58065033|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
58273742|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
58273743|NCT06474650|DRUG|LPM3770164 sustained release tablet|Single-dose of 30 mg of LPM3770164 sustained release tablet
58273744|NCT01153620|DRUG|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
58273745|NCT01153620|OTHER|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
58273746|NCT05638516|BEHAVIORAL|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
58065034|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
58065035|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
58273747|NCT05638516|BEHAVIORAL|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
58391380|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
58391381|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
58391382|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
58391383|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
58391384|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
58391385|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
58391386|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
57919657|NCT00666679|DRUG|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
58391387|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
58391388|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
58391389|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
58391390|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
58391391|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
57919658|NCT02037841|OTHER|Nursing-driven clinical pathway for management of inpatient asthma|
57919659|NCT00676377|DRUG|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
58065036|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
58065037|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
58391392|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
58391393|NCT05336929|OTHER|Roy adaptation model-based nursing education|
57721787|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
57721788|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
57721789|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
57721790|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
58273748|NCT05441891|OTHER|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH \& Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
57721791|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
58273749|NCT01499641|DRUG|Methylprednisolone|Epidural methylprednisolone 40 mg or none
58065038|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
58065039|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
58065040|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
58273750|NCT04709341|DEVICE|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
58273751|NCT04709341|DEVICE|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
58273752|NCT05322356|OTHER|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
57721792|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
57721793|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
58391394|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
58391395|NCT03776812|DRUG|Relacorilant, 100mg QD|Relacorilant is supplied as capsules for oral dosing
58391396|NCT03776812|DRUG|Nab-paclitaxel, 80mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
57721794|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
57721795|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
57721796|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
57721797|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
57721798|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
57721799|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
57721800|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
57721801|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
57919660|NCT00676377|DRUG|Saline|Saline Placebo
57919661|NCT03412305|DRUG|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
58065041|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
58065042|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
58065043|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
58065044|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
58065045|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
58065046|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
58391397|NCT03776812|DRUG|Nab-paclitaxel, 100mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
58391398|NCT03776812|DRUG|Relacorilant, 150mg QD|Relacorilant is supplied as capsules for oral dosing
57919662|NCT03412305|OTHER|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
57721802|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
57721803|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) FET and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
57919663|NCT02125708|DEVICE|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
57919664|NCT04278001|DEVICE|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
57919665|NCT04012138|DRUG|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
57919666|NCT04012138|DRUG|Insulin Aspart|"Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
57919667|NCT05703074|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
57919668|NCT05703074|BEHAVIORAL|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
57919669|NCT05703074|BEHAVIORAL|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
57919670|NCT05703074|DIETARY_SUPPLEMENT|Placebo|4 capsules (empty) 2 times daily for 84 days.
57919671|NCT03613285|DEVICE|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
57919672|NCT03613285|DEVICE|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
58273753|NCT05030636|PROCEDURE|Acute moderate to vigorous exercise performed at a specific moment of the day|Treadmill (30 minutes) at 70% of maximal aerobic capacity
58273754|NCT06419010|PROCEDURE|Surgery with the use of L-PRF|The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes
58391399|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
58391400|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
58391401|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
57721804|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
57721805|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
57721806|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
57721807|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
57721808|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
57919673|NCT03613285|DEVICE|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
57919674|NCT03933930|OTHER|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct\>30%. If Hct \>30%, dopamine infusion starts.
57919675|NCT03933930|OTHER|Goal-directed therapy|If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
57919676|NCT04388774|DRUG|Ketamine|A single 40-minute intravenous infusion
58065047|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
58273755|NCT06419010|PROCEDURE|Standard surgery|The standard surgical treatment, taking place in the operating room under general anesthesia
58391402|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
58391403|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
58391404|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
58391405|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
58391406|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
58391407|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
58391408|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
57721809|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
57721810|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
57721811|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
58391409|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
57721812|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
57721813|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
57721814|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
57721815|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
57721816|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
57721817|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
57721818|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
57919677|NCT06485362|DIAGNOSTIC_TEST|Termography|Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).
58391410|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
58391411|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
58391412|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
57919678|NCT03139357|OTHER|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
57919679|NCT02485054|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
58391413|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
57919680|NCT03968120|OTHER|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
57919681|NCT01894633|DRUG|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
58391414|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
58391415|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
57919682|NCT01894633|RADIATION|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
57919683|NCT04507126|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Vaccine
58065048|NCT04569890|DRUG|Prednisone|10mg GC orally daily
58391416|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
58391417|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
58391418|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
58391419|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
58391420|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
57721819|NCT03770572|GENETIC|Low dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose
57721820|NCT03770572|GENETIC|High dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
57721821|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
57721822|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
57721823|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
57721824|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
57721825|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
58273756|NCT06191302|PROCEDURE|blood sample|Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.
58273757|NCT06191302|OTHER|Online questionaire|The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.
58391421|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
58391422|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
57721826|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
57721827|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
57721828|NCT01398605|OTHER|Exercise training|Different dose of exercise training
57721829|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
57721830|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
57721831|NCT01311830|BEHAVIORAL|Telephone Counseling|
57721832|NCT01311830|BEHAVIORAL|Written Materials|
57721833|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
57721834|NCT01842828|OTHER|Standard care plus electronic cigarettes|
57721835|NCT01842828|BEHAVIORAL|Standard care|
57721836|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
57721837|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
57919684|NCT01143974|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
58391423|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
58391424|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
57721838|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
57721839|NCT01876121|DRUG|Celecoxib|oral
57919685|NCT00225693|DEVICE|drug eluting coronary stent|
57919686|NCT03674463|DRUG|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
57919687|NCT04175821|RADIATION|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
57919688|NCT02536391|DRUG|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
58391425|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
58391426|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
57721840|NCT02569697|OTHER|HEC Placebo gel|
57721841|NCT02569697|OTHER|Placebo Intravaginal Ring|
57721842|NCT02569697|OTHER|Placebo Vaginal Film|
57721843|NCT02569697|OTHER|Placebo Vaginal Insert|
57721844|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
57721845|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
57721846|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
57721847|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
57919689|NCT02536391|DRUG|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
57919690|NCT03286257|BEHAVIORAL|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
57919691|NCT04154176|OTHER|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
57919692|NCT02019043|OTHER|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
57919693|NCT03074760|DIAGNOSTIC_TEST|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
57919694|NCT03074760|DIAGNOSTIC_TEST|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
57919695|NCT03074760|DIAGNOSTIC_TEST|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
57919696|NCT02838693|PROCEDURE|Not applicable. This is an observational study.|Not applicable. This is an observational study.
58065049|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
58065050|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
58065051|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
58065052|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
58065053|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
57721848|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
57721849|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
57721850|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
57919697|NCT04256382|OTHER|dementia pain care education|Participants are educated about dementia pain care.
57919698|NCT04256382|OTHER|dementia care education|Participants are educated about dementia pain care.
58065054|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
58273758|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
57721851|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
57721852|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
58065055|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
57721853|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
57721854|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
57721855|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
57721856|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
57721857|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
57721858|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
58391427|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
58391428|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
58391429|NCT01963182|DRUG|Irinotecan|
58391430|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
58391431|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
58391432|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
58391433|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
58391434|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
57721859|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
57721860|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
57721861|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
57919699|NCT00172484|PROCEDURE|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
58273759|NCT01505179|DRUG|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
58273760|NCT01505179|DRUG|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
58273761|NCT05786612|DEVICE|Biatain® Silicone|Wound care dressing
58391435|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
58391436|NCT00453609|DRUG|long-lasting injectable naltrexone|
58391437|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
58391438|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
58391439|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
57721862|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
57721863|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
57721864|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
57721865|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
57721866|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
57721867|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
57721868|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
57919700|NCT00172484|PROCEDURE|nursing program|To establish a systemic stroke prevention, education protocol
58273762|NCT05786612|DEVICE|Mepilex Border with Aquacel Extra Hydrofiber|Wound care dressing
57919701|NCT00172484|PROCEDURE|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
57721869|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
57721870|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
57721871|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
57721872|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
57721873|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
57721874|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
57721875|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
57721876|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
57721877|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
57721878|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
57721879|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
57721880|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
57721881|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
57721882|NCT02453789|DRUG|Placebo|
57721883|NCT01061060|DRUG|Prostaglandin I2|oral
57919702|NCT03719170|BEHAVIORAL|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
57919703|NCT05821231|COMBINATION_PRODUCT|SBRT + MEDI5752|"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
58273763|NCT06204120|DRUG|LPM3480392 Injection|PCA administration
58273764|NCT06204120|DRUG|Placebo|PCA administration
58273765|NCT06204120|DRUG|morphine hydrochloride injection|PCA administration
58273766|NCT03403621|DRUG|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
58273767|NCT03403621|DRUG|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
57721884|NCT01061060|DRUG|Placebo|oral
57721885|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
57721886|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
57721887|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
57721888|NCT00000463|DRUG|lovastatin|
57721889|NCT00000463|DRUG|cholestyramine|
57721890|NCT00000463|DRUG|warfarin|
57721891|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
58273768|NCT02589834|OTHER|Quran group|
57721892|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
57721893|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
57721894|NCT03864614|DRUG|SAGE-217|SAGE-217
57721895|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
57721896|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
57721897|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
57721898|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
57721899|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
57721900|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
57721901|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
57721902|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
57721903|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
58065056|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
58065057|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
58273769|NCT02358772|OTHER|thrombolysis in a pre-hospital setting (STEMO concept)|
58273770|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
58273771|NCT01526876|DRUG|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
58273772|NCT03602833|DRUG|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
57721904|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
57721905|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
57721906|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
57721907|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
57721908|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
57721909|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
57721910|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
57721911|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
57721912|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
57919704|NCT02614573|DEVICE|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is \> 4, then verification by venous measure and refer to general practitioner."
57919705|NCT01200420|DRUG|miravirsen|SC injection
57919706|NCT01200420|DRUG|saline|SC injection
57919707|NCT02164383|DRUG|Nicotine patch|4-week starter kit of nicotine patch
57919708|NCT02164383|BEHAVIORAL|Cessation Counseling|5 brief counseling sessions
57919709|NCT02164383|DEVICE|Mobile Games|
57919710|NCT00012298|BIOLOGICAL|rituximab|Given IV
57721913|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
57721914|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
57919711|NCT00012298|BIOLOGICAL|yttrium Y 90 ibritumomab tiuxetan|Given IV
57919712|NCT00012298|BIOLOGICAL|indium In 111 ibritumomab tiuxetan|Given IV
57919713|NCT00012298|BIOLOGICAL|oprelvekin|Given subcutaneously
57721915|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
58273773|NCT00231283|DEVICE|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
58273774|NCT02925377|BEHAVIORAL|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
58391440|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
58391441|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
57721916|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
57721917|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
57721918|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
57721919|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
58273775|NCT02925377|BEHAVIORAL|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
57721920|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
57721921|NCT01606982|DRUG|MDV3100|oral
57721922|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
57721923|NCT02230657|PROCEDURE|Same day discharge|
57721924|NCT02230657|PROCEDURE|Next day discharge|
57721925|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
57721926|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
57919714|NCT00012298|BIOLOGICAL|filgrastim|Given subcutaneously
57919715|NCT00264953|DRUG|Adriamycin|
57919716|NCT00264953|DRUG|Bleomycin|
57919717|NCT00264953|DRUG|Vinblastine|
57919718|NCT00264953|DRUG|DTIC|
57919719|NCT00264953|DRUG|Etoposide|
57919720|NCT00264953|DRUG|Procarbazine|
57919721|NCT00264953|DRUG|Prednisone|
58391442|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
58391443|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
57721927|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
57721928|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
57721929|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
57721930|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
57721931|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
57721932|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
57721933|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
58391444|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
58391445|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
57721934|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
57721935|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
57721936|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
57721937|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
57721938|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
57721939|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
58391446|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
58391447|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
58391448|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
57721940|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
57721941|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
57721942|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
57721943|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
57721944|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
57721945|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
58391449|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
58391450|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
57721946|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
57721947|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
57721948|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
57721949|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
57721950|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
57721951|NCT04486859|DEVICE|IPC|mechanical prevention
57721952|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
57721953|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
57721954|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
58391451|NCT05856929|OTHER|no Intervention|no intervention
57721955|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
57721956|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
57721957|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
57721958|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
57721959|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
57721960|NCT02798848|DEVICE|Tablet computer|iPad
57919722|NCT00264953|DRUG|Vincristine|
57919723|NCT00264953|RADIATION|radiation therapy|20 or 30Gy IF-RT
58065058|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
58065059|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
58065060|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
58065061|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
58065062|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
58391452|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
58391453|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
58391454|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
58065063|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
58065064|NCT01791088|DRUG|sirolimus|Given PO
58065065|NCT01791088|OTHER|pharmacological study|Correlative studies
58065066|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
58065067|NCT01711359|DRUG|Baricitinib|Administered orally
58065068|NCT01711359|DRUG|Methotrexate|Administered orally
58391455|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
58391456|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
58391457|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
58391458|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
57721961|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
57721962|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
57721963|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
57919724|NCT04647045|DIETARY_SUPPLEMENT|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
57919725|NCT04127890|DIETARY_SUPPLEMENT|ELO Water|oxygen-enriched water
57919726|NCT04127890|DIETARY_SUPPLEMENT|Placebo drinking water|bottled drinking water
57919727|NCT00573495|BIOLOGICAL|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
57919728|NCT05412849|RADIATION|Radiotherapy|Radiotherapy site, time perspective and dose
57919729|NCT05570123|DIETARY_SUPPLEMENT|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
57919730|NCT05570123|DIETARY_SUPPLEMENT|Placebo|2 tablets a day, one in the morning, one in the evening
57919731|NCT05900882|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
57919732|NCT05900882|DRUG|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
57919733|NCT05900882|DRUG|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
57919734|NCT05900882|DRUG|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
57919735|NCT04664673|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
58065069|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
57919736|NCT04664673|BEHAVIORAL|Regular care|customary or usual treatment given to any adult stroke survivor
57919737|NCT05254574|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
57721964|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
57919738|NCT05254574|DEVICE|Placebo Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.
57919739|NCT05254574|DRUG|1% Diclofenac Topical Gel|Topical pain-relief gel
57919740|NCT05710861|DEVICE|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
57919741|NCT05710861|PROCEDURE|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
57919742|NCT02855970|OTHER|completion of a quality of life questionnaire|
57919743|NCT02683941|DRUG|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
57919744|NCT02683941|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
57919745|NCT02683941|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator
58065070|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
58065071|NCT01711359|DRUG|Folic Acid|Administered orally every day
58065072|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
58065073|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
58065074|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
57721965|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
57721966|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
57721967|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
57721968|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
57919746|NCT02202668|DEVICE|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
57919747|NCT02418273|DRUG|denosumab|These subjects will receive two doses of denosumab.
57919748|NCT04299438|DRUG|Propranolol Hydrochloride|2mg/mL vials
57919749|NCT04299438|OTHER|Saline|0.9% saline in vials matching the vials of the active drug
57919750|NCT05231031|BEHAVIORAL|Aerobic exercise|continuous aerobic exercise on a treadmill
58273776|NCT01701505|DRUG|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
58273777|NCT01701505|DRUG|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
58273778|NCT01701505|DRUG|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
58273779|NCT03641313|DRUG|Berzosertib|Given IV
58273780|NCT03641313|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
58273781|NCT03641313|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
58273782|NCT03641313|DRUG|Irinotecan|Given IV
58273783|NCT03641313|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58273784|NCT05556265|DRUG|Deucravacitinib|Specified dose on specified days
58273785|NCT05556265|OTHER|Placebo|Specified dose on specified days
58273786|NCT05839184|DEVICE|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
58273787|NCT05226234|DEVICE|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
57919751|NCT05231031|BEHAVIORAL|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
57919752|NCT05231031|BEHAVIORAL|Relaxation training|continuous aerobic exercise plus relaxation training
58273788|NCT02710916|DEVICE|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
57919753|NCT00027495|DIETARY_SUPPLEMENT|curcumin|
57919754|NCT00701779|DRUG|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
58273789|NCT05654675|DIAGNOSTIC_TEST|FDG PET/CT|Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
58273790|NCT02278887|PROCEDURE|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
58273791|NCT02278887|DRUG|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
58273792|NCT02278887|DRUG|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
58273793|NCT02278887|DRUG|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
58273794|NCT02278887|DRUG|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
58273795|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
58273796|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
58273797|NCT05935033|DRUG|Emraclidine|Tablet
58273798|NCT02810015|DRUG|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
58273799|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
58273800|NCT05732558|PROCEDURE|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
57721969|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
58273801|NCT06174818|PROCEDURE|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
58273802|NCT03996564|DEVICE|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
57721970|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
57721971|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
57721972|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
57721973|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
57721974|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
58273803|NCT03996564|DRUG|Acetaminophen|Acetaminophen 500mg-1000mg,
58273804|NCT03996564|DRUG|Diclofenac|Diclofenac 50mg-75 mg orally
58273805|NCT03996564|DRUG|Diazepam|Diazepam 5mg-10 mg intravenous or oral
58391459|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
57721975|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
57721976|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
57721977|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
57721978|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
57721979|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
57721980|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
58273806|NCT03996564|DRUG|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
58273807|NCT03996564|DRUG|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
58273808|NCT02812251|DRUG|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
58273809|NCT02812251|DRUG|Placebo|Matching placebo will be administered.
58273810|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
58273811|NCT05164341|DRUG|Placebo|Placebo
58273812|NCT02388711|OTHER|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
58273813|NCT04811664|BIOLOGICAL|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
57919755|NCT03405441|DRUG|JNJ-55375515 Dose Level 1|Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
57919756|NCT03405441|DRUG|JNJ-55375515 Dose Level 2|Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
58273814|NCT05061602|DIAGNOSTIC_TEST|Evaluation of biomechanics and viscoelastic properties of plantar fascia|The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
58273815|NCT01732445|DRUG|ruxolitinib phosphate|Given PO
58391460|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
58391461|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
58391462|NCT02601638|OTHER|Demographics and Health History Questionnaire|
58391463|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
57721981|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
57721982|NCT02717091|DRUG|FOLFIRINOX|
57919757|NCT03405441|DRUG|JNJ-55375515 Dose Level 3|Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
57919758|NCT03405441|DRUG|JNJ-55375515 Dose Level 4|Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
58273816|NCT01732445|DRUG|danazol|Given PO
58273817|NCT01732445|OTHER|quality-of-life assessment|Ancillary studies
58273818|NCT01732445|OTHER|questionnaire administration|Ancillary studies
58273819|NCT05477992|PROCEDURE|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
58273820|NCT05718141|OTHER|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~* Cognitive Restructuring (labelled Flexible Thinking)~* Behavioural Activation (labelled Positive Activities)~* Gratitude~* Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
58273821|NCT06260475|PROCEDURE|Aortobifemoral bypass|Open surgery with aortic and iliac reconstruction
57721983|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
57721984|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
57721985|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
57721986|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
57721987|NCT02497664|OTHER|Active Breathing Control|
57919759|NCT03405441|DRUG|JNJ-55375515 Dose Level 5|Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
57919760|NCT03405441|DRUG|JNJ-55375515 Dose Level 6|Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
57919761|NCT03405441|DRUG|Placebo|All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
58391464|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
58391465|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
57919762|NCT03405441|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
57721988|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
57721989|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
57721990|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
57919763|NCT03271203|OTHER|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
57919764|NCT03271203|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
57919765|NCT03218241|BIOLOGICAL|PRT064445|Intravenous
57919766|NCT03218241|DRUG|Placebo|Intravenous to mimic PRT064445
57721991|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
57721992|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
57721993|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
57919767|NCT00121277|DRUG|capecitabine|
57919768|NCT00121277|DRUG|vorinostat|
57919769|NCT00275262|DRUG|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
57919770|NCT00275262|DRUG|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
57919771|NCT03126045|DEVICE|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
57919772|NCT03126045|DEVICE|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
57919773|NCT00167817|DRUG|Aripiprazole|
57919774|NCT05631301|OTHER|Exercise Circuits|Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination
57919775|NCT05631301|BEHAVIORAL|Goal Setting|Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities
57919776|NCT05631301|BEHAVIORAL|Psychoeducation-Youth|Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.
57919777|NCT05631301|BEHAVIORAL|Psychoeducation-Caregiver|Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms
57919778|NCT05631301|OTHER|Waitlist Control Surveys|Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
58391466|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
58391467|NCT02601638|OTHER|Day of Discharge Practicum|
57721994|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
57721995|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
58391468|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
57721996|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
57721997|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
57721998|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
57721999|NCT05056246|DRUG|maridebart cafraglutide|Solution for injection
57722000|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
57722001|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
57722002|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
57722003|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
57722004|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
57722005|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
57722006|NCT02479984|DEVICE|Laparoscopic ultrasound|
57722007|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
57722008|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
57722009|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
57722010|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
57722011|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
57722012|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
57722013|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
57722014|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
58273822|NCT06260475|PROCEDURE|aortoiliac stenting|"Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand"
57722015|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
57722016|NCT04629664|DRUG|FX-322|Active Comparator
57722017|NCT04629664|OTHER|Placebo|Placebo
57722018|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
57722019|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
57722020|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
57722021|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
57722022|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
57722023|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
57722024|NCT00612066|DRUG|rosiglitazone maleate|
57722025|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
57722026|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
57722027|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
57722028|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
57722029|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
57919779|NCT01095263|DEVICE|DBS|130Hz, 90us pulsewidth, 4V Amplitude
57919780|NCT01095263|DEVICE|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
58273823|NCT02589353|DRUG|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
58273824|NCT05451394|OTHER|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
58391469|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
58391470|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
58391471|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
58391472|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
57722030|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
57722031|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
57722032|NCT00411307|DRUG|OROS hydromorphone HCI|
57722033|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
57722034|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
57722035|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
57722036|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
57722037|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
57722038|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
57722039|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
58273825|NCT05451394|OTHER|Active Comparator|6 one-hour workshops on cognitive process
58273826|NCT01810783|DRUG|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
58273827|NCT00899704|GENETIC|microarray analysis|
58273828|NCT00899704|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
58273829|NCT00899704|OTHER|diagnostic laboratory biomarker analysis|
58273830|NCT01388504|DRUG|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
58273831|NCT01388504|OTHER|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
58273832|NCT06404840|DRUG|nimotuzumab|nimotuzumab (400 mg, iv, d1, qw)
58273833|NCT06404840|DRUG|AG chemotherapy|(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
58273834|NCT05817812|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
58273835|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
58273836|NCT02862925|PROCEDURE|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
57919781|NCT00593957|DRUG|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
58273837|NCT04293835|DIAGNOSTIC_TEST|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
58273838|NCT04559425|DRUG|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
58273839|NCT04559425|OTHER|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
58273840|NCT05247021|PROCEDURE|erector spinae block for group E|. The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
57722040|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
57722041|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
57722042|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
57722043|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
57722044|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
57722045|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
57722046|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
57722047|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
57722048|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
57919782|NCT00593957|DRUG|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
57722049|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
58065075|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
58065076|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
58065077|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
58391473|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
58391474|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
58391475|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
58273841|NCT05350345|OTHER|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
58273842|NCT05585554|RADIATION|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
58273843|NCT04696653|OTHER|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
58391476|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
57722050|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
57722051|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
57722052|NCT00541047|DRUG|bicalutamide|
57722053|NCT00541047|DRUG|goserelin acetate|
57722054|NCT00541047|DRUG|leuprolide acetate|
58065078|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
58273844|NCT06655701|DIAGNOSTIC_TEST|No intervention|No intervention
58273845|NCT04129775|DRUG|OTO-413|Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
58273846|NCT04129775|DRUG|Placebo|Single intratympanic injection of placebo
58273847|NCT03030885|DRUG|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
58273848|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
58391477|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
58391478|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
57722055|NCT00541047|PROCEDURE|adjuvant therapy|
57722056|NCT00541047|PROCEDURE|quality-of-life assessment|
57722057|NCT00541047|RADIATION|radiation therapy|
58273849|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
58391479|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
58391480|NCT00719498|DRUG|Epo-alpha|
58391481|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
58391482|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
58391483|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
58391484|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
57722058|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
57722059|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
57722060|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
57722061|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
57722062|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
57722063|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
57722064|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
57722065|NCT00357305|DRUG|vorinostat|Given orally
57722066|NCT00357305|DRUG|cytarabine|Given IV
57722067|NCT00357305|DRUG|etoposide|Given IV
57722068|NCT00357305|OTHER|pharmacological study|Correlative studies
57722069|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
57722070|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
57722071|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
57722072|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
57722073|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
57722074|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
57722075|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
57722076|NCT01075321|DRUG|everolimus|Given orally
57722077|NCT01075321|DRUG|lenalidomide|Given orally
57722078|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
57722079|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
57919783|NCT02911493|BEHAVIORAL|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
57919784|NCT02911493|BEHAVIORAL|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
57919785|NCT02707731|PROCEDURE|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
58391485|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
57722080|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
58391486|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
57722081|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
57722082|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
57722083|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
57722084|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
57722085|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
57722086|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
57722087|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
57919786|NCT05802641|RADIATION|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
57919787|NCT06215677|DRUG|Camrelizumab|Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
57919788|NCT01314820|OTHER|normal saline injection|20 cc normal saline injection into knee joint
57919789|NCT01314820|OTHER|sham injection|no saline injection
57919790|NCT04524884|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
57919791|NCT04524884|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
57919792|NCT03869723|PROCEDURE|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
57722088|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
57722089|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
57722090|NCT00099697|DRUG|DHEA|
57722091|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
57722092|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
57722093|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
57722094|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
57722095|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
57722096|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
57919793|NCT03869723|PROCEDURE|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
58065079|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
58391487|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
58391488|NCT04963855|DRUG|GT300|SIngle oral dose
58391489|NCT04963855|DRUG|Microcrystalline cellulose|placebo
58391490|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
57722097|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
57722098|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
57722099|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
57722100|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
57722101|NCT00003863|GENETIC|comparative genomic hybridization|
57722102|NCT00003863|GENETIC|cytogenetic analysis|
57722103|NCT00003863|GENETIC|fluorescence in situ hybridization|
57722104|NCT00003863|GENETIC|gene rearrangement analysis|
57722105|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
57919794|NCT05458557|DIAGNOSTIC_TEST|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
57919795|NCT03369561|DIAGNOSTIC_TEST|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
58065080|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
57919796|NCT05084443|DIETARY_SUPPLEMENT|Drink|Roselle and placebo drink for 6 months
57919797|NCT00575029|DRUG|megestrol acetate|600 mg by mouth daily
57919798|NCT04433585|DRUG|LY3471851|Administered SC
57919799|NCT04433585|DRUG|Placebo|Administered SC
58065081|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
58065082|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
58065083|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
58391491|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
58391492|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
57919800|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
58065084|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
58273850|NCT04260386|OTHER|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
57722106|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
57722107|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
57919801|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
58065085|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
58273851|NCT01315652|BEHAVIORAL|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
57722108|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
57722109|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
57722110|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
57722111|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
57722112|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
57722113|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
57722114|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
57919802|NCT00652860|BIOLOGICAL|aerosol sargramostim|
57919803|NCT00652860|BIOLOGICAL|sargramostim|
57919804|NCT00652860|DRUG|cisplatin|
57722115|NCT01851005|DRUG|Normal saline|Use as placebo
57919805|NCT00652860|DRUG|doxorubicin hydrochloride|
57722116|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
57722117|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
58065086|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
58065087|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
57919806|NCT00652860|DRUG|ifosfamide|
57919807|NCT00652860|DRUG|mitomycin C|
57919808|NCT00652860|OTHER|flow cytometry|
58273852|NCT01315652|BEHAVIORAL|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
58391493|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
58391494|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
57919809|NCT00652860|OTHER|immunological diagnostic method|
57919810|NCT00652860|OTHER|laboratory biomarker analysis|
57919811|NCT00652860|PROCEDURE|adjuvant therapy|
57919812|NCT00652860|PROCEDURE|multimodality therapy|
57919813|NCT00652860|PROCEDURE|neoadjuvant therapy|
57919814|NCT00652860|PROCEDURE|therapeutic conventional surgery|
57919815|NCT00652860|RADIATION|intraoperative radiation therapy|
57919816|NCT00652860|RADIATION|selective external radiation therapy|
57919817|NCT05637385|BEHAVIORAL|Training of perception and oculo-motor control|Behavioral training of eye movements and perception
58065088|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
58065089|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
58273853|NCT03796676|DRUG|Placebo|Placebo
58273854|NCT03796676|DRUG|PF-04965842|100 mg QD
58391495|NCT04079231|DRUG|Aflibercept|Intravitreal injection
58273855|NCT03796676|DRUG|PF04965842|200 mg QD
58273856|NCT05337917|PROCEDURE|Surgical of the digital nerve|All patients (cases and controls) were subject to surgical repair of digital nerve injury.
58273857|NCT03559803|DRUG|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
58391496|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
58391497|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
58391498|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
57919818|NCT00621387|DRUG|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
57919819|NCT00621387|DRUG|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
57919820|NCT04289766|OTHER|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
57919821|NCT04289766|OTHER|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
57919822|NCT04289766|OTHER|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
57919823|NCT06367010|COMBINATION_PRODUCT|Iodine-125 brachytherapy combine with Anlotinib|Iodine-125 brachytherapy combine with Anlotinib
58065090|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
58273858|NCT03737279|BEHAVIORAL|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
58391499|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
57919824|NCT04921137|OTHER|No endocrine therapy|No endocrine therapy given
57919825|NCT04921137|OTHER|Endocrine therapy|Endocrine therapy given for at least 5 years
57919826|NCT01812551|DRUG|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
57919827|NCT01812551|DRUG|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
57919828|NCT06076603|DRUG|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
57919829|NCT05955313|DRUG|Naltrexone Hydrochloride|treatment of vulvodynia
58273859|NCT03737279|BEHAVIORAL|Routine Care|"Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy"
57722118|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
57722119|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
57722120|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
57919830|NCT00311285|DEVICE|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
57919831|NCT02985320|BIOLOGICAL|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
57919832|NCT02985320|BIOLOGICAL|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
57919833|NCT02985320|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
57919834|NCT02985320|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
57919835|NCT02985320|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
57919836|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
57919837|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
57722121|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
57919838|NCT04417946|BEHAVIORAL|PrEP messages|The peer leaders and the study staff will post PrEP related health messages
57919839|NCT04417946|BEHAVIORAL|Heath messages|The peer leaders and study staff will post general health messages that are not related to sexual health
57919840|NCT00721669|DRUG|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
57919841|NCT01197859|DEVICE|Definitive Contact Lens|Daily wear contact lens
57919842|NCT01197859|DEVICE|Biofinity|Daily wear contact lens
57919843|NCT03616925|BIOLOGICAL|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
57919844|NCT03616925|PROCEDURE|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
57919845|NCT05400980|DEVICE|Urocross implant|Urocross implant inserted via delivery catheter
57919846|NCT05400980|DIAGNOSTIC_TEST|Sham-control|Cystoscopy
58273860|NCT03092934|DRUG|LY3295668|Oral capsules
58273861|NCT03118479|DRUG|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
58273862|NCT03118479|DRUG|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
57722122|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
57722123|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
57722124|NCT00965068|OTHER|Cholesterol|
57722125|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
57722126|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
57722127|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
57722128|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
57722129|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
57722130|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
57722131|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
57919847|NCT04658082|DEVICE|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
58273863|NCT03118479|DRUG|Placebo Oral Tablet|One tablet to be taken daily for 3 months
58273864|NCT04087616|BEHAVIORAL|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
58273865|NCT04087616|BEHAVIORAL|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
58273866|NCT01831505|DRUG|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
58273867|NCT02166749|PROCEDURE|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
58273868|NCT06731491|OTHER|Concurrent Training|Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes
58273869|NCT06731491|OTHER|Massage therapy and Aromatherapy|Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
58273870|NCT00002131|DRUG|Vesnarinone|
58273871|NCT01633099|DRUG|Decitabine|"1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,\>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,\>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,\>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,\>1h, on d1-3 of each 28day cycle)."
58273872|NCT04104087|PROCEDURE|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
58273873|NCT04517773|OTHER|writting test|Patients will be invitated to fill a questionary about self-autonomy
58273874|NCT00190658|DRUG|Somatropin (rDNA origin) for injection|
58273875|NCT01000181|OTHER|PET-CT with CuATSM|PET-CT with CuATSM
58273876|NCT01825239|OTHER|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
58273877|NCT05963451|OTHER|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
58273878|NCT06415175|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
58273879|NCT04790097|RADIATION|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
57722132|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
57722133|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
58273880|NCT00189527|PROCEDURE|respiratory settings|
58273881|NCT03681184|DRUG|Placebo|Placebo by SC injection
58273882|NCT03681184|DRUG|Lumasiran|Lumasiran by SC injection
58273883|NCT00671125|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
58273884|NCT00671125|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
58273885|NCT00671125|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
58273886|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
58273887|NCT00295516|PROCEDURE|Fetal Middle Cerebral Artery Doppler measurement|
58391500|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
57722134|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
58391501|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
58391502|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
58391503|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
58391504|NCT02181491|OTHER|[11C]-P943|
58391505|NCT03572231|DRUG|mirabegron|oral
58391506|NCT03572231|DEVICE|solifenacin|oral
57722135|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
58391507|NCT03572231|DRUG|darifenacin|oral
58391508|NCT03572231|DRUG|imidafenacin|oral
57722136|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
57722137|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
58391509|NCT03572231|DRUG|tolterodine|oral
58391510|NCT03572231|DRUG|oxybutynin|oral
58391511|NCT03572231|DRUG|trospium|oral
58391512|NCT03572231|DRUG|fesoterodine|oral
58391513|NCT03572231|DEVICE|propiverine|oral
58391514|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
58391515|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
57722138|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
57722139|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
57722140|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
57722141|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
57722142|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
57722143|NCT03808285|OTHER|mandibular osteomylitis|
57722144|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
57722145|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
57722146|NCT00861341|DRUG|Aspirin|81 mg
57722147|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
57919848|NCT06020807|DIAGNOSTIC_TEST|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
57919849|NCT00280943|BEHAVIORAL|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
57919850|NCT00790465|DIETARY_SUPPLEMENT|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
57722148|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
57722149|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
57722150|NCT00058890|DRUG|Placebo|
57722151|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
57722152|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
57722153|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
57722154|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
57919851|NCT00790465|DIETARY_SUPPLEMENT|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
57919852|NCT04327076|DEVICE|Using robot system of endotracheal intubation and airway cleaning|"1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
57919853|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
57919854|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
58273888|NCT04958759|OTHER|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
58273889|NCT04958759|OTHER|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
58273890|NCT04958759|OTHER|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
58273891|NCT02101333|DRUG|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
58391516|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
58391517|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
58391518|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
58391519|NCT02520544|DEVICE|Accolade stem|Total hip replacement
58391520|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
58391521|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
58391522|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
58391523|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
58391524|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
58391525|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
58391526|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
58391527|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
58391528|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
58391529|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
58391530|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
58391531|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
58391532|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
57722155|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
57919855|NCT04823221|DEVICE|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
57919856|NCT00752310|DRUG|Darunavir|
57919857|NCT05369273|OTHER|intra-articular injection|intra-articular injection
58391533|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
58391534|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
58391535|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
58391536|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
57919858|NCT05369273|RADIATION|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
57919859|NCT05369273|OTHER|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
58391537|NCT02590276|BEHAVIORAL|characterization|
58391538|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
58391539|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
58391540|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
58391541|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
58391542|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
58391543|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
57722156|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
57722157|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
57722158|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
57919860|NCT05369273|OTHER|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
57919861|NCT00436033|DRUG|milnacipran|
57919862|NCT00436033|DRUG|Placebo|
57919863|NCT04457167|DEVICE|Robot-assisted|robot-assisted surgery
57919864|NCT04457167|PROCEDURE|Not robot-assisted surgery|Not robot-assisted surgery
57919865|NCT01179425|OTHER|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
57919866|NCT05488574|OTHER|Deep breathing with Yoga positioning|Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
57919867|NCT06310057|DRUG|Tofacitinib|Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
57919868|NCT05379582|OTHER|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
57919869|NCT02585479|DRUG|Pirarubicin|"1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
57919870|NCT02585479|DRUG|Oxaliplatin|"1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
57919871|NCT02585479|DRUG|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
57919872|NCT02585479|DEVICE|Gelfoam|Hepatic artery embolization with Gelfoam.
58391544|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
57722159|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
57919873|NCT00743275|BIOLOGICAL|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
57919874|NCT00102609|DRUG|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
57919875|NCT00102609|DRUG|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
58391545|NCT00842283|OTHER|skin tissue sample|skin tissue sample
57722160|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
57919876|NCT00102609|DRUG|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
57919877|NCT02083874|DRUG|CBD|
57919878|NCT01139021|BIOLOGICAL|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
57919879|NCT01896154|DIETARY_SUPPLEMENT|NPS|Comparison of multiple dietary non-digestible polysaccharides
57919880|NCT00945308|DRUG|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
57919881|NCT00945308|DRUG|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
57919882|NCT03258164|BIOLOGICAL|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
58391546|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
57919883|NCT03258164|BIOLOGICAL|Standard Lipofilling|Non-ASC enriched fat grafts
57919884|NCT00838929|DRUG|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
57919885|NCT00838929|RADIATION|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
58391547|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
57722161|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
57722162|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
57919886|NCT02296970|PROCEDURE|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
57919887|NCT00372385|DRUG|Ribavirin|tablet
58273892|NCT04171817|DRUG|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
58273893|NCT05140616|DRUG|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
58273894|NCT01630954|PROCEDURE|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
58273895|NCT01630954|PROCEDURE|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
57722163|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
58273896|NCT03654391|DIETARY_SUPPLEMENT|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
58273897|NCT03654391|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
58273898|NCT05133583|OTHER|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
58273899|NCT01544192|DRUG|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
57722164|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
58391548|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
57722165|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
57722166|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
57722167|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
57722168|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
57722169|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
57722170|NCT06173154|OTHER|Routine care|standard care without any specific system in place
57722171|NCT02192450|DRUG|Insulin aspart/glargine|
57722172|NCT02192450|DRUG|Insulin aspart/degludec|
57722173|NCT01144104|BEHAVIORAL|Public Service Announcement|
57722174|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
57722175|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
57919888|NCT00372385|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
58273900|NCT01544192|DRUG|α-tocopherol|2x300 mg α-tocopherol
57919889|NCT00372385|DRUG|Placebo|tablet
57919890|NCT00372385|DRUG|Telaprevir|tablet
57722176|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
58273901|NCT01544192|DRUG|Placebo|control group did not receive oral neuroprotective agent
58273902|NCT01544192|DRUG|Antioxidant formula|2x1 tablet AOF
58273903|NCT04262804|DRUG|Margetuximab|Margetuximab IV
58273904|NCT04262804|DRUG|Trastuzumab|Trastuzumab IV
58273905|NCT04262804|DRUG|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
58273906|NCT04262804|DRUG|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
58273907|NCT04262804|DRUG|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
58273908|NCT01173419|DEVICE|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
57722177|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
57919891|NCT06444685|OTHER|Exercise and cognitive training interventino|Exercise and cognitive training based on Table tennis and Tabletop games.
57919892|NCT00988520|DRUG|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
58273909|NCT01173419|DEVICE|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
58273910|NCT00148655|DEVICE|Decision Board|Decision board that explains the risks and benefits of treatment options
58273911|NCT03090451|BEHAVIORAL|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
57722178|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
57722179|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
57919893|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
57919894|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
57919895|NCT00988520|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
57919896|NCT00988520|DRUG|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
57919897|NCT00138671|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
57919898|NCT00138671|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
57919899|NCT04131400|DIAGNOSTIC_TEST|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
57919900|NCT04130386|BEHAVIORAL|Motivational Interviewing|Participants receiving MI
57919901|NCT04130386|BEHAVIORAL|e-education|Participants receiving e-education
57919902|NCT01131871|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
57919903|NCT01131871|BEHAVIORAL|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
57919904|NCT03375216|BEHAVIORAL|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
57919905|NCT03375216|BEHAVIORAL|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
57919906|NCT02513745|DEVICE|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
57919907|NCT02513745|DEVICE|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
57919908|NCT03244735|OTHER|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
57919909|NCT05184088|DRUG|[18F]florbetaben|All enrolled patients will undergo \[18F\]florbetaben PET imaging.
57919910|NCT03226236|RADIATION|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
58273912|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
58273913|NCT03631654|DRUG|Placebos|Placebo
58273914|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
58273915|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
58273916|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
58273917|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
57722180|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
57722181|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
57722182|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
57722183|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
57722184|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
57722185|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
57919911|NCT03226236|BIOLOGICAL|Autologous DC vaccine|The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
57919912|NCT03226236|DRUG|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
57919913|NCT06304974|DRUG|BL-B01D1|Administration by intravenous infusion
57919914|NCT06304974|DRUG|Irinotecan|Administration by intravenous infusion
57722186|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
57722187|NCT06202885|DRUG|Immunotherapy|Immunotherapy
57919915|NCT06304974|DRUG|paclitaxel|Administration by intravenous infusion
57919916|NCT06304974|DRUG|docetaxel|Administration by intravenous infusion
57919917|NCT03103763|DRUG|Warfarin|Patients on warfarin for atrial fibrillation
57919918|NCT04647916|BIOLOGICAL|Sacituzumab Govitecan|Given IV
57919919|NCT02726685|OTHER|respiratory training.|breathing exercise.
57919920|NCT02726685|OTHER|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
57919921|NCT03697577|DIAGNOSTIC_TEST|CT scans|Patients will undergo CT or PETCT as part of their standard of care
57919922|NCT03697577|DIAGNOSTIC_TEST|DEXA scan|Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.
57722188|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
57722189|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
57919923|NCT00871780|DRUG|BG00002 (natalizumab)|
57919924|NCT00003193|DRUG|amifostine trihydrate|
57919925|NCT00003193|DRUG|paclitaxel|
58273918|NCT04061733|DEVICE|Hydrogel injection|Hydrogel injection
58273919|NCT00429611|PROCEDURE|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
57919926|NCT00003193|PROCEDURE|conventional surgery|
58273920|NCT00780624|DEVICE|NIPPV|Ventilator is Bird VIP.
57919927|NCT00003193|RADIATION|radiation therapy|
57919928|NCT05468346|DRUG|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
57919929|NCT03111693|OTHER|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
57919930|NCT02540057|PROCEDURE|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
57919931|NCT02540057|PROCEDURE|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
57919932|NCT02072447|DRUG|YH4808 PO and [14C]-YH4808 IV|
57919933|NCT00924261|OTHER|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
57919934|NCT00924261|OTHER|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
58273921|NCT00780624|DEVICE|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
58391549|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
57919935|NCT02179099|DEVICE|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
57919936|NCT02568865|OTHER|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
57919937|NCT02568865|OTHER|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
57919938|NCT02568865|OTHER|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
57919939|NCT02568865|OTHER|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
57919940|NCT04308772|BEHAVIORAL|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
57919941|NCT06089889|OTHER|ice application|"* Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential."
57919942|NCT06089889|OTHER|control group|"* Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential."
57919943|NCT03646500|PROCEDURE|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
57919944|NCT03646500|PROCEDURE|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
57919945|NCT04335812|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
57919946|NCT03022032|DEVICE|Fitbit Zip|Fitbit Zip
57919947|NCT03022032|OTHER|HOPE App|HOPE App
57919948|NCT03022032|OTHER|Standard of Care|Standard of Care
57919949|NCT03022032|DEVICE|Fitbit Charge 2|Fitbit Charge 2
57919950|NCT03022032|OTHER|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
57919951|NCT04753970|DRUG|Cilostazol|Cilostazol 100mg BID
57919952|NCT00686725|DRUG|Temozolomide|
57722190|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
57919953|NCT00686725|RADIATION|Radiotherapy|
57919954|NCT03496584|OTHER|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
57722191|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
57919955|NCT03496584|OTHER|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
57919956|NCT02444481|DRUG|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
57919957|NCT04001985|OTHER|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
57919958|NCT04001985|OTHER|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
57919959|NCT03448120|PROCEDURE|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
58391550|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
57722192|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
57722193|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
57722194|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
58273922|NCT00780624|DEVICE|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
57722195|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
58273923|NCT06014125|OTHER|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
57722196|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
57722197|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
57919960|NCT03448120|PROCEDURE|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
58273924|NCT02628509|DEVICE|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
58273925|NCT03516006|DRUG|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
58273926|NCT03516006|DRUG|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
58391551|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
58391552|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
58391553|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
58391554|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
58391555|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
57919961|NCT02744326|BEHAVIORAL|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
57919962|NCT04213430|OTHER|diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
58391556|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
57919963|NCT02924142|DEVICE|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
57722198|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
57722199|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
57919964|NCT01147237|DEVICE|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
57919965|NCT06071026|DEVICE|Net Ultra Filtration Rate|The net ultra filtration rate is modified every 6 hours accordingly to randomisation
58273927|NCT01458951|DRUG|tofacitinib|10 mg oral BID
58391557|NCT04793204|DRUG|fezolinetant|oral
57722200|NCT01358981|DRUG|LY2881835|Administered orally
57919966|NCT00690040|DEVICE|Foley catheter|Single balloon catheter
57919967|NCT00690040|DEVICE|Atad catheter|Double balloon catheter
57919968|NCT01092000|BEHAVIORAL|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
57919969|NCT01092000|OTHER|Education|Monthly exercise tips handout.
57919970|NCT00003998|DRUG|carboplatin|
57919971|NCT00003998|DRUG|docetaxel|
57919972|NCT00003998|DRUG|paclitaxel|
57919973|NCT00003998|PROCEDURE|surgical procedure|
57919974|NCT02186223|DEVICE|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
58273928|NCT01458951|DRUG|Placebo|Placebo oral BID
58273929|NCT06114498|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
58273930|NCT06114498|DIAGNOSTIC_TEST|Bioimpedance|Bioelectrical impedance analysis research
57722201|NCT01358981|DRUG|Placebo|Administered orally
57722202|NCT04679129|DRUG|ASC42|Oral tablets
58273931|NCT06114498|DIAGNOSTIC_TEST|Immunoassay|Enzyme immunoassay of heat shock proteins in blood serum
57722203|NCT04679129|DRUG|Placebo|Oral tablets
58065091|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
58065092|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
57722204|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
58391558|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
57722205|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
57722206|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
57722207|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
57722208|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
57722209|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
57722210|NCT02921412|DEVICE|fanfilcon A|contact lens
57722211|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
58065093|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
58273932|NCT06114498|DIAGNOSTIC_TEST|Routine biochemistry|Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
58273933|NCT05610072|DRUG|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
58273934|NCT05610072|DRUG|Hydromorphone|Subjects will receive up to 192 mg oral hydromorphone daily.
58273935|NCT05610072|DRUG|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
58273936|NCT05610072|DRUG|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
57722212|NCT05506982|DRUG|Psilocybin|Given PO
57722213|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
58391559|NCT00284414|PROCEDURE|Ultrasonography or MRI|
58391560|NCT03449940|PROCEDURE|Immediate repair|
58391561|NCT03449940|PROCEDURE|Delayed repair|
58391562|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
58391563|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
57722214|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
57722215|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
57722216|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
58273937|NCT00416793|DRUG|bortezomib|Given IV
58273938|NCT00416793|DRUG|carboplatin|Given IV
58273939|NCT00416793|OTHER|laboratory biomarker analysis|Correlative studies
58273940|NCT03338569|DRUG|Vitamin C|Continuous infusion of vitamin C
58391564|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
57722217|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
57722218|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
57722219|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
57722220|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
57722221|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
57722222|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
57722223|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
57722224|NCT01170780|DRUG|Saline|2 ml IV
57722225|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
57722226|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
57722227|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
58273941|NCT03338569|DRUG|Placebo|Placebo designed to mimic intervention
58273942|NCT05403528|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
58273943|NCT05403528|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
58273944|NCT05403528|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
58273945|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
58273946|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
58273947|NCT05020899|BEHAVIORAL|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
58273948|NCT05020899|OTHER|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
58273949|NCT05020899|OTHER|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
58273950|NCT05020899|OTHER|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
58273951|NCT05343091|DEVICE|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
58273952|NCT05260775|OTHER|Evaluation test: cataract surgery steps|The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
58273953|NCT05054699|DEVICE|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
58273954|NCT05054699|DEVICE|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
58273955|NCT01711775|DRUG|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
58391565|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
58391566|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
58391567|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
58391568|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
58273956|NCT02436902|PROCEDURE|TACE|TACE is performed one month after resection.
58273957|NCT02436902|DRUG|Sorafenib|Sorafenib is submitted one month after resection.
58273958|NCT02436902|DRUG|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
58273959|NCT02436902|OTHER|empty control|This group will not receive adjuvant therapy.
58273960|NCT01065064|PROCEDURE|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
58273961|NCT06281626|OTHER|Data collection|Data collection
58273962|NCT02261103|DRUG|Pramipexole ER tablets|
58273963|NCT02261103|DRUG|Pramipexole IR tablets|
58273964|NCT02261103|DRUG|Placebo matching Pramipexole ER tablets|
58273965|NCT02261103|DRUG|Placebo matching Pramipexole IR tablets|
58273966|NCT02261103|OTHER|Standard high-fat breakfast|
58273967|NCT06241313|DRUG|Atogepant|Oral Tablet
58273968|NCT06241313|DRUG|Placebo for Atogepant|Oral Tablet
58273969|NCT00441155|DRUG|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
58273970|NCT05313802|DRUG|LY3502970|Administered orally.
57722228|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
57722229|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
57722230|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
57722231|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
57722232|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
57722233|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
57722234|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
57722235|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
57722236|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
57722237|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
57722238|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
57722239|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
57722240|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
57722241|NCT02974361|DRUG|Ibuprofen|
57722242|NCT02974361|DRUG|Ibuprofen Lysine|
57722243|NCT02974361|DRUG|Ibuprofen-LDH|
57919975|NCT01607554|DRUG|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
57722244|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
57722245|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
57722246|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
57919976|NCT02286778|DIETARY_SUPPLEMENT|Acetogenins|Acetogenins BID for 12 months
57919977|NCT02286778|DIETARY_SUPPLEMENT|Placebo|
57919978|NCT06245720|OTHER||
57919979|NCT01406340|DRUG|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
58273971|NCT04691206|OTHER|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
58273972|NCT01715402|PROCEDURE|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
58273973|NCT02503254|OTHER|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
57722247|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
58065094|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
57722248|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
58065095|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
58065096|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
58065097|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
58065098|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
58273974|NCT02503254|OTHER|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
58273975|NCT05006846|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
58273976|NCT00135902|DRUG|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
58273977|NCT00135902|DRUG|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
58273978|NCT06516640|BEHAVIORAL|Continuous Glucose Monitoring Academy|Educational materials as well as online sessions with diabetes educators.
58273979|NCT06516640|BEHAVIORAL|Standard Education|Standard of care receives general education about diabetes.
58391569|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
57722249|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
57722250|NCT00000597|DRUG|antilymphocyte serum|
57722251|NCT00000597|DRUG|nandrolone|
58273980|NCT00586508|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
58391570|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
58391571|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
58391572|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
58391573|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
57722252|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
57722253|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
57722254|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
57919980|NCT00697879|DRUG|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
57919981|NCT05831813|BEHAVIORAL|Goal-Based Cognitive Behavioural Intervention|A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
58065099|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
57722255|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
57722256|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
57722257|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
57722258|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
57722259|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
57722260|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
57722261|NCT05558410|DRUG|VX-548|Tablets for oral administration.
57722262|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
57722263|NCT05558410|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
57722264|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
57722265|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
57722266|NCT01198184|DRUG|temsirolimus|Given IV or PO
57722267|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
57722268|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
57722269|NCT01198184|OTHER|pharmacological study|Correlative studies
57722270|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
57722271|NCT05660109|OTHER|Placebo|Placebo
57722272|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
57722273|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
57722274|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
57722275|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
58273981|NCT00586508|DRUG|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
58273982|NCT00586508|DRUG|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
57722276|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
57722277|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
57722278|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
57919982|NCT01216384|DRUG|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
58391574|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
58391575|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
57919983|NCT01216384|DRUG|placebo|Subjects will receive according to the dose group matching number of placebo tablets
58273983|NCT00586508|DRUG|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
58273984|NCT03994757|BEHAVIORAL|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
58273985|NCT03994757|BEHAVIORAL|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
58273986|NCT02742675|DRUG|Bicalutamide|Given orally
57722279|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
57722280|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
57722281|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
57722282|NCT00103649|DRUG|xaliproden (SR57746A)|
57722283|NCT04260191|DRUG|AMG 910|IV Infusion
57919984|NCT01295034|DIETARY_SUPPLEMENT|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
57919985|NCT01295034|DRUG|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
57722284|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
58273987|NCT02742675|DRUG|goserelin acetate|Given subcutaneously or as an injection
57919986|NCT01548157|DRUG|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
57919987|NCT06370260|DEVICE|Hydrogen Carbamide/Peroxide Gel|"UNISEPT® ORAL GEL is an oral gel containing 10% w/v urea peroxide which releases 3.50% w/w hydrogen peroxide, glycerin, propylene glycol, carbopol, disodium EDTA, sodium saccharin, methyl salicylate, menthol, and water, serving as the active ingredient.~Participants should apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0., i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following gel application.Participants are asked to maintain their usual oral hygiene routine.~UNISEPT® ORAL GEL is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A."
58273988|NCT02742675|DRUG|flutamide|Given orally
58273989|NCT02742675|DRUG|leuprolide acetate|Given subcutaneously or as an injection
58065100|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
58065101|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
58065102|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
58065103|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
58273990|NCT02742675|DRUG|triptorelin|Given subcutaneously or as an injection
58273991|NCT02742675|PROCEDURE|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
58273992|NCT00986947|DRUG|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
58273993|NCT04924023|BEHAVIORAL|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
58273994|NCT02267213|DRUG|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
58391576|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
57722285|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
57722286|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
57722287|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
57722288|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
57722289|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
57722290|NCT00144573|DRUG|MRA(Tocilizumab)|
58273995|NCT05666479|DEVICE|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
58273996|NCT05310318|PROCEDURE|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
58273997|NCT05598710|PROCEDURE|Pigtail Insertion|Pigtail is inserted for any reason of ureteral obstruction except for malignant
58273998|NCT06228833|DEVICE|monopolar radiofrequency|Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
58273999|NCT06228833|OTHER|SkinCeuticals A.G.E and Skinceuticals CE FERULIC|Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC
57722291|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
57722292|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
57722293|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
57722294|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
57722295|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
57722296|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
57722297|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
57722298|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
58274000|NCT06228833|OTHER|Standard Cream|Control Side applies Standard Cream
58274001|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
58274002|NCT05480865|DRUG|BBP-398|BBP-398 administered orally
58274003|NCT05480865|DRUG|sotorasib|sotorasib administered orally
58274004|NCT05042830|PROCEDURE|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
58274005|NCT05042830|PROCEDURE|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
58274006|NCT05042830|BIOLOGICAL|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
58274007|NCT05042830|PROCEDURE|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
58391577|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
58391578|NCT03818607|DRUG|ABP 959|intravenous infusion
57722299|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
57722300|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
57722301|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
57722302|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
58274008|NCT05042830|PROCEDURE|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
58391579|NCT03818607|DRUG|Eculizumab|intravenous infusion
57722303|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
57722304|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
57722305|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
57722306|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
57722307|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
57722308|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
58274009|NCT05042830|PROCEDURE|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
58274010|NCT05042830|PROCEDURE|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
58274011|NCT05042830|BIOLOGICAL|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
58274012|NCT03747302|OTHER|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
58274013|NCT03747302|OTHER|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
58274014|NCT04110717|DEVICE|Vestal Device|Vestibular nerve stimulator
58274015|NCT04110717|DEVICE|Control Device|Control Device
58274016|NCT04110717|BEHAVIORAL|Hypocaloric Diet|Hypocaloric diet
57722309|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
57722310|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
57722311|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
57722312|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
57722313|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
57722314|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
57722315|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
57722316|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
57722317|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
57722318|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
57722319|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
57722320|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
58274017|NCT01615978|DRUG|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
57722321|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
58274018|NCT01615978|DRUG|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
58274019|NCT01615978|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
58274020|NCT04653623|PROCEDURE|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
58274021|NCT04653623|DRUG|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
58274022|NCT06417866|OTHER|informed consent|standard verbal and written informed consent
58274023|NCT06417866|OTHER|spine model|standard verbal and written informed consent + visual spine model
58274024|NCT06016348|PROCEDURE|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
58274025|NCT04187040|PROCEDURE|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs"
57722322|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
57722323|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
57722324|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
57722325|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
57722326|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
57722327|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
57722328|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
57722329|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
57722330|NCT01767116|DRUG|Ribavirin|Capsule
57722331|NCT01767116|DRUG|Placebo for ribavirin|Capsule
57722332|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
57722333|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
57722334|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
58391580|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
58391581|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
58391582|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
58391583|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
58274026|NCT04187040|PROCEDURE|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
57722335|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
57919988|NCT06370260|DEVICE|Placebo Gel|"Placebo gel is a similar (look-and-taste-alike) product to UNISEPT® ORAL GEL, made by the same manufacturer, without active ingredients, containing glycerin, propylene glycol, carbomer, menthol, sodium saccharin, methyl salicylate, triethanolamine.~Participants are called upon to apply the gel in exactly the same way as the experimental product, i.e apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0."
57919989|NCT02890394|OTHER|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
57919990|NCT02317081|DEVICE|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
58274027|NCT05211141|DEVICE|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
58274028|NCT01715519|DRUG|Treatment (Viibryd)|
58274029|NCT04292639|DEVICE|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
58274030|NCT00279006|PROCEDURE|Percutaneous coronary intervention|
58274031|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
57919991|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
57919992|NCT03486457|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
57919993|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
57919994|NCT04568720|DIAGNOSTIC_TEST|blood sample|Isolated the blood sample and detected the CTC
58274032|NCT06415396|OTHER|Complete Decongestive Therapy|conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.
58274033|NCT06415396|DEVICE|ESWT|ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .
58274034|NCT06415396|DEVICE|LLLT|In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
58274035|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
58274036|NCT05105516|PROCEDURE|Ablation|Ablation of ectopic foci causing PVCs
58274037|NCT03652584|OTHER|High Protein Diet|
58274038|NCT03652584|OTHER|Control Diet|
58274039|NCT03370458|DIETARY_SUPPLEMENT|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
58274040|NCT03370458|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
58274041|NCT03988972|DEVICE|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
58391584|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
58391585|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
58391586|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
58391587|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
58391588|NCT02242136|BEHAVIORAL|FORNET|
57722336|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
57722337|NCT00259753|DRUG|Bevasiranib|
57722338|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
57919995|NCT02550717|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
57919996|NCT02550717|DRUG|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
57722339|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
57722340|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
57722341|NCT02096835|DRUG|Dexamethasone|will be given after induction
57722342|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
57722343|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
57722344|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
57722345|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M3, M6, and M12
57919997|NCT02207348|DRUG|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
57919998|NCT05228041|DRUG|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
57919999|NCT04822623|DIAGNOSTIC_TEST|MRI|MRI examination
58274042|NCT03988972|DEVICE|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
57722346|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
57722347|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
57722348|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
58391589|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
57722349|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
57722350|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
57920000|NCT04246320|OTHER|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
57920001|NCT04269330|PROCEDURE|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
57920002|NCT01324115|DRUG|NG-nitro-L-arginine|
57920003|NCT01324115|OTHER|laboratory biomarker analysis|
57920004|NCT01324115|OTHER|pharmacological study|
57920005|NCT01324115|PROCEDURE|computed tomography|
57920006|NCT01324115|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
57920007|NCT03487926|RADIATION|[18F]FEPPA|up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI
57920008|NCT06251453|DRUG|SGLT2 inhibitor|Dapagliflozin Empagliflzoin
57920009|NCT00003263|BIOLOGICAL|recombinant interferon alfa|vaccine
57920010|NCT00003263|DRUG|cisplatin|
57920011|NCT00003263|PROCEDURE|surgical procedure|
57920012|NCT00003263|RADIATION|radiation therapy|
57920013|NCT04700722|DIAGNOSTIC_TEST|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
58274043|NCT02272933|DEVICE|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
58274044|NCT02272933|DEVICE|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
58274045|NCT04192656|DEVICE|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
58274046|NCT04192656|DRUG|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
57722351|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
57722352|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
57722353|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
57722354|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
57722355|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
57722356|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
57722357|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
57722358|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
57722359|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
57920014|NCT03538249|OTHER|Aerobic training|
58274047|NCT04192656|DRUG|Ginaton|ginnaton is ginkgo biloba extract
58274048|NCT01651000|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
58274049|NCT01651000|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
58274050|NCT04387799|DIAGNOSTIC_TEST|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
58274051|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
58391590|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
58391591|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
58391592|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
57920015|NCT03538249|OTHER|Inspiratory muscle training|
57920016|NCT03538249|OTHER|Resistance Training|
57920017|NCT03538249|OTHER|Aerobic and Inspiratory training|
57920018|NCT03538249|OTHER|Combined|Aerobic, inspiratory and resistance training
57920019|NCT02842606|OTHER|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
57920020|NCT05353348|DRUG|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
57920021|NCT05353348|DRUG|saline|The standard treatment group will receive 200 ml of saline equal to the intervention group, and 1 ml of saline injected subcutaneously
57920022|NCT00103051|DRUG|cisplatin|
57920023|NCT00103051|DRUG|gefitinib|
57920024|NCT00103051|DRUG|gemcitabine hydrochloride|
57920025|NCT00103051|PROCEDURE|conventional surgery|
57920026|NCT00103051|PROCEDURE|neoadjuvant therapy|
57920027|NCT04068623|OTHER|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
57920028|NCT02742259|DEVICE|Blood Draw|Blood draws only - non-diagnostic, non-treatment
58391593|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
58391594|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
58391595|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
57722360|NCT04419636|DRUG|Lu AG06466|capsules, orally
57920029|NCT05020431|OTHER|Biological measuring of collagen fragments biomarker during orthodontic tooth movement|Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
57920030|NCT00031551|DRUG|Etanercept|
57920031|NCT00031551|DRUG|Placebo|
57920032|NCT03875677|DEVICE|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of \~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
57920033|NCT03875677|DEVICE|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
57920034|NCT03875677|DEVICE|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
57920035|NCT05937087|OTHER|Community engaged research|The university is working with Navajo communities to conduct an intervention study integrating community based participatory research using an Indigenous research paradigm. The innovative proposed project uses two approaches to build a research partnership to create capacity in the community for community-engaged multilevel behavioral and mental health research. Members from the three Navajo communities have never previously been involved in health research focused on wellbeing. Integrating CBPR with DCSR methodology becomes a powerful innovative intervention as the: 1) the community is driving the research to identify culture-based solutions for health related disparities; 2) the community is provided opportunities through research to center their perspectives and understandings about behavioral and mental health interventions; and 3) the community draws upon their collective community Indigenous knowledge.
57920036|NCT06353438|OTHER|Exercise Program|Concentric strengthening of multiple muscle groups 2x/week for 6 weeks.
57920037|NCT00475033|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
57920038|NCT00475033|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
57920039|NCT01749904|DRUG|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
57920040|NCT01749904|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
57920041|NCT01749904|DRUG|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
58274052|NCT03376373|BEHAVIORAL|neurofeedback|real-time feedback on accuracy of emotion recognition
58274053|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
58391596|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
58391597|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
58391598|NCT05302869|OTHER|None intervention|None intervention
58391599|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
58391600|NCT02763813|DEVICE|Retention type appliance (ORM)|
58391601|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
58391602|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
58274054|NCT06400407|DEVICE|Continuous Theta-burst Stimulation|Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.
58274055|NCT06400407|DEVICE|Sham stimulation|A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
58274056|NCT05281900|DIAGNOSTIC_TEST|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
58391603|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
58391604|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
58391605|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
58391606|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
57920042|NCT04214600|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills"
57920043|NCT01090622|DRUG|XPF-001|Oral capsule
57920044|NCT01090622|DRUG|Placebo|Oral capsule
57920045|NCT00992433|BIOLOGICAL|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
57920046|NCT05923268|DRUG|[99mTc]Tc-G3-(G3S)3C|One single injection of \[99mTc\]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
57920047|NCT06215430|DRUG|Caffeine Tablet|Administered orally.
58274057|NCT05281900|OTHER|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
58274058|NCT05281900|OTHER|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank"
58391607|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
58391608|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
58391609|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
58391610|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
58391611|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
57920048|NCT06215430|DRUG|Omeprazole capsule|Administered orally.
57920049|NCT06215430|DRUG|Warfarin tablet|Administered orally.
57920050|NCT06215430|DRUG|LOXO-305|Administered orally.
57920051|NCT04947423|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
57920052|NCT04947423|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
57920053|NCT00609882|OTHER|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
57920054|NCT00609882|OTHER|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
57920055|NCT03313921|DIAGNOSTIC_TEST|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
57920056|NCT05393284|DRUG|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
58391612|NCT05081167|DRUG|REL-1017|REL-1017 tablet
58391613|NCT05081167|DRUG|Placebo|Placebo tablet
58391614|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
58391615|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
58274059|NCT02644330|PROCEDURE|transthoracic device closure|minimally invasive transthoracic device closure
58274060|NCT02644330|PROCEDURE|surgical repair|surgical repair with cardiopulmonary bypass
58391616|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
58274061|NCT00475878|DRUG|escitalopram|10mg escitalopram/day for 3 months
58274062|NCT00475878|DRUG|placebo|placebo capsule/day for 3 months
58274063|NCT03080584|OTHER|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
58391617|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
58391618|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
57722361|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
57722362|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
58274064|NCT05024526|DRUG|edaravone dexborneol or edaravone|Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
58274065|NCT00380718|DRUG|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting)."
57722363|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
57920057|NCT05393284|DRUG|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
57920058|NCT00006098|DRUG|bortezomib|
58274066|NCT04291742|DIAGNOSTIC_TEST|cognitive vs software|cognitive vs software
58274067|NCT03941197|BEHAVIORAL|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
58391619|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
58391620|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
58391621|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
58391622|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
58391623|NCT01712581|OTHER|Magnetic Resonance Imaging|
58391624|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
58391625|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
58391626|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
58391627|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
58391628|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
58391629|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
58391630|NCT00025571|DRUG|HPPH|
58391631|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
57920059|NCT05696431|OTHER|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
57920060|NCT05696431|OTHER|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
57920061|NCT05696431|OTHER|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
58274068|NCT00318175|DRUG|Bosentan (Tracleer)|
58274069|NCT01738191|DRUG|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
58274070|NCT01738191|DRUG|Placebo|
58391632|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
58391633|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
58391634|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
57722364|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
57920062|NCT03177278|DRUG|[14C]-plazomicin|single intravenous dose
57920063|NCT01451125|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
57920064|NCT05750537|BEHAVIORAL|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
57920065|NCT04667897|DRUG|601 1.25mg|Solution for injection (intravitreal use)
57920066|NCT04667897|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
57920067|NCT04470466|DEVICE|short pulse and Q-switched ND-YAG laser with topical carbon|application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
58065104|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
58274071|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
57920068|NCT04470466|DEVICE|fractional CO2 laser|single pass of fractional CO2 laser on the other side of the face
57920069|NCT01652599|DRUG|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
57920070|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
57920071|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
57920072|NCT02590809|DRUG|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
58391635|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
58391636|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
57722365|NCT02256111|DRUG|Enzalutamide|
57920073|NCT02590809|DRUG|Placebo|Placebo will be given for 30 days
57920074|NCT02590809|OTHER|Walk distance test|Walk distance test during 6 minutes
57920075|NCT02590809|OTHER|Exercise echocardiography|
58065105|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
58065106|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
58274072|NCT03806023|DEVICE|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
58391637|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
58391638|NCT04806061|DRUG|standard care|standard care
57722366|NCT02256111|DRUG|Androgen deprivation therapy|
57722367|NCT02256111|BEHAVIORAL|Supervised exercise training|
57722368|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
57722369|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
57722370|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
57722371|NCT03511521|DRUG|glargine|basal insulin
57722372|NCT03511521|DRUG|Insulin Aspart|prandial insulin
57722373|NCT00002912|DRUG|etoposide|
57722374|NCT00002912|DRUG|mitoxantrone hydrochloride|
57722375|NCT00002912|DRUG|valspodar|
58274073|NCT01354548|DEVICE|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
58391639|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
57722376|NCT03169140|DEVICE|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
57722377|NCT03169140|DEVICE|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
57722378|NCT03169140|BEHAVIORAL|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
57722379|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
57722380|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
57722381|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
57722382|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
57920076|NCT02377804|OTHER|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
58391640|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
58391641|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
58391642|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
57920077|NCT02377804|OTHER|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
57920078|NCT02377804|DEVICE|stainless steel needles (0.3mm x 50mm)|
57920079|NCT04208776|DRUG|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
57920080|NCT04208776|DRUG|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
57722383|NCT06112236|OTHER|no intervention|no intervention
57722384|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
57920081|NCT00729768|DRUG|basiliximab|2 intravenous doses
57920082|NCT00729768|DRUG|efalizumab|Subcutaneous repeating dose
58391643|NCT02091362|DRUG|LY2409021|Administered orally
58391644|NCT02091362|DRUG|Placebo|Administered orally
58391645|NCT02091362|DRUG|Metformin|Administered as background therapy.
58391646|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
57920083|NCT00729768|DRUG|mycophenolate mofetil|Oral repeating dose
57920084|NCT00729768|DRUG|corticosteroids|Repeating doses
57920085|NCT00729768|DRUG|cyclosporine|Oral repeating dose
57920086|NCT02043678|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
57920087|NCT02043678|DRUG|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
57920088|NCT02043678|DRUG|Abiraterone|1000 mg once daily, oral, with best supportive care
58065107|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
58065108|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
58391647|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
58391648|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
58391649|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
57920089|NCT02043678|DRUG|Prednisone/Prednisolone|5 mg twice daily, oral, with best supportive care
57920090|NCT01808482|DRUG|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
58391650|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
58391651|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
58391652|NCT00094159|DRUG|SNS-595|
57920091|NCT01808482|DRUG|Part A: matching placebo|Matching placebo
57920092|NCT01808482|DRUG|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
57920093|NCT01808482|DRUG|Part B: matching placebo|Matching placebo
57920094|NCT01808482|DRUG|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
57920095|NCT04173637|BIOLOGICAL|AK101|an anti-IL-12/23p40 monoclonal antibody
57920096|NCT04173637|BIOLOGICAL|Placebo|matching placebo
57920097|NCT03609853|DRUG|Placebo|Placebo vapor (distilled water)
57920098|NCT03609853|DRUG|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
58065109|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
58065110|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
58065111|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
58065112|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
58065113|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
58065114|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
58391653|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
58391654|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
58391655|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
58391656|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
58391657|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
58391658|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
58391659|NCT01668446|DRUG|estradiol valerat|
58391660|NCT00382421|DRUG|bisoprolol|
58391661|NCT00382421|DRUG|amlodipine|
58391662|NCT00382421|DRUG|molsidomine|
58274074|NCT03984968|BIOLOGICAL|CD19 CAR-T cells infusion combined with feeding T cells (FTCs)|"Phase1 study Optimal biological doses of feeding T cells identification CAR-T cells infusion combined with FTCs will be given in Philadelphia chromosome positive B-ALL patients with remission. FTCs will be administered at the dose of 5×106/kg, 3.25×106/kg or 2×106/kg two hours after ssCART-19 infusion on day 1 and once again administered at the same dose on day 8.~Phase 2 Expansion Study CAR-T cells infusion combined with FTCs at optimal biological dosage determined in Phase 1 study will be given in expanded Philadelphia chromosome positive B-ALL patients with remission. Bayesian optimal design is applied in this Phase 2 study to monitor the toxicity and efficacy at the specified interim analyses. The total expected sample sizes are 40."
58274075|NCT00901979|DRUG|LCQ908A|
58274076|NCT00901979|DRUG|LCQ908A|
57722385|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
57920099|NCT00434915|DRUG|DHEA|
58065115|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
58274077|NCT00901979|DRUG|LCQ908A|
58274078|NCT00901979|DRUG|LCQ908A|
57722386|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
57722387|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
58274079|NCT00901979|DRUG|LCQ908A|
58274080|NCT00901979|DRUG|Placebo|
58274081|NCT00901979|DRUG|Sitagliptin|
58274082|NCT00901979|DRUG|metformin|
58274083|NCT02179749|DRUG|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
58274084|NCT02179749|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
58274085|NCT02179749|DRUG|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
58274086|NCT04222140|COMBINATION_PRODUCT|ERIPTO Protocol|combination biologic treatment
58274087|NCT04222140|BIOLOGICAL|BMAC Only|BMAC treatment only
58274088|NCT00402610|DRUG|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
58274089|NCT04341558|OTHER|Family supplemented patient monitoring|Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
57722388|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
57722389|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
57722390|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
57920100|NCT00502827|BEHAVIORAL|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
57920101|NCT00502827|OTHER|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
57920102|NCT05691556|PROCEDURE|HABIT ILE rehabilitation course|"The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course"
58391663|NCT00382421|DRUG|acetylsalicylic acid|
58391664|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
58065116|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
58274090|NCT04977414|BEHAVIORAL|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
58065117|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
58274091|NCT05342493|DRUG|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
57722391|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
57722392|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
57722393|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
57722394|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD-L1 Therapy
57722395|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
57722396|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
58065118|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
57722397|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
57722398|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
57722399|NCT05234346|OTHER|Placebo|No Description for the intervention
57722400|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
57722401|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
57722402|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
57722403|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
57722404|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
57722405|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
57722406|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
57722407|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
57722408|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
58065119|NCT02727452|OTHER|Skin-to-skin contact|
58065120|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
58065121|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
58065122|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
57722409|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
58274092|NCT00840593|PROCEDURE|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
58274093|NCT00840593|PROCEDURE|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
58274094|NCT04977492|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
58274095|NCT03689101|PROCEDURE|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
57722410|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
57722411|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
57722412|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
57722413|NCT02406144|DRUG|MLN9708|
57722414|NCT02406144|DRUG|Lenalidomide|
57722415|NCT02406144|DRUG|Dexamethasone|
58065123|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
58274096|NCT04967859|DRUG|0.1% gentamicin|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
58274097|NCT04967859|DRUG|Placebo|Patients using placebo ointment at the exit site of the hemodialysis catheter
58274098|NCT00403741|BEHAVIORAL|motivational interviewing|
58274099|NCT02431806|DRUG|Placebo|Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
58391665|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
58274100|NCT02431806|DRUG|Levomilnacipran|Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
58274101|NCT02431806|DRUG|Fluoxetine|Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
58274102|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
58274103|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
58274104|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
58274105|NCT01675375|DEVICE|Eye Shield|one application following refractive surgery
58274106|NCT06441422|OTHER|Blood flow restriction training|Participants randomized to blood flow restriction training will complete low load resistance training exercises while the limb is occluded at 80% arterial occlusion pressure.
58274107|NCT06441422|OTHER|No blood flow restriction training|Participants randomized to no blood flow restriction training will complete low load resistance without occlusion.
58274108|NCT02143830|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
58391666|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
58274109|NCT02143830|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
58391667|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
58065124|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
58391668|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
58391669|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
58391670|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
58391671|NCT02765815|DRUG|Ketorolac 30mg|
58391672|NCT02765815|DRUG|Morphine 10mg|
58065125|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
58274110|NCT02143830|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
58274111|NCT02143830|DRUG|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
58391673|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
58391674|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
58391675|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
58391676|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
58391677|NCT01168830|DEVICE|AMS-3.0|
58391678|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
58065126|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
58065127|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
58065128|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
58065129|NCT02743494|OTHER|Placebo|Specified dose on specified days
58391679|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
58391680|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
58391681|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
58274112|NCT02143830|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
58274113|NCT02143830|BIOLOGICAL|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
58274114|NCT02561663|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
58274115|NCT02561663|OTHER|Placebo|
58274116|NCT04268940|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time \[PT\], anti-Xa, activated clotting time\[ACT\], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
58274117|NCT01743118|DRUG|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
58274118|NCT01743118|DRUG|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
58274119|NCT01743118|DRUG|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
58391682|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
57920103|NCT05691556|PROCEDURE|botulinum toxin injections|"Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy."
57920104|NCT00892931|DRUG|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
58391683|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
57920105|NCT05112107|BEHAVIORAL|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
57920106|NCT05715866|DEVICE|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
57920107|NCT05715866|PROCEDURE|therapeutic exercise|patients receive adapted therapeutic exercise
57920108|NCT05715866|BEHAVIORAL|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
58065130|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
58274120|NCT00223730|DRUG|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
58274121|NCT00223730|DRUG|Placebo|
58274122|NCT02732236|OTHER|Rituximab|Cohort observation study
58274123|NCT02636803|DRUG|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
58274124|NCT02636803|DRUG|albendazole|group receives one 400 mg dose of albendazole
58274125|NCT03130140|PROCEDURE|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
58274126|NCT03130140|OTHER|Control|Conventional EUS-FNA
58391684|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
58391685|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
58391686|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
58391687|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
57920109|NCT03608540|DEVICE|Endomina|Suturing system with sutures apposition then bulging then cutting
58391688|NCT06290466|DRUG|Low dose group|300 mg,single dose.
58391689|NCT06290466|DRUG|High dose group|400 mg, single dose.
58391690|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
58391691|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
58391692|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
58391693|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
58391694|NCT02724579|DRUG|Cisplatin|Given IV
58391695|NCT02724579|DRUG|Cyclophosphamide|Given IV
58391696|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
58391697|NCT02724579|DRUG|Lomustine|Given PO
58274127|NCT06179732|COMBINATION_PRODUCT|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
58274128|NCT06179732|BEHAVIORAL|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
58274129|NCT06179732|DIAGNOSTIC_TEST|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
58274130|NCT05721690|DEVICE|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
58391698|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58391699|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
58274131|NCT05721690|DEVICE|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
58274132|NCT00382109|DRUG|thiotepa|Given IV
58274133|NCT00382109|DRUG|cyclophosphamide|Given IV
58274134|NCT00382109|DRUG|tacrolimus|Given IV or orally
58274135|NCT00382109|DRUG|methotrexate|Given IV
58391700|NCT02724579|DRUG|Vincristine|Given IV or via minibag
58391701|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
58391702|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
58391703|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
58391704|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
58391705|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
58274136|NCT00382109|DRUG|sirolimus|Given orally
58391706|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
58274137|NCT00382109|RADIATION|total body irradiation|Part of the transplant preparatory regimen
58274138|NCT04006509|BEHAVIORAL|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
58274139|NCT00004866|DRUG|exatecan mesylate|
58274140|NCT02548923|DRUG|Dexmedetomidine|comparison to propofol
58274141|NCT01164917|DRUG|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
58274142|NCT01164917|DRUG|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
58274143|NCT00865241|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
58274144|NCT00865241|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
58274145|NCT05907187|BEHAVIORAL|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
58274146|NCT02464644|OTHER|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
58274147|NCT02944435|DRUG|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
58274148|NCT02944435|DRUG|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
58274149|NCT03584516|DRUG|Itacitinib|In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
58274150|NCT03584516|DRUG|Placebo|In Part 2, participants will receive matching placebo.
58274151|NCT03584516|DRUG|Methylprednisolone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
58274152|NCT03584516|DRUG|Prednisone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
58274153|NCT06250179|PROCEDURE|free gingiva graft surgery|For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.
58274154|NCT05391919|OTHER|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
58274155|NCT05391919|OTHER|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
57722416|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
58274156|NCT05954936|OTHER|Risk factor|No therapeutic or diagnostic intervention will be provided; it is an observational study.
58274157|NCT00374218|DRUG|High Fructose Corn Syrup|
58274158|NCT00374218|DRUG|Sucromalt|
58274159|NCT00851019|BEHAVIORAL|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
58274160|NCT00851019|BEHAVIORAL|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
58274161|NCT03099694|PROCEDURE|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
57722417|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
58274162|NCT03099694|PROCEDURE|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
58274163|NCT06199271|DRUG|Adebrelimab and dalpiciclib|Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
57722418|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
58274164|NCT01368107|DRUG|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
57722419|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
57722420|NCT03185624|DRUG|Rifaximin|Antibiotics
57722421|NCT05873192|DRUG|ADT|Given by PO
57722422|NCT05873192|DRUG|Enzalutamide|Given by PO
58391707|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
58391708|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
58274165|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
58391709|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
58391710|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
58274166|NCT01368107|DRUG|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
58274167|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
58274168|NCT02748408|DEVICE|SMS femoral stem|
58274169|NCT00000448|DRUG|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
58274170|NCT00000448|DRUG|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
58274171|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
58274172|NCT03278782|DRUG|Romidepsin|Given IV
58274173|NCT02003963|BEHAVIORAL|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
58274174|NCT01933178|DEVICE|Cirrus AS-OCT|
58274175|NCT05935995|OTHER|microscopy confocal (Histolog Scanner)|"Surgical margins of tumor samples will be examined by conventional histopathology (H\&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase."
58274176|NCT00192348|BIOLOGICAL|CAIV-T|
58274177|NCT06083701|DRUG|Linperlisib in combined with Chidamide|"* Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~* Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
58274178|NCT03762005|OTHER|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
58274179|NCT03762005|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
58274180|NCT05038566|DEVICE|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
58391711|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
58391712|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
58391713|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
58391714|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
58391715|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
58391716|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
58274181|NCT05168072|DEVICE|m-Health app|M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
58274182|NCT05168072|OTHER|conventional outpatient obesity management|Diet and exercise guidance
58391717|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
58391718|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
58274183|NCT04657367|OTHER|Observational study - registry|Observational study - registry
58274184|NCT03932929|DEVICE|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
58274185|NCT06009809|DIAGNOSTIC_TEST|transesophageal echocardiogram|To measure mean blood velocity at the level of the right renal and superior mesenteric artery
58391719|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
58391720|NCT02177331|DRUG|Lacidipine|
58391721|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
58391722|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
58391723|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
58391724|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
58274186|NCT04889599|DRUG|BH009 (Docetaxel injection)|75mg/m2
58274187|NCT04889599|DRUG|Docetaxel injection|75mg/m2
58274188|NCT01039805|DRUG|GSK962040 (50 mg)|Cohort 1 = 50 mg
58391725|NCT00256360|DRUG|dose dense with neulasta|
58391726|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
58391727|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
58391728|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
58391729|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
58391730|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
58391731|NCT05532722|DRUG|ABC008|Given subcutaneous injection
58391732|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
58391733|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
58391734|NCT01903772|OTHER|Inspiratory Muscle Training|
57722423|NCT05873192|DRUG|Talazoparib|Given by PO
57722424|NCT05873192|DRUG|Degarelix|Given PO or given INJ
57722425|NCT05873192|DRUG|Luprolide|Given PO or given INJ
57722426|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
57722427|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
58274189|NCT01039805|DRUG|Placebo|matching placebo
58274190|NCT01039805|DRUG|GSK962040 (75 mg)|Cohort 2 = 75 mg
58274191|NCT06271759|OTHER|Fragrance inhalation|Inhalation of fragranced essential oils
58274192|NCT03130283|OTHER|Home Hospitalization|Visit every 24 hours
58274193|NCT03130283|OTHER|Conventional Hospitalization|No intervention
58274194|NCT04892992|BEHAVIORAL|DFG|
58274195|NCT01080729|DRUG|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
57722428|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
57722429|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
57722430|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
57722431|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
57722432|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
57722433|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
57722434|NCT02693444|DRUG|Lidocaine|
57722435|NCT02693444|DRUG|Saline|
57722436|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
57722437|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
57722438|NCT02143622|BIOLOGICAL|LJM716|antibody
57722439|NCT02143622|BIOLOGICAL|cetuximab|antibody
57722440|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
57722441|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
57722442|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
57722443|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
58274196|NCT02650622|PROCEDURE|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
58391735|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
58391736|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
58391737|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
57722444|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
58391738|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
58391739|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
58391740|NCT02438683|DRUG|Placebo|single dose, oral administration
58391741|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
57722445|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
57722446|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
57722447|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
57722448|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
57722449|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
57722450|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
57722451|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
57722452|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
57722453|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
57722454|NCT00509197|DRUG|Placebo (sham inhaler)|
57722455|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
57722456|NCT02268773|DRUG|Asasantin®|
57722457|NCT02268773|DRUG|Acetylsalicylic acid low dose|
57722458|NCT02268773|DRUG|Acetylsalicylic acid high dose|
57722459|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
58274197|NCT05555602|DEVICE|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
58274198|NCT03545269|DRUG|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
58391742|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
57722460|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
57722461|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
57722462|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
57722463|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
57722464|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
57722465|NCT01795001|OTHER|No intervention|
57722466|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
58391743|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
57722467|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
57722468|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
58274199|NCT03545269|PROCEDURE|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
57920110|NCT01871311|DRUG|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
57920111|NCT04926220|DEVICE|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
57920112|NCT04926220|DEVICE|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
57920113|NCT04926220|DEVICE|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
58274200|NCT02393430|DRUG|Rebamipide|Rebamipide is a
58274201|NCT02393430|BEHAVIORAL|optimization of life style|
58391744|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
58391745|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
58274202|NCT03786185|BEHAVIORAL|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
58391746|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
58391747|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
57722469|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
58391748|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
58391749|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
58391750|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
58391751|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
58391752|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
57722470|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
57722471|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
57722472|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
57722473|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
57722474|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
58391753|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
57722475|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
57722476|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
58391754|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
58391755|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
58391756|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
58391757|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
58391758|NCT00219193|DRUG|aliskiren|
57722477|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
57722478|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
57722479|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
58391759|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
57722480|NCT05095480|DRUG|Placebo|Placebo receiving group
57722481|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
57722482|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
57722483|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
57722484|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
57722485|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
57722486|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
57722487|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
57722488|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
57722489|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
57722490|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
57722491|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
58391760|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
58391761|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
58391762|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
58391763|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
58391764|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
58391765|NCT02706418|PROCEDURE|Clinical Massage Therapy|
58391766|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
58391767|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
58391768|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
58274203|NCT03786185|BEHAVIORAL|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
58274204|NCT06336278|DIAGNOSTIC_TEST|Pressure Algometer|Pressure algometer is used to detect pain pressure treshold.
58391769|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
58391770|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
58391771|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
58391772|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
58391773|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
58391774|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
57722492|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
57722493|NCT00519805|DRUG|dalteparin|
58274205|NCT01752868|DIETARY_SUPPLEMENT|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
58391775|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
58391776|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
58391777|NCT02456207|DRUG|SCT400|
58391778|NCT02456207|DRUG|Rituximab|
58391779|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
58391780|NCT03544424|OTHER|No intervention|No intervention
58391781|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
58391782|NCT01267864|DRUG|Metoclopramide|10mg IVSS
58391783|NCT01267864|DRUG|Ketorolac|30g IVSS
58391784|NCT01267864|DRUG|Valproate|1gm IVSS
58391785|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
58391786|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
58391787|NCT02262026|DRUG|Placebo|Placebo
58391788|NCT02470585|DRUG|Veliparib|Capsules for oral administration
58391789|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
58391790|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
58391791|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
57722494|NCT00519805|PROCEDURE|quality-of-life assessment|
57722495|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
57722496|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
57722497|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
57722498|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
58391792|NCT00353808|DRUG|[S,S]-Reboxetine|
58391793|NCT00407368|PROCEDURE|Blood Sample|
58274206|NCT03738761|DRUG|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
58274207|NCT03738761|DRUG|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
58391794|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
58391795|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
57722499|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
57722500|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
57722501|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
57920114|NCT02001610|DIETARY_SUPPLEMENT|Acidophilus pearls|"* Acidophilus pearls are encapsulated using patented process~* Subjects take one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
57920115|NCT02001610|DIETARY_SUPPLEMENT|Hard shell gelatin capsules|"* Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~* Subjects consume one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
58065131|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
58065132|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
58065133|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
58065134|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
58065135|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
58065136|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
58065137|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
58391796|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
58391797|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
58274208|NCT03718754|DEVICE|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
58391798|NCT02566187|DRUG|Fimasartan|
58391799|NCT02566187|DRUG|Atorvastatin|
57722502|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
57722503|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
58391800|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
58391801|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
57722504|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
58391802|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
57722505|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
57722506|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
57920116|NCT03090230|DEVICE|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
58391803|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
57722507|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
57722508|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
57722509|NCT04315311|DRUG|CREON|Capsule: Oral
57722510|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
58391804|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
58274209|NCT03718754|DEVICE|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
58274210|NCT01880905|PROCEDURE|Measure of uteroovarian ligament length during gynecological surgery|
58274211|NCT02150070|DRUG|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
58391805|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
58391806|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
58391807|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
58391808|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
58391809|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
58391810|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
57722511|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
58065138|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
58065139|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
58065140|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
58274212|NCT02150070|DRUG|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
58274213|NCT03296020|OTHER|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
58274214|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
58274215|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
58274216|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
58274217|NCT06730789|DEVICE|Epicondylitis bandage|A conservative treatment method of lateral epicondylitis.
58274218|NCT06730789|DEVICE|Wrist dorsiflexion splint|A conservative treatment method of lateral epicondylitis.
58274219|NCT06730789|DEVICE|Kinesio tape|A conservative treatment method of lateral epicondylitis
58391811|NCT04739319|OTHER|N/A Observational study|N/A Observational study
58391812|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
58391813|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
58391814|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
58391815|NCT00752739|OTHER|placebo|Given orally
57722512|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
57722513|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
57920117|NCT01450254|DEVICE|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
58274220|NCT01794598|BEHAVIORAL|Receiving educational material of depression care|The educational material provides patients about depression management
58274221|NCT00743288|DRUG|Melphalan|Same as above
58274222|NCT00743288|DRUG|Panobinostat|
58274223|NCT03702491|DRUG|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
58274224|NCT03702491|DRUG|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
58391816|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
58391817|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
58391818|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
58391819|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
58391820|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
58391821|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
58391822|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
58391823|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
58391824|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
58391825|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
57722514|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
57722515|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
57722516|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
57722517|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
57722518|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
57722519|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
58274225|NCT05871671|BEHAVIORAL|Pulmonary Rehabilitation|A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.
58391826|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
58391827|NCT02358200|DRUG|BMN-673|
58391828|NCT02358200|DRUG|Carboplatin|
57722520|NCT02211833|DRUG|BI 2536|
57722521|NCT02211833|DRUG|Pemetrexed|
58391829|NCT02358200|DRUG|Paclitaxel|
58391830|NCT00002297|DRUG|Inosine pranobex|
58391831|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
58391832|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
58391833|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
58391834|NCT03500016|OTHER|High intensity interval training|See under arm description.
58391835|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
58391836|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
58391837|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
58391838|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
57722522|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
57722523|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
57722524|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
57722525|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
57722526|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
57722527|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
57722528|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
57722529|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
57722530|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
58391839|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
57722531|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
58274226|NCT05871671|OTHER|Control|The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
58391840|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
58391841|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
58391842|NCT03248167|DRUG|Cannabidiol|600 mg daily
58391843|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
58274227|NCT03394417|DEVICE|StrataXRT|randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
58274228|NCT01413074|OTHER|Peritoneal Dialysis treatment|PD treatment
58391844|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
58274229|NCT01413074|OTHER|Hemodialysis treatment|HD treatment
58391845|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
58391846|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
58274230|NCT04542434|DRUG|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
58274231|NCT04542434|DRUG|Placebo|Matching placebo tablets 3 times daily for 14 days
58274232|NCT03758105|OTHER|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
58274233|NCT03758105|OTHER|Usual care|Medication and psychotherapy as prescribed in usual care
58391847|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
58274234|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
58391848|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
58391849|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
58391850|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
58391851|NCT00128024|DRUG|lipid-lowering treatment|
58391852|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
58391853|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
57722532|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
57722533|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
58274235|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
58274236|NCT04492917|OTHER|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
58274237|NCT04492917|OTHER|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
58274238|NCT04492917|OTHER|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
58274239|NCT04492917|OTHER|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
58274240|NCT00985426|BIOLOGICAL|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
58274241|NCT00985426|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
58391854|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
58391855|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
58391856|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
58391857|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
58391858|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
58391859|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
58391860|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
58391861|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
58391862|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
58391863|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
58391864|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
58391865|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
58274242|NCT00985426|OTHER|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
57722534|NCT02006030|DRUG|ADI-PEG 20|
58274243|NCT05952713|DRUG|Antidepressant|Treatment with an antidepressant according to Danish register data.
58274244|NCT06290804|OTHER|education|Training program on Health Impacts of Sustainable Behaviors and Climate Change
58391866|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
58391867|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
58274245|NCT00718484|DRUG|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
58274246|NCT00718484|DRUG|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
58391868|NCT06566170|DRUG|Donanemab|Administered IV
58391869|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
58391870|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
58391871|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
58391872|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
58391873|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
58391874|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
57722535|NCT02006030|DRUG|Transarterial chemoembolization|
58065141|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
58274247|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
58274248|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
58391875|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
58391876|NCT03358875|DRUG|Tislelizumab|Intravenous injection (Anti-PD-1 monoclonal antibody)
58065142|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
58274249|NCT03140956|DRUG|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
58065143|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
58065144|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
58274250|NCT05277350|DRUG|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
58274251|NCT05277350|DRUG|Placebo|Matching placebo
58391877|NCT03358875|DRUG|Docetaxel|Intravenous injection (Antineoplastic, cytotoxic, taxane)
58391878|NCT00442494|DRUG|intravenous hydrocortisone|
58391879|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
58391880|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
57722536|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
57722537|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
57722538|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
57722539|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
57722540|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
58274252|NCT06059157|DEVICE|Advanced MRI|resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
58274253|NCT04136275|BIOLOGICAL|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
58274254|NCT00003178|BIOLOGICAL|filgrastim|
58274255|NCT00003178|DRUG|cladribine|
58274256|NCT00003178|DRUG|idarubicin|
58391881|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
58391882|NCT00046293|DRUG|Reopro|
58391883|NCT00046293|DRUG|Retrovase|
58391884|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
58391885|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
58391886|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
58391887|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
58391888|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
58391889|NCT03138460|OTHER|standard medications crossed over to cannabis|
58391890|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
58391891|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
58391892|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
57722541|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
58065145|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
58274257|NCT00701844|BEHAVIORAL|Writing A (Experimental informative writing)|Experimental informative writing
58274258|NCT00701844|BEHAVIORAL|Writing B (Experimental noninformative writing)|Experimental noninformative writing
58274259|NCT00701844|BEHAVIORAL|Writing C (Control informative writing)|Control informative writing
58274260|NCT00701844|BEHAVIORAL|Writing D (Control noninformative writing)|Control noninformative writing
58274261|NCT03793374|OTHER|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
58274262|NCT05974956|OTHER|Mastitis care teaching protocol|It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
58274263|NCT00811993|DRUG|RG1507|Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
58274264|NCT00811993|DRUG|RO1507|27mg/kg iv, monotherapy
58274265|NCT00811993|DRUG|bevacizumab [Avastin]|as prescribed
58274266|NCT00811993|DRUG|capecitabine [Xeloda]|as prescribed
58274267|NCT00811993|DRUG|carboplatin|as prescribed
58274268|NCT00811993|DRUG|cetuximab|as prescribed
58274269|NCT00811993|DRUG|docetaxel|as prescribed
58274270|NCT00811993|DRUG|erlotinib [Tarceva]|as prescribed
58274271|NCT00811993|DRUG|etoposide|as prescribed
57722542|NCT04519632|OTHER|Qualitative study|Qualitative interviews
57722543|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
57722544|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
57722545|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
58274272|NCT00811993|DRUG|gemcitabine|as prescribed
58274273|NCT00811993|DRUG|irinotecan|as prescribed
58274274|NCT00811993|DRUG|mFOLFOX6|as prescribed
58274275|NCT00811993|DRUG|paclitaxel|as prescribed
58274276|NCT00811993|DRUG|pemetrexel|as prescribed
58274277|NCT00811993|DRUG|sorafenib|as prescribed
58274278|NCT00811993|DRUG|temozolomide|as prescribed
58274279|NCT00811993|DRUG|trastuzumab [Herceptin]|as prescribed
58274280|NCT03564795|DEVICE|KeraStat Gel|Wound dressing for partial thickness burns
58065146|NCT05353881|OTHER|No intervention|No intervention
58065147|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
58065148|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
58065149|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
58065150|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
58274281|NCT03564795|DEVICE|Silver Sulfadiazine|Wound dressing for partial thickness burns
58274282|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
58274283|NCT06056362|DIAGNOSTIC_TEST|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
58274284|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
58274285|NCT06056362|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
58274286|NCT04409015|DEVICE|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
58274287|NCT00486707|BEHAVIORAL|Questionnaire|A questionnaire will be completed.
58274288|NCT06731868|DRUG|LPM3770164 sustained release tablet 5 mg|LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
58274289|NCT06731868|DRUG|LPM3770164 sustained release tablet 10 mg|LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
58274290|NCT06731868|DRUG|LPM3770164 sustained release tablet 20 mg|LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
58274291|NCT06731868|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
58274292|NCT05369689|OTHER|No interventions|As this is a prognosis evaluation study, there are no interventions.
58391893|NCT00431444|DRUG|Raloxifene|
58391894|NCT00431444|DRUG|Zoledronic acid|
58391895|NCT00431444|DRUG|Placebo oral pills|
57920118|NCT01450254|OTHER|Control|No intervention will be prescribed to the control group during participation in the study.
57920119|NCT01208493|OTHER|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
57920120|NCT01208493|OTHER|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
57920121|NCT02694939|BEHAVIORAL|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
57920122|NCT02694939|BEHAVIORAL|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
57920123|NCT02522455|OTHER|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
57920124|NCT02522455|OTHER|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
57920125|NCT05868343|OTHER|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
58274293|NCT04420819|DEVICE|Ischemic Preconditioning|The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
58274294|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
58274295|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
58274296|NCT05691621|DRUG|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
58274297|NCT02979080|OTHER|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
58274298|NCT04317924|DEVICE|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
58274299|NCT04317924|OTHER|Standard of care|Standard of care after air leak post lung resection
58274300|NCT00006486|DRUG|carboxyamidotriazole|Given orally
58274301|NCT00006486|OTHER|placebo|Given orally
57920126|NCT05868343|OTHER|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
57920127|NCT02774031|DEVICE|Aisys with Et control|
57920128|NCT02774031|DEVICE|Aisys conventional|
57920129|NCT02774031|DEVICE|Flow-i with ACG|
58274302|NCT00625404|DRUG|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
58274303|NCT00625404|OTHER|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
58274304|NCT05539261|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
57920130|NCT02774031|DEVICE|Flow-i conventional|
57920131|NCT02957721|OTHER|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
57920132|NCT04712331|OTHER|Graduated abdominal strengthening exercises|"Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors)."
57920133|NCT04712331|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
57920134|NCT04712331|OTHER|Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation|"Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation."
58274305|NCT05539261|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
58274306|NCT03968055|OTHER|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
58274307|NCT04038554|DIAGNOSTIC_TEST|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
58274308|NCT04908111|BIOLOGICAL|ChAdOx1-MAGEA3-NYESO|"Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
58274309|NCT04908111|BIOLOGICAL|MVA-MAGEA3|"Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
58274310|NCT04908111|COMBINATION_PRODUCT|Standard of care treatment|Patients will continue to receive standard of care treatment (chemotherapy and checkpoint inhibitor).
58274311|NCT04908111|BIOLOGICAL|MVA-NYESO|"Patients commence their Standard of Care (SoC) chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
58274312|NCT02694458|OTHER|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
58274313|NCT02694458|OTHER|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
57920135|NCT05142137|DIETARY_SUPPLEMENT|Drinkable solution|The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
58274314|NCT01010399|DIETARY_SUPPLEMENT|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
58391896|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
58391897|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
58391898|NCT01766804|DIETARY_SUPPLEMENT|placebo|
58391899|NCT06463743|DRUG|metformin|metformin
58391900|NCT06463743|DRUG|Placebo|Placebo
58391901|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
58391902|NCT02088879|BEHAVIORAL|chest compression with standing position|
58391903|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
57722546|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
57722547|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
57722548|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
57722549|NCT03702829|DRUG|Inotersen|Open Label Study
57920136|NCT03226275|DRUG|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
58391904|NCT00512850|OTHER|Placebo|One placebo pill per day
58391905|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
58391906|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
58391907|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
58391908|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
58391909|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
58391910|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
57722550|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
57920137|NCT03226275|DRUG|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
58065151|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
58274315|NCT01010399|DRUG|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
58274316|NCT03436199|DRUG|ADS-5102, 137 mg|Oral capsules
57722551|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
57722552|NCT02841423|PROCEDURE|neuropsychological test battery|
57722553|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
57722554|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
57722555|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
57722556|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
57722557|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
57920138|NCT03226275|DRUG|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
57920139|NCT00344474|BEHAVIORAL|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
57920140|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
58065152|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
58065153|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
57920141|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
57920142|NCT01115296|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
57920143|NCT01115296|OTHER|Placebo|Placebo
58065154|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
58065155|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
58065156|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
58274317|NCT03436199|DRUG|ADS-5102, 274 mg|Oral capsules
58274318|NCT03436199|OTHER|Placebo|Oral capsules
58274319|NCT00410462|DRUG|brostallicin|
58274320|NCT00410462|DRUG|doxorubicin hydrochloride|
58274321|NCT00822224|DRUG|MEOPA|inhalation of MEOPA during the painful care
58274322|NCT03646149|BEHAVIORAL|Housing Skills Training Group|12-session social skills training group for persons with homeless experiences and serious mental illness delivered once a week for 12 weeks
58274323|NCT05543031|OTHER|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
58065157|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
58274324|NCT05543031|DIAGNOSTIC_TEST|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
57722558|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
57722559|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
57722560|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
57722561|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
57722562|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
58274325|NCT05543031|DIAGNOSTIC_TEST|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
57722563|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
57722564|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
58274326|NCT05543031|DIAGNOSTIC_TEST|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
58274327|NCT05543031|DIAGNOSTIC_TEST|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
57722565|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
57722566|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
57722567|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
57722568|NCT02086591|DRUG|Doxycycline|
57722569|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
58065158|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
58065159|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
58274328|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)|Integrated medication for opioid use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
58274329|NCT06513156|BEHAVIORAL|NavSTAR-CHOICE (NS)|Patient-centered social support intervention including motivational interviewing and patient navigation designed to overcome the barriers in accessing the recommended follow-up opioid use disorder treatment and medical care services for 6 months.
58274330|NCT03959904|PROCEDURE|Small stitch|Wound closure will be using small stiches or larger spaced stitches
58274331|NCT03959904|OTHER|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
58274332|NCT03959904|OTHER|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
58274333|NCT03959904|OTHER|Pain Score|A pain score will be recorded following the surgical procedure.
58274334|NCT03959904|OTHER|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
57722570|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
57722571|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
57722572|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
57722573|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
57722574|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
57722575|NCT02843789|DRUG|Tocilizumab|
57722576|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
57722577|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
57722578|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
57722579|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
57722580|NCT00248222|BEHAVIORAL|Supervised aerobic training|
57722581|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
57722582|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
57722583|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
57722584|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
57722585|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
57722586|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
57722587|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
58065160|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
58065161|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
57722588|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
57722589|NCT02464969|DRUG|Apixaban|Tablet or Solution
57722590|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
57722591|NCT05163860|OTHER|Survey|Participants will complete an online survey.
58065162|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
57722592|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
57722593|NCT00614939|DRUG|Placebo|Placebo
57722594|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
57722595|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
57722596|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
58065163|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
57722597|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
57722598|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
57722599|NCT05333445|OTHER|usual care|standard care
57722600|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
57722601|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
57722602|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
57722603|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
57722604|NCT00102791|DRUG|ICA-17043|
57722605|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
57722606|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
57722607|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
57722608|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
57722609|NCT06280300|OTHER|health services intervention|Health services intervention
57722610|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
57722611|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
57722612|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
57722613|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
58274335|NCT05194956|PROCEDURE|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
58274336|NCT05194956|PROCEDURE|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
57722614|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
57722615|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
57722616|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
57722617|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
57722618|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
57722619|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
57722620|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
57722621|NCT01038921|DRUG|Placebo|Placebo
57722622|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
57920144|NCT06189586|DRUG|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
57722623|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
57920145|NCT06189586|DRUG|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
57920146|NCT00400985|DEVICE|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
57920147|NCT00419666|DRUG|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
57920148|NCT03253926|DRUG|Lorcaserin|Lorcaserin 10mg BID
57920149|NCT03253926|DRUG|Placebo|Placebo capsule BID
57920150|NCT03253926|DRUG|Marijuana|Smoked marijuana cigarette
57722624|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
57722625|NCT00310687|PROCEDURE|BLOOD DRAW|
57722626|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
58274337|NCT05932849|DRUG|Benralizumab|Patients were initiated on benralizumab as part of routine clinical practice
57722627|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
57722628|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
57722629|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
57722630|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
57722631|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
58065164|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
58274338|NCT00006305|PROCEDURE|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
58391911|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
58274339|NCT00006305|PROCEDURE|Coronary Artery Bypass|Coronary Artery Bypass
58274340|NCT00006305|DRUG|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
58274341|NCT00006305|DRUG|Insulin, sulfonylurea|Insulin, sulfonylurea
58274342|NCT00006305|DRUG|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
58274343|NCT06731192|BIOLOGICAL|hUC-MSC|"This group of patients received a total of 2 peripheral intravenous Human umbilical cord mesenchymal stem cells (hUC-MSC) infusions during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days, and the single infusion dose was approximately 2×1000,000 cells/Kg.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
58274344|NCT06731192|DRUG|Placebo control drug|"This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
58274345|NCT01325194|DRUG|liposomal cytarabine|50 mg intrathecally three times
58274346|NCT02494401|OTHER|Internet-based self-management program|
58274347|NCT02494401|OTHER|Scleroderma book|
58274348|NCT03217968|DEVICE|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
58065165|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
58274349|NCT03777111|OTHER|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
58274350|NCT00065195|PROCEDURE|Moving touch therapy|
58274351|NCT00065195|PROCEDURE|Nonmoving touch therapy|
58274352|NCT00231309|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
58274353|NCT05304494|OTHER|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
58274354|NCT05338866|RADIATION|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
58274355|NCT05338866|DRUG|Chemotherapy|"For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
58274356|NCT00296127|DRUG|Celecoxib|
58274357|NCT04365049|RADIATION|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
58274358|NCT04365049|DRUG|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
58274359|NCT04365049|DRUG|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
58274360|NCT04365049|DRUG|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
58274361|NCT03050047|BIOLOGICAL|BCD-100|Anti-PD1 monoclonal antibody
58274362|NCT02106143|DEVICE|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
58274363|NCT00869557|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
58274364|NCT00869557|DRUG|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
58391912|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
58274365|NCT04471571|OTHER|Resin infiltration and microabrasion for MIH-affected incisors|MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
57920151|NCT06248970|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
58274366|NCT04471571|OTHER|Resin infiltration for MIH-affected incisors|MIH-affected incisors will be treated with resin infiltration alone
58391913|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
58391914|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
57722632|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
57722633|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
57722634|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
57722635|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
57920152|NCT06248970|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
58274367|NCT02503644|DRUG|IVA337|Capsules of 200mg IVA337
58274368|NCT02503644|DRUG|Placebo|Identical capsules without active substance
58274369|NCT00636636|DRUG|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
58274370|NCT00636636|DRUG|Placebo|Once daily; 300 mg and 600 mg tablets
58274371|NCT05234034|OTHER|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
58274372|NCT05681637|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
58274373|NCT00153010|DRUG|NS 2330 (Tesofensine)|
58391915|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
58391916|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
58391917|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
58391918|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
58065166|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
58274374|NCT06020209|DIAGNOSTIC_TEST|Cardiac Computed Tomography|A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.
58274375|NCT06020209|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
58391919|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
58391920|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
58391921|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
58391922|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
58391923|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
57722636|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
57722637|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
57722638|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
57920153|NCT06248970|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
57920154|NCT03360838|OTHER|CogCheck|Performance of study participants in the application
58274376|NCT01025375|DIETARY_SUPPLEMENT|inulin|10gram/day inulin for 13-day treatment
57722639|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
57722640|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
57920155|NCT04137900|DRUG|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
57920156|NCT04137900|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
58391924|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
58391925|NCT05306834|OTHER|Walking speed measurement|over 5 meters
58391926|NCT02859727|DRUG|CDZ173|140 mg/day
58391927|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
58391928|NCT00171457|DRUG|Tegaserod|
58391929|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
58391930|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
58391931|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
57920157|NCT01054846|OTHER|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
57920158|NCT01054846|OTHER|Bicycle helmet education only|As described under the respective arm
57920159|NCT00155935|PROCEDURE|venous puncture|
57920160|NCT03081754|RADIATION|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
57920161|NCT04007185|PROCEDURE|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
58274377|NCT01025375|DIETARY_SUPPLEMENT|inulin|16gram/day inulin for 13-day treatment
58274378|NCT01025375|DIETARY_SUPPLEMENT|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
58274379|NCT05016297|DRUG|Baricitinib|baricitinib 4mg per day
58274380|NCT05016297|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
58274381|NCT03011541|PROCEDURE|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
58274382|NCT02839876|DRUG|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
58391932|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
58391933|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
58391934|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
58391935|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
58391936|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
58391937|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
58391938|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
58391939|NCT00284505|DRUG|thalidomide|
58391940|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
58391941|NCT06412835|OTHER|cooperative learning|Students working in groups
57722641|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
57722642|NCT00173667|DRUG|Nifedipine 30 mg GITS|
57722643|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
57722644|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
57722645|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
57722646|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
57722647|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
57722648|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
57722649|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
57722650|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
57722651|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
57722652|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
57722653|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
57920162|NCT06391502|BEHAVIORAL|Multi-component Exercise Intervention Program|"The Vivifrail program (http://vivifrail.com) is a home-based exercise program that focuses on personalized multi-component exercise prescriptions based on an elderly person's functional abilities, including resistance/strength, balance, flexibility, and cardiovascular endurance exercise (i.e., walking).~During hospitalization, patients who meet the criteria of sodium intake will be screened, and then divided into groups according to the method of randomized controlled trial. The experimental group will carry out corresponding exercise plan according to the results of SPPB."
58274383|NCT02839876|DRUG|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
58391942|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
58391943|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
57920163|NCT01648335|DEVICE|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
57920164|NCT01648335|DEVICE|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
57920165|NCT00679627|DRUG|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
58274384|NCT03453281|DRUG|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
58391944|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
58391945|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
58391946|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
58391947|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
57722654|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
57722655|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
57722656|NCT01889589|OTHER|Surveillance|
57722657|NCT01903278|DRUG|PEG-IFN-SA /RBV|
57722658|NCT01903278|DRUG|Pegasys /RBV|
57722659|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
57722660|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
57722661|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
57722662|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
57722663|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
57722664|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
57722665|NCT03749226|DRUG|Aztreonam lysine|nebulization
57920166|NCT00679627|DRUG|Placebo|Matching placebo
57920167|NCT03872570|DRUG|Phenylephrine|intravenous administration
57722666|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
57920168|NCT03872570|DRUG|Norepinephrine|intravenous administration
57920169|NCT00858884|OTHER|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
57920170|NCT04975438|DRUG|GSK1070806|GSK1070806 will be administered
57920171|NCT04975438|DRUG|Placebo|Placebo will be administered
57920172|NCT02306486|OTHER|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
57920173|NCT02180022|DRUG|Placebo|After randomization, placebo was treated for 12 weeks
57920174|NCT02180022|DRUG|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
57920175|NCT01992042|DRUG|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
57920176|NCT01992042|DRUG|Pimonidazole|
57920177|NCT01912456|BIOLOGICAL|Low-volume C1-esterase inhibitor|
57920178|NCT01912456|BIOLOGICAL|Higher-volume C1-esterase inhibitor|
57920179|NCT01912456|BIOLOGICAL|Low-volume placebo|
57920180|NCT01912456|BIOLOGICAL|Higher-volume placebo|
57920181|NCT02577757|DEVICE|MRI|MRI
57920182|NCT02255266|DRUG|liraglutide|No treatment given.
57920183|NCT00133146|BIOLOGICAL|Grass MATA MPL|
57920184|NCT00004253|DRUG|carboplatin|
57920185|NCT00004253|DRUG|paclitaxel|
58274385|NCT06528171|PROCEDURE|Brain MRI|non injected brain MRI
58274386|NCT06528171|BIOLOGICAL|Specific blood samples|blood samples to find immunological and inflammatory markers
58274387|NCT03362580|DEVICE|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
58274388|NCT03362580|DEVICE|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
57920186|NCT00004253|RADIATION|radiation therapy|
57920187|NCT02373254|DRUG|Ibuprofen|Ibuprofen 400 mg and 800 mg
57920188|NCT02373254|DRUG|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
57920189|NCT00604812|DRUG|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
57920190|NCT00604812|DRUG|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
57920191|NCT00604812|DRUG|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
57920192|NCT00604812|DRUG|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
57920193|NCT02080312|DRUG|Magnevist (gadopentetate dimeglumine)|
57920194|NCT04413123|DRUG|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
57920195|NCT04413123|DRUG|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
58065167|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
57920196|NCT04413123|DRUG|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
57920197|NCT03752099|DRUG|VERU-111|VERU-111
57920198|NCT00572390|DRUG|oestrogen|Cyclic oestrogen substitution therapy
58065168|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
58065169|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
58274389|NCT03362580|DEVICE|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
58274390|NCT03362580|DEVICE|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
57920199|NCT00875654|GENETIC|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke
57920200|NCT05969054|DRUG|Lacosamide 100 mg|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
57920201|NCT05969054|DRUG|Levetiracetam 250mg|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
58274391|NCT03943927|OTHER|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
57722667|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
58274392|NCT00483704|DRUG|Telcagepant 140 mg|Telcagepant 140 mg tablets
58274393|NCT00483704|DRUG|Talcagepant 280 mg|Telcagepant 280 mg tablets
58274394|NCT00483704|DRUG|Placebo|Placebo tablets
58274395|NCT00161694|DIETARY_SUPPLEMENT|sucrose solution|
58274396|NCT00212316|DRUG|sodium phenylbutyrate|
58274397|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
58274398|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
58274399|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single sc injection
58274400|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
58274401|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
58274402|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single sc injection
58274403|NCT02719834|DRUG|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
58274404|NCT02719834|OTHER|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
58391948|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
58391949|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
57920202|NCT04290442|PROCEDURE|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
58391950|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
57722668|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
57722669|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
58065170|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
58065171|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
58065172|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
58274405|NCT00195494|DRUG|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
58274406|NCT00195494|DRUG|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
58274407|NCT00195494|DRUG|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
58274408|NCT01207115|DRUG|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
58274409|NCT01207115|DRUG|Placebo|Placebo capsules - twice daily for 8 weeks
58274410|NCT01207115|DRUG|Naproxen|Naproxen capsules - twice daily for 8 weeks
58274411|NCT01535586|DEVICE|CPAP versus MAD|Cross over design
58274412|NCT00098540|DRUG|sorafenib tosylate|Given orally
58274413|NCT00098540|OTHER|laboratory biomarker analysis|Correlative studies
57722670|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
57722671|NCT00002408|DRUG|Crofelemer|
57722672|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
57722673|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
57722674|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
57722675|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
57722676|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
57722677|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
57722678|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
57722679|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
57722680|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
57920203|NCT04290442|PROCEDURE|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
57920204|NCT04290442|DRUG|Ropivacaine|ropivacaine 0.5% will be use in the block
57920205|NCT05902234|BEHAVIORAL|interdiciplinary treatment|Normal interdiciplinary treatment path
57920206|NCT01749605|DRUG|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
57920207|NCT01749605|DRUG|ciprofloxacin 250 mg BID x 3 days|
58391951|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
58391952|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
58391953|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
58391954|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
58391955|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
58391956|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
58391957|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
57722681|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
57722682|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
57722683|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
57722684|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
57722685|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
57722686|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
57722687|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
57722688|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
57920208|NCT03260231|DIETARY_SUPPLEMENT|Milled seed mix|Dietary intervention with or without seed mix
57920209|NCT00969878|DRUG|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
57920210|NCT00969878|OTHER|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
57920211|NCT02361151|BEHAVIORAL|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
57920212|NCT02361151|BEHAVIORAL|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
58065173|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
58391958|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
58391959|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
58391960|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
58391961|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
57722689|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
57722690|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
57722691|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
58274414|NCT04982978|BEHAVIORAL|PMT Threat Appraisal|"The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university."
57722692|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
58274415|NCT04982978|BEHAVIORAL|General Nutrition and Lifestyle|The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
58274416|NCT03174678|DRUG|Dexmedetomidine|1µg/kg dexmedetomidine oral
58391962|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58391963|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58391964|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58274417|NCT03174678|OTHER|apple juice|apple juice
58274418|NCT00072059|BIOLOGICAL|methoxy polyethylene glycol epoetin beta|
58274419|NCT02552498|PROCEDURE|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
58391965|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58391966|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
58391967|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
58274420|NCT00829088|DRUG|AZD2066|1 dose oral solution
58274421|NCT05865847|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
58274422|NCT01580345|DIETARY_SUPPLEMENT|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
58391968|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
58391969|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
58391970|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
58391971|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
58391972|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
58391973|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
57722693|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
57722694|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
57722695|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
57920213|NCT05602948|BEHAVIORAL|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation (see Move \& Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
57920214|NCT05602948|BEHAVIORAL|'Move & Learn' intervention|"The physical activities in Move \& Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
57920215|NCT06375421|BEHAVIORAL|MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval|Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.
57920216|NCT06375421|BEHAVIORAL|Blocked Retrieval|Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.
57920217|NCT05804266|PROCEDURE|Coventional coagulation|In the conventional group, the haemostasis of vessels will be performed with the conventional coagulation technique under CO2 insufflation. First, submucosal fibres surrounding a blood vessel will be dissected and the vessel will be isolated. After, both sides of the isolated vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until the blood vessel turns white and can be finally cut.
57722696|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
57722697|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
57722698|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
57722699|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
57722700|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
57722701|NCT01675180|OTHER|Control|No intervention
57722702|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
57722703|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
57722704|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
57722705|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
31490227|NCT06625476|DRUG|GSK4771261|GSK4771261 will be administered.
31490228|NCT06625476|DRUG|Placebo|Placebo will be administered.
57722706|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
57722707|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
57722708|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
57722709|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
57722710|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
58391974|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
58274423|NCT01580345|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
57722711|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
57920218|NCT05804266|PROCEDURE|Underwater coagulation|In the treatment group, the prophylactic haemostasis of vessels will be accomplished by the underwater coagulation technique. First, physiological solution will be instilled until there is no more air around the blood vessel. Then, the vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until it turns white and, after the removal of all the physiological solution, can be finally cut.
58274424|NCT02068859|DRUG|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
58274425|NCT02068859|DRUG|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
58274426|NCT05659641|DEVICE|PerMed Stent Graft System In Surgical Operation|PerMed Branch Stent Graft
58391975|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
58391976|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
57722712|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
57722713|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
57722714|NCT03783559|DRUG|TACE|TACE
57722715|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
57722716|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
57722717|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
57722718|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
57722719|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
58274427|NCT05659641|DEVICE|Endovastec CRONUS® Intraoperative stent system|CRONUS® Branch Stent Graft
57722720|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
57722721|NCT03269591|DRUG|diclofenac tablets|drugs
57722722|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
57722723|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
57722724|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
57722725|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
57722726|NCT02540239|DRUG|2L PEG|
58391977|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
58391978|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
58391979|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
57722727|NCT02540239|DRUG|2L PEG+simethicone|
57920219|NCT00473135|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU
57920220|NCT00473135|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
57920221|NCT04143074|BEHAVIORAL|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
57722728|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
57722729|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
57722730|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
57722731|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
57722732|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
57722733|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
57722734|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
57722735|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
58391980|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
58391981|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
58391982|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
57722736|NCT02782481|DRUG|ND0612|
57722737|NCT02782481|DRUG|Placebo|
57722738|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
57920222|NCT04581889|OTHER|Diagnostic test|Presence of antibodies in saliva
57920223|NCT00510679|BEHAVIORAL|Health worker supports (supervision, job aids, incentives)|
57920224|NCT02009995|BEHAVIORAL|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
58274428|NCT02237560|BEHAVIORAL|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
58274429|NCT02237560|BEHAVIORAL|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
57722739|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
58274430|NCT02237560|BEHAVIORAL|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
58274431|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
58391983|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
57722740|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
57722741|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
57722742|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
57722743|NCT00672477|DRUG|Methylnaltrexone|
57722744|NCT00672477|DRUG|Placebo|
57722745|NCT02533882|BEHAVIORAL|Movement to Music|
57722746|NCT02533882|BEHAVIORAL|Adapted Yoga|
57722747|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
57722748|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
57722749|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
57722750|NCT03049059|DRUG|4% hydroquinone cream|
58065174|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
58065175|NCT00036816|BIOLOGICAL|MART-1 antigen|
58065176|NCT00036816|BIOLOGICAL|NA17-A antigen|
58065177|NCT00036816|BIOLOGICAL|gp100 antigen|
58065178|NCT00036816|BIOLOGICAL|tyrosinase peptide|
58065179|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
58065180|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
58065181|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
58065182|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
58391984|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
57722751|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
57722752|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
57722753|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
57722754|NCT01713803|DRUG|Buprenorphine and naloxone|
57722755|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
57722756|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
57722757|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
57722758|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
57722759|NCT00097591|DRUG|Prasugrel|Administered orally
57722760|NCT00097591|DRUG|Clopidogrel|Administered orally
57722761|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
58065183|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
58065184|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
58065185|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
58065186|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
58065187|NCT04342572|DRUG|Melphalan|-The drug is commerically available
58065188|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
57722762|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
57722763|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
58391985|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
58391986|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
58391987|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
58391988|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
58391989|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
58391990|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
58391991|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
58391992|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
58391993|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
57722764|NCT01474135|DRUG|0.004% Travoprost|
57722765|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
57722766|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
57722767|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
57722768|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
58274432|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
58274433|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
58274434|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
58391994|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
58391995|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
57722769|NCT02170727|DRUG|DCV/ASV/BMS-791325|
57722770|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
57722771|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
57722772|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
57722773|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
57722774|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
57722775|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
57722776|NCT05027191|DRUG|Desflurane|Desflurane
57722777|NCT05027191|DRUG|Sevoflurane|Sevoflurane
57722778|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
57722779|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
57722780|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
58065189|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
58391996|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
57722781|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
57722782|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
57722783|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
57722784|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
57722785|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
57722786|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
57722787|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
57722788|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
57722789|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
57722790|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
57722791|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
57722792|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
57722793|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
57722794|NCT00414752|DRUG|AFQ065|
58274435|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
57722795|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
57722796|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
57722797|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
57722798|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
57722799|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
58065190|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
58391997|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
58391998|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
58391999|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
58392000|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
58392001|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
58392002|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
58392003|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
58065191|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
58392004|NCT02665663|DEVICE|medical device|
58392005|NCT02308163|DRUG|Peficitinib|oral
58392006|NCT02308163|DRUG|Placebo|oral
58392007|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
58392008|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
57722800|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
57722801|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
57722802|NCT03901248|OTHER|No Intervention|Observational study
57722803|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
58065192|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
58274436|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
58274437|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
57920225|NCT02009995|BEHAVIORAL|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
57920226|NCT00565474|DRUG|Fluvastatin|Graft vasculopathy
57920227|NCT05125263|OTHER|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
57920228|NCT05125263|OTHER|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
57920229|NCT05255367|COMBINATION_PRODUCT|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
57920230|NCT00351130|DRUG|valsartan|
57920231|NCT00351130|DRUG|amlodipine|
57920232|NCT05596838|PROCEDURE|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
58274438|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
58274439|NCT02620085|PROCEDURE|blood sampling|blood sampling
58274440|NCT05940077|BEHAVIORAL|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
58392009|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
58392010|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
58392011|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
58392012|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
58392013|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
57722804|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
57722805|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
57722806|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
57722807|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
57722808|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
58392014|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
58392015|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
58065193|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
58392016|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
57722809|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
58274441|NCT00308750|DRUG|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
58274442|NCT00308750|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
58274443|NCT00308750|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
58392017|NCT06547697|OTHER|Dialysate sodium concentration|
58392018|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
58392019|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
58392020|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
58392021|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
58392022|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
58392023|NCT02889497|BIOLOGICAL|the first batch vaccine|
58392024|NCT02889497|BIOLOGICAL|the second batch vaccine|
57920233|NCT03754413|DEVICE|experimental|Neuramis® Deep Lidocaine
58274444|NCT00308750|DRUG|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
58392025|NCT02889497|BIOLOGICAL|the third batch vaccine|
58392026|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
57722810|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
57722811|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
57722812|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
57920234|NCT03754413|DRUG|comparator|No-treatment
57722813|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
57722814|NCT02710630|DRUG|Dabigatran etexilate capsule|
57722815|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
57722816|NCT05929014|DEVICE|Cathodal-Transcranial direct current stimulation (cathodal-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.
57722817|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
57722818|NCT05929014|DEVICE|Sham cathodal-tDCS|Sham cathodal-tDCS
57722819|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
57722820|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
58392027|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
58392028|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
58392029|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
57722821|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
57722822|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
57920235|NCT01315951|BIOLOGICAL|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
57920236|NCT06237686|DEVICE|CP363|All subjects will test both Test product A and B, with a minimum of 7 days apart. In total, each subject will be enrolled in the investigation for 8 days +3 days.
57920237|NCT02472769|DRUG|IBP-9414|
57920238|NCT02472769|DRUG|Placebo|Sterile water
57920239|NCT00516243|OTHER|placebo|Given PO
58274445|NCT00941824|DRUG|mycophénolate acid|"* Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily"
58274446|NCT00964015|DRUG|6% Hydroxyethyl Starch 130/0.4|
58274447|NCT00964015|DRUG|0.9% Normal Saline|
58274448|NCT01481272|DRUG|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
58274449|NCT01481272|DRUG|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
58392030|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
58392031|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
58392032|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
58392033|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
57722823|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
57920240|NCT00516243|OTHER|quality-of-life assessment|Ancillary studies
57920241|NCT00516243|PROCEDURE|questionnaire administration|Ancillary studies
57920242|NCT00516243|PROCEDURE|laboratory biomarker analysis|Correlative studies
57920243|NCT00516243|DRUG|defined green tea catechin extract|Given PO
58274450|NCT01481272|DRUG|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients \>/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
58274451|NCT01481272|DRUG|Mesna|300mg/m2 or 200mg/m2 (patients \>/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients \>/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
58274452|NCT01481272|DRUG|Cytarabine|2g/m2 or 0,5-1g/m2 (patients \>/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
58274453|NCT01481272|DRUG|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
58274454|NCT01481272|DRUG|Leukovorin|15mg, po 24 hours after methotrexate it
58392034|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
58392035|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
57722824|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
57722825|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
57722826|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
57722827|NCT01010581|DRUG|Placebo|oral administration
57920244|NCT06053723|OTHER|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
57920245|NCT06053723|OTHER|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
58274455|NCT01481272|DRUG|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC\>1.0x109/l
57722828|NCT01010581|DRUG|Methotrexate|oral administration
57722829|NCT01010581|DRUG|Folic Acid|oral administration
57722830|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
57722831|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
57920246|NCT06053723|OTHER|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
57920247|NCT03151096|DIETARY_SUPPLEMENT|Riboflavin|one pill of Riboflavin will be taken orally with water
57920248|NCT03151096|DIETARY_SUPPLEMENT|Placebo|one pill of placebo will be taken orally with water
57920249|NCT03569657|BEHAVIORAL|A positive psychology workshop|Group workshop
58274456|NCT06730282|DRUG|Danggui Shaoyao San (DSS)|Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
58274457|NCT06730282|DRUG|Cuscuta Chinensis (Tu Si Zi)|Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
58392036|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
58392037|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
58392038|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
58392039|NCT00601692|DRUG|cisplatin|Given IV
58392040|NCT00601692|DRUG|docetaxel|Given IV
58392041|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
58392042|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
58392043|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
57920250|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
58392044|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
57722832|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
57722833|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
57722834|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
57722835|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
57722836|NCT01886547|OTHER|Prostate health screening|
57722837|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
57920251|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
57920252|NCT00081770|DRUG|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
57920253|NCT00081770|BIOLOGICAL|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
57920254|NCT00081770|DRUG|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
57920255|NCT02938533|BEHAVIORAL|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
58274458|NCT06730282|DRUG|Combination Therapy (DSS + Tu Si Zi)|This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
57920256|NCT04182594|DRUG|Degarelix|Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days
57920257|NCT04182594|DRUG|GnRH agonist|GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
58274459|NCT06730282|DRUG|Placebo|Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
58274460|NCT01018160|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
58274461|NCT02445859|DRUG|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
58274462|NCT06112678|DRUG|CKD-348(6)|QD, PO
58392045|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
58392046|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
58392047|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
58392048|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
58392049|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
58392050|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
58392051|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
58392052|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
58274463|NCT06112678|DRUG|CKD-828, D097, D337|QD, PO
58274464|NCT03250585|DIAGNOSTIC_TEST|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
57722838|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
58274465|NCT03250585|DIAGNOSTIC_TEST|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
58274466|NCT02237040|PROCEDURE|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
58392053|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
57722839|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
57722840|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
57722841|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
57722842|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
57722843|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
57920258|NCT02583139|BEHAVIORAL|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
57920259|NCT00849277|DRUG|Lactobacillus casei Shirota|
57920260|NCT04329832|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
58392054|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
58392055|NCT04904744|OTHER|No message|No reminders are sent
58392056|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
58392057|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
58392058|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
57722844|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
57722845|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
58274467|NCT02331849|DEVICE|High resolution manometry (HRM)|High resolution manometry of the esophagus
58274468|NCT02811575|OTHER|Biopsy|Ileon and colon biopsy
58274469|NCT02565706|BEHAVIORAL|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
58274470|NCT02565706|BEHAVIORAL|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
58392059|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
58392060|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
58392061|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
58392062|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
57722846|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
57722847|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
57722848|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
57722849|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
57722850|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
57722851|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
58274471|NCT01612507|DRUG|600 mg Ceftaroline fosamil|1 h infusion
57722852|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
57920261|NCT04329832|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
57920262|NCT01551160|OTHER|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
58274472|NCT01612507|DRUG|Placebo|1 h infusion
58274473|NCT01612507|DRUG|600 mg Ceftaroline fosamil|2 h infusion
58274474|NCT01612507|DRUG|Placebo|2 h infusion
58274475|NCT01273155|DRUG|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
58274476|NCT03835065|PROCEDURE|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
58274477|NCT03835065|OTHER|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
58274478|NCT03835065|OTHER|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
58274479|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274480|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274481|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274482|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274483|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274484|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274485|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274486|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
58274487|NCT01069237|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
58274488|NCT01069237|DEVICE|Clear Care|Lens Care Solution for contact lenses
58274489|NCT05390463|OTHER|PERformance guided Fracture Rehablitation Method (PERFoRM) protocol.|A structured rehabilitation protocol for surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures).
58274490|NCT05105399|PROCEDURE|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
58274491|NCT04289090|DRUG|Sevoflurane Inhalant Product|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
58274492|NCT04289090|DRUG|Propofol 10 MG/ML|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
58274493|NCT04096898|DEVICE|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
58274494|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
57722853|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
57722854|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
57722855|NCT03108534|DRUG|Placebo|Rescue treatment
57722856|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
57722857|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
57722858|NCT02201602|DRUG|Gliclazide|
58274495|NCT00465543|OTHER|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
58274496|NCT00465543|OTHER|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
58274497|NCT03402347|RADIATION|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
58274498|NCT00568334|BIOLOGICAL|Varilrix (inactivated varicella vaccine)|subcutaneously injection
58274499|NCT05079321|DEVICE|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
57722859|NCT02201602|DRUG|Glibenclamide|
57722860|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
57722861|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
57722862|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
57722863|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
57722864|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
57722865|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
57722866|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
57722867|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
58065194|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
58065195|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
57722868|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
57722869|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
58065196|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
58065197|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
58065198|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
57722870|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
57722871|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
57722872|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
58065199|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
58065200|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
58065201|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
58065202|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
58065203|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
58065204|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
58065205|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
57722873|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
57722874|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
57722875|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
57722876|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
57722877|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
57722878|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
57722879|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
57722880|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
58274500|NCT05079321|DEVICE|Uncoated|Zen™ RC scleral lenses (non-coated)
58274501|NCT05958108|BEHAVIORAL|SinergiAPS intervention|Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
57722881|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
57722882|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
58274502|NCT06730451|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
58274503|NCT04663841|OTHER|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
58274504|NCT02195596|OTHER|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
58274505|NCT02195596|OTHER|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~--------------------------------------------------------------------------------"
57722883|NCT02642913|DRUG|Enzalutamide|
57920263|NCT04105309|BEHAVIORAL|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
57920264|NCT04105309|BEHAVIORAL|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
58274506|NCT02184910|DRUG|pepsinogen and gastrin|
58274507|NCT02572856|DEVICE|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
58274508|NCT06442202|DIETARY_SUPPLEMENT|Balanced Nutritional Diet|"Food was provided during the intervention period 3 (three) times each day, i.e. breakfast, lunch and dinner. The food menu used a 30-day menu cycle. The characteristics of the Balanced Nutrition Diet that have been provided based on the distribution of the composition of the macronutrients that will be intervened in are as follows: 45-55% carbohydrates, 15-20% protein, and 20-25% fat (Ministry of Health 2014). The type of diet and portions that were given were the same for each menu unless there were certain food restrictions or allergies, and then the type of food was adjusted specifically to that individual. The calories that will be given range from 300-400 Cal for breakfast, 400-500 Cal for lunch, and 300-500 Cal for dinner.~The choice of carbohydrates should be varied and prioritise complex carbohydrates such as whole grains. The choice of protein type is prioritised from low-fat protein sources and half of it is vegetable protein."
57722884|NCT02642913|DRUG|Enzalutamide with Sorafenib|
57722885|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
57722886|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
57722887|NCT00000838|DRUG|Lamivudine|
57722888|NCT00000838|DRUG|Stavudine|
57722889|NCT00000838|DRUG|Zidovudine|
57722890|NCT00000838|DRUG|Didanosine|
57722891|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
57722892|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
57722893|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
57722894|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
57722895|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
57722896|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
57722897|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
57722898|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
57722899|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
57722900|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
57722901|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
57722902|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
57722903|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
57722904|NCT03933293|DRUG|Statins|Lipid-lowering therapies
57722905|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
57722906|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
57920265|NCT04105309|BEHAVIORAL|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
57920266|NCT04105309|BEHAVIORAL|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
57920267|NCT02976454|BEHAVIORAL|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
58274509|NCT06442202|BEHAVIORAL|Nutritional Education|Nutritional education is provided via online Zoom meetings with the help of educational media in the form of PowerPoint presentations/videos before entering the intervention period. The educational material that will be provided is regarding Guidelines for Balanced Nutrition, Food Safety, and Healthy Lifestyles (stress management and sleep time). The subject's understanding of the material provided was evaluated using an online quiz platform.
57722907|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
57920268|NCT02976454|BEHAVIORAL|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
57920269|NCT04388241|BEHAVIORAL|The Balance Program|The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
57722908|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
57920270|NCT06115551|COMBINATION_PRODUCT|Fasting Mimicking Diet|FMD is a 5-day low calorie fasting-mimicking diet.
57920271|NCT02490553|OTHER|heteroevaluation scale by a nurse or doctor|
57920272|NCT02485535|OTHER|Laboratory Biomarker Analysis|Correlative studies
57920273|NCT02485535|DRUG|Selinexor|Given PO
57920274|NCT02904486|BEHAVIORAL|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
58065206|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
58274510|NCT00506207|DRUG|S-1, Irinotecan, Oxaliplatin|
58274511|NCT00340106|BEHAVIORAL|Counseling|
57722909|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
58392063|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
57722910|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
57722911|NCT05367453|OTHER|lactase tablet|lactase tablet
57722912|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
57722913|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain TAA and LOH.
57920275|NCT03952429|BEHAVIORAL|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
57920276|NCT03952429|BEHAVIORAL|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
57920277|NCT03221517|OTHER|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
57920278|NCT05822167|OTHER|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
57920279|NCT05822167|OTHER|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
57920280|NCT05822167|OTHER|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
57920281|NCT05822167|OTHER|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
57920282|NCT05822167|OTHER|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
57920283|NCT05822167|OTHER|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
57920284|NCT05822167|OTHER|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
58065207|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
58065208|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
58065209|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
58065210|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
58065211|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
58065212|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
58065213|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
58065214|NCT00136461|DRUG|All-trans retinoic acid|
58065215|NCT00136461|DRUG|Bryostatin 1|
58065216|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
58065217|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
58065218|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
58065219|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
58065220|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
58065221|NCT06234891|DRUG|Nsaid|Medical treatment
58065222|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
57722914|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
57722915|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
57722916|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
57722917|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
57722918|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
57722919|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
57722920|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
57722921|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
57722922|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
57722923|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
57722924|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
57722925|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
57722926|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
57722927|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
57722928|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
57722929|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
57722930|NCT00164801|DRUG|Baclofen, Diltiazem|
57722931|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
57722932|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
57722933|NCT00090012|DRUG|Olanzapine|
57722934|NCT00090012|DRUG|Quetiapine|
57722935|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
57722936|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
57722937|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
57722938|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
57722939|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
58274512|NCT06731569|DEVICE|Advanced intelligence drill|"The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included."
57722940|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
57722941|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
57722942|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
57722943|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
57722944|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
57722945|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
57722946|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
58392064|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
58392065|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
58392066|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
58392067|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
58392068|NCT05069597|DRUG|CREON|Capsule; Oral
58392069|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
58392070|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
58392071|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
58392072|NCT00079261|DRUG|CHOP regimen|
58392073|NCT00079261|DRUG|cyclophosphamide|
57722947|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
57722948|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
57722949|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
57722950|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
57722951|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
57722952|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
57722953|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
58392074|NCT00079261|DRUG|doxorubicin hydrochloride|
58274513|NCT06731569|DEVICE|Traditional rotary instrument|"Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone."
58274514|NCT03092336|OTHER|Electrical Stimulation|electrical stimulation training
58274515|NCT03092336|OTHER|Strength training|strength training group
58274516|NCT02168452|PROCEDURE|sentinel lymph node biopsy(SLNB)|"* incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~* double check after removal of the sentinel lymph node~* sending frozen biopsy"
58274517|NCT04415021|OTHER|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
58274518|NCT04415021|OTHER|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
58274519|NCT02124070|DRUG|rh Growth Hormone|
58392075|NCT00079261|DRUG|gemcitabine hydrochloride|
58392076|NCT00079261|DRUG|prednisone|
58392077|NCT00079261|DRUG|vincristine sulfate|
58392078|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
58392079|NCT05267470|DRUG|Docetaxel|IV infusion
58392080|NCT05267470|DRUG|Pembrolizumab|IV infusion
58392081|NCT05267470|DRUG|Carboplatin|IV infusion
57722954|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
58274520|NCT01968902|BIOLOGICAL|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
58274521|NCT01968902|BIOLOGICAL|Placebo|Saline injection on the day of injection visit
58274522|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
58274523|NCT04663347|DRUG|rituximab and lenalidomide|28-day cycles
58392082|NCT05267470|DRUG|Paclitaxel|IV infusion
58392083|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
58392084|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
58392085|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
57722955|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
57722956|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
58274524|NCT04663347|DRUG|rituximab and bendamustine|28-day cycles
58274525|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|21-day cycles
58274526|NCT04663347|DRUG|gemcitabine and oxaliplatin|28-day cycles
58274527|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
58274528|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|21-day cycles
58274529|NCT04663347|DRUG|Lenalidomide|28-day cycles
58274530|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|21-day cycles
58274531|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
58274532|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
58274533|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
58392086|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
58392087|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
58392088|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
58392089|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
58392090|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
58392091|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
57722957|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
57722958|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
57722959|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
57722960|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
57722961|NCT00390390|DRUG|Lansoprazole|
57722962|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
57722963|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
57722964|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
57722965|NCT02670590|BEHAVIORAL|diet|diet
57722966|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
57722967|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
57722968|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
58274534|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
58274535|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
58274536|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
58274537|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
58274538|NCT05998317|DRUG|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
58274539|NCT05998317|DRUG|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
57722969|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
58274540|NCT00970424|DRUG|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
58274541|NCT00970424|DRUG|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
58274542|NCT02149095|DRUG|TransCon PEG treprostinil|
58274543|NCT02022475|DRUG|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
58274544|NCT02022475|OTHER|placebo|2 placebo capsules will be applied as a single dose
57722970|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
57722971|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
57722972|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
57722973|NCT02509741|BEHAVIORAL|Education|
57722974|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
57722975|NCT02509741|BEHAVIORAL|IOT monitoring|
57722976|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
57722977|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
57722978|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
57722979|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
57722980|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
58392092|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
58392093|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
58392094|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
57722981|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
57722982|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
57722983|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
57722984|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
57722985|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
57722986|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
57722987|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
57722988|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
57722989|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
57722990|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
57722991|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
57722992|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
57722993|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
57722994|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
57722995|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
58392095|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
57722996|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
57722997|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
57722998|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
57722999|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
58065223|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
58274545|NCT02003456|DRUG|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
58274546|NCT05447910|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
57723000|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
57723001|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
57723002|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
58274547|NCT05447910|DRUG|Letrozole|Given PO
58274548|NCT04526574|BIOLOGICAL|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
58274549|NCT04526574|OTHER|Saline|Normal saline for injection
58274550|NCT04526574|BIOLOGICAL|Influenza vaccine|Seasonal inactivated influenza vaccine (SIIV)
58274551|NCT02371668|BIOLOGICAL|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
58392096|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
58392097|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
57723003|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
57723004|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
57723005|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
57723006|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
57723007|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
57723008|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
58065224|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
58274552|NCT02371668|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
58274553|NCT03684421|DIAGNOSTIC_TEST|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
57723009|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
58274554|NCT04935801|BIOLOGICAL|LD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
58274555|NCT04935801|BIOLOGICAL|LD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
58274556|NCT04935801|BIOLOGICAL|HD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
58274557|NCT04935801|BIOLOGICAL|HD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
58392098|NCT02515799|OTHER|Placebo|Inhaled Placebo
58392099|NCT02242214|DRUG|Misoprostol|
57723010|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
57723011|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
57723012|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
57723013|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
57723014|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
57723015|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
57723016|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
58065225|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
57723017|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
57723018|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
57723019|NCT02149589|PROCEDURE|Mechanical ventilation|
57723020|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
57723021|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
57723022|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
57723023|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
57723024|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
57723025|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
57723026|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
57723027|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
57723028|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
57723029|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
58065226|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
58392100|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
58392101|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
58392102|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
57723030|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
57723031|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
57723032|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
57723033|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
57723034|NCT00911365|BIOLOGICAL|normal saline|saline
57723035|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
57723036|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
57723037|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
57723038|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
57723039|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
57723040|NCT06572813|DRUG|Sintilimab|PD-1 antibody
57723041|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
57723042|NCT00046345|DRUG|Atazanavir (BMS-232632)|
57723043|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
57723044|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
57723045|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
57723046|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
57723047|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
57723048|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
57723049|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
58274558|NCT00248144|DRUG|Famciclovir|
58274559|NCT00106639|DRUG|CP-690,550|15 mg twice daily
58274560|NCT00106639|DRUG|CP-690,550|30 mg twice daily
58274561|NCT00106639|DRUG|tacrolimus|dose adjusted according to level
58274562|NCT04336852|PROCEDURE|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
57723050|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
57723051|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
57723052|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
57723053|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
57723054|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
57723055|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
57723056|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
57723057|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
57723058|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
57723059|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
57723060|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
57723061|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
57723062|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
57723063|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
57723064|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
57723065|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
57723066|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
57723067|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
57723068|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
57723069|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
57723070|NCT05351216|OTHER||No intervention
57723071|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
57723072|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
57723073|NCT03296189|DRUG|Placebos|10 mls normal saline
57723074|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
57723075|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
57723076|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
57723077|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
57920285|NCT05822167|OTHER|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
57920286|NCT05822167|OTHER|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
57723078|NCT02973659|DRUG|Placebos|
57723079|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
57723080|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
57723081|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
58274563|NCT04336852|PROCEDURE|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
57920287|NCT01717690|DRUG|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
57920288|NCT01658826|DRUG|AIC316|100 mg oral administration
57920289|NCT01658826|DRUG|Valacyclovir|500 mg oral administration
58274564|NCT04336852|PROCEDURE|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
57723082|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
57723083|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
57723084|NCT00665119|DRUG|placebo|NaCl 0.9 %
57723085|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
57723086|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
57723087|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
57723088|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
57723089|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
58274565|NCT06731400|DIETARY_SUPPLEMENT|EPA supplementation|Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
58274566|NCT03717168|DRUG|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
58274567|NCT03717168|OTHER|Control|All patients will not receive growth hormone.
58274568|NCT06076889|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
58274569|NCT02286375|BEHAVIORAL|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
58274570|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
57723090|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
58274571|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
58274572|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
58274573|NCT00723463|PROCEDURE|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
57723091|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
57723092|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
57723093|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
57723094|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
57723095|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
57723096|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
57723097|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
57723098|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
57723099|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
57723100|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
57723101|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
57723102|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
57723103|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
57723104|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
57723105|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
57723106|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
57723107|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
57723108|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
58392103|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
57723109|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
57723110|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
57723111|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
57723112|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
57723113|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
57723114|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
57920290|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
57920291|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
57920292|NCT00914160|DRUG|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
57920293|NCT03252275|OTHER|Peer learning|Peer learning plus HBB and ECEB
57920294|NCT05742737|OTHER|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
57920295|NCT00607022|DEVICE|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
57920296|NCT04101604|OTHER|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
57920297|NCT05925556|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
58392104|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
57920298|NCT00913653|DRUG|LCZ696|
57920299|NCT00000193|DRUG|Gamma hydroxybutyric|
57920300|NCT00322205|DRUG|zyban|
57920301|NCT00127777|DRUG|Amantadine sulphate (in addition to standard treatment)|
57920302|NCT00238147|DRUG|capecitabine|
57920303|NCT00238147|DRUG|carboplatin|
57920304|NCT00238147|DRUG|docetaxel|
57920305|NCT00238147|PROCEDURE|conventional surgery|
57920306|NCT00238147|PROCEDURE|neoadjuvant therapy|
58392105|NCT01638013|DRUG|Peficitinib|Oral Tablet
58392106|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
57723115|NCT04159831|DRUG|Placebo|normal saline
57723116|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
57723117|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
57723118|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
57723119|NCT02809495|OTHER|use of app in smartphone|
57723120|NCT01699399|PROCEDURE|water immersion|
57723121|NCT01699399|PROCEDURE|water exchange|
57723122|NCT01699399|PROCEDURE|air insufflation|
57723123|NCT00171977|DRUG|Imatinib Mesylate|
57920307|NCT00238147|RADIATION|radiation therapy|
57920308|NCT00606567|OTHER|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
57920309|NCT05997927|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
57920310|NCT05997927|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
57920311|NCT01498653|DRUG|GW685698/GW642444|ICS/LABA
57920312|NCT01498653|DRUG|CCI18781|ICS
57920313|NCT05273853|PROCEDURE|Partial Adenoidectomy|Partial removal of adenoid
57920314|NCT01174654|BEHAVIORAL|Contingency management|A 12-week contingency management intervention
57920315|NCT00069238|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
57920316|NCT00069238|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
57920317|NCT02127918|DRUG|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
58392107|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
58392108|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
57920318|NCT00203476|DRUG|Niacin|
57723124|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
57723125|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
57723126|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
57723127|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
57723128|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
57723129|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
57723130|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
57723131|NCT03032692|OTHER|Exercise with biofeedback|
57723132|NCT03032692|OTHER|exercise without biofeedback|
57723133|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
57723134|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
57723135|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
57920319|NCT00203476|DRUG|Colestipol|
57920320|NCT00203476|DRUG|Ezetimibe|
57920321|NCT02920333|PROCEDURE|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
57920322|NCT02920333|DEVICE|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
57920323|NCT02920333|DEVICE|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
57920324|NCT02920333|DEVICE|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
57920325|NCT03075007|RADIATION|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
58274574|NCT04153968|DIETARY_SUPPLEMENT|β-cryptoxanthin|"Phase 1:~2.0mg of \[13C14\]β-cryptoxanthin, 1.0mg of \[13C10\]β-carotene and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of \[13C14\]β-cryptoxanthin, 0.75mg of \[13C10\]β-carotene, 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of \[13C14\]β-cryptoxanthin, 1.5mg of \[13C10\]β-carotene, and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
58274575|NCT04650126|BIOLOGICAL|ATM001|monovalent anti-TNF-receptor 1 antibody format
58065227|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
58065228|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
57723136|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
57723137|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
57723138|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
57723139|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
57723140|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
57723141|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
58274576|NCT04650126|BIOLOGICAL|ATM001 Placebo|ATM001 Placebo
58274577|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
58274578|NCT02238756|BIOLOGICAL|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
58274579|NCT02238756|BIOLOGICAL|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
58392109|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
57723142|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
57723143|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
57723144|NCT06263777|OTHER|Nurses training program on early detection of disability|It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
57723145|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
57723146|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
57723147|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
58274580|NCT02238756|BIOLOGICAL|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
58274581|NCT06731751|OTHER|Management of spontaneous intracranial haemorrhage|Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
58274582|NCT03566056|OTHER|Complications to Whipples procedure|Patients undergoing the Whipple procedure often tend to have a lot of complications. This study aims to investigate what complications these patients experience
58274583|NCT04102683|BEHAVIORAL|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
58274584|NCT02507024|OTHER|Online questionnaire|
58274585|NCT06730373|DRUG|Disitamab Vedotin|2.5 mg/kg IV every 3 weeks
58274586|NCT06730373|DRUG|Sintilimab|200 mg IV every 3 weeks
58274587|NCT06730373|DRUG|S-1|40-60 mg BID for 14 days, every 3 weeks
58274588|NCT06730373|DRUG|Trastuzumab|First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
58274589|NCT06730373|DRUG|Oxaliplatin|130 mg/m2 Q3W
58274590|NCT06730373|DRUG|Capecitabine|1000 mg/m² Q3W
58274591|NCT06730373|DRUG|5-FU|800 mg/m²
58274592|NCT06730373|DRUG|Cisplatin|80 mg/m²
58274593|NCT01764659|OTHER|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
58274594|NCT06545630|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
58274595|NCT02305446|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
58274596|NCT05133258|OTHER|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
58274597|NCT04938713|DRUG|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
58274598|NCT04938713|DRUG|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
57723148|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
57723149|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
57723150|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
57723151|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
57723152|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
57723153|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
57723154|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
57723155|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
57723156|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
57723157|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
57723158|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
57723159|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
57723160|NCT00147186|DEVICE|Hylan G-F 20|
57723161|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
57723162|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
57723163|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
57723164|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
57723165|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
57723166|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
57723167|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
57723168|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.5cm and 1cm rounds, attached to a digitimer.
57723169|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
57723170|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
57723171|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
57723172|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
57723173|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
57723174|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
57723175|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
58274599|NCT00830518|DRUG|Alisertib|Alisertib capsules
58274600|NCT05270707|RADIATION|Stereotactic radiosurgery|HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
58274601|NCT00553293|DRUG|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
58274602|NCT00553293|DRUG|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
57723176|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
57920326|NCT03075007|PROCEDURE|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
57920327|NCT06384638|BIOLOGICAL|topical application of coconut oil|topical application of coconut oil
58065229|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
58274603|NCT05616091|DEVICE|painful stimulation by using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In each of the two sessions, 80 experimental painful stimuli of different intensities (2.5 J, 3 J, 3.5 J, 4 J) will be applied using the laser device listed above.
58274604|NCT05667207|DIAGNOSTIC_TEST|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
58274605|NCT00444860|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
58274606|NCT02423668|PROCEDURE|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
58274607|NCT02423668|PROCEDURE|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
58392110|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
57723177|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
57723178|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
57723179|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
57723180|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
58065230|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
58065231|NCT02918136|DRUG|Cortisone Injectable|
58065232|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
58065233|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
57723181|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
57723182|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
58065234|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
58065235|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
58274608|NCT02423668|PROCEDURE|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
57723183|NCT00002684|DRUG|cisplatin|
57723184|NCT00002684|DRUG|ifosfamide|
57723185|NCT00002684|DRUG|paclitaxel|
57920328|NCT06384638|OTHER|scaling and debridement|scaling and debridement
57920329|NCT03741569|DEVICE|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
57920330|NCT03120767|BEHAVIORAL|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
58065236|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
58065237|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
57723186|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
57723187|NCT00215293|DEVICE|Cervical I/F Cage|
57723188|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
57723189|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
57723190|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
57723191|NCT04237298|DEVICE|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
57723192|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
57723193|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
57723194|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
57723195|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
57723196|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
57920331|NCT03120767|BEHAVIORAL|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
57920332|NCT02275494|PROCEDURE|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
57920333|NCT03163485|DEVICE|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
57920334|NCT03163485|DEVICE|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
57920335|NCT04262973|OTHER|education|six-hour dementia care course
57920336|NCT04262973|OTHER|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
57920337|NCT02416817|OTHER|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
57920338|NCT02416817|OTHER|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
57920339|NCT01718782|DEVICE|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
57920340|NCT01718782|DEVICE|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
58065238|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
58065239|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
57723197|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
57723198|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
57723199|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
57723200|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
57723201|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
57723202|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
57723203|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
57723204|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
57723205|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
57723206|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
57723207|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
57723208|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
57723209|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
57920341|NCT03453931|DRUG|Corticosteroid injection|Intravenous high dose corticosteroids
57723210|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
57723211|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
57920342|NCT02457312|DRUG|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
58274609|NCT04135066|OTHER|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
58274610|NCT04135066|OTHER|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
57723212|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
57723213|NCT00005787|BIOLOGICAL|epoetin alfa|
57723214|NCT00005787|BIOLOGICAL|filgrastim|
57723215|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
57723216|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
57723217|NCT00005787|BIOLOGICAL|sargramostim|
57723218|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
57723219|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
57723220|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
57723221|NCT01427712|DRUG|Pancrelipase|
57920343|NCT02457312|DRUG|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
57920344|NCT00687817|DRUG|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
57920345|NCT02867293|PROCEDURE|ultrasound guided ascitic fluid drainage|
57920346|NCT02867293|PROCEDURE|operative drainage of ascites through small skin incision after induction of anesthesia|
57920347|NCT02867293|DEVICE|ultrasound|
57920348|NCT04399590|OTHER|Interficial Intelligence|Interficial Intelligence
57723222|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
57723223|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
57723224|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
57723225|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
57723226|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
57723227|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
57723228|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
57723229|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
57920349|NCT06247644|DEVICE|Device wear on skin|Participant will wear the device over a period of 28 hours to assess adhesive performance and potential skin effects.
57920350|NCT04568746|PROCEDURE|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
57920351|NCT04568746|PROCEDURE|box|patient with score \< 2 will be supported in box
58274611|NCT05398705|DRUG|Cepharanthine|Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
57723230|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
57723231|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
57723232|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
57723233|NCT02516059|DEVICE|epidural catheter|
57723234|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
57723235|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
57723236|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
57723237|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
57723238|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
57723239|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
57723240|NCT03884972|DRUG|Trabectedin|Given IV
57723241|NCT03884972|DRUG|Venetoclax|Given PO
57723242|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
58392111|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
57723243|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
57920352|NCT05647239|DEVICE|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
58274612|NCT05398705|DRUG|Placebo|"Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
58392112|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
58392113|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
58392114|NCT05582395|OTHER|Placebo|Specified dose on specified days
58392115|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
57920353|NCT01038063|DRUG|Artemether-lumefantrine combination|
58392116|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
58392117|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
58392118|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
58392119|NCT00001335|DRUG|ADR-529|
58392120|NCT00001335|DRUG|Topotecan|
58392121|NCT00001335|DRUG|G-CSF|
58392122|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
57723244|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
57723245|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
57723246|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
57723247|NCT05924828|OTHER|no intervention|no intervention
57723248|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
57723249|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
57723250|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
57723251|NCT05297045|OTHER|Placebo|Placebo comparator
57723252|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
57723253|NCT00000465|PROCEDURE|coronary artery bypass|
57723254|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
57723255|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
57723256|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
57723257|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
57723258|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
57723259|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
57723260|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
57723261|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
57723262|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
57723263|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
57920354|NCT06418828|OTHER|return to work|Ask patients if they are going back to work
57920355|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
57920356|NCT02757859|OTHER|Lavage|Receive EIPL-S
58274613|NCT05398705|DRUG|Cepharanthine|"High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
58392123|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
57920357|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
57920358|NCT02757859|OTHER|Lavage|Receive EIPL-D
57920359|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
57920360|NCT03436108|DIAGNOSTIC_TEST|Measurement of Bisphenol in urine|to see level of this material in blood of women
58274614|NCT02773745|BEHAVIORAL|Aquatic Prehab|Pool therapy
58274615|NCT05765448|OTHER|Soy control|Soy isolate control meal
57920361|NCT01344512|DRUG|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
58274616|NCT05765448|OTHER|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
58274617|NCT05765448|OTHER|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
58274618|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
58274619|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
58274620|NCT02338466|DRUG|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
58392124|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
57723264|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
57723265|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
58392125|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
58392126|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
57723266|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
57920362|NCT01344512|DRUG|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
57920363|NCT01344512|DRUG|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
57920364|NCT02873507|OTHER|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
57920365|NCT00227890|BEHAVIORAL|MI/CBT|
57920366|NCT00227890|BEHAVIORAL|RT/TU|
57920367|NCT05330637|OTHER|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
58392127|NCT01887613|DRUG|Regnite|oral
57920368|NCT02977117|OTHER|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
58274621|NCT02338466|DRUG|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
58392128|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
58392129|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
58274622|NCT05381922|OTHER|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
58392130|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
58392131|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
58392132|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
58392133|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
58392134|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
58392135|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
58392136|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
57723267|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
57723268|NCT00710333|DRUG|placebo|placebo
57723269|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
57723270|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
57723271|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
57723272|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
57723273|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
57723274|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
57723275|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
57723276|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
57723277|NCT04276272|OTHER|Imaging scan|PET/CT scan
57723278|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
57723279|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
57723280|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
57723281|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
57723282|NCT01351805|OTHER|placebo pill|placebo
57723283|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
57723284|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
57723285|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
57920369|NCT02977117|OTHER|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
57723286|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
57723287|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
57723288|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
57723289|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
58065240|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
57723290|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
57723291|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
57723292|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
57723293|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
57723294|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
57723295|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
57723296|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
57723297|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
57723298|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
57723299|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
57723300|NCT02510157|DRUG|Dexamethasone|active comparator
57723301|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
57920370|NCT03125525|DEVICE|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
57920371|NCT00194857|DRUG|erythropoietin, GCSF|
58065241|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
58392137|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
58392138|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
57920372|NCT04168333|BIOLOGICAL|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
57920373|NCT04168333|BIOLOGICAL|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
58065242|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
58065243|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
58065244|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
58274623|NCT02841956|OTHER|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
58392139|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
58392140|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
58392141|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
58392142|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
58392143|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
58392144|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
58392145|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
58392146|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
57723302|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
57723303|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
57723304|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
58392147|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
58392148|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
58392149|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
58392150|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
58392151|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
58392152|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
58392153|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
58392154|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
58392155|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
57723305|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
58065245|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
58392156|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
58392157|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
58392158|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
58392159|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
58392160|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
58392161|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
58392162|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
58392163|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
58392164|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
58392165|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
58392166|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
58392167|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
58392168|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
58392169|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
57723306|NCT00487201|PROCEDURE|plastic stent placement|
58065246|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
58392170|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
58392171|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
58392172|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
58392173|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
57723307|NCT03890302|DRUG|FB704A|Administered by IV infusion
57723308|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
57723309|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
57723310|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
57723311|NCT00145834|BEHAVIORAL|community based trial|
58274624|NCT02841956|OTHER|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis \& building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms \& changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy \& treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
58274625|NCT02841956|OTHER|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
57723312|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
57920374|NCT05363423|PROCEDURE|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
57920375|NCT05363423|PROCEDURE|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
57920376|NCT03408054|DRUG|Oxytocin|Oxytocin 10-5M solution
57920377|NCT03408054|DRUG|Nitroglycerin|Nitroglycerin 25-1000mcg
58392174|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
57723313|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
57723314|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
57723315|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
57723316|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
57723317|NCT05492318|DRUG|ITF2357 Givinostat 10mg/mL|Dose: 10 mg/mL; Dosage form: oral suspension
58065247|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
58065248|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
57723318|NCT05492318|DRUG|Midazolam 1Mg/Ml (Pf) Inj Syringe 5Ml|Dose: 1 mg/ml; Dosage form: solution for injection/infusion or rectal administration
57723319|NCT05492318|DRUG|Midazolam Oral Liquid Product|Dose: 2.5 mg; Dosage form: oromucosal solution
57920378|NCT05822453|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
57723320|NCT05492318|DRUG|Dabigatran Etexilate 75 MG [Pradaxa]|Dose: 75 mg; Dosage form: hard capsules
57723321|NCT05492318|DRUG|Clarithromycin 500Mg Tab|Dose: 500 mg; Dosage form: immediate-release film-coated tablets
57723322|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
57723323|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
57723324|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
57723325|NCT05848739|DRUG|ST316|IV
57723326|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
57723327|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
57723328|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
57920379|NCT05822453|DRUG|S1|S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
58392175|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
58392176|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
58392177|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
58392178|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
57723329|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
57723330|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
57723331|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
57723332|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
57920380|NCT05822453|DRUG|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
57723333|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
57723334|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
57920381|NCT05402748|OTHER|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
57920382|NCT01138579|DRUG|FBTA05|
57920383|NCT06485440|DRUG|Dysport 300 UNT Injection|300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
57920384|NCT05792969|BEHAVIORAL|Functional measures and public health outcomes|"Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)"
57920385|NCT05632445|DRUG|Apixaban vs. DAPT|Apixaban vs DAPT after LAAO
58392179|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
57723335|NCT03333746|DRUG|Lenalidomide|Given PO
57723336|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
57723337|NCT03333746|OTHER|Pharmacological Study|Correlative studies
57723338|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
57723339|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
57723340|NCT03766646|DEVICE|Optiflow|45l.min oxygen
57920386|NCT00338533|DEVICE|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
58392180|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
58392181|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
57723341|NCT02578524|OTHER|Survey|
57723342|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
57723343|NCT02041429|DRUG|Ruxolitinib|
57723344|NCT02041429|DRUG|Paclitaxel|
57920387|NCT00681330|BIOLOGICAL|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
57920388|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
57920389|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
57920390|NCT05617352|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
57920391|NCT00446628|BEHAVIORAL|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
57920392|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
57920393|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
57723345|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
58065249|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
57920394|NCT00597441|BIOLOGICAL|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
58392182|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
58392183|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
58392184|NCT02374281|DRUG|Glucose sucking|
57920395|NCT02241954|DEVICE|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
57920396|NCT03560089|DEVICE|Serious game|Serious game with movements
57920397|NCT03560089|DEVICE|Placebo serious game|Serious game without movement
57920398|NCT01813708|BEHAVIORAL|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
57920399|NCT01813708|BEHAVIORAL|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
57920400|NCT04578613|DRUG|ICP-022|ICP-022 at a dose of 150mg, QD
57920401|NCT04578613|DRUG|Chlorambucil|0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
58065250|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
58065251|NCT00340938|PROCEDURE|Blood testing|
58392185|NCT02374281|DRUG|Water sucking|
58392186|NCT02374281|OTHER|No sucking|
57723346|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
57723347|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
57723348|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
57723349|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
57723350|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
57723351|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
57723352|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
57920402|NCT04578613|DRUG|Rituximab|375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
57920403|NCT05052866|BEHAVIORAL|Social Robot|Participants will interact with a social robot companionbot for a period of 8-10 weeks. The robot will stay in participants' apartments.
57920404|NCT06144177|OTHER|Dark with star projector|When in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on.
57920405|NCT06144177|DRUG|Preoperative midazolam|Midazolam by mouth preoperatively.
57920406|NCT06144177|OTHER|Parental Presence|A parent or guardian will accompany the child into the OR and be present for the start of induction.
57723353|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
57920407|NCT03275753|OTHER|Visual Function Tests|All subjects will undergo a battery of visual function tests
58065252|NCT01087151|DRUG|ABT-263|Oral repeating dose
58065253|NCT01087151|DRUG|rituximab|Intravenous repeating dose
58065254|NCT00001126|DRUG|Cidofovir|
57920408|NCT02931825|BEHAVIORAL|Reminder letter|"The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
58065255|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
57920409|NCT06058169|DEVICE|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
57920410|NCT01803568|OTHER|Exercise|12 weeks of exercise; 4 times pr week
57920411|NCT04596696|BIOLOGICAL|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
58065256|NCT01959087|PROCEDURE|Multiport surgery|
58065257|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
58065258|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
57920412|NCT05276115|OTHER|Interview|Interview discussion with individuals with ptsd.
58274626|NCT02841956|OTHER|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
58274627|NCT00805519|DRUG|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
58274628|NCT00805519|DRUG|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
58274629|NCT00805519|DRUG|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
58274630|NCT00805519|DRUG|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
58274631|NCT05335915|OTHER|Nicotine|Nicotine pouches will be self-administered
57920413|NCT05647850|OTHER|No intervention|No intervention
57920414|NCT05024994|DRUG|E7820|100mg of E7820 QD
58065259|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
58065260|NCT00935766|DRUG|Placebo|
58274632|NCT05335915|OTHER|Cigarette|Cigarette will be smoked
58274633|NCT05389826|DEVICE|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
58274634|NCT02912455|DRUG|canagliflozin|encapsulated (gelatin capsule).
58274635|NCT02912455|DRUG|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
58274636|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58274637|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58274638|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58274639|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58274640|NCT00390624|DRUG|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
58274641|NCT00390624|DRUG|MANNITOL|
58274642|NCT05083052|OTHER|Propolis 15%|oothpaste formulation with 15% propolis.
58274643|NCT05083052|OTHER|Propolis 10%|Toothpaste formulation with 10% propolis.
58274644|NCT05083052|OTHER|Placebo|Formulation of toothpaste without active ingredient.
58274645|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
58274646|NCT05918861|DRUG|Placebo|matching placebo tablets
58274647|NCT03831269|DRUG|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
58274648|NCT03831269|OTHER|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
58274649|NCT02004327|DRUG|DW1029M300mg|DW1029M300mg PO Once
58274650|NCT02004327|DRUG|DW1029M600mg|DW1029M300mg 2 tablets Once
58274651|NCT02004327|DRUG|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
58274652|NCT04344535|BIOLOGICAL|Convalescent Plasma|450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally \> 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
58274653|NCT04344535|BIOLOGICAL|Standard Donor Plasma|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
58274654|NCT04536961|DRUG|Reference Treatment- BMS-986165-01|Specified dose on specified days
58274655|NCT04536961|DRUG|Prototype BMS-986165|Specified dose on specified days
58274656|NCT04536961|DRUG|Famotidine|Specified dose on specified days
58274657|NCT04536961|OTHER|Alcohol|Specified quantity on specified days
58274658|NCT03769194|BIOLOGICAL|VLA15|a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
57723354|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
57723355|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
58065261|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
58065262|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
58274659|NCT03769194|BIOLOGICAL|Placebo|Placebo: PBS (Phosphate Buffered Saline)
58274660|NCT05464251|OTHER|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
58274661|NCT04557956|PROCEDURE|Biopsy|Undergo tumor biopsy
58274662|NCT04557956|PROCEDURE|Computed Tomography|Undergo CT scan
57723356|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
57723357|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
58065263|NCT01742013|DRUG|Placebo|Comparator
58065264|NCT02705339|DRUG|Rociletinib|
58065265|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
58065266|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
58274663|NCT04557956|DRUG|Dabrafenib Mesylate|Given PO
58274664|NCT04557956|PROCEDURE|Echocardiography|Undergo ECHO
58274665|NCT04557956|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58274666|NCT04557956|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58274667|NCT04557956|DRUG|Tazemetostat Hydrobromide|Given PO
58274668|NCT04557956|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
58274669|NCT03433300|DEVICE|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
57723358|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
57723359|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
58065267|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
58274670|NCT03433300|DEVICE|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
58274671|NCT03886714|DIAGNOSTIC_TEST|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
58274672|NCT03886714|DIAGNOSTIC_TEST|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
58274673|NCT00261898|PROCEDURE|Increase sleep|
58274674|NCT05061485|OTHER|Sucrose|The participants consume A) water with 75 g sucrose
58274675|NCT05061485|OTHER|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
58274676|NCT05061485|OTHER|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
58274677|NCT01971632|DRUG|Oxycodone & naloxone combination, prolonged release|
58274678|NCT01971632|DRUG|placebo oxycodone / naloxone|
58274679|NCT01688141|OTHER|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
58274680|NCT05687838|OTHER|Music|Music medicine
58274681|NCT04026711|DRUG|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
58274682|NCT04026711|DRUG|Placebo oral tablet|Placebo daily for 12 weeks
58274683|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
57920415|NCT05097027|DEVICE|Blood flow restriction recovery|Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to \~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
57920416|NCT05097027|OTHER|Active recovery|Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
58274684|NCT05823467|DRUG|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
58274685|NCT05823467|DEVICE|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
58274686|NCT01839799|DRUG|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
58274687|NCT01839799|DRUG|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
58274688|NCT01839799|DRUG|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
58274689|NCT01839799|RADIATION|Chemoradiation|
58392187|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
58392188|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
57723360|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
57723361|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
57920417|NCT04440982|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
58065268|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
58065269|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
58065270|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
58065271|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
58065272|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
58065273|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
58274690|NCT00181649|DRUG|Recombinant human prolactin|
58274691|NCT02563691|RADIATION|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
58274692|NCT03186989|DRUG|IONIS MAPTRx|"Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48 weeks."
58274693|NCT03186989|OTHER|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
58274694|NCT03032172|DRUG|Risdiplam|Risdiplam will be administered orally once daily.
58274695|NCT01294748|DEVICE|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
58274696|NCT01294748|DEVICE|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
58274697|NCT02778386|DRUG|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
58274698|NCT02778386|OTHER|Placebo Capsule|Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
57723362|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
58065274|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
58274699|NCT01618916|DRUG|LY3015014|Administered SC
58274700|NCT01618916|OTHER|Placebo|Administered SC
58274701|NCT01944826|OTHER|Registry of patients with Tako-Tsubo cardiomyopathy|
58274702|NCT01926197|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
58274703|NCT01926197|DRUG|Irinotecan|Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.
58274704|NCT01926197|DRUG|Leucovorin|Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
58274705|NCT01926197|DRUG|5FU|5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
58274706|NCT01926197|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.
58274707|NCT03197740|DRUG|Donepezil patch|Treatment
58274708|NCT03197740|DRUG|aricept Tab|Comparator
58274709|NCT02685072|DRUG|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
58392189|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
57920418|NCT04597528|OTHER|Elective Induction|"All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet."
57920419|NCT05998356|DEVICE|Balloon Eustachian Tuboplasty (BET) under general anesthesia.|Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer.
57920420|NCT05998356|DEVICE|Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia|Participants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study.
58392190|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
58392191|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
58392192|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
57723363|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
58274710|NCT02685072|DRUG|Placebo|TNP + Placebo
58274711|NCT02957604|DRUG|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
58274712|NCT04256213|DRUG|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
58274713|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
58274714|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
58274715|NCT01761305|PROCEDURE|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
58274716|NCT01761305|BEHAVIORAL|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
58274717|NCT01761305|OTHER|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
58274718|NCT00421317|DRUG|Imatinib|800 mg/day until disease progression or toxicity
58274719|NCT00669019|DRUG|saracatinib|
58274720|NCT06730737|OTHER|Video preventive education|Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
57723364|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
58065275|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
58065276|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
57723365|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
57723366|NCT01734668|DEVICE|In Vitro Diagnostic device to aid in diagnosis|
57723367|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
58392193|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
57723368|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
57723369|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
57723370|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
57723371|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
57723372|NCT03299140|BEHAVIORAL|Family Focused Therapy|
57723373|NCT01421810|DRUG|Dexamethasone|1 mg PO
57723374|NCT01421810|DRUG|rhCG|25 mcg IV
58274721|NCT04849533|DRUG|Belatacept|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
57723375|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
57723376|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
57723377|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
57723378|NCT01154634|DRUG|Placebo|Capsule, oral
58274722|NCT04849533|DRUG|Everolimus|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
58274723|NCT04849533|DRUG|mycophenolate mofetil|belatacept with mycophenolate is approved regimen for prevention of rejection
58274724|NCT04849533|DRUG|corticosteroids|belatacept with chronic steroids is approved regimen for prevention of rejection
58274725|NCT04849533|DRUG|rabbit antithymocyte globulin|rabbit antithymocyte globulin induction for prevention of rejection
57723379|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
57723380|NCT00085410|DRUG|bortezomib|Given IV
57723381|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
57723382|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
57920421|NCT04316208|PROCEDURE|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
57920422|NCT05430893|OTHER|Botulinum Toxin A|100 UI IM in the adductor longus
57920423|NCT02982915|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
57920424|NCT02982915|BIOLOGICAL|Fluzone High Dose Vaccine|Intramuscular injection
57723383|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
57920425|NCT01556893|DEVICE|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
58274726|NCT00659776|DRUG|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
58392194|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
57723384|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
57920426|NCT00210977|DRUG|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
57920427|NCT04206579|DRUG|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
57920428|NCT04206579|DRUG|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
57920429|NCT02564926|DRUG|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
57920430|NCT02564926|DRUG|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
57920431|NCT00515983|BIOLOGICAL|DC/Apo-Nec|
57723385|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
57920432|NCT01941797|BEHAVIORAL|interruption of oral hygiene|
57920433|NCT06422780|OTHER|Maternal Role Preparation Training|Maternal Role Preparation Training: Maternal Role Preparation Training (MRHE) is an occupational training programme aimed at increasing the competence of first-time mothers regarding motherhood. In this four-session programme, pregnant women will be provided with written materials, face-to-face talks and practical training covering topics related to their babies (maternal attachment, training on the sensory and developmental abilities of babies) and themselves (training on adopting a new role as a mother).The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions.
57723386|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
57920434|NCT06422780|OTHER|Awareness Centred Occupational Therapy Group|Awareness Centred Occupational Therapy (FME); In FME, areas that affect the occupational performance of pregnant women in their daily lives will be identified and appropriate occupational therapy interventions will be applied. Awareness training on the applications will be given before starting the sessions. The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions. Awareness training will be given before starting the sessions.
57920435|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 3 weeks|3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
57920436|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 4.5 weeks|4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
57920437|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 6 weeks|6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
57920438|NCT04364854|OTHER|No Therapy 6 Weeks|Participants will not be getting any SET for 6 weeks
57920439|NCT03169322|PROCEDURE|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
57920440|NCT00771563|DRUG|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
58274727|NCT04104594|DIAGNOSTIC_TEST|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
58274728|NCT04104594|OTHER|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
57723387|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
57723388|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
57723389|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
57723390|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
57920441|NCT00771563|DRUG|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
57723391|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
57723392|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
57723393|NCT03046680|OTHER|Health Coaching|
58065277|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
58274729|NCT04104594|OTHER|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
58274730|NCT04104594|OTHER|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
58274731|NCT04104594|BIOLOGICAL|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
57723394|NCT03046680|OTHER|Multiprofessional Team|
57723395|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
57920442|NCT03588728|OTHER|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
57920443|NCT03588728|BEHAVIORAL|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
57920444|NCT02313233|DIETARY_SUPPLEMENT|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
57920445|NCT02313233|DIETARY_SUPPLEMENT|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
57920446|NCT02580695|BIOLOGICAL|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
57920447|NCT02580695|DRUG|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
58274732|NCT04482036|OTHER|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
58274733|NCT04482036|OTHER|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
58274734|NCT02174575|DRUG|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
58274735|NCT02174575|DRUG|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
58274736|NCT01126008|DRUG|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
58274737|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
58274738|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
57920448|NCT05121987|PROCEDURE|Erector Spinae Plane block|An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
58065278|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
57723396|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
58065279|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
58065280|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
58065281|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
58065282|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
58065283|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
57920449|NCT05121987|PROCEDURE|Continuous Wound Infusion|Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
58065284|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
58274739|NCT00372047|DEVICE|multiphoton laser imaging|
58274740|NCT03965455|DEVICE|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
58065285|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
57723397|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
58065286|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
58065287|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
58274741|NCT03965455|PROCEDURE|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
57723398|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
58065288|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
58065289|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
58065290|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
58065291|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
58065292|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
58274742|NCT02865200|OTHER|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
58490373|NCT06133062|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
58274743|NCT02865200|OTHER|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
58274744|NCT01879033|OTHER|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
58392195|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
58392196|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
58065293|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
58274745|NCT01879033|OTHER|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
58274746|NCT00222222|PROCEDURE|vein puncture|comparison of different inflammatory markers in the blood of septic patients
58274747|NCT04956627|DRUG|BMS-986166|Specified dose on specified days
58274748|NCT04956627|DRUG|Itraconazole|Specified dose on specified days
58274749|NCT04956627|DRUG|Extended Phenytoin Sodium|Specified dose on specified days
58274750|NCT04956627|DRUG|Gemfibrozil|Specified dose on specified days
58392197|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
58392198|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
58392199|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
58392200|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
58392201|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
58392202|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
58392203|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
58490374|NCT06133062|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
57723399|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
58490375|NCT00685568|DRUG|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
57723400|NCT05734482|BIOLOGICAL|Secukinumab|for subcutaneous injection only
57723401|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
57723402|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
58065294|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
58392204|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
57723403|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
57723404|NCT02567422|DRUG|Berzosertib|Given IV
57723405|NCT02567422|DRUG|Cisplatin|Given IV
57723406|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57723407|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
57723408|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57723409|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57723410|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
57920450|NCT00511472|DRUG|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
58065295|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
58065296|NCT00212615|DRUG|Capecitabine (Xeloda)|
58392205|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
58392206|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
58392207|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
57723411|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
57723412|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
57723413|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
57723414|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
57723415|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
57723416|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
57723417|NCT03320447|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
57723418|NCT03320447|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
57723419|NCT03320447|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
57723420|NCT03320447|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
57723421|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
57920451|NCT00511472|DRUG|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
58065297|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
57723422|NCT04695301|OTHER|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
57723423|NCT02317575|BIOLOGICAL|LY900014|Administered SC
57723424|NCT02317575|BIOLOGICAL|Insulin Lispro|Administered SC
58065298|NCT02026193|PROCEDURE|oocyte vitrification|
57723425|NCT01384344|OTHER|observational|Observation during a physical exercise
58065299|NCT02026193|PROCEDURE|embryo freezing|
58065300|NCT02565303|PROCEDURE|Intervertebral space|
58065301|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
58392208|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
57723426|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
57920452|NCT00511472|DRUG|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
57920453|NCT03045601|DIAGNOSTIC_TEST|CT-FFR|Invasive FFR and CCTA With CT-FFR
57920454|NCT03045601|DIAGNOSTIC_TEST|Stress echocardiography|Stress echocardiography and invasive FFR
57920455|NCT06367920|DIAGNOSTIC_TEST|Magnetic Resonance Imaging, Behavioral assessments|Magnetic Resonance Imaging, Behavioral assessments
57920456|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
57920457|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
57920458|NCT03553368|DIAGNOSTIC_TEST|MR|MRI data will be acquired without the use of any device as a reference.
57920459|NCT03553368|DIAGNOSTIC_TEST|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
57920460|NCT03553368|DIAGNOSTIC_TEST|CPAP-MR|MRI data will be acquired with the use of CPAP.
57920461|NCT01399333|DIETARY_SUPPLEMENT|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
58392209|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
58392210|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
58392211|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
58392212|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
58392213|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
58392214|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
58392215|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
58490376|NCT00685568|OTHER|placebo|Orally, twice daily for 3 months
57723427|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
57723428|NCT02455908|DRUG|Proleukin®|
57723429|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
57723430|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
57920462|NCT01399333|DIETARY_SUPPLEMENT|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
57920463|NCT01399333|DIETARY_SUPPLEMENT|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
57920464|NCT05269810|DRUG|SA001 Low dose|3 tablets b.i.d for 8 weeks
58490377|NCT01915069|DRUG|Cilostazol|
57723431|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
57723432|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
57920465|NCT05269810|DRUG|SA001 Mid dose|3 tablets b.i.d for 8 weeks
57920466|NCT05269810|DRUG|SA001 High dose|3 tablets b.i.d for 8 weeks
57920467|NCT05269810|DRUG|Placebo|3 tablets b.i.d for 8 weeks
57920468|NCT03728556|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
57920469|NCT03728556|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
57920470|NCT06526351|DEVICE|Early implant placement with immediate provisional restoration|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.
57920471|NCT06526351|DEVICE|Early implant placement with delayed loading|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
57920472|NCT02228655|DRUG|FMX-8|
57920473|NCT02136160|BEHAVIORAL|attitude change, behavioral change|
57920474|NCT02136160|BEHAVIORAL|prevention program|
58065302|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
58065303|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
58065304|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
58392216|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
57723433|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
57723434|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
57920475|NCT05291000|BEHAVIORAL|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
58065305|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
58274751|NCT01210144|DRUG|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
58274752|NCT01210144|DRUG|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
58392217|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
57920476|NCT03090815|GENETIC|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
58065306|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
58274753|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
57723435|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
57723436|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
57723437|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
57723438|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
57723439|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
57723440|NCT03578900|DRUG|Xeros|
57723441|NCT03578900|DRUG|Citric Acid based Mouthwash|
57723442|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
57723443|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
57723444|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
57723445|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
57920477|NCT03622554|OTHER|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
58065307|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
58065308|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
58065309|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
58065310|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
58065311|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
58065312|NCT01483378|OTHER|Choosing to receive the vaccine|
58065313|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
58065314|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
58065315|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
58065316|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
58065317|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
58065318|NCT00364351|DRUG|Vandetanib|once daily oral tablet
57723446|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
57723447|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
57723448|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
57920478|NCT03622554|OTHER|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
57723449|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
57723450|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
57723451|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
57723452|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
57723453|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
57723454|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
57723455|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
58065319|NCT00364351|DRUG|Erlotinib|oral dose
58065320|NCT00104429|DRUG|GW873140|
57723456|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
57920479|NCT03656523|OTHER|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
58065321|NCT00104429|DRUG|Combivir|
58065322|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
58065323|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
58065324|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
58065325|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
57723457|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
57723458|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
57723459|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
57723460|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
57920480|NCT00000577|DRUG|Albuterol|
57920481|NCT00000577|DRUG|Colchicine|
57920482|NCT00000577|DRUG|Adrenal Cortex Hormones|
57723461|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
57920483|NCT00000577|DRUG|Adrenergic-Beta Agonists|
57920484|NCT04732533|OTHER|tDCS (transcranial direct current stimulation)|"Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tDCS. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tDCS sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tDCS. The participant can complete up to 5 tDCS sessions per week over 52 weeks."
57920485|NCT03318705|DEVICE|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
57920486|NCT01210066|DRUG|Fentanyl|IV fentanyl 1mcg/kg
57920487|NCT01210066|OTHER|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
57920488|NCT01210066|OTHER|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
58274754|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
58065326|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
58274755|NCT04150068|DRUG|Oral Lenacapavir|Tablets administered without regard to food
58274756|NCT04150068|DRUG|Oral Lenacapavir Placebo|Tablets administered without regard to food
58065327|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
58274757|NCT04150068|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
58274758|NCT04150068|DRUG|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
58274759|NCT04150068|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
58274760|NCT05721300|DRUG|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
58274761|NCT05721300|DRUG|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
58065328|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
57723462|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
57723463|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
57920489|NCT00002023|DRUG|Zidovudine|
58065329|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
58065330|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
58065331|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
58065332|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
58065333|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
58065334|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
58274762|NCT01285492|DRUG|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
58274763|NCT01285492|DRUG|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
58274764|NCT04383340|BEHAVIORAL|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
58274765|NCT04383340|BEHAVIORAL|Treatment as usual|Standard hospital care and parental support
58274766|NCT05639504|DIAGNOSTIC_TEST|IMX-BVN-4 and IMX-SEV-4|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
58065335|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
58065336|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
58065337|NCT02041533|BIOLOGICAL|Nivolumab|
58065338|NCT02041533|DRUG|Gemcitabine|
58065339|NCT02041533|DRUG|Cisplatin|
58274767|NCT03905538|DRUG|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
58274768|NCT04621643|BEHAVIORAL|digital cognitive behavioral therapy (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
58274769|NCT04621643|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
58274770|NCT05822583|DRUG|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
58274771|NCT05822583|DRUG|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
58274772|NCT06184906|DIETARY_SUPPLEMENT|Weaning by Mediterranean Diet|Introduce solid foods typical of the Mediterranean Diet at weaning of infants
58274773|NCT00997217|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
58274774|NCT00766844|DEVICE|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
58274775|NCT04610450|DEVICE|HEARO|Robotic system for otological procedures
58065340|NCT02041533|DRUG|Carboplatin|
58065341|NCT02041533|DRUG|Paclitaxel|
58065342|NCT02041533|DRUG|Pemetrexed|
58065343|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
58065344|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
58065345|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
58065346|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
58065347|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
58065348|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
58274776|NCT04610450|DEVICE|OTOPLAN|Otological surgical planning software
58274777|NCT01980498|DRUG|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
58274778|NCT01980498|DRUG|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
57723464|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
57723465|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
57723466|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
58065349|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
58065350|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
58065351|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
58392218|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
58392219|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
58392220|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
57723467|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
57723468|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
57723469|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
57723470|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
57723471|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
57723472|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
57723473|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
57723474|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
57723475|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
57723476|NCT02329405|DRUG|Rifampicin|
57723477|NCT02329405|DRUG|Placebo|
57723478|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
57723479|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
57723480|NCT04321460|DRUG|Placebo|Capsules containing placebo
57723481|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
57723482|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
57723483|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
57723484|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
57723485|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
57723486|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
57723487|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
58065352|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
58065353|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
58065354|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
58065355|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
58065356|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
58065357|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
58065358|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
58065359|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
58065360|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
58065361|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
58274779|NCT00535392|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
57723488|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
57723489|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
58274780|NCT00201812|DRUG|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
58392221|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
58065362|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
58065363|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
58065364|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
58065365|NCT05867849|DRUG|Cannabidiol|Cannabinoid
58065366|NCT05867849|OTHER|Placebo|Inactive substance
58065367|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
58274781|NCT00201812|DRUG|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
58274782|NCT00201812|DRUG|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
58392222|NCT00432328|DRUG|Avotermin|
58392223|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
58392224|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
58392225|NCT02822183|OTHER|Online Survey|
58392226|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
57723490|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
57723491|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
57723492|NCT01834365|OTHER|Structured education|Formatted education about hypertension
57723493|NCT01834365|OTHER|Checklist|
57723494|NCT01834365|OTHER|Without structure education with checklist|
57723495|NCT03021187|DRUG|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
57723496|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
57920490|NCT02446886|DRUG|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
57920491|NCT02838433|OTHER|biological samples|blood and tissue samples
57920492|NCT02849288|DEVICE|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
57920493|NCT02674789|BEHAVIORAL|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
57920494|NCT01578759|PROCEDURE|Salpingectomy|Removal of the fallopian tubes
57920495|NCT00624143|DRUG|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
58065368|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
58274783|NCT02816541|OTHER|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
58274784|NCT02816541|OTHER|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
57723497|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
57723498|NCT03021187|DRUG|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
57723499|NCT04982042|OTHER|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
57920496|NCT02582723|OTHER|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
57920497|NCT02582723|OTHER|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
57920498|NCT02582723|OTHER|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
57920499|NCT04744285|OTHER|Cigarette packaging|receive normal packet cigarette
57920500|NCT04744285|OTHER|Data capture|Attend video sessions
57920501|NCT04744285|OTHER|Questionnaire administration|Ancillary studies
57920502|NCT05150496|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
58065369|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
58274785|NCT02816541|OTHER|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
58274786|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
58274787|NCT01025648|DRUG|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
57920503|NCT05150496|BIOLOGICAL|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
57920504|NCT00589082|DRUG|DaunoXome|
57920505|NCT00589082|DRUG|Daunorubicine|
57920506|NCT04217928|PROCEDURE|Arthroscopic Debridement|Arthroscopic debridement will be performed under portal site local anaesthesia.
57920507|NCT04217928|PROCEDURE|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
58065370|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
58274788|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
58274789|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
57920508|NCT01462838|BIOLOGICAL|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
57920509|NCT06078839|DRUG|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
57920510|NCT06078839|DRUG|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
57920511|NCT02179723|DEVICE|Leukosan Adhesive|Leukosan adhesive applied to one wound
57920512|NCT02179723|DEVICE|Transcutaneous suture|Transcutaneous suture applied to one wound
57920513|NCT01350336|DEVICE|Alair System|Treatment of airways with the Alair System
57920514|NCT00634660|DRUG|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
58392227|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
58274790|NCT01025648|DRUG|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
57920515|NCT02237651|DEVICE|topical anesthesia multi-use device|
58065371|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
58274791|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
58274792|NCT01832909|OTHER|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
58274793|NCT01832909|OTHER|Control Diet|Controlled diet without walnuts.
58274794|NCT00507832|DRUG|Pimecrolimus|twice daily topical
58274795|NCT00507832|DRUG|Hydrocortisone|twice daily topical
58274796|NCT00507832|DRUG|Pimecrolimus|topical application as a cream twice daily
58274797|NCT00494221|DRUG|AZD2171|oral tablet
58274798|NCT00494221|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
58274799|NCT00494221|DRUG|Placebo Cediranib|oral tablet
58274800|NCT01366638|DRUG|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
58274801|NCT01366638|DRUG|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
57723500|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
58274802|NCT01366638|DRUG|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
58392228|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
58392229|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
58392230|NCT04662775|BEHAVIORAL|HERizon Project|"1. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
57723501|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
57723502|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
57723503|NCT05341089|DRUG|LY3502970|Administered orally.
57920516|NCT02237651|DEVICE|topical anesthesia Intranasal Mucosal Atomization|
57920517|NCT06323018|PROCEDURE|Remote Ischemic Preconditioning|4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)
57920518|NCT06323018|OTHER|SHAM|4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
57920519|NCT06311604|DRUG|Isoflurane|"Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
57920520|NCT06236282|DEVICE|ArtiSential®|Articulated laparoscopic device made by Livsmed Co, South Korea.
57920521|NCT04743167|PROCEDURE|Surgery|Laparoscopic treatment of endometriotic lesions
57920522|NCT04743167|PROCEDURE|IVF|Up to three completed cycles of IVF
58392231|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
57920523|NCT02263937|PROCEDURE|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
57920524|NCT02263937|PROCEDURE|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
57920525|NCT02501538|DEVICE|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
57920526|NCT05328323|OTHER|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
57920527|NCT00465946|BEHAVIORAL|Salt Supplementation|
58392232|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
58065372|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
58065373|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
58392233|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
58392234|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
58065374|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
58392235|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
58392236|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
58392237|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
58392238|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
58392239|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
58392240|NCT01707680|OTHER|SOC|Patient are given standard of care
57723504|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
57920528|NCT04876742|OTHER|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
58392241|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
58392242|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
57920529|NCT04876742|OTHER|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
57920530|NCT00002565|BIOLOGICAL|bleomycin sulfate|
58392243|NCT00351767|DRUG|placebo|Topically applied
58392244|NCT00351767|DRUG|telbermin|Topically applied
57920531|NCT00002565|DRUG|CHOP regimen|
57920532|NCT00002565|DRUG|cisplatin|
57920533|NCT00002565|DRUG|cyclophosphamide|
57920534|NCT00002565|DRUG|cytarabine|
58065375|NCT00001343|DRUG|Humatrope|
58065376|NCT00001343|DRUG|Oxandrolone|
58065377|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
58065378|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
58065379|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
58065380|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
58065381|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
58392245|NCT01309997|DRUG|imatinib mesylate|Given PO
58392246|NCT01309997|BIOLOGICAL|rituximab|Given IV
58392247|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
58392248|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
58392249|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
58392250|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
57920535|NCT00002565|DRUG|doxorubicin hydrochloride|
57920536|NCT00002565|DRUG|etoposide|
57920537|NCT00002565|DRUG|idarubicin|
58065382|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
57920538|NCT00002565|DRUG|ifosfamide|
57920539|NCT00002565|DRUG|mesna|
57920540|NCT00002565|DRUG|methylprednisolone|
57723505|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
57920541|NCT00002565|DRUG|mitoxantrone hydrochloride|
57920542|NCT00002565|DRUG|prednisone|
57920543|NCT00002565|DRUG|vincristine sulfate|
57920544|NCT04934488|BEHAVIORAL|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
57920545|NCT03298685|OTHER|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
58065383|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
58392251|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
58392252|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
58392253|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
57920546|NCT05208866|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
57920547|NCT03458065|DEVICE|ICD|Implantable Cardioverter Defibrillator
57920548|NCT00165087|DRUG|asparaginase (E. Coli)|
57920549|NCT00165087|DRUG|asparaginase (Erwina)|
57920550|NCT00165087|DRUG|dexrazoxane|
57920551|NCT00165087|DRUG|doxorubicin|
57920552|NCT00165087|PROCEDURE|cranial radiation (once daily fractionation)|
57920553|NCT00165087|PROCEDURE|cranial radiation (twice-daily fractionation)|
57920554|NCT00165087|PROCEDURE|Intrathecal chemotherapy without radiation|
57920555|NCT03760705|OTHER|Data Collection|"1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
57920556|NCT02137720|BEHAVIORAL|Telephonic Diabetes Self-Management Support|
57920557|NCT02137720|OTHER|Educational Print Materials|
58065384|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
57723506|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
57723507|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
57920558|NCT00713115|PROCEDURE|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
57920559|NCT01247571|DRUG|Pazopanib Hydrochloride|Given PO
57920560|NCT05999968|DRUG|Abemaciclib|Administered orally.
57920561|NCT05999968|DRUG|Darolutamide|Administered orally.
58065385|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
58065386|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
57920562|NCT05999968|DRUG|LHRH agonist/antagonist|Physician's choice. Administered in accordance with the prescribing information.
57920563|NCT03207685|DEVICE|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
57920564|NCT03186196|DIETARY_SUPPLEMENT|Diet containing Folate|
57920565|NCT02920931|DRUG|Tenofovir disoproxil|
57723508|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
57723509|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
57723510|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
57723511|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
57723512|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
57723513|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
57723514|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
57723515|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
57723516|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
58274803|NCT03595267|OTHER|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations."
58274804|NCT05506514|OTHER|Water immersion|Comparison of 3 different water temperatures
58274805|NCT04627961|DRUG|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
58274806|NCT06112795|OTHER|Non-Interventional Study|Non-interventional study
58274807|NCT03246841|OTHER|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
58274808|NCT06671938|DRUG|exidavnemab|The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
58274809|NCT06671938|DRUG|Placebo Comparator|The trial medication will be administered as an intravenous (IV) infusion
58274810|NCT00006341|OTHER|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
58274811|NCT00889187|RADIATION|Neoadjuvant Short-Course Photon Radiation|
58274812|NCT00889187|DRUG|Capecitabine|
58274813|NCT05461937|BEHAVIORAL|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
58274814|NCT05461937|BEHAVIORAL|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
58274815|NCT03061240|DEVICE|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
58392254|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
58392255|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
57723517|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
57723518|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
57723519|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
57723520|NCT02677545|DRUG|Ticagrelor|
58274816|NCT05014269|PROCEDURE|Phacoemulsification in eyes with corneal opacities|senile cataract extraction using lens emulsification under the slit illuimnation of the surgical microscope
58274817|NCT05717803|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
58274818|NCT05999656|BIOLOGICAL|human cord blood-derived mononuclear cells (HCB-MNCs)|All patients received cell therapy for the first time. HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet, with an interval of about a centimeter between every two points and an injection volume of 0.2ml at each puncture point. The total injection volume required by the patients was the injection needles multiply 0.2ml (about 2ml of suspended cell in total). The remaining suspension was injected on both sides of the center of the main ischemic site. All patients received three injections of umbilical cord blood mononuclear cells at a week interval, with the latter two injections located around the site of the first injection. The adjuvant therapy remained unchanged within two weeks after cell injection. The follow-up period is 12 weeks after treatment to observe safety and efficacy. If the patient does not recover after 12 weeks, the follow-up period can be extended to 24 weeks.
58274819|NCT02253550|DRUG|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
58274820|NCT02253550|DRUG|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
58274821|NCT01054391|DEVICE|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
58274822|NCT01287975|OTHER|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
58274823|NCT01287975|DEVICE|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
58274824|NCT01287975|DEVICE|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
58274825|NCT04633902|DRUG|Olaparib|Olaparib 300 mg BID daily
58274826|NCT04633902|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
58274827|NCT04720950|OTHER|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
58392256|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
58392257|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
57723521|NCT02677545|DRUG|Clopidogrel|
57723522|NCT02677545|DRUG|Aspirin|
57723523|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
58274828|NCT02862132|DRUG|Vedolizumab|
58274829|NCT04902729|DRUG|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
58392258|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
58392259|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
58065387|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
58065388|NCT00347685|DRUG|tramadol ER|
58065389|NCT00003159|DRUG|carboplatin|
57723524|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
57723525|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
57723526|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
57723527|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
57723528|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
57920566|NCT02254525|DRUG|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
57920567|NCT02254525|DRUG|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
57920568|NCT00094042|DRUG|Iron Supplement, 120mg|
57920569|NCT06128993|OTHER|Transcoronary cooling and dilution|Transcoronary cooling and dilution
57920570|NCT06128993|OTHER|Standard of care|Routine clinical care
57920571|NCT00676819|DRUG|insulin aspart|
57920572|NCT00676819|DRUG|human insulin|
57920573|NCT01400555|DRUG|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
58065390|NCT00003159|DRUG|cisplatin|
58065391|NCT00003159|DRUG|docetaxel|
58065392|NCT00003159|DRUG|gemcitabine hydrochloride|
58065393|NCT00003159|DRUG|ifosfamide|
58065394|NCT00003159|DRUG|mitomycin C|
57920574|NCT01400555|DRUG|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
58065395|NCT00003159|DRUG|paclitaxel|
58065396|NCT00003159|DRUG|vinblastine sulfate|
58065397|NCT00003159|DRUG|vinorelbine tartrate|
58065398|NCT00003159|PROCEDURE|conventional surgery|
58065399|NCT00003159|PROCEDURE|neoadjuvant therapy|
58065400|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
58065401|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
58065402|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
58065403|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
58065404|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
58392260|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
57920575|NCT01400555|DRUG|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
58065405|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
58392261|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
58392262|NCT00002848|PROCEDURE|psychosocial assessment and care|
58065406|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
57920576|NCT01400555|DRUG|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
57920577|NCT03782025|DRUG|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
58065407|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
58065408|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
58392263|NCT00002848|PROCEDURE|quality-of-life assessment|
57920578|NCT05137353|BEHAVIORAL|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
57920579|NCT05137353|BEHAVIORAL|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
58065409|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
58065410|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
58065411|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
58065412|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
58274830|NCT04902729|DRUG|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
58274831|NCT01048086|DRUG|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.
58274832|NCT01048086|DRUG|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
58274833|NCT03611582|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
58274834|NCT03611582|DRUG|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
58274835|NCT04655534|OTHER|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
58274836|NCT04655534|OTHER|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
58274837|NCT04655534|OTHER|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
58274838|NCT06397924|DIETARY_SUPPLEMENT|Chitin Fiber|Dietary fiber isolated from an edible insect (chitin)
58392264|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
57723529|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
57920580|NCT06350578|PROCEDURE|Hall Crown Technique|The Hall technique (HT) involves cementing Stainless Steel Crowns SSC on carious primary teeth without using rotary instruments nor local anaesthesia, thus eliminating discomfort, and increasing child's behavior.
57920581|NCT06350578|PROCEDURE|Conventional SSC Technique|The conventional technique involves complete removal of the carious lesion using rotary instruments and local anesthesia, then restoring the tooth with Stainless Steel Crown SSC.
57920582|NCT03433248|DRUG|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
57920583|NCT03433248|DRUG|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
57920584|NCT03433248|DRUG|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
57920585|NCT06117098|DEVICE|Mobile application|Individual lifestyle intervention via an mobile application
57920586|NCT06117098|BEHAVIORAL|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"
57920587|NCT06117098|BEHAVIORAL|Group-based lifestyle intervention|Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
57723530|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
58274839|NCT06397924|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58392265|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
58392266|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
58392267|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
58392268|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
57723531|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
57723532|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
57723533|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
57723534|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
57723535|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
57920588|NCT00544388|DRUG|levocetirizine dihydrochloride|
57920589|NCT01284660|DIETARY_SUPPLEMENT|DHA|DHA ingested orally by heavy smokers
57920590|NCT01284660|DIETARY_SUPPLEMENT|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
57920591|NCT03739177|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
57920592|NCT05615090|PROCEDURE|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
57920593|NCT05615090|PROCEDURE|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
57920594|NCT03404830|OTHER|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
57920595|NCT05826574|DRUG|Brensocatib|Oral tablets.
57920596|NCT05826574|DRUG|Rifampin|Oral capsules.
57920597|NCT05826574|DRUG|Esomeprazole|Oral capsules.
57920598|NCT04697303|OTHER|anorectal function test|anorectal function test
57920599|NCT06151054|DIAGNOSTIC_TEST|Measure of aortic inflammation|Standard Uptake Value (SUV) measures of aortic wall
58392269|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
58392270|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
57723536|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
57723537|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
57723538|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
58065413|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
58065414|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
57920600|NCT05031403|OTHER|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
58065415|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
58065416|NCT02254694|OTHER|high heeled shoes|see detailed study description
58065417|NCT01840566|DRUG|Carmustine|
58392271|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
57920601|NCT05031403|OTHER|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
57920602|NCT02843971|DEVICE|Intraocular pressure measurement with the Sensimed triggerfish Device|
57920603|NCT02902003|BEHAVIORAL|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
58065418|NCT01840566|DRUG|Etoposide|
58065419|NCT01840566|DRUG|Cytarabine|
58065420|NCT01840566|DRUG|Melphalan|
58065421|NCT01840566|BIOLOGICAL|Pegfilgrastim|
58065422|NCT01840566|BIOLOGICAL|19-28z T CELLS|
58065423|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
58392272|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
58392273|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
58392274|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
58392275|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
58065424|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
58065425|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
58065426|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
58065427|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
58392276|NCT02110654|DRUG|Montelukast|
58392277|NCT02110654|DRUG|mometasone furoate nasal spray|
57723539|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
57723540|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
57723541|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
57723542|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
57723543|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
57723544|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
57723545|NCT01427244|DRUG|trastuzumab|monoclonal antibody
58065428|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
57723546|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
57723547|NCT00766415|DRUG|Placebo|Placebo
58065429|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
58065430|NCT03894111|OTHER|decesased patients|mortality ratio
58065431|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
58065432|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
58065433|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
57723548|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
58065434|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
58065435|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
58065436|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
58065437|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
58065438|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
57723549|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
57723550|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
57723551|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
57723552|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
57723553|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
57723554|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
57723555|NCT02454426|DRUG|Vortioxetine|open label treatment
57723556|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
57723557|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
57723558|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
57723559|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
57723560|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
57723561|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
57920604|NCT01207726|DRUG|Azacitidine|Given SC
57920605|NCT01207726|DRUG|Entinostat|Given PO
58065439|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
58065440|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
58065441|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
58065442|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
57920606|NCT01207726|OTHER|Laboratory Biomarker Analysis|Correlative studies
58392278|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
57920607|NCT03800641|DRUG|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
58274840|NCT06730269|BEHAVIORAL|Face-to-Face Rehabilitation Program|The Face-to-Face Rehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group engaged in the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction. The exercises were performed three times per week over six weeks, under the direct supervision of a trained therapist. This setup ensured real-time feedback, personalized adjustments, and guidance during each session, optimizing the effectiveness of the rehabilitation process.
57920608|NCT02260882|BIOLOGICAL|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
57920609|NCT02778711|DRUG|secukinumab|anti-IL-17
57920610|NCT00004252|DRUG|fluorouracil|
58274841|NCT06730269|BEHAVIORAL|Telerehabilitation Program|The Telerehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group followed the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction, performed three times per week over six weeks. The program was delivered remotely through the Fiziu platform, allowing therapists to provide virtual guidance, feedback, and monitoring during the sessions. This approach offered flexibility for families and ensured accessibility to rehabilitation services from the comfort of their homes.
58274842|NCT04750200|PROCEDURE|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
57920611|NCT00004252|DRUG|leucovorin calcium|
57920612|NCT00004252|DRUG|semaxanib|
58274843|NCT06521112|DRUG|Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.|Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
58392279|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
58392280|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
57920613|NCT00081874|DRUG|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
57920614|NCT01391585|OTHER|Text Message prompts|In this single armed intervention, patients will receive text message prompts
58065443|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
58065444|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
57920615|NCT02373553|OTHER|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
57920616|NCT02373553|OTHER|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
58065445|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
57920617|NCT00006380|BIOLOGICAL|monoclonal antibody muJ591|
57920618|NCT00006380|RADIATION|iodine I 131 monoclonal antibody muJ591|
57920619|NCT04834206|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
57920620|NCT04834206|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
57920621|NCT04834206|DRUG|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
57920622|NCT04357860|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
58274844|NCT04875689|OTHER|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations"
58274845|NCT04875689|DIAGNOSTIC_TEST|Group B (Control)|"1. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
57920623|NCT04357860|DRUG|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
57920624|NCT04357860|DRUG|Best available treatment|Best available treatment up to 14 days
57920625|NCT06389253|OTHER|Histological Analysis|For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed
57920626|NCT03201705|DEVICE|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
57920627|NCT05090748|DEVICE|Echocardiographic.|Echocardiographic test.
57920628|NCT04129853|DEVICE|Cyberlegs Xleg|Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
57920629|NCT05244889|BEHAVIORAL|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
58065446|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
58274846|NCT01084213|DRUG|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
58274847|NCT01084213|DRUG|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
58065447|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
58065448|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
58065449|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
58392281|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
58392282|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
57920630|NCT05244889|BEHAVIORAL|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
57920631|NCT00293631|DRUG|Lornoxicam 8 mg|
57920632|NCT00293631|DRUG|Lornoxicam 16 mg|
57920633|NCT00293631|DRUG|Ketorolac 30 mg|
58392283|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
58065450|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
58392284|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
58392285|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
58392286|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
58392287|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
58065451|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
58274848|NCT04018807|OTHER|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
58274849|NCT04018807|BEHAVIORAL|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
58392288|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
58392289|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
57920634|NCT00293631|DRUG|Placebo|
57920635|NCT00624923|DRUG|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
57920636|NCT00624923|DRUG|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
57920637|NCT00434473|DRUG|A-001|A-001
57920638|NCT00434473|OTHER|Placebo|Placebo
57920639|NCT00642382|DEVICE|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
57920640|NCT00642382|DEVICE|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
57920641|NCT02020629|DRUG|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
57920642|NCT01144767|BEHAVIORAL|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
57723562|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
57723563|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
58392290|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
58274850|NCT04650334|BEHAVIORAL|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
58274851|NCT00309790|DRUG|sildenafil|
58274852|NCT05926752|DEVICE|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
57723564|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
58065452|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
58274853|NCT05926752|OTHER|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
58274854|NCT03660124|DEVICE|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
58274855|NCT01804153|DRUG|Adipose-derived expanded stem cells|Intralesional application ASC
58274856|NCT05849506|DEVICE|Touch® Prosthesis|The Touch® prosthesis is a medical device approved in Switzerland, which is an effective surgical treatment for advanced CMC I osteoarthritis.
57723565|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
57723566|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
57920643|NCT01144767|BEHAVIORAL|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
58274857|NCT02164032|DRUG|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
58274858|NCT02164032|DRUG|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
58274859|NCT02164032|OTHER|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
58274860|NCT03854604|OTHER|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
58274861|NCT05762055|DEVICE|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
58274862|NCT05762055|DEVICE|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
58274863|NCT04621162|BEHAVIORAL|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
58392291|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
57723567|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
57723568|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
57723569|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
57723570|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
57723571|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
57723572|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
57723573|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
57723574|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
57723575|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
57723576|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
57723577|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
57723578|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
57723579|NCT01224041|DRUG|Tacrolimus|oral
57723580|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
57723581|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
57723582|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
57723583|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
57723584|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
57723585|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
57723586|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
57723587|NCT04287062|DRUG|Placebos|Weight and color matched placebo
57723588|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
57920644|NCT00265447|BEHAVIORAL|Strength training|3 months of strength training
57920645|NCT00265447|BEHAVIORAL|Aerobic conditioning|3 months of aerobic conditioning
57920646|NCT00265447|BEHAVIORAL|Delayed exercise|delayed exercise control group
57723589|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
57723590|NCT00025350|DRUG|gefitinib|
57723591|NCT00529945|DEVICE|PFx Closure System|
58065453|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
58065454|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
58065455|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
58065456|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
58065457|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
58065458|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
58065459|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
58065460|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
58065461|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
57723592|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
57723593|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
58065462|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
58274864|NCT04621162|BEHAVIORAL|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
58274865|NCT04621162|BEHAVIORAL|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
58274866|NCT04621162|BEHAVIORAL|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
57723594|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
58065463|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
58065464|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
58065465|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
58065466|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
58065467|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
58065468|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
58274867|NCT04621162|BEHAVIORAL|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
58274868|NCT04621162|BEHAVIORAL|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
57723595|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
57723596|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
57723597|NCT01793857|OTHER|Data collection|Paper questionnaire
57723598|NCT02599168|DRUG|Propofol|
57723599|NCT02599168|DRUG|Dexmedetomidine|
57723600|NCT02599168|DRUG|Placebo (normal saline)|
57723601|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
57723602|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
58065469|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
58065470|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
58274869|NCT02209025|DIETARY_SUPPLEMENT|Theobromine|Theobromine a compound for cocoa
58274870|NCT02209025|DIETARY_SUPPLEMENT|Placebo drink|
58274871|NCT01001806|DRUG|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
58274872|NCT01001806|DRUG|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
58274873|NCT01001806|DRUG|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
58274874|NCT05960032|DRUG|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
57920647|NCT00921960|OTHER|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
57920648|NCT01543724|DRUG|Lithium|10mg/kg/day for 12 weeks
58065471|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
58065472|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
58065473|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
58065474|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
58065475|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
58065476|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
58065477|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
57723603|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
57920649|NCT05332405|DRUG|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
58065478|NCT04129138|OTHER|Survey Administration|Complete survey
58065479|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
58065480|NCT05610228|OTHER|NO intervention|No intervention
58274875|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
58274876|NCT06729905|DIETARY_SUPPLEMENT|Yerba mate tea|Consumption of three cups per day of a beverage prepared with yerba mate
58274877|NCT06729905|DIETARY_SUPPLEMENT|Control drink|Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
57920650|NCT00000274|DRUG|Flupenthixol|
58065481|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
58065482|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
58065483|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
58065484|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
57920651|NCT02170935|DRUG|BIBR 1048 capsule|
57920652|NCT05843188|DRUG|Hydroxychloroquine|Anti-Inflammatory - antimalarial - aminoquinolines
58065485|NCT00689611|DRUG|Placebo|Placebo
58274878|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
58274879|NCT05551689|DRUG|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
58274880|NCT05551689|DEVICE|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
58274881|NCT00008775|DEVICE|Pressure support ventilation|
58274882|NCT01565798|OTHER|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
57920653|NCT05843188|DRUG|Irinotecan|Antineoplastic agent
57920654|NCT05843188|DRUG|Leucovorin|Folic acid derivative
57920655|NCT05843188|DRUG|Fluorouracil|Antineoplastic agent
57920656|NCT05843188|DRUG|Bevacizumab|Antineoplastic agent
57920657|NCT03583177|DIAGNOSTIC_TEST|No intervention|No intervention
57920658|NCT03451162|DRUG|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
57920659|NCT00000198|DRUG|Piracetam|
57920660|NCT00302627|DRUG|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
57920661|NCT00302627|DRUG|vitamin D|baseline, 6,12 months
57920662|NCT00302627|DRUG|Calcium Carbonate|baseline, 6,12 months
57920663|NCT00073112|DRUG|ABT-751|
57920664|NCT04878731|BIOLOGICAL|PF-06741086|single dose SC injection of 300 mg PF-06741086
58274883|NCT00667797|DRUG|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
58392292|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
58392293|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
58392294|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
58392295|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
58274884|NCT00667797|DRUG|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
58392296|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
57723604|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
57723605|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
57920665|NCT02768051|PROCEDURE|AF Ablation|
57920666|NCT05868174|DIAGNOSTIC_TEST|89Zr-TLX250|Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible). The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
57920667|NCT05868174|COMBINATION_PRODUCT|177Lu-TLX250 and Peposertib|"Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose.~All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle."
57920668|NCT04242589|RADIATION|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
57920669|NCT04242589|PROCEDURE|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
57920670|NCT01640054|DRUG|Fostamatinib|Fostamatinib 100mg once daily
58274885|NCT02135705|DRUG|Lomitapide|As prescribed by Physician.
58274886|NCT02101749|BIOLOGICAL|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
58274887|NCT01315795|DRUG|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
58274888|NCT01745107|RADIATION|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
58392297|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
57920671|NCT02882828|DRUG|switched from Prograf® to Envarsus®|
57920672|NCT04902833|PROCEDURE|Blood Draw|Blood specimen 2-4 teaspoons
58274889|NCT04170244|OTHER|AD subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
58274890|NCT04170244|OTHER|PS subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
58392298|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
58392299|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
57920673|NCT03999320|OTHER|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
57920674|NCT03999320|OTHER|usual care|usual care
57920675|NCT02234245|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
58065486|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
58065487|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
58065488|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
58274891|NCT04170244|OTHER|Healthy control visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
58274892|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
58392300|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
58392301|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
58392302|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
58392303|NCT00003420|PROCEDURE|computed tomography|
58392304|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
58392305|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
58392306|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
58392307|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
57723606|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
57723607|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
57723608|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
57723609|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
57723610|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
58274893|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
58274894|NCT04064580|OTHER|diagnostic test|performing a capnography examination
58392308|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
58065489|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
58065490|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
58392309|NCT00883168|DRUG|Placebo|Placebo
58392310|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
58392311|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
58392312|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
58392313|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
58392314|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
58392315|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
58392316|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
57723611|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
57723612|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
57920676|NCT04011618|DRUG|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
58065491|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
58065492|NCT01297621|OTHER|control|follow up, questionnaire responses
58065493|NCT05486715|DRUG|Vit D|Vit D
58274895|NCT00004770|DRUG|thioctic acid|
58274896|NCT01782560|DRUG|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
58274897|NCT01782560|DRUG|Placebo|
58274898|NCT03877224|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
58274899|NCT03877224|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
58392317|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
57723613|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
58065494|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
58065495|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
58065496|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
58065497|NCT02962973|DEVICE|CARMAT TAH|
58065498|NCT02962973|PROCEDURE|Surgical intervention|
58065499|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
58274900|NCT00232466|PROCEDURE|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
58274901|NCT05490823|DEVICE|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
58392318|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
57920677|NCT04011618|DRUG|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
57920678|NCT01561209|DRUG|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
57920679|NCT01561209|DRUG|Placebo|"Placebo pill~1 before bedtime"
57920680|NCT03917680|DIAGNOSTIC_TEST|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
57920681|NCT03917680|GENETIC|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
57920682|NCT03917680|DIAGNOSTIC_TEST|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
57723614|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
57723615|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
57920683|NCT02583035|OTHER|Nurse telephone contact|Nurse will contact patient 3 days before consultation
57920684|NCT06409780|DIAGNOSTIC_TEST|Comparative analysis of CUS, CAD and CXR in pulmonary TB|The strumental analysis of pulmonary TB signs with chest ultrasound, chest x-ray and CAD will be compared in two different settings: index cases and household contacts
58065500|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
58065501|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
58274902|NCT05062720|RADIATION|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
57723616|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
57723617|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
57723618|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
58274903|NCT02689310|OTHER|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
58274904|NCT02689310|OTHER|Standard of Care Treatment|No information available- PI left- study being withdrawn.
58274905|NCT01691703|DEVICE|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
57920685|NCT06346860|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
57920686|NCT03975166|DRUG|Test Product|2 inhalations in one study period
57920687|NCT03975166|DRUG|Reference Product|2 inhalations in one study period
58274906|NCT04294797|DIAGNOSTIC_TEST|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
58274907|NCT02095405|DRUG|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
58274908|NCT02095405|OTHER|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
58065502|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
57920688|NCT03113903|BEHAVIORAL|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
57920689|NCT00321113|DRUG|tacrolimus|immunosuppression
57920690|NCT00321113|DRUG|mycophenolate mofetil|oral
57920691|NCT00321113|DRUG|steroids|oral
58065503|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
58274909|NCT06065228|OTHER|AlgometRx Nociometer|Physiologic characterization of disease activity
58274910|NCT00107354|BIOLOGICAL|aldesleukin|
58274911|NCT00107354|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58274912|NCT00107354|BIOLOGICAL|therapeutic autologous lymphocytes|
58274913|NCT00107354|DRUG|cytarabine|
58274914|NCT00107354|DRUG|etoposide|
58274915|NCT00107354|DRUG|mitoxantrone hydrochloride|
58392319|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
58274916|NCT00107354|PROCEDURE|allogeneic bone marrow transplantation|
58274917|NCT00107354|PROCEDURE|peripheral blood stem cell transplantation|
58274918|NCT06509789|DEVICE|Transcranial magnetic stimulation (TMS) - Theta burst stimulation (TBS) protocol|This procedure uses magnetic fields to stimulate nerve cells in the brain involved in various neurological functions, such as motor control. Theta burst stimulation is a patterned form of TMS protocol.
58274919|NCT00968097|DRUG|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
58274920|NCT02262416|DRUG|leuprolide|normal saline
58274921|NCT06206122|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58274922|NCT06206122|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58274923|NCT06206122|BEHAVIORAL|Comprehensive rehabilitation training|"1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58274924|NCT03466749|DEVICE|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
57920692|NCT00234546|BIOLOGICAL|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
57920693|NCT00234546|DRUG|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
58392320|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
58392321|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
58392322|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
57920694|NCT06419829|OTHER|psychoprophylactic program aimed at normalizing body weight through medical training|"Based on the assessment of body weight and composition, a 12-week physiophylactic program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that reduce fat mass, increase the flexibility and productivity of muscle mass. The classes will be conducted as part of medical training with a training load increasing to at least 85% of HR Max.~The project will include theoretical classes for parents, children and seniors on eating habits, a proper age-appropriate diet, diet changes depending on the subject's health condition and physical activity, and the impact of diet on the process of puberty, adulthood and aging."
58065504|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
58392323|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
58392324|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
58392325|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
58392326|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
58392327|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
57723619|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
58392328|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
57723620|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
57723621|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
58392329|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
58392330|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
58392331|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
58392332|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
58392333|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
57723622|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
57723623|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
57723624|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
57920695|NCT06419829|OTHER|psychoprophylactic program aimed at improving body posture|"Based on the body posture assessment, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that strengthen the muscle corset, reducing asymmetrical positioning, habitual and during the implementation of professional tasks. The classes will be conducted using medical training and resistance exercises.~The project will include theoretical classes for parents on sitting habits, the importance of physical activity in a child's development, the selection of footwear..."
58274925|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
58274926|NCT01990872|DIETARY_SUPPLEMENT|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
57920696|NCT06419829|OTHER|psychoprophylactic program aimed at improving physical fitness|Based on the assessment of physical fitness, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the participants. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises aimed at improving physical fitness, with particular emphasis on impaired motor skills. The classes will be conducted using functional training, resistance and stretching exercises, strengthening all muscle groups. In the case of children, special attention will be paid to the strength of the upper limbs, in the case of seniors, balance and coordination exercises will be introduced to improve time and space orientation. In all groups, the main goal is to improve functional fitness The project will include theoretical classes for parents, children and seniors on the importance of physical activity in the quality of life, in the process of maturation and aging.
57920697|NCT06419829|DIAGNOSTIC_TEST|Body composition assessment|"Body composition assessment will be carried out using the BIA method on an eight-electrode body composition analyzer from TAnita. They will be marked:~total mass, Total fat mass (FM) and segmental fat mass for five body segments: right leg (RL FM), Left leg (LL FM), right arm (RA FM), Left Arm (LA FM) trunk (TR FM).~total fat-free mass (FFM) and segmental for five body segments: right leg (RL FFM), Left leg (LL FFM), right arm (RA FFM), Left Arm (LA FMM) trunk (TR FMM).~Predicted total and segmental muscle mass (PMM) for five body segments: right leg (RL PMM), Left leg (LL PMM), right arm (RA PMM), Left Arm (LA PMM) trunk (TR PMM).~Total water content (TBW) including intracellular water (ICW) and extracellular water (ECW)"
58065505|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
58274927|NCT01990872|DIETARY_SUPPLEMENT|Placebo|Placebo (0 micrograms vitamin D3/day)
58274928|NCT06731725|DEVICE|DayDrop®|The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
58274929|NCT01053130|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
58274930|NCT01053130|BEHAVIORAL|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
58274931|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
58274932|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
58274933|NCT03782805|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
58274934|NCT03782805|DIETARY_SUPPLEMENT|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
58392334|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
58392335|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
58392336|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
58392337|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
57920698|NCT06419829|DIAGNOSTIC_TEST|assessment of body posture using the Kasperczyk method|The Kasperczyk method was used to assess body posture, including physiotherapeutic assessment in both standing and sitting positions. The symmetry of the head, shoulders, spine curvatures, knee joints and foot positioning were assessed. The symmetry of the head position was examined in all three planes and in all movements, i.e. flexion - extension, right turn - left turn, rotation and combined movements. The lateral curvatures of the spine (scoliosis) and their physiological curvatures, their deepening or shallowing in all sections of the spine, as well as the mobility of the spine in all physiological planes of movement were assessed. The position of the shoulder and hip girdle was assessed, as well as the position of the upper limbs at the level of the knees and feet. The mobility of the lower and upper limbs was examined.
57920699|NCT06419829|DIAGNOSTIC_TEST|Assessment of physical fitness|It depends on the age of the person being examined. In the case of children, the EUROFIT physical fitness test is carried out with modifications for age and gender. For the senior group, the Rikli and Jones test is used
57920700|NCT06419829|DIAGNOSTIC_TEST|Balance assessment|"Balance assessment using the Zebris platform Static measurement - with eyes open and closed, assessing the load on the limbs during standing expressed in %, Balance analysis measurement - with eyes open and closed, test in a standing position, barefoot. The measurement duration is 30 seconds and the break between measurements is 30-60 seconds.~Deflections of the center of gravity in the frontal and sagittal planes Length of the center of gravity swing path CoP - SPL \[cm\]. Inside the calculated ellipse lies 95% of the CoP location measurement data: amplitude, amplitude height, ellipse area (orientation of the direction of the ellipse's longitudinal axis relative to the platform's longitudinal axis, indicating clockwise rotation)."
58274935|NCT03315611|DRUG|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
58274936|NCT03315611|OTHER|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
58274937|NCT04480333|DRUG|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
58392338|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
58392339|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
58392340|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
58392341|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
57920701|NCT00096720|DRUG|levodopa|
57920702|NCT00096720|DRUG|Mirapex (pramipexole)|
57920703|NCT00096720|PROCEDURE|[123I]ß-CIT and SPECT imaging|
57920704|NCT02800577|DEVICE|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
58274938|NCT04480333|DRUG|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
58274939|NCT04480333|DRUG|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
58274940|NCT04480333|DRUG|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
58274941|NCT04480333|DRUG|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
58274942|NCT04480333|DRUG|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
58274943|NCT04480333|DRUG|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
57723625|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
58274944|NCT04480333|DRUG|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
58274945|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
58274946|NCT04480333|COMBINATION_PRODUCT|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
58274947|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
58274948|NCT04480333|COMBINATION_PRODUCT|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
58065506|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
58065507|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
57723626|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
57723627|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
58065508|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
58065509|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
58065510|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
57723628|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
57920705|NCT04294563|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
57920706|NCT04294563|OTHER|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
58065511|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
57723629|NCT02346565|PROCEDURE|Exercise ECG|
57723630|NCT02346565|PROCEDURE|Stress Echocardiography|
57723631|NCT02769091|DRUG|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
58274949|NCT02408952|BEHAVIORAL|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
58274950|NCT02408952|BEHAVIORAL|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
58274951|NCT03107975|BIOLOGICAL|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
58274952|NCT04683354|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
57723632|NCT02769091|DRUG|Placebo|
57723633|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
57723634|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
57723635|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
57723636|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
58065512|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
57723637|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
57723638|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
57723639|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
57723640|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
57723641|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
57723642|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
57920707|NCT03549312|DRUG|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48."
57920708|NCT03549312|DRUG|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
57920709|NCT03549312|DRUG|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96."
57920710|NCT02289612|OTHER|Yellow Mustard Gum Fibre|
57920711|NCT02289612|OTHER|Soluble Flaxseed Gum Fibre|
57920712|NCT02289612|OTHER|Fenugreek Gum Fibre|
57920713|NCT02463643|DRUG|Z-215 10mg|Z-215 10mg, capsules
57920714|NCT02463643|DRUG|Z-215 20mg|Z-215 20mg, capsules
57920715|NCT02463643|DRUG|Z-215 Placebo|Z-215 placebo-matching capsules
57920716|NCT02463643|DRUG|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
57920717|NCT02463643|DRUG|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
57920718|NCT04019548|DEVICE|Percutaneous Endoscopic Gastrotomy tube placement|placement of the PEG tube depends on arm
58274953|NCT04112095|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
58274954|NCT01583205|BEHAVIORAL|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
58274955|NCT05818319|OTHER|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
57920719|NCT04019548|DRUG|Cisplatin injection|"Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV"
58392342|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
58392343|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
58392344|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
57723643|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
57723644|NCT04533841|DRUG|Placebo|placebo
57723645|NCT04533841|DRUG|Propranolol|Propranolol
57920720|NCT04019548|RADIATION|Radiotherapy|Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
57920721|NCT01484730|DEVICE|Multi-Spectral and Laser Speckle Imaging|Changes in skin tissue and blood flow.
57920722|NCT00755703|BIOLOGICAL|Pandemic Influenza Vaccine|Undetermined
57920723|NCT00755703|BIOLOGICAL|Placebo|
57920724|NCT04130529|BEHAVIORAL|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
57920725|NCT04130529|OTHER|Sleep lectures|Lectures on the topic of sleep.
57920726|NCT02018835|DEVICE|MRI|
57920727|NCT02018835|DEVICE|cardiac echography transthoracic|
57920728|NCT01570036|DRUG|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
58274956|NCT05818319|OTHER|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
58274957|NCT05818319|OTHER|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
58274958|NCT00336388|DEVICE|Paracheck Device|
58392345|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
58392346|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
57723646|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
57920729|NCT01570036|DRUG|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
57723647|NCT02359721|DRUG|tablet clarithromycin 500 mg (Clarino-500) orally|orally
57920730|NCT01570036|DRUG|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
57920731|NCT02718937|DRUG|BTA-C585 oral capsule|
57920732|NCT02718937|DRUG|Matching placebo capsules|
57920733|NCT04002609|OTHER|oxygen|oxygen supplementation during brronchoscopy
58065513|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
58274959|NCT02325245|DRUG|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
58274960|NCT02325245|DRUG|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
58274961|NCT04060199|DRUG|Viltolarsen|IV infusion
58274962|NCT04060199|DRUG|Placebo|IV infusion
58274963|NCT04039321|DRUG|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
58274964|NCT04039321|DRUG|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
58274965|NCT02974920|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
58274966|NCT02974920|DRUG|Aspirin|Aspirin 100 mg once daily for 180 days
57723648|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
57723649|NCT00256789|PROCEDURE|Radiation|
57723650|NCT00256789|DRUG|Chemotherapy|
57723651|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
57723652|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
58274967|NCT04328610|PROCEDURE|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
58274968|NCT05180955|OTHER|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
58274969|NCT05180955|OTHER|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
58274970|NCT04788875|PROCEDURE|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
58274971|NCT04788875|PROCEDURE|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
57723653|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
57723654|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
58274972|NCT03567161|PROCEDURE|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
57723655|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
57723656|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
57920734|NCT05889065|PROCEDURE|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
58274973|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
57723657|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
58274974|NCT03007134|OTHER|Retrospective Chart Review|No intervention.
57723658|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
58274975|NCT03464942|RADIATION|SABR|Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
57723659|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
57723660|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
57920735|NCT05889065|PROCEDURE|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
57920736|NCT04616703|RADIATION|CT imaging|CT of abdomen
57920737|NCT01637623|DRUG|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
57920738|NCT01637623|DRUG|Allopurinol|Allopurinol 300 mg daily for 6 weeks
57920739|NCT01637623|DRUG|Placebo|Placebo capsule daily for 6 weeks
58274976|NCT03464942|DRUG|Atezolizumab|All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
57723661|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
57723662|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
57920740|NCT02855424|OTHER|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
57920741|NCT02855424|OTHER|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
57920742|NCT00828841|DRUG|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
57920743|NCT00828841|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
57920744|NCT00828841|DRUG|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
57920745|NCT00828841|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
57920746|NCT00828841|DRUG|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
57920747|NCT02749656|DRUG|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
58274977|NCT02669914|DRUG|MEDI4736|
57920748|NCT02749656|DRUG|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
57920749|NCT02749656|DRUG|Placebo|apply on the scalp psoriasis lesion twice a day
57920750|NCT02804776|DRUG|Gefitinib|250mg oral daily for 4 weeks
58392347|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1,3,6,9, and 12 months
58392348|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
58392349|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
58392350|NCT00346658|DRUG|magnesium|
57723663|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
57920751|NCT05895565|DRUG|PMG1015|Including 3 dose levels: level 1, level 2 and level 3
58274978|NCT03723421|OTHER|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
57920752|NCT05895565|DRUG|PMG1015 placebo|Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
58274979|NCT03723421|OTHER|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
58392351|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
57723664|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
57920753|NCT01778023|DRUG|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
57920754|NCT02184650|OTHER|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
57920755|NCT02071667|OTHER|Blood draw|
58392352|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
58392353|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
58392354|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
57723665|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
57920756|NCT01487031|OTHER|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
57920757|NCT01487031|OTHER|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
57920758|NCT00459160|PROCEDURE|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
57723666|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
58274980|NCT02798354|BEHAVIORAL|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
58274981|NCT06355843|DRUG|68Ga-PSMA|"PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved."
58274982|NCT01589679|OTHER|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
58274983|NCT01589679|DEVICE|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
58274984|NCT01378832|PROCEDURE|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
58274985|NCT00528632|OTHER|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
58274986|NCT00601822|BEHAVIORAL|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
58274987|NCT00601822|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
58274988|NCT03982940|DEVICE|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
58274989|NCT06730555|BEHAVIORAL|ACCESS Intervention|Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.
58392355|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
58274990|NCT06730555|BEHAVIORAL|Control Group|Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.
58392356|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
58392357|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
58392358|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
57723667|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
57723668|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
57723669|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
57723670|NCT00272701|DRUG|Esomeprazole|
57723671|NCT00272701|DRUG|Other PPI marketed in Sweden|
58392359|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
57723672|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
58392360|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
58392361|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
58392362|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
57723673|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
58392363|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
58392364|NCT05891080|DRUG|JS004|Specified dose on specified days.
58392365|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
58392366|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
58392367|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
57920759|NCT05798533|BIOLOGICAL|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
58392368|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
57723674|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
57723675|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
57723676|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
57723677|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
57920760|NCT05798533|COMBINATION_PRODUCT|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
57920761|NCT05798533|COMBINATION_PRODUCT|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
57920762|NCT02552641|OTHER|Food effect|
57920763|NCT02552641|DRUG|Esomeprazole|
57920764|NCT02552641|DRUG|Amoxicillin|
57920765|NCT02552641|DRUG|Clarythromycin|
58392369|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
58392370|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
58392371|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
58392372|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
58392373|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
58392374|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
58392375|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
58392376|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
58392377|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
58274991|NCT04172857|PROCEDURE|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch \& Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
58392378|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
58274992|NCT04697212|BEHAVIORAL|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
58392379|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
57723678|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
58392380|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
58392381|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
58392382|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
58392383|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
58392384|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
58392385|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
57723679|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
57920766|NCT00824811|DRUG|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
58392386|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
57920767|NCT00824811|DRUG|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
57920768|NCT00824811|DRUG|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
57920769|NCT01958970|DRUG|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
57920770|NCT01958970|DRUG|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
58392387|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
57920771|NCT05019378|PROCEDURE|SVF treatment|autologous SVF (10E8 cells)
58392388|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
58392389|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
58392390|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
58392391|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
58392392|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
58392393|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
58392394|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
58392395|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
57723680|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
57723681|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
57920772|NCT00359151|DRUG|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
58065514|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
58065515|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
58065516|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
58065517|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
58065518|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
57723682|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
57723683|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
57723684|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
57723685|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
57723686|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
57723687|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
57723688|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
57723689|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
57723690|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
57723691|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
57723692|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
58392396|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
58392397|NCT02580032|OTHER|No treatment given|No treatment given.
58392398|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
58392399|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
57723693|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
57920773|NCT00359151|DRUG|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
58065519|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
58392400|NCT04979793|DRUG|Placebo|Milk powder placebo
58392401|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
58392402|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
57920774|NCT05000502|BEHAVIORAL|Home-based exercise intervention|A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
57920775|NCT04910854|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
57920776|NCT00724308|OTHER|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
57920777|NCT00724308|OTHER|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
57920778|NCT01383772|PROCEDURE|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
57920779|NCT06135077|OTHER|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
58274993|NCT04697212|BEHAVIORAL|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
57920780|NCT06135077|OTHER|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
57920781|NCT00315432|DRUG|Pegylated Interferon and Ribavirin|
57920782|NCT02982733|OTHER|ABS|Ankaferd Blood Stopper
57920783|NCT02982733|DEVICE|TR Band|Transradial band
58274994|NCT00033306|DRUG|ixabepilone|
57920784|NCT02982733|OTHER|CS|Sterile Gauze
57920785|NCT04536987|DEVICE|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
58274995|NCT00033306|DRUG|Fluoropyrimidine|
58274996|NCT00033306|DRUG|Irinotecan|
58274997|NCT05525780|DRUG|GB-5001|Depending on the cohort, volume will be varied to administer.
58274998|NCT05525780|DRUG|Placebo|A matched volume of placebo product will be administered to each subject in each cohort.
58274999|NCT05525780|DRUG|Oral cohort|Single dose of Aricept tablet
58275000|NCT06356818|OTHER|Conventional physiotherapy program|Physiotherapy and rehabilitation treatment program will be applied to the patients. In this program, a 30-40-minute exercise protocol covering proprioceptive, balance and strengthening exercises will be implemented. For a total of 12 sessions, 3 days a week, over a 4-week period
58275001|NCT06356818|OTHER|Virtual reality (VR)|virtual reality (VR) program will be applied using balance and strengthening games by Nintendo Wii Fit Plus; warm-up exercise (5 minutes), workout (20 minutes) and cool-down exercise (5 minutes) for a total of 30 minutes. For a total of 12 sessions, 3 days a week, over a 4-week period
58275002|NCT06356818|OTHER|Motor imagery (MI)|Patients will be introduced to explicit Motor imagery program which the content of the imagery program will last 20 minutes in total, with 5 minutes of relaxation and 15 minutes of imagery training. For a total of 12 sessions, 3 days a week, over a 4-week period.
58275003|NCT02393326|PROCEDURE|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
58275004|NCT02393326|PROCEDURE|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
58275005|NCT05631782|DRUG|Shenkang decoction|Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
58275006|NCT02424864|OTHER|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
57920786|NCT00454441|DRUG|MF101|
57920787|NCT05525611|DRUG|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
57920788|NCT05525611|OTHER|Placebo|Placebo once a week in 12 weeks
57920789|NCT02169453|DRUG|BIA 9-1067|OPC, Opicapone
57920790|NCT02169453|DRUG|Placebo|PLC, Placebo
57920791|NCT02169453|DRUG|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
57920792|NCT04259073|DRUG|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
57920793|NCT04259073|DRUG|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
57920794|NCT04259073|DRUG|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
58275007|NCT00053508|BIOLOGICAL|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
58275008|NCT00053508|BIOLOGICAL|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
58275009|NCT01550107|DRUG|Allopurinol|300mg b.d for 24 weeks
58275010|NCT01550107|DRUG|Lactose tablets|matched placebo tablets b.d
58275011|NCT06371066|OTHER|experimental group|the experimental group was educated by video
58275012|NCT06371066|OTHER|Control group|the control group was educated by traditional formal training
58275013|NCT04127175|DEVICE|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
58392403|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
58392404|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
58392405|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
58392406|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
57920795|NCT04775589|BEHAVIORAL|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
57920796|NCT05679856|RADIATION|Hypofractionated single vocal cord irradiation|Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
57920797|NCT05679856|RADIATION|Whole laryngeal radiotherapy|The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
58392407|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
58392408|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
57920798|NCT00706433|DRUG|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
57920799|NCT00706433|OTHER|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
57920800|NCT00622453|OTHER|Screening|Electrocardiography Blood Test
57920801|NCT00701077|DRUG|3,4-Di-amino-Pyridine|a single 20 mg dosing
58275014|NCT02358018|DRUG|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
58275015|NCT05622227|DIAGNOSTIC_TEST|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
58275016|NCT05786638|DRUG|Allergen Immunotherapy Extract|Sublingual subcutaneous allergen immunotherapy
58275017|NCT03286231|DIAGNOSTIC_TEST|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
58275018|NCT02893423|DRUG|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
58275019|NCT02147067|DRUG|Ranolazine|Ranolazine 1,000 mg twice daily
58392409|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
58275020|NCT02147067|DRUG|Placebo|Placebo
58275021|NCT02585388|DRUG|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
58392410|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
57920802|NCT00701077|DRUG|placebo|placebo
58065520|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
58275022|NCT02585388|DRUG|Letrozole|Lestrozole at 2,5 mg every day , per oral
58275023|NCT02585388|DRUG|Anastrozole|Anastrozole at 1 mg every day, per oral
58065521|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
58275024|NCT04866680|PROCEDURE|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
58275025|NCT05055856|DIAGNOSTIC_TEST|urine sample|Each participant will give a urine sample for diagnose of asymptomatic bacteriuria
58275026|NCT05055856|DIAGNOSTIC_TEST|Blood and urine sample|Each participant will give a urine and blood sample for diagnose of SIADH
58275027|NCT03146975|PROCEDURE|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
58275028|NCT01366300|DRUG|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
58275029|NCT01366300|OTHER|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
58275030|NCT01366300|DRUG|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
58275031|NCT01366300|PROCEDURE|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
58275032|NCT02919007|DEVICE|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
58275033|NCT01337323|DRUG|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
58392411|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
58275034|NCT02612688|BEHAVIORAL|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
58275035|NCT01627782|DRUG|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
58392412|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
57723694|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
57920803|NCT06202235|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both CKD Patients and Healthy Volunteers will undergo Magnetic Resonance Elastography (MRE) to evaluate liver and renal viscoelasticity. For CKD patients, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, CKD patients will undergo a renal biopsy to assess the extent of fibrosis
57920804|NCT00261768|BEHAVIORAL|Digital noise reduction|
57920805|NCT00718354|DRUG|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
57920806|NCT00718354|DRUG|Standard Chemotherapy|Investigator's discretion
57920807|NCT00988871|DEVICE|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
58275036|NCT01627782|DRUG|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
58392413|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
57723695|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
57723696|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
57723697|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
57723698|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
57920808|NCT00199940|DRUG|Ziprasidone|
58275037|NCT04786665|OTHER|Strawberry|Freeze dried strawberry powder
58275038|NCT04786665|OTHER|Placebo group|Comparative placebo powder
58275039|NCT00543998|DEVICE|Optical Measurement transillumination|Optical Measurement of sinus
57723699|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
57920809|NCT00597298|DEVICE|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
57920810|NCT00597298|DEVICE|sham threshold|non-training physical activity
57920811|NCT04923152|DRUG|moderate statin dose|5 mg rosuvastatin per day
58275040|NCT06548594|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
58392414|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
58392415|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
58392416|NCT03216343|DRUG|Chiauranib|CS2164
58392417|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
57723700|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
57723701|NCT00271336|DRUG|Pentoxifylline|
57723702|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
57723703|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
57723704|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
57920812|NCT04923152|DRUG|high dose statin|40 mg rosuvastatin per day
57920813|NCT00037128|DRUG|GL701|
57920814|NCT02422056|DRUG|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
57920815|NCT02422056|DRUG|Saline|Infusion of saline in the same rate used for the intervention group
58392418|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
57723705|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
57723706|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
57723707|NCT01817972|BIOLOGICAL|Certolizumab pegol|Subcutaneous injection
57723708|NCT01817972|DRUG|Azathioprine|50mg tablets
57723709|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
57723710|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
57723711|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
57920816|NCT05690100|DRUG|GeliO3|Anti-inflammatory Gel which has a beneficial role on wound healing
57920817|NCT05690100|DRUG|Gingi gel|Anti-inflammatory Gel which has a beneficial role on wound healing
57920818|NCT02839642|DRUG|Rivastigmine|
58392419|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
58392420|NCT00136695|DRUG|anastrozole|1 mg QD
57723712|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
57723713|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
57723714|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
57920819|NCT02839642|DRUG|Placebo|
57920820|NCT05201014|DIAGNOSTIC_TEST|NT-pro-BNP|Blood draw
57920821|NCT05201014|DIAGNOSTIC_TEST|Electrocardiogram|electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart
57920822|NCT05201014|DIAGNOSTIC_TEST|Echocardiogram|medical imaging of the heart
57920823|NCT04502628|PROCEDURE|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
57920824|NCT02086266|OTHER|PILATES|
58065522|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
57723715|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
57723716|NCT01513304|PROCEDURE|Manual therapy|
57723717|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
57723718|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
57723719|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
57920825|NCT02086266|OTHER|PFMT and AES|
58065523|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
58065524|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
58065525|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
58065526|NCT04812821|OTHER|questionnaire|questionnaire post delivery
58065527|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
58065528|NCT00515866|DRUG|Gemcitabine|intravenous injection
58275041|NCT04400071|BEHAVIORAL|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
58392421|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
58275042|NCT04400071|BEHAVIORAL|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
58392422|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
58392423|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
58275043|NCT00630201|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
58275044|NCT06730035|OTHER|Blood analysis|This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
58392424|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
58392425|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
58392426|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
57723720|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
58065529|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
58275045|NCT04338191|DRUG|mFOLFOXIRI adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
58275046|NCT04338191|DRUG|mFOLFOX6 adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
58275047|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
58275048|NCT03193749|DRUG|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
58275049|NCT03193749|DRUG|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
57723721|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
58392427|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
58392428|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
58392429|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
58392430|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
57723722|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
58275050|NCT00760812|BEHAVIORAL|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
57723723|NCT04095858|DRUG|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
57723724|NCT04095858|DRUG|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
57920826|NCT01074619|DRUG|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
57920827|NCT01074619|DRUG|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
57723725|NCT04095858|DRUG|Methotrexate|IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
58275051|NCT00760812|BEHAVIORAL|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
58275052|NCT00791830|DRUG|Irbesartan|Tablets, 300 mg \* 1 daily, 1 year
58275053|NCT00791830|DRUG|Placebo matching irbesartan 150 mg|Tablets, 300 mg \* 1 daily, 1 year
58275054|NCT00230919|BEHAVIORAL|Diet counseling|
58275055|NCT01762449|OTHER|Followup survey|
58275056|NCT03822494|RADIATION|CyberKnife SBRT|Radiation Therapy
57723726|NCT04095858|DRUG|Tacrolimus|Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
57723727|NCT04198610|PROCEDURE|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
58275057|NCT04442438|OTHER|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
57920828|NCT02660307|OTHER|PROGRESS group|
57920829|NCT01832441|OTHER|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
57920830|NCT03005860|DRUG|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
57920831|NCT03005860|DRUG|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
57920832|NCT03005860|DRUG|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
58275058|NCT04548388|OTHER|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
57723728|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
57920833|NCT03005860|DRUG|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
57920834|NCT03690648|OTHER|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
58275059|NCT06125340|DRUG|Placebo|5 days of placebo to be given after 3-5 days of antibiotics
57920835|NCT03690648|GENETIC|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
58275060|NCT06125340|DRUG|Amoxicillin|Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
58275061|NCT01669785|DEVICE|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58275062|NCT01669785|DEVICE|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58275063|NCT01669785|DEVICE|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58392431|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
57723729|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
57723730|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
57723731|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
57723732|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
57723733|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
57723734|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
57723735|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
57723736|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
57723737|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
57723738|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
57920836|NCT03690648|GENETIC|Blood collection|Collection of 20 ml of blood with kit of blood collection
58275064|NCT05844163|OTHER|observation|observation
58275065|NCT06188104|DRUG|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
58275066|NCT00336323|PROCEDURE|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
58275067|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
58275068|NCT00336323|DRUG|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
58392432|NCT01260688|DRUG|cediranib maleate|Given orally
58392433|NCT01260688|DRUG|dasatinib|Given orally
58392434|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
58392435|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
58392436|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
58392437|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
58392438|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
57723739|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
57723740|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
57723741|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
57723742|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
57723743|NCT02573324|DRUG|Temozolomide|Oral Capsule
57723744|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
57723745|NCT02573324|RADIATION|Radiation|
57920837|NCT03740997|DRUG|Optison|Optison is administered intravenously
58275069|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
58275070|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
57723746|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
57920838|NCT00710281|RADIATION|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
57723747|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
57920839|NCT01266733|BEHAVIORAL|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
57920840|NCT01266733|BEHAVIORAL|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
57920841|NCT05634980|OTHER|FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam
57920842|NCT02502097|DRUG|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
58275071|NCT01493700|PROCEDURE|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
58275072|NCT01493700|PROCEDURE|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
58275073|NCT04030325|BEHAVIORAL|Sequential Personalized Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
58275074|NCT04030325|BEHAVIORAL|Simultaneous Personalized Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
58275075|NCT04030325|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking events
58275076|NCT02525536|DRUG|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
58275077|NCT02525536|DRUG|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
58275078|NCT02525536|DRUG|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
58275079|NCT04847102|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine|"The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000)."
58275080|NCT04847102|BIOLOGICAL|Placebo|0.9% sodium chloride solution, 0.5 mL/vial
58275081|NCT00332631|DRUG|N-acetylcysteine|
58275082|NCT00332631|DRUG|Placebo|
57723748|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
57723749|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
58275083|NCT03027323|DEVICE|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
58275084|NCT03973697|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
57723750|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
57920843|NCT02502097|OTHER|Placebo|Matching placebo to gefapixant, tablet administered by mouth
57920844|NCT01386060|OTHER|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
57920845|NCT02853253|DIETARY_SUPPLEMENT|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
57920846|NCT02853253|DIETARY_SUPPLEMENT|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
57920847|NCT00370409|PROCEDURE|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
57920848|NCT00760903|OTHER|Conventional MRI of the brain|
57920849|NCT00760903|OTHER|MR spectroscopy (MRS)|
58275085|NCT03973697|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
58275086|NCT03973697|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
58275087|NCT01920659|BEHAVIORAL|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
58392439|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
58392440|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
58275088|NCT01920659|BEHAVIORAL|REHIT|6 weeks 3 x week (20sec intervals)
58275089|NCT00638209|DRUG|Human insulin|
58275090|NCT00638209|DRUG|Saline|
58275091|NCT04609709|OTHER|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
58392441|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
58392442|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
58392443|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
57723751|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
57723752|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
57723753|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
57723754|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
57723755|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
58275092|NCT04609709|OTHER|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
58065530|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
58065531|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
58065532|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
58065533|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
58065534|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
57723756|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
57723757|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
57723758|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
57723759|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
57723760|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
57920850|NCT00760903|OTHER|MR Diffusion Tensor Imaging (DTI)|
58275093|NCT03146728|OTHER|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
58275094|NCT02454634|DRUG|IDH1 peptide vaccine|
58275095|NCT06361615|OTHER|Single-Task|Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.
58275096|NCT06361615|OTHER|Dual-Task|DT training (multicomponent physical exercise + cognitive tasks)
58275097|NCT04322786|DRUG|ACE inhibitor|Any prescription of ACE inhibitor
57920851|NCT00388557|DRUG|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
58065535|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
58065536|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
58065537|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
58275098|NCT01333956|DRUG|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
58275099|NCT01333956|DRUG|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
58275100|NCT01333956|DRUG|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
58275101|NCT01333956|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
57920852|NCT04012229|GENETIC|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
58392444|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
58275102|NCT05558800|PROCEDURE|Implant placement|Implant placement with different surface types
58275103|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
58392445|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
58392446|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
57723761|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
58392447|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
58392448|NCT05297786|DRUG|Placebo|Placebo injection
57723762|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
57723763|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
57723764|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
57723765|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
57723766|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
58065538|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
58065539|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
58275104|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
58392449|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
58392450|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
58392451|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
58392452|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
58392453|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
58392454|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
58392455|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
58392456|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
57723767|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
58392457|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
58392458|NCT06049095|DRUG|LTG-001|Oral doses
58392459|NCT06049095|DRUG|Placebo|Oral doses
58392460|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
57723768|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
57723769|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
57920853|NCT05869630|OTHER|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
57920854|NCT05869630|OTHER|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
57920855|NCT05997498|PROCEDURE|mechanical cervical dilatation|mechanical cervical dilatation during elective cesarean section
57920856|NCT02004548|DRUG|Metatinib Tromethamine|
58275105|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
58275106|NCT03743402|BEHAVIORAL|Pain self-management training|"This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider."
58275107|NCT03743402|BEHAVIORAL|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
58275108|NCT03743402|BEHAVIORAL|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
58275109|NCT03743402|BEHAVIORAL|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
58275110|NCT03743402|OTHER|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
58275111|NCT02086409|DIETARY_SUPPLEMENT|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
58275112|NCT02086409|DIETARY_SUPPLEMENT|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
58275113|NCT02456961|PROCEDURE|iontophoresis of riboflavin|
58275114|NCT02456961|PROCEDURE|epithelium-off|
58275115|NCT02456961|PROCEDURE|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
58275116|NCT02456961|DEVICE|galvanizator, Potok-1|Device for providing iontophoresis procedure
58275117|NCT02456961|DRUG|Dextralink|Riboflavin 0,1% + Dextran T-500
58275118|NCT02456961|DRUG|Riboflavin 0,1%|
58392461|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
58275119|NCT02456961|DEVICE|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
58275120|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
57723770|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
57723771|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
57723772|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
57920857|NCT04248985|OTHER|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
57723773|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
57723774|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
57723775|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
57723776|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
57723777|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
57723778|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
57723779|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
57920858|NCT02170792|DRUG|BIBR 1048 MS|Low, medium or high dose
58275121|NCT00458575|DRUG|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
58275122|NCT04776278|BEHAVIORAL|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
58392462|NCT05755932|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
57920859|NCT02170792|DRUG|Ranitidine|150mg
57920860|NCT02340767|DEVICE|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
57920861|NCT02340767|DEVICE|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
57920862|NCT01029652|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
57920863|NCT01029652|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
57920864|NCT01029652|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
57920865|NCT01029652|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
57920866|NCT00573885|DRUG|defined green tea catechin extract|Given orally
57723780|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
57920867|NCT00573885|OTHER|placebo|Given orally
57920868|NCT05880550|OTHER|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
57920869|NCT05880550|OTHER|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
57920870|NCT03252171|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
58276775|NCT06534827|BEHAVIORAL|Great Life Mentoring|The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
57723781|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
57723782|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
57723783|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
57723784|NCT06206005|OTHER|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
58392463|NCT05755932|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
57723785|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
57723786|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
57723787|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
57723788|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
57723789|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
57723790|NCT01235039|DRUG|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
57723791|NCT01235039|DRUG|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
57723792|NCT01235039|DRUG|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
57723793|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
57723794|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
57723795|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
57723796|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
57723797|NCT01877421|DRUG|2 mg KSL-W|
57723798|NCT01877421|DRUG|4 mg KSL-W|
57723799|NCT01877421|DRUG|6 mg KSL-W|
57723800|NCT01877421|DRUG|10 mg KSL-W|
57723801|NCT01877421|DRUG|20 mg KSL-W|
57723802|NCT01877421|DRUG|30 mg KSL-W|
57723803|NCT01877421|DRUG|50 mg KSL-W|
57723804|NCT01877421|DRUG|75 mg KSL-W|
57723805|NCT01877421|DRUG|100 mg KSL-W|
57723806|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
57920871|NCT05724823|OTHER|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
57920872|NCT01708993|DRUG|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
58275123|NCT04776278|BEHAVIORAL|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
58275124|NCT04776278|BEHAVIORAL|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
57723807|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
58392464|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
57723808|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
57723809|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
57920873|NCT01708993|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
58276776|NCT03241433|OTHER|High intensity interval training|exercise by use of stationary cycles
58392465|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
58392466|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
58392467|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
58392468|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
57723810|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
57723811|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
57723812|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
57723813|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
57920874|NCT01708993|DRUG|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
57920875|NCT01708993|DRUG|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
58392469|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
57723814|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
57723815|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
57723816|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
57723817|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
57723818|NCT04153409|DRUG|Placebo|Two capsules of placebo
57723819|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
58065540|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
58275125|NCT04776278|OTHER|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
57723820|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
57723821|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
57723822|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
57723823|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
57723824|NCT02923037|OTHER|ldex measurement of arms|
58065541|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
58065542|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
58275126|NCT03438058|OTHER|Graft survival and/or Rejection appearance|
58275127|NCT05429099|PROCEDURE|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
58275128|NCT05429099|PROCEDURE|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
58276777|NCT03241433|OTHER|Moderate intensity continuous training|exercise by use of stationary cycles
58276778|NCT03241433|OTHER|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
58392470|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
58392471|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
57723825|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
57723826|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
57723827|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
57723828|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
57920876|NCT02425930|PROCEDURE|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
57920877|NCT02425930|DRUG|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
58065543|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
58275129|NCT06376305|DEVICE|EndoBarrier|"During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires."
58392472|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
58392473|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
58392474|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
58275130|NCT03220568|OTHER|Fatty acids present in adipose tissue samples|
57920878|NCT06327750|DEVICE|Hemodialysis (DNa = PNa)|High-flux hemodialysis with an expected zero diffusive sodium balance (DNa = PNa)
57920879|NCT06327750|DEVICE|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
58065544|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
58275131|NCT04748952|DEVICE|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
58275132|NCT03414905|DEVICE|Aspira Catheter|"* 15.5Fr catheter~* Standard of care"
58275133|NCT03414905|PROCEDURE|Ultrasound|Standard of care
58275134|NCT05892549|DEVICE|COVOICE application use - initial|Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
58275135|NCT05892549|DEVICE|COVOICE application use - follow-up|Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
58275136|NCT06438575|DIAGNOSTIC_TEST|Xpert® Xpress MVP test|The Xpert® Xpress MVP is an FDA-cleared point-of-care test for vaginitis diagnosis
58275137|NCT06438575|DIAGNOSTIC_TEST|Usual Care|Usual methods used by the healthcare provider for vaginitis diagnosis
58275138|NCT02952872|BEHAVIORAL|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
58275139|NCT06730932|DRUG|JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)|"Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol"
58275140|NCT05865158|OTHER|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
58392475|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
58392476|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
58392477|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
58392478|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
57920880|NCT06327750|DEVICE|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with an expected zero diffusive sodium balance (DNa=PNa)
57920881|NCT06327750|DEVICE|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with an expected zero diffusive sodium balance (DNa=PNa) Convection volume: ≥23L/session
57920882|NCT06327750|DEVICE|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L) Convection volume: ≥23L/session
57920883|NCT00256451|DRUG|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
57920884|NCT00256451|DRUG|placebo|placebo pills
57920885|NCT00256451|OTHER|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
57920886|NCT00256451|OTHER|Sham alcohol|non-alcoholic placebo alcohol
57920887|NCT04656925|BEHAVIORAL|Contingency management|Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
58065545|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
58065546|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
58392479|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
58392480|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
58392481|NCT00392834|BIOLOGICAL|rituximab|given IV
58392482|NCT00392834|DRUG|cyclophosphamide|given IV
58392483|NCT00392834|DRUG|cytarabine|given intrathecally
58392484|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
58392485|NCT00392834|DRUG|etoposide|given IV
57723829|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
58275141|NCT05672589|DIAGNOSTIC_TEST|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
58392486|NCT00392834|DRUG|ifosfamide|given IV
57723830|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
57723831|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
57723832|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
57723833|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
57723834|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
57723835|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
57723836|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
58065547|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
58065548|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
58065549|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
58275142|NCT05672589|DIAGNOSTIC_TEST|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
58275143|NCT02373007|PROCEDURE|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
58275144|NCT01900860|DIETARY_SUPPLEMENT|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
58392487|NCT00392834|DRUG|leucovorin calcium|given IV
58392488|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
58392489|NCT00392834|DRUG|methotrexate|given intrathecally
58392490|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
58392491|NCT00392834|DRUG|vincristine sulfate|given IV
58392492|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
58275145|NCT06346171|BEHAVIORAL|Virtual Reality Integrative Psychotherapy|"Music therapy: Weightless by Marconi Union plays continuously, bridging VR distraction and psychotherapy.~Before: Patients pick a VR scene (-13 to -10 min), learn VR navigation, and practice 4-7-8 breathing with a VR flower for grounding and resilience (-10 to -9 min). They continue 4-7-8 doing Progressive Muscle Relaxation (4+7 contraction, 8 relaxation), moving from lower body to facial muscles (-8 to -5 min). Values and commitment to action are discussed (-4 to -2 min), emphasizing present-focused thoughts and acceptance (-1 min).~During: Mindfulness and relaxation are encouraged, with PMR during intense moments. Empowerment and procedural feedback are provided (0 to 30/45 min).~After: Debriefing normalizes the experience, reinforcing proactive health actions (35 to 50 min)."
58275146|NCT06346171|DEVICE|Virtual Reality Distraction|"Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience."
58275147|NCT03443258|OTHER|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
57920888|NCT03616041|DEVICE|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
57920889|NCT05755360|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
57920890|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
57920891|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
57920892|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
57920893|NCT04740554|BEHAVIORAL|Control Group Typically Developing|Control group with tipical development.
57920894|NCT00862355|DRUG|SPARC147609|IV infusion
57920895|NCT00862355|DRUG|Reference147609|IV infusion
57920896|NCT06110325|OTHER|Cawthorne and Cooksey exercise program|Participants in this group will receive an exercise program based on Cawthorne and Cooksey exercises. The intervention will last for 4 weeks, taking place three times a week, with the first session conducted in person and the remaining two assisted via video from their homes.
57920897|NCT06110325|OTHER|Control|Control group will receive counseling focused on fall prevention and promotion of an active, healthy lifestyle through informational leaflets.
58065550|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
58065551|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
58275148|NCT01260961|DIETARY_SUPPLEMENT|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
58275149|NCT01260961|DIETARY_SUPPLEMENT|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
57723837|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
57723838|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
57920898|NCT03203720|BEHAVIORAL|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
57920899|NCT00711893|DEVICE|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
58275150|NCT05426109|OTHER|Peanut snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal peanut-containing (whole peanuts or peanut butter) snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
58275151|NCT05426109|OTHER|No peanut-containing snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal non-peanut-containing high carbohydrate snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
58275152|NCT02768922|OTHER|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
58275153|NCT02768922|OTHER|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
58275154|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
58275155|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
58275156|NCT04436705|OTHER|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
58275157|NCT06158009|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
58276779|NCT05404633|DEVICE|Ergogycle prototype testing for acceptability|The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
58276780|NCT00300443|DRUG|bimatoprost|
58392493|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
58392494|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
58392495|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
58392496|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
58392497|NCT00068263|RADIATION|radiation therapy|
58392498|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
58392499|NCT02400606|OTHER|Solving VP cases|See above
57920900|NCT01041352|DEVICE|laryngeal mask|LMA Proseal
57920901|NCT01041352|DEVICE|endotracheal tube|Unomedical endotracheal tube
57920902|NCT03929315|BEHAVIORAL|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
57920903|NCT06023082|DIETARY_SUPPLEMENT|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
57920904|NCT01683487|PROCEDURE|Observation|Observational study only, no intervention.
57920905|NCT03417336|RADIATION|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
57920906|NCT00547131|DRUG|temozolomide|
57920907|NCT00547131|OTHER|laboratory biomarker analysis|
58275158|NCT06158009|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
58392500|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
58392501|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
58392502|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
57723839|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
58275159|NCT04819412|BIOLOGICAL|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
58275160|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
58275161|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F2|ROTAVAC 5C formulation BBIL-R2014-2
58275162|NCT06597968|DEVICE|AI Based CAD Software (qXR-Ln)|All x-ray images have already been obtained and will then be run through CAD software for secondary nodule detection
57723840|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
57723841|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
58275163|NCT06197308|DRUG|oral vancomycin and oral amoxicillin|In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.
58275164|NCT03750409|DEVICE|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
58275165|NCT00814541|DRUG|Bortezomib|
58275166|NCT00814541|DRUG|Doxorubicin|
58275167|NCT00814541|DRUG|Dexamethasone|
58275168|NCT00300833|DRUG|Tirofiban|pci
58275169|NCT03797989|BIOLOGICAL|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
57723842|NCT00005619|GENETIC|polymerase chain reaction|
57723843|NCT00005619|OTHER|flow cytometry|
57723844|NCT00005619|OTHER|immunohistochemistry staining method|
57920908|NCT00547131|OTHER|liquid chromatography|
58275170|NCT04931719|COMBINATION_PRODUCT|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
58275171|NCT04931719|COMBINATION_PRODUCT|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
58275172|NCT04420117|OTHER|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
58275173|NCT00396916|DEVICE|PET/CT imaging|
57723845|NCT04202159|DRUG|Perampanel|Perampanel tablets.
57723846|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
57723847|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
57723848|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
57723849|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
57723850|NCT00165724|DRUG|Donepezil Hydrochloride|
57723851|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
57723852|NCT01825551|DRUG|Placebo|
57723853|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
57723854|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
57723855|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
57723856|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
57723857|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
57723858|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
57920909|NCT00547131|OTHER|mass spectrometry|
57920910|NCT00547131|OTHER|pharmacological study|
58275174|NCT02795936|PROCEDURE|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
58275175|NCT00041041|DRUG|imatinib mesylate|Given PO
58275176|NCT00041041|OTHER|laboratory biomarker analysis|Correlative studies
58275177|NCT04222842|DRUG|CM082|Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
58275178|NCT03529344|DIETARY_SUPPLEMENT|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
58275179|NCT03529344|DIETARY_SUPPLEMENT|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
58275180|NCT03329105|OTHER|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
58392503|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
58392504|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
58275181|NCT03329105|OTHER|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
58275182|NCT04490018|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
58392505|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
58392506|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
58392507|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
58392508|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
58392509|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
58392510|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
58392511|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
58392512|NCT02661737|DEVICE|YVOIRE volume s|
58392513|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
58392514|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
58392515|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
58392516|NCT00559104|DRUG|etoposide|Used in Both Arms
58392517|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
57920911|NCT00547131|PROCEDURE|conventional surgery|
57723859|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
57723860|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
57920912|NCT00547131|RADIATION|stereotactic radiosurgery|
57920913|NCT02414737|DRUG|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
58275183|NCT04490018|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
58275184|NCT04490018|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58275185|NCT04490018|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58276781|NCT01603394|DRUG|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
58392518|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
58392519|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
58392520|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
58392521|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
58392522|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
58392523|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
58392524|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
58275186|NCT01624402|BEHAVIORAL|Education on Stroke and Depression (ESD)|"* Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
58392525|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
58392526|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
58392527|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
58392528|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
58392529|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
58392530|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
58065552|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
57920914|NCT01211522|DRUG|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
58392531|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
58275187|NCT01624402|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|"1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
58275188|NCT02062775|PROCEDURE|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
58275189|NCT02062775|PROCEDURE|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
58275190|NCT02062775|PROCEDURE|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures \>2cm
58392532|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
58392533|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
57723861|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
57723862|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
57723863|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
57723864|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
57920915|NCT01211522|DRUG|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
57920916|NCT01211522|DRUG|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
57920917|NCT04065178|BEHAVIORAL|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
57920918|NCT02024763|BEHAVIORAL|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
58065553|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
58065554|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
58065555|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
58065556|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
58275191|NCT04825496|GENETIC|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
57723865|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
57920919|NCT02852473|OTHER|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
58065557|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
57920920|NCT01173198|DEVICE|WAVEFRONT Optimized LASIK|30 patients
57920921|NCT01173198|DEVICE|WAVEFRONT GUIDED LASIK|30 patients
58275192|NCT04825496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
58275193|NCT04825496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
58275194|NCT02265757|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
58275195|NCT02265757|BEHAVIORAL|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
58275196|NCT02265757|BEHAVIORAL|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
58392534|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
58392535|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
57723866|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
57723867|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
57723868|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
58275197|NCT02265757|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
57723869|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
57723870|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
57920922|NCT05854550|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
57920923|NCT04355910|BEHAVIORAL|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
57920924|NCT05477459|DRUG|LSD tartrate|LSD tartrate equivalent to 25 microgram LSD base
57920925|NCT05477459|DRUG|Placebo|Placebo vials with equal appearance
57920926|NCT00200460|DRUG|Nebivolol|
57920927|NCT03015818|OTHER|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
57920928|NCT00313001|DRUG|biphasic insulin aspart|
57920929|NCT00313001|DRUG|exenatide|
57920930|NCT06062732|BEHAVIORAL|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
57920931|NCT06062732|BEHAVIORAL|Control|Services as usual
57920932|NCT02686060|DEVICE|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
57920933|NCT05225350|BEHAVIORAL|Dietary Intervention|"See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months."
57920934|NCT02946970|OTHER|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
57920935|NCT02946970|OTHER|Control|Intragastric administration of distilled water
57920936|NCT01810120|BIOLOGICAL|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
57920937|NCT01932554|DRUG|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
58275198|NCT02265757|BEHAVIORAL|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
57723871|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
57723872|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
57723873|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
57723874|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
57723875|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
57920938|NCT01932554|DRUG|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
57920939|NCT01932554|OTHER|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
57920940|NCT01932554|DRUG|Ibuprofen|Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
57920941|NCT01932554|DRUG|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
57920942|NCT01932554|OTHER|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
57920943|NCT01932554|OTHER|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
57920944|NCT04654065|DRUG|IN-C004|One time dose of IN-C004 taken orally.
57920945|NCT01115790|DRUG|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
58065558|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
58065559|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
57723876|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
58065560|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
58065561|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
58275199|NCT06434363|DRUG|Tafasitamab|Given by vein (IV)
58275200|NCT06434363|DRUG|Fludarabine phosphate|Given by vein (IV)
58275201|NCT06434363|DRUG|Cyclophosphamide|Given by vein (IV)
58392536|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
58392537|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
58392538|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
57723877|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
57723878|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
57920946|NCT02411500|DRUG|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
57920947|NCT04705636|DEVICE|"Connected device named Leo from Ludocare society"|"Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device."
57920948|NCT01690611|PROCEDURE|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
58275202|NCT05844085|OTHER|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
58275203|NCT05844085|OTHER|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
58275204|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
58275205|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
58275206|NCT00001341|DRUG|ZD1694 (TOMUDEX)|
58275207|NCT00381329|BEHAVIORAL|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
58275208|NCT00381329|BEHAVIORAL|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
58275209|NCT03712267|BEHAVIORAL|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
58275210|NCT03712267|BEHAVIORAL|Treatment as Usual|Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
58275211|NCT01118572|DRUG|YM177|oral
58275212|NCT01118572|DRUG|etodolac|oral
58392539|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
58392540|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
58275213|NCT01118572|DRUG|Placebo|oral
58275214|NCT02696434|DRUG|Naltrexone|daily dosing
58392541|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
57723879|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
57920949|NCT01690611|OTHER|Visual Feedback|Real time feedback regarding body motion while walking.
58065562|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
58065563|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
58065564|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
58275215|NCT02696434|DRUG|Placebo|daily dosing
58275216|NCT02696434|DRUG|Buprenorphine|daily dosing
58275217|NCT06731556|DRUG|Intravenous paracetamol|Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.
58275218|NCT06731556|DRUG|Intranasal Paracetamol|Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.
58275219|NCT06731556|DRUG|Intranasal Diclofenac Sodium|Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
58275220|NCT06731556|DRUG|Intranasal Ibuprofen|Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
58275221|NCT06162377|DRUG|Methylnaltrexone|Given by SC (injection)
58275222|NCT04174937|DRUG|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
57723880|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
57920950|NCT02916680|PROCEDURE|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
57920951|NCT03448133|DEVICE|Magstim rTMS|The device is made in London,UK
58275223|NCT04174937|OTHER|Placebo PA|Intervention is administered to patients in this Arm
58275224|NCT02203162|DEVICE|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
57723881|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
58275225|NCT04049006|OTHER|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
57723882|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
57723883|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
57723884|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
57723885|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
58275226|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
58275227|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
58275228|NCT03131934|PROCEDURE|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
57723886|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
57920952|NCT00125281|DRUG|S-adenosyl-methionine (SAMe) capsules|
57920953|NCT03610165|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
57920954|NCT03610165|DEVICE|Control|Arterial waveform and pressures
57920955|NCT02539537|DRUG|Gemcitabine|
57920956|NCT02539537|DRUG|Folinic Acid|
57920957|NCT02539537|DRUG|5-Fluoro-uracil|
57920958|NCT02539537|DRUG|Oxaliplatin|
57920959|NCT02539537|DRUG|Irinotecan|
57920960|NCT02539537|DRUG|L-folinic|
57920961|NCT04191044|OTHER|A complete cardiovascular and liver characterization will be carried out|A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
57920962|NCT05478551|DRUG|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
57920963|NCT05478551|DRUG|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
57920964|NCT02736604|DRUG|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
58275229|NCT04929860|BEHAVIORAL|social marketing campaign|social marketing campaign delivered over 4 weeks in 4 separate sessions
58392542|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
57723887|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
57723888|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
57723889|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
57723890|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
57723891|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
57723892|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
57920965|NCT02736604|DRUG|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
57920966|NCT02736604|DEVICE|laryngeal mask airway (LMA Supreme Size 3/4|
57920967|NCT02736604|DRUG|sevoflurane|
57920968|NCT02791373|DRUG|Vinorelbine|Mobilisation Chemotherapy
57920969|NCT02791373|DRUG|Gemcitabine|Mobilisation Chemotherapy
57920970|NCT03885830|DRUG|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
57920971|NCT03885830|DRUG|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
57920972|NCT03885830|DRUG|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
57920973|NCT03885830|DRUG|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
57723893|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
57723894|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
58275230|NCT05621967|BEHAVIORAL|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
58275231|NCT05621967|BEHAVIORAL|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
58275232|NCT05621967|BEHAVIORAL|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
58275233|NCT02485418|DRUG|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
58275234|NCT05835427|OTHER|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
58275235|NCT05835427|OTHER|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
58392543|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
57723895|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
57723896|NCT02575664|DRUG|Placebo|Placebo patch
57723897|NCT01334697|DRUG|recombinant human cardiotrophin-1|Single dose intravenous administration
57723898|NCT01334697|OTHER|Placebo|Single dose intravenous administration
57723899|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
57920974|NCT06434454|BEHAVIORAL|EFT Group:Emotional Free Technıcal|The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
57920975|NCT05438368|BIOLOGICAL|bi-4SCAR GD2/CD70 T cells|Infusion of bi-4SCAR GD2/CD70 T cells at 10\^6 cells/kg body weight via IV
57920976|NCT05735795|OTHER|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
57920977|NCT03668353|BIOLOGICAL|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
57920978|NCT01016977|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
58275236|NCT00426660|DRUG|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
58275237|NCT01555918|DRUG|Isavuconazole|oral
58275238|NCT01555918|DRUG|Isavuconazole (IV)|intravenous (IV)
58275239|NCT01739764|DRUG|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
58275240|NCT04220099|PROCEDURE|Electroconvulsive therapy(ECT)|Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
58275241|NCT05307718|DRUG|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
58275242|NCT03818555|OTHER|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
58275243|NCT04936113|BIOLOGICAL|FB-401|Topical
58275244|NCT00987597|BEHAVIORAL|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
58275245|NCT00987597|BEHAVIORAL|conventional follow-up|nicotinic substitutes
57723900|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
57723901|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
57723902|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
57920979|NCT01016977|DRUG|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
57920980|NCT01507818|DEVICE|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0\>
58275246|NCT05432219|PROCEDURE|endoscopic surgery|endoscopic resection of recurrent nasopharyngeal carcinoma via the transoral retropterygoid nasopharyngectomy approach
58392544|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
58392545|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
58392546|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
58275247|NCT00049075|DRUG|fludarabine phosphate|
58275248|NCT03157726|PROCEDURE|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
58392547|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58392548|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
57920981|NCT01507818|DEVICE|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
57920982|NCT05419362|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
57920983|NCT05419362|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
57920984|NCT04746443|OTHER|NOT APPLICABLE (NA)|THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
58275249|NCT03157726|PROCEDURE|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
58275250|NCT01081405|OTHER|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
58275251|NCT05509010|PROCEDURE|CTCA|CTCA is performed as part of routine care procedure.
58392549|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
58392550|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
58392551|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
58392552|NCT01282242|DRUG|IV rt-PA|open-label
58392553|NCT02222688|DRUG|cirmtuzumab|
58392554|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
58392555|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
58392556|NCT00405392|DRUG|Ibandronate (SB743830HD)|
58392557|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
58392558|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
57920985|NCT02370810|BEHAVIORAL|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
57920986|NCT03248154|DEVICE|Procellera|burn dressing
58392559|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
58392560|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
58392561|NCT00600106|DRUG|Placebo|1 mg placebo
58392562|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
58392563|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
58392564|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
58392565|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
58392566|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
58392567|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
58392568|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
57920987|NCT03098420|DRUG|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
57920988|NCT03098420|DRUG|4mg Dexamethasone|1 mL (4mg) of dexamethasone
57920989|NCT03098420|DRUG|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
57920990|NCT03098420|DRUG|Morphine|
57920991|NCT03098420|DRUG|Bupivacaine Hydrochloride|
57920992|NCT03098420|DRUG|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
57920993|NCT03098420|DRUG|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
58275252|NCT04792372|PROCEDURE|Initial periodontal treatment|Conventional periodontal treatment (scaling and root debridement) will be conducted
58275253|NCT04172922|DRUG|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
58275254|NCT03856333|OTHER|Assigned Interventions|exercises, physical agents
58275255|NCT06442449|BIOLOGICAL|sIPV|vaccination with sIPV
58275256|NCT06442449|BIOLOGICAL|MMR|vaccination with MMR
58275257|NCT06442449|BIOLOGICAL|HepA-I|vaccination with HepA-I
58275258|NCT06593652|BEHAVIORAL|Teen Intervene - Adolescent Only|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills.
58275259|NCT06593652|BEHAVIORAL|Teen Intervene with Caregiver Session|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills. In this condition, the caregiver session will address caregiver expectations around youth substance use and strategies for promoting positive youth behavior change including reduced substance use.
57920994|NCT06003946|BEHAVIORAL|BreLax: Antenatal education class|An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.
58275260|NCT06593652|BEHAVIORAL|Family Check Up|Family Check-Up Online (FCU-O) is a self-paced, parent-driven, fully HIPAA compliant online version of the Family Check-Up (FCU), a brief intervention that integrates assessment, motivation-enhancement, and skill building to help parents effectively manage behavior and build positive relationships with their children aged 2-17 in order to reduce emotional and behavioral problems among youth.
58275261|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
58275262|NCT03057964|DEVICE|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
58275263|NCT03057964|DEVICE|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
58275264|NCT00123461|DRUG|Hectorol (doxercalciferol capsules), 0.5mcg|
57920995|NCT06003946|BEHAVIORAL|Standard care (control)|An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.
57920996|NCT02424513|RADIATION|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
58275265|NCT02093403|DRUG|decitabine|Given IV
58275266|NCT02093403|DRUG|selinexor|Given PO
58392569|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
58275267|NCT02093403|OTHER|pharmacological study|Correlative studies
58275268|NCT02093403|OTHER|laboratory biomarker analysis|Correlative studies
58275269|NCT01390571|DRUG|olaparib|
58275270|NCT01390571|DRUG|temozolomide|
58392570|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
58275271|NCT01390571|GENETIC|gene expression analysis|
58275272|NCT01390571|GENETIC|protein expression analysis|
58392571|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
58392572|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
57920997|NCT02123433|BIOLOGICAL|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
58275273|NCT01390571|OTHER|laboratory biomarker analysis|
58275274|NCT01390571|OTHER|pharmacological study|
58275275|NCT01390571|PROCEDURE|diffusion-weighted magnetic resonance imaging|
58275276|NCT01390571|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
58275277|NCT01390571|PROCEDURE|therapeutic conventional surgery|
58275278|NCT05456633|DEVICE|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
58275279|NCT05456633|OTHER|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
58275280|NCT05456633|DEVICE|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
58275281|NCT02468713|DRUG|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
58275282|NCT02468713|DRUG|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
58275283|NCT04283474|DRUG|XG005-03|3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
58275284|NCT04283474|DRUG|Placebo|Placebo topical formulation
58392573|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
58065565|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
58065566|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
58065567|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
58065568|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
58275285|NCT04081831|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
58275286|NCT00203463|DRUG|topiramate|
58065569|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
57723903|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
58065570|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
58065571|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
58065572|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
58065573|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
58065574|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
58275287|NCT02735096|DEVICE|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
58275288|NCT04772521|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
58392574|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
58392575|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58392576|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
58392577|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
58392578|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58392579|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
57920998|NCT06385756|DRUG|Amobarbital|Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.
57920999|NCT06385756|DRUG|Propofol|propofol
58065575|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
58065576|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
58392580|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided liver biopsy
58392581|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
58065577|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
58065578|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
58392582|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
58392583|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
58392584|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
58392585|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
58392586|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
57921000|NCT02142660|PROCEDURE|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
58065579|NCT04421105|DRUG|Placebo|
58065580|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
58065581|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
58065582|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
58065583|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
58392587|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
58392588|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
58392589|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
58392590|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
58392591|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
58392592|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
58392593|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
58392594|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
58392595|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
58392596|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
58392597|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
58392598|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
58392599|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
58275289|NCT04772521|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
58392600|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
58392601|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
58392602|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
58392603|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
58392604|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
58392605|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
57921001|NCT00373815|DRUG|Everolimus|
57921002|NCT01749020|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
58392606|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
57921003|NCT01749020|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
58392607|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
58392608|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
58275290|NCT04772521|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
57723904|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
57921004|NCT02919657|DIETARY_SUPPLEMENT|Genepro Protein|weekly blood draws to measure blood protein levels
57921005|NCT02919657|DIETARY_SUPPLEMENT|Whey Protein|weekly blood draws to measure blood protein levels
58275291|NCT04772521|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
58392609|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
58392610|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58392611|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
58392612|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57921006|NCT02600338|OTHER|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
57921007|NCT00822172|DIETARY_SUPPLEMENT|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
57921008|NCT00822172|DRUG|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
57921009|NCT02483182|DRUG|ZEP-3 ointment 1.0%|
57921010|NCT02483182|DRUG|Acyclovir cream 5%|
57921011|NCT02972866|DRUG|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
57921012|NCT04187053|PROCEDURE|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
58392613|NCT06661811|DRUG|CAR-T|CAR-T cells
58392614|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
58392615|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
58392616|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
57921013|NCT04187053|DRUG|Saline|Sham group will receive saline as a sham for methylene blue
57921014|NCT04187053|DRUG|Methylene Blue|Experimental arm will receive methylene blue
57921015|NCT04187053|DEVICE|Light emitting laser|Experimental arm will receive Light emitting laser
57921016|NCT04187053|DEVICE|Non-light emitting laser|Sham group will receive Non-light emitting laser
58275292|NCT04772521|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
58275293|NCT06084624|DRUG|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
58275294|NCT06084624|DRUG|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
58275295|NCT01475032|DRUG|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
58392617|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
57921017|NCT00692978|DRUG|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
57921018|NCT00692978|DRUG|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
57921019|NCT00692978|DRUG|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
57921020|NCT00692978|DRUG|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
58275296|NCT01475032|DRUG|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
58065584|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
57921021|NCT04866498|DRUG|Infusion Intravenous|
58275297|NCT01475032|DRUG|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
58065585|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
58065586|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
58275298|NCT06001541|BEHAVIORAL|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
58275299|NCT03063099|OTHER|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
58275300|NCT01389258|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
58275301|NCT02074800|DRUG|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
58275302|NCT02074800|DRUG|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
58275303|NCT02074800|DRUG|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
58275304|NCT04448639|DIAGNOSTIC_TEST|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
58275305|NCT04448639|DIAGNOSTIC_TEST|Bloodtest|cardiac biomarkers
58392618|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
57921022|NCT02888704|DRUG|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
57921023|NCT01122251|DRUG|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
57921024|NCT01122251|DRUG|Lercanidipine or Valsartan|L10, L20, V80, V160
58275306|NCT05155930|BEHAVIORAL|Internal Family Systems (IFS)|Weekly individual psychotherapy
58275307|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
58392619|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
57921025|NCT01122251|DRUG|Placebo|Placebo of Lercanidipine and Valsartan
57921026|NCT05866926|DRUG|FAB122|FAB122 Daily dose 100 mg
57921027|NCT00146354|BEHAVIORAL|Hospitalists Results Manager|
58275308|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
58275309|NCT01464853|OTHER|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
58275310|NCT01464853|OTHER|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
58275311|NCT03156569|DIAGNOSTIC_TEST|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
58275312|NCT02971800|DRUG|sodium fluorescein injection 10%|
58275313|NCT05288933|DEVICE|Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound|"Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects."
57723905|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
57921028|NCT06181565|OTHER|Datas of Medistim machine|Datas will be collected by Medistim machine before and after pericardial closure: Flow through the grafts, Resistance on grafts, Pulsatility of the grafts, Systolic and diastolic curves before and after pericardial closure
58392620|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
58392621|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
58392622|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
58392623|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
58392624|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
58392625|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
57723906|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
57921029|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
57921030|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
57921031|NCT06323577|PROCEDURE|Restricted kinematic alignment|TKA using restricted kinematic alignment under robotic assisted surgery (MAKO).
58392626|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
57921032|NCT06323577|PROCEDURE|Mechanical alignment|TKA using mechanical alignment under robotic assisted surgery (MAKO).
57921033|NCT00402363|DRUG|omega-3-acid ethyl esters|
57921034|NCT00402363|DRUG|Placebo|
57921035|NCT03155256|PROCEDURE|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
57921036|NCT03155256|PROCEDURE|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
57921037|NCT01725542|DRUG|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
58275314|NCT04106271|OTHER|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
58275315|NCT01469975|DRUG|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
58392627|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
57921038|NCT02521220|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
57921039|NCT02521220|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
57921040|NCT05158582|OTHER|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
58392628|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
58275316|NCT01469975|DRUG|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
58275317|NCT01469975|DRUG|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
58392629|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
58392630|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
58392631|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
58392632|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
57921041|NCT05158582|OTHER|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
58392633|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
57921042|NCT02182570|DRUG|WAL 801 CL dry syrup|
57921043|NCT04123392|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
57921044|NCT04123392|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
58392634|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
58392635|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
58392636|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
57921045|NCT04123392|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
57921046|NCT01424150|OTHER|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
57921047|NCT01424150|OTHER|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
57921048|NCT00191867|DRUG|Teriparatide|
57921049|NCT06060093|DIETARY_SUPPLEMENT|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
58392637|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
58392638|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
58392639|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
58392640|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
58392641|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
58392642|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
58275318|NCT04456166|DIETARY_SUPPLEMENT|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
58392643|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
58392644|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
58392645|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
58392646|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
58392647|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
58392648|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
58392649|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
57921050|NCT06060093|DIETARY_SUPPLEMENT|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
57921051|NCT03133520|DEVICE|High flow oxygen therapy|High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
57921052|NCT06450431|OTHER|SF-36 questionnaire French version and PAS.fr questionnaire|Patients will receive both the SF-36 questionnaire (control generic questionnaire for QoL evaluation validated in French language) and the PAS.fr questionnaire at the designated time (before surgery, 6, 12 or 36 months after surgery) during the consultation, or by mail. For concurrent validation of the PAS.fr questionnaire, a second questionnaire will be sent to the patients 2-4 weeks thereafter.
57921053|NCT00133887|DRUG|rapamycin|3 to 5 mg/day
57921054|NCT00133887|DRUG|ciclosporine|Blood residual level \< or = to 125 ng/ml
58392650|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
58392651|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
57921055|NCT00133887|DRUG|tacrolimus|Blood residual level \< or = to 8 ng/ml
57921056|NCT00430443|DRUG|Liposomal Annamycin|3-day IV infusion
57921057|NCT01703663|DEVICE|EPAP|
57921058|NCT04660266|DIAGNOSTIC_TEST|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
57921059|NCT05183854|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
57921060|NCT05183854|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
57921061|NCT05183854|OTHER|Questionnaire Administration|Ancillary studies
57921062|NCT01305525|DEVICE|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
57921063|NCT00084578|DRUG|celecoxib|
57921064|NCT00084578|DRUG|rosiglitazone maleate|
57921065|NCT00084578|PROCEDURE|conventional surgery|
57921066|NCT00084578|PROCEDURE|neoadjuvant therapy|
57921067|NCT02550665|DRUG|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
57921068|NCT02146651|DRUG|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
57921069|NCT02146651|DRUG|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
57921070|NCT02146651|DRUG|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
57921071|NCT02146651|DRUG|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
57921072|NCT04412915|OTHER|Labor induction|Labor induction with oxytocin or prostagladin
57921073|NCT01978860|DEVICE|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
58392652|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
58392653|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
58392654|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
58392655|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
58275319|NCT03116009|DRUG|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
58392656|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
58392657|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
58392658|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
57723907|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
57921074|NCT03732313|PROCEDURE|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
57921075|NCT03732313|PROCEDURE|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
58392659|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
58392660|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
57723908|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
57723909|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
57723910|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
57723911|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
57723912|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
57921076|NCT02910661|OTHER|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
57723913|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
57921077|NCT01662115|DRUG|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
58275320|NCT00103298|DRUG|FOLFOX regimen|
58392661|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
58392662|NCT01734785|DRUG|Linagliptin|tablet
58392663|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
57723914|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
58275321|NCT00103298|DRUG|fluorouracil|
58275322|NCT00103298|DRUG|isolated perfusion|
57723915|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
57723916|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
57723917|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
57723918|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
57723919|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
57723920|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
57921078|NCT01662115|OTHER|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
58065587|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
58392664|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
58392665|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
58392666|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
58392667|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
57723921|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
58275323|NCT00103298|DRUG|leucovorin calcium|
58275324|NCT00103298|DRUG|melphalan|
58275325|NCT00103298|DRUG|oxaliplatin|
58275326|NCT03468452|OTHER|extubation|Time of extubation
58275327|NCT02536781|DRUG|Anthocyanin|Anti-inflammation gel
58275328|NCT02536781|DRUG|Placebo|Blank gel
58275329|NCT06730984|OTHER|Endoscopy-Assisted Tracheal Intubation|Tracheal Intubation Under Endoscopic Guidance
58275330|NCT06730984|OTHER|Traditional Tracheal Intubation|Tracheal Intubation Under Video Laryngoscopy
57723922|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
58275331|NCT05392088|OTHER|DATA EXTRACTION|"For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status."
58275332|NCT05392088|OTHER|FOLLOW-UP|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
58275333|NCT02041052|PROCEDURE|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
58275334|NCT02041052|PROCEDURE|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
58275335|NCT00000290|DRUG|Cocaine|
58275336|NCT00000923|DRUG|Indinavir sulfate|
58392668|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
58392669|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
57723923|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
57723924|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
57921079|NCT02456077|BEHAVIORAL|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
57921080|NCT02737917|OTHER|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
57921081|NCT02737917|OTHER|Standard of care|Rapid sequence intubation
58392670|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
58392671|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
58392672|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
58275337|NCT00000923|DRUG|Lamivudine|
58275338|NCT00000923|DRUG|Stavudine|
58275339|NCT00000923|DRUG|Zidovudine|
58275340|NCT00000923|DRUG|Didanosine|
58275341|NCT00000923|DRUG|Aldesleukin|
58275342|NCT00870610|PROCEDURE|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
58275343|NCT01903993|DRUG|Docetaxel|Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
58275344|NCT01903993|DRUG|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
58275345|NCT05859763|DRUG|99mTc-HFAPI|Each patient receive a intravenous injection of 99mTc-HFAPI, and undergo SPECT/CT scan within specified time.
58275346|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
58275347|NCT04715217|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
58392673|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
58392674|NCT00191945|DRUG|Atomoxetine Hydrochloride|
58275348|NCT05376293|BEHAVIORAL|Behavioral Internet program|The 12-week behavioral Internet program is designed to increase physical activity to recommended levels. Participants will be asked to plan and report aerobic exercise weekly, watch weekly video lessons, and complete brief weekly homework assignments.
58275349|NCT05376293|BEHAVIORAL|Informational newsletter condition|Newsletters will focus on the health benefits of regular physical activity, exercise safety, and will provide information on national exercise guidelines.
58275350|NCT01025466|DRUG|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
58275351|NCT01025466|DRUG|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
58275352|NCT00094523|DRUG|Fosamprenavir|Fosamprenavir
58275353|NCT03278405|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
58275354|NCT06330220|DRUG|Aflibercept Injection [Eylea]|intravitreal injection
58392675|NCT00191945|DRUG|placebo|
58392676|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
58392677|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
58392678|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
58275355|NCT00862459|DRUG|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
58275356|NCT00862459|DRUG|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
58275357|NCT00862459|DRUG|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
58392679|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
58392680|NCT02159898|DEVICE|EndoMAXX|
58392681|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
58392682|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
58392683|NCT00297960|DRUG|ziprasidone or olanzapine|
58275358|NCT00862459|DRUG|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
58275359|NCT00396383|DRUG|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
58392684|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
58392685|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
58392686|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
58392687|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
58392688|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
58392689|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
58392690|NCT06661291|DEVICE|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
58392691|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
58392692|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
57921082|NCT05368987|DEVICE|Transcranial magnetic stimulation (TMS)|Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
57921083|NCT00100386|PROCEDURE|Intensive Control Strategy|
57921084|NCT00100386|BEHAVIORAL|Standard Control Strategy|
57921085|NCT02294916|DEVICE|AWS|Video-laryngoscopy 1
57921086|NCT02294916|DEVICE|Intubrite|Video-laryngoscopy 2
58275360|NCT00577005|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
58275361|NCT00577005|DRUG|Placebo|
58275362|NCT03472313|DRUG|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
58275363|NCT00401401|DRUG|zalutumumab|Eight weekly infusions
58275364|NCT00401401|DRUG|cisplatin|Infusions
58275365|NCT00401401|PROCEDURE|Radiotherapy|Daily in the treatment period
58275366|NCT01918072|OTHER|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
58275367|NCT02696928|DRUG|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
58275368|NCT02696928|DRUG|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
58275369|NCT02696928|DRUG|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
58275370|NCT02787083|DRUG|Mirabegron|
58275371|NCT02787083|DRUG|Placebo|
58275372|NCT01375634|DRUG|Midazolam|2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
58275373|NCT02273908|OTHER|No intervention|The study is observational
58275374|NCT02083653|DRUG|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
57921087|NCT02294916|DEVICE|AirTraq|Optical-laryngoscopy
57921088|NCT02294916|DEVICE|MIL|Direct-laryngoscopy
58275375|NCT02083653|DRUG|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
58275376|NCT02083653|OTHER|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
58275377|NCT02083653|DRUG|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
58275378|NCT02083653|DRUG|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
57921089|NCT02084641|OTHER|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
57921090|NCT02866110|BEHAVIORAL|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
57921091|NCT02866110|DEVICE|MRI|Echo-planar Imaging of brain BOLD signal
57921092|NCT03064035|DRUG|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
58275379|NCT06057181|GENETIC|Exome sequencing|Exome sequencing will be completed on each sample submitted.
58275380|NCT03998137|DEVICE|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
58275381|NCT03998137|PROCEDURE|Standard of Care|Autologous Bone Graft
58275382|NCT06731231|DRUG|SGLT2 inhibitor|Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
58275383|NCT06601465|DRUG|Vericiguat|Tablet - 2.5 mg, 5 mg, 10 mg
58275384|NCT02398370|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
58275385|NCT00546741|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
58275386|NCT00546741|DRUG|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
58275387|NCT00546741|DRUG|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
58275388|NCT04484844|DRUG|TOKUYAMA SHIELD FORCE PLUS|Self-reinforcing (SR) monomer technology
57921093|NCT04089969|DIAGNOSTIC_TEST|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
57921094|NCT04089969|DIAGNOSTIC_TEST|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
57921095|NCT00156884|DRUG|strontium-89|
57921096|NCT00156884|DRUG|cisplatin|
57921097|NCT05397860|PROCEDURE|Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes|Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
57921098|NCT05296720|BEHAVIORAL|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
57921099|NCT04834856|DRUG|ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
57921100|NCT04938024|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
57921101|NCT06044402|OTHER|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
58275389|NCT04484844|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
58275390|NCT04081116|OTHER|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
58275391|NCT04081116|OTHER|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
58275392|NCT04081116|OTHER|Preinclusion settings|Settings in use at start of study
58275393|NCT02102100|DRUG|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
58275394|NCT02102100|DRUG|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
58275395|NCT02278692|DIETARY_SUPPLEMENT|Vitamin K|Oral vitamin K
58275396|NCT02278692|OTHER|Placebo|Oral placebo tablet
58275397|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
58275398|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
58275399|NCT02527915|OTHER|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
58275400|NCT02527915|OTHER|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
58275401|NCT03124355|DRUG|placebo sugar pill|placebo single oral dose
58275402|NCT03124355|DRUG|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
58275403|NCT03124355|DRUG|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
58275404|NCT03124355|DEVICE|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
57921102|NCT06044402|OTHER|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
57921103|NCT05525884|OTHER|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
57921104|NCT00223522|DEVICE|MEMS caps|
57921105|NCT00219453|DEVICE|Jet Injector with Protector Cap (HSI-500)|
57921106|NCT05988255|DEVICE|Static progressive stretching|A stretching technique applies a mechanical progressive stretch
57921107|NCT05988255|OTHER|Cyclic manual stretching|A stretching technique applies an intermittent manual stretch
57921108|NCT03765320|PROCEDURE|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
57921109|NCT03765320|PROCEDURE|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
58065588|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
57921110|NCT03688607|PROCEDURE|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
58392693|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
58392694|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
58275405|NCT03124355|DEVICE|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
57921111|NCT04261023|DRUG|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
57921112|NCT02905994|DRUG|Volasertib|Polo-Like Kinase Inhibitor
57921113|NCT02905994|DRUG|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
57921114|NCT02905994|DRUG|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
57921115|NCT02905994|PROCEDURE|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
57921116|NCT05321888|OTHER|Mechanical Ventilation|Standard Protocol
57921117|NCT05321888|OTHER|Mechanical Ventilation with Postural drainage|This Group will be treated by postural drainage and mechanical ventilation for two consecutive days
57921118|NCT02049151|DRUG|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
57921119|NCT02049151|DRUG|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
58275406|NCT00076258|BEHAVIORAL|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
57921120|NCT02049151|DRUG|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
57921121|NCT02049151|DRUG|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
57921122|NCT04362605|PROCEDURE|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
57921123|NCT02564354|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
58065589|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
58065590|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
58275407|NCT00076258|BEHAVIORAL|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
58275408|NCT03930784|OTHER|Nil intervention|
58392695|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
58392696|NCT04829786|DRUG|palovarotene low-dose|oral capsules
58392697|NCT04829786|DRUG|palovarotene high-dose|oral capsules
58392698|NCT01023685|BIOLOGICAL|CAD106|
58392699|NCT05536414|DRUG|Centanafadine|capsule
58392700|NCT05536414|DRUG|Escitalopram|capsule
58392701|NCT05536414|DRUG|Placebo|capsule
57723925|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
58275409|NCT03213418|BEHAVIORAL|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
58392702|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
58392703|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
58392704|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
58275410|NCT02115061|DEVICE|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
58275411|NCT02115061|DEVICE|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
58275412|NCT04785560|DEVICE|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
58275413|NCT02254057|DRUG|BIBT 986 BS - single rising dose|
58275414|NCT02254057|DRUG|Placebo|
58392705|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
58392706|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
58392707|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
58392708|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
58392709|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
58392710|NCT00460460|DRUG|AZD4877|
58392711|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
58275415|NCT02709681|OTHER|Physician standard-of-care in SCD patients|
58275416|NCT05769920|DRUG|TTHX1114(NM141) Ophthalmic Solution|Eye drop twice daily
58276782|NCT05514743|PROCEDURE|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
58392712|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
58392713|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
57723926|NCT02966080|DRUG|HEP-IV|
57723927|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
57723928|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
58392714|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
58392715|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
58392716|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
58392717|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
58392718|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
57723929|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
57921124|NCT01588834|PROCEDURE|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
58065591|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
58065592|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
58275417|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
58275418|NCT03648554|DRUG|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
58275419|NCT03648554|OTHER|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
58275420|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly"
58275421|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly"
58392719|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
58392720|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
57723930|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
58392721|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
58392722|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
57723931|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
57723932|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
58065593|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
58065594|NCT00693524|DRUG|tacrolimus|oral
58392723|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
58392724|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
58392725|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
57921125|NCT01703351|DRUG|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
57921126|NCT01703351|DRUG|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
57921127|NCT00938470|DRUG|capecitabine|Given PO
57921128|NCT00938470|DRUG|docetaxel|Given IV
57723933|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
58392726|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
57921129|NCT00938470|DRUG|fluorouracil|Given IV
58392727|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
58392728|NCT01703091|DRUG|Ramucirumab|Administered IV
58392729|NCT01703091|DRUG|Placebo|Administered IV
57921130|NCT00938470|DRUG|oxaliplatin|Given IV
58392730|NCT01703091|DRUG|Docetaxel|Administered IV
58392731|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
58065595|NCT00693524|DRUG|Anti-IL2R AB|i.v.
58275422|NCT03271671|OTHER|NAVA during Non invasive ventilation|NIV during respiratory failure
58275423|NCT03271671|OTHER|PSV during Non invasive ventilation|PSV during respiratory failure
58275424|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
58392732|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
58065596|NCT00693524|DRUG|Mycophenolate mofetil|oral
58392733|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
58392734|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
58392735|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
58392736|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
58392737|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
57723934|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
57723935|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
58065597|NCT00693524|DRUG|prednisone|oral
58065598|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
58065599|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
58275425|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
58275426|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
58275427|NCT00422292|BIOLOGICAL|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
57723936|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
57723937|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
57921131|NCT00938470|RADIATION|radiation therapy|Undergo radiation therapy
57921132|NCT00938470|PROCEDURE|therapeutic conventional surgery|Undergo surgery
57921133|NCT00381303|DRUG|darunavir|600mg bid for 48 wks
57921134|NCT00381303|DRUG|ritonavir|100mg bid for 48 wks
57921135|NCT04295980|PROCEDURE|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
57921136|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
57921137|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
57921138|NCT06148974|DIETARY_SUPPLEMENT|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
57921139|NCT06148974|OTHER|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
58065600|NCT02050256|OTHER|continuing medical education and electronic decision support|
58065601|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
58065602|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
58275428|NCT04812405|DIAGNOSTIC_TEST|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
58275429|NCT06655467|BEHAVIORAL|Routine Care|This study involves no change in clinical care and no study specific interventions for participants.
58276783|NCT01134289|PROCEDURE|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
57723938|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
57723939|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
57723940|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
57723941|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
57921140|NCT04811209|OTHER|1.Baseline Measurements Before Surgery|"* Baseline demographic data~* Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~* Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~* Preoperative pain state using NRS (0-10)~* Preoperative functional state using the QoR-15 questionnaire~* Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~* Pain castastrophizing scale"
57921141|NCT04811209|OTHER|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
57921142|NCT04811209|OTHER|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~1. acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~2. NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~3. Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~4. In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
57921143|NCT04811209|OTHER|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
57921144|NCT04811209|OTHER|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
58275430|NCT03295175|DIAGNOSTIC_TEST|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
58275431|NCT03307122|OTHER|Routine Infant Formula 1|Routine infant formula with probiotic
58275432|NCT03307122|OTHER|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
58275433|NCT03669484|DRUG|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
58275434|NCT03669484|DRUG|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
58275435|NCT03669484|DRUG|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
58275436|NCT03669484|DRUG|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
58275437|NCT06233877|DRUG|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
58275438|NCT06731374|BIOLOGICAL|PCV15|VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.
58275439|NCT06731374|BIOLOGICAL|Streptococcus pneumoniae serotype 3|Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.
58275440|NCT06731374|BIOLOGICAL|Placebo|The placebo consists of 0.9% sodium chloride for injection
58275441|NCT01242501|BEHAVIORAL|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
58276784|NCT01713894|OTHER|Decision Aid|
58276785|NCT01713894|OTHER|Standard|
57723942|NCT04909697|DRUG|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
57723943|NCT04909697|DRUG|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
57723944|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
58275442|NCT01242501|BEHAVIORAL|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
58275443|NCT04148859|PROCEDURE|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
58275444|NCT03926468|DIAGNOSTIC_TEST|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
58275445|NCT03588013|OTHER|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
58275446|NCT03588013|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food|If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
58275447|NCT03588013|PROCEDURE|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
58275448|NCT02084914|PROCEDURE|Endometrial scratching|Group A: pipelle Group B: sound
58275449|NCT04565821|DEVICE|IPD Probe via TNIT|A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
58275450|NCT03081091|DEVICE|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
58275451|NCT03081091|DEVICE|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
58275452|NCT04842799|OTHER|Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|"Participants will receive a link to the digital pre-test information. This will consist of text covering: Genetics and cancer risk; Genetics testing; What will happen if your test is positive; What will happen if your test is negative; Implications for insurance.~Where relevant, parts of the text will be linked through to additional information, such as insurance advice from the Association of British Insurers. Participants will be able to call a genetic counsellor on the hotline during weekday office hours, should they have any questions or require further information."
58275453|NCT04842799|OTHER|Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform|Participants will receive a digital message that their results are available. When they click this, they will receive digital notification of their negative (normal) result in short form. Full details will be provided in an individualised letter.
57723945|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
57723946|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
57723947|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
58275454|NCT02791646|BEHAVIORAL|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
58275455|NCT02791646|BEHAVIORAL|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
58275456|NCT01665677|DRUG|Atorvastatin calcium|40 mg PO daily
58275457|NCT04485494|DIAGNOSTIC_TEST|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
58275458|NCT01156051|DRUG|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
58275459|NCT01156051|DRUG|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
58275460|NCT02503371|OTHER|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
58275461|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
58275462|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
58275463|NCT04241393|DRUG|Tavapadon tablet|Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
58275464|NCT04241393|DRUG|Tavapadon [14C] suspension|Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
58275465|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
58275466|NCT06605118|DRUG|Placebo|250 mL of normal saline
58275467|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
58275468|NCT01726621|DEVICE|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
58275469|NCT05422768|BEHAVIORAL|Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
58275470|NCT05422768|BEHAVIORAL|Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
58392738|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
57723948|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
57723949|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
57723950|NCT02991209|DRUG|Testosterone|
57723951|NCT02991209|DRUG|Placebos|
57723952|NCT02065466|DRUG|nab-paclitaxel|
57723953|NCT02065466|DRUG|Temozolomide|
57723954|NCT02065466|DRUG|Bevacizumab|
57723955|NCT01746823|DRUG|Cyclosporins|
58275471|NCT01135875|OTHER|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
58275472|NCT01135875|OTHER|Normal Controls|2 teaspoons of blood will be collected once.
58275473|NCT03904368|PROCEDURE|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
58275474|NCT03904368|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
58275475|NCT03904368|DRUG|Human chorionic gonadotropin|HCG triggering of ovulation
58275476|NCT03904368|PROCEDURE|Ovum pick up|34 to 36 hours after HCG triggering
58275477|NCT03904368|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
58275478|NCT01030471|BEHAVIORAL|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
58275479|NCT03001479|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
58275480|NCT00000997|DRUG|Zalcitabine|
57723956|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
57723957|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
57723958|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
57723959|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
57723960|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
57723961|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
57723962|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
57723963|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
57723964|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
58392739|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
58392740|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
58392741|NCT00488020|PROCEDURE|stem cells transplant|
58392742|NCT05645107|DRUG|Xembify|SC infusion pump
57723965|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
57723966|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
57723967|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
57723968|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
57723969|NCT01640301|DRUG|Cyclophosphamide|Given IV
57723970|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
57723971|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
58392743|NCT05645107|DRUG|Placebo|SC infusion pump
58392744|NCT00061854|DRUG|soblidotin|
57723972|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
57723973|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
57723974|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
58392745|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
57723975|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
57723976|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
57723977|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
57723978|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
57723979|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
57723980|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
58275481|NCT05083806|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
58392746|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
58392747|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
58392748|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
57723981|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
57723982|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
57723983|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
57723984|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
57723985|NCT02174536|BIOLOGICAL|Placebo|
57723986|NCT02721212|DEVICE|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
57723987|NCT02721212|OTHER|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
57723988|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
57723989|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
57723990|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
57723991|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
57723992|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
57723993|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
57723994|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
57723995|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
57723996|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
57723997|NCT03774641|DRUG|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
57723998|NCT02042482|DIETARY_SUPPLEMENT|Coenzyme Q10U, L-carnitine|
57723999|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
57724000|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
57724001|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
57724002|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
57724003|NCT02639884|DEVICE|SedLine EEG|
57724004|NCT02639884|DEVICE|RRa monitoring|
57724005|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
57724006|NCT00217698|DRUG|cisplatin|
57724007|NCT00217698|DRUG|gefitinib|
57724008|NCT00217698|DRUG|gemcitabine hydrochloride|
57724009|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
57724010|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
57724011|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
58392749|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
58275482|NCT04296851|DRUG|Niclosamide|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
58392750|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
58275483|NCT04296851|DRUG|placebo|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
58392751|NCT06456008|OTHER|Standard of care|Standard of care
58392752|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
57724012|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
57724013|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
57921145|NCT04811209|OTHER|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
58275484|NCT01239082|PROCEDURE|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
58275485|NCT01239082|PROCEDURE|FIT|Annual FIT testing
58275486|NCT01353573|RADIATION|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
58275487|NCT01353573|RADIATION|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
58275488|NCT01375582|DRUG|B & L Soothe Lubricant Eye Drops|Eye Drop
58275489|NCT01375582|DRUG|Liposic EDO|Eye Drop
58275490|NCT01375582|DRUG|OcuFresh Eye Wash|Saline drop
58275491|NCT02702141|DRUG|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
58392753|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
58392754|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
58392755|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
57724014|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
57724015|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
58275492|NCT04825886|DEVICE|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
58275493|NCT05095311|DRUG|Cetirizine HCl|Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
58275494|NCT05095311|OTHER|Placebo|The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
58275495|NCT01108692|OTHER|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
58275496|NCT05838911|OTHER|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
58392756|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
57724016|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
57724017|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
57724018|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
57724019|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
57724020|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
58275497|NCT05838911|OTHER|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
58275498|NCT03900221|OTHER|No intervention|No intervention
58275499|NCT01160094|DRUG|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
58392757|NCT00577707|PROCEDURE|Resection|
58392758|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
58392759|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
58392760|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
58392761|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
58065603|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
58275500|NCT05677815|PROCEDURE|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
57724021|NCT02464501|OTHER|Paclitaxel administration using the OPC|
57921146|NCT04811209|OTHER|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
57921147|NCT04811209|OTHER|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
58065604|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
58275501|NCT00911586|DRUG|Testosterone undecanoate|
57724022|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
57724023|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
57724024|NCT02866682|DRUG|Tacrolimus|Generic
57724025|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
57921148|NCT02647866|DRUG|KHK4083|IV Infusion
57921149|NCT02647866|DRUG|Placebo|IV Infusion
57921150|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- real tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, 2 mA stimulation with 1x1 tDCS mini-CT device by Soterix Medical
58065605|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
58065606|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
58275502|NCT00520767|DRUG|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
58275503|NCT00520767|DRUG|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
58275504|NCT00520767|DRUG|melphalan|Melphalan 9 mg/m2/day days 1-4
58275505|NCT00520767|GENETIC|microarray analysis|≤28 days prior to enrollment
57724026|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
57724027|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
57724028|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
57724029|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
57724030|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
57724031|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
57724032|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
57724033|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
57724034|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
57724035|NCT03778216|BEHAVIORAL|Family Based Treatment|
57724036|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
57724037|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
58275506|NCT00520767|OTHER|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
57724038|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
57724039|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
57724040|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
58275507|NCT00520767|OTHER|laboratory biomarker analysis|≤28 days prior to enrollment
57921151|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- sham tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, sham stimulation with tDCS mini-CT device by Soterix Medical
57921152|NCT06416553|BEHAVIORAL|Lee-Silverman voice treatment|Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
57724041|NCT01661660|OTHER|observationnal|Observation during a physical exercise
57921153|NCT05390983|PROCEDURE|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
58275508|NCT00520767|PROCEDURE|quality-of-life assessment|Start of each cycle
58275509|NCT01245153|OTHER|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
58275510|NCT01245153|OTHER|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
57724042|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
57724043|NCT05847777|RADIATION|CBCT|cone beam computer tomography
57724044|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
57724045|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
58392762|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
58392763|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
58392764|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
58392765|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
58392766|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
58392767|NCT00048022|DRUG|Dual Integrin Antagonist|
58392768|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
58392769|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
58392770|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
58392771|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
58392772|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
58392773|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
58392774|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
58392775|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
58392776|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
58392777|NCT05609305|OTHER|Discharge|observational study, not intervention
58392778|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
58392779|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
57724046|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
57724047|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
57724048|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
57724049|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
57724050|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
57724051|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
57724052|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
57724053|NCT04552782|BEHAVIORAL|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
57724054|NCT04552782|BEHAVIORAL|PTSD CBM|Trains approach or avoidance responses to trauma cues.
57724055|NCT04552782|BEHAVIORAL|Alcohol Sham|Will not train approach or avoidance responses.
57724056|NCT04552782|BEHAVIORAL|PTSD Sham|Will not train approach or avoidance responses.
57724057|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
57724058|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
57724059|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
57724060|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
57724061|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
57724062|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
57724063|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
57724064|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
57724065|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
58065607|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
58275511|NCT01638403|DRUG|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
58275512|NCT01638403|DRUG|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
58275513|NCT01638403|DRUG|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
58392780|NCT00489320|DEVICE|Cypher Stent|
57724066|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
57724067|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
57724068|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
57724069|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
57724070|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
57724071|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
57724072|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
57724073|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
57724074|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
57921154|NCT02939248|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
57921155|NCT02939248|DRUG|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
58065608|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
58065609|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
58392781|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
58392782|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
58392783|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
58392784|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
58392785|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
58392786|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
58392787|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
57724075|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
57724076|NCT02585739|GENETIC|blood sample|
57724077|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
58392788|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
58392789|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
57724078|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
57724079|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
57724080|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
58065610|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
58275514|NCT05032729|OTHER|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
58392790|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
58392791|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
58392792|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
58392793|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
57724081|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
57724082|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
57724083|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
57724084|NCT04289753|BEHAVIORAL|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
57724085|NCT04289753|BEHAVIORAL|Brief clinician education|Clinicians will be invited to view brief education material.
57724086|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
57724087|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
57724088|NCT00206063|DRUG|EXANTA|
57921156|NCT01972711|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
57921157|NCT01972711|DRUG|Amisulpride|Amisulpride as a single oral dose of 400 mg
57921158|NCT01972711|DRUG|Placebo|single oral dose placebo
58275515|NCT05032729|OTHER|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
58392794|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
58392795|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
58392796|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
58392797|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
58490378|NCT05252780|BEHAVIORAL|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
58490379|NCT02074410|DRUG|OMS643762|
57724089|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
57724090|NCT01831089|DRUG|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
57724091|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
57724092|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
57724093|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
57724094|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
57724095|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
57724096|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
57724097|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
57724098|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
57724099|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
57921159|NCT01276431|DRUG|Buprenorphine transdermal patch|
57921160|NCT02386709|DEVICE|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
57921161|NCT01264822|DRUG|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
57921162|NCT04291599|DRUG|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
57921163|NCT04291599|DRUG|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
57921164|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
57921165|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
57921166|NCT01306487|PROCEDURE|Vitrectomy|Macular hole surgery
57724100|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
57724101|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
57724102|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
57724103|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
57724104|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
57921167|NCT05384353|OTHER|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
57921168|NCT06328426|DIETARY_SUPPLEMENT|Vitamin D|The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
57921169|NCT06328426|DIETARY_SUPPLEMENT|Omega-3|The dose of omega-3 will be 1000 mg /day taken orally. The duration of the intervention will be 4 months.
57921170|NCT06328426|DRUG|Metformin|The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
57921171|NCT06328426|DIETARY_SUPPLEMENT|Placebo|The duration of the intervention will be 4 months.
57724105|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
57724106|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
57724107|NCT00812292|DRUG|TMC278|
57724108|NCT04087057|OTHER|Interview|Participate in interview
57724109|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
57724110|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
57724111|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
57724112|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
57724113|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
57724114|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
57724115|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
57724116|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
57724117|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
57724118|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
57724119|NCT02177344|DRUG|Placebo|
57921172|NCT02648750|BEHAVIORAL|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
57724120|NCT02798198|OTHER|T2DM|T2DM without DKD
57921173|NCT00830648|BIOLOGICAL|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
58392798|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
57724121|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
58392799|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
58392800|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
58490380|NCT02074410|DRUG|Placebo|
58490381|NCT03116152|BIOLOGICAL|IBI308|IBI308 200mg Intravenous drip every three weeks；
57724122|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
57724123|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
57724124|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
57724125|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
57921174|NCT03861377|DRUG|Remifentanil R2|0,7 microg/kg
58490382|NCT03116152|DRUG|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
57724126|NCT00871481|DRUG|cyclophosphamide|Given IV
57724127|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
57724128|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
57724129|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
57724130|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
57724131|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
57724132|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
57724133|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
57724134|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
57724135|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
57724136|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
57724137|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
57921175|NCT03861377|DRUG|Remifentanil R4|1,1 microg/kg
57921176|NCT03861377|DRUG|Remifentanil R8|1,7 microg/kg
57921177|NCT04916522|DRUG|Colchicine|0.5 mg once daily
57921178|NCT04916522|DRUG|Placebo|Once daily
57921179|NCT00334555|OTHER|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
57921180|NCT00334555|OTHER|partner delivered meds|patient given meds to give to her partner
57921181|NCT00334555|OTHER|field intervention|health worker finds partners
57921182|NCT05021523|OTHER|Hot ambient conditions exposures|Participants rest or exercise for 40min to 1h daily in hot ambient conditions
57921183|NCT05021523|OTHER|Immobilization|Participants are wearing a walking boot (with crutches) for 2 weeks
58392801|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
57921184|NCT02681133|OTHER|Epidemiological study Survey|
58392802|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
57921185|NCT05082129|DEVICE|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
58392803|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
58392804|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
57921186|NCT00351949|BIOLOGICAL|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
58065611|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
58392805|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
57921187|NCT00571831|PROCEDURE|intraocular lens implantation|Intraocular lens implantation
57921188|NCT02638935|DEVICE|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
58065612|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
58392806|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
58392807|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
58392808|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
58392809|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
58392810|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
58392811|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
58392812|NCT00729495|DRUG|celecoxib|dose form
58392813|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
58392814|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
57921189|NCT00144651|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
58065613|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
58275516|NCT04851418|DEVICE|Possible NSTE-ACS|As mentioned in the group description
57724138|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
57724139|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
57724140|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
57724141|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
57724142|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
57724143|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
57724144|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
57724145|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
58275517|NCT00676416|DRUG|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
58392815|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
58392816|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
58392817|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
58392818|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
58392819|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
57724146|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
57724147|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
57724148|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
58392820|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
58392821|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
57724149|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
57724150|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
57724151|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
57724152|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
57724153|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
57724154|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
57724155|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
58275518|NCT00028522|DRUG|R(+)XK469|Given IV
58275519|NCT05219097|DIAGNOSTIC_TEST|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
58275520|NCT00371709|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
58065614|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
58392822|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
57724156|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
57724157|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
58065615|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
58065616|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
58065617|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
58065618|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
58392823|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
58392824|NCT01162954|DRUG|DA-6034|
58392825|NCT01162954|DRUG|Placebo|
58392826|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
58392827|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
58392828|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
57724158|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
57724159|NCT03430154|OTHER|No treatment given|No treatment given
57724160|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
58065619|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
58065620|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
57724161|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
57724162|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
57921190|NCT04822012|DIAGNOSTIC_TEST|Anti COVID19 IgG Antibodies|Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
58065621|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
58065622|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
58065623|NCT00459680|DEVICE|Laser acupoint treatment|Laser
58065624|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
58065625|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
58065626|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
58275521|NCT00371709|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
58275522|NCT03782532|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
58275523|NCT03782532|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
58275524|NCT03782532|DRUG|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
58275525|NCT03782532|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
58275526|NCT03763058|OTHER|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
58392829|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
58392830|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
58392831|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
58392832|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
58392833|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
58392834|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
58065627|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
58392835|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
58065628|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
58065629|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
58275527|NCT01014481|DRUG|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
58275528|NCT01997970|BEHAVIORAL|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
58275529|NCT01997970|BEHAVIORAL|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
58275530|NCT02464865|DRUG|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
58392836|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
58392837|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
58392838|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
58392839|NCT04989556|OTHER|Interview|Participate in interview
58392840|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
58392841|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
58392842|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
58392843|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
58392844|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
58490383|NCT05959148|OTHER|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
58275531|NCT02464865|OTHER|Non-thiamine|no symptoms and signs of thiamine deficiency
58275532|NCT02464865|DRUG|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
57921191|NCT00905138|DRUG|GLPG0259|single ascending doses, oral solution
57921192|NCT00905138|DRUG|placebo|single dose, oral solution
57921193|NCT00905138|DRUG|GLPG0259|multiple dose, oral solution, 5 days
57921194|NCT00905138|DRUG|placebo|oral solution, 5 days
57921195|NCT03774251|BIOLOGICAL|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
57921196|NCT03774251|DEVICE|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
57921197|NCT02361138|DRUG|SHR3824|
58065630|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
58065631|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
58392845|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
58392846|NCT04102800|DRUG|Benralizumab|subcutaneous injection
58392847|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
58392848|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
58392849|NCT06619392|DRUG|HRS-2129|HRS-2129
58392850|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
58392851|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
58392852|NCT00602225|DRUG|clofarabine|Given IV
58392853|NCT00602225|DRUG|cytarabine|Given IV
58392854|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
58392855|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
58392856|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
58392857|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
57921198|NCT02361138|DRUG|Placebo|
57921199|NCT00782522|PROCEDURE|Eccentric training program|Eccentric training program
57921200|NCT00782522|PROCEDURE|Traditional training program|Traditional training program
57921201|NCT02882087|DRUG|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
58392858|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
58392859|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
58392860|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
57921202|NCT02882087|DRUG|RC18 160 mg plus MTX|
57921203|NCT05622851|DEVICE|Restylane Contour|Hyaluronic Acid dermal filler
57921204|NCT05622851|DEVICE|Juvederm Voluma|Hyaluronic Acid dermal filler
57921205|NCT02562495|DEVICE|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
57921206|NCT00852046|DRUG|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
58392861|NCT01766297|RADIATION|Proton Radiotherapy|
58392862|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
58392863|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
58392864|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
58392865|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
58275533|NCT01052623|DRUG|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
57724163|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
57724164|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
57724165|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
57724166|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
57724167|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
57724168|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
57724169|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
57724170|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
57724171|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
57724172|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
57724173|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
57724174|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
57921207|NCT03658668|DEVICE|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.
57921208|NCT03658668|DEVICE|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
57921209|NCT03658668|OTHER|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
57921210|NCT02802098|DRUG|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
57921211|NCT02802098|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
58065632|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
57921212|NCT00440700|BEHAVIORAL|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
58065633|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
58275534|NCT05080361|DRUG|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
58275535|NCT04544163|DRUG|Magnesium sulfate- Fentanyl|drug administration before intubation
57724175|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
57724176|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
58065634|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
58065635|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
58275536|NCT04544163|DRUG|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
58392866|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
58275537|NCT04544163|DRUG|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
58275538|NCT04544163|DRUG|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
58275539|NCT04441749|DEVICE|Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)|Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
58275540|NCT03518411|OTHER|Cognitive Behavioral Therapy|One-Session Unified Protocol
58392867|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
58392868|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
58392869|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
57724177|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
58065636|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
58065637|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
58065638|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
58065639|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
58065640|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
58275541|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
58275542|NCT01134861|DRUG|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
58275543|NCT01134861|DRUG|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
58065641|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
58065642|NCT04921111|DRUG|placebo|aluminium phosphate
58065643|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
58065644|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
58065645|NCT02348931|PROCEDURE|corrective surgery|
58065646|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
58065647|NCT05430230|DRUG|Placebo|lactose NF
58065648|NCT00517673|DRUG|GSK945237|
58065649|NCT00517673|DRUG|Sugar Pill|Placebo
58065650|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
58065651|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
58275544|NCT01134861|DRUG|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
58065652|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
58065653|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
58065654|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
58065655|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
58065656|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
58275545|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
58275546|NCT01134861|DRUG|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
58275547|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
58275548|NCT01134861|RADIATION|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
58275549|NCT03488069|OTHER|Survey|Submission of survey answers
57921213|NCT00440700|BEHAVIORAL|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
57921214|NCT00440700|BEHAVIORAL|Control 2: Standard of Care|Usual ICU nursing care.
57921215|NCT04604548|DRUG|Oral administration of 100 mg KH176 twice daily|Drug: KH176
57921216|NCT00271427|DRUG|L-Selenomethionine|
58392870|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
58392871|NCT05076773|DRUG|IV morphine|given when VAS\>3
57921217|NCT00077220|DRUG|carboplatin|
57921218|NCT00077220|DRUG|paclitaxel|
58275550|NCT03541707|DEVICE|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
58392872|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
58392873|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
57921219|NCT00077220|PROCEDURE|adjuvant therapy|
57921220|NCT00077220|RADIATION|radiation therapy|
57921221|NCT03124095|BEHAVIORAL|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
58392874|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
58392875|NCT01195376|DRUG|BEZ235|
58392876|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
57921222|NCT04785235|PROCEDURE|Non-Surgical Periodontal Therapy|
57921223|NCT01687530|PROCEDURE|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
57921224|NCT01844245|PROCEDURE|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
57921225|NCT04651907|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
58392877|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
58392878|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
57724178|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
57724179|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
57921226|NCT04651907|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
57921227|NCT02918123|BIOLOGICAL|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
57921228|NCT01003990|DRUG|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
57921229|NCT01003990|DRUG|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
57921230|NCT01003990|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
57921231|NCT01003990|DRUG|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
57921232|NCT04929743|DEVICE|BTI Implant|Placement of dental implants of 5.5 vs \>6.5 mm length
57921233|NCT00835120|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
57921234|NCT03371030|PROCEDURE|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
58490384|NCT05959148|OTHER|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
57921235|NCT04677868|DRUG|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
57921236|NCT02829788|OTHER|Non interventional|Peroperative data collection
57921237|NCT02370043|DRUG|KQ-791|Capsules administered orally while fasting, in up to 3 periods
58065657|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
57724180|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
57921238|NCT02370043|DRUG|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
58392879|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
58392880|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
58392881|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
58392882|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
58392883|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
58392884|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
58392885|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
57921239|NCT02370043|DRUG|Placebo|Capsules, administered orally, in 1 period
58065658|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
58392886|NCT06405438|OTHER|No intervention|No intervention.
58392887|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
58392888|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
58392889|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
58392890|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
58392891|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
58392892|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
58392893|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
58392894|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
57724181|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
57724182|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
58065659|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
58065660|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
58275551|NCT02787057|DRUG|vancomycin|IP vancomycin 1g every 5 days
57921240|NCT05889481|GENETIC|cytogenetic analysis on tumour tissue|Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.
58275552|NCT02787057|DRUG|moxifloxacin|oral moxifloxacin 400mg QD
58275553|NCT02787057|DRUG|ceftazidime|IP ceftazidime 1g QD
58392895|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
58392896|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
58490385|NCT02210494|DRUG|Secretrol|
58490386|NCT01901913|DEVICE|MD-bolus calculator for pre-meal bolus|
57724183|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
57724184|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
58275554|NCT05983510|PROCEDURE|Aortic endarteriectomy|Thoraco-phreno-lumbotomy with thoracic aortic cross clamping Longitudinal aortotomy Endarteriectomy of the aorta Direct closure more or less bypass to the visceral arteries and downstream aorta reconstruction.
57921241|NCT05889481|BIOLOGICAL|Digital Pathology|Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma
57921242|NCT04768270|OTHER|no intervention|It is an observation trial.
57921243|NCT05895838|DRUG|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
57724185|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
57921244|NCT05895838|PROCEDURE|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
57921245|NCT05895838|PROCEDURE|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
57921246|NCT05895838|DRUG|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
57921247|NCT03614910|DEVICE|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
57921248|NCT01838252|PROCEDURE|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
58275555|NCT00313287|DRUG|clevudine|
57724186|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
57724187|NCT04338815|OTHER|Exoskeleton optimization|Participants will walk 10 times of 1 minute duration while an optimization algorithm changes the assistance profile of an exoskeleton.
57921249|NCT01838252|PROCEDURE|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
58490387|NCT01901913|DEVICE|No MD-bolus calculator for pre-meal bolus|
57724188|NCT04338815|OTHER|Endurance evaluation|Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
58275556|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
58275557|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
58275558|NCT01835028|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
57724189|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
57724190|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
57724191|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
57724192|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
57724193|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
57724194|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
57724195|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
57724196|NCT05604729|DRUG|Placebo|Saline solution
57724197|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
57921250|NCT00211497|DRUG|MBI 226 Acne Solutions|
57921251|NCT00010712|DRUG|Black Cohosh|
58065661|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
58065662|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
58275559|NCT01835028|OTHER|Computed tomography|Observational Study using Imaging and Biomarkers
58275560|NCT01835028|OTHER|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
58490388|NCT02840799|DRUG|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
58490389|NCT02840799|DRUG|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
57724198|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
57921252|NCT06225934|BEHAVIORAL|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
57724199|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
57724200|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
57724201|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
57724202|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
57724203|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
57724204|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
57724205|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
57724206|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
57724207|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
57724208|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
57921253|NCT03717831|OTHER|Observational study of standard of care|Observational cohort study
57921254|NCT02196454|OTHER|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
57921255|NCT06475443|DRUG|pyrotinib plus capecitabine|oral
57921256|NCT01020448|DRUG|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
57921257|NCT03798093|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
57921258|NCT03798093|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
58065663|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
57724209|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
57724210|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
57724211|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
57724212|NCT00422539|DRUG|70% trichloroacetic acid|
57724213|NCT04090736|DRUG|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
57724214|NCT04090736|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
57724215|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
57724216|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
57724217|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
57724218|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
57724219|NCT01148810|DRUG|BAF312|
57724220|NCT01148810|DRUG|Placebo|
57724221|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
57724222|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
57724223|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
57921259|NCT02778243|BIOLOGICAL|steroids concentrations determination|
57921260|NCT00180921|DRUG|Imatinib|
58065664|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
58065665|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
58275561|NCT01835028|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
57921261|NCT06455150|OTHER|Assessment of pelvic floor dysfunctions' symptoms and sings, pelvic floor muscle strength and quality of life|"It will be assessed the presence of urinary incontinence, anal incontinence, pelvic organ prolapse and female sexual dysfunction' symptoms by using the questionaries validated to Spanish population International Consultation on Incontinence Questionnaire-Short Form, Pelvic Floor Distress Inventory Short Form and Female Sexual Function Index; in addition, the sign of stress urinary incontinence and pelvic organ prolapse will be assessed by using the cough stress test and Pelvic Organ Prolapse Quantification System, the pelvic floor muscle strength by using manometry, and quality of life by using SF-12 questionnaire."
58275562|NCT01835028|OTHER|Stress echocardiography|Observational Study using Imaging and Biomarkers
58275563|NCT02661061|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
58275564|NCT02661061|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
58275565|NCT05887024|DEVICE|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
58275566|NCT05887024|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
58275567|NCT05887024|PROCEDURE|McKenzie Back exercises|Graduated Progressive back exercise program.
58275568|NCT05887024|DEVICE|electric heating pads|electrical conducting heat pack.
58392897|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
58392898|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
58392899|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
58392900|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
58392901|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
58275569|NCT03331731|DRUG|pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58275570|NCT01724684|OTHER|Telehealth program|
58275571|NCT01724684|OTHER|Usual care|
58275572|NCT06319560|DRUG|Hydroxychloroquine Oral Tablet|200mg daily
58275573|NCT01643278|DRUG|Dasatinib|Given PO
58275574|NCT01643278|BIOLOGICAL|Ipilimumab|Given IV
57724224|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
57921262|NCT02871310|DIETARY_SUPPLEMENT|IQP-AS-118|1 tablet in the morning
58275575|NCT01643278|OTHER|Laboratory Biomarker Analysis|Correlative studies
58275576|NCT01643278|OTHER|Pharmacological Study|Correlative studies
58275577|NCT06252467|DEVICE|Photobiomodulation Therapy|"Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
57921263|NCT02871310|DIETARY_SUPPLEMENT|Placebo|1 tablet in the morning
57921264|NCT03489174|OTHER|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
57724225|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
57921265|NCT03489174|OTHER|Usual Care|Usual care.
57921266|NCT00395148|DRUG|rHDL|
57921267|NCT04760054|BEHAVIORAL|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
57921268|NCT04760054|BEHAVIORAL|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
57921269|NCT04760054|BEHAVIORAL|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
57921270|NCT05401279|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
57921271|NCT05401279|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
57921272|NCT05401279|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four to six 21-day cycles.
57921273|NCT06178926|DRUG|Propofol|Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
58065666|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
58490390|NCT03173001|DIAGNOSTIC_TEST|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
57921274|NCT06178926|DRUG|Ciprofol|Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
57921275|NCT01947192|PROCEDURE|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
57921276|NCT01947192|PROCEDURE|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
57921277|NCT04685226|DRUG|ICP-723|ICP-723 is a white, round, uncoated table
57921278|NCT00874341|OTHER|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
57921279|NCT00350896|DEVICE|Thumb orthoses|
57921280|NCT04431817|DEVICE|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
57921281|NCT05773989|DRUG|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
57921282|NCT05773989|DRUG|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
57921283|NCT01142596|DRUG|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
57921284|NCT01142596|DRUG|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
57921285|NCT05977114|BEHAVIORAL|family conflict intervention group|The family conflict preventive intervention includes the introduction to the occurrence of family conflicts, communication skills training, and role play to practice the skills.
57921286|NCT05977114|BEHAVIORAL|handicraft-making group|The group involves handicraft-making.
57921287|NCT02319525|OTHER|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
58065667|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
58065668|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
58065669|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
58490391|NCT00724087|OTHER|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
58490392|NCT00724087|OTHER|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
58490393|NCT01518764|DIETARY_SUPPLEMENT|Red Wine Polyphenols 600mg/day|
57921288|NCT02319525|OTHER|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
57921289|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
58065670|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
58065671|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
58065672|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
58275578|NCT06252467|DEVICE|Placebo Photobiomodulation|The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
57724226|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
57724227|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
57724228|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
57724229|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
57724230|NCT00148057|BEHAVIORAL|Low-fat diet|
57724231|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
57724232|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
57724233|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
57724234|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
57724235|NCT02684591|DRUG|Placebo|Placebo
57724236|NCT03391843|DRUG|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
57724237|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
58275579|NCT06400004|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
58275580|NCT06400004|DRUG|Lumason|Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
58392902|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
57724238|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
57921290|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
58275581|NCT03394625|PROCEDURE|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
58275582|NCT03394625|PROCEDURE|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
57724239|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
58275583|NCT06046209|DEVICE|Control Lens|Daily disposable contact lens for 90 minutes
58275584|NCT06046209|DEVICE|Test Lens|Monthly replacement contact lens for 90 minutes
58275585|NCT04373564|PROCEDURE|Motor Tests|To assess motor function annually
58275586|NCT04373564|PROCEDURE|Cognitive Tests|To assess cognitive function annually
57724240|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
57724241|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
57724242|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
57921291|NCT01259726|OTHER|Placebo|10 mL placebo once daily for 14 days
57921292|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 14 days
57921293|NCT01946841|DIETARY_SUPPLEMENT|RealDiet®Renal|
57921294|NCT00482950|DRUG|PHX1149T|
57921295|NCT05503654|BEHAVIORAL|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
57921296|NCT04692415|DRUG|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
57921297|NCT04692415|DRUG|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
57921298|NCT05975151|DRUG|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
57921299|NCT00334724|PROCEDURE|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
57921300|NCT00334724|PROCEDURE|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
57921301|NCT04870853|OTHER|Electronic Health Record Review|Medical records reviewed
57921302|NCT05605587|DRUG|Leflunomide 20 mg|once daily for 6 months
58275587|NCT04373564|PROCEDURE|Unenhanced-MRI of the brain|The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
58275588|NCT04373564|PROCEDURE|Gadolinium Measurements|Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
58275589|NCT04373564|DRUG|Gadoxetate disodium|Administered as defined by the treating physician as part of routine clinical practice
58392903|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
58490394|NCT01518764|DIETARY_SUPPLEMENT|placebo|
58065673|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
58275590|NCT04373564|DRUG|Gadobenate dimeglumine|Administered as defined by the treating physician as part of routine clinical practice
58275591|NCT04373564|DRUG|Gadodiamide|Administered as defined by the treating physician as part of routine clinical practice
58275592|NCT04373564|DRUG|Gadoterate meglumine|Administered as defined by the treating physician as part of routine clinical practice
58275593|NCT04373564|DRUG|Gadobutrol|Administered as defined by the treating physician as part of routine clinical practice
58275594|NCT04373564|DRUG|Gadoteridol|Administered as defined by the treating physician as part of routine clinical practice
58490395|NCT00120419|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
57724243|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
57724244|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
57921303|NCT02170389|OTHER|Laboratory Biomarker Analysis|Correlative studies
58065674|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
58065675|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
58065676|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
58275595|NCT06176469|OTHER|No intervention|No intervention
58490396|NCT02083913|BEHAVIORAL|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
58490397|NCT06293651|DRUG|DA-4505|Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
57724245|NCT00153101|DRUG|Telmisartan|
57724246|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
57724247|NCT00153101|DRUG|Ramipril|
57724248|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
57921304|NCT02170389|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
57921305|NCT02170389|BIOLOGICAL|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
57921306|NCT04502966|BIOLOGICAL|Dupixent®|An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.
58275596|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
58275597|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
57921307|NCT04502966|BIOLOGICAL|Grazax®|"One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA."
58275598|NCT02942043|DRUG|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
58275599|NCT05981014|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
58275600|NCT05981014|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
57724249|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
57724250|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
58392904|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
57921308|NCT04502966|DRUG|Dupixent® Placebo|"Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient."
58392905|NCT00037518|DRUG|AMG 073|
58392906|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
57724251|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
57724252|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
57724253|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
58065677|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
58065678|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
58065679|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
58392907|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
58490398|NCT06293651|DRUG|DA-4505 + Pembrolizumab|Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
57724254|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
58065680|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
58065681|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
57724255|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
57724256|NCT02799433|BEHAVIORAL|Usual services|Control condition
58275601|NCT05981014|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
57724257|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
57724258|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
58275602|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
58275603|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
57724259|NCT01954017|OTHER|Control|Sterile Water
57724260|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
57921309|NCT04502966|DRUG|Grazax® Placebo|"One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units."
58275604|NCT05981014|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
58392908|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
57724261|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
57724262|NCT06155981|OTHER|Coke Zero|Coca-Cola Zero Sugar drink will be given.
57724263|NCT06155981|OTHER|Coke|Coca-Cola drink will be given.
58392909|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
58392910|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
58392911|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
58392912|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
58392913|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
58392914|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
58392915|NCT05090163|OTHER|PREP|Group based exercise
58392916|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
58392917|NCT05961241|OTHER|runnin training program|gradual training program
57724264|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
57724265|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
57724266|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
57724267|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
57724268|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
57724269|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
57724270|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
57724271|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
57724272|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
57724273|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
57724274|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
57724275|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
57724276|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
57724277|NCT00208208|DRUG|Ziprasidone|
57921310|NCT00866723|DRUG|bevacizumab|
57921311|NCT02088307|DIETARY_SUPPLEMENT|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
57921312|NCT02650245|DIETARY_SUPPLEMENT|EAS Myoplex Protein Drink + 10gm lactulose|
58065682|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
57724278|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
57724279|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
57724280|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
57724281|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
57724282|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
57921313|NCT04162340|BIOLOGICAL|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
57921314|NCT02158520|BIOLOGICAL|Bevacizumab|Given IV
57921315|NCT02158520|BIOLOGICAL|Ipilimumab|Given IV
58275605|NCT05981014|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
58275606|NCT05981014|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
58392918|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
57724283|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
57921316|NCT02158520|OTHER|Laboratory Biomarker Analysis|Correlative studies
57921317|NCT02158520|DRUG|Nab-paclitaxel|Given IV
57921318|NCT02158520|OTHER|Pharmacological Study|Correlative studies
57921319|NCT05760053|DRUG|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
57921320|NCT05709795|PROCEDURE|Confluent areas|Use of omnipolar technology to guide CTI ablation in sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
57921321|NCT05709795|PROCEDURE|Wave Speed|Use of omnipolar technology to guide CTI ablation in sites with low wave speed. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
57921322|NCT05709795|PROCEDURE|Voltage|Use of omnipolar technology to guide CTI ablation in sites with high voltage. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then CTI line (gold standard)
57921323|NCT05709795|PROCEDURE|CTI line|Do not use omnipolar information. CTI line performance
57921324|NCT02928107|OTHER|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
58275607|NCT05981014|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
58392919|NCT03222362|OTHER|Surgery|
58392920|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
57921325|NCT02928107|OTHER|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
57921326|NCT00948493|DRUG|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
57921327|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
58275608|NCT00397592|DRUG|Growth Hormone|
58392921|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
58275609|NCT02045732|BIOLOGICAL|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
58275610|NCT02045732|BIOLOGICAL|Placebo|Bi-Weekly Subcutaneous Injections X 6
58275611|NCT02045732|BIOLOGICAL|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
58275612|NCT02045732|BIOLOGICAL|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
58275613|NCT06209281|DRUG|Lower dose atropine sulfate eye drops|Administer to eyes
58275614|NCT06209281|DRUG|Low dose atropine sulfate eye drops|Administer to eyes
58275615|NCT06209281|DRUG|placebo|Administer to eyes
58275616|NCT01714856|DRUG|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
58392922|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
58392923|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
57724284|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
58392924|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
57724285|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
57921328|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
58392925|NCT04296305|DRUG|Hydromorphone|Given IV after
58392926|NCT04296305|DRUG|Placebo Administration|Given IV after
58392927|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
58392928|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
57921329|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
58065683|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
58065684|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
58275617|NCT01420042|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
58275618|NCT01420042|DRUG|Placebo|Lemon flavoured cordial and Water for Injection
58275619|NCT03236116|OTHER|Almonds|Participants will consume almonds everyday for 6 months.
58392929|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
58392930|NCT03981094|DRUG|BMS-986278|suspension
58392931|NCT03981094|DRUG|Pirfenidone|capsule
58392932|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
58392933|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
58392934|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
58392935|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
58392936|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
58392937|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
58392938|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
58392939|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
58392940|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
58392941|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
58392942|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
58392943|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
58392944|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
58065685|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
58275620|NCT03236116|OTHER|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
58275621|NCT00571025|BEHAVIORAL|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
58275622|NCT01657656|DIETARY_SUPPLEMENT|Vitamin D|
58392945|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
58392946|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
58392947|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
58392948|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
57921330|NCT04386707|BIOLOGICAL|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
57724286|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
57921331|NCT02373410|PROCEDURE|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
58275623|NCT02005900|DRUG|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
58275624|NCT04150705|DEVICE|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
58392949|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
58392950|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
58392951|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
58392952|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
58392953|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
57724287|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
57921332|NCT02373410|PROCEDURE|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
57921333|NCT02373410|PROCEDURE|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
57921334|NCT02373410|PROCEDURE|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
57921335|NCT02373410|DRUG|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
58275625|NCT00006378|DRUG|carboplatin|
58275626|NCT00006378|DRUG|paclitaxel|
58392954|NCT00003321|PROCEDURE|psychosocial assessment and care|
58392955|NCT00003321|PROCEDURE|quality-of-life assessment|
58392956|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
57921336|NCT02373410|DRUG|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
57921337|NCT02373410|DRUG|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
57921338|NCT02373410|DRUG|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
57921339|NCT03237182|DRUG|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
58065686|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
58065687|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
58275627|NCT00006378|RADIATION|radiation therapy|
58275628|NCT00586898|DRUG|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
58275629|NCT00586898|DRUG|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
58275630|NCT00586898|DRUG|Bicalutamide|A pure nonsteroidal antiandrogen
58275631|NCT00586898|DRUG|Testosterone transdermal gel|an androgenic anabolic steroid
57724288|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
57724289|NCT06535815|OTHER|Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
57724290|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
57724291|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
57921340|NCT03237182|DRUG|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
57724292|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
57724293|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
57724294|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
57921341|NCT05003726|PROCEDURE|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
57921342|NCT05003726|PROCEDURE|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
57921343|NCT03272425|DRUG|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
57921344|NCT03272425|DRUG|lesinurad 200 mg|Comparator 1
57921345|NCT03272425|DRUG|allopurinol 300 mg|Comparator 2
57921346|NCT02091050|OTHER|2D HDR planning|HDR planning using simple radiograph (2D)
57921347|NCT02091050|OTHER|3D HDR planning|HDR planning using computed tomography (3D)
57921348|NCT01222260|DRUG|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
57724295|NCT03468439|OTHER|Femoral nerve block with phenol|
57724296|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
57724297|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
57724298|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
57724299|NCT02233712|BIOLOGICAL|G17DT|
57724300|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
57724301|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
57921349|NCT01222260|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
57921350|NCT05566613|RADIATION|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
57921351|NCT01690364|OTHER|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
58275632|NCT00586898|DRUG|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
58392957|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
58392958|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
58392959|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
58392960|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
58392961|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
58392962|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
58392963|NCT01153711|DRUG|Ketoconazole|400 mg tablet
58392964|NCT01153711|DRUG|Ketoconazole|400 mg tablet
58392965|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
58392966|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
58392967|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
57921352|NCT01690364|OTHER|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
57921353|NCT04827745|DRUG|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
57921354|NCT00613262|OTHER|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
58065688|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
58065689|NCT00372580|PROCEDURE|blood test|
58065690|NCT02749643|DEVICE|Vibrotactile feedback system|
58275633|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
58275634|NCT00004901|DRUG|ethynyluracil|
58275635|NCT00004901|DRUG|fluorouracil|
58275636|NCT00004901|DRUG|hydroxyurea|
58275637|NCT00004901|RADIATION|radiation therapy|
58275638|NCT01709773|PROCEDURE|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
58275639|NCT06730399|DEVICE|Computed-assisted-cryotherapy|cryotherapy device
58275640|NCT04902079|DEVICE|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
58275641|NCT05914389|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
58275642|NCT05914389|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
58275643|NCT05914389|DRUG|Anti-PD-L1 Monoclonal Antibody|The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
58275644|NCT05914389|DRUG|Clostridium butyricum|Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
58275645|NCT05914389|PROCEDURE|Colectomy|The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
58275646|NCT04960397|OTHER|Placebo|Physiological saline, i.e., 0.9% sodium chloride.
58275647|NCT04960397|BIOLOGICAL|Sing2016 M2SR H3N2|Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.
58275648|NCT04168840|DIAGNOSTIC_TEST|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
58275649|NCT05111509|DRUG|[203Pb]VMT-α-NET|3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.
58275650|NCT05111509|DEVICE|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
58275651|NCT02290145|DRUG|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
58275652|NCT02290145|PROCEDURE|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
58275653|NCT02290145|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
58275654|NCT00002575|PROCEDURE|conventional surgery|
58275655|NCT00002575|PROCEDURE|laparoscopic surgery|
58275656|NCT03555942|DRUG|Follicular phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
58275657|NCT03555942|DRUG|Luteal phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
58275658|NCT03129295|DRUG|MPC-SHRC|Oral tablet four times a day for 3 days
58275659|NCT03129295|DRUG|Placebo Oral Tablet|Oral tablet four times a day for 3 days
58275660|NCT06217744|BEHAVIORAL|Automated Intervention|Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.
58275661|NCT06217744|BEHAVIORAL|Blended Intervention|Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
58275662|NCT01587417|DRUG|Placebo to BI 187004 CL|1 single dose per subject as oral solution
58275663|NCT01587417|DRUG|BI 187004 CL|1 single dose per subject as oral solution
57724302|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
57724303|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
57724304|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
57724305|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
58275664|NCT01708720|DRUG|IPV|
57724306|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
57724307|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
58275665|NCT01708720|DRUG|Sabin-IPV|
58275666|NCT01708720|DRUG|Adjuvanted Sabin-IPV|
58275667|NCT04478500|DRUG|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
58275668|NCT05057117|DEVICE|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
58275669|NCT05057117|DRUG|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
58275670|NCT00851864|DRUG|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
58275671|NCT01074151|DRUG|duloxetine|any exposure to duloxetine that occurred during pregnancy
58275672|NCT02900261|OTHER|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
58275673|NCT04937907|DRUG|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
58275674|NCT04937907|DRUG|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
58275675|NCT05971472|PROCEDURE|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior Root tears
58275676|NCT05971472|PROCEDURE|High tibial osteotomy|Open Wedge High tibial osteotomy for medial meniscus posterior Root tears
58275677|NCT02810171|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
58275678|NCT02810171|BEHAVIORAL|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
58275679|NCT04239443|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
58275680|NCT04239443|DRUG|Apatinib|NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
58275681|NCT05013281|PROCEDURE|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
58392968|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
58275682|NCT05948332|BEHAVIORAL|Delphi Rounds to generate consensus opinions among Experts|The Investigators (Steering Committee) will select the experts from across the globe based on pre-specified qualification criteria and will conduct iterative Delphi rounds to generate consensus on the definition and management of acute RVI in patients with receiving V-V ECMO, among the Experts. The selection criteria will be self-assessed through a survey among the potential Experts.
57921355|NCT03809741|OTHER|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
57921356|NCT01716117|DEVICE|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
57921357|NCT04547153|DRUG|5-fluorouracil|200mg/square metre/day civ D1-D21
57921358|NCT04547153|DRUG|Docetaxel|25mg/square metre ivdrip D1, D8, D15
58065691|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
57921359|NCT03718078|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   - Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
58275683|NCT03341117|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
58275684|NCT03341117|DRUG|Calcined magnesia|Calcined magnesia 300 mg per capsule
58275685|NCT05167916|PROCEDURE|Outpatient check cytoscopy|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
58275686|NCT05167916|DIAGNOSTIC_TEST|Urine cytology|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
58392969|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
58392970|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
58392971|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
57921360|NCT04354844|BEHAVIORAL|questionnaire|questionnaire
57921361|NCT05588687|BEHAVIORAL|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
57921362|NCT05588687|DEVICE|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
57921363|NCT02369770|DEVICE|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
57921364|NCT04579133|DRUG|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)
57921365|NCT04579133|DRUG|Durvalumab|Durvalumab 1500 mg IV
57921366|NCT04098315|OTHER|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
58065692|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
58392972|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
58392973|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
57921367|NCT05209750|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
57921368|NCT00758056|GENETIC|polymorphism analysis|
57921369|NCT00758056|OTHER|laboratory biomarker analysis|
57921370|NCT00758056|OTHER|questionnaire administration|
57921371|NCT04567290|DRUG|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
57921372|NCT04567290|DRUG|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
57921373|NCT02803892|DRUG|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
57921374|NCT02803892|DRUG|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
58065693|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
58275687|NCT05360914|OTHER|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
58275688|NCT05360914|OTHER|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
58275689|NCT01250171|BIOLOGICAL|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
57921375|NCT02803892|DRUG|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
57921376|NCT02803892|DRUG|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
57921377|NCT02730364|DRUG|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
57921378|NCT04534556|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
57921379|NCT04534556|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
57921380|NCT03138928|DEVICE|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
58275690|NCT01250171|BIOLOGICAL|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
57921381|NCT02698969|DRUG|Sugammadex|
57921382|NCT02698969|DEVICE|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
57921383|NCT02698969|DRUG|Neostigmine|
57921384|NCT02698969|DRUG|Atropine|
57921385|NCT02698969|DEVICE|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
57921386|NCT02698969|DRUG|Rocuronium|Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
57921387|NCT02698969|DRUG|Fentanyl|Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
57921388|NCT02698969|DRUG|Propofol|Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia
57921389|NCT02698969|DRUG|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
57921390|NCT04727853|DRUG|irinotecan liposome injection|Drug: irinotecan liposome injection
58275691|NCT01250171|BIOLOGICAL|Placebo|The placebo solution for infusion contained 5% glucose.
58392974|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
58392975|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
58392976|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
58065694|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
58065695|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
58275692|NCT04111861|OTHER|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
58275693|NCT02024737|OTHER|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
58275694|NCT01608516|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
58275695|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
58275696|NCT05278494|DRUG|Placebo|PO
58275697|NCT05691166|BEHAVIORAL|High-intensity progressive resistance training|Supervised high-intensity progressive resistance training twice per week for 12 months
58275698|NCT05691166|OTHER|General practitioner care|Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
57921391|NCT03791671|OTHER|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
57921392|NCT03791671|OTHER|group balance training|Like the individual balance training
57921393|NCT01661478|OTHER|Training on motivational interviewing|
57921394|NCT05147961|OTHER|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
57921395|NCT05147961|OTHER|Standard care|Conventional recommendations on diet and exercise
57921396|NCT02391857|PROCEDURE|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
57921397|NCT03634514|DRUG|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
57921398|NCT03634514|DRUG|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
57921399|NCT05685589|BEHAVIORAL|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
58065696|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
58065697|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
58276786|NCT01540084|DRUG|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
57921400|NCT02369445|BEHAVIORAL|Moisture Pager Intervention for Toilet Training|
57921401|NCT02369445|BEHAVIORAL|Standard of Care|
57921402|NCT03881553|DEVICE|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
57921403|NCT03881553|DEVICE|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
57921404|NCT00044538|DRUG|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
57921405|NCT01769235|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
58065698|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
58065699|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
58065700|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
58065701|NCT01362062|DRUG|Tocilizumab|
58065702|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
57921406|NCT01769235|DRUG|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
57921407|NCT01769235|DRUG|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
57921408|NCT01520298|DRUG|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
57921409|NCT01520298|DRUG|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
57921410|NCT05427903|PROCEDURE|Cryotherapy|Ice packs application for 5 minutes after IANB injection
57921411|NCT05427903|PROCEDURE|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
57921412|NCT00104676|BIOLOGICAL|bleomycin sulfate|At least one course administered
57921413|NCT00104676|DRUG|cisplatin|At least one course administered
17267668|NCT06399965|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 21 h.
17267669|NCT06399965|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
57921414|NCT00104676|DRUG|etoposide|At least one course administered
57921415|NCT00104676|DRUG|ifosfamide|Given in a dose-dense sequential fashion
57921416|NCT00104676|DRUG|oxaliplatin|Given in a dose-dense sequential fashion
57921417|NCT00104676|DRUG|paclitaxel|Given in a dose-dense sequential fashion
57921418|NCT04317703|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
57921419|NCT04317703|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
57921420|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
57921421|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
57921422|NCT02569957|DRUG|Acetylcysteine|Given IV and PO
57921423|NCT00903656|DRUG|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
57921424|NCT04473430|DEVICE|Dexcom real-time G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance. The sensor uses a novel semi-permeable membrane that blocks interference with most clinically relevant substances, including high levels of urea and creatinine, and commonly used medications. Dexcom G6 CGM is a commercially-available, minimally invasive sensor, with a flexible and thin wire that is inserted into the abdominal subcutaneous tissue. Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes)."
58065703|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
58276787|NCT01476306|OTHER|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
57921425|NCT04473430|DIAGNOSTIC_TEST|POC BG|POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.
57921426|NCT03960307|OTHER|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
57921427|NCT05134051|DEVICE|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
57921428|NCT00850785|BIOLOGICAL|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
57921429|NCT05402397|DRUG|Losartan Potassium|Patients will receive losartan potassium for 30 days.
58065704|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
58276788|NCT01476306|OTHER|Usual care|Patients in this group will receive care as they usually do with the physician.
57921430|NCT05166980|DIETARY_SUPPLEMENT|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
58392977|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
57724308|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
57724309|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
57724310|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
57724311|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
57921431|NCT05166980|DIETARY_SUPPLEMENT|Iodized salt|Salt fortified with iodine
57921432|NCT00265746|DRUG|Metformin|
57921433|NCT00265746|BEHAVIORAL|Lifestyle intervention - diet, physical activity|
57921434|NCT02493543|OTHER|Blood collection|Blood collection from the subject's arm
57921435|NCT02088346|OTHER|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
57921436|NCT05782686|PROCEDURE|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
57921437|NCT00762970|DEVICE|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
57921438|NCT00762970|DEVICE|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
57921439|NCT00762970|DEVICE|Control Lens|Spectacle Lenses.
58065705|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
57724312|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
57724313|NCT04574362|DRUG|Placebo|Matching placebo
57724314|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
58065706|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
58065707|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
58392978|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
58392979|NCT00684710|DRUG|PAZ-417|
57921440|NCT01444833|DRUG|Candesartan|32 mg per day duration 6 months
57921441|NCT03018054|DRUG|E6007|once daily administration
57921442|NCT03018054|DRUG|Placebo|once daily administration
57921443|NCT00558337|DRUG|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
58392980|NCT00684710|DRUG|Placebo|
57921444|NCT03118674|DRUG|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
57921445|NCT02957864|DRUG|tenofovir alafenamide|
57921446|NCT02957864|DRUG|abacavir|
57921447|NCT01519466|DEVICE|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
57921448|NCT01519466|DEVICE|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
57921449|NCT02489123|DRUG|Enzalutamide|Given PO
57921450|NCT02489123|OTHER|Laboratory Biomarker Analysis|Correlative studies
57921451|NCT03821389|DEVICE|NIOD Frequencer|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
58065708|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
58065709|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
58065710|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
58065711|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
58392981|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
58392982|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
58392983|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
57724315|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
57724316|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
57724317|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
57724318|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
57724319|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
57724320|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
57724321|NCT02066298|DRUG|Placebo|
57724322|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
57724323|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
57724324|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
57724325|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
57724326|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
58065712|NCT01716585|DRUG|Placebo for ABT-333|Tablet
57921452|NCT04842656|OTHER|Post isometric relaxation|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
58065713|NCT01716585|DRUG|Placebo for ribavirin|Capsule
58065714|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
58392984|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
58065715|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
58065716|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
58392985|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
58392986|NCT02830854|OTHER|Molecular Hydrogen|
58392987|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
58392988|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
58392989|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
58392990|NCT05504187|DRUG|KP104|KP104 will be administered.
57724327|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
58275699|NCT03252197|DEVICE|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
58275700|NCT03252197|DEVICE|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
58275701|NCT03597139|DRUG|Voclosporin Ophthalmic Solution|Investigational Drug
58275702|NCT03597139|DRUG|Restasis®|Comparator
58275703|NCT06731842|OTHER|18F-RO948|Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease
58275704|NCT01446250|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
58275705|NCT01446250|DRUG|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
58275706|NCT01446250|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
58392991|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
57724328|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
58392992|NCT00425022|PROCEDURE|thoracoscopy|
58392993|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
57724329|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
57724330|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
58275707|NCT01446250|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
58275708|NCT05471336|PROCEDURE|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
58275709|NCT03970200|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
58275710|NCT03970200|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
58275711|NCT03970200|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
57921453|NCT04842656|OTHER|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
58275712|NCT03970200|DRUG|Antibiotics|Standard of care antibiotics
58275713|NCT03906851|BEHAVIORAL|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
58275714|NCT01282333|DRUG|gemcitabine hydrochloride|Given IV
58275715|NCT01282333|DRUG|veliparib|Given orally
58392994|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
58392995|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
58392996|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
58392997|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
58392998|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
58392999|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
58393000|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
58393001|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
58393002|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
58393003|NCT03718884|DRUG|Mirikizumab|Administered SC
58490399|NCT02153619|BEHAVIORAL|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
57724331|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
57921454|NCT04795882|BIOLOGICAL|BCMA CAR T cells|Infusion with ATIMP: BCMA CAR T-cells
57921455|NCT04795882|BIOLOGICAL|BCMA/CD19 CAR T cells|Infusion with ATIMP: BCMA/CD19 CAR T-cells
57921456|NCT00111527|OTHER|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
57921457|NCT00111527|OTHER|normal RV pacing|PM or ICD implant according to patient indication
57921458|NCT02951741|OTHER|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
57921459|NCT04919239|BIOLOGICAL|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
57921460|NCT04919239|BIOLOGICAL|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
57921461|NCT04008602|DEVICE|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
57921462|NCT04008602|DEVICE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
58275716|NCT01282333|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
58275717|NCT01282333|OTHER|pharmacological study|Correlative studies
58275718|NCT01282333|DRUG|cisplatin|Given IV
58275719|NCT00198432|DRUG|Paclitaxel, vinorelbine, cisplatin|
58275720|NCT04499105|DRUG|Mesenchymal Stem Cell + NaCl 0,9% 2ml|Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
58275721|NCT04422314|DIAGNOSTIC_TEST|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
58275722|NCT02411318|BEHAVIORAL|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
58275723|NCT02411318|DRUG|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
57724332|NCT01316744|DRUG|ketamine hydrochloride|
57921463|NCT01489410|DRUG|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
57724333|NCT01316744|OTHER|pharmacogenomic studies|
57724334|NCT01316744|OTHER|questionnaire administration|
57921464|NCT01489410|DRUG|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
57921465|NCT04889547|DRUG|Dexamethasone|Intraoperative intravenous dexamethasone
57921466|NCT04889547|OTHER|No dexamethasone|No intraoperative intravenous dexamethasone
57921467|NCT03832413|DIAGNOSTIC_TEST|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
57921468|NCT02686905|DIETARY_SUPPLEMENT|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
57921469|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
57921470|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
58065717|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
58275724|NCT02411318|OTHER|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
58275725|NCT02411318|DRUG|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
58275726|NCT01935128|DRUG|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
58275727|NCT00005896|DRUG|filgrastim|
58275728|NCT00005896|GENETIC|Autologous stem cells transduced with FACC retroviral vector|
58275729|NCT00005896|PROCEDURE|Autologous Stem Cell Transplantation|
58275730|NCT01511003|DRUG|Tacrolimus|oral
58275731|NCT00133653|BEHAVIORAL|Observational|
58275732|NCT05636358|OTHER|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
58393004|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
58393005|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
58393006|NCT01178944|DRUG|Oxaliplatin|Given IV
58393007|NCT01178944|DRUG|Pralatrexate|Given IV
58393008|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
58393009|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
58393010|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
58393011|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
58393012|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
58393013|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
58393014|NCT02819258|OTHER|Endodontic treatment|
57724335|NCT01316744|PROCEDURE|assessment of therapy complications|
57724336|NCT01316744|PROCEDURE|quality-of-life assessment|
57921471|NCT02686905|DIETARY_SUPPLEMENT|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
57921472|NCT02686905|DIETARY_SUPPLEMENT|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
58065718|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
58393015|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
58393016|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
57724337|NCT00002934|PROCEDURE|long-term screening|
57724338|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
57724339|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
57921473|NCT02686905|DIETARY_SUPPLEMENT|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
57724340|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
57724341|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
57724342|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
57724343|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
57724344|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
58065719|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
57724345|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
57921474|NCT03049176|DRUG|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
57921475|NCT03049176|DRUG|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
58065720|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
58065721|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
58065722|NCT00841854|DRUG|bismuth|bismuth 300mg qid
58065723|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
58393017|NCT06376162|DRUG|Ziftomenib|Oral capsule
58393018|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
58393019|NCT06376162|DRUG|Fludarabine|IV infusion
58393020|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
58393021|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
58393022|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
58393023|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
58393024|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
58393025|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
58393026|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
58393027|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
58393028|NCT03427814|DRUG|Placebo|60 mg orally twice daily
58393029|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
58393030|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
58393031|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
58393032|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
58393033|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
58393034|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
58393035|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
58393036|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
58393037|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
58393038|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
58393039|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
58393040|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
58393041|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
58393042|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
58393043|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
58393044|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
57921476|NCT03049176|PROCEDURE|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
57921477|NCT03049176|PROCEDURE|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
57921478|NCT02745743|DRUG|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
57921479|NCT04643288|PROCEDURE|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
57921480|NCT04643288|PROCEDURE|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
57724346|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
57724347|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
57921481|NCT02274194|DEVICE|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
57921482|NCT02274194|DEVICE|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
57921483|NCT01510496|PROCEDURE|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
57921484|NCT01510496|PROCEDURE|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
57724348|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
57921485|NCT01510496|PROCEDURE|Thoracotomy .|Thoracotomy (non laparoscopic).
57921486|NCT05257031|DRUG|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
57921487|NCT03200600|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
57921488|NCT03200600|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
58393045|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
57724349|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
57921489|NCT03200600|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
57921490|NCT03200600|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
57921491|NCT01453530|DRUG|Sugammadex|A single dose of sugammadex 2 mg/kg iv
57921492|NCT01453530|DRUG|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
57921493|NCT01453530|OTHER|Placebo|Placebo
57921494|NCT05621031|DEVICE|Whole body Vibration|Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
57724350|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
57921495|NCT05621031|OTHER|Habitual Therapy|Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
57921496|NCT05621031|DEVICE|Placebo whole body vibration|Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
57921497|NCT05417633|PROCEDURE|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
57921498|NCT02934321|DIETARY_SUPPLEMENT|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
57921499|NCT02934321|DIETARY_SUPPLEMENT|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
57724351|NCT00548782|OTHER|Paleolithic diet|diet
57724352|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
57921500|NCT03495128|OTHER|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
57921501|NCT03495128|OTHER|Reconditioning|daily resistance training (for 3 days) on one leg
58275733|NCT02867202|DEVICE|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
58275734|NCT02867202|DEVICE|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
57724353|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
57724354|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
57724355|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
57724356|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
57724357|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
57724358|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
57921502|NCT04494581|OTHER|questionnaire|Questionnaire survey
57921503|NCT02612753|PROCEDURE|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
57921504|NCT02612753|DEVICE|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
57724359|NCT01363323|DRUG|Placebo|
57921505|NCT02612753|DEVICE|tDCs|
57921506|NCT06023277|BIOLOGICAL|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
57921507|NCT01610011|DIETARY_SUPPLEMENT|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
57921508|NCT01800422|DRUG|telapristone acetate|Given orally
57921509|NCT01800422|OTHER|placebo|Given orally
57921510|NCT01800422|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
57921511|NCT01800422|OTHER|laboratory biomarker analysis|Correlative studies
57921512|NCT01800422|OTHER|questionnaire administration|Ancillary studies
57724360|NCT01363323|DRUG|Moxifloxacin|
57921513|NCT03339128|DRUG|Eluxadoline|Oral tablets
57921514|NCT03339128|DRUG|Placebo|Oral tablets
57921515|NCT03509233|OTHER|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
57921516|NCT03509233|OTHER|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
57921517|NCT03509233|OTHER|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
57921518|NCT03509233|OTHER|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
57921519|NCT05664386|DRUG|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
58065724|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
58065725|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
57724361|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
57724362|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
57724363|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
57724364|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
57724365|NCT01625793|DRUG|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
57724366|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
57724367|NCT04028375|OTHER|No intervention|No intervention
57724368|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
57724369|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
57724370|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
57724371|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
57724372|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
57724373|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
57724374|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
57724375|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
57724376|NCT01065961|DRUG|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
57724377|NCT01065961|DRUG|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
57724378|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
57724379|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
57724380|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
58065726|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
58393046|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
57724381|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
57724382|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
58065727|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
58275735|NCT00819572|BIOLOGICAL|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
58275736|NCT00819572|DRUG|Placebo|
58275737|NCT06195475|OTHER|high vs low tidal volume|The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.
58275738|NCT01216046|DRUG|VX-809|capsule, taken once daily
58275739|NCT01216046|DRUG|VX-770|tablet, taken once every 12 hours
58393047|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
58490400|NCT02153619|BEHAVIORAL|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
58490401|NCT02153619|BEHAVIORAL|questionnaires assessments|
57724383|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
57724384|NCT01859455|DRUG|Placebo|Placebo comparator
57724385|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
57724386|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
58065728|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
57724387|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
58065729|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
58275740|NCT01216046|DRUG|VX-809 placebo|capsule, taken once daily
57724388|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
57724389|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
57724390|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
57724391|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
57724392|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
57724393|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
58275741|NCT01216046|DRUG|VX-770 placebo|tablet, taken once every 12 hours
58275742|NCT05339412|BEHAVIORAL|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
58275743|NCT05836675|OTHER|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
58275744|NCT03710369|DRUG|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
58490402|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
58490403|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
57724394|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
57921520|NCT05664386|DRUG|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
58275745|NCT03710369|DRUG|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
58275746|NCT00033878|DRUG|Noni Extract|
58275747|NCT05917808|OTHER|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
58275748|NCT04375501|OTHER|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
58275749|NCT05917067|DIAGNOSTIC_TEST|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
58275750|NCT03905356|BEHAVIORAL|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
58275751|NCT05807438|OTHER|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
58275752|NCT05807438|OTHER|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
58275753|NCT06351852|DRUG|Combination of Neostigmine and Glycopyrrolate|Transcutaneous
58275754|NCT06351852|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
58275755|NCT00715845|PROCEDURE|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
58275756|NCT04728555|PROCEDURE|Game about radiotherapy|A digital pedagogical game about radiotherapy
58393048|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
58393049|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
58393050|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
58393051|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
58275757|NCT05011097|DRUG|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
58275758|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
58275759|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
58275760|NCT06240988|DEVICE|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy
58275761|NCT06240988|OTHER|Motor Imagery Technique|Motor Imagery Technique
57724395|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
57921521|NCT00830557|OTHER|medical chart review|baseline, 12 month and 36 months
57921522|NCT00830557|OTHER|survey administration|baseline, 6 month, 12 month
57921523|NCT00830557|OTHER|biospecimen collection|baseline
57724396|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
57921524|NCT02622958|DRUG|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
58275762|NCT02656563|RADIATION|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
58275763|NCT06730152|BEHAVIORAL|WeChat Intervention Based on the IMB Model|The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
58275764|NCT02295787|DRUG|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
58275765|NCT02295787|DRUG|Placebo|
58275766|NCT00636961|DRUG|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
58275767|NCT00636961|DRUG|Placebo|Matching placebo devices and hard gelatin capsules
58275768|NCT01666210|DRUG|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
58275769|NCT01666210|DRUG|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
58275770|NCT05869877|DEVICE|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
58275771|NCT04023305|DRUG|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
58393052|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
58393053|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
58393054|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
57724397|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
57724398|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
57724399|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
57724400|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
57921525|NCT02622958|OTHER|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
58275772|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
58275773|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
58275774|NCT02742714|DEVICE|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
58275775|NCT01417585|BEHAVIORAL|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
58393055|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
58393056|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
58393057|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
58393058|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
58393059|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
58393060|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
58393061|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
57724401|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
57724402|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
57724403|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
57724404|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
57724405|NCT04757012|DEVICE|calinange|calinange
57724406|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
57724407|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
57724408|NCT02291718|DRUG|Isovue|iodine contrast
57724409|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
57724410|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
57724411|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
58065730|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
58393062|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
58393063|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
57724412|NCT04177693|DRUG|Letrozole|5 mg for 5 days
57724413|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
57724414|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
57724415|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
58275776|NCT01417585|BEHAVIORAL|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
58393064|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
57724416|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
57724417|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
57724418|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
57724419|NCT01982916|DRUG|AGR tablet|
57724420|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
57724421|NCT01982916|DRUG|Active Comparator|
57724422|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
57724423|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
57724424|NCT03450031|OTHER|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
58065731|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
58065732|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
58065733|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
58065734|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
57724425|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
58275777|NCT02156973|OTHER|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
57724426|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
57724427|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
57724428|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
57921526|NCT06531161|DRUG|Suxiao Jiuxin Pill|Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
57921527|NCT06531161|DRUG|Placebo|Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
57921528|NCT06473129|BEHAVIORAL|Food for Life Culinary Workshops|Whole food, plant based 2hr workshop, which includes background information on diabetes, how to shop for food, etc and then a culinary demonstration and tasting of whole food, plant based dishes.
57921529|NCT03603028|DEVICE|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
57921530|NCT00285987|PROCEDURE|Reconstruction of the cruciate ligament|
57921531|NCT00002123|DRUG|Delavirdine mesylate|
58065735|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
58065736|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
58065737|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
58065738|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
58275778|NCT01451164|DRUG|OPC-34712|orally administered once daily
58275779|NCT01451164|DRUG|OPC-34712|orally administered once daily
58275780|NCT01451164|DRUG|OPC-34712|orally administered once daily
57724429|NCT03023735|OTHER|None. This is an observational study|
57724430|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
57921532|NCT00002123|DRUG|Didanosine|
57921533|NCT03898947|PROCEDURE|Diagnostic hysteroscopy and targeted endometrial biopsy|Diagnostic hysteroscopy and targeted endometrial biopsy
57921534|NCT04326504|OTHER|No intervention|This will be an observational study, no intervention will be performed
58065739|NCT02517502|DRUG|Placebo|Matched, blinded placebo
58065740|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
58065741|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
58275781|NCT01451164|DRUG|Placebo|orally administered once daily
58275782|NCT06510920|BEHAVIORAL|Aerobic exercise|The mixed design scheme of football and volleyball sports technology and competition will be adopted.aerobic exercise intensity will be moderate-intensity aerobic exercise load , and the intervention time was 12 weeks, 60 minutes each time, twice a week. The main preparation activities were jogging and special preparation activities (10 minutes), and the main part was technical teaching combined with competition (60 minutes).The end part is mostly jogging and stretching (10 minutes). Two subjects in each group were selected to wear Decathlon Bluetooth heart rate band, and the exercise intensity was controlled by detecting the heart rate of the subjects.
58275783|NCT03580499|DIETARY_SUPPLEMENT|Vitamin B6|Given PO
57921535|NCT03832634|DIAGNOSTIC_TEST|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
57921536|NCT05053425|DRUG|Venetoclax|given po.
57921537|NCT05053425|DRUG|Azacitidine|given sc.
57921538|NCT05053425|DRUG|Cladribine|given ivgtt.
57921539|NCT05053425|DRUG|Cytarabine|given sc or ivgtt.
57921540|NCT05053425|DRUG|Idarubicin|given ivgtt.
57921541|NCT00381368|DRUG|Ibandronic acid|
57921542|NCT05968547|OTHER|Driving assessment in glaucoma patient|One group of patient will be given questionnaire while the other group will respond to a questionnaire while the other group will have vision assessment. Patients could participate in both groups.
58393065|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
58490404|NCT04812392|DEVICE|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
57921543|NCT02095951|DRUG|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
57921544|NCT00882427|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
57921545|NCT02358382|DRUG|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
57921546|NCT00182390|PROCEDURE|Red blood cell transfusion|
57921547|NCT06298253|BEHAVIORAL|Behavioral economics-enhanced SWAP implementation|Intervention will include behavioral nudges at baseline and over 12 months to promote use of the SWAP nutrition program for pantries.
57921548|NCT06298253|BEHAVIORAL|Basic SWAP implementation|Intervention will include basic information about the SWAP program and encouragement to obtain SWAP toolkits.
57921549|NCT00948142|DRUG|CEM-102|600 mg BID oral tablets for 10-14 days
57921550|NCT00948142|DRUG|Linezolid|600 mg BID oral tablets
57921551|NCT00948142|DRUG|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
57921552|NCT04774770|BEHAVIORAL|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
57921553|NCT04578769|PROCEDURE|conventional myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
57921554|NCT04578769|PROCEDURE|short myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
57921555|NCT04578769|PROCEDURE|full-thickness myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
57921556|NCT04578769|PROCEDURE|tailored myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
57921557|NCT06154486|DRUG|semaglutide use|patient using semaglutide for at least 7 days
57921558|NCT01180998|DEVICE|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
57921559|NCT01180998|DEVICE|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
57921560|NCT00450060|DEVICE|lumbar puncture with Quincke-design needles|
57921561|NCT00450060|DEVICE|lumbar puncture with Sprotte-design needles|
57921562|NCT03555474|PROCEDURE|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
58065742|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
58065743|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
57921563|NCT03555474|PROCEDURE|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
58065744|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
58275784|NCT03580499|OTHER|Questionnaire Administration|Ancillary studies
58275785|NCT02801526|DRUG|CKD-330 16/5mg - A|
58275786|NCT02801526|DRUG|Candesartan 16mg and Amlodipine 5mg|
58275787|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
58275788|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
58275789|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
58275790|NCT03339336|DRUG|BIIB074|Administered as specified in the treatment arm.
58275791|NCT03339336|DRUG|Placebo|Administered as specified in the treatment arm.
58275792|NCT02398513|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
58275793|NCT05571423|BEHAVIORAL|Medical Play|Study subject will be engage in the medical play.
58275794|NCT05571423|BEHAVIORAL|Routine Play|Study subject will be engage in the routine play (coloring exercise).
58275795|NCT02890849|OTHER|Liquid biopsy|
58275796|NCT01053338|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
58275797|NCT04739332|BEHAVIORAL|The Newborn behavioral observations system|The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
58275798|NCT04647994|DIAGNOSTIC_TEST|SARS-CoV-2 serology|Serology test of SARS-CoV-2 for pregnant women
58275799|NCT00935064|DRUG|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
58275800|NCT00935064|OTHER|Placebo|Placebo orally one tablet once a day for 6 weeks.
58275801|NCT01725360|DRUG|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
58275802|NCT00089635|DRUG|Panitumumab|Administered by intravenous infusion
58275803|NCT03139864|PROCEDURE|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
57921564|NCT03555474|PROCEDURE|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
57921565|NCT05793918|OTHER|Therapeutic Percutaneous Electrolysis an neuromodulation|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
58065745|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
58275804|NCT05888181|OTHER|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
58275805|NCT01699308|DRUG|Genotropin|
58275806|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
58275807|NCT06239571|BEHAVIORAL|Resilient Families (R-FAM)|Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
58275808|NCT01669200|OTHER|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
58275809|NCT01669200|OTHER|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
58275810|NCT05920668|DRUG|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
58275811|NCT04424771|BEHAVIORAL|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
58275812|NCT02254122|DRUG|BEA 2180 BR|
58275813|NCT02254122|DRUG|Placebo|
58275814|NCT02254122|DEVICE|Respimat®|
58275815|NCT04257253|OTHER|Targeted exercise program|Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
58275816|NCT04257253|OTHER|General exercise program|Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
57921566|NCT05793918|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
57921567|NCT01522105|DRUG|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
57921568|NCT01562457|DRUG|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
57921569|NCT01535950|DRUG|LFG316|
57921570|NCT01535950|DRUG|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
57921571|NCT02222051|BEHAVIORAL|Tai Chi|traditional chinese martial art meditative movement technique
57921572|NCT02222051|BEHAVIORAL|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
58275817|NCT04108663|BEHAVIORAL|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
58275818|NCT03482570|DEVICE|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
58275819|NCT03438188|OTHER|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
58275820|NCT01790516|DRUG|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
58275821|NCT01790516|DRUG|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
58275822|NCT01790516|RADIATION|Radiation|daily radiation for 7 weeks
57921573|NCT06485609|PROCEDURE|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
57921574|NCT03025386|OTHER|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
57921575|NCT03025386|OTHER|Electroencephalography|Mesure of the mismatch negativity wave
57921576|NCT04497142|DRUG|Perampanel|Tablet taken orally 1x daily.
57921577|NCT04497142|DRUG|Standard of Care|Predetermined standard of care drug and dosing
57921578|NCT00320541|DRUG|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
57921579|NCT00320541|DRUG|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
57921580|NCT00320541|DRUG|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
57921581|NCT03278106|OTHER|Laboratory Biomarker Analysis|Correlative studies
57921582|NCT03278106|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
57921583|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
57921584|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
57921585|NCT03711851|OTHER|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
57921586|NCT00216697|DRUG|bortezomib|
57921587|NCT01340196|DRUG|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
57921588|NCT03947437|BIOLOGICAL|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
57921589|NCT03947437|BIOLOGICAL|Placebo|Sterile normal saline for injection.
57921590|NCT00742482|DRUG|HL 10|Freeze dried HL 10
57921591|NCT00534573|DRUG|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
58065746|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
58065747|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
58065748|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
58275823|NCT00495859|DIETARY_SUPPLEMENT|Immunonutrition|food for special medical purpose (FSMP)
58275824|NCT00495859|DIETARY_SUPPLEMENT|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
58275825|NCT01065363|BEHAVIORAL|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
58275826|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
58275827|NCT03807401|BEHAVIORAL|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
57921592|NCT02895451|BEHAVIORAL|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
58275828|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
58275829|NCT01004718|RADIATION|Fludeoxyglucose F18|Undergo FDG PET/CT scans
57921593|NCT05694754|DEVICE|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
57921594|NCT02851082|OTHER|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
57921595|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
58393066|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
57921596|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
58275830|NCT01004718|PROCEDURE|Computed Tomography|Undergo FDG PET/CT scans
57921597|NCT00292877|DRUG|SB-240563 (Mepolizumab)|
57921598|NCT01477333|DRUG|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
58065749|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
58275831|NCT01004718|PROCEDURE|Positron emission tomography|Undergo FDG PET/CT scans
58275832|NCT01593254|DRUG|Imatinib|
57921599|NCT01477333|DRUG|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
57921600|NCT04483986|PROCEDURE|Rectus muscle re-approximation|Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
58275833|NCT01593254|DRUG|Dasatinib|
58275834|NCT05843240|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
57921601|NCT03631160|DEVICE|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
57921602|NCT03631160|DEVICE|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
57921603|NCT03650257|BIOLOGICAL|gp96|25 mcg IH
58275835|NCT05843240|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
58275836|NCT00221039|DRUG|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
58065750|NCT01083615|DRUG|docetaxel|
58065751|NCT01083615|DRUG|cabazitaxel|
58065752|NCT01083615|DRUG|prednisone|
58065753|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
58275837|NCT03583905|DRUG|CKD-330|CKD-330 Tab.
58275838|NCT03583905|DRUG|Placebo of CKD-330|Placebo of CKD-330 Tab.
58275839|NCT03583905|DRUG|D086|D086 Tab.
58275840|NCT03583905|DRUG|Placebo of D086|Placebo of D086 Tab.
58275841|NCT03583905|DRUG|D723|D723 Tab.
58275842|NCT03583905|DRUG|Placebo of D723|Placebo of D723 Tab.
58275843|NCT06365450|OTHER|Educational Intervention|Participants will receive hybrid educational intervention on breast and cervical cancer
58275844|NCT06182618|OTHER|dietary, semaglutide or/and metformin|patients were prescribed dietary and pharmaceuticals for weight loss
58275845|NCT02769936|DRUG|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
58275846|NCT02769936|OTHER|Placebo|Placebo administered orally as encapsulated pill
57921604|NCT03650257|DRUG|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
57921605|NCT03650257|RADIATION|radiotherapy|Stupp regimen of radiotherapy
57921606|NCT04578574|OTHER|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
57921607|NCT04578574|DEVICE|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
57921608|NCT04578574|OTHER|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
57921609|NCT04555538|DIAGNOSTIC_TEST|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
57921610|NCT01498289|DRUG|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
57921611|NCT01498289|DRUG|docetaxel|30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
57921612|NCT01498289|DRUG|fluorouracil|400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
57921613|NCT01498289|DRUG|irinotecan hydrochloride|65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
57921614|NCT01498289|DRUG|leucovorin calcium|400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
57921615|NCT01498289|DRUG|oxaliplatin|85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
57921616|NCT02261597|BEHAVIORAL|Cold Pressor Test|Repeated immersion of hand in ice-cold water
57921617|NCT00526032|PROCEDURE|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
57921618|NCT01652950|BEHAVIORAL|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was \>3000 fitness points/month - equivalent to \>20 gym visits/month."
57921619|NCT04782843|OTHER|HEP score assessement|Assessement of the HEP score between 2 physician.
57921620|NCT01285271|DRUG|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
57921621|NCT01285271|DRUG|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
57921622|NCT02271997|DRUG|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
58275847|NCT01621971|DRUG|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
58490405|NCT06362057|OTHER|Subperiosteal implant framework|"A 3D image of an edentulous maxilla bone will be derived from a computed tomography scan of an adult patient and saved as stl data. The solid geometry of the maxilla, including the cortical and spongious bone, was rebuilt from the stl data into the Digital Imaging and Communications in Medicine (DICOM) format with 3D-Doctor (Able Software Corp., MA, USA).~With the Boolean method, force loading will be achieved between prosthetic parts, subperiosteal implant screws and bone tissues"
57921623|NCT02271997|DRUG|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
57921624|NCT02271997|DRUG|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
57921625|NCT00734383|DRUG|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
58065754|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
58275848|NCT01621971|DRUG|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
58275849|NCT04736641|OTHER|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
58275850|NCT01912352|DRUG|Methylphenidate|
58065755|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
58065756|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
58065757|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
58065758|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
58275851|NCT05691959|DRUG|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
58275852|NCT05691959|DRUG|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
58275853|NCT03303391|OTHER|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
58275854|NCT01910220|DRUG|REGN1033 (SAR391786)|
58065759|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
58065760|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
58275855|NCT01910220|OTHER|placebo|
57921626|NCT00734383|DRUG|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
57921627|NCT01980550|DRUG|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
57921628|NCT01078675|DRUG|rosuvastatin calcium|5 mg, oral, once daily, 24 months
57921629|NCT01078675|DRUG|rosuvastatin calcium|10 mg, oral, once daily, 24 months
57921630|NCT01078675|DRUG|rosuvastatin calcium|20 mg, oral, once daily, 24 months
57921631|NCT00001521|DRUG|Fludrocortisone|Since hydrocortisone dosage will be reduced , some patients may develop symptoms or signs of adrenal insufficiency. Patients will continue to receive an optimal fludrocortisone dose
57921632|NCT00001521|DRUG|Hydrocortisone|reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia
57921633|NCT00001521|DRUG|Letrozole|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
57921634|NCT00001521|DRUG|Flutamide|Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
57921635|NCT00409773|DRUG|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
57921636|NCT00409773|DRUG|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
58065761|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
58065762|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
58275856|NCT04991038|DEVICE|DAISe Device|Thrombectomy using the DAISE device
58275857|NCT04991038|DEVICE|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
57921637|NCT00409773|DRUG|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
57921638|NCT02152657|OTHER|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
57921639|NCT02751567|OTHER|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
58065763|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
58065764|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
58275858|NCT04792307|OTHER|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
58490406|NCT05114252|DEVICE|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
57921640|NCT02751567|OTHER|Untreated skin|One site is patched without treatment as control
57921641|NCT05115604|BEHAVIORAL|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
57921642|NCT04507061|DRUG|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
57921643|NCT04507061|OTHER|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
58393067|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
58393068|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
58393069|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
57921644|NCT03770637|DRUG|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
57921645|NCT03770637|OTHER|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
57921646|NCT01006928|OTHER|Questionaire|Questionaire to mothers
57921647|NCT00108147|PROCEDURE|Circuit Training|
57921648|NCT00108147|PROCEDURE|Cardiac Rehabilitation|
57921649|NCT00108147|PROCEDURE|Flexibility and toning|
57921650|NCT06528886|PROCEDURE|hysterectomy by V-NOTES|V-notes is like laparoscopy via the vaginal route.
57921651|NCT02782403|DRUG|Axitinib|Given PO
57921652|NCT02782403|DRUG|Bosutinib|Given PO
57921653|NCT02782403|OTHER|Laboratory Biomarker Analysis|Correlative studies
57921654|NCT05751863|OTHER|Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects|"The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects."
57921655|NCT05751863|OTHER|Protocol Directed Sedation and Daily Sedation Interruption|The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
57921656|NCT03969147|DEVICE|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
57921657|NCT03969147|DEVICE|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
57921658|NCT03969147|DEVICE|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
57921659|NCT01602562|DRUG|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
57921660|NCT02652013|OTHER|cognitive evaluation|
57921661|NCT01882751|DEVICE|Conformis CR Total Knee Replacement|iTotal CR by Conformis
57921662|NCT01882751|DEVICE|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
57921663|NCT02882724|BEHAVIORAL|Exercise|8-week aquatic exercise training program
57921664|NCT02882724|BEHAVIORAL|Control|Control group did not do the exercise training.
57921665|NCT00395460|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
57921666|NCT00395460|DRUG|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
57921667|NCT05323006|OTHER|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
57921668|NCT04152460|DEVICE|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
57921669|NCT04152460|OTHER|Grandioso x-tra|Nanohybrid Bulk Resin Composite
57921670|NCT00473681|BEHAVIORAL|Self-Help Intervention Program-High Blood Pressure|
57921671|NCT05863858|DRUG|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
57921672|NCT05863858|DRUG|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
57921673|NCT00064610|DRUG|VELCADE TM (bortezomib) for Injection|
58393070|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
58393071|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
58393072|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
58393073|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
58393074|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
58275859|NCT06533267|PROCEDURE|Endoscopic nasopharyngectomy followed close follow-up|"Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years."
58275860|NCT06533267|RADIATION|Intensity-modulated Radiotherapy|"GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years."
57724431|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
58275861|NCT00006220|DRUG|arsenic trioxide|
58275862|NCT00006220|DRUG|tretinoin|
58393075|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
58393076|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
58393077|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
58393078|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
58490407|NCT05114252|BEHAVIORAL|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
58490408|NCT01657019|DRUG|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
57921674|NCT00389233|DRUG|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
57921675|NCT00389233|DRUG|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
57921676|NCT03739541|DRUG|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
57921677|NCT01894061|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
57921678|NCT01894061|DEVICE|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
58065765|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
58065766|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
58275863|NCT01803776|BEHAVIORAL|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
58275864|NCT05386732|DEVICE|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
58275865|NCT00928655|DRUG|acetazolamide|acetazolamide 250mg 1/0/2
58275866|NCT00928655|PROCEDURE|nocturnal continuous positive airway pressure|continuous positive airway pressure
58065767|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
58065768|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
57921679|NCT01894061|OTHER|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
57921680|NCT04085315|DRUG|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
57921681|NCT04085315|DRUG|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
57921682|NCT03133325|DEVICE|GP0045|Hyaluronic acid gel
57921683|NCT03133325|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid gel
57921684|NCT02981654|DEVICE|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
57921685|NCT02779478|PROCEDURE|Bronchoscopy|
58275867|NCT00928655|DRUG|placebo|placebo capsules
58393079|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
58393080|NCT00615693|DRUG|AEB071|
58393081|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
58393082|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
58393083|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
58393084|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
58393085|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
58393086|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
57921686|NCT04079803|DRUG|Placebo oral tablet|Oral placebo tablet
57921687|NCT04079803|DRUG|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
57921688|NCT04079803|DRUG|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
58275868|NCT03545646|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
58275869|NCT06460610|OTHER|Blow Bottle technique|Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing
58275870|NCT06460610|OTHER|Acapella along with Diaphragmatic Breathing|Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
58275871|NCT04236336|DEVICE|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
58275872|NCT00422422|DRUG|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5"
58275873|NCT00348426|DRUG|Botulinum AntiToxin|
58275874|NCT00348426|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
58275875|NCT00348426|PROCEDURE|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
58275876|NCT01326507|BIOLOGICAL|Dosage de l'h-FABP|Dosage de l'h-FABP
58393087|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
58393088|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
58393089|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
57921689|NCT00713726|DRUG|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
57921690|NCT00713726|DRUG|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
57921691|NCT03141008|OTHER|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
57921692|NCT02308020|DRUG|Abemaciclib|Administered orally
57921693|NCT03591302|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
57921694|NCT03591302|RADIATION|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
57921695|NCT02016456|DEVICE|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
57921696|NCT02016456|DEVICE|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
57921697|NCT01224795|DRUG|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
57921698|NCT01224795|DRUG|Placebo Comparator|Placebo Peramivir, administered intravenously.
57921699|NCT05176535|DIETARY_SUPPLEMENT|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
57921700|NCT04372407|DRUG|Surufatinib|Surufatinib: 200 mg as single dose on Days 1 and 9
57921701|NCT04372407|DRUG|Itraconazole|Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
57921702|NCT04532138|DEVICE|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
57921703|NCT04532138|DEVICE|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
57724432|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
57724433|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
57724434|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
57724435|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
57724436|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
57921704|NCT06080893|DRUG|Ferric carboxymaltose|"FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
57921705|NCT05748054|DRUG|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
57921706|NCT02171325|DRUG|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
57921707|NCT02070796|DRUG|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
57921708|NCT02070796|DRUG|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
57921709|NCT06101849|BEHAVIORAL|I-Can-Manage-Pain after cancer (Pain Management Program)|6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
57921710|NCT05612165|DEVICE|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(2000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
57921711|NCT05612165|DEVICE|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
57921712|NCT02843204|DRUG|Pembrolizumab|Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
57921713|NCT02843204|BIOLOGICAL|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
57921714|NCT02133053|OTHER|Medical Device, drug-like|Ectoin Allergy Nasal Spray
57921715|NCT02133053|DRUG|Beclomethasone|Beclomethasone nasal spray
58065769|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
58065770|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
57921716|NCT00629434|OTHER|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
58275877|NCT02565199|DEVICE|rTMS over Premotor Cortex (Contralateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
58275878|NCT02565199|DEVICE|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
58393090|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
57921717|NCT00629434|OTHER|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
57921718|NCT01164124|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
57921719|NCT01164124|OTHER|Placebo|routine feedings
57921720|NCT02918760|DRUG|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
57921721|NCT02918760|OTHER|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
57921722|NCT02647320|DRUG|Sitagliptin 100 mg|Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
58065771|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
58065772|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
58275879|NCT02565199|DEVICE|rTMS (Control 1)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
58275880|NCT02565199|DEVICE|rTMS (Control 2)|"* Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
58275881|NCT02565199|DEVICE|rTMS (Control 3)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
58275882|NCT02565199|OTHER|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
58393091|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
58065773|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
58275883|NCT00722163|OTHER|Cognitive Behavioural Therapy|
58275884|NCT00722163|OTHER|befriending|
57921723|NCT02647320|DRUG|DS-8500a 25mg|DS-8500a 25mg tablet for oral administration
58275885|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
58275886|NCT02362152|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
58275887|NCT02362152|DRUG|5-fluorouracil|Topical field treatment as prescribed by dermatologist
58275888|NCT02362152|DRUG|Imiquimod|Topical field treatment as prescribed by dermatologist
58275889|NCT02362152|DRUG|Diclofenac|Topical field treatment as prescribed by dermatologist
58275890|NCT05935423|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell transplantation|50 million UC MSC will be transplanted 10-15 days after primary PCI
57921724|NCT02647320|DRUG|Placebo Tablet|Placebo matching DS-8500a tablet for oral administration
57921725|NCT02647320|DRUG|Placebo Capsule|Placebo matching sitagliptin over-capsule for oral administration
57724437|NCT03269032|OTHER|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
57921726|NCT04003220|PROCEDURE|blood sample|The extra samples will be taken Blood sampling
57921727|NCT04003220|PROCEDURE|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
57921728|NCT04225221|DRUG|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
57921729|NCT04225221|DRUG|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
58275891|NCT06084247|DEVICE|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
58275892|NCT06084247|DEVICE|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
58393092|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
58393093|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
58393094|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
58275893|NCT03203174|DEVICE|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
58275894|NCT03203174|DEVICE|Sham Microneedle|Flat roller with no needles on the roller
57921730|NCT04225221|DRUG|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
57921731|NCT04225221|DRUG|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
58275895|NCT03203174|DRUG|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
58275896|NCT03203174|OTHER|Saline|Saline applied to the palm
58275897|NCT02907775|DEVICE|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
58393095|NCT01825148|OTHER|radiolabeled Exendin|
58393096|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
58393097|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
58393098|NCT03637361|DRUG|Placebo|
58393099|NCT01764269|OTHER|text message surveillance for fever|
58393100|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
58393101|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
58393102|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
58393103|NCT04216472|DRUG|Alpelisib|Given PO
58393104|NCT04216472|DRUG|Nab-paclitaxel|Given IV
58393105|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
58393106|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
57921732|NCT03645954|PROCEDURE|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
58275898|NCT02907775|DEVICE|Electrodes|electrodes placed over the radial nerve in radial grove
58275899|NCT05118048|DIAGNOSTIC_TEST|Lactate, Hemoglobin, Hematocrit|Compare diagnostic tests to reference methods
58275900|NCT03623295|OTHER|Blood sample|Blood withdrawal.
58393107|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
58393108|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
58065774|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
58065775|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
58065776|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
58065777|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
58065778|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
58065779|NCT02772042|OTHER|Intervention Group|
58065780|NCT02772042|OTHER|Control Group|
58275901|NCT03623295|OTHER|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
58275902|NCT03623295|OTHER|MRI-imaging|MRI imaging of joints.
58275903|NCT03623295|OTHER|Physical examination|Physical examination of joint status.
58275904|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
58275905|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
58275906|NCT03462992|DIAGNOSTIC_TEST|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
58275907|NCT01397240|DRUG|Albis Tab|2 Tab, twice a day, 12 weeks
58275908|NCT01397240|DRUG|Placebo|2 Tab, twice a day, 12 weeks
58275909|NCT03338244|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
58275910|NCT03338244|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
58393109|NCT02144402|OTHER|infant formula with DHASCO|
58393110|NCT02144402|OTHER|infant formula with DHASCO-B|
58393111|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
58393112|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
58393113|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
58393114|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
58393115|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
58490409|NCT03110913|OTHER|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
58065781|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
58275911|NCT00099632|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
58275912|NCT00099632|DRUG|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
58275913|NCT00099632|DRUG|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
58275914|NCT00099632|DRUG|single dose Nevirapine|one 200 mg tablet taken orally
58275915|NCT04760223|BEHAVIORAL|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
58275916|NCT01488396|DRUG|0.05%cyclosporin eye drop|use twice daily for 6 months
58275917|NCT03478189|PROCEDURE|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
58275918|NCT03385616|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
58490410|NCT05428657|OTHER|EC Brain After-school Program|"* Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet"
58393116|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
58393117|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
58393118|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
58393119|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
58393120|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
58393121|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
58393122|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
58393123|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
58393124|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
58065782|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
58065783|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
58275919|NCT04255966|DEVICE|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
58275920|NCT06396013|DRUG|Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
58275921|NCT06396013|DRUG|placebo|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
58275922|NCT05501067|OTHER|tai chi exercise|specific tai chi exercise
58275923|NCT05501067|OTHER|no intervention|no intervention
58275924|NCT05266924|DRUG|Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen|fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
58275925|NCT06192498|OTHER|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
58275926|NCT06192498|OTHER|Kaleidoscope|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
58275927|NCT06192498|OTHER|Distraction Cards|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
58275928|NCT04521114|DRUG|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
58275929|NCT04521114|DRUG|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
58275930|NCT04521114|DRUG|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
58393125|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
58393126|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
58393127|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
58393128|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
58393129|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
58490411|NCT05428657|OTHER|conventional intervention|Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
57921733|NCT03645954|PROCEDURE|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle \& Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
57921734|NCT00247377|PROCEDURE|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
58065784|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
57921735|NCT00247377|PROCEDURE|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
58065785|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
58065786|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
57921736|NCT04099017|OTHER|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~   Procedural detail:~   Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~2. Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~3. Kinesiotaping:"
58065787|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
58065788|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
58065789|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
58065790|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
58065791|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
58065792|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
58065793|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
58065794|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
58065795|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
58065796|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
58065797|NCT00422955|DRUG|rosiglitazone|
58065798|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
58065799|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
58065800|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
58275931|NCT03174691|DIAGNOSTIC_TEST|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
58275932|NCT01260584|DRUG|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
58275933|NCT01260584|DRUG|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
58393130|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
58065801|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
58065802|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
58065803|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
57921737|NCT04099017|OTHER|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~   Procedural detail:~   i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:"
58065804|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
57921738|NCT04099017|OTHER|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
57921739|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
57921740|NCT00892723|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
57921741|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
57921742|NCT00158899|DRUG|GW501516 oral tablets|
57921743|NCT02147353|DRUG|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
57921744|NCT02147353|DRUG|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
58065805|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
58065806|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
58065807|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
58065808|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
58065809|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
58065810|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
58065811|NCT02183220|DRUG|Metamizol|
58065812|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
58065813|NCT02183220|DRUG|Metamizol placebo|
58065814|NCT02183220|DRUG|ASA placebo|
58065815|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
58065816|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
58393131|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
57724438|NCT03269032|OTHER|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
57724439|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
58065817|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
58065818|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
58393132|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
58393133|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
58393134|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
57724440|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
57724441|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
58275934|NCT05577234|OTHER|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
57921745|NCT02146456|DRUG|Tranexamic Acid|
58275935|NCT05577234|BEHAVIORAL|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
58275936|NCT04504149|BEHAVIORAL|Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD|A primary care-based shared decision making intervention
58275937|NCT05646966|OTHER|one time testing|
58275938|NCT00540488|OTHER|Adult enteral formula|
57724442|NCT00725426|DRUG|Bosutinib|
57724443|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
57724444|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
57724445|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
57921746|NCT02777385|DRUG|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
58275939|NCT00047229|BIOLOGICAL|oblimersen sodium|
58275940|NCT00047229|DRUG|doxorubicin hydrochloride|
58275941|NCT01790152|OTHER|Assessment of Therapy Complications|Ancillary studies
58275942|NCT01790152|OTHER|Laboratory Biomarker Analysis|Correlative studies
58393135|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
58275943|NCT01790152|OTHER|Quality-of-Life Assessment|Ancillary studies
57921747|NCT02777385|DRUG|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
57921748|NCT02777385|RADIATION|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
58275944|NCT01790152|OTHER|Questionnaire Administration|Ancillary studies
58275945|NCT06105541|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
58393136|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
58393137|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
58393138|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
58393139|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
58393140|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
58393141|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
58393142|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
58393143|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
58393144|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
57921749|NCT00718640|DRUG|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
57724446|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
57921750|NCT00718640|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
57921751|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
57921752|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
57921753|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
58275946|NCT04291365|DIAGNOSTIC_TEST|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
58275947|NCT02623608|OTHER|Reference breakfast|A high fat, high calorie breakfast
58275948|NCT02623608|OTHER|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
58275949|NCT02623608|OTHER|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
58275950|NCT02623608|OTHER|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
58275951|NCT02623608|OTHER|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
58275952|NCT01425606|OTHER|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
58275953|NCT05967923|RADIATION|Shock wave therapy|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
58393145|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
58490412|NCT00393861|DRUG|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
58490413|NCT03823313|BEHAVIORAL|SCAI (Spiritual Care Assessment and Intervention)|4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
58490414|NCT00002076|DRUG|Fluconazole|
58393146|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
58393147|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
58393148|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
57724447|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
58275954|NCT05967923|RADIATION|Low level lazer therapy|Patients in this group will receive low level lazer therapy three times a week week for four weeks in addition to routine physical therapy program.
58275955|NCT05967923|OTHER|Routine physical therapy program|Patients in this group will receive only routine physical therapy program three times a week for four weeks.
58393149|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
58393150|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
58393151|NCT02147210|OTHER|biological analysis|
58393152|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
58393153|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
58393154|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
58393155|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
57724448|NCT04284423|DIAGNOSTIC_TEST|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
57724449|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
58275956|NCT02800941|DRUG|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
58275957|NCT00827658|PROCEDURE|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
58393156|NCT00006144|DRUG|Lopinavir/Ritonavir|
58393157|NCT00006144|DRUG|Emtricitabine|
58393158|NCT00006144|DRUG|Stavudine|
58393159|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
57921754|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
58275958|NCT00827658|PROCEDURE|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
58275959|NCT01163006|OTHER|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
58275960|NCT01981148|DEVICE|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
58275961|NCT05805605|BIOLOGICAL|Peripheral Blood Stem Cell Transplant|On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.
58275962|NCT05805605|DRUG|Allopurinol 300 MG|300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
58275963|NCT05805605|DRUG|Fludarabine|30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
58393160|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
58275964|NCT05805605|DRUG|Cyclophosphamide|Administered as a 2 hour IV infusion on day -6, +3, and +4.
58393161|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
58393162|NCT00066599|DRUG|voriconazole|
58393163|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
58393164|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
58393165|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
58393166|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
58393167|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
58275965|NCT05805605|BIOLOGICAL|Bone Marrow Cell Transplant|On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.
57724450|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
57724451|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
58275966|NCT05805605|RADIATION|Total Body Irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
58275967|NCT05805605|DRUG|Sirolimus Pill|"All participants begin +5 to day +100.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg)."
58393168|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
57724452|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
57724453|NCT03280277|DRUG|Ferumoxytol|Given IV
57724454|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
58393169|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
58393170|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
58393171|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
57724455|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
57724456|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
58393172|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
57724457|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
57724458|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
57724459|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
57724460|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
57724461|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
57724462|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
57921755|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
58275968|NCT05805605|DRUG|Mycophenolate Mofetil|"All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours."
58275969|NCT04426669|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
58393173|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
58393174|NCT02860234|DRUG|Oxaliplatin|
58393175|NCT02860234|DRUG|Capecitabine|
58393176|NCT02860234|RADIATION|intensity modulated radiotherapy|
58393177|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
58393178|NCT02860234|PROCEDURE|Nonoperative Management|
58393179|NCT02860234|PROCEDURE|Local Excision|
58393180|NCT02860234|PROCEDURE|Total Mesorectal Excision|
58393181|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
58393182|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
58393183|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
57921756|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
58275970|NCT04426669|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
58275971|NCT04426669|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
58275972|NCT04426669|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
58275973|NCT00461110|DRUG|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
58275974|NCT00354042|DRUG|GW597901X|
58275975|NCT05086666|DRUG|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
58275976|NCT00607542|DRUG|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
58275977|NCT04050579|DEVICE|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
58275978|NCT03218228|PROCEDURE|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
58275979|NCT00395642|DEVICE|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
58275980|NCT00347321|PROCEDURE|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
58275981|NCT06294444|OTHER|Constraint Induced Movement Therapy|Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.
58275982|NCT06294444|OTHER|Mirror therapy|Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
58275983|NCT04318132|DEVICE|Nidek Mirante|The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
58275984|NCT04318132|DEVICE|Optovue RTVue XR Avanti|The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
58275985|NCT04318132|DEVICE|Optos P200DTx|The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
58275986|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
58275987|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
57921757|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
57921758|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
57921759|NCT03027492|OTHER|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
57921760|NCT06475872|DRUG|Crecheck Tablet 2.5 mg|2 tablets orally once a day
57921761|NCT06475872|DRUG|Crestor Tablet 5 mg|1 tablet orally once a day
58275988|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
58275989|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
58065819|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
58275990|NCT02001272|DRUG|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
58275991|NCT02001272|DRUG|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
58275992|NCT02001272|DRUG|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
58275993|NCT00473824|BIOLOGICAL|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
58275994|NCT02972333|DRUG|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
58275995|NCT02972333|RADIATION|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
58275996|NCT03402230|DRUG|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
58275997|NCT03402230|OTHER|Laboratory Biomarker Analysis|Correlative studies
58275998|NCT03402230|OTHER|Questionnaire Administration|Ancillary studies
57921762|NCT02823535|BEHAVIORAL|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
57921763|NCT01267877|OTHER|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
57921764|NCT01267877|OTHER|read favorable article prior to answering questions|"read A Backlash of Mistrust"
57921765|NCT04341766|OTHER|No special intervention|No special intervention : Ultrasound data will be collected
57921766|NCT01346436|PROCEDURE|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
58065820|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
57921767|NCT01925287|DIETARY_SUPPLEMENT|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
58065821|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
58065822|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
58065823|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
57921768|NCT05206019|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
57921769|NCT01593306|DRUG|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
57921770|NCT01593306|DRUG|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
57921771|NCT03017274|OTHER|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
57921772|NCT05902923|PROCEDURE|endovascular intervention|endovascular intervention
58065824|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
58065825|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
58065826|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
58065827|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
58065828|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
58065829|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
58065830|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
57921773|NCT03681197|DRUG|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
58065831|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
58065832|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
57724463|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
57921774|NCT03681197|DRUG|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
57921775|NCT03681197|DRUG|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
57921776|NCT03270423|DEVICE|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
57724464|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
57724465|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
57724466|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
57724467|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
57724468|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
57724469|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
57724470|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
57724471|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
57724472|NCT01045447|DRUG|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
57724473|NCT01045447|DRUG|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
57724474|NCT02897804|BEHAVIORAL|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
57724475|NCT02897804|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57921777|NCT03270423|DEVICE|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
57724476|NCT02897804|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57724477|NCT02897804|BEHAVIORAL|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
58065833|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
57921778|NCT04534504|PROCEDURE|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
57921779|NCT02877979|DRUG|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
57921780|NCT02877979|DRUG|Placebo|
57921781|NCT06096896|PROCEDURE|MWA|Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
57921782|NCT03646656|BEHAVIORAL|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
57921783|NCT02961296|OTHER|No intervention|No intervention will be needed.
57921784|NCT03107650|PROCEDURE|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
57921785|NCT03123809|DEVICE|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
57921786|NCT00108212|BEHAVIORAL|Diet|
58065834|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
58275999|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
58276000|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
58276001|NCT02590757|DEVICE|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
58276002|NCT02590757|DEVICE|N-CPAP|Nasal-continuous positive airway pressure
58276003|NCT02498509|DRUG|CKD-342|treatment for 4 weeks after randomization
58276004|NCT02498509|DRUG|Mometasone furoate|treatment for 4 weeks after randomization
58276005|NCT02498509|DRUG|Levocabastine HCL|treatment for 4 weeks after randomization
57921787|NCT00189033|DRUG|psyllium fibre (dietary supplement)|
57921788|NCT00189033|DRUG|wheat bran (dietary supplement)|
57921789|NCT00189033|DRUG|rice wheat (placebo)|
57921790|NCT02482870|DEVICE|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
57921791|NCT02482870|DEVICE|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
58065835|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
58065836|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
57724478|NCT02897804|BEHAVIORAL|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
57724479|NCT02897804|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57921792|NCT01924728|DEVICE|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
57921793|NCT01924728|DEVICE|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
57921794|NCT02913235|PROCEDURE|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
58065837|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
58065838|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
58276006|NCT05863793|OTHER|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
58276007|NCT05863793|OTHER|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
58393184|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
58276008|NCT06263517|DRUG|Clodronate|For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
58393185|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
58393186|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
57921795|NCT02498470|PROCEDURE|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
57724480|NCT02897804|BEHAVIORAL|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57921796|NCT04496063|DRUG|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
57921797|NCT04496063|DRUG|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
57921798|NCT02116985|DEVICE|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
57921799|NCT02116985|DEVICE|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
57921800|NCT00364026|DRUG|darusentan|
57921801|NCT04742322|DIETARY_SUPPLEMENT|Bifidobacterium Lactis CCT7858|Probiotic B Lactis
57921802|NCT04742322|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
58276009|NCT06263517|DRUG|Clodronate|For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
58276010|NCT06263517|DRUG|Clodronate|For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
58276011|NCT06263517|DRUG|Placebo|For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
57921803|NCT02701348|OTHER|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
58276012|NCT02440854|DRUG|afatinib|Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
58276013|NCT05445700|DEVICE|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
58393187|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
58393188|NCT05447520|DRUG|Placebo|Oral tablet once daily
57921804|NCT02701348|DRUG|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
57921805|NCT02701348|PROCEDURE|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
57921806|NCT02701348|OTHER|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
57921807|NCT02050230|BIOLOGICAL|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
58065839|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
58276014|NCT04854083|DRUG|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
58276015|NCT04854083|DRUG|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
58276016|NCT06266520|PROCEDURE|MNK therapy to release the superficial fascia|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
58276017|NCT06266520|PROCEDURE|acupuncture|Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
58276018|NCT06249321|DRUG|mFOLFIRINOX plus IMRT|Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
58276019|NCT00700154|PROCEDURE|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
58276020|NCT05817214|DRUG|Cadonilimab|All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
58276021|NCT05817214|DRUG|Anlotinib|All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
58276022|NCT05817214|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
58276023|NCT02301039|DRUG|Pembrolizumab|
58276024|NCT00366652|DRUG|desvenlafaxine SR|
58276025|NCT00366652|DRUG|desipramine|
58276026|NCT00366652|DRUG|duloxetine|
58276027|NCT05571215|DEVICE|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
58393189|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
58393190|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
57921808|NCT04580485|DRUG|INCB106385|INCB106385 will be administered orally QD
57921809|NCT04580485|DRUG|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
58065840|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
58065841|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
58065842|NCT00902473|DRUG|Topiramate|25mg tablets
58393191|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
58393192|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
58393193|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
58393194|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
58393195|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
58393196|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
57921810|NCT05767671|OTHER|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
57921811|NCT00244231|DRUG|Nidadd|
57921812|NCT02426879|PROCEDURE|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
58065843|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
58065844|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
58065845|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
58065846|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
58065847|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
58393197|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
57921813|NCT01998009|OTHER|fecal occult blood tests|
57921814|NCT03759860|COMBINATION_PRODUCT|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
58065848|NCT00470223|DRUG|cisplatin|
58065849|NCT00470223|DRUG|doxorubicin hydrochloride|
58065850|NCT00470223|DRUG|etoposide|
58065851|NCT00470223|DRUG|ifosfamide|
58065852|NCT00470223|DRUG|methotrexate|
58065853|NCT00470223|DRUG|zoledronic acid|
58065854|NCT00470223|PROCEDURE|conventional surgery|
58065855|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
58065856|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
58065857|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
58065858|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
58065859|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
58065860|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
58393198|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
58393199|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
58393200|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
58393201|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
58393202|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
58393203|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
58393204|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
57921815|NCT05263479|DRUG|HS-20089 (Phase Ia：Dose escalation )|Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
57921816|NCT05263479|DRUG|HS-20089 (Phase Ib: Dose expansion)|IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
57921817|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
57921818|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
58276028|NCT05571215|BEHAVIORAL|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
58393205|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
58393206|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
57921819|NCT01347346|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
57921820|NCT00688831|DRUG|AZD1305|Solution for iv infusion , single dose
58393207|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
58393208|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
58393209|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
58393210|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
58393211|NCT04809766|DRUG|Cyclophosphamide|Given IV
58393212|NCT04809766|DRUG|Fludarabine|Given IV
57921821|NCT00688831|DRUG|Placebo|NaCl solution for iv infusion, single dose
57921822|NCT00185679|DEVICE|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer"
57921823|NCT02052089|PROCEDURE|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
58065861|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
58276029|NCT03111615|DRUG|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
58393213|NCT04809766|DRUG|Bendamustine|Given IV
58393214|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
58393215|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
58065862|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
58065863|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
58065864|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
58065865|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
58065866|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
58065867|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
58065868|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
58276030|NCT01575041|DIETARY_SUPPLEMENT|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
58276031|NCT01575041|DRUG|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
58276032|NCT01575041|DRUG|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
58393216|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
57724481|NCT02897804|BEHAVIORAL|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724482|NCT02897804|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
57724483|NCT02897804|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724484|NCT02897804|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57724485|NCT02897804|BEHAVIORAL|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724486|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
57724487|NCT02897804|BEHAVIORAL|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724488|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57921824|NCT02052089|PROCEDURE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (\<0.2 mJ/mm2) or high energy (\>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
58276033|NCT01785758|DRUG|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
58276034|NCT05223088|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
58276035|NCT05223088|DRUG|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
58276036|NCT05223088|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
58276037|NCT05223088|DRUG|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
58276038|NCT01438931|DRUG|DA-9501|Dexmedetomidine hydrochloride variable dose
58276039|NCT01438931|DRUG|placebo|
58393217|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
58393218|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
58393219|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
57921825|NCT02052089|PROCEDURE|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
57921826|NCT02052089|PROCEDURE|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
57921827|NCT04239716|OTHER|regional anesthesia|combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
58065869|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
58276040|NCT04632056|DRUG|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
58276041|NCT03919344|OTHER|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
58276042|NCT03919344|OTHER|Acoustic pharyngometry|Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
58276043|NCT03919344|OTHER|High density surface electroencephalogram neural mapping|Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
58276044|NCT02977728|OTHER|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
58276045|NCT00567697|DRUG|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
58276046|NCT00567697|DRUG|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
58276047|NCT03986229|OTHER|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference."
58276048|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
58276049|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
58276050|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
58276051|NCT00978393|DRUG|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
58276052|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
58276053|NCT00978393|DRUG|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
58276054|NCT04371211|BEHAVIORAL|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
58276055|NCT04993599|DEVICE|Social robot interaction|The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
58276056|NCT01955109|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
58065870|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
58065871|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
57724489|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724490|NCT02897804|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
57724491|NCT02897804|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724492|NCT02897804|BEHAVIORAL|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
58065872|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
57724493|NCT02897804|BEHAVIORAL|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724494|NCT02897804|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
57724495|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724496|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57724497|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724498|NCT02897804|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
57724499|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724500|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57724501|NCT02897804|BEHAVIORAL|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724502|NCT02897804|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
58065873|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
58065874|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
58065875|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
58393220|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
57724503|NCT02897804|BEHAVIORAL|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
58065876|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
58065877|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
58276057|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
58276789|NCT05206786|OTHER|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
57724504|NCT02897804|BEHAVIORAL|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57724505|NCT02897804|BEHAVIORAL|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57724506|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
57724507|NCT02172209|DRUG|BI 10773|
57724508|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
57724509|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
57724510|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
57724511|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
57724512|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
57724513|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
57724514|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
57724515|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
57724516|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
57724517|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
57724518|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
57724519|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
57724520|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
57724521|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
57724522|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
57724523|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
57921828|NCT02857998|DRUG|HMPL-523|Oral administration, once daily
57921829|NCT05029960|DRUG|Brivaracetam|Dose of 50 mg twice daily for 6 months
58065878|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
57921830|NCT05735821|OTHER|Giving breastfeeding training|The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
57921831|NCT04687228|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
57921832|NCT04687228|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
57921833|NCT04066790|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
58490415|NCT01474018|DRUG|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
58276058|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve injection.|"While in prone position, lumbar facet joints are identified by fluoroscopy. An anteroposterior image of the lumbar vertebrae is obtained. Then, the fluoroscope is tilted between 10 to 20 degrees to the side to inject. 22 gauge needles are then advanced aiming to the medial branch of lumbar facet joints.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous medial branch nerve injection."
58490416|NCT04216797|DRUG|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
57921834|NCT04066790|DRUG|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
57921835|NCT04066790|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
57921836|NCT04066790|DRUG|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
57921837|NCT04066790|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
57921838|NCT01211743|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
57921839|NCT01211743|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
57921840|NCT03345134|DRUG|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
57921841|NCT04875741|OTHER|Neural mobilization|Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.
57921842|NCT04875741|OTHER|Muscle energy technique|Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
57921843|NCT01461239|PROCEDURE|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
57921844|NCT01461239|PROCEDURE|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
57921845|NCT01461239|PROCEDURE|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
58490417|NCT05147090|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
58490418|NCT05147090|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
58490419|NCT00424892|DRUG|Desvenlafaxine Sustained Release|
58490420|NCT03710200|OTHER|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
58490421|NCT03710200|OTHER|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
58490422|NCT03710200|OTHER|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
58065879|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
58276059|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
57921846|NCT04823715|OTHER|TACE + hypofractionated EBRT|One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
57921847|NCT04823715|PROCEDURE|Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
57921848|NCT03559478|PROCEDURE|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
57921849|NCT03559478|PROCEDURE|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
57921850|NCT04547673|DIAGNOSTIC_TEST|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
57921851|NCT04531215|DRUG|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
57921852|NCT04531215|DRUG|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
57921853|NCT05373589|OTHER|conventional ventilation, group C|In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
57921854|NCT05373589|OTHER|pressure support, group PS|In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
58490423|NCT03710200|OTHER|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
58490424|NCT03710200|OTHER|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
58490425|NCT03710200|OTHER|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
57921855|NCT03171831|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
57724524|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
57921856|NCT03171831|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
57921857|NCT03171831|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
58490426|NCT03710200|OTHER|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
58490427|NCT03710200|OTHER|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
58490428|NCT05334212|DEVICE|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
58490429|NCT02422199|DRUG|pyrotinib|
58490430|NCT02422199|DRUG|Lapatinib|
58490431|NCT02422199|DRUG|capecitabine|
58490432|NCT00554216|DRUG|VI-0521|3.75 mg phentermine/23 mg topiramate
58490433|NCT00554216|DRUG|VI-0521|15 mg phentermine/92 mg topiramate
58490434|NCT00554216|DRUG|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
57724525|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
57724526|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
57724527|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
57724528|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
57724529|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
57921858|NCT03171831|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
57921859|NCT03171831|DRUG|Tacrolimus|Tacrolimus（0.03mg/kg/day）
58490435|NCT00971152|DRUG|menotropins for injection|comparison of different dosages
57921860|NCT03171831|DRUG|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
57921861|NCT03171831|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
58490436|NCT00971152|DRUG|urofollitropin for injection|comparison of different dosages
57921862|NCT03171831|DRUG|Basiliximab|Basiliximab（10mg on day 0 and +4）
57921863|NCT03463967|DIETARY_SUPPLEMENT|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
57921864|NCT03463967|OTHER|Energy-restricted diet|
57724530|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
57724531|NCT00296101|BEHAVIORAL|Physical Activity|
57921865|NCT05974774|DRUG|iMAB|no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.
57921866|NCT05974774|DRUG|cMAB|LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
57921867|NCT02489903|DRUG|RRx-001|
57921868|NCT02489903|DRUG|Cisplatin|
58065880|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
58490437|NCT04228380|OTHER|No intervention|No intervention
57921869|NCT02489903|DRUG|Etoposide|
57921870|NCT02489903|DRUG|Carboplatin|
57921871|NCT02489903|DRUG|Irinotecan|
58490438|NCT05002075|OTHER|m-health cardiac rehabilitation|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California). This app includes a patient-facing iOS and Android compatible smartphone app and an integrated hospital-facing online dashboard for remote monitoring and care coordination by a trained coach
58490439|NCT06241391|DIAGNOSTIC_TEST|PSMA PET-CT|Prostate Specific Membrane Antigen PET-CT
58490440|NCT04373252|BIOLOGICAL|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
57921872|NCT02489903|DRUG|Vinorelbine|
57921873|NCT02489903|DRUG|Doxil|
57921874|NCT02489903|DRUG|Gemcitabine|
57921875|NCT02489903|DRUG|Taxane|
57921876|NCT02489903|DRUG|Paclitaxel|
57921877|NCT02489903|DRUG|Nab-Paclitaxel|
57921878|NCT02489903|DRUG|Pemetrexed|
57921879|NCT03726814|BIOLOGICAL|EPC treatment group|Brain injection EPC
57921880|NCT02667717|BEHAVIORAL|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
58490441|NCT04159753|DEVICE|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
58490442|NCT00330967|DRUG|20% Intralipid|lipid infusion
58490443|NCT03372681|PROCEDURE|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
58490444|NCT03372681|PROCEDURE|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
58490445|NCT05156021|DRUG|anti-VEGF|To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
58490446|NCT04851262|BEHAVIORAL|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
57921881|NCT02667717|BEHAVIORAL|Usual care|Patients will have the usual care as an intervention.
57724532|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
57724533|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
57724534|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
57724535|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
57724536|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
57724537|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
57724538|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
57724539|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
57921882|NCT00793000|DRUG|PF-04287881|75 mg oral dose (prepared solution) given once
57921883|NCT00793000|DRUG|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
57921884|NCT00793000|DRUG|PF-04287881|150 mg oral dose (prepared solution) given once
57921885|NCT00793000|DRUG|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
58276060|NCT04451252|PROCEDURE|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
58393221|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
57724540|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
57724541|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
57921886|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
57921887|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
57921888|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
57921889|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
57921890|NCT00793000|DRUG|PF-04287881|1000 mg oral dose (prepared solution) given once
57921891|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
57921892|NCT00793000|DRUG|PF-04287881|1250 mg oral dose (prepared solution) given once
57921893|NCT00793000|DRUG|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
57921894|NCT00793000|DRUG|PF-04287881|1500 mg oral dose (prepared solution) given once
57921895|NCT00793000|DRUG|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
57921896|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
57921897|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
57921898|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
57921899|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
57921900|NCT00793000|DRUG|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
58065881|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
58490447|NCT01170572|OTHER|No intervention|No intervention
58490448|NCT01561313|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
57921901|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
57921902|NCT04040400|RADIATION|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
58065882|NCT01701531|DRUG|RBCPF|
57724542|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
57724543|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
57724544|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
57724545|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
57724546|NCT00030550|DRUG|thalidomide|
57724547|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
57724548|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
57724549|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
57724550|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
57724551|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
57724552|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
57724553|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
57724554|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
57724555|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
57724556|NCT00006508|PROCEDURE|formula meal|
57724557|NCT06538532|OTHER|Zamzam water|Zamzam water
58276061|NCT04451252|PROCEDURE|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
58393222|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
58393223|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
57724558|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
57724559|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
57724560|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
57724561|NCT05491733|DRUG|APX001|Low-load oral tablet
57724562|NCT05491733|DRUG|APX001A|High-load oral tablet
57724563|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
57724564|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
57724565|NCT00182689|DRUG|sorafenib tosylate|Given orally
57724566|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
58393224|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
57724567|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
57724568|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
57724569|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
57724570|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
57724571|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
57724572|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
57724573|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
57921903|NCT01545570|DRUG|GSK2376497|GSK2376497 Active Comparator
57921904|NCT01545570|DRUG|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
57921905|NCT06243419|DEVICE|vein viewer|The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
58393225|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
58276062|NCT04451252|PROCEDURE|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
57921906|NCT06243419|DEVICE|virtual reality|The child watched the application by wearing virtual glasses during the PIC insertion
57921907|NCT06243419|DEVICE|vein viewer and virtual reality|"The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion"
57921908|NCT00091585|DRUG|SNS-595|
57921909|NCT03993912|DRUG|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression"
57921910|NCT03993912|DRUG|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
57921911|NCT03993912|DRUG|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
57921912|NCT00994500|DRUG|vorinostat|Given orally
57921913|NCT00994500|DRUG|bortezomib|Given IV
57921914|NCT00994500|OTHER|pharmacological study|Correlative studies
57921915|NCT00994500|OTHER|laboratory biomarker analysis|Correlative studies
57921916|NCT05902182|DEVICE|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
57921917|NCT02609854|DEVICE|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
57921918|NCT02609854|DEVICE|Sham Device|Inactive ultrasound device
57921919|NCT01019512|OTHER|questionnaire administration|Ancillary studies
57724574|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
57921920|NCT01019512|OTHER|lymphedema management|
57921921|NCT02601196|DRUG|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
57921922|NCT01740323|DRUG|Placebo|daily placebo for 6 weeks
58276063|NCT00003215|BIOLOGICAL|filgrastim|
58276064|NCT00003215|DRUG|CHOP regimen|
58276065|NCT00003215|DRUG|cyclophosphamide|
57921923|NCT01740323|DRUG|Curcumin|500 mg BID
57921924|NCT02877160|DRUG|AL-794 suspension|
57921925|NCT02877160|DRUG|AL-794 tablet|
57921926|NCT05404308|OTHER|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
57921927|NCT05404308|OTHER|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
57921928|NCT05573087|OTHER|Aquatic Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
57921929|NCT05573087|OTHER|Land Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
57921930|NCT02513888|DIETARY_SUPPLEMENT|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
57921931|NCT02513888|DIETARY_SUPPLEMENT|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
57921932|NCT01538797|DRUG|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
58276066|NCT00003215|DRUG|cytarabine|
58276067|NCT00003215|DRUG|doxorubicin hydrochloride|
58276068|NCT00003215|DRUG|etoposide|
58276069|NCT00003215|DRUG|leucovorin calcium|
58276070|NCT00003215|DRUG|melphalan|
57921933|NCT01538797|DRUG|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
57921934|NCT01249430|DRUG|Azacitidine|Given IV
57921935|NCT01249430|DRUG|Cytarabine|Given IV
57921936|NCT01249430|DRUG|Etoposide Phosphate|Given IV
57921937|NCT01249430|OTHER|Laboratory Biomarker Analysis|Correlative studies
57921938|NCT01249430|DRUG|Mitoxantrone Hydrochloride|Given IV
57921939|NCT01249430|OTHER|Pharmacological Study|Correlative studies
57921940|NCT04266665|DRUG|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
57921941|NCT04266665|OTHER|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
57921942|NCT02027623|BEHAVIORAL|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
57921943|NCT02027623|BEHAVIORAL|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
58276071|NCT00003215|DRUG|methotrexate|
57921944|NCT03546933|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
58276072|NCT00003215|DRUG|methylprednisolone|
58276073|NCT00003215|DRUG|mitoxantrone hydrochloride|
58276074|NCT00003215|DRUG|prednisone|
58276075|NCT00003215|DRUG|therapeutic hydrocortisone|
57921945|NCT01769066|DRUG|Sequential Gefitinib With Pemetrexed/Platinum|
57921946|NCT01769066|DRUG|Pemetrexed/Platinum|
57921947|NCT02065141|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
58276076|NCT00003215|DRUG|vincristine sulfate|
58276077|NCT00003215|PROCEDURE|bone marrow ablation with stem cell support|
58276078|NCT00003215|PROCEDURE|peripheral blood stem cell transplantation|
58276079|NCT00003215|RADIATION|radiation therapy|
58276080|NCT05811078|BEHAVIORAL|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
58276081|NCT00179894|BEHAVIORAL|Physician training|Physicians are trained in guidelines for medication management.
58276082|NCT02006056|DRUG|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
58276083|NCT05941442|DRUG|Darigabat|Oral tablets
58276084|NCT05941442|DRUG|Placebo|Oral tablets
58276085|NCT02250950|BEHAVIORAL|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
58276086|NCT02250950|BEHAVIORAL|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
58276087|NCT02245919|OTHER|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
58276088|NCT01454414|OTHER|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
58276089|NCT00550264|OTHER|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
58276090|NCT03292471|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
58393226|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
58393227|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
58393228|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
58393229|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
58393230|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
58393231|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
58393232|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
58393233|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
57921948|NCT00221247|PROCEDURE|Acupuncture|acupuncture
57921949|NCT02715154|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
57921950|NCT02715154|DRUG|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
57921951|NCT02673957|OTHER|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
57921952|NCT03565731|BEHAVIORAL|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
57921953|NCT00202566|DRUG|Ivabradine|
57921954|NCT05521802|BIOLOGICAL|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
57921955|NCT00707512|DRUG|natalizumab|Administered as specified in the TOUCH Prescribing Program
57921956|NCT03595839|PROCEDURE|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
57921957|NCT03595839|PROCEDURE|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
58276091|NCT02433899|PROCEDURE|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
58276092|NCT02433899|PROCEDURE|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
58393234|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
58393235|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
58393236|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
58393237|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
58393238|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
58490449|NCT03464539|DIETARY_SUPPLEMENT|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
57921958|NCT02762253|DRUG|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
57921959|NCT05610176|DEVICE|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
57921960|NCT03541096|BEHAVIORAL|Winter Swimming|Supervised Winter Swimming in Copenhagen
57921961|NCT03541096|BEHAVIORAL|Control group|No winter swimming activities.
58276093|NCT02433899|DRUG|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
58276094|NCT02433899|DRUG|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
58276095|NCT02433899|DRUG|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
58276096|NCT04451668|DRUG|FT218|once nightly sodium oxybate extended release
58276097|NCT02711943|DRUG|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
58276098|NCT03252366|DEVICE|GELFOAM|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
58393239|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
58393240|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
58276099|NCT03252366|DEVICE|xenograft|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
58393241|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
58393242|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
58393243|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
58393244|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
58393245|NCT02690688|DEVICE|determination of dynamic preload variables|
58393246|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
58393247|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
58393248|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
57724575|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
57921962|NCT00014313|DRUG|cisplatin|
58276100|NCT01899105|DRUG|lumacaftor|
58276101|NCT01899105|DRUG|ivacaftor|
58276102|NCT05869656|BEHAVIORAL|Fluid restriction|Oral fluid restriction of 1000ml per day
58276103|NCT05869656|BEHAVIORAL|Free fluids|Continue care without any oral fluid restriction
58276104|NCT01399489|BEHAVIORAL|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
58393249|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
58276105|NCT01055080|DIETARY_SUPPLEMENT|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
58276106|NCT01296594|OTHER|Usual Care|Usual Care
58393250|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
58393251|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
58393252|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
58393253|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
58393254|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
58393255|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
58393256|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
58393257|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
58393258|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
58393259|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
58393260|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
58393261|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
57921963|NCT00014313|DRUG|etoposide|
57921964|NCT04028882|OTHER|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
57921965|NCT02092220|DEVICE|Bionic Pancreas|
57921966|NCT02092220|DEVICE|Insulin pump with or without CGM|
57921967|NCT00221169|PROCEDURE|Surgical resection|pet ct prior to surgery
57921968|NCT04674670|DRUG|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
57921969|NCT04674670|DRUG|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
57921970|NCT04674670|DRUG|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
57921971|NCT05131620|PROCEDURE|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
57921972|NCT05131620|PROCEDURE|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
57921973|NCT06445283|OTHER|Determination of VTE risk levels|Determination of VTE risk levels of patients using IMPROVE risk assessment tool according to deep vein thrombosis and pulmonary embolism risk factors
57921974|NCT05924685|BIOLOGICAL|COVID-19 vaccination|Vaccination
57921975|NCT00232141|DRUG|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
57921976|NCT00232141|DRUG|Placebo|Placebo
57921977|NCT00846547|DRUG|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
57921978|NCT00219648|DRUG|PEP03|
57921979|NCT02442323|BEHAVIORAL|Walking Intervention|12-week walking program
57921980|NCT06200831|PROCEDURE|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
58393262|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
57921981|NCT06200831|PROCEDURE|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
57921982|NCT04098965|OTHER|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
57921983|NCT04098965|OTHER|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
57724576|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
57921984|NCT01874860|DRUG|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
57921985|NCT01874860|DRUG|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
57921986|NCT01874860|OTHER|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
57921987|NCT01874860|OTHER|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
57921988|NCT01874860|DRUG|Clindamycin|Recommended for daily use if rash returns (Topical cream)
57921989|NCT01874860|DRUG|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
57921990|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
57921991|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
58276107|NCT01296594|BEHAVIORAL|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
58393263|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
58393264|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
58393265|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
58490450|NCT06104436|BEHAVIORAL|Individualized music playlist|Individualized music playlist composed of preferred music genres sequenced according to the ISO-Principle. It will be played at the state of agitation.
58276108|NCT05166850|BEHAVIORAL|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
58276109|NCT05166850|OTHER|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
58276110|NCT00069563|BEHAVIORAL|Reaching Educators, Children, and Parents (RECAP)|
58065883|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
58276111|NCT03602794|PROCEDURE|PECs Block|Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
58276112|NCT03602794|PROCEDURE|Local infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
58276113|NCT03071510|DEVICE|Atlas Genetics io® system|Specimen Collection
58276114|NCT05908500|OTHER|CPR Training|Various methods of CPR training are implemented and compared
58276115|NCT00509353|DRUG|irinotecan hydrochloride|
58393266|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
58393267|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
58393268|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
58393269|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
58393270|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
58393271|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
58276116|NCT00509353|DRUG|vincristine sulfate|
58276117|NCT00509353|RADIATION|iobenguane I 131|
58276118|NCT04554342|OTHER|V01 candy|candy with sweetener (Isomalt) and apple flavour
58276119|NCT04554342|OTHER|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
58276120|NCT04554342|OTHER|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
58276121|NCT04554342|OTHER|V04 candy|candy with sweetener (Isomalt) (control group 1)
58393272|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
58393273|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
58490451|NCT06104436|BEHAVIORAL|Preferred music|Preferred music is composed of the genres selected by the participants, and to be played at random sequence.
58490452|NCT06104436|BEHAVIORAL|Usual care|Usual technique for calming agitated older adults with dementia
58490453|NCT01099449|DRUG|calcium gluconate|Given IV
58490454|NCT01099449|DRUG|magnesium sulfate|Given IV
58490455|NCT01099449|OTHER|placebo|Given IV
58276122|NCT04554342|OTHER|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
58276123|NCT02733575|OTHER|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
58276124|NCT03439462|DRUG|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
58276125|NCT03471234|DEVICE|Angioplasty|Inspiron Drug Eluting stent implantation
58490456|NCT01099449|DRUG|oxaliplatin|
58276126|NCT00926640|DRUG|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
58276127|NCT00926640|DRUG|Cisplatin|6 cycles at 60mg/m2 IV on day 2
58276128|NCT00926640|DRUG|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
58276129|NCT05958069|DRUG|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
58065884|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
58490457|NCT06314828|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
57921992|NCT05488223|DIETARY_SUPPLEMENT|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
57921993|NCT00714597|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
57921994|NCT00714597|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
58065885|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
58065886|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
58065887|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
58065888|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
57921995|NCT05380492|BIOLOGICAL|VOY-101|Intravitreal injection of VOY-101
57921996|NCT00093808|BIOLOGICAL|trastuzumab|
57921997|NCT00093808|DRUG|capecitabine|
57921998|NCT00093808|DRUG|vinorelbine tartrate|
58065889|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
58276130|NCT05768009|PROCEDURE|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
58276131|NCT00467402|DRUG|agomelatine|
58276132|NCT00467402|DRUG|placebo|
58490458|NCT00734539|DRUG|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
58490459|NCT00734539|DRUG|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
58490460|NCT02627261|BIOLOGICAL|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
57921999|NCT00916825|BEHAVIORAL|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
57922000|NCT03401541|DRUG|Calcifediol|One capsule of 900 micrograms of 25(OH)D
57922001|NCT03401541|DRUG|Calciferol|One capsule of 900 micrograms of Vitamin D
58276133|NCT01491269|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
58276134|NCT05593237|DEVICE|High Frequency rTMS|Stimulation provided at 10 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (3,000 pulses/session)
58276135|NCT05593237|DEVICE|Low Frequency rTMS|Stimulation provided at 1 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (300 pulses/session)
58276136|NCT01272375|DRUG|Treatment A|PF-04764793 250/50 using inhaler A
58276137|NCT01272375|DRUG|Treatment B|PF-04764793 250/50 using inhaler A
58490461|NCT01385527|BEHAVIORAL|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
57922002|NCT02262143|DRUG|Rosuvastatin|Rosuvastatin 10 mg, qd, po
57922003|NCT02262143|DRUG|Fenofibrate|Fenofibrate 160mg, qd, po
57922004|NCT02972125|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
57922005|NCT02972125|DRUG|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
57922006|NCT00681746|DRUG|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
57922007|NCT00681746|DRUG|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
57922008|NCT00219622|DRUG|tofimilast|
57922009|NCT05310487|BIOLOGICAL|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
57922010|NCT05310487|OTHER|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
57724577|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
57724578|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
57724579|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
57724580|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
57724581|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
58065890|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
58065891|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
58065892|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
58065893|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
58276138|NCT01272375|DRUG|Treatment C|PF-04764793 250/50 using inhaler A
58276139|NCT01272375|DRUG|Treatment D|PF-04764793 250/50 using inhaler A
58276140|NCT01272375|DRUG|Treatment E|PF-04764793 250/50 using inhaler B
58490462|NCT01385527|DRUG|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
58490463|NCT03298659|DIAGNOSTIC_TEST|iFR|Treatment guided by instantaneous wave-free ratio
58490464|NCT03298659|DIAGNOSTIC_TEST|CMR|Treatment guided by stress perfusion CMR
58490465|NCT03566485|DRUG|Atezolizumab|Given by IV
57724582|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
57724583|NCT02242786|RADIATION|External beam radiation therapy|
57724584|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
57724585|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
57724586|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
57724587|NCT02700646|BEHAVIORAL|Developmental recommendations|
57724588|NCT02700646|BEHAVIORAL|Standard care|standard care
57724589|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
57922011|NCT00455338|BEHAVIORAL|Meal Composition|
57922012|NCT06525961|DEVICE|iTEAR100 Neurostimulator|To apply an iTEAR100 Neurostimulator for the stimulation to the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
57922013|NCT04136665|OTHER|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
57922014|NCT01091753|DRUG|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
57922015|NCT05417867|PROCEDURE|Biospecimen Collection|Undergo collection of stool and blood samples
57922016|NCT05417867|OTHER|Questionnaire Administration|Complete questionnaires
57922017|NCT01607112|BIOLOGICAL|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
57922018|NCT01100034|DRUG|Etanercept|Expected duration of 24 weeks as one course
57724590|NCT02009618|DRUG|placebo|
57922019|NCT00816686|BIOLOGICAL|AGS-16M18|IV Infusion
57922020|NCT06137222|DEVICE|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
57922021|NCT06137222|OTHER|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
57922022|NCT00802009|DRUG|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
57922023|NCT00802009|DRUG|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
57922024|NCT00051363|DEVICE|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
57922025|NCT00051363|DEVICE|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
57922026|NCT02390830|OTHER|Falls Prevention|
57922027|NCT02390830|OTHER|Reduction of limitations at body function and activity levels|
58065894|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
57922028|NCT02318823|OTHER|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
58065895|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
58065896|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
58065897|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
58065898|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
58065899|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
58065900|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
57724591|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
57724592|NCT00358241|PROCEDURE|Nerve block|
57724593|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
57922029|NCT02318823|OTHER|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
57922030|NCT04987723|OTHER|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
57922031|NCT04987723|OTHER|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
57922032|NCT04987723|OTHER|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
58065901|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
58065902|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
57922033|NCT04987723|OTHER|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
57922034|NCT01893892|DIETARY_SUPPLEMENT|levocarnitine|Given PO
57922035|NCT01893892|OTHER|placebo|Given PO
57922036|NCT01893892|OTHER|questionnaire administration|Ancillary studies
57922037|NCT04849936|DIAGNOSTIC_TEST|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
57922038|NCT01954381|DEVICE|transthoracic echocardiographic|
57922039|NCT01954381|DEVICE|Doppler ultrasound.|
57922040|NCT01954381|BIOLOGICAL|blood samples|
57922041|NCT03188926|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
57922042|NCT05959694|DRUG|TQB3909 tablet|TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
57922043|NCT02940938|OTHER|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
58490466|NCT03566485|DRUG|Cobimetinib|Given by mouth
58065903|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
58276141|NCT01272375|DRUG|Treatment F|PF-04764793 250/50 using inhaler B
57922044|NCT01658150|DRUG|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
57922045|NCT01274585|DEVICE|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
57922046|NCT01274585|DEVICE|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
57922047|NCT04563338|DRUG|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
57922048|NCT04563338|DRUG|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
57922049|NCT01205256|DRUG|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
57922050|NCT02960347|DEVICE|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
58276142|NCT01272375|DRUG|Treatment G|PF-04764793 250/50 using inhaler B
58276143|NCT02357615|DRUG|nifedipine CR tablets (Xin Ran)|
58276144|NCT02357615|DRUG|Adalat|
58276145|NCT03737266|PROCEDURE|Sonographically assisted breast surgery|Sonography
58276146|NCT03737266|PROCEDURE|Conventional breast surgery|Conventional
58490467|NCT03566485|DRUG|Idasanutlin|Given by mouth
58490468|NCT02093819|DRUG|Placebo to BI 416970|single rising doses
58490469|NCT02093819|DRUG|BI 416970|single rising doses
58490470|NCT04333719|OTHER|Type of sedations|Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
58490471|NCT02677519|DRUG|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
57922051|NCT06402422|DEVICE|Theta-burst stimulation|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). Concurrent iTBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
58276147|NCT03346304|OTHER|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
58276148|NCT00743678|DRUG|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
58393274|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
58490472|NCT01734603|PROCEDURE|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
57922052|NCT01281150|DRUG|Carboplatin|Given IV
58276149|NCT00001237|DRUG|granulocyte-macrophage colony stimulating factor (GM-CSF)|
57724594|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
57724595|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
57724596|NCT02881281|OTHER|educational program for Development of problem-solving skills|
57922053|NCT01281150|OTHER|Laboratory Biomarker Analysis|Correlative studies
57922054|NCT01281150|DRUG|Paclitaxel|Given IV
57922055|NCT01281150|OTHER|Pharmacological Study|Correlative studies
57922056|NCT01281150|DRUG|Veliparib|Given PO
57922057|NCT01143038|BIOLOGICAL|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
57922058|NCT03806387|DRUG|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
58276150|NCT04131491|PROCEDURE|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
57922059|NCT04371861|DEVICE|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
57922060|NCT00005825|DRUG|cisplatin|
57922061|NCT00005825|DRUG|mitomycin C|
57922062|NCT00005825|DRUG|tretinoin|
57922063|NCT00005825|DRUG|vinorelbine tartrate|
58065904|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
57724597|NCT02881281|OTHER|no education program|no education program
58065905|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
58065906|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
58065907|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
58065908|NCT02712892|GENETIC|Non Interventional Study|
58276151|NCT02287259|DRUG|olanzapine|
58276152|NCT02287259|DRUG|lithium|
58276153|NCT04177888|DEVICE|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
58065909|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
57922064|NCT01272804|DRUG|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
57922065|NCT01272804|DRUG|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
57922066|NCT04589754|DRUG|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
58065910|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
58065911|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
58065912|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
58065913|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
58065914|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
57922067|NCT04589754|DRUG|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
57922068|NCT00298090|DEVICE|StO2 monitoring|placement of the StO2 device/ external noninvasive
57922069|NCT03891576|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
58065915|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
58065916|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
58065917|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
58065918|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
57724598|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
58276154|NCT01524068|DRUG|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
58276155|NCT01524068|DRUG|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
58276156|NCT00360802|BEHAVIORAL|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
58276157|NCT00360802|BEHAVIORAL|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
58276158|NCT05328284|DEVICE|PASCAL leaflet repair system|transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
58276159|NCT03845101|BEHAVIORAL|CBT with virtual reality exposure therapy|The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.
58276160|NCT03845101|BEHAVIORAL|CBT in vivo|The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg \& Magee and Graske \& Barlow with worksheets from Arendt \& Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
58276161|NCT05547776|BEHAVIORAL|Mindfulness app|The mindfulness app contains 6 modules with a variety of features to help caregivers reduce their stress.
58276162|NCT06294873|DIAGNOSTIC_TEST|A screening device for the detection of colorectal and other aerodigestive tract cancers|DNA test to screen to detect colon cancer and precancerous lesions
58276163|NCT02240303|PROCEDURE|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
58276164|NCT02240303|PROCEDURE|Physical Performance|Participants in both groups will have a Physical Performance test.
58276165|NCT02240303|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
58276166|NCT02240303|PROCEDURE|Blood Sample|Participants in both groups will have blood samples taken.
58276167|NCT03014622|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
58276168|NCT03014622|BIOLOGICAL|Placebos|Intramuscular injection
58276169|NCT04799106|BEHAVIORAL|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
58276170|NCT05427747|DRUG|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
57724599|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
58276171|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
57724600|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
57724601|NCT00279123|DRUG|pantoprazole infusion|
58276172|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
58276173|NCT03709121|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
58276174|NCT03442699|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
58276175|NCT00019422|DRUG|carboplatin|
58276176|NCT00019422|DRUG|lobradimil|
57724602|NCT00279123|DRUG|pantoprazole bolus|
57724603|NCT00279123|DRUG|no treatment|
57724604|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
57724605|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
57724606|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
57724607|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
57724608|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
57922070|NCT03048799|DEVICE|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
57922071|NCT03216057|DIETARY_SUPPLEMENT|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
57922072|NCT03216057|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
57922073|NCT03939455|OTHER|Mobile Augmented Screening tool|Tablet-based intervention
57922074|NCT02330783|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
57922075|NCT02330783|DRUG|Sorafenib|400mg twice daily by oral of each 4-week cycle
57922076|NCT05847725|OTHER|Elastic bandaging|"The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally."
57922077|NCT05847725|OTHER|Short stretch bandaging|Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
57922078|NCT05847725|OTHER|Kinesio taping|Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
57922079|NCT00369304|DRUG|pharmacokinetic (how the body absorbs and eliminates) interaction|
58065919|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
58065920|NCT01032057|DRUG|capecitabine|
58276177|NCT06285136|PROCEDURE|DEC3-VEN|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
58276178|NCT03737630|DEVICE|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
58276179|NCT05956522|DRUG|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
58276180|NCT05956522|DRUG|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
58276181|NCT00204477|DIETARY_SUPPLEMENT|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
57724609|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
57922080|NCT02216643|PROCEDURE|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
58065921|NCT01032057|DRUG|gemcitabine hydrochloride|
58065922|NCT01032057|PROCEDURE|quality-of-life assessment|
58065923|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
58065924|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
58065925|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
58276182|NCT00204477|DIETARY_SUPPLEMENT|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
58276183|NCT01553435|DRUG|Dextromethorphan|The study medicines shall be administered via tube.
58276184|NCT01553435|DRUG|Placebo|The study medicines shall be administered via tube.
58276185|NCT00030680|RADIATION|radiation therapy|
58276186|NCT00795769|DRUG|ondansetron|Given IV
58276187|NCT00795769|OTHER|survey administration|Correlative studies
58276188|NCT00795769|PROCEDURE|management of therapy complications|Ondansetron IV
57922081|NCT02216643|DEVICE|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
57724610|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
57724611|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
57922082|NCT06248346|DRUG|Dexmedetomidine|whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
58065926|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
58065927|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
58065928|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
57724612|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
57724613|NCT01136837|OTHER|primary pcı|
57724614|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
57724615|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
57724616|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
58065929|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
58065930|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
58065931|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
57724617|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
57724618|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
57724619|NCT00111943|DRUG|1% tenofovir gel|
57724620|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
57724621|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
57724622|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
57724623|NCT00765115|DRUG|LY450139|
57724624|NCT00765115|DRUG|placebo|
57724625|NCT02223390|BEHAVIORAL|Improving AIDS Care after Trauma (ImpACT)|
57724626|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
57922083|NCT04896112|DRUG|LNK01002|LNK01002 will be administrated orally.
57724627|NCT04923386|OTHER|None (not interventional)|This is not an intervention
57724628|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
57724629|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
57922084|NCT04643860|DIAGNOSTIC_TEST|Differential Leucocyte Count (CLDC) device and algorithm|Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
57922085|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
57922086|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
57724630|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
57724631|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
57724632|NCT03119103|DEVICE|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
57724633|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
57724634|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
57724635|NCT00020410|BIOLOGICAL|filgrastim|
57724636|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
57724637|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
58065932|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
57724638|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
57724639|NCT03449303|OTHER|EOI|Topically-applied oil
57724640|NCT03449303|OTHER|Placebo|Topically-applied oil
57724641|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
57724642|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
57724643|NCT02813031|OTHER|Functional meat products|
57724644|NCT02813031|OTHER|Traditional meat products|
57724645|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
57724646|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
57724647|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
57724648|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
57724649|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
57724650|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
57724651|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
57724652|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
57724653|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
57724654|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
57724655|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
57724656|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
57922087|NCT00679653|DRUG|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
57922088|NCT00679653|DRUG|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
57922089|NCT00679653|DRUG|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
57922090|NCT04174144|PROCEDURE|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
57922091|NCT02880033|DRUG|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
58065933|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
58065934|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
58065935|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
58065936|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
58065937|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
58065938|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
57922092|NCT02880033|DRUG|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
57922093|NCT05291767|OTHER|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
57922094|NCT05291767|BEHAVIORAL|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
57922095|NCT01444209|RADIATION|Iodine Implants|Interstitial Radioactive Iodine Implants
57922096|NCT02700945|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
57922097|NCT01136811|DEVICE|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
57922098|NCT01474499|DRUG|Glycerine|
57922099|NCT01474499|DRUG|Docusate sodium and sorbitol rectal solution|
57922100|NCT05128734|DRUG|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
57922101|NCT05128734|DRUG|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
57724657|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
57724658|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
57724659|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
57724660|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
57724661|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
57724662|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
57724663|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
57724664|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
57724665|NCT02911402|OTHER|sea sickness questionnaires|
57724666|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
57724667|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
57724668|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
57724669|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
57724670|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
57724671|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
57724672|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
57724673|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
57724674|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
57724675|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
57724676|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
57922102|NCT03993860|DIETARY_SUPPLEMENT|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
57724677|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
57724678|NCT06536296|OTHER|Music|Arm 1: Music only
57724679|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
57724680|NCT06536296|OTHER|Standard Care|Standard Care
57724681|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
57724682|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
57724683|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
57922103|NCT03993860|DIETARY_SUPPLEMENT|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
57922104|NCT00002428|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
58393275|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
58393276|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
57922105|NCT00002428|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
57922106|NCT00193999|DEVICE|Placement of nasogastric tube|
57922107|NCT01037244|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
57922108|NCT01037244|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
57922109|NCT00402597|DRUG|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
57922110|NCT00402597|DRUG|Placebo|1 placebo tablet twice daily for 6 months.
58276189|NCT05804461|BEHAVIORAL|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase Pre-Exposure Prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
58276190|NCT00803309|DRUG|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
58393277|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
58393278|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
57724684|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
57922111|NCT00402597|DRUG|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
57922112|NCT01378923|BEHAVIORAL|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
57922113|NCT01378923|BEHAVIORAL|TAU|have access to standard jail programs and services
57922114|NCT04086433|DEVICE|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
57922115|NCT01592864|DRUG|Stannous Fluoride|dentifice
57922116|NCT01592864|DRUG|Sodium Monofluorophosphate|dentifrice
57922117|NCT04530331|BEHAVIORAL|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
57922118|NCT03217305|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
57922119|NCT01684267|DEVICE|Robotic Gait Rehabilitation (RGR) Trainer|
57922120|NCT05222607|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
57922121|NCT03765411|PROCEDURE|Proctectomy|Resection of the rectum
57922122|NCT01414777|DRUG|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
57922123|NCT01414777|DRUG|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
57922124|NCT04829929|DEVICE|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
57922125|NCT02404207|OTHER|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
57922126|NCT02404207|OTHER|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
57922127|NCT02404207|OTHER|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
57922128|NCT02404207|OTHER|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
57922129|NCT03011502|OTHER|Biological samples collection of blood and feces|
57724685|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
57724686|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
57724687|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
58393279|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
58393280|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
58393281|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
57724688|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
57724689|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
57724690|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
57724691|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
57724692|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
57724693|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
57724694|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
57724695|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
57724696|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
57724697|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
58276191|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
57724698|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
57724699|NCT05155436|DRUG|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
58276192|NCT00803309|DRUG|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
58393282|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
58393283|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
58393284|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
57724700|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
57724701|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
57724702|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
57922130|NCT06099847|DEVICE|Sham TENS Stimulation|Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
57922131|NCT06099847|DEVICE|Sacral TENS Stimulation|Sacral TENS stimulation have been applied to directly the skin of sacral area.
58276193|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
58393285|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
58393286|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
58393287|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
58393288|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
57724703|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
57922132|NCT00213291|DRUG|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
57922133|NCT02630888|DRUG|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
57922134|NCT02630888|DRUG|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
57922135|NCT02910154|DIETARY_SUPPLEMENT|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
58065939|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
58276194|NCT03229967|DIAGNOSTIC_TEST|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
58276195|NCT01245816|DRUG|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
58276196|NCT01245816|DRUG|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
58276197|NCT01245816|DRUG|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
58276198|NCT05172791|BEHAVIORAL|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
58393289|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
58393290|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
58393291|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
58393292|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
58393293|NCT06485713|DRUG|fufuquitinib|fufuquitinib
58393294|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
58393295|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
58393296|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
58393297|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
58393298|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
57724704|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
58276199|NCT05649943|DRUG|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
58276200|NCT05649943|PROCEDURE|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
58276201|NCT00463840|DRUG|Oxaliplatin|
57724705|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
57724706|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
57724707|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
57724708|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
57724709|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
57724710|NCT00574860|DRUG|EN3285|Oral rinse
57724711|NCT00574860|DRUG|Placebo|Oral rinse
57724712|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
57922136|NCT02910154|BEHAVIORAL|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
57922137|NCT02910154|DRUG|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
57922138|NCT03289377|BEHAVIORAL|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
57922139|NCT02800239|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
58276202|NCT00463840|DRUG|5FU|
58276203|NCT00463840|RADIATION|Radiation|
58276204|NCT00463840|PROCEDURE|Surgery|
58276205|NCT00463840|DRUG|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
58276206|NCT02926417|PROCEDURE|High Density-Electroencephalogram|
58276207|NCT02804867|PROCEDURE|Online questionnaire and self-administered blood spot|
57922140|NCT02225496|PROCEDURE|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
57922141|NCT02225496|PROCEDURE|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
58276208|NCT01715142|DRUG|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
58276209|NCT01715142|DRUG|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
58276210|NCT00438256|PROCEDURE|Proton Beam Radiation|Given over different schedules and duration
58276211|NCT00438256|DRUG|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
57922142|NCT02225496|BEHAVIORAL|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
57922143|NCT00744185|DRUG|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
57922144|NCT00744185|DRUG|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
58393299|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
57724713|NCT02256475|DRUG|NBI-98854|
57724714|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
58393300|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
57724715|NCT04790253|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
57724716|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
57724717|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
57724718|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
57922145|NCT05239351|DEVICE|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
57922146|NCT05535465|OTHER|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
58276212|NCT02009371|DEVICE|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
58276213|NCT02009371|DEVICE|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
58276214|NCT05022628|DRUG|Donafenib|"Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
58276215|NCT04660773|DEVICE|NB UVB phototherapy|ultraviolet phototherapy sessions
58276216|NCT04660773|DRUG|Pregabalin|oral medication
58276217|NCT00426972|DRUG|estradiol (Zesteem)|
58276218|NCT03756818|DRUG|Mivavotinib|Given PO
58276219|NCT03756818|DRUG|Paclitaxel|Given IV
58276220|NCT03756818|OTHER|Pharmacokinetic Study|Correlative studies
58276221|NCT05583045|OTHER|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
58276222|NCT05583045|BEHAVIORAL|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
58276223|NCT05583045|OTHER|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
58276224|NCT02343380|OTHER|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
58276225|NCT05821465|DEVICE|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
58276226|NCT01022216|DEVICE|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
57922147|NCT02583087|PROCEDURE|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
58276227|NCT01022216|DEVICE|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
58276228|NCT02703818|DEVICE|Senza|Spinal Cord Stimulation
58276229|NCT03851978|BEHAVIORAL|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
58276230|NCT01158014|PROCEDURE|Fibrin Glue, Quixil|quixil 0.1 ml
58276231|NCT01158014|PROCEDURE|Suture|vicryl 10/0
58276232|NCT02578940|DRUG|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
58393301|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
58393302|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
58393303|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
57724719|NCT05519839|DRUG|qNIV Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
57724720|NCT05519839|DRUG|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
57724721|NCT05519839|DRUG|CIC Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
57724722|NCT05519839|OTHER|Placebo Comparator|Intramuscular (deltoid) injection of placebo given on Day 70.
57724723|NCT05519839|DRUG|SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
57724724|NCT00004327|DRUG|octreotide|
57724725|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
57724726|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
57724727|NCT02755493|BEHAVIORAL|Sleep deprivation|
57724728|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
57724729|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
57724730|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
57724731|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
57724732|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
57724733|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
57724734|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
57724735|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
57724736|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
57724737|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
58276233|NCT06511115|OTHER|Experimental Group|"Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits."
58276234|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
58276235|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
58276236|NCT03944993|DEVICE|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
58276237|NCT01187264|DRUG|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
58276238|NCT03646487|DIETARY_SUPPLEMENT|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
57724738|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
57724739|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
57724740|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
57724741|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
57724742|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
57724743|NCT02464735|DEVICE|Polysomnography|
57724744|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
57724745|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
57724746|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
57724747|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
57724748|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
57724749|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
57724750|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
57724751|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
57922148|NCT02907138|OTHER|Medical Yoga|
57922149|NCT02907138|OTHER|Treatment as Usual (physical therapy)|
57922150|NCT04905147|DRUG|Mosapride|Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
57922151|NCT04905147|DRUG|Placebo|Placebo drug 15 mg
58065940|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
58393304|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
58065941|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
58065942|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
58393305|NCT04097028|DRUG|Oxaliplatin|Given IV
58393306|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
57724752|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
57724753|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
58065943|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
58276239|NCT03646487|OTHER|Placebo in capsule form|Daily placebo in capsule form
58393307|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
58393308|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
58393309|NCT00231686|BEHAVIORAL|Supervised aerobic training|
57724754|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
57922152|NCT02397811|DIETARY_SUPPLEMENT|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
57922153|NCT02397811|DIETARY_SUPPLEMENT|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
57922154|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
57922155|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
57922156|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
57922157|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
57922158|NCT01244451|DRUG|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
57922159|NCT01244451|DRUG|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
58065944|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
58065945|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
58065946|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
58393310|NCT00231686|BEHAVIORAL|Supervised strength training|
58393311|NCT00231686|BEHAVIORAL|Unsupervised training|
58393312|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
58393313|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
58393314|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
57922160|NCT05240352|DEVICE|active tDCS|Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
57922161|NCT05240352|DEVICE|sham tDCS|"Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later"
57922162|NCT01453426|DRUG|BG00012 Dose 1|
57724755|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
57922163|NCT01453426|DRUG|BG00012 Dose 2|
57922164|NCT01440374|DRUG|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
57922165|NCT01440374|DRUG|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
57922166|NCT01171105|DRUG|AZD5213|oral solution, multiple ascending doses
57922167|NCT01171105|DRUG|Placebo to AZD5213|
57922168|NCT03057808|BEHAVIORAL|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
58065947|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
58065948|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
58393315|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
57922169|NCT03057808|BEHAVIORAL|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
57922170|NCT05809817|PROCEDURE|Periodontal treatment|Scaling and root planing
57922171|NCT03741647|DIAGNOSTIC_TEST|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
57922172|NCT00759291|DRUG|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
57922173|NCT00759291|DRUG|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
57922174|NCT01679574|DRUG|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
57922175|NCT01679574|DRUG|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
57922176|NCT01679574|DRUG|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
58065949|NCT00103207|BIOLOGICAL|cetuximab|
58065950|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
58393316|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
58393317|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
57724756|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
57724757|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
57922177|NCT06240091|DEVICE|DISC-MA|DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
57922178|NCT00592085|BEHAVIORAL|Questionnaires|Participants will use a computer to complete a series of questionnaires.
57922179|NCT00592085|BEHAVIORAL|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
57922180|NCT00592085|BEHAVIORAL|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
57922181|NCT03227796|DRUG|LEVI-04|LEVI-04 intravenous infusion
58065951|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
57724758|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
57724759|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
57724760|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
57724761|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
57724762|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
57724763|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
57724764|NCT02731001|RADIATION|Proton therapy|
57724765|NCT02731001|RADIATION|Photon therapy|
57724766|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
57922182|NCT03227796|DRUG|Placebo|Placebo intravenous infusion
58276240|NCT05606770|BEHAVIORAL|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
58276241|NCT05606770|BEHAVIORAL|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
58276242|NCT05929248|DRUG|Telitacicept|160mg once a week for 48 weeks
58276243|NCT05929248|DRUG|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
58276244|NCT05929248|DRUG|Placebo|Used once a week in combination with standard treatment
58276245|NCT05772507|DEVICE|URGO AWC_008 dressing or URGO AWC_022 dressing|local management of acute or chronic wounds
58276246|NCT03715387|DRUG|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
58276247|NCT03715387|DRUG|Polysporin Ointment|Polysporin ointment
58276248|NCT00047788|DRUG|ZD6474|
58276249|NCT00047788|DRUG|VEGF-receptor tyrosine kinase (KDR)|
58276250|NCT03721211|DRUG|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
58393318|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
58393319|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
58393320|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
57724767|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
57922183|NCT02682641|DRUG|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
57922184|NCT02682641|DRUG|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
57922185|NCT05727254|BEHAVIORAL|Agility training|Multi-component (strength, balance, cognition) exercise training.
57724768|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
57724769|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
57724770|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
57724771|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
57724772|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
57724773|NCT04478097|DRUG|CKD-333 Tab.|1T
57724774|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
57724775|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
57724776|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
57724777|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
57724778|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
57922186|NCT05727254|BEHAVIORAL|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
57922187|NCT05727254|BEHAVIORAL|Exercise diary|Participants are instructed to write down their physical activity and exercises.
57922188|NCT01313650|DRUG|62.5/25mcg|GSK573719/GW64244
57922189|NCT01313650|DRUG|62.5mcg|GSK573719
57922190|NCT01313650|DRUG|25mcg|GW642444
57922191|NCT01313650|DRUG|Placebo|Placebo
57922192|NCT03438851|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
57922193|NCT03032471|OTHER|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
57922194|NCT01059136|DRUG|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
57922195|NCT04279938|DRUG|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
57724779|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
57724780|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
57922196|NCT04279938|DRUG|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
58490473|NCT01734603|PROCEDURE|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
58490474|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
57724781|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
57724782|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
57724783|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
57922197|NCT04279938|DRUG|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
57922198|NCT00186641|PROCEDURE|high dose chemo and auto hematopoietic cell transplant|
57922199|NCT01279096|DRUG|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
57922200|NCT00004660|RADIATION|Radiotherapy|
57922201|NCT00004660|RADIATION|Sham treatment|
57922202|NCT03358966|OTHER|Doubly-labelled water technique|
57922203|NCT03358966|OTHER|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
57922204|NCT00465556|BEHAVIORAL|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
57922205|NCT00465556|BEHAVIORAL|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
57724784|NCT00058305|DRUG|bryostatin 1|Given IV
57922206|NCT05024227|BEHAVIORAL|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
57922207|NCT00767273|PROCEDURE|PET Scan|
57922208|NCT00767273|DRUG|FLT|
57922209|NCT00767273|DRUG|FDG|
57922210|NCT01412463|DEVICE|stent placement|"* pre-dilation of the study lesion is mandatory~* stent placement with 1 Protégé Everflex+ stent~* only 1 stent is allowed within the study protocol~* post-dilation may be performed but is not mandatory"
57922211|NCT05210218|DIETARY_SUPPLEMENT|Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
57922212|NCT05210218|DIETARY_SUPPLEMENT|placebo|cellulose
57922213|NCT00283257|BEHAVIORAL|Patients and caregivers are taught problem solving skills|
57724785|NCT00058305|DRUG|vincristine sulfate|Given IV
57724786|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
57724787|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
57922214|NCT04734327|PROCEDURE|Orthokine periradicular injection|Ultrasound guided injections
57922215|NCT04734327|PROCEDURE|Orthokine epidural injection|Ultrasound guided injections
57922216|NCT00418925|DRUG|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
57922217|NCT00860613|OTHER|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
57922218|NCT03764956|OTHER|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
58393321|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
58393322|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
58393323|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
57922219|NCT03764956|OTHER|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
57922220|NCT02876666|BEHAVIORAL|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
58065952|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
58065953|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
58065954|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
58065955|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
58065956|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
58065957|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
58065958|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
58065959|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
58065960|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
57922221|NCT00334347|DRUG|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
57922222|NCT00334347|DRUG|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
57922223|NCT05217654|DRUG|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
58065961|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
58393324|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
57922224|NCT05217654|DRUG|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
57922225|NCT00098384|DRUG|rifaximin|
57922226|NCT00006332|DRUG|Tetrathiomolybdate|
57922227|NCT02168842|DRUG|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
57922228|NCT02168842|DRUG|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
58276251|NCT03721211|DEVICE|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
57922229|NCT00001024|DRUG|Zidovudine|
57922230|NCT00001024|DRUG|Didanosine|
57922231|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
57922232|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
58276252|NCT02334098|DIETARY_SUPPLEMENT|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
58276253|NCT02334098|DIETARY_SUPPLEMENT|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
58276254|NCT05197205|PROCEDURE|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
58276255|NCT00004982|DRUG|Combination Iron Chelation Therapy|
57922233|NCT02963181|DRUG|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
57922234|NCT02963181|DRUG|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
57922235|NCT01847118|DRUG|Sevacizumab|
57922236|NCT00747825|DRUG|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
57922237|NCT04251260|OTHER|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
57922238|NCT03674125|BIOLOGICAL|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
58065962|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
58276256|NCT04538287|DEVICE|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
58276257|NCT01140828|DRUG|Rabeprazole|Rabeprazole 20mg once daily
58276258|NCT01140828|DRUG|Rabeprazole Placebo|one tab once daily
58276259|NCT03372642|DEVICE|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
58393325|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
58393326|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
57922239|NCT00473941|BEHAVIORAL|Expressive writing|Behavioral intervention using writing about cancer to improve quality of life outcomes
57922240|NCT03681951|DRUG|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
57922241|NCT03681951|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
57922242|NCT01928498|DEVICE|Paclitaxel Eluting Balloon Angioplasty|
57922243|NCT01928498|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|
57922244|NCT00052182|BIOLOGICAL|EP HIV-1090|
57922245|NCT04993612|DIAGNOSTIC_TEST|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
58065963|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
58065964|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
58065965|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
58276260|NCT01652625|DRUG|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
58276261|NCT01652625|DRUG|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
58490475|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
58490476|NCT03112577|DRUG|REGN3500|Intravenous (IV) use
58490477|NCT03112577|DRUG|Dupilumab|Subcutaneous (SC) use
58490478|NCT03112577|DRUG|Placebo|Matching placebo
58490479|NCT03112577|DRUG|Fluticasone propionate|Inhalation use
57922246|NCT04902469|BEHAVIORAL|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
57922247|NCT04902469|BEHAVIORAL|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
57922248|NCT00891345|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
57922249|NCT05552209|DEVICE|Elbow MID 500|15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.
57922250|NCT05552209|OTHER|Control group Elbow MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.
57922251|NCT05552209|DEVICE|Elbow STRAP|15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.
57922252|NCT05552209|OTHER|Control group Elbow STRAP|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
57922253|NCT04922489|PROCEDURE|Dental implant placement|Dental implant placemente on edentulous jaw.
57922254|NCT01058408|RADIATION|Intensity modulated radiotherapy|Administered daily 5 days per week
57922255|NCT01058408|DRUG|RAD001|Taken orally once a day
57922256|NCT01058408|DRUG|cisplatin|Administered intravenously once a week
57922257|NCT02474160|OTHER|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
58276262|NCT01631838|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
57922258|NCT01894373|DRUG|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
57922259|NCT01894373|BIOLOGICAL|CIK|
58065966|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
58065967|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
58276263|NCT01631838|DIETARY_SUPPLEMENT|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
58276264|NCT03985189|DRUG|ME-401|"\[Phase 1 study (DLT evaluation)\] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~\[Roll over study\] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
57922260|NCT01995877|PROCEDURE|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
57922261|NCT00892684|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
57922262|NCT00892684|DIETARY_SUPPLEMENT|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
57922263|NCT00701220|DRUG|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
58065968|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
58065969|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
58065970|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
58065971|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
58065972|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 5 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
58065973|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
58065974|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
58276265|NCT00727987|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
57724788|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
57724789|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
57724790|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
57724791|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
57724792|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
57724793|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
57724794|NCT01465334|DRUG|Ofatumumab|
57922264|NCT04631172|OTHER|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
57724795|NCT01465334|DRUG|High-Dose Methylprednisolone|
57724796|NCT01465334|DRUG|Alemtuzumab|
57724797|NCT00364481|DRUG|omeprazole|
57922265|NCT02053038|DEVICE|iFR|Treatment guided by instantaneous wave-free ratio
57922266|NCT02053038|DEVICE|FFR|Treatment guided by Fractional Flow Reserve
57922267|NCT00705523|DRUG|varenicline|1.0 mg BID for 12 weeks
58065975|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
58065976|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
58065977|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
58065978|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
58065979|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
57724798|NCT00364481|BEHAVIORAL|Tongue exercises|
57724799|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
57724800|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
57724801|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
57724802|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
57724803|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
57724804|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
57724805|NCT02182544|DRUG|WAL801CL dry syrup|
57724806|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
57724807|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
57724808|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
57724809|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
57724810|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
57724811|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
57724812|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
57724813|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
57922268|NCT00705523|DRUG|placebo|BID 12 weeks
57922269|NCT04607525|DRUG|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\]."
57922270|NCT04607525|DRUG|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
57922271|NCT00285337|PROCEDURE|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
57922272|NCT00913666|DRUG|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
57922273|NCT00223678|DRUG|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
57922274|NCT02080221|DRUG|FOLFOXA|
57922275|NCT01670123|BEHAVIORAL|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
57922276|NCT04497194|OTHER|not applicable (observational study)|not applicable (observational study)
58276266|NCT00727987|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
58276267|NCT00727987|DRUG|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
58276268|NCT02634983|DRUG|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
58276269|NCT02634983|DRUG|Placebo|Matching placebo
58276270|NCT02962206|DEVICE|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
58276271|NCT02962206|PROCEDURE|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
58393327|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
57724814|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
57724815|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
57724816|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
57724817|NCT04964089|DRUG|KSI-301|Intravitreal Injection
57724818|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
57724819|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
57724820|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
57724821|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
57724822|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
57724823|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
57724824|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
57724825|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
57724826|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
57724827|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
57724828|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
57922277|NCT05210296|BEHAVIORAL|Exercises|Therapeutic exercise will be applied to the elderly
57922278|NCT05141123|PROCEDURE|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
57922279|NCT03639233|BEHAVIORAL|YESS!|Web based self-management education
57922280|NCT00582868|DEVICE|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
57922281|NCT00582868|OTHER|CSF|analysis of CSF for cleaved tau protein
57922282|NCT00582868|OTHER|Whole blood|Analysis of whole blood for cleaved-tau protein
58276272|NCT02771925|DRUG|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
58276273|NCT02771925|DRUG|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
58276274|NCT03718195|OTHER|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
58276275|NCT00957905|DRUG|Alvocidib Hydrochloride|Given IV
58276276|NCT00957905|DRUG|Fluorouracil|Given IV
58276277|NCT00957905|DRUG|Leucovorin Calcium|Given IV
58065980|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
57922283|NCT02722720|PROCEDURE|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
58065981|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
58065982|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
58065983|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
58065984|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
58065985|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
58065986|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
58065987|NCT00006025|DRUG|irinotecan hydrochloride|
58065988|NCT00006025|DRUG|temozolomide|
58065989|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
58065990|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
57724829|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
57724830|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
58065991|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
58065992|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
58065993|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
58065994|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
58065995|NCT05814107|DRUG|CT-996|Capsule of CT-996
58065996|NCT05814107|DRUG|Placebo|Capsule of Placebo
58065997|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
58065998|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
58065999|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
58066000|NCT02538705|DRUG|Neovasculgen|
58066001|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
58066002|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
58066003|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
58066004|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
58066005|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
58276278|NCT00957905|DRUG|Oxaliplatin|Given IV
57724831|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
57724832|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
57922284|NCT02722720|PROCEDURE|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
57922285|NCT00108654|DRUG|VRC-HIVADV014-00-VP|
57922286|NCT02839837|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
57922287|NCT02839837|DEVICE|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
57922288|NCT05395910|DRUG|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
58066006|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
58066007|NCT04643769|DRUG|Placebo|Oral tablet - placebo
58066008|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
58066009|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
57922289|NCT04652167|DIAGNOSTIC_TEST|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
58066010|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
58066011|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
58066012|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
58276279|NCT02444039|DEVICE|SL-D301|Slit Lamp
58276280|NCT02444039|DEVICE|DC-4|Digital Camera Attachment
58276281|NCT02444039|DEVICE|SL-3G|Slit Lamp
58276282|NCT02425202|DRUG|Ketamine|Post-operative continuous infusion until 0600 the next day
58276283|NCT02425202|OTHER|Saline infusion|Post-operative continuous infusion until 0600 the next day
58276284|NCT01621828|OTHER|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
57724833|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
57724834|NCT02362399|DRUG|sildenafil citrate|single oral dose of 50 mg
57724835|NCT02362399|OTHER|placebo|single oral dose of placebo tablet
58066013|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
58276285|NCT01621828|OTHER|leaflet|a written leaflet, about the operating room experience and environment.
57724836|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
58393328|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
57922290|NCT04652167|DIAGNOSTIC_TEST|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
58393329|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
58393330|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
57922291|NCT04652167|DIAGNOSTIC_TEST|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
57922292|NCT04519112|PROCEDURE|Catheter Ablation|Catheter Ablation with RMN and MCN
57922293|NCT02966392|DEVICE|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
57922294|NCT04200131|DIAGNOSTIC_TEST|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
57922295|NCT02374021|DRUG|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
57724837|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
57922296|NCT02374021|DRUG|Sulfasalazine|1 gm bid
57922297|NCT02374021|DRUG|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
57922298|NCT02374021|DRUG|Etanercept|50 mg SC weekly
57922299|NCT02374021|DRUG|Adalimumab|40 mg SQ every other week
57922300|NCT04513704|DRUG|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
58276286|NCT03409120|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
58276287|NCT02914431|DEVICE|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
58276288|NCT06730828|COMBINATION_PRODUCT|The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)|Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
57922301|NCT05078320|BEHAVIORAL|Exposure and response prevention (ERP)|"The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).~Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns."
57922302|NCT00802425|DRUG|AM-111|single intratympanic injection
57922303|NCT00802425|DRUG|placebo|single intratympanic injection
57922304|NCT04662762|OTHER|Nursing intervention programme|educational information
58276289|NCT03705845|DRUG|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
58276290|NCT03705845|DRUG|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
58276291|NCT03887117|OTHER|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
58276292|NCT03887117|OTHER|IQOS without Exercise Training Program|Switch to IQOS use only, without participation in a training program
58276293|NCT03887117|OTHER|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
58276294|NCT03887117|OTHER|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
58276295|NCT00871364|DRUG|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
58276296|NCT00871364|DRUG|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
58276297|NCT02097459|DRUG|Anastrozole|
58276298|NCT02097459|DRUG|Tamoxifen|
58276299|NCT02097459|DRUG|Toremifene|
58276300|NCT02249013|PROCEDURE|Cytoreductive Surgery (CRS)|CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
58276301|NCT02249013|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
57724838|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
57724839|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
57724840|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
57724841|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
57724842|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
57724843|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
57724844|NCT02504645|DRUG|IPP-201101|
57724845|NCT02504645|DRUG|Placebo|
57724846|NCT02504645|OTHER|Standard of Care|
57724847|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
57922305|NCT02343731|OTHER|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
57922306|NCT01351753|DRUG|Metformin|
57922307|NCT01351753|DRUG|Orlistat|
57922308|NCT01351753|DRUG|Topiramate|
57922309|NCT01351753|DRUG|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
57922310|NCT05997888|BEHAVIORAL|At-Home Strength Training Intervention|A six-week strength training intervention in which participants will choose workouts to complete on their own. These workouts are 20-25 minutes light-intensity strength training with light strength bands. Exercises will have multiple options to account for various levels of ability. Additionally, there will be a group counseling session once per week via Zoom and a group strength training program.
57922311|NCT06155448|OTHER|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
57922312|NCT00330486|DRUG|Acamprosate|
57922313|NCT04238065|DEVICE|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
58276302|NCT02249013|DRUG|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
57922314|NCT04238065|DEVICE|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
57922315|NCT04238065|DEVICE|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
57922316|NCT05516550|DRUG|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
57922317|NCT05516550|DRUG|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
57922318|NCT05516550|DRUG|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
57922319|NCT05516550|DRUG|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
58276303|NCT02249013|DRUG|Adjuvant Chemotherapy|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
57922320|NCT04761302|OTHER|Use of non-steroid anti-inflammatory drugs (NSAIDS) as an alternative for post-operative pain management after a femur and tibia fracture|This is a randomized controlled, single blind, parallel groups, opioid control trial of all patients (total of 150 patients) who suffered tibial and femoral shaft fractures and were treated with intramedullary nailing. Patients will be aleatory assigned to two study groups: Group-1 will receive non-opioid medications, and Group-2 will receive opioid medications. During the inpatient postoperative period, patients will undergo subjective evaluation of pain utilizing a previously validated questionnaire, the Visual Analogue Score (VAS). The first questionnaire will be completed twelve hours after surgery and during subsequent twelve-hour intervals until discharge. Secondary outcomes will include efficiency such as time to gastrointestinal motility, time to weight bearing of affected limb, resumption of ambulation, and length of hospital stay. The evaluation will take approximately 15 minutes to complete each time, we the entire participation time to be 60 minutes.
57922321|NCT02720536|DRUG|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
57922322|NCT02645695|DEVICE|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
57922323|NCT02645695|DEVICE|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
57922324|NCT02046824|DEVICE|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
57922325|NCT02046824|DEVICE|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
57922326|NCT02046824|DEVICE|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
57922327|NCT02046824|OTHER|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
57922328|NCT00343135|DRUG|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
57922329|NCT03675178|DRUG|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
57922330|NCT03675178|DRUG|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
57922331|NCT01413100|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57922332|NCT01413100|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
58276304|NCT02249013|PROCEDURE|Fast-track recovery strategy|A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
58276305|NCT02477709|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
57922333|NCT01413100|DRUG|Cyclophosphamide|Given IV
57922334|NCT01413100|BIOLOGICAL|Filgrastim|Given SC
57922335|NCT01413100|OTHER|Laboratory Biomarker Analysis|Correlative studies
57922336|NCT01413100|DRUG|Mycophenolate Mofetil|Given PO
58066014|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
58066015|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
58276306|NCT00220233|DRUG|olmesartan medoxomil|
58276307|NCT00220233|DRUG|amlodipine|
58276308|NCT00220233|DRUG|hydrochlorothiazide|
57724848|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
57922337|NCT01413100|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
57922338|NCT01413100|DRUG|Plerixafor|Given SC
57922339|NCT01413100|OTHER|Quality-of-Life Assessment|Ancillary studies
57922340|NCT01413100|OTHER|Questionnaire Administration|Ancillary studies
57922341|NCT05080998|DIAGNOSTIC_TEST|CxBladder Monitor|CxBladder Monitor (CxbM) is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
57922342|NCT01562951|DRUG|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
57922343|NCT01562951|DRUG|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
57922344|NCT05712733|OTHER|Microbiological and histopathological investigation of bile and gallbladder wall specimens.|Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
57922345|NCT01942720|DEVICE|Capsule endoscopy and Ileocolonoscopy tests|
58276309|NCT02238938|PROCEDURE|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
58276310|NCT02238938|PROCEDURE|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
58276311|NCT02940873|BEHAVIORAL|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
57922346|NCT06176339|DRUG|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
57922347|NCT06176339|DRUG|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
57922348|NCT03167931|OTHER|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
57922349|NCT03167931|OTHER|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
57922350|NCT04793802|OTHER|PHYSIO|session of physiotherapy
57922351|NCT04637308|DRUG|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
58276312|NCT02940873|BEHAVIORAL|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
58276313|NCT03057067|PROCEDURE|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
58276314|NCT00870506|BEHAVIORAL|video|5-minute video compared (intervention) to no video and no other intervention (control)
57922352|NCT04579627|BEHAVIORAL|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
57922353|NCT01688674|DRUG|10% dextrose|
57922354|NCT01594008|OTHER|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
57922355|NCT01594008|OTHER|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
57922356|NCT01594008|OTHER|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
57922357|NCT02575820|PROCEDURE|Old red blood cells transfusion|Red blood cells (shelf life \> 14 days) transfusion during the operation (total hip replacement arthroplasty)
57922358|NCT02575820|PROCEDURE|New red blood cells transfusion|Red blood cells (shelf life =\< 14 days) transfusion during the operation (total hip replacement arthroplasty)
57922359|NCT02924974|DRUG|Morphine|mixed with bupivacaine
57922360|NCT02924974|DRUG|Lidocaine|sham procedure (s.c. lidocaïne)
57922361|NCT06435130|OTHER|Dietary intervention with chokeberry juices|The first stage of the dietary intervention lasted 8 weeks. Study participants consumed 100 ml of chokeberry juice daily. Chokeberry juice came from ecological cultivation (Poland). Participants qualified for the study had specific biochemical parameters tested: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. Blood tests were performed in a certified external laboratory before and after 8 weeks of intervention. In addition, blood pressure and waist circumference were tested.
57724849|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
57724850|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
57724851|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
57724852|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
57724853|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
57724854|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
57922362|NCT06435130|OTHER|Dietary intervention with chokeberry juices and fibers|The second stage of the dietary intervention lasted 4 weeks. Study participants consumed 100 ml of chokeberry juice daily and 10 g chokeberry fiber daily (from ecological cultivation, Poland). Blood tests were performed in a certified external laboratory after 4 weeks of intervention. The following blood tests were performed: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. In addition, blood pressure and waist circumference were tested.
57922363|NCT05243030|BEHAVIORAL|Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
57724855|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
57724856|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
57724857|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
57724858|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
57724859|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
57724860|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
57724861|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
57724862|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
57724863|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
57724864|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
57724865|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
57724866|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
57724867|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
57724868|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
57724869|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
57724870|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
57724871|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
57724872|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
57724873|NCT03388580|PROCEDURE|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
57724874|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
57922364|NCT05243030|BEHAVIORAL|Motivational Interactive Text Messaging (MTM)|"Participants will receive automated motivational text messages to promote PrEP initiation and adherence. These contents will be customized based on their readiness to change in regards to PrEP. The message content is individualized based on participant response to baseline survey. Those participants who indicate that they are ready to set the goal to take PrEP will receive text messages reminding them to take PrEP. Those who indicate that they are less than ready to take their PrEP can choose from a range of alternatives, such as taking on-demand PrEP or just think about taking PrEP. For those who are not ready to take PrEP, the content will be individualized based on the participant's choice, i.e., a daily message encouraging them to work toward their chosen goal. Participants who are currently not on PrEP will receive daily text messages regarding PrEP effectiveness, HIV risk and where to access PrEP."
57922365|NCT05243030|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3 and 6. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
58393331|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
57922366|NCT03072277|DIETARY_SUPPLEMENT|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
57922367|NCT03072277|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
57922368|NCT04620226|OTHER|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
57922369|NCT04080791|DEVICE|Virtual Reality (VR) System|The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.
57922370|NCT04080791|PROCEDURE|Standard of care|Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
57922371|NCT05079256|DEVICE|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
57922372|NCT02529813|DRUG|Cyclophosphamide|Given IV
57922373|NCT02529813|DRUG|Fludarabine Phosphate|Given IV
58276315|NCT04183465|OTHER|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
58393332|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
58393333|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
58393334|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
58393335|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
58393336|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
57922374|NCT02529813|OTHER|Laboratory Biomarker Analysis|Correlative studies
57922375|NCT02529813|BIOLOGICAL|Tisagenlecleucel|Given IV
57922376|NCT04551625|DEVICE|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
57922377|NCT00426153|DRUG|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
58393337|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
57724875|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
57724876|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
57724877|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
57724878|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
57724879|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
57724880|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
57724881|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
57724882|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
58393338|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
57724883|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
57724884|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
57724885|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
57724886|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
57724887|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
57922378|NCT00426153|DRUG|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
57922379|NCT04823520|DRUG|TCA|All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
57724888|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
57724889|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
57724890|NCT00001631|PROCEDURE|Magnetic resonance imaging|
57922380|NCT05078216|OTHER|Physical exercise intervention|"12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity."
57922381|NCT04951401|OTHER|lipid profile|lipid profile
57922382|NCT04951401|OTHER|ECG|ECG
57922383|NCT05110274|PROCEDURE|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
57922384|NCT05110274|PROCEDURE|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
57922385|NCT04644458|OTHER|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
57922386|NCT06101433|DIETARY_SUPPLEMENT|Soy isoflavone|the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
57922387|NCT06101433|OTHER|Placebo|the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
57922388|NCT01395316|DRUG|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
58393339|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
58393340|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
58393341|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
58393342|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
58393343|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
57922389|NCT03376945|DRUG|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
57922390|NCT03376945|DRUG|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
58276316|NCT04183465|OTHER|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
57724891|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57724892|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
57724893|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
57724894|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
57922391|NCT00995020|PROCEDURE|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
57922392|NCT00995020|PROCEDURE|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
57922393|NCT04743154|OTHER|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
57922394|NCT04743154|OTHER|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
57922395|NCT04964414|OTHER|Smell Retraining|Smell practice with household scented items
57922396|NCT04964414|DRUG|Budesonide|Nasal irrigation with liquid steroid
57922397|NCT04261335|BIOLOGICAL|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
58276317|NCT03173365|DRUG|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
58276318|NCT00758134|DRUG|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
58276319|NCT00592592|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
58393344|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
58393345|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
58066016|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
58276320|NCT03412006|DRUG|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
58393346|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
58393347|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
57724895|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
57724896|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
57724897|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
57724898|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
57724899|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
57724900|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
57724901|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
57724902|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
57724903|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
57724904|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
57724905|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
57724906|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
57724907|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
57724908|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
57724909|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
57724910|NCT02032901|DRUG|Daclatasvir|
57724911|NCT02032901|DRUG|Sofosbuvir|
57724912|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
57724913|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
57724914|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
57724915|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
57724916|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
57724917|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
57724918|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
57724919|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
57724920|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
57724921|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
57724922|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
58066017|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
58276321|NCT03412006|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
58276322|NCT00479297|DRUG|SAM-531|
58276323|NCT01063231|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
58276324|NCT04277767|DIAGNOSTIC_TEST|observational|No intervention
57724923|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
57724924|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
57724925|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
58276325|NCT04214405|PROCEDURE|fixation of tripodal zygomatic fractures|One point versus two point fixation of tripodal zygomatic fractures
58393348|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
58393349|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
58393350|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
58393351|NCT02030925|DRUG|IW-3718|
57724926|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
57724927|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
57724928|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
58066018|NCT04980300|BEHAVIORAL|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
58066019|NCT04980300|BEHAVIORAL|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
58066020|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
57724929|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
57724930|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
57724931|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
57724932|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
57724933|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
57724934|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
58066021|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
58393352|NCT02030925|DRUG|Matching Placebo|
58393353|NCT06284460|DRUG|ASTX029|Given by PO
58393354|NCT06284460|DRUG|ASTX727|Given by PO
58393355|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
58393356|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
58393357|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
58393358|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
58393359|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
57724935|NCT01993524|OTHER|placebo|antibiotic plus placebo
57922398|NCT04015856|BEHAVIORAL|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
57922399|NCT04015856|BEHAVIORAL|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
57922400|NCT06220903|OTHER|Complex Decongestive Therapy|"1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
57922401|NCT06372028|DEVICE|transcutaneous vagus nerve stimulation (tVNS)|tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
57922402|NCT05923957|OTHER|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
58393360|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
58393361|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
58393362|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
58393363|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
57724936|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
57724937|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
57724938|NCT00001022|DRUG|Zidovudine|
57724939|NCT00001022|DRUG|Zalcitabine|
57724940|NCT00001022|DRUG|Didanosine|
57724941|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
57724942|NCT04598516|DIAGNOSTIC_TEST|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
58393364|NCT04587830|DRUG|Placebo|Investigational Medicine
58393365|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
58393366|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
58393367|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
58393368|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
57724943|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
57724944|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
57724945|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
57724946|NCT02897544|BEHAVIORAL|Individualized Manualized Health Education Intervention|
57724947|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
57724948|NCT02396641|OTHER|Best Supportive Care Checklist|
57724949|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
57724950|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
57724951|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
57724952|NCT00467181|DRUG|Fenoldopam|
57724953|NCT04634487|OTHER|No intervention|No intervention
57724954|NCT00114686|DRUG|Quetiapine fumarate|
57724955|NCT00114686|DRUG|lithium|
57724956|NCT00114686|DRUG|divalproex|
57724957|NCT00647920|BIOLOGICAL|adalimumab|40 mg adalimumab sc, every other week
57724958|NCT00647920|BIOLOGICAL|placebo|placebo sc, every other week
57922403|NCT01749449|OTHER|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
57922404|NCT05055986|DEVICE|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
57922405|NCT03514212|BEHAVIORAL|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
57922406|NCT05576818|DRUG|Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers|Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
57922407|NCT05199974|PROCEDURE|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
57922408|NCT03328533|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
57922409|NCT03328533|DRUG|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
57922410|NCT03328533|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
57922411|NCT00002566|DRUG|carboplatin|
57922412|NCT00002566|DRUG|cisplatin|
57922413|NCT00002566|DRUG|cyclophosphamide|
57922414|NCT00002566|DRUG|etoposide|
57922415|NCT00002566|DRUG|ifosfamide|
58393369|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
58393370|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
58393371|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
57922416|NCT00002566|DRUG|vinblastine sulfate|
57922417|NCT00002566|PROCEDURE|autologous bone marrow transplantation|
57922418|NCT00002566|PROCEDURE|conventional surgery|
57922419|NCT00002566|PROCEDURE|peripheral blood stem cell transplantation|
57922420|NCT02727166|DIETARY_SUPPLEMENT|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
57922421|NCT02727166|DIETARY_SUPPLEMENT|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
57922422|NCT01771328|DRUG|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
57922423|NCT01771328|DRUG|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
57922424|NCT04421521|PROCEDURE|Acupuncture|Acupuncture with disposable needles will be implemented
57922425|NCT04559880|DRUG|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
57922426|NCT05584969|BEHAVIORAL|Peer-led integrated nutrition education intervention delivered through Care Groups|The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
57922427|NCT04754477|DEVICE|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
58066022|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
57922428|NCT02811185|DRUG|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
58066023|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
58066024|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
58393372|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
58393373|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
58393374|NCT00956007|BIOLOGICAL|cetuximab|intravenously
57724959|NCT04511715|DRUG|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
57724960|NCT04511715|OTHER|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
57724961|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
57724962|NCT05331183|DRUG|IVA|Tablets for oral administration.
57724963|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
57724964|NCT03286959|PROCEDURE|PCR with RMGIC|
57724965|NCT03286959|PROCEDURE|PCR with direct composite|
57724966|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
57724967|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
57724968|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
57724969|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
57724970|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
57724971|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
57724972|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
57724973|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
57724974|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
57724975|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
57724976|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
57724977|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
58066025|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
57724978|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
57724979|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
57724980|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
57724981|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
57724982|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
57724983|NCT04871139|OTHER|Radioactive Iodine|Given IV
57724984|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
57724985|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
58276326|NCT05524038|DRUG|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
58276327|NCT05524038|DEVICE|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
57724986|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
57724987|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
57724988|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
58276328|NCT05524038|DRUG|Dexamethasone|injection of 4mg dexamethasone in each block
57922429|NCT04523766|BEHAVIORAL|Mindfulness of Breath|The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
58393375|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
57922430|NCT04523766|BEHAVIORAL|Mindful Interoceptive Mapping|The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
57922431|NCT01692691|DRUG|Dacarbazine|Dacarbazine IV - Day 1
57922432|NCT01692691|DRUG|Carmustine|Carmustine IV- Day 2
57922433|NCT01692691|DRUG|Neulasta|Neulasta SC - Day 3
57922434|NCT02773875|DEVICE|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
57922435|NCT04911556|DIETARY_SUPPLEMENT|Bifidobacterium longum|types of intestinal flora
57922436|NCT04911556|DIETARY_SUPPLEMENT|A placebo made of starch|placebo
58066026|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
57724989|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
57724990|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
57724991|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
58066027|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
58066028|NCT00427687|DRUG|AGG-523|
57724992|NCT05090501|BEHAVIORAL|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
57724993|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
57724994|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
57922437|NCT03330353|DIAGNOSTIC_TEST|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
57922438|NCT05572333|DRUG|EP395|Capsule for oral use
57922439|NCT05572333|DRUG|Placebo|Capsule for oral use
57922440|NCT03545659|OTHER|Mode of relapse/SMN detection|Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
57922441|NCT04531553|PROCEDURE|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
58066029|NCT00377273|DRUG|fluorouracil cream 0.5%|
58066030|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
58066031|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
58066032|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
58066033|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
58490480|NCT06519851|OTHER|suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%|postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
58490481|NCT06519851|OTHER|Interscalene block with 20 ml bupivacaine 0.25%|postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
57922442|NCT04531553|PROCEDURE|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
57922443|NCT04531553|PROCEDURE|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
57922444|NCT06494202|OTHER|Innovative rehabilitation|Conventional rehabilitation program associated with innovative therapies.
57922445|NCT06494202|OTHER|Conventional rehabilitation program.|Conventional rehabilitation program
57922446|NCT02253303|OTHER|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
58066034|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
58066035|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
58066036|NCT00060333|RADIATION|radiation therapy|
58066037|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
58066038|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
58066039|NCT00754312|DRUG|SNDX-275|
58066040|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)|"Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated."
58066041|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
58066042|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
58066043|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
58276329|NCT05524038|DEVICE|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
58066044|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
58066045|NCT01817218|DRUG|Platelet Rich Plasma|
58276330|NCT04687566|DRUG|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
58276331|NCT04687566|DRUG|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
57922447|NCT05925166|DRUG|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
57922448|NCT05925166|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
57922449|NCT02489513|DRUG|[14C]-AG-120|Labeled investigational drug
57922450|NCT02824263|OTHER|CPAP withdrawal|CPAP is discontinued for 3 nights.
58276332|NCT04687566|DRUG|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
58276333|NCT04687566|DRUG|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
57922451|NCT05441917|DEVICE|Sanae method with LED|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
57922452|NCT05441917|DEVICE|Sanae method with Radiofrecuency|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
57922453|NCT00692302|BEHAVIORAL|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
57922454|NCT00692302|BEHAVIORAL|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
57922455|NCT01121835|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
57922456|NCT01121835|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
57922457|NCT01121835|DRUG|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
57922458|NCT02105350|DRUG|MEK 162|
57922459|NCT02105350|DRUG|Gemcitabine|
57922460|NCT02105350|DRUG|Oxaliplatin|
57922461|NCT03000361|PROCEDURE|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
57922462|NCT05105789|DIAGNOSTIC_TEST|BinaxNOW Test|diagnostic test for SARS-CoV-2
57922463|NCT05105789|DIAGNOSTIC_TEST|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
57922464|NCT04293315|BEHAVIORAL|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
57922465|NCT01779687|DRUG|raltegravir|Raltegravir 400 mg BID for 7 days
57922466|NCT01779687|DRUG|Atorvastatin|Atorvastatin 20 mg QD for 7 days
57922467|NCT03207555|DRUG|Ibrutinib|420 mg by mouth once daily.
57922468|NCT02765607|PROCEDURE|Heart surgery|
57922469|NCT01783587|DRUG|Afatinib|Taken orally once per day
58066046|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
58276334|NCT01290198|DRUG|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
58276335|NCT04268628|OTHER|Serum and plasma samples analysis|This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
57922470|NCT01783587|DRUG|Docetaxel|15 mg/m2, given intravenously once per week
57922471|NCT01783587|RADIATION|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
57922472|NCT02083666|DRUG|SOBI002|Test Product
57922473|NCT02083666|DRUG|Placebo|Reference product
57922474|NCT05779397|DEVICE|Masimo RAD-GT|Non-contact infrared thermometry device
57922475|NCT00216879|DRUG|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
57922476|NCT03916848|PROCEDURE|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
57922477|NCT04317950|OTHER|Vojta|Reflex locomotion stimulus
57922478|NCT04317950|OTHER|Sham|sham stimulus
57922479|NCT05381779|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
58066047|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
58276336|NCT03739580|DEVICE|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
57922480|NCT05381779|OTHER|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
57922481|NCT05381779|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
57922482|NCT00537485|DRUG|SPM 962|transdermal application, 1 time per day
57922483|NCT00537485|DRUG|placebo|transdermal application, 1 time per day
57922484|NCT03442049|OTHER|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
57922485|NCT03442049|OTHER|Physiotherapy - control group|Home exercise program
57922486|NCT00825617|DRUG|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
57922487|NCT04314141|PROCEDURE|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes"
58276337|NCT03739580|DEVICE|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
58276338|NCT05310526|OTHER|Training Group|Training for prescribing the Brazilian cardioprotective diet
58276339|NCT02550704|PROCEDURE|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
57922488|NCT02151422|BEHAVIORAL|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
57922489|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
58276340|NCT03960424|OTHER|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
57922490|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
57922491|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
57922492|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
57922493|NCT05941767|DRUG|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
57922494|NCT05941767|DRUG|Lidocaine nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
57922495|NCT05941767|DRUG|Dexmedetomidine IV|The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
58066048|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
58066049|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
58066050|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
58066051|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
58066052|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
58276341|NCT03960424|BEHAVIORAL|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
58276342|NCT00771979|DRUG|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
58276343|NCT00771979|DRUG|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
58276344|NCT02236078|DRUG|High dose isoniazid|See arm description
58276345|NCT00951106|DRUG|Pyrimethamine/sulfdoxine (Fansidar)|
58490482|NCT00452192|DRUG|Telmisartan|telmisartan 80 mg daily over 2 weeks
57724995|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
57724996|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
57724997|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
57724998|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
57724999|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
57725000|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
57725001|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
57725002|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
57725003|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
57725004|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
57725005|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
57725006|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
57725007|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
57725008|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
57725009|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
57725010|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
57725011|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
57725012|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
57725013|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
57725014|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
57725015|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
57922496|NCT05941767|DRUG|Lidocaine IV|The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
57922497|NCT06434376|BIOLOGICAL|Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology|Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
57725016|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
57725017|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
57725018|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
57725019|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
57725020|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
57725021|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
57725022|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
57725023|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
57725024|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
57725025|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
57725026|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
57725027|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
57725028|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
57725029|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
57725030|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
57725031|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
58066053|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
57725032|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
57725033|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
57725034|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
57725035|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
57725036|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
57725037|NCT01747681|PROCEDURE|Microfracture|
57725038|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
57725039|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
57725040|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
57725041|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
57725042|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
57725043|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
57922498|NCT00688181|DEVICE|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
57725044|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
57725045|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
57725046|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
57725047|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
57725048|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
57725049|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
57922499|NCT05432778|DRUG|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
57725050|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
58066054|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
58490483|NCT00324597|DRUG|gemcitabine hydrochloride|
57725051|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
57725052|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
57725053|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
57725054|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
57725055|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
57922500|NCT00926211|DEVICE|ARTAS™ System|Hair harvest using a computer-assisted system
57922501|NCT00926211|PROCEDURE|Manual Hair Harvest|Hair harvesting via the manual technique
57922502|NCT03800459|BEHAVIORAL|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
57922503|NCT01520896|DRUG|NKTR-118|Oral 25 mg
57922504|NCT01520896|DRUG|Ketoconazole|Oral 400 mg
57922505|NCT03832296|BEHAVIORAL|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
57922506|NCT03832296|BEHAVIORAL|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
57922507|NCT00881608|DRUG|Placebo|Placebo, 1 capsule daily for five days
57922508|NCT00881608|DRUG|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
57725056|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
57725057|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
57725058|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
57725059|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
57725060|NCT01563861|GENETIC|RNA analysis|
57725061|NCT01563861|GENETIC|gene expression analysis|
57725062|NCT01563861|OTHER|immunohistochemistry staining method|
57725063|NCT01563861|OTHER|laboratory biomarker analysis|
57725064|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
57922509|NCT04300101|OTHER|molecular characterization|"immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis"
57725065|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
57725066|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
57725067|NCT01771003|DEVICE|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
57725068|NCT00893659|DIETARY_SUPPLEMENT|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
57725069|NCT00893659|DIETARY_SUPPLEMENT|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
57725070|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
57725071|NCT00004867|PROCEDURE|conventional surgery|
57725072|NCT00004867|PROCEDURE|positron emission tomography|
57725073|NCT00004867|PROCEDURE|radionuclide imaging|
57725074|NCT00004867|RADIATION|fludeoxyglucose F 18|
57725075|NCT00004867|DRUG|chemotherapy|
57922510|NCT04577196|OTHER|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
57922511|NCT01840787|DEVICE|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
57922512|NCT01840787|DEVICE|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
57922513|NCT01840787|DEVICE|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
57725076|NCT00004867|RADIATION|Radiotherapy|
57725077|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
57725078|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
57725079|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
57725080|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
57725081|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
57725082|NCT03794089|BEHAVIORAL|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
57725083|NCT03794089|BEHAVIORAL|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
57725084|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
57725085|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
57725086|NCT01431066|DEVICE|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
57725087|NCT01431066|DEVICE|ActiPatch PRFE Device|Actipatch PRFE device
57725088|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
57725089|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
57725090|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
57725091|NCT02855294|DRUG|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
57725092|NCT00260923|DRUG|aliskiren|
57725093|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
57725094|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
57725095|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
57725096|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
57725097|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
57725098|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
57725099|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
57725100|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
57725101|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
57725102|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
57725103|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
57725104|NCT06531720|OTHER|control group|no medication has been prescribed
57725105|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
57725106|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
57725107|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
57725108|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
57922514|NCT05033418|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|4-session CBT-I group in addition to IPRP
57922515|NCT05033418|BEHAVIORAL|Interdisciplinary Pain Rehabilitation Program (IPRP)|10-week IPRP usual care
58490484|NCT00324597|DRUG|motesanib diphosphate|
57725109|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
57725110|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
57725111|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
58490485|NCT00324597|OTHER|pharmacological study|
57725112|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
57725113|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
57725114|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
57725115|NCT01213758|OTHER|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
57725116|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
57725117|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
57725118|NCT00920192|DRUG|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
57725119|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
57725120|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
57725121|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
57725122|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
57725123|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
57725124|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
57725125|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
57725126|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
57725127|NCT00674310|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
57725128|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
57725129|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
57725130|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
57725131|NCT00958919|DRUG|normal saline|25 ml
58066055|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
58066056|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
57725132|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
57725133|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
57725134|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
57725135|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
57725136|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
57725137|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
57725138|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
57725139|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
57725140|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
57725141|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
57725142|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
57725143|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
57922516|NCT02605421|DRUG|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
57922517|NCT02605421|DRUG|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
57725144|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
57725145|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
57922518|NCT02605421|DRUG|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
57922519|NCT02605421|DRUG|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
57922520|NCT02605421|DRUG|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
57922521|NCT02605421|BIOLOGICAL|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
57922522|NCT02605421|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \> 2000/μL for 3 consecutive days.
57922523|NCT00491543|DRUG|ALT-2074|
57922524|NCT00645541|PROCEDURE|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
57922525|NCT00189566|DRUG|Paclitaxel|
57922526|NCT00189566|DRUG|Topotecan|
57922527|NCT00189566|DRUG|Carboplatin|
57922528|NCT03421093|PROCEDURE|Surgeries|Surgeries or surgeries plus adjuvant therapies
57922529|NCT02244996|DIETARY_SUPPLEMENT|Lycium Barbarum|Traditional Chinese Herbs
57922530|NCT02244996|DIETARY_SUPPLEMENT|Placebo|Placebo
58066057|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
58066058|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
58276346|NCT05619770|DRUG|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
57922531|NCT04792957|DIAGNOSTIC_TEST|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
57922532|NCT01115972|DRUG|ASP1585|oral
57922533|NCT01115972|DRUG|valsartan|oral
57922534|NCT02582125|DRUG|ONO-4538|
57922535|NCT00553423|DRUG|Lactulose|Lactulose 30 ml q6h for 48 hrs
57922536|NCT00553423|DRUG|Placebo|Placebo 30 ml q6hrly for 48 hrs
57922537|NCT00637923|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
58066059|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
58066060|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
58066061|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
58066062|NCT04047342|BEHAVIORAL|Welcome email|Email
58066063|NCT04047342|BEHAVIORAL|Loss frame|Email
58066064|NCT00153699|DRUG|Topiramate|
58066065|NCT00917553|DRUG|doxycycline monohydrate|50 mg
58066066|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
58066067|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
58066068|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
58276347|NCT02348554|BEHAVIORAL|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
58276348|NCT02348554|BEHAVIORAL|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
58490486|NCT03665727|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
58490487|NCT03665727|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
58490488|NCT03665727|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
58490489|NCT01214733|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
58490490|NCT01134705|DRUG|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
58490491|NCT01134705|DRUG|Placebo Nasal Aerosol|HFA Vehicle Aerosol
58490492|NCT05825352|DEVICE|Carmellose eye drops|Ocular drops based upon carmellose
58490493|NCT05296109|DIAGNOSTIC_TEST|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
58490494|NCT00553371|OTHER|biomarker analysis|
58066069|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
58066070|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
57725146|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
57725147|NCT05926297|PROCEDURE|Application NaOCl gel + HA gel|First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel
57725148|NCT05926297|PROCEDURE|Non-surgical mechanical debridement|Only mechanical debridement with curettes ans scaler tips
57725149|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
57725150|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
57725151|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
57725152|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
57725153|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
57725154|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
57725155|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
58066071|NCT01914042|DRUG|Morphine|
57725156|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
57725157|NCT00727857|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
57725158|NCT00727857|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
57922538|NCT00637923|DRUG|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
57922539|NCT00637923|BIOLOGICAL|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
57922540|NCT00637923|DRUG|Ribavirin|Weight-based ribavirin for 48 weeks.
57725159|NCT00727857|DRUG|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
57725160|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
57922541|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
57922542|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
57922543|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
57922544|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
58066072|NCT01914042|DRUG|Milnacipran|
57725161|NCT00278707|DRUG|GTA: Glyceryltriacetate|
57725162|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
57725163|NCT01231698|OTHER|control|standard treatment without strict heart rate control
57725164|NCT04211103|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
57725165|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
57725166|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
57725167|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
57922545|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
57922546|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
57922547|NCT05384262|DRUG|Rosuvastatin|Subjects will receive rosuvastatin orally.
57922548|NCT02388646|OTHER|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
57922549|NCT02388646|DEVICE|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
58490495|NCT00553371|PROCEDURE|computed tomography|
58490496|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
58490497|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
58490498|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
58490499|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
58490500|NCT06070961|DIAGNOSTIC_TEST|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
58490501|NCT06070961|DIAGNOSTIC_TEST|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
57922550|NCT02388646|OTHER|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
57922551|NCT05363462|DRUG|Vancomycin 1000 MG|Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
57922552|NCT06401460|OTHER|Yannianjiuzhuan method combined with reverse breathing training|"Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days."
57922553|NCT01941134|DRUG|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
57922554|NCT06058260|OTHER|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
57922555|NCT02802709|DEVICE|SB-061|delivered via intra-articular injection
58490502|NCT06070961|DIAGNOSTIC_TEST|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
57922556|NCT02802709|OTHER|Placebo|Placebo
58490503|NCT01620216|OTHER|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
58490504|NCT01620216|DRUG|Dasatinib|Given PO
58490505|NCT01620216|DRUG|Idelalisib|Given PO
58490506|NCT01620216|OTHER|Laboratory Biomarker Analysis|Correlative studies
58490507|NCT01620216|DRUG|Pacritinib|Given PO
57725168|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
58490508|NCT01620216|OTHER|Pharmacological Study|Correlative studies
58490509|NCT01620216|DRUG|Ponatinib|Given PO
58490510|NCT01620216|DRUG|Ponatinib Hydrochloride|Given PO
58490511|NCT01620216|DRUG|Ruxolitinib|Given PO
58490512|NCT01620216|DRUG|Sorafenib|Given PO
58490513|NCT01620216|DRUG|Sorafenib Tosylate|Given PO
58490514|NCT01620216|DRUG|Sunitinib|Given PO
58490515|NCT01620216|DRUG|Sunitinib Malate|Given PO
58490516|NCT00955916|DRUG|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
58490517|NCT00955916|DRUG|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
58490518|NCT06370403|OTHER|Cooling of the head and neck|Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects
58490519|NCT06370403|OTHER|Heating of the head and neck|Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
58490520|NCT03241719|DRUG|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
58490521|NCT02724748|BEHAVIORAL|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
58490522|NCT01867697|DRUG|Cetuximab|
58490523|NCT01867697|DRUG|Irinotecan|
58490524|NCT01867697|DRUG|Oxaliplatin|
58490525|NCT01867697|DRUG|Folinic Acid|
58490526|NCT01867697|DRUG|Calcium Carbonate|
58490527|NCT03699215|DRUG|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
58490528|NCT03699215|DRUG|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
58490529|NCT00578734|DRUG|Lucinactant|Slow intra-tracheal instillation
58490530|NCT00578734|OTHER|Sham Comparator|Slow intra-tracheal instillation
58490531|NCT02709382|DRUG|Cefepime and Tazobactam combination|
58490532|NCT02135913|DIETARY_SUPPLEMENT|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
58393376|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
58393377|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
57725169|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
57725170|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
57725171|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
57725172|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
57725173|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
57725174|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
57725175|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
57725176|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
57725177|NCT06475157|OTHER|No intervention|No intervention is applied.
57725178|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
57725179|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
57725180|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
57725181|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
57725182|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
57725183|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
57725184|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
57725185|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
57725186|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
57725187|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
57922557|NCT03849950|OTHER|SMARTCare|"1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~2. An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~3. An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~4. Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
57922558|NCT03849950|OTHER|Control|1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
58066073|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
57922559|NCT01937325|DRUG|ivacaftor|active arm
57922560|NCT01937325|DRUG|placebo|active arm
57922561|NCT01971203|DRUG|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
57922562|NCT01971203|BEHAVIORAL|CBT|16 weeks of treatment
58276349|NCT02895139|DEVICE|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
58393378|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
58276350|NCT02895139|DEVICE|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
58276351|NCT02895139|DEVICE|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
58276352|NCT04930653|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
57922563|NCT04181151|OTHER|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
58393379|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
58393380|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
57922564|NCT06200064|OTHER|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
58066074|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
58066075|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
58066076|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
58276353|NCT04930653|BIOLOGICAL|Mogamulizumab|Given IV
58276354|NCT04930653|OTHER|Quality-of-Life Assessment|Ancillary studies
58276355|NCT04930653|OTHER|Questionnaire Administration|Ancillary studies
58393381|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
58490533|NCT04870489|COMBINATION_PRODUCT|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
58066077|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
58276356|NCT05369494|OTHER|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
58276357|NCT06088368|PROCEDURE|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
58393382|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
58393383|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
58393384|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
58066078|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
58066079|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
57725188|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
58066080|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
58066081|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
58066082|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
58066083|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
58066084|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
58066085|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
58276358|NCT06088368|PROCEDURE|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
58276359|NCT01892878|PROCEDURE|VerteLoc|Single Arm
58276360|NCT03216655|OTHER|phone call|Investigators give a regular follow-up to participants: phone call monthly
58276361|NCT03216655|OTHER|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
58276362|NCT06118450|OTHER|Non-intervention|non-intervention
58276363|NCT05640388|OTHER|RV3278A - ET0943 cosmetic product|RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
58276364|NCT05640388|OTHER|RV4632A - RY1845 cosmetic product|RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
58276365|NCT05982808|PROCEDURE|CLIF correction|CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach
57725189|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
58276366|NCT05982808|PROCEDURE|conventional correction strategy|conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
58276367|NCT00003037|DRUG|cisplatin|
58066086|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
58066087|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
58276368|NCT00003037|DRUG|docetaxel|
58066088|NCT05870891|OTHER|Food|Food
58066089|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
58066090|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
58066091|NCT03497975|OTHER|Matching Placebo Tablets|Matching Tablets with no active substance
58276369|NCT00003037|DRUG|gemcitabine hydrochloride|
58276370|NCT00821015|DEVICE|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
58276371|NCT01028495|DRUG|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
58276372|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
58276373|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
58276374|NCT05162755|DRUG|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
58276375|NCT05162755|DRUG|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
58276376|NCT00856843|DRUG|BLI800|Solution for oral administration prior to colonoscopy
58276377|NCT00856843|DRUG|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
58276378|NCT05816759|DRUG|CKD-383|QD, PO
58276379|NCT05816759|DRUG|CKD-501, D744, D150|QD, PO
58066092|NCT03497975|DRUG|Nalbuphine ER Tablets|Open Label Extension
58066093|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
58066094|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
57725190|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
58066095|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
58276380|NCT02325921|DEVICE|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
58276381|NCT04965636|DRUG|Mepolizumab|Mepolizumab will be provided in pre-filled safety syringe
58276382|NCT02342977|DRUG|Placebo|Patients will randomly receive placebo
58276383|NCT02342977|DRUG|Lacosamide|Patients will randomly receive lacosamide
58276384|NCT00610233|PROCEDURE|deep brain stimulation ON|deep brain stimulation in the ON state
58276385|NCT00610233|PROCEDURE|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
58276386|NCT05805007|DRUG|ZVS203e|ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
58276387|NCT00890240|DRUG|JNJ-31001074|
58276388|NCT06444711|OTHER|NICE guidance|Patients will be assessed to determine whether their current treatment is in line with NICE guidelines. Changes will be made to their treatment plan in order for them to comply with NICE guidelines with the aim of reducing the number of serious adverse events in the group. They will be followed up until 6 months to identify improvements in their conditions
58276389|NCT04151966|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
58276390|NCT00699712|DRUG|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
58276391|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
58393385|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
58066096|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
57725191|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
57725192|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
58066097|NCT00139373|DRUG|donepezil|
58066098|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
58066099|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
58276392|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
57725193|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
57725194|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
57725195|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
57725196|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
57725197|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
58276393|NCT01349127|DIETARY_SUPPLEMENT|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
58276394|NCT00082459|BIOLOGICAL|autologous human tumor-derived HSPPC-96|
58276395|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
57725198|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
57725199|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
57725200|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
57725201|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
57725202|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
57725203|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
58276396|NCT01196936|DRUG|Placebo|1 tablet daily
58276397|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
58276398|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
58276399|NCT01196936|OTHER|pharmacological study|Correlative Studies
58276400|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
58276401|NCT01196936|GENETIC|protein expression analysis|correlative studies
58393386|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
58393387|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
58393388|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
58393389|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
58393390|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
58393391|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
58393392|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
58393393|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
58393394|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
58393395|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
58393396|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
58393397|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
58066100|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
58066101|NCT03377985|PROCEDURE|brachial plexus block|
58066102|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
58066103|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
58393398|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
58393399|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
58393400|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
58393401|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
57725204|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
57725205|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
58393402|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
58393403|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
57725206|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
57725207|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
58066104|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
58066105|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
58393404|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
58393405|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
58393406|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
58490534|NCT04870489|DEVICE|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
58066106|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
58066107|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
58066108|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
58066109|NCT03178591|DRUG|vildagliptin|
58066110|NCT03178591|DRUG|Dapagliflozin|
58066111|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
58066112|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
58066113|NCT01880320|DRUG|Topical Gel Vehicle|
58393407|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
58393408|NCT00488449|DRUG|GSK256073A tablets|
58393409|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
58393410|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
58393411|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
58393412|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
58393413|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
58393414|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
58393415|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
58393416|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
58393417|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
57725208|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
58066114|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
58393418|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
58393419|NCT03978598|DEVICE|Nexplanon|Implant.
58393420|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
58393421|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
57725209|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
57725210|NCT02905526|OTHER|Mobile phone app|Mobile phone app
57725211|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
57725212|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
57725213|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
57725214|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
57725215|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
57725216|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
57725217|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
57725218|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
57725219|NCT03065387|DRUG|Everolimus|Given PO
57725220|NCT03065387|DRUG|Neratinib|Given PO
57725221|NCT03065387|DRUG|Palbociclib|Given PO
58276402|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
58276403|NCT01196936|OTHER|questionnaire administration|Ancillary studies
58276404|NCT01196936|PROCEDURE|Fine needle aspiration|
58393422|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
58393423|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
58393424|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
58393425|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
58393426|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
58393427|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
58393428|NCT00000487|DRUG|antihypertensive agents|
57725222|NCT03065387|DRUG|Trametinib|Given PO
57725223|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
57725224|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
58393429|NCT00000487|BEHAVIORAL|smoking cessation|
58393430|NCT00000487|BEHAVIORAL|diet, fat-restricted|
58393431|NCT00000487|DRUG|diuretics|
58393432|NCT00311740|DRUG|Valsartan|
58393433|NCT00311740|DRUG|Hydrochlorothiazide|
58393434|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
57725225|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
57725226|NCT04920760|DIETARY_SUPPLEMENT|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children \> 1 or for infants of \< 1 year of age, respectively).
57725227|NCT03270761|OTHER||
57725228|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
57725229|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
57725230|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
58066115|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
58066116|NCT03962127|OTHER|no intervention|no intervention
58276405|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
58276406|NCT00237276|PROCEDURE|colonoscopy|
58276407|NCT06731257|OTHER|virtual ward early discharge|Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
58276408|NCT05131932|PROCEDURE|Endoscopic ablation of inlet patch|Endoscopic ablation of inlet patch using argon plasma coagulation (APC)
58276409|NCT02666638|OTHER|Control Volunteers|MRI on up to a 7T scanner without contrast.
57725231|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
57725232|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
57725233|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
57725234|NCT01229345|DRUG|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
57725235|NCT00501384|DRUG|satavaptan (SR121463B)|
57725236|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
57725237|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
57725238|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
57725239|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
57725240|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
57725241|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
58066117|NCT01183299|OTHER|Dietary salt intake|
58276410|NCT02666638|OTHER|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
58276411|NCT05698537|DIAGNOSTIC_TEST|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
57725242|NCT03841786|OTHER|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
58066118|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
58066119|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
58066120|NCT06292026|OTHER|standard of care|apply non adherent dressing
57725243|NCT03841786|OTHER|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
57725244|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
57725245|NCT02222220|DRUG|placebo|
57725246|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
57725247|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
57725248|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
57725249|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
57725250|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
57725251|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
57725252|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
57725253|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
58066121|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
58066122|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
58066123|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
57725254|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
57725255|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
57725256|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
57725257|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
57725258|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
57725259|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
57725260|NCT01659918|DRUG|Montelukast|
57725261|NCT01659918|DRUG|Singulair|
57725262|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
57725263|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
57725264|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
57725265|NCT05875324|DEVICE|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
57725266|NCT05875324|OTHER|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
57725267|NCT02326402|DEVICE|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
57725268|NCT04897516|DRUG|Short regimen of benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
58066124|NCT02536209|DRUG|MT-8554 low dose|
58066125|NCT02536209|DRUG|MT-8554 high dose|
58066126|NCT02536209|DRUG|Oxycodone hydrochloride|
58066127|NCT02536209|DRUG|Placebo|
58066128|NCT04252872|DRUG|HCP0605|
58066129|NCT04252872|DRUG|HGP1405|
58066130|NCT04252872|DRUG|HCP1401|
58066131|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
58066132|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
58066133|NCT00287976|DRUG|irinotecan hydrochloride|
58066134|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
58066135|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
58066136|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
58276412|NCT05698537|DIAGNOSTIC_TEST|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
57725269|NCT04897516|DRUG|Short treatment with benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
57725270|NCT04897516|DRUG|Standard treatment with benznidazole|Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
57725271|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
57725272|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
57725273|NCT02448303|DRUG|Pembrolizumab|
57725274|NCT02448303|DRUG|Acalabrutinib|
57725275|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
58066137|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
58276413|NCT05698537|DIAGNOSTIC_TEST|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
58276414|NCT05698537|OTHER|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
58276415|NCT05433272|BIOLOGICAL|Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain|The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
58276416|NCT05433272|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
58276417|NCT04617964|OTHER|Ultrasound|Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
58276418|NCT01815775|OTHER|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
57922565|NCT06200064|OTHER|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
57922566|NCT04255069|DRUG|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
58066138|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
57725276|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
57922567|NCT04255069|DRUG|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
57922568|NCT04255069|DRUG|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
57922569|NCT05467397|DRUG|[11C]acetate|Positron Emission Tomography (PET)
58066139|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
58066140|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
58066141|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
58066142|NCT01097057|DRUG|Carboplatin|Given IV
58066143|NCT01097057|DRUG|Etoposide|Given IV
58066144|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
58066145|NCT01097057|DRUG|Ifosfamide|Given IV
58066146|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
57922570|NCT02598817|OTHER|Standard Infant Formula|Standard Infant Formula containing High Sn-2
57922571|NCT00482508|DRUG|Omalizumab|
57922572|NCT00893646|BEHAVIORAL|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
58066147|NCT01097057|DRUG|Plerixafor|Given SC
58066148|NCT01097057|BIOLOGICAL|Rituximab|Given IV
57725277|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
58066149|NCT05133102|OTHER|Sample collection|Collection of saliva sample
57725278|NCT02136173|DEVICE|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
57725279|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
57922573|NCT04527120|OTHER|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
57922574|NCT03245970|DRUG|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
58066150|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
58066151|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
58066152|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
58066153|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
58066154|NCT06444724|PROCEDURE|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
57725280|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
57725281|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
57725282|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
57725283|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
57922575|NCT03245970|DRUG|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
57922576|NCT03245970|DRUG|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
57922577|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
57922578|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
58066155|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
58066156|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
58066157|NCT02180854|OTHER|Control group|
58066158|NCT02180854|OTHER|Increased monitoring frequency|
58066159|NCT01130831|DRUG|Lanthanum carbonate|
58066160|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
58066161|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
58066162|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
58066163|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
58066164|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
58066165|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
58276419|NCT04685928|DIAGNOSTIC_TEST|MRI and MRI-guided prostate biopsy|Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.
57922579|NCT00832637|DRUG|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
57922580|NCT00832637|DRUG|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
57922581|NCT00832637|DRUG|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
57922582|NCT02752321|DEVICE|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
57922583|NCT01155375|DRUG|Ferumoxytol|Experimental: Ferumoxytol
57922584|NCT01155375|DRUG|Oral Iron|Active Comparator: Oral iron
57922585|NCT04906447|BEHAVIORAL|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
57922586|NCT04906447|OTHER|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
57922587|NCT00294554|DRUG|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
57922588|NCT00294554|DRUG|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
57922589|NCT02497625|BEHAVIORAL|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
57922590|NCT02497625|BEHAVIORAL|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
57922591|NCT02497625|OTHER|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
57922592|NCT00003600|BIOLOGICAL|epoetin alfa|
57922593|NCT00003600|OTHER|placebo|
57922594|NCT03394430|DRUG|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
57922595|NCT03394430|DRUG|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
57922596|NCT03394430|DRUG|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
57922597|NCT03305354|BEHAVIORAL|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
58066166|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
58066167|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
58066168|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
58276420|NCT04685928|DIAGNOSTIC_TEST|TP-arm Systematic biopsy|Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
58276421|NCT01239524|PROCEDURE|denervation of thoracodorsal nerve or saving the nerve|
58276422|NCT05628857|DRUG|RC108|RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
58276423|NCT06504524|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
58276424|NCT06504524|DRUG|Standard of Care|control arm
58393435|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
57725284|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
57725285|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
57725286|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
57725287|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
57725288|NCT02450994|DRUG|Dexamethasone|
57725289|NCT02450994|DRUG|Placebo|
57922598|NCT03305354|BEHAVIORAL|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
57922599|NCT03267940|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
58276425|NCT00516802|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
58276426|NCT00516802|DRUG|dacarbazine|intravenous injection over at least 20 minutes
58276427|NCT05960149|DRUG|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
58276428|NCT05960149|PROCEDURE|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
58276429|NCT06281158|DRUG|[14C]-DNL343|Single dose
58276430|NCT00442481|DRUG|Escitalopram|
58276431|NCT00442481|PROCEDURE|A baseline overnight polysomnography (oPSG)|
58393436|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
58393437|NCT00002050|DRUG|Thymopentin|
58393438|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
57725290|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
57725291|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
57725292|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter _________~  * Type and duration of central venous catheter use~  * Indication of urinary catheter _________~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
57725293|NCT06087445|DEVICE|NeuroLife EMG-FES Sleeve System|Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
57725294|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
57725295|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
57725296|NCT01902017|DRUG|Ketotifen|5 mg PO bid
57725297|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
57725298|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
57725299|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
57725300|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
57725301|NCT06416215|OTHER|Psychological intervention based on WBT and cognitive restructuring|Participants will engage in 6 weekly group session of two hours. One part will be held by a trained dietician and will focus on nutritional education, particularly emphasizing the adoption of healthy and sustainable eating behaviors. The remaining part will be dedicated to a group psychological intervention inspired by the principles of Well-Being Therapy and will be held by a trained psychologist. During these sessions, participants will be introduced to the six dimensions of psychological well-being and will be gradually provided with cognitive-behavioral strategies to enhance psychological well-being and seek a balance between the presented dimensions. Participants will be given cognitive-behavioral tools to recognize justification cognitive mechanisms and replace them with more functional cognitions. These objectives will also be achieved through the use of a food diary to highlight emotions and thoughts experienced during food intake.
57922600|NCT03267940|DRUG|CIS|CIS will be administered as per the schedule specified in the respective arms.
58393439|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
58393440|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
58393441|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
58393442|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
58276432|NCT02772809|DEVICE|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
57725302|NCT06416215|OTHER|Basic Nutritional Intervention|Participants will receive treatment as usual (TAU) by participating in 6 weekly group sessions of two hours of a Basic Nutritional Intervention (BNI) held by a trained dietician. This course focuses on promoting healthier lifestyles through nutritional education, diet monitoring using a dedicated food diary, and recommendations for proper physical activity.
57725303|NCT04396951|DEVICE|Active external overheating with heating plate, Aragonia ® MTC 400|It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
57725304|NCT04396951|DEVICE|Active external overheating with air blanket, Equator Level 1® de Smiths Medical|Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
57725305|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
57725306|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
57725307|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
58276433|NCT01618461|BEHAVIORAL|Drug indication icons|Icons illustrate the purpose of each medication
58276434|NCT01618461|BEHAVIORAL|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
58276435|NCT04990271|DRUG|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0\~5 months
57725308|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
57725309|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
58276436|NCT03193034|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
58276437|NCT01230216|DRUG|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
58276438|NCT01230216|DRUG|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
58276439|NCT01827709|OTHER|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
58393443|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
58393444|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
58393445|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
58276440|NCT01827709|OTHER|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
57725310|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
57725311|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
57725312|NCT06266221|DRUG|Oral Placebo|Oral placebo
57725313|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
57725314|NCT06266221|DRUG|IV Placebo|IV placebo
57922601|NCT03267940|DRUG|GEM|GEM will be administered as per the schedule specified in the respective arms.
58276441|NCT01827709|OTHER|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
57922602|NCT03267940|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
57922603|NCT05429333|OTHER|Artificial intelligence-assisted personalized diet|"The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings."
57922604|NCT02308826|BEHAVIORAL|Turtle Program|
58066169|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
58066170|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
58276442|NCT01827709|OTHER|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
58393446|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
58393447|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
58393448|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
57725315|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
57922605|NCT02308826|BEHAVIORAL|Cool Little Kids|
57922606|NCT04308525|BEHAVIORAL|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
57922607|NCT04308525|BEHAVIORAL|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
58066171|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
58066172|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
57922608|NCT04308525|OTHER|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
57922609|NCT04308525|PROCEDURE|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
57922610|NCT04308525|PROCEDURE|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
57922611|NCT04308525|OTHER|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
57922612|NCT04308525|OTHER|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
57922613|NCT05062083|DRUG|11C-MC1|Up to 20 mCi injected IV followed by PET scanning
57922614|NCT05062083|DRUG|11C-PS13|Up to 20 mCi injected IV followed by PET Scanning
57922615|NCT05062083|DRUG|Ketoprofen|Ketoprofen 75 mg orally once
57922616|NCT05062083|DRUG|Celecoxib|celecoxib 600 mg orally once
57922617|NCT04221386|BEHAVIORAL|Melodic Intonation Therapy (MIT)|Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
57922618|NCT03411460|DEVICE|FreeStyle Libre™ system|Measured non-invasively via scanner
57922619|NCT03411460|PROCEDURE|Finger prick|Blood test
58066173|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
58066174|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
58066175|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
58393449|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
58490535|NCT00742261|DRUG|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
58066176|NCT00004024|BIOLOGICAL|aldesleukin|
57922620|NCT04612387|BEHAVIORAL|Mind-body therapy|Online yoga, meditation and nutrition tips.
58066177|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
58066178|NCT00004024|BIOLOGICAL|muromonab-CD3|
57922621|NCT04942093|DIETARY_SUPPLEMENT|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
57922622|NCT04942093|DIETARY_SUPPLEMENT|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
58066179|NCT00004024|BIOLOGICAL|sargramostim|
58066180|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
58066181|NCT00004024|PROCEDURE|surgical procedure|
58066182|NCT00004024|RADIATION|radiation therapy|
58066183|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
58066184|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
58066185|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
58066186|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
58066187|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
57922623|NCT02742623|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
57922624|NCT03956823|DRUG|telmisartan|Telmisartan group: telmisartan 80 mg once a day
57922625|NCT03956823|DRUG|amlodipine|amlodipine group: amlodipine 5 mg once a day
57922626|NCT04409886|BIOLOGICAL|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
57922627|NCT03077360|BEHAVIORAL|Lifestyle|Lifestyle changes to lose weight or become more fit
58066188|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
58066189|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
57922628|NCT03240757|DIETARY_SUPPLEMENT|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
57725316|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
57922629|NCT03240757|OTHER|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
57922630|NCT04532372|OTHER|Best Practice|Receive standard of care drugs
57922631|NCT04532372|DRUG|Leflunomide|Given PO
57922632|NCT04532372|DRUG|Placebo Administration|Given PO
57922633|NCT03442985|DRUG|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
57922634|NCT03442985|DRUG|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
57725317|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
57725318|NCT02005341|DEVICE|nanOSS|
57725319|NCT02005341|DEVICE|Autograft|
57725320|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
57725321|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
57922635|NCT03442985|OTHER|Placebo|Subjects received placebo, once daily, for up to 24 months.
57922636|NCT00286520|PROCEDURE|Transanal irrigation with Peristeen Anal Irrigation|
57922637|NCT05090215|BEHAVIORAL|Aerobic and resistance training 12 week exercise programme|See arm/group description
57922638|NCT05090215|DIAGNOSTIC_TEST|Venous blood sampling|full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
57922639|NCT05090215|DIAGNOSTIC_TEST|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
57922640|NCT05090215|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
57922641|NCT05090215|BEHAVIORAL|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
57922642|NCT02401360|DRUG|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
57922643|NCT02401360|DRUG|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
57922644|NCT02740972|DRUG|NS-065/NCNP-01|
57922645|NCT02740972|DRUG|Placebo|
57922646|NCT06312280|BEHAVIORAL|Mediterranean diet|The composition of the diet will be distributed as follows: 55-60% of carbohydrates (45-50% complex carbohydrates and no more than 10% of simple sugars), 25-30% of lipids and 15% of proteins. It will be studied in accordance with the LARN (Italian Society of Human Nutrition, 2014) guidelines.
57922647|NCT03136328|DRUG|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
57922648|NCT02688283|OTHER|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
57922649|NCT02271425|DRUG|Evacetrapib Tablet|Oral administration
57922650|NCT02271425|DRUG|Evacetrapib Intravenous|Intravenous administration
57922651|NCT00171704|DRUG|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
57725322|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
57725323|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
57725324|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
57725325|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
57922652|NCT00171704|DRUG|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
57922653|NCT01236651|DRUG|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
57922654|NCT01236651|DRUG|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
58276443|NCT01827709|OTHER|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
58066190|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
57725326|NCT02422277|DEVICE|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
57725327|NCT02422277|DRUG|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
57725328|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
57725329|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
57725330|NCT00648232|BEHAVIORAL|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
57922655|NCT02902627|DEVICE|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
57922656|NCT06503562|OTHER|central nervous system focused treatment program|Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery
57922657|NCT06503562|OTHER|Classical Physiotherapy|All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
57922658|NCT00551460|DRUG|arsenic trioxide|
57922659|NCT00551460|DRUG|gemtuzumab ozogamicin|
57922660|NCT00551460|DRUG|mercaptopurine|
57922661|NCT00551460|DRUG|methotrexate|
58066191|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
58066192|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
58066193|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
57725331|NCT00648232|BEHAVIORAL|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
57725332|NCT00648232|BEHAVIORAL|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
57725333|NCT00648232|BEHAVIORAL|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
57725334|NCT02861690|DRUG|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
57922662|NCT00551460|DRUG|tretinoin|
58066194|NCT02966912|OTHER|Open label (none)|
58066195|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
58276444|NCT00596999|PROCEDURE|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
57725335|NCT02861690|DRUG|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
57725336|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
58276445|NCT02303834|DEVICE|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
58276446|NCT01326000|DRUG|FOLFIRI|standard iv chemotherapy
58066196|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
58066197|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
58066198|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
58066199|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
58066200|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
58066201|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
58066202|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
58066203|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
58066204|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
58066205|NCT02134912|DRUG|crizotinib|Given PO
58066206|NCT02134912|DRUG|pemetrexed disodium|Given IV
58066207|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
58066208|NCT02134912|OTHER|pharmacological study|Correlative studies
58066209|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
58066210|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
58066211|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
58066212|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
58066213|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
58066214|NCT00312390|PROCEDURE|Flicker|
58276447|NCT01326000|DRUG|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
57922663|NCT00353379|DRUG|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
58066215|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
58066216|NCT00312390|PROCEDURE|Retinal Blood Flow|
58276448|NCT01326000|DRUG|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
58276449|NCT03171740|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
58276450|NCT03171740|DRUG|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
58276451|NCT03171740|DRUG|Oral saline|Oral saline, 0.25ml/kg
58276452|NCT03171740|DRUG|Nasal saline|Nasal saline 0.01ml/kg
58276453|NCT06730724|OTHER|No intervention|No intervention
58276454|NCT02094950|PROCEDURE|Acupuncture|
58276455|NCT04634032|GENETIC|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
58276456|NCT04634032|DIAGNOSTIC_TEST|Blood sampling|Peripheral blood sampling for SNP analysis
57922664|NCT00353379|DRUG|Placebo|Participants will take placebo for 6 weeks.
57922665|NCT01136772|DRUG|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
57922666|NCT01136772|DRUG|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
57922667|NCT04893954|DIAGNOSTIC_TEST|Full Spine Radiography|Full Spine Radiography
57922668|NCT04893954|DIAGNOSTIC_TEST|Lumbar spine MRI|Lumbar spine MRI
58066217|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
58066218|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
58066219|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
58066220|NCT00041119|DRUG|AC regimen|Given IV
58066221|NCT00041119|DRUG|cyclophosphamide|Given IV
58066222|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
58066223|NCT00041119|DRUG|paclitaxel|Given IV
58066224|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
58066225|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
58066226|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
58066227|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
58066228|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
58066229|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
57922669|NCT04615247|OTHER|Yoga Program|The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.
57922670|NCT04615247|OTHER|Physical Conditioning Program|The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
57922671|NCT04127149|DIAGNOSTIC_TEST|Ultrasound scan|The group uses an ultrasound device for the consultation.
57922672|NCT02586922|DEVICE|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
57922673|NCT04367987|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
57922674|NCT06406556|COMBINATION_PRODUCT|Pegaspargase combined with concurrent radiotherapy.|Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.
58066230|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
58066231|NCT03520842|DRUG|Methotrexate|Given PO
58066232|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
58066233|NCT03520842|DRUG|Regorafenib|Given PO
58066234|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
58066235|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
58066236|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
58066237|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
58066238|NCT01393561|DRUG|Group 2|Placebo
57922675|NCT00050388|GENETIC|Allovectin-7®|
57922676|NCT01919710|DRUG|rHSA/GCSF|for treatment of neutropenia
58066239|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
58066240|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
58066241|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
58066242|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
58066243|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
58066244|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
58276457|NCT03726736|DRUG|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
58276458|NCT03726736|DRUG|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
57922677|NCT00086034|DRUG|Motexafin gadolinium|
57922678|NCT00822588|DEVICE|Sangvia® System|Sangvia® Intra- and Post-op System
57922679|NCT00184821|PROCEDURE|Ischemic preconditioning|
57922680|NCT00184821|PROCEDURE|Forearm ischemic exercise|
57922681|NCT00184821|PROCEDURE|Annexin A5 scintigraphy|
57922682|NCT00184821|DRUG|Diazoxide|
57922683|NCT00184821|DRUG|glibenclamide|
57922684|NCT00184821|DRUG|adenosine|
57922685|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
57922686|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
57922687|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
58276459|NCT04481165|OTHER|Survey|Oral interview and written questions
58276460|NCT04283526|DRUG|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
58276461|NCT04283526|DRUG|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
58276462|NCT04283526|DRUG|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
58276463|NCT04283526|DRUG|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
58066245|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
58276464|NCT01601002|DRUG|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
58276465|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
58276466|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
58276467|NCT03333408|DRUG|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
58276468|NCT03752060|BEHAVIORAL|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
58276469|NCT03752060|BEHAVIORAL|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
57922688|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
57922689|NCT01074671|DEVICE|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
57922690|NCT01177787|DEVICE|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
57922691|NCT01177787|DEVICE|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
57922692|NCT04777526|OTHER|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
57922693|NCT04777526|OTHER|Joint protection program|Reeducation in the activities daily life
57922694|NCT04777526|OTHER|Thumb orthosis|Thumb night orthosis
58276470|NCT04483284|DRUG|TACE combined with Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
58276471|NCT04483284|PROCEDURE|TACE plus Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
58276472|NCT06143787|DRUG|Tranexamic acid|7 days Oral rinsing following tooth extraction
57922695|NCT04777526|OTHER|Manual distraction|Manual distraction of CMC joint
57922696|NCT00649090|DRUG|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
57922697|NCT03225495|PROCEDURE|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
58276473|NCT03623659|PROCEDURE|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
57922698|NCT03225495|PROCEDURE|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
57922699|NCT06411483|DEVICE|ObeEnd Band|The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
57922700|NCT06411483|OTHER|Placebo|The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
57922701|NCT02732054|BIOLOGICAL|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
57922702|NCT01243697|DRUG|desogestrel|Tablets of 75 µg, once daily during 112 days
57922703|NCT04598204|DRUG|Treatment with oral rapmycin|To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
57922704|NCT05031208|DIAGNOSTIC_TEST|Memory task|Word recognition task
57922705|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
57922706|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
57922707|NCT04888325|OTHER|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
57922708|NCT04888325|OTHER|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
57922709|NCT01762722|DEVICE|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
57922710|NCT02455219|DEVICE|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
57922711|NCT00815672|BEHAVIORAL|Exercise|Progressive walking and resistance exercise treatment
58276474|NCT00554541|OTHER|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
58276475|NCT06449508|DRUG|Probiotic Formula|drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
58276476|NCT00315042|DRUG|Telithromycin (HMR3647)|
58276477|NCT00315042|DRUG|Penicillin|
58276478|NCT04148898|DRUG|Osimertinib|Treatment of LM With osimertinb
58276479|NCT04148898|DRUG|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
58276480|NCT02647489|BIOLOGICAL|PAMVAC|
58393450|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
58393451|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
58393452|NCT04956640|DRUG|LY3537982|Oral
58393453|NCT04956640|DRUG|Pembrolizumab|Intravenous
57725337|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
58066246|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
58066247|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
58276481|NCT02647489|BIOLOGICAL|Alhydrogel|
58393454|NCT04956640|DRUG|Cetuximab|Intravenous
58393455|NCT04956640|DRUG|Pemetrexed|Intravenous
58066248|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
58276482|NCT02647489|BIOLOGICAL|GLA-SE|
58276483|NCT02647489|BIOLOGICAL|GLA-LSQ|
58276484|NCT02647489|OTHER|Placebo|
58276485|NCT03885999|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
58393456|NCT04956640|DRUG|Cisplatin|Intravenous
58393457|NCT04956640|DRUG|Carboplatin|Intravenous
58393458|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
58393459|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
58393460|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
58393461|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
58393462|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
58393463|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
58393464|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
57725338|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
57725339|NCT05961202|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg qd
57725340|NCT05961202|DRUG|Prednisolone|Prednisolone 20mg qd
57725341|NCT06432712|DRUG|Dexamethasone 4mg|2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
57725342|NCT03086447|DEVICE|Investigational Contact Lens|Senofilcon C Toric
57725343|NCT03086447|DEVICE|Marketed Contact Lens|Air Optix for Astigmatism
57922712|NCT02917278|DIETARY_SUPPLEMENT|Meals|High Protein renal-specific meals
58276486|NCT02998359|DEVICE|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
58276487|NCT02998359|DEVICE|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
58276488|NCT06230952|OTHER|BASDAI and BASFI reliability|The study will be carried out on volunteer patients who are diagnosed with axial spondyloarthritis and are followed up in the outpatient clinic of Dokuz Eylül University, Department of Internal Medicine, Rheumatology and Immunology Department, and who meet the inclusion criteria. Patients who volunteer to participate in the study will be contacted by phone and BASDAI and BASFI questionaires will be administered.
58276489|NCT02860390|OTHER|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
58276490|NCT02860390|OTHER|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
58066249|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
58066250|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
58066251|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
58276491|NCT05507502|BIOLOGICAL|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
58276492|NCT02941354|DRUG|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
57922713|NCT03797079|PROCEDURE|ESP block|A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
58276493|NCT04093557|OTHER|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
57922714|NCT03797079|PROCEDURE|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
57922715|NCT03797079|DEVICE|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
57922716|NCT03797079|DRUG|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
58066252|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
58066253|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
58276494|NCT04093557|OTHER|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
58276495|NCT02802644|DRUG|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
58276496|NCT02802644|DRUG|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
58276497|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
58066254|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
58066255|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
58276498|NCT00466206|DEVICE|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
58276499|NCT00466206|DEVICE|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
58276500|NCT00466206|PROCEDURE|3MP (Magnetic Mini-Mover Procedure)|"* Subject has EKG performed to measure baseline cardiac activity.~* Magnimplant is implanted.~* After one week, Magnatract is fitted.~* Chest x-ray and 2nd EKG performed 30 days post-implantation.~* Patient and parents complete QoL questionnaire 30d post-implantation.~* Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~* At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~* At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~* Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~* CT scan and third EKG performed after explanation.~* Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
58393465|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
58393466|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
58066256|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
58066257|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
58066258|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
58066259|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
58066260|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
58066261|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58066262|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
58066263|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
58276501|NCT04255407|DEVICE|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
58276502|NCT04255407|DRUG|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
57725344|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
57725345|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
57725346|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
58066264|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
58276503|NCT00268684|DRUG|Erlotinib, Temozolomide|
58276504|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
58276505|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
58276506|NCT03366961|PROCEDURE|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
58276507|NCT02414802|DEVICE|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
58276508|NCT02414802|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
58276509|NCT02414802|DRUG|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
57725347|NCT03200392|DEVICE|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
57725348|NCT03200392|DEVICE|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
57725349|NCT03200392|PROCEDURE|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
58066265|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
58066266|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
58066267|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
58276510|NCT02414802|DRUG|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
58276511|NCT03889938|DIAGNOSTIC_TEST|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
58276512|NCT01196663|DEVICE|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
58393467|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
58393468|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
58393469|NCT05397041|DRUG|Placebo|Matched Placebo
57725350|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
57725351|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
57725352|NCT04563858|DIAGNOSTIC_TEST|Validation|Assessment of Polish version of the 4AT
57725353|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
57725354|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
57725355|NCT01053026|DRUG|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
57725356|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
57725357|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
57725358|NCT03022357|RADIATION|DATScan|In small subgroup
57725359|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
57725360|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
58276513|NCT01196663|DEVICE|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
58276514|NCT01589809|DRUG|nicotinamide|dose-escalation, 2-8 grams, oral
58276515|NCT01072981|BIOLOGICAL|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
58276516|NCT01072981|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
58393470|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
58393471|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
58393472|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
57725361|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
57725362|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
57725363|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
57725364|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
57725365|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
57725366|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
57725367|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5mL) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
57725368|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
57725369|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
57725370|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
58066268|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
58276517|NCT01072981|RADIATION|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
58276518|NCT01399476|PROCEDURE|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
58276519|NCT01399476|PROCEDURE|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
58393473|NCT00434447|DRUG|Zoledronic acid|
58393474|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
58393475|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
58393476|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
58393477|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
58393478|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
57725371|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
57725372|NCT05819749|BEHAVIORAL|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
58066269|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
58066270|NCT02020811|DEVICE|Sentinel|
58066271|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
58066272|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
58066273|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
58276520|NCT01620333|DRUG|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
58276521|NCT01620333|DRUG|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
58276522|NCT04275102|OTHER|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
58276523|NCT03129113|DRUG|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
58276524|NCT03129113|DRUG|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
58276525|NCT02716506|PROCEDURE|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
58276526|NCT05565352|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
58276527|NCT02179476|DEVICE|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
58276528|NCT05988333|OTHER|Psychoeducational Family Intervention|Supportive intervention administered to families with a member affected by MDD
58276529|NCT05988333|OTHER|Informative intervention|Informative intervention administered to families with a member affected by MDD
58276530|NCT04339309|PROCEDURE|Non-surgical periodontal treatment with interdental hygiene devices|
58276531|NCT04339309|PROCEDURE|Non-surgical periodontal treatment without interdental hygiene devices|
58276532|NCT03402672|OTHER|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
58393479|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
58066274|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
58066275|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
58066276|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
58066277|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
58066278|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
58276533|NCT00085098|BIOLOGICAL|filgrastim|Given by infusion or injection
58276534|NCT00085098|DRUG|carboplatin|Given IV over 1 hour
58276535|NCT00085098|DRUG|cisplatin|Given IV over 6 hours
58276536|NCT00085098|DRUG|cyclophosphamide|Given IV over 1 hour
58276537|NCT00085098|DRUG|etoposide|Given IV over 2 hours
58276538|NCT00085098|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week
58276539|NCT01142765|BIOLOGICAL|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
58393480|NCT00151684|DRUG|Diazoxide|
58276540|NCT01142765|BIOLOGICAL|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
58276541|NCT01142765|BIOLOGICAL|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
58276542|NCT01142765|BIOLOGICAL|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
57725373|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
57725374|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
57725375|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
57725376|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
57725377|NCT01255358|DRUG|Dexamethasone|"Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)"
57725378|NCT02199457|DEVICE|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
58393481|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
58393482|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
57725379|NCT02199457|DEVICE|SVSS and reference devices|Body temperature taken with infrared thermometer
57725380|NCT02199457|DEVICE|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
58276543|NCT01142765|BIOLOGICAL|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
58393483|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
58393484|NCT05359276|DRUG|Olipudase alfa|GZ402665
58393485|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
58393486|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
58393487|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
58393488|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
58393489|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
57725381|NCT02199457|DEVICE|SVSS and reference devices|Measurement of respiration rate
57725382|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
58393490|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
58393491|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
58393492|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
58393493|NCT06215859|DRUG|MR-107A-02|tablet
57725383|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
58066279|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
58066280|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
58066281|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
58066282|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
57725384|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
57725385|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
57725386|NCT05772767|OTHER|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
57922717|NCT02782130|BEHAVIORAL|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
57922718|NCT02782130|BEHAVIORAL|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
57922719|NCT01679353|DRUG|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
57922720|NCT01679353|DRUG|normal saline 0.5ml|
58066283|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
57922721|NCT05090553|PROCEDURE|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
57922722|NCT05090553|BIOLOGICAL|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
57922723|NCT05090553|GENETIC|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
57922724|NCT05090553|GENETIC|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
57922725|NCT03311542|BIOLOGICAL|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
57922726|NCT00454389|DEVICE|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
57922727|NCT00454389|DRUG|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
57922728|NCT03181750|BEHAVIORAL|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
57922729|NCT02047292|DEVICE|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
57922730|NCT02047292|DEVICE|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
57922731|NCT02047292|DEVICE|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
58276544|NCT04904783|RADIATION|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
58276545|NCT04554758|PROCEDURE|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
58393494|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
57922732|NCT01008215|OTHER|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
57922733|NCT05578144|OTHER|Patients Decision Aids (PDA)|Patient Decision Aids (PDA) administer to case group
57725387|NCT05772767|DIAGNOSTIC_TEST|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
57922734|NCT00214838|DRUG|Atiprimod|
58066284|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
58393495|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
57725388|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
58276546|NCT04554758|PROCEDURE|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
58393496|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
58276547|NCT03943823|DRUG|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
58276548|NCT03943823|DRUG|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
58393497|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
58393498|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
58393499|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
57725389|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
57922735|NCT02931799|BEHAVIORAL|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
57922736|NCT02931799|OTHER|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~* PRO-2 Scale for patients with Crohn's Disease~* 6-Point Mayo Score for patients with Ulcerative Colitis~* Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
58393500|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
58393501|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
57725390|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
57725391|NCT00006060|DRUG|standard gadolinium contrast|
57922737|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
57922738|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
58276549|NCT03920423|PROCEDURE|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
58276550|NCT02911259|DEVICE|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
58276551|NCT02911259|DEVICE|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
58276552|NCT00002525|DRUG|fluorouracil|"Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5"
58276553|NCT00002525|DRUG|leucovorin calcium|given after surgery at dose of 20mg/m\^2 IV push on days 1-5
58393502|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
58393503|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
58393504|NCT00392158|DEVICE|Closed-loop anesthesia system|
58393505|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
58393506|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
58393507|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
58393508|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
57725392|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
57725393|NCT02243787|DRUG|COVA322|
57725394|NCT02243787|OTHER|Placebo|
57725395|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
58393509|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
58066285|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
58066286|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
58066287|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
58393510|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
58066288|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
58066289|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
58066290|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
58066291|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
58393511|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
58393512|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
57922739|NCT02931799|OTHER|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
57922740|NCT02225353|DRUG|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
58066292|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
58066293|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
58066294|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
58066295|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
58066296|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
58066297|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
58066298|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
58066299|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
58066300|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
58066301|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
58276554|NCT03489902|PROCEDURE|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
57725396|NCT02288429|DRUG|colistimethate sodium|
57725397|NCT04896957|BEHAVIORAL|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
57922741|NCT02225353|DRUG|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
57922742|NCT02225353|DRUG|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
57922743|NCT04557111|DEVICE|remote monitoring|CIED monitoiring with remote monitoring device
57922744|NCT03911011|OTHER|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
57922745|NCT03607539|DRUG|Sintilimab|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
57922746|NCT03607539|DRUG|Pemetrexed|500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
57922747|NCT03607539|DRUG|Platinum|Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
58066302|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
58066303|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
58066304|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
58066305|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
58066306|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
58066307|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
58276555|NCT03489902|PROCEDURE|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
58276556|NCT00513266|BIOLOGICAL|bevacizumab|
58276557|NCT00513266|BIOLOGICAL|cetuximab|
58276558|NCT00513266|DRUG|fluorouracil|
58276559|NCT00513266|DRUG|irinotecan hydrochloride|
58276560|NCT00513266|DRUG|leucovorin calcium|
58276561|NCT00513266|DRUG|oxaliplatin|
58276562|NCT00513266|OTHER|laboratory biomarker analysis|
58066308|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
57725398|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
57725399|NCT00210834|DRUG|epoetin alfa|
57922748|NCT03607539|DRUG|Placebos|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
57922749|NCT02230553|DRUG|Lapatinib|
57922750|NCT02230553|DRUG|trametinib|
57922751|NCT02805608|DRUG|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
57922752|NCT02805608|DRUG|Injection of 18F-FDG|One injection intravenously of 18F-FDG
57922753|NCT02805608|DEVICE|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
57922754|NCT02805608|DEVICE|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
57922755|NCT00461838|PROCEDURE|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
57922756|NCT00461838|OTHER|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
57922757|NCT02844881|DRUG|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
58066309|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
58066310|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
58276563|NCT00513266|PROCEDURE|adjuvant therapy|
58276564|NCT00513266|PROCEDURE|biopsy|
58276565|NCT00513266|PROCEDURE|conventional surgery|
58276566|NCT00513266|PROCEDURE|neoadjuvant therapy|
58276567|NCT01225289|DIETARY_SUPPLEMENT|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
58276568|NCT01225289|DRUG|Placebo|1 capsule per day for six months
58276569|NCT06025994|OTHER|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
58276570|NCT02717442|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
58276571|NCT02717442|DRUG|Placebo|Single intratympanic injection of placebo
58276572|NCT01308632|DRUG|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
57922758|NCT02844881|BIOLOGICAL|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
57725400|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
57922759|NCT03969550|OTHER|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
58066311|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
58066312|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
58066313|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
58066314|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
58276573|NCT05241275|DRUG|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
58276574|NCT03208608|DIAGNOSTIC_TEST|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
58276575|NCT04555499|OTHER|Standardized neurological examination|
58276576|NCT01403259|DRUG|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
58393513|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
57725401|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
57922760|NCT01541553|PROCEDURE|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
58276577|NCT02094248|DRUG|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
57922761|NCT01541553|DRUG|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
57922762|NCT01541553|DRUG|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
57922763|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
57922764|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
57922765|NCT00751842|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
57922766|NCT03445351|OTHER|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
57922767|NCT01829399|DRUG|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
58276578|NCT02094248|DRUG|control|Normal saline，1ml/day, s.c injection
58276579|NCT01683877|PROCEDURE|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
57922768|NCT01829399|DRUG|Normal Saline|
58276580|NCT01683877|PROCEDURE|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
58276581|NCT06215794|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
57725402|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
57725403|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
57922769|NCT00001984|DRUG|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
57922770|NCT02453360|PROCEDURE|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
57922771|NCT02453360|DRUG|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
58276582|NCT06215794|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
58276583|NCT04966078|PROCEDURE|liposuction|suction-assisted liposuction
58276584|NCT04966078|PROCEDURE|surgical excision|periareolar surgical excision
58276585|NCT04886362|DRUG|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
58276586|NCT04886362|DRUG|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
57725404|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
57725405|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
57725406|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
57725407|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
57922772|NCT06370468|OTHER|Epidemiological investigation|Epidemiological investigation
57922773|NCT05604638|DRUG|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
57922774|NCT05604638|DRUG|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
57922775|NCT03867058|BEHAVIORAL|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
57922776|NCT00675805|DEVICE|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
57922777|NCT00675805|DEVICE|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
57922778|NCT05912582|RADIATION|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
58276587|NCT04631107|DRUG|AD109 dose1- A|Oral administration at bedtime
58276588|NCT04631107|DRUG|AD109 dose2- B|Oral administration at bedtime
58066315|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
58066316|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
57922779|NCT05545657|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
58066317|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
58066318|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
58066319|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58276589|NCT04631107|DRUG|Placebo- C|Oral administration at bedtime
57922780|NCT05545657|OTHER|Simultaneous EEG-fMRI scan|EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.
57922781|NCT05545657|OTHER|Multimodal magnetic resonance imaging|3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.
57922782|NCT05545657|OTHER|Peripheral blood neuropathology biomarkers assay|Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
57922783|NCT06385405|DEVICE|Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment|The target site for alpha frequency Transcranial Magnetic Stimulation (αTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
58276590|NCT04562220|OTHER|Routine conventional physical therapy plus Vibration session|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
58276591|NCT04562220|OTHER|Routine conventional physical therapy|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
58276592|NCT04565483|DRUG|Benralizumab Prefilled Syringe|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
58276593|NCT05765825|DRUG|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
58276594|NCT05765825|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
58276595|NCT05765825|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
58276596|NCT05765825|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
58276597|NCT05765825|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
58276598|NCT01259674|DEVICE|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
58276599|NCT01259674|OTHER|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
57922784|NCT06385405|DEVICE|10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)|Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.
57922785|NCT05937139|OTHER|Breastfeeding education|Breastfeeding education will be given to fathers.
57922786|NCT01386281|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
57922787|NCT03416998|OTHER|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
57922788|NCT06502431|OTHER|phase contrast sequences|patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.
57922789|NCT01326533|DRUG|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
57922790|NCT01326533|OTHER|Placebo|Thirteen weeks of oral placebo provided as capsules
57922791|NCT05741151|DIAGNOSTIC_TEST|PET-Neck Parkinsonian patients|Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
57922792|NCT05566314|DIETARY_SUPPLEMENT|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
57922793|NCT05566314|OTHER|Placebo|12 oz. flavored beverage
57922794|NCT04196608|DRUG|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
57922795|NCT04196608|DRUG|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
57922796|NCT03559998|OTHER|lecture|"* Empathy (1 hour)~* Doctor- patient relationship (1, 5 hour)"
57922797|NCT03559998|OTHER|Simulation using Role play|"* serious illness announcement~* abuse demand management~* reticent patient management"
57922798|NCT03559998|OTHER|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
57922799|NCT03559998|OTHER|Simulation using Simulated patient|"* HIV announcement~* Refuse of antibiotic prescription"
58066320|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
57922800|NCT03294109|DRUG|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
58066321|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
58066322|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
58066323|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
58276600|NCT01532206|OTHER|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
57922801|NCT04768257|BEHAVIORAL|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
57922802|NCT02100397|BIOLOGICAL|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
57922803|NCT04237766|OTHER|Experimental group|"The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively)."
58066324|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
58066325|NCT01611558|BIOLOGICAL|Ipilimumab|
58276601|NCT03503734|BEHAVIORAL|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
58066326|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
58276602|NCT01065714|DRUG|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
58276603|NCT01065714|DRUG|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
58276604|NCT00513890|DEVICE|Infantflow [EME, Brighton, England]|
58276605|NCT01010009|DIETARY_SUPPLEMENT|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
58276606|NCT01010009|OTHER|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
58393514|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58393515|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
58393516|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
57725408|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
57725409|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
57725410|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
57725411|NCT00616967|DRUG|carboplatin|Given IV
57725412|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
57725413|NCT00616967|DRUG|vorinostat|Given orally
58066327|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
58066328|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
58066329|NCT02189239|DRUG|Placebo|
58066330|NCT02189239|OTHER|No Treatment|
57922804|NCT05446688|DRUG|6MW3211|6MW3211 injection, 45mg/kg, Q2W
57922805|NCT01794923|DRUG|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
58066331|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
58066332|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
58066333|NCT00189059|DRUG|amitriptyline|
57922806|NCT01794923|DRUG|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
57922807|NCT01794923|DRUG|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
57922808|NCT01794923|DRUG|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
57922809|NCT00169520|DRUG|docetaxel|
57922810|NCT00169520|DRUG|SB-715992|
57922811|NCT00712309|DEVICE|Lifestent|Stent for endovascular treatment of popliteal artery lesions
58066334|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
58066335|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
58276607|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
57922812|NCT00712309|DEVICE|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
57922813|NCT02359877|DRUG|BCD-054|
58066336|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
58066337|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
58276608|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
57922814|NCT02359877|DRUG|Rebif|
57922815|NCT02359877|DRUG|Avonex|
58066338|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
58276609|NCT05145608|DRUG|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
58276610|NCT02474355|PROCEDURE|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
58276611|NCT02474355|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
58276612|NCT02474355|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
57922816|NCT02623881|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
58276613|NCT02474355|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
57922817|NCT02623881|DRUG|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
57922818|NCT00542529|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
57922819|NCT05213910|DIETARY_SUPPLEMENT|Lactichoc|dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days
57922820|NCT05213910|OTHER|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
57922821|NCT01349725|DRUG|ARRY-502|Oral; multiple dose, escalating
57922822|NCT01349725|DRUG|Placebo|Oral; matching placebo
57922823|NCT05420883|OTHER|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
57922824|NCT05420883|OTHER|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
57922825|NCT05420883|OTHER|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
58276614|NCT02474355|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
58393517|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
58393518|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
58276615|NCT06730594|DIETARY_SUPPLEMENT|VL-BK-02 (25 billion CFU/Capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
58276616|NCT06730594|DIETARY_SUPPLEMENT|Placebo (Microcrystalline Cellulose - 375 mg/capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
58393519|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
58393520|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
57725414|NCT00616967|OTHER|placebo|Given orally
57725415|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
57725416|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
57725417|NCT02322944|BEHAVIORAL|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
57922826|NCT05617651|DRUG|IY-NT-T|Ilaprazole 20mg
57922827|NCT05617651|DRUG|IY-NT-R|Ilaprazole 10mg
57922828|NCT00427336|DRUG|Fludarabine|30 mg/m\^2 by vein daily over 30 minutes
58066339|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
58276617|NCT05458440|OTHER|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
58276618|NCT05067894|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
58276619|NCT05067894|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
58276620|NCT01022164|PROCEDURE|fibrin glue|
58276621|NCT05636982|OTHER|Telecare-based intervention program|A 3-month telecare-based intervention program
58393521|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
58393522|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
58393523|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
58393524|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
58393525|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
58393526|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
57922829|NCT00427336|DRUG|Cyclophosphamide|300 mg/m\^2 by vein daily over 2 hours
57922830|NCT00427336|DRUG|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
57922831|NCT00388453|DEVICE|Dx-pH Probe|24 hour ph monitoring
57922832|NCT00388453|PROCEDURE|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
57922833|NCT03708822|DRUG|Docetaxel and Cisplatin and Nimotuzumab|Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
58276622|NCT05345756|DEVICE|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
58276623|NCT05345756|DEVICE|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
58276624|NCT01301885|PROCEDURE|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
58276625|NCT00369161|DRUG|Everolimus (RAD001)|
58276626|NCT00369161|DRUG|Tacrolimus|
58276627|NCT00369161|DRUG|Basiliximab|
58276628|NCT00369161|DRUG|Corticosteroids|
58276629|NCT06355856|DRUG|DNN.22.17.036|Apply twice daily to the affected area and around it.
58276630|NCT06355856|DRUG|10573048700|Apply twice daily to the affected area and around it.
58276631|NCT02626650|OTHER|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
58276632|NCT05470855|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
58393527|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
58393528|NCT02709551|BEHAVIORAL|HRV_Bfb|
58276633|NCT00895570|DRUG|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
58276634|NCT00895570|DRUG|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
58276635|NCT01085084|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
58276636|NCT01085084|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
58276637|NCT04224220|OTHER|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
58276638|NCT04224220|OTHER|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
57725418|NCT02322944|BEHAVIORAL|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
57922834|NCT04123834|PROCEDURE|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
57922835|NCT04123834|PROCEDURE|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
57922836|NCT04123834|DEVICE|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
58276639|NCT06169956|DRUG|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
58276640|NCT01689233|DRUG|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
58276641|NCT01689233|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
58276642|NCT02859688|GENETIC|pyrosequencing|
58276643|NCT02859688|GENETIC|Methylome|
58276644|NCT00201617|DEVICE|Bone-anchored hearing aid|
58276645|NCT06405659|OTHER|correction for pedicle fixation|The patient was diagnosed with idiopathic scoliosis and underwent a posterior idiopathic scoliosis procedure and correction for pedicle fixation.
58276646|NCT00596726|DEVICE|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
58276647|NCT04395313|OTHER|no intervention carried out|no intervention was done
58393529|NCT02709551|BEHAVIORAL|MBI|
58393530|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
58393531|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
58393532|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
58393533|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
58393534|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
58393535|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
58393536|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
58306657|NCT01551667|BIOLOGICAL|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
57725579|NCT06341218|OTHER|Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management|"The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed."
58393720|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
57725580|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
57725581|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
57725582|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
58306658|NCT01551667|BIOLOGICAL|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
58306659|NCT06492083|OTHER|traditional Chinese medicine hot bag|traditional Chinese medicine hot bag
58306660|NCT01107548|OTHER|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
58306661|NCT00266708|DRUG|Risedronate|risedronate 35 mg weekly
58306662|NCT00266708|DRUG|Placebo|Risedronate Placebo 35 mg weekly
58393721|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by healthy family instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes low-sodium diet, weight management, physical exercise, BP monitoring and antihypertensive treatment."
57725583|NCT06057012|DRUG|BRII-296|2 intramuscular injections 300 mg each of BRII-296 admixed with Depo Medrol 40 mg/mL per injection, will be administered in participants with PPD.
57725584|NCT00054535|BIOLOGICAL|aldesleukin|
57725585|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
57725586|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
57950999|NCT04506008|RADIATION|Moderately-Hypo-fractionation Radiotherapy|15 fractions of pre-operative radiation
57951000|NCT05040594|DEVICE|PavéDerm J-Fill Soft Dermal Filler|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
58066628|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
58066629|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
58066630|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
58393722|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
58393723|NCT00203866|DRUG|G250 peptide|
58066631|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
58066632|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
58066633|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
57725587|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
57725588|NCT01046643|DRUG|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
57951001|NCT05040594|DEVICE|Restylane® Lyft Lidocaine|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
58066634|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
58066635|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
58276790|NCT05206786|OTHER|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~1. Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~2. Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~3. Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~4. Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
58306663|NCT03377465|DIAGNOSTIC_TEST|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
58393724|NCT00203866|DRUG|IL-2|
58393725|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
58393726|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
58066636|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
58066637|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
58393727|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
58393728|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
58422680|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
58393729|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
58393730|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
58393731|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
58393732|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
58393733|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
58393734|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
58393735|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
58393736|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
58393737|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
58393738|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
58393739|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
58393740|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
58393741|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
58393742|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
58393743|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
58393744|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
58393745|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
58393746|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
58393747|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
58393748|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
58393749|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
58276791|NCT05194852|PROCEDURE|ultrasound-guided posterior hydrodilatation|Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
58393750|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
58393751|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
58393752|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
58393753|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
58393754|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
58393755|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
58393756|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
58276792|NCT05194852|DRUG|corticosteroid, saline, and local anesthetic|corticosteroid, saline, and local anesthetic
58066638|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
58393757|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
58393758|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
58393759|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
58393760|NCT02569476|DRUG|Zanubrutinib|
58393761|NCT02569476|DRUG|Obinutuzumab|
58393762|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
58393763|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
58393764|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
58393765|NCT00332384|DRUG|brimonidine/timolol fixed combination|
58393766|NCT05627232|DRUG|Tazemetostat|Given PO
58393767|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
58393768|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
58393769|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58393770|NCT05627232|DRUG|Palbociclib|Given PO
58393771|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
58393772|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
58393773|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
58393774|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
58393775|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
58393776|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
58393777|NCT03302884|OTHER|biological sampling|Tumor and blood samples
58393778|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
58393779|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
58393780|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
58066639|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
58066640|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
58066641|NCT02337075|DEVICE|Activity Mentor|
58393781|NCT00150111|DRUG|Methimazole|
58393782|NCT00150111|DRUG|Rituximab|
58393783|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
58393784|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
58393785|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
58393786|NCT01741233|GENETIC|VitDgen|
58422681|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
58422682|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
58393787|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
58393788|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
57725589|NCT01046643|DRUG|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
57922918|NCT04382274|PROCEDURE|Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
58066642|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
58066643|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
58066644|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
58066645|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
58066646|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
58066647|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
58066648|NCT02638285|DRUG|LH|
58066649|NCT02638285|DRUG|HCG|
57725590|NCT01046643|DRUG|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
58066650|NCT02638285|DRUG|Clomiphene|
58066651|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
58066652|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
58066653|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
58066654|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
58066655|NCT00004333|DRUG|NTBC|
58066656|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
58066657|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
58066658|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
58066659|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
58066660|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
58066661|NCT00000799|DRUG|Cidofovir|
58066662|NCT00000799|DRUG|Probenecid|
58393789|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
58393790|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
57725591|NCT02332486|DRUG|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
57922919|NCT05114577|BEHAVIORAL|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (\~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
57922920|NCT05114577|BEHAVIORAL|Email recommendations|Receive recommendations (via email) to help improve sleep
57725592|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
57725593|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
57725594|NCT03640910|DEVICE|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
57725595|NCT03640910|DEVICE|Locator® (Zest)|Attachment systems to retain an implant overdenture
57922921|NCT03681704|DRUG|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
57922922|NCT03681704|DRUG|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
58393791|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
58393792|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
58393793|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
57922923|NCT03056911|DRUG|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
57922924|NCT05730270|BEHAVIORAL|Stress reduction program 1|Participants will receive daily online lessons
57922925|NCT05730270|BEHAVIORAL|Stress reduction program 2|Participants will receive daily online lessons
57922926|NCT03134157|DRUG|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
57725596|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
57725597|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
57922927|NCT03134157|DRUG|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
57922928|NCT03134157|DRUG|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
58393794|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
58393795|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
57725598|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
57725599|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
57725600|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
58393796|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
57725601|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
57725602|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
57725603|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
57725604|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
57725605|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
58066663|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
57922929|NCT06093126|DRUG|Lemborexant 5 MG|The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
57922930|NCT01800266|BEHAVIORAL|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
58066664|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
58066665|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
58066666|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
58066667|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
58066668|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
58066669|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
58393797|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
58066670|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
58066671|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
58393798|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
57922931|NCT03182725|DRUG|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
57922932|NCT03182725|DRUG|Placebo|A substance that has no therapeutic effect and will act as a control.
57922933|NCT06190678|DRUG|Pirtobrutinib|Administered orally
58066672|NCT00702949|DRUG|pregabalin|Given orally
58066673|NCT00702949|OTHER|placebo|Given orally
58066674|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
58066675|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
58066676|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
57922934|NCT05965661|OTHER|virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
58393799|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
58393800|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
58393801|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
58393802|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
58393803|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
58393804|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
58393805|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
57922935|NCT05965661|OTHER|virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
57922936|NCT06065865|BEHAVIORAL|Guidance document|"The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task."
57922937|NCT04311060|DIAGNOSTIC_TEST|Molecular panel|"* Detection of CBF rearrangements using PCR: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~* NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
57922938|NCT05095701|BIOLOGICAL|Investigational Live Attenuated Varicella Vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
58066677|NCT01967082|OTHER|Survey Administration|Complete survey
58393806|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
57922939|NCT05095701|BIOLOGICAL|Placebo (Freeze Dired Dilution)|The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
57922940|NCT03558360|DIAGNOSTIC_TEST|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
58276793|NCT05194852|OTHER|guided stretching and strengthening exercise program|guided stretching and strengthening exercise program
58276794|NCT01170819|DEVICE|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
58276795|NCT01170819|DRUG|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
58276796|NCT06066255|DRUG|Thymoglobulin Injectable Product|single intravenous injection of thymoglobulin
58276797|NCT00239499|DRUG|Tiotropium|
58276798|NCT00239499|DRUG|Salmeterol plus Fluticasone|
58393807|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
58276799|NCT06465069|DRUG|LY4052031|Intravenous
58276800|NCT01922154|DRUG|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
58276801|NCT01922154|PROCEDURE|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
58276802|NCT03539185|DEVICE|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
58276803|NCT03539185|DEVICE|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
58276804|NCT02687295|DIETARY_SUPPLEMENT|Thylakoids|
58276805|NCT02687295|OTHER|Control|
58276806|NCT03882957|BEHAVIORAL|Sustained attention|participants will complete a sustained attention task
58276807|NCT03882957|BEHAVIORAL|media multi-task|participants will complete multiple media tasks at the same time
58276808|NCT03882957|OTHER|Video|participants will watch a video of media tasks being completed
58276809|NCT01966302|DRUG|BPS-314d-MR|15-150 mcg po BID,
58393808|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
58393809|NCT05223179|OTHER|Saline|Saline
58393810|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
57922941|NCT03195738|OTHER|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
57922942|NCT02214433|DRUG|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
57922943|NCT02214433|DRUG|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
57922944|NCT02214433|DRUG|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
57922945|NCT02214433|DRUG|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
57922946|NCT02214433|DRUG|Debio 1450 Capsule|Debio 1450 40 mg capsules
57922947|NCT02214433|DRUG|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
58276810|NCT05535400|BEHAVIORAL|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
58276811|NCT05535400|DEVICE|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
58276812|NCT04497974|OTHER|Dietary intervention|Varying the exposure to sweetness via diet manipulation.
58276813|NCT00307853|DRUG|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
58276814|NCT00307853|OTHER|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
58276815|NCT00307853|OTHER|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
58393811|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
58393812|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
58393813|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
58393814|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
58393815|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
58393816|NCT06504459|DRUG|Azacitidine|Given IV or SC
58393817|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58393818|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58393819|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
57725606|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
57725607|NCT00302224|DRUG|2S, 4R Ketoconazole (DIO-902)|
57922948|NCT02214433|DRUG|Pantoprazole|Pantoprazole 40 mg orally
57922949|NCT01978262|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
58066678|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
57922950|NCT03260595|DRUG|Crisaborole ointment 2%|Crisaborole ointment 2%
57922951|NCT03260595|DRUG|Vehicle|Vehicle
57922952|NCT00002863|DRUG|chemotherapy|
57922953|NCT00002863|PROCEDURE|conventional surgery|
57922954|NCT00002863|PROCEDURE|cryosurgery|
57922955|NCT02454179|DRUG|pembrolizumab|
58393820|NCT06504459|DRUG|Cladribine|Given IV
57922956|NCT02454179|DRUG|Acalabrutinib|
57725608|NCT00600600|DRUG|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
57725609|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
57725610|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
57725611|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
57922957|NCT04501913|PROCEDURE|Patient Monitoring|Undergo remote perioperative telemonitoring
57922958|NCT04501913|OTHER|Questionnaire Administration|Complete questionnaires
57922959|NCT03168789|BEHAVIORAL|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
57922960|NCT03168789|BEHAVIORAL|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
57922961|NCT01247233|RADIATION|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
57922962|NCT01247233|RADIATION|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
58276816|NCT01233752|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
57725612|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
57725613|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
57725614|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
58276817|NCT01603407|DRUG|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
58276818|NCT01603407|DRUG|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
58393821|NCT06504459|DRUG|Cytarabine|Given SC
58393822|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
58393823|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
57725615|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
57725616|NCT02348216|DRUG|Fludarabine|Administered according to package insert
58393824|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57725617|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
57725618|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
57725619|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
57725620|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
57725621|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
57922963|NCT02271516|RADIATION|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
57922964|NCT05064189|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
57922965|NCT00939679|PROCEDURE|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
57922966|NCT00939679|DIETARY_SUPPLEMENT|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
58276819|NCT01603407|DRUG|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
58276820|NCT05230745|DEVICE|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
58276821|NCT01031017|DRUG|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
57725622|NCT02348216|DRUG|Bendamustine|Administered according to package insert
57725623|NCT02348216|DRUG|Rituximab|Administered according to package insert
57725624|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
57725625|NCT02348216|DRUG|Prednisone|Administered according to package insert
57725626|NCT02348216|DRUG|Vincristine|Administered according to package insert
57725627|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
57725628|NCT02348216|DRUG|Carboplatin|Administered according to package insert
58276822|NCT01031017|DRUG|placebo|placebo
58393825|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
58393826|NCT06504459|DRUG|Venetoclax|Given PO
58393827|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
58393828|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
57922967|NCT00248846|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
58066679|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
58066680|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
58066681|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
58066682|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
58066683|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
58276823|NCT02949141|DEVICE|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
58276824|NCT02949141|DEVICE|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
57725629|NCT02348216|DRUG|Etoposide|Administered according to package insert
57725630|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
57922968|NCT02518022|DRUG|Insulin|Insulin for beer
57922969|NCT06268769|DRUG|Tacrolimus Pill|Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
57922970|NCT06268769|DRUG|Tacrolimus capsule|Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
57922971|NCT04023825|DRUG|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
57922972|NCT05648526|DRUG|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
57922973|NCT05648526|DRUG|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
58066684|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
58276825|NCT02949141|DEVICE|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
58276826|NCT05947435|DRUG|Tranexamic acid|Tranexamic acid was administered in intravenous or locally within irrigation fluid
57922974|NCT05283486|DRUG|MYMD-1 600MG|Cohort 1: 600mg drug
57922975|NCT05283486|DRUG|MYMD-1 750mg|Cohort 2: 750mg drug
57922976|NCT05283486|DRUG|MYMD-1 900mg|Cohort 3: 900mg drug
57922977|NCT05283486|DRUG|MYMD-1 1050mg|Cohort 4: 1050mg drug
57922978|NCT05283486|DRUG|placebo 600mg|Cohort 1: 600mg placebo
57922979|NCT05283486|DRUG|placebo 750mg|Cohort 2: 750mg placebo
58066685|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
57725631|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
57725632|NCT02348216|DRUG|Cisplatin|Administered according to package insert
57725633|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
57725634|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
58276827|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
58276828|NCT05724199|OTHER|Placebo|SC injection
58276829|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.05%|
58276830|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.10%|
58276831|NCT00893139|DRUG|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
58276832|NCT06306768|DEVICE|Activity Monitoring|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
58276833|NCT05979974|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
58393829|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
58276834|NCT05979974|OTHER|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
58276835|NCT05979974|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
58276836|NCT06131216|DRUG|SHR-2022 Injection|SHR-2022 Injection is administered by intravenous (IV) infusion
58276837|NCT02905643|OTHER|Study subjects|This study does not include an intervention it is only observational.
58393830|NCT02360670|OTHER|control imaging|
58393831|NCT02360670|OTHER|additional multimodal imaging|
58393832|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
58393833|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
58393834|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
58393835|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
58393836|NCT01794208|DRUG|Follitropin Epsilon|
58393837|NCT01794208|DRUG|Follitropin Alfa|
58393838|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
57922980|NCT05283486|DRUG|placebo 900mg|Cohort 3: 900mg placebo
57922981|NCT05283486|DRUG|placebo 1050mg|Cohort 4: 1050mg placebo
57922982|NCT04605887|DRUG|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
58393839|NCT00568763|BIOLOGICAL|sargramostim|
57922983|NCT02204176|OTHER|Exercise info|"Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries"
57922984|NCT02204176|OTHER|Implementation intentions|"Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans"
57922985|NCT02204176|OTHER|Industriousness|"Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise"
57922986|NCT02204176|DEVICE|pedometer|
57922987|NCT03604523|DEVICE|Dilation by Balloon|Esophageal dilation by balloon device.
57922988|NCT03604523|DEVICE|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
57922989|NCT06475781|DRUG|Mirivadelgat|Selective aldehyde dehydrogenase 2 (ALDH2) activator
57922990|NCT06475781|DRUG|placebo|placebo
57922991|NCT01350453|BEHAVIORAL|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
57922992|NCT01350453|BEHAVIORAL|Standard Care|Participants will receive their usual care from their NHS provider.
57922993|NCT01326234|BEHAVIORAL|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
57922994|NCT01326234|BEHAVIORAL|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
57922995|NCT03265834|OTHER|< 10 days of antibiotics|Antibiotic duration
57922996|NCT03265834|OTHER|28 days of antibiotics|Antibiotic duration
57922997|NCT05049278|DRUG|Norepinephrine|"* Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
57922998|NCT05049278|DRUG|Phenylephrine|"* Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
57922999|NCT02601651|DRUG|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
57923000|NCT02601651|DRUG|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
58066686|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
58066687|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
58066688|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
58393840|NCT00568763|OTHER|immunoenzyme technique|
58066689|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
58276838|NCT05498064|DRUG|Ensartinib|Ensartinib 225 mg administered once daily orally
58276839|NCT00335010|DRUG|Nitroglycerin|
58276840|NCT01350375|DRUG|Botox|
58276841|NCT01350375|DRUG|Saline|
58276842|NCT05697302|BEHAVIORAL|Education|Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
58276843|NCT05697302|BEHAVIORAL|Follow-up|Among the data collection forms, LATCH-Breastfeeding Diagnostic Scale and IMDAT-The Baby's Breastmilk Scoring System will be applied at each interview, and the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale will be applied at the first interview, at the end of the 1st month and at the end of the 2nd month. Interviews will be held between the 3rd and 7th days of the week, between 10:00 and 16:00, at the mothers' homes or at the Family Health Center (whichever they prefer). At each meeting, an appointment schedule will be made for the next meeting and this information will be shared with the mothers in writing.
58276844|NCT05697302|BEHAVIORAL|Referral to Lactation and Relactation Polyclinic|Due to the nature of the research, mothers in the control group will not be given any training, and they will be referred to the Lactation and Relaxation Polyclinic in Erzincan Mengücek Gazi Training and Research Hospital.
58393841|NCT00568763|OTHER|immunohistochemistry staining method|
58393842|NCT00568763|OTHER|immunologic technique|
58066690|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
58066691|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
58066692|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
58066693|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
58066694|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
58066695|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
58066696|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
58276845|NCT04582565|COMBINATION_PRODUCT|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
58276846|NCT04582565|OTHER|Standard Care|
58276847|NCT04015778|BIOLOGICAL|Nivolumab|240mg Q2W or 360mg Q3W
58276848|NCT04015778|DRUG|carboplatin|AUC 5, d1 every three weeks
58276849|NCT04015778|DRUG|nab-paclitaxel|135 mg/m2, d1, 8
58393843|NCT00568763|OTHER|laboratory biomarker analysis|
58393844|NCT00568763|PROCEDURE|biopsy|
58393845|NCT00568763|PROCEDURE|cryosurgery|
58393846|NCT00568763|PROCEDURE|radiofrequency ablation|
58393847|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
57923001|NCT01567982|DEVICE|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
57923002|NCT03437278|DRUG|Ligelizumab|Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
57923003|NCT03437278|DRUG|Placebo|Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
57923004|NCT00133692|DRUG|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
57923005|NCT00133692|DRUG|Atenolol/HCTZ/Trandolapril|
57923006|NCT00184977|DRUG|N-acetylcysteine|
58276850|NCT00492232|DRUG|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
58276851|NCT00492232|DRUG|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
58276852|NCT02897167|GENETIC|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
58393848|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
57725635|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
58393849|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
58393850|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
58393851|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
57923007|NCT00184977|DRUG|fluticasone propionate|
57923008|NCT06108037|BEHAVIORAL|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
57923009|NCT03331016|BEHAVIORAL|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
57923010|NCT04103697|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
57923011|NCT04103697|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
57923012|NCT04103697|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
57923013|NCT04103697|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
57923014|NCT04103697|PROCEDURE|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
57923015|NCT06130748|DEVICE|Hybrid Hyrax|these patents will be treated using Two mini-screws supported hybrid hyrax
57923016|NCT05785234|DRUG|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
57923017|NCT05785234|DRUG|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
58276853|NCT02897167|GENETIC|Prospective study of fresh samples|Samples of serum and cells will be drawn.
58276854|NCT04883684|OTHER|Personal health wallet service for Chronic Patients in Emergency Department|Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
58276855|NCT01251497|BEHAVIORAL|diabetes self-management education|
58393852|NCT00002032|DRUG|Rifabutin|
58393853|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
58066697|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
58276856|NCT06668103|DRUG|ABSK043 in combination with Firmonertinib|"Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
58276857|NCT03073356|BIOLOGICAL|Infusion of 3-OHB|Increase in 3-OHB levels
58276858|NCT03073356|BIOLOGICAL|Infusion of placebo|NaCl
58276859|NCT03383094|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
58276860|NCT03383094|RADIATION|Radiation therapy|70 Gy in 33-35 fractions
58276861|NCT03383094|DRUG|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
58276862|NCT01438385|PROCEDURE|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
58276863|NCT03304275|BEHAVIORAL|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
58276864|NCT01260272|OTHER|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
58276865|NCT01260272|OTHER|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
58276866|NCT00579332|DIETARY_SUPPLEMENT|brassica intervention|diet and phyto-chemical intervention
58276867|NCT06071572|OTHER|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
58276868|NCT05233579|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
58276869|NCT00214214|DRUG|Campath 1H® (Alemtuzumab)|
58276870|NCT03181243|PROCEDURE|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
58276871|NCT03181243|PROCEDURE|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
58276872|NCT00462176|PROCEDURE|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
58066698|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
58066699|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
58066700|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
58393854|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
58393855|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
58393856|NCT06405607|DRUG|Psilocybin|30 mg single dose
58393857|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
58066701|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
58276873|NCT00462176|OTHER|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
58393858|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
58276874|NCT03299725|DRUG|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
58276875|NCT02012959|DRUG|Tolvaptan|
58276876|NCT02968680|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
58276877|NCT02968680|DEVICE|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
58276878|NCT02968680|DRUG|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
58276879|NCT01846468|DRUG|LHW090|1 mg, 12.5 mg, 100 mg capsules
58276880|NCT01846468|DRUG|Placebo|Matching placebo capsules
58276881|NCT05636072|BEHAVIORAL|WISER|Participants will engage in one or more positive psychology well-being tool(s).
58276882|NCT02854605|DRUG|GS-9674|Tablet administered orally once daily
58276883|NCT02854605|DRUG|Placebo to match GS-9674|Tablet(s) administered orally once daily
58276884|NCT05097599|DRUG|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
58276885|NCT05097599|DRUG|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
58276886|NCT05097599|DRUG|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
58393859|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
58393860|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
58393861|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
58393862|NCT01937663|DRUG|KWA-0711|
58393863|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
58393864|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
58066702|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
58066703|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
58276887|NCT05097599|DRUG|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
58276888|NCT05097599|DRUG|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
58276889|NCT04845945|BIOLOGICAL|PCV15|Blood draw after the vaccination
58276890|NCT01040715|BIOLOGICAL|TNFa Kinoid|TNFa kinoid
58276891|NCT01040715|BIOLOGICAL|TNF kinoid|IM administration 2 or 3 injections within 28 days
58393865|NCT02621541|DEVICE|PET/CT|
58393866|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
57923018|NCT04586582|DIAGNOSTIC_TEST|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
57923019|NCT05256576|OTHER|Implementation of an innovative multi-modal peri-operative care pathway|The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
57923020|NCT00928174|DRUG|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
57923021|NCT03093987|OTHER|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
57923022|NCT02980237|OTHER|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
57923023|NCT02980237|OTHER|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
57923024|NCT00117845|BIOLOGICAL|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
58276892|NCT00750256|DRUG|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
58276893|NCT03581617|DIAGNOSTIC_TEST|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
58276894|NCT03581617|DIAGNOSTIC_TEST|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
58276895|NCT03581617|DIAGNOSTIC_TEST|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
58276896|NCT03581617|DIAGNOSTIC_TEST|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
58276897|NCT03581617|DIAGNOSTIC_TEST|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
58393867|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
58393868|NCT04481204|DRUG|Cisplatin|Given IV
58276898|NCT06497504|DRUG|Bepirovirsen|Bepirovirsen will be administered.
58276899|NCT06497504|DRUG|Placebo|Placebo will be administered.
58276900|NCT02109406|DRUG|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
58276901|NCT02109406|DRUG|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
58276902|NCT02109406|DRUG|Placebo MDI|Placebo MDI administered as two inhalations BID
58276903|NCT05175521|OTHER|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
58276904|NCT05175521|OTHER|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
58393869|NCT04481204|DRUG|Fluorouracil|Given IV
58276905|NCT03919591|OTHER|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
58393870|NCT04481204|DRUG|Gemcitabine|Given IV
57923025|NCT05938231|DEVICE|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
57923026|NCT05938231|BEHAVIORAL|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
57923027|NCT00302419|DRUG|intracoronary infusion,|streptokinase, 250,000 units
57923028|NCT00302419|PROCEDURE|primary percutaneous coronary angioplasty|
57923029|NCT00153517|DRUG|oral versus vaginal metronidazole|
57923030|NCT04174456|DIAGNOSTIC_TEST|FDG PET|baseline and 6-month follow-up FDG PET
57923031|NCT03507374|DRUG|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
57923032|NCT03507374|DRUG|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
57923033|NCT04138797|PROCEDURE|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
57923034|NCT04138797|DEVICE|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
57923035|NCT05139290|BEHAVIORAL|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
57923036|NCT06007274|OTHER|No intervention|No intervention
58066704|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
58276906|NCT03951545|PROCEDURE|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
58276907|NCT03502694|DRUG|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
58276908|NCT03502694|DRUG|Placebo|Participants will receive matching placebo tablets orally.
58276909|NCT02690597|OTHER|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
58393871|NCT04481204|DRUG|Irinotecan|Given IV
58393872|NCT04481204|DRUG|Leucovorin|Given IV
58393873|NCT04481204|DRUG|Nab-paclitaxel|Given IV
57725636|NCT05437627|DIAGNOSTIC_TEST|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
57725637|NCT04116931|DRUG|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
57725638|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
57923037|NCT01206777|DRUG|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
57923038|NCT05639335|OTHER|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
57923039|NCT05639335|OTHER|Experimental Characters|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
57923040|NCT02953171|OTHER|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
58393874|NCT04481204|DRUG|Oxaliplatin|Given IV
58393875|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
58393876|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
58393877|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
58393878|NCT01435473|PROCEDURE|Cardiac Surgery|
58393879|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
58393880|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
58393881|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
57725639|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
57725640|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
57923041|NCT02953171|DIETARY_SUPPLEMENT|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
57923042|NCT02953171|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
58276910|NCT00675870|DRUG|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
58393882|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
57923043|NCT02953171|OTHER|Placebo capsule|Capsules without probiotics
57923044|NCT00166426|DRUG|Exisulind|
57923045|NCT01642173|DEVICE|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
57923046|NCT03230656|OTHER|Early cognitive-communication therapy|
57923047|NCT05089136|DEVICE|transcatheter paravalvular leak closure|Transcatheter paravalvular leak closure (PVLc) was first described in 1992 and has since then emerged as an attractive alternative to repeat surgery. Many implantable devices that can be used for transcatheter PVLc have been marketed, although few are specifically designed for this purpose. It consist in implanting an occluder in the paravalvular leak to stop or reduce the regurgitant flow.
57923048|NCT05622617|DRUG|no intervention|no intervention
58393883|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
57923049|NCT01114061|DEVICE|Insupatch|Applying heat to the infusion site using the insupatch device
57923050|NCT03897881|DRUG|mRNA-4157|Individualized Neoantigen Therapy
57923051|NCT03897881|BIOLOGICAL|Pembrolizumab|Intravenous infusion
57923052|NCT01118611|DRUG|Aurora B/C kinase inhibitor GSK1070916A|
57923053|NCT01118611|OTHER|laboratory biomarker analysis|
57923054|NCT01118611|OTHER|pharmacological study|
58276911|NCT06730659|BIOLOGICAL|CHT101|CHT101: CD 70 UCAR T
58276912|NCT02570750|BEHAVIORAL|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
58276913|NCT02278965|DRUG|Metformin|Metformin 850mg, oral, twice a day for 12 months
58393884|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
58393885|NCT03940638|OTHER|Data collection|Data collection
57923055|NCT01118611|PROCEDURE|diffusion-weighted magnetic resonance imaging + PET CT|
57923056|NCT01118611|RADIATION|fludeoxyglucose F 18 dynomic contrast|
57923057|NCT00440804|DRUG|ibuprofen l-lysine iv solution (NeoProfen (R) )|
57923058|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CBF|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
58393886|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
58422683|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
57725641|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
57923059|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CSP|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
57923060|NCT01694355|DRUG|Vitamin D|
57923061|NCT04762953|DRUG|Paclitaxel|Intraperitoneal Paclitaxel
57923062|NCT04762953|DRUG|Paclitaxel|IV Paclitaxel
57923063|NCT04762953|DRUG|Leucovorin|IV Leucovorin
57923064|NCT04762953|DRUG|Fluorouracil|IV 5-FU
57923065|NCT00377247|BIOLOGICAL|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
57923066|NCT03234790|OTHER|Filtered Air Exposure|Exposure to Filtered air
57923067|NCT03234790|OTHER|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
57923068|NCT03384654|DRUG|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
57923069|NCT03384654|DRUG|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
57923070|NCT03384654|DRUG|Prednisone|Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
57923071|NCT03384654|DRUG|Doxorubicin|Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
57923072|NCT03384654|BIOLOGICAL|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
57923073|NCT03384654|DRUG|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
57923074|NCT03384654|DRUG|Cytarabine|Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
57923075|NCT03384654|DRUG|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
57923076|NCT03384654|DRUG|Methotrexate|Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
57923077|NCT03702556|DEVICE|MRI scan|7.0 tesla functional MRI scan
57923078|NCT04250987|DEVICE|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
57923079|NCT04360486|BIOLOGICAL|Anti-Sars-CoV-2 Convalescent Plasma|Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
57923080|NCT01488487|DRUG|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
57923081|NCT01488487|DRUG|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
57923082|NCT00619762|DEVICE|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
57923083|NCT03379922|BEHAVIORAL|Stress balls|Squeezing stress balls while receiving ESWL treatment
57923084|NCT03379922|BEHAVIORAL|Headphones|Listening to music while receiving ESWL treatment
57923085|NCT02302404|DRUG|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
57923086|NCT02302404|DRUG|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
57923087|NCT02302404|DRUG|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
58276914|NCT02278965|DRUG|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
57923088|NCT02302404|DRUG|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
57923089|NCT06015425|DEVICE|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
58276915|NCT04361214|DRUG|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
58276916|NCT05690763|OTHER|XP-endo Finisher to use irrigation activation|XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.
57923090|NCT00911794|OTHER|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
57923091|NCT00911794|OTHER|Neutral (Sham) Writing|Patients write about neutral subjects
57923092|NCT03084224|GENETIC|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
57923093|NCT02634346|DRUG|ALK3831|Daily dosing
57923094|NCT02634346|DRUG|Olanzapine|Daily dosing
57923095|NCT02634346|DRUG|Placebo|Daily dosing
57923096|NCT05854433|OTHER|Non-interventional study|No intervention will be administered as part of this study.
57923097|NCT06168188|DRUG|Neulasta® (pegfilgrastim)|Intravitreal injection of Neulasta® (pegfilgrastim) after TON
57923098|NCT02750150|DRUG|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
57923099|NCT02750150|DRUG|Fresh-frozen plasma|
57923100|NCT03061630|DRUG|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
57923101|NCT03061630|DRUG|Cisplatin|D1: CISPLATIN 60G/M2
57923102|NCT02775825|OTHER|survey|
57923103|NCT00447382|DRUG|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
57923104|NCT00447382|DRUG|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
57923105|NCT00447382|DRUG|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
57923106|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
57923107|NCT01589666|DRUG|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
57923108|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
57923109|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
57923110|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
57923111|NCT02844049|DEVICE|Deep Brain Stimulation|surgical procedure
57923112|NCT03418337|DRUG|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
57923113|NCT03418337|DRUG|lansoprazole (Takepron OD 30 mg)|lansoprazole group
58066705|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
57923114|NCT01849822|DEVICE|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
58066706|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
58276917|NCT05690763|OTHER|EndoActivator to use irrigation activation|The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
57923115|NCT00336752|PROCEDURE|non operative treatment|non operative treatment -casting for 6 weeks
57923116|NCT00336752|PROCEDURE|operative treatment of ankle fractures|operative treatment of ankle fractures
57923117|NCT04572412|RADIATION|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
57923118|NCT05721820|PROCEDURE|TAVR|Transcatheter aortic valve replacement
57923119|NCT06294522|PROCEDURE|reconstruction of alveolar cleft|after elevation of mucoperiosteal flap related to cleft side. suturing of nasal floor and palatal tissue. harvesting of autogenous graft and reconstruction of nasal floor and labial plate of cleft then suturing of flap labially without tension
57923120|NCT04854629|OTHER|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
57923121|NCT02640885|DEVICE|Foley's cather ballon|
57923122|NCT01581151|DRUG|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
57923123|NCT01581151|DRUG|Monthly Ranibizumab|30 days between treatments
57923124|NCT03400332|DRUG|BMS-986253|Specified dose on specified days
58066707|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
58066708|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
58066709|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
58276918|NCT06424509|OTHER|High degree of long (>5 days) and/or compulsory psychiatric inpatient care|High degree of long (\>5 days) and/or compulsory psychiatric inpatient care
57923125|NCT03400332|BIOLOGICAL|Nivolumab|Specified dose on specified days
57923126|NCT03400332|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58276919|NCT00839787|DRUG|Morphine Sulfate|Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
58276920|NCT04909372|BEHAVIORAL|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
57923127|NCT03400332|OTHER|Placebo|Specified dose on specified days
58066710|NCT01226602|DRUG|Placebo|
58066711|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
58276921|NCT03528564|DRUG|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
57923128|NCT00480584|DRUG|gemcitabine|Levels 1 through 4: 1000 mg/m\^2
57923129|NCT00480584|DRUG|capecitabine|Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
57923130|NCT00480584|DRUG|erlotinib|Levels 1 through 4: 100 mg
58066712|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
58066713|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
58066714|NCT02872090|DRUG|Indacaterol|inhalation
58066715|NCT02872090|DRUG|Glycopyrronium|inhalation
58066716|NCT02872090|DRUG|Tiotropium|inhalation
58066717|NCT02872090|DRUG|Placebo|
58066718|NCT02872090|PROCEDURE|photoplethysmography|inhalation
57725642|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
58276922|NCT03528564|DRUG|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
57725643|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
57725644|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
57951002|NCT05076383|OTHER|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
58276923|NCT03528564|DRUG|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
58276924|NCT02364154|OTHER|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
58276925|NCT02364154|OTHER|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
57725645|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
57725646|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
57725647|NCT04995380|PROCEDURE|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
58066719|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
58276926|NCT05412966|DEVICE|PEAR-002B|PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
58276927|NCT05412966|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
58276928|NCT02281240|DRUG|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
58276929|NCT05587413|PROCEDURE|periodontal care|periodontal treatment
58276930|NCT00581425|BIOLOGICAL|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
58276931|NCT01547052|BEHAVIORAL|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
58276932|NCT01547052|BEHAVIORAL|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
57923131|NCT02480257|BEHAVIORAL|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
57923132|NCT05474599|OTHER|conventional physical therapy|TENS
57923133|NCT05474599|OTHER|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
57923134|NCT00973362|DEVICE|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
57923135|NCT00973362|DEVICE|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
57923136|NCT04508023|DRUG|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
57923137|NCT04508023|OTHER|Placebo|Participants will receive matching placebo tablet orally once daily.
57923138|NCT04508023|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
57923139|NCT04572087|OTHER|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
57923140|NCT04572087|OTHER|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
57923141|NCT03641612|OTHER|one shape|canal fluid sample before and after root canal instrumentation
57923142|NCT03641612|OTHER|protaper next|canal fluid sample before and after root canal instrumentation
57923143|NCT00632398|BEHAVIORAL|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
57923144|NCT00632398|BEHAVIORAL|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
57923145|NCT02423239|DRUG|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
58276933|NCT02190409|DEVICE|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
57725648|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
57725649|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
57923146|NCT02423239|DRUG|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
57923147|NCT02423239|DRUG|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
57923148|NCT02423239|DRUG|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
57923149|NCT02259907|DRUG|KUC 7483 CL|
57923150|NCT02259907|DRUG|Placebo|
57923151|NCT02259907|OTHER|High fat meal|
57923152|NCT05336331|PROCEDURE|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
57923153|NCT04312321|DEVICE|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
57923154|NCT04312321|DEVICE|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
57923155|NCT04265560|OTHER|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
57923156|NCT01690312|DIETARY_SUPPLEMENT|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].
58066720|NCT03973827|DRUG|Placebo|Placebo Comparator: Sham transplantation (placebo) Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
58276934|NCT02379507|OTHER|DEC033 Study Product|Apply twice daily
58276935|NCT05132790|DRUG|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
57923157|NCT01690312|DIETARY_SUPPLEMENT|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
57923158|NCT05252156|DEVICE|eXciteOSA|eXciteOSA
57923159|NCT03143660|BEHAVIORAL|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
57923160|NCT03143660|BEHAVIORAL|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
57923161|NCT02973074|DIETARY_SUPPLEMENT|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
57923162|NCT04395703|OTHER|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
57923163|NCT03913975|OTHER|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
57923164|NCT02216617|DRUG|Taxotere, Cisplatin, Afatinib|
57923165|NCT05087485|OTHER|education|digital education in skin cancer diagnostics
57923166|NCT00028743|DRUG|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
57923167|NCT00028743|DRUG|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
57923168|NCT00028743|DRUG|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
57923169|NCT00028743|DRUG|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
57923170|NCT00247338|DRUG|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
57923171|NCT02147665|OTHER|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
57923172|NCT04487834|DRUG|Simethicone Solution|Oral daily treatment for four weeks
57923173|NCT04487834|DIETARY_SUPPLEMENT|Vivatlac Baby|Oral daily treatment for four weeks
57923174|NCT02883283|PROCEDURE|Epidural loading dose|Labor epidural analgesia loading dose
57923175|NCT02883283|DEVICE|Epidural catheter|Epidural loading dose via epidural catheter
57725650|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
57725651|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
57923176|NCT02883283|DEVICE|Epidural needle|Epidural loading dose via epidural needle
57725652|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
57725653|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
57923177|NCT03840239|DRUG|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
57923178|NCT03840239|RADIATION|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
57923179|NCT03840239|PROCEDURE|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
57923180|NCT03840239|OTHER|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
57923181|NCT01756612|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
57923182|NCT00756470|DRUG|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
57923183|NCT00756470|DRUG|Paclitaxel|80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
57923184|NCT00756470|DRUG|5-Fluorouracil (5-FU)|500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
57923185|NCT00756470|DRUG|Epirubicin|75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
57923186|NCT00756470|DRUG|Cyclophosphamide|500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
57923187|NCT05300269|DRUG|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w"
57923188|NCT04017325|OTHER|no intervention (post study follow up)|No intervention (post study follow up)
57923189|NCT00674869|OTHER|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
57923190|NCT05633602|DRUG|Chemotherapy|Receive standard of care chemotherapy
57725654|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
57725655|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
57725656|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
57923191|NCT05633602|BIOLOGICAL|Pembrolizumab|Given IV
57923192|NCT05633602|BIOLOGICAL|Ramucirumab|Given IV
57923193|NCT01259284|DRUG|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
57923194|NCT01259284|DIETARY_SUPPLEMENT|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
57923195|NCT01259284|OTHER|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
57923196|NCT00568945|DRUG|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
57923197|NCT00447759|DRUG|Celecoxib|200-400mg daily in divided doses
57923198|NCT00447759|DRUG|Diclofenac|prescribed medication taken orally
57923199|NCT02521311|DRUG|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
57923200|NCT02521311|DRUG|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
57923201|NCT04124393|PROCEDURE|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
57923202|NCT00002184|DRUG|Nelfinavir mesylate|
57923203|NCT00002184|DRUG|Levocarnitine|
57923204|NCT00002184|DRUG|Adefovir dipivoxil|
57923205|NCT00002184|DRUG|Saquinavir|
57923206|NCT00002184|DRUG|Lamivudine|
57923207|NCT00002184|DRUG|Stavudine|
57923208|NCT00002184|DRUG|Zidovudine|
57923209|NCT04134676|DRUG|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
57923210|NCT04112901|DEVICE|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
58276936|NCT05132790|DRUG|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
57923211|NCT04112901|DEVICE|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
58276937|NCT05132790|RADIATION|SBRT|radiation therapy for breast cance before surgery.
57923212|NCT01831856|DRUG|1g of F373280|Oral administration, one capsule each evening with dinner.
57923213|NCT01831856|DRUG|Placebo|Oral administration, one capsule each evening with dinner.
57923214|NCT02807792|DEVICE|Perianal access device|Perianal access device
57923215|NCT01343485|BEHAVIORAL|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
57923216|NCT01625572|PROCEDURE|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
57923217|NCT01625572|PROCEDURE|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
57923218|NCT00541723|DRUG|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
58276938|NCT03954717|BEHAVIORAL|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
58276939|NCT01516645|DRUG|KHK2898|injection
58276940|NCT03693001|DEVICE|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
58276941|NCT05255237|DRUG|Jaktinib|75mg BID
57923219|NCT00541723|DRUG|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
57923220|NCT03650478|DEVICE|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
57923221|NCT03650478|DEVICE|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
57923222|NCT04395430|BEHAVIORAL|Usual Care|"Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker"
57951003|NCT05076383|OTHER|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
57951004|NCT04474756|DEVICE|custom-made adjustable mandibular advancement device|a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
57725657|NCT05193994|DRUG|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
57725658|NCT05193994|DRUG|Placebo|Matching placebo.
57923223|NCT04395430|BEHAVIORAL|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
57923224|NCT01087931|DRUG|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
57923225|NCT01087931|OTHER|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
57923226|NCT00002060|DRUG|Inosine pranobex|
57923227|NCT00606073|OTHER|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
57923228|NCT01917513|DEVICE|G-EYE™ colonoscopy|G-EYE™ colonoscopy
57923229|NCT01917513|DEVICE|Standard Colonoscopy|Standard Colonoscopy
57923230|NCT00358553|DRUG|Insulin|
57923231|NCT05040477|OTHER|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
57923232|NCT03289897|DIAGNOSTIC_TEST|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
57923233|NCT05760391|RADIATION|Radiotherapy|IMRT or SABR for patients with ESCC.
57923234|NCT00092495|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
57923235|NCT05717608|OTHER|high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects|oral ingestion of food supplement for 4 weeks
57923236|NCT02347033|DRUG|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
57923237|NCT02347033|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
57923238|NCT03035968|OTHER|Vojta therapy|
57923239|NCT03035968|OTHER|conventional physiotherapy|
57923240|NCT04173065|DRUG|VK2809|Capsule
57923241|NCT04173065|DRUG|Placebos|Capsule
58393887|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
57725659|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
57725660|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
57725661|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
57725662|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
57725663|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
57725664|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
57725665|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
57725666|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
57725667|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
58276942|NCT05998460|BEHAVIORAL|Glucose-Guided Eating with CGM|The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
58393888|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
58393889|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
58393890|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
58393891|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
57725668|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
57725669|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
57725670|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
57725671|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
57725672|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
57725673|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
57725674|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
57725675|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
57725676|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
57725677|NCT02185352|DRUG|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
57725678|NCT03934385|BEHAVIORAL|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
57725679|NCT03934385|BEHAVIORAL|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
57725680|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
57725681|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
57725682|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
57725683|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
57725684|NCT03129334|BEHAVIORAL|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
57725685|NCT06532266|DEVICE|TechTrade Ready Heat Half Body Temperature Management Blankets|"The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn."
57725686|NCT06532266|OTHER|Control|3 layers of 100% cotton woven blankets
57725687|NCT00507793|DRUG|Sirolimus|
57725688|NCT00507793|DRUG|Cyclosporine|
57725689|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
57725690|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
57725691|NCT02001727|OTHER|Questionaire|
57725692|NCT00003801|PROCEDURE|management of therapy complications|
57725693|NCT00003801|PROCEDURE|quality-of-life assessment|
57735415|NCT05133596|OTHER|Neurological examination and neuropsychological assessment|"* MOCA, BREF~* CVLT~* WAIS IV, MEM III~* Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~* Benton's Line Judgement, VOSP~* Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression \& anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
58066721|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
58393892|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
58393893|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
57725694|NCT06573346|OTHER|Cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
57725695|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
57725696|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
57725697|NCT02929810|BEHAVIORAL|sleep extension|
57725698|NCT02929810|BEHAVIORAL|sleep maintenance|
57725699|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
57725700|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
57725701|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
57725702|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
58393894|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
58066722|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
58066723|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
57725703|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
58066724|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
58393895|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
57725704|NCT05507411|RADIATION|Neoadjuvant Radiotherapy|41.4Gy/23F
57725705|NCT05507411|DRUG|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
57725706|NCT05507411|DRUG|Immunotherapy|Camrelizumab 200mg Q3W
57725707|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
57725708|NCT02747940|DRUG|flunarizine and/or pregabalin|
57725709|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
57725710|NCT01870843|DRUG|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
57725711|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
57725712|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
57725713|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
57725714|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
57725715|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
57923242|NCT02170454|PROCEDURE|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
58066725|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
58066726|NCT02949544|OTHER|water immersion|warm water immersion
57725716|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
57725717|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
58066727|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
58066728|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
58276943|NCT05998460|OTHER|CGM only|Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
57725718|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
57951005|NCT00597480|DRUG|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
58066729|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
58066730|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
58066731|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
58066732|NCT03918356|OTHER|healthy control group|healthy control
57725719|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
57725720|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
57725721|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
57725722|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
57725723|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
57725724|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
57725725|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
57725726|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
57725727|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
57725728|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
57725729|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
57725730|NCT02010385|DRUG|Octreotide|
57725731|NCT02010385|DRUG|Saline|
57725732|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
57725733|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
57725734|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
57725735|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
57725736|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
57725737|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
57725738|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
58066733|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
57725739|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
57725740|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
57725741|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
57725742|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
57725743|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
57725744|NCT04497441|OTHER|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
57735416|NCT05133596|OTHER|Nasal endoscopy|Nasal endoscopy
57735417|NCT05133596|OTHER|Assessment of olfactory and taste functions|"* scales: VAS and TSS~* Sniffin Stick test"
57735418|NCT04039672|PROCEDURE|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
58066734|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
58066735|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
58066736|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
58393896|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
57725745|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
58393897|NCT00146926|DRUG|kétamine 20mg|
58393898|NCT00146926|DRUG|ephedrine 3mg|
57725746|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
57725747|NCT02709967|OTHER|Material support|Writing materials
57725748|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
57725749|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
57725750|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
57725751|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
57725752|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
57725753|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
57725754|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
57725755|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
57725756|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
57725757|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
57725758|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
57725759|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
57725760|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
57725761|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
57725762|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
57725763|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
57725764|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57951006|NCT00597480|DRUG|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
57725765|NCT02467777|DEVICE|Bair Hugger|
57725766|NCT02467777|DEVICE|VitaHeat|
57725767|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
57725768|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
57725769|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
57725770|NCT02241226|BEHAVIORAL|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
57725771|NCT03779386|OTHER|music|music during labor and delivery
57725772|NCT01636310|OTHER|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
57725773|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
58393899|NCT00146926|DRUG|lidocaine 40mg|
58393900|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
58393901|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
57923243|NCT06236464|OTHER|Multiparameter analysis of each sample|Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
57923244|NCT04427501|DRUG|LY3819253|Administered IV
57923245|NCT04427501|DRUG|LY3832479|Administered IV
57923246|NCT04427501|DRUG|LY3853113|Administered IV
57923247|NCT04427501|DRUG|Placebo|Administered IV
57923248|NCT04675021|DRUG|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
57923249|NCT04675021|DRUG|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
57923250|NCT04675021|DRUG|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
57923251|NCT01394653|DRUG|YM060|oral, with water
57923252|NCT02880202|OTHER|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
57923253|NCT05428137|DIETARY_SUPPLEMENT|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
57923254|NCT05428137|DIETARY_SUPPLEMENT|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
58276944|NCT04460131|DIAGNOSTIC_TEST|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
57725774|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
57725775|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
57923255|NCT05428137|OTHER|Placebo|Placebo in a form of a capsule given for 16 weeks
57923256|NCT02101034|BIOLOGICAL|Cetuximab|
57923257|NCT02101034|DRUG|PD 0332991|
57725776|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
57725777|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
57923258|NCT01188213|DIETARY_SUPPLEMENT|Methylsulfonylmethane (MSM)|
57923259|NCT01679795|DRUG|Tibolone|
57923260|NCT01679795|DRUG|Placebo|
57923261|NCT02699034|PROCEDURE|ablation for typical atrial flutter|
57923262|NCT02699034|DEVICE|Vision-MR ablation catheter|
57923263|NCT02530853|OTHER|Laser acupuncture|Laser acupuncture
57923264|NCT00978692|DEVICE|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
57923265|NCT00978692|DEVICE|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
57923266|NCT05718310|DRUG|Nitroglycerin|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
57923267|NCT05718310|DRUG|Saline|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
57923268|NCT05048420|PROCEDURE|surgery|ACL reconstruction and RAMP lesion repair
57923269|NCT00954525|DRUG|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
57923270|NCT00954525|DIETARY_SUPPLEMENT|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
57725778|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
57923271|NCT03252951|BEHAVIORAL|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
57923272|NCT03252951|BEHAVIORAL|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
58276945|NCT02958332|OTHER|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
57725779|NCT05969353|OTHER|accupunture|BFA
57725780|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
57923273|NCT03252951|BEHAVIORAL|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
57923274|NCT03252951|BEHAVIORAL|Biofeedback|Standard of Care Biofeedback Training
57923275|NCT03368911|DEVICE|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
57923276|NCT03368911|DEVICE|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
57923277|NCT00638131|DRUG|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
57923278|NCT03325998|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
57923279|NCT05156632|BIOLOGICAL|Medium-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.
58066737|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
57923280|NCT05156632|BIOLOGICAL|High-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
57923281|NCT05156632|BIOLOGICAL|Placebo-comparator group|The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
57923282|NCT01633814|DRUG|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
57923283|NCT01633814|DRUG|Placebo|placebo patch.
57923284|NCT04579965|DRUG|medical treatment of isthmocele|comparison between different drugs
57923285|NCT00935194|DRUG|oseltamivir|75mg,bid,for 5 days
58276946|NCT01678599|DRUG|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
58276947|NCT01897571|DRUG|Tazemetostat|Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
58276948|NCT01897571|DRUG|Prednisolone|Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
58276949|NCT01897571|DRUG|Tazemetostat|Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
58276950|NCT05981404|DIETARY_SUPPLEMENT|β-glucan|Consuming 3g β-glucan with each meal.
58276951|NCT05981404|DIETARY_SUPPLEMENT|Placebo|Consuming 3g Cellulose with each meal.
58276952|NCT01429974|OTHER|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
57725781|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
57923286|NCT00935194|OTHER|blank|no antiviral therapy
57923287|NCT00935194|DRUG|chinese medicinal herbs|200ml,p.o,qid,for 5 days
57923288|NCT00935194|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
57923289|NCT04014725|DEVICE|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
57923290|NCT01727622|DRUG|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
57923291|NCT01727622|OTHER|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
57923292|NCT01727622|PROCEDURE|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
57923293|NCT04894123|DRUG|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
57923294|NCT04894123|DRUG|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
57923295|NCT03456271|OTHER||
57923296|NCT02986334|DRUG|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
57923297|NCT02986334|DRUG|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
57923298|NCT02986334|DRUG|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
57923299|NCT02925026|DIETARY_SUPPLEMENT|Lactoferrin|
58276953|NCT04491526|DRUG|TAMSULOSIN Mepha Ret Depocaps 0.4 mg|"0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)"
57725782|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
57725783|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
57923300|NCT02925026|DIETARY_SUPPLEMENT|Lysozyme|
57923301|NCT02925026|DIETARY_SUPPLEMENT|Placebo|
57923302|NCT00460551|BIOLOGICAL|Zalutumumab|8 mg/kg
58276954|NCT04491526|DRUG|Control Intervention|One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
58276955|NCT00714584|DRUG|Naltrexone HCl.|
58276956|NCT03071679|DRUG|Omiganan|Omignan 1%, 2.5%
58276957|NCT03071679|DRUG|Imiquimod|Imiquimod 15mg
58276958|NCT03071679|DRUG|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
58276959|NCT03071679|DRUG|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
58276960|NCT03071679|DRUG|Placebo|Vehicle
58276961|NCT01137461|PROCEDURE|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
58276962|NCT05258799|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
58276963|NCT05775926|OTHER|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
58066738|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
58066739|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
57923303|NCT00460551|DRUG|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
57923304|NCT00460551|RADIATION|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
57923305|NCT04835701|BEHAVIORAL|Music|Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
57923306|NCT04632433|DRUG|Cemiplimab|350 mg every 3 weeks
57923307|NCT05729880|DIAGNOSTIC_TEST|MRI, MRS|Scan of right calf and thigh
58066740|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
58066741|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
58066742|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
58066743|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
58066744|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
58066745|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
58066746|NCT02249377|DRUG|Corticosteroid|Corticosteroid
57725784|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
57923308|NCT05729880|DIAGNOSTIC_TEST|Ultrasound|Scan of right calf and thigh
57923309|NCT03459274|DEVICE|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
57923310|NCT00005951|DRUG|irinotecan hydrochloride|
57923311|NCT00005951|DRUG|temozolomide|
57923312|NCT00300898|PROCEDURE|Nucleoplasty|
57923313|NCT00300898|PROCEDURE|Percutaneous decompression|
57923314|NCT00300898|PROCEDURE|Intervertebral electrothermal disc decompression (IDET)|
58066747|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
57923315|NCT00300898|BEHAVIORAL|Conservative treatment|
57923316|NCT02070133|DRUG|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
58066748|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
58066749|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
58066750|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
58066751|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
57725785|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
58066752|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
58066753|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
57725786|NCT00648479|DEVICE|The Guiding Star|
57923317|NCT02070133|DRUG|Placebo|Placebo once a day during 12 weeks
57923318|NCT00348231|DRUG|dual-action insulin analog|
57923319|NCT00884338|OTHER|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
57923320|NCT00884338|OTHER|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
57923321|NCT05270785|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
58066754|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
58066755|NCT01234558|DRUG|GLYX-13|single IV dose
58066756|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
58393902|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
58393903|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
57725787|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
57725788|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
58066757|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
58066758|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
58066759|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
58276964|NCT02699476|BEHAVIORAL|Psycho-Social Therapy|
57725789|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
57725790|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
57725791|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
57725792|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
57725793|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
57725794|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
57725795|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
57725796|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
57725797|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
57735419|NCT03312556|DEVICE|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
57735420|NCT03312556|DRUG|Placebo|Placebo pill or patch. Single dose
57951007|NCT04845100|OTHER|Animal Assisted Activity Program|"Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)"
58066760|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
58066761|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
58066762|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
58066763|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
58066764|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
58276965|NCT02699476|DEVICE|Cognitive Behavioral Computer Training|
58276966|NCT02699476|BEHAVIORAL|Interactive Trainer-Subject Sessions|
58276967|NCT02699476|DEVICE|Active Control Games|
58066765|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
58066766|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
58066767|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
58066768|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
58276968|NCT00627809|DRUG|Streptokinase|intracoronary infusion, 250.000 Units
58276969|NCT00627809|PROCEDURE|primary percutaneous coronary intervention|balloon catheter, stent
58276970|NCT00871013|DRUG|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 \& 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
58276971|NCT00871013|DRUG|Velcade|Given by vein, Days 1, 5, 8, 11
58276972|NCT00871013|DRUG|Thalidomide|Given by mouth at bedtime, Days 5-8
58393904|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
58393905|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
57923322|NCT05270785|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
57923323|NCT04508231|OTHER|Gender-affirming hormone therapy|Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
57923324|NCT02594163|DRUG|Brentuximab Vedotin|
57923325|NCT02594163|DRUG|Rituximab|
57923326|NCT02594163|DRUG|Bendamustine|
57923327|NCT03758287|DRUG|CT053PTSA|
57923328|NCT03758287|DRUG|Gefitinib|
57923329|NCT05280756|DEVICE|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
57923330|NCT05280756|DEVICE|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
57923331|NCT05751291|DRUG|Bupivacaine Hydrochloride|"Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve."
57923332|NCT00695253|DEVICE|Talent Endoluminal Spring Graft System|Endovascular repair for patients with AAA who meet the inclusion criteria for the study
57923333|NCT04305080|OTHER|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
57923334|NCT04305080|OTHER|Untreated abutment|Abutment will be left untreated with its gray color.
57923335|NCT06248554|DRUG|PD-1 Inhibitors|Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
58066769|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
57923336|NCT00437580|DRUG|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
58066770|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
58066771|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
58066772|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
58066773|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
58066774|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
58066775|NCT00072215|DRUG|cisplatin|given IV
58066776|NCT00072215|DRUG|ifosfamide|given IV
58066777|NCT00072215|DRUG|paclitaxel|given IV
58066778|NCT00072215|DRUG|vinblastine|given IV
57923337|NCT04780750|DRUG|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
57951008|NCT01068171|OTHER|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
57951009|NCT01068171|OTHER|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
57951010|NCT03829319|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
58066779|NCT05836428|OTHER|no intervention|no intervention
58066780|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
58066781|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
58066782|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
57923338|NCT04580966|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
57923339|NCT00306696|DRUG|Rosiglitazone|
57923340|NCT00306696|DRUG|spironolactone|
58393906|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
58393907|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
57923341|NCT00306696|DRUG|hydrochlorothiazide|
57923342|NCT00306696|DRUG|frusemide|
57923343|NCT03861819|BEHAVIORAL|Vigorous-intensity interval training (VIIT)|Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
57923344|NCT00151957|DRUG|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
57923345|NCT01142856|BIOLOGICAL|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
57923346|NCT05645835|BEHAVIORAL|intervention|the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.
57923347|NCT05645835|BEHAVIORAL|waitlist control|Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
57923348|NCT03618823|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
57725798|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
58276973|NCT00871013|DRUG|Dexamethasone|Given by mouth, once per day Days 5-8
58276974|NCT00871013|DRUG|Cisplatin|Given by vein, Days 5-8 continuous infusion
58393908|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
58393909|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
58393910|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
57923349|NCT03618823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
58276975|NCT00871013|DRUG|Adriamycin|Given by vein, days 5-8 continuous infusion
57951011|NCT03829319|DRUG|Carboplatin|IV infusion Q3W
57951012|NCT03829319|DRUG|Cisplatin|IV infusion Q3W
58276976|NCT00871013|DRUG|Cyclophosphamide|Given by vein days 5-8 continuous infusion
58276977|NCT00871013|DRUG|Etoposide|Given by vein days 5-8 continuous infusion
58276978|NCT03341494|DRUG|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
58393911|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
58393912|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
58393913|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
57923350|NCT03618823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
58276979|NCT01551706|DIETARY_SUPPLEMENT|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
58393914|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
58393915|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
58393916|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
57725799|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
57725800|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
57725801|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
57725802|NCT00131794|BIOLOGICAL|BCG|
57725803|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
57725804|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
57725805|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
57725806|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
57725807|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
57725808|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
57725809|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
57725810|NCT01853449|DRUG|Fentanyl Citrate|
57923351|NCT00195507|DRUG|Etanercept|
57923352|NCT06124872|OTHER|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
57923353|NCT06124872|OTHER|Key informant interview|Semi-structured interview with selected key informants
57725811|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
57725812|NCT01853449|DRUG|Placebo|0.9% saline
57725813|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
57725814|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
57725815|NCT00032292|DRUG|Visilizumab|
57725816|NCT01496352|DRUG|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
57725817|NCT01496352|DRUG|Placebo|DFA-02 placebo
57725818|NCT01371318|OTHER|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
57725819|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
57923354|NCT00276029|DRUG|Etanercept|
58276980|NCT01551706|OTHER|Placebo|Placebo
58276981|NCT03699813|OTHER|Comparison of two approaches to bleeding management|
58393917|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
58393918|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
58393919|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
58393920|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
57923355|NCT05537688|BEHAVIORAL|Identification of Graphic Markers|"The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team."
57923356|NCT02088918|DRUG|Nateglinide|
57923357|NCT02088918|DRUG|Nateglinide/Metformin|
57923358|NCT02088918|DRUG|Metformin|
57923359|NCT04778774|PROCEDURE|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
57923360|NCT02808143|BIOLOGICAL|BCG Solution|Given intravesically
57923361|NCT02808143|OTHER|Laboratory Biomarker Analysis|Correlative studies
57923362|NCT02808143|BIOLOGICAL|Pembrolizumab|Given intravesically
57923363|NCT02808143|OTHER|Pharmacological Study|Correlative studies
57923364|NCT00885651|DRUG|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
58066783|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
58066784|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
58393921|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
58393922|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
58393923|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
58393924|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
58393925|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
58276982|NCT06182436|DEVICE|Virtual Reality Distraction|For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.
57725820|NCT05818449|OTHER|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee"
57725821|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
57725822|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
57923365|NCT00885651|DRUG|Placebo|
57923366|NCT01743625|DRUG|COV155|COV155 tablets
57923367|NCT01743625|DRUG|placebo|
57923368|NCT02652273|DRUG|Abatacept|Abatacept 125mg/ml
57923369|NCT04362410|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab single dose subcutaneously injection.
57923370|NCT04362410|OTHER|Placebo|Placebo single dose subcutaneously injection.
57923371|NCT02930356|OTHER|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
57923372|NCT02930356|OTHER|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
57951013|NCT03829319|DRUG|Pemetrexed|IV infusion Q3W
57951014|NCT03829319|DRUG|Lenvatinib|Oral capsule once daily
57951015|NCT03829319|DRUG|Placebo matching lenvatinib|Oral capsule once daily
57951016|NCT01652183|DRUG|intravenous paracetamol|
57951017|NCT01652183|DRUG|Placebo|
58066785|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
58066786|NCT01678469|OTHER|blood sample|
58066787|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
58066788|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
58066789|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
58066790|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
58066791|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
58066792|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
58276983|NCT06182436|OTHER|Standard Treatment|"Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention.~Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented"
58276984|NCT04939454|PROCEDURE|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
57725823|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
57725824|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
57725825|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
57725826|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
57725827|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
57725828|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
57725829|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
57725830|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
57725831|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
57725832|NCT05906693|OTHER|Tremor amplitude|Electromyography
57725833|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
57725834|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
57725835|NCT01719965|OTHER|Interviews and Focus Group Discussions|
57725836|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
57725837|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
57725838|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
57725839|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
57725840|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
57725841|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
57725842|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
57725843|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
57725844|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
57725845|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
57725846|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
57725847|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
57725848|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
57725849|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
57725850|NCT00087074|DRUG|temsirolimus|Given IV
57951018|NCT05522075|BEHAVIORAL|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
58276985|NCT00034918|DRUG|ZD6474|
57725851|NCT00087074|OTHER|laboratory biomarker analysis|Optional correlative studies
57725852|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
57725853|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
57923373|NCT04787497|DIETARY_SUPPLEMENT|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
57923374|NCT03811353|DIAGNOSTIC_TEST|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
57923375|NCT03336151|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
57923376|NCT06441084|BIOLOGICAL|NCR300 injection|Subjects will receive at least 1 cycle of NCR300 injection.
57923377|NCT01709747|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
57923378|NCT01709747|DEVICE|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
57923379|NCT00050726|DRUG|Interleukin-2|
57923380|NCT02623153|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
57923381|NCT02623153|DRUG|capecitabine|capecitabine of 1000 mg/m2
57923382|NCT02623153|DRUG|S1|S1 of 40 mg/m2
57923383|NCT02623153|DRUG|Docetaxel|docetaxel 40 mg/m2
57923384|NCT04818138|DEVICE|Narrowband UVB phototherapy|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
57923385|NCT04818138|DEVICE|Broadband UVB phototherapy|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
57923386|NCT06231966|DRUG|Combination therapy of high-intensity dose rosuvastatin and ezetimibe|Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
57923387|NCT06231966|DRUG|Rosuvastatin monotherapy for treat-to-target|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
57923388|NCT04610437|PROCEDURE|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
57923389|NCT06185647|OTHER|No intervention. Observational retrospective study|No intervention.
57923390|NCT05302349|OTHER|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * Active pelvic floor exercise (supine position)~  * Bridge exercise (supine position)~  * Back Extension and Ball Back Extension exercises (prone position)~  * Abdominal and Oblique Crunch exercises (supin position)~  * Leg lift exercise (prone position)~  * Plank and Side Plank exercise~  * Superman exercise~Weeks 5-8 (Three days a week)~1. Stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * The same exercises as for Weeks 1-4 will perform."
57923391|NCT05302349|OTHER|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
57923392|NCT00210730|DRUG|epoetin alfa|
57725854|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
57923393|NCT01849484|RADIATION|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
57923394|NCT01849484|RADIATION|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
57725855|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
57923395|NCT04017728|DEVICE|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
57923396|NCT04017728|DEVICE|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
57923397|NCT04600232|DIAGNOSTIC_TEST|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
57923398|NCT01987141|OTHER|EMR Intervention|Electronic medical record flag/notification in the patient's chart
57923399|NCT02719678|OTHER|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
58066793|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
57923400|NCT02265367|DRUG|Levomilnacipran|
57923401|NCT02265367|DRUG|Placebo|
57923402|NCT00442065|DEVICE|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
57923403|NCT04742647|PROCEDURE|Double cerclage|Two cervical cerlages will be placed
57923404|NCT04742647|PROCEDURE|Single cerclage|One cerclage will be placed
57923405|NCT01148966|DRUG|aminolevulinic acid|Given PO
57923406|NCT01148966|OTHER|laboratory biomarker analysis|Correlative studies
58066794|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
58276986|NCT02657070|BEHAVIORAL|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
57923407|NCT01148966|PROCEDURE|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
57923408|NCT04344600|DRUG|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
57923409|NCT04344600|OTHER|Saline|Saline subcutaneous injection
57923410|NCT02882113|DRUG|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
57923411|NCT01329965|DRUG|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
57923412|NCT06320613|OTHER|Acupuncture therapy|After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.
57923413|NCT06320613|OTHER|Ginger Acupuncture Point Patch|Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.
57923414|NCT05105308|BEHAVIORAL|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
57923415|NCT05105308|BEHAVIORAL|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
57923416|NCT01333163|BIOLOGICAL|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
57923417|NCT01333163|BIOLOGICAL|Isotone NaCl|2 hours IV infusion.
57923418|NCT04409249|DIAGNOSTIC_TEST|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
57923419|NCT00991263|GENETIC|gene expression analysis|
57923420|NCT00991263|GENETIC|polymerase chain reaction|
58066795|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
57725856|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
57923421|NCT00991263|OTHER|laboratory biomarker analysis|
57923422|NCT02859532|RADIATION|elastography SWIRE|
57923423|NCT05312788|OTHER|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
57923424|NCT01214187|DRUG|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
57725857|NCT03434717|OTHER|Care as usual|Patients will get care as usual
57923425|NCT01214187|OTHER|Oxygen|Room air oxygen concentrations will be administered as placebo
57923426|NCT03501186|OTHER|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
57923427|NCT06191770|PROCEDURE|Morphine,|Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
57923428|NCT02027701|BIOLOGICAL|IgPro20|
57923429|NCT03211650|DRUG|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
57923430|NCT03211650|DRUG|hyaluronic acid|Intra-articular injections of hyaluronic acid
57923431|NCT03211650|DRUG|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
57923432|NCT06389019|OTHER|Deep learning system for prognostication prediction in bladder cancer|develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
57923433|NCT00007917|DRUG|alvocidib|
57923434|NCT00007917|DRUG|gemcitabine hydrochloride|
58066796|NCT01741285|DRUG|Fluticasone|Course particle treatment
58066797|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
58066798|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
58066799|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
58066800|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
58276987|NCT02657070|BEHAVIORAL|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
58066801|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
58066802|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
58276988|NCT05881122|BEHAVIORAL|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
58276989|NCT02394015|DRUG|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
57725858|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
57725859|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
57725860|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
57725861|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
57725862|NCT00902200|DRUG|AR-12286|See arms
57725863|NCT00902200|DRUG|AR-12286 vehicle|See arms
57725864|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
57725865|NCT03579836|DRUG|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
57725866|NCT03579836|COMBINATION_PRODUCT|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
57725867|NCT05360524|PROCEDURE|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
57725868|NCT00761501|DRUG|PN400|Oral
57725869|NCT00761501|DRUG|Naproxen (Proxen S)|Oral
57725870|NCT00761501|DRUG|Naproxen (Naprosyn E)|Oral
57725871|NCT00750789|DIETARY_SUPPLEMENT|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
57725872|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
57725873|NCT01748994|DRUG|Placebo|
58066803|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
58276990|NCT06249828|DEVICE|MegaCarti^®|MegaCarti® application after microfracture through athroscopic or incision surgery
58276991|NCT06249828|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
57725874|NCT00755586|PROCEDURE|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
57725875|NCT00755586|PROCEDURE|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
57725876|NCT00755586|PROCEDURE|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
57725877|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
57725878|NCT02419157|DRUG|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
57725879|NCT02419157|DRUG|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
57725880|NCT02419157|DEVICE|Clearfil SE Bond|
57725881|NCT02419157|DEVICE|Xeno V|
57923435|NCT04581616|PROCEDURE|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
57923436|NCT04581616|PROCEDURE|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
57923437|NCT03740594|BEHAVIORAL|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
57923438|NCT05394376|OTHER|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
57923439|NCT00413738|DEVICE|Antiseptic-coated central venous catheters|
57923440|NCT03588507|COMBINATION_PRODUCT|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
57923441|NCT04147650|DRUG|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
57923442|NCT04147650|DRUG|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
57923443|NCT04147650|DRUG|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
57923444|NCT04147650|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
57923445|NCT01080677|DRUG|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
57923446|NCT01080677|DRUG|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
57923447|NCT04931186|OTHER|retrospective analyis|retrospective analysis of data
57923448|NCT01950026|PROCEDURE|cryotherapy application|"* Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
57923449|NCT05593679|DIAGNOSTIC_TEST|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
57923450|NCT04762654|OTHER|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
57923451|NCT01959048|DRUG|fecal microbiota transplantation|
57923452|NCT03267693|DIAGNOSTIC_TEST|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
57923453|NCT05551585|DEVICE|Transcranial pulse stimulation|TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,
57923454|NCT01688856|DEVICE|Electrical Stimulator|"The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
57923455|NCT04038593|OTHER|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
57923456|NCT04038593|DEVICE|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
57923457|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume
57923458|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume
57923459|NCT00617032|GENETIC|tgAAC94 placebo|Single dose
57923460|NCT05658874|DRUG|Multimodal Bundle Drugs|multimodal pain therapy
57923461|NCT05658874|PROCEDURE|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
57923462|NCT05658874|BEHAVIORAL|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
57923463|NCT05658874|OTHER|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
57923464|NCT05658874|OTHER|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
57923465|NCT05658874|DRUG|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
57923466|NCT05658874|DRUG|Vaginal estrogen|Topical vaginal estradiol application
57923467|NCT05658874|DRUG|Methenamine|UTI prevention/bladder therapeutic
57923468|NCT05658874|DRUG|Amitriptyline/Gabapentin|Part of multimodal pain therapy
57923469|NCT00261001|BIOLOGICAL|Transcutaneous mode of administration|
57923470|NCT00261001|BIOLOGICAL|Intramuscular mode of administration|
57923471|NCT05138913|DRUG|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
57923472|NCT05138913|DRUG|Saline|After the arthroscopic operation was completed, a local saline injection was performed
57923473|NCT02899013|OTHER|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
57923474|NCT00450905|DEVICE|PRIMA Device|
57923475|NCT01701596|PROCEDURE|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
57923476|NCT01701596|PROCEDURE|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
57923477|NCT02430974|DRUG|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
57923478|NCT05594823|OTHER|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
57951019|NCT05522075|BEHAVIORAL|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
57923479|NCT05594823|OTHER|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
57923480|NCT04517552|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
57923481|NCT03575754|DEVICE|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
57923482|NCT02873273|DRUG|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
57923483|NCT04553042|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
57923484|NCT04616976|BIOLOGICAL|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
57923485|NCT02947776|BEHAVIORAL|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
57923486|NCT02947776|BEHAVIORAL|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
57923487|NCT01230788|DRUG|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
57923488|NCT05058625|DEVICE|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
57923489|NCT05058625|OTHER|Control Group|Normal volleyball training
57923490|NCT04709380|OTHER|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
57923491|NCT04709380|DRUG|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
57923492|NCT05666388|PROCEDURE|Rescue stenting|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
57923493|NCT00539890|DRUG|Technosphere Insulin|
57923494|NCT00002765|BIOLOGICAL|LMB-2 immunotoxin|
57923495|NCT05381987|DEVICE|Radial shockwave therapy|Shockwave Storz Medical device, Doulith SD1, Tower (BT)
57923496|NCT01389765|DRUG|LY2216684|Administered orally
57923497|NCT00000730|DRUG|Trimetrexate glucuronate|
57923498|NCT00000730|DRUG|Methylprednisolone|
57923499|NCT00000730|DRUG|Pentamidine isethionate|
57923500|NCT00000730|DRUG|Sulfamethoxazole-Trimethoprim|
57923501|NCT00000730|DRUG|Leucovorin calcium|
57923502|NCT04826211|DIAGNOSTIC_TEST|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
57923503|NCT02702726|OTHER|Congee and juice with coconut gel|25g coconut oleogel
57923504|NCT02702726|OTHER|Congee and juice with coconut oil|25g coconut oil
57923505|NCT02702726|OTHER|Congee and juice with sunflower gel|25g sunflower oleogel
57923506|NCT02702726|OTHER|Congee and juice with sunflower oil|25g sunflower oil
57923507|NCT02954640|BIOLOGICAL|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
57923508|NCT02159196|DRUG|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
58066804|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
58066805|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
58066806|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
58066807|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
58393926|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
57923509|NCT02159196|DRUG|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
58066808|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
58066809|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
58066810|NCT00052494|DRUG|cisplatin|
58066811|NCT00052494|DRUG|imatinib mesylate|
58066812|NCT00052494|DRUG|irinotecan hydrochloride|
58393927|NCT01143363|BEHAVIORAL|resting - control|
58393928|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
58393929|NCT01143363|BEHAVIORAL|High intensity intermittent training|
58066813|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
58066814|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
58066815|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
57923510|NCT02159196|DRUG|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
57923511|NCT00246402|DRUG|Acipimox|
57923512|NCT03046784|OTHER|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
57923513|NCT00555490|DIETARY_SUPPLEMENT|Soy protein|35 % of protein from soy protein for 4-years
58066816|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
58066817|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
58066818|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
58066819|NCT00002362|DRUG|Abacavir sulfate|
58066820|NCT00002362|DRUG|Efavirenz|
58066821|NCT00002362|DRUG|Emtricitabine|
58066822|NCT00002362|DRUG|Stavudine|
58066823|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
58066824|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
58066825|NCT01122992|PROCEDURE|Limbal relaxing incision|
58066826|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
58066827|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
58066828|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
58066829|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
58393930|NCT01143363|BEHAVIORAL|Short sprint|
58393931|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
58066830|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
58393932|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
58393933|NCT02638467|DRUG|Bone Marrow cells|
58393934|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
58393935|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
58393936|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
58066831|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
58276992|NCT01516294|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
58276993|NCT01211132|DEVICE|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
58276994|NCT01211132|DEVICE|Standard|Without attaching a transparent cap to the tip of colonoscope.
58276995|NCT01273662|DRUG|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
58276996|NCT01722032|OTHER|Childhood Obesity|
58276997|NCT05279118|DIETARY_SUPPLEMENT|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
58276998|NCT05279118|DRUG|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
58276999|NCT06264037|OTHER|semi structured interview|semistructured interview on patient\&#39;s experience of hospitalization.
58277000|NCT05891106|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
58277001|NCT03859180|BEHAVIORAL|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
58277002|NCT00253370|DRUG|BAY 43-9006|Given orally
58277003|NCT00253370|DRUG|docetaxel|Given IV
58393937|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
57923514|NCT04500756|DRUG|Metformin|Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
57923515|NCT04500756|OTHER|Placebo|One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
58277004|NCT00253370|DRUG|cisplatin|Given IV
58277005|NCT00524706|DRUG|S-1, oral Leucovorin, Oxaliplatin|
58277006|NCT05262166|DRUG|INTRATHECAL dexmedetomidine INJECTION|intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
57923516|NCT04990492|DIAGNOSTIC_TEST|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
57923517|NCT04990492|DIAGNOSTIC_TEST|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
57923518|NCT00754143|DRUG|FG-3019|Placebo every 2 weeks IV for all infusions
57923519|NCT00754143|DRUG|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
57923520|NCT00754143|DRUG|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
57923521|NCT00245934|DRUG|Enbrel|
57923522|NCT04415463|DEVICE|Multisegmented fully covered self-expandable metal stent|Esophageal FC-SEMS
57923523|NCT03097133|DRUG|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
57923524|NCT03097133|DRUG|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
57923525|NCT03097133|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
57923526|NCT05085223|OTHER|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
57923527|NCT05085223|OTHER|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
57923528|NCT06485752|BIOLOGICAL|tNIV 1 and Matrix-M Adjuvant|tNIV will be administered as a single 0.5 mL IM injection Day 0
57923529|NCT03586687|DRUG|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
57923530|NCT02767401|DEVICE|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
57923531|NCT02767401|DRUG|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
58066832|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
58393938|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
58393939|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
58393940|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
57923532|NCT03931733|OTHER|Music Therapy|Single thirty minute receptive music therapy intervention.
57923533|NCT00639223|DIETARY_SUPPLEMENT|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
58393941|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
58393942|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
57923534|NCT00639223|DRUG|Pravastatin|One 20mg capsule twice daily for 12 weeks
57923535|NCT00639223|BEHAVIORAL|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
57923536|NCT01526070|DRUG|Intravitreal injection of Aflibercept|
57923537|NCT01688414|PROCEDURE|photoacoustic imaging|Undergo PAI
57923538|NCT01688414|PROCEDURE|fluorescence imaging|Undergo fluorescence imaging
58066833|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
58066834|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
58393943|NCT01213459|OTHER|Data collection|Questionnaire completion
58393944|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
57923539|NCT01688414|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
57923540|NCT00861224|OTHER|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
57923541|NCT00846391|DRUG|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
57923542|NCT00846391|DRUG|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
58393945|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
58393946|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
58393947|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
58393948|NCT00463138|BEHAVIORAL|Crisis intervention|
58277007|NCT03126253|DIAGNOSTIC_TEST|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
57923543|NCT00846391|DRUG|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
57923544|NCT05023343|DRUG|Ropivacaine|30 mL Ropivacaine 0,75% administered as a unilateral TQL block
57923545|NCT05023343|OTHER|Quadriceps muscle strength|Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after
57923546|NCT05023343|OTHER|Timed Up and Go|To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after
57923547|NCT05023343|OTHER|Single-leg 6 meter timed hop test|To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after
58277008|NCT03184129|DEVICE|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
58393949|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
58393950|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
57923548|NCT05023343|OTHER|Temperature discrimination|Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration
57923549|NCT05023343|OTHER|Pinprick test|"Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.~Approximately 60 minutes after block administration"
57923550|NCT05023343|DIAGNOSTIC_TEST|Blood samples|As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration
58393951|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
57923551|NCT05023343|DIAGNOSTIC_TEST|Non-invasive blood pressure measurement|Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration
57923552|NCT02921204|OTHER|Vitamin D status|There is no intervention in this study
57923553|NCT04824521|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
57923554|NCT02705144|OTHER|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
57923555|NCT02092974|PROCEDURE|tDCS|
57923556|NCT02092974|DRUG|Citalopram|
58066835|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
58277009|NCT03184129|DEVICE|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
58277010|NCT00692497|BEHAVIORAL|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
58393952|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
58393953|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
58393954|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
58393955|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
58393956|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
58393957|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
57923557|NCT02092974|OTHER|sham-tDCS + placebo|
57923558|NCT02435966|DEVICE|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
57923559|NCT02435966|DEVICE|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
57923560|NCT02435966|OTHER|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
57923561|NCT01722149|GENETIC|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
57923562|NCT02377791|GENETIC|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5\*1/\*1 vs CYP3A5\*1/\*3 or CYP3A5\*3/\*3
57923563|NCT04495803|OTHER|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
57923564|NCT03894254|OTHER|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
57923565|NCT02721745|BEHAVIORAL|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
57923566|NCT02721745|DEVICE|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
57923567|NCT02721745|DEVICE|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
57923568|NCT04086654|DIAGNOSTIC_TEST|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
57923569|NCT02475486|DEVICE|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
57923570|NCT03660553|DRUG|Insulin Glargine|0.40 units/kg body weight
57923571|NCT03660553|DRUG|Insulin Glargine|0.20 units/kg body weight
57923572|NCT03660553|DRUG|Insulin Aspart|0.20 units/kg body weight
57923573|NCT03660553|DRUG|Insulin Lispro|0.20 units/kg body weight
57923574|NCT04530409|DRUG|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
57923575|NCT03608982|OTHER|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
57923576|NCT03608982|OTHER|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
58393958|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
58393959|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
58393960|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
57923577|NCT01262703|DEVICE|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
57923578|NCT01246752|BIOLOGICAL|Human Stem Cell Transplantation|Human allogenic stem cells
58066836|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
58393961|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
58066837|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
58066838|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
57923579|NCT01246752|DRUG|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
57923580|NCT00316134|PROCEDURE|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
57923581|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
57923582|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
57923583|NCT03613987|DEVICE|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
57923584|NCT01493648|DRUG|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
58066839|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
58066840|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
58066841|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
57923585|NCT01493648|DRUG|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
57923586|NCT01973946|OTHER|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
58066842|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
58066843|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
58066844|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
58277011|NCT01403506|DRUG|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
58393962|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
58393963|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
58393964|NCT04379635|DRUG|Carboplatin|administered via IV infusion
58393965|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
57923587|NCT00730171|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
57923588|NCT02604433|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
57923589|NCT02604433|OTHER|Placebo|Placebo, Subcutaneous, every 21 days.
57923590|NCT00699452|DRUG|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
58066845|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
58277012|NCT04280614|BEHAVIORAL|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
58393966|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
57725882|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
57725883|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
57725884|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
57725885|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
57725886|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
57725887|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
57923591|NCT00699452|DRUG|placebo|placebo
57923592|NCT01285050|DRUG|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
58066846|NCT01974414|DRUG|orally administered cedar honey|
58277013|NCT04829630|BIOLOGICAL|rabies vaccine|"* day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~* day 7 : questionnaire and blood sampling"
58277014|NCT05720117|DRUG|PYX-201|Intravenous (IV) infusion
58393967|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
58393968|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
58393969|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
58393970|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
58393971|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
57923593|NCT01285050|DRUG|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
57923594|NCT01285050|DRUG|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
57923595|NCT00132223|DRUG|Contrast agent|
58066847|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
58066848|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
57923596|NCT01610362|BIOLOGICAL|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
58393972|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
58393973|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
58393974|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
58393975|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
57923597|NCT01099423|PROCEDURE|timing of surgery|
57923598|NCT01099423|GENETIC|gene expression analysis|
57923599|NCT01099423|OTHER|biologic sample preservation procedure|
57923600|NCT01099423|OTHER|laboratory biomarker analysis|
57923601|NCT01099423|PROCEDURE|therapeutic conventional surgery|
57923602|NCT01365143|PROCEDURE|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
57923603|NCT01365143|PROCEDURE|Open Radical Prostatectomy|Open radical prostatectomy
57923604|NCT03095430|DEVICE|Monitoring|Monitoring
58277015|NCT06476431|OTHER|dual task|The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.
58277016|NCT06476431|OTHER|non dual task|No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
57923605|NCT02960113|DRUG|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
58277017|NCT02290379|DRUG|TNX-201 35 mg|Drug: TNX-201 35 mg
58277018|NCT02290379|DRUG|TNX-201 70 mg|Drug: TNX-201 70 mg
58277019|NCT02290379|DRUG|TNX-201 140 mg|Drug: TNX-201 140 mg
58277020|NCT02290379|DRUG|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
58277021|NCT02290379|DRUG|Placebo|Drug: Placebo
58277022|NCT02820181|DEVICE|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
58277023|NCT02820181|DEVICE|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
58277024|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 1|Carbohydrate based food
58277025|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 2|Carbohydrate based food
58277026|NCT01734590|DIETARY_SUPPLEMENT|Control carbohydrate based food|Carbohydrate based food
57923606|NCT02960113|DEVICE|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
58066849|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
58066850|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
58066851|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
58066852|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
58066853|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
58066854|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
58066855|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
58066856|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
58066857|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
57923607|NCT04609059|DRUG|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
57923608|NCT04609059|DRUG|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
57923609|NCT00657059|DRUG|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
58066858|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
58066859|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
58066860|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
58066861|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
58393976|NCT04552041|DRUG|Prospekta|Oral administration.
58393977|NCT04552041|DRUG|Placebo|Oral administration.
58393978|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
57923610|NCT00657059|DRUG|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
58393979|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
58393980|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
57923611|NCT00657059|DRUG|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
57923612|NCT00926549|DEVICE|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
57923613|NCT02108587|DEVICE|optical coherence tomography|Undergo optical coherence tomography
57923614|NCT02861443|BEHAVIORAL|practice of colonic irrigation|
58066862|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
58066863|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
58066864|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
58066865|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
58066866|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
58066867|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
57923615|NCT04911816|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
57923616|NCT02753140|DRUG|Cetuximab|
57923617|NCT02753140|RADIATION|radiation|
57923618|NCT02753140|DRUG|Docetaxel|
57923619|NCT02753140|DRUG|Cisplatin|
57923620|NCT00679588|DRUG|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
57923621|NCT00679588|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
57923622|NCT00679588|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
57923623|NCT02145689|BIOLOGICAL|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
58393981|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
58393982|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
58393983|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
58393984|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
58393985|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
58393986|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
57923624|NCT00261313|DRUG|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
57923625|NCT00261313|DRUG|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
57923626|NCT01638117|OTHER|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
57923627|NCT01638117|DRUG|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
57923628|NCT01638117|DRUG|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
57923629|NCT01638117|DRUG|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
57923630|NCT01638117|OTHER|Saline|Saline, Daily for up to 21 days
57923631|NCT01638117|OTHER|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
57923632|NCT00597467|DEVICE|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
57923633|NCT00597467|DEVICE|Acuvue 2 Soft Contact Lens|Control device
57923634|NCT04351022|BIOLOGICAL|CART-38|Split intravenous infusion of CART-38 cells \[dose escalating infusion of (5-20)x10\^6 CART-38 cells/kg\].
58066868|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
57923635|NCT01673568|DEVICE|ETO garments|patients wearing abdominal binder for 7 days postoperatively
57923636|NCT02714725|DRUG|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
57923637|NCT02714725|DRUG|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
57923638|NCT02714725|DRUG|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
57923639|NCT02803047|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
57923640|NCT01538953|OTHER|handwashing|participants received weekly in-home handwashing promotion and soap as needed
57923641|NCT01538953|OTHER|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
57923642|NCT01538953|OTHER|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
57923643|NCT05964803|DIAGNOSTIC_TEST|Questionnaires|MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
57923644|NCT04146415|DIAGNOSTIC_TEST|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
57923645|NCT01236248|BEHAVIORAL|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
57923646|NCT04588623|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair (OBSR)|OBSR is given orally once daily (3g) for 3 months
58066869|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
58066870|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
58393987|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
57923647|NCT04588623|OTHER|Placebo|Placebo is given orally once daily (3g) for 3 months
57923648|NCT04694846|DRUG|Nicotine Replacement|Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
57923649|NCT04694846|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
57923650|NCT04694846|DRUG|Varenicline|Given PO
57923651|NCT04694846|OTHER|Tobacco Cessation Counseling|Receive counseling
57923652|NCT04694846|OTHER|Questionnaire Administration|Ancillary studies
57923653|NCT04694846|OTHER|Quality of Life Assessment|Ancillary studies
58066871|NCT00004937|DRUG|acridine carboxamide|
58066872|NCT00420823|DRUG|Taurine 4g|
58066873|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
58277027|NCT02447575|OTHER|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
57923654|NCT04694846|OTHER|Best Practice|Receive standard treatment
57923655|NCT00701870|DRUG|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
58066874|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
58066875|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
58066876|NCT00133640|DRUG|cholecalciferol|
58066877|NCT00133640|BEHAVIORAL|Physiotherapy|
58066878|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
58066879|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
58066880|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
58066881|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
58277028|NCT00815334|PROCEDURE|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
58277029|NCT03012295|OTHER||
58277030|NCT00575510|BEHAVIORAL|Intervention|Multiple component intervention based in the unified theory of behavior
58277031|NCT00575510|BEHAVIORAL|Active control|Partial intervention (full intervention minus cultural-specific component)
58277032|NCT04402359|DRUG|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
58277033|NCT04402359|DRUG|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
58277034|NCT04402359|DEVICE|ventilator|all patients selected to be ventilated for 14 days
58277035|NCT01037036|DRUG|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
58277036|NCT01037036|DRUG|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
58277037|NCT04519762|DRUG|Glycophos (Sodium Glycerophosphate)|Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
58277038|NCT04519762|DRUG|Antibiotics|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
57923656|NCT01549054|DRUG|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
57923657|NCT01549054|DRUG|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
57923658|NCT01549054|DRUG|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
57923659|NCT01549054|DRUG|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
57923660|NCT04663100|OTHER|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
57923661|NCT04663100|OTHER|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
57923662|NCT04663100|OTHER|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
57923663|NCT01989767|BEHAVIORAL|control Rehabilitation as usual|Rehabilitation as usual
57923664|NCT01989767|BEHAVIORAL|education|Education as add on to to rehabilitation as usual
57923665|NCT02519309|OTHER|Virta Program|
57923666|NCT03355170|COMBINATION_PRODUCT|Lansoprazole/Domperidone|Experimental
57923667|NCT03355170|DRUG|Lansoprazole|Active comparator
57923668|NCT02689596|DRUG|Oxytocin|
57923669|NCT02689596|OTHER|Placebo|
57923670|NCT02934022|DRUG|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
57923671|NCT05048537|RADIATION|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
57923672|NCT02316366|DEVICE|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
57923673|NCT02858869|BIOLOGICAL|Pembrolizumab|Given IV
57923674|NCT02858869|RADIATION|Stereotactic Radiosurgery|Undergo SRS
57923675|NCT04050137|OTHER|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
57923676|NCT02869776|BEHAVIORAL|Questionnaire|Behavioral questionnaires
57923677|NCT02869776|PROCEDURE|Rapid finger stick|HIV and HCV testing through rapid finger stick
57923678|NCT02869776|PROCEDURE|Venipuncture|HIV and HCV testing through venipuncture
57923679|NCT00485160|DRUG|Continuous indomethacin|
57923680|NCT00485160|DRUG|ibuprofen|
57923681|NCT03909217|PROCEDURE|TECAS Procedure|"Location:~1. Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~2. Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
57923682|NCT03909217|DRUG|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
57923683|NCT03909217|DRUG|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
57923684|NCT03635307|OTHER|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
57923685|NCT05699226|DEVICE|Soterix Medical Incorporated 4x1 adapter|Device permits individualized amplitudes
57923686|NCT05699226|DEVICE|Traditional ECT device|FDA approved ECT device with fixed amplitude.
57923687|NCT05422287|OTHER|Virtual Reality Glasses|Group 1
57923688|NCT05422287|OTHER|Thermomechanical Stimulation Device|Group 2
57923689|NCT00171574|DRUG|Valsartan|
57923690|NCT00171574|DRUG|Valsartan plus HCTZ|
57923691|NCT00171574|DRUG|Lisinopril|
57923692|NCT04038853|DRUG|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
57923693|NCT04038853|DRUG|Placebo|Placebo identical to the study intervention drug
57923694|NCT02628301|DIETARY_SUPPLEMENT|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
58277039|NCT04519762|DRUG|Inotropes|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
57923695|NCT02628301|OTHER|Normocaloric diet|Normocaloric diet
57923696|NCT01376349|DRUG|prasterone|Applied vaginally
57923697|NCT01376349|OTHER|placebo|Applied vaginally
57923698|NCT05332379|DIAGNOSTIC_TEST|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
57923699|NCT03998254|DRUG|V503|9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
57923700|NCT03998254|DRUG|Gardasil|qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
57923701|NCT00371046|PROCEDURE|Transvaginal ultrasound cervical length|
57923702|NCT00371046|PROCEDURE|Cervicovaginal fetal fibronectin|
57923703|NCT00947713|DRUG|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
57923704|NCT00947713|DRUG|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
57923705|NCT00755651|PROCEDURE|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
57923706|NCT04068259|DRUG|PBI-4547|PBI-4547 tablet
57923707|NCT04068259|OTHER|Placebo|Placebo tablet
58277040|NCT04358315|BEHAVIORAL|Behavioral Intervention|Smell or puff e-liquids
58277041|NCT04358315|OTHER|Questionnaire Administration|Ancillary studies
58277042|NCT00182533|DRUG|Sertraline|25 - 200 mg/day x 16 weeks
57923708|NCT05561829|BEHAVIORAL|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
57923709|NCT05561829|BEHAVIORAL|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
58066882|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
58066883|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
58066884|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
58393988|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
58393989|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
57725888|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
57725889|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
57923710|NCT05561829|BEHAVIORAL|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
57923711|NCT05561829|BEHAVIORAL|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
57923712|NCT05561829|BEHAVIORAL|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
57923713|NCT02077595|DEVICE|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
58066885|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
58277043|NCT00182533|DRUG|Placebo|25 - 200 mg/day x 16 weeks
58277044|NCT04707365|BIOLOGICAL|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
58277045|NCT04949763|OTHER|rehabilitation|Patients underwent ususal rehabilitation treatment
58277046|NCT04271540|DRUG|Tildrakizumab|"Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan and echocardiogram will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months~Other cardiac Imaging: An echocardiogram will be performed at baseline and at 6-months."
58277047|NCT03888183|DRUG|salt solution without 0.15% HA|received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
58277048|NCT03888183|DRUG|preservative-free 0.15% HA|received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
58277049|NCT06729944|DIAGNOSTIC_TEST|NGS|Tissue samples will be processed and analysed at the U.O. of Pathological Anatomy
58277050|NCT03004547|OTHER|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
58277051|NCT06079632|BEHAVIORAL|parent coaching via telehealth|Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.
58393990|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
58393991|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
58393992|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
57725890|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
58277052|NCT06079632|BEHAVIORAL|weekly self-learning materials and group discussion session|Participants receive 1-hour self-learning materials, including parent-child interaction and sensory processing strategies, and 1-hour remote group discussion session weekly.
57725891|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
57725892|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
57725893|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
57725894|NCT04554862|DRUG|Magnesium sulfate|magnesium sulfate will be added to the block
57725895|NCT04554862|DRUG|Ketorolac Tromethamine|ketorolac will be added to the block
57725896|NCT04554862|PROCEDURE|supraclavicular block|it is done by ultrasound- guided
57725897|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
57725898|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
57725899|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
57725900|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
57725901|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
57725902|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
57725903|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
57923714|NCT05617911|DEVICE|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
58066886|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
57725904|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
57725905|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
57725906|NCT01202773|DRUG|LY2127399|Administered Subcutaneously (SC)
57725907|NCT01202773|DRUG|Placebo Q4W|Administered SC
57725908|NCT01202773|DRUG|Placebo Q2W|Administered SC
57725909|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
57725910|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
57923715|NCT05617911|PROCEDURE|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
57923716|NCT04179331|OTHER|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
57923717|NCT04179331|OTHER|Saline|Isotonic saline will serve as a placebo.
57923718|NCT00180362|DEVICE|procedure|
57923719|NCT04271007|DRUG|Mometasone Furoate|mometasone furoate
57923720|NCT01836653|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
58066887|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
58066888|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
58277053|NCT04793373|DEVICE|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
57923721|NCT01836653|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
58277054|NCT02453256|DRUG|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
58277055|NCT02453256|DRUG|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
58277056|NCT04769739|OTHER|CO2|using CO2 insufflation to help insertion
57923722|NCT01836653|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
58277057|NCT04769739|OTHER|Water|using water instead of traditional gas to help insertion
58393993|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
58393994|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
57923723|NCT01836653|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
57923724|NCT01836653|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
57923725|NCT01836653|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
57923726|NCT02896179|DEVICE|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
57923727|NCT02896179|DEVICE|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
57923728|NCT04998734|DIAGNOSTIC_TEST|ASI-SR|Psychometric properties of ASI-SR
58277058|NCT04769739|OTHER|50% saline|using 50% saline solution instead of traditional gas to help insertion
58277059|NCT04769739|OTHER|25% saline|using 25% saline solution instead of traditional gas to help insertion
58277060|NCT05731752|DRUG|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
58277061|NCT00256620|PROCEDURE|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
58277062|NCT01814215|BEHAVIORAL|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
58393995|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
58393996|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
58393997|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
58393998|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
58393999|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
58277063|NCT00211315|DRUG|anecortave acetate|
58277064|NCT04265300|DIETARY_SUPPLEMENT|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
58277065|NCT06141421|PROCEDURE|procedure|procedure
58277066|NCT05387694|OTHER|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
58277067|NCT04510389|DIETARY_SUPPLEMENT|Maltodextrin|Bariatric patients with or without sarcopenia receiving maltodextrin
58277068|NCT04510389|DIETARY_SUPPLEMENT|Whey|Bariatric patients with or without sarcopenia receiving whey protein
58277069|NCT03374657|BIOLOGICAL|CPK850|In one of 4 dose levels administered via subretinal injection under anesthesia
57923729|NCT00182351|PROCEDURE|D-dimer|
57923730|NCT00182351|PROCEDURE|Serial Compression Ultrasound|
57923731|NCT02901366|DRUG|14C-FYU-981|14C-FYU-981, (Oral single dosing)
57923732|NCT01382420|PROCEDURE|surgery|adrenalectomy
57923733|NCT06206369|OTHER|No intervention, retrospective study|No intervention, retrospective study
57923734|NCT04980885|DRUG|AK117|Subjects receive AK117 intravenously.
57923735|NCT04980885|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
57923736|NCT04430465|DIETARY_SUPPLEMENT|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
57923737|NCT04430465|DIETARY_SUPPLEMENT|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
57923738|NCT00985166|BIOLOGICAL|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
57923739|NCT00985166|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
57923740|NCT00985166|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
57923741|NCT00985166|BIOLOGICAL|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
58066889|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
58066890|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
58066891|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
57923742|NCT02414581|DRUG|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
57923743|NCT02414581|DRUG|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
57923744|NCT02414581|DRUG|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
58066892|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
58066893|NCT01638546|OTHER|Placebo|Given PO
58066894|NCT01638546|DRUG|Temozolomide|Given PO
58066895|NCT01638546|DRUG|Veliparib|Given PO
58066896|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
57923745|NCT01308957|DIETARY_SUPPLEMENT|Omega-3 fatty acids|4 grams per day for 24 weeks
58394000|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
57923746|NCT01308957|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 24 weeks
57923747|NCT03248674|DIAGNOSTIC_TEST|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
57923748|NCT04054609|DIAGNOSTIC_TEST|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
57923749|NCT02837835|DRUG|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
57923750|NCT02837835|DRUG|ceftazidime|20 mg/kg over 30 min every 8 h
57923751|NCT03995901|BIOLOGICAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
57923752|NCT05686382|PROCEDURE|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
57923753|NCT05686382|PROCEDURE|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
57923754|NCT02566265|BIOLOGICAL|Fluzone High Dose Vaccine|
58066897|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
58066898|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
58066899|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
58066900|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
58066901|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
58066902|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
58394001|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
57923755|NCT02566265|BIOLOGICAL|Standard of care/Placebo|
58394002|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
58394003|NCT04470050|DRUG|Placebo|Sublingual Placebo film
57923756|NCT06412328|OTHER|Psychoeducation|The psychoeducation program based on psychosocial support is a total of 8 sessions. Families participating in the study received the psychoeducation program over 4 weeks, with two sessions per week, each session lasting 60 minutes. Parents were included in group work during the psychoeducation program.
57923757|NCT04395118|BEHAVIORAL|Mailed Outreach|The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
57923758|NCT01228708|OTHER|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
58277070|NCT06393010|BEHAVIORAL|online rehabilitation program|Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
58394004|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
57725911|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
57923759|NCT02548260|DEVICE|Syndactyly without compression|three week relative immobilization by syndactyly
58277071|NCT00183833|DRUG|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
58394005|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
58394006|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
58394007|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
58394008|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
58394009|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
58394010|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
58394011|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
58394012|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
57725912|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
57923760|NCT02548260|DEVICE|Syndactyly with compression|three week relative immobilization by syndactyly and compression
57923761|NCT02548260|DEVICE|Rigid splint without compression|three week rigid immobilization by splint
58277072|NCT00184093|DRUG|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
58277073|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
58394013|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
58394014|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
58394015|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
57923762|NCT02548260|DEVICE|Rigid splint with compression|three week rigid immobilization by splint and compression
57923763|NCT00451100|DRUG|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
58277074|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
58277075|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
58277076|NCT04165096|DRUG|diphenhydramine|PO
58277077|NCT04165096|DRUG|acetaminophen|PO
58277078|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
58277079|NCT03530319|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
58394016|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
58394017|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
57923764|NCT00451100|DRUG|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
57923765|NCT06403189|OTHER|Biologic samples and MRI|"* blood sample~* lumbar punction~* MRI"
57923766|NCT01845220|DRUG|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
57923767|NCT01845220|DRUG|Placebo|80% acetone
57923768|NCT02972463|DIETARY_SUPPLEMENT|Immunoglobulin Y|
57923769|NCT02972463|OTHER|Placebo|
57923770|NCT00329485|DRUG|CORvalen (D-Ribose)|
57923771|NCT02272049|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
57923772|NCT05144009|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
57923773|NCT05144009|DRUG|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
57923774|NCT03354806|PROCEDURE|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
57923775|NCT03354806|PROCEDURE|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
57923776|NCT05335954|DRUG|noradrenaline|noradrenaline
57923777|NCT00863109|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
58066903|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
58066904|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
58066905|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
58066906|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
58277080|NCT03530319|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
58277081|NCT05482906|OTHER|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
58394018|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
58394019|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
57923778|NCT00863109|DRUG|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
57923779|NCT00572520|BEHAVIORAL|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
57923780|NCT00572520|BEHAVIORAL|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
57923781|NCT00572520|BEHAVIORAL|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
57923782|NCT03975452|RADIATION|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
57951020|NCT06053255|DEVICE|High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR|HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.
57951021|NCT02337374|DEVICE|Midurethral sling mesh|
58066907|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
58277082|NCT04516863|DIAGNOSTIC_TEST|German Autobiographical Memory Interview short-form|Diagnostic Test
58277083|NCT00076869|DRUG|MK0991, caspofungin acetate|
58277084|NCT00076869|DRUG|Comparator: amphotericin B|
58277085|NCT00076869|DRUG|Comparator: lipid formulation of amphotericin B and/or azole|
58277086|NCT00041210|BIOLOGICAL|bleomycin sulfate|
58277087|NCT00041210|DRUG|ABVD regimen|
58277088|NCT00041210|DRUG|Stanford V regimen|
58277089|NCT00041210|DRUG|dacarbazine|
58277090|NCT00041210|DRUG|doxorubicin hydrochloride|
58277091|NCT00041210|DRUG|etoposide|
58277092|NCT00041210|DRUG|mechlorethamine hydrochloride|
58277093|NCT00041210|DRUG|prednisone|
58277094|NCT00041210|DRUG|vinblastine sulfate|
58277095|NCT00041210|DRUG|vincristine sulfate|
58277096|NCT00041210|RADIATION|radiation therapy|
58394020|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
57725913|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
57923783|NCT02345122|BEHAVIORAL|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
57923784|NCT02345122|OTHER|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
57923785|NCT03406260|DRUG|Lasmiditan|Administered orally.
57923786|NCT03406260|DRUG|Placebo|Administered orally.
57923787|NCT03281837|DEVICE|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
57923788|NCT03281837|OTHER|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
57923789|NCT04074785|DRUG|Abemaciclib|Abemaciclib 150 mg po bid
57923790|NCT04074785|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
57923791|NCT04159337|OTHER|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
58277097|NCT00662428|OTHER|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
58277098|NCT00662428|OTHER|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
58277099|NCT02864316|DRUG|Nivolumab|
58277100|NCT00000356|DRUG|LAAM|
58277101|NCT00072488|PROCEDURE|computed tomography|
58277102|NCT00072488|PROCEDURE|magnetic resonance imaging|
58277103|NCT00072488|PROCEDURE|positron emission tomography|
58394021|NCT03783442|DRUG|Cisplatin|Administered IV
58394022|NCT03783442|DRUG|Oxaliplatin|Administered IV
58394023|NCT03783442|DRUG|Fluorouracil (5-FU)|Administered IV
58394024|NCT03783442|DRUG|Capecitabine|Administered orally
58394025|NCT03783442|DRUG|Paclitaxel|Administered IV
57923792|NCT04452396|DEVICE|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
57923793|NCT04476056|OTHER|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
57951022|NCT03461328|DRUG|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
58277104|NCT02410213|DRUG|Ferric Carboxymaltose (FCM)|
58277105|NCT03526055|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
58394026|NCT03783442|DRUG|Tislelizumab|Administered IV
58394027|NCT03783442|DRUG|Placebo|Placebo to match Tislelizumab
58394028|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
58394029|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
58394030|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
58394031|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
58277106|NCT00980655|BIOLOGICAL|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
58277107|NCT00980655|BIOLOGICAL|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
58277108|NCT04938414|DIAGNOSTIC_TEST|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
57725914|NCT01089140|DRUG|Saline solution|Saline placebo
58277109|NCT03922841|OTHER|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
58277110|NCT05569993|DRUG|Glutamine|.3 mg/kg of glutamine
57725915|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
57923794|NCT00998426|PROCEDURE|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
57923795|NCT00998426|BIOLOGICAL|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
58066908|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
58066909|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
57923796|NCT00079742|DRUG|Nutropin AQ [somatropin (DNA origin) injection]|
57923797|NCT03977662|COMBINATION_PRODUCT|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
57923798|NCT05768256|BEHAVIORAL|Mindfulness-Based Cognitive-behavioral Therapy for Distress|Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
57923799|NCT02019589|DRUG|Progesterone|
57923800|NCT02019589|DRUG|Placebo|
57923801|NCT00273767|DRUG|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
58066910|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
58277111|NCT05569993|OTHER|Placcebo|Patients will recieve placcebo
57725916|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
57725917|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
57923802|NCT00273767|DRUG|placebo|60ml of NaCl IV slow
58066911|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
58066912|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
58066913|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
58277112|NCT00783328|DRUG|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
57923803|NCT04923854|OTHER|No intervention|No intervention
57923804|NCT02624323|PROCEDURE|Real-time ultrasound-guided central vein catheterization.|
57923805|NCT01415154|DEVICE|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
57923806|NCT00908232|DRUG|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
57923807|NCT00908232|DRUG|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
57923808|NCT00908232|DRUG|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
57923809|NCT00908232|DRUG|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
57923810|NCT00328900|DRUG|Administration of 0,7 mg of atropine|
57923811|NCT00328900|DEVICE|Measurement of skin conductance with Pain detector|
57951023|NCT03326076|DIAGNOSTIC_TEST|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
58277113|NCT02560857|OTHER|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
57725918|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
57725919|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
57725920|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
57725921|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
58277114|NCT04043208|BEHAVIORAL|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
57725922|NCT01745263|DRUG|Vitamin D3|2000 IU/d
58394032|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
58394033|NCT00309985|DRUG|docetaxel|Given IV
57725923|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
58394034|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
57725924|NCT01745263|PROCEDURE|Strength Home Exercise|
57725925|NCT01745263|PROCEDURE|Flexibility Home Exercise|
58394035|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
58394036|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
58394037|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
58394038|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
58394039|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
58394040|NCT01530178|DRUG|Placebo Oral Tablet|
58394041|NCT01814397|DRUG|Anastrozole|1 mg orally daily
58394042|NCT01814397|DRUG|exemestane|25 mg orally daily
58394043|NCT01814397|DRUG|letrozole|2.5 mg orally daily
57725926|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
57725927|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
57725928|NCT00043446|DRUG|intravenous T900607-sodium|
57725929|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
57725930|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
57725931|NCT02691455|PROCEDURE|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
58394044|NCT00152828|DRUG|Celecoxib|
58394045|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
58394046|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
57923812|NCT06354686|DEVICE|TMS Tolerability|The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
58066914|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
58277115|NCT04043208|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
58277116|NCT05186259|DIAGNOSTIC_TEST|Self-reported signs of central sensitization|Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
58277117|NCT05186259|DIAGNOSTIC_TEST|Objective signs of central sensitization|Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
58277118|NCT05186259|DIAGNOSTIC_TEST|Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain|"* Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~* Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~* Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. ."
58277119|NCT05186259|DIAGNOSTIC_TEST|Cognitive functioning|"Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task"
58277120|NCT05186259|DIAGNOSTIC_TEST|Listening effort|Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .
58277121|NCT05186259|DIAGNOSTIC_TEST|Self-reported psychological factors|"Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale"
58277122|NCT05186259|DIAGNOSTIC_TEST|Self-reported lifestyle factors|"Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21"
58277123|NCT05186259|DIAGNOSTIC_TEST|Self-reported measure of pain processing|Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
58277124|NCT05186259|DIAGNOSTIC_TEST|Self-reported quality of life|Self-reported quality of life by means of the SF-36 questionnaire
58277125|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus severity and impact on daily life|Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
58277126|NCT05186259|DIAGNOSTIC_TEST|Self-reported hyperacusis|Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
58394047|NCT04699838|DRUG|Cisplatin|Cisplatin
58394048|NCT04699838|DRUG|Carboplatin|Carboplatin
58394049|NCT04699838|DRUG|Etoposide|Etoposide
58394050|NCT04699838|DRUG|Durvalumab|Durvalumab
58394051|NCT04699838|DRUG|Ceralasertib|Ceralasertib
58394052|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
57725932|NCT02691455|DEVICE|Ahmed Model FP7 Flexible Plate|
57725933|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
57725934|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
58394053|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
58394054|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
58394055|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
57725935|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
57923813|NCT00975507|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
57923814|NCT00975507|BIOLOGICAL|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
58066915|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
58066916|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
58394056|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
57923815|NCT00975507|BIOLOGICAL|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
57923816|NCT00975507|BIOLOGICAL|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
57923817|NCT02528565|DEVICE|Adhesix Bioring|
58277127|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus characteristics|Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
58277128|NCT05186259|DIAGNOSTIC_TEST|Self reported neck pain related disability|Evaluation of self-reported neck pain related disability using the Neck Disability Index
58277129|NCT04604964|OTHER|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
58277130|NCT05469022|DRUG|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
58277131|NCT04528329|DRUG|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
58277132|NCT04528329|DRUG|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
58277133|NCT05535322|DRUG|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
58277134|NCT05535322|DRUG|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
58277135|NCT05535322|DRUG|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
58277136|NCT05535322|DRUG|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
57923818|NCT03458286|DEVICE|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
57923819|NCT05694520|OTHER|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
58277137|NCT05919524|RADIATION|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~* mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~* Additional urethra and bladder trigone sparing constrains~* Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
58394057|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
58277138|NCT06220487|DRUG|Prednisone, Olverembatinib, Blinatumomab, Chidamide|"Phase One. Induction Consolidation, for 1 year. 1.1 Pretreatment ×1 cycle. Prednisone，1mg/kg/d, from day 1 to 14;~1.2 Induction Therapy × 1 cycle. A: OlverembAtinib (at a dose of 40 mg Qod), from day 8 to 42. B: Blinatumomab (at a dose of 28 μg per day), from day 15 to 28. C: Chidamide (at a dose of 10 mg Qod), from day 9 to 41.~1.3 Consolidation Block × 5 cycles. A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42. B: Blinatumomab (at a dose of 28 μg perday) was administered from day 1 to 14. C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Two. Maintenance Therapy, for 3 years. 2.1 A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42.~C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Three. Follow-up, for 5 years."
58394058|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
57923820|NCT03572322|OTHER|Focus Group|Focus Group
57923821|NCT03572322|OTHER|Interviews|Interviews
57923822|NCT00141323|DRUG|lasofoxifene|0.5 mg once per day, orally
58277139|NCT01658397|BEHAVIORAL|Fasting|Ten day fast
58277140|NCT04379765|BEHAVIORAL|Exercise and physical therapy|Decompression operation
58277141|NCT02650700|RADIATION|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
57923823|NCT00141323|OTHER|placebo|placebo
57923824|NCT00141323|DRUG|lasofoxifene|0.25 mg once per day, orally
57923825|NCT04788498|PROCEDURE|Laparoendoscpoic single site surgery LESS|• A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
57923826|NCT04788498|PROCEDURE|Conventional multiport laparoscopy|• It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
58394059|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
58394060|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
58066917|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
58066918|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
58066919|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
58066920|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
58066921|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
58066922|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
58277142|NCT05850104|OTHER|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
58394061|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
58394062|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
58394063|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
58066923|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
58066924|NCT02389868|DRUG|Lovastatin|
58277143|NCT05850104|OTHER|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
58277144|NCT00236899|DRUG|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
58277145|NCT00236899|DRUG|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
58394064|NCT02516995|DEVICE|Functional magnetic resonance imaging|
58394065|NCT02516995|DEVICE|Ultrasound|
58394066|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
58394067|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
58394068|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
58394069|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
58394070|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
58394071|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
58066925|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
58066926|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
58066927|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
57923827|NCT03343847|BIOLOGICAL|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
57923828|NCT03343847|OTHER|Placebo|Placebo Comparator
57923829|NCT06221150|PROCEDURE|Bilateral two level serratus anterior block|A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
57923830|NCT01862640|DRUG|Brexpiprazole, OPC-34712|Once-daily, tablets
57923831|NCT01862640|DRUG|Placebo Oral Tablet|Once-daily, tablets
57923832|NCT03736161|DRUG|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
57923833|NCT03736161|DRUG|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
57923834|NCT02441712|DEVICE|PENS|
57923835|NCT01906346|DRUG|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
57923836|NCT01906346|DRUG|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
58066928|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
58394072|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
58394073|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
58066929|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
58066930|NCT02132312|DRUG|OMS302|
58066931|NCT02132312|DRUG|Phenylephrine HCl|
58066932|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
58066933|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
58066934|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
58066935|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
58066936|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
58066937|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
58394074|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
58394075|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
58066938|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
57923837|NCT02357381|DEVICE|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
57923838|NCT04484831|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
57923839|NCT04484831|OTHER|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
57923840|NCT00107120|DRUG|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
57923841|NCT00107120|DRUG|Placebo|Placebo once daily for up to 8 weeks
57923842|NCT00724295|DRUG|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
58066939|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
58066940|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
58066941|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
58066942|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
58066943|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
58066944|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
58066945|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
58066946|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
58277146|NCT00236899|DRUG|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
58277147|NCT01492101|DRUG|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
57725936|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
57923843|NCT00724295|DRUG|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
58277148|NCT01492101|DRUG|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
58277149|NCT06239805|DEVICE|QMR|"A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off."
58394076|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
58394077|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
58394078|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
57923844|NCT00394953|DRUG|Darbepoetin alfa|As prescribed, iv.
57923845|NCT00394953|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
57923846|NCT04173650|DRUG|AGLE 102|Exosomes from MSCs
57923847|NCT00567216|DRUG|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
57923848|NCT06528639|BEHAVIORAL|HIIT|Three times a week, 10 sets each session, for 24 weeks of high-intensity interval training.
58066947|NCT01732380|DRUG|Raltitrexed|
58066948|NCT01732380|DRUG|Oxaliplatin|
58277150|NCT01590849|DRUG|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
58277151|NCT04766099|OTHER|Childbirth Educational Video|Educational video describing techniques for pushing
58066949|NCT01732380|RADIATION|Radiotherapy|
58066950|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
58277152|NCT00729040|BEHAVIORAL|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
58277153|NCT02658708|OTHER|Bright blue-green light using light visor cap|
58394079|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
58394080|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
57725937|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
57725938|NCT02081651|DIETARY_SUPPLEMENT|Parmigiano Reggiano cheese|
57725939|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
57725940|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
57923849|NCT06051916|OTHER|residual urine|The study includes two group, A and B. Se previously
57923850|NCT05572268|DRUG|to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection|to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
57923851|NCT05335720|DRUG|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
58066951|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
58066952|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
58066953|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
58066954|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
58394081|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
58394082|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
58394083|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
58394084|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
58394085|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
58394086|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
58394087|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
58394088|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
58394089|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
57923852|NCT01569165|PROCEDURE|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
58066955|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
58066956|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
57725941|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
57923853|NCT04318951|BEHAVIORAL|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[...\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
58066957|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
58277154|NCT02658708|OTHER|Dim red light using light visor cap|
58066958|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
58066959|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
58066960|NCT02827747|OTHER|Placebo|Placebo pill
58066961|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
58066962|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
58277155|NCT02658708|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
58277156|NCT02658708|OTHER|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
58394090|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
58394091|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
58394092|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
58394093|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
58394094|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
58394095|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
58394096|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
58394097|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
58394098|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
58394099|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
58066963|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
58066964|NCT05034029|DRUG|Placebo|Placebo
58066965|NCT00132405|DRUG|ALGRX 3268|
58066966|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
58066967|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
58394100|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
58394101|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
58394102|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
57725942|NCT01031823|BEHAVIORAL|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
58066968|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
58066969|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
58066970|NCT06143449|OTHER|Observational study - registry|Observational study - registry
58066971|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
58066972|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
58066973|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
58066974|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
58066975|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
58066976|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
58066977|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
58066978|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
58066979|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
58066980|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
58066981|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
58066982|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
58066983|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
58066984|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
58066985|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
58066986|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
58066987|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
58066988|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
58066989|NCT00038116|PROCEDURE|placebo|sham surgery
58066990|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
58066991|NCT02723539|DRUG|MBN-101|Topical application
58066992|NCT02723539|DRUG|Placebo|Topical application
58066993|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
58066994|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
58066995|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
58066996|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
57923854|NCT04318951|BEHAVIORAL|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
57923855|NCT04483076|DRUG|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.
57923856|NCT04483076|PROCEDURE|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
57923857|NCT04483076|PROCEDURE|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
57923858|NCT01390181|DRUG|Cozaar|Angiotensin II Receptor Blocker
57923859|NCT01557283|OTHER|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
57923860|NCT00091117|DRUG|bortezomib|Given IV
57923861|NCT00091117|OTHER|pharmacological study|Correlative studies
57923862|NCT01121120|DRUG|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
58394103|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
57725943|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
57725944|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
57725945|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
57725946|NCT00265057|DRUG|ADH -1 (Exherin™)|
57725947|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
57725948|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
57725949|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
57725950|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
57923863|NCT01121120|DRUG|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
57923864|NCT04808622|DRUG|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
57923865|NCT04808622|DRUG|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
57923866|NCT00876694|DRUG|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
57923867|NCT00876694|DRUG|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
57923868|NCT04750174|OTHER|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
57923869|NCT04727879|PROCEDURE|Synovial membrane biopsy with puncture of synovial fluid|The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
58066997|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
58394104|NCT00499330|PROCEDURE|lobectomy|
57725951|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
57725952|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
57725953|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
58066998|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
58066999|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
58067000|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
57923870|NCT04727879|PROCEDURE|Joint fluid sampling|In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
58067001|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
58067002|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
58067003|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
58067004|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
58067005|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
58067006|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
57923871|NCT04727879|PROCEDURE|Blood sample|A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
58394105|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
58394106|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
57923872|NCT06375889|OTHER|blood test|During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
57923873|NCT00594126|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
58067007|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
58067008|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
58277157|NCT02658708|OTHER|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
58277158|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
58277159|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
58394107|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
57923874|NCT03967639|PROCEDURE|Elective cardiac surgery|Elective cardiac surgery
58394108|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58394109|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
58394110|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
58394111|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58394112|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
58394113|NCT03267433|BIOLOGICAL|Rituximab|Given IV
58394114|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
58394115|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
58394116|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
57923875|NCT04744051|DRUG|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
57923876|NCT04744051|DRUG|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
58394117|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
58394118|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
58394119|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
58067009|NCT00004911|PROCEDURE|bowel obstruction management|
58067010|NCT00004911|PROCEDURE|quality-of-life assessment|
58067011|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
57923877|NCT04744051|DRUG|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
57923878|NCT04744051|DRUG|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
57923879|NCT01833715|DRUG|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
57923880|NCT01833715|DRUG|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
58067012|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
58067013|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
58067014|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
58067015|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
58067016|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
58067017|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
58067018|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
58277160|NCT02658708|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
58277161|NCT02658708|DIAGNOSTIC_TEST|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
57725954|NCT05126238|DRUG|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
57725955|NCT05126238|DRUG|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
58277162|NCT02658708|OTHER|Horne-Ostberg Morningness-Eveningness Questionnaire|
58394120|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
58394121|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
58394122|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
57725956|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
57725957|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
57725958|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
57725959|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
57923881|NCT01833715|DRUG|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
57923882|NCT00489892|DRUG|Modafinil|
57923883|NCT03228381|DEVICE|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
58277163|NCT02658708|OTHER|Daily Fatigue and Sleep Log|"* Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~* Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
58277164|NCT05799404|DIAGNOSTIC_TEST|ultra-high resolution CT|stapes footplate thickness measurement
58277165|NCT00359294|DRUG|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
58394123|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
58394124|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
58394125|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
58067019|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
58277166|NCT05031377|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
58277167|NCT05031377|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
58277168|NCT05626218|OTHER|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
58394126|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
57923884|NCT04780308|PROCEDURE|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
57923885|NCT03311334|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
58277169|NCT00464555|PROCEDURE|Islet transplant|Transplantation of pancreatic islet cells
58394127|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
58277170|NCT00464555|DRUG|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
58394128|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
58394129|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
58394130|NCT04216563|DRUG|Asciminib|Given PO
58394131|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
57923886|NCT03311334|DRUG|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
57923887|NCT03311334|DRUG|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
58277171|NCT00464555|DRUG|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
58277172|NCT00464555|DRUG|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
58277173|NCT00464555|DRUG|Sirolimus|Maintenance immunosuppressive therapy
58277174|NCT00464555|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
58394132|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
58394133|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
57951024|NCT03326076|OTHER|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
57725960|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
58277175|NCT05070143|BEHAVIORAL|RISE-UP Routine|The participants in this condition will be instructed to substitute their current sleep habits with the RISE-UP routine that has been developed by our team (Kaplan, Talavera, \& Harvey, 2018). This involves instructing participants to devise an individually tailored routine that will help them get up each morning (e.g., open blinds, make the bed, head for the shower).
58277176|NCT05070143|BEHAVIORAL|Awareness Training|The participants in this condition will be instructed in dismantling/disrupting the association between the cue and the habit via awareness training from habit reversal approaches (Azrin \& Nunn, 1973; Ladouceur, 1979). This condition involves instructing the participant to develop an awareness of their decisions to stay in bed and snooze.
57725961|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
57725962|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
58067020|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
58277177|NCT05070143|BEHAVIORAL|Vigilant Monitoring|"The participants in this condition will be instructed in vigilant monitoring which involves internal repetition of get up! and don't do it and watching carefully for slipups (Quinn, Pascoe, Wood, \& Neal, 2010)."
58394134|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
58277178|NCT05070143|BEHAVIORAL|Implementation Intentions|"The participants in this condition will be instructed in counter habitual implementation intentions. This involves instructing the participant to engage in implementation intentions in which they imagine replacing snoozing with getting up out of bed (Adriaanse, Gollwitzer, De Ridder, De Wit, \& Kroese, 2011). The structure of this implementation intention is: If I wake up in the morning and I want a sleep-in then I will get up and start my day."
58277179|NCT05070143|BEHAVIORAL|Values-based Approach|The participants in this condition will be instructed in a values-based approach (Anshel, Brinthaupt, \& Kang, 2010; Anshel \& Kang, 2007). This involves asking the participants to reflect on how getting up consistently at the same time each day does or does not align with their values. They are asked to compare the costs and long-term consequences of continuing to engage in the unwanted habit and clearly articulating the disconnect between the habit and their values.
58277180|NCT05070143|BEHAVIORAL|Brief Education|"In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time.~First, education about the importance of regular wake times and sleep inertia that is a normal transitional stage between sleep and wake. The education will be delivered in this video format: https://www.youtube.com/watch?v=P6zcSFA7ymo. Second, after viewing the video, the key points will be summarized. Lastly, participants will be asked to summarize the four key takeaways for good sleep habits."
58277181|NCT05584085|BEHAVIORAL|ACT-DE|Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
58394135|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
58394136|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
58394137|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
58394138|NCT03779867|OTHER|Resting|Seated resting
58394139|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
58394140|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
58394141|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
58394142|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
58394143|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
58394144|NCT04938310|DEVICE|support garment|A custom made support garment
58394145|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
58394146|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
58394147|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
58394148|NCT00115271|DRUG|Nutritional supplements|
57725963|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
57725964|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
57725965|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
57725966|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
57725967|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
57725968|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
57725969|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
57725970|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
57725971|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
57725972|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
57725973|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
57725974|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
57725975|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
57923888|NCT01482663|BEHAVIORAL|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
58394149|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
57725976|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
57725977|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
57725978|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
57725979|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
57725980|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
57725981|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
57725982|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
57725983|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
57725984|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
57725985|NCT05233826|BIOLOGICAL|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
57923889|NCT05274984|DRUG|Placebo|the control group will be given the same volume of saline.
57923890|NCT05274984|DRUG|Lidocaine|the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
57725986|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
57725987|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
57725988|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
57725989|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
57725990|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
57725991|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
57725992|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
57923891|NCT05185544|OTHER|Neoadjuvant pemetrexed and cisplatin chemotherapy|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
57923892|NCT06000020|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
57923893|NCT04581096|OTHER|no intervention|just descriptive analysis of clinical data
57923894|NCT04841551|DRUG|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
57923895|NCT00128076|PROCEDURE|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
57923896|NCT00128076|PROCEDURE|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
58067021|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
58067022|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
58067023|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
58067024|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
58067025|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
58277182|NCT00956488|BEHAVIORAL|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
58277183|NCT01797094|BIOLOGICAL|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
57923897|NCT05212454|DRUG|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
57923898|NCT04217122|OTHER|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
57923899|NCT04217122|OTHER|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
57923900|NCT01658098|BEHAVIORAL|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
57923901|NCT06119269|DIAGNOSTIC_TEST|Therapeutic drug monitoring|At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)
58422684|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
57923902|NCT06119269|DIAGNOSTIC_TEST|Molecular Response|BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib
57923903|NCT02895438|DIETARY_SUPPLEMENT|gluten|
57923904|NCT04101708|DRUG|Lansoprazole, Amoxicillin|high dose dual regimen
57923905|NCT04101708|DRUG|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
58067026|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
57923906|NCT00521547|PROCEDURE|Electroacupuncture|
57923907|NCT00606970|DIETARY_SUPPLEMENT|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
58067027|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
58067028|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
58067029|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
58067030|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
58067031|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
58067032|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
58067033|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
58067034|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
58067035|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
58067036|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
58277184|NCT01797094|BIOLOGICAL|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
58277185|NCT00000841|DRUG|Indinavir sulfate|
58277186|NCT00000841|DRUG|Lamivudine|
58277187|NCT00000841|DRUG|Stavudine|
58277188|NCT00000841|DRUG|Zidovudine|
58277189|NCT01111422|DRUG|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
58277190|NCT04679948|DRUG|Percoffedrinol®|Tablet
58277191|NCT04679948|DRUG|Coumadin®|Tablet
58277192|NCT04679948|DRUG|Antra MUPS®|Gastro-resistant tablet
57923908|NCT00606970|DIETARY_SUPPLEMENT|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
57923909|NCT05172141|BIOLOGICAL|IBI314(low dose)|intravenously, once, on Day 1
57923910|NCT05172141|BIOLOGICAL|IBI314(high dose)|intravenously, once, on Day 1
57923911|NCT05172141|BIOLOGICAL|IBI314(medium dose)|intravenously, once, on Day 1
57923912|NCT05172141|OTHER|Placebo|intravenously, once, on Day 1
57923913|NCT05898893|DEVICE|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
57923914|NCT06317896|DIAGNOSTIC_TEST|circulating tumor cells|blood sample and tissue specimen for circulating tumor cell and DNA will be done to patient with hepatocellular carcinoma
57923915|NCT02670941|DRUG|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
58067037|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
58067038|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
58067039|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
58067040|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
58067041|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
58067042|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
58067043|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
58067044|NCT00417898|DRUG|Aspirin|
58067045|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
58067046|NCT00107536|DRUG|lapatinib ditosylate|
58067047|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
58067048|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
58067049|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
57923916|NCT02670941|DRUG|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
57923917|NCT02670941|DRUG|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
57923918|NCT02670941|DRUG|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
58422685|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
58067050|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
58067051|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
58067052|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
58422686|NCT00186277|DRUG|Taxotere|Calculated per patient
58422687|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
57725993|NCT05684484|DRUG|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
58067053|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
58067054|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
58067055|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
58067056|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
58422688|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
57725994|NCT05684484|DRUG|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
57725995|NCT02073045|OTHER|educational intervention|Receive educational handouts
57725996|NCT02073045|OTHER|lymphedema survey|Ancillary studies
57923919|NCT00124852|BEHAVIORAL|n-3 Fatty Acid Supplementation|
57923920|NCT04039256|DEVICE|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
57923921|NCT02561533|OTHER|BRAF detection on fine needle aspiration biopsy (FNAB)|
58067057|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
58067058|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
58067059|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
58067060|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
58422689|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
58067061|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
58067062|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
58277193|NCT04679948|DRUG|Midazolam-ratiopharm®|Oral solution
57725997|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
58277194|NCT04679948|DRUG|BI 730357|Film-coated tablet
57923922|NCT05631977|OTHER|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
58277195|NCT01507532|OTHER|pharmacokinetic monitoring|pharmacokinetic monitoring
58277196|NCT00264030|DEVICE|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
57923923|NCT04549337|BEHAVIORAL|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity."
57923924|NCT02749630|DRUG|Placebo|Matching placebo to UTTR1147A administered intravenously
58277197|NCT00264030|OTHER|PTCA|PTCA
58277198|NCT02739451|PROCEDURE|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]"
57923925|NCT02749630|DRUG|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
57923926|NCT00001407|DRUG|Interferon Gamma|
57923927|NCT06061016|OTHER|No intervention|No intervention
57923928|NCT00338364|BEHAVIORAL|PAT|Coping and Distraction Intervention
57923929|NCT04586062|DRUG|Plasminogen|Human Plasminogen
57923930|NCT00985322|DRUG|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
58277199|NCT02739451|PROCEDURE|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
58277200|NCT06133478|DRUG|NUV001 active cohort 1|6 participants will be assigned to receive active treatment
58277201|NCT06133478|DRUG|NUV001 active cohort 2|6 participants will be assigned to receive active treatment
57923931|NCT00985322|DRUG|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
58277202|NCT06133478|DRUG|NUV001 active cohort 3|6 participants will be assigned to receive active treatment
58277203|NCT06133478|DRUG|NUV001 active cohort 4|6 participants will be assigned to receive active treatment
57725998|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
57725999|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
57726000|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
58277204|NCT06133478|DRUG|NUV001 placebo cohort 1|2 participants will be assigned to receive placebo
58277205|NCT06133478|DRUG|NUV001 placebo cohort 2|2 participants will be assigned to receive placebo
58277206|NCT06133478|DRUG|NUV001 placebo cohort 3|2 participants will be assigned to receive placebo
58277207|NCT06133478|DRUG|NUV001 placebo cohort 4|2 participants will be assigned to receive placebo
58277208|NCT00753844|BIOLOGICAL|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
57923932|NCT04370457|OTHER|Administration of the MyPal ePRO system|Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
57923933|NCT00803270|DRUG|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
57923934|NCT00803270|PROCEDURE|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
57923935|NCT02913534|RADIATION|whole brain radiotherapy|
57923936|NCT03200340|DRUG|EC-18|Oral administration of EC-18 twice daily
58277209|NCT00063297|DRUG|R209130|
58277210|NCT03056365|PROCEDURE|Advanced Nurse (AN)|Protocoled AN-based management of detox
58277211|NCT03056365|PROCEDURE|General Practitioner (GP)|'As usual' medical management of detox
58277212|NCT02412254|OTHER|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
58277213|NCT02412254|OTHER|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
58394150|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
58394151|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
58277214|NCT02622087|BEHAVIORAL|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
58394152|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
58394153|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
58394154|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
58277215|NCT00513357|DRUG|Melatonin|20 mg by mouth daily for 4 Weeks
58277216|NCT00513357|DRUG|Placebo|Capsule by mouth daily for 4 Weeks
58277217|NCT02308371|DEVICE|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
58277218|NCT05743062|BEHAVIORAL|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
58277219|NCT05743062|OTHER|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
57726001|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
58277220|NCT01465256|DRUG|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
58394155|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
58394156|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
58394157|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
58394158|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
57726002|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
57726003|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
57726004|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
58394159|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
57726005|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
58394160|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
57923937|NCT03200340|DRUG|Placebo|Placebo to match EC-18 capsule administration
57923938|NCT02672709|DRUG|apixaban|
57923939|NCT04576741|BEHAVIORAL|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
57923940|NCT04576741|BEHAVIORAL|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
57923941|NCT06452186|DEVICE|direct EMG controlled prosthetic ankle|Patients are trained to use the powered prosthetic ankles
57923942|NCT06452186|BEHAVIORAL|PT guided prosthetic training|Amputees are trained to use prosthetic ankles
57923943|NCT03480256|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
58277221|NCT00723697|DRUG|buprenorphine|0.4, 2, or 8 mg sublingual tablets
58277222|NCT01048905|DRUG|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
58277223|NCT00085813|DRUG|Ispinesib|
58277224|NCT05127655|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
57726006|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
57923944|NCT02053987|OTHER|Intensive rehabilitation in the home.|
57923945|NCT03093350|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
57923946|NCT00003941|BIOLOGICAL|bleomycin sulfate|
57923947|NCT00003941|BIOLOGICAL|filgrastim|
57923948|NCT00003941|DRUG|cisplatin|
57923949|NCT00003941|DRUG|etoposide|
57923950|NCT00003941|DRUG|ifosfamide|
58277225|NCT05472818|DRUG|[11C]APP311|For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
58277226|NCT04928469|OTHER|No intervention performed|Collection of clinical and laboratory data
58277227|NCT02773277|OTHER|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
58277228|NCT02299505|DRUG|ceritinib|The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
58277229|NCT04842643|BIOLOGICAL|IGSC 20% infusion|IGSC 20% infusion, The dose of IGSC will be established in previous study (TAK-664-3001)
58277230|NCT03886389|DIETARY_SUPPLEMENT|PreOP|Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
58277231|NCT03017521|DRUG|TAS-117|TAS-117 16mg, daily
58277232|NCT03863691|DRUG|Amisulpride 300 MG|A single dose of 300 mg amisulpride that looks identical to placebo control capsules.
58277233|NCT03863691|DRUG|Placebo oral capsule|A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
58277234|NCT00098202|DRUG|Low phytic acid maize|
58277235|NCT00098202|DRUG|Zinc|
58277236|NCT00047736|DRUG|Tarceva (erlotinib HCl)|
58277237|NCT01611428|DRUG|Ipragliflozin|Oral and Intravenous (i.v.)
58277238|NCT01836185|DRUG|Evacetrapib|
58277239|NCT01904747|DRUG|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
57923951|NCT00003941|PROCEDURE|bone marrow ablation with stem cell support|
57923952|NCT00003941|PROCEDURE|peripheral blood stem cell transplantation|
57923953|NCT00281333|BEHAVIORAL|"Karate exercises and strengthening exercises"|
57923954|NCT02149082|DEVICE|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
57923955|NCT03739437|BEHAVIORAL|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
57923956|NCT03739437|BEHAVIORAL|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
58277240|NCT01904747|DRUG|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
58277241|NCT01904747|DRUG|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
58277242|NCT01904747|DRUG|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
58277243|NCT06210386|DEVICE|Noninvasive ventilation|noninvasive ventilation
58277244|NCT05476666|PROCEDURE|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
58277245|NCT05380986|DRUG|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
58277246|NCT06536322|OTHER|OHS-interRAI|An oral health screening tool is being tested. Former name was the optimized oral health-related section of the interRAI (ohr-interRAI). This was further optimized into the OHS-interRAI. The OHS-interRAI comprises of 3 oral health-related items that are assessed through questioning the resident, and 6 items that require visual inspection of the mouth.
58277247|NCT01980745|DRUG|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
58277248|NCT01980745|DRUG|Placebo|
57923957|NCT00329342|BEHAVIORAL|Occupational ergonomic training|Adequate postural habits in activities of daily living
58277249|NCT01232374|DRUG|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
58277250|NCT01232374|DRUG|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
58277251|NCT01232374|DRUG|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
58277252|NCT01232374|RADIATION|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
58277253|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
58277254|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
58277255|NCT03544125|BIOLOGICAL|Durvalumab|Given IV
58277256|NCT03544125|DRUG|Olaparib|Given PO
58394161|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
58067063|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
58067064|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
58394162|NCT02468531|OTHER|oxygen|50% oxygen inhalation
58394163|NCT02468531|DRUG|Xenon|50% Xenon inhalation
58394164|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
57923958|NCT02022319|DEVICE|Ultrasonographic Shear Wave Elastography|
57923959|NCT00617188|DRUG|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
57923960|NCT05975385|DEVICE|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
58067065|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
58067066|NCT00723489|DRUG|YFV-17D Placebo|
57923961|NCT04557605|OTHER|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
58067067|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
58277257|NCT04374292|BEHAVIORAL|Family intervention|"Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
57726007|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
57726008|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
57726009|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
57726010|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
57726011|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
57726012|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
58277258|NCT04374292|OTHER|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
58277259|NCT03306979|DRUG|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
58394165|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
58394166|NCT00318318|DRUG|Premarin|
57726013|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
57726014|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
57726015|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
57726016|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
57726017|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
57726018|NCT05507268|OTHER|no intervention|no intervention
57726019|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
57726020|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
57726021|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
57726022|NCT00003878|PROCEDURE|conventional surgery|
57726023|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
57726024|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
57726025|NCT01801059|OTHER|questionnaire administration|Ancillary studies
57726026|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
57726027|NCT04955626|OTHER|Placebo|Intramuscular Injection
57726028|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
57951025|NCT03326076|DIAGNOSTIC_TEST|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
58067068|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
58067069|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
57726029|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
57726030|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
57726031|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
58067070|NCT04805606|DRUG|CKD-843 A|Single Dose
58067071|NCT04805606|DRUG|CKD-843 B|Single Dose
58067072|NCT04805606|DRUG|CKD-843-R|QD, PO
57923962|NCT04962802|BEHAVIORAL|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
57923963|NCT04962802|BEHAVIORAL|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
57923964|NCT04047238|OTHER|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~* Welcome to the patient and reality orientation therapy (7 minutes)~* Conducting the main activity of reminiscence (40 minutes)~* Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
57923965|NCT01774110|OTHER|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
57923966|NCT04854369|DRUG|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
58277260|NCT03306979|OTHER|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
58277261|NCT00824434|DEVICE|PROMUS Element™|Drug eluting coronary stent system
58277262|NCT03595865|DRUG|tafluprostin|Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
58277263|NCT03024827|DRUG|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
58277264|NCT02463006|DRUG|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
58277265|NCT02463006|DRUG|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
58277266|NCT03322436|DIAGNOSTIC_TEST|HeartLinc kit|Samples are collected and analyzed afterwards
57726032|NCT01476046|DRUG|Placebo|Single intravenous dose
57726033|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
57923967|NCT01767207|OTHER|mental disorders|mental disorders
57923968|NCT01767207|BEHAVIORAL|screening for mental disorders|screening for mental disorders
58394167|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
57923969|NCT03776019|DEVICE|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
58394168|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
58277267|NCT04889352|OTHER|Access to colonoscopy web app|There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.
58277268|NCT02046278|DEVICE|LifeSeal™ Kit|
57923970|NCT04473183|DIAGNOSTIC_TEST|Specimen Collection|"Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container."
57923971|NCT04473183|DIAGNOSTIC_TEST|Surveys|Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
57923972|NCT05484245|DEVICE|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
57923973|NCT00988195|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
58277269|NCT00614757|DRUG|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
58277270|NCT00614757|DRUG|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
58277271|NCT01080859|DEVICE|OCT|Optical coherence tomography
58277272|NCT01080859|DEVICE|OCT|Optical coherence tomography
58277273|NCT03647072|DRUG|CHOP|CHOP only
58277274|NCT03647072|DRUG|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
58277275|NCT03647072|DRUG|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
58277276|NCT00913224|DRUG|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
58277277|NCT00913224|DRUG|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
58394169|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
57923974|NCT00988195|DRUG|Doxorubicin|Weeks 13-24 (once every 3 weeks)
58277278|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
58277279|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
58277280|NCT01530724|OTHER|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
58277281|NCT01530724|OTHER|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
58277282|NCT05763056|PROCEDURE|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
58394170|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
58394171|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
57923975|NCT05472948|DRUG|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
57923976|NCT05472948|DRUG|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
57923977|NCT05472948|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
57923978|NCT06073626|BEHAVIORAL|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
57923979|NCT06073626|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
58277283|NCT05763056|PROCEDURE|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
58277284|NCT05763056|DEVICE|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
58277285|NCT04719429|DIETARY_SUPPLEMENT|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
58277286|NCT04719429|DIETARY_SUPPLEMENT|Beef-derived Protein|Beverage containing 25 g beef-derived protein
58394172|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
58394173|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
58394174|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
57923980|NCT01000636|PROCEDURE|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
57923981|NCT02723409|PROCEDURE|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
58394175|NCT00395824|PROCEDURE|anticoagulation procedure|
57923982|NCT02723409|PROCEDURE|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
57923983|NCT02723409|PROCEDURE|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
57923984|NCT02723409|PROCEDURE|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
57923985|NCT02723409|PROCEDURE|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
58394176|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
57923986|NCT05280587|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
57923987|NCT00823056|DIETARY_SUPPLEMENT|probiotics|placebo
57923988|NCT00823056|DIETARY_SUPPLEMENT|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
57923989|NCT01387230|DRUG|GSK573719|62.5 mcg
57923990|NCT01387230|DRUG|GSK573719|125mcg
57923991|NCT01387230|OTHER|Placebo|Placebo
57923992|NCT03333837|BEHAVIORAL|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
57923993|NCT03333837|BEHAVIORAL|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
57923994|NCT03333837|BEHAVIORAL|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
57923995|NCT03333837|BEHAVIORAL|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
57923996|NCT05604833|BEHAVIORAL|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
57923997|NCT04855266|DRUG|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
57923998|NCT04855266|DRUG|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
57923999|NCT04855266|DIAGNOSTIC_TEST|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
57924000|NCT02864420|OTHER|Home hospitalization|
58394177|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
58394178|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
58394179|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
57924001|NCT02864420|OTHER|Inpatient Hospitalization|
57924002|NCT03189043|DEVICE|Antimicrobial Surface|Antimicrobial Surface
57924003|NCT06172881|DEVICE|Investigational Contact Lens|A soft contact lens that will be worn only at the study visit.
57924004|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
57924005|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
57924006|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Coleman technique
57924007|NCT02677012|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery
57924008|NCT06027190|DEVICE|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~2. 70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
57924009|NCT06027190|DEVICE|Sham|Placebo coil (Magstim Company, Whitland, UK):
57726034|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
57924010|NCT03706339|OTHER|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
57924011|NCT03706339|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
57924012|NCT03706339|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
58277287|NCT04579614|BEHAVIORAL|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
58394180|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
58394181|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia.
57924013|NCT03882905|DRUG|Ezetimibe|10 mg tablet, oral, once daily
57924014|NCT03882905|DRUG|Placebo|one tablet, oral, once daily
57924015|NCT03882905|DRUG|Simivastatin|Once daily administration at dose to be determined
57924016|NCT03882905|DRUG|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
57924017|NCT05252052|OTHER|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
58277288|NCT00337779|DRUG|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
58277289|NCT00337779|DRUG|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
58394182|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
58394183|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
58394184|NCT01712997|DRUG|Iloprost|
58394185|NCT01712997|DRUG|Bosentan|
58394186|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
58394187|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
57924018|NCT06352047|OTHER|The effect of positioning on respiratory functions of preterm infants after extubation.|Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
57924019|NCT04160338|DEVICE|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
57924020|NCT02038439|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
57924021|NCT02038439|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
57924022|NCT02038439|BEHAVIORAL|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
58277290|NCT01826045|DRUG|Poly-gamma Glutamic Acid|
58277291|NCT01826045|DRUG|Placebo|
57924023|NCT01890304|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
57924024|NCT04752878|DIAGNOSTIC_TEST|Ottawa sitting scale|The Ottawa Sitting Scale is a performance-based balance measurement consisting of 10 items that aims to evaluate the sitting balance in a comprehensive, specific, efficient and functional manner.
57924025|NCT05015946|BEHAVIORAL|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
57924026|NCT02769546|OTHER|Surveys|
57924027|NCT00560053|DRUG|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
57924028|NCT00560053|PROCEDURE|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
57924029|NCT00560053|DRUG|Maintenance|"At 3 months of transplantation or with \>1.500 neutrophiles/ \> 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
57924030|NCT00560053|PROCEDURE|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
57924031|NCT00560053|PROCEDURE|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
57924032|NCT01702597|DEVICE|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
57924033|NCT01702597|OTHER|Physiotherapy|Patients will receive a standardized physical therapy.
57924034|NCT03686280|OTHER|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
57924035|NCT03686280|OTHER|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
57924036|NCT03686280|OTHER|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
57924037|NCT03686280|OTHER|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
57924038|NCT03686280|OTHER|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
57924039|NCT03686280|OTHER|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
57924040|NCT03686280|OTHER|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
57924041|NCT04124081|DRUG|Hydronidone capsules& Entecavir capsules|take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
58277292|NCT06460337|OTHER|Modified Otago exercises|Participants will engage in modified Otago exercise sessions, either individually or in groups, for 45 minutes, thrice weekly over an 8-week period. The program entails moderate-intensity strengthening exercises targeting various muscle groups such as hip extensors, abductors, knee flexors and extensors, inner range quadriceps, ankle plantar flexors, and dorsiflexors, performed at 10 repetitions maximum (RM) with ankle cuff weights ranging from 0.5 to 1 kg. Additionally, balance exercises will be conducted, initially with support and gradually progressing to without support, including knee bends, backwards walking, sideways walking, tandem stance and walk, one leg stance, heel and toe walking, sit-to-stand, stair climbing, stepping over objects, and bending to pick up objects from the floor. Participants are also encouraged to walk outdoors at their usual pace for 30 minutes at least three times weekly.
57924042|NCT00656123|BIOLOGICAL|Colon GVAX|Dose escalation: 1.4x10\^8 to 7x10\^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
57726035|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
57726036|NCT02416323|OTHER|AIM HI Training|
57924043|NCT00656123|DRUG|cyclophosphamide|200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
57924044|NCT01868113|DRUG|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
57924045|NCT01868113|OTHER|Placebo|Placebo to be administered 12hourly
57924046|NCT00100854|DRUG|erlotinib hydrochloride|Given orally
57924047|NCT00100854|DRUG|fulvestrant|Given intramuscularly
57924048|NCT04660630|DIAGNOSTIC_TEST|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
57924049|NCT04660630|BEHAVIORAL|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
57924050|NCT02672215|BEHAVIORAL|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
57924051|NCT02672215|BEHAVIORAL|generic advice|general, non-tailored web-based generic advice with tips
57924052|NCT03040622|DEVICE|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
57924053|NCT00205491|DRUG|Venlafaxine|
57924054|NCT05399121|BEHAVIORAL|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
58394188|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
57924055|NCT05399121|BEHAVIORAL|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
58394189|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
57924056|NCT05149430|OTHER|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
57924057|NCT05433350|DRUG|Acoziborole|"Two different formulations will be used during the study depending on the body weight and on the step of the study:~Tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 Granules in bottle of 160 mg for paediatric patients weighing 10 to 40 kg in step 2"
57924058|NCT01405937|DRUG|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
57924059|NCT01405937|BIOLOGICAL|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
57924060|NCT01405937|DRUG|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
57924061|NCT01789125|DRUG|Nicotine Patch|
58394190|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
58394191|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
58394192|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
57924062|NCT01789125|BEHAVIORAL|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
57924063|NCT01789125|BEHAVIORAL|Education-Supportive Psychotherapy|
57924064|NCT01875172|DRUG|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
57924065|NCT01875172|DRUG|placebo|
57924066|NCT01875172|BEHAVIORAL|smoking cessation counseling|
57924067|NCT03878498|OTHER|therapeutic management|therapeutic management of anal fistula in Crohn Disease
57924068|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
57726037|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
57924069|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
57924070|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
57924071|NCT01272947|DRUG|Diclofenac sodium|Topical gel 1%- 4 times daily
57924072|NCT01272947|OTHER|Placebo|Topical gel - 4 times daily
57924073|NCT00359190|DRUG|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
57924074|NCT00009620|DRUG|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
57924075|NCT00009620|DRUG|Saline|Infusion of normal sal
57924076|NCT03543696|RADIATION|Single Dose Radiotherapy (SDRT)|
57924077|NCT01840605|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
58394193|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
57924078|NCT01840605|DRUG|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
57726038|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
57726039|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
57924079|NCT00312533|DRUG|Hylan F- 20|
57924080|NCT00696982|DRUG|sitagliptin|sitagliptin 100 mg once daily for 3 months
57924081|NCT00696982|DRUG|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
57924082|NCT02993484|DRUG|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
57924083|NCT02993484|BIOLOGICAL|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
57924084|NCT02993484|OTHER|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
57924085|NCT02993484|OTHER|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
57924086|NCT02088749|BEHAVIORAL|lifestyle intervention for obesity|
58277293|NCT06460337|OTHER|Frenkel's exercises|Frenkel's exercise regimen comprises a series of movements performed in lying, sitting, stride standing, and standing positions aimed at improving coordination and motor control. In the lying position, exercises include alternating hip and knee flexion/extensions, hip abduction/adduction, pedaling the lower limbs, and simultaneous movements of hips and knees. These are executed slowly to enhance coordination. In sitting, exercises involve leg stretching, hip flexion with knees flexed or straightened, and transitions from sitting to standing and back. Stride standing exercises focus on weight transfer and sideways walking, while standing exercises encompass walking on marked paths, trunk rotations, 360-degree turns, smaller arcs of hip abduction/adduction and flexion/extension, straight-line walking, and directional changes to simulate real-life obstacles. 3 sets comprising 10 repetitions are performed for each exercise, aiming for motor skill improvement and balance enhancement
58277294|NCT00286065|DRUG|AeroLEF|
58277295|NCT02929615|OTHER|Hematopoietic stem cell transplantation|
58277296|NCT01029613|DRUG|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
57924087|NCT04448509|OTHER|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
57924088|NCT01016964|DEVICE|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
57924089|NCT01016964|DEVICE|Sham Device|Sham Device
57924090|NCT06419751|BEHAVIORAL|Regular exercise|Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1\~2 muscle groups each time, 4\~5 movements, repeat each action 8\~12 times, repeat 2\~3 sets)
57924091|NCT06419751|BEHAVIORAL|Baduanjin|A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
57924092|NCT04459065|DRUG|IRDye800CW-nimotuzumab|50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
58277297|NCT03350204|PROCEDURE|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
58277298|NCT03350204|OTHER|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
58277299|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
58277300|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
58277301|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
58277302|NCT01147003|DRUG|Placebo|
58277303|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
57924093|NCT04025463|BEHAVIORAL|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
58277304|NCT03453996|OTHER|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
58277305|NCT03453996|OTHER|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
58277306|NCT04610502|BIOLOGICAL|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
58277307|NCT05475457|BEHAVIORAL|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
58277308|NCT04525131|DRUG|CPX-POM|CPX-POM
57924094|NCT02715531|DRUG|5-FU|5-FU (400 mg/m\^2) will be administered as an IV bolus, followed by 2400 mg/m\^2 by continuous IV infusion over 46 (± 1) hours, q2w.
57924095|NCT02715531|DRUG|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
57924096|NCT02715531|DRUG|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
58277309|NCT01476163|DRUG|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
58277310|NCT05993091|OTHER|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
58277311|NCT05993091|OTHER|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
58277312|NCT05993091|OTHER|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
58277313|NCT02008006|DRUG|BeEAM|"High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
58277314|NCT06096298|OTHER|Vitamin B12 bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.
58277315|NCT06096298|OTHER|Control bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
58277316|NCT01455285|DEVICE|transcutaneous electrical nerve stimulation|
58277317|NCT00935454|PROCEDURE|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
58277318|NCT05773625|DEVICE|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
58277319|NCT02069093|DRUG|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
58277320|NCT02069093|DRUG|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
58277321|NCT02069093|DRUG|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
58394194|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
57924097|NCT02715531|DRUG|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
57924098|NCT02715531|DRUG|Leucovorin|Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
58394195|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
57924099|NCT02715531|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
57726040|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
57726041|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
57726042|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
57726043|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
57726044|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
57726045|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
57726046|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
57924100|NCT02715531|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 will be administered IV over 120 (± 5) minutes q2w.
57924101|NCT02715531|DRUG|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
57924102|NCT02715531|DRUG|Cisplatin|Cisplatin will be administered as 80 mg/m\^2 IV over 120 minutes q3w (Group E2).
57924103|NCT04264078|BIOLOGICAL|CD7 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
57924104|NCT04264078|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
58277322|NCT05899647|DIAGNOSTIC_TEST|Ultraviolet Microscopic Analysis|"Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected."
58277323|NCT04659902|DIETARY_SUPPLEMENT|Protein form|Protein form and absence or presence of calcium manipulated
58277324|NCT02620358|OTHER|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
57726047|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
58277325|NCT02620358|OTHER|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
57726048|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
57726049|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
57726050|NCT02326103|DRUG|Placebo|
57726051|NCT06478784|OTHER|Resistance training|"The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
57924105|NCT04264078|DRUG|Cytoxan|600mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
57924106|NCT04264078|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
58277326|NCT01892904|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
58277327|NCT03201393|DRUG|Low-dose naltrexone and acetaminophen combination|Twice a day
58277328|NCT03201393|DRUG|Placebo|Twice a day
57951026|NCT03326076|DIAGNOSTIC_TEST|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
57951027|NCT01685827|DRUG|Fexinidazole|
57951028|NCT01685827|DRUG|Nifurtimox|
57951029|NCT01685827|DRUG|Eflornithine|
58277329|NCT05144048|OTHER|Inpatient setting|These women stay at the maternity unit
58277330|NCT05144048|OTHER|Outpatient setting|These women leave the maternity unit
58067073|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
58394196|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
57924107|NCT06246708|OTHER|Self-help app with information for grieving Syrian Refugees|This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.
57924108|NCT06246708|OTHER|Wait-list|Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
57924109|NCT04071015|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
57924110|NCT00421200|DRUG|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
57924111|NCT00421200|DRUG|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
57924112|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10\^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
58067074|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
58067075|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
58067076|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
58067077|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
58067078|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
58277331|NCT04423575|OTHER|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
58277332|NCT01828216|DEVICE|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
58277333|NCT01828216|DEVICE|conventional polysomnography|conventional type I sleep study according to international guidelines
58277334|NCT01448863|OTHER|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
58277335|NCT03084315|DEVICE|E-Cig Zero Nicotine|E-Cig Zero Nicotine
58277336|NCT03084315|DEVICE|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
58277337|NCT01122017|PROCEDURE|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
58277338|NCT02105649|OTHER|Strengthening exercise + Electrical stimulation of calf muscle|
58394197|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
58394198|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
58394199|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
58394200|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
58394201|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
57924113|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
57924114|NCT02251288|DRUG|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
58394202|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
58394203|NCT00107432|DRUG|sorafenib tosylate|Given orally
58394204|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
58277339|NCT02105649|OTHER|selected physical therapy program|
58277340|NCT05410704|OTHER|exercises|Pelvic floor muscle exercises and diaphragmatic breathing exercise
57726052|NCT06478784|OTHER|Low aerobic training|"Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
57924115|NCT00029497|PROCEDURE|Acupuncture|
57924116|NCT00029497|DRUG|Amitriptyline|
57924117|NCT03622853|DRUG|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
57924118|NCT01734408|BIOLOGICAL|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
58277341|NCT05509686|DEVICE|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
58394205|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
58394206|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
57924119|NCT01734408|BIOLOGICAL|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
57924120|NCT01734408|BIOLOGICAL|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
58067079|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
58277342|NCT05509686|DEVICE|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
58394207|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
58394208|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
58394209|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
58394210|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
58394211|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
57726053|NCT00053131|BIOLOGICAL|filgrastim|
57726054|NCT00053131|BIOLOGICAL|sargramostim|
57726055|NCT00053131|DRUG|cytarabine|
57726056|NCT00053131|DRUG|mitoxantrone hydrochloride|
57924121|NCT01734408|BIOLOGICAL|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
57924122|NCT01734408|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo
57924123|NCT04144634|OTHER|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
58277343|NCT01813734|DRUG|Ponatinib|28 day cycle
58277344|NCT04026334|DEVICE|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
58277345|NCT04167683|OTHER|No intervention|No intervention
58394212|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
58394213|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
58394214|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
58394215|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
58394216|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
58394217|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
57924124|NCT04144634|OTHER|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
58394218|NCT00564733|DRUG|carboplatin|Given IV
58394219|NCT00564733|DRUG|docetaxel|Given IV
58394220|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
58394221|NCT00564733|DRUG|paclitaxel|Given IV
58067080|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
58067081|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
58067082|NCT03060109|OTHER|Blood draw within 12 hours of injury|
58067083|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
58067084|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
57726057|NCT00162851|DRUG|alemtuzumab|
57726058|NCT02545894|BEHAVIORAL|Cognitive therapy|"The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
57726059|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
58277346|NCT06350786|OTHER|P-Dragees blue Lichtenstein, Placebo dragees|"In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points:~1. Opioids work by telling the body that participants are not experiencing as much pain;~2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies);~3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid;~4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids."
58394222|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
57924125|NCT04897672|OTHER|Observational study|Observational study
57924126|NCT00286078|DEVICE|Precision|Implantable neurostimulator
57924127|NCT04233593|BIOLOGICAL|Lipopolysaccharide|Endotoxin E Coli
58067085|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
58067086|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
58067087|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
58394223|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
58394224|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
58394225|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
58394226|NCT03530995|DRUG|Belumosudil|Development candidate
58394227|NCT03530995|DRUG|Itraconazole|Perpetrator drug
58394228|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
57726060|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
58067088|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
58067089|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
58394229|NCT03530995|DRUG|Rifampicin|Perpetrator drug
57924128|NCT01088256|DRUG|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
57924129|NCT01088256|DRUG|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
58394230|NCT03530995|DRUG|Omeprazole|Perpetrator drug
58394231|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
57726061|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
57726062|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
57726063|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
58394232|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
58394233|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
58394234|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
58394235|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
58394236|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
57726064|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
57726065|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
57924130|NCT06428591|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|Participants will use the Tandem Freedom system for 3 day/nights in a supervised hotel setting, performing meal and exercise challenges.
57924131|NCT01553097|OTHER|Neurocognitive impairment observation|None - observational
57924132|NCT00385372|PROCEDURE|elimination diet|
57924133|NCT00385372|PROCEDURE|provocation diet|
57924134|NCT00118833|DRUG|Hypericum perforatum (St. John's wort)|
58067090|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
58067091|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
57924135|NCT02039960|DRUG|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
57924136|NCT05094466|BEHAVIORAL|Behavioral Intervention|Receive peer support sessions
57924137|NCT05094466|OTHER|Counseling|Receive health coaching sessions
57924138|NCT05094466|PROCEDURE|Discussion|Attend focus groups
58067092|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
58067093|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
58067094|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
58067095|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
58067096|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
58067097|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
58067098|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
58277347|NCT06350786|OTHER|Control group (EM)|"In the EM control group, the focus lies on the electronic monitoring (EM) of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points:~1. The collection of EM data allows for greater patients' sense of agency over medication treatment;~2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies);~3. The EM is a useful tool, and daily recording of opioid medication intake should be done;~4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids."
57726066|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
58067099|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
58067100|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
58067101|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
58067102|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
58067103|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
58067104|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
58067105|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
58067106|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
58067107|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
58277348|NCT06097273|BIOLOGICAL|mRNA-1083|Suspension for injection
58277349|NCT06097273|BIOLOGICAL|Placebo|0.9% sodium chloride suspension for injection
58277350|NCT06097273|BIOLOGICAL|Influenza Vaccine|Commercially available formulation (Suspension for injection \[pre-filled syringe\])
58277351|NCT06097273|BIOLOGICAL|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
58277352|NCT01048970|OTHER|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
58277353|NCT01048970|DIETARY_SUPPLEMENT|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
57924139|NCT05094466|OTHER|Educational Intervention|Receive handbook
57924140|NCT05094466|OTHER|Informational Intervention|Receive navigation sessions
57924141|NCT05094466|OTHER|Interview|Participate in interview
57924142|NCT00337519|PROCEDURE|allogeneic stem cell transplantation|see detailed description
57924143|NCT00337519|DRUG|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
57924144|NCT05121363|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
58067108|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
57726067|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
57726068|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
58277354|NCT01529411|DRUG|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).
57726069|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
57726070|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
57726071|NCT01705457|DRUG|placebo|
58277355|NCT01529411|OTHER|Undefined (standard care)|All the current interventions used by each institution for the study disease.
58277356|NCT04062071|OTHER|no intervention|no intervention
57726072|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
57726073|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
57726074|NCT05625204|BEHAVIORAL|Center based attention control|Center based attention control
57726075|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
57726076|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
57726077|NCT02449824|OTHER|magnetic resonance imaging|early MRI
57726078|NCT00406029|DRUG|Preladenant|1 mg BID capsules
57726079|NCT00406029|DRUG|Preladenant|2 mg BID capsules
57726080|NCT00406029|DRUG|Preladenant|5 mg BID capsules
58277357|NCT04549623|DEVICE|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
58277358|NCT04549623|DEVICE|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
57726081|NCT00406029|DRUG|Preladenant|10 mg BID capsules
57726082|NCT00406029|DRUG|Placebo|BID capsules
57726083|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
57726084|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
57726085|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
57726086|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
57726087|NCT00215852|DRUG|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
57726088|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
57726089|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
57726090|NCT03191084|DRUG|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
58277359|NCT04685278|BIOLOGICAL|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
58277360|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
58277361|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
58277362|NCT04209439|DRUG|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
58277363|NCT04209439|DRUG|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
58277364|NCT05725876|DRUG|Ustekinumab|Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
57726091|NCT03191084|DRUG|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
57924145|NCT05121363|DRUG|Anlotinib Hydrochloride capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
57924146|NCT00177983|BEHAVIORAL|(relapse rate)|
58277365|NCT02253732|BEHAVIORAL|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
58277366|NCT02671656|DEVICE|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
58277367|NCT01994902|DEVICE|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
57924147|NCT03581201|DIAGNOSTIC_TEST|Laboratory measurements|"Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry"
57924148|NCT03581201|DIAGNOSTIC_TEST|Stool samples|For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
57924149|NCT03581201|DIAGNOSTIC_TEST|Bioimpedance analysis|The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
57924150|NCT02208154|DRUG|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
57924151|NCT02208154|DRUG|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.
58067109|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
58067110|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
57726092|NCT03191084|DRUG|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
57726093|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
58394237|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
58394238|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
58394239|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
57726094|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
57924152|NCT02208154|DRUG|Selective Digestive Decontamination (SDD)|"SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
57924153|NCT04508322|DEVICE|HGA|Headgear Activator
57924154|NCT04508322|DEVICE|FA|Fixed Orthodontic Appliance
58277368|NCT01994902|DEVICE|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
58394240|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
58394241|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
58394242|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
58394243|NCT06106581|BIOLOGICAL|Control|Nimenrix
57924155|NCT04721093|DEVICE|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
57924156|NCT02376075|DRUG|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
58277369|NCT05977465|DRUG|Empagliflozin 25 MG|treatment
58277370|NCT02215785|OTHER|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
58394244|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
58394245|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
58394246|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
57924157|NCT02376075|DRUG|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
57924158|NCT01037881|DRUG|LEO 29102|comparison of different dosages of drug
58067111|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
58067112|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
58067113|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
58067114|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
58067115|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
58067116|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
58067117|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
58067118|NCT02242305|DRUG|Placebo|
58067119|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
58067120|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
58067121|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
58067122|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
58067123|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
58067124|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
58067125|NCT02471625|DEVICE|ClearView Scanning|
58067126|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
58067127|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
58067128|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
57924159|NCT01037881|DRUG|Elidel®|comparison
58067129|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
58067130|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
58067131|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
58277371|NCT00037037|BIOLOGICAL|MAGE-10.A2|
57726095|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
57924160|NCT00769860|DRUG|Arimoclomol|Arimoclomol 100 mg TID for 4 months
57924161|NCT00769860|OTHER|Placebo|Placebo for 4 months
57924162|NCT01384422|DRUG|GLPG0634|
57924163|NCT02451241|OTHER|acupuncture|electroacupuncture
57924164|NCT01177605|OTHER|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
57924165|NCT03575767|OTHER|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
57924166|NCT02742766|DRUG|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
57924167|NCT02742766|DRUG|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
57924168|NCT03891303|OTHER|Allogenic blood transfusion (ABT)|During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
58277372|NCT00037037|BIOLOGICAL|MART-1 antigen|
58277373|NCT00037037|BIOLOGICAL|NY-ESO-1 peptide vaccine|
58277374|NCT00037037|BIOLOGICAL|sargramostim|
58277375|NCT00037037|BIOLOGICAL|tyrosinase peptide|
58277376|NCT04328415|RADIATION|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
57924169|NCT00528892|DRUG|Raltegravir|switching PI to raltegravir
57924170|NCT00528892|DRUG|boosted PI|continue on boosted-PI
57924171|NCT04945590|BEHAVIORAL|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
57924172|NCT02342743|DEVICE|CEFALY|
57924173|NCT01412099|BEHAVIORAL|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
57924174|NCT01412099|BEHAVIORAL|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
57924175|NCT00295360|BEHAVIORAL|no intervention, pathophysiological study|
57924176|NCT00655486|DRUG|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
58067132|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
58067133|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
58277377|NCT01968512|DEVICE|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
58277378|NCT01968512|DEVICE|Sham|Same character of Transcranial Direct Current Stimulation but without current
57924177|NCT02787954|PROCEDURE|TACE|Procedure for giving chemotherapy directly to tumor cells.
58394247|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
57924178|NCT02787954|PROCEDURE|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
57924179|NCT02787954|PROCEDURE|MWA|Using heat to kill tumor cells.
57924180|NCT02787954|PROCEDURE|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
57924181|NCT02366377|DRUG|SHR3824|
57924182|NCT02366377|DRUG|Placebo|
58067134|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
58394248|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
57924183|NCT02366377|DRUG|Metformin|
57924184|NCT04102306|OTHER|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
57924185|NCT02215460|PROCEDURE|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924186|NCT02215460|PROCEDURE|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924187|NCT02215460|DRUG|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924188|NCT02215460|DRUG|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924189|NCT02215460|DRUG|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924190|NCT02215460|DRUG|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
58067135|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
58067136|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
58067137|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
58067138|NCT05032196|DRUG|WVE-003|WVE-003 is a stereopure antisense oligonucleotide (ASO)
57726096|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
58067139|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
58067140|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
58067141|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
58067142|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
58394249|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
58394250|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
58394251|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
58394252|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
57924191|NCT02215460|DRUG|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
58067143|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
57924192|NCT02215460|DRUG|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
58067144|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
58067145|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
57924193|NCT02215460|DRUG|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924194|NCT02215460|DRUG|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
57924195|NCT03376607|OTHER|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
57924196|NCT03376607|BEHAVIORAL|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
57924197|NCT04025723|OTHER|Downhill running|60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
57924198|NCT05610748|PROCEDURE|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
58067146|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
58067147|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
58067148|NCT00014560|BIOLOGICAL|sargramostim|
58067149|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
58067150|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
58277379|NCT02488590|DRUG|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
58394253|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
58394254|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
58394255|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
58394256|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
58277380|NCT02488590|DRUG|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
57924199|NCT05610748|PROCEDURE|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
57924200|NCT00625950|PROCEDURE|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
57924201|NCT01295281|DEVICE|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
57924202|NCT01295281|DEVICE|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
57924203|NCT02404974|BEHAVIORAL|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
58394257|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
58067151|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
58394258|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
58394259|NCT03296748|PROCEDURE|anterior colporraphy|
57924204|NCT00009841|BIOLOGICAL|EGFR antisense DNA|
57924205|NCT00009841|BIOLOGICAL|growth factor antagonist therapy|
57924206|NCT00009841|DRUG|DC-cholesterol liposome|
57924207|NCT04740008|DRUG|Low Nicotine Content Cigarettes|Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
57924208|NCT04740008|OTHER|Control message|Participants will read control message
57924209|NCT04740008|OTHER|Test message|Participants will read test message
58394260|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
57924210|NCT06078280|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
57924211|NCT01917019|DRUG|Placebo|matching placebo tablets
57924212|NCT01917019|DRUG|BIIB041 (fampridine)|fampridine prolonged-release tablets
58394261|NCT00073411|DRUG|duloxetine|
58394262|NCT00073411|DRUG|escitalopram|
58394263|NCT00073411|DRUG|placebo|
58067152|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
58067153|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
58394264|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
58394265|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
58394266|NCT04493424|DRUG|Spesolimab|Spesolimab
57924213|NCT03329443|DRUG|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
57924214|NCT03329443|DRUG|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
57924215|NCT00669799|DRUG|gentamyacin|topical internasal
57924216|NCT00669799|DRUG|gentamyacin|intranasal
57924217|NCT00621647|DRUG|Quetiapine Fumarate|
57924218|NCT00621647|DRUG|Quetiapine Fumarate|
57924219|NCT00621647|DRUG|Placebo|
57924220|NCT00984763|BIOLOGICAL|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
57924221|NCT00046085|BEHAVIORAL|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
58067154|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
58394267|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
58394268|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
58394269|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
58394270|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
58394271|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
58394272|NCT01173107|DRUG|colchicine|colchicine 1T tid
58394273|NCT02048137|DEVICE|Transcranial direct current stimulation|
58394274|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
58394275|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
58394276|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
58394277|NCT01468948|DRUG|Octanoic Acid|
58394278|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
58067155|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
57726097|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
57924222|NCT00046085|BEHAVIORAL|Customary care|Participants received care as usual.
57924223|NCT02699112|OTHER|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
57924224|NCT05283304|DRUG|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
57924225|NCT05283304|OTHER|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
57924226|NCT01071525|DRUG|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
58277381|NCT02488590|DRUG|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
58277382|NCT02488590|DRUG|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
58277383|NCT02488590|DRUG|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
58277384|NCT02928146|PROCEDURE|Hernia Repair|
58277385|NCT03900156|OTHER|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
57924227|NCT01303263|BEHAVIORAL|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
57924228|NCT00124098|DRUG|Aranesp® (darbepoetin alfa)|
57924229|NCT04189237|OTHER|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
58067156|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
58277386|NCT03853902|BEHAVIORAL|Mindfulness Program|Mindfulness Program
58277387|NCT00630591|BEHAVIORAL|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
58277388|NCT00630591|BEHAVIORAL|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
58277389|NCT00630591|BEHAVIORAL|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
58277390|NCT02061644|OTHER|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
58277391|NCT03476655|DRUG|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
58067157|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
58067158|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
58277392|NCT00427999|DRUG|imatinib mesylate|
58277393|NCT00427999|DRUG|Treosulfane|
58277394|NCT00427999|DRUG|etoricoxib|
57924230|NCT05620251|DIAGNOSTIC_TEST|Blood test|Assessment of humoral immune response
57924231|NCT00604864|DRUG|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
57924232|NCT00604864|DRUG|placebo|Placebo
58277395|NCT00427999|DRUG|pioglitazone|
57924233|NCT01208688|DEVICE|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
57951030|NCT00684255|PROCEDURE|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
58277396|NCT00427999|DRUG|dexamethasone|
57924234|NCT01208688|DEVICE|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
57924235|NCT01208688|OTHER|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
57924236|NCT01159379|DRUG|ertapenem|intravenous, 1 gram, once
57924237|NCT00279773|DRUG|TKI258|
57924238|NCT02148419|OTHER|no intervention|
57951031|NCT00684255|DRUG|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
58067159|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
58067160|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
57951032|NCT00684255|DRUG|Busulfan|Busulfan 3.2 mg/kg Days _8, -7, -6, -5
57951033|NCT00684255|DRUG|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
57951034|NCT01579188|DRUG|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
58067161|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
58067162|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
58067163|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
58277397|NCT03466879|DEVICE|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
58277398|NCT02562092|BEHAVIORAL|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
58277399|NCT02562092|BEHAVIORAL|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
58277400|NCT00182000|DRUG|seromycin|100mg tablet administered 1 hour prior to each therapy session
58277401|NCT00182000|BEHAVIORAL|Behavior Therapy|10 weekly hour-long behavior therapy sessions
58277402|NCT01711619|DEVICE|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
58277403|NCT01711619|OTHER|Optimized Medical Management|Optimized medical management
58277404|NCT05986864|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
58277405|NCT03951753|DRUG|Tirzepatide|Administered SC
58394279|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
58394280|NCT01039324|OTHER|Usual care|This is the study's control group
58394281|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
58277406|NCT03951753|DRUG|Semaglutide|Administered SC
58277407|NCT03951753|DRUG|Placebo|Administered SC
58277408|NCT00467558|DRUG|Naltrexone|daily
58277409|NCT00467558|DRUG|Sugar pill|daily
58277410|NCT02193711|OTHER|Topical Arthritis Cream|
58277411|NCT02206737|DEVICE|No nicotine e-cigarette|
58277412|NCT02206737|DEVICE|Low dose nicotine e-cigarette|
57924239|NCT06383520|DRUG|68Ga-aGPC3-scFv/Fab|"For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
57924240|NCT03774160|BEHAVIORAL|Generacion Actual|See description in arm description.
57924241|NCT04771611|DRUG|Fisetin|\~20mg/kg /day oral for four days (days 0,1 and days 8,9)
57924242|NCT04771611|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
57726098|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
57924243|NCT03349892|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
57924244|NCT00452088|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
57924245|NCT00452088|BIOLOGICAL|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
57924246|NCT00452088|BIOLOGICAL|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
57924247|NCT06306885|BEHAVIORAL|Action observation plus motor imagery followed by sleep|Participants will be asked to observe video-clips showing motor contents immediately before sleeping
58394282|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
57726099|NCT05307224|DEVICE|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
57726100|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
57726101|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
57726102|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
57726103|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
57726104|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
57726105|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
57726106|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
57726107|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
57924248|NCT06306885|BEHAVIORAL|Action observation plus motor imagery|Participants will be asked to observe video-clips showing motor contents at least 12 hours before sleeping
57924249|NCT06306885|BEHAVIORAL|Control|Participants will be asked to observe video-clips showing landscapes before sleeping
58067164|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
58067165|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
58067166|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
58067167|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
57726108|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
57726109|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
57726110|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
57726111|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
57726112|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
58067168|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
58067169|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
58067170|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
58277413|NCT02206737|DEVICE|High dose nicotine e-cigarette|
58394283|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
58394284|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
57726113|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
57924250|NCT02975024|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
57924251|NCT02975024|DEVICE|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
57924252|NCT02975024|DEVICE|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
57924253|NCT02690558|DRUG|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
57924254|NCT02530203|DEVICE|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
57924255|NCT02530203|DEVICE|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
58394285|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
57726114|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
57726115|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
57924256|NCT05166460|DEVICE|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
57924257|NCT04940039|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
57924258|NCT04940039|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
57924259|NCT04940039|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
58067171|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
58394286|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
58394287|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
57726116|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
57726117|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
57726118|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
57726119|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
57726120|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
57726121|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
58394288|NCT05694871|DRUG|Palbociclib|Given PO
57726122|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
57924260|NCT04940039|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
57924261|NCT04940039|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
57924262|NCT04940039|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
57924263|NCT04940039|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
58394289|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
58394290|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
58394291|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
58394292|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
57726123|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
57924264|NCT04940039|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
57924265|NCT04940039|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
57924266|NCT03741933|DRUG|Apremilast 30mg|Apremilast 30 mg tablet
57924267|NCT05781776|OTHER|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
57924268|NCT05781776|OTHER|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
57924269|NCT01902056|PROCEDURE|One layer allograft|The acellular dermal matrix was placed on the facial surface.
57924270|NCT01902056|PROCEDURE|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
57924271|NCT01944735|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
57924272|NCT01944735|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
57924273|NCT06351306|DRUG|Thioguanine (Tabloid ®)|60-80mg/m\^2 oral tablet
57924274|NCT06351306|DRUG|DecitabineCedazuridine (Inqovi ®)|35 mg decitabine and 100 mg cedazuridine oral tablet
57924275|NCT01172405|DRUG|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
57924276|NCT01172405|DRUG|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
57924277|NCT05844787|DRUG|MT101-5|Tablet
57924278|NCT00524719|PROCEDURE|Open Reduction and Internal Fixation|Fixation with volar locked plate
57924279|NCT00524719|PROCEDURE|Non-Spanning External Fixation|Radio-radial external fixation
57924280|NCT00524719|PROCEDURE|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
57924281|NCT05135949|OTHER|Patient Reported Outcomes|Satisfaction, Disabilities of the Shoulder, Arm and Hand
57924282|NCT05135949|OTHER|Strength Test|Handheld dynamometer to measure tricep extension
57924283|NCT06094270|DEVICE|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
57924284|NCT06433804|DIAGNOSTIC_TEST|HER2 IHC|Immunohistochemistry for HER2
57924285|NCT00797498|OTHER|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
57924286|NCT04027322|DRUG|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
57924287|NCT04027322|DRUG|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
57924288|NCT04027322|DRUG|Normal saline|Placebo for the control group.
57924289|NCT00911079|PROCEDURE|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
57924290|NCT00911079|RADIATION|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
57924291|NCT04294732|DRUG|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
57924292|NCT04294732|DRUG|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
57924293|NCT02222636|DRUG|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
57924294|NCT02222636|DRUG|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
58067172|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
58067173|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
58394293|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
57924295|NCT02222636|DRUG|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
58277414|NCT06524895|OTHER|Medical Reiki|Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
58277415|NCT06524895|OTHER|Sham Reiki|Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
58277416|NCT05559372|DIETARY_SUPPLEMENT|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
58277417|NCT02282163|DRUG|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
58277418|NCT00588939|DEVICE|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
58394294|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
58394295|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
58394296|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
58394297|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
58394298|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
58394299|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
58394300|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
58394301|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
58277419|NCT04986943|DEVICE|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
58394302|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
58394303|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
58394304|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
58394305|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
58394306|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
58277420|NCT02669667|DRUG|MEDI9314|single dose of MEDI9314
58394307|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
58394308|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
58394309|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
58394310|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
58394311|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
58394312|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
58394313|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
58394314|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
58394315|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
58394316|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
58394317|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
58394318|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
57924296|NCT02222636|DRUG|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
57924297|NCT02222636|DRUG|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
57924298|NCT06048692|DRUG|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
57924299|NCT06048692|DRUG|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
57924300|NCT00398736|PROCEDURE|sonographic measurement of inferior caval vein diameter|
57924301|NCT02967354|RADIATION|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
57924302|NCT03392025|OTHER|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
58277421|NCT02669667|DRUG|placebo|single dose of placebo
58277422|NCT00970515|PROCEDURE|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
58277423|NCT00970515|PROCEDURE|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
58394319|NCT01150058|GENETIC|western blotting|
58394320|NCT01150058|OTHER|flow cytometry|
58394321|NCT01150058|OTHER|laboratory biomarker analysis|
58394322|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
58394323|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
58394324|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
58394325|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
57924303|NCT03392025|OTHER|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
57924304|NCT03392025|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
57924305|NCT01616433|BEHAVIORAL|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
57924306|NCT01616433|BEHAVIORAL|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
58067174|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
58067175|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
58067176|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
58277424|NCT02982148|DEVICE|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
58277425|NCT02982148|DEVICE|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
58394326|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
58394327|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
57726124|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
57726125|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
57726126|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
57726127|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
58067177|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
58394328|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
57726128|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
58067178|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
58067179|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
58067180|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
58067181|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
58067182|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
58067183|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
58067184|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
58067185|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
57726129|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
57726130|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
57726131|NCT05153837|OTHER|oral water|500 ml oral water
57726132|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
57726133|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
57726134|NCT02038738|DRUG|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
57726135|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
57726136|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
57924307|NCT00842881|DEVICE|Healingstone navel belt|6\~8hours/day for 3months
57924308|NCT01739153|OTHER|Dietary intervention: CHEESE (High cheese intake)|
57924309|NCT01739153|OTHER|Dietary intervention: MEAT (High Meat intake)|
57924310|NCT01739153|OTHER|Dietary intervention: CARB (High Carbohydrate intake)|
57924311|NCT03278951|BEHAVIORAL|Video Conferencing Group|
57924312|NCT03278951|BEHAVIORAL|In Person Group|
57924313|NCT01892137|DRUG|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
57924314|NCT03450720|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single dose
57924315|NCT03613753|DRUG|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
57924316|NCT03613753|DRUG|irinotecan|irinotecan chemotherapy alone
57924317|NCT02425709|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
58067186|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
58067187|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
58277426|NCT02676635|BEHAVIORAL|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
58394329|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
57726137|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
57726138|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
57726139|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
57726140|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
57726141|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
57726142|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
57726143|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
57726144|NCT03710434|DRUG|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
57726145|NCT03710434|DRUG|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
57726146|NCT03710434|DRUG|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
57726147|NCT03710434|DRUG|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
57726148|NCT03710434|DRUG|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
57726149|NCT03710434|DRUG|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
57726150|NCT03710434|DRUG|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
57924318|NCT02425709|DRUG|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
57924319|NCT02425709|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
57924320|NCT05337163|DIAGNOSTIC_TEST|Diagnostic Test: Sputum DNA methylation analysis|Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
58067188|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
57924321|NCT05337163|PROCEDURE|chest CT or pathological examination|Subjects will undergo chest CT or pathological examination.
57924322|NCT03652025|PROCEDURE|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
57924323|NCT05625594|PROCEDURE|Aspiration|Undergo CSF aspiration
57924324|NCT05625594|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57924325|NCT05625594|PROCEDURE|Catheterization|Undergo catheterization
58067189|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
58067190|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
58067191|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
57924326|NCT05625594|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given ICV
57924327|NCT05625594|PROCEDURE|Computed Tomography|Undergo CT
57924328|NCT05625594|DRUG|Cyclophosphamide|Given IV
57924329|NCT05625594|DRUG|Fludarabine|Given IV
57924330|NCT05625594|PROCEDURE|Leukapheresis|Undergo leukapheresis
57924331|NCT05625594|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
57924332|NCT05625594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57924333|NCT05625594|PROCEDURE|Positron Emission Tomography|Undergo PET
57924334|NCT01465204|BEHAVIORAL|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
57924335|NCT01465204|BEHAVIORAL|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
57924336|NCT03006354|DEVICE|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
57924337|NCT03006354|DEVICE|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
58394330|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
58394331|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
57924338|NCT06464003|OTHER|Questionnaire|Malocclusion impact questionnaire
57924339|NCT04107350|DEVICE|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
57924340|NCT04493190|PROCEDURE|Scapular control training|Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
57924341|NCT04493190|PROCEDURE|General exercise|Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
57924342|NCT01013766|DRUG|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
57924343|NCT01013766|DRUG|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
57924344|NCT05866887|BEHAVIORAL|Sleep ALL Night|Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
58067192|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
58067193|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
57924345|NCT02441166|PROCEDURE|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
57924346|NCT04029935|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
57924347|NCT04029935|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
57924348|NCT05343026|DEVICE|Hearing aids|As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
57924349|NCT00037791|DRUG|(PN-152,243)/PN-196,444|
57924350|NCT01088100|GENETIC|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
57924351|NCT01562509|OTHER|Implementation tools|"* Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings."
57924352|NCT01562509|OTHER|Standard intervention|Standard intervention consists of audit\&feedback
57726151|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
57726152|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
57726153|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
57726154|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
57726155|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
57726156|NCT04498936|DRUG|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
57726157|NCT04498936|DRUG|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
57726158|NCT03807362|DRUG|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
57726159|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
57726160|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
57726161|NCT00560833|DRUG|esmirtazapine|
57726162|NCT00560833|DRUG|Placebo|
57726163|NCT04081207|BEHAVIORAL|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
57924353|NCT05859061|DEVICE|cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe|Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
57924354|NCT03630341|DRUG|Clomiphene Citrate 50mg|oral 50 mg tablets
57924355|NCT03630341|DRUG|L-carnitine|1000 mg oral tablet
57924356|NCT03630341|DRUG|Placebo Oral Tablet|oral tablets identical to L-carnitine
57924357|NCT04302454|RADIATION|Radiotherapy|Radiotherapy
58277427|NCT02943785|DRUG|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
57726164|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
57726165|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
57924358|NCT04302454|DRUG|Leuprorelin|Hormonal therapy
57924359|NCT01969591|PROCEDURE|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
58067194|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
58277428|NCT02943785|DRUG|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
58067195|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
58067196|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
58067197|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
58067198|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
58277429|NCT06212713|OTHER|Questionnaire administration|Questionnaire administration - version older adults and informal caregivers
57924360|NCT01969591|OTHER|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
58277430|NCT05347745|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
58277431|NCT00542100|DEVICE|PCMRI|
57924361|NCT00538889|DRUG|Lecozotan SR|
57924362|NCT00538889|DRUG|Citalopram|
57924363|NCT01612741|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
57924364|NCT01354808|DRUG|Dual Anti-Platelet Therapy (DAPT)|"* Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
57924365|NCT01354808|DRUG|Triple Anti-Platelet Therapy (TAPT)|"* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
57924366|NCT03279133|DRUG|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
58277432|NCT03159845|DRUG|Zinc Sulfate Oral Product|
58277433|NCT03159845|DRUG|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
57924367|NCT00288353|DRUG|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
57924368|NCT00288353|DRUG|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
57924369|NCT04571866|OTHER|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
58067199|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
58067200|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
58277434|NCT03159845|DRUG|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
58277435|NCT03159845|DRUG|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
58277436|NCT00005821|DRUG|patent blue V dye|
57924370|NCT03265041|DIAGNOSTIC_TEST|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
57924371|NCT03428737|PROCEDURE|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
57924372|NCT03428737|PROCEDURE|Pressure support ventilation|use of a pressure support level identical during the night to the pressure support level at the end of the day.
57924373|NCT01278251|PROCEDURE|Distal Biceps Re-Insertion|
58067201|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
58067202|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
58067203|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
58277437|NCT00005821|PROCEDURE|conventional surgery|
58277438|NCT00005821|PROCEDURE|lymphangiography|
58277439|NCT00005821|PROCEDURE|radionuclide imaging|
58277440|NCT00005821|PROCEDURE|sentinel lymph node biopsy|
58277441|NCT00005821|RADIATION|Technetium Tc 99m human serum albumin colloid|
58277442|NCT04191122|OTHER|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
58277443|NCT03828682|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet \[Envarsus\]
57924374|NCT00297570|DRUG|Pegylated Interferon and Imatinib|
57924375|NCT00350805|PROCEDURE|EEG|One 20 minutes session
57924376|NCT04182503|OTHER|No intervention|This is a multi-city observational cohort study without intervention.
57924377|NCT03299257|DRUG|donepezil treatment|30-day donepezil treatment
57924378|NCT04980937|PROCEDURE|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
58277444|NCT03828682|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
58277445|NCT03828682|DRUG|Mycophenolic Acid Oral Product|mycophenolic acid tablets
58394332|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
57726166|NCT02445079|OTHER|This is an observational study only|Observational study only
57726167|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
58067204|NCT00003410|DRUG|motexafin gadolinium|
58277446|NCT03828682|DRUG|Tacrolimus|Twice daily tacrolimus
58277447|NCT03828682|DRUG|Methylprednisolone|Methylprednisolone taper
58277448|NCT03828682|DRUG|Prednisone|Prednisone taper
58394333|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
57726168|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
57726169|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
57726170|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
57726171|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
57726172|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
57924379|NCT02318992|BIOLOGICAL|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
57924380|NCT02762812|BIOLOGICAL|BCD-055|
57924381|NCT02762812|BIOLOGICAL|Remicade®|
57924382|NCT01734174|PROCEDURE|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
57924383|NCT01734174|PROCEDURE|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
57924384|NCT01734174|PROCEDURE|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
58067205|NCT00003410|PROCEDURE|magnetic resonance imaging|
58067206|NCT00003410|PROCEDURE|surgical procedure|
58067207|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
58067208|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
58067209|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
58277449|NCT03828682|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
58277450|NCT03353948|DRUG|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
58277451|NCT03353948|DRUG|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
58277452|NCT00817505|DRUG|AZD1656|Single dose oral tablet
58277453|NCT00817505|DRUG|AZD1656|Single dose oral suspension
58277454|NCT02157597|OTHER|NIRS based management|"1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
57924385|NCT01487356|OTHER|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
57924386|NCT00505869|BEHAVIORAL|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
58067210|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
58277455|NCT02157597|OTHER|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
58277456|NCT06286020|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
58277457|NCT06286020|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
58277458|NCT04102384|OTHER|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
58394334|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
58394335|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
58394336|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
57726173|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
57924387|NCT00505869|BEHAVIORAL|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
58067211|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
58277459|NCT00285376|DRUG|vilazodone|titration to 40mg tablets qd for 8 weeks
58277460|NCT04414189|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis
58394337|NCT01827436|BEHAVIORAL|Conventional physical therapy|
58277461|NCT05056571|BEHAVIORAL|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
58277462|NCT02901301|DRUG|Pembrolizumab|200mg, IV, q3weeks, Day 1
58277463|NCT02901301|DRUG|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
57726174|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
58277464|NCT02901301|DRUG|Capecitabine|1000mg/m2, PO, BID, Day 1-14
57726175|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
57924388|NCT00505869|BEHAVIORAL|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
58277465|NCT02901301|DRUG|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
58277466|NCT06274151|DRUG|Naproxen 500 Mg|Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
58394338|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
58394339|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
58394340|NCT04305509|OTHER|no intervention|no intervention
58394341|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
58394342|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
58394343|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
57924389|NCT04851925|OTHER|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
57924390|NCT02189356|BEHAVIORAL|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
57924391|NCT02189356|BEHAVIORAL|standard care|standard pregnancy follow up
57924392|NCT01924351|RADIATION|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
57924393|NCT01066468|DRUG|Gleevec/Glivec|
57951035|NCT01579188|DRUG|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
58067212|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
58067213|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
58067214|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
57924394|NCT05781217|DRUG|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
57924395|NCT00405470|DEVICE|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
57924396|NCT00852592|DEVICE|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
58067215|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
58067216|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
58067217|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
58067218|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
58067219|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
58067220|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
58067221|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
58067222|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
58277467|NCT06274151|PROCEDURE|Rehabilitation|Rehabilitation after muscle strain injury
57726176|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
57726177|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
57726178|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
58394344|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
57726179|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
57726180|NCT01629082|DRUG|Clofarabine|
57726181|NCT01629082|DRUG|Lenalidomide|
57726182|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
57726183|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
57726184|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
57726185|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
57726186|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
57726187|NCT02826226|DEVICE|multiple-breath-washout test|
57726188|NCT02826226|DRUG|Bronchodilator Agents|
57726189|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
57924397|NCT00852592|DEVICE|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
57924398|NCT01367353|PROCEDURE|surgery or debulking surgery|surgery or debulking surgery
57726190|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
57726191|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
57726192|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
57726193|NCT03328897|DRUG|Omalizumab|injection of 150mg or 300 mg
57726194|NCT03328897|DRUG|Placebo|Injection of placebo
57726195|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
57924399|NCT01510522|DRUG|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
57924400|NCT01510522|DRUG|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month"
57924401|NCT02623374|BEHAVIORAL|self-help CBT intervention (SHCBT)|See 'Arms' section
58067223|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
58067224|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
58067225|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
58067226|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
58067227|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
58067228|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
58067229|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
58067230|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
58067231|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
58067232|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
58067233|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
58067234|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
58277468|NCT06274151|DRUG|Placebo|Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
58277469|NCT03079076|DRUG|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
58277470|NCT03079076|DRUG|Saline|2 ml saline subcutaneously bilaterally
57924402|NCT00270465|DRUG|VRC-HIVDNA016-00-VP|
57924403|NCT00270465|DRUG|VRC-HIVADV014-00-VP|
58277471|NCT04833400|DEVICE|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
57924404|NCT05412381|PROCEDURE|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
57924405|NCT05412381|PROCEDURE|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
57924406|NCT03520933|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
57924407|NCT03520933|DIAGNOSTIC_TEST|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
57924408|NCT01360060|DRUG|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
57924409|NCT01339741|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
58394345|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
58394346|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
58394347|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
58394348|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
58394349|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
58394350|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
58394351|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
57726196|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
57726197|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
57726198|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
57726199|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
57726200|NCT00426075|DEVICE|Elastic stockings|
57726201|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
57726202|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
57726203|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
57726204|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
57924410|NCT01339741|DRUG|Placebo|Placebo, oral route, 12 weeks
57924411|NCT05877183|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
57951036|NCT03201458|DRUG|Atezolizumab|Given IV
57951037|NCT03201458|PROCEDURE|Biopsy|Undergo tumor biopsy
57951038|NCT03201458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57951039|NCT03201458|DRUG|Cobimetinib|Given PO
57951040|NCT03201458|PROCEDURE|Computed Tomography|Undergo CT
58277472|NCT04833400|DEVICE|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
58277473|NCT03955900|OTHER|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
58394352|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
58394353|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
58394354|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
58394355|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
58394356|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
58067235|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
57726205|NCT05201157|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
57726206|NCT05201157|OTHER|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
57726207|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
57924412|NCT05877183|DEVICE|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
57924413|NCT00308386|BEHAVIORAL|Nurse Case Management intervention|Intervention is meeting with nurse case managers
57924414|NCT06251609|DRUG|Naloxone 2 MG|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
57924415|NCT06251609|DRUG|Saline 2ml|Placebo
57726208|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
57726209|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
57924416|NCT04111042|DEVICE|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
57924417|NCT03149471|DIAGNOSTIC_TEST|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
57924418|NCT00615836|DRUG|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
57924419|NCT05149365|DRUG|Sitagliptin + Standard Prophylaxis|Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
57924420|NCT05149365|DRUG|Standard Prophylaxis|Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
57924421|NCT04439721|DRUG|γδT Cell infusion agent|γδT
57924422|NCT05363696|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting surgery procedure
57924423|NCT05363696|PROCEDURE|Heart valve surgery|Heart valve surgery procedure
57726210|NCT04181710|PROCEDURE|Kidney transplant|Organ preserved in preservation solution
57726211|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
57924424|NCT06071273|OTHER|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
57951041|NCT03201458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57951042|NCT04894500|DIAGNOSTIC_TEST|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
58067236|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
58067237|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
57726212|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
57726213|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
57726214|NCT02376049|DRUG|Pimecrolimus cream|
57924425|NCT06071273|OTHER|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
57924426|NCT01480674|DRUG|Trastuzumab|
57924427|NCT02334033|OTHER|other|
57924428|NCT03753633|OTHER|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
57924429|NCT03753633|OTHER|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
57924430|NCT02032303|PROCEDURE|Assessment of coronary flow reserve|
57924431|NCT02032303|PROCEDURE|Percutaneous Coronary Intervention|
57924432|NCT02032303|DRUG|Ticagrelor loading|
57924433|NCT02032303|DRUG|Prasugrel loading|
57924434|NCT04286490|OTHER|Prone position|Abdomen suspension in prone position
57924435|NCT04065152|DRUG|Talimogene laherparepvec|Talimogene laherparepvec
57924436|NCT05073237|OTHER|Placebo|Daily placebo tablet
57924437|NCT05073237|DRUG|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
58277474|NCT04707560|PROCEDURE|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
57726215|NCT02376049|DRUG|Betamethasone dipropionate cream|
57924438|NCT03024853|BEHAVIORAL|BPS PAST|
57924439|NCT03024853|BEHAVIORAL|BPS PRESENT|
58277475|NCT03013985|DRUG|Glargine U300|Glargine U300 is a new generation long-acting insulin.
57726216|NCT02376049|DRUG|Clobetasol propionate cream|
57924440|NCT03024853|BEHAVIORAL|BPS FUTURE|
58277476|NCT03013985|DRUG|Glargine U100|Glargine U100 is a long-acting insulin.
58277477|NCT03013985|DRUG|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
57726217|NCT02376049|DRUG|Glaxal Base cream vehicle|
57726218|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
57924441|NCT03024853|BEHAVIORAL|CONTROL|
58277478|NCT04697654|DRUG|TLC19|Hydroxychloroquine Liposome Inhalation Suspension
57924442|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
57924443|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
57924444|NCT01220232|DRUG|Lersivirine|Lersivirine 750 mg QD for 10 days
57924445|NCT00733993|DRUG|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
57924446|NCT00733993|DRUG|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
57924447|NCT00733993|DRUG|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
58277479|NCT04697654|DRUG|TLC19 Vehicle|Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
58394357|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
57726219|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
57726220|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
57924448|NCT00733993|DRUG|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
57924449|NCT03029169|DRUG|Propafenone i.v.|Treatment
57924450|NCT03029169|DRUG|Amiodarone i.v.|Treatment
57924451|NCT00577161|DRUG|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
57924452|NCT00577161|DRUG|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
57924453|NCT03714204|BEHAVIORAL|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
57924454|NCT01839500|DRUG|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
57924455|NCT04856644|DRUG|4-month rifapentine-based regimen|8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
57924456|NCT01891721|BEHAVIORAL|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
57951043|NCT02361502|DRUG|mirabegron|
57951044|NCT02361502|DRUG|placebo|
57924457|NCT01891721|BEHAVIORAL|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
58277480|NCT00507988|BEHAVIORAL|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
57951045|NCT00841802|DRUG|Prednisone|Prednisone 30mg once daily x 5 days
58277481|NCT00507988|BEHAVIORAL|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
58277482|NCT00886925|DRUG|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
58277483|NCT00886925|DRUG|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
58277484|NCT05553535|DIAGNOSTIC_TEST|MRI|retrospective review of shoulder MRI
58277485|NCT05492422|DEVICE|Central Executive Training (CET)|Central Executive Training (CET)
58277486|NCT05492422|BEHAVIORAL|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
58277487|NCT05589402|DRUG|Lidocaine Cream 5%|Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
58277488|NCT05589402|OTHER|Rehabilitation Movement Training|reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
58277489|NCT05837546|OTHER|Animal-assisted intervention|presence of a dog, contact between dog and participant
58277490|NCT05837546|OTHER|Factice dog intervention|presence of a factice dog, contact between factice dog and participant
58277491|NCT05837546|OTHER|Plant intervention|presence of a plant, contact between plant and participant
57951046|NCT03997435|DRUG|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
57951047|NCT03997435|DRUG|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
58277492|NCT03768921|OTHER|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
57924458|NCT01891721|BEHAVIORAL|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
57924459|NCT04193488|BEHAVIORAL|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
57924460|NCT04193488|BEHAVIORAL|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
57924461|NCT04193488|BEHAVIORAL|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
57924462|NCT00510523|DEVICE|Whole Body Vibration machine|
57924463|NCT03919188|PROCEDURE|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
57924464|NCT03919188|PROCEDURE|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
57924465|NCT02041741|BEHAVIORAL|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
58067238|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
58067239|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
58067240|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
58067241|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
58277493|NCT03230136|OTHER|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
58277494|NCT03230136|OTHER|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
57726221|NCT03977844|OTHER|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
57924466|NCT02041741|BEHAVIORAL|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
57951048|NCT03611192|OTHER|Multicomponent exercise|Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins
58067242|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
58067243|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
58067244|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
58067245|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
58277495|NCT00768339|DRUG|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
58277496|NCT03647423|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
58277497|NCT03647423|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
58067246|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
58067247|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
58067248|NCT05620160|DRUG|Placebo|placebo （tablet）
58277498|NCT03647423|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
58277499|NCT03647423|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
58277500|NCT03647423|BIOLOGICAL|GI-6301|Brachyury yeast
58277501|NCT03647423|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
58277502|NCT03647423|DRUG|Avelumab|injection
58277503|NCT03647423|DRUG|Cetuximab|Injection
57951049|NCT03611192|OTHER|Home-program exercise|60 mins exercise
57951050|NCT02198703|DIETARY_SUPPLEMENT|Probiotics bacterial strains|
57951051|NCT02198703|DIETARY_SUPPLEMENT|Placebo|
57951052|NCT03094234|DEVICE|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
57951053|NCT03094234|PROCEDURE|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
57951054|NCT03094234|DRUG|Propranolol|Appropriate dose of propranolol was administered to the patients.
57951055|NCT02577614|DRUG|FEIBA|Administration of FEIBA after cardiopulmonary bypass
57951056|NCT02577614|DRUG|Normal Saline|Administration of placebo after cardiopulmonary bypass
57951057|NCT05143892|DRUG|Avatrombopag|Avatrombopag administered at the described frequency to achieve a target platelet count
57951058|NCT05143892|OTHER|Supportive care|Supportive care other than TPO-RAs or recombinant human thrombopoietin.
57951059|NCT05227521|BEHAVIORAL|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
57951060|NCT03587220|DRUG|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
57951061|NCT03587220|RADIATION|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
57951062|NCT03587220|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
57951063|NCT03587220|DRUG|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
57951064|NCT02249143|DEVICE|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
57951065|NCT02707120|DRUG|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
57951066|NCT02707120|DRUG|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
57951067|NCT04159220|PROCEDURE|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
57951068|NCT05464888|BEHAVIORAL|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
57951069|NCT05464888|BEHAVIORAL|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
57951070|NCT05464888|BEHAVIORAL|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
57951071|NCT00952497|DRUG|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
57951072|NCT03717909|DRUG|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
57951073|NCT03717909|DRUG|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
57951074|NCT04558866|DRUG|Testosterone Cypionate|One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
57951075|NCT04558866|DRUG|Darolutamide|During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
57951076|NCT02864368|DRUG|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
57951077|NCT02864368|DRUG|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
57951078|NCT02864368|BIOLOGICAL|PEP-CMV: Component A|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
57924467|NCT05781919|OTHER|Immersive virtual reality imaging|Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
57924468|NCT05781919|OTHER|Gold standard imaging|Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
58394358|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
57924469|NCT04098354|DIAGNOSTIC_TEST|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
57924470|NCT01072877|DRUG|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
57924471|NCT01072877|DRUG|Placebo Vehicle|Placebo vehicle
57924472|NCT03302000|OTHER|Early Visual Stimulation|Early visual stimulation
57924473|NCT03302000|OTHER|standard care|standard care
58277504|NCT03647423|DRUG|Cyclophosphamide|Capsules
58277505|NCT03647423|RADIATION|SBRT|Stereotactic body radiation therapy
58277506|NCT02401061|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
58277507|NCT00404924|DRUG|ZD6474 (vandetanib)|once daily oral tablet
58277508|NCT00404924|OTHER|Best Supportive Care|standard of care
58394359|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
57924474|NCT05068518|OTHER|No intervention|no intervention
58277509|NCT03757403|DRUG|RDD1609|RDD1609 to be applied on the perianal area BID
57924475|NCT00003741|BIOLOGICAL|monoclonal antibody HeFi-1|
57924476|NCT00198627|DRUG|Co-Trimoxazole; TMP-SMZ|
57924477|NCT03629951|DRUG|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
57924478|NCT04051827|DRUG|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
58277510|NCT03757403|DRUG|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
58277511|NCT05563935|DEVICE|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
57924479|NCT04051827|DRUG|TAK-788|TAK-788 Oral Capsules.
57924480|NCT03598088|DEVICE|Ovaprene|non-hormonal contraceptive ring
57924481|NCT04254185|PROCEDURE|Simple decompression|Surgical technique
57924482|NCT04254185|PROCEDURE|Subcutaneous anterior transposition|Surgical technique
57924483|NCT03700749|DRUG|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
58277512|NCT04712513|DIAGNOSTIC_TEST|Dynamic cardiac CT perfusion imaging|Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
57924484|NCT03700749|DRUG|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
57924485|NCT03700749|DRUG|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
57924486|NCT03700749|DRUG|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
57924487|NCT04740892|OTHER|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
57924488|NCT04740892|OTHER|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
57924489|NCT02025569|OTHER|Strain Counterstrain|
57924490|NCT02025569|OTHER|Sham strain counterstrain|
57924491|NCT03125213|DRUG|AL-3778|AL-3778 tablets
57924492|NCT03125213|DRUG|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
57924493|NCT03125213|DRUG|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
57924494|NCT00465725|DRUG|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
57924495|NCT03773822|COMBINATION_PRODUCT|Hydrocortisone + Flucortac|Low dose steroids
57924496|NCT03773822|OTHER|Placebo|Placebo
57924497|NCT01762033|DRUG|ASONEP|Intravenous infusion
57924498|NCT02090374|OTHER|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
57924499|NCT02090374|OTHER|Poly I:C|Single dose: 500ug
57924500|NCT02090374|OTHER|R848|High dose: 10ug Low dose: 1-2ug
57924501|NCT02090374|OTHER|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
57924502|NCT02090374|OTHER|Vitamin D|4000U orally
57924503|NCT02090374|OTHER|Tuberculin|Tuberculin PPD
57924504|NCT03130010|DRUG|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
57924505|NCT05908604|OTHER|Robot for madication management|The effect of a robot in medication management for older people's home care
57924506|NCT02354443|BIOLOGICAL|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
57924507|NCT01786174|DRUG|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
57924508|NCT01786174|OTHER|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
57924509|NCT01185925|DRUG|Sildenafil|Sildenafil, 50 mg 3 times/day
57924510|NCT01185925|DRUG|Placebo|Placebo
57924511|NCT05643846|PROCEDURE|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
58277513|NCT06305260|DIAGNOSTIC_TEST|Lumbar Ultrasound|Investigators will utilize our ultrasound machine to complete a pre-procedural lumbar ultrasound prior to epidural placement.
58277514|NCT03865394|BIOLOGICAL|Application of allogeneic ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
58277515|NCT03865394|PROCEDURE|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
57924512|NCT02051270|OTHER|Descriptive study|More than 65 years old elders
57924513|NCT02031289|DRUG|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
57924514|NCT04724226|DRUG|Camrelizumab; Apatinib|"Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD"
57924515|NCT03513874|DRUG|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
57924516|NCT03513874|DRUG|Insulin|Patients will continue insulin therapy following physicians' instructions.
57924517|NCT06277102|OTHER|music listening|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
57924518|NCT04602377|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
57924519|NCT03525990|OTHER|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
57924520|NCT04209621|DRUG|Duvelisib|twice daily as tolerated until disease progression
57924521|NCT04209621|DRUG|Ibrutinib|daily for the first six 28-day cycles
57924522|NCT01539304|DRUG|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
57924523|NCT01539304|DRUG|Placebo|Placebo dry syrup, b.i.d
57924524|NCT04386343|DRUG|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
57924525|NCT04386343|DRUG|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
57924526|NCT04386343|DRUG|Placebos|The placebo was used on patients as a control for the doses of CH1701
57924527|NCT00002151|DRUG|Celgosivir hydrochloride|
57951079|NCT02864368|DRUG|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
58394360|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
58394361|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
57924528|NCT04682171|OTHER|Low level laser therapy|"* Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~* Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~* On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
57924529|NCT04682171|OTHER|Conventional Exercise Therapy|"1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
57924530|NCT04803136|PROCEDURE|spine surgeries|all spine surgeries including stabilization and fusion surgeries
57924531|NCT01699789|OTHER|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
57924532|NCT01699789|BEHAVIORAL|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
57924533|NCT01699789|BEHAVIORAL|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
57924534|NCT04071353|DRUG|Interferon|Interferon combined with ribavirin antiviral therapy
57924535|NCT04071353|DRUG|ribavirin|Interferon combined with ribavirin antiviral therapy
57924536|NCT04071353|DRUG|DAAs|DAAs antiviral treatment
57924537|NCT01289171|DRUG|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
57924538|NCT01809184|DRUG|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
57924539|NCT01809184|DRUG|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
57924540|NCT01809184|DRUG|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
57924541|NCT04248270|DRUG|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
57924542|NCT00913120|DRUG|YM150|oral
57924543|NCT00913120|DRUG|Placebo|oral
57924544|NCT00913120|DRUG|Enoxaparin|injection
58277516|NCT02205697|BEHAVIORAL|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
58394362|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
58394363|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
58394364|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
58394365|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
58394366|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
58394367|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
58394368|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
58394369|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
58394370|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
58394371|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
57924545|NCT03920709|OTHER|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
57924546|NCT00225992|DRUG|Arsenic Trioxide|
57924547|NCT05946278|OTHER|Sample collection for gene expression|This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
57924548|NCT05427812|DRUG|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
57924549|NCT05427812|DRUG|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
57924550|NCT04891328|OTHER|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
57726222|NCT03977844|OTHER|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
57726223|NCT03977844|OTHER|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
57924551|NCT01315223|OTHER|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
57924552|NCT04658459|PROCEDURE|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
58067249|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
58277517|NCT02055274|DRUG|LY03003|
58277518|NCT02055274|DRUG|Neupro|
57924553|NCT00910351|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
58067250|NCT00012870|BEHAVIORAL|Behavioral Management|
58067251|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
58277519|NCT03124537|BEHAVIORAL|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
58277520|NCT03124537|BEHAVIORAL|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
58277521|NCT01991899|BIOLOGICAL|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
58277522|NCT01991899|BIOLOGICAL|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
58394372|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
58394373|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
57924554|NCT05292820|OTHER|Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure|Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
57924555|NCT05286697|DIAGNOSTIC_TEST|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
57924556|NCT02389114|OTHER|Soy Protein|Soy protein is commonly consumed in Asian diet.
57951080|NCT02864368|DRUG|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
57726224|NCT03977844|OTHER|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
57924557|NCT02389114|OTHER|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
57924558|NCT03141554|DRUG|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
57924559|NCT03141554|DRUG|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
57924560|NCT03141554|DRUG|Normal saline gargle|Normal saline gargle
57924561|NCT02488889|DRUG|Varenicline|
57924562|NCT02488889|DRUG|Placebo pill (for varenicline)|
57924563|NCT02488889|DRUG|Alcohol|
57924564|NCT02488889|DRUG|placebo beverage (for alcohol)|
57924565|NCT00367120|DRUG|Azithromycin Extended Release|
57924566|NCT00367120|DRUG|Amoxicillin/Clavulanate|
57924567|NCT02725099|DRUG|Chewing Ticagrelor|180 mg Chewing Ticagrelor
57924568|NCT02725099|DRUG|Oral Ticagrelor|180 mg oral Ticagrelor
58067252|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
57924569|NCT01631604|DEVICE|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
57924570|NCT01631604|DRUG|Muscle/nerve injection|Injection to muscle or nerve
57924571|NCT01631604|PROCEDURE|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
57924572|NCT01631604|OTHER|Physical therapy treatment|
57924573|NCT04328051|OTHER|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
57924574|NCT04359004|OTHER|Vagus Nerve Stimulation (VNS)|Vagus Nerve Stimulation (VNS) will be performed percutaneously through the internal jugular vein during the patient's routine VT ablation procedure. The nerve will be stimulated using standard pacing systems used for clinical purposes. A series of stimulation frequencies and pulse widths will be used to define optimal effects and 'dosing'. Activation recovery interval (ARI) will be measured from the unipolar electrograms. In addition, heart rate and blood pressure responses will be continuously recorded.
57924575|NCT03310268|OTHER|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57924576|NCT03310268|OTHER|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57951081|NCT02864368|BIOLOGICAL|PEP-CMV: Component B|500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
57726225|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
58277523|NCT00428922|DRUG|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
57726226|NCT00432380|BIOLOGICAL|Placebo|oral dose
57726227|NCT04996784|OTHER|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
57726228|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
57726229|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
57726230|NCT00013312|PROCEDURE|Determine colonic tone|
57726231|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
57726232|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
57726233|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
57726234|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
57726235|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
57726236|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
57726237|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
57726238|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
57726239|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
57726240|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
58277524|NCT00428922|DRUG|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
58277525|NCT00428922|DRUG|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
58277526|NCT02227719|DEVICE|CTI|CTI is the titanium mesh
58277527|NCT02227719|DEVICE|Collagen membrane|
57726241|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
57726242|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
57726243|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
57726244|NCT02736539|DRUG|Placebo|Placebo treatment
57726245|NCT00001402|DEVICE|PET scan|
57726246|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
57726247|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
57726248|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
57726249|NCT03574129|BEHAVIORAL|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
57726250|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
57726251|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
57726252|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
57726253|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
57726254|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
57726255|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
57726256|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
57726257|NCT00501605|DRUG|AZD2171|
57951082|NCT00400673|BEHAVIORAL|Two-step remission induction and risk-oriented consolidation|
57951083|NCT03703882|DRUG|Edasalonexent|100 mg/kg/day
57924577|NCT03310268|OTHER|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
57726258|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
57924578|NCT05141214|BEHAVIORAL|Virtual Reality Application|In VR application, Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
57924579|NCT05192538|DEVICE|Endoscopic endoloop pre-test treatment|A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
57924580|NCT05793177|BEHAVIORAL|Everyday Life is Rehabilitation|Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
58067253|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
58067254|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
58067255|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
58067256|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
57726259|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
57726260|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
57726261|NCT04321837|DRUG|Ibandronate|Bisphosphonate
57726262|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
57726263|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
57726264|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
57726265|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
57726266|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
57726267|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
57726268|NCT02983578|DRUG|Danvatirsen|Given IV
57726269|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
57726270|NCT02745379|PROCEDURE|BFPSCs+ DFDBA+ PRF|
57924581|NCT05708326|BEHAVIORAL|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
57924582|NCT05708326|BEHAVIORAL|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
57924583|NCT00186771|DEVICE|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
57924584|NCT00186771|DEVICE|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
57726271|NCT02745379|PROCEDURE|DFDBA + PRF|
57726272|NCT01698060|BIOLOGICAL|ND1.1|
57726273|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
57726274|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
57726275|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
57726276|NCT00276445|DRUG|beta-1,3-glucan|
57726277|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
57726278|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
57726279|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
57726280|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
57726281|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
57726282|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
57924585|NCT04756960|DRUG|CHF6001|4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
57924586|NCT03054480|DEVICE|Fractional Micro-Needle Radiofrequency|
58067257|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
58067258|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
57924587|NCT03054480|DRUG|Botulinum toxin type A|
57924588|NCT03602066|DRUG|Chlorine Dioxide Sterilization|Given via oral rinse
57924589|NCT03602066|OTHER|Laboratory Biomarker Analysis|Correlative studies
57924590|NCT03602066|OTHER|Placebo|Given via oral rinse
57924591|NCT02863887|BEHAVIORAL|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
57924592|NCT04561752|DRUG|ZN-c5|ZN-c5 is the study drug.
58067259|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
58067260|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
58067261|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
57924593|NCT04624451|DRUG|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
57924594|NCT04950088|OTHER|Hand-held video game device|
57924595|NCT01048567|OTHER|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
57924596|NCT01048567|OTHER|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
57924597|NCT02679742|DIETARY_SUPPLEMENT|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
57924598|NCT02679742|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
57924599|NCT04100473|DRUG|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
57924600|NCT04100473|DRUG|Insulin Lispro (Humalog U-100)|Lispro
57924601|NCT03321487|DEVICE|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
57924602|NCT01793220|OTHER|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
57924603|NCT03701113|DIETARY_SUPPLEMENT|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
58067262|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
58067263|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
58067264|NCT00000610|DRUG|magnesium|
58067265|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
57726283|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
58277528|NCT04843358|BEHAVIORAL|Emotional Disclosure|"The trial member will deliver instructions For the next three days, I want you to write about your experience with cancer. In your writing, I want you to really let go and explore your very deepest emotions and thoughts. It is critical that you delve deeply. Ideally, I would like you to write about those parts of the experience you found hard to share with others. Perhaps this will provide an opportunity to really examine those thoughts and emotions. You might tie your personal experiences to other parts of your life. How is it related to your family life, relationship with your spouse, your children, your sexuality, daily activities, hobbies, your past, your childhood, your work? These are just some examples."
58277529|NCT04843358|BEHAVIORAL|Non-Emotional Writing|"The trial member will deliver instructions were as follows. For the next three days, I want you to write about how you use your time. We are interested in everything you do during the course of a day. In your writing I want you to be completely objective. We are not interested in your emotions or opinions. Feel free to be as detailed as possible"
58277530|NCT01555710|DRUG|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
58277531|NCT01555710|DRUG|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
58277532|NCT01555710|DRUG|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
57726284|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
57726285|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
57726286|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
57726287|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
57726288|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
57726289|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
57726290|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
57726291|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
57924604|NCT03701113|DIETARY_SUPPLEMENT|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
57924605|NCT04571281|DIAGNOSTIC_TEST|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
57924606|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
57924607|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
58067266|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
58277533|NCT01555710|DRUG|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
58067267|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
58067268|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
58067269|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
58277534|NCT06171594|COMBINATION_PRODUCT|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
58394374|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
57924608|NCT00231387|DRUG|rosiglitazone|
57924609|NCT01257789|PROCEDURE|laparoscopic gastric bypass|laparoscopic gastric bypass
57924610|NCT01019317|DRUG|Cytarabine|0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).
57924611|NCT01019317|DRUG|Fludarabine|15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
57924612|NCT04629001|DIAGNOSTIC_TEST|Covid-19 PCR , IGM|test for Covid-19
57924613|NCT00414128|DRUG|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
57924614|NCT00414128|DRUG|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
57924615|NCT04307082|DRUG|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
57924616|NCT01366495|BEHAVIORAL|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
57726292|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
58067270|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
58067271|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
58067272|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
57726293|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
57726294|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
57924617|NCT02532153|DRUG|Ketamine Hydrochloride|Single open-label infusions
58067273|NCT00085189|DRUG|agatolimod sodium|Given SC
58067274|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
58067275|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
58067276|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
58067277|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
58067278|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
58277535|NCT00005796|PROCEDURE|filgrastim|GCSF is given after chemo administration
58394375|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
57924618|NCT02475174|OTHER|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
57924619|NCT02475174|OTHER|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
57924620|NCT03566810|DRUG|Test GXR|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
57924621|NCT03566810|DRUG|Reference GXR|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
57924622|NCT03540953|DRUG|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
57924623|NCT05906823|OTHER|Detection of pleural effusion|Detection of pleural effusion
57924624|NCT06227663|BEHAVIORAL|KOALOU(®) digital application|Digital app that prepares children for the ambulatory surgery care pathway by assessing their anxiety and educating them about anesthesia and surgery
57924625|NCT01561222|DRUG|Calcitriol|0.25 ug per day for one year
57924626|NCT01561222|DRUG|placebo|one pill per day
57924627|NCT02776345|OTHER|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
57951084|NCT03703882|DRUG|Placebo|Placebo
58067279|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
58067280|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
58067281|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
58067282|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
58067283|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
58067284|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
58067285|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
58067286|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
58067287|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
57924628|NCT02776345|OTHER|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
57951085|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
58067288|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
58067289|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
58067290|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
58067291|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
58067292|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
58067293|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
58067294|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
58067295|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
58067296|NCT03570476|DRUG|Olaparib|Given orally
58067297|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
58067298|NCT02081664|BEHAVIORAL|lifestyle intervention|
58277536|NCT00005796|BIOLOGICAL|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
58067299|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
58277537|NCT00005796|DRUG|lomustine|chemotherapy is administered every 21 days
58277538|NCT00005796|DRUG|procarbazine hydrochloride|chemotherapy is administered every 21 days.
58277539|NCT00005796|DRUG|vincristine sulfate|chemotherapy is administered every 21 days
58277540|NCT00005796|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
58277541|NCT00696228|DIETARY_SUPPLEMENT|Placebo|Placebo
58277542|NCT00696228|DIETARY_SUPPLEMENT|MUFA|MUFA
58277543|NCT00696228|DIETARY_SUPPLEMENT|PUFA|PUFA
58277544|NCT00696228|DIETARY_SUPPLEMENT|SFA|SFA
58277545|NCT02372435|PROCEDURE|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
58277546|NCT01658904|DRUG|Carfilzomib|
58277547|NCT01658904|DRUG|Melphalan|
58277548|NCT01658904|DRUG|Filgrastim|
58277549|NCT01911780|DRUG|placebo|placebo matching amlodipine capsule
58277550|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
58277551|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
58277552|NCT01911780|DRUG|amlodipine|capsule
58394376|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
57924629|NCT02776345|OTHER|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
57924630|NCT03527914|OTHER|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
57924631|NCT03527914|OTHER|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
57924632|NCT03459014|OTHER|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
57924633|NCT03459014|OTHER|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
57924634|NCT01748487|DRUG|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
57924635|NCT01176773|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
57924636|NCT00059839|DRUG|doxorubicin hydrochloride|Given IV
57924637|NCT00059839|DRUG|mercaptopurine|Given by mouth
57924638|NCT00059839|DRUG|methotrexate|Given IV and intrathecally
57924639|NCT00059839|DRUG|prednisone|Given by mouth
57924640|NCT00059839|DRUG|vinblastine sulfate|Given IV
57924641|NCT00059839|DRUG|vincristine sulfate|Given IV
57924642|NCT01653184|DIETARY_SUPPLEMENT|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
57924643|NCT01117857|DRUG|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
57924644|NCT04208009|BEHAVIORAL|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
58277553|NCT06031675|OTHER|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
58277554|NCT05175950|BIOLOGICAL|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
57924645|NCT03890419|DEVICE|Green light|Green light exposure
57924646|NCT03890419|DEVICE|Clear light|Full spectrum light exposure
57924647|NCT03890419|DEVICE|Blue Light|Blue light exposure
57924648|NCT03373487|BEHAVIORAL|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
58277555|NCT05175950|OTHER|Normal saline|Normal saline
57924649|NCT02332109|DEVICE|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
57924650|NCT03292718|DEVICE|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
57924651|NCT00001962|DRUG|Daclizumab|Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
58277556|NCT00573586|DEVICE|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
57924652|NCT04700046|DRUG|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
57924653|NCT04700046|DRUG|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
57924654|NCT06031896|OTHER|No interventions|No interventions
57924655|NCT01387919|BEHAVIORAL|Prolonged fasting|48 hours of fasting
57924656|NCT01681056|BEHAVIORAL|Autosuggestion for 30 days|
57924657|NCT02042196|DRUG|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
57924658|NCT02042196|DRUG|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
57924659|NCT02042196|DRUG|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
58067300|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
58067301|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
58067302|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
58067303|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
58067304|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
58067305|NCT01209299|GENETIC|DNA methylation analysis|
58067306|NCT01209299|GENETIC|gene expression analysis|
57924660|NCT02042196|DRUG|Climara|0.075mg/d transdermal patch will be placed on skin.
58067307|NCT01209299|OTHER|laboratory biomarker analysis|
58067308|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
58067309|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
58067310|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
58067311|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
58067312|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
58277557|NCT03891823|DEVICE|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
57924661|NCT02042196|DRUG|Placebo transdermal patch|Inactive transdermal patch
57924662|NCT04036032|OTHER|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
57924663|NCT01179451|DEVICE|echocardiogram|echocardiogram
57924664|NCT00634010|DRUG|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
57924665|NCT00634010|DRUG|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
58067313|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
58067314|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
58067315|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
58067316|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
58067317|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
58067318|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
58067319|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
58067320|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
58067321|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
58067322|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
57924666|NCT03739931|BIOLOGICAL|mRNA-2752|Solution for intratumoral injection
58067323|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
58067324|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
58067325|NCT02528461|PROCEDURE|Gastroscopy|
58067326|NCT02528461|PROCEDURE|Liver biopsy|
57726295|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
57726296|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
57726297|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
58277558|NCT03891823|DRUG|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
58277559|NCT01180049|DRUG|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
57726298|NCT00045994|DRUG|ALT-711|
58067327|NCT02528461|PROCEDURE|Fibroscan|
58067328|NCT02528461|PROCEDURE|Liver vein catheterization|
57726299|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
57726300|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
57726301|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
57726302|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
58067329|NCT02528461|DRUG|Sofosbuvir|
58067330|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
58277560|NCT01180049|DRUG|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
58394377|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
57726303|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
57726304|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
57924667|NCT03739931|BIOLOGICAL|Durvalumab|Solution for infusion after dilution
57924668|NCT02626754|DRUG|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
57924669|NCT02652650|DRUG|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
58067331|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
58067332|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
58067333|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
58394378|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
57726305|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
57726306|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
57726307|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
57726308|NCT02660944|DRUG|RSLV-132|RNase-Fc fusion protein
57726309|NCT02660944|DRUG|Placebo|Saline placebo
57726310|NCT01538745|DRUG|Ketamine|0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.
57726311|NCT01538745|DRUG|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
57726312|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
57726313|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
57726314|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
57726315|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
57726316|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
57726317|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
57726318|NCT06533124|DEVICE|The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.|In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
57726319|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
57726320|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
57726321|NCT03354000|BEHAVIORAL|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
57726322|NCT03354000|BEHAVIORAL|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
57726323|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
57726324|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
57726325|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
57726326|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
57726327|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
57726328|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
57924670|NCT02652650|DRUG|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
57924671|NCT02652650|DRUG|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
58067334|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
58067335|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
58394379|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
57726329|NCT03502343|DRUG|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
57726330|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
57726331|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
57924672|NCT04723186|DRUG|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
57924673|NCT04256434|DRUG|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
57726332|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
57726333|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
57726334|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
57924674|NCT04256434|DRUG|Nalbuphine HCl|20 mg Nalbuphine
57924675|NCT01938469|OTHER|Liquid Meal|
57924676|NCT01938469|OTHER|Solid Meal|
58067336|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
58067337|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
58067338|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
58394380|NCT04941183|DRUG|NTR-441|NTR-441
58394381|NCT04941183|DRUG|Placebo|Placebo
58394382|NCT04963244|OTHER||
57924677|NCT05009745|PROCEDURE|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
57924678|NCT01728532|DEVICE|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
58394383|NCT00321243|BEHAVIORAL|Visual clues|
58394384|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
58394385|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
58394386|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
58394387|NCT01887730|BEHAVIORAL|Control|
57924679|NCT01728532|DEVICE|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
57924680|NCT02652962|DEVICE|Gelesis200|3 capsules each containing 0.70 g
58067339|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
58067340|NCT00000322|BEHAVIORAL|Tyrosine|
57726335|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
57726336|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
57726337|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
57726338|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
57924681|NCT02652962|OTHER|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
57924682|NCT05247138|DEVICE|BioRootTM RCS|BioRoot™ RCS is a hydrophilic mineral root canal sealer prepared from the mixture of a powder part and a liquid part. BioRoot™ RCS is a class III implantable medical device. This device is intended to be used in dentistry for permanent obturation of root canals of permanent and mature teeth with adjunction of gutta-percha points. Exposure to the sealer BioRootTM RCS starts from the day when the root canal treatment is performed until the end of individual observational period or the removal of the sealer in case of extraction or retreatment, if this event occurs before the end of individual observational period.
57924683|NCT02045966|DRUG|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
57924684|NCT02045966|DRUG|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
58067341|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
58067342|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
58067343|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
58067344|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
58067345|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
58067346|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
58067347|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
57924685|NCT02045966|DRUG|BMS-791325|
57924686|NCT00728481|DRUG|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
57924687|NCT00728481|DRUG|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
57924688|NCT04186299|DRUG|Clonidine|Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
57924689|NCT04186299|DRUG|Articaine Hydrochloride + Epinephrine|Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
57924690|NCT01135706|OTHER|No Intervention|This study does not include an intervention but is observational in nature.
57924691|NCT03635333|DRUG|Nicotine|Nicotine level (6 or 18 mg)
57924692|NCT03635333|DRUG|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
57924693|NCT05988554|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
57924694|NCT05988554|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract and collagen products|Consume 1 sachet daily
57726339|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
57924695|NCT05300074|OTHER|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
57924696|NCT01097239|DEVICE|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
57924697|NCT02797353|OTHER|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
57726340|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
57924698|NCT04335240|OTHER|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
57924699|NCT00701233|DRUG|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
57924700|NCT00701233|DRUG|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
57924701|NCT04571827|OTHER|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
57924702|NCT02277405|DEVICE|Shikani Optical Stylet|Optical intubation
57924703|NCT02277405|DEVICE|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
57924704|NCT05050253|DEVICE|Super-oxidized solution (SOS)|Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
57924705|NCT05050253|DEVICE|Ringer's solution|Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
57924706|NCT03188354|DIAGNOSTIC_TEST|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
57924707|NCT03188354|DIAGNOSTIC_TEST|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
57924708|NCT03188354|DIAGNOSTIC_TEST|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
57924709|NCT04777747|OTHER|viral infection|a child is infected by virus only
57924710|NCT04777747|OTHER|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
57924711|NCT03008447|DRUG|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
57924712|NCT03008447|DRUG|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
57924713|NCT03008447|DRUG|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
58067348|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
57924714|NCT03008447|DRUG|PBO|Single dose of placebo administered within 5 minutes before bedtime.
57924715|NCT00114192|DRUG|docetaxel|
57924716|NCT00114192|DRUG|thalidomide|
57924717|NCT04426448|BEHAVIORAL|Brief Relaxation, Education And Trauma HEaling|A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
57924718|NCT02701738|DIETARY_SUPPLEMENT|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
57924719|NCT02573454|BEHAVIORAL|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
57924720|NCT03837379|BEHAVIORAL|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
57924721|NCT03837379|COMBINATION_PRODUCT|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
57924722|NCT04354805|DRUG|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
57924723|NCT02804243|DEVICE|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
57924724|NCT01207661|BIOLOGICAL|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
57924725|NCT05259254|OTHER|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
57924726|NCT05259254|OTHER|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
57924727|NCT04109196|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
57924728|NCT00221195|DRUG|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
58067349|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
57924729|NCT03099200|OTHER|No Intervention|
57924730|NCT00298909|BEHAVIORAL|physical exercise|physical exercise
57924731|NCT00298909|DRUG|niaspan (extended-release niacin)|niaspan (extended-release niacin)
57924732|NCT00298909|DRUG|niacin|niacin extended-release
57924733|NCT00298909|OTHER|control|control
57924734|NCT05424913|OTHER|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
58067350|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
58067351|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
58306664|NCT06130995|DRUG|Relugolix and Enzalutamide|"Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily"
58067352|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
58067353|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
58067354|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
57924735|NCT04326127|DEVICE|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
57726341|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
57726342|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
57924736|NCT00002997|PROCEDURE|cryosurgery|
57924737|NCT01208441|DRUG|letrozole|
57924738|NCT01208441|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
57924739|NCT01208441|PROCEDURE|therapeutic conventional surgery|
57924740|NCT01208441|PROCEDURE|breast biopsy|
57924741|NCT01208441|OTHER|diagnostic laboratory biomarker analysis|
57924742|NCT01208441|OTHER|pharmacological study|
57924743|NCT06186453|BEHAVIORAL|Father-Preterm Newborn Bonding Program|B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
57924744|NCT03057977|DRUG|Empagliflozin|once daily
57924745|NCT03057977|DRUG|Placebo|once daily
57924746|NCT04291352|DIETARY_SUPPLEMENT|Taurine|675mg taurine four times daily
57924747|NCT04291352|OTHER|Placebo|placebo four times daily
57924748|NCT05519397|DIAGNOSTIC_TEST|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
57924749|NCT00217529|BIOLOGICAL|pegfilgrastim|
58067355|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
57924750|NCT00217529|DRUG|carboplatin|
57924751|NCT00217529|DRUG|docetaxel|
57924752|NCT00217529|DRUG|erlotinib hydrochloride|
57924753|NCT02901041|DRUG|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
57924754|NCT02901041|BEHAVIORAL|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
57726343|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
57726344|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
57924755|NCT02901041|DRUG|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
57924756|NCT02608281|DEVICE|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
57924757|NCT05264428|DIETARY_SUPPLEMENT|Honey|Participants need to drink honey every day for four weeks.
57924758|NCT05264428|DIETARY_SUPPLEMENT|Water|Participants need to drink water every day for four weeks.
57924759|NCT01110811|PROCEDURE|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
57924760|NCT01298518|DRUG|PF-04620110|5 mg of PF-04620110 given once daily
57924761|NCT01298518|DRUG|PF-04620110|2.5 mg of PF-04620110 given twice daily
58067356|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
58306665|NCT02402400|DRUG|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
57924762|NCT01298518|DRUG|Placebo|Matching placebo giving for 4 weeks
57924763|NCT05798897|DRUG|MT-601|Multi-antigen specific CD4+ andCD8+ T cells
57924764|NCT04487574|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
57924765|NCT04487574|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 days
57924766|NCT03823560|DEVICE|Celegyn®|Medical device Celegyn® presents itself as a cream.
57924767|NCT03823560|DEVICE|Matching placebo|IP placebo presents itself as a cream.
58277561|NCT04439058|OTHER|ultrasound guided left stellate ganglion block|"Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
58394388|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
57924768|NCT03295656|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
57924769|NCT05928130|OTHER|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
57924770|NCT00010972|PROCEDURE|Acupuncture|
58394389|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
58394390|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
58277562|NCT01162720|PROCEDURE|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
58277563|NCT01162720|PROCEDURE|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
58277564|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
58277565|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
58277566|NCT03453112|DRUG|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
58277567|NCT03453112|DRUG|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant
58277568|NCT04570163|DEVICE|Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)|Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
58277569|NCT04246502|DRUG|Capecitabine and Pyrotinib|Pyrotinib 400mg orally daily until progressive disease
58277570|NCT04246502|DRUG|Capecitabine,Trastuzumab, and Pertuzumab|as instruction
58394391|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
58394392|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
58394393|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
57924771|NCT01306955|DRUG|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
58277571|NCT02769039|OTHER|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
58277572|NCT01559688|BEHAVIORAL|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
58277573|NCT01559688|BEHAVIORAL|Waitlist|Fitness assessment or career counseling
58277574|NCT06336122|BEHAVIORAL|Peer Coach Training - Weekly|Peer participants will be contacted by peer coaches on a weekly basis.
58277575|NCT06336122|BEHAVIORAL|Peer Coach Training - Biweekly|Peer participants will be contacted by peer coaches on a bi-weekly basis
58277576|NCT02269254|DEVICE|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
58394394|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
58394395|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
58394396|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
58067357|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
58067358|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
58067359|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
58067360|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
57924772|NCT01306955|OTHER|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
58067361|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
57924773|NCT04725825|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
57924774|NCT04725825|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
57924775|NCT04490733|BEHAVIORAL|dual-task walking|Participants will receive 3 times interventions during 10th to 12th course of chemotherapy and 12 weekly phone-call to assess effect and barriers of dual-task walking.
57924776|NCT01163721|DRUG|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
57924777|NCT01163721|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily
57924778|NCT03197363|OTHER|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
57924779|NCT03130543|DIETARY_SUPPLEMENT|Rice cereal|Standard formula thickened with rice cereal
57924780|NCT03130543|DIETARY_SUPPLEMENT|Enfamil AR|Enfamil AR formula
57924781|NCT06138340|DRUG|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
57924782|NCT06138340|DRUG|Propofol|Participants will be sedated and maintained by propofol during the surgery.
57924783|NCT02905760|DRUG|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
57924784|NCT02905760|DRUG|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
57924785|NCT02905760|DRUG|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
58067362|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
58067363|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
57726345|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
58067364|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
58067365|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
58277577|NCT02269254|DEVICE|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
58306666|NCT01093768|DRUG|Oxytocin|
58306667|NCT01093768|DRUG|Vasopressin|
58394397|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
57924786|NCT02905760|DRUG|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
57924787|NCT01004380|DRUG|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
57924788|NCT02580955|DEVICE|LEGFLOW DCB|
57924789|NCT01603186|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
57924790|NCT01603186|DRUG|Quetiapine Fumarate|25 mg tablet once a day
57924791|NCT00529022|DRUG|Azacitidine|75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
57924792|NCT00529022|DRUG|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
58277578|NCT05415241|DRUG|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
58277579|NCT03864666|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
57726346|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
57924793|NCT00529022|DRUG|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
57924794|NCT05848505|DRUG|Dexmedetomidine|Intranasal administration Dosage 2 mcg/kg
57924795|NCT01929980|DRUG|Bortezomib|
57924796|NCT01868139|DEVICE|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
57924797|NCT01834196|DEVICE|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
58277580|NCT03864666|DRUG|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
58277581|NCT06509490|DRUG|KD-025 cell injection|This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
57924798|NCT06258330|DRUG|AM003|Bispecific Personalized Aptamer for intratumoral administration
58277582|NCT04953286|OTHER|Measure of visual acuity|ETDRS and Parinaud scale
57951086|NCT00271817|DRUG|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
58277583|NCT04953286|OTHER|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
58277584|NCT04953286|OTHER|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
58277585|NCT04953286|OTHER|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
58277586|NCT04953286|OTHER|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
58394398|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
58277587|NCT04953286|OTHER|Conjunctival impression|Conjunctival impression with anesthetic instillation
58277588|NCT04953286|OTHER|Evaluation of the corneal innervation|Contact corneal confocal microscopy
57726347|NCT02200822|DRUG|beta blockers|
58394399|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
58394400|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
58394401|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
58394402|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
58394403|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
58394404|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
58394405|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
58394406|NCT05546697|BEHAVIORAL|Online- BA|See arms description
58394407|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
58394408|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
58394409|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
58394410|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
58277589|NCT05517733|BIOLOGICAL|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
58277590|NCT05517733|DEVICE|Diode laser|"* A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~* The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
58277591|NCT05107206|DEVICE|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
58394411|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
58394412|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
58394413|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
58394414|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
58394415|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
58394416|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
57726348|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
58394417|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
58394418|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
58394419|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
58394420|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
58394421|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
58394422|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
58394423|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
58394424|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
58394425|NCT00372619|DRUG|clofarabine|Given IV for 5 days
58394426|NCT00372619|DRUG|cytarabine|Given IV
58394427|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
58394428|NCT00372619|OTHER|laboratory biomarker analysis|
58394429|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
58394430|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
58394431|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
58394432|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
58394433|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
58394434|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
58394435|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
58067366|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
58067367|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
58394436|NCT03208660|DRUG|Fycompa|Oral suspension
58394437|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
57726349|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
57726350|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
57726351|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
57726352|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
57726353|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
57726354|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
57726355|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
57726356|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
58067368|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
58277592|NCT05107206|DEVICE|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
58277593|NCT01844973|DRUG|M518101|Proper quantity twice a day
58277594|NCT01844973|DRUG|Vehicle|Proper quantity twice a day
58277595|NCT03309514|BIOLOGICAL|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
57726357|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
57951087|NCT00271817|DRUG|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
58277596|NCT00405782|BEHAVIORAL|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
58277597|NCT02232555|DRUG|Duloxetine|
58277598|NCT02232555|DRUG|Placebo|
58394438|NCT06024239|DRUG|ABBV-932|Capsule; oral
58394439|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
58394440|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
58394441|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
58394442|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
58394443|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
58394444|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
57726358|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
58067369|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
58067370|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
58067371|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
58067372|NCT00284726|DEVICE|Celsior Cold Storage Solution|
58394445|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
58394446|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
57924799|NCT05609409|BEHAVIORAL|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
57924800|NCT05882253|OTHER|Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)|An advanced imaging software that supports improved prostate cancer detection and diagnosis
57924801|NCT01067157|BEHAVIORAL|LOGIC|"Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
58394447|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
57924802|NCT01410136|PROCEDURE|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
57924803|NCT03499197|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
57924804|NCT03113253|DRUG|Tranexamic Acid|
57924805|NCT03113253|DRUG|Placebo|0.9% sodium chloride to mimic tranexamic acid
57951088|NCT00271817|DRUG|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
58067373|NCT00863434|DRUG|clofarabine|Given IV
58067374|NCT00863434|DRUG|cytarabine|Given IV
58067375|NCT00863434|BIOLOGICAL|filgrastim|Given SC
58067376|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
58067377|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
58067378|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
58277599|NCT00349635|DRUG|Metformin and Metformin + Fenofibrate|
58277600|NCT03887429|DRUG|SXC-2023|SXC-2023 oral capsules
58394448|NCT06662136|BEHAVIORAL|motivational interview|Participants in the experimental group will be given motivational interviews about HPV at 4 different times and will also be given an educational brochure.
57924806|NCT06461403|DEVICE|Inhaler Trainer System|The system consists of an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. The inhaler trainer system consists of a detachable/disposable mouthpiece and a reusable electronics module. The electronics module measures flow/pressure achieved by the patient and wirelessly transmits this data to a PC. The PC software analyzes the real-time inhalation flow data to enable the monitoring of the following quantities: Flow Rate, Duration, and Maximum Pressure Slope. These quantities will be used in the computation of the assessment metric, providing the user with real-time feedback about their inhalation technique. In addition, the software includes features to support the human study and provides fully functional inhaler education features for the expert test evaluators.
57924807|NCT06461403|OTHER|Initial Inhaler Use Assessment|Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists
58067379|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
58067380|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
57924808|NCT06461403|OTHER|Inhaler Use Instruction|Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.
57924809|NCT00915733|DRUG|cilostazol|100 mg twice daily for at least 1 month
57924810|NCT00915733|DRUG|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
57726359|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
57924811|NCT00915733|GENETIC|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
57924812|NCT00915733|DRUG|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
57924813|NCT05428033|DRUG|centanafadine capsule|capsule
57924814|NCT05428033|OTHER|placebo capsule|capsule
57924815|NCT05861154|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation."
57924816|NCT05861154|DRUG|Benzocaine Gel|a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
58067381|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
58067382|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
58067383|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
58067384|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
57726360|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
57726361|NCT05456581|BEHAVIORAL|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
57726362|NCT05456581|BEHAVIORAL|Control Training|The task will be performed in the control group without the visible scotoma.
57726363|NCT00650468|DRUG|tacrolimus|Oral
57726364|NCT00650468|DRUG|CellCept|IV or Oral
57924817|NCT00683566|PROCEDURE|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
57924818|NCT00031187|DRUG|SGN-15 (cBR96-doxorubicin immunoconjugate)|
57726365|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
57924819|NCT00031187|DRUG|Taxotere (docetaxel)|
58394449|NCT06662136|OTHER|Control|Participants in the control group will not receive any intervention.
58394450|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
58394451|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
58394452|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
58394453|NCT05731817|OTHER|Observational study|N/A - observational study.
57924820|NCT06475573|DIETARY_SUPPLEMENT|dietary fiber probiotic beverages|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner."
58277601|NCT03887429|DRUG|Placebos|Matching Placebo oral capsules
58394454|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
57924821|NCT06475573|OTHER|whole grain porridge|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner."
57924822|NCT00984425|DRUG|Lapatinib and Sorafenib|Comparison of different dosages of two drug
57924823|NCT01175356|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
57924824|NCT01175356|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
57924825|NCT01175356|DRUG|Busulfan|Given IV
57924826|NCT01175356|DRUG|Cisplatin|Given IV
57924827|NCT01175356|DRUG|Cyclophosphamide|Given IV
57924828|NCT01175356|DRUG|Doxorubicin Hydrochloride|Given IV
58067385|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
58277602|NCT01827878|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
58277603|NCT01827878|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
58277604|NCT05907252|BEHAVIORAL|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
58277605|NCT05907252|BEHAVIORAL|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
58306668|NCT02507570|DRUG|Enzalutamide|used concomitantly
58394455|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
58394456|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
58067386|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
58394457|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
58394458|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
58394459|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
58394460|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
57924829|NCT01175356|DRUG|Etoposide Phosphate|Given IV
58067387|NCT04450394|DRUG|LY3209590|Administered SC
58067388|NCT04450394|DRUG|Insulin Degludec|Administered SC
58067389|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
58277606|NCT05907252|BEHAVIORAL|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
58277607|NCT05330585|DEVICE|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
58277608|NCT05330585|OTHER|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
58277609|NCT02546076|DEVICE|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
58277610|NCT02546076|DEVICE|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
58277611|NCT02107950|BIOLOGICAL|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
58277612|NCT02107950|DRUG|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
58277613|NCT02272153|OTHER|Egg refined grain|
58277614|NCT02272153|OTHER|Egg Whole Grain|
58277615|NCT02272153|OTHER|Cereal Refined grain|
58277616|NCT00524680|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
58277617|NCT03519113|BIOLOGICAL|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
58394461|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
58394462|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
58394463|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
57924830|NCT01175356|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
57924831|NCT01175356|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
57924832|NCT01175356|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
57924833|NCT01175356|RADIATION|Iobenguane I-131|Given IV
57924834|NCT01175356|DRUG|Isotretinoin|Given PO
57924835|NCT01175356|OTHER|Laboratory Biomarker Analysis|Correlative studies
57924836|NCT01175356|DRUG|Melphalan|Given IV
57924837|NCT01175356|OTHER|Pharmacological Study|Correlative studies
57924838|NCT01175356|OTHER|Questionnaire Administration|Ancillary studies
57924839|NCT01175356|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57924840|NCT01175356|DRUG|Topotecan Hydrochloride|Given IV
57924841|NCT01175356|DRUG|Vincristine Sulfate|Given IV
58067390|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
58067391|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
58067392|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
58067393|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
58067394|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
58277618|NCT03519113|BIOLOGICAL|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
58277619|NCT03519113|BIOLOGICAL|I.V HBIG|human anti-hepatitis B Immunoglobulin
58277620|NCT04573166|PROCEDURE|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
58277621|NCT03717415|DRUG|Rebastinib|Administered orally
57924842|NCT04656509|OTHER|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
57924843|NCT02546895|OTHER|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
57924844|NCT00298454|DRUG|Furosemide|
57924845|NCT04716530|OTHER|No intervention is associated with the study.|No intervention is associated with the study.
57924846|NCT02949089|DRUG|ACH04|The subjects will receive the study medication in each group
57924847|NCT05708625|DRUG|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
57924848|NCT05708625|PROCEDURE|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
57924849|NCT05708625|DRUG|Intralesional Voriconazole|Weekly intralesional Voriconazole
57924850|NCT05708625|DRUG|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
57924851|NCT04452487|BEHAVIORAL|decisions of limitations and stop processing|Compliance of the modalities of decisions of limitations and stop processing
57924852|NCT01859780|OTHER|Visual distractor|
58067395|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
58067396|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
58067397|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
58067398|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
58067399|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
58067400|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
58067401|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
58277622|NCT03717415|DRUG|Carboplatin|Administered by IV infusion
58277623|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
57924853|NCT03082131|DIETARY_SUPPLEMENT|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
57924854|NCT01354171|DEVICE|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
57924855|NCT04525482|OTHER|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
57924856|NCT01067326|DRUG|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
57924857|NCT01067326|DRUG|Placebo|1 pill per day by mouth for 4 months
57924858|NCT00979433|DEVICE|Bubble CPAP|Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
57951089|NCT00271817|DRUG|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
58067402|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
58067403|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
58067404|NCT03092141|OTHER|Physical training|
58067405|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
58067406|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
58277624|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
58277625|NCT02089087|BIOLOGICAL|CFZ533|Single dose at varying dosage levels depending on treatment assignment
58277626|NCT02089087|DRUG|Placebo|
58067407|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
58067408|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
58067409|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
58067410|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
58067411|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
58067412|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
58067413|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
58067414|NCT00019331|BIOLOGICAL|aldesleukin|
58067415|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
58067416|NCT00019331|BIOLOGICAL|sargramostim|
58067417|NCT00019331|DRUG|DetoxPC|
57924859|NCT00979433|DEVICE|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
57924860|NCT01013285|BIOLOGICAL|bevacizumab|
58067418|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
58067419|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
58067420|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
58067421|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
58067422|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
58277627|NCT06261541|DEVICE|ABLE Exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
58277628|NCT02451397|OTHER||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
58394464|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
57924861|NCT01013285|DRUG|temozolomide|
57924862|NCT01013285|RADIATION|external beam radiation therapy|
57924863|NCT00243750|DRUG|Methotrexate|
57924864|NCT02215538|DRUG|OROS methylphenidate|
57924865|NCT02215538|DRUG|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
57924866|NCT02340091|DEVICE|HA IDF plus|
57924867|NCT02340091|DEVICE|HA IDF|
58067423|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
57924868|NCT05083338|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57924869|NCT05083338|PROCEDURE|Pain Assessment|Undergo pain assessment
57924870|NCT05083338|OTHER|Questionnaire Administration|Complete questionnaires
58067424|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
58067425|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
58067426|NCT00208715|DRUG|Provigil|
58067427|NCT00003389|DRUG|Doxorubicin|given IV
58067428|NCT00003389|DRUG|Bleomycin|given IV
58067429|NCT00003389|DRUG|Vinblastine|given IV
58067430|NCT00003389|DRUG|Dacarbazine|given IV
58067431|NCT00003389|DRUG|Vincristine|given IV
58067432|NCT00003389|DRUG|Mechlorethamine|given IV
58067433|NCT00003389|DRUG|Etoposide|given IV
58067434|NCT00003389|DRUG|Prednisone|taken orally
58067435|NCT00003389|DRUG|Cyclophosphamide|given IV
58067436|NCT00003389|RADIATION|Radiotherapy|
58067437|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
58067438|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
58067439|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
58067440|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
58067441|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
58067442|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
58067443|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
58277629|NCT01653327|DRUG|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
58277630|NCT01653327|DRUG|Placebo|
58277631|NCT02018978|BEHAVIORAL|Comprehensive Triaged HIV Prevention (CTHP)|"1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
57924871|NCT00711529|BEHAVIORAL|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
58067444|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
58277632|NCT01080391|DRUG|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
58277633|NCT01080391|DRUG|Lenalidomide|25 mg orally on days 1-21
58277634|NCT01080391|DRUG|Carfilzomib|20 mg/m², 27 mg/m² intravenously
57726366|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
57726367|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
57726368|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
57726369|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
57924872|NCT00711529|DRUG|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
57924873|NCT05330338|BIOLOGICAL|Genetic analyses: whole genome sequencing|Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
57951090|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
57951091|NCT00271817|DRUG|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
58277635|NCT02945111|BEHAVIORAL|Real-time view|
58277636|NCT02945111|BEHAVIORAL|No visual support|
57924874|NCT04359875|BEHAVIORAL|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~* How are you doing? (with a Likert scale from 1=very bad to 10=very well)~* Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~* Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
57924875|NCT02587429|BEHAVIORAL|Patient education|
57924876|NCT05167123|DRUG|Light cured tri-calcium silicate base material|TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
57924877|NCT04003857|BIOLOGICAL|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)
58067445|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
58067446|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
58067447|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
58067448|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
58067449|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
58067450|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
58067451|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
58067452|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
58067453|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
58067454|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
58067455|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
58067456|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
58067457|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
58067458|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
58067459|NCT00003089|DRUG|amifostine trihydrate|
58067460|NCT00003089|DRUG|carboplatin|
57726370|NCT01762761|DRUG|eltrombopag|TPO-R agonist
57726371|NCT01762761|DRUG|placebo|placebo
57924878|NCT04003857|BIOLOGICAL|normal saline|A single intratracheal administration of normal saline
57924879|NCT00198952|DRUG|DietPro|
57924880|NCT00198952|DRUG|Placebo|
57924881|NCT00292461|DRUG|Zonisamide|Tablet once or twice daily orally for 16 weeks
57924882|NCT00292461|DRUG|Lamotrigine|Tablet once daily orally for 16 weeks
57924883|NCT05057286|PROCEDURE|Clinical crown lengthening surgery|"* Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection."
57924884|NCT01813851|DEVICE|Exercise training in addition to nutritional support|
57924885|NCT00827801|BEHAVIORAL|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
57924886|NCT01319214|DRUG|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
57924887|NCT01509131|DRUG|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
58067461|NCT00003089|DRUG|paclitaxel|
58067462|NCT00003089|RADIATION|radiation therapy|
58067463|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
57924888|NCT01509131|DRUG|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
57924889|NCT05059834|BEHAVIORAL|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
57924890|NCT05059834|BEHAVIORAL|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
57924891|NCT00820027|DRUG|Etoricoxib 90 mg|One 90 mg tablet once daily
57924892|NCT00820027|DRUG|Etoricoxib 120 mg|Two 60 mg tablets once daily
57924893|NCT00820027|DRUG|Ibuprofen 600 mg|One tablet three times daily
57924894|NCT00820027|DRUG|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
57924895|NCT00820027|DRUG|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
57924896|NCT00820027|DRUG|Matching Placebo for Ibuprofen|One tablet three times daily
58067464|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
58067465|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
58067466|NCT01634087|DRUG|Placebo|Placebo administered orally
58067467|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
58067468|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
58067469|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
57726372|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
57726373|NCT05178628|DRUG|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
57726374|NCT05178628|DRUG|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
57726375|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
57924897|NCT00820027|DRUG|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
57924898|NCT00820027|DRUG|Oxycodone|5 mg as needed
57924899|NCT00212628|DRUG|Minodronic acid hydrate|
57924900|NCT05373953|DRUG|CHF6001|CHF6001 will be administered using the NEXThaler® DPI device
57924901|NCT02656160|DRUG|Placebo|Placebo 3 hrs before sleep
58067470|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
58067471|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
58067472|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
58067473|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
58067474|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
57924902|NCT02656160|DRUG|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
57924903|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream low-dose|travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
57924904|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream mid-dose|travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
57924905|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream high-dose|travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
57924906|NCT06152861|DRUG|Timolol maleate ophthalmic solution, 0.5%|timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes
57924907|NCT06152861|DRUG|Travoprost Ophthalmic Solution, 0.004%|travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
57924908|NCT02496910|DRUG|YH22162|
57924909|NCT02496910|DRUG|Telmisartan/Amlodipine 80/5 mg (FDC)|
57924910|NCT02496910|DRUG|Chlorthalidone 25mg|
57924911|NCT02262923|DRUG|metoclopramide|
57924912|NCT04508634|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
57924913|NCT04508634|DRUG|Metformin Pill|Metformin 1000mg bid
57924914|NCT05900960|DIETARY_SUPPLEMENT|Tea|Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
58067475|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
58067476|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
58067477|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
58067478|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
58067479|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
58306669|NCT02507570|RADIATION|Radium ra 223 dichloride|
58306670|NCT02219256|DRUG|TAK-079|TAK-079 solution
57924915|NCT02496520|BIOLOGICAL|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
58277637|NCT06446284|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
58277638|NCT06446284|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
58277639|NCT02181218|DRUG|Romidepsin|
58277640|NCT02181218|DRUG|Gemcitabine|
57726376|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
57924916|NCT02496520|PROCEDURE|Surgery as needed by the patient´s tumor and stage|
57924917|NCT02496520|DRUG|Chemotherapy as needed by the patient´s tumor and stage|
57924918|NCT02496520|RADIATION|Radiation therapy as needed by the patient´s tumor and stage|
57924919|NCT00225576|OTHER|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
57951092|NCT00271817|DRUG|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
57951093|NCT03632733|DRUG|Tetracycline|Tetracycline cream
57951094|NCT03632733|DRUG|Clotrimazole|Clotrimazole cream
58277641|NCT02181218|DRUG|Oxaliplatin|
58277642|NCT02181218|DRUG|Dexamethasone|
58277643|NCT02181218|DRUG|Pegfilgrastim|
58277644|NCT00178269|DRUG|docetaxel|
58277645|NCT00178269|PROCEDURE|Radiation Therapy|
58394465|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
57726377|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
57726378|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
58277646|NCT02781376|OTHER|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
58277647|NCT02781376|OTHER|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
58277648|NCT00791492|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
57726379|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
57726380|NCT06635005|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57726381|NCT06635005|OTHER|Dietary Intervention|Receive the Low-EDIH dietary pattern intervention
57726382|NCT06635005|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
57951095|NCT03632733|DRUG|Tetracycline and Clotrimazole|Combination cream
57951096|NCT03632733|OTHER|Placebo|Placebo cream without active drug ingredients
58277649|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|Intramuscular injection
58277650|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed|Intramuscular injection
58277651|NCT05091619|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|Intramuscular injection
58277652|NCT00561691|DRUG|nimotuzumab|monoclonal antibody
58067480|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
57924920|NCT04805554|OTHER|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
57924921|NCT03313453|DEVICE|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
57951097|NCT02688595|DEVICE|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
57951098|NCT02688595|OTHER|General anesthesia|Scheduled operation under general anesthesia
58067481|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
58067482|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
58067483|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
58067484|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
58067485|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
58394466|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
57726383|NCT06635005|BEHAVIORAL|Motivational Interviewing|Undergo motivational interviews
58067486|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
58067487|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
58067488|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
57951099|NCT03440814|DRUG|DCCR|Once daily oral administration
58067489|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
58394467|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
58394468|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
57726384|NCT06635005|OTHER|Nutritional Assessment|Participate in nutrition counseling
57726385|NCT06635005|OTHER|Questionnaire Administration|Ancillary studies
58067490|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
58067491|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
58067492|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
58067493|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
58277653|NCT06245798|PROCEDURE|transarterial chemoembolisation|During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
57924922|NCT03313453|DEVICE|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
57951100|NCT03440814|DRUG|Placebo for DCCR|Once daily oral administration
58277654|NCT05921422|OTHER|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
57951101|NCT01890642|DEVICE|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
58277655|NCT03030274|DEVICE|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
58394469|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
58394470|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
58394471|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
58394472|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
58394473|NCT00145210|DRUG|Nebivolol and Atenolol|
58067494|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
58067495|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
58067496|NCT03024151|DRUG|Synthroid|T4 mono replacement
58067497|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
58067498|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
58394474|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
58394475|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
58394476|NCT02443246|DRUG|Placebo|
57951102|NCT01890642|OTHER|Pain Ease Spray|Cold Spray used to anesthetize the skin
57951103|NCT01890642|DRUG|1% buffered lidocaine|Lidocaine placed using Jet Injection
57951104|NCT01890642|OTHER|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
58067499|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
58067500|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
58277656|NCT04475718|BEHAVIORAL|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
58277657|NCT01538394|DRUG|Varenicline|
58277658|NCT01538394|DRUG|Nicotine patches|
58277659|NCT01538394|DRUG|Placebo (nicotine patches)|
58306671|NCT02219256|DRUG|Placebo to TAK-079|Placebo to TAK-079 solution
58306672|NCT00006077|DRUG|NS2330|
58306673|NCT00006077|DRUG|Levodopa and Domperidone|
58394477|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
58394478|NCT02402504|OTHER|Control|Non pulse extruded snack
58394479|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
58394480|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
58394481|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
58394482|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
58394483|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
58067501|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
58067502|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
58067503|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
58067504|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
58067505|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
58067506|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
57924923|NCT03035266|OTHER|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
57924924|NCT03035266|OTHER|Standard rehabilitation|Standard of care for post-operative condition
57924925|NCT02441062|DRUG|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
57924926|NCT05217563|BEHAVIORAL|Memory-reframing intervention (Reframe the Pain)|Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
57951105|NCT01890642|OTHER|Sucrose|Oral Sucrose used for children \< 1 year
58067507|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
58067508|NCT02651038|DRUG|Micafungin|Measurement of PK
58067509|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
58067510|NCT00160147|DRUG|Placebo|Placebo
58067511|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
58067512|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
58067513|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
58067514|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
58067515|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
58394484|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
58067516|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
58067517|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
58067518|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
58067519|NCT00741624|OTHER|Bandage|one application for one week
58067520|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
58067521|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
58067522|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
58067523|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
58394485|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
58394486|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
58394487|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
58394488|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
58067524|NCT00508118|DRUG|Nicardipine|on bypass
58067525|NCT00508118|DRUG|0.9% saline|on bypass
58067526|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
58067527|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
58277660|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
58277661|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
58277662|NCT02972450|DRUG|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
58277663|NCT02972450|OTHER|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
58277664|NCT02455713|DEVICE|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
58277665|NCT03351153|RADIATION|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
58277666|NCT03351153|RADIATION|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
58277667|NCT03351153|OTHER|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
58394489|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
58394490|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
57726386|NCT03669003|BIOLOGICAL|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
57726387|NCT03669003|PROCEDURE|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
58394491|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
57726388|NCT04096092|OTHER|No intervention|No intervention
57726389|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
58067528|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
58067529|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
58067530|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
58067531|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
58067532|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
58067533|NCT03486067|DRUG|CC-93269|Specified dose on specified days
58067534|NCT00155428|PROCEDURE|rapid prototyping|
58067535|NCT00155428|PROCEDURE|computed tomography|
58067536|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
58067537|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
58067538|NCT02408016|DRUG|Cyclophosphamide|Given IV
58067539|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
58067540|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
58277668|NCT01672294|OTHER|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
58277669|NCT01672294|OTHER|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
58277670|NCT00682994|BEHAVIORAL|Interview|Interview lasting about 5-10 minutes.
58277671|NCT00682994|BEHAVIORAL|Questionnaire|Questionnaires taking 20-30 minutes to complete.
58277672|NCT03798392|DEVICE|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
58277673|NCT03798392|DEVICE|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
58394492|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
58394493|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
58394494|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
58394495|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
58067541|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
58067542|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
58067543|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
58277674|NCT02249689|OTHER|Definitive 65|
57924927|NCT01969318|DRUG|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
57924928|NCT01969318|DRUG|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
57924929|NCT01969318|DRUG|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
57924930|NCT04331353|BEHAVIORAL|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
57924931|NCT04331353|BEHAVIORAL|Comparator 2 (insecticidal bait)|Cockroach bait
57924932|NCT00516451|DRUG|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
57924933|NCT02537626|DEVICE|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
57924934|NCT02537626|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
58277675|NCT02249689|OTHER|Definitive 74|
58394496|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
57924935|NCT04637477|BEHAVIORAL|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
57924936|NCT00026208|DRUG|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
57924937|NCT00026208|DRUG|Cyclophosphamide|650 mg/m², on week 1 and 5
58277676|NCT03718169|BEHAVIORAL|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
58277677|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
58277678|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
58277679|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
58277680|NCT00960167|RADIATION|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
58277681|NCT02074332|BEHAVIORAL|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement
58277682|NCT02074332|BEHAVIORAL|Health education|Knowledge of obesity prevention and control
58394497|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
58394498|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
58394499|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
58394500|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
57924938|NCT00026208|DRUG|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
57924939|NCT00026208|DRUG|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
57924940|NCT00026208|DRUG|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
57924941|NCT00026208|DRUG|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
57924942|NCT00026208|RADIATION|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
57951106|NCT04879043|DRUG|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
57924943|NCT04223830|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
57924944|NCT05336253|BEHAVIORAL|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
57924945|NCT05336253|BEHAVIORAL|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
57924946|NCT04033848|PROCEDURE|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
57924947|NCT02827253|DEVICE|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
57924948|NCT02207270|BEHAVIORAL|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
57924949|NCT02207270|BEHAVIORAL|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
57924950|NCT04526197|DRUG|ALXN1840|ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.
58067544|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
58277683|NCT05337384|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
58277684|NCT02588664|OTHER|COMPASS Intervention|"* A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
57726390|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
57726391|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
57924951|NCT04526197|DRUG|Celecoxib|Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
57924952|NCT06334302|OTHER|"Omega Galil Hazelnut Chocolate Spread O'Sweet Spread"|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
57924953|NCT06334302|OTHER|Active Control-Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
57924954|NCT00151736|DRUG|Chlorambucil|Chlorambucil 2mg tablets
57924955|NCT00151736|DRUG|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
57924956|NCT06374355|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
57924957|NCT05001854|DRUG|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
57924958|NCT05001854|DRUG|Placebo|100 μg every 6 hours of placebo per os
57924959|NCT02007889|DRUG|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
57924960|NCT02594826|BEHAVIORAL|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
57924961|NCT02594826|BEHAVIORAL|General health education control|General health and cancer education
58067545|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
58067546|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
57924962|NCT02752646|DRUG|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
57924963|NCT02752646|DRUG|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
57924964|NCT00504010|DRUG|Arnica Montana|Applied to lower extremity once a day for 3 days
57924965|NCT00504010|DRUG|placebo cream|placebo cream applied to leg daily for 3 days
57924966|NCT05197751|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
58394501|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
57924967|NCT01026454|DRUG|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
57924968|NCT01026454|DRUG|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
57924969|NCT00441415|DRUG|Adapalene BPO|
58067547|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
58067548|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
58277685|NCT05994300|RADIATION|Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy|"Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2"
58277686|NCT05423366|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
58394502|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
58394503|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
58394504|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
58394505|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
58394506|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
58394507|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
57924970|NCT03092895|BIOLOGICAL|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
57924971|NCT03092895|DRUG|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
57924972|NCT03092895|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
58067549|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
58394508|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
58394509|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
58394510|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
58394511|NCT06180629|OTHER|normal treatment routine|normal treatment routine
57924973|NCT03092895|DRUG|GEMOX|Subjects receive GEMOX treatment every 2 weeks
57924974|NCT05737186|DRUG|SGLT-2 inhibitor|dapagliflozin
57924975|NCT06503029|DEVICE|Invisalign Cleaning Crystals|Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
58067550|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
58067551|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
58067552|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
58067553|NCT00006162|BEHAVIORAL|exercise and diet|
58394512|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
58394513|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
57924976|NCT06503029|DEVICE|Fittey Dent Cleaning Tablet|Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
57924977|NCT06503029|DRUG|Listeren Mouthwash|Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
57924978|NCT06503029|DEVICE|Toothbrush and Water|Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
57951107|NCT03983577|OTHER|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
58067554|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
58394514|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
58394515|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
58394516|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
57924979|NCT03270566|DEVICE|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
57924980|NCT01353079|BIOLOGICAL|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
58067555|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
58067556|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
58067557|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
58067558|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
58277687|NCT00691561|BEHAVIORAL|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
58277688|NCT05268016|DRUG|ME3183|ME3183 capsule
58277689|NCT05268016|DRUG|Placebo|Placebo capsule
58277690|NCT02622490|OTHER|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
58277691|NCT04494594|BEHAVIORAL|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
58277692|NCT02265939|DRUG|NPO-13|
58277693|NCT00110799|DRUG|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
58277694|NCT00110799|OTHER|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
58277695|NCT00865579|DRUG|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
58394517|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
58394518|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
57726392|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
58067559|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
58394519|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
58394520|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
58394521|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
57726393|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
57726394|NCT06028594|DRUG|Pozelimab|Subcutaneous (SC) administration
57726395|NCT06028594|DRUG|Cemdisiran|Subcutaneous (SC) administration
58067560|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
57726396|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
57726397|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
57924981|NCT01353079|BIOLOGICAL|Placebo|Placebo: Glycero-COCAs sublingual
58277696|NCT01289574|DRUG|ASC-J9|Cream for twice daily topical application to the face
58394522|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
58394523|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
57924982|NCT03279874|OTHER|Interviews|Semi-structured one-on-one interviews
57924983|NCT05863520|BEHAVIORAL|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
57924984|NCT05863520|BEHAVIORAL|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
57924985|NCT03902847|BEHAVIORAL|motor imagery|All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
57924986|NCT03902847|BEHAVIORAL|Action observation|A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
57924987|NCT03902847|BEHAVIORAL|Motor Control Exercises|The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
57924988|NCT06305000|PROCEDURE|Non-surgical treatment|Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.
58067561|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
58067562|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
58067563|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
58277697|NCT03009253|OTHER|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
58277698|NCT03749109|DRUG|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
58277699|NCT03749109|DRUG|Placebo|Matching placebo
58277700|NCT02450422|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
58277701|NCT02450422|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
58277702|NCT00525876|DRUG|Cyclophosphamide|"Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
57924989|NCT06305000|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
57924990|NCT00366704|DRUG|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
57924991|NCT00366704|DRUG|risperidone|4mg, QD, 8 week treatment
57924992|NCT03959371|DRUG|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
57924993|NCT05882669|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
57924994|NCT02211352|DRUG|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
58277703|NCT00525876|DRUG|Fludarabine|"30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
58277704|NCT00525876|DRUG|Rituximab|"Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
57726398|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
57726399|NCT03041415|BEHAVIORAL|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
57726400|NCT03041415|BEHAVIORAL|ALED + Our Voice PA Program|"* 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
58277705|NCT00525876|DRUG|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
58277706|NCT00525876|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells.
58277707|NCT02651649|DEVICE|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
58394524|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
57924995|NCT02211352|DRUG|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
57924996|NCT05010187|BEHAVIORAL|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
57924997|NCT05010187|BEHAVIORAL|Behavioral: Health Coaching (HC)|Single-session health coaching.
57924998|NCT03965325|OTHER|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
57924999|NCT04497909|BEHAVIORAL|Mindfulness|Mindfulness online training
57925000|NCT04309864|DEVICE|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
57925001|NCT04309864|DEVICE|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
57925002|NCT04001907|BEHAVIORAL|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
57925003|NCT04001907|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate|
57925004|NCT04001907|DIETARY_SUPPLEMENT|placebo|
57925005|NCT01686854|BEHAVIORAL|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
57925006|NCT01686854|OTHER|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
57925007|NCT02203292|BEHAVIORAL|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb \< 9.0 g/dL
58277708|NCT00453830|PROCEDURE|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
57925008|NCT02203292|BEHAVIORAL|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
57925009|NCT00435474|PROCEDURE|Wound treatment|wound treatment (silver product, alginate and foam dressing)
58394525|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
57925010|NCT00435474|PROCEDURE|wound treatment|wound treatment (honey product, alginate and foam dressing)
57925011|NCT00435474|OTHER|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
57925012|NCT00435474|OTHER|relaxation therapy|relaxation therapy
57925013|NCT05755074|PROCEDURE|Ablation through left arm|Ablation through left arm
57925014|NCT05755074|PROCEDURE|Ablation through femoral vein|Ablation through femoral vein
57925015|NCT04162223|BIOLOGICAL|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
57925016|NCT04162223|BIOLOGICAL|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
57925017|NCT04201756|DRUG|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
57925018|NCT06494605|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is an early naturalistic and behavioural intervention for children with initial signs of neurodivergence or on the autism spectrum between the ages of 12-48 months. This early intervention aims to increase the rates of development in several domains and to decrease the characteristics of autism conditions that hinder children's ability to learn from everyday experiences and interactions.
57925019|NCT04696042|DRUG|Lanreotide autogel|Lanreotide autogel 90-120 mcg, every 4 weeks
57925020|NCT05580419|BEHAVIORAL|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
57925021|NCT05280951|OTHER|Focused-PPC Care|Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
57951108|NCT02603874|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
58067564|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
58067565|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
58067566|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
58067567|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
58277709|NCT05540730|DIAGNOSTIC_TEST|Gait Analysis|Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
58394526|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
58394527|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
58394528|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
57726401|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
57726402|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
57726403|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
57925022|NCT05280951|OTHER|Usual Care|Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
57925023|NCT00662350|DEVICE|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
57925024|NCT03612284|DEVICE|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
57925025|NCT00069316|DRUG|Omr-IgG-am|
58277710|NCT02638376|RADIATION|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
58277711|NCT02638376|PROCEDURE|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
58277712|NCT02578849|DRUG|L-DOPA|Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
58277713|NCT03298308|DEVICE|Cranial Electric Stimulation|Micro amperage TCDS
58277714|NCT01870297|DRUG|LY3025876|Administered SQ
58394529|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
57726404|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
57726405|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
57925026|NCT02110147|DRUG|uridine triacetate|
57925027|NCT01201343|DRUG|Interferon beta-1a|
57925028|NCT02469896|DRUG|Tocilizumab|IV Infusion
57925029|NCT02469896|OTHER|Placebo|IV Infusion
57925030|NCT06264778|DRUG|Dabrafenib|"Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery."
57925031|NCT01141348|BEHAVIORAL|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
58067568|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
58277715|NCT01870297|DRUG|Placebo|Administered SQ
58394530|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
57726406|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
57726407|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
57925032|NCT01141348|BEHAVIORAL|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
57925033|NCT00514657|DRUG|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
58277716|NCT01870297|DRUG|Liraglutide|Administered SQ
58277717|NCT06532058|DRUG|QHRD107 capsule，Venclexta and Azacitidine|QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
58277718|NCT04309903|OTHER|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
58277719|NCT00004896|DRUG|busulfan|
58277720|NCT00004896|DRUG|cyclophosphamide|
58277721|NCT00004896|PROCEDURE|allogeneic bone marrow transplantation|
58277722|NCT00004896|PROCEDURE|bone marrow ablation with stem cell support|
58422690|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
57726408|NCT00179088|BEHAVIORAL|Patient may be able to put weight on the operated leg|
57726409|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
57925034|NCT01888835|DRUG|Mirtazapine|
57925035|NCT01888835|DRUG|Placebo|
57925036|NCT02248220|DRUG|Pramipexole|
57925037|NCT00093171|DRUG|rFIX|
58067569|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
58067570|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
58067571|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
58277723|NCT00004896|RADIATION|radiation therapy|
58277724|NCT02380859|BEHAVIORAL|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
58277725|NCT02910934|OTHER|Actellic CS|Indoor residual spray with Actellic CS
58277726|NCT03152487|OTHER|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
58277727|NCT03152487|OTHER|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
58277728|NCT06145529|OTHER|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
58277729|NCT02013102|DRUG|Decitabine Injection|Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
58277730|NCT03561545|OTHER|weightlessness (parabolic flight)|weightlessness (parabolic flight)
58277731|NCT06272695|BIOLOGICAL|Volagidemab|Administered by SC injection once weekly for 6 weeks
57925038|NCT00188422|PROCEDURE|low dose CT|
57925039|NCT00321659|BEHAVIORAL|Aerobic|3x/week of walking and cycling
57925040|NCT00321659|BEHAVIORAL|Strength training|3x/week of resistance training activities
57925041|NCT00321659|BEHAVIORAL|Combination|3x/week of aerobic and strength training activities
57925042|NCT00321659|BEHAVIORAL|FSHC|Biweekly group education group meetings
57925043|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
57925044|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
57925045|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
57925046|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
57925047|NCT04233736|PROCEDURE|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
57925048|NCT03678103|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
57925049|NCT03756350|DEVICE|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
57925050|NCT03385070|DIAGNOSTIC_TEST|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
57925051|NCT02716467|OTHER|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
57925052|NCT02716467|RADIATION|Radiotherapy|All participants will receive treatment by radiotherapy
57925053|NCT00464230|PROCEDURE|Bipolar hemiarthroplasty (Charnley/Hastings)|
57925054|NCT00464230|PROCEDURE|Internal fixation with two parallel screws (Olmed)|
57925055|NCT02172339|DRUG|Tiotropium, solution ampoules|
57925056|NCT03003559|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
57925057|NCT03731832|DRUG|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
57925058|NCT03731832|DRUG|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
57925059|NCT03731832|DRUG|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
57925060|NCT03731832|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
57925061|NCT01602523|DRUG|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
57925062|NCT01602523|DRUG|Placebo|Placebo inhaler once daily 28 days
57925063|NCT04719767|DEVICE|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
57925064|NCT00523042|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
57925065|NCT00523042|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
57925066|NCT03963752|DRUG|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
57925067|NCT03963752|DRUG|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
57925068|NCT03963752|DRUG|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
57925069|NCT01322984|BEHAVIORAL|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
57925070|NCT01322984|BEHAVIORAL|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
57925071|NCT03772353|DRUG|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
57925072|NCT03772353|DRUG|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
57925073|NCT03772353|DRUG|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
57925074|NCT03772353|DRUG|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
57925075|NCT00362453|BEHAVIORAL|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
57925076|NCT05224336|DRUG|Psilocybin|25mg oral psilocybin
57925077|NCT05224336|DRUG|Placebo Niacin|100mg oral niacin
57925078|NCT05494060|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
57925079|NCT05494060|DRUG|Penpulimab Injection|Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
57925080|NCT05494060|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
57925081|NCT03181451|DRUG|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
57925082|NCT05127538|DIAGNOSTIC_TEST|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
57925083|NCT05127538|DIAGNOSTIC_TEST|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
57925084|NCT02591199|DRUG|URG101|
57925085|NCT02591199|DRUG|Placebo|
57925086|NCT02591199|DRUG|Lidocaine|
57925087|NCT02591199|DRUG|Heparin|
57925088|NCT04766931|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
57925089|NCT04766931|DRUG|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
57925090|NCT03457454|OTHER|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
57925091|NCT03457454|OTHER|Patient Participant Interview|-Approximately 45-60 minute interview
57925092|NCT03457454|OTHER|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
57925093|NCT03457454|OTHER|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
57925094|NCT05638893|DRUG|Placebo Tablet|Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
57925095|NCT05638893|DRUG|Metformin Hcl 500Mg Tab|Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
57925096|NCT05426759|DEVICE|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
57925097|NCT02285426|DEVICE|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality \[visual scale adapted from Herth 2009 and Zaric 2013\] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
57925098|NCT00778622|DRUG|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
57925099|NCT04445181|DRUG|The physician's prescription in routine clinical practice|This is an Observational study that will not involve prescription of the drugs.
57925100|NCT01001923|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
57925101|NCT01001923|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
57925102|NCT03308409|OTHER|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
57925103|NCT00629655|OTHER|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
57925104|NCT05285488|OTHER|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
57925105|NCT01886820|DRUG|[18F]NAV4694|
57925106|NCT00792805|DRUG|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
57925107|NCT00792805|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
57925108|NCT00792805|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
57925109|NCT04024774|BIOLOGICAL|Biological samples|blood samples, urine samples, tissue samples
58394531|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
58394532|NCT05302167|DEVICE|Molehill Mountain app|As above.
58394533|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
58394534|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
58394535|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
58394536|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
58394537|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
58277732|NCT06034678|BEHAVIORAL|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
58394538|NCT01755962|OTHER|Glycemic Load|
58277733|NCT03233789|BEHAVIORAL|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
58277734|NCT01665482|OTHER|A 2000 kcal test meal|
58277735|NCT01665482|OTHER|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
58277736|NCT03385551|DRUG|Estradiol|Estradiol or Promestriene depending on the arm
58277737|NCT04274309|DEVICE|EndoSWIR|Exposition of the respected tissues to the camera
58394539|NCT01755962|OTHER|Resistance Training|
58394540|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
58394541|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
58394542|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
58394543|NCT00080080|DRUG|talabostat (PT-100) tablets|
57726410|NCT06572566|OTHER|Non-invasive examination and assessment.|1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
57925110|NCT04024774|GENETIC|Genetic test|anamnesis and NGS sequencing
57925111|NCT05961280|PROCEDURE|Mastectomy with sentinel lymph node biopsy|
58277738|NCT05235971|BEHAVIORAL|Episodic Future thinking|"During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected"
58277739|NCT05235971|BEHAVIORAL|Volitional choice|"Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
58277740|NCT05235971|BEHAVIORAL|Monitoring only|"Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
58277741|NCT00279604|BEHAVIORAL|'Problem Profile Intervention' vs. WHO-Brief Intervention|
58277742|NCT04626700|DEVICE|iNAP|iNAP for the treatment of OSA
58394544|NCT00080080|DRUG|Docetaxel|
58394545|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
57925112|NCT01918553|OTHER|clinical parameters|
57925113|NCT01918553|OTHER|visual acuity exams|
57925114|NCT01918553|OTHER|retinophotography|
57925115|NCT01918553|OTHER|SD-OCT|
58277743|NCT04626700|DEVICE|CPAP|CPAP for the treatment of OSA
57925116|NCT01918553|OTHER|Intra ocular Pressure (IOP)|
58067572|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
58067573|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
58067574|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
58394546|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
57925117|NCT01918553|OTHER|retinal imaging (OPTOMAP)|
57925118|NCT01918553|OTHER|axial length (IOL master)|
58067575|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
58067576|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
58067577|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
58067578|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
58067579|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
58067580|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
58394547|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
58394548|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
58394549|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
57726411|NCT02627677|DRUG|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
57726412|NCT02627677|DRUG|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
58067581|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
58067582|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
58067583|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
58067584|NCT00405795|DEVICE|Envision® Patient Support System|
58067585|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
57726413|NCT02627677|DRUG|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
57726414|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
57925119|NCT03658746|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
57925120|NCT03658746|DRUG|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
58067586|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
58067587|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
58067588|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
58067589|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
58067590|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
58067591|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
57925121|NCT03658746|DRUG|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
57925122|NCT03707925|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
57925123|NCT03707925|PROCEDURE|Conventional Surgery|Undergo standard resection
57925124|NCT03707925|PROCEDURE|Laser Ablation|Undergo bronchoscopic laser ablation
57925125|NCT04622189|DEVICE|Action observation training|"Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform."
58277744|NCT04723407|OTHER|questionnaires|Questionnaire completion
57925126|NCT00519961|DEVICE|Elecsys®proBNP|
57925127|NCT01439919|DRUG|SSR411298|"Form: tablet~Route: oral administration with food"
57925128|NCT01439919|DRUG|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
57925129|NCT03855553|BEHAVIORAL|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
57951109|NCT03836391|BEHAVIORAL|Nudge|Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
58067592|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
58067593|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
57726415|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
57726416|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
58277745|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
57726417|NCT02811562|DEVICE|manikin|
58277746|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
58277747|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
58277748|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
58277749|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
58277750|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
58277751|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
58394550|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
57726418|NCT02811562|DEVICE|fiberoptic bronchoscope|
57726419|NCT02811562|DEVICE|pentax-airwayscope|
58277752|NCT03983785|OTHER|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
58277753|NCT03983785|OTHER|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
58277754|NCT05271123|DIAGNOSTIC_TEST|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
58277755|NCT04558489|BEHAVIORAL|IPR + GMI|The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
58277756|NCT01064635|DRUG|Letrozole|letrozole for 2-3 years after Tam
58277757|NCT01064635|DRUG|Letrozole|Letrozole for 5 years after Tam
58277758|NCT02994641|PROCEDURE|COMA Score Assessment|
58277759|NCT05538923|OTHER|No intervention was given to the patients|This study was an observational epidemiological study.
58277760|NCT00120341|DEVICE|Anodyne Therapy System|
57925130|NCT03855553|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
57925131|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)
57925132|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
58067594|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
58067595|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
58067596|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
58277761|NCT05857332|DRUG|SG1906|Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
58277762|NCT01490307|BEHAVIORAL|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
58277763|NCT00533559|DRUG|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
58277764|NCT00533559|DRUG|Placebo|Placebo comparator
58394551|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
58394552|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
58394553|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
57925133|NCT00920920|RADIATION|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
57925134|NCT05703867|DEVICE|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
57925135|NCT02787525|OTHER|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
57925136|NCT03147079|BEHAVIORAL|Lifestyle intervention|
57925137|NCT01290601|DRUG|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
58067597|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
58394554|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
58394555|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
57925138|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
58067598|NCT06482957|OTHER|Surveys|Complete surveys
58067599|NCT06482957|OTHER|Blood Collection|Undergo blood collection
58067600|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
58067601|NCT06482957|OTHER|Urine Collection|Undergo urine collection
58067602|NCT06482957|OTHER|Stool Collection|Undergo stool collection
58067603|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
58394556|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
58394557|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
58394558|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
58394559|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
58394560|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
57925139|NCT01290601|DRUG|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
57925140|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
57925141|NCT06124053|BEHAVIORAL|Group Voice Therapy|"The group voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. Each group is composed of three participants. The session durations are planned to be 45-60 minutes each."
58277765|NCT04467710|PROCEDURE|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
58277766|NCT02452554|OTHER|Laboratory Biomarker Analysis|Correlative studies
58277767|NCT02452554|BIOLOGICAL|Lorvotuzumab Mertansine|Given IV
58277768|NCT02452554|OTHER|Pharmacological Study|Correlative studies
58277769|NCT03274362|BEHAVIORAL|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
58277770|NCT04810559|DEVICE|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
58277771|NCT04103515|DEVICE|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
58277772|NCT04103515|DEVICE|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
58277773|NCT04176081|DRUG|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
58277774|NCT04176081|DRUG|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
58277775|NCT04176081|RADIATION|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
58277776|NCT04186897|PROCEDURE|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
58277777|NCT04186897|PROCEDURE|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
58277778|NCT00624039|OTHER|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
58277779|NCT03593187|DRUG|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
58277780|NCT03948763|BIOLOGICAL|V941|V941 administered IM, Q3W for 9 3-week cycles
58277781|NCT03948763|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
57925142|NCT06124053|BEHAVIORAL|Individual Voice Therapy|"The individual voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. The session durations are planned to be 45-60 minutes each."
57925143|NCT06124053|BEHAVIORAL|Vocal Hygiene Education|Regarding vocal hygiene training, information related to voice production and respiratory characteristics will be provided, and guidance on correct and incorrect voice use will be given.
57726420|NCT04135053|BIOLOGICAL|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
57726421|NCT03591744|DRUG|Bortezomib|Given SC
57726422|NCT03591744|BIOLOGICAL|Daratumumab|Given IV
57726423|NCT03591744|DRUG|Dexamethasone|Given IV and PO
57726424|NCT03591744|DRUG|Lenalidomide|Given PO
58067604|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
58067605|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
58067606|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
58067607|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
58067608|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
58067609|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
57925144|NCT01231516|DRUG|GSK1349572|50mg once daily
58067610|NCT00027027|DRUG|rhuMAb 2C4|
58067611|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
58067612|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
58277782|NCT05090306|DIAGNOSTIC_TEST|Routine ultrasound examination|ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
58277783|NCT05588999|PROCEDURE|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
58277784|NCT05588999|COMBINATION_PRODUCT|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
58277785|NCT02516956|OTHER|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
57925145|NCT01231516|DRUG|Raltegravir|400mg twice daily
57925146|NCT01231516|DRUG|GSK1349572 Placebo|Inactive placebo tablet once daily
57925147|NCT01231516|DRUG|Raltegravir Placebo|Inactive placebo tablet twice daily
57925148|NCT02818088|BEHAVIORAL|n-Back (Cognitive Training)|
58067613|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
58067614|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
58067615|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
58067616|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
58067617|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
58067618|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
58067619|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
57925149|NCT00056862|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
57925150|NCT00056862|DRUG|Peginterferon alfa-2a|180 mcg/week
57925151|NCT00056862|DRUG|Ribavirin|800 mg/day
57925152|NCT02831205|DEVICE|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
57925153|NCT02831205|DEVICE|everolimus-eluting cobalt-chromium (Xience) stent|
57925154|NCT00109499|DRUG|AdGVPEDF.11D|
57925155|NCT01211197|DRUG|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
57925156|NCT01211197|DRUG|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
57925157|NCT01211197|DRUG|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
57925158|NCT00979784|BEHAVIORAL|Better Weight|Standard cognitive behavioral treatment focused on dietary \& exercise behavior
57925159|NCT00979784|BEHAVIORAL|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
57925160|NCT00328991|DEVICE|duct tape occlusion therapy|
58067620|NCT01957904|DEVICE|ArterX Surgical Sealant|
58067621|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
57925161|NCT05424003|DRUG|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
57925162|NCT05424003|DRUG|Placebo|Placebo solution injected weekly for 72 weeks
57925163|NCT02854293|OTHER|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
58067622|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
57925164|NCT05267860|DEVICE|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
57925165|NCT00975351|DIETARY_SUPPLEMENT|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
58067623|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
58067624|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
58277786|NCT02516956|OTHER|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
58277787|NCT02516956|OTHER|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
58277788|NCT02516956|OTHER|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
58277789|NCT02516956|OTHER|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
57726425|NCT03591744|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
57726426|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
57726427|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
57726428|NCT01964573|DRUG|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
57726429|NCT01964573|OTHER|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
57726430|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
57925166|NCT06279065|DIAGNOSTIC_TEST|Analysis of blood and microbiome samples (stool, oral lavage)|Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells
57925167|NCT03457207|PROCEDURE|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
57925168|NCT00887679|DRUG|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
57925169|NCT05000892|DRUG|Sintilimab , Carboplatin, Nab-paclitaxel|Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
58277790|NCT02327013|DRUG|vortioxetine 10 mg tablet|Oral tablets, once daily
58277791|NCT02327013|DRUG|vortioxetine 20 mg tablet|Oral tablets, once daily
58277792|NCT02327013|OTHER|Placebo tablet|Oral tablets, once daily
58277793|NCT05290428|DIAGNOSTIC_TEST|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
58277794|NCT00004358|DRUG|calcitonin|
58277795|NCT02188524|OTHER|Exercise|Tai Chi and Compensatory Stepping
58277796|NCT05290077|DIAGNOSTIC_TEST|NGAL|Serum NGAL in blood for early detection of CVR
57925170|NCT02379481|DIETARY_SUPPLEMENT|NS 550mg|
57925171|NCT02379481|DIETARY_SUPPLEMENT|NS 1100mg|
57925172|NCT02379481|DIETARY_SUPPLEMENT|placebo|
58067625|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
58067626|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
58277797|NCT05368922|DEVICE|Virtual reality rehabilitation|"The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks."
58277798|NCT00926536|DEVICE|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
58277799|NCT00926536|DEVICE|DSA only|DSA imaging only
57726431|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
58277800|NCT03419130|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
57925173|NCT03266354|PROCEDURE|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
58277801|NCT03419130|OTHER|Laboratory Biomarker Analysis|Correlative studies
58277802|NCT03419130|BIOLOGICAL|Pembrolizumab|Given IV
58277803|NCT03419130|RADIATION|Radiation Therapy|Undergo conventionally fractionated RT
58277804|NCT03213925|RADIATION|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
58277805|NCT06445582|DIAGNOSTIC_TEST|[18F]SDM-8|synaptic vesicle glycoprotein 2 A（SV2A）PET tracer \[18F\]SDM-8
58277806|NCT01472978|DRUG|metronidazole|Metronidazole, 500 mg three times a for 10 days
58277807|NCT02585687|DEVICE|liver Perfusion MRI|
58277808|NCT04509817|DEVICE|Acupuncture+Usual care|"Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise."
58277809|NCT04509817|BEHAVIORAL|Usual care|Usual care intervention The subjects will receive the health advice
58277810|NCT05777564|OTHER|High intensity exercise|High intensity exercise on a indoor aerobic exercise device.
57925174|NCT01522157|DIETARY_SUPPLEMENT|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
57925175|NCT01522157|DIETARY_SUPPLEMENT|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
57925176|NCT01522157|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
57925177|NCT02113241|DRUG|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
57925178|NCT02113241|DRUG|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
57925179|NCT00412971|DRUG|Hexvix|Single installation, TURB
58277811|NCT01303614|DRUG|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
58277812|NCT01303614|DRUG|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
58277813|NCT04126317|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
58277814|NCT04126317|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
58277815|NCT03682029|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
58277816|NCT03682029|OTHER|Placebo|Placebo
57925180|NCT00412971|OTHER|Standard white light cystoscopy|
57925181|NCT05486546|PROCEDURE|Contoura with Phorcides|Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
57925182|NCT05486546|DEVICE|WaveLight Wavefront Optimized|Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
57925183|NCT02885090|PROCEDURE|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
57925184|NCT03783546|DEVICE|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
57925185|NCT03783546|OTHER|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
58277817|NCT03173261|DIAGNOSTIC_TEST|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
58394561|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
57925186|NCT02695641|DRUG|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
57925187|NCT02695641|DRUG|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
57925188|NCT03943862|BEHAVIORAL|2Share|"The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
57925189|NCT02712229|BEHAVIORAL|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
57925190|NCT00482924|OTHER|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
57925191|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
57925192|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
57925193|NCT02196714|DRUG|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
58277818|NCT06257160|PROCEDURE|Surgical infiltration|"During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles."
57925194|NCT02196714|DRUG|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
58067627|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
58277819|NCT06257160|PROCEDURE|PENG Block ultrasound-guided|"We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases."
58277820|NCT01133288|DEVICE|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (\~30 minutes per day) over a 3 month period.
58277821|NCT02850549|OTHER|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
58394562|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
58394563|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
58394564|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
58394565|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
58394566|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
58394567|NCT02693080|DRUG|Isovue-200|Contrast agent
58394568|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
58394569|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
58394570|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
58394571|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
58067628|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
57925195|NCT00465244|DRUG|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
58394572|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
57925196|NCT00465244|DRUG|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
57925197|NCT01759212|BIOLOGICAL|Allogeneic stem cells implantation|
57925198|NCT05659277|OTHER|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
57925199|NCT03212430|DRUG|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
57925200|NCT02422251|DEVICE|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
57925201|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
57925202|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
57925203|NCT04498065|BIOLOGICAL|Biological data|Biological data
57925204|NCT04498065|OTHER|Clinical data|Clinical data
58067629|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
57925205|NCT01388790|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
57925206|NCT01388790|DRUG|Cisplatin|Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
57925207|NCT01388790|DRUG|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
57925208|NCT05807607|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
57925209|NCT05807607|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
58067630|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
58067631|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
58067632|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
57925210|NCT05807607|PROCEDURE|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
57925211|NCT01708213|DEVICE|Aline HA|Implantable dermal filler
57925212|NCT02997371|DRUG|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
57925213|NCT02997371|DRUG|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
57925214|NCT03067012|OTHER|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
57951110|NCT05112536|DRUG|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
57951111|NCT05112536|DRUG|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
58067633|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
58067634|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
58067635|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
58394573|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
58394574|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
58394575|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
58277822|NCT02005627|DRUG|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
57925215|NCT04969887|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
57925216|NCT04969887|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
57925217|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
57925218|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
58277823|NCT02005627|DRUG|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
58277824|NCT05643326|DEVICE|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
57726432|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
57925219|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
57925220|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
57925221|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
57951112|NCT05112536|DRUG|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
58067636|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
58277825|NCT05643326|DEVICE|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
58277826|NCT05542394|DIETARY_SUPPLEMENT|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
58277827|NCT01758159|DIETARY_SUPPLEMENT|Iron supplementation|
58277828|NCT01758159|OTHER|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
58277829|NCT05519072|DRUG|Nitrofurantoin|For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
58277830|NCT00519792|DRUG|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
58277831|NCT00360009|PROCEDURE|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
58277832|NCT00360009|PROCEDURE|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
58277833|NCT05286164|DRUG|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
58277834|NCT00594386|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
58277835|NCT04334889|OTHER|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
58277836|NCT04401280|DRUG|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
58277837|NCT04401280|DRUG|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
57925222|NCT02886767|OTHER|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
57925223|NCT04326647|OTHER|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
57925224|NCT04326647|OTHER|Exercise|Exercises about balance and gait
57925225|NCT04592861|RADIATION|carbon ion RT|daily carbon ion radiotherapy
57925226|NCT04592861|DRUG|Chemotherapy drug|Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
57925227|NCT04723862|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
57726433|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
57925228|NCT04723862|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
57925229|NCT05786443|DRUG|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
57925230|NCT05786443|DRUG|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
57925231|NCT04579601|PROCEDURE|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
57925232|NCT04626895|DEVICE|Paxman Scalp Cooling Device|Paxman scalp cooling device
58394576|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
57925233|NCT05914246|DEVICE|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
57925234|NCT01791803|BEHAVIORAL|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
57925235|NCT01791803|DRUG|Nicotine|free one month supply after hospital discharge
58067637|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
58067638|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
58394577|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
58394578|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
57925236|NCT02284048|DRUG|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
58067639|NCT03374059|OTHER|Exercise program|
58067640|NCT03374059|OTHER|Life modification|
58067641|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
57925237|NCT02263534|PROCEDURE|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
57925238|NCT02263534|PROCEDURE|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
57925239|NCT03525899|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
57925240|NCT02643836|DEVICE|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
57925241|NCT00000712|DRUG|Zidovudine|
58067642|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
58067643|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
57925242|NCT00000712|DRUG|Acyclovir|
57925243|NCT02322138|OTHER|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
57726434|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
57925244|NCT02322138|OTHER|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
58394579|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
57925245|NCT02322138|OTHER|Reference Group|Breast fed ad libitum
57925246|NCT01964807|OTHER|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
57925247|NCT01964807|OTHER|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
57925248|NCT01964807|OTHER|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
57925249|NCT01964807|OTHER|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
58067644|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
58067645|NCT00769821|OTHER|questionnaire administration|
58067646|NCT00769821|PROCEDURE|assessment of therapy complications|
58067647|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
58394580|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
58394581|NCT01252160|DRUG|QUTENZA|Cutaneous patch
58394582|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
57925250|NCT01964807|OTHER|Moist snuff|Use moist snuff for 30 minutes
58067648|NCT00769821|PROCEDURE|quality-of-life assessment|
57925251|NCT01964807|OTHER|Sham Smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
57925252|NCT01964807|OTHER|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
57925253|NCT01964807|OTHER|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
58067649|NCT01074060|DRUG|plerixafor|Given IV
58067650|NCT01074060|BIOLOGICAL|filgrastim|Given SC
57726435|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
57726436|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
57925254|NCT01964807|OTHER|Sham Moist Snuff|Chew gum for 30 minutes
57925255|NCT03770559|PROCEDURE|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
57925256|NCT03770559|PROCEDURE|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
57925257|NCT04227548|DIAGNOSTIC_TEST|needle electromyography|Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
57925258|NCT05155241|BEHAVIORAL|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
57925259|NCT05155241|BEHAVIORAL|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
57925260|NCT00226850|BEHAVIORAL|hypnosis|
57925261|NCT02438319|OTHER|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
57925262|NCT02438319|OTHER|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
57925263|NCT00044915|DRUG|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
57925264|NCT00044915|DRUG|Placebo|All patients receive 1.25 mg of placebo
57925265|NCT03552822|OTHER|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
58067651|NCT01074060|DRUG|cyclophosphamide|Given IV
58067652|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
58067653|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
58067654|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
58067655|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
58067656|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
58067657|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
58067658|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
58067659|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
58394583|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
58067660|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
58067661|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
58067662|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
58067663|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
58394584|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
57925266|NCT01137955|DRUG|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
57925267|NCT01137955|DRUG|Placebo|Placebo orally three times a day for 10 days total
58394585|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
58394586|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
58394587|NCT02245269|DRUG|Tipranavir|
57925268|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
58067664|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
58067665|NCT02409017|PROCEDURE|Insulin drip|
58067666|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
58067667|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
58067668|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
58067669|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
58394588|NCT02245269|DRUG|Ritonavir|
58394589|NCT02245269|DRUG|Atorvastatin|
58394590|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
58394591|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
57925269|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
57925270|NCT01568437|PROCEDURE|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
57925271|NCT01568437|OTHER|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
57925272|NCT00090090|DRUG|Elsamitrucin|
58067670|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
58067671|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
58067672|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
58067673|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
58394592|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
58394593|NCT04521946|DRUG|Etoposide|Given IV
58394594|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
58394595|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
58394596|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
58394597|NCT04521946|DRUG|Melphalan|Given IV
58394598|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
58394599|NCT04521946|DRUG|Tacrolimus|Given IV
58394600|NCT04521946|DRUG|Thiotepa|Given IV
58394601|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
58394602|NCT00158249|DRUG|placebo|matched for physical appearance
58394603|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
58394604|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
58394605|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
58394606|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
58394607|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
58394608|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
58394609|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
58067674|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
58067675|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
58067676|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
58067677|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
58067678|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
57925273|NCT03491709|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
57925274|NCT03491709|DRUG|Cetuximab injection|Cetuximab injection
57925275|NCT03524300|PROCEDURE|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
58277838|NCT04401280|DRUG|CPP-ACP|applied in accordance with the manufacturer's specifications
58277839|NCT00208234|DRUG|Omalizumab|0.016 mg/kg IgE
58277840|NCT00208234|DRUG|Placebo for Omalizumab|Placebo
58394610|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
57726437|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
57726438|NCT01229228|DRUG|Naproxen Test|200-mg single dose
57726439|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
57726440|NCT01229228|DRUG|Naprosyn|single dose
57726441|NCT01229228|DRUG|Naprosyn|single dose
57726442|NCT01229228|DRUG|Placebo|single dose
57925276|NCT03524300|PROCEDURE|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
57925277|NCT05736991|DIAGNOSTIC_TEST|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
57925278|NCT05624385|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
57925279|NCT03600857|OTHER|Home administration of misoprostol|First dose of misoprostol administration at home
57925280|NCT03584113|OTHER|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
57925281|NCT03584113|OTHER|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase \[5mg\] and alteplase \[10mg\] Q12hours).
57925282|NCT02054325|DRUG|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
57925283|NCT02054325|DRUG|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
57925284|NCT00442299|DEVICE|Fractionated Plasma Separation and Adsorption (FPSA)|
57925285|NCT04021251|DEVICE|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
57925286|NCT03933774|DRUG|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
57925287|NCT03933774|DRUG|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
57925288|NCT02628756|PROCEDURE|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
58067679|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
58067680|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
58067681|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
58277841|NCT00208234|DRUG|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
58277842|NCT02577627|DEVICE|PrediCare|
58277843|NCT05457114|DEVICE|Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)|PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
57925289|NCT00402038|DRUG|SC Methylnaltrexone|Dose 1
57925290|NCT00402038|DRUG|SC Placebo|
57925291|NCT02460666|BEHAVIORAL|Tai-Chi-Chih (TCC)|
57925292|NCT02460666|BEHAVIORAL|Health Education and Wellness Classes (HEW)|
57925293|NCT03651986|DIAGNOSTIC_TEST|ctDNA methylation analysis by NGS|A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)
57925294|NCT01589354|PROCEDURE|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
57925295|NCT01589354|PROCEDURE|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
57925296|NCT01589354|DEVICE|Ultrasound guided technique|The block will be performed under U/S guidance
58067682|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
58067683|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
58067684|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
58067685|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
58067686|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
58067687|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
58277844|NCT05457114|DEVICE|FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)|Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
58277845|NCT04782414|PROCEDURE|Hot AXIOS® prosthesis|endoscopic trans digestive drainage using of the Hot AXIOS prosthesis in the treatment of pancreatic collections (incompletely fluid or necrotic)
58277846|NCT04562857|BEHAVIORAL|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
57925297|NCT01589354|DRUG|Ropivacaine|20ml of 0.375% Ropivacaine
58067688|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
58067689|NCT02432027|DRUG|Daivonex cream|comparator
58277847|NCT04629872|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
58277848|NCT02537652|OTHER|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
58277849|NCT03358680|DEVICE|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
58067690|NCT02432027|DRUG|Diprosis gel|comparator
58067691|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
58067692|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
57925298|NCT01589354|DRUG|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
57925299|NCT03761446|BEHAVIORAL|Bed rest|The participant will remain in bed rest for 10 complete days.
57925300|NCT06270927|DIAGNOSTIC_TEST|MRI|neuroimaging using MRI scanner
57925301|NCT06270927|DIAGNOSTIC_TEST|CT|neuroimaging using CT scanner
57925302|NCT04578912|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
57925303|NCT04578912|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
57925304|NCT04578912|DEVICE|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
57951113|NCT05112536|DRUG|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
58067693|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
58067694|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
58394611|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
58394612|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
58394613|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
58394614|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
58394615|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
58394616|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
57925305|NCT03357952|DRUG|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
57925306|NCT03357952|DRUG|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
58067695|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
58067696|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
58067697|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
58067698|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
58277850|NCT01904630|GENETIC|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
58277851|NCT01230099|BEHAVIORAL|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
58277852|NCT02700880|DEVICE|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
58277853|NCT03632538|DIAGNOSTIC_TEST|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
58277854|NCT03510078|DRUG|Insulin|Insulin for glycemic control according to the allocation
58277855|NCT01082796|DRUG|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
57925307|NCT00688012|DRUG|SPC3649|
57925308|NCT02039791|BIOLOGICAL|Nimotuzumab|200mg/w,weekly, 6 weeks
57925309|NCT02039791|DRUG|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
57925310|NCT02039791|DRUG|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
57925311|NCT02347228|DRUG|OB318 capsule|Oral qd, at least 30 minutes before breakfast
57925312|NCT00003555|DRUG|amifostine trihydrate|
58067699|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
58067700|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
58067701|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
58067702|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
58277856|NCT05383833|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
58277857|NCT00546494|DRUG|Effexor® (Venlafaxine)|
58394617|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
58394618|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
58394619|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
58394620|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
58394621|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
58394622|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
58394623|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
57925313|NCT00003555|DRUG|paclitaxel|
58394624|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
58394625|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
58394626|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
58277858|NCT01738256|BEHAVIORAL|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
58277859|NCT01738256|BEHAVIORAL|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
58277860|NCT01738256|BEHAVIORAL|No intervention|No intervention
58277861|NCT04878302|BEHAVIORAL|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
58277862|NCT05212779|DIAGNOSTIC_TEST|Signatera testing|26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
58277863|NCT05212779|DIAGNOSTIC_TEST|Altera Testing|6ml blood and tissue sample.
58277864|NCT04638803|DRUG|PRX-P4-003, (-)-FCF|sequential study
58277865|NCT02204358|PROCEDURE|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
58277866|NCT01874418|OTHER|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
58277867|NCT05508945|DEVICE|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
58277868|NCT05508945|DEVICE|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
58277869|NCT05508945|DEVICE|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
58277870|NCT03163459|DRUG|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
58394627|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
58394628|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
58394629|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
57925314|NCT00963833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
57925315|NCT06120348|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
58067703|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
58277871|NCT03163459|DEVICE|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
58277872|NCT01655134|OTHER|Blood simples|
58277873|NCT01655134|OTHER|Capillary punction|
58277874|NCT01655134|OTHER|Urine simples|
58277875|NCT00001037|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
58277876|NCT03358381|PROCEDURE|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
58277877|NCT03358381|PROCEDURE|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
58277878|NCT04052360|DRUG|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
57925316|NCT06120348|DEVICE|Sham Stimulation|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
58067704|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
58394630|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
58394631|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
58394632|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
58394633|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
57925317|NCT06236698|DIAGNOSTIC_TEST|24-hour urinary aldosterone|Collect 24-hour urine from each participant and complete the detection of urinary aldosterone content.
57925318|NCT04664010|DRUG|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
58067705|NCT00402662|DRUG|everolimus|
58067706|NCT00402662|DRUG|Imatinib|
58067707|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
58067708|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
58277879|NCT04052360|DRUG|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
58277880|NCT01917604|PROCEDURE|open exposure|the open surgical methods of exposing the canine is compared with control
58394634|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
58394635|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
58394636|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
58394637|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
58394638|NCT00036855|BIOLOGICAL|rituximab|Given IV
58394639|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
57925319|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
57925320|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
57925321|NCT00243360|BEHAVIORAL|diagnostic and treatment clinical algorithms|
57925322|NCT04331054|DRUG|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
57925323|NCT04331054|OTHER|1: Usual practice|Usual practice
57925324|NCT02674100|OTHER|Registry|
58067709|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
58067710|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
58067711|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
58277881|NCT01917604|PROCEDURE|closed exposure|closed exposure is compared with control
58394640|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
58394641|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
58394642|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
57925325|NCT06127056|DEVICE|High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
58277882|NCT02070978|DRUG|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
58277883|NCT02070978|DRUG|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
58394643|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
58394644|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
58394645|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
58394646|NCT06096090|DRUG|Placebo|Placebo administration
58394647|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
57925326|NCT06127056|DEVICE|sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
57925327|NCT00846456|BIOLOGICAL|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
57925328|NCT02174796|PROCEDURE|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
58394648|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
58277884|NCT02070978|DRUG|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
58277885|NCT05409508|OTHER|mindfulness meditation care|mindfulness meditation care
58277886|NCT05409508|OTHER|no mindfulness meditation care|no mindfulness meditation care
58277887|NCT04553003|DRUG|Glucocorticoids+hepatoprotectant|Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
58277888|NCT04553003|DRUG|hepatoprotectant|Participants received hepatoprotectants (i.v.gtt.) for 7 days.
58277889|NCT03077386|BEHAVIORAL|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
58277890|NCT06038006|DIAGNOSTIC_TEST|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
58277891|NCT01528137|BIOLOGICAL|talactoferrin|Given PO
58277892|NCT01528137|OTHER|laboratory biomarker analysis|Correlative studies
58394649|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
58394650|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
57925329|NCT02174796|PROCEDURE|orthopedic treatment|orthopedic treatment by vacuum bell.
57925330|NCT00084266|DRUG|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
58277893|NCT03208413|DRUG|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
58277894|NCT04296669|DEVICE|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
58394651|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
58394652|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
58394653|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
58394654|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
57925331|NCT00084266|DRUG|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
57925332|NCT02235974|BEHAVIORAL|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
57925333|NCT02235974|BEHAVIORAL|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
58277895|NCT03191123|PROCEDURE|hepatic resection|The aim of this intervention is to reach curative resection.
58277896|NCT03191123|PROCEDURE|TACE|The aim of this intervention is one of the palliative treatment.
58277897|NCT02652598|DRUG|Tolcapone|
58277898|NCT02907619|BIOLOGICAL|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
58277899|NCT01329666|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
58277900|NCT01329666|DIETARY_SUPPLEMENT|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
58394655|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
58394656|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
58394657|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
58394658|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
58394659|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
58394660|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
58394661|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
57925334|NCT02235974|BEHAVIORAL|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
57925335|NCT02235974|BEHAVIORAL|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
57925336|NCT04242160|OTHER|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
57925337|NCT04242160|OTHER|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
57925338|NCT01504750|PROCEDURE|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
57951114|NCT05112536|DRUG|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
57951115|NCT05112536|BIOLOGICAL|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
58277901|NCT00846690|DRUG|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
58277902|NCT00846690|DRUG|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
58277903|NCT01478607|DRUG|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
58277904|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
58277905|NCT02668159|DIETARY_SUPPLEMENT|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
58277906|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
58277907|NCT02668159|DIETARY_SUPPLEMENT|Placebo|7 tablets of placebos administered prior to one the OGTT
58277908|NCT03541434|DIAGNOSTIC_TEST|Complete Blood Count|White blood cell subgroups count
58277909|NCT03541434|DIAGNOSTIC_TEST|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
58277910|NCT03541434|PROCEDURE|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
58277911|NCT04794114|DEVICE|experimental ankle foot orthosis|On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
58277912|NCT04794114|DEVICE|traditional ankle foot orthosis|The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
58277913|NCT05436678|DRUG|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
58277914|NCT05436678|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
58277915|NCT05436678|DRUG|Celecoxib 200mg|Celecoxib
58277916|NCT01330056|PROCEDURE|FOPS|"* Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group."
58394662|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
58394663|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
58394664|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
58394665|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
58394666|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
58277917|NCT01330056|RADIATION|CRT|"* Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
58394667|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
58277918|NCT06229613|DEVICE|medical device for exhaled breath aerosols (XBAs) collection|To evaluate the feasibility of XBAs collection and analysis (index test) using the molecular tests currently in use at San Raffaele Hospital for the detection of respiratory pathogens in clinical samples, compared to upper respiratory secretion and sputum samples, that will be collected using standard procedures and analysed using the same kits (comparator tests).
58277919|NCT04065581|DRUG|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
58394668|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
58394669|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
58394670|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
57925339|NCT01101477|PROCEDURE|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~1. Patients become irritant and interfere procedures.~2. Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~1. Systolic blood pressure is less than 90mmHg;~2. Mean arterial blood pressure is less than 65mmHg;~3. Oxyhemoglobin saturation is less than 90 %~with any duration."
58277920|NCT04065581|DRUG|Glucobay|Single dose: 50 mg tablet, oral
58277921|NCT04065581|DRUG|Glucophage|Single dose: 500 mg tablet, oral
58277922|NCT00408187|DRUG|voclosporin|voclosporin 0.4 mg/kg po BID
58277923|NCT00408187|DRUG|Ciclosporin|ciclosporin 1.5 mg/kg po BID
58394671|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
58394672|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
58394673|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
57925340|NCT03672422|DIAGNOSTIC_TEST|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
57925341|NCT03672422|BEHAVIORAL|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
58277924|NCT00408187|DRUG|Placebo|Placebo
58277925|NCT01824121|BIOLOGICAL|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
58277926|NCT02860871|OTHER|infrared spectroscopy|
58277927|NCT00392496|DRUG|sunitinib malate|Given orally
58277928|NCT02634905|OTHER|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
58277929|NCT02634905|OTHER|Phone Call|
58277930|NCT03576352|OTHER|a rapid sequence tracheostomy (RST) on rabbit cadaver|"The Rapid Sequence Tracheostomy (RST) consists of the following steps:~1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated."
58277931|NCT04759456|OTHER|Remotely-supervised rehabilitation program|Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
58277932|NCT01832818|DEVICE|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
58277933|NCT01438814|DRUG|metformin placebo|metformin placebo tablets 500mg
58277934|NCT01438814|DRUG|linagliptin placebo|linagliptin placebo tablets 5mg
58277935|NCT01438814|DRUG|metformin|metformin tablets 500mg
58277936|NCT01438814|DRUG|metformin|metformin tablets 500 mg
58394674|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
58394675|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
58394676|NCT04217811|OTHER|No intervention|No intervention
58394677|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
58394678|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
58394679|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
58394680|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
58394681|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
58394682|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
58394683|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
58394684|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
58394685|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
58394686|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
58394687|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
58394688|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
57925342|NCT03672422|DIAGNOSTIC_TEST|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
57925343|NCT03672422|DIAGNOSTIC_TEST|Urine sample|50 ml of urine in collection container.
57925344|NCT03193788|DRUG|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
57925345|NCT03193788|DRUG|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
58277937|NCT01438814|DRUG|linagliptin|linagliptin tablets 5mg
58277938|NCT00396877|DRUG|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
58277939|NCT00396877|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
58277940|NCT00312104|DRUG|insulin detemir|
58394689|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
57925346|NCT03193788|DRUG|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
57925347|NCT03193788|DRUG|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
57925348|NCT05722054|OTHER|Diagnostic tests|"Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination."
57925349|NCT05722054|OTHER|Equilibrate diet|Nutritionally-balanced Alimentation
57925350|NCT04747782|OTHER|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
57925351|NCT04143750|DRUG|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
58394690|NCT00077714|DRUG|Paliperidone ER|
58394691|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
58394692|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
57925352|NCT00253877|OTHER|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
57925353|NCT03693456|OTHER|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
57925354|NCT00599976|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation
57925355|NCT04631796|DEVICE|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
57925356|NCT04631796|DEVICE|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
58067712|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
58277941|NCT00312104|DRUG|insulin glargine|
58277942|NCT00312104|DRUG|insulin aspart|
58277943|NCT02510703|OTHER|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
58277944|NCT04628078|OTHER|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
58277945|NCT00840736|PROCEDURE|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
58277946|NCT00840736|PROCEDURE|vertical banded gastroplasty|vertical banded gastroplasty
58277947|NCT03321409|DIAGNOSTIC_TEST|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
58277948|NCT03321409|DIAGNOSTIC_TEST|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
58277949|NCT03927326|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
58277950|NCT04166292|DEVICE|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
58277951|NCT03313011|DIAGNOSTIC_TEST|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
58277952|NCT03245190|DRUG|Chiauranib|50mg, orally once daily
58277953|NCT01226680|DRUG|Tasocitinib|0.005% QD for 12 weeks
58277954|NCT01226680|DRUG|Tasocitinib|0.003% QD for 12 weeks
58277955|NCT01226680|DRUG|vehicle for Tasocitinib|vehicle QD for 12 weeks
58277956|NCT05855408|BIOLOGICAL|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
58277957|NCT05855408|BIOLOGICAL|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
58277958|NCT05855408|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
57925357|NCT06526832|BIOLOGICAL|BST02|BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.
57925358|NCT00872196|DRUG|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
57925359|NCT00735735|OTHER|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
58067713|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
58067714|NCT00993694|DRUG|chemotherapy|
58067715|NCT00993694|DRUG|dapsone|
57925360|NCT06321549|OTHER|The reference point of minimally invasive mastectomy procedure conducted|November 2018 as a temporal reference point was predicated on the milestone of the medical center's inaugural minimally invasive mastectomy procedure conducted
57925361|NCT00210301|DRUG|Provigil (modafinil)|
58067716|NCT00993694|OTHER|medical chart review|
58067717|NCT00993694|PROCEDURE|assessment of therapy complications|
58277959|NCT05855408|BIOLOGICAL|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
58277960|NCT02826252|DRUG|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
58277961|NCT02826252|DEVICE|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
58277962|NCT05239117|DEVICE|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
58306674|NCT02757157|BEHAVIORAL|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
57925362|NCT01975454|DRUG|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
57925363|NCT01975454|DRUG|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
57925364|NCT04134364|DRUG|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
57925365|NCT04743479|DIAGNOSTIC_TEST|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
57925366|NCT00846339|DRUG|Bupropion|bupropion
57925367|NCT04729764|DRUG|GP681 Tablet|Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
57925368|NCT03812497|BEHAVIORAL|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
57925369|NCT03834987|OTHER|Neurodevelopmental Assessment|Developmental assessment at baseline and longitudinally as measured by age and ability-appropriate scales, including: the Mullen Scales of Early Learning, the Peabody Scales of Motor Development, the Vineland 3, and Beery Visual Motor Integration
57925370|NCT00499356|DEVICE|pressure reducing insole|
57925371|NCT00499356|DEVICE|GlideSoft®|
57925372|NCT00509587|DRUG|pazopanib hydrochloride|Given orally
57925373|NCT00509587|PROCEDURE|pharmacological study|Correlative studies
57925374|NCT00509587|PROCEDURE|laboratory biomarker analysis|Correlative studies
58067718|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
58067719|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
58394693|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
57925375|NCT01626703|OTHER|Reminding call|
57925376|NCT05608902|OTHER|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
57925377|NCT05803590|DRUG|Green tea mouthwash|effictive against caries and periodontal diseases
57925378|NCT05803590|DRUG|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
57925379|NCT04720222|DEVICE|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
58067720|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
58067721|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
58067722|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
57925380|NCT04599400|OTHER|There is no intervention in our study|There is no intervention in our study
57925381|NCT06087016|OTHER|Urine vibrational analysis|Urine vibrational analysis
57925382|NCT03699436|OTHER|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
57925383|NCT03699436|OTHER|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
57925384|NCT05627713|OTHER|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
57925385|NCT05627713|OTHER|urine sample collection|urine sample collection at inclusion
57925386|NCT04576143|DRUG|Epirubicin|i.v. 90 mg/m2
57925387|NCT04576143|DRUG|Cyclophosphamid|i.v. 600 mg/m2
57925388|NCT04576143|DRUG|Docetaxel|i.v. 100 mg/m2
57925389|NCT04576143|DRUG|Paclitaxel|i.v. 175 mg/m2
57925390|NCT02823756|PROCEDURE|Physical Therapy|Exercise, education, spinal manipulation
57925391|NCT03722056|PROCEDURE|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
57951116|NCT04945603|OTHER|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
58067723|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
58277963|NCT03573401|COMBINATION_PRODUCT|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
58277964|NCT03573401|COMBINATION_PRODUCT|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
58277965|NCT03904316|BIOLOGICAL|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
58277966|NCT03904316|OTHER|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
58277967|NCT03850405|DIETARY_SUPPLEMENT|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
58277968|NCT05639686|DRUG|Tranexamic acid injection|Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
58277969|NCT05639686|DRUG|Total Intravenous Anesthesia|Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
58277970|NCT05639686|DRUG|Inhalational isoflurane|Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
58277971|NCT05528484|PROCEDURE|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
58277972|NCT05528484|PROCEDURE|non eras nursing|Patients were under the routine management without eras protocol
58394694|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
58394695|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
57925392|NCT05821751|DIETARY_SUPPLEMENT|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
57925393|NCT05821751|DRUG|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
57925394|NCT05821751|DRUG|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
57925395|NCT04175002|DRUG|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
57925396|NCT02183532|DRUG|BI 1356 BS|single dose
57925397|NCT02183532|DRUG|BI 1356 BS|multiple doses
58067724|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
58067725|NCT00188162|DEVICE|CT|
58067726|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
57925398|NCT02211144|DRUG|BIBR 796 BS|
57925399|NCT02211144|DRUG|Placebo|
58067727|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
58394696|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
57925400|NCT04510909|OTHER|COMMIT mHealth application|The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
57925401|NCT03877432|DEVICE|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
57925402|NCT04417374|OTHER|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
57925403|NCT00482196|DRUG|MK0493|
57925404|NCT02720614|RADIATION|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
57925405|NCT02781272|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
57925406|NCT02781272|PROCEDURE|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
57925407|NCT02781272|PROCEDURE|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
57925408|NCT06038136|BEHAVIORAL|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
57925409|NCT04908605|DRUG|Mirtazapine|Every patient will be given mirtazapine 30 mg tablet
57925410|NCT04908605|DRUG|Melatonin|Every patient will be given melatonin 5 mg tablet
58067728|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
58394697|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
58394698|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
57925411|NCT04908605|DRUG|Placebo|Every patient will be given a matching placebo tablet
57925412|NCT04858139|DRUG|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
57925413|NCT04858139|DRUG|Placebo|Intravenous injection (20 min)
57925414|NCT00557583|DRUG|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
57925415|NCT05282615|DEVICE|Emanate Tray|Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
58277973|NCT04416646|DRUG|Cabozantinib|The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.
58394699|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
57925416|NCT06209671|BIOLOGICAL|INS19 CAR-T Cells|INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
57925417|NCT05127369|DRUG|Dental pulp mesenchymal cell injection|Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
58067729|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
58067730|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
57925418|NCT05127369|DRUG|Dental pulp mesenchymal cell vehicle|Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
57925419|NCT05127369|DRUG|fluoxetine hydrochloride capsule|fluoxetine hydrochloride capsule
57925420|NCT01933113|DEVICE|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
58067731|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
58067732|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
58067733|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
58277974|NCT05876559|OTHER|Joyuus Self-care Mobile App|Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.
58277975|NCT05876559|OTHER|Standard Care|Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
58277976|NCT02175342|DRUG|Tiotropium 0.625 mcg/puff|
57726443|NCT06296940|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.
57925421|NCT03178929|DRUG|S-Adenosyl Methionine|2000mg, po
57925422|NCT04218955|COMBINATION_PRODUCT|Silver Diamine Flouride|Material used to arrest caries in children
57925423|NCT04272970|DIAGNOSTIC_TEST|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
57925424|NCT04085627|DRUG|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg\& Amlodipine 5mg
57925425|NCT03047759|DEVICE|water flosser|Powered
57925426|NCT03047759|DEVICE|air floss|Powered
58067734|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
58067735|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
58067736|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
58067737|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
58067738|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
57925427|NCT00419783|DRUG|bilastine|20 mg tablets.
58067739|NCT04927858|DRUG|Empagliflozin|Empagliflozin
58067740|NCT00252798|DRUG|Gefitinib|
58277977|NCT02175342|DRUG|Tiotropium 1.25 mcg/puff|
58067741|NCT00252798|DRUG|Carboplatin|
58067742|NCT00252798|DRUG|Paclitaxel|
58067743|NCT00252798|PROCEDURE|Radiation|
58067744|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
58067745|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
58067746|NCT02576106|DEVICE|Cryoablation|
58277978|NCT02175342|DRUG|Tiotropium 2.5 mcg/puff|
58277979|NCT02175342|DRUG|Tiotropium 5 mcg/puff|
58277980|NCT02175342|DRUG|Placebo solution|
58277981|NCT02175342|DRUG|Tiotropium-18 lactose powder|
58277982|NCT02175342|DRUG|Placebo lactose powder|
58277983|NCT02175342|DRUG|Tiotropium 10 mcg/puff|
58277984|NCT02175342|DEVICE|Respimat|
58277985|NCT02175342|DEVICE|Handihaler|
58277986|NCT02256306|OTHER|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
58277987|NCT01636947|DRUG|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
58277988|NCT01636947|DRUG|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
57925428|NCT00419783|DRUG|Bilastine|100 mg (5 tablets of 20 mg)
57925429|NCT00419783|DRUG|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
57925430|NCT00419783|DRUG|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
57925431|NCT00419783|DRUG|Placebo|Placebo tablets
58277989|NCT01636947|DRUG|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
57726444|NCT06296940|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
57925432|NCT06430944|PROCEDURE|Placing a hip spica cast for patients with femur fractures|Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
58277990|NCT01636947|DRUG|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
58277991|NCT01636947|DRUG|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
58277992|NCT01636947|DRUG|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
58277993|NCT05603156|DRUG|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
58277994|NCT01985958|DEVICE|Radiation therapy|
58277995|NCT05296200|DEVICE|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
58277996|NCT00957424|BEHAVIORAL|telephone-based intervention|10-15 minute web-based survey on a computer
57925433|NCT00522912|PROCEDURE|Trichiasis surgery|Posterior lamella tarsal rotation
57925434|NCT00522912|PROCEDURE|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
57925435|NCT00126022|DRUG|Tedisamil sesquifumarate|
57925436|NCT00477854|DRUG|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
57925437|NCT05584228|DRUG|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
57925438|NCT05584228|PROCEDURE|Intestinal resection|Ileocolonic or small bowel resection
58394700|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
58394701|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
57726445|NCT03437499|PROCEDURE|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
57726446|NCT03437499|PROCEDURE|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
57726447|NCT02842398|BEHAVIORAL|Balance Master|
57726448|NCT02842398|BEHAVIORAL|Customary Care|
57925439|NCT04359251|OTHER|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
57925440|NCT04359251|OTHER|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
57925441|NCT04359251|OTHER|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
57925442|NCT05214196|DRUG|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
57925443|NCT05615532|DRUG|LY3209590 (SC)|Administered SC.
57925444|NCT05615532|DRUG|LY3209590 (IV)|Administered IV.
57925445|NCT00647322|OTHER|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
57925446|NCT00647322|PROCEDURE|No drug change|No change in anti-epileptic treatment
57925447|NCT02950324|BEHAVIORAL|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
57925448|NCT02950324|BEHAVIORAL|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
57925449|NCT05031169|PROCEDURE|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
58277997|NCT00957424|DRUG|nicotine replacement therapy|One week supply
58277998|NCT00957424|OTHER|informational intervention|
58277999|NCT00957424|OTHER|internet-based intervention|
58278000|NCT00957424|OTHER|questionnaire administration|Given out week 2, 3 and 4.
58278001|NCT01781052|DRUG|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
57925450|NCT03545009|DIETARY_SUPPLEMENT|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
58067747|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
58067748|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
58067749|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
58067750|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
58067751|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
58278002|NCT04719130|OTHER|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
58278003|NCT04719130|OTHER|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
58067752|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
58278004|NCT02577926|DRUG|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
58278005|NCT02577926|DRUG|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
58278006|NCT05072587|BEHAVIORAL|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
58278007|NCT05072587|BEHAVIORAL|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
58278008|NCT03035916|OTHER|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
58278009|NCT03035916|OTHER|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
58278010|NCT03035916|OTHER|control|The Control group receives standard IV-inhaled general anesthesia.
58278011|NCT04286334|DEVICE|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
58394702|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
57925451|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
58067753|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
58067754|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
57925452|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice|70ml Concentrated Beetroot Juice
57925453|NCT04973878|PROCEDURE|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
57925454|NCT04973878|PROCEDURE|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
57925455|NCT03142763|OTHER|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
57925456|NCT03142763|DIETARY_SUPPLEMENT|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
57925457|NCT05601791|PROCEDURE|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
58067755|NCT00367146|DRUG|MMF|
58278012|NCT06304402|DEVICE|The Percussive Massage Treatment|In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.
58278013|NCT06304402|BEHAVIORAL|The Proprioceptive Neuromuscular Facilitation Stretching|Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
58278014|NCT05475626|PROCEDURE|Arthroereisis-|Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
58394703|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
58394704|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
58394705|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
58394706|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
58394707|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
58394708|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
58394709|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
57925458|NCT05601791|PROCEDURE|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
57925459|NCT04635683|DRUG|Lenalidomide|Given PO
57925460|NCT04635683|BIOLOGICAL|Ublituximab|Given IV
57925461|NCT04635683|DRUG|Umbralisib|Given PO
58394710|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
58394711|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
58394712|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
57925462|NCT00662779|DRUG|arformoterol|15 mcg arformoterol nebulizer
57925463|NCT00662779|DRUG|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
57925464|NCT00662779|DRUG|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
57925465|NCT06330168|DRUG|bupivacaine-calcitonin-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml).
57925466|NCT06330168|DRUG|Bupivacaine-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
57925467|NCT03242551|DRUG|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
58394713|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
57925468|NCT06073379|OTHER|Korean manupuncture|Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
57925469|NCT06073379|OTHER|Placebo session|Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
57925470|NCT04580797|DRUG|PF-06700841 IR|Immediate release formulation
57925471|NCT04580797|DRUG|PF-06700841 MR1|Modified release formulation 1
57925472|NCT04580797|DRUG|PF-06700841 MR2|Modified release formulation 2
57925473|NCT04580797|DRUG|PF-06700841 MR3|Modified release formulation 3
57925474|NCT04580797|OTHER|Placebo|Matching placebo
57925475|NCT03892993|OTHER|Decision Aid|Use decision aid
57925476|NCT03892993|OTHER|Questionnaire Administration|Ancillary studies
57925477|NCT06248931|DRUG|Valproic acid|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
58067756|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
58278015|NCT05277064|OTHER|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
58278016|NCT02811653|DEVICE|Brain MRI|
58278017|NCT02811653|OTHER|neuropsychological evaluation|
58278018|NCT02811653|BIOLOGICAL|Blood|
58278019|NCT03129789|OTHER|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
58278020|NCT04315844|DEVICE|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
58278021|NCT02053259|BEHAVIORAL|Adaptive Goals|
58278022|NCT02053259|BEHAVIORAL|Reinforcement|
58278023|NCT02053259|BEHAVIORAL|Static Goals|
58394714|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
57925478|NCT06248931|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
57925479|NCT02013505|OTHER|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
57925480|NCT02629289|DRUG|HSP-130|
58278024|NCT04092088|DEVICE|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
58278025|NCT04092088|DEVICE|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
58278026|NCT04092088|DEVICE|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
58278027|NCT04092088|DEVICE|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
58278028|NCT04093492|OTHER|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
58278029|NCT04093492|OTHER|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
58278030|NCT01290497|DRUG|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
58278031|NCT01290497|DRUG|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
58278032|NCT01290497|DRUG|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
58394715|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
57925481|NCT02629289|DRUG|US-approved Neulasta|
57925482|NCT02629289|DRUG|EU-approved Neulasta|
58067757|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
58067758|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
58067759|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
58278033|NCT00553358|DRUG|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
58278034|NCT00553358|BIOLOGICAL|Trastuzumab|Therapeutic Monoclonal Antibody
58278035|NCT00553358|DRUG|Paclitaxel|antimicrotubule agent
57925483|NCT04171622|DRUG|Lenvatinib|Given PO
57925484|NCT04171622|BIOLOGICAL|Pembrolizumab|Given IV
57925485|NCT04624373|OTHER|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
57925486|NCT04727086|DRUG|BP1.3656|BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
57925487|NCT04727086|DRUG|Placebo|Administered once daily in tablet form.
57925488|NCT05564351|OTHER|eye mask and ear plug|black eye mask and silicon ear plug
57925489|NCT01561781|DRUG|Digoxin|Oral tablets 0.25mg, single dose
57925490|NCT01561781|DRUG|Vandetanib|Oral tablets, 300 mg, single dose
57925491|NCT04748796|OTHER|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
57925492|NCT04748796|DRUG|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
58278036|NCT00570180|DRUG|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
58278037|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|All drugs on awakening
58278038|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
57925493|NCT01504308|DEVICE|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
57925494|NCT01504308|DEVICE|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
57925495|NCT00231153|DRUG|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
57925496|NCT00231153|DRUG|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
57925497|NCT03844490|OTHER|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
57925498|NCT03844490|OTHER|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
57925499|NCT05937633|OTHER|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
57925500|NCT05360498|BEHAVIORAL|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
58278039|NCT00741585|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
58278040|NCT01456364|DRUG|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
58278041|NCT01456364|DRUG|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
58278042|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
57925501|NCT05360498|BEHAVIORAL|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
58278043|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
58278044|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
57925502|NCT02823808|DRUG|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
57925503|NCT02823808|DRUG|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
57925504|NCT05309434|BEHAVIORAL|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
57925505|NCT06211335|DRUG|Losartan|Given PO
57925506|NCT06211335|BIOLOGICAL|Pembrolizumab|Given IV
57925507|NCT06211335|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57925508|NCT00564018|DRUG|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
58278045|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
58278046|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
58278047|NCT00409032|DRUG|Strontium malonate|
57925509|NCT00564018|DRUG|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
57925510|NCT00564018|DRUG|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
57925511|NCT00759330|DRUG|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
57925512|NCT00759330|DRUG|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
57925513|NCT00759330|DRUG|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
57925514|NCT00759330|DRUG|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
57925515|NCT06005818|DRUG|Pembrolizumab injection|PD-1 antibody
58278048|NCT02510300|DRUG|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
57925516|NCT04973254|OTHER|CAB-RPV LA|Monthly administration of injectable HIV medication
58278049|NCT02510300|DRUG|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
58278050|NCT02510300|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
58278051|NCT02510300|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
58278052|NCT02540967|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
57925517|NCT04973254|OTHER|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
58278053|NCT03601741|OTHER|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
58278054|NCT03601741|OTHER|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
58278055|NCT02178527|OTHER|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
58278056|NCT02178527|OTHER|Usual Care|Usual general podiatry care provded by UK National Health Service
58278057|NCT05559944|BEHAVIORAL|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.
58278058|NCT05559944|BEHAVIORAL|Self-Affirmation|Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
58278059|NCT05559944|BEHAVIORAL|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
58278060|NCT02407587|DEVICE|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
58278061|NCT04757324|OTHER|breastfeeding education|
58278062|NCT04419766|OTHER|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
58278063|NCT06229977|DRUG|Palmitoylethanolamide (PEA)|Participants will receive PEA at a dose of 600mg twice daily for 6 weeks.
58278064|NCT06229977|DRUG|Placebo|Participants will receive placebo (a tablet that contains no active ingredient) to be taken twice daily for 6 weeks
58278065|NCT06229977|DRUG|Treatment as Usual (TAU)|subjects will receive a mood stabilizer per usual care
57726449|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
57726450|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
57726451|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
57726452|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
57925518|NCT02463825|DRUG|Pimozide 2 mg per day|
57925519|NCT02463825|DRUG|Pimozide 4 mg per day|
58278066|NCT00939406|DEVICE|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
58278067|NCT02649426|DEVICE|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
57925520|NCT02463825|DRUG|Placebo (Lactose tablet)|
58278068|NCT02649426|DEVICE|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
58278069|NCT05040919|OTHER|collection of medical and socio-demographic data|collection of medical and socio-demographic data
57925521|NCT05713279|DRUG|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
57925522|NCT00823901|DRUG|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
58278070|NCT04205487|BEHAVIORAL|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
58278071|NCT04205487|BEHAVIORAL|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
58278072|NCT04956341|DEVICE|Auricular acupuncture|Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.
58278073|NCT04956341|OTHER|Standard treatment|Standard treatment from Primary Care Manager (PCM) or Mental Health or both
58278074|NCT01906281|OTHER|Blood analyse, arthrocentesis, ultrasound examination|
58067760|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
58278075|NCT03129711|OTHER|glazed Celtra Duo|zirconia reinforced lithium silicate
58278076|NCT03129711|OTHER|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
58278077|NCT00430456|PROCEDURE|Exercise|Treadmill Training
58278078|NCT01250353|PROCEDURE|pterygium surgery|pterygium was removed surgically
58278079|NCT05761704|DRUG|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
58278080|NCT05761704|DRUG|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
57925523|NCT00823901|DRUG|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
58278081|NCT02133833|DEVICE|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
58278082|NCT03848624|DEVICE|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
58394716|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
57925524|NCT04065009|DRUG|Ropivacaine|Experimental drug will be administered intraperitoneally
57925525|NCT04065009|DRUG|Saline Solution|Placebo will be administered intraperitoneally
57925526|NCT01530022|DRUG|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
58278083|NCT00506714|DEVICE|single point cane|Adjustable single point cane with SureGrip handle
58278084|NCT03301831|BEHAVIORAL|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
58278085|NCT01309984|DRUG|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
58394717|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
58394718|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
58394719|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
58394720|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
58278086|NCT01309984|DRUG|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
57925527|NCT01530022|DRUG|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
57925528|NCT01464229|DRUG|Iloperidone|Iloperidone 1-8 mg for 4 weeks
57925529|NCT01464229|DRUG|Placebo|Placebo
57925530|NCT03425981|OTHER|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
57726453|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
57925531|NCT04668586|DEVICE|Holmium:YAG laser machine|Ureteroscopy with Holmium:YAG laser lithotripsy
57925532|NCT04668586|DEVICE|Thulium Fiber laser machine|Ureteroscopy with Thulium Fiber laser lithotripsy
58067761|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
58067762|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
58067763|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
58067764|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
58278087|NCT05254470|DEVICE|Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
57726454|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
57925533|NCT03010930|OTHER|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
58278088|NCT03267602|DEVICE|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI\> 15 and present obvious symptoms or~2. less than 18 years, AHI still\> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
58278089|NCT05730348|BEHAVIORAL|Post mealtime activity|Therapist lead movement post meals
58278090|NCT00004197|BIOLOGICAL|keyhole limpet hemocyanin|
58278091|NCT00004197|BIOLOGICAL|sargramostim|
58278092|NCT00004197|BIOLOGICAL|tumor cell-based vaccine therapy|
58278093|NCT00004197|DRUG|cyclophosphamide|
58278094|NCT00004197|DRUG|doxorubicin hydrochloride|
57726455|NCT04815603|DRUG|BGE-117|Active Treatment
57726456|NCT04815603|OTHER|Placebo|Placebo
57925534|NCT03010930|OTHER|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
57925535|NCT02407366|DRUG|Icotinib|Icotinib (125 mg ,Three times daily)
57925536|NCT02407366|DRUG|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
57925537|NCT02407366|DRUG|Carboplatin|Carboplatin (AUC，5) every 21 days
57925538|NCT02407366|RADIATION|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
57925539|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
57925540|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
58278095|NCT00004197|DRUG|mitoxantrone hydrochloride|
58278096|NCT00004197|DRUG|prednisone|
58278097|NCT00004197|DRUG|vincristine sulfate|
58278098|NCT03316066|PROCEDURE|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
58278099|NCT03316066|PROCEDURE|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
58278100|NCT06234527|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
58394721|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
57726457|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
57925541|NCT02456662|DRUG|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
58278101|NCT00901082|BEHAVIORAL|Relaxation and information session|Relaxation and information session before the medial branch block
58278102|NCT01486186|DRUG|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
57925542|NCT02456662|DRUG|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
58278103|NCT01486186|DRUG|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
58278104|NCT03871829|DRUG|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
58278105|NCT03871829|DRUG|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m\^2 will be administered IV.
58394722|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
58394723|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
58394724|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
58394725|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
58394726|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
57925543|NCT02338349|DRUG|Elacestrant|
57925544|NCT01266135|DRUG|QAX576|QAX576 10 mg/kg intravenous infusion
58394727|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
58394728|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
58278106|NCT03871829|DRUG|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
58278107|NCT03871829|DRUG|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
58278108|NCT03871829|DRUG|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
58278109|NCT02743065|DEVICE|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
58278110|NCT01717391|DRUG|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
58278111|NCT04787861|OTHER|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
58394729|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
57925545|NCT01266135|DRUG|Placebo|Placebo to QAX576 intravenous infusion
57925546|NCT05049486|RADIATION|CT scan|Patients will undergone a pelvic CT scan.
57925547|NCT06265766|DEVICE|cTBS|10 sessions of cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
57925548|NCT02231853|BIOLOGICAL|MVST|MVST Infusion
57925549|NCT02231853|BIOLOGICAL|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
57925550|NCT00867113|DRUG|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
57925551|NCT02039726|DRUG|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
58394730|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
57925552|NCT02039726|DRUG|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
58278112|NCT05243667|OTHER|Wearable wrist Smart Device of Huami|"All enrolled patients underwent continuous monitoring by wearing huami blood oxygen testing equipment, and signed the informed consent for the clinical trial.Smart wrist wristbands will be issued, and patient information will be bound to the Migang Health platform, and clinical trial doctors will improve relevant personal information and clinical data.After binding to the APP Migu Health, you can start collecting and recording dynamic data such as peripheral blood oxygen saturation, heart rate, exercise steps, sleep data, etc., and upload the data once a day."
58278113|NCT01132300|DEVICE|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
58278114|NCT02544958|DEVICE|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
58278115|NCT04774276|OTHER|cardiac rehabilitation protocol without occupational therapist|cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
58394731|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
57925553|NCT00954421|DEVICE|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
57925554|NCT01968070|DRUG|LY3127760|Administered orally
57925555|NCT01968070|DRUG|Celecoxib|Administered orally
57925556|NCT01968070|DRUG|Placebo|Administered orally
57925557|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
57925558|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
58278116|NCT04774276|OTHER|cardiac rehabilitation protocol with occupational therapist|"This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month."
58394732|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
58394733|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
58394734|NCT03263910|DRUG|NPO-11|20 ml NPO-11
58394735|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
58394736|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
58394737|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
57726458|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
57925559|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
57925560|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
58278117|NCT02000882|DRUG|BKM120|
58278118|NCT02000882|DRUG|capecitabine|
58278119|NCT02000882|DRUG|Trastuzumab|
58278120|NCT06404905|DRUG|BT02 monoclonal antibody injection|It is expected to include 10-30 patients assigned to dose escalation cohorts.
57925561|NCT02115425|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
57925562|NCT02115425|OTHER|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
58278121|NCT03810235|DRUG|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
58278122|NCT03810235|DRUG|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
58278123|NCT00394316|DRUG|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
58278124|NCT06201208|BEHAVIORAL|The ST-Facilitation Psychoeducation Program|"One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse."
58278125|NCT01723020|DRUG|AMG 232|Given an an oral tablet in escalating doses.
58278126|NCT01892800|PROCEDURE|Lung resection|
58278127|NCT04865991|PROCEDURE|TCI Propofol|Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
58278128|NCT04865991|PROCEDURE|Sevoflurane|subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
58394738|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
58394739|NCT01926899|DRUG|Bortezomib administration|
58394740|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
58394741|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
58394742|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
58394743|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
58394744|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
58394745|NCT02013557|BEHAVIORAL|Text-message reminder|
58394746|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
58278129|NCT02579317|BEHAVIORAL|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
58067765|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
58278130|NCT02579317|BEHAVIORAL|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
58278131|NCT00819949|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
58278132|NCT02721017|DEVICE|Cryoanalgesia|
58278133|NCT02721017|DRUG|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
58278134|NCT04909814|BIOLOGICAL|The performance of colposcopy in vaccinated women|Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
58278135|NCT04402450|PROCEDURE|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
57726459|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
57726460|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
57726461|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
57726462|NCT06481241|DRUG|Venetoclax|VEN
57726463|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
57925563|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
58278136|NCT04402450|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
57726464|NCT02596451|DRUG|Voltaren® Gel|
57726465|NCT02596451|DRUG|Placebo|
57726466|NCT05745857|DRUG|Avastin|Orally administered
57726467|NCT05745857|DRUG|Erbitux|Orally administered
57726468|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
57726469|NCT02295111|DEVICE|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
57726470|NCT02295111|BEHAVIORAL|TCM health consult|Traditional Chinese Medicine Health Consult without needling
57726471|NCT02295111|OTHER|Usual Care|Standard NHS care
57726472|NCT02057055|OTHER|Soap 300000027003|
57726473|NCT02057055|OTHER|Soap 300000029240|
57726474|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
57925564|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
57925565|NCT02115425|OTHER|add name here|
57925566|NCT04731766|BEHAVIORAL|Citrine 5 % sodium fluoride|Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
57925567|NCT04731766|BEHAVIORAL|concocted nano-silver fluoride|Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
57726475|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
57726476|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
57925568|NCT03298321|OTHER|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
57925569|NCT00909454|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
58394747|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
57925570|NCT00909454|DIETARY_SUPPLEMENT|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
57925571|NCT04195958|DRUG|Omalizumab|Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
57726477|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
57726478|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
57726479|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
57925572|NCT05482152|BEHAVIORAL|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
57925573|NCT03837314|DEVICE|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
58394748|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
57925574|NCT05406804|BEHAVIORAL|Olfactory stimulation|1) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time \> 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
57925575|NCT05406804|BEHAVIORAL|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
57925576|NCT06027125|OTHER|Action observation Therapy|The patients in the AOT group will be required to observe the upper limb movements or functional actions in video clips and to execute what they had observed to the best of their ability.
57925577|NCT06027125|OTHER|Mirror Therapy|The patients will be seated in front of a mirror box placed at their midsagittal plane to perform the movements. The affected arm of the participants was placed inside of the mirror box, and the unaffected arm was infront ofthe mirror.
57925578|NCT04876118|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
57925579|NCT04478656|BIOLOGICAL|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
57925580|NCT00650572|DRUG|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
57925581|NCT00893126|PROCEDURE|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
57925582|NCT02684279|DRUG|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
57925583|NCT05275712|OTHER|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
57925584|NCT03840226|DRUG|Placebo Oral Tablet|Placebo tablets
57925585|NCT03840226|DRUG|Magnesium Oxide|Magnesium tablets
57925586|NCT05198687|PROCEDURE|Long implant and partial overdentures|insertion of long implants anterior to the maxillary sinus to retain partial overdentures
58067766|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
58278137|NCT06147752|BEHAVIORAL|"mobile internet healthcare and co-management of three disciplines"|"co-management of three disciplines:~Endocrinologist:~Assess disease status and rule out secondary obesity; Identify the causes of overweight/obesity and the status and extent of associated diseases; receive patients for return visits. Timely reply to patients' questions on the mobile medical platform, and timely adjust medication plans according to changes in patients' conditions.~Dietitians:~Conduct diet assessment, develop personalized medicine nutrition treatment plan and provide daily real-time guidance and follow up patients' daily diet outside the hospital.~Weight managers:~Establish weight loss record for patients, guide the installation and use of mobile medical Application , including weight monitoring, real-time uploading of daily diet and online interactive consultation; Follow up patients' weight changes; Assist patients in making appointments for follow-up visits."
58394749|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58394750|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
58422691|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
57726480|NCT02631798|DIETARY_SUPPLEMENT|Food grade dye mucosal staining|mucosal staining with food grade dye
57726481|NCT06432127|DRUG|Placebo|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
57726482|NCT06432127|DRUG|Bupivacaine|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using 0.5% Bupivacaine 3 mL
57925587|NCT05198687|PROCEDURE|Sinus lift and long implant|performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
57925588|NCT05198687|PROCEDURE|short implant without sinus lift|placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
57925589|NCT05198687|DEVICE|Partial overdentures|Distal extension metallic partial dentures retained by attachments to the implants
57925590|NCT05198687|DEVICE|Metal ceramic prosthesis on long implants|porcelain fused to metal fixed screw-retained prosthesis supported by long implants
57925591|NCT05198687|DEVICE|Metal ceramic prosthesis on short implants|porcelain fused to metal fixed screw-retained prosthesis supported by short implants
57925592|NCT00002646|DRUG|fenretinide|
57925593|NCT00002646|DRUG|tamoxifen citrate|
57925594|NCT02328287|DRUG|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
57726483|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
57925595|NCT06267573|DEVICE|Fenestrated and branched endovascular devices for TAAA|Devices for TAAA
58394751|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
57726484|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
57726485|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
57925596|NCT03425838|DRUG|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
57726486|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
57726487|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
57726488|NCT01301963|DRUG|plerixafor|Given SC
57726489|NCT01301963|BIOLOGICAL|filgrastim|Given SC
57726490|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
57726491|NCT01455441|OTHER|Training and liraglutide|
57726492|NCT01455441|OTHER|Training and placebo|
57726493|NCT00554866|OTHER|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
57726494|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
57726495|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
57726496|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
57726497|NCT06321718|PROCEDURE|PENG + LFCN block versus S-FICB|1. Group (A) will receive PENG + LFCN block:
57726498|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
57726499|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
57726500|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
57925597|NCT03425838|DRUG|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
58394752|NCT00426595|DRUG|Administration of omeprazole suspension|
57726501|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
57726502|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
57726503|NCT03604250|DIETARY_SUPPLEMENT|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
57726504|NCT02620553|DRUG|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
57726505|NCT02620553|OTHER|Oral Placebo|Oral Placebo is given orally daily
57726506|NCT02663817|DEVICE|CT Scan|
58394753|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
57726507|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
57726508|NCT02235766|OTHER|Echocardiographic assessment|
57726509|NCT02541253|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
57925598|NCT03425838|DRUG|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
57925599|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
57925600|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
58278138|NCT04012424|DRUG|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
58278139|NCT04012424|DIETARY_SUPPLEMENT|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
58394754|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
58394755|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
58394756|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
57726510|NCT02541253|BIOLOGICAL|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
57726511|NCT02445820|DRUG|HES|2500 mL of balanced HES 130/0.4
57726512|NCT02445820|DRUG|Crystalloid|2500 mL of balanced crystalloid.
57726513|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
57726514|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
57726515|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
57726516|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
58394757|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
58394758|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
58394759|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
58394760|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
58394761|NCT01935323|OTHER|High Intensity Interval Training|
58394762|NCT01935323|OTHER|Moderate Intensity Training|
57726517|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
57726518|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
57726519|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
57726520|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
57726521|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
57726522|NCT04781764|PROCEDURE|surgery|surgery
57726523|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
57726524|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
57726525|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
57726526|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
57726527|NCT00475826|DRUG|Statins and Ezetimibe|
57726528|NCT06288113|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57726529|NCT06288113|PROCEDURE|Computed Tomography|Undergo PET/CT and SPECT/CT
57726530|NCT06288113|OTHER|Gallium Ga 68 Gozetotide|Given IV
57726531|NCT06288113|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
57726532|NCT06288113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57726533|NCT06288113|OTHER|Questionnaire Administration|Ancillary studies
57925601|NCT05042037|DIETARY_SUPPLEMENT|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
57925602|NCT05042037|OTHER|Placebo|Placebo sachet with no microbial cell preparation
57925603|NCT02302690|BIOLOGICAL|Blood sample for immunology|
57925604|NCT00639561|DIETARY_SUPPLEMENT|10 g of fibres per day|10 g of fibres per day
57925605|NCT00639561|DIETARY_SUPPLEMENT|40 g of fibres per day|40g of fibres per day
58394763|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
57726534|NCT06288113|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58278140|NCT00853879|DIETARY_SUPPLEMENT|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
58394764|NCT05577000|DRUG|Fludarabine|Given IV
58394765|NCT05577000|DRUG|Cyclophosphamide|Given IV
58394766|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
58394767|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
58394768|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
58394769|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
58394770|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
57726535|NCT05831293|BEHAVIORAL|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
57925606|NCT03199937|BEHAVIORAL|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
58067767|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
58278141|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
58278142|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
58067768|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
58278143|NCT00003394|DRUG|carboplatin|
58394771|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
58394772|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
58394773|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
57726536|NCT00401570|DRUG|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
57726537|NCT00401570|DRUG|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
57726538|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
58278144|NCT00003394|DRUG|endocrine-modulating drug therapy|
57726539|NCT04841343|DRUG|Triamcinolone|Triamcinolone in sinus
58278145|NCT00003394|DRUG|estramustine phosphate sodium|
57726540|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
57726541|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
58278146|NCT00003394|DRUG|goserelin acetate|
58278147|NCT00003394|DRUG|leuprolide acetate|
57726542|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
58067769|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
58067770|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
58278148|NCT00003394|DRUG|paclitaxel|
58278149|NCT03704012|BEHAVIORAL|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
58394774|NCT01887561|DRUG|dasatinib|
58394775|NCT02540187|OTHER|blood specimen|
58394776|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
58394777|NCT04973683|DRUG|AL101|Given IV
58394778|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
58394779|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
58422692|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
57925607|NCT03199937|OTHER|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
58067771|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
57726543|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
57726544|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
57925608|NCT04615767|DIETARY_SUPPLEMENT|D-chiro-inositol|as described previously
57925609|NCT05146687|OTHER|Aflibercept|intravitreal injection
57925610|NCT05146687|OTHER|Ranibizumab|intravitreal injection
57925611|NCT05146687|OTHER|Bevacizumab|intravitreal injection
57925612|NCT03002519|BIOLOGICAL|PLX-R18|Intramuscular (IM) administration of PLX-R18
57925613|NCT05651750|DRUG|Montelukast|receiving 2 months treatment with Montelukast once a day
57925614|NCT05651750|DRUG|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
57925615|NCT02076750|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
58067772|NCT01549327|OTHER|Oncology Interactive Navigator|
58067773|NCT01549327|OTHER|Routine Care|
58067774|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
58067775|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
58067776|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
58067777|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
58278150|NCT02479464|GENETIC|Genotyping results|Genotyping results provided in Phase II
58278151|NCT05699876|DRUG|Melatonin 6 MG|melatonin will be administered orally preoperatively as premedication
57925616|NCT04427553|DEVICE|Percutaneous Peripheral Nerve Stimulation|Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
58067778|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
58067779|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
58067780|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
58067781|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
58278152|NCT05699876|DRUG|Gabapentin|melatonin will be administered orally preoperatively as premedication
58278153|NCT00493987|DRUG|Testosterone Enanthate|testosterone ester
58278154|NCT00493987|DRUG|Dutasteride|5 alpha-reductase inhibitor
58278155|NCT06232395|DIAGNOSTIC_TEST|DNA test|circulating DNA test
57925617|NCT04427553|OTHER|Control Group|No intervention
57726545|NCT06158633|DRUG|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
57726546|NCT01591746|DRUG|Botulinum Toxin Type A|
57726547|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
57726548|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
57726549|NCT06534567|OTHER|Physical activity|Physical activity level
57726550|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
57726551|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
57726552|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
57925618|NCT02709525|DRUG|hyaluronic acid|
57925619|NCT02709525|OTHER|Placebo|
58067782|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
58067783|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
58067784|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
58306675|NCT02757157|BEHAVIORAL|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
57726553|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
57726554|NCT00326508|DRUG|Daclizumab|
57726555|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
57726556|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
57925620|NCT04032769|OTHER|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
57925621|NCT02023255|DRUG|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
57925622|NCT02023255|OTHER|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
57925623|NCT01372410|DRUG|GSK573719|125 mcg once daily
57925624|NCT01372410|DRUG|GSK573719|62.5 mcg once daily
57925625|NCT01372410|DRUG|GSK573719|31.25 mcg once daily
57925626|NCT01372410|DRUG|GSK573719|15.6 mcg once daily
57925627|NCT01372410|DRUG|GSK573719|31.25 mcg twice daily
57925628|NCT01372410|DRUG|GSK573719|15.6 mcg twice daily
57925629|NCT01372410|DRUG|Tiotropium|18 mcg once daily
57925630|NCT01372410|DRUG|Placebo|once or twice daily
57925631|NCT04220125|DRUG|Ketamine Group|Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
57925632|NCT04220125|DRUG|Midazolam injection|Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
57925633|NCT03412370|OTHER|Cognitive Assessment|Complete cognitive assessments
57925634|NCT03412370|OTHER|Questionnaire Administration|Complete questionnaires
57925635|NCT02877758|OTHER|Tomorrowlabs cosmeceutical formulation|
57925636|NCT02877758|OTHER|Sham cosmeceutical formulation|
57925637|NCT02685670|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
57925638|NCT02685670|DRUG|Fludarabine|
57925639|NCT02685670|DRUG|Cyclophosphamide|
57925640|NCT00519155|DRUG|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
57925641|NCT00519155|PROCEDURE|Open flap debridement|Open flap debridement alone
57925642|NCT05447533|OTHER|Comprehensive geriatric assessment (CGA)|"Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe)."
57925643|NCT05447533|OTHER|Continued geriatric care|"Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured."
57726557|NCT04833829|BEHAVIORAL|CHIMES Intervention|"There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings."
57726558|NCT04833829|BEHAVIORAL|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
57925644|NCT05447533|OTHER|Faecal microbiota transplantation (FMT)|When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
57925645|NCT05447533|OTHER|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
57925646|NCT04265924|OTHER|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
57925647|NCT05863312|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
58306676|NCT03107429|DRUG|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
58306677|NCT03107429|DRUG|Placebo|Placebo was a sugar based placebo placed in a capsule.
58306678|NCT03107429|OTHER|Trendelenburg Position|Placed in Trendelenburg Position
57726559|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
57726560|NCT01573702|DRUG|Erlotinib|150mg once daily
57726561|NCT03286491|DIAGNOSTIC_TEST|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
57726562|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
57726563|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
57726564|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
57726565|NCT02579993|PROCEDURE|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
57726566|NCT02579993|PROCEDURE|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
58278156|NCT02030496|PROCEDURE|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
58278157|NCT02030496|OTHER|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
58278158|NCT04918407|DRUG|Empagliflozin 25 MG|25 mg
57726567|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
57726568|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
57726569|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
57726570|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
57726571|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
57726572|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
57726573|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
57726574|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
57726575|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
57726576|NCT05388448|DRUG|Amoxicillin/clavulanic acid|Amx/CA will be administered orally as Amx/CA 250/125 mg, 1 tablet twice daily for 14 days alongside with sanfetrinem cilexetil.
57726577|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
57726578|NCT00618657|DRUG|Carboplatin|Given IV
57925648|NCT05863312|PROCEDURE|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
57925649|NCT05863312|OTHER|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
58278159|NCT04918407|DRUG|Insulin|Insulin
58394780|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
58394781|NCT03601442|BIOLOGICAL|CTL019|CTL019
58394782|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide 5mg.
58394783|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
58394784|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
58394785|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
58394786|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
57726579|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
57925650|NCT05863312|OTHER|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
57925651|NCT00480246|DRUG|BL 1020|
58278160|NCT04466605|OTHER|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
58278161|NCT04466605|OTHER|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
58278162|NCT00469495|DRUG|Anti-helminthic|
58394787|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
58394788|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
57925652|NCT00480246|DRUG|Perphenazine|
57925653|NCT03963687|OTHER|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
58394789|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
57726580|NCT00618657|DRUG|bevacizumab|Given IV
57726581|NCT00618657|DRUG|trastuzumab|Given IV
57726582|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
57726583|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
57925654|NCT03963687|OTHER|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
58278163|NCT00469495|DRUG|meglumine antimony|
58278164|NCT03373461|DRUG|LNP023|LNP023 5, 25, 100 mg capsles
58278165|NCT03373461|OTHER|Placebo|Matching placebo to LNP023
58278166|NCT00282152|DEVICE|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
57726584|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
57726585|NCT03747029|OTHER|No intervention is provided|No intervention is provided
57925655|NCT06108804|OTHER|mulligan pain release phenomenon with tapping|Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks
57925656|NCT06108804|OTHER|mulligan pain release phenomenon|Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
57925657|NCT04770311|BEHAVIORAL|Microbiome friendly diet|Families in the intervention group will have a microbiome-friendly nutrition assessment and will also receive groceries one time per week for four weeks to help achieve a more microbiome-friendly diet.
58394790|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
58394791|NCT00014443|DRUG|thalidomide|
58394792|NCT00014443|DRUG|topotecan hydrochloride|
58394793|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
58095055|NCT06154122|DEVICE|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
58394794|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
57726586|NCT05198232|BEHAVIORAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
58278167|NCT00282152|DRUG|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
58278168|NCT04148235|OTHER|No Intervention|There is no intervention for this study
58278169|NCT03326752|DRUG|DV281|- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
58278170|NCT03326752|DEVICE|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
58278171|NCT03326752|DRUG|DV281 (RP2D)|- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
58278172|NCT03326752|DRUG|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
58278173|NCT01473706|OTHER|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
58394795|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
58278174|NCT06443606|DRUG|Bezafibrate 400 mg in addition to UDCA therapy|"* Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
58278175|NCT06443606|DRUG|Bezafibrate 200 mg in addition to UDCA therapy|"* Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
57925658|NCT00594529|PROCEDURE|Surgery|Liver resection for metastatic liver lesions
58278176|NCT06443606|DRUG|Placebo in addition to UDCA therapy|"* Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks placebo /UDCA = daily oral dose."
58278177|NCT01313351|DEVICE|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
58278178|NCT00288808|DEVICE|Hemosense (PT/InR point of care device)|
58278179|NCT04085159|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
58278180|NCT00750919|DRUG|esmirtazapine|
58278181|NCT02738229|DRUG|Valacyclovir|
58278182|NCT02738229|DRUG|placebo|
58278183|NCT04746365|DRUG|ivermectin|ivermectin is anthelmintic
58278184|NCT04746365|DRUG|hydroxychloroquine|hydroxychloroquine is antimalarial.
58278185|NCT04746365|DRUG|Placebo|Standard treatments
58278186|NCT01026337|GENETIC|mutation analysis|Correlative study
58278187|NCT01026337|OTHER|pharmacological study|Correlative study
58278188|NCT01026337|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
58278189|NCT01026337|DRUG|sunitinib malate|Given orally
58278190|NCT01026337|OTHER|immunohistochemistry staining method|Correlative study
58278191|NCT01026337|OTHER|laboratory biomarker analysis|Correlative study
58278192|NCT01044758|DRUG|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
57925659|NCT00633061|DRUG|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
58278193|NCT01044758|DRUG|Levetiracetam 125mg|125mg twice daily (2 weeks)
58278194|NCT01044758|DRUG|Levetiracetam 250mg|250mg twice daily (2 weeks)
58278195|NCT01044758|DRUG|Placebo|placebo capsule twice daily (2 weeks)
57925660|NCT04673565|BEHAVIORAL|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
57925661|NCT05486117|DRUG|Delgocitinib|Cream for topical application 20 mg/g
57925662|NCT00323297|DRUG|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
57925663|NCT00323297|OTHER|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
58278196|NCT05128149|OTHER|no intervention|no intervention
58278197|NCT02152098|PROCEDURE|Acute Early onset of rehabilitation|Early onset of rehabilitation
58278198|NCT02152098|PROCEDURE|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
58278199|NCT02152098|PROCEDURE|Chronic Exercise|Exercise
58278200|NCT02152098|PROCEDURE|Chronic Control|Control
58278201|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
58278202|NCT02830932|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
58278203|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
58278204|NCT01402505|PROCEDURE|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
58278205|NCT00369148|DRUG|nateglinide(drug) mitiglinide(drug)|
58278206|NCT01840800|DRUG|Ropivacaine|
58278207|NCT01840800|DRUG|placebo|
58278208|NCT04674735|DRUG|APSLXR|Oral coated tablets once a day for 60 days.
58278209|NCT04665518|OTHER|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
58278210|NCT00413309|PROCEDURE|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
58278211|NCT02026869|DRUG|Metformin|Metformin is taken either orally or vaginally every 12 hours
58278212|NCT03246802|RADIATION|HDR partial prostate brachytherapy|temporary radioactive implant
58278213|NCT03985488|RADIATION|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
58278214|NCT03552042|BEHAVIORAL|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
58278215|NCT03552042|BEHAVIORAL|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
58278216|NCT04958291|DRUG|CC-99677|CC-99677
58278217|NCT04958291|OTHER|Placebo|Placebo
58278218|NCT01935713|DRUG|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
58278219|NCT01935713|DRUG|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
58278220|NCT01935713|DRUG|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, \>2 packs per day).
57925664|NCT00323297|DRUG|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
58095056|NCT06154122|OTHER|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
58278221|NCT04212832|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
58278222|NCT04212832|OTHER|Standard pain|Standard pain follow up and monitorization
58278223|NCT05775861|DRUG|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
58278224|NCT05775861|DRUG|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
58278225|NCT01840137|OTHER|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
58278226|NCT01840137|OTHER|Exercise|Treadmill and muscle exercises.
58278227|NCT04959214|BEHAVIORAL|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
58278228|NCT01069770|DRUG|Sunitinib|50mg daily(4 weeks on \& 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
58278229|NCT00784056|DRUG|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
58278230|NCT04267588|OTHER|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
58278231|NCT01402986|OTHER|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
58278232|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
58278233|NCT01402986|OTHER|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
58394796|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
58394797|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
58394798|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
57925665|NCT00323297|DRUG|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
57925666|NCT00915304|BEHAVIORAL|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
58095057|NCT03899506|DRUG|Olanzapine|Patients receiving Olanzapine per the ED protocol
58278234|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
57925667|NCT04866654|DRUG|Nivolumab 10 MG/ML|Nivolumab, 100 mg, 10 mg/ml
58095058|NCT03899506|DRUG|Midazolam|Patients receiving Midazolam per the ED protocol
58095059|NCT05208944|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
58095060|NCT05208944|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
58278235|NCT01027897|DRUG|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
58278236|NCT04146623|BIOLOGICAL|CodaVax-H1N1 influenza vaccine|CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).
57726587|NCT05198232|BEHAVIORAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
57925668|NCT04515069|PROCEDURE|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
57925669|NCT04515069|PROCEDURE|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
57925670|NCT03193489|OTHER|Follow-up|
57925671|NCT03193489|OTHER|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
57925672|NCT03193489|OTHER|Control Parkinson group|No treatment.
58278237|NCT04146623|BIOLOGICAL|Normal Saline Placebo|Saline (0.9%) administered intranasally via sprayer
58278238|NCT03061799|DIETARY_SUPPLEMENT|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
58394799|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
57726588|NCT04017026|DEVICE|Implantation|Implantation of 6 mm short implants
57726589|NCT04587089|PROCEDURE|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
57726590|NCT04587089|PROCEDURE|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
57726591|NCT04587089|PROCEDURE|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula \& Ação (F\&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
57726592|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
58278239|NCT03061799|DIETARY_SUPPLEMENT|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
58278240|NCT02574416|OTHER|There is no intervention|The study is observational and there is no intervention
58394800|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
58394801|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
58394802|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
57726593|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
57726594|NCT00268528|BEHAVIORAL|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
57726595|NCT00268528|OTHER|Laboratory Biomarker Analysis|Correlative studies
57726596|NCT00268528|DRUG|Mercaptopurine|Given PO
57726597|NCT00268528|DRUG|Methotrexate|Given PO
57726598|NCT00268528|OTHER|Questionnaire Administration|Ancillary studies
58278241|NCT03142373|OTHER|CV4 technique|
58278242|NCT03142373|OTHER|RR technique|
58394803|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
58394804|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
58394805|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
58278243|NCT03142373|OTHER|Placebo treatment|
57925673|NCT06235931|DRUG|Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib|"Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day)."
58067785|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
58067786|NCT00003309|BIOLOGICAL|filgrastim|
58278244|NCT01004458|BEHAVIORAL|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
58278245|NCT01004458|OTHER|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
58278246|NCT05879224|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total)(Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
58278247|NCT02427802|DRUG|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
58278248|NCT02427802|OTHER|Placebo|Matching collagen sponge
58278249|NCT00004036|BIOLOGICAL|sargramostim|
57726599|NCT00268528|OTHER|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
57726600|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
57726601|NCT06388018|OTHER|Clinical Observation|Undergo observation
58067787|NCT00003309|DRUG|cisplatin|
58278250|NCT00004036|DRUG|amifostine trihydrate|
57726602|NCT06388018|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58067788|NCT00003309|DRUG|cyclophosphamide|
58278251|NCT00004036|DRUG|carboplatin|
58278252|NCT00004036|DRUG|cyclophosphamide|
58278253|NCT01368887|DRUG|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
58278254|NCT01368887|OTHER|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
58278255|NCT01368887|DRUG|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
57726603|NCT06388018|RADIATION|External Beam Radiation Therapy|Undergo EBRT
57726604|NCT06388018|PROCEDURE|High-Dose-Rate Vaginal Brachytherapy|Undergo vaginal brachytherapy
57726605|NCT06388018|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57726606|NCT06388018|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57726607|NCT06388018|OTHER|Questionnaire Administration|Ancillary studies
57726608|NCT06388018|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
58394806|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
57726609|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
57726610|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
57726611|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
58278256|NCT01368887|DRUG|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
57726612|NCT02378142|DRUG|Pazopanib|
57726613|NCT05812573|OTHER|no intervention|No intervention, only observation
57726614|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
58278257|NCT03604575|DRUG|Insulin Lispro|
58278258|NCT03604575|DRUG|Humalog®|
58278259|NCT05052697|BIOLOGICAL|mIRV|Intramuscular injection
58278260|NCT05052697|BIOLOGICAL|bIRV AB|Intramuscular injection
58278261|NCT05052697|BIOLOGICAL|qIRV|Intramuscular injection
58278262|NCT05052697|BIOLOGICAL|QIV|Intramuscular injection
58278263|NCT05052697|BIOLOGICAL|bIRV AA|Intramuscular injection
58394807|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
58394808|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
57726615|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
58278264|NCT05052697|BIOLOGICAL|bIRV BB|Intramuscular injection
58278265|NCT03459859|DRUG|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
58278266|NCT03459859|DRUG|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
58394809|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
58394810|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
57726616|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
57925674|NCT02927418|BEHAVIORAL|Strength & Conditioning|
58278267|NCT01634451|OTHER|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
58278268|NCT01634451|OTHER|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
58278269|NCT01634451|DEVICE|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
58278270|NCT03300713|OTHER|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
58394811|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
58278271|NCT03300713|OTHER|usual follow-up|usual follow-up
58394812|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
58394813|NCT03539744|DRUG|Pomalidomide|capsule, oral
57925675|NCT02927418|BEHAVIORAL|Control|
57925676|NCT01601483|DRUG|MC-1101|1% Ophthalmic Solution TID
57925677|NCT01601483|DRUG|MC-1101 Vehicle|Ophthalmic solution, TID
57925678|NCT02718807|OTHER|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
57925679|NCT01416688|PROCEDURE|assessment of therapy complications|Will be given by questionnaire
57925680|NCT01416688|PROCEDURE|psychosocial assessment and care|Will be given by questionnaire
58278272|NCT05933564|OTHER|No intervention (cross-sectional study)|This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
58278273|NCT03626324|DEVICE|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
58394814|NCT03539744|DRUG|Dexamethasone|oral, locally available form
58394815|NCT03539744|DRUG|Venetoclax|tablet; oral
58278274|NCT02260349|DRUG|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
58394816|NCT00002389|DRUG|Abacavir sulfate|
58394817|NCT00002389|DRUG|Lamivudine|
58394818|NCT00002389|DRUG|Zidovudine|
58394819|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
58394820|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
58394821|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
57925681|NCT01416688|PROCEDURE|quality-of-life assessment|Will be given by questionnaire
58278275|NCT00607659|OTHER|No intervention, only observational|No intervention, only observational
58394822|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
58394823|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
57925682|NCT05568602|DIAGNOSTIC_TEST|Dexamethasone suppression test|1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
57925683|NCT00309556|DRUG|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
57925684|NCT00309556|DRUG|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
57925685|NCT00309556|DRUG|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
58278276|NCT04976530|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
58278277|NCT04976530|DEVICE|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
58278278|NCT03609957|OTHER|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
58278279|NCT03609957|OTHER|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
57925686|NCT00309556|DRUG|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
57925687|NCT01128894|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
57925688|NCT01128894|DRUG|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
57925689|NCT00288509|BIOLOGICAL|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
58067789|NCT00003309|DRUG|etoposide|
58067790|NCT00003309|DRUG|vincristine sulfate|
57925690|NCT01721005|OTHER|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
58278280|NCT02803359|PROCEDURE|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
58278281|NCT00435188|BEHAVIORAL|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
57726617|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
57726618|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
57726619|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
57726620|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
57726621|NCT01058200|DEVICE|iCup|new vacuum extractor: sterile disposable plastic cup
57726622|NCT01058200|DEVICE|reference cup|reference cup of the obstetrical ward: metallic cup
57925691|NCT02894112|DIETARY_SUPPLEMENT|non-fat milk|1 serving of non-fat fluid milk
57925692|NCT02894112|DIETARY_SUPPLEMENT|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
57925693|NCT02894112|DIETARY_SUPPLEMENT|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
57925694|NCT01170546|OTHER|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
57925695|NCT01170546|OTHER|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
58278282|NCT03590990|DIAGNOSTIC_TEST|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
58278283|NCT01156883|DRUG|asparaginase|
58278284|NCT01156883|DRUG|cyclophosphamide|
58278285|NCT01156883|DRUG|cytarabine|
58278286|NCT01156883|DRUG|daunorubicin hydrochloride|
58278287|NCT01156883|DRUG|dexamethasone|
58278288|NCT01156883|DRUG|doxorubicin hydrochloride|
58278289|NCT01156883|DRUG|ifosfamide|
58278290|NCT01156883|DRUG|mercaptopurine|
58278291|NCT01156883|DRUG|methotrexate|
58278292|NCT01156883|DRUG|methylprednisolone|
58278293|NCT01156883|DRUG|prednisone|
58278294|NCT01156883|DRUG|thioguanine|
57726623|NCT03719066|BIOLOGICAL|killed whole cell oral cholera vaccine|two week interval
57726624|NCT03891810|BEHAVIORAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
57726625|NCT04495712|DRUG|spironolactone|aldosterone blocker
57726626|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
57726627|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
57726628|NCT02669329|DEVICE|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
57726629|NCT02018055|DRUG|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
57726630|NCT02018055|DRUG|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
57726631|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
57726632|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
57925696|NCT01170546|OTHER|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
58278295|NCT01156883|DRUG|vincristine sulfate|
58278296|NCT01156883|DRUG|vindesine|
58278297|NCT02617134|BIOLOGICAL|anti-MUC1 CAR-T cells|
58278298|NCT05110989|DEVICE|AtriCure Cryo Nerve Block (cryoNB) Device Family|Use of Atricure Cryo Nerve Block Device Family to generate cryoanalgesia for the management of post operative pain.
58278299|NCT04701489|DEVICE|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
58278300|NCT02385110|DRUG|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
58278301|NCT02385110|DRUG|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
58394824|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
58394825|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
58278302|NCT02385110|DRUG|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
58278303|NCT02385110|DRUG|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
58278304|NCT02385110|BEHAVIORAL|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
58278305|NCT02385110|DRUG|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
58278306|NCT00602446|DRUG|deferasirox|20 mg/kg once daily orally for 6 months
58278307|NCT02159885|OTHER|Telemonitoring|
58278308|NCT04262960|DEVICE|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
58278309|NCT04262960|DEVICE|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
58278310|NCT05699785|OTHER|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
58278311|NCT05699785|OTHER|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
58278312|NCT03813641|DRUG|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
58278313|NCT03813641|DRUG|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
58278314|NCT03500926|DEVICE|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
58394826|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
58394827|NCT05157971|DRUG|Cyclophosphamide|Given IV
58394828|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
58394829|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
58394830|NCT05157971|DRUG|Mercaptopurine|Given PO
58067791|NCT00003309|PROCEDURE|adjuvant therapy|
58067792|NCT00003309|RADIATION|radiation therapy|
58067793|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
58067794|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
58394831|NCT05157971|DRUG|Methotrexate|Given IT
58067795|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
58394832|NCT05157971|DRUG|Pegaspargase|Given IM or IV
58394833|NCT05157971|DRUG|Prednisone|Given PO
58394834|NCT05157971|DRUG|Venetoclax|Given PO
58394835|NCT05157971|DRUG|Vincristine Sulfate|Given IV
58394836|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
58394837|NCT05677490|DRUG|Fluorouracil|Given IV
58067796|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
58067797|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
58067798|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
58067799|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
58067800|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
58067801|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
58278315|NCT03500926|DEVICE|total hip replacement - short femoral stem|total hip replacement with short femoral stem
58278316|NCT02323737|DRUG|Irinotecan and cisplatin|
58278317|NCT02323737|DRUG|Etoposide and cisplatin|
58278318|NCT01851980|OTHER|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
58278319|NCT01851980|DRUG|Furosemide|40 mg and 120 mg
58278320|NCT01851980|DRUG|Placebo|0.9% saline
58278321|NCT05788107|DRUG|HLX51|anti-OX40 tetravalent agonistic humanized monoclonal antibody
58278322|NCT04008485|DEVICE|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
58278323|NCT00538954|DRUG|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
58394838|NCT05677490|DRUG|Leucovorin Calcium|Given IV
58394839|NCT05677490|DRUG|Oxaliplatin|Given IV
58394840|NCT05677490|DRUG|Irinotecan|Given IV
58394841|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
58394842|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58394843|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
58394844|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58394845|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
58394846|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
58394847|NCT03941873|DRUG|Tislelizumab|Administered intravenously
58394848|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
58394849|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
58394850|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
58394851|NCT00964002|DRUG|efavirenz|
58394852|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
58394853|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
58394854|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
58095061|NCT04114578|OTHER|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
58278324|NCT00538954|DIETARY_SUPPLEMENT|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
58278325|NCT00538954|OTHER|Standard ERAS group|
58394855|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
58394856|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
58278326|NCT04933617|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 intravenous (IV) per protocol on Day 1 of each cycle up to 6 cycles
58278327|NCT04933617|DRUG|Etoposide|Etoposide 50 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
58278328|NCT04933617|BIOLOGICAL|Copanlisib|Copanlisib intravenous (IV) is administered at a fixed dose (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle for up to 6 cycles
57925697|NCT00147823|DEVICE|Vitoss Alone|Synthetic bone graft material
58278329|NCT04933617|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
58278330|NCT04933617|DRUG|Doxorubicin|Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
58278331|NCT04933617|DRUG|Vincristine|Vincristine 0.4 mg/m\^2/day (no cap) continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
58278332|NCT04933617|DRUG|Prednisone|Prednisone 60 mg/m\^2 by mouth (PO) twice a day (BID) Days 1-5 (total 120mg/m\^2/day)
58278333|NCT04933617|DIAGNOSTIC_TEST|ECHO|At screening.
58278334|NCT04933617|DIAGNOSTIC_TEST|EKG|At screening.
58278335|NCT04933617|DIAGNOSTIC_TEST|MRI Brain|At screening.
58394857|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
58394858|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
58394859|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
58394860|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
58394861|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
58394862|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
58394863|NCT00345566|PROCEDURE|Nutrition composition|
58394864|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
58394865|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
58394866|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
57925698|NCT00147823|DEVICE|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
57925699|NCT06473376|PROCEDURE|arthrocentesis|TMJ arthrocentesis and arthroscopy
57925700|NCT05227222|DEVICE|PEP-device|PEP-device
57925701|NCT03187977|BEHAVIORAL|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
57925702|NCT05873946|DIAGNOSTIC_TEST|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
58278336|NCT04933617|DIAGNOSTIC_TEST|18F-FDG - PET|At screening, baseline, after cycle 1, 3, and 6, and end of treatment.
58278337|NCT04933617|DIAGNOSTIC_TEST|CT Scan|At screening, baseline, after cycle 1, 3, and 6, end of treatment and follow-up.
58278338|NCT04933617|PROCEDURE|Bone Marrow Aspiration|At screening and end of treatment.
58278339|NCT04933617|PROCEDURE|Bone Marrow Biopsy|At screening and end of treatment.
58278340|NCT04933617|DIAGNOSTIC_TEST|Lumbar Puncture (LP)|Baseline and end of treatment.
58278341|NCT06386900|OTHER|Cyclist|Participating in the Grand Tour as cyclist
57925703|NCT00410397|PROCEDURE|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
57925704|NCT00410397|PROCEDURE|Sham Manipulation|Neutral positional, gentle palpation
57925705|NCT05221463|BEHAVIORAL|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
58278342|NCT02748733|OTHER|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
58278343|NCT02748733|OTHER|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
58278344|NCT03972020|BEHAVIORAL|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
58278345|NCT03972020|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
58278346|NCT01733823|RADIATION|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
58278347|NCT05173285|DIAGNOSTIC_TEST|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
58278348|NCT05173285|BEHAVIORAL|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
58278349|NCT05173285|DIAGNOSTIC_TEST|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
58278350|NCT05173285|DIAGNOSTIC_TEST|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
58278351|NCT05262790|OTHER|This is not an intervention study|
58278352|NCT05262790|OTHER|This is not an intervention study|
58278353|NCT05262790|OTHER|This is not an intervention study|
58278354|NCT04575584|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
58278355|NCT04575584|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
58278356|NCT03681041|OTHER|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
57925706|NCT05221463|BEHAVIORAL|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
57925707|NCT06258915|DRUG|Adalimumab|Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)
57925708|NCT06258915|DRUG|Mycophenolate Mofetil|2 g/day orally for 36 weeks
58278357|NCT01325571|DRUG|Tacrolimus capsule|oral
58394867|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
57925709|NCT00041067|BIOLOGICAL|filgrastim|
57925710|NCT00041067|BIOLOGICAL|trastuzumab|
57925711|NCT00041067|DRUG|docetaxel|
57925712|NCT00041067|DRUG|vinorelbine|
57925713|NCT03283280|OTHER|Ever X Posterior|Resin composite restoration can be made as a direct onlay
57925714|NCT00301522|DEVICE|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
57925715|NCT00301522|DEVICE|Express2|Coronary Stent System
57925716|NCT06224608|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
58278358|NCT01325571|DRUG|Placebo|oral
58394868|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
57726633|NCT04256733|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
57925717|NCT06081452|BEHAVIORAL|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
57925718|NCT04768387|DIETARY_SUPPLEMENT|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
57925719|NCT00671554|BIOLOGICAL|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
57925720|NCT03537287|DRUG|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
57925721|NCT03537287|DRUG|Vaginal progesterone|200 mg of vaginal progesterone daily
57925722|NCT03537287|DRUG|Oral dydrogesterone|2 tablets of dydrogesterone daily
57925723|NCT00286884|PROCEDURE|Monitoring of heart rate variability|
57925724|NCT01320267|PROCEDURE|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
57925725|NCT00124371|BEHAVIORAL|a nurse led home-based education and support programme|
57925726|NCT06015451|OTHER|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
57925727|NCT04209699|DRUG|BMS-986165|Single dose
57925728|NCT04209699|DRUG|Famotidine|Single dose
57925729|NCT01080378|PROCEDURE|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
57925730|NCT02407184|OTHER|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
57925731|NCT03249025|DRUG|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
57925732|NCT03249025|DRUG|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
58278359|NCT03433859|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
58278360|NCT03433859|OTHER|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
58394869|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
58394870|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
57951117|NCT03496246|DIAGNOSTIC_TEST|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
58278361|NCT03429283|OTHER|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
58278362|NCT00824707|DRUG|Entecavir|Entecavir 0.5mg per day
58278363|NCT00824707|DRUG|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
58278364|NCT06432946|OTHER|Video|A 7-minute video demonstrating the sensing-glove system, how it can be used to assess manual therapy biomechanics, and its relevance in research and clinical contexts. The video was created by the research team via a voiceover PowerPoint presentation.
58394871|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
58394872|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
57925733|NCT05251818|OTHER|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
58394873|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
58394874|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
57925734|NCT05251818|OTHER|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
57726634|NCT04256733|BIOLOGICAL|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
58067802|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
58067803|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
58067804|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
58067805|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
58067806|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
58067807|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
58067808|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
58394875|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
58067809|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
57925735|NCT02309060|BEHAVIORAL|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
58394876|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
58394877|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
58394878|NCT03661307|DRUG|Decitabine|Given IV
58067810|NCT00899626|GENETIC|protein analysis|
58394879|NCT03661307|DRUG|Quizartinib|Given PO
58394880|NCT03661307|DRUG|Venetoclax|Given PO
58394881|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
58394882|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
58394883|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
58067811|NCT00899626|GENETIC|proteomic profiling|
58067812|NCT00899626|OTHER|biologic sample preservation procedure|
58067813|NCT00899626|OTHER|laboratory biomarker analysis|
58394884|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
58394885|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
57925736|NCT05711966|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
58067814|NCT00899626|OTHER|medical chart review|
58067815|NCT00899626|PROCEDURE|diagnostic colonoscopy|
58067816|NCT00899626|PROCEDURE|diagnostic endoscopic procedure|
58067817|NCT00899626|PROCEDURE|diagnostic endoscopic surgery|
58067818|NCT00899626|PROCEDURE|diagnostic surgical procedure|
58067819|NCT00899626|PROCEDURE|endoscopic surgery|
58067820|NCT00899626|PROCEDURE|screening colonoscopy|
58067821|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
58067822|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
58278365|NCT06432946|OTHER|Practice session|A 20-minute practice session during which participants received verbal information about the sensing-glove system. While wearing the sensing glove, participants performed palpation and manual therapy techniques (palpation, spinal mobilization/manipulation to the cervical and thoracic spine) on a human-sized manikin, guided by the researcher.
58278366|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
58278367|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
58394886|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
58394887|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
58394888|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
57925737|NCT05711966|DEVICE|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
58394889|NCT01071252|DRUG|AIN457|
58394890|NCT01071252|DRUG|Placebo|
57925738|NCT02138721|PROCEDURE|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
57925739|NCT00725634|BIOLOGICAL|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
57925740|NCT00725634|BIOLOGICAL|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
57925741|NCT05232123|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
57925742|NCT05232123|DRUG|Cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
57925743|NCT05805098|DRUG|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
57925744|NCT05805098|DRUG|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
57925745|NCT05805098|DRUG|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
57925746|NCT00157183|DEVICE|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
57925747|NCT04334434|OTHER|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
57925748|NCT03196232|DRUG|Epacadostat|Given PO
57925749|NCT03196232|DRUG|Pembrolizumab|Given IV
58278368|NCT01262924|BIOLOGICAL|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
58394891|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
57925750|NCT06512272|OTHER|Video recorded shared using a mobile application|"The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times"
57925751|NCT05829928|DIAGNOSTIC_TEST|Infectious Disease Testing|Participants will undergo infectious disease testing.
57925752|NCT05829928|PROCEDURE|Gonadal Tissue Removal|Removal of gonadal tissue will be done through a surgical procedure.
57925753|NCT02652143|DEVICE|AneVivo (Medical device for in vivo culture of embryos)|
57925754|NCT02652143|OTHER|comparator for embryo culture in vitro|
57925755|NCT03093779|OTHER|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
58278369|NCT00282386|DRUG|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
58278370|NCT00282386|DRUG|Placebo/ Duration of Treatment: 156 weeks|
58278371|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
58278372|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
58278373|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
58394892|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
58394893|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
57925756|NCT00219713|DRUG|nitrous oxide and oxygen|
57925757|NCT05650320|DRUG|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
57925758|NCT05650320|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
57925759|NCT05650320|OTHER|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
57951118|NCT03496246|DIAGNOSTIC_TEST|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
58394894|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
58067823|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
58067824|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
58067825|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
57925760|NCT04183972|PROCEDURE|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
57925761|NCT02592512|OTHER|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
57925762|NCT02592512|OTHER|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
58067826|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
58067827|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
58067828|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
58067829|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
58067830|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
58067831|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
58067832|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
58067833|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
58278374|NCT00618124|DRUG|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
58278375|NCT05391945|DIAGNOSTIC_TEST|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
58394895|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
58394896|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
58394897|NCT01974206|DRUG|Placebo|intramuscular injection
58067834|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
58067835|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
58067836|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
58067837|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
58278376|NCT03787199|DEVICE|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
57925763|NCT04868539|OTHER|Artificial Light At Night|90 lux lighting for 19hr/day
58067838|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
57925764|NCT04868539|BEHAVIORAL|Sleep Restriction|5-hr of sleep/night
57925765|NCT02827630|OTHER|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
57925766|NCT02827630|OTHER|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
57925767|NCT06277336|DRUG|Placebo|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)"
57951119|NCT03496246|DIAGNOSTIC_TEST|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
58067839|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
58067840|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
58067841|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
58278377|NCT03787199|OTHER|Treadmill|Bodyweight supported treadmill walking
58278378|NCT06307509|OTHER|Diagnosis of sepsis|Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
58278379|NCT00520754|DRUG|levocetirizine dihydrochloride|
58095062|NCT02627885|BEHAVIORAL|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
58278380|NCT02897180|BIOLOGICAL|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
58394898|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
57925768|NCT06277336|DRUG|Apelin Low Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 1 nmol/min (60ml per h)"
57925769|NCT06277336|DRUG|Apelin High Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 10 nmol/min (60ml per h)"
57925770|NCT06277336|DRUG|Selected Apelin Dose|"Study infusions (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours based on the best performing apelin dose (from Low Dose or High Dose) in healthy volunteers corresponding to one of the following options:~  1. at an infusion rate of 1 nmol/min (60ml per h) OR~ 2. at an infusion rate of 10 nmol/min (60ml per h)~In case both apelin dosis performed equally well in the healthy volunteers population the lower dose will be selected."
58278381|NCT02897180|BIOLOGICAL|Placebo|Capsules containin Placebo
58095063|NCT02627885|OTHER|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
58278382|NCT03131700|BIOLOGICAL|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
58278383|NCT03131700|BIOLOGICAL|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
58278384|NCT03229317|OTHER|Plethysmography|Lung plethysmography
58278385|NCT00511485|DRUG|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
58278386|NCT00511485|DRUG|Etarfolatide|
58278387|NCT06511271|OTHER|relaxation exercises|"The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation.~purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just consists of relaxation music"
58278388|NCT04886245|OTHER|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound \[o\], the labial protrusion on the sound \[pu\] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
58278389|NCT04375098|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
58278390|NCT01200277|PROCEDURE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
58306679|NCT05285748|BEHAVIORAL|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
58394899|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
58394900|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
58394901|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
58394902|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
58394903|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
58394904|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
57951120|NCT03496246|DIAGNOSTIC_TEST|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
57951121|NCT03496246|DIAGNOSTIC_TEST|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
57951122|NCT03496246|DIAGNOSTIC_TEST|serum creatinine|for assessment of renal function
57951123|NCT03496246|DIAGNOSTIC_TEST|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
58394905|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
58067842|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
57925771|NCT01486953|DRUG|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
57925772|NCT01486953|DRUG|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
58278391|NCT01200277|PROCEDURE|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
58394906|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
57925773|NCT03557723|OTHER|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~1. Cultural mediation workshop~2. Supervised visit and tour of the museum~3. Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
57925774|NCT04258527|DRUG|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
58067843|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
58067844|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
58306680|NCT05285748|BEHAVIORAL|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
58306681|NCT00002441|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
57951124|NCT03496246|DIAGNOSTIC_TEST|seum alanine aminotransferase|for assessment of liver function
58394907|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
58394908|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
58394909|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
58394910|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
58394911|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
58394912|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
58394913|NCT00163241|DRUG|celecoxib|
58394914|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
58394915|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
58394916|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
57951125|NCT03496246|DIAGNOSTIC_TEST|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
57951126|NCT03496246|DIAGNOSTIC_TEST|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
58394917|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
58394918|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
58394919|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
58394920|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
58394921|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
58394922|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
58394923|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
58394924|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
57726635|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
58278392|NCT04229199|BEHAVIORAL|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
58278393|NCT04837105|OTHER|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
58278394|NCT04837105|OTHER|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
58278395|NCT05329727|DRUG|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
58278396|NCT05329727|DRUG|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
57726636|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
57726637|NCT02832895|OTHER|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
57726638|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
58278397|NCT00006110|BIOLOGICAL|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
58278398|NCT00006110|DRUG|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
58394925|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
58394926|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
58394927|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
58394928|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
58394929|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
58394930|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
58394931|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
58394932|NCT03985943|DRUG|Placebo|Placebo
58394933|NCT03985943|DRUG|Nemolizumab|Nemolizumab
58394934|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
58394935|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
58394936|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
58394937|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
57951127|NCT02705651|DRUG|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
57726639|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
57726640|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
57726641|NCT03900936|DIAGNOSTIC_TEST|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
58278399|NCT00006110|DRUG|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
58278400|NCT00006110|DRUG|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
58278401|NCT00006110|PROCEDURE|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
58278402|NCT06333782|DEVICE|Experimental- Genefill Contour®|Genefill Contour® Hyaluronic Acid Injection
58278403|NCT06333782|DEVICE|Marketed comparator - Desirial®Plus|DESIRIAL®PLUS Hyaluronic Acid Injection
58278404|NCT01210352|DRUG|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
58278405|NCT00590538|DRUG|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
58278406|NCT00590538|DRUG|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
58278407|NCT00590538|DRUG|Placebo|The placebo is given to match the active comparator for four days.
58278408|NCT00944307|DRUG|raltegravir|raltegravir 400mg orally once
58278409|NCT00944307|DRUG|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
58278410|NCT02824588|BEHAVIORAL|Working Memory Training|Training mental flexibility
58278411|NCT02824588|BEHAVIORAL|Internet use|Used as control for time spent on computer
58278412|NCT06135116|DIAGNOSTIC_TEST|Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA|"Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab."
58278413|NCT00401427|DRUG|trastuzumab|
57726642|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
57726643|NCT02088996|DEVICE|longwave diathermy on low power|
58278414|NCT00401427|DRUG|vinorelbine|
58278415|NCT00940641|DRUG|AZD7325|IV Dose
58278416|NCT00940641|DRUG|AZD7325|oral dose
58278417|NCT01082393|DRUG|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
57726644|NCT00681317|DRUG|AZD6280|oral
57726645|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
58278418|NCT01082393|DRUG|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
57726646|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
57951128|NCT01026831|DRUG|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
57951129|NCT01026831|DRUG|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
58278419|NCT01082393|DRUG|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
58278420|NCT01082393|DRUG|cold cream|4 applications (day 1, day 3, day 6 and day 10)
58278421|NCT01330199|OTHER|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
58278422|NCT05715424|OTHER|Six interventions for children and adolescents|"* Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action."
58278423|NCT05908747|DRUG|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
58278424|NCT06073756|RADIATION|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
58278425|NCT00196430|DEVICE|silver-contained textiles|
58278426|NCT00196430|DRUG|corticosteroid|
58278427|NCT02673242|DEVICE|Threshold IMT Philips Respironics|Inspiratory muscle training
58278428|NCT02483572|BEHAVIORAL|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
57726647|NCT04593992|DEVICE|Placebo|Placebo stimulation
57726648|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
57726649|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
57726650|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
57951130|NCT05980624|DIETARY_SUPPLEMENT|oral nutrition supplement|patients receive ONS 300kcal in daily basis
57726651|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
57951131|NCT00170287|PROCEDURE|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
58278429|NCT06061250|DIETARY_SUPPLEMENT|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
57726652|NCT01233817|OTHER|Progressive strength training|the systematic increase in resistance weights
57726653|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
57726654|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
57726655|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
57726656|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
57726657|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
57726658|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
57726659|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
57726660|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
57726661|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
57726662|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
57951132|NCT00170287|DEVICE|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
58278430|NCT02152215|PROCEDURE|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
58278431|NCT02152215|PROCEDURE|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
58278432|NCT02932813|BEHAVIORAL|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
58394938|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
57726663|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
57726664|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57726665|NCT05642572|DRUG|Capmatinib|Given PO
57726666|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
57726667|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57726668|NCT05642572|DRUG|Osimertinib|Given PO
57726669|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
57726670|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
57726671|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
57726672|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
57726673|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
57726674|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
57726675|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
57726676|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
57951133|NCT01452763|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
58394939|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
57925775|NCT05532748|DEVICE|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
57726677|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
57925776|NCT05532748|DEVICE|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
57925777|NCT01881750|BEHAVIORAL|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
57925778|NCT01881750|BEHAVIORAL|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
57925779|NCT04642768|DIETARY_SUPPLEMENT|KetoneAid Ketone Ester|Commercially available ketone supplement
58067845|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
58067846|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
58067847|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
58278433|NCT06377332|DIAGNOSTIC_TEST|High density electroencephalogram (HdEEG)|High-density electroencephalography (HdEEG) will be utilised in the investigation of sleep-mediated neuronal functions in controls, OSA, COPD and overlap syndrome and the association with accelerated brain ageing and cognitive impairment.
58278434|NCT06377332|DIAGNOSTIC_TEST|Functional near infrared spectroscopy (fNIRS)|Functional near infrared spectroscopy (fNIRS) is one of the most advanced techniques in measuring brain oxygen content and hemodynamic activity. This information indirectly displays neuronal activity and provides a novel opportunity understand brain oxygenation, neurodegenerative diseases, and cognitive function.
58306682|NCT02233530|BEHAVIORAL|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
57726678|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
57726679|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
57726680|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
57726681|NCT02408614|DEVICE|Treadmill|
57726682|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
57726683|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
57726684|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
57726685|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
58394940|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
58394941|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
58394942|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
58394943|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
58394944|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
57726686|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
58394945|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
58394946|NCT00356772|DRUG|Azithromycin|
58394947|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
57925780|NCT04642768|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
57925781|NCT04563000|DRUG|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
57925782|NCT04563000|DRUG|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
57925783|NCT03507790|DRUG|CT1812|Active Study Drug
57925784|NCT03507790|DRUG|Placebo|Non-active study drug
57925785|NCT02998736|DRUG|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
57925786|NCT02998736|BIOLOGICAL|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
57925787|NCT04717284|OTHER|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
57925788|NCT04717284|OTHER|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
57925789|NCT05032079|PROCEDURE|cryoablation|single probe ultrasound guided cryoablation
57925790|NCT01423253|DRUG|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
58278435|NCT06377332|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be utilised to assess potential structural neuronal changes associated with neurodegenerative disease in those with COPD, OSA and overlap syndrome. MRI has the capacity to provide vital information regarding neuroimaging standards in cerebral vascular damage such as white matter hyperintensities (WMH), lacunes, cerebral microbleeds, brain atrophy and subcortical infarct. Through the utility of MRI sequences such as T1 and T2 weighted imaging, diffusion weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) and resting-state fMRI (rs-fMRI), the investigators will assess neurodegenerative-related structural brain changes in individuals with COPD, OSA and overlap syndrome and examine the differences between these target groups.
58394948|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
57925791|NCT02247908|OTHER|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~1. SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~2. SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~3. SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~4. SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
57925792|NCT02247908|OTHER|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~1. Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~2. Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~3. Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~4. Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
57925793|NCT05171101|OTHER|MAVEN|The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
57925794|NCT00435890|BEHAVIORAL|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
58394949|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
58394950|NCT01803100|OTHER|No intervention|There is no intervention in this trial
57925795|NCT03346057|DRUG|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
57951134|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
57951135|NCT01452763|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
57925796|NCT03346057|DRUG|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
57925797|NCT03346057|DRUG|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
58067848|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
58278436|NCT06377332|BIOLOGICAL|Blood collection|"A fasting 50mL blood sample will be collected at the experimental visit in the morning following the overnight sleep study. Blood samples will be processed after collection and stored at -80 degrees for future batch analyses. Analyses will include markers for inflammation and dementia including but not limited to ptau217 and beta amyloid. Routine blood analyses will be conducted on 17.5mL of the sample collected for baseline measures. Routine blood analyses includes lipid profile, glucose studies, insulin, high-sensitivity C-reactive protein (hs-CRP), iron studies, thyroid function, b12/folate, homocysteine, prolactin, calcium, full blood count and biochemistry panel for the OSA, COPD and overlap syndrome groups.~Routine blood analyses for controls include glucose studies, lipid profile, hs-CRP and biochemistry panel."
58278437|NCT06377332|DIAGNOSTIC_TEST|Neuropsychological battery|"A. Montreal Cognitive Assessment (MoCA):~B. Test of Premorbid Functioning (TOPF):~C. Rey Auditory Verbal Learning Test (RAVLT):~D. D-KEFS Colour Word Interference Test (D-CWIT):~E. Trail Making Test (TMT):~F. Symbol Digit Modalities Test (SDMT) - Oral Version:~G. RAVLT 20-minute recall~H. Controlled Oral Word Association Test (COWAT):"
58278438|NCT06377332|OTHER|Questionnaires|"1. Epworth Sleepiness Scale (ESS)~2. PROMIS sleep questionnaire 8a,~3. PROMIS sleep questionnaire 8b~4. EQ-5D-5L~5. Insomnia Severity Index (ISI)~6. Pittsburgh Sleep Quality Index (PSQ-I)~7. St George's Respiratory Questionnaire (SGRQ)~8. COPD Assessment Test (CAT)"
58278439|NCT06377332|DIAGNOSTIC_TEST|Pulmonary Function Test (PFT)|Full pulmonary function testing will be conducted in control, COPD, OSA and overlap syndrome groups. Full lung function testing will include spirometry with pre and post bronchodilator, oscillometry, lung diffusion testing (DLCO) and lung volumes.
58394951|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
58394952|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
58394953|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
58394954|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
58394955|NCT01684696|BEHAVIORAL|Virtual experience|
57925798|NCT03346057|DRUG|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
57925799|NCT03346057|DRUG|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
58394956|NCT01684696|BEHAVIORAL|Videos|
58394957|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
58394958|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
58394959|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
57925800|NCT03346057|DRUG|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
57925801|NCT03865147|DRUG|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
57925802|NCT03865147|DRUG|EMLA cream|Active Comparator
57925803|NCT03865147|DRUG|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
57925804|NCT03471871|DRUG|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
57925805|NCT03471871|DRUG|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
57925806|NCT03471871|DRUG|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
57951136|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
57951137|NCT01452763|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
58067849|NCT00069654|PROCEDURE|Forearm blood flow study|
58067850|NCT00069654|PROCEDURE|Brachial artery reactivity study|
58067851|NCT00069654|PROCEDURE|Treadmill exercise test|
58067852|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
58067853|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
58394960|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
58394961|NCT04428788|DRUG|CC-94676|Specified dose on specified days
58394962|NCT04428788|DRUG|CC1083611|Specified dose on specified days
58394963|NCT04428788|DRUG|CC1083610|Specified dose on specified days
58394964|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
58394965|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
58394966|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
58394967|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
58394968|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
58394969|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
58394970|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
58394971|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
58067854|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
57925807|NCT03471871|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
57925808|NCT03471871|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
57925809|NCT02311946|DRUG|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
57925810|NCT02311946|DRUG|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
57925811|NCT04056936|PROCEDURE|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
58394972|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
57925812|NCT01890148|DRUG|AZD5069|oral BD administration of 45 mg AZD5069
57925813|NCT00056355|DRUG|UVADEX and UVAR XTS Photopheresis System|
58394973|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
58394974|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
58394975|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
58394976|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
57925814|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
57925815|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
58067855|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
58067856|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
58067857|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
58278440|NCT06377332|OTHER|Cognitive Assessment|"The following cognitive assessments will be administered using a digital format on CANTAB:~1. Motor Screening Task (MOT) Used to assess sensorimotor function and comprehension and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease. This task acts as a practice trial for the subsequent tasks.~2. Reaction Time (RTI) Used to assess processing and psychomotor speed and is applicable in the assessment of general cognitive function and Alzheimer's disease.~3. Paired Associate Learning (PAL) Used to assess visual episodic memory and is applicable in the assessment of general cognitive function, Alzheimer's disease, Parkinson's disease and cerebrovascular disease.~4. Spatial Working Memory (SWM) Used to assess working memory and strategy and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease."
58278441|NCT06377332|DIAGNOSTIC_TEST|Polysomnogram (PSG)|During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.
57726687|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
57925816|NCT00185250|DRUG|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
57925817|NCT00185250|DRUG|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
57925818|NCT00693316|DRUG|ORM-12741|Alternating panel single dose escalation.
57925819|NCT01744951|BEHAVIORAL|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
58067858|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
58067859|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
58067860|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
58067861|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
57925820|NCT02129920|OTHER|This is an observational study|
57925821|NCT00508248|DIETARY_SUPPLEMENT|omega 3 fatty acids|1g daily
57925822|NCT00508248|DIETARY_SUPPLEMENT|placebo|olive oil capsule
57925823|NCT03985085|OTHER|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
57925824|NCT04549025|DRUG|Pimivalimab|Specified dose on specified days
57925825|NCT04549025|DRUG|Vopratelimab|Specified dose on specified days
57925826|NCT00292799|DRUG|Orlistat Vs Metformin|
57951138|NCT01452763|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
57951139|NCT06493773|BEHAVIORAL|Offer of referral to specialized alcohol use disorder treatment|Patients are offered referral to specialized alcohol use disorder treatment.
57925827|NCT04464265|OTHER|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
57726688|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
57726689|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
57925828|NCT02447757|DRUG|remifentanil|Remifentanil analgesia during delivery
57925829|NCT05744271|DEVICE|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
57925830|NCT00221182|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
57925831|NCT04758182|DEVICE|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
57925832|NCT04758182|DEVICE|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
57925833|NCT00969046|DRUG|EPO906 (patupilone)|
57925834|NCT01507558|PROCEDURE|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
57925835|NCT03545776|OTHER|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
57925836|NCT02411578|DRUG|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
57925837|NCT02411578|OTHER|Glucose Tablets|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
57925838|NCT03715309|DRUG|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
57925839|NCT05722132|BEHAVIORAL|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
57925840|NCT05722132|BEHAVIORAL|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
57925841|NCT05722132|BEHAVIORAL|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
57925842|NCT05722132|BEHAVIORAL|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
57925843|NCT01608542|DRUG|Fostamatinib 100mg|oral tablet
57925844|NCT01608542|DRUG|Fostamatinib 200mg|oral tablet
57726690|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
57726691|NCT02678546|OTHER|Other|case review of diagnosed disease
57925845|NCT05439434|OTHER|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
57726692|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
58278442|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for two weeks|nutritional intervention received two weeks before surgical intervention
57726693|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
57726694|NCT03373591|DRUG|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
57726695|NCT03373591|DRUG|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
57726696|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
57726697|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
57925846|NCT06323122|DEVICE|2.0 miniplates|2.0 miniplates
57925847|NCT06323122|DEVICE|2.3 high profile miniplates|2.3 high profile miniplates
58278443|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for one week|nutritional intervention received one weeks before surgical intervention
58278444|NCT00379171|BEHAVIORAL|Cow's milk with fish oil|
58278445|NCT00379171|BEHAVIORAL|Cow's milk without fish oil|
58278446|NCT00379171|BEHAVIORAL|Formula with fish oil|
58394977|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
57726698|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
57726699|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
58394978|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
58394979|NCT03122678|DRUG|Thiamine|
57925848|NCT06323122|DEVICE|3D miniplates|3D miniplates
57925849|NCT00483314|DRUG|N-acetylcysteine|2 g p.o. BID x 60 days
57925850|NCT02909270|DEVICE|Mediclore|to apply mediclore fully around thyroid gland
57925851|NCT04890678|DEVICE|22 residentsat risk for PU development|"mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning."
58067862|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
58278447|NCT00379171|BEHAVIORAL|Formula without fish oil|
58278448|NCT05033483|DIETARY_SUPPLEMENT|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
58278449|NCT05033483|DIETARY_SUPPLEMENT|Placebo|Gelatin capsule containing microcrystalline cellulose
58278450|NCT03843645|PROCEDURE|general anesthesia|surgical procedure under general anesthesia
58278451|NCT03843645|PROCEDURE|regional anesthesia|surgical procedure under regional anesthesia
58278452|NCT04908475|DRUG|Risankizumab|Subcutaneous injection
58278453|NCT04908475|DRUG|Apremilast|Oral Tablets
58278454|NCT05394454|PROCEDURE|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
58278455|NCT05192395|DRUG|DWJ1525|DWJ1525
58278456|NCT05192395|DRUG|DWP16001|DWP16001
58394980|NCT03122678|DRUG|Placebos|
57925852|NCT04890678|DEVICE|18 residents at least one PU category III-IV in the sacral area|"mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed."
57925853|NCT02069210|OTHER|Blood transfusion|Intraoperative blood transfusion
57925854|NCT00416377|BIOLOGICAL|bleomycin sulfate|
57925855|NCT00416377|DRUG|chlorambucil|
57925856|NCT00416377|DRUG|dacarbazine|
57925857|NCT00416377|DRUG|doxorubicin hydrochloride|
57925858|NCT00416377|DRUG|prednisolone|
57925859|NCT00416377|DRUG|procarbazine hydrochloride|
57925860|NCT00416377|DRUG|vinblastine sulfate|
57925861|NCT00416377|DRUG|vincristine sulfate|
57925862|NCT00416377|RADIATION|radiation therapy|
57925863|NCT01538563|DRUG|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
57925864|NCT04683640|DIETARY_SUPPLEMENT|GABA|Daily oral GABA for 4 weeks
58278457|NCT05192395|DRUG|DWC202101|DWC202101
57925865|NCT04683640|DRUG|Placebo|Daily oral Placebo for 4 weeks
57925866|NCT00551902|PROCEDURE|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
57925867|NCT00551902|PROCEDURE|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
57925868|NCT01486771|DRUG|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
57925869|NCT01178671|DRUG|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
57925870|NCT01178671|DRUG|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
57925871|NCT01178671|OTHER|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
58067863|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
58278458|NCT03632577|DEVICE|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
58394981|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
57925872|NCT00499629|DRUG|FXR 450|capsule, single oral doses from 10 mg to 450 mg
57925873|NCT00499629|DRUG|placebo|capsule similar to active drug
57925874|NCT02745392|DRUG|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
57925875|NCT02745392|DRUG|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
57925876|NCT04757350|OTHER|Observational research, not applicable|Observational research, not applicable
57925877|NCT01198353|DRUG|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
57925878|NCT03602456|OTHER|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
57925879|NCT01810237|DRUG|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
57925880|NCT06079489|OTHER|Brochure-Based Exercise Program|Simple posture exercises
57925881|NCT06079489|OTHER|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
58067864|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
58067865|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
58067866|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
57925882|NCT01037907|DRUG|Pleneva TM BGC20-0134|Placebo or 5 g dose
57925883|NCT01037907|DRUG|Placebo|Placebo or 5 g dose
57925884|NCT06394440|COMBINATION_PRODUCT|Self-Adhesive Bulkfill Composite (Surefil One)|It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
57925885|NCT02463188|BEHAVIORAL|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
57925886|NCT05828043|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
57925887|NCT00647673|DRUG|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
57925888|NCT00647673|DRUG|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
57925889|NCT00895674|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
57925890|NCT00429312|BIOLOGICAL|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
57925891|NCT02537535|OTHER|survey|This is a cross-sectional study without specific intervention
57925892|NCT00150969|DIETARY_SUPPLEMENT|vitamin K1 (phylloquinone)|
57925893|NCT00150969|DIETARY_SUPPLEMENT|placebo|1 pill daily
57925894|NCT01475578|DRUG|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
57925895|NCT01475578|DRUG|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
57925896|NCT00339170|BEHAVIORAL|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
57925897|NCT00339170|BEHAVIORAL|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
57925898|NCT01742598|DEVICE|Portico Transapical Aortic Valve System|
58278459|NCT03632577|DEVICE|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
57925899|NCT02827136|DRUG|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
58278460|NCT04640038|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
58278461|NCT02020070|DRUG|Degarelix|
57726700|NCT03826277|OTHER|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
57925900|NCT02827136|DRUG|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
57925901|NCT00638612|BIOLOGICAL|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
57925902|NCT00638612|DRUG|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
57925903|NCT00320021|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
57951140|NCT02526706|OTHER|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
58278462|NCT02020070|DRUG|Ipilimumab|
58278463|NCT02020070|PROCEDURE|Radical Prostatectomy|
57925904|NCT04847960|DIETARY_SUPPLEMENT|BioGaia Probiotic Lozenges|BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
57925905|NCT04556643|OTHER|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
57925906|NCT05372822|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
57925907|NCT05372822|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
58278464|NCT04858360|DRUG|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
58394982|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
58394983|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
58394984|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
57726701|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
57726702|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
57925908|NCT05372822|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead"
57925909|NCT02120716|BEHAVIORAL|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
57925910|NCT02858349|BEHAVIORAL|No intervention|No intervention
57925911|NCT02858349|BEHAVIORAL|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
57925912|NCT04923841|OTHER|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
57925913|NCT04923841|OTHER|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
58394985|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
58394986|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
57726703|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
57726704|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
57726705|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
58394987|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
57726706|NCT00358046|DRUG|ILY101|
57726707|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
57726708|NCT01863017|DEVICE|tDCS|
57726709|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
57726710|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
57726711|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
57726712|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
57726713|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
57726714|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
57726715|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
57726716|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
57726717|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
57925914|NCT04923841|OTHER|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
57925915|NCT04923841|OTHER|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
57925916|NCT04242511|DIAGNOSTIC_TEST|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
57925917|NCT05351853|DIETARY_SUPPLEMENT|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
57925918|NCT05351853|DIETARY_SUPPLEMENT|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
57925919|NCT05351853|DIETARY_SUPPLEMENT|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
58394988|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
58394989|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
58394990|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
57925920|NCT01245075|OTHER|Deep brain stimulation|Deep brain stimulation on
57925921|NCT01245075|OTHER|Placebo|deep brain stimulation off
57925922|NCT05123963|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
57925923|NCT00956514|DEVICE|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
57925924|NCT01648738|OTHER|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
57925925|NCT01648738|OTHER|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
57925926|NCT03236246|DRUG|KRX-0502|Oral ferric citrate with meals
57925927|NCT04112654|PROCEDURE|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
57925928|NCT04112654|PROCEDURE|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
57925929|NCT05968287|DIAGNOSTIC_TEST|The Leukocyte ImmunoTest™ (LIT™)|The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
57925930|NCT05311098|DEVICE|cryoablation|Treatment of atrial fibrillation with cryoablation catheters
58278465|NCT04858360|DRUG|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
58278466|NCT04858360|OTHER|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
57726718|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
57925931|NCT03099317|OTHER|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
57925932|NCT03099317|OTHER|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
57925933|NCT06026085|OTHER|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
57925934|NCT06026085|OTHER|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
57726719|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
57925935|NCT06026085|OTHER|0.9% normal saline|0.9% normal saline+routine sun protection
57925936|NCT00544362|BIOLOGICAL|cetuximab|
57925937|NCT00544362|DRUG|cisplatin|
58067867|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
58278467|NCT04858360|OTHER|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
57925938|NCT00544362|DRUG|fluorouracil|
57925939|NCT00544362|PROCEDURE|conventional surgery|
57925940|NCT04547049|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
57925941|NCT04547049|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
57925942|NCT04547049|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
57925943|NCT04547049|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
57925944|NCT04547049|DRUG|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
57925945|NCT04547049|PROCEDURE|Allogeneic HSCT|Day 0
57925946|NCT04547049|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
57925947|NCT04547049|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
57925948|NCT04547049|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
57925949|NCT00135759|DRUG|Naltrexone|low dose naltrexone in addition to daily methadone taper
57925950|NCT00135759|DRUG|Placebo comparator|1 capsule/day for 6 days
57925951|NCT00135759|DRUG|naltrexone|0.125 mg capsule/day for 6 days
57925952|NCT00135759|DRUG|naltrexone|0.250 mg capsule/day for 6 days
58278468|NCT04858360|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
57925953|NCT01566656|DRUG|total lymphoid irradiation and anti-thymocyte globulin|"* TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
57925954|NCT00458809|DRUG|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
57925955|NCT02557321|DRUG|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
57925956|NCT02557321|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
57925957|NCT05419063|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
58067868|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
58278469|NCT03103217|BEHAVIORAL|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
58278470|NCT00427219|DRUG|Ozarelix|Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
58278471|NCT00427219|DRUG|Placebo|Placebo will be administered IM on Day 0 and Day 14.
58394991|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
58422693|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
58278472|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (face-to-face care)|A Program structured in 28 visits (in group and individual) and 21 contacts (through phone calls or video calls) to guide the improvement of diet quality, self-care, and regular practice of physical activity
58278473|NCT06426277|BEHAVIORAL|Diet|Hypocaloric diet prescription
58422694|NCT00548717|DRUG|Sirolimus|
57925958|NCT05419063|BEHAVIORAL|text-based and email feedback|Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
57925959|NCT00287339|DRUG|Esomeprazole|40mg capsule BID for 12 weeks
57925960|NCT00287339|DRUG|Placebo|placebo capsule BID for 12 weeks
57925961|NCT01369511|DRUG|LY2495655|Administered subcutaneously
57925962|NCT01369511|DRUG|Placebo|Administered subcutaneously
57925963|NCT00277108|DRUG|Escitalopram (Lexapro)|
57925964|NCT00780754|DRUG|dutasteride|0.5mg
57925965|NCT00780754|PROCEDURE|prostate biopsy|prostate biopsy
57925966|NCT00506233|BEHAVIORAL|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
57925967|NCT00732628|DEVICE|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
57925968|NCT04271787|OTHER|questionnaire|Questionnaire
57925969|NCT04680494|OTHER|moderate intensity physical exercise|
57925970|NCT04680494|OTHER|high intensity physical exercise|
57925971|NCT04680494|OTHER|rest|
58278474|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (remote care)|A Program structured in 49 contacts delivered through telehealth (through phone calls or video calls between professional and participant) to guide the improvement of diet quality, self-care, and regular practice of physical activity
58278475|NCT04342013|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
58278476|NCT02792335|DRUG|apixaban|
58278477|NCT02792335|DRUG|dabigatran|
57925972|NCT02655302|OTHER|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
57925973|NCT02655302|OTHER|Lung function measure|Measure lung function and follow it during 4 years
57925974|NCT01141738|BEHAVIORAL|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
57925975|NCT01141738|BEHAVIORAL|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
57925976|NCT01744353|DRUG|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
57925977|NCT01744353|DRUG|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
57925978|NCT01744353|DRUG|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
57925979|NCT05689723|PROCEDURE|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
57925980|NCT05689723|PROCEDURE|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
57925981|NCT00364156|DRUG|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
57925982|NCT00364156|DRUG|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
58278478|NCT02792335|DRUG|rivaroxaban|
58278479|NCT02792335|DRUG|warfarin|
58278480|NCT00983138|DRUG|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
58278481|NCT02981732|OTHER|Liuwei Dihuang Pill|
58278482|NCT04886388|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
58278483|NCT04886388|OTHER|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
58278484|NCT03310892|BEHAVIORAL|Generic message|Generic message
58278485|NCT03310892|BEHAVIORAL|Tailored message|Tailored message
58278486|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
58278487|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
58422695|NCT00548717|DRUG|Mycophenolate mofetil|
58278488|NCT01636089|DRUG|bicarbonates|sodium bicarbonates 1,4%
58278489|NCT01636089|DRUG|saline|sodium chloride 0,9%
58278490|NCT03439410|OTHER|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
58278491|NCT06040216|OTHER|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
58278492|NCT03132974|DRUG|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
58278493|NCT03132974|OTHER|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
58278494|NCT03132974|OTHER|Placebo with manipulation procedure|Placebo granule with manipulation procedure
58278495|NCT01556932|DRUG|ABH gel|Given topically
58278496|NCT01556932|OTHER|placebo|Given topically
58278497|NCT06367777|DEVICE|cervical a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
58278498|NCT06367777|DEVICE|thoracic a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
58278499|NCT06367777|DEVICE|sham tsDCS|Sham transcutaneous spinal direct current stimulation (s-tsDCS)
58278500|NCT05275634|OTHER|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
58278501|NCT05275634|DEVICE|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
58278502|NCT05275634|DEVICE|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
58278503|NCT05275634|DEVICE|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
58278504|NCT05275634|DEVICE|placebo interferential current|Interferential current intensity will not be raised.
58278505|NCT06001853|DRUG|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
58422696|NCT00548717|DRUG|Bortezomib|
57925983|NCT01910805|BEHAVIORAL|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
57925984|NCT04556058|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
57925985|NCT04556058|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
57925986|NCT01294683|DRUG|Simvastatin|
57925987|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
57925988|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant (N/LRPT)|
57925989|NCT01294683|DRUG|Placebo|
57925990|NCT00176345|BEHAVIORAL|Exercise Training|
57925991|NCT03473704|BEHAVIORAL|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
57925992|NCT03473704|BEHAVIORAL|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
57925993|NCT02685943|BEHAVIORAL|Psychotherapy|
57925994|NCT00506545|DRUG|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
57925995|NCT00506545|DRUG|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
57925996|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
57925997|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
58278506|NCT06001853|DRUG|DSMO Injection|After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
58394992|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
57925998|NCT00553956|BEHAVIORAL|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
58278507|NCT04432454|DRUG|Lasofoxifene and abemaciclib (VERZENIO (R)).|Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
58278508|NCT05128045|BEHAVIORAL|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
58278509|NCT02268682|OTHER|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
58394993|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
58394994|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
57925999|NCT05755490|BEHAVIORAL|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
57926000|NCT02839954|BIOLOGICAL|anti-MUC1 CAR-pNK cells|
57926001|NCT05467774|BEHAVIORAL|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
57926002|NCT00140231|DRUG|r-metHuLeptin|recombinant human leptin
57926003|NCT00140231|OTHER|placebo|placebo (no active drug)
57926004|NCT03537950|DRUG|PLC|Single oral dose of PLC.
57926005|NCT03537950|DRUG|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
58067869|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
57926006|NCT03537950|DRUG|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
57926007|NCT02484339|DRUG|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
57926008|NCT02484339|OTHER|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy
58278510|NCT02268682|OTHER|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
58278511|NCT02380963|DIETARY_SUPPLEMENT|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
58278512|NCT02380963|BEHAVIORAL|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
58278513|NCT02764203|OTHER|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
58278514|NCT02764203|DEVICE|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
58278515|NCT01162122|BIOLOGICAL|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
57926009|NCT04488497|BEHAVIORAL|Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis|This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.
57926010|NCT04488497|BEHAVIORAL|Standard of care|Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
57926011|NCT02564939|DRUG|ramelteon|double-blind RCT
57926012|NCT02564939|DRUG|Placebo|double-blind RCT
57926013|NCT02691260|BEHAVIORAL|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
57926014|NCT02691260|BEHAVIORAL|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
57926015|NCT02691260|BEHAVIORAL|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
57926016|NCT04119973|OTHER|standard treatment|standard medical treatment
58067870|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
58067871|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
58067872|NCT01038609|DRUG|Acetaminophen|
57926017|NCT03118349|DRUG|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
57926018|NCT03118349|DRUG|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
57926019|NCT03645057|DRUG|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
57926020|NCT03645057|DRUG|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
57926021|NCT04251650|OTHER|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
58067873|NCT01038609|DRUG|Morphine Extended Release|
58394995|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
58067874|NCT01038609|DRUG|Placebo|
58067875|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
58067876|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
58394996|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
58394997|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
58394998|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
58394999|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
58395000|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
58395001|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
57926022|NCT04251650|OTHER|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
57926023|NCT03045042|DRUG|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
57926024|NCT00813163|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
57926025|NCT05566925|OTHER|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
57926026|NCT00373750|PROCEDURE|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
57926027|NCT01033253|BEHAVIORAL|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
57926028|NCT02678013|PROCEDURE|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
57926029|NCT02678013|PROCEDURE|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
57926030|NCT04111432|BIOLOGICAL|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
57926031|NCT04111432|BIOLOGICAL|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
57926032|NCT04111432|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
57926033|NCT01463384|DRUG|Minocycline|50mg, twice daily for 6 months.
57926034|NCT04298723|DEVICE|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
58395002|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
58395003|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
58395004|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
58395005|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
58395006|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
58395007|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
58395008|NCT00050206|DRUG|Olanzapine|
58395009|NCT00050206|DRUG|Placebo|
58395010|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
58395011|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
58395012|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57926035|NCT01002365|OTHER|Oxygen delivery|
57926036|NCT01002365|OTHER|Oxygen administration|
57926037|NCT00730561|BIOLOGICAL|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
57926038|NCT03099668|OTHER|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
57926039|NCT05509933|DRUG|Budesonide|budesonide starting day 5 after transplant
57926040|NCT06296745|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
58067877|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
57926041|NCT02326012|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents|
57926042|NCT04156230|DRUG|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
57926043|NCT01281007|DRUG|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
57926044|NCT01281007|DRUG|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
57926045|NCT00164125|DRUG|polyethyleneglycol3350|
57926046|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
57926047|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
57926048|NCT03641105|DIAGNOSTIC_TEST|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
58395013|NCT04549571|OTHER|Interview|Participate in interview
58395014|NCT04549571|OTHER|Training|Receive training
57926049|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 2.5 mg, twice daily, oral
57926050|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 5 mg, twice daily, oral
57926051|NCT01776424|DRUG|Aspirin|Tablet, 100 mg, once daily, oral
57926052|NCT01776424|DRUG|Aspirin placebo|Aspirin matching placebo, once daily, oral
57926053|NCT01776424|DRUG|Rivaroxaban placebo|Rivaroxaban matching placebo, twice daily, oral
57926054|NCT01776424|DRUG|Pantoprazole|Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
57926055|NCT01776424|DRUG|Pantoprazole placebo|Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
57926056|NCT05137860|DRUG|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
58395015|NCT04549571|OTHER|Media Intervention|Utilize the CDB
58395016|NCT04549571|OTHER|Best Practice|Utilize usual care
58395017|NCT04549571|OTHER|Survey Administration|Ancillary studies
57926057|NCT03539341|BEHAVIORAL|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
57926058|NCT03539341|OTHER|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
57926059|NCT04029961|OTHER|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
58067878|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
58395018|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
58395019|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
58395020|NCT02214888|DRUG|BIRB 796 BS, low dose|
58395021|NCT02214888|DRUG|BIRB 796 BS, high dose|
57726720|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
57926060|NCT04029961|OTHER|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
57926061|NCT00984035|OTHER|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
57926062|NCT00984035|OTHER|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
57926063|NCT00984035|OTHER|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
57926064|NCT02598752|OTHER|Symptom-limited cardiopulmonary exercise test (CPET)|
57926065|NCT02598752|OTHER|Resting assessment of cardiac function by echocardiography|
57926066|NCT02598752|OTHER|Post-exercise assessment of cardiac function by echocardiography|
57926067|NCT02598752|OTHER|Pulmonary function|
57926068|NCT02598752|BEHAVIORAL|Patient-reported outcomes questionnaire|
58067879|NCT03955211|DRUG|HTX-011|300 mg
58067880|NCT03955211|DRUG|HTX-011|400 mg
58067881|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
58067882|NCT03955211|DRUG|Ibuprofen|400 mg
58067883|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
58395022|NCT02214888|DRUG|Placebo|
58395023|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
58395024|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
58395025|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
58395026|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
58395027|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
58278516|NCT01162122|BIOLOGICAL|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
57926069|NCT00132613|PROCEDURE|Observation alone after pericardial drainage|
57926070|NCT00132613|DRUG|Pericardial instillation of bleomycin after drainage|
57926071|NCT00303641|DEVICE|Medtronic Resting Heart Bypass System|
57926072|NCT02593786|DRUG|Nivolumab|
57926073|NCT05997251|OTHER|Keeping a 1-day food consumption record by the patient|Checking and receiving the 1-day food consumption record recorded by the patient by the researcher
57926074|NCT05997251|OTHER|Measurement of adiponectin level|Adiponectin level will be measured for each group
58395028|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
58395029|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
58395030|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
57926075|NCT00604279|DRUG|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
57926076|NCT00604279|DRUG|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
57926077|NCT04867889|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
57926078|NCT04867889|DEVICE|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
57926079|NCT04369989|OTHER|No intervention|No intervention
57926080|NCT04886453|DRUG|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
58067884|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
58278517|NCT00442819|PROCEDURE|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
58278518|NCT00135590|DIETARY_SUPPLEMENT|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
58278519|NCT00135590|DIETARY_SUPPLEMENT|Spread diet|Dietary protein was spread over the four meals.
58278520|NCT03067259|OTHER|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
58278521|NCT06337747|DEVICE|Traditional technique|Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.
57926081|NCT04886453|DRUG|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
57926082|NCT04886453|OTHER|Data collection|Data collection
57926083|NCT04886453|OTHER|Assessment of pain|visual analog scale
57926084|NCT04886453|OTHER|Recovery quality score|QoR15 questionnaire
57926085|NCT05722704|PROCEDURE|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
57926086|NCT05722704|PROCEDURE|Occlusal reduction|Reduction of the functional and non-functional cusps
57926087|NCT01324323|DRUG|Romidepsin|14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
57926088|NCT01324323|DRUG|Rifampin|600 mg oral once daily on Days 4-8
57926089|NCT01289821|DRUG|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
57926090|NCT01289821|DRUG|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
57926091|NCT01289821|DRUG|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
58067885|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
58067886|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
58278522|NCT06337747|DEVICE|Experimental technique|Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
58278523|NCT02548884|PROCEDURE|Biliary cannulation|
57926092|NCT01289821|DRUG|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
57926093|NCT04337333|DEVICE|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
57926094|NCT03351166|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
57926095|NCT01416987|DRUG|Pergoveris®|Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
57926096|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
57926097|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
57926098|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
57926099|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
57926100|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
57926101|NCT01644344|OTHER|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
57926102|NCT01644344|OTHER|Xray|
57926103|NCT02491268|DRUG|Cilostazol|
57926104|NCT02491268|DRUG|Placebo|
57926105|NCT04771585|OTHER|Community Mask|Fabric mask, no medical device
57926106|NCT04771585|OTHER|Surgical Mask|Medical face mask (personal protective equipment), CE-certified
57926107|NCT04771585|OTHER|FFP2 respirator|Filtering Face Piece with no less than 94% filtering capacity, CE-certified
57926108|NCT04771585|OTHER|FFP3 respirator|Filtering Face Piece with no less than 99% filtering capacity, CE-certified
57926109|NCT00118820|DRUG|IV Preoperative antibiotic or placebo|
57926110|NCT05518864|DEVICE|IALURIL Prefill|GAG therapy (bladder instillations with glycosaminoglycans)
57926111|NCT04322942|DIAGNOSTIC_TEST|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
57926112|NCT02842892|OTHER|Tissue stiffness|
57926113|NCT04702282|DIAGNOSTIC_TEST|ropivacain concentration measurements|Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
57926114|NCT02393274|DEVICE|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
57926115|NCT01096342|DRUG|dinaciclib|Given IV
57926116|NCT01096342|OTHER|laboratory biomarker analysis|Correlative studies
57926117|NCT02141074|DRUG|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
57926118|NCT04113668|DRUG|BMS-986165|Specified Dose on Specified Days
57926119|NCT04113668|DRUG|diflunisal|Specified Dose on Specified Days
57926120|NCT02477579|DEVICE|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
57926121|NCT02745262|OTHER|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
57926122|NCT05413174|BEHAVIORAL|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
57926123|NCT04544345|DEVICE|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
57926124|NCT04544345|DEVICE|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
57926125|NCT00710827|DRUG|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
57926126|NCT00710827|DRUG|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
57926127|NCT01491048|PROCEDURE|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
57926128|NCT01491048|PROCEDURE|No physiotherapy after THA|No physiotherapy after THA
57926129|NCT05266586|DRUG|Obicetrapib|tablets
57926130|NCT05266586|DRUG|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
57926131|NCT05266586|OTHER|Obicetrapib placebo|tablets; no active ingredient
57926132|NCT05266586|OTHER|Ezetimibe placebo|capsules; no active ingredient
57926133|NCT04474223|DRUG|Dexamethasone|"In mother in whom 2° AVB or AV interval \>170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery"
57926134|NCT04474223|DRUG|IVIG|"In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval \> 170 ms will not be treated with maternal IVIG, only dexamethasone."
57926135|NCT06318767|PROCEDURE|hemodynamic measure of the Systolic Time Rise|The hemodynamic measure of the Systolic Time Rise will be added in the routine doppler echography, planned in preoperative, postoperative and at 6 months of following up. This measure is taken on the foot, with ultrasound probe.
57926136|NCT02136420|DRUG|Promethazine|Subject receives promethazine
57926137|NCT02136420|BEHAVIORAL|Hyper gravity training|Subject receives hypergravity training before testing
57926138|NCT02136420|DRUG|Placebo|Placebo
57926139|NCT02136420|BEHAVIORAL|No hypergravity training|Subjects do not receive normal Earth gravity
57926140|NCT02804178|DRUG|ATR-101|125-1000 mg twice per week
57926141|NCT04896138|OTHER|Interstitial Lung Disease|Not applicable - this is not an interventional trial
57926142|NCT00327054|DRUG|Nigella sativa seed|
57926143|NCT02608541|OTHER|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
57926144|NCT00768391|BIOLOGICAL|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
57926145|NCT04008758|DIAGNOSTIC_TEST|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
57926146|NCT00514761|DRUG|AZD6244|oral vial
57926147|NCT00514761|DRUG|Capecitabine|oral tablet
58395031|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
57926148|NCT00556153|DRUG|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
57926149|NCT03252054|DIAGNOSTIC_TEST|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
57926150|NCT00690833|DRUG|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
58395032|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
58395033|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
58395034|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
57926151|NCT05387226|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
58278524|NCT06311526|OTHER|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
58278525|NCT04468815|DRUG|BMS-986278 Tablet|Specified dose on specified days
57926152|NCT04003935|OTHER|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
57926153|NCT04003935|DIETARY_SUPPLEMENT|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
57926154|NCT04026139|OTHER|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
57926155|NCT04026139|OTHER|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
57926156|NCT00597077|OTHER|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
58067887|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
58278526|NCT04468815|DRUG|Esomeprazole|Specified dose on specified days
58278527|NCT04468815|DRUG|BMS-986278 suspension|Specified dose on specified days
58278528|NCT04544553|OTHER|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
58278529|NCT04544553|OTHER|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
58278530|NCT05562141|BIOLOGICAL|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
58278531|NCT03192410|BEHAVIORAL|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
58278532|NCT03192410|BEHAVIORAL|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
57926157|NCT00597077|OTHER|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
57926158|NCT00861263|DEVICE|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
57926159|NCT01152762|PROCEDURE|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
58278533|NCT03192410|BIOLOGICAL|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
58278534|NCT03192410|BIOLOGICAL|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
58278535|NCT03192410|GENETIC|DNA|SNPs (GWAS)
58278536|NCT03192410|BIOLOGICAL|Mental well-being|Cognitive function; dispositional optimism; depression.
58278537|NCT04891627|DIAGNOSTIC_TEST|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
58278538|NCT05232799|OTHER|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
58278539|NCT00123656|DRUG|esomeprazole|esomeprazole dosed qam for 8 weeks
58395035|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
58395036|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
58395037|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
58395038|NCT02832557|OTHER|Medical history questionaire|
58395039|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
58395040|NCT02832557|OTHER|Mullen Scales of Early Learning|
58395041|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
57926160|NCT06493812|PROCEDURE|Fascia lata|This intervention involves the harvesting of fascia lata from the thigh and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left thigh, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
58067888|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
58067889|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
58067890|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
58067891|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
58278540|NCT00123656|DRUG|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
58278541|NCT01244217|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
58278542|NCT05063526|DEVICE|ultrasound|ultrasound on diaphragm
58278543|NCT06428994|RADIATION|Radiotherapy|Post-operative radiotherapy for head and neck cancer
58067892|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
58278544|NCT00407407|DRUG|ABI-007|80mg/m\^2 to 150mg/m\^2 IV every 3 weeks
58278545|NCT00407407|DRUG|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
58278546|NCT04012307|DRUG|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
58278547|NCT04012307|DRUG|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
58278548|NCT04620694|DEVICE|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
58278549|NCT04823806|DIETARY_SUPPLEMENT|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
58278550|NCT03527862|OTHER|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
58395042|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
58395043|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
58395044|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
57926161|NCT06493812|PROCEDURE|Temporal fascia|This intervention involves the harvesting of temporal muscle fascia from the temporal region of the head and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left temporal region, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
57926162|NCT04100850|OTHER|Aquatic Exercises|twice a week, lasting 50 minutes, for two months.
58395045|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
58395046|NCT02855866|PROCEDURE|thyroidectomy|
58395047|NCT02855866|OTHER|cryotherapy|
58395048|NCT02855866|DRUG|cortisone aerosol|
57926163|NCT04100850|OTHER|Watsu|twice a week, lasting 50 minutes, for two months.
57926164|NCT01051700|DRUG|GW786034|Investigational product
57926165|NCT01051700|OTHER|Placebo|Placebo
57926166|NCT04207866|OTHER|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
57926167|NCT04207866|OTHER|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
57926168|NCT04417101|DRUG|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
57926169|NCT00460057|DRUG|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
58395049|NCT02855866|DRUG|Dexamethasone acetate|
58395050|NCT02855866|DRUG|paracetamol|
58395051|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
57926170|NCT00651157|BIOLOGICAL|wild-type reovirus|Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
57926171|NCT01849666|DRUG|phenprocoumon|6 mg oral single dose
57926172|NCT01849666|DRUG|vemurafenib|960 mg bid orally
57926173|NCT00880035|DEVICE|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
57926174|NCT02906839|OTHER|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
57926175|NCT04270357|PROCEDURE|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
57926176|NCT03678987|DIAGNOSTIC_TEST|P-MPA concentration|We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA
57926177|NCT03678987|DRUG|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
57926178|NCT04687449|DIETARY_SUPPLEMENT|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
57926179|NCT04687449|OTHER|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
57926180|NCT04687449|OTHER|Standard care|The standard of care for COPD.
57926181|NCT05649033|OTHER|data collection|Work-related stress evaluation
58395052|NCT00479505|DRUG|Placebo|Placebo
58395053|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
58395054|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
58395055|NCT00515606|DRUG|helium:oxygen|
58395056|NCT00461149|DRUG|Octreotide-LAR|
58395057|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
58395058|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
58395059|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
58395060|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
58395061|NCT05055011|OTHER|Survey Administration|Complete survey
58395062|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
58395063|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
58395064|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
58395065|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
58395066|NCT04246775|DEVICE|Peristeen|rectal irrigation
58395067|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
58395068|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
57926182|NCT01056133|OTHER|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be\< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
58067893|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
58278551|NCT05073861|BEHAVIORAL|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
58278552|NCT05368909|DIETARY_SUPPLEMENT|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
58278553|NCT05368909|DIETARY_SUPPLEMENT|Placebo|Placebo product
58278554|NCT01063894|OTHER|breakfast cereal|breakfast cereal and milk
58278555|NCT01063894|OTHER|water|water
58278556|NCT06413745|DRUG|SHR-A1811|SHR-A1811
58278557|NCT04184778|DEVICE|Smaller tube size|Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
57926183|NCT04496986|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
58067894|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
58067895|NCT00300794|DRUG|Ketamine|
58067896|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
58067897|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
58067898|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
58278558|NCT01865604|DEVICE|Anodal tDCS|
58278559|NCT01865604|DEVICE|Cathodal tDCS|
58278560|NCT01865604|DEVICE|sham tDCS|
58067899|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
58278561|NCT00280813|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|
58278562|NCT00445744|DRUG|cyclophosphamide|Given IV
58278563|NCT00445744|DRUG|busulfan|Given IV
58278564|NCT00445744|DRUG|tacrolimus|Given IV or PO
58278565|NCT00445744|DRUG|methotrexate|Given IV
58278566|NCT00445744|GENETIC|cytogenetic analysis|Correlative studies
58278567|NCT00445744|OTHER|flow cytometry|Correlative studies
58278568|NCT00445744|OTHER|pharmacological study|Correlative studies
58278569|NCT00445744|OTHER|pharmacogenomic studies|Correlative studies
58278570|NCT00445744|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBPC transplantation
58278571|NCT00445744|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
58278572|NCT02346994|DIETARY_SUPPLEMENT|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
58278573|NCT02346994|DIETARY_SUPPLEMENT|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
58278574|NCT05707949|DRUG|Atogepant|Oral Tablet
58278575|NCT04616846|DIAGNOSTIC_TEST|Peripheral venous ultrasound|Screening for VTE from D7 to 42
58278576|NCT01304303|DRUG|SPARC1023 I|IV administration
58278577|NCT01304303|DRUG|SPARC1023 II|IV administration
58278578|NCT00262002|BIOLOGICAL|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
58278579|NCT00262002|BIOLOGICAL|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
58278580|NCT00262002|BIOLOGICAL|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
58278581|NCT00262002|BIOLOGICAL|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
58278582|NCT00262002|BIOLOGICAL|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
58278583|NCT00262002|BIOLOGICAL|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
57926184|NCT04496986|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
57926185|NCT04496986|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
57726721|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
57926186|NCT04496986|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
58278584|NCT00262002|BIOLOGICAL|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
58278585|NCT00262002|BIOLOGICAL|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
58278586|NCT06224036|DRUG|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
58278587|NCT06224036|DRUG|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
58278588|NCT06224036|DRUG|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
58278589|NCT03089801|OTHER|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
57926187|NCT04496986|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
57726722|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
57926188|NCT04496986|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
57926189|NCT01052688|OTHER|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
57926190|NCT05591482|PROCEDURE|mesh repair|mesh repair of diaphragmatic hernia
57926191|NCT02465463|PROCEDURE|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
57926192|NCT02465463|DEVICE|flexible sigmoidoscopy|
58067900|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|According to the results of structural phase magnetic resonance and electroencephalogram, four optimal stimulation parameters will be determined.Transcranial electrical stimulation devices (Sorterix)will be used for intervention.In each cycle, the stimulation will be performed every night during weekdays,a total of 10 times.A maximum of four cycles of intervention will be performed for each patient, depending on the efficacy and the their wishes.
58067901|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
58067902|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
58067903|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
58067904|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
58067905|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
57926193|NCT02579174|DEVICE|Medacta GMK Sphere|
57926194|NCT01993446|DRUG|DRM02|
57926195|NCT01993446|OTHER|Vehicle|
57926196|NCT02472080|DRUG|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
57926197|NCT03080688|DEVICE|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
57926198|NCT02005081|DEVICE|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
57926199|NCT02005081|DEVICE|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
57926200|NCT02069353|DEVICE|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
57926201|NCT02069353|DEVICE|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
57926202|NCT00897351|GENETIC|mutation analysis|
57926203|NCT00897351|GENETIC|polymorphism analysis|
57926204|NCT00897351|GENETIC|protein expression analysis|
58067906|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
58067907|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
57726723|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
57726724|NCT00172510|PROCEDURE|blood drawing|
57926205|NCT00897351|OTHER|immunohistochemistry staining method|
57926206|NCT00897351|OTHER|laboratory biomarker analysis|
57926207|NCT02336178|DRUG|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
57926208|NCT00280046|DRUG|biphasic insulin aspart|
57926209|NCT01098136|OTHER|Chiropractic|Manual treatment of musculoskeletal complaints
57926210|NCT01098136|OTHER|Conventional medical intervention|Medical, physiotherapy
58067908|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
58395069|NCT06592833|DRUG|Placebo|Matching placebo.
57926211|NCT01098136|OTHER|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
57951141|NCT05389163|DEVICE|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
57926212|NCT00760669|DRUG|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
57926213|NCT00760669|DRUG|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
57926214|NCT04992962|DRUG|CBD/CBN|A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
57926215|NCT04992962|DRUG|CBD/THC|A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
57926216|NCT04992962|DRUG|Placebo|An inactive compound.
57926217|NCT04833322|DIETARY_SUPPLEMENT|D-Galactose|Galactose supplementation, once per day, up to 1.5g/kg per day
57926218|NCT04214301|DRUG|BLI800|BLI800 Bowel Preparation
57926219|NCT02702973|OTHER|Observe the fundus characteristics after therapy.|
57926220|NCT00496795|OTHER|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
57926221|NCT02099903|DEVICE|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
57926222|NCT00109720|BEHAVIORAL|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
57926223|NCT00109720|BEHAVIORAL|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
57926224|NCT05179720|OTHER|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
57926225|NCT00439530|DRUG|oseltamivir|
57926226|NCT00439530|DRUG|probenecid|
57926227|NCT05898464|BIOLOGICAL|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
57926228|NCT02203123|DEVICE|Ultrasound|
57926229|NCT02203123|DRUG|normal saline|
57926230|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
58278590|NCT05689008|BIOLOGICAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
58278591|NCT05995951|DEVICE|Deep Bran Stimulation (DBS)|Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)
57926231|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
57926232|NCT05509985|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
57926233|NCT00529724|BEHAVIORAL|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
57926234|NCT05205057|OTHER|Saliva|Unstimulated whole saliva is collected
57926235|NCT05074849|BEHAVIORAL|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
58278592|NCT05995951|DEVICE|Sham-stimulation|Deep brain stimulation (DBS) surgery - Sham stimulation
57726725|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
58278593|NCT00163033|DRUG|estetrol|
57726726|NCT03047616|OTHER|Blood and Urine Collection|
57926236|NCT02974088|DEVICE|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
57926237|NCT02974088|DEVICE|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
57926238|NCT03015441|OTHER|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
57926239|NCT02729623|DRUG|Kite Systems cannaHALER cannabis Inhaler.|
57926240|NCT04470609|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
58067909|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
58067910|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
58278594|NCT04780243|OTHER|counseling|Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
58278595|NCT06303414|PROCEDURE|Carotid Endarterectomy (CEA)|Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
58422697|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
57926241|NCT04470609|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
57926242|NCT04470609|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
57926243|NCT04470609|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
57926244|NCT04907695|DEVICE|I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700|All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
57726727|NCT04855734|BEHAVIORAL|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
57926245|NCT01523639|DRUG|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
57926246|NCT06165939|DRUG|Intra-articular corticosteroid injection|Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
57926247|NCT06165939|DRUG|hydrodilation with 15% hypertonic dextrose|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
58067911|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
58067912|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
58067913|NCT03463720|OTHER|Infected|Extremity wound, infected
58278596|NCT06303414|PROCEDURE|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.
57926248|NCT06165939|DRUG|hydrodilation with Normal saline|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
57926249|NCT05158556|OTHER|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
57926250|NCT05158556|OTHER|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
57926251|NCT06420895|OTHER|Clinical follow-up|Clinical follow-up of patients
57926252|NCT06420895|OTHER|Transthoracic Echocardiogram (TTE)|Transthoracic Echocardiogram
57926253|NCT06420895|OTHER|Magnetic resonance imaging (MRI)|Magnetic resonance imaging
57926254|NCT06420895|OTHER|Transesophageal echocardiogram (TEE)|Transesophageal echocardiogram
57926255|NCT00670189|DRUG|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
57926256|NCT02569554|DRUG|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
57926257|NCT02569554|DRUG|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
57926258|NCT05579158|BEHAVIORAL|Mobile application and wearable device|Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
58278597|NCT06303414|PROCEDURE|Hybrid Surgery|Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
58278598|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
57726728|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
57726729|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
57726730|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
57726731|NCT00142974|DRUG|Tegaserod|
57726732|NCT04480645|DEVICE|CivaDerm|radioactive bandage
57926259|NCT05579158|BEHAVIORAL|Time-restricted eating|Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
57926260|NCT03165539|DEVICE|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
57926261|NCT01936142|DEVICE|Use of RenalGuard|
57926262|NCT05277129|OTHER|Analysis of post-stroke immune responses|Analysis of immune responses in peripheral blood
57926263|NCT02810899|DRUG|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
57926264|NCT02810899|DRUG|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
57926265|NCT02812901|PROCEDURE|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
57926266|NCT02812901|PROCEDURE|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
58067914|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
57926267|NCT04897451|OTHER|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
57926268|NCT05281965|DRUG|Retinoic acid|Retinoic acid oral
57926269|NCT06017141|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
57926270|NCT06017141|OTHER|Electronic Health Record Review|Ancillary studies
57926271|NCT06017141|DRUG|Fentanyl Citrate|Given via injection
57926272|NCT06017141|DRUG|Propofol|Given IV
57926273|NCT06017141|OTHER|Questionnaire Administration|Ancillary studies
57926274|NCT06017141|DRUG|Sevoflurane|Given via inhalation
57926275|NCT06017141|PROCEDURE|Surgical Procedure|Undergo SOC surgery
58067915|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
58278599|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
58278600|NCT04748848|DRUG|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
58278601|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
58278602|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
58278603|NCT04686812|BEHAVIORAL|Worksite health promotion program|Physical activity, nutrition, and stress management programs
57926276|NCT04932538|OTHER|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
58278604|NCT01422707|DRUG|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
58278605|NCT01056913|DEVICE|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
58278606|NCT01056913|OTHER|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
58278607|NCT06333483|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
58278608|NCT04337476|DEVICE|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
58278609|NCT01941537|DRUG|ILV-094|IV infusion of ILV-094
58278610|NCT01941537|DRUG|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
57926277|NCT03484520|DRUG|Venetoclax|tablet, oral
57926278|NCT03484520|DRUG|Dinaciclib|intravenous
57926279|NCT05119426|BIOLOGICAL|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
58278611|NCT02127736|DRUG|Amitriptyline|
58278612|NCT02127736|DRUG|Placebo|
58278613|NCT02838472|DRUG|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
58278614|NCT01381380|PROCEDURE|Manual therapy|Manual therapy, once a week for 8 weeks
58278615|NCT03486964|DRUG|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
58278616|NCT01587625|DRUG|Oxytocin|
58278617|NCT00808470|DRUG|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
58278618|NCT00808470|OTHER|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
58278619|NCT03300180|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
57926280|NCT01939054|DRUG|Nimotuzumab|
57926281|NCT01939054|DRUG|docetaxel|
57926282|NCT01939054|DRUG|capecitabine|
57926283|NCT00593801|DRUG|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
57926284|NCT00593801|DRUG|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
57926285|NCT00829582|DRUG|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
57926286|NCT00829582|OTHER|placebo|single intravenous infusion
57926287|NCT00919555|DRUG|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
57926288|NCT00919555|DRUG|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
57926289|NCT00919555|DRUG|Placebo|Placebo
57951142|NCT05389163|DEVICE|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
58067916|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
58278620|NCT03300180|OTHER|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
58278621|NCT04333225|DRUG|Hydroxychloroquine|Weekly treatment in individuals at high risk
58278622|NCT04624542|DEVICE|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
58278623|NCT04368832|OTHER|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
58278624|NCT01421992|DRUG|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
58278625|NCT01421992|DRUG|Placebo|one tablet placebo per day during 3 weeks
58278626|NCT00574691|DEVICE|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
58278627|NCT06142734|PROCEDURE|pyeloplasty|"* For laparoscopic pyeloplasty:~* Anaesthesia: general~* Position: a 45-degree lateral decubitus position with the concerned side up. Patient is secured to the operating table. Pneumoperitoneum is adopted through a camera port lateral to the umbilicus~* extra operating ports are created at subcostal and at spinoumbilial line.~* the UPJ is transperitoneally accessed by incising the white line of Toldt and the ipsilateral colon is reflected and the proximal ureter and the pelvis are identified an mobilized~* then Anderson- Hynes pyeloplasty is carried out with insertion of nephroureterostomy or pyeloureterostomy tube."
57735421|NCT00872144|DRUG|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
58395070|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
57926290|NCT03988322|OTHER|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
57926291|NCT03988322|OTHER|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
57926292|NCT05987722|OTHER|Enoxolone|The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
57926293|NCT05987722|OTHER|Sensodyne|The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
57926294|NCT03096366|DEVICE|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
58278628|NCT06347393|DIAGNOSTIC_TEST|Mammography and Breast Ultrasound|Patients will be scanned using mammography and Breast Ultrasound for Breast Cancer Screening
58278629|NCT05680142|DRUG|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
58278630|NCT05680142|DRUG|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
58395071|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
58395072|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
58395073|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
58395074|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
58395075|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
58395076|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
58395077|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
58395078|NCT00711048|DRUG|AZD1386|oral, single dose
58395079|NCT00711048|DRUG|Placebo|Oral solution, single dose
58395080|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
58395081|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
58395082|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
58395083|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
57726733|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
57726734|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
57726735|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
57926295|NCT03096366|OTHER|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
58067917|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
58278631|NCT05975918|BEHAVIORAL|Motivational İnterview|Participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.
58278632|NCT05975918|OTHER|Psychoeducation|2 hours of training on coping with stress and problem solving skills will be provided.
58278633|NCT02637388|DIETARY_SUPPLEMENT|Oatwell28 Oatwell Original Powder|
58278634|NCT02637388|DIETARY_SUPPLEMENT|Control Breakfast|Isocaloric breakfast without added beta-glucans
58278635|NCT01857102|DEVICE|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
58278636|NCT01857102|DEVICE|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
58395084|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
58395085|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
57726736|NCT02759900|DEVICE|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
57926296|NCT01057498|DRUG|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
57926297|NCT01057498|DRUG|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
57926298|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
58067918|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
58067919|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
58278637|NCT01074255|DRUG|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
58067920|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
58278638|NCT01873157|DRUG|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
58395086|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
58395087|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
58395088|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
57926299|NCT00521742|DRUG|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
58278639|NCT01873157|DRUG|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
58278640|NCT01197014|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan high dose
58278641|NCT01197014|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
58278642|NCT00816322|DIETARY_SUPPLEMENT|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
58278643|NCT00816322|DIETARY_SUPPLEMENT|Placebo|high oleic oil
58278644|NCT06434688|OTHER|Mental Fatigue:|The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.
58395089|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
58067921|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
58395090|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
58395091|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
57926300|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
57926301|NCT00521742|DRUG|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
57926302|NCT02789735|DEVICE|Active laser therapy|Laser therapy at predetermined sites
57926303|NCT02789735|DEVICE|Sham laser therapy|Sham therapy at predetermined sites
58395092|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
57926304|NCT04005053|DRUG|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
58395093|NCT00395486|DRUG|Rosuvastatin|10mg
58067922|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
58306683|NCT04127617|OTHER|Osteopathic Manipulative Treatment|"Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment"
58395094|NCT00395486|DRUG|Atorvastatin|10mg
58395095|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
58395096|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
57926305|NCT04005053|DRUG|Placebo oral tablet|Placebo
58067923|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
58422698|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
57926306|NCT01695915|PROCEDURE|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
57926307|NCT00555542|DRUG|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
57926308|NCT03519165|DEVICE|EV1000(FloTrac System 4.0)|
57951143|NCT02286700|DRUG|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
58067924|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
58395097|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
57926309|NCT05023395|DRUG|MEE-HU Medicus|This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
58278645|NCT06434688|OTHER|Body Awareness:|"Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception."
58278646|NCT06434688|OTHER|Neck Disability Level|Neck disability index will be used to assess this parameter.
58278647|NCT06434688|OTHER|Quality Of Life|SF-12 will be used to assess quality of life.
58278648|NCT06434688|OTHER|Pain Assessment:|Pain intensity will be assessed by Visual Analog Scale (VAS). In addition, pain duration and pain frequency will be questioned. The Pain Self-Efficacy Questionnaire will be used to assess the confidence of people with chronic pain to perform certain tasks and behaviors despite their pain.
58278649|NCT06434688|OTHER|Physical Condition:|"Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated."
58278650|NCT06434688|OTHER|Anxiety and Depression:|Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.
58278651|NCT05366296|BIOLOGICAL|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide), DSPC \[1,2- distearoyl-sn-glycero-3-phosphocholine\], Cholesterol, Trometamol and Sucrose
58278652|NCT05366296|BIOLOGICAL|Placebo|Normal saline (0.9% sodium chloride solution
58395098|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
58395099|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
58395100|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
58395101|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
58395102|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
58395103|NCT04798352|OTHER|6-minute walk test|6-minute walk test
58395104|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
58395105|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
58395106|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
58395107|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
58395108|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
58395109|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
57726737|NCT02759900|DEVICE|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
57926310|NCT05023395|OTHER|Placebo|Placebo
57926311|NCT05516823|OTHER|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
57926312|NCT01030679|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
58278653|NCT03027245|DRUG|Eribulin|
58278654|NCT01189708|DEVICE|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
57926313|NCT01030679|DRUG|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
57926314|NCT01030679|DRUG|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
57926315|NCT01030679|DRUG|Placebo|orally, 1 tablet once daily for 8 weeks
57926316|NCT02579707|DRUG|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
57926317|NCT02881957|DRUG|Cholecalciferol|
57926318|NCT02881957|OTHER|Placebo|Oral syrup placebo
57926319|NCT01382264|OTHER|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
58278655|NCT01189708|OTHER|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
58278656|NCT04789057|DRUG|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
57926320|NCT01798277|PROCEDURE|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
57926321|NCT01798277|DRUG|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
57926322|NCT03653533|DEVICE|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
58278657|NCT04789057|DRUG|Placebo|p.o., once daily
58278658|NCT05484596|PROCEDURE|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
58278659|NCT04103034|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
58067925|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
58067926|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
58278660|NCT04103034|DRUG|Desmopressin|Sterile solution for injection
58278661|NCT04103034|DRUG|Placebo|Sterile saline for injection
57926323|NCT03653533|DEVICE|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
57926324|NCT03653533|DEVICE|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
57926325|NCT02267356|DRUG|VT-1161|
58067927|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
58067928|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
57926326|NCT02267356|DRUG|Placebo|
58067929|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
58067930|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
57926327|NCT01885325|OTHER|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
58278662|NCT00111306|DRUG|epratuzumab|
58278663|NCT05054686|OTHER|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
58278664|NCT05054686|OTHER|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
58278665|NCT05054686|OTHER|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
58278666|NCT01807728|OTHER|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
58278667|NCT01807728|OTHER|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
58278668|NCT03409939|DIETARY_SUPPLEMENT|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
58278669|NCT00255320|DRUG|VIP|
58306684|NCT04127617|OTHER|Nursing Educational Care|"Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs."
57926328|NCT04234425|BEHAVIORAL|Trauma-Informed Yoga|Trauma-Informed Yoga practice held within a high school weight training class
57926329|NCT05364372|BEHAVIORAL|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
57951144|NCT02286700|OTHER|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
58067931|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
57726738|NCT02073513|DEVICE|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
58395110|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
58395111|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
58395112|NCT03315793|DRUG|Placebo|Administered orally
57926330|NCT05364372|BEHAVIORAL|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
58278670|NCT04912414|BEHAVIORAL|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
58395113|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
58395114|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
58278671|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
58278672|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
58278673|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
58278674|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
58395115|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
58395116|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
58395117|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
58395118|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
58395119|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
58395120|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
58395121|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
57726739|NCT02073513|DEVICE|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
57726740|NCT03361813|OTHER|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
57926331|NCT03528863|BEHAVIORAL|Online Mindfulness Meditation|Receive web-based mindfulness meditation
57926332|NCT03528863|OTHER|Questionnaire Administration|Ancillary studies
57926333|NCT01197833|DRUG|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
57926334|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
58278675|NCT04764383|DRUG|L-Histidine|1000 mg capsules taken by mouth (PO) twice daily (BID).
58278676|NCT04764383|DRUG|Placebo|Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
57926335|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
57926336|NCT01505010|PROCEDURE|Renal denervation|Renal denervation in the intervention group
58278677|NCT04764383|DRUG|Lodosyn|50 mg capsules taken PO BID.
58278678|NCT04792047|DIAGNOSTIC_TEST|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
58278679|NCT03491397|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
58395122|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
57926337|NCT04384848|OTHER|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
58278680|NCT01994473|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
58395123|NCT02920528|DRUG|Placebo|Normal Saline
58395124|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
58395125|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
58395126|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
58395127|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
58395128|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
58395129|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
58395130|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
58395131|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
57926338|NCT04888130|GENETIC|Phylogenetic Analysis|The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
58067932|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
58067933|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
58395132|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
58395133|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
58395134|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
58395135|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
58278681|NCT01994473|DRUG|Placebo|single oral dose placebo
58278682|NCT01994473|DRUG|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
58278683|NCT06482619|DIETARY_SUPPLEMENT|Creatine supplementation|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained creatine monohidrate (Creapure, Crown Sport Nutrition, Arnedo, Spain)
58278684|NCT06482619|DIETARY_SUPPLEMENT|Placebo|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained placebo (i.e., sucrose)
58278685|NCT02085070|DRUG|MK-3475|IV MK-3475
58278686|NCT03620383|PROCEDURE|Topical Heat|Warm heat pack applied topically in participant hand.
57926339|NCT04888130|OTHER|Data collection|Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
57926340|NCT06236529|BEHAVIORAL|Health Behavior Change Counseling|A telephone-based intervention employing principles and practices of motivational interviewing.
57926341|NCT06236529|BEHAVIORAL|Self-management program|An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
57926342|NCT03844542|DEVICE|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
58278687|NCT02476864|DRUG|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
58278688|NCT02476864|DRUG|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
58278689|NCT05804253|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
58278690|NCT01537991|RADIATION|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
58278691|NCT02261831|OTHER|obese patients|collection of blood sampling and biopsies
58278692|NCT02261831|OTHER|diabetic patients|collection of blood sampling and biopsies
58278693|NCT02261831|OTHER|patients free of obesity and diabetes|collection of blood sampling and biopsies
58278694|NCT02261831|OTHER|patients free type 2 diabetes|collection of blood sampling and biopsies
58278695|NCT02087137|BEHAVIORAL|Memory and Aging Program|
58278696|NCT04838431|OTHER|Blood sample and ultrasound at first trimester|The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants
58278697|NCT05480553|DRUG|NPC-06|"1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
57726741|NCT03361813|OTHER|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
57726742|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
57726743|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
57726744|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
57726745|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
57726746|NCT01799174|PROCEDURE|Placebo|
58278698|NCT05480553|DRUG|Placebo|"1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
58278699|NCT01256385|BIOLOGICAL|Cetuximab|Given IV
58278700|NCT01256385|OTHER|Laboratory Biomarker Analysis|Correlative studies
58278701|NCT01256385|DRUG|Temsirolimus|Given IV
58278702|NCT00153816|DRUG|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
58278703|NCT00153816|DRUG|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
58278704|NCT00153816|DRUG|placebo|placebo; two tablets per day
57926343|NCT00520104|DRUG|intranasal ketamine|drug interaction
57926344|NCT03838107|BEHAVIORAL|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
57926345|NCT00559442|OTHER|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
57926346|NCT04773613|OTHER|Experimental SLP|SLP was given to the infant during bottle-feeding.
57926347|NCT04773613|OTHER|Experimental SEP|SEP was given to the infant during bottle-feeding.
58067934|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
58395136|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
57726747|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
57726748|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
58067935|NCT01832753|DRUG|Levothyroxine|
58278705|NCT04735159|DEVICE|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
58278706|NCT02838589|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
58278707|NCT02838589|DRUG|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
58278708|NCT00543920|DRUG|MK0777|
58278709|NCT01864252|OTHER|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
58278710|NCT01864252|DRUG|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
58395137|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
58395138|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
58395139|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
58395140|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
58395141|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
58395142|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
58395143|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
58395144|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
58395145|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
58395146|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
58395147|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
58395148|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
58395149|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
57726749|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
57726750|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
58067936|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
58278711|NCT01864252|DRUG|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
58278712|NCT04159324|OTHER|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
58278713|NCT05951920|PROCEDURE|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
58278714|NCT04239196|DRUG|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
58306685|NCT06251804|OTHER|Water exercise program|The exercise program includes a short foot exercise and will be given in water.
57726751|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
57726752|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
58395150|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
58395151|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
58395152|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
58395153|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
58395154|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
58395155|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
58395156|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
57726753|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
57726754|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1|Participants wear a VR headset which plays VR content/material pre- endoscopy only.
57726755|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1&2|Participants wear a VR headset which plays VR content/material pre- endoscopy and during endoscopy.
57726756|NCT02577705|BEHAVIORAL|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
57926348|NCT05997524|DRUG|Trastuzumab|Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).
57926349|NCT05997524|DRUG|Oxaliplatin|Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.
57926350|NCT05997524|DRUG|Capecitabine|Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
58278715|NCT04239196|OTHER|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
58278716|NCT02614404|DRUG|Imatinib combination therapy|Imatinib plus dihydroartemisinin plus piperaquine
58278717|NCT02614404|DRUG|Dihydroartemisinin-piperaquine|Standard of care
58278718|NCT05574907|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
58278719|NCT04631237|OTHER|Observational, no intervention|No intervention involved
58278720|NCT02760121|DRUG|Acetazolamide|
58278721|NCT02760121|DRUG|Methazolamide|
58278722|NCT02760121|DRUG|Placebo|
58278723|NCT02066077|DRUG|Etomidate|
58395157|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
58395158|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
58278724|NCT02066077|DRUG|Propofol|
58278725|NCT02066077|DEVICE|Bilateral temporal MECT|
58278726|NCT02066077|DEVICE|The right temporal MECT|
58278727|NCT02066077|DEVICE|Bilateral frontal MECT|
58278728|NCT00777192|BEHAVIORAL|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
58278729|NCT02749799|DRUG|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
58278730|NCT05619380|PROCEDURE|physiotherapy treatment|Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
58395159|NCT03350035|DRUG|IV Ganaxolone active|IV
58395160|NCT03350035|DRUG|IV Placebo, non-active|IV
58395161|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
58395162|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
57726757|NCT02577705|BEHAVIORAL|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
57726758|NCT02577705|BEHAVIORAL|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
58278731|NCT03294200|DEVICE|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
58278732|NCT02635009|RADIATION|Three-Dimensional Conformal Radiation Therapy|daily fractions
58278733|NCT02635009|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
58278734|NCT03287648|DIAGNOSTIC_TEST|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
57926351|NCT03168386|PROCEDURE|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
57926352|NCT02711488|BEHAVIORAL|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
57926353|NCT00705835|BIOLOGICAL|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
57926354|NCT00070863|BEHAVIORAL|Individual Cognitive Behavioral Therapy|
57926355|NCT05022225|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
57951145|NCT06494631|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
57951146|NCT02353156|OTHER|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
57951147|NCT02353156|OTHER|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
58278735|NCT01130324|DRUG|VIBATIV|Observational
58278736|NCT00482599|DRUG|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
58278737|NCT02249507|OTHER|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
58278738|NCT03421275|DRUG|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
58278739|NCT03421275|DRUG|Fentanyl Citrate|intravenous fentanyl given intranasally
58278740|NCT03421275|DRUG|Saline Nasal|intravenous saline given intranasally as placebo
58306686|NCT06251804|OTHER|Land-based-program|The exercise program includes a short foot exercise and will be given on land.
58306687|NCT01287936|BIOLOGICAL|SB623|SB623, a modified stem-cell product
58306688|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 1
58306689|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 2
58067937|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
58278741|NCT04649034|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
58278742|NCT04649034|DIAGNOSTIC_TEST|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
58278743|NCT04649034|DIAGNOSTIC_TEST|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
58278744|NCT04649034|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
57926356|NCT05429151|DRUG|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
58278745|NCT04649034|DIAGNOSTIC_TEST|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
58278746|NCT00615147|PROCEDURE|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
58278747|NCT02146820|DEVICE|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
58278748|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract|2 capsules, one dose
58278749|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract with mustard seed powder|2 capsules, one dose
58278750|NCT05904132|DEVICE|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
58278751|NCT01179646|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
58278752|NCT00904917|BEHAVIORAL|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
58278753|NCT00904917|BEHAVIORAL|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
58278754|NCT02376205|DRUG|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
58278755|NCT02376205|DRUG|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
58278756|NCT03585946|DRUG|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
58278757|NCT04723836|DIETARY_SUPPLEMENT|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
57926357|NCT05411367|DRUG|SI-614|1 drop in each eye
57926358|NCT05411367|DRUG|Vehicle|1 drop in each eye
57951148|NCT00385502|DRUG|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
58067938|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
58278758|NCT04723836|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
58278759|NCT04723836|DIETARY_SUPPLEMENT|Placebo|From 16th week gestation until end of pregnancy
58278760|NCT04925778|DRUG|monomethyl fumarate|Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,
57926359|NCT06341153|BEHAVIORAL|Breast Milk Odor Stimulation|In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
57926360|NCT06341153|BEHAVIORAL|Stimulation of Breast Milk Smell and Taste|In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
57926361|NCT04846374|DEVICE|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
57926362|NCT05114915|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
57926363|NCT02959450|DIETARY_SUPPLEMENT|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
57926364|NCT00903955|OTHER|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
57926365|NCT00003108|DRUG|bryostatin 1|
58067939|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
58067940|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
58278761|NCT05572892|OTHER|FAC scale|"Measurement of walking dependency according to the FAC scale :~* in the first week after stroke (in neurology by physiotherapists),~* then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
58278762|NCT04122625|DRUG|Debio 1143|Administered as capsules.
58278763|NCT04122625|DRUG|Nivolumab|Administered as IV infusion.
58278764|NCT04401202|DIETARY_SUPPLEMENT|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
58067941|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
58067942|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
58278765|NCT01529294|DRUG|Iloperidone|
58278766|NCT01118988|BEHAVIORAL|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
58278767|NCT04171141|DRUG|PF-07062119|PF-07062119
58278768|NCT04171141|DRUG|Anti-PD1|Anti-PD1 PF-06801591
58278769|NCT04171141|DRUG|Anti-VEGF|Anti-VEGF IV (bevacizumab)
58278770|NCT00825981|OTHER|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
58278771|NCT02375828|DRUG|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
58278772|NCT04577222|PROCEDURE|Technical modification during radical prostatectomy|Covering the NVB with fat
57726759|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
58067943|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
58067944|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
58278773|NCT05560009|DRUG|Fluorodopa F 18|Given IV
58278774|NCT05560009|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58278775|NCT05560009|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
58278776|NCT05560009|RADIATION|Radiation Therapy|Receive standard of care radiation therapy
58278777|NCT05560009|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
58278778|NCT00088816|DRUG|cisplatin|
58278779|NCT00088816|DRUG|tegafur-gimeracil-oteracil potassium|
58278780|NCT00088816|PROCEDURE|adjuvant therapy|
58278781|NCT00088816|PROCEDURE|conventional surgery|
58278782|NCT00088816|PROCEDURE|neoadjuvant therapy|
58278783|NCT03834714|DEVICE|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
58278784|NCT03834714|OTHER|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
58278785|NCT03834714|DEVICE|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
58278786|NCT01584505|DRUG|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
58278787|NCT01584505|DRUG|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
57726760|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
58067945|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
57726761|NCT00389324|BIOLOGICAL|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
58067946|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
58278788|NCT01584505|DRUG|CHF1535 daily dose|CHF1535 daily dose for 14 days
58278789|NCT05047484|DRUG|ALXN2050|Powder-in-capsule (PIC).
58278790|NCT05047484|DRUG|Placebo|PIC.
58278791|NCT01544764|OTHER|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
58278792|NCT05461365|DRUG|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
58278793|NCT01047124|OTHER|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
58278794|NCT03571022|BEHAVIORAL|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
58278795|NCT05964439|DEVICE|HoloUS app for ultrasound visualization|Study participants will wear HoloLens see-through glasses and use the HoloUS app for ultrasound visualization in the conduct of a vascular access procedure in a phantom.
58278796|NCT03494244|PROCEDURE|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
57726762|NCT04388293|OTHER|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
57926366|NCT00003108|DRUG|cisplatin|
57926367|NCT04727320|DRUG|Tauroursodeoxycholic acid|Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
57926368|NCT04727320|DRUG|Placebo|Oral placebo, once a day, one tablet at a time for 6 months
57926369|NCT06502873|PROCEDURE|biological samples collection|Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
57926370|NCT01165645|DRUG|lopinavir|Given orally
57926371|NCT01165645|DRUG|ritonavir|Given orally
57926372|NCT01165645|GENETIC|polymerase chain reaction|Correlative studies
57926373|NCT01165645|OTHER|flow cytometry|Correlative studies
57926374|NCT01165645|OTHER|enzyme-linked immunosorbent assay|Correlative studies
57926375|NCT01165645|OTHER|laboratory biomarker analysis|Correlative studies
57926376|NCT04731077|DEVICE|Avenir Complete Femoral Stem|All enrolled subjects will receive the Avenir Complete Femoral Stem
57926377|NCT03819010|DRUG|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
57926378|NCT03819010|DRUG|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
57926379|NCT03907410|OTHER|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
57926380|NCT03907410|OTHER|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
57926381|NCT04023721|DRUG|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
57926382|NCT04023721|DRUG|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
57926383|NCT01907802|DRUG|Dabrafenib|Given PO
57926384|NCT01907802|OTHER|Laboratory Biomarker Analysis|Correlative studies
57926385|NCT01907802|OTHER|Pharmacogenomic Study|Correlative studies
57926386|NCT01907802|OTHER|Pharmacological Study|Correlative studies
57926387|NCT01601847|DIETARY_SUPPLEMENT|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
57926388|NCT01601847|DRUG|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
57926389|NCT00409253|DRUG|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
58067947|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
58278797|NCT03494244|DEVICE|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
58278798|NCT03510221|DIETARY_SUPPLEMENT|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
58278799|NCT00914082|BEHAVIORAL|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
58278800|NCT00285792|BEHAVIORAL|Physical Activity|
58278801|NCT04045990|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
57926390|NCT00409253|DRUG|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
57926391|NCT05332184|PROCEDURE|aortic valve surgery|
57926392|NCT05329545|DRUG|Upifitimab rilsodotin|Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
57926393|NCT05329545|OTHER|Placebo|Placebo controlled arm.
57926394|NCT02882932|PROCEDURE|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
58067948|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
57926395|NCT05342220|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values \> 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
57926396|NCT05342220|PROCEDURE|Sham preconditioning|Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion
57926397|NCT04029350|DRUG|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
57926398|NCT05269836|DEVICE|Surgify Safety Burr|Use of Surgify Safety Burr in hard tissue cutting, head and spine area
57926399|NCT00913354|DEVICE|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
58067949|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
58278802|NCT01807468|PROCEDURE|haploidentical stem cell transplantation and NK cell therapy|
58278803|NCT04104997|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
58278804|NCT04104997|DRUG|Placebos|Placebo as eye drops
58278805|NCT00087464|DRUG|Emtricitabine|
58278806|NCT00087464|DRUG|Nevirapine|
58278807|NCT00087464|DRUG|Tenofovir disoproxil fumarate|
58278808|NCT01742416|PROCEDURE|Ultrasound|Arterial cannulation facilitated by ultrasound.
58278809|NCT01742416|PROCEDURE|Palpation Method|Arterial cannulation by palpation method.
58395163|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
58395164|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
58395165|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
58395166|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
58395167|NCT02912494|DRUG|JR-131|
57951149|NCT03209102|OTHER|Clinical assessment|"* Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~* and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
58395168|NCT02912494|DRUG|Darbepoetin alfa|
58395169|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
58395170|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
58395171|NCT06555016|BEHAVIORAL|Walking|Overground walking.
58395172|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
58395173|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
58395174|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
58395175|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
58395176|NCT00189800|DRUG|Solifenacin succinate|
58395177|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
58395178|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
58395179|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
58395180|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
58395181|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
58395182|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
58395183|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
58395184|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
58395185|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
58395186|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
58395187|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
58395188|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
58395189|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
58395190|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
58395191|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
58395192|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
58395193|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
58395194|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
57726763|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
58395195|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
58395196|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
58395197|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
58395198|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
58395199|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
57726764|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
57926400|NCT00913354|DEVICE|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
57926401|NCT04536753|PROCEDURE|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
57926402|NCT00438347|BEHAVIORAL|Aerobic Exercise|One hour per day three times a week for one year
57926403|NCT00438347|BEHAVIORAL|Stretching and toning|One hour per day three times a week for one year
57926404|NCT05295888|DEVICE|Temporal Interference stimulation|TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
57926405|NCT05295888|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
57926406|NCT05213754|PROCEDURE|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
57926407|NCT04342832|PROCEDURE|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
57926408|NCT01062633|DIETARY_SUPPLEMENT|A, erythritol|2,5 g 3 times a day
57926409|NCT01062633|DIETARY_SUPPLEMENT|xylitol|2,5 g 3 times a day
57926410|NCT01062633|DIETARY_SUPPLEMENT|C, sorbitol|2,5 g 3 times aday
57926411|NCT03979560|OTHER|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
58278810|NCT00489294|DRUG|Syntropin|
58278811|NCT01476397|OTHER|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
57926412|NCT01060826|OTHER|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
57926413|NCT01060826|DRUG|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
57926414|NCT01060826|DRUG|somatostatin|Intravenous bolus 250 micrograms
57926415|NCT04745767|DRUG|TAK-994|T2 formulation.
57926416|NCT04745767|DRUG|TAK-994|T1 formulation.
58278812|NCT01476397|OTHER|Test infant formula|partially hydrolyzed whey formula with probiotic
58278813|NCT03888326|DEVICE|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
58278814|NCT03888326|DEVICE|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
58278815|NCT03888326|BEHAVIORAL|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
58278816|NCT04688606|DIAGNOSTIC_TEST|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
58278817|NCT06018922|BEHAVIORAL|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
58278818|NCT00116636|DRUG|Kaletra|
58278819|NCT00520052|DRUG|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
58306690|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 3
58306691|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 4
57726765|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
57726766|NCT01359553|OTHER|Quantitative MRI imaging of knee|
57726767|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
57726768|NCT01405391|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
57926417|NCT04745767|DRUG|TAK-994|T3 formulation.
57926418|NCT04745767|DRUG|TAK-994|T4 formulation.
58278820|NCT05890300|DEVICE|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
58278821|NCT00164164|DRUG|HalfLytely|
58278822|NCT00164164|DRUG|NuLytely|
58278823|NCT06216405|PROCEDURE|Colonoscopy|Colonoscopy
58278824|NCT03387501|DRUG|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
58278825|NCT00072904|DRUG|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
58278826|NCT00072904|DRUG|Repaglinide|0.5mg tab with meals tid
58278827|NCT03015194|DEVICE|Edwards SAPIEN 3 transcatheter heart valve|"Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position."
58278828|NCT03015194|DEVICE|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
58278829|NCT06156137|OTHER|Glucose variability|A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
58278830|NCT02143167|DRUG|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
58278831|NCT02143167|DRUG|Placebo|
58278832|NCT02419794|PROCEDURE|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
58278833|NCT04656366|DIAGNOSTIC_TEST|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
58278834|NCT03406988|PROCEDURE|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
58278835|NCT03406988|PROCEDURE|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
58278836|NCT01294059|DRUG|Milnacipran|50 mg BID Oral x 6 Weeks
58278837|NCT00478907|DRUG|KETAMINE, PROPOFOL, THIOPENTAL|
58278838|NCT05905133|DRUG|CBP-201|subcutaneous injection
58278839|NCT01129804|BEHAVIORAL|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
57926419|NCT04745767|DRUG|TAK-994|T5 formulation.
57926420|NCT05098613|DRUG|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
57926421|NCT02273726|DRUG|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
58278840|NCT03259906|OTHER|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
57926422|NCT02273726|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
58278841|NCT03259906|PROCEDURE|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
58278842|NCT03259906|PROCEDURE|posterior osteosynthesis|Osteosynthesis using a posterior plate
58422699|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
57926423|NCT02729103|DRUG|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
57926424|NCT04058613|DRUG|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
57926425|NCT04058613|OTHER|placebo|placebo
57926426|NCT00149422|DEVICE|NT-proBNP measurements|
57926427|NCT06108180|OTHER|Dry Needling|3 treatment to eliminate active trigger points that patients have
57926428|NCT00454532|DRUG|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
57926429|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
57926430|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
57926431|NCT00752622|BIOLOGICAL|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
58278843|NCT03259906|PROCEDURE|Anterior osteosynthesis|Osteosynthesis using an anterior plate
58278844|NCT05018988|DIETARY_SUPPLEMENT|Oral vitamin D spray|1 spray (10µg) /day for 12 weeks
58278845|NCT05018988|DIETARY_SUPPLEMENT|Placebo|1 spray / day for 12 weeks
58278846|NCT03862092|DIAGNOSTIC_TEST|Salivary VZV-DNA PCR|VZV-DNA PCR of saliva samples
58278847|NCT04968522|DRUG|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
57926432|NCT02523560|OTHER|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
57926433|NCT02279862|DRUG|Ipilimumab|
57926434|NCT05956054|OTHER|needle type|straight or curved
57926435|NCT02929797|BIOLOGICAL|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
57926436|NCT02929797|DRUG|Gemcitabine|gemcitabine
58278848|NCT04968522|DRUG|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
58278849|NCT04968522|DRUG|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
58278850|NCT04968522|DRUG|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
58278851|NCT04968522|DRUG|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
58278852|NCT04489732|BIOLOGICAL|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland"
58278853|NCT01558713|DRUG|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
58278854|NCT01558713|DRUG|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
58278855|NCT01558713|DRUG|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
58278856|NCT01558713|DRUG|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
58395200|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
58395201|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
58395202|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
58395203|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
58395204|NCT00626509|DRUG|sunitinib malate|
57926437|NCT03502954|BIOLOGICAL|ABY-039|ABY-039
58278857|NCT01558713|DRUG|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
58278858|NCT01558713|DRUG|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
58278859|NCT02720159|DEVICE|Percutaneous Osseintegrated Prosthesis|
58278860|NCT00032630|PROCEDURE|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
58278861|NCT00032630|PROCEDURE|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
58278862|NCT02550925|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
58278863|NCT02550925|BEHAVIORAL|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
58306692|NCT05346796|BEHAVIORAL|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
58306693|NCT00218907|PROCEDURE|Educational video|
58395205|NCT00626509|PROCEDURE|adjuvant therapy|
58395206|NCT00626509|PROCEDURE|neoadjuvant therapy|
58395207|NCT00626509|PROCEDURE|therapeutic conventional surgery|
58422700|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
57926438|NCT03502954|BIOLOGICAL|Placebo|Placebo
57926439|NCT04327492|DIAGNOSTIC_TEST|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
57926440|NCT04586517|OTHER|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
57926441|NCT04586517|OTHER|Control|Activity as usual during chemotherapy
57926442|NCT02229045|DRUG|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
57926443|NCT02229045|DRUG|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
57726769|NCT04044729|DRUG|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
57726770|NCT04044729|DRUG|Placebo|Placebo
57726771|NCT06425120|DRUG|Xuesaitong Soft Capsule|Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
57726772|NCT06425120|DRUG|Placebo|Each participant in the placebo group will take matching placebo.
57926444|NCT01758263|DRUG|Metoprolol|Metoprolol, oral administration
58278864|NCT05241444|BIOLOGICAL|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood."
58278865|NCT05559684|PROCEDURE|Erector spinae plane block|Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
58306694|NCT06550492|DEVICE|smoke filtering electrocautery device|A smoke-filtering electrocautery device was used during surgery.
58306695|NCT06550492|OTHER|double mask|A double-layer mask was used during the operation.
58422701|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
58422702|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
57726773|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
57926445|NCT01758263|DRUG|Nebivolol|Nebivolol, oral administration
57926446|NCT01162213|DIETARY_SUPPLEMENT|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
57926447|NCT01453777|PROCEDURE|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
57926448|NCT01660126|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
57926449|NCT01660126|DRUG|Placebo|
57926450|NCT04461808|DIAGNOSTIC_TEST|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
57926451|NCT04461808|DIAGNOSTIC_TEST|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
57926452|NCT02513420|BEHAVIORAL|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
57926453|NCT06441721|DEVICE|Vitamin b12 measure|Measure vitamin b12 in serum and its impact on Haemodialysis patient
57926454|NCT01603082|DRUG|Ticagrelor|180 mg loading dose
57926455|NCT01603082|DRUG|Clopidogrel|600 mg loading dose
57926456|NCT01862133|OTHER|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
57926457|NCT04064983|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
57926458|NCT00003251|DRUG|amifostine trihydrate|
57926459|NCT00003251|DRUG|cisplatin|
57726774|NCT04757649|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
57726775|NCT02340039|DIETARY_SUPPLEMENT|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
57926460|NCT00003251|DRUG|paclitaxel|
57926461|NCT00003251|RADIATION|radiation therapy|
57926462|NCT06298812|DEVICE|REFLECT Scoliosis Correction System|The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials.
57926463|NCT05188326|DRUG|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
57926464|NCT05188326|OTHER|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
58395208|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
58278866|NCT05559684|PROCEDURE|Transversus thoracis plane block|Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
58278867|NCT00427427|DRUG|Trastuzumab|
58278868|NCT03472521|DRUG|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
58395209|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
58395210|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
58395211|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
58395212|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
58395213|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
58395214|NCT03673085|DRUG|CN128|CN128
58395215|NCT03673085|OTHER|placebo|The tablets without CN128
57726776|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
57726777|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
57926465|NCT02862860|BIOLOGICAL|blood sample|
57926466|NCT02862860|BIOLOGICAL|urine sample|
58278869|NCT03472521|DRUG|Placebo|Placebo to match gabapentin
58395216|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
57726778|NCT05970029|BEHAVIORAL|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
57726779|NCT00463450|DRUG|Gynodian® Depot (BAY86-5032)|Injection monthly
57726780|NCT00463450|DRUG|BAY86-4980|orally
57926467|NCT02862860|DEVICE|installation of Holter|
58067950|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
58067951|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
57726781|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
57926468|NCT03142971|PROCEDURE|focused shock wave therapy|
57926469|NCT03142971|PROCEDURE|ultrasound therapy|
57926470|NCT06076486|DRUG|Elagolix|Elagolix 200 mg tablets administered orally BID
57926471|NCT06076486|DRUG|Elagolix placebo|Elagolix placebo administered orally BID
57926472|NCT03217149|DRUG|heliox combined with MV|heliox combined with MV is given to infant with ARDS
57926473|NCT03217149|DRUG|MV|MV is given to infant with ARDS
57926474|NCT00568321|DRUG|RN624|50 mcg/kg
57926475|NCT00568321|DRUG|RN624|200 mcg/kg
58067952|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
58067953|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
58278870|NCT05202015|DRUG|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
58306696|NCT05287815|BEHAVIORAL|training/observation|In the study, elderly individuals who met the sampling criteria and accepted to participate in the study were 30 in the experimental group and 30 in the control group, using the stratified randomization method to control and balance the effects of age (65-75 years, 76 and over) and gender (female and male) variables. It will be planned to be an elderly individual. Computer-assisted randomization, which is one of the simple randomization methods, was assigned to the groups according to the determined.
58306697|NCT00049816|BEHAVIORAL|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
58306698|NCT00049816|BEHAVIORAL|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
58395217|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
58395218|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
58395219|NCT02712983|DRUG|TIP|TIP dose regimen
58395220|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
58395221|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
58395222|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
58395223|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
58395224|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
58278871|NCT01530802|PROCEDURE|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
58278872|NCT02603107|DRUG|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
58278873|NCT02603107|DRUG|ATV|300 mg capsule administered orally once daily with food
58395225|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
57726782|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
57926476|NCT00568321|DRUG|Placebo|placebo
57926477|NCT02767375|DRUG|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
57926478|NCT02767375|PROCEDURE|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
57926479|NCT00548054|BIOLOGICAL|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
57926480|NCT00548054|BIOLOGICAL|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
57926481|NCT01674751|OTHER|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
57926482|NCT00082303|BEHAVIORAL|Music Imagery|
57926483|NCT03353558|DEVICE|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
57926484|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
57926485|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
58278874|NCT02603107|DRUG|DRV|800 mg tablet administered orally once daily with food
58278875|NCT02603107|DRUG|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
58278876|NCT02603107|DRUG|ATV/co|300/150 mg FDC tablet administered orally once daily with food
58278877|NCT02603107|DRUG|DRV/co|800/150 mg FDC tablet administered orally once daily with food
58278878|NCT02603107|DRUG|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
58278879|NCT02603107|DRUG|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
58278880|NCT02603107|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
58278881|NCT04393207|DRUG|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
58278882|NCT04393207|DRUG|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
58395226|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
58395227|NCT00000805|DRUG|Ganciclovir|
58395228|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
58395229|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
58395230|NCT01777464|BIOLOGICAL|sham|sham solution
58395231|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
58422703|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
58422704|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
57726783|NCT02290665|OTHER|Saline enema|
57726784|NCT01198600|DEVICE|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
57726785|NCT01198600|DEVICE|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
57926486|NCT02860663|DIETARY_SUPPLEMENT|25OHD|10 ug/d of vitamin D3 for 6 weeks
57926487|NCT00873353|DRUG|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
57926488|NCT03208322|OTHER|Non-Interventional|Non-Interventional
57926489|NCT05016856|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System|A personalized and adaptive text message reminder system.
57926490|NCT05016856|BEHAVIORAL|Standard Reminder System (Active Control)|A typical text message reminder system.
57926491|NCT03404765|BEHAVIORAL|Tai Chi|
57926492|NCT06428136|DIAGNOSTIC_TEST|Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)|"Side-lying clamshells: 3 sets of 10 repetitions per leg, 3 times per week Hip abduction with theraband: 3 sets of 10 repetitions per leg, 3 times per week Bridge with hip abduction: 3 sets of 10 repetitions per leg, 3 times per week~Electrical muscle stimulation:~Applied to the gluteus medius and minimus muscles for 20 minutes per session, 3 times per week Frequency and intensity adjusted to individual tolerance"
58395232|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
58395233|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
58395234|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
58395235|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
58278883|NCT04393207|DRUG|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
58278884|NCT03570008|BEHAVIORAL|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
58395236|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
58278885|NCT03570008|BEHAVIORAL|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
58278886|NCT01146561|BIOLOGICAL|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
58278887|NCT01146561|OTHER|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
58278888|NCT00502099|DRUG|Pegylated interferon alpha 2a|Injections: 180 ug once per week
57926493|NCT06428136|OTHER|Conservative Treatment (CT)|Stretching: Iliotibial band stretch: 30-second hold, 3 repetitions per leg, 2 times per day Quadriceps stretch: 30-second hold, 3 repetitions per leg, 2 times per day Hamstring stretch: 30-second hold, 3 repetitions per leg, 2 times per day
58278889|NCT00502099|DRUG|Ribavirin|Tablets, 1000-1200 daily
58278890|NCT00502099|DRUG|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
58395237|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
58395238|NCT04060069|OTHER|Ringer Lactate|Fluids
58395239|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
58278891|NCT02131636|DRUG|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
58278892|NCT02131636|DRUG|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
58306699|NCT04703413|DEVICE|LoFric® OrigoTM and LoFric® SenseTM|The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
58395240|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
58067954|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
58306700|NCT06305663|DEVICE|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
58306701|NCT06305663|DEVICE|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
58395241|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
58422705|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
58422706|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
58422707|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
57726786|NCT01198600|DEVICE|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
57735422|NCT03641482|DRUG|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
57951150|NCT03209102|BEHAVIORAL|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
58067955|NCT04220645|OTHER|Standard of care|Referral at discharge
57726787|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
58067956|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
58278893|NCT05746767|BEHAVIORAL|Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
58278894|NCT05746767|BEHAVIORAL|Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
58278895|NCT03836456|BEHAVIORAL|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
58278896|NCT03836456|BEHAVIORAL|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
58395242|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
58395243|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
58395244|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
58395245|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
58395246|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
58395247|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
57726788|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
58067957|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
58067958|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
58395248|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
58067959|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
58067960|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
58395249|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
58395250|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
58395251|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
58395252|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
58067961|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
58395253|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
58395254|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
58395255|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
58395256|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
58395257|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
58278897|NCT02599337|DRUG|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
58278898|NCT02599337|DRUG|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
58422708|NCT00924404|DRUG|Saline|saline for sinus rinse
58422709|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
58422710|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
57726789|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
57726790|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
58278899|NCT00650286|DRUG|Modafinil Tablets 200 mg|200mg, single dose fed
57726791|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
58067962|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
58278900|NCT00650286|DRUG|Provigil® Tablets 200 mg|200mg, single dose fed
58278901|NCT00865657|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
58278902|NCT00865657|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
58278903|NCT05926414|DRUG|Enavogliflozin|treated with Envlo tab. 0.3mg
58278904|NCT05926414|DRUG|Enavogliflozin|Envlomet SR Tablet 0.3/1,000mg
57726792|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
57726793|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
57726794|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
57726795|NCT03067441|DRUG|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
58278905|NCT00910117|DRUG|nimotuzumab|nimotuzumab 400 mg d1
58278906|NCT00910117|DRUG|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
58278907|NCT01937715|DRUG|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
58278908|NCT01937715|DRUG|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
58278909|NCT01937715|BIOLOGICAL|Bevacizumab|5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks
58067963|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
58067964|NCT01842282|DRUG|Amlexanox|
58278910|NCT01937715|DRUG|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
58278911|NCT00899613|OTHER|laboratory biomarker analysis|
58278912|NCT00899613|PROCEDURE|study of high risk factors|
58278913|NCT04698083|DIAGNOSTIC_TEST|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
58278914|NCT02111681|DEVICE|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
57726796|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
57926494|NCT06059781|OTHER|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
58067965|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
58067966|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
58067967|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
58278915|NCT03706976|DEVICE|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
58278916|NCT05376020|DEVICE|Densah Burs|Densah Burs will be used in the intervention group
58278917|NCT05376020|DEVICE|Conventional Burs|Conventional Burs will be used in the control group
58278918|NCT04272957|DRUG|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
58278919|NCT05096598|DRUG|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
58278920|NCT05096598|DRUG|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
58278921|NCT04964167|COMBINATION_PRODUCT|Plant extract|Natural plant extract
58278922|NCT02027857|DEVICE|EIT monitoring|
58278923|NCT02027857|DEVICE|non-invasive ICP monitoring|
58278924|NCT02007278|DRUG|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
58278925|NCT02007278|DRUG|glimepiride|
58278926|NCT02007278|DRUG|Metformin|
58278927|NCT03927586|OTHER|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
58278928|NCT03927586|OTHER|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
58067968|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
58395258|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
57926495|NCT06059781|OTHER|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
57926496|NCT02864381|DRUG|Andecaliximab|800 mg administered via IV infusion
57926497|NCT02864381|DRUG|Nivolumab|3 mg/kg administered via IV infusion
57926498|NCT06209346|OTHER|TeleRehab Group|"The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform."
57926499|NCT06209346|OTHER|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
57926500|NCT01026142|DRUG|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
58278929|NCT06509347|OTHER|Preassure release|Preassure release in Flexor digitorum brevis trigger point muscle.
58278930|NCT06509347|OTHER|Non-emision laser|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
58395259|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
58395260|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
58395261|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
58395262|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
58395263|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
58395264|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
58395265|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
57926501|NCT01026142|DRUG|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
57926502|NCT01026142|DRUG|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
57926503|NCT01026142|DRUG|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
57926504|NCT04178967|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
57735423|NCT03641482|DEVICE|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
57926505|NCT04178967|OTHER|Placebo|Subcutaneous Injection
57926506|NCT03717948|OTHER|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
57926507|NCT03717948|OTHER|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
57735424|NCT05795725|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
57735425|NCT05795725|PROCEDURE|Colonoscopy|Colonoscopy procedure
57926508|NCT00906360|DRUG|sunitinib malate|Given orally or by percutaneous gastrostomy tube
57926509|NCT00906360|OTHER|pharmacological study|Correlative studies
57926510|NCT00906360|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
57926511|NCT00906360|BIOLOGICAL|cetuximab|Given IV
58278931|NCT02731170|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
57926512|NCT03492788|OTHER|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
57926513|NCT03492788|OTHER|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
57926514|NCT03553654|DIAGNOSTIC_TEST|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
57726797|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
57926515|NCT06178237|DEVICE|Purabond|Application of Purabond to surgical field
57926516|NCT03037164|DEVICE|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
58278932|NCT03519100|OTHER|quality of life evaluation|quality of life evaluation post surgery
58278933|NCT00275665|DRUG|Valganciclovir|
57726798|NCT04725331|BIOLOGICAL|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.
57726799|NCT04725331|DRUG|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
57726800|NCT01786356|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
57726801|NCT01786356|OTHER|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
58278934|NCT04269824|BEHAVIORAL|Behavioral intervention package|"Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior"
58278935|NCT04123379|DRUG|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
58278936|NCT04123379|DRUG|BMS-813160|300mg oral twice a day for 28 days
57726802|NCT04660357|OTHER|survey study|survey study
57926517|NCT03037164|DEVICE|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
57926518|NCT03679806|OTHER|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
58067969|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
58278937|NCT04123379|DRUG|BMS-986253|2400mg once by injection
58278938|NCT05485233|DEVICE|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
58278939|NCT01072747|BIOLOGICAL|bovine heparin|5.000UI/mL bottle with 5mL
58278940|NCT01072747|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
58395266|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
58395267|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
58395268|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
58067970|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
58395269|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
58395270|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
58278941|NCT03879551|DEVICE|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
58278942|NCT01122459|OTHER|fluid administration|1.5mls/kg/hr fasting
58278943|NCT02875717|DRUG|Acetylsalicylic acid|
58278944|NCT02875717|DRUG|low molecular weight heparin|
58278945|NCT04659317|DRUG|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
58278946|NCT04659317|DRUG|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
58278947|NCT01858025|RADIATION|Pencil Beam scanning Radiation|
58278948|NCT01858025|DRUG|5-fluorouracil|
58278949|NCT01858025|DRUG|Mitomycin-C|
58278950|NCT01773018|DRUG|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
58278951|NCT01689753|DEVICE|TEGO connector®|
58278952|NCT01689753|DRUG|Trisodium citrate|
58395271|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
58278953|NCT04671355|DRUG|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
58278954|NCT04671355|DRUG|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
58278955|NCT05905250|BEHAVIORAL|an empirically supported protocol, further refined with evidence-based strategies|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
58278956|NCT05905250|BEHAVIORAL|Health education|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
58278957|NCT03706469|DRUG|TAK-831 T2|TAK-831 T2 Tablets.
58278958|NCT03706469|DRUG|TAK-831 T3|TAK-831 T3 Tablets.
58278959|NCT02084433|PROCEDURE|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
58278960|NCT02084433|PROCEDURE|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
58278961|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
58278962|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
58278963|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
58278964|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
58395272|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
58067971|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
58067972|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
58278965|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
58278966|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
58278967|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
58395273|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
58395274|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
58395275|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
58278968|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
58278969|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
58278970|NCT03275389|BIOLOGICAL|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
58278971|NCT03275389|BIOLOGICAL|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
58278972|NCT04974606|DIETARY_SUPPLEMENT|Cherry-flavored still beverage|10 oz bottle
58278973|NCT04974606|OTHER|Placebo cherry-flavored still beverage|10 oz bottle
58278974|NCT00701571|PROCEDURE|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
58278975|NCT04344522|PROCEDURE|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
58278976|NCT04344522|PROCEDURE|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
58278977|NCT04344522|PROCEDURE|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
58278978|NCT04344522|PROCEDURE|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
58278979|NCT05363813|DEVICE|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
58278980|NCT00893971|DRUG|PT001|Inhaled PT001, single dose
58278981|NCT00893971|DRUG|PT005|Inhaled PT005, single dose
58278982|NCT00893971|DRUG|PT003|Inhaled PT003, single dose
58278983|NCT00893971|DRUG|PT001 + PT005|Inhaled PT001 + PT005, single dose
58278984|NCT03947775|DRUG|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
58278985|NCT04505306|PROCEDURE|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
58278986|NCT01051726|OTHER|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
58278987|NCT01051726|OTHER|None essential oil|Baby oil
58278988|NCT03825185|PROCEDURE|Transcervical Thymectomy|Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.
58395276|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
58395277|NCT05241860|OTHER|Follow-Up|Undergo follow-up
58395278|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
58395279|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
58395280|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
58395281|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
57926519|NCT03679806|OTHER|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
57926520|NCT02926131|OTHER|Blood sampling|"* One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
57926521|NCT00278460|DRUG|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
57926522|NCT00278460|DRUG|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
57926523|NCT02521467|BIOLOGICAL|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
58278989|NCT03825185|PROCEDURE|Transsternal Thymectomy|Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
58278990|NCT01110785|BIOLOGICAL|panitumumab|
58278991|NCT01110785|DRUG|simvastatin|
58278992|NCT01110785|OTHER|laboratory biomarker analysis|
58278993|NCT02703896|DRUG|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
58278994|NCT02703896|PROCEDURE|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
58278995|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|"* individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks"
58278996|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|- placebo treatment: sham coil
58278997|NCT03529708|RADIATION|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
58278998|NCT05396352|DEVICE|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
58278999|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|280 mg three times daily for four weeks
58279000|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|420 mg three times daily for four weeks
58279001|NCT00755950|OTHER|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
58279002|NCT02242019|DEVICE|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
58279003|NCT03688802|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
58279004|NCT03688802|DRUG|Placebo (vehicle control) nasal spray|Placebo
57926524|NCT02521467|OTHER|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
57926525|NCT06082089|BEHAVIORAL|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
57926526|NCT00934141|OTHER|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
58067973|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
58279005|NCT00423813|DRUG|placebo|Oral Solution
58279006|NCT00423813|DRUG|Xyrem®|two doses
58279007|NCT04418089|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
58279008|NCT04418089|DRUG|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
58279009|NCT01017757|PROCEDURE|High-resolution CT scanning|High-resolution CT scanning
58279010|NCT03518398|DEVICE|Intense Pulsed Light|E\> Eye (E-SWIN, Paris, France) IPL machine
58279011|NCT03518398|COMBINATION_PRODUCT|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
58279012|NCT01900899|PROCEDURE|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
58279013|NCT05974228|DEVICE|Bioactive glass wound dressing|Bioactive glass wound dressing is a dressing covered on the wound bed
58395282|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
57926527|NCT00934141|OTHER|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
57926528|NCT00934141|OTHER|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
57926529|NCT00934141|OTHER|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
57926530|NCT04994327|OTHER|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
57926531|NCT04632472|DEVICE|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
57926532|NCT04744441|PROCEDURE|CHOLECYSTECTOMY|Surgical treatment
57926533|NCT04744441|PROCEDURE|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
57926534|NCT04744441|PROCEDURE|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
57926535|NCT03744325|DIETARY_SUPPLEMENT|Hen's egg OIT|Increasing doses of egg white protein administered orally
57926536|NCT03224325|DRUG|TAK-831 Tablet T2|Tak-831 tablets.
57926537|NCT03224325|DRUG|Placebo|TAK-831 placebo-matching suspension.
57926538|NCT03224325|DRUG|TAK-831 Suspension|TAK-831 Suspension.
57926539|NCT02643160|OTHER|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
57926540|NCT00186069|DRUG|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
57926541|NCT00186069|OTHER|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
58279014|NCT03153345|DEVICE|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
58279015|NCT03153345|BEHAVIORAL|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
58279016|NCT04716036|OTHER|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
58279017|NCT04716036|OTHER|Placebo beverage|placebo beverage condition.
58279018|NCT03200977|OTHER|Non-Interventional|Non-Interventional
58279019|NCT03289299|DRUG|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
58279020|NCT03289299|DRUG|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
58279021|NCT03289299|DRUG|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
58395283|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
57726803|NCT04157244|BEHAVIORAL|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
58395284|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
57926542|NCT03496480|DIAGNOSTIC_TEST|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
57926543|NCT04051788|OTHER|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
57926544|NCT04051788|OTHER|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
57926545|NCT04376853|DEVICE|Apple Watch Series 5|Digital monitoring via Apple Watch
57926546|NCT04286698|OTHER|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes \[25\]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
58067974|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
58067975|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
58067976|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
58067977|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
58067978|NCT00000291|DRUG|Labetalol|
58395285|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
57926547|NCT04286698|OTHER|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point \[3\]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
58067979|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
57926548|NCT00002790|DRUG|cyclosporine|
57926549|NCT00002790|DRUG|methotrexate|
57926550|NCT00002790|DRUG|sirolimus|
57926551|NCT00470145|DRUG|SB-568859|
57926552|NCT04237922|DRUG|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
57726804|NCT00359112|DRUG|metformin|
57726805|NCT00359112|DRUG|sulphonylurea|
57726806|NCT00359112|DRUG|Avandamet|
57726807|NCT04408469|BEHAVIORAL|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
57926553|NCT04237922|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
57926554|NCT00106522|DRUG|Methotrexate|10-25mg weekly
57926555|NCT00106522|DRUG|Placebo|iv every 4 weeks
57926556|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
57926557|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
58067980|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
58067981|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
57926558|NCT00697723|PROCEDURE|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
58067982|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
57926559|NCT01774084|DIETARY_SUPPLEMENT|Experimental: PreOp, NutriciaNordica AB|
57926560|NCT01774084|DIETARY_SUPPLEMENT|Placebo Comparator: Water|
57926561|NCT01366287|DRUG|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
57926562|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
57926563|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
58067983|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
58067984|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
58067985|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
58067986|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
58067987|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
58067988|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
58279022|NCT03289299|DRUG|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
58067989|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
58067990|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
58279023|NCT03435159|DIAGNOSTIC_TEST|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
57726808|NCT04408469|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
58395286|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
57726809|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
57926564|NCT00622882|OTHER|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
57926565|NCT02367365|OTHER|No Intervention|No intervention
57926566|NCT02367365|OTHER|No Intervention|No intervention
57926567|NCT04201821|BIOLOGICAL|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
57926568|NCT05843513|OTHER|Monitoring (observational study)|The relationship between dental wear and the behaviour of the participants will be analysed.
57926569|NCT05743322|DEVICE|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
57926570|NCT05197023|DRUG|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
57926571|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
57926572|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
57926573|NCT00866697|DRUG|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
57926574|NCT00866697|DRUG|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
57926575|NCT05147883|BEHAVIORAL|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
57926576|NCT05313126|OTHER|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
57926577|NCT03408782|PROCEDURE|Insertion of drainage|
57926578|NCT05785702|DEVICE|The anti-wandering system|During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
57926579|NCT00972777|DRUG|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
58395287|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
58395288|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
58395289|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
58395290|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
57926580|NCT00972777|DRUG|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
58395291|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
58422711|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
58279024|NCT03435159|PROCEDURE|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
57926581|NCT00080496|DRUG|Tigecycline|
57926582|NCT00080496|DRUG|Imipenem|
57926583|NCT00080496|DRUG|Cilastatin|
57926584|NCT00416169|DRUG|galantamine hydrobromide|
57726810|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
57726811|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
57726812|NCT06494111|DRUG|Pravastatin|Given by PO
57726813|NCT06494111|DRUG|Pentoxifylline|Given by PO
57726814|NCT06494111|DRUG|Tocopherol|Given by PO
57726815|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
57926585|NCT01475552|DRUG|Abciximab|Patients, who showed PRU \>270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
57926586|NCT01475552|DRUG|control|"Patients,who showed PRU \>270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
57926587|NCT05781633|DRUG|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
58067991|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
58067992|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
58279025|NCT03435159|DEVICE|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
58279026|NCT02419651|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
58279027|NCT02419651|DRUG|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
58279028|NCT02419651|DRUG|Placebo|Women will receive a placebo 1 hour before the procedure
58279029|NCT02859519|DRUG|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
58279030|NCT02859519|DRUG|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
58279031|NCT02557516|DRUG|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
58279032|NCT00609713|BEHAVIORAL|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
58279033|NCT00609713|OTHER|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
58279034|NCT05546814|PROCEDURE|Sodium algorithm|Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
58279035|NCT04091204|DRUG|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
58279036|NCT05637190|OTHER|Expressive Arts Therapy group intervention|Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
58279037|NCT02481180|DRUG|T0001|injection (SC) T0001 15mg weekly for 12 weeks
58279038|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg weekly for 12 weeks
58279039|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
58279040|NCT02481180|DRUG|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
58279041|NCT02481180|DRUG|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
58395292|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
58067993|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
57726816|NCT01391377|DRUG|Sugar pill|Placebo
58067994|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
57926588|NCT04631627|DRUG|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
57926589|NCT04283981|DEVICE|Control group without use of VSP|The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)
58279042|NCT01139671|DRUG|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
58279043|NCT04625933|OTHER|No intervention|No intervention
58279044|NCT02254798|OTHER|no intervention|this is a non interventional study
58279045|NCT00892515|BEHAVIORAL|exercise intervention|
58395293|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
58395294|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
58395295|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
58395296|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
57726817|NCT05902715|DEVICE|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
57726818|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
57926590|NCT04283981|DEVICE|Treatment Group with use of VSP|The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
58279046|NCT00892515|OTHER|counseling intervention|
58279047|NCT00892515|OTHER|gas chromatography|
58279048|NCT00892515|OTHER|immunoenzyme technique|
58279049|NCT00892515|OTHER|immunologic technique|
58279050|NCT00892515|OTHER|laboratory biomarker analysis|
58279051|NCT00892515|OTHER|mass spectrometry|
58395297|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
58395298|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
58395299|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
58395300|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
58395301|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
58279052|NCT00892515|OTHER|physiologic testing|
58279053|NCT00892515|OTHER|questionnaire administration|
57726819|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
57726820|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
57726821|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
58279054|NCT00892515|OTHER|survey administration|
58279055|NCT00892515|PROCEDURE|dual x-ray absorptometry|
58279056|NCT00892515|PROCEDURE|magnetic resonance imaging|
58279057|NCT00892515|PROCEDURE|study of high risk factors|
58279058|NCT01317524|DIETARY_SUPPLEMENT|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
58279059|NCT01317524|DIETARY_SUPPLEMENT|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
58279060|NCT01317524|DIETARY_SUPPLEMENT|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
58279061|NCT01881698|OTHER|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
58279062|NCT03807622|DEVICE|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
58279063|NCT03054285|DRUG|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
58279064|NCT00634686|DIETARY_SUPPLEMENT|DHA/EPA|1.2 gram capsule daily for 6 months
58279065|NCT00634686|DIETARY_SUPPLEMENT|Placebo capsule|daily for 6 months
57926591|NCT00999713|DRUG|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
57926592|NCT00999713|OTHER|Air placebo|Endotracheal air administration
57926593|NCT02031939|DRUG|Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
57926594|NCT02031939|RADIATION|standard chemoradiotherapy|All rectal patients in this group will receive standard radiotherapy and surgical resection.
58067995|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
58067996|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
58067997|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
58067998|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
58067999|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
58068000|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
58395302|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
58395303|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
57726822|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
57726823|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
57726824|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
57726825|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
57926595|NCT06037369|BEHAVIORAL|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
58068001|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
57726826|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
57726827|NCT03827629|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
58068002|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
57726828|NCT03827629|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
57926596|NCT03421431|DRUG|EDP-305 Dose 1|Two tablets daily for 12 weeks
58279066|NCT00634686|DIETARY_SUPPLEMENT|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
57726829|NCT03827629|DRUG|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
57726830|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
57726831|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
58279067|NCT01897792|DIETARY_SUPPLEMENT|Vitamin C|
57726832|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
57726833|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
57726834|NCT06461858|OTHER|cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks
57726835|NCT06461858|OTHER|conventional therapy|Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
57926597|NCT03421431|DRUG|EDP-305 Dose 2|Two tablets daily for 12 weeks
57926598|NCT03421431|DRUG|Placebo|Two tablets daily for 12 weeks
57926599|NCT04014361|DRUG|LY3154885 - Capsule|Administered orally.
57926600|NCT04014361|DRUG|Placebo - Capsule|Administered orally.
57926601|NCT04014361|DRUG|Itraconazole|Administered orally.
57926602|NCT04014361|DRUG|LY3154885 - Tablet|Administered orally.
58068003|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
58068004|NCT03802331|DRUG|BI 1323495,|single oral doses
58279068|NCT01897792|DIETARY_SUPPLEMENT|Vitamin E|
58279069|NCT01897792|DIETARY_SUPPLEMENT|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
58279070|NCT01897792|DRUG|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
58279071|NCT01146028|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
58395304|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
58395305|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
57926603|NCT03592290|DIAGNOSTIC_TEST|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
57926604|NCT01659372|RADIATION|low level laser therapy|
57926605|NCT01659372|DRUG|Naproxen|
57926606|NCT03255837|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
57926607|NCT02796820|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
57926608|NCT06029725|DEVICE|radiofrequency microneedling combined with 1927 nm thulium laser|"1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy"
57926609|NCT06029725|DEVICE|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
57926610|NCT02249767|DRUG|Tretinoin|Treatment of acne once daily in evening
57926611|NCT00226187|PROCEDURE|Supplement of fatty acid (DHA and AA)|
57926612|NCT03249714|DRUG|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
57926613|NCT03249714|DRUG|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
57926614|NCT06347653|DRUG|linperlisib combined with CHOP regimen|"Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles."
57926615|NCT06339619|DRUG|Adebrelimab|20mg/kg ivgtt D1 Q3W
57926616|NCT06339619|DRUG|Apatinib|250mg PO QD
57926617|NCT06339619|DRUG|Tegafur|dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
57926618|NCT02730988|BEHAVIORAL|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
57726836|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
57726837|NCT01286779|BIOLOGICAL|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
57926619|NCT02715167|DRUG|Budesonide novolizer|
57926620|NCT02715167|DRUG|Placebo|
57926621|NCT01765192|DRUG|Roflumilast|Roflumilast was supplied in tablets.
57926622|NCT01765192|DRUG|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
58279072|NCT06052514|DEVICE|Continuous positive airway pressure|Patients with moderate or severe OSA will be treated with CPAP
57926623|NCT01765192|DRUG|Montelukast|Montelukast was supplied in tablets.
57926624|NCT01071135|DRUG|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
58279073|NCT03653312|DEVICE|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
57926625|NCT00247585|DRUG|Ethanol (Bourbon or Vodka)|
57926626|NCT02437734|PROCEDURE|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
57926627|NCT04390750|BEHAVIORAL|Care Partner-Assisted Intervention|Tailored teaching and coaching
57926628|NCT04569383|BIOLOGICAL|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
57926629|NCT04569383|BIOLOGICAL|Comirnaty|Vaccination with Comirnaty (21 day interval)
57926630|NCT03966261|OTHER|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
57926631|NCT02949960|DRUG|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
57926632|NCT02949960|DRUG|Vehicle Control|Topical Vehicle Gel applied twice daily
58279074|NCT02983253|OTHER|blood sample|none, only laboratory tests on blood serum
57926633|NCT00372749|BEHAVIORAL|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
57926634|NCT03786250|PROCEDURE|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
57926635|NCT03392506|DEVICE|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
57926636|NCT05073887|PROCEDURE|Current Targets|blockade and radio frequency stimulation of genicular nerves
57926637|NCT00457184|PROCEDURE|Blood tests|
58279075|NCT04178616|DIAGNOSTIC_TEST|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
58279076|NCT03609190|DRUG|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
58279077|NCT03609190|DRUG|Placebo|i.v. infusion of NaCl over 40 min
58279078|NCT05464082|OTHER|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
58068005|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
58279079|NCT03307187|BEHAVIORAL|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
58279080|NCT03996226|DRUG|E7386|E7386 oral tablets.
58279081|NCT04229056|BEHAVIORAL|Computer-based cognitive rehabilitation (CBCR)|CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
58279082|NCT04229056|BEHAVIORAL|General computer-based cognitive stimulation|For this trial we have developed a webpage for cognitive sham-training, which is designed to provide general computer-based cognitive stimulation.
58279083|NCT03214549|PROCEDURE|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
58068006|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
58068007|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
58279084|NCT03214549|PROCEDURE|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
58279085|NCT00683306|DRUG|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
58279086|NCT03776526|BEHAVIORAL|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
58279087|NCT02334384|BIOLOGICAL|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
58279088|NCT00003781|DRUG|docetaxel|
58279089|NCT00003781|PROCEDURE|pain therapy|
58279090|NCT00003781|PROCEDURE|quality-of-life assessment|
57926638|NCT03271346|BEHAVIORAL|intensive trauma-focused therapy|
57926639|NCT03085108|OTHER|No Intervention|No Intervention
57926640|NCT02016833|PROCEDURE|Blood Sampling|Sampling of 80mL of whole blood
57926641|NCT00512304|PROCEDURE|association chemotherapy and radiochemotherapy|
57926642|NCT01869257|DEVICE|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
57926643|NCT01869257|DEVICE|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
57926644|NCT02537938|DRUG|NGP 555|
57926645|NCT02821468|DRUG|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
57926646|NCT02821468|DRUG|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
57926647|NCT05918939|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
57926648|NCT05918939|BIOLOGICAL|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
57926649|NCT05350878|OTHER|Implementation Intervention|Virtual and in-person implementation support
57926650|NCT00276588|DRUG|carboplatin|
57926651|NCT00276588|DRUG|gemcitabine hydrochloride|
57926652|NCT00276588|DRUG|paclitaxel|
58279091|NCT02720861|GENETIC|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
58395306|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
57726838|NCT01601587|OTHER|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
57926653|NCT06513286|BIOLOGICAL|TherVacB (HEPLISAV B)|Administration of the described combinations via the intramuscular route
57926654|NCT06513286|BIOLOGICAL|TherVacB (HBsAg ± c-di-AMP)|Administration of the described combinations via the intramuscular route
57926655|NCT01087112|BEHAVIORAL|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
58279092|NCT04290377|DEVICE|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
58279093|NCT04290377|OTHER|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
58279094|NCT04060771|DRUG|Palonosetron|prophylaxis of postoperative nausea and vomiting
58279095|NCT04060771|DRUG|Dexamethasone|prophylaxis of postoperative nausea and vomiting
58279096|NCT02508415|OTHER|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
58279097|NCT00635986|DRUG|Fentanyl|100 mcg Fentanyl intravenous or epidural route
58279098|NCT03055494|BIOLOGICAL|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
58279099|NCT03055494|BIOLOGICAL|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
58279100|NCT02305524|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
58395307|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
58395308|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
58395309|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
58395310|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
58395311|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
58395312|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
58395313|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
58395314|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
58395315|NCT06652412|DRUG|Sintilimab|200 mg q3w
57926656|NCT01087112|BEHAVIORAL|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
58279101|NCT02305524|DEVICE|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
58279102|NCT00653978|PROCEDURE|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
58279103|NCT00653978|PROCEDURE|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
58395316|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
58279104|NCT04938596|COMBINATION_PRODUCT|Respiratory bundle|"* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~* Promotion of strategies to improve house ventilation during 2 weeks~* Provision of a TB leaflet and nurse education about TB transmission."
58279105|NCT01560715|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
58395317|NCT06652412|DRUG|Raltitrexed|Raltitrexed
58395318|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
58395319|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
58395320|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
58395321|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
57926657|NCT04047654|DRUG|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
57926658|NCT00215878|DRUG|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
58068008|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
58279106|NCT05058092|DEVICE|Immediate Remedee Solution|"* D0 to M3: Remedee Solution + medical care~* M3 to M6: Remedee Solution without personalized support + medical care~* M6 to M9: medical care only"
58279107|NCT05058092|DEVICE|Delayed Remedee Solution|"* D0 to M3: medical care only~* M3 to M6: Remedee Solution + medical care~* M6 to M9: Remedee Solution without personalized support + medical care"
58279108|NCT05437016|BEHAVIORAL|HUBER exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.
58279109|NCT05437016|BEHAVIORAL|Standard exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
58279110|NCT03557814|DEVICE|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
58279111|NCT03557814|DEVICE|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
58279112|NCT03557814|DEVICE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
58279113|NCT02773420|PROCEDURE|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
58279114|NCT03501654|DEVICE|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
58279115|NCT02584959|DRUG|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days
58279116|NCT02584959|DRUG|Placebo|Placebo
58279117|NCT00830583|PROCEDURE|blood test|There is only a blood test at the beginning.
58279118|NCT03510429|DIETARY_SUPPLEMENT|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
58279119|NCT03510429|OTHER|Routine post-op care|Routine post-operative care
57926659|NCT04239521|OTHER|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
57926660|NCT01138007|DRUG|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
58068009|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
58279120|NCT04136262|DRUG|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
58279121|NCT04136262|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
58279122|NCT04136262|OTHER|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
58068010|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
58068011|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
58068012|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
58279123|NCT02414789|PROCEDURE|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
58279124|NCT01938989|DEVICE|Clear clip-on glasses|Clip-on glasses with no light filtering properties
58279125|NCT01938989|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
57926661|NCT01138007|DRUG|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
58279126|NCT00166049|BEHAVIORAL|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
58279127|NCT00166049|BEHAVIORAL|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
58279128|NCT00166049|BEHAVIORAL|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
58279129|NCT02219386|OTHER|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
58279130|NCT02219386|OTHER|group 2. Passive analitical stretch (performed in both groups)|
58395322|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
58395323|NCT02676947|DRUG|Tocilizumab|
58395324|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
58395325|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
58395326|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
57726839|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
57726840|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
57726841|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
57926662|NCT04643509|DEVICE|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
57926663|NCT04154410|OTHER|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
57926664|NCT04154410|OTHER|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
57926665|NCT02536703|DEVICE|Lotus Valve System|Lotus Valve System
57926666|NCT05147623|PROCEDURE|Any surgery/procedure|Any surgery/procedure in all adult patients that were performed in an operating room
57926667|NCT04217590|DRUG|Sodium Zirconium Cyclosilicate|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
57926668|NCT04217590|DRUG|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
57926669|NCT03493841|DRUG|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
57926670|NCT01594866|DRUG|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
57926671|NCT01594866|DRUG|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
57926672|NCT02231125|DRUG|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
58279131|NCT03774394|DRUG|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
57926673|NCT02231125|DRUG|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
57926674|NCT04160169|OTHER|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
57926675|NCT02673151|PROCEDURE|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
57926676|NCT02673151|DRUG|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
57926677|NCT02673151|PROCEDURE|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
57926678|NCT01375361|DRUG|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
57926679|NCT01375361|DRUG|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
57926680|NCT00730834|DEVICE|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
57926681|NCT01050348|DRUG|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
57926682|NCT01050348|DRUG|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
57926683|NCT06027723|DRUG|Nicotine|Nicotine delivered through a vape
57926684|NCT06027723|OTHER|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
57926685|NCT01244243|DEVICE|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
57926686|NCT03140774|BIOLOGICAL|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
57926687|NCT01174238|DRUG|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
57926688|NCT01174238|DRUG|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
58068013|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
58068014|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
57926689|NCT01174238|DRUG|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
57926690|NCT03064386|PROCEDURE|Plate fixation|internal fixation with the plate
57926691|NCT03064386|PROCEDURE|Screw fixation|internal fixation with the screw
58068015|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
58068016|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
58068017|NCT02185040|DRUG|Placebo|Matching oral placebo daily
58068018|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
58068019|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
58068020|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
57726842|NCT00871559|DRUG|REGN421(SAR153192)|
57726843|NCT04414982|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
57726844|NCT04414982|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
57726845|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
57926692|NCT01832363|DRUG|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
57926693|NCT01832363|OTHER|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
57726846|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
57726847|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
57926694|NCT03628365|DIETARY_SUPPLEMENT|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
57926695|NCT00330850|DRUG|PRO-513|
58279132|NCT03774394|DRUG|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
57726848|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
57726849|NCT03190382|OTHER|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
57726850|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
57726851|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
57726852|NCT00383435|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
57726853|NCT00383435|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
57726854|NCT00383435|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
57726855|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
57726856|NCT00139750|DRUG|CP-526,555 (varenicline)|
57726857|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
57726858|NCT04421144|PROCEDURE|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
57926696|NCT00047203|DRUG|alvocidib|Given IV
57926697|NCT03258333|PROCEDURE|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
57926698|NCT03437018|OTHER|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
58279133|NCT02445131|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
57726859|NCT00668460|DRUG|Lactic acid (Dermacid)|
58279134|NCT02445131|DRUG|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
57726860|NCT04169841|DRUG|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
57726861|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
57926699|NCT03975023|DEVICE|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
57926700|NCT00455325|DRUG|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
57926701|NCT00455325|DRUG|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
57926702|NCT00455325|DRUG|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
57926703|NCT00455325|DRUG|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
57926704|NCT03673865|DEVICE|office-based 3-dimensional printers (OB3DP)|In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.
58279135|NCT02445131|DRUG|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
58279136|NCT04895488|DRUG|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
57726862|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
57726863|NCT01681693|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
57726864|NCT01663493|PROCEDURE|FNB|
57726865|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
57726866|NCT02055352|DRUG|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
57726867|NCT02055352|DRUG|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
57726868|NCT02055352|DRUG|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
57726869|NCT02055352|DRUG|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
57735426|NCT05184725|DEVICE|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
57926705|NCT03673865|DEVICE|standard stock orbital plate|In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
57926706|NCT03937726|OTHER|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
57926707|NCT03937726|OTHER|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
57926708|NCT04379050|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
57926709|NCT04024748|DEVICE|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
57926710|NCT06233721|OTHER|Online education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
58279137|NCT04895488|DRUG|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
58422712|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
58422713|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
57926711|NCT06233721|OTHER|Face-to-face education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
57926712|NCT01394471|DRUG|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
58068021|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
57926713|NCT01585636|DRUG|SQ109|Single oral dose
57926714|NCT03638934|OTHER|Videos about ACP|Three videos about advanced care planning are provided for self-education.
57726870|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
57726871|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
57726872|NCT01053858|PROCEDURE|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
57726873|NCT02553330|DRUG|Placebo Cream|
57726874|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
57926715|NCT03638934|OTHER|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
57926716|NCT01215422|PROCEDURE|timed intubation|timed intubation
57926717|NCT06362590|DRUG|ladiratuzumab vedotin|
57926718|NCT02209337|DEVICE|SRS|
57926719|NCT03926156|DRUG|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
58068022|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
58068023|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
58422714|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
58422715|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
57726875|NCT04461522|PROCEDURE|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
57726876|NCT03219944|PROCEDURE|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
57726877|NCT03219944|PROCEDURE|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
57726878|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
57726879|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
57726880|NCT01185574|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
57726881|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
57726882|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
58422716|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
58422717|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
58422718|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
57726883|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
57926720|NCT03926156|DRUG|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
57926721|NCT03359590|DRUG|Sitagliptin 100 mg|The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
58279138|NCT01990716|OTHER|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
57926722|NCT03359590|DRUG|Placebo|The treatment consists of placebo tablets for up to 24 weeks.
57926723|NCT03240913|BEHAVIORAL|Baseline and Follow-up Surveys|(completed online)
57926724|NCT03240913|OTHER|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
58279139|NCT06498726|DEVICE|transcranial doppler|Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
58279140|NCT03489200|OTHER|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
58279141|NCT03489200|OTHER|Placebo|No intervention- placebo
58279142|NCT05049473|DRUG|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
58279143|NCT05049473|DRUG|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
58279144|NCT05049473|DRUG|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.
58279145|NCT05049473|DRUG|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*."
58279146|NCT05049473|DRUG|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*
58279147|NCT05049473|DRUG|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.
58279148|NCT05049473|DRUG|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*
58279149|NCT05049473|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
58279150|NCT05049473|DRUG|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
58279151|NCT05049473|DRUG|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
58279152|NCT05049473|DRUG|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
58279153|NCT05049473|DRUG|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
58279154|NCT05049473|DRUG|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
58279155|NCT05049473|DRUG|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
57726884|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
57926725|NCT03240913|OTHER|Pamphlet|(usual care)
57926726|NCT02832700|DIETARY_SUPPLEMENT|Casein glycomacropeptide|
58279156|NCT04114656|DRUG|Placebo|Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).
57726885|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
57726886|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
57926727|NCT02832700|DIETARY_SUPPLEMENT|Placebo|
57926728|NCT03665896|DEVICE|intubation with VivaSight double-lumen tube|
57926729|NCT03665896|DEVICE|intubation with standard double-lumen tube|
57926730|NCT03665896|PROCEDURE|fiberoptic bronchoscopy|
58279157|NCT04114656|DRUG|GSK3858279|GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
58279158|NCT02470663|DIETARY_SUPPLEMENT|DENSITYTM caplets (marketed as Amorphical)|supplementation
58395327|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
58395328|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
57726887|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
57726888|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
58279159|NCT02470663|DIETARY_SUPPLEMENT|Calcium carbonate 600 mg once daily|supplementation
58279160|NCT04881279|OTHER|Event|Ransomware attack
58279161|NCT03066778|BIOLOGICAL|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
58279162|NCT03066778|DRUG|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
58279163|NCT03066778|DRUG|Carboplatin|IV infusion on Day 1 of each cycle
58279164|NCT03066778|DRUG|Cisplatin|IV infusion on Day 1 of each cycle
58279165|NCT03066778|DRUG|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
58279166|NCT01096498|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
58279167|NCT01096498|DRUG|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
58279168|NCT01348100|DRUG|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
57726889|NCT01332305|DRUG|Placebo|Placebo orally once daily
57726890|NCT00374530|DRUG|PGE2|
57726891|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
57735427|NCT05549037|DRUG|Pembrolizumab, Sintilimab|One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
58279169|NCT01348100|DRUG|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
58279170|NCT01348100|DRUG|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
58279171|NCT06275737|OTHER|Prehabilitation program|"Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)"
58279172|NCT04535557|DRUG|Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
58279173|NCT03051373|DRUG|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
58279174|NCT03051373|DRUG|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
58279175|NCT06396299|OTHER|No intervention|No intervention
58279176|NCT00123682|PROCEDURE|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
58279177|NCT00123682|PROCEDURE|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
58279178|NCT00123682|PROCEDURE|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
58279179|NCT00123682|PROCEDURE|Self-help|Project staff send out self-help materials for smoking cessation
58068024|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
58068025|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
58068026|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
57926731|NCT01217268|BEHAVIORAL|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
57926732|NCT02850211|DRUG|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
57926733|NCT02850211|DRUG|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
57926734|NCT02850211|DRUG|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
57926735|NCT05810272|BEHAVIORAL|Metabolic Trial|Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
57926736|NCT05810272|BEHAVIORAL|15 sit-to-stands with calf raises|Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
58068027|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
58068028|NCT03054311|BEHAVIORAL|Lifestyle Matters|
58279180|NCT02074319|DRUG|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
58068029|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
58068030|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
58395329|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
57926737|NCT04974515|DEVICE|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
57926738|NCT01134016|DRUG|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
57926739|NCT00473421|PROCEDURE|Barium Sulphate and Zirconium Oxide|
57926740|NCT00987688|OTHER|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
57926741|NCT00190827|DRUG|duloxetine|
58068031|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
57926742|NCT00190827|DRUG|placebo|
57926743|NCT02900469|BIOLOGICAL|denosumab|denosumab: 120 mg subcutaneous injection
57926744|NCT02900469|PROCEDURE|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
57926745|NCT00196872|DRUG|Epirubicine|Epirbubicne is given
57926746|NCT00196872|DRUG|Cyclophosphamide|Cyclophosphamide is given
57926747|NCT00196872|DRUG|Taxol|Taxol is given
57926748|NCT00196872|DRUG|Xeloda|Xeloda is given
57926749|NCT00196872|DRUG|Ibandronat|Ibandronat is given
58068032|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
58068033|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
58068034|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
58068035|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
58068036|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
58068037|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
58068038|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
58395330|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
57926750|NCT04317560|PROCEDURE|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
57726892|NCT00462384|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
57726893|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
57926751|NCT04317560|PROCEDURE|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
57926752|NCT03182166|DRUG|Golimumab (Optimization)|"Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
57926753|NCT03182166|DIAGNOSTIC_TEST|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
57926754|NCT03182166|BIOLOGICAL|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
57926755|NCT03196986|DRUG|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
57926756|NCT03196986|DRUG|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
57926757|NCT00861835|OTHER|ROSE|rapid on-site evaluation by cytopathology
57926758|NCT03243045|PROCEDURE|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
57926759|NCT00307528|BIOLOGICAL|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
58279181|NCT06209762|OTHER|Exercise|The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
57726894|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
57726895|NCT05676411|DRUG|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
57926760|NCT00307528|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection.
57926761|NCT05222763|BEHAVIORAL|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
57926762|NCT05222763|BEHAVIORAL|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
58068039|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
57726896|NCT05676411|PROCEDURE|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
57726897|NCT03039413|DRUG|Copper Cu 64 TP3805|Given IV
57726898|NCT03039413|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
57726899|NCT03039413|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
57735428|NCT04779801|BEHAVIORAL|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
57735429|NCT01206738|BEHAVIORAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
57735430|NCT01206738|BEHAVIORAL|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
57926763|NCT03431181|BEHAVIORAL|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
57926764|NCT03431181|BEHAVIORAL|Usual care|Patients in the control arm will receive usual care (as per local practices).
57926765|NCT01068353|BIOLOGICAL|Etanercept|50 mg given as a once weekly subcutaneous injection
57926766|NCT01068353|OTHER|Placebo|Placebo injection given once weekly
57926767|NCT00474669|DRUG|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
58279182|NCT04284163|BEHAVIORAL|Gamification|Teaching through gamification
58279183|NCT04284163|BEHAVIORAL|Traditional teaching|Teaching through master lesson methodology
58279184|NCT06255600|OTHER|High Definition-transcranial Direct Current Stimulation|High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
57926768|NCT05659355|OTHER|Constraint Induced Movement Therapy (CIMT)|I will apply CIMT on effected hand to observe the hand dexterity and grip strength
57926769|NCT05659355|OTHER|Mirror Therapy (MT)|I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
57926770|NCT00928746|DEVICE|Ipratropium bromide|
57926771|NCT03370848|DIETARY_SUPPLEMENT|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
57926772|NCT03370848|DRUG|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
57926773|NCT05223465|OTHER|Survey|Google form distributed for students and faculties
57926774|NCT00036686|DIETARY_SUPPLEMENT|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
57926775|NCT00036686|OTHER|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
57926776|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
57926777|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
57926778|NCT04184440|DIETARY_SUPPLEMENT|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
57926779|NCT00281021|DRUG|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
57926780|NCT01380639|OTHER|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
57926781|NCT04575480|PROCEDURE|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
57926782|NCT03623685|DIAGNOSTIC_TEST|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
57926783|NCT04315987|BIOLOGICAL|NestaCell®|A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
57926784|NCT04315987|BIOLOGICAL|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
57926785|NCT02301936|DRUG|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
57926786|NCT05255081|DEVICE|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
57926787|NCT05255081|PROCEDURE|Placebo-control|Spray with saline would be applied to organs under incision
57926788|NCT01266525|DRUG|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
57926789|NCT01266525|DRUG|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
57926790|NCT01266525|DRUG|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
57926791|NCT00587353|OTHER|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
57926792|NCT06512168|BEHAVIORAL|AAC Generative Language Intervention|Aided AAC Language Input/Output Intervention
57926793|NCT00498134|DRUG|Triple therapy for H. pylori infection|
57926794|NCT00498134|DRUG|Cox-2 inhibitor|
57926795|NCT05890872|DEVICE|Aliya Pulsed Electric Fields (PEF)|Percutaneous or Endobronchial PEF
57926796|NCT02783716|PROCEDURE|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
57926797|NCT02783716|DIAGNOSTIC_TEST|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
58395331|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
57926798|NCT00052754|DRUG|gefitinib|
57926799|NCT03200964|OTHER|anesthesia given as required for surgical procedure|
57926800|NCT01884233|BEHAVIORAL|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
57926801|NCT01884233|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
57926802|NCT03427333|DEVICE|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
57926803|NCT03474471|BEHAVIORAL|Pulmonary rehabilitation|Following a PR program
57926804|NCT03474471|DEVICE|EBV treatment|Bronchoscopic lung volume reduction using endobronchial valves (EBV)
58395332|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
58395333|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
58395334|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
58395335|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
57726900|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
57726901|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
57926805|NCT02210377|OTHER|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
57926806|NCT02210377|OTHER|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
57926807|NCT00537368|DRUG|CNTO 888|
58068040|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
58068041|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
58068042|NCT04586920|DRUG|LY3509754|Administered orally
58279185|NCT06255600|DIETARY_SUPPLEMENT|Chlorella Pyrenoidosa|functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
58395336|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
58395337|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
58395338|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
58395339|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
58395340|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
58395341|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
57726902|NCT00221936|BEHAVIORAL|Self-administration or nurse administered medication|
57926808|NCT00919087|DEVICE|Avivo System|Non invasive external monitoring deive
57926809|NCT01549366|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
58068043|NCT04586920|DRUG|Placebo|Administered orally
58068044|NCT04586920|DRUG|Itraconazole|Administered orally
58279186|NCT00076401|DRUG|Motexafin gadolinium|
58279187|NCT02509078|DRUG|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
58395342|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
58395343|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
58395344|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
58395345|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
58395346|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
58395347|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
58395348|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
58068045|NCT04586920|DRUG|Midazolam|Administered orally
58068046|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
58068047|NCT00495963|PROCEDURE|bronchoaleolar lavage|
58068048|NCT00495963|PROCEDURE|Bronchoscopy|
58395349|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
58395350|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
58395351|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
58395352|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
58395353|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
58395354|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
58422719|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
57726903|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
57926810|NCT01549366|DEVICE|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
57926811|NCT00646061|DRUG|buscopan|
57926812|NCT03500250|OTHER|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
58279188|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
58279189|NCT05077813|COMBINATION_PRODUCT|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
58279190|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
58306702|NCT05728476|PROCEDURE|Vitrectomy combined with ILM peeling|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
58306703|NCT05728476|DRUG|Conbercept intravitreal injection|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
58395355|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
58395356|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
58395357|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
58395358|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
58395359|NCT06659081|PROCEDURE|implant placement|implant placement
58395360|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
57726904|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
57926813|NCT03780426|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
57926814|NCT03780426|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
57926815|NCT05161832|BEHAVIORAL|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
57926816|NCT05161832|BEHAVIORAL|Placebo|Placebo ultrasound with no diagnosis of injury.
57926817|NCT02897401|BIOLOGICAL|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
57926818|NCT02897401|BIOLOGICAL|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
57926819|NCT02897401|BIOLOGICAL|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
57926820|NCT02897401|BEHAVIORAL|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
57926821|NCT02897401|PROCEDURE|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
57926822|NCT00233805|DEVICE|Sirolimus coated Bx Velocity™|drug-eluting stent
57926823|NCT00233805|DEVICE|Bare metal Bx Velocity™|bare-metal stent
57926824|NCT05934851|PROCEDURE|Frozen-Section Directed Excision|Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
58068049|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
58068050|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
58068051|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
58395361|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
57926825|NCT05934851|PROCEDURE|Wide Local Excision|Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
57926826|NCT06286007|DIAGNOSTIC_TEST|PCR|Depending on the symptoms presented and date of symptom onset, for pertussis, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 3 weeks For RSV, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 72 hours.
57926827|NCT00626964|PROCEDURE|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
57926828|NCT00626964|BEHAVIORAL|Conservative Treatment:|Intensive Lifestyle Intervention Program
57926829|NCT01261754|RADIATION|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
57926830|NCT01261754|RADIATION|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
57926831|NCT06472219|DRUG|Prednisolone 30 mg|This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
58068052|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
58395362|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
58395363|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
57926832|NCT06472219|DRUG|Placebo|This a tablet identical to prednisolone.
58068053|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
58068054|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
58306704|NCT03350386|DRUG|FYU-981|Single administration
58068055|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
58068056|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
57726905|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
57726906|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
57726907|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
57726908|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
57726909|NCT04239989|DRUG|Itacitinib|Given PO
57726910|NCT04239989|DRUG|Itacitinib Adipate|Given PO
57726911|NCT05569395|OTHER|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
57726912|NCT05569395|OTHER|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
57726913|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
57726914|NCT01385059|DRUG|axitinib|Given PO
57726915|NCT01385059|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
57726916|NCT01385059|OTHER|enzyme-linked immunosorbent assay|Correlative studies
57726917|NCT01385059|OTHER|laboratory biomarker analysis|Correlative studies
57726918|NCT01519206|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
58306705|NCT03350386|DRUG|Oxaprozin|Repeated administration
58306706|NCT02643693|OTHER|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
57726919|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
57726920|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
57726921|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
57726922|NCT03758898|OTHER|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
57726923|NCT03758898|OTHER|Group 2|Only mobilization was applied twice a day, 8 times in total.
57726924|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
57726925|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
57726926|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
57735431|NCT01206738|BEHAVIORAL|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
58306707|NCT02643693|OTHER|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
57926833|NCT03498846|PROCEDURE|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
57926834|NCT03498846|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
57726927|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
57726928|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
57726929|NCT02546544|DRUG|Linsitinib|
57726930|NCT06632041|DIAGNOSTIC_TEST|Complete blood count|Study haemtological disturbances in neonates with necrotizing enterocolities
57726931|NCT06632041|OTHER|Complete blood count|Haemtological disturbances in neonates with necrotizing enterocolities
57726932|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
57726933|NCT02357836|DRUG|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
57726934|NCT04825457|PROCEDURE|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
57726935|NCT02687152|OTHER|N-hydroxy-nor-L-arginine|
58068057|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
58068058|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
58068059|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
58306708|NCT02643693|OTHER|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
58306709|NCT04872283|PROCEDURE|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
57926835|NCT01050205|BEHAVIORAL|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
57926836|NCT01050205|BEHAVIORAL|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
57926837|NCT01249937|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
58068060|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
58068061|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
58068062|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
58068063|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
58306710|NCT04872283|DRUG|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
58306711|NCT04872283|DRUG|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
58395364|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
58395365|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
58395366|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
58395367|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
58395368|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
57926838|NCT01249937|DRUG|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
58395369|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
58395370|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
58395371|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
58395372|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
58395373|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
58395374|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
57926839|NCT00082745|OTHER|Laboratory Biomarker Analysis|Correlative studies
57926840|NCT00082745|OTHER|Questionnaire Administration|Ancillary studies
57926841|NCT03511547|DEVICE|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.
57926842|NCT03511547|DEVICE|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
57926843|NCT04213924|DRUG|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
57926844|NCT04213924|DRUG|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
57926845|NCT01012479|DRUG|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
57926846|NCT02057120|PROCEDURE|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
57926847|NCT02057120|DEVICE|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
57926848|NCT02335125|BEHAVIORAL|Motivational Interviewing|
57926849|NCT02335125|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
57926850|NCT02335125|DRUG|Psychotropic Drugs|
57926851|NCT02335125|OTHER|Care Management|
57926852|NCT05181865|DRUG|1 mg/kg IV FL-301|N = 1
58068064|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
57926853|NCT05181865|DRUG|3 mg/kg IV FL-301|N = 3-6
57926854|NCT05181865|DRUG|10 mg/kg IV FL-301|N = 3-6
57926855|NCT05181865|DRUG|20 mg/kg IV FL-301|N = 3-6
57926856|NCT05181865|DRUG|30 mg/kg IV FL-301|N = 3-6
57926857|NCT05181865|DRUG|RP2D, IV FL-301|Pancreatic Cancer N = 30
57926858|NCT05181865|DRUG|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
57926859|NCT05181865|DRUG|RP2D, IV FL-301|Other Solid Tumors N = 30
57926860|NCT04726462|OTHER|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
57926861|NCT04726462|OTHER|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
57926862|NCT02629471|BEHAVIORAL|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
57926863|NCT04012437|DEVICE|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
57926864|NCT04012437|BEHAVIORAL|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
57926865|NCT04641780|DRUG|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
57926866|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate
57926867|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot Placebo|Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate
58068065|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
58395375|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
57726936|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
57726937|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
57735432|NCT04844164|DRUG|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
58395376|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
58395377|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
58395378|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
58395379|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
58068066|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
57926868|NCT06085651|PROCEDURE|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
58279191|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
58306712|NCT04872283|DRUG|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
58306713|NCT04872283|DRUG|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
58306714|NCT05760599|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
58306715|NCT05760599|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
58395380|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
58395381|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
58395382|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
58395383|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
58395384|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
58395385|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
58395386|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
58395387|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
58395388|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
58395389|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
57926869|NCT06486311|PROCEDURE|satellite implant|Satellite implant is a additional holding component as a stabilizer to provide a polygonal support to distribute forces and moments on single-standing implants give the implant sufficient resistance to withstand masticatory forces or at least keep it in a stable position during an unloaded healing period to achieve stabilization and subsequent osseointegration of implants.
57926870|NCT02349451|BIOLOGICAL|adalimumab|
57926871|NCT02349451|BIOLOGICAL|ABT-122|
58395390|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
58395391|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
58395392|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
58395393|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
58395394|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
58395395|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
58395396|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
58068067|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
58068068|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
58068069|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
58395397|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
58279192|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
58279193|NCT05077813|OTHER|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
58279194|NCT01682018|DEVICE|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
58279195|NCT00316407|DRUG|lapatinib (GW572016)|1000 mg po qd
58279196|NCT00316407|DRUG|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
58279197|NCT00316407|DRUG|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
58279198|NCT02259829|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
58279199|NCT02259829|DRUG|Telmisartan|
58279200|NCT02259829|DRUG|Amlodipine|
58279201|NCT02483494|OTHER|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
58279202|NCT03078309|DRUG|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
58279203|NCT00841308|OTHER|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
58395398|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
58395399|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
58279204|NCT03900247|DEVICE|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
58279205|NCT04940585|OTHER|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
58279206|NCT05436353|OTHER|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
58279207|NCT01068587|DRUG|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
58279208|NCT01068587|DRUG|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
58279209|NCT01068587|OTHER|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
58395400|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
58395401|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
58395402|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
58395403|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
58395404|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
58279210|NCT04338243|DRUG|Glumetinib|Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
58306716|NCT02982707|DRUG|BMS-986177|Single oral dose
58306717|NCT05573230|DRUG|Midazolam|Administered orally.
58395405|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
58395406|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
57926872|NCT03605563|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
57926873|NCT03605563|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
57926874|NCT03617965|DIAGNOSTIC_TEST|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
57926875|NCT00047320|DRUG|carboplatin|Given IV
57926876|NCT00047320|DRUG|etoposide|Given IV
58395407|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
58395408|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
57926877|NCT00047320|DRUG|ifosfamide|Given IV
57926878|NCT00047320|DRUG|thiotepa|Given IV
57926879|NCT00047320|PROCEDURE|adjuvant therapy|
57926880|NCT00047320|PROCEDURE|conventional surgery|
57926881|NCT00047320|PROCEDURE|neoadjuvant therapy|
57926882|NCT00047320|PROCEDURE|peripheral blood stem cell transplantation|
57926883|NCT00047320|RADIATION|radiation therapy|craniospinal irradiation
58395409|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
58395410|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
57926884|NCT04069351|DIETARY_SUPPLEMENT|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
57926885|NCT04069351|OTHER|Resistance Training|All participants will complete a 6-week supervised resistance training program.
57926886|NCT03024177|DRUG|Vapendavir|Vapendavir Tablets, 264 mg
57926887|NCT03024177|DRUG|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
57926888|NCT01128738|DRUG|GSK1358820|Onabotulinum toxin type A
57926889|NCT01128738|DRUG|Placebo|Placebo
57926890|NCT05880017|PROCEDURE|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
57926891|NCT05880017|PROCEDURE|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
57926892|NCT05880017|DRUG|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
57926893|NCT05880017|DRUG|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
57926894|NCT04785339|BEHAVIORAL|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
57926895|NCT02344433|BEHAVIORAL|VICKY|Relational agent/virtual counselor
57926896|NCT02344433|BEHAVIORAL|MFHP|US Surgeon General's family history tool
57926897|NCT05146362|OTHER|Vermont RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
57926898|NCT00559585|DRUG|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
57926899|NCT00559585|DRUG|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
57926900|NCT03996499|DIAGNOSTIC_TEST|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
57926901|NCT05196581|DRUG|Dispersible NaCl powder 10 sessions|Dispersible NaCl powder 10 sessions
58279211|NCT02032771|DEVICE|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
57926902|NCT05196581|DRUG|Dispersible NaCl powder 5 sessions|Dispersible NaCl powder 5 sessions
57926903|NCT03884998|DRUG|Copanlisib|Given IV
58279212|NCT01487239|DRUG|[14C]-GDC-0980|100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
58279213|NCT05695820|OTHER|Blood Flow Restriction training|It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
57926904|NCT03884998|BIOLOGICAL|Nivolumab|Given IV
58279214|NCT01687842|OTHER|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
58306718|NCT05573230|DRUG|LY3502970|Administered orally.
57926905|NCT05093725|DEVICE|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
57926906|NCT04918238|OTHER|Conventional program|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
58395411|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
58395412|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
58395413|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
58279215|NCT02929134|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
58279216|NCT02929134|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
58395414|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
58395415|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
58279217|NCT01858623|DRUG|Losartan/hydrochlorothiazide|
58279218|NCT01858623|DRUG|Losartan|
58279219|NCT01858623|DRUG|Hydrochlorothiazide|
58395416|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
58395417|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
58395418|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
58395419|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
58395420|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
58395421|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
58422720|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
58279220|NCT04663932|PROCEDURE|immediate stenting group(one-step strategy)|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
58279221|NCT04663932|PROCEDURE|deferred stenting group (two-step strategy)|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
58279222|NCT04754399|DRUG|Cannabidiol (CBD)|"week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food"
58279223|NCT03749408|DRUG|bupivacaine plus mannitol|local anesthesia
58279224|NCT03749408|DRUG|bupivacaine alone|local anesthesia
57926907|NCT04918238|OTHER|Muscle energy technique|The patient was in the lateral recumbent position on the side opposite to his, her side-bending dysfunction while the physiotherapist stood facing the subject. The physiotherapist monitored the lumbar area with one hand while with the other hand flexed the subject's knees and hips until the barrier was engaged at the vertebral segment being treated.
57926908|NCT04646512|DIETARY_SUPPLEMENT|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
58395422|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
58395423|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
58395424|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
58395425|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
58395426|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
58395427|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
58395428|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
58395429|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
58395430|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
58395431|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
57726938|NCT03999606|BEHAVIORAL|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
57726939|NCT03789422|DRUG|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
57726940|NCT03789422|DRUG|Levocetirizine only|levocetirizine 20 mg/day
57726941|NCT04824547|OTHER|exercise|All exercises programs will applied two sessions per week, totally eight week..
57726942|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
57926909|NCT04646512|OTHER|Physical training with Deep Water Running|There will be a physical training for eight weeks.
57926910|NCT04201132|DEVICE|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
57926911|NCT02602054|PROCEDURE|Surgical treatment|Standard left thoracotomy
58395432|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
58395433|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
58395434|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
58395435|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
58395436|NCT00239993|DRUG|glatiramer acetate|
58395437|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
58395438|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
57726943|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
57726944|NCT00002980|DRUG|decitabine|
57726945|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
57726946|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
57726947|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
57726948|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
57726949|NCT06275646|OTHER|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
57726950|NCT06275646|OTHER|dartos flap|dartos flap alone was used
58395439|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
58395440|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
58395441|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
57726951|NCT02332031|DRUG|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
57726952|NCT02332031|DRUG|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
57726953|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
57726954|NCT00693992|OTHER|Placebo|Given PO
57726955|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
57726956|NCT00693992|DRUG|Sunitinib Malate|Given PO
57726957|NCT03564496|DEVICE|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
57735433|NCT03223363|DIAGNOSTIC_TEST|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
58306719|NCT05573230|DRUG|Cyclosporine|Administered orally.
58395442|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
58395443|NCT05422495|OTHER|non intervention|non intervention
58395444|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
58395445|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
58395446|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
58279225|NCT05513755|PROCEDURE|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
58279226|NCT03145051|OTHER|Saline solution|a nasal irrigation care
58279227|NCT03145051|OTHER|Respimer Netiflow|a nasal irrigation care
58395447|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
58068070|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
58068071|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
58068072|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
58279228|NCT02910726|PROCEDURE|Sentinel Lymph Node Biopsy|
58279229|NCT02910726|DRUG|indocyanine green (ICG)|
58279230|NCT03103685|DRUG|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
58279231|NCT02366403|BEHAVIORAL|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
58279232|NCT02366403|BEHAVIORAL|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
58279233|NCT01196377|DRUG|Albuterol|Nebulized albuterol
58279234|NCT04261010|PROCEDURE|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
58279235|NCT01415375|BEHAVIORAL|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
58279236|NCT01415375|BEHAVIORAL|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
58306720|NCT02064556|DRUG|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
58306721|NCT02064556|DRUG|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
58306722|NCT00848523|DRUG|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
58306723|NCT01066572|DRUG|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
57726958|NCT03564496|DEVICE|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
57926912|NCT02602054|DRUG|Control group|"- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
58395448|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
58395449|NCT02888691|OTHER|Low carbohydrate diet|
58395450|NCT02888691|OTHER|High carbohydrate diet|
58395451|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
57726959|NCT03564496|DEVICE|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
57726960|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
57726961|NCT04344067|DEVICE|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
57726962|NCT02067247|DEVICE|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
57726963|NCT00112073|DRUG|bapineuzumab|IV, Q13w
57726964|NCT00112073|OTHER|placebo|IV Q13w
57726965|NCT01281930|PROCEDURE|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
57726966|NCT01281930|PROCEDURE|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
57726967|NCT01194674|DRUG|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
57726968|NCT00591292|DRUG|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
57926913|NCT04640389|OTHER|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
58306724|NCT01066572|DRUG|Placebo|Matched placebo; identical tablets to Lisinopril.
57926914|NCT00197808|BIOLOGICAL|menjugate|men C conjugate vaccine
57926915|NCT00197808|BIOLOGICAL|Men C conjugate vaccine|men C conjugate vaccine
58306725|NCT00023231|DRUG|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
58306726|NCT00023231|DRUG|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
58306727|NCT00023231|DRUG|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
58306728|NCT00023231|DRUG|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
58306729|NCT00023231|DRUG|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
58306730|NCT00023231|DRUG|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
58306731|NCT00023231|DRUG|Lipitor|Oral tablet taken daily
58306732|NCT05334394|OTHER|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
58306733|NCT05334394|OTHER|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
58306734|NCT00003537|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
57926916|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
57926917|NCT00197808|BIOLOGICAL|Men C Conjugate|men C conjugate vaccine
58068073|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
58068074|NCT00003855|PROCEDURE|axillary lymph node dissection|
58068075|NCT00003855|RADIATION|whole breast irradiation|
58279237|NCT05136430|BEHAVIORAL|Self-Regulation strategies + large changes (SR)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
58279238|NCT05136430|BEHAVIORAL|Healthy Lifestyle Education (LE)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
58306735|NCT00449839|DRUG|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
58306736|NCT00345124|BEHAVIORAL|high sodium diet|250-350 mmol
58395452|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
58395453|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
58395454|NCT02461290|RADIATION|Chemotherapy|
57726969|NCT04346758|PROCEDURE|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
57926918|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
57926919|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
57726970|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
57726971|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
57735434|NCT01060982|DEVICE|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
57926920|NCT04697121|DIETARY_SUPPLEMENT|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
57926921|NCT04697121|COMBINATION_PRODUCT|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
57926922|NCT05408104|DRUG|tolvaptan|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
58395455|NCT02461290|DRUG|Rituximab|
57926923|NCT02700204|DEVICE|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
57926924|NCT02700204|DEVICE|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
58395456|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
58395457|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
58395458|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
58395459|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
58279239|NCT05136430|OTHER|Smoking Cessation Treatment|The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
58279240|NCT04875871|RADIATION|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
58395460|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
58395461|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
58395462|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
58395463|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
58395464|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
58395465|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
58395466|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
57926925|NCT04876534|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Intravenous administration
57926926|NCT04876534|DRUG|MethylPREDNISolone Injectable Solution|Intravenous administration
57926927|NCT03963453|OTHER|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
58068076|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
57726972|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
58395467|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
58395468|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
58395469|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
58395470|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
58395471|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
57926928|NCT01083628|BEHAVIORAL|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
57926929|NCT01083628|BEHAVIORAL|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
57926930|NCT04151953|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
57926931|NCT00643669|DRUG|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
58068077|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
58279241|NCT04875871|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
58279242|NCT04875871|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
57926932|NCT01119001|DEVICE|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
57926933|NCT02400034|OTHER|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
58306737|NCT00345124|BEHAVIORAL|Low Sodium Diet|25-35 mmol
57726973|NCT06576063|DEVICE|Lumoral Treatment|Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
57726974|NCT06576063|BEHAVIORAL|Standard oral hygiene methods|Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
57926934|NCT05904054|BIOLOGICAL|SARS-CoV-2 DNA Vaccine (ICCOV)|The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.
57926935|NCT00849654|DRUG|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
57926936|NCT03875989|PROCEDURE|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
58068078|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
58068079|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
58279243|NCT04875871|DIAGNOSTIC_TEST|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
58279244|NCT04875871|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
58279245|NCT04875871|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
58279246|NCT02283320|DRUG|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
57726975|NCT03161834|OTHER|Observational|
57726976|NCT02391402|BEHAVIORAL|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
58068080|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
58068081|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
58279247|NCT00003902|DRUG|capecitabine|
58279248|NCT00003902|DRUG|vinorelbine tartrate|
58279249|NCT03447106|PROCEDURE|laparotomy|This is a kind of traditional surgical method.
58279250|NCT03447106|PROCEDURE|Laparoscopic|laparoscopic surgery
58279251|NCT03447106|PROCEDURE|Robotic|the Da Vinci robot assisted gastric resection
58279252|NCT01600599|DRUG|Tranexamic Acid|intravenous 1g and topical 1g
57926937|NCT03875989|PROCEDURE|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
58279253|NCT01600599|DRUG|saline|100mls of topical saline
58279254|NCT05387512|DRUG|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
58279255|NCT00755885|DRUG|abiraterone acetate|
58279256|NCT00755885|OTHER|laboratory biomarker analysis|
58279257|NCT00755885|OTHER|pharmacogenomic studies|
58279258|NCT00675337|PROCEDURE|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
58279259|NCT00675337|PROCEDURE|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
58279260|NCT02332161|OTHER|surveys, evaluative tests for leg function|See outcome measures
58279261|NCT03666949|DRUG|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
57735435|NCT00293735|DRUG|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
57735436|NCT00293735|DRUG|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
57735437|NCT06537453|OTHER|Virtual Care|Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
58395472|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
58395473|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
58395474|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
58395475|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
58279262|NCT03666949|DRUG|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
57726977|NCT02391402|BEHAVIORAL|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
57726978|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
58279263|NCT01310244|DRUG|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
58279264|NCT01356329|DRUG|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
58279265|NCT01046357|DRUG|AZD7687|Single oral dose
58395476|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
57726979|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
58395477|NCT05143528|DRUG|Placebo|placebo capsule
57726980|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
57926938|NCT02620267|DEVICE|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
58395478|NCT03419897|DRUG|Tislelizumab|Administered intravenously
58395479|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
58395480|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
58395481|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
58395482|NCT03907176|DRUG|HTX-011|300 mg
57726981|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
57726982|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
58279266|NCT01046357|DRUG|Placebo|Single oral dose
58279267|NCT04290325|DRUG|HMPL-453|HMPL-453 tablet
58395483|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
58395484|NCT03907176|DRUG|Ibuprofen|600 mg
58395485|NCT03907176|DRUG|Acetaminophen|1 g
57726983|NCT05266690|DIETARY_SUPPLEMENT|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
58306738|NCT00677898|BEHAVIORAL|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
58306739|NCT00677898|BEHAVIORAL|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
58306740|NCT00000755|BIOLOGICAL|rgp120/HIV-1MN|
58306741|NCT00000755|DRUG|Zidovudine|
58395486|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
58395487|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
58395488|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
58279268|NCT05721183|BEHAVIORAL|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
58279269|NCT02501083|OTHER|no intervention|The study will not include any intervention.
58395489|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
58395490|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
57726984|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
57926939|NCT04625998|BEHAVIORAL|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
57926940|NCT04625998|BEHAVIORAL|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
57726985|NCT05266690|DIETARY_SUPPLEMENT|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
57726986|NCT05216172|DRUG|AZD1656|active drug
57726987|NCT05216172|DRUG|Placebo|placebo
57726988|NCT00884481|OTHER|Natalizumab|Participants treated with Tysabri
57926941|NCT04811638|OTHER|Validation of the Chelsea Critical Care Physical Assesment Tools|The validation of the CPAX tools will focus on the validity of constructs, internal consistency reliability and test-retest reliability. PFIT used for criterion validity.
57926942|NCT05953779|BEHAVIORAL|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
57926943|NCT05640466|DEVICE|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
57926944|NCT02523053|PROCEDURE|Hepatectomy|Surgical removal of all lesions
57926945|NCT02523053|DRUG|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
58395491|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
58395492|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
58395493|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
57726989|NCT00444158|DRUG|MOA-728|
57726990|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
57726991|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
57726992|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
57726993|NCT02800707|OTHER|Sucralose|Sweetner
57726994|NCT02800707|OTHER|Stevia|Sweetner
58395494|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
58395495|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
58395496|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
58395497|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
58395498|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
57926946|NCT06151145|BEHAVIORAL|Usual care|Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.
58279270|NCT01560572|DRUG|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
58279271|NCT02453659|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
58279272|NCT02453659|BEHAVIORAL|Health Education (HE)|
58279273|NCT02453659|BEHAVIORAL|Smoking Cessation counseling|
58279274|NCT02453659|DRUG|Transdermal Nicotine Patch|
58395499|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
58395500|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
58395501|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging.
58395502|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
58395503|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
58395504|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
58279275|NCT06366698|DRUG|Venofer 200 MG Per 10 ML Injection|200 mg IV every 2 days until the targeted dose
58395505|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
58395506|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
57726995|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
58279276|NCT06366698|DRUG|Ferrous sulfate|Take 1 tablet every other day with lemon/orange juice
58279277|NCT03209518|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
58279278|NCT01051258|DEVICE|AeriSeal System|AeriSeal System for Lung Volume Reduction
58279279|NCT04819750|DEVICE|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
57726996|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
58279280|NCT04819750|DEVICE|Headphones with noise reduction|Headphones with noise reduction without music
58279281|NCT06291623|DRUG|Glycyrrhizin|used as intracanal medication for one week
58279282|NCT01141166|BEHAVIORAL|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
58279283|NCT03580395|DRUG|Apatinib|500mg, day1-21,neoadjuvant therapy
58279284|NCT03580395|DRUG|paclitaxel|paclitaxel 165mg/m2 day 1
58395507|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
58068082|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
58068083|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
58068084|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
58279285|NCT03580395|DRUG|cisplatin|cisplatin 40mg, day 1-3
58279286|NCT00595101|DRUG|PF-03187207|
58279287|NCT00595101|DRUG|Latanoprost 0.005%|
58395508|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
58395509|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
58395510|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
58395511|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
58395512|NCT02672059|OTHER|Observation|No intervention
58279288|NCT00595101|DRUG|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
58279289|NCT00595101|DRUG|Latanoprost Vehicle|
58279290|NCT02986698|BIOLOGICAL|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
58279291|NCT04203251|DEVICE|Caption Health Guidance Technology|
58279292|NCT02981563|OTHER|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
58068085|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
58068086|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
58068087|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
58068088|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
58279293|NCT01658254|OTHER|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
58279294|NCT04059341|DEVICE|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
58279295|NCT04527978|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
58279296|NCT04527978|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
58279297|NCT04393376|DIAGNOSTIC_TEST|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
58279298|NCT01124370|DEVICE|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
58279299|NCT03326232|DEVICE|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
58279300|NCT05790642|DEVICE|Pulse wave measurement and analysis|Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.
58279301|NCT03525808|DEVICE|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
58279302|NCT00350779|DRUG|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
58279303|NCT00350779|DRUG|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
58279304|NCT00350779|DRUG|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
58279305|NCT00350779|DRUG|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
58279306|NCT00350779|DRUG|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
58279307|NCT01318746|PROCEDURE|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
58279308|NCT06327360|OTHER|Psychological questionnaires|The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
58279309|NCT02518841|DEVICE|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
58279310|NCT02518841|OTHER|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
57726997|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
57726998|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
58279311|NCT05112159|DRUG|IPG1094|The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.
58279312|NCT05112159|DRUG|placebo|Matching placebo tablets to IPG1094 50mg and 100mg
58279313|NCT05418660|DRUG|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
58279314|NCT02748629|DEVICE|Covidien Parietex ProGrip Self-Fixating Mesh|
58279315|NCT02748629|DEVICE|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
58279316|NCT00000613|BEHAVIORAL|dietary supplements|
58279317|NCT00000613|DRUG|genistein|
58279318|NCT00000613|BEHAVIORAL|diet, soy proteins|
58279319|NCT04856397|DRUG|Intravitreal Implant in Applicator|Dexamethasone intravitreal implant
58279320|NCT04856397|DRUG|Eylea|anti-VEGF medication
58279321|NCT05529732|OTHER|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
58279322|NCT03634202|COMBINATION_PRODUCT|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
57726999|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
57727000|NCT06272734|DEVICE|Reprieve System|"The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features."
58279323|NCT02966821|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
57926947|NCT06151145|BEHAVIORAL|SELF|"The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages."
57926948|NCT06151145|BEHAVIORAL|STEP|The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
57926949|NCT01473160|DEVICE|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
57926950|NCT01473160|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
57926951|NCT05100485|DIAGNOSTIC_TEST|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
58279324|NCT01302210|DRUG|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
58279325|NCT02777424|DRUG|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
58279326|NCT02777424|BIOLOGICAL|Fresh Frozen Plasma|Pooled collection of plasma from donors
58395513|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
58279327|NCT04260568|OTHER|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
58279328|NCT03905681|DEVICE|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
58279329|NCT00528073|DRUG|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
58395514|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
58395515|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
58279330|NCT04853966|BEHAVIORAL|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
58395516|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
58279331|NCT04500678|DRUG|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
58279332|NCT02105519|BIOLOGICAL|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
58279333|NCT01838772|DRUG|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
57926952|NCT05100485|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
58279334|NCT04100590|DRUG|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
58395517|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
58395518|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
58068089|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
58068090|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
58279335|NCT03479138|DIAGNOSTIC_TEST|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
58279336|NCT00651144|DRUG|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
58279337|NCT00651144|DRUG|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
58279338|NCT00651144|DRUG|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
58279339|NCT00651144|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
58306742|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
58395519|NCT05034627|DRUG|Cobimetinib|Given PO
58395520|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
57727001|NCT05511987|DEVICE|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
57926953|NCT02479334|OTHER|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
57926954|NCT02479334|OTHER|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
57926955|NCT02479334|OTHER|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
57926956|NCT02479334|OTHER|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
57926957|NCT04600700|DEVICE|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
57926958|NCT05532254|DRUG|Aripiprazole 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
57926959|NCT05532254|DRUG|Abilify® 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
57926960|NCT03296891|OTHER|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
58068091|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
58068092|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
58068093|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
58279340|NCT03917979|BEHAVIORAL|Individual GIM|Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
58279341|NCT03917979|BEHAVIORAL|Waitlist Control|Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
57926961|NCT05428254|OTHER|Capacitive and Resistive Radiofrequency therapy|"TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues."
57926962|NCT05428254|OTHER|Exercise therapy|Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
57926963|NCT00004239|DRUG|Compound 506U78|
57926964|NCT00308269|DRUG|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
57926965|NCT00308269|DRUG|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
57926966|NCT00409097|DRUG|Rosiglitazone|
57926967|NCT02918604|DEVICE|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
57926968|NCT02725957|DRUG|Trehalose for IV Infusion|
58068094|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
58068095|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
58068096|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
58068097|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
58068098|NCT03049189|DRUG|Everolimus|Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
58068099|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
58068100|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
58068101|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
58279342|NCT00362531|DRUG|tacrolimus combined with prednisone|
58395521|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
58395522|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58395523|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
58395524|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
57727002|NCT05511987|DEVICE|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
57727003|NCT02824276|DRUG|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
57926969|NCT02725957|DRUG|Saline 0.9% IV|
58068102|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
58068103|NCT06207864|PROCEDURE|Return of Results|Receive results
58068104|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
57951151|NCT03209102|OTHER|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
58068105|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
58068106|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
58068107|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
58068108|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
58279343|NCT04618809|BEHAVIORAL|Didactic Session|This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
58279344|NCT04618809|BEHAVIORAL|Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.|"* The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded."
58279345|NCT04607681|BEHAVIORAL|EDUCATION|WEB BASED EDUCATION
58279346|NCT03287011|OTHER|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
58279347|NCT03287011|OTHER|Colgate toothpaste|fluoridated
58279348|NCT05454852|OTHER|Survey|Interviewer-administered survey
58279349|NCT05454852|OTHER|Focus group|Focus group for selected participants
58395525|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
58395526|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
58395527|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
58395528|NCT00630006|GENETIC|TNF-alpha and IL-10|
58395529|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
58395530|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
58068109|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
58068110|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
58068111|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
58068112|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
57926970|NCT04538612|DEVICE|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~* Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~* Veinous vascular occlusion test (30mmHg),~* Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
57926971|NCT01106027|DRUG|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
57951152|NCT03209102|BIOLOGICAL|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
57951153|NCT03009214|DRUG|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
58068113|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58068114|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58068115|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
58068116|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
58068117|NCT02473029|RADIATION|Vascular tomodensitometry|
58068118|NCT02473029|OTHER|Magnetic resonance angiography|
58279350|NCT02420483|OTHER|Cardiopulmonary resuscitation chest compressions|
58279351|NCT06024707|DRUG|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
58279352|NCT00719394|DRUG|GSI 136|
58279353|NCT00719394|DRUG|placebo|
57727004|NCT02824276|DRUG|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
58279354|NCT00530790|DRUG|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
58279355|NCT00772187|DRUG|morphine|Single dose: 0.1-0.5 mg
58279356|NCT00772187|DRUG|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
58279357|NCT00772187|DRUG|general anesthesia (fentanyl)|general anesthesia alone
58279358|NCT04053244|BEHAVIORAL|internet-based cognitive behavioural therapy|Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
58279359|NCT01410240|PROCEDURE|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
57727005|NCT05413876|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
57727006|NCT05413876|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
57951154|NCT01191073|DEVICE|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
57951155|NCT01191073|DEVICE|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
58068119|NCT02473029|OTHER|Vascular ultrasonography|
58068120|NCT02473029|OTHER|Retinal angiography|
58068121|NCT02473029|OTHER|Retinal optical coherence tomography|
58068122|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
58068123|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
58068124|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
58068125|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
58068126|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
58068127|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
58068128|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
57926972|NCT06261086|DIAGNOSTIC_TEST|evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)|2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
57926973|NCT03321734|DRUG|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
57926974|NCT03321734|DRUG|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
57926975|NCT04008355|DRUG|AZP2006 oral solution|Once daily intake in the morning
57926976|NCT04008355|DRUG|Placebo oral solution|Once daily intake in the morning
57727007|NCT02009176|PROCEDURE|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
57926977|NCT02885805|DRUG|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
57926978|NCT02885805|DRUG|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
57926979|NCT02674191|DEVICE|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
57926980|NCT02674191|PROCEDURE|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
57926981|NCT02674191|PROCEDURE|Administration of , Mepivacaine-l|local anesthesia
57926982|NCT02674191|PROCEDURE|BETADINE povidone-iodine 10%|a local disinfectant
57926983|NCT02674191|DRUG|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
58068129|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
58279360|NCT01410240|DRUG|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
58279361|NCT04879836|DEVICE|Teething Gel|Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks
57926984|NCT02674191|DRUG|(Cataflam 25mg), are prescribed post-operatively|an analgesic
58279362|NCT04879836|DEVICE|Teething Ring|The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks
58279363|NCT00671047|OTHER|non-interventional|SLE nature history observational
58279364|NCT04622072|DRUG|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
58279365|NCT01043133|BEHAVIORAL|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
58279366|NCT00840034|DRUG|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
58279367|NCT00840034|DRUG|Placebo|3 tablets PO QD for up to 12 weeks
58279368|NCT00309023|DRUG|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
58279369|NCT03872817|OTHER|Intervention ProLiSMentAl|"Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available."
58279370|NCT04015752|DIAGNOSTIC_TEST|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
58279371|NCT01100190|DEVICE|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
57926985|NCT04142450|DEVICE|CoolSculpting® System|Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
57951156|NCT04971876|DEVICE|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
58068130|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
58068131|NCT02609087|DRUG|Sevoflurane|
58068132|NCT02609087|DRUG|Propofol|
58279372|NCT02417961|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
57727008|NCT02009176|PROCEDURE|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
57951157|NCT04971876|DEVICE|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
58279373|NCT05735678|DEVICE|Single-Use Duodenoscopes|Single-Use Duodenoscopes
58395531|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
58395532|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
58395533|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
58068133|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
58068134|NCT04629105|OTHER|Placebo|Placebo
58279374|NCT04092829|PROCEDURE|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
58279375|NCT02795468|PROCEDURE|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
58279376|NCT05709405|OTHER|Reading intervention|"The intervention will use a reading program called Lesing for alle (Reading for all) based on the research of Accessible Literacy Learning (ALL) which is an evidence-based approach, designed to teach reading skills to students with various intellectual disabilities, including autism spectrum disorders"
58279377|NCT04081857|DRUG|HGP1810|HGP1810: Vildagliptin/Metformin
58279378|NCT04081857|DRUG|HCP1704|HCP1704: Vildagliptin/Metformin
58279379|NCT04699370|OTHER|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
58279380|NCT04699370|BEHAVIORAL|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
58279381|NCT04699370|OTHER|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
58279382|NCT00927225|DRUG|ropivacaine 0.2%, 50 mL|
58279383|NCT00927225|DRUG|normal saline|
58279384|NCT00869973|DRUG|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
58279385|NCT00869973|DRUG|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
58279386|NCT04066322|PROCEDURE|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
58279387|NCT04066322|OTHER|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
58279388|NCT01249326|OTHER|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
58279389|NCT03590223|PROCEDURE|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
58279390|NCT04059939|OTHER|Reading|Small group reading instruction
58279391|NCT04059939|BEHAVIORAL|Anxiety Management|small group anxiety management skills instruction
58279392|NCT04059939|OTHER|Classroom Business as Usual|Classroom Business as Usual
58279393|NCT04059939|OTHER|Attention Control (math practice)|Attention Control (math practice)
58279394|NCT01393106|DRUG|Idelalisib|Idelalisib tablets administered orally
58279395|NCT06321497|DEVICE|Extracorporeal carbon dioxide removal|Low flow extracorporeal carbon dioxide removal with PrismaLung+
58279396|NCT04940689|DRUG|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
58395534|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
58395535|NCT01709110|DRUG|Teriparatide|Administered SC
58395536|NCT01709110|DRUG|Risedronate|Administered orally
58395537|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
58395538|NCT01709110|DRUG|Calcium|Administered orally
58395539|NCT01709110|DRUG|Vitamin D|Administered orally
58395540|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
58395541|NCT01140100|DRUG|propofol|
58395542|NCT01140100|DRUG|thiopental,propofol|
58395543|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
58395544|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
58395545|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
58395546|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
57727009|NCT06063629|PROCEDURE|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
57727010|NCT06063629|PROCEDURE|No drain|No drain will be inserted into patients allocated to this group
58068135|NCT00266331|DRUG|Reduced glutathione|
58068136|NCT00000758|DRUG|Fluorouracil|
58279397|NCT04940689|DRUG|Remifentanil|The patient will be anesthetized with morphin.
58395547|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
58395548|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
58395549|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
58395550|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
58279398|NCT06404515|OTHER|Telehealth Group Counseling|Group counseling for women via telehealth to provide educational materials about atherosclerotic heart disease and provide information about risk factors and modification of risk factors. Women then have an opportunity to discuss / ask questions.
58279399|NCT02028962|BEHAVIORAL|Lifestyle counseling|
58395551|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
58068137|NCT00072085|BIOLOGICAL|aldesleukin|
58068138|NCT00072085|BIOLOGICAL|gp100 antigen|
58068139|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
58279400|NCT02748291|OTHER|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
58279401|NCT02748291|OTHER|Department of Health Physical Activity Guidelines|"1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.~4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
58279402|NCT03086109|OTHER|Risk factors|Risk factors associated bone degenerative diseases
58306743|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
58306744|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
58395552|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
58395553|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
57727011|NCT03865212|DRUG|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
57727012|NCT00001101|DRUG|ceftriaxone|
57727013|NCT00001101|DRUG|doxycycline|
57926986|NCT04774991|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
58395554|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
58279403|NCT01538537|DRUG|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
58279404|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
58395555|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
58279405|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
57727014|NCT05056103|DEVICE|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
57727015|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57727016|NCT04121728|DRUG|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
57727017|NCT04121728|DRUG|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
58279406|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
58395556|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
58395557|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
57727018|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
57727019|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
57926987|NCT02779725|BEHAVIORAL|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
57926988|NCT02779725|BEHAVIORAL|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
57926989|NCT02779725|BEHAVIORAL|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
58306745|NCT03810183|DRUG|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
58395558|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
58395559|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
58395560|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
58395561|NCT02625480|DRUG|Fludarabine|Administered intravenously
58395562|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
58395563|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
58395564|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
58395565|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
58395566|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
57926990|NCT02779725|BEHAVIORAL|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
57926991|NCT02779725|BEHAVIORAL|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
58068140|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
58068141|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
58068142|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
58068143|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
58068144|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
58279407|NCT01351948|BIOLOGICAL|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
58279408|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
58279409|NCT05749406|OTHER|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
57727020|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
57926992|NCT01400789|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
57727021|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
57735438|NCT06102941|DEVICE|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
57735439|NCT01846130|DIETARY_SUPPLEMENT|Leucine|
57735440|NCT01846130|BEHAVIORAL|Exercise|
57735441|NCT01846130|DIETARY_SUPPLEMENT|Whey protein|
57951158|NCT04971876|DEVICE|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
57951159|NCT03480100|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
57951160|NCT03480100|DEVICE|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
58068145|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
58068146|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
58068147|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
58068148|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
58068149|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
58068150|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
58068151|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
58279410|NCT05749406|OTHER|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
58279411|NCT05302947|DRUG|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
58279412|NCT05302947|DRUG|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
58395567|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
58395568|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
58395569|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
58395570|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
58395571|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
58395572|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
58395573|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
58395574|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
58395575|NCT06325657|BIOLOGICAL|Placebp|Placebo
58395576|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
58395577|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
58395578|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
57926993|NCT05794750|DRUG|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
58279413|NCT05302947|DRUG|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
58279414|NCT05302947|OTHER|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
58279415|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3|
58395579|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
58395580|NCT00503412|DRUG|AZD2171|oral 14C
58395581|NCT01943058|DRUG|megestrol acetate|Given PO
58395582|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
58395583|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
58395584|NCT01943058|OTHER|questionnaire administration|Ancillary studies
58068152|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
58395585|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
58395586|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
58279416|NCT01728571|DIETARY_SUPPLEMENT|fish oil|
58279417|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
58279418|NCT01728571|DIETARY_SUPPLEMENT|Fish oil placebo|
58279419|NCT03182491|DIAGNOSTIC_TEST|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
58279420|NCT00496704|DRUG|capecitabine|
58279421|NCT00496704|DRUG|gemcitabine hydrochloride|
58279422|NCT00496704|DRUG|oxaliplatin|
58279423|NCT04112550|DRUG|Methadone Hydrochloride|FDA approved medication to treat pain
58279424|NCT04112550|DRUG|Oxycodone-Acetaminophen|FDA approved medication to treat pain
58279425|NCT05420831|PROCEDURE|Vaginal|Sacrospinous hysteropexy using the synthetic mesh
58279426|NCT05420831|PROCEDURE|Laparoscopic|Laparoscopic Sacrohysteropexy
58279427|NCT06488872|PROCEDURE|comparison of CT scan with routinely assessed methods of muscle mass and strength|comparison of CT scan with routinely assessed methods of muscle mass and strength
58279428|NCT06180083|DRUG|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
58279429|NCT06180083|DRUG|'DYMISTA' NASAL SPRAY|A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
58279430|NCT00752141|DRUG|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
58279431|NCT00752141|DRUG|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
58279432|NCT00752141|OTHER|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
58279433|NCT01635309|OTHER|Coronary CT Angiogram|pre-operative coronary CTA
58279434|NCT03497767|DRUG|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
58279435|NCT03497767|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
58279436|NCT05741814|DRUG|Propofol|Gynecologist guided individualised propofol only sedation
58279437|NCT04273932|DRUG|Lithium|Lithium aspartate of lithium carbonate will be administered by mouth.
58279438|NCT04578509|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
58395587|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
58395588|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
57926994|NCT05794750|PROCEDURE|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
57926995|NCT05794750|DRUG|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
57951161|NCT05566951|OTHER|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
58068153|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
58279439|NCT04578509|DIAGNOSTIC_TEST|Saliva sample|Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
58279440|NCT04578509|DIAGNOSTIC_TEST|axillary sweat sample|Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
58279441|NCT04578509|OTHER|Data collection|Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
58279442|NCT05491395|RADIATION|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
58279443|NCT03127761|OTHER|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
58279444|NCT02215499|DRUG|Placebo|
58279445|NCT02215499|DRUG|Sodium Oxybate|
58279446|NCT02215499|DRUG|JZP-386|
58279447|NCT05068011|DEVICE|Spinal Cord Stimulation|differential target multiplexed stimulation
58279448|NCT01741571|DEVICE|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
58306746|NCT03810183|DRUG|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
58395589|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
58395590|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
58395591|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
58395592|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
58395593|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
58279449|NCT05176613|DEVICE|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
57727022|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
57926996|NCT05794750|DRUG|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
57926997|NCT04567550|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
57926998|NCT04567550|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
57926999|NCT04567550|GENETIC|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
57927000|NCT04567550|DRUG|Topical Steroid|Topical Steroid
57927001|NCT00328822|DRUG|Quetiapine|
58306747|NCT04763993|PROCEDURE|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
58395594|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
58395595|NCT05010486|PROCEDURE|rectal surgery|
58395596|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
58395597|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
57727023|NCT01201525|PROCEDURE|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
57727024|NCT01201525|PROCEDURE|Control|Part 2 of the surgical scar will serve as a within patient control.
57727025|NCT00038493|DRUG|Temozolomide and SCH66336|
57727026|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
57927002|NCT00328822|DRUG|placebo|
57927003|NCT05192304|DRUG|TPN-672|single dose of TPN-672 maleate tablet
57927004|NCT04141956|OTHER|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
57927005|NCT05515120|DRUG|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
58395598|NCT06460493|DRUG|Ensifentrine 3mg|All subjects will receive ensifentrine.
57927006|NCT05515120|DRUG|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
57927007|NCT05515120|DRUG|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
57927008|NCT01332565|DRUG|GSK1349572|50mg tablet
57927009|NCT00779051|DRUG|Zolpidem 10mg tablets|
57927010|NCT00403728|DRUG|ciclosporine A|
57927011|NCT00628251|DRUG|AZD2281|400mg Oral twice daily
57927012|NCT00628251|DRUG|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
57927013|NCT00628251|DRUG|AZD2281|200mg oral twice daily
57927014|NCT05745675|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
57927015|NCT01609751|DIETARY_SUPPLEMENT|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
57927016|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
57927017|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
57927018|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
58279450|NCT05176613|BEHAVIORAL|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
58279451|NCT05176613|DEVICE|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
57927019|NCT00874770|DRUG|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
57927020|NCT00874770|DRUG|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
57927021|NCT00874770|DRUG|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
57927022|NCT01207232|BEHAVIORAL|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
57927023|NCT01207232|BEHAVIORAL|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
57927024|NCT04078165|DEVICE|Zero-Gravity|Free-floating, suspended personal radiation protection
57927025|NCT04078165|DEVICE|Conventional radiation protection|Standard lead shields and aprons
57927026|NCT00569816|DRUG|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
57927027|NCT00194844|BEHAVIORAL|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
57927028|NCT00194844|BEHAVIORAL|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
58068154|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
58279452|NCT05160298|DRUG|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
58279453|NCT05160298|OTHER|Control group|Sham block
58395599|NCT05634694|OTHER|No interventions.|No interventions.
58395600|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
58395601|NCT01863069|DRUG|Interferon beta 1a|
57927029|NCT00194844|BEHAVIORAL|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
57927030|NCT06295835|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingersticks.
57927031|NCT00195858|BEHAVIORAL|aerobic and resistance exercise|aerobic and resistance exercise
57927032|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with hysterectomy|After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.
57951162|NCT05566951|OTHER|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
58068155|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
58068156|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
58068157|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
58068158|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
58068159|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
58068160|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
58068161|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
58068162|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
57927033|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with cervical amputation|After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
58279454|NCT04971083|BEHAVIORAL|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
58279455|NCT05854849|DRUG|Camrelizumab|200mg, D1, Q3W, iv drip.
58279456|NCT05854849|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
57927034|NCT00257686|DRUG|Pitavastatin|
58068163|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
58095064|NCT05069168|DIAGNOSTIC_TEST|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
58279457|NCT05854849|DRUG|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
58279458|NCT05854849|DRUG|Apatinib|250mg, PO, QD
58279459|NCT04151901|OTHER|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
58279460|NCT04151901|OTHER|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
58279461|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
58395602|NCT01863069|DRUG|(IM) AVONEX®|
58395603|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
57727027|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
57727028|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
57927035|NCT00257686|DRUG|Pravastatin|
58279462|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
58279463|NCT01733992|DRUG|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
58279464|NCT01733992|DRUG|Placebo|Placebo, single and multiple ascending dose
58279465|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
58279466|NCT00715520|DRUG|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
57927036|NCT06359951|BEHAVIORAL|Project YES|Digital SSI
58395604|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
58395605|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
58395606|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
57927037|NCT02701088|DRUG|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
58395607|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
57927038|NCT02701088|RADIATION|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
58068164|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
58068165|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
58068166|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
58068167|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
58068168|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
58068169|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
58068170|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
58279467|NCT00715520|DRUG|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
58279468|NCT00715520|DRUG|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
58279469|NCT00715520|DRUG|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
58279470|NCT00715520|OTHER|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
58068171|NCT03033290|DRUG|placebo|placebo control
58068172|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
58068173|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
58068174|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
58068175|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
58068176|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
58068177|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
58068178|NCT00483431|DIETARY_SUPPLEMENT|MK7|
58068179|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
58068180|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
57927039|NCT00462189|DRUG|Immunotoxin therapy|
57927040|NCT00462189|DRUG|CAT-8015 Immunotoxin|
58395608|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
57927041|NCT00462189|PROCEDURE|Biological therapy|
57927042|NCT02952001|DRUG|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
58068181|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
58095065|NCT03464045|DRUG|empagliflozin|drug
58068182|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
58068183|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
58279471|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
58279472|NCT04008264|DRUG|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
58279473|NCT06147323|OTHER|Normal Healthy Diet|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
58395609|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
58395610|NCT02791932|BEHAVIORAL|Exercise|See description above.
58395611|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58395612|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
58395613|NCT02193737|PROCEDURE|Early oral fluid recovery.|
58395614|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
58395615|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
58395616|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
58395617|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
58395618|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
58395619|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
58395620|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
58395621|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
58395622|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
58395623|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
57927043|NCT02952001|DRUG|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
57951163|NCT02604277|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
58279474|NCT06147323|DIETARY_SUPPLEMENT|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
58279475|NCT06147323|OTHER|Placebo Diet Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
58395624|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
58395625|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
58395626|NCT04047706|DRUG|Nivolumab|Given IV
58395627|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
58395628|NCT04047706|DRUG|Temozolomide|Given PO
58395629|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
58395630|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
58068184|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
58068185|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
58095066|NCT03464045|DRUG|DPP-4 inhibitors|drug
57927044|NCT03496181|BEHAVIORAL|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
58279476|NCT00912106|OTHER|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
58279477|NCT04390308|PROCEDURE|Ovarian puncture|Egg collection
58279478|NCT04390308|OTHER|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
58279479|NCT04390308|DIAGNOSTIC_TEST|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
58279480|NCT04691687|DRUG|Furosemide|IV loop diuretic therapy
58279481|NCT04691687|DRUG|IV Solution|IV Placebo comparator
58279482|NCT03001466|DRUG|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
57727029|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
57727030|NCT00059657|DRUG|Ecraprost in lipid emulsion|
57927045|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
57927046|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms\* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
58279483|NCT03001466|DRUG|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
57727031|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
57727032|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
58279484|NCT01863732|BIOLOGICAL|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
57727033|NCT04474184|OTHER|Survey Administration|Ancillary studies
58279485|NCT01863732|OTHER|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
58279486|NCT03463252|DRUG|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
58279487|NCT03463252|DEVICE|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
58279488|NCT03463252|DRUG|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
58279489|NCT04361097|BIOLOGICAL|Faecal microbiota transplant|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
58279490|NCT04361097|BIOLOGICAL|Placebo|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
58279491|NCT00153725|DRUG|Aspirin and Pantoloc|
58395631|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
58279492|NCT01256580|DRUG|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
58279493|NCT01256580|DRUG|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
58279494|NCT04992624|DRUG|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
58279495|NCT04992624|DRUG|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
58279496|NCT04992624|DRUG|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
58279497|NCT03236571|DEVICE|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
58395632|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
58395633|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
57927047|NCT00909792|DEVICE|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
57927048|NCT00909792|DEVICE|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
57927049|NCT00898443|OTHER|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
57927050|NCT00898443|OTHER|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
58395634|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
58395635|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
58395636|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
57927051|NCT00150332|DRUG|linezolid|
57927052|NCT01055262|DEVICE|Heatwrap 1|8 hours continuous topically-applied heat
57927053|NCT00826111|DRUG|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
57927054|NCT00826111|DRUG|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
57927055|NCT02589717|DRUG|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
58095067|NCT05204888|DEVICE|myAirvo3|For patients assigned to the HFNT intervention group, a myAirvo 3 device will be provided. The myAirvo 3 is for the treatment of spontaneously breathing patients, infant to adult, who would benefit from receiving high flow warmed and humidified respiratory gases. This includes patients who have had upper airways bypassed. The flow may be from 2 - 60 L/min depending on the patient interface. The myAirvo 3 is for patients in homes and long-term care facilities.
57927056|NCT04958850|OTHER|a cross-sectional survey|Collect the data of this year and compare it with that of ten years ago
57927057|NCT04940065|OTHER|Kesimpta|Prospective observational cohort study. There is no treatment allocation.
58068186|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
57727034|NCT05970393|PROCEDURE|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
57727035|NCT03854344|DRUG|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
58279498|NCT05080725|OTHER|TelePEPP intervention|TelePEPP sessions will be conducted twice per week by a Speech Language Pathologist and/or graduate student clinician, on the study team. This clinician will deliver the intervention from the NYU Voice Center using the web conferencing software Webex (institutional license) on a Dell desktop computer with a 3.1 GHz intel core processor and high definition camera. Each exercise set will include 40 repetitions (10 reps of effortful swallows, tongue hold swallows, effortful pitch glides and maximal posterior tongue presses). All exercises are widely-adopted by clinicians as standard of care exercises. The number of sets will be gradually increased as tolerance builds \[2 sets in week 1, 3 sets in week 2, 4 sets in weeks 3+\].
57927058|NCT03594851|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
58068187|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
58279499|NCT04034316|OTHER|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
58279500|NCT03337906|OTHER|Observation|
58068188|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
58306748|NCT04763993|PROCEDURE|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
58422721|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
57727036|NCT03854344|DRUG|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
57727037|NCT03854344|DRUG|Bupivacaine Hydrochloride|Used for regional nerve block for skin graft harvesting
57727038|NCT05054023|DRUG|Soulagel®|topic gel
57727039|NCT05054023|DRUG|Arthrosyl®|topic gel
57727040|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
57727041|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
57727042|NCT02256501|BIOLOGICAL|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
57727043|NCT03855722|PROCEDURE|RIPC|Remote Ischaemic Preconditioning
57727044|NCT03855722|PROCEDURE|Sham-RIPC|Sham procedure
57727045|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
57727046|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
57727047|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
57727048|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
57727049|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
57727050|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
57727051|NCT03647514|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
58068189|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
58306749|NCT03469544|OTHER|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
58395637|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
57927059|NCT03594851|BEHAVIORAL|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
57927060|NCT03594851|BEHAVIORAL|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
57927061|NCT03594851|BEHAVIORAL|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
57927062|NCT03594851|BEHAVIORAL|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
57927063|NCT03594851|BEHAVIORAL|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
57927064|NCT03594851|BEHAVIORAL|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
58068190|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
58068191|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
57727052|NCT03647514|DRUG|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
58068192|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
58306750|NCT01207193|BIOLOGICAL|cell injection|injection of mesenchymal cells to bone cyst defect
58306751|NCT04582656|DEVICE|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
58306752|NCT05433610|DEVICE|Non-invasive Ventilation|Exercise capacity testing using the device
58395638|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
58395639|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
58395640|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
58395641|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
58395642|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
58395643|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
58395644|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
58395645|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
58395646|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
58395647|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
58395648|NCT06169319|BIOLOGICAL|EN3835|Biologic: Intrafascial injection
58395649|NCT06169319|OTHER|Placebo|Intrafascial injection
58395650|NCT06403982|OTHER|Continuation of oxytocin after ELA|"The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery."
58395651|NCT06403982|OTHER|Discontinuation of oxytocin after ELA|The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
57927065|NCT03594851|BEHAVIORAL|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
57727053|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
57927066|NCT03594851|BEHAVIORAL|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses \& includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
57927067|NCT01268722|DEVICE|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
57927068|NCT01268722|DEVICE|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
58395652|NCT00298623|DRUG|XP13512 (GSK1838262)|
58395653|NCT00298623|OTHER|placebo|
58395654|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
58395655|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
58395656|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
58395657|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
58395658|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
58395659|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
58395660|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
58422722|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
58068193|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
57927069|NCT06288321|DRUG|Microdrop Mydrin-P|Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.
57927070|NCT06288321|DRUG|Standard Mydrin-P|Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
57927071|NCT01562171|OTHER|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
57927072|NCT01562171|OTHER|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
57927073|NCT03510988|DIAGNOSTIC_TEST|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
57927074|NCT04312464|OTHER|non|no intervention
58068194|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
58068195|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
58095068|NCT05204888|DEVICE|Pulse oximeter|A pulse oximeter will be provided to measure heart rate and pulse oximetry; subjects will enter and transmit the data on the smartphone once daily before 11AM. Heart rate and pulse oximetry measures will be taken after wearing the device for approximately 2 minutes.
58279501|NCT05786599|DRUG|methadone|"The treatment arm will take methadone 2 mg PO q8h and a placebo called placeboD PO qdaily. PlaceboD and duloxetine will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
58279502|NCT05786599|DRUG|duloxetine|"The control arm will receive duloxetine 30 mg PO qdaily, and a placebo called placeboM PO q8h. PlaceboM and methadone will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
58279503|NCT05112757|OTHER|Smartphone application use|Use of a smartphone application
58279504|NCT04606667|OTHER|Exercise Program|Exercise program
58279505|NCT05196477|DRUG|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
58279506|NCT05196477|DRUG|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
58395661|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
58395662|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
58395663|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
57927075|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
57927076|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
57927077|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
58068196|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
58068197|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
58068198|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
58068199|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
58068200|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
58279507|NCT01501032|DEVICE|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
58068201|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
58068202|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
58279508|NCT04745507|OTHER|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
58279509|NCT01172808|DRUG|Placebo|Placebo that represents comparator
58279510|NCT01172808|DRUG|tiotropium Respimat® low dose|IMP
58279511|NCT01172808|DRUG|Placebo|Placebo that represents comparator
58279512|NCT01172808|DRUG|Placebo|Placebo that represents comparator
58279513|NCT01172808|DRUG|tiotropium Respimat® high dose|IMP
58279514|NCT01172808|DRUG|50 mcg salmeterol HFA MDI|Active comparator
58279515|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
58279516|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
58279517|NCT00464295|DRUG|Capecitabine in HCC|
58279518|NCT00025753|DRUG|rosiglitazone (Avandia)|
58395664|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
58395665|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
57927078|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
57927079|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
57927080|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
57927081|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
58279519|NCT00025753|BEHAVIORAL|Aerobic and weight lifting exercise training|
58279520|NCT03964701|OTHER|no intervention|no interventional study
58279521|NCT03899012|PROCEDURE|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
58279522|NCT05135793|DRUG|Topoprazan|1 tablet contains 20 mg vonoprazan
58279523|NCT05135793|DRUG|Takecab|1 tablet contains 20 mg vonoprazan
58279524|NCT04399538|DRUG|PF-06865571|Tablet
58422723|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
58422724|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
58422725|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
58395666|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
58395667|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
58395668|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
58395669|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
58395670|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
58395671|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
58395672|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
58422726|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
57927082|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
57927083|NCT05066698|BIOLOGICAL|ST266|Topical ocular application: one drop four times a day for eight weeks
57927084|NCT05066698|OTHER|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
57927085|NCT05066698|BIOLOGICAL|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
58068203|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
58068204|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
58068205|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
58068206|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
58068207|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
58068208|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
58279525|NCT04399538|DRUG|PF-05221304|Tablet
57727054|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
57927086|NCT00424866|DRUG|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
58279526|NCT04399538|DRUG|Placebo|Tablet
58279527|NCT05127928|DIETARY_SUPPLEMENT|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
57927087|NCT00424866|DRUG|Placebo|Vehicle: 0 µg/kg
57927088|NCT01774851|DRUG|MM-111|MM-111 (IV)
57927089|NCT01774851|DRUG|Paclitaxel|Paclitaxel (IV)
57927090|NCT01774851|DRUG|Trastuzumab|Trastuzumab (IV)
57927091|NCT01956500|DIETARY_SUPPLEMENT|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
57927092|NCT01956500|DIETARY_SUPPLEMENT|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
57927093|NCT01764113|BEHAVIORAL|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
57927094|NCT01764113|BEHAVIORAL|Standard dietary counselling|
57927095|NCT03023228|BEHAVIORAL|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
57927096|NCT03291704|DEVICE|Thermal therapy device|Thermal therapy of blocked Meibomian glands
57927097|NCT01765179|DRUG|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
57927098|NCT05555511|OTHER|Control Group|Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
57927099|NCT00550368|BIOLOGICAL|Biological intervention: Enteropathogenic E. coli|5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
57927100|NCT05689983|DRUG|Maintenance ICS and Symptom Driven SABA|In this intervention, patients will be assigned to a standard therapy with a maintenance inhaled corticosteroid (Flovent) and an as needed short-acting beta-agonist and their adherence to this regimen will be assessed and compared to patients taking a regimen with an as needed inhaled corticosteroid and long-acting beta-agonist.
57927101|NCT05689983|DRUG|Symptom-driven budesonide/formoterol combination|In this intervention, patients will be assigned to a symptom-driven budesonide/formoterol combination therapy (Symbicort) and their adherence to this regimen will be assessed and compared to patients taking a standard therapy with a maintenance inhaled corticosteroid and as needed short-acting beta-agonist.
57927102|NCT03953703|DRUG|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
57927103|NCT03953703|DRUG|Placebo|Placebo 1000 mg twice per day for 6 weeks
57927104|NCT04777253|OTHER|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
57927105|NCT04777253|OTHER|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
57927106|NCT00118443|BEHAVIORAL|Question, Persuade, Refer (QPR) training|
57927107|NCT05325697|COMBINATION_PRODUCT|Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement|The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
57927108|NCT00533741|DRUG|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
58068209|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
58279528|NCT05127928|DIETARY_SUPPLEMENT|Placebo|Placebo administration
58279529|NCT00617513|DRUG|Prucalopride|0.5 mg once daily
58279530|NCT00617513|OTHER|Placebo|o.d.
58279531|NCT00617513|DRUG|Prucalopride|1 mg o.d.
58279532|NCT00617513|DRUG|Prucalopride|2 mg o.d.
58279533|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
57927109|NCT00533741|DRUG|Placebo|Saline for injection.
58068210|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
58068211|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
58068212|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
58279534|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
58279535|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
58279536|NCT04591457|DRUG|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
58279537|NCT04591457|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
58279538|NCT00946127|PROCEDURE|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
58279539|NCT00946127|PROCEDURE|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
58279540|NCT00441948|DEVICE|Peterio|
58279541|NCT05202860|BIOLOGICAL|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
57927110|NCT00533741|BIOLOGICAL|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
57927111|NCT03114007|BEHAVIORAL|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
57927112|NCT03114007|BEHAVIORAL|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
57927113|NCT03114007|BEHAVIORAL|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
57927114|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
57927115|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
57927116|NCT06048354|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
57927117|NCT06435754|PROCEDURE|Intervention group Vestibular Socket Preservation|After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
58068213|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
58068214|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
58068215|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
58068216|NCT03138707|OTHER|patients who die|
58068217|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
58068218|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
58068219|NCT04937127|OTHER|usual care|usual care
58068220|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
58279542|NCT05202860|BIOLOGICAL|PLACEBO vaccine|Isotonic saltwater sham vaccine
58279543|NCT03811054|DRUG|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
58306753|NCT01035138|DRUG|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
58306754|NCT04040686|DRUG|Injection of 99mTc-NM-02|Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
57927118|NCT06435754|PROCEDURE|Control Group ice cream cone technique|After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
57927119|NCT00209456|DRUG|DatSCAN|
57927120|NCT02549560|DEVICE|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
57927121|NCT05467878|OTHER|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
58068221|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
58395673|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
57727055|NCT05816421|BEHAVIORAL|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
57727056|NCT05816421|BEHAVIORAL|Non-Affinity KEEP|Non-Affinity KEEP
57927122|NCT03159923|OTHER|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
57927123|NCT06348940|BEHAVIORAL|behavioral activation|Behavioral activation, an emerging psychological intervention approach, has potential in alleviating negative emotions among cancer patients. The intervention group underwent an eight-week behavioral activation program designed to promote engagement in meaningful activities that are physically and emotionally rewarding while reducing involvement in maladaptive emotional cycles.
57927124|NCT00931554|PROCEDURE|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
57927125|NCT02272855|BIOLOGICAL|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
57927126|NCT03675672|DRUG|Misoprostol Oral Tablet|Misoprostol 200mcg
57927127|NCT03675672|DRUG|Placebo Oral Tablet|Placebo Tablet
57927128|NCT03898115|BEHAVIORAL|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
57927129|NCT00934804|DEVICE|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
57927130|NCT02904434|OTHER|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
57927131|NCT05898386|BEHAVIORAL|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
57927132|NCT04910646|DRUG|orange peel fermentation|To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
58306755|NCT00968461|DRUG|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
57727057|NCT06077006|OTHER|questionnaires Only|questionnaires Only
57927133|NCT04910646|DRUG|Placebo|Placebo without orange peel fermentation
58068222|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
58306756|NCT00333528|DRUG|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
58306757|NCT00333528|DRUG|Placebo: Normal saline|Intramuscular administration
58395674|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
58395675|NCT03636438|OTHER|No Intervention|No Intervention
58395676|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
58395677|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
58395678|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
57927134|NCT05227547|OTHER|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
58395679|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
58395680|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
57727058|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
57927135|NCT06493604|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
58068223|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
57727059|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
58068224|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
58068225|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
58068226|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
58068227|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
58068228|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
58095069|NCT00998582|DRUG|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
58279544|NCT05679297|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~2. Thermal pain threshold~3. Mechanical detection thresholds for touch~4. Mechanical pain threshold for pinprick stimuli~5. Stimulus-response functions~6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~7. Vibration detection threshold~8. Pressure pain threshold"
58395681|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
58395682|NCT00093197|DRUG|Placebo|
58395683|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
58395684|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
58395685|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
58395686|NCT02497365|DRUG|Besifloxacin|
58395687|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
58395688|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
57727060|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
57727061|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
57927136|NCT06493604|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
57927137|NCT05101616|DRUG|camrelizumab+chemotherapy|camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
58395689|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
58395690|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
58395691|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
58395692|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
58395693|NCT04771520|DRUG|Avapritinib|Given PO
58395694|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
58395695|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
58395696|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
58395697|NCT00033566|DRUG|S-3304|
58279545|NCT05679297|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
58279546|NCT05679297|OTHER|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
58279547|NCT05679297|OTHER|Follow-up interview|"Structured telephone interview with 3 Questionnaires~1. The german pain questionnaire~2. Questionnaire regarding clinical development since the last visit designed by the investigators~3. German translation of 12-item-allodynia symptom checklist (ASC-12)"
58279548|NCT02148315|BEHAVIORAL|garden|
58279549|NCT00017680|DRUG|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
58095070|NCT02263586|BEHAVIORAL|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
58279550|NCT00017680|PROCEDURE|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
58279551|NCT05911672|DEVICE|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa_token=tC5fSN8-k5EAAAAA:56_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
58279552|NCT02927496|DRUG|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)"
58279553|NCT02927496|DRUG|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
58395698|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
58306758|NCT04795635|DEVICE|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
58395699|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
58395700|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
58395701|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
58395702|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
58306759|NCT04005040|PROCEDURE|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
58395703|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
58395704|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
58395705|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
57727062|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
57727063|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
57727064|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
58095071|NCT01990079|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
58395706|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
58395707|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
58395708|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
58395709|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
58395710|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
57727065|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
57927138|NCT05101616|DRUG|Chemotherapy|albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
57927139|NCT01431534|DRUG|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
57927140|NCT00863863|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
57927141|NCT00863863|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
58068229|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
58068230|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
58068231|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
58068232|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
58422727|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
57727066|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
57727067|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.
57727068|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.
57727069|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.
57727070|NCT03890341|DRUG|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
57727071|NCT03890341|DRUG|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
57727072|NCT03890341|DRUG|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
57727073|NCT03331120|DEVICE|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
57727074|NCT06300021|DIETARY_SUPPLEMENT|TPG capsule|A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
57927142|NCT00719563|DRUG|American ginseng|Given orally
58422728|NCT06137768|DRUG|HRS-5965|HRS-5965
57927143|NCT00719563|OTHER|placebo|Given orally
57927144|NCT00490009|DRUG|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy"
57927145|NCT00490009|DRUG|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
57927146|NCT00490009|DRUG|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
57927147|NCT00490009|DRUG|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
58395711|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
58395712|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
58395713|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
57927148|NCT02616523|DRUG|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
58279554|NCT04293172|DRUG|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
58395714|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
58395715|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
58279555|NCT04293172|DRUG|Placebo|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
58279556|NCT06215144|DRUG|NRCT-101SR|NRCT-101SR is a sustained release formulation.
57927149|NCT02616523|DRUG|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
58068233|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
58068234|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
58068235|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
58279557|NCT04752306|OTHER|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
58279558|NCT05023070|DRUG|Cannabidiol|Cannabidiol 200 mg
58279559|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
58279560|NCT05023070|DRUG|Cannabidiol|Epidiolex 400 mg
58279561|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
58395716|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
58395717|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
58395718|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
58422729|NCT06137768|DRUG|Placebo|Placebo.
57927150|NCT02616523|OTHER|placebo|The participants will be given infusion of normal saline intravenously.
57927151|NCT02616523|DRUG|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
57927152|NCT02411682|OTHER|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
57927153|NCT02411682|OTHER|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
57927154|NCT02870413|BEHAVIORAL|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
57927155|NCT00139087|BEHAVIORAL|Telephone Outreach for Therapy|
57927156|NCT00986440|DRUG|CS-7017|CS-7017
57927157|NCT00986440|DRUG|Placebo|Placebo
57927158|NCT00142051|DRUG|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
57927159|NCT00142051|DRUG|oxygen|oxygen fi02 21% (room air)
58068236|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
58068237|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
58068238|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
58068239|NCT01636076|DRUG|QMF149|delivered via Concept1 device
58068240|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
58068241|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
58068242|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
58068243|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
58279562|NCT04735796|DRUG|Drug：LM-102|Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
58279563|NCT02797418|BEHAVIORAL|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
58279564|NCT00170014|DEVICE|Magnetocardiograph|
58279565|NCT00878605|DRUG|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
58279566|NCT00878605|DRUG|Placebo|Placebo control
58279567|NCT05872880|PROCEDURE|Modified radical surgery|The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.
58279568|NCT05872880|PROCEDURE|Radical surgery|Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
58279569|NCT05047614|DEVICE|including sham|Repositiong feedback training and biofeedback pressure training unit
58279570|NCT04304261|DRUG|Canagliflozin|12 weeks of Canagliflozin(100mg/day) treatment
58279571|NCT04304261|DRUG|Sitagliptin|12 weeks of Sitagliptin (100mg/day) treatment
58279572|NCT04575532|DEVICE|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
58279573|NCT04118777|DRUG|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
57727075|NCT06300021|DIETARY_SUPPLEMENT|TPG ready to drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
57727076|NCT06300021|DIETARY_SUPPLEMENT|TPG dairy analog|Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
58068244|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
58068245|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
58068246|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
58068247|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
58068248|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
58068249|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
58068250|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
58068251|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
58279574|NCT00549601|DRUG|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
58279575|NCT00549601|DRUG|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
57927160|NCT06032936|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
57927161|NCT06032936|DRUG|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
58068252|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
58068253|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
58068254|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
58068255|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
57927162|NCT05066009|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consistent contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
57927163|NCT05066009|DEVICE|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
58068256|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
57927164|NCT05066009|OTHER|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
58068257|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
58068258|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
58068259|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
58068260|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
58068261|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
58068262|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
58068263|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
58068264|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
58068265|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
58068266|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
58068267|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
58068268|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
58068269|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
58068270|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
58395719|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
57727077|NCT06300021|DIETARY_SUPPLEMENT|TPG probiotic drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
57727078|NCT06300021|DIETARY_SUPPLEMENT|TPG gummies|Pectin gummies containing 300 mg Turmipure Gold®
57927165|NCT01240083|DEVICE|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
58279576|NCT00549601|DRUG|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
57727079|NCT06300021|DIETARY_SUPPLEMENT|TPG sport bar|Sport nutrition bar containing 300 mg Turmipure Gold®
58279577|NCT03280316|PROCEDURE|surgery|patients with SVMs receive surgery
58279578|NCT03280316|PROCEDURE|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
58279579|NCT03280316|PROCEDURE|botulinum toxin A injection|BOTOX
57727080|NCT00548821|DRUG|Cisplatin|
57727081|NCT03032120|DIETARY_SUPPLEMENT|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
57727082|NCT03032120|DIETARY_SUPPLEMENT|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
57727083|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
57727084|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
57727085|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
57727086|NCT03466580|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
57927166|NCT01240083|DEVICE|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
58068271|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
58279580|NCT03280316|DRUG|M receptor antagonist|Tolterodine
58279581|NCT04129125|DEVICE|Zoom Reperfusion System|Thrombectomy
57727087|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
57727088|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
57727089|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
57727090|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
57727091|NCT05550246|DRUG|Atomoxetine|Treatment given for 3 nights
57727092|NCT05550246|DRUG|Oxybutynin|Treatment given for 3 nights
57927167|NCT01240083|DEVICE|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
57927168|NCT02300909|PROCEDURE|Lumbar Decompression Surgery|Lumbar Decompression Surgery
57927169|NCT02300909|PROCEDURE|Microdiscectomy Surgery|Microdiscectomy Surgery
57927170|NCT02300909|OTHER|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
58068272|NCT01809158|DRUG|minocycline|
58068273|NCT01809158|DRUG|placebo|
58279582|NCT04006678|PROCEDURE|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
58279583|NCT01741155|DRUG|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
58279584|NCT01741155|DRUG|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
58279585|NCT03761004|DRUG|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
58279586|NCT00478088|DEVICE|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
58279587|NCT00478088|DEVICE|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
58279588|NCT03613688|DIETARY_SUPPLEMENT|Deepure|Pu'erh Tea extract
58279589|NCT01786031|OTHER|metastasis biopsy|
58279590|NCT02171832|DRUG|BI 1744 CL, low dose|
58279591|NCT02171832|DRUG|BI 1744 CL, high dose|
58279592|NCT01123772|DRUG|INO-8875|eye drops for 14 days in one eye
57927171|NCT01922479|DRUG|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
57927172|NCT01922479|DRUG|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
57727093|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
57727094|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
57927173|NCT00499954|PROCEDURE|Microdialysis|
57927174|NCT00499954|DEVICE|Guardian RT|
57927175|NCT00499954|DEVICE|Glucoday S|
58279593|NCT01123772|OTHER|Placebo control|Matched placebo
58279594|NCT04347655|PROCEDURE|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
58279595|NCT04859309|BEHAVIORAL|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
58279596|NCT04859309|PROCEDURE|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
58279597|NCT03149822|DRUG|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
57727095|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
57727096|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
57927176|NCT00647751|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
57927177|NCT00647751|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fed
58279598|NCT03149822|DRUG|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
57727097|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
57727098|NCT03006406|DRUG|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
57727099|NCT02683538|DEVICE|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
57727100|NCT01772992|BEHAVIORAL|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
57927178|NCT00707850|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
57927179|NCT03318939|DRUG|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID"
57927180|NCT02350179|DRUG|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
58068274|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
58279599|NCT02217800|DRUG|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
58279600|NCT02217800|DRUG|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
58395720|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
58395721|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
58395722|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
58395723|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
58395724|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
58395725|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
58395726|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
57927181|NCT02350179|DRUG|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
57927182|NCT04709822|BEHAVIORAL|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
58279601|NCT02217800|DRUG|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
58395727|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
58395728|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
58395729|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
57927183|NCT02245126|DRUG|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
57927184|NCT02245126|DRUG|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
58068275|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
58279602|NCT05521113|BEHAVIORAL|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
58279603|NCT05521113|BEHAVIORAL|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
58279604|NCT02686788|DRUG|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
58395730|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
58395731|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
58068276|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
58068277|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
58279605|NCT03371056|BIOLOGICAL|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
58279606|NCT00441987|DRUG|GSI-953|
58279607|NCT01634568|DRUG|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
58279608|NCT03001245|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
58068278|NCT03907072|DRUG|Placebo|Buffered saline solution
58068279|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
58279609|NCT03001245|BEHAVIORAL|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
58279610|NCT04808414|DRUG|QPX9003 for IV Infusion|antibiotic
58279611|NCT04808414|DRUG|Placebo for IV infusion|Placebo comparator
58279612|NCT02372942|DRUG|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
58395732|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
58395733|NCT01905046|DRUG|metformin hydrochloride|given PO
58395734|NCT01905046|OTHER|placebo|given PO
58395735|NCT03702959|DRUG|Betamethasone|Corticosteroids
58395736|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
58395737|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
58395738|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
58395739|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
58395740|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
58395741|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
57927185|NCT04589182|DEVICE|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
57927186|NCT04589182|DEVICE|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
57927187|NCT04946903|DRUG|RLD2007|Take it once per period.
57927188|NCT04946903|DRUG|RLD2008|Take it once per period.
57927189|NCT04946903|DRUG|HCP1902|Take it once per period.
57927190|NCT02297360|DIETARY_SUPPLEMENT|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
57927191|NCT02297360|OTHER|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
57927192|NCT06146023|DEVICE|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
57927193|NCT06146023|PROCEDURE|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
57927194|NCT03930368|OTHER|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
57927195|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
57927196|NCT04584203|PROCEDURE|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
57927197|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
57927198|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
57927199|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
57927200|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
57927201|NCT03570853|BEHAVIORAL|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
57927202|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
58068280|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
58395742|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
58395743|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
58395744|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
58395745|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
58395746|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
57927203|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
58068281|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
58068282|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
58068283|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
58068284|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
58068285|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
58068286|NCT02741336|BEHAVIORAL|Self-Monitoring|
58279613|NCT02372942|DRUG|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
58395747|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
57727101|NCT00438516|BEHAVIORAL|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
57727102|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
57727103|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
57927204|NCT01509326|OTHER|chiropractic treatment|12 sessions over 4 weeks
57927205|NCT01509326|DEVICE|Dr. Zaxx pillow|Daily use of an acupressure pillow
57927206|NCT05395104|DRUG|Midazolam|Syrup for oral administration
58068287|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
58068288|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
58068289|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
58068290|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
58068291|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
58095072|NCT01990079|DRUG|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
58279614|NCT01464619|OTHER|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
58279615|NCT01464619|OTHER|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
58279616|NCT02815150|DIETARY_SUPPLEMENT|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
58395748|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
58395749|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
58395750|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
58395751|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
58395752|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
57727104|NCT05123248|DEVICE|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
57927207|NCT05395104|DRUG|Cefiderocol|Liquid for intravenous infusion
57927208|NCT00892177|BIOLOGICAL|bevacizumab|Given intravenously
57927209|NCT00892177|DRUG|dasatinib|Given orally
57927210|NCT00892177|OTHER|placebo|Given orally
57927211|NCT00975715|DRUG|TRI476|TRI476 oral suspension doses, based on body weight twice daily
58395753|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
58395754|NCT00711230|BIOLOGICAL|DermaVir|
58395755|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
57927212|NCT00975715|DRUG|Placebo to TRI476|Placebo oral suspension, taken twice daily
57927213|NCT00975715|DRUG|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
57927214|NCT01966393|OTHER|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
57927215|NCT05933187|DRUG|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
57927216|NCT05933187|DRUG|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
57927217|NCT05933187|DRUG|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
57927218|NCT05933187|DRUG|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
57727105|NCT05123248|DEVICE|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
57927219|NCT01873495|DRUG|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
57927220|NCT00432887|DRUG|caffeine administration|
57927221|NCT05398250|BEHAVIORAL|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
57927222|NCT05398250|BEHAVIORAL|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation"
57927223|NCT02678416|DRUG|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
57927224|NCT02678416|DRUG|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
57927225|NCT02678416|DRUG|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
57927226|NCT02678416|OTHER|Morphine (Treatment D)|Morphine administered by IV infusion
57927227|NCT05893277|BEHAVIORAL|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
57927228|NCT05815290|DRUG|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
57927229|NCT01210079|DRUG|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
57727106|NCT02331134|DRUG|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
57927230|NCT01210079|DRUG|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
57927231|NCT05419843|OTHER|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
58279617|NCT03850691|DRUG|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
57927232|NCT05386784|DRUG|Raloxifene plus cholecalciferol|Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
57927233|NCT05386784|DRUG|Cholecalciferol|D3 oral base drop, 4 drops once daily (800 IU)
58279618|NCT03850691|DRUG|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
58395756|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
58395757|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
58395758|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
58395759|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
58395760|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
58395761|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
58395762|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
58395763|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
58395764|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
58395765|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
58395766|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
58395767|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
58395768|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
58395769|NCT02381717|DRUG|bupivacaine|
57927234|NCT06026228|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit"
57927235|NCT06026228|OTHER|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
57927236|NCT03431857|DEVICE|TESS V2|Patients requiring the TESS V2 prosthesis.
58395770|NCT02381717|DRUG|morphine|
57727107|NCT03832946|DRUG|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
57727108|NCT03832946|DRUG|Placebo|Placebo is administered as inhalation once a day
57927237|NCT02887807|DRUG|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
57927238|NCT02887807|DRUG|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
57927239|NCT00498251|DRUG|inhalation of salbutamol (5 mg)|
57927240|NCT00498251|DRUG|ipratropium|
57927241|NCT05529823|BEHAVIORAL|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
57927242|NCT01196533|DEVICE|Non invasive peripheral blood monitoring|non invasive monitoring
57927243|NCT05032768|RADIATION|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
57927244|NCT05198479|RADIATION|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
57927245|NCT04209465|DRUG|BDTX-189|Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
57927246|NCT05099653|OTHER|physical activity|physical activity
57927247|NCT06170112|OTHER|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
58395771|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
58395772|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
58395773|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
58395774|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
58395775|NCT02182024|DRUG|Dabigatran etexilate high dose|
58395776|NCT02182024|DRUG|Dabigatran etexilate low dose|
57927248|NCT02920086|BEHAVIORAL|Nutrition Education Program|"* The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
57927249|NCT02920086|OTHER|Decision Support Program|"* Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care"
57927250|NCT05848622|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
57927251|NCT05848622|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
58095073|NCT01990079|OTHER|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
57927252|NCT02505581|DRUG|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
58279619|NCT03850691|DRUG|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
58395777|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
58395778|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
57927253|NCT02505581|PROCEDURE|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
57927254|NCT02505581|DRUG|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
57927255|NCT02505581|DRUG|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
57927256|NCT02505581|DRUG|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
57927257|NCT02505581|DRUG|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
57927258|NCT00443638|BEHAVIORAL|nurse home visitation|Nurse home visitation
57927259|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
57927260|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
57927261|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
57927262|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
57927263|NCT05860023|OTHER|Exercise|Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
57927264|NCT01317212|DRUG|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
57927265|NCT03150316|DRUG|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
57927266|NCT02907931|OTHER|Point of Care Ultrasound|
57927267|NCT00174265|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
57927268|NCT00174265|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
57927269|NCT05928091|OTHER|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
57927270|NCT00993135|DRUG|methotrexate|
57927271|NCT00993135|OTHER|medical chart review|
58395779|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
58395780|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
57927272|NCT00993135|PROCEDURE|assessment of therapy complications|
58068292|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
58279620|NCT03850691|DRUG|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
58279621|NCT01796314|BEHAVIORAL|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~1. Knowledge of the disease~2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~3. Crisis situations. Prevention of caregiver's exhaustion~4. Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
58279622|NCT02175329|DEVICE|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
58279623|NCT02175329|DEVICE|Manually layered veneering|
58279624|NCT05849792|BEHAVIORAL|Exercise and psychological intervention|"Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive."
58279625|NCT01400906|DRUG|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
58279626|NCT01400906|DRUG|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
58279627|NCT01400906|DRUG|lactose powder|lactose powder in dry powder device : placebo comparator
58279628|NCT06059729|DEVICE|Al-Lisaan|Al-Lisaan is a digital application for the self assessment and management of adult stutters.
58279629|NCT00006087|PROCEDURE|annual screening|
58395781|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
57927273|NCT02741583|OTHER|altitude rehabilitation program|altitude exposure
57927274|NCT02741583|OTHER|rehabilitation program|Rehabilitation at low altitude
58279630|NCT00006087|PROCEDURE|bronchoscopic and lung imaging studies|
58279631|NCT00006087|PROCEDURE|comparison of screening methods|
58279632|NCT00006087|PROCEDURE|computed tomography|
58279633|NCT00006087|PROCEDURE|radiography|
58279634|NCT00006087|PROCEDURE|study of high risk factors|
58279635|NCT04346771|BEHAVIORAL|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
58279636|NCT04346771|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
58279637|NCT02342600|DRUG|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
58395782|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
58395783|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
58395784|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
58395785|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
58395786|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
58422730|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
57927275|NCT03327116|DRUG|Methotrexate|oral, 15 mg per week, 24 weeks
57927276|NCT00470210|DRUG|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
57927277|NCT00470210|DRUG|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
57927278|NCT00470210|DRUG|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
57927279|NCT00204971|DIETARY_SUPPLEMENT|Enteral glutamine powder|nutritional supplement
57927280|NCT00204971|OTHER|placebo|placebo control
57927281|NCT05629195|DEVICE|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
57927282|NCT01679366|DRUG|Placebo|1 tablet 2 times daily
57927283|NCT01679366|DRUG|Probiotics|1 tablet twice daily
57927284|NCT06225635|DRUG|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
58395787|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
57927285|NCT06225635|DRUG|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
58068293|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
57927286|NCT02687425|DRUG|Pioglitazone|15mg/day,po
58068294|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
57927287|NCT02687425|DRUG|imatinib mesylate|400mg/day,po
58068295|NCT04415749|OTHER|Placebo|Normal saline
58279638|NCT02342600|DRUG|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
57927288|NCT02993653|RADIATION|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
57927289|NCT06175546|DEVICE|Compression socks|Wearing of compression sock in prescribed regimen
58279639|NCT02806830|DRUG|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
58279640|NCT01234701|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
58279641|NCT01234701|PROCEDURE|Liver resection|Hepatectomy with an intention to cure
58279642|NCT01234701|OTHER|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
58279643|NCT06292130|BEHAVIORAL|refresh|A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
58279644|NCT02682511|DRUG|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
58279645|NCT02682511|DRUG|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
57927290|NCT01480284|DRUG|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
57927291|NCT01480284|DRUG|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
57927292|NCT00286351|DRUG|Combined treatment with Arimidex and Zoladex before IVF|
57927293|NCT03272568|DRUG|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
58068296|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
58068297|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
58068298|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
58068299|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
58068300|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
58068301|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
58068302|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
58068303|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
58068304|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
58068305|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
58068306|NCT02174406|PROCEDURE|breast ultrasound|
58068307|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
58279646|NCT01922856|BIOLOGICAL|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
58279647|NCT01922856|OTHER|No Intervention|Controls only receive challenge
58279648|NCT02017626|BIOLOGICAL|mCyp c 1|2 patient groups with different doses of allergen.
58279649|NCT04542278|DRUG|Prednisone|used to reduce inflammation
58279650|NCT00770666|DRUG|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
58279651|NCT00770666|DRUG|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
58279652|NCT02886884|DRUG|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
58279653|NCT02886884|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
58279654|NCT00564317|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
57927294|NCT03272568|DRUG|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
57927295|NCT03272568|DEVICE|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
57927296|NCT06227208|DEVICE|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
57927297|NCT00187772|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|
57927298|NCT06190795|OTHER|AMPLIFY Smartphone Application|AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform
57927299|NCT06190795|OTHER|Hardcopy Manual|Hardcopy Manual
57927300|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
57927301|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
57927302|NCT01409616|DRUG|darexaban|oral
57927303|NCT01409616|DRUG|darexaban (double dose)|oral
57927304|NCT01409616|DRUG|Acetyl Salicylic Acid|oral
57927305|NCT01409616|DRUG|clopidogrel|oral
57927306|NCT00888433|DEVICE|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
57927307|NCT00210756|DRUG|epoetin alfa|
58068308|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
58068309|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
58068310|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
58068311|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
58068312|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
58068313|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
58068314|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
58068315|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
58068316|NCT05302999|DRUG|Gabapentin|Generic gabapentin
58068317|NCT05302999|DRUG|Placebo|Inert cellulose
58068318|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
58068319|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
58095074|NCT01990079|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
58279655|NCT00564317|BEHAVIORAL|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
58279656|NCT00386230|DRUG|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
57927308|NCT05754554|PROCEDURE|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
57927309|NCT02173041|OTHER|Prevention Awareness Groups (PAG)|
58068320|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
58068321|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
58068322|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
57727109|NCT06331221|OTHER|Muscle fatigue Protocol|Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
57727110|NCT01734512|DRUG|Everolimus|Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
58068323|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
58068324|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
57727111|NCT00444548|DRUG|[S,S]-Reboxetine|
57727112|NCT00931177|OTHER|weight|weight and dehydration scores
57727113|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
57727114|NCT03365765|DRUG|Apatinib|Apatinib tablet
57727115|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
58068325|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
58068326|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
58068327|NCT00795717|DRUG|Placebo|2 capsules given twice daily
58068328|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
58068329|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
58068330|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
58068331|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
58068332|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
58068333|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
58068334|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
58068335|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
57727116|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
57727117|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
57727118|NCT01290367|PROCEDURE|Single injection of saline solution|Intradiscal control injection with saline solution
57927310|NCT02173041|OTHER|Standard Care|
57927311|NCT01800357|DRUG|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
57927312|NCT01800357|DRUG|placebo|infusion of plabcebo once a day and for 14 days
57927313|NCT01800357|DRUG|aspirin|infusion of aspirin (100mg) once a day for days
57927314|NCT02624765|DRUG|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
58068336|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
58279657|NCT00386230|DRUG|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
58395788|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
57727119|NCT01290367|PROCEDURE|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
57727120|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
57727121|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
57727122|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
57727123|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
57727124|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
57727125|NCT00931021|DRUG|Nicotine Patch|21 mg
57727126|NCT03351023|OTHER|no intervention-this was an observational study|
57727127|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
57727128|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
57727129|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
57727130|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
57727131|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
57727132|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
57927315|NCT02624765|DRUG|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
57927316|NCT02624765|DRUG|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
57927317|NCT02624765|DRUG|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
58279658|NCT00386230|DRUG|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
58279659|NCT00386230|DRUG|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
58279660|NCT04848753|COMBINATION_PRODUCT|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
58279661|NCT04848753|COMBINATION_PRODUCT|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
57727133|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
57727134|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
57727135|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
57727136|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
57727137|NCT04120506|DRUG|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
57727138|NCT00381394|DRUG|sitamaquine|
57727139|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
57727140|NCT06478927|DRUG|Palbociclib capsules|Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
57727141|NCT01646476|DEVICE|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
57727142|NCT01646476|DEVICE|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
57727143|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
57727144|NCT04937569|DRUG|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
57727145|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
57727146|NCT02370654|BEHAVIORAL|Tai chi|
57927318|NCT02624765|DRUG|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
57727147|NCT02370654|BEHAVIORAL|Conventional exercise|
57927319|NCT02624765|DRUG|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
57951164|NCT02604277|BEHAVIORAL|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
57927320|NCT06398860|PROCEDURE|SIOHPS|The intervention is comprised of several core components such as targeted education, daily team reflections and support for systematic management. First, a two hour education will be conducted for management, HCW involved in patient safety work, safety representatives and intervention facilitators. The second core component is a short daily team reflection conducted by HCW at the unit in connection to the end of work shifts. These are standardized to support identification of situations at work related to both Safety I and II perspective for both occupational health and patient safety as well as learning. The third component includes risk assessment, planning and implementation of appropriate measures, follow up and evaluation, based in information identified in the second component. The steps in this component targets the management and should be conducted in close collaboration with HCW involved in patient safety work and the safety representatives.
57927321|NCT06398860|PROCEDURE|Wait-list|No intervention
57927322|NCT04112329|BEHAVIORAL|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
57927323|NCT02887937|DRUG|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
57927324|NCT05620043|DEVICE|Sculptra|Biostimulator
57927325|NCT05620043|DEVICE|Radiesse Plus|Semi-permanent filler
57927326|NCT06503094|DRUG|CD19&CD20 bispecific CAR-T cells|Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
57927327|NCT02415465|PROCEDURE|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
57927328|NCT02415465|PROCEDURE|General|General Intraoperative Anesthesia
57927329|NCT02415465|PROCEDURE|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
57927330|NCT02415465|PROCEDURE|Spinal|Spinal Intraoperative Anesthesia
57927331|NCT04157140|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
57927332|NCT04157140|DEVICE|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
58279662|NCT02424994|OTHER|No intervention|
58279663|NCT01309750|RADIATION|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
58279664|NCT01024361|DEVICE|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
58279665|NCT04957199|OTHER||
58279666|NCT02510820|DEVICE|comfilcon A|soft contact lens
58279667|NCT02510820|DEVICE|Synergi|Multipurpose solution
58279668|NCT02510820|DEVICE|Biotrue|Multipurpose solution
58279669|NCT02510820|OTHER|stenfilcon A|daily disposable contact lenses for washout period
58279670|NCT04352738|DIAGNOSTIC_TEST|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
58279671|NCT02003989|OTHER|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
57927333|NCT03726762|BEHAVIORAL|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
57927334|NCT03726762|BEHAVIORAL|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
57927335|NCT05171439|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
57927336|NCT03972007|DEVICE|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
58279672|NCT02986347|PROCEDURE|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
58279673|NCT02986347|PROCEDURE|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
58279674|NCT06463379|DRUG|Solumedrol|2 days pulse steroid injection 125 mg methylrednisolone
58279675|NCT04084899|DEVICE|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
57927337|NCT00190632|DRUG|Duloxetine|
58279676|NCT03046056|DRUG|Filgotinib|Tablet(s) administered orally once daily
58279677|NCT03046056|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
58279678|NCT00742027|DRUG|Panobinostat|Panobinostat hard gelatin capsules.
58279679|NCT04893187|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
58279680|NCT04893187|DRUG|Placebo|Matched placebo.
58279681|NCT03437161|RADIATION|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
58279682|NCT05930405|PROCEDURE|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
58279683|NCT05930405|PROCEDURE|continuous epidural infusion|continuous epidural infusion
58279684|NCT05930405|DRUG|ropivacaine and sufentanil|0.15% ropivacaine and 0.4μg/ml sufentanil
58279685|NCT01660802|DRUG|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
58279686|NCT01660802|OTHER|Sham|Sham administered in the study eye on Day 1.
57927338|NCT03538379|BEHAVIORAL|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
58068337|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
57927339|NCT05202717|DEVICE|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
57927340|NCT05202717|DEVICE|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
57927341|NCT00509665|DRUG|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
57927342|NCT00509665|DRUG|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
58068338|NCT00027846|PROCEDURE|therapeutic conventional surgery|
58279687|NCT01734083|DEVICE|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
58279688|NCT01734083|BEHAVIORAL|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
58279689|NCT00703118|DRUG|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
58279690|NCT00703118|DRUG|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
58395789|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
58395790|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
58395791|NCT00042952|DRUG|imatinib mesylate|Given orally
58395792|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
58395793|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
58395794|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
58395795|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
58395796|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
58395797|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
58395798|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
58395799|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
57727148|NCT05168774|DRUG|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
57927343|NCT02797210|DEVICE|Continuous theta-burst stimulation|
57927344|NCT02884765|PROCEDURE|Non-surgical|Non-surgical treatment in both condylar fractures
57927345|NCT02884765|PROCEDURE|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
57927346|NCT02884765|PROCEDURE|Surgical|Surgical treatment in both condylar fractures
57927347|NCT01704833|BEHAVIORAL|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
57927348|NCT03521414|DEVICE|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
57927349|NCT03521414|DRUG|Sevoflurane|we used sevoflurane drug at inoperative
58068339|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells
58068340|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
58068341|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
58068342|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
58068343|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
58279691|NCT00703118|DRUG|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
58395800|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
58395801|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
58395802|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
58395803|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
57727149|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
57727150|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
57727151|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
57727152|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
57727153|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
57927350|NCT00375219|DRUG|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
57927351|NCT04903808|DRUG|Allium Sativum Oil|Garlic oil Captain Company (CAP-PHARM)
57927352|NCT04903808|DRUG|Mineral Tri-Oxide Aggregate|ProRoot MTA, Dentsply
58279692|NCT00703118|DRUG|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
58279693|NCT03765229|DRUG|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
58279694|NCT03765229|DRUG|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
58279695|NCT03230838|DRUG|Ceftolozane/Tazobactam|12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
57727154|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
57727155|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
57727156|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
57727157|NCT06157931|BEHAVIORAL|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
57727158|NCT00612612|DRUG|obatoclax mesylate|Given IV
57727159|NCT00612612|DRUG|fludarabine phosphate|Given IV
57927353|NCT01222637|DRUG|CetuGEX™|
57927354|NCT00874666|OTHER|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
57927355|NCT00874666|DIETARY_SUPPLEMENT|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
58279696|NCT03230838|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
58395804|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
58395805|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
58395806|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
58395807|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
58395808|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
57927356|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
58395809|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
57727160|NCT00612612|BIOLOGICAL|rituximab|Given IV
57927357|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
57927358|NCT03558256|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
57927359|NCT03558256|DRUG|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
57927360|NCT06234254|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
57927361|NCT01778660|OTHER|Type of Counselling (Mnemonic)|
57927362|NCT01778660|OTHER|Standard|
57927363|NCT00556920|DRUG|COREG CR|
57927364|NCT01581541|DRUG|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
57927365|NCT02842840|BEHAVIORAL|Patient-based intervention|
57927366|NCT02842840|BEHAVIORAL|Family based intervention|
58279697|NCT03278847|DIETARY_SUPPLEMENT|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
58279698|NCT03278847|DIETARY_SUPPLEMENT|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
57927367|NCT02842840|OTHER|Routine counseling|
57927368|NCT04377828|DEVICE|Pigment laser|one to two session of pigment laser (532 nm)
58279699|NCT03278847|DIETARY_SUPPLEMENT|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
57727161|NCT00612612|OTHER|laboratory biomarker analysis|Correlative study
57727162|NCT04824313|DIAGNOSTIC_TEST|Chest CT|Chest CT without intravenous contrast material
57727163|NCT04824313|DIAGNOSTIC_TEST|Chest CTA|Chest CT with intravenous contrast material
57927369|NCT03749603|DEVICE|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
57927370|NCT00388154|DRUG|Gemcitabine|900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
57927371|NCT00388154|DRUG|Cisplatin|30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
57927372|NCT00530296|BEHAVIORAL|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
57927373|NCT03142438|DEVICE|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
58279700|NCT03278847|DIETARY_SUPPLEMENT|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
58395810|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
58395811|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
58395812|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
58395813|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
58068344|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
58068345|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
58068346|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
58068347|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
57927374|NCT01688583|DRUG|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
57927375|NCT06102577|DIETARY_SUPPLEMENT|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
57927376|NCT06102577|OTHER|1gr Placebo|ake 1g. of placebo at the end of an osteopathic manual treatment
57927377|NCT06102577|OTHER|control group|control
58068348|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
58068349|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
58068350|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
58068351|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
58279701|NCT02634944|DIAGNOSTIC_TEST|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
58279702|NCT06455345|DEVICE|Self-Guided Online ACT Program|Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.
58279703|NCT06455345|OTHER|Treatment As Usual|Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
58279704|NCT06316388|PROCEDURE|vitrectomy|pars plana vitrectomy
58279705|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
58395814|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
58395815|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
58395816|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
58422731|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
57927378|NCT06491407|DIAGNOSTIC_TEST|Chewing and swallowing performance assessment and related factors|In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
57927379|NCT01009203|DRUG|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
57927380|NCT01009203|DRUG|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
58068352|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
58068353|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
58068354|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
58068355|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
58068356|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
58068357|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
58068358|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
58068359|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
58068360|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
58068361|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
58068362|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
58068363|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
58068364|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
58068365|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
58068366|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
57927381|NCT05265910|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
57927382|NCT05265910|DRUG|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
57927383|NCT05265910|DRUG|Tears Naturale|Tears Naturale® II (eyedrop)
58068367|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
58068368|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
58068369|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
58068370|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
58068371|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
58068372|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
58395817|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
58395818|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
58068373|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
58068374|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
58068375|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
57927384|NCT05265910|DRUG|Placebo|Placebo tablet (tablet)
57927385|NCT04260009|DRUG|Brigatinib|Brigatinib tablets
57927386|NCT04260009|DRUG|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
58068376|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
58068377|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
58068378|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
58068379|NCT02184520|DEVICE|TRANSITION|
58068380|NCT02184520|DEVICE|REVERE|
58068381|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
58068382|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
57727164|NCT01990053|BEHAVIORAL|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
58068383|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
57727165|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
57727166|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
57927387|NCT03299751|BIOLOGICAL|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
58068384|NCT01682694|DIETARY_SUPPLEMENT|placebo|
58068385|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
57927388|NCT02798263|OTHER|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
57927389|NCT02798263|OTHER|Acupuncture|30 minutes of classical acupuncture using predefined points.
57927390|NCT02798263|OTHER|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
57927391|NCT03445923|OTHER|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
57927392|NCT01822977|DRUG|omeprazole|
57927393|NCT05543655|OTHER|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
57927394|NCT03159741|OTHER|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
57927395|NCT03159741|OTHER|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
58068386|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
58068387|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
58068388|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
58068389|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
58068390|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
58068391|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
58068392|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
58068393|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
58068394|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
58068395|NCT06167031|OTHER|chatbot facilitate teaching|"The experimental group will use chatbot to facilitate teaching."
58068396|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
58068397|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
58068398|NCT02013999|OTHER|standard occupational therapy|
58068399|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
58279706|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
58279707|NCT01313221|BIOLOGICAL|etanercept|Administered by subcutaneous injection
57727167|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
58068400|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
58068401|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
57927396|NCT03159741|OTHER|Placebo + GIP|Placebo and GIP are used as study tools.
57927397|NCT03159741|OTHER|Placebo + Saline|Placebo
58279708|NCT01313221|DRUG|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%"
58279709|NCT05837702|PROCEDURE|ESPB|Erector spinae plane block
57927398|NCT04181944|OTHER|Exercise Treatment Group|be specific
57927399|NCT02080455|DRUG|lomitapide|20 mg dose
57927400|NCT02080455|DRUG|Atorvastatin|80 mg
58395819|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
57727168|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
57927401|NCT02883530|PROCEDURE|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
57927402|NCT05097716|DRUG|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
57927403|NCT05097716|DRUG|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
58279710|NCT05837702|PROCEDURE|PVB|Paravertebral Block
58279711|NCT05837702|PROCEDURE|CONTROL|No block has been done
58279712|NCT05442541|BEHAVIORAL|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
58279713|NCT02412878|DRUG|Carfilzomib|Carfilzomib was administered as an IV infusion
58279714|NCT02412878|DRUG|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
58279715|NCT01145794|BEHAVIORAL|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
58279716|NCT00908596|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
58279717|NCT06188845|OTHER|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
58279718|NCT06009289|BEHAVIORAL|Light therapy|One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
58279719|NCT04282720|DEVICE|SurgiMend Mesh|Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
57727169|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
57927404|NCT00538304|DRUG|bimatoprost eye drops|1 drop in each eye daily for 1 month
58279720|NCT03582514|RADIATION|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
58279721|NCT04455776|DRUG|Propofol|Sedation by propofol
58279722|NCT02197442|DRUG|Valsartan|
58279723|NCT01243177|DRUG|Lacosamide|"Lacosamide:~* Strengths: 50 mg / 100 mg~* Form: tablets~* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~* Duration: up to 118 weeks"
58279724|NCT01243177|DRUG|Carbamazepine-Controlled Release|"Carbamazepine-CR:~* Strengths: 200 mg~* Form: tablets~* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~* Duration: up to 118 weeks"
58279725|NCT06118333|DRUG|BL-B01D1|Administration by intravenous infusion
57927405|NCT00538304|DRUG|placebo|1 drop in each eye daily for 1 month
57927406|NCT01494454|DEVICE|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
58395820|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
58395821|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
58395822|NCT02377752|DRUG|Doxorubicin|Administered IV
58395823|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
58395824|NCT00606541|DRUG|Placebo|Placebo
57927407|NCT01494454|DEVICE|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
58068402|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
58395825|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
58395826|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
58395827|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
57727170|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
57727171|NCT05980936|OTHER|Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
57727172|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
57727173|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
57727174|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
57927408|NCT02868177|DIETARY_SUPPLEMENT|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
57927409|NCT02868177|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
57927410|NCT04190433|DRUG|Carvedilol|Given PO
57927411|NCT04190433|DRUG|Lisinopril|Given PO
57927412|NCT04190433|DRUG|Pravastatin|Given PO
57927413|NCT04190433|DRUG|Spironolactone|Given PO
57927414|NCT00954174|DRUG|Carboplatin|Given IV
58395828|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
58395829|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
57927415|NCT00954174|DRUG|Ifosfamide|Given IV
57927416|NCT00954174|DRUG|Paclitaxel|Given IV
57927417|NCT00954174|OTHER|Quality-of-Life Assessment|Ancillary studies
57927418|NCT04286568|BEHAVIORAL|WOW Intervention|Health education and coaching, health care navigation,
58395830|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
57927419|NCT02711618|DEVICE|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
57927420|NCT00471796|BEHAVIORAL|Biofeedback|
57927421|NCT05659433|PROCEDURE|CEUS-guided percutaneous biopsy|A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
58068403|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
58395831|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
58395832|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
58395833|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
58422732|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
58422733|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
57727175|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
57927422|NCT05659433|PROCEDURE|B-mode US-guided percutaneous biopsy|Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
58395834|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
58395835|NCT01651065|BEHAVIORAL|Control|
57727176|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
57727177|NCT01881308|DRUG|TNF inhibitors|
57727178|NCT01881308|DRUG|Synthetic DMARD(s)|
57727179|NCT01881308|DRUG|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
57727180|NCT02582905|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
57727181|NCT02582905|DIETARY_SUPPLEMENT|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
57727182|NCT02582905|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
57727183|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
57727184|NCT04896489|OTHER|Placebo|Participants receive placebo
57727185|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
57727186|NCT01777919|DRUG|Temozolomide|
57727187|NCT01777919|DRUG|Disulfiram|
57727188|NCT01777919|DRUG|Copper|
57727189|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
57727190|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
57727191|NCT01823744|DIETARY_SUPPLEMENT|micronutrient supplementation|
57727192|NCT01692704|DRUG|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
57927423|NCT02292368|BEHAVIORAL|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
57927424|NCT02292368|PROCEDURE|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
57927425|NCT02292368|PROCEDURE|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
58279726|NCT06118333|DRUG|capecitabine|Oral administration
57927426|NCT01209312|OTHER|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
58279727|NCT06118333|DRUG|gemcitabine|Administration by intravenous infusion
58279728|NCT06118333|DRUG|docetaxel|Administration by intravenous infusion
58279729|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan|Porridge rich in arabinoxylan
58279730|NCT01583270|DIETARY_SUPPLEMENT|Rye kernel|Porridge made of rye kernels
58279731|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
57927427|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
57927428|NCT00982007|DRUG|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
57927429|NCT00982007|DRUG|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
57927430|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
57927431|NCT06287723|BIOLOGICAL|Blood sample/Liquid biopsy|ctDNA analysis
57927432|NCT01881581|BIOLOGICAL|Saline Solution|Saline Solution is used as control in all arms.
57927433|NCT01881581|BIOLOGICAL|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
57927434|NCT01881581|BIOLOGICAL|M-GPE|M-GPE is used in Arm D,E,F,G and H
57927435|NCT03035903|DEVICE|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
57927436|NCT03035903|DEVICE|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
57927437|NCT05211739|DEVICE|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
57927438|NCT05211739|DEVICE|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
57927439|NCT05211739|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
57927440|NCT02755623|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
57927441|NCT02755623|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
57927442|NCT04817891|DEVICE|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
57927443|NCT05051137|BIOLOGICAL|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
57927444|NCT05051137|DRUG|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
57927445|NCT03876990|DIAGNOSTIC_TEST|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
57927446|NCT03876990|DIAGNOSTIC_TEST|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
57927447|NCT01419353|DRUG|estradiol valerate|2 mg P.O / day for 1-6 days.
57927448|NCT04256603|DRUG|Gabapentin|Timing of gabapentin initiation
57927449|NCT04256603|OTHER|No gabapentin|No gabapentin
57927450|NCT06072560|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
57927451|NCT06072560|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
57927452|NCT00064389|DRUG|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
57927453|NCT00064389|DRUG|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
57927454|NCT04695496|DEVICE|Theta bust stimulating|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
58279732|NCT01583270|DIETARY_SUPPLEMENT|Semolina|Semoline porridge. control meal.
57927455|NCT04260802|DRUG|OC-001|Administered IV.
57927456|NCT04260802|DRUG|Drug: OC-001 in Combination with Avelumab|Administered IV.
57927457|NCT00820937|PROCEDURE|Single photon emission computed tomography and Magnetic Resonance Imaging|
57927458|NCT04560569|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
57927459|NCT04560569|DRUG|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
57927460|NCT05536609|PROCEDURE|Epineural suture|2 or three sutures
58279733|NCT04413942|BIOLOGICAL|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
58279734|NCT04413942|OTHER|Placebo|Formulation buffer
58279735|NCT01160380|DRUG|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
58279736|NCT01160380|DRUG|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
58279737|NCT02946489|DRUG|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
57927461|NCT05536609|PROCEDURE|Non-operative treatment|The injured finger is protected in a plaster cast
57927462|NCT03587857|OTHER|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
57927463|NCT05683249|DRUG|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
57927464|NCT05683249|DRUG|Placebo|Matching placebo
57927465|NCT05559021|OTHER|Myofascial Therapy Treatments|"• Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat"
58068404|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
57727193|NCT05443035|PROCEDURE|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula \& Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
57727194|NCT05443035|PROCEDURE|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
57727195|NCT05443035|PROCEDURE|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
57727196|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
57727197|NCT06046313|DRUG|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
57727198|NCT06046313|DRUG|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
57727199|NCT04446663|DRUG|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
57727200|NCT04446663|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
57727201|NCT04446663|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
57727202|NCT04446663|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
57727203|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
57727204|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
57727205|NCT05164510|GENETIC|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
57727206|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
57727207|NCT00214877|DRUG|Methylene Blue|
57727208|NCT01360359|OTHER|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
58279738|NCT02114294|OTHER|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
58279739|NCT02114294|OTHER|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
57727209|NCT01360359|OTHER|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
57727210|NCT01836692|RADIATION|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
57727211|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
57727212|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
57727213|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
58395836|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
58395837|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
57727214|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
57727215|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
57927466|NCT05559021|OTHER|Passive Mobilizations Approach|"• Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage"
57927467|NCT05715853|OTHER|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
57927468|NCT01351623|DRUG|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
57927469|NCT04087954|BEHAVIORAL|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
58068405|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
57927470|NCT02870569|DRUG|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
58068406|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
58068407|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
57927471|NCT02870569|DRUG|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
57927472|NCT06072287|DIAGNOSTIC_TEST|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
57927473|NCT00782288|DRUG|digitoxin|0.05mg tabs, once daily for 28 days
58068408|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
58068409|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
58068410|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
57927474|NCT00782288|DRUG|digitoxin|0.1mg pills, once daily for 28 days.
57927475|NCT00782288|OTHER|placebo|pill taken once daily for 28 days
57927476|NCT05427721|DRUG|Thymol|200 mg each 8 hours for 90 days
58068411|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
58068412|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
58068413|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
58068414|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
58068415|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
58068416|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
58068417|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
58068418|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
58068419|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
58068420|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
58068421|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
58068422|NCT02508012|OTHER|Immuno monitoring|treatment optimization
57927477|NCT02778256|DEVICE|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
57927478|NCT02778256|DEVICE|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
57927479|NCT03990857|OTHER|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
58068423|NCT00103831|DRUG|Oral Taxane|
58068424|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
58068425|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
58068426|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
58068427|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
57727216|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
57727217|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
57927480|NCT00001023|DRUG|Clarithromycin|
57927481|NCT00001023|DRUG|Azithromycin|
57927482|NCT00001023|DRUG|Rifabutin|
57927483|NCT05541211|OTHER|Coeliac plexus neurolysis|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
57927484|NCT05541211|OTHER|Splanchnic nerve neurolysis|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
57927485|NCT03672877|BEHAVIORAL|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
57927486|NCT04292002|BEHAVIORAL|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
57927487|NCT00324129|DRUG|MGCD0103|MGCD0103 given orally three times per week.
57927488|NCT04740528|DIAGNOSTIC_TEST|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
58068428|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
58068429|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
58068430|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
58068431|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
58068432|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
58068433|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
57727218|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
57727219|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
57727220|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
57927489|NCT00493545|BIOLOGICAL|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
57927490|NCT01842685|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
57927491|NCT00293722|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
58068434|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
58068435|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
58068436|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
58395838|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
58395839|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
57927492|NCT04580862|OTHER|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
57927493|NCT05615324|BEHAVIORAL|Family Talk Preventive Intervention|This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
57927494|NCT04630756|DRUG|AZD4573|AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
57927495|NCT04630756|DRUG|Acalabrutinib|Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
57927496|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
58068437|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
58068438|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
58068439|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
58068440|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
58279740|NCT02114294|OTHER|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
58279741|NCT02169388|DRUG|Probiotic|Microbial composition using probiotic
58279742|NCT02169388|DRUG|placebo（for probiotic）|microbiota modulation using placebo
58395840|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
57727221|NCT05294640|DRUG|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
57727222|NCT05294640|DRUG|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
57927497|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
57927498|NCT03782142|DRUG|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
57927499|NCT03782142|DRUG|Rilpivirine|NNRTI
57927500|NCT03782142|DRUG|Prezcobix|PI
57927501|NCT03782142|DRUG|Dolutegravir|II
57927502|NCT01903018|DRUG|P276-00|
58068441|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
58068442|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
58068443|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
58279743|NCT03472001|OTHER|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
58279744|NCT03472001|OTHER|Lecture|Traditional didactic lecture which uses the same clinical cases
58279745|NCT01412892|DRUG|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
58279746|NCT00502853|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
57927503|NCT01903018|RADIATION|Radiation Therapy|
57927504|NCT01903018|DRUG|Cisplatin|
57927505|NCT04169386|DRUG|AK102|AK102 single dose administered subcutaneously
57927506|NCT04169386|DRUG|Placebo|Placebo single dose administered subcutaneously
57927507|NCT02547233|DRUG|LEO 43204 gel|
57927508|NCT02547233|DRUG|Vehicle gel|
57927509|NCT02801903|DRUG|SB204 4%|Topically Once Daily (AM)
57927510|NCT05817760|PROCEDURE|Z-scrotoplasty|Z shape incision of the penoscrotal web and closure
57927511|NCT05817760|PROCEDURE|Heineke-Mikulicz scrotoplasty|Transverse incision of the penoscrotal web with vertical closure
57927512|NCT04757532|DRUG|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
57927513|NCT04757532|DRUG|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
57927514|NCT04757532|DRUG|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
57927515|NCT04757532|DRUG|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
57927516|NCT04757532|DRUG|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
57927517|NCT04815954|PROCEDURE|Urinary catheter removal|Removal of urinary catheter which was placed during kidney transplantation.
57927518|NCT01143103|DEVICE|Cough assist (Philips,respironics)|
57927519|NCT01143103|OTHER|Usual respiratory therapy|
58068444|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
57927520|NCT02882919|BEHAVIORAL|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
58279747|NCT00502853|DRUG|Methotrexate|10-25mg/week
57927521|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
57927522|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
57927523|NCT01788267|OTHER|scan examination HR-pQCT|
57927524|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
57927525|NCT02563093|BIOLOGICAL|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
57927526|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
57927527|NCT02563093|BIOLOGICAL|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
57927528|NCT01009034|OTHER|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
57927529|NCT02460497|DRUG|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
57927530|NCT02626325|OTHER|High-carbohydrate or High-monounsaturated fat diets|
57927531|NCT00315003|DRUG|Telithromycin|
57927532|NCT00315003|DRUG|Azithromycin|
57927533|NCT00472329|PROCEDURE|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
57927534|NCT00472329|DRUG|fludarabine|
57927535|NCT00472329|PROCEDURE|TBI|
57927536|NCT03272542|DIETARY_SUPPLEMENT|Prebiotic: soluble corn fiber|prebiotic
57927537|NCT03272542|DIETARY_SUPPLEMENT|Placebo: maltodextrin|placebo
57927538|NCT04620811|DRUG|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
57927539|NCT05665088|DRUG|BXCL501|Sublingual Film
57927540|NCT05665088|DRUG|Matching Placebo|Sublingual Placebo Film
57927541|NCT03798223|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
57927542|NCT05138523|COMBINATION_PRODUCT|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
57927543|NCT01103635|BIOLOGICAL|CD40 agonist monoclonal antibody CP-870,893|Given IV
57927544|NCT01103635|BIOLOGICAL|tremelimumab|Given IV
57927545|NCT01103635|OTHER|laboratory biomarker analysis|Correlative studies
57927546|NCT03539783|DIAGNOSTIC_TEST|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
57927547|NCT06046755|OTHER|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
58279748|NCT01956864|DRUG|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
57927548|NCT06046755|BEHAVIORAL|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
57927549|NCT06101953|BEHAVIORAL|Stress management|It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
57927550|NCT00528866|DRUG|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
57927551|NCT00528866|DRUG|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
57927552|NCT00528866|DRUG|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
57927553|NCT00528866|DRUG|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
57927554|NCT00528866|RADIATION|3-dimensional conformal radiation therapy|
57927555|NCT00528866|RADIATION|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
57927556|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
57927557|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
58068445|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
58279749|NCT04641702|DRUG|Atropine challenge|Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
58279750|NCT04641702|PROCEDURE|Esophageal muscle biopsy|Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
58279751|NCT04465656|DIAGNOSTIC_TEST|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)"
58279752|NCT02020512|DRUG|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
58279753|NCT04606875|DIAGNOSTIC_TEST|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
58395841|NCT04840485|DRUG|Placebo|Placebo
57927558|NCT01605253|DRUG|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
57927559|NCT01605253|DRUG|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
57927560|NCT01478360|DRUG|AIN457 (secukinumab)|Secukinumab intravenous injection
57927561|NCT01478360|DRUG|Placebo|Placebo intravenous injection
57927562|NCT01572701|DRUG|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
57927563|NCT00168480|BIOLOGICAL|Botulinum Toxin Type A|100 U, repeated treatments at \> 4 month intervals up to Month 32, over a 36-month study period
58395842|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
58395843|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
58395844|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
58279754|NCT06124105|DIAGNOSTIC_TEST|arterial blood gases|measurement of partial oxygen pressure in urine by arterial blood gas device
57727223|NCT05294640|PROCEDURE|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
57727224|NCT03424876|DRUG|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
57727225|NCT03424876|DRUG|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
57727226|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
57727227|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
57927564|NCT05165147|OTHER|no intervention|no intervention
57927565|NCT03933397|OTHER|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
57927566|NCT03933397|OTHER|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
57927567|NCT03933397|DRUG|Morphine|4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
58068446|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
58068447|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
58068448|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
58068449|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
57727228|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
57727229|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
57727230|NCT06148129|DIAGNOSTIC_TEST|Tissue Biopsy|The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
58395845|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
58395846|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
57927568|NCT03933397|DRUG|Hydromorphone|1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
57927569|NCT02690805|DEVICE|MR-compatible scinti-mammography (MRI-SMM) system|
57927570|NCT02315677|DEVICE|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
57927571|NCT02315677|DEVICE|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
57927572|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus.|Minimally invasive procedures for the Hallux Abductus Valgus
57927573|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
57927574|NCT04062253|DIAGNOSTIC_TEST|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
58068450|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
58068451|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
58068452|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
58068453|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
58068454|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
58068455|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
58068456|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
58068457|NCT01790451|PROCEDURE|Irreversible Electroporation|
58306760|NCT00597272|BIOLOGICAL|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
58068458|NCT00580827|DRUG|Placebo|Matched placebo.
58068459|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
58068460|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
58068461|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
57927575|NCT05777096|DIAGNOSTIC_TEST|Standardised Nordic questionnaires|participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
57927576|NCT04760886|OTHER|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
57927577|NCT04968197|DEVICE|Vestibular Intervention via Portable Electrical Stimulator (VIPES) system|A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
57927578|NCT00126633|BIOLOGICAL|bevacizumab|
57927579|NCT00126633|DRUG|cisplatin|
57927580|NCT00126633|DRUG|gemcitabine hydrochloride|
57927581|NCT00122928|BEHAVIORAL|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
57927582|NCT00122928|BEHAVIORAL|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
57927583|NCT00122928|BEHAVIORAL|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
57927584|NCT04293289|OTHER|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
57927585|NCT02710773|OTHER|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
58068462|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
58068463|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
57927586|NCT02710773|OTHER|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
58395847|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
57927587|NCT04193267|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
57927588|NCT05737966|OTHER|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
58068464|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
58068465|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
58068466|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
57727231|NCT06300541|PROCEDURE|Colectomy|Observational study.
57927589|NCT04338555|PROCEDURE|Transcutaneous electrical acupoint stimulation|TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.
57927590|NCT01108250|GENETIC|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
57927591|NCT03358511|DIETARY_SUPPLEMENT|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
57927592|NCT00350662|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
58068467|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
58068468|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
58068469|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
58068470|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
58068471|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
58279755|NCT04958161|OTHER|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
58279756|NCT04861441|DEVICE|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
58306761|NCT06294288|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (Dose 1) was administered intravenously.
57927593|NCT00350662|DRUG|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
58395848|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
58395849|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
58395850|NCT01882556|DRUG|onabotulinumtoxinA|
58395851|NCT01882556|DRUG|Placebo|
58395852|NCT06660043|OTHER|physical activity|40 min circuit training session
58395853|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
57727232|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
57727233|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
57727234|NCT01471002|DEVICE|Galil Medical patented 17G Cryoablation Needles|
57727235|NCT00244608|DRUG|Budesonide/Formoterol Turbuhaler|
57727236|NCT00244608|DRUG|Budesonide Turbuhaler (Pulmicort)|
57727237|NCT00244608|DRUG|Terbutaline Turbuhaler|
57727238|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
57927594|NCT05107050|DEVICE|Normal Saline and Amorphous gel|Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
58068472|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
58395854|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
58395855|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
57927595|NCT05107050|DEVICE|BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel|"Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
57927596|NCT01909687|DEVICE|Blood glucose monitoring systems|
58279757|NCT04861441|DEVICE|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
58279758|NCT04599192|OTHER|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
58279759|NCT00897975|DIETARY_SUPPLEMENT|red yeast rice|600 mg 3 capsules bid
58279760|NCT00897975|DRUG|phytosterol|phytosterol 450 mg 2 tabs bid with food
58279761|NCT00897975|BEHAVIORAL|therapeutic lifestyle program|TLC - 12 weeks
58279762|NCT00897975|DRUG|placebo|placebo
58279763|NCT00315484|DRUG|Epoetin alfa and Darbepoetin alfa|
58279764|NCT04054726|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
58279765|NCT04054726|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
58279766|NCT02708797|OTHER|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
58279767|NCT02708797|OTHER|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
58279768|NCT00968188|BEHAVIORAL|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
58279769|NCT00968188|BEHAVIORAL|Information only|Medically fact based HIV information delivered online.
58279770|NCT05521152|DRUG|Norepinephrine Bitartrate|"anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision."
58279771|NCT05521152|DRUG|Placebo|Placebo
58279772|NCT01979237|PROCEDURE|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
58279773|NCT04099537|BEHAVIORAL|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
58279774|NCT04438798|OTHER|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
58279775|NCT04438798|OTHER|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
58279776|NCT00954200|DRUG|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
58279777|NCT00954200|DRUG|ibuprofen|10mg/kg syrup - single dose
58279778|NCT05812430|DRUG|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
58279779|NCT00006113|BIOLOGICAL|MART-1 antigen|
58279780|NCT00006113|BIOLOGICAL|aldesleukin|
58279781|NCT00006113|BIOLOGICAL|gp100 antigen|
58279782|NCT00006113|BIOLOGICAL|recombinant CD40-ligand|
58279783|NCT00006113|BIOLOGICAL|recombinant interferon gamma|
58279784|NCT00006113|BIOLOGICAL|recombinant interleukin-4|
58279785|NCT00006113|BIOLOGICAL|sargramostim|
58279786|NCT00006113|BIOLOGICAL|therapeutic autologous dendritic cells|
58279787|NCT00006113|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58279788|NCT00006113|BIOLOGICAL|tyrosinase peptide|
58279789|NCT00006113|RADIATION|Candida albicans skin test reagent|
58306762|NCT06294288|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (Dose 2) was administered intravenously.
58395856|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
57727239|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
57927597|NCT05483205|DRUG|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
58395857|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
58395858|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
58395859|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
58395860|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
58395861|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
57927598|NCT04916041|DEVICE|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
58395862|NCT05255991|DRUG|Placebo|Placebo administered QID
57927599|NCT02717754|DRUG|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
57927600|NCT02717754|DRUG|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
57927601|NCT00198549|DRUG|Vitrase (ovine hyaluronidase) Lyophilized|
58306763|NCT06294288|BIOLOGICAL|LP-003 Dose 3 (Single)|A single dose of LP-003 (Dose 3) was administered intravenously.
58395863|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
58395864|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
58395865|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
58395866|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
58395867|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
58395868|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
57927602|NCT06041386|DRUG|Mepolizumab|Mepolizumab will be prescribed based on physician decision.
57927603|NCT06041386|OTHER|Spirometry|Lung function via spirometry will be collected.
57927604|NCT03226405|OTHER|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
57927605|NCT03226405|OTHER|Usual Care|the standard of care provided by the institution
58395869|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
58395870|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
58395871|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
57927606|NCT06143085|PROCEDURE|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
57927607|NCT01397864|DRUG|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
57927608|NCT04657419|OTHER|survey|"Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID"
58395872|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
57927609|NCT02204566|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
58068473|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
58306764|NCT06294288|BIOLOGICAL|LP-003 Dose 4 (Single)|A single dose of LP-003 (Dose 4) was administered intravenously.
57927610|NCT01691391|BEHAVIORAL|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
57927611|NCT05370066|DEVICE|CS6BP watches will be used in the study.|CS6BP watches will be used with FDA approved Blood pressure monitors
57927612|NCT03483558|OTHER|Control|A standardized diet without any vegetables was provided.
57927613|NCT03483558|OTHER|Spinach|A standardized diet with 200g spinach was provided.
57927614|NCT03483558|OTHER|Celery|A standardized diet with 200g celery was provided.
57927615|NCT03483558|OTHER|Onion|A standardized diet with 200g onion was provided.
57927616|NCT03483558|OTHER|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
58068474|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
58279790|NCT03147807|DEVICE|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
57927617|NCT00162032|DRUG|Sestamibi|Sestamibi
57927618|NCT02800226|DEVICE|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
57927619|NCT02800226|DEVICE|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
57927620|NCT02701426|BEHAVIORAL|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
58279791|NCT06207760|DRUG|Minocycline|Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
58279792|NCT05314179|BEHAVIORAL|Doula - Patient engagement|"Ubuntu ambassador/Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2) practical assistance, 3) family support, and/or 4) legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
57927621|NCT00576836|BIOLOGICAL|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not \>18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
57927622|NCT00576836|OTHER|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest \& transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced \& placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
57927623|NCT04498455|DIETARY_SUPPLEMENT|Prebiotin|Fructo-oligosaccharide dietary supplement powder
58068475|NCT04694820|OTHER|Survey Administration|Ancillary studies
58306765|NCT06294288|BIOLOGICAL|LP-003 Dose 5 (Single)|A single dose of LP-003 (Dose 5) was administered intravenously.
58395873|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
57727240|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
58279793|NCT01308996|DEVICE|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
58395874|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
58395875|NCT01524224|DRUG|LY2495655|administered intravenously
58395876|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
58395877|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
58395878|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
58395879|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
58395880|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
58395881|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
58395882|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
58395883|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
58395884|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
57727241|NCT04912505|DRUG|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
57727242|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
57727243|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
57727244|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
57727245|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
57727246|NCT02707055|OTHER|Placebo|Placebo
57727247|NCT04056806|DRUG|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
57727248|NCT04483869|OTHER|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
58395885|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
57727249|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
57727250|NCT04602624|DRUG|SAGE-718|SAGE-718 oral tablets.
58279794|NCT01308996|PROCEDURE|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
58279795|NCT03642600|DIETARY_SUPPLEMENT|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
58279796|NCT03642600|DRUG|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
57727251|NCT02578394|DRUG|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
57727252|NCT02578394|DRUG|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
57727253|NCT00353704|DRUG|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
57727254|NCT00353704|DRUG|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
57727255|NCT00353704|DRUG|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
57727256|NCT01022814|DEVICE|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
57727257|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
57727258|NCT05907369|OTHER|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
57727259|NCT05907369|OTHER|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
57727260|NCT05907369|OTHER|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
57727261|NCT05907369|OTHER|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
57727262|NCT01468402|PROCEDURE|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
57727263|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
57727264|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
57727265|NCT03257982|PROCEDURE|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
57951165|NCT02604277|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
58279797|NCT04485637|OTHER|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
58279798|NCT04485637|OTHER|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
58279799|NCT04485637|OTHER|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
58279800|NCT04965428|BEHAVIORAL|Fear-focused Self-Compassion Therapy|The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
58279801|NCT03268512|OTHER|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
58279802|NCT03268512|OTHER|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
58279803|NCT02711020|BEHAVIORAL|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
58306766|NCT06294288|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
57727266|NCT03125668|BEHAVIORAL|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
57927624|NCT03725163|BEHAVIORAL|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
57927625|NCT02838485|OTHER|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
58395886|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
57727267|NCT03125668|BEHAVIORAL|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
57727268|NCT03125668|BEHAVIORAL|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
57927626|NCT02838485|OTHER|Imagery|The subject will be asked to imagine performing hand movements.
58279804|NCT02711020|BEHAVIORAL|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
58279805|NCT02533297|OTHER|Providing clinical skills conditions|
57927627|NCT06153771|OTHER|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
57927628|NCT06153771|OTHER|echocardiography|on day 2, day 4 and day 7 of life
57927629|NCT02187809|DRUG|Clobazam|
58279806|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
58279807|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
57927630|NCT04079166|BIOLOGICAL|SCIB1 or iSCIB1+ DNA vaccine|"Participants receive up to 10 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment."
57927631|NCT06502899|OTHER|Cardiac MRI|Patients with a diagnosis of MINOCA and completed CMR were included in this study
57927632|NCT05355233|OTHER|bebo concept|techniques to remove urinary incontinence
57927633|NCT05355233|OTHER|diaphragmatic breathing|techniques to remove urinary incontinence
58279808|NCT01703559|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
58279809|NCT02978612|DRUG|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
58306767|NCT06294288|BIOLOGICAL|LP-003 Dose 6 (Multiple)|LP-003 (Dose 6) was administered multiple times subcutaneously.
58306768|NCT06294288|BIOLOGICAL|LP-003 Dose 7 (Multiple)|LP-003 (Dose 7) was administered multiple times subcutaneously.
58306769|NCT06294288|BIOLOGICAL|LP-003 Dose 8 (Multiple)|LP-003 (Dose 8) was administered multiple times subcutaneously.
58395887|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
58395888|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
58395889|NCT06435416|OTHER|No intervention|No intervention
58395890|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
57927634|NCT02642510|OTHER|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
57927635|NCT02642510|OTHER|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
57927636|NCT04950725|BEHAVIORAL|Strength RMT|2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
57927637|NCT04950725|BEHAVIORAL|Strength RMT and nasal breathing|2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
57927638|NCT04950725|BEHAVIORAL|Endurance RMT|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
57927639|NCT04950725|BEHAVIORAL|Endurance RMT and nasal breathing|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
57927640|NCT04950725|BEHAVIORAL|Low dose RMT|10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
57927641|NCT01353456|DRUG|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
57727269|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
57727270|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
57727271|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
57927642|NCT01353456|DRUG|Normal Saline|Same volume as dexmedetomidine given
57927643|NCT04864509|DRUG|Melatonin 10 MG|Nightly dose
57927644|NCT04864509|DRUG|Placebo|Nightly dose
57927645|NCT01106404|DEVICE|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
58279810|NCT05230199|BEHAVIORAL|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
58279811|NCT05230199|BEHAVIORAL|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
57927646|NCT03874325|DRUG|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
57927647|NCT03874325|DRUG|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
57927648|NCT03874325|DRUG|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
57927649|NCT03874325|DRUG|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
57927650|NCT00355979|DEVICE|intragastric balloon|
57927651|NCT01975428|DEVICE|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
57927652|NCT01975428|BEHAVIORAL|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
57927653|NCT04034550|OTHER|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
58279812|NCT02992184|DEVICE|HCV RNA detection with Genedrive assay|
57927654|NCT01568645|DRUG|Carvedilol|
57927655|NCT01568645|DRUG|Imatinib|
58279813|NCT02992184|DEVICE|HCV RNA detection with RealTime HCV|
58279814|NCT01222663|DEVICE|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
58279815|NCT01222663|DEVICE|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
57727272|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
58395891|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
58279816|NCT01459393|DRUG|5-ALA Photodynamic Therapy|
57727273|NCT05409443|PROCEDURE|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"* Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~* The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
57927656|NCT05317754|BEHAVIORAL|Mindful breathing|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
58279817|NCT01459393|DRUG|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
58279818|NCT02572960|DRUG|Valsartan|2 weeks of Valsartan 80 mg per day
58279819|NCT02572960|DRUG|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
58279820|NCT02572960|DIETARY_SUPPLEMENT|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
58279821|NCT02572960|DIETARY_SUPPLEMENT|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
58279822|NCT05460078|BEHAVIORAL|Virtual Psychiatric Transition of Care Program|"Behavioral Health facility or units that have discharged patients meeting inclusion criteria will be randomly assigned as either an intervention or standard care site. Intervention sites will be those using the VPTC program. This evaluation design will integrate into current workflows for the measurement of outcomes. Prior to discharge, patients may be referred to the VPTC program if they report residency or shelter in North Carolina, are 18 years of age or older on the day of discharge and can access virtual care (phone/video).~The VPTC program is defined by:~* Psychiatric consultation~* Medication management services with pharmacological consultation~* following of Health Coaching participation and provide treatment recommendations~* Tracking of behavioral health symptoms and provide treatment recommendations~* Health coaching; Psychoeducational support~* Treatment and safety planning~* Assistance connecting with an outpatient care provider"
58279823|NCT01942811|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
58279824|NCT06187272|BEHAVIORAL|Listening to music|Students listened to background music during a practical examination of 60 bpm.
58306770|NCT06294288|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
58306771|NCT06508255|BEHAVIORAL|Early Time-Restricted Eating|Eat between 8:00 and 16:00 for 2 weeks
58279825|NCT03910140|PROCEDURE|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
57927657|NCT05317754|BEHAVIORAL|Prostrations, according to Tibetan Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
57927658|NCT05317754|BEHAVIORAL|The Koan Mu, according to Zen Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
58279826|NCT05994053|DEVICE|high definition transcranial alternating current stimulation|low intensity alternating current to OFC
58279827|NCT01915550|DRUG|Metformin|
58279828|NCT01915550|DRUG|Humulin Insulin Mixtard|
58279829|NCT04123249|DRUG|Propofol|Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation
58279830|NCT04123249|DRUG|Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation；
58279831|NCT05029245|BIOLOGICAL|Comirnaty®|intradermal injection or intramuscular injection
58279832|NCT06486285|BEHAVIORAL|Auditory-cognitive dual-task training (ACDT)|The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
58279833|NCT04616040|DRUG|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
58279834|NCT02665923|OTHER|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
58279835|NCT04474977|OTHER|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
58279836|NCT01300156|DRUG|Oxaliplatin-based chemotherapy (ESHAOx)|"* Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1"
58279837|NCT03033927|DIAGNOSTIC_TEST|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
58279838|NCT02454868|DRUG|Remifentanil|Remifentanil for intubation without neuromuscular blockade
58279839|NCT01693185|DRUG|Remifentanil|continuous infusion 0.4 mcg/kg/min
58279840|NCT01693185|DRUG|Midazolam|bolus injection
58279841|NCT01693185|DRUG|Meperidine|bolus injection for 30 sec 1.0 mg/kg
58279842|NCT01693185|DRUG|placebo (for remifentanil)|normal saline mimic diluted remifentanil
58279843|NCT01693185|DRUG|placebo (for midazolam)|normal saline mimic to midazolam injection
58279844|NCT01693185|DRUG|placebo (for meperidine)|normal saline mimic meperidine injection
58279845|NCT04750278|DRUG|FP-025 100 mg|FP-025 100 mg BID
58279846|NCT04750278|DRUG|FP-025 300 mg|FP-025 300 mg BID
58279847|NCT04750278|DRUG|Placebo|Placebo BID
58279848|NCT02208050|DRUG|Fampridine|
58279849|NCT02208050|DRUG|Placebo|
58279850|NCT06266299|DRUG|KK2269|KK2269 administered intravenously
58279851|NCT06266299|DRUG|Docetaxel|antineoplastic drug administered intravenously
58279852|NCT05831709|OTHER|Exercise program|The intervention consists of a supervised exercise program
58279853|NCT03911947|DEVICE|Vibrolung|Device for vibroacoustic respiratory therapy
58279854|NCT02839382|OTHER|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
58306772|NCT06508255|BEHAVIORAL|Late Time-Restricted Eating|Eat between 13:00 and 21:00 for 2 weeks
58306773|NCT05089214|DEVICE|Intra oral cameras|Diagnostic comparison of two intra oral cameras
58068476|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
58068477|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
58068478|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
58279855|NCT02839382|OTHER|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
58279856|NCT02839382|OTHER|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
58279857|NCT06011096|OTHER|skin-to-skin contact and delayed cord clamping|Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
58395892|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
58395893|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
58395894|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
58395895|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
58395896|NCT00695916|PROCEDURE|Breast MRI|
58395897|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
58395898|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
58068479|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
58068480|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
58279858|NCT06011096|OTHER|avoiding skin-to-skin contact and early cord clamping|After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
58068481|NCT02297620|DRUG|Suglat®|oral
58068482|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
58068483|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
58068484|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
58068485|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
58068486|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
58068487|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
58068488|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
58068489|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
58068490|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
58279859|NCT05880225|BEHAVIORAL|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
58279860|NCT05880225|BEHAVIORAL|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
58395899|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
58395900|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
58395901|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
58395902|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
57927659|NCT05317754|BEHAVIORAL|The mirror exercise, according to Toltec tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
58395903|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
58279861|NCT02003261|BEHAVIORAL|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
58279862|NCT02003261|OTHER|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
58395904|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
58395905|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
57927660|NCT06335992|OTHER|Exercise regime|Exercise
57927661|NCT02153372|OTHER|BMC2012|
57927662|NCT00279630|PROCEDURE|Orthoses and Exercise|orthrose and exercise - daily
57927663|NCT02853721|OTHER|iPTH|iPTH assay six hours after surgery
57927664|NCT02853721|OTHER|no dosage of iPTH|Ca and P on postoperative day 1 and 2
57927665|NCT04930224|DIAGNOSTIC_TEST|The effect of GPER-1 on the formation of diabetic retinopathy|Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
58279863|NCT06137911|DRUG|JYP0061|JYP0061 orally administered
58279864|NCT06137911|DRUG|placebo|Placebo orally administered
58279865|NCT06363994|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
58279866|NCT06363994|DRUG|Bendamustine Injection|Eligible patients will receive Bendamustine by injection as per the protocol
58279867|NCT06363994|DRUG|Rituximab|Eligible patients will receive Rituximab by injection as per the protocol
58279868|NCT06363994|DRUG|Orelabrutinib Placebo|Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
58279869|NCT00456820|DRUG|Wellbutrin XL|
58279870|NCT05096962|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
58279871|NCT05096962|DIAGNOSTIC_TEST|Cellular immunity|Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
58279872|NCT01135836|PROCEDURE|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
58279873|NCT01135836|PROCEDURE|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
58279874|NCT01135836|PROCEDURE|Control group|CO2 was removed by passive exsufflation through the port site.
58279875|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
58279876|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
58279877|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
58279878|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
58279879|NCT02110628|PROCEDURE|Roux-en-Y anastomosis|Roux-en-Y anastomosis
58279880|NCT02110628|PROCEDURE|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
58395906|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
58395907|NCT01697423|DRUG|platelet-rich plasma|
58395908|NCT01697423|DRUG|durolane|
58395909|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
58395910|NCT02512874|DEVICE|Dynamometer|Grip Test
58395911|NCT02512874|RADIATION|DEXA|Body Composition Testing
58395912|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
58395913|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
58395914|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
58395915|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
58395916|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
58395917|NCT00140049|DRUG|Xalacom|
58395918|NCT00140049|DRUG|Cosopt|
58395919|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
57927666|NCT00881218|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
58279881|NCT00477204|DRUG|Simvastatin|simvastatin 20 mg daily
58279882|NCT00477204|DRUG|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
57727274|NCT05409443|PROCEDURE|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"* To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~* A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~* The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
57727275|NCT04634201|DIETARY_SUPPLEMENT|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
57727276|NCT04634201|DIETARY_SUPPLEMENT|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
57727277|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
57727278|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
57727279|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
57727280|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
57727281|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
57727282|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
57727283|NCT04345848|DRUG|Enoxaparin|Two different doses of anticoagulation
57727284|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
57727285|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
57727286|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
57727287|NCT00010517|PROCEDURE|Acupuncture|
57727288|NCT00834457|DRUG|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
57927667|NCT05671913|DRUG|Ketamine|Treatment arm
57927668|NCT05671913|DRUG|Placebo|Control arm
57927669|NCT04011254|PROCEDURE|haemodialysis|Routine haemodialysis session
57927670|NCT02736136|BEHAVIORAL|joint observation and video feedback|
57927671|NCT01669304|DRUG|Verapamil|
58395920|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
58395921|NCT06660823|DRUG|Placebo|patients will receive placebo in form of inert starch tablet
57727289|NCT00834457|DRUG|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
57727290|NCT03450551|DEVICE|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
58279883|NCT02377128|PROCEDURE|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
58279884|NCT02377128|PROCEDURE|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
58279885|NCT03268005|DRUG|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
57727291|NCT05651477|DEVICE|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
57727292|NCT05651477|DEVICE|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
57727293|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
57727294|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
57727295|NCT06529653|PROCEDURE|autogenous bone wedge|autogenous bone block harvested from chin and adjusted to be wedged intercortical in split ridge
57927672|NCT01669304|DRUG|Sertraline|
57927673|NCT03643120|OTHER|Qualitative interview|Explorative study of gender dysphoria.
57927674|NCT01615380|BEHAVIORAL|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
58095075|NCT01990079|OTHER|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
58395922|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
58279886|NCT03268005|DRUG|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
58395923|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
58395924|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
58395925|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
58395926|NCT00146016|DRUG|Amantadine|
58395927|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
58395928|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
58395929|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
58279887|NCT03268005|DRUG|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
58279888|NCT03268005|DRUG|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
58279889|NCT02034760|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
58395930|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
58395931|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
57727296|NCT02069600|DEVICE|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
57727297|NCT02899728|DRUG|Carboplatin|Given IV
57727298|NCT02899728|DRUG|Cediranib|Given PO
57727299|NCT02899728|DRUG|Cediranib Maleate|Given PO
58279890|NCT02034760|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
58279891|NCT02034760|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
58279892|NCT02034760|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
58279893|NCT02034760|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
58279894|NCT06229899|DIAGNOSTIC_TEST|Serum follistatin levels|blood samples are taken
58395932|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
58395933|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
58395934|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
58395935|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
58395936|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
58395937|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
57727300|NCT02899728|DRUG|Cisplatin|Given IV
57727301|NCT02899728|DRUG|Etoposide|Given IV
57727302|NCT02899728|DRUG|Olaparib|Given PO
57727303|NCT05954897|DRUG|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
57727304|NCT02308033|DRUG|Metronidazole|
58279895|NCT03611101|COMBINATION_PRODUCT|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
58279896|NCT03611101|DRUG|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
58279897|NCT03611101|DEVICE|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
58279898|NCT04962035|OTHER|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
58306774|NCT04324229|DRUG|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
57927675|NCT01615380|BEHAVIORAL|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
57927676|NCT01243541|PROCEDURE|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
58279899|NCT02882464|DEVICE|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
58279900|NCT02882464|DEVICE|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
58279901|NCT02882464|PROCEDURE|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
58279902|NCT00143468|BEHAVIORAL|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
58279903|NCT00384371|DRUG|Botulinum Toxin A|Botulinum Toxin A
58279904|NCT00384371|DRUG|Placebo|Placebo
58279905|NCT00731731|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
58279906|NCT00731731|PROCEDURE|Cognitive Assessment|Ancillary studies
58279907|NCT00731731|OTHER|Laboratory Biomarker Analysis|Correlative studies
58279908|NCT00731731|DRUG|Temozolomide|Given PO
58279909|NCT00731731|DRUG|Vorinostat|Given PO
58279910|NCT01421745|OTHER|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
58279911|NCT02679456|DRUG|SCY-078|
58279912|NCT02679456|DRUG|Fluconazole|
58279913|NCT05318833|DRUG|HRS7415|Drug: HRS7415
58279914|NCT03120494|DRUG|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
58279915|NCT02548715|DRUG|Levothyroxine|
58279916|NCT02548715|DRUG|Placebo|
58279917|NCT02500771|BEHAVIORAL|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
58279918|NCT03363308|BEHAVIORAL|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
58279919|NCT02443272|PROCEDURE|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
58279920|NCT02443272|PROCEDURE|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
58279921|NCT01048099|PROCEDURE|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
58279922|NCT01048099|DRUG|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
58279923|NCT01048099|DRUG|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
57727305|NCT02308033|DRUG|Gel vehicle|
57927677|NCT01243541|OTHER|questionnaire administration|Ancillary studies
57927678|NCT01243541|PROCEDURE|quality-of-life assessment|Ancillary studies
58095076|NCT00463814|DRUG|AZD6244|Participants will receive single oral dose of AZD6244 as described in arm description.
58279924|NCT04170101|PROCEDURE|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
58279925|NCT04170101|PROCEDURE|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
58279926|NCT05180565|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
58279927|NCT05292612|BEHAVIORAL|iCBT(C&W) for SAD|iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
58279928|NCT06352125|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
58068491|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
58068492|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
58279929|NCT06352125|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
58279930|NCT04849585|OTHER|semi-directed entretien|semi-directed entretien
58279931|NCT05704283|DEVICE|Ultrasound Imaging|Undergo 3D-US
58279932|NCT01016574|DEVICE|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
58279933|NCT04775719|OTHER|Patient-Specific Prediction of Functional Outcome|Information sheet that describes whether a patient is more likely to improve on or maintain their current preoperative function.
57727306|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
57927679|NCT01243541|PROCEDURE|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
57927680|NCT01243541|PROCEDURE|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
57927681|NCT02645513|BEHAVIORAL|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
57927682|NCT02645513|BEHAVIORAL|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
57927683|NCT02645513|BEHAVIORAL|Control|No text message reminders
57927684|NCT04009850|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
58068493|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
58068494|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
58068495|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
58068496|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
58279934|NCT04775719|OTHER|Standard Pre-Operative Total Knee Arthroplasty Information|Standard of care information that is routinely provided at patient preadmission appointments.
58279935|NCT06155032|PROCEDURE|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
57727307|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
58068497|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
58068498|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
58279936|NCT06155032|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
58279937|NCT05743647|DEVICE|Observation (OBS)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement."
58279938|NCT05743647|DEVICE|Observation and imagination (OBS-IM)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it."
58306775|NCT04324229|DRUG|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
58068499|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
58068500|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
58068501|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
58068502|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
58068503|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
58279939|NCT05743647|DEVICE|Observation and realization (OBS-REAL)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it"
58395938|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
58395939|NCT04082845|OTHER|Education|Web-based patient education
57727308|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
57927685|NCT04009850|OTHER|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
57927686|NCT06064656|OTHER|Non-Interventional|No study treatment will be administered on this study.
58068504|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
58068505|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
58068506|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
58068507|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
57927687|NCT01940354|DEVICE|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
58068508|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
58068509|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
58068510|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
57727309|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
58279940|NCT00288444|DRUG|Lonafarnib|
58279941|NCT00288444|DRUG|Docetaxel|
58279942|NCT01387945|BEHAVIORAL|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
58279943|NCT03518502|PROCEDURE|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
58279944|NCT03518502|DRUG|Sorafenib|Standard therapy for advanced HCC
58279945|NCT01590316|DEVICE|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
57727310|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
57927688|NCT01940354|DEVICE|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
57927689|NCT00897416|OTHER|laboratory biomarker analysis|
57927690|NCT03794908|DEVICE|Light therapy A (Bright) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
58068511|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
58068512|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
58068513|NCT00134199|DRUG|CP-945,598|
58068514|NCT00134199|DRUG|sibutramine|
58068515|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
58068516|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
58068517|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
58279946|NCT01066871|DRUG|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
57927691|NCT03794908|DEVICE|Light therapy B (Dim) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
57927692|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
57927693|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
57927694|NCT06044844|DRUG|Tofacitinib|tofacitinib efficacy
58068518|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
58279947|NCT01066871|DRUG|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
58279948|NCT01066871|DRUG|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
58279949|NCT01066871|OTHER|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
58279950|NCT04702997|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
58279951|NCT04702997|DRUG|Placebo oral capsule|Capsule containing an inert placebo
58279952|NCT06433817|RADIATION|Spectral computed tomography scan|Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
58279953|NCT03107533|OTHER|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
58279954|NCT03927833|DEVICE|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
58395940|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
58395941|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
58395942|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
58395943|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
58395944|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
57927695|NCT00982215|DRUG|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
57927696|NCT00982215|DRUG|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
57927697|NCT03456531|DEVICE|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
57927698|NCT03456531|DRUG|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
57927699|NCT05975957|DEVICE|Photomodulation Therapy with the Light-Aid system|Patients in the intervention group (FBM) will be submitted to 10 treatment sessions (twice a week/five weeks) with the Light-Aid system (Bright Photomedicine, SP, Brazil), operated in continuous mode, with 100 LEDs of 850nm wave per tip, with application time varying from 4 to 8 minutes. Irradiation parameters will be customized based on pain intensity, skin phototype and Body Mass Index (BMI).
58068519|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
58068520|NCT00982800|DRUG|Placebo Sugar Pill|
58068521|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
58068522|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
58068523|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
58395945|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
58395946|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
58395947|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
58395948|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
58395949|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
57927700|NCT05975957|DEVICE|Control|Patients in the placebo group will undergo the same therapeutic protocol as the FBM group using a device with the same appearance as the Light-Aid System, but with inert light emission. In both groups, the treatment will be administered in contact with the skin over the knee, with the patient positioned in dorsal decubitus. The three tips of the device will be positioned horizontally over the anterior region of the knee with the central tip over the patella.
58395950|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
58395951|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
57727311|NCT05715580|OTHER|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
57927701|NCT01361295|PROCEDURE|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
57927702|NCT01361295|PROCEDURE|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
57927703|NCT02536573|OTHER|Radlink Surgical Positioning Software|
57927704|NCT01810692|DEVICE|Group1:Spiriva® Respimat®|COPD patients using Respimat®
57927705|NCT01810692|DEVICE|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
57927706|NCT05182996|BEHAVIORAL|smoking education|Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
57927707|NCT01158651|DRUG|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
58395952|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
58395953|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
58395954|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
58395955|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
58395956|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
57727312|NCT05715580|OTHER|Usual clinical practice|Nursing information following the usual clinical practice
58395957|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
57927708|NCT01728220|COMBINATION_PRODUCT|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
58068524|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
58068525|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
58068526|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
58068527|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
58068528|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
58068529|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
58068530|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
58068531|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
58279955|NCT01765608|DRUG|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
58279956|NCT01765608|DRUG|Placebo|
58279957|NCT01765608|DEVICE|nCPAP|
58395958|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
58395959|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
58395960|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
58395961|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
58279958|NCT02812225|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
58395962|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
58395963|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
58395964|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
58395965|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
58395966|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
58395967|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
58395968|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
58395969|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
58395970|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
58395971|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
58395972|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
58395973|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
57927709|NCT01728220|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
58068532|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
57727313|NCT05505838|DRUG|Patisiran|Patisiran administered by intravenous (IV) infusion
58068533|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
58279959|NCT00179764|PROCEDURE|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
58279960|NCT00179764|PROCEDURE|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
58068534|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
58068535|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
58068536|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
58068537|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
58068538|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
58068539|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
58068540|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
58395974|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
58395975|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
58395976|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
58395977|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
58395978|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
58395979|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
58068541|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
58068542|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
58068543|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
58068544|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
58395980|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
58395981|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
58068545|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
58395982|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
58395983|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
58395984|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
58395985|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
58395986|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
58395987|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
58395988|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
57927710|NCT03304353|OTHER|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
57927711|NCT03304353|OTHER|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
57927712|NCT00120640|DRUG|17 hydroxyprogesterone caproate intramuscular injections|
57927713|NCT02467348|DRUG|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
58068546|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
58068547|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
58068548|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
58068549|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
58068550|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
58068551|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
58068552|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
58068553|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
58068554|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
58068555|NCT00270010|DRUG|epoetin alfa|
58068556|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
58068557|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
58279961|NCT00179764|RADIATION|Central Nervous System (CNS) prophylaxis radiation|"* Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
58279962|NCT02888275|DRUG|Dexmedetomidine|
58279963|NCT02888275|DRUG|normal saline|
58279964|NCT03577132|DRUG|Neoadjuvant atezolizumab|"Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy"
58279965|NCT05163730|DEVICE|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
57727314|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
57727315|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
57727316|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
57927714|NCT02467348|DRUG|Ascitic fluid|
57927715|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
57927716|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
58068558|NCT03804476|DRUG|Placebo|Placebo control for this study.
58068559|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
58068560|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
58068561|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
58279966|NCT01059019|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
57727317|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
57727318|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
58068562|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
58068563|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
58068564|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
58068565|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
58068566|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
58279967|NCT04170036|DIETARY_SUPPLEMENT|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
58279968|NCT05187559|OTHER|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
58279969|NCT05187559|DEVICE|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
58279970|NCT00857961|DRUG|Testosterone MD-Lotion|Administered Topically
57727319|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
57927717|NCT01287065|DRUG|Placebo AM|Inhalation powder
57927718|NCT01287065|DRUG|Placebo PM|Inhalation powder
58068567|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
58068568|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
58279971|NCT04150653|DEVICE|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
58279972|NCT05176925|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
58279973|NCT05176925|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
58279974|NCT03630133|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
58279975|NCT02673294|OTHER|balance virtual rehabilitation|
58279976|NCT06201468|OTHER|Group A SCAPULAR MOBILIZATION|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."
58279977|NCT00096759|BEHAVIORAL|Tai Chi Chih|
58279978|NCT00096759|BEHAVIORAL|Relaxation training|
58279979|NCT04424030|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography exam performed as part of clinical management.
58279980|NCT04424030|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
58279981|NCT04424030|DIAGNOSTIC_TEST|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
58395989|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
57927719|NCT00078754|DRUG|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
57927720|NCT00078754|DRUG|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
58068569|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
58068570|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
58068571|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
58279982|NCT04017871|OTHER|MRI|MRI at baseline and J90
58279983|NCT04017871|OTHER|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
58279984|NCT04017871|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
58279985|NCT04017871|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
58279986|NCT04017871|DEVICE|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
58279987|NCT06194058|OTHER|rapid sequence anesthetic induction|Rapid sequence induction and intubation (or crash induction) is a process for inducing general anesthesia when the patient is at a high risk of pulmonary aspiration. It aims at minimizing the time between giving the induction drugs and securing the tube, during which period the patient's airway is essentially unprotected.
58279988|NCT05933694|OTHER|Artificial Intelligence-powered Spirometry Interpretation Report|A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
58279989|NCT03039608|DRUG|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
57727320|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
57727321|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
57927721|NCT00078754|DRUG|Placebo|Placebo capsules by mouth, up to 8 capsules daily
57927722|NCT01524341|DRUG|KAE609|KAE609 was supplied as capsules for oral use.
57927723|NCT01301651|BEHAVIORAL|balance training|30 minute each time, 2 times per week for 6 weeks.
57927724|NCT03047551|PROCEDURE|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
57927725|NCT03047551|PROCEDURE|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
57927726|NCT02047643|DEVICE|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
57727322|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
57927727|NCT05995639|PROCEDURE|Dry Needling|Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.
57927728|NCT05995639|PROCEDURE|Ozone Injection|Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
58068572|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
58068573|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
58068574|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
58068575|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
58279990|NCT03039608|DRUG|oral steroid administration（prednisone）|oral steroid
58279991|NCT02033278|DRUG|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
58279992|NCT02033278|DRUG|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
58395990|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
58395991|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
58395992|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
58068576|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
58068577|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
58068578|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
58068579|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
58068580|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
58068581|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
57727323|NCT00268749|DRUG|glycine|0.8 g/kg/day
57727324|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
57727325|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
58068582|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
58068583|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
58279993|NCT04350177|DRUG|IkT-148009|Oral administration gelatin capsule
58279994|NCT04350177|DRUG|Placebo|Oral administration gelatin capsule
58279995|NCT03564093|DRUG|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
58279996|NCT03564093|DRUG|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
58279997|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
58279998|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
58279999|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
58280000|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
58280001|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
58280002|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
57727326|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
57927729|NCT04423354|PROCEDURE|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
58068584|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
57727327|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
57727328|NCT06243653|DIAGNOSTIC_TEST|CMD test|Measured CFR and IMR
57951166|NCT02604277|BEHAVIORAL|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education \& Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education \& Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
57727329|NCT03877367|OTHER|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
57727330|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
57951167|NCT00820677|BEHAVIORAL|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
58280003|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
58280004|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
58280005|NCT01957943|DIETARY_SUPPLEMENT|SMOFLipid|
58280006|NCT01957943|DIETARY_SUPPLEMENT|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
58280007|NCT03765853|OTHER|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
58280008|NCT02704559|DRUG|DWC20155|
58280009|NCT02704559|DRUG|DWC20156|
58280010|NCT05229627|DRUG|MPH|the drug would be prescribed to patients without any contraindication
58280011|NCT05229627|DRUG|ATX|the drug would be prescribed to patients without any contraindication
58280012|NCT05968690|DRUG|Propranolol|Propranolol will be administered to patients in all cohorts.
58280013|NCT05968690|DRUG|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
58280014|NCT05237739|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.
58280015|NCT05237739|PROCEDURE|Open Flap Debridement (OFD)|Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
58395993|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
57727331|NCT04218019|DEVICE|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
57727332|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
57727333|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
58280016|NCT02493530|DRUG|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
58280017|NCT02493530|DRUG|ruxolitinib|
58280018|NCT00942539|DRUG|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
57727334|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
57727335|NCT04102501|DRUG|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
57727336|NCT04102501|DRUG|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
58280019|NCT02234336|PROCEDURE|Noncontrast echocardiography|
58280020|NCT02234336|PROCEDURE|Contrast Echocardiography|
58280021|NCT02234336|PROCEDURE|Cardiac magnetic resonance imaging|
58280022|NCT02061423|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
58280023|NCT04595084|BEHAVIORAL|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
58280024|NCT04595084|BEHAVIORAL|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
58280025|NCT04595084|BEHAVIORAL|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
58280026|NCT01638195|DEVICE|Focused Ultrasound|Focused Ultrasound
58280027|NCT03731026|COMBINATION_PRODUCT|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
57727337|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
57727338|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
57727339|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
57727340|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
57727341|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
57727342|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
58280028|NCT03731026|DRUG|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
58280029|NCT02392702|DRUG|C-10355|
58280030|NCT02392702|DRUG|C-10358|
58280031|NCT02392702|DRUG|Kalydeco|
58280032|NCT01539928|OTHER|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
58068585|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
58068586|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
58395994|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
58395995|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
58395996|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
58395997|NCT00464061|DRUG|Volinanserin|oral administration
58068587|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
58280033|NCT02555930|OTHER|No Intervention|No intervention - observational only
58280034|NCT02756598|DRUG|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
58280035|NCT02756598|DRUG|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
58280036|NCT02756598|DRUG|Propofol I|Continued dose of propofol 0.03 mg/kg/min
58280037|NCT02756598|DRUG|Propofol II|Continued dose of propofol 0.06 mg/kg/min
58280038|NCT04437446|DIAGNOSTIC_TEST|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
58280039|NCT04437446|DIAGNOSTIC_TEST|Control Group|"The additional examinations correspond to:~* OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~* OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~* Visual field"
58280040|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
58280041|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
58395998|NCT00464061|DRUG|Placebo|oral administration
57927730|NCT03935503|PROCEDURE|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
57927731|NCT03935503|PROCEDURE|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
57927732|NCT00916630|DRUG|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
57927733|NCT06051578|OTHER|Abdominal wall tension measurement|"All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
58068588|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
58280042|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
58280043|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
58280044|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
58280045|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
58280046|NCT02814617|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
58395999|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
58396000|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
58280047|NCT02814617|DIETARY_SUPPLEMENT|Placebo|
58396001|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
58396002|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
57927734|NCT05700201|BEHAVIORAL|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
57927735|NCT05700201|OTHER|standard care|Standard care (psychotherapy)
58068589|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
58068590|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
58068591|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
58068592|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
58068593|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
58068594|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
58068595|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
58068596|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
58280048|NCT06200272|COMBINATION_PRODUCT|Germ and Carob Molasses Pulp added standard whole wheat breads|Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
58280049|NCT02350699|DEVICE|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
58280050|NCT04125940|DIETARY_SUPPLEMENT|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
58280051|NCT04125940|DIETARY_SUPPLEMENT|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
58280052|NCT04125940|OTHER|Placebo|12oz water + food coloring
58396003|NCT00084708|DRUG|dexamethasone|
58396004|NCT00084708|DRUG|gefitinib|
58396005|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
58396006|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
58396007|NCT03347526|DRUG|Vigabatrin|oral
58396008|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
58396009|NCT04960059|OTHER|No intervention|This is an observational study
58396010|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
57927736|NCT01264367|DRUG|Clevudine|30mg,QD
57927737|NCT01264367|DRUG|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
57927738|NCT01285466|DRUG|BEZ235 + paclitaxel|
57927739|NCT01285466|DRUG|BKM120 + paclitaxel|
57927740|NCT01285466|DRUG|BEZ235 + paclitaxel + trastuzumab|
57927741|NCT01285466|DRUG|BKM120 + paclitaxel + trastuzumab|
57927742|NCT03205215|OTHER|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
57927743|NCT03205215|OTHER|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
57927744|NCT05467254|BIOLOGICAL|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
57927745|NCT01446016|DRUG|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
57927746|NCT01446016|DRUG|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
57927747|NCT01446016|DRUG|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
57927748|NCT01446016|DRUG|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
57927749|NCT02499081|DRUG|Ixazomib|
58280053|NCT03637530|OTHER|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
58280054|NCT05175820|OTHER|No intervention|Survey questions were sent through the mailing list of the Turkish Dental Association, where all dentists in Turkey are registered
58396011|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
58396012|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
58396013|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
57927750|NCT04398641|OTHER|Evaluation of pre- and postoperative gastrointestinal functional outcomes|Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
57927751|NCT04247009|OTHER|Meal based on red meat, fish products or vegan products|Three meals will be served
57927752|NCT04247009|OTHER|Meal based on red meat|Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
57927753|NCT01377077|PROCEDURE|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
57927754|NCT01377077|PROCEDURE|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
57927755|NCT00567268|DRUG|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
57927756|NCT03450798|DEVICE|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
57927757|NCT03450798|DEVICE|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
57927758|NCT02506478|OTHER|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
57927759|NCT01322048|DRUG|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
57927760|NCT01322048|DRUG|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
57927761|NCT03330457|BIOLOGICAL|Andexanet alfa (bolus)|fXa inhibitor antidote
57927762|NCT03330457|DRUG|Betrixaban 80 mg PO QD|fXa inhibitor
57927763|NCT03330457|BIOLOGICAL|Andexanet alfa (infusion IV)|fXa inhibitor antidote
57927764|NCT05918172|DEVICE|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
57927765|NCT05918172|DEVICE|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
57927766|NCT05211154|DRUG|Diclofenac Potassium 50Mg/Pkt Oral Pwdr|Treatment for an acute, moderate to severe migraine attack
58280055|NCT04273867|OTHER|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
58280056|NCT04842552|DRUG|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
58280057|NCT04842552|DRUG|Placebo|Placebo
58280058|NCT04542811|OTHER|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
58280059|NCT03790618|DRUG|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
58280060|NCT03790618|DRUG|methamphetamine|Please see above.
58280061|NCT01019460|PROCEDURE|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
58280062|NCT02389374|DRUG|chloroquine|standard dose
58280063|NCT02389374|DRUG|Artemether-lumefantrine combination|standard dose
58280064|NCT02389374|DRUG|Primaquine|single dose
58280065|NCT02389374|DRUG|Primaquine|14 days
58280066|NCT02924805|OTHER|Telemedical care|Telemedically guided care based on a standard operating procedure
58280067|NCT06268496|OTHER|serum formula 2039125 03|application twice a day of the tested product (in the morning and evening) to the face for 3 months
58280068|NCT02611765|DRUG|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
58068597|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
58068598|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
58396014|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
58396015|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
58396016|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
58396017|NCT06446375|OTHER|Regular daily activity|Regular physical activity
58396018|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
58396019|NCT00204594|DRUG|rM28|
58396020|NCT00204594|DRUG|autologous PBMCs|
58396021|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
58396022|NCT06014606|DRUG|placebo|oral formulation
58396023|NCT06014606|DRUG|haloperidol 2mg|oral formulation
58396024|NCT06014606|DRUG|propranolol 40mg|oral formulation
57727343|NCT05294757|OTHER|Physical exercise|1. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
57727344|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
57927767|NCT05211154|DRUG|Rimegepant 75 MG|Treatment for an acute, moderate to severe migraine attack
57927768|NCT02944994|OTHER|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
57927769|NCT02944994|OTHER|Routine Care|This arm will reflect typical care received in routine mental health care
57927770|NCT00000913|DRUG|Ritonavir|
57927771|NCT00000913|DRUG|Nelfinavir mesylate|
57927772|NCT00000913|DRUG|Saquinavir|
57927773|NCT06393790|BEHAVIORAL|FMG (Fibromyalgia group)|This intervention will report results of a strength training programme in people with fibromyalgia
57927774|NCT06393790|BEHAVIORAL|HG (Healthy group)|This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
58068599|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
58068600|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
58068601|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
58396025|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
58396026|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
58396027|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
58396028|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
58396029|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
58396030|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
58068602|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
57927775|NCT00172107|DRUG|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
57927776|NCT00172107|DRUG|placebo|placebo powder for subcutaneous injection
57927777|NCT00172107|DRUG|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
57927778|NCT00172107|DRUG|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
57927779|NCT02977208|PROCEDURE|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
57927780|NCT02977208|PROCEDURE|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
58396031|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
58396032|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
58396033|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
58396034|NCT02806336|BEHAVIORAL|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
57927781|NCT02977208|PROCEDURE|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms
57927782|NCT02977208|DRUG|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
58396035|NCT02806336|BEHAVIORAL|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
58396036|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
58396037|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
58396038|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
58396039|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
58396040|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
58396041|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
57727345|NCT02007486|OTHER|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
57727346|NCT02349958|DEVICE|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
57927783|NCT06470802|BEHAVIORAL|Familiar voice|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
57927784|NCT06470802|BEHAVIORAL|Nature sounds|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
57927785|NCT06470802|BEHAVIORAL|Control|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
58068603|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
58068604|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
57727347|NCT02349958|DEVICE|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
57727348|NCT02349958|DEVICE|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
57927786|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 soft gelatine capsules|
57927787|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 film-coated tablets|
58068605|NCT01868126|DRUG|DE-117 ophthalmic solution|
58068606|NCT01868126|DRUG|latanoprost ophthalmic solution|
57727349|NCT02349958|DEVICE|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
57727350|NCT00006172|DEVICE|Bright light box|60-min light therapy shortly after awakening
57727351|NCT00006172|DEVICE|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
57727352|NCT00006172|DEVICE|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
57727353|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
57727354|NCT04719585|DRUG|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
57727355|NCT00489450|DRUG|SK3530|
57727356|NCT00610051|DRUG|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
57727357|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
58280069|NCT02611765|DRUG|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
58280070|NCT05253118|DRUG|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
58280071|NCT05253118|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
58280072|NCT04710368|DRUG|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
58280073|NCT01066793|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
58280074|NCT01066793|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
58280075|NCT04118179|OTHER|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
58280076|NCT02599064|DRUG|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
58280077|NCT02782754|DRUG|Carboplatin|
58280078|NCT02782754|DRUG|Etoposide|
58280079|NCT02782754|DRUG|Cyclophosphamide|
58280080|NCT02782754|DRUG|Bleomycin|
58280081|NCT02782754|RADIATION|Reduced dose of radiotherapy|
58280082|NCT06314412|OTHER|Stoller's Afferent Nerve Stimulation (SANS)|15 sessions of SANS (5 sessions/week for 3 weeks)
57727358|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
57727359|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
57727360|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
58396042|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
57727361|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
57727362|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
58068607|NCT01868126|OTHER|Placebo|
58280083|NCT03513783|OTHER|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~* A clinical exam is performed by the Physical Medicine \& Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~* Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~* The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
57727363|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
58280084|NCT03749421|OTHER|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
58280085|NCT00323843|DRUG|Isoproterenol|
58280086|NCT05365334|BEHAVIORAL|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
58280087|NCT05365334|BEHAVIORAL|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
58396043|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
58396044|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
58396045|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
58396046|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
58396047|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
58396048|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
58396049|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
57727364|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
57727365|NCT04023006|DEVICE|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
57727366|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
57727367|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
57727368|NCT05056350|OTHER|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
57727369|NCT05056350|OTHER|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
58280088|NCT05365334|BEHAVIORAL|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
58280089|NCT00882661|DEVICE|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
58396050|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
58396051|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58396052|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58396053|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
58396054|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
58396055|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
58280090|NCT00882661|DEVICE|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
58280091|NCT00370422|DRUG|Triamcinolone, Bevacizumab|
58280092|NCT00157716|DRUG|(MC-1) Pyridoxal-5'-phosphate|
58280093|NCT03207308|DIETARY_SUPPLEMENT|Vitamin A supplementation|200,000 IU of preformed vitamin A
58280094|NCT03236129|PROCEDURE|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
57927788|NCT02183285|DIETARY_SUPPLEMENT|Placebo film-coated tablets (fct)|
57927789|NCT02183285|DIETARY_SUPPLEMENT|Placebo soft gelatine capsules|
57927790|NCT01980654|DRUG|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
58280095|NCT03236129|PROCEDURE|Standard DLI|The patients in this arm benefit of a standard DLI.
58280096|NCT02474134|DRUG|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
58280097|NCT02536274|DEVICE|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
58280098|NCT02536274|DEVICE|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
58280099|NCT01322698|BIOLOGICAL|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
58280100|NCT04292145|BEHAVIORAL|Relaxation Application|The use of an application for relaxation.
58280101|NCT04292145|BEHAVIORAL|Relaxation Only|The individual's personal method to relax.
57927791|NCT01980654|DRUG|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
58280102|NCT02205294|OTHER|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
58280103|NCT04397549|OTHER|Cervical erector spinae plane block|Cervical erector spinae plane block will be administered before the surgery
58280104|NCT04397549|DEVICE|Intravenous morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
58280105|NCT04150120|DEVICE|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
58280106|NCT01030718|DRUG|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
57927792|NCT03679156|DEVICE|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
58280107|NCT05430685|DIETARY_SUPPLEMENT|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
58280108|NCT05430685|OTHER|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
58280109|NCT02336347|DRUG|AVP-786|
58280110|NCT02336347|DRUG|AVP-923|
58280111|NCT02836951|OTHER|Withdrawal of blood|Withdrawal of blood
58280112|NCT03699540|DRUG|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
57727370|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
58280113|NCT03699540|DRUG|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
57727371|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
58280114|NCT03699540|DRUG|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
58280115|NCT03699540|DRUG|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
58280116|NCT04796207|DIETARY_SUPPLEMENT|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
57927793|NCT03397849|BEHAVIORAL|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
57927794|NCT05777473|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
57951168|NCT00563186|OTHER|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
58280117|NCT04796207|DIETARY_SUPPLEMENT|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season."
57727372|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
57727373|NCT05239091|DRUG|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
57727374|NCT05239091|DRUG|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
57727375|NCT05546281|OTHER|No intervention|No intervention
57727376|NCT05287867|BIOLOGICAL|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
57727377|NCT05287867|OTHER|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
57727378|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
57727379|NCT01476215|DRUG|Paracetamol fast dissolution suspension|
57727380|NCT01476215|DRUG|Paracetamol medium dissolution suspension|
57727381|NCT01476215|DRUG|Paracetamol slow dissolution suspension|
57727382|NCT01476215|DRUG|Paracetamol|
57727383|NCT05869305|DIETARY_SUPPLEMENT|whey protein isolate|Take 1 sachet/day for 12 weeks.
58280118|NCT04029259|DIAGNOSTIC_TEST|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
58280119|NCT02933528|DRUG|DSXS Topical product|once daily for 28 days
58280120|NCT03578133|DIAGNOSTIC_TEST|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
57927795|NCT05777473|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
57927796|NCT05777473|BEHAVIORAL|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
58280121|NCT05921240|OTHER|observational study, no intervention|no intervention
57727384|NCT05869305|DIETARY_SUPPLEMENT|isolated soy protein|Take 1 sachet/day for 12 weeks.
57727385|NCT05869305|DIETARY_SUPPLEMENT|placebo|Take 1 sachet/day for 12 weeks.
57727386|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
57927797|NCT00561496|DRUG|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
58068608|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
58068609|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
57727387|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
57727388|NCT01320410|DRUG|ISM®|
57727389|NCT03517644|OTHER|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
58068610|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
58280122|NCT01494701|DRUG|nusinersen|Administered by intrathecal (IT) injection
58280123|NCT00898326|OTHER|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
58280124|NCT05573464|DRUG|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
58280125|NCT05573464|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
58280126|NCT00031044|DRUG|Enfuvirtide|
58280127|NCT00031044|DRUG|Amdoxovir|
58280128|NCT03340298|DIETARY_SUPPLEMENT|fiber|the intervention of different sources of dietary fibers
57927798|NCT06421896|BEHAVIORAL|motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is a systematic intervention that focuses on eliciting and strengthening a person's intrinsic motivation to change. MET is rooted in motivational interviewing principles, emphasizing empathy, autonomy, and the evocation of the patient's own motivations for change. The therapy typically involves several sessions where therapists help patients identify personal goals, explore ambivalence towards change, and develop actionable plans to achieve their desired outcomes.
57927799|NCT00901030|PROCEDURE|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
57927800|NCT01215175|BIOLOGICAL|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
57927801|NCT01215175|BIOLOGICAL|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
57927802|NCT01215175|BIOLOGICAL|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
57927803|NCT03985345|DEVICE|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
57927804|NCT02939872|DRUG|aspirin and clopidogrel|at the discretion of investigator
57927805|NCT02939872|DRUG|Clopidogrel only|at the discretion of investigator
57927806|NCT02482766|DRUG|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
57927807|NCT02482766|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
58068611|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
58068612|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
58068613|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
58068614|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
58068615|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
58068616|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
58068617|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
58068618|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
58068619|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
58068620|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
58068621|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
58280129|NCT00770471|DRUG|temozolomide|
58280130|NCT00770471|DRUG|veliparib|
57927808|NCT02482766|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
57927809|NCT02748837|DRUG|ERY974|
57927810|NCT01002456|OTHER|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
57927811|NCT01002456|OTHER|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
58068622|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
58068623|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
58280131|NCT00770471|GENETIC|DNA methylation analysis|
58280132|NCT00770471|GENETIC|gene expression analysis|
58280133|NCT00770471|GENETIC|mutation analysis|
58280134|NCT00770471|GENETIC|proteomic profiling|
58280135|NCT00770471|OTHER|high performance liquid chromatography|
58280136|NCT00770471|OTHER|immunoenzyme technique|
58280137|NCT00770471|OTHER|laboratory biomarker analysis|
58280138|NCT00770471|OTHER|mass spectrometry|
58280139|NCT00770471|OTHER|pharmacogenomic studies|
58280140|NCT00770471|OTHER|pharmacological study|
58280141|NCT00770471|PROCEDURE|adjuvant therapy|
57927812|NCT04836663|DRUG|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
58068624|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
58280142|NCT00770471|RADIATION|radiation therapy|
58280143|NCT02735473|DRUG|Choline bitartrate|
58280144|NCT02735473|DRUG|Placebo|
58280145|NCT00462449|DEVICE|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
57927813|NCT02020863|DEVICE|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
57927814|NCT03082703|BEHAVIORAL|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
57927815|NCT00764751|DRUG|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
57927816|NCT00764751|DRUG|Dovonex® cream|Twice daily application
57927817|NCT00764751|DRUG|Cream vehicle|Twice daily application
57927818|NCT04294069|DRUG|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
58068625|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
58068626|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
58068627|NCT02344758|BEHAVIORAL|gluten-containing diet|
58068628|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
58068629|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
58068630|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
58068631|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
58280146|NCT03576209|BEHAVIORAL|healthy lifestyle program|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
57727390|NCT03517644|OTHER|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
57727391|NCT03517644|OTHER|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
58306776|NCT06520956|BEHAVIORAL|Video based exercise group|In each session, 2 videos will be applied and each will be repeated 2-3 times, with a 3-minute rest break between each video. The total session will last an average of 20-30 minutes and 16 sessions of physical activity will be performed twice a week for a total of 8 weeks.
57727392|NCT03517644|OTHER|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
57727393|NCT03517644|OTHER|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
57727394|NCT05404529|DRUG|Tavapadon|Oral tablets
58068632|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
58068633|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
58068634|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
58068635|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
57727395|NCT03547661|OTHER|P-Dragees rosa Lichtenstein|Placebo dragées
57927819|NCT04294069|DRUG|Azithromycin Oral Product|1000mg azithromycin PO once at admission
57927820|NCT03231943|DRUG|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
58306777|NCT02390232|BIOLOGICAL|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
58306778|NCT02390232|BIOLOGICAL|collection of stools|collection of stools
58306779|NCT02390232|BIOLOGICAL|blood sample|collection of blood sample
57927821|NCT03231943|DRUG|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
57927822|NCT04158596|DEVICE|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
57927823|NCT04506307|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
57927824|NCT02467218|OTHER|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
57927825|NCT05880277|DIAGNOSTIC_TEST|POCUS|Point of Care Ultrasound
57927826|NCT03475017|DIETARY_SUPPLEMENT|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
58068636|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
57727396|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
57927827|NCT03475017|DIETARY_SUPPLEMENT|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
57927828|NCT00154336|DRUG|Imatinib|
57927829|NCT00154336|DRUG|Methotrexate|
57927830|NCT00154336|DRUG|Imatinib Placebo|
57927831|NCT04206592|DEVICE|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
57927832|NCT01023854|PROCEDURE|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
57927833|NCT04010513|BEHAVIORAL|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
57927834|NCT04010513|OTHER|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
58280147|NCT05629676|BEHAVIORAL|BMT-VR|BMT-VR is a novel psychosocial intervention that addresses the supportive care needs of patients undergoing BMT. BMT-VR includes six sections focused on: 1) psychoeducation to help patients increase their awareness to stress and challenges that may accompany the BMT journey; 2) supportive psychotherapy strategies to help patients adjust to the intense BMT hospitalization; 3) psychosocial skill building to promote mindfulness, acceptance and gratitude while living with uncertainty; 4) psychoeducation to manage expectations and enhance preparedness for extended hospitalization; 5) psychosocial skill-building to promote effective coping; and 6) an overview of psychosocial skills grounded in cognitive behavior therapy, mindfulness, and positive psychology
58280148|NCT00002073|DRUG|Epoetin alfa|
57927835|NCT05794646|OTHER|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
57927836|NCT06494917|OTHER|pelvic floor exercises|First arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied.
58280149|NCT06111001|OTHER|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
58280150|NCT06111001|OTHER|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
58280151|NCT06111001|OTHER|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
58280152|NCT01614106|BEHAVIORAL|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
58280153|NCT04656678|DEVICE|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
58280154|NCT02587754|DEVICE|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
58280155|NCT05012410|BEHAVIORAL|Immediate treatment group with High-Intensity Prompts|Caregivers in the immediate treatment group with high-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive telephone and email prompts to use the tool.
58280156|NCT05012410|BEHAVIORAL|Immediate treatment group with Low-Intensity Prompts|Caregivers in the immediate treatment group with low-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive email prompts to use the tool.
58068637|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
58068638|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
58068639|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
58068640|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
58068641|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
58068642|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
58068643|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
58280157|NCT05012410|BEHAVIORAL|Waitlist Control after three months with High-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive telephone and email prompts. Once the caregiver receives the WeCareAdvisor tool, they will receive a weekly automated email as well as a weekly telephone call from study staff to prompt them to use the tool.
58280158|NCT05012410|BEHAVIORAL|Waitlist Control after three months with Low-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive email prompts.
58280159|NCT03942367|DEVICE|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
58280160|NCT03942367|DEVICE|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
58280161|NCT02150681|BEHAVIORAL|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
58280162|NCT02801370|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
58280163|NCT02801370|DRUG|Sham Control|Simulated, single adminstration
58280164|NCT05111938|BEHAVIORAL|Friends, Family, and Food App (F3A-App)|
58280165|NCT02446535|OTHER|achievement of the DW by means of the BIA DW (RE.S.T.)|
58280166|NCT05194943|PROCEDURE|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
58280167|NCT02226848|DRUG|Erythropoeitin|
57951169|NCT02954497|DEVICE|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
57951170|NCT02954497|PROCEDURE|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
57951171|NCT04772495|GENETIC|miRNA|miRNA effect on Multiple sclerosis pathology
57927837|NCT06494917|OTHER|Pelvic floor exercises and manual therapy techniques|Second arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied. In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods such as momentum minus mobilisation, sphincter opening, colon massage, global fascia manipulation, trigger point and myofascial release will be applied.
57927838|NCT01649570|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
57927839|NCT05140733|PROCEDURE|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
57927840|NCT05140733|PROCEDURE|Fusion surgery|Fusion surgery for patients with foraminal stenosis
57927841|NCT06434389|DIAGNOSTIC_TEST|the Electrochemical-based device|Electrochemical-based device for rapid detection of fibrinogen is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.
57927842|NCT00506428|BEHAVIORAL|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
57927843|NCT04898413|BEHAVIORAL|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
57927844|NCT04898413|BEHAVIORAL|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
57927845|NCT04026841|DRUG|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
57927846|NCT03732508|DRUG|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
57927847|NCT03732508|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
57927848|NCT03732508|DRUG|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
57927849|NCT04572022|OTHER|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
58280168|NCT02365038|OTHER|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
58280169|NCT02365038|OTHER|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
58396056|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
57927850|NCT05261971|DRUG|Etodolac 400 MG|Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
57927851|NCT05261971|DRUG|Thiocolchicoside|Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
57927852|NCT01862302|DRUG|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
57927853|NCT01862302|DRUG|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
57927854|NCT04549519|OTHER|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
57927855|NCT00635726|DRUG|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
57927856|NCT00635726|DRUG|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
58306780|NCT05605353|DIAGNOSTIC_TEST|Faecal microbiota sampling and blood sampling|There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
57927857|NCT00635726|DRUG|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
57927858|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
57927859|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
57927860|NCT00635726|DRUG|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
58280170|NCT04586465|DRUG|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
58396057|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
58396058|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
58396059|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
58396060|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
58396061|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
58280171|NCT00514982|DRUG|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
58396062|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
58396063|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
58396064|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
57727397|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
58068644|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
58068645|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
58068646|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
58068647|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
58280172|NCT00514982|DRUG|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
58280173|NCT00514982|DRUG|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
58280174|NCT00514982|DRUG|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
58280175|NCT00514982|DRUG|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
57727398|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
58280176|NCT00514982|DRUG|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
58280177|NCT04091815|OTHER|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
58396065|NCT01555853|DRUG|Abraxane|
58396066|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
58396067|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
58396068|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
58396069|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
58396070|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
58396071|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
58396072|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
58280178|NCT03734445|DIETARY_SUPPLEMENT|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
58280179|NCT03734445|OTHER|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
58280180|NCT03460366|DRUG|Enalapril|Patients are tested for their normal prescription enalapril medication
58280181|NCT04100655|DRUG|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
58280182|NCT04100655|DRUG|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
58280183|NCT03420222|DRUG|AVP-786|oral capsules
58280184|NCT03420222|DRUG|Placebo|oral capsules
58280185|NCT02867800|DRUG|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
58280186|NCT02867800|DRUG|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
58280187|NCT02867800|DRUG|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
58280188|NCT02867800|DRUG|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
58280189|NCT02867800|DRUG|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
58280190|NCT02867800|DRUG|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
58280191|NCT02867800|DRUG|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
58280192|NCT02867800|DRUG|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
57927861|NCT05241509|DRUG|Cymbopogon citratus (lemongrass) oil gel|Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
58280193|NCT02867800|DRUG|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
58280194|NCT02867800|DRUG|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
58280195|NCT02867800|DRUG|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
58280196|NCT02867800|DRUG|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
58280197|NCT02867800|DRUG|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
57927862|NCT05628116|DRUG|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
57927863|NCT05628116|DRUG|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
57927864|NCT05628116|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
57927865|NCT05628116|DRUG|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
57927866|NCT05628116|DRUG|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
57927867|NCT05628116|DRUG|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
57927868|NCT05628116|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
57927869|NCT01210989|DRUG|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
57927870|NCT01210989|DRUG|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
57927871|NCT04936841|DRUG|NKTR-214|Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
57927872|NCT04936841|DRUG|anti-PD-1 therapy|immunotherapy drug, monoclonal antibody
57927873|NCT04936841|RADIATION|Palliative Radiation|radiation to relieve symptoms
57927874|NCT01721603|DRUG|Dabrafenib|150 mg capsule by mouth twice daily
57927875|NCT01721603|PROCEDURE|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
57927876|NCT01721603|DRUG|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
57927877|NCT02729389|BEHAVIORAL|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
57927878|NCT02729389|BEHAVIORAL|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
58280198|NCT02867800|PROCEDURE|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
57927879|NCT00165633|DRUG|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
57927880|NCT00165633|DRUG|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
58068648|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
57927881|NCT00165633|DRUG|Placebo|Placebo capsule, orally, three times a day, after meals.
58068649|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
57927882|NCT01248702|OTHER|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
58068650|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
58068651|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
58068652|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
58068653|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
58068654|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
57727399|NCT05774808|PROCEDURE|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
57727400|NCT05774808|PROCEDURE|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
57927883|NCT00928564|DRUG|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
57927884|NCT00928564|DRUG|Placebo|5ml of saline at each block site.
57927885|NCT04586998|DEVICE|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
57927886|NCT00153361|BEHAVIORAL|Discussion Group|
57927887|NCT00153361|BEHAVIORAL|Video Discussion Group|
57927888|NCT03270332|DRUG|Albuterol|inhalation of 270μg albuterol through a spacer
57927889|NCT03270332|DRUG|Placebo|inhalation of placebo through a spacer
58068655|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
58280199|NCT02867800|DRUG|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
58396073|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
57727401|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
57727402|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
58068656|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
58280200|NCT02867800|DRUG|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
58280201|NCT00719940|BEHAVIORAL|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
58280202|NCT00719940|OTHER|Waiting group|No intervention
58280203|NCT03748121|BEHAVIORAL|Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)|The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
58280204|NCT03748121|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
58280205|NCT00549471|OTHER|physiotherapy|CG children will undergo a program of intensive physiotherapy
58280206|NCT00549471|OTHER|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
58280207|NCT00661453|DRUG|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
58280208|NCT03728621|BEHAVIORAL|Normocaloric and balanced diet, physical activity|Promotion of normocaloric \& balanced diet and physical activity
58280209|NCT02874833|OTHER|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
58280210|NCT00450853|DRUG|granisetron|Granisetron SC followed by granisetron IV
58280211|NCT03571724|OTHER|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
58280212|NCT03571724|OTHER|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
58280213|NCT03571724|OTHER|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
58280214|NCT03571724|OTHER|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
58280215|NCT05745753|OTHER|sample blood|At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
58396074|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
58396075|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
58396076|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
58396077|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
58396078|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
58396079|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
58396080|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
58396081|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
58396082|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
58396083|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
57727403|NCT05363033|DEVICE|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
58068657|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
57927890|NCT02535663|DIETARY_SUPPLEMENT|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
57927891|NCT02535663|DIETARY_SUPPLEMENT|Placebo|Same product without RG
57927892|NCT03706950|DRUG|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
57927893|NCT05490979|BEHAVIORAL|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
58280216|NCT01249586|OTHER|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
58280217|NCT05373030|BIOLOGICAL|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
58396084|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
58396085|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
58396086|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
57727404|NCT00002872|BIOLOGICAL|bleomycin sulfate|
57727405|NCT00002872|DRUG|doxycycline|
57727406|NCT00002872|OTHER|talc|
57727407|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
57927894|NCT05490979|BEHAVIORAL|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
57927895|NCT00827762|DRUG|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
57927896|NCT00565942|PROCEDURE|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
57927897|NCT00565942|PROCEDURE|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
57927898|NCT00752531|BEHAVIORAL|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
57927899|NCT00160355|PROCEDURE|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
58280218|NCT00565175|DRUG|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
58280219|NCT00565175|DRUG|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
57727408|NCT03457259|DEVICE|Midline|Pt. will receive midline
57727409|NCT04193813|OTHER|Observational|Observational study
57727410|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
57727411|NCT02232529|DRUG|MIN-101|
57727412|NCT02232529|DRUG|Placebo|
57727413|NCT04296565|BEHAVIORAL|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
57727414|NCT04296565|BEHAVIORAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
57727415|NCT02012374|BEHAVIORAL|Intensive Language Action Therapy|
57927900|NCT00160355|DEVICE|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
58280220|NCT05061433|OTHER|Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support|MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
58280221|NCT06083545|BEHAVIORAL|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
58280222|NCT05409755|OTHER|Vivacy|Vivacy and minoxidil
57927901|NCT00160355|DRUG|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
58068658|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
57927902|NCT02896504|DRUG|Exposure: Adjuvant chemotherapy treatment|
57927903|NCT02896504|DRUG|Exposure: Adjuvant hormonal therapy treatment|
57927904|NCT01034293|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
57927905|NCT01034293|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
57927906|NCT02306382|PROCEDURE|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
57927907|NCT02306382|DEVICE|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
57927908|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
58068659|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
58068660|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
58068661|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
58280223|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with radiofrequency|The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.
58280224|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with pulsed field ablation|The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.
58280225|NCT06351553|PROCEDURE|Combined pulmonary vein isolation|"The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group."
58396087|NCT02621151|BIOLOGICAL|Pembrolizumab|
58396088|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
57727416|NCT02807948|DEVICE|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
57727417|NCT00592995|DRUG|Creatine monohydrate|10 to 30 grams daily
57927909|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
57927910|NCT00882453|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
57927911|NCT04013516|BEHAVIORAL|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
57927912|NCT04013516|BEHAVIORAL|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
57927913|NCT01979835|DEVICE|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
57927914|NCT04110119|DRUG|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
57927915|NCT04110119|OTHER|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
57927916|NCT00004639|PROCEDURE|Furlow double z-plasty palatoplasty palate repair|
57927917|NCT00004639|PROCEDURE|Von Langenbeck palatoplasty palate repair|
57927918|NCT02422485|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
58068662|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
58068663|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
58068664|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
58068665|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
57927919|NCT01859286|OTHER|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
57927920|NCT01337804|DRUG|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
57927921|NCT01337804|DRUG|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
57927922|NCT01684904|RADIATION|Proton radiation|
57927923|NCT00833911|DRUG|Tramadol Once A Day|
57927924|NCT00233844|PROCEDURE|"Venipuncture with cough-trick"|
57927925|NCT04869280|OTHER|No Intervention|This is a non-interventional study.
57927926|NCT01238289|BEHAVIORAL|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
57927927|NCT01238289|BEHAVIORAL|Control|This group continues with standard care at the community health center
57927928|NCT02838147|DEVICE|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
57927929|NCT02838147|DEVICE|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
57927930|NCT01704820|PROCEDURE|Retroflexion in the right colon|
57927931|NCT03270904|DEVICE|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
57927932|NCT04005651|DEVICE|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
58068666|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
58068667|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
58280226|NCT06178562|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58396089|NCT02621151|DRUG|Gemcitabine|
57927933|NCT04005651|DEVICE|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
57927934|NCT04005651|DEVICE|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
57727418|NCT00592995|DRUG|Placebo|10 to 30 grams daily
57927935|NCT06068660|BEHAVIORAL|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
57927936|NCT06068660|BEHAVIORAL|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
57927937|NCT02494466|DRUG|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
57927938|NCT05781568|DIAGNOSTIC_TEST|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
57927939|NCT05245409|OTHER|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
58068668|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
58068669|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
58396090|NCT02621151|RADIATION|External Beam Radiation Therapy|
57927940|NCT01306890|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
57927941|NCT05145062|DRUG|BIVV003|Solution for intravenous administration
57927942|NCT05145062|DRUG|ST-400|Solution for intravenous administration
57927943|NCT04691999|BEHAVIORAL|Intermittent Fasting|16-18 hour fasting period four times per week
58068670|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
58068671|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
58068672|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
58068673|NCT03942029|DRUG|Placebo|Administered orally as tablet
58068674|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
58068675|NCT01116895|DRUG|LEO 22811|Oral solution
58068676|NCT01116895|DRUG|Placebo|Placebo
58396091|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
57727419|NCT03064425|BIOLOGICAL|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
57927944|NCT01549782|DIETARY_SUPPLEMENT|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
57727420|NCT02289391|DRUG|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
58396092|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
57727421|NCT02289391|DRUG|Anesthesia maintenance|"* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60."
57727422|NCT02289391|DRUG|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
57727423|NCT02863562|OTHER|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
57727424|NCT02863562|OTHER|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
57727425|NCT02863562|OTHER|Placebo Kinesio taping|
57727426|NCT02394743|RADIATION|18FDG-PET|
57727427|NCT06215846|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
57727428|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
58396093|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
58396094|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
57727429|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
57727430|NCT05883306|DRUG|[14C]LXI-15028|\[14C\]LXI-15028
57727431|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
57727432|NCT01043874|DRUG|Nilotinib|400 mg BID
57927945|NCT01549782|DIETARY_SUPPLEMENT|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
57927946|NCT02120625|DEVICE|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
57927947|NCT01009554|DEVICE|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
57927948|NCT01009554|DRUG|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
58068677|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
58280227|NCT06178562|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
57927949|NCT03154762|DEVICE|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
58280228|NCT06178562|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
57727433|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
58280229|NCT00884845|DRUG|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
58280230|NCT00884845|DRUG|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
58280231|NCT03884309|OTHER|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
58280232|NCT03002532|RADIATION|whole brain radiotherapy|
58280233|NCT03420287|COMBINATION_PRODUCT|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
57927950|NCT03154762|DEVICE|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
57927951|NCT01677351|DRUG|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
57927952|NCT01677351|DRUG|placebo|
57927953|NCT00786396|BEHAVIORAL|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
57927954|NCT00809081|PROCEDURE|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
57927955|NCT01398293|DRUG|danoprevir|100 mg single dose orally
58280234|NCT03420287|OTHER|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
57927956|NCT01398293|DRUG|danoprevir|400 mg single dose orally
58280235|NCT06384235|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
57927957|NCT01398293|DRUG|danoprevir placebo|single oral dose
58280236|NCT04270695|BEHAVIORAL|blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.
57927958|NCT01398293|DRUG|moxifloxacin|400 mg single dose orally
57927959|NCT01398293|DRUG|moxifloxacin placebo|single oral dose
57927960|NCT01398293|DRUG|ritonavir|100 mg single dose orally
57927961|NCT01398293|DRUG|ritonavir placebo|single oral dose
57927962|NCT04005417|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
57927963|NCT04005417|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
57927964|NCT04005417|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
57927965|NCT03241212|BEHAVIORAL|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
57927966|NCT06396793|OTHER|no intervention because it is an observational study|it is an observational study thus there is no intervention
57927967|NCT02274636|DIETARY_SUPPLEMENT|Xylitol|A comparison between discs and gel
57927968|NCT01835197|DRUG|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
58280237|NCT04270695|BEHAVIORAL|sham blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
58280238|NCT03339557|DEVICE|NexGen|Comparing two conventional designs and one novel design
58280239|NCT03339557|DEVICE|Persona|Comparing two conventional designs and one novel design
58280240|NCT03339557|DEVICE|PFC|Comparing two conventional designs and one novel design
58280241|NCT00490672|BEHAVIORAL|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
58280242|NCT00490672|BEHAVIORAL|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
57927969|NCT01835197|DRUG|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
57927970|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
57927971|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
57927972|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
57927973|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
57927974|NCT01835197|DRUG|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
58280243|NCT03206840|BEHAVIORAL|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
57927975|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
57927976|NCT01835197|DRUG|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
57927977|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
57927978|NCT00462865|DRUG|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
57927979|NCT00821431|DEVICE|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
57927980|NCT00821431|DEVICE|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
57927981|NCT05409833|DIAGNOSTIC_TEST|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
57927982|NCT02685553|DEVICE|NIR|Laparoscopic use of NIR
57927983|NCT02608879|PROCEDURE|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
57927984|NCT02608879|PROCEDURE|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
57927985|NCT02608879|PROCEDURE|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
57927986|NCT02608879|OTHER|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
57927987|NCT05886582|DRUG|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
57927988|NCT05886582|DRUG|Placebo|Placebo drug
57927989|NCT06072443|BEHAVIORAL|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
57927990|NCT04184960|DIAGNOSTIC_TEST|Gastroscopy and gastric biopsies|Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
57927991|NCT00208897|DRUG|Fluoxetine|
57927992|NCT01596907|DRUG|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
57927993|NCT01596907|DRUG|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
57927994|NCT01877863|OTHER|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
57927995|NCT02129153|BEHAVIORAL|LIFT (Parent Information)|"1. Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~2. Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
57927996|NCT04561804|PROCEDURE|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
57927997|NCT00593749|BEHAVIORAL|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
57927998|NCT00593749|BEHAVIORAL|Control|control group in study
57927999|NCT05001282|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
57928000|NCT00723879|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
57928001|NCT00723879|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
57928002|NCT00723879|BEHAVIORAL|Patient assistance program|"Patient assistance programs will be classified as follows:~1. medications, including psychiatric medications (antidepressants);~2. other interventions, including nurse telephone calls and nurse support in the office: and~3. educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
57928003|NCT01578967|DRUG|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
57928004|NCT01578967|DRUG|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
57928005|NCT02898311|DEVICE|immediate loading of posterior implants with chairside CAD-CAM composite crown|
57928006|NCT00269165|PROCEDURE|Balloon Aortic Valvuloplasty|
57928007|NCT00269165|PROCEDURE|External Beam Radiation|
58068678|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
58280244|NCT02752711|PROCEDURE|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
58396095|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
58396096|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
57928008|NCT02014155|OTHER|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
57928009|NCT02014155|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
57928010|NCT01868451|DRUG|Brentuximab vedotin (SGN-35)|
57928011|NCT01868451|DRUG|Doxorubicin HCL|
57928012|NCT01868451|DRUG|Vinblastine Sulfate|
58280245|NCT03958474|DRUG|Oxycodone|Participants receive oxycodone or placebo.
58280246|NCT03958474|DRUG|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
58280247|NCT06227715|OTHER|universal adhesive|
58280248|NCT00441363|DRUG|Bromocriptine Mesylate|0.8 mg tablet
58280249|NCT03594955|DRUG|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
58396097|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
58396098|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
58396099|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
58396100|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
57928013|NCT01868451|DRUG|Dacarbazine|
57928014|NCT01868451|RADIATION|Involved-Site Radiation Therapy (ISRT)|
57928015|NCT01868451|PROCEDURE|Interim PET|
57928016|NCT01868451|RADIATION|consolidation volume RT (CVRT)|
57928017|NCT04370977|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
57928018|NCT04370977|DRUG|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
57928019|NCT04367532|OTHER|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
57928020|NCT04367532|OTHER|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
58068679|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
58068680|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
58280250|NCT05961189|DRUG|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
58280251|NCT05610475|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
58280252|NCT05618158|BEHAVIORAL|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
58280253|NCT02362425|DRUG|N-acetylcysteine|
58280254|NCT02362425|DRUG|Placebo|
58280255|NCT02547896|DRUG|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
58280256|NCT02547896|DRUG|Diclofenac|The patients will receive only diclofenac
58280257|NCT01885663|PROCEDURE|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
58280258|NCT00429975|DRUG|levofloxacin|
58396101|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
58396102|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
58396103|NCT01096368|DRUG|Carboplatin|Given IV
58396104|NCT01096368|DRUG|Cisplatin|Given IV
58396105|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
58396106|NCT01096368|DRUG|Cyclophosphamide|Given IV
58396107|NCT01096368|DRUG|Etoposide|Given IV
58396108|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
58396109|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58280259|NCT00429975|DRUG|ceftriaxone|
58280260|NCT02148016|PROCEDURE|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
58280261|NCT02148016|PROCEDURE|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
58396110|NCT01096368|DRUG|Mesna|Given IV
57727434|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
57727435|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
57727436|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
57727437|NCT03994861|DIAGNOSTIC_TEST|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
57727438|NCT05104606|OTHER|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~* The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~* The second TEE will be performed at H24 to performed new measurements."
57727439|NCT05104606|OTHER|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
57727440|NCT01977911|OTHER|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
57928021|NCT00331812|PROCEDURE|Mitochondrial functions and oxidative stress|
57928022|NCT05437198|OTHER|collection of human exhalation|"the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device"
58280262|NCT02148016|PROCEDURE|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
58280263|NCT02148016|PROCEDURE|PRK only (Traditional Technique)|PRK alone will be performed.
58280264|NCT02148016|DRUG|Levofloxacin|
58280265|NCT02148016|DRUG|Betamethasone|
58280266|NCT02148016|DRUG|Limbal stem cells (LSCs)|
58280267|NCT00073645|BEHAVIORAL|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
58396111|NCT01096368|DRUG|Vincristine|Given IV
57928023|NCT01794585|BEHAVIORAL|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
57928024|NCT01794585|BEHAVIORAL|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
57928025|NCT03236051|PROCEDURE|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
57928026|NCT03236051|PROCEDURE|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
57928027|NCT03595592|DRUG|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
57928028|NCT03595592|DRUG|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
57928029|NCT03595592|DRUG|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
57928030|NCT03595592|DRUG|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
57928031|NCT03595592|DRUG|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
57928032|NCT03595592|DRUG|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
57928033|NCT03595592|DRUG|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
57928034|NCT03595592|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
57928035|NCT03641053|OTHER|Honey|Substance is given topically after the wound has been sutured
57928036|NCT03641053|OTHER|Povidone-iodine|Substance is given topically after the wound has been sutured
57928037|NCT03641053|OTHER|Paraffin gauze|Substance is given topically after the wound has been sutured
57928038|NCT00399451|DRUG|Polidocanol Sclerotherapy|
57928039|NCT02378454|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
57928040|NCT03952806|DRUG|Verdiperstat|300mg 2 oral tablets, twice daily
58068681|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
58068682|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
58068683|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
58068684|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
58280268|NCT00073645|BEHAVIORAL|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
58280269|NCT01773356|DIETARY_SUPPLEMENT|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
58280270|NCT03085771|DRUG|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
58280271|NCT03085771|DRUG|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
58280272|NCT00681265|DRUG|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
58280273|NCT00681265|DRUG|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
58280274|NCT03972241|DEVICE|foot insole|arch support and toe extension
58280275|NCT02960477|OTHER|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
57727441|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
57928041|NCT03952806|DRUG|Placebo|Matching placebo
57928042|NCT02442713|DRUG|fluvoxamine|fluvoxamine: 50-300mg/day
58280276|NCT02960477|OTHER|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
58280277|NCT02844036|PROCEDURE|Percutaneous angioplasty|
58280278|NCT02844036|PROCEDURE|Balloon angioplasty|
58068685|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
58280279|NCT02844036|PROCEDURE|Right heart catheterization|
57928043|NCT04566627|BEHAVIORAL|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
57928044|NCT00769613|BIOLOGICAL|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
57928045|NCT00769613|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
57928046|NCT00769613|BIOLOGICAL|therapeutic allogeneic lymphocytes|
57928047|NCT00769613|GENETIC|polymerase chain reaction|
57928048|NCT00769613|OTHER|flow cytometry|
57928049|NCT00769613|OTHER|immunological diagnostic method|
57928050|NCT00769613|OTHER|laboratory biomarker analysis|
57928051|NCT05134090|DEVICE|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
57928052|NCT05196672|BEHAVIORAL|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
57928053|NCT02926469|DEVICE|Virtual Reality|Using Virtual Reality during labor
57928054|NCT00312325|DRUG|Prednisolone|
57928055|NCT00399230|DRUG|Optive|
57928056|NCT05511896|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
57928057|NCT01522482|DIETARY_SUPPLEMENT|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
57928058|NCT01522482|DIETARY_SUPPLEMENT|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
57928059|NCT01522482|DIETARY_SUPPLEMENT|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
57928060|NCT02833480|DRUG|Fluticasone group|
57928061|NCT02833480|DRUG|Budesonide group|
57928062|NCT02833480|DRUG|Formoterol group|
58396112|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
57928063|NCT03872453|DRUG|Zavegepant|A single dose of zavegepant
58068686|NCT02004457|BEHAVIORAL|ABBT|
58280280|NCT02844036|PROCEDURE|Echocardiography|
58396113|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
57727442|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
57928064|NCT03872453|DRUG|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
58068687|NCT02004457|OTHER|TAU|
58068688|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
57928065|NCT03872453|DEVICE|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
57928066|NCT00238667|DRUG|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
57928067|NCT00238667|DRUG|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
57928068|NCT00291811|DRUG|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
57928069|NCT04548414|OTHER|No.|This is an observational study with no intervention.
57928070|NCT05741346|DRUG|BCX9930|Taken orally at 400 mg twice daily (BID)
57928071|NCT04460677|BEHAVIORAL|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
57928072|NCT04460677|BEHAVIORAL|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
57928073|NCT04119960|DEVICE|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
57928074|NCT01068925|DRUG|GSK1349572|"1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
57928075|NCT01535014|DRUG|Dietressa|Comparison of different dosages (frequency) of drug
57928076|NCT01535014|DRUG|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
57928077|NCT02178553|DRUG|Epidural|
57928078|NCT02178553|DRUG|Intercostal Bupivicaine (Exparel)|
58068689|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
58068690|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
58068691|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
58280281|NCT02844036|OTHER|A six-minute walking test|
58280282|NCT02844036|PROCEDURE|Functional respiratory investigations|
58280283|NCT02844036|PROCEDURE|Pulmonary tomography or pulmonary angiography|
58280284|NCT02844036|OTHER|Biological parameters|
58396114|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
58068692|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
57727443|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
57727444|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
57928079|NCT00973154|DRUG|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
57928080|NCT00770237|BEHAVIORAL|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
57928081|NCT00770237|BEHAVIORAL|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
57928082|NCT03040310|OTHER|Back Rx program|The Back Rx program can be viewed via a smartphone app.
57928083|NCT01422850|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
57928084|NCT06459323|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
57928085|NCT02795416|DRUG|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
57928086|NCT01746680|DRUG|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
57928087|NCT01251120|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
57928088|NCT01251120|DRUG|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
58068693|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
58068694|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
58068695|NCT00976521|OTHER|No local infusion|Intervention without local infusion
58068696|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
58068697|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
58068698|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
57727445|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
57727446|NCT04979819|OTHER|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
57727447|NCT03815071|DRUG|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
57727448|NCT02389543|DRUG|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
57928089|NCT04010773|OTHER|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
57928090|NCT00704002|PROCEDURE|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
57928091|NCT00704002|PROCEDURE|conservative treatment|conservative treatment with 2-finger splint for one week
57928092|NCT00922103|PROCEDURE|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
57928093|NCT00922103|PROCEDURE|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
57928094|NCT01153802|DRUG|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
57727449|NCT02389543|DRUG|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
57727450|NCT02389543|DRUG|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
57928095|NCT04288895|DRUG|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
57928096|NCT06200298|PROCEDURE|Erector spinae plane block with naropeine [3,75 mg/mL]|"Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process"
57928097|NCT06200298|PROCEDURE|ESPB with saline 0,9%|"Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process"
57928098|NCT06348368|OTHER|Pentacam and autorefractometry|Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children
57727451|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
58068699|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
58280285|NCT05029609|DRUG|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
58396115|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
57928099|NCT01768650|BEHAVIORAL|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
58068700|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
58068701|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
58068702|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
58068703|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
58068704|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
58068705|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
57727452|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
57727453|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
58068706|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
58068707|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
58280286|NCT05029609|DRUG|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
58280287|NCT05885776|DRUG|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
58280288|NCT00650728|PROCEDURE|placing gastric tube|
58280289|NCT05941624|DEVICE|Ha-330 Hemoperfusion Filter Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
58280290|NCT05941624|DEVICE|Conventional Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
58280291|NCT06553963|OTHER|Control group|The control group maintained their regular diet and training without additional nutritional support.
58280292|NCT06553963|OTHER|Experimental group|Biochemical Monitoring and Nutritional Support
58396116|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
57727454|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
57727455|NCT01388387|OTHER|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
57727456|NCT04620473|DRUG|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
57727457|NCT04620473|DRUG|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
57727458|NCT01243450|DRUG|Tretinoin|Treatment of acne
57928100|NCT01768650|BEHAVIORAL|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
57928101|NCT05425706|OTHER|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
57928102|NCT03459144|DRUG|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
57928103|NCT03459144|DRUG|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
57928104|NCT05802758|BEHAVIORAL|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
57928105|NCT06064513|OTHER|verbal empathy training|Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.
57928106|NCT06064513|OTHER|video based empathy training|Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
57928107|NCT01296035|BIOLOGICAL|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
57928108|NCT06104202|OTHER|Early Maladaptive Schemas|"Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory"
57928109|NCT02600455|DRUG|Orencia|
57928110|NCT02636153|OTHER|normal diet|Diet containing 1500mg of phosphorus
57928111|NCT02636153|OTHER|restricted phosphate diet|Diet containing 500mg of phosphorus
57928112|NCT06280326|OTHER|Sunflower oil|In the experimental group, patch removal will be performed using sunflower oil.
57928113|NCT06280326|OTHER|Slicone based spray|In the control group, clinical routine procedure will be used to remove the patch (silicone based spray.
57928114|NCT02884726|DRUG|BMS-986148|Specified dose on specified days
57928115|NCT01364363|PROCEDURE|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
58068708|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
58068709|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
58396117|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
58396118|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
58396119|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
57727459|NCT01243450|DRUG|placebo|treatment of acne
57727460|NCT05400096|OTHER|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
57727461|NCT00119509|PROCEDURE|HPV DNA testing|
57727462|NCT00119509|PROCEDURE|Conventional management (repeat Pap smear at 6 months)|
57727463|NCT00119509|PROCEDURE|Decision aid with choice of management|
58068710|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
58068711|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
58068712|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
57928116|NCT06466863|OTHER|Validity and Reliability|"Participants were included in the study after obtaining consent from both the participants and their parents. Participants were informed about the study prior to the survey, and only those who volunteered were included in the study. The data collection process was conducted online via Google Forms. The assessment form was sent to the participants through social media platforms, messages, and emails. Participants completed the YAP-T twice, 7 days apart, and all measurements were taken on weekdays under similar conditions by the same evaluators (4 evaluators) in the same region (Istanbul).~Test-retest reliability will be determined by calculating the Intraclass Correlation Coefficient (ICC) between the total scores obtained from the two assessments."
57928117|NCT03136419|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
57928118|NCT03136419|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
58280293|NCT01758718|PROCEDURE|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
58280294|NCT03484403|OTHER|Lumbar back brace|A brace that supports the lumbar region of the spine.
58280295|NCT03484403|BEHAVIORAL|Back school|Back school consists of patient education physical therapy exercise instruction.
58280296|NCT06465771|BEHAVIORAL|Youth-led NCD risk reduction intervention|With the help of Youth (students of grades 9 and 10), their parents and other stakeholders, including teachers, headteachers, and canteen staff through qualitative interviews, we will develop an intervention focuses on NCD risk reduction among younger peers (students of grades 5 and 6). A nutritionist will train the youth on how to deliver the intervention among their younger peers.
58280297|NCT01870167|DRUG|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
58280298|NCT01870167|DIETARY_SUPPLEMENT|Placebo|Placebo
58280299|NCT01496417|DRUG|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
58280300|NCT03471806|BEHAVIORAL|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
58280301|NCT03471806|BEHAVIORAL|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
58280302|NCT06452290|DEVICE|brain 18F-FDG PET-CT|PET scanner, Philips VEREOS PET/CT scanner. Three Philips VEREOS digital PET/CT scanners are installed in the nuclear medicine department.
58280303|NCT01210222|BIOLOGICAL|Trebananib|Given IV
57727464|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
57928119|NCT04543604|BEHAVIORAL|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
57928120|NCT04543604|BEHAVIORAL|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
58280304|NCT04605926|BIOLOGICAL|EQ001|itolizumab \[Bmab600\]
58280305|NCT04605926|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
58280306|NCT05777083|DIAGNOSTIC_TEST|KardiaMobile 6L|Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).
58280307|NCT06364202|DIETARY_SUPPLEMENT|Peanut Butter|2 tablespoons of peanut butter
58280308|NCT05538936|OTHER|Baby SPA|"Salus Per Aquam, Sanitas Per Aquam, Salut Per Aqua or Solus Per Aqua (SPA) means health that comes with water. Baby SPA is a physiotherapy method that stimulates the baby's motor movements through water (hydrotherapy) and performs it in an integrated way to balance the body, mind, and emotions. Baby SPA is applied in specially designed bathtubs. The size of the tub is designed in such a way that children can move their hands and feet freely and not be narrow. A neck ring/ring is used to keep the baby on the water surface during SPA treatment."
58280309|NCT05538936|OTHER|Massage|"The best way to communicate with a baby is to touch it. When babies are born, unlike their other senses, the most developed one is the sense of touch. Because this process begins while in the womb. The baby communicates by touch and begins to recognize his environment. The sense of touch is a priority for the development of all senses. They need to perceive their environment, especially in newborns and infancy periods. Touching the body in a systematic way for a therapeutic purpose is called Massage. Massage is soft touches to body tissues to relax muscles, accelerate circulation, reduce infantile colic symptoms and pain, regulate sleep, and increase its duration. Baby massage has many benefits such as reducing colic symptoms, increasing weight gain, providing motor development and coordination, strengthening the parent and baby bond, supporting growth and development, and reducing stress."
58280310|NCT00034047|PROCEDURE|Acupuncture|
58280311|NCT00034047|DRUG|Chinese Products|
58280312|NCT00034047|DRUG|Nafarelin|
58280313|NCT01530711|DRUG|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
57727465|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
57928121|NCT05506501|PROCEDURE|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
57928122|NCT05506501|PROCEDURE|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
57928123|NCT00640016|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
57928124|NCT00640016|BIOLOGICAL|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
58280314|NCT01415726|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
58280315|NCT04046263|DRUG|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
57727466|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
57727467|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
57727468|NCT05937438|DRUG|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
57928125|NCT00640016|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
57928126|NCT00640016|OTHER|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
57928127|NCT05203523|DEVICE|transcranial alternative current stimulation (tACS)|A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.
58068713|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
58280316|NCT00937092|DRUG|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
58280317|NCT00937092|DRUG|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
58280318|NCT04191343|DRUG|Toripalimab injection combined with GEMOX|Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
58280319|NCT00302887|DEVICE|combined ultrasound therapy|
58280320|NCT00302887|PROCEDURE|connective tissue manipulation|
58280321|NCT00149370|PROCEDURE|Breast reduction surgery|
58068714|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
58068715|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
58280322|NCT01075464|DRUG|MEGF0444A|Intravenous escalating dose
58280323|NCT01075464|DRUG|bevacizumab|Intravenous repeating dose
57727469|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
57727470|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
57928128|NCT05203523|OTHER|cognitive exercises|"Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant."
57928129|NCT06249503|DRUG|platelet rich plasma|The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.
58068716|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
58068717|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
58068718|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
58068719|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
57928130|NCT04540848|DRUG|Group A (Exparel plus supraclavicular block)|"Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
57928131|NCT04540848|DRUG|Group B (Bupivacaine HCL plus supraclavicular block)|"Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
57928132|NCT04540848|DRUG|Group C(supraclavicular block only)|"In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
57928133|NCT03513172|DRUG|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
57928134|NCT00300781|DRUG|neratinib|
57928135|NCT03840850|OTHER|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
57928136|NCT03786939|PROCEDURE|On-pump CABG.|On-pump coronary artery bypass grafting.
57928137|NCT03786939|PROCEDURE|Off-pump CABG.|Off-pump coronary artery bypass grafting.
57928138|NCT03786939|PROCEDURE|Pump-assisted CABG.|Pump-assisted CABG.
57928139|NCT02640820|DRUG|Sensitizing DPCP Ointment|Sensitization
57928140|NCT02640820|DRUG|Treatment DPCP Ointment|Treatment
57928141|NCT00051480|GENETIC|TNFerade|
57928142|NCT00408603|DRUG|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
57928143|NCT03576703|OTHER|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
57928144|NCT01256658|DRUG|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
57928145|NCT03712189|DEVICE|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
57928146|NCT02300051|BEHAVIORAL|STPGP and RPGT|
58068720|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
58068721|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
58280324|NCT01075464|DRUG|paclitaxel|Intravenous repeating dose
58068722|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
58068723|NCT02582008|DRUG|Nicotine Replacement|Given NRT
58068724|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
58280325|NCT01527708|PROCEDURE|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
58280326|NCT04933396|DIAGNOSTIC_TEST|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).
58068725|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
57928147|NCT02300051|DRUG|TAU|
57928148|NCT00577850|DRUG|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
58068726|NCT02582008|DRUG|Varenicline|Given PO
58068727|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
57928149|NCT00577850|DRUG|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
57928150|NCT02171650|DRUG|BIBW 2992|
57928151|NCT00125879|BIOLOGICAL|Myozyme|20 mg/kg qow or 40 mg/kg qow
57928152|NCT05635916|DRUG|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
57928153|NCT05635916|DRUG|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
57928154|NCT05987566|OTHER|Morning meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten after 1 hour of waking up in the morning
57928155|NCT05987566|OTHER|Evening meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten within 1 hour of going to bed
57928156|NCT02291302|OTHER|integrated pest management|integrated pest management and environmental strategy
57928157|NCT02291302|OTHER|air purifier|air purifiers
57928158|NCT02291302|OTHER|No intervention (control)|no integrated pest management and sham air purifier
58068728|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
58068729|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
57727471|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
58068730|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
58396120|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
57928159|NCT00001333|DRUG|topotecan|
57928160|NCT02855671|DEVICE|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
57928161|NCT04712825|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
57928162|NCT04712825|DEVICE|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
57928163|NCT02924298|BEHAVIORAL|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
57928164|NCT06075238|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
57928165|NCT06323200|PROCEDURE|lymphaticovenous anastomosis|The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
57928166|NCT03533621|DIETARY_SUPPLEMENT|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
58068731|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
58068732|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
58068733|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
58068734|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
57727472|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
57727473|NCT05026957|DEVICE|SharedHeart|A smartphone application
57727474|NCT05003817|DEVICE|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
57928167|NCT03533621|DIETARY_SUPPLEMENT|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
57928168|NCT02927587|DRUG|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
57928169|NCT01369901|BEHAVIORAL|A functional exercise program|
58068735|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
57727475|NCT05879744|DRUG|CLN-978|CD19xCD3 T cell engager
57727476|NCT01019330|OTHER|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
57727477|NCT01019330|OTHER|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
57928170|NCT01369901|BEHAVIORAL|A stretching exercise program|
57727478|NCT03141502|DEVICE|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
57727479|NCT03141502|PROCEDURE|Skin grafting|the standard technique of skin grafting after wound preparation.
57727480|NCT00745017|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
57727481|NCT00745017|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
57928171|NCT03354442|DEVICE|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
57928172|NCT01708239|OTHER|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
57928173|NCT04536454|DRUG|[18F]FPyGal|Radiotracer for PET-imaging
57928174|NCT05827211|PROCEDURE|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
57928175|NCT05827211|PROCEDURE|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
57928176|NCT04792658|BEHAVIORAL|Detailed interview with personal demographic data|, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
57928177|NCT04792658|BEHAVIORAL|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
57928178|NCT04792658|BEHAVIORAL|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
57928179|NCT04792658|BEHAVIORAL|the Hamilton Depression Rating Scale|it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
57928180|NCT04792658|BEHAVIORAL|The Hamilton Anxiety Rating Scale|it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
58068736|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
58068737|NCT04361695|DRUG|Placebo|Placebo
58068738|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
58068739|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
58068740|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
58068741|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
57928181|NCT04792658|BEHAVIORAL|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)|It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
58068742|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
58068743|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
58068744|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
58068745|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58068746|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58068747|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
58068748|NCT02690506|DRUG|Placebo|
58068749|NCT02690506|DRUG|Pregabalin|
58068750|NCT00166595|DRUG|Risperidone|
58068751|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
58068752|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
58068753|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
57928182|NCT04645771|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
57928183|NCT04213014|BEHAVIORAL|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
57928184|NCT02982187|DEVICE|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
57928185|NCT02982187|DEVICE|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
57928186|NCT02982187|DEVICE|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
57928187|NCT02982187|DEVICE|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
57928188|NCT02982187|OTHER|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
57928189|NCT02982187|OTHER|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
57928190|NCT02982187|OTHER|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
57928191|NCT02982187|OTHER|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
57928192|NCT03054207|DRUG|Clopidogrel 300Mg Tablet|
57928193|NCT03054207|DRUG|Prasugrel 60Mg|
57928194|NCT03654313|BIOLOGICAL|MEDI6570|MEDI6570
57928195|NCT03654313|BIOLOGICAL|Placebo|Placebo
57928196|NCT03654313|BIOLOGICAL|Part B Placebo|Placebo
57928197|NCT03644251|OTHER|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
57928198|NCT03198598|BEHAVIORAL|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
57928199|NCT03198598|BEHAVIORAL|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
57928200|NCT05461482|OTHER|Pre-procedural consultation and audiovisual tools|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
57928201|NCT00563667|PROCEDURE|pterygium excision|
57928202|NCT05686187|OTHER|AR's platform for gender empowerment|The intervention of the experimental group is to accept the courses of the gender empowerment platform introduced by AR. The preliminary plan is 50-60 minutes each time. The content of the teaching plan course will adopt the course module design. Group content, and among the three module courses, there must be a core module course unit that is the workplace sexual harassment prevention unit
57928203|NCT01584154|PROCEDURE|cryoablation|cryoablation with an 8mm-tip catheter
57928204|NCT01584154|PROCEDURE|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
57928205|NCT02089841|DRUG|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
57928206|NCT03157141|PROCEDURE|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
57928207|NCT03157141|PROCEDURE|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
57928208|NCT04283266|DIETARY_SUPPLEMENT|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
57928209|NCT04283266|DIETARY_SUPPLEMENT|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
57928210|NCT00376454|DRUG|GW493838|
57928211|NCT03282487|DRUG|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
57928212|NCT01898689|DRUG|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
57928213|NCT01898689|DRUG|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
58396121|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
57928214|NCT02598557|DRUG|Exemestane|Given PO
57928215|NCT02598557|OTHER|Laboratory Biomarker Analysis|Correlative studies
58068754|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
58280327|NCT00534417|DRUG|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
58280328|NCT00534417|DRUG|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
57928216|NCT02598557|OTHER|Pharmacological Study|Correlative studies
57928217|NCT02598557|OTHER|Placebo Administration|Given PO
57928218|NCT02598557|OTHER|Quality-of-Life Assessment|Ancillary studies
57928219|NCT02598557|OTHER|Questionnaire Administration|Ancillary studies
57928220|NCT02598557|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57928221|NCT01969825|BEHAVIORAL|Massage|
57928222|NCT04423861|DRUG|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
57928223|NCT04423861|DRUG|Placebo|Patients will receive matching placebo BID for 7 days.
58280329|NCT05277389|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
58280330|NCT05277389|OTHER|Sham Control|Practice of Movement task without START
58396122|NCT00140283|PROCEDURE|Educational interactive intervention|
58396123|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
58068755|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
58068756|NCT02622217|BEHAVIORAL|Sleep deprivation|
57928224|NCT05232253|DEVICE|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
57928225|NCT06296134|BEHAVIORAL|perineal massage|"women affected by LAM co-activation allocated to the intervention perineal massage are asked to perform the perineal massage once daily from 34 gestational weeks until delivery. Women are trained to correctly perform the perineal massage at 30 gestaitonal weeks."
58068757|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
58280331|NCT05940766|OTHER|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
57928226|NCT05452590|PROCEDURE|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
58280332|NCT02288481|DRUG|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
58280333|NCT02288481|OTHER|Placebo|Placebo Suspension
58280334|NCT01090141|DRUG|Micafungin|100 mg IV infusion over 1 hour
57928227|NCT02953366|DRUG|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
57928228|NCT02953366|DRUG|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
57928229|NCT04820777|OTHER|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
57928230|NCT04820777|OTHER|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
57928231|NCT03597412|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
57928232|NCT03597412|DRUG|Monorova|Rosuvastatin 20mg
57928233|NCT04431050|DIAGNOSTIC_TEST|Point of care testing of respiratory viruses.|Single use point of care diagnostic device.
57928234|NCT01008696|DRUG|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
57928235|NCT01008696|DRUG|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
57951172|NCT01303094|DRUG|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
58280335|NCT01090141|DRUG|Micafungin|300 mg IV infusion over 1 hour
58280336|NCT06165913|PROCEDURE|Early implant placement(type II)|in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed
58280337|NCT06165913|PROCEDURE|Early implant placement (type III)|in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
58280338|NCT00679224|DRUG|ambrisentan|ambrisentan
58280339|NCT05626075|DIAGNOSTIC_TEST|Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.|Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
58280340|NCT02119806|DRUG|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
58280341|NCT02119806|DRUG|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
58068758|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
58280342|NCT02119806|DRUG|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
58280343|NCT05773339|OTHER|AIMS65 score|"The AIMS65 score consists of five factors:~(i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years)."
58280344|NCT04482738|OTHER|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
58068759|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
58068760|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
58068761|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
57928236|NCT05356468|OTHER|Structured pain neuroscience education|"Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT"
57928237|NCT05356468|OTHER|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)"
57928238|NCT04914143|OTHER|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
57928239|NCT04914143|OTHER|placebo|the control group was treated with placebo after chemotherapy
57727482|NCT00745017|DRUG|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
57727483|NCT02324491|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
57928240|NCT00319332|DRUG|Ibritumomab Tiuxetan|
57928241|NCT00319332|DRUG|Iodine I 131 Tositumomab|
57928242|NCT04281589|OTHER|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
57928243|NCT01272154|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
57928244|NCT04144751|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
57928245|NCT03595605|BEHAVIORAL|Ambulation|This group will be encouraged twice daily to ambulate
57928246|NCT03595605|OTHER|Standard of Care|Care as usual at inpatient NYU Langone
57928247|NCT01891435|DRUG|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
57928248|NCT01891435|DRUG|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
58280345|NCT04231968|DRUG|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
58280346|NCT04231968|DRUG|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
57727484|NCT02324491|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
57928249|NCT01891435|DRUG|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
57928250|NCT01998126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
57928251|NCT01998126|DRUG|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
57928252|NCT01998126|DRUG|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
58280347|NCT03271099|OTHER|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
57928253|NCT01998126|DRUG|Nivolumab|
57928254|NCT03991091|DRUG|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
57928255|NCT03991091|DRUG|continuation of oxytocin administration|continuation of oxytocin administration
58396124|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
57727485|NCT05996354|DEVICE|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
57727486|NCT02548962|DRUG|Ibrutinib|
57727487|NCT02548962|DRUG|Pomalidomide|
57727488|NCT02548962|DRUG|Dexamethasone|
57727489|NCT02548962|DRUG|Placebo|
57727490|NCT04269772|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
57727491|NCT04269772|OTHER|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
57727492|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
57928256|NCT00264225|DRUG|Lamaline® , 3 different doses, Dafalgan codeine|
57928257|NCT00705432|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
57928258|NCT00705432|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
57928259|NCT00705432|DRUG|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
57928260|NCT00705432|DRUG|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
57928261|NCT05169125|PROCEDURE|standard hemodialysis|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
57928262|NCT05169125|PROCEDURE|lower dialysate sodium dialysis|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
57928263|NCT02429297|OTHER|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
57928264|NCT02429297|OTHER|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
57928265|NCT04392453|DEVICE|Robotic therapy|The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
57928266|NCT00148954|DEVICE|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
57928267|NCT00148954|DEVICE|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
57928268|NCT03807674|PROCEDURE|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
57928269|NCT03037619|BEHAVIORAL|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
57928270|NCT03037619|BEHAVIORAL|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
57928271|NCT01126151|BEHAVIORAL|parent handbook|parent handbook
57928272|NCT06153238|DRUG|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
57928273|NCT06153238|DRUG|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
57928274|NCT06153238|DRUG|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
57928275|NCT03552796|OTHER|Pharmacokinetic Study|Correlative studies
57928276|NCT03552796|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given intravesically
57928277|NCT04678323|DRUG|Lifestyle Management|Participants in this group will receive lifestyle management.
57928278|NCT03532646|PROCEDURE|upper endoscopy|endoscopy of the gastrointestinal tract
57727493|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
57928279|NCT01230853|DRUG|Active Comparator: A|Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
57928280|NCT01230853|DRUG|Placebo Comparator B|Placebo Matching Placebo Infusion
58280348|NCT02399969|OTHER|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
58306781|NCT06011642|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter, digitale Version (Kinder-eDIPS)|The Kinder-eDIPS is a digital, structured interviews which assesses the most frequent psychological disorders. It exists in a parent and a child version. It can be delivered by trained clinicians and takes between 60 and 120 minutes.
57928281|NCT01230853|DRUG|Active Comparator B|Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
57928282|NCT01230853|DRUG|Placebo Comparator A|Placebo Matching Placebo Infusion
57928283|NCT03868969|DRUG|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
57928284|NCT05373524|BIOLOGICAL|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
57928285|NCT05109676|OTHER|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
57928286|NCT06196983|OTHER|Rhythmic aerobic exercises|The experimental group's pattern of functional movements includes both right and left foot movements. To improve muscle strength and the capacity to maintain balance, exercises including running in place, side steps, walking while eating, and turning in place can also be used. The rhythmic aerobic group linked their motions to the rhythmic auditory stimuli in order to perform in a rhythmic manner.
57928287|NCT06196983|OTHER|Control group, strength and balance exercises|The control group engaged in strength and balance exercises where they stood with weight on one leg and raised the other leg to the side or back. In a tandem stance, place your foot heel directly in front of your toe. Get out of a chair, then take a seat without using your hands.
57928288|NCT02955576|DEVICE|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
57928289|NCT02955576|DEVICE|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
57928290|NCT02955576|OTHER|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
58280349|NCT05210270|RADIATION|Hypofractionation|"Phase 1 (Dose Escalation Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with nSIB 45 Gy (first dose level) and 48 Gy (second dose level); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)~Phase 2 (Efficacy Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with (or without) nSIB 45-48 Gy (depending on phase 1 results); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)"
58280350|NCT04219839|BEHAVIORAL|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
58396125|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
58396126|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
58396127|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
58396128|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
58396129|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
58396130|NCT04732702|OTHER|no intervention|There will be no intervention.
57928291|NCT02018757|DRUG|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
57928292|NCT02018757|DRUG|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
57928293|NCT01550913|BEHAVIORAL|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
57928294|NCT01550913|OTHER|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
57928295|NCT03503513|DRUG|Gentamicin Sulfate|Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
57928296|NCT05019157|OTHER|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
58280351|NCT01229813|DRUG|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
58280352|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
58396131|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
58396132|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
58396133|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
58396134|NCT02353702|DRUG|Infusion of placebo during 48 hours|
58396135|NCT02353702|DRUG|NaCl|
57727494|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
57951173|NCT01303094|OTHER|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
58396136|NCT06444867|DRUG|LEO 158968|SC injection
58396137|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
58396138|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
57727495|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
57928297|NCT05019157|OTHER|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
57928298|NCT02150525|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO (by mouth) daily
57928299|NCT02150525|OTHER|placebo|Given PO(by mouth)daily
57928300|NCT02150525|BEHAVIORAL|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
57928301|NCT06065501|BEHAVIORAL|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
57928302|NCT06065501|BEHAVIORAL|Usual care|Nurses provide routine education and consultation
58280353|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
58396139|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
58396140|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
58396141|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
58396142|NCT03023579|OTHER|The star excursion balance test|
57928303|NCT02401412|DEVICE|Test Ostomy Barrier|
58396143|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
57928304|NCT02401412|DEVICE|Control Ostomy Barrier|
57928305|NCT02772523|OTHER|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
57928306|NCT00839943|OTHER|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
57928307|NCT00407589|DRUG|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
57928308|NCT00583570|BEHAVIORAL|dietary education|dietary education
58280354|NCT01229813|DRUG|low dose capecitabine|capecitabine 500 mg twice daily
58280355|NCT06314399|DIAGNOSTIC_TEST|Bile culture and phenotypic antibiogram resistance test|Extraction of 3-5ml of bile from surgical specimen (gallbladder) to be taken for bacterial culture testing and phenotypical antibiogram resistance if positive
58280356|NCT00346567|DRUG|Zidovudine and Lamivudine (Combivir)|
58396144|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
58396145|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
57727496|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
57928309|NCT00065325|DRUG|Fulvestrant|intramuscular injection
57928310|NCT00065325|DRUG|Exemestane|oral capsule
58396146|NCT03791281|BEHAVIORAL|BASIS|
58396147|NCT03791281|BEHAVIORAL|Attention Control|
57928311|NCT03277326|PROCEDURE|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
57928312|NCT03277326|PROCEDURE|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
57928313|NCT03277326|PROCEDURE|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
57928314|NCT03537599|BIOLOGICAL|Daratumumab|Given IV
57928315|NCT03537599|PROCEDURE|Donor Lymphocyte Infusion|Given via infusion
57928316|NCT03537599|OTHER|Laboratory Biomarker Analysis|Correlative studies
57928317|NCT02686021|DRUG|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
57928318|NCT02686021|DRUG|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
57928319|NCT02686021|DRUG|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
58280357|NCT00346567|DRUG|Emtricitabine and Tenofovir (Truvada)|
58280358|NCT00467207|DRUG|Botulinum Toxin A|
58280359|NCT00467207|BEHAVIORAL|Resistance training|
58306782|NCT03733808|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
57928320|NCT02622880|DIETARY_SUPPLEMENT|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
57928321|NCT02622880|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
57928322|NCT00601991|BIOLOGICAL|VEGF Trap|Drug under investigation
57928323|NCT00601991|PROCEDURE|Bone marrow biopsy|To determine response to treatment
57928324|NCT00601991|PROCEDURE|bone marrow aspiration|To determine response to treatment
57928325|NCT00601991|PROCEDURE|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
57928326|NCT00410293|PROCEDURE|NT-proBNP testing|
57928327|NCT03689647|DEVICE|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
57928328|NCT01504256|DRUG|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
57928329|NCT01504256|DRUG|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
57928330|NCT00143481|DRUG|Tolterodine ER 4mg QD|
58280360|NCT01937585|BEHAVIORAL|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
58280361|NCT01937585|BEHAVIORAL|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
58280362|NCT04624802|BEHAVIORAL|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
58280363|NCT03846128|BIOLOGICAL|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
58280364|NCT05207085|DRUG|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
58280365|NCT05207085|OTHER|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
58396148|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
58396149|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
58396150|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
57727497|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
58280366|NCT00440635|DRUG|Bortezomib, tradename Velcade|
58280367|NCT02770768|DRUG|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
58280368|NCT02770768|DRUG|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
57928331|NCT03461874|BEHAVIORAL|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
57951174|NCT00671021|OTHER|Platelet aggregation|Platelet aggregation TxA2 formation
58280369|NCT02786706|DEVICE|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
58396151|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
58396152|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
58396153|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
58396154|NCT04458441|OTHER|warm group/cold group|sequential randomization
58396155|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
58280370|NCT02844894|DRUG|Dexmedetomidine|
58280371|NCT02844894|DRUG|Esmolol|
58280372|NCT02844894|DRUG|Placebo|normal saline
58396156|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
58280373|NCT00093977|DRUG|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
58396157|NCT06495060|OTHER|No intervention (Only observation)|No intervention
58396158|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
58396159|NCT04122911|DRUG|Temozolomide|pharmacological
58396160|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
57727498|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
57727499|NCT00133289|DEVICE|Pacemaker with Automatic Capture|
57727500|NCT02330835|BEHAVIORAL|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
57727501|NCT02330835|BEHAVIORAL|School bus driver training videos|Basic bus driving safety videos
57727502|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
57727503|NCT04504045|DRUG|Metformin|500 mg tablet
57727504|NCT04504045|DRUG|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
57727505|NCT04504045|DRUG|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
57727506|NCT04504045|DRUG|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
57727507|NCT04504045|DRUG|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
57727508|NCT04504045|DRUG|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
57727509|NCT04504045|DRUG|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
57727510|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
58280374|NCT01962623|OTHER|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
58280375|NCT05332717|DIETARY_SUPPLEMENT|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
57727511|NCT05631067|BEHAVIORAL|Remote blood pressure monitoring|Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum
57727512|NCT05631067|DIAGNOSTIC_TEST|NT proBNP assessment|Participants will have biomarker assessment at 0-2 days postpartum
57951175|NCT02375230|PROCEDURE|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
57727513|NCT02888405|OTHER|High-carbohydrate diet|
57727514|NCT02888405|OTHER|Low-carbohydrate diet|
57727515|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
58068762|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
58068763|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
57928332|NCT03461874|BEHAVIORAL|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
58068764|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
58068765|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
58068766|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
58280376|NCT05332717|DIETARY_SUPPLEMENT|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
58280377|NCT04594109|BEHAVIORAL|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
58280378|NCT04594109|BEHAVIORAL|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
58280379|NCT02860507|DRUG|sugammadex|
58280380|NCT02860507|DRUG|Neostigmine|
58280381|NCT02860507|DRUG|Glycopyrrolate|
58280382|NCT03151213|DRUG|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
58280383|NCT03151213|OTHER|Placebo|Placebo before RFA of liver cancer
58280384|NCT03183479|DRUG|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
58280385|NCT03183479|DRUG|Normal saline|100mL normal saline will be administered to patients in control group as placebo
58280386|NCT04539756|BEHAVIORAL|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
58280387|NCT04539756|BEHAVIORAL|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
58068767|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
58068768|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
58280388|NCT05020704|DRUG|Empagliflozin 10 MG|SGLT2inhibitor
58280389|NCT05020704|DRUG|Placebo|Matched placebo
58280390|NCT04611776|DRUG|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
58068769|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
58068770|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
58068771|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
58068772|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
58068773|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
58068774|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
58068775|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
57727516|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
57928333|NCT03461874|DRUG|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
57928334|NCT02017041|DEVICE|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
57928335|NCT02017041|DEVICE|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
57928336|NCT03859713|BEHAVIORAL|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
57928337|NCT03859713|BEHAVIORAL|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
57928338|NCT03859713|BEHAVIORAL|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
57928339|NCT04492345|OTHER|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
57928340|NCT04492345|OTHER|Conventional reeducation|Conventional rehabilitation session during 7 weeks
57928341|NCT00747630|OTHER|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
58068776|NCT00026819|DRUG|Rofecoxib|
58068777|NCT03547219|DRUG|Escitalopram|
58068778|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
58068779|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
58280391|NCT04611776|DRUG|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
58280392|NCT04611776|DRUG|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
58280393|NCT04611776|DRUG|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
57928342|NCT03478150|OTHER|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
58280394|NCT04611776|DRUG|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
58280395|NCT04611776|DRUG|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
58068780|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
58068781|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
58068782|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
58068783|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
58068784|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
58068785|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
58280396|NCT04611776|DRUG|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
58280397|NCT05964127|DEVICE|Air flow device|An air/powder device for surface decontamination
58280398|NCT05964127|OTHER|Hand instruments|Periodontal hand instruments
58280399|NCT05964127|PROCEDURE|Access flap surgery|To improve the surgical access for implant decontamination
58280400|NCT04723056|DEVICE|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
58068786|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
58068787|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
58068788|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
58068789|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
58280401|NCT02983461|DRUG|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
58280402|NCT02983461|DRUG|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
58280403|NCT03592784|BEHAVIORAL|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
58280404|NCT03592784|BEHAVIORAL|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
58280405|NCT02432144|DRUG|UX003|solution for intravenous (IV) infusion
58280406|NCT01915771|DRUG|lomitapide|20 mg dose
58280407|NCT01096680|DRUG|SPD489 20 mg|Single oral dose of 20 mg
58280408|NCT01096680|DRUG|SPD489 50 mg|Single oral dose of 50 mg
58280409|NCT01096680|DRUG|SPD489 70 mg|Single oral dose of 70 mg
58280410|NCT01096680|DRUG|Armodafinil|Single oral dose of 250 mg
58280411|NCT01096680|DRUG|Placebo|Single oral dose
58280412|NCT05296070|DRUG|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
57928343|NCT03478150|DEVICE|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
57928344|NCT04193878|DRUG|Inhaled budesonide and formoterol|aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
58280413|NCT05296070|DRUG|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
58280414|NCT05831306|OTHER|Diet A|Modified Diet A
58280415|NCT05831306|OTHER|Diet B|Modified Diet B
58280416|NCT04685096|OTHER|Test product creme|twice daily application of creme containing 2% NMN
58280417|NCT04685096|OTHER|Reference creme|twice daily application of reference creme
58280418|NCT03231137|COMBINATION_PRODUCT|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
58280419|NCT03231137|DRUG|ATV gel|Atorvastatin gel
58280420|NCT03231137|BIOLOGICAL|PRF|Platelet rich fibrin
58280421|NCT03231137|BIOLOGICAL|PRGF|plasma rich in growth factor
58280422|NCT05392595|OTHER|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
58280423|NCT05392595|OTHER|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
58280424|NCT04657094|DRUG|Acalabrutinib|Given PO
58280425|NCT03637309|BEHAVIORAL|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
58280426|NCT03942926|DRUG|Sirolimus|Patients will receive sirolimus for 6 months.
58280427|NCT02020837|PROCEDURE|Lymphaticovenous Micro-Anastomosis|
58280428|NCT01648192|DRUG|Losmapimod for single dose|Film coated white tablet
58280429|NCT01648192|DRUG|Losmapimod for repeat dose|Film coated white tablet
58280430|NCT01841034|DRUG|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
58280431|NCT03538704|DRUG|Metformin|Metformin is given to patients 1-1.5g/d.
58280432|NCT05337995|OTHER|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
58280433|NCT00452153|PROCEDURE|Characterization Legionnella|"* Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
58280434|NCT01026818|DRUG|Tadalafil|Administered by mouth for 9 months
58280435|NCT01026818|DRUG|Placebo|Administered by mouth, daily or on demand for 9 months
58280436|NCT01142492|DRUG|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
58280437|NCT02624622|PROCEDURE|Chlorhexidine application to cord by mother|
58280438|NCT02624622|PROCEDURE|Chlorhexidine application by CHW|
57928345|NCT04193878|DRUG|Inhaled placebo|aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
57928346|NCT06357351|PROCEDURE|vestibular incision sub periosteal tunnel access ( VISTA) technique.|In comparison between the two groups, the first group uses collagen membrane and the other group uses advanced PRF using the same surgical technique (VISTA)
57928347|NCT02580396|DEVICE|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
57928348|NCT01309230|BIOLOGICAL|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
57928349|NCT05434962|DEVICE|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms"
57928350|NCT01458704|OTHER|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
57928351|NCT04687761|DRUG|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle
57928352|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
57928353|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
57928354|NCT04687761|DRUG|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
57928355|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
57928356|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
57928357|NCT00201838|DRUG|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
57928358|NCT00201838|DRUG|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
58068790|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
58068791|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
58068792|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
58068793|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
58068794|NCT02127580|PROCEDURE|BAV|
58396161|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
58396162|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
58068795|NCT02127580|PROCEDURE|without BAV|
58068796|NCT00002176|DRUG|Hydroxyurea|
58068797|NCT00002176|DRUG|Nelfinavir mesylate|
58068798|NCT00002176|DRUG|Stavudine|
58068799|NCT00002176|DRUG|Didanosine|
58068800|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
58068801|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
58068802|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
58068803|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
58068804|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
58068805|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
58068806|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
58068807|NCT01490385|DEVICE|LED Phototherapy|
58068808|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
58068809|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
58068810|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
58068811|NCT06227429|DRUG|Nitisinone|According to prescription
58068812|NCT01031368|DRUG|cytarabine|Given IV
58068813|NCT01031368|DRUG|clofarabine|Given IV
58068814|NCT01031368|DRUG|filgrastim|Given SC
58068815|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
58068816|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
58068817|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
58068818|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
58068819|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
58280439|NCT06313554|DRUG|Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin|"The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
58280440|NCT02284386|DRUG|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
58280441|NCT02284386|DRUG|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
58280442|NCT01422746|DRUG|Metformin|500-1000 mg PO BID (X12 weeks)
58280443|NCT03283332|OTHER|No intervention|
58280444|NCT05476640|GENETIC|NGS|In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
58396163|NCT06658444|OTHER|sham ultrasound|sham ultrasound
57727517|NCT03883672|BEHAVIORAL|Personality and transactional factors|"1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
57727518|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
57727519|NCT06098521|BEHAVIORAL|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
57727520|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
57727521|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
58068820|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
58068821|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
58068822|NCT04440176|BIOLOGICAL|Saline|Placebo
58068823|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
58068824|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
58068825|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
58280445|NCT04588844|DRUG|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
58280446|NCT04659057|DRUG|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
58280447|NCT04659057|DRUG|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
58280448|NCT04659057|DRUG|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
58280449|NCT04659057|OTHER|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
58280450|NCT03404934|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
58396164|NCT04109807|OTHER|Ozone|ozone exposure
58396165|NCT04109807|OTHER|FA|Filtered air exposure
58396166|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
58068826|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
58068827|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
58068828|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
58068829|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
57727522|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
57727523|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
58396167|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
58396168|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
58396169|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
58396170|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
58396171|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
58396172|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
58396173|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
58396174|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
58396175|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
58396176|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
58396177|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
58396178|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
58396179|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
58396180|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
58068830|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
58068831|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
58280451|NCT02716922|PROCEDURE|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
58280452|NCT03125850|OTHER|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
58280453|NCT03125850|OTHER|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
58280454|NCT04357938|DEVICE|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
58280455|NCT03353181|DEVICE|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
58280456|NCT03353181|DEVICE|Biliary stent|Standard placement of biliary stent
58396181|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
58396182|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
57727524|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
58280457|NCT03416010|BEHAVIORAL|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
57727525|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
57727526|NCT02250404|OTHER|cytology specimen collection procedure|Correlative studies
57727527|NCT02250404|OTHER|laboratory biomarker analysis|Correlative studies
57928359|NCT05632107|DEVICE|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
57928360|NCT01171352|PROCEDURE|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
57928361|NCT00187395|PROCEDURE|Randomized to either a 'less tight' group or a 'tight' group|
58068832|NCT02491593|DEVICE|fecal occult blood test|
58068833|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
58068834|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
58068835|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
58280458|NCT01401543|DRUG|LY2452473|Administered orally
58280459|NCT01401543|DRUG|Tadalafil|Administered orally
57727528|NCT06535126|DRUG|CanProFem-AK|Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
57928362|NCT00794443|DRUG|YM529 / ONO-5920|Oral
57928363|NCT04308824|OTHER|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
57928364|NCT04308824|OTHER|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
58068836|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
58068837|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
58068838|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
58068839|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
58068840|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
58068841|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
58068842|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
58068843|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
58068844|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
57727529|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
57727530|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
57928365|NCT05839756|DRUG|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
57928366|NCT05839756|DRUG|normal saline|5 ml normal saline will be nebulized preoperatively
58068845|NCT01072227|PROCEDURE|Sample Collection|Tissue
58068846|NCT00208702|DRUG|Triiodothyronine|
58068847|NCT00208702|OTHER|Placebo|
58068848|NCT00208702|DRUG|Sertraline|
58068849|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
58396183|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
57928367|NCT00195923|DRUG|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
57928368|NCT00803829|OTHER|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
57928369|NCT02067182|DRUG|Dabigatran|"* Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
57928370|NCT00816309|DEVICE|Acapella Physiotherapy|twice daily- around 20 minutes
57928371|NCT01990534|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
58068850|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
58068851|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
58068852|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
58068853|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
58068854|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
58068855|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
58068856|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
58068857|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
58068858|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
57928372|NCT04586504|DRUG|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
57928373|NCT01526551|OTHER|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
57928374|NCT01526551|OTHER|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
57727531|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
57727532|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
57727533|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
57727534|NCT01538017|DRUG|Xiapex|Collagenase Clostridium Histolyticum
57928375|NCT01810016|BIOLOGICAL|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
57928376|NCT01810016|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
57928377|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
57928378|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
57928379|NCT03877250|DIAGNOSTIC_TEST|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
57928380|NCT03877250|DIAGNOSTIC_TEST|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
57928381|NCT03877250|DIAGNOSTIC_TEST|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
57928382|NCT03877250|DIAGNOSTIC_TEST|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
57928383|NCT04176965|DEVICE|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
57928384|NCT04176965|DEVICE|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
57928385|NCT03455192|DRUG|Synbiotic Supplement|
57928386|NCT03455192|DRUG|Placebo Oral Tablet|
57928387|NCT00320333|PROCEDURE|pulmonary rehabilitation programme|
57928388|NCT04398511|DRUG|L brevis|Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.
57928389|NCT04398511|DRUG|Placebo|Placebo lozenges after breakfast, lunch and dinner for 21 days.
57727535|NCT01538017|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
57727536|NCT04812353|OTHER|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
57727537|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
57727538|NCT03691805|DEVICE|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
58068859|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
58068860|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
57727539|NCT03691805|DEVICE|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
57727540|NCT01891825|PROCEDURE|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
57928390|NCT05532436|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
57928391|NCT05508750|OTHER|New Infant Formula|New infant formula fed daily ad libitum
57928392|NCT05508750|OTHER|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
57928393|NCT00002951|DRUG|fluorouracil|
57928394|NCT00002951|DRUG|hydroxyurea|
58068861|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
58280460|NCT01401543|DRUG|LY900010|Administered orally
57727541|NCT01891825|PROCEDURE|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
57727542|NCT02804958|PROCEDURE|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
57727543|NCT00919269|OTHER|Cytology Specimen Collection Procedure|Correlative studies
57928395|NCT00002951|PROCEDURE|surgical procedure|
57928396|NCT00002951|RADIATION|radiation therapy|
57928397|NCT00907257|DRUG|benzoyl peroxide wash|5% benzoyl peroxide wash
57928398|NCT00907257|DRUG|Tretinoin gel|0.04% tretinoin gel
57928399|NCT02708017|PROCEDURE|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
57928400|NCT02708017|PROCEDURE|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
57727544|NCT00919269|OTHER|Laboratory Biomarker Analysis|Correlative studies
57727545|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
57727546|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
57727547|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
57928401|NCT02206165|DRUG|Candesartan 8mg|Once a day, 8 weeks
58068862|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
58068863|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
57727548|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
57727549|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
57727550|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
57727551|NCT02410395|PROCEDURE|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
57928402|NCT02206165|DRUG|Candesartan 16mg|Once a day, 8 weeks
58068864|NCT03331393|OTHER|Non-interventional|Non-interventional
57727552|NCT02410395|PROCEDURE|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
57727553|NCT06393062|DIAGNOSTIC_TEST|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
57727554|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
57928403|NCT02206165|DRUG|Amlodipine 5mg|Once a day, 8 weeks
58068865|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
58068866|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
58068867|NCT02968277|DEVICE|Standard Rollator|A control rollator device
58068868|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
58280461|NCT00404716|DRUG|Cilostazol|
58280462|NCT03529799|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
58280463|NCT00072748|DRUG|EKB-569|
57727555|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
58280464|NCT05382013|DRUG|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
58396184|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
57727556|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
57727557|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
57727558|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
57727559|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
57727560|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
57727561|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
57727562|NCT03727204|PROCEDURE|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
57727563|NCT04071002|OTHER|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
57928404|NCT02206165|DRUG|Amlodipine 10mg|Once a day, 8 weeks
57928405|NCT01050686|PROCEDURE|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
57928406|NCT01050686|PROCEDURE|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
58068869|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
58068870|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
58068871|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
58068872|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
58068873|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
58068874|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
58068875|NCT04041648|OTHER|Placebo Solution|Single ascending dose
58068876|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
58068877|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58068878|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58068879|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58068880|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
58068881|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
58068882|NCT00002075|DRUG|Flucytosine|
58068883|NCT00002075|DRUG|Fluconazole|
58068884|NCT00002075|DRUG|Amphotericin B|
58068885|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
58068886|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
58068887|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
58068888|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
58068889|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
58068890|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
58068891|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
58068892|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
58068893|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
57928407|NCT00536809|DRUG|lapatinib|onced daily Days 1-21
57928408|NCT00536809|DRUG|oxaliplatin|Day one of each cycle
57928409|NCT00536809|DRUG|capecitabine|given BID days 1-14
57928410|NCT05929560|OTHER|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
57928411|NCT05929560|OTHER|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
57928412|NCT02715661|OTHER|exercise|six-month interval of exercise
58068894|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
58068895|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
58068896|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
58068897|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
58068898|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
58068899|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
58068900|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
58068901|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
58068902|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
58068903|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
58396185|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
57727564|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
57928413|NCT02805049|DRUG|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
57928414|NCT03457883|DEVICE|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
57727565|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
57727566|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
57928415|NCT03457883|DEVICE|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
58396186|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
57727567|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
57727568|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
57727569|NCT03314987|DIETARY_SUPPLEMENT|L-carnosine|a naturally occurring di-peptide
57727570|NCT03314987|OTHER|placebo|an identically appearing supplement
57727571|NCT00968669|BIOLOGICAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
57727572|NCT00968669|BIOLOGICAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
57727573|NCT00968669|BIOLOGICAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
57727574|NCT00968669|OTHER|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
57727575|NCT01076400|DRUG|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
57727576|NCT01076400|DRUG|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
57928416|NCT03042078|DEVICE|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
57928417|NCT03042078|DEVICE|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
57928418|NCT04092972|OTHER|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
58068904|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
58068905|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
58068906|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
58068907|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
58068908|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
58396187|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
58396188|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
58396189|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
58396190|NCT05609370|DRUG|LBL-007|Low dose intravenously (IV) once every 3 weeks.
58396191|NCT05609370|DRUG|LBL-007|Medium dose IV once every 3 weeks
58396192|NCT05609370|DRUG|LBL-007|High dose IV once every 2 or 3 weeks
58396193|NCT05609370|DRUG|Tislelizumab|Low dose IV once every 3 weeks
58396194|NCT05609370|DRUG|Tislelizumab|High dose IV once every 4 weeks
58396195|NCT05609370|DRUG|Bevacizumab biosimilar|7.5 mg/kg IV every 3 weeks
58396196|NCT05609370|DRUG|Bevacizumab biosimilar|5 mg/kg IV once every 2 weeks
58396197|NCT05609370|DRUG|Capecitabine|850 milligrams per square meter (mg/m\^2) twice daily orally for 2 weeks, followed by a one-week treatment break every 3 weeks
57727577|NCT01076400|DRUG|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
57727578|NCT01076400|DRUG|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
57727579|NCT02306915|DRUG|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
57727580|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
57727581|NCT02641548|DEVICE|Sock of silicone|
57727582|NCT02641548|OTHER|Heel cream|
57727583|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
57727584|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
57727585|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
57928419|NCT04092972|OTHER|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
57928420|NCT00261846|DRUG|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
57928421|NCT01032382|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
57928422|NCT01032382|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
57928423|NCT03030235|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
57928424|NCT03030235|DRUG|Dapagliflozin matching placebo|Dapagliflozin matching placebo
57928425|NCT04646070|PROCEDURE|Reduction mammaplasty|Breast reduction surgery
57928426|NCT02340728|DEVICE|ERCP with SEMS plus radiofrequency ablation|
57928427|NCT02340728|DEVICE|ERCP with SEMS alone (standard of care)|
57928428|NCT06465888|OTHER|egg whites|Participants will eat four egg whites daily for the 4-week study
57928429|NCT06465888|OTHER|whole eggs|Participants will eat two eggs daily for the 4-week study
57928430|NCT06465888|OTHER|Omega-3 eggs|Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.
57928431|NCT06465888|OTHER|egg yolk|Participants will eat four egg yolks daily for the 4-week study
57928432|NCT05885880|OTHER|Blue-button screening|Patients will be screened for clinical trial matches using the Blue-button tool
57928433|NCT02700243|BEHAVIORAL|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
57928434|NCT01130974|DEVICE|Bausch & Lomb contact lens|Bausch \& Lomb daily disposable cosmetic tint contact lens
57928435|NCT01130974|DEVICE|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
57928436|NCT01974596|DIETARY_SUPPLEMENT|Probiotic tablets of Lactobacillus reuteri|
57928437|NCT01974596|DIETARY_SUPPLEMENT|Placebo tablets|
57928438|NCT02221986|BEHAVIORAL|Interdisciplinary rehabilitation|
58396198|NCT05609370|DRUG|5-Fluorouracil|1600 to 2400 mg/m\^2 IV every 2 weeks
58396199|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
57928439|NCT01947452|BEHAVIORAL|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
57928440|NCT01947452|BEHAVIORAL|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
57928441|NCT02670681|BEHAVIORAL|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
57928442|NCT05176184|DIAGNOSTIC_TEST|A deep learning model for predicting a difficult laryngoscopy based on a cervical spine lateral X-ray image|"The deep learning model uses the input of preprocessed C-spine lateral X-ray images and outputs the level of difficulty of a laryngoscopy. The easy laryngoscopy is defined as a combination of the Cormack-Lehane grades 1-2 and the difficult laryngoscopy is defined as a combination of grades 3-4.~In addition, before general anesthesia, airway evaluations related to the difficulty of laryngoscopy are performed and the results are compared with the actual level of difficulty."
58396200|NCT00501722|DRUG|satavaptan (SR121463B)|
58396201|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
58396202|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
58396203|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
58396204|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
57727586|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
57928443|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
58396205|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
58396206|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
58396207|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
57928444|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
57928445|NCT02466438|DRUG|Piperacillin-tazobactam|"* Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician"
58396208|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
58396209|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
57928446|NCT06071403|OTHER|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
57928447|NCT04900922|DEVICE|isokinetic dynamometer|We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
57928448|NCT04575103|DRUG|Antipsychotic|Antipsychotic treatment \>0.5 DDD
57928449|NCT02590263|RADIATION|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
57928450|NCT02590263|DRUG|Temozolomide|Temozolomide will be administered per label.
57928451|NCT02590263|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
57928452|NCT02581293|PROCEDURE|Group 1: Only visceral peritoneum will be closed|
58280465|NCT05382013|OTHER|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
57727587|NCT06297538|DEVICE|gamma transcranial alternating current stimulation (tACS)|Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
57727588|NCT06297538|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
57727589|NCT01267123|PROCEDURE|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
57727590|NCT01267123|PROCEDURE|Standard care|The patient will be placed in the standard horizontal position
57727591|NCT03871647|DRUG|Beta blocker|perioperative beta blockers
57727592|NCT02114892|DRUG|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
57727593|NCT02114892|DRUG|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
58280466|NCT05382013|OTHER|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
58280467|NCT03326518|DIAGNOSTIC_TEST|Lumentin® 44|Contrast agent
58280468|NCT03326518|DIAGNOSTIC_TEST|Diluted Omnipaque®|Contrast agent
57727594|NCT04064281|OTHER|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
57727595|NCT04064281|OTHER|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
57928453|NCT02581293|PROCEDURE|Group 2 : Only parietal peritoneum will be closed|
57928454|NCT02581293|PROCEDURE|Group 3 : Both of them will be closed|
57928455|NCT02581293|PROCEDURE|Group 4: None of them will be closed|
57928456|NCT03075423|DRUG|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
58068909|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
58068910|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
58280469|NCT03326518|DIAGNOSTIC_TEST|Movprep®|Contrast agent
58280470|NCT00433017|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
58280471|NCT00433017|DRUG|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
57727596|NCT01547572|PROCEDURE|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
57928457|NCT03075423|DRUG|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
57928458|NCT04092062|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
57928459|NCT04092062|DEVICE|powered toothbrush|regular powered toothbrush with no RF
57928460|NCT00805662|DRUG|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
57928461|NCT03607123|OTHER|programing of pacemaker|Different programing parameters will be set in different group/stage
57928462|NCT03607123|PROCEDURE|AF ablation|AF ablation can only be performed in Step 3
57928463|NCT03607123|DRUG|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
57928464|NCT03970551|OTHER|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
57928465|NCT03970551|OTHER|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
57928466|NCT03970551|OTHER|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
57928467|NCT05538273|OTHER|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
57928468|NCT05538273|OTHER|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
57928469|NCT03919981|OTHER|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
58068911|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
58068912|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
58068913|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
58068914|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
57928470|NCT01187069|BEHAVIORAL|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
57928471|NCT02326714|OTHER|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
57928472|NCT02326714|OTHER|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
57928473|NCT01449318|DEVICE|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
58068915|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
58068916|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
58280472|NCT00433017|DRUG|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
58280473|NCT01109628|DIETARY_SUPPLEMENT|Protein drink|Twice a day during 6 months
58280474|NCT01109628|DIETARY_SUPPLEMENT|Placebo drink|Twice a day during 6 months
58068917|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
58068918|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
58068919|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
58280475|NCT00154843|DRUG|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
58396210|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
58068920|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
58068921|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
58068922|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
58068923|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
58068924|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
58068925|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
58280476|NCT02333422|OTHER|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
58280477|NCT00481013|DRUG|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
58280478|NCT00481013|DRUG|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
58396211|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
58396212|NCT00680979|BEHAVIORAL|Health Education|
57727597|NCT01547572|PROCEDURE|The control group will receive a leaflet only|The control group will receive a leaflet only
57727598|NCT00389935|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
57727599|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
57928474|NCT00966823|DEVICE|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
57928475|NCT05079412|OTHER|Chest ultrasound|Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
57928476|NCT04641507|DRUG|Tadalafil versus tamsulosin as MET|166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
57928477|NCT05335148|DRUG|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
57928478|NCT02329665|DEVICE|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
57727600|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
57928479|NCT05626049|OTHER|Primary Spine Provider Model|Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.
57928480|NCT05626049|OTHER|Usual Care|Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
57928481|NCT03606837|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
57928482|NCT03606837|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
57928483|NCT03146468|DRUG|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
58396213|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
57727601|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
57727602|NCT03616210|PROCEDURE|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
57727603|NCT02580149|DRUG|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
57727604|NCT02580149|DRUG|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
57727605|NCT02073968|DRUG|Carboplatin|Given IV
57727606|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
57928484|NCT04864483|OTHER|Meal timing in relation to time of starting the fast|as described
57928485|NCT04140383|PROCEDURE|Cataract Surgery|Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
57727607|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
57928486|NCT00887250|DRUG|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
57928487|NCT00887250|DRUG|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
57928488|NCT00887250|DRUG|Comparator: Placebo|Placebo to Losartan
57928489|NCT04100395|DEVICE|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
57727608|NCT02073968|DRUG|Paclitaxel|Given IV
57727609|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
58396214|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
58396215|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
58396216|NCT01601106|DRUG|Placebo|
58396217|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
58396218|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
58396219|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
58396220|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
58396221|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
58396222|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
58396223|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
58396224|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
58396225|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
58396226|NCT02139878|OTHER|Wild blueberry juice|
58396227|NCT02139878|OTHER|Placebo wild blueberry juice|
58396228|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
58396229|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
57928490|NCT03873493|DRUG|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
58396230|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
57727610|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
57928491|NCT03873493|DRUG|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
57928492|NCT03258125|GENETIC|real time PCR (rPCR)|A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
57928493|NCT01513525|DRUG|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
57928494|NCT04157504|OTHER|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
58396231|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
58396232|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
58396233|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
57928495|NCT05549778|DRUG|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
58280479|NCT03121794|PROCEDURE|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
58068926|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
58068927|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
58068928|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
58068929|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
58280480|NCT03121794|DEVICE|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
58280481|NCT01441856|PROCEDURE|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
58280482|NCT01441856|PROCEDURE|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
58280483|NCT02215746|DRUG|BI 44370 powder for oral solution|
58280484|NCT02215746|DRUG|BI 44370 tablet|
58280485|NCT02215746|OTHER|high fat breakfast|
58280486|NCT01375374|DRUG|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
58280487|NCT01375374|DRUG|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
58280488|NCT01962246|DRUG|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
58280489|NCT01962246|OTHER|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
58280490|NCT01437371|DRUG|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
58280491|NCT03957902|DRUG|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
58280492|NCT05327088|DRUG|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
58280493|NCT05327088|DRUG|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
58280494|NCT00079651|BEHAVIORAL|Montessori-based dementia programming|
58280495|NCT02797678|DEVICE|Powersleep|Participants will receive 5 nights of stimulation
58280496|NCT02797678|DEVICE|Sham Powersleep|Participants will receive 5 nights of no stimulation
58280497|NCT05545085|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
58280498|NCT04116606|DRUG|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
58396234|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
57928496|NCT05549778|DRUG|Control group|Abiraterone, radio- or chemotherapy
57928497|NCT03698890|DEVICE|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
58068930|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
58068931|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
58068932|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
58280499|NCT04116606|DRUG|Placebo|Matching placebo containing the same excipients
58280500|NCT03690362|DRUG|VNRX-5133 and VNRX-5022|intravenous infusion
58280501|NCT00373802|DRUG|Phenylephrine|
58280502|NCT04571385|DRUG|AP30663|Administer by intravenous infusion.
58280503|NCT04571385|DRUG|Placebo|Placebo matched to AP30663.
58280504|NCT03062397|DRUG|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
58280505|NCT03062397|DRUG|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
58280506|NCT03062397|DRUG|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
58396235|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
58396236|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58396237|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
58396238|NCT04195399|PROCEDURE|Echocardiography|Undergo ECHO
58396239|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58396240|NCT04195399|DRUG|Nirogacestat|Given PO
58396241|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
58396242|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
58396243|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
57928498|NCT05827250|DEVICE|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
57928499|NCT01317225|DRUG|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
57928500|NCT01317225|DRUG|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
57928501|NCT06414915|DRUG|Surufatinib|250 mg, po, qd, q3w
58280507|NCT05579132|DRUG|CN201|The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 7 cycles of maintenance treatment. During the Treatment Period, subjects will receive CN201 by intravenous (IV) infusion once every week (QW), 4 weeks per treatment cycle. The subjects will receive 2 cycles of CN201 for induction. After induction treatment, the drug is discontinued for 2 weeks (treatment-free interval) before consolidation therapy is started, and each subsequent treatment cycle (4 weeks/treatment cycle) is followed by a 2-week treatment-free interval. Responders to induction treatment will continue to receive 3 cycles of consolidation treatment, followed by an additional up to 7 cycles of maintenance treatment, or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first.
58280508|NCT05003830|DEVICE|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
58280509|NCT04617483|BIOLOGICAL|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
58280510|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
58396244|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
58396245|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
58396246|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
58396247|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
58396248|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
57928502|NCT06414915|DRUG|Tislelizumab|200mg, iv, q3w
57928503|NCT06267157|DEVICE|virtual reality training|Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
57928504|NCT06267157|OTHER|theoretical breastfeeding training|Classic 2-hour theoretical breastfeeding training with ppt
57928505|NCT04118296|DRUG|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
57928506|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
57928507|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
57928508|NCT01039025|DRUG|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.
57928509|NCT01039025|DRUG|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
57928510|NCT01039025|DRUG|Melphalan|After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.
57928511|NCT01039025|OTHER|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
57928512|NCT01277770|DRUG|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
57928513|NCT01277770|OTHER|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
57928514|NCT01277770|DRUG|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
57928515|NCT03478163|DRUG|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
57928516|NCT03478163|DRUG|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
58280511|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
58280512|NCT03634813|DEVICE|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
58280513|NCT03634813|PROCEDURE|Usual Care|Usual Care
58280514|NCT05276960|DRUG|Cholecalciferol Pill|Dose increments according to serum levels determined every 2 months
58280515|NCT00086398|BEHAVIORAL|Behavior Therapy|
58280516|NCT02352376|OTHER|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
58280517|NCT02352376|OTHER|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
58280518|NCT04862832|OTHER|Music intervention|"The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions."
58280519|NCT01685385|OTHER|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
58280520|NCT05656885|DEVICE|Lens A|Soft spherical hydrogel contact lens for 15 minutes
58280521|NCT05656885|DEVICE|Lens B|Soft spherical silicone hydrogel contact lens for 15 minutes
58396249|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
58396250|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
58396251|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
58280522|NCT04295213|OTHER|oligosaccharides|1 dose a day of oligosaccharides or placebo
58280523|NCT01533688|DRUG|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
58280524|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
58280525|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
58280526|NCT00813436|DRUG|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
58280527|NCT00813436|DRUG|Placebo|saline liquid, intranasally administered
58280528|NCT05610579|OTHER|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.
57928517|NCT01615653|PROCEDURE|EUS|EUS Guided Therapy
57928518|NCT04830956|OTHER|FID123238|Lubricant applied to the ocular surface
57928519|NCT04830956|OTHER|Systane Hydration|Drops applied to the ocular surface
57928520|NCT05356117|BEHAVIORAL|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
57928521|NCT05356117|BEHAVIORAL|Resistance Training (RT)|Aerobic and resistance exercise
57928522|NCT05356117|BEHAVIORAL|Attention Control (AC|Stretching
57928523|NCT05989607|OTHER|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
57928524|NCT05989607|OTHER|Plain Water|Commercially available bottled, spring water.
57928525|NCT02407522|DIETARY_SUPPLEMENT|Black rice|They asked to keep their normal life style during intervention
57928526|NCT02407522|OTHER|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
57928527|NCT06140212|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
57727611|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
57727612|NCT02427529|DRUG|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
57727613|NCT02427529|DRUG|Placebo|
58068933|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
58280529|NCT05610579|OTHER|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
58280530|NCT03423147|DRUG|2% chlorhexidine gluconate cloth|applied to their abdomen
57727614|NCT02427529|OTHER|Low calorie diet|
57727615|NCT05453474|GENETIC|Whole genome amplification|DNA is amplified by whole genome amplification
57727616|NCT03650205|DRUG|Ivabradine|Ivabradine capsule
57727617|NCT03650205|DRUG|Placebo|Placebo oral capsule.
57727618|NCT03305679|PROCEDURE|Direct provisional technique|The method of implantation will be accomplished directly.
57727619|NCT03305679|PROCEDURE|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
57727620|NCT02013765|DRUG|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
57727621|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
57727622|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
57727623|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
57727624|NCT01408589|DRUG|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
57727625|NCT00780091|OTHER|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
58396252|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
58396253|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
57727626|NCT00780091|OTHER|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
57928528|NCT06140212|BEHAVIORAL|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
57928529|NCT06140212|BEHAVIORAL|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
57928530|NCT04793269|OTHER|No intervention|no intervention
58068934|NCT03083262|OTHER|no intervention|None, there is no intervention
58068935|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
57928531|NCT00781820|DRUG|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
57928532|NCT00781820|DRUG|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
57928533|NCT05055414|DRUG|UI030|Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
57928534|NCT04433351|DEVICE|Enriched rehabilitation|"The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter."
57727627|NCT06257147|BEHAVIORAL|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
57928535|NCT04433351|DEVICE|Simple rehabilitation|The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
58068936|NCT00031824|DRUG|cyclosporine|
58068937|NCT00031824|DRUG|hydroxychloroquine|
58068938|NCT00031824|DRUG|prednisone|
58068939|NCT00031824|DRUG|tacrolimus|
58068940|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
58068941|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
58068942|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
58280531|NCT03423147|DRUG|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
58280532|NCT01013389|PROCEDURE|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
58280533|NCT01013389|PROCEDURE|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
58068943|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
58068944|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
58068945|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
58280534|NCT06366438|BEHAVIORAL|ABC-teen|See above
58280535|NCT06366438|BEHAVIORAL|ParentWeb|See above
58068946|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
58068947|NCT01745159|DRUG|tacrolimus|
58068948|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
58068949|NCT01156636|DRUG|Placebo|
58068950|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
58068951|NCT00307073|DEVICE|Implantable Pulse Generator|
58306783|NCT00614835|DRUG|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
58280536|NCT01483456|OTHER|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases"
58280537|NCT04102332|DEVICE|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
58280538|NCT00507065|DRUG|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
58396254|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
58280539|NCT00507065|DRUG|Placebo|
58280540|NCT01281943|DRUG|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
58280541|NCT04185584|OTHER|Not Applicable (Observational Study)|Not Applicable (Observational Study)
57727628|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
57727629|NCT05425004|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
57727630|NCT04756219|OTHER|Contact Video|No additional information necessary.
57727631|NCT04756219|OTHER|Contact Text|No additional information necessary.
57928536|NCT01685190|RADIATION|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
57928537|NCT01685190|RADIATION|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
57928538|NCT05231486|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
57928539|NCT04574479|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
57928540|NCT04574479|DRUG|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
57928541|NCT01617850|OTHER|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
58068952|NCT04084275|BEHAVIORAL|breastfeeding education|
58068953|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
58068954|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
58280542|NCT02400892|OTHER|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
58280543|NCT02247297|PROCEDURE|Blood collection|Diagnostic blood collection
58280544|NCT04422964|DEVICE|3D Obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
58280545|NCT00496587|DRUG|Capecitabine|800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
58280546|NCT00496587|DRUG|Gemcitabine|900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
58280547|NCT00496587|DRUG|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
58280548|NCT01504672|OTHER|Medication review|"In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs"
58306784|NCT04927910|OTHER|Ture self-acupressure|8-week intervention of self-acupressure on acupoints
57727632|NCT04756219|OTHER|Education Video|No additional information necessary.
57727633|NCT04756219|OTHER|Education Text|No additional information necessary.
57727634|NCT05778305|DRUG|Dexmedetomidine|a central sympatholytic drug
57727635|NCT05778305|OTHER|normal saline|saline is given to control group
57727636|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
57727637|NCT00733265|DRUG|AZD6140|single oral dose
57727638|NCT01389908|DRUG|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
57928542|NCT01617850|OTHER|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
57928543|NCT02249754|BEHAVIORAL|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
57928544|NCT02249754|BEHAVIORAL|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
57928545|NCT00760396|DRUG|VGX-1027|Subjects will
57928546|NCT03785678|BIOLOGICAL|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
57928547|NCT03785678|OTHER|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
57928548|NCT00786123|DIETARY_SUPPLEMENT|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
57928549|NCT00786123|DIETARY_SUPPLEMENT|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
57928550|NCT02973425|BEHAVIORAL|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience \& Suite of mHealth motivational tools and mini-games.
57928551|NCT02973425|BEHAVIORAL|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
57928552|NCT03496324|DRUG|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
57928553|NCT03496324|DRUG|Algifor® Junior|Algifor® Junior 400 mg/20 ml
57928554|NCT00531882|DRUG|Pioglitazone|30 mg once a day
57928555|NCT00531882|DRUG|Simvastatin|40 mg once a day
57928556|NCT00531882|DRUG|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
57928557|NCT05169216|BEHAVIORAL|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided."
57928558|NCT01749540|DRUG|luspatercept|subcutaneous injection
58068955|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
58280549|NCT05926466|DRUG|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
57928559|NCT00818181|DRUG|Biological: AL0206st|
57928560|NCT03393715|DRUG|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
57928561|NCT05227157|OTHER|swab with iron sulfate solution|measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
57928562|NCT02218190|DRUG|Alvimopan|
57928563|NCT02218190|DRUG|Placebo|
57928564|NCT00617604|DRUG|Alefacept|IV and subcutaneous injection
57928565|NCT00617604|DRUG|placebo|IV and subcutaneous injection
58280550|NCT05926466|DRUG|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
57928566|NCT00617604|DRUG|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
57928567|NCT00617604|DRUG|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
58068956|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
57928568|NCT00617604|DRUG|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
57928569|NCT01168739|DIETARY_SUPPLEMENT|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
57928570|NCT01168739|DIETARY_SUPPLEMENT|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
57928571|NCT05089409|DRUG|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
57928572|NCT05089409|DRUG|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
57928573|NCT05089409|DRUG|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
57928574|NCT05089409|DRUG|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
57928575|NCT05089409|DRUG|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
57928576|NCT05089409|OTHER|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
57928577|NCT04448756|DRUG|M5049|Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
57928578|NCT04448756|DRUG|M5049|Participants received M5049 100 mg orally twice daily for 14 days.
58280551|NCT05926466|DRUG|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
58280552|NCT05926466|DRUG|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
58280553|NCT03747718|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
58280554|NCT03747718|OTHER|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
58280555|NCT02349282|DIETARY_SUPPLEMENT|Calcifediol 10ug/day|
57928579|NCT04448756|DRUG|Placebo|Participants received placebo tablets matched to M5049 daily for 14 days.
57928580|NCT01798992|DRUG|Carvedilol|
58280556|NCT02349282|DIETARY_SUPPLEMENT|Vitamin D3 20ug/day|
57928581|NCT01798992|DRUG|Metoprolol succinate|
58280557|NCT02349282|DIETARY_SUPPLEMENT|Placebo|
58280558|NCT02247232|DRUG|Z-100|
57928582|NCT01798992|DRUG|Metoprolol succinate + doxazosin|
58280559|NCT02247232|DRUG|Placebo|
57928583|NCT04444622|BIOLOGICAL|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
57928584|NCT05576922|OTHER|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
57928585|NCT05576922|OTHER|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
57928586|NCT00355056|OTHER|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
57928587|NCT00355056|DEVICE|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
57928588|NCT03938038|DIAGNOSTIC_TEST|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
57928589|NCT03938038|DIAGNOSTIC_TEST|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
57928590|NCT01028456|OTHER|Light Therapy|10,000 lux / 30 minutes a day
57928591|NCT01028456|OTHER|100 lux|Placebo light
58280560|NCT01041274|DRUG|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
58280561|NCT01041274|DRUG|Placebo|Placebo by mouth daily for 12 months.
58280562|NCT01041274|BEHAVIORAL|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
57928592|NCT04663750|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy
57928593|NCT04663750|DRUG|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
57928594|NCT04663750|DRUG|subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls|Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
57928595|NCT04663750|DRUG|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
57928596|NCT03971656|DIETARY_SUPPLEMENT|Nutritional Supplement|Oral nutritional supplementation
57928597|NCT03971656|BEHAVIORAL|Preoperative Dietitian Consult|Nutritional assessment
57928598|NCT03971656|BEHAVIORAL|Education|Informational materials about nutrition
57928599|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
57928600|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
57928601|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
57928602|NCT05713773|DRUG|coated beads glucose (8 g)|After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
57928603|NCT05713773|DRUG|uncoated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
57928604|NCT01622179|PROCEDURE|sewed indirectly|The epitenon was repaired and sewed indirectly.
57928605|NCT01622179|PROCEDURE|sewed directly|The epitenon was unrepaired and sewed directly.
57928606|NCT02301650|DRUG|Lamivudine|mothers use Lamivudine in late pregnancy
57928607|NCT02301650|DRUG|Telbivudine|mothers use Telbivudine in late pregnancy
58306785|NCT04927910|OTHER|Sham self-acupressure|8-week intervention of self-acupressure on non-acupoints
57928608|NCT02301650|DRUG|Tenofovir|mothers use Tenofovir in late pregnancy
57928609|NCT00501527|BIOLOGICAL|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
57928610|NCT00501527|OTHER|Placebo|Placebo 2 drops daily
57928611|NCT00701207|DRUG|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
57928612|NCT01209845|DRUG|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
58068957|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
57727639|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
57928613|NCT02885298|PROCEDURE|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
58306786|NCT04927910|OTHER|Usual care|routine care by hospitals
57727640|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
57727641|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
57727642|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
58068958|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
58068959|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
58068960|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
58306787|NCT01751282|GENETIC|Stem Cell|
57727643|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
57727644|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
57727645|NCT00059475|DRUG|Montanide ISA 51|
57928614|NCT00146679|BEHAVIORAL|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
57928615|NCT00146679|BEHAVIORAL|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
58396255|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
58280563|NCT01041274|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
58280564|NCT01041274|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
58280565|NCT06465628|BEHAVIORAL|Self-administered acupressure|The participants should perform self-administered acupressure 12 weeks after training
58280566|NCT06465628|OTHER|Oral health education|The participants should perform general oral care by themselves after the oral health education relating to xerostomia
58280567|NCT01267422|DRUG|rAAV2-ND4|injection
58280568|NCT00060372|DRUG|ipilimumab|Given IV
58280569|NCT00060372|DRUG|therapeutic allogeneic lymphocytes|Given IV
58280570|NCT05413941|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
58280571|NCT00220948|PROCEDURE|CERSR Myoelectric monitoring during standardized tasks|
58280572|NCT01778751|BEHAVIORAL|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
58280573|NCT05979584|DEVICE|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
58280574|NCT05979584|DEVICE|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
58280575|NCT01125813|BIOLOGICAL|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
58280576|NCT04727255|BEHAVIORAL|Engaged and Resilient intervention|"Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology."
58280577|NCT01158105|DRUG|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
58280578|NCT00394394|DRUG|Amiloride 2,5/d or Enalapril/d 10 mg|
58396256|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
58396257|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
57928616|NCT00146679|BEHAVIORAL|Usual Care|Usual Care provided by providers
58068961|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
58280579|NCT04725890|DEVICE|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
58280580|NCT06300944|DRUG|saline|A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
58280581|NCT06300944|DRUG|Esketamine|A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
58280582|NCT02697734|DRUG|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
58280583|NCT02697734|DRUG|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
58396258|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
58396259|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
58396260|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
58306788|NCT06213116|DEVICE|MADgic Atomizer|Device to deliver directly lignocaine
58306789|NCT06213116|DEVICE|Lignocaine pump spray|Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
58396261|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
58396262|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
57928617|NCT02627755|DEVICE|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
57928618|NCT02627755|DEVICE|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
58068962|NCT00006358|DRUG|temozolomide|
58068963|NCT00006358|DRUG|thalidomide|
57928619|NCT04894162|OTHER|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
58280584|NCT04404829|OTHER|Manual Therapy|"The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM."
58280585|NCT03519919|DEVICE|somofilcon A multifocal lens|contact lens
58280586|NCT03246919|DRUG|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
58280587|NCT03246919|DRUG|Placebo|Placebo will be administered after delivery of the placenta
58280588|NCT00214292|PROCEDURE|fluorescence spectroscopy and diffuse spectroscopy|
58280589|NCT05358977|BIOLOGICAL|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of \< 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
58280590|NCT05868278|OTHER|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
58280591|NCT00002267|DRUG|Rifabutin|
58280592|NCT05005767|PROCEDURE|scaling and root planing|will receive scaling and root planing only
58280593|NCT05005767|PROCEDURE|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
58280594|NCT02581033|DRUG|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
58280595|NCT03202732|OTHER|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
58280596|NCT05635422|DIAGNOSTIC_TEST|isokinetism test|measure of muscular fatigability by isokinetism
58280597|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
58280598|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
58280599|NCT00638261|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
58280600|NCT04209907|OTHER|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
58280601|NCT05393687|OTHER|Eccentric exercise|progressive eccentric exercise with elastic band
58396263|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
57727646|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
57727647|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
57727648|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
57727649|NCT00623220|OTHER|N2O|EMONO
57928620|NCT05653323|DRUG|VX-993|Suspension for oral administration.
58396264|NCT03367923|OTHER|Communication Intervention|Receive email/text
57727650|NCT00623220|OTHER|oxygen|oxygen
57727651|NCT06670404|DEVICE|Vertebroplasty|Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
57928621|NCT05653323|DRUG|Placebo|Suspension for oral administration.
57928622|NCT05212896|DRUG|BC006|BC006 monoclonal antibody injection
57928623|NCT00463268|DRUG|alendronate|alendronate 70 mg every 2 weeks
57928624|NCT00463268|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
57928625|NCT00463268|DRUG|placebo|identical placebo every 2 weeks
57928626|NCT05226754|DRUG|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
58280602|NCT03827551|BEHAVIORAL|Delivery of oral hygiene advices|Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
58280603|NCT04850378|DRUG|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
58280604|NCT04850378|DRUG|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
58280605|NCT01470144|DRUG|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
58280606|NCT06187649|PROCEDURE|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
58396265|NCT03367923|OTHER|Counseling|Undergo exercise counseling
58396266|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
58396267|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
58396268|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
58396269|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
58396270|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
58396271|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
58396272|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
58396273|NCT00001106|DRUG|Zidovudine|
58396274|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
58396275|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
58396276|NCT00585442|DRUG|calcitriol|1.0 mcg daily
58396277|NCT00585442|DRUG|Placebo|Placebo
58396278|NCT00425997|DRUG|Valsartan/HCTZ|
58280607|NCT05917483|DIAGNOSTIC_TEST|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
58396279|NCT00425997|DRUG|amlodipine|
58396280|NCT00425997|DRUG|HCTZ|
58396281|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
57928627|NCT05226754|DRUG|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
58396282|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
58396283|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
58396284|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
57928628|NCT04225468|BEHAVIORAL|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
58396285|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
58396286|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
58396287|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
58280608|NCT02858232|BIOLOGICAL|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
58280609|NCT05920148|PROCEDURE|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
58280610|NCT02731547|BEHAVIORAL|Education Against Tobacco School-Based Intervention|
58280611|NCT03668522|OTHER|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
57951176|NCT02375230|PROCEDURE|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
58280612|NCT00934232|DRUG|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
58280613|NCT00290693|DRUG|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
58396288|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
58396289|NCT04530487|DRUG|Cyclosporine|Given IV and PO
58396290|NCT04530487|DRUG|Etoposide|Given IV
58396291|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
58396292|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
58396293|NCT04530487|DRUG|Melphalan|Given IV
58396294|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
58396295|NCT04530487|DRUG|Tacrolimus|Given IV and PO
58396296|NCT04530487|DRUG|Thiotepa|Given IV
58396297|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
57727652|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
57951177|NCT00002689|DRUG|dexamethasone|
58280614|NCT00290693|DRUG|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
58280615|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
58280616|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
58280617|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
58280618|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
58280619|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
58280620|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
58280621|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
58396298|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
58396299|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
58396300|NCT02269813|OTHER|MammaPrint|
58396301|NCT02269813|OTHER|BluePrint|
58396302|NCT02269813|OTHER|TargetPrint|
58396303|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
58396304|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
58396305|NCT00320905|BEHAVIORAL|Observational|No intervention
58396306|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
58396307|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
58396308|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
57928629|NCT05887817|DRUG|Finerenone|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
58280622|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
57928630|NCT05887817|DRUG|Placebo|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
58280623|NCT04457934|DRUG|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
58280624|NCT02855177|DRUG|Placebo|Placebo as suspension administered every 8 hours, with food
58396309|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
58396310|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
58396311|NCT02094378|DRUG|Placebo|Placebo administered intranasally
58396312|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
58396313|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
58396314|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
58396315|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
58396316|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
58396317|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
58396318|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
58396319|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
58280625|NCT02855177|DRUG|PF-06427878|500 mg suspension administered every 8 hours, with food
58396320|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
58396321|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
57928631|NCT00682565|DRUG|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
57928632|NCT00682565|DRUG|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
57951178|NCT00002689|DRUG|fluorouracil|
58396322|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
58396323|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
58396324|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
57951179|NCT00002689|RADIATION|brachytherapy|
58280626|NCT00670657|DRUG|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
58280627|NCT03051347|OTHER|Itch Questionnaire and Interview|
58280628|NCT03051347|OTHER|Stigma Questionnaire and Interview|
58280629|NCT03051347|OTHER|Cognitive Interview and PROMIS Itch Questionnaire|
58396325|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
58396326|NCT05005403|DRUG|ABBV-514|Intravenous (IV) Infusion
58396327|NCT05005403|DRUG|Budigalimab|IV Infusion
58396328|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
57928633|NCT00682565|DRUG|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
57727653|NCT04268017|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
57928634|NCT00682565|DRUG|CK-1827452 25mg capsule|25mg oral immediate release capsule
58396329|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
58396330|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
58396331|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
57928635|NCT00682565|DRUG|Placebo iv infusion|Matching placebo iv infusion
57928636|NCT00682565|DRUG|Placebo capsule|Matching placebo oral immediate release capsule
57928637|NCT04339114|OTHER|Breakfast: control meal|The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
57928638|NCT04339114|OTHER|Breakfast: Cinnamon meal|The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
57928639|NCT04339114|OTHER|Breakfast: Italian herbs meal|The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
57928640|NCT04339114|OTHER|Breakfast: pumpkin spice|The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
58396332|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
58396333|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
57928641|NCT04334733|OTHER|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
57928642|NCT04334733|OTHER|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
58280630|NCT06033170|DEVICE|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
58280631|NCT03574038|DEVICE|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
58396334|NCT00303654|PROCEDURE|biopsy|
58396335|NCT00303654|PROCEDURE|therapeutic conventional surgery|
58396336|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
58396337|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
58396338|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
57727654|NCT06452459|OTHER|No interventinon|No intervention is anticipated. This is an observational study.
57727655|NCT00004093|DRUG|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
57928643|NCT04334733|OTHER|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
57951180|NCT00002689|RADIATION|phosphorus P32|
57951181|NCT00002689|RADIATION|radiation therapy|
57951182|NCT01999803|DRUG|sNN0029|
57951183|NCT01999803|DRUG|Placebo|
57951184|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
58396339|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
58396340|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
58396341|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
58068964|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
58068965|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
58068966|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
58280632|NCT03574038|OTHER|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
58280633|NCT05749497|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
58280634|NCT04303468|DIETARY_SUPPLEMENT|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
58280635|NCT04303468|OTHER|Placebo|Gelatin capsule containing powdered cellulose
58280636|NCT03648138|BEHAVIORAL|Sugary drink warning labels|This information appears in the description of the study arms.
58280637|NCT06380972|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
58280638|NCT00544908|DRUG|dasatinib|
58280639|NCT00544908|OTHER|immunoenzyme technique|
58280640|NCT00544908|OTHER|immunohistochemistry staining method|
58280641|NCT00544908|OTHER|laboratory biomarker analysis|
58280642|NCT00544908|PROCEDURE|quality-of-life assessment|
58280643|NCT04110496|DRUG|RTX-134|RTX-134 is a cellular therapy containing AvPAL
58280644|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
58280645|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
57727656|NCT00004093|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
58068967|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
58280646|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
58280647|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
58280648|NCT06537050|DRUG|JX2105|Oral capsule
58280649|NCT06537050|DRUG|Placebo|Oral capsule
58396342|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
58396343|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
58396344|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
58396345|NCT02970630|DRUG|Tacrolimus|once a day
57727657|NCT00004093|DRUG|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
58068968|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
58068969|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
58068970|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
58068971|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
58280650|NCT01077102|OTHER|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
58280651|NCT02674126|BEHAVIORAL|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
58280652|NCT02674126|BEHAVIORAL|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
58280653|NCT03754972|DIAGNOSTIC_TEST|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
58396346|NCT02970630|DRUG|Everolimus|twice daily
57951185|NCT01141504|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
58068972|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
57928644|NCT02673203|DEVICE|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
57928645|NCT02673203|BEHAVIORAL|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
57928646|NCT00066742|DRUG|tirapazamine|Given IV
57928647|NCT00066742|DRUG|cisplatin|Given IV
57928648|NCT00066742|DRUG|etoposide|Given IV
57928649|NCT00066742|RADIATION|radiation therapy|Undergo radiation therapy
57928650|NCT00066742|OTHER|laboratory biomarker analysis|Correlative studies
57928651|NCT01119326|PROCEDURE|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
58068973|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
58068974|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
58280654|NCT02273765|DRUG|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
58280655|NCT02273765|DRUG|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
58280656|NCT05584878|OTHER|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
58280657|NCT05584878|OTHER|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
58280658|NCT05584878|OTHER|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
58280659|NCT00057005|DRUG|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
58280660|NCT00057005|DRUG|Anti-CD45|Day-5 400 μg/kg
58280661|NCT00057005|DRUG|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
58280662|NCT00057005|DRUG|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
58280663|NCT00057005|DRUG|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
58280664|NCT00057005|RADIATION|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
58280665|NCT00840697|BEHAVIORAL|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
57727658|NCT00004093|DRUG|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
57928652|NCT03882710|DRUG|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
57928653|NCT05511623|DRUG|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
58068975|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
58280666|NCT00840697|BEHAVIORAL|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
58280667|NCT00840697|BEHAVIORAL|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
57928654|NCT05511623|OTHER|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
57928655|NCT02072434|DRUG|Edoxaban|Edoxaban 30 mg tablets for oral administration
57928656|NCT02072434|DRUG|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
57928657|NCT02072434|DRUG|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
57928658|NCT02959567|DEVICE|Aqueduct 100 dilation|
57951186|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
58396347|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
57928659|NCT05128721|BIOLOGICAL|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
58068976|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
58068977|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
58280668|NCT05843032|DIAGNOSTIC_TEST|3D ultrasound, MRI, resected specimen examination by surgeon|3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
58280669|NCT06074627|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
58280670|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
58396348|NCT02989584|DRUG|Atezolizumab|
58280671|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
58280672|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
58396349|NCT02989584|DRUG|Gemcitabine|
58396350|NCT02989584|DRUG|Cisplatin|
57928660|NCT04888520|DEVICE|Adhesive elastic bandage|"The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist."
58396351|NCT00346606|DRUG|Denosin® and Xyzal®|
57928661|NCT04393051|DRUG|Baricitinib Oral Tablet|Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
58280673|NCT02435056|OTHER|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management"
58280674|NCT05491863|OTHER|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
58280675|NCT05491863|OTHER|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
58280676|NCT03935334|BIOLOGICAL|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
58280677|NCT03935334|BIOLOGICAL|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
58396352|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
58396353|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
58396354|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
58396355|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
58396356|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
58396357|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
58396358|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
58396359|NCT00260767|DRUG|HEC placebo gel|
57928662|NCT05871866|PROCEDURE|"minimally invasive internal fixation device infix"|An INFIX involves the insertion of spinal pedicle screws in the anterior pelvis (supra-acetabular entry) and the placement of a connecting rod in the subcutaneous tissue of the patient
57928663|NCT04376970|DRUG|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
57951187|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
58396360|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
57951188|NCT04705194|PROCEDURE|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
57951189|NCT04705194|PROCEDURE|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
58068978|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
58396361|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
58068979|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
58068980|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
58280678|NCT02085226|OTHER|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
58280679|NCT02085226|OTHER|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
58280680|NCT01358240|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
58280681|NCT01358240|DRUG|Vehicle Foam|Vehicle Foam applied once a day for 4 week
58280682|NCT01358240|DRUG|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
58280683|NCT01358240|OTHER|Placebo Cream|Placebo cream applied once a day for 4 weeks
58280684|NCT05033977|OTHER|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
58280685|NCT05033977|OTHER|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
58280686|NCT06052644|OTHER|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
58280687|NCT00046540|DRUG|Liposome-encapsulated SN38|
58280688|NCT05962827|DIAGNOSTIC_TEST|lipoprotein (a)|dosage of lipoprotein (a)
58280689|NCT01111682|DRUG|Mannitol|0.9% normal saline infusion and boluses of mannitol
58280690|NCT01111682|DRUG|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
58280691|NCT04475770|OTHER|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
58396362|NCT02684877|OTHER|Questionnaire|
58396363|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
58396364|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
58396365|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
58396366|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
58396367|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
58396368|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
58396369|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
58396370|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
58068981|NCT01738906|OTHER|Orange juice|
58068982|NCT01738906|OTHER|maltodextrin|
58068983|NCT01738906|OTHER|Vodka|
58068984|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
58068985|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
58068986|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
58068987|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
58068988|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
58068989|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
58280692|NCT04475770|OTHER|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
58396371|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
57928664|NCT04376970|DRUG|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
58396372|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
58396373|NCT02899455|DRUG|HGP0904|
58396374|NCT02899455|DRUG|HGP0608|
57928665|NCT05679284|RADIATION|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
57928666|NCT02234323|BIOLOGICAL|rFVIIIFc|Administered as specified in arm description
57928667|NCT02544217|DRUG|KH176|
57928668|NCT02544217|DRUG|placebo|
57928669|NCT03065023|DRUG|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
57928670|NCT04140279|DRUG|Latanoprostene Bunod|Ophthalmic solution
57928671|NCT04140279|DRUG|Placebo|Ophthalmic solution, no active ingredient.
57928672|NCT03551964|DRUG|Cangrelor|"Cangrelor: IV bolus 30 μg/kg (application \< 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.~* Cangrelor therapy will be stopped after circulatory stabilization - when sBP \> 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI~* 30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months."
58280693|NCT00546312|DEVICE|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
58280694|NCT02462109|DRUG|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.
58280695|NCT00297050|DRUG|Peramivir|
58280696|NCT03185494|BIOLOGICAL|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
58280697|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
58280698|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
58396375|NCT02899455|DRUG|HGP0816|
57727659|NCT00004093|RADIATION|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
57928673|NCT03551964|DRUG|Ticagrelor|Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.
58068990|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
58068991|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
58280699|NCT02578459|DEVICE|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
58396376|NCT02899455|DRUG|HGP0904 Placebo|
58396377|NCT02899455|DRUG|HGP0816 Placebo|
58396378|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
58396379|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
58396380|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
58396381|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
58396382|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
58396383|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
58396384|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
58396385|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
58396386|NCT02814240|OTHER|NMR|
58396387|NCT02814240|BIOLOGICAL|Blood samples|
58396388|NCT02814240|OTHER|fibroscan|
58280700|NCT02578459|OTHER|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
58396389|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
57928674|NCT04703478|OTHER|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
57928675|NCT04628299|OTHER|Sham Laser|Sham Laser in plantar fascia
57928676|NCT04628299|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
57928677|NCT00702845|DRUG|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
57928678|NCT00702845|DRUG|recFSH (follitropin beta)|150 IU recFSH SC injection
57928679|NCT00702845|DRUG|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
57928680|NCT00702845|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
58280701|NCT02191046|DEVICE|squeezable bottle|nasal irrigation twice daily for 2 weeks period
58396390|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
58396391|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
58280702|NCT02191046|DEVICE|syringe 20 ml|nasal irrigation twice daily for 2 weeks
58396392|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
57727660|NCT00004093|DRUG|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
58396393|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
58396394|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
57928681|NCT00702845|BIOLOGICAL|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
58280703|NCT03534739|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
57928682|NCT00702845|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
58396395|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
57928683|NCT00702845|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
57928684|NCT00702845|BIOLOGICAL|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
58068992|NCT00611351|DRUG|busulfan|
58068993|NCT00611351|DRUG|cyclophosphamide|
58068994|NCT00611351|DRUG|mycophenolate mofetil|
58068995|NCT00611351|DRUG|tacrolimus|
58068996|NCT00611351|GENETIC|polymerase chain reaction|
58396396|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
58396397|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
58396398|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
58396399|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
58396400|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
58396401|NCT04451226|DRUG|Fezolinetant|Oral
58280704|NCT03534739|OTHER|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
58280705|NCT03534739|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
58396402|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
58396403|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
58396404|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
58396405|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
58396406|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
58396407|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
58396408|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
58396409|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
58396410|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
58396411|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
58396412|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
58396413|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
58396414|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
58396415|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
58396416|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
58396417|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
58396418|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
58396419|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
58396420|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
58396421|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
58396422|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
58396423|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
58280706|NCT06279494|DRUG|Sirolimus|Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT
58280707|NCT06279494|DRUG|Abatacept|5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT
58280708|NCT06279494|DRUG|MMF|0.5g bid orally, from -3d to +60d post haplo-HSCT
58280709|NCT06279494|DRUG|ATG|2.5 mg/kg, from -5d to -2d
58280710|NCT03872765|DEVICE|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
58280711|NCT05167331|DRUG|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
58280712|NCT05167331|DEVICE|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
58280713|NCT02774187|DRUG|Sorafenib|administration of Sorafenib
58068997|NCT00611351|GENETIC|polymorphism analysis|
57928685|NCT02936934|DRUG|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
57928686|NCT02936934|DRUG|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
58068998|NCT00611351|OTHER|flow cytometry|
58280714|NCT02774187|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
58280715|NCT02774187|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
58280716|NCT02958410|BIOLOGICAL|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
58280717|NCT00006355|DRUG|pyrazoloacridine|
58068999|NCT00611351|OTHER|laboratory biomarker analysis|
58069000|NCT00611351|OTHER|pharmacogenomic studies|
58280718|NCT00006355|PROCEDURE|adjuvant therapy|
58280719|NCT00006355|RADIATION|radiation therapy|
58280720|NCT00560703|DRUG|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
58280721|NCT00560703|DRUG|placebo|sugar capsule
58280722|NCT04468113|DEVICE|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
58280723|NCT05717205|DIAGNOSTIC_TEST|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
58280724|NCT00275015|BIOLOGICAL|filgrastim|
58280725|NCT00275015|DRUG|carmustine|
58280726|NCT00275015|DRUG|cyclophosphamide|
58280727|NCT00275015|DRUG|cytarabine|
57727661|NCT00004093|DRUG|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
57928687|NCT00551109|DRUG|placebo|placebo, oral administration, once daily for 8 weeks
58069001|NCT00611351|OTHER|pharmacological study|
57928688|NCT00551109|DRUG|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
57928689|NCT00551109|DRUG|SA4503 High|High dose, oral administration, once daily for 8 weeks
58069002|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
58069003|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58069004|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
58069005|NCT05959876|OTHER|Training group|Face-to-face perineal care training
58069006|NCT05959876|OTHER|Control group|No intervention
58069007|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
58069008|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
58069009|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
58069010|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
58280728|NCT00275015|DRUG|dexamethasone|
58280729|NCT00275015|DRUG|etoposide|
58280730|NCT00275015|DRUG|fludarabine phosphate|
58280731|NCT00275015|DRUG|melphalan|
58280732|NCT00275015|PROCEDURE|bone marrow ablation with stem cell support|
58280733|NCT00275015|PROCEDURE|peripheral blood stem cell transplantation|
58280734|NCT00275015|RADIATION|radiation therapy|
58280735|NCT01240395|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
58280736|NCT01469598|DRUG|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
58280737|NCT01609088|DIETARY_SUPPLEMENT|Erythritol-containing beverage|Orange flavored beverage containing erythritol
57928690|NCT01353625|DRUG|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
57928691|NCT04908176|DRUG|Avapritinib|avapritinib tablets
58280738|NCT00966901|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
58280739|NCT00966901|DRUG|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
58280740|NCT00966901|DRUG|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
58280741|NCT00966901|RADIATION|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
57928692|NCT04908176|DRUG|midazolam|midazolam syrup
57928693|NCT01821378|DRUG|Lurasidone|Lurasidone 20 mg once daily
58069011|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
58069012|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
58069013|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
58069014|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
58069015|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
58069016|NCT02463812|DRUG|Intralipid|
58069017|NCT02463812|DRUG|Saline|
58069018|NCT00507312|DEVICE|HD medical device (ViScope)|Device
58069019|NCT00507312|DEVICE|CSIRO device|device
58280742|NCT03474146|OTHER|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
58280743|NCT03474146|OTHER|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
58280744|NCT03474146|OTHER|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
58280745|NCT05339165|BEHAVIORAL|Psychotherapy|
58280746|NCT00933985|DRUG|dexrazoxane hydrochloride|Given IV
58280747|NCT00933985|DRUG|doxorubicin hydrochloride|Given IV
58280748|NCT00933985|DRUG|obatoclax mesylate|Given IV
58280749|NCT00933985|DRUG|liposomal vincristine sulfate|Given IV
58280750|NCT00933985|OTHER|pharmacological study|Correlative studies
58280751|NCT00933985|OTHER|laboratory biomarker analysis|Correlative studies
58280752|NCT02145637|DRUG|Afatinib plus Ruxolitinib combination therapy|
58280753|NCT05433675|DRUG|Macitentan|Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
58280754|NCT00183508|BEHAVIORAL|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
58280755|NCT00183508|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
58280756|NCT00303472|DRUG|Romiplostim|
58280757|NCT02304354|DRUG|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
58280758|NCT02560623|PROCEDURE|Biopsy|Undergo biopsy
58069020|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
58069021|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
58069022|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
58069023|NCT00097916|DRUG|memantine HCl|
58069024|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
58069025|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
58280759|NCT02560623|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58280760|NCT02560623|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
58280761|NCT02560623|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
58280762|NCT03627715|DRUG|Propagermanium|Immediate release capsule
58280763|NCT03627715|DRUG|Placebo|Placebo capsule
58280764|NCT02400203|OTHER|Control|
58280765|NCT02400203|OTHER|Hemp foods|
58280766|NCT02387424|BEHAVIORAL|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
58280767|NCT02387424|BEHAVIORAL|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
58280768|NCT02530697|DRUG|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
58280769|NCT02530697|DRUG|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
58280770|NCT02530697|DRUG|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
58280771|NCT01684124|OTHER|conservative O2 therapy|target lower O2 saturation
58280772|NCT01684124|OTHER|standard care|
58280773|NCT04140084|DEVICE|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
58280774|NCT04442698|PROCEDURE|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
58396424|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
57928694|NCT01821378|DRUG|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
58280775|NCT00290654|DRUG|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
58280776|NCT00290654|PROCEDURE|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
58280777|NCT00290654|RADIATION|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
58280778|NCT01690299|DRUG|Apremilast|Apremilast 30 mg tablet orally BID
58280779|NCT01690299|DRUG|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
58280780|NCT01690299|DRUG|Placebo tablet|Placebo tablets BID
58280781|NCT01690299|DRUG|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
58280782|NCT02373137|PROCEDURE|DSAEK|
58280783|NCT02373137|PROCEDURE|DMEK|
58280784|NCT02373137|DEVICE|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
58280785|NCT02373137|DRUG|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
58280786|NCT02373137|DRUG|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
58280787|NCT02373137|DRUG|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
58280788|NCT02373137|DRUG|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
57928695|NCT01821378|DRUG|Placebo|Once Daily
57928696|NCT03267953|BEHAVIORAL|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
57928697|NCT03267953|BEHAVIORAL|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
58280789|NCT02373137|DEVICE|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
58280790|NCT00431899|BEHAVIORAL|fish oil supplementation|
57727662|NCT02811237|OTHER|HESTIA|"Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
57727663|NCT02811237|OTHER|sPESI|"Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
58280791|NCT04171856|DEVICE|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
58396425|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
58396426|NCT00104416|DRUG|Placebo|Placebo control
58396427|NCT02966145|OTHER|Observational Study|
58396428|NCT00455819|PROCEDURE|home treatment|
57928698|NCT03267953|BEHAVIORAL|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
57928699|NCT01479829|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
57928700|NCT01479829|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug
57928701|NCT01479829|DRUG|Placebo|Placebo is a manufactured capsule with no active ingredient
57928702|NCT00584168|DRUG|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
58069026|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
58069027|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
58069028|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
57928703|NCT00584168|DRUG|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
58069029|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
58069030|NCT04274361|DRUG|Ketamine|Ketamine infusion
58069031|NCT04274361|DRUG|Placebo|Placebo infusion
58069032|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
57928704|NCT05175651|BEHAVIORAL|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
57928705|NCT04872881|PROCEDURE|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
57928706|NCT04872881|PROCEDURE|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
57928707|NCT04872881|PROCEDURE|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
57928708|NCT04872881|PROCEDURE|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
58069033|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
58069034|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
57727664|NCT02343458|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
57727665|NCT02343458|DRUG|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
57727666|NCT02343458|DRUG|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
57727667|NCT02343458|DRUG|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
58069035|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
57727668|NCT01844323|OTHER|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
58069036|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
58396429|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
58396430|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
58396431|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
58306790|NCT05401175|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
57727669|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
58396432|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
57727670|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
57727671|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
57727672|NCT00418171|DRUG|Ziprasidone|
58396433|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
58396434|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
58396435|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
58396436|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
58396437|NCT00060541|PROCEDURE|Laboratory tests|
57727673|NCT00418171|DRUG|Olanzapine|
57727674|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
57727675|NCT04287933|DEVICE|Drain insertion|insertion of a drain
57727676|NCT00686400|OTHER|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
57727677|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
57928709|NCT04872881|DIAGNOSTIC_TEST|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
57928710|NCT04872881|DIAGNOSTIC_TEST|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
58396438|NCT00060541|PROCEDURE|Radiological exams|
58396439|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
58396440|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
58396441|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
58396442|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
58396443|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
57727678|NCT03701555|OTHER|PvP001 placebo|placebo
57727679|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
57727680|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
57727681|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
57727682|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
57727683|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
57727684|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
57727685|NCT03701555|OTHER|PvP002 placebo|Placebo
57727686|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
57727687|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
57727688|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
57727689|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
57727690|NCT00954369|DRUG|[F-18]W372|"The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
57727691|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
58396444|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
58396445|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
58396446|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
57727692|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
58069037|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
58069038|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
58069039|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
58069040|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
58069041|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
58280792|NCT05693025|BEHAVIORAL|Group Exercise|The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
58280793|NCT05693025|BEHAVIORAL|Behavioral Training|The study evaluates two different approaches for promoting behavior change. Participants in the Standard Training (ST) model follow the standardized Walk with Ease training to support behavior change. Participants are provided with goal setting tools and an online tracker to monitor their progress. Weekly video-based lessons, resource links and eBook content support behavior change. Primary BCTs include Goal Setting (BCT #1.1) and self-monitoring (BCT#2.3). Participants in the Enhanced Training (ET) model access the same basic content as the ST model, but the weekly education-based videos are replaced with lessons focus on habit-formation training. Student coaches are also assigned to individual participants to support behavior change efforts using motivational interviewing strategies. Thus, participants in the ET model also receive two additional theory- and evidence-based BCTs: (1) habit formation training (BCT#1.2, #1.4, #8.3) and (2 health coaching (BCT# 3.3).
58280794|NCT01889732|DEVICE|ROTEM|
58396447|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
58396448|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
58396449|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
57928711|NCT04872881|DRUG|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
57928712|NCT04872881|DRUG|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
58396450|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
57727693|NCT05995912|DRUG|etoricoxib-tramadol|Oral administration (with or without food)
57727694|NCT05995912|DRUG|Naproxen|Oral administration (with or without food)
57727695|NCT05995912|DRUG|Tramadol|Oral administration (with or without food)
57727696|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
57928713|NCT04872881|DRUG|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
57928714|NCT00145925|DRUG|Perindopril-indapamide|
57928715|NCT00145925|DRUG|Gliclazide MR-based glucose lowering|
58069042|NCT00002276|DRUG|Ibuprofen|
58069043|NCT00002276|DRUG|Zidovudine|
58069044|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
58280795|NCT01943955|BEHAVIORAL|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
58280796|NCT01717157|DRUG|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
58396451|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
58396452|NCT03493451|DRUG|Tislelizumab|Administered intravenously
58396453|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
58396454|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
57928716|NCT05374304|OTHER|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
58280797|NCT01717157|DRUG|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
58280798|NCT01717157|DRUG|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
58280799|NCT01717157|DRUG|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
58280800|NCT01717157|DRUG|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
58280801|NCT00004176|DRUG|amifostine trihydrate|
58280802|NCT00004176|DRUG|cisplatin|
58280803|NCT00004176|DRUG|etoposide|
58396455|NCT00113399|BIOLOGICAL|filgrastim|
58396456|NCT00113399|DRUG|cisplatin|
58396457|NCT00113399|DRUG|docetaxel|
58396458|NCT00113399|DRUG|fluorouracil|
58396459|NCT00113399|DRUG|paclitaxel|
58280804|NCT00004176|RADIATION|radiation therapy|
58396460|NCT00113399|RADIATION|radiation therapy|
58396461|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
58396462|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
58396463|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
58280805|NCT00003513|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58280806|NCT05952791|OTHER|Surgery|Laparoscopic transabdominal preperitoneal (TAPP) groin hernia repair
58280807|NCT05271097|OTHER|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
58280808|NCT05271097|OTHER|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
58280809|NCT01471275|DRUG|Metformin|250 mg or 500mg three times a day
58280810|NCT01471275|DRUG|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
58280811|NCT01254084|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
58280812|NCT01254084|DIETARY_SUPPLEMENT|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
58280813|NCT06174545|DRUG|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
58280814|NCT05816460|OTHER|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)
58280815|NCT05816460|OTHER|Sleep Hygiene Education (SHE)|Sleep Hygiene Education (SHE) will be provided electronically
58396464|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
58396465|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
58396466|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
58396467|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
58396468|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
58396469|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
58396470|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
58396471|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
58396472|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
58396473|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
57727697|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
58280816|NCT01309451|DRUG|Bevacizumab|intravitreal, 1.25mg., monthly
58280817|NCT01309451|DRUG|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
58280818|NCT06283407|OTHER|ICF-based cross-country comparative analysis|ICF-based cross-country comparative analysis
57727698|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
57928717|NCT02121496|BEHAVIORAL|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
57928718|NCT00024414|DRUG|DHA-paclitaxel|
57727699|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
57727700|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
57727701|NCT01924325|DRUG|placebo|
57727702|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
57727703|NCT01973790|DRUG|Z-338|100mg TID
57928719|NCT04680403|OTHER|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
57928720|NCT04147325|DRUG|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
57928721|NCT01786239|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
57928722|NCT01786239|DRUG|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
57928723|NCT01786239|DRUG|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
57928724|NCT05318222|DIAGNOSTIC_TEST|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
57928725|NCT00528567|DRUG|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
57928726|NCT00528567|DRUG|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
57928727|NCT04660071|OTHER|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
57928728|NCT04660071|OTHER|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
58280819|NCT05190965|DEVICE|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
58280820|NCT03522207|DIAGNOSTIC_TEST|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
57928729|NCT01956656|DRUG|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
57928730|NCT00931333|PROCEDURE|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
58280821|NCT03522207|DRUG|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
58280822|NCT03522207|DRUG|Placebos|placebo per os 30 minutes prior to 2nd PSG
58280823|NCT03522207|DIAGNOSTIC_TEST|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
57727704|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
57727705|NCT04020120|OTHER|questionnaires|answer questionnaires
57727706|NCT04369027|DIAGNOSTIC_TEST|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
58280824|NCT03522207|DRUG|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
58280825|NCT03522207|DRUG|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
57727707|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
57928731|NCT04873414|BIOLOGICAL|Convalescent plasma treatment|Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
57727708|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
58280826|NCT03522207|DIAGNOSTIC_TEST|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
58396474|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
58396475|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
58396476|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
58396477|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
58396478|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
58396479|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
58396480|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
58396481|NCT06274034|OTHER|Survey Administration|Ancillary studies
58396482|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
57727709|NCT00799812|DRUG|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
57727710|NCT00799812|OTHER|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
57727711|NCT00799812|OTHER|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
57727712|NCT02652728|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
58069045|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
58396483|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
58396484|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
58396485|NCT00397852|PROCEDURE|Kirschner-wires or not|
57727713|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
57727714|NCT01390012|DRUG|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
58280827|NCT04990765|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
58396486|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
58396487|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
58396488|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
58396489|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
58396490|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
58396491|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
57727715|NCT01390012|DRUG|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
57727716|NCT02754635|OTHER|Induction of labour|Induction of labour
57727717|NCT02754635|OTHER|Expectant management|Expectant management
57727718|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
57727719|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
57928732|NCT03250832|DRUG|TSR-033|TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
57928733|NCT03250832|DRUG|Dostarlimab|Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
58280828|NCT04990765|BEHAVIORAL|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
58280829|NCT04242485|OTHER|Osteopathic manipulative treatment|Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques
58280830|NCT04242485|OTHER|Sham treatment|"The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure"
57928734|NCT03250832|DRUG|mFOLFOX6|mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
58396492|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
58396493|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
58069046|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
58069047|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
58069048|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
58280831|NCT00348335|DRUG|Cyclosporine 0.05%|
58280832|NCT00348335|DRUG|Ocular lubricant|
58280833|NCT03795662|OTHER|No intervention|Obervational
57928735|NCT03250832|DRUG|FOLFIRI|FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
58280834|NCT00744406|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
58280835|NCT00744406|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
57928736|NCT03250832|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
58396494|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
57928737|NCT04035850|DRUG|Vortioxetine Tablets|Strength 5-20 mg
57928738|NCT02914691|DRUG|Dapagliflozine 10 mg once daily tablet treatment|
58069049|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
58069050|NCT00352404|DEVICE|Endomicroscope|
57928739|NCT02914691|DRUG|Placebo identical once daily tablet treatment|
58396495|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
58396496|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
58396497|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
58396498|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
58396499|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
58396500|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
58396501|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
58396502|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
58396503|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
58396504|NCT00802997|DEVICE|Placebo sham|sham procedure
58396505|NCT04616183|DRUG|Abemaciclib|Given PO
58396506|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
58396507|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
58396508|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
58396509|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
57928740|NCT00959972|DRUG|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
57928741|NCT00959972|DRUG|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
58280836|NCT00744406|DRUG|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
58396510|NCT06445647|OTHER|core Stability exercise|core stability exercise training
58396511|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
58396512|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
58069051|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
58069052|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
58280837|NCT03816007|BEHAVIORAL|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
58280838|NCT03816007|BEHAVIORAL|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
58396513|NCT01997606|OTHER|placebo|
58396514|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
58396515|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
58396516|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
58396517|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of bilateral genioglossus muscle stimulation on upper airway collapsibility during drug-induced sleep endoscopy in patients implanted with the Inspire hypoglossal nerve stimulator
58396518|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
58396519|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
58396520|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
58396521|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
58396522|NCT06660641|DEVICE|0.9 % saline|placebo
57928742|NCT02673619|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
57928743|NCT02673619|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
58280839|NCT02946021|DEVICE|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
58280840|NCT02946021|DRUG|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
58280841|NCT06108583|BEHAVIORAL|TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder|The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
58280842|NCT04725123|DIAGNOSTIC_TEST|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
58069053|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
58280843|NCT04934982|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
58280844|NCT04934982|OTHER|Total Abdominal Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
58280845|NCT05124483|BIOLOGICAL|AKS-452X|subcutaneous injection of 90 µg AKS-452X
58280846|NCT02259699|OTHER|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
58280847|NCT00910546|DEVICE|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
58280848|NCT04648527|PROCEDURE|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
58280849|NCT02642783|BEHAVIORAL|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
58280850|NCT02642783|BEHAVIORAL|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
58396523|NCT01436656|DRUG|LGX818|
58069054|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
58069055|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
58069056|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
58280851|NCT00833014|DEVICE|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
58280852|NCT05357885|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
58396524|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
58280853|NCT01043484|DRUG|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
58280854|NCT01043484|DRUG|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
58280855|NCT01461473|DEVICE|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
58280856|NCT01461473|DEVICE|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
58280857|NCT05964010|BEHAVIORAL|Standard Screening|All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report \> 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
58280858|NCT05964010|BEHAVIORAL|Standard Psychoeducation|In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
58396525|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
58396526|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
58396527|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
58396528|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
57928744|NCT00352885|DRUG|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
58396529|NCT00258765|DRUG|Zoledronic Acid|
58396530|NCT00258765|DRUG|Docetaxel|
58396531|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
58396532|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
58396533|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
58396534|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
58396535|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
58396536|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
57727720|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
57727721|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
57727722|NCT01509859|DEVICE|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
57727723|NCT01509859|DEVICE|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith\&Nephew INTERTAN proximal femur nail device"
57928745|NCT00352885|DRUG|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
58069057|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
58396537|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
58396538|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
58396539|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
58396540|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
58396541|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
57928746|NCT00352885|DRUG|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
58396542|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
57928747|NCT04706754|OTHER|Questionnaires|Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
58280859|NCT05964010|BEHAVIORAL|Standard Brief Negotiated Interview (BNI)|In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
58280860|NCT05964010|BEHAVIORAL|Standard Referral to Treatment (RT)|In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes \& Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
58280861|NCT05964010|BEHAVIORAL|Family Screening|Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach \& Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
58280862|NCT05964010|BEHAVIORAL|Family Psychoeducation|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche \& Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
58280863|NCT05964010|BEHAVIORAL|Family Brief Negotiated Interview (BNI)|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
58306791|NCT00053625|PROCEDURE|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
58306792|NCT00906126|DRUG|Misoprostol|Oral misoprostol
58306793|NCT02190188|DEVICE|Wedge Insole 5mm|
58306794|NCT02190188|DEVICE|Knee Brace|
58306795|NCT01530269|DRUG|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
58396543|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
58396544|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
58396545|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
58396546|NCT02728648|DRUG|Oxycodone|Pain Management
58396547|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
58396548|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
58396549|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
58396550|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
58396551|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
58069058|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
58069059|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
57727724|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
57727725|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
57928748|NCT04657757|OTHER|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
57928749|NCT00525889|DRUG|IL-2|Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
57928750|NCT00525889|DRUG|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
57928751|NCT03655379|DEVICE|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
57928752|NCT06449950|BEHAVIORAL|Behavioral: Verbal Oral Hygiene Instructions|OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).
57928753|NCT06449950|BEHAVIORAL|Behavioral: Video-Based Oral Hygiene Instructions|OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
57928754|NCT06290063|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
57928755|NCT06290063|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
57928756|NCT06290063|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
58280864|NCT05964010|BEHAVIORAL|Family Facilitated Conversation (FC) & Referral to Treatment (RT)|In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
58280865|NCT03029026|OTHER|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
58280866|NCT03029026|PROCEDURE|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
58280867|NCT03029026|PROCEDURE|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
58280868|NCT03029026|RADIATION|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
58280869|NCT03029026|PROCEDURE|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
58280870|NCT03029026|PROCEDURE|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
58280871|NCT03029026|OTHER|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
58280872|NCT05704179|OTHER|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
58280873|NCT00597064|DRUG|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
57928757|NCT05208801|DRUG|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
57928758|NCT05208801|DRUG|Morphine|Intrathecal injection of morphine 400mcg
57928759|NCT05208801|DRUG|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
57928760|NCT02847351|DIETARY_SUPPLEMENT|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
58069060|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
58280874|NCT03102008|BEHAVIORAL|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
58280875|NCT01304290|OTHER|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
58280876|NCT05259618|OTHER|Tasso+ SST|alternative site blood sample collection.
58396552|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
58280877|NCT00695214|DRUG|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
58280878|NCT00511654|DRUG|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
58280879|NCT00511654|DRUG|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
58280880|NCT00511654|DRUG|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
58280881|NCT03092791|BIOLOGICAL|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
58280882|NCT03092791|BIOLOGICAL|Reference IPV|Reference IPV intramuscular injection
58280883|NCT03092791|BIOLOGICAL|sIPV Placebo|sIPV placebo-matching intramuscular injection
58280884|NCT00230984|BEHAVIORAL|education|
58280885|NCT00230984|DRUG|Oral dietary supplements (563 kcal/d), RESPIFOR|
58280886|NCT00230984|BEHAVIORAL|exercises on an ergometric bicycle 3 to 5 times a week|
58280887|NCT00230984|DRUG|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
58280888|NCT04721639|OTHER|Sphinx Yoga Therapy|Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
58280889|NCT03376126|OTHER|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
58280890|NCT02974803|DRUG|Dabrafenib|Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
58280891|NCT02974803|DRUG|Trametinib|Trametinib 2 mg once daily until progression or unaccepted toxicity.
58280892|NCT03246191|OTHER|blood sample collection|blood sample collection
58280893|NCT01554163|DRUG|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
58280894|NCT01554163|DRUG|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
58280895|NCT03170609|BIOLOGICAL|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
58280896|NCT03170609|BIOLOGICAL|Placebo|Saline Control
58280897|NCT02870764|DRUG|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
58280898|NCT02870764|DRUG|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
58280899|NCT02870764|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
58280900|NCT00792714|DRUG|Mannitol|400mg twice daily for 7 days
58280901|NCT00662987|DRUG|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
58280902|NCT00662987|DRUG|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
58280903|NCT01482299|DRUG|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
58280904|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
58280905|NCT02187029|OTHER|Placebo|Daily dosing (tablet) for 14 days
58280906|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
58280907|NCT02187029|OTHER|Placebo|Daily dosing (tablets) for 14 days
58280908|NCT00270504|DEVICE|Memokath stenting|Urethral Stenting
58280909|NCT02298036|BEHAVIORAL|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
58396553|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
57928761|NCT01875822|DIETARY_SUPPLEMENT|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
57928762|NCT01381354|OTHER|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
58396554|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
58396555|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
57928763|NCT01381354|DEVICE|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
57928764|NCT01381354|OTHER|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
57928765|NCT01381354|DIETARY_SUPPLEMENT|Omega 3 fatty acids|4 grams daily by mouth.
57928766|NCT01381354|DIETARY_SUPPLEMENT|Full Spectrum vitamin|Two capsules daily.
57928767|NCT01381354|DIETARY_SUPPLEMENT|Essential - hydroxytyrosol|Two capsules twice daily.
57928768|NCT01381354|DIETARY_SUPPLEMENT|Maltodextrin fiber supplement|One scoop daily.
57928769|NCT01381354|DIETARY_SUPPLEMENT|Mineral boost (magnesium)|Two capsules daily
57928770|NCT01381354|DIETARY_SUPPLEMENT|Niacinamide|500 mg daily
57928771|NCT01381354|DIETARY_SUPPLEMENT|Methyl B12|Methyl B12 1000 mcg daily
57928772|NCT01381354|DIETARY_SUPPLEMENT|Taurine|one gram daily
57928773|NCT01381354|DIETARY_SUPPLEMENT|creatine|one teaspoon daily
57928774|NCT01381354|DIETARY_SUPPLEMENT|thiamine|100 mg daily
58280910|NCT01793350|DRUG|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
58280911|NCT06494618|DEVICE|Radial Extracorporeal Shockwave Therapy|1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
58280912|NCT00392756|DRUG|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
57928775|NCT01381354|DIETARY_SUPPLEMENT|riboflavin|200 mg daily
58280913|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
58280914|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
58280915|NCT04624607|DEVICE|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
57928776|NCT01381354|DIETARY_SUPPLEMENT|N acetylcysteine|1 gram daily
57928777|NCT01381354|DIETARY_SUPPLEMENT|alpha lipoic acid|300 mg twice daily
57928778|NCT01381354|DIETARY_SUPPLEMENT|L acetyl carnitine|500 mg twice daily
57928779|NCT01381354|DIETARY_SUPPLEMENT|methyl folate|1000 mcg one pill four times a week
57928780|NCT01381354|DIETARY_SUPPLEMENT|coenzyme Q|100 mg daily
57928781|NCT01381354|BEHAVIORAL|meditation|meditation 15 minutes daily
57928782|NCT01381354|BEHAVIORAL|self massage|self massage of hands, feet, ears 15 minutes daily
57928783|NCT01381354|BEHAVIORAL|learning|completing puzzles or learning 15 minutes daily
57928784|NCT01381354|DIETARY_SUPPLEMENT|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
57928785|NCT01869075|OTHER|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
57928786|NCT02877927|DRUG|Omadacycline|po tablets
57928787|NCT02877927|DRUG|Linezolid|po tablets
57928788|NCT05116046|BIOLOGICAL|Recifercept|Recifercept
57928789|NCT02435589|OTHER|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
57928790|NCT02435589|OTHER|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
57928791|NCT00795951|BIOLOGICAL|T.R.U.E. Test|48 hour application of 28 allergens and negative control
57928792|NCT02884427|DEVICE|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
57928793|NCT02884427|DEVICE|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
57727726|NCT00752375|DRUG|Trimethoprim Sulfamethoxazole|"* Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
57727727|NCT00752375|DRUG|placebo|"* Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
57727728|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
57928794|NCT02884427|DEVICE|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
57928795|NCT02847741|OTHER|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
58280916|NCT04624607|DEVICE|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
58280917|NCT03190785|OTHER|Benzoic acid washout and exposure|see above
58280918|NCT05913596|DRUG|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
58280919|NCT03545633|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
58280920|NCT00968357|DRUG|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
58280921|NCT01841801|DEVICE|Thermal Adhesive Patch|
58280922|NCT01841801|DEVICE|Marketed Thermal Adhesive Patch|
57727729|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
57928796|NCT06257992|OTHER|Dry Needling|3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
57928797|NCT06257992|OTHER|Stretch|3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
57928798|NCT01554488|DRUG|Inhaled Fluticasone Propionate|Inhaled corticosteroid
57928799|NCT01875536|DEVICE|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
58280923|NCT01841801|DEVICE|Placebo Patch|
58280924|NCT01924104|DRUG|Low molecular weight heparin|2500 mIU/day, subcutaneously
58280925|NCT01924104|DRUG|Low dose aspirin|75 mg/day, orally
57727730|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
57727731|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
57928800|NCT01875536|BEHAVIORAL|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
58069061|NCT02906644|DRUG|lorcaserin|
57727732|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
57727733|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
57727734|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
57928801|NCT01442116|PROCEDURE|stress echocardiography|safety and efficacy of stress echocardiography
57928802|NCT00010062|DRUG|fluorouracil|
57928803|NCT00010062|RADIATION|radiation therapy|
57928804|NCT01678209|OTHER|fMRI scans|2 fMRI scans 6-8 weeks apart
57928805|NCT01678209|DRUG|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
57928806|NCT01678209|DRUG|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
57928807|NCT00154076|DRUG|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
57928808|NCT00154076|DRUG|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
58069062|NCT02906644|DRUG|nicotine patch|
58396556|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
58396557|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
58280926|NCT01924104|DRUG|Heparin & aspirin|Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)
58396558|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
58396559|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
58396560|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
58396561|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
58396562|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
58396563|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
58396564|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
58280927|NCT01924104|OTHER|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
57928809|NCT04608669|DRUG|Paracetamol|Give paracetamol or placebo and compare temperature
57928810|NCT03248934|OTHER|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
58280928|NCT00404833|DRUG|prednisolone and mycophenolate mofetil|
58280929|NCT00404833|DRUG|prednisolone and chlorambucil|
57727735|NCT04180826|OTHER|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
57928811|NCT03248934|OTHER|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
57928812|NCT03228758|PROCEDURE|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
57727736|NCT00411021|PROCEDURE|Pipelle (Endometrial Sampling)|
57928813|NCT03027557|DRUG|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
57928814|NCT03027557|DRUG|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
58069063|NCT02906644|DRUG|placebo lorcaserin|
58069064|NCT00034476|DRUG|sPLA2 Inhibitor|
58280930|NCT00521885|DRUG|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
58280931|NCT00521885|DRUG|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
58280932|NCT01520519|DRUG|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
58280933|NCT01520519|DRUG|PCI-32765|420 mg (3 \* 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
58396565|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
58396566|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
58396567|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
58396568|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
58396569|NCT02118181|DIETARY_SUPPLEMENT|HMB|
58396570|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396571|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
58396572|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396573|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396574|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58280934|NCT03778060|DEVICE|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
58280935|NCT01982799|DRUG|Oral placebo|placebo
58280936|NCT01982799|DRUG|Oral ibuprofen|Ibuprofen
58280937|NCT01982799|DRUG|oral naproxen|naproxen
58280938|NCT01982799|DRUG|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
58396575|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396576|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
57727737|NCT01744236|DRUG|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
57727738|NCT01744236|DRUG|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
57727739|NCT01744236|DRUG|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
58280939|NCT00343655|DRUG|Atorvastatin|
58280940|NCT00039481|BIOLOGICAL|oblimersen sodium|Given IV
58280941|NCT00039481|DRUG|dexrazoxane hydrochloride|Given IV
58280942|NCT00039481|DRUG|doxorubicin hydrochloride|Given IV
58280943|NCT00039481|DRUG|cyclophosphamide|Given IV
58280944|NCT00039481|BIOLOGICAL|filgrastim|Given SC
58280945|NCT00039481|OTHER|laboratory biomarker analysis|Correlative studies
58280946|NCT00039481|OTHER|pharmacological study|Correlative studies
58280947|NCT03337048|DEVICE|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
58306796|NCT05123573|BEHAVIORAL|Clinical Skills|evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
58306797|NCT01768663|DRUG|Lumacaftor|tablet, 200mg taken every 12 hours
58306798|NCT01768663|DRUG|Ivacaftor|tablet, 250mg taken every 12 hours
58306799|NCT01768663|DRUG|Ciprofloxacin|750 mg taken every 12 hours
58069065|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
58396577|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396578|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396579|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
58396580|NCT06659991|DRUG|alcohol condition|Ethanol
57727740|NCT01744236|DRUG|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
58396581|NCT06659991|OTHER|control condition|sparkling water
57928815|NCT03027557|OTHER|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
58396582|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
57928816|NCT03027557|OTHER|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
57928817|NCT00596934|DRUG|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
57928818|NCT06141044|PROCEDURE|Avoid surgical drainage|Patients who undergo distal pancreatectomy, avoid placing a drain.
57928819|NCT02929745|PROCEDURE|Skin biopsy|Four 4-5 mm punch biopsies of the skin
58069066|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
57928820|NCT02929745|PROCEDURE|Blood draw|Blood will be drawn to test for HLA-cw6 status
57928821|NCT03343951|OTHER|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~* diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~* if the patient needs a new appointment at the shoulder clinic~* if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
57928822|NCT06093789|OTHER|PBQ-S1|All patients will fill out Personality Belief Scale-Short Form (PBQ-S1) and Beck Anxiety Scale one day before the procedure and they will be registered.
57928823|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
57928824|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
57928825|NCT01856166|DRUG|Levobupivacaine|
58069067|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
58069068|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
58306800|NCT01768663|DRUG|Itraconazole|200mg taken once daily
58396583|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
58396584|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
57928826|NCT01856166|DRUG|Sufentanil|
58069069|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
58069070|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
58069071|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
58306801|NCT01768663|DRUG|Rifampin|600mg taken once daily
57727741|NCT01744236|DRUG|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
57928827|NCT00301223|DRUG|Pregabalin|
57928828|NCT00786825|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
57928829|NCT01920594|DRUG|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
57928830|NCT01920594|DRUG|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
58280948|NCT06172790|OTHER|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
58280949|NCT04939844|DRUG|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
58396585|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
58396586|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
57727742|NCT01744236|DRUG|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
57727743|NCT01744236|DRUG|L-NMMA|
57928831|NCT06188169|PROCEDURE|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
57727744|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
57928832|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
57928833|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
57928834|NCT06119009|OTHER|non interventions|
57928835|NCT04624490|DRUG|Hyperpolarized Xe129|During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
57928836|NCT02357823|OTHER|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
57727745|NCT03498534|DRUG|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
57727746|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
57727747|NCT02083523|BEHAVIORAL|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
57928837|NCT02357823|OTHER|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
57928838|NCT02160704|DRUG|Enclomiphene citrate|25 mg daily for 16 weeks
58069072|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
57727748|NCT02083523|BEHAVIORAL|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
57928839|NCT02160704|OTHER|Placebo|placebo daily for 16 weeks
57928840|NCT02157350|PROCEDURE|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
58069073|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
57928841|NCT02849301|DEVICE|Arabin cervical pessary|
57928842|NCT06094426|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
57928843|NCT05294354|BEHAVIORAL|aerobic exercise group (AE)|The participants will ride the cycle ergometer for 35 minutes. The training consisted of a 5-minute warm-up period followed by 25 minutes of moderate exercise and a 5-minute recovery.
58069074|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
58069075|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
58069076|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
58069077|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
58280950|NCT01713296|DRUG|Pazopanib|
58280951|NCT03601156|DEVICE|intraarterial chemoembolization|
58280952|NCT03601156|DEVICE|intravenous chemotherapy|
58069078|NCT00056472|DRUG|Olanzapine|10-20mg/day
58069079|NCT00056472|DRUG|Sertraline|150-200mg/day
58069080|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
58396587|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
58396588|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
58069081|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
57928844|NCT05294354|BEHAVIORAL|aerobic exercise with virtual reality group (AE-VR)|The participants will receive the 3D VR training program and ride the cycle ergometer at the same time. The training protocol is similar to the aerobic exercise group.
57928845|NCT05294354|BEHAVIORAL|combined exercise group (CE)|The intervention consists of 5-minutes aerobic warm-up, 25-minutes bodyweight exercise, and 5-minutes mindfulness meditation for recovery. The participants will follow the video to do the program.
58069082|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
58069083|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
58396589|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
57928846|NCT05294354|BEHAVIORAL|Control group|Participants will watch a 35-min video about exercise science.
57928847|NCT03889431|DIETARY_SUPPLEMENT|Iodine capsule|225 µg of iodine daily as a capsule of potassium iodide
57928848|NCT03889431|OTHER|Iodized Salt|450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
58069084|NCT00302731|DRUG|Estradiol , estriol , progesterone|
58069085|NCT00302731|DRUG|estradiol, progesterone|
58280953|NCT01556230|PROCEDURE|Surgical intervention for CNFA|(non-experimental) standard procedure
58069086|NCT00302731|DRUG|estriol, progesterone|
58280954|NCT01556230|RADIATION|Radiotherapy for CNFA|(non-experimental) standard procedure
58280955|NCT03102749|OTHER|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
58280956|NCT01588405|DRUG|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
58280957|NCT01153789|PROCEDURE|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
58396590|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
58396591|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
58396592|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
58396593|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
57928849|NCT00296179|DRUG|zolpidem tartrate|
58280958|NCT01153789|OTHER|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
58280959|NCT04864145|DEVICE|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
58280960|NCT04864145|DRUG|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
57928850|NCT00372021|PROCEDURE|optic nerve neurotomy|
57928851|NCT01241552|BIOLOGICAL|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
57928852|NCT01241552|BIOLOGICAL|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
57928853|NCT01241552|BIOLOGICAL|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
57928854|NCT01241552|BIOLOGICAL|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
57928855|NCT01241552|DRUG|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
57928856|NCT06397807|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.
57928857|NCT06397807|DRUG|Analgesic injectables|Opioids, NSAIDs or acetamol will be administrated as need.
57928858|NCT06397807|DRUG|Enteral analgesics|Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
58280961|NCT06311071|DIAGNOSTIC_TEST|calcium score|Calcium score of coronaries obtained fro coronary CT angiography
58396594|NCT03037359|BIOLOGICAL|Other|Human immune globulin
57928859|NCT04699734|DIAGNOSTIC_TEST|Xylocaine 1%|Nerve block
57928860|NCT04699734|DIAGNOSTIC_TEST|NaCl 9mg/ml|Nerve block
58069087|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
58069088|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
58069089|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
58069090|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
58069091|NCT02049385|DRUG|Placebo|Placebo
58280962|NCT06311071|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography from radial artery with contrast injection
57727749|NCT02252055|BIOLOGICAL|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
57727750|NCT02855060|DEVICE|Pelvic Binder|
57727751|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
57727752|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
57727753|NCT05903274|DRUG|JSP191|Subjects will receive intravenous JSP191
57727754|NCT06298006|OTHER|Follow-up|Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
57727755|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
57727756|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
57727757|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
57727758|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
57727759|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
57727760|NCT00207441|BEHAVIORAL|Arthritis Self management program|
57727761|NCT00207441|BEHAVIORAL|Chronic Disease Self Management Program|
57727762|NCT05858528|DIAGNOSTIC_TEST|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
57928861|NCT00652392|DRUG|budesonide/formoterol|
57928862|NCT00652392|DRUG|budesonide and placebo|
57928863|NCT05564871|OTHER|occupation-based teleintervention|Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.
57727763|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
57727764|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
57727765|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
58280963|NCT00915265|OTHER|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
57727766|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
57928864|NCT02746666|BEHAVIORAL|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
57928865|NCT06062225|PROCEDURE|Kamikawa|Kamikawa reconstruction after proximal gastrectomy
57928866|NCT06062225|PROCEDURE|STJI|Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy
57928867|NCT06062225|PROCEDURE|SOFY|SOFY reconstruction after proximal gastrectomy
57928868|NCT01386658|DRUG|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
57928869|NCT01270087|DRUG|Adalimumab|40 mg IV every 14 days
58396595|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
58396596|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
58069092|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
58280964|NCT00915265|OTHER|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
58280965|NCT00140036|PROCEDURE|Blood draw|
58280966|NCT03077100|OTHER|Laboratory identification of positive cultures|Laboratory identification of positive cultures
58280967|NCT06122467|OTHER|EQ Exfoliating Cleanser|Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
58280968|NCT06122467|OTHER|EQ Gel|Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
58280969|NCT06122467|OTHER|EQ Moisturizer|Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
58280970|NCT04121767|DRUG|Edoxaban|oral edoxaban 60mg once daily for 3 months
58280971|NCT04121767|DRUG|Warfarin|oral warfarin once daily for 3 months according to prothrombin time
58280972|NCT04460963|OTHER|Adrenomedullin|Adrenomedullin sample evaluation
58280973|NCT04054674|PROCEDURE|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
58280974|NCT00265408|DRUG|aspirin|
58280975|NCT00265408|DRUG|warfarin|
58280976|NCT06210815|DRUG|HLX42|HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
58280977|NCT02455973|BEHAVIORAL|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
58396597|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
58396598|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
58280978|NCT02455973|BEHAVIORAL|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
58280979|NCT00999700|DRUG|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
58280980|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
58280981|NCT00999700|DRUG|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
58280982|NCT00999700|DRUG|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
57928870|NCT02119325|DIETARY_SUPPLEMENT|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
58069093|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
58069094|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
58069095|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
58069096|NCT02540811|DEVICE|dCELL® ACL Scaffold|
58069097|NCT00055939|DRUG|exatecan mesylate|
58069098|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
58396599|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
58069099|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
58069100|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
58069101|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
58069102|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
58396600|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
57727767|NCT02298218|DRUG|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
57727768|NCT01855009|DIETARY_SUPPLEMENT|MannaBears|Subjects will be administered 4 MannaBears daily
57727769|NCT01855009|DIETARY_SUPPLEMENT|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
58069103|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
57727770|NCT01855009|DIETARY_SUPPLEMENT|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
57727771|NCT01855009|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be administered 800 IU vitamin D3
57727772|NCT04108312|DIAGNOSTIC_TEST|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
57727773|NCT01899924|BEHAVIORAL|Event Related Potentials recording|
58396601|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
58396602|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
57727774|NCT01019655|DRUG|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
57727775|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
57727776|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
57727777|NCT05794867|DIAGNOSTIC_TEST|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
57727778|NCT04413604|OTHER|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
57928871|NCT02119325|DIETARY_SUPPLEMENT|0% fibre|Placebo is an energy matched powdered beverage
58069104|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
58069105|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
58069106|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
58069107|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
58396603|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
58396604|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
58396605|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
58396606|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
58396607|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
58280983|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
58280984|NCT01954199|PROCEDURE|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
58280985|NCT06033677|PROCEDURE|Distal radial artery cannulation|Interventional application for invasive blood pressure monitoring
58280986|NCT06033677|PROCEDURE|Forearm radial artery cannulation|Interventional application for invasive blood pressure monitoring
58280987|NCT05200845|OTHER|Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose|Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
58396608|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
58069108|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
58069109|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
58069110|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
58280988|NCT05200845|OTHER|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose|Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
58280989|NCT05200845|OTHER|High-Fat Test Meal Inside a Metabolic Chamber|A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
58280990|NCT05200845|OTHER|High-Carbohydrate Test Meal Inside a Metabolic Chamber|A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
58280991|NCT00823758|BEHAVIORAL|Focus Groups|6 to 8 participants per group.
58280992|NCT00823758|BEHAVIORAL|Personal Interviews|Conducted by phone and audiotaped.
58280993|NCT03832673|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
58280994|NCT03832673|DRUG|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
58280995|NCT05284903|OTHER|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
58280996|NCT05284903|OTHER|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
58280997|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
58280998|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
58280999|NCT00596063|BIOLOGICAL|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
58281000|NCT00596063|BIOLOGICAL|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
57928872|NCT05257408|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
57928873|NCT05257408|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
57928874|NCT05257408|DRUG|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
57928875|NCT04410250|BEHAVIORAL|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
57928876|NCT02512198|BEHAVIORAL|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
57928877|NCT02493894|DRUG|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
57928878|NCT02493894|DRUG|placebo|placebo each 8 hours for 24 hours
58069111|NCT02833142|DRUG|BIIB033 (opicinumab)|
57928879|NCT02493894|DRUG|Cefazolin|cefazolin 1gram, every 6hours for 2 days
57928880|NCT02047825|OTHER|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
57928881|NCT02047825|OTHER|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
57928882|NCT01318720|OTHER|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
57928883|NCT01047696|DEVICE|Plancha|locally developed chimney stove
57928884|NCT00016263|BIOLOGICAL|oblimersen sodium|
57928885|NCT00016263|DRUG|dacarbazine|
57928886|NCT01116141|DRUG|CH-4051|Different doses CH-4051 to be compared
57928887|NCT01116141|DRUG|Methotrexate (MTX)|20 mg MTX weekly
57928888|NCT01116141|DRUG|Folic Acid|1 mg folic acid daily
57928889|NCT04586595|OTHER|REVISiT intervention|REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
57928890|NCT06010069|DIAGNOSTIC_TEST|body temperature measurament|body temperature of every patient was measured with tympanic thermometer during surgical procedure
57928891|NCT05033808|DRUG|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
57928892|NCT05033808|DRUG|Placebo|NaCl is given once over 15 Minutes via a central line
57928893|NCT06379308|OTHER|questionaries|"Questionaries will be administered :~* Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI)~* Tegner Activity Scale (TAS)~* Simple Knee Value (SKV)~* International Knee Documentation Commitee (IKDC)"
58069112|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
58069113|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
58069114|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
58069115|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
58069116|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
58069117|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
58069118|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
58069119|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
58069120|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
58069121|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
58069122|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
58069123|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
58069124|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
58069125|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
58069126|NCT00004795|DRUG|dehydroepiandrosterone|
58069127|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
58069128|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
58069129|NCT00987558|DRUG|Eslicarbazepine acetate|
58069130|NCT00987558|DRUG|Simvastatin|
58069131|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
58069132|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
58281001|NCT03052348|OTHER|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
58281002|NCT03052348|OTHER|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
58069133|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
58069134|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
58069135|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
58069136|NCT00000912|DRUG|Indinavir sulfate|
58396609|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
58069137|NCT00000912|DRUG|Abacavir sulfate|
58069138|NCT00000912|DRUG|Amprenavir|
58069139|NCT00000912|DRUG|Nelfinavir mesylate|
58069140|NCT00000912|DRUG|Efavirenz|
58069141|NCT00000912|DRUG|Levocarnitine|
58069142|NCT00000912|DRUG|Adefovir dipivoxil|
58069143|NCT00000912|DRUG|Saquinavir|
58069144|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
58069145|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
58069146|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
58069147|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
58069148|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
58069149|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
58069150|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
58069151|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
58069152|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
58069153|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
58281003|NCT05790668|BEHAVIORAL|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
58306802|NCT00843492|DRUG|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
57928894|NCT06379308|OTHER|datas of medical record|datas of medical record will be collected : epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication.
57928895|NCT05061563|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
57928896|NCT05061563|DRUG|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
57928897|NCT05817175|PROCEDURE|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
57928898|NCT05229926|DEVICE|CareCube|modular, disposable, negative pressure, isolation patient care system
57928899|NCT00711256|OTHER|sunscreen MATAS sunlotion SPF 8|
57928900|NCT00711256|RADIATION|UVB light|duration 4 times 1 minute radiation on the trunk.
57928901|NCT04273698|BEHAVIORAL|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
57928902|NCT01121978|PROCEDURE|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
58069154|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
58069155|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
58069156|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
58069157|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
58069158|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
58069159|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
58069160|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
58069161|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
58069162|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
58069163|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
58069164|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
58069165|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
57727779|NCT06024304|DEVICE|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
57727780|NCT06024304|DEVICE|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
58281004|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
58281005|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
57727781|NCT06189040|DRUG|BNT162b2 30µg|intramuscular administration of 30µg
57928903|NCT06191471|OTHER|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis
57928904|NCT03956368|DRUG|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
57928905|NCT03956368|DRUG|Placebos|20mg (every evening orally) for 8 weeks.
57928906|NCT03598322|PROCEDURE|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
57928907|NCT03598322|PROCEDURE|Dextrose 2mL injection|Dextrose 2mL injection
57928908|NCT03598322|PROCEDURE|Dextrose 4mL injection|Dextrose 4mL injection
57928909|NCT03619538|DRUG|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
57928910|NCT03619538|OTHER|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
57928911|NCT02921269|DRUG|Atezolizumab|Given IV
57928912|NCT02921269|BIOLOGICAL|Bevacizumab|Given IV
57727782|NCT06189040|DRUG|BNT162b2 20µg|intramuscular administration of 20µg
57727783|NCT06189040|DRUG|BNT162b2 6µg|intradermal administration of 6µg
57928913|NCT02921269|OTHER|Laboratory Biomarker Analysis|Correlative studies
57928914|NCT05783102|BEHAVIORAL|Knowledge and Interpersonal Skills to Develop Exemplary Relationships|During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
57928915|NCT01480453|DEVICE|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
57928916|NCT04638582|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
57928917|NCT04638582|DRUG|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
57928918|NCT04638582|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
58396610|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
58281006|NCT00868751|BIOLOGICAL|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
58281007|NCT01967979|DRUG|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
58069166|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
58281008|NCT01967979|DRUG|fluoxetine|Multiple doses
58281009|NCT01967979|DRUG|itraconazole|Multiple doses
58281010|NCT03280745|DRUG|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
58281011|NCT03280745|DRUG|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
58281012|NCT04691167|DEVICE|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
58281013|NCT00084877|DRUG|triapine|Given IV
58281014|NCT00084877|DRUG|irinotecan hydrochloride|Given IV
58281015|NCT00084877|OTHER|laboratory biomarker analysis|Correlative studies
58281016|NCT00084877|OTHER|pharmacological study|Correlative studies
58281017|NCT03370692|OTHER|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
58281018|NCT04012346|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
58069167|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
58069168|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
58069169|NCT00627991|DRUG|Valsartan|
58281019|NCT06485011|PROCEDURE|Paltysma suturing|platysma muscle was sutured in this group with vicryl
58281020|NCT06485011|PROCEDURE|Without Platysma suturing|platysma muscle was not sutured in this group
58281021|NCT05172401|DEVICE|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
58281022|NCT01313013|BEHAVIORAL|question prompt sheet|
58281023|NCT03797131|OTHER|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
58281024|NCT01268189|DEVICE|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
58281025|NCT01268189|DEVICE|Standard of care dressing|Xeroform control dressing applied to control wound
58306803|NCT00843492|DRUG|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
58306804|NCT05273762|DEVICE|FlowTriever|Mechanical thrombectomy for pulmonary embolism
57928919|NCT04638582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
57928920|NCT00947778|OTHER|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
57727784|NCT06189040|DRUG|mRNA-1273 100µg|intramuscular administration of 100µg
57928921|NCT00947778|OTHER|1 training session|20 sessions of 30 minutes by week during 24 semaines
57928922|NCT05193240|DIAGNOSTIC_TEST|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
57928923|NCT03106181|DEVICE|iStent inject®|Insertion of iStent inject®
57928924|NCT03106181|PROCEDURE|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
57928925|NCT04095078|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
57928926|NCT04436237|OTHER|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
57928927|NCT05041036|DRUG|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
57928928|NCT04028908|DIAGNOSTIC_TEST|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
57928929|NCT03656978|BEHAVIORAL|dynamic|Use the according methods in dynamic arm descriptions.
57928930|NCT03656978|BEHAVIORAL|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
57928931|NCT05528250|OTHER|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
58281026|NCT00842777|BEHAVIORAL|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
58281027|NCT00842777|BEHAVIORAL|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
58281028|NCT00994214|DRUG|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
58281029|NCT00828269|PROCEDURE|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
58281030|NCT01270321|DRUG|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
58281031|NCT01270321|DRUG|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
58281032|NCT01270321|DRUG|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
58281033|NCT02891486|PROCEDURE|Spinal surgery|Elective spinal surgery performed
58281034|NCT01903759|OTHER|Blood samples|
57727785|NCT06189040|DRUG|mRNA-1273 50µg|intramuscular administration of 50µg
57727786|NCT06189040|DRUG|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10\^8 infectious units
57727787|NCT03574792|DRUG|Gabapentin|Given PO
57727788|NCT03574792|DRUG|Methadone|Given PO
57727789|NCT03574792|DRUG|Oxycodone|Given PO
58069170|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
58069171|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
58281035|NCT02142205|BIOLOGICAL|BG00002|IV Infusion
57727790|NCT03574792|OTHER|Quality-of-Life Assessment|Ancillary studies
57727791|NCT03574792|OTHER|Questionnaire Administration|Ancillary studies
57727792|NCT03574792|DRUG|Venlafaxine|Given PO
57727793|NCT03574792|DRUG|Venlafaxine Hydrochloride Extended Release|Given PO
57727794|NCT05262153|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
57727795|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
57727796|NCT02283814|DRUG|BIA 2-093|
57727797|NCT02283814|DRUG|Topamax|
58396611|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
58396612|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
58396613|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
58396614|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
57928932|NCT05528250|DEVICE|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
57928933|NCT01297413|BIOLOGICAL|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
58069172|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
58069173|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
58281036|NCT01017601|BIOLOGICAL|Seneca Valley virus-001|Given IV
58396615|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
58396616|NCT02337998|OTHER|load carriage|
58396617|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
58396618|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
58069174|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
58069175|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
58069176|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
58069177|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
58069178|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
58069179|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
58069180|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
58281037|NCT01017601|OTHER|placebo|Given IV
58281038|NCT03840408|OTHER|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
58281039|NCT03840408|PROCEDURE|Surgery|Patients will be treated with surgery
58281040|NCT01390428|DRUG|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
58281041|NCT00913770|BEHAVIORAL|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
58396619|NCT02550288|DRUG|Ezetimibe 10 mg|
58069181|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
58069182|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
58069183|NCT02926833|DRUG|Fludarabine|Administered intravenously
58069184|NCT05015959|OTHER|observation|quality
58069185|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
58069186|NCT00768040|DRUG|Aliskiren|300 mg once daily
58069187|NCT00768040|DRUG|Placebo|Matching placebo once daily
58281042|NCT00913770|DRUG|Buprenorphine Initiation|
57727798|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
58396620|NCT02550288|DRUG|Atorvastatin 10 mg|
58396621|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
58396622|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
58396623|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
58396624|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
58396625|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
57928934|NCT01556035|DRUG|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
57928935|NCT03516851|PROCEDURE|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
57928936|NCT03434353|DRUG|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
57928937|NCT03434353|DRUG|TAF|Administered orally once daily with food
57928938|NCT03259594|PROCEDURE|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
57928939|NCT03259594|DRUG|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
57928940|NCT01118325|DRUG|ticagrelor|Drug oral treatment
58281043|NCT04437797|PROCEDURE|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
58281044|NCT04437797|PROCEDURE|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
57928941|NCT01118325|DRUG|clopidogrel|Drug oral treatment
58281045|NCT04957784|OTHER|questionnaire survey|Understand the current situation of hypertension management in a poor county in Shanxi Province through questionnaire surveys, and explore the factors that affect patients' blood pressure control based on local conditions
58281046|NCT03652688|BEHAVIORAL|Three 0's|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
58281047|NCT03652688|BEHAVIORAL|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
58281048|NCT02913105|DRUG|LMB763|Hard Gelatin Capsules
58281049|NCT02913105|DRUG|Placebo|Hard Gelatin Capsule
58281050|NCT05537285|DEVICE|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
58281051|NCT05537285|DEVICE|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
58281052|NCT05537285|DEVICE|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
57928942|NCT00253487|DRUG|O6-benzylguanine|
57928943|NCT00253487|DRUG|busulfan|
57928944|NCT00253487|DRUG|temozolomide|
57928945|NCT00253487|PROCEDURE|adjuvant therapy|
57928946|NCT00253487|PROCEDURE|autologous bone marrow transplantation|
57928947|NCT00253487|PROCEDURE|conventional surgery|
57928948|NCT00253487|PROCEDURE|peripheral blood stem cell transplantation|
57928949|NCT00253487|RADIATION|radiation therapy|
57928950|NCT00523718|DRUG|riluzole|50 mg PO bid, 12 weeks
58396626|NCT02454439|OTHER|CRT implantation|
57928951|NCT00523718|DRUG|placebo|placebo, 1 capsule PO bid, 12 weeks
57928952|NCT02087748|DRUG|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
57928953|NCT02087748|DRUG|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
57928954|NCT04097522|OTHER|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
57928955|NCT01521819|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
57928956|NCT01521819|DRUG|Lucentis|Intravitreal injection of Lucentis as needed.
58396627|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
57928957|NCT05678322|DRUG|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
57928958|NCT05678322|DEVICE|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
58069188|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
58069189|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
58069190|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
58281053|NCT05035849|DRUG|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
57928959|NCT01770912|DRUG|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
57928960|NCT01770912|DRUG|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
57928961|NCT01019291|OTHER|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
57928962|NCT01019291|OTHER|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
58281054|NCT03873311|DRUG|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
58281055|NCT03873311|DRUG|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
58281056|NCT01879202|DRUG|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
58281057|NCT01879202|DRUG|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
58281058|NCT03913871|BEHAVIORAL|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
58281059|NCT03913871|BEHAVIORAL|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
58281060|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
58281061|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
58281062|NCT01038752|DRUG|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
58396628|NCT00788931|DRUG|IV LBH589|
58396629|NCT00788931|DRUG|Oral LBH589|
58396630|NCT00788931|DRUG|trastuzumab|
58396631|NCT00788931|DRUG|paclitaxel|
57928963|NCT04379648|OTHER|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
57928964|NCT03872232|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
57928965|NCT03872232|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
57928966|NCT02870699|DEVICE|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
57928967|NCT02870699|DEVICE|Placebo excipient|film forming excipient solution
58396632|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
58396633|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
58281063|NCT01038752|DRUG|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
58281064|NCT04825613|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
58281065|NCT00135356|DRUG|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
58281066|NCT00135356|DRUG|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor \[PI\] combination + 2 NRTIs
58281067|NCT05732077|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
58281068|NCT05732077|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
58281069|NCT05732077|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
58281070|NCT03013790|DRUG|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
58281071|NCT04086381|DIETARY_SUPPLEMENT|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
58281072|NCT04086381|DIETARY_SUPPLEMENT|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
58396634|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
58396635|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
58396636|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
58396637|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
58396638|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
58396639|NCT00487942|DRUG|placebo|placebo
58396640|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
58396641|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
58396642|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
58281073|NCT00552890|OTHER|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
58281074|NCT00552890|OTHER|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
58281075|NCT06485570|OTHER|creative drama training|"The trainings prepared by the researcher in line with the literature information on Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with creative drama teaching method to the experimental group. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
58281076|NCT06485570|OTHER|control|control group
58281077|NCT02593955|BEHAVIORAL|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
58396643|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
58396644|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
58396645|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
58396646|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
58396647|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
58396648|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
58396649|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
58396650|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
58396651|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
58396652|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
58396653|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
58396654|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
58396655|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
57928968|NCT03073226|DEVICE|Olympus Elite|New generation Olympus endoscope
58396656|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
58396657|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
58396658|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
58396659|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
57928969|NCT03073226|DEVICE|Olympus Spectrum|Current generation Olympus endoscope
57928970|NCT05932004|OTHER|Reformer pilates exercise|The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
58069191|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
58069192|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
58069193|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
58069194|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
58069195|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
58069196|NCT02142075|DRUG|Daptomycin|
58281078|NCT02593955|BEHAVIORAL|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
58281079|NCT01961167|DEVICE|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
58281080|NCT05614583|DEVICE|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
58281081|NCT05614583|OTHER|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
58281082|NCT06543420|PROCEDURE|lateral reconstruction|In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
58281083|NCT06543420|PROCEDURE|posterior reconstruction|In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
58281084|NCT04413383|OTHER|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
58281085|NCT04413383|OTHER|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
58281086|NCT04413383|OTHER|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
58281087|NCT02499510|DEVICE|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
58281088|NCT04720625|BEHAVIORAL|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
58281089|NCT04720625|BEHAVIORAL|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
58281090|NCT02624128|DRUG|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
58281091|NCT02624128|DRUG|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
58281092|NCT02624128|DRUG|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
58281093|NCT00523809|DRUG|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
58396660|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
58396661|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
58281094|NCT00523809|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
58281095|NCT00523809|DRUG|Fludarabine|25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days
58281096|NCT00523809|DRUG|Melphalan|70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days
58281097|NCT00523809|DRUG|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
58281098|NCT05859282|BEHAVIORAL|Survey|A short 25-item tool was developed and can be applied in clinics to assess the awareness of pregnancy hypertension.
58281099|NCT05635500|PROCEDURE|Different Approach to endotracheal intubation.|Different insertion way.
58396662|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
58396663|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
58396664|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
58396665|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
58396666|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
58396667|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
58396668|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
58396669|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
58396670|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
58396671|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
58396672|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
58396673|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
58396674|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
58396675|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
58396676|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
58281100|NCT01044589|DEVICE|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
58281101|NCT01044589|OTHER|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
58396677|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
58396678|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
58396679|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
58396680|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
58396681|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
58396682|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
58281102|NCT01523327|OTHER|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
58281103|NCT06408350|BEHAVIORAL|Text Me, Alexis!|Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
58396683|NCT02713386|DRUG|Carboplatin|Given IV
58396684|NCT02713386|DRUG|Paclitaxel|Given IV
58396685|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
58396686|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
58396687|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
58396688|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
58396689|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
58396690|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
58396691|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
58396692|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
58396693|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
58396694|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
58396695|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
58396696|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
58396697|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
58396698|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
57928971|NCT01630434|DEVICE|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
58281104|NCT04857853|OTHER|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
58281105|NCT04857853|OTHER|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
58281106|NCT04857853|OTHER|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
58281107|NCT03701685|PROCEDURE|nerve flap|sensory reconstruction via a nerve graft included in the flap
58281108|NCT04037852|DEVICE|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
58281109|NCT04037852|PROCEDURE|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
58281110|NCT04037852|PROCEDURE|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
58281111|NCT02529098|OTHER|fMRI|functional magnetic resonance imaging
58281112|NCT00374257|PROCEDURE|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
58281113|NCT02222116|DEVICE|MGuard Prime|
58281114|NCT02222116|DEVICE|Control BMS DES|
58281115|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
58281116|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
58281117|NCT01108237|OTHER|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
58281118|NCT01108237|DEVICE|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
58281119|NCT06549881|PROCEDURE|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
58281120|NCT05390723|BEHAVIORAL|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
58281121|NCT02411981|OTHER|Autogenic drainage|
58281122|NCT06139705|OTHER|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
58281123|NCT06139705|OTHER|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
58281124|NCT03307460|DRUG|68Ga-NOTA-AE105|PET/MRI scan
58281125|NCT04765670|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
57928972|NCT01630434|DEVICE|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
57928973|NCT02281279|BIOLOGICAL|rituximab|Given IV
57928974|NCT02281279|DRUG|lenalidomide|Given PO
57928975|NCT02281279|DRUG|romidepsin|Given IV
57928976|NCT02281279|OTHER|laboratory biomarker analysis|Correlative studies
58281126|NCT04765670|OTHER|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
58281127|NCT03642444|DEVICE|Cane|Assistive walking device
58281128|NCT03642444|DEVICE|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
58281129|NCT05456854|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Administration of a hyperglycemic clamp
58281130|NCT05456854|DRUG|Kisspeptin-10|Administration of kisspeptin-10 \* 16 hr
58281131|NCT05456854|DRUG|Placebo|Administration of placebo \*16 hr
58281132|NCT01955577|DRUG|Placebo orally everyday|
58281133|NCT01955577|DRUG|Vitamin D3 cholecalciferol|
58069197|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
58069198|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
58281134|NCT03628716|BIOLOGICAL|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
58281135|NCT03628716|BIOLOGICAL|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
58281136|NCT02041780|PROCEDURE|Shearwave electrography|
58281137|NCT00251498|DRUG|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
58281138|NCT03313310|BEHAVIORAL|Employment Intervention|Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
58281139|NCT02030886|DEVICE|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
58281140|NCT01602679|DRUG|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
58281141|NCT01602679|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
58281142|NCT02588092|DRUG|ADCT-301|Intravenous infusion
58281143|NCT03034135|DRUG|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
58281144|NCT03034135|DRUG|Temozolomide (TMZ)|TMZ is given per standard of care
58281145|NCT00100152|DRUG|MK0752, (Notch Inhibitor)|
58281146|NCT00487097|DIETARY_SUPPLEMENT|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
58281147|NCT04365673|OTHER|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
58281148|NCT04886752|DIETARY_SUPPLEMENT|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
58281149|NCT04886752|DIETARY_SUPPLEMENT|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
58281150|NCT04886752|DIETARY_SUPPLEMENT|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
58281151|NCT02769312|DEVICE|Theta burst stimulation|Theta burst transcranial magnetic stimulation
58396699|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
58396700|NCT00632047|OTHER|active surveillance|
58396701|NCT00632047|OTHER|educational intervention|
58069199|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
58281152|NCT02769312|DEVICE|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
58396702|NCT00632047|PROCEDURE|examination|
58396703|NCT00632047|PROCEDURE|long-term screening|
58069200|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
58281153|NCT03089853|DEVICE|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
57928977|NCT03370471|BEHAVIORAL|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
57928978|NCT03370471|BEHAVIORAL|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
57928979|NCT03370471|BEHAVIORAL|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
57928980|NCT03370471|BEHAVIORAL|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
57928981|NCT01409863|PROCEDURE|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
57928982|NCT01708122|DRUG|Fentanyl|100 mcg in 1 mL intranasal spray
57928983|NCT01708122|DRUG|saline|Sodium Chloride 0.9% intranasal spray
57928984|NCT04710888|DRUG|use of basil extract gel in treatment of aphthus ulcer|This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
58069201|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
58069202|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
57928985|NCT04710888|OTHER|muco adhesive placebo gel|mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
57928986|NCT04710888|OTHER|no treatment|(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
57928987|NCT02936063|PROCEDURE|Surgical staples|Closure of surgical wound at skin level with surgical staples
57928988|NCT02936063|PROCEDURE|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
57928989|NCT00260117|BEHAVIORAL|Exercise|Referal to a website
57928990|NCT01794364|DRUG|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
57928991|NCT01794364|OTHER|placebo|Correspondingly, placebo doses will be administered as suspension.
57928992|NCT04897269|PROCEDURE|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
57928993|NCT01233453|DEVICE|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
57928994|NCT01233453|DEVICE|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
57928995|NCT01349335|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
57928996|NCT01349335|DRUG|Tolvaptan|tablet, 30 mg, Qd, 7 days
57928997|NCT01349335|DRUG|placebo|tablet, 30 mg, Qd, 7days.
57928998|NCT04721821|DRUG|Tofacitinib|Patients who received Tofacitinib for RA
57928999|NCT00433342|DRUG|Flucloxacillin|500 mg QD oral
57929000|NCT03691090|DRUG|SHR-1210|SHR-1210 200mg
57929001|NCT03691090|DRUG|Placebo|Placebo
57929002|NCT03691090|DRUG|paclitaxel|paclitaxel 175mg/m2
57929003|NCT03691090|DRUG|cisplatin|cisplatin 75mg/m2
57929004|NCT02420132|OTHER|Ranibizumab|Ranibizumab administered as part of standard-of-care
57929005|NCT06087679|BEHAVIORAL|PPS guided selfcare based intervention program|Guided selfcare programme (Please refer to project description)
57929006|NCT00042406|DRUG|HuMax-CD4|HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
57929007|NCT00042406|DRUG|Placebo|Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
57929008|NCT00042406|DRUG|Humax-CD4|HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
57929009|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
57929010|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
57929011|NCT01681810|DRUG|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
58281154|NCT04513899|BEHAVIORAL|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
58281155|NCT04513899|BEHAVIORAL|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
58281156|NCT00098462|DRUG|gefitinib|
58281157|NCT00098462|DRUG|sirolimus|
58281158|NCT03747913|DIETARY_SUPPLEMENT|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
58281159|NCT04386161|OTHER|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
58281160|NCT06330675|OTHER|Early mobilization|Short-term bed-rest and immobilization
58281161|NCT06330675|OTHER|Standard of care|Bed-rest and immobility until the day-after procedure
57929012|NCT02570893|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
57929013|NCT02570893|RADIATION|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
57929014|NCT02570893|DRUG|Paclitaxel and carboplatin|
57929015|NCT00672061|DRUG|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
57929016|NCT00186862|DRUG|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
57929017|NCT02614534|DRUG|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
58281162|NCT04321941|DIAGNOSTIC_TEST|Lumentin|Contrast agent used in combination with CTE
58281163|NCT04321941|DIAGNOSTIC_TEST|Movprep|Contrast agent used in combination with MRE
58281164|NCT04052516|DRUG|Icosabutate|Icosabutate oral capsule once daily
58281165|NCT04052516|DRUG|Placebo|Matching placebo oral capsule
58281166|NCT01204918|DRUG|Riluzole|Riluzole 100mg PO
58281167|NCT01204918|DRUG|placebo|placebo
57929018|NCT02614534|PROCEDURE|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
57929019|NCT00445068|DRUG|LBH589|
57929020|NCT05298982|BEHAVIORAL|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
58281168|NCT01343966|DRUG|MABT5102A|Repeating subcutaneous injection
58281169|NCT01343966|DRUG|MABT5102A|Repeating intravenous infusion
58281170|NCT01343966|DRUG|placebo|Repeating subcutaneous injection
58281171|NCT01343966|DRUG|placebo|Repeating intravenous infusion
58281172|NCT03610321|DRUG|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
58281173|NCT03610321|DRUG|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
58281174|NCT00974038|BEHAVIORAL|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
58281175|NCT00724802|DIETARY_SUPPLEMENT|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
58281176|NCT00724802|DRUG|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
58281177|NCT01905774|DRUG|Deferasirox|
58069203|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
57929021|NCT05627206|BEHAVIORAL|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
57929022|NCT02366728|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
57929023|NCT02366728|BIOLOGICAL|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
57929024|NCT02366728|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
58069204|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
58069205|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
58069206|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
58069207|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
58069208|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
58069209|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
57929025|NCT02366728|BIOLOGICAL|111In-labeled DCs|111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
57929026|NCT02366728|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
57929027|NCT02366728|DRUG|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
57929028|NCT02366728|DRUG|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
57929029|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
57929030|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
57929031|NCT05088902|DIAGNOSTIC_TEST|TERABio Ltd.|Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).
57929032|NCT05729568|DRUG|Teropavimab|Administered intravenously
57929033|NCT05729568|DRUG|Zinlirvimab|Administered intravenously
58069210|NCT00247962|DRUG|etanercept|50 mg
58069211|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
58069212|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
58281178|NCT06043492|OTHER|High Intensity Interval Training|10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
58281179|NCT06043492|OTHER|Coninuous Running|40 min continuous running at lactate threshold
58069213|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
58069214|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
58069215|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
58069216|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
58069217|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
58069218|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
58281180|NCT06043492|OTHER|Control Trial|The participants will perform only the baseline and post acute-training evaluations, without performing exercise
57929034|NCT05729568|DRUG|Lenacapavir Tablet|Administered orally
58281181|NCT04234594|DRUG|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
58281182|NCT04234594|DRUG|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
58281183|NCT00909220|BEHAVIORAL|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis \& Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
58281184|NCT03409484|OTHER|Concord Grape Juice|Concord Grape Juice
58281185|NCT03409484|OTHER|Low flavoniod low essence beverage|Low flavoniod low essence beverage
58281186|NCT03409484|OTHER|Low flavonoid beverage|Low flavonoid beverage
58281187|NCT02671617|OTHER|High intensity interval training (HIIT)|Preoperative HIIT protocol.
58281188|NCT04424914|DIAGNOSTIC_TEST|Scintigraphy|scintigraphy
58281189|NCT03605472|OTHER|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
57929035|NCT05729568|DRUG|Lenacapavir Injection|Administered subcutaneously
57929036|NCT05729568|DRUG|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
57929037|NCT04066803|DRUG|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
57929038|NCT04066803|DRUG|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
57929039|NCT04066803|DRUG|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
57929040|NCT05945966|OTHER|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
58281190|NCT03489122|BEHAVIORAL|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
58281191|NCT03489122|BEHAVIORAL|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
58281192|NCT04064255|OTHER|Practical Body Image (session 1 - 7)|Practical body image therapy
58281193|NCT04064255|OTHER|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
58281194|NCT02156063|DRUG|NT100|
58281195|NCT02156063|DRUG|Placebo|
58281196|NCT02343432|DRUG|Triamcinolone|Triamcinolone
58069219|NCT02277418|DEVICE|VAVL|Videolaryngoscope
58069220|NCT02277418|DEVICE|MIL|Direct laryngoscopy
57929041|NCT05945966|OTHER|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
58069221|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
58069222|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
58069223|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
58069224|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
58281197|NCT02343432|DRUG|Epidural Volume|Epidural Volume
58281198|NCT02343432|DRUG|Bupivacaine|Bupivacaine
58281199|NCT00055510|DRUG|BO-653|
57929042|NCT06211465|PROCEDURE|Total joint arthroplasty|Hip or knee total joint arthroplasty
57929043|NCT03305068|DRUG|Celecoxib|
57727799|NCT05007457|OTHER|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
58281200|NCT06004323|BEHAVIORAL|Digital health literacy intervention|Participants from the intervention group will be invited to join virtual or face-to-face training, watch short videos on social media, participate in virtual bi-weekly group discussion, and fill in questionnaires for five times during the course of the study
58281201|NCT04051814|OTHER|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
58281202|NCT00285766|DRUG|Selegiline Transdermal System|
58281203|NCT02553798|DRUG|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
58281204|NCT02313805|OTHER|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
58281205|NCT00555776|DRUG|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
57929044|NCT03805009|DEVICE|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
57929045|NCT02576236|OTHER|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
58396704|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
57929046|NCT02576236|OTHER|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
58069225|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
58069226|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
58281206|NCT00555776|DRUG|placebo|placebo is given with the same definition as Gabapentin
58069227|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
58281207|NCT01777139|DRUG|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
58281208|NCT02570230|OTHER|NSS|NSS infusion
58281209|NCT02570230|DRUG|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
58281210|NCT04839432|BEHAVIORAL|implementation of albumin solution in the priming of the cardiopulmonary bypass machine|In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
58281211|NCT01905592|DRUG|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
58281212|NCT01905592|DRUG|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
58281213|NCT00624364|DRUG|biphasic insulin aspart|
58281214|NCT00624364|DRUG|metformin|
58281215|NCT04951713|DRUG|XZP-3287 combined with clarithromycin|Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
58281216|NCT04951713|DRUG|XZP-3287 combined with rifampicin|Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
58281217|NCT06039605|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
58281218|NCT02324699|DRUG|Prednisone|
58281219|NCT02324699|DRUG|Placebo|
58396705|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
57727800|NCT06489548|DRUG|Foralumab TZLS-401 50 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
57727801|NCT06489548|DRUG|Foralumab TZLS-401 100 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
58281220|NCT02324699|DRUG|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
58281221|NCT05205629|DRUG|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
58281222|NCT00594074|OTHER|white wine|3.25 ounces of white wine twice a day with lunch and dinner
58281223|NCT02126124|DEVICE|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
58281224|NCT02126124|DEVICE|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
58281225|NCT03704506|DRUG|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
58281226|NCT03704506|DRUG|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
58396706|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
58396707|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
58396708|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
58396709|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
58396710|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
58396711|NCT06657859|DRUG|GLM101|GLM101 IV infusion
58396712|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
58396713|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
57727802|NCT06336070|BEHAVIORAL|HIIT program (8 weeks)|Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
57727803|NCT06336070|BEHAVIORAL|MPI program (8 weeks)|Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
57727804|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
57727805|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
57727806|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
57727807|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
57727808|NCT01736826|BIOLOGICAL|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
57727809|NCT01736826|BIOLOGICAL|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 \& 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
57727810|NCT01736826|BIOLOGICAL|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
57727811|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
58281227|NCT03704506|DRUG|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
58281228|NCT03704506|DRUG|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
58281229|NCT01502488|PROCEDURE|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
58281230|NCT00312052|DRUG|E5555|50 mg or 100 mg E5555 tablets
58281231|NCT00312052|DRUG|Placebo|50 mg and/or 100 mg placebo tablets
58281232|NCT02653898|DRUG|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
58396714|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
58281233|NCT02653898|DRUG|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
58396715|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
58396716|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
57727812|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
57727813|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
57727814|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
58281234|NCT02653898|DRUG|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
58281235|NCT02653898|DRUG|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
58396717|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
58396718|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
58396719|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
58396720|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
57929047|NCT03732079|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
57929048|NCT03839407|DEVICE|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
57929049|NCT06350851|BIOLOGICAL|Biological samples collection (blood drawing + feces)|Blood and feces samples will be collected from each volunteer.
57929050|NCT02927743|BEHAVIORAL|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
57929051|NCT02461030|DRUG|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
57929052|NCT02461030|DRUG|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
57929053|NCT02461030|PROCEDURE|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
57929054|NCT01839253|DRUG|b-blocker(Atenolol)|
57929055|NCT01839253|DRUG|ACE inhibitor(Enapril)|
57929056|NCT01839253|OTHER|control|
57929057|NCT02992483|DRUG|MIK665|MIK665
58396721|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
57727815|NCT01958151|OTHER|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
57929058|NCT03659279|BEHAVIORAL|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
57929059|NCT00256880|DRUG|GW786034|
57929060|NCT04603586|RADIATION|SBRT|SBRT: in 5-6 fractions with CyberKnife
57929061|NCT04603586|DRUG|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
57929062|NCT00527254|DEVICE|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
57727816|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
57929063|NCT04396314|BEHAVIORAL|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
58396722|NCT02384473|PROCEDURE|SWE|Undergo SWE
58396723|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
58396724|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
58396725|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
58396726|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
58396727|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
58396728|NCT04785534|OTHER|Survey Administration|Complete survey
58396729|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
57727817|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
57929064|NCT04396314|BEHAVIORAL|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
57929065|NCT05573321|OTHER|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
57929066|NCT05573321|OTHER|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
57929067|NCT02271074|OTHER|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
58069228|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
58396730|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
58396731|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
58396732|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
58281236|NCT05366114|OTHER|No intervention, additional video data collection only|No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time
58396733|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
57727818|NCT04000165|DRUG|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
58281237|NCT05440721|DEVICE|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
57727819|NCT02995967|PROCEDURE|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
57727820|NCT02995967|DRUG|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
57929068|NCT02271074|BEHAVIORAL|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
57929069|NCT02271074|OTHER|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
57929070|NCT02545322|RADIATION|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
57929071|NCT02797067|DRUG|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
57929072|NCT02797067|DRUG|Glycerin Suppository|30min before ESWL
57929073|NCT02003014|DRUG|Pioglitazone|Pioglitazone Tablets
57929074|NCT03702803|DIETARY_SUPPLEMENT|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
57929075|NCT03702803|DRUG|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
57929076|NCT05097014|DRUG|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
57929077|NCT05097014|DRUG|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
57929078|NCT05097014|OTHER|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
57929079|NCT00557388|DIETARY_SUPPLEMENT|Protein/Amino Acids|Casein Whey Leucine
58069229|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
58281238|NCT05440721|DEVICE|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
58396734|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
58396735|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
58396736|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
57727821|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
58281239|NCT06435078|DEVICE|mPETS(modified-PETS system)|The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
57727822|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
58396737|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
57727823|NCT01592708|OTHER|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
57929080|NCT00557388|OTHER|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
58281240|NCT03173495|DIETARY_SUPPLEMENT|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
58281241|NCT03173495|DIETARY_SUPPLEMENT|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
58281242|NCT03173495|DIETARY_SUPPLEMENT|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
58281243|NCT02788318|OTHER|Brain samples|Collected in patients died
58396738|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
58396739|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
58396740|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
57727824|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
57727825|NCT00003289|DRUG|7-hydroxystaurosporine|
57929081|NCT02790957|DRUG|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
57929082|NCT02790957|DRUG|Placebo|Single injection of an equal volume of NaCl solution
57929083|NCT02887690|DEVICE|Modular Prosthetic Limb|
58396741|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
58396742|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
58396743|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
57929084|NCT04369222|OTHER|Observational|Maternal consumption of mild analgesics
58281244|NCT02788318|OTHER|Skin samples|Collected in patients died
58281245|NCT03165084|BEHAVIORAL|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
57727826|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
57727827|NCT04777682|PROCEDURE|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
57929085|NCT00201435|DRUG|Paclitaxel weekly in combination with capecitabine|
57929086|NCT00201435|DRUG|Docetaxel every 3 week in combination with capecitabine|
58281246|NCT03165084|OTHER|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
58281247|NCT03165084|OTHER|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
58281248|NCT01194193|DRUG|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
58281249|NCT01607346|DRUG|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
58281250|NCT02509793|DRUG|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
58281251|NCT04525209|OTHER|No intervention|No intervention
58281252|NCT02252926|DRUG|Bupivacaine|25 mg bupivacaine lozenge
58281253|NCT02252926|DRUG|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
57929087|NCT04071795|BEHAVIORAL|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
57929088|NCT04071795|BEHAVIORAL|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
57929089|NCT02233283|OTHER|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
57929090|NCT02233283|OTHER|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
57929091|NCT02233283|OTHER|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
57929092|NCT02233283|OTHER|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
58281254|NCT05668572|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
58281255|NCT05668572|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
57929093|NCT01681134|DRUG|Advagraf®|oral
58281256|NCT03029845|DRUG|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
57929094|NCT01681134|DRUG|Prograf®|oral
57929095|NCT00974090|DRUG|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
57929096|NCT00974090|DRUG|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
57929097|NCT06242054|DIAGNOSTIC_TEST|Motor Function Assessment System|Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
57929098|NCT06059651|PROCEDURE|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
57929099|NCT03435003|DRUG|Aprepitant 80 mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
57929100|NCT03435003|DRUG|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
57929101|NCT03435003|PROCEDURE|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
57929102|NCT03435003|DRUG|Dexamethasone|Dexamethasone 8 mg intraoperatively
57929103|NCT03435003|DRUG|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
57929104|NCT03435003|DRUG|Reglan|Postoperatively scheduled Reglan
58396744|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
58396745|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
58396746|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
57727828|NCT06463015|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
58069230|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
58069231|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
58069232|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
58069233|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
58069234|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
58069235|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
58069236|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
58281257|NCT03029845|DRUG|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
58281258|NCT03029845|DRUG|Placebo|Participants will take placebo twice a day for 2 weeks
58281259|NCT06543082|DRUG|Colchicine 0.6 mg|Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
58281260|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
58281261|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
58281262|NCT00581061|DRUG|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
58281263|NCT04324515|PROCEDURE|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
58281264|NCT04165135|DRUG|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
58281265|NCT03495115|DEVICE|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
58281266|NCT03495115|DEVICE|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
58281267|NCT02374619|DIETARY_SUPPLEMENT|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]
58281268|NCT02374619|DIETARY_SUPPLEMENT|Placebo|
58281269|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
58281270|NCT02083302|BEHAVIORAL|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
58281271|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 4|Booster Session
58281272|NCT02840227|PROCEDURE|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
58396747|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
58396748|NCT01780337|OTHER|Saline|Intranasal dose of saline
58396749|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
57929105|NCT03435003|DRUG|Ondansetron|Postoperatively scheduled ondansetron
57929106|NCT03435003|DRUG|Compazine|Postoperatively as needed compazine for breakthrough PONV
58281273|NCT02840227|PROCEDURE|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
58281274|NCT00164502|BEHAVIORAL|Community-based eight session group self-management program|
58281275|NCT06320353|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
58396750|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
58396751|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
58396752|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
58396753|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
58396754|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
58396755|NCT01511614|DEVICE|sham|Sham Comparator
58396756|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
58396757|NCT01511614|DRUG|Placebo patch|Nicotine deprived
58396758|NCT01511614|DRUG|Varenicline Pill|Treatment
58281276|NCT06320353|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
58281277|NCT05753540|OTHER|Laser therapy|Multiwave locked system laser therapy
58281278|NCT05753540|OTHER|Sham laser therapy|Sham laser therapy
58281279|NCT01508390|RADIATION|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
58281280|NCT02530918|DRUG|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
58281281|NCT02530918|DRUG|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
58281282|NCT06020248|OTHER|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
58281283|NCT05956405|BEHAVIORAL|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
58396759|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
58396760|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
57727829|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
57727830|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
58396761|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
58396762|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
58396763|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
57727831|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
57929107|NCT03435003|DRUG|Sugammadex|Reversal with sugammadex
57929108|NCT03435003|DRUG|Propofol|Intravenous anesthesia will be maintained through IV propofol
57929109|NCT03435003|DRUG|dexmedetomidine|maintenance of anesthesia in the intervention arm
57929110|NCT03435003|DRUG|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
57929111|NCT03435003|DRUG|Sevoflurane|inhalational anesthesia
57929112|NCT03435003|DRUG|Desflurane|inhalational anesthesia
57929113|NCT06177249|BIOLOGICAL|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
57929114|NCT06177249|BIOLOGICAL|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
58069237|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
58281284|NCT05956405|BEHAVIORAL|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
58281285|NCT01633970|DRUG|5-FU|Participants will receive 5-FU 400 mg/m\^2 IV q2w.
58396764|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
58396765|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
58396766|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
57727832|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
57929115|NCT05496751|BEHAVIORAL|Low amount, low intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
58281286|NCT01633970|DRUG|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
57929116|NCT05496751|BEHAVIORAL|Low amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
58281287|NCT01633970|DRUG|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
58281288|NCT01633970|DRUG|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
57929117|NCT05496751|BEHAVIORAL|High amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
57929118|NCT03015792|DRUG|Dexamethasone|Given PO
57929119|NCT03015792|DRUG|Ibrutinib|Given PO
57929120|NCT03015792|OTHER|Laboratory Biomarker Analysis|Correlative studies
58281289|NCT01633970|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV q2w.
57727833|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
57929121|NCT03015792|DRUG|Lenalidomide|Given PO
57929122|NCT03015792|OTHER|Pharmacological Study|Correlative studies
57929123|NCT03015792|OTHER|Quality-of-Life Assessment|Ancillary studies
57929124|NCT06168136|OTHER|protein diet|this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)
57929125|NCT06168136|OTHER|Normal protein diet|this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
57929126|NCT03600623|DRUG|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
58281290|NCT01633970|DRUG|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.
58281291|NCT01633970|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.
58281292|NCT01633970|DRUG|Paclitaxel|Participants will receive paclitaxel 200 mg/m\^2 IV q3w.
57727834|NCT03595345|PROCEDURE|Liver transplantation|Liver transplantation
57727835|NCT00434057|DEVICE|MelaFind(R)|Biopsy ratio comparison
57929127|NCT03600623|DRUG|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
57929128|NCT04214314|BEHAVIORAL|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
58281293|NCT01633970|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
58281294|NCT01897519|DRUG|Placebo|Placebo infusion
58281295|NCT01897519|DRUG|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
58281296|NCT01842906|DEVICE|Theravent|nasal EPAP device
58281297|NCT01842906|DEVICE|Control|Sham device without EPAP
58281298|NCT06026839|OTHER|Conventional nursing|Conventional nursing
58396767|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
58396768|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
58396769|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
58396770|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
58396771|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
58396772|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
58396773|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
58396774|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
58396775|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
58396776|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
58396777|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
58396778|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
57929129|NCT06495450|DEVICE|Omnidirectional Virtual Reality and Treadmill Training|Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
57929130|NCT06495450|BEHAVIORAL|Traditional Exercise|A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
58281299|NCT05435560|DRUG|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
58281300|NCT05435560|DRUG|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
58281301|NCT05326256|OTHER|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
58281302|NCT05326256|OTHER|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
58281303|NCT03340467|DEVICE|CGM patch|Patient receives four CGM patches.
58281304|NCT00815503|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
58396779|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
58396780|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
57727836|NCT05578404|DRUG|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
57929131|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
57929132|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
58281305|NCT00815503|DRUG|Placebo|Saline
58281306|NCT05682729|BEHAVIORAL|Book Reading Intervention|Children read books containing relevant stimuli.
58396781|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
58396782|NCT04607512|OTHER|moxifloxicin|positive control
58396783|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
58396784|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
58396785|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
58396786|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
57727837|NCT05578404|DRUG|Placebo|matching placebo to Vit D
57727838|NCT00408993|DRUG|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
57727839|NCT00408993|DRUG|Placebo|Placebo every day (QD), by mouth (PO)
57727840|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
57727841|NCT03660683|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
57727842|NCT03660683|DRUG|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
58396787|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
58396788|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
58396789|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
58396790|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
58396791|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
58396792|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
58396793|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
58396794|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
58396795|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
58396796|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
58396797|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
57727843|NCT03660683|DRUG|Placebo Oral Tablet|Matching Placebo Tablets
57929133|NCT01437696|OTHER|placebo|No liquid cholecalciferol will be added to the food.
57929134|NCT03948360|DEVICE|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
58069238|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
58069239|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
58069240|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
58069241|NCT00511966|DRUG|Rabeprazole|As prescribed
58069242|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
58069243|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
58396798|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
58396799|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
58396800|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
58396801|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
58281307|NCT05415514|OTHER|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
58396802|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
58396803|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
58396804|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
58396805|NCT02191657|DRUG|Deferiprone|Oral iron chelator
57727844|NCT00919282|DRUG|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
57727845|NCT04119284|DEVICE|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
57727846|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
57727847|NCT02384148|OTHER|Circadian rhythm measurement|
57727848|NCT02384148|PROCEDURE|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
57929135|NCT03948360|OTHER|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
58396806|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
58396807|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
58396808|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
58396809|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
58396810|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
58396811|NCT00416065|DEVICE|PET/CT imaging|
58396812|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
58396813|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
58396814|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
58396815|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
58396816|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
58396817|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
58396818|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
58396819|NCT00234663|DRUG|PTC124|
58396820|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
58396821|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
58396822|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
58396823|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
58281308|NCT00415324|DRUG|eribulin mesylate|Given IV
58281309|NCT00415324|DRUG|cisplatin|Given IV
58396824|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
58396825|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
57727849|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
58281310|NCT00415324|OTHER|laboratory biomarker analysis|correlative study
58281311|NCT00415324|OTHER|pharmacological study|correlative study
58281312|NCT06337227|DIAGNOSTIC_TEST|lncRNA signature analyses|Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
58281313|NCT00548249|DEVICE|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
58281314|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
58396826|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
58396827|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
57929136|NCT01399190|BIOLOGICAL|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
57929137|NCT01399190|BIOLOGICAL|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
57929138|NCT01399190|DRUG|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
57929139|NCT03787225|DRUG|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
57929140|NCT03787225|DRUG|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
57929141|NCT00261911|DRUG|sibutramine|
58281315|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
58281316|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
58281317|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
58281318|NCT00564291|OTHER|Examination with an OCT device|
58396828|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
58396829|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
58396830|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
58396831|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
58396832|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
58396833|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
57951190|NCT00959868|DRUG|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
57951191|NCT03869528|DRUG|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
57951192|NCT03869528|DRUG|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
58281319|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
58281320|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
58281321|NCT05445388|DEVICE|Aurisvue|OCT imaging of the middle ear
58281322|NCT02107313|DRUG|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
58281323|NCT02107313|DRUG|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
58281324|NCT02535377|OTHER|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
58281325|NCT02182830|DRUG|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
58281326|NCT02182830|DRUG|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
58281327|NCT02182830|DRUG|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
58281328|NCT03996122|OTHER|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
58281329|NCT03014141|OTHER|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
58281330|NCT03014141|OTHER|Maltodextrin|11 g of Maltodextrin
58281331|NCT01241331|DRUG|BLI1100|BLI110 topical cream
58281332|NCT01241331|DRUG|Vehicle cream|Vehicle topical cream
58281333|NCT05282589|OTHER|lumbopelvic manipulation and conventional therapy|"Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
58396834|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
58396835|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
57727850|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
57929142|NCT01736085|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
57929143|NCT01736085|BEHAVIORAL|Voucher|"Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
58281334|NCT05282589|OTHER|conventional therapy|"Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
58281335|NCT00142272|DRUG|Ciprofloxacin|
58281336|NCT00043563|BEHAVIORAL|Cognitive-Behavior Therapy|
58281337|NCT01586702|BEHAVIORAL|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~* Measurement of risk factors~* Assessment of medication intake~* Monitoring of antithrombotic therapy~* Joint agreement of an individual target plan~Target values for risk factors:~* Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile~* HbA1c \<7.5%~* Nicotine abstinence~* LDL \< 100mg/dl (\< 70mg/dl in high risk patients)~* Physical activity ≥ 30min \>2 x / week~Targets for pharmaceutical treatment:~* Platelet inhibitors for strokes / TIA of arterial etiology~* Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~* Cumarins (INR 2-3) or new oral anticoagulants in AF patients~* Statin treatment in patients with LDL \>100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
58281338|NCT00095459|DRUG|Bevacizumab|
58281339|NCT00095459|DRUG|BAY 43-9006|
58281340|NCT00623857|DIETARY_SUPPLEMENT|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
58281341|NCT00623857|DIETARY_SUPPLEMENT|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
58281342|NCT00623857|DIETARY_SUPPLEMENT|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
58281343|NCT00623857|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
58281344|NCT03240185|BEHAVIORAL|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
58281345|NCT03264534|PROCEDURE|limbal relaxing incisions|Manually performed surgical procedure
58396836|NCT01794312|DEVICE|T4020|
57727851|NCT06428747|DIAGNOSTIC_TEST|b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).|detection of micro-particles
58281346|NCT03264534|PROCEDURE|astigmatic keratotomy|femtosecond laser guided surgical procedure
58281347|NCT05057858|DRUG|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
58281348|NCT03244267|BEHAVIORAL|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
58281349|NCT03244267|BEHAVIORAL|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
58281350|NCT04049305|DEVICE|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
58281351|NCT04049305|PROCEDURE|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
58396837|NCT01794312|DEVICE|Vehicle|
58396838|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
58396839|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
58396840|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 24 weeks
58396841|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 24 weeks
57929144|NCT01736085|DRUG|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
57929145|NCT04553068|DRUG|EVO100|EVO100 vaginal gel
57929146|NCT04553068|DRUG|Placebo|Placebo vaginal gel
58069244|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
58281352|NCT04049305|PROCEDURE|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
58281353|NCT02540161|DRUG|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
58281354|NCT02540161|DRUG|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
58281355|NCT03544281|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as an infusion.
58281356|NCT03544281|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
58396842|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
58396843|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
57929147|NCT00889226|DRUG|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
57929148|NCT00889226|DRUG|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
57929149|NCT02702622|OTHER|Provitamin A-biofortified transgenic bananas|
57929150|NCT05742503|OTHER|Depo-Provera|Injectable progesterone
57929151|NCT05742503|OTHER|Implanon|Etonogestrel implant
58281357|NCT03544281|DRUG|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
58281358|NCT03544281|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
58281359|NCT04998383|DEVICE|HVNI|High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
58281360|NCT05912985|OTHER|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
58281361|NCT00759655|BIOLOGICAL|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
58281362|NCT03585972|BEHAVIORAL|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
58281363|NCT01741350|BEHAVIORAL|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
58069245|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
58069246|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
58281364|NCT01741350|BEHAVIORAL|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
58281365|NCT05461989|OTHER|Anthropometric measurement|It will be measured with the Xiaomi Body Composition Scale II, and a total of 9 measurements will be made as a result of the measurements.
58396844|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
58396845|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
58396846|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
58396847|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
58396848|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
58396849|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
58396850|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
58396851|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
58396852|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
58396853|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
57929152|NCT05742503|OTHER|Norgestrel|Pill containing progesterone
57929153|NCT05742503|OTHER|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
57929154|NCT00427232|DRUG|BQ-123 and BQ-788|
57929155|NCT01685424|DRUG|Etoricoxib|As per routine clinical practice in the United Kingdom
58281366|NCT05461989|OTHER|Level of Physical Activity|The scale to be used for this purpose is the Child Physical Activity Questionnaire (CPAQ) developed by Kowalski et al. It is a seven-day self-reported recall scale designed to assess moderate-intensity physical activity in children aged 8-14 years. CFAQ is designed to be implemented throughout the school year.
58281367|NCT05461989|OTHER|Physical Activity Barriers Scale|"It consists of three surveys in total, which are:~A) Scale of Expectations Regarding Physical Activity for Children~B) Children's perception of family support regarding physical activity scale~C) Physical Activity Barriers Scale for Parents"
58281368|NCT05461989|OTHER|Hand Grip Strength|Hand grip strength will be measured using a hand dynamometer (Jamar, Sammons Preston, Rolyon, Bolingbrook, IL).
58281369|NCT05461989|OTHER|Arterial stiffness|Arterial stiffness will be evaluated using the pulse wave velocity (PWV) technique with the blood pressure holter-ABPM (Mobil-O-Graph, I.E.M., Stolberg, Germany) device. The measurement is made from the non-dominant arm based on the principle of blood pressure measurement with the appropriate cuff determined according to the arm diameter. After two consecutive measurements taken 30 seconds apart, the average of the measurement values will be recorded.
58281370|NCT02651688|DRUG|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
58281371|NCT02651688|DRUG|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
58281372|NCT03876496|DEVICE|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
58281373|NCT04622202|DRUG|Pregabalin 150mg|oral capsule pregabalin 150 mg.
58281374|NCT04622202|DRUG|multivitamin|oral placebo in the form of oral multivitamin capsule.
58281375|NCT01768923|PROCEDURE|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)
58281376|NCT01768923|PROCEDURE|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
58281377|NCT00002823|DRUG|cisplatin|
58281378|NCT00002823|DRUG|etoposide|
58281379|NCT00002823|DRUG|vinblastine sulfate|
57929156|NCT06099210|DIAGNOSTIC_TEST|Glasgow coma scale|Closed tach brain injury due to external force was included according to the GCS score
57929157|NCT00893282|DEVICE|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
57929158|NCT00893282|DEVICE|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
57929159|NCT05044026|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
57929160|NCT01728051|DRUG|Melphalan|
57929161|NCT01728051|DEVICE|Percutaneous Hepatic Perfusion|
57929162|NCT00475618|PROCEDURE|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
57929163|NCT00475618|PROCEDURE|professional cleaning|Daily use fluoride toothpaste 500 ppm.
57929164|NCT00475618|PROCEDURE|No fluoride toothpaste|Daily use no fluoride toothpaste.
57929165|NCT05591820|BEHAVIORAL|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's behavioral difficulties in three (bi)weekly sessions and optional booster sessions.
57929166|NCT05591820|BEHAVIORAL|Care as usual|The care that is usually provided by the clinical institutions to treat children's behavioral difficulties. There are no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
57929167|NCT03061461|DEVICE|rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
58069247|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
58069248|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
58069249|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
57929168|NCT03061461|DEVICE|Sham rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
58069250|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
58069251|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
58281380|NCT00002823|DRUG|vindesine|
58281381|NCT00002823|DRUG|vinorelbine tartrate|
57727852|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
57727853|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
57727854|NCT00659269|DRUG|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
57727855|NCT06247176|BEHAVIORAL|Sensory Habituation Protocol|"The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated.~At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation.~VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video.~Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit."
57727856|NCT03073889|PROCEDURE|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
58069252|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
58281382|NCT00002823|RADIATION|radiation therapy|
58281383|NCT03079973|DRUG|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
58281384|NCT03079973|DRUG|Vehicle of P-3073|Once daily for 24 weeks.
58281385|NCT00591019|DRUG|Modafinil|200 mg/day, morning dose
58281386|NCT00591019|OTHER|Placebo|Sugar pill once per day in the morning.
58281387|NCT01950156|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
58281388|NCT00284154|DRUG|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
58281389|NCT02528617|DRUG|Velaglucerase alfa|Enzyme replacement therapy
58281390|NCT01331135|DRUG|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
58281391|NCT01227239|DRUG|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
58281392|NCT01227239|DRUG|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
58281393|NCT01227239|RADIATION|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
57929169|NCT02166866|OTHER|Quality of Life Questionairre and Education|
57929170|NCT04733781|DRUG|Tumescent Lidocaine and Epinephrine|Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
57929171|NCT04617756|DRUG|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
57929172|NCT03575286|DIAGNOSTIC_TEST|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
58281394|NCT05215353|OTHER|Music Therapy|Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.
57929173|NCT02637115|DIETARY_SUPPLEMENT|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
57929174|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
57929175|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
57929176|NCT02637115|DIETARY_SUPPLEMENT|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
57929177|NCT01102803|BEHAVIORAL|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
57929178|NCT01102803|DRUG|D-Cycloserine|D-Cycloserine
57929179|NCT01102803|DRUG|Placebo|Sugar Pill
57929180|NCT01695577|OTHER|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
57929181|NCT01695577|OTHER|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
57929182|NCT03342248|OTHER|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
57929183|NCT00181987|DRUG|methylphenidate HCl (Concerta)|
57929184|NCT05045326|BEHAVIORAL|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
57929185|NCT05045326|BEHAVIORAL|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
57929186|NCT05184686|OTHER|noise expose|simulate noise expose environments
57929187|NCT05184686|OTHER|RF expose|simulate RF expose environments
57929188|NCT06005389|PROCEDURE|cryotherapy|Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.
57929189|NCT06005389|DIAGNOSTIC_TEST|serum Galectin-3 assay|From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
57929190|NCT04880447|BIOLOGICAL|BNT162b2|COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
58281395|NCT05215353|OTHER|Cognitive Behavioral Therapy|Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.
58281396|NCT05215353|OTHER|assessments|Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
57727857|NCT03073889|PROCEDURE|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
57929191|NCT04116424|OTHER|nurse training of the patient|visit + telephone follow-up
58069253|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
58281397|NCT05308849|OTHER|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
58281398|NCT03909698|OTHER|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
58281399|NCT05497817|BEHAVIORAL|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
58281400|NCT05497817|BEHAVIORAL|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
58281401|NCT00332306|DRUG|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients \<60kg, 400mg patients \> 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
57727858|NCT03073889|DRUG|Ropivacaine|
57727859|NCT05217732|DRUG|ZX-7101A|tablet
57727860|NCT05217732|DRUG|Placebo|Tablet
57727861|NCT04510064|DRUG|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
57727862|NCT04510064|PROCEDURE|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
57727863|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
57929192|NCT04116424|OTHER|neurologist accompaniement|presentation during consultation by neurologist
57951193|NCT03075527|DRUG|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
58069254|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
58069255|NCT04450420|OTHER|Standard training|See arm/group description
58069256|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
58069257|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
58281402|NCT00332306|DRUG|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients \< 60kg, 400 mg OD patients \> 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
58281403|NCT03126123|PROCEDURE|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
58281404|NCT01066702|BIOLOGICAL|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
58281405|NCT01066702|PROCEDURE|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
58281406|NCT01612078|DRUG|Droxidopa|200mg/tab 2tablets, po, three times a week
58281407|NCT01612078|DRUG|Placebo|200mg/tab, po, three times a week.
58281408|NCT03579121|OTHER|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
58281409|NCT03579121|OTHER|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
58281410|NCT00791700|DRUG|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
58281411|NCT05717621|DRUG|VTD-101 ointment|Self-administration of VTD-101 ointment (Decitabine ointment)
58281412|NCT06154720|DRUG|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
58396854|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
57929193|NCT00584883|DRUG|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
57929194|NCT00583024|BIOLOGICAL|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
58281413|NCT02851212|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
58281414|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58281415|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58281416|NCT02851212|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58281417|NCT00489437|DEVICE|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
58281418|NCT00489437|PROCEDURE|Clinical Prediction Score-HIT Score Card|"1. clinical prediction rule~2. rapid immunoassay"
58281419|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
58281420|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
58281421|NCT02610530|OTHER|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
58281422|NCT02502695|OTHER|VATS-associated best practices|
58281423|NCT01447719|DRUG|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
58281424|NCT02751619|DRUG|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
58281425|NCT02751619|DRUG|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
58281426|NCT01958398|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback.
58281427|NCT01958398|BEHAVIORAL|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
58281428|NCT01908582|DRUG|Evacetrapib|Administered orally
58281429|NCT01908582|DRUG|Rifampin|Administered orally
58281430|NCT00343629|DRUG|sulindac|
58281431|NCT00343629|OTHER|pharmacological study|
57929195|NCT03019471|GENETIC|Isolation of tumor DNA|
58281432|NCT04825925|DEVICE|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
58281433|NCT03349489|OTHER|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
58396855|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
58396856|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
58396857|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
58396858|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
57929196|NCT03367715|DRUG|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
58281434|NCT03349489|OTHER|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
58281435|NCT03349489|DEVICE|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
58281436|NCT03349489|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used.
58281437|NCT03349489|DEVICE|Insulin pump|Participant's insulin pump will be used to infuse insulin.
58281438|NCT05460637|BEHAVIORAL|No BS just Fitness|The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
58281439|NCT05050422|DIAGNOSTIC_TEST|Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)|control/study group
58281440|NCT03013192|OTHER|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
58281441|NCT03370185|DRUG|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
58281442|NCT00109941|BIOLOGICAL|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
58281443|NCT00109941|BIOLOGICAL|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
58281444|NCT04283110|DRUG|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
58281445|NCT00925197|OTHER|INR self-testing program|
58281446|NCT03274752|DRUG|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
58281447|NCT03274752|DRUG|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
58396859|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
58396860|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
58396861|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
58069258|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
58396862|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
58396863|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
58281448|NCT05263297|OTHER|control group|no intervention will be made.
58281449|NCT06171568|OTHER|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~* Modified Rankin Scale;~* Instrumental Activities of Daily Living (IADL) questionnaire;~* Montreal Cognitive Assessment (MoCA);~* Frontal assessment battery (BREF);~* Rivermead questionnaire;~* Short Form (36) Health Survey (SF-36)~* Community Integration Questionnaire - Revised (CIQ-R)~* Posttraumatic stress disorder CheckList (PCL-5)"
58396864|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
58396865|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
58396866|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
58396867|NCT06661720|DRUG|Tivozanib|Given orally
57929197|NCT03367715|DRUG|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
58281450|NCT01385956|DRUG|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
58281451|NCT01385956|DRUG|Gemcitabine|Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
58281452|NCT00508157|DRUG|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
57929198|NCT03367715|RADIATION|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
57929199|NCT03910712|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
57929200|NCT03910712|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
57929201|NCT03910712|DRUG|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
57929202|NCT03436706|OTHER|exposure|exposure to chronic stress
57929203|NCT00770835|DRUG|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
58069259|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
58069260|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
58281453|NCT00508157|DRUG|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
57929204|NCT00770835|DRUG|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
57929205|NCT01326195|BEHAVIORAL|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
57929206|NCT01326195|BEHAVIORAL|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
57929207|NCT06331780|DEVICE|Visual acuity|VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
57929208|NCT06331780|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
57929209|NCT06331780|DEVICE|Objective monocular accommodation amplitude measurement|Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance
58069261|NCT02314299|DRUG|MTP-131|
58069262|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
58069263|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
58069264|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
58281454|NCT02324621|DRUG|Oral ONC201|Given PO
58281455|NCT02324621|OTHER|pharmacological study|Correlative studies
57929210|NCT06331780|DEVICE|"Subjective monocular accommodation amplitude measurement with the Push-Up method"|"The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived."
57951194|NCT03075527|DRUG|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
57951195|NCT00251940|DRUG|Tesaglitazar 0.5 or 1 mg|
57951196|NCT00251940|DRUG|Glibenclamide 2.5, 5, 10 or 15 mg|
58069265|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
58281456|NCT02324621|OTHER|laboratory biomarker analysis|Correlative studies
58281457|NCT04183569|OTHER|Sequencing RNA.|RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
58281458|NCT02945696|PROCEDURE|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
58396868|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58396869|NCT06661720|PROCEDURE|MRI|Undergo MRI
58396870|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
58396871|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
58396872|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
58396873|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
58396874|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
58396875|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
58396876|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
58281459|NCT02945696|DRUG|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
58281460|NCT03251482|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
58396877|NCT02414607|BIOLOGICAL|Elderberry Juice|
58396878|NCT02414607|OTHER|Placebo|
58396879|NCT04781855|DRUG|Ibrutinib|Given PO
58396880|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
58396881|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
58396882|NCT02390440|DRUG|EXPAREL|
58396883|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
58396884|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
58396885|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
58396886|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
57727864|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
57727865|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
58396887|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
58396888|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
58396889|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
58396890|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
58396891|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
58396892|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
58396893|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
58396894|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
57951197|NCT01750385|DRUG|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
57951198|NCT01750385|DRUG|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
58281461|NCT03251482|DRUG|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
58281462|NCT03251482|DRUG|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
58281463|NCT03251482|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
58396895|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
58396896|NCT02930382|OTHER|Baroreflex assessment|
58396897|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
58396898|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
58396899|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
58396900|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
58396901|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
58396902|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
58281464|NCT03251482|DRUG|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
58281465|NCT03251482|DRUG|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
57929211|NCT06331780|DEVICE|"Subjective monocular accommodation facility measurement with the Rock method:"|"The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc... You have to do the maximum number of rotations in one minute."
58396903|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
58281466|NCT03251482|DRUG|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
58281467|NCT03251482|DRUG|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
58281468|NCT03251482|DRUG|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
58281469|NCT03251482|DRUG|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
57727866|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
57727867|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
57727868|NCT00377767|BEHAVIORAL|To change structure and roles of primary care teams to optimize prevention of obesity|
57929212|NCT06331780|OTHER|CISS Questionnaire|This questionnaire relating to the use of the near vision will be submitted
58281470|NCT03251482|DRUG|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
58281471|NCT00102154|DRUG|MK0928, gaboxadol / Duration of Treatment: 10 months|
58281472|NCT00004892|DRUG|O6-benzylguanine|
57727869|NCT04121104|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
58281473|NCT00004892|DRUG|polifeprosan 20 with carmustine implant|
58281474|NCT00004892|PROCEDURE|conventional surgery|
58281475|NCT02163317|RADIATION|stereotactic radiosurgery|Undergo MRI-guided focal SRS
58281476|NCT02163317|DEVICE|magnetic resonance imaging|Undergo staging MRI with contrast
58281477|NCT02163317|OTHER|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
58281478|NCT02163317|PROCEDURE|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
58281479|NCT02163317|PROCEDURE|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
58281480|NCT02163317|BEHAVIORAL|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
58281481|NCT06380933|OTHER|experimental group|first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
57727870|NCT04121104|OTHER|SCS is switched on|Spinal cord stimulator is on
57727871|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
57929213|NCT06331780|OTHER|Difficulty assessment questionnaire|After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.
57929214|NCT06331780|OTHER|Subjective evaluation questionnaire|A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
58281482|NCT05642416|DRUG|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
58281483|NCT05642416|DRUG|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
58281484|NCT00329095|DRUG|travoprost, latanoprost, or bimatoprost|
58281485|NCT00329095|DRUG|Additional ocular hypotensive medication|
58281486|NCT00080483|DRUG|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
58281487|NCT00080483|DRUG|testosterone|AndroGel transdermally 5 g a day for two years
58281488|NCT04384198|PROCEDURE|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
58281489|NCT03142256|BEHAVIORAL|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
58281490|NCT03142256|DRUG|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
58281491|NCT00269828|DRUG|paclitaxel|
58281492|NCT00269828|DRUG|paclitaxel poliglumex|
58281493|NCT01644760|PROCEDURE|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
58396904|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
58396905|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
58396906|NCT02604368|DRUG|SC411|Soft gelatin capsule
58396907|NCT02604368|DRUG|Placebo|Soft gelatin capsule
57727872|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
57727873|NCT03989817|DRUG|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
58281494|NCT00618852|DRUG|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
58281495|NCT00618852|DRUG|Saline|1 mg/kg by intravenous bolus injection
58396908|NCT02265536|DRUG|LY3022855|Administered IV
57929215|NCT04304781|DRUG|KSP/QRH dimer|Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
57929216|NCT04141254|OTHER|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
57929217|NCT04141254|OTHER|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
57929218|NCT04758299|OTHER|decision science-based design|decision science-based design explaining actions to take for a negative or positive COVID-19 test
57929219|NCT05683587|OTHER|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
57929220|NCT02228187|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
57929221|NCT01748409|OTHER|Biopsies of peripheral autonomic nervous system|
58069266|NCT04808141|OTHER|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
58281496|NCT05739175|DEVICE|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
58281497|NCT03713996|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
58281498|NCT03713996|OTHER|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
58281499|NCT02192853|DRUG|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
58281500|NCT02192853|DRUG|Placebo|Day 4: placebo tablet
58396909|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
57727874|NCT00374842|BIOLOGICAL|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
58281501|NCT05239546|DRUG|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
57727875|NCT00374842|BIOLOGICAL|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
57727876|NCT01473654|BEHAVIORAL|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
57727877|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
57929222|NCT01748409|OTHER|Autonomic dysfunction questionnaires|
57929223|NCT01748409|OTHER|Electrophysiological tests|
57929224|NCT05334537|OTHER|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
57951199|NCT04724564|DIAGNOSTIC_TEST|THE SURGICAL PLETH INDEX|CORRELATION OF DIFFERENT TIME MEASUREMENTS OF THE SURGICAL PLETH INDEX WITH POSTOPERATIVE PAIN
57727878|NCT05031910|OTHER|Best Practice|Receive standard of care
57727879|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
57727880|NCT05651581|OTHER|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
57727881|NCT03269812|PROCEDURE|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
57727882|NCT05399498|DRUG|Psilocybin|Psilocybin 25mg capsule
57727883|NCT00759109|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
57929225|NCT05334537|OTHER|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
57929226|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
57929227|NCT01135680|DRUG|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
57929228|NCT01135680|DRUG|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
57929229|NCT01135680|DRUG|Moxifloxacin|single oral 400-mg dose on study Day 3
57929230|NCT01135680|DRUG|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
57929231|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
57929232|NCT06227884|OTHER|APN intervention|"Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
58281502|NCT06405802|OTHER|Tele-evaluation|Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
58281503|NCT05943184|BEHAVIORAL|Cognitive Behavioral Nursing Model|(1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
58281504|NCT02242370|DRUG|Low dose of telmisartan|
58281505|NCT02242370|DRUG|High dose of telmisartan|
58281506|NCT02318654|OTHER|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
58281507|NCT02318654|DRUG|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
58281508|NCT04321551|DRUG|Testosterone Cyp 200Mg/Ml Inj (in Oil)|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
58281509|NCT04321551|DRUG|Letrozole|Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
58281510|NCT04611282|PROCEDURE|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
58281511|NCT03331705|DEVICE|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
58281512|NCT04242407|DRUG|DMTS|DMTS applied before surgery and worn for 96 hours
58281513|NCT04242407|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 96 hours
57727884|NCT00759109|OTHER|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
58281514|NCT03009175|DEVICE|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
57727885|NCT03125265|OTHER|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
57727886|NCT03047447|BEHAVIORAL|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
57727887|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
57727888|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
57929233|NCT06227884|OTHER|No APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months)
57929234|NCT06008886|BEHAVIORAL|Vegan diet|Normocaloric diet based solely on foods of plant sources.
57929235|NCT06008886|BEHAVIORAL|Mediterranean diet|Diet with a predominance of plant foods fruits, vegetables, whole grains, nuts and legumes); moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
57929236|NCT03460379|DRUG|Escitalopram|Patients are tested for their normal prescription escitalopram medication
57929237|NCT01217151|DEVICE|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
57929238|NCT01217151|OTHER|Usual treatment|Hemodynamic monitoring based on common practice
57929239|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
57929240|NCT01306422|OTHER|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
57929241|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
57929242|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
57929243|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
57929244|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
57929245|NCT01771068|BEHAVIORAL|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
57929246|NCT06450756|BEHAVIORAL|Couples arm|The Couples Arm aims to improve family planning (FP) utilization in pastoralist communities, addressing significant disparities in contraceptive use and unmet FP needs between pastoralist and agrarian communities in Ethiopia. Pastoralist areas face challenges such as low contraceptive usage, high unmet FP needs, and elevated rates of maternal and child morbidity and mortality. In 2016, only 9.1% of women in pastoralist areas used contraceptives, compared to a 41% prevalence rate in 2019 for the general population in Ethiopia. Reasons for non-use of contraceptives include lack of knowledge, unwillingness, negative perceptions, desire for many children due to child mortality concerns, and male dominance in FP decision-making. The study hypothesizes that engaging men and educating women about FP could enhance FP utilization, increase male involvement in family planning, and empower women.
57929247|NCT06450756|BEHAVIORAL|Male arm|This arm focused on promoting male involvement in family planning (FP) through comprehensive health education and video messages. Husbands were encouraged to become supportive partners and share FP information with their wives. Separate education sessions were held for men, recognizing their greater exposure to social activities and information in pastoralist contexts. Pastoralist wives typically rely on their husbands for information due to limited social access. Women in pastoral communities have significant informal power in family decisions, influenced by factors such as age, husband's status, sons' ages, eloquence, and wisdom. Reproductive health discussions are primarily between husband and wife. Education aimed to improve modern contraceptive use, overcoming common barriers like husband objection and religious influence on decision-making.
58281515|NCT04636671|DRUG|Methylprednisolone|Per-protocol methylprednisolone administration and tapering (see arm description)
58281516|NCT04636671|DRUG|Dexamethasone|Per-protocol dexamethasone administration (see arm description)
58281517|NCT02547701|DRUG|P-3058|
58281518|NCT03267459|DEVICE|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
58281519|NCT01071434|PROCEDURE|MR Imaging|
58281520|NCT01636648|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
58281521|NCT03135574|DIAGNOSTIC_TEST|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
57727889|NCT03175653|OTHER|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
57727890|NCT03175653|OTHER|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
57929248|NCT03820089|DIAGNOSTIC_TEST|Ultrasonography TP|TP us will be made to the included women
58281522|NCT01358578|DRUG|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
58281523|NCT01358578|DRUG|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
57727891|NCT02009475|OTHER|Interval exercise training|
57727892|NCT02009475|OTHER|Continues aerobic training|
57727893|NCT05473195|DRUG|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
58281524|NCT01358578|DRUG|etanercept|etanercept 50mg subcutaneous
58281525|NCT03141034|DRUG|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
58281526|NCT03141034|DRUG|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
58281527|NCT03141034|GENETIC|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
58281528|NCT03141034|GENETIC|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
58281529|NCT00560898|DRUG|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
58396910|NCT02234713|BEHAVIORAL|Motivational Interview|
57727894|NCT05473195|DRUG|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
57727895|NCT05473195|DRUG|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
57727896|NCT05473195|DRUG|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
57727897|NCT05724186|DEVICE|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
58396911|NCT02234713|OTHER|Video Attention Control|
57929249|NCT02323633|DEVICE|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
57929250|NCT02323633|DEVICE|Sham|No transcranial Pulsed Current Stimulation (tPCS)
57929251|NCT00615238|BEHAVIORAL|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
57929252|NCT00615238|BEHAVIORAL|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
57929253|NCT00615238|BEHAVIORAL|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
57929254|NCT00849719|DRUG|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
57929255|NCT00849719|DRUG|PCA MO only|When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
57929256|NCT02257216|OTHER|Vayarin®|Medical Food
57929257|NCT02257216|OTHER|Placebo|Cellulose
57929258|NCT05459285|BIOLOGICAL|14028 injection|14028 injection, single dose, s.c. injection
57929259|NCT05459285|BIOLOGICAL|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
57929260|NCT04058379|RADIATION|CT scan|3 ct scans : D0, D1 and D3
57929261|NCT00603655|OTHER|Low glycemic load diet|Low glycemic load diet
57929262|NCT00603655|OTHER|High glycemic load diet|High glycemic load diet
57929263|NCT00000820|DRUG|Aldesleukin|
57929264|NCT06360809|BEHAVIORAL|Prehabilitation exercise program|After the allocation, the intervention will consist of a prehabilitation program lasting 4 weeks. Each week, there will be three sessions, with one being face-to-face and the other two being unsupervised sessions but with online video-support. Face-to-face sessions will be organized in small groups, and each patient of the PEP group will have an individualized plan based on data obtained during the initial assessment. Each session will include a combination of strength training and moderate aerobic training in a circuit format with movements especially involving the upper body.
57929265|NCT03836807|DRUG|OKITASK®|A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
58396912|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
57929266|NCT03836807|OTHER|Placebo|A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
57929267|NCT02018367|DRUG|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
57929268|NCT03575390|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
58396913|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
57929269|NCT03575390|DIETARY_SUPPLEMENT|Pomegranate|Pomegranate extract 500mg
57929270|NCT02960373|OTHER|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
57929271|NCT02960373|OTHER|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
57929272|NCT02960373|OTHER|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
57929273|NCT02960373|OTHER|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
57929274|NCT01612143|DRUG|setrobuvir|200 mg capsule formulation, single oral dose
57929275|NCT01612143|DRUG|setrobuvir|200 mg tablet formulation, single oral dose
57929276|NCT03050151|DRUG|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
57929277|NCT03050151|DEVICE|Auto-injector Device|Delivery of Dupilumab by auto-injector device
57929278|NCT03050151|DEVICE|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
57929279|NCT05807880|DRUG|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
57929280|NCT04636866|OTHER|NO intervention|NO intervention
57929281|NCT01372670|DRUG|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
57929282|NCT01372670|DRUG|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
57929283|NCT01372670|OTHER|Placebo|Placebo given 3 times per day
57929284|NCT04985890|BIOLOGICAL|UB-421|10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy
57929285|NCT04985890|OTHER|UB-421+chidamide|10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
58095077|NCT06239792|BEHAVIORAL|Sleep Promotion Program|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
58281530|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
58281531|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
58281532|NCT00560898|DRUG|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
58396914|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
58396915|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
58396916|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
57727898|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
57929286|NCT06024681|OTHER|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
58396917|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
57929287|NCT00716053|DRUG|BLVR|BLVR 20 mL
57929288|NCT00256425|BEHAVIORAL|Cognitive rehabilitation|
57929289|NCT05974592|OTHER|Education|Diabetic Foot Self-Management Training Program will be implemented.
57929290|NCT04356248|BEHAVIORAL|Endurance Training|Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
57929291|NCT04356248|BEHAVIORAL|Education|Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
57929292|NCT00105950|DRUG|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
57929293|NCT03355313|RADIATION|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
57929294|NCT01349023|OTHER|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
57929295|NCT01351012|OTHER|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
57727899|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
57929296|NCT01351012|OTHER|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
57929297|NCT01351012|OTHER|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
57929298|NCT01351012|OTHER|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
57727900|NCT01153633|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
57929299|NCT01351012|OTHER|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
57929300|NCT06412484|BEHAVIORAL|Pain Free Session|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.
57929301|NCT06412484|BEHAVIORAL|Low Back Pain Session (= clinically relevant pain)|On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.
57929302|NCT06412484|BEHAVIORAL|Experimental Pain Session (= clinically irrelevant pain)|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
58069267|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
58396918|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
57929303|NCT03180749|OTHER|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
58396919|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
58396920|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
57929304|NCT03388255|DRUG|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication."
57929305|NCT03354741|OTHER|laser therapy|stimulation of the acupuncture point P6 by laser therapy
57929306|NCT05069896|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
58396921|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
57727901|NCT01153633|DEVICE|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
57929307|NCT05069896|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
58396922|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
57929308|NCT00620568|DRUG|SLV-313 SR|sustained release tablets taken once daily for 14 days
57929309|NCT03986866|OTHER|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
58396923|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
58396924|NCT00153140|DRUG|polyethyleneglycol3350|
58396925|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
58396926|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
57929310|NCT00895336|BIOLOGICAL|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
57929311|NCT03049735|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
57929312|NCT03049735|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
57929313|NCT03049735|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
57929314|NCT03049735|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
57929315|NCT02809573|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
57929316|NCT02809573|DRUG|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
57929317|NCT02809573|DRUG|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.
57929318|NCT02809573|DRUG|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.
57929319|NCT02809573|DRUG|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
58069268|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
58069269|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
58069270|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
58396927|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
58396928|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
58396929|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
58396930|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
58396931|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
58396932|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
57929320|NCT04556136|DEVICE|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
57929321|NCT04556136|DIETARY_SUPPLEMENT|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
57929322|NCT01540383|BEHAVIORAL|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, \>=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
57929323|NCT01540383|BEHAVIORAL|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
57929324|NCT03249077|BEHAVIORAL|Digital DPP|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
58069271|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
58069272|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
58069273|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
58069274|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
58069275|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
58069276|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
58069277|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
58069278|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
58069279|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
58396933|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
58396934|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
58396935|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
58396936|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
57929325|NCT03249077|BEHAVIORAL|In-person DPP|The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
57929326|NCT03249077|OTHER|DPP not enrolled|Access to usual care services without restrictions.
57929327|NCT05009186|OTHER|PSA value|We measure PSA value during and after covid-19 infection
57929328|NCT00529451|DRUG|Aliskiren|Aliskiren
57929329|NCT00529451|DRUG|Ramipril|comparator
57929330|NCT00253188|DRUG|galantamine hydrobromide|
57929331|NCT01638091|BEHAVIORAL|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
58396937|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
58396938|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
58281533|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
58396939|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
58396940|NCT01731158|DRUG|Avastin in combination with Roferon-A|
58396941|NCT01731158|DRUG|Afinitor|
58396942|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
58396943|NCT05033886|DRUG|fezolinetant|oral
57929332|NCT01638091|BEHAVIORAL|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
57929333|NCT05784987|DRUG|Rituximab|375 mg/m2, d0, Cycle 1\~4
58396944|NCT05033886|DRUG|placebo|oral
58396945|NCT00040781|DRUG|gefitinib|Given orally
58396946|NCT00040781|OTHER|pharmacological study|Correlative studies
58396947|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
58396948|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
57929334|NCT05784987|DRUG|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1\~4
57929335|NCT05784987|DRUG|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1\~4
57929336|NCT05784987|DRUG|Etoposide|65 mg/m2, d1-3, Cycle 1\~4
57929337|NCT05784987|DRUG|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2\~4
57929338|NCT05784987|DRUG|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4
57929339|NCT05784987|DRUG|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2\~4
57929340|NCT05784987|DRUG|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2\~4
57929341|NCT01605981|DRUG|AMN107|
57929342|NCT00708175|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
57929343|NCT00708175|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
57929344|NCT04058951|OTHER|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
57929345|NCT04058951|OTHER|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
57929346|NCT02307864|DRUG|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
57929347|NCT02307864|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
57929348|NCT02307864|DRUG|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
58396949|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
58396950|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
58396951|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
58396952|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
58396953|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
57727902|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
57929349|NCT02307864|DRUG|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
57929350|NCT05374720|PROCEDURE|salpingectomy|Removal of one of the fallopian tubes.
57929351|NCT05374720|PROCEDURE|hysterectomy|remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.
57929352|NCT06312748|DRUG|L-Citrulline|100 mg tablet
58069280|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
57727903|NCT02950493|OTHER|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
58281534|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
57727904|NCT03359980|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
58281535|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
58306805|NCT05588258|OTHER|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
58396954|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
57727905|NCT05029648|OTHER|Cohort|Cohort
57727906|NCT02873624|PROCEDURE|Laparoscopic cholecystectomy|
57727907|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
57727908|NCT05761431|DRUG|SYHX2008 injection|Subcutaneous administration on Day 1.
58396955|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
58396956|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
58396957|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
57727909|NCT05761431|DRUG|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
57727910|NCT05761431|DRUG|Sandostatin ® injection|Subcutaneous administration on Day 1.
57727911|NCT05761431|DRUG|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
57727912|NCT02672046|OTHER|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
57929353|NCT06312748|DRUG|Placebo for L-Citrulline|L-Citrulline-matched Placebo tablet
57929354|NCT06312748|DRUG|BH4|10mg/kg
57929355|NCT06312748|DRUG|Placebo for BH4|BH4-matched Placebo
57929356|NCT06312748|DRUG|Atorvastatin|10 mg tablet
57929357|NCT06312748|DRUG|Placebo for Atorvastatin|Atorvastatin-matched Placebo
58069281|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
58069282|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
58069283|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
58069284|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
58069285|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
58069286|NCT06497816|OTHER|No intervention|No intervention
58069287|NCT06080308|OTHER|No intervention|No intervention
58069288|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
58069289|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
58396958|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
58281536|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
58281537|NCT01768221|BEHAVIORAL|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
58281538|NCT00855699|DRUG|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
58281539|NCT00802672|DRUG|Ciclopirox Olamine Cream|topical cream
58281540|NCT00802672|DRUG|Loprox Cream 0.77%|topical cream
58281541|NCT00802672|DRUG|Placebo|topical cream
58281542|NCT06196697|BIOLOGICAL|Cadonilimab|Subjects will receive AK104 by intravenous administration
58281543|NCT06196697|BIOLOGICAL|Ivonescimab|Subjects will receive AK112 by intravenous administration
58281544|NCT06196697|DRUG|XELOX|Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
58281545|NCT06196697|DRUG|SOX|Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
58281546|NCT03406624|PROCEDURE|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
58281547|NCT04897035|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
58281548|NCT02004314|DRUG|Chloroquine|
58281549|NCT06288542|OTHER|group d|this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
58281550|NCT06288542|OTHER|group R|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
58281551|NCT02770846|PROCEDURE|Immediate loading|
58281552|NCT02770846|PROCEDURE|Delayed loading|
58281553|NCT00431145|DRUG|Niacin|
58281554|NCT00431145|DRUG|Niacin+Statin|
58281555|NCT02322333|DRUG|MLD10|
58281556|NCT02322333|DRUG|Placebo|
58281557|NCT04677387|BEHAVIORAL|Nalox-comm Training Module|The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
58281558|NCT04677387|BEHAVIORAL|Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists|A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
58281559|NCT00898495|GENETIC|loss of heterozygosity analysis|
58281560|NCT00898495|GENETIC|polymerase chain reaction|
57727913|NCT04306380|OTHER|no intervention, database study|data collection from EMR for database
57727914|NCT05750381|OTHER|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
58281561|NCT00898495|GENETIC|polymorphism analysis|
58281562|NCT05050500|DRUG|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
57727915|NCT05750381|OTHER|Placebo balm|Placebo balm formulation for topical applications.
58281563|NCT05050500|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
58281564|NCT05012774|BEHAVIORAL|Speech Recognition Training|Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
58281565|NCT01379105|OTHER|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
58281566|NCT01379105|OTHER|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
58396959|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
57727916|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
57727917|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
57929358|NCT06509178|OTHER|Peyton group|The same procedures were applied to the students in the experimental group as the students in the control group, except for laboratory applications. Students were asked to watch the video contents after the theoretical course, and in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach. Before the skill demonstration, students were given information about the research. Students were given 15-20 minutes to fill out the voluntary consent form and the urinary catheterization success pre-test. Students were taught the sterile urinary catheter procedure in accordance with Peyton's 4-step approach.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
58069290|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
58281567|NCT03630029|DRUG|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
58281568|NCT04876313|DRUG|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8
58281569|NCT04876313|DRUG|Nivolumab|360 mg IV Q3W x 13 cycles
58281570|NCT00305422|DRUG|Quetiapine fumarate|
58281571|NCT00305422|DRUG|Risperidone|
58281572|NCT02226120|DRUG|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
58281573|NCT02702232|OTHER|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
58281574|NCT05045404|DRUG|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
58281575|NCT05045404|BIOLOGICAL|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
58281576|NCT02932605|DRUG|Placebo|Placebo
58281577|NCT02932605|DRUG|Cannabidiol|Cannabidiol
58281578|NCT01467193|DIETARY_SUPPLEMENT|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
58281579|NCT01467193|OTHER|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
58281580|NCT03469999|DRUG|Dysport Injectable Product|Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
58281581|NCT00300846|DRUG|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
58281582|NCT00300846|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
58281583|NCT01265004|PROCEDURE|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
57727918|NCT06372093|DEVICE|Picterus Jaundice Pro|Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
57727919|NCT05561959|OTHER|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
58281584|NCT01265004|PROCEDURE|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
58281585|NCT01265004|PROCEDURE|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
58281586|NCT02437188|BEHAVIORAL|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
58281587|NCT06188676|DRUG|Cyclophosphamide|Ciclofosfamida
58281588|NCT06188676|DRUG|Doxorubicin Hydrochloride|Adriamycin
58281589|NCT06188676|DRUG|Etoposide Phosphate|Etopophos
58281590|NCT06188676|DRUG|Prednisolone|Prednisolonum
58281591|NCT06188676|DRUG|Rituximab|Chimeric Anti-CD20 Antibody
58281592|NCT06188676|DRUG|Vincristine Sulfate|Oncovin
58281593|NCT06188676|DRUG|Filgrastim|G-CSF
58281594|NCT06188676|DRUG|Pegfilgrastim|PEG-filgrastim
58281595|NCT06188676|DRUG|Nivolumab 40 mg in 4 ml Injection|Opdivo
58281596|NCT02356107|DRUG|5-hydroxytryptophan and Creatine monohydrate|
58281597|NCT03850990|BEHAVIORAL|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
58396960|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
58396961|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
58396962|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
57929359|NCT06509178|OTHER|Halsed group|After the control group students attended the course in accordance with the routine procedures, the students were asked to watch videos of the online urinary catheter application course and the students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice. Students were informed about the research and voluntary consent forms were obtained. Students were given 15-20 minutes to complete the urinary catheterization success pre-test. During the demonstration, the students' questions were answered, the researcher went over the points that the student did not understand, corrected any incorrect behavior, and gave feedback. Afterwards, each student was asked to demonstrate the skill steps individually.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
57929360|NCT00366483|DRUG|Lecozotan SR|
57929361|NCT01955122|DEVICE|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
58281598|NCT03853291|BEHAVIORAL|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
58281599|NCT03853291|BEHAVIORAL|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
57727920|NCT05561959|OTHER|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
57727921|NCT00111657|BIOLOGICAL|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
57727922|NCT00010218|DRUG|karenitecin|
57727923|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
57929362|NCT00619905|DRUG|ACZ885|
57929363|NCT00619905|DRUG|ACZ885|
57929364|NCT03920813|DRUG|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
58069291|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
58281600|NCT03577314|OTHER|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
58396963|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
57727924|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
57727925|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
57727926|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
57727927|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
57727928|NCT06390410|DRUG|Simufilam|100 mg PTI-125
57727929|NCT04975568|OTHER|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
57727930|NCT04975568|OTHER|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
57727931|NCT06358482|BEHAVIORAL|oscillating toothbrush|oscillating toothbrush
57727932|NCT06358482|BEHAVIORAL|standard manual toothbrush|standard manual toothbrush
57727933|NCT05228613|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
57929365|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
57929366|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
57929367|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
57929368|NCT00930514|DRUG|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
58281601|NCT04884971|DRUG|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
58281602|NCT06004830|DRUG|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
58281603|NCT00460356|OTHER|Laboratory Biomarker Analysis|Correlative studies
58281604|NCT00460356|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
58396964|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
58396965|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
58281605|NCT05388422|DEVICE|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
58396966|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
57727934|NCT05228613|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
57727935|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
57727936|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
57727937|NCT06025955|PROCEDURE|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
57727938|NCT06025955|PROCEDURE|open flap debridement|flap surgery will be done
57727939|NCT02045758|DEVICE|Fingerstick|
57727940|NCT02045758|DEVICE|TAP20-C|
57727941|NCT00930111|OTHER|2-week rotation|Attending physician is assigned to a 2-week rotation.
57727942|NCT00930111|OTHER|4-week rotation|Attending physician is assigned to a 4-week rotation.
57727943|NCT04475744|DRUG|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
58281606|NCT00994799|DRUG|ranibizumab|10mg/ml intravitreal injection
57727944|NCT04475744|PROCEDURE|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
57727945|NCT05626829|DRUG|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
57727946|NCT03673436|PROCEDURE|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
57929369|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
57929370|NCT01571765|OTHER|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
58281607|NCT00994799|RADIATION|macular grid-pattern laser|macular grid-pattern laser therapy
58281608|NCT06005090|PROCEDURE|Far Cortical Locking Technique|Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
58281609|NCT03157596|OTHER|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
58281610|NCT03492905|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
58396967|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
58396968|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
58396969|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
57727947|NCT04080973|DIAGNOSTIC_TEST|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
57727948|NCT04080973|DIAGNOSTIC_TEST|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
57727949|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
57727950|NCT00418392|PROCEDURE|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
57727951|NCT00418392|PROCEDURE|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
57727952|NCT04302792|BEHAVIORAL|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
57727953|NCT04302792|BEHAVIORAL|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
57727954|NCT04015193|PROCEDURE|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
57929371|NCT00002016|DRUG|Sevirumab|
57929372|NCT00294385|DRUG|Docetaxel|
58069292|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
58069293|NCT01376115|DRUG|Nelarabine|
58069294|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
57929373|NCT00294385|DRUG|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
58281611|NCT06015919|BEHAVIORAL|dash diet|"* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
58281612|NCT06015919|DEVICE|Acupuncture|acupuncture
58281613|NCT01054313|DRUG|Docetaxel (Taxotere)|Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
58281614|NCT01054313|DRUG|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
58281615|NCT01054313|DRUG|Prednisone|5 mg by mouth twice a day with prostate cancer.
58281616|NCT05872659|OTHER|normal saline|iv at D0, D30, D60
58281617|NCT05872659|BIOLOGICAL|Mesenchymal stem cells|iv at D0, D30, D60
58281618|NCT06080165|DRUG|Sirolimus|Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
58281619|NCT06080165|DRUG|Placebo|matching placebo
58281620|NCT00190112|PROCEDURE|ventral cardiac denervation|
58281621|NCT05735405|BEHAVIORAL|Neuropsychological evaluation|Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.
58281622|NCT05735405|BIOLOGICAL|BDNF evaluation|During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).
58281623|NCT05735405|BEHAVIORAL|Pedaling as a moderate intensity aerobic exercise|During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.
58281624|NCT05735405|OTHER|Cognitive Training|During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.
58281625|NCT05735405|DIAGNOSTIC_TEST|VO2 assessment|"To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF."
58281626|NCT01121536|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
58281627|NCT02315664|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
58281628|NCT02315664|BEHAVIORAL|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
58281629|NCT02863653|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
58281630|NCT03564132|DRUG|Yigansan|Yigansan granules
58396970|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
58396971|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
57929374|NCT00294385|DRUG|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
57929375|NCT06277908|PROCEDURE|Elective Surgery for gastric cancer|Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
57929376|NCT01170039|DRUG|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
58281631|NCT03564132|DRUG|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
58281632|NCT03724019|DRUG|Ketamine|Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
58281633|NCT03464474|DEVICE|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
58281634|NCT02118259|OTHER|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
58281635|NCT05131347|BEHAVIORAL|motor intervention|Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.
58281636|NCT05131347|BEHAVIORAL|cognitive intervention|Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
58281637|NCT00370435|DRUG|GW274150|
58281638|NCT04721366|OTHER|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
58281639|NCT00421109|DRUG|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
58281640|NCT00421109|DRUG|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
57727955|NCT03567226|BEHAVIORAL|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise"
57727956|NCT03567226|BEHAVIORAL|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
57727957|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
57727958|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
57727959|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
57727960|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
57727961|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
57727962|NCT01932164|PROCEDURE|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
57727963|NCT01932164|PROCEDURE|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
57727964|NCT02546752|OTHER|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
57727965|NCT03599063|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
57727966|NCT03599063|OTHER|Placebo|Placebo, administered subcutaneously
57727967|NCT02775383|OTHER|Therapeutic|Observational Study
57727968|NCT03495024|DRUG|Varenicline|Oral medication approved to facilitate smoking cessation
57929377|NCT01170039|DRUG|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
57929378|NCT06214871|DEVICE|rTMS|Transcranial Magnetic Stimulation
58281641|NCT00421109|DRUG|Placebo|Encapsulated tablet. Once daily for 28 days
58396972|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
57727969|NCT00809757|DRUG|Levalbuterol|90 ug Levalbuterol (2 actuations)
57727970|NCT00809757|DRUG|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
57727971|NCT00809757|DRUG|Placebo|Placebo (2 actuations)
57727972|NCT05436574|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
57727973|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
57929379|NCT03653221|OTHER|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
57929380|NCT03653221|OTHER|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
57929381|NCT05867953|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
57929382|NCT03299634|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
58069295|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
58281642|NCT00038311|DRUG|PN-152,243)/PN-196,444|
58396973|NCT01404403|DEVICE|Rapid System|
57727974|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
57727975|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
58396974|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
58396975|NCT02926027|DRUG|placebo|placebo
58396976|NCT00192660|DRUG|Lamivudine|
58396977|NCT00192660|DRUG|Stavudine|
58396978|NCT00192660|DRUG|Didanosine|
58396979|NCT00192660|DRUG|Zidovudine|
57727976|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
57929383|NCT01106820|OTHER|Supervised progressive resistance training|Supervised progressive resistance training
57929384|NCT01106820|OTHER|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
57929385|NCT01481389|DIETARY_SUPPLEMENT|Theobromine|200 ml drink with added theobromine (no cocoa added)
57929386|NCT01481389|DIETARY_SUPPLEMENT|Cocoa|200 ml drink with cocoa (no theobromine added)
58069296|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
58281643|NCT04163926|PROCEDURE|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
58281644|NCT04163926|PROCEDURE|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
58281645|NCT02779270|DRUG|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
58281646|NCT02779270|DRUG|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
58281647|NCT04609449|PROCEDURE|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
58281648|NCT04609449|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
57727977|NCT03094689|OTHER|Cold water immersion|
57727978|NCT03094689|OTHER|Water immersion|
58281649|NCT00797407|DIETARY_SUPPLEMENT|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
58281650|NCT00161967|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
58281651|NCT02535754|BEHAVIORAL|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
58281652|NCT02535754|BEHAVIORAL|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
58281653|NCT02535754|BEHAVIORAL|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
57727979|NCT06425393|DIAGNOSTIC_TEST|Urea beath test (UBT)|H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
57727980|NCT01903655|OTHER|telomere length|
57727981|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
57727982|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
57727983|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
57727984|NCT04877301|DEVICE|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
57727985|NCT04877301|PROCEDURE|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
57727986|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
57929387|NCT01481389|DIETARY_SUPPLEMENT|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
57929388|NCT01481389|DIETARY_SUPPLEMENT|Placebo|200 ml drink (no added theobromine or cocoa)
57929389|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
57929390|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
57929391|NCT03445988|BEHAVIORAL|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
58069297|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
58069298|NCT00002021|DRUG|Foscarnet sodium|
58069299|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
58095078|NCT06702371|BEHAVIORAL|Mindset Intervention|"The EMBody intervention contains seven short documentary-style films and paired reflection activities across three modules.~Module 1: Introducing Mindsets (Film 1: A New normal; Film 2: What is a Mindset?; Film 3: Your Body is Capable; Film 4: How to Choose Your Mindset).~Module 2: Challenges and Setbacks (Film 5: Living with Uncertainty; Film 6: The Long and Winding Road).~Module 3: Looking to the Future (Film 7: Opportunities Emerge)."
58095079|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.
57929392|NCT03445988|BEHAVIORAL|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
58281654|NCT00562731|DRUG|ARD-0403|Daily transdermal ARD-0403
58281655|NCT04708496|DRUG|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
57727987|NCT00216151|DRUG|Zoledronic Acid|Zoledronic Acid 4mg, every three months
58281656|NCT05223166|DRUG|Pitolisant|Wakix tablet
58281657|NCT05223166|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
58281658|NCT01483599|DRUG|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
58281659|NCT01483599|DRUG|CNTO 1959 (15 mg)|SC injections
58281660|NCT01483599|DRUG|CNTO 1959 (50 mg)|SC injections
58281661|NCT01483599|DRUG|CNTO 1959 (100 mg)|SC injections
58281662|NCT01483599|DRUG|CNTO 1959 (200 mg)|SC injections
58281663|NCT01483599|DRUG|Adalimumab|SC injections
58281664|NCT01483599|DRUG|Placebo|SC injections
58281665|NCT00005872|DRUG|rubitecan|
58396980|NCT00192660|DRUG|Tenofovir|
58396981|NCT00192660|DRUG|Abacavir|
58396982|NCT00192660|DRUG|Efavirenz (EFV)|
57929393|NCT03445988|OTHER|Usual Care|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
58069300|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
58069301|NCT04378855|OTHER|Questionnaire|Quality of life assessment
58069302|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
58281666|NCT04627948|DIAGNOSTIC_TEST|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
57727988|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
58281667|NCT05938322|OTHER|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates \< 30g/day, 1.2g-1.5g protein/kg/day and lipids \> 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
57727989|NCT06283004|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
58281668|NCT05938322|OTHER|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
58281669|NCT01796275|BEHAVIORAL|Core intervention program|
58396983|NCT00192660|DRUG|Nevirapine|
57727990|NCT06283004|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
57727991|NCT06283004|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
57727992|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
58281670|NCT01796275|BEHAVIORAL|Booster session|
58281671|NCT01796275|BEHAVIORAL|Control only (Tea gathering)|
58281672|NCT03446209|DRUG|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
58281673|NCT03446209|DRUG|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
58281674|NCT03290183|DEVICE|Confocal laser endomicroscopy|Real-time microscopic imaging technique
58281675|NCT02985021|DRUG|Carboplatin|Chemotherapy
58281676|NCT02985021|DRUG|Docetaxel|Chemotherapy
58281677|NCT00983541|DRUG|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
58396984|NCT00192660|DRUG|Indinavir|
58396985|NCT00192660|DRUG|Saquinavir|
58396986|NCT00192660|DRUG|Amprenavir|
58396987|NCT00192660|DRUG|Ritonavir|
58396988|NCT00192660|DRUG|Nelfinavir|
58396989|NCT00192660|DRUG|Tipranavir|
58396990|NCT00192660|DRUG|enfuvirtide (T20)|
57727993|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
57727994|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
57727995|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
57727996|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
57727997|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
57727998|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
57727999|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
57728000|NCT02331992|BEHAVIORAL|Adherence program|Participants will receive supportive messages while enrolled in the program.
57728001|NCT02912533|DRUG|JR-131|
57728002|NCT05430412|DEVICE|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
57728003|NCT02605057|DRUG|LEO 80185 gel|
57728004|NCT02605057|DRUG|Dovobet(r) Ointment|
57728005|NCT02564198|DRUG|Ramucirumab|Administered IV
57728006|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
57728007|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
57929394|NCT06510647|OTHER|Hormonal Therapy Agent|"With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy."
57929395|NCT02323763|OTHER|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
57929396|NCT00958620|PROCEDURE|Shock Wave Therapy|Extracorporal shock-wave therapy
57929397|NCT04629716|OTHER|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
57929398|NCT03759977|OTHER|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
57929399|NCT04129918|BEHAVIORAL|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
57929400|NCT01643954|PROCEDURE|robotic radical prostatectomy|robotic assisted surgery
57929401|NCT03318809|DRUG|AMG 986|tablets for oral administration
57929402|NCT02429622|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
57929403|NCT02429622|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
57728008|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
57728009|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
57728010|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
57728011|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
57728012|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
57728013|NCT02614976|DEVICE|Padding|"Padding webrill (Covidian) TM 6"
57929404|NCT02429622|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
57929405|NCT02429622|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
58396991|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
57728014|NCT03103620|DEVICE|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
58281678|NCT00983541|RADIATION|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
58396992|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
58396993|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
58396994|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
58396995|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
57728015|NCT00736996|DRUG|Pioglitazone|30 - 45mg tablet daily for 6 months
58281679|NCT00983541|DRUG|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
58396996|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
58396997|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
58396998|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
57728016|NCT00736996|DRUG|Placebo|Matching tablet daily for 6 months
57728017|NCT00736996|BEHAVIORAL|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
57728018|NCT06039748|OTHER|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
57728019|NCT06634667|DRUG|third-generation EGFR-TKI combined with anlotinib|third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
57728020|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
57728021|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
57728022|NCT02552836|BEHAVIORAL|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
58396999|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
58397000|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
58397001|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
58397002|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
58397003|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
58397004|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
57728023|NCT02552836|BEHAVIORAL|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
57728024|NCT04546087|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
57728025|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
57728026|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
57728027|NCT01765140|DRUG|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
57728028|NCT01645709|DRUG|Verapamil|
57728029|NCT01645709|DRUG|Placebo|
57728030|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
58281680|NCT02624154|PROCEDURE|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
58281681|NCT00202891|DRUG|sisomicin|
58281682|NCT04350164|DRUG|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
58397005|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
57728031|NCT00094380|DRUG|Cyclophosphamide|
58281683|NCT04394663|DRUG|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
58281684|NCT04394663|DRUG|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
58281685|NCT02904395|OTHER|observational (no intervention)|
58281686|NCT05919355|OTHER|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
58281687|NCT03428399|OTHER|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
58281688|NCT03276845|DIAGNOSTIC_TEST|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
58281689|NCT01993641|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
58281690|NCT01993641|DRUG|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
58281691|NCT01993641|DRUG|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
58281692|NCT00568568|DRUG|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
58281693|NCT05634642|DEVICE|Ultrasound|Using ultrasound to measure the diameter of distal radial artery
57929406|NCT06038825|DEVICE|topical vibration|topical vibration (Aprilla brand, giving 6000 vibrations per minute) is a device for pain relief during injection of local anesthetic.
57929407|NCT00006159|BEHAVIORAL|lifestyle (exercise, diet, and family and community support)|
58281694|NCT02756364|DRUG|Fulvestrant|Fulvestrant IM injection.
58281695|NCT02756364|DRUG|Sapanisertib|Sapanisertib capsule.
58281696|NCT04213833|DRUG|Propofol Injection [Diprivan]|patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
58281697|NCT04213833|DRUG|Dexmedetomidine [Precedex]|patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
58281698|NCT04213833|DRUG|Palatable Lidocaine Topical Gel|15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
58397006|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
58397007|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
58397008|NCT06563466|OTHER|Treatment as usual|See arm description
58397009|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
57728032|NCT05647447|DRUG|Osanetant|Osanetant 200 mg orally, twice per day
58281699|NCT04779710|OTHER|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
58281700|NCT00888290|DRUG|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
58281701|NCT00888290|DRUG|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
58397010|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
58397011|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
58397012|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
58281702|NCT03549065|DEVICE|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
58281703|NCT03167255|DRUG|NS-065/NCNP-01|Received during weekly intravenous infusions
58281704|NCT00201318|DRUG|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
58281705|NCT04652518|DRUG|LYT-100|oral administration
58281706|NCT04652518|OTHER|Placebo|oral administration
58281707|NCT01480817|DRUG|Sorafenib|Sorafenib 400mg po bid
58281708|NCT01480817|PROCEDURE|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
58281709|NCT02783313|DEVICE|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
58281710|NCT02783313|OTHER|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
58281711|NCT04540731|OTHER|This is an observational study without intervention|This is an observational study without intervention
58397013|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
57728033|NCT02505932|PROCEDURE|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
57728034|NCT02505932|PROCEDURE|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
57929408|NCT05406388|PROCEDURE|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
58281712|NCT00463034|GENETIC|microarray analysis|
58281713|NCT00463034|GENETIC|polymerase chain reaction|
58281714|NCT00463034|GENETIC|polymorphism analysis|
58397014|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
58397015|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
58397016|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
58397017|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
58397018|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
58397019|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
58397020|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
58397021|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
58281715|NCT00463034|OTHER|high performance liquid chromatography|
58281716|NCT00463034|OTHER|immunohistochemistry staining method|
58281717|NCT00463034|OTHER|laboratory biomarker analysis|
58281718|NCT00463034|OTHER|questionnaire administration|
58281719|NCT01002248|DRUG|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
58281720|NCT01002248|DRUG|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
58281721|NCT01002248|DRUG|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
58281722|NCT01002248|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
58281723|NCT01615159|BEHAVIORAL|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
57929409|NCT05406388|PROCEDURE|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
57929410|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
58281724|NCT03494049|PROCEDURE|Veil sparring HoLEP|"Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
58281725|NCT03494049|PROCEDURE|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
58281726|NCT03884270|BEHAVIORAL|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
58281727|NCT02741115|DRUG|Udenafil|Active drug
58281728|NCT02741115|DRUG|Placebo|Matching Placebo
58281729|NCT00743847|DRUG|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
58281730|NCT00743847|DRUG|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
58281731|NCT00743847|DRUG|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
58281732|NCT01133496|DRUG|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
58281733|NCT01181947|DEVICE|TEVAR|Thoracic endovascular aneurysm repair
58281734|NCT03116724|PROCEDURE|central venous catheterization through Rt. IJV|"* insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point"
58281735|NCT05487820|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
58281736|NCT03447964|OTHER|dosing of sphingolipids|- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
58281737|NCT03436069|OTHER|Conventional treatment protocols of breast cancer|
58281738|NCT04719195|OTHER|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
58281739|NCT00312767|DRUG|Fabrazyme (agalsidase beta)|
58397022|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
57929411|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
57929412|NCT02593669|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
58397023|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
58397024|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
58281740|NCT04685356|OTHER|IBAIP : Infant Behaviour Assessment and Intervention Program|The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
58397025|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
57929413|NCT02593669|DRUG|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
57929414|NCT02762825|BEHAVIORAL|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
57929415|NCT02762825|BEHAVIORAL|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
57929416|NCT05226026|BEHAVIORAL|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
57929417|NCT05226026|OTHER|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
57929418|NCT01303965|DRUG|Sirolimus|Start on Day -3 and continue for 1 year
57929419|NCT01303965|DRUG|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
57929420|NCT01303965|DRUG|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
58069303|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
58069304|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
57728035|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
58281741|NCT04685356|OTHER|Standard Support|One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
58397026|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
58397027|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
58397028|NCT00024024|DRUG|rebimastat|
58397029|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
58397030|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
58397031|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
58397032|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
58397033|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
58397034|NCT03016624|DEVICE|OCT guided PCI|oct guided
58397035|NCT03016624|DEVICE|Angiography guided PCI|angio guided
58397036|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
58397037|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
58397038|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
57728036|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
58397039|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
58397040|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
58397041|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
58397042|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
57728037|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
57728038|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
58281742|NCT04685356|OTHER|Ages and Stages Questionnaire (ASQ)|Global development screening tool
58281743|NCT04685356|OTHER|Parenting Stress Index (PSI)|Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
58281744|NCT04685356|OTHER|Bayley Scales of Infant and Toddler Development (BSID-III)|This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
58281745|NCT01756248|DRUG|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
57728039|NCT03074422|PROCEDURE|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
58281746|NCT00073008|DRUG|GW572016 (lapatinib)|tyrosine kinase inhibitor
58281747|NCT01711008|DIETARY_SUPPLEMENT|Cereal|
58281748|NCT01711008|DIETARY_SUPPLEMENT|No breakfast|
58397043|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
58281749|NCT02314312|DRUG|Everolimus + low dose cyclosporin A + prednisolone|
58281750|NCT02314312|DRUG|Standard immunosupressive regimen|
58397044|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
58397045|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
58397046|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
58397047|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
58397048|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
58397049|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
58397050|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
58397051|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
58397052|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
58397053|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
58397054|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
57728040|NCT00618514|DEVICE|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
57929421|NCT02091895|PROCEDURE|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
57929422|NCT00771004|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
57929423|NCT00771004|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
57929424|NCT03133806|DEVICE|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
57929425|NCT04978142|DEVICE|transcranial Direct Current Stimulation (tDCS)|Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
58069305|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
58069306|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
58397055|NCT02924246|OTHER|raw milk|raw milk
58397056|NCT02924246|OTHER|pasteurized milk|pasteurized milk
58397057|NCT02924246|OTHER|UHT milk|UHT milk
58397058|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
58397059|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
58397060|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
58397061|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
58397062|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
58397063|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
58397064|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
58095080|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
58095081|NCT06315569|BEHAVIORAL|Run 3000 meters|Participants in both groups were asked to do two 3,000-meter runs at different intervals
58095082|NCT02380248|OTHER|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
58281751|NCT02727309|DRUG|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
58397065|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
58397066|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
58397067|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
58397068|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
58397069|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
58069307|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
58069308|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
58069309|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
58069310|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
58397070|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
58397071|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
57929426|NCT01448213|DRUG|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
58069311|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
58069312|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
58069313|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
58069314|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
58069315|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
58069316|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
58069317|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
58069318|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
57929427|NCT01448213|DRUG|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
58069319|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
58069320|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
58069321|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
58069322|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
58069323|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
58069324|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
58281752|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
58281753|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
58281754|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
58281755|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
58281756|NCT05987943|PROCEDURE|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
58281757|NCT03293446|DIAGNOSTIC_TEST|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
58397072|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
58397073|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
58069325|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
58069326|NCT06371560|OTHER|Questionnaire|online based questionnaire
58069327|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
58069328|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
58069329|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
58069330|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
58069331|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
58281758|NCT03162328|DEVICE|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
58281759|NCT03162328|DEVICE|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
58281760|NCT00714155|OTHER|Questionnaires, Physical Examination|Questionnaires, Physical Examination
58281761|NCT00240656|DRUG|spironolactone captopril carvedilol|
58281762|NCT02278705|OTHER|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
58281763|NCT02278705|OTHER|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
58281764|NCT02278705|OTHER|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
58281765|NCT03947502|BEHAVIORAL|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
57929428|NCT02805725|DRUG|Phase 1: Trabectedin|"Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)"
58397074|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
57929429|NCT02805725|DRUG|Phase 2: Trabectedin|"Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial."
57929430|NCT02805725|DRUG|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
58069332|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
58069333|NCT04846543|OTHER|MRI Scan|MRI scan
58069334|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
58069335|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
58069336|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
58069337|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
58069338|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
58069339|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
58069340|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus push-ups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, feet will be placed flat on the ground. Participants will then move their heels up and down continuously.~Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till their 60-80% of their maximum heart rate is achieved and maintained"
58069341|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
58069342|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
58069343|NCT02911285|DRUG|Placebo|Placebo pills bid
58069344|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
58069345|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
58069346|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
58397075|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
58069347|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
58069348|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
58069349|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
58281766|NCT04888858|DRUG|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
58397076|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
58069350|NCT00052403|PROCEDURE|anti-cytokine therapy|
58069351|NCT00052403|PROCEDURE|antiangiogenesis therapy|
58069352|NCT00052403|PROCEDURE|antibody therapy|
58069353|NCT00052403|PROCEDURE|biological response modifier therapy|
58069354|NCT00052403|PROCEDURE|growth factor antagonist therapy|
58069355|NCT00052403|PROCEDURE|monoclonal antibody therapy|
58069356|NCT00004409|DRUG|collagenase|
58281767|NCT00845676|DRUG|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
58281768|NCT06006637|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
58281769|NCT01362023|BEHAVIORAL|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home"
58281770|NCT01753414|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
58281771|NCT01753414|PROCEDURE|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
58281772|NCT03541447|DRUG|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
58281773|NCT03541447|DRUG|Octreotide LAR|A single dose of two 20 mg i.m. injections.
58281774|NCT03541447|OTHER|Placebo|A single dose of two 20 mg i.m. injections.
58281775|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart
58281776|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart
57728041|NCT00618514|DEVICE|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
57728042|NCT02011880|DIETARY_SUPPLEMENT|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
58069357|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
58281777|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart
58281778|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
58281779|NCT05574829|DEVICE|Esophageal manometry and monitoring of electrical activity of the diaphragm|Esophageal manometry and monitoring of electrical activity of the diaphragm
58281780|NCT03016468|DRUG|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
58281781|NCT03016468|DRUG|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
58281782|NCT06454643|DRUG|Flucloxacillin and gentamicin|This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
58281783|NCT06454643|DRUG|Flucloxacillin and ceftriaxone|Control group
57728043|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
57728044|NCT03706599|BEHAVIORAL|Therapeutic education on fever|Session for therapeutique education on fever
57728045|NCT03706599|BEHAVIORAL|Therapeutic education on household accidents|Session for therapeutic education on household accidents
58281784|NCT02698709|OTHER|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
58281785|NCT02488967|DRUG|Carboplatin|Given IV
58281786|NCT02488967|DRUG|Cyclophosphamide|Given IV
58281787|NCT02488967|DRUG|Doxorubicin Hydrochloride|Given IV
58281788|NCT02488967|OTHER|Laboratory Biomarker Analysis|Correlative studies
58281789|NCT02488967|DRUG|Paclitaxel|Given IV
57929431|NCT02805725|DRUG|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
58069358|NCT01960036|BEHAVIORAL|Womens Health Education|
58281790|NCT04202536|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
58069359|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
58069360|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
58069361|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
58281791|NCT04202536|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
58281792|NCT00419159|DRUG|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
58281793|NCT02710552|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
58281794|NCT02710552|DRUG|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
58069362|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
58281795|NCT04649970|PROCEDURE|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
58281796|NCT01198535|BIOLOGICAL|Cetuximab|Given IV
58281797|NCT01198535|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
58281798|NCT01198535|OTHER|Laboratory Biomarker Analysis|Correlative studies
58281799|NCT01198535|OTHER|Pharmacological Study|Correlative studies
58397077|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
57728046|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
57728047|NCT06535217|PROCEDURE|Liver transplantation|Liver transplantation
57728048|NCT00145431|DRUG|torcetrapib/atorvastatin|
57728049|NCT00145431|DRUG|atorvastatin|
57728050|NCT00145431|DRUG|fenofibrate|
58069363|NCT03164304|DRUG|Magnesium Sulfate|intravenous
58069364|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
58095083|NCT06702007|BEHAVIORAL|eHaRT-A|Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
58095084|NCT03843034|GENETIC|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
58281800|NCT02102672|DRUG|Trimetazidine|
58281801|NCT06468163|DEVICE|Drug infusion into joint through catheter.|With or without using catheter after DAIR operation for drug infusion.
58397078|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
57728051|NCT04459611|BIOLOGICAL|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
57728052|NCT04459611|DRUG|pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
57728053|NCT04459611|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
57728054|NCT04459611|DRUG|albumin-bound paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
57728055|NCT00366626|DRUG|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
57728056|NCT00366626|DRUG|Placebo|Placebo for 7 days matched to Naltrexone
57728057|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
57728058|NCT05013892|DRUG|Memantine|Capsule, taken orally
57728059|NCT00439959|DRUG|GSK625433/placebo|
57728060|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
57728061|NCT02536508|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
57929432|NCT00076362|DRUG|Sandostatin LAR|
58397079|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
58397080|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
58397081|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
58397082|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
58397083|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
58397084|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
57929433|NCT04195581|DEVICE|comfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
58069365|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
58281802|NCT01742715|OTHER|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
58397085|NCT00000293|DRUG|Nefazodone|
58397086|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
58069366|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
58397087|NCT05787587|DRUG|IDE-161|Oral Medication
58397088|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
57728062|NCT02536508|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
57728063|NCT02536508|DRUG|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
57929434|NCT04195581|DEVICE|fanfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
57929435|NCT02970734|BEHAVIORAL|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
57929436|NCT02970734|BEHAVIORAL|Resource Webpage|Static webpage listing anxiety resources.
57728064|NCT05203029|OTHER|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
58069367|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
58281803|NCT01742715|OTHER|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
58281804|NCT01742715|OTHER|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
58281805|NCT02202889|BEHAVIORAL|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
58281806|NCT00729300|DRUG|placebo|0mg daily
58281807|NCT00729300|DRUG|disulfiram|250mg daily
58281808|NCT04013152|OTHER|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
58281809|NCT03040349|BEHAVIORAL|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
57929437|NCT00691886|DRUG|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
58281810|NCT03040349|BEHAVIORAL|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
58281811|NCT03040349|BEHAVIORAL|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
58281812|NCT03573570|OTHER|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
58281813|NCT03369873|OTHER|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
58281814|NCT03470623|DEVICE|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
57728065|NCT01813500|OTHER|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
57728066|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
58069368|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
57728067|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
57929438|NCT00800423|DRUG|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
58069369|NCT05407168|OTHER|Best Practice|Receive standard of care
58069370|NCT05407168|OTHER|Health Promotion and Education|View decision aid
58069371|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
58069372|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
58069373|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
58095085|NCT00272623|PROCEDURE|Seldinger technique or venous cut-down for port placement|
58281815|NCT03470623|DEVICE|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
57929439|NCT00800423|DRUG|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
58281816|NCT05683951|DRUG|DWKH|Administration of DWKH three times daily
58281817|NCT05683951|DRUG|DWKH-R|Administration of DWKH-R three times daily
58281818|NCT05683951|DRUG|Placebo|Administration of Placebo three times daily
58281819|NCT00621517|DRUG|Bupropion|Partipants will receive 150 mg bupropion per night
58281820|NCT00621517|DRUG|Placebo|1 capsule nightly for six weeks
58281821|NCT00012389|DRUG|irinotecan hydrochloride|
58281822|NCT00012389|DRUG|oxaliplatin|
58281823|NCT03983434|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
58281824|NCT05249621|DRUG|MZE001|Small molecule inhibitor of muscle glycogen synthase
58281825|NCT05249621|DRUG|Placebo|Product containing excipients with no active ingredients
58281826|NCT02446847|DRUG|3BNC117|3BNC117 infusions
57929440|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
58397089|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
57929441|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
57728068|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
57929442|NCT02183922|DIETARY_SUPPLEMENT|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
58281827|NCT02446847|OTHER|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
57728069|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
58095086|NCT06393673|DRUG|HS-10384 tablet Dose 1|Administered orally QD
58281828|NCT00755261|DRUG|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
58281829|NCT00755261|DRUG|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
58281830|NCT00191802|DRUG|teriparatide|
58281831|NCT01125085|RADIATION|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"* Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks"
58281832|NCT00104793|DRUG|carboplatin|
58281833|NCT00104793|DRUG|irinotecan hydrochloride|
58281834|NCT01810744|OTHER|capillaroscopy|
58281835|NCT01810744|OTHER|blood pressure measurement|
58281836|NCT03894761|OTHER|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
58281837|NCT01759394|DRUG|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
58281838|NCT00538512|BIOLOGICAL|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
58281839|NCT00538512|BIOLOGICAL|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
58281840|NCT00538512|OTHER|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
58281841|NCT02097771|DEVICE|LMA SupremeTM|
58397090|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
58069374|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
58069375|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
58281842|NCT02097771|DEVICE|AuraOnceTM|
57929443|NCT06470412|OTHER|Control group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
57929444|NCT06470412|OTHER|AI-Guided Group|Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
57929445|NCT02536755|DRUG|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
57929446|NCT00002313|DRUG|Nystatin|
57929447|NCT00002313|DRUG|Didanosine|
58069376|NCT02983968|OTHER|Description of the cirrhosis management|
58069377|NCT02135848|DRUG|GSK1278863|GSK1278863
58069378|NCT02135848|DRUG|Placebo|Placebo
58095087|NCT06393673|DRUG|HS-10384 tablet Dose 2|Administered orally QD
58095088|NCT06393673|DRUG|HS-10384-matched placebo tablets|Administered orally QD
58281843|NCT01383252|PROCEDURE|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
58281844|NCT01383252|PROCEDURE|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
58281845|NCT06525974|DRUG|Febuxostat|40mg of Febuxostat once daily
58281846|NCT06525974|DRUG|Mesalamine|1 g mesalamine three times daily for 3 months.
58281847|NCT01119846|DRUG|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
58281848|NCT01119846|DRUG|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
58281849|NCT01119846|DRUG|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
58281850|NCT05008445|BIOLOGICAL|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
58281851|NCT05008445|COMBINATION_PRODUCT|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
58281852|NCT06307171|DIAGNOSTIC_TEST|In-house Western blot, specific for Leishmania|"Sample will be collected at the collaborating centres and at the DITM, if not already stored at -80°C. The samples will be delivered to the DITM. For the CONTROL groups, two serological tests for Leishmaniasis, based on different antigenic fraction, will be performed on serum samples.~Different strains of Leishmania infantum and Leishmania donovani will be cultivated axenically at the DITM.~Whole soluble fraction of promastigote (WSF), the whole membrane protein fraction (WMF) and the whole soluble fraction secreted by promastigotes (WSFe) of Leishmania spp. will be obtained and the ARPs from WSF, WMF and WSFe, of each Leishmania will be checked trough Western-blot analysis testing at a final dilution of 1/100 each serum sample. The predominant bands detected by Western-blot analysis will be identified by SDS-PAGE separation. Selected bands, corresponding to the immunogenic bands, will be excised, digested and identified with Mass Spectrometry analysis."
58281853|NCT06450093|OTHER|Preformed stainless steel crown.|A well-fitted preformed stainless-steel crown will be chosen by measuring the mesiodistal dimension of the tooth or its contralateral counterpart, using a graduated periodontal probe for guidance. (6) Tooth preparation will be carried out with #835 diamond fissure bur to reduce occlusal surface up to 1 to 1.5 mm. The interproximal reduction will be made mesially and distally using #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. The selected crown size will be checked, and a trial fit will be done before cementation. The crown will be cemented using self-cured RMGI luting cement. The excess will be removed, and proper occlusion will be checked.
58281854|NCT06450093|OTHER|Preformed zirconia crown|The material for crown restoration for this group is the preformed zirconia crown. Tooth preparation will be started by occlusal reduction (1 to 1.5 mm) using #835 diamond fissure bur. The interproximal reduction will be done mesially and distally with #169 L tapered diamond bur in such a way that a straight probe passes freely through the contact area. Rounding of line angles will be done and a knife-edge finish margin of the proximal surface will be obtained avoiding any ledge formation. The selected crown will be placed and checked for a passive fit. Consistent firm finger pressure will be applied during cementation with self-cured RMGI luting cement. Finally, crown placement will be checked.
58281855|NCT06450093|OTHER|Preformed BioFlx crown|The prefabricated BioFlx crown will be used in this group. A similar-sized preformed crown will be selected. Tooth preparation will be carried out similarly to traditional SSCs with #835 diamond fissure bur for occlusal reduction by 1-1.5 mm including the central groove. The proximal preparation will be done mesially and distally with #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. Placement of the crown will be achieved by a snug fit. Crown cementation will be carried out using self-cured RMGI luting cement and the excess cement will be removed using a floss or an explorer. (13) Finally, crown placement will be checked
58281856|NCT00226525|PROCEDURE|skin sensitivity test|
58281857|NCT01601067|BEHAVIORAL|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
58397091|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
58397092|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
57929448|NCT02962544|PROCEDURE|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
57929449|NCT02962544|PROCEDURE|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
57929450|NCT02962544|DEVICE|Visumax device|
57929451|NCT02962544|DEVICE|FS 200 device|
58281858|NCT01601067|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
58281859|NCT05827588|DEVICE|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
58281860|NCT05911698|DEVICE|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
58281861|NCT03461302|DRUG|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
58281862|NCT03461302|DRUG|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
58281863|NCT00560911|BEHAVIORAL|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
58281864|NCT00560911|BEHAVIORAL|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
58281865|NCT04017117|PROCEDURE|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
58281866|NCT02415231|BEHAVIORAL|humor|
58397093|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
57728070|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
57929452|NCT02354313|DRUG|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
57929453|NCT04956042|DRUG|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
58069379|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
57929454|NCT04956042|DRUG|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
57929455|NCT00170612|BIOLOGICAL|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
57929456|NCT00170612|BIOLOGICAL|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
58281867|NCT05450406|OTHER|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
57728071|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
57728072|NCT05046457|DIETARY_SUPPLEMENT|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
57929457|NCT04604678|DRUG|Metformin|Metformin at 1500 mg/day
58397094|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
58397095|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
58069380|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
58069381|NCT02073292|PROCEDURE|c-RFA|
58069382|NCT02073292|PROCEDURE|tRFA|
58069383|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
58281868|NCT00048165|DRUG|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
58069384|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
58069385|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
58069386|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
58281869|NCT00048165|DRUG|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
58281870|NCT00048165|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
58281871|NCT00048165|DRUG|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
58281872|NCT00048165|DRUG|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
58281873|NCT03627650|PROCEDURE|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
58397096|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
58397097|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
57728073|NCT05213845|PROCEDURE|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
58397098|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
58069387|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
58069388|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
58397099|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
58069389|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
58069390|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
58069391|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
58069392|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
58069393|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
58069394|NCT00493909|PROCEDURE|thoracic epidural analgesia|
58095089|NCT04066192|DRUG|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
58281874|NCT03627650|PROCEDURE|placebo injection|
58281875|NCT02918097|DRUG|Lithium Carbonate|
58281876|NCT02918097|DRUG|Sertraline|
58281877|NCT02918097|DRUG|Nortriptyline|
58281878|NCT02918097|DRUG|Risperidone|
58281879|NCT02724566|DRUG|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
58281880|NCT02724566|DRUG|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
58281881|NCT01908309|DRUG|Iobitridol 350|
58281882|NCT01908309|DRUG|Iodixanol 320|
58397100|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
58397101|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
57929458|NCT04604678|DRUG|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
57929459|NCT02220309|DRUG|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
58069395|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
58069396|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
58069397|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
58069398|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
58069399|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58069400|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
58397102|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
58397103|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
58397104|NCT05769855|DRUG|HR18034|HR18034 380mg
57929460|NCT04273256|DRUG|Myo-inositol|patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
57929461|NCT01245634|DRUG|Placebo|iv infusion every 4 weeks, 32 weeks
57929462|NCT01245634|DRUG|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
57929463|NCT01176968|DRUG|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
58397105|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
58397106|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
57929464|NCT01176968|DRUG|Placebo|Matching placebo tablets
57929465|NCT00438321|DRUG|Zoladex|
57929466|NCT00438321|DRUG|Testosterone gel|
57929467|NCT00438321|DRUG|Anastrozole Pill|
57929468|NCT00438321|OTHER|Placebo|
58281883|NCT00674895|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
58397107|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
58397108|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
58069401|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
58281884|NCT02696174|OTHER|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
58281885|NCT02009423|DRUG|Masitinib|
58281886|NCT02009423|DRUG|Placebo|
58281887|NCT02741466|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
58281888|NCT01608191|BEHAVIORAL|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
58069402|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
58281889|NCT05712837|DRUG|25% TRICHLOROACETIC ACID|Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
58281890|NCT05712837|DRUG|30% salicylic acid|Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
58397109|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
58397110|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
58069403|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
58069404|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
58069405|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
58069406|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
58069407|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
58069408|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
58069409|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
58281891|NCT00528372|DRUG|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
58281892|NCT00528372|DRUG|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
58281893|NCT00528372|DRUG|Metformin|
58281894|NCT02102594|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
58281895|NCT03152266|OTHER|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
58281896|NCT00147511|DRUG|linezolid|
58397111|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
58397112|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
58397113|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
58397114|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
58397115|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
57728074|NCT04336202|RADIATION|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
57728075|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
57728076|NCT00005853|BIOLOGICAL|etanercept|
58281897|NCT04786366|OTHER|The study does not have an intervention, but observe the AF incidence of the UK disease-free population|The study does not have an intervention, but observe the AF incidence of the UK disease-free population.
58281898|NCT01758042|PROCEDURE|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
58281899|NCT02928601|DRUG|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
58281900|NCT02928601|DRUG|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
58281901|NCT04872738|OTHER|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
58281902|NCT02609373|BEHAVIORAL|Sleep intervention|"Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring."
58281903|NCT05957185|DIETARY_SUPPLEMENT|OPTIZIOME® P³ HYDROLYZER® - WHEY|One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
58397116|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
58397117|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
58397118|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
58397119|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
58397120|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
58397121|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
58397122|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
58281904|NCT05957185|OTHER|Placebo|One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
58281905|NCT03430856|DRUG|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
58397123|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
58397124|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
58397125|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
58397126|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
58397127|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
57728077|NCT05842057|BIOLOGICAL|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
57728078|NCT05842057|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
58281906|NCT03430856|DRUG|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
58281907|NCT01914965|DRUG|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
58281908|NCT01914965|DRUG|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
58281909|NCT04728984|DRUG|Nalfurafine Hydrochloride|"Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days"
58281910|NCT04728984|DRUG|Nalfurafine Hydrochloride+Placebo|Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
58281911|NCT04728984|DRUG|Placebo|two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
58281912|NCT05593328|DRUG|Onvansertib|Oral capsule
58281913|NCT05593328|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
58281914|NCT05593328|DRUG|Bevacizumab|IV infusion
58397128|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
58397129|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
58397130|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
58397131|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
58397132|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
58397133|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
58397134|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
58397135|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
58281915|NCT02546596|DEVICE|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
58281916|NCT03090503|DRUG|Aripiprazole|Initial dose: 10 mg.
58281917|NCT03090503|DRUG|Risperidone|Initial dose: 2 mg.
58281918|NCT05674409|BEHAVIORAL|Brief Family-Involved Treatment (B-FIT)|Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.
58281919|NCT05674409|BEHAVIORAL|Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)|Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
58281920|NCT02350088|DRUG|probiotics|probiotics
58281921|NCT02350088|DRUG|placebo|placebo
58397136|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
57728079|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
57728080|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
57728081|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
58281922|NCT01138527|OTHER|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
57728082|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
58069410|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
58281923|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
58281924|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
58281925|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
58281926|NCT03975725|DEVICE|the use of the WitCard|electrocardiogram (ECG)
58281927|NCT03975725|OTHER|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
58281928|NCT02780960|DEVICE|HPV self-testing|Patients will perform HPV testing themselves at home.
58281929|NCT00198809|DRUG|Biolean + Diet education|
58281930|NCT00198809|DRUG|Biolean Free + Diet education|
58281931|NCT00198809|DRUG|Placebo + Diet education|
58281932|NCT06389383|OTHER|Nasal Swab|"* Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home"
58397137|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
58397138|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
57728083|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
57728084|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
57728085|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
57728086|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-5 minutes|
57728087|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-1 minute|
57728088|NCT03691038|DRUG|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
57728089|NCT03691038|DRUG|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
57728090|NCT02973958|DRUG|Bupivacaine|See active comparator description
57728091|NCT02973958|DRUG|Sevoflurane|See active comparator description
57728092|NCT02973958|DRUG|Acetaminophen|See active comparator description
57728093|NCT02973958|DRUG|Ibuprofen|See active comparator description
57728094|NCT02973958|DRUG|Ketorolac|See experimental arm description
57728095|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
57728096|NCT02736084|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
57728097|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
57728098|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
58069411|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
58069412|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
58069413|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
58069414|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
58069415|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
58397139|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
58397140|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
58397141|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
58069416|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
58069417|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
58281933|NCT02963272|OTHER|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
58281934|NCT02963272|OTHER|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
58281935|NCT02552953|DRUG|CYC065|
58281936|NCT05808270|BEHAVIORAL|Nutrition care process|"According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities."
58397142|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
58397143|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
58069418|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
58069419|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
58281937|NCT05194241|BEHAVIORAL|One MORE|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
58281938|NCT00886964|BIOLOGICAL|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
58281939|NCT00886964|BIOLOGICAL|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
58281940|NCT05326126|DEVICE|coronary physiology|To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
58281941|NCT00055497|BIOLOGICAL|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
58281942|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
58281943|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
58281944|NCT00055497|BIOLOGICAL|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
58281945|NCT00516490|DRUG|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
58281946|NCT00516490|DRUG|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
58281947|NCT05393297|DIAGNOSTIC_TEST|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
58281948|NCT05393297|RADIATION|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
58397144|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
58397145|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
58397146|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
58397147|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
58281949|NCT00966355|DRUG|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
58281950|NCT00966355|DRUG|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
58281951|NCT00966355|DRUG|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
58281952|NCT01090297|DEVICE|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
58281953|NCT01090297|DEVICE|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
58281954|NCT01090297|DEVICE|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
58281955|NCT05589220|OTHER|Music Intervention|Music therapy carried out with MUSIC CARE©
58281956|NCT05589220|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
58397148|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
58397149|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
58397150|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
58069420|NCT01478490|DRUG|mirabegron|oral
58069421|NCT01478490|DRUG|metoprolol|oral
58069422|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
58069423|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
58069424|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
58069425|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
58069426|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
58069427|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
58069428|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
58069429|NCT03646916|OTHER|No dexamethasone|Nothing
58281957|NCT05438758|BEHAVIORAL|Almond Therapy|Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
58281958|NCT05438758|DRUG|Intranasal ketamine (Esketamine)|Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
58397151|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
58397152|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
58397153|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
58397154|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
58397155|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
57728099|NCT03593668|DRUG|Metformin|"2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
58069430|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
58281959|NCT05438758|BEHAVIORAL|Treatment as Usual|Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
58281960|NCT04089501|DIAGNOSTIC_TEST|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
58281961|NCT04089501|DIAGNOSTIC_TEST|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
58281962|NCT00977691|PROCEDURE|PBSC Transplant|PBSC transplant
58281963|NCT00977691|DRUG|Alemtuzumab|alemtuzumab
58281964|NCT00977691|DRUG|Sirolimus|sirolimus
58281965|NCT00977691|DRUG|Cyclophosphamide|cyclophosphamide
58281966|NCT00977691|PROCEDURE|Low Dose Irradiation|low dose irradiation
58281967|NCT02187861|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
58281968|NCT02187861|DRUG|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
58281969|NCT02187861|DRUG|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
58281970|NCT00632632|DRUG|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
58281971|NCT00632632|OTHER|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
58281972|NCT01872806|RADIATION|a dialing smartphone will be placed on the chest and the ear|
58281973|NCT06386159|OTHER|Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation|Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
58397156|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
58397157|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
58397158|NCT00602004|DRUG|losartan|losartan 50 mg a day
58069431|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
58397159|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
58281974|NCT06040671|OTHER|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
58397160|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
58281975|NCT00333632|DRUG|Dexmedetomidine|
58397161|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
58397162|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
58397163|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
58397164|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
58397165|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
58397166|NCT00868140|DRUG|Placebo|placebo daily
58397167|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
58397168|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
58397169|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
58397170|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
58397171|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
58397172|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
58397173|NCT03155087|DRUG|Metformin|
58397174|NCT05172245|PROCEDURE|Biopsy|Undergo tumor biopsy
58069432|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
58069433|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
58281976|NCT00333632|DRUG|Propofol|
58281977|NCT00333632|DRUG|Midazolam|
58281978|NCT00333632|DRUG|Fentanyl|
58281979|NCT00333632|DRUG|Isoflurane|
58281980|NCT00575471|DRUG|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
58281981|NCT00575471|DRUG|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
58281982|NCT00575471|DRUG|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
58069434|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
58069435|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
58281983|NCT00575471|DRUG|Placebo|Matching placebo tablets once daily for 12 weeks
58281984|NCT00930527|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|4g per day for 3 weeks
58281985|NCT03057717|OTHER|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
58397175|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58397176|NCT05172245|DRUG|Cisplatin|Given IV
58397177|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58397178|NCT05172245|DRUG|Ipatasertib|Given PO
58397179|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58397180|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58397181|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
58397182|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
58397183|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
57929469|NCT03909204|PROCEDURE|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
58069436|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
58069437|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
58069438|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
58069439|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
58069440|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
58069441|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
58069442|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
58069443|NCT04896476|DEVICE|EchoMark|The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
58069444|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
58281986|NCT01687855|DEVICE|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
58281987|NCT01047111|PROCEDURE|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
58281988|NCT03153683|OTHER|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
57929470|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
58281989|NCT00671099|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
57929471|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
58069445|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
58069446|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
57929472|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
58069447|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
58069448|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
58069449|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
58069450|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
58069451|NCT01294319|DRUG|Mifepristone|
58069452|NCT01294319|DRUG|Placebo|
58281990|NCT00671099|DIETARY_SUPPLEMENT|Placebo|Placebo
58281991|NCT00647036|DIETARY_SUPPLEMENT|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
58069453|NCT01294319|DRUG|Spironolactone|
58069454|NCT01294319|DRUG|Combined|
58069455|NCT01294319|DRUG|Dexamethasone|
58281992|NCT00647036|DRUG|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
57929473|NCT06425276|DRUG|Melphalan Hydrochloride for Injection|During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
57929474|NCT04825769|DEVICE|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
57929475|NCT04603664|DIAGNOSTIC_TEST|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
58281993|NCT03488602|BEHAVIORAL|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
58281994|NCT03488602|BEHAVIORAL|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
58281995|NCT00600158|DRUG|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
58281996|NCT00600158|DRUG|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients \> 70 kg)
58281997|NCT03604705|DRUG|APX001|APX001
58281998|NCT04124328|PROCEDURE|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
58281999|NCT04124328|PROCEDURE|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
58282000|NCT03051438|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
58282001|NCT03051438|PROCEDURE|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
58397184|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
58397185|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
58397186|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
58282002|NCT04786171|DIAGNOSTIC_TEST|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
58282003|NCT00391742|BEHAVIORAL|Brief intervention|
58282004|NCT06075043|DRUG|AND017|Oral administration of AND017 capsules three times per week
58397187|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
58397188|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
58397189|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
58397190|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
57929476|NCT00459966|PROCEDURE|Preoperative rehabilitation|
57929477|NCT03982342|DEVICE|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
57929478|NCT03982342|OTHER|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
57929479|NCT00565383|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural
57929480|NCT00565383|PROCEDURE|Intravenous fentanyl (50mcg)|Intravenous fentanyl
57929481|NCT04923048|BIOLOGICAL|GB261|Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
58069456|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
58282005|NCT05068479|DEVICE|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
58282006|NCT06034132|OTHER|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
58282007|NCT06034132|OTHER|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
57929482|NCT06219070|OTHER|Core straining|The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
57929483|NCT00665743|DRUG|PN400|naproxen 500 mg /esomeprazole 20 mg
58282008|NCT00669851|DRUG|AI-700|
58282009|NCT01459835|BEHAVIORAL|media diet|advice and tips and tools for healthy non violent TV viewing
58282010|NCT01459835|BEHAVIORAL|nutritional intervention|advice on healthy eating
58282011|NCT01957839|DRUG|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
58282012|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
58397191|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
58397192|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
58397193|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
57728100|NCT03593668|DRUG|Benaglutide|"2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
57929484|NCT00665743|DRUG|naproxen|naproxen 500 mg tablet
58397194|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
58397195|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
58397196|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
57728101|NCT06434701|DIAGNOSTIC_TEST|Nasopharyngeal swab sampling for COVID-19|The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
57929485|NCT00665743|DRUG|naproxen|naproxen 500 mg
57929486|NCT05757115|BEHAVIORAL|Play Skills Training|"Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised."
57929487|NCT00274404|DRUG|valacyclovir|
57929488|NCT03696615|OTHER|Tabata Kettlebell Swing Workout|See description of experimental arm.
57929489|NCT03696615|OTHER|Control|see description of control arm
57929490|NCT04469166|PROCEDURE|tourniquet|Use of tourniquet
57929491|NCT04469166|PROCEDURE|No tourniquet|No use of tourniquet
57929492|NCT04637698|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
57929493|NCT05638750|OTHER|Rehabilitation Intervention|12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
57929494|NCT05619978|OTHER|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
57929495|NCT05619978|OTHER|T315I|Patients with chronic myeloid leukemia with T315I mutation
57929496|NCT05761223|DRUG|Phase Ia dose-escalation part of FB849 Monotherapy|At a given level dose once daily
58282013|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
58282014|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
58282015|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
58282016|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
58282017|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
58282018|NCT05683925|DEVICE|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
58282019|NCT04740996|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
58282020|NCT05742113|DEVICE|Masimo Radical-7|perfusion index measuring device
58282021|NCT00678964|DRUG|Erlotinib|Erlotinib 150 mg, p.o., once daily
58282022|NCT00678964|DRUG|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
58282023|NCT00351559|DEVICE|AlloMap molecular expression testing|
58282024|NCT00351559|PROCEDURE|Right ventricular endomyocardial biopsy|
58282025|NCT02425423|DIETARY_SUPPLEMENT|New thickened formula|
58282026|NCT05294809|BEHAVIORAL|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
57929497|NCT05761223|DRUG|Phase Ib dose-expansion of FB849 monotherapy|At recommended dose for expansion cohort once daily
57929498|NCT05761223|DRUG|Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab|At recommended dose for expansion cohort once daily in combination with pembrolizumab
57929499|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
57929500|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
57929501|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
57929502|NCT02336763|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
57929503|NCT02336763|OTHER|Laboratory Biomarker Analysis|Correlative studies
57929504|NCT05867459|DIAGNOSTIC_TEST|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
57929505|NCT05867459|DIAGNOSTIC_TEST|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
57929506|NCT05867459|DIAGNOSTIC_TEST|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
57929507|NCT05867459|DIAGNOSTIC_TEST|Urine analysis|It is mirror of kidney
57929508|NCT05867459|DIAGNOSTIC_TEST|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
58069457|NCT01884142|OTHER|Aerobic Exercise Training|
58069458|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
58069459|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
58069460|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
57929509|NCT05867459|DIAGNOSTIC_TEST|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
57929510|NCT05867459|OTHER|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm \> 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
57929511|NCT03937284|OTHER|Patients not treated|
57929512|NCT04437160|DRUG|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
57929513|NCT04437160|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
57929514|NCT05282277|DRUG|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
57929515|NCT05282277|DRUG|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
57929516|NCT05282277|DRUG|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
57929517|NCT05282277|DRUG|Raclopride C11|All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
57929518|NCT00696930|DRUG|90Y-SMT487|
57929519|NCT05421962|DRUG|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
57929520|NCT04706351|OTHER|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
58069461|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
58069462|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
58069463|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
58069464|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
58069465|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
58095090|NCT04066192|DRUG|Placebo|A medically inert placebo medication will be used as described in the study arms.
58397197|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
58397198|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
58397199|NCT02986672|OTHER|Medical Paraffin|2ml per day
58397200|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
58397201|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
58397202|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
58397203|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
58397204|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
58397205|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
58397206|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
58397207|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
58397208|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
58397209|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
58397210|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
58397211|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
58397212|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
58397213|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
58397214|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
58397215|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
57728102|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
57929521|NCT05474586|OTHER|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
58397216|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
58397217|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
58397218|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
58397219|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
58397220|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
58397221|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
58397222|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
57728103|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
57728104|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
57728105|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
58069466|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
58069467|NCT04348825|DEVICE|Electroconvulsive therapy|
58282027|NCT05294809|BEHAVIORAL|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
57728106|NCT01196975|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
57728107|NCT01196975|BIOLOGICAL|FluLavalTM-VB|Single intramuscular dose
57728108|NCT01196975|BIOLOGICAL|FluLavalTM-YB|Single intramuscular dose
57929522|NCT05474586|OTHER|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
58282028|NCT05294809|BEHAVIORAL|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
58282029|NCT04918472|PROCEDURE|MCCE|Mangetically controlled capsule endoscopy will be performed
58282030|NCT06028386|DEVICE|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
58397223|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
57929523|NCT05474586|OTHER|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
57929524|NCT01460186|OTHER|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
58397224|NCT04019288|DRUG|Batiraxcept|Given IV
58397225|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
57728109|NCT04558957|DEVICE|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
57728110|NCT01191489|DEVICE|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
57728111|NCT01191489|DEVICE|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
57728112|NCT01191489|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
57929525|NCT05039398|BEHAVIORAL|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
57929526|NCT05039398|BEHAVIORAL|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
57929527|NCT05039398|BEHAVIORAL|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
57929528|NCT04669977|DIETARY_SUPPLEMENT|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
57929529|NCT00690625|DRUG|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
57929530|NCT00690625|DRUG|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
57929531|NCT00006036|DRUG|cisplatin|
57929532|NCT00006036|DRUG|lurtotecan liposome|
57929533|NCT04118517|OTHER|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing \>50% of the protein.
57929534|NCT00398970|DEVICE|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
57929535|NCT03082950|DIAGNOSTIC_TEST|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
57929536|NCT05295316|OTHER|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
57929537|NCT00510250|DRUG|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
57929538|NCT00510250|DRUG|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
57929539|NCT00510250|PROCEDURE|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
57929540|NCT02213432|BIOLOGICAL|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
57929541|NCT02342756|DEVICE|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
57929542|NCT02290522|PROCEDURE|Tumor biopsy|Biopsy of lesion for molecular characterization
57929543|NCT06132854|OTHER|VR|The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.
57929544|NCT06132854|OTHER|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
57929545|NCT01306188|BIOLOGICAL|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
57929546|NCT01306188|BIOLOGICAL|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
57728113|NCT04336215|OTHER|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
57728114|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
57728115|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
57728116|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
57728117|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
57728118|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
57728119|NCT02328664|PROCEDURE|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
57728120|NCT04251468|DEVICE|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
57728121|NCT04251468|DEVICE|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
57728122|NCT03335358|BEHAVIORAL|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
57728123|NCT01296568|DRUG|LY2603618|Administered intravenously
57728124|NCT01296568|DRUG|Pemetrexed|Administered intravenously
57929547|NCT03042780|DRUG|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
57929548|NCT03042780|DRUG|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
57929549|NCT05400642|DEVICE|THRIVE|Apneic ventilation
57929550|NCT05400642|DEVICE|mechanical ventilation|mechanical ventilation in Positive Pressure
57929551|NCT05915897|DIAGNOSTIC_TEST|Specimen Donation|blood donation
57929552|NCT02055521|PROCEDURE|Blood sample, biopsy|
57929553|NCT03831425|DIETARY_SUPPLEMENT|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
57728125|NCT01296568|DRUG|Gemcitabine|Administered intravenously
57929554|NCT03831425|OTHER|Placebo|6 week trial of either treatment with Placebo
57929555|NCT04850157|DRUG|Tislelizumab|200mg, Q3W
57929556|NCT04850157|RADIATION|IMRT|4 Gy\* 5 Fx,5Fx/Week
57929557|NCT01544699|DEVICE|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
57929558|NCT00325039|PROCEDURE|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
58069468|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
57929559|NCT00325039|PROCEDURE|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
57929560|NCT03156127|DRUG|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
57929561|NCT03954574|DIAGNOSTIC_TEST|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
58069469|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
58069470|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
58282031|NCT06028386|DEVICE|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
58282032|NCT02940236|OTHER|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
58282033|NCT04949204|PROCEDURE|Wearable sensor detection|Empatica E4 wearable wrist sensor
58282034|NCT04633291|DEVICE|Novel swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
58282035|NCT04633291|DEVICE|Comparator swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
58282036|NCT05118763|DRUG|INNA-051|Liquid for intranasal administration
58282037|NCT05118763|OTHER|Placebo|Liquid for intranasal administration
58282038|NCT03048071|OTHER|Data collection within medical files|Data collection within medical files
58282039|NCT06081491|DIAGNOSTIC_TEST|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
58282040|NCT00949871|OTHER|communication analysis|
58282041|NCT00949871|OTHER|questionnaire administration|
58397226|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
58397227|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
58397228|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
58397229|NCT01905345|PROCEDURE|Training|
58397230|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
57728126|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
57929562|NCT02525861|BIOLOGICAL|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
57929563|NCT02216487|DRUG|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
57929564|NCT02761746|BEHAVIORAL|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
57929565|NCT05136365|DRUG|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
57929566|NCT01782079|DIETARY_SUPPLEMENT|L. brevis|
57929567|NCT02030405|DRUG|Ixazomib|Given orally (PO)
58282042|NCT00949871|PROCEDURE|psychosocial assessment and care|
58282043|NCT00949871|PROCEDURE|support group therapy|
58282044|NCT04608890|DIAGNOSTIC_TEST|Eye-tracking video test|An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
58282045|NCT00693485|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
58282046|NCT00693485|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
58282047|NCT00693485|DRUG|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
58282048|NCT00500253|DEVICE|exhaled nitric oxide measurement|exhaled nitric oxide measurement
58282049|NCT00500253|PROCEDURE|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
58397231|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
57929568|NCT00937833|PROCEDURE|Prostatectomy|
57929569|NCT00937833|DEVICE|Surgisis Male Sling|
57929570|NCT00219050|DRUG|aliskiren|
57929571|NCT03326895|DEVICE|Left-sided colon resection|Left-sided colon resection with powered stapler
57929572|NCT01212250|DRUG|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
57929573|NCT01212250|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
58069471|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
58282050|NCT00500253|PROCEDURE|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
58282051|NCT05266859|OTHER|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
58282052|NCT05266859|OTHER|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
58282053|NCT05266859|OTHER|PRF|PRF will be placed directly over the exposed pulp
58282054|NCT01863719|DRUG|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
58282055|NCT01863719|DRUG|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
58282056|NCT01754766|DRUG|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
58282057|NCT01754766|OTHER|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
58282058|NCT05682274|PROCEDURE|Partial restoration approach combined with CAF+CTG|The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
58282059|NCT06041282|PROCEDURE|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
58282060|NCT06041282|PROCEDURE|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
58282061|NCT02734225|OTHER|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
58282062|NCT02734225|OTHER|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
58397232|NCT06658093|DRUG|Everolimus|mTOR inhibitor
57929574|NCT00056511|DRUG|Fresh garlic or garlic supplements|
57929575|NCT04849182|DIETARY_SUPPLEMENT|Vertistop D|Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals
57929576|NCT04849182|DIETARY_SUPPLEMENT|Vertistop L|Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
58282063|NCT02734225|OTHER|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
58282064|NCT02137226|DRUG|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
58282065|NCT02137226|DRUG|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
58397233|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
58397234|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
58397235|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
57929577|NCT04633707|DEVICE|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.
58282066|NCT02439788|DRUG|cyclophosphamide|500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
58397236|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
58397237|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
58397238|NCT00349011|PROCEDURE|Personalized risk assessment|
58397239|NCT00349011|PROCEDURE|genetic counseling intervention|
58397240|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
58397241|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
58397242|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
58397243|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
58397244|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
58282067|NCT02439788|DRUG|Fludarabine|30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
58282068|NCT02439788|GENETIC|GINAKIT Cells|"* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
58282069|NCT03887156|DIAGNOSTIC_TEST|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
58282070|NCT01578499|DRUG|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
58282071|NCT01578499|DRUG|Methotrexate|Methotrexate tablets.
58282072|NCT01578499|DRUG|Bexarotene|Bexarotene tablets.
58282073|NCT01627795|DRUG|Oshadi D and Oshadi R|anti cancer agents
58282074|NCT02614508|DRUG|Buparlisib|Given PO
58397245|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
58282075|NCT02614508|DRUG|Ibrutinib|Given PO
58282076|NCT02614508|BIOLOGICAL|Ofatumumab|Given IV
58282077|NCT02301845|DRUG|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
58282078|NCT00348465|PROCEDURE|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
58282079|NCT02411344|DRUG|Pertuzumab|"* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
58282080|NCT05431114|DIAGNOSTIC_TEST|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
58282081|NCT05041777|DEVICE|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
58282082|NCT02336009|DEVICE|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
58397246|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
58397247|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
57929578|NCT04633707|DEVICE|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
57929579|NCT04633707|DEVICE|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
57929580|NCT03152279|DIAGNOSTIC_TEST|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
57929581|NCT03152279|DIAGNOSTIC_TEST|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
57929582|NCT01283698|DRUG|Experimental: LAS 41004 dosage 1|dosage 1, once daily
57929583|NCT01283698|DRUG|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
57929584|NCT01283698|DRUG|Experimental: LAS 41004 dosage 3|dosage 3, once daily
57929585|NCT01283698|DRUG|Placebo Comparator: placebo|once daily
57929586|NCT01283698|DRUG|Reference|Active Comparator,once daily
57929587|NCT02092350|DRUG|Grazoprevir|Grazoprevir 100 mg tablet
58397248|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
58397249|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
58397250|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
58397251|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
57929588|NCT02092350|DRUG|Elbasvir|Elbasvir 50 mg tablet
57929589|NCT02092350|DRUG|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
57929590|NCT02092350|DRUG|Placebo to Elbasvir|Placebo tablet matched to elbasvir
57929591|NCT01647750|DRUG|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
57929592|NCT01647750|DRUG|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
57929593|NCT05522816|DRUG|KX01 0.01% (0.1 mg/g)|Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
57929594|NCT05522816|DRUG|Placebo|
57929595|NCT05522816|DRUG|KX01 0.1% (1.0 mg/g)|Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
57929596|NCT05522816|DRUG|KX01 1% (10 mg/g) for 5 days|Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
57929597|NCT05522816|DRUG|KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles|Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
57929598|NCT04228809|DEVICE|tDCS|transcranial direct current stimulation
57929599|NCT04381455|DEVICE|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
57728127|NCT03895060|DEVICE|autogenous ring blockls with GBR covered by collagen membrane|"* A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
57929600|NCT04978311|BEHAVIORAL|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
58069472|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
58069473|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
58282083|NCT05692804|DIAGNOSTIC_TEST|Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )|MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
58282084|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
58282085|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
58282086|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
58282087|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
58282088|NCT02708030|OTHER|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
58282089|NCT02708030|OTHER|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
58282090|NCT02708030|OTHER|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
58282091|NCT04726774|BEHAVIORAL|Hypnosis|"Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion."
58282092|NCT04726774|BEHAVIORAL|Rehabilitation program|Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
58282093|NCT06613308|DRUG|Neoadjuvant immunotherapy combined with chemotherapy|The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
58397252|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
58397253|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
58069474|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
58069475|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
58069476|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
58069477|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
58397254|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor and tissue sample collection
58397255|NCT05504291|DRUG|Carboplatin|Given IV
57728128|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
57728129|NCT00916877|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
57929601|NCT04978311|BEHAVIORAL|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
57929602|NCT04978311|BEHAVIORAL|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
57929603|NCT01184053|DRUG|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
57929604|NCT03947125|DRUG|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
57929605|NCT05285709|DIAGNOSTIC_TEST|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
57929606|NCT05285709|DIAGNOSTIC_TEST|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
57929607|NCT02750098|OTHER|Glucose measurement|"1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test"
57929608|NCT02706301|BEHAVIORAL|Telephone-Based Coping Skills Training (CST)|
57929609|NCT00300287|DRUG|Vildagliptin|
57929610|NCT02679950|GENETIC|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
58069478|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
58282094|NCT06613308|DRUG|Neoadjuvant chemotherapy|"A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments."
58282095|NCT00413933|PROCEDURE|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
58282096|NCT04854941|OTHER|Probiotics|Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
58282097|NCT06344689|OTHER|Surgical treatment|Patients underwent surgical treatment of ectropion were included in this study.
58282098|NCT00263471|DRUG|7-methylxanthine|
58306806|NCT04500951|OTHER|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
58397256|NCT05504291|DRUG|Etoposide|Given IV
57728130|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
57728131|NCT06636500|DRUG|CG001419|Oral doses
57728132|NCT06636500|DRUG|Placebo|Oral doses
57728133|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
58069479|NCT02515604|DRUG|Misoprostol|
57728134|NCT00097812|DRUG|zoledronic acid|
57728135|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
57728136|NCT05575947|DEVICE|da Vinci Surgical System|da Vinci Surgical System
57728137|NCT05575947|PROCEDURE|laparoscopic bariatric surgery|laparoscopic bariatric surgery
57929611|NCT06176170|DEVICE|VividWhite Glaucoma Implant (VW-51)|Subconjunctival surgical implantation of the VW-51 implant in the study eye.
58069480|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
58397257|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
57929612|NCT05003713|DRUG|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
57728138|NCT05794854|OTHER|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
57929613|NCT05003713|DRUG|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
57929614|NCT05003713|DRUG|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
58282099|NCT05977556|BEHAVIORAL|Combined neuromuscular exercise training and 'sit less, move more' program|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
58282100|NCT00849290|BIOLOGICAL|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
58282101|NCT05591534|RADIATION|Endorectal brachytherapy|Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
58282102|NCT03592849|PROCEDURE|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
57929615|NCT00005074|DRUG|alvocidib|
58282103|NCT00423358|DIETARY_SUPPLEMENT|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
58282104|NCT00423358|DIETARY_SUPPLEMENT|placebo|matching placebo
58397258|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58397259|NCT05504291|DRUG|Melphalan|Given I-VITRE
58397260|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
57728139|NCT05794854|OTHER|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
57929616|NCT05036616|DEVICE|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
57929617|NCT05922176|OTHER|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
57929618|NCT05922176|OTHER|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
58397261|NCT05504291|DRUG|Vincristine|Given IV
58397262|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
58397263|NCT05933356|OTHER|scheduled activities|scheduled activities
58397264|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
58397265|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
58397266|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
58397267|NCT02756962|DRUG|Cytarabine|
58397268|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
58397269|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
58397270|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
58397271|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
58397272|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
58397273|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
58397274|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
58397275|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
58397276|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
58282105|NCT02169297|PROCEDURE|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
58282106|NCT02169297|PROCEDURE|PCA only|Patients received intravenous PCA post-operatively
58397277|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
58397278|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
58397279|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
58397280|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
58397281|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
58397282|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
57929619|NCT03220087|OTHER|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
58397283|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
58397284|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
58397285|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
58397286|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
58397287|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
58397288|NCT01323088|OTHER|Control|Standard care control (no exercise)
58397289|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
58397290|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
58397291|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
57929620|NCT04286425|OTHER|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
57929621|NCT04286425|OTHER|saline solution|saline solution
57929622|NCT02900534|OTHER|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
58069481|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
58069482|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
58282107|NCT01474161|DRUG|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
58282108|NCT01474161|DRUG|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
57929623|NCT05788822|DIETARY_SUPPLEMENT|Mevalproic acid|Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
58397292|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
57929624|NCT04628884|DRUG|Conventional dose|Conventional dose used to calculated the protamine dose
58282109|NCT01474161|DRUG|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
58282110|NCT01474161|DRUG|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
57929625|NCT04628884|DRUG|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
57929626|NCT02624466|OTHER|CKD progress|CKD progress
58282111|NCT01474161|DRUG|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
58282112|NCT01474161|DRUG|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
58282113|NCT00149032|PROCEDURE|DLI sensitized against antigens expressed by the host.|
58282114|NCT00621998|DRUG|risperidone|0.5-6 mg/day
58282115|NCT00621998|DRUG|olanzapine|2.5-20 mg/day
58282116|NCT04137341|DRUG|GLPG1972 - A|Film-coated tablet, formulation A
58282117|NCT04137341|DRUG|GLPG1972 - B|Film-coated tablet, formulation B
58282118|NCT04137341|DRUG|GLPG1972 - C|Film-coated tablet, formulation C
58282119|NCT02088398|DRUG|ACY-1215|
58282120|NCT03323970|OTHER|semi-structured interviews|individual semi-structured interviews
57929627|NCT02257957|DRUG|PRP injection|
58069483|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
58282121|NCT04077710|RADIATION|Radioactive Iodine-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing template includes information on the path of the implantation needle, characteristics of the surface of the therapy area of the patient, and positioning and orientation effects which can make the operation more accurate.
58282122|NCT00151164|PROCEDURE|donor bone marrow cell injection into thymus gland|
58282123|NCT01500655|PROCEDURE|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
58282124|NCT01500655|PROCEDURE|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
58282125|NCT06356324|OTHER|Music Intervention|Participants assigned to 20 minutes of music listening
58282126|NCT06356324|OTHER|Television Intervention|Participants assigned to 20 minutes of television viewing
58282127|NCT01439490|OTHER|FES-PET|Patients undergo FES-PET prior to obtaining histology
58282128|NCT05373563|PROCEDURE|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
58282129|NCT01990768|DRUG|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
58069484|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
58282130|NCT01990768|DRUG|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
58282131|NCT01990768|DRUG|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
58282132|NCT03038776|BIOLOGICAL|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
58282133|NCT05203679|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 1×10\^13 vg/ kg
58397293|NCT06661902|DRUG|1% Lidocaine HCL|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
58397294|NCT00235235|PROCEDURE|Biopsy|core biopsy
58282134|NCT05152199|PROCEDURE|Cystoscopy - with use of obturator sheath|The intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
58397295|NCT00235235|PROCEDURE|Serum Collection|serum collection
58397296|NCT00235235|PROCEDURE|Urine Collection|urine collection
58397297|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
58397298|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
58397299|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
58397300|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
58397301|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
58282135|NCT05152199|PROCEDURE|Cystoscopy - without use of obturator sheath|The intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
58282136|NCT04187716|DRUG|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
58282137|NCT00963846|DRUG|placebo|matching pill placebo
58282138|NCT00963846|DRUG|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
58069485|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
58282139|NCT00963846|DRUG|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
58282140|NCT00963846|DRUG|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
58282141|NCT06323213|DRUG|610|610 subcutaneously injection.
58282142|NCT06323213|DRUG|Placebo|Placebo subcutaneously injection.
58282143|NCT00631163|DRUG|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
58282144|NCT03006263|PROCEDURE|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
58397302|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
58397303|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
58397304|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
58397305|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
58397306|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
58397307|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
58397308|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
58397309|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
58397310|NCT05432596|DRUG|Vehicle|Vehicle topical solution
58397311|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
58397312|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
58397313|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
58397314|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
58397315|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
58397316|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
58397317|NCT06658743|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In addition to time with their clinician, they will also have group activities that address relevant topics.
58397318|NCT06658743|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
58397319|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
58397320|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
58397321|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
58397322|NCT00000149|DRUG|Beta Blocker|
58397323|NCT00000149|PROCEDURE|Trabeculectomy|
58397324|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
57929628|NCT02257957|DRUG|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
58397325|NCT00002412|DRUG|Emivirine|
57929629|NCT00820976|DRUG|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
57929630|NCT02696772|OTHER|Energy intake|
57929631|NCT02693613|DRUG|ASP1517|Oral
57929632|NCT02693613|DRUG|Kremezin®|Oral
57929633|NCT02987179|OTHER|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
58069486|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
58397326|NCT00002412|DRUG|Hydroxyurea|
58397327|NCT00002412|DRUG|Stavudine|
58397328|NCT00002412|DRUG|Didanosine|
58397329|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
58397330|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
58397331|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
58397332|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
58397333|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
58397334|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
58397335|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
58397336|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
58397337|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
58397338|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
58069487|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
58069488|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
58069489|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
58069490|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
58069491|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
57929634|NCT04845360|DEVICE|pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)|The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.
57929635|NCT05805566|OTHER|Blood collection|Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
57929636|NCT02169817|DRUG|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
57929637|NCT02169817|DRUG|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
57929638|NCT00151554|BEHAVIORAL|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
58069492|NCT02735876|DRUG|acalabrutinib|
58069493|NCT02735876|DRUG|ibrutinib|
58397339|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
58397340|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
57929639|NCT06270433|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
57929640|NCT06270433|DRUG|Desvenlafaxine succinate sustained-release tablets|50 mg orally once daily dosing for 8 weeks
57929641|NCT02997488|DEVICE|Pentax Airwayscope|intubation using Pentax Airwayscope
57929642|NCT02997488|DEVICE|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
57929643|NCT01641211|BEHAVIORAL|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
57929644|NCT01641211|OTHER|Nutrition video|Children in this group will watch a 2-minute nutrition video.
57929645|NCT02849340|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
57929646|NCT02849340|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
57929647|NCT05717426|OTHER|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
57929648|NCT05717426|OTHER|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
57929649|NCT05319028|DRUG|Mivavotinib|oral tablet
58069494|NCT02735876|DRUG|rituximab|
58069495|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
58069496|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
57929650|NCT02945150|DRUG|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
57929651|NCT01975818|DRUG|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
57929652|NCT01975818|BIOLOGICAL|Epoetin alfa/beta|
57929653|NCT04696991|BEHAVIORAL|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
57929654|NCT04725383|DRUG|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
58069497|NCT01809717|OTHER|Weight Lifting Exercises|
58069498|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
58069499|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
58069500|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
57929655|NCT00592761|BEHAVIORAL|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
57929656|NCT01685710|DRUG|GTN patch|
57929657|NCT01685710|DRUG|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
57929658|NCT04052568|DRUG|Psilocybin|Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
58069501|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
58069502|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
58069503|NCT02450656|DRUG|Afatinib|Tablet
58069504|NCT02450656|DRUG|Selumetinib|Capsule
58069505|NCT02450656|DRUG|Docetaxel|
58069506|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
58069507|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
58069508|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
58069509|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
58069510|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
58069511|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
58069512|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
58069513|NCT02050945|BEHAVIORAL|Resistance training|
58069514|NCT02050945|BEHAVIORAL|Endurance training|
58069515|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
58069516|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
58069517|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
58069518|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
57728140|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
58282145|NCT03006263|PROCEDURE|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
58282146|NCT03633916|BEHAVIORAL|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
58282147|NCT03633916|BEHAVIORAL|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
58282148|NCT06002256|PROCEDURE|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
58282149|NCT06002256|PROCEDURE|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
58282150|NCT01392456|PROCEDURE|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
58282151|NCT01543737|DEVICE|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
58282152|NCT01543737|DEVICE|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
58282153|NCT01065298|BIOLOGICAL|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of \>40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
58282154|NCT02951793|OTHER|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.
57728141|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
57728142|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
58069519|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
58069520|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
57929659|NCT01674335|BEHAVIORAL|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
58397341|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
57728143|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
57728144|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
57929660|NCT01674335|BEHAVIORAL|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
57929661|NCT06046911|OTHER|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
57929662|NCT06046911|OTHER|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
57929663|NCT02802930|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
57929664|NCT02802930|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
58282155|NCT02951793|OTHER|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
58282156|NCT02951793|OTHER|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
58282157|NCT05401487|OTHER|Pre-hospital and hospital care|Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
58282158|NCT05309330|OTHER|No Intervention|This is a non-interventional study.
58282159|NCT05034835|DEVICE|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
58282160|NCT05034835|OTHER|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
58282161|NCT05624216|DEVICE|BTL-084|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
58282162|NCT02495818|PROCEDURE|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
58282163|NCT02495818|PROCEDURE|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
58282164|NCT02495818|OTHER|Homemade exercises|Codman and Hughston exercises.
58282165|NCT01033708|BEHAVIORAL|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
58282166|NCT00978341|DRUG|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
58397342|NCT06153420|DRUG|CIN-103|CIN-103 BID
58397343|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
58397344|NCT00044837|DRUG|Medroxyprogesterone acetate|
58397345|NCT00044837|DRUG|Estradiol|
58397346|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
58397347|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
57728145|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
57929665|NCT02802930|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
57929666|NCT02802930|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
57929667|NCT02423018|DRUG|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
57929668|NCT02423018|DRUG|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
57929669|NCT02169180|DRUG|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
57929670|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
57929671|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
57929672|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
58069521|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
58069522|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
58069523|NCT04455958|DRUG|Placebo Administration|Given PO
58069524|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
58069525|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
58069526|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
58282167|NCT00978341|DRUG|Placebo for pregabalin|Placebo capsules BID for 7.5 days
58282168|NCT02540122|DEVICE|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
57929673|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
57929674|NCT01672788|DRUG|Empagliflozin|empagliflozin tablets and metformin tablet
58069527|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
58069528|NCT00241371|DRUG|Clofarabine|
58282169|NCT02540122|DEVICE|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
58282170|NCT02540122|DEVICE|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
58282171|NCT02540122|DEVICE|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
58282172|NCT05262855|DRUG|[68Ga]FAPI-46|\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
58397348|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
58397349|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
58397350|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
57728146|NCT02751281|PROCEDURE|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
57929675|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
57929676|NCT01672788|DRUG|Metformin|empagliflozin tablets and metformin tablet
57929677|NCT01672788|DRUG|Metformin|empagliflozin tablet and metformin tablet
57929678|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
57929679|NCT01672788|DRUG|Empagliflozin|empagliflozin tablet and metformin tablet
58069529|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
58069530|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
58069531|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
58282173|NCT06274502|OTHER|YOLOv8|After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model.
58282174|NCT01146015|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
58282175|NCT02801981|DRUG|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
58282176|NCT02801981|DRUG|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
57929680|NCT01418820|DEVICE|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
57929681|NCT01418820|DEVICE|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
57929682|NCT04980950|DIETARY_SUPPLEMENT|Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science|Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
57929683|NCT04111965|DRUG|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
58397351|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
58397352|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
57728147|NCT02751281|PROCEDURE|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
57728148|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
57929684|NCT04111965|DRUG|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
57929685|NCT01790126|DRUG|ARN-509|
57929686|NCT01790126|DRUG|LHRH Agonist|
57728149|NCT00559559|DEVICE|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
57929687|NCT01822522|DRUG|Cabozantinib S-malate|Given PO
58069532|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
58069533|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
58069534|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
57929688|NCT01822522|OTHER|Laboratory Biomarker Analysis|Correlative studies
58069535|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
58282177|NCT00652808|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
58282178|NCT00652808|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
57728150|NCT00559559|PROCEDURE|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
57929689|NCT01822522|OTHER|Pharmacological Study|Correlative studies
57929690|NCT04803799|OTHER|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
57929691|NCT06494527|DRUG|RG002C0106|RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
57929692|NCT00906919|BEHAVIORAL|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
57929693|NCT00906919|BEHAVIORAL|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
58069536|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
58069537|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
58069538|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
58069539|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
58069540|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
58282179|NCT04351477|DEVICE|Massage chair|Mechanical massage chair
58282180|NCT02427243|DRUG|Crenezumab|
57929694|NCT01693081|DRUG|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
57929695|NCT01693081|DRUG|placebo|
57929696|NCT02488187|DEVICE|ABUS|Automated breast ultrasound
57929697|NCT06402981|OTHER|High risk prediction model for liver injury|Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
58282181|NCT02427243|DRUG|Crenezumab|
58282182|NCT03947593|OTHER|No Intervention|No intervention is being administered.
58282183|NCT05624736|DIAGNOSTIC_TEST|multi-parametric magnetic resonance imaging scan|Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
58282184|NCT05624736|DIAGNOSTIC_TEST|Pathology examination|The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
58282185|NCT05274087|DRUG|Risankizumab|Subcutaneous autoinjector
58282186|NCT03285165|DRUG|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
58397353|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
58397354|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
57728151|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
57929698|NCT04921007|PROCEDURE|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
57929699|NCT04921007|PROCEDURE|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
57929700|NCT04921007|DRUG|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
57929701|NCT05364268|DEVICE|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
57929702|NCT04403750|PROCEDURE|Combined laser-surgical technology of RRD treatment|"1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
57929703|NCT06226831|OTHER|Structured interview|In-person structured interviews will be performed by the investigators.
57929704|NCT00809211|DRUG|nilotinib|
57929705|NCT00809211|GENETIC|cytogenetic analysis|
57929706|NCT00809211|GENETIC|mutation analysis|
57929707|NCT00809211|GENETIC|polymerase chain reaction|
57929708|NCT00809211|OTHER|pharmacological study|
57929709|NCT06046625|OTHER|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
57929710|NCT05385133|PROCEDURE|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
57929711|NCT05385133|PROCEDURE|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
58069541|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
58397355|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
58397356|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
58397357|NCT01787396|DRUG|Gemigliptin 50mg|
57929712|NCT01195545|DEVICE|Veritas® Collagen Matrix|biological mesh in hernia repair
57929713|NCT02646748|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
57929714|NCT02646748|DRUG|itacitinib|Itacitinib tablets administered orally once daily.
57929715|NCT02646748|DRUG|INCB050465|INCB050465 tablets administered orally once daily.
57929716|NCT03088722|OTHER|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
57929717|NCT02665065|DRUG|Iomab-B|
57929718|NCT02665065|DRUG|Conventional Care|
57929719|NCT02665065|PROCEDURE|HCT|
57929720|NCT04408261|DRUG|Buqitongluo Granule|Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
57929721|NCT04408261|DRUG|Buqitongluo Granule Placebo|Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
57929722|NCT04408261|OTHER|Standard care|Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
57929723|NCT03366493|COMBINATION_PRODUCT|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
58282187|NCT03285165|DRUG|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
58397358|NCT01787396|DRUG|Placebo(Metformin)|
58397359|NCT01787396|DRUG|Metformin|
58397360|NCT01787396|DRUG|Placebo(Gemigliptin)|
58397361|NCT05051722|DIAGNOSTIC_TEST|Tampon Collection|A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
58397362|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
58397363|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
57929724|NCT03366493|OTHER|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
57929725|NCT03366493|OTHER|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
57929726|NCT03366493|PROCEDURE|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
57929727|NCT03366493|PROCEDURE|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
58282188|NCT03949738|DIAGNOSTIC_TEST|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
58282189|NCT04668872|RADIATION|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
58397364|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
57728152|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
57728153|NCT01100164|DRUG|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
57728154|NCT01100164|DRUG|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
57728155|NCT01165281|DRUG|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
57728156|NCT01165281|DRUG|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
57728157|NCT05711069|OTHER|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
57728158|NCT05711069|OTHER|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
57728159|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
57728160|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
57728161|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
57728162|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
57728163|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
57929728|NCT03366493|PROCEDURE|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
57929729|NCT02431650|DRUG|OZ439|
57929730|NCT02431650|DRUG|Primaquine|
57929731|NCT01729156|DRUG|Metformin|1000 mg metformin twice daily in 3 months
57929732|NCT01729156|DRUG|Placebo|2 tablets twice daily in 3 months
57929733|NCT04063254|RADIATION|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
57929734|NCT05092633|DEVICE|Miniscrew|Application of laser on miniscrew
58397365|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
58397366|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
58397367|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
58397368|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
57929735|NCT00400309|BIOLOGICAL|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
57929736|NCT00400309|BIOLOGICAL|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
58282190|NCT04668872|DIAGNOSTIC_TEST|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
58282191|NCT04668872|DIAGNOSTIC_TEST|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
58282192|NCT03556397|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
58282193|NCT03556397|PROCEDURE|Axillary dissection|Axillary dissection procedure will be performed in the patients
58282194|NCT04309487|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
58397369|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
58397370|NCT00822419|DRUG|ketamine|ketamine 5%
58397371|NCT00822419|DRUG|non-drug cream|will be put on the skin
58397372|NCT02789345|DRUG|Ramucirumab|Administered IV
57929737|NCT00072332|DRUG|cisplatin|
58282195|NCT03301935|PROCEDURE|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
58282196|NCT04037293|DIAGNOSTIC_TEST|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
58282197|NCT01343784|OTHER|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
58282198|NCT03402425|DIAGNOSTIC_TEST|18F-FET PET|Patient are investigated with an 18F-FET PET
58282199|NCT02437643|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
58282200|NCT02437643|DIETARY_SUPPLEMENT|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
58282201|NCT02437643|BEHAVIORAL|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
58397373|NCT02789345|DRUG|Necitumumab|Administered IV
58397374|NCT02789345|DRUG|Osimertinib|Administered orally
57728164|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
57728165|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
57728166|NCT04425083|OTHER|no intervention|no intervention
57728167|NCT02280603|DRUG|DA-4001C|1ml by topical application twice a day
57728168|NCT02280603|DRUG|5% minoxidil|1ml by topical application twice a day
57728169|NCT04092426|OTHER|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
57929738|NCT00072332|DRUG|edotecarin|
57929739|NCT03559920|DRUG|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
57929740|NCT03559920|DRUG|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
57929741|NCT05912387|DRUG|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
57929742|NCT02390817|DRUG|Sugammadex|Administration of Sugammadex
57929743|NCT02390817|DRUG|Neostigmine|Administration of Neostigmine
58282202|NCT00030966|DRUG|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
58282203|NCT00030966|DRUG|Placebo|Placebo monthly infusion for up to 116 weeks.
58282204|NCT00332774|DRUG|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
58282205|NCT00332774|DRUG|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
58282206|NCT00332774|OTHER|Nepafenac ophthalmic suspension vehicle|
58397375|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
58397376|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
58397377|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
58397378|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
58397379|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
58397380|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
57728170|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
57728171|NCT05006365|DEVICE|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
57929744|NCT01854645|DRUG|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
58282207|NCT04350931|BIOLOGICAL|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
58397381|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
58397382|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
58397383|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
58397384|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
57929745|NCT01854645|DRUG|GP MDI|GP MDI administered as two puffs BID
57929746|NCT01854645|DRUG|FF MDI|FF MDI administered as two puffs BID
57929747|NCT01854645|DRUG|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
57929748|NCT01854645|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID
57929749|NCT01772004|DRUG|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
57929750|NCT04722926|OTHER|PJI|patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
57929751|NCT03519958|DIAGNOSTIC_TEST|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
57929752|NCT05020288|DRUG|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
57929753|NCT04622033|BIOLOGICAL|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
57929754|NCT00388622|BEHAVIORAL|Pharmacist intervention|
57929755|NCT04350216|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
57929756|NCT02405923|OTHER|HRF|The subject will take the formula for a period of 12 months.
57929757|NCT02405923|OTHER|eHF|The subject will take the formula for a period of 12 months.
57929758|NCT00960960|DRUG|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
58282208|NCT04350931|OTHER|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
58397385|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
57728172|NCT01952912|PROCEDURE|PkEP|
57728173|NCT01952912|PROCEDURE|OP|
57728174|NCT05783180|DRUG|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
57728175|NCT05783180|DRUG|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
57929759|NCT00960960|DRUG|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
57929760|NCT00960960|DRUG|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
57929761|NCT00960960|DRUG|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
57929762|NCT00960960|DRUG|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
57929763|NCT04081454|BEHAVIORAL|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
57929764|NCT04081454|BEHAVIORAL|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
58282209|NCT06197477|DEVICE|OurAir SQ 1750 - Mobile Air Purification System for indoor|Filtration device will be placed in classrooms. Computational Fluid Dynamics simulations will be used to find optimal position and operation mode for air purification systems in classrooms.
58282210|NCT06197477|DEVICE|Sham intervention|Filtration will be turned off in the control part of the study and then will be turned on during the intervention.
58397386|NCT00149136|DRUG|imatinib|
58397387|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
58397388|NCT02724917|DRUG|Placebo|Placebo to match
58397389|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
57929765|NCT00179725|DRUG|CC-5013|
57929766|NCT00179725|DRUG|liposomal doxorubicin|
57929767|NCT03730974|DEVICE|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
57929768|NCT05558176|DRUG|Sildenafil citrate|The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
58282211|NCT01085240|OTHER|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
58422734|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
57728176|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
57728177|NCT03942718|OTHER|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
57728178|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®)|ADM (Novomatrix®) will be used alone
57728179|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF|ADM in combination with L-Prf will be applied
57728180|NCT05255016|COMBINATION_PRODUCT|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
57728181|NCT05255016|OTHER|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
57728182|NCT00034034|PROCEDURE|Acupuncture|
57728183|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
57728184|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
57728185|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
57728186|NCT06635239|OTHER|Co-creation and assessment|"1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)"
57728187|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
57929769|NCT01581944|DRUG|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
57929770|NCT01581944|DRUG|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
57929771|NCT05539859|PROCEDURE|Endoscopic surgery|Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management
57929772|NCT05539859|OTHER|Medical management|Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
57929773|NCT05737290|DEVICE|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
57929774|NCT05737290|DEVICE|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
57929775|NCT01118689|DRUG|MLN0128|MLN0128 administered orally once daily for 28 days
57929776|NCT01054651|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
57929777|NCT01054651|DRUG|Praziquantel|
57728188|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
57929778|NCT04027231|OTHER|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
57728189|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
57929779|NCT00654342|PROCEDURE|Intraoperative injection (in vivo)|Intraoperative injection
57929780|NCT00654342|PROCEDURE|Postoperative injection (ex vivo)|postoperative injection
58069542|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
57728190|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
57728191|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
58282212|NCT04858867|RADIATION|rhTSH-stimulated I-124 dosimetry|"Preparation:~* Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~* Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~* Ingestion of capsule with 37±10% MBq I-124~* I-124 PET/CT at 24 and 96h post-ingestion~* Blood draws at 2, 24 and 96h post-ingestion~* Whole body counting at 2, 24 and 96h post-ingestion"
58282213|NCT04858867|RADIATION|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~* I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~* Blood draws at 2, 6, 24, 96 and 144h post-ingestion~* Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
58282214|NCT03323697|OTHER|SZ-05|2.5g a day (3 capsules twice a day)
57728192|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
57728193|NCT00004010|BIOLOGICAL|bleomycin sulfate|
57728194|NCT00004010|BIOLOGICAL|filgrastim|
57929781|NCT05104008|OTHER|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
58069543|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
58069544|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
58069545|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
58069546|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
58282215|NCT03323697|DRUG|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
58282216|NCT00316329|DRUG|Artesunate + Amodiaquine|
58422735|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
57728195|NCT00004010|DRUG|ABVD regimen|
57728196|NCT00004010|DRUG|cyclophosphamide|
57728197|NCT00004010|DRUG|dacarbazine|
57728198|NCT00004010|DRUG|doxorubicin hydrochloride|
57728199|NCT00004010|DRUG|etoposide|
57728200|NCT00004010|DRUG|prednisone|
57728201|NCT00004010|DRUG|procarbazine hydrochloride|
57728202|NCT00004010|DRUG|vinblastine sulfate|
57728203|NCT00004010|DRUG|vincristine sulfate|
57728204|NCT00004010|RADIATION|radiation therapy|
57728205|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
58069547|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
58069548|NCT00000721|DRUG|CD4 Antigens|
58069549|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
58069550|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
58282217|NCT00154375|DRUG|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
58282218|NCT00154375|DRUG|Hydroxyurea|
58069551|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
58069552|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
58282219|NCT05430113|DEVICE|Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)|2-4 leads FDA-approved for treatment of symptoms of refractory pain
58282220|NCT02869893|DRUG|Secretin|
58397390|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
58397391|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
58397392|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
58397393|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
58397394|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
57929782|NCT05104008|OTHER|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
57929783|NCT03620019|DRUG|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
57929784|NCT03620019|DRUG|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
57929785|NCT03620019|DRUG|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
58282221|NCT01109134|DRUG|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
58282222|NCT01109134|DRUG|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
58282223|NCT03616392|DRUG|D308, CKD-501|"1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg"
58282224|NCT03838029|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
58282225|NCT03838029|OTHER|Placebo|Placebo
58282226|NCT03685500|DRUG|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
57929786|NCT05699135|DRUG|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
57929787|NCT04441112|DRUG|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
57929788|NCT04441112|DRUG|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
58282227|NCT03685500|DRUG|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
58282228|NCT03326115|BEHAVIORAL|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
58282229|NCT03488563|BIOLOGICAL|B244|B244 Suspension
58282230|NCT03488563|BIOLOGICAL|Vehicle|Vehicle Suspension
57728206|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
57929789|NCT01723813|BIOLOGICAL|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
57929790|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
57929791|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
57929792|NCT01831830|BEHAVIORAL|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
57929793|NCT00034450|DRUG|L-carnitine|
57929794|NCT01499953|DRUG|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
57929795|NCT01499953|DRUG|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
57929796|NCT01641809|DRUG|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
57929797|NCT01641809|DRUG|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
57929798|NCT01641809|DRUG|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
58282231|NCT03992677|OTHER|No intervention|No intervention
57728207|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
57728208|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
57929799|NCT01641809|DRUG|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
58282232|NCT00559663|DIETARY_SUPPLEMENT|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
58397395|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
58397396|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
58397397|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
58397398|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
58397399|NCT04234204|DRUG|Fezolinetant|Oral
58397400|NCT04234204|DRUG|Placebo|Oral
57728209|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
57728210|NCT01269892|DIETARY_SUPPLEMENT|lactose-free milk|a milk without lactose
58069553|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
58069554|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
58282233|NCT00559663|DIETARY_SUPPLEMENT|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
58282234|NCT01607853|DRUG|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
58282235|NCT01607853|DRUG|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
57728211|NCT01269892|DIETARY_SUPPLEMENT|conventional milk|a milk with lactose
57728212|NCT04798781|DRUG|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
58069555|NCT04196010|DRUG|Cladribine|Given IV
58069556|NCT04196010|DRUG|Cytarabine|Given IV
58282236|NCT01607853|DRUG|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
58422736|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
58422737|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
57929800|NCT01641809|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
57929801|NCT01641809|DRUG|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
57929802|NCT01641809|DRUG|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
57929803|NCT04399122|DRUG|acetaminophen/codeine vs acetaminophen/oxycodone|pain medications
57929804|NCT03552861|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
57929805|NCT00028821|DRUG|2-methoxyestradiol|Given orally
57929806|NCT00028821|OTHER|pharmacological study|Correlative studies
57929807|NCT00028821|OTHER|laboratory biomarker analysis|Correlative studies
57929808|NCT05047783|DRUG|Masitinib Mesylate|3CL-protease inhibitor
58282237|NCT01607853|DRUG|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
57929809|NCT05047783|DRUG|Placebo|Placebo
57929810|NCT06274671|OTHER|Magnetic Resonance Imaging|A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
58397401|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
57728213|NCT04798781|DRUG|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
57929811|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
57929812|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
57929813|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
57929814|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
57929815|NCT00737919|DIETARY_SUPPLEMENT|Plant Stanol|Plant stanols in margarines daily 2 grams
57929816|NCT00737919|DIETARY_SUPPLEMENT|Plant Sterol|Plant sterols in margarines daily 2 grams
57929817|NCT02838069|BIOLOGICAL|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
57929818|NCT02838069|BIOLOGICAL|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
57929819|NCT02838069|OTHER|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
58069557|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
58069558|NCT04196010|DRUG|Mitoxantrone|Given IV
58069559|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58069560|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58282238|NCT02849171|DEVICE|PET scan|
58282239|NCT02849171|RADIATION|C-Choline|
58282240|NCT01209247|OTHER|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
58282241|NCT02360748|DIETARY_SUPPLEMENT|Plant based high protein food items|Patients will add high protein plant based food items to their diet
57929820|NCT06148857|DIAGNOSTIC_TEST|IOLMaster 700|"The IOLMaster 700, one of the most commonly used optical biometers for IOL power calculation, measures the anterior corneal surface radius using a telecentric keratometry. Additionally, it employs swept-source optical coherence tomography (SS-OCT) technology to simultaneously measures the posterior cornea surface radius and central corneal thickness (CCT).~The AK formula, described by Abulafia et al., is a regression formula that calculates an estimated TCA using K astigmatism.~The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements."
58069561|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58069562|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58069563|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
58069564|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
58069565|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
58069566|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
58069567|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
58282242|NCT04247451|DIAGNOSTIC_TEST|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
58282243|NCT04144868|OTHER|Normobaric Oxygen|
58282244|NCT00921206|BIOLOGICAL|VAX102|1 ug i.m. compared to 2 ug s.c.
58282245|NCT04605718|DRUG|RO7223280|For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
58282246|NCT05792137|OTHER|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
58282247|NCT05792137|OTHER|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
58282248|NCT00571753|DRUG|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
58282249|NCT00571753|DRUG|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
57728214|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
57728215|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
57728216|NCT05515055|OTHER|Blood test|1 blood sample extra to standard of care is taken
57728217|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
57728218|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients on Hydroxyurea
57728219|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients on Hydroxyurea
58069568|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
58069569|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
58069570|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
58069571|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
58069572|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
58069573|NCT01922336|BIOLOGICAL|SB2|IV infusion
58069574|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
58069575|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
58069576|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
58069577|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
58069578|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
58282250|NCT00287521|DRUG|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
58282251|NCT00287521|DRUG|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
58282252|NCT00287521|OTHER|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
57929821|NCT05276557|COMBINATION_PRODUCT|PyloPlus Urea Breath Test System|System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
58397402|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
58397403|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
58282253|NCT00287521|DRUG|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
58397404|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
58397405|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
58397406|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
57929822|NCT05276557|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patients' stool for H. pylori
57929823|NCT03580772|DEVICE|Persona TKR|Persona® TKR (Zimmer Biomet)
57929824|NCT03580772|DEVICE|Attune TKR|Attune® TKR (Depuy synthes)
57929825|NCT02540538|BIOLOGICAL|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
57929826|NCT02540538|BIOLOGICAL|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
58282254|NCT02598778|DRUG|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
58282255|NCT02598778|DRUG|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
58282256|NCT02598778|OTHER|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
57929827|NCT03985215|OTHER|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
58282257|NCT02598778|OTHER|Deionized water|30 second oral rinse of 10mL of solution
58282258|NCT03250247|DEVICE|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices \> 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
58282259|NCT03621241|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometry
57929828|NCT03334409|DRUG|Ascorbic Acid|Given IV
57929829|NCT03334409|DRUG|Pazopanib Hydrochloride|Given PO
57929830|NCT00859950|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
57929831|NCT01557023|DRUG|barrier methods|
58282260|NCT05527899|DRUG|Zinc gluconate|30 and 60 mg/d of zinc gluconate
58397407|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
58397408|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
58397409|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
58397410|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
58397411|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
58397412|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
58397413|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
57929832|NCT01557023|DRUG|barrier methods|
57929833|NCT02941926|DRUG|Ribociclib|Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
57929834|NCT02941926|DRUG|Letrozole|Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
57728220|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients not on Hydroxyurea
57728221|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients not on Hydroxyurea
57728222|NCT01184014|DRUG|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
57728223|NCT01184014|DRUG|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
57728224|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
57728225|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
57728226|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
57728227|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
58069579|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
58069580|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
57728228|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
57728229|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
57728230|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
57728231|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
58069581|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
58069582|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
58069583|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
58069584|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
58397414|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58422738|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
57728232|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
57728233|NCT02817789|DRUG|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
57728234|NCT02817789|DRUG|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
57728235|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
57728236|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
57728237|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
57728238|NCT02613481|DRUG|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
57728239|NCT00333034|DRUG|Etanercept|
57728240|NCT00815841|DRUG|METHYLPHENIDATE|15-20mg during one of the two sessions
57728241|NCT04046874|DRUG|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
57728242|NCT04046874|OTHER|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
57728243|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
58422739|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
58397415|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
58397416|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
58397417|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
58397418|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
58397419|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
58397420|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
57728244|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
57728245|NCT04844281|DEVICE|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
57728246|NCT02958644|DIETARY_SUPPLEMENT|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
57929835|NCT02941926|DRUG|Goserelin|Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
57929836|NCT02941926|DRUG|Leuprolide|Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
57929837|NCT06059066|PROCEDURE|Standard number of injection sites|200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.
58397421|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
57728247|NCT02958644|DIETARY_SUPPLEMENT|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
57728248|NCT01834820|DRUG|Epinephrine and Dexamethasone|
57728249|NCT01834820|DRUG|Hypertonic Saline|
57929838|NCT06059066|PROCEDURE|Reduced number of injection sites|200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.
57929839|NCT03049787|OTHER|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
57929840|NCT03049787|OTHER|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
57929841|NCT02141542|DRUG|Tremelimumab|
57929842|NCT02141542|DRUG|MEDI3617|
57929843|NCT04877717|DRUG|SHR-A1904|SHR-A1904
57728250|NCT01834820|DRUG|Normal Saline|
57929844|NCT04581967|GENETIC|polymorphism analysis|"* DNA will be purified from whole blood samples by commercial DNA isolation kits.~* Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
57929845|NCT04581967|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
57929846|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
57929847|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
57929848|NCT01109173|OTHER|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
57929849|NCT01109173|OTHER|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
58397422|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
58069585|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
58069586|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
58282261|NCT03992898|OTHER|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
58282262|NCT00441038|BEHAVIORAL|The Back Guide|Education on postural hygiene and handout of The Back Guide
58282263|NCT00441038|BEHAVIORAL|The Back Book|Education on active management and Handout of The Back Book
58282264|NCT00441038|BEHAVIORAL|Cardiovascular and general health|Education on cardiovascular and general health
58282265|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
58282266|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
58282267|NCT05395533|DRUG|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection|The dose of the enrolled subjects was increased according to the following 7 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg. (according to the data of the previous study, when the dose climbs to 1.5 mg / kg, there is a serious decline of neutrophils, which shall be subject to the principle of 3 + 3.
58282268|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
58282269|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
58282270|NCT02851316|OTHER|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
58282271|NCT02612545|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
58282272|NCT02612545|DRUG|Mefloquine (MQ)|ACT partner drug
58282273|NCT05037890|DIETARY_SUPPLEMENT|Margarine|Intake of margarine
58282274|NCT00826150|BIOLOGICAL|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
58282275|NCT00565890|DRUG|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
58282276|NCT04501016|BEHAVIORAL|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
57728251|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
57728252|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
57929850|NCT04987892|DEVICE|UroLift System|Prostatic lift
58069587|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
58282277|NCT04501016|DRUG|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
58282278|NCT02483325|DRUG|Allogeneic transplant conditioning|Allogeneic transplant
58282279|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
58282280|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
58282281|NCT00255840|DRUG|Efavirenz|600 mg tablet taken orally daily
58282282|NCT00255840|DRUG|Lamivudine|150 mg tablet taken orally daily
58282283|NCT00255840|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
58282284|NCT00255840|DRUG|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
57929851|NCT04987892|DRUG|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
58282285|NCT00255840|DRUG|Stavudine|Tablet taken orally daily. Dosage depends on weight.
58282286|NCT02121353|DRUG|Lucentis|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
58282287|NCT02121353|DRUG|PF582|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
58282288|NCT04848246|DRUG|Bupropion|This group received Bupropion 150 mg twice daily for 10 weeks
58282289|NCT04848246|BEHAVIORAL|Behavioural Change Communication|This group will receive Behavioural Change Communication
58397423|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
57929852|NCT00120406|DEVICE|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
57929853|NCT00120406|PROCEDURE|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
57929854|NCT00134316|BEHAVIORAL|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
58282290|NCT00463125|DRUG|Platelet Gel|
58282291|NCT00683761|DRUG|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
57929855|NCT03504514|DEVICE|speech trials during different ventilation conditions|ventilator parameters are modified
58397424|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
57929856|NCT03504514|OTHER|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
58069588|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
58282292|NCT00004832|DRUG|3,4-diaminopyridine|
58282293|NCT04802083|BIOLOGICAL|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
58282294|NCT04844983|DRUG|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
58282295|NCT04844983|OTHER|Placebo Saline|Normal Saline
57929857|NCT04943003|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
57929858|NCT05713188|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
58282296|NCT04498039|DEVICE|Portable Neuromodulation Stimulator|Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
58282297|NCT02550080|DRUG|Dapsone|For the HLA-B\*1301 positive subjects, dapsone will not be administrated.
58282298|NCT02550080|GENETIC|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
58282299|NCT05446220|BEHAVIORAL|Lifestyle intervention|Dietary advise and/or advise on physical activity monitored by pedometer
58282300|NCT01197209|BIOLOGICAL|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
58282301|NCT00459368|BEHAVIORAL|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
58282302|NCT00459368|BEHAVIORAL|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
58282303|NCT04641533|PROCEDURE|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
58282304|NCT04641533|PROCEDURE|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
58282305|NCT06186596|DEVICE|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
58282306|NCT02113007|DRUG|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
58397425|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
57929859|NCT02540863|OTHER|myofascial release protocol and Rocabado exercise therapy|
58397426|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
58397427|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
58397428|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
57728253|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
57929860|NCT02540863|OTHER|exercise therapy|
58282307|NCT03792542|DRUG|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
58282308|NCT01378715|DRUG|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
58282309|NCT05208268|DRUG|Pariet|Pariet Tablets.
58282310|NCT00043277|DRUG|Angiomax (bivalirudin)|
58282311|NCT05472571|OTHER|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
58282312|NCT00119483|DRUG|Nebido (Testosterone Undecanoate)|
58282313|NCT03581955|OTHER|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
58282314|NCT03581955|OTHER|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
58282315|NCT03581955|OTHER|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
58282316|NCT00329745|BIOLOGICAL|Rotarix™|Oral administration, 2 doses
57929861|NCT00021450|DRUG|bicalutamide|
58282317|NCT00329745|BIOLOGICAL|Placebo|Oral administration, 2 doses
58282318|NCT00335855|DEVICE|Auto-injector for IM/SC vaccine administration|
58282319|NCT01137656|DRUG|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
58282320|NCT06478368|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
58282321|NCT04805164|PROCEDURE|Corticotomy and use of the bone substitute : Cerament-G device.|Corticotomy and Cerament-G device
58282322|NCT04805164|PROCEDURE|Corticotomy|Corticotomy
58282323|NCT02703376|DRUG|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
58282324|NCT00061750|DRUG|ICL670|
58282325|NCT00061750|DRUG|deferoxamine|
58282326|NCT06262022|OTHER|cold therapy|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
57728254|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
58282327|NCT03538691|DRUG|Brexpiprazole|Administered as tablets.
58282328|NCT03538691|DRUG|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
58282329|NCT03718234|DRUG|Subcutaneous hydrocortisone|Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
58282330|NCT03718234|DRUG|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
58282331|NCT02018770|RADIATION|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
58282332|NCT02018770|RADIATION|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
58282333|NCT05739656|PROCEDURE|CATARACT SURGERY|Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.
58282334|NCT04281628|DRUG|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
58282335|NCT04281628|DRUG|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
58282336|NCT02740335|DRUG|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
58282337|NCT02740335|DRUG|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
58282338|NCT03780972|DRUG|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
58282339|NCT03780972|PROCEDURE|Intravitreal Injection|Injection of study drug into the eye
58282340|NCT03780972|PROCEDURE|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
57728255|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
57728256|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
57929862|NCT00021450|DRUG|goserelin acetate|
57929863|NCT00021450|PROCEDURE|adjuvant therapy|
57929864|NCT00021450|RADIATION|radiation therapy|
57929865|NCT01326728|BIOLOGICAL|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
58397429|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
58397430|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
58282341|NCT03735745|OTHER|Blood collection|30cc of blood will be collected.
58282342|NCT03735745|OTHER|Saliva collection|5cc of saliva will be collected.
58282343|NCT03735745|OTHER|Tissue collection|Up to 10mg of tissue will be collected.
57728257|NCT05377398|BEHAVIORAL|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
57929866|NCT00422526|DRUG|Micronised progesterone (Utrogestan)|
57929867|NCT03786978|BEHAVIORAL|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
57929868|NCT03786978|BEHAVIORAL|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
57929869|NCT03878004|BIOLOGICAL|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
58282344|NCT03735745|OTHER|Surveys|The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
58306807|NCT04500951|OTHER|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
58397431|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
58397432|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
58397433|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
58397434|NCT04181593|DRUG|Placebos|Mineral oil Softgels
58397435|NCT06661317|OTHER|no intervention|no intervention
58397436|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
57728258|NCT05377398|BEHAVIORAL|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
57728259|NCT05377398|BEHAVIORAL|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
57929870|NCT03878004|BIOLOGICAL|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
58069589|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
58069590|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
58069591|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
58069592|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
58282345|NCT04933864|DRUG|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed."
58282346|NCT03734809|DRUG|Pembrolizumab|200mg every 3 weeks infusion
58282347|NCT02523404|PROCEDURE|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
58282348|NCT02984644|DRUG|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
58397437|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
58397438|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
58397439|NCT06087237|DRUG|Pentoxifylline|400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
58397440|NCT06087237|DRUG|Placebo|placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
58397441|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
58069593|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
58397442|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
58069594|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
58069595|NCT02297867|DRUG|ADSCs|autologous ADSCs
58069596|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
58069597|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
58069598|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
58306808|NCT00001091|DRUG|Ritonavir|
58397443|NCT01675297|DRUG|Risedronate|Risedronate once a week
58282349|NCT02984644|DRUG|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
58282350|NCT03942003|PROCEDURE|rhomboid blocks|Rhomboid nerve block was performed
58397444|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
57728260|NCT05377398|BEHAVIORAL|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
57728261|NCT02199847|DRUG|Pharmaton® Caplets|
58282351|NCT03942003|PROCEDURE|PEC blocks|PEC I-II blocks was performed
58282352|NCT03942003|PROCEDURE|Control groups|Infiltration analgesia was performed
57728262|NCT02199847|DRUG|Placebo|
57728263|NCT02525133|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
58069599|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
58069600|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
58282353|NCT04592796|DEVICE|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
58282354|NCT04592796|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
58282355|NCT04592796|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
58282356|NCT04592796|OTHER|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
58282357|NCT04592796|OTHER|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
58397445|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
58069601|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
58069602|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
58282358|NCT04592796|OTHER|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
58282359|NCT04592796|OTHER|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
57728264|NCT02525133|OTHER|Placebo|Plain collagen implant (vehicle)
57728265|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
58069603|NCT03220620|OTHER|GDT|individualized fluid therapy
58069604|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
58069605|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
58069606|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
58069607|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
58282360|NCT01859871|BEHAVIORAL|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
58282361|NCT03615820|DRUG|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
58306809|NCT00001091|DRUG|Nelfinavir mesylate|
58306810|NCT00001091|DRUG|Nevirapine|
58397446|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
58397447|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
58397448|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
58397449|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
57929871|NCT06493877|OTHER|Retraining program after thoracic surgery|"An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2)."
57728266|NCT01527201|PROCEDURE|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
57929872|NCT02859961|DRUG|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
57929873|NCT02859961|DRUG|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
57929874|NCT02859961|DRUG|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
57728267|NCT02369029|DRUG|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
57728268|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
58069608|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
58282362|NCT03615820|DRUG|Oromucoadhesive film|Oromucoadhesive film without PPE control testing which represents Placebo group
58306811|NCT00001091|DRUG|Lamivudine|
58397450|NCT02931513|OTHER|Blood samples|
58397451|NCT02931513|DEVICE|Fibroscan|
58397452|NCT02931513|OTHER|Questionnaires|
58397453|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
58397454|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
58397455|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
58397456|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
58397457|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
58397458|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
58397459|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
58397460|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
58397461|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
58397462|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
58397463|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
58397464|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
57929875|NCT04866888|PROCEDURE|closure of the uterine wall defect|Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
58397465|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
58397466|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
57728269|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
58069609|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
58282363|NCT03963778|BEHAVIORAL|Improving nutritional care|The interventions will be co-designed with the action research team
58397467|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
58397468|NCT00491946|DRUG|Actinomycin-D|
58397469|NCT00491946|DRUG|Vincristine|
58397470|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
58306812|NCT00001091|DRUG|Stavudine|
57929876|NCT04866888|DIAGNOSTIC_TEST|ultrasound|"Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded."
57929877|NCT04866888|DIAGNOSTIC_TEST|outpatient hysteroscopy|Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
57728270|NCT03219983|DRUG|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
57728271|NCT03219983|DRUG|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
58069610|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
58282364|NCT03743844|BEHAVIORAL|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
58282365|NCT02036541|DEVICE|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
58282366|NCT00497341|DRUG|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
58282367|NCT00497341|DRUG|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
58282368|NCT01888250|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
58282369|NCT05294965|DRUG|Fenoterol|Intravenous infusion
58282370|NCT05294965|OTHER|Mild cold exposure|Body surface cooling
58397471|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
58397472|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
57728272|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
58282371|NCT02258906|DRUG|ulinastatin|
58282372|NCT02258906|DRUG|normal saline|
58282373|NCT05992688|OTHER|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
58282374|NCT05992688|OTHER|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
58282375|NCT05992688|OTHER|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
58282376|NCT02849210|BIOLOGICAL|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
58282377|NCT00973284|BIOLOGICAL|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
58282378|NCT00973284|BIOLOGICAL|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
58282379|NCT00973284|BIOLOGICAL|Norwalk virus|Norwalk virus solution
58282380|NCT00758329|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
58397473|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
58397474|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
58397475|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
58397476|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
58282381|NCT05061381|BEHAVIORAL|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
58397477|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
58397478|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
58397479|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
58397480|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
58397481|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
58397482|NCT02897037|DRUG|heparin|heparin monotherapy
58397483|NCT04295681|DRUG|MMH-MAP|Oral administration
58282382|NCT04303234|OTHER|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
58397484|NCT04295681|DRUG|Placebo|Oral administration
58397485|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
58397486|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
58397487|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
58282383|NCT04303234|OTHER|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
58397488|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
58397489|NCT05686746|DRUG|MMF|1000 mg oral daily
58397490|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
58397491|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
57728273|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
57728274|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
58397492|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
57728275|NCT02021279|PROCEDURE|native tissue repair|
57929878|NCT04834687|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
58282384|NCT03695328|BEHAVIORAL|physical activity level|
58282385|NCT03695328|BEHAVIORAL|Dietary Intake|
58282386|NCT03439891|BIOLOGICAL|Nivolumab|Given IV
58282387|NCT03439891|DRUG|Sorafenib|Given PO
57728276|NCT02997566|OTHER|Autonomic evaluation|
57728277|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
57728278|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
58306813|NCT05319548|OTHER|Purple-Red Carrot Juice|Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins
58306814|NCT05319548|OTHER|Red Carrot Juice|Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..
58397493|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
58397494|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
58397495|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
58069611|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
58069612|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
58069613|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
58069614|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
58069615|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
58069616|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
58282388|NCT05334459|RADIATION|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~  o ER / PR /Her2 /Ki67 study)~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice."
58282389|NCT00488137|DRUG|Prucalopride|2 mg o.d.
58282390|NCT00488137|OTHER|Placebo|o.d.
58282391|NCT00488137|DRUG|Prucalopride|4 mg o.d.
58282392|NCT00284011|DIETARY_SUPPLEMENT|SAMe|800 mg dose daily for 4 weeks.
58282393|NCT00284011|OTHER|Placebo|2 placebo pills daily for 4 weeks.
58282394|NCT02147392|DRUG|[11C]ER-176|
58282395|NCT00001119|BIOLOGICAL|Tetanus Toxoid Vaccine|
58282396|NCT00001119|DRUG|Indinavir sulfate|
57728279|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
57728280|NCT03746860|DRUG|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
58069617|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
58069618|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
58069619|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
58069620|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
58069621|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
58069622|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
58069623|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
58069624|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
58282397|NCT00001119|DRUG|Lamivudine/Zidovudine|
58282398|NCT00001119|DRUG|Ritonavir|
58069625|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
58282399|NCT00001119|DRUG|Abacavir sulfate|
58282400|NCT00001119|DRUG|Amprenavir|
58282401|NCT00001119|DRUG|Efavirenz|
58282402|NCT00001119|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
58282403|NCT00001119|DRUG|Lamivudine|
58282404|NCT00001119|DRUG|Zidovudine|
58282405|NCT01575002|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
58282406|NCT05989971|OTHER|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
58282407|NCT03411902|DRUG|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
58069626|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
58069627|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
58069628|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
58069629|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
58397496|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
57929879|NCT04834687|BEHAVIORAL|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~1. Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~2. According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
57929880|NCT04047693|DRUG|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
57929881|NCT00438503|PROCEDURE|Procedure|
57929882|NCT00953719|DEVICE|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
57929883|NCT00953719|DEVICE|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
57929884|NCT03067155|GENETIC|CMV-specific T cells|
57929885|NCT03067155|DRUG|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
57929886|NCT02809742|DRUG|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
57929887|NCT02610153|DRUG|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
57929888|NCT04288830|BEHAVIORAL|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
58069630|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
58069631|NCT05411705|DRUG|Control|Non-rhTPO treatment
58069632|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
58069633|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
58069634|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
57929889|NCT04288830|BEHAVIORAL|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
57929890|NCT01580280|OTHER|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
57929891|NCT01580280|OTHER|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
57929892|NCT04820374|PROCEDURE|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
58069635|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
58397497|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
58397498|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
58397499|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
58397500|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
58397501|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
57728281|NCT05890183|BEHAVIORAL|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
57728282|NCT05890183|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
57728283|NCT05890183|BEHAVIORAL|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.
57728284|NCT05890183|BEHAVIORAL|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.
58069636|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
58282408|NCT03411902|OTHER|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
58282409|NCT02393235|OTHER|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
58282410|NCT02072070|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
58282411|NCT02072070|DRUG|Placebo|Placebo control(Normal Saline)
58282412|NCT00019656|DRUG|perifosine|
58282413|NCT02875873|DRUG|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
58282414|NCT02875873|DRUG|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
58282415|NCT02875873|OTHER|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
58282416|NCT02875873|OTHER|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
58282417|NCT05392777|DIAGNOSTIC_TEST|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
58397502|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
58069637|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
58069638|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
58069639|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
58282418|NCT00529178|DRUG|Pravastatin|
58282419|NCT05889208|DEVICE|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
58397503|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
58397504|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
58397505|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
58069640|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
58282420|NCT04755738|COMBINATION_PRODUCT|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
58282421|NCT02128334|DRUG|Eligard 45 mg Exposure|Subcutaneous injections
58282422|NCT01234064|DEVICE|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
58282423|NCT01234064|DEVICE|No Graduated Compression Stockings|No stockings will be applied.
58282424|NCT04040465|DRUG|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
58282425|NCT03158610|DRUG|Capecitabine|Oral fluorouracil
58282426|NCT01675388|OTHER|Hypothermia|Hypothermia to 33.5 deg C
58397506|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
57929893|NCT04194281|OTHER|Action Observation Training [AOT]|Parents are instructed to show their child repetitive arm, hand and finger movements in a playful and age-appropriate way for about 20 minutes a day, divided into several short sequences. AOT is to be carried out for four weeks at home by the parents and, if necessary, other caregivers. The parents receive instructions which contain background information on the possible importance of AOT for improving the functions of the upper limb, information about positions, promoting motivation, attention and interest as well as tips for promoting movement observation in everyday life.
57929894|NCT02915471|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
57929895|NCT05522049|DEVICE|hyperangulated videolaryngoscope|Intubation using a hyperangulated videolaryngoscope
57929896|NCT05522049|DEVICE|Macintosh videolaryngoscope|Intubation using a Macintosh videolaryngoscope
57929897|NCT04311567|DRUG|Tofacitinib|Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
57929898|NCT04311567|DRUG|Methotrexate|Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
57929899|NCT05881889|DEVICE|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
58282427|NCT04456400|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography (MSOT)|cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.
58282428|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.25 milliamps (mA)
58282429|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.5-1.0 mA
58282430|NCT00305565|DEVICE|VNS Therapy|Received output current of 1.0-1.5 mA
58282431|NCT00523055|DRUG|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
58282432|NCT04150536|DRUG|Lidocaine topical system 1.8%|
58282433|NCT06330571|DEVICE|Molar distalization by aligners with attachment|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months."
58282434|NCT00895934|DRUG|vorinostat|Given orally
58282435|NCT00895934|DRUG|gemtuzumab ozogamicin|Given intravenously (IV)
58282436|NCT00895934|DRUG|azacitidine|Given IV or subcutaneously (SC)
58282437|NCT00002030|DRUG|Pentamidine isethionate|
58282438|NCT05119686|DRUG|AR882 Dose 1|Solid Oral Capsule
58282439|NCT05119686|DRUG|AR882 Dose 2|Solid Oral Capsule
58282440|NCT05119686|DRUG|Placebo|Matching Solid Oral Capsule Placebo
58282441|NCT04163315|OTHER|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
58282442|NCT01759719|DEVICE|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
58306815|NCT05319548|OTHER|Purple Carrot Juice|Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
58306816|NCT06132971|BEHAVIORAL|New Beginnings Program|
58397507|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
58397508|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
58397509|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
58397510|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
58397511|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
57728285|NCT05890183|BEHAVIORAL|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
58282443|NCT02693899|OTHER|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
58282444|NCT04174365|DRUG|Brexpiprazole|Oral tablet; take once daily
58282445|NCT04174365|DRUG|Placebo|Administered orally daily for up to Week 8.
58282446|NCT03013712|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
58282447|NCT05727150|PROCEDURE|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
58282448|NCT03110081|PROCEDURE|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
58282449|NCT03110081|PROCEDURE|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
58282450|NCT06070675|DEVICE|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
58282451|NCT06070675|OTHER|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
58282452|NCT04657575|PROCEDURE|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
58282453|NCT01911793|DEVICE|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
58282454|NCT05979207|DRUG|MMV367|Single dose
58282455|NCT05979207|OTHER|P. falciparum IBSM infection|Induced Blood Stage Malaria
58282456|NCT02954588|DIETARY_SUPPLEMENT|Pyridoxamine|
58282457|NCT02954588|DIETARY_SUPPLEMENT|Placebo|
58282458|NCT00357890|DEVICE|Insulin pump therapy|CSII initiated within 1 month of diagnosis
58282459|NCT00357890|DRUG|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
58282460|NCT01583283|DRUG|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
58282461|NCT01583283|DRUG|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
58282462|NCT01583283|DRUG|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
58282463|NCT03818009|OTHER|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
58397512|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
58282464|NCT03974529|BEHAVIORAL|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
58282465|NCT03974529|BEHAVIORAL|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
58282466|NCT00985933|DRUG|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
58282467|NCT00985933|DRUG|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
58282468|NCT03270033|DRUG|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
58282469|NCT03270033|DRUG|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
58282470|NCT05351593|DRUG|Tafasitamab|Given IV
58282471|NCT05351593|DRUG|Lenalidomide|Given Orally
58282472|NCT01427543|BEHAVIORAL|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
58282473|NCT04869852|OTHER|Food|85g mango, 4x/week
58282474|NCT02021110|DRUG|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
57728286|NCT01649284|DRUG|afatinib|40, 30, and 20 mg film-coated tablets
57929900|NCT05881889|DEVICE|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
57929901|NCT04626817|DEVICE|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
58282475|NCT04792060|PROCEDURE|Hook plate|We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
58282476|NCT00264290|DRUG|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
58282477|NCT00264290|DRUG|Placebo|Placebo designed to resemble Valganciclovir
58306817|NCT02097732|DRUG|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
58306818|NCT02097732|PROCEDURE|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
58306819|NCT02343861|BEHAVIORAL|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
58397513|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
58397514|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
58397515|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
58397516|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
58282478|NCT01971515|DRUG|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
58282479|NCT01971515|DRUG|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
58397517|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
58397518|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
58397519|NCT00257582|DRUG|Cetirizine Dry Syrup|
57929902|NCT02785497|OTHER|Control group|will be turn on the equipment, positioning the patient but no put intensity
57929903|NCT02785497|OTHER|Treatment group|This group will receive electrostimulation
57929904|NCT05570474|DIETARY_SUPPLEMENT|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
58306820|NCT02343861|BEHAVIORAL|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
58306821|NCT04830735|DRUG|Dasatinib Anhydrous|Given PO
58306822|NCT04830735|DRUG|Placebo Administration|Given PO
58306823|NCT00318695|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
57929905|NCT05570474|DIETARY_SUPPLEMENT|Placebo|Daily placebo drink
57929906|NCT00120913|DRUG|Birth control pills|
57929907|NCT06159192|DEVICE|Low intensity extracorporeal shock wave|Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.
57929908|NCT03096925|BEHAVIORAL|Guided self-help|Web-based guided self-help intervention
57929909|NCT00866749|DRUG|Daunorubicin|Starting Dose 25 mg/m\^2 by vein weekly
58397520|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
58397521|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
57929910|NCT00866749|DRUG|Vincristine|Starting Dose 2 mg by vein weekly
57929911|NCT00866749|DRUG|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
57929912|NCT00866749|DRUG|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
57929913|NCT00866749|DRUG|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
57929914|NCT00866749|DRUG|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
57929915|NCT00866749|DRUG|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
57929916|NCT00866749|DRUG|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
57929917|NCT00866749|DRUG|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
58306824|NCT00318695|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
58397522|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
58397523|NCT00789594|BEHAVIORAL|Result management module|Result management module
58397524|NCT05735184|DRUG|Ziftomenib|Oral Administration
58397525|NCT05735184|DRUG|Venetoclax|Oral Administration
58397526|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
58397527|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
58397528|NCT05735184|DRUG|Cytarabine|Intravenous Administration
57929918|NCT00866749|DRUG|Thioguanine|60 mg/m2 by mouth daily for two weeks
57929919|NCT03365050|OTHER|No Intervention Given|No Intervention to be given
57929920|NCT05881980|DRUG|Terbinafine Tablets|Terbinafine 250 mg/day
57929921|NCT05881980|DRUG|Itraconazole|Itraconazole 200 mg/day
58282480|NCT01971515|DRUG|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
57929922|NCT05187156|BEHAVIORAL|Behavioral Activation and Social Engagement|brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
57929923|NCT05187156|BEHAVIORAL|Treatment as usual|treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
57929924|NCT03940547|OTHER|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
57929925|NCT03940547|OTHER|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
57929926|NCT05987397|DRUG|idebenone 30 mg for 14 days|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
57929927|NCT05987397|DRUG|idebenone 30 mg for 3 months|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
57929928|NCT01219647|BEHAVIORAL|exercise|subjects will participate in one of two forms of exercise
57929929|NCT01219647|BEHAVIORAL|stretching|subjects will particiopate in supervised stretching as described in arm description.
57929930|NCT05296525|DRUG|GDA-201|NAM-expanded allogeneic NK cells
57929931|NCT01423812|DRUG|Twice-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
58282481|NCT03896178|OTHER|None, observational study|None, observational study
58282482|NCT06274242|DIETARY_SUPPLEMENT|Haruna|Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
58282483|NCT06274242|DIETARY_SUPPLEMENT|Placebo Powder|Isolate Soy Protein and Isomalt
58282484|NCT05313646|BIOLOGICAL|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
58282485|NCT05313646|BIOLOGICAL|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
58282486|NCT05313646|BIOLOGICAL|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
58282487|NCT04966819|OTHER|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
58282488|NCT02669043|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
58397529|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
58397530|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
58397531|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
57929932|NCT01423812|DRUG|Once-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
57929933|NCT05933486|DRUG|Tongluo-Kaibi tablet plus placebo of pregabalin|Tongluo-Kaibi Tablet 0.93g qd； Placebo of pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
57929934|NCT05933486|DRUG|placebo of Tongluo-Kaibi tablet plus pregabalin|placebo of Tongluo-Kaibi Tablet 0.93g qd； Pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
57929935|NCT05216900|RADIATION|Neoadjuvant radiotherapy|"The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap."
58282489|NCT04885790|OTHER|"Respiratory assessment using Spiropalm 6MWT portable spirometry"|"Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry."
58306825|NCT00937534|DRUG|Fimasartan|Fimasartan 240mg/day
58397532|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
57929936|NCT00588510|OTHER|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
57929937|NCT01464125|DRUG|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
57929938|NCT01464125|DRUG|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
57929939|NCT04806698|DEVICE|Menicon Z Night|Children wearing Menicon Z Night orthokeratology contact lenses
58069641|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
58095388|NCT04885816|DEVICE|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
58282490|NCT04885790|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity of patients will be evaluated using six-minute walk test.
58282491|NCT04885790|OTHER|Evaluation of peripheral muscle strength|Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.
58397533|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
58397534|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
58397535|NCT02042586|OTHER|Analysis of movement before total hip replacement|
58397536|NCT02042586|OTHER|Analysis of movement after total hip replacement|
58397537|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
57929940|NCT04806698|DEVICE|Control|Children wearing distance single-vision glasses or distance single-vision soft contact lenses
57929941|NCT04202952|DRUG|HEC110114 Tablet|administered orally once daily
57929942|NCT04202952|DRUG|Sofosbuvir Tablet|administered orally once daily
58397538|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
58397539|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
58397540|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
58397541|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
57929943|NCT04254744|DRUG|Sevoflurane|Sevoflurane inhalation for anesthesia
58397542|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
58397543|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
58397544|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
57929944|NCT00049556|DRUG|gefitinib|
57929945|NCT00049556|OTHER|immunohistochemistry staining method|
57929946|NCT00049556|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
57929947|NCT00049556|PROCEDURE|biopsy|
57929948|NCT00049556|PROCEDURE|sentinel lymph node biopsy|
57929949|NCT03738969|PROCEDURE|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
57929950|NCT03738969|PROCEDURE|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
57929951|NCT01499472|DEVICE|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
57929952|NCT01499472|DEVICE|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
57929953|NCT01499472|PROCEDURE|standard of care|regular care including debridement and bandaging.
58282492|NCT04885790|OTHER|Evaluation of chronic cough|The Leicester Cough Questionnaire will be used for evaluating cough.
58397545|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
58397546|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
58397547|NCT02412891|DEVICE|Sham UroShield device|
58397548|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
58397549|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
58397550|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
58397551|NCT00206128|DRUG|Seroquel SR|
58397552|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
58397553|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
57929954|NCT02082236|DRUG|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
57929955|NCT02082236|DRUG|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
57929956|NCT02082236|DRUG|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
57929957|NCT02082236|DRUG|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
58397554|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
58397555|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
57929958|NCT04997928|OTHER|Serum PAI-1 alpha analysis.|After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
57929959|NCT00597753|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
57929960|NCT00597753|DRUG|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
57929961|NCT05545033|DEVICE|Virtual reality|5 to 15 minutes of virtual reality exposure
57929962|NCT01431326|DRUG|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
57929963|NCT03661164|PROCEDURE|corneal cross linking|Iontophoretic corneal cross linking
57929964|NCT01033617|PROCEDURE|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
57929965|NCT04160143|PROCEDURE|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
57929966|NCT04537273|OTHER|Descriptive and analytical|
58095389|NCT04885816|DEVICE|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
58397556|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
58397557|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
58397558|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
58397559|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
58397560|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
58397561|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
58397562|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
58397563|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
58397564|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
58397565|NCT00515658|DEVICE|theta-burst rTMS|
58397566|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
58397567|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
58397568|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
58397569|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
58397570|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
58397571|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
58397572|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
58397573|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
58397574|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
58397575|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
58397576|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
58397577|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
57929967|NCT03948217|OTHER|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
57929968|NCT05542485|DIAGNOSTIC_TEST|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
57929969|NCT05117697|OTHER|lateral subcutaneous sphincterotomy|"Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."
57929970|NCT02734823|OTHER|Cytology Specimen Collection Procedure|Undergo collection of serum
57929971|NCT02734823|OTHER|Laboratory Biomarker Analysis|Correlative studies
57929972|NCT02734823|OTHER|Questionnaire Administration|Ancillary studies
57929973|NCT02734823|PROCEDURE|Ultrasonography|Undergo transvaginal pelvic ultrasonography
57929974|NCT04370288|DRUG|MCN (Methylene blue, vitamin C, N-acetyl cysteine)|A mixture of MCN will be injected to covid-19 patients.
58397578|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
58397579|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
57929975|NCT03175965|DEVICE|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
58397580|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
58397581|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
58397582|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
58397583|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
58397584|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
58397585|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
58397586|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
58397587|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
58397588|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
58397589|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
58095390|NCT00399919|DRUG|Propionyl-L-Carnitine|2 grams per day for six months
58095391|NCT00399919|DRUG|PLC|2 grams/day for six months
58095392|NCT06696313|DEVICE|Insignia|"* Insignia hip stem~* Trident hemispherical shell~* X3 polyethylene liner~* Metal or ceramic head"
58282493|NCT02557685|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
58069642|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
58069643|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
58282494|NCT00000888|DRUG|Ritonavir|
58282495|NCT00000888|DRUG|Lamivudine|
58282496|NCT00000888|DRUG|Zidovudine|
58397590|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
58397591|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
58282497|NCT04358211|BIOLOGICAL|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
58397592|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
58397593|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
57929976|NCT00555555|BIOLOGICAL|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
58282498|NCT01613079|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
58282499|NCT01613079|DRUG|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
58282500|NCT05299762|DEVICE|INFUSE™ Bone Graft|Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
58306826|NCT03694379|OTHER|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
57929977|NCT00315081|DRUG|Bromocriptin|
57929978|NCT06466811|OTHER|Patients of intensive care unit|Patients of intensive care unit having an EVD
57929979|NCT06466811|OTHER|Patients of surgical intensive care unit|Patients of surgical intensive care unit having an EVD.
58069644|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
58282501|NCT02574936|PROCEDURE|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
58069645|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
58069646|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
58282502|NCT00548483|DRUG|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
58069647|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
58069648|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
58282503|NCT03739801|DRUG|Liposomal Irinotecan|Given IV
58282504|NCT03739801|OTHER|Quality-of-Life Assessment|Ancillary studies
58282505|NCT03739801|OTHER|Questionnaire Administration|Ancillary studies
58282506|NCT03739801|BIOLOGICAL|Ramucirumab|Given IV
58282507|NCT04063605|OTHER|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
58282508|NCT04063605|OTHER|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
58282509|NCT06114771|OTHER|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
58282510|NCT06114771|OTHER|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
58282511|NCT00013923|DRUG|Nutritional Supplement|
58282512|NCT02842008|BEHAVIORAL|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
58397594|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
57929980|NCT01717963|DRUG|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
57929981|NCT01717963|DRUG|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
58069649|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
58397595|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
57929982|NCT02486809|DRUG|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
58397596|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
57929983|NCT01436071|DRUG|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
57929984|NCT01436071|DRUG|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
57929985|NCT05592067|OTHER|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
57929986|NCT05592067|OTHER|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
57929987|NCT05592067|OTHER|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day
57929988|NCT05908955|PROCEDURE|PVI|pulmonary vein isolation
57929989|NCT05908955|PROCEDURE|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
58069650|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
58069651|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
57728287|NCT06532955|DEVICE|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|"The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure."
57728288|NCT06532955|PROCEDURE|Lymphaticovenous anastomosis (manual)|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
57929990|NCT00227188|DRUG|Pneumococcal 7-valent conjugate vaccine Prevnar|
57929991|NCT05535634|DIAGNOSTIC_TEST|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
57929992|NCT05103696|DRUG|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
57929993|NCT05103696|DRUG|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
57929994|NCT01753154|DRUG|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
57929995|NCT01753154|DRUG|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
57929996|NCT03383549|OTHER|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
57929997|NCT05279209|PROCEDURE|catheter-directed sclerotherapy|Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.
57929998|NCT05279209|PROCEDURE|surgical resection|Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
57929999|NCT02261038|OTHER|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
58282513|NCT05202535|OTHER|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
58282514|NCT05202535|OTHER|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
57930000|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
57930001|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
57930002|NCT01866397|OTHER|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
57930003|NCT03849443|DRUG|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
57930004|NCT03849443|DRUG|Vitamin C 250 MG Oral Tablet|Oral method of placebo
58282515|NCT04653155|BEHAVIORAL|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
58282516|NCT02759835|DRUG|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
58282517|NCT02759835|OTHER|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
58282518|NCT04794673|OTHER|brain damage|Have or not have the brain damage and the location of the damage
58282519|NCT06239181|BEHAVIORAL|Breathing Exercises|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
57930005|NCT03849443|DRUG|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
57930006|NCT02367326|OTHER|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
57930007|NCT06054412|DEVICE|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
58069652|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
58069653|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
58069654|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
58069655|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
57930008|NCT02478723|DEVICE|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
57930009|NCT01109836|BEHAVIORAL|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
57930010|NCT00046397|DRUG|Modified Vaccinia Virus Ankara TBC-M|
57930011|NCT01193881|DRUG|Erlotinib Hydrochloride|Given PO
57930012|NCT01193881|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
57930013|NCT01193881|OTHER|Laboratory Biomarker Analysis|Correlative studies
57930014|NCT01193881|OTHER|Pharmacological Study|Correlative studies
57930015|NCT04852263|OTHER|Group I|Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
57930016|NCT04852263|OTHER|Group II (NPA group)|Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
57930017|NCT04817384|OTHER|Graston technique|For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
57930018|NCT04817384|OTHER|Classical Massage|In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
57930019|NCT05158933|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57930020|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.
57930021|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.
58069656|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
57930022|NCT02676856|DRUG|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
58282520|NCT06239181|OTHER|no intervention/routine procedure|Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
58282521|NCT05319262|RADIATION|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
58282522|NCT05319262|RADIATION|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
58282523|NCT05583786|DIAGNOSTIC_TEST|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
58282524|NCT01882803|DRUG|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
58282525|NCT04671056|DRUG|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
58282526|NCT04671056|DRUG|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
58282527|NCT00565097|DRUG|Placebo|
58282528|NCT00565097|DRUG|Lanreotide|
57930023|NCT02676856|DRUG|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
57930024|NCT05571046|DRUG|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
57930025|NCT05571046|OTHER|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
58095393|NCT04883411|DEVICE|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
58282529|NCT04063995|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
57930026|NCT03187171|OTHER|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
57930027|NCT03187171|DEVICE|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
58282530|NCT05411601|OTHER|Methodology of attachment of external foot prothesis|establishing the methodology of specific measurements of attachment of external foot prothesis
58282531|NCT01370616|DRUG|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
58282532|NCT01370616|DRUG|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
58282533|NCT01370616|DRUG|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
58282534|NCT01370616|DRUG|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
58282535|NCT04525326|DRUG|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
58282536|NCT04525326|DRUG|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
58282537|NCT04525326|DRUG|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
58282538|NCT06138717|OTHER|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
58282539|NCT00193557|DRUG|Bortezomib|
58282540|NCT03658642|BEHAVIORAL|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
58282541|NCT01797588|PROCEDURE|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
58397597|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
58397598|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
57728289|NCT00506961|DRUG|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
57930028|NCT02653300|BIOLOGICAL|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
57728290|NCT00506961|DRUG|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
58282542|NCT01797588|PROCEDURE|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
58282543|NCT06321185|PROCEDURE|Subcostal TAP block|"Subcostal TAP block will be applied after intubation and before surgery. A local anesthetic solution of 20 ml 0.25% bupivacaine for each side will be injected bilaterally between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
58282544|NCT06321185|OTHER|Port site local anesthetic infiltration|"After intubation and before port placements, a solution of 20 ml 0.25% bupivacaine will be infiltrated into the laparoscopic port sites. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
58282545|NCT06321185|OTHER|No intervention or local anesthetic administration|"There will not be an intervention or local anesthetic administration. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
58282546|NCT00696995|DRUG|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
58282547|NCT00946062|OTHER|orientation and mobility training|orientation and mobility training
58282548|NCT03189069|DRUG|Apixaban|Treatment for NVAF patients
58282549|NCT03189069|DRUG|Dabigatran|Treatment for NVAF patients
58282550|NCT03189069|DRUG|Rivaroxaban|Treatment for NVAF patients
58282551|NCT03189069|DRUG|Warfarin|Treatment for NVAF patients
58282552|NCT04993703|OTHER|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
58282553|NCT04993703|OTHER|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
58282554|NCT04993703|OTHER|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
58282555|NCT01570842|OTHER|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
58282556|NCT01570842|PROCEDURE|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
58282557|NCT00280696|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use"
58282558|NCT00280696|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use"
58282559|NCT00280696|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use"
58282560|NCT05597449|BEHAVIORAL|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
57930029|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
57930030|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
58282561|NCT02496741|DRUG|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
58282562|NCT01173900|BIOLOGICAL|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
57930031|NCT02030756|DEVICE|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
57930032|NCT02030756|DEVICE|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
58282563|NCT03457844|DRUG|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
57930033|NCT06085911|BEHAVIORAL|One day course|a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.
57930034|NCT06085911|BEHAVIORAL|Individual follow-ups|the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
58282564|NCT00585325|DRUG|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
57930035|NCT06456450|BIOLOGICAL|Biological Treatment for severe asthma patients|Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
57930036|NCT00931944|DRUG|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
57930037|NCT02445196|BEHAVIORAL|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
58282565|NCT00585325|OTHER|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
58282566|NCT00657995|DEVICE|Artificial Pancreas (STG-22)|safe tool
58282567|NCT05787743|OTHER|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
58282568|NCT05787743|OTHER|Base cream|Apply on the face twice a day
58282569|NCT03952026|PROCEDURE|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
58282570|NCT02824562|BEHAVIORAL|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
58282571|NCT02824562|BEHAVIORAL|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
57930038|NCT02445196|DEVICE|Smartphone|All participants must have a smartphone, either apple or android.
58282572|NCT05300659|OTHER|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
58282573|NCT00104806|DIETARY_SUPPLEMENT|cholecalciferol|100 milligrams orally once a day for 28 days
58282574|NCT00104806|DRUG|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
58282575|NCT01608672|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
58282576|NCT05137002|DRUG|CIN-107|CIN-107 tablets by mouth once daily
58282577|NCT05137002|DRUG|Placebo|Placebo tablets by mouth once daily
58282578|NCT00351936|DRUG|Aripiprazole|
58397599|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
58069657|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
58069658|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
58397600|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
58069659|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
58282579|NCT00351936|DRUG|placebo|
58397601|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
58397602|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
58397603|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
58397604|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
58397605|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
58397606|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
58397607|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
58397608|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
58397609|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
58397610|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
58069660|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
58069661|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
58069662|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
58282580|NCT06168747|OTHER|Passive Joint Mobilization|Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
58282581|NCT02227368|DRUG|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
58282582|NCT02227368|DRUG|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
58282583|NCT02374437|DRUG|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
58282584|NCT02374437|DRUG|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
58282585|NCT00747253|DEVICE|AutoLITT system|laser treatment with the AutoLITT system
58282586|NCT04677452|BIOLOGICAL|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
58282587|NCT01171469|BIOLOGICAL|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
58282588|NCT01171469|DRUG|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
58282589|NCT03890978|OTHER|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
58282590|NCT05582759|BEHAVIORAL|teleCBT-I + SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
58282591|NCT05582759|BEHAVIORAL|SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics and education on sleep hygiene
58282592|NCT02008032|DEVICE|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
58282593|NCT02247271|BEHAVIORAL|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
58282594|NCT03510897|DRUG|teprasiran|IV injection
58282595|NCT03510897|DRUG|Placebo|isotonic saline
58282596|NCT02641405|DEVICE|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
58397611|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
58397612|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
58397613|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
58397614|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
58397615|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
58397616|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
58397617|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
58397618|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
58422740|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
57930039|NCT04970043|DRUG|Camrelizumab+ pemetrexed + platinum|"Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years)."
57930040|NCT01569360|DEVICE|Corset|the patients are assigned the use of a custome made corset during daytime
58069663|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
58069664|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
58069665|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
58069666|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
58282597|NCT02641405|DEVICE|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
58282598|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
58397619|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
58282599|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
58397620|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
58397621|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
58069667|NCT02986321|DRUG|Budesonide|active control
58069668|NCT02986321|DRUG|Placebo|placebo control
58069669|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
58282600|NCT01575730|DRUG|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
58282601|NCT03816111|BEHAVIORAL|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
57930041|NCT00993915|DRUG|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
57930042|NCT00324701|BEHAVIORAL|Telepsychology|therapy done at patients house
57930043|NCT00324701|BEHAVIORAL|Face-to-face therapy|therapy delivered at the VAMC
58282602|NCT03816111|BEHAVIORAL|Current standard PD training|Current PD training materials and plan
58069670|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
58069671|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
58069672|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
58069673|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
58069674|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
58282603|NCT03247881|OTHER|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
58282604|NCT03247881|OTHER|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
57930044|NCT00270478|DRUG|Erythropoietin and Hydroxyurea|
57930045|NCT06052150|PROCEDURE|Dental exam and periodontal cleaning if needed|Dental exam and periodontal cleaning if needed
57930046|NCT00000138|DRUG|Prednisolone Phosphate|
57930047|NCT00000138|DRUG|Acyclovir|
57930048|NCT05745454|BIOLOGICAL|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
57930049|NCT00980681|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
57930050|NCT00980681|OTHER|Time of Flight|Each subject will undergo a TOF MRA
58282605|NCT06277713|BEHAVIORAL|Standing interruptions|A mobile sit-to-stand desk will be installed at the workplace and participants are instructed to alternate their working position every 30 minutes during two working days (8h).
58282606|NCT06277713|BEHAVIORAL|Exercise bout|Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
58282607|NCT06277713|BEHAVIORAL|Sedentary|Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
58282608|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
58282609|NCT03178851|DRUG|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
58282610|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
58282611|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
58282612|NCT03147976|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
58282613|NCT06000553|OTHER|blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.|If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
57930051|NCT00667355|BIOLOGICAL|adalimumab|40 mg or 80 mg every other week, subcutaneous
57930052|NCT05780411|OTHER|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
58282614|NCT04910737|PROCEDURE|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
58282615|NCT06609031|PROCEDURE|endoscopic mucosal resection|The SSLs less than 10mm in size in this group will be treated by EMR
58282616|NCT06609031|PROCEDURE|Cold snare polypectomy|The SSLs less than 10mm in size in this group will be treated by CSP
58282617|NCT01796301|DRUG|Romozosumab|Administered by subcutaneous injection once a month.
58282618|NCT01796301|DRUG|Teriparatide|Administered by subcutaneous injection once a day.
58282619|NCT05524727|OTHER|Concept-guided, personalized, motor-cognitive training by means of an exergame|12 weeks, two times per week for 30-40min
58282620|NCT04819477|BEHAVIORAL|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
58282621|NCT04819477|BEHAVIORAL|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
57930053|NCT06171412|BEHAVIORAL|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
58282622|NCT00619125|OTHER|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
57930054|NCT06171412|BEHAVIORAL|Enhanced standard-of-care (ESOC)|This group will receive ESOC including additional training and support on CGM beyond routine clinical practice.
57930055|NCT04679779|OTHER|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
57930056|NCT04679779|OTHER|Wii virtual reality games|"1. Bowling~2. Frisbee~3. Basketball~4. Boxing"
58282623|NCT02726984|DRUG|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
58282624|NCT00099177|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
57930057|NCT02347475|OTHER|Observational Study|Ultrasound and NIRS
57930058|NCT03247036|DRUG|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
57930059|NCT02410941|BEHAVIORAL|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
58069675|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
58069676|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
58282625|NCT00099177|DRUG|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
57930060|NCT05955404|OTHER|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
57930061|NCT05149703|OTHER|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
57930062|NCT05662410|DRUG|Three monthly injections of intravitreal aflibercept|Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
57930063|NCT00878852|BEHAVIORAL|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
57930064|NCT00878852|BEHAVIORAL|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
57930065|NCT05053477|DRUG|mehylprednisolone injection|(40 mg)
57930066|NCT05053477|DEVICE|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
57930067|NCT05053477|BIOLOGICAL|platelet-rich plasma|2 ml of PRP
57930068|NCT04537169|PROCEDURE|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
58069677|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
58282626|NCT04295369|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
58282627|NCT03250338|DRUG|Crenolanib|Crenolanib will be administered orally
58282628|NCT03250338|DRUG|Cytarabine|"HAM regimen~FLAG-Ida"
58282629|NCT03250338|DRUG|Mitoxantrone|HAM regimen
58282630|NCT03250338|DRUG|Placebo Oral Tablet|Placebo will be administered orally
58282631|NCT03250338|DRUG|Fludarabine|FLAG-Ida regimen
58282632|NCT03250338|DRUG|Idarubicin|FLAG-Ida regimen
58282633|NCT03250338|DRUG|G-CSF|FLAG-Ida regimen
58282634|NCT01398358|BEHAVIORAL|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
58282635|NCT01398358|BEHAVIORAL|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
57930069|NCT02075411|DRUG|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
57930070|NCT02075411|DRUG|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
57930071|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
58069678|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
57930072|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
57930073|NCT04536584|OTHER|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
57930074|NCT04536584|OTHER|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
58069679|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
58069680|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
58282636|NCT02005237|BEHAVIORAL|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
58282637|NCT04389307|OTHER|Electrical stimulation (IVES)|IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
58282638|NCT04389307|OTHER|Bladder Training|Bladder Training
58282639|NCT00815477|BEHAVIORAL|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
58282640|NCT00815477|BEHAVIORAL|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
58282641|NCT03042910|DRUG|Talazoparib|Talazoparib 1 mg orally once daily.
58282642|NCT04250428|BEHAVIORAL|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
58282643|NCT04250428|BEHAVIORAL|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
57930075|NCT04640844|BIOLOGICAL|blood sample|measuring the expression and function of lymphocyte A2A receptors.
57930076|NCT02367235|PROCEDURE|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
57930077|NCT02367235|PROCEDURE|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
57930078|NCT01859078|DRUG|Baricitinib|Administered orally
57930079|NCT01859078|DRUG|Digoxin|Administered orally
58069681|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
58069682|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
58069683|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
58069684|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
58282644|NCT04455737|OTHER|injection of indigo carmine|Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
58282645|NCT03395847|BIOLOGICAL|Pembrolizumab|Given IV
58282646|NCT03574688|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
58282647|NCT04769492|OTHER|#ChopViolence/#ChopHIV|Tailored, community-based violence prevention intervention
58397622|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
58397623|NCT00397761|DRUG|capecitabine|
58397624|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
58397625|NCT00397761|PROCEDURE|neoadjuvant therapy|
58397626|NCT01396824|OTHER|No intervention|No intervention
58397627|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
57930080|NCT06138964|DRUG|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
57930081|NCT06138964|DRUG|siSPARC microneedle patch|siSPARC microneedle patch
57930082|NCT04828694|DRUG|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
57930083|NCT04828694|DRUG|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
57728291|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
57728292|NCT06306534|OTHER|Auditory Nerve Acute (ANA) Electrode Array|To measure eABRs when stimulating the human auditory nerve
57728293|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
57930084|NCT02383589|DRUG|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
57930085|NCT02383589|DRUG|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
57930086|NCT02383589|DRUG|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
57930087|NCT02383589|DRUG|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
57930088|NCT00301158|BEHAVIORAL|exercise intervention|
57930089|NCT00301158|OTHER|counseling intervention|
57930090|NCT00301158|OTHER|educational intervention|
57930091|NCT00301158|PROCEDURE|complementary or alternative medicine procedure|
57930092|NCT05453019|DEVICE|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
58282648|NCT02306421|PROCEDURE|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
57728294|NCT01813240|DRUG|Minocycline|
57728295|NCT01813240|DRUG|placebo|
57728296|NCT00899223|OTHER|biologic sample preservation procedure|
57728297|NCT05786924|DRUG|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
57728298|NCT05528120|DRUG|VC004 Capsules|Oral administration after fasting/high-fat meal
57728299|NCT05528120|DRUG|VC004 Capsules|Oral administration after high-fat/fasting meal
57930093|NCT04249414|DEVICE|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
57930094|NCT04009317|DRUG|TQ-B3139|a multi-target protein kinase inhibitor.
57930095|NCT04009317|DRUG|Crizotinib|a multi-target protein kinase inhibitor.
57930096|NCT00908063|DRUG|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
57930097|NCT00908063|DRUG|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
57728300|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
57728301|NCT02475408|DEVICE|Amplatzer vascular plug|
57728302|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
57728303|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
57930098|NCT05042518|BEHAVIORAL|Experiment|breathing control and self-talk with objectives
57930099|NCT05042518|OTHER|Control|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month)
57930100|NCT04257565|DEVICE|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
57930101|NCT04257565|OTHER|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
57930102|NCT03998293|DRUG|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
57930103|NCT01725048|DRUG|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
57930104|NCT01725048|DRUG|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
57930105|NCT00611195|DRUG|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
57930106|NCT02217189|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
58282649|NCT02306421|PROCEDURE|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
58282650|NCT02306421|PROCEDURE|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
58282651|NCT02306421|PROCEDURE|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
57930107|NCT03165318|DEVICE|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
57930108|NCT03165318|DEVICE|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
57930109|NCT06012383|DRUG|Bortezomib|Alvocade® was given with a dose of 1.3 mg/m2.
57930110|NCT06445309|OTHER|Sensory test of functional plant-based drink|Once the volunteers have been recruited, a telephone interview lasting less than 10 minutes will be carried out where what the study consists of will be explained as well as the information sheet for the participant will be read to them so that they understand what the study consists of. study. Once the necessary questions have been asked according to the inclusion criteria, if the participant enters the study, data such as name, surname, age, gender, smoker, consumer of vegetable drinks, pathologies and contact information will be collected. If the participant does not enter the study, their personal data will no longer be collected and they will be informed that according to the exclusion criteria they can no longer participate in the study. Once these data are obtained, it will be randomized using the EXCEL program.
57930111|NCT02202551|DRUG|ADS-5102|
57930112|NCT06090526|DIAGNOSTIC_TEST|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
57930113|NCT04638517|DRUG|Danazol|Danazol up to 800mg daily in two-divided doses.
57930114|NCT04638517|DRUG|Placebo|Matching placebo.
57930115|NCT06371287|BEHAVIORAL|Treinamento Auditivo Musical|Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.
57930116|NCT06371287|BEHAVIORAL|Placebo|"This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009)."
58069685|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
58069686|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
58069687|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
58069688|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
58069689|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
58069690|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
58069691|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
58069692|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
58069693|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
58069694|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
58069695|NCT01730768|DRUG|AQW051|
58069696|NCT01730768|DRUG|Placebo|
57930117|NCT03716050|DRUG|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
57930118|NCT03716050|DEVICE|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
57930119|NCT03716050|OTHER|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
57930120|NCT03716050|OTHER|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
58069697|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
58069698|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
58069699|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
58282652|NCT02306421|PROCEDURE|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
58282653|NCT03711136|PROCEDURE|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
58282654|NCT01129271|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
57930121|NCT02743416|OTHER|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
57930122|NCT05128825|DRUG|ZN-c3|ZN-c3 is an investigational drug.
57930123|NCT00288977|PROCEDURE|Islet Infusion|
57930124|NCT02052063|DEVICE|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
57930125|NCT02052063|DEVICE|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
58282655|NCT01129271|DRUG|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
57930126|NCT04910503|DRUG|Dexamethasone intravitreal implant|Implant every 4 months if necessary
57930127|NCT04910503|DRUG|Fluocinolone Acetonide Intravitreal Implant|Implantation
57930128|NCT05761730|DRUG|Dexamethasone Oral|For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
57930129|NCT04553510|DRUG|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
57930130|NCT04553510|DRUG|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
58069700|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
58069701|NCT01099670|DRUG|Placebo|Placebo
58069702|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
58069703|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
58069704|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
58069705|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
58069706|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
58069707|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
58069708|NCT02206230|RADIATION|Hypofractionated radiation therapy|
58069709|NCT02206230|RADIATION|Standard radiation therapy|
58069710|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
58282656|NCT05287854|DEVICE|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
58282657|NCT00405847|DRUG|Dexmedetomidine|
58282658|NCT00211432|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
58282659|NCT04217642|PROCEDURE|Osteosynthesis|The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
58282660|NCT01979601|DRUG|LGT209|150 mg lyophilized powder in glass vial
58069711|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
58282661|NCT01979601|DRUG|Placebo|Placebo comparator
58282662|NCT05388084|BEHAVIORAL|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
58282663|NCT05388084|BEHAVIORAL|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
58282664|NCT02328937|DEVICE|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
58282665|NCT02328937|DEVICE|lotrafilcon B|
58282666|NCT02328937|DEVICE|comfilcon A|
58282667|NCT05578677|OTHER|Biopsy technique|"* Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively."
58282668|NCT03928379|DRUG|LY3305677|Administered SC
58282669|NCT03928379|DRUG|Placebo|Administered SC
58069712|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
58069713|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
58069714|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
58069715|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
58069716|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
58282670|NCT04592679|DEVICE|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
58282671|NCT04592679|OTHER|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
58282672|NCT05180981|DEVICE|Transcutaneous vagal nerve stimulation|Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
58282673|NCT05180981|BEHAVIORAL|Breathing task|Participants will be asked to breathe in specific patterns.
58282674|NCT05719298|DEVICE|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
58069717|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
58282675|NCT01456143|DEVICE|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
58282676|NCT01456143|OTHER|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
58282677|NCT04019886|OTHER|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
58282678|NCT01782352|DRUG|Omega-3 fatty acids (fish oil)|
58282679|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3|
58282680|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
58282681|NCT01782352|DIETARY_SUPPLEMENT|Fish oil placebo|
58282682|NCT06073509|DIAGNOSTIC_TEST|Screening for atrial fibrillation and other cardiac arrhythmias and diseases|"In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~* connected smartwatches for atrial fibrillation screening~* complete ECG for other cardiac arrhythmias~* echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)"
58282683|NCT05969587|COMBINATION_PRODUCT|5% cysteamine cream|5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
58282684|NCT05969587|COMBINATION_PRODUCT|hydroquinone cream group|4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
58282685|NCT03440970|DRUG|Lysine Chloride|Patients will receive the study drug twice a day for 5 days.
58282686|NCT03440970|OTHER|Placebo|Patients will receive the placebo twice a day for 5 days.
58282687|NCT04763616|DRUG|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
58282688|NCT04763616|DRUG|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
58397628|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
58397629|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
58397630|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
58282689|NCT00936676|DRUG|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
58282690|NCT01763203|BEHAVIORAL|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
58282691|NCT01763203|BEHAVIORAL|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
58282692|NCT01981070|BEHAVIORAL|Mindfulness Intervention for Parents|See Study Arms
58282693|NCT01981070|BEHAVIORAL|Support and Information for Parents|See Study Arms
58282694|NCT02301819|DEVICE|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
58282695|NCT02301819|OTHER|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
58282696|NCT02130700|DRUG|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
58282697|NCT02130700|DRUG|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
58282698|NCT00799799|BIOLOGICAL|NK cells|NK cells infusion after immunosuppressive chemotherapy
58282699|NCT04521842|PROCEDURE|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
58397631|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
58397632|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
58397633|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
58397634|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
57728304|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
58069718|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
58069719|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
58069720|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
58069721|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
58069722|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
58282700|NCT01651754|BIOLOGICAL|Seasonal influenza vaccination|single dose of influenza vaccination
58282701|NCT01648998|DRUG|Fludrocortisone|single dose 500 mg, capsule
58282702|NCT01648998|DRUG|Placebo|
58282703|NCT00040144|DRUG|ACH126, 433|
58282704|NCT05887960|OTHER|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
58397635|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
58397636|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
57728305|NCT00333593|DEVICE|Large pore dialyser|
57728306|NCT00333593|DEVICE|Standard dialyser|
57728307|NCT00731315|OTHER|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
57728308|NCT00731315|OTHER|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
57728309|NCT03251846|DEVICE|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
57728310|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
57728311|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
58282705|NCT02632370|DRUG|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
58282706|NCT02632370|PROCEDURE|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
58282707|NCT03231397|DRUG|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
58282708|NCT03231397|DRUG|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
58282709|NCT03231397|DIAGNOSTIC_TEST|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
58397637|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
58397638|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
58397639|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
58397640|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
57728312|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
58069723|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
58069724|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
58282710|NCT04282616|OTHER|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
58282711|NCT04282616|OTHER|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
58282712|NCT04282616|OTHER|In-hospital structured supervised physical activity program|Supervised exercise training program
58282713|NCT02900664|BIOLOGICAL|PDR001|Powder for solution for infusion
58282714|NCT02900664|BIOLOGICAL|ACZ885|Solution for injection
58282715|NCT02900664|BIOLOGICAL|CJM112|Solution for infusion
57728313|NCT00177229|BEHAVIORAL|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
57930131|NCT04907110|DIETARY_SUPPLEMENT|Niagen|Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day
58282716|NCT02900664|DRUG|TMT212|Tablets
58282717|NCT02900664|DRUG|EGF816|Tablets
58282718|NCT00096187|DRUG|pemetrexed disodium|
58282719|NCT00645671|DRUG|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
58422741|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
57930132|NCT04907110|OTHER|Exercise|During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
58069725|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
58069726|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
58069727|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
58069728|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
57728314|NCT01807273|OTHER|Walking test|
57728315|NCT06057246|OTHER|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
58282720|NCT00645671|DRUG|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
58282721|NCT01894971|DEVICE|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
58282722|NCT05091996|PROCEDURE|Post-isometric muscle relaxation technique|"1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier."
58422742|NCT02303106|DRUG|Lamotrigine|
58069729|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
57728316|NCT00698568|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
57728317|NCT00698568|BIOLOGICAL|Placebo|Intramuscular injection, 3 doses
57728318|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
57728319|NCT00058266|DIETARY_SUPPLEMENT|genistein|Given orally
57728320|NCT00058266|PROCEDURE|conventional surgery|Patients undergo surgery
57728321|NCT04040127|BIOLOGICAL|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
58282723|NCT05091996|PROCEDURE|Myofascial release technique|The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
58282724|NCT01765816|BEHAVIORAL|high intensity interval training|
57728322|NCT04040127|OTHER|Saline solution|saline solution used to rinse the canal.
58282725|NCT01765816|BEHAVIORAL|moderate intensity training|
58282726|NCT02186899|OTHER|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
58282727|NCT02186899|OTHER|General Anesthesia femoral bolus|
58282728|NCT02186899|OTHER|General anesthesia femoral continuous|
58282729|NCT04536298|DIETARY_SUPPLEMENT|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
57728323|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
57728324|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
57728325|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
57728326|NCT05378711|DRUG|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
57930133|NCT05218681|OTHER|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
57930134|NCT05218681|OTHER|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
57930135|NCT05606887|OTHER|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~1. Completion of brief text-message based surveys 2-3 times per week~2. Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~3. Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
57930136|NCT01840891|BEHAVIORAL|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
58282730|NCT04536298|DIETARY_SUPPLEMENT|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
58282731|NCT05597878|DRUG|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
57728327|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
58282732|NCT05597878|DRUG|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
58282733|NCT05597878|DRUG|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
58282734|NCT05597878|DRUG|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
58282735|NCT05597878|DRUG|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
58282736|NCT05887362|BEHAVIORAL|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
58282737|NCT04318262|BIOLOGICAL|Determination of the clinical and biological characteristics|"* clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis...), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications...~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP..."
58282738|NCT04318262|BIOLOGICAL|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
57728328|NCT01946711|DRUG|Budesonide|Inhalation
57728329|NCT01946711|DRUG|Budesonide|Nasal spray
57728330|NCT01704339|DRUG|QUTENZA|Single treatment with topical capsaicin 8%
57728331|NCT02176889|DIETARY_SUPPLEMENT|Lactospore|Bacillus coagulans MTCC 5856
58282739|NCT04318262|BIOLOGICAL|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
58282740|NCT03548350|BEHAVIORAL|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
58282741|NCT00292916|BEHAVIORAL|whole body vibration|
58282742|NCT00292916|BEHAVIORAL|resistance exercise|
58282743|NCT00292916|BEHAVIORAL|"wellness"|
58282744|NCT04750941|DRUG|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
58282745|NCT04750941|OTHER|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
58282746|NCT00495989|PROCEDURE|saliva sampling + dental calculus collection|
58282747|NCT03234920|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
58282748|NCT03234920|OTHER|Placebo|The placebo will be 200 ml of fruit juice given twice daily
58282749|NCT03747783|PROCEDURE|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
57728332|NCT02176889|OTHER|Placebo|
57728333|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
57728334|NCT03792594|OTHER|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
58282750|NCT02022735|DEVICE|Deep Brain Stimulator|DBS will provide brain stimulation.
58282751|NCT03142776|PROCEDURE|periodontal debridement|
58282752|NCT03142776|PROCEDURE|photodynamic therapy|
58397641|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
58397642|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
57930137|NCT06246617|DEVICE|da Vinci SP Surgical System for Single-Port Thoracic Surgeries|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
57930138|NCT03051581|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
57930139|NCT03697434|BEHAVIORAL|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
58282753|NCT03142776|DRUG|systemic clarithromycin|
58282754|NCT00493506|DRUG|ProAlgaZyme|
57930140|NCT03750383|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
57930141|NCT03750383|DRUG|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
58397643|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
58397644|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
58397645|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
57930142|NCT03750383|DRUG|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
57930143|NCT03750383|DRUG|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
58282755|NCT00593606|DRUG|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
58282756|NCT00547417|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
58282757|NCT03425994|DRUG|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
58397646|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
57930144|NCT00752687|DRUG|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
57930145|NCT00752687|DRUG|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
57930146|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 200 mg of bosutinib
57930147|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
58282758|NCT00898872|OTHER|cryopreservation|
58282759|NCT05130645|DIAGNOSTIC_TEST|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
58282760|NCT03405571|OTHER|No intervention|No intervention
58282761|NCT02992756|DRUG|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
58397647|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
57930148|NCT01233869|DRUG|Placebo|Once daily oral dose of placebo
57930149|NCT03548987|DRUG|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
57930150|NCT03548987|DRUG|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
57930151|NCT01338129|DIETARY_SUPPLEMENT|vitamin c|1000 mg of vitamin c for 45 days
57930152|NCT01338129|DRUG|placebo|placebo pills
57930153|NCT05355025|BEHAVIORAL|WiserAD|"See Arms"
57930154|NCT05355025|BEHAVIORAL|Attention control|"See Arms"
57930155|NCT00564005|OTHER|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
57930156|NCT00564005|OTHER|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
57930157|NCT00564005|OTHER|Combined therapy (CT)|combined different treatment approaches
57930158|NCT00564005|BEHAVIORAL|Control intervention|Conventional treatment program
58282762|NCT05158842|DEVICE|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
58282763|NCT05546320|DRUG|Aspirin 100mg|Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
58282764|NCT05546320|DRUG|Metoprolol 25 Mg Oral Tablet|Metoprolol 25mg will be provided for the participants twice a day.
57930159|NCT00279110|BEHAVIORAL|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
57930160|NCT03661125|DRUG|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
57930161|NCT03661125|DRUG|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
57930162|NCT03513510|BEHAVIORAL|iChoose|
57930163|NCT04226833|DRUG|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
58282765|NCT05546320|DRUG|Clopidogrel 75mg|Clopidogrel 75mg will be provided for the participant once a day.
58282766|NCT05546320|DRUG|Rivaroxaban 20mg|Rivaroxaban 20mg will be provided for the participant once a day.
58282767|NCT02178358|DRUG|LY2157299|Administered orally
57930164|NCT02376751|DRUG|sebelipase alfa|
57930165|NCT03475810|DEVICE|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
57930166|NCT03475810|DRUG|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
57930167|NCT00234494|DRUG|Cisplatin|Cisplatin 70 mg/m2, day 1
58282768|NCT02178358|DRUG|Sorafenib|Administered orally
58282769|NCT02178358|DRUG|Placebo|Administered orally
58282770|NCT00565227|DRUG|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
58282771|NCT00565227|DRUG|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
58282772|NCT00258193|DRUG|MD-1100 Acetate|
57930168|NCT00234494|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
57930169|NCT00234494|DRUG|Bevacizumab|Bevacizumab 15mg/kg, day 1
57930170|NCT03234062|OTHER|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
57930171|NCT03234062|OTHER|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
57930172|NCT03234062|OTHER|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
57930173|NCT00720655|OTHER|Dietary intervention|Fatty fish at least 4 meals per week.
57930174|NCT00720655|OTHER|Dietary intervention|Lean fish at least 4 meals per week.
57930175|NCT00720655|OTHER|Dietary intervention|Control diet with lean meat and chicken.
57930176|NCT04267718|OTHER|Application of Padua and IMPROVE Bleeding scores|Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
58282773|NCT00006244|DRUG|melphalan|Given IV
58282774|NCT00006244|BIOLOGICAL|recombinant interferon alfa|Given SC
58282775|NCT00006244|BIOLOGICAL|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
58282776|NCT00006244|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
58397648|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
58282777|NCT00845273|DRUG|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
57728335|NCT03792594|OTHER|arthroscopic repair|arthroscopic repair only
57728336|NCT05719974|OTHER|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
58282778|NCT00639392|DRUG|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
58282779|NCT00639392|DRUG|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
57728337|NCT02646423|BEHAVIORAL|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
57728338|NCT05388903|DRUG|DS-2325a|Subcutaneous injection (starting dose 30 mg)
58282780|NCT04672876|DRUG|Telotristat Ethyl Oral Tablet|XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
58282781|NCT00691652|BIOLOGICAL|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
58397649|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
58397650|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
58397651|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
57930177|NCT01348386|DRUG|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
58397652|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
58397653|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
58397654|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
58397655|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
58397656|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
58397657|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
58397658|NCT02414945|DRUG|Cyclophosphamide|
58397659|NCT02414945|DRUG|Fludarabine|
58397660|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
57728339|NCT05388903|DRUG|DS-2325a|Intravenous infusion (starting dose 100 mg)
57728340|NCT05388903|DRUG|Placebo|Subcutaneous injection
58282782|NCT00691652|DRUG|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
58282783|NCT00691652|GENETIC|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
57728341|NCT05388903|DRUG|Placebo|Intravenous infusion
57728342|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
57728343|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
57728344|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
57728345|NCT06525181|OTHER|Generative Artificial Intelligence|Gen AI assisted symptom intake summarization
57728346|NCT06525181|OTHER|Standard weekly symptom intake|Standard weekly symptom intake performed by a physician
57728347|NCT04329104|BIOLOGICAL|VRC-MALMAB0100-00-AB (CIS43LS)|Administered via one-time IV infusion
57728348|NCT04329104|OTHER|Normal saline|Administered via one-time IV infusion
57930178|NCT01348386|DRUG|Placebo|
57930179|NCT04332601|BEHAVIORAL|Fatigue Management Therapy|14 sessions of 1h CBT intervention
58282784|NCT00691652|GENETIC|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
58282785|NCT00691652|GENETIC|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
58282786|NCT00691652|GENETIC|polymerase chain reaction|
58282787|NCT00691652|OTHER|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
58282788|NCT00691652|OTHER|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
58282789|NCT03824366|DEVICE|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
58397661|NCT02414945|BIOLOGICAL|Interleukin-2|
58397662|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
58397663|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
58397664|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
57728349|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
57930180|NCT04332601|OTHER|TAU (Treatment as usual)|No CBT intervention
57930181|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
57930182|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
58397665|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
58397666|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
58397667|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
57930183|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
57930184|NCT01284062|OTHER|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
58069730|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
58282790|NCT03824366|RADIATION|Radiation therapy|-Standard of care
58282791|NCT06010628|DRUG|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
58282792|NCT03701152|DEVICE|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
58282793|NCT04096001|DEVICE|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
58282794|NCT00888498|OTHER|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
58282795|NCT00888498|OTHER|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
58282796|NCT00888498|OTHER|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
58282797|NCT04969588|DIAGNOSTIC_TEST|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
58282798|NCT04969588|DIAGNOSTIC_TEST|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
58282799|NCT04969588|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
58282800|NCT02156440|DIETARY_SUPPLEMENT|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
58282801|NCT02156440|DIETARY_SUPPLEMENT|Placebo|
58282802|NCT05633589|BIOLOGICAL|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
58397668|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
57728350|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
57930185|NCT00418951|DRUG|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
57930186|NCT00418951|DRUG|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
57930187|NCT00418951|DRUG|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
57930188|NCT05292014|DEVICE|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
58069731|NCT02249858|PROCEDURE|Cranial Vault Hold|
58069732|NCT02249858|PROCEDURE|Cervical HVLA|
58069733|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
58069734|NCT02108158|DRUG|Azzalure|
58069735|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
58282803|NCT00621725|DRUG|AZD2171|Oral dose
58282804|NCT00313586|DRUG|Azacitidine|Given SC
58282805|NCT00313586|DRUG|Entinostat|Given PO
58282806|NCT00313586|OTHER|Laboratory Biomarker Analysis|Correlative studies
58282807|NCT06012526|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is done for patients to find any sleep disordered breathing
58282808|NCT04965337|DRUG|ASC42|ASC42 tablet administered orally
58282809|NCT04965337|DRUG|Placebo|Matching placebo administered orally
58397669|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
58397670|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
58397671|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
58397672|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
58397673|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
58397674|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
58397675|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
58069736|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
58069737|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
58282810|NCT02993965|OTHER|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
58282811|NCT05390385|DIETARY_SUPPLEMENT|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
58397676|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
58397677|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
58397678|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
57728351|NCT02937246|DEVICE|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
57728352|NCT02937246|DEVICE|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
57930189|NCT02724124|OTHER|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
57930190|NCT02724124|OTHER|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
57930191|NCT02724124|OTHER|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
57930192|NCT02724124|OTHER|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
57930193|NCT02724124|OTHER|Control|No intervention
57930194|NCT04295096|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
57930195|NCT04032730|DEVICE|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
57930196|NCT05175612|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
58069738|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
58069739|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
58069740|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
58282812|NCT05390385|DIETARY_SUPPLEMENT|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
58282813|NCT05390385|DIETARY_SUPPLEMENT|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
58282814|NCT05390385|DIETARY_SUPPLEMENT|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
58397679|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
58282815|NCT05390385|OTHER|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
58397680|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
58397681|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
58397682|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
58397683|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
58397684|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
58397685|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
58397686|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
58397687|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
58397688|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
57728353|NCT04644328|BEHAVIORAL|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
57728354|NCT00673049|DRUG|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
57728355|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
57728356|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
57728357|NCT04307212|OTHER|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
58282816|NCT04591392|DEVICE|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
58282817|NCT04414423|PROCEDURE|bone marrow concentrate alveolar cleft grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
58282818|NCT04414423|PROCEDURE|Autogenous alveolar grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft
58282819|NCT06133959|BEHAVIORAL|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
58282820|NCT05643209|PROCEDURE|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
58282821|NCT00708474|DEVICE|OsseoFit™ Porous Tissue Matrix™|Bone void filler
58282822|NCT01872650|DEVICE|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
58282823|NCT03859648|DEVICE|BONEBRIDGE|Bone Conduction Implant
58282824|NCT00564395|DRUG|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
58397689|NCT02125916|OTHER|oxygen therapy|
58397690|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
58397691|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
58397692|NCT02503670|OTHER|Control Group|Continue with standard care.
58397693|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
58397694|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
58397695|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
58397696|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
57728358|NCT04307212|OTHER|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
57728359|NCT04307212|OTHER|Control no exercise|Trained and untrained participants will have a no exercise control day
57728360|NCT01908777|OTHER|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
57728361|NCT02763384|DRUG|BL-8040|
57728362|NCT02763384|DRUG|Nelarabine|
58282825|NCT00564395|DRUG|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
58282826|NCT02829385|DRUG|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
58282827|NCT06304298|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride
58282828|NCT06304298|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine
57930197|NCT01432834|OTHER|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
58282829|NCT06054945|PROCEDURE|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
58282830|NCT06054945|OTHER|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
58282831|NCT06054945|DEVICE|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
58282832|NCT03482908|BEHAVIORAL|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
58282833|NCT03482908|BEHAVIORAL|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
58282834|NCT03482908|BEHAVIORAL|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
58282835|NCT00048997|RADIATION|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
57728363|NCT02359669|BEHAVIORAL|StimuLearn Intervention|"* StimuLearn apps~* Cognitive questionnaires"
57728364|NCT02359669|BEHAVIORAL|Without StimuLearn intervention|Cognitive Questionnaires
57728365|NCT00138931|PROCEDURE|Blood draw (genetic testing)|Blood draw (genetic testing)
57728366|NCT05450432|DRUG|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
57728367|NCT05450432|DRUG|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
57728368|NCT00680316|DRUG|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
57930198|NCT01432834|OTHER|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
57930199|NCT06475391|DIETARY_SUPPLEMENT|L-arginine|2 grams iof L-arginine will be ingested before an acute testing bout of exercise tasks in 250 mL of cranberry juice.
58282836|NCT00048997|OTHER|Observation|
58282837|NCT01247389|PROCEDURE|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
58282838|NCT00222014|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
57728369|NCT00680316|DRUG|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
57930200|NCT06475391|DIETARY_SUPPLEMENT|Placebo|Placebo
58282839|NCT00222014|PROCEDURE|Paracenthese|Paracenthese
58282840|NCT03732222|PROCEDURE|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
58282841|NCT03732222|PROCEDURE|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
58282842|NCT03732222|PROCEDURE|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
57728370|NCT01329029|DRUG|Roflumilast|500 µg, once daily
57728371|NCT01329029|DRUG|Placebo|once daily
57728372|NCT03557437|DRUG|Esomeprazole|Proton pump inhibitor
58282843|NCT05823974|BIOLOGICAL|Flu mRNA|Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.
58397697|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
58282844|NCT05823974|COMBINATION_PRODUCT|Control 1|Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.
58282845|NCT05823974|COMBINATION_PRODUCT|Control 2|Control 2 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control OA group from Phase 2, at Day 1.
58397698|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
58397699|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
57728373|NCT03557437|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
57728374|NCT03557437|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
57728375|NCT04231630|OTHER|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
57728376|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
57728377|NCT05599594|OTHER|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
57930201|NCT01978353|BEHAVIORAL|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
57930202|NCT01978353|BEHAVIORAL|Psychoeducation|Participants receive information about memory functioning and aging
57930203|NCT00350922|BEHAVIORAL|Psychoeducation|
57930204|NCT02274168|PROCEDURE|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
57930205|NCT02274168|PROCEDURE|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
58069741|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
58282846|NCT01041677|DRUG|R256918|10 mg capsule twice daily
58282847|NCT01041677|DRUG|placebo|placebo capsule twice daily
58282848|NCT01041677|DRUG|R256918|15 mg capsule twice daily
58282849|NCT03041467|DEVICE|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
58282850|NCT03041467|DEVICE|Standard Balloon Angioplasty|Standard PTA Balloon
58282851|NCT02800915|OTHER|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
58282852|NCT04235816|DRUG|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
58282853|NCT04235816|DRUG|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
58397700|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
58397701|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
57728378|NCT04106999|DRUG|Dexmedetomidine|Drug infusion will be delivered intra-operatively
57728379|NCT04106999|DRUG|Placebos|Normal Saline will be infused as a control drug
57728380|NCT04361357|OTHER|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
57728381|NCT04279808|PROCEDURE|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
57728382|NCT03524404|BEHAVIORAL|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
58282854|NCT04551235|OTHER|there are not any interventions in this study|there are not any interventions in this study
58282855|NCT01709864|DRUG|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
58282856|NCT01709864|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
58282857|NCT06439472|OTHER|Suboccipital Inhibition Technique|"The researcher will place their palms under the patient's head and use their fingers to contact the occipital condyles. Next, the researcher will place the 3rd and 4th fingers of each hand in the space between the occiput and the spinous process of C2. The metacarpophalangeal joints are at 90º flexion, with the base of the skull resting on their hands while they apply constant, non-painful pressure in a postero-anterior direction, keeping the 2nd, 3rd and 4th fingers together in extension. Afterwards, the researcher applies a light and gentle traction in a cephalad direction in order to relieve the suboccipital area. Once the suboccipital muscles have relaxed, the researcher gently removes the contact, leaving the participant's head resting on the table.~This technique is performed for 4 minutes."
58282858|NCT06439472|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 4 minutes.
58282859|NCT06228495|BEHAVIORAL|Daily Intervention for Active Recovery|"Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy."
58282860|NCT01281956|DRUG|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
58282861|NCT01281956|DRUG|Placebo|Placebo
58282862|NCT03958942|OTHER|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
58282863|NCT03958942|OTHER|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
58282864|NCT03585712|DRUG|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
58282865|NCT02732015|DRUG|Dexamethasone|Given IV
58282866|NCT02732015|DRUG|Doxorubicin|Given IV
58282867|NCT02732015|DRUG|Fosaprepitant Dimeglumine|Given IV
58282868|NCT02732015|DRUG|Ifosfamide|Given IV
58282869|NCT02732015|OTHER|Laboratory Biomarker Analysis|Correlative studies
58282870|NCT02732015|DRUG|Mesna|Given IV
58282871|NCT02732015|DRUG|Ondansetron|Given IV
58282872|NCT02732015|OTHER|Questionnaire Administration|Ancillary studies
58282873|NCT02732015|DRUG|Rolapitant Hydrochloride|Given PO
58282874|NCT02732015|DRUG|Vincristine Sulfate|Given IV
58282875|NCT05483465|DRUG|Nicotinamide riboside|Oral NR, 1g/day per os for 8 weeks
58282876|NCT05483465|DRUG|Placebo|Visually identical pill to NR, daily per os for 8 weeks
58282877|NCT02007655|DRUG|Eliquis|
58282878|NCT04652947|DIAGNOSTIC_TEST|MRI diagnostic|no intervention, patient only have MRI
58282879|NCT01522131|PROCEDURE|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
58282880|NCT04046822|DRUG|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
58282881|NCT04046822|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
58282882|NCT03899402|DRUG|Insulin|Standard of care insulin for pump or injection and serves as a control
58282883|NCT03899402|DRUG|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
58282884|NCT03899402|DRUG|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
58282885|NCT03899402|DRUG|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
58282886|NCT00004794|DRUG|cidofovir|
58397702|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
58397703|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
58397704|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
58069742|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
58282887|NCT05745233|DRUG|Nivolumab|Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
58397705|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
58397706|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
58282888|NCT05745233|DRUG|Pembrolizumab|Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
58282889|NCT00774072|DRUG|Tobramycin (Gernebcin®)|1 ml / day in each nostril
58282890|NCT00615810|DRUG|Atripla|Open label once daily for oral administration to be taken on an empty stomach
58282891|NCT00615810|DRUG|Kivexa plus Sustiva|Open label once daily for oral administration
58282892|NCT04964583|DRUG|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
58397707|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
58397708|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
58397709|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
58397710|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
58397711|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
58397712|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
58397713|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
57728383|NCT01060865|DRUG|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
58282893|NCT03990779|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
58282894|NCT04024566|DEVICE|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
58282895|NCT05950165|DRUG|CHO-H01|"Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
58282896|NCT05950165|DRUG|CHO-H01 at RP2D|"Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
58282897|NCT05950165|DRUG|Lenalidomide|Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
58282898|NCT05041660|OTHER|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
58397714|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
58397715|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
58397716|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
58397717|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
58397718|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
58397719|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
57728384|NCT01995123|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
58282899|NCT05041660|OTHER|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
58069743|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
58069744|NCT02698020|PROCEDURE|Room-air|Provision of room-air
58069745|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
58069746|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
58069747|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
58282900|NCT05041660|OTHER|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
58282901|NCT05041660|OTHER|Computerized training|Uses a relatively simplistic computerized training.
58282902|NCT00030485|DRUG|erlotinib hydrochloride|
58282903|NCT04202965|DRUG|PTG-300|Active treatment with PTG-300 injected subcutaneously.
58282904|NCT06397209|OTHER|Propioceptive Neuromascular facilitation|Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks
58282905|NCT06397209|OTHER|Neural Flossing|Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
58282906|NCT00633490|DRUG|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
58282907|NCT06217445|DEVICE|high intensity focused ultrasound|High-intensity focused ultrasound (HIFU) therapy is becoming more familiar in medical field because it is non-invasive technique with fewer side effects and provides promising therapeutic results. Several HIFU therapy applications have approved by many approval authorities of deferent countries since last decade
57930206|NCT02155036|OTHER|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
57930207|NCT01762670|DRUG|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
58282908|NCT06217445|OTHER|Doubled chin exercises|1. Straight jaw jut. 2-ball exercise. 3-Pucker up 4. Tongue stretch 5. Neck stretch 6-bottom jaw jut.
58282909|NCT00781924|PROCEDURE|biopsy|ultrasound guided biopsy of tumors.
58282910|NCT02758197|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
58282911|NCT02431104|DEVICE|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
58282912|NCT01084538|DRUG|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
57930208|NCT01762670|DRUG|Metronidazole|500 mg twice daily for 7 days
57930209|NCT05887453|DEVICE|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
57930210|NCT05398068|OTHER|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
58282913|NCT04747665|OTHER|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
57728385|NCT01995123|BEHAVIORAL|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
57728386|NCT01995123|BEHAVIORAL|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
57728387|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
57930211|NCT05398068|OTHER|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
58069748|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
58282914|NCT03582319|OTHER|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
58282915|NCT03582319|OTHER|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
58282916|NCT04926506|DRUG|Xiyanping injection|Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
58282917|NCT02634632|BEHAVIORAL|Choosing to write advance directives|
58282918|NCT04856059|DIAGNOSTIC_TEST|Cardiac MRI, ECG/Holter and Blood Biomarkers|Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
58282919|NCT00627926|BIOLOGICAL|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
57728388|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
58282920|NCT00627926|DRUG|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
58397720|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
58397721|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
58397722|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
58397723|NCT00274859|DRUG|gemcitabine hydrochloride|
58397724|NCT00274859|DRUG|oxaliplatin|
58397725|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
58397726|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
58397727|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
58282921|NCT00627926|DRUG|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
58282922|NCT00627926|OTHER|Placebo|Telaprevir matching placebo
58282923|NCT05565885|OTHER|Sampling|4 blood sampling per patient and an additional one in case of relapse
58282924|NCT02751164|OTHER|Day/time of admission to the critical care unit|
58282925|NCT05762809|DIAGNOSTIC_TEST|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
58282926|NCT05762809|DIAGNOSTIC_TEST|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
58282927|NCT05762809|DIAGNOSTIC_TEST|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
57728389|NCT05153434|DRUG|ARD-101|Twice Daily, Oral Administration
58282928|NCT05762809|DIAGNOSTIC_TEST|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
58282929|NCT05762809|DIAGNOSTIC_TEST|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
57728390|NCT00059813|BIOLOGICAL|recombinant interferon alfa|Given SC
57728391|NCT00059813|BIOLOGICAL|oblimersen sodium|Given IV
57728392|NCT00059813|OTHER|pharmacological study|Correlative studies
57728393|NCT05648591|DRUG|Iloperidone|oral tablet
57728394|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
57728395|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
57728396|NCT06296173|OTHER|"Protective open-lung extubation"|Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
58397728|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
57728397|NCT06296173|OTHER|Conventional extubation|Emergence using 100% FiO2, dorsal decubitus position with manual bag ventilation without PEEP
57728398|NCT01173848|DRUG|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
58282930|NCT05762809|DIAGNOSTIC_TEST|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
58282931|NCT05762809|DIAGNOSTIC_TEST|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
58282932|NCT00359177|DRUG|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
58282933|NCT01519973|RADIATION|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
58282934|NCT05208580|BEHAVIORAL|Virtual education|Participants undergo virtual education activities on an on-line platform 10-14 days before the surgery
58282935|NCT05208580|BEHAVIORAL|Contact education|Participants attend live educational classes 10-14 days before the surgery
58282936|NCT02834832|DEVICE|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
58282937|NCT06345391|OTHER|Co-creation|Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.
58282938|NCT06345391|OTHER|Concept Mapping|Concept mapping to create a pain science education intervention for children living beyond cancer.
58282939|NCT05376072|OTHER|Electromyographic Biofeedback|"The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial."
58282940|NCT03745248|BEHAVIORAL|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
58282941|NCT03745248|BEHAVIORAL|Balance Training|Standard of care
58282942|NCT04692272|BEHAVIORAL|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
58282943|NCT01404897|OTHER|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
58282944|NCT01404897|OTHER|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
58282945|NCT01404897|OTHER|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
58397729|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
58397730|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
58397731|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
57728399|NCT01173848|DRUG|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
57728400|NCT04057495|OTHER|further fasting|2 hours of fasting
57728401|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
57728402|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
57728403|NCT02433353|DRUG|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
57728404|NCT02433353|BEHAVIORAL|EMDR|psychotherapy
57728405|NCT02433353|DRUG|Placebo|Look-alike venlafaxine XR tablets containing no active drug
58282946|NCT04476498|PROCEDURE|Pull-PEG with Gastropexy|Additionally to a conventional pull-PEG a gastropexy will be performed.
58397732|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
58397733|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
58397734|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
58397735|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
58397736|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
58397737|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
58397738|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
58397739|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
58397740|NCT00322452|DRUG|Gefitinib|oral tablet
58397741|NCT00322452|DRUG|Carboplatin|IV
58397742|NCT00322452|DRUG|Paclitaxel|IV
58397743|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
58397744|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
58397745|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
58397746|NCT00467194|DRUG|Rapamycin|
58397747|NCT00467194|DRUG|Bevacizumab|
58397748|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
57728406|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
57728407|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
57728408|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
57728409|NCT06232408|DRUG|RP-1664|RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
58069749|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
58282947|NCT05770349|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass grafting
58397749|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
58397750|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
58397751|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
58397752|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
58397753|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
58397754|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
57930212|NCT06006338|OTHER|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
58282948|NCT05693324|BEHAVIORAL|Minority stress|Intervention based on Cognitive Behavioural and Compassion Focused Treatments
58282949|NCT02328794|BEHAVIORAL|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
57930213|NCT01978795|OTHER|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
57930214|NCT01978795|OTHER|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
57930215|NCT00528255|DRUG|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
57930216|NCT03707509|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
58282950|NCT02328794|BEHAVIORAL|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
57930217|NCT03707509|DRUG|Placebos|Maximum 6 cycles for combined therapy.
57930218|NCT03707509|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
57930219|NCT03707509|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
57930220|NCT01088191|BIOLOGICAL|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
58282951|NCT02328794|BEHAVIORAL|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
58282952|NCT02328794|BEHAVIORAL|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
58282953|NCT02328794|BEHAVIORAL|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
58397755|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
58397756|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
58397757|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
58282954|NCT04959292|DIAGNOSTIC_TEST|arthroscopy|arthroscopy
58282955|NCT00939237|DRUG|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
57728410|NCT05704959|DIAGNOSTIC_TEST|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
58282956|NCT00939237|DRUG|Placebo|
58282957|NCT02383355|DRUG|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
58282958|NCT02383355|DRUG|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
58282959|NCT00316914|DRUG|calcium gluconate|Given IV
58282960|NCT00316914|DRUG|magnesium sulfate|Given IV
58282961|NCT00316914|OTHER|placebo|Given IV
58282962|NCT01937884|DRUG|Parenteral Nutrition|
58282963|NCT06307834|BEHAVIORAL|Neurofeedback - based therapy|This intervention will include mental practice of various hand movements accompanied by guided visual feedback, aimed at regulating brain activation patterns to facilitate the restoration of hand movements. We will also incorporate EMG signals to control a hand exoskeleton.
58282964|NCT06307834|BEHAVIORAL|Standard hand exercise therapy|This intervention will include engaging in a set of particular hand exercises with the aim of enhancing hand movements.
58282965|NCT02625246|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
58282966|NCT05867680|BEHAVIORAL|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
58282967|NCT06414876|BEHAVIORAL|Hospital dog|The hospital dog always has a well educated dog instructor beside.
58282968|NCT02843165|DRUG|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
58282969|NCT02843165|RADIATION|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
58282970|NCT01584700|PROCEDURE|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
58282971|NCT00018421|PROCEDURE|Treadmill Exercise|
58282972|NCT00456781|DEVICE|Augmentation|Rotator Cuff Repair plus Graft Jacket
58282973|NCT00456781|PROCEDURE|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
58397758|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
58397759|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
57728411|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
57930221|NCT01088191|DRUG|Hyaluronan|Hyaluronan alone
57930222|NCT04439071|DRUG|PTC299|Oral tablets
58282974|NCT01004432|DRUG|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
58282975|NCT01004432|DRUG|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
58397760|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
58397761|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
58397762|NCT04313374|DRUG|Placebo|the PCA will contain placebo
58397763|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
58397764|NCT02374814|DRUG|Placebo|Placebo
58282976|NCT01004432|DRUG|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
58282977|NCT01004432|DRUG|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
58282978|NCT01004432|DRUG|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
58282979|NCT03280706|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 50g in water 500ml
58282980|NCT03280706|DIETARY_SUPPLEMENT|Orange Juice|Orange juice 480ml + 20ml of water
58397765|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
57930223|NCT04439071|OTHER|SOC|As defined per local written policies or guidelines.
57930224|NCT04439071|DRUG|Placebo|Oral tablets
57930225|NCT02106754|BEHAVIORAL|Brief Intervention|
58282981|NCT03280706|DIETARY_SUPPLEMENT|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
58282982|NCT05761457|OTHER|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
58282983|NCT00624832|DRUG|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
58282984|NCT00624832|DRUG|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
57930226|NCT02106754|BEHAVIORAL|Brief Intervention with Coaching|
58282985|NCT00892814|RADIATION|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
57930227|NCT02106754|BEHAVIORAL|Treatment as Usual|
57930228|NCT05642182|DRUG|Drug (SFA002) Vitamin D, Magnesium|Capsules
58282986|NCT00892814|RADIATION|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
58397766|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
57930229|NCT05642182|DRUG|Drug (SFA002) Vitamin D, Magnesium and Propionate|Capsules
57930230|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 1.0 mg/kg/week
58282987|NCT04088539|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
58282988|NCT04088539|BEHAVIORAL|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
58282989|NCT05491681|BIOLOGICAL|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
58282990|NCT00913302|BEHAVIORAL|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
58282991|NCT02670421|BEHAVIORAL|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
58282992|NCT02670421|BEHAVIORAL|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
58397767|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
58397768|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
58397769|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
58397770|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
58397771|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
58397772|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
58397773|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
58397774|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
57930231|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 2.0 mg/kg/week
58397775|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
58397776|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
58397777|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
58397778|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
58397779|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
57930232|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 4.0 mg/kg/week
57930233|NCT03623581|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
58397780|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
58397781|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
58397782|NCT02975479|DRUG|ALK Diluent|
58397783|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
58282993|NCT02670421|BEHAVIORAL|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
58282994|NCT00975546|OTHER|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
58282995|NCT00975546|PROCEDURE|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
58282996|NCT05437614|PROCEDURE|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
58282997|NCT05437614|PROCEDURE|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
58282998|NCT02741232|DRUG|Lidocaine 1% with epinephrine 1/400000|
58282999|NCT02741232|OTHER|sham block|
58283000|NCT00456261|DRUG|Pemetrexed|pemetrexed 500 mg/m2
58283001|NCT00456261|DRUG|Gemcitabine|gemcitabine 1500 mg/m2
58397784|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
57930234|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
58283002|NCT00456261|DRUG|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
58283003|NCT00456261|DRUG|Carboplatin|carboplatin AUC=5
58283004|NCT04261647|OTHER|kinesio-taping techniques.|
58283005|NCT04261647|OTHER|Pelvic floor exercise|
58283006|NCT04261647|OTHER|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
58283007|NCT03191825|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
58397785|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
58397786|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
58397787|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
58397788|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
58397789|NCT01986192|DRUG|rivaroxaban|
57930235|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
58397790|NCT01986192|DRUG|Warfarin|
58397791|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
58397792|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
58283008|NCT03191825|OTHER|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
58283009|NCT03191825|OTHER|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
58283010|NCT04436653|DEVICE|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
58283011|NCT02151214|OTHER|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
58283012|NCT04818723|DRUG|Montelukast|We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
58283013|NCT03691506|OTHER|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
58283014|NCT03691506|OTHER|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
58069750|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
58069751|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
58283015|NCT03387657|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
58283016|NCT03387657|DRUG|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
58283017|NCT04305860|DIETARY_SUPPLEMENT|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
58283018|NCT04305860|DIETARY_SUPPLEMENT|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
58283019|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
58283020|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
58283021|NCT03454386|BEHAVIORAL|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
58283022|NCT03454386|BEHAVIORAL|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
58283023|NCT04243226|DEVICE|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
58283024|NCT00852280|DEVICE|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
58283025|NCT02800395|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
58283026|NCT02524626|PROCEDURE|Sham stimulation|Sham stimulation
58283027|NCT02524626|PROCEDURE|Vagus stimulation|Vagus stimulation
58283028|NCT04348500|DRUG|Clazakizumab|IV Infusion
58283029|NCT04554381|BIOLOGICAL|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
58283030|NCT04852211|PROCEDURE|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~1. Laparoscopic group: LMH~2. Open group: OMH"
58283031|NCT03756597|DEVICE|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
58283032|NCT03756597|DEVICE|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
57930236|NCT03938077|DEVICE|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
58397793|NCT06440967|DRUG|Fezolinetant|oral
58397794|NCT06440967|DRUG|Placebo|oral
58397795|NCT06440967|DRUG|Tamoxifen|oral
58397796|NCT06440967|DRUG|Aromatase inhibitor|oral
58397797|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
57728412|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
57728413|NCT00318006|PROCEDURE|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
57728414|NCT00318006|PROCEDURE|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
57728415|NCT05843968|DRUG|Rituximab|"2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
58283033|NCT02025270|BIOLOGICAL|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
58283034|NCT04208672|DEVICE|UMindSleep|CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
58283035|NCT04160637|DIAGNOSTIC_TEST|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
58283036|NCT05007171|DEVICE|Very low calorie diet|During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
58283037|NCT03717649|DEVICE|Conventional 2-stage venous cannula|venous cannula
58283038|NCT03717649|DEVICE|Conventional 3-stage venous cannula|venous cannula
58283039|NCT03717649|DEVICE|Fenestrated 3-stage venous cannula|venous cannula
58283040|NCT06055153|DRUG|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If \> 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
58283041|NCT02547909|PROCEDURE|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
58283042|NCT02547909|DEVICE|Cellvizio|
58283043|NCT02547909|DRUG|fluorescein 10%|
58283044|NCT03188523|DRUG|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
58283045|NCT05689788|DEVICE|High-intensity laser therapy|punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
58283046|NCT05689788|PROCEDURE|Stretching exercise|Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
58397798|NCT02184091|DRUG|Nevirapine|
58397799|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
58397800|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
58397801|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
58397802|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
58397803|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
58397804|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
58397805|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
58397806|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
58397807|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
58397808|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
58397809|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
58397810|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
58283047|NCT05689788|DEVICE|Sham High-intensity laser therapy|Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
58283048|NCT00877539|DRUG|PF-03526299|Inhaled, two doses 4 hours apart
58283049|NCT00877539|DRUG|Placebo|Inhaled, two doses 4 hours apart
58283050|NCT00877539|DRUG|Fluticasone propionate|Inhaled
58283051|NCT05042986|DRUG|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
58283052|NCT04217824|PROCEDURE|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
58283053|NCT05700331|PROCEDURE|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
58283054|NCT05700331|PROCEDURE|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
58283055|NCT02065518|DEVICE|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
58283056|NCT02065518|BEHAVIORAL|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
58283057|NCT02065518|BEHAVIORAL|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
57728416|NCT05843968|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
58283058|NCT00200941|DRUG|Topiramate|
58283059|NCT03105856|BIOLOGICAL|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
58283060|NCT03105856|BIOLOGICAL|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
58283061|NCT05459558|DRUG|Experimental Dentifrice 1|5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).
58397811|NCT00303771|DRUG|fluorouracil|
57728417|NCT00153738|DRUG|phytosterol|
57728418|NCT01858662|PROCEDURE|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
57728419|NCT01858662|DRUG|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
57728420|NCT01858662|DRUG|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
58397812|NCT00303771|DRUG|irinotecan hydrochloride|
58397813|NCT00303771|DRUG|leucovorin calcium|
57728421|NCT01858662|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
58397814|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
58397815|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
57728422|NCT01858662|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
58283062|NCT05459558|DRUG|Experimental Dentifrice 2|5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.
58283063|NCT05459558|DRUG|Reference Dentifrice|Regular Fluoride Dentifrice.
58283064|NCT00102856|DRUG|Pramipexole|
58283065|NCT00102856|DRUG|Rivastigmine|
58397816|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
58397817|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
58397818|NCT06236061|DRUG|LCZ|LCZ 200 mg
58397819|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
58397820|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
58397821|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
58397822|NCT00057733|PROCEDURE|psychosocial assessment and care|
57728423|NCT01858662|DRUG|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
58283066|NCT06145113|DEVICE|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
57728424|NCT00723775|DRUG|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
57728425|NCT05839769|DIAGNOSTIC_TEST|Evaluation of median nerve with ultrasound|ultrasound examination wrist
58283067|NCT04660786|DRUG|triamcinolone acetonide|local immunosuprresent
58397823|NCT00057733|PROCEDURE|quality-of-life assessment|
57728426|NCT02571452|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
58283068|NCT04660786|DRUG|vitamin D|local immunomodulator
58397824|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
58397825|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
58283069|NCT06265571|OTHER|perineural injection|perineural injection of local anesthestetic for postoperative pain management
58283070|NCT01687283|DRUG|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
58283071|NCT01687283|DRUG|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
58283072|NCT02626000|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
58283073|NCT02626000|BIOLOGICAL|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
58283074|NCT00355511|BEHAVIORAL|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
58397826|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
58397827|NCT06279364|DRUG|SKB264|IV Infusion
58397828|NCT06279364|DRUG|Paclitaxel|IV Infusion.
58397829|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
58397830|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
58397831|NCT06279364|DRUG|Eribulin|IV infusion.
58397832|NCT06279364|DRUG|Carboplatin|IV infusion.
58397833|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
58397834|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
58397835|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
58397836|NCT03006458|DEVICE|comfilcon A|toric contact lens
58397837|NCT03006458|DEVICE|omafilcon B|toric contact lens
58397838|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
58397839|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
58283075|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
58283076|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
58397840|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
58397841|NCT02182063|DRUG|BIBF 1120 low dose|
58283077|NCT04722536|PROCEDURE|Cervico-isthmic cerclage|There is no intervention in this study. It's an observational retrospective study, before/after.
58283078|NCT01044368|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
57728427|NCT02571452|BEHAVIORAL|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
57728428|NCT06535685|DRUG|Romiplostim|Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
57728429|NCT05861674|BIOLOGICAL|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
58283079|NCT02570035|DRUG|Mirabegron|oral
58283080|NCT04646811|PROCEDURE|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
58283081|NCT04646811|OTHER|Best medical treatment|Best medical therapy alone
58283082|NCT02112877|DEVICE|Veniti Vici™ Venous Stent System|
58283083|NCT03315494|DRUG|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
58397842|NCT02182063|DRUG|BIBF 1120 high dose|
58397843|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
58397844|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
57728430|NCT05861674|BIOLOGICAL|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
57728431|NCT05861674|DRUG|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
57728432|NCT04708873|OTHER|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
58283084|NCT03315494|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
58283085|NCT05897827|BEHAVIORAL|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
58283086|NCT05897827|BEHAVIORAL|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
58283087|NCT05861206|OTHER|GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
58397845|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
58397846|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
58397847|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
58397848|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
58397849|NCT04627675|DRUG|IL-12 plasmid|cytokine
58397850|NCT04627675|DEVICE|Cliniporator|electroporation system
57728433|NCT04708873|OTHER|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
57930237|NCT06207357|PROCEDURE|optical trocar to create the pneumoperitoneum for bariatric surgery|The technique involves the use of 4 12 mm trocars. Pneumoperitoneum is induced by a 0° optical trocar and maintained at 15 mmHg. The first trocar is usually inserted along the left mid-clavicular line approximately 2 fingers from the costal arch, another trocar along the left axillary line, a third trocar 1 cm to the right of the midline, and the fourth trocar along the right mid-clavicular line. A 10 mm, 30 ° laparoscope is used.
58283088|NCT05861206|OTHER|CHX-MW group (0.12% CHX, as a positive control group)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
57930238|NCT00913250|DRUG|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
57930239|NCT00913250|DRUG|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
57930240|NCT03575455|BEHAVIORAL|Exercise|HR-controlled treadmill walking
58283089|NCT05231070|OTHER|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
58283090|NCT01917695|DRUG|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
58283091|NCT01917695|RADIATION|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
58283092|NCT01917695|RADIATION|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
58283093|NCT01917695|PROCEDURE|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
58283094|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
58283095|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
58283096|NCT02707172|BEHAVIORAL|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
58283097|NCT02707172|BEHAVIORAL|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
58283098|NCT02935296|BEHAVIORAL|Integrated Intervention|systems navigation, psychosocial counseling
58283099|NCT02057432|DEVICE|intra-operative MRI|Patients will undergo an MRI during surgery.
58283100|NCT03148067|PROCEDURE|Intramedullary nailing for fracture fixation|
58283101|NCT00561535|DIETARY_SUPPLEMENT|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
58283102|NCT00561535|DIETARY_SUPPLEMENT|placebo (starch)|Once daily
58283103|NCT00312117|DRUG|Sodium bicarbonate|
58069752|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
58283104|NCT06612918|DEVICE|high-intensity laser acupuncture and the exercise program|The experimental group will receive high-intensity lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises.
58283105|NCT06612918|OTHER|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
58283106|NCT03039465|DEVICE|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
58283107|NCT06222814|PROCEDURE|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
58283108|NCT06222814|PROCEDURE|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
58283109|NCT03662035|DRUG|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
58283110|NCT03662035|DRUG|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
58397851|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
58069753|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
58397852|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
57930241|NCT02749448|OTHER|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
58397853|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
57930242|NCT01474863|DRUG|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
57930243|NCT01474863|DRUG|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
57930244|NCT01474863|DRUG|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
58397854|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
58397855|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
58397856|NCT01335724|DRUG|Placebo gel|Placebo gel
58397857|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
58397858|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
58397859|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
58397860|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
57930245|NCT01444651|DRUG|Tadalafil|20 mg Tadalafil taken once a day for 3 months
57930246|NCT01444651|DRUG|Placebo|Placebo tablet taken by mouth once a day for 3 months
57930247|NCT01916863|DRUG|LX4211 400 mg|
57930248|NCT01916863|DRUG|canagliflozin 300 mg|
57930249|NCT01916863|DRUG|LX4211 Placebo|
57930250|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
58397861|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
58397862|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
58397863|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
58397864|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
58397865|NCT03011970|DRUG|Oxytocin|
57930251|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
57930252|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
57930253|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
57930254|NCT01750541|DRUG|Haloperidol|
57930255|NCT01750541|DRUG|Valproate|
57930256|NCT05477381|DIAGNOSTIC_TEST|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
58069754|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
58397866|NCT03011970|DRUG|Placebo|
58069755|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
58397867|NCT03401944|DRUG|TPN|
58397868|NCT03401944|OTHER|Control|
58397869|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
58397870|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
58397871|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
58397872|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
58397873|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
58397874|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
58397875|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
58397876|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
58397877|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
58397878|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
58397879|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
58397880|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
58397881|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
58397882|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
58397883|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
58397884|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
58397885|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
58397886|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
58283111|NCT03635008|DEVICE|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
58397887|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
58397888|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
58397889|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
58283112|NCT04755894|DRUG|HDDO-1756|single dose
58283113|NCT04755894|DRUG|HDDO-17561/HDDO-17562|single dose
58397890|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
58397891|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
58397892|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
58397893|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
58397894|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
58397895|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
58397896|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
58397897|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
58397898|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
58397899|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
58283114|NCT04198142|BEHAVIORAL|Imagery Rehearsal Therapy|"The Imagery Rehearsal Therapy (IRT) intervention used in this study is a short version of the treatment, consisting of 1-2 sessions.~The protocol starts with a very brief explanation of the treatment. Then the patient will be guided through an imagery exercise. The next step is to choose a nightmare. This nightmare is then rescripted to a new narrative, which is in no way distressing to the patient anymore. Subsequently, the therapist will guide the patient through an imagery exercise with the new narrative. The new narrative is then either written down or recorded. Lastly, the therapist will explain to the patient, that he or she should rehearse the new narrative daily with imagery exercises."
58397900|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
58397901|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
58397902|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
58397903|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
58397904|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
58397905|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
58397906|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
58397907|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
58397908|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
58069756|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
58069757|NCT03579862|OTHER|Blood Draw|
58069758|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
58069759|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
58283115|NCT04198142|BEHAVIORAL|Treatment as Usual with dream diaries|Treatment as Usual means that patients in this arm will receive usual inpatient care. Additionally, they will keep a dream diary. It has been shown in previous studies that keeping a dream diary has a positive effect on nightmares.
58069760|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
58397909|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
58397910|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
58397911|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
58397912|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
58397913|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
58397914|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
58397915|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
58397916|NCT02752685|DRUG|Pembrolizumab|
58397917|NCT02752685|DRUG|Nab-Paclitaxel|
58422743|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
58422744|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
58422745|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
57930257|NCT06437964|OTHER|No use of prophylactic antibiotics|In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
57930258|NCT06736002|OTHER|Vitamin D|Vitamin D
58283116|NCT05522946|OTHER|Gameplay between parent and child or adolescent with or without a disability|Parent and child or adolescent will play the game using the provided sensors for 10-15 minutes total. Depending on the cognitive and/or physical ability of the child or adolescent, the two may take turns wearing the sensors or if the child or adolescent does not have the physical or cognitive ability to deliberately touch the sensor, then the child or adolescent will wear the sensors and the parent will touch the sensors in order to move the game forward.
58397918|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
58397919|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
58397920|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
58397921|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
58397922|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
58397923|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
58397924|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
58397925|NCT05307705|DRUG|LOXO-783|Oral
58397926|NCT05307705|DRUG|Fulvestrant|Intramuscular
58283117|NCT05774002|BEHAVIORAL|Aims to Decrease Anxiety and Pain Treatment (ADAPT)|One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
57728434|NCT05710523|BEHAVIORAL|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
58283118|NCT01548768|DRUG|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
57930259|NCT06736002|OTHER|Placebo|Placebo oral solution
57930260|NCT00347672|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
57930261|NCT04112446|DRUG|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
57930262|NCT00036894|DRUG|lenalidomide|
57930263|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Bangladesh|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
57930264|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Uganda|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
58397927|NCT05307705|DRUG|Imlunestrant|Oral
58397928|NCT05307705|DRUG|Abemaciclib|Oral
58397929|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
58397930|NCT05307705|DRUG|Paclitaxel|Intravenous
58397931|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
58397932|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
58397933|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
58397934|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
57930265|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in India|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
58283119|NCT01548768|DRUG|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
58283120|NCT04544839|DEVICE|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
58283121|NCT04161105|PROCEDURE|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
58283122|NCT00031772|PROCEDURE|psychosocial assessment and care|Questionnaire and telephone intervention
58283123|NCT02591030|DRUG|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
58283124|NCT02591030|DRUG|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
57728435|NCT05710523|OTHER|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
58069761|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
58069762|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
58283125|NCT04131582|COMBINATION_PRODUCT|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
58283126|NCT04131582|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
58397935|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
58397936|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
58397937|NCT04336046|DRUG|Bupivacaine|bupivacaine
58397938|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
58397939|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
58397940|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
58397941|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
58069763|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
58397942|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
57930266|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
57930267|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
57930268|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
58283127|NCT02494648|DEVICE|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
58283128|NCT02494648|OTHER|Control|
58283129|NCT02883621|PROCEDURE|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
58283130|NCT02883621|PROCEDURE|standard upper endoscopy|standard examination without using a cap
58283131|NCT03396822|DRUG|Gadoteridol|gadolinium MRI contrast
58283132|NCT04186221|DEVICE|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
58283133|NCT00998205|DRUG|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
58283134|NCT00998205|DRUG|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
58283135|NCT03011437|OTHER|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
58283136|NCT00272844|DRUG|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
58283137|NCT05216640|DEVICE|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
58283138|NCT00534105|OTHER|Total Cholesterol|
58283139|NCT00534105|OTHER|Triglyceride|
58283140|NCT00534105|OTHER|HDL|
58283141|NCT00534105|OTHER|LDL|
58283142|NCT05061901|DRUG|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
58283143|NCT05061901|DRUG|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
58283144|NCT04235842|OTHER|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
58283145|NCT04235842|OTHER|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
58397943|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
58397944|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
58283146|NCT01664507|DRUG|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
58283147|NCT01664507|DRUG|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
58283148|NCT05979480|DIAGNOSTIC_TEST|Dual energy X-ray absorptiometry (DXA)|DXA scan to assess bone mineral density, fat mass and muscle mass.
58283149|NCT02937636|OTHER|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
58283150|NCT02937636|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
58283151|NCT00619372|DRUG|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
58283152|NCT00619372|DRUG|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
58283153|NCT00619372|DRUG|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
58397945|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
58397946|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
58069764|NCT01768624|PROCEDURE|dialysis, kidney transplant|
58283154|NCT00619372|DRUG|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
58283155|NCT00619372|DRUG|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
58283156|NCT00619372|DRUG|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
58397947|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
58397948|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
58422746|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
58397949|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
58397950|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
58397951|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
57930269|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
58069765|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
58069766|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
58283157|NCT05054205|BEHAVIORAL|Motivational İnterviewing|"The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy."
58283158|NCT02143934|DRUG|Primaquine|
58283159|NCT02143934|DRUG|Placebo|Sugar pills, appearance identical to Primaquine tablets
58283160|NCT02143934|DRUG|Chloroquine|
58283161|NCT02143934|DRUG|Artemether Lumefantrine|
58283162|NCT03714776|DRUG|Placebo|Placebo matching solution administered as SC injection.
58283163|NCT03714776|DRUG|ISIS 757456|Administered as SC injection.
58283164|NCT03788980|PROCEDURE|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
58283165|NCT03788980|DIAGNOSTIC_TEST|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
58283166|NCT03729791|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
58283167|NCT00964405|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist
58283168|NCT00964405|DRUG|Placebo|Matching placebo
58283169|NCT03072823|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
58283170|NCT03072823|DIETARY_SUPPLEMENT|placebo|olive oil ethyl esters
58283171|NCT00994227|PROCEDURE|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
58283172|NCT01812616|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
58283173|NCT01812616|DRUG|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
58283174|NCT00472485|PROCEDURE|eye movement therapy|
58283175|NCT06232746|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
58397952|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
58069767|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
58283176|NCT01637883|DRUG|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
58283177|NCT00741598|DRUG|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
58283178|NCT00741598|DRUG|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
58283179|NCT00673374|DEVICE|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
58283180|NCT00079885|DRUG|tigecycline|
58283181|NCT02394184|PROCEDURE|transcatheter aortic valve replacement|
58397953|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
58397954|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
58283182|NCT05206383|BEHAVIORAL|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
57930270|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
57930271|NCT05651932|DRUG|Cohort A1 & A2|KTX-1001 will be administered orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
57930272|NCT05651932|DRUG|Cohort C1 & C2|KTX-1001: Orally for 28 days each cycle until progression Carfilzomib: IV, once weekly for 3 weeks in each 28-day cycle Dexamethasone: Orally once weekly
57930273|NCT05651932|DRUG|Cohort D|KTX-1001: Orally daily for 28 days each cycle until progression Pomalidomide: Orally, for 21 days in each 28-day cycle Dexamethasone: Orally once a week
57930274|NCT01491217|DRUG|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
57930275|NCT01320787|DRUG|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
57930276|NCT04127825|PROCEDURE|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
58069768|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
58069769|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
58283183|NCT05206383|BEHAVIORAL|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
58397955|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
58397956|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
58069770|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
58283184|NCT05206383|BEHAVIORAL|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
58283185|NCT03354052|DEVICE|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
58283186|NCT03354052|DEVICE|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
57930277|NCT05330403|PROCEDURE|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
57930278|NCT02041754|DEVICE|IQP-AK-102|
57930279|NCT02041754|DEVICE|Placebo|
57930280|NCT03942406|COMBINATION_PRODUCT|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
58397957|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
58397958|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
58397959|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
58397960|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
58397961|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
58397962|NCT00025207|DRUG|gefitinib|Given orally
58069771|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
58069772|NCT00308568|BEHAVIORAL|Mailed educational brochure|
57728436|NCT02465229|PROCEDURE|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
58283187|NCT06387446|PROCEDURE|Valve transplant|Heart valves from an organ donor will be transplanted into recipient
58283188|NCT01592123|PROCEDURE|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
58283189|NCT01592123|BEHAVIORAL|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score \>5 is considered to be suggestive of significant sleep disturbance.
58283190|NCT01592123|BEHAVIORAL|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
58283191|NCT01592123|BEHAVIORAL|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
57728437|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
58283192|NCT00869583|BEHAVIORAL|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
58397963|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
58397964|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
58397965|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
58397966|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
58397967|NCT00406874|DRUG|folic acid|800 micrograms daily
58397968|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
58397969|NCT06649942|DRUG|KP-001|KP-001 400 mg
58397970|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
57728438|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
57728439|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
57728440|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
57728441|NCT03818373|PROCEDURE|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
57728442|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 14
57728443|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 23
58397971|NCT06649942|DRUG|Placebo|Placebo
58397972|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
58397973|NCT05096247|DEVICE|TempSure|This device is an RF device.
58397974|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
58397975|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
58397976|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
57728444|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 8
57728445|NCT04783753|DRUG|Itraconazole|Subjects will receive itraconazole QD for 14 days
57728446|NCT04783753|DRUG|Carbamazepin|Subjects will receive carbamazepine BID for 23 days
57728447|NCT04783753|DRUG|Quinidine|Subjects will receive quinidine BID for 8 days
57728448|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
57930281|NCT03511404|OTHER|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
57930282|NCT06717230|OTHER|EverX Posterior|Restoration
57930283|NCT02952391|OTHER|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol
57930284|NCT04780490|OTHER|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
57930285|NCT04780490|OTHER|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
57930286|NCT00002326|DRUG|Adefovir|
57930287|NCT00002326|DRUG|Zidovudine|
57930288|NCT04289740|BEHAVIORAL|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
58397977|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
58397978|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
58397979|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
58397980|NCT01932229|DRUG|Afatinib treatment|
58397981|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
58397982|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
58397983|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
58397984|NCT06658990|DRUG|control|Sufentanil is used after surgery
58397985|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
58397986|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
58397987|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
58397988|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
58422747|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
58397989|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
58397990|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
58397991|NCT00211757|DRUG|Divalproex sodium|Study drug.
58069773|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
58283193|NCT02857036|OTHER|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
58397992|NCT00211757|DRUG|Placebo|Placebo comparator.
58397993|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
58397994|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
58283194|NCT02857036|BEHAVIORAL|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
58283195|NCT01692522|PROCEDURE|Intubation|visualized blind intubation
58283196|NCT00106158|BIOLOGICAL|protein vaccination|
58283197|NCT04238338|OTHER|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
58283198|NCT05513768|DIAGNOSTIC_TEST|level of myosin binding protein c in serum|Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
58283199|NCT02923401|OTHER|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
58283200|NCT02923401|BEHAVIORAL|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
58283201|NCT02923401|BEHAVIORAL|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
58397995|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
58397996|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
58397997|NCT00270088|DRUG|epoetin alfa|
58283202|NCT02923401|BEHAVIORAL|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
58397998|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
58397999|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
58398000|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
58398001|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
58069774|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
58283203|NCT02923401|OTHER|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
58398002|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
58398003|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
58398004|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
58398005|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
58398006|NCT01292356|DRUG|cetuximab|
58398007|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
58398008|NCT04171219|DRUG|Talabostat Mesylate|Given PO
58398009|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
58398010|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
58069775|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
58398011|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
58398012|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
58398013|NCT06660992|DRUG|Placebo|the placebo comparator of study
57728449|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
58398014|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
58069776|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
58069777|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
57728450|NCT00000218|DRUG|Carbamazepine|
58398015|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
58398016|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
58398017|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
58398018|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
58398019|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
58069778|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
58398020|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
58398021|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
58398022|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
57728451|NCT03023891|DRUG|Prednisone|Prednisone 60 mg tablet once
57728452|NCT04358445|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
57728453|NCT02555046|PROCEDURE|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
57728454|NCT03985618|PROCEDURE|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
58069779|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
58069780|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
58069781|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
58398023|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
58398024|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
58398025|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
58398026|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
58422748|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
57930289|NCT04289740|BEHAVIORAL|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
57930290|NCT04081584|DEVICE|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
57930291|NCT01717768|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
58069782|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
58398027|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
58398028|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
58398029|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
58398030|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
58398031|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
58398032|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
58398033|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
58398034|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
58398035|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
58398036|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
58398037|NCT00025064|BIOLOGICAL|bleomycin sulfate|
58398038|NCT00025064|DRUG|chlorambucil|
58398039|NCT00025064|DRUG|cisplatin|
58398040|NCT00025064|DRUG|dacarbazine|
58069783|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
58398041|NCT00025064|DRUG|doxorubicin hydrochloride|
58398042|NCT00025064|DRUG|etoposide|
58398043|NCT00025064|DRUG|ifosfamide|
58398044|NCT00025064|DRUG|melphalan|
58398045|NCT00025064|DRUG|prednisolone|
58398046|NCT00025064|DRUG|procarbazine hydrochloride|
58398047|NCT00025064|DRUG|vinblastine sulfate|
58398048|NCT00025064|DRUG|vincristine sulfate|
58398049|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
58398050|NCT00025064|RADIATION|radiation therapy|
58398051|NCT00798460|DRUG|adefovir|adefovir 10mg
58398052|NCT00798460|DRUG|clevudine|clevudine 30mg
58398053|NCT00798460|DRUG|lamivudine|lamivudine 100mg
58398054|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
58398055|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
58398056|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
58398057|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
58398058|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
58398059|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
58398060|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
58398061|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
58398062|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
58398063|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
58398064|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
57930292|NCT04806139|BEHAVIORAL|Remote Enhance Fitness|The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
58398065|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
58398066|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
58398067|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
58398068|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
58398069|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
58069784|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
58069785|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
58069786|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
58069787|NCT00544154|DRUG|CDP870|
58069788|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
58069789|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
58069790|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
58069791|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
58069792|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
58398070|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
58398071|NCT00439543|DRUG|Iloprost inhalation|
58398072|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
58069793|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
58398073|NCT06130254|DRUG|Adagrasib|Given by PO BID
58398074|NCT06130254|DRUG|Olaparib|Given by PO BID
58398075|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
58398076|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
58398077|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
58398078|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
58069794|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
58422749|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
58398079|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
58398080|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
58398081|NCT02604602|OTHER|blood exam|laboratory test
57930293|NCT01179672|DRUG|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
57930294|NCT01179672|DRUG|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
57930295|NCT00822354|DRUG|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
57930296|NCT06725121|BIOLOGICAL|Atezolizumab & Bevacizumab|Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
57930297|NCT06725121|DRUG|Yttrium-90 (Y-90)|Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
58069795|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
58069796|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
58069797|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
58069798|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
57930298|NCT06725121|RADIATION|Stereotactic body radiotherapy (SBRT)|Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
58069799|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
58069800|NCT00291109|DRUG|letrozole 2.5 mg|
57930299|NCT00164827|DEVICE|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
57930300|NCT00049452|DRUG|zoledronic acid|
58069801|NCT00532233|DRUG|QAX576|
57930301|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
57930302|NCT01548924|DRUG|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
58069802|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
58069803|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
58069804|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
58069805|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
58069806|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
58069807|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
58069808|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
58069809|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
58069810|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
57930303|NCT01548924|DRUG|Dovitinib + Paclitaxel|"* Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
57930304|NCT03671746|DRUG|Ketorolac|Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization
57930305|NCT03671746|DRUG|Saline Solution|Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
57930306|NCT01881503|BIOLOGICAL|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
57930307|NCT02639468|DEVICE|Stroke Volume estimation using electrical impedance tomography|
57930308|NCT01329016|DRUG|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
58398082|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
58283204|NCT04829617|BEHAVIORAL|PP-MI Intervention|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
58283205|NCT04829617|BEHAVIORAL|MI-alone Intervention|The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
58398083|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
58398084|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
58398085|NCT00189332|DRUG|852A|
58398086|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
58398087|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
58398088|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
57930309|NCT01329016|DRUG|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
57930310|NCT01329016|DRUG|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
58283206|NCT00408551|DRUG|floxuridine|Given IV
58283207|NCT00408551|DRUG|fluorouracil|Given IV
58283208|NCT00408551|DRUG|irinotecan hydrochloride|Given IV
58283209|NCT00408551|DRUG|leucovorin calcium|Given IV
58283210|NCT00408551|DRUG|oxaliplatin|Given IV
58283211|NCT02688764|DRUG|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
58398089|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
58398090|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
58398091|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
58398092|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
57930311|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
57930312|NCT04987658|DRUG|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
57930313|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
57930314|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
57930315|NCT06018272|BEHAVIORAL|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
57930316|NCT06018272|BEHAVIORAL|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (\>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
57930317|NCT03509896|OTHER|Non-Interventional|Non-Interventional
58283212|NCT02688764|DRUG|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
58283213|NCT01168609|PROCEDURE|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
58283214|NCT02452255|DRUG|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
58283215|NCT02452255|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
58283216|NCT02452255|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
58283217|NCT03237052|OTHER|model|a model that has been established in advance.
58283218|NCT03237052|OTHER|non-model|real-world psychiatrist decision
58283219|NCT05000736|DRUG|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
58283220|NCT05000736|DRUG|fulvestrant|fulvestrant monotherapy
58283221|NCT00504543|DRUG|AEB071|oral, twice daily
58283222|NCT00504543|DRUG|Certican|twice daily
58283223|NCT00504543|DRUG|Neoral|twice daily
58283224|NCT05509101|OTHER|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
58283225|NCT05509101|OTHER|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
58283226|NCT05834478|DEVICE|Transcutaneous Cervical Vagal Nerve Stimulation|Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
58283227|NCT05834478|DEVICE|Sham Stimulation|Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
58283228|NCT05834478|DRUG|[F-18]Fallypride|\[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
57930318|NCT00382603|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
58398093|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
58398094|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
58398095|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
58398096|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
58398097|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
57930319|NCT05492188|BEHAVIORAL|Operant Conditioning of Cutaneous Reflexes|This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
57930320|NCT05679466|BIOLOGICAL|randomized, double-blinded, placebo-controlled|Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
57930321|NCT05046574|OTHER|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
58283229|NCT06129097|OTHER|Thyme honey mouthwash|"* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."
58283230|NCT05905081|OTHER|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
58283231|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
58283232|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
58283233|NCT00255164|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
58283234|NCT01960062|DEVICE|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
58283235|NCT04229771|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
58283236|NCT04229771|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
58283237|NCT01090050|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
58283238|NCT01090050|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
58283239|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
58398098|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
58398099|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
57728455|NCT03985618|PROCEDURE|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
57728456|NCT02752620|OTHER|Osteopathic Manipulative Treatment|
57728457|NCT02752620|OTHER|Exercise Therapy|
57728458|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
57728459|NCT00223418|DRUG|aripiprazole|
57728460|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
57728461|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
58283240|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
57728462|NCT04134663|DRUG|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
57728463|NCT04134663|DRUG|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
58283241|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
58283242|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
58283243|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
58283244|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
58283245|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
58283246|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
58283247|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
58283248|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
58283249|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
58398100|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
58398101|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
58069811|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
58069812|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
58069813|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
58069814|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
58069815|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
57930322|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
58069816|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
58069817|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
58069818|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
58069819|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
57728464|NCT04134663|DRUG|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
57728465|NCT05469568|OTHER|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
58069820|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
58069821|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
58069822|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
58069823|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
58069824|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
57728466|NCT05469568|OTHER|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
58283250|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
57728467|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
57930323|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
57930324|NCT02852161|DEVICE|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
58283251|NCT01247675|DRUG|Omnitrope|s.c., daily injection
57930325|NCT05737134|OTHER|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
57930326|NCT00530868|OTHER|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
58283252|NCT02650492|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
57728468|NCT01289067|DRUG|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
57728469|NCT01274546|DEVICE|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
57930327|NCT00530868|DRUG|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
57728470|NCT01886976|BIOLOGICAL|CART-138 cells|
57728471|NCT05020483|DRUG|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
57728472|NCT05020483|DRUG|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
57728473|NCT04666272|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
57728474|NCT04666272|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
57728475|NCT01298791|BEHAVIORAL|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
57728476|NCT01298791|BEHAVIORAL|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
57728477|NCT01281358|OTHER|HOP-ON|A programme of activities which promote motor development
57728478|NCT01281358|OTHER|SMILES|Details are provided on ways for parents to interact with their premature infants
57728479|NCT01153646|GENETIC|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
57728480|NCT00004179|BIOLOGICAL|rituximab|
57930328|NCT04166383|BIOLOGICAL|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
58283253|NCT01482234|BEHAVIORAL|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
58283254|NCT04282837|DIAGNOSTIC_TEST|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
58283255|NCT05857800|OTHER|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
58283256|NCT01875263|DRUG|Cloxacilin|2g/4 hours i.v., 5 days
58283257|NCT01875263|DRUG|Cloxacillin|2g/4h 14 days Standard therapy
58283258|NCT01875263|DRUG|Levofloxacin|500 mg v.o./24h, 9 days
57728481|NCT00004179|DRUG|CHOP regimen|
57728482|NCT00004179|DRUG|cyclophosphamide|
57728483|NCT00004179|DRUG|doxorubicin hydrochloride|
57728484|NCT00004179|DRUG|prednisone|
57728485|NCT00004179|DRUG|vincristine sulfate|
57728486|NCT00270491|DRUG|Paclitaxel|
57728487|NCT00270491|DRUG|Capecitabine|
57728488|NCT01286259|DRUG|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
57728489|NCT02187757|DIETARY_SUPPLEMENT|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
57728490|NCT02187757|DIETARY_SUPPLEMENT|Placebo|
57728491|NCT06634563|OTHER|mindfulness meditation|the patients will receive mindfulness meditation in the form of Attention-focusing technique (body scan, directing attention throughout the body in a relaxed, supine state) guided by audiotapes. Relaxing every part of the body by guided audiotape from head to toes and Sitting meditation (systematically directing attention to breath) guided by audiotapes. Relaxing deep rhythmic breathing with concentration on every breath.
57728492|NCT06634563|OTHER|cognitive behavioral training|Training sessions will include three cognitive training tasks each of them target a particular core cognitive capability and are grouped into three categories by target domain: memory (working memory), attention (selective attention), and problem solving (logical reasoning) through these games (organic order and fuse clues for logical reasoning training, lost in migration, trouble brewing, assist ants and train of thought for attention training and memory match and memory match one drive for working memory training).
57728493|NCT04159688|DRUG|Alcohol|Alcohol Challenge
57728494|NCT06634654|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty is performed using conventional surgical techniques.
57930329|NCT04166383|DRUG|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
57930330|NCT00648089|DRUG|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
57930331|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
58398102|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
57930332|NCT06032338|OTHER|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
57930333|NCT06032338|OTHER|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
57930334|NCT06032338|OTHER|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
58398103|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
57728495|NCT06634654|DIAGNOSTIC_TEST|Multifaceted diagnostic assessments|Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.
57930335|NCT00611962|DRUG|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
58283259|NCT05034289|BEHAVIORAL|PINPOINT Digital Educational Tool|"The intervention prototype called the PINPOINT Digital Educational Tool will be comprised of four main sections that include information about: 1) precision oncology; 2) clinical trials; 3) Learn More screens; and 4) discussion points and questions for the treating clinician. The intervention prototype will also include a search function, short videos of patient testimonials, patient-provider interaction about immunotherapy and clinical trials, as well as a list of questions/concerns that the patient could print (or save electronically) and take with them to their provider visit. An optional chatbot will be available in the corner of the screen. Users can ask the chatbot questions about any of the material on the website or request additional information. The chatbot will also be able to help patients search for molecularly targeted and immunotherapy clinical trials and offer additional resources (such as websites and online support groups)."
58283260|NCT01680952|DRUG|A) TEST|"1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
58283261|NCT01680952|DRUG|B) CONTROL|"1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
58283262|NCT06378203|OTHER|tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)|"A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system."
58283263|NCT05011578|RADIATION|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
58283264|NCT02915250|DRUG|BioChaperone® Combo|Injection of BioChaperone® Combo
58283265|NCT02915250|DRUG|Humalog® Mix25|Injection of Humalog® Mix25
58283266|NCT02915250|DRUG|Humalog®|Injection of Humalog®
57728496|NCT06634654|BEHAVIORAL|Follow-ups|Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.
57728497|NCT06634654|GENETIC|Genetic screening|Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
57728498|NCT06074094|DRUG|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
57728499|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
57728500|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
57728501|NCT04389840|DRUG|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
57728502|NCT04389840|DRUG|Placebo|0.9% Normal Saline
58283267|NCT02915250|DRUG|Lantus®|Injection of Lantus®
57728503|NCT02024334|DRUG|Leflunomide|
58283268|NCT02915250|DRUG|Placebo|Injection of 0.9% NaCl
58283269|NCT03099226|DRUG|Placebo|Placebo blue hard gelatine capsules
57728504|NCT01217931|DRUG|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
57930336|NCT04011228|DIAGNOSTIC_TEST|Blood sampling|After a fasting period over night blood samples will be taken.
57930337|NCT04011228|DIAGNOSTIC_TEST|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
58283270|NCT03099226|DRUG|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
58283271|NCT04826835|BEHAVIORAL|Prehabilitation intervention|"Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care."
58283272|NCT04826835|BEHAVIORAL|Health education control|"Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care."
58283273|NCT06063161|BEHAVIORAL|Music therapy intervention|Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.
58283274|NCT06063161|OTHER|Non-guided music listening|Participants will listen to generic music playlists.
58283275|NCT06063161|OTHER|Standard of care|placebo arm, routine standard of care
58283276|NCT01912053|RADIATION|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
58283277|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under Lidocaine alone|In this conventional procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.
58283278|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under a combination of Lidocaine and Ropivacaine|In this experimental procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 18 mL + ropivacaine 7.5 mg/mL 2 mL or 15 mg. For a total of 20 mL: lidocaine 9mg/mL, ropivacaine 0.75 mg/mL, adrenaline 0.005 mg/mL
58283279|NCT01891682|OTHER|Observational|Observational, Translational non-treatment study
58283280|NCT02522793|OTHER|No intervention; this is an observational study|
58283281|NCT03993977|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
58283282|NCT03993977|OTHER|Conventional treatment|Clinical judgement and conventional coagulation tests
58283283|NCT05761119|OTHER|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
58283284|NCT00003367|DIETARY_SUPPLEMENT|green tea|
58283285|NCT00003367|DIETARY_SUPPLEMENT|soy protein isolate|
58283286|NCT00003367|DIETARY_SUPPLEMENT|vitamin E|
58283287|NCT03699072|DEVICE|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
58283288|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
58283289|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
57930338|NCT04011228|DIAGNOSTIC_TEST|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
58283290|NCT03286660|DIAGNOSTIC_TEST|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise"
58283291|NCT02629042|PROCEDURE|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
58283292|NCT02629042|DRUG|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
58398104|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
57728505|NCT01217931|DRUG|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
58283293|NCT05665426|OTHER|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
58283294|NCT05665426|OTHER|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
58283295|NCT01114295|DEVICE|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
58283296|NCT01114295|RADIATION|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
58283297|NCT00568217|DRUG|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
57728506|NCT01217931|DRUG|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
57728507|NCT05103761|OTHER|Study diet|A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
57728508|NCT05103761|OTHER|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
57728509|NCT02293187|DIETARY_SUPPLEMENT|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
57728510|NCT02293187|OTHER|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
57728511|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
57728512|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
57728513|NCT00107419|DRUG|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
57728514|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
57728515|NCT01513850|DRUG|Hepabulin IV|I.V.
57728516|NCT01131312|DEVICE|Thinprep|Pap test
57728517|NCT01131312|DEVICE|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
57728518|NCT01131312|PROCEDURE|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
57728519|NCT01259713|DRUG|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
57728520|NCT01259713|DRUG|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
57728521|NCT02998242|DRUG|Apatinib|
57728522|NCT02998242|RADIATION|SBRT to symptomatic bony metastatic bony site(s)|
57728523|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
57728524|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
57728525|NCT06530316|DRUG|RET Inhibitor|RET inhibitors for neoadjuvant treatment
57728526|NCT06530316|PROCEDURE|Surgery|Operable patients receive surgery after neoadjuvant therapy
57930339|NCT04471948|DEVICE|Fractional picosecond 1064 nm laser|The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
57930340|NCT03531281|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
57930341|NCT03531281|DRUG|Cyclophosphamide|Given IV
57930342|NCT03531281|DRUG|Etoposide|Given IV
58283298|NCT04452552|OTHER|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
58398105|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
58283299|NCT01760213|OTHER|CBT delivered via Internet|
58283300|NCT03485703|DRUG|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
58283301|NCT03485703|DRUG|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
58283302|NCT02627482|DEVICE|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
58283303|NCT02086955|BEHAVIORAL|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
58283304|NCT01207011|DRUG|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
58283305|NCT01207011|DRUG|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
58283306|NCT04264754|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
58283307|NCT01359020|DRUG|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
58283308|NCT00634296|OTHER|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
58283309|NCT02273128|GENETIC|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
58283310|NCT05054816|DEVICE|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
58283311|NCT05054816|DEVICE|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
58283312|NCT05054816|DEVICE|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
58398106|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
57930343|NCT03531281|DRUG|Goat Milk|Given human lysozyme goat milk PO
57930344|NCT03531281|OTHER|Laboratory Biomarker Analysis|Correlative studies
57930345|NCT03531281|BIOLOGICAL|Palifermin|Given IV
58283313|NCT05307003|DRUG|Trazodone|Medication used to treat ICU delirium
58283314|NCT05307003|DRUG|Quetiapine|Medication used to treat ICU delirium
58283315|NCT01515696|DRUG|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
58283316|NCT01515696|DRUG|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
58283317|NCT02657824|OTHER|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
58283318|NCT01643486|OTHER|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
58398107|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
58398108|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
58398109|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
58398110|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
58398111|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
58398112|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
58398113|NCT04433741|DRUG|Placebo|Placebo administered intravenously
58398114|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
58398115|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
58398116|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
57930346|NCT03531281|DRUG|Sirolimus|Given PO
58069825|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
58283319|NCT01643486|OTHER|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
58283320|NCT02840773|OTHER|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
58283321|NCT02840773|OTHER|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
57930347|NCT03531281|DRUG|Tacrolimus|Given IV and PO
58283322|NCT02840773|OTHER|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
58283323|NCT02840773|OTHER|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
57930348|NCT03531281|RADIATION|Total-Body Irradiation|Undergo FTBI
57930349|NCT00698464|DRUG|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
57930350|NCT05317988|BEHAVIORAL|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
57930351|NCT05317988|BEHAVIORAL|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
58283324|NCT02840773|OTHER|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
58283325|NCT00860080|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
57930352|NCT05343897|BEHAVIORAL|Low intensity exercise - Ping-Shuai Gong (PSG)|Participants were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
58398117|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
57728527|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
57728528|NCT04631822|PROCEDURE|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
57930353|NCT05343897|BEHAVIORAL|Low intensity exercise - Arm-Swing Exercise (ASE)|Participants were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
57930354|NCT03613662|DRUG|SP-102|Injection
57930355|NCT05821530|DEVICE|HFIT|At least 1 hour daily for 4 weeks
57930356|NCT05821530|DEVICE|TENS|At least 1 hour daily for 4 weeks
57930357|NCT05821530|OTHER|Control|Users will continue to use the digital MSK program as needed
57930358|NCT03916289|OTHER|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
57930359|NCT00288795|OTHER|Massage Therapy|Therapeutic Touch
57930360|NCT00288795|OTHER|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
58069826|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
58069827|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
58069828|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
58069829|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
58069830|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
58398118|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
58398119|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
58398120|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
58398121|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
58283326|NCT00860080|DRUG|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
58398122|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
58398123|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
58283327|NCT01394341|DRUG|Liraglutide|Daily sc. injection, individual dosage
58283328|NCT04656184|DRUG|ANAKINRA|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
58398124|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
58398125|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
58398126|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
58398127|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
58398128|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
58398129|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
58398130|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
57930361|NCT02592018|DRUG|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
57930362|NCT03558022|DIETARY_SUPPLEMENT|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
57930363|NCT03558022|DIETARY_SUPPLEMENT|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
58069831|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
58069832|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
58069833|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
58069834|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
58069835|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
58069836|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
58069837|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
58398131|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
58069838|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
57930364|NCT03296462|OTHER|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
57930365|NCT03296462|OTHER|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
57930366|NCT00395551|DRUG|ranibizumab|0.5mg intravitreal injection
57930367|NCT04382196|OTHER|Online survey|An online survey will be administered
57930368|NCT03778814|BIOLOGICAL|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
57930369|NCT02827240|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
57930370|NCT05488236|OTHER|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
58069839|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
57930371|NCT00378833|DRUG|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
57930372|NCT00378833|DRUG|niacin|Duration of Treatment: 18 Weeks
57930373|NCT02243098|DRUG|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
57930374|NCT02243098|DRUG|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
58283329|NCT04656184|DRUG|Intravenous immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
57930375|NCT02243098|DRUG|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
57930376|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
57930377|NCT01542268|DRUG|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
57930378|NCT01542268|DRUG|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
57930379|NCT04226807|OTHER|Early Postpartum Phone Call|Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
57930380|NCT00038584|DRUG|SCH66336|
57930381|NCT06050954|DRUG|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
57930382|NCT06050954|DRUG|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
57930383|NCT06050954|DIAGNOSTIC_TEST|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
57930384|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
57930385|NCT00146328|DRUG|Tipranavir|
57930386|NCT06273605|OTHER|Egg Ladder|12 month protocol of graded and gradual egg introduction
57930387|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
58095394|NCT06627244|DRUG|Tebentafusp|Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
58283330|NCT02131116|BEHAVIORAL|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
58283331|NCT02131116|BEHAVIORAL|Treatment as Usual|Treatment as Usual
58398132|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
58398133|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
57930388|NCT06418854|OTHER|Questionnaire|Adapted design questionnaire to estimate the vaccine hesitancy specifically for dengue vaccine
58283332|NCT01883661|BIOLOGICAL|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
58283333|NCT00323076|DRUG|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
58283334|NCT00479115|DRUG|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
58283335|NCT00479115|DEVICE|AmCell CliniMACs|CD34+ cell selection from peripheral collection
58283336|NCT02283580|OTHER|Single limb|"Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
58283337|NCT02283580|OTHER|Two limb|"Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
58283338|NCT02253381|PROCEDURE|Right|Right lateral decubitus position during spinal anesthesia
58283339|NCT02253381|PROCEDURE|Left|Left lateral decubitus position during spinal anesthesia
58283340|NCT04891926|DIAGNOSTIC_TEST|ICIQ FLUTS Questionaires|Questionnaire observing the impact on voiding disfunctions
58283341|NCT04891926|DIAGNOSTIC_TEST|Frequency Volume Chart|Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency
58283342|NCT04891926|DIAGNOSTIC_TEST|Renal Function Profile|The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.
58283343|NCT04891926|DIAGNOSTIC_TEST|Blood Analysis|Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
58283344|NCT05964829|DEVICE|Cionic Neural Sleeve NS-100|The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
58283345|NCT05964829|DEVICE|Actigraph accelerometer|Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip.
57930389|NCT04793620|OTHER|TQL1055|Semisynthetic saponin adjuvant
57930390|NCT04793620|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis vaccine
58283346|NCT04736095|DIAGNOSTIC_TEST|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
58283347|NCT04736095|DIAGNOSTIC_TEST|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
58283348|NCT02076815|DRUG|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
58283349|NCT02076815|DRUG|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
58283350|NCT01593449|BEHAVIORAL|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
58283351|NCT02890563|DEVICE|Class II Compression Stockings|
58283352|NCT04406116|DEVICE|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
58283353|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts supplemented with L. Rhamnosus GG|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
58283354|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
57930391|NCT06396650|DEVICE|Home-based training|"1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another."
57930392|NCT06396650|DEVICE|Lab-based training|In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
57930393|NCT03382652|DEVICE|Metal-on-Metal Articulation|\<Metal-on-Metal Articulation\>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component\>:Continuum Acetabular Shell, \<Femoral Component\>: Zimmer® M/L Taper Hip Stem
57930394|NCT02818920|DRUG|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
58069840|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
58069841|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
58069842|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
58069843|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
58069844|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
58398134|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
58398135|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
58398136|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
58398137|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
58069845|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
58069846|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
58069847|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
58095395|NCT06627244|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
57930395|NCT04307277|DRUG|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
57930396|NCT04307277|OTHER|Standard of care|Surgical excision with external radiotherapy (if applicable)
57930397|NCT05503563|PROCEDURE|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
58283355|NCT01724944|PROCEDURE|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
58283356|NCT02644447|BIOLOGICAL|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
57930398|NCT05302934|DEVICE|Pheno4U|Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
57930399|NCT05070039|GENETIC|Expression of Cortactin anti body|assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
57930400|NCT04521699|DEVICE|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
58283357|NCT02644447|BIOLOGICAL|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
58283358|NCT04687865|OTHER|Biobank|"For each patient included in the study the following samples will be collected at the indicated time points after transplantation:~* Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.~* Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.~* Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.~* Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction."
58283359|NCT05180890|DRUG|Danavorexton|Danavorexton intravenous infusion.
58283360|NCT05180890|DRUG|Placebo|Placebo intravenous infusion.
58283361|NCT02889146|OTHER|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
58283362|NCT02889146|OTHER|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
58283363|NCT02889146|OTHER|Respiratory therapy|Respiratory therapy according to the service routine.
58283364|NCT06342856|DRUG|co enzyme Q10 , L- Carnitine|Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
58283365|NCT02868736|DEVICE|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
58283366|NCT00640406|DEVICE|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
57930401|NCT01585220|DEVICE|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
58095396|NCT03888131|DRUG|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
58283367|NCT00640406|DRUG|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
58283368|NCT00176514|DRUG|Administration of the antineoplastic|
58398138|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
58095397|NCT03888131|DRUG|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
57930402|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
57930403|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
57930404|NCT05773950|DRUG|fosaprepitant|"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
57930405|NCT05773950|DRUG|normal saline|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."
57930406|NCT05532449|DRUG|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
57930407|NCT05579990|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
57930408|NCT06735885|DEVICE|Matter Neuroscience App|An iPhone smartphone application
57930409|NCT06735885|DEVICE|Stock Photos|Stock Photos
57930410|NCT06735885|OTHER|No Home Training|No Home Training
57930411|NCT05033652|OTHER|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR\<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
58283369|NCT05972642|DEVICE|HIFU-treatment|The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
58283370|NCT06331975|DIAGNOSTIC_TEST|Radiomic signature|Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
58398139|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
58398140|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
58398141|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
57930412|NCT01159912|DRUG|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
57930413|NCT01159912|DRUG|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
57930414|NCT01159912|DRUG|Placebo|Placebo inhalation powder
58069848|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
58069849|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
58283371|NCT05495529|PROCEDURE|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
58283372|NCT04385979|OTHER|Gel|containing herbal Curcumin or NanoCurcumin
58283373|NCT00986323|DEVICE|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
58283374|NCT00986323|DEVICE|Placebo TLA|Placebo TLA (without filtration and TLA function)
58283375|NCT04561986|DRUG|Tocilizumab|Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor
58422750|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
58283376|NCT04625413|BEHAVIORAL|Behavioral: UR-GOAL communication tool|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
58283377|NCT05345678|DRUG|Durvalumab|Dose: 1500mg Route: IV
58283378|NCT05345678|DRUG|Tremelimumab|Dose: 300mg Route: IV
58283379|NCT02517021|DRUG|Pro-netupitant/Palonosetron|
58283380|NCT02517021|DRUG|Netupitant/Palonosetron|
58283381|NCT02517021|DRUG|Dexamethasone|
58283382|NCT00560482|DRUG|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
58283383|NCT00560482|DRUG|Placebo|Identical appearing gelatin capsules containing placebo
58283384|NCT03802734|DEVICE|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
58283385|NCT03860766|OTHER|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
58283386|NCT00193739|DRUG|NACT|3 cycles of neoadjuvant chemotherapy
58283387|NCT00193739|PROCEDURE|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
58283388|NCT00193739|DRUG|Inj.Cisplatin|Concurrent chemo radiotherapy
58283389|NCT00193739|RADIATION|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
58283390|NCT01167725|BIOLOGICAL|bevacizumab|Given IV
58283391|NCT01167725|BIOLOGICAL|cetuximab|Given IV
58283392|NCT01167725|DRUG|FOLFIRI regimen|Given IV
58283393|NCT01167725|DRUG|FOLFOX regimen|Given IV
58283394|NCT01167725|DRUG|capecitabine|Given IV
58283395|NCT01167725|DRUG|fluorouracil|Given IV
58283396|NCT01167725|DRUG|irinotecan hydrochloride|Given IV
58283397|NCT01167725|DRUG|leucovorin calcium|Given IV
58283398|NCT01167725|DRUG|mitomycin C|Given intraperitoneally
58283399|NCT01167725|DRUG|oxaliplatin|Given IV
58283400|NCT01167725|PROCEDURE|therapeutic conventional surgery|Patients undergo cytoreductive surgery
58283401|NCT05126173|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
58283402|NCT03534999|DEVICE|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
58283403|NCT03534999|OTHER|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
58283404|NCT00463008|DRUG|methotrexate|
58283405|NCT00463008|OTHER|pharmacological study|
58283406|NCT05505695|OTHER|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
58283407|NCT05505695|OTHER|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
58283408|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
58283409|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
58283410|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
58283411|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
58283412|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
58283413|NCT01911702|OTHER|Standard fluidic resuscitation.|"Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE\> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
58283414|NCT01911702|OTHER|Volemic small treatment|"Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE\> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be \> 10-15 ml / kg / h an infusion of furosemide should be initiated"
58283415|NCT02652559|DEVICE|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
58283416|NCT02652559|DEVICE|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
58283417|NCT02652559|DEVICE|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
58283418|NCT02652559|OTHER|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
58398142|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
58398143|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
58069850|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
58069851|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
58283419|NCT02652559|OTHER|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
58283420|NCT02044562|DIETARY_SUPPLEMENT|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
58283421|NCT02044562|DIETARY_SUPPLEMENT|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
58283422|NCT01043094|DRUG|Pitavastatin 4mg|Pitavastatin 4mg single dose
58283423|NCT00000809|BIOLOGICAL|Aluminum hydroxide|
58283424|NCT00000809|BIOLOGICAL|QS-21|
58283425|NCT00000809|BIOLOGICAL|MN rsgp120/HIV-1|
58283426|NCT02736708|DEVICE|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
58283427|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
58283428|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
58283429|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
58283430|NCT00768287|BIOLOGICAL|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
58283431|NCT00768287|BIOLOGICAL|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
58283432|NCT01641471|DEVICE|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
58069852|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
58069853|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
58069854|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
58069855|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
58069856|NCT03216499|OTHER|Pharmacological Study|Correlative studies
58069857|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
58069858|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
58069859|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
58069860|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
58283433|NCT01641471|DEVICE|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
58283434|NCT04901234|RADIATION|Standard radiotherapy +/- chemotherapy|No radiotherapy adaptation unless major dosimetric deviation
58283435|NCT04901234|RADIATION|Experimental radiotherapy +/- chemotherapy|Systemic MRI-based radiotherapy adaptation mid-treatment
58283436|NCT02039323|DRUG|Tenofovir|
58283437|NCT02039323|DRUG|Maraviroc|
58283438|NCT02697591|DRUG|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
58283439|NCT01134393|DRUG|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
58283440|NCT04663854|DRUG|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
58283441|NCT04175041|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
57728529|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
57930415|NCT01768988|DRUG|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
58283442|NCT00797940|DRUG|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
58283443|NCT03450408|PROCEDURE|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
58283444|NCT02956707|OTHER|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
58283445|NCT05499871|BEHAVIORAL|Gait retraining intervention|Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.
58283446|NCT05499871|DEVICE|Transition to minimalist footwear.|Participants will receive a running minimalist footwear.
58283447|NCT02134392|BIOLOGICAL|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
57728530|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
57728531|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine"
57728532|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
57728533|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
57728534|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
57728535|NCT06184698|DRUG|liposomal irinotecan|liposomal irinotecan 70 mg/m²
57728536|NCT06184698|DRUG|5-FU|5-FU 2400 mg/m²
57930416|NCT01768988|DRUG|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
57930417|NCT03374085|DRUG|CC-92480|CC-92480
58283448|NCT05436171|OTHER|No intervention|No intervention
58283449|NCT06526325|DEVICE|Enhanced golgi tendon organ stimulation|Enhanced Golgi Tendon Organ Stimulation is a method that can be used by physiotherapists and doctors. The Golgi tendon organ is the proprioceptors located in the tendon adjacent to the myotendinous junction. It is applied using two separate heads, the stimulator and the algometer. The sternocleidomastoideus, platysma, colli longus, capitis longus, scalene, rhomboid major and minor, levator scapulae and trapezius muscles and their tendons will be vibrated with a stimulator for 30 seconds, then 0.5 kilograms of pressure will be applied with an algometer from the origin to the insertion of the muscle in the region at 0.5 centimetre intervals at an angle of 90 degrees.
58283450|NCT04039425|PROCEDURE|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
58283451|NCT00157001|PROCEDURE|Photopheresis Post Angioplasty|
58283452|NCT06212570|DEVICE|KeySuite|KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
58398144|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
57930418|NCT03374085|DRUG|Dexamethasone|Dexamethasone
57728537|NCT06184698|DRUG|LV|5-FU 2400 mg/m²
58069861|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
58069862|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
58069863|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
58069864|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
58069865|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
58069866|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
58069867|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
58069868|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
58283453|NCT01065571|DIETARY_SUPPLEMENT|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
58283454|NCT01065571|OTHER|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
58283455|NCT00639925|BIOLOGICAL|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
57930419|NCT02964858|RADIATION|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
58069869|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
58069870|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
58069871|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
58069872|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
58283456|NCT00761371|DRUG|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
58283457|NCT06294158|OTHER|Brightness measurement|Measurement of ambience brightness using lux meters
58283458|NCT06294158|OTHER|Sound level measurement|Measurement of ambience sound levels using sound level meters
58398145|NCT02172573|DRUG|Pramipexole|
58398146|NCT02172573|DRUG|Bromocriptine|
58398147|NCT02172573|DRUG|Placebo pramipexole|
58398148|NCT02172573|DRUG|Placebo bromocriptine|
58398149|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
58069873|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
58398150|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
58398151|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
57728538|NCT06184698|DRUG|Bevacizumab|bevacizumab 5 mg/kg
57728539|NCT04442555|DIETARY_SUPPLEMENT|HVMN Ketone Ester|Commercially available ketone supplement
57728540|NCT04442555|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
58069874|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
58069875|NCT03284931|DRUG|SAGE-217 high dose|high dose
58069876|NCT03284931|DRUG|Placebo|placebo
58069877|NCT03284931|DRUG|SAGE-217 low dose|low dose
58069878|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
57930420|NCT02964858|RADIATION|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
57930421|NCT00004912|DRUG|megestrol acetate|
57930422|NCT00004912|PROCEDURE|physical therapy|
58283459|NCT01179932|OTHER|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
58283460|NCT00311870|DRUG|nisoldipine|
57930423|NCT06140472|BEHAVIORAL|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
57930424|NCT06140472|BEHAVIORAL|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
57930425|NCT05520645|DRUG|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
58069879|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
58069880|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
58069881|NCT02176031|DRUG|Natalizumab|
58069882|NCT02176031|DRUG|Methylprednisolone|
58283461|NCT00311870|DRUG|lisinopril|
58398152|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
58398153|NCT00970892|DRUG|Warfarin dose titration|Dosage
58398154|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
58398155|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
57930426|NCT05520645|DRUG|propofol|use propofol for anesthesia induction in hysteroscopic surgery
57930427|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
57930428|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
57930429|NCT02515578|OTHER|Enhanced practice transformation support|
57930430|NCT02515578|OTHER|Standard practice transformation support|
57930431|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
57930432|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
58069883|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
58069884|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
58069885|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
58069886|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
58069887|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
58069888|NCT01733394|DRUG|lamotrigine|
58069889|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
58069890|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
58398156|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
57930433|NCT06734884|DRUG|Benralizumab 30 MG/ML [Fasenra]|Subcutaneous injection 30 mg at day 2, week 4 and week 8.
57930434|NCT06734884|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Subcutaneous injection at day 2, week 4 and week 8
58283462|NCT05573178|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
58283463|NCT02794506|DRUG|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
58283464|NCT02794506|DRUG|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
58283465|NCT01027377|DRUG|rFVIIIFc|Single dose
58398157|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
57930435|NCT02642484|DRUG|Gabapentin|Gapapentin twice daily
57930436|NCT02642484|DRUG|Calcium Carbonate|calcium carbonate twice daily
57930437|NCT04510688|DRUG|Cabozantinib|Observation of treatment with Cabozantinib
58069891|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
58283466|NCT01027377|DRUG|rFVIIIFc|Single dose
58283467|NCT02217670|DRUG|Metformin 1000 mg granules|
58283468|NCT02217670|DRUG|Metformin 1000 mg film-coated tablets|
58283469|NCT01210014|DRUG|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
58283470|NCT01210014|DRUG|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
58283471|NCT05720195|DIAGNOSTIC_TEST|ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC
58283472|NCT05205200|DRUG|SHR-1316|PD-L1 antibody
58283473|NCT05205200|DRUG|SHR6390|CDK4/6 inhibitor
58283474|NCT05205200|DRUG|Nab paclitaxel|Albumin bound paclitaxel
58283475|NCT05205200|DRUG|SERD|Fulvestrant
58283476|NCT05205200|DRUG|AI|aromatase inhibitor
58398158|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
58398159|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
58398160|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
58398161|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
58398162|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
58069892|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
58069893|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
58069894|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
58069895|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
58069896|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
58283477|NCT05163938|DEVICE|REThink Therapeutic Game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
58398163|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
58398164|NCT03438279|OTHER|Non-Interventional|Non-Interventional
58398165|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
58398166|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
58398167|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
58398168|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
58398169|NCT01760538|BEHAVIORAL|Exercise training|exercise training
58398170|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
57930438|NCT05629650|BEHAVIORAL|Tai Chi for memory|The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
58069897|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
58069898|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
58283478|NCT05163938|DEVICE|Treatment as Usual|Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
58283479|NCT00703326|BIOLOGICAL|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
58283480|NCT00703326|DRUG|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
58283481|NCT00703326|OTHER|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
58283482|NCT05633628|BEHAVIORAL|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
58283483|NCT01100632|DIETARY_SUPPLEMENT|Ginseng, vitamins, minerals|2 capsules per day
58283484|NCT01100632|OTHER|Placebo - Gelatin capsule|2 capsules per day
58283485|NCT00920413|DIETARY_SUPPLEMENT|Vitamin C|vitamin C 500mg orally once a day
58283486|NCT00920413|DIETARY_SUPPLEMENT|placebo|
58283487|NCT04193553|DRUG|Lenvatinib|"Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met."
58283488|NCT04193553|DRUG|Placebo|"Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm."
58283489|NCT04193553|OTHER|Best supportive care|At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy...
58283490|NCT01131390|DEVICE|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
58283491|NCT00694356|BIOLOGICAL|Dalotuzumab|IV infusion
58283492|NCT03579823|DRUG|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
58398171|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
58398172|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
58398173|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
58398174|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
58398175|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
58069899|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
58069900|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
58069901|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
58283493|NCT03579823|DRUG|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
58283494|NCT05471427|DRUG|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
58283495|NCT05461352|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
58398176|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
58398177|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
58283496|NCT05461352|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
58283497|NCT04477967|OTHER|No intervention|There are no interventions because it is a protocol study
58283498|NCT01089452|DRUG|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
57930439|NCT02455934|DIETARY_SUPPLEMENT|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
58283499|NCT01089452|DRUG|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
57930440|NCT05452096|BEHAVIORAL|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
57930441|NCT03920150|DRUG|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
57930442|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
57930443|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
57930444|NCT06707636|BEHAVIORAL|Experimental: Black Women's Stress and Wellness (B-SWELL) arm|The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
57930445|NCT06707636|BEHAVIORAL|Active Comparator: Wellness (WE) arm|This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.
57930446|NCT06735287|PROCEDURE|bladder sparing set|after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered
57930447|NCT06735287|PROCEDURE|RC|Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
57930448|NCT04681248|DRUG|DKN-01|Administered by IV infusion
57930449|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
57930450|NCT02950402|OTHER|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
57930451|NCT02950402|OTHER|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
58283500|NCT01089452|DRUG|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
57930452|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
57930453|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
57930454|NCT02500381|DRUG|SRP-4045|SRP-4045 solution for IV infusion
57930455|NCT02500381|DRUG|SRP-4053|SRP-4053 solution for IV infusion
57930456|NCT02500381|DRUG|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
57930457|NCT04244487|PROCEDURE|laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation|"The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm."
58283501|NCT05249387|DRUG|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
58283502|NCT05249387|DRUG|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
57728541|NCT06175819|OTHER|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
57930458|NCT06735989|OTHER|Lecture on moral reasoning|One and a half-hour long lecture on moral justification and moral reasoning
57930459|NCT06735989|OTHER|Lecture on logical reasoning|One and a half-hour long lecture on logical and argumentative principles
57930460|NCT04628468|DEVICE|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
57930461|NCT04628468|OTHER|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
58283503|NCT05249387|DRUG|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
58283504|NCT05249387|DRUG|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
58283505|NCT02290925|DRUG|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
57930462|NCT01958190|DRUG|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
58283506|NCT02290925|DIETARY_SUPPLEMENT|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
58283507|NCT00878579|DEVICE|PDS System|Percutaneous Dynamic Stabilization System
58283508|NCT00878579|DEVICE|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
58283509|NCT01830907|DIETARY_SUPPLEMENT|carbohydrates|
58283510|NCT01830907|DIETARY_SUPPLEMENT|vitamins|
57728542|NCT01640158|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
57728543|NCT01640158|OTHER|Commercially available computerized training|Commercially available computerized training, up to 65 hours
57728544|NCT06635564|DIAGNOSTIC_TEST|Viscoelastic testing|viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
57728545|NCT04616651|BEHAVIORAL|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
57728546|NCT04616651|BEHAVIORAL|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
57728547|NCT04616651|BEHAVIORAL|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
57728548|NCT00354354|DRUG|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
57728549|NCT05203419|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
57728550|NCT05203419|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
57728551|NCT01299493|OTHER|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
57728552|NCT04026100|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
57728553|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
57930463|NCT01958190|DRUG|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
58283511|NCT02707900|DRUG|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
58283512|NCT02707900|BIOLOGICAL|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
58283513|NCT06106672|DRUG|CNP-106|CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
57728554|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
57728555|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
57728556|NCT01318889|DRUG|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
57930464|NCT05320250|OTHER|Single saliva collection|1 ml of saliva will be collected with Salivette swabs.
57930465|NCT05320250|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects diagnosed with PD will undergo assessments and saliva sampling before starting rehabilitation treatment (T0), at the end of treatment (T1) and 3 months after the end of treatment (T2).
58095398|NCT02944682|OTHER|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
58283514|NCT06106672|OTHER|Placebo|CNP-106 Placebo
58283515|NCT02898636|OTHER|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
58283516|NCT01720485|DRUG|Desloratadine + Prednisolone|1 tablet 3 times a day
58283517|NCT01720485|DRUG|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
58283518|NCT02118350|BEHAVIORAL|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
57728557|NCT03207529|DRUG|Alpelisib|Given PO
57728558|NCT03207529|DRUG|Enzalutamide|Given PO
57728559|NCT05124457|DRUG|Insulin Detemir|Patients are to receive insulin detemir
57728560|NCT05124457|DRUG|Insulin NPH|Patients are to receive insulin NPH
57728561|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
57728562|NCT06403592|OTHER|optic nerve sheath diamater|Measurement of optic nerve sheath diameter
57728563|NCT05990062|DEVICE|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
58283519|NCT05742191|OTHER|Daylight Savings time transitions|Daylight Savings time transitions.
58283520|NCT03333486|DRUG|Cyclophosphamide|Given IV
58283521|NCT03333486|DRUG|Fludarabine Phosphate|Given IV
57930466|NCT01829425|DRUG|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
57930467|NCT01829425|BEHAVIORAL|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
57930468|NCT05553704|DRUG|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
57930469|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
57930470|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
57728564|NCT02311179|DEVICE|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
57728565|NCT02311179|DEVICE|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
57728566|NCT05877001|DRUG|Tislelizumab|200mg, IV, Q3W
57728567|NCT05877001|DRUG|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
57728568|NCT05877001|OTHER|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
57930471|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
57930472|NCT01852604|DRUG|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
57930473|NCT01852604|DRUG|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
58069902|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
58069903|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
58283522|NCT03333486|OTHER|Laboratory Biomarker Analysis|Correlative studies
58283523|NCT03333486|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
58283524|NCT03333486|RADIATION|Total-Body Irradiation|Undergo TBI
58283525|NCT04276077|OTHER|High-frequency electrical muscle stimulation training|High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks
58283526|NCT04276077|OTHER|Low-frequency electrical muscle stimulation training|Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
57728569|NCT01600300|DEVICE|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
57728570|NCT01600300|DEVICE|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
57728571|NCT01263743|BEHAVIORAL|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
57728572|NCT01263743|BEHAVIORAL|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
58283527|NCT06323395|DRUG|Vizol S LIPID BALANCE eye drops|1 drop 4 times a day
58283528|NCT06323395|DRUG|ophthalmic saline eye drops|1 drop 4 times a day
58283529|NCT06485622|PROCEDURE|open bypass group|After heparinization, the target artery is clamped above and below the anastomosis. The target artery is dissected along the anterior wall, calcium portions or mural thrombus are removed. Graft (autologous or prosthetic graft) is cut obliquely and anastomosis suturing starts with distal angle. Next stage is tunnel creating for graft conduction.
58283530|NCT06485622|PROCEDURE|bare metal stent group|Bare metal stent implantation during the index procedure.
58283531|NCT06485622|PROCEDURE|plain old balloon angioplasty group|Only plain old balloon was used during the index procedure.
57728573|NCT00918294|DEVICE|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
57728574|NCT02621606|DRUG|[11C]MK-6884|IV bolus dose of \~370 MBq \[11C\]MK-6884
58283532|NCT06485622|PROCEDURE|drug-coated balloon group|Drug-coated balloon was used during the index procedure.
58283533|NCT06485622|PROCEDURE|directional atherectomy group|Directional atherectomy (with or without drug-coated balloon) during the index procedure.
57728575|NCT06262035|OTHER|Periodontitis and Peri-implantitis|Defined periodontitis at ≤ 2 non-adjacent teeth AND Defined peri-implantitis at ≤ 1 implant, in function of at least 1 year.
58069904|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
58069905|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
58069906|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
58069907|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
57728576|NCT03737370|DRUG|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
58069908|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
58069909|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
58069910|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
58069911|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
58283534|NCT06485622|PROCEDURE|hybrid repair group|Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery. Arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological). Endovascular revascularization followed.
58283535|NCT03184779|OTHER|Ski and Snowboard Safety Video|The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
58283536|NCT02504047|PROCEDURE|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
58283537|NCT04325165|DEVICE|DBS Implantation|Bilateral implantation of PPN DBS electrodes
58283538|NCT02727179|PROCEDURE|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
58283539|NCT05143606|OTHER|3D-printed airway simulator|Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
58283540|NCT05143606|OTHER|virtual reality software, AirwayEx|Two self-directed training on AirwayEx. With additional training as necessary.
58283541|NCT00004763|DRUG|leuprolide|
58398178|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
57728577|NCT03737370|RADIATION|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
58069912|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
58069913|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
58069914|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
58069915|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
58069916|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
58283542|NCT00004763|DRUG|Ethinyl estradiol/norethindrone|
58398179|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
58069917|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
58069918|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
58069919|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
58069920|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
58069921|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
58398180|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
58398181|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
58398182|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
58398183|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
58095399|NCT06555133|COMBINATION_PRODUCT|yttrium-90 radioembolization|yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
58095400|NCT05565872|BEHAVIORAL|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
58095401|NCT06702306|DIAGNOSTIC_TEST|Ultrasound Surveillance|Lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 and 12 months.
57728578|NCT05348681|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
57728579|NCT05348681|DRUG|Placebo|Matching placebo
57728580|NCT05669391|DIAGNOSTIC_TEST|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
57728581|NCT00127959|DRUG|tenofovir|
57728582|NCT00127959|DRUG|emtricitabine|
57728583|NCT00127959|DRUG|zidovudine|
57728584|NCT00127959|DRUG|efavirenz|
57728585|NCT01133652|DEVICE|Veinviewer|Veinviewer machine
57728586|NCT01133652|DEVICE|Ultrasound|Ultrasound
57728587|NCT01133652|OTHER|Conventional technique|Conventional IV placement by nurses
57728588|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
57728589|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
57728590|NCT02397395|DRUG|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
57728591|NCT02397395|DRUG|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
57728592|NCT04283929|OTHER|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
57728593|NCT04283929|OTHER|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
57728594|NCT04283929|OTHER|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
57728595|NCT02221115|DEVICE|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
57728596|NCT00233935|OTHER|placebo|Given PO
57728597|NCT00233935|DRUG|defined green tea catechin extract|Given PO
57728598|NCT00901290|DRUG|monophasic oral contraceptive|mg, oral dose
57728599|NCT00901290|DRUG|AZD7325|mg, oral dose
57728600|NCT00323102|DRUG|Multihance|
57728601|NCT00775749|DRUG|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
57728602|NCT00775749|DRUG|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
58398184|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
58398185|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
58398186|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
58398187|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
58398188|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
58398189|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
57930474|NCT01852604|DRUG|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
57930475|NCT01852604|DRUG|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
58398190|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
58398191|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
58398192|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
57930476|NCT01852604|DRUG|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
57930477|NCT01852604|BIOLOGICAL|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
58398193|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
58422751|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
57930478|NCT01852604|OTHER|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
57930479|NCT03356171|PROCEDURE|Cardiac Coherence|"* 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
57930480|NCT03356171|PROCEDURE|Adapted Physical Activity|- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
57930481|NCT02705209|OTHER|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
57930482|NCT02705209|OTHER|Placebo Cataplasm|Poultice of Kaolin and Water
57930483|NCT03417518|DRUG|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
57930484|NCT03417518|DRUG|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
57930485|NCT06736145|OTHER|Traditional Physical Therapy|"Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
57930486|NCT06736145|OTHER|Mulligan Glides|"Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.~Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
58095402|NCT05327790|DRUG|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
58095403|NCT05327790|OTHER|Placebo|Placebo
58398194|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
57930487|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
57930488|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
57930489|NCT05555667|DRUG|Remimazolam besylate|Sedation drug
57930490|NCT05555667|DRUG|Propofol|Propofol. Sedation drug
57930491|NCT04243603|BEHAVIORAL|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
57930492|NCT02079012|BEHAVIORAL|10-week walking program|
57930493|NCT05467683|BEHAVIORAL|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
57930494|NCT02774551|BEHAVIORAL|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
57930495|NCT03079232|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
57930496|NCT03079232|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
57728603|NCT01391104|DRUG|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
57728604|NCT01391104|DRUG|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
57728605|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
57728606|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
57728607|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
57728608|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
58283543|NCT02002871|DEVICE|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
58283544|NCT01031004|DEVICE|narafilcon B|contact lens
58283545|NCT01031004|DEVICE|etafilcon A|contact lens
58283546|NCT05331105|DRUG|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
58283547|NCT06178718|DRUG|TNP-2092|The drug will be administered once in each group.
58283548|NCT06178718|DRUG|Placebo|The Placebo will be administered once in each group.
58283549|NCT02139774|BEHAVIORAL|Walk with Ease|A six week walking program by the Arthritis Foundation
58398195|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
58398196|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
58069922|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
58283550|NCT05985330|OTHER|Measurement of FeNO|Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
58283551|NCT00082186|DRUG|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
58283552|NCT01603199|DIETARY_SUPPLEMENT|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
57728609|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
57930497|NCT02215837|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
57930498|NCT02215837|BIOLOGICAL|Ag-D-CIK|8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
57930499|NCT00800943|BIOLOGICAL|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
57930500|NCT05813717|DRUG|BMS-986325|Specified dose on specified days
58069923|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
58283553|NCT03700918|DEVICE|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
58283554|NCT04184596|OTHER|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
58283555|NCT04274075|DRUG|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
58283556|NCT04274075|DRUG|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
58283557|NCT04274075|DRUG|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
58283558|NCT00338221|DRUG|alanyl-glutamine|
58283559|NCT00338221|DRUG|glycine|
58283560|NCT04396145|DIAGNOSTIC_TEST|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
58283561|NCT04708899|BEHAVIORAL|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
58283562|NCT04708899|BEHAVIORAL|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
58283563|NCT01119820|OTHER|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
58283564|NCT01206023|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
58283565|NCT00042653|DRUG|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
57728610|NCT00993447|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
57930501|NCT05813717|DRUG|Placebo|Specified dose on specified days
57930502|NCT00420602|DIETARY_SUPPLEMENT|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
57930503|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
57930504|NCT00365898|DRUG|Hydromorphone Hydrochloride Extended-Release|
57930505|NCT02612025|BEHAVIORAL|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
57930506|NCT04622683|PROCEDURE|Ultrasound|To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
57930507|NCT06516952|DRUG|Povorcitinib|Oral Tablet
57930508|NCT06516952|DRUG|Placebo|Oral Tablet
57930509|NCT01426516|DEVICE|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
58095404|NCT06702813|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
58283566|NCT00042653|DRUG|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
58283567|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
58283568|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 3T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
58398197|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
58398198|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
58398199|NCT02998411|OTHER|Titration|
58398200|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
57930510|NCT01920945|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
57930511|NCT00447850|PROCEDURE|endometrial biopsy|
57930512|NCT01949155|DRUG|OTO-201|Single, intratympanic injection
57930513|NCT01949155|DRUG|Sham|Simulated single, intratympanic injection
58095405|NCT03393312|DEVICE|Transcranial direct current stimulation (tDCS)|Electric current
58095406|NCT02168205|DRUG|Pomalidomide|Capsules
58095407|NCT02168205|OTHER|Caffeine|Capsules
58095408|NCT02168205|OTHER|Tobacco|Cigarettes
58283569|NCT01760447|DRUG|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
58283570|NCT01760447|DRUG|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
58283571|NCT01760447|DRUG|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
58283572|NCT01760447|DRUG|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
58283573|NCT01760447|DRUG|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
58398201|NCT03824678|DRUG|CC-220|CC-220
58398202|NCT00320554|BEHAVIORAL|Durometer analysis|
58398203|NCT05139953|OTHER|No intervention|No intervention
58283574|NCT01760447|DRUG|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
58398204|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
58398205|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
58398206|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
58422752|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
57728611|NCT00993447|BIOLOGICAL|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
58422753|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
57930514|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
58069924|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
58283575|NCT01760447|DRUG|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
58283576|NCT01760447|DRUG|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
58283577|NCT01760447|DRUG|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
58283578|NCT04396522|DEVICE|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
57930515|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
57930516|NCT03025399|DRUG|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
57930517|NCT03025399|DRUG|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
57930518|NCT05207670|DRUG|Mosunetuzumab (Cohorts A-C)|Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
57930519|NCT05207670|DRUG|Mosunetuzumab (Cohorts D-E)|Participants will receive SC mosunetuzumab for up to 34 cycles
57930520|NCT05207670|DRUG|Tocilizumab|Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
57728612|NCT06266923|DRUG|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
57930521|NCT00437671|DRUG|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
57930522|NCT00437671|BIOLOGICAL|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
57930523|NCT00137124|DRUG|L-Arginine|oral administration of L-arginine for 4 weeks
57930524|NCT04376060|DEVICE|Gen-Os®; The soft lamina (OsteoBiol®)|"The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects."
57930525|NCT02556866|DRUG|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
57930526|NCT02556866|DRUG|Prednisone|
57930527|NCT02556866|DRUG|Placebo|
57930528|NCT02225717|PROCEDURE|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
57930529|NCT00419718|DRUG|inhaled human insulin|
58069925|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
57728613|NCT01579344|DRUG|Radioiodine therapy|Radioiodine therapy with NaI131
57930530|NCT01367964|DRUG|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
57930531|NCT05071495|DEVICE|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
57930532|NCT04231136|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
57930533|NCT04231136|DRUG|EAPA115|EAPA115
57930534|NCT04231136|DRUG|RAPA115|RAPA115
57930535|NCT02279823|DRUG|CB-03-01 solution|Investigational drug solution
57930536|NCT02279823|DRUG|Minoxidil Solution 5%|FDA approved marketed product
57930537|NCT02279823|DRUG|Placebo solution|Vehicle solution
57930538|NCT02315599|DRUG|anti-CD19 CAR|
57930539|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
58069926|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
58069927|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
58069928|NCT00005627|DRUG|carboplatin|
58069929|NCT00005627|DRUG|docetaxel|
58069930|NCT00005627|DRUG|estramustine phosphate sodium|
58069931|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
58069932|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
58069933|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
58283579|NCT03445403|OTHER|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
58283580|NCT03216369|OTHER|MRI|MRI perfusion imaging
58283581|NCT02006433|DEVICE|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
58283582|NCT02445742|DRUG|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
58283583|NCT03365518|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
58283584|NCT03365518|BEHAVIORAL|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
58283585|NCT00493311|DRUG|IV Placebo|IV Placebo
58283586|NCT00493311|DRUG|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
58283587|NCT00493311|BIOLOGICAL|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
58283588|NCT01319487|DRUG|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
58283589|NCT01319487|DRUG|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
58283590|NCT01319487|DRUG|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
57930540|NCT04381091|DRUG|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
57930541|NCT03910426|OTHER|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
58069934|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
58069935|NCT00205010|PROCEDURE|Lymphoscintigraphy|
58283591|NCT00298363|DRUG|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
58283592|NCT00298363|DRUG|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
58283593|NCT00298363|DRUG|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
58283594|NCT00298363|DRUG|TDF placebo|Placebo to match TDF QD
58283595|NCT00298363|DRUG|FTC/TDF placebo|Placebo to match FTC/TDF QD
58283596|NCT00298363|DRUG|ETV placebo|Placebo to match ETV QD
58283597|NCT05647720|PROCEDURE|Distalization combined with upper third molars extraction|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
58283598|NCT05647720|PROCEDURE|Distalization without upper third molars extraction|The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
58283599|NCT03066583|BIOLOGICAL|trephination with placebo|trephination under US guidance and placebo injection
58283600|NCT03066583|BIOLOGICAL|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
57930542|NCT03910426|OTHER|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
57930543|NCT03910426|OTHER|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
57930544|NCT03910426|OTHER|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
57930545|NCT03910426|OTHER|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
57930546|NCT04863664|DEVICE|Defibrillation (RV Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
58069936|NCT00026559|DEVICE|Shock Device|Shock Device
58283601|NCT02425462|DRUG|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
58283602|NCT02259686|DRUG|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
58283603|NCT02259686|DRUG|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
58398207|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
58398208|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
58069937|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
58283604|NCT02259686|DRUG|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
58283605|NCT02259686|DRUG|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
58283606|NCT02259686|DRUG|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
58283607|NCT00369772|DRUG|darbepoetin alfa|
58283608|NCT03679819|DEVICE|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
58283609|NCT04956939|DRUG|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
58398209|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
58398210|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
58283610|NCT04956939|DRUG|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
58283611|NCT05541913|OTHER|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
58398211|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
58283612|NCT03801577|DIETARY_SUPPLEMENT|Hepaxa|High concentrate EPA and DHA
58283613|NCT03438864|DEVICE|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
58095409|NCT00954694|DEVICE|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
58283614|NCT03438864|OTHER|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
58283615|NCT03825822|BEHAVIORAL|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
57930547|NCT04863664|DEVICE|Defibrillation (LBBAP Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
57930548|NCT00007813|BIOLOGICAL|filgrastim|
57930549|NCT00007813|DRUG|carboplatin|
57930550|NCT00007813|DRUG|cyclophosphamide|
57930551|NCT00007813|DRUG|etoposide|
57930552|NCT00007813|PROCEDURE|autologous bone marrow transplantation|
57930553|NCT00007813|PROCEDURE|peripheral blood stem cell transplantation|
57930554|NCT05794113|DEVICE|Mobile app - CanImmunize|Using a mobile app
57930555|NCT05794113|DEVICE|Web based notification|Using a web-based version of a survey
58069938|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
58069939|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
58283616|NCT03825822|OTHER|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
58283617|NCT04835883|BIOLOGICAL|CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)|Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
58283618|NCT02173379|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
58283619|NCT02173379|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
58283620|NCT00000256|DRUG|20% N2O|
58283621|NCT00000256|DRUG|40% N2O|
58283622|NCT00000256|DRUG|60% N2O|
57930556|NCT01288872|DRUG|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
57930557|NCT02558192|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
57930558|NCT02558192|DIETARY_SUPPLEMENT|PLACEBO|1 vials q12 for 15 days
57930559|NCT00762749|DRUG|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
57930560|NCT06735495|DRUG|CD19&CD22 bispecific CAR-T cells|Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
57930561|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
57930562|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
57930563|NCT06378411|DEVICE|Music Game Intervention|Use of music to induce improvements in cognitive and motor outcomes.
57930564|NCT05013853|PROCEDURE|Restoration teeth|Remove caries and restore with resin composite
58283623|NCT00000256|DRUG|80% N2O|
57930565|NCT04592913|DRUG|Durvalumab|Human monoclonal antibody
58283624|NCT00551525|RADIATION|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
57930566|NCT04592913|DRUG|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
57930567|NCT04426604|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
57930568|NCT04426604|DIAGNOSTIC_TEST|Laser-induced fluorescence device|Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
57930569|NCT04426604|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
58398212|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
58398213|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
58398214|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
58398215|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
58398216|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
57930570|NCT03589690|DIETARY_SUPPLEMENT|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
57930571|NCT03589690|DIETARY_SUPPLEMENT|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
57930572|NCT00144612|DRUG|MRA(Tocilizumab)|8mg/kg/2weeks
57930573|NCT05581979|DIAGNOSTIC_TEST|68-Ga PSMA PET scan|"On the scheduled visit date for the study,~* An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes.~* PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously."
57930574|NCT01777087|OTHER|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
58069940|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
58283625|NCT00551525|DRUG|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
58283626|NCT00664365|DRUG|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
58283627|NCT00664365|DRUG|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
57930575|NCT00005002|DRUG|Lamivudine/Zidovudine|
57930576|NCT00005002|BIOLOGICAL|HIV-1 Immunogen|
57930577|NCT00005002|DRUG|Nelfinavir mesylate|
57930578|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
58095410|NCT02125734|DRUG|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
58283628|NCT02799121|DEVICE|ReGenerCell™ Autologous Cell Harvesting Device|
57930579|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
57930580|NCT04203862|DRUG|NPC-22|Single administration of low dose NPC-22
57930581|NCT04203862|DRUG|NPC-22|Single administration of low/middle dose NPC-22
57930582|NCT04203862|DRUG|NPC-22|Single administration of middle dose NPC-22
58095411|NCT02125734|DRUG|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
58283629|NCT04552171|BEHAVIORAL|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
58283630|NCT06427629|DEVICE|Imaging of conjunctival goblet cell|After instillation of moxifloxacin and illuminating with a 405nm light source using confocal fluorescence microscopy, conjunctival goblet cell imaging will be performed in patients with ocular surface disease and patients scheduled for ocular surgery without ocular surface disease
58398217|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
58398218|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
58398219|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
58398220|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
57930583|NCT04203862|DRUG|NPC-22|Single administration of middle/high dose NPC-22
57930584|NCT04203862|DRUG|NPC-22|Single administration of high dose NPC-22
57930585|NCT04203862|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
57728614|NCT04700306|BEHAVIORAL|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
57728615|NCT02600130|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
58069941|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
58283631|NCT03990311|OTHER|Sodium Restricted Meals|2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
58283632|NCT03990311|OTHER|Control|Usual Care
58283633|NCT00004500|DRUG|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
58283634|NCT00004500|OTHER|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
57728616|NCT02600130|BIOLOGICAL|Placebo|via peripheral intravenous infusion
57728617|NCT01691300|OTHER|ACT PET/CT|Old tracer but new indication
57728618|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
57728619|NCT01156701|DRUG|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
57728620|NCT01156701|OTHER|No prophylaxis with Relenza|No prophylaxis with Relenza
57728621|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
57728622|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
57728623|NCT00974168|RADIATION|Cumulative BED ≤ 100|Radiation
57728624|NCT00974168|RADIATION|Cumulative BED ≤ 130 Gy2|Radiation
58283635|NCT05363956|DRUG|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
58283636|NCT05363956|DRUG|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
58283637|NCT02822833|PROCEDURE|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
57728625|NCT04622358|DRUG|AD-214-02|1 tablet administered before the breakfast during 7 days
57728626|NCT04622358|DRUG|Rabeprazole|1 tablet administered before the breakfast during 7 days
57728627|NCT03021382|OTHER|data collection, non-intervention|
57930586|NCT00486876|DRUG|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
58283638|NCT02917655|BEHAVIORAL|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
57728628|NCT03750487|BEHAVIORAL|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
57728629|NCT03750487|BEHAVIORAL|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
57728630|NCT04880551|RADIATION|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
57930587|NCT06102603|OTHER|the biobased polyester cast|long arm casting
57930588|NCT06102603|OTHER|the synthetic fiberglass cast|long arm casting
57930589|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
57728631|NCT01203189|DRUG|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
57728632|NCT01203189|DRUG|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
57728633|NCT02855905|OTHER|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
57728634|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
57728635|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
57728636|NCT01223313|DEVICE|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
57930590|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
58069942|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
58069943|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
57930591|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
57930592|NCT01123954|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
57930593|NCT04822168|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
57930594|NCT04822168|OTHER|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
57930595|NCT01970488|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
57930596|NCT01970488|BIOLOGICAL|ABP 501|Administered by subcutaneous injection
57930597|NCT01255852|DRUG|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
57930598|NCT02150330|DRUG|Dehydroepiandrosterone (DHEAS)|
57930599|NCT04212988|PROCEDURE|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
57930600|NCT05010954|DRUG|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
57930601|NCT05010954|DRUG|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
58283639|NCT02917655|BEHAVIORAL|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
58283640|NCT02917655|BEHAVIORAL|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
58283641|NCT02917655|BEHAVIORAL|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
58283642|NCT02917655|BEHAVIORAL|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
58283643|NCT02917655|BEHAVIORAL|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
58283644|NCT02917655|BEHAVIORAL|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
58283645|NCT02917655|BEHAVIORAL|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
58283646|NCT02917655|BEHAVIORAL|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
58283647|NCT02917655|BEHAVIORAL|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
58398221|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
58398222|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
58398223|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
57930602|NCT03818087|BEHAVIORAL|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
57930603|NCT05452850|DIAGNOSTIC_TEST|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
57930604|NCT04094896|DRUG|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
58283648|NCT02917655|BEHAVIORAL|Sessions with the physical educators team|Participate in a extra session group with the physical educators
58283649|NCT02917655|BEHAVIORAL|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
58283650|NCT02917655|BEHAVIORAL|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
58283651|NCT00814593|BIOLOGICAL|lymphokine-activated killer cells|Instilled into the tumor bed cavity
58283652|NCT00814593|DRUG|polifeprosan 20 with carmustine implant|Intracranial placement
58283653|NCT00007995|BIOLOGICAL|filgrastim|
58283654|NCT00007995|BIOLOGICAL|recombinant interferon alfa|
58283655|NCT00007995|BIOLOGICAL|sargramostim|
58398224|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
58398225|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
58398226|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
58398227|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
58283656|NCT00007995|DRUG|busulfan|
58283657|NCT00007995|DRUG|cyclophosphamide|
58283658|NCT00007995|DRUG|melphalan|
58283659|NCT00007995|PROCEDURE|autologous bone marrow transplantation|
58283660|NCT00007995|PROCEDURE|bone marrow ablation with stem cell support|
58283661|NCT00007995|PROCEDURE|peripheral blood stem cell transplantation|
58283662|NCT01118663|DRUG|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
58283663|NCT01118663|DRUG|Acetadote|Acetadote \[old formulation\] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
58283664|NCT02871284|BEHAVIORAL|Exercise|
58283665|NCT06613321|DIAGNOSTIC_TEST|Respiratory function tests before introduction of vasodilator therapy|Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
58283666|NCT06613321|DIAGNOSTIC_TEST|3 month follow up evaluation of response to treatment.|Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
58283667|NCT04453410|OTHER|Questionnaire Quality-of-recovery 15 (QoR-15)|Children will use the questionnaire Quality-of-recovery 15 (QoR-15)
58283668|NCT03934840|DRUG|Cabazitaxel|20 mg/m2 Q 21 days
58283669|NCT03934840|DRUG|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
58283670|NCT03934840|DRUG|Abiraterone|1000 mg PO daily
58283671|NCT03934840|DRUG|Prednisone|5 mg PO daily on chemotherapy completion
58283672|NCT01308463|DEVICE|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
58398228|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
58283673|NCT05963932|DRUG|BMS-986419 DR Capsule|Specified dose on specified days
58283674|NCT05963932|DRUG|BMS-986419 IR Tablet|Specified dose on specified days
58283675|NCT00021645|DRUG|Vitamin E|
58283676|NCT02838875|PROCEDURE|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
58283677|NCT02333994|DEVICE|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
58283678|NCT02333994|OTHER|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
58283679|NCT02150252|DRUG|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
58283680|NCT06435546|DIAGNOSTIC_TEST|Blood samples|Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
58398229|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
58398230|NCT05001152|DRUG|Ozanimod|Taste assessment
58398231|NCT02274480|DEVICE|cardiac MRI with DWI|
57728637|NCT02167633|PROCEDURE|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
58283681|NCT06435546|OTHER|Adherence to anti-cancer therapies questionnaires|GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
58283682|NCT03731208|DEVICE|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~* a tablet with a keyboard and a fingerprint sensor~* two wearable sensors~* a wireless modem~* measuring tape"
58283683|NCT02190123|DRUG|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
58283684|NCT00403026|DRUG|Bevacizumab ( Avastin)|
58283685|NCT04331093|DRUG|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
58283686|NCT02583412|BIOLOGICAL|Bexsero®|Multicomponent meningococcal B vaccine
58283687|NCT02583412|BIOLOGICAL|Havrix®|Hepatitis A vaccine
58283688|NCT00002478|DRUG|etoposide|
58283689|NCT00893529|DIETARY_SUPPLEMENT|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
58283690|NCT00893529|DIETARY_SUPPLEMENT|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
58283691|NCT06476938|OTHER|Gene PilotLX|eHealth decision making tool regarding tumor genomic profiling
58283692|NCT00914498|DRUG|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
58283693|NCT00134758|DRUG|Ursodeoxycholic acid|"During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day"
57930605|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
57930606|NCT03463733|DRUG|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
57930607|NCT03463733|DRUG|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
57930608|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
57930609|NCT01479933|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
57930610|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
57930611|NCT02690779|OTHER|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
57930612|NCT02690779|OTHER|Routine Care Instructions|patients will follow routine care and instructions
57930613|NCT04406623|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
57930614|NCT06375434|OTHER|No intervention|No intervention
57930615|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
57930616|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
57930617|NCT02066051|DEVICE|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
57930618|NCT02066051|PROCEDURE|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
57930619|NCT04357145|OTHER|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
57930620|NCT04357145|OTHER|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
57930621|NCT05432869|OTHER|ES and lifestyle advices|"The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs."
57930622|NCT05432869|OTHER|Lifestyle advices|The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
57930623|NCT04871165|DIAGNOSTIC_TEST|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
58283694|NCT00134758|DRUG|Placebo|"During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day"
57728638|NCT02167633|RADIATION|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
57728639|NCT02167633|RADIATION|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
57930624|NCT04871165|DIAGNOSTIC_TEST|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
57930625|NCT04871165|DIAGNOSTIC_TEST|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
57930626|NCT00772213|PROCEDURE|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
57930627|NCT00595023|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
57930628|NCT04165590|OTHER|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
57930629|NCT02606461|DRUG|Selinexor|Selinexor 60mg
57930630|NCT02606461|DRUG|Placebo|
58069944|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
58069945|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
58283695|NCT05795972|DIETARY_SUPPLEMENT|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
58283696|NCT05795972|OTHER|standard therapy|control group (patients treated also with standard therapy)
58283697|NCT03585517|DRUG|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
57930631|NCT00249353|DRUG|methylphenidate hydrochloride|
58069946|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
58069947|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
58069948|NCT04115020|DRUG|Placebo|Placebo oral suspension
58069949|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
58283698|NCT04745871|DIAGNOSTIC_TEST|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA will be performed to patient by a single intravenous injection.
58283699|NCT00328445|BEHAVIORAL|Positive Action|See publications
58283700|NCT03047564|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
58283701|NCT03047564|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
58283702|NCT00932386|DRUG|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
58283703|NCT00932386|DRUG|normal saline|0.9% normal saline infusing
58283704|NCT02309723|DEVICE|Beta amyloid imaging|
58283705|NCT02080338|DEVICE|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
58283706|NCT05867225|PROCEDURE|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
58283707|NCT06395519|DRUG|ETX-19477|Oral medication taken daily
58283708|NCT04089878|PROCEDURE|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
58283709|NCT04089878|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
58283710|NCT00106834|DRUG|Infliximab|
58095412|NCT05359640|OTHER|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
58283711|NCT03139409|PROCEDURE|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
58283712|NCT03139409|OTHER|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
58283713|NCT00000267|DRUG|Risperidone|
58283714|NCT01916421|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
58283715|NCT00559169|DRUG|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
58283716|NCT01728441|DEVICE|Paclitaxel Eluting Stent|
58283717|NCT01728441|DEVICE|Paclitaxel Eluting Balloon|
58283718|NCT04945564|PROCEDURE|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
58283719|NCT04945564|DEVICE|Oxygen therapy|Patients receive oxygen therapy
58283720|NCT00000548|PROCEDURE|mechanical ventilation|
58283721|NCT06179043|BEHAVIORAL|Nutrient warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars"
57728640|NCT02167633|DRUG|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
57728641|NCT02167633|DRUG|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
57728642|NCT06099171|DRUG|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
57930632|NCT04687150|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
58283722|NCT06179043|BEHAVIORAL|Text-only health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay"
58398232|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
57930633|NCT04687150|OTHER|Colored water|Colored water (placebo)
57930634|NCT05398510|DRUG|SHR-2010 injection|Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
57930635|NCT05398510|DRUG|SHR-2010 injection placebo|Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
57930636|NCT01494350|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
57930637|NCT06026683|DEVICE|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
57930638|NCT01764048|DRUG|Fix protocol|Please see arm description
57930639|NCT01764048|DRUG|medications following demand protocol|Please see arm description
57930640|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
57930641|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
57728643|NCT06099171|DEVICE|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
57728644|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
58283723|NCT06179043|BEHAVIORAL|Graphic health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay"
57728645|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
57728646|NCT06182865|DRUG|Ga-68 Dolacga Injection|Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
57728647|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
57930642|NCT03352011|BEHAVIORAL|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
57930643|NCT03352011|BEHAVIORAL|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
57930644|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
57930645|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
57930646|NCT02072928|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
57930647|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
57930648|NCT04162925|BEHAVIORAL|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
57930649|NCT03447951|DRUG|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
57930650|NCT00799279|BEHAVIORAL|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
57930651|NCT00799279|BEHAVIORAL|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
57930652|NCT04694872|OTHER|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
57930653|NCT04694872|OTHER|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
58095413|NCT06702696|DIETARY_SUPPLEMENT|Black chokeberry (Aronia melanocarpa)|The aronia group, who will consume 30 g of freeze-dried aronia powder (n=25)
58398233|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
57728648|NCT02449538|DRUG|everolimus|everolimus 10 mg qd daily one cycle is 28days.
57728649|NCT03934502|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
57728650|NCT02802345|DRUG|Nintedanib|
57728651|NCT02802345|DRUG|Placebo|
57728652|NCT02802345|DRUG|Sildenafil|
57728653|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
57728654|NCT06370637|OTHER|MASD Control Arm|Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.
57930654|NCT05809128|OTHER|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
57930655|NCT03681886|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
57930656|NCT03681886|PROCEDURE|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
57930657|NCT05788978|OTHER|Scale development|Scale development
58283724|NCT06179043|BEHAVIORAL|Control labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)"
58283725|NCT00709527|DRUG|ARC1905|intravitreal injection
58283726|NCT06611488|OTHER|No Intervention: Observational Cohort|No Intervention as the study is bservational Cohort
58398234|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
57728655|NCT00850616|BIOLOGICAL|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
57728656|NCT00850616|BIOLOGICAL|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
57930658|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
57930659|NCT02627352|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
57930660|NCT02259998|DRUG|Persantin® new formulation|
57930661|NCT02259998|DRUG|Persantin® commercial formulation|
57930662|NCT04258371|DRUG|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
57930663|NCT04258371|DRUG|Placebo oral tablet|Placebo once daily for 12 weeks
57728657|NCT03556657|OTHER|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
57728658|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
57728659|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
57930664|NCT01923116|DRUG|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
57930665|NCT06717867|DIETARY_SUPPLEMENT|Palmitoylethanolamide (PEA)|Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.
57930666|NCT06717867|OTHER|Placebo|Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
58095414|NCT06702696|OTHER|Placebo powder|The placebo group, who will consume placebo powder (n=25).
58095415|NCT06279481|OTHER|Nonpharmacological method|Virtual reality
58283727|NCT05977101|BIOLOGICAL|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
58283728|NCT05977101|OTHER|Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
58283729|NCT01693770|PROCEDURE|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
57728660|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
58283730|NCT01834664|BIOLOGICAL|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
58283731|NCT05315648|PROCEDURE|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
58283732|NCT05709912|BEHAVIORAL|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
58283733|NCT05709912|BEHAVIORAL|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
58283734|NCT03675529|BEHAVIORAL|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
58283735|NCT03401632|OTHER|Enteral nutrition|Enteral nutrition support
58283736|NCT05411991|DIAGNOSTIC_TEST|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
58283737|NCT05411991|DRUG|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.
57728661|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
57728662|NCT01448746|DRUG|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
57930667|NCT02400450|DIETARY_SUPPLEMENT|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
57930668|NCT02400450|DIETARY_SUPPLEMENT|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
57930669|NCT06493981|DRUG|Eltrombopag|Treatment with eltrombopag in a dose of (50-150mg/d)
57930670|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
57930671|NCT06512337|DRUG|Deucravacitinib|As per product label
57930672|NCT02613351|DEVICE|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
57930673|NCT00285077|DRUG|SR57667B|
57930674|NCT04977310|DEVICE|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
57930675|NCT06581263|DEVICE|Meta Quest 3|Meta Quest 3 is a virtual reality headset device
57930676|NCT04170712|OTHER|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
58069950|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
58069951|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
58283738|NCT05411991|DRUG|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
58283739|NCT05411991|DRUG|Oral chlorthalidone OD|In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
58283740|NCT05411991|DRUG|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are \>5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
58398235|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
57728663|NCT04950101|OTHER|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
57930677|NCT00800787|BIOLOGICAL|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly"
57930678|NCT04280965|DRUG|Quetiapine Fumarate|Atypical antipsychotic
57930679|NCT04280965|OTHER|Standard of care meducations|SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
58069952|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
58398236|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
58398237|NCT00599534|DRUG|Montelukast|4 mg oral tablets
58398238|NCT00599534|DRUG|Placebo|5mg tablets
58398239|NCT04622670|OTHER|Media Intervention|Receive DVD
58283741|NCT05411991|OTHER|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are \<4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration \<130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
58398240|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
58398241|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
58398242|NCT04622670|OTHER|Survey Administration|Ancillary studies
58398243|NCT04622670|PROCEDURE|Yoga|Attend yoga class
58398244|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
58398245|NCT03582553|OTHER|Placebo|Cellulose
58398246|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
58398247|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
58398248|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
58283742|NCT05411991|DRUG|Oral potassium supplements|If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels \>4 mmol/L
58283743|NCT05411991|OTHER|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration \<125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
58398249|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
58398250|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
58398251|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
58398252|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
58398253|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
58398254|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
57728664|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
58283744|NCT05411991|OTHER|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa \<80 mmol/L, intravenous diuretics are switched to an oral schedule including:~* Loop diuretics with dose \& frequency at the discretion of the treating physician~* Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~* Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
58398255|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
58398256|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
58398257|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
58398258|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
58398259|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
58398260|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
58398261|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
58398262|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
58398263|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
58398264|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
58398265|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
57728665|NCT02845908|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
57728666|NCT02845908|DRUG|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
57728667|NCT02845908|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
57728668|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
57930680|NCT02841228|RADIATION|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
57930681|NCT02679339|DRUG|CNTX-2022 (lidocaine gel, 40%)|
57930682|NCT02679339|DRUG|Placebo|
57930683|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
57930684|NCT03701763|OTHER|Placebo|Placebo
57930685|NCT03571763|OTHER|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
57930686|NCT00364871|DRUG|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
57930687|NCT04924504|OTHER|No interventions|No interventions
57930688|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening|"The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice."
57930689|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening + FDG PET/CT|The limited cancer screening (as described above) in combination with a FDG PET/CT.
57728669|NCT06173219|COMBINATION_PRODUCT|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
57930690|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
58283745|NCT05411991|OTHER|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
58283746|NCT03956030|OTHER|Contraception Handout|Handout covering contraception options
58283747|NCT03956030|OTHER|Nutritional Handout|Handout covering nutrition
57930691|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
57930692|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
57930693|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
57930694|NCT06736262|DRUG|Briquilimab|No additional details needed
58283748|NCT02797860|DRUG|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
58283749|NCT03332095|DRUG|Doravirine (DOR)|100 mg of DOR administered orally
58283750|NCT03332095|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
58398266|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
58422754|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
58422755|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
57728670|NCT06238323|BEHAVIORAL|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
57930695|NCT00227487|OTHER|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
58069953|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
58069954|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
58069955|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
58283751|NCT03332095|DRUG|Antiretroviral (ARV) medications|Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
58283752|NCT06058273|BEHAVIORAL|Bruni® training|10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R\&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
58283753|NCT06467539|DRUG|DAOIB plus AO|oral, for 24 weeks
58283754|NCT06467539|DRUG|DAOIB plus placebo|oral, for 24 weeks
58283755|NCT00214656|DRUG|Recombinant Activated Factor VII|
57930696|NCT00227487|OTHER|Administration of carbohydrate solution during clinically indicated endoscopy|"* A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
57930697|NCT00227487|OTHER|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
57930698|NCT05191069|OTHER|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
57930699|NCT05191069|OTHER|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
57930700|NCT04260451|OTHER|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
57930701|NCT03733067|DRUG|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
57930702|NCT03733067|OTHER|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
57930703|NCT01291199|DRUG|vardenafil|10 mg p.o. bid for 6 weeks
57930704|NCT01291199|DRUG|Placebo|Placebo p.o. 6 weeks bid
57930705|NCT02414724|DRUG|Gemcitabine Hydrochloride|Given IV
58283756|NCT03181685|DRUG|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
58283757|NCT03181685|DRUG|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
57930706|NCT02414724|OTHER|Laboratory Biomarker Analysis|Correlative studies
57930707|NCT02414724|OTHER|Pharmacological Study|Correlative studies
57930708|NCT02414724|DRUG|Ribociclib|Given PO
57930709|NCT03470675|DRUG|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
57930710|NCT03470675|DRUG|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
57930711|NCT03470675|DRUG|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
58283758|NCT03181685|DRUG|recombinant FSH|Controlled ovarian stimulation (COS)
57930712|NCT00152698|DRUG|Irbesartan|
58283759|NCT03181685|DRUG|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
58283760|NCT04041492|DIETARY_SUPPLEMENT|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
58283761|NCT00121290|DRUG|SJG-136|Given IV
58283762|NCT00121290|OTHER|laboratory biomarker analysis|Correlative studies
58283763|NCT00121290|OTHER|pharmacological study|Correlative studies
58283764|NCT03815435|PROCEDURE|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field.
58398267|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
57728671|NCT01760954|DRUG|Elagolix|Elagolix tablets administered orally
58283765|NCT05184387|OTHER|Blood samples|Collection of blood samples and completion of an electronic Diary (eDiary)
57930713|NCT05082116|DRUG|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
58283766|NCT03058471|DRUG|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
58283767|NCT03058471|DRUG|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
58283768|NCT03058471|DRUG|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
58283769|NCT01905332|OTHER|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
57930714|NCT04694898|BEHAVIORAL|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
57930715|NCT04694898|BEHAVIORAL|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
57930716|NCT01543386|DRUG|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
57930717|NCT00141804|DRUG|Sirolimus|
57930718|NCT00818389|DRUG|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
57728672|NCT03399760|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
57728673|NCT03399760|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
57930719|NCT00818389|DRUG|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
57930720|NCT00818389|DRUG|placebo|an inactive substance
58069956|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
58069957|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
58069958|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
58069959|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
58069960|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
58069961|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
58069962|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
58069963|NCT02028052|DEVICE|22 gauge Vizishot needles|
58069964|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
58283770|NCT01905332|OTHER|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
57728674|NCT06365736|BEHAVIORAL|Contemplating in nature|"Participants will spend 30 minutes in nature per day for 10 times over 14 days.~Each time, participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes."
57728675|NCT06365736|BEHAVIORAL|Walking in nature|Participants will be asked to walk for 30 minutes in nature per day for 10 times over 14 days without further instruction.
57728676|NCT01075074|PROCEDURE|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
57930721|NCT03253939|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
57930722|NCT03253939|PROCEDURE|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
57930723|NCT03540472|DRUG|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
58069965|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
58069966|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
58283771|NCT04403165|PROCEDURE|Nocturnal polysomnography (NPSG)|Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
58283772|NCT04403165|PROCEDURE|Lumbar Puncture (LP)|Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
58283773|NCT04403165|OTHER|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
58398268|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
58398269|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
58398270|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
58398271|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
58398272|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
58069967|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
58069968|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
58283774|NCT04403165|BEHAVIORAL|Psychomotor Vigilance Task (PVT)|Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
58398273|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
58398274|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
58398275|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
58398276|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
58398277|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
58398278|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
58283775|NCT05347693|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."
57728677|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
57728678|NCT05637463|OTHER|No intervention|no intervention was made
57728679|NCT04393701|PROCEDURE|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
57728680|NCT00395044|DRUG|Placebo|Placebo
58069969|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
58069970|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
58069971|NCT01354964|DRUG|Vitamin D|
58069972|NCT01354964|DRUG|Placebo|
57728681|NCT00395044|DRUG|Gabapentin|
57728682|NCT04388982|BIOLOGICAL|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
58069973|NCT00660829|DRUG|Placebo|Placebo
58069974|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
58283776|NCT05347693|DRUG|Local standard of care|Local SoC in the country to be used as per local label
58283777|NCT05937516|DEVICE|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
57930724|NCT04919252|DRUG|Vedolizumab|"* Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
58398279|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
58398280|NCT02578966|BEHAVIORAL|Motivational Interview|
58398281|NCT02578966|OTHER|Traditional health education|
58398282|NCT00776672|DRUG|Fosinopril 40mg Tablets|
58398283|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
58398284|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
58398285|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
58398286|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
57930725|NCT01096888|BEHAVIORAL|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
58398287|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
57728683|NCT04388982|BIOLOGICAL|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
57930726|NCT00685685|DRUG|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
58069975|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
58069976|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
58069977|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
58069978|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
57930727|NCT00685685|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
57930728|NCT00307125|DRUG|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
57930729|NCT00307125|DRUG|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
58069979|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
58069980|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
58069981|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
58069982|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
57930730|NCT06734234|DRUG|GSK4771261|GSK4771261 will be administered.
58398288|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
58422756|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
58069983|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
58069984|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
58069985|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
58069986|NCT01673204|DRUG|Placebo|
58069987|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
58398289|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
58398290|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
58398291|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
58398292|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
58398293|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
58398294|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
57930731|NCT06734234|DRUG|Placebo matching GSK4771261|Placebo matching GSK4771261 will be administered.
58283778|NCT05937516|DEVICE|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
58283779|NCT06486051|DRUG|Fludarabine|30 mg/m\^2/day IV for three consecutive days
58283780|NCT06486051|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for three consecutive days
58398295|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
58398296|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
58398297|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
58398298|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
57930732|NCT01323621|DRUG|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
58398299|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
58398300|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
58398301|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
58398302|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
58398303|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
58398304|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
57930733|NCT01323621|DRUG|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
57930734|NCT01323621|DRUG|Double-dummy placebo|inhalation powder
57930735|NCT01323621|DRUG|Salbutamol as needed|inhalation powder
57930736|NCT05572684|DRUG|NC410|NC410 will be given intravenously (IV) every 2 weeks
57930737|NCT05572684|DRUG|pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
57930738|NCT03445260|OTHER|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
57930739|NCT03445260|OTHER|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
57930740|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
57930741|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
57930742|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
58398305|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
58398306|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
58398307|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
58398308|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
58398309|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
58398310|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
58398311|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
58398312|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
58398313|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
57728684|NCT04388982|BIOLOGICAL|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
57930743|NCT06735443|DRUG|Bupivacaine with Dexmetedomidine|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
58283781|NCT06486051|BIOLOGICAL|WZTL-002 CAR T-cells|"WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy."
58283782|NCT06062095|PROCEDURE|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
57728685|NCT02286544|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
58069988|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
58069989|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
58069990|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
58283783|NCT00045734|DRUG|imatinib mesylate|Given orally
58283784|NCT00045734|OTHER|laboratory biomarker analysis|Correlative studies
58283785|NCT00045734|OTHER|pharmacological study|Correlative studies
58283786|NCT01429441|DRUG|Ocriplasmin|0.125 mg single intravitreal injection
58283787|NCT01429441|OTHER|Sham injection|Sham injection
58283788|NCT01756339|DRUG|Solithromycin|
58283789|NCT01756339|DRUG|Moxifloxacin|
58283790|NCT01756339|OTHER|Placebo to match solithromycin|
58398314|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
58398315|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
58398316|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
58398317|NCT02973204|DRUG|Sorafenib|
58398318|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
58398319|NCT02973204|DRUG|Everolimus|
57930744|NCT06735443|DRUG|Bupivacaine with Tramadol|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
58398320|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
58398321|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
57930745|NCT06734117|DIAGNOSTIC_TEST|Elecsys® Troponin T hs Gen 6|It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.
57930746|NCT06734117|PROCEDURE|Blood sample collection|Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.
57930747|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
57930748|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
58283791|NCT03577379|OTHER|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
58283792|NCT05903638|BEHAVIORAL|Mindfulness-Based Stress Reduction course|8-week, 26-hour, virtual mindfulness course
58283793|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
58283794|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a.|3 months of treatment
58398322|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
58398323|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
58398324|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
58398325|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
58398326|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
58398327|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
58069991|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
58398328|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
58398329|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
58398330|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
58398331|NCT03192280|DEVICE|iPhone 7|Smart phone
58398332|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
58398333|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
57930749|NCT02830997|DEVICE|Stereotactic guidance system|
58398334|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
58398335|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
58398336|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
58398337|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
58398338|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
58398339|NCT00634725|DRUG|capecitabine|
58398340|NCT00634725|DRUG|erlotinib hydrochloride|
58398341|NCT00634725|DRUG|gemcitabine hydrochloride|
58398342|NCT00634725|OTHER|laboratory biomarker analysis|
58398343|NCT00634725|RADIATION|radiation therapy|
58398344|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
58398345|NCT00851981|OTHER|Placebo|TID
58398346|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
57930750|NCT04435379|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
57930751|NCT04435379|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
57930752|NCT02743819|DRUG|Pembrolizumab|Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
57930753|NCT02743819|DRUG|Ipilimumab|Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
57930754|NCT01400581|BEHAVIORAL|Collaborative Care Intervention|See description of Intervention arm
57930755|NCT02231788|DRUG|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
57930756|NCT02231788|DRUG|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
57930757|NCT00152139|PROCEDURE|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
57930758|NCT00152139|DRUG|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
57930759|NCT05541029|BEHAVIORAL|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
57930760|NCT05541029|BEHAVIORAL|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
57930761|NCT05541029|OTHER|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of \>1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
57930762|NCT03606980|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
57930763|NCT03606980|PROCEDURE|Iontophoresis|Iontophoresis on affected knee
57930764|NCT03606980|PROCEDURE|Physical Therapy|Physical therapy of affected knee
57930765|NCT01650285|DRUG|Cabazitaxel|"Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2"
57930766|NCT00160381|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
57930767|NCT00160381|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
57930768|NCT00160381|DRUG|Placebo|Tablet, oral Daily for 12 months
57930769|NCT06735456|OTHER|Mandala|The patient will undergo mandala painting during 1 session of chemotherapy.
57930770|NCT01260727|BIOLOGICAL|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
57930771|NCT01260727|BIOLOGICAL|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
57728686|NCT02286544|DRUG|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
57930772|NCT01260727|BIOLOGICAL|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
57930773|NCT01260727|BIOLOGICAL|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
58398347|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
58398348|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
58398349|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
58398350|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
58398351|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
57930774|NCT05905510|DRUG|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
57930775|NCT05905510|DRUG|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
57930776|NCT05905510|DRUG|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
57930777|NCT03157232|DEVICE|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
57930778|NCT05940610|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
57930779|NCT01521897|BIOLOGICAL|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
57930780|NCT02017379|DRUG|Erythromycin|
57930781|NCT02017379|DRUG|Metoclopromide|
58069992|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
58069993|NCT00282373|DEVICE|mild hypothermia|
58283795|NCT06432907|OTHER|motor tasks|"During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes."
58283796|NCT02448745|DEVICE|Insecticide treated wall lining|Polypropylene non-woven fabric.
58283797|NCT02963129|DRUG|Mupirocin|Mupirocin ointment in the nose for 5 days
58283798|NCT02963129|OTHER|Placebo|Placebo ointment in the nose for 5 days
58283799|NCT02853071|DRUG|Estramustine|
58283800|NCT02853071|DRUG|standard practice|standard practice
58283801|NCT01342783|GENETIC|DNA analysis|
58283802|NCT01342783|GENETIC|RNA analysis|
58283803|NCT01342783|GENETIC|mutation analysis|
58283804|NCT01342783|GENETIC|nucleic acid sequencing|
58283805|NCT01342783|OTHER|laboratory biomarker analysis|
58283806|NCT02865629|DRUG|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
58283807|NCT02263729|DRUG|Losartan|Cozaar
58283808|NCT02263729|DRUG|Placebo|
58283809|NCT05039125|RADIATION|ultrasonic cavitation|"* From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
58283810|NCT00939588|DRUG|Aliskiren/ Valsartan|
58283811|NCT00939588|DRUG|Telmisartan/ Ramipril|
58422757|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
58283812|NCT01375452|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
58283813|NCT01441245|DRUG|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
58283814|NCT04120909|DEVICE|Cardiac resynchronization therapy|Biventricular pacing according to current standards.
58283815|NCT03107559|DIAGNOSTIC_TEST|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
57930782|NCT02728882|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
57930783|NCT05734183|OTHER|MIME|Multisensorial IMmersive Experiences
57930784|NCT05734183|OTHER|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
57930785|NCT00067951|DRUG|rosiglitazone/metformin|
57930786|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
57930787|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
57930788|NCT01012154|DEVICE|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
57930789|NCT02090153|DRUG|S-1|40\~60mg bid，d1\~7 q2W
57930790|NCT02090153|DRUG|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
57930791|NCT05172167|DIAGNOSTIC_TEST|Levels of IgG and IgM SARS-CoV-2 antibodies blood test.|0,1,2 months
57930792|NCT05172167|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2 nasopharyngeal swab|0,1,2 months
57930793|NCT01839721|DRUG|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
57930794|NCT01839721|OTHER|placebo|
57930795|NCT04385888|BEHAVIORAL|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
57930796|NCT05772468|DEVICE|Virtual Reality ('VRelax' VR system)|The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
57930797|NCT04287842|DRUG|Desflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
57930798|NCT04287842|DRUG|Sevoflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
57930799|NCT04287842|PROCEDURE|Cardiac arrest|Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
57930800|NCT02956512|DRUG|Dexibuprofen|Dexibuprofen 300mg
57930801|NCT06441526|DRUG|anti-tumour necrosis factor α antibodies|Biological drug
57930802|NCT06441526|PROCEDURE|Advancement plasty|Surgical closure of the internal opening
57930803|NCT05241782|OTHER|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks"
57930804|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
57930805|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
57930806|NCT01647529|DRUG|Ganciclovir|Treatment with topical ganciclovir ointment
58283816|NCT03596515|OTHER|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
58283817|NCT02102347|OTHER|exercise|
57930807|NCT04363073|DEVICE|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
57930808|NCT04363073|DEVICE|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
57930809|NCT06330883|DIAGNOSTIC_TEST|Prognosis|survival/mortalite
57930810|NCT01479114|DRUG|rh-GCSF|10 ug/kg/day intravenously for 3 days
57930811|NCT01667107|DRUG|Posaconazole|
57930812|NCT01667107|DRUG|Calogen®|
57930813|NCT02827357|OTHER|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
58069994|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
58069995|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
58069996|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
58283818|NCT02102347|OTHER|Phototherapy|
58283819|NCT04279990|OTHER|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
58283820|NCT06408779|PROCEDURE|mitral valve repair|coronary artery bypass grafting concomitant mitral valve repair
57930814|NCT06735027|OTHER|intraarticular corticosteroid injection (IACI)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the glenohumeral joint. The injection site will then be disinfected with an alcohol wipe. A 21, 22, or 23-gauge needle (depending on provider preference) will be advanced into the glenohumeral joint under direct ultrasound visualization. After entry into the glenohumeral joint, a negative aspiration will be performed. At that time, up to 1 mL of 40mg/mL methylprednisolone acetate will be injected be injected into the joint space.
57930815|NCT06735027|OTHER|suprascapular nerve block (SSNB)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the suprascapular nerve in its path at the suprascapular notch. After disinfection of the injection site with alcohol, anatomic landmarks for SSNB as described by Dangoisse et al. \[10\] will be marked with a marking pen. Ultrasound will be utilized to guide the tip of a 21, 22, or 23 gauge (depending on provider preference) needle to the floor of the suprascapular fossa while avoiding neurovascular structures. At that time, a mixture of up to 10 mL of 0.5% bupivacaine and 20 mg triamcinolone will be slowly injected to fill the fascial contents of the suprascapular fossa under direct ultrasound guidance.
57728687|NCT02286544|DRUG|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
57728688|NCT04517721|OTHER|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
57930816|NCT06343012|OTHER|Caring leadership Intervention program|Caring leadership intervention program
57930817|NCT06057545|DRUG|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
57930818|NCT06057545|DRUG|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
57930819|NCT04960423|PROCEDURE|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
57930820|NCT00087750|DRUG|Quetiapine|
57930821|NCT05930782|DRUG|Piperaquine Phosphate|PQP hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
57930822|NCT05930782|DRUG|Piperaquine Phosphate|PQP dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
57930823|NCT00261404|DRUG|TNFerade™|
57930824|NCT03442790|PROCEDURE|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
57930825|NCT03442790|PROCEDURE|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
57728689|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
57930826|NCT00950430|DRUG|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
58283821|NCT05492747|OTHER|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
58283822|NCT02965508|OTHER|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
58283823|NCT02965508|OTHER|Usual Care|Office based care
58422758|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
58422759|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
57930827|NCT00950430|DRUG|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
58398352|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
58398353|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
58398354|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
58398355|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
58398356|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
58283824|NCT00779987|DRUG|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
58283825|NCT00779987|DRUG|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
58398357|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
58398358|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
58398359|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
58398360|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
58398361|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
58398362|NCT05799521|DRUG|Optate|Alkaline Buffer
58398363|NCT05799521|DRUG|Placebo|Normal Saline
58283826|NCT02496039|DRUG|NUEDEXTA®|NUEDEXTA® only
58283827|NCT03297021|DRUG|Ondansetron 4 MG|dose as per arm selection
58398364|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
58398365|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
57728690|NCT03876041|DRUG|solumedrol|intravenous solution for injection
57728691|NCT03876041|DRUG|Dexamethasone phosphate|intravenous solution for injection
58283828|NCT03297021|DRUG|Ondansetron 8mg|dose as per arm selection
58283829|NCT05273229|OTHER|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
58398366|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
58398367|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
58398368|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
58398369|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
58422760|NCT02694497|OTHER|Chlamydia care as usual|
57728692|NCT00737841|DRUG|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
57728693|NCT00737841|DRUG|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
57728694|NCT06526572|DIAGNOSTIC_TEST|Brain wave analysis using electroencephalography (EEG).|Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
57728695|NCT06526572|DIAGNOSTIC_TEST|Numerical rate Scale (NRS)|Asessment of pain with the subjective numercal rate scale method (NRS
58283830|NCT05273229|OTHER|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~* Coordination exercises: normal and lateral parallel walking and walking with obstacles.~* Functional exercises such as climbing stairs, etc.~* Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
58283831|NCT05273229|OTHER|Sham Virtual Gait|only the placebo virtual gait.
58283832|NCT01284751|OTHER|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
58398370|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
58398371|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
58398372|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
58283833|NCT05295199|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
58283834|NCT06351085|BEHAVIORAL|Pre-Visit Planner|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process.
58283835|NCT06351085|BEHAVIORAL|Pre-Visit Planner + MyChart|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process as well as testing if watching educational videos about the Lung Cancer Screening (LCS) process prior to talking to an LVN will help with LCS uptake.
58398373|NCT02661555|OTHER|Aerobic exercise|
58398374|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
58283836|NCT03336814|DRUG|Terlipressin|Administration of terlipressine
58398375|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
58283837|NCT03336814|OTHER|Placebo|Administration of placebo
58398376|NCT04767581|DRUG|KHK7791|oral administration
58283838|NCT00702026|DIETARY_SUPPLEMENT|multispecies probiotic (Ecologic 801)|once daily, 5 gram \[10e9 cfu/gram\]
58283839|NCT00702026|DIETARY_SUPPLEMENT|Placebo|once daily, 5 gram \[10e9 cfu/gram\]
58398377|NCT04767581|DRUG|Placebo|oral administration
58398378|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58398379|NCT05806515|DRUG|Carboplatin|Given IV
58398380|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
58398381|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
58398382|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58398383|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
58283840|NCT00124085|BEHAVIORAL|Disease Management|
58283841|NCT00124085|BEHAVIORAL|Disease Management + Educational Home Visits|
58283842|NCT05885061|DEVICE|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
58283843|NCT05885061|DEVICE|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
58283844|NCT05885061|DEVICE|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
58283845|NCT00170391|BEHAVIORAL|Quarter of an Hour rule|
57728696|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
58283846|NCT05556941|BEHAVIORAL|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
58283847|NCT05556941|BEHAVIORAL|Occupational therapy standard care|Occupational therapy standard care
58283848|NCT02609984|BIOLOGICAL|CMB305|A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
58283849|NCT02609984|BIOLOGICAL|atezolizumab|IV Infusion
58283850|NCT01331707|DEVICE|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
58283851|NCT01331707|DEVICE|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
58283852|NCT02394119|DRUG|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
58398384|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
58398385|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
58398386|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
58398387|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
58398388|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
58398389|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
58398390|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
58398391|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
58398392|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
57930828|NCT00950430|DRUG|Tau (18-F-AV-1451)|"1. PIB PET scan, Tau PET scan and/or FDG PET scan~2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
57930829|NCT04644380|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
57930830|NCT05211310|OTHER|High-Activity Arthroplasty Score (HAAS)|The questionnaire developed by Talbot et al. in 2010 consists of 4 sub-dimensions. 0-18 points can be obtained from the survey. High scores are associated with higher functional ability.
57930831|NCT05211310|OTHER|Western Ontario and McMaster Universities osteoarthritis score (WOMAC)|It is used to evaluate disability in patients with hip and knee osteoarthritis. Each sub-dimension is standardized within the range of 0-100 points, with high scores indicating poor health.
57930832|NCT05211310|OTHER|The Knee injury and Osteoarthritis Outcome Score (KOOS)|It is calculated between 0 and 100 points. 0 points indicate severe knee problem, 100 points no knee problem
57930833|NCT05211310|OTHER|The Forgotten Joint Score-12 (FJS-12)|It evaluates how much an individual can forget an artificial joint during activities of daily living. A total of 100 points can be obtained. A high score is associated with the ability to forget.
57930834|NCT05211310|OTHER|EQ-5D-5L|It is a questionnaire evaluating the quality of life. The higher the total score, the higher the quality of life.
57930835|NCT05211310|OTHER|Numerical pain scale (NPS)|It is the numerical expression of perceived pain intensity. It is rated from 0-10 points. 10 points indicate the highest pain intensity, 0 points the absence of pain.
57930836|NCT03886792|BEHAVIORAL|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
57930837|NCT03886792|BEHAVIORAL|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
57930838|NCT03288870|DRUG|BCD-100|monoclonal antibody to PD-1 receptor
57930839|NCT03288870|DRUG|Docetaxel|Chemotherapy drug (taxane)
57930840|NCT01938807|BEHAVIORAL|CareCoach mobile application to assist in diabetes management|
57930841|NCT06048315|DRUG|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
58398393|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
57930842|NCT06048315|DRUG|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
57930843|NCT03171727|DRUG|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
57930844|NCT06101823|BIOLOGICAL|OpSCF|Monoclonal Antibody
57930845|NCT06101823|BIOLOGICAL|Placebo|Formulation buffer without active agent
57930846|NCT06101823|BIOLOGICAL|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
58283853|NCT02394119|DRUG|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
58283854|NCT03866629|DRUG|Lifitegrast|Lifitegrast ophthalmic solution 5%
58283855|NCT02775292|BIOLOGICAL|Aldesleukin|Given SC
58283856|NCT02775292|DRUG|Cyclophosphamide|Given IV
58283857|NCT02775292|DRUG|Fludarabine Phosphate|Given IV
58398394|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
58398395|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
58283858|NCT02775292|OTHER|Laboratory Biomarker Analysis|Correlative studies
58283859|NCT02775292|BIOLOGICAL|Nivolumab|Given IV
58283860|NCT02775292|BIOLOGICAL|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
58398396|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
58283861|NCT02775292|BIOLOGICAL|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
58283862|NCT02775292|PROCEDURE|Positron Emission Tomography|Correlative studies
58398397|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
58398398|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
58398399|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
58398400|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
58398401|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
58398402|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
58398403|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
58398404|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
58398405|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
58398406|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
58398407|NCT00222235|DRUG|d-cycloserine|
58398408|NCT00222235|DRUG|glycine|
58398409|NCT00222235|DRUG|placebo|
58398410|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
58398411|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
57930847|NCT04706611|PROCEDURE|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
57930848|NCT02311998|DRUG|Bosutinib|Given PO
57930849|NCT02311998|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
57930850|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
57930851|NCT02068365|DRUG|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
58283863|NCT04156386|DIETARY_SUPPLEMENT|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
58398412|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
58398413|NCT03203811|DRUG|HTI-2088|3 dose levels
57930852|NCT00248690|DEVICE|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
58398414|NCT03203811|DRUG|Placebo|placebo oral tablet
58398415|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
58398416|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
58398417|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
58398418|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
58398419|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
58398420|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
58398421|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
58398422|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
58398423|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
58398424|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
58398425|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
57930853|NCT02618824|DRUG|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
57930854|NCT02618824|OTHER|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
58069997|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
58398426|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
58398427|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
58398428|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
58398429|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
58398430|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
58422761|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
58283864|NCT04156386|DIETARY_SUPPLEMENT|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
58283865|NCT04156386|DIETARY_SUPPLEMENT|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
58069998|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
58283866|NCT02534519|OTHER|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
58283867|NCT00784589|DRUG|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
58283868|NCT00784589|DRUG|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
58283869|NCT02700425|DEVICE|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
58283870|NCT03782571|DEVICE|etafilcon a Test 1|1-DAY ACUVUE® MOIST
58398431|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
58283871|NCT03782571|DEVICE|etafilcon A Test 2|1-DAY ACUVUE® MOIST for ASTIGMATISM
58283872|NCT03782571|DEVICE|etafilcon A Test 3|1-DAY ACUVUE® MOIST MULTIFOCAL
58398432|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
58283873|NCT03782571|OTHER|Control|Bare Eye
58283874|NCT01424241|DRUG|Sandostatin LAR|Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
58283875|NCT04671940|OTHER|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies \& subsequent resections
58283876|NCT02824211|DEVICE|Right Dose System|Automated titration of oxygen system during exertion
58398433|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
58398434|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
58398435|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
58398436|NCT00499291|PROCEDURE|gene expression analysis|
58398437|NCT00499291|PROCEDURE|laboratory biomarker analysis|
58283877|NCT00527124|DRUG|cediranib maleate|Given orally
58283878|NCT00527124|DRUG|docetaxel|Given IV
58283879|NCT00527124|DRUG|prednisone|Given orally
58283880|NCT00527124|OTHER|laboratory biomarker analysis|Correlative studies
58283881|NCT05327595|DRUG|LY3549492|Administered orally.
58283882|NCT05327595|DRUG|Placebo|Administered orally.
58283883|NCT05327595|DRUG|Atorvastatin|Administered orally.
58283884|NCT05327595|DRUG|Midazolam|Administered orally.
58283885|NCT05759065|BEHAVIORAL|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
58283886|NCT05759065|BEHAVIORAL|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
58283887|NCT00564278|DRUG|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
58283888|NCT00564278|BEHAVIORAL|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
58283889|NCT02651493|DEVICE|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
57728697|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
57728698|NCT06025331|PROCEDURE|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
58283890|NCT00082095|DRUG|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
58283891|NCT00082095|DRUG|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
58283892|NCT05942521|BEHAVIORAL|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
58283893|NCT05942521|BEHAVIORAL|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
58283894|NCT05942521|BEHAVIORAL|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
58283895|NCT02210325|DRUG|solithromycin|
58283896|NCT02210325|DRUG|ceftriaxone|
58283897|NCT02210325|DRUG|azithromycin|
58283898|NCT03812263|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
58283899|NCT03550547|OTHER|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
58283900|NCT03550547|OTHER|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
58283901|NCT05784402|DRUG|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
58283902|NCT05784402|DRUG|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
58283903|NCT03637790|DRUG|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
58283904|NCT03637790|OTHER|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
58283905|NCT06410417|BEHAVIORAL|Shorten abstinence time|In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
58398438|NCT00499291|PROCEDURE|pharmacological study|
57728699|NCT06025331|PROCEDURE|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
57728700|NCT04519840|OTHER|nill|nill
57728701|NCT04036916|OTHER|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
57728702|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
57728703|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
58283906|NCT01602497|DEVICE|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
58283907|NCT01602497|DEVICE|sham rTMS|Patients will undergo ten session of sham rTMS.
58283908|NCT05327751|DRUG|Celecoxib 200mg|200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.
58283909|NCT05327751|DRUG|Capecitabine-based chemotherapy|Capecitabine-based chemotherapy
58283910|NCT04889170|OTHER|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
58283911|NCT06027255|DIAGNOSTIC_TEST|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
58283912|NCT06027255|DIAGNOSTIC_TEST|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
58283913|NCT06027255|BEHAVIORAL|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
58283914|NCT05588934|DIETARY_SUPPLEMENT|Caffeine Gum|Commercially available caffeinated gum that contains 100mg of caffeine per piece of gum.
57728704|NCT04532697|OTHER|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
58283915|NCT05588934|OTHER|Placebo Gum|Commercially available non-caffeinated gum.
58283916|NCT05255445|BIOLOGICAL|Red Blood Cell (RBC) Transfusion|Simple RBC transfusion or partial manual exchange
58283917|NCT00499343|DRUG|Etoposide|150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.
58283918|NCT00499343|DRUG|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
58283919|NCT00499343|DRUG|GM-CSF|250 mcg/m\^2 injection given every evening till the completion of apheresis.
58283920|NCT00499343|DRUG|Isophosphamide|10 g/m\^2 given intravenously continuous infusion over 72 hours.
58283921|NCT00499343|DRUG|Rituximab|Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.
58283922|NCT00499343|PROCEDURE|Apheresis|Peripheral blood stem cell collection.
58283923|NCT01502033|DEVICE|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
58283924|NCT00809094|DRUG|N-acetylcysteine (NAC)|
58283925|NCT00809094|DRUG|Placebo|
58283926|NCT06399991|BEHAVIORAL|Champion strategy|The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
58283927|NCT06399991|BEHAVIORAL|Adapted LOCI leadership and climate alignment strategy plus champion strategy|The LOCI strategy involves engaging with district health leadership through data and feedback, leadership development trainings, coaching, and alignment strategy activities to align leadership and climate in support of implementing the evidence-based mental health package. The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
58283928|NCT05369143|OTHER|Chiropractic care|The mechanical properties of chiropractic adjustment have been investigated; and although the actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent68 and the duration of the thrust is always less than 200 milliseconds.
57728705|NCT04532697|OTHER|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
57728706|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
57930855|NCT06734793|DEVICE|Wearable stethoscope|The device is a soft, wearable stethoscope designed for continuous, comfortable monitoring of patients for abnormal breath sounds, such as wheezing, which can indicate asthma exacerbations. It automatically detects and diagnoses abnormal breath frequencies, wirelessly transmitting data for analysis. Preliminary materials have shown biocompatibility, ensuring the device is safe for use in children. A key feature is its machine-learning algorithm, which can classify and differentiate normal from abnormal sounds with an expected accuracy above 80%. Initial in vivo tests will compare the device's findings to those of a commercial-grade stethoscope in healthy subjects and individuals with asthma. Breath sound data will be used to improve the detection of wheezing sounds from these continuous recordings based on frequency and amplitude analysis of the recordings.
58069999|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
58398439|NCT00499291|PROCEDURE|polymerase chain reaction|
58398440|NCT05143749|OTHER|video tutorial|get video tutorial
58398441|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
58398442|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
58398443|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
58398444|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
58070000|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
58070001|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
58070002|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
58070003|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
57728707|NCT04890340|DIAGNOSTIC_TEST|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
57728708|NCT02052349|DRUG|ABT-333|Dose of ABT-333
57728709|NCT04097132|DEVICE|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
58070004|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
58070005|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
58070006|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
58398445|NCT03069248|DRUG|Rituximab|
58070007|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
58070008|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
58070009|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
58070010|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
58070011|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
58398446|NCT03069248|DRUG|Alpha Interferon|
58398447|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
58422762|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
58283929|NCT05369143|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
58398448|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
58398449|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
58398450|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
58398451|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
58070012|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
58283930|NCT04063722|PROCEDURE|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
58283931|NCT03762681|DRUG|RO7239958|Solution for injection, subcutaneous use (SC).
58283932|NCT03762681|OTHER|Placebo|Sodium chloride solution for injection, SC
58283933|NCT04233437|DRUG|MLC1501|MLC1501 capsules (4 capcules (2000 mg) twice a day)
58398452|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
58398453|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
58070013|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
58283934|NCT04233437|DRUG|CYP Cocktail|Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
58283935|NCT04233437|DRUG|Transporter Cocktail|Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
58283936|NCT00349193|DRUG|laquinimod 0.3|laquinimod 0.3mg
58283937|NCT00349193|DRUG|laquinimod 0.6|laquinimod 0.6mg
58283938|NCT00349193|OTHER|Placebo|Blinded Placebo
58283939|NCT05401409|DIETARY_SUPPLEMENT|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
58283940|NCT05401409|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
58398454|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
58398455|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
58070014|NCT01722552|BEHAVIORAL|adherence feedback|
58070015|NCT01722552|BEHAVIORAL|standard of care|
58070016|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
58070017|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
58283941|NCT03872141|DIAGNOSTIC_TEST|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
58398456|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
58398457|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
58398458|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
58398459|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
57930856|NCT06734793|OTHER|Routine Clinical lung Auscultation|The study PI will auscultate the participant's lungs at enrollment to ensure that wheezing is present before beginning the continuous recording of the participant's lung sounds. The PI will assess the participant's respiratory status daily at the start of each breath sound recording session.
57930857|NCT00841893|DIETARY_SUPPLEMENT|Mustard (dijon)|The specific spice added to a brunch meal
57930858|NCT00841893|DIETARY_SUPPLEMENT|Placebo|Placebo added to a brunch meal
57930859|NCT00588536|DRUG|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
58070018|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
57930860|NCT00588536|DRUG|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
57930861|NCT00588536|DRUG|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
57930862|NCT03350776|BEHAVIORAL|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
57930863|NCT03517384|BEHAVIORAL|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
57930864|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
58283942|NCT04251416|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
58283943|NCT06379529|OTHER|NuvoAir clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
58283944|NCT02969083|PROCEDURE|RNU|Radical surgical removal by open or laparoscopic access
58283945|NCT02969083|DRUG|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
57728710|NCT04665856|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
57728711|NCT04665856|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
57930865|NCT03374098|BEHAVIORAL|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
58070019|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
58070020|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
58283946|NCT02969083|DRUG|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
58283947|NCT04515277|DIETARY_SUPPLEMENT|40 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
58283948|NCT04515277|DIETARY_SUPPLEMENT|20 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
58283949|NCT04515277|DIETARY_SUPPLEMENT|0 g Gum acacia (FibregumTM)|300 mL of orange juice with breakfast (single use at visit)
58283950|NCT01317004|DRUG|Fingolimod|0.5 mg/day oral capsule
58283951|NCT01317004|DRUG|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
58283952|NCT00823485|PROCEDURE|fibrinolysis in situ|intraventricular injection of actilyse
58283953|NCT00823485|PROCEDURE|drainage|drainage
58283954|NCT02108899|BEHAVIORAL|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
58398460|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
58398461|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
58398462|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
58398463|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
58398464|NCT01728558|OTHER|Early goal Directed Sedation|
58398465|NCT01728558|OTHER|Standard care sedation|
58398466|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
58398467|NCT01825486|BEHAVIORAL|accidental falls|
58398468|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
58398469|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
58398470|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
58398471|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
58398472|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
58398473|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
58398474|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
58398475|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
58398476|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
58398477|NCT00374946|DEVICE|THA|
58398478|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
57728712|NCT04665856|DRUG|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
57930866|NCT03374098|BEHAVIORAL|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
58283955|NCT05765071|BIOLOGICAL|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
58398479|NCT00479817|DRUG|AMG 386|10mg/kg
58070021|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
58070022|NCT00034801|DRUG|olanzapine|
58070023|NCT00034801|DRUG|ziprasidone|
58070024|NCT00003230|DRUG|paclitaxel|
58070025|NCT02960802|PROCEDURE|kidney transplantation|
58398480|NCT00479817|DRUG|AMG 386|3 mg/kg
58398481|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
58398482|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
58398483|NCT02720055|OTHER|Psychological workbook|
58398484|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
58398485|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
58398486|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
58398487|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
58398488|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
58398489|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
58070026|NCT01829529|DRUG|Amoxicillin|Amoxicillin
58398490|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
58398491|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
58398492|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
57728713|NCT04665856|DRUG|Etoposide|Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
57728714|NCT04665856|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
58283956|NCT05765071|BIOLOGICAL|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
58283957|NCT04627558|OTHER|stroke patients, balance assessment|validity relability dubousset functional test
58398493|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
57728715|NCT05799495|DRUG|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
57728716|NCT05799495|DRUG|Placebo|Placebo
58283958|NCT02776670|OTHER|Propylene glycol, 0.6% eye drops|
58283959|NCT02776670|OTHER|Lubricant eye drops|
58283960|NCT00660595|DRUG|Quetiapine|Oral administration
58283961|NCT00660595|DRUG|Risperidone|Oral administration
58283962|NCT00470561|DRUG|Aspirin|Two 325 mg doses of aspirin per day for 6 months
58398494|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
58398495|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
58398496|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
57728717|NCT02584049|OTHER|Osteopathy|3 sessions of osteopathy during 60 minutes each
57728718|NCT02584049|OTHER|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
58283963|NCT00470561|DRUG|Placebo|Two placebo pills per day for 6 months
58283964|NCT01619072|OTHER|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
58283965|NCT01619072|OTHER|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
58283966|NCT00003328|DRUG|porfiromycin|
58283967|NCT00003328|RADIATION|radiation therapy|
58283968|NCT06345014|DRUG|OM-89 [Uro-Vaxom® Capsule]|Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
57728719|NCT06535061|OTHER|white noise|The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
58283969|NCT06345014|DRUG|OM-89 Placebo [Uro-Vaxom® Capsule Placebo]|Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
58283970|NCT03309345|OTHER|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
58398497|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
57728720|NCT05140278|DRUG|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
57728721|NCT05140278|DRUG|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
57728722|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
57930867|NCT00764933|BEHAVIORAL|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
57930868|NCT00764933|OTHER|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
57930869|NCT06428825|DRUG|BAY3283142|oral administration
57930870|NCT06428825|DRUG|Placebo to BAY3283142|oral administration
57930871|NCT06736054|DRUG|Copper 61-PSMA PET/CT|TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
57930872|NCT04570111|OTHER|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
57930873|NCT04570111|OTHER|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
57728723|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
57728724|NCT01205685|DRUG|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day"
57728725|NCT01205685|DRUG|Erlotinib|"During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d"
57728726|NCT01205685|DRUG|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
57728727|NCT01205685|DRUG|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
57728728|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
57930874|NCT06735105|DIAGNOSTIC_TEST|Scanning parameter|Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.
58070027|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
58070028|NCT00000740|DRUG|Sitamaquine|
58283971|NCT04733625|DRUG|Cholecalciferol|single injection of Vitamin D (200000 I.U
58283972|NCT04733625|DRUG|Placebo|placebo medication
58283973|NCT00160264|DRUG|Lactulose, Vitamin D, Calcium|
58283974|NCT01955317|BEHAVIORAL|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
58283975|NCT01955317|BEHAVIORAL|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
58283976|NCT00765947|DRUG|Aliskiren|Aliskiren 150 or 300 mg
58283977|NCT00765947|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
58283978|NCT00765947|DRUG|Amlodipine|Amlodipine 5 or 10 mg
58283979|NCT04651166|DRUG|Tranexamic acid|1g tranexamic acid mixed in 100mL saline or lactated ringer
58283980|NCT04651166|DRUG|Placebo|100mL saline or lactated ringers
58283981|NCT05475834|DRUG|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
58283982|NCT05186051|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
58283983|NCT01557192|DEVICE|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
57728729|NCT06615531|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
58283984|NCT06364436|BEHAVIORAL|Reiki energy therapy|In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
58283985|NCT04168320|RADIATION|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
58283986|NCT00429650|BEHAVIORAL|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
58283987|NCT00429650|BEHAVIORAL|diet|Use a prescribed diet to maintain weight loss
58283988|NCT00429650|BEHAVIORAL|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
58283989|NCT05109208|DIAGNOSTIC_TEST|Ulrasound Vibroelastography (UVE)|Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).
57728730|NCT06052852|DRUG|BDC-3042|Dectin-2 agonist antibody
58283990|NCT03457623|OTHER|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
58283991|NCT00599742|BEHAVIORAL|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
58283992|NCT00599742|BEHAVIORAL|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
58283993|NCT03999528|DIAGNOSTIC_TEST|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
58283994|NCT01742754|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
58070029|NCT02780869|DEVICE|HEMOBLAST Bellows|
58283995|NCT01789801|PROCEDURE|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
58283996|NCT01789801|PROCEDURE|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
58283997|NCT00069823|DRUG|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
58283998|NCT00069823|DRUG|Placebo proton pump inhibitor|Placebo proton pump inhibitor
58283999|NCT05601180|OTHER|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
58284000|NCT05601180|OTHER|Standard of care|standard treatment is prescribed by the treating physician.
58284001|NCT03466723|GENETIC|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
58284002|NCT04686825|DRUG|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
58284003|NCT04686825|DRUG|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
58284004|NCT04686825|DRUG|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
58284005|NCT04686825|DRUG|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
58284006|NCT01663857|DRUG|LY2228820|Administered Orally
58284007|NCT01663857|DRUG|Carboplatin|Administered IV
58284008|NCT01663857|DRUG|Placebo|Administered Orally
58284009|NCT01663857|DRUG|Gemcitabine|Administered IV
58284010|NCT04028323|DRUG|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
58284011|NCT04028323|DRUG|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
58284012|NCT06472687|OTHER|FIFA 11+ warm-up exercise training|FIFA 11+ warm-up training program was applied to the experimentel group. control group (CG) did their usual warm-up program.
58284013|NCT06472687|OTHER|warm-up exercise training|exercise training
58284014|NCT01456546|DRUG|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
58284015|NCT01456546|DRUG|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
58070030|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
58070031|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
58070032|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
58284016|NCT03389880|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
58284017|NCT03389880|PROCEDURE|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
58284018|NCT03706716|OTHER|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
58284019|NCT02116725|OTHER|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
58284020|NCT02116725|OTHER|Plain shower gel|Standard shower gel (Sanex).
58284021|NCT02116725|OTHER|Distilled water|Sterile distilled Water.
58284022|NCT03102671|OTHER|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
58284023|NCT03102671|OTHER|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
58284024|NCT00623298|BEHAVIORAL|Narrative Exposure Therapy|
58284025|NCT00623298|BEHAVIORAL|group IPT|
58284026|NCT00623298|OTHER|6 months-baseline|
58284027|NCT05607121|DEVICE|intermittent theta burst stimulation|transcranial magnetic stimulation
58284028|NCT05607121|DEVICE|continuous theta burst stimulation|transcranial magnetic stimulation
58284029|NCT03843320|DEVICE|SAPIEN 3|Transcatheter aortic valve replacement
58284030|NCT03843320|DEVICE|SAPIEN XT|Transcatheter aortic valve replacement
58284031|NCT03843320|DEVICE|INSPIRIS RESILIA|Surgical aortic valve replacement
58284032|NCT03843320|DEVICE|EDWARDS INTUITY|Surgical aortic valve replacement
58284033|NCT03843320|DEVICE|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
58070033|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
58070034|NCT02661789|DRUG|Placebo|Injection of saline
58284034|NCT05034380|BEHAVIORAL|Acute exercise|All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
58284035|NCT05176639|DRUG|Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED)|2 IV Infusions of multiple ascending doses of veligrotug (VRDN-001), ranging from 3 mg/kg to 20 mg/kg
58284036|NCT05176639|DRUG|VRDN-001 Phase 3 Cohort (THRIVE)|5 IV Infusions of veligrotug (VRDN-001) 10mg/kg
58284037|NCT05176639|DRUG|VRDN-001 Placebo|5 IV Infusions of veligrotug (VRDN-001) placebo
58284038|NCT01042392|DRUG|Aliskiren|150 mg Aliskiren as film-coated tablet
58284039|NCT01042392|DRUG|Ramipril|Ramipril 5 mg was given in capsule form.
58284040|NCT01042392|DRUG|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
58284041|NCT01042392|DRUG|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
58398498|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
58398499|NCT04521686|DRUG|LY3410738|Oral LY3410738
58070035|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
58284042|NCT03180931|DEVICE|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
58284043|NCT01616758|DRUG|GTx-024 9mg|
58284044|NCT05326438|BEHAVIORAL|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
58284045|NCT03850015|DIAGNOSTIC_TEST|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
58284046|NCT03850015|OTHER|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
58284047|NCT05667168|PROCEDURE|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
58284048|NCT03672344|DEVICE|Lookware TM|Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
58284049|NCT03672344|DEVICE|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
58284050|NCT00417521|BEHAVIORAL|Family-Based Treatment|
57728731|NCT06052852|DRUG|Cemiplimab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
57728732|NCT00525317|DRUG|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
58284051|NCT04739592|DRUG|alendronate sodium vitamin D3 tablets|once per week for one year
58284052|NCT04739592|DRUG|Placebo|once per week for one year
58284053|NCT03675971|DRUG|Cannabinol|Postoperative pain treatment
58284054|NCT03675971|DRUG|Placebo oral capsule|Placebo comparator
58398500|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
57728733|NCT02491320|OTHER|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
57728734|NCT02491320|DRUG|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
58398501|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
58398502|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
58398503|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
58398504|NCT04622891|DRUG|Azithromycin|azithromycin group
58398505|NCT04622891|DRUG|Placebo|control group
58398506|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
58398507|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
58398508|NCT02748668|OTHER|Blood specimen collection|
58284055|NCT00843011|DRUG|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
58398509|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
58398510|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
58398511|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
58398512|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
57728735|NCT03713762|DRUG|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
57728736|NCT03713762|DRUG|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
58284056|NCT03696199|DRUG|Long-Acting Local Anesthesia|"The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
58284057|NCT03696199|DRUG|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
58284058|NCT01981811|DRUG|Aripiprazole|
58284059|NCT01981811|DEVICE|Ingestible Event Marker (IEM)|
58398513|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
57728737|NCT01146236|DEVICE|Sutures|Orthopedic surgical wounds closed with sutures
57728738|NCT01146236|DEVICE|Staples|Orthopedic surgical wounds closed with metallic staples
57728739|NCT05215574|DRUG|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
57930875|NCT01704963|DRUG|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
57930876|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
57930877|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
57930878|NCT01473316|DRUG|GDC-0980|Single oral dose
57930879|NCT01473316|DRUG|Ketoconazole|Repeating Oral Dose
57930880|NCT01132066|OTHER|tDCS|tDCS will lead to an increase in cortical excitability
57930881|NCT01132066|OTHER|Sham|Sham will provide identical subjective sensation as tDCS
58284060|NCT00545935|DRUG|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
58284061|NCT00545935|DRUG|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
58284062|NCT00545935|DRUG|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
58398514|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
58398515|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
58398516|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
57728740|NCT05215574|DRUG|NGM831 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."
57728741|NCT05215574|DRUG|NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."
57930882|NCT01301820|DRUG|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
57930883|NCT01301820|DRUG|Lenalidomide|lenalidomide 10mg/d (d1- d21)
57930884|NCT04828083|DRUG|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
57930885|NCT04828083|DRUG|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
57930886|NCT02209155|DRUG|R-verapamil 75 mg tablet|
57728742|NCT03096418|DRUG|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
58284063|NCT03937674|BEHAVIORAL|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
58284064|NCT00498810|PROCEDURE|complete repair|
58284065|NCT00498810|PROCEDURE|partial repair of the abdominal wall|
58284066|NCT01510964|BEHAVIORAL|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
58284067|NCT01510964|BEHAVIORAL|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
58284068|NCT05805020|PROCEDURE|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
58284069|NCT02303197|DRUG|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
58284070|NCT03172377|OTHER|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
58284071|NCT04813107|DRUG|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
58284072|NCT04813107|DRUG|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
58284073|NCT02204436|OTHER|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
58284074|NCT05643729|DRUG|Zofin|Intravenous Infusion (IV) of Zofin
58284075|NCT05643729|OTHER|Placebo|Intravenous Infusion of sterile saline
58422763|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
57930887|NCT02209155|DRUG|Placebo|
57930888|NCT06736418|DRUG|225Ac-ABD147|A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
57930889|NCT00935545|BIOLOGICAL|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
58398517|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
58284076|NCT05552742|OTHER|Conservative rehabilitation|The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.
57930890|NCT06725719|DIAGNOSTIC_TEST|18F-DPA714/FDPA|Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.
58070036|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
58070037|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
58284077|NCT05552742|DEVICE|Virtual Balance Training|Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
58284078|NCT04876131|DRUG|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
58398518|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
58398519|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
57728743|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
57930891|NCT02223403|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
58398520|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
58398521|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
58398522|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
58398523|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
58398524|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
58398525|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
58070038|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
58070039|NCT00401726|DRUG|Venlafaxine ER|
57930892|NCT02223403|DIETARY_SUPPLEMENT|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
57930893|NCT00292656|PROCEDURE|NAET|
58070040|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
58070041|NCT00303004|DRUG|Bosentan and Sildenafil|
58070042|NCT00002102|DRUG|Trimetrexate glucuronate|
58284079|NCT04876131|DRUG|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
58284080|NCT04876131|DRUG|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
58284081|NCT04876131|DRUG|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
58284082|NCT04876131|DRUG|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
58284083|NCT04723589|BIOLOGICAL|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
58284084|NCT06612931|PROCEDURE|Dual-lumen catheter-guided mini-forceps biopsy is performed first|In ERCP procedures, catheter-guided mini-forceps biopsy is performed before biliary brush cytology.
58284085|NCT06612931|PROCEDURE|Biliary brush cytology with vacuum aspiration is performed first|In ERCP procedures, biliary brush cytology with vacuum aspiration is performed before dilation catheter-guided mini-forceps biopsy.
58284086|NCT05948137|DIAGNOSTIC_TEST|F-18 FDOPA PET/CT|Nuclear medicine imaging modalities
58284087|NCT02364076|DRUG|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
58284088|NCT02364076|DRUG|Epacadostat|100mg taken by mouth twice daily
58284089|NCT04930705|DEVICE|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
58070043|NCT00002102|DRUG|Leucovorin calcium|
58070044|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
58284090|NCT01397149|DRUG|Placebo|Dosage form, frequency and duration exactly as experimental arm.
58284091|NCT01397149|DRUG|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to \> 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
58284092|NCT04835961|OTHER|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
58284093|NCT02264938|DIETARY_SUPPLEMENT|Antioxidant|Oral supplemmentation with antioxidants
58284094|NCT02168777|DRUG|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
58284095|NCT02168777|DRUG|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
58398526|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
57930894|NCT01383161|DRUG|Curcumin|Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
57930895|NCT01383161|OTHER|Placebo|Six capsules per day for 18 months.
57930896|NCT04582981|DRUG|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
57930897|NCT04582981|DRUG|Fruquintinib|Fruquintinib 5mg qd monotherapy
57930898|NCT05798078|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
57930899|NCT05798078|BEHAVIORAL|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
57930900|NCT04662151|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
57930901|NCT04662151|PROCEDURE|Air-sham|room air for intratracheal administration
57930902|NCT01313403|OTHER|Antidepressant (SSRI)|
57930903|NCT01186939|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
57930904|NCT00564785|DRUG|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
58398527|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
57930905|NCT00564785|OTHER|Placebo patch|placebo patch applied 20 minutes prior to epidural
57930906|NCT04423913|OTHER|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
57930907|NCT05803616|DIAGNOSTIC_TEST|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
57930908|NCT03218462|BEHAVIORAL|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
58398528|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
58398529|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
57930909|NCT00348062|DRUG|Bimatoprost|
57930910|NCT00486798|DRUG|Quetiapine|
57930911|NCT00486798|PROCEDURE|Rating Scales|
57930912|NCT00486798|PROCEDURE|Self Assessment Form|
57930913|NCT00486798|PROCEDURE|Blood and urine samples|
57930914|NCT00486798|PROCEDURE|Sleeping pattern|
57930915|NCT02876835|DRUG|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
57930916|NCT02876835|DRUG|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
57930917|NCT02876835|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
57930918|NCT02876835|DRUG|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
57930919|NCT06211673|OTHER|Semi-structured interviews|"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."
57930920|NCT06211673|OTHER|Heteroquestionnaires|7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
57930921|NCT01127945|DRUG|statin|"1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy"
57930922|NCT02511678|DEVICE|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
57930923|NCT00309868|DRUG|neseritide|
57930924|NCT00152555|BEHAVIORAL|Physical Therapy or Relaxation Therapy|
58398530|NCT01794078|OTHER|Placebo|
58398531|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
58398532|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
58398533|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
57930925|NCT01310803|DRUG|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
57930926|NCT01310803|OTHER|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
58070045|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
58070046|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
58070047|NCT03080675|DIETARY_SUPPLEMENT|Control|
58398534|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
58398535|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
58398536|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
58398537|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
58398538|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
58398539|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
58070048|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
58398540|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
58398541|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
58398542|NCT00044681|DRUG|risperidone|
58398543|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
58398544|NCT01916252|DRUG|bortezomib (Velcade ®)|
58398545|NCT01916252|DRUG|lenalidomide (Revlimid®)|
57930927|NCT05938855|DEVICE|Electrical stimulation and biofeedback with the medical device Phenix Liberty|"The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session"
57930928|NCT00088907|DRUG|docetaxel|Given IV
57930929|NCT00088907|OTHER|placebo|Given orally
58398546|NCT01916252|DRUG|busulfan (Busilvex ®)|
58398547|NCT01916252|DRUG|Dexamethasone acetate|
58070049|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
58070050|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
58070051|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
58070052|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
58070053|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
58070054|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
58070055|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
58398548|NCT01916252|DRUG|Melphalan|
58398549|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
58398550|NCT04353375|DRUG|HMPL-453|Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
58398551|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
58398552|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
58284096|NCT01453790|BEHAVIORAL|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
58284097|NCT01453790|BEHAVIORAL|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
58284098|NCT01662856|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
58398553|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
58284099|NCT01662856|PROCEDURE|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
58284100|NCT05397340|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
58284101|NCT04428528|DEVICE|Photoacoustics Imaging System|Characterizing breast masses for photoacoustic markers measurements
58284102|NCT03953599|BIOLOGICAL|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
58284103|NCT02352961|OTHER|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
58284104|NCT03397602|BEHAVIORAL|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
58284105|NCT03397602|BEHAVIORAL|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
58284106|NCT00888797|DRUG|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
58284107|NCT03973398|PROCEDURE|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
58284108|NCT05999591|PROCEDURE|Intrauterine insemination|Transfer of sperm into the fallopian tube through a specialised cannula
58284109|NCT00662311|DRUG|vorinostat|Given PO
58284110|NCT00662311|DRUG|paclitaxel|Given IV
58284111|NCT00662311|RADIATION|radiation therapy|Undergo radiation therapy
58284112|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
57930930|NCT00088907|DRUG|gefitinib|Given orally
58284113|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
58284114|NCT02044653|DRUG|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
58284115|NCT02044653|DRUG|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
58284116|NCT02044653|DRUG|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
58284117|NCT00242047|BIOLOGICAL|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
58284118|NCT00311922|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
58398554|NCT02589665|DRUG|Mirikizumab|
58284119|NCT00311922|BEHAVIORAL|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
58398555|NCT02589665|DRUG|Placebo|
58398556|NCT01858142|BEHAVIORAL|Parental presence decision tool|
58398557|NCT01858142|BEHAVIORAL|Standard preparation|
58398558|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
58398559|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
58398560|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
58284120|NCT01956760|OTHER|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
58284121|NCT04302207|BEHAVIORAL|De-implementation Strategy for Bronchiolitis|De-implementation strategy to reduce over-use of treatments for patients with bronchiolitis
58284122|NCT02861430|PROCEDURE|Immunochemistry and molecular biology on sentinel lymph node specimen|
58284123|NCT00003896|DRUG|cisplatin|
58284124|NCT00003896|DRUG|liposomal doxorubicin|
58284125|NCT00003896|DRUG|paclitaxel|
58284126|NCT05527795|OTHER|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"* Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
58398561|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
58398562|NCT00412347|DRUG|Insulin Drip Therapy|
58398563|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
58284127|NCT05527795|OTHER|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
58284128|NCT05527795|OTHER|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
57930931|NCT04259294|BEHAVIORAL|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
58284129|NCT05527795|OTHER|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
58398564|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
58398565|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
58398566|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
58398567|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
58398568|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
58398569|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
58398570|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
58398571|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
58398572|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
58398573|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
58398574|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
57930932|NCT06104644|DRUG|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
58422764|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
58284130|NCT05527795|OTHER|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
58284131|NCT05527795|OTHER|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
58284132|NCT00287729|DRUG|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
58284133|NCT00287729|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
58284134|NCT04159441|OTHER|None intervetion|None intervetion
58398575|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
58398576|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
58398577|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
58398578|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
58398579|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
57930933|NCT05750797|DRUG|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
57930934|NCT06734663|PROCEDURE|Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision|Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.
57930935|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft suturing|pterygium is surgically removed, and a conjuctival graft is placed on bare sclera using sutures to surrounding conjuctiva.
58284135|NCT04690335|BIOLOGICAL|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
58284136|NCT04690335|OTHER|Placebo|Saline solution
58284137|NCT02417558|BEHAVIORAL|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
58284138|NCT02417558|BEHAVIORAL|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
58284139|NCT01994707|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
58284140|NCT01994707|PROCEDURE|Placebo|Deflated cuff on arm for 30 minutes.
58284141|NCT03848897|OTHER|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
58284142|NCT03418597|PROCEDURE|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
58284143|NCT03418597|PROCEDURE|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
58284144|NCT01396551|DEVICE|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
58284145|NCT05009134|BIOLOGICAL|There is no intervention in this study.|There is no intervention in this study.
58284146|NCT05447026|DEVICE|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
58284147|NCT05447026|DEVICE|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
58284148|NCT05447026|DEVICE|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
58284149|NCT05447026|DEVICE|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
58284150|NCT05509998|BEHAVIORAL|Screening Method (SM)|All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
58284151|NCT05509998|BEHAVIORAL|Screening and Communication Method (SCM)|Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
58284152|NCT04404348|BEHAVIORAL|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
58284153|NCT04404348|BEHAVIORAL|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
58284154|NCT05325372|PROCEDURE|axillary block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
58284155|NCT05325372|PROCEDURE|infraclavicular block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
58284156|NCT05028205|BEHAVIORAL|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
58284157|NCT00898794|BIOLOGICAL|bevacizumab|
58284158|NCT00898794|OTHER|coagulation study|
58284159|NCT00898794|OTHER|laboratory biomarker analysis|
58284160|NCT00898794|OTHER|platelet aggregation test|
58284161|NCT06239545|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
58284162|NCT02905357|DEVICE|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
58284163|NCT02905357|OTHER|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
58284164|NCT05251636|RADIATION|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
58284165|NCT05251636|DRUG|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
58284166|NCT03011398|PROCEDURE|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
58398580|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
58398581|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
57930936|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft placement by autologous blood|pterygium is surgically removed and a conjuctival graft is placed on bare sclera on which the patient's blood remains. the graft is left without sutures, adhering only by autologous blood.
58070056|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
58070057|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
58070058|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
58070059|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
58070060|NCT02015858|PROCEDURE|Chest drain withdrawal|
58070061|NCT02015858|DEVICE|Pain Monitor|
58070062|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
58284167|NCT01183507|BEHAVIORAL|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
58284168|NCT01183507|BEHAVIORAL|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
57930937|NCT00490880|DRUG|gemcitabine|
57930938|NCT00490880|DRUG|cisplatin|
57930939|NCT00490880|PROCEDURE|radical cystectomy|
57930940|NCT00490880|PROCEDURE|radiotherapy|
57930941|NCT05344768|OTHER|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
57930942|NCT05344768|OTHER|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
58070063|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
58070064|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
58070065|NCT03405324|DEVICE|sham tDCS|sham tDCS
58070066|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
58070067|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
58070068|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
58070069|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
58070070|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
58070071|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
58070072|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
58284169|NCT03376113|BEHAVIORAL|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
58398582|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
58070073|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
58398583|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
58398584|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
58398585|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
58398586|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
58398587|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
58070074|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
58070075|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
58284170|NCT05767164|PROCEDURE|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
58284171|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout Each Hour|One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
58284172|NCT05316571|BEHAVIORAL|One 15-Minute Standing Bout Each Hour|One 15-minute standing break per hour throughout the 4-hour SB condition
58284173|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
58284174|NCT05316571|BEHAVIORAL|Uninterrupted Sitting|No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
58070076|NCT00702637|DRUG|Modafinil|
58070077|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
58070078|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
58070079|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
58070080|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
58070081|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
58398588|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
58398589|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
58398590|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
58398591|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
58398592|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
58398593|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
58398594|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
58398595|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
58398596|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
58398597|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
58398598|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
58284175|NCT04647513|DEVICE|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
57930943|NCT05344768|OTHER|resistance exercise training|resistance exercise training will be applied
57930944|NCT06249945|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
57930945|NCT06249945|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
58284176|NCT01761929|RADIATION|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
57930946|NCT06342284|RADIATION|Proton Beam Radiation with or without concurrent chemotherapy|Curative-intent fractionated proton beam thoracic radiotherapy, with or without concurrent chemotherapy
58284177|NCT05168618|BIOLOGICAL|Atezolizumab|Given IV
58284178|NCT05168618|DRUG|Cabozantinib S-malate|Given PO
58284179|NCT05475899|DEVICE|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
58284180|NCT06529159|PROCEDURE|HEAPE|The stomach is filled with sodium chloride solution which is then treated with APC to activate it into an antibacterial solution.
57930947|NCT01438021|OTHER|pharmacological study|Correlative studies
57930948|NCT01438021|DRUG|methotrexate|Given intraventricularly
58284181|NCT06529159|PROCEDURE|Pre-HEAPE|Plasma activated sodium chloride solution (prepared outside of the body) is administered into the patients stomach through an endoscope channel using a syringe.
58284182|NCT05411380|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
58284183|NCT05411380|DRUG|Capecitabine|500mg orally three times a day (continuously)
58284184|NCT05411380|DRUG|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
58284185|NCT04246528|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
58284186|NCT05134779|PROCEDURE|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
58284187|NCT04617405|OTHER|No interventions|No interventions
58284188|NCT06297551|DIAGNOSTIC_TEST|Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry|During induction therapy for AML, researchers will measure the relative percentage of hematopoietic stem cells (defined by markers CD34+/CD38-) that test positive for CLL1 and CD45RA surface markers in the blood of participants on day 3, 5 and 7 days of systemic therapy. The variation of blood cells positivity for these markers, will be correlated with treatment outcome (complete response, partial response, no response), as determined by a bone marrow biopsy done approximately 4 weeks after induction chemotherapy.
58284189|NCT03934918|OTHER|Treatment|Patients for IOL are sent home after placement of intracervical balloon
58284190|NCT04252963|DRUG|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
58284191|NCT04252963|DRUG|Placebo|Placebo of MUCOLASE tablet
57930949|NCT01019980|DRUG|Diclofenac potassium|Diclofenac potassium
57930950|NCT01019980|DRUG|Acetaminophen|Acetaminophen
58284192|NCT05567471|BIOLOGICAL|BBV154 Intranasal Vaccine|Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route
58284193|NCT05567471|BIOLOGICAL|Intramuscular vaccine COVAXIN|Administered BBV152 vaccine via intramuscular route
58284194|NCT05567471|BIOLOGICAL|Covishield|Administered vaccine via intramuscular route
57930951|NCT03214133|OTHER|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
57930952|NCT03214133|OTHER|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
57930953|NCT04298463|DRUG|Xydalba|Drugs were administered i.v.
57930954|NCT04298463|DRUG|vancomycin, teicoplanin or daptomycin|Drugs were administered i.v.
58398599|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
58398600|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
58398601|NCT04597359|DRUG|Placebo Administration|Given PO
58398602|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
58398603|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
58398604|NCT04597359|DRUG|Sinecatechins|Given PO
58398605|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
58070082|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
58070083|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
58070084|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
58284195|NCT02711358|DRUG|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
58284196|NCT02711358|DRUG|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
58284197|NCT04730752|DIAGNOSTIC_TEST|Appendicitis Inflammatory Response|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
58070085|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
58284198|NCT04730752|DIAGNOSTIC_TEST|Adult Appendicitis Score|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
58284199|NCT03307837|DRUG|CA-008|Local administration during surgery
58284200|NCT03307837|DRUG|Placebo|Local administration during surgery
58284201|NCT05511259|OTHER|exercise|Square stepping exercise
58284202|NCT00572455|DRUG|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
58284203|NCT00572455|DRUG|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
58284204|NCT00572455|DRUG|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
58284205|NCT00572455|DRUG|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
58284206|NCT00572455|DRUG|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
58284207|NCT00572455|DRUG|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
58284208|NCT00572455|DRUG|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
58284209|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
58284210|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
58398606|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
58398607|NCT02126553|DRUG|Lenalidomide|Given PO
58398608|NCT00046761|DRUG|ONO-2506|
58398609|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
58398610|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
58398611|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
58284211|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
58284212|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
58398612|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
58398613|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
58398614|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
57728744|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
58070086|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
58070087|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
58284213|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
58284214|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
58284215|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
58284216|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
58284217|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
58284218|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
58284219|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
58284220|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
58284221|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
58284222|NCT00572455|DRUG|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
58284223|NCT03964259|DRUG|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
58284224|NCT01557868|DEVICE|hylan G-F 20|Three 2 cc injections at weekly intervals
58284225|NCT01557868|DEVICE|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
58284226|NCT06025201|BEHAVIORAL|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
58398615|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
58398616|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
58398617|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
58398618|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
58398619|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
58398620|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
58284227|NCT06025201|BEHAVIORAL|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
58284228|NCT06025201|BEHAVIORAL|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
57930955|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
58284229|NCT05496465|DRUG|ARS-1|A single treatment of ARS-1.
58284230|NCT05496465|DRUG|Placebo|A single treatment of placebo nasal spray
58284231|NCT03019029|OTHER|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
58284232|NCT00253006|PROCEDURE|Tissue examination for protein- and mRNA-expression of NO|
58284233|NCT02974348|DRUG|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
58284234|NCT02974348|DRUG|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
58284235|NCT02974348|DRUG|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
58284236|NCT02974348|DRUG|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
58284237|NCT02974348|DRUG|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
58284238|NCT02974348|DRUG|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
58398621|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
58398622|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
58398623|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
58398624|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
57930956|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
57930957|NCT05390359|OTHER|High-intensity and short-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
58284239|NCT01718587|PROCEDURE|stem cell transplantation through interventional procedure|interventional procedure once
58284240|NCT01718587|DRUG|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
58284241|NCT02693717|OTHER|Laboratory Biomarker Analysis|Correlative studies
58284242|NCT02693717|DRUG|Pemetrexed Disodium|Given IV
57930958|NCT05390359|OTHER|Low-intensity and long-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds."
57930959|NCT05390359|OTHER|High-intensity, short-duration and 20 Hz|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
57930960|NCT05390359|OTHER|Sham electrolysis|The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
58284243|NCT04322097|DEVICE|Lingual Muscle Stimulation|Tongue protrudor muscles will be stimulated
58284244|NCT04322097|OTHER|Mandibular advancement|Outcome variables will be assess with and without mandibular advancement
58284245|NCT04322097|OTHER|Postural maneuvers|Outcome variables will be measured with and without postural maneuvers
58284246|NCT04322097|OTHER|Digital Morphometrics|A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).
58284247|NCT04322097|OTHER|Tongue Force Exercise|The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.
58284248|NCT04322097|OTHER|Magnetic resonance imaging (MRI)|The patient will undergo an MRI scan of the head and neck.
58284249|NCT04322097|OTHER|Polysomnography (PSG) - Split Night|The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
58398625|NCT00395187|PROCEDURE|Photodynamic Therapy|
58398626|NCT00223405|DEVICE|crown placement|
58398627|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
58398628|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
58398629|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
58398630|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
58398631|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
57930961|NCT06315842|OTHER|Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.|During the intervention periods, participating physicians will integrate into their usual clinical practice a tool for adjusting diagnostic and therapeutic intensity designed by Fontecha-Gómez and colleagues. The tool for adjusting the level of diagnostic and therapeutic intensity classifies patients' profiles into 5 groups based on the recommended level of adjustment.
57930962|NCT06315842|OTHER|Usual clinical practice|The participating physicians will carry out the standard clinical practice currently performed in the study centers. This means that during this period, the diagnostic and therapeutic adjustment tool or any similar tool will not be introduced into routine clinical practice.
58284250|NCT06399016|DEVICE|augmented reality book|The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.
57930963|NCT00222053|DRUG|Thalidomide|Per os thalidomide
58284251|NCT06399016|DEVICE|book|This group will be asked to just read the book without turning on the augmented reality feature of the book.
58284252|NCT04844008|DIETARY_SUPPLEMENT|Nanobubble drink|Commercially available sports drink
58284253|NCT00869310|DRUG|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
58284254|NCT00869310|DRUG|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
58284255|NCT04262011|PROCEDURE|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
58284256|NCT04262011|PROCEDURE|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
58284257|NCT04598308|DIAGNOSTIC_TEST|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
58284258|NCT02400619|DEVICE|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
58284259|NCT02400619|DRUG|Botulinum Toxin Type A|Botulinum toxin type A Botox
58284260|NCT00160121|DRUG|Lanthanum carbonate|
58284261|NCT06477640|BEHAVIORAL|Exercise|The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.
58284262|NCT06477640|BEHAVIORAL|Standard of Care|"The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
58284263|NCT00651300|DRUG|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
58284264|NCT00651300|DRUG|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
58398632|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
58398633|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
58284265|NCT03457324|DRUG|JCM-16021|This prescription with seven ingredients.
58284266|NCT03457324|DRUG|Placebo|Placebo
58284267|NCT01226017|OTHER|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
58398634|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
58398635|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
58398636|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
58398637|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
58398638|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
58398639|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
58398640|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
58398641|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
58398642|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
58398643|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
58398644|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
58398645|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
58398646|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
58398647|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
58398648|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
58398649|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
58398650|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
58398651|NCT01579058|DRUG|placebo|placebo for 4 years
58398652|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
58398653|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
58398654|NCT00182715|BIOLOGICAL|cetuximab|
58398655|NCT00182715|DRUG|capecitabine|
58398656|NCT00182715|DRUG|fluorouracil|
58398657|NCT00182715|DRUG|leucovorin calcium|
58398658|NCT00182715|DRUG|oxaliplatin|
58398659|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
58398660|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
58398661|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
58398662|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
58398663|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
58398664|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
58398665|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
58398666|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
58398667|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
58398668|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
58398669|NCT04813614|DEVICE|Active control group|Injection in the lips
58398670|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
58422765|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
58422766|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
57728745|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
58070088|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
58070089|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
58070090|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
58070091|NCT02264132|DRUG|Pramipexole ER tablet|
58284268|NCT06124651|PROCEDURE|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
58398671|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
57728746|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
58070092|NCT02264132|DRUG|Pramipexole IR tablet|
58095416|NCT03476837|BEHAVIORAL|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
57930964|NCT00222053|DRUG|Biphosphonates|Biphosphonates
57930965|NCT01636414|PROCEDURE|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
57930966|NCT01636414|PROCEDURE|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
58398672|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
57930967|NCT01636414|PROCEDURE|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
57930968|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
57930969|NCT04989699|DRUG|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
58070093|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
58284269|NCT06124651|PROCEDURE|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
58284270|NCT02442206|DRUG|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
58284271|NCT02442206|DRUG|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
58284272|NCT05576961|DRUG|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
58284273|NCT05576961|DRUG|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
58284274|NCT05576961|DRUG|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
58284275|NCT04598295|DRUG|DS-01|synbiotic
58284276|NCT06223308|DRUG|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
58284277|NCT01744158|OTHER|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history"
58284278|NCT03131687|DRUG|tirzepatide|Administered SC
58284279|NCT03131687|DRUG|Dulaglutide|Administered SC
58284280|NCT03131687|DRUG|Placebo|Administered SC
58284281|NCT02215889|PROCEDURE|Liver transplantation|
58284282|NCT03668340|DRUG|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
58284283|NCT01290575|DRUG|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
58284284|NCT01290575|DRUG|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
58284285|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
58284286|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
58398673|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
58284287|NCT01290575|DRUG|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
58284288|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
58284289|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
58284290|NCT01290575|DRUG|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
57728747|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
58284291|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
58284292|NCT02561546|DRUG|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
58284293|NCT02561546|DRUG|Trans-catheter embolization|Trans-catheter embolization alone
58284294|NCT01288651|DRUG|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
58284295|NCT00001919|DRUG|Hypericum (LI-160)|
58284296|NCT06121531|DEVICE|Soft Contact Lens|Vision Correction
58284297|NCT04297696|OTHER|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
58284298|NCT06435039|DRUG|APL-1202|APL-1202 IR tablets.
58284299|NCT06435039|DRUG|APL-1501|APL-1501 ER capsules.
58398674|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
58398675|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
58070094|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
57930970|NCT04989699|DRUG|Aflibercept/Sham|Aflibercept administered every 8 weeks
58070095|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
58070096|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
58284300|NCT02983175|OTHER|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA."
58284301|NCT02280733|OTHER|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
58284302|NCT03862872|DIETARY_SUPPLEMENT|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
58284303|NCT03862872|DIETARY_SUPPLEMENT|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
58284304|NCT03862872|OTHER|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
57728748|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
57728749|NCT05284968|DRUG|Cell injection|All subjects will be treated with cell injection
58284305|NCT00574093|DRUG|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
58284306|NCT05406271|DIAGNOSTIC_TEST|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
58284307|NCT06341062|OTHER|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge
58284308|NCT01677182|DRUG|Ramelteon|Ramelteon tablets for sublingual administration
58284309|NCT01677182|DRUG|Placebo|Ramelteon placebo-matching tablets for sublingual administration
58284310|NCT02640898|RADIATION|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
58284311|NCT02640898|RADIATION|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
58284312|NCT03278236|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
58284313|NCT00013377|PROCEDURE|Low vision|
58284314|NCT05253144|RADIATION|Radiotherapy|Radiotherapy
58284315|NCT05253144|PROCEDURE|Surgery|Surgery
58284316|NCT00003832|DRUG|bromodeoxyuridine|Given IV
58284317|NCT00003832|PROCEDURE|conventional surgery|Undergo surgery
58284318|NCT00003832|OTHER|laboratory biomarker analysis|Correlative studies
58284319|NCT01679028|DRUG|T89 Group A|150mg single dose on day 1
57728750|NCT02602301|DRUG|Oxytocin|different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
57728751|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).
57728752|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
58284320|NCT01679028|DRUG|Placebo Group A|150mg single dose
58284321|NCT01679028|DRUG|Placebo Group B|300mg single dose
58284322|NCT01679028|DRUG|T89 Group B|300mg single dose
58284323|NCT01679028|DRUG|Placebo Group C|225mg bid
58284324|NCT01679028|DRUG|T89 Group C|225mg bid
58284325|NCT01913522|PROCEDURE|Pulmonary Vein Isolation|
58284326|NCT03895450|BEHAVIORAL|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
58422767|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
58422768|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
58398676|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
58398677|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
58398678|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
58398679|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
58070097|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
58070098|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
57728753|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
57728754|NCT01595919|OTHER|Nutritional Intervention|Ad libitum amounts of beverage at a meal
58070099|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
58070100|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
58070101|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
58070102|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
58070103|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
58070104|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
58070105|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
58070106|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2_Advanced All-In-One Virtual Reality Headset_ 128 GB)).
58070107|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
58070108|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
58070109|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
58070110|NCT03844620|OTHER|Best Practice|Receive SOC
58398680|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
58398681|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
58398682|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
58398683|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
58398684|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
58398685|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
57728755|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
57728756|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
57728757|NCT03791125|DRUG|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
58070111|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
58070112|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
58070113|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
58070114|NCT03844620|DRUG|Regorafenib|Given by mouth
58070115|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
58070116|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
58070117|NCT00232531|DRUG|Niaspan|
58398686|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
58070118|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
58095417|NCT03476837|BEHAVIORAL|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
58095418|NCT02494583|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
58284327|NCT03895450|BEHAVIORAL|Stretching Protocol|Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
58284328|NCT03412292|DRUG|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
58284329|NCT02961387|DEVICE|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
58284330|NCT02961387|DEVICE|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
58284331|NCT05699525|BEHAVIORAL|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
58284332|NCT05699525|BEHAVIORAL|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
58284333|NCT03521752|OTHER|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
58284334|NCT00734461|DRUG|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
58284335|NCT00625183|DIETARY_SUPPLEMENT|selenomethionine|
58284336|NCT00625183|DRUG|capecitabine|
58284337|NCT00625183|DRUG|oxaliplatin|
58284338|NCT00625183|OTHER|laboratory biomarker analysis|
58284339|NCT00625183|OTHER|pharmacological study|
58284340|NCT00625183|PROCEDURE|adjuvant therapy|
58284341|NCT00625183|PROCEDURE|neoadjuvant therapy|
58284342|NCT00625183|PROCEDURE|therapeutic conventional surgery|
58284343|NCT00625183|RADIATION|radiation therapy|
58284344|NCT02362191|DEVICE|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
58284345|NCT05867966|BEHAVIORAL|psychoeduc/self-care/self-hypnosis group|See arm description.
58284346|NCT00897871|DRUG|carboplatin|
58284347|NCT00897871|DRUG|cyclophosphamide|
58284348|NCT00897871|DRUG|etoposide phosphate|
58284349|NCT00897871|GENETIC|gene expression analysis|
58284350|NCT00897871|GENETIC|polymorphism analysis|
58284351|NCT00897871|OTHER|pharmacological study|
58284352|NCT02066727|DRUG|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
58284353|NCT02066727|DRUG|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
58284354|NCT01900847|DRUG|Ketamine|0.3mg/kg ketamine
58284355|NCT01900847|DRUG|Morphine|Dosage of morphine determined by treating physician
58284356|NCT01900847|DRUG|placebo|saline of same volume as appropriate weight based dose of ketamine
58284357|NCT01739504|PROCEDURE|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
58284358|NCT01739504|BIOLOGICAL|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
58284359|NCT02020135|DRUG|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
58284360|NCT06174194|DIETARY_SUPPLEMENT|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
57728758|NCT03791125|DRUG|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
58398687|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
57728759|NCT06636188|OTHER|Digi-Coach Chatbot|Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
57930971|NCT02024451|DEVICE|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
58284361|NCT03584425|DIAGNOSTIC_TEST|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
58284362|NCT03584425|DIAGNOSTIC_TEST|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
58398688|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
58398689|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
58398690|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
58398691|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
57728760|NCT00375089|OTHER|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
57728761|NCT00375089|OTHER|Group 2|Individuals with Early-onset Morbid Obesity.
57728762|NCT00723177|DRUG|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
57930972|NCT02024451|DEVICE|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
57930973|NCT03020238|PROCEDURE|BiClamp group|electric energy
57930974|NCT03020238|PROCEDURE|water jet group|water jet energy
57930975|NCT04420650|DEVICE|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
57930976|NCT05302583|OTHER|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
57930977|NCT02599454|DRUG|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
57930978|NCT02599454|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
57930979|NCT00609843|OTHER|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
58398692|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
58398693|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
57728763|NCT00723177|DRUG|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
58398694|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
58398695|NCT00005077|DRUG|oxaliplatin|
57728764|NCT06669013|DRUG|dinutuximab beta|Chemotherapy + Immunotherapy (dinutuximab beta)
57728765|NCT01228162|PROCEDURE|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
57728766|NCT00016289|BIOLOGICAL|recombinant interleukin-12|Given intraperitoneally
57728767|NCT06531356|BIOLOGICAL|autologous amniotic fluid|10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
57728768|NCT06531356|OTHER|No amniotic fluid injected in skin edges|conventional closure of skin
57728769|NCT01480700|OTHER|Nutritional study|subjects consume 2 eggs per day during 4 months
57728770|NCT04013542|BIOLOGICAL|Ipilimumab|Given IV
57728771|NCT04013542|BIOLOGICAL|Nivolumab|Given IV
57728772|NCT04013542|RADIATION|Radiation Therapy|Undergo radiation therapy
57728773|NCT05652751|DRUG|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
57930980|NCT04450654|DRUG|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
57930981|NCT04450654|DRUG|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
58095419|NCT02494583|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
57930982|NCT01188473|OTHER|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
57930983|NCT01557179|DEVICE|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
57930984|NCT01557179|DEVICE|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
57930985|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
57930986|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
57930987|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
57930988|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
57930989|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
57930990|NCT00313040|BEHAVIORAL|Brief Consultation with Health Counselor, workbook|
57930991|NCT00313040|BEHAVIORAL|Usual Care wait list|
57930992|NCT05999396|DRUG|Administration of CC-3|Accelerated titration phase, Standard 3+3 titration phase, expansion phase
57930993|NCT02877836|OTHER|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
57930994|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
57930995|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
57930996|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
57930997|NCT01177722|BIOLOGICAL|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
57930998|NCT05189769|BEHAVIORAL|CP no REACT|Coping Power no REACT
57930999|NCT05189769|BEHAVIORAL|CP+/No REACT|CP+ and no REACT
57931000|NCT05189769|BEHAVIORAL|CP and REACT|Coping Power traditional and REACT
58095420|NCT02494583|DRUG|5-FU|5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
58284363|NCT03584425|DIAGNOSTIC_TEST|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
58284364|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
57931001|NCT05189769|BEHAVIORAL|CP+ and REACT|CP+ and REACT
58284365|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with fibromyalgia|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
57931002|NCT04123990|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
57931003|NCT05915988|DEVICE|UNEEG EpiSight solution|Implantation subcutis under local anesthetics
58095421|NCT02494583|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
57931004|NCT00636688|BEHAVIORAL|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
57931005|NCT00636688|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
57931006|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
58095422|NCT02494583|DRUG|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
57728774|NCT05652751|DRUG|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
57728775|NCT05652751|DEVICE|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
57931007|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
57931008|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
57931009|NCT03382184|DEVICE|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
57931010|NCT03382184|DEVICE|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
58284366|NCT03074461|PROCEDURE|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
57728776|NCT05652751|DEVICE|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
58284367|NCT03074461|PROCEDURE|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
58284368|NCT05059925|OTHER|Structured gym activities|"Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
58284369|NCT05059925|OTHER|Traditional aerobic activities|"Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
58284370|NCT00270621|BEHAVIORAL|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
58284371|NCT02963519|DEVICE|VistaCare®|
58284372|NCT02963519|DEVICE|Dressings|
58284373|NCT06128681|PROCEDURE|Intraairway ultrasound-guided mediastinal opening technique|Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses
58284374|NCT00482482|BEHAVIORAL|psychoeducation|on weekly basis for 8 weeks
57728777|NCT00370162|DRUG|lactoserum|
57931011|NCT03331653|OTHER|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
57931012|NCT03331653|OTHER|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
57931013|NCT04536610|BEHAVIORAL|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
58284375|NCT00482482|BEHAVIORAL|Yoga|on weekly basis for 8 weeks
58284376|NCT03253536|OTHER|observational|none (observational study)
58398696|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
57728778|NCT06412276|BEHAVIORAL|Control|Food menu will be provided as is typical for the out of home outlet
57728779|NCT06412276|BEHAVIORAL|Product price promotions removed|Food menus with no price reductions to products
57728780|NCT06412276|BEHAVIORAL|Bulk buy reductions removed|Food menus with bundles provided but not at reduced prices
58398697|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
58398698|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
58398699|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
57728781|NCT06412276|BEHAVIORAL|Volume value pricing removed|Food menus with proportionate pricing for multi-size products
57728782|NCT06412276|BEHAVIORAL|No price-based incentives|Food menus with no price-based incentives offered
57728783|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
58070119|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
58070120|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
58070121|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
58070122|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
58070123|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
58070124|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
58070125|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
58070126|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
58070127|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
58070128|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
58070129|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
58070130|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
58070131|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
58070132|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
58398700|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
58398701|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
58398702|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
58398703|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
58398704|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
57728784|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
57931014|NCT04536610|BEHAVIORAL|Giving informative leaflet|Leaflets containe the same information as the OP education program
58284377|NCT01599481|BEHAVIORAL|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
58284378|NCT01599481|BEHAVIORAL|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
58284379|NCT03627078|OTHER|motor interference therapy|
58284380|NCT03627078|OTHER|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
58284381|NCT04551365|BEHAVIORAL|Lifestyle changes|Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
58284382|NCT04551365|DIETARY_SUPPLEMENT|Chitosan|Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
58284383|NCT04551365|OTHER|Placebo|Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
58284384|NCT01928199|DRUG|Sitagliptin|
58284385|NCT01928199|DRUG|Placebo|
58284386|NCT05687409|DRUG|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
58284387|NCT05687409|DRUG|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
58284388|NCT05687409|DIETARY_SUPPLEMENT|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
58284389|NCT05345366|OTHER|non-applicable|non-applicable
58284390|NCT00957489|OTHER|Dynamax appliance|
58284391|NCT00957489|OTHER|Twin-block appliance|
58284392|NCT02779075|DRUG|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
58284393|NCT02779075|DRUG|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
58284394|NCT03606057|DRUG|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
58284395|NCT03606057|DRUG|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
58284396|NCT03606057|DRUG|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
58284397|NCT03606057|DRUG|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
58284398|NCT02706145|OTHER|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
58284399|NCT02829502|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
58284400|NCT02829502|DRUG|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
58284401|NCT01006590|DRUG|Saxagliptin|5 mg, oral tablet, once daily
58284402|NCT01006590|DRUG|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
58398705|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
58070133|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
58070134|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
58070135|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
57931015|NCT00902954|DRUG|anastrozole|anastrozole 1 mg qd
58070136|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
58070137|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
58070138|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
58070139|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
58070140|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
58070141|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
58284403|NCT02628158|PROCEDURE|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
58284404|NCT01679444|PROCEDURE|Magnetic Resonance Spectroscopy|
58284405|NCT05754671|OTHER|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
58284406|NCT05754671|OTHER|voice recording|voice recording
58284407|NCT03539484|DRUG|RO7172508|RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
58284408|NCT03539484|DRUG|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
58284409|NCT03539484|DRUG|Tocilizumab|Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
58284410|NCT03531476|BEHAVIORAL|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
58284411|NCT00580749|PROCEDURE|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
58284412|NCT00580749|PROCEDURE|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
58284413|NCT01489852|DRUG|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
58284414|NCT02094313|DRUG|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
57931016|NCT00902954|DRUG|letrozole|letrozole 2.5 mg qd
57931017|NCT00902954|DRUG|exemestane|exemestane 25 mg qd
57931018|NCT01910116|DRUG|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
57931019|NCT01910116|DRUG|Placebo|The study medication and placebo were identical in appearance.
57931020|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
58284415|NCT00596453|DRUG|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
58284416|NCT00596453|DRUG|Placebo|Placebo twice a day for 14 days
58284417|NCT02566499|DEVICE|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
58284418|NCT06500650|BEHAVIORAL|Person-centred Occupational Therapy Intervention|Person-centred Occupational Therapy Intervention
58284419|NCT06402877|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
58284420|NCT00568737|DRUG|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
58284421|NCT00568737|DRUG|Placebo|0.9% sodium chloride
58284422|NCT03816618|DRUG|Medihoney Gel in A Tube|TREATMENT1
58284423|NCT03816618|DRUG|Hydrogel|PURLOIN GEL
58284424|NCT03816618|DRUG|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
58284425|NCT01025102|DRUG|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
58284426|NCT04465084|OTHER|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
58398706|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
58398707|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
58398708|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
58398709|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
58398710|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
58398711|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
58284427|NCT04465084|OTHER|Withness|Experimental language tasks MRI
58284428|NCT02330172|OTHER|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
58284429|NCT03998371|DIAGNOSTIC_TEST|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
58284430|NCT03917277|DEVICE|Musculoskeletal ultrasound|"Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal"
58284431|NCT00768573|DRUG|sildenafil|Oral suspension of sildenafil.
58284432|NCT02331784|BEHAVIORAL|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
58284433|NCT02331784|BEHAVIORAL|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
58284434|NCT01399398|PROCEDURE|Brain Scan-PET|
58284435|NCT01399398|PROCEDURE|Brain Scan-MRI|
58284436|NCT01399398|PROCEDURE|Arterial Line|
58284437|NCT01399398|PROCEDURE|Venous Line|
58398712|NCT04322331|OTHER|no intervention|no intervention
58398713|NCT02885480|BEHAVIORAL|questionnaires|
58284438|NCT01399398|PROCEDURE|Blood Sampling|
58398714|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
58398715|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
57728785|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
57728786|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
58284439|NCT03373357|OTHER|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~* Cardiovascular events arisen during the duration of the study~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
58284440|NCT03373357|OTHER|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~* Questionnaire of evaluation of the global quality of life of the SAHOS~* Appearance of new cardiovascular risk factors~* Cardiovascular events arisen during the duration of the study~* Modification of the current treatments~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
58284441|NCT05979896|DRUG|Standard age based SPAQ administration for SMC|"Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine."
58284442|NCT00003190|DRUG|cytarabine|Given IV
57931021|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
57931022|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
57931023|NCT06007742|OTHER|parent-administered pediatric tuina|"Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention."
58070142|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
58070143|NCT02984228|BIOLOGICAL|PRP|
58070144|NCT02984228|DRUG|Hyaluronic Acid|
58284443|NCT00003190|DRUG|daunorubicin hydrochloride|Given IV
58284444|NCT00003190|DRUG|etoposide|Given IV
58284445|NCT00003190|DRUG|valspodar|Given IV
58284446|NCT06046131|OTHER|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
58284447|NCT02567097|BEHAVIORAL|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
58284448|NCT04188886|OTHER|Practice survey|Practice survey on
58284449|NCT01089010|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
58284450|NCT01089010|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
58284451|NCT01089010|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
58284452|NCT03867968|BEHAVIORAL|TIPS Intervention|Web-based training for family member.
58398716|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
58284453|NCT03867968|BEHAVIORAL|Control|Traumatic Brain Injury website for family members.
58398717|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
58398718|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
58398719|NCT03786081|DRUG|Bevacizumab|Given via IV
58398720|NCT03786081|DRUG|Pembrolizumab|Given via IV
58398721|NCT03786081|DRUG|Carboplatin|Given via IV
58398722|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
58398723|NCT02855957|OTHER|Free α-Hb pool analysis|
58398724|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
57931024|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
57931025|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
58070145|NCT02984228|DEVICE|Ultrasound|
58070146|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
58284454|NCT01473225|OTHER|Calorie information|Nutrition label featuring calorie information will be provided.
58284455|NCT01473225|OTHER|No calorie information|No nutrition label will be provided in this condition.
58284456|NCT02018432|DRUG|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
58284457|NCT02018432|DRUG|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
58284458|NCT01148459|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
58398725|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
58398726|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
58398727|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
58398728|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
58398729|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
58398730|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
58398731|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
58398732|NCT00083954|DRUG|Quetiapine Fumarate|
58398733|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
58398734|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
58398735|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
57931026|NCT01559194|BEHAVIORAL|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
58070147|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
57931027|NCT01559194|BEHAVIORAL|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
57931028|NCT00626210|DRUG|modafinil|100-400 mg daily for 4 weeks
57931029|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
57931030|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
57931031|NCT00147290|DEVICE|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
57931032|NCT04309279|BEHAVIORAL|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
58284459|NCT01148459|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
58284460|NCT01148459|BIOLOGICAL|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
58284461|NCT00259428|DRUG|Dronedarone (SR33589)|oral administration
58284462|NCT00259428|DRUG|placebo|oral administration
58284463|NCT01506687|BEHAVIORAL|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
58284464|NCT01506687|BEHAVIORAL|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
58284465|NCT05677958|DIETARY_SUPPLEMENT|125 mL Fortimel/Nutridrink Compact Protein|125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
58284466|NCT01104987|DRUG|alendronate|One tablet of alendronate à 70 mg once a week during two years.
58284467|NCT00571116|DRUG|Disulfiram|Given PO
58284468|NCT00571116|DRUG|Arsenic trioxide|Given IV
57931033|NCT03508167|DEVICE|Thermal Band|Thermal Band used 8 hours per day
58284469|NCT03992833|OTHER|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume \> 300 mm3 (positive)."
58284470|NCT01454219|OTHER|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
58284471|NCT01023425|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
57931034|NCT03508167|DRUG|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
57931035|NCT03508167|DRUG|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
57931036|NCT06493682|BEHAVIORAL|Experimental (Motivational Interviews)|Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
57931037|NCT00774865|PROCEDURE|MIBI and CTA|Rest and Stress MIBI and CT Angiography
57931038|NCT00819260|DEVICE|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
57931039|NCT00819260|DEVICE|Electrocautery|Electrocautery used to reduce breast on this side
57931040|NCT05208164|BEHAVIORAL|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
57931041|NCT06735508|DRUG|mRNA Neoantigen Vaccine|mRNA Neoantigen Vaccine
57931042|NCT06735508|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
58070148|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
58070149|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
58070150|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
58070151|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
58070152|NCT01207427|DRUG|Placebo|
58284472|NCT02772146|DEVICE|CLS UF|One single ultrafiltration session of 10 hours.
58284473|NCT04444336|BEHAVIORAL|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
58284474|NCT00818740|DRUG|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
58284475|NCT03363893|DRUG|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
57931043|NCT00619190|DRUG|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
58398736|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
57931044|NCT02513186|DRUG|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
57931045|NCT02513186|DRUG|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
57931046|NCT02513186|DRUG|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
57931047|NCT02513186|DRUG|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
57931048|NCT02513186|DRUG|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
57931049|NCT02869555|OTHER|Data collection|
57931050|NCT00824824|DRUG|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
58070153|NCT01207427|DRUG|ADL5945 0.1 mg|
58070154|NCT01207427|DRUG|ADL5945 0.25 mg|
58284476|NCT03363893|DRUG|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
58284477|NCT02514200|PROCEDURE|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
58284478|NCT02514200|PROCEDURE|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
58284479|NCT02514200|DRUG|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
58284480|NCT02514200|DEVICE|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
58284481|NCT04231240|DEVICE|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
58398737|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
57931051|NCT00824824|DRUG|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
57931052|NCT04110964|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
57931053|NCT01493258|OTHER|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
57931054|NCT01878643|DRUG|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
58070155|NCT00021346|DRUG|carboplatin|
58070156|NCT00021346|DRUG|gemcitabine hydrochloride|
57931055|NCT01878643|DRUG|Placebo|normal saline administered to patient via nebulization
57931056|NCT06736015|DIETARY_SUPPLEMENT|Myo-Inositol 600 mg + Selenium 83 mcg|Myo-Inositol 600 mg + Selenium 83 mcg: 1 tablet once a day for 6 months
58070157|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
58284482|NCT01681095|DRUG|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
58284483|NCT01681095|DRUG|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
58284484|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
58284485|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
58398738|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
58070158|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
58070159|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
58070160|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
58070161|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
58070162|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
58070163|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
58398739|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
58398740|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
58398741|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
58398742|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
58398743|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
57728787|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
57931057|NCT02190669|OTHER|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
57931058|NCT03312088|DEVICE|Freedom Knee PCK Components|Total Knee Revision
58398744|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
58398745|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
58398746|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
58398747|NCT00501592|DRUG|Placebo|Placebo
57931059|NCT06693310|OTHER|de-escalation or discontinuation of therapy|De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.
57931060|NCT06693310|OTHER|continuation of current therapy|continuation of current maintenance medical therapy for ulcerative colitis
58070164|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
58070165|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
58070166|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
58070167|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
58398748|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
58398749|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
58422769|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
58422770|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
57931061|NCT02037646|OTHER|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
57931062|NCT02037646|OTHER|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
57931063|NCT02037646|PROCEDURE|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
57931064|NCT02037646|OTHER|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
57931065|NCT02037646|OTHER|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
57931066|NCT02037646|OTHER|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
57931067|NCT03675776|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
57931068|NCT03675776|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration).
57931069|NCT01636791|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
57931070|NCT01636791|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
57931071|NCT06441890|DRUG|Paclitaxel|80mg/m2 IV D1, 8, 15
57931072|NCT06441890|DRUG|Nab-paclitaxel|125mg/m2 IV D1, 8, 15
57931073|NCT06441890|DRUG|Docetaxel|75mg/m2 IV D1
57931074|NCT06441890|DRUG|Trastuzumab|8mg/kg loading, then 6mg/kg IV/SQ D1
57931075|NCT06441890|DRUG|Pertuzumab|840 mg loading, then 420mg IV/SQ D1
58422771|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
57931076|NCT00613054|DRUG|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations."
57931077|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
58422772|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
57931078|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
57931079|NCT00979251|DRUG|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
57931080|NCT00979251|DRUG|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
57931081|NCT02294123|OTHER|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
57931082|NCT04689997|BEHAVIORAL|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
58422773|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
57931083|NCT04583891|BEHAVIORAL|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
58070168|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
58070169|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
58070170|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
58070171|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
58422774|NCT00265018|DRUG|Adriamycin|
58422775|NCT00265018|DRUG|Bleomycin|
58422776|NCT00265018|DRUG|Vinblastine|
58422777|NCT00265018|DRUG|DTIC|
58422778|NCT00265018|RADIATION|30 Gy IF-RT|
58398750|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
58398751|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
58398752|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
58398753|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
58398754|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
58398755|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
58398756|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
58398757|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
58398758|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
58398759|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
58398760|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
58398761|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
58398762|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
58398763|NCT03783000|DRUG|BI 425809|Treatment T
58398764|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
58398765|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
58398766|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
58398767|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
58398768|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
58070172|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
58070173|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
58398769|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
58398770|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
58422779|NCT00265018|RADIATION|20 Gy IF-RT|
58070174|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
58284486|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
58398771|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
58398772|NCT00146809|DRUG|Minocyline|
58422780|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
57931084|NCT04583891|BEHAVIORAL|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
57931085|NCT04583891|BEHAVIORAL|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
57931086|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
57931087|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
57931088|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
57931089|NCT01674712|DRUG|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
57931090|NCT01674712|DRUG|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
57931091|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
57931092|NCT01674712|DRUG|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
58284487|NCT04513171|DRUG|Norditropin®|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
58284488|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
58284489|NCT04513171|DRUG|Norditropin|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
58284490|NCT01468571|DRUG|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
58284491|NCT01468571|DRUG|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
58284492|NCT00507858|DRUG|Pemetrexed|Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks
58284493|NCT00507858|DRUG|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
58284494|NCT06406166|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
58284495|NCT06406166|OTHER|Conventional treatment with Western medicine|Conventional treatment with Western medicine
58284496|NCT03151083|BEHAVIORAL|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
58284497|NCT04296578|DRUG|Abiraterone Acetate|Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
58284498|NCT04296578|DRUG|Sodium Selenite|11 mg tablets
58284499|NCT04296578|DRUG|Prednisone|SOC prednisone 5 mg PO twice daily
58284500|NCT00822328|DIETARY_SUPPLEMENT|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
58284501|NCT00822328|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
58284502|NCT03453957|OTHER|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
58284503|NCT00187278|DEVICE|Biventricular Pacing|Biventricular Pacemaker implant
58284504|NCT00187278|DEVICE|RV Pacing|Standard Pacemaker implant
58284505|NCT02025933|OTHER|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
58284506|NCT02025933|OTHER|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
57931093|NCT01762176|PROCEDURE|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
57931094|NCT01762176|PROCEDURE|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
58398773|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
58398774|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
58398775|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
58398776|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
58398777|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
57931095|NCT01793363|PROCEDURE|Tracheotomy|
57931096|NCT01230554|DEVICE|Daily disposable cosmetic tint lens|Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
58070175|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
58398778|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
58398779|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
58398780|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
58398781|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
58398782|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
58398783|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
58422781|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
58422782|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
58422783|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
58070176|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
58070177|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
58070178|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
57931097|NCT04858906|DEVICE|McGrath laryngoscope|The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).
57931098|NCT04858906|DEVICE|C-MAC D-blade laryngoscope|The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
57931099|NCT06495385|DIAGNOSTIC_TEST|Evolution of renal function|Plasma creatinine levels and glomerular filtration rate estimated using the CKD-Epi formula adjusted for 1.73 m2 body surface area will be measured.
58070179|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
58284507|NCT02025933|OTHER|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
58284508|NCT04010084|RADIATION|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
58284509|NCT04010084|PROCEDURE|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
58284510|NCT03925181|BEHAVIORAL|Counselling Group|All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
58284511|NCT03140098|DEVICE|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
58284512|NCT02837302|DRUG|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
58284513|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Rind|watermelon rind
58284514|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Flesh|watermelon flesh
58284515|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Seeds|watermelon seeds
58398784|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
58398785|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
58398786|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
58398787|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
58398788|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
58398789|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
58398790|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
58070180|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
58284516|NCT03365960|DIETARY_SUPPLEMENT|Placebo|Control Comparator
58284517|NCT03671785|DRUG|PRIM-DJ2727|Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
58284518|NCT03671785|DRUG|Placebo oral capsule|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
58398791|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
58398792|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
58422784|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
58070181|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
58070182|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
58398793|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
57728788|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
58070183|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
58070184|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
58070185|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
58070186|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
58284519|NCT00966732|BEHAVIORAL|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
58284520|NCT03678675|DRUG|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
58284521|NCT03514056|DIAGNOSTIC_TEST|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
58284522|NCT03514056|DIAGNOSTIC_TEST|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
58284523|NCT05248906|DIAGNOSTIC_TEST|Giant cell arteritis|Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy
58284524|NCT03061578|DIAGNOSTIC_TEST|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
58284525|NCT03061578|DIAGNOSTIC_TEST|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
58398794|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
58070187|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
58070188|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
58070189|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
58070190|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
58070191|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
58070192|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
58070193|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
58070194|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
58070195|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
58284526|NCT03210012|DIAGNOSTIC_TEST|Transthoracic echocardiography|Diagnostic test done prior and after the dive
58284527|NCT03210012|DIAGNOSTIC_TEST|Blood samples|Diagnostic test done prior and after the dive
58284528|NCT05056155|OTHER|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
58284529|NCT04170946|OTHER|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
58284530|NCT01180023|PROCEDURE|Sweeping|Sweeping of membranes during digital exam
58284531|NCT01589588|DEVICE|Open Hudson Mask|Mask type 1 oxygen
58284532|NCT01589588|DEVICE|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
58284533|NCT01589588|DEVICE|Mask 3|Mask type 3 oxygen
58284534|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 oxygen
58284535|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 placebo
58284536|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
58284537|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
58422785|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
58422786|NCT02210832|BEHAVIORAL|Best practices|
58422787|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
58422788|NCT00563823|DRUG|vatalanib|
58422789|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
58422790|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
57931100|NCT06495385|DIAGNOSTIC_TEST|Measurement of haemoglobin levels|Haemoglobin levels will be measured.
57931101|NCT06495385|DIAGNOSTIC_TEST|Measurement of biological parameters|Plasma levels of urea, calcium, phosphorus and parathyroid hormone, as well as alkaline reserve, will be measured.
58070196|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
58070197|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
58070198|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
58070199|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
58070200|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
58398795|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
58070201|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
58070202|NCT01102439|DRUG|Aspirin|81 mg daily
58070203|NCT01102439|DRUG|Aspirin|325 mg daily
58070204|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
58070205|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
58284538|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
58284539|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
58284540|NCT01306214|DRUG|BI 10773|BI 10773 low dose once daily
58284541|NCT01306214|DRUG|BI 10773|BI 10773 high dose once daily
58284542|NCT04687189|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
58398796|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
58070206|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
58070207|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
58070208|NCT02972658|DRUG|Lanabecestat|Administered orally
57931102|NCT06495385|DIAGNOSTIC_TEST|Measure sodium and protein consumption|24-hour urine volume, proteinuria, urea and sodium, will be measured.
57931103|NCT06495385|BEHAVIORAL|Quality of life questionnaire EUROQOL 5 dimensions (EQ-5D-5L)|"The descriptive system comprises five dimensions: mobility, personal care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The figures for the five dimensions can be combined into a 5-digit number describing the patient's state of health. Scores close to 1 indicate the best health you can imagine and those close to 0 the worst health you can imagine."
57931104|NCT06719544|DRUG|lithium carbonate|Oral capsule
57931105|NCT06719544|DRUG|enlicitide|Oral tablet
57931106|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
58070209|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
58070210|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
58070211|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
58070212|NCT00394173|DRUG|Placebo|Matching placebo
58070213|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
58070214|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
58095423|NCT03591107|OTHER|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
58284543|NCT06613243|DRUG|Esketamine 0.2 mg/kg|Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
58284544|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
57931107|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
57931108|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
57931109|NCT00642551|DIETARY_SUPPLEMENT|menaquinone-7|180 µg menaquinone-7 daily for three years
58070215|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
58070216|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
58095424|NCT03591107|OTHER|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
58095425|NCT03315910|BEHAVIORAL|Motivational Interviewing (MI)|two counseling sessions
58095426|NCT03315910|DRUG|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
58095427|NCT03315910|DRUG|Nicotine Lozenge|6 packs of NRT 2mg lozenge
58284545|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
58284546|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
57728789|NCT05531539|DEVICE|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
57728790|NCT00534729|DRUG|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
57728791|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
57728792|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
57728793|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
57728794|NCT04894253|BIOLOGICAL|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
57728795|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
57931110|NCT00642551|DIETARY_SUPPLEMENT|placebo|1 placebo capsule daily for three years
57931111|NCT05922020|OTHER|Oxygen gas|Administration of Oxygen by inhalation
57931112|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
57931113|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
58284547|NCT01490840|OTHER|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
58284548|NCT06613256|OTHER|Endothelial cell biopsy|Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
58284549|NCT03319810|BIOLOGICAL|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
58284550|NCT05240703|DEVICE|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
58284551|NCT04709497|PROCEDURE|viscotrabeculotomy (VT)|viscotrabeculotomy (VT)
58284552|NCT04709497|PROCEDURE|visco-circumferential-suture-trabeculotomy (VCST) .|visco-circumferential-suture-trabeculotomy (VCST)
58284553|NCT04709497|PROCEDURE|combined VT-Trabeculectomy with MMC (VT-Trab).|combined VT-Trabeculectomy with MMC (VT-Trab).
58284554|NCT02390713|DEVICE|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
58284555|NCT00077155|DRUG|cilengitide|
58284556|NCT05779787|PROCEDURE|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
58284557|NCT05779787|PROCEDURE|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
58284558|NCT00190398|DEVICE|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
58284559|NCT03743727|DRUG|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
58284560|NCT02685332|RADIATION|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30"
58095428|NCT03315910|BEHAVIORAL|Message Framing|health communication literature and quitting messages
58095429|NCT03315910|OTHER|saliva sample|saliva samples from those reporting abstinence and analyze samples
58095430|NCT06582888|DRUG|Varenicline Tartrate|varenicline (target dose 1mg twice daily)
58398797|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
58398798|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
58398799|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
58284561|NCT00915603|DRUG|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
57931114|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
58284562|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
58284563|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
58284564|NCT00915603|DRUG|Placebo|Placebo PO daily continuously for all 28 days of a cycle
58284565|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
58284566|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
58284567|NCT04788186|DRUG|De-prescribe beta blocker therapy|"Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue"
58284568|NCT03994237|OTHER|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
58284569|NCT01009255|DRUG|GSK239512|Histamine H3 Antagonist
58284570|NCT01009255|DRUG|Placebo|Placebo to match GSK239512
58284571|NCT04230772|PROCEDURE|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
58284572|NCT04230772|PROCEDURE|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
58284573|NCT01476800|DRUG|YM178 OCAS|oral
58284574|NCT01476800|DRUG|Ketoconazole|oral
58284575|NCT05916053|DIETARY_SUPPLEMENT|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
57931115|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
58095431|NCT06582888|DRUG|Placebo|matched placebo
58284576|NCT05223790|DEVICE|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
58284577|NCT04442152|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
58284578|NCT00399711|DRUG|repaglinide and metformin combination tablet|
58284579|NCT00399711|DRUG|rosiglitazone and metformin combination tablet|
58284580|NCT06439693|DRUG|Nab-Paclitaxel|Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.
58284581|NCT06439693|DRUG|Paclitaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
58284582|NCT06439693|DRUG|Docetaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
58284583|NCT06439693|DRUG|Phesgo|Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.
58398800|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
57931116|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
58070217|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
58070218|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
58070219|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
57728796|NCT04092660|BEHAVIORAL|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits"
58070220|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
58070221|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
58070222|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
58070223|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
58070224|NCT03016520|DRUG|DWJ1392|
58070225|NCT03016520|DRUG|DWC20164|
57931117|NCT06717399|OTHER|Mindfulness meditation|Each mindfulness meditation session will be 30 minutes long, consisting of a 5-minute introduction, 15 minutes of guided mindfulness meditation, and 10 minutes of educational discussion.
58070226|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
57931118|NCT03427125|DRUG|Tenapanor|Active Drug
57931119|NCT03427125|DRUG|Placebo|Inactive Drug
57931120|NCT03427125|DRUG|Sevelamer Carbonate|Active control
57931121|NCT06198842|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
58070227|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
58070228|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
58070229|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
58070230|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
58070231|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
58070232|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
58070233|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
58070234|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
58070235|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
58070236|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
58398801|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
58398802|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
58398803|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
58398804|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
58398805|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
58398806|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
57931122|NCT06589258|BIOLOGICAL|Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding|Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
57931123|NCT01983397|OTHER|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
57931124|NCT01983397|OTHER|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
57931125|NCT00129623|DRUG|Placebo|po monthly for 1 year
58070237|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
57931126|NCT00129623|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
57931127|NCT04442360|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
58070238|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
58284584|NCT06439693|DRUG|T-DM1|HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.
58284585|NCT06439693|DRUG|Pertuzumab|Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
58284586|NCT06439693|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.
58284587|NCT06439693|DRUG|Trastuzumab Subcutaneous Subcutaneous|Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.
57931128|NCT03875287|DRUG|Decitabine|"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5"
57931129|NCT03875287|DRUG|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5"
58070239|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
58070240|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
58070241|NCT00247052|DRUG|matching placebo|
58070242|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
58284588|NCT06439693|DRUG|Tucatinib|Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.
58284589|NCT06439693|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
58284590|NCT03115593|PROCEDURE|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
58284591|NCT03115593|PROCEDURE|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
58398807|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
58398808|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
58398809|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
58284592|NCT05840549|PROCEDURE|TURP|TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
58284593|NCT05840549|PROCEDURE|UroLift|UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
57728797|NCT04092660|DEVICE|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
57931130|NCT02616666|DRUG|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
58095432|NCT04534127|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
58095433|NCT06538805|OTHER|Minimal invasive management of dental caries|Minimal invasive management of dental caries among dentists
58284594|NCT06101888|DEVICE|TaurusTrio™ Heart Valve System|The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
58284595|NCT04409977|DIAGNOSTIC_TEST|MRI examination|Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
58284596|NCT06337734|BEHAVIORAL|AI-Driven Lifestyle Coaching Program|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
58284597|NCT05689567|DEVICE|DEFOG glasses(peripheral focus-out glasses)|Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.
58284598|NCT04539548|DRUG|Dextenza Ophthalmic Insert|0.4mg insert for intracanalicular use
58284599|NCT04539548|DRUG|Prednisolone acetate ophthalmic suspension USP 1%|"1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week"
58284600|NCT01301079|DRUG|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
58284601|NCT01301079|DRUG|Saline|Patients in group N (placebo) was administrated saline during surgery.
58284602|NCT02414217|BEHAVIORAL|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
58284603|NCT02414217|BEHAVIORAL|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
58284604|NCT02092649|DIETARY_SUPPLEMENT|Omega-3 Complete|
58284605|NCT02092649|DIETARY_SUPPLEMENT|Placebo Pill|
58284606|NCT00717795|BEHAVIORAL|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
58398810|NCT05240157|DRUG|Corticosteroid Derivatives|observational
58398811|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
58398812|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
58398813|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
58398814|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
58398815|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
58398816|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
58398817|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
58398818|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
57728798|NCT06068686|DRUG|Vildagliptin 50 MG|vildagliptin plus their metformin.
58070243|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
58284607|NCT00717795|BEHAVIORAL|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
58284608|NCT06145997|OTHER|Acupuncture therapy|Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
58284609|NCT03668977|DIETARY_SUPPLEMENT|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
58284610|NCT02419391|BIOLOGICAL|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
58284611|NCT02419391|OTHER|Placebo|Tris Buffered Saline, sterile
58284612|NCT02016911|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
57728799|NCT06068686|DRUG|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
57728800|NCT01012882|BIOLOGICAL|sublingual immunotherapy with allergen extract|sublingual application
58284613|NCT04480996|DRUG|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
57728801|NCT01012882|BIOLOGICAL|sublingual immunotherapy with placebo|sublingual application
57728802|NCT00335660|DRUG|AV608|
58284614|NCT00315614|BIOLOGICAL|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
58284615|NCT01949142|DRUG|OTO-201|Single, intratympanic injection
58284616|NCT01949142|DRUG|Sham|Simulated single, intratympanic injection
58284617|NCT01324921|OTHER|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
58284618|NCT01324921|OTHER|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
58284619|NCT01324921|OTHER|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
58284620|NCT01516736|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
58284621|NCT01516736|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
58284622|NCT03374163|DRUG|intralipid 20%|milky soulation for energey supplement.
58284623|NCT02897466|OTHER|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
58284624|NCT06006598|DRUG|BI 1584862|BI 1584862
58284625|NCT06006598|DRUG|Placebo matching BI 1584862|Placebo matching BI 1584862
58284626|NCT06006598|DRUG|midazolam|midazolam
58284627|NCT01541072|DRUG|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
58284628|NCT01541072|DRUG|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
58284629|NCT01310582|DRUG|Desflurane|
58284630|NCT01310582|DRUG|Sevoflurane|
58284631|NCT01007383|DRUG|LEO 27847|First in man
58284632|NCT05671159|OTHER|Blood sample|A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
58284633|NCT00287209|DRUG|Amiodarone|
58284634|NCT04204304|DRUG|Isotretinoin|ISO
58284635|NCT04564105|BEHAVIORAL|simulation education|Intubation protocol will be trained by simulation exercise.
57728803|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
58070244|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
58070245|NCT02490111|DRUG|DWJ1319|
58070246|NCT02490111|DRUG|Placebo|
58070247|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
58284636|NCT01142505|DRUG|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
58284637|NCT01142505|DRUG|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
58284638|NCT03724045|DIETARY_SUPPLEMENT|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
58284639|NCT04529317|DIETARY_SUPPLEMENT|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
58398819|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
58398820|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
58398821|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
58398822|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
58398823|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
58398824|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
58398825|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
58398826|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
58398827|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
58398828|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
58398829|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
58398830|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
58398831|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
58398832|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
58398833|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
58398834|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
58398835|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
58398836|NCT00006447|PROCEDURE|Social Support|
58398837|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
58284640|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, high Positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 5 cmH2O
58070248|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
58284641|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
58070249|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
58070250|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
58070251|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
58284642|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Zero support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
58284643|NCT00824629|PROCEDURE|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
58284644|NCT00824629|PROCEDURE|Direct embryo transfer procedure|Direct embryo transfer procedure
58284645|NCT01285479|DRUG|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
58284646|NCT06087705|DEVICE|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~* Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~* Check the integrity of the sterility protector.~* Take the syringe and remove the protective tip.~* Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~* Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~* A visual check of the attachment of the needle will be carried out.~* Remove the needle cap.~* Inject slowly."
58284647|NCT05622643|OTHER|MRI|Comparison between groups
57931131|NCT02616666|DRUG|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
57931132|NCT05207735|DRUG|Sintilimab|"* Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
57931133|NCT01765868|DRUG|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
57931134|NCT02185209|DRUG|Placebo|Place capsule to mimic antibiotics
57931135|NCT02185209|DRUG|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
57931136|NCT02185209|DRUG|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
57931137|NCT02185209|DRUG|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
57931138|NCT00517777|DEVICE|continuous positive airway pressure ventilation|nighttime
57931139|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
57931140|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
57931141|NCT03786159|OTHER|No intervention|No intervention
57931142|NCT01292798|DRUG|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
57931143|NCT01428661|DRUG|tasimelteon|20 mg once daily
57931144|NCT01428661|DRUG|placebo|once daily
57931145|NCT04895072|PROCEDURE|Standard group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a standard injection rate.
57931146|NCT04895072|PROCEDURE|Long group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a long injection rate.
57931147|NCT02212873|OTHER|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
57931148|NCT03423823|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
57931149|NCT03423823|DRUG|Ranibizumab|Anti-VEGF standard of care injection
57931150|NCT01410435|DRUG|Monofer|Infusion according to current HB level
57931151|NCT06735313|DIAGNOSTIC_TEST|Periodontal examination and saliva collection|Before the periodontal examination, saliva samples are collected from each patient participating in the study and periodontal measurements are made.
57931152|NCT03838354|DRUG|Chidamide|Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
58284648|NCT02347072|DRUG|GFF MDI (PT003)|
58284649|NCT02347072|DRUG|Placebo MDI|
58284650|NCT02347072|DRUG|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
58284651|NCT01887678|DRUG|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
58284652|NCT01887678|DRUG|Placebo|Placebo is an injection of Saline
58284653|NCT05206396|DIAGNOSTIC_TEST|TIL assessment in pre-existing histopathological specimens|TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
58284654|NCT06397053|PROCEDURE|robotic surgery|robotic surgery
57931153|NCT03838354|DRUG|Chidamide|Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
58398838|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
58398839|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
58398840|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
58398841|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
57931154|NCT01791023|OTHER|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
58284655|NCT04926285|DRUG|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
58284656|NCT04926285|DRUG|Venetoclax|Venetoclax at 400mg
58284657|NCT02434159|OTHER|Heart scan|
58284658|NCT01272505|PROCEDURE|converntional SILC|
58284659|NCT01272505|PROCEDURE|Harmonic scalpel Single incision laparoscopic cholecystectomy|
58284660|NCT05912075|DRUG|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
57728804|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
57728805|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
57728806|NCT03391648|OTHER|Observation|Observation only
57728807|NCT00147966|DRUG|rituximab|treatment with rituximab
57728808|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
57728809|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
57728810|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
57931155|NCT06431009|OTHER|Treatment-as-usual|Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
57931156|NCT06166979|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)
58284661|NCT05912075|RADIATION|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
58284662|NCT05912075|DRUG|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
58284663|NCT05912075|DRUG|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
58284664|NCT05912075|RADIATION|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
58284665|NCT05912075|DRUG|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
58284666|NCT05912075|DRUG|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
58284667|NCT01048944|DRUG|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
58284668|NCT01048944|DRUG|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
58284669|NCT01048944|DRUG|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
58398842|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
58398843|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
58398844|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
58398845|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
58398846|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
57931157|NCT06166979|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
57931158|NCT05682079|OTHER|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
57931159|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
58070252|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
58284670|NCT00029861|DRUG|Rimonabant (SR141716)|
58284671|NCT04356599|OTHER|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
58284672|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
58284673|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
58284674|NCT03638830|OTHER|placebo+Maxipim|placebo
58284675|NCT04719845|PROCEDURE|Endoscopic laser resection|Laser resection
58284676|NCT04719845|PROCEDURE|Dilatation|Dilatation
58284677|NCT01447641|OTHER|Polysomnography|Overnight physiological recording of sleep
58284678|NCT01447641|OTHER|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
58070253|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
58070254|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
58095434|NCT03145558|DRUG|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
58284679|NCT01015105|OTHER|observation|observation
58284680|NCT02333500|OTHER|olfactory workshop|olfactory workshop
58284681|NCT02333500|OTHER|other workshop|other workshop: discussion group, dance and body Expression
58284682|NCT02333500|OTHER|No intervention|control group
58284683|NCT01727362|OTHER|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
58284684|NCT01727362|OTHER|Usual care|Patients of this group receive usual care only
58284685|NCT03959488|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
58284686|NCT03959488|DRUG|Palivizumab|Approved anti-RSV monoclonal antibody
58284687|NCT00559143|OTHER|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
58284688|NCT04110899|OTHER|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
58284689|NCT04630782|DIAGNOSTIC_TEST|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
58284690|NCT05247346|DEVICE|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
58284691|NCT05816850|DIAGNOSTIC_TEST|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
57931160|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
57931161|NCT03462472|BEHAVIORAL|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
57931162|NCT03462472|BEHAVIORAL|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
58070255|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
58284692|NCT05816850|DIAGNOSTIC_TEST|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
58284693|NCT03910881|OTHER|Open-platform patient support system (PSS) app|The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
58284694|NCT05943431|DEVICE|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
58284695|NCT05943431|DEVICE|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
58284696|NCT05943431|DEVICE|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
58284697|NCT00086606|DRUG|Xolair (omalizumab)|
58284698|NCT01654263|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
58284699|NCT01327092|OTHER|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
58284700|NCT04146857|OTHER|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
58284701|NCT04146857|OTHER|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
58284702|NCT04146857|OTHER|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
58284703|NCT05243069|PROCEDURE|Imaging Technique|Undergo 3D scanning
58284704|NCT02652702|PROCEDURE|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
58284705|NCT02652702|PROCEDURE|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
58284706|NCT00675077|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
58284707|NCT02330224|OTHER|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses"
58284708|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
58284709|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
58284710|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
58070256|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
58070257|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
58095435|NCT03145558|DRUG|Doxorubicin|Standard of care for TACE
58095436|NCT06274697|DEVICE|Evaluation by magnetic sensor|Evaluation by magnetic sensor on arm and leg
58398847|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
58398848|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
58398849|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
58398850|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
58398851|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
58398852|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
58398853|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
58398854|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
58398855|NCT01595971|OTHER|usual care|Received the usual care provided
57931163|NCT05497648|BEHAVIORAL|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
57931164|NCT00526981|OTHER|Prone position|Prone position during spontaneous breathing.
57931165|NCT01515293|PROCEDURE|Single Incision Laparoscopic Appendectomy|
57931166|NCT01515293|PROCEDURE|Conventional appendectomy|
57931167|NCT00984490|DRUG|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
58284711|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
57728811|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
57728812|NCT03343262|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
58284712|NCT01134263|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 ml, SC
58284713|NCT00960973|DRUG|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
58284714|NCT00960973|DRUG|Placebo|Placebo
58284715|NCT03528382|BEHAVIORAL|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
57728813|NCT03343262|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
58284716|NCT05201443|DEVICE|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
58284717|NCT05201443|DEVICE|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
58284718|NCT00146549|DRUG|Trastuzumab|
58284719|NCT00146549|DRUG|Vinorelbine|
58284720|NCT00146549|DRUG|Paclitaxel|
58284721|NCT00146549|DRUG|Docetaxel|
58284722|NCT04705532|DEVICE|tDCS|Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
57931168|NCT00984490|OTHER|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
57931169|NCT04562194|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
57931170|NCT02796001|BIOLOGICAL|human rhinovirus|human rhinovirus
57931171|NCT02796001|OTHER|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
57931172|NCT01387048|DRUG|skinoren|gel 15%, twice daily, 36 weeks
57931173|NCT01387048|DRUG|differin|0.1% gel, once daily in the evening
58070258|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
58070259|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
58070260|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
58070261|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
58070262|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
58070263|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
58070264|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
58070265|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
58284723|NCT04705532|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
58284724|NCT04705532|OTHER|Music|Subjects will listen to their preferred music for 20 minutes
58284725|NCT04705532|OTHER|White noise|Subjects will listen to a white noise for 20 minutes
57931174|NCT01387048|DRUG|skinoren|12 weeks treatment, the following 24 months only observation
58284726|NCT05873868|OTHER|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
58284727|NCT05873868|OTHER|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
58284728|NCT05873868|OTHER|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
58284729|NCT02447770|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
57931175|NCT06735651|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
57931176|NCT06735651|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks
57931177|NCT00680563|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
57931178|NCT03533595|DEVICE|Barbed|Barbed Suture
57931179|NCT02221232|DRUG|Chloraprep|Apply topically.
57931180|NCT02221232|DRUG|ZuraPrep|Apply topically.
57931181|NCT02221232|DRUG|ZuraPrep Vehicle|Apply topically.
57931182|NCT01817855|DRUG|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
57931183|NCT01817855|DRUG|Placebo to match|Multiple doses inhaled placebo via a nebulizer
57931184|NCT05593874|DIAGNOSTIC_TEST|Histones H3.1 blood levels|Measure of blood concentrations of histone subtype H3.1
57931185|NCT01200108|DRUG|Budesonide|
57931186|NCT01200108|DRUG|Budesonide|
57931187|NCT01200108|DRUG|Budesonide|
57931188|NCT03201913|DRUG|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
57931189|NCT05737043|DIAGNOSTIC_TEST|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
57931190|NCT02941133|OTHER|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
58070266|NCT06313567|OTHER|Observation|observation
58284730|NCT00510055|PROCEDURE|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
58398856|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
58398857|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
57931191|NCT02941133|OTHER|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
57931192|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
57931193|NCT02849158|OTHER|Biopsy|Rectoscopy with biopsy
57931194|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
57931195|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
57931196|NCT06683560|DEVICE|": photopolymer resin material graphy Tera Harz 85 will be used to print 3D printed aligners for NAM treatment"|3d printed NAM aligner is made from novel photopolymer resin as a novel device
57931197|NCT01050907|DRUG|Miltefosine|2.5 mg/kg/day for 28 days
57931198|NCT01727583|DIETARY_SUPPLEMENT|meal intake|Intake of meals characterized by lipid composition
57931199|NCT01727583|DIETARY_SUPPLEMENT|Placebo|
57931200|NCT06655610|DEVICE|External Trigeminal Nerve Stimulation|Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.
57931201|NCT06655610|DEVICE|Sham device|The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
57931202|NCT05493852|DEVICE|FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.
58070267|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
58070268|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
58284731|NCT00510055|PROCEDURE|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
58284732|NCT05080738|OTHER|Upper Extremity Home Exercises|"The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders."
58284733|NCT01421147|DRUG|LY2963016|Administered subcutaneously
58284734|NCT01421147|DRUG|Lantus|Administered subcutaneously
58284735|NCT01421147|DRUG|Insulin Lispro|Administered subcutaneously
58284736|NCT00833404|DRUG|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
58284737|NCT02484768|DRUG|Iron isomaltoside 1000|Intravenous treatment
58284738|NCT02484768|DRUG|Sodium Chloride 0.9%|Intravenous treatment
58398858|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
58398859|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
58398860|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
57931203|NCT03902561|DEVICE|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
57931204|NCT03430219|DEVICE|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
58070269|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
57931205|NCT04778969|DEVICE|drug-eluting stent|A group of percutaneous coronary intervention (PCI) using drug-eluting stents (DES)
57931206|NCT04778969|DEVICE|drug-coated balloon|A group of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB)
57728814|NCT05237622|DEVICE|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
57931207|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
57931208|NCT02627222|OTHER|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
57931209|NCT02627222|OTHER|White cassava|Conventional white cassava
57931210|NCT06735118|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy
57931211|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
57931212|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
57931213|NCT04338152|BEHAVIORAL|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
57931214|NCT04338152|BEHAVIORAL|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
58070270|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
58070271|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
58070272|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
58284739|NCT04416919|OTHER|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
58284740|NCT04919148|BEHAVIORAL|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
58284741|NCT00463489|BEHAVIORAL|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
58070273|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
58070274|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
58070275|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
58070276|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
58070277|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
58070278|NCT06306417|DEVICE|acupuncture|acupuncture
58070279|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
58070280|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
58070281|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
58095437|NCT06565689|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
58095438|NCT02296047|DRUG|Placebo|physiological saline
57728815|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
57931215|NCT03765775|BIOLOGICAL|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
57931216|NCT03765775|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
57931217|NCT03265535|DIAGNOSTIC_TEST|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
57931218|NCT03854396|DRUG|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
57931219|NCT03854396|DRUG|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
57931220|NCT06704620|DRUG|Diphenhydramine|Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
57931221|NCT06704620|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d1
57931222|NCT06704620|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
58070282|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
58070283|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
58070284|NCT02033486|DEVICE|TOBI + DBT|
57931223|NCT06704620|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d1
58070285|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
58070286|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
58070287|NCT00516945|DRUG|Lamivudine|
58070288|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
58284742|NCT00463489|BEHAVIORAL|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
58284743|NCT02104167|DEVICE|ROIC interbody cage with VerteBRIDGE plating|
58284744|NCT00004533|DRUG|Adeno-associated virus-CFTR vector|
58284745|NCT00475293|DRUG|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
58284746|NCT02936089|OTHER|Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)|"For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT."
57931224|NCT06704620|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d1
57931225|NCT06704620|DRUG|Cisplatin|Cisplatin intravenous infusion 75mg/m2 d1
57931226|NCT01012843|DRUG|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
57931227|NCT01012843|DRUG|Placebo|oral Placebo tablets two times a day for 10 days
58284747|NCT02936089|OTHER|Consolidation with auto-HSCT or HLA-matched HSCT|"For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients."
58284748|NCT02936089|OTHER|allogeneic HSCT|For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
58284749|NCT01532258|BEHAVIORAL|Go! Foods for You without Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
58284750|NCT01532258|BEHAVIORAL|Go! Foods for You with Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
58070289|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
57931228|NCT05802992|DRUG|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
57931229|NCT05802992|DRUG|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
57931230|NCT02676388|PROCEDURE|Freeze-dried, Capsulized FMT|
57931231|NCT02676388|PROCEDURE|Fresh FMT|
58284751|NCT04611139|DRUG|SP-2577|Daily oral doses
58284752|NCT04611139|DRUG|Pembrolizumab|200mg Q3W by IV infusion
58284753|NCT03010241|DRUG|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
58284754|NCT03010241|DRUG|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
58398861|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
58398862|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
58398863|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
57931232|NCT04292028|OTHER|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
57931233|NCT04292028|OTHER|Home exercises|Control group were given a home-based exercise program.
57931234|NCT02322229|DRUG|Ocriplasmin 0.125 mg in a 0.1 mL volume|
57931235|NCT04997187|DIETARY_SUPPLEMENT|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
57931236|NCT04997187|DIETARY_SUPPLEMENT|Control group|Placebo 400 mg/day for 12 weeks
57931237|NCT00256334|DRUG|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
58070290|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
58070291|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
58070292|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
58070293|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
58095439|NCT02296047|DRUG|ipratropium bromide|80 µg inhalation once
58284755|NCT06438887|DIETARY_SUPPLEMENT|Placebo|Corn-Starch Maltodextrin
58284756|NCT06438887|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine
58284757|NCT03961750|OTHER|OTAGO|12 Week exercise class programme
58284758|NCT00004088|BIOLOGICAL|filgrastim|
58284759|NCT00004088|BIOLOGICAL|recombinant interferon alfa|
58284760|NCT00004088|DRUG|busulfan|
58284761|NCT00004088|DRUG|cyclophosphamide|
58284762|NCT00004088|DRUG|melphalan|
58284763|NCT00004088|DRUG|pamidronate disodium|
58284764|NCT00004088|DRUG|thalidomide|
58284765|NCT00004088|PROCEDURE|peripheral blood stem cell transplantation|
58284766|NCT00347230|DEVICE|Intacs intracorneal ring insertion for the treatment of keratoconus|
58284767|NCT02888561|DRUG|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
58284768|NCT02888561|DRUG|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
58398864|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
58398865|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
58398866|NCT03772834|DRUG|Methylphenidate|Given PO
58398867|NCT03772834|OTHER|Placebo|Given PO
58398868|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
58398869|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
58398870|NCT03772834|OTHER|Stretching|Undergo stretching
58398871|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
58398872|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
58398873|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
58398874|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
58398875|NCT02746887|OTHER|Preterm/term cohort|
58398876|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
58398877|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
58284769|NCT04626661|DEVICE|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
58284770|NCT04210739|DRUG|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
58284771|NCT02155088|DRUG|BYL719|Dose escalation beginning at 250 mg/day
58284772|NCT02155088|DRUG|Gemcitabine|Dose escalation beginning at 800 mg/m\^2
58284773|NCT02155088|DRUG|(nab)-paclitaxel|125 mg/m\^2 dose
58284774|NCT06144541|OTHER|Survey administration for Fitzpatrick skin type|Survey administration for Fitzpatrick skin type
58284775|NCT06144541|DEVICE|Measurement of ITA based on SkinColorCatch instrument|Measurement of ITA based on SkinColorCatch instrument
58284776|NCT05988346|PROCEDURE|abdominal plastic intervention|According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
58284777|NCT00003703|DRUG|SarCNU|
58284778|NCT04760106|DIAGNOSTIC_TEST|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
58284779|NCT02338115|DRUG|Paclitaxel 80mg/m2 weekly x 12 weeks|
58284780|NCT05273905|DIAGNOSTIC_TEST|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
58284781|NCT02756819|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
58284782|NCT02348008|DRUG|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
58284783|NCT02348008|DRUG|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
58398878|NCT02227069|DRUG|M518101|
58398879|NCT02227069|DRUG|M518101 Vehicle|
58095440|NCT02296047|DRUG|salbutamol|400 µg inhalation once
58095441|NCT03810742|DRUG|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
58284784|NCT02348008|DRUG|MK-3475|Arm B: Phase II Treatment: 200mg IV
58284785|NCT02348008|DRUG|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
58284786|NCT03232216|DIETARY_SUPPLEMENT|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
58284787|NCT03232216|DIETARY_SUPPLEMENT|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
58284788|NCT05614401|OTHER|functional and medical information|1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
58284789|NCT02469012|DRUG|Combination #1|Sofosbuvir + Ribavirin
58284790|NCT02469012|DRUG|Combination #2|Sofosbuvir + Daclatasvir
58284791|NCT02469012|DRUG|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
58284792|NCT02469012|DRUG|Combination #4|Sofosbuvir + Ledipasvir
58284793|NCT02469012|DRUG|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
57931238|NCT06426043|DRUG|Lusutrombopag|Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×109/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
58070294|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
58070295|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
58070296|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
58070297|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
58070298|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
58070299|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
58284794|NCT01597297|DRUG|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
58284795|NCT01597297|OTHER|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
58284796|NCT05844072|PROCEDURE|Mobilization with movement|All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
58284797|NCT04177966|BEHAVIORAL|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
58284798|NCT04177966|BEHAVIORAL|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
58284799|NCT03809325|DRUG|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
58284800|NCT03826966|DEVICE|reSET|reSET is a mobile app created by Pear Therapeutics, Inc., which has previously been approved by the FDA.
58398880|NCT02227069|OTHER|sodium lauryl sulfate|
58070300|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
58398881|NCT02227069|OTHER|saline|
58070301|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
58070302|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
58070303|NCT00106860|DRUG|a benzodiazepine drug|
58070304|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
58070305|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
58284801|NCT06458777|DIAGNOSTIC_TEST|poligraphy|OSA diagnosis
58284802|NCT01537380|DRUG|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
58398882|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
58398883|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
58398884|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
58398885|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
58284803|NCT04973709|DIAGNOSTIC_TEST|Confussion assessment method (CAM)|Participants enrolled in the Delirium group according to the CAM.
58284804|NCT04973709|DIAGNOSTIC_TEST|Dementia diagnosis|Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria
58284805|NCT02226263|DIETARY_SUPPLEMENT|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
58284806|NCT05868239|DEVICE|Aerosol box|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
58284807|NCT01597492|BIOLOGICAL|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
58284808|NCT01597492|BIOLOGICAL|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
58284809|NCT01915901|DRUG|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
58284810|NCT01915901|DRUG|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
58284811|NCT01915901|DRUG|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
58284812|NCT06308900|OTHER|Clinical simulation|Carrying out a total of 9 clinical simulation in three days, one day a week, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
58284813|NCT01366183|PROCEDURE|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
58398886|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
58398887|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
57931239|NCT01161901|PROCEDURE|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
58398888|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
58284814|NCT01366183|DRUG|Carboplatin|Undergo chemotherapy
58284815|NCT01366183|BIOLOGICAL|Filgrastim|Undergo chemotherapy
58398889|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
58398890|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
57931240|NCT01883986|BEHAVIORAL|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
57931241|NCT00523120|DRUG|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
57931242|NCT00523120|DRUG|dexotc|aural drops
57931243|NCT00163423|DRUG|Ciclesonide|
58284816|NCT01366183|DRUG|Paclitaxel|Undergo chemotherapy
58284817|NCT01366183|OTHER|Pharmacological Study|Correlative studies
58284818|NCT01366183|OTHER|Quality-of-Life Assessment|Ancillary studies
58284819|NCT01366183|OTHER|Questionnaire Administration|Ancillary studies
58284820|NCT05060107|BIOLOGICAL|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
58284821|NCT04668443|OTHER|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
58284822|NCT01216332|DRUG|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
58284823|NCT01216332|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
57931244|NCT04411927|OTHER|assessment of postural stability|assessment of postural stability
58284824|NCT05754541|DEVICE|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
58284825|NCT06101537|DEVICE|Brain temperature-pressure monitoring|An intracranial pressure monitoring device that continuously records brain temperature-pressure data was used during treatment.
58284826|NCT06349915|BEHAVIORAL|Supporting Wellbeing with Everyday Experiences of Peers (SWEEP)|Each day during a 14-day trial period, participants will receive one narrative featuring lived experience with and recovery from suicidal thoughts and behaviors. These narratives will be presented in audio and text format via a smartphone app. Participants will also complete self-report surveys assessing study outcomes using the same smartphone app five times per day.
58284827|NCT03403452|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
58398891|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
58398892|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
58398893|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
58398894|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
58284828|NCT05346354|DRUG|Ravulizumab|"Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight."
58398895|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
58398896|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
58398897|NCT01696019|OTHER|Contact and testing only|
58398898|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
58398899|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
58398900|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
58398901|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
58398902|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
58398903|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
58398904|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
58398905|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
57931245|NCT04962789|DIAGNOSTIC_TEST|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
57931246|NCT03203551|OTHER|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
57931247|NCT01215500|RADIATION|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy"
57931248|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
57931249|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
57931250|NCT02183636|DRUG|Linagliptin tablet|5 mg
57931251|NCT02183636|DRUG|pioglitazone tablet (Actos®)|45 mg
57931252|NCT04767737|OTHER|Topically Administered Lavender Aromatherapy|3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
57931253|NCT04767737|OTHER|Topically Administered Water|3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
58284829|NCT04529707|BEHAVIORAL|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
58284830|NCT02209818|RADIATION|Laser Irradiation One dose|
58284831|NCT02209818|RADIATION|Laser Irradiation Two doses|
58284832|NCT06538857|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
58398906|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
58398907|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
58398908|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
58398909|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
58398910|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
58398911|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
58398912|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
58398913|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
57931254|NCT04321980|DRUG|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
57931255|NCT02693769|DRUG|fluticasone propionate/formoterol fumarate breath actuated inhaler|
57931256|NCT02693769|DRUG|Indacaterol maleate / glycopyrronium bromide capsules|
57931257|NCT00726934|OTHER|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
58284833|NCT06538857|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
58284834|NCT00479830|BEHAVIORAL|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
58284835|NCT00479830|BEHAVIORAL|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
58284836|NCT00479830|BEHAVIORAL|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
57931258|NCT00726934|OTHER|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~1. Avoid raw vegetables and fruit (Oranges and bananas are okay.)~2. Avoid take-out foods and fast foods and fountain drinks.~3. Avoid aged cheese (blue, Roquefort, Brie).~4. Cook all produce to well done. Eggs must be hard-boiled.~5. Avoid deli meats.~6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~7. No well water~8. No yogurt"
57931259|NCT00850850|DRUG|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
57931260|NCT00850850|DRUG|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
58284837|NCT02461056|DRUG|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
58284838|NCT02461056|DRUG|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
58284839|NCT04551768|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
58284840|NCT04551768|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
58284841|NCT04714645|DEVICE|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
57931261|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
57931262|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
57931263|NCT03211247|BIOLOGICAL|Part A Placebo|Placebo patch, once daily
57931264|NCT03211247|BIOLOGICAL|Part B Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
57931265|NCT03211247|BIOLOGICAL|Part B Placebo|Placebo patch, once daily
57931266|NCT04980508|DIAGNOSTIC_TEST|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
58284842|NCT04714645|DEVICE|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
57931267|NCT01629784|BEHAVIORAL|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
57931268|NCT00495404|BEHAVIORAL|Physician Treatment Guidelines|
58284843|NCT03571178|OTHER|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
58284844|NCT04009161|PROCEDURE|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
58284845|NCT06307405|DIAGNOSTIC_TEST|next generation sequencing|All the enrolled patients had undergone fiberbronchoscopy and sputum had been retained. The collected alveolar lavage fluid and sputum were examined for mNGS and routine etiology, respectively
58284846|NCT02075008|DRUG|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
58284847|NCT01314027|DRUG|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
58284848|NCT01314027|DRUG|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
58284849|NCT02481752|OTHER|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
58284850|NCT02481752|OTHER|SHAM Training|
58284851|NCT01716520|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
58284852|NCT01716520|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
58284853|NCT01716520|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
58284854|NCT02855710|OTHER|Rhythm workers training Perceptive timing|Perceptive timing training
58284855|NCT02855710|OTHER|Rhythm workers training sensorimotor timing|Sensorimotor timing training
57931269|NCT06734702|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks for 2 cycles.
57931270|NCT06734702|RADIATION|Concurrent chemoradiotherapy|Definitive dose of thoracic radiotherapy with concurrent chemotherapy
57931271|NCT06734702|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
57931272|NCT03374995|OTHER|Best Practice|Receive standard of care
57931273|NCT03374995|OTHER|Quality-of-Life Assessment|Ancillary studies
57931274|NCT03374995|DEVICE|Topical Keratin|Given topically
57931275|NCT05117255|BEHAVIORAL|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
57931276|NCT05117255|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
57931277|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
57931278|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
57931279|NCT06352411|DRUG|BI 456906|Solution for injection
57931280|NCT02577601|DRUG|Ulipristal Acetate|
58284856|NCT02855710|OTHER|No Rhythm workers training|No training
58284857|NCT01038154|DRUG|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
58284858|NCT05667818|DRUG|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
58284859|NCT05667818|DRUG|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
57931281|NCT02577601|DRUG|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
57931282|NCT06111482|DEVICE|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
57931283|NCT06111482|DEVICE|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
57931284|NCT06111482|DEVICE|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
57931285|NCT06111482|DEVICE|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
57931286|NCT03951779|DIAGNOSTIC_TEST|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
57931287|NCT05011682|BEHAVIORAL|Regular diet|participant's usual diet during 2 weeks
57931288|NCT05011682|BEHAVIORAL|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
57931289|NCT04393025|DEVICE|Intracranial Stenting by Intracranial Stent Device|Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted
57931290|NCT04393025|DRUG|Optimum medical treatment|Optimum Medical treatment
57931291|NCT04390048|DEVICE|Anodal tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
57931292|NCT04390048|DEVICE|Sham tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
57931293|NCT06735417|BEHAVIORAL|Indashyikirwa program|"Indashyikirwa training curriculum is delivered to heterosexual married couples in Syrian communities in Al-Hasakah governorate. The curriculum includes between 21 and 22 sessions, delivered to groups of up to 30 couples. Each week, participants will attend one session, lasting at least 3 hours.~Topics covered include: gender, power imbalance, triggers for GBV, conflict management, building healthy relationships, and coping mechanisms for managing GBV-related triggers.~The curriculum is designed to address both the wife and her husband and includes interactive exercises, take-home assignments, and reflections.~The sessions are delivered by trained facilitators."
58284860|NCT02461680|PROCEDURE|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
58284861|NCT02461680|PROCEDURE|suture|
58284862|NCT00997347|DRUG|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
58284863|NCT01050335|BEHAVIORAL|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
58284864|NCT04078854|BEHAVIORAL|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
58284865|NCT02051335|DRUG|Roflumilast|Roflumilast tablets
58284866|NCT02051335|DRUG|Roflumilast placebo|Roflumilast placebo-matching tablets
58284867|NCT02051335|DRUG|Donepezil|Donepezil overencapsulated tablets
57931294|NCT02177890|DEVICE|Transcutaneous vagal nerve stimulation|
57931295|NCT02177890|DEVICE|Sham vagal nerve stimulation|
58284868|NCT02051335|DRUG|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
58284869|NCT02051335|DRUG|Scopolamine|Scopolamine subcutaneous injection
58284870|NCT03454451|DRUG|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
58284871|NCT03454451|DRUG|CPI-006 + ciforadenant|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
58284872|NCT03454451|DRUG|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
58398914|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
58070306|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
58070307|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
57931296|NCT01846325|DIETARY_SUPPLEMENT|vitamin E|
57931297|NCT01846325|DIETARY_SUPPLEMENT|DHA|
57931298|NCT01846325|OTHER|placebo|
57931299|NCT01449877|DRUG|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
57931300|NCT00638560|DIETARY_SUPPLEMENT|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
57931301|NCT00638560|DIETARY_SUPPLEMENT|Antioxidant treatment|no treatment
58070308|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
58070309|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
58070310|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
58070311|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
58070312|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
58070313|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58398915|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
58398916|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
57931302|NCT04264429|DEVICE|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
57931303|NCT04264429|OTHER|Elastic band|Orthotic device which is positioned over the patellar tendon
57931304|NCT03085758|BIOLOGICAL|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
58284873|NCT03454451|DRUG|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
58284874|NCT03454451|DRUG|CPI-006 + ciforadenant|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
57931305|NCT03085758|BIOLOGICAL|Placebo|Single i.v. dose of placebo (control group)
57931306|NCT05111041|BEHAVIORAL|#EnufSnuff.TXT- First Responder|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
57931307|NCT05111041|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
57931308|NCT02196623|OTHER|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
57931309|NCT02196623|OTHER|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
58070314|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58070315|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58070316|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58070317|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58070318|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58284875|NCT03454451|DRUG|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
58284876|NCT00550576|DRUG|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
58284877|NCT00177645|PROCEDURE|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
58284878|NCT03221179|BIOLOGICAL|RO7049665|A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.
58284879|NCT03221179|BIOLOGICAL|Placebo|Matching placebo will be administered SC once.
58284880|NCT00845936|DRUG|Metformin|Metformin 850 mg bid
58284881|NCT00029783|PROCEDURE|Distant Healing|
57931310|NCT03690141|DRUG|eFT508|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
57931311|NCT04227951|DEVICE|Avoid drain placement|In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
57931312|NCT04227951|DEVICE|Drain placement|In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
57931313|NCT04426955|DRUG|Camrelizumab|IV infusion
58070319|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
58284882|NCT03005639|DRUG|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
57931314|NCT04426955|DRUG|Paclitaxel|IV infusion
58284883|NCT00004464|DRUG|cyclophosphamide|
58284884|NCT00004464|DRUG|filgrastim|
58284885|NCT03545620|DEVICE|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
58284886|NCT06322277|OTHER|Analysis of biological sample|Confermation of type of infection with RT-PCR.
58284887|NCT00162084|DRUG|apadenoson|
58284888|NCT04711343|DRUG|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
58284889|NCT04711343|DRUG|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
58284890|NCT04711343|DRUG|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
58284891|NCT01088711|DRUG|Omarigliptin|Once-weekly 50 mg capsule
58284892|NCT01088711|DRUG|Placebo|Once-weekly placebo capsule
58070320|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
58070321|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
58284893|NCT00642954|DRUG|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
58284894|NCT00642954|DRUG|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
58284895|NCT00642954|DRUG|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
58284896|NCT03636048|DRUG|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
58284897|NCT03636048|DRUG|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
58284898|NCT00779753|DIETARY_SUPPLEMENT|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
58284899|NCT05576428|BEHAVIORAL|Diet and exercise|diet and exercise in patients of NAFLD
58284900|NCT05576428|DRUG|NAC with diet and exercise|NAC with diet and exercise in patients of NAFLD
57931315|NCT04426955|DRUG|Cisplatin|IV infusion
57931316|NCT04426955|DRUG|Placebo|IV infusion
57931317|NCT04426955|RADIATION|Radiation|Concurrent Radiation
57931318|NCT05981911|DEVICE|XIENCE Skypoint™ stent|Percutaneous coronary intervention with Xience-Skypoint™ stent
58284901|NCT02404129|OTHER|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
58284902|NCT05695963|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
57931319|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
57931320|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
57931321|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
57931322|NCT01782118|DIETARY_SUPPLEMENT|Lactobacillus GG|
58284903|NCT05695963|BEHAVIORAL|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
58284904|NCT05695963|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
57931323|NCT06735339|OTHER|Clinic for Multimorbidity|"The patient is assigned a healthcare coordinator. A review of the patient's medication history and a medication review are conducted. A functional assessment is performed, along with relevant measurements, and the patient consults with a specialist physician. A multidisciplinary team (MDT) conference is held with selected specialists, depending on the patient's needs. This may include a cardiologist, endocrinologist, pulmonologist, gastroenterologist, rheumatologist, nephrologist, geriatrician, clinical pharmacologist, psychiatrist, pain nurse, physiotherapist, occupational therapist, and the patient's GP.~The handover of information to the GP is agreed upon at the time of referral and can be carried out in writing, through virtual MDT participation, or by telephone.~In agreement with the patient, the clinic may initiate follow-up actions, such as counseling on medication or disease management. Additionally, the clinic may facilitate cross-sectoral activities, such as therapy."
57931324|NCT06504342|DEVICE|Blue-blocking glasses|These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.
57931325|NCT06504342|BEHAVIORAL|Time-restricted eating|Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m
57931326|NCT06504342|DEVICE|Lightly tinted glasses|These lenses block shorter wavelengths of light, mainly ultraviolet light.
57931327|NCT06253221|DRUG|Mavacamten|Specified dose on specified days
57931328|NCT06253221|DRUG|Placebo|Specified dose on specified days
57931329|NCT06735664|PROCEDURE|Biopsy|Undergo ultrasound guided biopsy
58284905|NCT05695963|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
58284906|NCT05689853|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
58284907|NCT05689853|DRUG|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
57931330|NCT06735664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57931331|NCT06735664|PROCEDURE|Bone Marrow Biopsy|Undergo optional bone marrow biopsy
57931332|NCT06735664|PROCEDURE|Computed Tomography|Undergo CT
57931333|NCT06735664|PROCEDURE|Echocardiography|Undergo ECHO
57931334|NCT06735664|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58284908|NCT04628000|OTHER|Vitamin D|Clinical Correlation
58284909|NCT06462170|DIETARY_SUPPLEMENT|Boost Original meal replacement shake|One bottle of Boost Original meal replacement shake.
58284910|NCT05769478|DRUG|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
58284911|NCT05177549|OTHER|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
58284912|NCT05424354|DEVICE|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
57931335|NCT06735664|BIOLOGICAL|Odronextamab|Given IV
57931336|NCT06735664|PROCEDURE|Positron Emission Tomography|Undergo PET
57931337|NCT06735664|PROCEDURE|Ultrasound Imaging|Undergo ultrasound guided biopsy
57931338|NCT06735664|DRUG|Zanubrutinib|Given PO
57931339|NCT00674193|OTHER|pharmacological study|Correlative studies
57931340|NCT00674193|OTHER|laboratory biomarker analysis|Correlative studies
57931341|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
57931342|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
58095442|NCT06400329|OTHER|Pain Neuroscience Education|PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active
58398917|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
58398918|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
58398919|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
58398920|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
58398921|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
57931343|NCT03945006|OTHER|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
57931344|NCT03945006|OTHER|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
57931345|NCT03945006|OTHER|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
57931346|NCT03945006|OTHER|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
58284913|NCT05424354|OTHER|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
58284914|NCT06097871|DIETARY_SUPPLEMENT|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
57931347|NCT01357577|BEHAVIORAL|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
58284915|NCT06097871|OTHER|Placebo pill|A placebo pill containing non-active ingredients
58284916|NCT04325867|OTHER|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
58284917|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
58398922|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
58398923|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
57931348|NCT03703245|OTHER|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
57931349|NCT03703245|OTHER|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
57931350|NCT02774902|DRUG|TAK-438|TAK-438 tablets
57931351|NCT02774902|DRUG|Clarithromycin|Clarithromycin tablets
57931352|NCT04093427|OTHER|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
57931353|NCT00650065|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
57931354|NCT00650065|DRUG|Zyrtec® Tablets 10 mg|10mg, single dose fasting
58284918|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
58284919|NCT05469620|DIETARY_SUPPLEMENT|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
58398924|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
58398925|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
58398926|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
58398927|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
58284920|NCT05469620|OTHER|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
58284921|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
57931355|NCT03739762|BEHAVIORAL|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
57931356|NCT03739762|OTHER|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
58284922|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
58284923|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
58284924|NCT06212284|DRUG|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
58284925|NCT06212284|DRUG|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
58284926|NCT04105842|DEVICE|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
58284927|NCT03692923|OTHER|virtual community|
58284928|NCT01066663|DRUG|pyrimethamine|Taken orally once a day
58284929|NCT02228018|DEVICE|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
58284930|NCT00640731|DEVICE|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
58284931|NCT00821197|PROCEDURE|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
57931357|NCT02073734|DRUG|Dexamethasone|Dexamethasone 8mg/IV
57931358|NCT02073734|DRUG|Placebo|Placebo given IV
58284932|NCT00821197|PROCEDURE|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
58284933|NCT02950038|DRUG|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
58284934|NCT02950038|DRUG|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
58284935|NCT01210482|DRUG|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
58284936|NCT03377062|DIAGNOSTIC_TEST|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
58284937|NCT00844779|PROCEDURE|Bariatric surgery|Gastric bypass.
58284938|NCT00844779|PROCEDURE|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
58284939|NCT00632125|DRUG|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
58284940|NCT03885245|DRUG|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
58070322|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
58284941|NCT03885245|DRUG|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
58284942|NCT04035122|OTHER|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
58284943|NCT04035122|OTHER|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
58284944|NCT03286621|OTHER|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
58284945|NCT04671394|PROCEDURE|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
58284946|NCT04671394|PROCEDURE|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
58398928|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
57931359|NCT06134206|DIAGNOSTIC_TEST|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
57931360|NCT00216203|DRUG|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
57931361|NCT00216203|DRUG|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
58284947|NCT00005069|DRUG|arsenic trioxide|
58284948|NCT00635921|DRUG|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
58284949|NCT00635921|DRUG|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
58284950|NCT05157555|OTHER|Data collection|Description: quality of life assessment
58284951|NCT02309450|DRUG|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
58284952|NCT04985227|OTHER|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
57931362|NCT04631926|BEHAVIORAL|Hip Muscle Exercise|Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
57931363|NCT05823701|DRUG|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
57931364|NCT05823701|DRUG|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
57931365|NCT05823701|BIOLOGICAL|obinutuzumab|1000mg d4 intravenous infusion per cycle
57931366|NCT05823701|DRUG|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
58284953|NCT00459719|DRUG|Tacrolimus modified-release|oral
58284954|NCT00459719|DRUG|Prograf|oral
58284955|NCT01605825|DRUG|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
58284956|NCT01605825|DRUG|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
58284957|NCT06329986|DEVICE|TAMER Lens Spectacle|Regular daily wear of TAMER lens spectacle
58284958|NCT06329986|DEVICE|SV lenses|SV lenses
58284959|NCT06612710|DRUG|extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）
58284960|NCT06612710|DRUG|a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles placebo (4×10\^9 particles/kg)
58284961|NCT00461097|DRUG|Egg oral immunotherapy|Egg white solid powder
58284962|NCT00461097|DRUG|Control Group|Placebo for egg white solid
58284963|NCT03386188|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
58284964|NCT03386188|DEVICE|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
58284965|NCT01305707|DEVICE|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
58398929|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
58398930|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
58398931|NCT04068519|DRUG|Tislelizumab|Administered intravenously
58398932|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
57931367|NCT05027763|BEHAVIORAL|high-fiber/low fat|high fiber/low fat preoperative diet
58284966|NCT01305707|DRUG|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
58284967|NCT00658892|BIOLOGICAL|B7-DC cross-linking antibody rHIgM12B7|
58284968|NCT00658892|OTHER|flow cytometry|
58284969|NCT00658892|OTHER|immunologic technique|
58284970|NCT00658892|OTHER|laboratory biomarker analysis|
58284971|NCT03290391|OTHER|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
58284972|NCT03290391|DRUG|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
58284973|NCT03290391|BEHAVIORAL|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
58284974|NCT01808261|DRUG|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
58284975|NCT01808261|DRUG|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
58284976|NCT00383370|DRUG|VEGF Trap|VEGF Trap formulation 1, ITV-1
58284977|NCT00383370|BIOLOGICAL|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
58284978|NCT06137820|DEVICE|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
58284979|NCT06137820|DEVICE|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
58284980|NCT01863342|PROCEDURE|CSI score < 40|
58398933|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
58398934|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
58398935|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
57931368|NCT05027763|BEHAVIORAL|fermented|fermented preoperative diet
57931369|NCT04254588|OTHER|Abdominal examination|Examination by in-person physician vs. remote physician.
58284981|NCT01863342|PROCEDURE|CSI score ≥ 40|
58284982|NCT01064362|DRUG|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
58284983|NCT01064362|DRUG|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
58284984|NCT01821274|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
58398936|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
58398937|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
58398938|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
57931370|NCT06467487|OTHER|Traditional Letter|Patients receive a traditional letter.
57931371|NCT06467487|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
58398939|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
58398940|NCT04234529|OTHER|Placebo|1.35g of microcellulose
57931372|NCT06467487|OTHER|Optimized Letter|Patients receive an optimized letter.
57931373|NCT06467487|OTHER|Direct to Patient Message - Optimized|Patients receive an optimized direct to patient message via the portal.
57931374|NCT04919525|DEVICE|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
58284985|NCT01821274|DRUG|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
58284986|NCT01821274|DRUG|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
58284987|NCT01821274|DRUG|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
58284988|NCT01962194|DEVICE|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
58284989|NCT03033160|DRUG|Estradiol Ring|
58284990|NCT03291028|BIOLOGICAL|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
58284991|NCT02728284|PROCEDURE|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
58284992|NCT02728284|PROCEDURE|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
58284993|NCT04886297|DRUG|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
58398941|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
58398942|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
58398943|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
58398944|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
58398945|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
58398946|NCT06653751|DEVICE|Reminder App|he purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
58398947|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
58398948|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
58398949|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
58398950|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
58398951|NCT06587334|PROCEDURE|SRP|SRP alone
58398952|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
58284994|NCT04886297|DRUG|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
58284995|NCT02460432|DEVICE|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
58284996|NCT02460432|DEVICE|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
58284997|NCT00001013|DRUG|Trimetrexate glucuronate|
58284998|NCT00001013|DRUG|Pentamidine isethionate|
58284999|NCT00001013|DRUG|Sulfamethoxazole-Trimethoprim|
58285000|NCT00001013|DRUG|Leucovorin calcium|
58285001|NCT00428428|DRUG|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
58285002|NCT05089812|PROCEDURE|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
58285003|NCT00334165|PROCEDURE|Auricular acupuncture (procedure)|
58285004|NCT04892199|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
58285005|NCT04892199|DRUG|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
58285006|NCT03020277|OTHER|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
58285007|NCT05266482|OTHER|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
58285008|NCT03228940|DRUG|RVX000222|oral, BID
58285009|NCT02976402|RADIATION|SBRT|"Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
58285010|NCT01408901|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
58285011|NCT01408901|OTHER|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
58285012|NCT01408901|DRUG|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
58285013|NCT02020889|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
58285014|NCT02020889|DRUG|Placebo|Placebo will be available as 0.9% sodium chloride
58398953|NCT04924894|OTHER|no intervention|no intervention
58398954|NCT01243372|GENETIC|mutation analysis|
58398955|NCT01243372|OTHER|laboratory biomarker analysis|
58398956|NCT00022763|DRUG|Enfuvirtide|
58398957|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
58398958|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
58398959|NCT02043106|OTHER|plantar vibration|
58398960|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
57931375|NCT02403622|DRUG|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
58070323|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
58070324|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
58070325|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
58070326|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
58070327|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
58070328|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
58070329|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
58070330|NCT00208858|DRUG|Topiramate|
58285015|NCT03313531|DIAGNOSTIC_TEST|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
58285016|NCT03313531|DRUG|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
58285017|NCT05980897|BEHAVIORAL|Naming treatment|"In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing."
58285018|NCT05041803|DRUG|CTP-543|Twice daily dosing
58285019|NCT03448172|DRUG|[14C]PF-05221304|a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
58285020|NCT05680428|OTHER|early feeding|oral feeding within 12hours after stoma reversal
57931376|NCT04460014|BEHAVIORAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
57931377|NCT04460014|BEHAVIORAL|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
57931378|NCT04775251|OTHER|Upward rotation exercise|Treatment for correction of depressed scapular Alignment by exercise ( Upward Rotation Exercises) for 6 weeks.
58070331|NCT01352923|OTHER|blood test|preparation of blood platelets
58070332|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
58070333|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
58070334|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
58070335|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
58070336|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
58285021|NCT05680428|PROCEDURE|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
58285022|NCT05298436|OTHER|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
58398961|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
58398962|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
58398963|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
58398964|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
58398965|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
58398966|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
58398967|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
58398968|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
58398969|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
58398970|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
58398971|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
58398972|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
58398973|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
58398974|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
58398975|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
57931379|NCT01536236|DEVICE|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
57931380|NCT01536236|DEVICE|Placebo|Placebo
57931381|NCT06736301|DEVICE|a fully covered stent|a double pig-tail stent for cross fixation of a fully covered stent
57931382|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
58285023|NCT01317498|OTHER|Standard Care|CD4, liver function and CBC every 6 months
58285024|NCT01317498|OTHER|Virological Monitoring|Viral Load test every 6 months
58285025|NCT05307679|DRUG|Basmisanil|Participants will receive oral basmisanil at age-appropriate dosages
58285026|NCT05307679|DRUG|Placebo|Participants will receive oral placebo
57931383|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
57931384|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
57931385|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
58285027|NCT01058291|DRUG|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
58398976|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
58398977|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
58398978|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
58398979|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
58398980|NCT02292082|DRUG|Bupivacaine|
58398981|NCT02292082|DRUG|Morphine|
58398982|NCT02292082|DRUG|Methylprednisolone|
58398983|NCT02292082|DRUG|Cefazolin|
58398984|NCT02292082|DRUG|Normal saline|
58398985|NCT02292082|DRUG|Midazolam|
58398986|NCT02292082|DRUG|Propofol|
58398987|NCT02292082|DRUG|Dexamethasone|
58398988|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
58398989|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
57931386|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
57931387|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
58070337|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
58285028|NCT01058291|DRUG|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
58285029|NCT01342445|DRUG|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
58398990|NCT00306293|DRUG|valacyclovir|valacyclovir
58398991|NCT02082080|OTHER|Education|
58398992|NCT02082080|OTHER|Social support|
58398993|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
57728816|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
57728817|NCT05449639|DEVICE|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
57728818|NCT00898716|DRUG|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
58070338|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
58070339|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
58070340|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
58095443|NCT06400329|OTHER|Standard Pain Education|In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
58095444|NCT02437539|DRUG|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
58285030|NCT01342445|DRUG|Placebo|
58285031|NCT04070248|OTHER|No intervention|No intervention
58285032|NCT03461783|DEVICE|Zorflex Activated Carbon Dressing|Antimicrobial dressing
58285033|NCT03461783|DEVICE|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
58285034|NCT02872909|DEVICE|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
58285035|NCT00985660|DRUG|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
58285036|NCT00985660|DRUG|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
58285037|NCT05846568|BIOLOGICAL|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
58285038|NCT05846568|BIOLOGICAL|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
58285039|NCT05846568|BIOLOGICAL|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
58285040|NCT03831919|DEVICE|SYNC III|Hoya SYNC III design spectacle lenses
58285041|NCT03831919|DEVICE|single vision lenses|single vision spectacle lenses with no addition
58285042|NCT01491841|DRUG|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
58285043|NCT01491841|DRUG|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
58285044|NCT02036684|BEHAVIORAL|Prehabilitation (PREHAB)|
58285045|NCT05911789|RADIATION|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
58285046|NCT00495690|DRUG|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
58285047|NCT01884545|BEHAVIORAL|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
58285048|NCT01884545|GENETIC|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
58285049|NCT01884545|BEHAVIORAL|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
58285050|NCT03260114|OTHER|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
58398994|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
58398995|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
58398996|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
58398997|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
58398998|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
58398999|NCT01549808|OTHER|mobilization|sitting, standing and walking
58399000|NCT01944098|DRUG|Lidocaine|
58399001|NCT01944098|DRUG|Placebo|
58399002|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
58070341|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
58399003|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
58399004|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
57931388|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
58095445|NCT02437539|DEVICE|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
58399005|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
58399006|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
58399007|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
58399008|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
58399009|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
58399010|NCT06657989|BEHAVIORAL|Walking|Overground walking
57931389|NCT06734572|DRUG|18F-FAPIBiotin|The dose will be 148-296 MBq given intravenously.
57931390|NCT01430351|DRUG|Mefloquine|Given PO
57931391|NCT01430351|DRUG|Memantine Hydrochloride|Given PO
57931392|NCT01430351|DRUG|Metformin Hydrochloride|Given PO
57931393|NCT01430351|DRUG|Temozolomide|Given PO
57931394|NCT05181722|OTHER|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
57931395|NCT05746481|DRUG|Tiragolumab|Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
57931396|NCT05746481|DRUG|Atezolizumab|Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
58070342|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
58285051|NCT04729751|DRUG|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
58285052|NCT02298088|DRUG|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
58285053|NCT02298088|DRUG|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg."
58285054|NCT02874716|OTHER|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
58285055|NCT03769701|PROCEDURE|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
58285056|NCT01994421|OTHER|Kinesiotape|
58285057|NCT03491787|DEVICE|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
58285058|NCT01220726|DRUG|Botox|Botox injection
58285059|NCT01220726|DRUG|Placebo|Placebo injection
58285060|NCT01269099|DRUG|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
58285061|NCT01269099|DRUG|Control|control group (No-PCA group)
58285062|NCT02099383|OTHER|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
58285063|NCT03682289|DRUG|Ceralasertib|Given orally
58285064|NCT03682289|DRUG|Olaparib|Given orally
58285065|NCT03682289|DRUG|Durvalumab|Given intravenously (IV)
58399011|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
58399012|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
57931397|NCT05746481|DRUG|Pemetrexed|Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
58285066|NCT01651975|DIETARY_SUPPLEMENT|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
58285067|NCT01651975|DIETARY_SUPPLEMENT|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
58285068|NCT00547924|BEHAVIORAL|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
58285069|NCT04060160|OTHER|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
58285070|NCT04060160|OTHER|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
58285071|NCT03190980|OTHER|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
58285072|NCT03190980|OTHER|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
58285073|NCT03190980|OTHER|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
58285074|NCT05691777|DEVICE|Hand and shoulder task|"Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed."
58285075|NCT00715871|DRUG|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
58285076|NCT00715871|DEVICE|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
58285077|NCT01709409|DRUG|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
58285078|NCT01709409|DRUG|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
58399013|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
58399014|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
57931398|NCT05746481|DRUG|Carboplatin|Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
57931399|NCT06318455|OTHER|Breathing exercise|For 12 weeks they will do kumbaka breathing exercise for 5 minutes twice a day in the morning and evening
57931400|NCT03457350|PROCEDURE|cervical negotiation|trial to bypass severe cervical stenosis
58285079|NCT02649517|PROCEDURE|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
58399015|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
58399016|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
58399017|NCT02383888|DRUG|BI 425809|
58285080|NCT02344771|PROCEDURE|Elective colon cancer surgery|
58285081|NCT06415474|PROCEDURE|Lymphocyte Phenotyping Procedure|"For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture."
58285082|NCT04581018|OTHER|Health supplements|28 days of health supplements (synbiotic), 4g daily
58285083|NCT04769674|OTHER|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
58285084|NCT06065189|BIOLOGICAL|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
58285085|NCT03328442|PROCEDURE|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
58285086|NCT03328442|PROCEDURE|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
58399018|NCT02383888|DRUG|BI 425809|
58399019|NCT02383888|DRUG|Placebo|
58399020|NCT02383888|DRUG|BI 425809|
58399021|NCT00221000|DRUG|Methoxsalen|
58399022|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
57931401|NCT03292861|DRUG|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
58285087|NCT04927923|OTHER|hope-focused motivational interview|The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
58285088|NCT03945071|DEVICE|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
58399023|NCT03539822|DRUG|Cabozantinib|by mouth
58399024|NCT03539822|DRUG|Durvalumab|infusion
58399025|NCT03539822|DRUG|Tremelimumab|infusion
58399026|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
58399027|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
58399028|NCT00002249|DRUG|Levofloxacin|
58285089|NCT04936178|DRUG|NB003 tablets|NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
58285090|NCT01087203|BIOLOGICAL|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
58399029|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
58399030|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
58285091|NCT01087203|BIOLOGICAL|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
58399031|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
58399032|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
58399033|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
58399034|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
57931402|NCT03292861|DRUG|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
58399035|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
57728819|NCT06227000|BEHAVIORAL|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
58070343|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
58070344|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
58070345|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
58070346|NCT02039687|OTHER|Placebo|Formulation buffer
58070347|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
57728820|NCT06227000|BEHAVIORAL|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
57728821|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
58070348|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
58070349|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
58399036|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
58399037|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
58399038|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
58399039|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
57728822|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
57728823|NCT02090738|DRUG|Acetazolamide group|
57728824|NCT02090738|DRUG|Standard regimen group|
57728825|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
57728826|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
57728827|NCT05898542|PROCEDURE|Nature-based therapy|Therapy sessions conducted outdoors
57728828|NCT02542748|DRUG|Norepinephrine|norepinephrine injection
57728829|NCT02542748|DRUG|Ephedrine|Ephedrine injection
58399040|NCT02018848|BEHAVIORAL|Attention Training Program|
58399041|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
58399042|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
58399043|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
58399044|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
58399045|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
58399046|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
58399047|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
58399048|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
58399049|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
58399050|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
58399051|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
58399052|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
58399053|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
58399054|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
57931403|NCT03292861|DRUG|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
58285092|NCT04687540|DRUG|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
57931404|NCT03292861|DRUG|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
57931405|NCT03292861|DRUG|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
58285093|NCT04687540|DRUG|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
58285094|NCT06584812|DRUG|Tiprogrel|Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
58285095|NCT06584812|DRUG|Tiprogrel|Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
58285096|NCT06584812|DRUG|Clopidogrel|Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.
58399055|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
58399056|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
58399057|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
58399058|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
58285097|NCT06584812|DRUG|Ticagrelor|Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.
58399059|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
58399060|NCT02030197|OTHER|Control Group|no treatment
58399061|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
57728830|NCT06371794|PROCEDURE|skin punch biopsy|skin punch biopsy (around 4 mm2) from each studied subject.
58070350|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
58285098|NCT03418142|BEHAVIORAL|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
58285099|NCT03418142|OTHER|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
58285100|NCT05869396|DIAGNOSTIC_TEST|echocardiography|Bedside echocardiography
58285101|NCT06218342|DRUG|Henagliflozin|Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
58285102|NCT06218342|OTHER|Background medication|Participants will only receive lifestyle intervention and background medication.
58285103|NCT01299896|OTHER|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
58285104|NCT01299896|OTHER|Usual Care|Standard therapy to help participants with smoking cessation.
58285105|NCT05695118|DIAGNOSTIC_TEST|Non-contrast low-dose abdomen CT|target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
58285106|NCT05695118|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
58285107|NCT05695118|DIAGNOSTIC_TEST|bioelectrical impedance analysis (BIA)|BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
58285108|NCT05443074|OTHER|Face to face intervention group|"Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI)."
58399062|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
58399063|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
57728831|NCT05809518|DRUG|Propofol injection|sedation after cardiac surgery
57728832|NCT05809518|DRUG|Dexmedetomidine injection|sedation after cardiac surgery
57728833|NCT05809518|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
57728834|NCT01094080|OTHER|standard infant formula|infants are fed a commercial formula
57728835|NCT01094080|OTHER|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
57728836|NCT01094080|OTHER|breast milk|infants are breast fed
58070351|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
58070352|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
58070353|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
58285109|NCT05443074|OTHER|Remote intervention group|"Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI."
58285110|NCT05443074|OTHER|Control group|Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
58285111|NCT02603510|DRUG|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
58285112|NCT02603510|DRUG|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
58285113|NCT00652717|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
58285114|NCT00652717|DRUG|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
58285115|NCT04636411|DIETARY_SUPPLEMENT|Oral Magnesium Supplementation|250 mg of elemental magnesium daily for three months
58285116|NCT04636411|OTHER|Standard Care for diabetic patients|Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
58285117|NCT03173456|DRUG|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
58285118|NCT03173456|DRUG|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
58285119|NCT03173456|DRUG|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
58285120|NCT03173456|DRUG|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
58285121|NCT03173456|DRUG|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
58285122|NCT05977868|DRUG|Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid|COpAT (oral antimicrobial therapy) on hospital discharge
58285123|NCT05977868|DRUG|Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem|Standard of care (IV antimicrobial therapy) on hospital discharge
58285124|NCT04474054|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
58285125|NCT03193333|DRUG|PRO-122|Posology: 1 drop every 12 hours for 90 days
58285126|NCT03193333|DRUG|Timolol eye drops|1 drop every 12 hours for 90 days
58285127|NCT03193333|DRUG|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
58285128|NCT03193333|DRUG|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
58070354|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
58285129|NCT03193333|OTHER|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
58285130|NCT03193333|OTHER|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
58285131|NCT03193333|DRUG|Krytantek|Posology: 1 drop every 12 hours for 90 days
58285132|NCT03955588|DIAGNOSTIC_TEST|aCGH|
58285133|NCT02999841|DRUG|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
58070355|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
58285134|NCT02999841|DRUG|Vildagliptin|1-24 week: 50mg bid
58285135|NCT05955144|DEVICE|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
58285136|NCT06359197|DRUG|Caffeine Pill|Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
58285137|NCT06359197|DRUG|Placebo|Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
58399064|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
58399065|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
58070356|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
58285138|NCT06359197|DEVICE|TASSO+ Device|TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
58285139|NCT06359197|DEVICE|Finger prick and collection on Whatman Protein 903 Saver Cards|The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
58285140|NCT06359197|DEVICE|Intravenous Sampling|Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
58285141|NCT06107855|OTHER|Leg Press Resistance Training Machine|Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
58285142|NCT01945476|DRUG|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
58285143|NCT00190164|PROCEDURE|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
58285144|NCT00190164|PROCEDURE|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
58285145|NCT06463197|BEHAVIORAL|Self-Administered Acupressure Group|Subjects will attend two weekly 120-minute of self-administered acupressure training according to the group allocation in a classroom at the School Nursing, the Hong Kong Polytechnic University. The subjects will be trained to perform self-administered acupressure by an acupuncturist. To enhance interaction and ensure the quality of teaching, each class will be conducted in a small group of 5 to 7 subjects. Participants in this group will learn the self-acupressure technique and passed fidelity check. The treatment protocol included 6 acupoints, namely, Baihui (GV20) and bilateral Fenchi (GB20), Neiguan (PC6), Shenmen (HT7), Shenxu (BL23) and Yongquan (KI1) (Table 1). Subjects were given an acupressure log to record their practice at home, and they were phoned twice a week to remind their practice during the 4-week treatment period.
58285146|NCT06463197|BEHAVIORAL|Sleep Hygiene Education group|The participants in this group will receive education on sleep hygiene. The treatment duration, frequency, and telephone follow-up schedule for the SHE group will be the same as the self-administered acupressure group (2 sessions, 2 hours each). Sleep hygiene education is often used as a comparison group in randomized controlled trials of self-help and psychological interventions for insomnia. The SHE group will provide subjects with the same amount of contact hours with the healthcare professional (instructor) in order to control the non-specific effects of practitioner-patient interaction in the self-administered acupressure group.
58285147|NCT04087369|OTHER|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
58399066|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
58399067|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
58399068|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
58070357|NCT01384513|DRUG|Fludarabine|Given IV
58399069|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
57931406|NCT04117009|DRUG|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
58399070|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
58399071|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
58285148|NCT00948922|DRUG|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
58285149|NCT00948922|DRUG|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes.
58285150|NCT00948922|PROCEDURE|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
58399072|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
58399073|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
58399074|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
58399075|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
58399076|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
57931407|NCT04117009|DIAGNOSTIC_TEST|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
57931408|NCT00139646|DRUG|Parecoxib|
57931409|NCT00139646|DRUG|Diclofenac|
58285151|NCT00948922|DRUG|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
58285152|NCT00948922|PROCEDURE|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
58285153|NCT03038711|DRUG|BMS-986166|Specified dose on specified days
58285154|NCT03038711|OTHER|Placebo matching BMS-986166|Specified dose on specified days
58285155|NCT02831946|DEVICE|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
58285156|NCT02831946|DEVICE|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
57931410|NCT03269643|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
58070358|NCT01384513|DRUG|Busulfan|Given IV
58285157|NCT02182154|DRUG|BIBF 1120 ES|
58285158|NCT04073290|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
57931411|NCT03269643|DEVICE|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
58285159|NCT04073290|DRUG|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
58285160|NCT04073290|DRUG|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
58285161|NCT03369626|BEHAVIORAL|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
58285162|NCT03852498|GENETIC|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
58285163|NCT02906579|DRUG|Matching Placebo|
58285164|NCT02906579|DRUG|IW-1973|
58285165|NCT00168155|DRUG|perioperative chemotherapy|
58285166|NCT02253576|OTHER|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
58285167|NCT02253576|OTHER|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
58285168|NCT04074330|DRUG|TAK-981|TAK-981 intravenous infusion.
58285169|NCT04074330|DRUG|Rituximab|Rituximab intravenous infusion.
58285170|NCT01716611|DRUG|Tolvaptan|15 - 60 mg/day for 28 days
58285171|NCT01716611|DRUG|placebo|
58285172|NCT06171516|BEHAVIORAL|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
58285173|NCT05833867|DRUG|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
58285174|NCT05833867|RADIATION|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
58285175|NCT04336475|OTHER|orofacial exercise program|combined stretching\&strengthening exercise regimen
58285176|NCT05362149|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
58285177|NCT05362149|DRUG|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
58285178|NCT05362149|DRUG|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
58285179|NCT04753333|BEHAVIORAL|Electromyography biofeedback (EMG-BF)|Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
58399077|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
57931412|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
58285180|NCT04753333|BEHAVIORAL|Sham electromyography biofeedback (EMG-BF)|Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
58285181|NCT05361135|DIAGNOSTIC_TEST|PET/CT|Enhanced imaging with PET/CT
58285182|NCT05215405|DRUG|Venetoclax|"Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast.~* Day 1 (200 mg equivalent):~  * Patients 20 \< 30 kg will take 70 mg~ * Patients 30 \< 35 kg will take120 mg~ * Patients 35 to 45 kg will take 200 mg~* Day 2 onwards (400 mg equivalent):~  * Patients 20 \< 30 kg will take 170 mg~ * Patients 30 \< 35 kg will take 250 mg~ * Patients 35 to 45 kg will take 400 mg"
58285183|NCT05215405|DRUG|Navitoclax|"Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations.~* Patients 20 \< 45 kg will take 25 mg~* Patients 45 kg or more will take 50 mg"
58285184|NCT04879706|OTHER|None planned|No intervention planned
58285185|NCT01256099|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
58285186|NCT01256099|BEHAVIORAL|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
58285187|NCT01256099|BEHAVIORAL|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
58285188|NCT04537013|PROCEDURE|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
58285189|NCT04537013|DEVICE|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
57931413|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
57931414|NCT01794533|DRUG|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
57931415|NCT01794533|DRUG|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
57931416|NCT02198092|OTHER|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
57931417|NCT00194766|DRUG|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
58285190|NCT06224686|OTHER|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
57931418|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
57931419|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
57728837|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
57728838|NCT02181530|OTHER|No Intervention|No treatment (intervention) is being administered as part of this study.
57728839|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
57728840|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
57728841|NCT00337766|DRUG|Desmopressin (DDAVP)|
57728842|NCT00337766|DRUG|Placebo|
58399078|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
58399079|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
58399080|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
58285191|NCT06224686|OTHER|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
57728843|NCT06141135|OTHER|Preimplantation genetic testing for aneuploidy (PGTA)|24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
57931420|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
58070359|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
58070360|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
58070361|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
58285192|NCT02841358|BIOLOGICAL|Blood sampling|
58285193|NCT02841358|BIOLOGICAL|Biopsy|
58285194|NCT00386074|DRUG|NaFeEDTA, Electrolytic Iron|
58285195|NCT02081014|DRUG|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
58285196|NCT01509664|BEHAVIORAL|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
58399081|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
58399082|NCT01700998|DRUG|Magnesium|
58399083|NCT01700998|DRUG|Placebo|
58399084|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
58399085|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
57728844|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
58070362|NCT01384513|DRUG|Tacrolimus|Given IV or PO
58070363|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
58070364|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
58070365|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
58070366|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
58285197|NCT02082769|DRUG|Febuxostat|
58285198|NCT02082769|DRUG|Allopurinol|
58285199|NCT03083808|DRUG|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8"
58399086|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
58399087|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
58399088|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
58399089|NCT00116675|DRUG|Resiquimod|
58399090|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
58399091|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
58399092|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
58399093|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
57931421|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
57931422|NCT04084964|OTHER|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
58285200|NCT03881202|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
57931423|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
57931424|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
57931425|NCT01729858|DEVICE|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
57931426|NCT01729858|DEVICE|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
57931427|NCT02693782|DIETARY_SUPPLEMENT|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
57931428|NCT02693782|DIETARY_SUPPLEMENT|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
57931429|NCT00518388|BEHAVIORAL|Focus Group|Focus groups each lasting about 2 hours.
58285201|NCT03891355|DRUG|Carfilzomib|Carfilzomib
58285202|NCT03891355|DRUG|Lenalidomide|Lenalidomide
58285203|NCT03891355|DRUG|Dexamethasone|Dexamethasone
58285204|NCT02472262|DIETARY_SUPPLEMENT|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
57931430|NCT00518388|BEHAVIORAL|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
57931431|NCT01205997|DRUG|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
58070367|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
58070368|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
58285205|NCT02472262|DIETARY_SUPPLEMENT|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
58285206|NCT02472262|DIETARY_SUPPLEMENT|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
57728845|NCT02805569|DEVICE|articulating stylet|patient who intubated with articulating stylet
57728846|NCT02805569|DEVICE|conventional stylet|patient who intubated with conventional stylet
58070369|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
58399094|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
58399095|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
58399096|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
58285207|NCT01344694|OTHER|patient with liver fat|30 patient with liver fat
58285208|NCT01344694|OTHER|pts. with excess of visceral fat|pts. with excess of visceral fat
58285209|NCT01344694|OTHER|control|30 control subjects
58285210|NCT01887288|DRUG|Capecitabine|650 mg/m\^2 PO b.i.d.
58285211|NCT01887288|DRUG|Digoxin|0.25 mg once daily
58285212|NCT04330222|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
58399097|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
58399098|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
58399099|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
58399100|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
58399101|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
57728847|NCT05663047|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
58285213|NCT04330222|OTHER|Brief Memory and Executive Test|Cognitive Assessment
58285214|NCT06082726|DIETARY_SUPPLEMENT|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
58285215|NCT03845244|DEVICE|Flow reduction first|-10L/min q 1hr
58285216|NCT03845244|DEVICE|FiO2 reduction first|- 0.1 q 1hr
58285217|NCT03845244|DEVICE|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
58285218|NCT01183416|DRUG|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
58285219|NCT05762640|DRUG|Ruxolitinib|"Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT."
58285220|NCT03846544|DRUG|Corifollitoropin alfa (CFA)-double pick up|In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
58285221|NCT01115387|OTHER|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
58285222|NCT01115387|OTHER|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
58285223|NCT00005049|DRUG|carboplatin|
58399102|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
58399103|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
57728848|NCT05663047|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
57931432|NCT01205997|DRUG|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
57931433|NCT01205997|DRUG|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
58070370|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
58070371|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
58070372|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
58070373|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
58070374|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
57728849|NCT01839734|DRUG|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
57728850|NCT03216837|DEVICE|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
58070375|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
58070376|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
58070377|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
58070378|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
58070379|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
58070380|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
58070381|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
58285224|NCT00005049|DRUG|cisplatin|
58285225|NCT00005049|DRUG|floxuridine|
58070382|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
58070383|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
58285226|NCT04638556|DIAGNOSTIC_TEST|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
58285227|NCT01184612|BEHAVIORAL|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
58285228|NCT02112019|PROCEDURE|Sialoendoscopy|
58285229|NCT02112019|DRUG|saline|
58070384|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
58285230|NCT02112019|DRUG|hydrocortisone|
58285231|NCT04470479|DRUG|Pilocarpine Hydrochloride|Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
58285232|NCT04470479|DRUG|Placebo|Placebo
58285233|NCT05233215|BEHAVIORAL|GROW (Glioma Specialists Reaching Out With Support) Support Program|Follow-up survivorship care plan for patients and caregivers
58070385|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
58285234|NCT01831271|OTHER|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
58070386|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
58285235|NCT01831271|OTHER|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
58285236|NCT03793959|DIETARY_SUPPLEMENT|Synbiotic Supplement|
58285237|NCT03793959|DIETARY_SUPPLEMENT|Placebo|
58285238|NCT05680662|COMBINATION_PRODUCT|quercetin, EGCG, metformin , zinc|this intervention target many mechanisms at tumorigenesis, metastasis autophagy, apoptosis, interleukin 6, cathepsin L, and also epigenetic DNA methylation
58285239|NCT05823103|DIAGNOSTIC_TEST|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
58285240|NCT05823103|DIAGNOSTIC_TEST|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
58285241|NCT02436499|DRUG|Botulinum Toxin-A|
58285242|NCT05489107|OTHER|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
58285243|NCT04831996|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
58285244|NCT04664907|OTHER|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
58285245|NCT06551298|OTHER|Menggongzi Tibetan Tea Special Drink|Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
58285246|NCT06551298|DRUG|Atorvastatin Calcium 20Mg Tab|Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
58285247|NCT06551298|OTHER|Low fat diet|Low fat diet
58285248|NCT01358786|PROCEDURE|quilting suture|"* quilting sutures and drains~* quilting sutures but no drains"
57931434|NCT06428500|DRUG|QTX3046|QTX3046 will be administered at protocol defined dose.
57931435|NCT06428500|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
57931436|NCT06735599|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
58070387|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
58070388|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
57931437|NCT06735599|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
58070389|NCT00218439|DRUG|Placebo|
58285249|NCT00797394|DIETARY_SUPPLEMENT|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
58285250|NCT00797394|DIETARY_SUPPLEMENT|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
58285251|NCT02069106|DIETARY_SUPPLEMENT|Pro-Omega LDL|
58285252|NCT02069106|OTHER|Placebo|
58285253|NCT02624635|OTHER|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
58399104|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
58399105|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
58399106|NCT02524275|DRUG|Capecitabine|Given PO
57931438|NCT06734650|OTHER|peripheral waveform collection|The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
58070390|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
58070391|NCT03511222|DRUG|Nivolumab|Standard of care
58070392|NCT03511222|DRUG|Pembrolizumab|Standard of care
58070393|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
58070394|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
58070395|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
58070396|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
58070397|NCT02554721|DRUG|Cilostazol|
58070398|NCT02554721|DRUG|Acetylsalicylic acid|
58070399|NCT02554721|DRUG|Clopidogrel|
58399107|NCT02524275|DRUG|Docetaxel|Given IV
58399108|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
58399109|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
58399110|NCT04523818|DRUG|Capecitabine|Given PO
58399111|NCT04523818|DRUG|Fluorouracil|Given IV
58285254|NCT02624635|OTHER|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
58070400|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
58070401|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
58070402|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
57728851|NCT03216837|DEVICE|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
57728852|NCT02332070|PROCEDURE|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
58070403|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
58070404|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
58285255|NCT01225926|DEVICE|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
58285256|NCT01225926|DEVICE|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
58285257|NCT00828061|DRUG|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
58285258|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
58285259|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
58285260|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58070405|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
58285261|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58285262|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58285263|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58285264|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58285265|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
58285266|NCT04704271|DRUG|Inhaled THC|4 mg inhaled THC
58285267|NCT04704271|DRUG|Placebo|Inhaled placebo (no active cannabinoids)
58285268|NCT03969615|DEVICE|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
58285269|NCT03969615|DEVICE|Supplemental oxygen|5lpm of supplemental oxygen
58399112|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
58399113|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
58399114|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
58070406|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
58070407|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
57728853|NCT02317458|BIOLOGICAL|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
58399115|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
58399116|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
58399117|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
58399118|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
58399119|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
58399120|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
57931439|NCT03149614|OTHER|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
58285270|NCT06252155|OTHER|Music|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
58285271|NCT01815502|DIAGNOSTIC_TEST|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
58285272|NCT06045611|DIETARY_SUPPLEMENT|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
58285273|NCT06045611|DIETARY_SUPPLEMENT|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
58285274|NCT06045611|DIETARY_SUPPLEMENT|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
58285275|NCT06045611|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
58399121|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
58399122|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
58399123|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
58399124|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
58399125|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
58399126|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
57728854|NCT02317458|BIOLOGICAL|Sham comparator|One arm with standard of care undergoing a sham procedure
57728855|NCT03836053|DRUG|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
57728856|NCT03845608|COMBINATION_PRODUCT|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
57728857|NCT01134874|BEHAVIORAL|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
57931440|NCT03149614|OTHER|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
57931441|NCT05388851|OTHER|Educational Intervention|Complete educational training module
57931442|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
57931443|NCT05706012|OTHER|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
57931444|NCT05322850|BIOLOGICAL|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
58399127|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
57931445|NCT00628303|BIOLOGICAL|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
57931446|NCT00628303|OTHER|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
58070408|NCT03647098|DRUG|Chemotherapy.|pemetrexed, 500mg/m2, ivgtt every 21 day.
58399128|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
58399129|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
58399130|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
58399131|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
57931447|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol acetate (HT-Ac)|Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA
58285276|NCT02950922|DRUG|RVT-501 0.2% ointment|
58285277|NCT02950922|DRUG|RVT-501 0.5% ointment|
58285278|NCT02950922|OTHER|Vehicle ointment|Placebo comparator
58285279|NCT03928275|BIOLOGICAL|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
58285280|NCT03928275|BIOLOGICAL|Combination therapy Interleukin-2 and Bacillus Calmette Guerin|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
58070409|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
58070410|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
58070411|NCT00481533|DRUG|Oxytocin|
58070412|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
58070413|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
58070414|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
58070415|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
58070416|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
58070417|NCT01787019|OTHER|Oral feeding|
58070418|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
58070419|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
58070420|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
58070421|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
58070422|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
58070423|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
58070424|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
58285281|NCT00088309|PROCEDURE|Eye exam|
58399132|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
58399133|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
58399134|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
58285282|NCT00088309|PROCEDURE|Oral exam|
58285283|NCT00088309|PROCEDURE|CT scan|
58285284|NCT00088309|PROCEDURE|Neuropsychological testing|
58285285|NCT00088309|PROCEDURE|Electrocardiogram|
58285286|NCT00088309|PROCEDURE|Echocardiogram|
58285287|NCT04776577|DEVICE|Wirecath@ and Abbott PressureWire® (20 patients)|Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
58285288|NCT04776577|DEVICE|Wirecath® (20 patients)|FFR measurement with Wirecath® only
58285289|NCT04776577|DEVICE|Coronary flow reserve|Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
58285290|NCT05195099|OTHER|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
57931448|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol eicosapentanoate (HT-EPA)|Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.
58399135|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
58399136|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
58399137|NCT04278768|DRUG|Venetoclax|Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
58399138|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
58399139|NCT02516098|DRUG|hyoscine butylbromide|
58399140|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
58399141|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
58399142|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
58399143|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
57931449|NCT06735222|DIETARY_SUPPLEMENT|Oleacore®|Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA
57931450|NCT02978079|DEVICE|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
58399144|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
57931451|NCT03944135|OTHER|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
58285291|NCT02064699|BIOLOGICAL|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
58399145|NCT00408382|DRUG|atorvastatin, Lipitor|
57931452|NCT02877472|DEVICE|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
58399146|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
57931453|NCT02877472|PROCEDURE|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
57931454|NCT00025454|DRUG|tipifarnib|
57931455|NCT01770613|BIOLOGICAL|Stem cells|Allogeneic mesenchymal stem cells
58399147|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
58399148|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
58399149|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
58399150|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
58399151|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
57931456|NCT04575025|DRUG|Tabrecta tablets|There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
57931457|NCT00244127|DRUG|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
57931458|NCT02682472|OTHER|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
57931459|NCT00387764|DRUG|pazopanib|800 mg daily dosing continously until progression
57931460|NCT00404456|DRUG|Melatonin|Melatonin 3 mg once-daily
57931461|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
58285292|NCT02194894|DRUG|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
58285293|NCT01018745|DRUG|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
58285294|NCT00999622|OTHER|laboratory biomarker analysis|
58285295|NCT00999622|OTHER|questionnaire administration|
58285296|NCT01440985|DRUG|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
58399152|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
57728858|NCT01134874|BEHAVIORAL|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
58285297|NCT01440985|DRUG|Nicotine|Nicotine gum 4 mg, Lot number GC962A
58285298|NCT01440985|DRUG|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
58285299|NCT02117609|DIETARY_SUPPLEMENT|New DELICAL formula|3 months with the option of continuing until 6 months.
58285300|NCT02117609|DIETARY_SUPPLEMENT|Standard DELICAL formula|3 months with the option of continuing until 6 months.
58285301|NCT01340742|PROCEDURE|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
58285302|NCT01340742|PROCEDURE|Control|Cuff placed on arm uninflated for 30 minutes.
58285303|NCT02250456|PROCEDURE|Echo doppler|vascular ultrasound explorations
58285304|NCT02051088|PROCEDURE|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
58285305|NCT02051088|PROCEDURE|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
58399153|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
58399154|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
58399155|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
57728859|NCT01134874|BEHAVIORAL|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
58285306|NCT02051088|DEVICE|drug-coated balloons and/or drug-eluting stents|
58285307|NCT04953741|DRUG|Fluticasone propionate inhaled aerosol|The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
58285308|NCT02065401|DRUG|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
58285309|NCT02065401|DRUG|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
58285310|NCT02065401|DRUG|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
58285311|NCT00813878|GENETIC|protein analysis|protein analysis
58399156|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
57728860|NCT04855253|DRUG|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
58285312|NCT00813878|GENETIC|protein expression analysis|protein expression analysis
58285313|NCT00813878|GENETIC|proteomic profiling|proteomic profiling
58285314|NCT00813878|OTHER|diagnostic laboratory biomarker analysis|Performed one time on study
58285315|NCT00813878|OTHER|immunohistochemistry staining method|Performed one time on study
58285316|NCT00813878|OTHER|liquid chromatography|Performed on samples collected one time on study
58285317|NCT00813878|OTHER|mass spectrometry|Performed on samples collected one time on study
58285318|NCT00813878|PROCEDURE|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
58285319|NCT00813878|PROCEDURE|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
58399157|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
58399158|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
58285320|NCT00813878|PROCEDURE|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
58285321|NCT02190721|DRUG|tbo-filgrastim|5 μg/kg
58285322|NCT06349707|OTHER|other: Observational|For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)
58285323|NCT01737879|DRUG|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
58285324|NCT01737879|DRUG|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
58399159|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
58399160|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
58399161|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
58399162|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
58399163|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
58399164|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
58399165|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
58399166|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
58399167|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
57931462|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
58285325|NCT05223816|DRUG|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
58285326|NCT05223816|DRUG|Nivolumab Injection [Opdivo]|immunotherapy treatment
58285327|NCT03883776|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
58285328|NCT03883776|DEVICE|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
58399168|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
58399169|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
58399170|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
58399171|NCT00886886|DRUG|MDMA|125 mg, single dose
58285329|NCT03883776|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
58399172|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
58399173|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
58285330|NCT03123003|DEVICE|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
57931463|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
57931464|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
57931465|NCT04191187|DRUG|Fludarabine|Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2
58285331|NCT03123003|DEVICE|Wrist X-ray|Bone age assessment by Wrist X-ray
58285332|NCT01385540|BEHAVIORAL|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
58399174|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
58399175|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
58399176|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
57931466|NCT04191187|DRUG|Melphalan|Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
57931467|NCT04191187|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
57931468|NCT03298672|DRUG|NDX-1017|Solution of NDX-1017 for subcutaneous injection
57931469|NCT03298672|DRUG|Placebo|Placebo solution for subcutaneous injection
57931470|NCT04061551|OTHER|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses"
57931471|NCT02088814|BEHAVIORAL|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
57931472|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
57931473|NCT00516620|BEHAVIORAL|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
57931474|NCT00516620|BEHAVIORAL|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
58070425|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
58285333|NCT00235248|DRUG|Warfarin|Warfarin
58285334|NCT00235248|DRUG|Clopidogrel-aspirin|Clopidogrel-aspirin
58399177|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
58285335|NCT02776540|DRUG|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
58285336|NCT02776540|DRUG|Aspirin|there's another group will receive 400 mg Aspirin
58285337|NCT01179438|DRUG|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
58285338|NCT03282591|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
58285339|NCT03282591|DRUG|Matching Placebo Tablets|Placebo Tablets
58399178|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
58399179|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
58399180|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
58399181|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
58399182|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
58399183|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
58399184|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
58399185|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
58399186|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
58399187|NCT02559323|OTHER|Survey|
58399188|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
58399189|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
58070426|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
57931475|NCT00516620|BEHAVIORAL|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
57931476|NCT00516620|BEHAVIORAL|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
57931477|NCT00516620|BEHAVIORAL|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
58070427|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
58070428|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
58070429|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
58285340|NCT06136260|OTHER|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will text and/or call the parent after receiving the referral; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, subsequent calls or texts from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
58399190|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
58399191|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
58399192|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
58399193|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
58399194|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
57728861|NCT00991926|DRUG|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
57728862|NCT00991926|OTHER|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
57728863|NCT02672904|DEVICE|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
58070430|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
58070431|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
58070432|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
58070433|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
58070434|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
58399195|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
58399196|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
58399197|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
58399198|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
58070435|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
57728864|NCT02672904|DEVICE|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
57728865|NCT00412087|DRUG|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
57728866|NCT00412087|DRUG|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
58070436|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
58070437|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
58070438|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
58070439|NCT00052013|DRUG|PTK787/ZK 222584|
58070440|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
58070441|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
58399199|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
58399200|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
58399201|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
58399202|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
58399203|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
58399204|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
58399205|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
58399206|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
58399207|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
58399208|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
58399209|NCT06637527|DRUG|Placebo|Placebo
58399210|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
58399211|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
58399212|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
58399213|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
58399214|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
58399215|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
58399216|NCT00123370|DRUG|Modafinil|
58399217|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
58399218|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
58070442|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
58399219|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
58399220|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
58399221|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
58399222|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
58399223|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
58399224|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
58399225|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
58399226|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
58399227|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
58399228|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
58399229|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
58399230|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
58399231|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
58399232|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
58399233|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
58399234|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
58399235|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
58399236|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
58399237|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
58399238|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
58399239|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
58399240|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
58399241|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
57728867|NCT00412087|DRUG|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
58399242|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
58399243|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
58399244|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
58399245|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
58399246|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
57728868|NCT02513654|DRUG|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
57728869|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
57728870|NCT01970033|DRUG|Placebo|"* Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
58070443|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
57728871|NCT01970033|DRUG|SP2086 50 mg b.i.d.|"* Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks"
57728872|NCT01970033|DRUG|SP2086 100 mg q.d.|"* Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks"
58070444|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
58070445|NCT00237146|DRUG|Zoledronic acid|
58070446|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
58399247|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
58399248|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
58399249|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
57728873|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
57728874|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
57728875|NCT02673658|BEHAVIORAL|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
57728876|NCT02673658|BEHAVIORAL|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
58070447|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
58399250|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
58399251|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
58399252|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
58399253|NCT06362473|DRUG|Lipid-lowering treatments|
58399254|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
58399255|NCT02340247|OTHER|Water|
58399256|NCT02340247|DRUG|Ursodeoxycholic Acid|
58399257|NCT02340247|DRUG|Chenodeoxycholic Acid|
58399258|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
58399259|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
58399260|NCT00116701|DRUG|Aranesp®|
58399261|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
58399262|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
58399263|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
58399264|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
58399265|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
58399266|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
58399267|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
58399268|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
58399269|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
58399270|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
58399271|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
57728877|NCT02639702|DRUG|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
57728878|NCT00659334|DRUG|Ferumoxtran-10 (Combidex)|2.6 mg/kg
58399272|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
58399273|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
58399274|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
58399275|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
58399276|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
58399277|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
58399278|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
58399279|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
58070448|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
58399280|NCT04726592|DRUG|Placebo|Placebo IV
58399281|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
58399282|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
58399283|NCT02315807|DEVICE|transcranial direct current stimulation|
58399284|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
58399285|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
58399286|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
58399287|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
58399288|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
58399289|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
58399290|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
58399291|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
58399292|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
58399293|NCT00132756|DRUG|Doxil and Estramustine|
58399294|NCT03136146|DRUG|Bortezomib|Given SC
58399295|NCT03136146|DRUG|Clofarabine|Given IV
58399296|NCT03136146|DRUG|Cyclophosphamide|Given IV
58399297|NCT03136146|DRUG|Dexamethasone|Given IV or PO
58399298|NCT03136146|DRUG|Etoposide|Given IV
58399299|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
58285341|NCT06136260|OTHER|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a link to a webpage with a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
58399300|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
58399301|NCT03136146|BIOLOGICAL|Rituximab|Given IV
58399302|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
58399303|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
58399304|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
58399305|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
58399306|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
58399307|NCT03271372|DRUG|Avelumab|Given IV
58399308|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
58399309|NCT03271372|OTHER|Placebo|Given IV
58399310|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
58399311|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
58399312|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
58399313|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
58399314|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
58285342|NCT06513832|BEHAVIORAL|The asthma navigator|The asthma navigator is a Registered Respiratory Therapist and Certified Asthma Educator who will review the care plan at discharge and provide asthma education; assist with follow-up clinic appointment scheduling, medication access, and transportation; and daily as-needed telephone support.
58070449|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
58285343|NCT01187277|BEHAVIORAL|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
57728879|NCT00659334|PROCEDURE|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
57931478|NCT00516620|BEHAVIORAL|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
58285344|NCT01187277|DEVICE|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
58285345|NCT04999449|DRUG|Scopolamine|Intranasal scopolamine at 0.2 mg or 0.4 mg
58285346|NCT04999449|DRUG|Placebo|Intranasal saline placebo
58285347|NCT04962087|BEHAVIORAL|Experimental: Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
58285348|NCT04962087|BEHAVIORAL|Experimental: Health enSuite Insomnia - Deprescribing|All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
57728880|NCT03726905|OTHER|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
58285349|NCT02186158|DRUG|Vitamin C|
58285350|NCT02186158|DRUG|Placebo|
58285351|NCT00399698|DRUG|Risperdal|
58285352|NCT04424472|DIAGNOSTIC_TEST|Ultrasonography|Abdominal Ultrasonography
58285353|NCT06202274|DEVICE|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
58285354|NCT01449864|RADIATION|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
57728881|NCT03726905|OTHER|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
57931479|NCT00516620|BEHAVIORAL|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
58070450|NCT00125138|DRUG|Placebo|Syrup formulation
58285355|NCT01408719|DIETARY_SUPPLEMENT|Control|Minimal beta-glucan
58070451|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
58285356|NCT01408719|DIETARY_SUPPLEMENT|3g LMW beta-glucan|3grams beta-glucan
58285357|NCT01408719|DIETARY_SUPPLEMENT|5g LMW beta-glucan|5 grams beta-glucan
57728882|NCT03726905|OTHER|aerobic training|12 weeks treadmill walking
57728883|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
58070452|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
58070453|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
58070454|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
58070455|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
58070456|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
58285358|NCT01408719|DIETARY_SUPPLEMENT|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
58285359|NCT06236113|DRUG|Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution|administered at rate of 0.1 mg/kg/hr
58285360|NCT00884260|DRUG|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
58285361|NCT02018302|DRUG|Triheptanoin|
58285362|NCT06336811|DEVICE|passive virtual reality distraction|watching the application by wearing virtual glasses to the child during the phlebotomy
58285363|NCT06336811|DEVICE|active virtual reality distraction|The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.
58285364|NCT01393418|OTHER|Cardiac Surgery|
58285365|NCT03478085|OTHER|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
58399315|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
58285366|NCT05930171|PROCEDURE|Ultrasound guided L-ESPB and PENG block using Bupivacaine|Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
58285367|NCT05930171|DRUG|Postoperative conventional analgesia in form of Acetaminophen|Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
58285368|NCT00567424|DRUG|GW273225|
58285369|NCT04818203|BIOLOGICAL|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10\^7 cells/1 mL/vial
58285370|NCT04818203|OTHER|Placebo|The injection solution without clusters of autologous dermal fibroblasts
58285371|NCT02393131|RADIATION|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
58285372|NCT02393131|RADIATION|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
58285373|NCT04923932|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
58285374|NCT00835835|OTHER|Body-weight supported treadmill training +/- Lokomat assistance|walking
58285375|NCT00835835|OTHER|Usual Care - no active intervention|No treatment used for comparison
58399316|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
58399317|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
58399318|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
58399319|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
58399320|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
58399321|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
58399322|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
58399323|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
57728884|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
58070457|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
57728885|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
58070458|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
58285376|NCT04773821|OTHER|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
58285377|NCT04064515|DIAGNOSTIC_TEST|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
58285378|NCT02878200|BIOLOGICAL|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
58285379|NCT02328482|DRUG|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
58285380|NCT02742025|OTHER|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
58285381|NCT02742025|OTHER|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
58285382|NCT02742025|OTHER|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
58285383|NCT02742025|PROCEDURE|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
58285384|NCT03715452|DEVICE|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
58285385|NCT03634527|BEHAVIORAL|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
58285386|NCT03634527|BEHAVIORAL|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
58285387|NCT00777062|DRUG|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
58070459|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
58070460|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
58285388|NCT00777062|DRUG|Placebo|Placebo injection at the start of weeks 2 and 6.
58285389|NCT06492382|DIAGNOSTIC_TEST|Home Oxygen Monitors|Weaning of home oxygen using information gathered from home moniotr devise
58285390|NCT04972422|DRUG|ZN-c3|ZN-c3 is a study drug
58285391|NCT02814383|OTHER|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
58285392|NCT04862975|DRUG|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
58285393|NCT04862975|DRUG|Lamivudine|Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
58285394|NCT04862975|DRUG|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
58399324|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
58399325|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
58399326|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
58399327|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
58399328|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
58399329|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
57728886|NCT00874029|DEVICE|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
58070461|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
58070462|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
58070463|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
58070464|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
58399330|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
58399331|NCT05076409|DRUG|BI 425809|Period 1 and period 2
58285395|NCT04862975|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
58285396|NCT05309239|OTHER|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
58285397|NCT05430477|DEVICE|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
58285398|NCT05599347|DRUG|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
58285399|NCT05599347|OTHER|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
58285400|NCT03864003|BEHAVIORAL|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.
58285401|NCT02844270|DEVICE|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
58285402|NCT00812500|OTHER|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
58399332|NCT05076409|DRUG|fluconazole|Period 2
58399333|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
58399334|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
58399335|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
58285403|NCT00812500|OTHER|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
58285404|NCT00812500|OTHER|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
58285405|NCT01648920|DEVICE|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
58285406|NCT06148155|RADIATION|[68Ga]Ga-NOTA-RG2 PET Imaging|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
58285407|NCT02078596|DRUG|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
58285408|NCT04037800|PROCEDURE|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
58285409|NCT04037800|PROCEDURE|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
58285410|NCT01439984|DRUG|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
58285411|NCT06053632|BEHAVIORAL|Low-load and high-velocity - lying prone - eccentric hamstring exercise|Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
58285412|NCT00460746|DRUG|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
58285413|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
58285414|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
58285415|NCT00807612|DRUG|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
58285416|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
58285417|NCT00807612|DRUG|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
58285418|NCT03968913|DRUG|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
58285419|NCT03968913|PROCEDURE|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
58285420|NCT00830635|OTHER|educational intervention|
58285421|NCT00830635|OTHER|informational intervention|
57728887|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
58285422|NCT00830635|OTHER|internet-based intervention|
58285423|NCT00830635|OTHER|questionnaire administration|
58285424|NCT00830635|OTHER|study of socioeconomic and demographic variables|
58285425|NCT00830635|OTHER|survey administration|
58285426|NCT00830635|PROCEDURE|psychosocial assessment and care|
58285427|NCT00830635|PROCEDURE|quality-of-life assessment|
58285428|NCT01404949|DRUG|Tretinoin and Arsenic Trioxide|See Detailed Description
58285429|NCT03923049|DIAGNOSTIC_TEST|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
58285430|NCT01569698|PROCEDURE|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
58285431|NCT00667914|PROCEDURE|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
57728888|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
58285432|NCT00667914|PROCEDURE|Orthopedic care as usual|treatment in ordinary orthopedic unit
58285433|NCT03472937|PROCEDURE|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
58285434|NCT03271593|OTHER|No intervention|No intervention
58285435|NCT04268758|DEVICE|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
58285436|NCT02032615|DIETARY_SUPPLEMENT|Education plus Gudness Nutritional Bar|
58285437|NCT02032615|OTHER|Education|
58285438|NCT02616198|OTHER|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
58285439|NCT02616198|OTHER|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
58399336|NCT02305849|DRUG|Peficitinib|oral tablet
58285440|NCT02616198|OTHER|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
58285441|NCT02616198|OTHER|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
58285442|NCT05447455|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
58285443|NCT05447455|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
58285444|NCT03584230|BEHAVIORAL|Assigned to positive group|See arm description
58285445|NCT03584230|BEHAVIORAL|Assigned to negative group|See arm description
58285446|NCT05409716|PROCEDURE|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
58285447|NCT05409716|PROCEDURE|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
58285448|NCT00202943|PROCEDURE|TCRFVR and LAUP|
58285449|NCT03077425|BEHAVIORAL|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
58285450|NCT03077425|BEHAVIORAL|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
58285451|NCT05644678|DEVICE|Fixed appliances|Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
58285452|NCT05644678|PROCEDURE|Corticotomy|Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
58285453|NCT02927678|OTHER|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
58285454|NCT00003522|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58399337|NCT02305849|DRUG|Placebo|oral tablet
58399338|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
58399339|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
58399340|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
58399341|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
58399342|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
58399343|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
58399344|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
58399345|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
58399346|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
58399347|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
58285455|NCT04536675|DRUG|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
58285456|NCT04536675|DRUG|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
58285457|NCT05100303|DRUG|Mitoxantrone Hydrochloride liposome injection|Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
58285458|NCT05100303|DRUG|Cytarabine (LoDAC)|Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
58285459|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
58285460|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
58285461|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
58285462|NCT06137066|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
58285463|NCT04388124|DRUG|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
58285464|NCT04388124|DRUG|Placebo|Placebo
58285465|NCT04171362|OTHER|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
58285466|NCT04171362|OTHER|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
58399348|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
58399349|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
58399350|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
58399351|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
58399352|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
58285467|NCT05951036|PROCEDURE|Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 70% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
58285468|NCT05951036|PROCEDURE|Sham Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 10% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
58285469|NCT05951036|PROCEDURE|High-load Eccentric training|Physical therapist will ask participants to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 70% of repetition maximum.
58285470|NCT04137809|DEVICE|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
58285471|NCT03187184|DEVICE|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
58285472|NCT02975531|OTHER|Simulator's construction|Model to build the mold for the simulator
58285473|NCT02975531|OTHER|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
58285474|NCT02975531|OTHER|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
58285475|NCT02975531|OTHER|Simulator training|Training of pompage technique using the simulator.
58285476|NCT02975531|OTHER|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
58285477|NCT06461689|DRUG|177Lu-PSMA-617|All patients treated with 177Lu-PSMA had a post-therapy 68Ga-PSMA PET scan and a post-therapy 177Lu-PSMA-617 SPECT/CT scan. These scans are available in the CHRU PACS, and patients are informed that their data may be used for research purposes, via posters in the nuclear medicine department or via the welcome booklet,
58285478|NCT05612269|DIAGNOSTIC_TEST|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
58285479|NCT04642482|DIETARY_SUPPLEMENT|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
58285480|NCT04642482|DRUG|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
58285481|NCT04839666|DRUG|Propofol|Perioperatively propofol administration
58285482|NCT03256357|BEHAVIORAL|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
58285483|NCT03256357|BEHAVIORAL|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
58285484|NCT03256357|BEHAVIORAL|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
58285485|NCT06002659|BIOLOGICAL|CAR20(NAP)-T|Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
57931480|NCT00516620|BEHAVIORAL|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
58070465|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
57728889|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
58070466|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
58285486|NCT06002659|DRUG|Cyclophosphamide|pre-conditioning chemotherapy
58285487|NCT06002659|DRUG|Fludarabine|pre-conditioning chemotherapy
58285488|NCT00492700|DRUG|rosiglitazone|
58285489|NCT00098007|DRUG|Everolimus (Certican)|
58285490|NCT01408082|DRUG|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
58285491|NCT01408082|DRUG|Azasite|Azasite twice daily for 2 weeks
58285492|NCT01408082|DRUG|Dexamethasone|Dexamethasone twice daily for 2 weeks
58285493|NCT01408082|OTHER|Vehicle|Vehicle twice daily for 2 weeks
58285494|NCT03117361|DRUG|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
58285495|NCT03117361|DRUG|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
58399353|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
58399354|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
58399355|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
58399356|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
58399357|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
58399358|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
58399359|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
58399360|NCT06067100|DRUG|Placebo|Participants are administered placebo
58399361|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
58399362|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
58399363|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
58399364|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
57931481|NCT06105788|OTHER|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
58285496|NCT03117361|DRUG|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
58285497|NCT00980733|DIETARY_SUPPLEMENT|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
58285498|NCT00980733|DIETARY_SUPPLEMENT|Yoghurt|Plain yoghurt same as in intervention group without fortification
58285499|NCT05473793|DIETARY_SUPPLEMENT|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).
58285500|NCT05473793|OTHER|Placebo|The control arm receives a placebo consisting of rice puff particles.
58399365|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
58399366|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
57931482|NCT04351763|DRUG|Amiodarone|Ion channel blocker
57931483|NCT04351763|DRUG|Verapamil|Ion channel blocker
58285501|NCT02501161|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
58285502|NCT02501161|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
58285503|NCT04953806|BEHAVIORAL|Step-CBT|Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
58399367|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
58399368|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
58399369|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
58399370|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
57931484|NCT05483309|DIAGNOSTIC_TEST|CT scan|Patients receive a CT scan
57931485|NCT05483309|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia
57931486|NCT03483467|OTHER|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
58399371|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
58070467|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
58285504|NCT03310632|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
58285505|NCT03264612|BEHAVIORAL|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
58285506|NCT01544647|OTHER|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
58285507|NCT01544647|OTHER|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
58285508|NCT02746094|DEVICE|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
58285509|NCT01696656|DRUG|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
58285510|NCT00003115|DRUG|hydromorphone hydrochloride|
58285511|NCT04365075|DEVICE|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
58285512|NCT04365075|DEVICE|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
58285513|NCT04742881|PROCEDURE|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
58285514|NCT04742881|PROCEDURE|Low pressure + standard instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of standard instruments (5mm and 10mm instruments)
58285515|NCT03070275|BIOLOGICAL|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
58285516|NCT03070275|PROCEDURE|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
58285517|NCT00043849|DRUG|Quetiapine|
58285518|NCT06491017|DEVICE|MI-E Intervention protocol|"The endotracheal tube cuff will be inflated to 40 cmH2O and MI-E device will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set.~Before initiation of the MI-E intervention protocol, the investigators will carry out a short-period test to find the appropriate MI-E settings to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min. Concretely, inspiratory and expiratory time will always be set at 4 seconds and 2 seconds, respectively, and inspiratory flow will always be in slow mode. Once the appropriate inspiratory pressure will be found, the expiratory pressure will be initially set to exceed in 30 cmH2O the inspiratory pressure and, if required, this will be increased by 5 cmH2O until achieving a PEF ≥80 L/min with a maximum expiratory pressure of 70 cmH2O."
58285519|NCT06491017|DEVICE|Standard MI-E setting|"Cough Assist E70 device (Philips Respironics, USA, Andover, Massachusetts) will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set. During the 1-minute pause between sets, the patient will be reconnected to the ventilator to avoid desaturation and de-recruitment during procedures. PEEP will remain stable during the protocol.~The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause."
58285520|NCT06344546|DIAGNOSTIC_TEST|Metabolomics|Analysis of the metabolome in plasma samples.
58285521|NCT04298879|DRUG|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
58285522|NCT05984173|DRUG|Vitamin E application|patients received vitamin E inside the socket after extraction
58285523|NCT03678194|DEVICE|Smartphone Support System|6 weeks smartphone application with daily evaluations
58285524|NCT06187233|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
58399372|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
58399373|NCT02497144|OTHER|Control Group|Breathing exercises
58070468|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
58285525|NCT00616447|DEVICE|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
58285526|NCT00616447|DEVICE|placebo sham|Sham treatment will mimic active treatment mentioned above.
58285527|NCT00407342|DRUG|Alefacept (drug)|alefaceptgiven iv
58285528|NCT00407342|PROCEDURE|Narrowband UVB phototherapy|
58285529|NCT00459771|DRUG|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
58285530|NCT00459771|DRUG|Placebo|Placebo, 32 mg, oral QD
58285531|NCT00582426|DRUG|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
58285532|NCT00582426|OTHER|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
58285533|NCT00451113|DRUG|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
58285534|NCT00003974|BIOLOGICAL|lung tumor associated antigen|
58285535|NCT00003974|DRUG|DetoxPC|
58285536|NCT00003974|DRUG|chemotherapy|
58285537|NCT00003974|DRUG|cyclophosphamide|
58399374|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
57728890|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
57728891|NCT03735550|DEVICE|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
57931487|NCT03483467|OTHER|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
58285538|NCT02757625|DRUG|Dexmedetomidine hydrochloride|"* 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
58285539|NCT03942887|DRUG|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
58285540|NCT03942887|DRUG|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
58285541|NCT03942887|DRUG|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
58285542|NCT03942887|DRUG|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
58285543|NCT02916953|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
58285544|NCT02648464|DRUG|Hydroxychloroquine|
58285545|NCT02648464|DRUG|Placebo|
58285546|NCT04931771|DEVICE|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
58285547|NCT04931771|DEVICE|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
58285548|NCT05309694|COMBINATION_PRODUCT|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
58285549|NCT01831427|DRUG|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
58285550|NCT01831427|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
58399375|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
58399376|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
58399377|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
58285551|NCT06163014|BEHAVIORAL|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~1. Symptom explanations and facts about frequent symptoms including brief animated explanations~2. Physical energy (sleep, diet and activity)~3. Working with resources and strain in everyday life~4. Values and choices (meaning and existential issues)~5. Thoughts~6. Feelings (emotion regulation)~7. Self-care (attention incl. mindfulness and audio exercises)~8. Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
58285552|NCT00232206|DRUG|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
58285553|NCT03547258|GENETIC|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
58285554|NCT00298883|DRUG|Myfortic|Myfortic 360mg PO BID for six weeks
58285555|NCT06598137|PROCEDURE|Ex vivo confocal laser microscopy|Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
58285556|NCT00178646|DRUG|Botox|Botox 75-150 units, single treatment only
58285557|NCT01770808|DIETARY_SUPPLEMENT|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
58285558|NCT01770808|DIETARY_SUPPLEMENT|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
58285559|NCT01770808|DIETARY_SUPPLEMENT|Placebo|Subjects swallowed 4 capsules/day for six weeks.
58285560|NCT01790802|DEVICE|2RT nanosecond laser|active laser therapy
58285561|NCT01727830|OTHER|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
57931488|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
57931489|NCT02764450|DEVICE|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
57931490|NCT02764450|DEVICE|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
58285562|NCT02401698|OTHER|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
58285563|NCT05872061|OTHER|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
58285564|NCT04855331|PROCEDURE|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
58285565|NCT04855331|PROCEDURE|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
58285566|NCT00156091|DRUG|Olanzapine|5- 20 mg QD
58285567|NCT00156091|DRUG|Asenapine|5 or 10 mg BID
58285568|NCT00156091|OTHER|Placebo|
58285569|NCT00802321|DRUG|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
58285570|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
58285571|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
58285572|NCT02763917|DEVICE|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
58399378|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
57931491|NCT02031783|DIETARY_SUPPLEMENT|Mixture of glucose and fructose|
58399379|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
58399380|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
58399381|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
58399382|NCT05348993|DRUG|Placebo|placebo
58399383|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
58399384|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
58399385|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
58399386|NCT04945707|DRUG|Placebo|Normal saline
58399387|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
58399388|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
58399389|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
58399390|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
58399391|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
58399392|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
58399393|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
58399394|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
58399395|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
58399396|NCT00003783|BIOLOGICAL|filgrastim|
58399397|NCT00003783|DRUG|asparaginase|
58399398|NCT00003783|DRUG|cyclophosphamide|
58399399|NCT00003783|DRUG|cytarabine|
57931492|NCT02031783|DIETARY_SUPPLEMENT|glucose|
58399400|NCT00003783|DRUG|daunorubicin hydrochloride|
58399401|NCT00003783|DRUG|dexamethasone|
58399402|NCT00003783|DRUG|etoposide|
58399403|NCT00003783|DRUG|idarubicin|
58399404|NCT00003783|DRUG|leucovorin calcium|
58399405|NCT00003783|DRUG|mercaptopurine|
58399406|NCT00003783|DRUG|methotrexate|
58399407|NCT00003783|DRUG|prednisone|
58399408|NCT00003783|DRUG|vincristine sulfate|
58399409|NCT00003783|RADIATION|radiation therapy|
58399410|NCT00002873|RADIATION|brachytherapy|
58399411|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
58399412|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
58399413|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
58399414|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
58399415|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
58399416|NCT02503358|DRUG|Paclitaxel|Given IV
58399417|NCT02503358|OTHER|Pharmacological Study|Correlative studies
58399418|NCT02503358|DRUG|Selumetinib|Given PO
58399419|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
58399420|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
58399421|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
58399422|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
58399423|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
58399424|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
58399425|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
58399426|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
58399427|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
58399428|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
58399429|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
58399430|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
58399431|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
58399432|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
58399433|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
58399434|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
58399435|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
58399436|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
58399437|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
58399438|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
58399439|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
58399440|NCT01681069|OTHER|Placebo|
58399441|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
58399442|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
58399443|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
58399444|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
57728892|NCT04623294|PROCEDURE|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
57931493|NCT00775736|DRUG|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
57931494|NCT00775736|DRUG|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
57931495|NCT00775736|DRUG|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
58399445|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
58399446|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
58399447|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks.
58399448|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
58399449|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
58399450|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
58399451|NCT03020134|DRUG|Placebo|Placebo
58399452|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
58399453|NCT04807088|OTHER|Placebo|
58399454|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
58399455|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
58399456|NCT00075725|DRUG|Cyclophosphamide|Given IV
58399457|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
58399458|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
58399459|NCT00075725|DRUG|Dexamethasone|Given PO or IV
58399460|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
58399461|NCT00075725|DRUG|Leucovorin Calcium|Given IV
58399462|NCT00075725|DRUG|Mercaptopurine|Given PO
58399463|NCT00075725|DRUG|Methotrexate|Given IT or IV
58399464|NCT00075725|DRUG|Pegaspargase|Given IM
58399465|NCT00075725|DRUG|Prednisone|Given PO or IV
58399466|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
58399467|NCT00075725|DRUG|Thioguanine|Given PO
58399468|NCT00075725|DRUG|Vincristine Sulfate|Given IV
58399469|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
58399470|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
58399471|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
58399472|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
58399473|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
58399474|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
58399475|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
58399476|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
58399477|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
58285573|NCT02763917|DEVICE|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
58285574|NCT05903755|DEVICE|speed dependent treadmill training on moderate speed|Experimental group will receive 14 session of speed dependent treadmill training on moderate speed (3 to 6) for 25 minutes along with strengthening, stretching and range of motion exercises.
58285575|NCT05903755|DEVICE|speed dependent treadmill training on slow speed|Control group will receive 14 session of speed dependent treadmill training on slow speed (1 to 2) for 25 min along with physiotherapy.
58285576|NCT03382405|BIOLOGICAL|mRNA-1647|Escalating dose levels
58285577|NCT03382405|BIOLOGICAL|mRNA-1443|Escalating dose levels
58285578|NCT03382405|OTHER|Placebo|Saline
58285579|NCT01719159|DRUG|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
58285580|NCT02373423|OTHER|Advocacy|See above for description
58285581|NCT04613440|OTHER|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
58285582|NCT04613440|OTHER|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
58285583|NCT04613440|OTHER|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
58285584|NCT04613440|OTHER|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
58285585|NCT05826340|BEHAVIORAL|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
58285586|NCT05826340|BEHAVIORAL|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
58399478|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
58285587|NCT00805129|DRUG|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
58070469|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
58070470|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
58285588|NCT04875572|DEVICE|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
58285589|NCT03442088|DRUG|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
58285590|NCT06573619|OTHER|Validation of questionnaire|Validation of questionnaire
58285591|NCT05236855|DIAGNOSTIC_TEST|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
58285592|NCT02497404|DRUG|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
58285593|NCT02497404|DRUG|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
58285594|NCT02497404|DRUG|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
58285595|NCT02497404|DRUG|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
58285596|NCT02497404|RADIATION|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
58285597|NCT06553482|OTHER|FatMAx training intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them
58285598|NCT06553482|OTHER|FatMax and physical endurance exercise intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise
58285599|NCT06553482|OTHER|Control|No intervention pf physical activity
58285600|NCT05446142|DRUG|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
58285601|NCT05446142|DRUG|Encorafenib first formulation|first formulation
58285602|NCT05446142|DRUG|Encorafenib second formulation|second formulation
58285603|NCT05446142|DRUG|Rabeprazole tablet|Proton-pump inhibitor
57728893|NCT04623294|PROCEDURE|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
58070471|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
57931496|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
58285604|NCT03130933|PROCEDURE|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
58285605|NCT03130933|DRUG|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
58399479|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
58285606|NCT03130933|OTHER|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
58285607|NCT02634801|DRUG|Fumaric Acid Esters|Administered orally
58285608|NCT02634801|DRUG|Methotrexate|Administered orally
58285609|NCT02634801|DRUG|Ixekizumab|Administered SC
58285610|NCT01829997|DEVICE|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
58285611|NCT01050322|DRUG|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
57728894|NCT01560520|BEHAVIORAL|Physical activity|Observation only
57728895|NCT03579979|DRUG|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
58285612|NCT01050322|DRUG|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
58285613|NCT01050322|DRUG|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
58399480|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
58399481|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
57728896|NCT03579979|DRUG|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
57728897|NCT04502329|OTHER|Diet|Energy Restriction Intermittent Fasting Diet
57931497|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
57931498|NCT05920356|DRUG|Sotorasib|Oral administration
58070472|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
58070473|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
58070474|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
58070475|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
58399482|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
58399483|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
58399484|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
57931499|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
57931500|NCT02441673|DRUG|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
58070476|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
58070477|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
58399485|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
58399486|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
58399487|NCT06601517|DRUG|HDM1002|Administered orally
58399488|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
58399489|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
58399490|NCT05711381|DRUG|HM15912|Drug: HM15912 Active 0.5mg/kg
58399491|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
58399492|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
58070478|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
58285614|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
58285615|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
58285616|NCT02538406|OTHER|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
58285617|NCT04787614|OTHER|No intervention|No intervention
58285618|NCT04508647|DRUG|Ublituximab|"Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes."
58285619|NCT04508647|DRUG|Umbralisib|Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
58285620|NCT01963091|DRUG|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
58399493|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
58399494|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
58399495|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
58399496|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
58399497|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
58399498|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
57728898|NCT06226844|DEVICE|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
57728899|NCT05800392|DRUG|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
57728900|NCT05800392|DRUG|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
58070479|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
58070480|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
58285621|NCT01963091|DRUG|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
58285622|NCT06222177|DIAGNOSTIC_TEST|Pathophysiologic evaluation|High-resolution manometry and pH study
58070481|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
57931501|NCT02441673|DRUG|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
58070482|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
58070483|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
58285623|NCT02797509|BEHAVIORAL|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
58285624|NCT05768529|DRUG|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
58399499|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
58399500|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
58399501|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
58399502|NCT01942668|DRUG|Estradiol|
58399503|NCT01942668|DRUG|Progesterone|
58285625|NCT01860716|DRUG|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
58285626|NCT01860716|DRUG|Placebo|
58285627|NCT03279601|DRUG|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
58285628|NCT03279601|DRUG|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
58285629|NCT04184011|DEVICE|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
58285630|NCT01817166|DRUG|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
58285631|NCT01817166|DRUG|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
58285632|NCT01817166|OTHER|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
58285633|NCT01817166|BIOLOGICAL|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
58285634|NCT01817166|BIOLOGICAL|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
58285635|NCT01817166|BIOLOGICAL|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
58285636|NCT02781818|DRUG|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
58285637|NCT02781818|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
58399504|NCT01942668|DRUG|Placebo|
57931502|NCT02441673|DRUG|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
58285638|NCT02781818|DRUG|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
58285639|NCT02370056|DIAGNOSTIC_TEST|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
58285640|NCT02370056|DIAGNOSTIC_TEST|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
58285641|NCT01277432|OTHER|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)"
58399505|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
58399506|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
58399507|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
58399508|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
58399509|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
58399510|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
58399511|NCT00370760|DRUG|placebo|
58399512|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
58070484|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
58285642|NCT01277432|OTHER|Depression screening - control|"All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life"
58399513|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
58399514|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
58399515|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
58399516|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58399517|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
58399518|NCT06325046|OTHER|Survey Administration|Ancillary studies
58399519|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
58399520|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
58399521|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
58399522|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
58399523|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
58285643|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
58285644|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
58399524|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
58285645|NCT02721914|PROCEDURE|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
58285646|NCT00209950|DRUG|Gaboxadol|
58285647|NCT00726258|DRUG|ketamine|ketamine with various concentrations
58285648|NCT00726258|DRUG|placebo|physiological serum
58285649|NCT03795285|DIAGNOSTIC_TEST|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
58285650|NCT04676724|DRUG|GSK3228836|Participants will be administered GSK3228836.
58285651|NCT04676724|DRUG|PegIFN|Participants will be administered PegIFN.
58285652|NCT04676724|DRUG|NA therapy|Participants will continue to receive their NA therapy for the duration of the study.
58285653|NCT02802696|DRUG|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
58399525|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
58399526|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
58399527|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
58399528|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
58285654|NCT02802696|DRUG|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
58285655|NCT03450616|DEVICE|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
58285656|NCT03450616|PROCEDURE|Compression Dressing|Standard of Care Compression Dressing
58285657|NCT03315598|PROCEDURE|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
58399529|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
58399530|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
58399531|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
58399532|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
58285658|NCT04786236|DEVICE|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
58285659|NCT04349540|OTHER|no intervention|no intervention
57931503|NCT02441673|DRUG|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
57931504|NCT02441673|DRUG|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
58399533|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
58399534|NCT03575065|DRUG|BGB-290|Administered orally
58399535|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
57728901|NCT04936282|DRUG|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
57728902|NCT04936282|DRUG|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
58070485|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
58285660|NCT04728698|DRUG|COVI-MSC|1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
58285661|NCT04728698|DRUG|Placebo|Equivalent volume of placebo will be administered
58285662|NCT02711566|DEVICE|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
58285663|NCT02711566|DEVICE|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
58285664|NCT00497055|DRUG|Aripiprazole|
58285665|NCT00497055|DRUG|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
58285666|NCT05447156|BEHAVIORAL|Tailored QuitGuide app|This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.
58285667|NCT05447156|BEHAVIORAL|Standard QuitGuide app|This is an app available to the public.
58285668|NCT03130270|DRUG|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
58285669|NCT05886907|DEVICE|Lehfilcon A multifocal toric contact lenses|Investigational silicone hydrogel contact lenses
58285670|NCT05886907|DEVICE|Samfilcon A multifocal toric contact lenses|Commercially available silicone hydrogel contact lenses
58285671|NCT05886907|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
58285672|NCT00000589|PROCEDURE|platelet transfusion|
58285673|NCT02739659|DEVICE|carbon-ion radiotherapy|
58285674|NCT00293800|DRUG|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
58285675|NCT00293800|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
58285676|NCT00293800|DRUG|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
57728903|NCT05442580|DRUG|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
57728904|NCT05442580|DRUG|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
57728905|NCT05442580|DRUG|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
57728906|NCT05442580|DRUG|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
57728907|NCT05442580|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
58285677|NCT00293800|OTHER|Timolol Vehicle|Placebo
58285678|NCT00282685|PROCEDURE|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
58399536|NCT01557777|DRUG|Navitoclax|QD
58399537|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
58399538|NCT06411912|DRUG|Placebo|Placebo oral tablets
57728908|NCT05442580|DRUG|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
57728909|NCT01279226|DEVICE|Auralevée device|Single treatment with Auralevée device.
57728910|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
57728911|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.
57728912|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with MMR|Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.
57728913|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine administered alone|Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
57728914|NCT05273164|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
58070486|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
58399539|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
58399540|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
58399541|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
58399542|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
58399543|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
57728915|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
58095446|NCT05622799|BEHAVIORAL|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
58285679|NCT05772611|BIOLOGICAL|Genetic and immunology tests|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes."
58285680|NCT00543673|OTHER|Milk based formula A|feed as per HCP directions
58285681|NCT00543673|OTHER|#2 Standard formula|Feed as per HCP directions
58285682|NCT00543673|OTHER|#3 Human Milk|Feed as per HCP directions
58285683|NCT00543673|OTHER|Milk based formula C|Feed as per HCP direction
58285684|NCT01784926|PROCEDURE|Intraocular lens repositioning by scleral suturing|
58285685|NCT01784926|PROCEDURE|Intraocular lens exchange with retropupillary iris-claw lens|
58285686|NCT01466075|DEVICE|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
58285687|NCT05114564|DEVICE|Lens A (comfilcon A lens)|1 month
58285688|NCT05114564|DEVICE|Lens B (lehfilcon A lens)|1 month
58285689|NCT04812314|BEHAVIORAL|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
58285690|NCT04812314|BEHAVIORAL|No exercise|Participants will remain sedentary throughout the duration of the study.
58285691|NCT03865719|BEHAVIORAL|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
58285692|NCT01238341|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
58285693|NCT03302507|PROCEDURE|BESS|Biportal endoscopic surgery
58399544|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
58399545|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
58399546|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
58399547|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
58399548|NCT00274898|DRUG|celecoxib|
58399549|NCT00274898|DRUG|docetaxel|
58399550|NCT00274898|PROCEDURE|adjuvant therapy|
57728916|NCT04011150|DEVICE|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
57728917|NCT04011150|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
57931505|NCT02441673|DRUG|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
58095447|NCT06094543|BEHAVIORAL|Patient Engagement Tool|8 week daily patient education and engagement tool
58095448|NCT06654960|DRUG|HRS9531 injection|HRS9531 injection single dose.
58285694|NCT03302507|PROCEDURE|ULBD|Unilateral laminotomy bilateral decompression
58285695|NCT00038870|BIOLOGICAL|Dendritic Cell Activated Lymphocyte|
58399551|NCT00274898|RADIATION|radiation therapy|
58399552|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
58399553|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
58399554|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
58399555|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
58399556|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
57931506|NCT02441673|DRUG|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
57931507|NCT04004429|DRUG|50 mg AP1189|50 mg AP1189 powder in bottle
58285696|NCT06283433|DIAGNOSTIC_TEST|Finger Prick|Blood sample obtained via drop of capillary blood by finger prick onto filter paper
58285697|NCT06283433|DIAGNOSTIC_TEST|Venipuncture|Blood sample obtained trough venipuncture
58285698|NCT04979533|DEVICE|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
58285699|NCT01488747|DIETARY_SUPPLEMENT|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
58285700|NCT01488747|DIETARY_SUPPLEMENT|Coromega Nectar|660 mg EPA, 436 mg DHA
57931508|NCT04004429|DRUG|AP1189|100 mg AP1189 powder in bottle
57931509|NCT04004429|DRUG|Placebo|Placebo powder in bottle
57931510|NCT06724016|DRUG|HM16390|HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
57931511|NCT04219696|OTHER|Reactive balance training|A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
57931512|NCT05717478|COMBINATION_PRODUCT|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
57931513|NCT05717478|DEVICE|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
57931514|NCT00616434|DRUG|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
57931515|NCT00616434|DRUG|Placebo|Placebo IM injection, self-administered per protocol.
57931516|NCT02616445|DRUG|UE2343|"* UE2343~* 10mg, 20, 35mg~* twice daily for 9 days"
58285701|NCT01488747|DIETARY_SUPPLEMENT|Barleans Swirl|660 mg EPA, 660 mg DHA
58285702|NCT01488747|DIETARY_SUPPLEMENT|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
58285703|NCT01372540|DRUG|Carfilzomib|Given IV
58285704|NCT01372540|DRUG|Filanesib|Given IV
58285705|NCT01372540|OTHER|Laboratory Biomarker Analysis|Correlative studies
58285706|NCT02784288|PROCEDURE|Neck Dissection|All patients will undergo neck dissection of the cervical lymph nodes
58285707|NCT02784288|PROCEDURE|Standard-of-Care (SOC) Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
58285708|NCT02784288|RADIATION|SOC Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
58399557|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
58399558|NCT00098046|DRUG|famciclovir|
58399559|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
58399560|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
58399561|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
58399562|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
58399563|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
58399564|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
58399565|NCT01809509|PROCEDURE|Endometrial biopsy|
58399566|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
58285709|NCT02784288|DRUG|SOC Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
58285710|NCT02784288|DRUG|SOC Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
58285711|NCT02784288|PROCEDURE|Videofluoroscopy|All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
58285712|NCT02683239|DRUG|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
58285713|NCT02683239|DRUG|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
58285714|NCT04854070|DEVICE|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
58285715|NCT04854070|DEVICE|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
58399567|NCT03241940|DRUG|Cyclophosphamide|Given IV
58399568|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
58399569|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
58399570|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
58399571|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
58399572|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
58399573|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
57728918|NCT04011150|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
57931517|NCT02616445|DRUG|Placebo|"* 10mg, 20, 35mg~* twice daily for 9 days"
58285716|NCT00368459|DRUG|raloxifene|Raloxifene is a selective estrogen receptor modulator
58285717|NCT00368459|DRUG|Placebo|Identical appearing placebo
58285718|NCT00385827|DRUG|Mitoxantrone|Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
58285719|NCT00385827|DRUG|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
58285720|NCT00385827|DRUG|Prednisone|Prednisone 5 mg orally twice daily
58285721|NCT05799898|OTHER|No intervention for research purposes only|No intervention for research purposes only
58285722|NCT05535426|DEVICE|Tetranite Implant Stabilization Material|Dental adhesive for increased implant stabilization
58285723|NCT03743025|DRUG|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
58285724|NCT03743025|OTHER|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
58285725|NCT05635877|DRUG|Esmolol|The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
58399574|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
58399575|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
58399576|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
58399577|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
57931518|NCT02616445|DRUG|Placebo|"* Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
57931519|NCT02616445|DRUG|UE2343|"* Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
57931520|NCT02616445|DRUG|UE2343|"* UE2343~* twice daily for 3 days~* single dose on day 4"
57931521|NCT04530461|DIAGNOSTIC_TEST|Serological test|Positive serological test of SARS Cov2
57931522|NCT01535183|DRUG|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
57931523|NCT02597803|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
57931524|NCT02597803|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
57931525|NCT04654585|OTHER|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
57931526|NCT04654585|OTHER|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
58070487|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
58285726|NCT05635877|DRUG|Placebo Comparator: Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
58285727|NCT00396474|OTHER|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
58399578|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
58399579|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
57728919|NCT04483479|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
57931527|NCT04808986|DIAGNOSTIC_TEST|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
57931528|NCT00235820|DRUG|adalimumab|40 mg every other week following an 80 mg dose
57931529|NCT00235820|DRUG|MTX|MTX 7.5 to 25 mg once weekly
57931530|NCT00235820|DRUG|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
57931531|NCT02885948|DRUG|Naloxone|used to block the effects of opioids, especially in overdose
57931532|NCT02885948|DRUG|Placebo|Placebo, ineffective control arm
57931533|NCT03099239|BIOLOGICAL|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
57931534|NCT05712057|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|high frequency rTMS over the right dlPFC
57931535|NCT05712057|DEVICE|electrical scalp stimulation|electrical scalp stimulation over the right dlPFC
58070488|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
58399580|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
58399581|NCT00853242|DRUG|Placebo|
58399582|NCT00853242|DRUG|Genz-644470|
57931536|NCT05712057|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal.
58399583|NCT00853242|DRUG|Sevelamer carbonate|
58285728|NCT00202098|PROCEDURE|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
57728920|NCT03431168|DRUG|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
57728921|NCT03431168|DRUG|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
57728922|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
57728923|NCT05883852|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
57728924|NCT05883852|DRUG|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
57728925|NCT05883852|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
58285729|NCT04718805|DRUG|Darunavir|Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
58285730|NCT04718805|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
58285731|NCT04718805|DRUG|Darunavir/Cobicistat FDC|Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
58285732|NCT03058718|OTHER|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
58285733|NCT03058718|OTHER|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
58285734|NCT05624190|DRUG|Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)|The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
58285735|NCT05624190|OTHER|Best Medical Management|Best Medical Management
58285736|NCT04069143|DIAGNOSTIC_TEST|18F-BMS-986327|Imaging Agent
58285737|NCT02660437|OTHER|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
58285738|NCT05891717|OTHER|Resistance training|Twice per week for 8 weeks. Total 16 sessions will given.
58285739|NCT05891717|OTHER|Flexibility training|Twice per week for 8 weeks. Total 16 sessions will given.
58285740|NCT03945318|DRUG|BION-1301 Single Dose|A solution for IV infusion administered as a single dose.
58285741|NCT03945318|DRUG|Placebo Single Dose|A solution by IV infusion administered as a single dose.
58285742|NCT03945318|DRUG|BION-1301 Multiple Doses|A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
57728926|NCT05883852|DRUG|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
57728927|NCT05883852|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
57728928|NCT05883852|DRUG|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
57931537|NCT05712057|BEHAVIORAL|Emotional Awareness Training|Emotional awareness training is a behavioral intervention through which participants learn how to identify and evaluate their emotions and the components that make up each emotion.
58070489|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
58285743|NCT03945318|DRUG|Placebo Multiple Doses|A solution by IV infusion administered as multiple doses.
58285744|NCT03945318|DRUG|BION-1301 Single Dose|SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
58285745|NCT02651337|DEVICE|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
57931538|NCT02187614|DRUG|Diclofenac|
57931539|NCT02187614|DRUG|Morphine|
57931540|NCT02187614|DRUG|Paracetamol|
57931541|NCT02187614|DRUG|Placebos|
58070490|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
58070491|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
58285746|NCT02144077|DRUG|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
58285747|NCT02144077|DRUG|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
58285748|NCT01619098|OTHER|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
58285749|NCT01619098|OTHER|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
58285750|NCT04825756|BEHAVIORAL|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
58285751|NCT00696319|OTHER|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
58285752|NCT00696319|OTHER|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
58285753|NCT02401035|DRUG|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
58285754|NCT02830074|BEHAVIORAL|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
58285755|NCT02830074|BEHAVIORAL|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
58285756|NCT04525040|DIETARY_SUPPLEMENT|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
58285757|NCT04525040|OTHER|Pragmatic comparator|Standard of care as usual without a preventive intervention
58285758|NCT04075669|DIAGNOSTIC_TEST|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
58285759|NCT05356650|OTHER|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
58285760|NCT05356650|OTHER|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
58399584|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
58399585|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
58399586|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
58399587|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
57728929|NCT02818738|DRUG|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
57931542|NCT05315453|BEHAVIORAL|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
57728930|NCT02818738|OTHER|Placebo|matching verum
57931543|NCT03298568|DIETARY_SUPPLEMENT|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
58399588|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
57728931|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
57728932|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
57728933|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
58285761|NCT04994808|DRUG|Clofarabine|Given IV
58285762|NCT04994808|DRUG|Fludarabine|Given IV
58285763|NCT04994808|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
58285764|NCT04994808|RADIATION|Total-Body Irradiation|Undergo TBI
58285765|NCT04994808|DRUG|Treosulfan|Given IV
58285766|NCT04994808|PROCEDURE|Echocardiography|Undergo ECHO
58285767|NCT04994808|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58285768|NCT04994808|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
58285769|NCT04994808|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58399589|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
57728934|NCT01194115|DRUG|placebo|placebo representing standard of care
57728935|NCT01748916|OTHER|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
57931544|NCT02231021|DRUG|alogliptin|alogliptin 25 mg add-on background medication metformin
57728936|NCT01748916|OTHER|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
57728937|NCT01748916|OTHER|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
57728938|NCT05846581|DEVICE|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
57728939|NCT02099734|BEHAVIORAL|Questionnaires|
57931545|NCT02231021|DRUG|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
57931546|NCT02231021|DRUG|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
58285770|NCT04994808|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58285771|NCT04994808|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58285772|NCT04211558|DRUG|Ozanimod|Ozanimod
58285773|NCT02748759|DEVICE|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
58285774|NCT02748759|OTHER|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
58285775|NCT03163316|OTHER|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
58285776|NCT00078845|DRUG|Amifostine|500 mg three times a week.
58285777|NCT06127758|OTHER|virtual reality glasses application|The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.
58285778|NCT06127758|OTHER|classical training|Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
58399590|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
58399591|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
58285779|NCT03336931|DIAGNOSTIC_TEST|Molecular profiling and drug testing|"1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy"
58285780|NCT04035525|DIETARY_SUPPLEMENT|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
58285781|NCT04035525|DIETARY_SUPPLEMENT|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
58285782|NCT04035525|DIETARY_SUPPLEMENT|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
58285783|NCT03758235|DRUG|IncobotulinumtoxinA 100 UNT Injection [Xeomin]|Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
58285784|NCT03758235|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
58285785|NCT04987931|DRUG|Talazoparib|This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
58285786|NCT02990871|OTHER|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
58285787|NCT02990871|OTHER|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
58285788|NCT00734656|DRUG|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
58070492|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
58285789|NCT00734656|DRUG|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
58285790|NCT00734656|DRUG|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
58285791|NCT00734656|DRUG|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
58399592|NCT05475483|DRUG|SOM3355 capsules|Treatment will be blind for the whole duration of the study.
58399593|NCT05475483|DRUG|Placebo capsules|Treatment will be blind for the whole duration of the study.
58399594|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
58399595|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
58399596|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
58399597|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
58399598|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
58399599|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
57728940|NCT02099734|OTHER|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
57728941|NCT00736242|BIOLOGICAL|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
57931547|NCT02704338|BIOLOGICAL|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
58070493|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
58070494|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
58070495|NCT00656136|DRUG|placebo|Patients receive placebo once daily
58070496|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
58070497|NCT00211133|DRUG|epoetin alfa|
58070498|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
58070499|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
58070500|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
58070501|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
58070502|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
58070503|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
58070504|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
58399600|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
58399601|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
57728942|NCT00736242|DRUG|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
57728943|NCT05467644|PROCEDURE|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
58070505|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58070506|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58399602|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
57728944|NCT01373086|DRUG|LFF269|
57728945|NCT01373086|DRUG|Eplerenone|
57728946|NCT01373086|DRUG|Placebo|
58070507|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58070508|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
58070509|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
58070510|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
58399603|NCT00015860|DRUG|daunorubicin hydrochloride|
58399604|NCT00015860|DRUG|imatinib mesylate|
58399605|NCT00015860|DRUG|prednisone|
58399606|NCT00015860|DRUG|vincristine sulfate|
57728947|NCT00863850|DRUG|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
58070511|NCT04235959|DRUG|Tirzepatide|Administered SC
58070512|NCT04235959|DRUG|Placebo|Administered SC
58070513|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
58070514|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
58070515|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
58070516|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
58070517|NCT02078674|BIOLOGICAL|Placebo|
58399607|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
58399608|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
58070518|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
58399609|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
58399610|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
57728948|NCT02488486|DEVICE|Automated postoperative sedation|
57728949|NCT02488486|DRUG|propofol|
57728950|NCT02488486|DRUG|remifentanil|
57728951|NCT05774600|BEHAVIORAL|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
58070519|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
58070520|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
58070521|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
58095449|NCT06654960|DRUG|Metformin Hydrochloride tablets|Metformin Hydrochloride tablets 500mg.
58095450|NCT00728988|DRUG|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
58399611|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
58399612|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
58399613|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
58399614|NCT00964665|DRUG|albinterferon alfa-2b|
58399615|NCT00964665|DRUG|albinterferon alfa-2b|
58285792|NCT03192124|DEVICE|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
58285793|NCT04003376|DEVICE|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
58285794|NCT04003376|DRUG|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
58285795|NCT04003376|BIOLOGICAL|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
58285796|NCT04003376|DRUG|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
58285797|NCT01861002|DRUG|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
58399616|NCT00964665|DRUG|albinterferon alfa-2b|
58399617|NCT00964665|DRUG|albinterferon alfa-2b|
58399618|NCT00964665|DRUG|Pegasys®|
58399619|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
57728952|NCT05774600|BEHAVIORAL|Minimal Information Control|Provision of online materials for skin cancer prevention.
57728953|NCT00838344|OTHER|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
57728954|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
57728955|NCT03808662|RADIATION|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
57728956|NCT03808662|DRUG|Standard of care|Standard of care per physician discretion
58095451|NCT00728988|DRUG|Atorvastatin|40mg daily after PCI for 30 days.
58399620|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
58399621|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
58399622|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
58399623|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
58399624|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
58399625|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
58399626|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
58399627|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
58399628|NCT04553744|OTHER|Survey Administration|Complete survey
58399629|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
58399630|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
58399631|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
58399632|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
58399633|NCT01683747|DRUG|Tranexamic Acid|
58399634|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
57728957|NCT01387568|DRUG|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
58095452|NCT01950195|PROCEDURE|Stereotactic Radiosurgery (SRS)|
58285798|NCT01861002|DRUG|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
58399635|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
58399636|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
58399637|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
58399638|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
58399639|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
58399640|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
58399641|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
58399642|NCT04522336|DRUG|Docetaxel|Given IV
58399643|NCT04522336|DRUG|Fluorouracil|Given IV
58399644|NCT04522336|DRUG|Oxaliplatin|Given IV
58399645|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
58399646|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
58399647|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
58399648|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
57728958|NCT01387568|DRUG|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
57728959|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
57931548|NCT02017639|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
57931549|NCT02017639|DRUG|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
57931550|NCT01699854|DRUG|capsaicin patch (qutenza)|
57931551|NCT01699854|DRUG|Placebo|
57931552|NCT03932825|DRUG|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
57931553|NCT03932825|DRUG|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
57931554|NCT00119041|BEHAVIORAL|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
57931555|NCT00119041|BEHAVIORAL|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
58285799|NCT01861002|DRUG|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
58285800|NCT01861002|DRUG|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~* Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~2. - 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~   * 3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
58285801|NCT01861002|DRUG|Intrathecal Methotrexate (IT MTX)|"* Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. - 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. - 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
58399649|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
58399650|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
57728960|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
57931556|NCT00119041|BEHAVIORAL|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
57931557|NCT01883479|BEHAVIORAL|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
57931558|NCT01883479|BEHAVIORAL|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
58095453|NCT01950195|BIOLOGICAL|Ipilimumab|
58095454|NCT03474640|BIOLOGICAL|Part A|Part A: 80, 240, and 480 mg IV every 14 days.
57931559|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
58095455|NCT03474640|BIOLOGICAL|Part B|Part B: 240 mg IV every 3 weeks
58285802|NCT00198523|DRUG|Prednisolone and Tobramycin|
58285803|NCT00198523|DRUG|Prednisolone|
57728961|NCT02170168|OTHER|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
57728962|NCT02461121|GENETIC|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
57931560|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
57931561|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
57931562|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
57728963|NCT02461121|GENETIC|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
57931563|NCT04881461|DRUG|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
57931564|NCT04881461|DRUG|Placebo|Placebo
57931565|NCT06734403|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
58285804|NCT01315522|DEVICE|ComVi stent|Endoscopic insertion of ComVi stent
58285805|NCT01315522|DEVICE|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
57728964|NCT02461121|DRUG|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
57728965|NCT02461121|DRUG|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
57931566|NCT03788395|DEVICE|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
57931567|NCT03788395|DRUG|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
57931568|NCT06735209|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
58095456|NCT00500656|DRUG|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
58095457|NCT00500656|DRUG|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
58095458|NCT00500656|DRUG|Oral Placebo|hard capsule matched to tranexamic acid
58285806|NCT06580340|OTHER|AFA (Adapted Physical Activity)|An exercise program to improve joint mobility, muscle strength, static and dynamic balance, motor coordination will be performed 2 times/week for 6 months.
57728966|NCT02461121|DRUG|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
57728967|NCT02461121|DRUG|fludarabine|30 mg/m2/d for 5days
57728968|NCT02461121|DRUG|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
57728969|NCT02461121|DRUG|cyclophosphamide|40 mg/kg/d for 2 days
57728970|NCT06628206|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
58399651|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
58399652|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
58399653|NCT00152711|DEVICE|nCPAP|
58399654|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
58399655|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
58399656|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
58399657|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
58399658|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
58399659|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
58399660|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
58399661|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
58399662|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
58399663|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
58399664|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
57728971|NCT06628206|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
58285807|NCT01008813|BIOLOGICAL|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A
58285808|NCT01008813|BIOLOGICAL|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
58285809|NCT04917705|OTHER|Collection of biological samples|Skin, muscle fiber and blood sampling
58285810|NCT04218279|OTHER|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
58285811|NCT02815267|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
58285812|NCT02815267|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
58285813|NCT02469233|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
58399665|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
58399666|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
58399667|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
58399668|NCT02050802|DRUG|Moxifloxacin 400 mg|
58399669|NCT02050802|DRUG|Macitentan 10 mg|
58399670|NCT02050802|DRUG|Macitentan 30 mg|
57728972|NCT01186523|OTHER|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
57931569|NCT06735209|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) Challenge consists of cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ Challenge (7G8) contains a laboratory malaria clone derived from Brazil.
57931570|NCT06735209|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
58285814|NCT02432209|OTHER|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
58399671|NCT02050802|OTHER|Placebo|
58399672|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
58399673|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
58399674|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
58399675|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
58399676|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
57728973|NCT05956431|DRUG|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
58399677|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
58399678|NCT00000593|PROCEDURE|blood transfusion|
57931571|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
57931572|NCT01133379|DEVICE|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
57931573|NCT01133379|DEVICE|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
57728974|NCT05956431|DRUG|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
57931574|NCT01133379|DEVICE|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
57931575|NCT02289352|DRUG|Brimonidine|
57931576|NCT02289352|DRUG|placebo|
57931577|NCT05870254|OTHER|ExeRVIEM Program|Virtual exercise based program
57931578|NCT05870254|OTHER|Usual center program|Usual center cares
57931579|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
57931580|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
57931581|NCT00269568|DRUG|mifepristone and misoprostol|
57931582|NCT01217216|BEHAVIORAL|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
57931583|NCT01217216|BEHAVIORAL|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
57931584|NCT00378235|DRUG|IL13-PE38QQR|
58399679|NCT01027234|DRUG|AZD8418|Single oral dose
57931585|NCT04088383|OTHER|Amnios™ RT|Acellular human allograft
57931586|NCT04088383|OTHER|Saline|Sterile saline
58399680|NCT01027234|DRUG|Placebo|single oral dose
57931587|NCT06632444|DRUG|Survodutide|Subcutaneous injection
57931588|NCT06632444|DRUG|Placebo|Subcutaneous injection
57931589|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
57931590|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
57931591|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
57931592|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
57931593|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
58399681|NCT00678769|DRUG|Cixutumumab|Given IV
58399682|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
57931594|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
57931595|NCT04194853|DEVICE|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
57931596|NCT04194853|OTHER|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
57931597|NCT05895604|BEHAVIORAL|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
58399683|NCT00678769|OTHER|Pharmacological Study|Correlative studies
58399684|NCT00678769|DRUG|Temsirolimus|Given IV
58399685|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
57931598|NCT05326113|OTHER|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
57931599|NCT05326113|DRUG|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
57931600|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
57931601|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
57931602|NCT01483833|DRUG|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
57931603|NCT01483833|DRUG|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
57931604|NCT03144804|DRUG|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
57931605|NCT06423612|BEHAVIORAL|POC urine assay informed enhanced ART adherence counselling for viral suppression|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their ART adherence with provision of enhanced ART adherence counseling for viral suppression.
57931606|NCT00179166|DRUG|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
57931607|NCT02407470|DRUG|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
58070522|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
58399686|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
58399687|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
57931608|NCT02407470|PROCEDURE|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
57931609|NCT02407470|PROCEDURE|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
57931610|NCT03913481|PROCEDURE|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
57931611|NCT03913481|PROCEDURE|Standard care|Best available treatment without ANH
57931612|NCT05802394|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
57931613|NCT02764164|DEVICE|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
57931614|NCT01807923|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
57931615|NCT01807923|DRUG|Ivacaftor|Film-coated tablet
57931616|NCT01807923|DRUG|Placebo|Matching placebo tablet
57931617|NCT00497601|DRUG|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
58070523|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
58399688|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
58399689|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
58399690|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
58399691|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
58399692|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
58399693|NCT05688215|DRUG|Fluorouracil|Given IV
58399694|NCT05688215|DRUG|Irinotecan|Given IV
58399695|NCT05688215|DRUG|Leucovorin|Given IV
58399696|NCT05688215|DRUG|Leucovorin Calcium|Given IV
58399697|NCT05688215|DRUG|Oxaliplatin|Given IV
58399698|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
57931618|NCT00497601|DRUG|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
57931619|NCT00497601|DRUG|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
57931620|NCT00819286|DEVICE|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
58399699|NCT05688215|DRUG|Zimberelimab|Given IV
57931621|NCT00819286|DEVICE|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
57931622|NCT05192798|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
57931623|NCT05192798|DRUG|Apatinib Mesylate|Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
58399700|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
58399701|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
57931624|NCT05192798|DRUG|Bevacizumab|Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
57931625|NCT06734897|OTHER|music therapy after Cochlear Implantation|The music therapy is specially designed for the rehabilitation of CI-patients. It focuses on learning to distinguish different sound sources, especially when they occur at the same time. Training involves familiarization with different aspects of music such as rhythm, melody, and pitch while at the same time also getting to know the sound of different musical instruments, including singing. The training is also aimed at learning to concentrate on spoken instructions while the music is going on. This latter aim is fundamental to the goal of this study and plays a central role in the therapy.
57931626|NCT06734897|OTHER|no music therapy after Cochlear Implantation|Group C consists of persons who do not receive any music therapy after Cochlear Implantation.
57931627|NCT00325962|DRUG|6R-BH4 (sapropterin dihydrochloride)|
58070524|NCT00044811|DRUG|Fexofenadine|
58070525|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
58070526|NCT05405738|OTHER|normal group|control normal group
58070527|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
58070528|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
58070529|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
58399702|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
58399703|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
58399704|NCT02043912|DRUG|Haloperidol|
58399705|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
58399706|NCT01904474|OTHER|Standard treatment protocol|
58399707|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
58399708|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
58070530|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
58070531|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
58070532|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
58070533|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
58070534|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
58070535|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
58070536|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
58399709|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
58399710|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
58399711|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
57931628|NCT00846885|DRUG|Sumatriptan Succinate|100 mg Tablet
57931629|NCT00846885|DRUG|Imitrex®|100 mg Tablet
57931630|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
57931631|NCT02947477|BEHAVIORAL|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
58399712|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
58399713|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
58399714|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
57931632|NCT00000604|PROCEDURE|cardiopulmonary bypass|
57931633|NCT00000604|PROCEDURE|heart arrest, induced|
57931634|NCT01177384|DRUG|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
57931635|NCT01177384|DRUG|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
58070537|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
58285815|NCT02432209|DRUG|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
58285816|NCT02432209|OTHER|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
58285817|NCT02383303|BEHAVIORAL|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
58285818|NCT06611670|DEVICE|Cataract surgery with Active Sentry|Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.
58285819|NCT06611670|PROCEDURE|Traditional cataract surgery|Cataract surgery performed with high intraocular pressures
58285820|NCT01310127|DRUG|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
58285821|NCT01310127|DRUG|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
58399715|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
57931636|NCT01177384|DRUG|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
57931637|NCT01177384|DRUG|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
57931638|NCT03612011|OTHER|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
57931639|NCT02258503|OTHER|pain in elderly patients|
57931640|NCT03099005|DRUG|Cannabis|vaporization of cannabis
57931641|NCT01554735|BEHAVIORAL|Exercise and diet|24 weeks of exercise and diet counselling
57931642|NCT02019420|DRUG|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
57931643|NCT02019420|DRUG|Linezolid|Linezolid IV 600 mg twice daily
57931644|NCT05594758|DRUG|Olverembatinib|Oral Olverembatinib
57931645|NCT06012929|DRUG|ONC201|ONC201 is an oral medication given once per week
57931646|NCT06734585|DRUG|Gilteritinib|tablet, oral
58070538|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
58070539|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
58070540|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
58070541|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
58095459|NCT00500656|DRUG|S.C. Placebo|solution for injection, matched to icatibant for injection
58399716|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
58399717|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
58399718|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
58399719|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
58399720|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
58399721|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
58399722|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
57931647|NCT03538353|OTHER|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
58285822|NCT00050635|DRUG|Sandostatin LAR Depot|
58070542|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
58070543|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
58285823|NCT06477380|BEHAVIORAL|ACCEPT intervention|"* Training package (1 day)~* A toolkit/manual for clinicians to guide them through the disclosure process~* Trauma-informed changes to the physical environment~* Monthly trauma-focussed reflective group for care co-ordinators"
58285824|NCT03883477|DEVICE|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
58285825|NCT03883477|PROCEDURE|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
58285826|NCT06075550|OTHER|single cone technique using TotalFill BC Sealer|Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
58285827|NCT06075550|OTHER|warm vertical compaction technique using TotalFill BC Sealer HiFlow|TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
58285828|NCT05185635|DIAGNOSTIC_TEST|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
58285829|NCT01150903|OTHER|no intervention|non-interventional study
58399723|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
58399724|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
58399725|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
58399726|NCT00005841|BIOLOGICAL|MART-1 antigen|
58399727|NCT00005841|BIOLOGICAL|gp100 antigen|
58399728|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
58399729|NCT00005841|BIOLOGICAL|progenipoietin|
58399730|NCT00005841|BIOLOGICAL|tyrosinase peptide|
58070544|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
58070545|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
58070546|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
58399731|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
58399732|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
58399733|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
58399734|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
58399735|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
58399736|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
58399737|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
58399738|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
58399739|NCT01087658|DRUG|Glutamine|Per os
57728975|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
57931648|NCT06734221|DEVICE|Paclitaxel Coated Peripheral Angioplasty Balloon Catheter|"Paclitaxel coated peripheral angioplasty balloon catheters are catheters of over the wire (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty."
57931649|NCT04585646|DEVICE|Orion daily disposable contact lens|Subjects will be randomized to wear Orion lens for 2 weeks.
57931650|NCT04585646|DEVICE|Gemini daily disposable contact lens|Subjects will be randomized to wear Gemini lens for 2 weeks.
57931651|NCT03412279|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
57931652|NCT03412279|BEHAVIORAL|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
58285830|NCT01150903|OTHER|no intervention|non-interventional study
58285831|NCT00704951|DRUG|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
58285832|NCT00819481|DEVICE|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
58285833|NCT00152243|DRUG|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
58285834|NCT00152243|PROCEDURE|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
58399740|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
58399741|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
58399742|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
58399743|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
58399744|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
58399745|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
58399746|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
58399747|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
58399748|NCT00196027|DEVICE|PFX Closure System|
57931653|NCT03274609|COMBINATION_PRODUCT|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
58285835|NCT03061487|PROCEDURE|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
58285836|NCT00632645|DRUG|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
58285837|NCT00632645|DRUG|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
58285838|NCT00632645|DRUG|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
58285839|NCT02080208|DEVICE|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
58285840|NCT06078644|OTHER|respiratory exercise diary|Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
58285841|NCT04560868|DEVICE|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
58399749|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
57728976|NCT00326378|DRUG|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
58399750|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
58399751|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
58399752|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
58399753|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
57728977|NCT00326378|DRUG|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
58399754|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
58399755|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
58399756|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
58399757|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
58399758|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
58399759|NCT03831191|DRUG|LY3375880|Administered SC
58399760|NCT03831191|DRUG|Placebo|Administered SC
58399761|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
58399762|NCT00280618|DRUG|Oxaliplatin|
58399763|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
58070547|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
58285842|NCT04560868|DEVICE|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
58285843|NCT04560868|DRUG|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
58399764|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
58399765|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
57728978|NCT02671487|BEHAVIORAL|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
57931654|NCT06388681|DEVICE|The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography|The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
57931655|NCT00517751|DEVICE|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
57931656|NCT05017220|OTHER|Nature-based sensory stimuli|A program based on stimulation using nature-based sensory stimuli will be implemented
58285844|NCT00620646|DRUG|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
58070548|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
58070549|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
58070550|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
58070551|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
58285845|NCT00620646|DRUG|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
58285846|NCT01888653|BEHAVIORAL|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
58285847|NCT01888653|BEHAVIORAL|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
58399766|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
58399767|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
58399768|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
58399769|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
58399770|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
58399771|NCT03070171|DRUG|dabigatran etexilate|single dose
58399772|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
57931657|NCT05017220|OTHER|Control group intervention|An activity based on a placebo intervention will be implemented
57931658|NCT03687814|OTHER|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
57931659|NCT03687814|OTHER|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
57931660|NCT01125943|DRUG|Acetylcholine|Intra-arterial infusion
57931661|NCT01125943|DRUG|Nitroprusside|Intra arterial infusion
57931662|NCT01125943|DRUG|Bevacizumab|Intra arterial infusion
57931663|NCT01081457|DEVICE|Deep brain stimulation|Comparison ON vs OFF
57931664|NCT00199433|DRUG|Istradefylline (KW-6002)|
57931665|NCT01116518|PROCEDURE|physiotherapy|
57931666|NCT01116518|PROCEDURE|acromioplasty|
57931667|NCT01116518|PROCEDURE|acromioplasty and rotator cuff reconstruction|
57931668|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
58399773|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
57728979|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
57931669|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
57931670|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
57931671|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
57931672|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
57931673|NCT03846739|DRUG|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
57931674|NCT03846739|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
57931675|NCT05474066|DEVICE|ERP Testing|"* Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:"
57931676|NCT05794763|BEHAVIORAL|Peer Led Group Intervention|A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
57931677|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
57931678|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
57931679|NCT05891353|OTHER|Cold Water Immersion|Cold Water Immersion task of hand
57931680|NCT05891353|OTHER|Pain Inducing Stretch|Moderately painful stretch of the neck
57931681|NCT05891353|OTHER|Pain Free Stretch|Pain free stretch of the neck
57931682|NCT03651583|BEHAVIORAL|Kiko exercises-combines breathing and movement|
58285848|NCT05063084|PROCEDURE|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
57931683|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
57931684|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
57931685|NCT06559163|DRUG|Placebo|Placebo
58399774|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
57931686|NCT06734143|DIAGNOSTIC_TEST|Neuropad|Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
57931687|NCT00738413|DRUG|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
57931688|NCT00738413|DRUG|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
57931689|NCT05360082|OTHER|[11C]UCB-J|11C-labeled SV2A binding PET radioligand
57931690|NCT05360082|OTHER|[18F]SynVest-1|18F-labeled SV2A binding PET radioligand
57931691|NCT06692153|DEVICE|An AID System.|The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
57931692|NCT06692153|OTHER|Standard of Care (SC)|Participants will continue to use their current therapy for T2D.
57931693|NCT04554238|DEVICE|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
58285849|NCT05063084|PROCEDURE|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
57931694|NCT04554238|OTHER|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
57931695|NCT05726045|BEHAVIORAL|Standard smoking cessation program (SCP)|Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
57931696|NCT05726045|BEHAVIORAL|Cognitive remediation treatment (CRT)|The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
57931697|NCT05726045|BEHAVIORAL|High-intensity interval training (HIIT evening)|"The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise)."
57931698|NCT06493331|OTHER|Talking Circle|"step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received."
58070552|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
58070553|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
58070554|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
58285850|NCT05008471|DIETARY_SUPPLEMENT|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
58399775|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
57728980|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
57931699|NCT01686360|BEHAVIORAL|Decision Aid|
57931700|NCT00460174|BIOLOGICAL|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
57931701|NCT00460174|DRUG|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
57931702|NCT00460174|PROCEDURE|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
57931703|NCT00460174|RADIATION|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
57931704|NCT04418544|DEVICE|Device used to record voice for screening|voice recording
58070555|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
58070556|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
58070557|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
58285851|NCT03374488|DRUG|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
58285852|NCT03374488|DRUG|Epacadostat|Epacadostat administered orally twice daily.
57931705|NCT04328779|OTHER|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
57931706|NCT04328779|DEVICE|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
57931707|NCT04328779|OTHER|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
58070558|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
57931708|NCT00095355|DRUG|Lithium|
57931709|NCT00095355|DRUG|Divalproex|
57931710|NCT06734598|DRUG|Echo-guided Botox injection|Echo-guided Botox injection to the masticatory muscles
57931711|NCT06734598|PROCEDURE|echo-guided normal saline injection|echo-guided normal saline injection
57931712|NCT01882218|DRUG|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
57931713|NCT01882218|DRUG|Standard Treatment|Standard liver surgery.
58070559|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
58070560|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
58070561|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
58070562|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
58070563|NCT01354834|DRUG|hMG|Patients with a condition
57728981|NCT03317704|BEHAVIORAL|Speed endurance training|Speed endurance training
57931714|NCT02131909|PROCEDURE|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
57931715|NCT02131909|PROCEDURE|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
57931716|NCT06735846|DEVICE|Guide wire|Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
57931717|NCT05274802|DRUG|ALS-4|Single dose of ALS-4 before Breakfast
57931718|NCT05274802|DRUG|Placebo|Single dose of placebo before Breakfast
57931719|NCT05274802|DRUG|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
57931720|NCT05274802|DRUG|ALS-4|Multiple dose of ALS-4 up to two times daily
57931721|NCT05274802|DRUG|Placebo|Multiple dose of placebo up to two times daily
57931722|NCT00730431|DRUG|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
57931723|NCT00730431|DRUG|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
57931724|NCT04353453|DEVICE|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
58070564|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
58070565|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
58070566|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
58070567|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
58070568|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
58070569|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
58070570|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
58070571|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
58070572|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
58285853|NCT03374488|DRUG|Placebo|Matching placebo administered orally twice daily.
58285854|NCT04412798|OTHER|orange juice concentrate|250mL of 100% orange juice made from concentrate
57931725|NCT04353453|DEVICE|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
58070573|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
57931726|NCT05943535|DRUG|Placebo|Placebo administered QID
57931727|NCT05943535|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
57931728|NCT05943535|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
57931729|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.
57931730|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with only physiological saline|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
57931731|NCT04978181|DRUG|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
57931732|NCT04301362|DIAGNOSTIC_TEST|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
57931733|NCT03057314|DRUG|Amorphous Calcium Carbonate|"Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
58285855|NCT04412798|OTHER|Sugar-sweetened orange-flavoured beverage|Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
58285856|NCT04412798|OTHER|Whole orange juice with skin removed|Whole orange pieces with skin removed, energy-matched to the orange juice condition
57931734|NCT01864772|DRUG|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
58285857|NCT06611852|OTHER|Aerobic exercise|"Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue."
58285858|NCT06611852|OTHER|electronic cupping therapy in addition to aerobic exercise|Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).
57728982|NCT02276482|DRUG|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
57931735|NCT02880826|BEHAVIORAL|Measure the culture of safety in the reanimation units|
57931736|NCT01430806|DRUG|Dronedarone arm|PO Dronedarone 400 mg BID
57931737|NCT01430806|DRUG|Dronedarone|Dronedarone PO 400 MG BID
57931738|NCT05440643|BIOLOGICAL|Peanut SLIT-tablet|Peanut extract
57931739|NCT05440643|OTHER|Placebo|Placebo
57931740|NCT06690138|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
58070574|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
57931741|NCT06690138|DRUG|Itraconazole|Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
58070575|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
58070576|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
58070577|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
58070578|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
58070579|NCT03017131|DRUG|Cyclophosphamide|Given IV
58070580|NCT03017131|DRUG|Decitabine|Given IV
58070581|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
58285859|NCT06611852|OTHER|interferential therapy in addition to aerobic exercise|interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy
58285860|NCT06611852|OTHER|interferential therapy, electronic cupping therapy in addition to aerobic exercises|interferential therapy, electronic cupping therapy in addition to aerobic exercises
57728983|NCT02276482|DRUG|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
57931742|NCT00823303|DRUG|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
57931743|NCT00823303|DRUG|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
57931744|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
57931745|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
57931746|NCT05767866|DRUG|YK-029A|Daily dose of YK-029A
57931747|NCT02341703|DRUG|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
57931748|NCT02341703|DRUG|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
57931749|NCT02341703|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
57931750|NCT02341703|OTHER|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
57931751|NCT01104142|DEVICE|CGM|Continuous Glucose Monitoring System
57931752|NCT04452903|BEHAVIORAL|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
57931753|NCT00912652|BEHAVIORAL|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
57931754|NCT00912652|BEHAVIORAL|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
58285861|NCT04421157|OTHER|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
58285862|NCT04421157|OTHER|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
58399776|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
57728984|NCT02276482|DRUG|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
57931755|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
57931756|NCT06390319|DRUG|Vincristine|Given IV.
57931757|NCT06390319|DRUG|Daunorubicin|Given IV.
57931758|NCT06390319|DRUG|Calaspargase pegol|Given IV.
58399777|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
57728985|NCT02276482|DRUG|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
57931759|NCT06390319|DRUG|Dasatinib|Given PO
57728986|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
57728987|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
57931760|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
57931761|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
57931762|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
57931763|NCT06390319|DRUG|Cyclophosphamide|Given IV.
57931764|NCT06390319|DRUG|Cytarabine|Given IV or IT.
57931765|NCT06390319|DRUG|Mercaptopurine|Given PO.
57931766|NCT06390319|DRUG|Nelarabine|Given IV
57931767|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
57931768|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
57931769|NCT05251623|OTHER|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
57931770|NCT04728126|OTHER|Survey|"The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales."
57931771|NCT01252810|DRUG|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
58070582|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
58070583|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
58070584|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
58070585|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
57931772|NCT06282276|BEHAVIORAL|cross sectional survey|filling out the electronic survey form
58070586|NCT03143465|DRUG|Sildenafil|
58285863|NCT06060340|DRUG|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
58285864|NCT05733845|OTHER|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
58285865|NCT03613792|DRUG|Remifentanil|Opioid analgesic
58070587|NCT03143465|DRUG|Placebo|
58070588|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
58285866|NCT03613792|DRUG|Fentanyl|Opioid analgesic
58285867|NCT03613792|DRUG|Midazolam|Benzodiazepine
58285868|NCT03613792|DRUG|Ketamine|Analgesic
58285869|NCT02588729|OTHER|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
58285870|NCT05803759|DIETARY_SUPPLEMENT|Allicor|Each capsule contains 150 mg dried garlic powder
58285871|NCT05803759|DRUG|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
58285872|NCT01761643|DEVICE|SoC + iTab|Text messaging reminders to improve adherence to PrEP
58285873|NCT00225108|DRUG|Tinzaparin|
58285874|NCT04553770|DRUG|Anastrozole|Given PO
58285875|NCT04553770|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58285876|NCT04553770|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
58285877|NCT01832883|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
58285878|NCT02081001|DRUG|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
58285879|NCT02081001|DRUG|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
58070589|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
58070590|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
58285880|NCT00320697|DRUG|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
58285881|NCT00320697|DRUG|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
58285882|NCT03632070|BEHAVIORAL|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
58285883|NCT03646942|RADIATION|low level laser therapy|low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.
58285884|NCT03646942|DEVICE|Lingual Orthodontics|Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
58285885|NCT06613035|DRUG|Selinexor|Selinexor: 60 mg/day from days -9 to -5.
58285886|NCT06613035|DRUG|Melphalan|Selinexor: 60 mg/day from days -9 to -5.
57931773|NCT04048980|BEHAVIORAL|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
57931774|NCT01068392|DRUG|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
57931775|NCT06725147|BEHAVIORAL|AI enabled wellness chatbot|Elomia uses generative AI to respond to user input about psychological stress and distress. It was trained on the responses of real therapists with expertise in cognitive-behavioral therapy. It provides an array of wellness interventions including exercises for calming; • exercises for falling asleep; • grounding techniques; • exercises to reduce anxiety; • breathing exercises; • exercises to improve self-esteem.
57931776|NCT06725147|BEHAVIORAL|Penn Digital Wellness Resources|This active control intervention consists of a variety of digital wellness and stress management resources that are freely available to all Penn students.
57931777|NCT01448122|OTHER|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
57931778|NCT05227872|DEVICE|ultrasound|POCUS
57931779|NCT06637501|DRUG|Sonrotoclax|Administered orally
58285887|NCT06613035|DRUG|Intravenous Busulfan|3.2 mg/kg on days
58285888|NCT06613035|DRUG|Fludarabine|30 mg/m² on days
58285889|NCT02406963|OTHER|Digital Photograph|A digital photograph sent by the family of the surgical site
58285890|NCT02406963|OTHER|Telephone Call|Standard telephone call with the nurse practitioner
58285891|NCT04877418|PROCEDURE|TeleCIMT|Mode applied remotely, through the principles and components of the CIMT protocol.
57931780|NCT06637501|DRUG|Zanubrutinib|Administered orally
57931781|NCT01726452|DRUG|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
57931782|NCT01726452|DRUG|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
57931783|NCT01726452|DRUG|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
57931784|NCT01726452|RADIATION|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
57931785|NCT01726452|DRUG|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
57931786|NCT01726452|DRUG|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
57931787|NCT01726452|DRUG|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
58285892|NCT05350813|PROCEDURE|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
58285893|NCT05350813|PROCEDURE|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
58285894|NCT04441632|BEHAVIORAL|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
58399778|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
58399779|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
57728988|NCT05061121|OTHER|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
57728989|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
58285895|NCT05960175|DEVICE|New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application|"The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary.~If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram."
58285896|NCT03961516|DEVICE|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
58285897|NCT03961516|RADIATION|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
58285898|NCT05048615|DRUG|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
58285899|NCT05048615|DRUG|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
58399780|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
57728990|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
57728991|NCT00656838|BEHAVIORAL|Patients receives letter, phone call, office visit, educational materials|Behavioral
57728992|NCT03198000|DRUG|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
57728993|NCT03198000|DRUG|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
58399781|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
58399782|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
58399783|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
58399784|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
58399785|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
58399786|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
58399787|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
57728994|NCT03198000|DRUG|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
57728995|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
57728996|NCT03926507|OTHER|Fluciclovine F18|Given IV
57728997|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
57728998|NCT06446037|DEVICE|Non-invasive EMG band instrumentation|The sensed EMG signals from the subjects will be decoded by Phantom X algorithm and used to drive various gestures in a desk-mounted hand prosthesis
58399788|NCT02312999|DRUG|Plasmalyte|
58399789|NCT02312999|DRUG|Volulyte|
58399790|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
57728999|NCT03039673|DRUG|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
57729000|NCT03039673|DRUG|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
57931788|NCT01726452|DRUG|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
57931789|NCT01726452|DRUG|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
58070591|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
57931790|NCT01726452|DRUG|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
57931791|NCT02033603|DRUG|Ropivacaine|30mls of 0.5% ropivacaine
57931792|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
57931793|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
57931794|NCT03692572|DIETARY_SUPPLEMENT|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
57931795|NCT03692572|DIETARY_SUPPLEMENT|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
57931796|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
57931797|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
57931798|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
57931799|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
57931800|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57931801|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
57931802|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57931803|NCT06320405|DRUG|Paclitaxel|Given IV
58070592|NCT00002624|PROCEDURE|adjuvant therapy|
57931804|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57931805|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
58070593|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
58070594|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
58070595|NCT00002624|PROCEDURE|video-assisted surgery|
58070596|NCT00002624|RADIATION|radiation therapy|
58070597|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
58285900|NCT05048615|DRUG|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
58285901|NCT03782129|BIOLOGICAL|blood samples|Blood samples drawn during hospitalisations when needed
58285902|NCT03782129|OTHER|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
58285903|NCT06423794|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
58399791|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
58399792|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
58399793|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
58399794|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
57931806|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
57931807|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
57931808|NCT03166163|DRUG|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
57931809|NCT03166163|DRUG|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
57931810|NCT05059236|DRUG|Darolutamide (BAY1841788, Nubeqa)|300 mg per tablet, oral administration with food
57931811|NCT05059236|OTHER|ADT|LHRH agonist/antagonist or orchiectomy
57931812|NCT05931003|PROCEDURE|Carotid stenting|In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
58070598|NCT02395445|DEVICE|orotracheal intubation|
58070599|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
58070600|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
58070601|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
58070602|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
58070603|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
58399795|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
58399796|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
57931813|NCT05931003|PROCEDURE|Carotid endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery."
57931814|NCT04866368|PROCEDURE|The ultrasound-guided Sacral Erector spinae plane block|postoperative pain procedure
57931815|NCT04866368|PROCEDURE|The dorsal penile block|postoperative pain procedure
57931816|NCT00108992|DRUG|Diclofenac, topical|
57931817|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
58070604|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
58070605|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
58070606|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
58285904|NCT05340296|BEHAVIORAL|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
58285905|NCT05485714|OTHER|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
58285906|NCT05028387|DRUG|medical abortion|medical abortion
58285907|NCT05573256|BEHAVIORAL|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
58285908|NCT05573256|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
58285909|NCT02942121|OTHER|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
58285910|NCT03798548|BEHAVIORAL|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
58285911|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-anodal group|2mA/20mins/session; 2sessions/day,5days
58285912|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-sham group|0mA/20mins/session; 2sessions/day,5days
58285913|NCT05599386|DIAGNOSTIC_TEST|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
58399797|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
58399798|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
58399799|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
57931818|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
57931819|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
57931820|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
57931821|NCT03876171|BEHAVIORAL|Haitian youth family-based intervention study: family functioning|A weekly group therapy with the youth in presence of a parent or caretaker in the family.
57931822|NCT03876171|BEHAVIORAL|Haitian youth intervention study: youth psychoeducational|Weekly one and one psychoeducational module will be delivered to the youth.
57931823|NCT03876171|BEHAVIORAL|Haitian family-based intervention study: psychoeducational|Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.
57931824|NCT03876171|BEHAVIORAL|Diversion Programs|Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
58399800|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
58399801|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
58399802|NCT01517165|DRUG|Pioglitazone|
58285914|NCT03594799|OTHER|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
58285915|NCT03594799|DIETARY_SUPPLEMENT|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
58285916|NCT01698944|DRUG|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
58285917|NCT05140252|BEHAVIORAL|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
58285918|NCT02796521|OTHER|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
58285919|NCT02796521|OTHER|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
58399803|NCT01517165|DRUG|Placebo|
58285920|NCT05022888|DEVICE|regional tissue saturation|tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
58285921|NCT03272347|DRUG|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
58285922|NCT03272347|DRUG|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
58285923|NCT03272347|DRUG|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
58285924|NCT03272347|DRUG|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
58399804|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
58399805|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
58399806|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
58399807|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
58399808|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
58399809|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
58399810|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
58399811|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
58399812|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
58399813|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
58399814|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
58399815|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
58399816|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
58399817|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
58399818|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
58399819|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
58399820|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
58399821|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
58399822|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
58399823|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
58399824|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
58399825|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
58285925|NCT03272347|DRUG|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
58285926|NCT03272347|DRUG|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
58285927|NCT03272347|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
57931825|NCT06735235|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
57931826|NCT06735235|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
57931827|NCT06735235|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
58070607|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
58070608|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
58070609|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
58070610|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
58285928|NCT03272347|DRUG|Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
58285929|NCT03272347|DRUG|Doravirine/Islatravir|Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
58285930|NCT06609642|BEHAVIORAL|Art application|"First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application."
58285931|NCT05194683|BEHAVIORAL|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
58285932|NCT04423562|OTHER|No intervention|No intervention
58285933|NCT04582383|DRUG|Spironolactone|Dispensation of spironolactone according to the arm description.
58285934|NCT04582383|DRUG|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
58285935|NCT00038805|DRUG|Mylotarg|
58285936|NCT00415896|DEVICE|positive pressure ventilation|
57931828|NCT06735235|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
58285937|NCT03508180|BEHAVIORAL|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
58285938|NCT03508180|OTHER|CONTROL|None intervention.
58285939|NCT05784376|BEHAVIORAL|Education-based|Nutrition education delivered via text messages through mobile applications (e.g. WhatsApp).
58285940|NCT03513471|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
58285941|NCT03513471|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
57931829|NCT00633711|DEVICE|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
57931830|NCT00633711|DEVICE|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
57931831|NCT04555837|DRUG|Alisertib|Given PO
57931832|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
57931833|NCT01572922|DEVICE|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
58070611|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
57729001|NCT03039673|DRUG|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
57931834|NCT01572922|DEVICE|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
58070612|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
58285942|NCT03513471|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
58285943|NCT05742074|OTHER|Faecal microbiota transplantation|25-30 capsules of faecal material
58285944|NCT05742074|OTHER|Placebo|25-30 placebo capsules
58285945|NCT00639106|PROCEDURE|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
58285946|NCT00639106|PROCEDURE|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
58285947|NCT03941028|DEVICE|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
58285948|NCT03295032|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
58285949|NCT01695382|BEHAVIORAL|Navigation|As per Arm description
58285950|NCT03181945|OTHER|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
58285951|NCT03181945|OTHER|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
58285952|NCT02624882|PROCEDURE|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
58285953|NCT02624882|PROCEDURE|Negative rapid GAS test|Usual care
58285954|NCT04780633|BEHAVIORAL|Precede-Proceed based Training Program on Genital Hygiene Behaviors|A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.
58285955|NCT02378974|BIOLOGICAL|Cordstem-ST|
58285956|NCT02378974|BIOLOGICAL|Placebo|
58399826|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
58399827|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
58070613|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
58070614|NCT01616173|DRUG|Dexamethasone|8mg/2mL
58070615|NCT01616173|DRUG|Saline|2mL
58399828|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
58399829|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
58070616|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
57729002|NCT01346657|DRUG|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
57729003|NCT00584688|DRUG|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
57729004|NCT01017406|DEVICE|PSU heel cushion and plantar fascia specific stretching exercise|"* Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day"
57729005|NCT00311077|DRUG|Insulin Glulisine|
58070617|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
58070618|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
58070619|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
58070620|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
57931835|NCT01572922|PROCEDURE|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
57931836|NCT02717663|BEHAVIORAL|Adaptive Goals|Prescribed goals change daily based on participant's performance
57931837|NCT02717663|BEHAVIORAL|Static Goals|Prescribed goals remain the same throughout study
57931838|NCT02717663|BEHAVIORAL|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
58399830|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
58399831|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
58399832|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
58399833|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
58070621|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
58399834|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
58399835|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
58399836|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
58285957|NCT03278366|BEHAVIORAL|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
58399837|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
58399838|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
58070622|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
58070623|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
58070624|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
58285958|NCT06169826|DRUG|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
57931839|NCT02717663|BEHAVIORAL|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
58285959|NCT06169826|OTHER|Control|Control
57729006|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
57931840|NCT03829709|OTHER|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
57931841|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
58070625|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
58070626|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
58070627|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
58070628|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
58285960|NCT00159107|DRUG|Acamprosate|Acamprosate
58285961|NCT00159107|BEHAVIORAL|Integrative behavior therapy|Integrative behavior therapy
58285962|NCT00159107|DRUG|Placebo|Placebo
57931842|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
57931843|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
57931844|NCT06735690|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHSCT
57931845|NCT06735690|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
57931846|NCT06735690|PROCEDURE|Biospecimen Collection|Undergo blood and optional CSF sample collection
57931847|NCT06735690|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
57931848|NCT06735690|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
57931849|NCT06735690|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57931850|NCT06735690|PROCEDURE|Echocardiography|Undergo ECHO
57931851|NCT06735690|PROCEDURE|Leukapheresis|Undergo leukapheresis
57931852|NCT06735690|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
57931853|NCT06735690|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57931854|NCT06735690|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
57931855|NCT06735690|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57931856|NCT06735690|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57931857|NCT06735690|OTHER|Transplant Conditioning|Given HSCT conditioning regimen
57931858|NCT06735690|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
57931859|NCT00729781|DEVICE|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
57931860|NCT03139825|OTHER|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
57931861|NCT05179642|OTHER|OPTIM-EHPAD tool|"This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
57931862|NCT04693260|DEVICE|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
57931863|NCT06726928|DEVICE|Sinus Stenting|Stenting of symptomatic sinus stenosis
58070629|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
58070630|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
57729007|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
57729008|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
57729009|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
57931864|NCT05560581|BEHAVIORAL|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
57729010|NCT03936491|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
57931865|NCT05560581|BEHAVIORAL|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
57931866|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
57931867|NCT00403754|DRUG|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
57931868|NCT00403754|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
57931869|NCT00403754|DRUG|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
57931870|NCT06120166|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
57931871|NCT02659579|BEHAVIORAL|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
57931872|NCT02659579|BEHAVIORAL|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
57931873|NCT05216757|DRUG|Iguratimod|iguratimod, 25mg bid po.
57931874|NCT05216757|DRUG|placebo|placebo 1 tablet bid po.
57729011|NCT03936491|DRUG|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
57729012|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
57729013|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
57931875|NCT02792179|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
57931876|NCT00807963|DRUG|rHuPH20|recombinant human hyaluronidase PH20 injection
58070631|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
58070632|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
58285963|NCT06355726|BIOLOGICAL|Plasma Exchange|Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure
58285964|NCT06355726|OTHER|Standard Medical Treatment|Standard Medical Treatment
57729014|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
57729015|NCT05481021|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
57931877|NCT00807963|DRUG|zoledronic acid|subcutaneous injection
57931878|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
57931879|NCT00549627|DEVICE|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
57931880|NCT00932685|DRUG|Midazolam|Midazolam 0.5mg/kg
57931881|NCT00932685|DEVICE|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
58285965|NCT00057525|BIOLOGICAL|Anthrax|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
58285966|NCT00057525|BIOLOGICAL|Alhdryogel or PBS|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
58285967|NCT00212264|BEHAVIORAL|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
57931882|NCT02907710|DRUG|Endostar|intravenous infusion
57931883|NCT02907710|DRUG|DDP|
57931884|NCT01981239|DEVICE|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
57931885|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
57931886|NCT01843868|DRUG|Standard anti-emetics in conjunction with R-CHOP|
57931887|NCT01764126|DRUG|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
57931888|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
58070633|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
58285968|NCT00212264|DEVICE|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
58285969|NCT00212264|BEHAVIORAL|Biofeedback|Pelvic Floor Muscle training via biofeedback
58285970|NCT00212264|OTHER|No Treatment|No treatment
57729016|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
58070634|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
58070635|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
58070636|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
58070637|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
58070638|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
58285971|NCT05727748|OTHER|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
58285972|NCT05727748|OTHER|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
57729017|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
57729018|NCT02438449|PROCEDURE|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
57729019|NCT04050592|DRUG|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
57931889|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
58285973|NCT05727748|OTHER|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
58285974|NCT05030571|DEVICE|DPMAS|DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
57931890|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
57931891|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
57931892|NCT05037526|DEVICE|Dexcom G System|Continuous glucose monitoring system
57931893|NCT05037526|DEVICE|Self monitoring blood glucose|Standard Care
57931894|NCT03878446|DRUG|Somapacitan|Somapacitan injected under the skin once a week.
57931895|NCT03878446|DRUG|Norditropin®|Norditropin® injected under the skin once a day.
57931896|NCT03793426|BIOLOGICAL|Fibryga|Human plasma-derived fibrinogen concentrate
57931897|NCT01508546|PROCEDURE|axillary dissection|Conservative breast surgery with or without axillary dissection
57931898|NCT06736444|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
57931899|NCT06736444|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
57931900|NCT06736444|BEHAVIORAL|Attention Control|Attention Control is comprised of 4 weekly 20-minute check-ins with a study therapists regarding the daily monitoring and mood/functioning. Referrals for additional services will be provided as needed.
57931901|NCT03152357|DEVICE|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
57931902|NCT06735638|PROCEDURE|OTC MIE Esophagectomy|"Consenting patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic-assisted technique. The procedure will follow the exact standard steps of traditional VATS/RATS esophagectomy, except the thoracic ports will be placed in the subcostal plane. The number of ports (1-4) will be determined based on the patient and case characteristics.~The Da Vinci Xi® surgical system will be used to perform the thoracic portion of the esophagectomy through subcostal ports using the standard technique. Once the procedure is completed, the robotic arms and ports will be removed from the chest, and figure-of-8 stitches with non-absorbable sutures will be placed to close the diaphragm at the port sites. A 24 Fr soft chest tube will be left in place, as per standard VATS/RATS esophagectomy protocols. Incisions will be closed in the standard manner."
57931903|NCT03644654|PROCEDURE|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
57931904|NCT03644654|PROCEDURE|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
57931905|NCT06070194|BEHAVIORAL|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
57931906|NCT03876314|BEHAVIORAL|Physical Activity Condition|Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
57931907|NCT03587688|PROCEDURE|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
57931908|NCT03999658|BIOLOGICAL|STI-3031|anti-PD-L1 antibody
57931909|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
57931910|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
57931911|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
57931912|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
57931913|NCT04642599|DEVICE|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
57931914|NCT06736431|BEHAVIORAL|Text-based resource referral platform with diabetes educational materials|Text-based resource referral platform with diabetes educational materials
57931915|NCT01481623|OTHER|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
57931916|NCT01481623|OTHER|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
57931917|NCT05120856|BEHAVIORAL|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
58070639|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
58070640|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
57729020|NCT04050592|OTHER|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
58070641|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
57729021|NCT00396604|DRUG|indacaterol maleate|
57729022|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
57729023|NCT04153370|DEVICE|Airtraq|airtraq video laryngoscope was used for intubation of the infant
57931918|NCT05120856|BEHAVIORAL|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
57931919|NCT05131581|OTHER|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
57931920|NCT05131581|BEHAVIORAL|Extra time allotted|Extra time allotted for each visit for CST
57931921|NCT05131581|BEHAVIORAL|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
57931922|NCT04235023|OTHER|myeloid PTP1B expression analysis|peripheral blood macrophage PTP1B expression
57931923|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
57931924|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
57931925|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
57931926|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
57931927|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
57931928|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
57931929|NCT05236114|OTHER|Observation|No intervention
57931930|NCT05905575|BEHAVIORAL|Family dyad diabetes intervention|The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
57931931|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|25 μg p.o.
57931932|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|100 or 200 μg p.o.
57931933|NCT05879913|DEVICE|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
58070642|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
58070643|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
58070644|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
58070645|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
58070646|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
58070647|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
58070648|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
58070649|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
58070650|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
58070651|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
58070652|NCT02861521|DEVICE|Sham|Sham shoe modification
57931934|NCT06735248|BIOLOGICAL|mRNA-1195|IM injection
57931935|NCT06735248|BIOLOGICAL|Placebo|IM injection
57931936|NCT06736275|DRUG|SXRN|"SXRN is a naked plasmid DNA drug targeting miRNA. Accelerated titration and 3+3 dose escalation:In light of ethical considerations and with the aim of minimizing the number of patients possibly exposed to potentially ineffective doses, an accelerated titration strategy will be implemented in the early dose escalation phase (2 mg dose group) in this study, with only 1 subject enrolled. If no DLT occurs to the 3 subjects under the given dose in the DLT valuation window (the 1st cycle, 3 weeks), the study will proceed to the next dose (dose escalation in the same subject is not allowed); if one subject develops DLT, 3 additional subject s will be included to the current dose group; if ≥2 DLTs occur in the dose group with 3 or 6 subject s, the dose escalation will be stopped. The decision is made by discussion among the investigators whether to terminate the escalation or consider adjusting the dose for exploration."
58070653|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
58070654|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
58070655|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
57931937|NCT06549530|DRUG|MVA-BN|All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
57931938|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
57931939|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
58070656|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
58070657|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
58070658|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
57931940|NCT04713423|DIAGNOSTIC_TEST|Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.
57931941|NCT04666571|DEVICE|TOKA|The device is a digitally planned (using individual CT scan measured anatomic data) personalised opening wedge high tibial osteotomy (HTO) procedure using a custom 3D printed surgical guide and plate.
57931942|NCT04666571|DEVICE|Tomofix or ActivMotion|The comparators, Tomofix and ActivMotion, are the most widely used devices for HTO procedures in the UK. Surgical procedures using the Tomofix and ActiveMotion are similar to TOKA, however, they are not patient specific and do not use custom-made plates.
57931943|NCT06249386|BEHAVIORAL|Behavioral Activation (BA)|BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.
57931944|NCT06249386|BEHAVIORAL|Relapse Prevention (RP)|RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
57931945|NCT06607172|DEVICE|oral irrigator|water flosser device
57931946|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
57931947|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
57931948|NCT06274723|OTHER|Expert|Participants will view a brief description of an expert source.
57931949|NCT06274723|OTHER|Peer|Participants will view a brief description of a peer source.
57931950|NCT06274723|OTHER|1 Sided|Participants will view e-cigarette education messages in one-sided.
57931951|NCT06274723|OTHER|2 Sided|Participants will view e-cigarette education messages in two-sided.
57931952|NCT04567667|DRUG|[14C] BMS-986278|Specified dose on specified days
57931953|NCT04567667|DRUG|Kinevac®|Specified dose on specified days
58070659|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
58285975|NCT05030571|OTHER|standard treatment|standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
58285976|NCT05323175|DRUG|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
58285977|NCT05323175|OTHER|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
57931954|NCT05805709|OTHER|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
57931955|NCT05805709|OTHER|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
57931956|NCT05805709|OTHER|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
57931957|NCT05805709|OTHER|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
57931958|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
57931959|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
57931960|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
57931961|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
57931962|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
57931963|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
57931964|NCT06735755|DRUG|BEAM-301: Single dose of BEAM-301 administered by IV|BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
58285978|NCT06385327|DRUG|ABI-5366|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)
58285979|NCT06385327|DRUG|ABI-5366 Placebo|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)
57729024|NCT04153370|DEVICE|glidescope|glidescope video laryngoscope was used for intubation of the infant
57729025|NCT04153370|DEVICE|c-mac|c-mac video laryngoscope was used for intubation of the infant
58285980|NCT00313833|DRUG|Buprenorphine transdermal delivery system|
58285981|NCT03416478|DIAGNOSTIC_TEST|ctDNA test|ctDNA test to find some possible mutation.
58285982|NCT02683408|OTHER|placebo|inactive placebo
58285983|NCT02683408|DIETARY_SUPPLEMENT|diosmiplex|diosmiplex is an FDA regulated medical food product
58285984|NCT01155349|BEHAVIORAL|InSight|A cognitive intervention designed to enhance speed of visual processing.
57931965|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
57931966|NCT03811639|PROCEDURE|Radio-frequency ablation|Ablation for atrial fibrillation
57931967|NCT03811639|PROCEDURE|Cryoballoon ablation|Ablation for atrial fibrillation
57931968|NCT06447818|OTHER|Change in airway markers|Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
57931969|NCT05440266|DIAGNOSTIC_TEST|Study Intervention: 25 ms half-sine wave stimulation|Part I: Threshold detection and Flare response: 6 pulses of 25 ms half-sine are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 25 ms half-sine is administered continuously.
57931970|NCT05440266|DIAGNOSTIC_TEST|Control Intervention: 500 µs rectangular shaped stimulation|Part I: Threshold detection and Flare response: 6 pulses of 500 µs rectangular shaped stimulation are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 500 µs rectangular shaped stimulation is administered continuously.
57931971|NCT01889056|DRUG|Erythropoietin (Epoetin beta)|
57931972|NCT01889056|DRUG|Placebo|0.9% sodium chloride solution
57931973|NCT00003181|BIOLOGICAL|aldesleukin|
58070660|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
58070661|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
58070662|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
57931974|NCT00003181|BIOLOGICAL|sargramostim|
57931975|NCT00003181|DRUG|vinblastine sulfate|
57931976|NCT05686590|BEHAVIORAL|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
57931977|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
58070663|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
58070664|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
58070665|NCT00039936|BEHAVIORAL|Self Help|
58285985|NCT01155349|OTHER|No contact-control group|No contact-control group.
58285986|NCT02485756|OTHER|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
58285987|NCT02532283|DRUG|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
58285988|NCT02532283|DRUG|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
58285989|NCT02532283|DRUG|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
57931978|NCT00621894|DRUG|Placebo|Placebo
57931979|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
57931980|NCT06086886|OTHER|Placebo|Specified dose on specified days
57931981|NCT05578495|OTHER|Accelerometer data|Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
57931982|NCT02112435|DEVICE|Somnyx ®|Active mandibular advancement splint
57931983|NCT02112435|DEVICE|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
57931984|NCT05328583|DRUG|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
57931985|NCT01710592|DRUG|Epirubicin|
57931986|NCT01710592|DRUG|Oxaliplatin|
58070666|NCT00039936|BEHAVIORAL|Partial Self Help|
58070667|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
58070668|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
58070669|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
58070670|NCT02418000|DRUG|E6201|Single Group Assignment
58070671|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
58070672|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
58070673|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
58070674|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
58070675|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
57931987|NCT01710592|DRUG|Capecitabine|
57931988|NCT01710592|DRUG|Docetaxel|
57931989|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
57931990|NCT06611111|DRUG|Ceftriaxone (Rocephin®)|Slightly yellow liquid.
57931991|NCT06611111|DRUG|Dextrose 5% (D5W)|Colorless liquid
58070676|NCT05896800|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
57729026|NCT03867877|OTHER|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
58285990|NCT04893681|OTHER|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
58285991|NCT04893681|OTHER|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
58285992|NCT04360473|OTHER|General anesthesia|Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
58285993|NCT04360473|DRUG|Ketamine plus general anesthesia|ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
58285994|NCT04360473|DRUG|Magnesium sulfate plus general anesthesia|Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
58285995|NCT04360473|DRUG|ketamine plus magnesium sulfate plus general anesthesia|Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
58285996|NCT02801461|DEVICE|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
58285997|NCT03134911|DRUG|DOAC or VKA|6 months - 2 years
57729027|NCT03867877|OTHER|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
57729028|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
57729029|NCT00378417|BIOLOGICAL|7-valent pneumococcal-CRM197 conjugate vaccine|
57729030|NCT00378417|BIOLOGICAL|7-valent pneumococcal-OMPC conjugate vaccine|
58285998|NCT03134911|DRUG|VKA|6 months - 2 years
58285999|NCT02903420|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
58286000|NCT03833232|DEVICE|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
58286001|NCT00528359|DRUG|quetiapine or olanzapine or risperidone or aripiprazole|
58286002|NCT00547157|DRUG|Panitumumab|Arm 2 consists of panitmumab plus RT
58286003|NCT00547157|DRUG|Cisplatin|Cisplatin
58286004|NCT00070564|BIOLOGICAL|pegfilgrastim|Given IV
58286005|NCT00070564|DRUG|AC regimen|Given IV
58286006|NCT00070564|DRUG|cyclophosphamide|Given IV
58286007|NCT00070564|DRUG|doxorubicin hydrochloride|Given IV
58286008|NCT00070564|DRUG|paclitaxel|Given IV
57729031|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
57931992|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
57931993|NCT04066049|BEHAVIORAL|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
57931994|NCT06735794|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-20 and Pre-10). Participants will then complete iTBS-c (active comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-c, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right abductor pollicis brevis (APB) muscle to assess the effects of the stimulation.~The MCF-B65 (active iTBS) and Cool-B65 A/P (sham/active iTBS) TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
58286009|NCT05006274|DEVICE|Persona Trabecular Metal Tibia|Total knee arthroplasty
57931995|NCT06735794|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-20 and Pre-10). Participants will then complete iTBS-s (experimental study intervention), which will be delivered unilaterally to the left motor cortex. Following iTBS-s, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right abductor pollicis brevis (APB) muscle to assess the effects of the stimulation.~The MCF-B65 (active iTBS) and Cool-B65 A/P (sham/active iTBS) TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
57931996|NCT06735794|DEVICE|Sham iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-20 and Pre-10). Participants will then complete iTBS-sh (sham comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-sh, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right abductor pollicis brevis (APB) muscle to assess the effects of the stimulation.~The MCF-P-B65 (sham iTBS), and Cool-B65 A/P (sham/active iTBS) TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
58070677|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
57729032|NCT02942199|OTHER|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
57729033|NCT05476224|BIOLOGICAL|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
57729034|NCT05298176|DRUG|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
57729035|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
57729036|NCT04489446|DRUG|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
57931997|NCT06386640|OTHER|Intervention Development|Phase I: Research to inform intervention design, Phase II: Co-design and production of intervention with relevant stakeholders, Phase IIa: Physical activity accelerometer data collection and analysis to develop an individualised rehabilitation programme, Phase III: Pilot and refine the intervention across to two NHS sites (University Hospitals of Leicester NHS Trust, Portsmouth Hospitals University NHS Trust).
57931998|NCT00020501|DRUG|FOLFIRI regimen|
57931999|NCT00020501|DRUG|floxuridine|
57932000|NCT00020501|DRUG|fluorouracil|
57932001|NCT00020501|DRUG|irinotecan hydrochloride|
57932002|NCT00020501|DRUG|leucovorin calcium|
57932003|NCT00020501|DRUG|melphalan|
58070678|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
58070679|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
58070680|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
57729037|NCT04489446|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
57729038|NCT06015776|OTHER|Gender|Differences between men and women will be observed
57932004|NCT00020501|PROCEDURE|hyperthermia treatment|
57932005|NCT06408649|DEVICE|Lehfilcon A spherical contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)
57932006|NCT06408649|DEVICE|Lehfilcon A toric contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
57932007|NCT04458272|DRUG|DS-1001b|250 mg, twice daily, continuous oral administration
58070681|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
58286010|NCT05006274|DEVICE|Verasense technology|Instrumented tibial trial component
58070682|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
58070683|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
58070684|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
58070685|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
58070686|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
58070687|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
58070688|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
58070689|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
58070690|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
58070691|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
58070692|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
58070693|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
58070694|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
58070695|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
57729039|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
57932008|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
58070696|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
58070697|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
58070698|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
58070699|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
58070700|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
58070701|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
58286011|NCT05006274|DEVICE|MUVR|Knee motion and gait sensing wearable device
57729040|NCT03207412|BIOLOGICAL|hAECs|human amniotic epithelial cells
57729041|NCT03207412|PROCEDURE|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
57729042|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
57932009|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
57932010|NCT06735092|OTHER|Exercise-Only Group (Control Group)|Participants in this group will only undergo a standardized exercise protocol. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
57932011|NCT06735092|OTHER|Exercise + Forearm Counterforce Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a counterforce forearm brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
58070702|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
58070703|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
58070704|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
58070705|NCT04679064|DRUG|Niraparib|PARP-inihibitor
58070706|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
58070707|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
58286012|NCT04565405|OTHER|Detergent|The tracheostomy inner cannulas will be washed with detergent.
58286013|NCT04565405|OTHER|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
58286014|NCT00532727|DRUG|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
58286015|NCT00532727|DRUG|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
58286016|NCT04013880|DRUG|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
58286017|NCT04013880|DRUG|IDH-1 Inhibitor FT-2102|Given by mouth
58286018|NCT06608407|BIOLOGICAL|PRP group|After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
57729043|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
58070708|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
58070709|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
58070710|NCT04679064|DRUG|Topotecan|Chemotherapy drug
58070711|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
58286019|NCT00170352|PROCEDURE|Hyperbaric Oxygen Treatment (HBOT)|
58286020|NCT00170352|PROCEDURE|Enhanced Oxygen Treatment (Enhanced FiO2)|
58286021|NCT00003032|BIOLOGICAL|filgrastim|
58286022|NCT00003032|DRUG|cisplatin|
58286023|NCT00003032|DRUG|cyclophosphamide|
58286024|NCT00003032|DRUG|mitoxantrone hydrochloride|
58286025|NCT00003032|DRUG|tamoxifen citrate|
58286026|NCT01563198|BEHAVIORAL|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
57729044|NCT00844623|GENETIC|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
58070712|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
58070713|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
58095460|NCT04350073|DEVICE|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
58286027|NCT02486172|BEHAVIORAL|Peer support program|Peer support program as an additional service to the routine clinical service
58286028|NCT04388176|DRUG|C21|C21 as first treatment
58286029|NCT04388176|DRUG|C21|C21 as second treatment
58286030|NCT04388176|DRUG|Placebo|Placebo as second treatment
58286031|NCT04388176|DRUG|Placebo|Placebo as first treatment
57729045|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
57729046|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
58070714|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
58070715|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
58286032|NCT02849704|DRUG|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
58286033|NCT05857410|DRUG|Dexmetomidine|Dexmetomidine (H20183219) 0.4μg / (kg·min)；
58286034|NCT05857410|DEVICE|Lower limb heating blanket|Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
58286035|NCT04595929|PROCEDURE|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
58286036|NCT04595929|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
58286037|NCT04595929|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
58286038|NCT04595929|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
58286039|NCT04595929|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
58286040|NCT04595929|PROCEDURE|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
58286041|NCT04595929|PROCEDURE|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
58286042|NCT04595929|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
58286043|NCT00614978|DRUG|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
58286044|NCT04386005|DEVICE|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age \>2 years).
58286045|NCT06007560|OTHER|Exercise|Aerobe cycling training consisting of 12-weeks of HR-controlled training at 50-60% of VO2max (maximal oxygen uptake) for 1 hour, for 2 times (week: 1-6) to 3 times (week: 7-12) per week
58286046|NCT02855567|DEVICE|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
58286047|NCT02500719|DEVICE|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
58286048|NCT04350879|OTHER|Data record|Data record
58286049|NCT00281723|DRUG|Pro-Pe adhesive tablet|
58286050|NCT04615221|OTHER|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
58286051|NCT00962078|OTHER|continuous endurance training|at 60 percent of peak Watt
58286052|NCT00962078|OTHER|interval training|at 100 percent of peak Watt
58286053|NCT03092648|BIOLOGICAL|Bronchial basal cell|autologous bronchial basal cell transplantation
57729047|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
57729048|NCT06535412|DRUG|IMC-002 + SOC|intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
58286054|NCT02335385|PROCEDURE|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
57729049|NCT06535412|DRUG|Placebo + SOC|intravenous injection of Placebo
57729050|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
57729051|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
57729052|NCT02961972|DIETARY_SUPPLEMENT|monohydrate and micronized creatine|oral supplementation with creatine
58286055|NCT02335385|PROCEDURE|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
58286056|NCT01288365|BEHAVIORAL|Exercise training|Exercise training program for 3 months (two times a week).
58286057|NCT01902511|DRUG|G-CSF+Erythropoetin|
58286058|NCT01902511|DRUG|G-CSF|
58286059|NCT05614635|DEVICE|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
58286060|NCT06248593|DRUG|Continuous infusion of Norepinephrine|The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
58286061|NCT06248593|DRUG|Continuous infusion of Phenylephrine|The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
58286062|NCT00405340|DRUG|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
57729053|NCT02961972|OTHER|placebo|oral supplementation with maltodextrin (control group)
58286063|NCT01800799|DRUG|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
58286064|NCT01800799|DRUG|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
58286065|NCT05702099|DIAGNOSTIC_TEST|ultrasonography|By performing transvaginal or transabdominal ultrasonography on women, ovarian volume will be calculated and antral follicle will be counted.
58286066|NCT01502956|DEVICE|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
58286067|NCT01502956|DRUG|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
58286068|NCT02334345|DRUG|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
58286069|NCT02334345|DRUG|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
58286070|NCT04153565|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
58286071|NCT04153565|DRUG|Pemetrexed|Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
58286072|NCT04153565|DRUG|Cisplatin|Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
58286073|NCT06399354|DIETARY_SUPPLEMENT|acute intake of medium-chain fatty acids or long-chain fatty acids in patients|The intake of an oil comprising of either medium -chain fatty acids or long-chail fatty acids
58286074|NCT06399354|DIETARY_SUPPLEMENT|Acute intake of medium-chain fatty acids or long-chain fatty acids in healthy individuals|Acute intake of MCT and LCT in healthy individuals in a cross-over design
57729054|NCT04571346|PROCEDURE|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
57932012|NCT06735092|OTHER|Exercise + Wrist Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a wrist brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
57932013|NCT06735404|OTHER|Hybrid care|"The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online"
57932014|NCT02612740|BIOLOGICAL|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
57932015|NCT02612740|DEVICE|granules of deproteinized bovine bone (Bio-Oss)|
57932016|NCT03858452|PROCEDURE|Muscles exercises program|
57932017|NCT04296097|DEVICE|DBS|Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
57932018|NCT06735469|OTHER|Discrete choice experiment|Participants will state their preferences for 1) return of full versus limited results to participants (trust/personal benefit), 2) balancing a study's participant burden with the study's ability to address multiple research aims (burden/knowledge generation), 3) incentivizing clinical assessments vs. conducting home-based assessments (personal benefit/burden), and 4) results generalizable to specific social groups versus the broader population. Participants will evaluate these attributes within a hypothetical trial to prevent chronic diseases.
57932019|NCT06736184|DRUG|Sodium Zirconium Cyclosilicate (SZC)|5g/meal\*3meals/day
57932020|NCT05419401|DRUG|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
57932021|NCT05419401|DRUG|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
58399839|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
58399840|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
58399841|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
58399842|NCT00014989|DRUG|magnesium sulfate|
58399843|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
58286075|NCT01493115|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58399844|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
57932022|NCT06734182|DRUG|Envafolimab injections+intravenous Disitamab Vedotin+carboplatin|Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
57932023|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
57932024|NCT05909059|DRUG|Fludarabine|Received IV on Days -5 to -3 before CAR T cell therapy
58070716|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
58070717|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
58070718|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
58070719|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
58286076|NCT01493115|DRUG|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58399845|NCT00059943|DRUG|docetaxel|
58399846|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
58399847|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
58399848|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
58399849|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
57932025|NCT05909059|DRUG|Cyclophosphamide|Received IV on Days -5 to -3 before CAR T cell therapy
57932026|NCT06734936|OTHER|Playing videos with sgg|Playing videos with sgg
57932027|NCT06578117|DEVICE|Vision Training and Learning Task|"Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard."
57932028|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
57932029|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
58286077|NCT06443515|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score
58286078|NCT00306410|DRUG|colecalciferol|
58286079|NCT01639703|DRUG|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
58286080|NCT00613379|DRUG|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
58399850|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
58286081|NCT00613379|DRUG|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
58399851|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
58399852|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
57932030|NCT05471908|BEHAVIORAL|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
58070720|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
58070721|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
58070722|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
58070723|NCT03162380|OTHER|Date collection|Date collection
58070724|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
58070725|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
58070726|NCT02020681|DEVICE|Fluoride|Single application on day D90
58286082|NCT00613379|DRUG|Placebo|PBO, one IV dose (N=10)
57932031|NCT05471908|BEHAVIORAL|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
58399853|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
58399854|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
58399855|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
57932032|NCT06735001|PROCEDURE|FA ablation|Ablation of the FA
57932033|NCT06735001|BIOLOGICAL|Lab test|Blood collection
57932034|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
57932035|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
57932036|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
57932037|NCT06259396|BEHAVIORAL|The 8x5 Diet|A virtual, dietitian-counselled, healthy dietary pattern defined by its fat intake, its daily eating pattern, keeping adequately hydrated, having a variety of whole grains, fruit and vegetables, and use of certain plant fibres.
57932038|NCT06734910|BEHAVIORAL|HealthyPregnancy|"A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle."
58070727|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
58286083|NCT06076122|DIETARY_SUPPLEMENT|Food supplement based on Salicornia extracts|Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.
58286084|NCT06076122|DIETARY_SUPPLEMENT|Placebo|Placebo capsules physically equal to the Salicornia extracts capsules
58286085|NCT03646071|DRUG|RX108|RX108
58286086|NCT02468999|DRUG|human insulin|
58286087|NCT04760535|DEVICE|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
58399856|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
58399857|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
58399858|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
58399859|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
58399860|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
58399861|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
58399862|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
58399863|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
58399864|NCT02502435|OTHER|Observation|Observational study
58070728|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
58070729|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
58070730|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
58070731|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
58070732|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
58399865|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
58070733|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
57729055|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
57729056|NCT05071001|PROCEDURE|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes."
57729057|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
57729058|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
57932039|NCT04663308|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
57932040|NCT04663308|DRUG|Placebo|Capsules matched to study drug minus active substance
58070734|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
58070735|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
58286088|NCT04760535|DEVICE|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
58286089|NCT01616160|DRUG|mometasone furoate|2 sprays/nostril BID
58286090|NCT03791801|DRUG|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
58399866|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
58399867|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
58399868|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
58399869|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
58399870|NCT01285570|DRUG|5% dextrose in water|Placebo
58399871|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
58399872|NCT02982434|DRUG|0.9% normal saline|
58399873|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
58399874|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
58399875|NCT05725005|DRUG|ASN51|ASN51 formulation for oral capsule
58399876|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
58399877|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
58399878|NCT00054327|DRUG|cyclophosphamide|Given IV
58399879|NCT00054327|DRUG|cytarabine|Given IV
58399880|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
58070736|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
58070737|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
58070738|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
58070739|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
58070740|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
58286091|NCT03791801|DRUG|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
58286092|NCT03791801|DRUG|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
58286093|NCT03791801|DRUG|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
58399881|NCT00054327|DRUG|Etoposide|infusion
58399882|NCT00054327|PROCEDURE|Stem Cell Transfusion|
58399883|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
58399884|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
58399885|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
58399886|NCT00666588|DRUG|idarubicin|Given IV
58399887|NCT00666588|DRUG|cytarabine|Given IV or IT
58399888|NCT00666588|DRUG|bortezomib|Given IV
58399889|NCT00666588|DRUG|etoposide|Given IV
58399890|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
58399891|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
58399892|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
58399893|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
58399894|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
58399895|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
58399896|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
58399897|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
58399898|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
58399899|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
58399900|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
57932041|NCT04557085|DRUG|Cenobamate|Cenobamate tablets
57932042|NCT04557085|DRUG|Placebo|Matching placebo tablets
57932043|NCT03386513|DRUG|IMGN632|CD123-targeted ADC
57729059|NCT01283789|DRUG|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
57729060|NCT02863640|DEVICE|Color retinography|
58286094|NCT05853029|COMBINATION_PRODUCT|Combined shockwave therapy & conventional therapy , focused shockwave therapy& conventional therapy , conventional therapy|"The device used for management is from Storz-Medical company; Duolith-SD1 with focused and radial module.~- Conventional therapy in the form of eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007)."
58286095|NCT06610097|OTHER|Nutritional Counseling|The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as (1) a 60-minute initial telehealth consultation within the first week of study enrollment, and (2) up to two 30-minute follow-ups throughout the study, ideally the first follow-up within 6 weeks of study enrollment. These sessions will be led by a registered dietitian using cultural awareness and symptom assessment.
58286096|NCT04122209|OTHER|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
58286097|NCT04122209|OTHER|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
58286098|NCT00573872|RADIATION|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
58286099|NCT01515566|DRUG|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
58286100|NCT01515566|OTHER|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
58286101|NCT01515566|OTHER|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
58286102|NCT01515566|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
58286103|NCT01592604|DEVICE|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
58286104|NCT01592604|DEVICE|Below knee walking cast|Below knee walking cast for 4 weeks
58286105|NCT05463588|OTHER|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
58286106|NCT04684108|DRUG|SG301|Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
58286107|NCT05455333|OTHER|Questionnaires|Sends and returns questionnaires to families.
58286108|NCT00985686|OTHER|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
58286109|NCT05449444|DRUG|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
58286110|NCT05449444|DRUG|Placebo|Matching placebo
58286111|NCT05449444|OTHER|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
58286112|NCT05449444|DRUG|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
58286113|NCT04027179|DRUG|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
58286114|NCT04027179|PROCEDURE|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
57729061|NCT02863640|DEVICE|Optical coherence tomography|
58286115|NCT04027179|DRUG|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
58286116|NCT04724785|OTHER|only monitoring|monitoring the viraemia only
58286117|NCT04724785|OTHER|monitoring and regimen change if necessary|if those patients agree, the regimen will be changed.
58286118|NCT04724785|DRUG|regimen change|Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
58399901|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
57729062|NCT02863640|DEVICE|Fundus autofluorescence imaging|
57932044|NCT06548750|OTHER|Intrinsic and Ectrinsic Exercise|Intrinsic and extrinsic muscle strengthening exercises
58399902|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
58399903|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
57932045|NCT06548750|OTHER|Intrinsic Exercise|Intrinsic muscle strengthening exercises
58399904|NCT03883919|DRUG|5-FU|-Standard of care drug
58399905|NCT03883919|DRUG|Leucovorin|-Standard of care drug
58399906|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
58399907|NCT03883919|DRUG|Paricalcitol|-Investigational drug
58399908|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
57932046|NCT05538897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57932047|NCT05538897|PROCEDURE|Computed Tomography|Undergo CT scan
57932048|NCT05538897|DRUG|Ipatasertib|Given PO
57932049|NCT05538897|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58399909|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
58399910|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
58286119|NCT06583798|PROCEDURE|Resurgery In Silicone Oil Filled Eyes|"* Alcon Luxor Biomicroscope with Non-contact BIOM (binocular indirect ophthalmomicroscope) viewing system was used.~* 2 ports were made in Pars plana.~* Top up of Silicone oil was done whenever needed.~* Membrane peeling with relaxing retinectomy / drainage retinotomy, haemostasis and endolaser were done under Silicone oil as required.~* After the re surgery, the patients were advised to maintain prone position."
58286120|NCT03955809|DRUG|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
58286121|NCT03955809|DRUG|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
58286122|NCT03955809|DRUG|% 0.9 NaCl|Intraarticular %0.9 NaCl
58286123|NCT00186485|DEVICE|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
58286124|NCT06253247|COMBINATION_PRODUCT|NanoChitosan impregnated Calcium Hydroxide|NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
58286125|NCT03334188|BEHAVIORAL|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
58399911|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
58399912|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
58399913|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
58399914|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
58399915|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
58399916|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
58399917|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
58399918|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
57932050|NCT05538897|DRUG|Megestrol Acetate|Given PO
57932051|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
57932052|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
57932053|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
57932054|NCT03039023|DIETARY_SUPPLEMENT|Choline Bitartrate|500mg choline bitartrate tablets
58286126|NCT03334188|BEHAVIORAL|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
58399919|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
58399920|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
58399921|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
58399922|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
58399923|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
58399924|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
58399925|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
58399926|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
58399927|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
58399928|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
58399929|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
58399930|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
58399931|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
58399932|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
58399933|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
58399934|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
57729063|NCT00595244|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
57932055|NCT03039023|OTHER|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
58286127|NCT04299867|PROCEDURE|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
58286128|NCT03603288|DRUG|idebenone 150 mg film-coated tablets|900 mg idebenone/day
58286129|NCT01156493|OTHER|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
57729064|NCT06668961|DRUG|SI-B001|Administration by intravenous infusion
57932056|NCT03039023|OTHER|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
57932057|NCT03039023|DIETARY_SUPPLEMENT|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
57932058|NCT01350830|PROCEDURE|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
57932059|NCT01350830|PROCEDURE|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
57932060|NCT02243865|DEVICE|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
57932061|NCT02243865|DEVICE|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
57932062|NCT06278207|DRUG|Finerenone (BAY 94-8862)|10 mg or 20 mg daily
57932063|NCT06735352|OTHER|virtual reality intervention|Evaluated the effect of virtual reality use in elderly people with mild cognitive impairment compared to a control group.
57729065|NCT06668961|DRUG|SI-B003|Administration by intravenous infusion
58286130|NCT03526991|DEVICE|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
58286131|NCT00501137|BIOLOGICAL|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
58286132|NCT02699827|DRUG|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
58286133|NCT02699827|DRUG|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
58286134|NCT02699827|DRUG|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
58399935|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
57729066|NCT06646666|DRUG|All-trans retinoic acid|10mg，tid，po (After apheresis and continued until post-infusion)
57729067|NCT06646666|DRUG|zanubrutinib|160mg，bid，po (prior to apheresis and continued until post-infusion)
57729068|NCT06646666|RADIATION|radiotherapy|If the patient's specific lesions are suitable for radiotherapy
57729069|NCT06646666|DRUG|CAR-T|CAR-T cell therapy
57729070|NCT06646666|DRUG|PD-1 inhibitor|IV 200 mg on D1, Q3W
57729071|NCT00796718|RADIATION|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
57932064|NCT02656420|DRUG|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
57932065|NCT02656420|DRUG|Placebos|Placebo as comparison to broccoli sprout-derived beverages
57932066|NCT04261569|DEVICE|Ev-NIRT|Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
58070741|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
58070742|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
58286135|NCT03817099|OTHER|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
58286136|NCT03817099|OTHER|Usual Care|Subjects in the group continue with the usual care
58286137|NCT00612651|DRUG|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
58286138|NCT01504191|BEHAVIORAL|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
58286139|NCT03989596|RADIATION|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
58286140|NCT03989596|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
58286141|NCT05942391|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
57729072|NCT00796718|DRUG|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
57729073|NCT02124642|DIETARY_SUPPLEMENT|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
58286142|NCT01393522|DRUG|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
58286143|NCT01393522|DRUG|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
58286144|NCT03335683|DRUG|Lenidase|drug per os twice day for 7 days, or for 10 days
58286145|NCT02290119|DEVICE|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
58286146|NCT02290119|PROCEDURE|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
58286147|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
58286148|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
58286149|NCT02548663|OTHER|Sport therapy|"Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises."
58286150|NCT02548663|OTHER|Osteopathic treatment|Frequency: 60 min weekly
58286151|NCT04644159|OTHER|Human biological samples|Blood , saliva, nasopharyngeal mucosa
58286152|NCT00305409|DRUG|Synbiotic (Synergy I / B.longum)|
58286153|NCT02966717|DRUG|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
58286154|NCT02966717|DRUG|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
58286155|NCT02966717|DRUG|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
58286156|NCT05171205|DEVICE|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
58286157|NCT06258707|DEVICE|LuxBoost IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
58070743|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
58070744|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58070745|NCT01319539|OTHER|Pharmacological Study|Correlative studies
58070746|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
58070747|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
58286158|NCT06258707|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
58286159|NCT04130152|DRUG|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
58286160|NCT04130152|DRUG|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
58286161|NCT05141929|BEHAVIORAL|web based education|In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
58286162|NCT04288427|DRUG|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
58286163|NCT05723952|OTHER|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
58286164|NCT05723952|OTHER|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
58286165|NCT02766036|DRUG|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
58286166|NCT02766036|DRUG|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
58286167|NCT02193555|DEVICE|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
58286168|NCT05312970|DRUG|Varithena®|Varithena® (polidocanol injectable foam) 1%
58286169|NCT05312970|DEVICE|FDA-approved Endothermal Ablation (ETA) systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
58286170|NCT00814723|DRUG|fluvastatin|80 mg MR, 12 weeks
58070748|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
58286171|NCT00814723|DRUG|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
58286172|NCT03552601|OTHER|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
58286173|NCT03552601|OTHER|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
58286174|NCT03381859|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
58286175|NCT02888990|DRUG|Dasatinib|
58286176|NCT01308892|DIETARY_SUPPLEMENT|High flavanol chocolate|chocolate high in flavanols
58286177|NCT01308892|DIETARY_SUPPLEMENT|Low flavanol chocolate|chocolate low in flavanols
58286178|NCT01308892|DIETARY_SUPPLEMENT|High fat challenge|Milkshake with 95g fat
58286179|NCT06082310|OTHER|Exercise|Two HIIT modalities
58286180|NCT04003623|DRUG|Pemigatinib|Pemigatinib administered orally once daily.
57729074|NCT02124642|DIETARY_SUPPLEMENT|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
58286181|NCT02926261|OTHER|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
57729075|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
58286182|NCT04221568|DRUG|Bupivacaine-fentanyl|local anathetic\&analgesic drugs
58286183|NCT04221568|DRUG|levobupivacaine-fentanyl|local anathetic\&analgesic drugs
58286184|NCT02090387|OTHER|ONS without AN777|2 servings a day
58286185|NCT02090387|OTHER|ONS containing AN777|2 servings a day
58286186|NCT04563637|DIAGNOSTIC_TEST|Computer based vision application by video|patients will be tested by computer based analysis of a video as well as by dexa scan.
58286187|NCT04563637|RADIATION|whole body dual energy x-ray absorptiometry scan|subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
58286188|NCT05989919|OTHER|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
58286189|NCT06493318|PROCEDURE|Dorsal ligamentoplasty reinforced with an internal brace|After a longitudinal dorsal incision of the wrist, an ECRB (extensor carpi radialis brevis) or palmaris longus hemi-tendon is harvested. The scapholunate positioning is adjusted using joystick pins. A 2.5 mm blind tunnel is made in the lunate and two 2.5 mm blind tunnels are made in the proximal and distal poles of the scaphoid. The tendon graft is threaded using a fiberloop and reinforced with suture tape. The graft is fixed in the proximal pole of the scaphoid with a swive-lock anchor (Arthrex®), then in the lunate, and finally fixed in the distal pole of the scaphoid by the same method. An anti-rotation scapho-capitate pin is then placed. This is maintained for 6 weeks during post-operative immobilization with a wrist orthosis. Rehabilitation begins after the pin is removed.
58070749|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
58070750|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
57932067|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
58286190|NCT00683488|BEHAVIORAL|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
58286191|NCT00683488|BEHAVIORAL|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~* Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~* Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~* Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
58399936|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
58399937|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
58399938|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
58399939|NCT00438269|DRUG|Piperacillin/tazobactam|
58399940|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
57932068|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
57932069|NCT00354081|DRUG|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
57932070|NCT00354081|DRUG|placebo|placebo, in a capsule, taken orally once a day
57932071|NCT06735807|BEHAVIORAL|Generated AI-based intervention (Emohaa)|Participants will complete the intervention process by interacting with the Wechat applet. Participants will be required to complete a 6-week self-help therapy. Participants will be required to have a 30-minute dialogue including input and reflection time with Emohaa each week simultaneously with group ACT. Participants are free to dialogue with Emohaa for the rest of the week. An independent research assistant will monitor the intervention process from the platform. If the corresponding dialogue is not completed on time each week, the participant will be reminded via WeChat to complete this session before the start of the next session in the following week.
57932072|NCT06735807|BEHAVIORAL|group ACT|A 6-week group ACT intervention. Each group has 6-10 participants. Each session is one hour.
57932073|NCT06735807|BEHAVIORAL|wailist (delayed intervenion)|During the intervention period, participants in the WLG were only required to complete the appropriate assessments without receiving any intervention. Upon completion of the 15-day follow-up assessment, participants in the WLG could be free to choose to receive one of the two interventions. The intervention will be the same as the corresponding experimental group.
57932074|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
57932075|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
57932076|NCT01034540|DRUG|POM3|4 g/day
58286192|NCT00683488|BEHAVIORAL|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
58286193|NCT04769102|DEVICE|seat cushions|flat versus contoured customized seat cushions
58286194|NCT03282422|DEVICE|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
58399941|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
58399942|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
58399943|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
57932077|NCT01034540|DRUG|Placebo|matching placebo capsule, 4 g/day
57932078|NCT00067457|DRUG|alosetron|
57932079|NCT03050996|PROCEDURE|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
57932080|NCT06736392|PROCEDURE|Ultrasound guided Pericapsular Nerve Group Block|"With the patient in the supine position and the leg slightly abducted, a curvilinear transducer (2.5-7.5 MHz) is prepared with sterile conduction gel and covered with a sterile probe cover. The transducer is placed transversely over the anterior superior iliac spine (ASIS), then aligned with the pubic ramus and rotated approximately 45° parallel to the inguinal crease. The probe is slid medially to identify key landmarks: the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas tendon, femoral artery, and femoral nerve. Sliding the probe distally or tilting caudally exposes the femoral head.~A 20-22 gauge echogenic needle (100 mm) is inserted in-plane from lateral to medial, targeting the plane between the psoas tendon and the pubic ramus. the anesthetic agent is deposited to lift the psoas tendon while avoiding tendon puncture."
57932081|NCT06736392|DRUG|Isobaric Bupivacaine 0. 25%|group c will receive PENG block with only 20ml isobaric bupivacaine 0.25%
57932082|NCT06736392|DRUG|20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine|group D will receive PENG block with 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine
58070751|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
58286195|NCT03282422|DEVICE|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
58286196|NCT02904083|BEHAVIORAL|self assessment of adherence|
58286197|NCT01825746|OTHER|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
58286198|NCT04762394|BEHAVIORAL|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
58070752|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
58286199|NCT02995629|PROCEDURE|laser indirect ophthalmoscopy pan retinal photocoagulation|"* Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
58070753|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
58070754|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
58286200|NCT04387409|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
58399944|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
58399945|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
58399946|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
58070755|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
58070756|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
58070757|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
58070758|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
58070759|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
58070760|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
58070761|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
58070762|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
58399947|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
58070763|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
58286201|NCT04387409|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
58070764|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
58286202|NCT06236048|PROCEDURE|MRI scan|7 Tesla MRI scan
58286203|NCT06236048|PROCEDURE|PET-MR scan|18F-fluorodeoxyglucose PET-MR scan
58286204|NCT06272149|DRUG|VGN-R08b|VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
58399948|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
57729076|NCT06636630|PROCEDURE|Quadruple scleral flap|Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
58070765|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
57729077|NCT06636630|PROCEDURE|Double scleral flap|The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
57729078|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
57729079|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
57729080|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
57729081|NCT06318676|DRUG|Mezigdomide|Specified dose on specified days
57729082|NCT01540123|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
57932083|NCT06736392|DEVICE|the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)|the two groups will receive the PENG block under ultrasound guidance
58070766|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
58070767|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
58286205|NCT01744483|DEVICE|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
58286206|NCT01744483|DEVICE|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
58286207|NCT01744483|DEVICE|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
58286208|NCT03603561|DEVICE|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
58286209|NCT03603561|DEVICE|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
58286210|NCT04767971|DEVICE|Standard Colonoscopy|Colonoscopy with a standard colonoscope
58286211|NCT04767971|DEVICE|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
58399949|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
58399950|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
57729083|NCT01540123|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
57729084|NCT02270320|BEHAVIORAL|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
58286212|NCT02296762|DRUG|Sirolimus|Sirolimus tablets 2 mg
58286213|NCT03056014|DRUG|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
58286214|NCT03056014|DIETARY_SUPPLEMENT|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
58286215|NCT03056014|DIETARY_SUPPLEMENT|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
58286216|NCT03887208|PROCEDURE|Laser therapy|non-ablative fractional laser therapy of skin
58286217|NCT03887208|BIOLOGICAL|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
58286218|NCT03887208|PROCEDURE|Normal saline injection|Subcutaneous Normal saline injection
58286219|NCT04798326|DRUG|MW032|Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
58286220|NCT04798326|DRUG|Xgeva®|Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
58286221|NCT04662723|DRUG|Corticosteroid|To reduce the progression of renal damage in IgAN Patients
58286222|NCT04662723|DRUG|Renin-angiotensin sytem blockers|To reduce the progression of renal damage in IgAN Patients
58286223|NCT04662723|DRUG|Sodium-glucose cotransporter 2 inhibitor|To reduce the progression of renal damage in IgAN Patients
58286224|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
58286225|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
58286226|NCT00642603|DRUG|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
58286227|NCT00642603|DRUG|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
58286228|NCT00642603|DRUG|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
58286229|NCT01113307|BIOLOGICAL|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
58286230|NCT00274378|DEVICE|ALLOMATRIX injectable putty in distal radius fractures|
58286231|NCT00199849|BIOLOGICAL|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
58399951|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
58399952|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
57729085|NCT00034762|DRUG|risperidone|
57729086|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
57729087|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
57729088|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
57729089|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
57729090|NCT04584372|DIETARY_SUPPLEMENT|High-nitrate intervention|The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
58286232|NCT02799888|DRUG|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
57729091|NCT04584372|DIETARY_SUPPLEMENT|Low-nitrate intervention|The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
57729092|NCT04020510|DRUG|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
58286233|NCT02799888|DRUG|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
58286234|NCT02799888|DRUG|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
57729093|NCT06459921|DRUG|SOX+Sintilimab|Patients would be allocated to the SOX+Sintilimab group.
57729094|NCT06459921|DRUG|FLOT+Sintilimab|Patients would be allocated to the FLOT+Sintilimab group.
57729095|NCT02696317|DEVICE|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
57729096|NCT02696317|DEVICE|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
58286235|NCT02799888|DRUG|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
58286236|NCT02508103|DRUG|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
58286237|NCT02508103|DRUG|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
57729097|NCT03248284|PROCEDURE|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
57932084|NCT06736392|DEVICE|a standard echogenic 20-22 gauge 100mm needle|the two groups will receive the PENG block using a standard echogenic 20-22 gauge 100mm needle
57932085|NCT06506565|DRUG|Ketamine|Infusion during wound care
58399953|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
58070768|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
58070769|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
58070770|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
58286238|NCT02477371|PROCEDURE|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values \> 0,8 are deferred.
58286239|NCT02477371|PROCEDURE|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
58286240|NCT02237989|DRUG|paracetamol|1500 mg
58286241|NCT02237989|DRUG|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
58286242|NCT00680615|BEHAVIORAL|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
58286243|NCT00680615|BEHAVIORAL|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
58286244|NCT01411514|DRUG|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
58286245|NCT01411514|DRUG|Placebo|Placebo tablets. They will be administered during 25 days
58286246|NCT02254356|DEVICE|Zilver Flex Bare Metal Stent|
58286247|NCT00768885|DEVICE|PureVision 1|Currently marketed PureVision soft contact lens.
58286248|NCT00768885|DEVICE|PureVision 2|Alternate design soft contact lens.
58286249|NCT06013514|DEVICE|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
58286250|NCT00071838|DRUG|Daclizumab|
57729098|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
57729099|NCT01787526|DRUG|ferric carboxymaltose|1 g intravenously per infusion
57729100|NCT01787526|DRUG|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
57729101|NCT04730297|DRUG|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
57729102|NCT04730297|DRUG|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
58286251|NCT04645329|DEVICE|shoulder immovilization sling|immobilization of the arm after surgery
58286252|NCT06045494|DIETARY_SUPPLEMENT|Meiji Yogurt Group|Participants in this arm need to eat assigned product for 12 weeks, one bottle each day.
58286253|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
58286254|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
57729103|NCT04730297|DRUG|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
57932086|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
57729104|NCT06057389|DIETARY_SUPPLEMENT|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
58070771|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
58070772|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
58286255|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
58286256|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
58286257|NCT01219192|DRUG|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
58286258|NCT01219192|DRUG|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
58286259|NCT03075332|OTHER|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
58070773|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
58070774|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
58286260|NCT03067922|OTHER|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
58286261|NCT05659303|PROCEDURE|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
58286262|NCT04040647|BEHAVIORAL|mobilization and ambulation|6-min walk test (6-MWT)
58286263|NCT04464408|DRUG|Favipiravir|1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
58286264|NCT04464408|DRUG|Placebo|(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
57729105|NCT01925716|OTHER|Corn oil|corn oil 56 g/day for 21 days
57729106|NCT01925716|OTHER|Olive oil|olive oil 56 g /day for 21 days
57729107|NCT06535477|DEVICE|Fall risk assessment|"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"
57729108|NCT03522662|DRUG|GSK1070806|Single 10mg/kg infusion on Day 0
57729109|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
57729110|NCT06013176|OTHER|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
57729111|NCT06013176|OTHER|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
57729112|NCT03267680|DRUG|Cyclophosphamide|Given IV
57729113|NCT03267680|DRUG|Indomethacin|Given PO
57729114|NCT03267680|BIOLOGICAL|IRX-2|Given via submucosal injection or SC
57729115|NCT03267680|OTHER|Laboratory Biomarker Analysis|Correlative studies
57729116|NCT03267680|DIETARY_SUPPLEMENT|Multivitamin|Given zinc-containing multivitamin PO
57729117|NCT03267680|DRUG|Omeprazole|Given PO
57729118|NCT03267680|OTHER|Placebo|Given via submucosal injections or SC
57729119|NCT03267680|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
58070775|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
58286265|NCT04140812|DIAGNOSTIC_TEST|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
58286266|NCT02813473|RADIATION|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
58286267|NCT02813473|RADIATION|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
58286268|NCT02442648|DRUG|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
58286269|NCT02442648|DRUG|Rituximab|Rituximab will be administered for desensitization per study protocol.
57729120|NCT01069783|DRUG|A3309|A3309 in two different dosage levels
57729121|NCT01069783|DRUG|A3309|A3309 in two different dosage levels for the duration of the study
57729122|NCT01069783|DRUG|Placebo|Placebo comparator once daily for the duration of the trial
57729123|NCT05890053|DRUG|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
58070776|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
58399954|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
58399955|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
58286270|NCT06253910|OTHER|Patients selection|Patient selection were selected according to selected criteria.
57932087|NCT04711798|OTHER|passive leg raising maneuver (PLR)|Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
57932088|NCT04711798|OTHER|lung recruitment maneuver (LRM)|lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
57932089|NCT04711798|OTHER|echographic evaluation of the right cardiac function|echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
57932090|NCT02275585|OTHER|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
57932091|NCT04139265|DIAGNOSTIC_TEST|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
57932092|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
57932093|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
57932094|NCT05851274|PROCEDURE|transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm
58070777|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
58286271|NCT06253910|OTHER|Recall visits|Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
58399956|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
58399957|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
58399958|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
58399959|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
58399960|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
58399961|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
58399962|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
58399963|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
57729124|NCT02500225|DRUG|Etomidate|0.2 mg/kg etomidate
57729125|NCT02500225|DRUG|Sevoflurane|8% Sevoflurane
58399964|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
58399965|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
58399966|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
57729126|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
57729127|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
57729128|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
57729129|NCT05759598|OTHER|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
57932095|NCT05851274|PROCEDURE|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
57932096|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
58070778|NCT02173158|DRUG|lomitapide|
58286272|NCT00299403|PROCEDURE|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
58286273|NCT00299403|PROCEDURE|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
58399967|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
58399968|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
58399969|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
58399970|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
58399971|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
57932097|NCT05341648|OTHER|Aerobic Exercise Training|Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
58070779|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
58286274|NCT03000322|DEVICE|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
58286275|NCT00274547|DRUG|Tiotropium|
58286276|NCT02308228|BEHAVIORAL|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
58286277|NCT02308228|DRUG|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
58399972|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
58399973|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
58399974|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
58399975|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
58399976|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
58399977|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
58399978|NCT00002858|DRUG|cisplatin|
57729130|NCT05759598|OTHER|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
58070780|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
58070781|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
58070782|NCT02218424|DRUG|Magnesium|
58286278|NCT03570203|DIAGNOSTIC_TEST|Serum Sodium|Measurement of serum sodium.
58286279|NCT05329350|DEVICE|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
58399979|NCT00002858|DRUG|cyclophosphamide|
58399980|NCT00002858|DRUG|doxorubicin hydrochloride|
58399981|NCT00002858|DRUG|etoposide|
58399982|NCT00002858|RADIATION|radiation therapy|
58399983|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
58399984|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
58399985|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
58399986|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
58399987|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
58286280|NCT00528918|DRUG|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
58286281|NCT02066597|DEVICE|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
58286282|NCT05756751|DEVICE|Device: Impella 5.5 with SmartAssist|Patients who are deemed high-risk due to low preoperative ejection fraction undergoing cardiac surgery with cardiopulmonary bypass (CPB) which will be supported by the Impella 5.5 System.
58399988|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
58399989|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
58399990|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
58286283|NCT02379455|OTHER|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
58286284|NCT05391880|DRUG|BEBT-503 20mg|BEBT-503 capsule
58286285|NCT05391880|DRUG|BEBT-503 40mg|BEBT-503 capsule
58286286|NCT05391880|DRUG|BEBT-503 80mg|BEBT-503 capsule
58399991|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
58399992|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
58399993|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
58399994|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
58070783|NCT02218424|DRUG|Normal saline|
58070784|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58070785|NCT00006082|DRUG|rubitecan|
58286287|NCT05391880|DRUG|BEBT-503 120mg|BEBT-503 capsule
58286288|NCT05391880|DRUG|BEBT-503 180mg|BEBT-503 capsule
58399995|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
58399996|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
58399997|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
58399998|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
58399999|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
58400000|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
58400001|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
58400002|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
58400003|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
58400004|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
58400005|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
58400006|NCT00685269|DRUG|Placebo|Placebo tablet
58286289|NCT05391880|DRUG|placebo 20mg|placebo capsule
58286290|NCT05391880|DRUG|placebo 40mg|placebo capsule
58286291|NCT05391880|DRUG|placebo 80mg|placebo capsule
58286292|NCT05391880|DRUG|placebo 120mg|placebo capsule
58286293|NCT05391880|DRUG|placebo 180mg|placebo capsule
58286294|NCT02100735|OTHER|Sedation protocol|Nursing driven sedation protocol
58286295|NCT00151086|DRUG|Estramustine|
58286296|NCT00151086|DRUG|Vinorelbine|
58400007|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
58400008|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
58400009|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
58400010|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
58400011|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
58286297|NCT05649696|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
58286298|NCT05649696|DRUG|Normal Saline|Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
58286299|NCT03180957|DRUG|Adalimumab|
58286300|NCT03180957|DRUG|Saline|
58286301|NCT06199427|DRUG|Cyclophosphamide|Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
58286302|NCT06199427|DRUG|Ruxolitinib|Ruxolitinib 7 mg/m2 from day +5 after HSCT
58286303|NCT02816320|OTHER|Hospitalization|Patients who were hospitalized in acute care
58286304|NCT04520906|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
58286305|NCT03664921|DRUG|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
58286306|NCT03664921|DRUG|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
58286307|NCT01227525|DEVICE|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
58286308|NCT03049423|DEVICE|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
58286309|NCT03049423|DIAGNOSTIC_TEST|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
58400012|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
58400013|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
58286310|NCT00264251|BEHAVIORAL|Weight loss through diet and exercise|
58286311|NCT00264251|DRUG|Rosiglitazone insulin sensitizing agent|
58286312|NCT00823030|PROCEDURE|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
58286313|NCT00823030|DRUG|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
58286314|NCT00823030|OTHER|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
58286315|NCT01998347|DRUG|Paclitaxel liposome|
58286316|NCT01998347|DRUG|Cisplatin|
58286317|NCT01998347|DRUG|5-fluorouracil|
58286318|NCT00250809|PROCEDURE|Placement of a central venous catheter|Placement of a central venous catheter
58286319|NCT05365919|OTHER|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
58286320|NCT04351880|OTHER|Medically Tailored Meals|Compare 2 and 4 weeks of meal delivery
58400014|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
58400015|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
58400016|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
58400017|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
58400018|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
58400019|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
58400020|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
58400021|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
58400022|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
58286321|NCT03300362|DRUG|Seasonal influenza vaccine|Seasonal influenza vaccine
58286322|NCT03300362|DRUG|MVA-NP+M1|Trial vaccine
58286323|NCT03300362|DRUG|Sodium chloride|Saline placebo
58286324|NCT06414772|OTHER|Use of MARTI application in addition with a classical consultation/support|Participants will use MARTI in order to establish the medical history during their waiting time.
58286325|NCT03070756|DEVICE|Minimal-Intervention - Specification of device settings|- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
58286326|NCT04396379|DEVICE|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
57932098|NCT05341648|OTHER|Home Plan|"* Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks."
58286327|NCT05460858|DRUG|N-acetyl cysteine|One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
58286328|NCT05460858|DRUG|placebo|placebo
58400023|NCT05698017|DRUG|hOMSC300|Human Oral Mucosa Stem Cells
58095461|NCT04350073|DEVICE|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
58286329|NCT04757805|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
58286330|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
58286331|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
58286332|NCT00885378|DRUG|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
58400024|NCT05698017|OTHER|Sham Procedure|Lumbar Puncture Only
58400025|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
58400026|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
58400027|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
58400028|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
58400029|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
58400030|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
58400031|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
58400032|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
58400033|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
58400034|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
58400035|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
58400036|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
58400037|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
58095462|NCT04350073|DEVICE|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
58286333|NCT00885378|DRUG|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
58286334|NCT01672905|OTHER|laboratory biomarker analysis|
58286335|NCT04499833|PROCEDURE|liver transplant|liver transplant
58286336|NCT04446429|DRUG|Proxalutamide|200 mg q.d.
58286337|NCT04446429|OTHER|Standard of Care|Standard of care as determined by the PI
58286338|NCT02584374|OTHER|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
58286339|NCT04023214|DIAGNOSTIC_TEST|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
58286340|NCT00076310|DRUG|Docetaxel|60 mg/m\^2 IV repeated every 21 days.
58286341|NCT00076310|DRUG|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
58286342|NCT00076310|DRUG|Cisplatin|75 mg/m\^2 IV every 21 days.
58286343|NCT06285370|DRUG|Mogamulizumab|Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
58400038|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
58400039|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
58286344|NCT05682599|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
58286345|NCT05682599|DRUG|Placebo|Placebo
58286346|NCT00389467|DEVICE|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
58286347|NCT04321083|DIAGNOSTIC_TEST|INVOS|INVOS monitoring brain o2 saturation
58286348|NCT03124498|BIOLOGICAL|CIK Cell|Autologous cytokine-induced killer (CIK) cell
58286349|NCT04473534|BEHAVIORAL|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
58286350|NCT06612125|OTHER|volume controlled ventilation|Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
58286351|NCT06612125|OTHER|pressure controlled ventilation|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
58286352|NCT06612125|OTHER|pressure controlled volume grantanteed ventilation|Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
58286353|NCT01624285|DRUG|sorafenib tosylate|Given PO
58286354|NCT01624285|OTHER|placebo|Given PO
58286355|NCT01624285|OTHER|laboratory biomarker analysis|Correlative studies
58286356|NCT04730401|BIOLOGICAL|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
58286357|NCT04730401|BIOLOGICAL|Placebo|200mL saline
58286358|NCT00027287|DRUG|Vitamin E|
58286359|NCT05016375|OTHER|Interview|Interview with individuals with T2DM
58286360|NCT05621707|DRUG|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
58286361|NCT01514877|DRUG|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
58286362|NCT05355077|DRUG|JT001 200mg Bid|JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
58286363|NCT05355077|DRUG|JT001 400mg Bid|JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
58286364|NCT05355077|DRUG|JT001 600mg Bid|JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
58286365|NCT01671137|OTHER|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
57729131|NCT01559402|PROCEDURE|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
57729132|NCT01559402|PROCEDURE|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
57729133|NCT01559402|PROCEDURE|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
58095463|NCT04870307|OTHER|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
58286366|NCT05725824|DEVICE|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
58286367|NCT01962948|DRUG|paclitaxel|Given IV
58286368|NCT01962948|DRUG|ganetespib|Given IV
58286369|NCT01962948|OTHER|laboratory biomarker analysis|Correlative studies
58286370|NCT04425811|OTHER|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
58286371|NCT00005802|BIOLOGICAL|aldesleukin|
58286372|NCT00005802|BIOLOGICAL|filgrastim|
58286373|NCT00005802|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58286374|NCT00005802|DRUG|cytarabine|
58286375|NCT00005802|DRUG|etoposide|
58286376|NCT00005802|DRUG|fludarabine phosphate|
58286377|NCT00005802|DRUG|methotrexate|
58286378|NCT00005802|DRUG|mitoxantrone hydrochloride|
58286379|NCT00005802|DRUG|therapeutic hydrocortisone|
58286380|NCT00005802|RADIATION|radiation therapy|
58286381|NCT05221320|DRUG|Ulixertinib|small molecule ERK 1/2 inhibitor
58286382|NCT05221320|DRUG|Hydroxychloroquine|Autophagy inhibitor
58286383|NCT06188325|DRUG|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
58286384|NCT03459508|DIAGNOSTIC_TEST|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
58286385|NCT05291923|OTHER|no intervention|no intervention
58286386|NCT02450838|BIOLOGICAL|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
58286387|NCT02450838|BIOLOGICAL|Alhydrogel™|Aluminum hydroxide gel adjuvant
58400040|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
58400041|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
58400042|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58400043|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
58400044|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
58400045|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
58400046|NCT06056895|DRUG|Tuparstobart|Given IV
58400047|NCT06056895|DRUG|Verzistobart|Given IV
57729134|NCT00487110|DRUG|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
58286388|NCT02450838|BIOLOGICAL|Placebo|
58286389|NCT01861353|OTHER|Cranberry-lingonberry juice|
58286390|NCT01861353|OTHER|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
58286391|NCT04226014|PROCEDURE|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
58286392|NCT04872387|DRUG|BAY2586116|Nasal administration
58400048|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
58400049|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
58400050|NCT06606197|OTHER|Having sex with other men|Having sex with other men
57729135|NCT00487110|DRUG|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
58400051|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
58400052|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58400053|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
58400054|NCT04851119|DRUG|Tegavivint|Given IV
57729136|NCT03524326|DRUG|Lenvatinib Pill|24 mg oral daily
57729137|NCT03524326|DRUG|Lenvatinib Pill|20 mg oral daily
57729138|NCT03524326|DRUG|Lenvatinib Pill|14 mg oral daily
57729139|NCT03524326|DRUG|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
58400055|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
57729140|NCT03524326|DRUG|Lenvatinib Pill|10 mg oral daily
58400056|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
58400057|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
58400058|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
58400059|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
58400060|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
58400061|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
58400062|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
57729141|NCT03524326|DRUG|Lenvatinib Pill|4 mg oral daily
57729142|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
57729143|NCT03356912|DRUG|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
57729144|NCT03356912|DRUG|Prednisone|Prednisone should be administred by oral route
57729145|NCT06404580|PROCEDURE|R anastomosis|R anastomosis
57729146|NCT05956652|DEVICE|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
57729147|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
58286393|NCT04872387|DRUG|Placebo|Matching placebo
58286394|NCT04361760|DEVICE|single-puls TMS|Medical Device (MD): MagPro X100
58286395|NCT04361760|DEVICE|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
58286396|NCT04433923|DEVICE|Phototherapy with aluminum foil|
58286397|NCT04433923|DEVICE|Phototherapy without aluminum foil|
58286398|NCT00240968|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
58286399|NCT01909960|OTHER|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
57729148|NCT02790385|OTHER|Standard Gauze Treatment|
58286400|NCT06155474|DIETARY_SUPPLEMENT|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
58286401|NCT06155474|DIETARY_SUPPLEMENT|Starch Only|The Starch Solution is a low-fat diet.
58286402|NCT06155474|DIETARY_SUPPLEMENT|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
58286403|NCT04693299|DIAGNOSTIC_TEST|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
58286404|NCT02617498|DEVICE|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
58286405|NCT02617498|DEVICE|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
58286406|NCT06524167|RADIATION|adjuvant radiotherapy|The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose.
58286407|NCT00481364|DRUG|atorvastatin|atorvastatin 40 mg/day
58286408|NCT00481364|DRUG|placebo|1 tb/day
58286409|NCT00748163|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
58286410|NCT00748163|DRUG|sunitinib malate|
58286411|NCT01706432|RADIATION|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
58286412|NCT01706432|OTHER|laboratory biomarker analysis|Correlative studies
58286413|NCT01706432|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
58286414|NCT02924233|DRUG|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
58286415|NCT02924233|DRUG|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
58286416|NCT03403881|BEHAVIORAL|Physical activity promotion + TAU|"Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual"
58286417|NCT03403881|BEHAVIORAL|Control|Weekly call on general health aspects + treatment as usual
58286418|NCT01983163|OTHER|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
58286419|NCT01983163|OTHER|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
58286420|NCT03368118|DRUG|ABX464|All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
58400063|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
58400064|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
57729149|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
57729150|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
58286421|NCT00315718|DRUG|Extract from Hintonia latiflora bark|
58286422|NCT03292614|DIAGNOSTIC_TEST|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
58286423|NCT05234268|OTHER|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
58400065|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
58400066|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
58400067|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
58400068|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
58400069|NCT02767726|DEVICE|non-invasive multimodal imaging|
58286424|NCT05234268|OTHER|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
58400070|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
58400071|NCT04845009|BEHAVIORAL|Usual care|Usual care
58400072|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
58400073|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
58400074|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
58400075|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
58400076|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
58400077|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
58400078|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
58400079|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
58400080|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
58400081|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
58400082|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
58400083|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
58400084|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
58400085|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
58400086|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
58400087|NCT02776462|DEVICE|EyeBox CNS|
58400088|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
58400089|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
58400090|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
58400091|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
58400092|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
58400093|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
58400094|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
58400095|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
58400096|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
58400097|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
58400098|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
57729151|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
58400099|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
58400100|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
58400101|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
58400102|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
58400103|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
58400104|NCT02202213|DRUG|Placebo|
58400105|NCT02202213|DRUG|Lu AF11167|
57729152|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
57932099|NCT06174987|DRUG|T-DXd|T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
57932100|NCT03579082|DRUG|Decitabine|Given ivgtt
57932101|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
58286425|NCT05234268|OTHER|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
58400106|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
58400107|NCT03082183|DRUG|Rifampicin|once daily
57729153|NCT06405373|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
58286426|NCT03465709|DRUG|Pegcetacoplan|Study Drug
58286427|NCT06304480|DIETARY_SUPPLEMENT|100g fermented Tofu|"* Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.~* Participants will consume the first Study Product on the day of their Visit 3 (Day 0) and will consume their last Study Product the day prior to Visit 5 (Day 56).~* Participants will be instructed to return any unused Study Product at Visit 5 (Day 56)."
58400108|NCT03082183|DRUG|BI 425809|once daily
57729154|NCT06405373|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
58400109|NCT02585024|DRUG|Cytisine|
58400110|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
58400111|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
58400112|NCT05638269|OTHER|no intervention|Observational studies, no intervention
58400113|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
57932102|NCT04692454|OTHER|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
57932103|NCT03628937|DIETARY_SUPPLEMENT|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
58400114|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
57932104|NCT03628937|OTHER|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
58400115|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
58400116|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
58400117|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
58400118|NCT00113204|DRUG|IPI-504|
58400119|NCT06429397|DRUG|Anlotinib and Penpulimab|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
58400120|NCT00284284|DEVICE|Use of a rehabilitation brace|
58286428|NCT04923880|OTHER|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
58286429|NCT01191099|DEVICE|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
58400121|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
58400122|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
58400123|NCT00122876|PROCEDURE|Photodynamic therapy|
58400124|NCT00122876|DRUG|Talaporfin Sodium|
58400125|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
58400126|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
58400127|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
58400128|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
58400129|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
57729155|NCT06371885|DEVICE|shock wave therapy|shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
57932105|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
58400130|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
58400131|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
58400132|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
58400133|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
58286430|NCT03748368|OTHER|Cataract presentation|Presentation about cataract surgery
58286431|NCT03748368|OTHER|Placebo presentation|Presentation about the history of the hospital
58286432|NCT01124799|DRUG|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
58400134|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
58400135|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
57729156|NCT06371885|OTHER|traditional physical therapy|the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
58286433|NCT01124799|DRUG|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
58286434|NCT01124799|DRUG|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
58400136|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
58400137|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
58400138|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
58400139|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
58400140|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses."
58400141|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
58400142|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
58400143|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
58400144|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
58400145|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
58400146|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
58400147|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
57932106|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
58286435|NCT04084587|DEVICE|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
58286436|NCT05223803|RADIATION|Prostate radiation (XRT)|Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.
58286437|NCT05223803|DRUG|Systemic Therapy|All systemic therapy is provided as best prescribed for patient per their medical oncologist.
58286438|NCT05223803|RADIATION|Stereotactic ablative radiation therapy (SABR)|SABR is delivered to those randomized to Arm 2.
58286439|NCT02740790|BIOLOGICAL|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
58286440|NCT02740790|BIOLOGICAL|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
58286441|NCT06411522|DEVICE|Mouthwash containing 0.12% CHX (Chlorhexidine)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.2% CHX mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
58286442|NCT06411522|DEVICE|Mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.05% CHX + 0.05% CPC mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
58286443|NCT04990609|DEVICE|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
58286444|NCT04990609|DRUG|Neoadjuvant Chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician \[possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)\].
58286445|NCT03086005|DRUG|Metformin|
58286446|NCT05481827|GENETIC|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
58286447|NCT03644420|DIAGNOSTIC_TEST|Clinical evaluation|Functional scores for the pathological joint will be determined
58286448|NCT03644420|DIAGNOSTIC_TEST|Radiology|
58286449|NCT03644420|DIAGNOSTIC_TEST|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
58286450|NCT03644420|DIAGNOSTIC_TEST|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
58286451|NCT02542592|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
58286452|NCT02542592|DRUG|Isotonic Sodium Chloride|Placebo
58286453|NCT00344838|DEVICE|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
58286454|NCT00460863|PROCEDURE|using cool versus warm dialysate during hemodialysis|
58286455|NCT04033406|DRUG|VIR-2482|VIR-2482 given by intramuscular injection
58286456|NCT04033406|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
58286457|NCT00001070|DRUG|Oral Vitamin C|
58400148|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
58400149|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
58400150|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
57932107|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
58400151|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
58400152|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
57932108|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
58400153|NCT02172131|DRUG|BI 1744 CL|
58400154|NCT02172131|DRUG|Placebo|
58400155|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
57932109|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
58400156|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
57932110|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
57932111|NCT03255057|DEVICE|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
57932112|NCT03255057|DEVICE|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
57932113|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
58400157|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
58400158|NCT04628169|OTHER|no intervention applied|no intervention applied
58400159|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
58400160|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
58400161|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
58400162|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
57729157|NCT04545268|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
57932114|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
57932115|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
57932116|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
57932117|NCT01286454|DRUG|fesoterodine|single dose of tablet
57932118|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
57932119|NCT04304820|DRUG|Eltrombopag|Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
57932120|NCT04304820|DRUG|Cyclosporine|Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
58070786|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
58286458|NCT03338504|DIAGNOSTIC_TEST|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
58286459|NCT03338504|RADIATION|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
58306827|NCT02988661|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
57932121|NCT04304820|DRUG|Horse-Anti-thymocyte-Globulin|h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
57932122|NCT05323084|DIETARY_SUPPLEMENT|Dietary supplement|1 week of each intervention at bedtime with a 2-week washout period in between interventions
57932123|NCT05146284|DRUG|PXL770|Tablet
57932124|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
57932125|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
57932126|NCT06070649|DRUG|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
57932127|NCT06070649|DRUG|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
57932128|NCT06070649|DRUG|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
57932129|NCT02754882|DRUG|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
57932130|NCT02754882|DRUG|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
58400163|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
58400164|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
58400165|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
58400166|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
57932131|NCT02754882|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
57932132|NCT02754882|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
58286460|NCT03338504|DIAGNOSTIC_TEST|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
58286461|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplement|Hair growth supplement for women ages 18 - 44
58286462|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70
58286463|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
58286464|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
58286465|NCT03446118|DIAGNOSTIC_TEST|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
58286466|NCT00401518|DEVICE|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
58286467|NCT00401518|DEVICE|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
58286468|NCT00401518|DEVICE|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
58400167|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
58400168|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
57932133|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
58400169|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
58400170|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1_Adults_Dose C_GR1 and ST2_Adults_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2_Children_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1_Adults_Dose C_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose C_Safety and ST2_Infants_Dose C_Dose find groups in Stage 2 (Africa).
58070787|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
57729158|NCT04545268|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
58306828|NCT04976127|DRUG|Talineuren|Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
58286469|NCT02535650|DRUG|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
58286470|NCT04605653|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
57932134|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
57932135|NCT06089239|OTHER|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
57932136|NCT06089239|OTHER|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
58286471|NCT02841384|OTHER|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
57932137|NCT06679803|BEHAVIORAL|Physical Activity Chats after Stroke (PA-ChatS)|"PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety."
57932138|NCT02076217|DRUG|Copper T-380 IUD|
57932139|NCT02076217|DRUG|LNG IUD|
57932140|NCT02076217|DEVICE|Contraceptive implant Nexplanon|
57932141|NCT02076217|DRUG|Depo-Provera|
57932142|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
57932143|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
57932144|NCT06723418|OTHER|Malnutriton Screening Tool (PYMS)|In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
58400171|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2_Children_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose B_Safety and ST2_Infants_Dose B_Dose find groups in Stage 2 (Africa).
58400172|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose A_Safety and ST2_Infants_Dose A_Dose find groups in Stage 2 (Africa).
58400173|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2_Adults_Control C group and children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
58400174|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2_Adults_Control C group in Stage 2 (Africa).
58400175|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
58286472|NCT02841384|OTHER|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
58400176|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa).
58286473|NCT01808222|DRUG|FACBC|Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
58286474|NCT04875780|BEHAVIORAL|Digital diabetes prevention app intervention|"16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
58286475|NCT04875780|BEHAVIORAL|Digital weight loss tracking app intervention|"All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
58286476|NCT04875780|BEHAVIORAL|Wait-list control (usual care)|Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
58286477|NCT01703169|DRUG|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
58286478|NCT00523692|DRUG|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
58400177|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
58400178|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
58400179|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
57932145|NCT03654014|DEVICE|SofPulse|SofPulse PEMF device treatment of the brain after traumatic injury
57932146|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
58286479|NCT00523692|DRUG|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
58286480|NCT05861895|DRUG|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286481|NCT05861895|DRUG|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286482|NCT05861895|DRUG|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286483|NCT05861895|DRUG|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286484|NCT05861895|DRUG|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286485|NCT05861895|DRUG|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
58286486|NCT01563913|DRUG|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
58286487|NCT01563913|DRUG|Placebo|Sugar Pill, taken for 1.5 years
58286488|NCT06373055|OTHER|neoadjuvant chemotherapy followed by radical cystectomy|combination of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or combination of gemcitabine and cisplatin (GC) followed by radical cystectomy
58286489|NCT00664118|PROCEDURE|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
58286490|NCT00664118|PROCEDURE|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
58286491|NCT00039299|BIOLOGICAL|therapeutic autologous lymphocytes|
58286492|NCT03246061|DEVICE|Intracept System|BVN ablation using radiofrequency energy
58286493|NCT03246061|OTHER|Standard Care|Non-surgical standard care
58286494|NCT01289301|DRUG|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
58286495|NCT01289301|DRUG|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
58286496|NCT04239352|DIAGNOSTIC_TEST|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
58286497|NCT04239352|DIAGNOSTIC_TEST|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
58286498|NCT00771940|DRUG|Ghrelin|Solvent, cont. infusion
58286499|NCT01240499|OTHER|Health-At-Every-Size (HAES)|"1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
58286500|NCT04161521|PROCEDURE|Novel Technique of Placenta Accreta in Menoufia University Hospital|"* Classical CS to decrease haemorrhage from placental bed.~* Delievery of the fetus.~* At the delivery 10 UI of oxytocin IV will be injected.~* The placenta is not attempted to be delievered.~* Opening of the broad ligament via round ligament division and ligation.~* Gentle dissection of the urinary bladder from lateral to medial.~* Bilateral uterine artery clamping at low level below the placental bed .~* Gentle attempt to deliver The placenta.~* If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~* If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~* Intraperitoneal drain insertion."
58286501|NCT01463943|OTHER|Probiotic|
58286502|NCT01463943|OTHER|Probiotic|
58286503|NCT01463943|OTHER|Probiotic|
58286504|NCT04981197|BEHAVIORAL|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
58400180|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
57932147|NCT06528964|DIAGNOSTIC_TEST|Immunohistochemistry and immunofluorescence|Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
58306829|NCT05363202|DRUG|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
58286505|NCT05401461|OTHER|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
58286506|NCT06480136|DRUG|SHR-A1921 injection and adebrelimab injection|The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
58400181|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
58400182|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
58400183|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
58400184|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
58400185|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
58400186|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
58400187|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
57932148|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
58286507|NCT04692116|DEVICE|ExAblate treatment|Subthalamotomy using the ExAblate
58286508|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
58286509|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
58286510|NCT01462305|DEVICE|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
58286511|NCT01462305|DEVICE|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
58400188|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
58400189|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
58400190|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
58400191|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
58400192|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
58286512|NCT04099238|DRUG|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
58286513|NCT02788188|BIOLOGICAL|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
58286514|NCT02788188|OTHER|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
58286515|NCT03877588|DIETARY_SUPPLEMENT|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
58286516|NCT01980628|DRUG|ibrutinib|
58400193|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
58400194|NCT01882426|OTHER|Usual Care|usual step care practice
58400195|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
57932149|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
57932150|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
57932151|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
57932152|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
57932153|NCT06179160|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
58070788|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
58286517|NCT06229964|OTHER|SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
58286518|NCT06229964|OTHER|Sham SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
58286519|NCT01653340|DEVICE|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
58286520|NCT05771454|PROCEDURE|Histopathological confirmation|After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
58286521|NCT04801043|DRUG|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
58286522|NCT04801043|DRUG|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
58286523|NCT04801043|DRUG|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
58286524|NCT05085470|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
58286525|NCT05085470|BIOLOGICAL|Placebo mock infection|Placebo mock infection with water
58286526|NCT06480760|DRUG|Carnosine|Food ingredient (supplement)
58286527|NCT01270360|DEVICE|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
58286528|NCT02800369|BIOLOGICAL|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
58286529|NCT06144450|OTHER|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
58286530|NCT01005017|PROCEDURE|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
58286531|NCT01857804|DRUG|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
58286532|NCT01857804|DRUG|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
58286533|NCT01857804|DRUG|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
58286534|NCT01512433|PROCEDURE|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
58286535|NCT01512433|PROCEDURE|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
58286536|NCT04819100|DRUG|Selpercatinib|Administered orally.
58286537|NCT04819100|DRUG|Placebo|Administered orally.
58286538|NCT01238419|DEVICE|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
58286539|NCT01238419|DEVICE|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
57932154|NCT06179160|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
58070789|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
58070790|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
58070791|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
58286540|NCT02681458|OTHER|Direct Examination|It was an observational study and subjects received their routine treatment.
58286541|NCT00864305|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
58286542|NCT00864305|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
58286543|NCT00864305|DRUG|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
58286544|NCT00565201|DRUG|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
58286545|NCT00565201|DRUG|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
58286546|NCT05477875|DRUG|oral cannabinoid|dronabinol
58286547|NCT05477875|COMBINATION_PRODUCT|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
58286548|NCT04571216|DRUG|NFL-101 dose 1|Subcutaneous injections
58286549|NCT04571216|DRUG|NFL-101 dose 2|Subcutaneous injections
58286550|NCT04571216|DRUG|Placebo|Subcutaneous injections
58286551|NCT06272825|OTHER|Virtual reality|VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
58286552|NCT06272825|OTHER|conventional rehabilitation|The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
58286553|NCT05418959|DIAGNOSTIC_TEST|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
58286554|NCT06608095|BEHAVIORAL|hypothermia group|Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.
58286555|NCT06608095|BEHAVIORAL|normothermia group|Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
58286556|NCT01398657|DRUG|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
58306830|NCT05363202|DRUG|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
58400196|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
58400197|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
58400198|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
58400199|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
58070792|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
58070793|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
58400200|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
58400201|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
58400202|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
58400203|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
58070794|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
58286557|NCT05226117|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 10 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
58286558|NCT02482753|DRUG|Chidamide|30 mg, administered orally twice per week (BIW)
58286559|NCT02482753|DRUG|exemestane|25 mg, PO daily
58286560|NCT02482753|DRUG|placebo|Administered orally twice per week (BIW)
58286561|NCT01569282|PROCEDURE|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
58286562|NCT01569282|PROCEDURE|Stent strategy|Biliary and/or enteral stents on demand
58400204|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit will be conducted of uses of Current Procedural Technology (CPT) Evaluation and Management (E/M) codes and evaluate for differences in complexity of CPT E/M code use for patients with disabilities (PWD) aged 3-89 years old with specific disabilities versus patients aged 3-89 without the specific disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying CPT code differences will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DO, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of CPT E/M among PWD after implementation of algorithms and EHR prompts, alerts and decision support will be conducted post-intervention."
58070795|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
58070796|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
58286563|NCT04442477|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
58286564|NCT04442477|DIETARY_SUPPLEMENT|Protein Fraction|Protein fractions
58286565|NCT02330185|DEVICE|ultrasonography|spinal anesthesia guided with ultrasonography
58286566|NCT03900572|BIOLOGICAL|HPV Vaccine|Intramuscular injection, 3 doses
58286567|NCT03900572|DRUG|Placebo|Intramuscular injection, 3 doses
58286568|NCT01215149|BIOLOGICAL|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
58286569|NCT01215149|BIOLOGICAL|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
58286570|NCT01215149|BIOLOGICAL|Placebo Control|Colorless 10mm Tris/HCl buffer
58286571|NCT01533402|BEHAVIORAL|therapist support|Weekly therapist support without CBT-interventions
58286572|NCT01533402|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
58286573|NCT01127594|DRUG|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
58286574|NCT05890014|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
58286575|NCT02555917|PROCEDURE|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
58400205|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
57932155|NCT02136745|BEHAVIORAL|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
58286576|NCT04127396|DRUG|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
58400206|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
58400207|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
58400208|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
58400209|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
58400210|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
57932156|NCT05118724|DRUG|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
58400211|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
58400212|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
58286577|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
57932157|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
57932158|NCT06736288|DRUG|BUCCALIN®|"Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach."
57932159|NCT06736288|OTHER|Placebo|Gastro-resistant tablets containing only excipients). The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
58286578|NCT04127396|DRUG|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
58286579|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
58306831|NCT05363202|DRUG|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
58400213|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
58400214|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
58400215|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
57932160|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
57932161|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
57932162|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
58286580|NCT04999085|OTHER|Supportive care interventions|Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
58286581|NCT03161067|DEVICE|BiCNS|Surgical implantation
58286582|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
58286583|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
58286584|NCT06372314|DRUG|Total parenteral nutrition (TPN): this is total nutrition provided by central vein.|isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
58286585|NCT06109350|OTHER|Supporting play exploration and early developmental intervention(SPEEDI)|SPEEDI will be performed by the parents
58286586|NCT06109350|OTHER|Standard care|Standard care will be performed by the parents
58286587|NCT01319942|OTHER|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
58286588|NCT02279615|DRUG|Mirabegron|50mg of mirabegron per day will be given.
58286589|NCT02279615|DRUG|Tamsulosin|0.4mg of flomax per day.
58286590|NCT02660684|DRUG|Prograf|Injection or oral
58286591|NCT02660684|DRUG|Methotrexate|Injection
58286592|NCT02660684|DRUG|Cyclosporine|Injection or oral
58286593|NCT00437060|PROCEDURE|Cognitive Assessment|Ancillary studies
58286594|NCT00437060|PROCEDURE|Diffusion Tensor Imaging|Correlative studies
58286595|NCT00437060|OTHER|Laboratory Biomarker Analysis|Correlative studies
58286596|NCT00437060|OTHER|Pharmacological Study|Correlative studies
58286597|NCT00437060|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
58286598|NCT03271632|BIOLOGICAL|CAR T cells|Infusion of multi-CAR T cells
58286599|NCT05341973|BEHAVIORAL|Education|Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
58070797|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
58070798|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
58286600|NCT00507520|PROCEDURE|Full dose almonds|
58286601|NCT00507520|PROCEDURE|Half dose almonds+half dose muffin|
58286602|NCT00507520|PROCEDURE|Full dose whole wheat muffin|
58070799|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
58070800|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
58286603|NCT05500014|OTHER|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
58286604|NCT05285059|BEHAVIORAL|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
58286605|NCT00537355|BIOLOGICAL|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
58286606|NCT00537355|DRUG|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
58286607|NCT06120478|OTHER|observe|observational study
58286608|NCT03923777|OTHER|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is \>3 cm in size or the VDT decreases to \<400 days.
58286609|NCT00216528|DRUG|risperidone|
58286610|NCT00457288|DRUG|TF 002|
58286611|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
58286612|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
58286613|NCT06198998|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
58286614|NCT00501709|DRUG|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
58286615|NCT03301077|OTHER|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
58286616|NCT01526278|DRUG|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
58400216|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
58400217|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
58400218|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
58400219|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
58400220|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
58286617|NCT03460626|DRUG|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
58286618|NCT03460626|OTHER|Placebo|an odorless oil without any therapeutic effect
58286619|NCT03373760|BIOLOGICAL|Durvalumab|Given IV
58286620|NCT03373760|OTHER|Laboratory Biomarker Analysis|Correlative studies
58286621|NCT03373760|BIOLOGICAL|Tremelimumab|Given IV
58286622|NCT04237545|DEVICE|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
58286623|NCT04237545|DEVICE|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
58286624|NCT03213392|DRUG|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
58286625|NCT02372994|OTHER|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
58286626|NCT05462236|DRUG|Tinodasertib|MNK inhibitor
58286627|NCT05462236|DRUG|Pembrolizumab|PD-1 Inhibitor
58400221|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
58400222|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
58400223|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
58400224|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
58286628|NCT05462236|DRUG|Irinotecan|Topoisomerase inhibitor
58400225|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
58400226|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
58286629|NCT00571103|DRUG|acamprosate|Two 333mg tablets taken three times daily.
58286630|NCT01212159|DEVICE|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
58286631|NCT02097511|DRUG|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
58286632|NCT02097511|DRUG|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
58286633|NCT02097511|DRUG|Metoprolol|Metoprolol Tartrate 100 mg once a day
58286634|NCT03188783|DRUG|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
58286635|NCT03188783|DRUG|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
58400227|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
58400228|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
58286636|NCT03750877|PROCEDURE|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
58286637|NCT03750877|PROCEDURE|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
58286638|NCT06149104|DRUG|sacubitril/valsartan|sacubiril/valsartan
58286639|NCT06404255|BEHAVIORAL|Stress management training|Stress management training
58286640|NCT00777335|DRUG|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
58286641|NCT00777335|DRUG|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
58286642|NCT02497937|DRUG|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
58286643|NCT02497937|DRUG|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
58400229|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
58400230|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
58286644|NCT00643981|BIOLOGICAL|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
58286645|NCT02044003|DEVICE|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
58400231|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
57932163|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
57932164|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphagia|Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
57932165|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphonia|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
57932166|NCT02761486|DRUG|Aspirin|325mg aspirin per day
58286646|NCT05187091|RADIATION|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
58286647|NCT01084902|DRUG|Latanoprost|once daily
58286648|NCT01084902|DRUG|Brinzolamide|Two times daily
58400232|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
58400233|NCT00436423|DRUG|gemcitabine, TS-1|
58286649|NCT02388087|DEVICE|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
58286650|NCT02388087|PROCEDURE|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
58286651|NCT04499196|DRUG|GlucoCorticoid|Administering glucocorticoid
58286652|NCT05400044|PROCEDURE|Three dimensional maxillary bone augmentation|mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
58286653|NCT00921258|PROCEDURE|prostate biopsy|"patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years"
58286654|NCT00926341|DRUG|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
58286655|NCT00926341|DRUG|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
58400234|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
57932167|NCT02761486|DRUG|Placebo|placebo in matching capsules
57932168|NCT06734715|OTHER|Conservative oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
57932169|NCT06734715|OTHER|Liberal oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
57932170|NCT01668719|DRUG|Bortezomib|Given SC or IV
57932171|NCT01668719|DRUG|Dexamethasone|Given PO or IV
57932172|NCT01668719|BIOLOGICAL|Elotuzumab|Given IV
58070801|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
58070802|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
58070803|NCT04884009|DRUG|SHR-1701|SHR-1701
58286656|NCT04047732|BIOLOGICAL|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
58286657|NCT02889770|OTHER|PEEP titration|Exposure to different PEEP levels
58286658|NCT04870632|OTHER|Education|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.
58286659|NCT04870632|OTHER|Video-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
58286660|NCT04870632|OTHER|Booklet-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
58286661|NCT00405015|DRUG|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
58286662|NCT05388656|DRUG|Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release|0.1 mg/day transdermal patch administered for 3 weeks
58286663|NCT05388656|DRUG|Placebo|Estradiol-matched placebo patch administered for 3 weeks
58286664|NCT05388656|DRUG|Progesterone 200 mg|200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study
58286665|NCT01135043|BEHAVIORAL|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
58286666|NCT01135043|BEHAVIORAL|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
58286667|NCT02927574|DEVICE|DCB|
58286668|NCT02927574|DEVICE|POBA|
58400235|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
58400236|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
58070804|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
58286669|NCT02693457|PROCEDURE|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
58400237|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
58286670|NCT02693457|PROCEDURE|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
58400238|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
58400239|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
58400240|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
58400241|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
58070805|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
58286671|NCT04037514|DRUG|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
58286672|NCT04037514|DRUG|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
58286673|NCT02469168|DEVICE|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
58286674|NCT02469168|PROCEDURE|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
58286675|NCT00420953|DRUG|Cordarone|
58286676|NCT04056312|BEHAVIORAL|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
58286677|NCT04056312|BEHAVIORAL|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
58286678|NCT03904810|BEHAVIORAL|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); \[i.e., (maximal HR - resting HR) × intensity + resting HR\]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
58286679|NCT01983826|DIETARY_SUPPLEMENT|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
58286680|NCT01983826|OTHER|Placebo|Microcrystalline cellulose (daily) for 8 weeks
58286681|NCT01698268|PROCEDURE|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
58286682|NCT01698268|PROCEDURE|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
58286683|NCT02878096|DRUG|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
57932173|NCT01668719|OTHER|Laboratory Biomarker Analysis|Correlative studies
57932174|NCT01668719|DRUG|Lenalidomide|Given PO
58070806|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
58070807|NCT00019565|PROCEDURE|magnetic resonance imaging|
58070808|NCT00019565|PROCEDURE|positron emission tomography|
58070809|NCT00019565|RADIATION|fludeoxyglucose F 18|
58070810|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
58095464|NCT06703346|DRUG|Experimental: Letetresgene autoleucel|Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
58286684|NCT03175315|BEHAVIORAL|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
58286685|NCT00374023|DRUG|Zinc, or Vitamin A or both|
58286686|NCT02889614|OTHER|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
58286687|NCT00672607|DRUG|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
58286688|NCT00672607|DRUG|Placebo|Placebo
58286689|NCT05456724|DRUG|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
58286690|NCT05456724|OTHER|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
58286691|NCT05752747|OTHER|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
58286692|NCT05752747|OTHER|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
58286693|NCT04648449|OTHER|Artificial intelligence on emergency calls|AI listens to all calls to Bergen EMCC, detecting calls regarding possible stroke.
58286694|NCT05971264|DIAGNOSTIC_TEST|Near infrared-spectroscopy|Comparison of regional intestinal oxygen saturation (measured with near infrared-spectroscopy) and indirect intraabdominal pressure measurement (bladder pressure) in muscle-relaxed, sedated patients compared to awake, non-sedated patients.
58286695|NCT02096276|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires.
58286696|NCT06479408|OTHER|progressive muscle relaxation (PMR) technique and vestibular rehabilitation exercises|A will be treated by progressive muscle relaxation (PMR) technique as a mean of stress relaxation and vestibular rehabilitation exercises for postural stability through Swiss ball, BOSU ball, balance board etc. Other components of vestibular rehab including gaze stability enhancement, improvement in vertigo and activities of daily living will also be focused.
58286697|NCT06479408|OTHER|virtual reality (VR)|virtual reality (VR) based intervention program where three dimensional-3D environments will be used reduce stress and improve balance. A Simulator Sickness Questionnaire (SSQ) will be filled by participants before and after each session of VR to discriminate whether VR is provoking the symptoms or not.
57932175|NCT04457466|DRUG|Nerve Growth Factor|Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
57932176|NCT02575040|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
58286698|NCT05395156|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
58286699|NCT02588586|DRUG|3BNC117|3BNC117 infusions
58286700|NCT02588586|OTHER|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
58286701|NCT04129294|DRUG|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
58286702|NCT02797977|DRUG|SRA737, gemcitabine, cisplatin|
58286703|NCT02797977|DRUG|SRA737, gemcitabine|
58286704|NCT02320448|DRUG|PIPAC|
58286705|NCT05259319|DRUG|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
58286706|NCT05259319|DRUG|Tiragolumab|Treatment given every 21 days during 24 months or until progression
57932177|NCT01927185|DEVICE|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
58286707|NCT05259319|RADIATION|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
58400242|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
58400243|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
58400244|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
57932178|NCT01927185|DEVICE|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
57932179|NCT00757003|DEVICE|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
57932180|NCT04824781|OTHER|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
57932181|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
57932182|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
58070811|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
58070812|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
58070813|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
58070814|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
58070815|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
58070816|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
58070817|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
58070818|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
58070819|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
58286708|NCT00308516|DRUG|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
58286709|NCT00308516|DRUG|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
58286710|NCT00308516|PROCEDURE|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
58286711|NCT00308516|DRUG|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
58286712|NCT00308516|DRUG|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
58400245|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
58400246|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
58400247|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
58400248|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
58400249|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
57932183|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
57932184|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
58400250|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
58400251|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
58400252|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
58400253|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
58400254|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
58400255|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
58400256|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
58400257|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
58286713|NCT02076347|BEHAVIORAL|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
58286714|NCT02076347|BEHAVIORAL|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
58400258|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
58400259|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
58400260|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
58400261|NCT03441997|OTHER|Mind-body exercise|Exercise program.
58400262|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
58400263|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
58400264|NCT01120236|DRUG|Bicalutamide|Given PO
58400265|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
58400266|NCT01120236|DRUG|Goserelin Acetate|Given SC
58400267|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
58400268|NCT01120236|DRUG|Leuprolide Acetate|Given IM
58286715|NCT04067596|PROCEDURE|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
58286716|NCT04141397|GENETIC|Initiation of POG-related WGTA|POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
58400269|NCT01120236|OTHER|Pharmacological Study|Correlative studies
57729159|NCT04223102|PROCEDURE|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
58286717|NCT04141397|GENETIC|Usual care|Usual care, not involving the initiation of POG-related WGTA
58286718|NCT05753735|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
58400270|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
58400271|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
58400272|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
58400273|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
58400274|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
58400275|NCT00002705|DRUG|topotecan hydrochloride|
58400276|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
58400277|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
58070820|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
58400278|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
58400279|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
58400280|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
58400281|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
58400282|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
58400283|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
58400284|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
58400285|NCT01823159|DRUG|placebo|Single oral administration of a tablet
58400286|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
57729160|NCT02595203|DRUG|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
58070821|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
58070822|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
58070823|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
58070824|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
58070825|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
58286719|NCT05753735|DRUG|Amoxicillin/ Clavulanic acid|Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
58286720|NCT02957617|DRUG|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
58286721|NCT03909737|DRUG|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
58286722|NCT03909737|DRUG|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
58286723|NCT03909737|OTHER|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
58286724|NCT03909737|OTHER|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
58286725|NCT03909737|OTHER|No intervention to pregnant women|No intervention to pregnant women
58286726|NCT03963921|DRUG|HepaStem|Heterologous human adult liver-derived progenitor cells
58286727|NCT02447913|BEHAVIORAL|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
58286728|NCT02105285|DRUG|OPC-1085EL ophthalmic solution|
58286729|NCT02105285|DRUG|Carteolol long-acting ophthalmic solution|
58286730|NCT04501055|BEHAVIORAL|perineal nerve block|An anesthesia method to block perineal nerve
58070826|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
58070827|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
58070828|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
58070829|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
58070830|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
58070831|NCT00516217|BIOLOGICAL|galiximab|
58070832|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
58070833|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
58070834|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
58070835|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
58070836|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
58070837|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
58070838|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
58070839|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
58286731|NCT04501055|BEHAVIORAL|periprostatic block|An anesthesia method to block periprostate
58286732|NCT06303206|DEVICE|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values."
58286733|NCT04585243|DEVICE|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
58286734|NCT02595112|OTHER|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
58286735|NCT00940576|DIETARY_SUPPLEMENT|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
58286736|NCT00940576|OTHER|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
58286737|NCT06553079|OTHER|Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy|"The intervention in this study involves the administration of the Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy, a newly developed tool designed to measure various aspects of surgeon satisfaction related to shoulder arthroscopy procedures."
58286738|NCT02149264|DRUG|Testosterone gel (FE 999303)|
58286739|NCT04227405|BEHAVIORAL|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
58070840|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
58070841|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
57932185|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
57932186|NCT06368167|DRUG|SHR2554|SHR2554
58070842|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
58070843|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
58070844|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
58095465|NCT06586255|RADIATION|Concurrent Immunotherapy and Radiation Therapy|Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
58095466|NCT04615286|OTHER|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
57932187|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
57932188|NCT05864001|BEHAVIORAL|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
58286740|NCT04227405|BEHAVIORAL|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
57729161|NCT02595203|DRUG|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
57729162|NCT00404157|DRUG|Rituximab|
57932189|NCT02296450|BEHAVIORAL|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
57932190|NCT03518554|DRUG|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
57932191|NCT06272435|DIETARY_SUPPLEMENT|Multiplier|Subjects will consume 1 Liter (2 servings) of commercially available Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
57932192|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free|Subjects will consume 1 Liter (2 servings) of experimental Sugar Free Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
57932193|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free with Amino Acids|Subjects will consume 1 Liter (2 servings) of commercially available Sugar Free Hydration Multiplier product that contains amino acids at a rate of 250 milliliters per 7.5 minutes.
57932194|NCT06272435|DIETARY_SUPPLEMENT|Water|Subjects will consume 1 Liter of water at a rate of 250 milliliters per 7.5 minutes.
57932195|NCT04175639|BEHAVIORAL|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
57932196|NCT06088199|DRUG|Apremilast|Oral tablet
58400287|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
58400288|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
58400289|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
57932197|NCT04661501|DEVICE|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
58070845|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
58095467|NCT04615286|OTHER|Standard (long course) of antibiotics|4-6 weeks of antibiotics
58286741|NCT04227405|BEHAVIORAL|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
58286742|NCT03017196|OTHER|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
58286743|NCT06076187|OTHER|Dual isotope method|Dual isotope method
58400290|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
58400291|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
58400292|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
58400293|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
58400294|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
57932198|NCT04661501|DEVICE|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
58286744|NCT00992017|BIOLOGICAL|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
58286745|NCT05991960|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
58286746|NCT01610856|DRUG|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
58286747|NCT01610856|DRUG|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
58286748|NCT00701792|PROCEDURE|liver transplantation|liver transplantation
58286749|NCT00701792|OTHER|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
58286750|NCT02811991|DRUG|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
57932199|NCT04661501|DEVICE|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
57932200|NCT04661501|DEVICE|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
57932201|NCT00162890|BEHAVIORAL|Therapeutic exercise|
57932202|NCT02296151|OTHER|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
57932203|NCT02296151|OTHER|iliotibial band stretches|Iliotibial band stretches
58400295|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
58400296|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
58070846|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
58070847|NCT01162031|DRUG|Velcade|IV
58286751|NCT02811991|DRUG|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
58286752|NCT02811991|DRUG|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
58286753|NCT06490783|OTHER|Noninvasive wearable devices (smartwatch and heart rate monitor band)|"Each enrolled subject will be equipped with noninvasive wearable devices (smartwatch and heart rate monitor band) to monitor physiological parameters and emotional states related to anxiety and stress. Each subject will be required to wear the smartwatch on his or her wrist for the duration of the study, about 3-6 months; while the heart rate monitor band will be worn for about 10 minutes a day. At the same time, a mobile application, RESILIENT, will be developed and implemented to serve as the main interface for self-assessment data entry and for feedback and recommendations.~The psycho-physical condition of each subject will be monitored by the app through customized and contextualized mental exercises based on daily activities. This approach will test the effectiveness of the proposed architecture in reducing unhealthy habits and promoting health and wellness recommendations"
58286754|NCT04911595|DIAGNOSTIC_TEST|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km\*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
58400297|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
58400298|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
58400299|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
58400300|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
58400301|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
58400302|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
58400303|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
58070848|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
58070849|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58070850|NCT02104232|BEHAVIORAL|THPP-I|
58070851|NCT02104232|BEHAVIORAL|EUC|
58070852|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
58070853|NCT01551043|BIOLOGICAL|CART-19|
58095468|NCT01658982|OTHER|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
58400304|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
58400305|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
57932204|NCT06716333|OTHER|Experimental Group (12-Week Wrestling Training)|The intervention consists of a structured 12-week intensive wrestling training program designed specifically for male wrestlers aged 12-14 years. This program was conducted at athlete training centers equipped with international standard facilities, and led by professional coaches. The training included 5 sessions per week, each lasting approximately 80 minutes, with a total weekly duration of 400 minutes. Each session consisted of 20 minutes of gymnastic warm-up, 50 minutes of basic technical and strength exercises (e.g., squats, push-ups, deadlifts), and 10 minutes of stretching.
57932205|NCT03801902|RADIATION|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
57932206|NCT03801902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57932207|NCT03801902|PROCEDURE|Computed Tomography|Undergo brain CT and chest CT
57932208|NCT03801902|BIOLOGICAL|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
57932209|NCT03801902|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
58286755|NCT04911595|DIAGNOSTIC_TEST|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km\*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
57932210|NCT03801902|BIOLOGICAL|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
58286756|NCT04322669|DRUG|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
58286757|NCT04322669|DRUG|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
58286758|NCT04391179|DRUG|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
58286759|NCT04391179|DRUG|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
58286760|NCT05013502|DRUG|Empagliflozin 10 MG|empagliflozin 10mg PO once daily
58286761|NCT00789685|DRUG|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
58286762|NCT06099925|DRUG|Hetrombopag|All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
58286763|NCT05965765|DIAGNOSTIC_TEST|Total knee arthroplasty|who got total knee arthroplasty because of osteoarthritis
58286764|NCT05965765|DIAGNOSTIC_TEST|osteoarthritis without surgery|who has osteoarthritis and didn't get any surgery
58286765|NCT05965765|DIAGNOSTIC_TEST|control group|healthy people
58286766|NCT03243123|DEVICE|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
58286767|NCT06017895|DRUG|doxepin solution|2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
58286768|NCT06017895|OTHER|Placebo|2.0 mL placebo sprayed to the posterior pharyngeal wall
58286769|NCT00002692|DRUG|fluorouracil|
58400306|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
58400307|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
58070854|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
58286770|NCT00002692|DRUG|isolated perfusion|
58286771|NCT00002692|DRUG|leucovorin calcium|
58286772|NCT06433843|BEHAVIORAL|Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)|12 weeks inpatient disorder specific psychotherapy
58286773|NCT06047223|DIAGNOSTIC_TEST|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
58286774|NCT02870556|DEVICE|cervical epidural analgesia|
58286775|NCT00700128|DRUG|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
58286776|NCT00700128|DRUG|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
58286777|NCT00700128|DRUG|placebo|placebo
57932211|NCT03801902|BIOLOGICAL|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
57932212|NCT03801902|RADIATION|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
58400308|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
58400309|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
58400310|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
58400311|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
58400312|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
57932213|NCT01839162|PROCEDURE|Coronary angiography|Diagnostic coronary angiography
57932214|NCT01839162|PROCEDURE|PCI|Percutaneous coronary intervention
57932215|NCT01839162|PROCEDURE|Right approach|Right transradial access
57932216|NCT01839162|PROCEDURE|Left approach|Left transradial access
57932217|NCT06734832|BIOLOGICAL|bivalent enterovirus vaccine (Vero cell), inactivated|Two doses are administered with a one-month interval between each dose.
58286778|NCT02456025|DRUG|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
58400313|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
58400314|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
58400315|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
58400316|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
58400317|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
58400318|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
57932218|NCT06734832|BIOLOGICAL|Enterovirus Type 71 Vaccine (Vero Cell), Inactivated|Two doses are administered with a one-month interval between each dose.
58286779|NCT04116008|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
58400319|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
57932219|NCT01224704|OTHER|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
58286780|NCT02677597|DRUG|Cisplatin Combined With S-1|
57932220|NCT01224704|OTHER|Water deprivation|24 hour water deprivation
57932221|NCT05359991|OTHER|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
57932222|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
57932223|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
57932224|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
57932225|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
57932226|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
57932227|NCT06734559|DIAGNOSTIC_TEST|Patients who have not antibiotic treatment for acute apical periodontitis in the last month and have not taken any anti-inflammatory medication in the past 24 hours.|Patients with acute apical periodontitis will first have masseter muscle measurements in the relevant area and then the decayed tooth will be treated with calcium hydroxide for 14 days. Then the dressing will be applied with calcium hydroxide again. At the end of 28 days, the patient will be measured again by ultrasonography and the initial and final data will be compared.
58286781|NCT02677597|DRUG|Cisplatin Combined With Paclitaxel|
58286782|NCT04108741|DEVICE|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
58286783|NCT05088681|OTHER|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
58286784|NCT00171158|DRUG|imatinib mesylate|
58286785|NCT00531947|DRUG|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
58286786|NCT00531947|DRUG|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
58286787|NCT04316260|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
58286788|NCT04316260|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
58286789|NCT05013632|DRUG|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
58286790|NCT05013632|DRUG|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
58286791|NCT03821246|DRUG|Atezolizumab|Given IV
58286792|NCT03821246|DRUG|Tocilizumab|Given IV
58286793|NCT03821246|DRUG|Etrumadenant|Given Orally
58286794|NCT03914274|DEVICE|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
58400320|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
58400321|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
58400322|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
58400323|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
58400324|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
58400325|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
58400326|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
58400327|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
58400328|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
57932228|NCT06734559|OTHER|patients who have not acute apical periodontitis|Masseter measurements will be made from day 1 to day 28 in healthy subjects without acute apical periodontitis.
58400329|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
58400330|NCT04049266|DRUG|KSI-301|Intravitreal Injection
58400331|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
58400332|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
58400333|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
58400334|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
58400335|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
58400336|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
58400337|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
58400338|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
58400339|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
58400340|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
58400341|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
58400342|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
57932229|NCT04134559|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
57932230|NCT03272763|DEVICE|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
58400343|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
57932231|NCT02877212|DRUG|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
57932232|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
57932233|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
58400344|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
58400345|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
58400346|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
58400347|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
58400348|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
58400349|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
58400350|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
58400351|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
58400352|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
58422791|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
58070855|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
58286795|NCT02764476|OTHER|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
58400353|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
58070856|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
58400354|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
58400355|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
58400356|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
58400357|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
58400358|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
57932234|NCT04534933|DEVICE|Evone|Airway ventilation device
57932235|NCT04534933|DEVICE|Primus|Airway ventilation device
58286796|NCT02764476|OTHER|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
58286797|NCT05415436|OTHER|Propofol slow administration|Propofol will be slowly administered over 120 seconds by anesthesia provider
58286798|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
58400359|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
58400360|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
58400361|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
58400362|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
57932236|NCT05342181|OTHER|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~1. supine bridge~2. plank~3. oblique crunch~4. side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
58070857|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
58095469|NCT05941299|DEVICE|REGENERA breast implant implantation|"Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up"
58095470|NCT02269501|OTHER|Exercise treatment|
58286799|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
58286800|NCT01014052|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
58286801|NCT02787122|BEHAVIORAL|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
58286802|NCT02787122|BEHAVIORAL|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
58286803|NCT05183347|DRUG|BI 1291583|BI 1291583
58286804|NCT05183347|DRUG|Placebo|Placebo
58286805|NCT04912479|DEVICE|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
58286806|NCT02963636|OTHER|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
58286807|NCT05703334|OTHER|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
58286808|NCT00314808|DRUG|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
58286809|NCT00158262|DRUG|Propranolol|Propranolol short-acting or long-acting capsule
58286810|NCT00158262|DRUG|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
58286811|NCT02834858|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
58286812|NCT02834858|BIOLOGICAL|saline|
58286813|NCT00951158|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
58286814|NCT00951158|DRUG|Conjugated Linoleic Acid|Phase I Dose Escalation Study
58400363|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
58400364|NCT00151710|DRUG|Pioglitazone|
58400365|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
58286815|NCT06060028|DEVICE|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
58400366|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
58400367|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
58400368|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
58095471|NCT06699940|DEVICE|Transcranial Magnetic Stimulation|Patients between the age of 12-21 received TMS treatment for MDD disorder.
58286816|NCT06060028|DEVICE|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
58286817|NCT03670511|OTHER|sit-to-stand test|to sit and stand from a chair
58286818|NCT03670511|OTHER|six minute walking test|to walk for six minutes
58286819|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.
58286820|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention on healthy lifestyle choices|The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
58286821|NCT04762563|OTHER|IASTM application|IASTM application .
58286822|NCT04762563|OTHER|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
58286823|NCT04050085|BIOLOGICAL|Nivolumab|Given IV
58286824|NCT04050085|RADIATION|Radiation Therapy|Undergo radiation therapy
58286825|NCT04050085|DRUG|TLR9 Agonist SD-101|Given intratumorally
58286826|NCT04204083|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
58286827|NCT02258594|OTHER|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
58286828|NCT02258594|BEHAVIORAL|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
58286829|NCT02425735|BIOLOGICAL|DC-CIK cells|DC-CIK cells will be used against tumor cells.
58286830|NCT02425735|BIOLOGICAL|γδ T cells|γδ T cells will be used against breast tumor.
58286831|NCT02425735|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
57729163|NCT03876067|DRUG|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
58286832|NCT00583011|DRUG|Local Anesthesia|Local anesthesia: 2 cc of 1% Lidocaine
58286833|NCT00583011|DRUG|Placebo Group|Placebo Group: 2cc Normal Saline
58286834|NCT02168023|DEVICE|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
58286835|NCT02168023|DEVICE|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
57729164|NCT03876067|DRUG|Cardioplegic Solutions|in which in which only cold blood cardioplegia
58286836|NCT00703677|DRUG|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
58286837|NCT04954417|DIAGNOSTIC_TEST|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
58286838|NCT04954417|OTHER|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
58286839|NCT04954417|PROCEDURE|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
58286840|NCT00556257|DRUG|Cyclosporine|Standard of care
58286841|NCT00556257|DRUG|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
58286842|NCT02662335|OTHER|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
58286843|NCT02662335|OTHER|Questionnaire Administration|Ancillary studies
58286844|NCT02662335|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
58286845|NCT05376761|DRUG|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
58286846|NCT00435461|DRUG|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
58286847|NCT03367234|BEHAVIORAL|Individual Therapy Sessions|One-on-one sessions with a counselor
58286848|NCT03367234|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
58286849|NCT03367234|BEHAVIORAL|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
58286850|NCT03367234|BEHAVIORAL|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
58286851|NCT03367234|BEHAVIORAL|Group Therapy Sessions|Group therapy sessions
58286852|NCT03367234|BEHAVIORAL|Psychiatric Consultation|Access to psychiatric consultation
58400369|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
58400370|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
58400371|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
58400372|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
57729165|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
58286853|NCT03367234|BEHAVIORAL|Contingency Management|Rewards for engagement in specified recovery behaviors
58286854|NCT02555085|BIOLOGICAL|BIIB063|Single ascending IV dose
58286855|NCT02555085|OTHER|Placebo|Single dose
58286856|NCT03442231|DEVICE|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
58286857|NCT02295332|DRUG|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
58286858|NCT02295332|DRUG|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
58286859|NCT00921713|OTHER|Oncology Nurse Care Management|
58286860|NCT00921713|OTHER|Patient-centered materials|
58286861|NCT05352880|DIAGNOSTIC_TEST|serum magnesium level, FEMg|"Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination."
58286862|NCT02029482|DRUG|ACT-128800|
58286863|NCT02029482|DRUG|Placebo|
58400373|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
57729166|NCT01438866|OTHER|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
57729167|NCT01438866|OTHER|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
57729168|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
57729169|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
57729170|NCT01546194|OTHER|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
58286864|NCT02099253|DRUG|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
58286865|NCT02099253|DRUG|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
58286866|NCT02725437|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection
58286867|NCT02725437|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
58286868|NCT03140540|OTHER|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.
58286869|NCT03140540|OTHER|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV \>10, 200 ml of colloid bolus to be given
58400374|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
58400375|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
58286870|NCT01251159|GENETIC|mutation analysis|
58286871|NCT01251159|GENETIC|polymerase chain reaction|
58286872|NCT01251159|OTHER|immunologic technique|
58286873|NCT01251159|OTHER|laboratory biomarker analysis|
58286874|NCT00790556|DRUG|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
58286875|NCT00790556|DRUG|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
58286876|NCT00484926|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
58286877|NCT00484926|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
58286878|NCT01853748|DRUG|Trastuzumab|
58286879|NCT01853748|DRUG|Paclitaxel|
58286880|NCT01853748|DRUG|Trastuzumab emtansine|
58400376|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
58286881|NCT03162068|OTHER|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
58286882|NCT04687826|OTHER|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
58286883|NCT04687826|OTHER|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
58286884|NCT00667303|OTHER|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
58286885|NCT00667303|OTHER|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
58286886|NCT00667303|OTHER|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
58286887|NCT00164632|BEHAVIORAL|counselling, exercise, referrals (behavior)|
58286888|NCT01509612|DRUG|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
58286889|NCT01509612|DRUG|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
58400377|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
58400378|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
58400379|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
58400380|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
58400381|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
58400382|NCT00006003|DRUG|semaxanib|Given IV
58400383|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
58400384|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
58400385|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
58400386|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
58400387|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
58400388|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
58400389|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
58400390|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
58400391|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
58286890|NCT02916134|PROCEDURE|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
58286891|NCT02916134|DRUG|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
58286892|NCT05162430|DRUG|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
58286893|NCT02335346|DRUG|Duloxetine|Administered orally
58286894|NCT06265909|DEVICE|AmDTx|AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
58400392|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
58400393|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
58400394|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
58400395|NCT00003191|DRUG|fenretinide|
58400396|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
58286895|NCT04481594|DRUG|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
58286896|NCT04481594|DRUG|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
58286897|NCT06291129|PROCEDURE|Periodontal therapy|Supragingival scaling sessions were performed with ultrasonic scalers (Dabi Atlante, Rio de Janeiro, RJ, Brazil) to remove all calculus and biofilms, in addition to oral hygiene guidelines, including brushing technique and interdental cleaning with dental floss.
58286898|NCT02705378|DRUG|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
58400397|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
58400398|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
58400399|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
57729171|NCT03819335|DEVICE|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
57729172|NCT03819335|OTHER|Standard care|Face-to-face visits
57729173|NCT04748354|BEHAVIORAL|Otago Exercise Program|An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
57729174|NCT04748354|OTHER|Usual Care|Clinical care provided by a geriatrician.
57729175|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
57729176|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
57729177|NCT01054729|DRUG|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
57729178|NCT01054729|DRUG|Placebo|Placebo to match sofosbuvir administered orally once daily
57729179|NCT01054729|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
57729180|NCT01054729|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
57729181|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
57729182|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
57729183|NCT04191772|OTHER|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
57729184|NCT02623673|DRUG|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
57729185|NCT01786694|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
57729186|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
57729187|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
58286899|NCT02705378|DRUG|naloxegol|Intervention would be given by OG or NG tube
58286900|NCT00817388|OTHER|No intervention|No intervention
58070858|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
58070859|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
58070860|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
58070861|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
58070862|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
58070863|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
58070864|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
58070865|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
57729188|NCT04722913|DIAGNOSTIC_TEST|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
57729189|NCT05190081|OTHER|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
57729190|NCT05897593|DEVICE|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
58070866|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
58286901|NCT04558671|OTHER|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
58286902|NCT00851188|BEHAVIORAL|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
58286903|NCT00851188|BEHAVIORAL|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
58286904|NCT00851188|OTHER|Waiting list|Waiting list
58286905|NCT01013831|DRUG|Erlotinib Hydrochloride|Given PO
58286906|NCT01013831|OTHER|Laboratory Biomarker Analysis|Correlative studies
58286907|NCT01013831|OTHER|Pharmacological Study|Correlative studies
58286908|NCT03488797|BEHAVIORAL|Supervised web- and home-based exercise intervention|"* The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
58286909|NCT00402623|DIETARY_SUPPLEMENT|quercetin|1000 mg quercetin within 24 hours
57729191|NCT01528228|DEVICE|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
57729192|NCT01615029|DRUG|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
58070867|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
58286910|NCT00402623|OTHER|placebo|
58286911|NCT01420341|DRUG|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
58286912|NCT01420341|DRUG|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
58286913|NCT06321120|DRUG|variability-based lenvatinib regimen|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
58286914|NCT03791112|DRUG|BPI-16350|BPI-16350 capsules administered orally
58286915|NCT01401946|DRUG|soy isoflavones|
58286916|NCT01401946|DRUG|Placebo|
58286917|NCT01337817|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
58286918|NCT01337817|OTHER|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
58286919|NCT00002773|BIOLOGICAL|allogeneic tumor cell vaccine|
58286920|NCT00002773|BIOLOGICAL|recombinant interferon alfa|
58286921|NCT00002773|BIOLOGICAL|sargramostim|
58286922|NCT00002773|DRUG|cyclophosphamide|
58286923|NCT00461929|PROCEDURE|bone marrow aspiration|
58286924|NCT05258682|DRUG|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
58286925|NCT05258682|DRUG|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
58286926|NCT02382809|DRUG|DC071|Mouthwash, twice daily
58286927|NCT02382809|DRUG|Placebo|Mouthwash, twice daily
58286928|NCT04472494|BIOLOGICAL|Abatacept|Specified dose on specified days
58286929|NCT04472494|OTHER|Placebo|Specified dose on specified days
58286930|NCT05964153|DIAGNOSTIC_TEST|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
58286931|NCT02359279|DEVICE|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
58286932|NCT02447471|DEVICE|Nexfin|Nexfin cuff placed on finger to measure blood pressure
58286933|NCT00032500|DRUG|Echinacea|
58286934|NCT00629759|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
58286935|NCT02799914|DEVICE|Sinus-Venous stent (Optimed GmbH)|Stent implantation
58286936|NCT03835507|DRUG|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
58286937|NCT01388712|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).
58286938|NCT01388712|DIETARY_SUPPLEMENT|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
58286939|NCT02347735|OTHER|No interventions, only data collection|Only data is collected from the subjects in both groups.
58286940|NCT01017081|OTHER|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
58286941|NCT01017081|OTHER|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
58400400|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
58286942|NCT01758614|PROCEDURE|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
58400401|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
58070868|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
58070869|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
58070870|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
58286943|NCT01758614|DRUG|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
58286944|NCT01758614|DRUG|Clopidogrel|
58286945|NCT01497067|DEVICE|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
58286946|NCT05230797|DRUG|Zinc oxide Propolis|antibacterial and anti-inflammatory
58286947|NCT05230797|DRUG|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
58286948|NCT04469634|DIAGNOSTIC_TEST|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
58286949|NCT02073539|DEVICE|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
58400402|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
58400403|NCT04703608|DRUG|Placebo|Non-identical placebo
57729193|NCT01615029|DRUG|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
57729194|NCT01615029|DRUG|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
57729195|NCT01615029|DRUG|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
57729196|NCT06669637|DEVICE|Ablation|Ablation procedure for Atrial Fibrillation
57729197|NCT00016133|BIOLOGICAL|BCG vaccine|
57729198|NCT00016133|BIOLOGICAL|autologous tumor cell vaccine|
57729199|NCT00016133|DRUG|fluorouracil|
57729200|NCT00016133|DRUG|leucovorin calcium|
57729201|NCT00016133|PROCEDURE|adjuvant therapy|
58070871|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
58070872|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
58070873|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
58286950|NCT02073539|DEVICE|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
58286951|NCT03171597|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
58286952|NCT03171597|DRUG|Lipid Regulating Drugs|Mainly including statins
58286953|NCT03171597|DRUG|Coronary Vasodilator|Mainly including nitrates
58286954|NCT03171597|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
58286955|NCT03171597|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
58286956|NCT03171597|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
58286957|NCT04753502|PROCEDURE|Laparoscopy|laparoscopic removal of pathologic appendix
58286958|NCT02839031|BEHAVIORAL|"CBT (Cognitive-Behavioral Therapy)"|
58286959|NCT02839031|BEHAVIORAL|Control (telephonic support without CBT content)|
58286960|NCT03056612|OTHER|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
58286961|NCT00738855|OTHER|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
58286962|NCT00738855|OTHER|Nothing per os|A nasogastric tube
58400404|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
58400405|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
58400406|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
58400407|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
58400408|NCT04847752|DRUG|Aspirin|the dosage and duration
58400409|NCT04847752|DRUG|Clopidogrel|the dosage and duration
58400410|NCT04847752|DRUG|Anticoagulant|the dosage and duration
58400411|NCT04847752|DRUG|Statin|the dosage and duration
58400412|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
58400413|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
58070874|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
58286963|NCT03076515|DEVICE|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
58286964|NCT03076515|DEVICE|Sham Nerivio Migra|electrical stimulation- shame mode
58286965|NCT05631145|OTHER|MT Combined With XKSA|Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
58286966|NCT05631145|OTHER|MT|Morita therapy (MT) comprised bed rest and light work.
58286967|NCT03852186|BEHAVIORAL|Cognitive behavioral therapy|Group based psychotherapy
58286968|NCT03852186|BEHAVIORAL|Acceptance and commitment therapy|Group based psychotherapy
58286969|NCT03088228|DIAGNOSTIC_TEST|gingival crevicular fluid collection|
58286970|NCT05730855|DIAGNOSTIC_TEST|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
58286971|NCT00005822|DRUG|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
58286972|NCT00005822|DRUG|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
58286973|NCT00005822|PROCEDURE|conventional surgery|Patients undergo a modified radical mastectomy.
58286974|NCT00005822|RADIATION|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
58286975|NCT00005822|DRUG|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
58286976|NCT05455619|DRUG|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
58286977|NCT03939533|DRUG|CUTAQUIG|Human normal immunoglobulin
58286978|NCT01935986|DIETARY_SUPPLEMENT|probiotic|
58286979|NCT01935986|DIETARY_SUPPLEMENT|placebo|
58286980|NCT05514613|OTHER|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
58400414|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
58400415|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
58400416|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
58400417|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
58070875|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
58070876|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
58286981|NCT01941199|DRUG|DA-1229|
58286982|NCT01941199|DRUG|metformin|
58286983|NCT01941199|DRUG|DA-1229 + metformin|
58286984|NCT03678415|BEHAVIORAL|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
58286985|NCT06365190|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
58286986|NCT06365190|DRUG|Pharmacotherapy（antiparkinsonian drugs）|Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
58286987|NCT02932800|PROCEDURE|"Fixation with ballerina technique and flip"|
58286988|NCT02932800|PROCEDURE|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
58286989|NCT02932800|OTHER|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
58286990|NCT02344511|DRUG|Dalbavancin|Drug
58286991|NCT02344511|DRUG|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
58286992|NCT04482088|BEHAVIORAL|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
58400418|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
58400419|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
58400420|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
58400421|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
58400422|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
58400423|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
58400424|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
58400425|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
58070877|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
58070878|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
58070879|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
58070880|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
58286993|NCT04482088|BEHAVIORAL|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
58286994|NCT05055154|DEVICE|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
58286995|NCT00520039|PROCEDURE|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
58400426|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
58400427|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
58400428|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
58070881|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
58286996|NCT03195322|PROCEDURE|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
58286997|NCT04481763|DRUG|Camrelizumab|Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
58286998|NCT04481763|RADIATION|radiotherapy|radiotherapy
58286999|NCT03518086|DRUG|Mirikizumab|Administered IV
58287000|NCT03518086|DRUG|Placebo|Administered IV
58287001|NCT04328428|OTHER|acupuncture|Use one acupuncture needle insert in a acupoint.
58400429|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
58400430|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
58400431|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
58400432|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
58400433|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
58287002|NCT04168255|PROCEDURE|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
58287003|NCT06612294|BEHAVIORAL|PEF Interventional Session|3 sessions over 6 weeks for asthma management
58400434|NCT02543177|PROCEDURE|coronary angiography|
58400435|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
58400436|NCT02543177|PROCEDURE|prior kidney irrigation|
58400437|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
58070882|NCT04853368|DRUG|ABBV-576|Oral capsules
58070883|NCT04853368|DRUG|Galicaftor|Oral capsules
58070884|NCT04853368|DRUG|Placebo|Oral capsules
58070885|NCT04853368|DRUG|Navocaftor|Oral capsules
58070886|NCT04853368|DRUG|ABBV-119|Oral capsules
58070887|NCT01467531|DRUG|Dolutegravir|50mg q 24h
58070888|NCT01467531|DRUG|Rlipivirine|25mg q24h
58070889|NCT01467531|DRUG|GSK1265744|30mg q24h
58070890|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
58287004|NCT06612294|BEHAVIORAL|Control Sessions|3 sessions over 6 weeks for asthma management
58287005|NCT06612294|BEHAVIORAL|Control Booster|A single booster session after the 6-months assessments are completed.
58070891|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
58287006|NCT06612294|BEHAVIORAL|Active booster|A single booster session after the 6-months assessments are completed.
58070892|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
58400438|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
58400439|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
58400440|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
58287007|NCT02349139|DRUG|ASN001: Escalating dose Part A|Androgen inhibitor
58287008|NCT02204345|DRUG|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
58287009|NCT02204345|DRUG|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
58287010|NCT02204345|DRUG|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
58287011|NCT03703674|DRUG|GCSF|Granulocyte-colony stimulating factors (G-CSF)
58287012|NCT01051440|DRUG|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
58287013|NCT01051440|DRUG|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
58287014|NCT00394888|DEVICE|MRI|MRI of the spine.
58287015|NCT00394888|DEVICE|MRI of head and neck|MRI of head and C-spine
58400441|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
58400442|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
58400443|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
58400444|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
57729202|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
57729203|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
58287016|NCT00394888|OTHER|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
58287017|NCT00394888|OTHER|Cardiac examination|Complete cardiac examination
58287018|NCT00394888|DEVICE|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
58070893|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
58070894|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
58070895|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
58070896|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
58287019|NCT04162405|BEHAVIORAL|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
58287020|NCT05524454|DEVICE|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
58287021|NCT06296277|OTHER|Intraoperative mechanical ventilation for surgery|Any IMV during general anesthesia for surgery
58287022|NCT05446051|DEVICE|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
58287023|NCT05446051|DEVICE|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
58287024|NCT02244788|DEVICE|SR™ PIP|
58287025|NCT06199544|DRUG|Metformin|Comparing the effect of drugs on symptoms of PCOS
58287026|NCT04484194|BEHAVIORAL|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
58287027|NCT05348954|OTHER|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
58287028|NCT04307524|PROCEDURE|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
58400445|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
57729204|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
57932237|NCT05342181|OTHER|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~1. bridging~2. straight leg raise in prone lying~3. straight leg raise with hand raise in prone lying~4. pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
58070897|NCT01005966|DRUG|Placebo|placebo and washout treatment
58070898|NCT01005966|DRUG|675 ppmf toothpaste|dose response
58070899|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
58070900|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
58070901|NCT01478542|DRUG|Conventional Vincristine|
58070902|NCT01478542|DRUG|Liposomal Vincristine|
58070903|NCT01478542|DRUG|Ricover-scheme rituximab|
58070904|NCT01478542|DRUG|optimised rituximab-schedule|
58070905|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
58070906|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
58070907|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
58070908|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
58070909|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
58070910|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
58070911|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
58070912|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
58070913|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
58070914|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
58070915|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
58070916|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
58070917|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
58287029|NCT04307524|DRUG|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
57932238|NCT02251925|BIOLOGICAL|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
58400446|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
58287030|NCT04932135|DIAGNOSTIC_TEST|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
58287031|NCT00223002|DRUG|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
58287032|NCT04198909|DIAGNOSTIC_TEST|Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways|Electrocochleography is a technique that analyses the functionality of inner ear.
58287033|NCT01462656|DRUG|Non-EZG containing AED polytherapy|AED polytherapy without EZG
58287034|NCT01462656|DRUG|EZG containing AED polytherapy|AED polytherapy including EZG
57729205|NCT05441930|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
57932239|NCT02251925|DRUG|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
57932240|NCT02251925|DRUG|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
57932241|NCT02251925|DRUG|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
57932242|NCT01365585|DRUG|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
57932243|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
57932244|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
57932245|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
57932246|NCT01965639|OTHER|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
58070918|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
58287035|NCT01462656|DRUG|Non-EZG AED monotherapy|AED monotherapy without EZG
58287036|NCT01462656|DRUG|EZG AED monotherapy|Any off-label use of EZG as monotherapy
58287037|NCT01775787|DRUG|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
58287038|NCT04337021|BEHAVIORAL|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
58287039|NCT06613282|DEVICE|Low Intensity Transcranial Magnetic Stimulation|"* Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters."
57729206|NCT05441930|DRUG|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
58287040|NCT06613282|DEVICE|Auditory and visual stimulation|"* Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx."
58287041|NCT02905045|DRUG|Ketoprofen|
57729207|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
58287042|NCT02905045|DRUG|placebo|
57729208|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
58070919|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
58400447|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
58400448|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
58400449|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
58287043|NCT04457401|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
58287044|NCT04457401|DIETARY_SUPPLEMENT|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
58287045|NCT01939223|DRUG|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
58287046|NCT01939223|DRUG|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
58287047|NCT00003007|BIOLOGICAL|recombinant interferon alfa|
58287048|NCT00003007|BIOLOGICAL|sargramostim|
58287049|NCT00003007|DRUG|cyclophosphamide|
58287050|NCT00003007|DRUG|dexamethasone|
58287051|NCT00003007|DRUG|melphalan|
58287052|NCT00003007|PROCEDURE|peripheral blood stem cell transplantation|
58287053|NCT03484624|DEVICE|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
58287054|NCT00000411|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
58287055|NCT00000411|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
57729209|NCT03888573|OTHER|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
57932247|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
57932248|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
57932249|NCT05697731|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
57932250|NCT04307381|DRUG|Donidalorsen|Donidalorsen administered SC
57932251|NCT05675579|DRUG|Sacituzumab Govitecan|Given by IV (vein)
57932252|NCT05675579|DRUG|Pembrolizumab|Given by IV (vein)
57932253|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
58287056|NCT06039137|DRUG|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
58287057|NCT06039137|DRUG|Clemastine IV|Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
58287058|NCT01505231|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.
58287059|NCT01505231|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
58287060|NCT02847910|PROCEDURE|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
58287061|NCT02847910|PROCEDURE|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
58287062|NCT05978219|DRUG|Mirtazapine Tablets|Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
58287063|NCT03247322|OTHER|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
58287064|NCT04350047|PROCEDURE|Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy|The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
58287065|NCT01856998|DRUG|Propofol|
58287066|NCT01856998|DRUG|Diprivan|
58287067|NCT04851366|BEHAVIORAL|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
58400450|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
58400451|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
57932254|NCT06260956|BEHAVIORAL|Consumption|Subjects consume peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
57932255|NCT06260956|BEHAVIORAL|Avoidance|Subjects avoid eating peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
58070920|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
57729210|NCT05043337|BEHAVIORAL|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
58070921|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
58287068|NCT04851366|BEHAVIORAL|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
58287069|NCT04851366|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
58287070|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
58400452|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
58400453|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
57932256|NCT02721823|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
57932257|NCT02721823|BEHAVIORAL|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
57932258|NCT03718663|OTHER|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
57932259|NCT03718663|OTHER|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
58287071|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
58400454|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
58400455|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
58400456|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
58400457|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
57932260|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
58070922|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
58070923|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
58287072|NCT04187274|DEVICE|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
58287073|NCT05256966|OTHER|Sauna (steam)|Steam Sauna
58287074|NCT02255071|DEVICE|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
58287075|NCT02255071|DEVICE|Sham wristband|A wristband over wrist but no acupressure for seven days.
58287076|NCT03454477|PROCEDURE|conventional open surgery|conventional open surgery
58287077|NCT03454477|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy
58287078|NCT03454477|DEVICE|robotic thyroidectomy|robotic thyroidectomy
58400458|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
58400459|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
58400460|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
58400461|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
58400462|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
57932261|NCT04795843|OTHER|Exercise and patient education|Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
57932262|NCT04795843|OTHER|Usual Care|Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
57932263|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
57932264|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
58070924|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
58070925|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
58070926|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
58070927|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
58070928|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
58070929|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
58287079|NCT03612479|BEHAVIORAL|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
58287080|NCT03612479|BEHAVIORAL|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
58287081|NCT02080364|DRUG|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
57729211|NCT05043337|BEHAVIORAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
57729212|NCT05043337|BEHAVIORAL|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
57729213|NCT01323699|BEHAVIORAL|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
57729214|NCT00512135|DRUG|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
57932265|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
58070930|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
58070931|NCT00984958|DEVICE|Bulkamid expectation|expectance
58287082|NCT02080364|DRUG|Placebo|Placebo administered orally, once daily for 18 months
58287083|NCT00931112|OTHER|individualized exercise training|Lower extremities resistance exercise and bicycle training
58287084|NCT02957487|DEVICE|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
58287085|NCT04648657|DEVICE|Lung Ultrasound|Echography of Lungs based on artifacts study
58287086|NCT04648657|DEVICE|Electric impedance tomography|Low alternating electrical currents (usually \<5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
58287087|NCT04285216|OTHER|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
57932266|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
58070932|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
58070933|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
58400463|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
58400464|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
58400465|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
58400466|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
58400467|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
58400468|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
58400469|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
58400470|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
57932267|NCT06734520|DRUG|super-transplantation in 3 severe β -thalassemia pediatric patients.|Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
57932268|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
57932269|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
57932270|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
58287088|NCT04285216|OTHER|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
58287089|NCT04142398|OTHER|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
58287090|NCT04142398|PROCEDURE|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
58400471|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
58400472|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
58400473|NCT00330408|BEHAVIORAL|GP training|
58400474|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
58400475|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
58400476|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
58400477|NCT01294306|OTHER|Pharmacological Study|Correlative studies
58400478|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
57932271|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
57932272|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
57932273|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
58070934|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
58070935|NCT02298790|BEHAVIORAL|Meal schedule|
58287091|NCT04142398|OTHER|Laboratory Biomarker Analysis|Correlative studies
58287092|NCT04142398|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
58287093|NCT04142398|PROCEDURE|Physical Examination|Undergo targeted physical exam
58287094|NCT04142398|OTHER|Questionnaire Administration|Ancillary studies
57932274|NCT04412538|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
57932275|NCT04412538|BIOLOGICAL|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
57932276|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
57932277|NCT04164199|DRUG|Pamiparib|Administered orally.
58287095|NCT00104377|BIOLOGICAL|Grass MATA MPL|
58287096|NCT01156805|OTHER|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
58287097|NCT05825963|DIETARY_SUPPLEMENT|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
58287098|NCT02714010|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
58287099|NCT02714010|RADIATION|whole brain radiotherapy|30Gy/10F
58287100|NCT06326086|DRUG|Chemotherapy drug|Chemotherapy drug as prescribed by primary treating physician
58287101|NCT06326086|DRUG|Targeted Agent|Targeted agents as prescribed by primary treating physician
58287102|NCT06326086|DRUG|Immunotherapy|Immunotherapy as prescribed by primary treating physician
57932278|NCT04164199|DRUG|Temozolomide|Administered orally.
57932279|NCT04164199|DRUG|Sitravatinib|Administered orally.
57932280|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
57932281|NCT04164199|DRUG|BAT1706|Administered intravenously.
57932282|NCT04164199|DRUG|Fruquintinib|Administered orally.
57932283|NCT04164199|DRUG|BGB-15025|Administered orally.
57932284|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
57932285|NCT04164199|DRUG|BGB-A445|Administered intravenously.
57932286|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
57932287|NCT04164199|DRUG|Lenvatinib|Administered orally.
57932288|NCT04164199|DRUG|LBL-007|Administered intravenously.
57932289|NCT02193360|DRUG|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
57932290|NCT04663737|DRUG|Silmitasertib|Capsules
57932291|NCT04663737|DRUG|SOC|Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
57932292|NCT06678945|PROCEDURE|Bar-Clip attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
57932293|NCT06678945|PROCEDURE|Bar- OT Equator attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
58287103|NCT03026283|DEVICE|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
58287104|NCT00568893|DRUG|drotrecogin alfa (activated)|
58287105|NCT05289388|DIAGNOSTIC_TEST|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
58287106|NCT02745483|DEVICE|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
58287107|NCT00287456|DEVICE|Insulin Pump|
58287108|NCT00287456|DRUG|Insulin|0
58287109|NCT00287456|PROCEDURE|Oral Glucose Tolerance Test|0
58287110|NCT00287456|PROCEDURE|Whole body Protein Turnover|0
58070936|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
58400479|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
57932294|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
57932295|NCT05976581|BEHAVIORAL|Electronic alert|An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
57932296|NCT05976581|BEHAVIORAL|Structured communication of test results|A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
57932297|NCT05583201|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
58070937|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
58070938|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
58070939|NCT06471686|DRUG|Acamprosate|2 pills three times a day
58070940|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
58287111|NCT00137787|DRUG|ciprofloxacin|
58287112|NCT00137787|DRUG|cefepime|
58287113|NCT01972464|DRUG|Progesterone|oral micronized progesterone
58287114|NCT01972464|DRUG|Placebo|
58287115|NCT06163027|DEVICE|Shotblocker|Shotblocher will be administered during spinal needle injection
58287116|NCT06163027|OTHER|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
58287117|NCT04245618|DRUG|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
58287118|NCT00604747|OTHER|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
58400480|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
58287119|NCT00144560|DRUG|MRA(Tocilizumab)|
58287120|NCT02506062|DEVICE|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
58287121|NCT03972501|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
58287122|NCT03972501|DRUG|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
58287123|NCT04192890|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
58287124|NCT06235320|OTHER|routine clinical treatment of pain with paracetamol or ibuprofen|No intervention beside clinical routine management
58287125|NCT00020202|DRUG|FR901228|
57932298|NCT00518414|OTHER|Marketed infant formula with DHA and ARA|
57932299|NCT00518414|OTHER|Milk-based infant formula with DHA and ARA|
58287126|NCT03845621|DEVICE|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
58287127|NCT03845621|DEVICE|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
58287128|NCT01450514|DRUG|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
58287129|NCT01450514|DRUG|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
58287130|NCT02311608|DRUG|Terlipressin|administered as a first-line medicine or as salvage
58287131|NCT02311608|DRUG|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
58287132|NCT02311608|DRUG|High Dose Somatostatin/Octreotide|administered as salvage
58287133|NCT00048633|DRUG|Chemotherapy|
57932300|NCT00518414|OTHER|Milk-based formula with DHA, ARA, prebiotics|
57932301|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
57932302|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
57932303|NCT06735326|DRUG|Fluzoparib|Fluzoparib capsule (50mg per capsule) 150mg po BID
57932304|NCT06735326|DRUG|Bevacizumab|Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W
57932305|NCT06735326|DRUG|Paclitaxel|Paclitaxel injection 135-175mg/㎡ ivdrip Q3W
57932306|NCT06735326|DRUG|Carboplatin|Carboplatin injection AUC=4-5 ivdrip Q3W
57932307|NCT05122897|DEVICE|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
57932308|NCT05122897|DEVICE|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
58070941|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
58070942|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
58070943|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
58070944|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
58070945|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
58070946|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
58070947|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
58070948|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
58070949|NCT00491062|PROCEDURE|Biopsies|
58070950|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
58070951|NCT00001961|PROCEDURE|MRI|
58070952|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
57932309|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel vehicle|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX® oral gel vehicle) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
58400481|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
57932310|NCT06731777|PROCEDURE|Scaling and root planing plus 0.12% chlorhexidine oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (0.12% chlorhexidine oral gel) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
58070953|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
58070954|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
57932311|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX®) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
57932312|NCT06678438|PROCEDURE|Ultrasound-guided brachial plexus block|The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
57932313|NCT06678438|PROCEDURE|Haematoma Block|Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
57932314|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
57932315|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
57932316|NCT01109329|BIOLOGICAL|HMPV challenge virus|Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
57932317|NCT04600479|DIAGNOSTIC_TEST|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
57932318|NCT04290299|OTHER|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
58070955|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
58070956|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
58070957|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
58070958|NCT00006382|PROCEDURE|comparison of screening methods|
58070959|NCT00006382|PROCEDURE|computed tomography|
58070960|NCT00006382|PROCEDURE|radiography|
58070961|NCT00006382|PROCEDURE|study of high risk factors|
58070962|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
58287134|NCT05006456|DEVICE|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
58287135|NCT01472133|OTHER|Recording of 12 lead ECG|Recording of 12 lead ECG
58070963|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
58070964|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
58070965|NCT04675034|BIOLOGICAL|MEDI7352|Dose A: MEDI7352 Q2W
58287136|NCT01472133|OTHER|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
58400482|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
58400483|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
58400484|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
58400485|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
57729215|NCT06069492|OTHER|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
57729216|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
58070966|NCT04675034|BIOLOGICAL|MEDI7352|Dose B: MEDI7352 Q2W
58070967|NCT04675034|BIOLOGICAL|MEDI7352|Dose C: MEDI7352 Q2W
58070968|NCT04675034|BIOLOGICAL|MEDI7352|Dose D: MEDI7352 Q2W
58070969|NCT04675034|BIOLOGICAL|Placebo|Placebo to match MEDI7352 Q2W
58287137|NCT01472133|OTHER|Recording of chest wall movement|Recording of chest wall movement
58287138|NCT01472133|OTHER|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
58287139|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
58287140|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
57932319|NCT06671730|BEHAVIORAL|8-Week Telehealth-based Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study)
57932320|NCT03228667|DRUG|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
57932321|NCT03228667|DRUG|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
58070970|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
58287141|NCT05772117|BEHAVIORAL|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
58287142|NCT05772117|BEHAVIORAL|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
58287143|NCT05019573|DIETARY_SUPPLEMENT|Black tea|Black tea twice a day for 4 weeks
58287144|NCT05019573|DIETARY_SUPPLEMENT|Placebo|Placebo tea twice a day for 4 weeks
58287145|NCT04536116|DEVICE|Virtual Reality headset|MRI simulation with a Virtual Reality headset
58400486|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
58400487|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
58400488|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
58400489|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
58400490|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
57729217|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
57729218|NCT04993690|DRUG|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
57729219|NCT00023829|DRUG|bicalutamide|
57729220|NCT00023829|DRUG|flutamide|
57729221|NCT00023829|DRUG|releasing hormone agonist therapy|
57729222|NCT00023829|PROCEDURE|adjuvant therapy|
57729223|NCT00023829|RADIATION|radiation therapy|
57729224|NCT00150631|DRUG|Candesartan|placebo controlled double blind
57729225|NCT00738842|DRUG|AZD6140|Oral tablets taken bid for 5 days
57729226|NCT00738842|DRUG|Placebo to match AZD6140|Oral tablets taken bid for 5 days
57729227|NCT05096338|OTHER|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
58287146|NCT05895643|DRUG|Semaglutide Injectable Product|Once weekly injections s.c with semaglutide (Wegovy)
58287147|NCT05895643|DRUG|Placebo|Once weekly injections s.c with placebo (BD Posiflush)
58306832|NCT01474486|DRUG|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
57729228|NCT03197792|OTHER|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
57729229|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
57729230|NCT00125489|DRUG|chloroquine sulfate|
57729231|NCT00125489|DRUG|sulfadoxine/pyrimethamine|
57729232|NCT03661853|BEHAVIORAL|Control|60 minute psycho-education on alcohol and drugs.
57932322|NCT03228667|DRUG|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
57932323|NCT03228667|DRUG|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
57932324|NCT03228667|DRUG|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
57932325|NCT03228667|DRUG|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
57932326|NCT03228667|DRUG|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
57932327|NCT03228667|DRUG|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
57932328|NCT03228667|DRUG|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
57932329|NCT03228667|DRUG|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
58287148|NCT03633253|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
58287149|NCT05435352|PROCEDURE|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
58287150|NCT05102435|OTHER|Tool Translation & Validation study|In this English version of POMA scale will be translated into Urdu.
58287151|NCT00700024|DRUG|Testim|50 mg/dose7day
58400491|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
57932330|NCT03228667|DRUG|N-803 + Docetaxel + Pembrolizumab|The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
58070971|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
58070972|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
58070973|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
58070974|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
58287152|NCT00700024|BEHAVIORAL|Strength training|three times a week
58400492|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
58400493|NCT01795495|DRUG|Remifentanil|
58070975|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
58287153|NCT00700024|DRUG|placebo|placebo
58287154|NCT03222453|BIOLOGICAL|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
58287155|NCT02477436|DRUG|Avanafil|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks."
58400494|NCT02959853|DRUG|Anastrazole|
58400495|NCT02959853|BEHAVIORAL|weight loss|
58400496|NCT06117969|DRUG|Tibolone|1.25mg po qd
58400497|NCT06117969|DRUG|Xiangshao granules|4g po tid
58400498|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
58400499|NCT03618732|OTHER|Bilateral movement-based computer training|
57932331|NCT03228667|DRUG|N-803 + Docetaxel + Nivolumab|The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
57932332|NCT04104321|DRUG|Aramchol free acid|Aramchol 300 mg BID
57932333|NCT04104321|DRUG|Placebo|Placebo BID
57932334|NCT05443594|DEVICE|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
57932335|NCT05443594|DEVICE|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
57932336|NCT01207596|DRUG|Hydromorphone|Oral hydromorphone extended release, once daily
57932337|NCT00504153|DRUG|dasatinib|
58400500|NCT03618732|OTHER|Video-directed conventional training|
58070976|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
58070977|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
58070978|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
58070979|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
58070980|NCT02063802|BEHAVIORAL|Healthy habits program|
58070981|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
58287156|NCT02477436|DRUG|Placebo|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks."
58400501|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
57932338|NCT00504153|OTHER|laboratory biomarker analysis|Correlative studies
57932339|NCT02719431|DRUG|Warfarin|
57932340|NCT02719431|DRUG|K-877|
57932341|NCT01025492|DRUG|Trilipix|135 mg po daily
57932342|NCT01025492|DRUG|placebo|one tablet po daily
58070982|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
58070983|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
58070984|NCT02101216|DRUG|Prurisol|Experimental Drug
58070985|NCT02101216|DRUG|Ziagen|Active comparator
58400502|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
57932343|NCT02374398|DRUG|Tranexamic Acid|see arm/group descriptions
57932344|NCT02374398|DEVICE|Aquamantys System|see arm/group descriptions
57932345|NCT02374398|OTHER|Control|Standard Electro-cautery and Saline
57932346|NCT00668031|DRUG|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
57932347|NCT00668031|DRUG|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
57932348|NCT04187105|DEVICE|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
57932349|NCT04187105|DRUG|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
57932350|NCT04187105|DRUG|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
57932351|NCT04187105|DEVICE|Arm 1|Total body irradiation 2Gy on day -1.
58070986|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
58070987|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
58070988|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
58070989|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
58287157|NCT04288882|DEVICE|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
58287158|NCT02498977|GENETIC|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
58287159|NCT02498977|DRUG|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
58287160|NCT01070433|DRUG|MEBO Wound Ointment (MEBO)|Topical application twice a day
58287161|NCT01070433|OTHER|Standard of Care|Topical application twice a day
58400503|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
58400504|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
58400505|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
58400506|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
58400507|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
58400508|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
58400509|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
58400510|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
58400511|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
58400512|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
58400513|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
58400514|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
58400515|NCT02674919|OTHER|Nordic Hamstring|
58400516|NCT02674919|OTHER|Control|
57729233|NCT03661853|BEHAVIORAL|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
57932352|NCT04187105|OTHER|Arm1|Stem cell infusion on day 0.
57932353|NCT04187105|DRUG|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
58400517|NCT00256035|PROCEDURE|Measuring IL-4 levels|
57932354|NCT04187105|DRUG|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
57932355|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
58287162|NCT02666833|DEVICE|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
58287163|NCT04324528|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
58287164|NCT04324528|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
58287165|NCT06500429|DRUG|NG101|Drug: Including placebo
58287166|NCT06500429|DRUG|Placebo|Drug: Including placebo
58287167|NCT06500429|DRUG|Semaglutide Injectable Product|Semaglutide 0.5 or 1 mg
58287168|NCT00778791|DRUG|metformin HC1 750 mg extended-release tablets|
58400518|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
58400519|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
58400520|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
58400521|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
58400522|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
58400523|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
58400524|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
58400525|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
57729234|NCT03661853|BEHAVIORAL|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
57729235|NCT03661853|BEHAVIORAL|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
57932356|NCT05939440|OTHER|Usual Care|As in Arm description
58287169|NCT00622492|OTHER|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
58400526|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
58400527|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
57729236|NCT06534801|DRUG|Oxycodone will be administered intravenously in the group 1|Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
58070990|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
58070991|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
58070992|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
58070993|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
58070994|NCT04166721|DRUG|Atezolizumab|Immunotherapy
58070995|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
58400528|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
58400529|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
58400530|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
57729237|NCT04575428|DRUG|Splanchnic nerve block|Percutaneous splanchnic nerve block
57729238|NCT00110240|DRUG|vildagliptin|
57729239|NCT01751022|DEVICE|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
57729240|NCT04941300|OTHER|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
57729241|NCT04941300|OTHER|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)"
57729242|NCT06525883|OTHER|No intervation|No intervention was made to the groups
57729243|NCT00841581|DRUG|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
57729244|NCT04511689|DEVICE|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
57729245|NCT01250860|OTHER|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
58400531|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
58400532|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
57729246|NCT01250860|BEHAVIORAL|Sham therapy|
57729247|NCT02626559|DRUG|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
58070996|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
58400533|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
58400534|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
58400535|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
58400536|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
58400537|NCT02627547|BEHAVIORAL|De-training|No training
58400538|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
58400539|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
58400540|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
58400541|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
58400542|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
58400543|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
58400544|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
58400545|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
58400546|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
57932357|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine
57932358|NCT02651051|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
57932359|NCT02651051|OTHER|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
57932360|NCT06704594|DRUG|sertraline 50 mg daily|The intervention will be in the form of an oral pill, taken daily, from the day of positive ovulation result (participants will be taking urine ovulation tests around the days of expected positive ovulation result), until the day of menses onset.
57932361|NCT06704594|DRUG|Placebo Oral Tablet|The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive ovulation result (participants will be taking urine ovulation tests around the days of expected positive ovulation result), until the day of menses onset.
57932362|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
57932363|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
57932364|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
58400547|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
57932365|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
58070997|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
57729248|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
58287170|NCT03529214|BEHAVIORAL|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
58287171|NCT04435899|OTHER|Physical exercise|Multi-modal exercise protocol
58287172|NCT03775967|DIAGNOSTIC_TEST|sialic acid|sialic acid level estimation in salivary samples
57729249|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
57729250|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
57729251|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
57729252|NCT03579459|BIOLOGICAL|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
57729253|NCT03579459|BIOLOGICAL|placebo|Normal saline solution
57729254|NCT06635460|OTHER|Motivational interviewing|This programme has been developed from the literature and structured according to expert opinion. It will consist of a total of 8 online sessions. The duration of the motivational interviewing sessions will be limited to 30-45 minutes, in line with the literature.
57932366|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
57932367|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
58070998|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
58287173|NCT03775967|DIAGNOSTIC_TEST|IL10|IL10 estimation in salivary samples
58287174|NCT06087497|OTHER|Early mobilization|Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
58400548|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
58400549|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
58400550|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
58400551|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
58070999|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
58071000|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
58071001|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
58071002|NCT02457130|DRUG|Ticagrelor|
58071003|NCT02457130|DRUG|Clopidogrel|
58071004|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
58071005|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
58071006|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
58071007|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
58071008|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
58287175|NCT03327857|BIOLOGICAL|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
58400552|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
58400553|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
58400554|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
57729255|NCT06635460|OTHER|Social media-based patient monitoring|Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
57729256|NCT05162820|DIETARY_SUPPLEMENT|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
57729257|NCT05162820|DIETARY_SUPPLEMENT|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
57729258|NCT02451657|OTHER|No Intervention|No intervention was administered in this study
57729259|NCT06444282|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
57729260|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
58071009|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
58071010|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
58071011|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
58071012|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
58071013|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
58095472|NCT03166709|BEHAVIORAL|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
57932368|NCT04379336|BIOLOGICAL|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
57932369|NCT04379336|OTHER|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
58287176|NCT06228235|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings."
57729261|NCT04944342|OTHER|No intervention.|No intervention.
57729262|NCT02105506|DRUG|Tachosil patch|
58287177|NCT04333212|DEVICE|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
58287178|NCT04702451|PROCEDURE|Dispersion ablation + PVI|Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
58287179|NCT04702451|DEVICE|VX1|VX1-based dispersion mapping
58287180|NCT04702451|PROCEDURE|PVI|Pulmonary vein antrum isolation
58287181|NCT04039659|DEVICE|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
58287182|NCT04272047|OTHER|Knee Control+ program|15-20 minute training program to be performed at all team training sessions during the season.
58287183|NCT04272047|OTHER|Adductor strengthening program|Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
57729263|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
57729264|NCT02266628|BIOLOGICAL|Saline Placebo|
57729265|NCT03264872|BEHAVIORAL|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
57729266|NCT03264872|OTHER|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
57729267|NCT02575599|BEHAVIORAL|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
57729268|NCT01735539|DIETARY_SUPPLEMENT|15g EAA bolus|Oral; in aqueous solution
57729269|NCT01735539|DIETARY_SUPPLEMENT|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
57729270|NCT01735539|DIETARY_SUPPLEMENT|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
57729271|NCT00452101|DRUG|Aquamin F|
57729272|NCT05385016|BEHAVIORAL|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
57729273|NCT05385016|BEHAVIORAL|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
57729274|NCT01490177|DRUG|Food proteins|Oral ingestion of Food proteins
57729275|NCT04463641|DEVICE|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
57932370|NCT06734208|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective cohort.
57932371|NCT06655493|OTHER|No treatment given|Participants will continue their normal care and will not get any treatment as part of this study.
57932372|NCT00179504|BEHAVIORAL|Relaxation Response|Relaxation training
57932373|NCT04109950|DRUG|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
57932374|NCT02042430|DRUG|Epacadostat|Given PO
57932375|NCT02042430|OTHER|Laboratory Biomarker Analysis|Correlative studies
57932376|NCT02042430|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57932377|NCT06734845|PROCEDURE|Total Knee Arthroplasty|Total Joint (Knee or Hip) Arthroplasty
57932378|NCT06734845|PROCEDURE|Total Joint Arthroplasty|Participants will be patients undergoing first total knee or total hip replacement
57932379|NCT00324051|DRUG|olanzapine therapy|
58400555|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
58400556|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
58400557|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
58400558|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
58400559|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
58400560|NCT00070876|BEHAVIORAL|Mental health communication skills training|
58400561|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
58400562|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
57932380|NCT04375228|DRUG|Rituximab|375mg/m\^2 IV weekly for 4 doses
58095473|NCT03166709|BEHAVIORAL|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
57729276|NCT06534281|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
57932381|NCT04375228|DRUG|Tocilizumab|4mg/kg IV once a month for up to 2 doses
57932382|NCT06736106|OTHER|screening|Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
57932383|NCT06506461|DRUG|Plerixafor|Given Subcutaneous (under the skin)
57729277|NCT00949247|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
57932384|NCT06506461|DRUG|Busulfan|Given Intravenous (IV)
57932385|NCT06506461|DRUG|Gene-modified CD34+ cells|Given Intravenous (IV)
57729278|NCT00949247|BIOLOGICAL|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
57729279|NCT00949247|DRUG|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
57932386|NCT06734013|DIAGNOSTIC_TEST|Molecular diagnostic|RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
57932387|NCT06283719|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
57932388|NCT04784767|BIOLOGICAL|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
58095474|NCT01747239|DRUG|Cabazitaxel|25 mg/m2 IV every three weeks
58287184|NCT04272047|OTHER|Knee Control program|15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
57932389|NCT04784767|DRUG|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
58400563|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
57729280|NCT00949247|DRUG|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
57932390|NCT04784767|BIOLOGICAL|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
57729281|NCT00949247|OTHER|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
57932391|NCT05255120|OTHER|Intiensified structured perioperative information|The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
58071014|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
58287185|NCT04877899|DEVICE|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
58287186|NCT02834078|DIETARY_SUPPLEMENT|BGG|
58287187|NCT02834078|OTHER|Placebo|
58287188|NCT05076877|DRUG|Lazertinib|Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
58287189|NCT05076877|DRUG|Midazolam|Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
58287190|NCT05076877|DRUG|Rosuvastatin|Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
58287191|NCT05076877|DRUG|Metformin|Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
58287192|NCT04241822|BEHAVIORAL|Vestibular exercises combined with body awareness exercises and cognitive therapy|The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
58287193|NCT04241822|BEHAVIORAL|Exergaming|The intervention consists of different balance exercises using non-immersive virtual reality
58400564|NCT02899650|OTHER|exercise|acute downhill running
57729282|NCT04914572|OTHER|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
58400565|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
58400566|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
58400567|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
58400568|NCT00134992|DRUG|Prednisolone acetate|
58400569|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
58400570|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
58400571|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
57729283|NCT04914572|OTHER|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
57729284|NCT04914572|OTHER|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
57729285|NCT05063344|DEVICE|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
57932392|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
57932393|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
57932394|NCT00960908|DEVICE|Endeavor Resolute stents|2nd generation ZES
57932395|NCT00960908|DEVICE|Endeavor Sprint stent|1st generation ZES
57932396|NCT05240183|DIAGNOSTIC_TEST|Daily SARS-CoV-2 PCR Testing for 10 days|Each participant will undergo daily SARS-CoV-2 PCR testing to assess viral dynamics
58287194|NCT01963507|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
58287195|NCT05301582|DIAGNOSTIC_TEST|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
58287196|NCT02876861|PROCEDURE|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
58287197|NCT02876861|PROCEDURE|Distal ureterectomy|Distal ureterectomy.
58400572|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
58400573|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
58400574|NCT02276352|DRUG|Treatment 1|
58400575|NCT02276352|DRUG|Treatment 2|
58400576|NCT02276352|DRUG|Treatment 3|
58287198|NCT02876861|DRUG|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
57932397|NCT06653426|DIETARY_SUPPLEMENT|Sodium Butyrate (NaBu)|Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
57932398|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
57932399|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
58400577|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
58422792|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
57729286|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
57729287|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
57932400|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
57932401|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
57932402|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
57932403|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
58287199|NCT02716584|BEHAVIORAL|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
58287200|NCT02716584|BEHAVIORAL|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
58071015|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
58287201|NCT04531332|DRUG|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
58287202|NCT04531332|DRUG|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
58287203|NCT01027468|DRUG|Bevacizumab|intraocular bevacizumab injection
58400578|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
57932404|NCT06063317|BIOLOGICAL|CF33-CD19 IT|"Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28-day cycle."
57932405|NCT06063317|BIOLOGICAL|CF33-CD19 IV|"Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle."
58287204|NCT01999764|DRUG|QLT091001|QLT091001 administered orally at multiple time points.
58287205|NCT01999764|OTHER|Placebo|Placebo is administered orally at multiple time points.
58287206|NCT05250986|DEVICE|GoCheck Kids (iOS)|"Visual Acuity method is used to measure of the sharpness or clearness of vision.~Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors."
58287207|NCT05250986|DEVICE|GoCheck Kids (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
58287208|NCT05250986|DEVICE|GoCheck at Home (iOS)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
58287209|NCT05250986|DEVICE|GoCheck at Home (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
58287210|NCT03116295|DRUG|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
58287211|NCT06314360|OTHER|No intervention.|There is no intervention in this study.
58287212|NCT05205980|BEHAVIORAL|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
58287213|NCT01625442|DRUG|Saffron tablet|Saffron tablets 100 mg
58287214|NCT01625442|DRUG|Barberry tablet|Barberry tablets 200 mg
58287215|NCT01625442|DRUG|Placebo|Placebo tablets received daily for 45 days
58400579|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
57932406|NCT06063317|BIOLOGICAL|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
57932407|NCT03599895|PROCEDURE|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
57932408|NCT03599895|PROCEDURE|non 3D printing model|da Vinci robot assisted radical gastrectomy
58287216|NCT06454123|DEVICE|OTX-401|Evidence-based treatments for obesity and binge eating
58287217|NCT05926141|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
58287218|NCT02667314|BEHAVIORAL|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
58287219|NCT02667314|BEHAVIORAL|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
58400580|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
58400581|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
58400582|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
58400583|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
58400584|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
58400585|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
57932409|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
58400586|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
57932410|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
57932411|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 1 sachet|1 dose day to be absorbed sublingually
57932412|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 2 sachet day|1 sachet two times a day to be sublingually absorbed
57932413|NCT06718452|DIETARY_SUPPLEMENT|Placebo|Same administration of PEA-LUT
57932414|NCT06500676|DRUG|GFH375|GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
58287220|NCT00001646|DRUG|Voriconazole|
58287221|NCT00001646|DRUG|Amphotericin B|
58287222|NCT03475758|DRUG|Goserelin|adding goserelin with chemotherapy
58400587|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
58400588|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
58422793|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
57932415|NCT04416061|DIAGNOSTIC_TEST|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
57932416|NCT05577078|PROCEDURE|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
57932417|NCT01748942|DRUG|Dexamethasone|Given IV
57932418|NCT01748942|DRUG|Dexamethasone|Given PO
57932419|NCT01748942|OTHER|Placebo|Given PO
57932420|NCT01748942|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
57932421|NCT01748942|OTHER|Questionnaire Administration|Ancillary studies
57932422|NCT01748942|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
58400589|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
57932423|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
57932424|NCT06735820|DRUG|APG-115|Combination therapy of APG-115 and Selumetinib
57932425|NCT06735820|DRUG|Selumetinib|Combination therapy of APG-115 and Selumetinib
57932426|NCT05500001|BEHAVIORAL|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
57932427|NCT04559828|OTHER|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
57932428|NCT02824731|RADIATION|Radiation with protons|
57932429|NCT02824731|RADIATION|Radiation with photons|
57932430|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
58400590|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
58400591|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
58400592|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
58400593|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
58400594|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
58400595|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
58400596|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
58400597|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
58400598|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
58400599|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
58400600|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
57932431|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
57932432|NCT02094833|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
57932433|NCT02094833|BIOLOGICAL|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
57932434|NCT05614973|PROCEDURE|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
57932435|NCT05614973|PROCEDURE|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
57932436|NCT06314776|OTHER|Usual physiotherapy without Whole-Body Vibration|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
57932437|NCT06314776|OTHER|Pre-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
57932438|NCT06314776|OTHER|Post-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
57932439|NCT03203421|BIOLOGICAL|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
57932440|NCT03203421|BIOLOGICAL|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
57932441|NCT06736223|DRUG|ITF2357|ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
57932442|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
57932443|NCT06077812|BEHAVIORAL|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
57932444|NCT06077812|BEHAVIORAL|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
57932445|NCT06077812|BEHAVIORAL|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
57932446|NCT04454437|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
57932447|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
57932448|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
57932449|NCT06726174|DRUG|ECCEC|0.5-1x10\^6 cells/300 uL, intracameral injection.
57932450|NCT06736210|OTHER|Muscle Elastic Properties Measurement|Using the MyotonPro device, the elastic properties, including stiffness, elasticity, and tone, were evaluated for the tibialis anterior, gastrocnemius medialis, gastrocnemius lateralis, and peroneus longus muscles. Measurements were performed in a controlled laboratory setting.
57932451|NCT06736210|OTHER|Muscle Oxygen Saturation (SmO2)|Muscle oxygenation levels were measured before and after a standardized exercise protocol using the MOXY device. The exercise protocol consisted of a light-intensity dynamic task tailored to minimize fatigue and mimic functional activity.
58287223|NCT02862938|DRUG|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
58287224|NCT02862938|OTHER|Sham|Sham surgery
58287225|NCT05341778|OTHER|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
58287226|NCT05341778|OTHER|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
58287227|NCT05341778|OTHER|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
58287228|NCT05341778|OTHER|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
58287229|NCT05341778|OTHER|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
58287230|NCT05341778|OTHER|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
58287231|NCT05341778|OTHER|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
58287232|NCT05341778|OTHER|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
58287233|NCT05341778|DEVICE|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
57932452|NCT06736210|OTHER|Plantar Pressure Analysis|Plantar pressure was assessed both statically and dynamically using a pressure-mapping platform. This provided data on pressure distribution, contact times, and high-pressure areas across the foot during various conditions.
57932453|NCT05548452|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
58287234|NCT01034228|OTHER|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
58400601|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
58400602|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
58400603|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
57932454|NCT05548452|DRUG|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
57932455|NCT06014242|DIAGNOSTIC_TEST|Peripheral vascular flow reserve measurement|Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
58071016|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
58071017|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
58287235|NCT01034228|OTHER|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
57932456|NCT02495350|OTHER|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
57932457|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
57932458|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
58287236|NCT04504578|PROCEDURE|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
58287237|NCT04919603|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
58287238|NCT04919603|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
58287239|NCT03566381|DEVICE|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
58287240|NCT04039204|DRUG|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
58400604|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
57932459|NCT06593249|OTHER|No Intervention: Observational Cohort|no intervention, observational study
57932460|NCT06735677|BEHAVIORAL|sexual health education|These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
58287241|NCT04039204|DRUG|Ortho Cyclen|Oral contraceptive prescribed by physician.
58400605|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
58400606|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
58400607|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
58400608|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
58400609|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
58400610|NCT00899197|DRUG|tamoxifen citrate|
58400611|NCT00899197|GENETIC|gene expression analysis|
58400612|NCT00899197|GENETIC|protein expression analysis|
58400613|NCT00899197|OTHER|immunoenzyme technique|
58400614|NCT00899197|OTHER|laboratory biomarker analysis|
58422794|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
57932461|NCT05096351|OTHER|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
57932462|NCT04836936|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
57932463|NCT04836936|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
57932464|NCT05615844|DRUG|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
58071018|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
57932465|NCT05615844|DEVICE|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
58400615|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
58400616|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
57932466|NCT01294150|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
57932467|NCT01294150|OTHER|Cystoscopy|The Control Group will undergo cystoscopy.
57932468|NCT01294150|DEVICE|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
58071019|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
58071020|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
58071021|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
58400617|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
57932469|NCT06700356|DEVICE|Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring|Epilepsy monitoring unit evaluation will follow standard of care practices for seizure characterization, and antiseizure medications may be reduced to facilitate the recording of seizures. Patient clinical management, and video-EEG interpretation will be completed by the clinical epilepsy monitoring unit team which consists of physicians, nurse practitioners, registered nurses, and in-house 24-hour 7-days-per-week EEG technicians. Continuous full-bandwidth thalamus recordings (250 Hz) will be acquired by the research study team using a standard clinician programmer and telemetry module. Hospital monitoring will last up to 4 days.
57932470|NCT06700356|DEVICE|Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient|Patients will then transition to the ambulatory phase. In the outpatient setting, patients will have constrained ambulatory thalamus recordings using recording parameters determined by Phase 1. DBS treatment stimulation will be programmed in the clinical epilepsy neuromodulation lab using typical high frequency (\>50 Hz) stimulation. High frequency stimulation is the conventional approach to DBS for epilepsy, as was used in the pivotal study leading to premarket approval (SANTE study)2 of anterior nucleus of the thalamus (ANT) DBS for focal epilepsy, which is typical for epilepsy DBS practice3, and several studies of DBS for generalized epilepsy4-6, in a sensing friendly electrode configuration. Patients will keep a detailed seizure diary. Ambulatory thalamus recordings by the DBS system and patient reported seizure diaries will be collected during routine clinical DBS programming visits (q3-9 months).
57932471|NCT05309668|DRUG|Selumetinib granule formulation|"Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment."
58287242|NCT03290118|OTHER|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
57729288|NCT00581945|DRUG|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
58287243|NCT03290118|OTHER|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
58287244|NCT03290118|OTHER|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
58400618|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
58400619|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
58400620|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
58400621|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
58400622|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
57729289|NCT00581945|DRUG|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
58400623|NCT02761187|OTHER|No Intervention|
58400624|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
58400625|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
58400626|NCT00431522|DRUG|Valproic acid, sodium salt|
58400627|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
58400628|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
58400629|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
58400630|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
58400631|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
58400632|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
58400633|NCT02220855|DRUG|BKM120|
57729290|NCT02061384|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
57729291|NCT02061384|DRUG|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
57729292|NCT01450358|OTHER|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
57729293|NCT05152693|OTHER|Low variety|Meal components are mixed together on the plate
57932472|NCT05309668|DRUG|Selumetinib capsule formulation|Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
58287245|NCT03290118|DEVICE|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
58287246|NCT03351634|DEVICE|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
58287247|NCT03043963|BEHAVIORAL|Sleep Extension|Lengthen the duration of sleep time.
58287248|NCT03043963|BEHAVIORAL|Sleep Timing|Regularize the timing of the sleep period.
58287249|NCT01451099|BIOLOGICAL|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
58287250|NCT06524154|BEHAVIORAL|positive reinforcement|normal treatment with with praising the child with encouraging words and pleasing smiles.
58287251|NCT06524154|BEHAVIORAL|rewarding|normal treatment with giving simple gifts like stickers at the end of the procedure.
58287252|NCT06524154|BEHAVIORAL|contingent escape|normal treatment with giving some rest of the procedure while the child on the chair.
58287253|NCT01748019|DRUG|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
58287254|NCT02211664|DEVICE|Passeo-18 balloon|
58287255|NCT02211664|DEVICE|Passeo-18 Lux drug releasing balloon|
58287256|NCT02211664|DEVICE|Pulsar-18 stent|
58287257|NCT02281955|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
58287258|NCT02281955|DRUG|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
57729294|NCT05152693|OTHER|High Variety|Meal components are served separately on the plate
57932473|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
57932474|NCT05829707|DRUG|Diclofenac Sodium|"A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4"
58287259|NCT02281955|PROCEDURE|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
58287260|NCT00177866|DRUG|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
58287261|NCT00177866|DRUG|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
58287262|NCT03921632|BEHAVIORAL|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
58287263|NCT02511132|BIOLOGICAL|Vigil|Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
58287264|NCT02511132|DRUG|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
58287265|NCT02511132|DRUG|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
58400634|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
58400635|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
57729295|NCT05152693|OTHER|Small Portion Size|Small meal portion size
58287266|NCT02511132|DRUG|Gemcitabine|675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
58287267|NCT02511132|DRUG|Docetaxel|75 mg/m2 IV administered on Day 8 and every 21 days
58287268|NCT01442649|DRUG|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
57729296|NCT05152693|OTHER|Large Portion Size|Large meal portion size
57729297|NCT05152693|OTHER|With Beverage|Meal served with water
57729298|NCT05152693|OTHER|Without Beverage|Meal served without water
58287269|NCT01442649|DRUG|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
58287270|NCT01442649|DRUG|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
58287271|NCT01442649|DRUG|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
58287272|NCT01442649|DRUG|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
58287273|NCT01442649|DRUG|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
58287274|NCT04326387|DIAGNOSTIC_TEST|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
58287275|NCT04326387|DIAGNOSTIC_TEST|Public Health England Gold Standard|Reverse Transcription PCR
58287276|NCT04326387|DIAGNOSTIC_TEST|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
58287277|NCT04326387|DIAGNOSTIC_TEST|Radiological Detection|Chest X-ray \& CT Scan detection of viral infection in the lungs
58287278|NCT02806271|BEHAVIORAL|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
58287279|NCT02806271|BEHAVIORAL|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
58287280|NCT06613178|DRUG|acetaminophen|Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
58287281|NCT01913574|DEVICE|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
58287282|NCT01913574|PROCEDURE|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
58287283|NCT04553081|DRUG|Dual versus triple therapy in treatment of HIV-1 infection.|cfr arm description
58287284|NCT02688803|DRUG|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
58287285|NCT02688803|DRUG|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
58287286|NCT02688803|DRUG|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
58287287|NCT04854057|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
58287288|NCT04854057|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
58400636|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
58422795|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
57729299|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
57729300|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
58287289|NCT04854057|DEVICE|TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice|Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
58287290|NCT06462742|PROCEDURE|Microwave ablation (MWA) versus Liver Resection (LR)|"Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors."
58287291|NCT00143169|DRUG|Parecoxib and placebo|
58287292|NCT00669188|OTHER|Information absent|Information
58287293|NCT00669188|OTHER|Information|Information
58287294|NCT04095325|DEVICE|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
58422796|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
58422797|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
58422798|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
58287295|NCT03944278|DEVICE|Thulium Laser|Thulium laser for skin resurfacing procedures
58287296|NCT01471444|DRUG|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
58287297|NCT01471444|DRUG|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
58287298|NCT01471444|DRUG|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
58287299|NCT01471444|DRUG|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
58287300|NCT01471444|PROCEDURE|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
58287301|NCT01471444|DRUG|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
58287302|NCT01471444|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
58287303|NCT05103800|BEHAVIORAL|invasive interventions|listening the white noise during the invasive interventions
58287304|NCT01353391|DRUG|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
58287305|NCT01353391|DRUG|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
58287306|NCT00132288|BEHAVIORAL|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
58287307|NCT00132288|BEHAVIORAL|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
58287308|NCT05573438|OTHER|Group fructose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
58287309|NCT05573438|OTHER|Group Sucrose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
58287310|NCT05573438|OTHER|Group Glucose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
58287311|NCT05103306|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
58287312|NCT05103306|DRUG|INS|Basal insulin add on the background OADs
58400637|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
58400638|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
58400639|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
58400640|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
58400641|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
58400642|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
58400643|NCT06662058|OTHER|Interview|Ancillary studies
58400644|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
58400645|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
58400646|NCT01792713|DRUG|Sertaconazole 2% cream|
58400647|NCT01792713|DRUG|Placebo|
58400648|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
58400649|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
58400650|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
58400651|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
58400652|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
58400653|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
58400654|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
58400655|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
58400656|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
58400657|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
58400658|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
58400659|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
58400660|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
58400661|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
58400662|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
58400663|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
58071022|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
58400664|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
58400665|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
58400666|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
58400667|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
58400668|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
58400669|NCT04670458|OTHER|no intervention|no intervention
58400670|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
58400671|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
58400672|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
58400673|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
58071023|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
58400674|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
58422799|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
58422800|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
58422801|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
57932475|NCT05829707|DRUG|Levobupivacaine bolus analgesia|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4."
57932476|NCT05829707|DRUG|Levobupivacaine PCA group|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4."
57932477|NCT06736119|BEHAVIORAL|Task Oriented Intervention|Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
57932478|NCT02868970|BIOLOGICAL|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
58071024|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
58071025|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
58071026|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
58287313|NCT04895852|DEVICE|TEAS|The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
58287314|NCT04895852|DEVICE|Sham TEAS|The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
58287315|NCT00078910|DRUG|exisulind|
58400675|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
58400676|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
57729301|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
58071027|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
58071028|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
58071029|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
58071030|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
58071031|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
58071032|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
58071033|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
58071034|NCT00003824|PROCEDURE|surgical procedure|
58400677|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
58400678|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
58422802|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
58422803|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
58287316|NCT00078910|PROCEDURE|conventional surgery|
58287317|NCT00078910|PROCEDURE|neoadjuvant therapy|
57932479|NCT02868970|BIOLOGICAL|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
57932480|NCT02868970|BIOLOGICAL|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
57932481|NCT02868970|BIOLOGICAL|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
57932482|NCT02868970|BIOLOGICAL|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
57729302|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
57932483|NCT02868970|BIOLOGICAL|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
57932484|NCT05552326|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
57932485|NCT05552326|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
57932486|NCT02885194|OTHER|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
57932487|NCT02823626|DRUG|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
57932488|NCT05472961|BEHAVIORAL|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
57932489|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
57932490|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
57932491|NCT06734949|OTHER|AI-guided patient classification|The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.
57932492|NCT05024630|PROCEDURE|Renal artery cryoablation|Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
57932493|NCT05024630|PROCEDURE|Pulmonary vein cryoablation|Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
58287318|NCT02072941|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
58287319|NCT03894475|DEVICE|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
58400679|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
58400680|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
58400681|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
57932494|NCT05024630|PROCEDURE|Renal arteriography|Renal artery was examined by renal arteriography
58287320|NCT03894475|DEVICE|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
57729303|NCT05489926|DRUG|Pamiparib|Pamiparib, 60mg PO BID
57729304|NCT06168708|PROCEDURE|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
57932495|NCT04694508|DEVICE|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
57932496|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
57932497|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
57932498|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
58400682|NCT03554941|DEVICE|noise stimulation|noise stimulation
57932499|NCT04091386|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
57932500|NCT06736080|DRUG|MUNC-CD34|"* Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0"
57932501|NCT06736080|DRUG|MUNC-T3|"* Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion"
57932502|NCT01096212|DRUG|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
57932503|NCT01096212|DRUG|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
57932504|NCT01141088|PROCEDURE|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
57932505|NCT01141088|PROCEDURE|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
57932506|NCT06734130|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) analog|The choice of the standard of care LHRH analog will be at the discretion of the treating physician.
57932507|NCT06734130|DRUG|Androgen Receptor Signal Inhibitor (ARSI)|The choice of the standard of care ARSI will be at the discretion of the treating physician.
57932508|NCT06734130|DRUG|Docetaxel|Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.
57932509|NCT05992623|DEVICE|Zoll external defibrillator|Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
57932510|NCT05992623|DEVICE|Lifepak external defibrillator|Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
57932511|NCT00016380|DRUG|dexamethasone|
57932512|NCT00016380|DRUG|ondansetron|
57932513|NCT00016380|PROCEDURE|quality-of-life assessment|
57932514|NCT04277637|DRUG|BGB-11417|Film-coated tablets administered once daily at a dose as specified in the treatment arm
57932515|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
57932516|NCT04277637|DRUG|obinutuzumab|Given as an intravenous infusion administered per label.
57932517|NCT05085665|DRUG|Ivermectin|single dose, 150 ug/kg
57932518|NCT03760341|PROCEDURE|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
58400683|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
57932519|NCT03760341|PROCEDURE|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
57932520|NCT00450216|DRUG|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
57932521|NCT00450216|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
57932522|NCT04579744|OTHER|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
57932523|NCT05546554|DRUG|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
57932524|NCT05546554|DRUG|Placebo|Matching Placebo given orally
58400684|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
58400685|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
58400686|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
58400687|NCT02450461|OTHER|no intervention|
58400688|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
58400689|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
58400690|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
58400691|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
58400692|NCT03319953|DRUG|TAK-041|TAK-041 suspension
58400693|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
58400694|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
58422804|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
58422805|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
58422806|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
57932525|NCT05211401|DRUG|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
57932526|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
58287321|NCT06402461|BEHAVIORAL|Mindfulness of the breath|A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy
58287322|NCT06402461|BEHAVIORAL|Mindfulness of sounds|A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy
58287323|NCT06402461|BEHAVIORAL|Audiobook control|Listening to a 10 minute extract from an audiobook
58287324|NCT02338401|DIETARY_SUPPLEMENT|Omega-3 Complete|Fish Oil Capsules
58287325|NCT02338401|DIETARY_SUPPLEMENT|Placebo Pill|Olive Oil Capsules
58287326|NCT04310293|OTHER|Femara,Grotwth hormone,HMG|NOVEL THERAPY
58287327|NCT06238219|DRUG|Neuromuscular Blocking Agent|Administration of any neuromuscular blocking agent for surgery under general anesthesia
58287328|NCT02819440|DRUG|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
58400695|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
58400696|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
58400697|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
58400698|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
58400699|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
58400700|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
58400701|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
57932527|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
57932528|NCT03471936|DIAGNOSTIC_TEST|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
58071035|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
58400702|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
58400703|NCT01059682|DRUG|Placebo|Placebo orally once daily
58400704|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
58400705|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
58400706|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
58400707|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
58400708|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
58400709|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
58071036|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
58071037|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
58287329|NCT02819440|DRUG|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
58287330|NCT03886584|OTHER|Monitoring source test|Internal- and external-monitoring correct responses and inversions
58287331|NCT04501952|DRUG|RDV|Administered as an intravenous infusion
58287332|NCT04501952|DRUG|Placebo to Match RDV|Administered as an intravenous infusion
58287333|NCT00019357|BIOLOGICAL|aldesleukin|
57932529|NCT06689618|DEVICE|Exercise|The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
57932530|NCT01938131|DEVICE|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
57932531|NCT06210009|OTHER|DASH-Style Diet|Participants will be randomized to a DASH-style diet
57932532|NCT06210009|OTHER|Western-Style Diet|Participants will be randomized to a Western-style diet
58400710|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
58400711|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
58400712|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
58400713|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
58400714|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
58400715|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
58400716|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
57932533|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
57932534|NCT05683171|DRUG|Rituximab|Given by IV (vein)
58400717|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
58400718|NCT04328753|OTHER|Distilled water|act as a negative control in this study
58400719|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
58400720|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
58400721|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
58400722|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
58400723|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
57729305|NCT06168708|DRUG|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
57729306|NCT06168708|DRUG|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
57729307|NCT06391112|OTHER|Painting Based Art intervention|Painting Based Art Effect of Intervention on Maternal Anxiety and Fetal Parameters
58071038|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
58071039|NCT02318082|DRUG|Interleukin-2|
58287334|NCT00019357|BIOLOGICAL|therapeutic autologous lymphocytes|
58287335|NCT00019357|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58400724|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
58400725|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
58400726|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
58400727|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
58400728|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
58400729|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
57729308|NCT05634226|DEVICE|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
58287336|NCT03504189|DEVICE|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
58400730|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
58400731|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
58400732|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
58400733|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
58400734|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
57729309|NCT03346668|DRUG|Topical gabapentin|topical gabapentin 6% solution
57932535|NCT05683171|DRUG|Lenalidomide|Given by PO
57932536|NCT05683171|DRUG|Valemetostat|Given by PO
57932537|NCT06518681|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
57932538|NCT06138639|GENETIC|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
58071040|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
58071041|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
58071042|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
58071043|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
58287337|NCT03504189|DEVICE|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
58287338|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
58287339|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
58287340|NCT02728817|PROCEDURE|End-cephalic vein to side-radial artery fistula creation|"* Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
58287341|NCT02728817|PROCEDURE|RADAR fistula creation|"* Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
58287342|NCT00401492|DRUG|gemcitabine prolonged continuous infusion|
58287343|NCT00401492|DRUG|cisplatin|
58287344|NCT00401492|DRUG|vinorelbine|
58400735|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
58400736|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
58400737|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
58422807|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
58422808|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
58422809|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
58422810|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
58287345|NCT06045000|DRUG|DC-806|Oral tablets
57729310|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
58287346|NCT06045000|DRUG|[14C]-DC-806|Oral capsules
58287347|NCT06462729|DEVICE|LDGraft|LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
58287348|NCT06462729|DEVICE|LDGraft|LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
58287349|NCT06462729|OTHER|Allograft Bone|Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
58287350|NCT06407492|OTHER|Leech|The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.
58287351|NCT06407492|OTHER|Conventional Physiotherapy|Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
58287352|NCT06407492|OTHER|Kinesiotape|"In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%."
58287353|NCT03061188|OTHER|Laboratory Biomarker Analysis|Correlative studies
58287354|NCT03061188|BIOLOGICAL|Nivolumab|Given IV
58287355|NCT03061188|OTHER|Pharmacological Study|Correlative studies
58287356|NCT03061188|DRUG|Veliparib|Given PO
58287357|NCT06014879|BEHAVIORAL|Teen Videos|All participants in the Teen Videos will create videos about living well with diabetes, which will be used in the the clinical trial of a new behavioral intervention.
58287358|NCT06014879|BEHAVIORAL|Type 1 Doing Well (T1DW) Program|"Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites."
58422811|NCT02064608|DRUG|AZD2014|mTOR inhibitor
58422812|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
58422813|NCT05173961|OTHER|Survey Administration|Complete survey
58422814|NCT04102722|DEVICE|MUST device|Imaging with MUST device
57932539|NCT06095505|DRUG|Alisertib|Alisertib enteric-coated tablets
57932540|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
58071044|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
58422815|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
58422816|NCT00003027|BIOLOGICAL|aldesleukin|
58422817|NCT00003027|BIOLOGICAL|filgrastim|
58422818|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
58422819|NCT00003027|DRUG|cisplatin|
58422820|NCT00003027|DRUG|dacarbazine|
58422821|NCT00003027|DRUG|vinblastine|
58071045|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
58071046|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
58287359|NCT06014879|BEHAVIORAL|Diabetes Care Provider Intervention Delivery|Providers will use data-driven youth profiles to discuss youths' diabetes-related strengths and self-management behaviors during a diabetes care visit. This intervention will occur with the parents and youth once in the 6-month period. After each visit, providers will complete a questionnaire.
58400738|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
58400739|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
58400740|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
58400741|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
58400742|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
58400743|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
58400744|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
58400745|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
58287360|NCT06014879|OTHER|Diabetes-Related Information and Resources Program|Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
58287361|NCT04116775|BIOLOGICAL|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
58287362|NCT04116775|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
58287363|NCT04116775|DRUG|Enzalutamide|Daily oral dose.
58287364|NCT00869128|DRUG|Circadin|2 mg prolonged-release melatonin
58400746|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
58400747|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
58400748|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
58071047|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
58287365|NCT00869128|DRUG|Placebo|
58287366|NCT05924841|DRUG|BL-B01D1|Administration by intravenous infusion
58287367|NCT05924841|DRUG|SI-B003|Administration by intravenous infusion
58287368|NCT02371876|DEVICE|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
58287369|NCT03967041|DIAGNOSTIC_TEST|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
58287370|NCT05834218|OTHER|split body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
58400749|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
58400750|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
58400751|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
58400752|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
58400753|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
58400754|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
58400755|NCT00446823|DEVICE|XCell cellulose wound dressing|
58400756|NCT00446823|DEVICE|Impregnated gauze dressing|
57729311|NCT01753193|BIOLOGICAL|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
57729312|NCT01024387|DRUG|AMG 479|
57729313|NCT02693990|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
58287371|NCT05834218|OTHER|full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
58287372|NCT01839071|PROCEDURE|biopsy|
58287373|NCT00866112|OTHER|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
58287374|NCT00866112|OTHER|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
58287375|NCT00565604|DEVICE|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
58287376|NCT01266005|DRUG|Clevudine|30mg,QD
58287377|NCT01266005|DRUG|Entecavir|0.5mg QD
58287378|NCT03939650|DEVICE|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
58287379|NCT05802303|DRUG|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
58287380|NCT05802303|DRUG|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
58287381|NCT04522570|DEVICE|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
58287382|NCT04522570|DEVICE|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
58287383|NCT04522570|DEVICE|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
58287384|NCT00311753|DRUG|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
58287385|NCT00311753|DRUG|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
58287386|NCT02922465|DRUG|K-877|
58287387|NCT02922465|DRUG|Clopidogrel|
58400757|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
58400758|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
58400759|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
58400760|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
58400761|NCT03802344|DRUG|Vehicle|Vehicle cream
57729314|NCT02095262|OTHER|reactive auditory training|
57729315|NCT02095262|OTHER|Interactive auditory training|
57729316|NCT03087591|OTHER|Laboratory Biomarker Analysis|Correlative studies
57729317|NCT03087591|BIOLOGICAL|siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401|Given IV
58400762|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
58400763|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
58400764|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
58287388|NCT01843803|OTHER|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
58287389|NCT01843803|OTHER|attention control|Patients will view a brief healthy living video on an iPad
58287390|NCT01874626|DRUG|Placebo|Placebo cream
58287391|NCT01874626|DRUG|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
58287392|NCT05122780|PROCEDURE|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
58287393|NCT05122780|DIAGNOSTIC_TEST|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
58287394|NCT05122780|PROCEDURE|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
58287395|NCT05122780|DIAGNOSTIC_TEST|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
58287396|NCT05122780|DIAGNOSTIC_TEST|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
58287397|NCT05122780|DIAGNOSTIC_TEST|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
58287398|NCT05122780|DIAGNOSTIC_TEST|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
58287399|NCT05122780|DIAGNOSTIC_TEST|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
58287400|NCT05122780|DRUG|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
58287401|NCT05122780|DRUG|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
58287402|NCT05122780|DRUG|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
58287403|NCT05122780|DRUG|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
58287404|NCT05122780|DRUG|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
58287405|NCT05122780|DRUG|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
58071048|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
58287406|NCT05122780|DRUG|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
58287407|NCT00460239|DRUG|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
58287408|NCT00460239|DRUG|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
58287409|NCT00460239|DRUG|Placebo|Intramuscular; double blind; once per week
58422822|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
57932541|NCT05410353|BEHAVIORAL|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing \< 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
58071049|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
58071050|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
58287410|NCT04953143|BEHAVIORAL|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~* Therapeutic relationship~* Symptom management~* Coping with illness~* Prognostic awareness and illness understanding~* Treatment decision-making~* End-of-life care"
58287411|NCT06172738|PROCEDURE|the left atrial appendage closure through surgery.|Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
58400765|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58422823|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
57729318|NCT00627705|DRUG|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
58071051|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
58071052|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
58287412|NCT06549738|DEVICE|Intermittent pneumatic compression therapy|Lympha Press Optimal Plus is an advanced intermittent pneumatic compression therapy device. It is FDA cleared (K170658) for the indication of lipedema as well as for other indications for use.
58287413|NCT03558685|BEHAVIORAL|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
58287414|NCT01765569|DRUG|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
58071053|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
58071054|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
58287415|NCT01765569|DRUG|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
58422824|NCT01378429|DRUG|Placebo|Placebo
58422825|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
58422826|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
57729319|NCT00627705|OTHER|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
57729320|NCT00931073|DRUG|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
57729321|NCT00931073|DRUG|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
58400766|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400767|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400768|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
57932542|NCT05410353|BEHAVIORAL|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
57932543|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation A
57932544|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation B
57932545|NCT06631430|DRUG|Placebo|Placebo
57932546|NCT06681922|DRUG|Cyclophosphamide, Bortezomib, Abatacept|Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
57932547|NCT02509897|OTHER|Hypoxic training|Hypoxic training 3 times per week four four weeks
57932548|NCT02509897|OTHER|Normoxic training|Normoxic training 3 times per week four four weeks
57932549|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
57932550|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
57932551|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
57932552|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
57932553|NCT06149156|BEHAVIORAL|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
58287416|NCT04378595|OTHER|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
58287417|NCT04378595|OTHER|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
58287418|NCT00645372|DRUG|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
58287419|NCT00645372|DRUG|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
58287420|NCT00202020|DRUG|Cilostazol 200mg/day Oral|
57932554|NCT06149156|BEHAVIORAL|Well-being Resources|List of well-being resources that comprises of online video links and books
57932555|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
57932556|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
58287421|NCT00202020|DRUG|Aspirin 100mg/day Oral|
58287422|NCT04245176|BEHAVIORAL|Standard Genetic Counseling|Standard genetic counseling: Standard of care discussion
58287423|NCT04245176|BEHAVIORAL|Quantitative Genetic Counseling|Quantitative genetic counseling: Discussion is guided by tables and graphs.
58287424|NCT01269619|DEVICE|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
58287425|NCT01269619|DEVICE|Static back support|A standard wrap-around sacro lumbar support
58287426|NCT02664064|BEHAVIORAL|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
58400769|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400770|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400771|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58422827|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
57729322|NCT00931073|DRUG|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
57729323|NCT01177111|OTHER|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
58071055|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
58422828|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
58400772|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400773|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58400774|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
58071056|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
57932557|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
57932558|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
57932559|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
57932560|NCT04616248|DRUG|Poly ICLC|Given IT
57932561|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
57932562|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
57932563|NCT04616248|DRUG|Pembrolizumab|Given IV
57932564|NCT04616248|DRUG|Tocilizumab|Given SC
57932565|NCT06506604|BEHAVIORAL|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
57729324|NCT01177111|OTHER|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
57729325|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
57729326|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
57729327|NCT05531994|DRUG|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
57932566|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
57932567|NCT06420661|BEHAVIORAL|SPACE for T1D|school-partnered collaborative care model
57932568|NCT06420661|BEHAVIORAL|Enhanced usual care|routine diabetes care with optional monthly insulin dose adjustment
57932569|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
57932570|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
57729328|NCT05531994|DRUG|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
57932571|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
57932572|NCT02905422|BEHAVIORAL|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
57932573|NCT00328744|BEHAVIORAL|Standard|18-month standard behavioral weight loss intervention
57932574|NCT00328744|BEHAVIORAL|Limited Variety|Two chosen snack foods
57932575|NCT06613100|DRUG|Xaluritamig|Intravenous (IV) infusion
58071057|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
58071058|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
58071059|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
58400775|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
58400776|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
58400777|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
58400778|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
57729329|NCT01910519|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
58071060|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
58071061|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
58071062|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
58400779|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
58400780|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
58400781|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
58400782|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
58400783|NCT01730326|DRUG|Paracetamol|1000 mg
58400784|NCT01730326|DRUG|Dexketoprofen|50 mg
58400785|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
58400786|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
58400787|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
58400788|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
58400789|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
58400790|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
58400791|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
58071063|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
58071064|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
58071065|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
58287427|NCT05466292|OTHER|Survey1|Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.
58400792|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
58400793|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
58400794|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
58400795|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
57932576|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
58287428|NCT05466292|OTHER|semi-structured interview_1|the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered
58287429|NCT05466292|OTHER|semi-structured interview_2|semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.
58400796|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
58400797|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
57932577|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
58400798|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
58400799|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
58400800|NCT00349921|DRUG|placebo|inactive substance
58400801|NCT00349921|DRUG|placebo|inactive substance
58400802|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
58400803|NCT01892436|DRUG|Placebo|Placebo
58400804|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
58400805|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
58400806|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
58400807|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
58400808|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
58400809|NCT00001399|DRUG|Transduced CD34+ Cells|
58400810|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
58400811|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
57932578|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
57932579|NCT05323591|DRUG|Filgotinib|Tablets are administered in accordance with the product label
57932580|NCT05551767|DRUG|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
58287430|NCT05466292|OTHER|semi-structured interview_3|semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee
58287431|NCT05466292|OTHER|survey_2|survey of 20 multiple-choice questions and supplemented by free-text questions.
58287432|NCT05951452|OTHER|Blood samples for testosterone and SHBG measurements|"Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
58400812|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
58422829|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
57932581|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
58287433|NCT05951452|OTHER|Saliva samples for oxytocin measurements|"Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
58287434|NCT04817176|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
57729330|NCT01910519|BIOLOGICAL|H5N1 vaccine without adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
57932582|NCT06734871|DRUG|CAR T cells|chimeric antigen receptor T cells
58287435|NCT04817176|OTHER|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
57932583|NCT05874713|BIOLOGICAL|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
58071066|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
57729331|NCT01822860|DRUG|Chlorthalidone 12.5 mg|
57932584|NCT05874713|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
58071067|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
58287436|NCT04516239|DEVICE|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
58287437|NCT04516239|DEVICE|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
58287438|NCT03092947|OTHER|No intervention|
58287439|NCT06612372|BEHAVIORAL|60-day-6° head-down bed rest|Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
58287440|NCT02279290|BEHAVIORAL|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
58287441|NCT02279290|BEHAVIORAL|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
58287442|NCT03943797|BIOLOGICAL|Cultivated oral mucosal epithelial cell transplantation|Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
58287443|NCT03300414|OTHER|One time blood draw|Same as part 1
58287444|NCT01995344|DRUG|Cyclophosphamide|
58287445|NCT01995344|DRUG|Fludarabine|
58287446|NCT01995344|GENETIC|Tumour Infiltrating Lymphocytes|
58400813|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
58400814|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
57729332|NCT01822860|DRUG|Hydrochlorothiazide 25 mg|
58071068|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
57932585|NCT05874713|BIOLOGICAL|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
57932586|NCT05874713|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
58071069|NCT00854776|DRUG|lansoprazole|30 mg once daily
58071070|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
58071071|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
58071072|NCT02434666|DRUG|CPC-201|
58071073|NCT05384756|DRUG|Alemtuzumab|Given IV
58071074|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
58071075|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
58287447|NCT01995344|DRUG|Interleukin-2|
58287448|NCT06611527|DEVICE|PS+PEEP group|Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%
58287449|NCT06611527|DEVICE|CPAP group|Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.
57729333|NCT01822860|DRUG|Placebo|
57729334|NCT05447546|DRUG|HT-6184|Oral capsule
57729335|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
58071076|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
58071077|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
58071078|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
58071079|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
58071080|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
57932587|NCT05874713|BIOLOGICAL|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
57932588|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
58287450|NCT03699371|PROCEDURE|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
58287451|NCT01773629|OTHER|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
58287452|NCT01773629|OTHER|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
58287453|NCT06376617|DEVICE|fibroptic bronchoscopy|take bal through fibrooptic bronchoscopy and send for stain and culcure
58287454|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
58287455|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
58287456|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
58287457|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
58287458|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
58287459|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
58287460|NCT05497297|DRUG|HSK7653 tablets|HSK7653, tablet, oral
57932589|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
58400815|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
57729336|NCT01144312|DRUG|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
57729337|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
57932590|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
57932591|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
57932592|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
58071081|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
58287461|NCT02263378|DRUG|ellagic acid + annona muricata|pills
58287462|NCT03876483|BEHAVIORAL|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
58287463|NCT06593834|DRUG|bacillus coagulans combined with the best treatment options for preventing aGVHD|BAT means the best treatment options for preventing aGVHD
58071082|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
58287464|NCT06593834|DRUG|BAT|BAT
57729338|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
58071083|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
58287465|NCT03183843|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
57729339|NCT03787940|DRUG|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
58071084|NCT02505945|DRUG|Omeprazole|
58287466|NCT03183843|DRUG|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
58287467|NCT02157571|DRUG|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
58071085|NCT02505945|DEVICE|LINX Reflux Management System|
58287468|NCT02157571|DRUG|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
58287469|NCT02157571|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
57729340|NCT00325299|DRUG|Magnesium|
57729341|NCT03769623|DEVICE|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
57729342|NCT03769623|DEVICE|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
58287470|NCT02157571|DRUG|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
58287471|NCT01674465|BIOLOGICAL|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
58400816|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
58400817|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
57729343|NCT00841867|PROCEDURE|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
58400818|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
58287472|NCT00929487|DEVICE|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
58287473|NCT00929487|OTHER|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
57729344|NCT02653521|RADIATION|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
57932593|NCT06734481|DRUG|Sodium bicarbonate pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days. For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage.Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days.
57932594|NCT06734481|DRUG|Saline pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of saline in 7days For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage. Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days..
57932595|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
58287474|NCT00929487|DEVICE|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
58287475|NCT02841475|OTHER|Charlson comorbidity index|Charlson comorbidity index
58287476|NCT02934555|DRUG|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
57932596|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
57932597|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
57932598|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
58287477|NCT02934555|DIETARY_SUPPLEMENT|Ensure|50 mL Ensure
58287478|NCT05686460|BEHAVIORAL|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
58306833|NCT06399601|OTHER|Drug allergy training program|Two identical didactic courses on drug allergy were designed. Each course will last 12 hours and conducted over 2 consecutive days (6 hours each day). All candidates will attend physically and on-site. Various aspects of drug allergy with pre-set learning objectives will be taught in-person by instructors (physicians or nurses specializing in drug allergy nominated by the University of Hong Kong). Course materials and instructors will be identical for each course.
57729345|NCT01877447|DEVICE|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
57729346|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
58400819|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
58400820|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
58400821|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
58400822|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
58400823|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
58400824|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
58400825|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
58400826|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
58400827|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
57729347|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
57729348|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
57729349|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
57729350|NCT01709019|BIOLOGICAL|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
58287479|NCT05686460|BEHAVIORAL|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
58287480|NCT03304106|DEVICE|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
58287481|NCT04075136|DRUG|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
58306834|NCT04775030|DRUG|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
58400828|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
58400829|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
58400830|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
58400831|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
58400832|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
58400833|NCT00004112|BIOLOGICAL|rituximab|
57729351|NCT03399110|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
57729352|NCT03399110|DRUG|Capecitabine|Capecitabine 1000mg/m2
57729353|NCT03116919|OTHER|Potato|Participants will be given an extra serving of potato a day
58306835|NCT04775030|DEVICE|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
57729354|NCT03116919|OTHER|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
57932599|NCT06575738|DRUG|Injectable semaglutide|Subcutaneous weekly injectable semaglutide
57932600|NCT06575738|BEHAVIORAL|Usual postoperative care|Usual postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
57932601|NCT06735976|DEVICE|PAVM Embolization|This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.
57932602|NCT06735976|DEVICE|PAVM Embolization with a LOBO™ device|Participants will undergo PAVM embolization with the LOBO™ device per standard of care.
57932603|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
57932604|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
57932605|NCT06534437|DRUG|MEN1703|MEN1703 is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
57932606|NCT06534437|DRUG|Glofitamab|Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
57932607|NCT05837182|PROCEDURE|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
57932608|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
57932609|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
57932610|NCT03769766|DRUG|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
58287482|NCT04075136|DEVICE|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
58287483|NCT04075136|DRUG|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
58287484|NCT04075136|DRUG|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
58400834|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
58400835|NCT00004112|DRUG|cyclophosphamide|
58287485|NCT01942876|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
58287486|NCT01942876|BEHAVIORAL|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
58287487|NCT01463800|BEHAVIORAL|Structured exercise training|12 weeks low level ambulatory structured exercise training
58287488|NCT00657657|BIOLOGICAL|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
57729355|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
58287489|NCT02827175|OTHER|blood sample|
57932611|NCT03769766|DRUG|Placebo|Take medication one 500mg pill twice daily
57932612|NCT06735170|PROCEDURE|biologic tuberoplasty|a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain
57932613|NCT06735170|PROCEDURE|subacromial balloon spacer|a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
57932614|NCT06476314|DEVICE|Virtual Reality Glasses Group|Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
58400836|NCT00004112|DRUG|doxorubicin hydrochloride|
58400837|NCT00004112|DRUG|prednisone|
58400838|NCT00004112|DRUG|vincristine sulfate|
58400839|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
58400840|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
57932615|NCT06476314|DEVICE|Stress Ball Group|Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
57932616|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
57932617|NCT04486157|DRUG|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
57932618|NCT04486157|DRUG|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
58071086|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
57932619|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
58071087|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
57932620|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
58071088|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
58071089|NCT04391894|DRUG|ECF843|Topical ocular eye drop
58071090|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
58071091|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
58071092|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
58071093|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
58287490|NCT03965520|BEHAVIORAL|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
58287491|NCT02800005|DEVICE|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
58287492|NCT02800005|OTHER|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
58287493|NCT00970671|OTHER|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
58287494|NCT00970671|OTHER|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
58287495|NCT00970671|OTHER|No treatment|No laser treatment
58400841|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
57729356|NCT04749719|DEVICE|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
57729357|NCT01628276|BEHAVIORAL|Cog Rehab|Cognitive rehab for MS patients
58287496|NCT05358990|OTHER|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
58287497|NCT05358990|OTHER|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
58287498|NCT04717089|OTHER|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A\&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
58287499|NCT05165719|DIAGNOSTIC_TEST|Corona-T-test|Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
58287500|NCT01443234|OTHER|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
58400842|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
58400843|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
58400844|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
58400845|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
58400846|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
58071094|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
58071095|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
58071096|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
58071097|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
58071098|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
58071099|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
58071100|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
58071101|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
58071102|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
58071103|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
57729358|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
57729359|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
57729360|NCT00084058|DRUG|Lopinavir/ritonavir|
57932621|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
57932622|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
58071104|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
58071105|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
58071106|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
57729361|NCT00084058|DRUG|Saquinavir|
57729362|NCT00714168|BEHAVIORAL|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
58071107|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
58071108|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
58071109|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
58071110|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
58071111|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
58071112|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
57729363|NCT00714168|BEHAVIORAL|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
57729364|NCT02265237|DRUG|ombitasvir/paritaprevir/ritonavir|tablets
57729365|NCT02265237|DRUG|ribavirin|tablets
57729366|NCT02446808|DEVICE|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
57729367|NCT03305120|OTHER|pain VAS evaluation|each patient has to answer to a questionnaire about pain
58071113|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
58071114|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
58071115|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
58071116|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
58071117|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
58400847|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
58400848|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
57932623|NCT06735053|OTHER|Virtual Reality group|Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.
57932624|NCT06735053|OTHER|Placebo virtual reality group|The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
58071118|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
58071119|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
57932625|NCT06548360|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
58071120|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
58071121|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
58071122|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
58071123|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
58071124|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
58071125|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
58071126|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
58071127|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
58071128|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
58071129|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
58071130|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
58071131|NCT02487524|OTHER|QST|Quantitative sensory testing.
58287501|NCT01443234|OTHER|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
58400849|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
58071132|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
58071133|NCT02503956|PROCEDURE|Crawford tube insertion|
58071134|NCT02503956|DEVICE|Crawford lacrimal tube|
58287502|NCT00352625|DRUG|Ketoprofen Topical Patch 20%|
58287503|NCT03159299|BEHAVIORAL|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
58287504|NCT00391872|DRUG|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
58400850|NCT05441683|PROCEDURE|horizontally extending incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the Intrasulcular incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
58400851|NCT05441683|PROCEDURE|vertical releasing incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the intrasulcular incision before a full-thickness flap is lifted.
58287505|NCT00391872|DRUG|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
58071135|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
58071136|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
58071137|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
58400852|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
57932626|NCT06548360|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
57932627|NCT04047797|DRUG|Ixazomib|Given by mouth
58071138|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
58071139|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
58071140|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
58071141|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
58071142|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
58071143|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
58071144|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
58071145|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
58071146|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
58071147|NCT04337463|DRUG|ATG-008|Tablet
58071148|NCT04337463|DRUG|Toripalimab|IV infusion
58287506|NCT02807831|BEHAVIORAL|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
58287507|NCT02807831|BEHAVIORAL|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
58287508|NCT02807831|OTHER|Regular school curriculum|Ministry of Education national school curriculum.
58287509|NCT01888952|DRUG|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
58287510|NCT01888952|DRUG|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
58287511|NCT05314777|PROCEDURE|Low dose ESWT application|Patients trained for low dose ESWT application.
58287512|NCT05314777|PROCEDURE|High dose ESWT application|Patients trained for high dose ESWT application.
58400853|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
58400854|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
58400855|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
58400856|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
57932628|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
57932629|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
57932630|NCT04192435|DRUG|Tranexamic Acid|100mg/ml
57932631|NCT04192435|DRUG|Placebos|Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
57932632|NCT03715088|BEHAVIORAL|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
58071149|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
58071150|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
58071151|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
58287513|NCT05314777|PROCEDURE|Sham ESWT|Patients trained for sham ESWT.
58287514|NCT05314777|PROCEDURE|Exercise Training|Patients trained for exercise training.
57932633|NCT06736132|DEVICE|High-flow nasal oxygen|In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.
57932634|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
57932635|NCT06679413|DRUG|midazolam|Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
57932636|NCT06679413|DRUG|metformin|Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
57932637|NCT06679413|DRUG|bupropion|Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
57932638|NCT06679413|DRUG|fenfluramine HCl|Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
57932639|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
57932640|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
58400857|NCT05695261|DRUG|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
57932641|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
57932642|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
57932643|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
58071152|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
58400858|NCT05695261|OTHER|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
57729368|NCT03178552|DRUG|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
57932644|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
58400859|NCT05695261|OTHER|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
57932645|NCT06735066|PROCEDURE|Ascending urethrocystography|"It will be performed after instructing the patient to evacuate the bladder. A contrast agent will be infused through the urethra under fluoroscopy, using a urethral catheter or Knutson's clamp at the external urethral meatus. When the bladder is full, an anteroposterior film and two oblique films will be taken. Voiding cystourethrography will be performed as a part of this imaging examination. From this procedure, the following findings may be diagnosed:~* Upper urinary tract: Vesicoureteral reflux (VUR); laterality and degrees of VUR will be defined.~* Bladder: Capacity (defunctionalized, Small-sized or contracted bladder), neurogenic bladder, bladder diverticulum, filling defects, etc.~* Urethra: Stricture and filling defects."
57932646|NCT06226285|DEVICE|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
57932647|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
57932648|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
57932649|NCT05285683|DRUG|Methylphenidate|0.5 mg/kg
57932650|NCT05285683|DRUG|carbidopa-levodopa|25 mg/100 mg
57932651|NCT05285683|DRUG|Placebo|oral pill
57932652|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
57932653|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
57932654|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
57932655|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
57932656|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
58071153|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
58071154|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
58071155|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
58071156|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
58400860|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
58400861|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
57932657|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
57932658|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
57729369|NCT03178552|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
57932659|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
57932660|NCT03914742|DRUG|Temozolomide|Given PO
58071157|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
58071158|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
58071159|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
58071160|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
57932661|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
58287515|NCT01443741|OTHER|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
58287516|NCT05693753|DEVICE|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
58287517|NCT05693753|PROCEDURE|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
58287518|NCT03774888|PROCEDURE|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
58400862|NCT04867720|DRUG|Everolimus|- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
58400863|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
58287519|NCT03774888|PROCEDURE|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
58287520|NCT03774888|PROCEDURE|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
58287521|NCT02494856|DRUG|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
58400864|NCT00538967|DRUG|doxycycline|2 weeks once daily
58400865|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
58400866|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
58400867|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
58400868|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
57729370|NCT03178552|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
58287522|NCT02494856|DRUG|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
57729371|NCT03178552|DRUG|Cisplatin|Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
57932662|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
57932663|NCT00298168|DRUG|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
57932664|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
58287523|NCT00005587|RADIATION|radiation therapy|
58400869|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
58400870|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
58400871|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
58400872|NCT00349323|BEHAVIORAL|Community directed treatment|
57932665|NCT06736249|DIAGNOSTIC_TEST|Sarcopenic group|The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.
57932666|NCT06736249|OTHER|Muscle harvesting|A piece of discarded muscle during surgery will be collected
58400873|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
58400874|NCT03898466|OTHER|Matching placebo|Placebo inhaler
58400875|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
58400876|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
58400877|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
57932667|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
57932668|NCT04408014|DIAGNOSTIC_TEST|Serological test|IgM and IgG for SARS-CoV-2
58287524|NCT05764954|DEVICE|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
58287525|NCT05916807|OTHER|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
57932669|NCT04408014|DIAGNOSTIC_TEST|Nasopharyngeal Swab|PCR for SARS-CoV-2
58287526|NCT05916807|OTHER|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
58400878|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
58400879|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
58400880|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
58287527|NCT03163537|DEVICE|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
58287528|NCT01730716|DEVICE|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
58287529|NCT05003869|PROCEDURE|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
58287530|NCT05498597|DRUG|AMT-151|Administered intravenously
58287531|NCT00519467|DRUG|Chlorproguanil-dapsone-artesunate (CDA)|
58287532|NCT05398796|BIOLOGICAL|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
58287533|NCT03731390|DRUG|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
58287534|NCT01060917|DEVICE|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
58287535|NCT01060917|PROCEDURE|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
58400881|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
58400882|NCT06145633|PROCEDURE|Biopsy|Undergo biopsy
57729372|NCT03178552|DRUG|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
57729373|NCT03178552|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
58287536|NCT01060917|DEVICE|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
57729374|NCT03178552|DRUG|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
57932670|NCT04408014|DIAGNOSTIC_TEST|Oropharyngeal Swab|PCR for SARS-CoV-2
57932671|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
57932672|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
57932673|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 14 day
57932674|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + low dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 2 times/day, oral, for 14 day
57932675|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 10 day
58306836|NCT04722562|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
57932676|NCT06686394|BIOLOGICAL|Patritumab deruxtecan|Patritumab deruxtecan administered via IV infusion
57932677|NCT06686394|BIOLOGICAL|Trastuzumab|Trastuzumab administered via IV infusion
58287537|NCT00884078|OTHER|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
58400883|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample colleciton
58287538|NCT02913781|PROCEDURE|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
58400884|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
58400885|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, SPECT/CT, PET/CT
57932678|NCT06686394|BIOLOGICAL|Trastuzumab Biosimilar|Trastuzumab biosimilar administered via IV infusion
57932679|NCT06686394|BIOLOGICAL|Pertuzumab|Pertuzumab administered via IV infusion
57932680|NCT06686394|BIOLOGICAL|Tucatinib|Tucatinib administered as oral tablets
58400886|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
58400887|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
57932681|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
57932682|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
58287539|NCT02913781|PROCEDURE|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
57932683|NCT06138782|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
57932684|NCT06736158|GENETIC|Genetic testing for inherited bleeding disorders|Gene panel for bleeding: This analysis will look at a list of genes known to be associated with rare coagulation, platelet, connective tissue, and bleeding disorders. There are currently 318 genes on the panel however this list may be updated throughout the study. Genes of study include those on the the International Society of Thrombosis and Haemostasis (ISTH) TIER-1 and TIER-2 gene list, as well as additional genes identified in published research.
57932685|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
57932686|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
57932687|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
58287540|NCT06033261|BIOLOGICAL|mRNA-1608|Sterile liquid for injection
58287541|NCT06033261|BIOLOGICAL|BEXSERO|A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.
58287542|NCT00647595|BEHAVIORAL|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
58287543|NCT04035499|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
58287544|NCT04693078|DEVICE|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
58287545|NCT00810498|DEVICE|Trilogy|Exposure for one hour on the Trilogy ventilator
57932688|NCT00041054|DRUG|carboplatin|
57932689|NCT00041054|DRUG|etoposide|
58400888|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
58400889|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
58400890|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58400891|NCT06145633|DRUG|Vorinostat|Given IV
58400892|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
58400893|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
58400894|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
58400895|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
58400896|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
58400897|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
58400898|NCT00620256|DRUG|Latanoprost ophthalmic solution|
57729375|NCT03178552|DRUG|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
57932690|NCT00041054|DRUG|exisulind|
57932691|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
57932692|NCT02338011|DRUG|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
57932693|NCT02338011|RADIATION|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
58400899|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
57932694|NCT06145724|BEHAVIORAL|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
57932695|NCT05553366|DRUG|VX-548|Tablets for oral administration.
58071161|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
58071162|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
58071163|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
58071164|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
58071165|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
58071166|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
58071167|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
58071168|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
57932696|NCT05553366|DRUG|HB/APAP|Capsules for oral administration.
57932697|NCT05553366|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
57932698|NCT05553366|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
57932699|NCT05728502|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
57932700|NCT05728502|DRUG|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
57932701|NCT06718907|BEHAVIORAL|Simulated stimuli|Participants will be exposed to a video stimuli in order to assess biophysiological and physiological responses to the stressor and relaxant.
57932702|NCT06718907|BEHAVIORAL|Stress Management|Participants will practice stress management and stress reduction at home, independently.
58071169|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
58071170|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
58071171|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
58071172|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
58071173|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
58287546|NCT00810498|DEVICE|Standard of Care|Exposure to participants current ventilator
58287547|NCT01018914|DRUG|Prograf|oral
58287548|NCT01018914|DRUG|Advagraf|oral
58287549|NCT01018914|DRUG|Myfortic|oral
57932703|NCT06675565|DRUG|ALN-AGT01 RVR|ALN-AGT01 RVR will be administered subcutaneously (SC)
57932704|NCT06675565|DRUG|Placebo|Placebo will be administered SC
57932705|NCT06735261|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
57932706|NCT06734741|DIAGNOSTIC_TEST|COVID/Flu Detect™ Rapid Self-Test|The COVID/Flu Detect™ Rapid Self-Test is an investigational qualitative lateral flow immunoassay designed for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. It is intended for non-prescription over-the-counter (OTC) use.
57932707|NCT05001880|BIOLOGICAL|Atezolizumab|Given IV
57932708|NCT05001880|BIOLOGICAL|Bevacizumab|Given IV
57932709|NCT05001880|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
57932710|NCT05001880|DRUG|Carboplatin|Given IV
57932711|NCT05001880|PROCEDURE|Computed Tomography|Undergo CT scan
57932712|NCT05001880|PROCEDURE|Cytoreductive Surgery|Undergo surgery
57932713|NCT05001880|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
57932714|NCT05001880|DRUG|Pemetrexed|Given IV
57932715|NCT05001880|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57932716|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
58071174|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
58071175|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
58071176|NCT02303470|BEHAVIORAL|Moderate Exercise|
58071177|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
58071178|NCT02382419|OTHER|Placebo|Applied vaginally
58071179|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
58306837|NCT00686972|DRUG|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
58071180|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
58071181|NCT03244280|DRUG|MOB015B|Topical formulation
58071182|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
58071183|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
58400900|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
58400901|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
58400902|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
58400903|NCT02584543|BIOLOGICAL|HEV vaccine|
58400904|NCT02584543|BIOLOGICAL|HBV vaccine|
58400905|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
58400906|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
57932717|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
57932718|NCT05621616|DRUG|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
57932719|NCT06487858|DRUG|BGB-R046|Intravenous administration
58071184|NCT04235673|DRUG|placebo|orally administered drops
58071185|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
58071186|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
58071187|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
58071188|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
58287550|NCT00494429|DRUG|Morphine|Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
58287551|NCT00494429|DRUG|Morphine|Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
58400907|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
57932720|NCT06487858|DRUG|Tislelizumab|Intravenous administration
58071189|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
58071190|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
58306838|NCT01387269|DRUG|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
58400908|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
58400909|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
58400910|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
58400911|NCT01689012|BEHAVIORAL|Facial Exercise|
58400912|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
58400913|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
57932721|NCT03399409|BEHAVIORAL|Motivational Interviewing|Motivation techniques
57932722|NCT03399409|BEHAVIORAL|Anti-inflammatory Information|Provision of information on anti-inflammatory products
57932723|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
58287552|NCT05534828|DIAGNOSTIC_TEST|A consultation|A consultation at three months of discharge from the intensive care unit in the population of patients surviving a multivalent intensive care unit stay
58287553|NCT05372185|BEHAVIORAL|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
58287554|NCT05372185|BEHAVIORAL|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
58287555|NCT02634619|PROCEDURE|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
58287556|NCT02634619|PROCEDURE|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
58287557|NCT05621850|OTHER|Blood sample|Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
57932724|NCT05267587|RADIATION|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
57932725|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
57932726|NCT06360796|DRUG|[(14)C]ADC189|Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
57932727|NCT05756153|DRUG|GFH925|GFH925 tablets administered orally daily.
58287558|NCT05593653|DRUG|Suvorexant|20mg taken at bedtime for 4 weeks
58287559|NCT05593653|DRUG|Placebo|placebo taken at bedtime for 4 weeks
58287560|NCT02697916|DRUG|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
58287561|NCT05298683|DRUG|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
58287562|NCT05298683|DRUG|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
58287563|NCT05298683|DRUG|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
58400914|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
58400915|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
58400916|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
58400917|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
57932728|NCT05756153|DRUG|Cetuximab|Cetuximab administered intravenously Q2W.
57932729|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
57932730|NCT05152927|DEVICE|Parathyroid Eye (PTeye)|Intraoperative Tool
57932731|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
57932732|NCT04274764|BEHAVIORAL|Personalized eHealth Education & Motivational Interviewing|This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web- based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
58400918|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
58400919|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
57729376|NCT03178552|DRUG|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
57932733|NCT04109365|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
58071191|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
57729377|NCT03178552|DRUG|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
58400920|NCT00190021|DRUG|donepezil|
57932734|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
58400921|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
58400922|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
57932735|NCT05540574|DRUG|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
57932736|NCT05540574|DRUG|Placebo|Matching Placebo given orally
57932737|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
57932738|NCT00233363|DRUG|Rebamipide|
57932739|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
57932740|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
58071192|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
58071193|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
58400923|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
57729378|NCT03178552|DRUG|Divarasib|Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
57729379|NCT03178552|DRUG|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
57729380|NCT06213025|BEHAVIORAL|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
57729381|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
57729382|NCT03032926|BEHAVIORAL|Open Trial|Behavioral Intervention
57729383|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
57932741|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
57932742|NCT06735560|RADIATION|89Zr-TLX250 PET/CT|Patients will receive 89Zr-TLX250 for detection of CAIX-expressing tumor by PET imaging.
57932743|NCT04711668|DRUG|Ketamine|intraoperative ketamine bolus and infusion
57932744|NCT04711668|DRUG|Lidocain|intraoperative lidocain bolus and infusion
57932745|NCT04711668|DRUG|Saline|intraoperative saline bolus and infusion
57932746|NCT00659893|DRUG|PEP005 Topical gel|0.05%, two day dose
57932747|NCT06734494|DEVICE|Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation|Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
57932748|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
58071194|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
58071195|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
58071196|NCT04563845|DRUG|Placebo|Placebo will be administered.
58071197|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
58071198|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
58400924|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
58400925|NCT00255138|DRUG|Atomoxetine|
58400926|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
58400927|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
58400928|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
58071199|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
58071200|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
58071201|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
58071202|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
58071203|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
58287564|NCT05298683|DRUG|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
58287565|NCT05298683|DRUG|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
58287566|NCT05298683|DRUG|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
58400929|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
57932749|NCT03652259|GENETIC|SRP-9003|SRP-9003 will be administered through a single systemic injection.
57932750|NCT03226704|PROCEDURE|Leukapheresis|Leukapheresis
58071204|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
58071205|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
58071206|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
58071207|NCT02581657|DRUG|Placebo Injection|Placebo Injection
58287567|NCT04589884|OTHER|Hyperspectral Imaging|Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
58287568|NCT02927054|OTHER|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
58287569|NCT00806858|DEVICE|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
58400930|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
58400931|NCT00283270|BEHAVIORAL|Brief counselling|
58400932|NCT00283270|BEHAVIORAL|Behavior|
58400933|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
57932751|NCT05978180|DEVICE|Medical Device : HO-1|The injection will be performed at Day 1.
57932752|NCT05978180|DEVICE|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
58400934|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
57932753|NCT05978180|DEVICE|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
57932754|NCT04202250|PROCEDURE|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
58071208|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
58287570|NCT03541148|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
58287571|NCT05613959|DEVICE|Veress +|The Veress+ safety mechanism was used
58287572|NCT05613959|DEVICE|Conventional Veress|The Conventional Veress Needle was used
57932755|NCT04202250|PROCEDURE|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
58287573|NCT00458861|BIOLOGICAL|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
58287574|NCT00458861|OTHER|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
58400935|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
57729384|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
57729385|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
57932756|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
57932757|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
58071209|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
58287575|NCT03608813|OTHER|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
58287576|NCT04833062|DIAGNOSTIC_TEST|Ultrasound|In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
58287577|NCT04833062|OTHER|Survey|"The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI."
58306839|NCT01387269|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
58400936|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
58400937|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
58400938|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
58400939|NCT02084706|DRUG|2% Lidocaine|
58400940|NCT02084706|DRUG|Triamcinolone (20 g)|
58400941|NCT02084706|PROCEDURE|J-tip lidocaine administration|
58400942|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
58071210|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
58287578|NCT01166711|DEVICE|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
58287579|NCT01166711|DEVICE|Coroflex Please (DES)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type"
58287580|NCT05542251|BEHAVIORAL|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
58287581|NCT00730574|DIETARY_SUPPLEMENT|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
58287582|NCT02122315|OTHER|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
58287583|NCT02122315|OTHER|Physical therapy|Best-evidence physical therapy intervention
58287584|NCT05230355|DEVICE|360 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied along 360 degrees over pars plana
58287585|NCT05230355|DEVICE|180 degrees subthreshold diode laser cyclophotocoagulation|cyclophotocoagulation is applied over one hemisphere only along 180 degrees in a double arc fashion
58287586|NCT06609408|OTHER|Nature and Game Based Activities|Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
58287587|NCT01302795|DRUG|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
58287588|NCT03182881|OTHER|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
58287589|NCT03182881|OTHER|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
58287590|NCT03107208|DRUG|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
58400943|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
58400944|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
57729386|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|Facial acne lesions will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer to the whole face. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
57729387|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
57932758|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
57932759|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
58287591|NCT03107208|DEVICE|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
58287592|NCT00498953|DRUG|carboplatin|
58287593|NCT00498953|DRUG|cisplatin|
58287594|NCT00498953|DRUG|docetaxel|
58400945|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
58400946|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
58400947|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
58400948|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
58400949|NCT00144248|DRUG|nevirapine|
58400950|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
57932760|NCT00096057|BIOLOGICAL|monoclonal antibody HuHMFG1|
57932761|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
57932762|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
57932763|NCT05406752|DRUG|paracetamol Uniflash (125 mg/ 1.25 mL)|Oromucosal solution (125 mg/ 1.25 mL) for buccal route
58287595|NCT00498953|DRUG|fluorouracil|
58287596|NCT00498953|DRUG|lapatinib ditosylate|
58287597|NCT00498953|GENETIC|cytogenetic analysis|
58287598|NCT00498953|GENETIC|fluorescence in situ hybridization|
58287599|NCT00498953|GENETIC|in situ hybridization|
58287600|NCT00498953|GENETIC|polymerase chain reaction|
58287601|NCT00498953|GENETIC|reverse transcriptase-polymerase chain reaction|
58287602|NCT00498953|OTHER|immunohistochemistry staining method|
58287603|NCT00498953|OTHER|laboratory biomarker analysis|
58287604|NCT00498953|PROCEDURE|conventional surgery|
58287605|NCT00498953|PROCEDURE|neoadjuvant therapy|
58287606|NCT00498953|RADIATION|fludeoxyglucose F 18|
58287607|NCT00498953|RADIATION|radiation therapy|
58287608|NCT04969783|OTHER|Ventilated Cigarette Filter|Ventilated Cigarette Filter
58287609|NCT04969783|OTHER|Unventilated Cigarette Filter|Unventilated Cigarette Filter
58287610|NCT05660668|OTHER|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
58287611|NCT05660668|OTHER|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
57729388|NCT05923944|BEHAVIORAL|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
57932764|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
57932765|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
57932766|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
57932767|NCT01182766|DRUG|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
57932768|NCT01182766|DRUG|Placebo with brief behavioral enhancement therapy|placebo
58287612|NCT02959333|BIOLOGICAL|hAEC|hAEC: human amniotic epithelial cells
58287613|NCT00116714|DRUG|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
58287614|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
58287615|NCT06015230|BIOLOGICAL|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
58287616|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
58287617|NCT06015230|BIOLOGICAL|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
58287618|NCT06015230|BIOLOGICAL|Placebo in phase Ⅱ|Placebo
58400951|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
58400952|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
58400953|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
58400954|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
57932769|NCT04650724|DRUG|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
57932770|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
57932771|NCT06222697|DRUG|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
58306840|NCT05139342|DEVICE|expiratory muscle strentgh training (EMST)|"All patients undergo EMST training, and results will be compared between groups.~After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days."
58306841|NCT04350593|DRUG|Dapagliflozin 10 milligram (mg)|Active Comparator: Dapagliflozin 10 mg
58306842|NCT04350593|DRUG|Placebo|Placebo Comparator
58306843|NCT02618746|OTHER|Telerehabilitation|
58306844|NCT02618746|OTHER|Hospital based Rehabilitation|
58400955|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
57932772|NCT06734676|DEVICE|Intermittent theta burst stimulation (iTBS)|iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
58400956|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
58400957|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
57932773|NCT04624880|DEVICE|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
57932774|NCT06519773|PROCEDURE|Modified periosteal inhibition|"After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant provided by Auto Fit Dental Implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A bone lamina and provided by GRANNTIE 1 mm thickness will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone."
57932775|NCT05078619|PROCEDURE|No PCI|Omission of PCI of significant coronary artery disease prior to TAVI
57932776|NCT03412045|DEVICE|hyperbaric oxygen therapy|hyperbaric oxygen therapy applied to patients in vaso-occlusive crisis
57932777|NCT02612051|DRUG|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
57932778|NCT02612051|DRUG|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
57932779|NCT02612051|RADIATION|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
58306845|NCT06550726|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
58400958|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
58400959|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
58400960|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
58400961|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
57729389|NCT05923944|BEHAVIORAL|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
57932780|NCT05794412|OTHER|No intervention|No intervention
58306846|NCT02766543|DEVICE|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
58306847|NCT02078817|DRUG|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
58400962|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
58400963|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
58400964|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
58400965|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
58400966|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
58400967|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
57729390|NCT06128616|DEVICE|ESWT|Extracorporeal Shock Wave Therapy
57729391|NCT06128616|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
57729392|NCT06128616|OTHER|Serial Casting|Serial Casting
57729393|NCT06128616|BEHAVIORAL|Physical Therapy|Physical Therapy
57932781|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
57932782|NCT06736197|PROCEDURE|Group TVB|Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.
58287619|NCT02047435|BEHAVIORAL|Information, event and workshops at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~   * A guided tour at the museum~  * A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~  * The museum serves a refreshment and offer participants a season pass to the museum.~   And~2. Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
58287620|NCT02047435|BEHAVIORAL|Information and event at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~* A guided tour at the museum~* A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~* The museum serves a refreshment and offer participants a season pass to the museum."
57729394|NCT06128616|BEHAVIORAL|Occupational Therapy|Occupational Therapy
57729395|NCT00404339|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
57729396|NCT00404339|BIOLOGICAL|tetanus toxoid helper peptide|
57729397|NCT00404339|PROCEDURE|adjuvant therapy|
57729398|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
57729399|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
57729400|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
57932783|NCT06736197|PROCEDURE|Group PSV|Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
58400968|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
58400969|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
58071211|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
58071212|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
58071213|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
58071214|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
58400970|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
58400971|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
58400972|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
58400973|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
58400974|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
58400975|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
58071215|NCT02259452|PROCEDURE|Pulmonary Function Tests|
58071216|NCT00526760|DRUG|Dexmedetomidine|
58071217|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
58071218|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
58071219|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
58071220|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
58071221|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
58071222|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
58071223|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
58287621|NCT06404879|OTHER|determining scores with tests|"Parents of children preparing for the operation will be given a child and family information form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will be asked to fill them out themselves.~An anesthesia technician blind to the content of the study will calculate and take notes on the children\&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative Anxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation mask is shown (T4).~FLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and complications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th minutes of all children taken to the recovery unit in the postoperative period will be recorded by the recovery unit nurse. . Children who are thought to have pain according to the FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be taken."
58400976|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
58400977|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
58400978|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
58400979|NCT04202224|DRUG|Glucose|Placebo.
58400980|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
58287622|NCT01010802|DRUG|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
58287623|NCT04140721|DRUG|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
58287624|NCT04140721|DRUG|Moxonidine Pill|Moxonidine pill administered for 4 weeks
58287625|NCT01494012|RADIATION|stereotactic body radiation therapy|Undergo SBRT
58287626|NCT01494012|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
58287627|NCT01494012|PROCEDURE|computed tomography|Undergo FDG-PET/CT
58287628|NCT01494012|OTHER|questionnaire administration|Ancillary studies
58287629|NCT01494012|DRUG|fludeoxyglucose F 18|Undergo FDG-PET/CT
58287630|NCT06606366|PROCEDURE|Blood sample taken for the liquid biopsy|36 mL will be taken for the study.
58400981|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
57729401|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
58287631|NCT00056303|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
58287632|NCT00056303|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
58287633|NCT01542086|PROCEDURE|Myocardial SPECT|
58287634|NCT01542086|PROCEDURE|64-channel coronary CT angiography (CCTA)|
58287635|NCT00469248|DEVICE|Intra-aortic balloon pump counterpulsation|
58287636|NCT00913211|DEVICE|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
58287637|NCT00913211|PROCEDURE|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
58287638|NCT00913211|PROCEDURE|rTMS and Tracking|Combination of rTMS and finger tracking
58287639|NCT00913211|DEVICE|Sham rTMS|Sham treatment of rTMS
58287640|NCT04663165|PROCEDURE|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
58287641|NCT04663165|PROCEDURE|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
58287642|NCT01259934|DRUG|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
58400982|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
58400983|NCT01097265|DRUG|capecitabine|
58400984|NCT01097265|DRUG|oxaliplatin|
58400985|NCT01097265|OTHER|active surveillance|
58400986|NCT01097265|OTHER|laboratory biomarker analysis|
58400987|NCT01097265|PROCEDURE|adjuvant therapy|
58400988|NCT01097265|PROCEDURE|lymph node mapping|
58400989|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
57729402|NCT00695331|DRUG|Misoprostol|Titrated Misoprostol Solution
57932784|NCT06736197|PROCEDURE|Group PSV+PEEP|At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
57932785|NCT06618859|BEHAVIORAL|Time-restricted eating|Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
57932786|NCT06618859|BEHAVIORAL|Active control|Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
58287643|NCT01259934|DRUG|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
58287644|NCT03085719|DRUG|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
58287645|NCT03085719|RADIATION|Radiation|Radiation is used to shrink the cancer
58287646|NCT00447551|DRUG|Poly-L-Lactic Acid|Deep dermal injection
58287647|NCT03665077|DIAGNOSTIC_TEST|Initial blood draw|At baseline, patients will undergo a blood draw.
58287648|NCT03665077|DIAGNOSTIC_TEST|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
58287649|NCT03665077|DIAGNOSTIC_TEST|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
57729403|NCT00695331|DRUG|Oxytocin|Titrated Intravenous Oxytocin
57729404|NCT06635057|DRUG|Tirzepatide|Administered SC
57729405|NCT04852614|DIAGNOSTIC_TEST|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
57932787|NCT06736509|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
57932788|NCT06318897|DRUG|Carboplatin|Given by IV
57932789|NCT06318897|DRUG|Paclitaxel|Given by IV
57932790|NCT06318897|DRUG|Pembrolizumab|Given by IV
57932791|NCT06318897|DRUG|Doxorubicin|Given by IV
57932792|NCT06318897|DRUG|Cyclophosphamide|Given by IV
57932793|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
57932794|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
57932795|NCT03531788|DEVICE|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
58287650|NCT03665077|DIAGNOSTIC_TEST|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
58287651|NCT03665077|DIAGNOSTIC_TEST|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
58287652|NCT03208894|DRUG|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
58287653|NCT05876884|DEVICE|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
58287654|NCT01472822|DIETARY_SUPPLEMENT|Omija extract.|Omija extract 1.2g/day for 12weeks
58287655|NCT01472822|DIETARY_SUPPLEMENT|Placebo|Placebo 1.2g/day for 12weeks
58287656|NCT03023267|BEHAVIORAL|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
57932796|NCT03531788|DEVICE|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
57729406|NCT04045457|PROCEDURE|dry needling|insertion of needle into active myofascial trigger point
57932797|NCT06735482|BEHAVIORAL|Therapeutic play program|Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
58071224|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
58287657|NCT03023267|BEHAVIORAL|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
58287658|NCT05555277|OTHER|No interventions - retrospective data collection|The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
58287659|NCT00005067|DRUG|motexafin lutetium|Given IV
58287660|NCT00005067|DRUG|photodynamic therapy|Undergo photodynamic therapy
58287661|NCT03922282|PROCEDURE|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
58287662|NCT03922282|PROCEDURE|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
58287663|NCT04077749|BIOLOGICAL|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
58287664|NCT04077749|OTHER|Normal Saline|50 mL normal saline at room temperature
58287665|NCT01383408|OTHER|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
57729407|NCT04576208|DRUG|TAK-788|TAK-788 capsules
57729408|NCT04576208|DRUG|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
57729409|NCT06139575|DRUG|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
58071225|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
58287666|NCT05274529|BEHAVIORAL|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
58287667|NCT05274529|BEHAVIORAL|Work ability|A remote coaching programme concentrating on work ability
58287668|NCT05274529|BEHAVIORAL|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
58287669|NCT05274529|BEHAVIORAL|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
58287670|NCT05274529|OTHER|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
58287671|NCT06222762|OTHER|Experimental arm|Personalized follow-up in adapted physical activities
58287672|NCT01594918|DRUG|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
58287673|NCT01594918|DRUG|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
58287674|NCT01594918|DRUG|Prednisone|5 mg PO BID
58287675|NCT01594918|DRUG|Pegfilgrastim|6 mg, SC, once every 21 days
58287676|NCT04652726|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
58287677|NCT04652726|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
58287678|NCT04520048|OTHER|Determination of the UEMP levels|Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.
58287679|NCT04520048|PROCEDURE|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical)
58287680|NCT04520048|OTHER|Vascular biomarker assay|Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.
58306848|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
58306849|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
58306850|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
57729410|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
57729411|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
57729412|NCT04906200|OTHER|Best Practice|Receive usual care
57729413|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
57729414|NCT04906200|OTHER|Survey Administration|Complete survey
57729415|NCT00086346|DRUG|Sirolimus (Rapamune)|
57729416|NCT00086346|DRUG|Cyclosporine or Tacrolimus|
57932798|NCT01134835|OTHER|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
57932799|NCT01134835|DRUG|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
57932800|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
57932801|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
57932802|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
57932803|NCT03666000|DRUG|IL-2|Specified dose on specified days
57932804|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
57932805|NCT04849741|DRUG|zilganersen|zilganersen will be administered by ITB injection.
57932806|NCT04849741|DRUG|Placebo|zilganersen-matching placebo will be administered by ITB injection.
58306851|NCT03180710|DRUG|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
58071226|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
58071227|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
58071228|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
58287681|NCT04520048|PROCEDURE|Measurement of the uterine artery diameter|This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
57729417|NCT02216331|DRUG|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
57932807|NCT05770375|DRUG|MDMA 40mg|MDMA 40mg
58071229|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
58287682|NCT03128853|DEVICE|Rad-67 and DCI Mini Sensor|
58287683|NCT04567004|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
58287684|NCT04567004|OTHER|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
58287685|NCT04567004|OTHER|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
58287686|NCT04567004|OTHER|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
58287687|NCT05206110|DRUG|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
58287688|NCT05206110|DRUG|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
57729418|NCT02216331|DRUG|rifapentine|
58071230|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
57932808|NCT05770375|DRUG|MDMA 80mg|MDMA 80mg
57932809|NCT05770375|DRUG|MDMA 120mg|MDMA 120mg
57932810|NCT03446391|PROCEDURE|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
58071231|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
58071232|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
58287689|NCT00528749|OTHER|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
58287690|NCT05121805|PROCEDURE|Snare tip soft coagulation|Thermal ablation of the entire resection margin
58287691|NCT01039779|BEHAVIORAL|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
58287692|NCT01997801|DRUG|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
58287693|NCT01997801|DRUG|NS infusion|Normal saline will be infused intraoperatively.
57729419|NCT02216331|DRUG|rifampicin|
57729420|NCT01344460|DRUG|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
57729421|NCT06114420|PROCEDURE|salvage surgery|Some patients who cannot undergo surgery
57729422|NCT03339076|DEVICE|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
57729423|NCT04218929|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
57729424|NCT04218929|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
57932811|NCT03446391|PROCEDURE|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
57932812|NCT03446391|DEVICE|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
58071233|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
58400990|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
57932813|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
57932814|NCT02321826|BEHAVIORAL|Music|Participants choice among 4 genres of music matched on music characteristics
57932815|NCT02321826|BEHAVIORAL|Audiobook|Participants choice among 4 types of audiobooks
57932816|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
58071234|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
58287694|NCT05612217|OTHER|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
58287695|NCT01084148|DRUG|V0034CR01B|
58287696|NCT01084148|DRUG|V0034CR01B vehicle|
58287697|NCT06612580|DRUG|68Ga-AAZTA-NI-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
58287698|NCT00558805|BEHAVIORAL|FISP + Usual Care|
58287699|NCT00558805|BEHAVIORAL|Usual Care|
58287700|NCT05464420|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
58287701|NCT05464420|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
58287702|NCT02801799|DRUG|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
57932817|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
57932818|NCT02595931|DRUG|Berzosertib|Given IV
57932819|NCT02595931|PROCEDURE|Biopsy Specimen|Undergo biopsy
57932820|NCT02595931|PROCEDURE|Biospecimen Collection|Correlative studies
57932821|NCT02595931|PROCEDURE|Computed Tomography|Undergo CT
57932822|NCT02595931|DRUG|Irinotecan Hydrochloride|Given IV
57932823|NCT04509960|DEVICE|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
57932824|NCT01563185|DRUG|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
57932825|NCT05828082|PROCEDURE|Biopsy|Undergo biopsy
58071235|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
58287703|NCT02256735|DRUG|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
58287704|NCT02256735|DRUG|Treatment B|
58287705|NCT02256735|DRUG|Treatment C|
58287706|NCT02256735|DRUG|Treatment D|
58287707|NCT02256735|DRUG|Placebo|
57932826|NCT05828082|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57932827|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
57932828|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58071236|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
58287708|NCT02256735|DRUG|Moxifloxacin|
58306852|NCT01685879|OTHER|Rice|Rice portion containing 50 g total carbohydrate
58400991|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
58400992|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
58400993|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
58400994|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
58400995|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
58400996|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
57932829|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
58287709|NCT02447328|DRUG|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
58287710|NCT02411734|BEHAVIORAL|Rehabilitation|Rehabilitation after hospitalization
58287711|NCT01384747|DRUG|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
58287712|NCT01384747|DRUG|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
58400997|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
58400998|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
57729425|NCT04529213|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
57932830|NCT05828082|DRUG|Tuvusertib|Given PO
57932831|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
57932832|NCT04269005|OTHER|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
57932833|NCT02649153|DRUG|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
57932834|NCT02649153|DRUG|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
58287713|NCT03492879|DEVICE|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
58287714|NCT03963219|DEVICE|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
58287715|NCT03963219|DEVICE|Standard Bolus Calculator|Standard bolus calculator
58287716|NCT02357745|PROCEDURE|Non surgical periodontal therapy|scaling and root planing
58287717|NCT04575090|DRUG|Simvastatin|Simvastatin 40 mg daily.
58287718|NCT03848793|DRUG|HS-20004|treatment
58287719|NCT00063336|BEHAVIORAL|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
58287720|NCT00063336|BEHAVIORAL|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
58287721|NCT03334422|DRUG|Baricitinib|Administered orally
58287722|NCT03334422|DRUG|Placebo|Administered orally
58287723|NCT04644120|DRUG|ABBV-47D11|Intravenous (IV) infusion.
58287724|NCT04644120|DRUG|Placebo for ABBV-47D11|Intravenous (IV) infusion.
58400999|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
58401000|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
58401001|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
58071237|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
58071238|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
58071239|NCT03924960|BEHAVIORAL|Control|Usual care control group
58071240|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
58071241|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
58401002|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
58071242|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
58071243|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
58071244|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
58071245|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
58071246|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
58071247|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
58287725|NCT04644120|DRUG|ABBV-2B04|Intervenous (IV) Infusion
58287726|NCT04644120|DRUG|Placebo for ABBV-2B04|Intervenous (IV) Infusion
58287727|NCT03812445|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8\*10\^9 Colony-Forming Units(CFU) \*2/d for 3 months.
58287728|NCT02095197|DRUG|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
58401003|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
58401004|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
58401005|NCT04717336|OTHER|SODIUM CHLORIDE|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
57932835|NCT03387475|DRUG|Deferasirox|iron chelation
57932836|NCT06734637|DRUG|Peginterferon α-2b injection|Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
57932837|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
57932838|NCT02632760|DRUG|Ferric carboxymaltose|treatment for Iron deficient anaemia
58071248|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
58071249|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
58287729|NCT02852057|DRUG|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
58401006|NCT04717336|OTHER|placebo|placebo capsules
58401007|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
57729426|NCT05115162|OTHER|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
57932839|NCT02632760|DRUG|Placebo|placebo - no active drug
57932840|NCT05539833|DRUG|KSH01 injection|TCR-T cell injection
57932841|NCT05964998|DEVICE|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
57932842|NCT05964998|DEVICE|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
57932843|NCT06601842|DEVICE|ICP monitoring|ICP monitoring
58287730|NCT03049020|PROCEDURE|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
58287731|NCT05936814|PROCEDURE|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
58287732|NCT02849886|DRUG|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
58287733|NCT02849886|DRUG|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC."
58287734|NCT00000200|DRUG|Methadone|normal maintenance dose
58287735|NCT02527317|DRUG|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
58287736|NCT01189461|DRUG|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
58287737|NCT01078142|DRUG|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
58287738|NCT00778349|DRUG|Metformin solution 100 mg/mL|
58287739|NCT00626652|DRUG|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
58287740|NCT06369831|DIAGNOSTIC_TEST|68Ga-NOTA-ABSCINT-HER2 PET/CT|68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
57932844|NCT06181461|OTHER|Gong's Mobilization|Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
57932845|NCT06181461|OTHER|Kaltenborn Mobilization|Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
57932846|NCT06069206|OTHER|T2Bacteria® Panel (direct-from-blood testing)|Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.
57932847|NCT06069206|OTHER|Usual Care|Standard blood cultures.
57932848|NCT01287364|DRUG|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
57932849|NCT01287364|DRUG|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
57932850|NCT06294769|OTHER|essencial oil of lavandula angustifolia|The intervention will consist of the application of aromatherapy with 2% lavender essential oil cutaneously and inhalation via by a nurse, associated with usual care, in the immediate postoperative period
57932851|NCT06294769|OTHER|grape seed vegetable oil|The placebo group will only receive the application of grape seed vegetable oil associated with usual care in the immediate postoperative period.
58071250|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
58071251|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
58287741|NCT00420719|DEVICE|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
58287742|NCT00717652|DRUG|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
58287743|NCT00717652|DRUG|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
58287744|NCT06056453|BEHAVIORAL|Interpersonal Psychotherapy|IPT group-virtual
58287745|NCT03317717|DRUG|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
58401008|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
58401009|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
57729427|NCT00587873|DRUG|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
57729428|NCT00587873|DRUG|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
57729429|NCT00587873|DRUG|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
57729430|NCT00244738|DIETARY_SUPPLEMENT|Castor oil|Patients who received castor oil for labor induction
57932852|NCT04858854|OTHER|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
57932853|NCT04160052|DRUG|Azacitidine|Given SC or IV
58071252|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
58071253|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
57729431|NCT00244738|DIETARY_SUPPLEMENT|Sunflower oil|Patients who received sunflower oil as a placebo
57729432|NCT03674229|OTHER|Informational Intervention|Receive information about weight management programs
58071254|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
58287746|NCT03317717|DRUG|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
58287747|NCT06350201|BEHAVIORAL|cognitive behavior therapy|Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
58287748|NCT06350201|OTHER|control group|Routine psychological care and guidance on mood management
58287749|NCT02706769|DRUG|Placebo|Study medication contains blinded placebo
58287750|NCT02706769|DRUG|Paracetamol|Study medication contains blinded paracetamol
58287751|NCT03739424|OTHER|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
58287752|NCT03739424|OTHER|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
58287753|NCT03739424|OTHER|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
58287754|NCT00398047|DRUG|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
57932854|NCT04160052|DRUG|Venetoclax|Given PO
57932855|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
57932856|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
58287755|NCT00519584|DRUG|Ropivacaine|30 ml 0.5%
58287756|NCT00519584|DRUG|dex|8 mg (2 ml)
58287757|NCT00519584|DRUG|Bupivacaine|30 ml 0.5%
58071255|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
58071256|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
58071257|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
58071258|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
58071259|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
58071260|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
58071261|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
57729433|NCT03674229|OTHER|Questionnaire Administration|Ancillary studies
57729434|NCT03674229|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
57729435|NCT05059691|OTHER|Electronic Health Record Review|Review of medical records
57729436|NCT05059691|PROCEDURE|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
57729437|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
57729438|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
57729439|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
57932857|NCT02199600|DEVICE|GMK Sphere Knee Replacement|
57932858|NCT06734546|OTHER|Exercise intervention|The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
58071262|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
58071263|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
58287758|NCT00519584|DRUG|Saline|0.9% saline; systemic and local
58287759|NCT02951026|OTHER|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
58287760|NCT02559570|DRUG|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
58401010|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
58401011|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
58401012|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
58401013|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
58071264|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
58287761|NCT02559570|DRUG|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
58287762|NCT02559570|DRUG|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
58401014|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
58401015|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
58401016|NCT06607783|DIAGNOSTIC_TEST|MRI|TBC
58401017|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
58401018|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
58401019|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
58401020|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
58401021|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
58401022|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
58401023|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
58401024|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
58401025|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
58401026|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
58401027|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
58401028|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
57932859|NCT06735430|DRUG|Ciprofol|Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
58401029|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
57932860|NCT06735430|DRUG|Propofol|Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
57932861|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
57932862|NCT03235622|DIAGNOSTIC_TEST|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
58401030|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
58401031|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
58401032|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
58401033|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
57932863|NCT06704932|DRUG|SAR446959|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
57932864|NCT06704932|DRUG|Placebo|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
57932865|NCT04115826|PROCEDURE|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
57932866|NCT04115826|PROCEDURE|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
58287763|NCT02559570|DRUG|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
58287764|NCT02559570|DRUG|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
58287765|NCT03091738|DRUG|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
58287766|NCT02085746|OTHER|Defining Sexual Activity Questionnaire|
58401034|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
58401035|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
58401036|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
57729440|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
58287767|NCT04235166|OTHER|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
58287768|NCT04235166|OTHER|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
57729441|NCT03526900|DRUG|Atezolizumab|"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
57729442|NCT06094153|DIETARY_SUPPLEMENT|Placebo|Consume placebo (Maltodextrin) once daily before going to bed for 28 days
57932867|NCT03633708|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
57932868|NCT01974388|PROCEDURE|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
57932869|NCT01974388|PROCEDURE|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
57932870|NCT04130503|DEVICE|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
57932871|NCT04130503|BEHAVIORAL|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
57932872|NCT05754073|DRUG|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
57932873|NCT05754073|DRUG|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
57932874|NCT05754073|DRUG|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
58287769|NCT06229041|DRUG|Camrelizumab ＋Immunotherapy|Camrelizumab was used in preoperative treatment.
58287770|NCT06225661|BEHAVIORAL|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
58287771|NCT06225661|BEHAVIORAL|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
58287772|NCT01614444|OTHER|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
58287773|NCT01614444|OTHER|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
57932875|NCT03769064|DRUG|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
57932876|NCT03769064|DRUG|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
58401037|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
57932877|NCT03769064|DRUG|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
57932878|NCT03769064|DRUG|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
57932879|NCT03769064|DRUG|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
57932880|NCT03769064|DRUG|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
58287774|NCT03971916|DRUG|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
58287775|NCT03971916|DRUG|Placebo|Subcutaneous injection; Single dose on Day 1
58287776|NCT06105814|DEVICE|Rapid diagnostics|Sputum sampes will in addition to standard diagnostics be investigated using a rapid diagnostic plattform (FilmArray)
58287777|NCT05265832|PROCEDURE|Phacoemulsification|Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
58401038|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
58287778|NCT00608218|DRUG|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
58287779|NCT01681953|DRUG|Lamazym|ERT, i.v. infusions weekly
58287780|NCT01681953|DRUG|Placebo|Infusions weekly
58287781|NCT04060797|DEVICE|endovascular denervation|Treating with endovascular denervation (EDN) at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
58287782|NCT04060797|DEVICE|PTA|Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
58287783|NCT01357005|OTHER|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
58287784|NCT04319926|DRUG|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
58287785|NCT04319926|DRUG|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
58287786|NCT04557436|DRUG|PBLTT52CAR19|gene therapy
58287787|NCT04034511|OTHER|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
58287788|NCT03141515|DEVICE|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
57729443|NCT06094153|DIETARY_SUPPLEMENT|HMO 1|Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
57729444|NCT06094153|DIETARY_SUPPLEMENT|HMO 2|Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
57729445|NCT06485232|DRUG|Universal BCMA CAR-T|Universal BCMA CAR-T
57932881|NCT04782388|DRUG|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
57932882|NCT04782388|OTHER|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
57932883|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
57932884|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
57932885|NCT05622812|DEVICE|Restylane Lyft Lidocaine|Treatment for Jawline definition
57932886|NCT06725225|BEHAVIORAL|Symptom cluster-based care intervention|The patient symptoms were surveyed to develop a symptom cluster care intervention plan. The specific steps were as follows: a research team was established, relevant literature was reviewed, and qualitative interviews were conducted. Guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, a draft of the care intervention was created. This draft was then refined through expert consultation to finalize the intervention plan.
57932887|NCT06725225|BEHAVIORAL|Conventional care intervention|Standard nursing intervention. This refers to routine clinical care without a specific care plan tailored to the patient's symptoms. For example, if a patient has symptoms, the nurse assists the patient in notifying the doctor but does not provide any special treatment themselves
57932888|NCT06735144|DRUG|FH-006|Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
58287789|NCT04959864|DIETARY_SUPPLEMENT|Isitol®|"1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
58287790|NCT04959864|OTHER|Placebo|"1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30."
58287791|NCT02164071|OTHER|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
58287792|NCT06352866|DRUG|Siltuximab|Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system
58287793|NCT06352866|DRUG|Teclistamab(FDA-approved)|Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
57729446|NCT06485232|DRUG|Universal CD19 CAR-T|Universal CD19 CAR-T
57729447|NCT06485232|DRUG|Universal BCMA CAR-T; Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T
57729448|NCT00290823|DRUG|Albendazole|400 mg tablet taken orally twice daily
57729449|NCT00290823|DRUG|Dexamethasone|6mg or 8mg taken daily
57729450|NCT00290823|DRUG|Omeprazole|20 mg tablet taken orally daily
57729451|NCT04538014|DRUG|Lu AF88434|Oral solution
57729452|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
57729453|NCT05903001|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
57729454|NCT05903001|DIAGNOSTIC_TEST|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
57932889|NCT06735144|DRUG|FH-006|administered once every 3 weeks (Q3W), with a treatment period of 21 days
58306853|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
58287794|NCT05320419|OTHER|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
58287795|NCT05320419|OTHER|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
58287796|NCT06132984|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
58287797|NCT00005083|PROCEDURE|conventional surgery|
58287798|NCT00005083|PROCEDURE|magnetic resonance imaging|
58287799|NCT00005083|PROCEDURE|magnetic resonance spectroscopic imaging|
58401039|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
58287800|NCT01602705|OTHER|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
58287801|NCT01602705|OTHER|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
58287802|NCT01602705|OTHER|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
58287803|NCT03009227|PROCEDURE|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
58287804|NCT03009227|PROCEDURE|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
58287805|NCT06185439|BEHAVIORAL|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
58287806|NCT05940961|DRUG|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
58287807|NCT03578445|DEVICE|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
58401040|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
58401041|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
58401042|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
57729455|NCT05903001|DIAGNOSTIC_TEST|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
57729456|NCT05903001|DIAGNOSTIC_TEST|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
57729457|NCT05903001|DIAGNOSTIC_TEST|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
57729458|NCT05903001|DIAGNOSTIC_TEST|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
57932890|NCT05927922|DRUG|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
58401043|NCT04700345|OTHER|Medical Management|best medical management
57729459|NCT05903001|DIAGNOSTIC_TEST|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
57729460|NCT05903001|DIAGNOSTIC_TEST|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
57729461|NCT05903001|DIAGNOSTIC_TEST|6-minute walking distance|The maximum walking distance achieved in 6 minutes
57729462|NCT05903001|DIAGNOSTIC_TEST|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
57729463|NCT05903001|DIAGNOSTIC_TEST|Electromyography|electromyography of the muscles of respiration via superficial electrodes
57932891|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
58287808|NCT03578445|DIAGNOSTIC_TEST|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
58287809|NCT01850394|DRUG|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
58287810|NCT01850394|DRUG|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
58287811|NCT05003284|DEVICE|acupressure wristband|acupressure after surgery
58401044|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
58071265|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
58071266|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
58071267|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
58071268|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
57932892|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
58071269|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
58071270|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
58071271|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
58071272|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
58071273|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
57932893|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
57932894|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
57932895|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
58071274|NCT02114346|DRUG|Atorvastatin|
58071275|NCT02114346|DRUG|Placebo|
57932896|NCT00376181|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
57932897|NCT05012982|DEVICE|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
58071276|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
58071277|NCT02961153|OTHER|death|
58071278|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
58071279|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
58071280|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
58071281|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
57932898|NCT05012982|DEVICE|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
57932899|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
58071282|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
58071283|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
58071284|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
58287812|NCT05003284|DEVICE|placebo wristband|acupressure after surgery
58306854|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
58071285|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
58401045|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
58401046|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
58401047|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
57729464|NCT05903001|DIAGNOSTIC_TEST|Lung Function|Measurement of lung function via body plethysmography
57729465|NCT05903001|DIAGNOSTIC_TEST|CAT-Questionnaire|COPD Assessment Test (CAT)
57729466|NCT05903001|DIAGNOSTIC_TEST|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
57729467|NCT00129987|BEHAVIORAL|Self management education|
58287813|NCT05519956|RADIATION|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
58287814|NCT05519956|RADIATION|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
58287815|NCT02171117|PROCEDURE|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
58287816|NCT02171117|BIOLOGICAL|HLA-mismatched donor peripheral stem cell infusion|
58287817|NCT04786405|BEHAVIORAL|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
58287818|NCT04786405|BEHAVIORAL|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
58287819|NCT05678712|DEVICE|Access to CGM data (Dexcom G6)|Acces to CGM data (not blinded CGM)
58287820|NCT05627947|DRUG|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
58287821|NCT04827758|PROCEDURE|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
58287822|NCT04053907|OTHER|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
58287823|NCT04053907|OTHER|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
58287824|NCT04053907|OTHER|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
58287825|NCT04053907|OTHER|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
57729468|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
58287826|NCT03823820|OTHER|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
58287827|NCT04285905|OTHER|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
58287828|NCT04285905|OTHER|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
57932900|NCT00314678|DRUG|Topotecan|
57932901|NCT00314678|DRUG|Cisplatin|
58287829|NCT04285905|OTHER|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
58287830|NCT04285905|OTHER|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
58287831|NCT04285905|OTHER|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
58287832|NCT05530655|DRUG|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
57932902|NCT00314678|DRUG|Paclitaxel|
58071286|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
58071287|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
58071288|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
58071289|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
58287833|NCT06019026|DEVICE|Tri-Lock|Implant Stem
58287834|NCT06019026|DEVICE|Summit|Implant Stem
58401048|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
58401049|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
57932903|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
57932904|NCT03148678|BEHAVIORAL|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
57932905|NCT03148678|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
57932906|NCT03148678|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
57932907|NCT03148678|BEHAVIORAL|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
57932908|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
58287835|NCT01473017|BEHAVIORAL|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
58287836|NCT00263419|BEHAVIORAL|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
58287837|NCT01551446|DRUG|Bardoxolone Methyl|Oral, once daily
58306855|NCT01685879|OTHER|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
58306856|NCT05578339|DEVICE|Biometry|Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
58306857|NCT03186313|DRUG|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
58401050|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
58401051|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
57932909|NCT02803853|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
57932910|NCT00331123|DRUG|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
58071290|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
58287838|NCT05565170|BEHAVIORAL|Structured ICT-assisted multimodal lifestyle intervention|The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.
58287839|NCT05565170|BEHAVIORAL|Self-guided multimodal lifestyle intervention|Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
58287840|NCT00230724|BEHAVIORAL|Exercise Counseling|
58287841|NCT02860962|DRUG|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
58287842|NCT02375425|OTHER|no intervention|no intervention-specimen collection study only
58287843|NCT06364371|OTHER|Medical examination|Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
58287844|NCT00990509|DRUG|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
58287845|NCT00990509|DRUG|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
58287846|NCT00990509|PROCEDURE|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)"
58287847|NCT02491970|DRUG|Fluticasone/Formoterol|
58287848|NCT02491970|DRUG|Fluticasone/Salmeterol|
58287849|NCT00064415|DRUG|arformoterol|Arformoterol inhalation solution, 50 mcg QD
58287850|NCT00064415|DRUG|Salmeterol|Salmeterol MDI, 42 mcg BID
58287851|NCT04331509|OTHER|No Intervention|No Intervention
58287852|NCT03655600|OTHER|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
58287853|NCT03694223|OTHER|Health education delivery methods|
57932911|NCT00331123|DRUG|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
57932912|NCT01701674|DRUG|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
58287854|NCT04824742|PROCEDURE|Neoadjuvant PDT + radical surgery|Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
58287855|NCT04824742|PROCEDURE|Radical surgery|Patients with cholangiocarcinoma will only receive radical surgery
58287856|NCT04369963|PROCEDURE|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
58287857|NCT05177068|DRUG|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA\<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
58287858|NCT01008774|DEVICE|Paxman Cooling Machine|Scalp cooling procedures
58401052|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
58071291|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
57932913|NCT01701674|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging \[MRI\] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
58287859|NCT01008774|DEVICE|Cold Caps|Scalp cooling procedures
58071292|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
58287860|NCT02686814|DEVICE|17mm MDT-2215 aortic valve bioprosthesis|
58287861|NCT04810910|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
58287862|NCT04810910|OTHER|GM-CSF|GM-CSF: 40 mcg
58287863|NCT02601222|DRUG|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
58287864|NCT02601222|DRUG|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
58287865|NCT02601222|DRUG|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
58287866|NCT05392530|DRUG|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
58287867|NCT05061147|DRUG|MAX-40279-01|"Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA"
58287868|NCT01067417|DRUG|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
58287869|NCT01067417|DRUG|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
58287870|NCT03800680|BEHAVIORAL|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed."
58287871|NCT03800680|BEHAVIORAL|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
58287872|NCT05603572|DRUG|KAT-101|oral dosage form
58287873|NCT05603572|DRUG|KAT-201|IT dosage form
58401053|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
58401054|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
58071293|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
58287874|NCT00635934|DEVICE|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
58287875|NCT04653259|OTHER|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
58287876|NCT03438942|DIETARY_SUPPLEMENT|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
58401055|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
58401056|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
57932914|NCT01701674|DRUG|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
57932915|NCT01701674|DRUG|Cyclophosphamide as Part of Lymphodepletion|
57932916|NCT01701674|DRUG|Fludarabine as Part of Lymphodepletion|
57932917|NCT01701674|DRUG|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
57932918|NCT01701674|BIOLOGICAL|Adoptive Cell Therapy with TIL|
58071294|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
58071295|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
58071296|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
58287877|NCT03438942|DIETARY_SUPPLEMENT|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
57729469|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
57932919|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
57932920|NCT06736457|PROCEDURE|AdvanCore bone grafting|AdvanCore medical device is implanted making sure that is in direct contact with all surfaces of the defect area.
57932921|NCT06291285|DRUG|Decitabine-THU|Orally administered immediate release tablets.
57932922|NCT06291285|DRUG|Decitabine-THU|Orally administered delayed release capsules.
57932923|NCT05758545|DEVICE|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.
58287878|NCT00893074|DRUG|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
58287879|NCT00893074|DRUG|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
58287880|NCT00893074|DRUG|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
58287881|NCT00893074|DRUG|Placebo|placebo dronabinol administered 3x/day for 5 days
57729470|NCT03452917|DRUG|Placebo|500 patients will 2 ml of normal saline
57729471|NCT03452917|DRUG|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
57729472|NCT03452917|DRUG|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
57729473|NCT03013010|DRUG|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
57729474|NCT03013010|RADIATION|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
57932924|NCT05758545|DEVICE|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
58071297|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
58071298|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
58071299|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
58071300|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
58287882|NCT02106741|BEHAVIORAL|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
58401057|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
58401058|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
58401059|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
58401060|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
58401061|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
58401062|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
58401063|NCT02047591|OTHER|Relaxing-touch method|
58287883|NCT02106741|BEHAVIORAL|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
57932925|NCT06730438|DEVICE|Transcranial Pulse Stimulation|Patients will receive TPS once a day for five days a week, each session will be separated from the previous one by 24h. Each stimulation and assessment session will be performed at the same hour of the day, in the morning preferably, to maximize the probability of observing responses to stimuli. Patients will be managed in a quiete room with stable light and temperature.
57932926|NCT06691165|OTHER|Low oxygen therapy (LOT)|"Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels."
58287884|NCT02935257|BIOLOGICAL|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
57932927|NCT06734767|BEHAVIORAL|Mindfulness Based Stress Reduction 8-week course|The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
58071301|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
58071302|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
58071303|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
58071304|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
58071305|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
58071306|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
58071307|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
58401064|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
58401065|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
58287885|NCT03836534|BEHAVIORAL|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
57932928|NCT06734065|BEHAVIORAL|ReDS-guided heart failure management program|"Remote dielectric sensing (ReDS) system (Sensible Medical Innovations Ltd., Netanya, Israel) is a novel electromagnetic energy-based technology that accurately quantifies changes in lung fluid concentration non-invasively.~Patients in the intervention group will receive a three-month, ReDS-guided heart failure management program in addition to usual care.~The program, led by nurses, will integrate algorithms for diuretic use, a structured follow-up schedule, and self-care support tailored to pulmonary fluid levels assessed by ReDS."
57932929|NCT03775174|DRUG|Mepsevii|
58071308|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
58071309|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
58287886|NCT03565705|PROCEDURE|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
58287887|NCT04656301|DRUG|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
58287888|NCT04727736|DRUG|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
58287889|NCT03562858|PROCEDURE|Immediate dentin sealing protocol|Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
58287890|NCT03562858|PROCEDURE|Delayed dentin sealing protocol|Sealing the dentin just prior to cementation
58287891|NCT00552214|DEVICE|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
58287892|NCT02233621|OTHER|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with \[18F\]FES before coelioscopy
58287893|NCT03872843|DRUG|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
58287894|NCT03872843|DRUG|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
58287895|NCT04158505|OTHER|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
57932930|NCT02673606|DRUG|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
58287896|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
58287897|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
58287898|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
58287899|NCT01579669|BEHAVIORAL|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
58287900|NCT04306393|DRUG|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively."
58287901|NCT03731949|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography to assess placental volume
58287902|NCT04020978|DIAGNOSTIC_TEST|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
58287903|NCT00204061|BEHAVIORAL|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
58401066|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
58071310|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
58401067|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
58401068|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
58401069|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
58401070|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
58401071|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
57932931|NCT02673606|DRUG|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
57932932|NCT02673606|DRUG|Placebo Pills|inactive placebo pills
57932933|NCT06664879|DRUG|MBG-453 + Azacitidine|Given intravenously (by vein)
57932934|NCT04539366|PROCEDURE|Biopsy|Undergo biopsy
58071311|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
58287904|NCT00204061|DRUG|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
57932935|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57932936|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58071312|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
58071313|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
58071314|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
58287905|NCT06294119|PROCEDURE|Major Cardiac surgery|From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
58287906|NCT01535469|DRUG|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
58401072|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
57932937|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57932938|NCT04539366|DRUG|Cyclophosphamide|Given IV
57932939|NCT04539366|PROCEDURE|Echocardiography|Undergo ECHO
57932940|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
57932941|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
58071315|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
58071316|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
58071317|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
58287907|NCT02287688|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
58287908|NCT00084227|DRUG|Azithromycin/Chloroquine|
58287909|NCT00084227|DRUG|Atovaquone/Proguanil|
58287910|NCT04900649|OTHER|chest resistance exercise|lung function.
57932942|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
57932943|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
57932944|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58287911|NCT04900649|OTHER|chest expansion exercises|thoracic excursion
57932945|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
57932946|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
58287912|NCT06612047|PROCEDURE|Prostate biopsy|All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
58071318|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
58071319|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
58287913|NCT04736719|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure group
58287914|NCT04736719|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
58287915|NCT02893046|OTHER|No intervention|
58287916|NCT05978700|DEVICE|Video-game|The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
58401073|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
57729475|NCT03013010|PROCEDURE|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
57932947|NCT06072482|DRUG|Avacopan|Administered orally.
57932948|NCT06072482|DRUG|Placebo|Administered orally.
57932949|NCT06072482|DRUG|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
57932950|NCT04662619|OTHER|B. infantis|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."
57932951|NCT04662619|OTHER|Lactose Placebo|Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
57932952|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
58071320|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
58071321|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
58287917|NCT05978700|BEHAVIORAL|Conventional therapy|The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
58306858|NCT03186313|DRUG|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.
58306859|NCT03186313|DRUG|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
58306860|NCT03186313|DRUG|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
58401074|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
58401075|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
58071322|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
58071323|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
58401076|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
58401077|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
58401078|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
58401079|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
58401080|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
58401081|NCT04669938|OTHER|host immune factors|analysis of host immune factors
58401082|NCT04669938|OTHER|viral sequence|analysis of viral sequence
58401083|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
58401084|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
58401085|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
58401086|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58401087|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
58401088|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
58401089|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
58401090|NCT00051012|DRUG|ONTAK|
58071324|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
58071325|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
58071326|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
58071327|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
58071328|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
58071329|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
58071330|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
58071331|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
58071332|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
58071333|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
58071334|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
58071335|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
58071336|NCT01247467|OTHER|Breast Tumor Blocks|
58071337|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
58071338|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
58071339|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
58401091|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
58401092|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
58401093|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
58401094|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
57729476|NCT03013010|DRUG|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
58401095|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
58401096|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
58401097|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
57932953|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
57932954|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
57932955|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
57932956|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
57932957|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
58401098|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
58401099|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
58401100|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
57729477|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
58401101|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
58401102|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
57729478|NCT03143218|BIOLOGICAL|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
57932958|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
57932959|NCT04354090|DRUG|JY09|Subcutaneous injection
57932960|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
57932961|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
58071340|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
57932962|NCT01842386|DRUG|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
58071341|NCT06412471|DRUG|SSGJ-707|bispecific antibody
58071342|NCT06412471|DRUG|carboplatin|chemotherapy
58071343|NCT06412471|DRUG|Pemetrexed|chemotherapy
58071344|NCT06412471|DRUG|paclitaxel|chemotherapy
58071345|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
58071346|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
58401103|NCT00139295|DEVICE|Hylastan|
57729479|NCT03143218|BIOLOGICAL|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
58401104|NCT00451009|DEVICE|Viacell's product Media Kits|
58401105|NCT04071262|DRUG|Abemaciclib|Administered orally
58401106|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
58401107|NCT04071262|DRUG|Prednisolone|Administered orally
58401108|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
58401109|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
58401110|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
58401111|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
58401112|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
58401113|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
58401114|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
58401115|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
58401116|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
58401117|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
57729480|NCT03143218|DRUG|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
58401118|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
58401119|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
58401120|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
58401121|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
58071347|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
58287918|NCT05288322|PROCEDURE|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
58287919|NCT02771860|DRUG|denosumab|60mg sc
58287920|NCT02771860|DRUG|Placebo|identical syringe
58401122|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
58401123|NCT05598125|DEVICE|conventional tobacco cigarette|
58401124|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
58401125|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
58401126|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
58401127|NCT05658627|OTHER|active release technique|Hamstring active release technique-
58401128|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
58401129|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
58401130|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
58401131|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
58401132|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
58401133|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
58071348|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
58287921|NCT02771860|DIETARY_SUPPLEMENT|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
58401134|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
58401135|NCT01050920|BIOLOGICAL|Blood collection|
58401136|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
58401137|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
58401138|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
58401139|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
58401140|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
58401141|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
57932963|NCT05932342|BEHAVIORAL|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
57932964|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
57932965|NCT06002750|OTHER|disease|Do you have dermatomyositis
57932966|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
57932967|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
57932968|NCT06467617|DRUG|Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab|"Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle"
58071349|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
58287922|NCT04030234|DRUG|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
58287923|NCT04030234|DRUG|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
58401142|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
58401143|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
58401144|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
58071350|NCT00081276|DRUG|triapine|Given IV
58071351|NCT00081276|DRUG|cisplatin|Given IV
58071352|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
58071353|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
58287924|NCT03499106|DRUG|IW-1973|Oral Tablet
58071354|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
58401145|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
57932969|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
57932970|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
57932971|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
57932972|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
57932973|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
57932974|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
57932975|NCT06588504|DRUG|Dasiglucagon|Participants will receive s.c. injection of dasiglucagon.
57932976|NCT06588504|DRUG|Glucagon|Participants will receive i.m. injection of glucagon.
57932977|NCT06735391|DRUG|JMT101|JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
58401146|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
57932978|NCT06735391|DRUG|Osimertinib|EGFR TKI
57932979|NCT01187849|DRUG|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
57932980|NCT01187849|DRUG|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
57932981|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
57932982|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
58071355|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
58071356|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
58071357|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
58071358|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
57932983|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
57932984|NCT03608267|DEVICE|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
58071359|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
58071360|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
58071361|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
58071362|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
57932985|NCT05993559|RADIATION|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
57932986|NCT05993559|RADIATION|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
57932987|NCT05965440|DRUG|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
57932988|NCT01580033|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
58071363|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
57932989|NCT01580033|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
58071364|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
58071365|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
57932990|NCT01580033|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
57932991|NCT01580033|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
57932992|NCT06305780|DRUG|IVIG + Coordinated Care|Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
58071366|NCT00553319|DRUG|Placebo|Placebo group
58071367|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
58071368|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
58071369|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
58071370|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
58287925|NCT03499106|DRUG|Itraconazole|Oral Capsule
58287926|NCT00028626|DRUG|embolization therapy|
58287927|NCT02734862|DRUG|CD101|Intravenous antifungal therapy
58287928|NCT02734862|DRUG|Caspofungin|Intravenous antifungal therapy
57729481|NCT03143218|DRUG|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
58071371|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
58071372|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
58071373|NCT00472628|PROCEDURE|Blood samples collected|
58071374|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
58071375|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
58071376|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
58071377|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
58071378|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
58287929|NCT02734862|DRUG|Fluconazole|oral antifungal therapy
58071379|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
58071380|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
58287930|NCT02734862|DRUG|intravenous placebo|normal saline
58287931|NCT02734862|DRUG|oral placebo|microcrystalline cellulose
58287932|NCT03839615|PROCEDURE|guided bone regenerations|"intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
58287933|NCT05718440|OTHER|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
58287934|NCT06299267|OTHER|dual task conditions|dual task conditions on manual skill tests
58287935|NCT01158937|DRUG|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
58287936|NCT04843540|DRUG|CTP-543|Rifampin as oral capsule
58287937|NCT02297425|DRUG|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
58287938|NCT04604977|BEHAVIORAL|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
58287939|NCT02702362|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
58287940|NCT02585713|DRUG|Apixaban|Given PO
57729482|NCT01283269|BEHAVIORAL|Memory Support System|Training in use of a memory notebook system
57729483|NCT01283269|BEHAVIORAL|Computer Training|Computer brain fitness training
58071381|NCT02098291|DRUG|G17DT|
58071382|NCT00764465|DRUG|Maraviroc|300 mg BID
58071383|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
58071384|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
58071385|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
58071386|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
58071387|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
58071388|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
58071389|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
58287941|NCT02585713|DRUG|Dalteparin|Given SC
58287942|NCT02585713|OTHER|Questionnaire Administration|Ancillary studies
58287943|NCT03581370|DRUG|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
58287944|NCT03581370|DRUG|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
58287945|NCT01349530|OTHER|Evaluating of usual care|RESEARCH IN CURRENT CARE
58287946|NCT01349530|OTHER|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
58287947|NCT03569826|OTHER|Observational; no intervention|Observational; no intervention
58401147|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
58401148|NCT02856243|DRUG|new antiviral therapy|
58401149|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
58401150|NCT00350870|DRUG|Placebo|Placebo plus CBT
58401151|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
57932993|NCT06305780|DRUG|IVIG Placebo + Coordinated Care|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.~Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator."
58287948|NCT00098670|BIOLOGICAL|alemtuzumab|Given SC
58401152|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
58401153|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
57932994|NCT06305780|DRUG|Ivabradine + Coordinated Care|Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
58401154|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
58287949|NCT00098670|BIOLOGICAL|rituximab|Given IV
58287950|NCT00098670|DRUG|fludarabine phosphate|Given IV
58287951|NCT04685642|DRUG|Aspirin|Aspirin (100mg/day)
58287952|NCT04685642|DRUG|Atorvastatin|Atorvastatin (20mg/day)
58287953|NCT00540644|DRUG|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
58287954|NCT00540644|DRUG|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
58287955|NCT00540644|DRUG|Prednisone|50 mg p.o. Q.O.D.
58287956|NCT06314126|DIETARY_SUPPLEMENT|D-Chiro-Inositol|Patients in the experimental group will receive 1200 mg of oral D-Chiro-Inositol per day.
58287957|NCT06314126|OTHER|Placebo|Patients in the control group will receive 1200 mg of placebo per day.
58401155|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
58401156|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
58401157|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
58401158|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
57932995|NCT06305780|DRUG|Ivabradine Placebo + Coordinated Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator."
57932996|NCT06305780|DRUG|IVIG + Usual Care|Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
58287958|NCT05145257|DIETARY_SUPPLEMENT|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
58287959|NCT03782987|DRUG|BI 730357|0 mg BI 730357 tablet orally on Day 1
57932997|NCT06305780|DRUG|IVIG Placebo + Usual Care|"Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.~Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration."
57932998|NCT06305780|DRUG|Ivabradine + Usual Care|Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
57932999|NCT06305780|DRUG|Ivabradine Placebo + Usual Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration."
58287960|NCT03782987|DRUG|Itraconazole|20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
58287961|NCT00232518|PROCEDURE|Infection with hookworm larvae|
58401159|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
57933000|NCT00019084|BIOLOGICAL|aldesleukin|
58287962|NCT02185456|DRUG|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
58287963|NCT02185456|DRUG|Standard of care|oral metronidazole 500 mg twice a day for 7 days
57933001|NCT00019084|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
57933002|NCT00019084|BIOLOGICAL|ras peptide cancer vaccine|
58287964|NCT00001031|BIOLOGICAL|rgp120/HIV-1MN|
58287965|NCT00001031|BIOLOGICAL|rgp120/HIV-1 SF-2|
58287966|NCT05645861|PROCEDURE|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
58287967|NCT00791037|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
58287968|NCT00791037|PROCEDURE|leukapheresis|Undergo leukapheresis
58287969|NCT00791037|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
58287970|NCT00791037|DRUG|cyclophosphamide|Given IV
58287971|NCT00791037|BIOLOGICAL|sargramostim|Given ID
58287972|NCT00791037|OTHER|laboratory biomarker analysis|Correlative study
58287973|NCT04094116|PROCEDURE|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
58401160|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
58401161|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
58401162|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
58401163|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
58401164|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
58401165|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
58401166|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
57729484|NCT00658346|DRUG|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
57729485|NCT00658346|DRUG|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
57729486|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
57933003|NCT00019084|BIOLOGICAL|sargramostim|
58287974|NCT02306850|DRUG|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
58287975|NCT04407143|DIAGNOSTIC_TEST|IgG test|IgG+ blood test by ELISA method.
58401167|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
58401168|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
58401169|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
58401170|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
57729487|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
57729488|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
57933004|NCT00019084|BIOLOGICAL|therapeutic autologous lymphocytes|
57933005|NCT00019084|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58287976|NCT00831402|DIETARY_SUPPLEMENT|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
58401171|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
58401172|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
57933006|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
57933007|NCT01205438|DRUG|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
57933008|NCT01205438|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
57933009|NCT01205438|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
58401173|NCT03887455|DRUG|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
58401174|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
57933010|NCT00000268|DRUG|Bupropion|
58401175|NCT03887455|DRUG|Lecanemab|720 milligram (mg) weekly administered as subcutaneous injection.
58401176|NCT03887455|DRUG|Lecanemab|360 mg weekly administered as subcutaneous injection.
58401177|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
58401178|NCT00459875|DRUG|sunitinib malate|
58401179|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
58401180|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
58401181|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
58401182|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
58401183|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
58401184|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
58401185|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
58401186|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
58401187|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
58401188|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
58287977|NCT00831402|DIETARY_SUPPLEMENT|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
58401189|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
58401190|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
57729489|NCT00435370|DRUG|Tropisetron|10 mg/day
58287978|NCT00609544|DRUG|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
58287979|NCT02754518|DRUG|Entresto|
58401191|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
58401192|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
58401193|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
58401194|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
58401195|NCT02966964|DRUG|DWPUR001|
57729490|NCT00435370|DRUG|Placebo|placebo
57729491|NCT00435370|DRUG|Risperidone|6mg/day
57729492|NCT04993924|DRUG|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
57729493|NCT05360875|PROCEDURE|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
57729494|NCT01175226|DRUG|BTA798|BTA798 twice daily
58287980|NCT06432101|OTHER|Acupuncture combined with oral hydroxychloroquine sulfate tablets|Acupuncture combined with oral hydroxychloroquine sulfate tablets
58287981|NCT01093586|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo transplantation
58287982|NCT01093586|OTHER|cytogenetic analysis|Correlative studies
58287983|NCT01093586|PROCEDURE|bone marrow aspiration|Correlative studies
58287984|NCT01093586|OTHER|fluorescence in situ hybridization|Correlative studies
58287985|NCT01093586|DRUG|busulfan|Given orally
58287986|NCT01093586|DRUG|cyclophosphamide|Given IV
58287987|NCT01093586|DRUG|anti-thymocyte globulin|Given IV
58287988|NCT01093586|DRUG|methylprednisolone|Given IV
58287989|NCT01093586|DRUG|cyclosporine|Given IV
58287990|NCT01093586|DRUG|mycophenolate mofetil|Given orally or IV
58287991|NCT01093586|OTHER|flow cytometry|Correlative studies
58287992|NCT01093586|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
58287993|NCT06195176|OTHER|Shoulder exercises|"Operational Definition:~* Lift the shoulders as high as possible toward the ears.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
58287994|NCT06195176|OTHER|Hand exercises|"Operational Definition:~* Open and close the hands, making a fist and applying force.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
58287995|NCT05592002|DEVICE|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
58287996|NCT04678609|OTHER|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
58287997|NCT00412789|DRUG|Patupilone|
58287998|NCT06549153|OTHER|Education Content|Participants will be offered group based education sessions expected to last 90 minutes
58287999|NCT06549153|OTHER|Focus Group|Participants will attend via Zoom
58288000|NCT06095479|DEVICE|2D ultrasound scan and MRI examination|All subjects will undergo a 2D ultrasound scan and MRI examination.
58288001|NCT02579382|DRUG|TDF|300 mg tablets administered orally once daily
58288002|NCT02579382|DRUG|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
58288003|NCT02579382|DRUG|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
58288004|NCT04078724|DIETARY_SUPPLEMENT|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
58288005|NCT04078724|OTHER|Without 5-HTP|Subject will not take 5-HTP
58288006|NCT02479113|PROCEDURE|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
58288007|NCT03240276|OTHER|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
57729495|NCT01175226|DRUG|Placebo|Placebo twice daily
58288008|NCT03240276|DEVICE|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
58288009|NCT03240276|OTHER|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
58288010|NCT05516771|DEVICE|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
58288011|NCT03260790|BIOLOGICAL|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
58401196|NCT02966964|DRUG|Placebo|
58288012|NCT03260790|BIOLOGICAL|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
58288013|NCT00572871|OTHER|plyometric exercise|single bout of plyometric exercise
58288014|NCT00572871|OTHER|resistance exercise|single bout of resistance exercise
58288015|NCT00572871|OTHER|No exercise|Will not do any exercise
58288016|NCT02087670|OTHER|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
58288017|NCT02087670|OTHER|exercise protocol no supervised|Exercise program at the community
58288018|NCT04465526|DIAGNOSTIC_TEST|computed tomography perfusion imaging|The new-generation dual-source computed tomography scanner Somatom® Force will be used for all CTP studies. Myocardial perfusion will be evaluated in a stress dynamic CT protocol. The scan range will be determined based on a low-dose non-contrast scan. Subsequently, regadenoson will be administered intravenously at a single dose of 0.4 mg, and followed after 50 seconds delay by 35 mL of the iodinated contrast agent (iohexol, concentration 350 mg I/mL) injected at the flow rate of 5 mL/s. Finally, low-dose non-contrast dual-energy CT scan will be performed 5-6 min after the dynamic scan to assess late enhancement of the myocardium.
58288019|NCT05660785|DRUG|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
58288020|NCT00257738|BIOLOGICAL|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
58288021|NCT00257738|BIOLOGICAL|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
58401197|NCT00271921|BEHAVIORAL|Calorie controlled diet|
58401198|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
58288022|NCT03300050|BIOLOGICAL|cH8/1N1 LAIV|"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."
58288023|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
58288024|NCT03300050|BIOLOGICAL|cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
58288025|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH8/1N1 IIV|"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
58288026|NCT03300050|BIOLOGICAL|Normal saline|Administered intranasally as 0.25 mL nasal drops per nostril
58288027|NCT03300050|BIOLOGICAL|Phosphate buffered saline (PBS)|Administered intramuscularly as 0.5 mL injection
58288028|NCT04324762|BEHAVIORAL|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
58401199|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
58401200|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
58288029|NCT05436639|DRUG|SPI-62 dose|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
58288030|NCT00002261|BIOLOGICAL|Smallpox Vaccine|
58401201|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
58401202|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
58401203|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
58288031|NCT00002261|BIOLOGICAL|HIVAC-1e|
58288032|NCT00002261|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
58401204|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
58401205|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
58288033|NCT02666820|PROCEDURE|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
58288034|NCT02666820|PROCEDURE|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
58288035|NCT01827592|DRUG|Elobixibat 10 mg|Elobixibat 10 mg/day
58288036|NCT01827592|DRUG|Elobixibat 5 mg|Elobixibat 5 mg/day
58288037|NCT01827592|DRUG|Placebo|Placebo
58288038|NCT05906394|PROCEDURE|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
58288039|NCT01344473|DEVICE|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
58288040|NCT03001908|OTHER|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
58288041|NCT03001908|OTHER|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
58288042|NCT05118217|OTHER|This is a non-interventional study|This is a non-interventional study
58288043|NCT03440138|PROCEDURE|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
58288044|NCT04304508|DRUG|BAY2433334|Tablet, taken orally once a day.
58288045|NCT04304508|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
58288046|NCT05667506|BIOLOGICAL|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
58288047|NCT04164797|DRUG|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
58288048|NCT04164797|OTHER|chemoradiotherapy|chemoradiotherapy
58288049|NCT02608814|PROCEDURE|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
58288050|NCT02608814|OTHER|Ultrasound|
58288051|NCT01750645|DRUG|Intradetrusor Injection of Type-A Botulinum Toxin|
58288052|NCT01750645|OTHER|Other interventions analyzed according to protocol|"* Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs"
57933011|NCT02049034|OTHER|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
58288053|NCT00280514|DRUG|cefpirome and moxifloxacin administration|
58288054|NCT01675674|OTHER|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
58288055|NCT06612112|OTHER|No Interventions|No Interventions
58288056|NCT00192777|DRUG|Xeloda|
58288057|NCT00192777|PROCEDURE|External Beam Radiotherapy|
58288058|NCT04275453|DRUG|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
58288059|NCT04275453|DIETARY_SUPPLEMENT|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
58288060|NCT04275453|OTHER|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
58288061|NCT02484092|BIOLOGICAL|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
58288062|NCT06612528|DEVICE|tDCS|"The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle."
58288063|NCT06612528|DEVICE|Flexible tube in water|"The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy."
58288064|NCT05891769|DRUG|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
58288065|NCT03184571|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
58288066|NCT00911417|DEVICE|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
58288067|NCT01673087|DRUG|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
58288068|NCT01673087|DRUG|Dexamethasone|"Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
58288069|NCT01673087|DRUG|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
58288070|NCT01673087|DRUG|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
58288071|NCT06165198|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
58288072|NCT00428012|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
58288073|NCT00428012|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
58288074|NCT03283046|DRUG|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
58288075|NCT03283046|DRUG|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
58288076|NCT03283046|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
58288077|NCT03283046|DRUG|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
58288078|NCT02695862|DRUG|Terlipressin|
58288079|NCT05310435|DEVICE|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
58288080|NCT05310435|DEVICE|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
58288081|NCT05310435|DEVICE|Single circumference measurement with tape measure|Single circumference measurement with tape measure
58288082|NCT05310435|DEVICE|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
58288083|NCT04472598|DRUG|Navitoclax|Tablet; Oral
58288084|NCT04472598|DRUG|Ruxolitinib|Tablet; Oral
58288085|NCT04472598|DRUG|Placebo for Navitoclax|Tablet; Oral
58288086|NCT01818089|DEVICE|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
58288087|NCT00361608|DEVICE|EarlySense ES 16|
58401206|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
58288088|NCT04332003|DEVICE|Remote Ischemic Conditioning (RIC) Treatment|RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
58288089|NCT03932916|DRUG|Donepezil Pamoate for Injection 17mg|A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
58288090|NCT03932916|DRUG|Donepezil Pamoate for Injection 34mg|A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
58288091|NCT03932916|DRUG|Donepezil Hydrochloride 5mg|A tablet of 5mg Donepezil Hydrochloride will be administered once.
58288092|NCT05964920|DRUG|Saline|Two placebo injections one at baseline and one week 3.
58288093|NCT05964920|DRUG|Testosterone Undecanoate|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
58288094|NCT05964920|DRUG|Saline + Resistance exercise training|Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
58288095|NCT05964920|DRUG|Testosterone Undecanoate + Resistance exercise training|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
58288096|NCT04873635|OTHER|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
58288097|NCT03289013|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
58288098|NCT03289013|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
58288099|NCT03289013|OTHER|LT-2|Newly developed adhesive
58288100|NCT03289013|OTHER|LT-21|Newly developed adhesive
58288101|NCT03289013|OTHER|LT-25|Newly developed adhesive
58288102|NCT03289013|OTHER|33-20|Newly developed adhesive
58288103|NCT03114085|DRUG|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
58288104|NCT03114085|DRUG|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
58288105|NCT04098796|DRUG|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
57729496|NCT03969238|BEHAVIORAL|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
57729497|NCT01466998|OTHER|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
57729498|NCT01466998|OTHER|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
57729499|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
57729500|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
57729501|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
57729502|NCT04001829|DRUG|Docetaxel|Given IV
57729503|NCT04001829|DRUG|Paclitaxel|Given IV
57729504|NCT04001829|OTHER|Quality-of-Life Assessment|Ancillary studies
57729505|NCT04001829|OTHER|Questionnaire Administration|Ancillary studies
57729506|NCT01822652|GENETIC|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
57729507|NCT01822652|GENETIC|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
57729508|NCT01822652|DRUG|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
57729509|NCT01822652|DRUG|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
57729510|NCT01822652|DRUG|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
57729511|NCT01822652|GENETIC|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
57729512|NCT01176253|PROCEDURE|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
57729513|NCT05633784|OTHER|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
57729514|NCT05633784|OTHER|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
57729515|NCT05633784|OTHER|Telerehabilitation|Support from a physiotherapist (if needed)
57729516|NCT05633784|OTHER|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
57729517|NCT05633784|OTHER|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
57729518|NCT05633784|OTHER|telepsycology|Psychological support (if necessary)
57729519|NCT05633784|OTHER|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
57729520|NCT05633784|OTHER|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
57729521|NCT05633784|OTHER|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
58288106|NCT04098796|DRUG|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
58288107|NCT00516685|BIOLOGICAL|Recombinant Human rEGF-P64K/Montanide Vaccine|
58288108|NCT02426034|DRUG|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
58288109|NCT03206827|OTHER|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
58288110|NCT03206827|OTHER|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
58401207|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
58401208|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
58401209|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
57933012|NCT02049034|OTHER|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
57933013|NCT04323839|OTHER|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
57933014|NCT04323839|OTHER|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
57933015|NCT06734312|DEVICE|Gastric Fundal Mucosal Ablation (GFMA)|Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy
57933016|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
57933017|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
57933018|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
57933019|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
57933020|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
57933021|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
57933022|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
57933023|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
57933024|NCT00164619|BEHAVIORAL|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]
57933025|NCT00164619|BIOLOGICAL|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
57933026|NCT01910909|RADIATION|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
58401210|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
57933027|NCT04671667|DRUG|Carboplatin|Given IV
57933028|NCT04671667|DRUG|Cisplatin|Given IV
58288111|NCT03206827|OTHER|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
58288112|NCT01423929|DRUG|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
58288113|NCT01423929|DEVICE|Room air|Fitting of Oxymask TM
58288114|NCT05102071|DRUG|empagliflozin|empagliflozin
57933029|NCT04671667|PROCEDURE|Computed Tomography|Undergo CT
57933030|NCT04671667|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57933031|NCT04671667|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57933032|NCT04671667|BIOLOGICAL|Pembrolizumab|Given IV
57933033|NCT04671667|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
57933034|NCT01608867|BIOLOGICAL|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
57933035|NCT03118037|DEVICE|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
57933036|NCT03519867|DRUG|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
57933037|NCT03519867|DRUG|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
57933038|NCT00177138|DRUG|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
57933039|NCT00177138|DRUG|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)
57933040|NCT00955851|OTHER|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
57933041|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
57933042|NCT04697810|DRUG|Namodenoson|25 mg q12hours x 36 weeks
57933043|NCT04697810|DRUG|Placebo|Matching capsules q12hours x 36 weeks
57933044|NCT01028222|DRUG|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
57933045|NCT01028222|DRUG|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
58288115|NCT05102071|DRUG|metformin|metformin
58288116|NCT05102071|DRUG|sulfonylurea|sulfonylurea
58288117|NCT06067581|BIOLOGICAL|SENL103|Patients will be treated with BCMA CAR-T cells
58288118|NCT06357520|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
58288119|NCT06357520|DRUG|Itraconazole|Itraconazole capsule will be administered orally.
58288120|NCT04691804|DRUG|Fuzuloparib , Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po"
57933046|NCT03167203|BIOLOGICAL|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
57933047|NCT06736067|BEHAVIORAL|Exercise|Thirty minutes of exercise on a treadmill, including a 5-minute warm-up followed by increments in speed until reaching optimal moderate to high intensity (60-80% of age-predicted maximal heart rate), which will be maintained for 20 min, followed by a 5-minute cool-down. Age-predicted maximal HR will be defined as 220 beats-per-minute (BPM) minus age in years.
58288121|NCT04691804|DRUG|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po"
58288122|NCT06003075|COMBINATION_PRODUCT|Nivolumab and Chemotherapy|3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
58288123|NCT06003075|DRUG|Nivolumab|Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
58288124|NCT06003075|PROCEDURE|Post Induction Surgery|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
58288125|NCT06003075|RADIATION|Post Induction XRT|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
58288126|NCT02714556|OTHER|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
58288127|NCT06037018|BIOLOGICAL|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
58288128|NCT03595059|DRUG|ABBV-155|Intravenous (IV) Infusion
58288129|NCT03595059|DRUG|Paclitaxel|Intravenous (IV) Infusion
58288130|NCT03595059|DRUG|Docetaxel|Intravenous (IV) Infusion
58288131|NCT00065702|DRUG|Active liquid remedy|
58288132|NCT03629808|PROCEDURE|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
58401211|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
58401212|NCT00642434|DRUG|carvedilol|variable
57933048|NCT05975801|OTHER|Dry Cupping Therapy|
57933049|NCT05975801|OTHER|Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound|
58288133|NCT03629808|PROCEDURE|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
58288134|NCT01322087|DIETARY_SUPPLEMENT|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
58288135|NCT03046771|BEHAVIORAL|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
58288136|NCT03029455|DRUG|VX-659|
58288137|NCT03029455|DRUG|Tezacaftor|
58288138|NCT03029455|DRUG|Ivacaftor|
58401213|NCT00642434|DRUG|metoprolol|variable
57729522|NCT05633784|OTHER|State of health of the patient|Severity Index and Comordbidity index
57933050|NCT06729918|OTHER|Virtual reality|Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
57933051|NCT06729918|OTHER|simulated patient|Thoracic lung physical examination will be studied using a simulated patient.
57933052|NCT06540768|OTHER|Therapeutic Normothermia Group|Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
57933053|NCT00257829|DRUG|Methazolamide|
57933054|NCT00257829|DRUG|Cisplatin|
58401214|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
58401215|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
58401216|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
58401217|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
57933055|NCT05309551|DEVICE|IMT- Intervention group|The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
58288139|NCT03029455|DRUG|VX-659 Matching Placebo|
57729523|NCT03627403|DRUG|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
57729524|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
58288140|NCT03029455|DRUG|Triple Combination (TC) Matching Placebos|
58288141|NCT02981914|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
58288142|NCT02482545|DIETARY_SUPPLEMENT|Meal replacement|
58288143|NCT04633772|DRUG|Angiotensin-(1-7)|Intravenous supplementation of Angiotensin-(1-7)
58288144|NCT04633772|DRUG|Placebo|NaCl 0.9%
58288145|NCT03770026|DRUG|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
58288146|NCT03770026|DRUG|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
58401218|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
58401219|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
58401220|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
57933056|NCT05309551|DEVICE|IMT- Placebo group|The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
57933057|NCT06736483|DRUG|Dexmedetomidine|Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
57933058|NCT06736483|DRUG|Placebo administration|Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
57933059|NCT06736483|OTHER|Face Legs Activity Cry Consolability scale|The pain will be assessed on admission and every 15 minutes until discharge from the PACU
57933060|NCT06736483|OTHER|Post-Hospitalization Behavior Questionnaire|The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7
58288147|NCT03770026|BIOLOGICAL|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
58288148|NCT02429102|DRUG|MT-8554|
58288149|NCT02429102|DRUG|Placebo|
57933061|NCT06736483|OTHER|Postoperative pain measure|The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months
57933062|NCT06736483|OTHER|Post-operative quality of life questionnaire|The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months
57933063|NCT05855941|DIAGNOSTIC_TEST|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
57933064|NCT03549000|OTHER|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
57933065|NCT03549000|OTHER|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
57933066|NCT03549000|DRUG|NIR178|NIR178 Specified dose on specified days, Orally
57933067|NCT00361491|DRUG|SSR149415|
57933068|NCT06626425|OTHER|Healthy Minds Program App|An 8-week meditation-based well-being training containing content for each of the four pillars of the training program: Awareness, Connection, Insight, and Purpose.
57933069|NCT06626425|OTHER|Hydro Coach App|The Hydro Coach app (HC). A smartphone-based wellness app to ensure proper hydration.
57933070|NCT03903874|BEHAVIORAL|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
57933071|NCT05917041|DEVICE|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
57933072|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
57933073|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
57933074|NCT06607263|DEVICE|Dental floss|Dental floss
57933075|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
57933076|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
57933077|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
57933078|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
58288150|NCT01859949|DRUG|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
58288151|NCT02117219|BIOLOGICAL|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
58401221|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
57933079|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
57933080|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
57933081|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
57933082|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
57933083|NCT06244641|OTHER|Auto-questionnaires, hetero-questionnaires and Evoked-potentials|Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
57933084|NCT06735300|DRUG|Nirmatrelvir/Ritonavir (Paxlovid)|After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.
57933085|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
57933086|NCT06279871|BIOLOGICAL|ARCT-2303|Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
57933087|NCT06279871|BIOLOGICAL|Influenza vaccine|Licensed cell-based influenza vaccine
58288152|NCT02117219|DRUG|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
57933088|NCT06279871|BIOLOGICAL|Influenza vaccine, adjuvanted|Licensed influenza vaccine, adjuvanted
57933089|NCT06279871|OTHER|Placebo|0.9% saline
58288153|NCT02117219|BIOLOGICAL|tremelimumab|tremelimumab will be administered by IV infusion
58288154|NCT05568797|BIOLOGICAL|RSVPreF3 OA vaccine|One dose of RSVPreF3 OA vaccine administered intramuscularly.
58288155|NCT05568797|BIOLOGICAL|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
57729525|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
57729526|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
57729527|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
57729528|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
57729529|NCT00208429|DEVICE|Pinnacle Acetabular System|
57729530|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
57729531|NCT04695327|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
57729532|NCT03418844|OTHER|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
57729533|NCT03418844|DIAGNOSTIC_TEST|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"
57729534|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
57729535|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
57729536|NCT00123227|DRUG|Rosiglitazone|
57729537|NCT03269474|PROCEDURE|Experimental Group|Subjects with EB diagnosis
57729538|NCT00583557|DRUG|belimumab|IV 10mg/kg Q28 days
57729539|NCT02846987|DRUG|Abemaciclib|
57729540|NCT02353793|DEVICE|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
57729541|NCT02353793|DEVICE|Cotton wool blanket|Using cotton wool blanket for patient warming
58288156|NCT06542900|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (SCC, VC/VS, ALIC, ITP, NAc, LHb, MFB, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
58288157|NCT03243253|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
58288158|NCT04993872|DRUG|Biktarvy Tab|Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
58288159|NCT03787602|DRUG|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
57729542|NCT01242527|DRUG|placebo|4 capsules (1g) daily for 12 weeks
57729543|NCT01242527|DRUG|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
57729544|NCT01242527|DRUG|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
57729545|NCT01242527|DRUG|omefas|4 capsules (1g)daily for 12 weeks
57729546|NCT02801045|BEHAVIORAL|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects."
57729547|NCT04750252|BIOLOGICAL|StroMel|Autologous MSC
57729548|NCT02574975|DRUG|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
57729549|NCT02574975|DRUG|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
57729550|NCT02574975|DRUG|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
57729551|NCT02574975|DEVICE|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
57729552|NCT02574975|DRUG|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
58288160|NCT03787602|DRUG|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
58288161|NCT03451955|OTHER|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
58288162|NCT03457818|DRUG|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
58288163|NCT03457818|OTHER|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
58288164|NCT04569929|OTHER|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
58288165|NCT00760487|DEVICE|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
58288166|NCT03327038|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
58288167|NCT03327038|OTHER|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
58288168|NCT03327038|BEHAVIORAL|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
58288169|NCT03327038|OTHER|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
58288170|NCT03327038|OTHER|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
58288171|NCT00362661|DRUG|Cortisol|Cortisol 10 mg/d for 3 months
58288172|NCT04854759|DRUG|Amantadine Hydrochloride|100 mg, capsule
58288173|NCT04854759|DRUG|Placebo|100 mg, capsule
58288174|NCT02768792|DRUG|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
58288175|NCT02096562|OTHER|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
58288176|NCT02096562|OTHER|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
57933090|NCT03877107|DIAGNOSTIC_TEST|Urinary symptoms profile questionnaire|Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
58071390|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
58288177|NCT00114829|PROCEDURE|MR colonography with dynamic contrast uptake|
58288178|NCT03130374|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
58071391|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
58071392|NCT03039699|DRUG|Ergoferon|
58071393|NCT03039699|DRUG|Placebo|
57933091|NCT03877107|DIAGNOSTIC_TEST|Micturition calendar|Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
58288179|NCT04321486|OTHER|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
58288180|NCT06478329|OTHER|Progressive Core Stabilization Exercise Training|The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
58288181|NCT04909515|DRUG|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
58288182|NCT04909515|DRUG|GM-CSF|250 - 500 microgram/m2/day
58288183|NCT04909515|DRUG|Isotretinoin|160 mg/m2/day
58288184|NCT05314829|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
58288185|NCT01486823|DRUG|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
58288186|NCT01486823|DRUG|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
58288187|NCT02164318|OTHER|Handgrip training|
58288188|NCT02164318|DRUG|Nitroglycerin ointment|
58288189|NCT00565552|DRUG|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
58288190|NCT00170274|DEVICE|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
58288191|NCT00170274|DEVICE|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
58288192|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
58288193|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
58288194|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
58288195|NCT03343366|DRUG|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
58071394|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
58288196|NCT03343366|PROCEDURE|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
58288197|NCT03343366|BEHAVIORAL|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
58288198|NCT02568462|DEVICE|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
58288199|NCT05110365|OTHER|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
58288200|NCT01792102|DRUG|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
58288201|NCT01409915|DRUG|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
58288202|NCT01409915|DRUG|Saline -- placebo comparator|subcutaneous injection
58288203|NCT01639248|DRUG|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
58288204|NCT06260917|DIAGNOSTIC_TEST|position of urination|effect of position on uroflowmetry parameters
58288205|NCT01199887|DRUG|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
57933092|NCT05043090|DRUG|savolitinib|Tablets : 3 × 200 mg tablets once daily
57933093|NCT05043090|DRUG|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
58071395|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
57933094|NCT05043090|DRUG|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
57933095|NCT04680351|PROCEDURE|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
57933096|NCT06292650|DRUG|ZM-02-L|rAAV-PsCatCh2.0 intravitreal injection of low dose
57933097|NCT06292650|DRUG|ZM-02-H|rAAV-PsCatCh2.0 intravitreal injection of high dose
57933098|NCT06292650|PROCEDURE|ZM-02-S|sham intravitreal injection of ZM-02 (not actual injection)
58288206|NCT03597191|OTHER|Exercises|Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
58288207|NCT00397189|DRUG|Circadin|Prolonged release melatonin 2 mg
58288208|NCT00397189|DRUG|placebo circadin|placebo circadin tablets
58288209|NCT02104245|DRUG|Ciprofloxacin dispersion for inhalation|
58288210|NCT02104245|DRUG|Placebo|
58288211|NCT01504373|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
58288212|NCT04462822|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
58288213|NCT04462822|DRUG|ADVAIR DISKUS® 250/50|2 inhalations of Test and Reference product in each study period
58288214|NCT01212146|DIETARY_SUPPLEMENT|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.
58288215|NCT01212146|DIETARY_SUPPLEMENT|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
58288216|NCT03790865|DRUG|Livoletide|Daily subcutaneous injection
58288217|NCT03790865|DRUG|Placebo|Daily subcutaneous injection
58288218|NCT05098366|DRUG|Furosemide|0.1mg/kg (max 5mg) of IV furosemide
58288219|NCT05098366|DRUG|Normal saline|20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
58288220|NCT06549192|OTHER|20 meter shuttle run test|20 Meter Shuttle Run Test: Subjects run distance of 20 meters round trip. Running speed is monitored at certain intervals with help of a tape recorder that gives a signal. Subjects start running when they hear first beep and must reach other line(one foot must cross the line) by second beep. When they hear second signal, they return to starting line. The speed, which is slow at beginning, gradually increases every 10 seconds. The subject adjusts his/her pace so that he/she is on the other line at the second signal. If subject misses one signal and catches second signal, test continues. If subject misses two signals in row and doesn't reach line at other signal, test is terminated. At end of test, aerobic power values are calculated from VO2max estimation table in ml/kg/min according to number of sit-ups run. At end of test, marks obtained by athlete are calculated and VO2max value of subject is calculated in ml/kg/min from evaluation table.
58288221|NCT06269146|DRUG|Pramipexole Pill|The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
58288222|NCT06269146|DRUG|Placebo Pill|Placebo will match the study drug in mode of administration, color, size, and taste.
57933099|NCT00786812|DRUG|Nilotinib|
57933100|NCT06735586|PROCEDURE|neuromuscular control exercise|All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.
58288223|NCT02358265|DRUG|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
58288224|NCT02358265|DRUG|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
58288225|NCT02358265|DRUG|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
58288226|NCT02358265|DRUG|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
58288227|NCT05305456|DRUG|Tanreqing capsule|3 capsules per time, 3 times a day
58288228|NCT05305456|DRUG|Tanreqing capsule simulator|3 capsules per time, 3 times a day
58288229|NCT01721447|DRUG|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
58071396|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
58071397|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
58071398|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
57933101|NCT06735586|PROCEDURE|neuromuscular control exercise and taping|Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
57933102|NCT00076557|GENETIC|Adeno-Associated Viral with Human Factor IX|
57933103|NCT00607880|PROCEDURE|vascular access device placement|
57933104|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
57933105|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
57933106|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
57933107|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
57933108|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
57933109|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
58071399|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
58288230|NCT04547686|BEHAVIORAL|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
58288231|NCT04547686|BEHAVIORAL|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
58288232|NCT06194162|DEVICE|Weighted blanket|"The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
58071400|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
58288233|NCT06194162|DEVICE|Non-weighted blanket|"The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
58288234|NCT04062721|DRUG|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
58288235|NCT04062721|PROCEDURE|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
58071401|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
58071402|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
58071403|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
57933110|NCT06734754|DEVICE|fetal heart sound listening|The pregnant women in the experimental group and their partners listened to fetal heart sounds for 7 days. After obtaining pre-test data from the participants in the intervention group, the midwifery intervention to be implemented was explained. A fetal heart rate monitoring device, which will be given to couples to listen to the fetal heart sound before sleep, was introduced. They were told that they had to listen to the fetal heart sound at least 7 times using this device. A supporting application was downloaded to the pregnant woman's phone for the installation of the fetal heart rate monitoring device. The way of using the application and the operation steps were introduced. It was explained to the couples that the application can detect the baby's heartbeat within seconds thanks to its smart search technology, and also provides step-by-step guidance by giving live feedback.
57933111|NCT03692897|OTHER|All approved therapies for the treatment of Chronic Hepatitis B (CHB)|All approved therapies for the treatment of Chronic Hepatitis B (CHB).
57933112|NCT03410017|OTHER|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
57933113|NCT06313073|RADIATION|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
57933114|NCT06313073|RADIATION|adjuvant radiotherapy|The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
57933115|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
58071404|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
58071405|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
58288236|NCT04062721|DRUG|In situ immunotherapy|Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
58288237|NCT00551395|PROCEDURE|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
58288238|NCT00551395|PROCEDURE|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
57933116|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
57933117|NCT05736159|DIAGNOSTIC_TEST|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
58288239|NCT04577794|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
58288240|NCT04577794|DRUG|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
58288241|NCT03486405|OTHER|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
58288242|NCT03486405|OTHER|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
58288243|NCT01808937|OTHER|Morphea|
58288244|NCT00090870|BIOLOGICAL|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
58288245|NCT00090870|BIOLOGICAL|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
58288246|NCT00090870|DRUG|thalidomide|200mg daily by mouth
57933118|NCT05736159|DIAGNOSTIC_TEST|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
57933119|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
57933120|NCT06585488|DRUG|BGB-53038|Administered orally
57933121|NCT06585488|DRUG|Tislelizumab|administered by intravenous infusion
57933122|NCT06585488|DRUG|Cetuximab|administered by intravenous infusion
58071406|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
58071407|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
58071408|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
58071409|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
58071410|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
58071411|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
58071412|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
58288247|NCT04682379|DIAGNOSTIC_TEST|Proprioceptive assessment|"1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test"
58288248|NCT06231134|DEVICE|Conventional surgery|an implant will be exposed using the conventional surgical exposure techniques with a tissue punch, the cover screw will be removed, and the healing abutment placed
57933123|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
58288249|NCT06231134|DEVICE|Diode laser 940 nm|implant will be uncovered using a diode laser (940nm) in contact type with a continuous mode at a power of 1.5 watts, the laser tip will be used in a circular motion to create a small opening which will be increased till large enough to expose and remove the cover screw and place the healing abutments.
58288250|NCT06231134|DEVICE|Electrosurgical|the monopolar electrosurgical device will be used in the same way as the laser tip with additional care avoiding contacting the implants during exposure.
58288251|NCT00321906|DRUG|azathioprine|azathioprine 2mg/kg
58288252|NCT00321906|DRUG|sirolimus|sirolimus 2-4mg daily
57933124|NCT03132532|DRUG|Carboplatin|Chemotherapy
58288253|NCT04301726|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
58288254|NCT04301726|DRUG|Placebo oral tablet|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
58288255|NCT02049983|DEVICE|Use of Levita Magnetics Grasper|
58288256|NCT04633993|BEHAVIORAL|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
58288257|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
58288258|NCT01075919|DIETARY_SUPPLEMENT|Placebo|1 g olive oil taken daily for 12 weeks
57933125|NCT03132532|DRUG|Cisplatin|Chemotherapy
57933126|NCT03132532|DRUG|Etoposide|Chemotherapy
57933127|NCT03132532|DRUG|Paclitaxel|Chemotherapy
57933128|NCT03132532|DRUG|Pemetrexed|Chemotherapy
57933129|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
57933130|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
57933131|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
58288259|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
58288260|NCT05858866|OTHER|Piper Fatigue Scale|The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
58288261|NCT03026829|DEVICE|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
58401222|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
58401223|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
57933132|NCT05011058|DRUG|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Other name: VRx-3996~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
57933133|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
57933134|NCT01879787|OTHER|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
57933135|NCT03444727|OTHER|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
57933136|NCT03444727|OTHER|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
58288262|NCT01877668|DRUG|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
58401224|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
57933137|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
57933138|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
58401225|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
58401226|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
58401227|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
58401228|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
58401229|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
58401230|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
58401231|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
58401232|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
57933139|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
57933140|NCT03410836|DRUG|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
57933141|NCT03410836|OTHER|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
57933142|NCT00239226|PROCEDURE|IAS pacing - study group|site of implant and permanent pacing
57933143|NCT00239226|PROCEDURE|IAS pacing control group|site of implant and permanent pacing
58288263|NCT01877668|DRUG|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
58288264|NCT01877668|DRUG|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
57933144|NCT00239226|PROCEDURE|Pacing RAA study group|site of implant and permanent pacing
57933145|NCT00239226|PROCEDURE|Pacing RAA control group|site of implant and permanent pacing
57933146|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
58288265|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
58288266|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
58288267|NCT00587795|DEVICE|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
57933147|NCT02887027|BEHAVIORAL|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
57933148|NCT06734273|DRUG|Mounjaro|In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
57933149|NCT06734273|PROCEDURE|Sleeve Gastrectomy|Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
57933150|NCT06044493|DRUG|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
57933151|NCT06044493|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
57933152|NCT02817230|DRUG|Statin|
57933153|NCT03346941|DRUG|DAA treatment|Direct-acting antiviral-based treatment
57933154|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
58288268|NCT00587795|OTHER|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
58401233|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
57933155|NCT06561386|DRUG|Nivolumab|Specified dose on specified days
57933156|NCT06561386|DRUG|Relatlimab|Specified dose on specified days
57933157|NCT06561386|DRUG|Pembrolizumab|Specified dose on specified days
57933158|NCT06561386|DRUG|Carboplatin|Specified dose on specified days
57933159|NCT06561386|DRUG|Pemetrexed|Specified dose on specified days
57933160|NCT06561386|DRUG|Cisplatin|Specified dose on specified days
57933161|NCT02550522|DEVICE|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
57933162|NCT05458024|DRUG|Vitamin D 2|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
58288269|NCT03339713|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.
58288270|NCT03339713|BIOLOGICAL|Fluarix|Fluarix will be administered as intramuscular injection.
58288271|NCT03339713|BIOLOGICAL|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
58288272|NCT00346762|BEHAVIORAL|Education|HIV prevention education and risk reduction counselig
57729553|NCT03236103|OTHER|Clinical Recommendations|"The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
57729554|NCT05960539|PROCEDURE|surgical training|surgical residency focussed on visceral robotic procedures
57729555|NCT04679220|PROCEDURE|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
58288273|NCT00886366|DRUG|AZD6714|Oral single doses a-h suspension
58288274|NCT00886366|DRUG|Placebo|Oral single doses suspension
58288275|NCT00886366|DRUG|AZD6714|Oral single doses a-d suspension
58288276|NCT00886366|DRUG|AZD6714|Oral single doses d and g suspension
58288277|NCT04110886|DRUG|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
58288278|NCT04110886|DRUG|Placebo|Single dose, injection matching placebo
58288279|NCT03130959|BIOLOGICAL|Nivolumab|Specified dose on specified days
58288280|NCT03130959|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58288281|NCT00705341|DRUG|fluticasone|Inhaled corticosteroid approved for treatment of asthma
58288282|NCT03821077|BIOLOGICAL|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
58288283|NCT05240807|DIAGNOSTIC_TEST|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
58288284|NCT01357395|DRUG|Amuvatinib|Amuvatinib 300 mg PO TID
58288285|NCT01960465|DEVICE|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
57729556|NCT00222339|BEHAVIORAL|task-specific training|
57729557|NCT05127343|PROCEDURE|Sealing deep pits and fissures|Application of the pit and fissure sealant
57729558|NCT04367168|DRUG|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
57729559|NCT04367168|DRUG|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
57729560|NCT06384651|DRUG|Intraosseous Vancomycin Injection|"* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus."
57729561|NCT06384651|DRUG|Intravenous Vancomycin|• Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
57729562|NCT06512662|PROCEDURE|Consultations with paramedics|"Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status)."
57729563|NCT02649686|DRUG|Durvalumab|
58288286|NCT04676152|DEVICE|Masimo Noninvasive Blood Pressure Device|Non-invasive blood pressure device
58288287|NCT02798107|DRUG|idarucizumab|drug
58288288|NCT03378245|BEHAVIORAL|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
58288289|NCT06610643|DRUG|combination therapy|A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
58288290|NCT06610643|DRUG|SOC|Standard of care
58288291|NCT03305692|DIAGNOSTIC_TEST|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
58288292|NCT00159770|DRUG|ziprasidone versus olanzapine , risperidone or quetiapine|
58288293|NCT00159770|BEHAVIORAL|Panss , CGI-C, UKU-SERS-Pa|
58288294|NCT00159770|PROCEDURE|Blood tests|
58288295|NCT04540328|OTHER|Non-surgical periodontal treatment|
58288296|NCT04663243|BEHAVIORAL|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
58288297|NCT01223937|DRUG|Desmopressin|
58288298|NCT01223937|DRUG|Placebo|
58288299|NCT02360423|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
57933163|NCT05458024|DRUG|Vitamin D2 Placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
57933164|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933165|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933166|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933167|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933168|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933169|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
57933170|NCT01984944|OTHER|Autistic functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
57933171|NCT01984944|OTHER|Control functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
57933172|NCT06708520|DRUG|Rupatadine|10 mg tablets
57933173|NCT06735157|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (intermittent theta burst stimulation) will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby iTBS will be delivered three times during the same study session. Each iTBS session will deliver 600 pulses in 50 Hz bursts of 3 pulses for a total of 1800 pulses delivered each day. iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
58288300|NCT02360423|DEVICE|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
58401234|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
58401235|NCT01186042|OTHER|Observational|No intervention
58401236|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
58401237|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
58401238|NCT02183480|DRUG|Linagliptin, low dose|
58288301|NCT00473447|BEHAVIORAL|Modified Constraint-induced movement therapy|
58288302|NCT04824937|DRUG|Telaglenastat|Capsule, taken by mouth
58401239|NCT02183480|DRUG|Linagliptin, medium dose|
58401240|NCT02183480|DRUG|Linagliptin, high dose|
58401241|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
58288303|NCT04824937|DRUG|Talazoparib|Capsule, taken by mouth
58288304|NCT00811980|DRUG|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
58288305|NCT01666912|DRUG|Contraceptive implant|
58401242|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
58401243|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
58401244|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
58401245|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
58401246|NCT00045149|BIOLOGICAL|aldesleukin|
57729564|NCT02649686|DRUG|Trastuzumab|
57729565|NCT02635477|BEHAVIORAL|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
57729566|NCT02635477|BEHAVIORAL|Control|Behavioral: actigraphy device, step count measurement only
57729567|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
57729568|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
58288306|NCT01620541|PROCEDURE|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
58288307|NCT01620541|PROCEDURE|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
58288308|NCT00624689|DIETARY_SUPPLEMENT|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
58288309|NCT05251116|DEVICE|FreeStyle Libre|FreeStyle Libre 2 continuous Glucose Monitoring System
58288310|NCT03326297|OTHER|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
58288311|NCT03326297|BEHAVIORAL|Measures to support and education to the family|Pedagogical intervention in parents and health education
58288312|NCT00185042|DRUG|Pactimibe, CS-505|
58288313|NCT00549549|DRUG|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
58288314|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
58288315|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
58288316|NCT00549549|DRUG|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
58288317|NCT03999359|OTHER|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
57729569|NCT04812912|DIAGNOSTIC_TEST|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
58288318|NCT03989336|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
58288319|NCT03989336|DRUG|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
58288320|NCT03989336|DRUG|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
58288321|NCT03989336|DRUG|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
58288322|NCT01871077|DRUG|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
58288323|NCT06224218|PROCEDURE|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
58288324|NCT06224218|PROCEDURE|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
58288325|NCT00546169|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
58288326|NCT02641275|OTHER|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
58288327|NCT01932749|DEVICE|Transcranial Magnetic stimulation|
57729570|NCT04812912|BEHAVIORAL|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
58071413|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
57933174|NCT06735157|BEHAVIORAL|Augmented reality vestibular rehabilitation therapy|Participants will complete the vestibular training through Nreal Air AR Glasses (Nreal, China). The vestibular training task was custom-made in Unity V2021.3.14fI software using C+ script language. Participants will be standing upright for the AR training, with a safety bar positioned directly in front of them should they need to hold onto something. A large cross-shaped target will be positioned approximately 3 feet in front of the participant's head with its vertical center aligned with the participant's midline. This will act as a visual starting point. The training is adapted from clinical vestibular rehabilitation training methods used in PCD. The vestibular training task consists of locating and tracking a series of moving 3-dimensional balls presented at random within the participant's field of view.
58071414|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
58071415|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
58071416|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
58288328|NCT00826098|BIOLOGICAL|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
58071417|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
58071418|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
58071419|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
58071420|NCT01291420|BIOLOGICAL|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10\*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
58071421|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
58071422|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
58288329|NCT04408664|DRUG|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
58288330|NCT04408664|DRUG|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
58071423|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
58288331|NCT00594230|DRUG|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
58288332|NCT05136079|PROCEDURE|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
58288333|NCT05441553|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
58288334|NCT05448742|DEVICE|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
58288335|NCT04577417|DRUG|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
58288336|NCT03441659|PROCEDURE|ACL reconstruction|Surgical ACL reconstruction
58288337|NCT06302049|DRUG|Esomeprazole|esomeprazole 20 mg once daily
58288338|NCT06302049|DRUG|Placebo|Placebo once daily
58288339|NCT00289224|BIOLOGICAL|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
58288340|NCT00289224|BIOLOGICAL|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
58288341|NCT02256917|BIOLOGICAL|Human cl rhFVIII|
58071424|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
58288342|NCT02285075|DRUG|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).
58288343|NCT01533961|DRUG|SCYX-7158|
58288344|NCT01533961|DRUG|Placebo|
58401247|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
57729571|NCT05372445|BEHAVIORAL|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
58071425|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
58071426|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
58071427|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
58401248|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
58071428|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
58401249|NCT00952445|DRUG|Placebo|Once daily, oral
58401250|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
58071429|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
58071430|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
58071431|NCT02967393|DRUG|ccIIV4|
58401251|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
58071432|NCT02967393|DRUG|IIV4|
58071433|NCT00324519|DEVICE|Foley bulb|
58071434|NCT00324519|DRUG|misoprostol|
58401252|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
58401253|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58401254|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
58401255|NCT04301076|DRUG|Cyclophosphamide|Given IV
58401256|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
58401257|NCT04301076|DRUG|Etoposide|Given IV
58401258|NCT04301076|DRUG|Lenalidomide|Given PO
58288345|NCT01726465|DRUG|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
58288346|NCT01726465|DRUG|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
58288347|NCT06014996|DEVICE|Pulsed Field Ablation (PFA) Therapy|Patients randomized to thePulsed Field Ablation group will undergo PVI using the PFA system (Insight Medtech).
57933175|NCT06735157|DEVICE|SHAM repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be delivered using a Magstim Rapid 2 sham stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of sham stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby sham iTBS will be delivered three times during the same study session. Each sham iTBS session will sound and feel identical to real iTBS delivery, but will not deliver a stimulating current. Sham iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Sham stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of sham iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
57933176|NCT04653740|PROCEDURE|specimen sample collection|"Before and during treatment, and at progression, collection of :~* Blood~* Exhaled air~* Saliva~* Sweat~* Tears~* Urine"
57933177|NCT01107340|DEVICE|AMIStem Hip System|
58071435|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
58288348|NCT06014996|DEVICE|Radiofrequency Ablation（RAF）Therapy|Patients randomized to Radiofrequency Ablation group will undergo PVI using the RFA system (Biosense Webster).
58288349|NCT01763827|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
58401259|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58401260|NCT04301076|DRUG|Prednisone|Given PO
58401261|NCT04301076|DRUG|Vincristine Sulfate|Given IV
58401262|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
58401263|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
58401264|NCT04309305|OTHER|No Intervention|Testing Only
58071436|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
58071437|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
58071438|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
58071439|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
58071440|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
58071441|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
58071442|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
58071443|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
58401265|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
58401266|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
58401267|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
58401268|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
58401269|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
58401270|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
58401271|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
58401272|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
58401273|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
58401274|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
58401275|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
57933178|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
57933179|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
58071444|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
58071445|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
58071446|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
58288350|NCT01763827|DRUG|Ezetimibe|Administered orally once a day
58288351|NCT01763827|BIOLOGICAL|Placebo to Evolocumab|Administered by subcutaneous injection
58288352|NCT01763827|OTHER|Placebo to Ezetimibe|Administered orally once daily
58288353|NCT03489980|OTHER|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
58288354|NCT01904032|DRUG|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
58288355|NCT01904032|DRUG|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
58288356|NCT03139136|DRUG|MBS2320|As described in the arm descriptions
58288357|NCT03139136|DRUG|Placebo|As described in the arm descriptions
58288358|NCT03763201|DIAGNOSTIC_TEST|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
58288359|NCT00534638|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
58401276|NCT03532854|DRUG|Valsartan|Valsartan P.O
58401277|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
58401278|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
58288360|NCT00534638|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
58288361|NCT01580826|OTHER|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
58288362|NCT00561938|PROCEDURE|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
58288363|NCT00561938|PROCEDURE|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
58288364|NCT02533583|DEVICE|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
58288365|NCT05403840|PROCEDURE|Mitral valve surgery|Surgical mitral valve repair or replacement
58288366|NCT05403840|PROCEDURE|Transcatheter mitral valve intervention|Transcatheter mitral valve repair or replacement
58288367|NCT04076852|OTHER|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~* Y-GTSS~* Y-BOCS or cY-BOCS"
58288368|NCT00184002|DRUG|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
58401279|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
58401280|NCT02060630|PROCEDURE|Open surgical revascularization|
58401281|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
58071447|NCT05689645|DRUG|F573 for injection|The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit
58288369|NCT02382315|BEHAVIORAL|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
58401282|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
58401283|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
58401284|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
58401285|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
58401286|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
58401287|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
58401288|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
58401289|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
58401290|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
57933180|NCT05790850|BEHAVIORAL|Pre-operative physical exercise|Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.
58288370|NCT04726111|OTHER|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
58288371|NCT02790918|OTHER|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
58288372|NCT02790918|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
58288373|NCT03643302|DEVICE|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
58288374|NCT05757752|BEHAVIORAL|Problem Solving Therapy and Integrated Care|The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
58288375|NCT03785314|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different posture
58288376|NCT01925976|BEHAVIORAL|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
58288377|NCT00722683|PROCEDURE|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
58288378|NCT04129112|DRUG|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
58288379|NCT01826097|DEVICE|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
58288380|NCT06257953|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
58288381|NCT06236854|OTHER|Delirium assessment (observational, not interventional)|As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
58401291|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
58401292|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
58401293|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
58401294|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
58401295|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
58401296|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
58401297|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
58401298|NCT02153424|DRUG|Apixaban|
58401299|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
58401300|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
58401301|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
58401302|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
58401303|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
58401304|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
58401305|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
58401306|NCT00064259|DRUG|cisplatin|Given IV
58401307|NCT00064259|DRUG|fluorouracil|Given IV
58401308|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
58401309|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
58401310|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
57933181|NCT05790850|BEHAVIORAL|Pre-operative mindfulness meditation practice|Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
57933182|NCT05900050|DRUG|VS-01 on top of SOC|Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
57933183|NCT05900050|OTHER|SOC (Control Group)|Patients will receive SOC for decompensated cirrhosis and ACLF
58071448|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
58288382|NCT01300247|DRUG|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
58288383|NCT01300247|DRUG|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
58288384|NCT01300247|DRUG|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
58288385|NCT01300247|DRUG|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
58288386|NCT01562652|DEVICE|AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)|
58288387|NCT06316596|PROCEDURE|Spinal Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
58401311|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
58401312|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
58401313|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
58401314|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
58401315|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
58401316|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
58401317|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
58401318|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
57729572|NCT05372445|BEHAVIORAL|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
57729573|NCT00941603|DRUG|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
57933184|NCT04090853|DEVICE|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
58071449|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
58071450|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
58071451|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
58071452|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
58071453|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
58071454|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
58071455|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
58071456|NCT04143815|DRUG|Placebo|Intramuscular injection
58071457|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
58288388|NCT06316596|PROCEDURE|Epidural Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
58288389|NCT02976246|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
58288390|NCT02976246|OTHER|Placebo|One tablet of placebo given once daily.
58288391|NCT03327285|BIOLOGICAL|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
58288392|NCT06611566|BEHAVIORAL|VR-guided aerobic exercise|The intervention was 5 minutes of VR-guided aerobic exercise
58288393|NCT06611566|BEHAVIORAL|VR-guided mindfulness exercise|The intervention was 5 minutes of VR-guided mindfulness exercise
58288394|NCT06611566|BEHAVIORAL|TV-guided aerobic exercises|The intervention was 5 minutes of TV-guided aerobic exercises
58288395|NCT06611566|BEHAVIORAL|TV-guided mindfulness exercises|The intervention was 5 minutes of VR-guided mindfulness exercises
58288396|NCT06014164|DIAGNOSTIC_TEST|Interview|An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
58288397|NCT03701438|BIOLOGICAL|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
58288398|NCT01345214|DRUG|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
58288399|NCT04135313|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14
58288400|NCT04135313|DRUG|Oxaliplatin|130 mg/m2 iv day 1
58288401|NCT04135313|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
58288402|NCT04135313|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
58288403|NCT04135313|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
58288404|NCT03610880|DRUG|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
58288405|NCT03610880|DRUG|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
58288406|NCT01957579|DRUG|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
58288407|NCT04633499|BEHAVIORAL|Social Cognition Task|Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
58288408|NCT04633499|DEVICE|tDCS|tDCS either over the dmPFC or the rTPJ.
58288409|NCT01770821|OTHER|Dietary supplement and/or physical training|
58288410|NCT03602703|DIAGNOSTIC_TEST|Flow cytometry and Western Blot analysis|Diagnostic tests
58288411|NCT02293239|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
58288412|NCT01315288|OTHER|One of 6 video presentation by one of 4 presenters|
58288413|NCT03079167|DRUG|Epoetin Alfa|
58288414|NCT03079167|DRUG|Normal saline|
57729574|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
57933185|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences.3 The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
57933186|NCT02253368|OTHER|sleep|
58401319|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
57933187|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
57933188|NCT03435016|DIAGNOSTIC_TEST|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
58288415|NCT01944644|DEVICE|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
58401320|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
57729575|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
57729576|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
57729577|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
57729578|NCT00941603|DRUG|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
57729579|NCT02386566|DRUG|natalizumab|As described in the treatment arm
57933189|NCT03525535|OTHER|data collection|data from patient included will be collected during the study
57933190|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm."
58288416|NCT01944644|DEVICE|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
57729580|NCT00053833|DRUG|irinotecan|
58288417|NCT03097432|DRUG|ORALVAC COMPACT BÄUME|
58288418|NCT03055910|DIAGNOSTIC_TEST|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
57933191|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
57933192|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
58288419|NCT02088892|DRUG|BCG SSI|Intradermal injection
58288420|NCT02088892|DRUG|BCG Tice|Intradermal injection
58288421|NCT00889915|DRUG|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
58401321|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
58401322|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
58401323|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
58401324|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
58401325|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
57729581|NCT01108081|BEHAVIORAL|Physical activity|Moderate-intensity physical activity
57729582|NCT01108081|BEHAVIORAL|Diet|Dietary weight loss
57729583|NCT01108081|BEHAVIORAL|Health education|Attention control intervention
57729584|NCT04915794|OTHER|Simulation of preeclamptic pregnancy care|It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
58401326|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
57933193|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
57933194|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
58401327|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
57933195|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
58401328|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
57933196|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
57933197|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
57933198|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
57933199|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
58401329|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
57729585|NCT06670092|OTHER|Vojta Therapy|"The intervention is carried out using Vojta therapy for one month, with one session per day, 5 days a week. This therapy is carried out by an expert physiotherapist. Vojta therapy is a non-experimental, painless, non-invasive therapy with no adverse effects, which is based on triggering repeated motor reactions or innate movement patterns (reflex locomotion patterns) in the trunk and limbs based on defined stimuli and starting from specific postures.~Both groups will undertake a pre-treatment assessment, a post-treatment assessment at the end of the one-month intervention period, and a final follow-up assessment one month after the end of the intervention."
57933200|NCT05901246|DIETARY_SUPPLEMENT|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
58288422|NCT00889915|DRUG|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
58401330|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
58401331|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
58401332|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
58401333|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
58401334|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
58401335|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
58401336|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
58401337|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
58401338|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
58401339|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
58401340|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
58288423|NCT00889915|DRUG|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
58288424|NCT00889915|DRUG|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
58288425|NCT03426943|BIOLOGICAL|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
58288426|NCT03426943|BIOLOGICAL|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
58288427|NCT03426943|DEVICE|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
58288428|NCT03426943|DEVICE|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
58288429|NCT01517308|DRUG|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
58288430|NCT02085928|OTHER|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"* The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
58288431|NCT00001338|DRUG|FLAC chemotherapy with GM-CSF|
58288432|NCT06585085|BEHAVIORAL|In person PA sessions|Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.
58401341|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
58401342|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
58401343|NCT02628431|DEVICE|Elfi tech monitor|
58401344|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
58401345|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
58401346|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
58401347|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
58401348|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
58401349|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
58401350|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
57729586|NCT06670092|OTHER|No intervetion|No intervetion group
57933201|NCT05901246|OTHER|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
57933202|NCT06734429|OTHER|Urinary Artificial Sphincter|Urinary Artificial Sphincter is a device used for patients with urethral sphincter incompetence
57933203|NCT04977869|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
58401351|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
58401352|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
58401353|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
58401354|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
58401355|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
58071458|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
57729587|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
57729588|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
57729589|NCT06477445|DEVICE|Visual feedback balance training system|Using an visual feedback balance training system to provide a dynamic balance training platform for patients to perform balance training based on visual feedback.
57729590|NCT06477445|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
57933204|NCT04977869|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
57933205|NCT06736171|DEVICE|Robotic Exoskeleton|EksoNR, Ekso Bionics, San Rafael, CA, USA Atalante X, Wandercraft, Paris, France ReStore™, Lifeward Inc, Marlborough, MA
57933206|NCT06736171|OTHER|SOC|Standard of Care
58071459|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
58288433|NCT06585085|BEHAVIORAL|Interactive videoconference PA sessions|Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.
58288434|NCT06585085|BEHAVIORAL|In person and by videoconference (mixed format) PA sessions.|Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
58288435|NCT03628833|DEVICE|Incontinence Management System|Incontinence detection device
58288436|NCT05018676|DRUG|ARX788|1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
58288437|NCT00939614|DRUG|Lamotrigine|
58288438|NCT00996034|BIOLOGICAL|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
58288439|NCT00996034|RADIATION|[123I]5-IA-85380|up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days
58288440|NCT00996034|DRUG|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
58288441|NCT05586542|COMBINATION_PRODUCT|DERMASEAL|a novel skin substitute formulated as planar, thin film
58288442|NCT05586542|BIOLOGICAL|Plasma Film|a planar, thin film made from human plasma
57729591|NCT06477445|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
57729592|NCT06635083|OTHER|Telerehabilitation|A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
57729593|NCT05004324|BIOLOGICAL|FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
57933207|NCT04408820|DRUG|Roxadustat|Oral
58071460|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
57729594|NCT05004324|BIOLOGICAL|Placebo|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
57729595|NCT00408369|DRUG|DB289|
58071461|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
58071462|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
58288443|NCT05586542|OTHER|Standard of Care|standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
58288444|NCT02799277|DRUG|Testosterone|Effect of testosterone on moral decision making
58288445|NCT02799277|DRUG|Placebo|Effect of testosterone on moral decision making
58288446|NCT01563731|DRUG|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
58288447|NCT00227019|DRUG|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
58288448|NCT00227019|DRUG|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
58288449|NCT00227019|DRUG|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
58401356|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
58401357|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
58401358|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
58401359|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
58401360|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
58401361|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
58288450|NCT00227019|DRUG|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
58401362|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
58401363|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
58401364|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
58401365|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
58288451|NCT00227019|DRUG|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
58288452|NCT05576792|OTHER|Ranibizumab|Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
58288453|NCT05164198|BIOLOGICAL|Adalimumab and its biosimilars|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
58288454|NCT05164198|BIOLOGICAL|Biological: Etanercept and its biosimilars|"1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection"
58401366|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
58401367|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
58401368|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
57729596|NCT02606838|DEVICE|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
57729597|NCT00001112|DRUG|Zidovudine|
58288455|NCT05164198|BIOLOGICAL|Golimumab|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
58288456|NCT05164198|BIOLOGICAL|Infliximab biosimilar|"1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection"
58288457|NCT04303416|DRUG|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
58401369|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
58401370|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
58401371|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
58401372|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
57729598|NCT00001112|DRUG|Interferon gamma-1b|
57729599|NCT03058770|OTHER|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
58401373|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
57729600|NCT03058770|OTHER|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
57729601|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
58401374|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
57729602|NCT03738410|BEHAVIORAL|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
57729603|NCT03738410|OTHER|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
57933208|NCT06601660|BEHAVIORAL|Morning Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 7 am to 10 am, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
58071463|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
58071464|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
58071465|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
58071466|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
58071467|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
58071468|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
58071469|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
58071470|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
58071471|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
58071472|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
58071473|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
58071474|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
58401375|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
58071475|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
58071476|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
58071477|NCT02577107|DRUG|ranibizumab|
58071478|NCT02577107|DRUG|Conbercept|
58071479|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
58071480|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
58401376|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
57729604|NCT01640756|DEVICE|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
57729605|NCT03259035|DRUG|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
57729606|NCT03259035|DRUG|Capox|4 cycles of q3weekly CAPOX
58401377|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
58401378|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
58401379|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
58071481|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
58071482|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
57729607|NCT03874676|OTHER|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
58071483|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
58071484|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
58071485|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
58071486|NCT00374920|DRUG|MEM 1003|
58071487|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
58071488|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
58071489|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
58071490|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
58071491|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
58071492|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
58071493|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
57729608|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
58071494|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
58071495|NCT02530580|DRUG|Placebo|A single oral dose
58071496|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
58071497|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
57729609|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
57729610|NCT02818205|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
57729611|NCT02192437|OTHER|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
57933209|NCT06601660|BEHAVIORAL|Night Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 6 pm to 9 pm, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
57933210|NCT06601660|OTHER|No intervention|Group of women who will not receive intervention with combined physical training, but will be evaluated before and after 8 weeks, and monitored, without any intervention with physical exercise.
57933211|NCT02978534|DRUG|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
57933212|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
57933213|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
57933214|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
58071498|NCT00759993|DRUG|chromium piccolinate|1000mg tab
58071499|NCT00759993|DRUG|placebo for chromium piccolinate|
58071500|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
58071501|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
58071502|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
58288458|NCT03413163|DRUG|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
58401380|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
58401381|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
58401382|NCT05010122|DRUG|Gilteritinib|Given PO
58401383|NCT05010122|DRUG|Venetoclax|Given PO
58401384|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
58071503|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
58071504|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
58071505|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
58071506|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
58071507|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
58071508|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
58071509|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
58071510|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
58071511|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
58071512|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
58401385|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
58288459|NCT03413163|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
58288460|NCT03602196|OTHER|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
58288461|NCT03602196|OTHER|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
58288462|NCT03602196|OTHER|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
58288463|NCT03405168|DRUG|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
58288464|NCT05720429|OTHER|Psychoeducational program|"A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art."
58288465|NCT03536663|DEVICE|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
58288466|NCT01014078|DRUG|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
58288467|NCT01014078|DRUG|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
58288468|NCT06251921|PROCEDURE|Restoration|with resin-based composite
58288469|NCT03259256|PROCEDURE|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
58288470|NCT04788849|DIAGNOSTIC_TEST|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
58288471|NCT00217581|BIOLOGICAL|Bevacizumab|Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
58288472|NCT00217581|DRUG|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
57729612|NCT01892748|DRUG|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
58071513|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
58071514|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
57729613|NCT01892748|DRUG|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
57729614|NCT01337089|DRUG|Nabiximols|
58071515|NCT02493712|DRUG|Placebo|Placebo
58071516|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
58071517|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
58071518|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
57729615|NCT04035941|BEHAVIORAL|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~1. Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~2. Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~3. Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~4. Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
57933215|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
58071519|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
58071520|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
58288473|NCT00217581|DRUG|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
58288474|NCT00916981|PROCEDURE|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
58288475|NCT05964985|DRUG|Normal saline|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
58288476|NCT05964985|DRUG|Ropivacaine|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
58401386|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
58401387|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
58401388|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
58401389|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
57729616|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57729617|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57933216|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
58401390|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
58401391|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
58401392|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
58401393|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
58071521|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
58071522|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
58288477|NCT05964985|DRUG|Compound lidocaine|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
58288478|NCT05964985|DRUG|Esketamine|After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
58288479|NCT02542137|RADIATION|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
58401394|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
58401395|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
58401396|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
58401397|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
58401398|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
58288480|NCT02542137|DRUG|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
58401399|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
58401400|NCT01791049|DRUG|TD-1607|
58401401|NCT01791049|DRUG|Placebo|
58401402|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
58401403|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
58401404|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
58401405|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
58401406|NCT06571591|DRUG|Metformin|tablets, oral administration
58401407|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
58401408|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
58401409|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
58401410|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
58401411|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
58401412|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
58288481|NCT02723448|DRUG|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
58288482|NCT00552708|DRUG|COREG CR|
58288483|NCT00552708|DRUG|Lisinopril|
58288484|NCT06274619|BIOLOGICAL|RSV A Memphis 37|RSV A Memphis 37 challenge agent
58288485|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support \& cognitive distortions, social skills \& peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
58288486|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support \& cognitive distortions, social skills \& peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
58401413|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
58401414|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
58401415|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
58401416|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
58401417|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
58401418|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
58288487|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
58401419|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
58401420|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
58401421|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
58401422|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
58401423|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
58401424|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
58401425|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
58401426|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
58401427|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
57933217|NCT02791113|OTHER|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
58401428|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
58288488|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support \& cognitive distortions, social skills \& peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
58288489|NCT04932343|DIAGNOSTIC_TEST|cohort study|no intervention
58401429|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
58401430|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
57933218|NCT06736340|DRUG|Rupatadine|10mg tablets
58288490|NCT04329845|PROCEDURE|open splenectomy|open splenectomy for treatment of splenic injury
58288491|NCT04329845|PROCEDURE|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
58071523|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
58288492|NCT05261243|DIAGNOSTIC_TEST|EEG / questionnaires / working memory task|EEG resting state measurements and analysis of frequency bands (gamma, beta, alpha, theta), peak frequencies and connectivity measures / questionnaires for depression, anxiety, social activities, cognition, pain, sleep, fatigue / digitalized block-tapping task
57933219|NCT06086301|OTHER|PICTURE-THIS|Discharge plans include scheduling post-discharge appointments, community support referrals, transportation arrangements, and addressing identified gaps. Transition care includes 8 check-ins over 3 months post-discharge, focusing on assessing, troubleshooting, and celebrating transition successes, using phone or video. Telehealth-assisted 'warm hand-offs' will connect interventionists with home health and primary care teams during initial visits. '1st touch daytime troubleshooting' offers extra support between check-ins. Problem-solving rehabilitation will be continued from hospital to home, with 7-10 sessions over 3 months, including a home safety survey. A Post-ICU Caregiver Toolkit provides workbooks, training videos, and resources. Lastly, referrals for patient and caregiver social/mental health support are provided.
57933220|NCT06086301|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will receive: (1) Patient and Family Re-sources published by the SCCM for PICS prior to hospital discharge; (2) ongoing assessments on the same schedule as the PICTURE-THIS intervention; (3) referral for urgent or emergent issues identified during assessments. The investigators will not provide the URL for the Post-ICU Caregiving Toolkit but the investigators will not restrict its access either. This control design balances 3 goals: 1) masking participants to group allocation; 2) responding ethically to harm/distress; 3) maintaining group separation to optimize efficacy testing of PICTURE-THIS.
57933221|NCT06086301|BEHAVIORAL|Run-In Phase|All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.
57933222|NCT00187213|DEVICE|Cardiac Resynchronization Therapy|
57933223|NCT04786951|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
58288493|NCT01940640|DIETARY_SUPPLEMENT|DHA|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
58288494|NCT01940640|DIETARY_SUPPLEMENT|control|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
58288495|NCT02821416|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
58288496|NCT02821416|OTHER|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
58288497|NCT01841047|RADIATION|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
58288498|NCT02575378|DRUG|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
58288499|NCT02575378|DRUG|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
58288500|NCT04568798|DEVICE|Sana Sham Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
58288501|NCT00809536|DRUG|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
58288502|NCT00809536|DRUG|Metformin|Single, oral, 500 mg of metformin immediate release
57729618|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58288503|NCT00809536|DRUG|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
57729619|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58288504|NCT00809536|DRUG|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
58288505|NCT06371274|DRUG|ATRA|ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
58288506|NCT06371274|DRUG|Toripalimab|Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
58288507|NCT04536805|DRUG|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
58401431|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
58401432|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
58401433|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
58401434|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
58401435|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
58401436|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
58401437|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
58401438|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
58401439|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
57933224|NCT04786951|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
58288508|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
58288509|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
58288510|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
58288511|NCT05421780|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
58288512|NCT05421780|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
58288513|NCT05421780|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits as breakfast.
58401440|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
58401441|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
58401442|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
57729620|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58288514|NCT04076436|OTHER|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
58401443|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
57933225|NCT04786951|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
57933226|NCT03566433|PROCEDURE|Tep surgery for inguinal hernia|TEP surgery
57933227|NCT03566433|PROCEDURE|Lichtenstein|Lichtenstein surgery for inguinal hernia
58288515|NCT04076436|OTHER|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
58288516|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
58401444|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
58401445|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
58401446|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
58401447|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
58401448|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
58401449|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
58401450|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
58401451|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
58401452|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
58401453|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
57933228|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
57933229|NCT04649268|DEVICE|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
57933230|NCT04649268|OTHER|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
58288517|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
58288518|NCT03160495|OTHER|All patients|All patients are scanned with PET/MR prior to surgery.
58288519|NCT06091098|OTHER|Dynamic CO2|2% inspired CO2 for 2-4 breaths
58288520|NCT06091098|OTHER|Sham CO2|Air
58288521|NCT05937620|DIAGNOSTIC_TEST|99mTC nanocolloid albumin injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
58288522|NCT05937620|DIAGNOSTIC_TEST|ICG injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
58288523|NCT03226808|DEVICE|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
58288524|NCT04063501|OTHER|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
58288525|NCT04063501|OTHER|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
58288526|NCT03705286|DEVICE|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
58288527|NCT03705286|DEVICE|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
58288528|NCT02385565|OTHER|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
58288529|NCT02385565|OTHER|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
58288530|NCT01858415|DEVICE|TriPollar|
58288531|NCT01852513|DRUG|QNASL|
58288532|NCT01852513|DRUG|Placebo nasal spray|
58288533|NCT05582876|RADIATION|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
58288534|NCT06224998|BEHAVIORAL|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
58288535|NCT04171193|DRUG|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
58288536|NCT04171193|DRUG|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
58288537|NCT00068029|DRUG|Pegvisomant/ Sandostatin LAR|
57933231|NCT03579849|DIAGNOSTIC_TEST|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
58071524|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
58288538|NCT00068029|DRUG|Sandostatin LAR|
58288539|NCT00068029|DRUG|Pegvisomant|
58288540|NCT04241913|BEHAVIORAL|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
58288541|NCT01912859|BEHAVIORAL|Nutrition/physical activity intervention|Nutrition/physical activity intervention
58288542|NCT02225808|BEHAVIORAL|CBT for anxiety in autism|
58288543|NCT02635256|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
58288544|NCT04283253|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
58288545|NCT02930681|DIETARY_SUPPLEMENT|Glucosanol 500mg|
58288546|NCT02930681|DIETARY_SUPPLEMENT|Placebo|
58288547|NCT02213588|DIETARY_SUPPLEMENT|AOX blend|Antioxidant supplement
58401454|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
58401455|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
58401456|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
58401457|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
58401458|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
58401459|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
58401460|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
58401461|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
57729621|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57933232|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
57933233|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
57933234|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
57933235|NCT05484050|OTHER|Immunohistochemistry analysis|Estimation of VEGF through Immunohistochemistry
57933236|NCT06734091|DIAGNOSTIC_TEST|PrestoCHILL|PrestoCHILL (Milestone Medical Technologies, Inc.MI 49009, USA)which by reducing the tissue freezing time to less than 60 seconds should eliminate freezing artefacts and improve the quality of sections for morphological and IHC examination. In selected cases and according to the diagnostic algorithm required for the diagnosis of specific neoplasms, rapid IHC analysis will be performed with the Benchmark ULTRA® immunostainer (Ventana Medical Systems), which is already in place to confirm or exclude the suspected neoplasm, as well as to confirm the histotype. For the latter purpose, commercially available antibody panels for routine examinations will be used (Ventana/Roche,Ventana Medical Systems, USA).
57933237|NCT00132496|DRUG|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
57933238|NCT06245356|DRUG|Lonsurf|Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)
58288548|NCT02213588|DIETARY_SUPPLEMENT|Placebo|
58288549|NCT03337620|DEVICE|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
58288550|NCT02903810|BIOLOGICAL|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
58288551|NCT06241885|BEHAVIORAL|Intervention group I|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
58288552|NCT05420142|DIETARY_SUPPLEMENT|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
58401462|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
58401463|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
58401464|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
58401465|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
58401466|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
58401467|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
58401468|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
58401469|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
57729622|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58288553|NCT03495297|PROCEDURE|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
58401470|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
58401471|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
58401472|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
58401473|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
58401474|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
58401475|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
57933239|NCT06245356|DRUG|Oxaliplatin|Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)
57933240|NCT06245356|DRUG|Panitumumab|Panitumumab intravenous injection 6 mg/kg (D1=D15)
57933241|NCT06245356|DRUG|Bevacizumab|Bevacizumab intravenous injection 5 mg/kg (D1=D15)
57933242|NCT06245356|DRUG|Trastuzumab|Trastuzumab intravenous injection 4 mg/kg (D1=D15)
57933243|NCT06245356|DRUG|Nivolumab|Nivolumab intravenous injection 240 mg (D1=D15)
58288554|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 800 mg/day|FADA is given twice a day (total dose of 800 per day per patient)
58288555|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 2000 mg/day|FADA is given twice a day (total dose of 2000 per day per patient)
58288556|NCT05033925|OTHER|Placebo capsule|Placebo capsule is given twice a day
58401476|NCT01190475|DRUG|Placebo treatment to blind study|
58401477|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
58401478|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
58401479|NCT06163183|DEVICE|Edi catheter|
58288557|NCT01670045|DRUG|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
58288558|NCT03094884|RADIATION|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
58288559|NCT03094884|DRUG|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
58288560|NCT03094884|DRUG|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
58288561|NCT01749046|DRUG|Remegal|Remegal 1500 mg for 12 weeks
58288562|NCT02721498|PROCEDURE|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
58288563|NCT02721498|OTHER|Rest period|A 30-60 minute of resting
58288564|NCT02487537|DIETARY_SUPPLEMENT|custom-made soft drink|
58288565|NCT00002255|DRUG|Filgrastim|
58288566|NCT00002255|DRUG|Epoetin alfa|
58401480|NCT03614481|GENETIC|Sampling|Sampling
58401481|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
58401482|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
57729623|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57729624|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
57729625|NCT06496828|PROCEDURE|Biologically-oriented preparation technique|The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
57933244|NCT05776225|PROCEDURE|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
57933245|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
58071525|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
58288567|NCT00002255|DRUG|Zidovudine|
58288568|NCT04542876|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
58288569|NCT01787006|DRUG|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
58401483|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
58401484|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
58401485|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
58401486|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
57729626|NCT06496828|PROCEDURE|Conventional method of preparation|Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
58071526|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
58288570|NCT01787006|DRUG|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
58288571|NCT01787006|RADIATION|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
58288572|NCT01923324|BEHAVIORAL|Physician telephone consultation|Pain physician support for family physician treating patient
57729627|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
57729628|NCT04074980|DIAGNOSTIC_TEST|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
57729629|NCT04074980|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to collect blood samples from subjects
58288573|NCT01923324|BEHAVIORAL|Usual family physician care|Usual family physician care without telephone consultation with pain physician
57729630|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
57729631|NCT01985594|DRUG|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
57729632|NCT01985594|DRUG|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
58401487|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
58401488|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
58071527|NCT03939429|DRUG|QPX2015|antibiotic
58071528|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
58071529|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
58401489|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
58401490|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
58401491|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
58401492|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
58401493|NCT01952548|DRUG|K-312|
58401494|NCT01952548|DRUG|Placebo|
58401495|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
58401496|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
58401497|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
58401498|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
58401499|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
58401500|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
58401501|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
58071530|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
58071531|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
58071532|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
58288574|NCT01990573|DRUG|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
58288575|NCT01990573|DRUG|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
58288576|NCT01990573|OTHER|control no methadone|The control group will not receive methadone.
58288577|NCT00441870|DRUG|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
58288578|NCT00441870|DRUG|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
58401502|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
58401503|NCT02959541|DRUG|Leucovorin|
58401504|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
58401505|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
58401506|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
58401507|NCT05732506|DRUG|Edoxaban|There are not intervention.
58401508|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
58401509|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
58401510|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
58401511|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
57933246|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
57933247|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
57933248|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
58401512|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
58401513|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
58401514|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
58401515|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
57933249|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
57933250|NCT05009160|DEVICE|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
58288579|NCT00061178|DRUG|rhuMAb VEGF (Bevacizumab)|
58401516|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
57933251|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
58071533|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
58071534|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
58071535|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
58071536|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
58071537|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
58071538|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
58071539|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
58071540|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
58071541|NCT00005068|DRUG|fluorouracil|
58288580|NCT03387969|PROCEDURE|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
58071542|NCT00005068|DRUG|irinotecan hydrochloride|
58071543|NCT00005068|DRUG|leucovorin calcium|
58071544|NCT00005068|DRUG|oxaliplatin|
58288581|NCT03147950|PROCEDURE|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
58288582|NCT03147950|PROCEDURE|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
58071545|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
57933252|NCT03763604|DRUG|Abemaciclib|Administered orally.
57933253|NCT05789797|DRUG|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
57933254|NCT06584071|DRUG|PM8002|PM8002 via IV infusion, Q3W
57933255|NCT06584071|DRUG|PM1009|PM8002 via IV infusion, Q3W
57933256|NCT06584071|DRUG|atezolizumab|atezolizumab,1200mg, via IV infusion, Q3W
58071546|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
58071547|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
58071548|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
58071549|NCT00381017|DRUG|Peg interferon alpha-2b|
58071550|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
58288583|NCT04235322|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
58288584|NCT04235322|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
58288585|NCT04655729|DRUG|Infliximab|Blood collection
58288586|NCT06476704|DRUG|Administration of L-TC|Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
58288587|NCT06476704|RADIATION|HFRT alone|"HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week."
58288588|NCT03959527|DRUG|zoliflodacin|Dose: 3g, oral administration
58288589|NCT03959527|DRUG|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
58401517|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
58401518|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
57729633|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
57729634|NCT04696068|OTHER|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
58288590|NCT03959527|DRUG|azithromycin|Dose: 1g, oral administration
58288591|NCT05122455|DRUG|ASA|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
58288592|NCT05122455|DRUG|Clopidogrel|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
58288593|NCT05122455|DRUG|Edoxaban|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
58288594|NCT02991963|OTHER|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
58288595|NCT02991963|OTHER|Blood collection (Dried Blood Spot)|Dried Blood Spot
58288596|NCT02991963|OTHER|Blood Collection (Venous Blood collection)|Venous Blood collection
58288597|NCT02991963|OTHER|Blood Smear|Slide blood smear
58401519|NCT02481648|OTHER|Exercise|
58401520|NCT04893239|BIOLOGICAL|LMN-201|Components of LMN-201
58401521|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
58401522|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
57729635|NCT02959489|BEHAVIORAL|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
57729636|NCT02959489|BEHAVIORAL|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
57729637|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
57729638|NCT03433742|OTHER|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
57729639|NCT02228213|BIOLOGICAL|MIS416|Intravenous administration weekly for 52 weeks
57729640|NCT02228213|DRUG|Saline|Intravenous administration weekly for 52 weeks
57933257|NCT06584071|DRUG|bevacizumab|bevacizumab,15mg/kg, via IV infusion, Q3W
57933258|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
57933259|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
57933260|NCT03732651|PROCEDURE|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
58288598|NCT02090283|DRUG|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
58288599|NCT00762190|DRUG|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
58288600|NCT00762190|DRUG|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
58401523|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
58401524|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
58401525|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
58401526|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
58401527|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
58288601|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
58288602|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
58288603|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
58288604|NCT04618991|OTHER|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
58288605|NCT06598124|OTHER|Investigational Product (IP)|1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
58288606|NCT06598124|OTHER|Comparator Product (CP)|1 single dose of CP consisting in 400 mL of milk with lactose
58288607|NCT06285071|DRUG|Concizumab|Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
58288608|NCT03941145|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training (REHIT)|REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
58288609|NCT01148264|DRUG|olanzapine|1x10mg per day for three days
58288610|NCT01148264|DRUG|metoclopramide|3x10mg per day for three days
58288611|NCT05851638|DEVICE|Lung Oxygen measurement with GASMAS system|A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.
58288612|NCT03698539|BEHAVIORAL|hand gestures|We observe the use of spontaneous hand gestures in all the groups.
58288613|NCT05004792|OTHER|DermLoop Learn|DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
57933261|NCT02911090|OTHER|Data Registry|Data Registry
57933262|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
57933263|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
58288614|NCT00095342|DRUG|TMI-005|
58288615|NCT02164643|DRUG|Flutemetamol (18F)|
58288616|NCT02164643|DRUG|Florbetapir (18F)|
58288617|NCT04030676|PROCEDURE|Biopsies|Two more biopsies in inflammatory zone will be collected.
58288618|NCT04030676|BIOLOGICAL|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
58288619|NCT05743777|DRUG|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
58401528|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
58401529|NCT00022360|DRUG|taurolidine|
58401530|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
58401531|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
57933264|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
57933265|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
57933266|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
57933267|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
57933268|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
58288620|NCT05743777|DRUG|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
58288621|NCT05743777|DRUG|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
58288622|NCT04640155|BEHAVIORAL|Low FODMAP Diet|Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
57933269|NCT06252519|DIETARY_SUPPLEMENT|NAC|1 375 mg capsule containing N-acetyl cysteine
57933270|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC|3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
58288623|NCT04640155|BEHAVIORAL|Regular Diet|Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
58288624|NCT02132728|OTHER|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
57729641|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
57933271|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC XS|3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester
58071551|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
58071552|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
58288625|NCT05569369|PROCEDURE|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
58288626|NCT06613009|DRUG|IBI3009|Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
58288627|NCT01237288|DRUG|Z-521|
58288628|NCT03295136|BEHAVIORAL|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
58288629|NCT00765817|DRUG|placebo|subcutaneous injection, twice a day
57729642|NCT03277313|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
57933272|NCT03875209|BIOLOGICAL|10E8.4/iMab|bispecific monoclonal antibody
57933273|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
57933274|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
58071553|NCT03345927|OTHER|no intervention|no intervention
58071554|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
57933275|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
57933276|NCT06225986|BEHAVIORAL|LMH-4-DCP|Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
58071555|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
58071556|NCT02643420|DRUG|Docetaxel|Standard therapy
58071557|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
58095475|NCT03613194|PROCEDURE|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
58288630|NCT00765817|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
58288631|NCT04120181|OTHER|There is no intervention.|There is no intervention.
58288632|NCT03453814|OTHER|Music Therapy|Subjects will receive one hour of music twice a day for three days.
58288633|NCT01167348|PROCEDURE|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
58288634|NCT04301739|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
58288635|NCT04301739|DRUG|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
58288636|NCT04301739|DRUG|Placebo|Placebo
58288637|NCT05859308|OTHER|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
58288638|NCT05859308|OTHER|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
58288639|NCT03746405|DEVICE|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
58288640|NCT03746405|DEVICE|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
58288641|NCT00243971|DRUG|SPM 962|
58288642|NCT04118647|DRUG|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
58288643|NCT04680247|PROCEDURE|VA-LCP|Surgery using the VA-LCP implant
58288644|NCT04680247|PROCEDURE|NCB-PT|Surgery using the NCB-PT implant
58288645|NCT00972283|DRUG|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
58288646|NCT00972283|DRUG|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
58288647|NCT00972283|DRUG|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
58288648|NCT04849624|OTHER|No Intervention|This is an observational study and involved no intervention
58288649|NCT03429621|DRUG|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
58288650|NCT04485663|DRUG|ALG-010133|Single or multiple doses of ALG-010133
58288651|NCT04485663|DRUG|Placebo|Single or multiple doses of Placebo
58288652|NCT01535443|DRUG|Bromfenac|Drug: Bromfenac Other names: PRO-155
58401532|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
58401533|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
58401534|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
58401535|NCT02392390|DRUG|Metvixia cream|
57933277|NCT06225986|BEHAVIORAL|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
58401536|NCT00227669|DRUG|docetaxel|
58401537|NCT00227669|DRUG|gemcitabine hydrochloride|
58401538|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
58401539|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
58401540|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
58401541|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
58401542|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
57933278|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
58095476|NCT03425773|BIOLOGICAL|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
58288653|NCT04716374|OTHER|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
58288654|NCT02748057|DRUG|Ezetimibe|
58288655|NCT02748057|DRUG|Rosuvastatin|
58288656|NCT03360214|DRUG|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
58288657|NCT03360214|OTHER|Placebo Drug|For sham drug, 0.9% saline, will be used.
58288658|NCT03360214|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
58288659|NCT03360214|OTHER|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
58288660|NCT03360214|DRUG|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
58288661|NCT06156605|PROCEDURE|Sidelying lumbar manipulation|R sided lumbar manipulation
58288662|NCT04724551|PROCEDURE|pancreatoduodenectomy (PD)|A pancreaticogastrostomy or -jejunostomy duct-to-mucosa was achieved according to the surgeon's preference and pancreatic texture.
58401543|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
58401544|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
58401545|NCT02379221|DRUG|Topical|4% Topicaine gel
58401546|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
58401547|NCT00460278|DRUG|XL418|
58401548|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
58401549|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
58401550|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
58401551|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
58401552|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
58401553|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
58401554|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
58401555|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
58401556|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
58401557|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
57933279|NCT04179448|PROCEDURE|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
57933280|NCT04179448|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
57933281|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
57933282|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
57933283|NCT00458341|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
58401558|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
58401559|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
58401560|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
58401561|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
58401562|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
58401563|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
58401564|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
58401565|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
58401566|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
58401567|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
58401568|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
58401569|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
58401570|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
58401571|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
58401572|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
58401573|NCT00022204|DRUG|pentoxifylline|
58401574|NCT00022204|PROCEDURE|quality-of-life assessment|
57933284|NCT06734195|DRUG|dexmedetomidine + propofol|Comparison of caudal dexmedetomidine + propofol sevoflurane-related emergence agitation in children undergoing congenital hernia repair.
57933285|NCT06734195|DRUG|Propofol alone|30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.
57933286|NCT06734195|DRUG|Dexmedetomidine|patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
57933287|NCT04155268|BEHAVIORAL|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
58401575|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
57933288|NCT04155268|BEHAVIORAL|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
58071558|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
58071559|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
58071560|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
58071561|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
58071562|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
58071563|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
58401576|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
58071564|NCT00337935|OTHER|Standard of care|
58401577|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
58401578|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
57729643|NCT03708939|DIETARY_SUPPLEMENT|Glucose|Daily consumption of 5g of glucose, for 14 days.
57933289|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
57933290|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
57933291|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
58401579|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
57729644|NCT03708939|DIETARY_SUPPLEMENT|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
57729645|NCT03708939|DIETARY_SUPPLEMENT|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
57729646|NCT03708939|DIETARY_SUPPLEMENT|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
57729647|NCT03708939|DIETARY_SUPPLEMENT|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
57729648|NCT03708939|OTHER|No Supplement|Follow up without any dietary supplementation.
57729649|NCT02206529|BEHAVIORAL|Social Network Engagement+Std Treatment|
58401580|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
58401581|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
57933292|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
57933293|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
57933294|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
57933295|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
58288663|NCT03138577|DIAGNOSTIC_TEST|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
57933296|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
57933297|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
58401582|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
58401583|NCT00346281|DEVICE|32P BioSilicon|
58401584|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
58401585|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
58401586|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
58401587|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
58401588|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
58401589|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
58401590|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
57933298|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
57933299|NCT03715023|DRUG|PC786|PC786 suspension for inhalation
57933300|NCT03715023|DRUG|Placebo|Placebo solution for inhalation
57933301|NCT03715023|DRUG|SOC|Standard treatment for RSV infection at study site
57933302|NCT06735365|OTHER|CRRT|Hemodiafiltration
58071565|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
57729650|NCT02206529|BEHAVIORAL|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
57729651|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
58071566|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
57729652|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
57729653|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
57729654|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
57729655|NCT03877718|DRUG|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
57933303|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
57933304|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
57933305|NCT03898492|OTHER|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
57933306|NCT06212999|DRUG|Povorcitinib|Oral; Tablet
58288664|NCT03138577|DRUG|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
58288665|NCT03138577|OTHER|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
58288666|NCT03621436|DEVICE|TRVD Therapy|A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
58288667|NCT01190189|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
58288668|NCT02833064|RADIATION|Non-contrast magnetic resonance imaging|
58288669|NCT02833064|OTHER|Biological sampling|Blood, urine, stool and breath sampling and analysis
58401591|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
58401592|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
57729656|NCT03877718|DRUG|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
57729657|NCT03877718|DRUG|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
57933307|NCT05666518|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
57933308|NCT05666518|DRUG|Standard of care|Dosage at the discretion of the treating physician
57933309|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
57729658|NCT03877718|DRUG|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
58288670|NCT05681832|BEHAVIORAL|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
58288671|NCT01343537|OTHER|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
58288672|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
58401593|NCT05704621|DRUG|chemotherapy|six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
57729659|NCT03877718|DRUG|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
57729660|NCT03877718|OTHER|Placebo|One capsule of placebo
57729661|NCT06636175|DRUG|64Cu-LLP2A|64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
58401594|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
58401595|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
58401596|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
58401597|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
58401598|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
58401599|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
58401600|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
58401601|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
58401602|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
58401603|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
58401604|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
57933310|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
58288673|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
58288674|NCT02861963|PROCEDURE|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
58288675|NCT02861963|PROCEDURE|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
58288676|NCT04438616|PROCEDURE|dome magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia~* A crestal incision is made using No. 15 c blade .~* Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure"
58288677|NCT04438616|PROCEDURE|flat magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia.~* A crestal incision is made using No. 15 c blade~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
58288678|NCT02362737|BEHAVIORAL|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
58288679|NCT01533948|DRUG|axitinib|Given PO
58288680|NCT01533948|OTHER|laboratory biomarker analysis|Correlative studies
58401605|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
58401606|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
58288681|NCT02384538|BIOLOGICAL|ABT-981|ABT-981 administered by subcutaneous injection
58401607|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
57933311|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
58401608|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
58401609|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
57729662|NCT06636175|DEVICE|PET/CT|The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
57729663|NCT04639414|DRUG|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
57729664|NCT04639414|DRUG|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
58288682|NCT02384538|BIOLOGICAL|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
58288683|NCT02264210|DRUG|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
58288684|NCT02235129|OTHER|breath-holding|
58288685|NCT04335058|DRUG|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
58288686|NCT04335058|DRUG|Iron Supplement|Oral iron supplement alone
58288687|NCT00613392|DIETARY_SUPPLEMENT|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
58288688|NCT00613392|DIETARY_SUPPLEMENT|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
58288689|NCT06180434|RADIATION|proton therapy|Radiotherapy delivered with protons
58288690|NCT06180434|RADIATION|photon therapy|Radiotherapy delivered with photons
58288691|NCT04823390|DRUG|Midazolam-Fentanyl combination|Sedation is given to patients undergoing cataract surgery under local anesthesia
58288692|NCT01038102|OTHER|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
58288693|NCT01038102|OTHER|SFA diet|Diet high in saturated fat (15E%)
58288694|NCT03287115|OTHER|Broccoli consumption|All subjects will eat broccoli on day 11
58288695|NCT01738529|DEVICE|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
58288696|NCT05007626|OTHER|axial length and refractive error|Comparing the correlation between heterophoria and refraction, even after age adjustment.
58288697|NCT05881031|OTHER|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
58288698|NCT03734523|COMBINATION_PRODUCT|Flourish Vaginal Care System|This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
58401610|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
57729665|NCT04639414|DRUG|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
58401611|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
57933312|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
58401612|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
58288699|NCT05926843|PROCEDURE|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
58288700|NCT06510907|BEHAVIORAL|mindfulness based stress reduction program|"Mindfulness training will be delivered through a generic 8-week MBSR. The MBSR will consist of weekly 2-hour classes, in which the techniques to various meditations (e.g., body scan, mindful awareness of breathing, body, sounds, thoughts, emotions, and mindful movements) will be taught and discussed. Participants will be asked to meditate for ≥40 minutes every day during the 8-week program as homework. Besides cultivating attention control and a non-judgemental stance to experience, psychoeducation about psychological stress and stress response will also be discussed during the MBSR classes. The MBSR teacher will discuss any difficulties encountered during homework meditations in every class to enhance adherence.~Each MBSR class can have up to 25 participants. The 8-week program will be taught by a qualified MBSR teacher"
58288701|NCT02665741|DEVICE|Olympus transparent cap|distal colonoscope attachment
58288702|NCT02665741|DEVICE|Medivators Endocuff|distal colonoscope attachment
58288703|NCT02665741|DEVICE|Control|No distal colonoscope attachments
58288704|NCT04021498|DRUG|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
58288705|NCT04021498|OTHER|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
58401613|NCT02704702|DRUG|Fimasartan|
58401614|NCT02704702|DRUG|Rosuvastatin|
58401615|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
58401616|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
57729666|NCT06534788|OTHER|Reciprocal Inhibition MET|Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.
57933313|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
58288706|NCT04877990|DRUG|Deucravacitinib|Specified dose on specified days
58401617|NCT02734771|DRUG|Brentuximab vedotin|
58401618|NCT02734771|DRUG|Rituximab|
58401619|NCT02734771|DRUG|Cyclophosphamide|
58401620|NCT02734771|DRUG|Doxorubicin|
58071567|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
58071568|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
58071569|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
58071570|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
58071571|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
58288707|NCT01965314|OTHER|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
58288708|NCT01965314|OTHER|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
58288709|NCT05275582|BEHAVIORAL|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
58288710|NCT05225389|DRUG|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
58288711|NCT01139346|DRUG|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
58288712|NCT03444259|PROCEDURE|Cardiac surgery|Open heart surgery
58306861|NCT05525260|DRUG|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
58071572|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
58071573|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
58071574|NCT01403415|DRUG|Dexamethasone|Given PO or IV
58306862|NCT05525260|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
58306863|NCT00695227|DIAGNOSTIC_TEST|Screening for Barrett's Esophagus|
58401621|NCT02734771|DRUG|Prednisone|
58401622|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
58401623|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
58401624|NCT00100997|DRUG|tanespimycin|
58401625|NCT03379857|OTHER|Drug urinal test|Non Applicable
58401626|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
58288713|NCT06414603|DIAGNOSTIC_TEST|The Prospera™ Test|"The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory."
58071575|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
58071576|NCT01403415|DRUG|Methotrexate|Given IT
58071577|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
58071578|NCT01403415|DRUG|Pegaspargase|Given IV
58071579|NCT01403415|OTHER|Pharmacological Study|Correlative studies
58071580|NCT01403415|DRUG|Temsirolimus|Given IV
58288714|NCT04569604|DIAGNOSTIC_TEST|MRI scans|Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
58288715|NCT04569604|DIAGNOSTIC_TEST|Neuro cognitive tests|Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
58288716|NCT04569604|DIAGNOSTIC_TEST|Questionnaires on Quality of Life|SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
58288717|NCT04569604|DIAGNOSTIC_TEST|Blood samples|Markers of calcium homeostasis, inflammatory markers and hematology.
58288718|NCT04569604|DIAGNOSTIC_TEST|24 hr urine samples|24 hr urine content of calcium, phosphate, magnesium, and creatinine.
58288719|NCT03800407|OTHER|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
58288720|NCT03021629|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
58288721|NCT04995263|BEHAVIORAL|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
58288722|NCT04995263|BEHAVIORAL|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
58288723|NCT04995263|BEHAVIORAL|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
58071581|NCT01403415|DRUG|Vincristine Sulfate|Given IV
57933314|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
58071582|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
58071583|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
58071584|NCT00231959|DRUG|Placebo|sugar pill
58071585|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
58071586|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
58071587|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
58071588|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
58071589|NCT00005803|DRUG|Carmustine|Given IV
58071590|NCT00005803|DRUG|Cyclophosphamide|Given IV
58071591|NCT00005803|DRUG|Cyclosporine|Given PO
58071592|NCT00005803|DRUG|Cytarabine|Given IV
58071593|NCT00005803|DRUG|Etoposide|Given IV
58071594|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
58071595|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
58071596|NCT00005803|DRUG|Melphalan|Given IV
58071597|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
58288724|NCT04995263|BEHAVIORAL|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
58288725|NCT04995263|OTHER|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
58401627|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
58071598|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
58071599|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
58071600|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
58071601|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
58288726|NCT04995263|DEVICE|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
58288727|NCT03828227|DRUG|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus"
58288728|NCT03828227|DRUG|Capecitabine plus bevacizumab|"* Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
58288729|NCT01292707|BEHAVIORAL|Control|Standard national training
58401628|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
58401629|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
58401630|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
58071602|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
58071603|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
58071604|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
58288730|NCT01292707|BEHAVIORAL|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
58288731|NCT01292707|BEHAVIORAL|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
58306864|NCT05678361|BEHAVIORAL|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
58401631|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
58071605|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
58071606|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
58071607|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
58071608|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
58071609|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
58071610|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
58401632|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
58401633|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
58401634|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
58401635|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
57729667|NCT06534788|OTHER|Post-facilitation MET|Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.
57729668|NCT06534788|OTHER|Conventional physical therapy|"TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
57933315|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
58288732|NCT03869762|DRUG|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
58288733|NCT03869762|DRUG|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
58288734|NCT02778035|DEVICE|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
58288735|NCT01304134|DRUG|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
58288736|NCT01304134|DRUG|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
58288737|NCT04967157|DIETARY_SUPPLEMENT|Placebo|Oral
58288738|NCT04967157|DIETARY_SUPPLEMENT|Cognizin®|Oral
58288739|NCT02638974|OTHER|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
58288740|NCT01853683|PROCEDURE|Conservative Management|
58288741|NCT01853683|PROCEDURE|Operative Management|
58401636|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
58401637|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
58401638|NCT01115894|DRUG|Placebo|Placebo
57933316|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
57933317|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
57933318|NCT00501826|DRUG|Cyclophosphamide|Given IV
57933319|NCT00501826|DRUG|Cytarabine|Given IV
58288742|NCT04346407|DRUG|Dronabinol 2.5mg Cap|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
58288743|NCT04346407|DRUG|Placebo|Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
58288744|NCT04727528|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
58288745|NCT04727528|DRUG|Placebo|Plabeco comparator
58288746|NCT04445090|DRUG|BI 1569912|BI 1569912
58288747|NCT04445090|DRUG|Placebo|Placebo
58288748|NCT06077162|OTHER|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
58288749|NCT06077162|OTHER|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
58401639|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
57933320|NCT00501826|DRUG|Dexamethasone|Given IV or PO
58288750|NCT03089645|BIOLOGICAL|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
58288751|NCT03089645|BIOLOGICAL|MEID5083 with Durvalumab or Tremelimumab|Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
58288752|NCT03089645|BIOLOGICAL|Medi5083 with Durvalumab and Docetaxel|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
58288753|NCT02522416|DEVICE|Central corneal thickness measurement|
58288754|NCT04442087|BIOLOGICAL|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
58288755|NCT04442087|BEHAVIORAL|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
58401640|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
58401641|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
58401642|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
58401643|NCT01940250|DRUG|Sterile water|H2O IV infusion
57933321|NCT00501826|DRUG|Doxorubicin Hydrochloride|Given IV
57933322|NCT00501826|DRUG|Mercaptopurine|Given PO
57933323|NCT00501826|DRUG|Methotrexate|Given IV and PO
57933324|NCT00501826|DRUG|Nelarabine|Given IV
58288756|NCT05782972|DRUG|dapagliflozin (Forxiga)|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
58288757|NCT02712918|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
58288758|NCT02712918|OTHER|Standard Care|Treatment as usual at the ward
58288759|NCT02118779|BEHAVIORAL|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
58288760|NCT04273997|DRUG|Metronidazole 10% ointment|Metronidazole 10% ointment
58288761|NCT04273997|DRUG|Placebo ointment|Placebo ointment
58288762|NCT06104566|DRUG|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
58288763|NCT06104566|DRUG|BTK inhibitor|BTK inhibitor
58288764|NCT02830399|DEVICE|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
58288765|NCT02830399|DEVICE|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
58288766|NCT04058028|DRUG|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
58288767|NCT04058028|DRUG|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
58288768|NCT05615142|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.
58288769|NCT05615142|RADIATION|stereotactic body radiation therapy|Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.
57933325|NCT00501826|DRUG|Pegaspargase|Given IV
57933326|NCT00501826|DRUG|Prednisone|Given PO
57933327|NCT00501826|DRUG|Venetoclax|Given PO
57933328|NCT00501826|DRUG|Vincristine Sulfate|Given IV
57933329|NCT06735781|DRUG|Nivolumab|As prescribed by the treating clinician
57933330|NCT03226418|DRUG|Cytarabine|Given IV
57933331|NCT03226418|DRUG|Decitabine|Given IV
58288770|NCT05615142|DRUG|PD-1 Inhibitors|Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.
58288771|NCT00940888|DEVICE|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
57933332|NCT03226418|DRUG|Idarubicin|Given IV
57933333|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
57933334|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
57933335|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
57933336|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
57933337|NCT03226418|DRUG|Azacitidine|Given by infusion
57933338|NCT03226418|DRUG|Venetoclax|oral tablet
57933339|NCT03226418|DRUG|glasdegib|oral tablet
57933340|NCT03382145|OTHER|No intervention|No intervention
57933341|NCT01553877|DIETARY_SUPPLEMENT|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
57933342|NCT01553877|DIETARY_SUPPLEMENT|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
57933343|NCT01553877|DIETARY_SUPPLEMENT|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
57933344|NCT00002860|PROCEDURE|Surgery|Complete surgical resection of metastatic melanoma
57933345|NCT03508258|OTHER|Non-interventional|Non-interventional
57933346|NCT03508258|OTHER|Non-Interventional|Non-Interventional
57933347|NCT01357421|DRUG|TT301|Single iv dose of TT301
58288772|NCT00421083|DRUG|tadalafil|
58288773|NCT05524766|DEVICE|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
58288774|NCT06052995|DRUG|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
58288775|NCT04541329|BIOLOGICAL|Tildrakizumab|IL-23 inhibitor
58288776|NCT05458947|PROCEDURE|pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
58288777|NCT05458947|PROCEDURE|electrical stimulation (ES)|high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
58288778|NCT05458947|PROCEDURE|electrical stimulation (ES) and pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
58401644|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
58401645|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
58401646|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
58401647|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
58401648|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
58071611|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
58071612|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
58071613|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
58071614|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
58071615|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
58288779|NCT06467747|OTHER|Music|Music group: wear earphones to listen to music and receive standardized anesthesia protocol
58288780|NCT06467747|OTHER|Mute|Mute group: wear earphones without music and receive standardized anesthesia protocol
58288781|NCT01213446|BIOLOGICAL|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
58288782|NCT02135016|DRUG|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
58288783|NCT02135016|DRUG|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
58288784|NCT02135016|DRUG|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
58288785|NCT01085422|DRUG|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
58288786|NCT01085422|DRUG|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
58288787|NCT06130085|DIETARY_SUPPLEMENT|Partially hydrolyzed formula|Partially hydrolyzed formula given as the milk supplement for cow milk allergy patients after 6 months of strict elimination diet
58288788|NCT06079996|OTHER|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
58288789|NCT04910581|PROCEDURE|rTMS|Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
58288790|NCT04910581|PROCEDURE|Sham stimulation|Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
58288791|NCT04617795|DEVICE|Omnipod 5 Automated Insulin Delivery System|"The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers."
58288792|NCT06157983|OTHER|measurement of lipoprotein(a)|Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
57933348|NCT01357421|DRUG|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
57933349|NCT04744571|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
57933350|NCT04744571|DEVICE|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
58401649|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
58401650|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
58401651|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
58401652|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
58401653|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
57933351|NCT04744571|OTHER|drug-coated balloon|Drug-coated balloon including all sizes and all brands
57933352|NCT04744571|DEVICE|drug-eluting stent|Drug-eluting stent including all sizes and all brands
58401654|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58401655|NCT00262886|DRUG|cyclophosphamide|
58401656|NCT00262886|DRUG|fludarabine phosphate|
58401657|NCT00262886|DRUG|mycophenolate mofetil|
57933353|NCT05185986|BEHAVIORAL|Home-Based Pilates exercise|The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.
57933354|NCT05185986|OTHER|Home-based Cognitive Rehabilitation|Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.
57933355|NCT05185986|OTHER|waiting list group|This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
57933356|NCT06418204|OTHER|Non-interventional Study|Non-interventional study
57933357|NCT06709196|DRUG|Pivmecillinam|Orally administered pivmecillinam 400mg
58401658|NCT00262886|DRUG|tacrolimus|
57933358|NCT06709196|DRUG|Pivmecillinam|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933359|NCT06709196|DRUG|Amoxicillin clavulanic acid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933360|NCT06709196|DRUG|Amoxicillin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933361|NCT06709196|DRUG|Cefuroxime|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933362|NCT06709196|DRUG|Ciprofloxacin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933363|NCT06709196|DRUG|Linezolid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
58401659|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
58401660|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
58401661|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
58401662|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
58401663|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
58401664|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
58401665|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
57933364|NCT06709196|DRUG|Nitrofurantoin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933365|NCT06709196|DRUG|Trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933366|NCT06709196|DRUG|Sulfamethoxazole trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933367|NCT06709196|DRUG|Fluconazole|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
57933368|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
58401666|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
58401667|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
58401668|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
58401669|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
58401670|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
58401671|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
58401672|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
58401673|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
58401674|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
58401675|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
58401676|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
58401677|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
57933369|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
57933370|NCT05900388|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
57933371|NCT05900388|DRUG|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
58401678|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
57933372|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
57933373|NCT04433806|BEHAVIORAL|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
58071616|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
58071617|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
58288793|NCT01176786|OTHER|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
58401679|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
58401680|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
58401681|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
58401682|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
57933374|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
57933375|NCT00570817|OTHER|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
57933376|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
57933377|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
58401683|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
58288794|NCT04806321|OTHER|Project SOLVE|This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
58288795|NCT04806321|OTHER|Project SUCCESS|This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
58401684|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
58401685|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
58401686|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
57729669|NCT04278053|DIETARY_SUPPLEMENT|inositol-stabilized arginine silicate|Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
57729670|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
58288796|NCT03919123|OTHER|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
58288797|NCT05906654|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
58288798|NCT06175039|OTHER|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
58288799|NCT06175039|OTHER|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
58288800|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility, plus specific training of the inspiratory muscles, 3 times a week, at a load between 50 and 80% of the maximum inspiratory pressure of each participant, after re-education of their diaphragmatic ventilation.
58288801|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility.
58401687|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
58401688|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
58401689|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
58401690|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
58401691|NCT01895231|DRUG|Placebo|
58401692|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
57729671|NCT01863680|DRUG|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
57729672|NCT01863680|DRUG|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
57729673|NCT01863680|DRUG|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
58288802|NCT03285035|DEVICE|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
58288803|NCT00638469|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
58288804|NCT00638469|OTHER|No treatment|no UV exposure
58288805|NCT03015298|DEVICE|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
58288806|NCT03015298|DEVICE|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
58288807|NCT02964338|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
58288808|NCT02964338|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
58306865|NCT06098989|PROCEDURE|Radio frequency ablation|Radio frequency ablation
58401693|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
58401694|NCT02862483|DRUG|Tamsulosin 0.2mg|
58401695|NCT02862483|DRUG|Tadalafil 5mg|
58401696|NCT02862483|DRUG|Placebo for Tamsulosin|
58401697|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
58401698|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
58401699|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
58401700|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
58401701|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
58401702|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
58401703|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
57933378|NCT01930149|BEHAVIORAL|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
58095091|NCT06238128|BEHAVIORAL|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
58401704|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
58401705|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
58401706|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
58401707|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
58401708|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
58401709|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
58401710|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
58401711|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
58401712|NCT06607757|DRUG|Capivasertib|find arm A description
58401713|NCT06607757|DRUG|Fulvestrant injection|find arm B description
58401714|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
58401715|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
58401716|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
58401717|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
58401718|NCT04746235|DRUG|Venetoclax|Given PO
58401719|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
58401720|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
58288809|NCT05768997|DRUG|Ferric Derisomaltose Injection|Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
58288810|NCT05768997|DRUG|Darbepoetin Alfa Injection|Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
58288811|NCT01844817|DRUG|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
58288812|NCT01844817|DRUG|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
58401721|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
58401722|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
58095092|NCT06238128|BEHAVIORAL|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
58071618|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
58071619|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
58071620|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
58288813|NCT00010751|PROCEDURE|Reiki|
58288814|NCT05122377|DRUG|3M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
58288815|NCT05122377|DRUG|1M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
58288816|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
57729674|NCT01863680|DRUG|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
57729675|NCT04852081|DRUG|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
57933379|NCT02061605|DEVICE|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
57933380|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
58288817|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
58288818|NCT01504139|DRUG|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
58288819|NCT01504139|DRUG|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
58288820|NCT04241016|PROCEDURE|Endoscopic sinus surgery (ESS)|Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
58288821|NCT04127877|DEVICE|NICAS|Electric regional bio impedance device
58288822|NCT04430088|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
58288823|NCT04430088|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
58288824|NCT04254081|DRUG|Buprenorphine 0.15 MG|Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
58288825|NCT04254081|DRUG|Lidocaine 1% Injectable Solution|20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
57729676|NCT04852081|DRUG|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
57729677|NCT04852081|DRUG|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
57729678|NCT04852081|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
57729679|NCT04852081|DRUG|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
57729680|NCT04852081|DRUG|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
57729681|NCT04852081|DRUG|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
58071621|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58288826|NCT03145103|DEVICE|CT ASPHINA 409|intraocular lens
58288827|NCT01941784|OTHER|educational intervention|Undergo health education program
58288828|NCT01941784|OTHER|counseling intervention|Undergo health education program
58288829|NCT01941784|BEHAVIORAL|telephone-based intervention|Receive follow-up phone calls
58288830|NCT01941784|OTHER|questionnaire administration|Ancillary studies
58288831|NCT01941784|PROCEDURE|quality-of-life assessment|Ancillary studies
58288832|NCT04521478|DRUG|BI 1358894|BI 1358894
58288833|NCT04521478|DRUG|Placebo|Placebo
58288834|NCT04521478|DRUG|Quetiapine|quetiapine
58288835|NCT01553448|GENETIC|gene expression analysis|
58288836|NCT01553448|GENETIC|protein expression analysis|
58288837|NCT01553448|OTHER|enzyme-linked immunosorbent assay|
58288838|NCT01553448|OTHER|immunohistochemistry staining method|
58288839|NCT01553448|OTHER|laboratory biomarker analysis|
58288840|NCT01553448|OTHER|medical chart review|
58288841|NCT06289777|PROCEDURE|TEVAR|minimally invasive endovascular intervention to treat aortic dissection
58288842|NCT03517241|DIAGNOSTIC_TEST|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
58288843|NCT03517241|DIAGNOSTIC_TEST|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
58288844|NCT03517241|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
58288845|NCT03517241|DIAGNOSTIC_TEST|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
58071622|NCT00483782|BIOLOGICAL|bevacizumab|
58071623|NCT00483782|DRUG|carboplatin|
58071624|NCT00483782|DRUG|paclitaxel|
58288846|NCT03517241|DIAGNOSTIC_TEST|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
58288847|NCT05935592|BEHAVIORAL|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
58288848|NCT05935592|BEHAVIORAL|Didactic health information|Web-based newsletters (for child and parent) by email and/or text
58288849|NCT05002504|DIAGNOSTIC_TEST|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
58288850|NCT05002504|DIAGNOSTIC_TEST|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
58288851|NCT05002504|PROCEDURE|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
58288852|NCT02169843|DRUG|Sevoflurane|inhale Sevoflurane
58288853|NCT02169843|DRUG|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
57729682|NCT04852081|DRUG|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
58071625|NCT00483782|OTHER|questionnaire administration|
58071626|NCT00483782|OTHER|study of socioeconomic and demographic variables|
58071627|NCT00483782|PROCEDURE|quality-of-life assessment|
58071628|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
58071629|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
58071630|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
58288854|NCT02169843|DRUG|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
58401723|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
57729683|NCT04852081|DRUG|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
57933381|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
58071631|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
58071632|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
58095093|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
58095094|NCT06236074|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
58288855|NCT05382429|PROCEDURE|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
58288856|NCT05382429|PROCEDURE|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
58288857|NCT02413671|DIETARY_SUPPLEMENT|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
58288858|NCT02413671|DIETARY_SUPPLEMENT|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
58288859|NCT02413671|OTHER|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
58288860|NCT05781087|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
58401724|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
58401725|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
58401726|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
58401727|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
57729684|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
57729685|NCT01775891|DRUG|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
57933382|NCT06402357|DEVICE|Focal One high intensity focused ultrasound device|Participants will be treated with one session of high intensity focused ultrasound using the Focal One device.
57933383|NCT05047263|DRUG|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
57933384|NCT05047263|DRUG|Placebo|Tablet, once daily, oral
57933385|NCT06735196|DEVICE|sampling capsule endoscopy|Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.
57933386|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
57933387|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
58095095|NCT03469362|PROCEDURE|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
58288861|NCT05781087|DIAGNOSTIC_TEST|Cardiac magnetic resonance angiogram|1.5T
58288862|NCT02435563|DRUG|ticagrelor 180 mg administrated alone|
58288863|NCT02435563|DRUG|Ticagrelor adjusted dose + ritonavir 100mg|
58288864|NCT05897372|DRUG|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
58288865|NCT01689441|DRUG|Calcitriol|
58288866|NCT01689441|DRUG|Placebo|
58288867|NCT02363712|DEVICE|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
58288868|NCT02363712|DEVICE|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
58288869|NCT01340729|DRUG|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
58288870|NCT00186407|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
58288871|NCT03540069|BEHAVIORAL|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
58401728|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
58401729|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
58401730|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
58401731|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
58401732|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
58401733|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
58401734|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
58401735|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
58401736|NCT00053976|BIOLOGICAL|Daclizumab|
58401737|NCT00053976|DRUG|methylprednisolone|
58401738|NCT00053976|DRUG|Placebo|
58401739|NCT00372372|DRUG|risedronate|
58401740|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
58401741|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
58401742|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
57933388|NCT03631745|BEHAVIORAL|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
58401743|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
58401744|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
58401745|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
58401746|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
58401747|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
58401748|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
58401749|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
58401750|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
58401751|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
58401752|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
58401753|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
58401754|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
58306866|NCT04511325|OTHER|Potato Regimen|100 grams cooked white russet potato with the skin
58401755|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
58401756|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
58401757|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
58401758|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
58401759|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
58401760|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
58401761|NCT02693054|DEVICE|HALO|Laser Treatment
57729686|NCT01775891|DRUG|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
58288872|NCT01569945|DRUG|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
58288873|NCT01569945|DRUG|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
58288874|NCT03480594|DRUG|MRI Tracer|Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
58288875|NCT01727856|DEVICE|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
58288876|NCT02741648|DEVICE|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
58288877|NCT05600153|PROCEDURE|implant exchange operation|To perform implant exchange via axillary incision.
58288878|NCT01690195|DRUG|ABT-126|See arm description
58288879|NCT06121440|OTHER|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
58288880|NCT06121440|OTHER|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
58288881|NCT03109626|DIETARY_SUPPLEMENT|DHA|
58288882|NCT01481883|DRUG|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
58401762|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
58401763|NCT00096226|DRUG|Induction Carboplatin|
57729687|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
57933389|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
57933390|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
57933391|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
58095096|NCT03469362|PROCEDURE|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
58288883|NCT01481883|DRUG|Placebo|1 capsule daily for 12 week trial
58288884|NCT02586311|DRUG|CKD-330 16/5mg|Once a day, 8 weeks
58288885|NCT02586311|DRUG|Amlodipine 5mg Placebo|Once a day, 8 weeks
58288886|NCT02586311|DRUG|CKD-330 16/5mg Placebo|Once a day, 8 weeks
58095097|NCT03469362|DEVICE|Da Vinci Robot|Da Vinci Robotic Surgical System
58288887|NCT02586311|DRUG|Amlodipine 5mg|Once a day, 8 weeks
58288888|NCT01307878|DRUG|chemotherapy ± targeted therapy|Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
58288889|NCT02608996|DRUG|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
58288890|NCT02608996|DRUG|Placebo|For comparison to elucidate the true effect of nesiritide
58288891|NCT00753298|DEVICE|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
58288892|NCT00753298|DEVICE|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
58288893|NCT02499120|DRUG|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
58401764|NCT00096226|DRUG|Induction Paclitaxel|
58401765|NCT00096226|PROCEDURE|Resection|
58401766|NCT00096226|DRUG|Consolidation Carboplatin|
58401767|NCT00096226|RADIATION|Radiation Therapy|
58401768|NCT00096226|DRUG|Consolidation Paclitaxel|
58401769|NCT01044212|DRUG|Docusate|Docusate 100mg BID
58401770|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
58401771|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
58401772|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
58401773|NCT01185418|DRUG|risperidone|
58401774|NCT01185418|DRUG|aripiprazole|
58288894|NCT02499120|DRUG|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
58288895|NCT02499120|DRUG|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
58306867|NCT04511325|OTHER|Refined Grain Regimen|75 grams of cooked long-grain white rice
58401775|NCT01185418|DRUG|haloperidol|
58401776|NCT01185418|DRUG|amisulpride|
58401777|NCT01185418|DRUG|lactose|
58401778|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
58306868|NCT00417066|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
58401779|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
58401780|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
58401781|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
58401782|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
58401783|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
58401784|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
58401785|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
58401786|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
57933392|NCT06525675|DRUG|Fulvestrant Injectable Product|500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.
58306869|NCT00417066|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
58401787|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
58401788|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
58401789|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
58401790|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
58401791|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
58401792|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
58401793|NCT00519376|DRUG|GW642444M|drug
58401794|NCT00519376|DRUG|GW642444H|drug
58401795|NCT00519376|DRUG|placebo|
58401796|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
58401797|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
58401798|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
57933393|NCT06525675|DRUG|Letrozole 2.5mg|2.5 mg letrozole per day, administered orally (continuous treatment)
57933394|NCT06525675|DRUG|Palbociclib 125mg|orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
57933395|NCT00408330|DRUG|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
58288896|NCT03328598|BEHAVIORAL|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
58288897|NCT03328598|BEHAVIORAL|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
58288898|NCT03328598|OTHER|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
58288899|NCT05965427|OTHER|No intervention|Study is retrospective data collection only
58288900|NCT02017093|DEVICE|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
58288901|NCT02017093|DEVICE|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
58288902|NCT06612684|DEVICE|Piezoelectric syndesmotomy|Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
58288903|NCT00629538|PROCEDURE|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
58288904|NCT06425211|BEHAVIORAL|Therapeutic exercises|Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.
58288905|NCT06425211|DEVICE|Perineal electromyographic biofeedback|Free muscle work and gross motor coordination:
58288906|NCT06425211|DEVICE|Electrical stimulation|Muscular proprioceptive work: 50 Hz 300 µs
58288907|NCT05171270|OTHER|Questionnaire|PsAID questionnaire
58401799|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
58401800|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
58401801|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
58401802|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
58288908|NCT03420339|DRUG|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
58288909|NCT06501807|DRUG|Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
58306870|NCT00688441|DRUG|Nasal CO2|Twice daily during the 14 day Treatment Period
57933396|NCT00408330|DRUG|Inactive 15% gel base|placebo, topically applied daily for six weeks
57933397|NCT02811549|DEVICE|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
57933398|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
58071633|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
58306871|NCT00688441|DRUG|Placebo|Use of the study drug dispenser at the same frequency as the active arm
57933399|NCT06734806|DIAGNOSTIC_TEST|Radiographic Imaging and Digital STL Analysis|This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.
57933400|NCT06734806|DIAGNOSTIC_TEST|FDI Criteria Evaluation and Plaque Index Measurement|This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
57933401|NCT01558583|OTHER|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
57933402|NCT01558583|OTHER|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
57933403|NCT01558583|OTHER|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
57933404|NCT06179498|BEHAVIORAL|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
58071634|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
58288910|NCT01285778|DRUG|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
58288911|NCT03214679|OTHER|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
58288912|NCT03214679|OTHER|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
58288913|NCT03706664|OTHER|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
58288914|NCT00905632|DRUG|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
58288915|NCT00905632|DRUG|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
58288916|NCT00905632|DRUG|Placebo + SOC|Placebo tid +SOC
58288917|NCT00905632|DRUG|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
58288918|NCT01539746|PROCEDURE|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
58288919|NCT01539746|PROCEDURE|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
58288920|NCT03568383|DRUG|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
58288921|NCT03568383|DRUG|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
58306872|NCT04349644|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.
58288922|NCT03568383|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
58288923|NCT04291118|PROCEDURE|Private system endoscopic sinus surgery|Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
58401803|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
58401804|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
57729688|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
58071635|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
58288924|NCT04291118|PROCEDURE|Public system endoscopic sinus surgery|Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
57729689|NCT06535984|OTHER|White Noise|White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.
58288925|NCT04291118|DRUG|Budesonide|Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
58288926|NCT03516162|OTHER|There is no study-specific intervention|There is no study-specific intervention
58288927|NCT05073445|BEHAVIORAL|SDNN measurement|SDNN measurement during pediatric simulation
58288928|NCT03017391|DRUG|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
58288929|NCT03017391|DRUG|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
58288930|NCT03017391|DRUG|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
58071636|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
58401805|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
58401806|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
57729690|NCT06535984|OTHER|Swaddling|Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.
58071637|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
58288931|NCT03017391|DRUG|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
58288932|NCT05405764|DIETARY_SUPPLEMENT|Porcine protein supplement|Porcine protein supplementation
58288933|NCT05405764|DIETARY_SUPPLEMENT|Control product maltodextrin supplement|Maltodextrin supplementation
58288934|NCT05359952|BEHAVIORAL|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
58288935|NCT05359952|BEHAVIORAL|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
58401807|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
58288936|NCT04200183|BEHAVIORAL|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
58288937|NCT04200183|BEHAVIORAL|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
58288938|NCT02840474|BIOLOGICAL|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
58288939|NCT02840474|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
58288940|NCT06122285|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
58288941|NCT00836446|OTHER|physical activity|physical activity routines 5 times a weeks for 12 weeks.
58288942|NCT00766623|DIETARY_SUPPLEMENT|high fat meal|milkshake containing 95g fat
58288943|NCT00766623|DIETARY_SUPPLEMENT|control meal|milkshake comparable with a normal breakfast
58288944|NCT01646840|DRUG|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
58401808|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
58401809|NCT02681796|DRUG|Bupivacaine|
58401810|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
58401811|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
58401812|NCT02292758|DRUG|Irinotecan|Given IV
58288945|NCT01646840|DRUG|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
58401813|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
58401814|NCT02292758|OTHER|Placebo|Given IV
58401815|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
57729691|NCT06535984|OTHER|White Noise+Swaddling|White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
57729692|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
57729693|NCT03822923|OTHER|Control group|Conventional treatment
58288946|NCT05912257|BEHAVIORAL|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
58288947|NCT05912257|BEHAVIORAL|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
58288948|NCT01712048|PROCEDURE|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
58288949|NCT01712048|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
58288950|NCT00815997|PROCEDURE|PCI (percutaneous coronary intervention)|PCI will be performed via the radial artery.
58288951|NCT02091401|DEVICE|Springfusor infusion pump|
58288952|NCT02091401|OTHER|IV administration|
58288953|NCT02091401|DRUG|Magnesium Sulfate|
58288954|NCT00610779|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
58288955|NCT00610779|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
58401816|NCT00215566|DRUG|DDP733|
57933405|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
57933406|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
58288956|NCT05880667|RADIATION|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
58288957|NCT01909973|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
58288958|NCT04497532|OTHER|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
58288959|NCT01155622|PROCEDURE|Endovascular Cooling|Infusion of \<8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
58288960|NCT04794517|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
58288961|NCT04794517|OTHER|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
58288962|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
58288963|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
58288964|NCT05524649|DIETARY_SUPPLEMENT|Placebo|5 drops/day for 3 months of sunflower oil
58288965|NCT00418028|DRUG|Capecitabine|
58288966|NCT05399147|OTHER|fiberoptic intubation classic technique|classic fiberoptic intubation
58288967|NCT05399147|OTHER|fiberoptic intubation tube 1st technique|tube 1st technique
58288968|NCT02217852|DRUG|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
58288969|NCT02217852|DRUG|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
58288970|NCT02217852|DRUG|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
58288971|NCT02217852|DRUG|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
58288972|NCT04566718|DRUG|Metformin|metformin cessation
58288973|NCT00478075|DRUG|bortezomib|
58288974|NCT00478075|OTHER|immunologic technique|
58288975|NCT00478075|RADIATION|samarium Sm 153 lexidronam pentasodium|
58288976|NCT01963559|DRUG|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
58288977|NCT01788319|PROCEDURE|lasertrabeculoplasty|
58288978|NCT04153955|BEHAVIORAL|Mobilization|Any movement out of bed
58288979|NCT00273598|PROCEDURE|Moss Miami Spine Instrumentation System|
58288980|NCT00273598|PROCEDURE|Universal Spine Instrumentation System|
58401817|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
57933407|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
58071638|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
58401818|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
58401819|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
58071639|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
58071640|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
58071641|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
58071642|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
58071643|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
58071644|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
58071645|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
58071646|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
57729694|NCT00650546|DRUG|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
58071647|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
57729695|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
58071648|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
58071649|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
57729696|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
58288981|NCT00161668|DRUG|Mylotarg|
58288982|NCT03543176|OTHER|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
58288983|NCT03543176|OTHER|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
58288984|NCT03543176|OTHER|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
58288985|NCT03543176|OTHER|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
58288986|NCT03543176|DEVICE|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
58288987|NCT03543176|DEVICE|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
58288988|NCT05518955|BEHAVIORAL|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
58071650|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
58288989|NCT02591641|DEVICE|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
58288990|NCT02591641|OTHER|Standard of Care|Standard ambulance stretcher mattress
58288991|NCT03104608|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
58288992|NCT03104608|OTHER|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
58288993|NCT04468724|BEHAVIORAL|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
58288994|NCT02232061|DRUG|Fingolimod|Fingolimod 0.5 mg tablet
58288995|NCT05035875|DEVICE|ultrasonography|ultrasound assessment of diaphragm function
58288996|NCT06092034|GENETIC|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
58288997|NCT02483988|DEVICE|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
58288998|NCT02787681|DEVICE|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
58288999|NCT01057290|GENETIC|gene expression analysis|
58289000|NCT01057290|GENETIC|protein expression analysis|
57729697|NCT06470932|DIAGNOSTIC_TEST|Follow-up consult|Patients will be ask to participate to a follow-up consult
57729698|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
57933408|NCT06130501|DEVICE|Sparrow Ascent tAN|The Sparrow Ascent device from Spark Biomedical (Dallas, TX), applies stimulation frequencies of 15 Hz at the cymba concha (vagal innervation) and 100 Hz anterior to the tragus (trigeminal innervation). Both tAN and active sham conditions have square biphasic waveforms with identical pulse widths of 250 µs separated by a 125 µs interval between pulses. Stimulation is applied using a duty cycle of 5-minutes ON and 10 seconds OFF. The stimulation intensities (mA) will be programmed for each individual based on the highest amplitude for each channel that is both comfortable and perceptible. Patients using the device may alter the intensity of stimulation at these sites using the Patient Controller to achieve the desired effect.
58289001|NCT01057290|OTHER|fluorescence activated cell sorting|
58289002|NCT01057290|OTHER|immunologic technique|
58289003|NCT01057290|OTHER|laboratory biomarker analysis|
58289004|NCT05834127|OTHER|Aerobic exercise|"Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month"
58289005|NCT05834127|OTHER|Yoga Exercises|"Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose"
58289006|NCT03097926|PROCEDURE|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
58289007|NCT03052920|DEVICE|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
58289008|NCT03077607|DRUG|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
58289009|NCT03077607|DRUG|Itraconazole|100 mg oral dose
58289010|NCT03077607|DRUG|Rifampin|600 mg oral dose
58306873|NCT04256343|OTHER|Deuterium Oxide (D2O) Dose|1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
57729699|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
58071651|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
58071652|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
58071653|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
58289011|NCT05515510|OTHER|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
58289012|NCT05515510|OTHER|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
58401820|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
58071654|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
58071655|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
58071656|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
58401821|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
58071657|NCT00122395|BEHAVIORAL|Screening via pen and paper|
58071658|NCT00122395|BEHAVIORAL|Screening via audiotape|
58071659|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
58071660|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
58289013|NCT03456687|DRUG|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
58289014|NCT02709837|OTHER|Nutritional|
58289015|NCT04620070|PROCEDURE|ECPR|Application of prehospital ECPR
58289016|NCT06478082|DEVICE|Home-based virtual reality training|8-week training with an advised frequency of 30 minutes per day, for 5 days per week.
58289017|NCT03671512|DEVICE|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
58401822|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
58401823|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
58401824|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
58401825|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
58401826|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
58401827|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
58401828|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
58401829|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
58401830|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
57933409|NCT06130501|DEVICE|Sparrow Ascent Active Sham|The Sparrow Ascent Active Sham is a modified version of the Sparrow Ascent tAN System that has been designed to provide sub-therapeutic stimulation to the trigeminal nerve only and no stimulation to the vagus nerve. The trigeminal nerve will receive 1 Hz stimulation at the temporomandibular region at an amplitude that is comfortable and perceptual. The pulse duration will be set to a value that does not exceed 250 μs in a square biphasic waveform. The patient controller device for the active sham will give the appearance that stimulation is being applied at both vagal and trigeminal electrode sites.
58071661|NCT00032058|PROCEDURE|magnetic resonance imaging|
58071662|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
58071663|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
58289018|NCT03671512|DEVICE|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
58289019|NCT03827694|DIAGNOSTIC_TEST|Non-Invasive Testing for PIFI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
58289020|NCT06481943|DEVICE|Sponsor MCG device (CardiAQ)|Unshielded magnetocardiography device for measuring cardiac magnetic fields
58289021|NCT04437836|DRUG|Evaluation of high dose rifampicin in children|Evaluation of severity of adverse event from grade 1 to 5
58401831|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
58401832|NCT05386550|DRUG|Xevinapant (Debio 1143)|Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
58401833|NCT05386550|RADIATION|IMRT|Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.
58401834|NCT05386550|DRUG|Placebo|Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
58401835|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
58401836|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
57933410|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
57933411|NCT05444335|DEVICE|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
58071664|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
58071665|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
58071666|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
58071667|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
58071668|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
58071669|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
58071670|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
58401837|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
58401838|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
58401839|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
58401840|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
58401841|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
58401842|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
58401843|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
58401844|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
58071671|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
58289022|NCT06508060|DEVICE|Neosensory Wristband|"The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location."
58289023|NCT06508060|OTHER|Tones only|Tones will be played through an app
58289024|NCT05013580|PROCEDURE|Guided bone regeneration (GBR)|Bone grafts will be placed in the patient's jawbone, along with a membrane to cover the bone grafts. A horizontal incision over the edentulous ridge crest will be made along with vertical incisions if indicated. Buccal and lingual full thickness mucoperiosteal flaps will be reflected to expose the alveolar bone. Intra-marrow penetration (decortication of the alveolar bone to increase vascular supply to the bone grafts) at the surgical site alveolar bone will be made with a high-speed hand piece and diamond bur. Bone allograft material will be placed to fill the alveolar bone defect. The bone graft will then be covered with a membrane and secured with sutures.
58289025|NCT01133704|BIOLOGICAL|sipuleucel-T|
58289026|NCT01133704|BIOLOGICAL|APC-Placebo|
58289027|NCT05227118|DRUG|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
58289028|NCT05227118|DRUG|Placebo|MK-8189 matching placebo administered orally QD
58289029|NCT04668209|DRUG|Silmitasertib|Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
58289030|NCT03903250|DIETARY_SUPPLEMENT|A-GPC|Taken orally in liquid form
58289031|NCT03903250|DIETARY_SUPPLEMENT|Sugar|Taken orally in liquid form
58289032|NCT03372382|DRUG|Ibuprofen|NSAID
58289033|NCT03372382|DRUG|Acetaminophen|analgesic
58289034|NCT03372382|DRUG|Norco|acetaminophen plus opioid
58289035|NCT00950729|PROCEDURE|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
58289036|NCT00950729|PROCEDURE|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
58289037|NCT00950729|PROCEDURE|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
58289038|NCT02716779|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
58289039|NCT02716779|DRUG|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
58289040|NCT02716779|DRUG|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
58401845|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
58289041|NCT02710019|OTHER|Back to Reality Series Video Games|Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
58401846|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
57729700|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
57933412|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
57933413|NCT06736314|DEVICE|a removable titanium clip|The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
57933414|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
58289042|NCT02710019|OTHER|Control Video Game|The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
57933415|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
57933416|NCT03798678|DRUG|Carfilzomib|Given IV
57933417|NCT03798678|DRUG|Dexamethasone|Given PO
57933418|NCT03798678|DRUG|Telaglenastat Hydrochloride|Given PO
57933419|NCT04782011|BEHAVIORAL|ATC/DDD|The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
57933420|NCT06460233|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Laparoscopic sleeve gastrectomy performed according to the current surgical standards
57933421|NCT02908425|OTHER|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
58071672|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
58071673|NCT00261599|DRUG|Midazolam HCI|
58071674|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
58289043|NCT04582201|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
58289044|NCT00478712|OTHER|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
58289045|NCT06009679|DRUG|Misoprostol 200mcg Tab|Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
58289046|NCT02360488|DEVICE|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
58289047|NCT02360488|BEHAVIORAL|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
58289048|NCT01205880|DRUG|Calcitriol ointment|twice daily
58289049|NCT01205880|DRUG|Clobetasol spray|twice daily
58289050|NCT04637594|DRUG|Pembrolizumab|Given IV
57933422|NCT06734286|OTHER|CogMed|CogMed which is a computerized working memory training program developed by Karolinska University.
57933423|NCT06734442|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
57933424|NCT05890222|BEHAVIORAL|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
58289051|NCT04637594|DRUG|Nivolumab|Given IV
58289052|NCT04637594|DRUG|Atezolizumab|Given IV
58289053|NCT04637594|DRUG|Durvalumab|Given IV
58289054|NCT04637594|DRUG|Avelumab|Given IV
58289055|NCT00869908|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58071675|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
58289056|NCT00869908|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58289057|NCT00869908|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58289058|NCT06544746|RADIATION|Periapical radiographs|oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
58289059|NCT03581916|DRUG|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
57933425|NCT05890222|BEHAVIORAL|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
57933426|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
58071676|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
58071677|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
58289060|NCT04091737|BIOLOGICAL|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"* Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200"
57933427|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
57933428|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
58289061|NCT05777837|PROCEDURE|laparoscopic repair of cesarean scar niche|Intentional perforation of the niche will be done using uterine sound and excision of the fibrotic edges then suturing the uterine incision using 2-0 absorbable suture.
57729701|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
57933429|NCT06736093|DRUG|Vitamin D3|Vitamin D3 60,000 IU given once weekly Pre Liver Transplant atleast for 6 weeks
57933430|NCT06736093|DRUG|Placebo|Placebo capsules once weekly for atleast 6 weeks pre liver transplant
57933431|NCT06593769|DIETARY_SUPPLEMENT|whey-protein microgel|The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.
57933432|NCT06593769|OTHER|Placebo|Water (isovoloumous amount)
57933433|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
57933434|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
57933435|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
57933436|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
57933437|NCT05151848|DRUG|Adalimumab Injection|Adalimumab Injection injected subcutaneously every other week for 78 weeks
57933438|NCT05151848|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 78 weeks
57933439|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
57933440|NCT05029414|PROCEDURE|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
57933441|NCT06540391|BIOLOGICAL|MB097|Live bacterial therapeutic for oral administration
57729702|NCT03264989|DRUG|crizanlizumab|Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
57933442|NCT06540391|BIOLOGICAL|Pembrolizumab|IV infusion
57933443|NCT06540391|DRUG|Vancomycin|Antibiotic
57933444|NCT06654947|DRUG|Surufatinib+Toripalimab+GEMOX|Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
57933445|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
57933446|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
58071678|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
58071679|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
58071680|NCT02617602|OTHER|Control|
58071681|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
58071682|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
58289062|NCT05777837|PROCEDURE|Combined hysteroscopic and laparoscopic repair of cesarean scar niche|Hysteroscopic resection of the niche under laparoscopic guide will be done to avoid perforation of the niche. After completion of the hysteroscopic approach, laparoscopic plication of the niche without opening it will be done using multiple interrupted 2-0 absorbable suture.
58289063|NCT03315455|DRUG|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
58289064|NCT04966650|BEHAVIORAL|5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)|The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
57933447|NCT06734299|OTHER|Sunscreen A|Sunscreen A will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
58289065|NCT04420169|OTHER|Questionnaire|A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
58289066|NCT06103071|PROCEDURE|Sweeping of membranes|After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
58289067|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
58289068|NCT04441788|DRUG|Placebo|Placebo administered by oral inhalation
58289069|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
58289070|NCT04555707|DRUG|Apremilast 30mg|30mg PO BID started within 10 days of baseline
58289071|NCT04555707|DRUG|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
58289072|NCT04694976|BIOLOGICAL|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
58289073|NCT06552403|DIETARY_SUPPLEMENT|A modified 5:2 intermittent fasting diet|The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
58289074|NCT02946892|DRUG|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
58401847|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
58289075|NCT02946892|DRUG|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
58289076|NCT05951361|DEVICE|980nm Diode Laser|300 mW, 4 J/cm2, 2mm non-contact mode up to 10 sessions
58401848|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
58401849|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
58401850|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
58401851|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
58401852|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
57729703|NCT01175668|DRUG|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
58289077|NCT05951361|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|three times daily for 4 weeks
58289078|NCT01951573|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
58289079|NCT01951573|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
58289080|NCT03864523|DRUG|Pioglitazone|
58289081|NCT01369745|DRUG|Prednisolone|Prednisolone 2.7 mg daily
58289082|NCT01369745|DRUG|dipyridamole|dipyridamole 360 mg daily
58289083|NCT01369745|DRUG|Prednisone|Prednisone 5 mg daily
58289084|NCT01369745|DRUG|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
58289085|NCT01369745|OTHER|placebo|
58401853|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
58289086|NCT02253888|DRUG|TPV - Room condition|
58289087|NCT02253888|DRUG|TPV - Refrigerated conditions|
58289088|NCT02253888|DRUG|Ritonavir (RTV)|
58289089|NCT01297543|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
58289090|NCT01297543|DRUG|G-CSF|Background therapy
58401854|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
58401855|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
57933448|NCT06734299|OTHER|Sunscreen B|Sunscreen B will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
57933449|NCT06734299|OTHER|Sunscreen C|Sunscreen C will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
57933450|NCT06107933|OTHER|Observational only|Exposure to micro and nano plastics
57933451|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
57933452|NCT03509636|DRUG|Fluzoparib|Fluzoparib capsule will be given twice daily orally
57933453|NCT06387394|DRUG|BOTOX|Intramuscular Injections
57933454|NCT06387394|DRUG|Placebo|Intramuscular Injections
57933455|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
57933456|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
57933457|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
57933458|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
58289091|NCT05024656|OTHER|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
58401856|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
58401857|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
58401858|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
57729704|NCT01175668|DRUG|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
57933459|NCT02634203|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
58401859|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
58401860|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
57933460|NCT02634203|DRUG|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
57933461|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
57933462|NCT06736574|DRUG|Omecamtiv Mecarbil (OM)|Oral Tablet
58289092|NCT05024656|OTHER|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
57729705|NCT00090389|PROCEDURE|Chinese Acupuncture|
57933463|NCT06736574|DRUG|Placebo|Oral Tablet
58289093|NCT02422004|OTHER|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
58401861|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
58401862|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
58401863|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
58401864|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
58401865|NCT01165112|DRUG|Carboplatin|Given IV
58289094|NCT02422004|OTHER|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
58401866|NCT01165112|BIOLOGICAL|Rituximab|Given IV
58401867|NCT01165112|DRUG|Etoposide|Given IV
58401868|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
58401869|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
58401870|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
58401871|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
58289095|NCT01156909|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
58401872|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
58401873|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of AVP (20 IU).
58401874|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
58401875|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
58401876|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
58401877|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
58401878|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
58401879|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
58401880|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
58401881|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
58289096|NCT05348044|OTHER|Res-ET intervention|Remote IMST delivery on Resilience
58289097|NCT01344759|DRUG|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
58401882|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
58401883|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
58401884|NCT05645406|DRUG|Estrogel 0.06 % Topical Gel|estradiol topical products
58401885|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
58401886|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
58401887|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
58401888|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
58401889|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
58401890|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
58401891|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
58401892|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
58401893|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
58401894|NCT03165240|DRUG|BI 690517|Film-coated tablet
58401895|NCT03165240|DRUG|Eplerenone|Film-coated tablet
58401896|NCT03165240|DRUG|Placebo|Film-coated tablet
58401897|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
58401898|NCT00798239|OTHER|Iliac crest autograft|autograft
58401899|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
58401900|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
58289098|NCT01344759|DRUG|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
58401901|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
58401902|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
58289099|NCT06111898|OTHER|No Intervention|No intervention
58401903|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
58289100|NCT04121676|DRUG|AGEN2373|An Anti-CD137 Monoclonal Antibody
58289101|NCT04121676|DRUG|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
58289102|NCT01779063|BEHAVIORAL|web based multimedia intervention|cognitive therapy based web intervention
58401904|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
58401905|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
58401906|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
58401907|NCT02813135|DRUG|Ribociclib|
58401908|NCT02813135|DRUG|Topotecan|
58401909|NCT02813135|DRUG|Temozolomide|
58401910|NCT02813135|DRUG|Everolimus|
58401911|NCT02813135|DRUG|Adavosertib|
58401912|NCT02813135|DRUG|Carboplatin|
58289103|NCT01779063|OTHER|educational booklet|patient education booklet
58289104|NCT00665483|OTHER|Skin Prick Test|Skin Prick Test
58289105|NCT05456243|BIOLOGICAL|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10\^5 cells/kg
58289106|NCT05456243|BIOLOGICAL|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
58289107|NCT02595385|DEVICE|Cell Salvage|Reinfusion of shed blood during the operation
58401913|NCT02813135|DRUG|Olaparib|
58401914|NCT02813135|DRUG|Irinotecan|
58401915|NCT02813135|DRUG|Vistusertib|
58401916|NCT02813135|DRUG|Nivolumab|
58401917|NCT02813135|DRUG|Cyclophosphamide|
58401918|NCT02813135|DRUG|Selumetinib|
58401919|NCT02813135|DRUG|Enasidenib|
58401920|NCT02813135|DRUG|Lirilumab|
58401921|NCT02813135|DRUG|Fadraciclib|
58401922|NCT02813135|DRUG|Cytarabine|
58401923|NCT02813135|DRUG|Dexamethasone|
58401924|NCT02813135|DRUG|Ceralasertib|
58401925|NCT02813135|DRUG|Futibatinib|
58401926|NCT02813135|DRUG|Capmatinib|
58401927|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
58401928|NCT01939002|DRUG|BIIB017|
58401929|NCT01939002|DRUG|naproxen|
58401930|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
57933464|NCT04679753|DEVICE|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
57933465|NCT04679753|DEVICE|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
58071683|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
58401931|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
58401932|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
58401933|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
58401934|NCT00503581|DRUG|Megestrol Acetate|given orally
58401935|NCT00503581|OTHER|Pharmacological Study|Correlative studies
57729706|NCT05870306|PROCEDURE|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
57729707|NCT05870306|PROCEDURE|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
58071684|NCT00182572|DRUG|buprenorphine|
58289108|NCT02595385|PROCEDURE|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
58071685|NCT00182572|DRUG|naltrexone|
58289109|NCT01280071|DRUG|aminophylline|
58289110|NCT00704977|PROCEDURE|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
58401936|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
58401937|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
58401938|NCT00252694|DRUG|candesartan|32 mg oral tablet
58401939|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
58401940|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
58401941|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
58401942|NCT02121106|BEHAVIORAL|Cognitive Remediation|
57729708|NCT04984044|DIETARY_SUPPLEMENT|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
57729709|NCT04984044|DIETARY_SUPPLEMENT|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
57729710|NCT04519229|BEHAVIORAL|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
57729711|NCT00275093|DRUG|temsirolimus|Given IV
57729712|NCT00275093|OTHER|laboratory biomarker analysis|Correlative studies
57729713|NCT00275093|OTHER|pharmacological study|Correlative studies
57933466|NCT06113471|DRUG|Povorcitinib|Oral, Tablet
57933467|NCT06113471|DRUG|Placebo|Oral, Tablet
57933468|NCT04275297|BEHAVIORAL|Psychosocial Treatment|The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
57933469|NCT04275297|BEHAVIORAL|Attention Control|The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
58071686|NCT00182572|PROCEDURE|behavior therapy|
58071687|NCT00182572|PROCEDURE|voucher-based contingency management|
58071688|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
58071689|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
58071690|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
58071691|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
58071692|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
58071693|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
58071694|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
58401943|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
58401944|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
58401945|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
58401946|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
58401947|NCT00068913|DRUG|Dichloroacetate|
58401948|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
58401949|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
58401950|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
58401951|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
58401952|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
58401953|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
58401954|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
58071695|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
58071696|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
58071697|NCT04027127|OTHER|netrin-1 value on admission to hospital|
58401955|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
58401956|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
58401957|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
58401958|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
57729714|NCT05046938|BEHAVIORAL|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
58071698|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
58071699|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
58071700|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
58071701|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
58071702|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
57933470|NCT05655091|DRUG|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
57933471|NCT05655091|DRUG|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
57933472|NCT06734611|DIETARY_SUPPLEMENT|Fortified Iodized Salt with Folic Acid (FISFA)|Addition of folic acid to iodized salt for daily consumption to assess folate levels.
57933473|NCT05084833|BEHAVIORAL|Control|Electronic educational materials
57933474|NCT05084833|BEHAVIORAL|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
57933475|NCT05084833|BEHAVIORAL|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
57933476|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
57933477|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
58289111|NCT01377636|DRUG|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
58289112|NCT06173518|BIOLOGICAL|AUTO1|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
58289113|NCT00844662|DRUG|Fermagate|Film coated tablet 500mg
58289114|NCT00844662|DRUG|Sevelamer hydrochloride|Tablet 800mg
58289115|NCT03072420|OTHER|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
58289116|NCT06118463|DIAGNOSTIC_TEST|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
58289117|NCT06277570|OTHER|conventional physiotherapy|Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.
58289118|NCT06277570|OTHER|NMES|Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.
58289119|NCT06277570|OTHER|Superimposed NMES|Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
58289120|NCT00271219|DRUG|Methadone|daily oral dosing 20-140 mg
58289121|NCT00271219|DRUG|Buprenorphine|sl daily 2-32 mg
58289122|NCT02785562|OTHER|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
58289123|NCT02290847|BEHAVIORAL|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
58289124|NCT06494592|BEHAVIORAL|Aerobic Exercise|Participants in the aerobic exercise intervention group will engage in a virtual aerobic exercise intervention three times a week for 12 weeks for a 30-minute session (5 minute warm up, 20 minutes of aerobic exercise, 5 minutes cooldown) and will receive information about the session prior to their appointment. Sessions have a goal of reaching at least 20 minutes of supervised exercise performed at 80% of the heart rate at symptom threshold.
58289125|NCT06494592|BEHAVIORAL|Balance Exercise|Participants in the balance exercise intervention group will participate in a staff-led virtual session three times a week for 12 weeks for a 30-minute session and will receive information about the session prior to their appointment. This group will focus on improving balance, with some additional work on flexibility and strength.
58289126|NCT05947162|BEHAVIORAL|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
58289127|NCT05947162|BEHAVIORAL|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
57933478|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
58289128|NCT05947162|BEHAVIORAL|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
58289129|NCT05947162|BEHAVIORAL|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
58289130|NCT05947162|BEHAVIORAL|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
57933479|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
57933480|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
57933481|NCT03219320|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
57933482|NCT03219320|DRUG|Placebo|Matching Placebo capsules.
57933483|NCT05944016|DRUG|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
57933484|NCT05944016|DRUG|Placebo|Placebo (standard dose p.o. once daily)
57933485|NCT00004022|BIOLOGICAL|aldesleukin|
57933486|NCT00004022|BIOLOGICAL|autologous tumor cell vaccine|
57933487|NCT00004022|BIOLOGICAL|muromonab-CD3|
57933488|NCT00004022|BIOLOGICAL|therapeutic autologous lymphocytes|
57933489|NCT00004022|PROCEDURE|surgical procedure|
57933490|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
58071703|NCT01370499|DRUG|LY2216684|
58289131|NCT05165641|PROCEDURE|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
57933491|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
57933492|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
57933493|NCT00813319|BEHAVIORAL|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
57933494|NCT05817942|DRUG|Filgotinib|Jyseleca
57933495|NCT05159154|DEVICE|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
57933496|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
57933497|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
57933498|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
57933499|NCT05050942|DRUG|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
57933500|NCT05050942|DRUG|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
58071704|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
57933501|NCT05050942|DRUG|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
57933502|NCT02834416|BEHAVIORAL|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
57933503|NCT02834416|BEHAVIORAL|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
57933504|NCT00108069|DRUG|Tamoxifen citrate|oral dose 120 mg twice a day, every day
57933505|NCT00108069|DRUG|Bortezomib|intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
58071705|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
58401959|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
58401960|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
58401961|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
58401962|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
58401963|NCT00017654|DRUG|anti-thymocyte globulin|
58401964|NCT00017654|DRUG|cyclophosphamide|
58401965|NCT00017654|DRUG|cyclosporine|
58401966|NCT00017654|DRUG|methylprednisolone|
58401967|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
58401968|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
58401969|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
58401970|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
58401971|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
58401972|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
58289132|NCT04350645|DRUG|Tranexamic acid injection|1g slow bolus of tranexamic acid over 2 minutes
58289133|NCT04350645|DRUG|Normal Saline 0.9%|10mls normal saline 0.9% over 2 minutes
58289134|NCT00540670|DRUG|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
58401973|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
58401974|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
57933506|NCT05119621|DEVICE|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
58289135|NCT00540670|DRUG|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
57933507|NCT02979925|DEVICE|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
57933508|NCT02979925|DEVICE|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
57933509|NCT04938830|BIOLOGICAL|Clesrovimab|IM injection
57933510|NCT04938830|BIOLOGICAL|Palivizumab|IM injection
57933511|NCT04938830|BIOLOGICAL|Placebo|IM injection
58289136|NCT00540670|DRUG|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
58289137|NCT00540670|DRUG|Placebo|Placebo (tablet) taken orally, once a day.
58401975|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
58401976|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
58401977|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
58401978|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
58401979|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
57933512|NCT06735378|OTHER|Intradialytic Cycling|The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
58289138|NCT01014195|OTHER|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
57933513|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
58289139|NCT00144950|DRUG|insertion of a chest drain with urokinase instillation|
58289140|NCT00144950|PROCEDURE|primary video-assisted thorascopic surgery|
58289141|NCT04418271|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
58289142|NCT00928850|PROCEDURE|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
58289143|NCT00928850|PROCEDURE|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
58289144|NCT00928850|PROCEDURE|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
58289145|NCT00928850|PROCEDURE|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
58289146|NCT01528280|BIOLOGICAL|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
58289147|NCT01528280|OTHER|No Intervention|No Intervention
58289148|NCT04225013|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
58289149|NCT04225013|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
58401980|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
57933514|NCT02819076|OTHER|pain scale|
57933515|NCT05008926|DRUG|Naloxegol|Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
57933516|NCT05008926|DRUG|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
58289150|NCT01054495|DRUG|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
58401981|NCT01676753|DRUG|Dinaciclib|Given IV
58401982|NCT01676753|DRUG|Pembrolizumab|Given IV
58401983|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
58401984|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
58401985|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
58289151|NCT01054495|DEVICE|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
58289152|NCT01054495|DEVICE|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
58289153|NCT00873067|PROCEDURE|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
58289154|NCT00873067|PROCEDURE|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
58289155|NCT01784276|BEHAVIORAL|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
58289156|NCT03397303|OTHER|elastography measurements|elastography measurements
58289157|NCT00758381|DRUG|Sorafenib 400 mg po bid, continuously|"NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
58289158|NCT00758381|DRUG|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
58289159|NCT04121455|DRUG|Olaptesed pegol|Olaptesed pegol continuous i.v. administration
58289160|NCT04121455|RADIATION|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
58289161|NCT04121455|DRUG|Bevacizumab|Bevacizumab every 2 weeks i.v. infusion
58289162|NCT04121455|DRUG|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
58289163|NCT04121455|DRUG|Temozolomide (TMZ)|oral treatment according to current SPC
58289164|NCT01996150|DRUG|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
58289165|NCT02026596|PROCEDURE|Magnetic resonance imaging|
58289166|NCT02026596|PROCEDURE|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
58401986|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
58401987|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
57933517|NCT06508541|PROCEDURE|ICG Guided surgery|In ICG guided surgery group,Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
58289167|NCT01141920|BEHAVIORAL|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
58289168|NCT01141920|BEHAVIORAL|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
58289169|NCT05051891|DRUG|Orelabrutinib and R-CHOP|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
58289170|NCT05051891|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
58289171|NCT03629145|BEHAVIORAL|Live Music Therapy|Investigator will begin play live guitar and voice music.
58289172|NCT03629145|BEHAVIORAL|Recorded Music Therapy|Investigator will play recorded music.
58289173|NCT02112409|PROCEDURE|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
58289174|NCT02112409|PROCEDURE|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
58289175|NCT00203697|DRUG|minocycline|
58289176|NCT00650338|DRUG|DE-104 ophthalmic solution, low concentration|Topical ocular application
58289177|NCT00650338|DRUG|DE-104 ophthalmic solution, medium concentration|Topical ocular application
58289178|NCT00650338|DRUG|DE-104 ophthalmic solution, high concentration|Topical ocular application
58289179|NCT00650338|DRUG|Placebo|placebo
58289180|NCT00650338|DRUG|0.005% latanoprost|Topical ocular application
58289181|NCT00328588|DRUG|YM155|IV
58289182|NCT05030532|BEHAVIORAL|EVERYbody Project|Brief behavioral group intervention (4 hours across two meetings)
58289183|NCT05030532|OTHER|Video + Expressive Writing|Brief video-based group intervention (4 hours across two meetings)
58289184|NCT04387461|BIOLOGICAL|CG0070|Engineered Oncolytic Adenovirus
58289185|NCT04387461|BIOLOGICAL|Pembrolizumab Injection|Immune checkpoint inhibitor, Monoclonal antibody
58289186|NCT04387461|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
58401988|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
58401989|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
58401990|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
58401991|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
58289187|NCT00060606|PROCEDURE|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
58289188|NCT00060606|PROCEDURE|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
58289189|NCT01537835|OTHER|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
58289190|NCT04428840|DEVICE|Self-measurement kiosk|Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
58289191|NCT06071546|DEVICE|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
58289192|NCT00219219|DRUG|Zoledronic acid|
58289193|NCT05984433|DEVICE|Auricular acupuncture|Electro auricular acupuncture
58289194|NCT05263518|PROCEDURE|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
58289195|NCT05263518|PROCEDURE|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
58289196|NCT06262646|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Trained FACT interventionists will be guided by manualized FACT intervention to identify how many psychopathological processes need support and which ACT process(es) need to work on first, then offer parents process-matched ACT intervention strategies following the principles of FACT. The intervention strategies include ACT metaphors, experiential exercises, audio-guided mindfulness exercises, guided imagery exercises and value clarification exercises. The FACT steps in each session depend on the client's situation/stage.
58289197|NCT06262646|OTHER|Control Group|Both study groups will receive standard family support from collaborating NGOs.
58289198|NCT02271217|DRUG|Placebo|
58289199|NCT02271217|DRUG|dalfampridine-ER 7.5mg|
58401992|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
58401993|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
57933518|NCT06508541|PROCEDURE|conventional surgery|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose
58289200|NCT02271217|DRUG|dalfampridine-ER 10mg|
58289201|NCT03094793|OTHER|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
58289202|NCT03875196|DEVICE|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
58289203|NCT03875196|DEVICE|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
58289204|NCT06346782|BEHAVIORAL|Internet-Based Parent-Child Interaction Therapy|I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
57933519|NCT06735547|DEVICE|Telerehabilitation|Patients in the Telerehabilitation group will perform an average of three therapy sessions per week, with data collected and monitored by TRAK's physiotherapists. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
58289205|NCT03448523|BEHAVIORAL|Right To Play's Positive Child and Youth Development program|"1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
57933520|NCT06735547|OTHER|Conventional therapy group|Patients in the conventional group will be assessed by a professional physiotherapist, scheduling appointments according to their own preferences and disponibility. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
57933521|NCT04784715|DRUG|Trastuzumab deruxtecan|Administered by intravenous infusion
57933522|NCT04784715|DRUG|Placebo|Administered by intravenous infusion
57933523|NCT04784715|DRUG|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
57933524|NCT04784715|DRUG|Pertuzumab|Administered by intravenous infusion
57933525|NCT04784715|DRUG|Trastuzumab|Administered by intravenous infusion
57933526|NCT05836051|OTHER|Flavor|E-liquid flavor chemicals
57933527|NCT01640210|DEVICE|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
57933528|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
57933529|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
57933530|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
57933531|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
57933532|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
57933533|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
57933534|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
57933535|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
57933536|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
57933537|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
57933538|NCT06734247|DIAGNOSTIC_TEST|Coronary computer tomography angiography (CCTA)|Use of standard equipment for usual care
58401994|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
57933539|NCT06734247|OTHER|Photoplethysmography (PPG) and single-lead ECG|Physiological data acquisition equipment
57933540|NCT06734247|DEVICE|Brachial single cuff-based arterial stiffness|Use of standard equipment
57933541|NCT04045951|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
57933542|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
57933543|NCT00378768|BIOLOGICAL|anti-thymocyte globulin|
57933544|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
57933545|NCT02708095|DRUG|Baricitinib|Administered orally
57933546|NCT02708095|DRUG|Placebo|Administered orally
58401995|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
57933547|NCT06565442|DEVICE|NeuraSignal transcranial doppler robot|measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
57933548|NCT04475666|OTHER|Replenish protein group|For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
57933549|NCT04475666|OTHER|Standard protein group|For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
57933550|NCT00935272|DEVICE|Restylane®|Restylane® injections in the lips
58289206|NCT04581408|DRUG|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
58289207|NCT02590991|OTHER|Prebiotics|To study the long term effect of supplementation in early life
58289208|NCT02590991|OTHER|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
58401996|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
58289209|NCT05812053|PROCEDURE|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
58289210|NCT05812053|RADIATION|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
58401997|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
58401998|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
57933551|NCT00935272|DEVICE|Non-Treatment|Non- Treatment
58289211|NCT05820243|OTHER|Moderate Intensity Aerobic Exercise|Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
58289212|NCT04716621|OTHER|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
58289213|NCT04716621|OTHER|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
58289214|NCT04241510|DEVICE|Kinesio Taping|Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
58401999|NCT00518648|OTHER|Usual care|Usual care
58402000|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
58402001|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
58402002|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
58402003|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
58402004|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
58402005|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
58402006|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
57933552|NCT06528691|DRUG|Entrectinib|Given orally (PO) or enterally
57933553|NCT06528691|DRUG|Cyclophosphamide|Given intravenous (IV)
57933554|NCT06528691|DRUG|Etoposide|Given IV
57933555|NCT06528691|DRUG|Carboplatin|Given IV
57933556|NCT06528691|BIOLOGICAL|G-CSF|Given subcutaneous (SQ) or IV
57933557|NCT06528691|BIOLOGICAL|Pegfilgrastim|Given SQ as part of recommended Bridging Therapy instead of G-CSF.
57933558|NCT06528691|PROCEDURE|Surgery|A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
57933559|NCT06735274|DIAGNOSTIC_TEST|Cerebral Autoregulation (CAR)|Cerebral Autoregulation (CAR) is the mechanism capable of maintaining cerebral blood flow constant despite fluctuations in blood pressure. The evaluation of dynamic CAR (dCAR) with spontaneous blood pressure variations allows it to be applied in acute and non-collaborating patients
57933560|NCT06735274|DIAGNOSTIC_TEST|Neurovascular coupling (NVC)|Neurovascular coupling (NVC) is the relationship between neural activity and cerebral blood flow, allowing this activity to be evaluated in spatiotemporal terms .
57933561|NCT06735274|DIAGNOSTIC_TEST|Microembolic signals (MES)|Microembolic signals (MES)
57933562|NCT06735274|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Montreal Cognitive Assessment (MoCA)
57933563|NCT06735274|DIAGNOSTIC_TEST|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
57933564|NCT06735274|DIAGNOSTIC_TEST|Instrumental Activities of Daily Living Scale (IADL)|Instrumental Activities of Daily Living Scale (IADL)
57933565|NCT06735274|DIAGNOSTIC_TEST|Modified Rankin Scale for Neurologic Disability (mRS)|Modified Rankin Scale for Neurologic Disability (mRS)
57933566|NCT05139849|DRUG|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
57729715|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
57933567|NCT05139849|DRUG|Sodium chloride|Sodium chloride 9 mg/ml
58289215|NCT06263283|OTHER|session of Kine-Yoga|"Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment"
58289216|NCT01768559|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
58289217|NCT01768559|DRUG|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
58289218|NCT01768559|DRUG|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
57729716|NCT06532292|DEVICE|Biofeedback|To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.
57729717|NCT06532292|DEVICE|HIFEM|The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
57729718|NCT02030977|DIETARY_SUPPLEMENT|Resveratrol|
57729719|NCT02030977|OTHER|placebo|
57933568|NCT05691504|PROCEDURE|Biopsy|Undergo biopsy
57933569|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57933570|NCT05691504|DRUG|Cobimetinib|Given PO
57933571|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
57933572|NCT05691504|PROCEDURE|Echocardiography|Undergo ECHO
57933573|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57933574|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57933575|NCT05691504|DRUG|Pelcitoclax|Given IV
57933576|NCT02884154|DEVICE|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
57933577|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
57729720|NCT01383538|DRUG|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
57933578|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
57933579|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
57933580|NCT02675023|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
57933581|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
57933582|NCT03116412|PROCEDURE|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
57933583|NCT04985305|BEHAVIORAL|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
57933584|NCT04985305|BEHAVIORAL|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
57933585|NCT04985305|BEHAVIORAL|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
57933586|NCT04985305|BEHAVIORAL|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
57933587|NCT04985305|BEHAVIORAL|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
57933588|NCT04333745|OTHER|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
57933589|NCT04333745|DIETARY_SUPPLEMENT|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
57933590|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
57933591|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
57933592|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58289219|NCT01768559|DRUG|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
58289220|NCT01768559|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
58289221|NCT01590901|DRUG|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
58289222|NCT03207490|DEVICE|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
58402007|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
58402008|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
57729721|NCT00709163|DRUG|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
57933593|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
57933594|NCT03203499|DRUG|ANS-6637 Oral Tablet|Ascending single doses administered orally.
57933595|NCT03203499|DRUG|Placebo Oral Tablet|Placebo administered orally.
57933596|NCT06374914|DRUG|Intravesical Solution|Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
57933597|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
57933598|NCT01264653|DRUG|adrenalin|adrenalin 0.01%
57933599|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
57933600|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
58289223|NCT04308876|OTHER|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
57933601|NCT00995007|DRUG|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
57933602|NCT00995007|DRUG|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
57933603|NCT03836755|DIAGNOSTIC_TEST|Metacos|Evaluation of stability of implant by RSA technique
58402009|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
58402010|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
58402011|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
58402012|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
58402013|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
57729722|NCT00709163|DRUG|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
57933604|NCT03747978|DRUG|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
57933605|NCT03747978|DRUG|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
57933606|NCT06217094|DRUG|NP-101 (3 g)|Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
57933607|NCT06217094|DRUG|NP-101 (4.8 g)|Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
57933608|NCT06217094|DRUG|NP-101 (6 g)|Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
57933609|NCT05161572|DRUG|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
58402014|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
57933610|NCT05161572|DRUG|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
58402015|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
58402016|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
58402017|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
58402018|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
58402019|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
58402020|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
57933611|NCT05161572|DRUG|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
58289224|NCT04308876|OTHER|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
58402021|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
58402022|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
58402023|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
58402024|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
58402025|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
57729723|NCT05212974|OTHER|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
57729724|NCT04717011|DIAGNOSTIC_TEST|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
57933612|NCT05161572|RADIATION|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
57933613|NCT05161572|PROCEDURE|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
57933614|NCT06735014|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs
57933615|NCT06735014|DIAGNOSTIC_TEST|Plasma neurofilament light chain (NfL) quantification|Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
57933616|NCT06735937|OTHER|Low flow anesthesia|Anesthesia management by using low flow anesthesia
57933617|NCT05827653|DRUG|NX210c|3 times a week, for 28 days
57933618|NCT05827653|DRUG|Placebo|3 times a week, for 28 days
58289225|NCT05208827|DRUG|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
58289226|NCT05208827|DRUG|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
58289227|NCT03470454|DRUG|Linagliptin Oral Tablet|Linagliptin for blood glucose control
58289228|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 60L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
58289229|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 40L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
57729725|NCT05976074|DEVICE|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
57933619|NCT06593093|OTHER|a bundled intervention|a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.
58289230|NCT03809234|DRUG|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
58289231|NCT03809234|DRUG|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
58289232|NCT02780271|BEHAVIORAL|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
58289233|NCT02780271|BEHAVIORAL|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
58289234|NCT02780271|BEHAVIORAL|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
58289235|NCT02029274|DRUG|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
58289236|NCT02029274|DRUG|Placebo|Matching placebo to BAF312 as tablets for oral administration.
58289237|NCT03915626|DRUG|Rivastigmine (RLD) transdermal patch|brand name patch
58289238|NCT03915626|DRUG|Rivastigmine (generic) transdermal patch|generic patch
58289239|NCT00494546|PROCEDURE|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
58289240|NCT02103699|DRUG|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
57933620|NCT06593093|OTHER|control group|participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.
57933621|NCT06715540|DRUG|BCD-261, dose 1|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933622|NCT06715540|DRUG|BCD-261, dose 2|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933623|NCT06715540|DRUG|BCD-261, dose 3|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933624|NCT06715540|DRUG|BCD-261, dose 4|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933625|NCT06715540|DRUG|BCD-261, dose 5|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933626|NCT06715540|DRUG|BCD-261, dose 6|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
57933627|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
58402026|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
57933628|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
58289241|NCT03563898|OTHER|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
58289242|NCT00210886|DRUG|levofloxacin|
58289243|NCT03758599|PROCEDURE|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
58289244|NCT03758599|PROCEDURE|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
58289245|NCT03758599|PROCEDURE|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
58289246|NCT06483906|DRUG|Venetoclax, Azacitidine and Homoharringtonine|Patients will receive the VAH regimen for the treatment of AML
58289247|NCT03999957|OTHER|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
58289248|NCT00549796|OTHER|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
58289249|NCT02583022|DRUG|PAC-14028 cream 1.0%|Topical application
58289250|NCT02583022|DRUG|PAC-14028 cream vehicle|Topical application
58289251|NCT02583022|DRUG|Elidel cream 1%|Topical application
58289252|NCT03351088|PROCEDURE|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
58289253|NCT01984957|PROCEDURE|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
58402027|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
58402028|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
58402029|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
58402030|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
58402031|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
57729726|NCT05976074|OTHER|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
58289254|NCT05934123|BEHAVIORAL|EMNODN NEC Care Bundle|A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born \<32 weeks' gestational age.
58289255|NCT04007510|COMBINATION_PRODUCT|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
57933629|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose Y|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
57933630|NCT06735131|RADIATION|radiotherapy 5 Gy × 5 fractions, once a day|5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
57933631|NCT06735131|RADIATION|radiotherapy 8 Gy × 5 fractions, once a day|8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
58402032|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
58402033|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
58402034|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
58402035|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
58071706|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
58402036|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
58402037|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
58402038|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
58402039|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
57933632|NCT06735131|RADIATION|radiotherapy 8 Gy × 3 fractions, once every other day|8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
57933633|NCT06735131|RADIATION|radiotherapy 10 Gy× 3 fractions, once every other day|10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
57933634|NCT06735131|RADIATION|radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)
57933635|NCT06735131|DRUG|Toripalimab|Toripalimab (240 mg IV, d1, Q3W)
57933636|NCT06735131|DRUG|chemotherapy regimen selected by the investigator|Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
57933637|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
57933638|NCT05501678|DRUG|Placebo|Matching Placebo given orally
58071707|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
58071708|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
58402040|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
58402041|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
58402042|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
57933639|NCT02779738|DRUG|Merestinib|Administered orally
57933640|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
57933641|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
57933642|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
57933643|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
57933644|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
57933645|NCT05257941|DRUG|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
57933646|NCT05257941|DRUG|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
57933647|NCT05987852|DEVICE|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
58071709|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
58402043|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
58402044|NCT00162747|DRUG|Aquaphor|
58402045|NCT00162747|DRUG|Sunflower Seed Oil|
58402046|NCT03479268|DRUG|Ibrutinib|Given PO
58402047|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
58402048|NCT03479268|DRUG|Pevonedistat|Given IV
58402049|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
58402050|NCT03479268|OTHER|Pharmacological Study|Correlative studies
58402051|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
58402052|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
57933648|NCT05987852|OTHER|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
57933649|NCT04450511|DEVICE|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
57933650|NCT04450511|OTHER|Bladder Training (BT)|Bladder Training (BT)
57933651|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
57933652|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
57933653|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
57933654|NCT01855698|OTHER|Observation|
57933655|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
58289256|NCT04007510|DIAGNOSTIC_TEST|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
58402053|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
57933656|NCT00075088|DEVICE|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
57933657|NCT00075088|OTHER|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
57933658|NCT06605807|OTHER|Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.|All clinicians will attend an educational session where they will be provided a clinical decision framework for management of chronic conditions in hospitalized older adults, reviewing guiding principles for managing chronic disease in the hospital, and working through case-based hypothetical examples.
57933659|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
57933660|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
57933661|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
57933662|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
58289257|NCT03476902|BEHAVIORAL|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
58402054|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
58402055|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
58402056|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
57933663|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
57933664|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
57933665|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
57933666|NCT05839041|DRUG|AVD-104|Intravitreal injection
58289258|NCT01601496|DEVICE|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
57729727|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
57933667|NCT05839041|DRUG|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
58289259|NCT00092963|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
58289260|NCT00092963|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
58402057|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
58402058|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
57729728|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
57933668|NCT02149212|DRUG|Phlebotonic|Aminaftone -- 75 mg BID
57933669|NCT02149212|DEVICE|Stent|Iliac Vein Stenting
57933670|NCT02149212|PROCEDURE|Limb elastic compression support|CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages
57933671|NCT02149212|PROCEDURE|Unna boot dressing|CEAP 6 \> Unna boot dressing
57933672|NCT05984277|DRUG|Volrustomig|Volrustomig
57933673|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
57933674|NCT05984277|DRUG|Carboplatin|Carboplatin
57933675|NCT05984277|DRUG|Paclitaxel|Paclitaxel
57933676|NCT05984277|DRUG|Pemetrexed|Pemetrexed
57933677|NCT04032691|DRUG|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
57933678|NCT06167317|DRUG|GS-0201|Pill administered orally
57933679|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
57933680|NCT05443230|DIAGNOSTIC_TEST|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
57933681|NCT02060383|DRUG|Pasireotide s.c.|Administered to Cushing's disease participants.
57933682|NCT02060383|DRUG|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
57933683|NCT02060383|DRUG|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
57933684|NCT02060383|DRUG|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
57933685|NCT02060383|DRUG|Pasireotide LAR|Administered to Acromegaly participants.
57933686|NCT02060383|DRUG|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
58289261|NCT05450172|OTHER|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
58289262|NCT02837393|PROCEDURE|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
58289263|NCT03826537|OTHER|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
58402059|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
57729729|NCT01420796|OTHER|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
58289264|NCT00921583|DEVICE|Long-term examination|Follow-up dental implants 20 year in function
57729730|NCT01420796|OTHER|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
57933687|NCT06734468|BEHAVIORAL|Lifestyle Management|"Each subject will receive a personalized intervention plan, comprised of:~1. An individualized exercise plan guided by a mobile phone app.~2. Healthy diet and nutrition recommendations.~3. Theriome metabolomics testing and individualized recommendations that include dietary supplements.~4. Guidance on healthy sleep patterns, stress management, and maximizing social engagement, as appropriate."
58289265|NCT00638092|DRUG|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
58289266|NCT00638092|DRUG|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
58289267|NCT02482883|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
58289268|NCT02865694|OTHER|Cascade|
58289269|NCT04697290|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
58289270|NCT04322084|OTHER|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
58289271|NCT04262193|DRUG|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
58289272|NCT04262193|DRUG|Suvorexant Placebo|Suvorexant Placebo
58289273|NCT06612905|OTHER|Detection of the time spent on social media|The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).
58071710|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
58289274|NCT06612905|OTHER|Evaluation of body composition and basal metabolic rate|They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)
58402060|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
58402061|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
58402062|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
57933688|NCT06735521|DIAGNOSTIC_TEST|Cardiac magnetic resonance stress-perfusion|"Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium.~Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest."
58289275|NCT06612905|OTHER|Evaluation of eating behavior among social media users|Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
58289276|NCT03665662|OTHER|Music|Intra-procedure music through headphones
58289277|NCT03090061|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
58402063|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
58402064|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
58402065|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
58402066|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
58402067|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
57933689|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
57933690|NCT06556147|BIOLOGICAL|VXB-241 60 mcg (Low Dose)|VXB-241 low dose, single, IM injection.
58289278|NCT03090061|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
58402068|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
58289279|NCT05534568|OTHER|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
58289280|NCT06612450|DEVICE|turbinate surgery|Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
58289281|NCT03042351|DEVICE|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
58289282|NCT02423811|DIETARY_SUPPLEMENT|Fursultiamine|Use of Fursultiamine in addition to CCRT
58289283|NCT06477705|OTHER|FAM|Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
58402069|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
58402070|NCT05865340|BEHAVIORAL|oral health|oral health education
58402071|NCT05865340|BEHAVIORAL|MED diet|MED diet education
58402072|NCT02141698|DRUG|TAK-438|TAK-438 tablets
57729731|NCT01420796|OTHER|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
57933691|NCT06556147|BIOLOGICAL|VXB-241 120 mcg (Medium Dose)|VXB-241 medium dose, single, IM injection.
57933692|NCT06556147|BIOLOGICAL|VXB-241 240 mcg (Medium-high Dose)|VXB-241 medium-high dose, single, IM injection.
57933693|NCT06556147|BIOLOGICAL|VXB-241 480 mcg (High Dose)|VXB-241 high dose, single, IM injection.
57933694|NCT06556147|BIOLOGICAL|VXB-241|VXB-241 dose to be decided based on Year-1 results, single, IM injection.
58402073|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
58402074|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
58402075|NCT02537587|OTHER|Control 1|67g of control bar
58402076|NCT02537587|OTHER|Control 2|86g of control bar
58402077|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
58402078|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
58402079|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
58402080|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
58402081|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
58402082|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
58402083|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
58402084|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
57933695|NCT06556147|OTHER|Placebo|Placebo, single, IM injection.
57933696|NCT06556147|BIOLOGICAL|Arexvy 120 mcg|Arexvy 120 mcg, single, IM injection.
57933697|NCT02743884|DEVICE|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
57933698|NCT02743884|DEVICE|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
57933699|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
57933700|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
57933701|NCT06736548|BEHAVIORAL|The Sleep Treatment Education Program Together (STEP-Together)|STEP-Together is a single session intervention intended to educate participants on core components of cognitive behavioral therapy for insomnia and provide suggestions for reducing symptoms of insomnia. Following self-management principles, the program supports participants in developing a personal sleep self-managment plan to apply progam suggestions to improve their sleep.
57933702|NCT06736548|BEHAVIORAL|Coaching Session|Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
57933703|NCT04870359|PROCEDURE|Pre-emptive increase of immunosuppressive treatments|"1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day."
57933704|NCT04870359|DRUG|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
57933705|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
57933706|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
57933707|NCT01955447|DIETARY_SUPPLEMENT|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
57933708|NCT01955447|DIETARY_SUPPLEMENT|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
57933709|NCT01955447|DIETARY_SUPPLEMENT|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
57933710|NCT01955447|DIETARY_SUPPLEMENT|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
57933711|NCT00044551|DRUG|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
57933712|NCT03292289|PROCEDURE|Pre- and post-operative consultation|Before and between the two interventions
57933713|NCT03292289|PROCEDURE|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
57933714|NCT03292289|PROCEDURE|Questionnaires|"* QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
57933715|NCT05384379|DRUG|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
57933716|NCT05173142|DRUG|HMPL-453|HMPL-453 administered orally.
58402085|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
57933717|NCT05173142|DRUG|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
57933718|NCT05173142|DRUG|toripalimab|Toripalimab administered intravenously.
57933719|NCT05173142|DRUG|Docetaxel|Docetaxel administered intravenously.
57933720|NCT03443505|DIAGNOSTIC_TEST|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
57933721|NCT05874323|GENETIC|Detection of RAGE gene polymorphism (rs1800625)|Detection of RAGE gene polymorphism (rs1800625) By Molecular analysis (real time PCR)
57933722|NCT00025441|BIOLOGICAL|dactinomycin|
57933723|NCT00025441|BIOLOGICAL|filgrastim|
57933724|NCT00025441|DRUG|carboplatin|
57933725|NCT00025441|DRUG|cyclophosphamide|
57933726|NCT00025441|DRUG|doxorubicin hydrochloride|
57933727|NCT00025441|DRUG|epirubicin hydrochloride|
57933728|NCT00025441|DRUG|etoposide|
57933729|NCT00025441|DRUG|ifosfamide|
57933730|NCT00025441|DRUG|vincristine sulfate|
58289284|NCT01865656|OTHER|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
57933731|NCT00025441|PROCEDURE|peripheral blood stem cell transplantation|
57933732|NCT00025441|RADIATION|radiation therapy|
57933733|NCT00103428|BIOLOGICAL|CG7870|
57933734|NCT00765986|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
58402086|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
58402087|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
58402088|NCT01711489|DRUG|isavuconazole|oral
57933735|NCT00765986|OTHER|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
57933736|NCT04853355|DRUG|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
57933737|NCT03920722|DRUG|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
57933738|NCT03920722|DRUG|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
57933739|NCT02428010|DEVICE|TMVR Implant|Implantation of the Twelve TMVR System
57933740|NCT05661227|DRUG|Dexmedetomidine|Whether apply DEX or not
57933741|NCT05661227|DRUG|0.9% Sodium chloride|Whether apply DEX or not
57933742|NCT05661227|DEVICE|Tourniquet(Early)|Timing of tourniquet application
57933743|NCT05661227|DEVICE|Tourniquet(Late)|Timing of tourniquet application
57933744|NCT06211192|OTHER|retrospective data collection|retrospective data collecting from medical records
57933745|NCT04282122|RADIATION|Radiotherapy|curative-intent radiotherapy
57933746|NCT02303704|PROCEDURE|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
58289285|NCT01865656|OTHER|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
58289286|NCT01865656|OTHER|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
58289287|NCT01865656|OTHER|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
57933747|NCT02303704|PROCEDURE|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
57933748|NCT00037869|DRUG|I-131 Metaiodobenzylguanidine|
57933749|NCT00626756|DEVICE|LiDCO technology|non invasive monitoring of cardiac output
57933750|NCT01438151|DRUG|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
57933751|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
57933752|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
58402089|NCT01711489|DRUG|Mycophenolate mofetil|oral
57933753|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
57933754|NCT03044886|DIETARY_SUPPLEMENT|vitamin D|Subjects took vitamin D or placebo
58289288|NCT01865656|OTHER|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
58289289|NCT02714036|DRUG|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
58289290|NCT02714036|DRUG|Ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
58289291|NCT03625700|DRUG|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
58289292|NCT00411723|DRUG|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
58289293|NCT00411723|DRUG|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
58402090|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
58402091|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
58402092|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
58402093|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
57933755|NCT05094336|DRUG|AMG 193|AMG 193: Orally via tablet
57933756|NCT05094336|DRUG|Docetaxel|Docetaxel: Intravenous infusion
57933757|NCT05094336|DRUG|Comparator AMG 193 Test Tablet|Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
57933758|NCT05949151|PROCEDURE|dental implants (K1 line conical connection double thread, OXY, Italy)|Six dental implants inserted on the edentulous mandible
57933759|NCT05949151|DEVICE|Occlusense (Bausch GmbH & Co. KG)|sensor used to evaluate the equilibration of occlusal forces.
57933760|NCT05949151|DEVICE|"electromyography (EMG) (Nemus II)."|EMG recordings were accomplished by a computer electromyography-based data acquisition system
57933761|NCT05949151|OTHER|oral health-related quality of life (OHRQoL)|Oral Health-related Quality of Life (OHRQoL) was estimated by employing the Oral Health Impact Profile questionnaire which comprises nineteen multiple questions that were translated into Arabic.
57933762|NCT04779190|DEVICE|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
57933763|NCT04779190|DEVICE|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
57933764|NCT04779190|OTHER|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
57933765|NCT05693168|DEVICE|ANNE Limb Sensor|Pulse Oximeter
57933766|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
57933767|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
57933768|NCT01009827|OTHER|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
57933769|NCT03659851|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
57933770|NCT06725017|DRUG|Live SK08 powder|SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.
57933771|NCT06725017|DRUG|Placebo|Placebo
57933772|NCT03447366|DIAGNOSTIC_TEST|mitral doppler|Mitral doppler before and after vascular filling
58402094|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
58402095|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
58402096|NCT03581695|OTHER|Blood test|Blood test
58402097|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
57933773|NCT05880940|DEVICE|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
57933774|NCT05880940|BEHAVIORAL|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
57933775|NCT02718599|DRUG|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
57933776|NCT02718599|DRUG|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
57933777|NCT00115791|DRUG|RSD1235|IV
57933778|NCT00115791|DRUG|placebo|IV
57933779|NCT02791022|DEVICE|SPYDER ECG sensor|
57933780|NCT01892306|BEHAVIORAL|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
58402098|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
58402099|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
57933781|NCT01892306|DRUG|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
57933782|NCT01313715|BIOLOGICAL|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
57933783|NCT01313715|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
58071711|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
58071712|NCT00456586|DRUG|KW-6002 (istradefylline)|
58071713|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
58289294|NCT02937740|DRUG|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
58289295|NCT04215796|DEVICE|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
58289296|NCT05116254|COMBINATION_PRODUCT|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
58289297|NCT05116254|COMBINATION_PRODUCT|AZD1390 + durvlaumab + radiotherapy|AZD1390 combined with durvalumab and preoperative radiotherapy
58289298|NCT02155309|DRUG|Scopolamine|
58289299|NCT02155309|DRUG|Placebo|
58289300|NCT06612788|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
58289301|NCT02406456|OTHER|Neurofeedback|
57933784|NCT01313715|BIOLOGICAL|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
57933785|NCT01313715|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
57933786|NCT00217191|DRUG|Ibuprofen|
57933787|NCT03173066|DRUG|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
57933788|NCT02462928|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
57933789|NCT02462928|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
58071714|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
58289302|NCT05936021|PROCEDURE|Algorithm model-based Aranesp doses|Patients will receive doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been. The model-based dosing will be more flexible than the protocol-based dosing. Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels. The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.
58289303|NCT05936021|PROCEDURE|Standard of care|Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
57933790|NCT02462928|OTHER|Sham Procedure|Sham injection.
57933791|NCT02163083|PROCEDURE|ICG|Improvement of detection of positive lymphnodes
57933792|NCT02740296|OTHER|No intervention|
57933793|NCT05520541|OTHER|Exercise|Both groups will receive exercise-based training
57933794|NCT02959749|DRUG|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
57933795|NCT02959749|DRUG|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
57933796|NCT03869281|PROCEDURE|Pancreas transplantation alone|Pancreas transplantation
57933797|NCT04621734|DEVICE|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
57933798|NCT04621734|DEVICE|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
57933799|NCT03724734|DEVICE|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
58071715|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
58071716|NCT04116905|BEHAVIORAL|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
58071717|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
58071718|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
58071719|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
58071720|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
58071721|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
58071722|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
58071723|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
58071724|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
58289304|NCT04626258|DRUG|Fluconazole|Fluconazol once a month 150 mg capsule
58289305|NCT04626258|OTHER|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
58289306|NCT05996822|DRUG|ACF injection|AcF injection 1 month after a DXM injection
58289307|NCT02216279|DRUG|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
58289308|NCT03921476|OTHER|Online survey|Online survey completion through Northwestern's REDCap
58289309|NCT04036591|DIAGNOSTIC_TEST|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
58071725|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
58071726|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
58071727|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
58289310|NCT05156996|DEVICE|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
58289311|NCT05156996|PROCEDURE|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
58289312|NCT00666159|DRUG|tacrolimus ointment|topical
57933800|NCT03724734|DEVICE|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
58071728|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
58071729|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
58071730|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
58071731|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
58071732|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
58289313|NCT00666159|DRUG|pimecrolimus cream|topical
58071733|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
58071734|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
57933801|NCT01162239|DRUG|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
57933802|NCT01162239|BEHAVIORAL|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
57933803|NCT01162239|BEHAVIORAL|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
57933804|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
57933805|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
57933806|NCT01211535|DEVICE|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
57933807|NCT01211535|DEVICE|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
57933808|NCT01211535|DEVICE|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
58071735|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
58289314|NCT02843815|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
58289315|NCT02843815|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
58289316|NCT05953155|OTHER|Control|Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
58289317|NCT05953155|OTHER|Yoga|Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
58289318|NCT05900908|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
58289319|NCT05900908|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
58289320|NCT05072210|OTHER|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
58289321|NCT03688347|PROCEDURE|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
57933809|NCT02595021|PROCEDURE|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
57933810|NCT02595021|PROCEDURE|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
58289322|NCT03688347|PROCEDURE|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
58289323|NCT03688347|OTHER|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
58289324|NCT03688347|GENETIC|Microbiome analysis|Study of microbial communities found in and on the human body.
58071736|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
58289325|NCT03688347|GENETIC|DNA Banking|Secure, long term storage of an individual's genetic material.
58289326|NCT03688347|PROCEDURE|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
57933811|NCT00096668|DRUG|TOCOSOL(R) Paclitaxel|
57933812|NCT02564107|DRUG|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
57933813|NCT05033665|BEHAVIORAL|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
58289327|NCT02263053|PROCEDURE|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
57933814|NCT05033665|BEHAVIORAL|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
57933815|NCT05835089|DIAGNOSTIC_TEST|serum kisspeptin levels|Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
57933816|NCT06734156|OTHER|No intervention: observational study|No intervention: observational study
57933817|NCT00051285|DRUG|Enoximone|Participants receive oral enoximone
57933818|NCT00051285|DRUG|Enoximone placebo|Participants receive placebo to match enoximone
57933819|NCT04749342|OTHER|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
57933820|NCT02699957|PROCEDURE|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
57933821|NCT05810831|DIAGNOSTIC_TEST|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
57933822|NCT05810831|DIAGNOSTIC_TEST|Massage|conservative physiotherapy protocol including massage
57933823|NCT04925986|DRUG|Sitravatinib|Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
57933824|NCT04925986|DRUG|Pembrolizumab|All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
57933825|NCT00908583|DRUG|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
57933826|NCT00908583|DRUG|Bortezomib|Patients will receive bortezomib as described in protocol
57933827|NCT00908583|DRUG|Rituximab|Patients will receive rituximab as described in protocol
57933828|NCT00908583|DRUG|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
58071737|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
58289328|NCT02263053|PROCEDURE|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
58289329|NCT04758247|DEVICE|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
57729732|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
57933829|NCT05326425|DRUG|lazertinib(YH25448)|- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
57933830|NCT04885036|BEHAVIORAL|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
57933831|NCT04885036|BEHAVIORAL|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
57933832|NCT00648804|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
58289330|NCT01543802|DRUG|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
57729733|NCT00768274|DRUG|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
57933833|NCT00648804|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fed
57933834|NCT04475900|DIAGNOSTIC_TEST|Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)|To measure corneal biomechanics with Scheimpflug based tonometry
57933835|NCT04475900|DIAGNOSTIC_TEST|Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)|To measure corneal topography and tomography with Scheimpflug tomograph
57933836|NCT04475900|DIAGNOSTIC_TEST|Optic nerve head measurement|To measure optic nerve excavation
57933837|NCT04199234|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
57933838|NCT04199234|DIETARY_SUPPLEMENT|Comparator product consumption (Iron sulphate)|Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
57933839|NCT06495242|PROCEDURE|Direct pulp capping and partial pulpotomy|Two types of vital pulp therapy procedures
57933840|NCT04268043|DEVICE|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
58402100|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
57933841|NCT04268043|DEVICE|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
57729734|NCT00768274|DRUG|Placebo|Placebo twice daily (b.i.d.) for 28 days
57933842|NCT00024401|DRUG|DHA-paclitaxel|
57933843|NCT03670706|BEHAVIORAL|Exercise|Package of care
57933844|NCT03670706|OTHER|analgesic optimisation|optimisation
57933845|NCT05206591|BIOLOGICAL|Secukinumab|Secukinumab 300 s.c.
57933846|NCT05206591|OTHER|Placebo|Placebo
57933847|NCT06723756|DRUG|Treatment A: BGF MDI HFO|Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.
57933848|NCT06723756|DRUG|Treatment B: BGF MDI HFA|Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
57933849|NCT02681250|PROCEDURE|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
58289331|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
58402101|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
58402102|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
58402103|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
57933850|NCT02681250|PROCEDURE|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
57933851|NCT04411953|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
57933852|NCT04411953|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
57933853|NCT01610687|DRUG|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
57933854|NCT02432313|DRUG|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
57933855|NCT00287274|DEVICE|computerized physician order entry|
57933856|NCT03005951|OTHER|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
57729735|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
57729736|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
57729737|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
57729738|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
57729739|NCT04148443|OTHER|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
57729740|NCT04148443|OTHER|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
57933857|NCT03005951|OTHER|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
57933858|NCT05957354|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
57933859|NCT05957354|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
57933860|NCT06363669|DIETARY_SUPPLEMENT|multi-ingredient pre-workout dietary supplement (caffeine-based)|The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
57933861|NCT00230438|PROCEDURE|External Beam Radiotherapy|
57933862|NCT02663284|DRUG|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
57933863|NCT04197726|OTHER|sbeIIa/b white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
57933864|NCT04197726|OTHER|Control white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
57933865|NCT00024167|DRUG|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
57933866|NCT00024167|DRUG|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
57933867|NCT00024167|DRUG|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
57933868|NCT00024167|DRUG|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
57933869|NCT00024167|DRUG|Prednisone|5 mg orally 2 x daily, weeks 1-14
57933870|NCT00024167|DRUG|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
58071738|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
58095098|NCT01793285|DRUG|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
58289332|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
57729741|NCT01242475|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
57729742|NCT01242475|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
57933871|NCT00024167|RADIATION|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
57933872|NCT00024167|DRUG|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
57933873|NCT05466812|DRUG|Sr-89|"1. strontium-89 chloride treatment~2. periodical evaluation and follow-up"
57933874|NCT01561495|RADIATION|Proton Therapy|
57933875|NCT03878173|OTHER|No intervention|No intervention
57933876|NCT05244707|BEHAVIORAL|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
57933877|NCT05244707|BEHAVIORAL|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
57933878|NCT02901873|DEVICE|Electrical Impedance Spectroscopy|
57933879|NCT02677376|OTHER|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a second NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
57933880|NCT01475604|DEVICE|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
57933881|NCT01475604|DEVICE|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
57933882|NCT02794454|OTHER|HeezOn Ultra-1|
57933883|NCT02794454|OTHER|HeezOn Ultra-2|
57933884|NCT02794454|OTHER|Placebo|
57933885|NCT01636479|DRUG|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
57933886|NCT03178968|OTHER|Orange juice|3 immersion times in orange juice were investigated
57933887|NCT01816412|DEVICE|MD02-LDCB Paclitaxel coated balloon catheter|
57933888|NCT01816412|PROCEDURE|Standard Uncoated Balloon Angioplasty Catheter|
58289333|NCT00200577|DRUG|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
58289334|NCT02027077|BEHAVIORAL|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
58289335|NCT02027077|BEHAVIORAL|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
58289336|NCT00165217|DRUG|Capecitabine|
58289337|NCT00165217|DRUG|Thalidomide|
58289338|NCT05027815|BIOLOGICAL|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
58289339|NCT02103660|DRUG|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
58289340|NCT02103660|DRUG|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
58289341|NCT00015652|DRUG|Ribavirin|
58289342|NCT00015652|DRUG|Aldesleukin|
58289343|NCT00015652|DRUG|Peginterferon alfa-2b|
58402104|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
57933889|NCT05881967|DIAGNOSTIC_TEST|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
57933890|NCT05690945|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
58289344|NCT06202014|RADIATION|concurrent radiotherapy with envafolimab and capecitabine|Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
58289345|NCT02541955|DRUG|Acthar|Injections will be self administered
58289346|NCT02797145|DRUG|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
58402105|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
58402106|NCT00438126|BEHAVIORAL|A lifestyle educational program|
57933891|NCT05690945|DRUG|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
57933892|NCT01919320|DEVICE|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
58289347|NCT02797145|DRUG|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
58289348|NCT04444765|OTHER|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
58402107|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
58402108|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
57729743|NCT03866993|BIOLOGICAL|AK105|IV infusion
58289349|NCT01400724|DIETARY_SUPPLEMENT|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
57729744|NCT03866993|DRUG|Paclitaxel|IV infusion
57729745|NCT03866993|DRUG|Carboplatin|IV infusion
57729746|NCT03866993|DRUG|Placebo|IV infusion
57933893|NCT01919320|DEVICE|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
57933894|NCT05279703|DRUG|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
57933895|NCT05279703|DRUG|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
57933896|NCT05279703|DRUG|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
57933897|NCT03599557|BEHAVIORAL|STOP-HPV communication intervention|This intervention will be communication skills training.
57933898|NCT00526396|DRUG|cisplatin|80 mg/m2 on day 1 for 6 cycles
57933899|NCT00526396|DRUG|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
57933900|NCT00526396|DRUG|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
57933901|NCT00526396|DRUG|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
57933902|NCT06494865|DEVICE|MRI device|"Standered breast coils with small field of veiw and thin sections will be used for the examinatio.~MRI breast including Axial T1WI, T2WI Stir contrast DWI and Stir sagittal T1WI with contrast traction and subtraction"
58289350|NCT00371475|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
58289351|NCT00371475|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
58402109|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
58402110|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
58289352|NCT05950880|OTHER|High intensity shoulder exercise|Exercises that target the rotator cuff muscles using 90% of one repetition maximum only for 5 repetitions
58289353|NCT05950880|OTHER|Conventional physical therapy|Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises
58289354|NCT00023738|BIOLOGICAL|filgrastim|
58289355|NCT00023738|DRUG|dacarbazine|
58289356|NCT00023738|DRUG|doxorubicin hydrochloride|
58289357|NCT00023738|DRUG|ifosfamide|
58289358|NCT00023738|DRUG|semaxanib|
58289359|NCT00023738|PROCEDURE|conventional surgery|
58289360|NCT00023738|RADIATION|radiation therapy|
58289361|NCT02421419|DRUG|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
58289362|NCT02421419|DRUG|Xylocaine|a local anesthetic agent
58289363|NCT02421419|DRUG|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
58289364|NCT03828214|DEVICE|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R\&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
58289365|NCT00291564|DEVICE|Cardiac Resynchronization Therapy Device|
58289366|NCT06501599|DIAGNOSTIC_TEST|Medical software (AI-based system)|Retrospective analysis of chest CT images with medical software (AI-based system)
58289367|NCT03309228|OTHER|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
58402111|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
58402112|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
58402113|NCT00937144|DRUG|placebo|
58402114|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
58289368|NCT06503978|COMBINATION_PRODUCT|MTP-101P|MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.
58289369|NCT06503978|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 14 Days"
58289370|NCT06503978|COMBINATION_PRODUCT|Miralax|Miralax is a common over-the-counter laxative and bowel cleanse
58289371|NCT06503978|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12 weeks"
58289372|NCT06503978|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12 weeks"
58289373|NCT06503978|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 14 days"
58402115|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
58402116|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
58402117|NCT02513290|DRUG|Bilastine|
58402118|NCT02513290|DRUG|Loratadine|
57729747|NCT02043782|DEVICE|Coloplast Test|Newly developed 1-piece convex ostomy product
57933903|NCT02119754|DRUG|Plurogel PN|
58289374|NCT01211145|DRUG|Placebo|Placebo nasal spray
58289375|NCT01211145|DRUG|Zolmitriptan|0.5 mg nasal spray
58289376|NCT01211145|DRUG|Zolmitriptan|2.5 mg nasal spray
58289377|NCT01211145|DRUG|Zolmitriptan|5.0 mg nasal spray
58289378|NCT06609291|BEHAVIORAL|Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology|The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
58402119|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
58402120|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
58402121|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
58402122|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
57933904|NCT04236648|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
57933905|NCT06197334|DEVICE|Gastro-intestinal biopotentials recording|Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.
58402123|NCT00192049|DRUG|Gemcitabine|
58402124|NCT00192049|DRUG|mitomycin C|
58402125|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
58402126|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
57933906|NCT00594321|DEVICE|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
58289379|NCT02729480|DEVICE|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
57729748|NCT02043782|DEVICE|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
57729749|NCT02043782|DEVICE|Competitor soft convex|A commercially available soft convex product
57729750|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
57729751|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
57933907|NCT00594321|DEVICE|standard vertebroplasty|standard vertebroplasty
57933908|NCT02603471|OTHER|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
58071739|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
58289380|NCT04491981|PROCEDURE|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
58289381|NCT04491981|PROCEDURE|Composite resin|Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
58289382|NCT02666001|DRUG|BMS-663068|BMS-663068
58289383|NCT02666001|DRUG|Methadone|Methadone
58289384|NCT02666001|DRUG|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
58289385|NCT04059289|OTHER|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
58289386|NCT05515484|OTHER|prone position with airbags|prone position with airbags
58289387|NCT05515484|OTHER|prone position without airbags|prone position without airbags
58402127|NCT06252961|DRUG|Placebo|Placebo for 5 days
58402128|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
58402129|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
58402130|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
58402131|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
58402132|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
58402133|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
58402134|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
58402135|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
58402136|NCT05499455|DEVICE|Control|Control Device
58402137|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
58402138|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
58402139|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
58402140|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
58289388|NCT04177992|OTHER|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
58289389|NCT05010317|BEHAVIORAL|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
58402141|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
57729752|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
58071740|NCT02103400|OTHER|Experimental group|Exercise Training Group
58071741|NCT02103400|OTHER|Control group|Exercise control group
58095099|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
58289390|NCT05010317|BEHAVIORAL|Standard of care|Usual clinic based counselling offered as routine care to adolescents
58289391|NCT02103023|DRUG|Imiquimod ointment|5% 250mg imiquimod ointment
58289392|NCT02103023|DRUG|Aqueous cream|aqueous cream
58402142|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
58402143|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
58402144|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
57729753|NCT01569516|DRUG|Placebo|0mg, tid
57729754|NCT00001059|DRUG|Doxorubicin hydrochloride (liposomal)|
57729755|NCT00001059|DRUG|Filgrastim|
57729756|NCT00001059|DRUG|Bleomycin sulfate|
57729757|NCT00001059|DRUG|Vincristine sulfate|
57729758|NCT06100926|DEVICE|software|virtual reality scene
58289393|NCT02103023|BIOLOGICAL|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
58289394|NCT02103023|BIOLOGICAL|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
58289395|NCT02136901|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
58289396|NCT02136901|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
58289397|NCT02136901|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
58071742|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
58071743|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
58071744|NCT00451776|DRUG|etomidate|patients who received etomidate
58071745|NCT00451776|DRUG|propofol|patients who received propofol
58289398|NCT02136901|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
58289399|NCT02675270|BEHAVIORAL|Phonological|This treatment involves picture viewing and word repetition.
58289400|NCT02675270|BEHAVIORAL|Orthographic|This treatment involves picture viewing, reading, and writing.
58402145|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
57729759|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
57729760|NCT01260246|DRUG|placebo|placebo match for 6 months
57729761|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
58071746|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
58071747|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
58071748|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
58289401|NCT02675270|BEHAVIORAL|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
58289402|NCT02675270|BEHAVIORAL|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
58289403|NCT02675270|BEHAVIORAL|Untrained|These words are not trained during the treatment phase.
58402146|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
58402147|NCT03298984|DRUG|Cytarabine|continuous infusion
58402148|NCT03298984|DRUG|Daunorubicin|IV bolus
58402149|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
58402150|NCT04270942|BIOLOGICAL|teplizumab|anti-CD3 humanized monoclonal antibody
58402151|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
58402152|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
58402153|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
58402154|NCT00086801|DRUG|vinblastine|given IV
58402155|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
58402156|NCT00086801|PROCEDURE|CT scan|
58402157|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
58402158|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
58402159|NCT01097317|DRUG|carboplatin|
58402160|NCT01097317|DRUG|vinorelbine tartrate|
58402161|NCT01097317|OTHER|neuromuscular electrical stimulation|
58402162|NCT01097317|OTHER|physiologic testing|
58402163|NCT01097317|PROCEDURE|fatigue assessment and management|
58402164|NCT01097317|PROCEDURE|quality-of-life assessment|
58402165|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
58289404|NCT05135936|BEHAVIORAL|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
57933909|NCT02603471|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
58289405|NCT05135936|BEHAVIORAL|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
58289406|NCT04866082|OTHER|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
58402166|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
58071749|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
58071750|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
58402167|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
58402168|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
58402169|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
58402170|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
58402171|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
58402172|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
58289407|NCT05212584|BIOLOGICAL|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
58402173|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
58289408|NCT01136564|DRUG|Zemplar|2 capsules of 1 microgram daily
58402174|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
58402175|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
58402176|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
58402177|NCT03114579|DEVICE|NEXFIN HD|
58289409|NCT01136564|DRUG|Placebo|2 capsules daily
58289410|NCT04996836|BIOLOGICAL|Next Generation Sequencing and Network Analysis|Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
58289411|NCT01768065|DEVICE|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
58289412|NCT01768065|DEVICE|placebo sham|
58289413|NCT05118035|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
58402178|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
58402179|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
58402180|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
58289414|NCT02146209|DRUG|Metronidazole benzoate|Single oral dose of 400 mg
58289415|NCT02146209|DRUG|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
58289416|NCT02146209|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
58289417|NCT05095194|PROCEDURE|Cataract surgery with IOL implantation and with/without capsular tension ring implatation|Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation
58289418|NCT06226337|OTHER|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
58289419|NCT00004057|DRUG|L-778,123|
58289420|NCT00004057|DRUG|paclitaxel|
58289421|NCT01305772|DRUG|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.
58402181|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
57933910|NCT04573751|DRUG|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
57933911|NCT04573751|DRUG|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
57933912|NCT04573751|DRUG|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
57933913|NCT04573751|DRUG|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
57933914|NCT03222739|DEVICE|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
57933915|NCT02091583|DIETARY_SUPPLEMENT|Butter, sunflower and safflower oil|
58402182|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
58402183|NCT00608023|DRUG|Tesamorelin|
58402184|NCT00608023|DRUG|Placebo for Tesamorelin|
58402185|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
58402186|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
58402187|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
58402188|NCT06193408|DRUG|VR-AD-1005|oral capsule
58402189|NCT06193408|DRUG|Placebo|oral capsule
58402190|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
57933916|NCT02091583|DIETARY_SUPPLEMENT|High Oleic Canola Oil and DHA (HOCO-DHA)|
57933917|NCT02091583|DIETARY_SUPPLEMENT|Barley beta-glucan|
57933918|NCT02091583|DIETARY_SUPPLEMENT|HOCO-DHA and Barley beta-glucan|
57933919|NCT02815917|DRUG|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
57933920|NCT02426528|OTHER|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
57933921|NCT00891319|DEVICE|Electrical stimulator|"• 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
57933922|NCT05804279|DRUG|BPDO-1603|donepezil/mematine
57933923|NCT00137163|DEVICE|Dermafill Dressing|
58071751|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
58402191|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
57933924|NCT00684229|PROCEDURE|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
57933925|NCT00684229|DRUG|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
58402192|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
58402193|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
58402194|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
58402195|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
58402196|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
58071752|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
58071753|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
58071754|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
58071755|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
58071756|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
58071757|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
58402197|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
58071758|NCT02030067|DRUG|RX-3117|
58071759|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
58071760|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
58071761|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
58402198|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
58402199|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
58402200|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
58402201|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
58402202|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
58402203|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
58071762|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
58071763|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
58071764|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
58071765|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
58071766|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
58071767|NCT02701374|DRUG|TRK-700|
58071768|NCT02701374|DRUG|Placebo|
58071769|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
58071770|NCT00124865|BIOLOGICAL|rFla-MBP|
58071771|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
58402204|NCT06377696|OTHER|Best Practice|Receive SOC
58402205|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
58402206|NCT06377696|DRUG|Metformin|Given PO
58402207|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
58402208|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
58402209|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
58402210|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
58071772|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
57933926|NCT00943020|DIETARY_SUPPLEMENT|Nutricia PreOp nutritional supplement|nutritional supplement
57933927|NCT00943020|DIETARY_SUPPLEMENT|Lipid|Drink
57933928|NCT00943020|DIETARY_SUPPLEMENT|Glutamine|Drink
57933929|NCT00000125|DRUG|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
57933930|NCT02811055|BIOLOGICAL|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
58071773|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
58071774|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
58289422|NCT01305772|PROCEDURE|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
57729762|NCT06388343|OTHER|Evaluation of Children's Listening and Processing Skills|The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
57933931|NCT02811055|PROCEDURE|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
57933932|NCT02811055|DEVICE|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
57933933|NCT02811055|PROCEDURE|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
57933934|NCT02811055|DRUG|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
57933935|NCT02811055|DRUG|Administration of placebo|Administration of placebo once per day during 14 days
57933936|NCT04578886|DRUG|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
57933937|NCT04578886|DRUG|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
57933938|NCT04515472|DRUG|Botnia Clamp|This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.
57933939|NCT04515472|OTHER|Withdrawal of Gender Affirming Hormone Therapy (GAHT)|GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.
58071775|NCT03391427|DRUG|Saline|This group will receive saline infusion
58071776|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
58071777|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
58071778|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
58289423|NCT01305772|PROCEDURE|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
58289424|NCT00812942|PROCEDURE|colonoscopy|colonoscopy screening
58289425|NCT00812942|PROCEDURE|faecal test|faecal occult blood test for screening
58289426|NCT00195195|DRUG|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
58289427|NCT03639129|DEVICE|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
57933940|NCT01714778|OTHER|e-Cigarette|
57933941|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
57933942|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
58071779|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58071780|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
58071781|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
58071782|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
58071783|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
58289428|NCT03639129|PROCEDURE|Biopsy|Standard of care
58289429|NCT00533221|DRUG|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
58289430|NCT00533221|DRUG|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
58289431|NCT01461733|DRUG|amiodarone|standard dose amiodarone
58289432|NCT01461733|DRUG|Placebo|placebo delivered blinded
58289433|NCT01727817|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
58289434|NCT00591929|OTHER|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
58289435|NCT03352492|PROCEDURE|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
58289436|NCT03352492|PROCEDURE|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
58402211|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
58402212|NCT00898300|OTHER|biologic sample preservation procedure|
58402213|NCT00898300|PROCEDURE|biopsy|
58402214|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
57933943|NCT04841512|BIOLOGICAL|XT-150|non-viral Plasmid DNA encoding an IL-10 variant transgene
57933944|NCT04147026|DEVICE|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
58289437|NCT05285787|DRUG|EPN-701 (Oral)|MK-7
57933945|NCT04147026|OTHER|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
58071784|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
58071785|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
58071786|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
58071787|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
58071788|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
58071789|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
58071790|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
58071791|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
58289438|NCT00593424|OTHER|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
58289439|NCT00593424|OTHER|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
58289440|NCT03472612|OTHER|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
58289441|NCT01427270|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
58289442|NCT01427270|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
58402215|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
58402216|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
58402217|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
58071792|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
58071793|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
58095100|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
58289443|NCT01427270|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
58289444|NCT05176717|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
58289445|NCT05176717|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
58289446|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
58289447|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
58289448|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
58289449|NCT00905567|DRUG|Topiramate 2 x 25 mg tablet|
58289450|NCT00905567|DRUG|Topamax® Tablet 2 x 25 mg|
58289451|NCT02317484|DRUG|Ipragliflozin (SGLT2 inhibitor)|
58289452|NCT04621058|DRUG|Vitamin D|In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
58289453|NCT04621058|DRUG|PLACEBO|Placebo capsules exactly the same as the above, but without the active component.
58289454|NCT02028780|DRUG|Placebo to dose|placebo
58289455|NCT02028780|DRUG|Idarucizumab|short infusion
58289456|NCT02028780|DRUG|Placebo to Idarucizumab|Placebo to Idarucizumab
58289457|NCT02028780|DRUG|dabigatran|2 capsules dabigatran
58289458|NCT02028780|DRUG|Idarucizumab|short infusion
58289459|NCT00707980|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
58289460|NCT03324477|DRUG|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
58289461|NCT05605522|DRUG|[225]-FPI-2059|"\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation."
58289462|NCT05605522|DRUG|[111In]-FPI-2058|\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
58289463|NCT03549598|DRUG|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
58289464|NCT03549598|DRUG|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
58289465|NCT03549598|DRUG|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
58289466|NCT04031326|BEHAVIORAL|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
58402218|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
58402219|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
58402220|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
58402221|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
58402222|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
58402223|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
57933946|NCT00846651|OTHER|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
57933947|NCT00846651|OTHER|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
58402224|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
58402225|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
58402226|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
57933948|NCT00846651|DRUG|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
57933949|NCT00437385|DRUG|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
57933950|NCT00437385|PROCEDURE|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
57933951|NCT00437385|BEHAVIORAL|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
57933952|NCT04441034|DRUG|Anti-convulsant medications|Anti-convulsants are very commonly used to treat patients with chronic pain.
57933953|NCT04441034|DRUG|Anti-depressant medications|Anti-depressants are very commonly used to treat patients with chronic pain.
58402227|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
58402228|NCT00385281|BIOLOGICAL|FluMist|
58402229|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
58402230|NCT02891148|DRUG|BI 690517|
58402231|NCT00441428|DRUG|solifenacin|
58402232|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
58402233|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
58402234|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
58289467|NCT02182986|PROCEDURE|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
57933954|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
57933955|NCT01591317|DRUG|Prasugrel|Tablets orally
57933956|NCT05903872|OTHER|aromatherapy massage|aromatherapy massage was applied using essential oils
57933957|NCT05903872|OTHER|back massage|back massage was applied using only almond oil
57933958|NCT04465097|DRUG|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
57933959|NCT04465097|DRUG|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
58289468|NCT02182986|DRUG|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
58289469|NCT01153009|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
58289470|NCT01153009|DRUG|Duloxetine|Overencapsulated duloxetine delayed-release capsules
58289471|NCT01153009|DRUG|Placebo|Placebo-matching capsules
58289472|NCT00063804|DRUG|Ritonavir|
58289473|NCT00063804|DRUG|AMD070|
58402235|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
58402236|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
58402237|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
58071794|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
58402238|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
58402239|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
58402240|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
58071795|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
58402241|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
58402242|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
58402243|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
58402244|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
58289474|NCT06548646|PROCEDURE|Thoracic Interfascial Plane Block|The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
58289475|NCT06548646|PROCEDURE|Erector Spinae Plane Block|The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
58402245|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
58402246|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
58402247|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
58402248|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
58289476|NCT01067898|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
58289477|NCT01067898|OTHER|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
58289478|NCT01067898|DIETARY_SUPPLEMENT|calcium carbonate|1000 mg calcium per os every day for one year
58402249|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
58402250|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
58402251|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
58402252|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
58402253|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
58402254|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
58402255|NCT04710550|DRUG|F18-3F4AP|PET Scan
58402256|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
58402257|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
58402258|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
57933960|NCT04465097|DRUG|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
58402259|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
58402260|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
58402261|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
58402262|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
58402263|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
58402264|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
57933961|NCT05940922|OTHER|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
57933962|NCT06407791|DEVICE|LymphaVibe|The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
57933963|NCT06730321|OTHER|Observations on clinicopathological factors influencing the assessment score of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
57933964|NCT00334126|DRUG|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
57933965|NCT06228651|DEVICE|Tourniquet|
57933966|NCT06228651|OTHER|The leg without the tourniquet|
57933967|NCT05912803|DEVICE|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed."
58289479|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
58289480|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
58289481|NCT05811559|OTHER|No intervention|No intervention
57933968|NCT05912803|OTHER|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
58095101|NCT05769192|OTHER|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
58289482|NCT04026750|DRUG|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
58289483|NCT06048393|DRUG|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
58289484|NCT03435627|DRUG|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
58289485|NCT02608242|DRUG|YH22189|
58289486|NCT02608242|DRUG|Twynsta 80/10mg|
58289487|NCT02608242|DRUG|Crestor 20mg|
58402265|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
57729763|NCT06388343|BEHAVIORAL|Multidisciplinary behavioral assessment|By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
57933969|NCT05439668|OTHER|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
58402266|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
58402267|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
58071796|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
58289488|NCT03784313|PROCEDURE|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
58289489|NCT03784313|PROCEDURE|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
58402268|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
58402269|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
58402270|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
58402271|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
58402272|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
58402273|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
58402274|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
57933970|NCT05439668|OTHER|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
58402275|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
57933971|NCT05682924|DIAGNOSTIC_TEST|taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry|In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
57933972|NCT01990092|OTHER|Metanx|Metanx is a prescription medical food.
57933973|NCT01990092|OTHER|Placebo|
57933974|NCT02365753|DEVICE|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
58402276|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
57933975|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
58402277|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
58402278|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
58402279|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
58402280|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
58402281|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
58402282|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
58402283|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
57933976|NCT02761551|BEHAVIORAL|Reminder notifications via autodialer|
57933977|NCT04939519|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
58071797|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
58071798|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
58071799|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
58071800|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
58289490|NCT01416077|OTHER|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase \> 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI \> 2,5.~4. If despite CI \> 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
58289491|NCT03709147|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
58289492|NCT03709147|DRUG|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
58289493|NCT03709147|DRUG|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
58289494|NCT03709147|DRUG|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
58289495|NCT03709147|DIETARY_SUPPLEMENT|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
58289496|NCT03709147|DRUG|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
58289497|NCT00920504|BEHAVIORAL|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
58289498|NCT00920504|OTHER|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
58289499|NCT03344146|BEHAVIORAL|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
58289500|NCT03344146|BEHAVIORAL|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
58289501|NCT01033630|DRUG|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
58289502|NCT01033630|DRUG|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
58289503|NCT01033630|DRUG|Placebo|Image-matched placebo, made with starch.
57933978|NCT04939519|BEHAVIORAL|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
58071801|NCT03854552|DRUG|BI 764198|capsule
58071802|NCT03854552|DRUG|Placebo|capsule
58289504|NCT00736294|DRUG|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
58402284|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
58402285|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
57933979|NCT04236895|DRUG|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
58071803|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
57933980|NCT04616196|DRUG|NKTR-255|NKTR-255 IV every 21 days
58071804|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
58289505|NCT00736294|DRUG|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
58289506|NCT01883739|OTHER|Parental Presence at Handover Rounds|
58289507|NCT03972384|BEHAVIORAL|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
58402286|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
58402287|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
58402288|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
58402289|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
58402290|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
58402291|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
58402292|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
57933981|NCT04616196|DRUG|Cetuximab|Cetuximab will be given at specified doses on specified days
57933982|NCT02770443|DRUG|withdrawal|withdrawal of beta blocker and ACE inhibitors
57933983|NCT02770443|DRUG|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
57933984|NCT02172287|DRUG|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
57933985|NCT02172287|DRUG|Salmeterol|Inhalation aerosol twice daily
57933986|NCT02172287|DRUG|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
57933987|NCT02172287|DRUG|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
58071805|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
58289508|NCT05201677|PROCEDURE|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
57933988|NCT01905124|DRUG|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
58289509|NCT05476354|DRUG|Irbesartan/Amlodipine low|Irbesartan/Amlodipine low once daily for 8 weeks
58289510|NCT05476354|DRUG|Irbesartan/Amlodipine high|Irbesartan/Amlodipine high once daily for 8 weeks
58289511|NCT05476354|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
57933989|NCT01905124|DRUG|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
58071806|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
57933990|NCT04699175|DRUG|HR021618|Treatment group A:HR021618; high dose
58071807|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
58071808|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
58289512|NCT04339205|OTHER|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
58289513|NCT01348685|OTHER|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
58289514|NCT01348685|OTHER|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
58289515|NCT01348685|OTHER|The effect of solid vs. liquid forms of whey protein on food intake|
58402293|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
58402294|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
58402295|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
58402296|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
58402297|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
57933991|NCT04699175|DRUG|HR021618|Treatment group B:HR021618; low dose
57933992|NCT04699175|DRUG|Placebo|Treatment group C: HR021618 blank preparation.
57933993|NCT01456689|DRUG|LGH447|
57933994|NCT01456689|DRUG|midazolam|
57933995|NCT01167751|BIOLOGICAL|MNC|Implantation of BM derived MNC
57933996|NCT01167751|BIOLOGICAL|AC 133|Implantation of BM derived AC133
57933997|NCT01167751|BIOLOGICAL|Control|Injection of cell carrier
57933998|NCT03426826|BIOLOGICAL|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
57933999|NCT05894265|OTHER|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
57934000|NCT05894265|OTHER|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
58402298|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
58402299|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
57934001|NCT05894265|PROCEDURE|Saline injection|Group 3 will receive saline injection
57934002|NCT00838214|DRUG|budesonide|3mg capsule, 3x per day for 6 months
57934003|NCT00838214|DRUG|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
57934004|NCT00857532|DRUG|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
58071809|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
58071810|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
57934005|NCT00190710|DRUG|Gemcitabine|
57934006|NCT00190710|DRUG|Carboplatin|
58071811|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
58071812|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
58071813|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
58071814|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
58071815|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
58071816|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
58289516|NCT00588705|BEHAVIORAL|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
58289517|NCT06165237|DRUG|BR6001-1|One tablet administered alone, Once a day
58071817|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
58071818|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
58402300|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
58402301|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58402302|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
58071819|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
58071820|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
58071821|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
58289518|NCT06165237|DRUG|BR6001-2|One tablet administered alone, Once a day
58289519|NCT01005784|DRUG|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
58289520|NCT01005784|DRUG|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
58289521|NCT01481402|DRUG|Liothyronine|Liothyronine 40 microgram per day
58289522|NCT01481402|DRUG|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
58289523|NCT01236625|PROCEDURE|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
58289524|NCT00944632|DRUG|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
57934007|NCT04357704|OTHER|S0N0|(no ITD)
57934008|NCT04357704|OTHER|S0N500|(ITD +500µs on noise)
58071822|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
58071823|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
58071824|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
58071825|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
58071826|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
58071827|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
58071828|NCT02492321|DRUG|EBI-005|
58071829|NCT02492321|DRUG|Placebo Comparator|
58289525|NCT00944632|DRUG|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
58402303|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
58402304|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
58402305|NCT06106009|DRUG|Midazolam|Midazolam oral solution
58402306|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
58402307|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
58402308|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
58402309|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
58402310|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
57934009|NCT04357704|OTHER|S-500N500|(ITD -500µs on signal and +500 µs on noise)
58071830|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
58289526|NCT03338283|OTHER|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
58289527|NCT03338283|OTHER|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
58289528|NCT03948971|PROCEDURE|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
58289529|NCT00205998|DEVICE|Locking Compression Plate 2,4mm|
58289530|NCT00205998|DEVICE|Locking Compression Plate 3,5mm|
58289531|NCT05977855|OTHER|BPSDiary|The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
58289532|NCT05333796|BEHAVIORAL|gait with leg length discrepancy|After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.
58289533|NCT01745614|DRUG|Nimesulide 100 mg tablets|Reference product
58289534|NCT01745614|DRUG|Nimesulide 100 mg tablets|Test product
58289535|NCT03155347|DRUG|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
58289536|NCT03155347|DRUG|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
58289537|NCT03155347|DRUG|Placebo Matched to MTX|Placebo matched to MTX.
58289538|NCT03155347|DRUG|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
58289539|NCT00041197|DRUG|imatinib mesylate|Given orally (PO)
58289540|NCT00041197|OTHER|placebo|Given PO
58289541|NCT00041197|OTHER|laboratory biomarker analysis|Correlative studies
58289542|NCT04028791|OTHER|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
57934010|NCT04357704|OTHER|S0N1000|(ITD + 1000 µs on noise)
57934011|NCT04357704|OTHER|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
57934012|NCT00335894|DRUG|hMG-IBSA|
57934013|NCT02488499|BEHAVIORAL|Coping Power|15 sessions of concurrent parent and child group treatment
57934014|NCT02488499|BEHAVIORAL|Individualized Treatment|15 sessions of individualized child and parent treatment
57934015|NCT02342366|DRUG|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
57934016|NCT02342366|DRUG|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
57934017|NCT01122576|DEVICE|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
57934018|NCT01122576|DEVICE|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
57934019|NCT01122576|DEVICE|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
57934020|NCT01526044|DEVICE|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
58071831|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
58071832|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
58289543|NCT06144203|BEHAVIORAL|Exercise|Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.
58402311|NCT04005560|OTHER|no interventional study|no interventional study
58402312|NCT00022685|BIOLOGICAL|epratuzumab|
57934021|NCT02992886|RADIATION|Preoperative radiation|Radiation treatment before surgery
57934022|NCT02992886|DRUG|Raltitrexed|concurrent chemotherapy
57934023|NCT02992886|PROCEDURE|Pelvic surgery|
58289544|NCT03308604|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
58289545|NCT03308604|RADIATION|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
58289546|NCT03308604|RADIATION|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
58289547|NCT03308604|DRUG|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
58289548|NCT04883151|BEHAVIORAL|SOFUS pilot program|"The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered."
58289549|NCT00671801|DRUG|Irinotecan|200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
58289550|NCT00671801|DRUG|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
58289551|NCT02778022|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
58289552|NCT04063735|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
58289553|NCT04063735|DIETARY_SUPPLEMENT|Placebo|Placebo was given to participants.
58289554|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
58289555|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
57934024|NCT03289910|DRUG|Carboplatin|Given IV
57934025|NCT03289910|DRUG|Topotecan|Given IV
57934026|NCT03289910|DRUG|Topotecan Hydrochloride|Given IV
57934027|NCT03289910|DRUG|Veliparib|Given PO
57934028|NCT00163462|DRUG|Ciclesonide|
57934029|NCT04344691|PROCEDURE|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
57934030|NCT00627029|BEHAVIORAL|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
57934031|NCT05125068|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
57934032|NCT03763669|DIETARY_SUPPLEMENT|Myoinositol|myo-inositol (2 g. twice a day)
57934033|NCT03763669|DIETARY_SUPPLEMENT|Placebo (for myoinositol)|(twice a day)
57934034|NCT00452049|PROCEDURE|parathyroidectomy|parathyroidectomy
57934035|NCT02877862|BEHAVIORAL|mAGIC app|7-day app to encourage uptake of genetic counseling
57934036|NCT05334004|DRUG|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
57934037|NCT04120610|DIAGNOSTIC_TEST|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
58402313|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
58402314|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
58071833|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
58071834|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
58071835|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
57934038|NCT04120610|DIAGNOSTIC_TEST|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
57934039|NCT04120610|DIAGNOSTIC_TEST|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
57934040|NCT05116150|DIETARY_SUPPLEMENT|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
58071836|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
58071837|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
58071838|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
58071839|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
58071840|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
57934041|NCT05116150|DIETARY_SUPPLEMENT|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
58071841|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
58071842|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
58071843|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
58071844|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
58071845|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
58071846|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
58071847|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
58071848|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
58402315|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
58402316|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
58402317|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
58402318|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
58402319|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
58402320|NCT06267937|OTHER|type of intitution|public or private health care facility
57934042|NCT05217303|DRUG|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
57951200|NCT03114176|DIETARY_SUPPLEMENT|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
57951201|NCT02855528|DEVICE|Tin Filter|
58071849|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
58071850|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
58071851|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
58071852|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
58402321|NCT01961284|DEVICE|Zygomatic implant placement|
58402322|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
58402323|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
58071853|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
58071854|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
58071855|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
58071856|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
58071857|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
58071858|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
58071859|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
58071860|NCT00957827|DRUG|placebo|placebo BID for five days
58071861|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
58071862|NCT06669585|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
58402324|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
58071863|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
58071864|NCT06724146|DEVICE|Sofwave and Pure Impact|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated."
58071865|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
58071866|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
58071867|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
58071868|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
58289556|NCT02820870|BEHAVIORAL|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
57934043|NCT06267287|DIAGNOSTIC_TEST|Microbiological examination of the patient's biological material and determination of antibiotic resistance|Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
57934044|NCT00302510|PROCEDURE|immunoadsorption|immunoadsorption
57934045|NCT02180620|OTHER|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
58071869|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
58071870|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
58071871|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
58071872|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
58289557|NCT01635374|PROCEDURE|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
58289558|NCT05227443|PROCEDURE|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
58402325|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
58071873|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
58071874|NCT02815670|DRUG|Idarucizumab|
58071875|NCT00039377|DRUG|imatinib mesylate|Given PO
58071876|NCT00039377|DRUG|methotrexate|Given IT and IV
58071877|NCT00039377|DRUG|vincristine sulfate|Given IV
58071878|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
58071879|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
58071880|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
58071881|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
58402326|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
58402327|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
58402328|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
58402329|NCT01863173|DRUG|metoprolol|using B blocker in patient group
58289559|NCT05227443|PROCEDURE|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
58289560|NCT03701412|RADIATION|MRI|MRI brain
58289561|NCT00617747|DRUG|Zolmitriptan|5mg Nasal Spray
58402330|NCT01863173|DRUG|placebo|placebo to control group
58402331|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
58402332|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
58071882|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
58289562|NCT00617747|DRUG|Placebo|
58402333|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
58402334|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
58289563|NCT03199950|DRUG|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
58402335|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
57934046|NCT02180620|OTHER|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
57934047|NCT02180620|OTHER|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
57934048|NCT00576433|DRUG|Methotrexate|As prescribed
57934049|NCT00576433|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
58071883|NCT00039377|DRUG|tacrolimus|Given IV or PO
58402336|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
58402337|NCT02894164|OTHER|No intervention|
58402338|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
57934050|NCT01954186|DRUG|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
57934051|NCT01954186|PROCEDURE|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
57951202|NCT00558870|DRUG|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
57951203|NCT00558870|DRUG|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
58289564|NCT03199950|DRUG|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
58289565|NCT01909843|BIOLOGICAL|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
58289566|NCT03327818|PROCEDURE|hysterectomy|
58289567|NCT03327818|PROCEDURE|uterine conservative study|
58289568|NCT02968459|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
58402339|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
58402340|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
58402341|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
58402342|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
57934052|NCT06200649|OTHER|massage|Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
58071884|NCT00039377|BIOLOGICAL|filgrastim|Given SC
58071885|NCT00039377|DRUG|etoposide|Given IV
58289569|NCT02968459|OTHER|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
58289570|NCT03454087|OTHER|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
58289571|NCT03454087|OTHER|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
58289572|NCT05521074|DEVICE|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
58289573|NCT05521074|DEVICE|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
58289574|NCT00472745|BEHAVIORAL|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
58289575|NCT00472745|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 months
57934053|NCT05001451|BIOLOGICAL|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
57934054|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
57934055|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
58071886|NCT00039377|DRUG|cyclophosphamide|Given IV
58071887|NCT00039377|DRUG|cytarabine|Given IV
58071888|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
58071889|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
58071890|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
58071891|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
58289576|NCT00576524|DEVICE|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
58402343|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
58402344|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
58402345|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
58402346|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
58402347|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
58402348|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
58402349|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
58402350|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
58402351|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
57934056|NCT01549626|DIETARY_SUPPLEMENT|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
58289577|NCT00576524|DEVICE|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
58289578|NCT05415462|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
58289579|NCT05415462|BIOLOGICAL|Fluarix Tetra|Sterile suspension for injection
57934057|NCT01549626|DIETARY_SUPPLEMENT|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
57934058|NCT01549626|DIETARY_SUPPLEMENT|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
57934059|NCT02633410|PROCEDURE|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
58071892|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
58071893|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
58071894|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
57934060|NCT03100201|OTHER|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
57934061|NCT03100201|OTHER|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
57934062|NCT06692322|DRUG|Zongertinib (BI 1810631)|Film-coated tablet
57934063|NCT01764971|OTHER|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
57934064|NCT01764971|OTHER|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
58071895|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
58071896|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
58071897|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
57934065|NCT05023863|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
57934066|NCT05023863|OTHER|Placebo tablets|placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
57934067|NCT05023863|RADIATION|radiation or concurrent chemoradiation|radiation or concurrent radiotherapy plus platinum-based chemotherapy
57934068|NCT03719638|DEVICE|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
58071898|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
58071899|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
57934069|NCT03719638|OTHER|simulated difficult airway|extension of head will be limited by using collar.
57934070|NCT03719638|DEVICE|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
57934071|NCT06074991|OTHER|musıc therapy|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
57934072|NCT05715528|DRUG|Obeldesivir|Tablet administered orally without regard to food.
57934073|NCT05715528|DRUG|Obeldesivir Placebo|Tablet administered orally without regard to food.
57934074|NCT03208751|BEHAVIORAL|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
57951204|NCT01423409|DEVICE|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
58289580|NCT06612190|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
57934075|NCT05506826|OTHER|fine motor activities|patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy
57934076|NCT05506826|OTHER|conventional therapy and mirror therapy|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
58289581|NCT06612190|PROCEDURE|Control|The sham group will be given no real magnetic stimulation.
58289582|NCT03444805|PROCEDURE|Autologous HSCT|1st AHSCT
58289583|NCT01901042|DIETARY_SUPPLEMENT|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
58289584|NCT01901042|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will receive sachets containing maltodextrin
57934077|NCT04069754|BEHAVIORAL|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
57934078|NCT02905253|DRUG|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
57934079|NCT02905253|DRUG|Placebo|Placebo capsules matching AC-084 capsules
57934080|NCT03585985|PROCEDURE|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
57934081|NCT03585985|PROCEDURE|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
58071900|NCT04052711|DRUG|FMX-101|
58071901|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
58071902|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
58289585|NCT03207997|OTHER|unenhanced MR sequences|2 additional unenhanced MR sequences
57951205|NCT01423409|DEVICE|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
58289586|NCT00339833|DRUG|Salsalate|The intervention was salsalate (3g/day) for 7 days.
58289587|NCT00339833|DRUG|Placebo|Identical placebo for 7 days.
58289588|NCT04398602|BEHAVIORAL|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
58289589|NCT03255928|DIAGNOSTIC_TEST|PAS assay, TGT|Evaluation of platelet function
58289590|NCT00770913|DRUG|E3810|20 mg taken orally, once a day for 8 weeks.
58289591|NCT00770913|DRUG|E3810|10 mg, taken orally, twice a day for 8 weeks.
58289592|NCT00770913|DRUG|E3810|20 mg taken orally, twice a day for 8 weeks.
58289593|NCT06548633|OTHER|Lumbar Vertebral Mobilisation|The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
58289594|NCT00222638|DRUG|Influenza vaccination|
58289595|NCT02998151|DRUG|Acamprosate|two 666mg pills
58289596|NCT02998151|DRUG|Lovastatin|two 20mg pills
58289597|NCT02998151|DRUG|Minocycline|two 135mg pills
58289598|NCT02998151|DRUG|Placebo|placebo pill
58289599|NCT02998151|DRUG|Baclofen|one 30mg pill
58289600|NCT02131233|DRUG|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
58289601|NCT02131233|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily
58402352|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
58402353|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
58402354|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
58402355|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
58402356|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
57934082|NCT04100629|BEHAVIORAL|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
58071903|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
58289602|NCT02131233|DRUG|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
57934083|NCT00659529|DRUG|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
58289603|NCT02131233|DRUG|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
58289604|NCT02131233|DRUG|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
58402357|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
58402358|NCT04452435|DRUG|C21|C21
58402359|NCT04452435|DRUG|Placebo|Placebo
58402360|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
58402361|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
57934084|NCT02004951|DEVICE|Misago RX|
58402362|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
58402363|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
58402364|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
57934085|NCT02004951|DEVICE|Zilver PTX|
57934086|NCT02558478|GENETIC|blood sampling|
57934087|NCT00404066|DRUG|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
58289605|NCT04783233|BIOLOGICAL|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
58289606|NCT04783233|BIOLOGICAL|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
58289607|NCT00806208|DRUG|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
58289608|NCT00806208|DRUG|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
58289609|NCT00806208|DRUG|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
58289610|NCT00806208|DRUG|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
58289611|NCT00806208|OTHER|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
58289612|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
58289613|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
58402365|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
58402366|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
58289614|NCT01440634|OTHER|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
58289615|NCT01204086|DRUG|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
58289616|NCT01204086|DRUG|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
58289617|NCT00178217|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
58289618|NCT02693262|DEVICE|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
58289619|NCT02693262|DEVICE|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
58289620|NCT04979416|BEHAVIORAL|Video messages|video messages aimed at increasing vaccination
58289621|NCT06612502|BEHAVIORAL|Static stretching|The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. The subjects were instructed to perform the following sequence of stretches: forward lunge, supine knee flexion, lateral quadriceps stretch, sitting toe touch, semi-straddle, straddle, butterfly stretch, and a straight knee ankle extensor wall stretch. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
58402367|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
57934088|NCT00404066|DRUG|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
57934089|NCT00404066|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
57934090|NCT00404066|DRUG|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
57934091|NCT00404066|DRUG|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
57934092|NCT00404066|DRUG|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
57934093|NCT00404066|DRUG|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
57934094|NCT00404066|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
57934095|NCT06735833|DEVICE|Middle Meningeal Artery embolization|Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system
57934096|NCT03560947|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
58402368|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
57934097|NCT03560947|OTHER|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
58402369|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
57934098|NCT05729295|PROCEDURE|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
57934099|NCT05710926|BEHAVIORAL|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
57934100|NCT05710926|BEHAVIORAL|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
57934101|NCT06013657|PROCEDURE|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
57934102|NCT02682225|DRUG|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
57934103|NCT02682225|DRUG|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
57934104|NCT02682225|DRUG|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
58402370|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
57934105|NCT02682225|DRUG|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
57934106|NCT02682225|DRUG|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
57934107|NCT04323826|OTHER|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
57934108|NCT04323826|OTHER|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
57934109|NCT04323826|OTHER|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
57934110|NCT04323826|OTHER|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
58071904|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
58071905|NCT04825639|OTHER|No intervention|no intervention
58071906|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
58289622|NCT06612502|DEVICE|Fascia gun ( Short-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The short time PMT was applied for 2.5 minutes per muscle site for a total of 25 minutes.
58289623|NCT06612502|DEVICE|Fascia gun ( Long-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The long time PMT was applied for 4 minutes per muscle site for a total of 40 minutes.
58402371|NCT00150319|DRUG|Vfend®; I.V.|
58402372|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
58402373|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
58402374|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
58402375|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
58402376|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
58402377|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
58402378|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
57934111|NCT01621997|BEHAVIORAL|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
57934112|NCT03516890|PROCEDURE|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
57934113|NCT02287376|DRUG|Diclofenac Potassium for Oral Solution|NSAID
58071907|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
57934114|NCT05221801|BEHAVIORAL|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
58071908|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
57934115|NCT05221801|OTHER|food type|the swallowing was tested with 3 food types
57934116|NCT05227053|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter|Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
58071909|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
58289624|NCT04407702|OTHER|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
58289625|NCT04407702|PROCEDURE|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
58289626|NCT04407702|RADIATION|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
58289627|NCT02455453|DRUG|18F-FFNP|
58289628|NCT02455453|DEVICE|CTI/Siemens Biograph 40 PET/CT Scanner|"* Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans"
58289629|NCT02455453|DRUG|Estradiol|
58289630|NCT02455453|DRUG|18F-FDG|
58289631|NCT02010905|DRUG|Losartan|
58289632|NCT02010905|DRUG|Placebo|
58289633|NCT04152083|DRUG|Eptinezumab|Injection for IV administration
58289634|NCT04152083|DRUG|Placebo|Injection for IV administration
57934117|NCT02509104|DRUG|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
57934118|NCT02509104|DRUG|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
57951206|NCT05142527|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
57951207|NCT05142527|OTHER|Placebo|Placebo
57951208|NCT04199637|OTHER|TVG|Therapeutic video game
57951209|NCT02888093|DEVICE|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
57951210|NCT02810756|DRUG|New Pazopanib formulation|
58289635|NCT05547880|DRUG|[11C]ER176|Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
58071910|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
58071911|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
58071912|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
58071913|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
58289636|NCT04235504|OTHER|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
58289637|NCT04235504|DEVICE|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
58289638|NCT01540981|DEVICE|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
58289639|NCT01540981|OTHER|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
58289640|NCT00030628|RADIATION|radiation therapy|
58289641|NCT00030628|PROCEDURE|surgery|
58289642|NCT00030628|RADIATION|WBRT|
58289643|NCT05555576|DIETARY_SUPPLEMENT|Vitamin C|1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
58402379|NCT00262236|DRUG|Aliskiren|
58402380|NCT00003234|DRUG|vinorelbine tartrate|
58402381|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
58402382|NCT00433160|DRUG|Placebo|daily, subcutaneous
58402383|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
58402384|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
58402385|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
57729764|NCT03186846|DEVICE|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
57729765|NCT03186846|DEVICE|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
57934119|NCT05411549|BEHAVIORAL|Diet Modification to Adopt Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
57934120|NCT03930147|PROCEDURE|ASV ventilation|Ventilation on ASV mode
57934121|NCT04611438|DRUG|Cannabidiol|"Intervention schedule for each patient is as follows:~1. Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~2. Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~   * Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~  * Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~  * Maintenance: no change in medication dosage"
57934122|NCT02806154|OTHER|DEXA|The appendicular muscle mass measured by DEXA
58289644|NCT05555576|OTHER|Placebo|Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
58289645|NCT01960166|BEHAVIORAL|Active Distraction|iPad will be used as active distraction
58289646|NCT01960166|BEHAVIORAL|Passive Distraction|child will watch TV as passive distraction
58289647|NCT00000332|DRUG|Nimodipine|
58289648|NCT03413475|BEHAVIORAL|quality of life|
58289649|NCT04826471|DEVICE|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
57951211|NCT02572752|DRUG|Nintedanib|1 soft gelatine capsule, single dose, oral
57951212|NCT02572752|DRUG|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
57951213|NCT02572752|DRUG|Nintedanib|
57951214|NCT04012047|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
58289650|NCT03767426|BEHAVIORAL|Sleep Deprivation|Subjects are sleep deprived for an entire night
58402386|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
58402387|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
58402388|NCT04379479|DRUG|Placebo oral|Placebo
58402389|NCT00563069|DRUG|Midazolam|
58402390|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
58402391|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
58402392|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
58402393|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
58402394|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
58402395|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
58289651|NCT03767426|BEHAVIORAL|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
58402396|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
58402397|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
58402398|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
58402399|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
58402400|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
58402401|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
58402402|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
58289652|NCT00585338|DEVICE|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
58289653|NCT03258645|DRUG|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
58289654|NCT01185002|OTHER|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
58289655|NCT01185002|OTHER|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
58289656|NCT01185002|OTHER|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
58289657|NCT01912794|OTHER|Sensory Intervention|"1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs."
58289658|NCT02302040|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
58289659|NCT02302040|BEHAVIORAL|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
58289660|NCT02329782|BEHAVIORAL|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
58289661|NCT03814902|DEVICE|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
58289662|NCT05276206|DRUG|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
57729766|NCT04612179|DEVICE|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
57729767|NCT00518024|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
57729768|NCT04658251|GENETIC|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
57934123|NCT04276766|OTHER|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
57934124|NCT04173715|BEHAVIORAL|Older Adults Group.|Physical activity and energy expenditure quantification
57934125|NCT04173715|BEHAVIORAL|Low Physical Function Status Group|Physical activity and energy expenditure quantification
58402403|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
58402404|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
57934126|NCT04173715|BEHAVIORAL|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
57934127|NCT04173715|BEHAVIORAL|High Physical Function Status Group|Physical activity and energy expenditure quantification
57934128|NCT04319302|PROCEDURE|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
57934129|NCT02241291|PROCEDURE|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
57934130|NCT06027567|DRUG|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
57934131|NCT06027567|DIETARY_SUPPLEMENT|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
57934132|NCT06027567|BEHAVIORAL|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
57934133|NCT03915808|DIETARY_SUPPLEMENT|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
57934134|NCT03915808|DIETARY_SUPPLEMENT|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
58402405|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
57729769|NCT01011010|DRUG|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
57729770|NCT01011010|DRUG|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
57729771|NCT01011010|DRUG|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
57934135|NCT06736496|DRUG|Nalbuphine|patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
57934136|NCT06736496|DRUG|Dexmedetomidine|patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
57934137|NCT02198612|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
57934138|NCT06235840|BEHAVIORAL|working memory adaptive training|The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each
58071914|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
57729772|NCT01011010|OTHER|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
57729773|NCT01011010|OTHER|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
57951215|NCT04012047|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
58071915|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
58071916|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
58071917|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
58402406|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
58402407|NCT03729037|OTHER|CPR self-training|
58402408|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
58402409|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
57934139|NCT06235840|BEHAVIORAL|multi-domain non-adaptive control training|The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
57934140|NCT04608513|DRUG|ACT-1014-6470|Soft capsules for oral administration
57934141|NCT04608513|DRUG|Placebo|Soft capsules for oral administration
57934142|NCT06162000|OTHER|The group that will use the developed software in case studies|"In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups."
57934143|NCT04356911|OTHER|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
57934144|NCT04356911|OTHER|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
57934145|NCT04356911|OTHER|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
57951216|NCT06450652|DRUG|Chinese Herbal Medicine granules|The intervention will be a 4 weeks of Chinese Herbal Medicine (CHM) granules, which will consist of six Chinese herbs. Subjects will take one sachet orally, twice daily after meals for 4 weeks. Way of taking CHM granules is as follow: Add 100ml boiling water into a cup, then pour one pack of granules into the cup and soap it for 2-3 mins. Stir until the granules completely dissolve before drinking.
58071918|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
58071919|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
58071920|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
58071921|NCT02267460|BIOLOGICAL|AA4500|
58289663|NCT06218771|DRUG|TQB3454 Tablets|TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
58402410|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
58071922|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
58071923|NCT02267460|PROCEDURE|Investigator Modeling|
58071924|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
58071925|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
58071926|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
58071927|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
58289664|NCT04665973|BEHAVIORAL|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
58402411|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
58402412|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
58402413|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
57934146|NCT04356911|OTHER|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
57934147|NCT03348865|BEHAVIORAL|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
57729774|NCT05166018|DIAGNOSTIC_TEST|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
57729775|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
57729776|NCT02607579|DRUG|Exparel|
57934148|NCT01889303|DRUG|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
57934149|NCT01889303|DRUG|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
57934150|NCT01889303|RADIATION|radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
57934151|NCT00351416|DRUG|Letrozole|Letrozole 20 mg orally one time
57934152|NCT00351416|DRUG|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
57934153|NCT03984903|OTHER|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
57934154|NCT03984903|OTHER|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
57934155|NCT03984903|OTHER|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
58071928|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
58071929|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
57934156|NCT03984903|OTHER|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
57934157|NCT05643612|DIAGNOSTIC_TEST|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
57934158|NCT02566577|BIOLOGICAL|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
57951217|NCT03825874|OTHER|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
58071930|NCT01363232|DRUG|BKM120 + MEK162|
57729777|NCT02607579|DRUG|Ropivacaine|
58071931|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
58071932|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
58071933|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
58402414|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
57934159|NCT02566577|BIOLOGICAL|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
57934160|NCT02566577|DEVICE|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
57934161|NCT01871636|PROCEDURE|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
58402415|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
57934162|NCT01871636|PROCEDURE|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
57934163|NCT01871636|DEVICE|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
57934164|NCT01235793|DRUG|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
57934165|NCT06154655|OTHER|E-zine|Health education will be delivered through an electronic magazine
58071934|NCT03708926|DRUG|Placebo|placebo injection pen
58071935|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
58071936|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
58071937|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
58071938|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
58071939|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
58071940|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
57729778|NCT01660763|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
58071941|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
58071942|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
58071943|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
58071944|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
58071945|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
58071946|NCT00450814|DRUG|Cyclophosphamide|Given IV
58071947|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
58071948|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
58071949|NCT00450814|OTHER|Pharmacological Study|Correlative studies
58071950|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
58071951|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
58071952|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
58071953|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
58071954|NCT01122719|DEVICE|Drug Eluting Stent|
58402416|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
58402417|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
57934166|NCT02378220|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
58071955|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
58289665|NCT04665973|BEHAVIORAL|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
58289666|NCT03467542|DEVICE|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
58289667|NCT01610869|DRUG|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
58289668|NCT05822193|OTHER|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
58289669|NCT06007495|DEVICE|Investigational full-face mask with expiratory washout|With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation
58289670|NCT06007495|DEVICE|Conventional full-face mask - single-limb|With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation
58289671|NCT06007495|DEVICE|Conventional full-face mask - dual-limb|With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
58289672|NCT05174156|DRUG|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
58289673|NCT00167518|DRUG|Triamcinolone acetate|
58289674|NCT01240902|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
58289675|NCT01240902|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
58289676|NCT00256932|DRUG|alvimopan|0.5 mg
58289677|NCT00256932|DRUG|Placebo|
58289678|NCT03153241|OTHER|No intervention|No intervention
58289679|NCT00652145|DRUG|mesalamine|Increase dose by 2.4gm per day over baseline dose
58289680|NCT04847583|DRUG|Telacebec|Telacebec 100 mg tablet
58289681|NCT04847583|DRUG|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
57934167|NCT05639413|OTHER|Collection of blood samples|A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
57934168|NCT05431101|PROCEDURE|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
57934169|NCT00388505|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
58071956|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
58071957|NCT01396811|DRUG|33525|Daily for 14 days
58071958|NCT01396811|DRUG|Placebo|Daily for 14 days
57934170|NCT00388505|DRUG|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
57934171|NCT06387849|OTHER|Aromatherapy|women enrolled in the experimental group received aromatherapy with lavender essential oil (EO) through dry inhalation (inhalation via a cotton support soaked in a few drops of EO)
57934172|NCT06387849|OTHER|Placebo|women enrolled in the placebo group received ihaled a cotton support soaked in a few drops of distilled water
57934173|NCT05245019|BIOLOGICAL|cardamom|cardamom is used as a flavoring agent in foods as well as for treating various cardiovascular, gastrointestinal, and neural problems
58071959|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
58289682|NCT04529239|DEVICE|Abbott Freestyle Libre Pro|Continuous glucose monitoring device to analyze diabetes biomarkers.
58289683|NCT02928523|DRUG|Autologous Fecal Microbiota Transplantation|
58289684|NCT04849117|PROCEDURE|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
58289685|NCT03464084|DRUG|placebo|Capsules containing microcrystalline cellulose
58289686|NCT03464084|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
58289687|NCT03464084|OTHER|bright light|room light will be bright
58289688|NCT03464084|OTHER|dim light|room light will be dim
58289689|NCT04747249|OTHER|Psychological support|Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
58289690|NCT00753129|PROCEDURE|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
58289691|NCT02105194|DRUG|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
58289692|NCT04880668|DEVICE|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
58402418|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
58402419|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
58402420|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
58402421|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
58402422|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
58402423|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
58402424|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
58402425|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
58289693|NCT01380652|PROCEDURE|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
58402426|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
58402427|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
58402428|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
58402429|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
58402430|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
58402431|NCT00470093|BIOLOGICAL|recombinant interferon-α|
58402432|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
58289694|NCT06192238|PROCEDURE|adrenal venous sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
58289695|NCT06361186|DRUG|Proximod|Single and multiple-dose to establish the safety and PK profile
58289696|NCT06361186|DRUG|Placebo|Placebo controlled
58289697|NCT01275989|OTHER|Ear acupuncture|
58289698|NCT01816932|PROCEDURE|Home Visit|The intervention is the location of the insertion visit.
58289699|NCT01816932|PROCEDURE|Office visit|
58289700|NCT02589509|BEHAVIORAL|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
58402433|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
58402434|NCT01180894|DRUG|Placebo|
58402435|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
58402436|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
58402437|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
58402438|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
58402439|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
58402440|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
58402441|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
58402442|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
58402443|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
58402444|NCT06006507|OTHER|control|no exercise will be given
58289701|NCT02589509|BEHAVIORAL|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
58402445|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
58402446|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
58402447|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
58402448|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
58402449|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
58071960|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
58289702|NCT04221360|DRUG|CKD-375|Test drug, QD, PO
58289703|NCT04221360|DRUG|D390|Reference drug, QD, PO
58289704|NCT06517745|PROCEDURE|Prone positioning|Prone positioning sessions: at least one session per day proning duration: 2 hours at least per session
58289705|NCT02412176|PROCEDURE|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
58289706|NCT02412176|PROCEDURE|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
58289707|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
58289708|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract|Take 4 tablets with warm water twice a day
58289709|NCT05497765|DIETARY_SUPPLEMENT|Placebo|Take 4 tablets with warm water twice a day
58289710|NCT06612489|DEVICE|biofeedback based dynamic-difficulty game|A biofeedback based dynamic-difficulty serious game rooted in distraction therapy.
58289711|NCT06612489|DEVICE|fixed difficulty game|A fixed difficulty serious game rooted in distraction therapy.
58402450|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
58402451|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
58402452|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
58402453|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
58402454|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
58402455|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
58071961|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
58071962|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
58071963|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
58071964|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
58289712|NCT01977768|BIOLOGICAL|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
58289713|NCT01977768|BIOLOGICAL|Placebo|
58289714|NCT05297461|OTHER|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
58289715|NCT01121939|DRUG|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
58289716|NCT01121939|DRUG|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
58402456|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
58402457|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
58071965|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
58071966|NCT01255449|DRUG|albuterol|400 mcg by inhalation
58402458|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
58402459|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
57729779|NCT01660763|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
58071967|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
58071968|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
58071969|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
58071970|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
58071971|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
58071972|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
58402460|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
58071973|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
58402461|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
58402462|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
58402463|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
58071974|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
58071975|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
58071976|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
58071977|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
58071978|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
58071979|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
58402464|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
58402465|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
58402466|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
58402467|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
58402468|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
57729780|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
57729781|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
57729782|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)"
57729783|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
57729784|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
57729785|NCT03424681|DRUG|Modafinil|Modafinil 300 mg by mouth daily
57729786|NCT03424681|OTHER|Placebo|Placebo
57729787|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
58071980|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
58071981|NCT02895477|DEVICE|hearing aid|
58071982|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
58289717|NCT01121939|DRUG|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
58289718|NCT05161026|OTHER|Bone osteodensitometry|Evaluation of bone osteodensitometry
58289719|NCT05053971|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
58289720|NCT05053971|PROCEDURE|Core Biopsy|Undergo core needle biopsy
58289721|NCT05053971|DRUG|Entinostat|Given PO
58289722|NCT02357056|OTHER|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
58289723|NCT02357056|OTHER|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
58289724|NCT02357056|OTHER|Virtual Reality|daVinci Surgical Skills simulation
58289725|NCT05598749|DIETARY_SUPPLEMENT|Placebo|Arabic gum, sucrose and silicon dioxide mix
58289726|NCT05598749|DIETARY_SUPPLEMENT|Verum|Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
58071983|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
58071984|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
58071985|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
58071986|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
58071987|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
58071988|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
58071989|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
57729788|NCT00856050|DRUG|letrozole|Taken orally once a day continuously
58071990|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
58071991|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
58289727|NCT00027547|BIOLOGICAL|therapeutic allogeneic lymphocytes|
57729789|NCT03903133|DRUG|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
58071992|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
58071993|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
58071994|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
58289728|NCT00027547|DRUG|cyclosporine|
58289729|NCT00027547|DRUG|cytarabine|
58289730|NCT00027547|DRUG|fludarabine phosphate|
58289731|NCT00027547|DRUG|methotrexate|
58289732|NCT00027547|DRUG|mycophenolate mofetil|
58289733|NCT00027547|PROCEDURE|allogeneic bone marrow transplantation|
58289734|NCT00027547|PROCEDURE|peripheral blood stem cell transplantation|
58289735|NCT00027547|RADIATION|radiation therapy|
58289736|NCT01462864|BEHAVIORAL|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
58289737|NCT03126461|RADIATION|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
58289738|NCT03126461|DRUG|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
58289739|NCT03126461|DRUG|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
58289740|NCT00297661|DEVICE|Sirolimus-eluting stent|
58289741|NCT00297661|DEVICE|Paclitaxel-eluting stent|
58289742|NCT00404209|PROCEDURE|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
58289743|NCT01684852|OTHER|Medical device, drug-like|
57934174|NCT05245019|BIOLOGICAL|fennel|fennel is Known for its anti-inflammatory, anti-spasmodic, and analgesic properties, it is also widely used for treating gastroenteritis and indigestion.
57934175|NCT03512691|BEHAVIORAL|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
57934176|NCT03512691|BEHAVIORAL|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
57934177|NCT03025763|OTHER|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
57934178|NCT03025763|OTHER|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
57934179|NCT03025763|PROCEDURE|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
57934180|NCT03025763|PROCEDURE|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
57934181|NCT03025763|PROCEDURE|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
57934182|NCT03025763|PROCEDURE|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
57934183|NCT03025763|PROCEDURE|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
57934184|NCT00285883|DRUG|Invirase|
57934185|NCT00285883|DRUG|Norvir|
57934186|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
57934187|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
57934188|NCT02823249|DIETARY_SUPPLEMENT|50 g Xylitol|
57934189|NCT02823249|DIETARY_SUPPLEMENT|75 g Erythritol|
57934190|NCT02823249|DIETARY_SUPPLEMENT|75 g Glucose|
57934191|NCT02823249|DIETARY_SUPPLEMENT|Tap water|
58289744|NCT00691288|DRUG|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
58289745|NCT00691288|DRUG|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
58289746|NCT04262063|BEHAVIORAL|Tell play do technique|it apply the concept of learning by doing .children will enjoy playing with customized dental models
58289747|NCT04262063|BEHAVIORAL|tell show do|Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
58289748|NCT00656175|DRUG|raltegravir|raltegravir
58289749|NCT05739071|DIETARY_SUPPLEMENT|JING SI HERBAL TEA|JING SI HERBAL TEA is a food, contain with herbal extracts
58289750|NCT05739071|DIETARY_SUPPLEMENT|Placebo|Placebo will have the same appearance as JING SI HERBAL TEA
57934192|NCT02823249|DIETARY_SUPPLEMENT|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
57934193|NCT02823249|DEVICE|Nasogastric Tube|
57934194|NCT02354781|BIOLOGICAL|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
57934195|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
57934196|NCT04042740|DRUG|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
57934197|NCT02237404|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
58071995|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
57934198|NCT01708291|BEHAVIORAL|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
58289751|NCT02943798|DRUG|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
58289752|NCT02943798|DRUG|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
58071996|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
57934199|NCT01708291|BEHAVIORAL|only pre and post evaluation measures|
57934200|NCT00448435|DRUG|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
57934201|NCT00448435|DRUG|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
57934202|NCT01817283|DRUG|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
58095102|NCT05769192|OTHER|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
58095103|NCT03260491|DRUG|HER3-DXd (FL-DP)|HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
58289753|NCT03984214|DRUG|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
58289754|NCT03984214|DRUG|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
58289755|NCT05482503|DEVICE|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
58289756|NCT00964379|PROCEDURE|intraperitoneal or extraperitoneal colostomy|creation of colostomy
58289757|NCT00420628|DRUG|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
58289758|NCT00420628|DRUG|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
58289759|NCT01863615|DRUG|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
57934203|NCT01817283|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
57729790|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
57934204|NCT01817283|DRUG|placebo|Placebo pills produced the same as Triptolide wilfordii.
57934205|NCT03661944|DIAGNOSTIC_TEST|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
57934206|NCT01717287|DRUG|Raltegravir Film-coated Tablet|
57934207|NCT01717287|DRUG|Raltegravir Chewable Tablet|
57934208|NCT01717287|DRUG|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
57934209|NCT04634396|BEHAVIORAL|ACT Acceptance and Commitment Therapy|6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
57934210|NCT05104021|DEVICE|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
58402469|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
58402470|NCT01888536|DRUG|Limaprost|
58402471|NCT01888536|DRUG|Pregabalin|
58402472|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
58402473|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
58402474|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
58402475|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
58402476|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
58402477|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
58402478|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
58402479|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
58402480|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
58095104|NCT03260491|DRUG|HER3-DXd (CTM-1 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
58289760|NCT01863615|DRUG|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
58289761|NCT04690634|PROCEDURE|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
58289762|NCT05767593|DEVICE|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
58289763|NCT03430908|OTHER|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
58289764|NCT02335879|BIOLOGICAL|Gonal-F|
58289765|NCT04964336|OTHER|Analysis of B cells|B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
58402481|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
58402482|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
58402483|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
58402484|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
58402485|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
58402486|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
58402487|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
58402488|NCT02947178|DRUG|Bupivacaine|
58402489|NCT02947178|DRUG|Liposomal Bupivacaine|
58402490|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
57934211|NCT00478101|DRUG|oxycodone fentanyl|
57934212|NCT04633174|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
57934213|NCT00251381|DRUG|Cetuximab|
57934214|NCT01951781|OTHER|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
57934215|NCT02500667|DRUG|N91115|200 mg BID
57934216|NCT02500667|DRUG|Rifampin|600 mg QD
57934217|NCT03305939|BEHAVIORAL|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
57934218|NCT01292447|DRUG|2% lidocaine gel|120mg lidocaine x 1
57934219|NCT01292447|DRUG|Placebo gel|Inert gel x 1
57934220|NCT01052896|DRUG|Gabapentin|300mg po TID
57934221|NCT01052896|DRUG|Placebo|Look-alike of gabapentin 300mg given po tid
57934222|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
57934223|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
57934224|NCT00356616|DRUG|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
57934225|NCT00356616|DRUG|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
58095105|NCT03260491|DRUG|HER3-DXd (CTM-3 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
58289766|NCT05118997|DEVICE|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
58289767|NCT05118997|DEVICE|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
58289768|NCT05207202|DEVICE|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
58289769|NCT01691417|DEVICE|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
58289770|NCT02090777|BEHAVIORAL|Health Coach|
58289771|NCT03970759|DRUG|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
58289772|NCT03970759|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
58289773|NCT03970759|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
58289774|NCT01351090|DRUG|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
58402491|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
58095106|NCT02912884|DRUG|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
58289775|NCT01351090|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
58289776|NCT01351090|DRUG|Placebo|Intranasal
58289777|NCT02259205|OTHER|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
58289778|NCT02259205|OTHER|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
58289779|NCT06404359|OTHER|Exercise|"There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets."
58289780|NCT06404359|OTHER|Physical activity recommendations|They will be provided with a physical activity plan to be followed on a weekly basis.
58289781|NCT06265337|DIETARY_SUPPLEMENT|Lactate|Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
57934226|NCT04119141|DIAGNOSTIC_TEST|X ray imaging|"Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions."
57934227|NCT03794583|DRUG|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
57934228|NCT01528813|DEVICE|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
57934229|NCT01528813|DRUG|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
57934230|NCT06734052|BEHAVIORAL|CAPPA|See CAPPA arm description.
57934231|NCT06734052|BEHAVIORAL|Health education|See health education arm description
57934232|NCT06292000|BEHAVIORAL|AM Exercise|Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
57934233|NCT06292000|BEHAVIORAL|PM Exercise|Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
57934234|NCT05368961|BEHAVIORAL|Distraction|Distraction (interactive tablet)
58071997|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
58071998|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
58071999|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
58072000|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
58072001|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
58072002|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
58072003|NCT04018716|DEVICE|MTA|Indirect capping with MTA
58402492|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
58402493|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
57934235|NCT05368961|OTHER|Usual care|Anxiolytic ordered by anesthesiologist is usual care
57934236|NCT02194036|BEHAVIORAL|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
57934237|NCT02194036|BEHAVIORAL|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
57934238|NCT02630446|OTHER|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
57934239|NCT06734364|DEVICE|buddy tape|Buddy-taping a finger dynamically splints one finger to an adjacent, uninjured finger.
57934240|NCT06734364|DEVICE|splint|Short arm splint immobilize and maintain stability of the injured finger, the hand is immobilized in the intrinsic plus position with syndactyly of the injured finger and adjacent finger
57934241|NCT00233688|DEVICE|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
57934242|NCT00233688|PROCEDURE|Open surgical repair|Open surgical repair
57934243|NCT02656498|DRUG|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
58072004|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
58289782|NCT06265337|OTHER|Placebo|Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
58289783|NCT03837457|DRUG|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
58289784|NCT00187785|BEHAVIORAL|Spanish speaker level|
58289785|NCT05853718|DRUG|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
58072005|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
57934244|NCT02917668|OTHER|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
57934245|NCT02917668|OTHER|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %
57934246|NCT02366975|DRUG|Testosterone gel 2%|testosterone gel 2% (50mg/die).
57934247|NCT02366975|OTHER|Placebo|placebo gel
57934248|NCT00763971|DRUG|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
57934249|NCT00763971|DRUG|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
57934250|NCT00763971|DRUG|Placebo|Placebo capsule once per day (Overencapsulated)
57934251|NCT04070755|DRUG|FMX-101|
57934252|NCT06735703|DRUG|To provide ampicillin sulbactam to pregnant women with premature rupture of membrane|To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
57934253|NCT06379048|PROCEDURE|Matress Suturing|Horizontal matress suture in interrupted fashion
58072006|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
58072007|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
58289786|NCT01830933|OTHER|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
58289787|NCT05038449|DRUG|Colchicine Tablets|Colchicine Tablets (Each tablet contains colchicine 0.5mg)
57934254|NCT06379048|PROCEDURE|Primary Suturing|Horizontal primary suture in interrupted fashion
57934255|NCT06379048|PROCEDURE|Continuous Subcutaneous Suturing|Subcutaneous suture in continuous fashion
57934256|NCT03979222|DEVICE|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
58289788|NCT05038449|DRUG|Standard therapy|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
58289789|NCT06361888|DRUG|Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
58289790|NCT06361888|DRUG|Nab-paclitaxel Plus Gemcitabine|"Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
57729791|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
57934257|NCT00000420|DRUG|Ortho-Novum 777|
57934258|NCT03602274|DIAGNOSTIC_TEST|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
57934259|NCT03602274|DIAGNOSTIC_TEST|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
57934260|NCT03602274|OTHER|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
57934261|NCT02459769|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
57934262|NCT00324753|BEHAVIORAL|Communication|Communication sheet
57934263|NCT00324753|BEHAVIORAL|Standard of care|Standard of care brochures
57934264|NCT05371509|DEVICE|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
57934265|NCT05371509|OTHER|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
57934266|NCT02903069|DRUG|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
57934267|NCT02903069|DRUG|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
57934268|NCT02903069|RADIATION|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
57934269|NCT02903069|DEVICE|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
57934270|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
58072008|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
58072009|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
58072010|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
58289791|NCT06361888|DRUG|Surufatinib with Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
58402494|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
58402495|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
57934271|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
57934272|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
57934273|NCT05762523|BIOLOGICAL|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
57934274|NCT01891097|PROCEDURE|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
57934275|NCT01891097|PROCEDURE|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
57729792|NCT05881044|OTHER|Psychiatric interview|"1. Psychiatric interview which include personal identification, present history, past history and family history~2. Complete physical and Neurological Examination.~3. Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~4. Symptom checklist 90(SCL 90)~5. Quality of life questionnaire.~6. Hamilton Depression scale.~7. Hamilton Anxiety scale.~8. Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
57934276|NCT02555696|DRUG|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
57934277|NCT01777412|DRUG|Bevacizumab|
57934278|NCT06296589|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Behavioral therapy for trauma related guilt and shame
57934279|NCT06296589|BEHAVIORAL|Prolonged Exposure Therapy|Behavioral exposure therapy for PTSD
58289792|NCT05341791|OTHER|Cartoon video describing study information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
58289793|NCT00073762|DRUG|DVS-233 SR|
58289794|NCT04232345|DRUG|AZD4831|Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
58289795|NCT04232345|DRUG|Placebo|Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
58402496|NCT00467545|DRUG|telbivudine|
58402497|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
57934280|NCT04752020|DRUG|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
57951218|NCT03825874|OTHER|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
57951219|NCT03572985|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
57951220|NCT03572985|OTHER|Car-following test|Driving with simulator program for DCV measurement
57951221|NCT03572985|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
57951222|NCT00923390|GENETIC|2G-1 TCR Retroviral Vector-Transduced lyn|
58289796|NCT00004067|BIOLOGICAL|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
58289797|NCT00004067|DRUG|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
58289798|NCT00004067|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
58289799|NCT00004067|DRUG|taxol|175 mg/m2 IV every 21 days for 4 cycles
58402498|NCT00003406|DRUG|carboplatin|
58402499|NCT00003406|DRUG|docetaxel|
58402500|NCT00003406|DRUG|ifosfamide|
58402501|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
58402502|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
58402503|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
58402504|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
57729793|NCT05776563|OTHER|Magnetic Resonance Spectroscopy Imaging (MRSI)|baseline 1HMRSI imaging study, then will undergo intensification of their diabetes management for a period of 12-week and at the end of the intervention they will undergo 1H MRSI scanning to measure intracerebral and plasma glucose levels at euglycemia and following 2 hours of hyperglycemia using the clamp technique (target glucose 220 mg/dl) in the occipital region
57934281|NCT03426423|OTHER|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
57934282|NCT03426423|OTHER|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
57729794|NCT00135954|DRUG|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
57934283|NCT05803434|DRUG|Cannabidiol oral solution|"Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks."
57934284|NCT05351047|DRUG|AZD2373 subcutaneous injection|Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
57934285|NCT05351047|DRUG|Placebo|Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
57951223|NCT00923390|DRUG|Aldesleukin|
58072011|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
58072012|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
58072013|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
58072014|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
58072015|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
58402505|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
57729795|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
57729796|NCT06021717|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
57729797|NCT06021717|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
57729798|NCT00941239|DRUG|metformin ER|850mg daily for 30 days
57729799|NCT00941239|DRUG|metformin|850 mg daily for 30 days
57729800|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
57729801|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
57729802|NCT01699594|DRUG|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
57729803|NCT01699594|DRUG|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
57729804|NCT04915963|DIETARY_SUPPLEMENT|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
57951224|NCT00923390|DRUG|Cyclophosphamide|
57951225|NCT00923390|DRUG|Fludarabine|
57951226|NCT00923390|DRUG|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
58072016|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
58072017|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
58072018|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
57934286|NCT04692038|DEVICE|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
57934287|NCT04613856|OTHER|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
58072019|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
58072020|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
58289800|NCT03943355|OTHER|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
58289801|NCT03943355|OTHER|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
58289802|NCT03911076|BIOLOGICAL|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
58289803|NCT03911076|OTHER|Placebo|PBS and PGC
58289804|NCT05718674|PROCEDURE|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
58289805|NCT00578279|DRUG|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
58289806|NCT04626609|OTHER|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
57934288|NCT04613856|OTHER|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
58072021|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
58289807|NCT04626609|OTHER|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
58289808|NCT06010602|PROCEDURE|Quadratus lumborum block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
58289809|NCT06010602|PROCEDURE|İlioinguinal-İliohipogastric nerve block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
58289810|NCT05582629|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
58289811|NCT05582629|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
58289812|NCT01973426|DEVICE|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
58289813|NCT03864991|DEVICE|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
58289814|NCT03864991|BEHAVIORAL|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
57934289|NCT00686270|DRUG|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
57934290|NCT04910477|DRUG|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
57934291|NCT04910477|DRUG|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
57934292|NCT04910477|OTHER|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
57934293|NCT01375335|DRUG|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
57934294|NCT01434251|OTHER|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
58289815|NCT03864991|BEHAVIORAL|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
57934295|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
57934296|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
57934297|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
57934298|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
57934299|NCT01921855|DRUG|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
57934300|NCT04652713|OTHER|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
57934301|NCT04652713|OTHER|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
57934302|NCT04652713|OTHER|No breakfast|1 glas of water (150 ml)
57934303|NCT00303420|DRUG|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
57934304|NCT00303420|DRUG|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
57934305|NCT03746951|DRUG|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
58095107|NCT04711824|DRUG|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
58289816|NCT03234803|OTHER|poly-amide|new denture base material
57934306|NCT02304848|OTHER|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
57934307|NCT05218590|DEVICE|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
57934308|NCT06727240|DEVICE|Intervention|The interventional device is a coupling device intended to prevent mechanical complications during peripheral intravenous infusions. While control will not receive the device.
57934309|NCT03706404|DIAGNOSTIC_TEST|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
57934310|NCT00347165|DRUG|bevacizumab intravitreal injection|
57934311|NCT03916887|BEHAVIORAL|Golf instruction|Non-golfers instructed to golf over 10 weeks
57934312|NCT04726007|DRUG|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
57934313|NCT04345081|PROCEDURE|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
57934314|NCT04345081|PROCEDURE|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
57934315|NCT01795300|RADIATION|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
57934316|NCT01795300|RADIATION|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
57951227|NCT04718974|OTHER|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
57951228|NCT05284942|DRUG|Mycophenolate mofetil combined with oral prednisone|Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108
58095108|NCT04711824|RADIATION|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
58095109|NCT04711824|DRUG|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
58289817|NCT03234803|OTHER|poly-methyl methacrylate|gold standard for denture base materials
58289818|NCT02446548|DRUG|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
58289819|NCT02446548|DRUG|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
58289820|NCT02446548|OTHER|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
58289821|NCT03883763|DRUG|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 20 mg
58289822|NCT03883763|DRUG|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 20 mg
58289823|NCT04719598|BEHAVIORAL|congnitive behavioural therapy|CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
58289824|NCT00417157|DRUG|recombinant FSH (Puregon, Organon, The Netherlands)|
58402506|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
58402507|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
58402508|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
57934317|NCT01795300|RADIATION|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
57934318|NCT01795300|RADIATION|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.
58402509|NCT03466099|OTHER|Sham Procedure|Sham Procedure
58402510|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
58402511|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
58402512|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
58402513|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
58402514|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
58402515|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
57934319|NCT03626584|OTHER|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
57934320|NCT02086851|BEHAVIORAL|Lifestyle Intervention|
57934321|NCT02086851|BEHAVIORAL|Parent Motivational Interviewing|
57934322|NCT04877795|DIAGNOSTIC_TEST|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
57934323|NCT05248451|OTHER|Not an Interventional Study|Not an Interventional Study
57934324|NCT06083831|OTHER|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
58289825|NCT00417157|DRUG|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
58289826|NCT00417157|DRUG|hCG (Pregnyl, Organon, The Netherlands)|
58289827|NCT03060369|DEVICE|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
58289828|NCT04391842|COMBINATION_PRODUCT|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device"
58289829|NCT06267820|DRUG|Bupivacain|analgesia
58289830|NCT06267820|DRUG|Ketorolac|analgesia
58289831|NCT04961697|BEHAVIORAL|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
58402516|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
58402517|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
58402518|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
58072022|NCT06713577|DEVICE|CEREC Cercon 4D|"One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations."
58402519|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
58402520|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
57934325|NCT06142760|RADIATION|MR-guided radiation|Dayly artifical intelligence-based treatment adaptation under weekly offline MR-guidance
57934326|NCT02393677|DRUG|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
57934327|NCT02393677|DRUG|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
58402521|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
57934328|NCT02187679|DRUG|Abobotulinum toxin A|
57934329|NCT04621396|OTHER|Observational screening study|
58402522|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
58402523|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
57934330|NCT02903082|BIOLOGICAL|Residue of blood further to NFS|
57934331|NCT02903082|BIOLOGICAL|Residue of blood further to preoperative workup|
57934332|NCT02903082|BIOLOGICAL|Bone marrow collected during a myelogram carried out for hematological pathology workup|
58072023|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
58072024|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
58072025|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
58402524|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
58402525|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
58402526|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
57934333|NCT02903082|BIOLOGICAL|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
57934334|NCT06007638|DRUG|LY3876602|Administered IV.
57934335|NCT06007638|DRUG|Placebo|Administered IV.
58402527|NCT02803177|BIOLOGICAL|BMC2012|
58402528|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
57934336|NCT02966223|RADIATION|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
57934337|NCT03967782|BEHAVIORAL|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
57951229|NCT01858077|DEVICE|ABSORB BVS™|Bioresorbable scaffold
57951230|NCT01858077|DEVICE|XIENCE™|Drug eluting metallic stent
58402529|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
58402530|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
58289832|NCT02731274|OTHER|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
58289833|NCT06054763|COMBINATION_PRODUCT|Buyang Huanwu Decoction|Buyang Huanwu Decoction is a common prescription for treating stroke. The possible mechanism is to replenish qi, activate blood circulation, and remove blood stasis.
58402531|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
57934338|NCT03967782|BEHAVIORAL|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
58072026|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
58072027|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
58072028|NCT06624475|DRUG|Nivolumab|Nivolumab is a fully humanized monoclonal antibody that binds to the PD-1 receptor, blocking its interactions with PD-L1 and PD-L2, and thus additionally inhibiting PD1-driven immune suppression. Nivolumab 490 mg via IV administration 28 day cycle
58072029|NCT06624475|DRUG|Opdualag|Opdualag (Opdualag) is supplied as a single dose vial containing 240 mg of Nivolumab and 80 mg. Relatlimab per 20 mL for intravenous administration ; 28 day cycle.
58072030|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
58072031|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
58072032|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
58402532|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
57729805|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
57729806|NCT01082666|DEVICE|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
57729807|NCT01082666|DEVICE|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
57934339|NCT03967782|BEHAVIORAL|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
57934340|NCT06131333|PROCEDURE|Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation|PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
58072033|NCT02399345|DRUG|ribavirin (RBV)|tablet
58072034|NCT04706026|OTHER|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
58289834|NCT06054763|OTHER|Placebo|90% starch and 10% Buyang Huanwu Decoction
58289835|NCT05883163|DEVICE|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
58289836|NCT02778152|DEVICE|Laser depilation|Laser depilation of natal cleft (pilonidal region)
58289837|NCT01923675|OTHER|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
58289838|NCT01923675|OTHER|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
58289839|NCT01923675|OTHER|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
58402533|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
58402534|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
58402535|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
58402536|NCT01777217|DRUG|Placebo|IGRT with placebo
58402537|NCT02965183|OTHER|Temperature measurements|
58402538|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
58402539|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
57934341|NCT05232006|DRUG|Niraparib|Niraparib, once daily
57934342|NCT06288945|OTHER|Educational Program|The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
57934343|NCT02073071|OTHER|Preterm infant formula per standard of care|Commercially available preterm infant formula
57934344|NCT00467389|DRUG|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
57934345|NCT00467389|OTHER|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
57934346|NCT02098720|DRUG|Conbercept|
57934347|NCT02247765|DEVICE|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
57934348|NCT02247765|DEVICE|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
57934349|NCT00796848|DEVICE|Navigator Continuous Glucose Monitor|
57934350|NCT05716009|DRUG|Dose Escalation -tagraxofusp-erzs|Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
57934351|NCT05716009|DRUG|Dose Expansion at RP2D -tagraxofusp-erzs|Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
57934352|NCT01756469|BEHAVIORAL|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
57934353|NCT06241209|OTHER|PowerPoint program visual stimulation|Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
57934354|NCT04830150|BEHAVIORAL|Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).|This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
58289840|NCT01923675|OTHER|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
58402540|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
58402541|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
58402542|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
58402543|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
57934355|NCT04788576|DIAGNOSTIC_TEST|Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)|In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
57934356|NCT06735963|DEVICE|Meta Quest 3 Virtual Reality|Immersive virtual reality Meta Quest 3 device
57934357|NCT06735963|PROCEDURE|Exercise|Traditional exercise program for knee OA patients
57934358|NCT06735963|DEVICE|Electrotherapy|Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
57934359|NCT04257383|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
57934360|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 6
57934361|NCT01843972|DRUG|BI 691751|oral solution
57934362|NCT01843972|DRUG|Placebo|placebo solution
57934363|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 2
58072035|NCT04706026|OTHER|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
58289841|NCT05708040|DEVICE|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
58289842|NCT05708040|DEVICE|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
57934364|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 5
57934365|NCT01843972|DRUG|BI 691751|1 tablet
57934366|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 3
58289843|NCT04245917|OTHER|Non-interventional|Non-interventional natural history study
57934367|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 4
57934368|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 7
57934369|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 1
57934370|NCT06494709|OTHER|photographs|"Standardized photographs presenting 10 control subjects (class I) and patients with dentofacial deformities (10 class II and 10 class III) before and after surgery - from the front and from the side - will be used to form an approximately 10 min video sequence using the Tobii Pro Lab® software (Tobii Pro AB, Danderyd, Sweden). The naive participants will look at the percept during which the faces of the controls and the patients will alternate, with the only instruction being free visual exploration of the percept.~The fixation duration in the defined areas of interest (eyes, nose, mouth, chin) will be recorded with a Tobii® Pro X3-120 eye-tracking device and the results will be processed with the Tobii Pro Lab® software."
58072036|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
57934371|NCT06249724|DEVICE|Active stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused low-intensity ultrasound stimulation
57934372|NCT06249724|DEVICE|Sham stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused zero-intensity ultrasound stimulation
57934373|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
57934374|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
57934375|NCT03536390|DRUG|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
57934376|NCT03536390|DRUG|Placebo|Placebo
57934377|NCT03707132|PROCEDURE|Tourniquet: Folley catheter in the low segment of the uterus|
58072037|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
58072038|NCT06722781|BEHAVIORAL|Unified Protocol|The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.
58072039|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
58072040|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
58072041|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
58072042|NCT05524376|OTHER|no intervention|no intervention
58072043|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
58072044|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
58072045|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
58072046|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
58072047|NCT06018766|DRUG|LAM-001|LAM-001 administered via dry powder inhaler
58072048|NCT06018766|DRUG|Placebo|Placebo administered via dry powder inhaler
57934378|NCT00470236|RADIATION|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
57934379|NCT00470236|RADIATION|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
57934380|NCT00470236|RADIATION|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
57934381|NCT00470236|RADIATION|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
57934382|NCT03176563|DRUG|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
57934383|NCT03176563|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
57934384|NCT03176563|DRUG|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
57934385|NCT03176563|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
57934386|NCT06706310|DRUG|Placebo|Placebo contains no active substance.
57934387|NCT06706310|DRUG|TQA3334 Tablet|Inhibit viral replication.
57934388|NCT06706310|DRUG|Nucleoside (acid) analogs (NAs)|Inhibit viral replication.
57934389|NCT02370680|DRUG|Aspirin|steady-state run-in prior to Durlaza treatment
58072049|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
58095110|NCT04711824|DRUG|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
58095111|NCT06420427|DIAGNOSTIC_TEST|Assess the risk of recurrence and the efficacy of medication|Evaluation of recurrence risk and medication efficacy through liquid biopsy
58095112|NCT03608072|DRUG|BI 690517|3 sequential dose groups
57934390|NCT02370680|DRUG|Durlaza™|comparison of different numbers of capsules
57934391|NCT04961853|RADIATION|Ultrasound and MRI|Ultrasound examination and magnetic resonance imaging on the hand
57934392|NCT00749879|DRUG|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
57934393|NCT01614821|DRUG|PCI-32765|Taken orally, once daily in the morning
57934394|NCT04906616|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
57934395|NCT02742467|DRUG|Perindopril plus Amlodipine|Group 1
57934396|NCT02742467|DRUG|Perindopril plus Hydrochlorothiazide|Group 2
57934397|NCT02742467|DRUG|Amlodipine plus Hydrochlorothiazide|Group 3
57934398|NCT03859726|DIAGNOSTIC_TEST|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
57934399|NCT03859726|DIAGNOSTIC_TEST|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
57934400|NCT05731570|BEHAVIORAL|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
57934401|NCT00727649|DRUG|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
57934402|NCT00727649|DRUG|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
57934403|NCT06091761|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
57934404|NCT06091761|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
57934405|NCT06091761|OTHER|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
57934406|NCT00390611|DRUG|Sorafenib|
58072050|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
58072051|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
58072052|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
58072053|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
58072054|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
58072055|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
58072056|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
58072057|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
58095113|NCT03608072|DRUG|Placebo|3 sequential dose groups
58289844|NCT00527137|DRUG|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
58402544|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
57934407|NCT00390611|DRUG|Paclitaxel|Paclitaxel
57934408|NCT00390611|DRUG|Carboplatin|Carboplatin
58402545|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
58402546|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
58402547|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
58402548|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
58402549|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
58402550|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
58402551|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
58402552|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
58402553|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
58402554|NCT01220973|DRUG|atorvastatin calcium|
58402555|NCT01220973|DRUG|celecoxib|
58402556|NCT01220973|OTHER|laboratory biomarker analysis|
58289845|NCT00527137|DRUG|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
58402557|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
58402558|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
58402559|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
58289846|NCT03193229|BEHAVIORAL|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
58289847|NCT03193229|DEVICE|Fitbit|Fitbit
58289848|NCT01792765|OTHER|Ultrasound guidance|Patient will have intraoperative ultrasound .
58289849|NCT04219592|DIAGNOSTIC_TEST|IgG4 measurement (non-interventional, just obtaining data from medical records)|IgG4 measurement in mg/dL
58289850|NCT01559610|OTHER|Intervention Group|The patients were instructed by a nurse
58289851|NCT00426764|DRUG|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
58289852|NCT05139420|OTHER|phentermine-topiramate combined with lifestyle intervention|participants will be enrolled in a medical weight loss program and will be offered a 6 month prescription for phentermine-topiramate (note: The goal of the study is NOT to assess efficacy or safety of this drug) in addition to lifestyle advice.
58289853|NCT05139420|OTHER|lifestyle intervention with meal replacement program|participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
58289854|NCT06587633|DEVICE|Endoscopic procedure|tSVFem injection + 3D scaffold placement
58289855|NCT03509181|BEHAVIORAL|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
58402560|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
58402561|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
58490719|NCT04207619|OTHER|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
58289856|NCT03509181|BEHAVIORAL|Symptom Tracking|smartphone delivered self-monitoring of anxiety and depression symptoms
58289857|NCT03987113|OTHER|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
58289858|NCT04482907|DIETARY_SUPPLEMENT|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
58490720|NCT04207619|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
58289859|NCT00448240|DRUG|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
58289860|NCT00878800|DRUG|PXD101|Administered in combination with doxorubicin (BelDox)
58289861|NCT00878800|DRUG|Doxorubicin|Administered in combination with PXD101 (BelDox)
58289862|NCT05640063|OTHER|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
58289863|NCT06101147|DRUG|Vitamin D3|These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
58289864|NCT06101147|DRUG|Placebo Oral Tablet|These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
58289865|NCT02991248|DEVICE|robotic training|robotic training by applying pelvis force perturbation
58289866|NCT02991248|DEVICE|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
58289867|NCT02991248|DEVICE|treadmill|conventional treadmill training only
58490721|NCT01549418|DRUG|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
58289868|NCT02732288|DIETARY_SUPPLEMENT|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
58289869|NCT01383018|DEVICE|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
58289870|NCT04611022|BEHAVIORAL|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
58289871|NCT01535313|DEVICE|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
58289872|NCT01229215|DRUG|FCFD4514S|Repeating intravitreal injection
58289873|NCT01229215|DRUG|sham|Repeating sham injection
58289874|NCT05695729|OTHER|PLYOMETRIC EXERCISE PROGRAM|"This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band"
58289875|NCT05695729|OTHER|CONVENTIONAL EXERCISE PROGRAM|"This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds"
58289876|NCT01488552|DRUG|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
58289877|NCT01488552|DRUG|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
58289878|NCT01488552|DRUG|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
58289879|NCT01488552|GENETIC|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
58289880|NCT01488552|DRUG|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
57729808|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
57934409|NCT02992314|DEVICE|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
58289881|NCT01488552|DRUG|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
58289882|NCT00002168|DRUG|Indinavir sulfate|
58289883|NCT00002168|DRUG|Lamivudine|
57934410|NCT02992314|DEVICE|Placebo|Placebo formulation with out the active ingredients
57934411|NCT01606020|OTHER|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
58289884|NCT00002168|DRUG|Stavudine|
58289885|NCT00002168|DRUG|Zidovudine|
58490722|NCT01549418|DRUG|Placebo|
58490723|NCT04197219|DRUG|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
57729809|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
57729810|NCT00004181|DRUG|busulfan|
57729811|NCT00004181|DRUG|cyclophosphamide|
57729812|NCT00004181|PROCEDURE|allogeneic bone marrow transplantation|
57729813|NCT00004181|RADIATION|radiation therapy|
57729814|NCT00817089|DRUG|Placebo Oral Tablet|Placebo pill
57729815|NCT00817089|DRUG|Naltrexone|50 mg of naltrexone prior to challenge session
57729816|NCT00237744|DEVICE|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
57729817|NCT00237744|DEVICE|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
57729818|NCT00237744|OTHER|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
57729819|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
57729820|NCT03998826|DRUG|Piroxicam|20mg piroxicam
57729821|NCT03998826|DRUG|Placebo|placebo
57729822|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
57729823|NCT02219932|DRUG|fampridine|
57729824|NCT02219932|DRUG|Placebo|Matched placebo
57729825|NCT05130112|DEVICE|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
57729826|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
57729827|NCT04775446|OTHER|Data collection|Data entered in a secure computer database
57934412|NCT01606020|OTHER|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
57934413|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
57934414|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
57934415|NCT00955487|DRUG|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
57934416|NCT00955487|DRUG|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
57934417|NCT01558427|PROCEDURE|Surveillance|Active clinical surveillance
57934418|NCT01558427|PROCEDURE|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
58289886|NCT00002168|DRUG|Didanosine|
58289887|NCT04686708|OTHER|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
58490724|NCT04197219|DRUG|Axitinib|5 mg PO BID continuously
58490725|NCT01519167|DRUG|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
58490726|NCT01519167|DRUG|Midazolam|0.025 - 2 mg/kg IV
58490727|NCT01519167|DRUG|Fentanyl|0.5 - 3 mcg/kg IV
57934419|NCT06272292|DIAGNOSTIC_TEST|EOS|Every subject in this study will undergo a radiographic analysis of the hip and spine using a low-dose, full-body biplanar X-ray acquisition (in standing, sitting and squatting position, EOS imaging).
57934420|NCT06272292|DIAGNOSTIC_TEST|3D motion lab analysis|"A hip-specific 3D motion analysis will be performed. The 3D motion protocol will be divided into 2 main sections.~First section: Consist of movements categorized within the activities of daily living (walking at self-selected speed, uphill walking, standardized deep squat and non-standardized deep squat)~Second section: Consists of movements that are categorized within athletic training and have been specifically chosen to induce large hip ranges of motion (Sumo squats, dead lifts, forward lunges, running uphill and downhill)~Each movements will be repeated 6 times. Three times with the dominant foot/opposite leg on the force plate to collect kinetic data. All data will be captured using two 10-15 camera 3D motion capture systems and one capturing an instrumented treadmill (M-gait)"
57934421|NCT06177028|DRUG|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
57934422|NCT04970550|OTHER|Non intervention|Non intervention
57934423|NCT02827669|BEHAVIORAL|One Drop Experts Program|
57934424|NCT02827669|BEHAVIORAL|One Drop Experts Program + Apple Watch|
57934425|NCT01660451|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
57934426|NCT03829241|DRUG|Troriluzole|100 mg capsule
57934427|NCT03829241|DRUG|Placebo|Placebo matched to troriluzole
57934428|NCT04295616|DEVICE|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
57934429|NCT04295616|BEHAVIORAL|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
58289888|NCT02954549|DIETARY_SUPPLEMENT|Vitamin D3|As in Arms
58402562|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
58402563|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
58402564|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
58402565|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
57934430|NCT03836820|OTHER|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
57934431|NCT03836820|OTHER|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
57951231|NCT02970890|DEVICE|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
58289889|NCT04162795|DRUG|Loratadine (Claritin, BAY76-2211)|Chewable tablet, oral, single dose
57934432|NCT03836820|OTHER|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
57934433|NCT05196425|GENETIC|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
57934434|NCT00631189|DRUG|Rosuvastatin|5mg oral
57934435|NCT00631189|DRUG|Pravastatin|40mg oral
57934436|NCT00631189|DRUG|Atorvastatin|10mg oral
57934437|NCT04528862|BEHAVIORAL|Nature slides|participants will view a presentation of nature slides
57934438|NCT04528862|BEHAVIORAL|Urban slides|participants will view a presentation of urban slides
57934439|NCT04300582|PROCEDURE|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
57934440|NCT04300582|PROCEDURE|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
57934441|NCT00890929|DRUG|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
57934442|NCT00890929|DRUG|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
58072058|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
58072059|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
58072060|NCT01778673|PROCEDURE|Cast immobilization|
58072061|NCT05776511|PROCEDURE|eVOG|video digital oculography
58072062|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
58072063|NCT05144516|BEHAVIORAL|Behavioral: COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
58072064|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
58072065|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
58072066|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
57934443|NCT03976791|PROCEDURE|enlarged internal incision|enlarging the internal incision about 0.4mm
57934444|NCT03976791|PROCEDURE|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
57934445|NCT00717054|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
57934446|NCT00717054|DRUG|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
57934447|NCT04733339|BEHAVIORAL|Secondary Prevention|behavioral changes in dieting and exercising up to one year after clinical discharge
57934448|NCT00158873|DRUG|midazolam|
57934449|NCT00158873|DRUG|lorazepam|
57934450|NCT00158873|DRUG|fentanyl|
57934451|NCT00158873|DRUG|morphine|
57934452|NCT00158873|DRUG|remifentanil|
57934453|NCT00158873|DRUG|propofol|
57934454|NCT05599789|DRUG|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
57934455|NCT01755845|DRUG|paclitaxel|
57934456|NCT01755845|DRUG|cisplatin|
57934457|NCT01755845|RADIATION|radiotherapy|
57934458|NCT00905684|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
57934459|NCT00905684|DRUG|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
57934460|NCT03864445|DRUG|KHK7791|oral administration
57934461|NCT03864445|DRUG|Placebp|oral administration
57934462|NCT00244972|OTHER|Laboratory Biomarker Analysis|Correlative studies
57934463|NCT00244972|DRUG|Sorafenib Tosylate|Given PO
57934464|NCT00244972|DRUG|Tipifarnib|Given PO
57934465|NCT06508112|DEVICE|Masimo Radical-7® Pulse CO-Oximeter|Masimo Radical-7® Pulse CO-Oximeter device was attached to the index finger of the patients in the supine position and photoplethysmographic perfusion index and plethysmographic variability index were measured noninvasively, rapidly and continuously.
57934466|NCT05327556|DRUG|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
57934467|NCT05327556|DRUG|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
57934468|NCT05126901|DRUG|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
57934469|NCT05126901|DRUG|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
58072067|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
58072068|NCT06097364|DRUG|Vincristine|Administered by IV infusion
58072069|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
58072070|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
58072071|NCT01365897|DRUG|Modafinil|Modafinil 200mg
58072072|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
58072073|NCT06290934|DRUG|GS-1427|Administered orally
58072074|NCT06290934|DRUG|Placebo-to-match GS-1427|Administered orally
58490728|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
57934470|NCT01584076|DRUG|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
57934471|NCT01584076|OTHER|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
57934472|NCT05351151|PROCEDURE|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
57934473|NCT05351151|PROCEDURE|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
57934474|NCT03398525|OTHER|usual care|usual care following local standard operational procedures
57934475|NCT03398525|OTHER|Musical intervention|Musical intervention using a marketed music program validated for music therapy
57934476|NCT00184080|DRUG|Elsamitrusin|
57934477|NCT05487339|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopy device
57934478|NCT00628173|PROCEDURE|AGV implantation|
57934479|NCT00016029|OTHER|screening questionnaire administration|
58072075|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
58072076|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
58072077|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
58072078|NCT03516461|PROCEDURE|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
58072079|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
58072080|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
57934480|NCT00016029|PROCEDURE|barium enema injection|
57934481|NCT00016029|PROCEDURE|computed tomography|
57934482|NCT00016029|PROCEDURE|computed tomography colonography|
57934483|NCT00016029|PROCEDURE|diagnostic colonoscopy|
57934484|NCT00016029|PROCEDURE|screening colonoscopy|
58072081|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
58072082|NCT02083406|DRUG|960mg PQP|
58072083|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
58072084|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
58072085|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
57934485|NCT04964570|BEHAVIORAL|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
57934486|NCT05273957|OTHER|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
57934487|NCT05273957|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
57934488|NCT00631501|DRUG|Placebo|
57934489|NCT00631501|DRUG|Doxycycline|
57934490|NCT01506960|DEVICE|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
57934491|NCT06734390|OTHER|Bladder Neck Surgery|Bladder Neck Surgery regroups many surgical procedures to cure urinary incontinence.
57934492|NCT00894686|BIOLOGICAL|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
57934493|NCT02888665|DRUG|Doxorubicin Hydrochloride|Given IV
57934494|NCT02888665|OTHER|Laboratory Biomarker Analysis|Correlative studies
57934495|NCT02888665|BIOLOGICAL|Pembrolizumab|Given IV
57934496|NCT00473577|DRUG|CRA-24781|
57934497|NCT03882242|BEHAVIORAL|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
57934498|NCT04900558|PROCEDURE|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
57934499|NCT05798234|DEVICE|high flow oxygen device|no intervention
57934500|NCT00247936|PROCEDURE|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
57934501|NCT02032602|OTHER|Deep Dry Needling|
57951232|NCT04827784|PROCEDURE|local anaesthetic injection|The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
58072086|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
57934502|NCT02946593|BEHAVIORAL|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
57934503|NCT02946593|BEHAVIORAL|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
57934504|NCT00232583|DRUG|Metformin|Metformin 1000mg/BID
57934505|NCT00232583|DRUG|Insulin|Insulin Novolg 70/30 per protocol titration
57934506|NCT00232583|DRUG|Metfomin|Metformin 1000mg/BID
57934507|NCT00232583|DRUG|Pioglitazone|Pioglitazone 45mg
57934508|NCT00232583|DRUG|glyburide|Glyburide per protocol titration
57934509|NCT05743504|DRUG|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
57934510|NCT05613166|DRUG|Everolimus|Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.
57934511|NCT05613166|DRUG|Placebo|Vitamin C
57934512|NCT00419120|BIOLOGICAL|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
57934513|NCT05087160|OTHER|mitigation measures against COVID 19|no intervention
58072087|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
58289890|NCT02403583|BEHAVIORAL|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
58289891|NCT04079686|DRUG|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
58289892|NCT04079686|OTHER|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
58289893|NCT02377609|DRUG|Tacrolimus|oral
58289894|NCT03697941|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
57934514|NCT02308007|DRUG|Terconazole|
57934515|NCT02308007|DRUG|Metronidazole|
57934516|NCT02308007|DRUG|Terconazole/metronidazole|
58072088|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
58072089|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
58072090|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
58072091|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
58072092|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
58072093|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
58289895|NCT03697941|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
58289896|NCT03559751|OTHER|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
58289897|NCT03559751|OTHER|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
58289898|NCT03559751|DRUG|Nicotine gum (C)|4 mg nicotine gum
58289899|NCT00767221|DRUG|Budesonide|8 mg PL-56 once daily for six months
58289900|NCT02710487|BEHAVIORAL|REMSA|Awakening from REM sleep during the last hour of the sleep period
57934517|NCT05638022|DIAGNOSTIC_TEST|Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test|Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.
57934518|NCT05638022|DIAGNOSTIC_TEST|DNA testing|DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
57934519|NCT00369785|DRUG|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
58072094|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
58072095|NCT06383988|OTHER|Support for Caregiver - Generic List|Receive a generic resource list
57934520|NCT00369785|DRUG|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
58289901|NCT02710487|BEHAVIORAL|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
58289902|NCT04526600|OTHER|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
58289903|NCT02197585|PROCEDURE|Inguinal mesh hernioplasty|
58289904|NCT00637026|DRUG|Gefitinib|Iressa
58289905|NCT01455584|DRUG|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
58289906|NCT03885323|DEVICE|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
58289907|NCT03885323|DEVICE|Control placebo with no RF|Placebo control, with no RF
58402566|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
57934521|NCT05455710|DEVICE|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
57934522|NCT00249210|DRUG|levofloxacin|
57934523|NCT05214170|DEVICE|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
57934524|NCT06495502|OTHER|semi-structured interview|Semi-structured interviews by qualitative health researchers
57934525|NCT00839709|PROCEDURE|blood sampling|peripheral blood draw
57934526|NCT03763851|RADIATION|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
57934527|NCT03763851|RADIATION|Radiotherapy|Palliative RadioTherapy to the symptomatic site
57934528|NCT05370612|DEVICE|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
57934529|NCT05370612|OTHER|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
57934530|NCT03684642|DRUG|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
57934531|NCT03684642|DRUG|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
57934532|NCT03684642|DRUG|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
57934533|NCT05531487|OTHER|Questionnaire Survey|All students received a 'QR code' link to the survey.
57934534|NCT00936403|DRUG|NNC126-0083|One single dose administered in four dose levels in an escalating order
58072096|NCT06383988|OTHER|Support for Caregiver - Personalized List|Receive personalized resource list
58072097|NCT06383988|OTHER|Internet-Based Intervention - CONNECT|Receive access to CONNECT tool
58072098|NCT06383988|BEHAVIORAL|Patient Navigation|Complete calls with caregiver navigator
57934535|NCT00936403|DRUG|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
58490729|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
57934536|NCT06734377|DEVICE|Delta TMS|TMS will be administered at the frequency of delta oscillation (2.2Hz)
57934537|NCT06734377|DEVICE|Theta TMS|TMS will be administered at the frequency of theta oscillation (6.5Hz)
57934538|NCT06734377|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency
57934539|NCT02613689|BEHAVIORAL|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
57934540|NCT02613689|BEHAVIORAL|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
58072099|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
57934541|NCT06227273|DIETARY_SUPPLEMENT|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
58289908|NCT03782181|DEVICE|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
57934542|NCT01383096|DRUG|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
57934543|NCT01383096|DRUG|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
57934544|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
58072100|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
58072101|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
58072102|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
58289909|NCT00735943|OTHER|No intervention|No intervention
58289910|NCT04332926|OTHER|Tobacco product administration and assessment|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
58490730|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
57934545|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
57934546|NCT04495010|BIOLOGICAL|Nivolumab|Specified dose on specified days
57934547|NCT04495010|BIOLOGICAL|Ipilimumab|Specified dose on specified days
57934548|NCT00612261|PROCEDURE|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
57934549|NCT00612261|PROCEDURE|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
57934550|NCT06723457|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57934551|NCT06723457|PROCEDURE|Computed Tomography|Undergo PET/CT
57934552|NCT06723457|BIOLOGICAL|Epcoritamab|Given SC
58072103|NCT05664412|DEVICE|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
58072104|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
58072105|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
58072106|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
58289911|NCT05816668|DRUG|Tranexamic acid|Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
58072107|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
58072108|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
58289912|NCT05816668|OTHER|Placebo|Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
58289913|NCT03583879|OTHER|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
58289914|NCT03583879|OTHER|Standard exercise|Functional exercise without a robotic exoskeleton
58289915|NCT03583879|OTHER|No treatment|Wait-list control
58289916|NCT04819789|OTHER|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
58289917|NCT04819789|OTHER|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
57729828|NCT02910622|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
57934553|NCT06723457|DRUG|Lenalidomide|Given PO
57934554|NCT06723457|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57934555|NCT06723457|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57934556|NCT04695392|OTHER|R2 Bundle|"During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries."
57934557|NCT01223521|DEVICE|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
57934558|NCT01910350|BEHAVIORAL|Kin KeeperSM Cancer Prevention Intervention|
58289918|NCT04819789|OTHER|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
58289919|NCT04819789|OTHER|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
58490731|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
57934559|NCT01910350|OTHER|Standard of care|
58072109|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
58072110|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
58072111|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
58072112|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
58072113|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
58072114|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
57934560|NCT04059016|OTHER|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
57934561|NCT00892619|PROCEDURE|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
57934562|NCT00892619|PROCEDURE|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
57934563|NCT00774813|DEVICE|Nexalin 1.3mA Device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant"
57934564|NCT00774813|DEVICE|Nexalin 15mA device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant"
57934565|NCT00774813|DRUG|placebo device and Citalopram|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)"
58072115|NCT01978717|PROCEDURE|epidural anesthesia|
58072116|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
58072117|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
58072118|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
58072119|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
58289920|NCT04294199|OTHER|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
58289921|NCT05621447|DRUG|TAS-303, [14C]TAS-303|oral administration on day 1
58289922|NCT03246022|OTHER|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
58289923|NCT03103256|DRUG|YHP1701|PO, Once daily (QD), 8 weeks
58289924|NCT03103256|DRUG|YHR1703|PO, Once daily (QD), 8 weeks
58289925|NCT03103256|DRUG|YHR1704|PO, Once daily (QD), 8 weeks
58289926|NCT00005033|BIOLOGICAL|trastuzumab|
58072120|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
58289927|NCT00005033|PROCEDURE|conventional surgery|
57934566|NCT03308942|DRUG|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
57934567|NCT03308942|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
57951233|NCT03043716|OTHER|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
58072121|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
58072122|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
58072123|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
58072124|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
58072125|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
58289928|NCT01954238|DRUG|GCC-4401C|"* Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
58289929|NCT01954238|DRUG|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
57934568|NCT03308942|BIOLOGICAL|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
57934569|NCT03262792|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
57934570|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 150 mg
57934571|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 300 mg
57934572|NCT00184236|BEHAVIORAL|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
57934573|NCT00184236|BEHAVIORAL|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
57934574|NCT04092517|OTHER|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
57934575|NCT04092517|OTHER|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
57934576|NCT03178708|DRUG|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
58289930|NCT01954238|DRUG|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
58289931|NCT01188668|DRUG|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
58289932|NCT01188668|DRUG|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
58289933|NCT06153615|OTHER|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
58402567|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
58402568|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
58402569|NCT03840772|DRUG|Eribulin|Treatment with eribulin
58402570|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
58402571|NCT01035463|DRUG|Carmustine|Given IV
57934577|NCT03178708|OTHER|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
57934578|NCT00399386|PROCEDURE|EP|
57934579|NCT00399386|PROCEDURE|ICD|
57934580|NCT00399386|PROCEDURE|Ablation|
57934581|NCT00640055|OTHER|Coordinator|Coordinator (non-physician) assigned cause of death
57934582|NCT00640055|OTHER|Physician-assigned cause of death|Physician (gold standard) cause of death
57934583|NCT05235399|OTHER|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
57934584|NCT06262854|DEVICE|Calcium-sulphate granules with tobramicina+vancomicina|Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
58072126|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
58072127|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
57934585|NCT02183155|DRUG|Meloxicam - low|
57934586|NCT02183155|DRUG|Meloxicam - medium|
57934587|NCT02183155|DRUG|Meloxicam - high|
57934588|NCT02183155|DRUG|Placebo|
57934589|NCT02183155|DRUG|Extended-release indomethacin|
57934590|NCT03627767|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
57934591|NCT03627767|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
57934592|NCT03627767|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
57934593|NCT04513262|PROCEDURE|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
57934594|NCT04158921|OTHER|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. \> 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
57934595|NCT01475929|DIETARY_SUPPLEMENT|Probiotic supplement|A single strain probiotic supplement given at two doses
57934596|NCT01713751|OTHER|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
57934597|NCT01713751|OTHER|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\]
57934598|NCT01472380|DRUG|efavirenz|600 mg
58402572|NCT01035463|DRUG|Cytarabine|Given IV
58402573|NCT01035463|DRUG|Etoposide|Given IV
58402574|NCT01035463|DRUG|Lenalidomide|Given PO
58402575|NCT01035463|DRUG|Melphalan|Given IV
58402576|NCT01035463|BIOLOGICAL|Rituximab|Given IV
57934599|NCT01472380|DRUG|fenofibric acid 105 mg|fenofibric acid 105 mg
57934600|NCT05698823|DEVICE|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
57934601|NCT02598609|BEHAVIORAL|Education program for NICU caregivers|"* standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries"
58289934|NCT06153615|OTHER|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
58289935|NCT06153615|OTHER|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
58289936|NCT06153615|OTHER|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
58289937|NCT02183012|DRUG|Ibuprofen extrudate|
58402577|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
58402578|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
58402579|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
58402580|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
57934602|NCT04162496|DEVICE|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
58402581|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
58402582|NCT03784599|DRUG|Osimertinib|Tablet
58402583|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
58402584|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
58402585|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
57934603|NCT00872664|DIETARY_SUPPLEMENT|carotenoids|beta-carotene, lycopene, lutein
58072128|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
58072129|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
58402586|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
58402587|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
58402588|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
58402589|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
58402590|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
58402591|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
58402592|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
58402593|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
57934604|NCT05817253|BEHAVIORAL|Portrait|In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
57934605|NCT05817253|BEHAVIORAL|Therapeutics Letter|The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
57934606|NCT00614705|DRUG|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
58289938|NCT02183012|DRUG|Ibuprofen lysinate|
58289939|NCT02183012|DRUG|Ibuprofen|
58289940|NCT05339815|DEVICE|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
58289941|NCT04090346|DRUG|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
58289942|NCT03126786|DRUG|IVT aflibercept|IVT aflibercept \[2 mg/0.05 mL\]
57934607|NCT00614705|DRUG|Placebo|oral capsule form, once daily for 28 days
57934608|NCT02529267|OTHER|Standard of care|
57934609|NCT04998487|DRUG|LY3471851|Administered SC.
57934610|NCT00446238|BEHAVIORAL|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
57934611|NCT00446238|BEHAVIORAL|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
57934612|NCT01754857|DRUG|Bendamustine|Given IV
57934613|NCT01754857|DRUG|Rituximab|Given IV
57934614|NCT01754857|DRUG|Lenalidomide|Given PO
57934615|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
57934616|NCT00473551|DRUG|Rituximab|375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.
58402594|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
57934617|NCT00473551|DRUG|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
57934618|NCT00473551|DRUG|Fludarabine|40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
57934619|NCT00473551|DRUG|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
57934620|NCT00473551|RADIATION|Radiation Treatment|2Gy Total body radiation day before transplantation
57934621|NCT00473551|PROCEDURE|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
57934622|NCT00473551|DRUG|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
57934623|NCT00473551|PROCEDURE|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
57934624|NCT01161290|BEHAVIORAL|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
57934625|NCT02827305|DRUG|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
57934626|NCT02827305|PROCEDURE|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
57934627|NCT05263063|OTHER|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
57934628|NCT05948475|DRUG|Tinengotinib 8 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
57934629|NCT05948475|DRUG|Tinengotinib 10 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
57934630|NCT05948475|DRUG|Physician's Choice|For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
57934631|NCT03570372|BEHAVIORAL|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
57934632|NCT03570372|BEHAVIORAL|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
57934633|NCT04801134|OTHER|Education|as per previous description
57934634|NCT05440838|DIAGNOSTIC_TEST|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
57934635|NCT00238628|DRUG|Bexarotene|
57934636|NCT00238628|DRUG|Iressa|
57934637|NCT06178965|PROCEDURE|Incisional Hernia Repair by Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|patients with incisional hernia will be operated by hernia reduction and sac closure followed by placement of onlay mesh after creating suitable flaps.
57934638|NCT05029466|DRUG|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
57934639|NCT00447486|DRUG|GW842166|
57934640|NCT02427880|DRUG|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
57934641|NCT02427880|DRUG|Furosemide and Hydrochlorothiazide Followed by Furosemide|
57934642|NCT05197413|DIETARY_SUPPLEMENT|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
58289943|NCT03126786|DRUG|Sham SC|sham SC
58289944|NCT03126786|DRUG|SC CLS-TA|CLS-TA \[4 mg/100 μL\] SC injection
58402595|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
58402596|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
58402597|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
58402598|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
58402599|NCT03019328|OTHER|Peanut in diet|
58402600|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
58402601|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
58402602|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
57934643|NCT04564144|DRUG|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
57934644|NCT02507622|OTHER|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
57934645|NCT02507622|OTHER|Parabolic flight|
57934646|NCT01320982|DRUG|minocycline|minocycline 100 mg/bid
57934647|NCT01320982|DRUG|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
57934648|NCT01320982|DRUG|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
57934649|NCT01320982|DRUG|placebo|placebo bid
57934650|NCT03574441|DEVICE|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
57934651|NCT03574441|DEVICE|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
57934652|NCT03574441|DEVICE|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
57934653|NCT06416735|DRUG|Amiloride|administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
57934654|NCT01600976|DRUG|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
58402603|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
57934655|NCT03564743|DIAGNOSTIC_TEST|Evaluation of ASAS criteria|Perform ASAS criteria at the time of physician diagnosis of chronic low back pain in rheumatological practice.
57934656|NCT05221723|BEHAVIORAL|High Intensity Interval Exercise Training Group|Participants will participate in a maximum of twice weekly exercise classes (90 minutes each class) for a total of 6 months. While participants will be encouraged to attend as many classes as able, there is no minimum requirement for class attendance. During the exercise classes, participants will participate in a 10-minute warm up, followed by 30-60 minutes of aerobic, resistance and/or balance training up to a maximum intensity of 8/10 on the rating of perceived exertion scale. Participants will finish each class with a 10-minute cool-down consisting of lower intensity exercise.
57934657|NCT05691517|PROCEDURE|Biopsy|Undergo tumor biopsy
57934658|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57934659|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
57934660|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
57934661|NCT05327621|DRUG|Pamiparib|40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
57934662|NCT01226823|DRUG|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
57934663|NCT01226823|DRUG|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
57934664|NCT02755168|PROCEDURE|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
57934665|NCT02755168|PROCEDURE|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
57934666|NCT02679599|OTHER|B-MOBILE-CARDIAC smartphone application|
57934667|NCT02679599|BEHAVIORAL|Cardiac rehabilitation as usual|
57934668|NCT03904745|DRUG|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
57934669|NCT04401748|DRUG|Venetoclax|Tablet: Oral
57934670|NCT04401748|DRUG|Azacitidine|Subcutaneous (SC) or Intravenous (IV) injection
57934671|NCT04401748|DRUG|Placebo|Tablet; Oral
57934672|NCT03528278|BEHAVIORAL|Motivational interviewing and environmental interventions|"* Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~* Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~* Training equipment~* Motivational Interviewing (MI) techniques applied by staff~* Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
57934673|NCT00551551|OTHER|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
58402604|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
57934674|NCT00551551|OTHER|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
57934675|NCT05146804|OTHER|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
57934676|NCT05146804|OTHER|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
57934677|NCT05339321|GENETIC|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
57934678|NCT05339321|BIOLOGICAL|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
57934679|NCT06006325|DEVICE|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
57934680|NCT06006325|DEVICE|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
57934681|NCT01418651|DRUG|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
57934682|NCT01112176|PROCEDURE|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
57934683|NCT00800683|DRUG|BI 1356|BI 1356 dosed once daily
57934684|NCT00800683|DRUG|placebo|placebo matching BI 1356 taken once daily
57934685|NCT00521053|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
57934686|NCT05444751|DRUG|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
57934687|NCT05444751|DRUG|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
57934688|NCT06073236|BEHAVIORAL|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
57934689|NCT00420017|DRUG|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
57934690|NCT00420017|OTHER|Control|No amiodarone
57934691|NCT02471950|PROCEDURE|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
58289945|NCT05495386|DEVICE|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant."
58402605|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
57934692|NCT00285129|DEVICE|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
57934693|NCT00916149|DRUG|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
58072130|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
57934694|NCT00916149|DRUG|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
57934695|NCT06494007|DRUG|Sodium chloride|The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.
57934696|NCT06494007|DRUG|90 mg of calcium|The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.
57934697|NCT06494007|DRUG|180 mg Calcium|The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.
57934698|NCT06442865|DEVICE|AMNIODERM+|"A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC."
57934699|NCT06494787|COMBINATION_PRODUCT|Aliya Pulse Electric Field sysem and pembrolizumab|This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
57934700|NCT02414568|DRUG|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
57934701|NCT02414568|DRUG|Prednisone|Prednisone 40 mg/m² PO
57934702|NCT02414568|DRUG|Vinblastine|Vinblastine 6 mg/m² IV
57934703|NCT02414568|DRUG|Doxorubicin|Doxorubicin 40 mg/m² IV
57934704|NCT05877222|DRUG|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
57934705|NCT05877222|DRUG|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
58072131|NCT00354120|DRUG|Alentuzumab|Alentuzumab
58072132|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
58072133|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
58095114|NCT06566755|DRUG|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
58289946|NCT00537290|DRUG|Rituximab|Rituximab 1000mg IV on Days 0 and 15
58402606|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
58402607|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
57934706|NCT06326892|PROCEDURE|Natural Orifice Specimen Extraction (NOSE)|Low rectal cancer resection with Total Mesorectal Excision (TME) and Natural Orifice Specimen Extraction (NOSE)
57934707|NCT06326892|PROCEDURE|Traditional specimen extraction|Low rectal cancer resection with Total Mesorectal Excision (TME) and specimen extraction through Pfannenstiel incision
58402608|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
58402609|NCT02349607|DRUG|Placebo|Placeco
58402610|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
58402611|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
58402612|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
57934708|NCT01909427|DRUG|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
57934709|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
57934710|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
57934711|NCT01909427|DRUG|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
57934712|NCT01909427|DRUG|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
57934713|NCT01909427|DRUG|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
57934714|NCT01909427|DRUG|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
57934715|NCT03624205|DEVICE|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
57934716|NCT01098812|DEVICE|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
57934717|NCT01098812|DEVICE|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
58402613|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
58402614|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
58402615|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
58402616|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
58402617|NCT01530035|OTHER|physical training|training
58289947|NCT00547248|BIOLOGICAL|Synflorix|Intramuscular injection, 1 dose
58402618|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
58402619|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
58402620|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
58402621|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
58402622|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
58289948|NCT00547248|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 1 dose
58289949|NCT00547248|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix-Hep B before injection
58289950|NCT00547248|BIOLOGICAL|Polio Sabin|Oral, 1 dose
58289951|NCT00547248|BIOLOGICAL|Poliorix|Intramuscular injection, 1 dose
58402623|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
58402624|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
58402625|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
58402626|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
58402627|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
58402628|NCT01611363|DRUG|ASP1941|Oral
58402629|NCT01611363|DRUG|Placebo|Oral
58402630|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
58402631|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
58402632|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
58402633|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
58402634|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
58402635|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
58402636|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
58402637|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
58490732|NCT03098732|DEVICE|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
58289952|NCT00547248|BIOLOGICAL|Prevenar (Wyeth)|Intramuscular injection, 1 dose
58289953|NCT03205475|BEHAVIORAL|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
58289954|NCT03205475|BEHAVIORAL|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
58289955|NCT03205475|BEHAVIORAL|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
58289956|NCT03205475|BEHAVIORAL|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
58289957|NCT03205475|BEHAVIORAL|Video Feedback Only Phase 2|Receive video feedback and calls only
58289958|NCT02421302|DIETARY_SUPPLEMENT|RUTF|This is ready-to-use-therapeutic-food
58289959|NCT03442244|DRUG|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
58289960|NCT03442244|DRUG|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
58289961|NCT04845880|DIAGNOSTIC_TEST|Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2|Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
58289962|NCT04615078|DEVICE|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~* A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~* An organizational solution relying on a nurse call center."
57934718|NCT02604225|DRUG|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
57934719|NCT02604225|DRUG|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
57934720|NCT04165993|DRUG|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
57934721|NCT04165993|DRUG|KN026 monotherapy|30 mg/kg Q3W KN026
57934722|NCT04165993|DRUG|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
57934723|NCT03931967|DIAGNOSTIC_TEST|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
57934724|NCT05125289|OTHER|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
57934725|NCT05125289|OTHER|Active release technique group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~ART steps:~* Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~* Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~* Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
57934726|NCT05125289|OTHER|Proprioceptive Neuromuscular Facilitation stretching group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~PNF technique steps:~* The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~* The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~* Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~* This sequence is repeated 5 times at a 20 second interval."
57934727|NCT01103245|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
57934728|NCT01103245|DRUG|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
57934729|NCT01103245|DRUG|Spironolactone (SPL 25)|spironolactone 25mg daily
57934730|NCT01103245|DRUG|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
57934731|NCT01103245|DRUG|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
57934732|NCT02191020|DRUG|Total glucosides of paeony & Acitretin Capsules|
57934733|NCT02191020|DRUG|Acitretin Capsules|
57934734|NCT01017588|DEVICE|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
57934735|NCT05556278|DIAGNOSTIC_TEST|Ultrasound study|based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
57934736|NCT05556278|DIAGNOSTIC_TEST|Neurophysiological test|ultrasound protocol described by Chen et al. (2)
57934737|NCT05378854|OTHER|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
57934738|NCT03967379|BEHAVIORAL|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
57934739|NCT03967379|OTHER|Enhanced Standard Care|Standard of care administered by the institution
57934740|NCT01368809|DRUG|Saline|2 ml at induction 1-2 ml boluses as needed
58072134|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
58095115|NCT04335565|OTHER|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
58490733|NCT03098732|DEVICE|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
58490734|NCT04772560|DEVICE|Precision1 for Astigmatism|Daily disposable soft toric contact lens
57934741|NCT01368809|DRUG|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
57934742|NCT00022048|BIOLOGICAL|bevacizumab|
57934743|NCT03971994|BEHAVIORAL|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
57934744|NCT06734533|OTHER|Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc|Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.
57934745|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
57934746|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with 5mm suction irrigation blunt dissection starting from fundus
58402638|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
58402639|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
58402640|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
58402641|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
58402642|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
58402643|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
58402644|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
57934747|NCT01288222|OTHER|KIR genotype|KIR genotype data from unrelated donor are collected
57934748|NCT01067755|DEVICE|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
57934749|NCT05672472|DRUG|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
57934750|NCT02798822|PROCEDURE|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
57934751|NCT02619968|OTHER|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
57934752|NCT04569409|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
58402645|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
58402646|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
58402647|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
58402648|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
58402649|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
58402650|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
58402651|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
57934753|NCT04569409|PROCEDURE|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
57934754|NCT04697043|PROCEDURE|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
57934755|NCT00002920|DRUG|medroxyprogesterone|
57934756|NCT00002920|DRUG|tamoxifen citrate|
57934757|NCT00002920|PROCEDURE|adjuvant therapy|
58095116|NCT00850837|DRUG|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
58402652|NCT00328562|DRUG|ZD1839 (Iressa)|
58402653|NCT00328562|RADIATION|Thoracic Radiotherapy|
58402654|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
58402655|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
58402656|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
58402657|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
58402658|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
58402659|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
58402660|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
58402661|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
58402662|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
58490735|NCT04772560|DEVICE|Precision1 Sphere|Daily disposable soft spherical contact lens
58490736|NCT01934595|DIETARY_SUPPLEMENT|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
58402663|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
58402664|NCT01234740|DRUG|bafetinib|Given orally
58402665|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
58402666|NCT01234740|OTHER|pharmacological study|Correlative studies
57934758|NCT03948633|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
57934759|NCT02946632|DRUG|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
58402667|NCT01234740|OTHER|liquid chromatography|Correlative studies
58402668|NCT01234740|OTHER|mass spectrometry|Correlative studies
57934760|NCT02946632|DRUG|Stepwise add-on therapy|metformin -\> glimepirde -\> sitagliptin
57934761|NCT06499025|BIOLOGICAL|targeted AML1-ETO neoantigen cytotoxic T cells (CTL)|After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.
57934762|NCT06499025|DRUG|Cyclophosphamide injection|Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion
57934763|NCT06499025|DRUG|Decitabine Injection|Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion
57934764|NCT06499025|DRUG|Liposome mitoxantrone|Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion
57934765|NCT06302647|OTHER|Questionnaires|Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment
57934766|NCT02367066|DRUG|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
58095117|NCT00850837|DRUG|HEC gel|5 g application of hydroxyethylcellulose gel
58402669|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
58402670|NCT01234740|GENETIC|protein expression analysis|Correlative studies
58402671|NCT01234740|GENETIC|western blotting|Correlative studies
58402672|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
58402673|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
58402674|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
58402675|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
57934767|NCT02367066|OTHER|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
57951234|NCT01577186|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
58095118|NCT06567132|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
58402676|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
58402677|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
58402678|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
58402679|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
58402680|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
58402681|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58402682|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
58402683|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
58402684|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
58402685|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
58402686|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
58402687|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
58402688|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
58402689|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
58402690|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
58402691|NCT01357135|DRUG|Metformin|
58402692|NCT01357135|DRUG|Sitagliptin|
58402693|NCT01357135|DRUG|Sulfonylurea|
58402694|NCT01357135|DRUG|Antihyperglycemic Medication|
58402695|NCT01748812|DRUG|Osteomalacia|
58402696|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
58402697|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
58402698|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
58402699|NCT00116064|DRUG|intranasal lorazepam|
58402700|NCT00116064|DRUG|intramuscular paraldehyde|
58402701|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
58402702|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
58402703|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
58402704|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
58402705|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
58402706|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
57729829|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
58402707|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
58402708|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
58402709|NCT00006042|BIOLOGICAL|filgrastim|
57729830|NCT02300714|PROCEDURE|oblique view approach|
57729831|NCT01629329|DRUG|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
57729832|NCT01629329|DRUG|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
57729833|NCT06077396|PROCEDURE|radial artery cannulation|radial artery cannulation
57729834|NCT00221793|PROCEDURE|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
57729835|NCT06336096|DRUG|Suzetrigine|Tablet(s) for oral administration.
57729836|NCT06336096|DRUG|Suzetrigine|Tablet(s) and Suspension for oral administration.
57951235|NCT05435651|BEHAVIORAL|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
58402710|NCT00006042|DRUG|cyclophosphamide|
58402711|NCT00006042|DRUG|fludarabine phosphate|
58402712|NCT00006042|DRUG|mycophenolate mofetil|
58402713|NCT00006042|DRUG|tacrolimus|
58402714|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
58402715|NCT00006042|RADIATION|radiation therapy|
58402716|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
58402717|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
58402718|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
58402719|NCT00434083|DRUG|sumatriptan|
58402720|NCT00434083|DRUG|naproxen sodium|
58402721|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
58402722|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
58402723|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
58402724|NCT02626234|DRUG|INC280|
58402725|NCT02626234|DRUG|digoxin|
58402726|NCT02626234|DRUG|rosuvastatin|
58402727|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
58402728|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
58402729|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
58402730|NCT05295901|DEVICE|mKOAH application|mobile app installed group
58402731|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
58402732|NCT05804513|DRUG|Placebo|s/c injection
58402733|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
58402734|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
58402735|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
58402736|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
58402737|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
58402738|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
58402739|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
58402740|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
58402741|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
57729837|NCT06386484|DEVICE|PolarCap System|The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
57934768|NCT02887872|OTHER|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
58402742|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
58402743|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
58402744|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
58402745|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
58402746|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
58402747|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
58402748|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
58402749|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
58402750|NCT06481228|DRUG|Olverembatinib|TKI
58402751|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
58402752|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
58402753|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
57934769|NCT05933161|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor (CGM)|Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
57934770|NCT00002355|DRUG|Fomivirsen sodium|
57934771|NCT00137813|DRUG|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
57934772|NCT00137813|DRUG|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
57934773|NCT05558306|PROCEDURE|Surgery of distal radius fracture|Surgery of distal radius fracture for displaced fractures
57934774|NCT05558306|PROCEDURE|Reduction and cast treatment of distal radius fracture|Reduction and cast treatment of distal radius fracture for minimally displaced fractures
58402754|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
57934775|NCT02208297|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
57934776|NCT02208297|DRUG|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
57934777|NCT01560923|BIOLOGICAL|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
57934778|NCT01560923|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
57934779|NCT01560923|OTHER|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
57934780|NCT01290705|BEHAVIORAL|High exercise therapy|
57934781|NCT01290705|BEHAVIORAL|Low exercise therapy|
57934782|NCT01573078|BEHAVIORAL|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
57934783|NCT04775225|DRUG|Lidocaine|denervation of the obturator and femoral genicular branches by Lidocaine 2 %
57934784|NCT04775225|DRUG|Placebo|an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
57934785|NCT04775225|DRUG|Steroid|Intra-articular injection of 80mg of triamcinolone
58402755|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
57934786|NCT06494930|OTHER|F-IMT|A core stabilization exercise protocol including functional respiratory muscle training will be applied to the F-IMT group. IMT will be provided with the red Powerbreath Plus MR exercise device. Initial training intensity will be set at 50% of the MIP value measured at the athlete's first evaluation. Every two weeks, the athlete will be re-evaluated the new MIP value will be measured, and the training intensity will be adjusted to 50% of the newly measured MIP value. After the nose clip is attached, the athlete will be asked to take the device's mouthpiece into his mouth, close his lips tightly, and take a deep, fast, and powerful breath, then exhale slowly and completely with minimal effort. While the athlete does breathing exercises with the device, he will also do core stabilization exercises. Athletes will be asked to train 30 minutes daily, five days a week, for six weeks.
58402756|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
58402757|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
58402758|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
58402759|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
58402760|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
58402761|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
58402762|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
58402763|NCT01772524|BIOLOGICAL|ALD403|
58402764|NCT01772524|DRUG|Placebo|
58402765|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
58402766|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
58402767|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
58402768|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
57934787|NCT06494930|OTHER|Core Stabilization Exercise|Only the core stabilization exercise protocol will be applied to the control group. Athletes will be asked to train 30 minutes a day, five days a week, for six weeks.
57934788|NCT05334017|DRUG|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
57934789|NCT05334017|DRUG|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
58289963|NCT05457179|BEHAVIORAL|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
58289964|NCT05457179|BEHAVIORAL|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
58289965|NCT01545141|DRUG|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
58289966|NCT01545141|DRUG|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
58289967|NCT01545141|DRUG|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
58289968|NCT02809950|OTHER|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
58289969|NCT02809950|OTHER|control group|NPO from midnight of the day before surgery
58289970|NCT04399889|BIOLOGICAL|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
58289971|NCT04399889|OTHER|Placebo|Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
58289972|NCT01668056|DRUG|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
58289973|NCT01668056|PROCEDURE|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
58289974|NCT01668056|OTHER|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
58289975|NCT03868839|DRUG|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
58289976|NCT00832988|OTHER|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
58289977|NCT02768402|DEVICE|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
58289978|NCT01363284|DRUG|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
58289979|NCT06355440|BEHAVIORAL|Financial Navigation|"One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting"
58289980|NCT06355440|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
58289981|NCT04008888|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
58402769|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
58490737|NCT03572608|OTHER|Acupuncture treatment|Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
57934790|NCT00493220|DRUG|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
58072135|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
58072136|NCT01042431|OTHER|No Intervention|No intervention
58072137|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
58402770|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
58402771|NCT00206050|DRUG|Esomeprazole|
58289982|NCT04008888|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
58072138|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
58095119|NCT01138852|DRUG|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
58289983|NCT04008888|DRUG|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
58289984|NCT04008888|DRUG|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
58289985|NCT04008888|DRUG|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
58289986|NCT04008888|DRUG|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
58289987|NCT06226519|DIAGNOSTIC_TEST|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
58289988|NCT01964989|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
58289989|NCT01964989|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
58289990|NCT04265261|DRUG|Placebo|Participants will receive oral placebo matched to RG7774
58402772|NCT00206050|DRUG|pantoprazole|
58402773|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
58402774|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
57934791|NCT00493220|DRUG|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
57934792|NCT00493220|DRUG|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
58289991|NCT04265261|DRUG|RG7774|Participants will receive oral RG7774
57934793|NCT03268733|DRUG|Folic Acid|Tablet 5 mg
57934794|NCT00076492|DRUG|CoQ10|
57934795|NCT00076492|DRUG|GPI 1485|
58402775|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
58402776|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
58402777|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
58402778|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
58402779|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
58402780|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
57934796|NCT00343876|DRUG|aspirin|
58289992|NCT05114187|OTHER|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. Ten selected multimedia e-learning lessons;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
58289993|NCT05114187|OTHER|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. One selected multimedia e-learning lesson;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
58289994|NCT04004260|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
58289995|NCT00674206|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
58402781|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
58402782|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
58402783|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
57934797|NCT00343876|DRUG|clopidogrel|
57934798|NCT05555355|DEVICE|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
57934799|NCT05555355|PROCEDURE|Spine surgery|Patients will receive spine surgery
58402784|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
58402785|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
58402786|NCT01057576|OTHER|Placebo|capsule, daily dosage
58402787|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
58402788|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
58402789|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
58402790|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
57934800|NCT02710617|DEVICE|Blood glucose monitoring systems for point-of-care-testing|
57934801|NCT05223751|BEHAVIORAL|Meo Health Breathing and humming exercises|"The Intervention Group will receive training on the Meo Health breathing therapy, which will include:~* Being shown the Meo Health Breathing Therapy On-Boarding video~* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.~* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.~Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.~A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.~A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group."
58402791|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
58402792|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
58402793|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
58402794|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
58402795|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
58402796|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
58402797|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
58402798|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
58402799|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
58402800|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
57934802|NCT03239483|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
57934803|NCT03239483|DRUG|Placebo gel|Universal HEC placebo gel; administered rectally
57934804|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
58402801|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
58402802|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
58289996|NCT00674206|DRUG|Oxaliplatin|Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
58289997|NCT03620526|DRUG|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
58289998|NCT03620526|DRUG|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
58289999|NCT02732392|PROCEDURE|standard lymphadenectomy|
58290000|NCT02732392|PROCEDURE|lymphadenectomy radio-isotope method|
58290001|NCT02403804|DIETARY_SUPPLEMENT|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
58290002|NCT02403804|DIETARY_SUPPLEMENT|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
58290003|NCT02403804|DIETARY_SUPPLEMENT|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
58290004|NCT06491680|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose."
58290005|NCT01082679|DRUG|Methadone|daily for 12 months
58290006|NCT01082679|DRUG|buprenorphine (Suboxone)|daily for 12 months
58290007|NCT01396889|DRUG|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
58290008|NCT01396889|DRUG|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
58290009|NCT03952962|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
58290010|NCT03373747|DIAGNOSTIC_TEST|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
58290011|NCT03373747|DIAGNOSTIC_TEST|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
58402803|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
58290012|NCT00382785|BEHAVIORAL|moderated support|one 12-week online support group led by a professional healthcare provider
58290013|NCT00382785|BEHAVIORAL|peer-led|12-week online support in a peer-led format
58290014|NCT03711305|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
58290015|NCT03711305|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
58402804|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
57729838|NCT03249623|DEVICE|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
58290016|NCT03711305|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
58290017|NCT03711305|DRUG|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
58290018|NCT02532062|DIETARY_SUPPLEMENT|Cholecalciferol|4,000 IU, oral, once a day for one year
58290019|NCT02532062|DIETARY_SUPPLEMENT|multivitamin|oral, once a day for one year
58402805|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
58402806|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
57729839|NCT04332705|DIAGNOSTIC_TEST|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
58290020|NCT02532062|DIETARY_SUPPLEMENT|Placebo|oral, once a day for one year
58402807|NCT01044745|DRUG|rituximab|Given IV
58402808|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
58402809|NCT01044745|DRUG|tacrolimus|Given IV
58402810|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
58402811|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
58402812|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
58490738|NCT02424578|DRUG|Diclofenac Capsules low dose|
58402813|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
57934805|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
57934806|NCT00640484|DRUG|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
58290021|NCT02501941|DRUG|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
58290022|NCT06173388|OTHER|Structured exercise training program + The swallow resistance exercise program.|Structured exercise training program + The swallow resistance exercise program.
58290023|NCT06173388|OTHER|Only the swallow resistance exercise program.|Only the swallow resistance exercise program.
58290024|NCT02260219|PROCEDURE|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
58290025|NCT03166839|OTHER|Experiencing PPH|No intervention given
58290026|NCT03958110|DIAGNOSTIC_TEST|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
58290027|NCT04793477|DEVICE|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
58290028|NCT01700257|RADIATION|CT scan & Early CDT Lung test|
58290029|NCT01700257|OTHER|CT scan & Early CDT Lung test|
58290030|NCT06180161|BEHAVIORAL|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
58290031|NCT02377492|DRUG|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
58290032|NCT01826981|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
57729840|NCT05680168|DEVICE|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
58290033|NCT01826981|DRUG|SOF|SOF 400 mg tablet administered orally once daily
58290034|NCT01826981|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58402814|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
58402815|NCT01044745|DRUG|fludarabine phosphate|Given IV
58290035|NCT01826981|DRUG|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
58402816|NCT01044745|DRUG|busulfan|Given IV
58402817|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
58402818|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
58402819|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
58402820|NCT00381511|DRUG|low molecular weight heparin|
58402821|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
57729841|NCT05680168|BEHAVIORAL|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
57934807|NCT00640484|DRUG|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
58290036|NCT01826981|DRUG|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
58290037|NCT01826981|DRUG|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
58290038|NCT04600791|DEVICE|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
58290039|NCT04855214|OTHER|Qualitative Analysis|Mixed methods analysis of the user's experience with upper limb prosthetics.
58290040|NCT00829699|PROCEDURE|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
57934808|NCT06167603|DIAGNOSTIC_TEST|FDG-PET|Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.
57934809|NCT06167603|DIAGNOSTIC_TEST|Blood test and clinical examination.|baseline, 12-months and 24 months.
57934810|NCT03184324|DRUG|DWP14012|tablet
58290041|NCT00829699|PROCEDURE|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
58290042|NCT00829699|PROCEDURE|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
58290043|NCT00829699|PROCEDURE|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
58402822|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
58402823|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
58402824|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
58402825|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
57729842|NCT00596765|BEHAVIORAL|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
57729843|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
57729844|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
57729845|NCT05814523|DRUG|Ganaxolone|Ganaxolone will be administered as IV solution.
57729846|NCT05814523|DRUG|Placebo|Placebo will be administered as IV solution.
57729847|NCT05814523|DRUG|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
57729848|NCT04452461|DRUG|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
57934811|NCT03184324|DRUG|Esomeprazole|tablet
57934812|NCT03184324|DRUG|DWP14012 placebo|tablet
57934813|NCT03184324|DRUG|Esomeprazole placebo|tablet
57934814|NCT00271778|PROCEDURE|mastoidotympanoplasty and tympanoplasty|
57934815|NCT05829590|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
57934816|NCT01159613|OTHER|Responders|Responders
57934817|NCT01159613|OTHER|Non Responders|Non Responders
58095120|NCT01138852|DRUG|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
58402826|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
57729849|NCT04452461|DRUG|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
57729850|NCT06410066|OTHER|no intervention|
57729851|NCT04318340|OTHER|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
57934818|NCT00252304|DRUG|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
58402827|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
57934819|NCT00252304|DRUG|Placebo|Placebo
58402828|NCT03051412|OTHER|No Intervention|No intervention
58402829|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
58402830|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
58402831|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
57729852|NCT04318340|OTHER|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
57934820|NCT03512639|DRUG|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
57934821|NCT03512639|DRUG|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
57934822|NCT06493487|OTHER|integrated neuromuscular inhibition technique|integrated neuromuscular inhibition technique for gastrocniemus muscle
57934823|NCT06493487|OTHER|instrument assissted soft tissue mobilization|instrument assissted soft tissue mobilization for calf muscle
57934824|NCT06493487|OTHER|convential treatment|convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
57934825|NCT01073241|PROCEDURE|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
57934826|NCT01073241|PROCEDURE|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
57934827|NCT00417040|OTHER|internet-based intervention|Use the STAR database system
58095121|NCT00003166|DRUG|bryostatin 1|Given IV
58490739|NCT02424578|DRUG|Diclofenac Capsules high dose|
57934828|NCT00417040|OTHER|assessment of therapy complications|Use the STAR database system
57934829|NCT00417040|OTHER|Questionnaire Administration|Ancillary studies
58095122|NCT00003166|DRUG|vincristine sulfate|Given IV
58402832|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
58402833|NCT06356935|OTHER|RT|Resistance training
58290044|NCT05644288|OTHER|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
58290045|NCT03626701|DEVICE|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
58290046|NCT03626701|COMBINATION_PRODUCT|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
58290047|NCT03626701|PROCEDURE|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
58290048|NCT05679453|DRUG|Lornoxicam 8 Mg Oral Tablet|Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
58290049|NCT00469716|DRUG|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
58290050|NCT05149547|DIAGNOSTIC_TEST|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
58402834|NCT06356935|OTHER|CON|Control group
58402835|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
58402836|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
57729853|NCT05675345|DEVICE|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
57934830|NCT06544694|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
57934831|NCT06544694|OTHER|Artificial Tears|Commercially available, preservative-free lubricant eye drops
57934832|NCT02376608|DIETARY_SUPPLEMENT|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
58290051|NCT00410072|DRUG|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
58290052|NCT00410072|DRUG|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
58290053|NCT04444518|BEHAVIORAL|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
58290054|NCT04444518|BEHAVIORAL|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
58290055|NCT00105989|DRUG|Duloxetine|
58290056|NCT00105989|DRUG|placebo|
58402837|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
58402838|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
58402839|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
58402840|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
58402841|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
58402842|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
58402843|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
58402844|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
57729854|NCT05675345|DEVICE|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
57729855|NCT05675345|DEVICE|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
57729856|NCT05675345|DEVICE|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
57729857|NCT00005981|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
57729858|NCT00005981|DRUG|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
57934833|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
57934834|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
57934835|NCT02376608|DIETARY_SUPPLEMENT|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
57934836|NCT01514136|DEVICE|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
58095123|NCT00003166|OTHER|laboratory biomarker analysis|Correlative studies
57951236|NCT05435651|BEHAVIORAL|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
57934837|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
57934838|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
57934839|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
58072139|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
58072140|NCT02452138|OTHER|Severe sepsis management|
58290057|NCT01523834|DRUG|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
58290058|NCT01473940|BIOLOGICAL|ipilimumab|Given IV
58290059|NCT01473940|DRUG|gemcitabine hydrochloride|Given IV
58290060|NCT01473940|OTHER|laboratory biomarker analysis|Correlative studies
58402845|NCT02984150|DIETARY_SUPPLEMENT|saline|
58402846|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
58072141|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
58290061|NCT03241576|BEHAVIORAL|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
58290062|NCT03241576|BEHAVIORAL|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
58290063|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 LipoMicel® soft gels|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
58290064|NCT05394701|DIETARY_SUPPLEMENT|RxOmega-3 soft gels (Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
58290065|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 Complete soft gels (Non-Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
58290066|NCT05258253|OTHER|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
58290067|NCT05258253|OTHER|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
58290068|NCT06415435|DEVICE|Radiofrequency Microneedling|Sylfirm X radiofrequency microneedling device
58290069|NCT01254656|DRUG|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
58290070|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
58290071|NCT01254656|DRUG|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
58402847|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
58290072|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
58290073|NCT01254656|DRUG|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
58402848|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
58402849|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
58402850|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
58402851|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
58402852|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
58402853|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
58402854|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
58402855|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
58402856|NCT00704483|DRUG|SBR759|1.5 g tid
57934840|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
58290074|NCT01254656|DRUG|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
58290075|NCT01678664|DRUG|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
58290076|NCT01678664|DEVICE|embolization|2 sessions embolization with spheric particles
58290077|NCT01678664|DRUG|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
58290078|NCT05419167|BEHAVIORAL|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
58290079|NCT01858207|PROCEDURE|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
58402857|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
58402858|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
58402859|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
58290080|NCT01858207|PROCEDURE|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
58402860|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
58402861|NCT02715024|DRUG|Tamsulosin|Oral
58402862|NCT02715024|DRUG|Solifenacin|Oral
58402863|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
58402864|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
58402865|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
58402866|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
57934841|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
58402867|NCT00199251|DRUG|RUPATADINE|
58402868|NCT02239835|DRUG|Tipranavir (TPV) low dose|
58402869|NCT02239835|DRUG|Tipranavir (TPV) high dose|
58402870|NCT02239835|DRUG|Ritonavir low dose|
58402871|NCT02239835|DRUG|Ritonavir high dose|
58402872|NCT02239835|DRUG|Saquinavir|
58402873|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
58402874|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
57934842|NCT01054950|BEHAVIORAL|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
57934843|NCT01054950|BEHAVIORAL|Placebo phone call|Phone call w/ no behavioral counseling
57934844|NCT04959955|DIAGNOSTIC_TEST||
57934845|NCT04389190|OTHER|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
57934846|NCT02462213|OTHER|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
58290081|NCT01858207|DRUG|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
58290082|NCT04156243|BIOLOGICAL|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
58290083|NCT02809352|BIOLOGICAL|Human papillomavirus genotyping|
58290084|NCT00330694|OTHER|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
58290085|NCT00330694|OTHER|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
58290086|NCT02899975|OTHER|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
58290087|NCT02487797|DRUG|Oxytocin|
58402875|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
58402876|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
58402877|NCT00350363|DRUG|Zymar|zymar qid
58402878|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
58402879|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
58402880|NCT02511834|DEVICE|VEST External Support|
58402881|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
57934847|NCT02462213|OTHER|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
57934848|NCT03247426|OTHER|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
57934849|NCT01237340|DRUG|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
57934850|NCT00956267|DRUG|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
57934851|NCT00956267|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
57934852|NCT00524849|BIOLOGICAL|Zoledronic acid|Zometa 1 mg weekly (intravenous)
57934853|NCT00524849|DRUG|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
57934854|NCT06727110|DEVICE|PILP Cement|PILP cement liner.
57934855|NCT06727110|DEVICE|PILP Conditioner|PILP solution.
57934856|NCT06724978|DRUG|S-740792|Participants will receive S-740792 as an oral suspension.
58290088|NCT02487797|OTHER|Sodium Chloride 0.9%|
58290089|NCT00176657|DRUG|HEMOBAG Assessment|
58290090|NCT06391359|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
58290091|NCT06391359|OTHER|Watchful waiting|Watchful waiting
58290092|NCT01836146|DEVICE|EnligHTN™ Renal Artery Ablation Catheter|
58290093|NCT01635621|DRUG|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
58290094|NCT01635621|DRUG|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
58290095|NCT02858271|DRUG|AKB-9778 subcutaneous injection|
58402882|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
58402883|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
58402884|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
58402885|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
58402886|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
58402887|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
58402888|NCT05515588|DRUG|BI 690517|BI 690517
58402889|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
58290096|NCT04351451|PROCEDURE|thyroidectomy|total thyroidectomy
58290097|NCT03122392|DEVICE|AMS 800|AMS 800 Artificial Urinary Sphincter
58290098|NCT06135571|PROCEDURE|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
58290099|NCT01749410|BIOLOGICAL|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
58290100|NCT03791762|PROCEDURE|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
58290101|NCT03791762|PROCEDURE|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
58290102|NCT03791762|PROCEDURE|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
58290103|NCT05101759|PROCEDURE|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
58290104|NCT04117542|OTHER|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
58290105|NCT02163681|DRUG|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
58290106|NCT03243305|DRUG|AMPHORA|non-hormonal contraceptive vaginal gel
58290107|NCT05873270|OTHER|Wrist and ankle acupuncture|Patients in the intervention arm started the wrist and ankle acupuncture treatment 1 day before the surgery. Take up and down 1,2 area as a needle point, use hua tuo brand sterile acupuncture needle (specification: 0.25mm 25mm), into the skin disinfection into the needle, keep 30 subcutaneous needle and skin, when the operator under the needle, patients without acid swelling, pain, close to the skin dermis, to about 1.5 inches, give tape fixed 24h, left under the skin, until postoperative 3 day.
57934857|NCT06724978|DRUG|Midazolam|Participants will receive midazolam as a syrup.
57934858|NCT06724978|DRUG|Placebo|Participants will receive placebo as an oral suspension.
57934859|NCT00407654|DRUG|aflibercept|Given intravenously
58290108|NCT05258734|OTHER|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
58290109|NCT05258734|OTHER|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
58290110|NCT03210051|DEVICE|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
58290111|NCT03210051|PROCEDURE|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
58290112|NCT05123352|OTHER|collection of biological samples and clinical data|blood and feces samples
58290113|NCT04418050|PROCEDURE|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
58290114|NCT00208260|DRUG|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
58290115|NCT00208260|DRUG|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
58290116|NCT00208260|DRUG|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
58290117|NCT00208260|DRUG|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
58290118|NCT00208260|DRUG|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
58290119|NCT04744506|DEVICE|Tissue Marker Clip|Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
58290120|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
58290121|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
58290122|NCT04602156|PROCEDURE|Trocar percutaneous cholecystostomy|Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
58290123|NCT04602156|PROCEDURE|Seldinger percutaneous cholecystostomy|Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
58290124|NCT00496158|DRUG|Clevudine|
58290125|NCT00496158|DRUG|Adefovir|
58290126|NCT03822156|OTHER|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
58290127|NCT05799430|BEHAVIORAL|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~5. FP and PCN communicate to PCP final agreement with patient and/or carer~6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
58290128|NCT05799430|BEHAVIORAL|Control group|Usual care by FP an PCN
58290129|NCT06611956|OTHER|No intervention (observational study)|No intervention (observational study)
58290130|NCT02158377|DEVICE|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
58290131|NCT02158377|DEVICE|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
58290132|NCT03082469|DEVICE|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
58290133|NCT01720524|DRUG|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
58290134|NCT01720524|DRUG|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
58290135|NCT05556460|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
57729859|NCT03111927|OTHER|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
57934860|NCT04987567|DIETARY_SUPPLEMENT|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
58290136|NCT05556460|DRUG|Medical therapy|Subjects will continue to be managed on medical therapy, per physician discretion
58290137|NCT03300440|DIETARY_SUPPLEMENT|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
57729860|NCT03111927|OTHER|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
57729861|NCT02730819|DRUG|Illuminate Cream|Topical compound applied daily
57934861|NCT04987567|DIETARY_SUPPLEMENT|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
57934862|NCT06502106|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
57934863|NCT00127868|DRUG|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
57934864|NCT01491295|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
57934865|NCT01491295|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
58072142|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
57934866|NCT03715153|DRUG|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
57934867|NCT03715153|DRUG|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
57934868|NCT03715153|DRUG|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
57934869|NCT05362383|DEVICE|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
57934870|NCT04338828|DRUG|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
57934871|NCT04338828|OTHER|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
57934872|NCT00909181|DRUG|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
57934873|NCT00909181|DRUG|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
57934874|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
57934875|NCT03533413|PROCEDURE|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
57934876|NCT03533413|PROCEDURE|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
57934877|NCT05425069|DRUG|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
57934878|NCT00932425|DEVICE|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
57934879|NCT03632109|DRUG|gentamicin 360mg IM|360mg IM of gentamicin
57934880|NCT02125305|DRUG|Metformin|
57934881|NCT01956825|DIETARY_SUPPLEMENT|"slim water"|
57934882|NCT00832117|DRUG|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
57934883|NCT00832117|DRUG|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
57934884|NCT00832117|DRUG|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
57934885|NCT00832117|DRUG|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
58072143|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
57934886|NCT01873716|DRUG|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
57934887|NCT06035991|PROCEDURE|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
57934888|NCT05611788|BEHAVIORAL|Structure Learning Training|Participants will undergo 12 sessions of structure learning training lasting about 1 hour each along with 2 testing sessions interspersed within the 12 training sessions. Each session will be conducted in a remote-guided manner with an approximate 1-day gap in between sessions. The entire training will last around two weeks
58290138|NCT03300440|DIETARY_SUPPLEMENT|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
58290139|NCT00677313|DRUG|metreleptin|metreleptin injection
57934889|NCT04874181|DEVICE|Silverfit 3D|Virtual reality game used for rehabilitation of stroke patients
57934890|NCT05778188|DRUG|RLS-0071|RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
57934891|NCT05778188|DRUG|Placebo|Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
57934892|NCT00809523|DEVICE|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
57934893|NCT00809523|DEVICE|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
57934894|NCT02684513|DIETARY_SUPPLEMENT|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
57934895|NCT02684513|DIETARY_SUPPLEMENT|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
57934896|NCT05370716|DRUG|Polmacoxib|Polmacoxib
58290140|NCT01643447|DRUG|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
57934897|NCT05370716|DRUG|Pregabalin|Pregabalin
57934898|NCT00050765|DRUG|MyoCell™ Autologous Myoblasts|
57934899|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
57934900|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
57934901|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
58290141|NCT01643447|DRUG|Diammonium glycyrrhizinate|
58290142|NCT04616677|DRUG|JNJ-42847922|JNJ-42847922 tablet will be administered orally.
57934902|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
57934903|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
57934904|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
57934905|NCT00978835|BEHAVIORAL|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
57934906|NCT00978835|BEHAVIORAL|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
57934907|NCT03686956|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
57934908|NCT05575154|DEVICE|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
57934909|NCT00120263|PROCEDURE|Plasma Exchange|
57934910|NCT03653104|BEHAVIORAL|Melodica Intervention|The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
57934911|NCT03653104|BEHAVIORAL|Pulmonary Health Education|A single session including education about COPD and related health topics.
57934912|NCT02615704|DEVICE|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
57934913|NCT02615704|DEVICE|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
58290143|NCT03866356|BEHAVIORAL|intervention group|The women in the intervention group were provided care according to SICP
58290144|NCT05917327|DEVICE|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
57729862|NCT03939286|OTHER|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
57729863|NCT03939286|DIAGNOSTIC_TEST|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
57934914|NCT02615704|DEVICE|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
57934915|NCT02615704|DEVICE|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
57934916|NCT00427089|DRUG|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
57934917|NCT00427089|DRUG|Sodium Phosphate solution (NaP)|45 ml solution; BID
57934918|NCT02232620|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
57934919|NCT05919290|OTHER|MRI|Non-invasive imaging technique that is used to take pictures of organs within the body.
57934920|NCT00457873|DRUG|0.9% saline in 5% dextrose (intravenous)|
57934921|NCT00457873|DRUG|0.45% saline in 5% dextrose (intravenous)|
58290145|NCT03314883|DIAGNOSTIC_TEST|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
58290146|NCT05661695|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
58290147|NCT05273723|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: You planned to walk today in the park at 3pm."
57951237|NCT03685266|OTHER|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
57951238|NCT01698164|DRUG|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
57951239|NCT01698164|DRUG|Ximingting Tablet|Participants are given phytoestrogen.
57951240|NCT01698164|DRUG|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
58290148|NCT02829658|BEHAVIORAL|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
58290149|NCT02829658|OTHER|No intervention|No intervention
58290150|NCT00995722|DRUG|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
58290151|NCT00995722|DRUG|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
58290152|NCT06333886|DEVICE|Sacral electromyography|Assessment of neuro-sacral function using point-of-care sacral surface electromyography
58290153|NCT00205660|OTHER|Stayers|Participants remain on their current antipsychotic.
58290154|NCT00205660|OTHER|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
58290155|NCT00324974|DRUG|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
58290156|NCT00324974|DRUG|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
58290157|NCT05868681|DEVICE|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
58290158|NCT05264909|DEVICE|Multi-channel Transcranial direct current stimulation|A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
58290159|NCT05798143|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
58290160|NCT05205512|OTHER|Exercise Intervention|Maintain current levels of physical activity
58290161|NCT05205512|OTHER|Questionnaire Administration|Ancillary studies
58290162|NCT05205512|OTHER|Telemedicine|Participate in telehealth exercise intervention
58290163|NCT00868647|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
58290164|NCT00610272|RADIATION|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
58290165|NCT00610272|RADIATION|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
58290166|NCT00610272|RADIATION|Radiotherapy|8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
58290167|NCT00610272|RADIATION|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
58290168|NCT03307941|DRUG|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
58290169|NCT03307941|DRUG|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
58290170|NCT03307941|DRUG|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
58290171|NCT03307941|RADIATION|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
58290172|NCT03307941|OTHER|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
58290173|NCT03307941|PROCEDURE|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
58290174|NCT03252145|DEVICE|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
58290175|NCT03252145|OTHER|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
57951241|NCT05347160|PROCEDURE|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
58402890|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
58402891|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
58402892|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
58402893|NCT04351464|OTHER|physical therapy and reflexology|
58402894|NCT06605820|OTHER|None - Interview Only|None - Interview Only
58402895|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
58402896|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
58290176|NCT02477358|PROCEDURE|Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
58290177|NCT02477358|PROCEDURE|Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
58402897|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
58402898|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
58402899|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
58072144|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
58290178|NCT05678439|DIETARY_SUPPLEMENT|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
58290179|NCT05678439|OTHER|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
58290180|NCT06404749|DIETARY_SUPPLEMENT|fungal fiber|fungal fiber from mycelium
58290181|NCT06404749|DIETARY_SUPPLEMENT|inulin|long chain, degree of polymerization DP\>23
58402900|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
58402901|NCT02199314|DRUG|Desflurane|
58402902|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
58402903|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
58402904|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
58402905|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
58402906|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
58402907|NCT06065059|DRUG|Olaparib|PARP inhibitor
57729864|NCT03939286|OTHER|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
57729865|NCT03939286|OTHER|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
57729866|NCT03144557|OTHER|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
58402908|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
58402909|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
58402910|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
58402911|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
57951242|NCT02115204|DRUG|Epirubicin|
57951243|NCT02115204|DRUG|Cyclophosphamide|
58072145|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
58072146|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
58072147|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
58072148|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
57934922|NCT05949996|OTHER|A nurse-led symptom distress screening program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
57934923|NCT02137122|DEVICE|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
57934924|NCT02137122|DEVICE|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
58072149|NCT02944604|DRUG|PEG-rhG-CSF|
57934925|NCT00680823|DRUG|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
58072150|NCT02010099|DRUG|PP110 Gel|
58072151|NCT02010099|DRUG|PP110 Medicated wipes|
58072152|NCT02010099|DRUG|Preparation-H Cream|
58072153|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
58072154|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
58290182|NCT03370965|DIAGNOSTIC_TEST|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
57934926|NCT00680823|DRUG|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
58072155|NCT01855919|DRUG|Duloxetine|Administered orally
58072156|NCT01855919|DRUG|Placebo|Administered orally
58072157|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
58072158|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
58072159|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
58290183|NCT01147718|BIOLOGICAL|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
58290184|NCT06158035|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
57729867|NCT05318729|DEVICE|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
57934927|NCT06117371|DRUG|BEBT-607Tablets|"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."
57934928|NCT01852682|DRUG|PA21|
58290185|NCT06158035|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
58402912|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
57934929|NCT04643314|OTHER|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
57934930|NCT00121693|BEHAVIORAL|Music therapy (listening to specific music)|Listening to Music
57934931|NCT01062945|DRUG|Placebo|Matching administration of a placebo pill.
57934932|NCT01062945|DRUG|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
57934933|NCT02320955|PROCEDURE|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
58072160|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
58072161|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
58072162|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
58072163|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
58290186|NCT03783377|DRUG|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
58402913|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
58402914|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
58402915|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
58402916|NCT00099944|DRUG|vildagliptin|
58402917|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
58402918|NCT00099944|DRUG|LAF237 placebo|
58402919|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
58402920|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
58402921|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
58402922|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
58402923|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
58402924|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
58402925|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
58402926|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
58402927|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
58402928|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
58402929|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
57934934|NCT05812040|DIAGNOSTIC_TEST|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
58072164|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
58072165|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
58072166|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
58072167|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
58072168|NCT02283801|DRUG|Eslicarbazepine acetate|
58072169|NCT02283801|DRUG|Lamotrigine|
58290187|NCT03783377|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
58290188|NCT02058589|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
58290189|NCT02058589|DRUG|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
58402930|NCT00391469|DRUG|Rapid infusion of cold normal saline|
57934935|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will be provided food to meet the ketogenic diet prescription for the 4-week weight maintenance phase.
58290190|NCT06212986|DEVICE|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
57934936|NCT06736028|BEHAVIORAL|Calorie Restriction|Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.
57934937|NCT06736028|BEHAVIORAL|Behavioral Support|Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.
57934938|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will have food provided to meet the standard low-fat diet prescription for the 4-week weight maintenance phase.
57934939|NCT02843685|DRUG|Drotrecogin alfa activated|
57934940|NCT05137496|DRUG|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
57934941|NCT05137496|DRUG|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
57934942|NCT00313222|DRUG|bosentan|
57934943|NCT01903291|DRUG|dimethyl fumarate|As described in the treatment arm
57934944|NCT01672034|PROCEDURE|Laparoscopic gastric bypass surgery|
58290191|NCT04090385|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
57934945|NCT04597814|OTHER|No Intervention|No Intervention
57934946|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
57934947|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
57934948|NCT02872077|OTHER|Auricular acupuncture|
57934949|NCT03565276|DRUG|Tranexamic Acid|A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
57934950|NCT00578786|DRUG|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
58095124|NCT01361698|BEHAVIORAL|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
58290192|NCT06506058|DEVICE|EVS and EEG|"The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included)."
58402931|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
58402932|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
58402933|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
58402934|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
58402935|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
58402936|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
57934951|NCT01655927|DRUG|Tranexamic Acid|
57934952|NCT01655927|DRUG|Placebo: Saline|
57934953|NCT02236884|PROCEDURE|no-scar transanal total mesorectal excision(TME)|
57934954|NCT06006663|DRUG|Ibuprofen 400 mg.|synthetic intracanal medicament
58290193|NCT01857180|OTHER|Curriculum|
58290194|NCT06355375|BEHAVIORAL|exercise in pregnancy|aerobic exercise
58290195|NCT03489252|DEVICE|Monitoring Device|Wear Fitbit Charge 3
57934955|NCT06006663|DRUG|modified triple antibiotic paste|synthetic intracanal medicament
57934956|NCT06006663|DIETARY_SUPPLEMENT|curcumin|herbal intracanal medicament
57934957|NCT06006663|DIETARY_SUPPLEMENT|olive leaves extract|herbal intracanal medicament
57934958|NCT04272541|BEHAVIORAL|Psychoeducation program|Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.
57934959|NCT04272541|DRUG|Psychopharmacology intervention|Intervention program consisted of psychopharmacology. This will be executed during 3 months.
58402937|NCT05978492|DRUG|TXN10128|Participants receive TXN10128 capsules orally once daily.
57934960|NCT01129726|DEVICE|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
57934961|NCT05656625|OTHER|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
57934962|NCT02900183|DRUG|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
57934963|NCT03517189|PROCEDURE|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
57934964|NCT01290055|BIOLOGICAL|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
57934965|NCT01290055|OTHER|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
57934966|NCT05135026|DIAGNOSTIC_TEST|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
57934967|NCT05097729|DEVICE|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
57934968|NCT06387121|DRUG|Vincristine|Anti-tumor alkaloids
57934969|NCT06387121|DRUG|Cyclophosphamide|Alkylating agent
57934970|NCT06387121|DRUG|Dexamethasone|Glucocorticoids
57934971|NCT06387121|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
57934972|NCT06387121|DRUG|Inotuzumab ozogamicin|A humanized monoclonal antibody-drug conjugate targeting CD22
57934973|NCT06387121|DRUG|Blinatumomab|Bi-specific anti-CD19/CD3 antibodies
57934974|NCT06387121|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
57934975|NCT06387121|DRUG|Methotrexate|Antifolate antineoplastic drug
57934976|NCT06387121|DRUG|Cytarabine|Pyrimidine antimetabolites
57934977|NCT06387121|DRUG|Prednisone|Glucocorticoids
57934978|NCT01131949|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
57934979|NCT03015519|DRUG|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
57934980|NCT03015519|DRUG|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
58402938|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
57729868|NCT05732168|DIAGNOSTIC_TEST|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
57729869|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
57934981|NCT00182182|BEHAVIORAL|Primary care based disease management strategy|
57934982|NCT06022783|OTHER|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
57934983|NCT00644553|DRUG|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
57934984|NCT00644553|DRUG|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
57729870|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
57729871|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
57934985|NCT03482687|BEHAVIORAL|Me & You: Building Healthy Relationships|Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game...Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
57934986|NCT02977754|OTHER|This is an observational study|Imaging
57934987|NCT06147570|DRUG|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
57934988|NCT01530412|OTHER|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
57934989|NCT00587392|DEVICE|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
57951244|NCT02115204|DRUG|Docetaxel|
57951245|NCT02115204|DRUG|Methotrexate|
57951246|NCT02115204|DRUG|5-fluorouracil|
58072170|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
58072171|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
58402939|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
58072172|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
58072173|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
58072174|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
58095125|NCT06254859|PROCEDURE|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
58290196|NCT04820296|OTHER|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
58402940|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
58290197|NCT05995587|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
58290198|NCT05906342|OTHER|20% fat meal|Provided to participants once throughout duration of study, contains 20% fat
58402941|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
58402942|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
58402943|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
58402944|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
58290199|NCT05906342|OTHER|40% fat meal|Provided to participants once throughout duration of study, contains 40% fat
58290200|NCT05906342|OTHER|60% fat meal|Provided to participants once throughout duration of study, contains 60% fat
58290201|NCT05906342|OTHER|80% fat meal|Provided to participants once throughout duration of study, contains 80% fat
58290202|NCT04136483|BEHAVIORAL|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
58402945|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
58402946|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
58402947|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
58402948|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
58402949|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
57729872|NCT05498259|DRUG|Orelabrutinib|Orelabrutinib 150mg qd PO
57729873|NCT05498259|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
58402950|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
58402951|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
58402952|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
58402953|NCT01421303|DRUG|Enbrel|Enbrel
58402954|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
57934990|NCT06179329|PROCEDURE|Coronary artery bypass graft|Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
57934991|NCT04662398|DEVICE|JT Device|Shocker giving electrical shocks on testes
57934992|NCT06428981|OTHER|degenerative cervical diseases|Including herniation of the intervertebral disc, ossification of the posterior longitudinal ligament, and spinal stenosis, resulting in cervical radiculopathy, or degenerative cervical myelopathy, and were scheduled to undergo anterior discectomy with fusion surgery.
58290203|NCT06072118|DRUG|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
58290204|NCT02741375|DEVICE|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
58290205|NCT03944863|DRUG|Antibiotics|
58290206|NCT05887700|DEVICE|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
58290207|NCT02033044|OTHER|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
58402955|NCT03587025|DRUG|Placebo|Placebo
58402956|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
58402957|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
58402958|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
58402959|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
57729874|NCT05498259|DRUG|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
57934993|NCT00581685|DRUG|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
57934994|NCT02952040|DRUG|ASP1517|Oral dose
57934995|NCT02952040|DRUG|Lanthanum carbonate hydrate|Oral dose
57934996|NCT04559204|BIOLOGICAL|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
57934997|NCT04559204|BIOLOGICAL|IIV4|administrated with IIV4 only
57934998|NCT04559204|BIOLOGICAL|PPV23|administrated with PPV23 only
57934999|NCT04414371|OTHER|Yoga|Yoga Namaskar and Nadi Shuddhi
57951247|NCT02323269|DRUG|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
58290208|NCT02033044|OTHER|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
58290209|NCT06572163|DEVICE|Eximis CS (Contained Segmentation) System|The Eximis CS System is an integrated system consisting of a 900 mL Capture Bag, Inflation Mechanism, two Eximis Segmenters, and the Eximis RF Generator.
58290210|NCT04303195|DRUG|NG101|Capsules
58290211|NCT04303195|DRUG|Placebo|Capsules
58290212|NCT02587195|DRUG|Teriflunomide|
58402960|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
58402961|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
58402962|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
58402963|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
58402964|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
58402965|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
58402966|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
58402967|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
58402968|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
58402969|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
58402970|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
58072175|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
58072176|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
58072177|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
58072178|NCT00277862|DRUG|Ribavirin|
58072179|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
57935000|NCT02416752|DRUG|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
58072180|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
58072181|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
58490740|NCT02037685|BEHAVIORAL|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~* Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~* Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
57935001|NCT02416752|DRUG|choice of intra-operative opioids were left to the discretion of anesthesiologist|
57935002|NCT04263012|OTHER|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
57935003|NCT04062773|BEHAVIORAL|TRF|time restricted feeding group
57935004|NCT04062773|BEHAVIORAL|Normal timing of food intake|no time restricted feeding
57935005|NCT03583450|DEVICE|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
57935006|NCT05336916|BEHAVIORAL|Buddy|Mindfulness-based Cognitive Behavioural Therapy
57935007|NCT04052529|OTHER|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
57935008|NCT02920424|DRUG|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
58072182|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
58072183|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
58072184|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
58072185|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
58072186|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
58072187|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
58072188|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
58072189|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
58072190|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
58072191|NCT00318032|DRUG|multi-factorial intervention|
57935009|NCT02920424|DRUG|Placebo|Subjects will receive matching placebo.
57935010|NCT03827772|OTHER|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
58072192|NCT03724318|PROCEDURE|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
58072193|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
58072194|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
58072195|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
58072196|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
58072197|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
58290213|NCT04041596|DEVICE|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
58290214|NCT03749057|DRUG|Rivaroxaban|Rivaroxaban 15-20 mg daily
57935011|NCT03827772|OTHER|Standard of care treatment|Nutritional supplementation, supportive management.
57935012|NCT04952740|PROCEDURE|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
57935013|NCT04952740|PROCEDURE|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
57935014|NCT00409929|DRUG|AEB071|
57935015|NCT02912416|DIETARY_SUPPLEMENT|Probiotics|
58490741|NCT02037685|OTHER|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
58490742|NCT03800147|DRUG|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
57935016|NCT02912416|DIETARY_SUPPLEMENT|Placebo|
57935017|NCT04229511|DIAGNOSTIC_TEST|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
57935018|NCT03477513|RADIATION|Radation Therapy|Personalized Radiation Therapy
57935019|NCT03505385|BEHAVIORAL|Co-created intervention - Get Ready (GR)|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
57935020|NCT03841695|DEVICE|RMTC finger-hand robot (Mirror Hand)|The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
57935021|NCT03841695|OTHER|Conventional OT|The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
57935022|NCT05354076|DRUG|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
57935023|NCT03965078|DRUG|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
57935024|NCT00914992|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
57935025|NCT00914992|OTHER|Squatting|Squatting
57935026|NCT03339869|OTHER|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
58290215|NCT02195973|DRUG|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
58290216|NCT02537600|DRUG|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
58290217|NCT04721197|OTHER|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
58290218|NCT04721197|OTHER|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
58290219|NCT02091414|DRUG|mycophenolate mofetil (MMF)|1.0 g PO BID
58290220|NCT02091414|DRUG|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
58290221|NCT02091414|DRUG|corticosteroids|As per the practice of each participating center
58490743|NCT03800147|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
58490744|NCT03800147|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
58490745|NCT03800147|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
58402971|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
58402972|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
57935027|NCT04085796|OTHER|ICCI|Intentional Compassionate Communication Intervention
57935028|NCT00514774|DRUG|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
58072198|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
58072199|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
58072200|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
58072201|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
58072202|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
58072203|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
58290222|NCT05830890|PROCEDURE|Sentinel lymph node biopsy|After the total mesorectal excision, the indocyanine green was injected around the tumor via the anus. The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed and sent for rapid frozen pathological examination. Subsequently, a lateral lymph node dissection was performed.
58402973|NCT02104596|DEVICE|Xylitol|
57935029|NCT00514774|DRUG|placebo|placebo 600mg twice daily for study days 0 through 28
57935030|NCT00617136|DEVICE|Intraoperative warming (Bair Hugger)|Intraoperative warming
57935031|NCT00617136|DEVICE|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
58072204|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
58290223|NCT05830890|DRUG|Indocyanine green solution|Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
58290224|NCT05830890|DEVICE|fluorescence laparoscope|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node.
57935032|NCT00617136|DEVICE|Intraoperative warming (HotDog)|Intraoperative warming
58072205|NCT03553121|OTHER|walking|walking and not walking
58290225|NCT05830890|DIAGNOSTIC_TEST|pathological examination|The surgical specimens and sentinel lymph nodes were routinely examined for pathology.
58402974|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
58402975|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
58072206|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
58072207|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
58072208|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
58072209|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
58290226|NCT05830890|DIAGNOSTIC_TEST|rapid frozen pathological examination|The lateral green fluorescence imaging sentinel lymph nodes found during surgery was sent to make cryosections. And then a pathologist makes a rapid diagnosis under a microscope。
58402976|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
57935033|NCT04611620|BEHAVIORAL|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
57935034|NCT03870516|PROCEDURE|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
57951248|NCT03609697|BEHAVIORAL|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
58490746|NCT01518270|OTHER|No treatment|No treatment will be provided
58490747|NCT00757471|PROCEDURE|Brillant Blue|Membrane Peeling with Brillant Blue
57935035|NCT03870516|DEVICE|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
57935036|NCT01561625|OTHER|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
58490748|NCT00757471|PROCEDURE|Indocyanine Green|Membrane Peeling with indocyanine Green
57935037|NCT06346184|DRUG|HCP2303|Take 1 tablet once per period
57935038|NCT06346184|DRUG|RLD2302|Take 1 tablet once per period
57935039|NCT06346184|DRUG|RLD2102|Take 1 tablet once per period
57935040|NCT05687903|DRUG|TAK-861|TAK-861 tablets
57935041|NCT05687903|DRUG|Placebo|TAK-861 placebo matching tablets
57935042|NCT01388231|BEHAVIORAL|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
57935043|NCT01388231|BEHAVIORAL|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
57935044|NCT03610399|DRUG|Primaquine|Different total dose and supervision.
57935045|NCT04055181|DEVICE|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
57935046|NCT04055181|DEVICE|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
57935047|NCT04055181|DEVICE|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
57935048|NCT04055181|DEVICE|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
57935049|NCT01236664|BEHAVIORAL|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
57935050|NCT01236664|BEHAVIORAL|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
57935051|NCT03779919|DEVICE|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
57935052|NCT00264524|PROCEDURE|venipuncture to withdraw patient's blood|
57935053|NCT03000088|DEVICE|intubate with 60° angled stylet|
57935054|NCT03000088|DEVICE|intubate with 60° angled stylet|
57935055|NCT01681628|BEHAVIORAL|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
57935056|NCT04327830|OTHER|Decisional needs assessment|Assessment of decision-making needs
57935057|NCT03351881|OTHER|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
58072210|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
57935058|NCT00659399|DRUG|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
57935059|NCT05491252|BEHAVIORAL|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
57951249|NCT03609697|BEHAVIORAL|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
58402977|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
58402978|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
57935060|NCT05558826|DEVICE|HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software|After induction of anesthesia, intra-arterial catheterization will be done for invasive blood pressure monitoring and blood sampling as routine clinical practice for major laparoscopic surgery. Arterial line will be connected to HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software for arterial pressure waveform analysis. Dynamic indices including pulse pressure variation (PPV), stroke volume variation (SVV), Hypotension Prediction Index (HPI), Dynamic arterial elastance (Eadyn) and dP/dt will be continuously recorded. Changes in levels of intra-abdominal pressure and angles of Trendelenburg position will be recorded. Data analysis and statistics will be particularly performed to explore the effects of levels of intra-abdominal pressure and angles of Trendelenburg position on dynamic indices of arterial pressure waveform.
57935061|NCT00496236|DRUG|TNFerade biologic|
57935062|NCT01829360|BEHAVIORAL|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
57935063|NCT00143065|DRUG|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
57935064|NCT00143065|DRUG|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
57951250|NCT04762537|OTHER|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
57951251|NCT04762537|OTHER|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
58072211|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
58072212|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
58072213|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
58072214|NCT06547502|DRUG|GZR4|single dose
58290227|NCT05830890|PROCEDURE|total mesorectal excision|"1. Sharply dissect the vascular interface between the pelvic fascia parietal layer and the visceral layer around the mesentery under direct vision to ensure that the rectal mesentery of the resected specimen is intact and tearless.~2. For medium and low rectal cancer: the distal intestinal tube of the tumor should be resected ≥ 2 cm.~3. TME or mesenteric distal resection margin ≥ 5 cm away from the tumor."
58290228|NCT00960804|BIOLOGICAL|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
58290229|NCT00960804|BIOLOGICAL|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
58290230|NCT00960804|OTHER|Placebo|IV, q 8 weeks, for up to 80 weeks
58402979|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
58402980|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
58402981|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
58072215|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
57935065|NCT00143065|DRUG|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
58290231|NCT03198429|BEHAVIORAL|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
58402982|NCT05655325|OTHER|Attention control|Health education and stretching
57935066|NCT01603329|OTHER|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
57935067|NCT02939989|DRUG|Sofosbuvir|Tablet for oral administration
58290232|NCT03198429|BEHAVIORAL|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
58402983|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
58402984|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
58402985|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
58402986|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
58402987|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
58402988|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
58402989|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
57935068|NCT02939989|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
58402990|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
58402991|NCT02030080|BEHAVIORAL|Financial incentives|
57935069|NCT02939989|DRUG|Ribavirin|Tablet for oral administration
57935070|NCT03934255|OTHER|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
58072216|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
58402992|NCT02030080|BEHAVIORAL|Teams|
58402993|NCT02030080|BEHAVIORAL|Framing of feedback|
58072217|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
58072218|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
58072219|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
58290233|NCT01005901|DRUG|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
58290234|NCT01005901|DRUG|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
58290235|NCT05077553|DIETARY_SUPPLEMENT|TCI999 probiotic sachet|Testing product
57935071|NCT00643526|DEVICE|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
57935072|NCT06086093|DIETARY_SUPPLEMENT|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
58402994|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
58402995|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
57935073|NCT02645929|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
57935074|NCT03407404|COMBINATION_PRODUCT|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
57935075|NCT03407404|COMBINATION_PRODUCT|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
57935076|NCT00847184|DEVICE|Intubation|Intubation using the standard MacIntosh blade
57935077|NCT00847184|DEVICE|Airtraq|Intubation with the use of the Airtraq technique
57935078|NCT02123316|BIOLOGICAL|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
57935079|NCT02123316|BIOLOGICAL|Placebo|Placebo for subcutaneous injection
57935080|NCT00691990|PROCEDURE|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
58072220|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
58072221|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
58402996|NCT04053400|DRUG|Ketamine|
57935081|NCT00146081|BEHAVIORAL|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
57935082|NCT03892512|DRUG|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
57935083|NCT03892512|DRUG|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
58072222|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
58402997|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
58402998|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
58402999|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
58403000|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
57935084|NCT02611661|DEVICE|PET/MRI|
57935085|NCT02611661|RADIATION|Percutaneous ablation|
57935086|NCT02611661|RADIATION|Stereotactic body radiotherapy|
57935087|NCT02975492|DRUG|Cholecalciferol sequential dose|sequential dose administration of the treatment
57935088|NCT02975492|DRUG|Cholecalciferol daily dose|daily dose administration of the treatment
57935089|NCT01049243|DRUG|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
57935090|NCT05065931|OTHER|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
57935091|NCT04603365|DRUG|Pamiparib|Given PO
57935092|NCT04603365|DRUG|Temozolomide|Given PO
57951252|NCT03854708|DRUG|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
58072223|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
58072224|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
58072225|NCT00283673|BEHAVIORAL|Exercise|
58072226|NCT06475365|OTHER|Sodium chloride gargle|15mL salt water gargle
58072227|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
57935093|NCT06494384|BEHAVIORAL|Problem Solving Treatment as usual (PST as usual)|PST is a skills-based intervention that teaches clients a 7-step approach in which they 1) select a specific problem and define it in concrete terms,2) select a goal that is feasible to reach before next session, 3) brainstorm various ways to accomplish the goal, 4) evaluate pros and cons of each solution, including the likelihood they can actually implement it, 5) select the best solution, 6) create a plan to implement the solution, and 7) evaluate the plan afterward to ascertain the effectiveness of the solution. Practitioners teach and illustrate the PST process to clients at each session and encourage clients to implement action plans developed using the PST process. Clients are also encouraged to practice the PST process with additional problems between sessions, in order to gain mastery over the PST skills, enhance behavioral activation and as a result improve their belief in their ability to solve problems on their own (self efficacy).
58290236|NCT05077553|DIETARY_SUPPLEMENT|Placebo sachet|Blank
58403001|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
58403002|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
58403003|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
58403004|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
58403005|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
58403006|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
58403007|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
58290237|NCT04282629|DRUG|Milrinone Injection|administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14
58290238|NCT04282629|OTHER|Placebo|administration of placebo (intravenous glucose 5%) from Day 4 to Day 14
58290239|NCT05219604|DRUG|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
57729875|NCT05548595|DIETARY_SUPPLEMENT|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
57729876|NCT05548595|OTHER|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
58290240|NCT00006146|BIOLOGICAL|Approved influenza virus vaccine.|
58290241|NCT01351454|BEHAVIORAL|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
58290242|NCT01351454|BEHAVIORAL|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
58290243|NCT05676788|DEVICE|Hyperspectral Imaging|Identification of the intersegmental plane
58290244|NCT03059537|DRUG|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
58290245|NCT05201326|DRUG|Bevacizumab，Irinotecan and Re-radiotherapy|All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
58290246|NCT00401193|DRUG|Tranexamic acid tablets|3900 mg/Day
58290247|NCT00401193|DRUG|Tranexamic acid tablets|1950 mg/Day
58290248|NCT00401193|DRUG|Placebo tablets|
58290249|NCT00002034|DRUG|Zidovudine|
58290250|NCT00002034|DRUG|Ganciclovir|
58290251|NCT03153800|BIOLOGICAL|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
58290252|NCT02643433|BIOLOGICAL|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
58290253|NCT02643433|BIOLOGICAL|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
58290254|NCT06611579|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve using a transcatheter approach
58290255|NCT01916460|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
58290256|NCT05693129|DRUG|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
58290257|NCT04947410|DEVICE|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
58290258|NCT06328257|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
58290259|NCT04002791|DEVICE|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
58290260|NCT01360788|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
58403008|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
58403009|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
58403010|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
58403011|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
58403012|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
58403013|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
58403014|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
58403015|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
58072228|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
58403016|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
58403017|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
58403018|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
58403019|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
58403020|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
58403021|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
58403022|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
57935094|NCT06494384|BEHAVIORAL|Problem Solving Treatment Aid (PST-Aid)|PST-Aid is an internet-based tool to support the delivery of PST. PST-Aid incorporates decision support for the practitioner as well as client and provides PST treatment support functions (i.e., scaffolding), including patient problem lists and session worksheets. PST-Aid was designed to be used during remote sessions, such that practitioners and clients can interact throughout the session while collaboratively viewing and editing worksheets on their own browsers.This system was developed into a prototype that was piloted and found to be acceptable and with adequate usability.
57935095|NCT02022085|DEVICE|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
57935096|NCT00034190|DRUG|S-8184 Paclitaxel Injectable Emulsion|
58072229|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
58072230|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
58072231|NCT00015912|DRUG|thalidomide|Given orally
58403023|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
58403024|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
58403025|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
58403026|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
58403027|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
57935097|NCT05989802|DIAGNOSTIC_TEST|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
57935098|NCT05989802|DIAGNOSTIC_TEST|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
57935099|NCT05989802|DIAGNOSTIC_TEST|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
57935100|NCT05989802|OTHER|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
57935101|NCT03575078|DRUG|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
57935102|NCT02786134|RADIATION|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
57935103|NCT02786134|RADIATION|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
57935104|NCT01444014|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
57935105|NCT02316184|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
57935106|NCT02316184|BEHAVIORAL|Brief Advice|
57935107|NCT05440396|DIAGNOSTIC_TEST|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
57935108|NCT06087887|OTHER|no interventions|no interventions
58290261|NCT02590237|DEVICE|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
58290262|NCT02590237|DEVICE|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
58290263|NCT03233815|DRUG|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
58290264|NCT03233815|DRUG|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
58290265|NCT02666989|DRUG|placebo|2 placebo pills twice a day
58290266|NCT02762071|DRUG|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
58290267|NCT02762071|DRUG|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
58290268|NCT02121548|BEHAVIORAL|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
58290269|NCT02121548|BEHAVIORAL|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
58290270|NCT06376708|OTHER|platelet rich fibrin|platelet rich fibrin
57935109|NCT05259579|PROCEDURE|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
57935110|NCT04549727|OTHER|Organoids creation|Organoids are created from discarded tissue
58290271|NCT06376708|OTHER|Polyether ether ketone|Polyether ether ketone
58403028|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
57935111|NCT05041023|OTHER|Relative section|"Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death."
58072232|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
58072233|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
58290272|NCT06164483|DIAGNOSTIC_TEST|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR"
57935112|NCT05041023|OTHER|Caregiver section|"Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist."
57935113|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
58072234|NCT06029439|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
58072235|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
57935114|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
58072236|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
58072237|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
58290273|NCT06164483|OTHER|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
58290274|NCT05013242|DRUG|Zoladex|evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
58290275|NCT05013242|DRUG|Visanne|valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
58290276|NCT02191345|BEHAVIORAL|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
57935115|NCT02468596|OTHER|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
58072238|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
58490749|NCT02285608|OTHER|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
58290277|NCT05290948|DRUG|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
58290278|NCT05290948|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
58490750|NCT04159298|DEVICE|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
57935116|NCT02468596|OTHER|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
57935117|NCT04450563|DRUG|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
57935118|NCT01776736|DEVICE|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
57935119|NCT00283036|DRUG|Irbesartan|
57935120|NCT00741325|DRUG|granulocyte colony-stimulating factor (G-CSF)|
57935121|NCT00741325|DRUG|plerixafor|
57935122|NCT00741325|DRUG|Placebo|
58072239|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
58072240|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
58072241|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
58072242|NCT01277757|OTHER|Pharmacological Study|Correlative studies
58072243|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
58072244|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
58072245|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
58072246|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
58290279|NCT01564992|OTHER|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
57935123|NCT02572791|DRUG|Chlorhexidine|
57935124|NCT02572791|DRUG|Mupirocin|
57935125|NCT02572791|BEHAVIORAL|Household cleaning|
57935126|NCT03987724|OTHER|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
57935127|NCT00703053|BIOLOGICAL|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
57935128|NCT00703053|BIOLOGICAL|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
57935129|NCT03086265|DEVICE|THRIVE|active nasal oxygen delivery system
57935130|NCT03086265|DEVICE|Endotracheal tube|Plastic tube for supporting ventilation during surgery
57935131|NCT04914325|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
58072247|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
58072248|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
58072249|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
58072250|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
58290280|NCT03166488|DEVICE|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
58490751|NCT04270370|DRUG|LY3478045|Administered orally.
57935132|NCT04343248|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
57935133|NCT04343248|DRUG|Placebo|Placebo administered orally twice daily for six weeks
57935134|NCT04343248|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
57935135|NCT04462341|DEVICE|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
57935136|NCT04462341|DEVICE|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
57935137|NCT02882490|BEHAVIORAL|Parent Training|
57935138|NCT02882490|OTHER|Supportive Therapy|
57935139|NCT05163470|OTHER|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
57951253|NCT03854708|DRUG|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
58072251|NCT05303428|OTHER|Neuromodulation with low-intensity focused ultrasound|application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
58490752|NCT04270370|DRUG|Placebo|Administered orally.
57935140|NCT05163470|OTHER|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
57935141|NCT05443893|DEVICE|Application Research of key points detection technology|"Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis"
57935142|NCT02765620|OTHER|drug&radiation|"1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
57935143|NCT00148265|DRUG|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
57935144|NCT03359525|DRUG|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
57935145|NCT04609332|DIAGNOSTIC_TEST|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
57935146|NCT02015325|BEHAVIORAL|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
57935147|NCT06155838|OTHER|"Early Adolescent Skills for Emotions (EASE)"|"Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care"
58290281|NCT03948152|OTHER|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
57935148|NCT04764851|DRUG|ecopipam HCl ~2mg/kg/day|oral tablet
57935149|NCT04764851|COMBINATION_PRODUCT|Cohort 1 Probe Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
58072252|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
58290282|NCT03948152|OTHER|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
58290283|NCT05328453|DIAGNOSTIC_TEST|Fetal prenatal ultrasonographic evaluation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
58290284|NCT01184170|BEHAVIORAL|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
58290285|NCT03929263|BEHAVIORAL|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
58490753|NCT04270370|DRUG|Atorvastatin|Administered orally.
58490754|NCT02292836|OTHER|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
58490755|NCT00710541|DEVICE|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
57935150|NCT04764851|COMBINATION_PRODUCT|Cohort 2 Probe Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
58290286|NCT03291951|BEHAVIORAL|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
58290287|NCT06132282|BEHAVIORAL|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
58072253|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
57935151|NCT04764851|COMBINATION_PRODUCT|Cohort 3 Probe Cocktail|bupropion
57935152|NCT04668651|OTHER|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
57935153|NCT04031820|PROCEDURE|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
58072254|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
57935154|NCT04031820|PROCEDURE|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
58072255|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
58072256|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
57935155|NCT02492477|PROCEDURE|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
57935156|NCT02492477|DRUG|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
57935157|NCT02492477|DRUG|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
57935158|NCT00376584|DRUG|MK-0524A|
57935159|NCT00376584|DRUG|ER Niacin|
57935160|NCT00376584|DRUG|Placebo|
58290288|NCT04240223|DRUG|Brilacidin|Brilacidin
58290289|NCT04240223|DRUG|Placebo|Placebo
58403029|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
58403030|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
58403031|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
58403032|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
57935161|NCT02442726|DEVICE|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
57935162|NCT02709590|DRUG|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
57935163|NCT02709590|DRUG|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
57935164|NCT01701999|BIOLOGICAL|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
57935165|NCT04261504|BEHAVIORAL|IBMT|mindful presence in a non-judgmental way
57935166|NCT04261504|BEHAVIORAL|RT|progressive muscle relaxation
57935167|NCT00125762|DEVICE|FibroScan|
57935168|NCT00911625|DRUG|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
57935169|NCT00911625|DRUG|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
57935170|NCT02290860|PROCEDURE|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
57935171|NCT04915651|DEVICE|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
57935172|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
57935173|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
57935174|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
58290290|NCT04240223|RADIATION|4Mq 99mTc-DTPA|4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
57935175|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
57935176|NCT05859750|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
58072257|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
58290291|NCT00672633|DRUG|Lovaza|Lovaza , 4 grams/day orally for 6 months
58290292|NCT00672633|DRUG|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
58290293|NCT05265039|BEHAVIORAL|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
58290294|NCT05265039|BEHAVIORAL|Relaxation Training|Guided relaxation
58290295|NCT02521597|DEVICE|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
58290296|NCT02521597|DEVICE|Traditional otoscope|Use of a regular otoscope
58490756|NCT04335019|OTHER|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
58490757|NCT01493167|OTHER|limb casting/splinting|ankle and arm cast
58490758|NCT02923297|OTHER|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
57935177|NCT05859750|DRUG|Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin|oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
57935178|NCT01827579|BIOLOGICAL|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
57935179|NCT00727233|DRUG|Nexavar (BAY 43-9006) (Sorafenib)|
58290297|NCT06110598|DRUG|Capecitabine|Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
58290298|NCT00735514|BEHAVIORAL|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
58290299|NCT00735514|OTHER|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
58290300|NCT00735514|PROCEDURE|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
58290301|NCT00735514|PROCEDURE|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
58290302|NCT00735514|PROCEDURE|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
58290303|NCT00758498|DRUG|armodafinil|50 mg/day orally, once daily in the morning for 3 days
58290304|NCT00758498|DRUG|armodafinil|150 mg/day orally, once daily in the morning for 3 days
58290305|NCT00758498|DRUG|placebo|placebo tablets, once daily in the morning for 3 days
58290306|NCT04616612|BEHAVIORAL|SystemCHANGE (TM)|Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.
58290307|NCT04616612|OTHER|Attention Control|Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
58290308|NCT01816178|BEHAVIORAL|communication training|Participants were instructed in the use of a voices output communication aid.
58490759|NCT00271453|DRUG|Durogesic® (fentanyl transdermal drug delivery system)|
58490760|NCT00339001|DRUG|erythropoietin and early iron supplements|
57935180|NCT00727233|DRUG|Toxicity, Pharmacokinetics|
57935181|NCT00727233|DRUG|Pharmacodynamics|
57935182|NCT00727233|DRUG|Radiographic Evaluation|
57935183|NCT00727233|DRUG|QOL assessment, Neuropsychological|
57935184|NCT00727233|DRUG|Bony Toxicity|
57935185|NCT01979224|OTHER|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
57935186|NCT03038750|OTHER|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
57935187|NCT03038750|OTHER|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
57935188|NCT03038750|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
58290309|NCT02527174|DRUG|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
58403033|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
58403034|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
58403035|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
58403036|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
58403037|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
58290310|NCT02527174|DRUG|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
58403038|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
58403039|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
58403040|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
58403041|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
58403042|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
58403043|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
58403044|NCT01222091|DRUG|Placebo to Match Propranolol|
58403045|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
57935189|NCT03038750|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
57935190|NCT03038750|OTHER|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
57935191|NCT03038750|OTHER|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
58403046|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
58072258|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
58290311|NCT02527174|DRUG|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
58403047|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
58403048|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
58403049|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying|"Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours.~To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine."
58403050|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
58290312|NCT00525473|DRUG|Azathioprine|azathioprine usual dosage 100mg per day
58290313|NCT05849363|PROCEDURE|Posterior fossa decompression|Posterior fossa decompression：Posterior arch of atlas removal, decompression of cerebellum, detection of foramen magnum.
58290314|NCT05849363|PROCEDURE|Posterior Compression-Distraction-Reduction-Fixation|"Posterior Compression-Distraction-Reduction-Fixation：After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
58290315|NCT06613191|DRUG|Aspirin|Participant will be on aspirin alone or P2Y12 inhibitor alone
58290316|NCT06613191|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|Participant will be taking either P2Y12 inhibitor at time of colonoscopy
58290317|NCT04392219|DRUG|EIDD-2801|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
58290318|NCT04392219|DRUG|Placebo|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
58290319|NCT03761485|OTHER|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
58290320|NCT02377232|BEHAVIORAL|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
58290321|NCT02377232|BEHAVIORAL|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
58290322|NCT04570709|OTHER|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
58290323|NCT05138055|OTHER|No intervention|No intervention
58290324|NCT02213380|PROCEDURE|method of anesthesia|"General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
58290325|NCT03132090|DIAGNOSTIC_TEST|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
58290326|NCT04047823|DEVICE|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
58290327|NCT02822521|OTHER|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
58290328|NCT02822521|OTHER|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
58290329|NCT02943187|BEHAVIORAL|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
58290330|NCT02943187|DIETARY_SUPPLEMENT|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
58290331|NCT04808934|DRUG|Apixaban|Adults receiving apixaban
58290332|NCT04808934|DRUG|dabigatran|Adults receiving dabigatran
58290333|NCT04808934|DRUG|rivaroxaban|Adults receiving rivaroxaban
58290334|NCT04808934|DRUG|VKAs|Adults receiving VKA
58290335|NCT04609020|DEVICE|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
58403051|NCT02471560|DRUG|injectable MS DMT|As described above.
57935192|NCT03038750|OTHER|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
57935193|NCT03038750|OTHER|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
58290336|NCT04609020|DRUG|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
58290337|NCT04609020|DEVICE|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
58290338|NCT00762034|DRUG|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
58290339|NCT00762034|DRUG|Pemetrexed|Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
58403052|NCT00121758|BIOLOGICAL|LIPO-5|
58403053|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
58403054|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
57935194|NCT03038750|OTHER|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
58290340|NCT00762034|DRUG|Paclitaxel|Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
58290341|NCT00762034|DRUG|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
58290342|NCT00762034|BIOLOGICAL|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
58403055|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
58403056|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
57935195|NCT03038750|OTHER|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
58290343|NCT00762034|BIOLOGICAL|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
58290344|NCT04839198|BEHAVIORAL|Android Wear smartwatch|All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).
58290345|NCT04839198|BEHAVIORAL|Adaptive Treatment|"Participants will have access to a Dashboard button in the InsightTM app that displays personalized statistics based on their progress and patterns in the study.The dashboard will update as more data is collected about the participant's smoking habits, starting in the pre-quit period and continuing through the post-quit period. Second, in the post-quit period, participants will receive treatment messages when the machine learning algorithm determines that they are at high risk for lapse.At the follow-up visit, participants will complete a survey to evaluate what they liked and disliked about the intervention, how accurate they thought the app was in predicting their risk, and how useful they found the dashboard."
58403057|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
58403058|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
58403059|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
58403060|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
58403061|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
58403062|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
58403063|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
58403064|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
58403065|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
57935196|NCT03038750|OTHER|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
57935197|NCT03038750|OTHER|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
57935198|NCT03038750|OTHER|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
58290346|NCT04839198|DRUG|Nicotine Patch|At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)
58403066|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
57729877|NCT04272450|DIAGNOSTIC_TEST|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
58290347|NCT04839198|BEHAVIORAL|interviewing-based counseling|At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.
58290348|NCT04284826|PROCEDURE|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
58290349|NCT05802940|BEHAVIORAL|Electronic health record best practice alert|The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
58290350|NCT04993079|DEVICE|Clotild®|Use of Clotild® as neurovascular guidewire
58403067|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
58403068|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
57729878|NCT03825380|DRUG|Bimatoprost|Eyedrops
57729879|NCT03825380|DRUG|Lumigan®|Eyedrops
57729880|NCT01384617|PROCEDURE|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
57729881|NCT01384617|PROCEDURE|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
58403069|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
58403070|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
58403071|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
58403072|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
58403073|NCT02509052|DRUG|Leflunomide|Given PO
57935199|NCT03038750|OTHER|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
57935200|NCT03038750|OTHER|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
58290351|NCT03128619|PROCEDURE|Biopsy of Breast|Undergo biopsy
58290352|NCT03128619|DRUG|Copanlisib|Given IV
58290353|NCT03128619|OTHER|Laboratory Biomarker Analysis|Correlative studies
58290354|NCT03128619|DRUG|Letrozole|Given PO
58290355|NCT03128619|DRUG|Palbociclib|Given PO
58403074|NCT02509052|OTHER|Pharmacological Study|Correlative studies
58403075|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
58403076|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
58403077|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
57935201|NCT03038750|OTHER|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
57935202|NCT03038750|OTHER|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
57935203|NCT03038750|OTHER|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
57935204|NCT03038750|OTHER|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
57935205|NCT03038750|OTHER|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
58290356|NCT03128619|OTHER|Pharmacological Study|Correlative studies
58290357|NCT03223155|DRUG|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
58403078|NCT01661777|DRUG|Nasal steroid|
58403079|NCT01661777|PROCEDURE|Myringotomy tube placement|
58403080|NCT01661777|DRUG|Diuretic|
58403081|NCT01661777|DRUG|Antihistamine|
58403082|NCT01661777|BEHAVIORAL|Low salt diet|
58403083|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
58403084|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
58403085|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
58403086|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
57935206|NCT04587011|DRUG|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
58403087|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
58403088|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
58403089|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
58403090|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
58403091|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
58403092|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
57935207|NCT04587011|DRUG|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
58403093|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
58403094|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
58403095|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
57935208|NCT04587011|DRUG|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
57935209|NCT04587011|DRUG|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
57935210|NCT00918047|DRUG|SPN-804O|Open Label study
57935211|NCT02091661|PROCEDURE|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
58403096|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
58403097|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
58403098|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
57951254|NCT03854708|DRUG|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
58072259|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
58290358|NCT03223155|DRUG|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
58290359|NCT03223155|RADIATION|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
57729882|NCT06635278|BEHAVIORAL|Mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by a study researcher based on the Smith's (2005) protocol.~The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Meditation of the body (Body sense meditation)~* Meditation of the body (Rocking meditation)~* Meditation of the body (Breathing meditation)~* Meditation of mind (Mentra meditation)~* Meditation of mind (visual Image)~* Meditation of sense (External image)~* Meditation of the senses (A sound)~* Open monitoring (Mindfulness)"
58290360|NCT04582279|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
58290361|NCT05195216|BEHAVIORAL|Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form|Online questionnaires were administered to individuals.
58290362|NCT00858806|DRUG|Imatinib|"Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
58290363|NCT00820287|PROCEDURE|Biopsy of testicular tumor|testicular biopsies performed through open surgery
58290364|NCT02537665|OTHER|heating precondition|
58290365|NCT03744403|DRUG|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
58290366|NCT00563914|DRUG|ferroquine (SSR97193)|associated with artesunate
58290367|NCT00563914|DRUG|amodiaquine|associated with artesunate
58290368|NCT00069849|DRUG|ABT-089|
58290369|NCT02143024|BEHAVIORAL|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
58290370|NCT02143024|BEHAVIORAL|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
58290371|NCT04808258|DEVICE|C3+ Holter Monitor|Long-Term ECG monitoring (up to 7 days)
58290372|NCT04932096|DRUG|melatonin|melatonin supplementation
58290373|NCT04932096|OTHER|placebo|microcrystalline cellulose filled capsule
58290374|NCT02562599|DRUG|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
58290375|NCT02562599|RADIATION|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
58290376|NCT04984122|PROCEDURE|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
58290377|NCT05006599|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
58290378|NCT05006599|DRUG|Placebo|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
58290379|NCT05006599|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
58290380|NCT02914535|DRUG|Filgotinib|Tablet(s) administered orally once daily
58290381|NCT02914535|DRUG|Placebo|Tablet(s) administered orally once daily
58290382|NCT02366299|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
58290383|NCT02366299|DRUG|Propofol|Treatment of delirium by Propofol i.v. infusion
58290384|NCT06458907|DEVICE|TricValve® Transcatheter Bicaval Valve System|TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.
58290385|NCT06458907|DRUG|Optimal medical therapy|Optimal medical therapy
58290386|NCT03638141|DRUG|Durvalumab|Durvalumab IV
58290387|NCT03638141|DRUG|Tremelimumab (Cohort A dose)|Tremelimumab IV
58290388|NCT03638141|DRUG|Tremelimumab (Cohort B dose)|Tremelimumab IV
58290389|NCT05254340|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
58290390|NCT00096538|DRUG|valganciclovir|
58290391|NCT03603119|DRUG|Normal saline, Midazolam|2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
58290392|NCT03603119|DRUG|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
58290393|NCT02063594|DRUG|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
57935212|NCT02091661|RADIATION|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
57935213|NCT03730441|DEVICE|Colonoscopy|Endoscopic examination of large bowel
57935214|NCT02863627|OTHER|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
57935215|NCT02111460|RADIATION|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
57935216|NCT06013592|DIETARY_SUPPLEMENT|0 kcal liquid meal|Flavoured water, given as one meal at one study visit only
57935217|NCT06013592|DIETARY_SUPPLEMENT|600 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
57935218|NCT06013592|DIETARY_SUPPLEMENT|900 kcal liquid meal (only for group without obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
57935219|NCT06013592|DIETARY_SUPPLEMENT|1200 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
58290394|NCT02063594|DRUG|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
58290395|NCT01403571|DIETARY_SUPPLEMENT|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
57935220|NCT06013592|DIETARY_SUPPLEMENT|1800 kcal liquid meal (only for group with obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
57935221|NCT04260412|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
57935222|NCT04260412|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
57935223|NCT04260412|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
57935224|NCT01546974|DEVICE|HME filter Twin Star 55, Drager Medical, Germany|
57935225|NCT01546974|DEVICE|Heated humidification|
57935226|NCT00503243|DRUG|Delayed and extended release mesalazine|
57935227|NCT03248830|DEVICE|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
57935228|NCT05603884|DRUG|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L"
57935229|NCT05300321|DEVICE|frame lens|The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
57935230|NCT05889455|DRUG|Sildenafil|Oral administration of 100mg
57935231|NCT05889455|OTHER|Placebo|Placebo
57951255|NCT06073600|DRUG|Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
58290396|NCT01403571|DIETARY_SUPPLEMENT|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
58290397|NCT04213092|PROCEDURE|ERCP+LC|Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
58290398|NCT04213092|PROCEDURE|OC+CBD|Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
58290399|NCT02052297|OTHER|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
58290400|NCT01634503|GENETIC|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
58490761|NCT04121793|DEVICE|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
57935232|NCT05546294|DEVICE|Aerobic and home exercise|"A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
57935233|NCT05546294|OTHER|Home exercise|"The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
57935234|NCT05546294|OTHER|Healthy control group|Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
57935235|NCT06212635|DIAGNOSTIC_TEST|T-TAS|Blood test, laboratory assays
57935236|NCT03343392|DRUG|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
57935237|NCT03343392|DRUG|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
57935238|NCT00057356|DRUG|conivaptan|IV
57935239|NCT00057356|DRUG|placebo|IV
57935240|NCT00598260|PROCEDURE|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
57935241|NCT00277251|DRUG|Alendronate|
57935242|NCT03248583|OTHER|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
57935243|NCT03248583|OTHER|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
58072260|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
58072261|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
58290401|NCT02335255|DRUG|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
58290402|NCT02335255|DRUG|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
58290403|NCT02335255|DRUG|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
58290404|NCT00684164|DRUG|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
58290405|NCT00684164|OTHER|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
58290406|NCT06371690|OTHER|Web-Based Double-Eye Control Program|Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
58290407|NCT06159543|BEHAVIORAL|Mango|1.5 cups/day of mango for 12 weeks
58290408|NCT02454010|BIOLOGICAL|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
58290409|NCT00324662|DEVICE|Implantable cardioverter-defibrillator|
58290410|NCT03064048|DIETARY_SUPPLEMENT|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
58290411|NCT03064048|DIETARY_SUPPLEMENT|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
58290412|NCT05532384|BEHAVIORAL|Early resumption of oral intake|as above
58290413|NCT05532384|BEHAVIORAL|Late resumption of oral intake|as above
58290414|NCT00503347|DRUG|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
58490762|NCT00900952|OTHER|Clinical record review|
58490763|NCT02279264|DEVICE|RightSpot Infant pH Indicator|pH indicator
58490764|NCT03859583|DIETARY_SUPPLEMENT|Capsaicin|4 tsp of cayenne in a breakfast omelette
57935244|NCT03248583|OTHER|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
58290415|NCT00616876|DRUG|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
58290416|NCT00616876|DIETARY_SUPPLEMENT|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
58403099|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
58403100|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
58290417|NCT02855801|OTHER|constant exercise|
58403101|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
58403102|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
58403103|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
58403104|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
58403105|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
58403106|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
58403107|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
58403108|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
58403109|NCT01124123|DRUG|Bilastine|20 mg oral tablet
58403110|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
58403111|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
58403112|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
58403113|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
58403114|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
58403115|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
58403116|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
57935245|NCT01516658|DEVICE|Hydrogel coil|at least one Hydrogel coil have to use for embolization
58490765|NCT03859583|DIETARY_SUPPLEMENT|Control|breakfast omelette without cayenne pepper
57935246|NCT01516658|DEVICE|Bare platinum coil|only bare platinum coil have to use for embolization
57935247|NCT06157957|DIAGNOSTIC_TEST|Lung cancer screening with low dose CT scan|Low dose CT scan in active smokers or ex-smokers with an age between 50 and 75 years old
57935248|NCT01969097|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
57935249|NCT01969097|BEHAVIORAL|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
57935250|NCT00635856|DRUG|Gefitinib|Iressa
57935251|NCT02615470|BEHAVIORAL|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
58403117|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
57935252|NCT02615470|OTHER|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
57935253|NCT00172653|PROCEDURE|functional tasks|
57935254|NCT00345189|DRUG|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
57935255|NCT02944253|OTHER|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
57935256|NCT02944253|OTHER|Low energy diet 100 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
57935257|NCT02944253|OTHER|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
57935258|NCT05834686|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC
58072262|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
58072263|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
58072264|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
58290418|NCT02855801|OTHER|cryotherapy|
58290419|NCT02855801|OTHER|intermittent exercise|
58290420|NCT05705921|RADIATION|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
58290421|NCT05705921|RADIATION|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
58072265|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
58072266|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
58290422|NCT00005959|BIOLOGICAL|filgrastim|
57935259|NCT04687813|DRUG|Placebo|Placebo is a tablet with the same appearance as FTP-198
57935260|NCT06267989|PROCEDURE|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
57935261|NCT06267989|PROCEDURE|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
57935262|NCT02878551|OTHER|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
58072267|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
58072268|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
58290423|NCT00005959|BIOLOGICAL|rituximab|
58290424|NCT00005959|DRUG|cyclophosphamide|
58290425|NCT00005959|DRUG|doxorubicin hydrochloride|
58290426|NCT00005959|DRUG|prednisone|
58290427|NCT00005959|DRUG|vincristine sulfate|
58290428|NCT01979523|OTHER|Laboratory Biomarker Analysis|Correlative studies
58290429|NCT01979523|OTHER|Pharmacological Study|Correlative studies
58290430|NCT01979523|DRUG|Trametinib|Given PO
58290431|NCT01979523|DRUG|Uprosertib|Given PO
58290432|NCT06319729|DRUG|CDD-2105|A Chinese herbal medicine formula containing four granular herbs.
58290433|NCT06319729|DRUG|Placebo|Placebo
57729883|NCT02537912|DIETARY_SUPPLEMENT|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
58403118|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
58403119|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
58403120|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
58290434|NCT02493452|DRUG|Plecanatide|
58403121|NCT03297073|PROCEDURE|hepatic surgery|
57935263|NCT03708172|DEVICE|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
57935264|NCT03708172|OTHER|Cognitive Training|Computer-based cognitive training designed to enhance executive function
57935265|NCT03708172|OTHER|sham Cognitive Training|Computer-based inactive sham training
57935266|NCT01326078|DRUG|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
58290435|NCT02493452|DRUG|Placebo|
58403122|NCT00461864|PROCEDURE|ultrasound examination of the hip|
58403123|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
58403124|NCT00874458|PROCEDURE|magnetic resonance imaging|
58403125|NCT00874458|PROCEDURE|radiomammography|
58403126|NCT00874458|PROCEDURE|ultrasound imaging|
57935267|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
57935268|NCT00010920|DRUG|Ginkgo Biloba Extract|
57935269|NCT02347488|DEVICE|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
58403127|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
58403128|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
57935270|NCT02347488|PROCEDURE|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
57935271|NCT00217243|OTHER|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
57935272|NCT02843763|OTHER|Blood sample|Blood sample (28 ml)
57935273|NCT00860951|DEVICE|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
57935274|NCT00005920|DRUG|L-743,872|
57935275|NCT04873050|DRUG|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
57935276|NCT04873050|DRUG|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
57935277|NCT02877940|DEVICE|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
58290436|NCT02696486|BEHAVIORAL|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
58290437|NCT00292253|DEVICE|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
58290438|NCT00292253|DEVICE|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
58403129|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
58403130|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
58403131|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
58403132|NCT00322023|DRUG|D-serine|
58072269|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
58290439|NCT00752336|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
58290440|NCT04461548|BEHAVIORAL|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
58290441|NCT04983290|DIETARY_SUPPLEMENT|weancare-domus|Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
58290442|NCT06222970|PROCEDURE|Bone lid repositioning in course of sinus lift|"A full-thickness flap was elevated to access the lateral maxillary bone wall. Subsequently, a lateral access window was prepared using a piezoelectric device with specific bone tips, delimitating a trapezoidal bone lid.~Once the antrostomy was completed, the bone lid was gently removed with a Lucas surgical curette and anatomical tweezers, with great care to avoid damages to the Schneiderian membrane. The Schneiderian membrane was detached from the bone layer using specific sinus curettes. In case of sinus membrane perforation, the membrane was raised in all directions. All clinical cases received a cortical bone lamina to avoid graft particles displacement in the maxillary sinus. The elevated space was filled with chips of cortico-spongious bone. The antrostomy was then covered with the bone lid (osteotomy window), previously removed and preserved in physiological solution and fixed in the original anatomical position with a surgical glue. The flap was then repositioned and sutured."
58290443|NCT05929989|DIAGNOSTIC_TEST|ELISA TEST|ELISA TEST for cystatin D and fibrinogen like protein
58290444|NCT05323877|DEVICE|Test Device (PerQseal+)|Percutaneous arterial closure device
58290445|NCT04506723|PROCEDURE|Percutaneous Nephrolithotomy|PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
58290446|NCT04506723|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
58290447|NCT04506723|PROCEDURE|Radical nephrectomy|Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
58290448|NCT01514110|DRUG|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
58290449|NCT03295240|DRUG|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
58290450|NCT03295240|DRUG|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
58290451|NCT04186624|DRUG|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
58290452|NCT05365815|BEHAVIORAL|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
58290453|NCT05150457|DRUG|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
58290454|NCT00171626|DRUG|Diclofenac Topical Sodium Gel 1%|
58290455|NCT01083992|DRUG|Galvus (vitagliptin)|Galvus (vitagliptin)
58290456|NCT01083992|DRUG|Galvus + vitamin D|Galvus + vitamin D
58290457|NCT04026230|DRUG|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
58290458|NCT04026230|DRUG|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
58403133|NCT00322023|DRUG|D-serine|
58403134|NCT00322023|DRUG|D-serine|
58072270|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
58290459|NCT00791427|DRUG|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
58290460|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
58290461|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
58403135|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
57935278|NCT02877940|DEVICE|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
57935279|NCT02877940|DEVICE|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
57935280|NCT01212978|BEHAVIORAL|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
57935281|NCT06178250|OTHER|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
57935282|NCT02649049|OTHER|there is no intervention|
57935283|NCT00000551|BEHAVIORAL|health education|
58290462|NCT02074293|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
58072271|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
58072272|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
58072273|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
58072274|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
58072275|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
58290463|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58072276|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
58290464|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
58290465|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
58290466|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58290467|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58290468|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58290469|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58072277|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
58290470|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58072278|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
58072279|NCT04301271|DRUG|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
58290471|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
57935284|NCT00335465|DRUG|Insulin glargine|once a daily, sc injection, 100IU/ml
57935285|NCT00005007|DRUG|Etanercept|
58072280|NCT04301271|DRUG|Placebo oral tablet|12 weeks Placebo add-on
57935286|NCT00430482|BEHAVIORAL|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
57935287|NCT00430482|BEHAVIORAL|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
57935288|NCT05290688|GENETIC|50 ml blodd sampling|50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
57935289|NCT05144568|OTHER|Nutrition education|Nutrition education will be given to improve PMS
57935290|NCT05644457|GENETIC|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
57935291|NCT00626249|DRUG|Technosphere Inhalation Powder|Technosphere Inhalation Powder
58072281|NCT06331429|BEHAVIORAL|EmoTiCare|"The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication"
58072282|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
58072283|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
58403136|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
57935292|NCT00961753|DRUG|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
57935293|NCT00961753|DRUG|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
58072284|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
58072285|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
58072286|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
58072287|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
58290472|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
58290473|NCT02074293|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
58290474|NCT02074293|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
58290475|NCT01065558|DRUG|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
58290476|NCT05651386|OTHER|Diet|No blinded, no controlled intervention.
57935294|NCT00633165|DRUG|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
58072288|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
58290477|NCT04230343|BEHAVIORAL|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
58290478|NCT04230343|BEHAVIORAL|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
58290479|NCT00910845|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
58290480|NCT00910845|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
58290481|NCT05618288|BEHAVIORAL|mobile Health Breastfeeding Counseling|a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
58290482|NCT05618288|BEHAVIORAL|Standard of care breastfeeding counseling|The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
57935295|NCT04711148|OTHER|placebo|placebo
57935296|NCT04711148|DRUG|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
57935297|NCT02530372|DEVICE|UriCap-F|non-invasive urine collection device for women
57935298|NCT05018767|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57935299|NCT05315362|DEVICE|solid microneedle skin patch|intradermal vaccination with a skin patch
57935300|NCT05315362|BIOLOGICAL|mRNA-1273|administration of mRNA-1273 vaccine
58072289|NCT00863564|DIETARY_SUPPLEMENT|Cod|
58072290|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
57935301|NCT05315362|DEVICE|standard needle|intramuscular vaccination with a standard needle
57935302|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
57935303|NCT01431274|DRUG|tiotropium|low dose
57935304|NCT01431274|DRUG|olodaterol|one dose only
57935305|NCT01431274|DRUG|tiotropium|high dose
57935306|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
57935307|NCT01431274|DEVICE|Respimat|Respimat inhaler
57935308|NCT03186118|BIOLOGICAL|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
58072291|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
57935309|NCT05490173|OTHER|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
57935310|NCT03919929|DRUG|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
57935311|NCT03919929|OTHER|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
58072292|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
57935312|NCT01157013|OTHER|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
57935313|NCT04219813|OTHER|Urinary test|Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
57935314|NCT01147198|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
57935315|NCT01147198|DIETARY_SUPPLEMENT|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
58072293|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
58072294|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
58072295|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
58072296|NCT00167713|DRUG|Ibuprofen|
58290483|NCT00433433|DRUG|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
58403137|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
58403138|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
57935316|NCT03210103|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
57935317|NCT03210103|PROCEDURE|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
57935318|NCT03817866|DIAGNOSTIC_TEST|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
57935319|NCT04384393|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight.
57935320|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
57935321|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
58072297|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
58290484|NCT00433433|DRUG|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l
58290485|NCT00433433|RADIATION|IN-RT 30 Gy (+ boost 6 Gy residual)|
58290486|NCT00433433|PROCEDURE|FDG-PET scan|
57935322|NCT03163979|BIOLOGICAL|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
58403139|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
58072298|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
58403140|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
58403141|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
58403142|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
58403143|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
58403144|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
58403145|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
58403146|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
58403147|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
57729884|NCT02537912|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
58403148|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
58403149|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
58403150|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
57729885|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
57729886|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
57729887|NCT03792113|PROCEDURE|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
57729888|NCT03792113|OTHER|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
58403151|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
58403152|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
58403153|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
57935323|NCT03163979|BIOLOGICAL|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
57729889|NCT03792113|OTHER|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
58072299|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
58072300|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
58072301|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
58072302|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
58290487|NCT02680171|BEHAVIORAL|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
58290488|NCT02680171|OTHER|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
58290489|NCT01655095|DRUG|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
58290490|NCT01655095|DRUG|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
58403154|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
58403155|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
57729890|NCT00198640|PROCEDURE|Antibiotic use|
58403156|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
58403157|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
57729891|NCT06309147|DRUG|BMS-9894923|50 mg capsules, oral administration
57729892|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
58403158|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
57935324|NCT02921568|DEVICE|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
57935325|NCT02921568|DEVICE|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
57951256|NCT06073600|DRUG|Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
58072303|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
58072304|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.
58072305|NCT06305767|BIOLOGICAL|V940|Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
58072306|NCT06305767|OTHER|Placebo|V940 diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
58072307|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.
58072308|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant V940 plus pembrolizumab plus EV treatment. Adjuvant V940 plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
58072309|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
58290491|NCT01655095|DRUG|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
58290492|NCT01655095|DRUG|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
58290493|NCT01655095|PROCEDURE|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
58290494|NCT01655095|PROCEDURE|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
58072310|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
58072311|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
58290495|NCT02953496|DRUG|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
58403159|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
58403160|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
57935326|NCT06234150|OTHER|Aerobic dance|Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
58072312|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
58072313|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
58072314|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
58072315|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
58072316|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
58072317|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
58403161|NCT02348879|DRUG|Placebo|contains no active drug
58403162|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
58072318|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
58403163|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
58403164|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
58403165|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
58403166|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
58403167|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
57729893|NCT00244075|DIETARY_SUPPLEMENT|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
58072319|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
58072320|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
58072321|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
58072322|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
58072323|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
58072324|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
58072325|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
58290496|NCT02603211|DEVICE|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
58290497|NCT02895191|DRUG|ulinastatin|Patients will receive the study drugs for 7 to 14 days
58290498|NCT02895191|DRUG|placebo|Patients will receive the placebo for 7 to 14 days
58403168|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
58403169|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
58403170|NCT02193386|OTHER|Intervention period|Predefined intervention program
58403171|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
58403172|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
58403173|NCT00144469|DRUG|peginterferon alfa-2a|
58072326|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
58290499|NCT02589847|BIOLOGICAL|RBX2660|suspension of intestinal microbes
58290500|NCT02589847|DRUG|Standard of Care Antibiotics|Standard of Care Antibiotics
58290501|NCT06480019|BEHAVIORAL|Interpersonal psychotherapy|Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
58290502|NCT04283435|DRUG|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
58290503|NCT04283435|OTHER|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
58290504|NCT04283435|DRUG|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
58290505|NCT04642417|OTHER|dietary fiber literacy|education
58290506|NCT04642417|OTHER|routine care|routine care
58403174|NCT00144469|DRUG|rivavirin|
58290507|NCT02006199|BEHAVIORAL|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
58290508|NCT06274944|DEVICE|nasogastric tube placement pH confirmation device|Each participation will get the contents tested by the novel device and the standard of care procedure.
58403175|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
58072327|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
58072328|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
58290509|NCT03571776|PROCEDURE|Surgery|Laparoscopic ovarian cystectomy
58290510|NCT03571776|PROCEDURE|Sclerotherapy|US-aspiration and alcohol sclerosis
58290511|NCT03591224|OTHER|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
58290512|NCT03591224|OTHER|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
58290513|NCT03063619|DRUG|Afimoxifene|Applied topically
58290514|NCT03063619|OTHER|Laboratory Biomarker Analysis|Correlative studies
58290515|NCT03063619|OTHER|Placebo|Applied topically
58290516|NCT03063619|OTHER|Questionnaire Administration|Ancillary studies
58290517|NCT02273362|DRUG|Erlotinib|Given PO
58290518|NCT02273362|DRUG|Erlotinib Hydrochloride|Given PO
58290519|NCT02273362|OTHER|Laboratory Biomarker Analysis|Correlative studies
58290520|NCT02273362|OTHER|Quality-of-Life Assessment|Ancillary studies
58403176|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
58403177|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
58403178|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
57729894|NCT00244075|DRUG|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
57951257|NCT04004637|DRUG|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg."
58072329|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
58072330|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
58072331|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
58072332|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
58072333|NCT02406586|DRUG|Placebo|One tablet
58072334|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
58072335|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
58290521|NCT06171529|DEVICE|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
58290522|NCT06171529|OTHER|Placebo|placebo/Saline control injection
58290523|NCT00685867|OTHER|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
58290524|NCT00685867|BEHAVIORAL|Hand hygiene promotion|"* Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)"
58290525|NCT05090943|OTHER|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
58290526|NCT04817267|DEVICE|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
58290527|NCT02627573|PROCEDURE|Unrelated allogeneic stem cell transplantation|
58290528|NCT02627573|DRUG|Busulfan|
57729895|NCT00244075|BEHAVIORAL|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
57729896|NCT02014116|DRUG|LY3009120 capsule|Administered orally.
57729897|NCT02756624|DRUG|AC-170 0.24%|
57729898|NCT02756624|DRUG|AC-170 Vehicle|
57729899|NCT03110289|OTHER|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
58072336|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
58072337|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
58072338|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
58290529|NCT02627573|DRUG|Fludarabine monophosphate|
58290530|NCT02627573|DRUG|Tacrolimus|
58290531|NCT02627573|DRUG|Mycophenolate mofetil|
58290532|NCT02627573|DRUG|Cyclophosphamide|
58290533|NCT02627573|DRUG|Thymoglobulin|
58290534|NCT04736069|OTHER|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
58290535|NCT02646319|OTHER|Laboratory Biomarker Analysis|Correlative studies
58290536|NCT02646319|DRUG|Nanoparticle Albumin-Bound Rapamycin|Given IV
58290537|NCT02646319|OTHER|Quality-of-Life Assessment|Ancillary studies
58290538|NCT02149563|DEVICE|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
58403179|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
57935327|NCT06234150|OTHER|Fast-walking|Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
57935328|NCT02113579|DEVICE|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
57935329|NCT02113579|OTHER|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
57935330|NCT00962390|DRUG|S-equol|10mg S-equol 50mg S-equol, \& 150mg S-equol
57935331|NCT00962390|DRUG|Placebo|Placebo
57935332|NCT01541579|OTHER|Cx601|120 million cells administered by intralesional injection.
57935333|NCT01541579|OTHER|Saline solution|24 mL saline solution by intralesional injection
57935334|NCT01326208|PROCEDURE|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
57935335|NCT05745051|DIAGNOSTIC_TEST|CVAid Flow|CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
57935336|NCT04014036|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
57935337|NCT05831553|DIAGNOSTIC_TEST|Tissue Immune Profile|Tissue samples of the patients will be analized for the presence of TILs, CD73 and PDL1 (\>=1%)
57935338|NCT04121611|DRUG|Unfractionated heparin|"1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
57935339|NCT04121611|DRUG|Acetylsalicylic Acid (ASA)|"1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose"
57935340|NCT04180150|DRUG|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
58290539|NCT06517095|PROCEDURE|improved capsular polishing|In the polished group,utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. This process also allows for simultaneous polishing of a portion of the posterior capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.
58290540|NCT06517095|PROCEDURE|the conventional I/A polishing|the conventional I/A polishing the capsule
58290541|NCT01151969|BEHAVIORAL|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
58290542|NCT05681364|OTHER|metabonomics|profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
58403180|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
58403181|NCT02152371|DRUG|Dulaglutide|Administered SQ
57935341|NCT04180150|DRUG|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
57935342|NCT04180150|DRUG|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
58290543|NCT04201236|OTHER|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
58403182|NCT02152371|DRUG|Placebo|Administered SQ
58403183|NCT02152371|DRUG|Insulin Glargine|Administered SQ
58403184|NCT02152371|DRUG|Metformin|Administered orally
58403185|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
57935343|NCT03858790|DEVICE|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
57935344|NCT01050504|OTHER|Cytology Specimen Collection Procedure|Correlative studies
57935345|NCT01050504|OTHER|Laboratory Biomarker Analysis|Correlative studies
57935346|NCT05378646|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
57935347|NCT00617539|DRUG|irinotecan hydrochloride|
57935348|NCT00617539|DRUG|temozolomide|
57935349|NCT00789750|DRUG|Colesevelam|Colesevelam 625 mg tablets
57935350|NCT00789750|DRUG|Placebo|Placebo tablets appearing to be colesevelam
57935351|NCT00789750|DRUG|Pioglitazone|30 mg or 45 mg pioglitazone therapy
57935352|NCT02838082|BEHAVIORAL|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
57935353|NCT02838082|BEHAVIORAL|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
57935354|NCT04262635|DRUG|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
57935355|NCT04262635|DRUG|Cetuximab|Maintenance treatment ( ArmB )
57935356|NCT01512563|DEVICE|Biliary stent|palliative treatment for malignant patients
57935357|NCT03767036|DRUG|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
57935358|NCT03767036|DRUG|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
57935359|NCT00005081|DRUG|O6-benzylguanine|
57935360|NCT00005081|DRUG|carmustine|
57935361|NCT04255147|BIOLOGICAL|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
57935362|NCT01221727|DRUG|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
57935363|NCT01221727|DRUG|Midazolam|All subjects will receive two oral dose administrations of midazolam.
57935364|NCT00041080|DRUG|tamoxifen citrate|Given orally
57935365|NCT00041080|DRUG|thalidomide|Given orally
57935366|NCT00041080|OTHER|laboratory biomarker analysis|Correlative studies
57935367|NCT01069250|OTHER|There are no interventions in this study|
57935368|NCT03407651|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
57935369|NCT05398887|RADIATION|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
57935370|NCT05398887|RADIATION|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
57935371|NCT05398887|OTHER|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
57935372|NCT05782322|BEHAVIORAL|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
57935373|NCT05782322|BEHAVIORAL|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
57935374|NCT03764163|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
58290544|NCT04201236|OTHER|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
57935375|NCT03764163|DIAGNOSTIC_TEST|CT Scans|volume scans, perfusion scan, ventilation scan
57935376|NCT03764163|BEHAVIORAL|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
57935377|NCT03764163|DIAGNOSTIC_TEST|MRI|proton scans, hyperpolarized 3-Helium scan
57935378|NCT03764163|BIOLOGICAL|Xenon gas|ventilation CT scans
57935379|NCT04454697|DEVICE|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
58072339|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
57935380|NCT01174511|DRUG|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
57935381|NCT00094796|PROCEDURE|Exercise cardiopulmonary metabolic testing|
57935382|NCT00094796|PROCEDURE|Skeletal muscle biopsy|
58072340|NCT06563102|COMBINATION_PRODUCT|Albuterol/Budesonide|Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation
58072341|NCT06563102|COMBINATION_PRODUCT|Albuterol|Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
58072342|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
58290545|NCT05437445|DIAGNOSTIC_TEST|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
58290546|NCT00384202|DRUG|Tacrolimus|Immunosuppression
58290547|NCT05082337|DEVICE|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
58403186|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
58403187|NCT02042053|DEVICE|PET/CT|
58403188|NCT02042053|DEVICE|PET/MRI|
58072343|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
58072344|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
58072345|NCT02879968|OTHER|Non-interventional study|
58072346|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
58072347|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
57935383|NCT00094796|PROCEDURE|Brachial artery reactivity testing|
57935384|NCT00684450|PROCEDURE|Titration protamine|10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
57935385|NCT00684450|DRUG|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
58072348|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
58072349|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
58072350|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
58072351|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
58072352|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
58072353|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
58072354|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
58290548|NCT05214209|BEHAVIORAL|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
58290549|NCT05214209|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
58290550|NCT03825081|DRUG|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
58290551|NCT02875795|PROCEDURE|automatic speech processing tool|
58290552|NCT01922258|DRUG|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
57935386|NCT02066623|DEVICE|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
57935387|NCT04088825|OTHER|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
57935388|NCT03155373|DIAGNOSTIC_TEST|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
58072355|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
58072356|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
58072357|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
58072358|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
58072359|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
58072360|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
57935389|NCT03155373|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
57935390|NCT03155373|DIAGNOSTIC_TEST|Pulmonary function tests|Pre and post-operative pulmonary function tests
58072361|NCT04677738|DIETARY_SUPPLEMENT|B. breve|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
57935391|NCT03155373|DIAGNOSTIC_TEST|Cardiac MRI|Pre and post-operative cardiac MRI
57935392|NCT03155373|OTHER|Quality of life survey|Pre and post-operative quality of life survey (SF36)
57935393|NCT03155373|PROCEDURE|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
57935394|NCT03155373|PROCEDURE|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
57935395|NCT05921396|PROCEDURE|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
58403189|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
58072362|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
58072363|NCT00545974|DRUG|memantine|memantine 10mg BID
58072364|NCT00545974|DRUG|Placebo pill|Placebo pill BID
58072365|NCT03378531|DRUG|AEB1102|modified human arginase I
58072366|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
58072367|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
58290553|NCT04530929|DIETARY_SUPPLEMENT|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
58290554|NCT04530929|DIETARY_SUPPLEMENT|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
57935396|NCT05921396|PROCEDURE|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
58072368|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
58072369|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
58072370|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
58072371|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
58072372|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
58072373|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
58072374|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
58072375|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
58072376|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
58072377|NCT02819882|OTHER|No intervention|
58072378|NCT02291952|BEHAVIORAL|Meal schedule|
58290555|NCT01218971|DRUG|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
58290556|NCT01218971|DRUG|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
58290557|NCT05205382|OTHER|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
58403190|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
58403191|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
58403192|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
57935397|NCT00900523|GENETIC|protein expression analysis|protein expression analysis
57935398|NCT00900523|OTHER|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
57935399|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid
57935400|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid.
57935401|NCT00528983|DRUG|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
57935402|NCT00528983|DRUG|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
57935403|NCT00528983|DRUG|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
57935404|NCT03684590|DEVICE|ANI-guided opioid administration|Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)
57935405|NCT03684590|OTHER|Standard opioid administration|Intraoperative opioid will be administered according to standard practice during surgery.
57935406|NCT04465448|OTHER|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
58290558|NCT05205382|OTHER|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
58290559|NCT05205382|OTHER|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
58403193|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
58403194|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
58403195|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
58403196|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
58403197|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
57935407|NCT02180971|PROCEDURE|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
57935408|NCT02180971|PROCEDURE|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
57935409|NCT00929656|PROCEDURE|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
57935410|NCT00929656|PROCEDURE|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
57935411|NCT00929656|PROCEDURE|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
57935412|NCT06159023|DEVICE|bronchial washing using a thin bronchoscope|For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
57935413|NCT06033157|BEHAVIORAL|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
58403198|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
58403199|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
58403200|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
58403201|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
57935414|NCT05662696|OTHER|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
57935415|NCT00713817|DRUG|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
57935416|NCT00713817|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
57935417|NCT05967117|DRUG|Iohexol (320mgI/mL) with 120kVp|Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
57935418|NCT05967117|DRUG|Iohexol (320mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
57935419|NCT05967117|DRUG|Iohexol (270mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
57951258|NCT04307992|DEVICE|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
58403202|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
58403203|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
58403204|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
58403205|NCT04660825|OTHER|Control|Maintained usual physical activity
58403206|NCT00724685|DRUG|Naropeine (Ropivacaine)|
57935420|NCT05967117|DRUG|Iohexol (240mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
57935421|NCT06232928|DEVICE|Early Class II elastics|Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
57935422|NCT06232928|DEVICE|Conventional Class II elastics|patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
57935423|NCT04480060|DIAGNOSTIC_TEST|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
57935424|NCT00512746|OTHER|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
57935425|NCT00512746|OTHER|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
57935426|NCT00512746|PROCEDURE|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
57935427|NCT00512746|PROCEDURE|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
57935428|NCT01379573|DRUG|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
57935429|NCT03762720|DEVICE|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
57935430|NCT00469001|PROCEDURE|Treatment according NT Pro BNP level|
57935431|NCT01791647|DRUG|metformin 1500 mg|
57935432|NCT01791647|DRUG|myoinositol 1500 mg|
57935433|NCT03640468|DRUG|Ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg
57935434|NCT03640468|DRUG|Ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
57935435|NCT03640468|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg
57935436|NCT03640468|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
57935437|NCT03640468|DRUG|Normal saline|This group will receive normal saline 10 mL
57935438|NCT01923350|BEHAVIORAL|Weight Reduction Intervention|"The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
58072379|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
58072380|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
58403207|NCT00724685|DRUG|Placebo|saline
58403208|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
58403209|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
58403210|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
58403211|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
58403212|NCT00634712|DRUG|Candesartan|
57729900|NCT03110289|OTHER|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
58403213|NCT00634712|DRUG|Placebo|
58403214|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
58403215|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
58403216|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
57935439|NCT01923350|BEHAVIORAL|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
57935440|NCT01923350|BEHAVIORAL|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
58290560|NCT06038500|OTHER|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
58403217|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
57935441|NCT01923350|BEHAVIORAL|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
58290561|NCT00596050|DRUG|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
57729901|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
58290562|NCT00596050|DRUG|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
58290563|NCT01127048|DRUG|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
58290564|NCT01127048|DRUG|Placebo|Suppositories containing no Ivy leaves dry extract
58290565|NCT02609386|BIOLOGICAL|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
58403218|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
58403219|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
58403220|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
57729902|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
57729903|NCT00424437|DRUG|Inhaled human insulin|
57729904|NCT06635980|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
57729905|NCT06635980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57729906|NCT06635980|PROCEDURE|Breast Surgery|Undergo breast surgery
57935442|NCT05915520|BEHAVIORAL|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
57935443|NCT05915520|OTHER|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
57935444|NCT03373981|DEVICE|rTMS|repetitive transcranial magnetic stimulation
58290566|NCT02609386|DRUG|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
58290567|NCT02609386|DRUG|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
58290568|NCT02609386|DIETARY_SUPPLEMENT|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
58290569|NCT02609386|DRUG|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
58290570|NCT05982106|DRUG|TQ05105 Tablets|TQ05105 tablet is a novel JAK2 inhibitor.
58290571|NCT00435110|PROCEDURE|standard ventilatory settings|
58290572|NCT00435110|PROCEDURE|PEEP and FiO2|
58290573|NCT04199377|PROCEDURE|HIP KNEE REPLACEMENT|HIP KNEE REPLACEMENT
58290574|NCT00482170|DEVICE|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
58290575|NCT00482170|DEVICE|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
58403221|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
58403222|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
58403223|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
58403224|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
58403225|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
57935445|NCT04329481|DIETARY_SUPPLEMENT|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
58290576|NCT03777280|DEVICE|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
58290577|NCT03777280|DEVICE|cobalt chromium framework RPD|standard framework device
57935446|NCT05671783|OTHER|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
57935447|NCT05145335|DEVICE|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
57935448|NCT05145335|DEVICE|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
58290578|NCT00089518|DRUG|Valsartan|
57935449|NCT01507467|RADIATION|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
57935450|NCT01507467|RADIATION|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
57935451|NCT02361944|DRUG|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
57935452|NCT02361944|DRUG|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
57935453|NCT03641495|OTHER|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
57935454|NCT03641495|OTHER|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
57935455|NCT01831921|BEHAVIORAL|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
57935456|NCT01831921|BEHAVIORAL|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
57935457|NCT01968850|DRUG|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
57951259|NCT00892385|DRUG|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
57951260|NCT00892385|DRUG|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
57951261|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
57951262|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
58290579|NCT02629744|DRUG|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
58290580|NCT02629744|DEVICE|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
58290581|NCT05722743|BEHAVIORAL|Harmony at HOME|The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
58290582|NCT05722743|BEHAVIORAL|National Institute on Aging Program|"Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage."
58290583|NCT03565003|DRUG|JAB-3068|25 mg,100 mg
58403226|NCT04193085|OTHER|Observational|Observational
57729907|NCT06635980|DRUG|Chemotherapy|Receive SOC chemotherapy
57935458|NCT00792454|BEHAVIORAL|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
57935459|NCT00385203|DRUG|AZD2171|45 mg oral tablet once daily dose
57935460|NCT05290922|DIAGNOSTIC_TEST|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
58403227|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
58403228|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
57935461|NCT04453436|DRUG|Tenofovir Disoproxil|Genotipic resistance test
57935462|NCT00482443|OTHER|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
58072381|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
58072382|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
58290584|NCT04411758|DIETARY_SUPPLEMENT|Propolis|Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
58290585|NCT04411758|DIETARY_SUPPLEMENT|Placebo|Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
58290586|NCT01475344|DRUG|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
58290587|NCT01475344|DRUG|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
58290588|NCT05621395|OTHER|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
58290589|NCT05621395|OTHER|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
58290590|NCT03235323|DEVICE|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
58290591|NCT05161845|BIOLOGICAL|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
58403229|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
58403230|NCT02354131|DRUG|Bevacizumab|
58403231|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
58403232|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
58403233|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
57729908|NCT06635980|PROCEDURE|Computed Tomography|Undergo CT
57935463|NCT00482443|OTHER|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
57935464|NCT01965977|DRUG|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
57935465|NCT02844621|DRUG|Omeprazole|20mg orally once daily
58072383|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
58072384|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
58403234|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
57729909|NCT06635980|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEDM
57729910|NCT06635980|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiotherapy
57729911|NCT06635980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57729912|NCT06635980|PROCEDURE|Positron Emission Tomography|Undergo PET
58290592|NCT04811807|DEVICE|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
58290593|NCT04369846|DRUG|GM-XANTHO onitment|Onitment application
58290594|NCT04369846|DRUG|Placebo onitment|Onitment application
58290595|NCT02119078|OTHER|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
58290596|NCT05828368|PROCEDURE|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
58290597|NCT05207527|OTHER|cardiovascular exercise|Exercise that mainly stimulates the cardiovascular and respiratory systems.
58290598|NCT05207527|OTHER|Muscle strength|Exercise that primarily stimulates the musculoskeletal system.
58290599|NCT05207527|OTHER|Mixed|Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
58290600|NCT01556997|DRUG|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
58290601|NCT01556997|DRUG|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
58290602|NCT01556997|DRUG|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
58290603|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
58403235|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
58403236|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
58403237|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
58403238|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
58403239|NCT00673205|DRUG|Placebo|
58403240|NCT02567370|DRUG|AMG 581|Active drug
58290604|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
58290605|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
58290606|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
58290607|NCT05138978|DRUG|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
57729913|NCT06635980|OTHER|Survey Administration|Ancillary studies
57729914|NCT06635980|PROCEDURE|Tissue Collection|Undergo tissue collection
57729915|NCT06635980|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
57729916|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
58072385|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
58072386|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
58290608|NCT05138978|DRUG|Colgate Cavity Protection|Toothpaste
58290609|NCT02019550|DEVICE|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
58290610|NCT02019550|DEVICE|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
58290611|NCT02239445|DRUG|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
58290612|NCT02239445|DRUG|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
58290613|NCT02239445|DRUG|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
58403241|NCT02567370|DRUG|Placebo|Placebo
58403242|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
58072387|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
58072388|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
58072389|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
58072390|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
58290614|NCT06067997|DIAGNOSTIC_TEST|pulmonary embolism diagnosis|"The diagnosis of pulmonary embolism will be made using the diagnostic algorithm suggested by the 2019 European guidelines . The pre-test clinical probability of pulmonary embolism will be defined based on the simplified Wells score. In patients with a low pre-test clinical probability and a D-dimer level below the threshold value the diagnosis of pulmonary embolism will be excluded. The D-dimer level will be measured using the quantitative assay routinely used in each participating center; the threshold value for a positive result compared to a negative result is 500 μg per milliliter for patients under 50 years of age. For each additional decade of age, the exclusion cutoff will increase by 100 μg per milliliter.~The criterion for the presence of pulmonary embolism is the detection of an intraluminal filling defect on CT."
58290615|NCT04293484|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
58290616|NCT04293484|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
58290617|NCT02210507|OTHER|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
58290618|NCT02210507|OTHER|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
58290619|NCT02210507|OTHER|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
58290620|NCT05065294|DRUG|Psilocybin therapy|- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
58403243|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
58403244|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
58403245|NCT02557100|DRUG|Abatacept|
58403246|NCT02557100|DRUG|Adalimumab|
58403247|NCT02557100|DRUG|Methotrexate|
58403248|NCT01163357|DRUG|bortezomib|Given IV
58403249|NCT01163357|DRUG|fludarabine phosphate|Given IV
58403250|NCT01163357|OTHER|melphalan|Given IV
58403251|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
58403252|NCT01163357|DRUG|tacrolimus|Given IV and orally
58403253|NCT01163357|DRUG|sirolimus|Given orally
58403254|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
58403255|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
58403256|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
58403257|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
58403258|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
58403259|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
58072391|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
58290621|NCT04955613|DEVICE|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
58290622|NCT04955613|DEVICE|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
58403260|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
58403261|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
58403262|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
57935466|NCT05197036|PROCEDURE|Total Knee Arthroplasty|A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
58403263|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
57935467|NCT00702325|DRUG|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
58072392|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
58403264|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
58403265|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
58403266|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
58072393|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
58072394|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
58072395|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
58290623|NCT05119075|OTHER|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
58403267|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
57935468|NCT00702325|DRUG|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
58290624|NCT05119075|OTHER|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
58290625|NCT01116622|DRUG|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
57951263|NCT04192487|DRUG|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
57951264|NCT01383577|PROCEDURE|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
57951265|NCT01383577|PROCEDURE|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
58290626|NCT01116622|DRUG|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
58290627|NCT04054817|DEVICE|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
58290628|NCT03479008|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
58290629|NCT06248684|OTHER|standardized prevention and therapy measures|Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
58290630|NCT05454020|DRUG|XG004|XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
58290631|NCT05454020|DRUG|Placebo|Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
58290632|NCT01465230|DRUG|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
58290633|NCT04346160|DIAGNOSTIC_TEST|Schirmer Test I|Collection of tear fluid
58290634|NCT01290952|PROCEDURE|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
58290635|NCT01290952|PROCEDURE|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
58290636|NCT03730376|OTHER|Cost Information|participants will be given information on the personal and societal costs
58290637|NCT06431529|BIOLOGICAL|tumor neoantigen specific T cell|Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
58290638|NCT01080092|BEHAVIORAL|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
58290639|NCT01080092|BEHAVIORAL|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
58290640|NCT05459337|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
58290641|NCT02565602|OTHER|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
58290642|NCT02565602|OTHER|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
58290643|NCT02565602|DIETARY_SUPPLEMENT|Vitamin D|One tablet daily (400IU per tablet)
58290644|NCT01298167|DEVICE|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
58290645|NCT04868578|DIETARY_SUPPLEMENT|study treatment PPI|patient take PPI every day during 12 months
58290646|NCT04868578|DIETARY_SUPPLEMENT|Placebo comparator|patient take PPI placebo every day during 12 months
58290647|NCT02637310|DRUG|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
58403268|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
58290648|NCT02637310|DRUG|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
58290649|NCT01947842|DEVICE|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
58290650|NCT06613152|DRUG|HS-IT201 Injection|Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
58290651|NCT04940663|BEHAVIORAL|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
58290652|NCT04970121|DRUG|Duloxetine|"Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition."
58290653|NCT00977613|BEHAVIORAL|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
58290654|NCT02496364|OTHER|Observational|
58290655|NCT04561661|PROCEDURE|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
58290656|NCT04561661|PROCEDURE|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
58290657|NCT03571685|BEHAVIORAL|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
58290658|NCT02258217|DRUG|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
58290659|NCT01570257|PROCEDURE|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
58290660|NCT05281757|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
58290661|NCT00848757|BEHAVIORAL|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
58290662|NCT05534243|OTHER|Standard neuromuscular blocker practices|Usual care neuromuscular blocker in the ED
58290663|NCT05534243|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
58290664|NCT01710397|OTHER|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
58290665|NCT03074604|PROCEDURE|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
58290666|NCT03074604|PROCEDURE|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
58290667|NCT03074604|PROCEDURE|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
58403269|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
57729917|NCT01552044|DRUG|Spironolactone|25mg tablet once a day for 1 month
57729918|NCT01552044|DRUG|Placebo|one tablet once a day for 1 month
57729919|NCT02169908|DEVICE|Thermotest|
57729920|NCT02169908|DEVICE|von Frey hairs|
58403270|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
58403271|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
58403272|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
58403273|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
58403274|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
58403275|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
58403276|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
58403277|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
58403278|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
58403279|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
58403280|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
58403281|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
58403282|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
58403283|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
58403284|NCT01314170|DEVICE|Susanna Implant|device
58403285|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
58403286|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
58403287|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
58403288|NCT00125463|DRUG|Candesartan cilexetil|
58403289|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
58403290|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
58403291|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
58403292|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
58403293|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
58403294|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
58403295|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
58403296|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
58403297|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
58403298|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
58403299|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
58403300|NCT02778555|BEHAVIORAL|Questionnaires|
58403301|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
58403302|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
58403303|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
58403304|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
58403305|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
58403306|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
58403307|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
58403308|NCT00236990|DRUG|pentosan polysulfate sodium|
58403309|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
58403310|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
58403311|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
58290668|NCT00136214|DIAGNOSTIC_TEST|MR brain and neuropsychiatric tests|
58403312|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
58403313|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
58290669|NCT00935077|OTHER|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
58290670|NCT00935077|OTHER|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
58290671|NCT00935077|OTHER|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
58290672|NCT01073163|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
58290673|NCT01073163|DRUG|Rituximab|Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
58290674|NCT06553404|DEVICE|Myoslow|The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
58290675|NCT06553404|DEVICE|Single Vision|Single vision glasses
58290676|NCT05204290|DRUG|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
58290677|NCT05204290|RADIATION|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
58290678|NCT05204290|OTHER|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
58290679|NCT03293394|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
58290680|NCT03293394|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
58290681|NCT03147118|DIAGNOSTIC_TEST|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
58290682|NCT04094779|OTHER|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
58290683|NCT04094779|OTHER|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
58290684|NCT00848029|BIOLOGICAL|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
58290685|NCT01737411|DRUG|solifenacin|
58290686|NCT01737411|PROCEDURE|cesa/vasa|surgical repair of USL
58290687|NCT00696007|DRUG|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
58290688|NCT00696007|OTHER|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
58403314|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
58403315|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
58403316|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
58403317|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
58403318|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
58290689|NCT00036088|DRUG|Olanzapine|
58290690|NCT00223665|DRUG|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
58290691|NCT00223665|DRUG|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
58403319|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
58403320|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
57729921|NCT00855517|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
57729922|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
58072396|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
58290692|NCT01263067|BEHAVIORAL|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
58290693|NCT01263067|BEHAVIORAL|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
58290694|NCT03238794|PROCEDURE|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
58290695|NCT03238794|OTHER|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
58290696|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
58290697|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
58290698|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
58290699|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
58290700|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
58290701|NCT04591756|OTHER|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
58290702|NCT04949282|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
58290703|NCT04949282|DEVICE|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
58290704|NCT01419535|DRUG|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
58290705|NCT01419535|DRUG|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
58290706|NCT04183725|DRUG|Reduning injection|"Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5."
58290707|NCT04183725|DRUG|Oseltamivir phosphate granules|"Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5."
58290708|NCT04811859|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
58290709|NCT03076996|BEHAVIORAL|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
58403321|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
58403322|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
57729923|NCT01545011|OTHER|Inspiratory muscle training|Inspiratory muscle training
57729924|NCT01492881|DRUG|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
58072397|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
58072398|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
58403323|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
58403324|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
58403325|NCT04774536|DRUG|CRISPR_SCD001|CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
57729925|NCT01492881|DRUG|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
57729926|NCT01492881|DRUG|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
57729927|NCT06193421|DRUG|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
58072399|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
58072400|NCT01274104|OTHER|Placebo|Placebo
58072401|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
58072402|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
57935469|NCT06159855|OTHER|Intervention group: nurse-led education for bowel preparation of colonoscopy|"1. PRE-TEST~   a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. INTERVENTION~   1. Patients will be given face-to-face training in the clinic training room of the unit.~  2. After face-to-face training is given, an educational brochure will be given to the patient.~  3. If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~  4. After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~3. LAST TEST~   1. Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
57935470|NCT03591354|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.
58290710|NCT04478162|OTHER|Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.|At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
58290711|NCT05867134|BEHAVIORAL|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
58290712|NCT05892250|BEHAVIORAL|Conventional physical therapy|Manual techniques and therapeutic exercise
57935471|NCT03591354|DEVICE|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
58290713|NCT05892250|BEHAVIORAL|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
57935472|NCT04076254|DRUG|Albumins|albumin 5%
57935473|NCT04076254|DRUG|Fluid|Ringer Lactate
57935474|NCT02722876|OTHER|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
58290714|NCT03285945|DRUG|PET3|Prednisolone 60 mg daily for 3 days
58290715|NCT03285945|DRUG|PET10|Prednisolone 60 mg daily for 10 days
58290716|NCT04068831|DRUG|Talazoparib|1 mg talazoparib daily
58290717|NCT04068831|DRUG|Avelumab|800 mg avelumab every 2 weeks
57935475|NCT02722876|OTHER|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
57935476|NCT00472173|DRUG|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
57935477|NCT00472173|DRUG|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
58290718|NCT04293497|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~1. conventional cytology staining method~2. new cytology staining method using antibody of methionyl-tRNA synthetase 1"
58290719|NCT00226798|DRUG|Capecitabine (Xeloda)|
58290720|NCT03135509|DRUG|CC-220|CC-220 gelatin capsules
58290721|NCT00293852|PROCEDURE|Outpatient clinic follow-up|
57935478|NCT06100653|DRUG|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
57935479|NCT00334386|DRUG|Torasemide Prolonged Release (loop diuretic)|
57935480|NCT00334386|DRUG|Torasemide Immediate Release (loop diuretic)|
57935481|NCT02744300|BEHAVIORAL|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
57935482|NCT04297501|DRUG|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
57935483|NCT02276664|BEHAVIORAL|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
57935484|NCT02276664|BEHAVIORAL|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
57935485|NCT03307434|OTHER|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
58290722|NCT02758288|OTHER|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
58290723|NCT02758288|OTHER|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
58290724|NCT05785039|DRUG|BL-B01D1|Administration by intravenous infusion
58290725|NCT04498702|DRUG|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
58290726|NCT03604848|DRUG|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
58290727|NCT03604848|DRUG|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
58290728|NCT03604848|DRUG|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
57935486|NCT03307434|OTHER|regular training|The regular training will be performed by control group according to the standard practice.
57935487|NCT05093322|DRUG|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
57935488|NCT05355779|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
58072403|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
57935489|NCT04374643|OTHER|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
57935490|NCT05971862|DRUG|SKI-G-801|Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
57935491|NCT03526354|DRUG|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
57935492|NCT03526354|OTHER|Treatment as Usual|Current antipsychotic medication for 12 weeks
57935493|NCT00411281|DRUG|cytarabine|Given subcutaneously
57935494|NCT00411281|PROCEDURE|observation|No intervention
57935495|NCT02101515|OTHER|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
57935496|NCT05665491|BEHAVIORAL|HabitWorks|Smartphone app-delivered interpretation bias intervention
57935497|NCT05665491|BEHAVIORAL|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
57935498|NCT03800290|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
57935499|NCT03800290|DRUG|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
57935500|NCT03862365|GENETIC|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
57951266|NCT00916266|PROCEDURE|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
57951267|NCT02783703|DIETARY_SUPPLEMENT|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
58072404|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
58290729|NCT03604848|DRUG|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;"
58290730|NCT06039072|DRUG|Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.|Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
58290731|NCT06234592|DRUG|Angiotensin II|Angiotensin II infusion
58072405|NCT06699849|BIOLOGICAL|CSL889|CSL889 is a solution for infusion to be administered by the IV route.
58290732|NCT06234592|DRUG|Vasopressin|Vasopressin infusion
58290733|NCT06234592|DRUG|Norepinephrine|Standard care vasopressor therapy, norepinephrine infusion
58290734|NCT04919408|OTHER|telephone survey|telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
58290735|NCT05242536|OTHER|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
58290736|NCT04145206|BEHAVIORAL|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
58290737|NCT01272908|DRUG|rituximab|1000 mg intravenously on Days 1 and 15
58290738|NCT06431984|DIAGNOSTIC_TEST|prick test|self-sampling of capillary blood using the finger prick test method
58290739|NCT06099093|DRUG|18F-DCFPyl|Fluorine-labeled small molecule, via intravenous infusion per protocol.
58290740|NCT06142344|DEVICE|Quiremspheres™|The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
58290741|NCT00716768|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
58290742|NCT00716768|PROCEDURE|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
58290743|NCT03677115|DRUG|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
58290744|NCT03112486|PROCEDURE|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
58290745|NCT05750563|DIETARY_SUPPLEMENT|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
58290746|NCT05750563|OTHER|Placebo|Use as comparator
58290747|NCT05075863|DRUG|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
57951268|NCT04870242|OTHER|Observational study, non-interventional|observational study for the ERAS protocols in pediatric surgery
57951269|NCT01851681|DRUG|Amoxicillin|
58072406|NCT06699849|DRUG|Placebo|Volume and regimen matched to CSL899 will be administered.
58072407|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
58290748|NCT00952315|DEVICE|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
58290749|NCT00952315|DEVICE|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
58072408|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
58072409|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
58072410|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
58072411|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
58290750|NCT00952315|DEVICE|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
58290751|NCT02980406|DIETARY_SUPPLEMENT|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
58290752|NCT02980406|DIETARY_SUPPLEMENT|Glucose (control)|Glucose is not a FODMAP.
57935501|NCT05986513|BEHAVIORAL|Cold Pressor Gel Test|This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.
58072412|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
58290753|NCT03111277|DEVICE|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
58290754|NCT01973517|DRUG|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
58290755|NCT01973517|DRUG|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
58290756|NCT04832451|BEHAVIORAL|Interpersonal Relational Role Analysis|"Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps."
58290757|NCT04516967|DRUG|Avatrombopag|Oral avatrombopag Tablet
58290758|NCT04516967|DRUG|Placebo|Placebo comparator tablet
58290759|NCT03363867|DRUG|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
58290760|NCT03363867|DRUG|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
58290761|NCT03363867|DRUG|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
58290762|NCT00387283|DRUG|AVI-4020 Injection|
58290763|NCT06517121|DEVICE|Personalized Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
58290764|NCT06517121|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
58290765|NCT06517121|DEVICE|Conventional Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
58290766|NCT02229799|DRUG|Actilyse|
58290767|NCT01142947|DRUG|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
58290768|NCT04403113|OTHER|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
58290769|NCT04403113|OTHER|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
58290770|NCT04403113|OTHER|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
57729928|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
58290771|NCT00192972|PROCEDURE|Catheter ablation (pulmonary vein isolation)|
58403326|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
58403327|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
58403328|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
58403329|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
58403330|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
58403331|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
58290772|NCT00882271|OTHER|Acupuncture|Ten Acupuncture treatments within six weeks
58290773|NCT00789607|DEVICE|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
58290774|NCT00789607|DEVICE|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
58290775|NCT01075997|DEVICE|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
58290776|NCT01075997|DEVICE|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
58290777|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
58403332|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
58403333|NCT00616811|DRUG|vildagliptin|
58403334|NCT00616811|DRUG|Sitagliptin|
58095126|NCT05179655|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
58290778|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
58290779|NCT03420430|BIOLOGICAL|GL-ONC1|
57729929|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
58290780|NCT02497508|DRUG|nivolumab|
58290781|NCT00215644|DRUG|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
58290782|NCT00215644|DRUG|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
58290783|NCT00215644|DRUG|Cisplatin|Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
58290784|NCT00215644|DRUG|Capecitabine|Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
57729930|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
57729931|NCT05466318|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
57729932|NCT05466318|DRUG|Cladribine|6 mg/m2 intravenously once daily @ Day -7 \~ -3
57729933|NCT05466318|DRUG|Gemcitabine|2500 mg/m2 intravenously @ Day -7, -3
58072413|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
58403335|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
58403336|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
57729934|NCT05466318|DRUG|Busulfan|3.2 mg/kg intravenously once daily @ Day -7 \~ -4
57935502|NCT06085027|PROCEDURE|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
57935503|NCT00041275|DRUG|megestrol acetate|
57935504|NCT00814567|RADIATION|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
57935505|NCT05426642|OTHER|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
57935506|NCT05426642|OTHER|Brochure|The brochure contain the information regarding cervical cancer and its screening
58290785|NCT04408651|BEHAVIORAL|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
57935507|NCT05871255|OTHER|Zantogin® Gel|Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
57935508|NCT02771314|DRUG|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
57935509|NCT02410655|DRUG|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
58403337|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
57935510|NCT02410655|DRUG|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
58290786|NCT04408651|BEHAVIORAL|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
58290787|NCT05200377|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
58290788|NCT01051557|OTHER|Laboratory Biomarker Analysis|Correlative studies
58403338|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
57729935|NCT05466318|DRUG|Carmustine|300 mg/m2 intravenously @ Day -8
57729936|NCT05466318|DRUG|Etoposide|200 mg/m2 intravenously once daily @ Day -7 \~ -4
57935511|NCT03635814|DRUG|YD312 50mg|YD312 50mg \* 1 + placebo 6 tablets
58403339|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
57729937|NCT05466318|DRUG|Cytarabine|400 mg/m2 intravenously once daily @ Day -7 \~ -4
57729938|NCT05466318|DRUG|Melphalan|140 mg/m2 intravenously @ Day -3
57935512|NCT03635814|DRUG|YD312 150mg|YD312 50mg \* 3 + placebo 6 tablets
57935513|NCT03635814|DRUG|YD312 350mg|YD312 50mg \* 7 tablets
57935514|NCT03635814|DRUG|Placebo|YD312 0mg \* 7 tabets
57935515|NCT04039854|DRUG|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
57935516|NCT04039854|DRUG|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
58290789|NCT01051557|DRUG|Perifosine|Given PO
58290790|NCT01051557|DRUG|Temsirolimus|Given IV
58290791|NCT01051557|PROCEDURE|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
58290792|NCT04425681|DRUG|Osimertinib|Treatment of LM With osimertinb
58290793|NCT04425681|DRUG|Bevacizumab|Treatment of LM With Bevacizumab
58403340|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
58403341|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
57729939|NCT05466318|PROCEDURE|Autologous hematopoietic stem cell transplant|autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
57729940|NCT02657278|PROCEDURE|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
57935517|NCT04992325|DIAGNOSTIC_TEST|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
57935518|NCT00067392|PROCEDURE|Dental Implant|Dental Implant 4 month time frame
57935519|NCT00383357|DRUG|zolpidem|
57935520|NCT02914054|DRUG|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
57935521|NCT02914054|DRUG|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
57935522|NCT02910765|DRUG|methylene blue|
57935523|NCT02910765|DRUG|ozone|
57935524|NCT02910765|OTHER|saline infusion|
57935525|NCT02910765|OTHER|oxygen|
57935526|NCT04084106|DRUG|Phenoxymethylpenicillin|Oral administration
57935527|NCT04084106|DRUG|Amoxicillin|Oral administration
57935528|NCT04084106|DRUG|Amoxicillin-clavulanic acid|Oral administration
58290794|NCT05641844|DEVICE|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
58290795|NCT05641844|OTHER|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
58290796|NCT05646732|DEVICE|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
58290797|NCT02104882|RADIATION|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
58290798|NCT04455217|OTHER|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
58290799|NCT04544059|DRUG|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
58290800|NCT03871985|PROCEDURE|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
58403342|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
58403343|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
58403344|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
58403345|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
57935529|NCT00150293|DRUG|Pregabalin|
58072414|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
58072415|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
57935530|NCT03053258|DEVICE|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
58072416|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
58072417|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
58290801|NCT03871985|PROCEDURE|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
58290802|NCT04560556|DIAGNOSTIC_TEST|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
58290803|NCT04560556|DIAGNOSTIC_TEST|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
58290804|NCT04319653|DEVICE|Dynamic pelvic MRI with intravaginal probe with pressure sensor|Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel
57729941|NCT03068403|PROCEDURE|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
58290805|NCT05789212|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A-mindfulness, B-yoga, and C-guided walking.
58290806|NCT05789212|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A-mindfulness, B-yoga, and C-guided walking.
57935531|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
57935532|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
58290807|NCT05283265|BEHAVIORAL|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
58403346|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
58403347|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
58403348|NCT04577300|OTHER|Sham comparator|Sham implantation
57729942|NCT01776645|BEHAVIORAL|Compassion Cultivation Training Course|
57935533|NCT03580239|DRUG|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
57935534|NCT03580239|DRUG|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
57935535|NCT02896829|BEHAVIORAL|Interruption of the treatment by Imatinib|
57935536|NCT04236063|OTHER|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
58403349|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
58403350|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
58403351|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
58403352|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
58290808|NCT05283265|OTHER|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
58290809|NCT01296139|DRUG|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
58403353|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
58403354|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
58290810|NCT06512922|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
58403355|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
58403356|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
58403357|NCT02692040|DRUG|G3215|Gut hormone analogue
58403358|NCT02692040|DRUG|Placebo|0.9% saline
58403359|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
58403360|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
58403361|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
58403362|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
58403363|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
58403364|NCT00004495|DRUG|cyanocobalamin|
58403365|NCT00004495|DRUG|folic acid|
58403366|NCT00004495|DRUG|pyridoxine|
57935537|NCT00199602|DRUG|warfarine - low molecular heparin|
57935538|NCT05486026|DRUG|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
58072418|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
58403367|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
58403368|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
58403369|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
58403370|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
58403371|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
58403372|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
58403373|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
58072419|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
58403374|NCT01342354|RADIATION|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
58403375|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
58403376|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
57935539|NCT05486026|DRUG|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
57935540|NCT03862157|DRUG|Azacitidine|Given IV or SC
57935541|NCT03862157|DRUG|Pevonedistat|Given IV
58403377|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
57935542|NCT03862157|DRUG|Venetoclax|Given PO
57935543|NCT03463798|DEVICE|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
57935544|NCT03463798|DEVICE|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
57935545|NCT01824680|BEHAVIORAL|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
57935546|NCT01855451|DRUG|Cetuximab|
57935547|NCT01855451|RADIATION|RT (70 Gy in 35 fractions)|
57935548|NCT01855451|DRUG|Cisplatin|
58072420|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
58072421|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
58290811|NCT06512922|DEVICE|placebo cognitive training|They received cognitive training tasks of fixed difficulty.
58403378|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
58403379|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
58403380|NCT04655755|DRUG|Venetoclax|Given PO
58290812|NCT01460602|DRUG|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
57935549|NCT02649296|OTHER|Skanlab bodywave|The intervention will be done twice a week
58290813|NCT00123994|BEHAVIORAL|Tai Chi classes|
58290814|NCT00123994|BEHAVIORAL|Hydrotherapy classes|
58290815|NCT03905304|BIOLOGICAL|Medytoxin|Intramuscular injection up to 300U.
58290816|NCT03905304|BIOLOGICAL|Botox|Intramuscular injection up to 300U.
58290817|NCT04928456|OTHER|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
58290818|NCT04421352|DRUG|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
58290819|NCT00249418|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
58290820|NCT00699023|DRUG|ezetimibe tablets|ezetimibe tablets 10 mg/die
58290821|NCT00699023|DRUG|simvastatin tablets|simvastatin tablets 20 mg/die
58290822|NCT00699023|DRUG|placebo|placebo
58290823|NCT00109746|DIETARY_SUPPLEMENT|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
58290824|NCT02198508|DRUG|DFX(Deferasirox)|
57935550|NCT01886313|DRUG|Civamide Nasal Spray|
57935551|NCT01886313|DRUG|Placebo|
57935552|NCT05593666|DRUG|LXE408|Film-coated tablets
58290825|NCT02198508|DRUG|DFP(Deferiprone)|
58290826|NCT04468893|BEHAVIORAL|Online Intervention Mental Health COVID-19|The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
58290827|NCT05279495|DEVICE|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
58290828|NCT05279495|DEVICE|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
57729943|NCT05870098|DIAGNOSTIC_TEST|All participants|"1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
57729944|NCT00345774|DRUG|PRX-08066|
57729945|NCT05234138|OTHER|Blood Sample|Blood Sample
57935553|NCT05593666|OTHER|Placebo|Placebo film-coated tablets
57935554|NCT05593666|DRUG|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
57935555|NCT00533026|DRUG|Duloxetine|
57935556|NCT00533026|DRUG|Warfarin|
57935557|NCT00221650|DRUG|Peginterferon alfa2a|
57935558|NCT00221650|DRUG|Ribavirin|
57951270|NCT01265550|DEVICE|Nissen fundoplication|laparoscopic antireflux surgery
57951271|NCT01265550|DRUG|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
57951272|NCT01265550|DRUG|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
58403381|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
58072422|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
58290829|NCT03508349|DIAGNOSTIC_TEST|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
58290830|NCT01930916|DEVICE|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
58290831|NCT01930916|OTHER|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
58290832|NCT03974802|DEVICE|somofilcon A contact lens|Contact Lens
58290833|NCT03974802|DEVICE|fanfilcon A contact lens|Contact Lens
58290834|NCT00823602|DRUG|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
58290835|NCT00823602|DRUG|suprefact|GnRH agonist, standard protocol
58290836|NCT03162042|PROCEDURE|Tumor removal|Surgery
58290837|NCT05929742|BEHAVIORAL|virtual reality training|The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
58290838|NCT05929742|BEHAVIORAL|early rehabilitation|Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
58290839|NCT01599169|DIETARY_SUPPLEMENT|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
58290840|NCT01599169|DIETARY_SUPPLEMENT|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
58290841|NCT05820490|OTHER|Whole Room Calorimeter|The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.
58290842|NCT05820490|OTHER|Mixed-Meal Tolerance Test (MMTT)|The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.
58290843|NCT05820490|OTHER|Core Body Temperature|Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.
58290844|NCT05820490|OTHER|Morningness-Eveningness Questionnaire|Participants will fill out a questionnaire that asks about your preference for morning or evening.
58290845|NCT05820490|PROCEDURE|Muscle Biopsy|Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.
58290846|NCT05820490|OTHER|Serial Blood Sampling|Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
58290847|NCT00512499|BEHAVIORAL|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
58290848|NCT00512499|BEHAVIORAL|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
58403382|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
58290849|NCT00512499|BEHAVIORAL|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
58290850|NCT05797441|BEHAVIORAL|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
58290851|NCT05797441|OTHER|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
58290852|NCT04825951|OTHER|CS 2000|treating growing Skeletal growing Class III patients
58290853|NCT03320174|DRUG|Tafenoquine|Tafenoquine 200mg
58290854|NCT03320174|OTHER|Placebo|Placebo
58290855|NCT00640419|DRUG|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
58290856|NCT00640419|DRUG|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
58290857|NCT02420262|DRUG|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
58290858|NCT02420262|DRUG|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
58290859|NCT02420262|DRUG|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
58290860|NCT00905424|DRUG|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
58290861|NCT00905424|DRUG|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
58290862|NCT03218371|PROCEDURE|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
58290863|NCT04727593|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
58403383|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
58403384|NCT00018330|BEHAVIORAL|Weight Loss|
58403385|NCT01872039|DRUG|Perdipine injection|IV
58403386|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
58403387|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
57729946|NCT02337647|OTHER|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
57729947|NCT00836823|DRUG|Alfuzosin|Alfuzosin 10mg once daily for 12 months
57729948|NCT03043664|DRUG|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
57729949|NCT03043664|DRUG|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
58290864|NCT04727593|OTHER|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
58290865|NCT02638987|PROCEDURE|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
58290866|NCT00925808|BEHAVIORAL|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
58290867|NCT02155452|PROCEDURE|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
58290868|NCT02232477|DRUG|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
58290869|NCT00005916|DRUG|rV-PSA|
58290870|NCT00005916|DRUG|rF-PSA|
57729950|NCT01151670|DRUG|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
58290871|NCT00005916|DRUG|rV-B7.1|
58290872|NCT03887585|PROCEDURE|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
58290873|NCT00260260|DRUG|Oxycodone|
58290874|NCT04711694|BEHAVIORAL|Minfulness-based Intervention|"The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice."
58290875|NCT01951118|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
58290876|NCT03382418|BIOLOGICAL|gp145 C.6980 Vaccine|Administered by intramuscular injection in the deltoid.
58403388|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
58403389|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
58290877|NCT03382418|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
58290878|NCT03382418|BIOLOGICAL|Aluminum Hydroxide Adjuvant|Administered by intramuscular injection in the deltoid.
58290879|NCT04816760|BIOLOGICAL|Peripheral blood samples|Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
58290880|NCT04687111|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
58290881|NCT04687111|DRUG|Valsartan|Valsartan is an Angiotensin Receptor Blocker
58290882|NCT05094414|DRUG|Valacyclovir|oral valacyclovir 500 mg twice per day for 4 weeks
58290883|NCT06515964|OTHER|observational study|observational study, no intervention
58290884|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
58290885|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
58403390|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
58290886|NCT05789056|DRUG|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
57729951|NCT01151670|DRUG|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
58290887|NCT00373126|DRUG|transdermal nicotine patch|
58290888|NCT00490919|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
58290889|NCT00490919|DRUG|Placebo|transdermal system (placebo) worn for 7 days
58290890|NCT01738919|PROCEDURE|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
58290891|NCT01738919|PROCEDURE|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
57729952|NCT02357212|PROCEDURE|coronary angiography|invasive procedure performed to determine coronary anatomy
57729953|NCT02357212|PROCEDURE|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
57729954|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
58290892|NCT04559646|PROCEDURE|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
58290893|NCT04559646|DRUG|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
58290894|NCT04559646|DRUG|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
58290895|NCT04559646|DIAGNOSTIC_TEST|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
58290896|NCT04559646|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
58290897|NCT04559646|DIAGNOSTIC_TEST|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
58290898|NCT02983760|DEVICE|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
58290899|NCT02983760|DEVICE|CTPA-based strategy|Strategy based on pulmonary angiography
58290900|NCT02983760|DEVICE|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
58290901|NCT03365934|DEVICE|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
58290902|NCT03365934|DEVICE|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
58290903|NCT03365934|DEVICE|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
58290904|NCT03365934|DEVICE|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
58290905|NCT03365934|OTHER|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
57729955|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
58290906|NCT03365934|OTHER|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
58290907|NCT06296472|OTHER|Rehabilitation|-the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.
58290908|NCT06296472|OTHER|Standard|-the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
57729956|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
57729957|NCT01957189|DRUG|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
57729958|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
58403391|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
57729959|NCT03445468|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
57729960|NCT03445468|BIOLOGICAL|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
57729961|NCT02779257|DRUG|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
57729962|NCT02779257|DRUG|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
57729963|NCT04859166|PROCEDURE|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
57729964|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
57729965|NCT03070522|DRUG|Placebos|Placebo
58290909|NCT04396600|BEHAVIORAL|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
58290910|NCT00289588|DRUG|Mupirocin (drug)|
58290911|NCT04086121|DRUG|Spesolimab|Solution for SC injection
58290912|NCT02028507|DRUG|Palbociclib|
58290913|NCT02028507|DRUG|Capecitabine|
58290914|NCT02028507|DRUG|Exemestane|
58290915|NCT02028507|DRUG|Fulvestrant|
58290916|NCT05300334|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase deficiency test
58290917|NCT05921656|OTHER|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"1. Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~2. Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
58290918|NCT05448378|DIETARY_SUPPLEMENT|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
58290919|NCT00412932|DRUG|Olmesartan medoxomil|Tablets
58290920|NCT00412932|DRUG|Olmesartan medoxomil/hydrochlorothiazide|Tablets
58403392|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
58403393|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
57935559|NCT06310954|DIETARY_SUPPLEMENT|Early ketogenic diet combined with conventional pharmacotherapy.|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
58072423|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
58072424|NCT02927990|OTHER|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
57935560|NCT06310954|DRUG|Common diet combined with conventional pharmacotherapy|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, and inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.We know that drug information for registering clinical information is necessary, but our research design is to add ketogenic diets as a supplementary treatment plan when traditional drug treatment is ineffective. Therefore, in terms of specific drug selection, this is not absolutely the same. Depending on individual differences, the choice of drugs will also vary. Control the number of episodes, time, etc., and everyone uses different drugs. Therefore, we cannot decide on a single drug for comparison like traditional content.
57935561|NCT05623397|OTHER|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
58072425|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
58072426|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
58072427|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
58072428|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
58072429|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
58072430|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
58072431|NCT06088017|DRUG|CKD-391(2)|QD, PO
58290921|NCT05115539|OTHER|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) \* 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
58290922|NCT06613113|DRUG|Fruquintinib|After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
58290923|NCT01634308|DRUG|Novosis(bongros/BMP-2)|
58072432|NCT06088017|DRUG|CKD-331, D337|QD, PO
58072433|NCT00275704|DRUG|Flaxseed|
58072434|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
58072435|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
58072436|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
57935562|NCT00314249|DRUG|Placebo|Placebo, oral administration, twice daily for 12 weeks
58290924|NCT01634308|DRUG|Bio-oss|
57729966|NCT01568047|DRUG|Placebo|once-daily
57935563|NCT00314249|DRUG|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID \[twice a day\])
57935564|NCT01033656|DRUG|anakinra|100 mg subcutaneous injection daily
57935565|NCT01033656|DRUG|comparators|po drugs, comparators
58290925|NCT03545932|OTHER|exercise program hydrogymnastics|4 months of practice hydrogymnastics
58290926|NCT03984955|DEVICE|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
58290927|NCT03984955|DEVICE|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
58290928|NCT03984955|OTHER|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
58290929|NCT03620149|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
58290930|NCT02440048|DEVICE|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
58290931|NCT02440048|DEVICE|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
58290932|NCT06056635|DEVICE|Karl Storz Curved Scope|The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
58290933|NCT06056635|DEVICE|Karl Storz Straight Scope|The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
58290934|NCT04948827|DRUG|SBP-9330|SBP-9330 oral capsules
58290935|NCT04948827|DRUG|Placebo|Placebo oral capsules
58490766|NCT00653926|DRUG|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
57729967|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
57729968|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
57729969|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
57729970|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
57729971|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
57935566|NCT02334787|DRUG|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
57935567|NCT02334787|DRUG|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
57935568|NCT02334787|DRUG|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
58490767|NCT00653926|DRUG|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
57935569|NCT02334787|DRUG|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
57729972|NCT03348254|DRUG|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
57935570|NCT03210272|DRUG|Placebo|Tablet
57935571|NCT03210272|DRUG|BI 1358894|Tablet
57935572|NCT03210272|DRUG|BI 1358894 (Test)|Fasting state
57935573|NCT03210272|DRUG|BI 1358894 (Reference)|Fed state
57935574|NCT03899363|PROCEDURE|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
57935575|NCT05755945|OTHER|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
58290936|NCT02953015|BEHAVIORAL|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
58290937|NCT02953015|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
58290938|NCT02953015|DRUG|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
58490768|NCT01161199|PROCEDURE|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
57935576|NCT06335108|PROCEDURE|General Anaesthesia|Breast surgery is carried out under general anesthesia.
57935577|NCT06335108|PROCEDURE|Local tumescent anaesthesia|Breast surgery is carried out under local tumescent anesthesia.
57935578|NCT03618186|COMBINATION_PRODUCT|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
58072437|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
58072438|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
58072439|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
57935579|NCT06418217|PROCEDURE|Exercise and Patient Education|"Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises."
58072440|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
58072441|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
58072442|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
58403394|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
57935580|NCT00886704|DIETARY_SUPPLEMENT|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
57935581|NCT00886704|DIETARY_SUPPLEMENT|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
58072443|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
58290939|NCT01681238|PROCEDURE|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb\> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
58290940|NCT01681238|PROCEDURE|Protocol group 1|The goal of this protocol is to ensure MAP\> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
58290941|NCT02512172|DRUG|Oral CC-486|
58290942|NCT02512172|DRUG|Romidepsin|
58290943|NCT02512172|DRUG|MK-3475|
58290944|NCT00168428|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
58290945|NCT00168428|OTHER|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
58290946|NCT00169104|DRUG|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
57935582|NCT01156233|PROCEDURE|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
58290947|NCT00169104|DRUG|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
58290948|NCT00169104|DRUG|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
58290949|NCT00169104|DRUG|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
58290950|NCT00169104|DRUG|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
58290951|NCT03293017|DRUG|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
58290952|NCT03293017|DRUG|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
57729973|NCT03348254|DRUG|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
57935583|NCT01156233|PROCEDURE|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
57935584|NCT04680442|DRUG|Trastuzumab|Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
58072444|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
58072445|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
58072446|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
58072447|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
58072448|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
58072449|NCT06722885|RADIATION|Standard radiotherapy treatment|"* 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases"
58072450|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
58072451|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
58072452|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
58072453|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
58072454|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
58072455|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
58072456|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
58290953|NCT03293017|DRUG|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
58290954|NCT02859350|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
58290955|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
58290956|NCT02859350|OTHER|Normal Saline|0.9% Sodium chloride
58290957|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
58290958|NCT06612892|DEVICE|Virtual reality games in immersive VR modality|virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.
58290959|NCT06612892|DEVICE|Virtual reality show in passive VR modality:|In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.
58290960|NCT06612892|OTHER|traditional physiotherapy|Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
58403395|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
58403396|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
58072457|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
58072458|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
58072459|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
58072460|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
58072461|NCT06722144|BEHAVIORAL|Animal-assisted Therapy|By the professor leader makes social interaction, and helping residents with rehabilitation through the Doctor dogs.
58403397|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
58290961|NCT06190600|OTHER|High Intensity Interval Training (HIIT)|HIIT training twice a week throughout the chemotherapy: treadmill, elliptical, stationary bicycle and indoor rower. The intensity of physical activity will be increasing during consecutive mesocycles. Each training session will begin with a 10-min. wole-body warm-up session at 50-60% hear rate (HR) max. Mesocycle 1 - one month with 4 sets of 1 min. 45 sec. of exercise at a maximal intensity of 75% HR max. Mesocycle 2 with exercises at 80% to 90% HR max divided into 3 periods: 1/ one month, session of 5 sets 1 min. 30 sec. each; 2/ two months, sessions of 5 sets 1 min. 45 sec. each; 3/ two months, sessions of 5 sets 2 min. each. Moreover patients will be instructed to individually perform- a 45-min. aerobic training session (e.g.: walking, jogging, roller skating, swimming) once a week, in patient's own time.
58290962|NCT06190600|DRUG|neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)|Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
58290963|NCT06190600|OTHER|Standard Supportive Care|Patients will be asked to perform 150-300 min. of moderate-intensity aerobic activity or 75-150 min. of vigorous aerobic activity. Each participant will be monitored by an activity watch worn at all times by the patient.
58290964|NCT02805946|DRUG|posaconazole|iv versus oral
58290965|NCT00618826|DRUG|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
58290966|NCT00618826|DRUG|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
58290967|NCT00618826|DRUG|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
58290968|NCT02407873|OTHER|Non|
58290969|NCT03306095|OTHER|Early refeeding group|Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
58290970|NCT03306095|OTHER|Delayed refeeding group|Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure
58290971|NCT02153125|DRUG|Eplerenone|
58290972|NCT04305028|DRUG|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
58290973|NCT04305028|DRUG|Aspirin|Aspirin 75-100 mg once daily, tablet
58290974|NCT04957212|DRUG|Trastuzumab|An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
58403398|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
58403399|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
58403400|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
58403401|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
58290975|NCT04957212|DRUG|Pertuzumab|An initial dose of 840 mg, followed by 420 mg every 3-weeks
58290976|NCT04957212|DRUG|Carboplatin|A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
58290977|NCT04957212|DRUG|Docetaxel|75 mg/m2 every 3-weeks
58290978|NCT01147562|PROCEDURE|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
58290979|NCT01438242|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
58290980|NCT06382129|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
58290981|NCT06382129|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
58290982|NCT01296854|OTHER|Spa therapy|3 weeks of spa therapy
58290983|NCT01734057|DRUG|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)
58403402|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
58403403|NCT00269269|DRUG|antihypertensive drug|
58403404|NCT00269269|BEHAVIORAL|placebo|
58072462|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
57935585|NCT04680442|DRUG|Pertuzumab|Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
58072463|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
58290984|NCT01734057|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
57935586|NCT04680442|DRUG|Trastuzumab emtansine|Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
58290985|NCT05028829|DRUG|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
57935587|NCT02478970|DEVICE|Konan SP4000|current standard of care at Kellogg Eye Center
57935588|NCT02478970|DEVICE|NIDEK CEM-350|newly marketed device
57935589|NCT00565591|DRUG|Albuterol sulfate|Single dose dry powder by inhalation
57935590|NCT04634981|PROCEDURE|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
57935591|NCT02747953|DRUG|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
57935592|NCT04812067|DRUG|TTHX1114|engineered FGF-1
57935593|NCT02435342|DRUG|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
57935594|NCT02435342|DRUG|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
58072464|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
58072465|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
58290986|NCT05028829|DRUG|Placebo|Oral administration of placebo
58290987|NCT03112226|OTHER|GnRHant + E2|GnRH antagonist with estradiol add-back
58290988|NCT03112226|OTHER|GnRHant + Placebo|GnRH antagonist with placebo add-back
58290989|NCT02757352|DRUG|Ixekizumab|Administered SC
58290990|NCT02757352|DRUG|Placebo|Administered SC
58290991|NCT05385341|OTHER|Telerehabilitation (Tele RCV)|20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.
58290992|NCT05385341|OTHER|Rehabilitation (RCV)|20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
58290993|NCT05349019|OTHER|Observational|This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.
57935595|NCT03311321|DIETARY_SUPPLEMENT|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
57935596|NCT03311321|DIETARY_SUPPLEMENT|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
58290994|NCT00179803|PROCEDURE|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
58290995|NCT02654158|DRUG|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
57935597|NCT03156751|DIAGNOSTIC_TEST|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
57935598|NCT04993833|DEVICE|NPi-200 and NPi-300 pupillometers|Device which measures PLR.
57935599|NCT04354298|BEHAVIORAL|Improvisational Dance Class|Hour long movement classes that meet weekly for 12 weeks.
57935600|NCT04216186|DRUG|Atomoxetine|Atomoxetine once daily
57935601|NCT04216186|DRUG|Coenzyme Q|Coenzyme Q once daily
57935602|NCT00836251|DIETARY_SUPPLEMENT|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
57935603|NCT00656773|DRUG|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
57935604|NCT00656773|DRUG|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
58072466|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
58403405|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
57935605|NCT00097942|DRUG|memantine HCl|
57935606|NCT04434196|DRUG|CC-99282|CC-99282
57935607|NCT04434196|DRUG|Obinutuzumab|Obinutuzumab
57935608|NCT00105404|DRUG|Triamcinolone Acetonide|
57935609|NCT02489136|OTHER|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
58290996|NCT02654158|DRUG|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"
58290997|NCT02996890|BIOLOGICAL|MV-ZIKA|MV-Zika vaccine
58290998|NCT02996890|OTHER|Placebo|physiological saline
58290999|NCT02506699|OTHER|analgesic effect of rTMS|
58291000|NCT06460454|DEVICE|PET scan of 18F-FDG|VEREOS PET scanner. Philips VEREOS digital PET-CT scanners are installed in the nuclear medicine department.
58291001|NCT01229969|OTHER|Wii Fit Balance Games|Ski Slaloms and Table Tilt
57729974|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
57935610|NCT01062048|DRUG|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
57935611|NCT01062048|DRUG|Sulfonylurea|Sulfonylurea administered in general use according to the local label
57935612|NCT01062048|BIOLOGICAL|Insulin|Insulin administered in general use according to the local label
57935613|NCT03985475|OTHER|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
57935614|NCT02714257|BEHAVIORAL|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
57935615|NCT00882310|DRUG|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
57935616|NCT00882310|DRUG|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
58291002|NCT01229969|OTHER|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
58403406|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
58403407|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
57729975|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
57935617|NCT00882310|DRUG|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
57935618|NCT03197857|BEHAVIORAL|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
58072467|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
58291003|NCT05279131|DRUG|Tirbanibulin ointment 1%|Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
57729976|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
58291004|NCT02742363|OTHER|Collecting data|Collecting data from patient records
58291005|NCT06484283|OTHER|Meditation|Guided meditation will be applied within the scope of the study. A guided meditation video prepared by a Yoga Alliance-certified researcher will be used for this intervention. Guided meditation aims to ensure being in the moment (here and now) with the help of breathing. Meditation practice will take participants 10 minutes.
58291006|NCT05017805|BIOLOGICAL|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
58291007|NCT02334826|PROCEDURE|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
58403408|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
58403409|NCT02101684|DRUG|Orteronel 300mg BID|
58403410|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
57729977|NCT02082054|DRUG|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
57935619|NCT03197857|BEHAVIORAL|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
57935620|NCT03197857|BEHAVIORAL|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
57935621|NCT03197857|BEHAVIORAL|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
57935622|NCT01092975|DRUG|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
57935623|NCT01759004|OTHER|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
57935624|NCT04175665|DRUG|Semaglutide|Prescription for semaglutide as part of usual clinical practice
57935625|NCT05110339|DRUG|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
57935626|NCT05110339|DRUG|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
58291008|NCT02334826|PROCEDURE|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
58291009|NCT06611826|DRUG|GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy|The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
58291010|NCT03025269|DRUG|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
57935627|NCT03300167|DEVICE|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
58291011|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
58291012|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
58291013|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
58291014|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
58291015|NCT01435759|DRUG|Antidepressant + Placebo|oral, once daily for 8 weeks
58291016|NCT01822210|DRUG|Botox|injection by gastroscopy (100 Allergen units)
57729978|NCT02082054|DRUG|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
57729979|NCT03362255|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
57935628|NCT00606450|DRUG|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
57935629|NCT00606450|DRUG|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
58291017|NCT02594059|OTHER|endothelial function|measure of reactive hyperemia-peripheral artery tone index
58291018|NCT01176123|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
58291019|NCT03902470|PROCEDURE|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
58291020|NCT00064103|BIOLOGICAL|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
58291021|NCT00064103|OTHER|laboratory biomarker analysis|Correlative studies
58291022|NCT00304460|BIOLOGICAL|aldesleukin|
58291023|NCT04928144|DRUG|SHJ - Low concentration|Topical ophthalmic
58291024|NCT04928144|DRUG|SHJ - Mid concentration|Topical ophthalmic
58291025|NCT04928144|DRUG|SHJ - High concentration|Topical ophthalmic
57935630|NCT00606450|DRUG|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
57935631|NCT03139708|DRUG|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
57935632|NCT03139708|DRUG|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
58291026|NCT04928144|DRUG|SHJ - Maximum tolerated|SHJ - Maximum tolerated
58291027|NCT00279344|DRUG|Fentanyl (Matrifen)|
58291028|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
58291029|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
58403411|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
57729980|NCT04866264|DEVICE|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH \[56\] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
57935633|NCT03139708|DRUG|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
57729981|NCT00319098|BIOLOGICAL|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
57729982|NCT00319098|BIOLOGICAL|Fluarix|One intramuscular injection
58291030|NCT05831124|BIOLOGICAL|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
58291031|NCT05831124|BIOLOGICAL|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
58291032|NCT00597389|DRUG|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
58291033|NCT03915483|DEVICE|transcranial direct current stimulation (tDCS)|sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
58291034|NCT02950116|DEVICE|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"* Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)"
58291035|NCT01515098|DIETARY_SUPPLEMENT|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
58291036|NCT01515098|DIETARY_SUPPLEMENT|Dextrose Placebo|Placebo developed to closely match blueberry powder.
58291037|NCT06515626|BIOLOGICAL|CAR-T cell reinfusion|Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
58291038|NCT04437914|DIAGNOSTIC_TEST|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
57729983|NCT00319098|BIOLOGICAL|Placebo|One intramuscular injection
57935634|NCT01017068|DRUG|OME|4g/100ml) dose: п gutt tid x 1/52
57935635|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
58291039|NCT05906147|OTHER|Regular follow-up|Follow-up of the population was conducted to track the incidence of fractures
58403412|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
58403413|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
57935636|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
57935637|NCT01017068|DRUG|OME|(4g/100ml) dose: п gutt tid x 1/52
57935638|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
57935639|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
57935640|NCT01826851|DRUG|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
57729984|NCT01981135|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
58403414|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
58291040|NCT06611501|DRUG|Metformin Hydrochloride|Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.
58291041|NCT06611501|DRUG|Placebo|1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
58291042|NCT04972799|OTHER|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
58291043|NCT04972799|OTHER|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
58291044|NCT04058457|DEVICE|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
58291045|NCT01833585|BIOLOGICAL|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
58291046|NCT00412126|DRUG|Insulin|
58291047|NCT03576443|DRUG|Idelalisib|Idelalisib 150 mg x 2 p o
57935641|NCT01826851|DRUG|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
57935642|NCT04415658|DRUG|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
57935643|NCT04415658|DRUG|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
57935644|NCT02761824|OTHER|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
57935645|NCT05119218|OTHER|No Intervention|No Intervention
57935646|NCT03819062|DEVICE|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
57935647|NCT04156503|OTHER|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
57935648|NCT04468620|BEHAVIORAL|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
57935649|NCT03173079|OTHER|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
57935650|NCT05151471|DRUG|MT-1186|Oral edaravone
58291048|NCT02212925|DRUG|BI 14332 CL|
58291049|NCT02212925|DRUG|Placebo|
58291050|NCT05886088|DRUG|LID104|Experimental
58291051|NCT05886088|DRUG|Dapagliflozin|Active comparator
58291052|NCT05886088|DRUG|Linagliptin|Active comparator
58291053|NCT05276583|BEHAVIORAL|Motivated Learning Task|"The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure)."
58403415|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
58403416|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
58490769|NCT05138952|BEHAVIORAL|Mindfulness Meditation|"30-day mediation program comprising:~1. Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~2. 10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
58490770|NCT00316043|BEHAVIORAL|Written information for parents|
58403417|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
58403418|NCT01931488|DEVICE|SPECT imaging|
57935651|NCT05151471|DRUG|Placebo|Oral
57935652|NCT02449681|DRUG|TH-4000 (Tarloxotinib)|
58291054|NCT02141906|OTHER|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
58291055|NCT04051697|BEHAVIORAL|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
58403419|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
58403420|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
58403421|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
58403422|NCT06345482|DRUG|MHB039A|a bispecific antibody
58403423|NCT05226780|DRUG|NBI-921352|Administered orally
58403424|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
58403425|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
58403426|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
57935653|NCT06041620|BIOLOGICAL|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
57935654|NCT03743883|DRUG|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
58291056|NCT02658669|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
58403427|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
58403428|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
58403429|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
58291057|NCT02658669|BEHAVIORAL|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
58291058|NCT01965002|DEVICE|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
58403430|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
58403431|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
58403432|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
58291059|NCT01965002|DRUG|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
58403433|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
58403434|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
58490771|NCT00316043|BEHAVIORAL|Distance learning package for General Practitioners|
58490772|NCT00316043|BEHAVIORAL|Distance learning package for practice assistants|
58490773|NCT02192281|OTHER|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
58490774|NCT03803241|DRUG|CD133+ infusion|Infusion of cells cd133+
57935655|NCT02955420|DRUG|BC 007|
57935656|NCT02955420|DRUG|NaCl 0.9 %|
57935657|NCT04667910|DRUG|601 1.25mg|Solution for injection (intravitreal use)
57935658|NCT04667910|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
57935659|NCT00201968|DEVICE|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
57935660|NCT00201968|DEVICE|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
57935661|NCT00201968|OTHER|Conventional Exercise|An aerobic and resistance training program.
57935662|NCT01599910|OTHER|Scribes|Scribe
57935663|NCT05067426|OTHER|Exercise|high-intensity interval training sessions
57935664|NCT01580150|OTHER|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
58403435|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
58403436|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
58403437|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
57935665|NCT01580150|OTHER|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
57935666|NCT02129205|DRUG|PF-06650808|Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
57935667|NCT02129205|DRUG|PF-06650808|Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
57935668|NCT01191541|DRUG|DNR:|DNR：45mg/m2 d1-3
57935669|NCT01191541|DRUG|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
57935670|NCT04939662|DRUG|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
57935671|NCT02873650|DRUG|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
57935672|NCT05488210|DIETARY_SUPPLEMENT|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
57935673|NCT01115530|OTHER|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
58072468|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
58403438|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
58403439|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
58291060|NCT01965002|DRUG|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
58403440|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
58403441|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
58403442|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
58403443|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
58403444|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
58403445|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
58072469|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
58403446|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
58403447|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
57935674|NCT01115530|DIETARY_SUPPLEMENT|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
57935675|NCT05138666|BIOLOGICAL|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
58072470|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
58490775|NCT03803241|OTHER|portal vein embolization|portal vein embolization
58490776|NCT01032109|DRUG|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
57729985|NCT01981135|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
57729986|NCT03732287|DEVICE|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
57729987|NCT00063947|DRUG|erlotinib hydrochloride|Given orally
57729988|NCT00063947|DRUG|gemcitabine hydrochloride|Given IV
57729989|NCT00063947|RADIATION|radiation therapy|Undergo radiotherapy
57935676|NCT05138666|BIOLOGICAL|blood sample|Blood sampling drawn from an existing arterial line twice a week
57935677|NCT03319407|DEVICE|EPAD monitoring system|EPAD system will be used as part of routine care
57935678|NCT00868426|DRUG|Budesonide/Formoterol Batch 1|Single, inhaled dose
57935679|NCT00868426|DRUG|Budesonide/Formoterol Batch 2|Single, inhaled dose
57935680|NCT00868426|DRUG|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
57935681|NCT04505904|DRUG|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
57935682|NCT04505904|DRUG|Placebo|Placebo spray with no active ingredient.
57935683|NCT05563922|COMBINATION_PRODUCT|Total Neoadjuvant Chemoradiotherapy|"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"
58072471|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
58072472|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
58072473|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
58072474|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
58072475|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
58072476|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
58072477|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
58072478|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
58072479|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
58291061|NCT04878939|OTHER|Power chain used for anterior segment retraction|Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
58291062|NCT04878939|OTHER|T-loop fabricated to perform anterior segment retraction|In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
58291063|NCT03108066|DRUG|MK-3795|800 mg twice daily (four 200 mg oral tablets twice daily)
58291064|NCT03887182|DIAGNOSTIC_TEST|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
58291065|NCT03887182|DIAGNOSTIC_TEST|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
58291066|NCT03887182|GENETIC|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
58291067|NCT03887182|DIAGNOSTIC_TEST|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
58291068|NCT03887182|DIAGNOSTIC_TEST|multidisciplinary consultation|"multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation"
58291069|NCT00834847|DRUG|pravastatin|40 mg tablet
58291070|NCT00834847|DRUG|Pravachol®|40 mg Tablet
58291071|NCT02861664|OTHER|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
58291072|NCT02861664|OTHER|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
58291073|NCT02170857|DRUG|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
57935684|NCT04160351|DEVICE|Theranova 400|medium cut-off dialyser
57935685|NCT04160351|DEVICE|Elisio-19H|high flux dialyser
57935686|NCT02543827|BIOLOGICAL|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
57935687|NCT02543827|BIOLOGICAL|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
57935688|NCT01803477|DRUG|once daily for two consecutive days (Picato)|
58072480|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
58072481|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
58072482|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
58072483|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
58072484|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
58072485|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
58072486|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
58072487|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
58072488|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
58072489|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8_1
58072490|NCT02658279|DRUG|Pembrolizumab|
58072491|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
58072492|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
58072493|NCT02988115|OTHER|placebo|Matching placebo tablet
58072494|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
58072495|NCT02419443|DRUG|Placebo|Control group
58072496|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
58072497|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
58072498|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
57729990|NCT00063947|OTHER|laboratory biomarker analysis|Correlative studies
57729991|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
57729992|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
58291074|NCT00872612|PROCEDURE|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
58291075|NCT00872612|PROCEDURE|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
58291076|NCT05205304|DRUG|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
57729993|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
57729994|NCT04276545|DRUG|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
57935689|NCT02807051|DRUG|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
57935690|NCT02807051|DRUG|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
57935691|NCT02807051|DRUG|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
57935692|NCT01892514|PROCEDURE|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
57935693|NCT03765242|OTHER|Non-Interventional|Non-Interventional
57935694|NCT04784897|DRUG|Brilacidin|Brilacidin IV infusion
57935695|NCT04784897|DRUG|Placebo|Placebo IV infusion
57935696|NCT04784897|DRUG|Standard of Care (SoC)|SoC therapies for COVID-19
58291077|NCT05516238|OTHER|Case management|Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
58291078|NCT02084017|DEVICE|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
58291079|NCT02084017|DEVICE|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
58291080|NCT06612593|DRUG|Cilostazol|2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
58291081|NCT06612593|DRUG|Placebo|The patient will receive 2 tablets twice daily
58291082|NCT06612593|DRUG|Standard treatment|It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
57935697|NCT02537548|OTHER|Laboratory Biomarker Analysis|Correlative studies
57935698|NCT02537548|PROCEDURE|Retroperitoneal Lymph Node Dissection|Undergo RPLND
57935699|NCT04066660|DIETARY_SUPPLEMENT|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
58291083|NCT05803694|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
58291084|NCT02567175|DRUG|Domperidone|
58291085|NCT05313399|DEVICE|Palatal Crib|An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
58291086|NCT05313399|DEVICE|bonded spur|Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
58291087|NCT05514457|BEHAVIORAL|visual stimulation with I pad|"At the beginning of the study, for baseline condition, children will do 4 tests (visuo-spatial perception test, visual attention span, visual research, phonology tests).~In the first group of the study, the children will do visual research exercises on I pad 10 minutes per day during one month = remediation. They will also do 4 reading aloud tests, once a month, for 3 months. The remediation exercises will be realized during the first, second or third month."
57935700|NCT04066660|DIETARY_SUPPLEMENT|Placebo|4.4 g placebo powder, oral, BID
57935701|NCT04555161|DEVICE|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
57935702|NCT03838198|BEHAVIORAL|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
57935703|NCT03838198|BEHAVIORAL|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
58403448|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
58403449|NCT00531557|DRUG|Darunavir ritonavir|
58072499|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
58403450|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
58403451|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
58403452|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
58403453|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
58403454|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
58403455|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
58072500|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
58072501|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
58072502|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
58072503|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
58072504|NCT02776631|DEVICE|Pinloc|Internal fixation device
58072505|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
58291088|NCT05514457|BEHAVIORAL|visual stimulation with lamp|"At the beginning of the study, for baseline condition, children will do the 4 tests like group 1.~In the second group of the study, the children will do reading aloud tests, with lamp adjusted with different parameters = remediation (passive visual stimulation of a specific frequency believed to promote visual processing of written symbols)."
58291089|NCT02313623|PROCEDURE|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
58291090|NCT06611293|DIAGNOSTIC_TEST|Breath test|"Participants will perform breath testing in Primary care followed by Secondary care on Day 1. At each location, participants will be asked to perform three breath tests (15 minutes apart). The environmental air will also be sampled.~This entire process will be repeated in the reverse order (i.e. breath testing in Secondary care followed by Primary care on Day 2).~Participants will be asked to maintain a clear fluid diet for a minimum of six hours prior to breath collection on both Day 1 and Day 2 of sampling."
58403456|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
58403457|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
58403458|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
58403459|NCT06605144|OTHER|1- Vasopressors - Mean arterial pressure 55-59|Vasopressors will be titrated according to 55-59 range.
58403460|NCT06605144|OTHER|2- Vasopressors - Mean arterial pressure 60-65|Vasopressors will be titrated according to 60-65 range.
58403461|NCT06605144|OTHER|3- Vasopressors - Mean arterial pressure 66-69|Vasopressors will be titrated according to 66-69 range.
57729995|NCT04276545|DRUG|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
57729996|NCT02843568|OTHER|Laboratory Biomarker Analysis|Correlative studies
57935704|NCT03838198|BEHAVIORAL|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
57935705|NCT01343589|DIETARY_SUPPLEMENT|milk fat|39 g milk fat per day in 12 weeks
57935706|NCT04688723|DRUG|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
57935707|NCT04688723|DRUG|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
57935708|NCT02542384|DRUG|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
57935709|NCT02542384|DRUG|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
57935710|NCT02542384|DRUG|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
57935711|NCT03419338|PROCEDURE|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
57935712|NCT03419338|PROCEDURE|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
57935713|NCT03419338|PROCEDURE|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
57935714|NCT03419338|PROCEDURE|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
57935715|NCT03419338|DEVICE|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
57935716|NCT00956657|BEHAVIORAL|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
58072506|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
58072507|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
58072508|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
58072509|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
58072510|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
58072511|NCT01811004|DEVICE|miraDry|miraDry
58072512|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
58072513|NCT01811004|DEVICE|Botox®|Botox®
58072514|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
58072515|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
58072516|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
58072517|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
58072518|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
58291091|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
57935717|NCT02422407|PROCEDURE|Biopsy|Salivary Gland
58072519|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
57935718|NCT00621231|DIETARY_SUPPLEMENT|Placebo|Placebo
57935719|NCT00621231|DIETARY_SUPPLEMENT|Protein|30 E% from protein
57935720|NCT01849497|BIOLOGICAL|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
57935721|NCT01849497|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
57935722|NCT00932984|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
58072520|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
57935723|NCT02292966|DRUG|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
57935724|NCT04490395|BEHAVIORAL|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
57935725|NCT04490395|OTHER|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
57935726|NCT01641237|DRUG|sodium fluoride|fluoride as sodium fluoride
57935727|NCT01641237|DRUG|no added fluoride in a silica base|no added fluoride
58072521|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
58072522|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
57935728|NCT00454285|DRUG|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
57935729|NCT00576017|DRUG|Fentanyl-TTS|
57935730|NCT00736034|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
57935731|NCT04615104|PROCEDURE|Operative|surgical treatment
58403462|NCT06605144|OTHER|4- Vasopressors - Mean arterial pressure 70-75|Vasopressors will be titrated according to 70-75 range.
57729997|NCT02843568|RADIATION|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
57729998|NCT02843568|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
57935732|NCT04615104|PROCEDURE|Nonoperative|nonsurgical treatment
57935733|NCT05804760|DIAGNOSTIC_TEST|Measurement of implant parameters|"1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
57935734|NCT01335009|BIOLOGICAL|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
57935735|NCT01318954|BIOLOGICAL|Allergen immunotherapy|
57935736|NCT01255969|OTHER|Exercise|Personalized exercise program
57935737|NCT00697450|DRUG|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
57935738|NCT00174590|DRUG|risperidone|
57935739|NCT02379767|DEVICE|Electroconvulsive therapy|
57935740|NCT02379767|OTHER|Positron emission tomography of the brain using [11C]harmine|
58072523|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
58072524|NCT03695471|BIOLOGICAL|Pembrolizumab|Given IV
58072525|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
58072526|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
58072527|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
58072528|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
58403463|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
58403464|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
57935741|NCT02379767|OTHER|Structural magnetic resonance imaging|
57935742|NCT03415126|DRUG|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
57935743|NCT03415126|DRUG|ASN007 RD|Oral drug for the treatment of advanced solid tumors
57935744|NCT04304976|DEVICE|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
57935745|NCT02933736|DRUG|Ribociclib|
57935746|NCT05902377|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
57935747|NCT00455013|DRUG|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
58072529|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
58072530|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
58072531|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
58291092|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
58291093|NCT03683563|OTHER|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
58291094|NCT03683563|OTHER|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
58291095|NCT04608916|PROCEDURE|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
58291096|NCT04608916|PROCEDURE|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
58291097|NCT01571141|DEVICE|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
58291098|NCT00826566|DIETARY_SUPPLEMENT|Caffeine|2 times 250 mg caffeine per day
58072532|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
58072533|NCT06383715|BEHAVIORAL|Cognitive-Behavioral Therapy Workshop for Content Moderators|"This 4-session group workshop is based on the principles of Cognitive Behavioral Therapy. It consists of four sessions:~1. Presentation. Scientific evidence of psychological consequences on content moderatos. Psicoeducation on the effects of vicarious trauma exposure.~2. Presentation of the cognitive model. Identification/operationalization of thoughts. Discussion of possible irrational thoughts.~3. Psychoeducation of emotions and their adaptive function. Behavioral strategies of emotions: exposure therapies and behavioral activation.~4. The role of social support. Strategies for appropriate work and sleep hygiene. Strategies for maintaining gains. Farewell."
58072534|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
58072535|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
58072536|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
58072537|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
58072538|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
58072539|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
58072540|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
58072541|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
58072542|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
58072543|NCT03153085|BIOLOGICAL|TBI-1401(HF10)|"1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
58072544|NCT03153085|DRUG|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
58072545|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
58072546|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
58072547|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
58072548|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
58072549|NCT04097106|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic dietary supplement in capsule form
58072550|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
58072551|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
58072552|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
58072553|NCT01869920|BEHAVIORAL|Usual care|Usual care
58291099|NCT00826566|DIETARY_SUPPLEMENT|placebo|2 times 250 mg per day
57935748|NCT00455013|DRUG|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
58072554|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
58072555|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
58072556|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
57935749|NCT00455013|DRUG|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
57935750|NCT00455013|DRUG|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
57935751|NCT00455013|DRUG|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
57935752|NCT04620850|DEVICE|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
57935753|NCT01859468|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|
57935754|NCT01859468|OTHER|Placebo|
57935755|NCT00108186|DRUG|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
58291100|NCT03099603|DRUG|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
58291101|NCT00361803|DRUG|topotecan|topotecan
58291102|NCT05292885|DIAGNOSTIC_TEST|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
58291103|NCT00159952|PROCEDURE|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
57935756|NCT00590044|DRUG|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
57935757|NCT00590044|DRUG|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
57935758|NCT05031988|OTHER|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
57935759|NCT06239298|DRUG|ZG005 Powder for Injection|intravenous infusion(IV), once every 3 weeks
57935760|NCT06239298|DRUG|Donafenib Tosilate Tablets|The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
58291104|NCT01150253|DIETARY_SUPPLEMENT|L. paracasei fermented milk|
58291105|NCT00497146|DRUG|paricalcitol|2 µg capsule
58403465|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
58403466|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
57935761|NCT01467453|DEVICE|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
57935762|NCT06075160|DIAGNOSTIC_TEST|Resting full-cycle ratio (RFR)-guided revascularization|The decision of coronary intervention is based on an RFR cut-value of 0.89. If RFR ≤ 0.89, target lesion will be revascularized, and if RFR \> 0.89, PCI will be deferred. However, even if RFR ≤ 0.89, PCI can be deferred if the RFR gradient of the lesion ≤ 0.02, or if the diffused type of stenosis, because physiological gain is expected to be very low.
57935763|NCT06075160|DIAGNOSTIC_TEST|Fractional flow ratio (FFR)-guided revascularization|Study participants of FFR-guided PCI arm will be selected from a large-scaled, ongoing FFR registry. The decision of coronary intervention is based on an FFR cut-value of 0.80. If FFR ≤ 0.80, target lesion will be revascularized, and if RFR \> 0.80, PCI will be deferred.
58291106|NCT00497146|DRUG|placebo|placebo capsule
58291107|NCT00627562|DEVICE|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
58291108|NCT01966887|GENETIC|MYDICAR-single intracoronary infusion|AAV1/Serca2a
58291109|NCT01966887|GENETIC|Placebo; single intracoronary infusion|single intracoronary infusion
58291110|NCT02812082|OTHER|web-based patient education|
58291111|NCT02812082|BEHAVIORAL|questionnaire|
58291112|NCT02853526|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
58403467|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
58403468|NCT00052611|DRUG|Celecoxib|
58403469|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
58403470|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
58291113|NCT02853526|DRUG|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
58291114|NCT02853526|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
58291115|NCT02853526|DRUG|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
58291116|NCT04646187|BIOLOGICAL|Infliximab|Dosing interval lengthening from 8 to 12 weeks
58291117|NCT04646187|BIOLOGICAL|Adalimumab|Dosing interval lengthening from 2 to 3 weeks
58291118|NCT01091870|DRUG|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
58403471|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
58403472|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
58403473|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
58403474|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
58403475|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
58403476|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
58403477|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
57935764|NCT05030454|DEVICE|ETHOS|Ring-gantry CT-guided radiotherapy unit, pairing a linear accelerator within a ring-gantry imaging unit.
58403478|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
58403479|NCT03933410|DRUG|KB195|KB195 is a novel glycan
58403480|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
58403481|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
58403482|NCT03730961|DRUG|BMS-986231|Intravenous administration
58403483|NCT03730961|DRUG|Furosemide|Intravenous administration
58403484|NCT03730961|DRUG|Placebo|Intravenous administration
58403485|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
57935765|NCT05030454|RADIATION|CT-guided stereotactic adaptive radiotherapy|All participants will be initially planned to at least 35 Gy in 5 fractions, subject to hard constraints based on the treatment site.
57935766|NCT05503862|DEVICE|YoSperm|The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
57935767|NCT04869254|OTHER|Lower lymphocyte/ATG ratio|
58403486|NCT03434431|OTHER|Reverse dieting|
58403487|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
58403488|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
58403489|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
58072557|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
58403490|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
58403491|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
58403492|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
58403493|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
58403494|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
58403495|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
57729999|NCT02843568|PROCEDURE|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
58072558|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
58072559|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
58072560|NCT02899884|OTHER|No Intervention|
58072561|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
58291119|NCT01091870|DRUG|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
58291120|NCT01091870|DRUG|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
58291121|NCT00621257|DIETARY_SUPPLEMENT|ergocalciferol|8000 units/ml
58291122|NCT00621257|DIETARY_SUPPLEMENT|Cholecalciferol|400 units per drop
58291123|NCT02664012|OTHER|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
58291124|NCT02664012|OTHER|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
58291125|NCT02664012|OTHER|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
58291126|NCT02664012|OTHER|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
58291127|NCT02664012|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
58403496|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
58403497|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
58403498|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
58403499|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
58403500|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
58403501|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
58403502|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
58291128|NCT04917354|DEVICE|Superb-Microvascular imaging|Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
58291129|NCT04797429|OTHER|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
58291130|NCT04797429|OTHER|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
58291131|NCT02750696|DRUG|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
58291132|NCT02750696|DRUG|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
58291133|NCT05621772|OTHER|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
58403503|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
58403504|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
58403505|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
58403506|NCT01328535|DRUG|temozolomide|Given PO
58403507|NCT01328535|OTHER|flow cytometry|Correlative studies
58403508|NCT01328535|OTHER|staining method|Correlative studies
58403509|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
57935768|NCT04869254|OTHER|Higher lymphocyte/ATG ratio|
57935769|NCT04044183|BEHAVIORAL|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
57935770|NCT04044183|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
58403510|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
58072562|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
58403511|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
58291134|NCT05447845|DIAGNOSTIC_TEST|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
58403512|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
58403513|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
58403514|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
58403515|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
58403516|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
58403517|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
58403518|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
58403519|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
58403520|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
58403521|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
58403522|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
58403523|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
58403524|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
58403525|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
58403526|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
58403527|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
58403528|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
58403529|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
58403530|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
58403531|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
58403532|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
58403533|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
58403534|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
57935771|NCT02830763|DIETARY_SUPPLEMENT|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
58072563|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
57935772|NCT01980420|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
58072564|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
58291135|NCT05525000|DEVICE|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
58291136|NCT03247088|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
58291137|NCT03247088|DRUG|Busulfan|Given IV
58291138|NCT03247088|DRUG|Cyclophosphamide|Given IV
58291139|NCT03247088|BIOLOGICAL|Filgrastim|Given SC
58291140|NCT03247088|DRUG|Fludarabine|Given IV
58291141|NCT03247088|DRUG|Mycophenolate Mofetil|Given PO
58291142|NCT03247088|DRUG|Sorafenib|Given PO
58291143|NCT03247088|DRUG|Tacrolimus|Given PO
58291144|NCT01431313|DRUG|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
58291145|NCT04639362|DRUG|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
58291146|NCT04639362|DRUG|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
58291147|NCT06523049|DRUG|Vorolanib Tablets|Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
58291148|NCT06523049|DRUG|Sintilimab Injection|Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
58291149|NCT05283577|OTHER|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
58291150|NCT05283577|OTHER|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
58291151|NCT04742504|BIOLOGICAL|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
57935773|NCT01318252|DRUG|AL-54478 0.005%|
57935774|NCT01318252|DRUG|Latanoprost 0.005%|
58072565|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
58291152|NCT01865721|DRUG|Entonox|Entonox will be used according to the allocated method
58291153|NCT04400149|DIAGNOSTIC_TEST|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
58072566|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
58072567|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
58291154|NCT05413226|DIETARY_SUPPLEMENT|Celastrol|Four increasing doses of Celastrol to each of five men.
58291155|NCT05819879|PROCEDURE|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
58072568|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
57935775|NCT01318252|DRUG|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
57935776|NCT04411628|DRUG|LY3819253|Administered IV.
57935777|NCT04411628|DRUG|Placebo|Administered IV.
57935778|NCT04353466|PROCEDURE|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
58072569|NCT01379911|OTHER|Yogurt|
58072570|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
58072571|NCT00296569|DRUG|MK0686|
58403535|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
58403536|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
58403537|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
57935779|NCT04353466|DRUG|Elelyso|intravenous (IV) infusions of Elelyso
58403538|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
58403539|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
58403540|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
57935780|NCT05837351|BEHAVIORAL|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
57935781|NCT03506737|OTHER|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
57935782|NCT03506737|OTHER|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
58072572|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
58072573|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
58291156|NCT05819879|PROCEDURE|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
58291157|NCT00553527|PROCEDURE|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
58291158|NCT03105557|DEVICE|Urinary collecting device|Urinary collecting device
58291159|NCT01956188|DIETARY_SUPPLEMENT|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
58291160|NCT01956188|DIETARY_SUPPLEMENT|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
58291161|NCT01648062|BEHAVIORAL|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
58291162|NCT04352777|DRUG|Abemaciclib|50 - 150mg tablet BID as prescribed per standard of care
58291163|NCT04352777|DRUG|Fulvestrant|500mg as prescribed per standard of care
58291164|NCT04352777|DRUG|Aromatase Inhibitors|Letrozole, anastrozole as prescribed per standard of care
58291165|NCT05982197|DRUG|Curcumin Gel|Curcuma longa oral gel for prevention radiation induced oral mucositis
58291166|NCT05982197|DRUG|Standard Preparation|Standard preparation for prevention radiation induced oral mucositis
58291167|NCT04032197|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
58291168|NCT04032197|DRUG|Placebo (semaglutide)|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
58403541|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
58403542|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
58403543|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
58403544|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
58403545|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
58403546|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
58403547|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
58403548|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
58403549|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
58403550|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
57935783|NCT05648058|DRUG|Nefopam ampule|nefopam ampule 50 mg
57935784|NCT05648058|DRUG|diphenhydramine ampule|diphenhydramine ampule 10 mg
57935785|NCT05470946|DEVICE|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
57935786|NCT06274008|DRUG|Exparel|Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
57935787|NCT02790125|DRUG|BMS-986166|
57935788|NCT02790125|DRUG|Placebo matching BMS-986166|
57935789|NCT02614391|OTHER|Active distraction using a tablet|Playing a videogame using a computer tablet
57935790|NCT02614391|OTHER|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
57935791|NCT02450604|GENETIC|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
57935792|NCT05132270|DRUG|hydroxyurea and thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
57935793|NCT00630461|BIOLOGICAL|Clinical Center Reference Endotoxin|single inhalation challenge
57935794|NCT03202784|DRUG|BCX7353|BCX7353
57935795|NCT01219049|DRUG|Tyrosine|1000 mg / day
58072574|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
58291169|NCT05781022|PROCEDURE|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
57935796|NCT01219049|DRUG|Tyrosine|2000 mg / day
57935797|NCT01219049|DRUG|Placebo|Placebo daily
57935798|NCT03312348|DEVICE|Infrared imaging|Infrared image image acquisition of study participants
57935799|NCT02654366|BEHAVIORAL|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
57935800|NCT03234166|OTHER|Non interventional study|Only data will be taken of patient's file.
57935801|NCT04607928|DRUG|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
57935802|NCT04607928|DRUG|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
57935803|NCT06113484|OTHER|DIET + EXERCISE|At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.
57935804|NCT06113484|OTHER|WITHOUT DIET + EXERCISE|"An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases."
57935805|NCT05394220|DIAGNOSTIC_TEST|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
57935806|NCT01753583|DEVICE|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
58072575|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
58072576|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
58072577|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
58072578|NCT00002715|DRUG|Stanford V regimen|
58072579|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
58291170|NCT02541409|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
57935807|NCT01753583|OTHER|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
57935808|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
57935809|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
58072580|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
58072581|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
58072582|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
58072583|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
58072584|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
58072585|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
58072586|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
58072587|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
57935810|NCT03459118|BEHAVIORAL|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
57935811|NCT05834309|OTHER|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
58072588|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
58072589|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
58072590|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
58072591|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
58072592|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
58072593|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
58072594|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
58291171|NCT02541409|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
58072595|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
58072596|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
58095477|NCT05664451|BEHAVIORAL|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
58291172|NCT02541409|DRUG|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
58291173|NCT04165356|PROCEDURE|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
58291174|NCT04165356|PROCEDURE|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
58291175|NCT04000126|DEVICE|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
58291176|NCT04000126|DEVICE|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
58291177|NCT04000126|DRUG|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
58403551|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
58403552|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
58403553|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
58291178|NCT04000126|DRUG|Placebo|100ml 0,9% NaCl iv 10min before intubation
58291179|NCT04000126|DEVICE|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
58403554|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
58291180|NCT04000126|DEVICE|HR|HR in beats/min will be measured by the electrocardiogram monitor
58291181|NCT04000126|DEVICE|BP|BP will be measured automatically by an occluding upper arm cuff
58403555|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
57935812|NCT03858036|DRUG|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
58403556|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
57935813|NCT03858036|DEVICE|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
57935814|NCT03887845|PROCEDURE|Surgery|The respective surgical approach for any gastric and colorectal surgery
57935815|NCT01802489|DRUG|Amiloride|
57935816|NCT01802489|DRUG|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
57935817|NCT03778853|DRUG|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
57935818|NCT06476236|DIETARY_SUPPLEMENT|M4C|Nutraceutical designed to enhance novel metabolic pathway activity.
57935819|NCT05377190|OTHER|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
58403557|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
57935820|NCT05377190|OTHER|Standard of care for the follow-up|No mobile application or digital therapeutics are used
57935821|NCT05377190|OTHER|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
58072597|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
58072598|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
58403558|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
58403559|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
58403560|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
57935822|NCT03768505|DRUG|Zandelisib (ME-401)|Zandelisib (ME-401) 60 mg
58403561|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
57935823|NCT05744336|OTHER|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
57935824|NCT05744336|OTHER|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
58403562|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
58403563|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
57935825|NCT05594316|DRUG|Trichloroacetic acid|5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
57935826|NCT00361426|DEVICE|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
57935827|NCT01115842|DRUG|Vitamin D|Vitamin D 4000IU per day for 5 days
58072599|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
58072600|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
58072601|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
58291182|NCT01853787|DRUG|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
58291183|NCT01853787|DRUG|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
58403564|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
57935828|NCT06224309|DIAGNOSTIC_TEST|18F-BL40 PET/CT|Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
57935829|NCT06224309|DIAGNOSTIC_TEST|18F-FDG PET/CT|"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
57935830|NCT06224309|DIAGNOSTIC_TEST|Routine Blood Draw - Phase 1 only|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
57935831|NCT03327441|OTHER|Almonds|Almonds will be provided as 15% energy
57935832|NCT03327441|OTHER|Omelette|Omelettes will be provided as 15% energy
57935833|NCT03480412|PROCEDURE|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
57935834|NCT03480412|PROCEDURE|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
57935835|NCT02053909|DRUG|Aspirin|
57935836|NCT02053909|DRUG|Ticagrelor|
57935837|NCT03792386|PROCEDURE|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
58072602|NCT04670523|PROCEDURE|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
58072603|NCT04670523|PROCEDURE|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
58072604|NCT02118909|DRUG|Pracinostat|
58072605|NCT02118909|DRUG|Itraconazole|
58072606|NCT02118909|DRUG|Ciprofloxacin|
58072607|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
58072608|NCT00088660|BIOLOGICAL|PANVAC™-VF|
58072609|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
58291184|NCT02035553|DRUG|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
58291185|NCT02035553|DRUG|Placebo|Placebo, two tablets, once daily by mouth
58291186|NCT00807885|DRUG|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
58291187|NCT01679392|DRUG|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
58291188|NCT05341050|DRUG|TKI|halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
58291189|NCT03311841|DRUG|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
58291190|NCT03311841|DRUG|Dabigatran and pitavastatin oral solution|375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
57730000|NCT03358667|PROCEDURE|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
57935838|NCT03792386|PROCEDURE|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
57935839|NCT03519685|BEHAVIORAL|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
57935840|NCT03519685|BEHAVIORAL|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
57935841|NCT04665336|BEHAVIORAL|Circadian Timing Program|"Sleep hygiene training will be provided to the participants. They will be asked to make lifestyle changes according to the Circadian Timing Program created by the researcher."
57935842|NCT04665336|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training will be given by the researcher. There will also be sleep hygiene training sections on the website.
57935843|NCT02678143|DRUG|Alemtuzumab|
57935844|NCT02678143|DRUG|Cyclophosphamide|
57935845|NCT02678143|DRUG|Mycophenolate mofetil|
57935846|NCT02678143|DRUG|Sirolimus|
57935847|NCT02678143|DRUG|Fludarabine|
57935848|NCT02678143|RADIATION|Total body irradiation|
58072610|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
58072611|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
58291191|NCT03311841|DRUG|Atorvastatin and rosuvastatin oral solution|100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
58291192|NCT03311841|DRUG|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
58291193|NCT00100347|DRUG|PPI-2458|
58291194|NCT00883415|DRUG|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
57935849|NCT02678143|PROCEDURE|Hematopoietic stem cell transplant|
58291195|NCT02251821|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
58291196|NCT02251821|DRUG|Busulfan|Given IV
58291197|NCT02251821|DRUG|Cyclophosphamide|Given IV
58291198|NCT02251821|DRUG|Fludarabine Phosphate|Given IV
57730001|NCT02591654|DRUG|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
57935850|NCT00918853|PROCEDURE|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
57935851|NCT02607449|DRUG|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
57935852|NCT02607449|DRUG|Placebo|Placebo without any active pharmaceutical ingredients
57935853|NCT03746899|BIOLOGICAL|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
58072612|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
57935854|NCT02082899|DRUG|Active Comparator EBI-005 5 mg/mL|
57935855|NCT02082899|DRUG|Placebo Comparator|
58072613|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
58072614|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
58072615|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
58072616|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
58072617|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
58072618|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
58291199|NCT02251821|OTHER|Laboratory Biomarker Analysis|Correlative studies
58291200|NCT02251821|DRUG|Melphalan|Given IV
58291201|NCT02251821|DRUG|Methotrexate|Given IV
58291202|NCT02251821|DRUG|Mycophenolate Mofetil|Given IV or PO
58291203|NCT02251821|DRUG|Ruxolitinib|Given PO
58291204|NCT02251821|DRUG|Tacrolimus|Given IV or PO
58291205|NCT02251821|RADIATION|Total-Body Irradiation|Undergo TBI
58291206|NCT02251821|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
58291207|NCT00193583|DRUG|Topotecan|
58291208|NCT00193583|DRUG|Carboplatin|
57935856|NCT00515957|GENETIC|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2"
57935857|NCT00210184|DRUG|Irinotecan associated to fluorouracil and leucovorin|
57935858|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
57935859|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
57935860|NCT02807649|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|Two tablets consume daily with meal.
57935861|NCT00591825|DRUG|D-cycloserine|D-cycloserine
57935862|NCT00591825|DRUG|Placebo|Placebo
57935863|NCT00255762|DRUG|carboplatin|Given IV
57935864|NCT00255762|DRUG|paclitaxel|Given IV
57935865|NCT00255762|BIOLOGICAL|bevacizumab|Given IV
57935866|NCT00255762|OTHER|laboratory biomarker analysis|Correlative studies
57935867|NCT06036251|OTHER|Questionnaires|Self-reported quality of life (QOL) measures completed online
58072619|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
58072620|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
58072621|NCT00466284|DRUG|Tarceva (erlotinib)|
57935868|NCT05452811|PROCEDURE|Burch colposuspension|Anti-incontinence surgery for stress urinary incontinence
57935869|NCT00105144|DRUG|Micafungin|IV
57935870|NCT00105144|DRUG|Caspofungin|IV
57935871|NCT05327374|DIAGNOSTIC_TEST|calculation of the inferior vena cava collapsibility index|the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure
57935872|NCT05597865|BEHAVIORAL|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
57935873|NCT05597865|BEHAVIORAL|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
57935874|NCT02493504|DRUG|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
57935875|NCT04457076|DRUG|LevoCept|Levonorgestrel-Releasing Intrauterine System
57935876|NCT01200238|DRUG|STA-9090|
57935877|NCT05881174|PROCEDURE|acupuncture|acupuncture
57935878|NCT04429854|BIOLOGICAL|Convalescent Plasma|"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."
57935879|NCT04429854|DRUG|Standard of care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
57935880|NCT02848950|DRUG|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
58072622|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
58072623|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
57935881|NCT02177721|BIOLOGICAL|Collection of samples|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA."
57935882|NCT02437617|PROCEDURE|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
57935883|NCT02567539|RADIATION|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
57935884|NCT02567539|DRUG|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
57935885|NCT02041208|PROCEDURE|kidney transplantation|kidney transplantation
57935886|NCT03368950|OTHER|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
58072624|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
58072625|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
58072626|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
57935887|NCT06427291|BIOLOGICAL|Herpes virus T3011 injection|T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
57935888|NCT02713035|BEHAVIORAL|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
58291209|NCT03681899|OTHER|Questionnaires|"* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
58072627|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
58403565|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
58403566|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
58403567|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
58403568|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
57935889|NCT01768897|DRUG|CPI-613|Given IV
57935890|NCT01768897|DRUG|cytarabine|Given IV
57935891|NCT01768897|DRUG|mitoxantrone hydrochloride|Given IV
57935892|NCT01768897|OTHER|laboratory biomarker analysis|Optional correlative studies
58072628|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
58072629|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
58291210|NCT03635827|COMBINATION_PRODUCT|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
58403569|NCT02436707|DRUG|Ibrutinib|
58403570|NCT02436707|DRUG|Rituximab|
58403571|NCT02436707|DRUG|Gemcitabine|
58403572|NCT02436707|DRUG|Dexamethasone|
58403573|NCT02436707|DRUG|Cisplatin|
58403574|NCT02436707|DRUG|Mesna|
58403575|NCT02436707|DRUG|Cyclophosphamide|
57935893|NCT01768897|OTHER|pharmacological study|Correlative studies
58072630|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
58072631|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
58403576|NCT02436707|DRUG|Etoposide|
58403577|NCT02436707|DRUG|G-CSF|
58403578|NCT02436707|DRUG|Selinexor|
58403579|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
58072632|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
57935894|NCT02294682|DRUG|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
57935895|NCT00962156|DRUG|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
57935896|NCT00962156|DRUG|Ringers acetate|Infusion for volume expansion in the ICU
57935897|NCT04332224|DEVICE|Blanketrol cooling device and water-perfused blankets|Blanketrol and water-perfused blankets
57935898|NCT04332224|DEVICE|Blanketrol and Kool Kit|Blanketrol cooling device with water-perfused vest, hood and lower body blanket
57935899|NCT04332224|DEVICE|Arctic Sun|Arctic Sun cooling device with gel cooling pads
57935900|NCT00993954|PROCEDURE|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
58072633|NCT06539715|DIAGNOSTIC_TEST|Visual field assessment|Automated perimetry
57935901|NCT02941653|DEVICE|Potassium nitrate 2% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
57935902|NCT02941653|DEVICE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
57935903|NCT05696275|BEHAVIORAL|exercise|20-30 minutes of walking and elastic band exercise per day
57935904|NCT02975193|BEHAVIORAL|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
58072634|NCT05090813|DEVICE|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
58072635|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
58291211|NCT03635827|COMBINATION_PRODUCT|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
58291212|NCT03132415|BEHAVIORAL|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
58291213|NCT03132415|BEHAVIORAL|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
58291214|NCT06128720|DEVICE|Hyperbaric Oxygen|Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen
58291215|NCT06128720|DEVICE|Sham Hyperbaric Oxygen|Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
58403580|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
58403581|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
57935905|NCT02975193|BEHAVIORAL|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
57935906|NCT02975193|PROCEDURE|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
57935907|NCT03404089|DEVICE|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
58072636|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
58291216|NCT05028816|DEVICE|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
58291217|NCT05028816|OTHER|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
58490777|NCT02587273|DRUG|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
57935908|NCT03404089|DEVICE|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
57935909|NCT06308432|OTHER|Low intensity|The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
58072637|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
58072638|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
58072639|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
57935910|NCT06308432|OTHER|Low temperature|The performance test will be carried out in a room conditioned to a temperature of 22º.
57935911|NCT06308432|OTHER|Low Humidity|The performance test will be carried out in a room conditioned to 40% humidity.
57935912|NCT06308432|OTHER|High intensity|The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
57935913|NCT06308432|OTHER|High temperature|The performance test will be carried out in a room conditioned to a temperature of 35º.
57935914|NCT06308432|OTHER|High humidity|The performance test will be carried out in a room conditioned to 65% humidity.
57935915|NCT05543278|DRUG|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
57935916|NCT03244748|PROCEDURE|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
57935917|NCT04597957|DIETARY_SUPPLEMENT|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
57935918|NCT02556125|DEVICE|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
57935919|NCT01789762|BIOLOGICAL|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
57935920|NCT01789762|BIOLOGICAL|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
58072640|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
58072641|NCT00136994|DRUG|Ziprasidone|
58291218|NCT05028816|DEVICE|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
58291219|NCT05028816|OTHER|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
58291220|NCT05485480|DRUG|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
58291221|NCT05485480|DRUG|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
58291222|NCT00812032|DRUG|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
58291223|NCT00812032|DRUG|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
58403582|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
58403583|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
58403584|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
57730002|NCT02591654|DRUG|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
57730003|NCT02909972|DRUG|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
57730004|NCT02909972|DRUG|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
57935921|NCT01789762|BIOLOGICAL|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
57935922|NCT00732251|DRUG|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
57935923|NCT00247741|DRUG|spinal administration of articaine|
57935924|NCT00247741|DRUG|spinal administration of lidocaine|
57935925|NCT06325618|OTHER|No intervention other than obtaining biopsies|Skin, fat, and muscle biopsies will be obtained
57935926|NCT06325618|DRUG|Indocyanine green (ICG)|Indocyanine green will be injected to evaluate the lymphatic system.
58291224|NCT01827735|DRUG|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
57730005|NCT05787418|DRUG|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
57730006|NCT05787418|DRUG|Placebo|Placebo 8 times per day for 7 consecutive days
57730007|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 250 Mcg|
57730008|NCT00877448|BIOLOGICAL|Multimeric-001 250 Mcg|
57935927|NCT02408107|BEHAVIORAL|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
57935928|NCT04769050|DRUG|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
57935929|NCT04769050|DRUG|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
57935930|NCT03706495|BEHAVIORAL|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
58291225|NCT05335655|DRUG|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
58403585|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
58403586|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
58403587|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
58403588|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
58403589|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
58403590|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
58403591|NCT02885740|BIOLOGICAL|Blood sample|
58403592|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
58403593|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
58403594|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
58403595|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
58403596|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
58291226|NCT05335655|DRUG|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
58403597|NCT01933438|OTHER|Control|Standard treatment
58403598|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
58403599|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
58403600|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
58403601|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
58403602|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
58403603|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
58403604|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
58403605|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
58403606|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
58403607|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
58403608|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
58403609|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
58403610|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
58403611|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
58403612|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
58403613|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
58403614|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
57730009|NCT00877448|BIOLOGICAL|Phosphate Buffered saline|
58291227|NCT06612957|PROCEDURE|Repair of uterine cicatricial diverticulum|Cut off the uterine cicatricial diverticular tissue in the lower portion of the uterus, and restore normal uterine muscle tissue.
58291228|NCT03298997|PROCEDURE|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
58403615|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
58403616|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
58403617|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
58403618|NCT06174688|DRUG|BOTOX|Intramuscular Injections
58403619|NCT06174688|DRUG|Placebo|Intramuscular Injections
58403620|NCT05437562|OTHER|Ewing Amputation|All patients will receive Ewing Amputation to test feasibility.
58403621|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
58403622|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
58403623|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
58403624|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
58403625|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
58403626|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
57730010|NCT00877448|BIOLOGICAL|Adjuvanted PBS|
58291229|NCT03298997|PROCEDURE|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
57730011|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 500 Mcg|
57730012|NCT00877448|BIOLOGICAL|Multimeric-001 500 Mcg|
57730013|NCT00877448|BIOLOGICAL|Multimeric-001 125 Mcg|
58291230|NCT00108290|DRUG|Chemotherapy|
58291231|NCT03938363|OTHER|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
58291232|NCT03938363|DRUG|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
58291233|NCT03938363|DIAGNOSTIC_TEST|Severity scale of the disease|JRS for BS TWSTRS for CD
58291234|NCT02413632|OTHER|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
58291235|NCT02413632|OTHER|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
57730014|NCT01577706|DRUG|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
57730015|NCT01577706|DRUG|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
57730016|NCT01577706|OTHER|Placebo|Placebo, gel-capsule, single-dose, 1-day
57730017|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
58291236|NCT02187237|DEVICE|YOLO TOUCH Low Level Laser|
58403627|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
58403628|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
57935931|NCT03706495|BEHAVIORAL|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
58403629|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
58403630|NCT00460759|DRUG|Moxifloxacin|
57730018|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
57730019|NCT01230593|DRUG|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
57935932|NCT00261612|DRUG|bortezomib|
57935933|NCT00261612|DRUG|rituximab|
58403631|NCT00460759|DRUG|Rifapentine|
57730020|NCT01230593|DRUG|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
57935934|NCT00261612|DRUG|dexamethasone|
58072642|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
57730021|NCT01230593|OTHER|Hot Compresses|Hot compresses 3x/day to eyelids
57730022|NCT05496582|DIAGNOSTIC_TEST|No intervention|No intervention
58291237|NCT04069728|OTHER|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
58403632|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
58403633|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
57730023|NCT01700608|DRUG|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
58403634|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
57730024|NCT04722965|PROCEDURE|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
57730025|NCT04722965|PROCEDURE|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
57730026|NCT04829838|DRUG|intravenous levetireacetam|phenytoin is considered as control drug in the study
57730027|NCT06670144|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan; Mediterranean diet)
57730028|NCT06670144|OTHER|Alcohol intake|(Frequency and intake of beer, wine, sherry, and spirits were collected by asking the number of specified units (pints, glasses or measures) of each type of alcoholic beverage (beer or cider, wine, sherry or fortified wines, and spirits) per week.)
57730029|NCT06670144|OTHER|Fruit and vegetables intake|(Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire)
57730030|NCT06670144|OTHER|Tea consumption|(Intake of tea from food frequency questionnaire)
57935935|NCT00261612|PROCEDURE|treatment protocol|
57730031|NCT06670144|OTHER|Coffee consumption|(Intake of caffeinated coffee and decaffeinated coffee from food frequency questionnaire)
57935936|NCT00267709|DRUG|Visilizumab|
57935937|NCT06165822|DRUG|TQB3909 tablets|TQB3909 100mg/tablet.
57935938|NCT06165822|DRUG|Itraconazole capsule|Itraconazole capsule is a strong inhibitor of CYP3A4.
57935939|NCT06165822|DRUG|Rifampicin capsule|Rifampicin capsule is a strong inducer of CYP3A4.
57935940|NCT00122811|DRUG|Indapamide SR 1.5mg; Perindopril 2-4mg|
58291238|NCT04069728|OTHER|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
58291239|NCT01955239|RADIATION|Intensity-modulated Radiotherapy|
58291240|NCT00443157|BIOLOGICAL|Meningococcal B Vaccine NZ|
58291241|NCT03143777|DEVICE|Sara Combilizer|Combined tilt table and stretcher chair
58403635|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
58403636|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
58403637|NCT06078202|DRUG|ABBV-903|Tablet; oral
58403638|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
58403639|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
57935941|NCT06033885|DEVICE|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
57935942|NCT05757336|DRUG|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
58403640|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
58403641|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
58403642|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
58403643|NCT01316757|BIOLOGICAL|cetuximab|Given IV
58403644|NCT01316757|DRUG|paclitaxel|Given IV
57730032|NCT06670144|OTHER|Fish intake|(Intake of fish from food frequency questionnaire)
57935943|NCT05716750|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vit D treatment for 8 weeks
57935944|NCT01387165|DRUG|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
57935945|NCT00710736|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
57935946|NCT00710736|DRUG|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
57935947|NCT01009892|DRUG|Codeine Sulfate|Tablet
57935948|NCT02104154|DEVICE|Samsung LABGEO PT10 Hepatic Panel|
57935949|NCT01025024|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
57935950|NCT04087278|DIETARY_SUPPLEMENT|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
57935951|NCT04087278|DIETARY_SUPPLEMENT|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
58291242|NCT01719991|OTHER|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
58403645|NCT01316757|DRUG|carboplatin|Given IV
58403646|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
58403647|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
57935952|NCT00298467|DRUG|MDX-060|
57730033|NCT06670144|OTHER|Meat intake|(Intake of red meat, processed meat, and poultry from food frequency questionnaire)
57730034|NCT06670144|OTHER|Vitamin D intake|(Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake)
57730035|NCT04666493|OTHER|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
57730036|NCT02429128|OTHER|14 weeks exercise training|
57730037|NCT05016492|DEVICE|Visual-perceptual interactive game system|Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.
57935953|NCT05275426|DRUG|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
57935954|NCT05275426|DRUG|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
57935955|NCT01105091|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
57935956|NCT01105091|DRUG|Flolan®|Per Prescribing Information
57935957|NCT02022345|PROCEDURE|Percutaneous Coronary Intervention|
58291243|NCT05765669|PROCEDURE|Percutaneous screw fixation|Surgical intervention in the form of percutaneous screw fixation
58291244|NCT05765669|OTHER|Pain management|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
58291245|NCT05765669|OTHER|Physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
58291246|NCT01137097|PROCEDURE|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
58403648|NCT02858986|PROCEDURE|3D laparoscopy|
58403649|NCT02858986|PROCEDURE|4K laparoscopy|
58403650|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
58403651|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
58403652|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
58403653|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
58403654|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
58403655|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
58403656|NCT03073018|DRUG|Fosinopril|oral administration, capsules
58403657|NCT03073018|DRUG|Pravastatin|oral administration, capsules
58403658|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
58403659|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
58403660|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
58403661|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
58403662|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
58403663|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
57730038|NCT05016492|BEHAVIORAL|standard rehabilitation|Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
57730039|NCT04040985|PROCEDURE|Total Knee Arthroplasty using LEGION™ Total Knee System|Primary Total Knee Arthroscopy using LEGION™ Total Knee System
57730040|NCT02534974|DEVICE|NOSTEN|
57730041|NCT05684016|OTHER|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
57935958|NCT01480921|BEHAVIORAL|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~* 5-10 min warm-up~* 30 min aerobic interval training (walking or stationary bicycle)~* 10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
57935959|NCT01480921|BEHAVIORAL|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~* 5-10 min of warm-up~* 30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~* 10 min of cool down~Exercise will be tracked by the participant in exercise log books."
58291247|NCT03758768|OTHER|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
58291248|NCT03758768|OTHER|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
58291249|NCT03101384|OTHER|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
58291250|NCT02426008|OTHER|Growth Factors and Cytokine adding to embryo culture media|
58291251|NCT02426008|OTHER|No Intervention|Nothing to Add
58291252|NCT01347593|DRUG|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
58291253|NCT00006929|DRUG|suramin|Given IV
58291254|NCT00006929|DRUG|carboplatin|Given IV
58291255|NCT00006929|DRUG|paclitaxel|Given IV
58291256|NCT00006929|OTHER|pharmacological study|Correlative studies
58291257|NCT00006929|OTHER|laboratory biomarker analysis|Correlative studies
58291258|NCT04504565|DIAGNOSTIC_TEST|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
58291259|NCT03610334|DRUG|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
58291260|NCT03610334|DRUG|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
58291261|NCT03610334|DRUG|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
58291262|NCT03610334|DRUG|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
58403664|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
58403665|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
58403666|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
57730042|NCT05684016|OTHER|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
58291263|NCT04547140|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
58291264|NCT04547140|DRUG|Placebo|Intravenous infusion
58291265|NCT04547140|DRUG|Standard Medical Treatment|SMT
58291266|NCT03576638|DRUG|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
58403667|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
58403668|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
58403669|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
57730043|NCT05684016|OTHER|EDSS|Extended Disability Status Score
57730044|NCT05684016|OTHER|Physical Examination|Physical Examination
57730045|NCT03558867|DRUG|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
57730046|NCT03558867|DRUG|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
58291267|NCT03576638|DRUG|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
58291268|NCT01149031|DEVICE|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
58291269|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
58291270|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
58291271|NCT05386290|DRUG|Infliximab|A TNFα inhibitor in UC and CD treatment
58291272|NCT05386290|DRUG|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
57730047|NCT02556021|DRUG|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
57730048|NCT02556021|DRUG|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
58403670|NCT06563180|BEHAVIORAL|Health-Promoting Lifestyle Profile II|"health promoting lifestyle behaviors (HPLBs). It included fifty-two elements within six dimensions: Physical activity, nutrition, spiritual growth, interpersonal relations, stress management, and health responsibility. Higher scores refer to higher adherence levels to healthier lifestyle behaviors. The total score ranged from (52 to 208). It used a four-point likert scale, ranged from one (never) to four (routinely) . The total score will be classified into four levels:~* Poor for the range 52-90~* Moderate for the range 91-129.~* Good for the range 130-168.~* Excellent for the range 169-208."
57935960|NCT02648516|COMBINATION_PRODUCT|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
58403671|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
58403672|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
58072643|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
58291273|NCT05386290|DRUG|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
58291274|NCT05386290|DRUG|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
58403673|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
58403674|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
58403675|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
58403676|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
58403677|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
58403678|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
58403679|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
58403680|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
58072644|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
58072645|NCT00000649|DRUG|Nevirapine|
58072646|NCT00000649|DRUG|Zidovudine|
58072647|NCT00423137|DRUG|BIBW 2948 BS|Capsule
58291275|NCT00065273|DRUG|risperidone|
58291276|NCT00065273|DRUG|clozapine|
58291277|NCT00065273|DRUG|olanzapine|
58291278|NCT00233584|PROCEDURE|Pulmicort (budesonide) pMDI|
58291279|NCT02252107|DRUG|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
58291280|NCT00985972|BEHAVIORAL|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
58291281|NCT00254423|DRUG|Dasatinib|Given PO
58291282|NCT00254423|OTHER|Laboratory Biomarker Analysis|Correlative studies
58291283|NCT00254423|OTHER|Pharmacological Study|Correlative studies
58403681|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
58072648|NCT00423137|DRUG|Placebo|Capsule
58291284|NCT00254423|OTHER|Quality-of-Life Assessment|Ancillary studies
58291285|NCT00254423|OTHER|Questionnaire Administration|Ancillary studies
58403682|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
58072649|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
57935961|NCT05646212|OTHER|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
58291286|NCT06183437|OTHER|Stopping Heart Failure Medication(s)|This group will stop their heart failure medication(s) under the supervision of the study team.
58291287|NCT03075189|DIETARY_SUPPLEMENT|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
58291288|NCT00419042|DRUG|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
58291289|NCT00419042|DRUG|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
58291290|NCT05841797|BEHAVIORAL|In-Person Program Management Plus (PM+)|PM+ sessions conducted in-person by mentor mothers
58291291|NCT05841797|BEHAVIORAL|Mobile Program Management Plus (mHealth PM+)|PM+ sessions conducted via phone
58291292|NCT05355909|PROCEDURE|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
58403683|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
58403684|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
58403685|NCT02281474|DRUG|Nilotinib|
58403686|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
58403687|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
58403688|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
58403689|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
58072650|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
58291293|NCT03003702|DEVICE|Nonin|
58291294|NCT06266130|DEVICE|Treatment Group Digital Bonding Tray|The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.
58291295|NCT06266130|DEVICE|Control Group Direct Bonding|The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.
58291296|NCT06299449|PROCEDURE|free-hand socket shield|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
58403690|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
58403691|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
58072651|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
58072652|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
58403692|NCT04140695|DRUG|Tradipitant|BID
58403693|NCT04140695|DRUG|Placebo|BID
58403694|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
58490778|NCT05360797|OTHER|Outpatient|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
58490779|NCT05360797|OTHER|Medical home care|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
58403695|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
57935962|NCT05646212|OTHER|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
58403696|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
58403697|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
58403698|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
58403699|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
58403700|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
57935963|NCT05053516|OTHER|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
58291297|NCT06299449|PROCEDURE|AI/guided socket shield|"The patient specific guides will be placed at the pre-planned positions at the labial buccal mucosa.~using artificial intelligence the socket shield approach will be planned to keep the buccal shield and using surgical guide the shield will be preciesly prepared followed by guided implant placement and whole tooth grafting of the jumping gap"
58403701|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
58403702|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
58403703|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
57935964|NCT04722770|DEVICE|PhotoniCare OtoSight Middle Ear Scope|PhotoniCare OtoSight imaging using a near-infrared laser
58072653|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
58072654|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
58072655|NCT04123743|OTHER|Placebo|Placebo topical cream
58072656|NCT01061073|DRUG|Omexel|
58072657|NCT01061073|DRUG|spasfon|
58291298|NCT04712864|BIOLOGICAL|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
58403704|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
58490780|NCT05360797|OTHER|Hospitalization|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI_1) in each center.
58490781|NCT01209325|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
58490782|NCT01209325|OTHER|laboratory biomarker analysis|
58490783|NCT02404025|DRUG|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
58490784|NCT02404025|DRUG|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
58490785|NCT02404025|DRUG|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
57730049|NCT02556021|DRUG|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
57730050|NCT06635044|OTHER|intradialytic exercise|HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
57935965|NCT03752008|BEHAVIORAL|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
57935966|NCT03752008|BEHAVIORAL|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
57935967|NCT03597971|DRUG|HMPL004-6599|For each cohort, 6 subjects will receive HMPL004-6599
57935968|NCT03597971|DRUG|Placebo|For each cohort, 2 subjects will receive placebo
57935969|NCT04394481|DRUG|Dexmedetomidine|IV injection (1 µg/kg - 100 mL) before anesthetic induction
57935970|NCT04394481|DRUG|Ropivacaine|Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
57935971|NCT04394481|DRUG|Dexamethasone|IV injection (0.15 mg/kg) during anesthetic induction
57935972|NCT00771641|PROCEDURE|conventional surgery|
57935973|NCT00771641|RADIATION|low-LET cobalt-60 gamma ray therapy|
57935974|NCT00771641|RADIATION|low-LET electron therapy|
57935975|NCT00771641|RADIATION|low-LET photon therapy|
57935976|NCT00771641|RADIATION|radiation therapy|
58490786|NCT04190888|OTHER|No intervention|No intervention - observational study
57935977|NCT04741386|BIOLOGICAL|SARS-CoV-2 vaccination|All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
57935978|NCT04830592|BIOLOGICAL|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
57935979|NCT04830592|BIOLOGICAL|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
58072658|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
58490787|NCT04729023|PROCEDURE|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
58291299|NCT03099577|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58291300|NCT03099577|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58403705|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
57935980|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
57935981|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
58072659|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
58403706|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
58403707|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
58403708|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
58403709|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
58403710|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
58403711|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
57935982|NCT00779922|DRUG|lenalidomide|
58072660|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
58072661|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
58072662|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
58072663|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
58291301|NCT03099577|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58291302|NCT03099577|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58291303|NCT03099577|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58291304|NCT03099577|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
57935983|NCT02069925|BEHAVIORAL|Early Detection (ED)|This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
58072664|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
58072665|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
58072666|NCT00772031|DRUG|placebo|an inactive substance
58072667|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
58291305|NCT03099577|RADIATION|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
58403712|NCT05179668|DRUG|Placebo|administered orally once daily
58403713|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
57935984|NCT02069925|BEHAVIORAL|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
57935985|NCT01493557|DRUG|pantoprazole|40 mg q.a.m, p.o.
57935986|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
57935987|NCT01493557|DRUG|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
58291306|NCT02749227|DRUG|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
58490788|NCT04729023|PROCEDURE|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
57935988|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
57935989|NCT00550654|OTHER|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
57935990|NCT00550654|RADIATION|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
57935991|NCT00550654|RADIATION|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
57935992|NCT00550654|RADIATION|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
57935993|NCT00550654|RADIATION|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
58072668|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
58072669|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
58072670|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
58072671|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
57935994|NCT02465385|DRUG|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
57935995|NCT01669967|DRUG|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
57935996|NCT01669967|DRUG|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
57935997|NCT05446428|OTHER|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
57935998|NCT02345304|DRUG|Omeprazole|
58072672|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
58072673|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
58072674|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
58072675|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
58072676|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
58072677|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
58403714|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
58403715|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
58291307|NCT03176641|OTHER|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
58291308|NCT03176641|OTHER|control|Meniscus repair surgery only
58403716|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
58403717|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
58403718|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
58403719|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
58403720|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
57730051|NCT02312739|PROCEDURE|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
58291309|NCT06473116|DRUG|Isoprenaline Only Product|Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
58291310|NCT06611449|OTHER|The minimal flow anesthesia with sevoflurane group|"In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
58291311|NCT06611449|OTHER|The high flow anesthesia with sevoflurane group|"Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
58291312|NCT03295734|BEHAVIORAL|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
58291313|NCT03295734|DRUG|Perindopril|4 mg qd titrated to 8 mg qd perindopril
58291314|NCT03295734|DRUG|Losartan|50 mg qd titrated to 100 qd losartan
58291315|NCT03295734|DRUG|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
58291316|NCT01572714|BEHAVIORAL|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
58403721|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
58403722|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
58403723|NCT06443177|DEVICE|Sham|No electrode is placed.
58403724|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
58490789|NCT00874419|DRUG|erlotinib|erlotinib 150 mg oral, once a day
58490790|NCT00874419|DRUG|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
58490791|NCT02659891|BIOLOGICAL|IVIg|
58490792|NCT02659891|OTHER|Placebo|
58490793|NCT04074408|PROCEDURE|stereotactic surgery|stereotactic aspiration surgery
57935999|NCT02345304|DRUG|Warfarin|
57936000|NCT02345304|DRUG|BI 1181181|
57936001|NCT02345304|DRUG|Midazolam|
57936002|NCT02345304|DRUG|Omeprazole|
57936003|NCT02345304|DRUG|BI 1181181|
57936004|NCT02345304|DRUG|Midazolam|
57936005|NCT02345304|DRUG|Midazolam|
57936006|NCT02345304|DRUG|Warfarin|
57936007|NCT02345304|DRUG|BI 1181181|
58291317|NCT01572714|BEHAVIORAL|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
58291318|NCT01572714|BEHAVIORAL|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
58291319|NCT06611995|OTHER|observational study|Observational study without intervention
58403725|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
58403726|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
58403727|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
58403728|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
58403729|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
58403730|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
58403731|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
58403732|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
58403733|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
58403734|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
58403735|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
57730052|NCT02312739|DRUG|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
57730053|NCT02312739|DRUG|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
57936008|NCT02345304|DRUG|Digoxin|
57730054|NCT02312739|DRUG|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
57730055|NCT02312739|OTHER|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
57936009|NCT02345304|DRUG|Digoxin|
57936010|NCT01961661|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
57936011|NCT01961661|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
57936012|NCT05573659|OTHER|time of cutaneous recoloration|In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
58291320|NCT04506931|OTHER|SMS Survey|Participants will receive a SMS survey
57730056|NCT02312739|OTHER|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
58291321|NCT04506931|OTHER|IVR Survey|Participants will receive an IVR survey
58291322|NCT04506931|OTHER|CATI Survey|Participants will receive a CATI survey
58291323|NCT04553614|BEHAVIORAL|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
58291324|NCT04553614|OTHER|Control|Usual exercise referral scheme procedure.
58291325|NCT03557918|DRUG|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
58403736|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
58490794|NCT04074408|BIOLOGICAL|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
58490795|NCT04074408|BIOLOGICAL|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
57936013|NCT05573659|OTHER|video assisted cutaneous recoloration|"Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second."
57936014|NCT01937572|OTHER|Visionaire system (Knee MRI)|
57936015|NCT01937572|OTHER|No Knee MRI|
57936016|NCT00892320|DRUG|ER OROS paliperidone|
57936017|NCT00851682|DEVICE|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
57936018|NCT02336841|OTHER|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
57936019|NCT02336841|OTHER|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
58291326|NCT01526564|DRUG|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks
57936020|NCT06465693|DEVICE|Unblinded CGM plus nutrition therapy|"will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.~will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together"
58291327|NCT01526564|DRUG|Placebo|3 t.i.d, two plates per time
58291328|NCT02030964|DRUG|DFMO|
58291329|NCT02030964|DRUG|Celecoxib|
58291330|NCT02030964|DRUG|Cyclophosphamide|
58291331|NCT02030964|DRUG|Topotecan|
58291332|NCT03677739|OTHER|Informational Intervention|Receive information focusing on skin cancer
58291333|NCT03677739|OTHER|Informational Intervention|Receive information on healthy lifestyle
58291334|NCT03677739|OTHER|Survey Administration|Ancillary studies
58291335|NCT02763319|DRUG|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
58291336|NCT02763319|DRUG|Tafasitamab|Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
57936021|NCT06465693|BEHAVIORAL|Nutrition therapy only|will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
58291337|NCT02763319|DRUG|Bendamustine (BEN)|
58291338|NCT06185738|OTHER|WCM app|WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
58291339|NCT02420119|OTHER|non interventional|
58291340|NCT01341899|PROCEDURE|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
58291341|NCT06392152|DRUG|Focal Mass Drug Administration with Primaquine|"A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year."
58291342|NCT00872521|DRUG|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)"
58403737|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
58291343|NCT02260206|DRUG|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
58403738|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
58403739|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
58403740|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
58403741|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
58403742|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
58291344|NCT03726801|OTHER|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
58403743|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
58403744|NCT06009237|DRUG|ABBV-903|Tablet; oral
57936022|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
58403745|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
58403746|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
58403747|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
58403748|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
58403749|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
58072678|NCT05867186|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
58403750|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
58403751|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
58403752|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
58403753|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
58403754|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
58403755|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
58072679|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
58072680|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
58403756|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
58403757|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
58403758|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
58403759|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
58403760|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
58072681|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
58072682|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
58072683|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58072684|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58291345|NCT06312397|OTHER|Acupressure|"For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity The symmetry of the three selected different points will also be applied to the other extremity.~After coronary angiography, acupressure will be applied for a total of 15 minutes."
58291346|NCT06312397|OTHER|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
58291347|NCT04298580|PROCEDURE|PVB block|PVB block before surgery versus after surgery
58403761|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
58072685|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58072686|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58072687|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
57730057|NCT02571218|DEVICE|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
57730058|NCT02571218|DEVICE|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
58291348|NCT01890759|BIOLOGICAL|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
58291349|NCT01462110|DEVICE|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
58291350|NCT01462110|DEVICE|W002194-0221P|5% hydroalcohol mouthrinse
58291351|NCT02804048|OTHER|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
58291352|NCT02804048|OTHER|superficial heat low back|Superficial heat application in the low back
58291353|NCT02804048|OTHER|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
58403762|NCT01774253|DRUG|Vismodegib|
58403763|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
57730059|NCT05846516|DRUG|VSV-GP154|Injection
57730060|NCT05846516|DRUG|ATP150|Injection
57730061|NCT05846516|DRUG|ATP152|Injection
57730062|NCT05846516|DRUG|Ezabenlimab|Infusion
57730063|NCT04992715|DIAGNOSTIC_TEST|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
57730064|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
58403764|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
58403765|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
58403766|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
58403767|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
58403768|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
57936023|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
58291354|NCT02804048|OTHER|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
58291355|NCT02804048|OTHER|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
58291356|NCT02804048|OTHER|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
57936024|NCT02427230|DRUG|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
58291357|NCT00436826|DRUG|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
58291358|NCT00436826|DRUG|Placebo|Participants were administered with placebo orally.
58291359|NCT00436826|DRUG|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
58291360|NCT00428480|BEHAVIORAL|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
58291361|NCT00428480|BEHAVIORAL|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
57936025|NCT02654249|DEVICE|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
57936026|NCT02654249|PROCEDURE|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
58291362|NCT01115777|OTHER|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
58403769|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
57936027|NCT02654249|DEVICE|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
58291363|NCT01775423|DRUG|BBI608|
58291364|NCT05358548|DRUG|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
58291365|NCT05358548|DRUG|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
58291366|NCT05358548|DRUG|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
58291367|NCT05358548|DRUG|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
58291368|NCT05358548|DRUG|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
58291369|NCT06101186|OTHER|NPECP based on NSM|A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
58291370|NCT03591601|OTHER|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
58291371|NCT03591601|OTHER|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
58403770|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
57730065|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
57730066|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
57936028|NCT02654249|DEVICE|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
57936029|NCT05024305|DRUG|TWP-102 injection|IV infusion
58291372|NCT03591601|OTHER|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
58291373|NCT00963976|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
57936030|NCT04466644|DIAGNOSTIC_TEST|ELISA|Antibody test (serology) in the blood samples to determine if the subject was previously infected.
58291374|NCT04423133|BEHAVIORAL|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
58490796|NCT02758483|OTHER|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
58490797|NCT02758483|OTHER|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
58291375|NCT06489314|BEHAVIORAL|LEAD (Learn, Engage, Act, Dedicate)|LEAD is a 5-session behavioral activation (BA) intervention delivered by peer-father counselors. LEAD also incorporates motivational interviewing (MI) and masculinity discussion strategies. This is a task-shifted intervention meaning mental health service tasks are delegated to non-specialist providers, in this case peer-fathers, as opposed to a specialized workforce (e.g., psychiatrists, psychologists).
57936031|NCT04466644|DIAGNOSTIC_TEST|RT-PCR|For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
57936032|NCT03352700|DRUG|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
57936033|NCT03352700|DRUG|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
57936034|NCT00000626|DRUG|Vinblastine sulfate|
57936035|NCT00000626|DRUG|Dacarbazine|
57936036|NCT00000626|DRUG|Filgrastim|
57936037|NCT00000626|DRUG|Bleomycin sulfate|
57936038|NCT00000626|DRUG|Doxorubicin hydrochloride|
57936039|NCT00068588|BIOLOGICAL|GTI-2040|Given IV
57936040|NCT00068588|DRUG|capecitabine|Given orally
57936041|NCT00992979|PROCEDURE|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
57936042|NCT00992979|PROCEDURE|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
57936043|NCT04216251|DRUG|AMR101|AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
57936044|NCT00627302|DRUG|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
57936045|NCT00627302|DRUG|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
58291376|NCT01818973|DRUG|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
58291377|NCT01818973|DRUG|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
57936046|NCT04440189|DEVICE|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
57936047|NCT00074854|DRUG|CP-547,632|
57936048|NCT05709236|DEVICE|Maxillary screw-retained prosthesis|Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
57936049|NCT04164576|GENETIC|Transplant patients|Study the specific immunity against Polyomavirus
57936050|NCT00726622|PROCEDURE|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
57936051|NCT00726622|PROCEDURE|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
57936052|NCT04047160|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
57936053|NCT01098981|DEVICE|Transcranial ultrasound as an adjunctive therapy to tPA|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes"
57936054|NCT01098981|DRUG|Standard of care tPA therapy for acute ischemic stroke|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
58072688|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58291378|NCT01818973|DRUG|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
58291379|NCT01818973|RADIATION|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
58490798|NCT01406613|OTHER|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
58490799|NCT03481686|DEVICE|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
57936055|NCT02698748|DRUG|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
57936056|NCT02698748|DRUG|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
57936057|NCT05830578|DEVICE|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
58291380|NCT01818973|PROCEDURE|surgery|Total Mesorectal Excision (TME)
57730067|NCT05954143|DRUG|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
57730068|NCT05954143|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
58072689|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58072690|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
58072691|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
58072692|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
58072693|NCT04537312|OTHER|Survey Administration|ancillary correlative
58072694|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
58291381|NCT01712139|DRUG|Irbesartan and Hydrochlorothiazide|
58291382|NCT01712139|DRUG|Avalide|
58291383|NCT01222312|DRUG|Cisplatin|75 mg/m2, d1 every 3 weeks
58291384|NCT01222312|DRUG|Oxaliplatin|85 mg/m², d1 every 2 weeks
58291385|NCT01222312|DRUG|Docetaxel|75 mg/m2, d1 every 3 weeks
58291386|NCT01222312|DRUG|Docetaxel|50mg/m2, d1 every 2 weeks
58291387|NCT01308034|DRUG|sunitinib|"All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
58291388|NCT03269903|DEVICE|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
58291389|NCT02793219|BIOLOGICAL|Sipuleucel-T|
58291390|NCT02793219|DRUG|Docetaxel|
58490800|NCT00329797|DIETARY_SUPPLEMENT|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
57936058|NCT02923089|OTHER|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936059|NCT02923089|OTHER|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936060|NCT02923089|OTHER|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936061|NCT02923089|OTHER|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936062|NCT02923089|OTHER|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936063|NCT02923089|OTHER|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936064|NCT02923089|OTHER|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936065|NCT02923089|OTHER|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
57936066|NCT02923089|OTHER|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
58072695|NCT03865550|DRUG|Isotonic saline|Placebo
58072696|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
57936067|NCT04872452|PROCEDURE|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
57936068|NCT03808688|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
57936069|NCT03663881|DRUG|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
57936070|NCT05929703|BEHAVIORAL|HELP|This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
57936071|NCT05929703|BEHAVIORAL|FAM-HELP|Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
57936072|NCT02690220|DEVICE|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
57936073|NCT04757441|OTHER|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire|"ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
58072697|NCT04682158|DRUG|Carboplatin|Given IV
58072698|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
58072699|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
58072700|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
57730069|NCT01598480|DRUG|Flamazine|Silver sulfadiazine cream
58072701|NCT04682158|DRUG|Paclitaxel|Given IV
58072702|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
57730070|NCT01598480|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
58072703|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
58072704|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
58072705|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
58072706|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
58072707|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
57936074|NCT04757441|OTHER|Group B: Conventional treatment|"Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
57936075|NCT04745013|BEHAVIORAL|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
58291391|NCT04921800|PROCEDURE|Anterior Cervical Discectomy & Fusion|Participants are undergoing previously scheduled anterior cervical discectomy \& fusion for single level or multiple level cervical disease
58291392|NCT04921800|DEVICE|Application of ADAM mechanoacoustic skin sensor|Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
58291393|NCT05503459|OTHER|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
58291394|NCT05503459|OTHER|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
58291395|NCT06047756|OTHER|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
58291396|NCT06047756|OTHER|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
58403771|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
58291397|NCT03713671|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
58291398|NCT02541864|DRUG|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
58403772|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
57936076|NCT04745013|BEHAVIORAL|Usual care|Only a written personalized exercise prescription will be provided.
57936077|NCT02906345|DEVICE|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
58291399|NCT02541864|DRUG|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
58291400|NCT05837091|DRUG|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
58403773|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
58403774|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
58403775|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
58403776|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
58490801|NCT00329797|DIETARY_SUPPLEMENT|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
58072708|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
58072709|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
58072710|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
58072711|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
58072712|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
58072713|NCT04130633|DRUG|THC|Pure THC vapor
58072714|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
58072715|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
58291401|NCT05837091|DIAGNOSTIC_TEST|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
58291402|NCT05837091|DEVICE|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
58403777|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
58072716|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
58072717|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
58072718|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
58291403|NCT05837091|DEVICE|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
58403778|NCT04048707|DRUG|Angiotensin II|Intravenous
58072719|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
57730071|NCT04255160|DRUG|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
58072720|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
58291404|NCT02824835|PROCEDURE|biopsy during colonoscopy|sampling the lesion with forcept biopter
58291405|NCT02374424|DRUG|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
58403779|NCT04048707|DRUG|Midodrine|Pill
58403780|NCT04048707|DRUG|Octreotide|Subcutaneous
58403781|NCT04048707|DRUG|Albumin solution|Intravenous suspension
58403782|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
57730072|NCT04255160|OTHER|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
57730073|NCT01126983|DEVICE|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
58072721|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
58072722|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
57936078|NCT03156348|OTHER|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
58403783|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
57936079|NCT02247154|BIOLOGICAL|Vigam® (Human Normal Immunoglobulin)|
58072723|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
58291406|NCT06548854|DRUG|STC314 Injection/STC314 Injection Placebo|All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
58291407|NCT02346877|BEHAVIORAL|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
58291408|NCT00536770|DRUG|placebo + gemcitabine + erlotinib|
58291409|NCT00536770|DRUG|Placebo + gemcitabine|
58291410|NCT00536770|DRUG|calcitriol + gemcitabine|
58291411|NCT00536770|DRUG|calcitriol + gemcitabine + erlotinib|
58403784|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
58291412|NCT03512353|DRUG|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
58291413|NCT03512353|DRUG|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
58291414|NCT00822146|DEVICE|CRT|classified
58291415|NCT02858635|OTHER|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
58291416|NCT03560869|OTHER|Normal hydration|see description in 'arms'
58291417|NCT03560869|OTHER|Dehydration|see description in 'arms'
58291418|NCT06344559|DEVICE|transcranial magnetic stimulation|"The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other."
58291419|NCT03726073|DEVICE|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
58291420|NCT03726073|OTHER|Usual care|Patients in this group only receive usual care developed by the study hospital
58072724|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
58403785|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
58072725|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
58072726|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
57936080|NCT00791336|DRUG|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
57936081|NCT02827123|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
57936082|NCT02827123|DRUG|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
57936083|NCT02607553|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
57936084|NCT05238129|OTHER|No intervention - standard care is assessed|No intervention - standard care is assessed
57936085|NCT00220558|DEVICE|Coronary placement of bare metal stent vs. drug eluting stent|
57936086|NCT05838404|BEHAVIORAL|M-O-M-S on the Bayou|Peer and mentor support and meetings across pregnancy
57936087|NCT03978221|OTHER|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
58072727|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
58072728|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
58291421|NCT01449292|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
58291422|NCT01449292|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
58291423|NCT05311020|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
57936088|NCT02525393|DEVICE|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
58072729|NCT00016068|DRUG|ganciclovir|
58072730|NCT00016068|DRUG|valganciclovir|
58072731|NCT06304493|DEVICE|Alarms|"The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
58072732|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
57936089|NCT02525393|DEVICE|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
57936090|NCT02525393|DEVICE|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
57936091|NCT02973087|BIOLOGICAL|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
58072733|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
58072734|NCT00231322|DRUG|praziquantel|
58072735|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
58291424|NCT05311020|DIETARY_SUPPLEMENT|Pitaya Ovule Extract Drink|consume 1 bottle per day
58072736|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
58072737|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
58291425|NCT02204644|DRUG|Flumatinib 600mg qd|
58291426|NCT02204644|DRUG|Imatinib 400mg qd|
58291427|NCT05141318|OTHER|FROM-16 Questionnaire|A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life
58072738|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
58072739|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
58072740|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
57936092|NCT02973087|BIOLOGICAL|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
57936093|NCT03371758|OTHER|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
57936094|NCT00904293|OTHER|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
57936095|NCT00904293|OTHER|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
57936096|NCT00789867|DRUG|pGM169/GL67A|Received a nebulized dose via an breath-actuated nebulizer
57936097|NCT04787094|OTHER|Yoga|Yoga
57936098|NCT04787094|OTHER|Spinal Stabilization Exercise|Spinal Stabilization Exercise
57936099|NCT04029116|DRUG|Fluconazole Tablet|150 mg every 72 hours for 3 doses
57936100|NCT04029116|DRUG|IBREXAFUNGERP|300 mg BID (one day) every 4 weeks for a total of 6 dosing days
57936101|NCT04029116|DRUG|Placebo oral tablet|BID (one day) every 4 weeks for a total of 6 dosing days
57936102|NCT06394596|OTHER|Prognostic factors affecting graft survival|The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation
57936103|NCT01099163|DIETARY_SUPPLEMENT|Tonalin SG1000T FFA|
58291428|NCT05141318|OTHER|Semi-structured two-part interview|A telephone/video interview to provide additional context to the FROM-16 responses
58291429|NCT00005032|BIOLOGICAL|oblimersen sodium|
57936104|NCT06439173|BIOLOGICAL|CAR-T cell therapy|Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy at the University Hospital of Salamanca
58291430|NCT00005032|DRUG|paclitaxel|
58291431|NCT03390595|COMBINATION_PRODUCT|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~* Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~  * Intravenously every 2 weeks for two cycles.~ * During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~ * Intravenously every 2 weeks until progressive disease or intolerance.~* Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~  * Carboplatin 5AUC day +1.~ * Gemcitabine 1000mg/m2 day +1 and +8."
58291432|NCT03390595|COMBINATION_PRODUCT|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~* Carboplatin 5AUC day +1.~* Gemcitabine 1000mg/m2 day +1 and +8."
58072741|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
58072742|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
58291433|NCT03630705|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
58291434|NCT03630705|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
58291435|NCT03630705|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
58291436|NCT03630705|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58291437|NCT03630705|BIOLOGICAL|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
57936105|NCT00357214|DIETARY_SUPPLEMENT|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
57936106|NCT00357214|DIETARY_SUPPLEMENT|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
57936107|NCT00357214|DIETARY_SUPPLEMENT|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
57936108|NCT00357214|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
57936109|NCT05547282|RADIATION|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
57936110|NCT00862303|BIOLOGICAL|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
57936111|NCT00862303|DRUG|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
58291438|NCT03630705|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58291439|NCT03630705|BIOLOGICAL|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
57936112|NCT06154551|DIAGNOSTIC_TEST|Paxillin biomarker|Paxillin used as a salivary biomarker
57730074|NCT01126983|DEVICE|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
57936113|NCT03245567|OTHER|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
57936114|NCT03245567|OTHER|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
58072743|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
57936115|NCT01557933|OTHER|No interventions will be used|No interventions will be used
58072744|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
58072745|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
58072746|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
58072747|NCT05898633|DRUG|Recombinant fragment of human surfactant protein D (rfhSP-D)|Administration of rfhSP-D
58072748|NCT06112314|BIOLOGICAL|Brenetafusp|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
58291440|NCT03630705|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
58291441|NCT06608017|DRUG|Chinese Herbal Medicine granules|Treatment group
58403786|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
58403787|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
57936116|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
58072749|NCT06112314|BIOLOGICAL|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
58072750|NCT06112314|BIOLOGICAL|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 16 mg/mL.
58072751|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
58072752|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
58072753|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
58072754|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
58291442|NCT06608017|OTHER|Placebo|Placebo-controlled group
58291443|NCT05035745|DRUG|Talazoparib|Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
58072755|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
58072756|NCT01503229|OTHER|Pharmacological Study|Correlative studies
58072757|NCT01503229|DRUG|Prednisone|Given PO
58291444|NCT05035745|DRUG|Selinexor|Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
58291445|NCT06249607|OTHER|storytelling|Storytelling android program: Subjects in group A or the storytelling group will be given headphones to listen to stories for 30 min (i.e., between 9 and 10 pm). While the subject listens to the story, a relative will present in a corner of the room to record when they fell asleep, the relative will present again in the room to record the time of falling asleep. The intervention will be done 7 nights a week for a period of 6 weeks.
58403788|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
57936117|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
57936118|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
58291446|NCT06249607|OTHER|Mindfulness breathing|"android program: Individuals in group B are instructed to sit upright in a comfortable position with eyes closed, focus on diaphragm movements while breathing in a slow, deep, relaxed manner, and to nonjudgmentally acknowledge and accept unwanted thoughts, ideas or images and return attention to the diaphragmatic breathing. In this exercise, individuals are instructed to notice the physical sensations of breathing, both inhalations and exhalations, with a focus on the natural rate of respiration as opposed to forcibly controlling the breath. Duration: 5 minutes in duration per session, before sleep for 7 days a week for a total duration of 6 weeks"
58403789|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
58403790|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
58403791|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
58403792|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
58403793|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
58403794|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
58403795|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
58403796|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
58403797|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
57936119|NCT00619528|BIOLOGICAL|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (\>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
57936120|NCT00408395|BIOLOGICAL|Influenza vaccine|Seasonal Influenza Vaccine
57936121|NCT05545605|DRUG|Sodium oligomannate|Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)
58072758|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
58403798|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
58403799|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
58291447|NCT06249607|OTHER|Sleep hygiene|"Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom."
58403800|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
58403801|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
58403802|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
58403803|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
57936122|NCT05545605|DRUG|Placebo capsule|the control group (receiving placebo capsule) for 24 weeks.
57936123|NCT02785679|DIETARY_SUPPLEMENT|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
57936124|NCT04830033|OTHER|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
58072759|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
58291448|NCT04142671|OTHER|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
58291449|NCT00006390|BIOLOGICAL|alemtuzumab|
58291450|NCT00006390|BIOLOGICAL|filgrastim|
58403804|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
57936125|NCT00798135|DRUG|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
57936126|NCT03138811|DRUG|CSJ117|inhaled once daily dose
57936127|NCT03138811|DRUG|Placebo Comparator|inhaled once daily dose
58403805|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
58291451|NCT00006390|DRUG|cyclophosphamide|
58291452|NCT00006390|PROCEDURE|peripheral blood stem cell transplantation|
58403806|NCT00362583|DRUG|Fentanyl|
58403807|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
58403808|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
58403809|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
57936128|NCT03998176|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
58403810|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
58072760|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
58072761|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
58072762|NCT05221840|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
58072763|NCT05221840|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
58072764|NCT05221840|DRUG|Monalizumab|Monalizumab IV (intravenous infusion)
58072765|NCT05221840|OTHER|Placebo|Placebo IV (intravenous infusion)
58291453|NCT00006390|RADIATION|radiation therapy|
58291454|NCT03230435|OTHER|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
58291455|NCT03803163|DRUG|TransCon Treprostinil|
58291456|NCT06611930|DRUG|CK-0045|Interleukin-22 agonist
58291457|NCT06611930|DRUG|Placebo|Placebo (liquid for injection, which includes no active ingredient).
58291458|NCT02248168|DRUG|Pramipexole|
58291459|NCT06574568|DRUG|YKST02|BCMA-CD3 bispecific antibody
58403811|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
58403812|NCT01880749|DRUG|RAD001|
58403813|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
58403814|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
58403815|NCT02253563|BEHAVIORAL|Resistance Training|
57936129|NCT04891341|OTHER|Technology Supported Task-Oriented Circuit Training|"Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~1. Sit to stand~2. Standing and trunk training~3. Standing and lower limb training~4. Stepping~5. Walking~6. Walking with object manipulation~7. Climbing and descending stairs~8. Unilateral upper extremity activity training (VR)~9. Bilateral upper extremity activity training (VR)~10. Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching)."
57936130|NCT04891341|OTHER|Home-based Telerehabilitation|Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
57936131|NCT00533468|DRUG|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
58403816|NCT02253563|BEHAVIORAL|Balance Training|
57936132|NCT00533468|DRUG|Placebo|inactive placebo without LMX4
57936133|NCT03422172|DRUG|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
57936134|NCT03422172|DRUG|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
57936135|NCT02626286|OTHER|HIV quarterly global care|
57936136|NCT05683535|DRUG|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
57936137|NCT02041260|DRUG|Cabozantinib|
57936138|NCT00074581|DRUG|Atazanavir|300 mg taken orally once daily
57936139|NCT00074581|DRUG|Didanosine|400 mg taken orally once daily
57936140|NCT00074581|DRUG|Efavirenz|600 mg taken orally once daily
57936141|NCT00074581|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
57936142|NCT00074581|DRUG|Lamivudine|300 mg taken orally once daily
58403817|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
57936143|NCT00074581|DRUG|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
57936144|NCT00074581|DRUG|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
57936145|NCT00074581|DRUG|Stavudine|Dosage depends on weight
57936146|NCT00074581|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally once daily
57936147|NCT00074581|DRUG|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
57936148|NCT01927328|DRUG|Iron isomaltoside 1000|
58403818|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
58403819|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
58403820|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
57936149|NCT00000353|DRUG|Buprenorphine/naloxone|
57936150|NCT04409899|DIAGNOSTIC_TEST|Blood tests|RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
57936151|NCT00981513|BIOLOGICAL|Trivalent live attenuated seasonal influenza vaccine|One dose
57936152|NCT00981513|BIOLOGICAL|Monovalent live attenuated pandemic influenza vaccine|One dose
57936153|NCT00981513|BIOLOGICAL|Saline|One dose
57936154|NCT06104982|DEVICE|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
57936155|NCT06104982|OTHER|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
57936156|NCT00445523|BIOLOGICAL|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
57936157|NCT00445523|DRUG|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
58403821|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
58403822|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
58291460|NCT01408212|PROCEDURE|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
58291461|NCT06490081|DRUG|Trilaciclib|During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
58291462|NCT03955159|DIETARY_SUPPLEMENT|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
58291463|NCT06245421|DEVICE|DM934|1 drop in each eye, 4 to 6 times per day
58291464|NCT06245421|DEVICE|Théalose|1 drop in each eye, 4 to 6 times per day
58291465|NCT05716685|OTHER|Health coaching|The intervention consisted of transferring the knowledge acquired on health coaching by the nurses of the cardiology unit to their care activity with CHF patients. To this end, all the nurses in the cardiology unit received two training packages: 1) five theoretical and practical sessions on health coaching competencies, emotional intelligence, communication and support for CHF patients in the hospital setting; and 2) training sessions 7 months after the first training package to reinforce the theoretical and practical knowledge acquired in health coaching. During this period, debriefing was carried out to provide feedback on the health coaching process with patients.
58291466|NCT04549636|OTHER|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
58403823|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
57936158|NCT04440787|PROCEDURE|Three point cuff palpation technique|the ETT is finally positioned according to the Three point cuff technique.
57936159|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
57936160|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
57936161|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
58291467|NCT04549636|OTHER|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
58291468|NCT04549636|OTHER|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
58403824|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
58403825|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
58403826|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
57730075|NCT06213883|OTHER|Biobehavioral Response to in-lab exposure to physical activity|ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
57730076|NCT02685254|BEHAVIORAL|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
57936162|NCT01516151|DRUG|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
57936163|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|4 capsules of 1 g total per day for 8 weeks.
57936164|NCT01865396|BEHAVIORAL|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
57936165|NCT01865396|BEHAVIORAL|Standard oncologic care|Patients will receive standard oncologic care.
57936166|NCT03229408|DRUG|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
57936167|NCT03229408|OTHER|Placebo|Appears identical to experimental drug
57936168|NCT03881228|BEHAVIORAL|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
57936169|NCT06461182|DRUG|Ga-68-CXCR4|Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
57936170|NCT00246597|DRUG|epoetin alfa|
57936171|NCT05823025|OTHER|PWV measurement|Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
57936172|NCT04562987|BEHAVIORAL|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
58291469|NCT04549636|OTHER|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
58291470|NCT04549636|OTHER|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
58291471|NCT04549636|OTHER|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
58291472|NCT04549636|OTHER|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
58403827|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
57730077|NCT02685254|OTHER|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
57936173|NCT04562987|BEHAVIORAL|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
57936174|NCT05712135|OTHER|supine position|The patient group whose cuff pressure was measured in the supine position
57936175|NCT05712135|OTHER|prone position|The patient group whose cuff pressure was measured in the prone position
57936176|NCT05712135|OTHER|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
57936177|NCT04347850|OTHER|blood sample|Collection
57936178|NCT04026061|BEHAVIORAL|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
57936179|NCT04026061|BEHAVIORAL|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
58291473|NCT01406314|DRUG|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
58291474|NCT06612996|DRUG|Tramadol|Intravenous tramadol
58291475|NCT06612996|DRUG|Magnesium sulphate|Intravenous magnesium sulphate
57936180|NCT01613495|DRUG|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
57936181|NCT01613495|DRUG|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
57936182|NCT00003370|DRUG|irofulven|
57936183|NCT03530917|DRUG|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
58403828|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
57936184|NCT03530917|DRUG|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
57936185|NCT02351479|BEHAVIORAL|Hula|
57936186|NCT01148706|DEVICE|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
57936187|NCT01135862|DRUG|platelets|6 packs of platelets will be administered
57936188|NCT05261035|BEHAVIORAL|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos \& pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
57936189|NCT05261035|OTHER|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
57936190|NCT03341741|DRUG|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
57936191|NCT03341741|DRUG|Colistin|Colistin solution 2 x daily 1 Mega continuously
57936192|NCT05361109|DRUG|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
57936193|NCT04739267|DEVICE|CardioFlux|Not an intervention
57936194|NCT01145495|OTHER|Laboratory Biomarker Analysis|Correlative studies
57936195|NCT01145495|DRUG|Lenalidomide|Given PO
57936196|NCT01145495|BIOLOGICAL|Rituximab|Given IV
58291476|NCT06612996|OTHER|Saline|Normal saline
58291477|NCT04584840|PROCEDURE|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
58291478|NCT00918593|DRUG|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
58403829|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
58403830|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
57730078|NCT02205710|OTHER|Computerized cognitive training|
57936197|NCT02483624|DRUG|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
57936198|NCT02483624|DRUG|Placebo|Placebo
58291479|NCT00918593|RADIATION|Radiotherapy|Radiotherapy according to hospital procedures.
58291480|NCT00918593|DRUG|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
58291481|NCT00402727|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
57730079|NCT02205710|OTHER|Computerized games|
57730080|NCT05006170|DRUG|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
57730081|NCT05006170|DRUG|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
58291482|NCT00402727|DRUG|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
58291483|NCT00929344|DRUG|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
58403831|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
58403832|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
58403833|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
58403834|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
58403835|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
58403836|NCT01375803|OTHER|Placebo|Oral consumption in beverage
58403837|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
58403838|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
58403839|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
58403840|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
58403841|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
58403842|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
58403843|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
58291484|NCT00929344|DRUG|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
58403844|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
58403845|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
58403846|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
58291485|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
58403847|NCT00325676|DRUG|Pantoprazole|
58403848|NCT00408655|DRUG|paclitaxel|Given IV
58403849|NCT00408655|DRUG|carboplatin|Given IV
58403850|NCT00408655|DRUG|temsirolimus|Given IV
58403851|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
58291486|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
58291487|NCT00929344|DRUG|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
58291488|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
58291489|NCT05543928|DRUG|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
58291490|NCT05543928|DRUG|Placebo|Placebo
58291491|NCT00726180|DRUG|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
57936199|NCT01668407|DEVICE|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
58291492|NCT04344652|DEVICE|Photoscreening -|external picture taken with a an phone based app
58291493|NCT01361828|PROCEDURE|Electrophysiology|Visual Evoked Potential and Elctroretinogram
58291494|NCT02895295|BEHAVIORAL|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
58291495|NCT02895295|BEHAVIORAL|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
58291496|NCT02895295|BEHAVIORAL|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
58291497|NCT00008125|BIOLOGICAL|filgrastim|
58291498|NCT00008125|DRUG|carboplatin|
58291499|NCT00008125|DRUG|docetaxel|
58291500|NCT00008125|DRUG|gemcitabine hydrochloride|
58291501|NCT03417752|OTHER|Exposure to firearm safety PSA|Exposed to firearm safety PSA
58291502|NCT03417752|OTHER|Exposure to health promotion PSA|Exposed to general health promotion PSA
58291503|NCT02992860|DRUG|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by \> 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
58291504|NCT02992860|PROCEDURE|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
58291505|NCT02992860|OTHER|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
58403852|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
58291506|NCT02992860|OTHER|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
58403853|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
58403854|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
58403855|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
58403856|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
58291507|NCT02992860|PROCEDURE|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
58291508|NCT02992860|GENETIC|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
58291509|NCT02992860|PROCEDURE|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
57730082|NCT02692300|PROCEDURE|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
58291510|NCT02992860|PROCEDURE|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
58291511|NCT02992860|PROCEDURE|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
58291512|NCT06612723|OTHER|high-intensity gait training|Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
58291513|NCT06612723|BEHAVIORAL|Physical activity coaching|Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
58291514|NCT01290510|DEVICE|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
58291515|NCT03744936|OTHER|DA4Afib Prototyping|We will develop a prototype from patients with atrial fibrillation
58291516|NCT00442234|DRUG|Monteplase|
58291517|NCT00511173|GENETIC|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
58291518|NCT02793947|DRUG|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
58291519|NCT02793947|DRUG|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
58291520|NCT02793947|DRUG|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
58291521|NCT02793947|DRUG|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
58291522|NCT03093441|OTHER|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
58291523|NCT00536510|DRUG|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
58291524|NCT00536510|DRUG|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
58291525|NCT01152996|DRUG|Vortioxetine|Vortioxetine tablets
58291526|NCT04423640|OTHER|Active COVID-19 disease|Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
58291527|NCT06050070|OTHER|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
58291528|NCT06050070|OTHER|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
58291529|NCT05023538|OTHER|Cycling|Exercise on bicycle ergometer
58291530|NCT06548503|DIETARY_SUPPLEMENT|Si.Pi.Mi product|Assumption of the product as detailed in the protocol
58403857|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
58403858|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
58403859|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
58403860|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
58291531|NCT06548503|OTHER|Placebo|Assumption of placebo
58291532|NCT02511041|DRUG|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
58403861|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
58291533|NCT02511041|DRUG|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
58403862|NCT02098499|DRUG|Haloperidol|5mg IV
58403863|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
58403864|NCT02098499|DRUG|Diphenhydramine|25mg IV
58403865|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
58403866|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
58403867|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
58403868|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
58403869|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
58403870|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
58403871|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
58403872|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
58403873|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
58403874|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
58403875|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
57936200|NCT01668407|PROCEDURE|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
57936201|NCT00478933|DEVICE|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
57936202|NCT00478933|PROCEDURE|Blood sampling|Blood sampling
57936203|NCT04682704|DEVICE|Parasym|Tragus stimulation
58291534|NCT01672268|OTHER|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
58291535|NCT04519983|DRUG|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
58403876|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
58403877|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
57936204|NCT02176187|DRUG|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
57936205|NCT02176187|DRUG|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
57936206|NCT01611753|OTHER|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
57936207|NCT00514163|DRUG|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
58403878|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
58403879|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
58403880|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
58403881|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
58403882|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
58403883|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
58403884|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
58403885|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
58403886|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
58490802|NCT00329797|RADIATION|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
58072766|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
57936208|NCT00514163|DRUG|gemcitabine|gemcitabine DIV on day one , 8th and 15th
58490803|NCT00329797|DRUG|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
57936209|NCT02615821|BEHAVIORAL|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
57936210|NCT02933632|OTHER|Physical Therapy-SAP|"* Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date."
57936211|NCT02933632|OTHER|Physical Therapy-ARP|"* Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach."
57936212|NCT03720899|DRUG|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
57936213|NCT03720899|DRUG|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
58072767|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
58072768|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
58072769|NCT04591782|OTHER|Water|Drink 8 oz water
58072770|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
58072771|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
58490804|NCT00329797|DIETARY_SUPPLEMENT|Vitamin D|400 IU (10μg), orally each day for 3 years.
58072772|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
58072773|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
58072774|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
58291536|NCT03522818|BEHAVIORAL|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
58291537|NCT03522818|BEHAVIORAL|Normal|Will use the alarm as provided by the manufacture.
58291538|NCT01534416|DRUG|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
57730083|NCT04239313|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
57730084|NCT04239313|BIOLOGICAL|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
58291539|NCT01534416|DRUG|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
58291540|NCT00856999|DRUG|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
58291541|NCT02951624|BEHAVIORAL|Control|Control intervention
58291542|NCT02951624|BEHAVIORAL|Breaker|Short breaks of physical activity
58291543|NCT02951624|BEHAVIORAL|Prolonger|longer breaks of physical activity
58291544|NCT02951624|BEHAVIORAL|Intermediate|Intermediate breaks of physical activity
58490805|NCT00674713|OTHER|Acupuncture|
58403887|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
58403888|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
58403889|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
58403890|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
57936214|NCT03298425|DEVICE|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
58291545|NCT01091246|BIOLOGICAL|Q/LAIV (MEDI3250)|10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
58291546|NCT01091246|BIOLOGICAL|FluMist/B/Yamagata|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
58291547|NCT01091246|BIOLOGICAL|FluMist/B/Victoria|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
58291548|NCT03810456|BEHAVIORAL|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
58291549|NCT03810456|BEHAVIORAL|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
58403891|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
58403892|NCT02839226|DRUG|AR/101|
58403893|NCT02839226|DRUG|Placebo|
58403894|NCT05411588|DRUG|PF-07275315|Active drug
58403895|NCT05411588|DRUG|Placebo|Placebo
58403896|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
58403897|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
58403898|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
58403899|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
58403900|NCT03100916|DRUG|BI 690517|once daily
58403901|NCT03100916|DRUG|Placebo|once daily
57936215|NCT03298425|DEVICE|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
57936216|NCT05744570|PROCEDURE|Epidural anesthesia|Regional anesthesia for labor pain
57936217|NCT03476564|DRUG|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
57936218|NCT03476564|DRUG|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
57936219|NCT02925572|OTHER|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
57936220|NCT05511493|DEVICE|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
57936221|NCT05511493|DEVICE|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
58291550|NCT04453020|DEVICE|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
58291551|NCT03176121|DRUG|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
57936222|NCT02261779|DRUG|Tranylcypromine|
58291552|NCT01499693|DRUG|Magnesium Pantoprazole 20 mg|oral dose, twice a day
58291553|NCT01499693|DRUG|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
58291554|NCT01499693|DRUG|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
58291555|NCT06043648|DEVICE|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
58291556|NCT03446976|BIOLOGICAL|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
57936223|NCT02261779|DRUG|Tretinoin|
58291557|NCT03446976|BIOLOGICAL|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
58403902|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
58403903|NCT03100916|DRUG|BI 690517|Non- fasting
58403904|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
58403905|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
58403906|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
58403907|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
58403908|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
58403909|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
58403910|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
58403911|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
57936224|NCT02334124|OTHER|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
58291558|NCT04978337|DRUG|Rilematovir|Rilematovir 250 mg will be administered orally.
58291559|NCT04978337|DRUG|Placebo|Placebo matching to rilematovir will be administered orally.
58291560|NCT03523195|BEHAVIORAL|Exercise Intervention|Complete exercise program
58291561|NCT03523195|OTHER|Informational Intervention|Receive written information on healthy exercise and diet recommendations
58291562|NCT03523195|OTHER|Laboratory Biomarker Analysis|Blood tests
58291563|NCT03523195|DEVICE|Monitoring Device|Wear Fitbit
58291564|NCT03523195|OTHER|Questionnaire Administration|Ancillary studies
58291565|NCT03523195|OTHER|Physical Performance Testing|Performance of physical tests
58291566|NCT06178042|COMBINATION_PRODUCT|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
58291567|NCT06178042|COMBINATION_PRODUCT|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
58291568|NCT06178042|COMBINATION_PRODUCT|Control|Patients instructed to follow a routine home care.
58291569|NCT05645302|DRUG|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
58291570|NCT06611865|PROCEDURE|Intraligamentary anaesthesia|Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
58291571|NCT06611865|PROCEDURE|Inferior alveolar nerve block|Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
58291572|NCT02388828|BIOLOGICAL|lentiviral-based CART meso therapy|
58291573|NCT05959967|BEHAVIORAL|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
58291574|NCT05959967|BEHAVIORAL|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
58291575|NCT02364583|DRUG|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
58291576|NCT04346576|DIETARY_SUPPLEMENT|Probiotics prevent health problems in children|A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
58291577|NCT04976439|OTHER|co-occuring mutation|APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
58291578|NCT06102720|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).
58291579|NCT06102720|DRUG|Clopidogrel|Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
58403912|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
58403913|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
57730085|NCT04239313|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
58291580|NCT05707390|DRUG|Mezigdomide|Specified dose on specified days
58490806|NCT00674713|DRUG|Ondansetron|
57730086|NCT06053489|OTHER|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
57936225|NCT02334124|OTHER|Ward|Admission to a hospital based ward
57936226|NCT02334124|DRUG|ceftriaxone|50mg/kg once daily
57936227|NCT02334124|DRUG|flucloxacillin|50mg/kg 6 hourly
57936228|NCT05723354|PROCEDURE|axillary block guided by ultrasound|axillary block using local anesthetics
57936229|NCT00186264|DRUG|venlafaxine XR|
57936230|NCT00186264|DRUG|hydrocortisone|
57936231|NCT06491082|DRUG|Cisplatin, Carboplatin, Paclitaxel, Docetaxel|Solid cancer Patients receiving any one drug or in combination
57936232|NCT02080247|DRUG|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
57936233|NCT02080247|DRUG|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
57936234|NCT05691049|DEVICE|HCC_45|"Dosage form: HCC_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
57936235|NCT01106495|DEVICE|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
57936236|NCT01106495|DRUG|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
58291581|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C antibody (anti-HCV) test|Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
58490807|NCT00674713|DRUG|Physiological saline solution|
58490808|NCT00674713|OTHER|Sham acupuncture|
58490809|NCT00674713|DRUG|Ondansetron|
58490810|NCT00674713|OTHER|Acupuncture at P6 point|
58490811|NCT00674713|DRUG|Physiological saline solution|
58490812|NCT00674713|OTHER|Sham acupuncture|
58490813|NCT01984528|BIOLOGICAL|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
58490814|NCT02659397|DRUG|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
58490815|NCT02659397|DRUG|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
58490816|NCT02659397|DRUG|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
58490817|NCT05828329|BEHAVIORAL|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
58291582|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C RNA test and genotype test|RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
58291583|NCT02383901|DRUG|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
58291584|NCT04335084|DRUG|Hydroxychloroquine|Prophylaxis treatment for COVID-19
58291585|NCT04335084|DIETARY_SUPPLEMENT|Vitamin C|Prophylaxis treatment for COVID-19
58291586|NCT04335084|DIETARY_SUPPLEMENT|Vitamin D|Prophylaxis treatment for COVID-19
58291587|NCT04335084|DIETARY_SUPPLEMENT|Zinc|Prophylaxis treatment for COVID-19
58403914|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
57936237|NCT03122275|OTHER|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
58403915|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
58403916|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
58403917|NCT06495229|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
57936238|NCT03122275|OTHER|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
57936239|NCT03122275|OTHER|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
57936240|NCT03122275|OTHER|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
57936241|NCT03122275|OTHER|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
57936242|NCT06417463|PROCEDURE|thyroidectomy opeartion|correlation between TIRADS and Bethesda scoring system (preoperative) and final histopathology (postoperative) in cases of thyroidectomy
57936243|NCT01782365|DEVICE|SHAM stimulation|no stimulation
58291588|NCT06612216|OTHER|No intervention was carried out|This study observed differences in microbiota among different groups and therefore did not involve intervention.
58291589|NCT05038683|BEHAVIORAL|Holbæk Obesity Treatment|"Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
58403918|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
58403919|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
58403920|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
58403921|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
58403922|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
58490818|NCT05828329|BEHAVIORAL|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
58490819|NCT00695929|DRUG|Levosimendan|Intravenous injection
58490820|NCT00695929|DRUG|Milrinone|Intravenous injection
57936244|NCT01782365|DEVICE|0,75 Hz stimulation|
57936245|NCT01942148|DRUG|Aripiprazole|
57936246|NCT04077450|BEHAVIORAL|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
58403923|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
58403924|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
57936247|NCT00343616|PROCEDURE|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
58291590|NCT05038683|BEHAVIORAL|Conventional Obesity Treatment|"Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
58291591|NCT04286620|DEVICE|LASIK|Correcting errors of refraction
58291592|NCT05736692|BEHAVIORAL|Brief Sleep Intervention|A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
58291593|NCT04687904|BEHAVIORAL|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
58403925|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
58403926|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
58403927|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
58403928|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
58403929|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
58403930|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
58403931|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
57936248|NCT00343616|PROCEDURE|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
58403932|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
58490821|NCT03507946|DEVICE|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
57936249|NCT00343616|PROCEDURE|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
57936250|NCT00343616|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
57936251|NCT01968395|DRUG|Caspofungin 70 mg|Intravenous use
57936252|NCT00916539|DEVICE|Cast that immobilizes the thumb|Cast that immobilizes the thumb
57936253|NCT00916539|DEVICE|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
57936254|NCT04056065|DRUG|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
57936255|NCT04056065|DRUG|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
57936256|NCT03332914|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
57936257|NCT05662475|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
57936258|NCT05662475|PROCEDURE|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
57936259|NCT05662475|DIAGNOSTIC_TEST|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
57936260|NCT05141162|BEHAVIORAL|case and control group|randomized controlled experimental study
58072775|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
58291594|NCT04687904|BEHAVIORAL|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
58291595|NCT06607796|DRUG|Toluenesulfonamide (PTS) Intratumoral Injection|intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
58291596|NCT01735149|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
58291597|NCT01735149|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
58291598|NCT04832256|DEVICE|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
58291599|NCT04124770|OTHER|Movement|Re-positioning of neck
58291600|NCT02155985|DRUG|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
58291601|NCT02155985|DRUG|Placebo|Placebo for aspirin
58291602|NCT04450693|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
58490822|NCT03926611|DRUG|LOU064 Arm 1|10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
58490823|NCT03926611|DRUG|LOU064 Arm 2|35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
58490824|NCT03926611|DRUG|LOU064 Arm 3|100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
58490825|NCT03926611|DRUG|LOU064 Arm 4|10mg bid of LOU064 orally, twice daily from Day 1 to 85
57936261|NCT03123250|DEVICE|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
57936262|NCT05112627|PROCEDURE|Biospecimen Collection|Undergo blood collection
57936263|NCT02671045|GENETIC|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
57936264|NCT02671045|GENETIC|Genomic profile by other methods|Genomic profiling by other testing methods.
57936265|NCT02079090|DRUG|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
57936266|NCT02079090|DRUG|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
57936267|NCT03171766|DIAGNOSTIC_TEST|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
57936268|NCT03171766|DIAGNOSTIC_TEST|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
57936269|NCT03171766|DIAGNOSTIC_TEST|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
57936270|NCT03759483|DIAGNOSTIC_TEST|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
57936271|NCT05018260|BEHAVIORAL|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
57936272|NCT05018260|BEHAVIORAL|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
57936273|NCT02232126|OTHER|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
57936274|NCT03182985|BEHAVIORAL|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
57936275|NCT03207113|BEHAVIORAL|Ned|Prostate cancer survivorship application.
57936276|NCT00228566|DRUG|Armodafinil|
57936277|NCT00647153|OTHER|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
57936278|NCT00647153|PROCEDURE|single photon emission computed tomography|One day post infusion
57936279|NCT00647153|RADIATION|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
57936280|NCT04858984|DEVICE|Virtual Reality|A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
57936281|NCT00910195|DEVICE|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
57936282|NCT00910195|DEVICE|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
57936283|NCT03805750|DRUG|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
57936284|NCT03805750|DRUG|Placebo oral capsule|Matched Placebo
57936285|NCT03436381|OTHER|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
57936286|NCT05085951|DEVICE|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
57936287|NCT05085951|DIAGNOSTIC_TEST|OGD|OGD (No dilatation)
58490826|NCT03926611|DRUG|LOU064 Arm 5|25 mg bid of LOU064 orally, twice daily from Day 1 to 85
57936288|NCT00618436|DRUG|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
58291603|NCT04450693|OTHER|Standard care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
58403933|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
58291604|NCT00441519|DRUG|aspirin|
58291605|NCT00441519|DRUG|omeprazole|
57936289|NCT00618436|DRUG|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
57936290|NCT00356889|DRUG|erlotinib hydrochloride|Given orally, 150 mg, once daily.
57936291|NCT00356889|BIOLOGICAL|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
57936292|NCT03426787|BEHAVIORAL|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
58291606|NCT00847418|DRUG|esketamine hydrochloride|
58291607|NCT01352273|DRUG|MEK162 + RAF265|
58291608|NCT01649115|OTHER|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
58291609|NCT06508827|DRUG|Iron dextran 1000 mg IV|Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
57936293|NCT05008536|BIOLOGICAL|Anti-BCMA CAR-NK Cells|1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion
57936294|NCT05008536|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
57936295|NCT05008536|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
57936296|NCT00126074|DRUG|Tedisamil sesquifumarate|
57936297|NCT01995578|DRUG|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
57936298|NCT00525044|DRUG|Ambroxol|
57936299|NCT00525044|DRUG|Placebo|
58291610|NCT05062746|OTHER|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
58291611|NCT05062746|OTHER|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
58291612|NCT05454995|OTHER|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
58403934|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
58403935|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
58490827|NCT03926611|DRUG|LOU064 Arm 6|100 mg bid of LOU064 orally, twice daily from Day 1 to 85
58490828|NCT03926611|DRUG|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
58490829|NCT01452841|OTHER|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
57936300|NCT02693522|DRUG|somatropin|Subcutaneous injection
57936301|NCT02693522|DRUG|Eutropin|Subcutaneous injection
57936302|NCT06378671|PROCEDURE|General treatment|routine bronchoscopy examination, lavage, and mucosal biopsy
57936303|NCT06378671|PROCEDURE|Cryotherapy Treatment|local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
57936304|NCT04422990|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
58291613|NCT05660382|DRUG|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
58291614|NCT05660382|OTHER|Placebo|Twice daily application, for 14 days
58291615|NCT02446444|DRUG|Enzalutamide|
58291616|NCT02446444|DRUG|Conventional NSAA|
58490830|NCT01452841|OTHER|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
57936305|NCT04422990|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
57936306|NCT04422990|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
57936307|NCT02293447|DRUG|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
58291617|NCT02446444|DRUG|LHRHA|
58291618|NCT02446444|RADIATION|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
58291619|NCT03367975|OTHER|near infrared spectroscopy|
58291620|NCT04135755|OTHER|no drug intervention|no drug or treatment intervention
58291621|NCT01420250|DRUG|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
58291622|NCT01420250|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
58291623|NCT01420250|DRUG|Anti-Androgen Therapy: Bicalutamide|"* Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT"
58291624|NCT01420250|GENETIC|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"* First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form"
58291625|NCT00901615|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
58291626|NCT01096381|OTHER|laboratory biomarker analysis|Blood collection
57936308|NCT02293447|DRUG|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
57936309|NCT04558463|DRUG|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
58291627|NCT01096381|OTHER|questionnaire administration|Survey regarding baseline health and activity level.
58291628|NCT03893760|DIAGNOSTIC_TEST|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
58291629|NCT04929977|DEVICE|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
58291630|NCT02411279|OTHER|Equiped group with telemedicine systems|
58291631|NCT02207400|DRUG|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
58291632|NCT02207400|DRUG|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
58291633|NCT04225455|DEVICE|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~\[Green: 5-15 mmol/L; Amber: 4 to \<5mmol/L and \>15 to 20mmol/L; Red: \<4mmol/L and \>20mmol/L\]"
58072776|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
58072777|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
58072778|NCT06524856|DEVICE|Lung Master (Pulmonary Exerciser)|During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
58291634|NCT06248814|DRUG|BMS-986326|Specified dose on specified days
58403936|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
58403937|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
58403938|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
58403939|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
58403940|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
58403941|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
58403942|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
58403943|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
58072779|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
58072780|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
58072781|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
58072782|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
58072783|NCT06681051|DEVICE|OSTENIL® TENDON|OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.
58072784|NCT02974764|OTHER|No intervention/exposures|
58072785|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
58072786|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
58291635|NCT06248814|OTHER|Placebo|Specified dose on specified days
58403944|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
58403945|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
58403946|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
57936310|NCT04558463|DRUG|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
57936311|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
57936312|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
57936313|NCT00286481|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
57936314|NCT01555151|DRUG|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
57936315|NCT01555151|DEVICE|Concept 1|A single dose dry powder inhaler (SDDPI)
57936316|NCT01555151|DEVICE|Twisthaler|A single dose dry powder inhaler (SDDPI)
57936317|NCT01378104|DRUG|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
57936318|NCT01378104|DRUG|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
57936319|NCT04818424|DEVICE|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
57936320|NCT04818424|BEHAVIORAL|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
57936321|NCT05269342|BEHAVIORAL|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
58072787|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
58072788|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
58291636|NCT03738163|DEVICE|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
58291637|NCT06437509|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
58291638|NCT06437509|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
58291639|NCT03660891|DIAGNOSTIC_TEST|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
58291640|NCT04373317|DRUG|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
58291641|NCT04373317|DRUG|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day Pimavanserin: 34 mg QHS~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg Pimavanserin: 34 mg QHS~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate Pimavanserin: 34 mg QHS~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS"
58072789|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
58072790|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
58072791|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
58291642|NCT04034212|OTHER|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
57936322|NCT05189613|BIOLOGICAL|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
57936323|NCT05016206|DRUG|Danicopan|Danicopan tablets administered as a single oral dose.
57936324|NCT05016206|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo was administered as a single oral dose.
57936325|NCT05016206|DRUG|Danicopan-matching placebo|Danicopan-matching placebo was administered as a single oral dose.
57936326|NCT05016206|DRUG|Moxifloxacin|Moxifloxacin 400 mg was administered as a single tablet oral dose.
57936327|NCT05972382|DIAGNOSTIC_TEST|Quantitative Sensory and Neurophysiological Testing|"Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded."
57936328|NCT00278850|BEHAVIORAL|Educational|three 1 hour long educational seminars
57936329|NCT02783131|DEVICE|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
57936330|NCT02483377|OTHER|Quality-of-Life Assessment|Ancillary studies
57936331|NCT02483377|OTHER|Questionnaire Administration|Complete questionnaires
57936332|NCT00268307|DRUG|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
57936333|NCT00199914|DEVICE|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
57936334|NCT02777229|DRUG|Dolutegravir 50 mg|1 tablet once a day
57936335|NCT02777229|DRUG|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
58291643|NCT04014218|DRUG|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
57936336|NCT02777229|DRUG|Efavirenz 400 mg|1 tablets once a day
58291644|NCT04014218|DRUG|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
58291645|NCT02300870|DRUG|Optison|Echocardiogram with IV contrast
57936337|NCT05151120|BIOLOGICAL|blood sample|In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
57936338|NCT00865904|DRUG|VX-809|Capsules
57936339|NCT00865904|DRUG|Placebo|Placebo matched to VX-809 capsules.
57936340|NCT01908972|DRUG|Prednisolone|2mg/kg/day for 16weeks
57936341|NCT01908972|DRUG|Propranolol|2mg/kg/day for 16weeks
57936342|NCT00421473|DRUG|Atovaquone / Proguanil|
57936343|NCT05806775|BEHAVIORAL|Low-load resistance training with blood flow restriction|A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
57936344|NCT04608760|DRUG|Meksibel|2 ml solution
58072792|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
58072793|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
58291646|NCT01268657|BEHAVIORAL|Education|Learning about anxiety
58291647|NCT01268657|BEHAVIORAL|Relaxation Training|Learning skills to reduce tension
58291648|NCT01268657|BEHAVIORAL|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
57936345|NCT00480688|BIOLOGICAL|BCG|
57936346|NCT03842163|DIAGNOSTIC_TEST|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
57936347|NCT04159766|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
57936348|NCT04159766|DRUG|Placebo|normal saline
57936349|NCT05844371|DRUG|tirelizumab|Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.
57936350|NCT05844371|DRUG|chemotherapy with oxaliplatin + heroda|chemotherapy with oxaliplatin + heroda
58403947|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
58403948|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
58403949|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
58403950|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
58291649|NCT01268657|BEHAVIORAL|Behavioral Activation|Learning to initiate healthy activity
57936351|NCT01582542|DRUG|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
58291650|NCT01268657|BEHAVIORAL|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
58291651|NCT00115206|DRUG|Neulasta® (pegfilgrastim)|
58291652|NCT04575441|OTHER|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
58291653|NCT04233242|OTHER|Clinical management informed by HIV-1 genotypic resistance testing|"The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support."
58291654|NCT05957861|BEHAVIORAL|web-based aerobic exercise|Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
58291655|NCT03046953|DRUG|Avelumab|anti-PDL1 antibody
58291656|NCT01429298|DRUG|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
58291657|NCT01429298|DRUG|Usual care|Attending administers IV opioid of his choosing
58291658|NCT05434663|DRUG|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
58291659|NCT02130388|DIETARY_SUPPLEMENT|Zinc|
58291660|NCT04323384|DEVICE|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
58291661|NCT05926648|DEVICE|INVSENSOR00061|Noninvasive pulse oximetry and pulse rate device
57936352|NCT02695433|DIETARY_SUPPLEMENT|Active|Active Treatment Diet Plan
57936353|NCT02695433|DIETARY_SUPPLEMENT|Control|Control Diet Plan
57936354|NCT01526096|DRUG|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
57936355|NCT01526096|DRUG|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
57936356|NCT01526096|PROCEDURE|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
57936357|NCT01526096|DRUG|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
58291662|NCT05755646|OTHER|Ice Plant Intensive Cream plus Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome. The nursing consultation on the standard treatment includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
58403951|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
58403952|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
58403953|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
58403954|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
57936358|NCT01526096|PROCEDURE|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
58403955|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
58403956|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
58403957|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
58403958|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
58403959|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
58403960|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
57730087|NCT01990235|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
57936359|NCT01526096|DRUG|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
58403961|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
58403962|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
57730088|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
57730089|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
57936360|NCT01526096|DEVICE|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
58072794|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
58072795|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
58072796|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
58072797|NCT05249504|OTHER|Community resources|Learn about community resources
58403963|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
58403964|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
58403965|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
58403966|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
58403967|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
58072798|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
58403968|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
58403969|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
58403970|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
57730090|NCT02504632|OTHER|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
58072799|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
58403971|NCT02629848|DRUG|Carboplatin|Carboplatin IV
58403972|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
58291663|NCT05755646|OTHER|Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome. The nursing consultation includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
57730091|NCT02504632|OTHER|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
58291664|NCT02179047|PROCEDURE|coronary angiography|percutaneous coronary intervention. coronary angiography.
58291665|NCT00193414|DRUG|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
57936361|NCT03420079|DRUG|FCN-411 Dose-escalation|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
57936362|NCT03420079|DRUG|FCN-411 Dose-expansion|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
57936363|NCT04575142|DEVICE|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
57936364|NCT01033435|OTHER|No intervention|
58072800|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
58291666|NCT00193414|DRUG|Gemcitabine|1500mg/m2, 30min IV
58291667|NCT02788721|DRUG|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
58291668|NCT02788721|DRUG|Placebo|Placebo, oral suspension, daily
58291669|NCT05902871|DEVICE|Eagle|Direct Selective Laser Trabeculoplasty (DSLT)
58490831|NCT05941195|OTHER|Psychoeducation|"In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included."
57936365|NCT00566917|PROCEDURE|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
57936366|NCT00566917|PROCEDURE|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
57936367|NCT00773136|DRUG|Bimatoprost Suspension|see prior
57936368|NCT04341168|OTHER|this study is non- interventional|this study is non- interventional
57936369|NCT02752750|OTHER|MRI|MR imaging (MRI) at 3 Tesla
57936370|NCT02094963|DRUG|Ticagrelor|180mg loading and 90mg bid
57936371|NCT02094963|DRUG|Clopidogrel|600mg loading and 75mg qd
57936372|NCT00947362|OTHER|Electro-thermo-coagulation|
58072801|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
57936373|NCT00947362|DRUG|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
57936374|NCT00947362|DRUG|saline|physiological saline
57936375|NCT00686296|OTHER|Taliderm™|taliderm™ dressing application once
57936376|NCT00686296|OTHER|Taliderm™|Taliderm™ dressing application up to three applications
57936377|NCT00686296|OTHER|standard wet to dry dressing with gauze|wet to dry dressing standard of care
58072802|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
58291670|NCT05204914|DEVICE|Supra glottic airway devices|Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
58291671|NCT05850702|DRUG|Lidocaine|inhale 5ml of 2% lidocaine by nebulization
58291672|NCT05850702|DRUG|Saline|inhale 5ml of saline by nebulization
58291673|NCT02811315|OTHER|Observational. Non interventional study|Observational. Non interventional study
58291674|NCT05660252|OTHER|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
58291675|NCT00738426|DEVICE|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
58291676|NCT00738426|DEVICE|Sham device|non-therapeutic light energy output
58291677|NCT04057378|DEVICE|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
58291678|NCT01258478|OTHER|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
58291679|NCT01258478|OTHER|Usual care|Usual care
58291680|NCT04939649|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
57936378|NCT04535180|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
57936379|NCT02991508|DRUG|Placebo|
57936380|NCT02991508|DRUG|Adrecizumab|
57936381|NCT04221854|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|Stool-based SDC2 DNA methylation test
57936382|NCT04221854|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test
57936383|NCT00611338|BEHAVIORAL|HIV Skills-based Prevention|
57936384|NCT02193048|OTHER|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
58291681|NCT04939649|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
58291682|NCT00670722|DRUG|insulin aspart|Intervention at the discretion of the physician
58291683|NCT00670722|DRUG|insulin detemir|Intervention at the discretion of the physician
58291684|NCT00670722|DRUG|biphasic insulin aspart 30|Intervention at the discretion of the physician
58291685|NCT01516489|BEHAVIORAL|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
58291686|NCT01516489|BEHAVIORAL|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
58291687|NCT00000311|DRUG|Buprenorphine|Medication and Behavioral
58291688|NCT00000311|DRUG|methadone|medication and behavioral
58291689|NCT04973657|DRUG|VK0214|API in capsule
57730092|NCT05520580|PROCEDURE|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
58072803|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
57936385|NCT02510781|DRUG|Epirubicin|75mg/m2 d1 evry 21days
57936386|NCT02510781|DRUG|Docetaxel|75mg/m2 d1 evry 21days
58291690|NCT04973657|OTHER|Placebo|API in capsule
58291691|NCT05833919|DRUG|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
58291692|NCT05833919|DRUG|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
58490832|NCT06050824|DRUG|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
57730093|NCT04932304|DEVICE|Transcranial direct current stimulation (tDCS)|
57936387|NCT02510781|DRUG|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
57936388|NCT02510781|DRUG|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
57936389|NCT00392353|DRUG|Azacitidine|Given SC
58072804|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
58490833|NCT03472261|DRUG|Botulinum toxin type A|Dysport
58490834|NCT03472261|OTHER|Upper extremity orthoses|Twister
58490835|NCT03472261|OTHER|Home exercise program|Specific exercises for pronation deformity
57730094|NCT04932304|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
57730095|NCT03052179|DIETARY_SUPPLEMENT|Poly-biotic|Before-after treatment
57936390|NCT00392353|OTHER|Laboratory Biomarker Analysis|Correlative studies
57936391|NCT00392353|OTHER|Pharmacological Study|Correlative studies
58072805|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
58072806|NCT03616652|DRUG|Placebo|Placebo pill
58490836|NCT00593190|DRUG|Gas SF6 (Sulfur Hexafluoride)|ONCE
58072807|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
58072808|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
58072809|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
58072810|NCT02806804|BIOLOGICAL|one dose test vaccine|
58072811|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
58291693|NCT03112070|OTHER|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
58291694|NCT05438342|BIOLOGICAL|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
58291695|NCT05438342|DEVICE|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
58291696|NCT05438342|DRUG|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
58291697|NCT05430802|DRUG|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
58291698|NCT05324449|DRUG|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
58291699|NCT05182801|DIETARY_SUPPLEMENT|Placebo sachet|Blank
58291700|NCT05182801|DIETARY_SUPPLEMENT|Banana flower extract sachet|Happy Angel Banana Flower Extract sachet
58291701|NCT02494895|DRUG|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
58291702|NCT02494895|DRUG|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
58291703|NCT02799017|OTHER|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
58291704|NCT02799017|OTHER|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
58291705|NCT06605846|OTHER|otago excercises|"Otago training is helpful, and one of the most powerful interventions where the original randomized controlled trials reported improvements in functional outcomes and a 35% reduction in falls for frail, high-risk older adults (Shubert et al., 2018). In Egypt, there are little researches about Otago Exercise Program.~Exercise is well-known as an economic and key adjuvant treatment in clinical oncology that improves QOL of cancer survivors. Many studies focused on investigating the benefits of exercise interventions on preventing falls and improving physical performance of older adults. Combination of strength and functional balance exercise has been demonstrated as an effective method to improve balance performance, rather than strength training alone"
58291706|NCT06605846|OTHER|Medical ADT treatment|Medical ADT treatment according to patient age, prostatic cancer stage
57730096|NCT00999479|DRUG|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
57730097|NCT00999479|DRUG|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
58072812|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
58072813|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
58072814|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
58072815|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
58072816|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
57936392|NCT00392353|DRUG|Vorinostat|Given PO
57936393|NCT05726539|BEHAVIORAL|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
57936394|NCT06318351|PROCEDURE|transcutaneous acupoint electrical stimulation|This is a safe and non-invasive procedure, similar to an electrode sheet, which applies a weak current to a specific site to achieve the purpose of acupoint stimulation.
57936395|NCT04358510|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
57936396|NCT02514408|PROCEDURE|Catheter Management|Insertion of venous catheter under ultrasound guidance
58291707|NCT03273920|PROCEDURE|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
58291708|NCT03273920|PROCEDURE|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
58291709|NCT02989402|DRUG|Rivastigmine|15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
58291710|NCT03944213|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
57730098|NCT00856401|DRUG|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
57730099|NCT05496504|OTHER|Holter ECG|
57936397|NCT02514408|OTHER|Cytology Specimen Collection Procedure|Collection of blood samples
57936398|NCT02514408|OTHER|Laboratory Biomarker Analysis|Correlative studies
57936399|NCT04677699|DIAGNOSTIC_TEST|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
58291711|NCT04543175|OTHER|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
58291712|NCT01451918|DRUG|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
58291713|NCT05060991|DRUG|Reduction in antimetabolite immunosuppression|Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
57936400|NCT00181584|DRUG|Zoledronic acid|Given intravenously once.
58072817|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
58072818|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
58291714|NCT00178516|OTHER|behavior, procedure|
58291715|NCT04410471|DIAGNOSTIC_TEST|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
58291716|NCT00956332|BIOLOGICAL|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
58291717|NCT00956332|BIOLOGICAL|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
58490837|NCT05070715|OTHER|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
57730100|NCT04357626|OTHER|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
57936401|NCT00181584|OTHER|Placebo|Given intravenously once.
57936402|NCT01509079|DRUG|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
57936403|NCT01509079|DRUG|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
57936404|NCT05597709|PROCEDURE|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
57936405|NCT05054595|BEHAVIORAL|Standard Pain Management|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
57936406|NCT05054595|BEHAVIORAL|Audio-Recorded Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
57730101|NCT01574300|OTHER|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
57936407|NCT05054595|BEHAVIORAL|Nurse-Led Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
57936408|NCT02560064|PROCEDURE|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
57936409|NCT01345396|BEHAVIORAL|Health education about asthma|Three face-to-face appointments (\<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
57936410|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
58072819|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
58072820|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
57730102|NCT05934045|BIOLOGICAL|RNAseq|there is no intervention done.
57730103|NCT02465593|DRUG|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
57730104|NCT02465593|DRUG|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
57730105|NCT02465593|DRUG|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
58072821|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
58291718|NCT03958188|OTHER|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
57730106|NCT02465593|PROCEDURE|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
57730107|NCT02465593|RADIATION|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
58072822|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
58072823|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
58291719|NCT06007846|DRUG|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
58291720|NCT02908984|BEHAVIORAL|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
58291721|NCT02908984|OTHER|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
58291722|NCT03905941|DRUG|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
57936411|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
57936412|NCT04635566|DRUG|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
57936413|NCT04635566|DRUG|Placebo|Placebo one time/day at the evening.
57936414|NCT04156217|BIOLOGICAL|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
57936415|NCT05990751|BIOLOGICAL|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
57936416|NCT01519076|DEVICE|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
57936417|NCT01726244|BEHAVIORAL|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
57936418|NCT02763228|BEHAVIORAL|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
57936419|NCT02763228|BEHAVIORAL|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
57936420|NCT02763228|BEHAVIORAL|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
57936421|NCT02763228|BEHAVIORAL|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
57936422|NCT02763228|BEHAVIORAL|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
57936423|NCT02763228|BEHAVIORAL|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
57936424|NCT02763228|BEHAVIORAL|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
57936425|NCT03718065|DRUG|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
57936426|NCT03718065|DRUG|Placebo|Placebo comparator.
57936427|NCT00930722|DRUG|quinapril|per label as non interventional study
57936428|NCT05518903|PROCEDURE|Computed Tomography|Undergo CT
57936429|NCT05518903|DRUG|Gallium Ga 68 FAPi-46|Given IV
57936430|NCT05518903|PROCEDURE|Positron Emission Tomography|Undergo PET
57936431|NCT05909930|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 6 months at home, with a frequency of 1-3 sessions per week at the hospital.
57936432|NCT05909930|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
58072824|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
58072825|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
58291723|NCT03905941|DRUG|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
57936433|NCT01956734|PROCEDURE|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
57936434|NCT01028950|DRUG|YM150|oral
57936435|NCT04593667|DEVICE|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
57936436|NCT02112136|OTHER|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
57936437|NCT02114775|DRUG|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
57936438|NCT02114775|DRUG|Sildenafil|50 mg by mouth daily
58291724|NCT04649086|OTHER|Rehabilitation by Eccentric exercises|Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
58291725|NCT04649086|OTHER|Rehabilitation by Concentric exercises|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
58291726|NCT02482142|DIETARY_SUPPLEMENT|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
57936439|NCT02114775|DRUG|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
57936440|NCT02472379|BEHAVIORAL|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
57936441|NCT02472379|OTHER|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
57936442|NCT01063829|DRUG|60 mg AIC246|Oral administration
57936443|NCT01063829|DRUG|120 mg AIC246|Oral administration
57936444|NCT01063829|DRUG|240 mg AIC246|Oral administration
57936445|NCT01063829|OTHER|Placebo|Oral administration
57936446|NCT02049268|DRUG|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
58072826|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
58072827|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
58072828|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
58072829|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
58072830|NCT06122961|OTHER|No treatment given|No treatment given
58072831|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
57936447|NCT02049268|DRUG|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
58072832|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
58072833|NCT06603571|DRUG|LY3841136|Administered SC
58072834|NCT06603571|DRUG|Tirzepatide|Administered SC
58072835|NCT06603571|DRUG|Placebo|Administered SC
58072836|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
58072837|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
58291727|NCT05973461|DEVICE|Exercise and virtual reality|Riding a cycle ergometer while experiencing virtual reality
58291728|NCT05973461|OTHER|Riding a cycle ergometer|Riding on a cycle ergometer without experiencing virtual reality
58291729|NCT06215066|OTHER|Modified Progressive Muscle Relaxation Exercise|The modified progressive muscle relaxation technique will be applied through muscle relaxation to a specific part of the body.
58291730|NCT06215066|DEVICE|The virtual reality box|a virtual reality box (VR- box) with 3D glasses (eye goggles)
58291731|NCT01854697|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
58291732|NCT01854697|DRUG|Ribavirin|Tablet
58291733|NCT01854697|DRUG|Telaprevir|Film-coated tablet
58291734|NCT01854697|DRUG|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
58291735|NCT05138601|OTHER|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
58291736|NCT05772676|DRUG|Aprepitant|80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
58291737|NCT05772676|OTHER|Placebo|Placebo + standard antiemetic regimen, once two hours before surgery
57936448|NCT02049268|DRUG|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
57936449|NCT04229953|DEVICE|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
57936450|NCT01846624|DRUG|Decitabine|Given IV
57936451|NCT01846624|DRUG|Midostaurin|Given PO
57936452|NCT04230707|OTHER|Endogenous Melatonin Levels|High Endogenous Melatonin Levels is Group 1 Low Endogenous Melatonin Levels is group 2
57936453|NCT03492554|OTHER|1-Lead ECG|All participants will record three single-lead ECGs
57936454|NCT03492554|DEVICE|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
58291738|NCT05513846|DEVICE|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
58291739|NCT05513846|DEVICE|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
58291740|NCT01013714|PROCEDURE|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
58291741|NCT01013714|DRUG|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
58291742|NCT03416192|DEVICE|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
58291743|NCT03416192|DEVICE|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
58291744|NCT02581488|BIOLOGICAL|Santyl|
57936455|NCT02632565|DRUG|Lidocaine|
57936456|NCT02632565|DRUG|Saline|
57936457|NCT00445705|DRUG|placebo|Part A: Placebo every 12 hours for 4 weeks
57936458|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
57936459|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
57936460|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
57936461|NCT04860986|DEVICE|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
57936462|NCT04338373|COMBINATION_PRODUCT|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
57936463|NCT00888381|BIOLOGICAL|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
57936464|NCT00990054|DRUG|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
57936465|NCT02982239|BEHAVIORAL|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
57936466|NCT02982239|DEVICE|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
57936467|NCT02982239|DEVICE|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
58291745|NCT02581488|OTHER|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
58291746|NCT03019991|DRUG|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
58291747|NCT03019991|DRUG|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
58291748|NCT03019991|DRUG|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
58291749|NCT04611568|OTHER|Educational Intervention|Receive educational and training material
58291750|NCT04611568|OTHER|Educational Intervention|Receive educational lecture
58291751|NCT04611568|BEHAVIORAL|Health Education|Receive melanoma curriculum
58291752|NCT04611568|BEHAVIORAL|Media Campaign|View digital media strategies
58291753|NCT04611568|OTHER|Survey Administration|Complete survey
58291754|NCT06079749|PROCEDURE|Simultaneous BTKA|Simultaneous BTKA
58291755|NCT06079749|PROCEDURE|Staged BTKA|Staged BTKA
58291756|NCT03571607|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
57936468|NCT02982239|DEVICE|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
57936469|NCT02982239|OTHER|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q\&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
57936470|NCT02982239|BEHAVIORAL|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
58072838|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
58072839|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
58072840|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
58072841|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
58072842|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
58072843|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
58291757|NCT03215875|DRUG|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
58291758|NCT03215875|DRUG|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
58291759|NCT05450913|DRUG|Priformis intramuscular injection with %2 lidocain|Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
58072844|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
58072845|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
58072846|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
58072847|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
58072848|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
58072849|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
58291760|NCT01228656|DRUG|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
58291761|NCT01228656|DRUG|Mometasone furoate|Dermatologic ointment applied once a day
58291762|NCT06312800|DRUG|Acamprosate|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
58291763|NCT06312800|DRUG|Placebo|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
58072850|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
58072851|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
58072852|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
58291764|NCT06312800|DRUG|Methazolamide|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
58291765|NCT04443647|DRUG|Oxytocin|Syntocinon nasal spray
58291766|NCT04443647|DRUG|Placebo|Placebo nasal spray
57936471|NCT06321926|DEVICE|ActiveWaiting App|"The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field."
57936472|NCT03472924|DEVICE|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
57936473|NCT02433171|PROCEDURE|Standard of Care FDG-PET Imaging|\[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
57936474|NCT05735808|BEHAVIORAL|Physician based education|Regular education provided by physician
57936475|NCT05735808|BEHAVIORAL|VR based education|VR based education
58072853|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
58072854|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
57936476|NCT01169220|DRUG|Go-Lytely|Bowel cleansing agent
57936477|NCT01169220|DRUG|Go Lytely|Bowel cleansing agent
57936478|NCT00444392|BEHAVIORAL|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
57936479|NCT00646594|DRUG|budesonide/formoterol (Symbicort)|
58072855|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
58072856|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
58072857|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
58072858|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
58291767|NCT02894814|BEHAVIORAL|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
58291768|NCT02894814|BEHAVIORAL|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
58291769|NCT04878055|DRUG|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
58291770|NCT04878055|OTHER|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
58291771|NCT06612619|BEHAVIORAL|Dyad instruction|Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
58291772|NCT01773603|DEVICE|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
57936480|NCT00646594|DRUG|fluticasone/salmeterol (Advair)|
57936481|NCT00005666|PROCEDURE|PET scan use in radiotherapy planning|
57936482|NCT05785572|PROCEDURE|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
57936483|NCT05785572|PROCEDURE|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
57936484|NCT02281929|DRUG|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
57936485|NCT02281929|DRUG|Placebo|Placebo in three daily doses during 30 days
57936486|NCT02281929|DRUG|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
57936487|NCT01576172|DRUG|Abiraterone Acetate|Given PO
57936488|NCT01576172|OTHER|Laboratory Biomarker Analysis|Correlative studies
57936489|NCT01576172|DRUG|Prednisone|Given PO
57936490|NCT01576172|DRUG|Veliparib|Given PO
58072859|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
58072860|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
58291773|NCT05947669|DRUG|Infliximab|Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
58403973|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
58291774|NCT05947669|DRUG|Methylprednisolone|Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
58291775|NCT05947669|DRUG|Prednisolone|Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
57936491|NCT01434550|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
57936492|NCT01434550|RADIATION|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~1. Necrosis/apoptosis~2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1. Aposense-PET imaging"
57936493|NCT03130179|DRUG|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
57936494|NCT03130179|DRUG|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
57936495|NCT03100669|PROCEDURE|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
57936496|NCT02080351|BEHAVIORAL|Simple cognitive task|
57936497|NCT02527525|BEHAVIORAL|Stepped Care|
57936498|NCT04967781|BEHAVIORAL|autoimmunity|autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
57936499|NCT04886310|DIAGNOSTIC_TEST|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
57936500|NCT00445484|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
57936501|NCT00445484|DRUG|lenalidomide|Given orally
58291776|NCT06311461|PROCEDURE|Acupuncture|The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).
58291777|NCT06311461|OTHER|Attention control|Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
58291778|NCT01004978|DRUG|Cisplatin|Undergo TACE
57936502|NCT03891290|OTHER|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
58291779|NCT01004978|PROCEDURE|Computed Tomography|Undergo CT scan
58291780|NCT01004978|DRUG|Doxorubicin Hydrochloride|Undergo TACE
58291781|NCT01004978|DRUG|Doxorubicin-Eluting Beads|Undergo TACE
58291782|NCT01004978|OTHER|Laboratory Biomarker Analysis|Correlative studies
58291783|NCT01004978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58291784|NCT01004978|DRUG|Mitomycin|Undergo TACE
57936503|NCT00730964|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
58072861|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
58072862|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
58291785|NCT01004978|OTHER|Pharmacological Study|Correlative studies
58291786|NCT01004978|OTHER|Placebo Administration|Given PO
58291787|NCT01004978|DRUG|Sorafenib Tosylate|Given PO
58291788|NCT02710084|DRUG|Oxytocin|Intranasal oxytocin
58291789|NCT02710084|DRUG|Saline|Placebo
58291790|NCT01968811|DEVICE|Avance Foam dressing kit|
58291791|NCT02912312|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
58291792|NCT02912312|OTHER|Laboratory Biomarker Analysis|Correlative studies
58291793|NCT02912312|OTHER|Quality-of-Life Assessment|Ancillary studies
57936504|NCT01919554|BIOLOGICAL|SLIT tablets of HDM allergen extracts|
57936505|NCT02710136|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
57936506|NCT03518138|DRUG|Q-122|oral capsule of Q-122
57936507|NCT03518138|DRUG|Placebo|oral capsule of placebo
57936508|NCT06417918|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
58072863|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
58072864|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
58072865|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
58072866|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
58291794|NCT02912312|OTHER|Questionnaire Administration|Ancillary studies
58291795|NCT02912312|RADIATION|Radiation Therapy|Undergo standard RNI
58291796|NCT04179279|DEVICE|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
58291797|NCT06452602|DRUG|Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f."
58291798|NCT06452602|DRUG|Induction immunochemotherapy followed by concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f."
58291799|NCT03832829|DEVICE|Indirect composite restoration|Restoration of tooth with extensive substance loss
58291800|NCT02108977|OTHER|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
58291801|NCT02108977|OTHER|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
58291802|NCT03651817|DEVICE|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
57936509|NCT05109286|BEHAVIORAL|CrossFit|CrossFit training
58403974|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
58403975|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
58403976|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
58403977|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
57936510|NCT02237781|DRUG|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
57936511|NCT02087072|OTHER|Collaborative visit with provider and pharmacist|
57936512|NCT06047847|DIETARY_SUPPLEMENT|TOTUM-448|The study is divided in two phases. The first clinical phase of the project is aimed at determining TOTUM-448's metabolites absorption peak (two galenic forms will be tested: capsules and powder). Then, human circulating metabolites from polyphenols will be quantified and characterized by ultra-high performance liquid chromatography hyphenated with tandem mass spectrometry (UPLC-MS/MS). Once the absorption profile is characterized, volunteers will visit once again the clinical center for the collection of serum fractions either naïve (before ingestion) or enriched (containing circulating metabolites following TOTUM-448 ingestion). The enriched fraction (circulating bioactive collection) will be collected at t-max as characterized in the first phase (absorption profil's peak). Finally, biological activity of TOTUM-448 on human hepatocytes will be studied by comparing naïve serum and serum containing circulating metabolites according to an in vitro protocol.
57936513|NCT02825004|BEHAVIORAL|Psychological Intervention|
57936514|NCT04179747|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
57936515|NCT04179747|DRUG|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
57936516|NCT06301672|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
57936517|NCT06301672|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
58403978|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
57936518|NCT06301672|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58072867|NCT05581810|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
58291803|NCT02298426|BEHAVIORAL|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
58403979|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
58403980|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
58403981|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
58403982|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
58403983|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
58403984|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
58072868|NCT05581810|BEHAVIORAL|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
57936519|NCT00298025|DRUG|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
57936520|NCT00298025|DRUG|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
58072869|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
58291804|NCT02298426|BEHAVIORAL|General Management|We provide general information about health. Information is provided through telephones and materials.
58403985|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
58403986|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
58403987|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
57936521|NCT00298025|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
57936522|NCT00298025|DRUG|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
57936523|NCT00298025|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
58072870|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
58072871|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
58072872|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
58072873|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
58072874|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
58291805|NCT02298426|OTHER|Placebo|We use placebo to replace the health product.
58403988|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
58403989|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
58403990|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
58403991|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
58403992|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
58072875|NCT00136344|DRUG|Cefuroxime|
58403993|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
58072876|NCT00136344|DRUG|Levofloxacin|
58072877|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
58072878|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
58072879|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
58072880|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
58072881|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
58072882|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
58072883|NCT05931614|OTHER|Unlimited fluid restrictions|Patients are recommended unlimited fluid intake
58291806|NCT02298426|DIETARY_SUPPLEMENT|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
58403994|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
58291807|NCT03510975|DRUG|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
58403995|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
58403996|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
58403997|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
57936524|NCT00445562|OTHER|biologic sample preservation procedure|
57936525|NCT00445562|OTHER|informational intervention|
57936526|NCT00401739|DRUG|CSL360|Weekly IV Infusion. Dose escalation study.
57936527|NCT00481897|BEHAVIORAL|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
57936528|NCT05120635|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
57936529|NCT03019250|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
57936530|NCT03019250|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
57936531|NCT01845454|DEVICE|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
57936532|NCT00979706|DRUG|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
57936533|NCT00979706|DRUG|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
57936534|NCT01552655|RADIATION|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
57936535|NCT06027736|OTHER|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
57936536|NCT03840694|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
57936537|NCT03840694|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
57936538|NCT03392792|DRUG|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
57936539|NCT03392792|PROCEDURE|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
58291808|NCT03510975|BEHAVIORAL|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
58403998|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
58403999|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
58404000|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
58404001|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
58404002|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
58404003|NCT00025298|DRUG|amifostine trihydrate|
57936540|NCT01638078|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
57936541|NCT01638078|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
57936542|NCT01731314|BEHAVIORAL|Learning and Memory of Pain|
57936543|NCT03428074|PROCEDURE|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
57936544|NCT01733342|DEVICE|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
57936545|NCT01733342|PROCEDURE|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
57936546|NCT01733342|DEVICE|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
57936547|NCT06495528|DEVICE|Pain management with BLISS DTx|Bliss DTx is a Digital Therapeutics (DTx) which uses virtual reality augmented with sound and visual stimuli to reduce pain during Port-A-Cath setting
57936548|NCT06495528|OTHER|Pain Management with site standard of care sedation protocol|Sedation (morphine and/or hypnotics and/or anxiolytics and/or conversational hypnosis) reduces pain during Port-A-Cath setting
57936549|NCT04559945|DEVICE|Aveir VR Leadless Pacemaker System|Patients will undergo an attempted leadless pacemaker implant
57936550|NCT00067860|DRUG|recombinant human growth hormone|
57936551|NCT00067860|BEHAVIORAL|diet modification|
58404004|NCT00025298|DRUG|carboplatin|
58404005|NCT00025298|DRUG|cisplatin|
58404006|NCT00025298|DRUG|paclitaxel|
58404007|NCT00025298|RADIATION|radiation therapy|
58291809|NCT03510975|BEHAVIORAL|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
58291810|NCT02045186|OTHER|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
58291811|NCT01325545|OTHER|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
58291812|NCT00320268|DRUG|Quetiapine fumarate|
58291813|NCT06612671|PROCEDURE|tumor wide excision|patients received properative or post-operative radiotherapy
58291814|NCT06453733|DEVICE|Crainio|Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
58291815|NCT02915172|DRUG|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
57936552|NCT02897232|OTHER|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
57936553|NCT02464228|DRUG|Tipifarnib|oral
57936554|NCT04474457|DRUG|Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
57936555|NCT03599037|OTHER|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
57936556|NCT05636189|PROCEDURE|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
57936557|NCT05636189|PROCEDURE|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
57936558|NCT04561596|DEVICE|OnComfort autohypnosis|"Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
57936559|NCT04561596|OTHER|Treatment as usual, without the OnComfort autohypnosis system|"The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
58291816|NCT02915172|DRUG|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
58291817|NCT00370773|DEVICE|Precision Spinal Cord Stimulation System|
58291818|NCT01344239|PROCEDURE|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
58291819|NCT02517736|DRUG|Sorafenib at a dose of 800 mg / day|
58291820|NCT05381454|DRUG|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
58291821|NCT06491355|DRUG|mfolfox6 and hlx04 regimen and Serplulimab|mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
57936560|NCT03027375|DRUG|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
57936561|NCT03027375|DRUG|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
57936562|NCT05340725|DRUG|DEX-IV|patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
58291822|NCT06491355|DRUG|mfolfox6 and hlx04 regimen|In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
58291823|NCT06346041|BIOLOGICAL|Oncolytic Virus injection(IDOV-SAFETM)|Administered by intravenous injection as single agent.
58291824|NCT02849080|DRUG|semaglutide|Oral administration once-daily.
58291825|NCT02849080|DRUG|sitagliptin|Oral administration once-daily.
58291826|NCT00206427|DRUG|GW572016|Lapatinib, 500 mg
58291827|NCT00206427|DRUG|lapatinib|Lapatinib 500 mg PO
57936563|NCT05340725|DRUG|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
58291828|NCT06487715|DRUG|albumin-bound paclitaxel (260 mg/m2, d1)|260 mg/m2, d1)
58291829|NCT06487715|DRUG|S-1|80 mg/m2, d1-14
57936564|NCT05340725|DRUG|DEX-Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
57936565|NCT04085341|DRUG|GB-102|Intravitreal injection of GB-102
57936566|NCT00418665|BIOLOGICAL|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
57936567|NCT00418665|DRUG|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
57936568|NCT02012296|DRUG|enzalutamide|Given PO
58291830|NCT06487715|DRUG|sintilimab|200 mg, d1
58404008|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
58404009|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
58404010|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
57936569|NCT02012296|DRUG|mifepristone|Given PO
57936570|NCT02012296|OTHER|laboratory biomarker analysis|Correlative studies
57936571|NCT02012296|OTHER|pharmacological study|Correlative studies
57936572|NCT03801954|BEHAVIORAL|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
57936573|NCT01893229|DRUG|Lithium|Lithium is used as a mood stabiliser
57936574|NCT01893229|DRUG|Valproate|Valproate is used as a mood stabiliser
57936575|NCT01893229|DRUG|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
57936576|NCT01893229|DRUG|Quetiapine|Quetiapine is used as a mood stabiliser
57936577|NCT01893229|DRUG|Olanzapine|Olanzapine is used as a mood stabiliser.
57936578|NCT01893229|DRUG|Ziprasidone|Ziprasidone is used as a mood stabiliser
57936579|NCT00558155|DRUG|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
57936580|NCT00558155|DRUG|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
57936581|NCT00558155|DRUG|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
57936582|NCT00558155|DRUG|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
58291831|NCT06487715|DRUG|bevacizumab|First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
58291832|NCT03000985|BEHAVIORAL|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
58291833|NCT01466413|DEVICE|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
58291834|NCT02812641|DRUG|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
58291835|NCT02812641|DRUG|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
58291836|NCT02812641|DRUG|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
58291837|NCT05293860|OTHER|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
58291838|NCT05293860|OTHER|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
57936583|NCT00018850|DRUG|ondansetron|
57936584|NCT00018850|BEHAVIORAL|neuropsychological testing|
57936585|NCT00018850|DRUG|nicotine|
58291839|NCT02085265|DRUG|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
58291840|NCT02085265|DRUG|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
58291841|NCT01351207|OTHER|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
58291842|NCT04680533|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
58291843|NCT06279195|DRUG|Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet|All participants will be instructed to take REL-CT.
58291844|NCT00385918|DEVICE|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
58291845|NCT00385918|OTHER|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
58291846|NCT02423083|DRUG|Guanabenz|
58291847|NCT05132660|DRUG|Sinemet CR|25 mg carbidopa/100 mg levodopa
58291848|NCT05132660|DRUG|placebo|Placebo pill of similar size/shape
58291849|NCT00018564|DRUG|treatments for essential tremor|
58291850|NCT06612983|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.
58291851|NCT06612983|OTHER|Walking Treatment|Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.
58291852|NCT06384027|OTHER|Non-invasive ventilation|Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
58291853|NCT03964077|DIAGNOSTIC_TEST|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
58291854|NCT01869088|DRUG|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
58291855|NCT01869088|PROCEDURE|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
58291856|NCT04714190|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
58291857|NCT04714190|DRUG|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
58291858|NCT04714190|DRUG|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
58291859|NCT04714190|DRUG|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
58291860|NCT03556969|OTHER|Observation|no intervention
58291861|NCT05530486|DEVICE|CC|Application of placebo LASER
57936586|NCT00018850|DRUG|haloperidol|
57936587|NCT00161486|DRUG|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
57936588|NCT00161486|DRUG|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
57936589|NCT00161486|DRUG|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
57936590|NCT00161486|DRUG|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
57936591|NCT05135221|BIOLOGICAL|dual biological therapy|Simultaneous use of two biologicals.
57936592|NCT04907747|DRUG|Vonoprazan|Potassium-competitive acid blocker
57936593|NCT04907747|DRUG|Esomeprazole|Proton pump inhibitor
57936594|NCT04907747|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
58291862|NCT05530486|DEVICE|LG1|Application of LASER GasAs 660nm 4 J/cm².
58291863|NCT05530486|DEVICE|LG2|Application of LASER GasAs 660nm 8 J/cm².
58291864|NCT05530486|DEVICE|LG3|Application of LASER GasAs 660nm 12 J/cm².
58291865|NCT05530486|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
58291866|NCT03284853|DRUG|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
58291867|NCT03284853|DRUG|GANFORT®|Topical sterile ophthalmic solution
58291868|NCT01492192|DRUG|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
58291869|NCT00455676|PROCEDURE|Chevron osteotomy versus Scarf osteotomy|
58291870|NCT06248307|DIETARY_SUPPLEMENT|Barrita experimental|Nutritional advice, as well as administration of protein bars.
58291871|NCT06248307|DIETARY_SUPPLEMENT|Barrita Placebo|Nutritional advice, as well as administration of placebo bars.
58291872|NCT00079053|DRUG|erlotinib hydrochloride|
58291873|NCT00079053|PROCEDURE|adjuvant therapy|
58291874|NCT06462898|DIETARY_SUPPLEMENT|Omega-3 Fortified Protein Smoothie|Omega-3 powder and protein supplementation.
58291875|NCT06462898|DIETARY_SUPPLEMENT|Non-Fortified Protein Smoothie|Protein without omega-3 powder supplementation.
58072884|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
58291876|NCT03894839|OTHER|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
58291877|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
58404011|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
58291878|NCT03894839|OTHER|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
58291879|NCT03894839|OTHER|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
58291880|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
58404012|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
58404013|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
58404014|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
58404015|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
58404016|NCT06238843|DRUG|irinotecan|Subjects in the contral arm will receive irinotecan 125mg/m2 IV D1, D8, Q3W in 3-weeks cycles or 150mg/m2 IV D1, Q2W in 2-week cycles
58404017|NCT06238843|DRUG|IBI343|IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles
58404018|NCT06238843|DRUG|paclitaxel|Subjects in the contral arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles.
58404019|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
58404020|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
58404021|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
58404022|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
58404023|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
58404024|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
58404025|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
58404026|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
58404027|NCT05996055|DEVICE|improved version_support device|designed the NTUH version_support device based on the clinical suggestion.
58404028|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
58404029|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
58404030|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
58404031|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
57936595|NCT04907747|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
58072885|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
58072886|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
58072887|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
58072888|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
58291881|NCT03894839|OTHER|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
57936596|NCT04907747|DRUG|Furazolidone|Antibiotic for H. pylori eradication
58404032|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
58404033|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
58404034|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
58072889|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
58072890|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
58291882|NCT06474572|DEVICE|Direct laryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
58291883|NCT06474572|DEVICE|Videolaryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
58291884|NCT06474572|DEVICE|Direct laryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
58291885|NCT06474572|DEVICE|Videolaryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
57936597|NCT00851123|BEHAVIORAL|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
57936598|NCT00851123|BEHAVIORAL|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
58291886|NCT05575739|DIAGNOSTIC_TEST|Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )|Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
58291887|NCT06447701|DRUG|Tocilizumab|Single dose intravenous application
58404035|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
58404036|NCT05707351|BIOLOGICAL|Adynovate|Adynovate will be injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
57936599|NCT06373471|OTHER|Comprehensive geriatric assessment (CGA) and treatment|"CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include:~* Assessment of comorbidity and treatments~* Review of medications including potential adjustment~* Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue~* Objective examination including blood tests and electrocardiogram~* Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires~* Assessment of domestic conditions, including need for assistance~* Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required"
57936600|NCT00509067|DRUG|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
58072891|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
58291888|NCT06447701|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
58291889|NCT06612749|OTHER|Integrative medicine including manual and/or mind-body treatments|Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
58291890|NCT02082171|OTHER|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
58404037|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
58404038|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
58404039|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
58404040|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
58404041|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
58072892|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
58072893|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
58404042|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
58404043|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
58404044|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
58404045|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
58404046|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
58404047|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
58404048|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
58404049|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
58404050|NCT04543266|PROCEDURE|Surgery|Resection of tumors
57936601|NCT00509067|DRUG|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
57936602|NCT00509067|DRUG|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
57936603|NCT00509067|DRUG|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
57936604|NCT00915772|DRUG|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
57936605|NCT00915772|DRUG|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
57936606|NCT00915772|DRUG|Metformin|Metformin 1000 mg tablet bid
58404051|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
57936607|NCT00189189|BEHAVIORAL|parent management training|
58072894|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
58072895|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
58072896|NCT06674733|PROCEDURE|Botox administration|Treatment for bruxism
58072897|NCT06674733|PROCEDURE|Aromatherapy|treatment for stress-bruxism
58072898|NCT06674733|PROCEDURE|Clinical evaluation|Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered
58072899|NCT06674733|PROCEDURE|Imaging Time|Panoramic radiographs will be taken before the procedure and three months after the procedure. Ultrasonography examination will be performed before the procedure, one month after, and three months after the procedure.
58072900|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
58404052|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
58404053|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
58404054|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
58404055|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
58404056|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
58404057|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
58404058|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
58404059|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
58404060|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
58404061|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
58404062|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
58404063|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
58072901|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
58404064|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
57936608|NCT01095367|PROCEDURE|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
58072902|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
58072903|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
58072904|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
58072905|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
58404065|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
57936609|NCT00222573|DRUG|clopidogrel and metoprolol|
57936610|NCT06461767|DEVICE|transcranial magnetic stimulation device|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30"
58404066|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
58404067|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
58404068|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
58072906|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
58072907|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
57936611|NCT02790255|OTHER|Cold air|
57936612|NCT02790255|OTHER|Cold water|
57936613|NCT02485457|PROCEDURE|Volume loading|Volume loading with Ringer Lactate
57936614|NCT02485457|DRUG|Ringer solution|
58072908|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
58072909|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
58072910|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
58291891|NCT06613373|DRUG|Dalpiciclib|Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
58291892|NCT05316181|PROCEDURE|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
58291893|NCT05042752|PROCEDURE|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
58404069|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
58404070|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
58404071|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
58291894|NCT03162406|DIETARY_SUPPLEMENT|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
58404072|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
58404073|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
58404074|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
58404075|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
58404076|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
58404077|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
58404078|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
57936615|NCT02163460|PROCEDURE|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
57936616|NCT02163460|PROCEDURE|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
57936617|NCT00870766|PROCEDURE|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
57936618|NCT00733304|DRUG|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
57936619|NCT06425484|OTHER|Bilateral US TAP block|epidural plus bilateral US guided TAP block
58072911|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
58291895|NCT03162406|DIETARY_SUPPLEMENT|Placebo|Oral supplementation once per week for 6 months
58291896|NCT02820519|DRUG|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
58404079|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
57936620|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
57936621|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
58072912|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
58072913|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
58072914|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
58404080|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
58404081|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
58291897|NCT04871152|DRUG|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
57936622|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
57936623|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
57936624|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
57936625|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
57936626|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
57936627|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
57936628|NCT01301456|BIOLOGICAL|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
58291898|NCT03140163|RADIATION|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
58291899|NCT03140163|RADIATION|CXR|Conventional chest radiograph
58291900|NCT04124380|BEHAVIORAL|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
58291901|NCT04124380|BEHAVIORAL|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
58404082|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
58404083|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
58291902|NCT04124380|BEHAVIORAL|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
58291903|NCT04084002|OTHER|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
57936629|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
57936630|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
58291904|NCT02869477|OTHER|Data collection|
58291905|NCT00844402|DRUG|Atorvastatin|oral, 10 mg, daily, 48 weeks
58291906|NCT02010112|OTHER|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
58291907|NCT01321632|DRUG|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
58291908|NCT02968108|DRUG|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
58291909|NCT02640313|DRUG|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
58291910|NCT00054223|PROCEDURE|psychosocial assessment and care|
58291911|NCT03635762|BEHAVIORAL|Be In Charge|comparison of pre and post-program weight and calorie intake
58291912|NCT05418907|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
58291913|NCT05477004|DRUG|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
57936631|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
58291914|NCT05927077|PROCEDURE|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
58291915|NCT03646747|DIAGNOSTIC_TEST|MRI scan|Additional imaging using MRI scan
57936632|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
57936633|NCT01486641|PROCEDURE|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
57936634|NCT04611854|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
58404084|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
58072915|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
58291916|NCT03812939|DRUG|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
58291917|NCT01148394|OTHER|Multimodal rehabilitation|
57936635|NCT04611854|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
57936636|NCT02871973|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
57936637|NCT02871973|BEHAVIORAL|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
58291918|NCT01659840|RADIATION|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
58291919|NCT01659840|RADIATION|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
58291920|NCT03908554|OTHER|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
58404085|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
57936638|NCT00709111|DRUG|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
57936639|NCT06383156|DEVICE|Double lumen endotracheal tube|correct position of LDLT during single lung ventilation
57936640|NCT02700568|DRUG|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
57936641|NCT03957395|DEVICE|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
57936642|NCT00003653|DRUG|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
57936643|NCT00003653|DRUG|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
58072916|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
58072917|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
58072918|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
58072919|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
58072920|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
58291921|NCT04900454|BIOLOGICAL|DVX201|Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
58291922|NCT06349239|OTHER|No intervention|Follow-up of disease
58291923|NCT04405323|DRUG|Lu AG06466|hard capsules, orally, single doses
58072921|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
58072922|NCT02136927|DRUG|SPARC1210|
58072923|NCT02136927|DRUG|Reference1210|
58072924|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
58291924|NCT04405323|DRUG|Itraconazole|200 and 300 mg, capsules, orally
58291925|NCT03560453|BEHAVIORAL|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
58072925|NCT03031327|DEVICE|Lubricin 20µg/ml|Lubricin 20µg/ml eye drops
58072926|NCT03031327|DEVICE|Lubricin 50µg/ml|Lubricin 50µg/ml eye drops
58072927|NCT03031327|DEVICE|Sodium hyaluronate 0.18%|Sodium hyaluronate (HA) 0.18% eye drops
57936644|NCT00003653|DRUG|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
57936645|NCT00003653|DRUG|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
57936646|NCT00003653|DRUG|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
57936647|NCT00003653|DRUG|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
58072928|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
58072929|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
58072930|NCT03219372|DRUG|Pravastatin Pill|statin
58072931|NCT03219372|DRUG|Placebo Oral Tablet|placebo
58072932|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
58072933|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
58072934|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
58072935|NCT06698133|OTHER|Participants in the intervention arm will be invited to join a private social media group|Education content
58072936|NCT02146911|DRUG|Bupropion|
58072937|NCT02146911|DRUG|Varenicline|
58072938|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
58291926|NCT05291130|DEVICE|Plasmafit® Vitelene® Vitamin E|Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
58291927|NCT01007604|DEVICE|Peristaltic pulse PCD|Daily use for two hours
58291928|NCT01007604|OTHER|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
58291929|NCT01388933|DRUG|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
58291930|NCT01388933|DRUG|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
58291931|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
58291932|NCT01938846|DRUG|exemestane|exemestane once daily
58291933|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
58291934|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
58291935|NCT01938846|DRUG|paclitaxel|paclitaxel once weekly
57936648|NCT00003653|DRUG|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
58404086|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
58404087|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
58404088|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
58404089|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
58404090|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
58404091|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
57936649|NCT00108914|DRUG|GW685698X|
57936650|NCT04652154|OTHER|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
57936651|NCT04521036|BIOLOGICAL|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
57936652|NCT00209365|PROCEDURE|exposure to grass pollen/starch granules|
57936653|NCT01992133|DIETARY_SUPPLEMENT|Vitamin D3|
57936654|NCT01992133|DIETARY_SUPPLEMENT|Placebo|
57936655|NCT00564824|DRUG|Caffeine|Caffeine 200 mg tablet
57936656|NCT00564824|DRUG|Placebo|Placebo pills
57936657|NCT04720404|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
57936658|NCT04720404|OTHER|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
57936659|NCT04720404|OTHER|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
57936660|NCT00853398|PROCEDURE|surgical technique|
57936661|NCT00487396|DEVICE|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
57936662|NCT04701385|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
57936663|NCT00127920|DRUG|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
57936664|NCT01364623|DRUG|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
57936665|NCT01364623|DRUG|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
57936666|NCT01364623|DRUG|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
57936667|NCT01364623|DRUG|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
58404092|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
58404093|NCT05474781|DRUG|Epclusa|HCV treatment
58404094|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
58404095|NCT00420004|DRUG|Placebo|
58404096|NCT00420004|DRUG|Escitalopram|10-mg capsules
57936668|NCT05425914|DRUG|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
57936669|NCT05425914|DRUG|Artificial tear|Conventional dry eye treatment
57936670|NCT05058287|DRUG|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
57936671|NCT05058287|DRUG|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
57936672|NCT02530983|OTHER|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
57936673|NCT02530983|OTHER|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1"
57936674|NCT03980834|BEHAVIORAL|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
57936675|NCT03980834|BEHAVIORAL|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
57936676|NCT03980834|BEHAVIORAL|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
57936677|NCT03980834|BEHAVIORAL|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
57936678|NCT03465631|DEVICE|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
58291936|NCT03360019|DEVICE|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
58291937|NCT03360019|OTHER|Activlink Phone Application|Smartphone tool used for monitoring location
58291938|NCT06451666|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
58291939|NCT06451666|DRUG|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
58291940|NCT00959283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58291941|NCT00959283|OTHER|Pharmacological Study|Correlative studies
58291942|NCT02332941|DRUG|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
58291943|NCT02372383|DRUG|Ethambutol|Anti-mycobacterial oral drug
58291944|NCT02372383|DRUG|Rifampin|Anti-mycobacterial oral drug
58291945|NCT02372383|DRUG|Azithromycin|Anti-mycobacterial oral drug
58291946|NCT02372383|DRUG|Pancrelipase|Pancreatic enzyme replacement therapy
58291947|NCT03758157|DIAGNOSTIC_TEST|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
58291948|NCT03758157|DIAGNOSTIC_TEST|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
58291949|NCT01873118|OTHER|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
57936679|NCT03465631|DEVICE|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
57936680|NCT01671423|DRUG|Prednisone|"See Prednisone arm description"
57936681|NCT01671423|DRUG|Placebo|"See Placebo arm description"
57936682|NCT00171444|BEHAVIORAL|Medical education|
57936683|NCT05944042|OTHER|Observational Transplant Analysis|Identify more accurate predictive models of transplant risk
57936684|NCT01447368|DRUG|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
57936685|NCT01447368|PROCEDURE|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
57936686|NCT03627897|DRUG|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
58291950|NCT01873118|OTHER|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
58404097|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
58404098|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
58404099|NCT01255813|OTHER|Control|No stimulation applied
58404100|NCT04929002|OTHER|No intervention|No intervention
58404101|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
58404102|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
57936687|NCT03627897|DRUG|saline|No drugs or interventions were administered to the control group.
57936688|NCT03517787|OTHER|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
57936689|NCT03517787|OTHER|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
58291951|NCT01873118|OTHER|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
58404103|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
58404104|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
58404105|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
58404106|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
58404107|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
58404108|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
57936690|NCT03517787|OTHER|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
57936691|NCT03517787|OTHER|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
57936692|NCT00440076|DRUG|Velcade|
57936693|NCT03753009|PROCEDURE|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
57936694|NCT01495858|DRUG|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
58072939|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
58072940|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
58072941|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
58072942|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
58072943|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
58072944|NCT06213831|DRUG|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
58072945|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
58072946|NCT00658918|DRUG|Placebo|placebo
58072947|NCT02118272|DEVICE|Physica KR|
58404109|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
58404110|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
58404111|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
58404112|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
58404113|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
58404114|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
58404115|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
58404116|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
58404117|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
58072948|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
58072949|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
58072950|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
58072951|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
58072952|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
58291952|NCT06005753|PROCEDURE|Ostheosynthesis of acetabular fractures|The using of plate for fixation of acetabular fractures in surgical treatment
58404118|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
58404119|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
58404120|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
58404121|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
58404122|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
58404123|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
58404124|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
58072953|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
58072954|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
58291953|NCT02235025|OTHER|Cardio-pulmonary exercise testing|
58291954|NCT05050305|DRUG|Marizomib|Intravenous Infusion
58072955|NCT06192108|DRUG|Orforglipron|Administered orally
58072956|NCT06192108|DRUG|Dapagliflozin|Administered orally
58072957|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
58291955|NCT05050305|DRUG|Pomalidomide|Taken orally
58291956|NCT05050305|DRUG|Dexamethasone|Taken orally
58291957|NCT06144112|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
57936695|NCT01495858|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
57936696|NCT01495858|DRUG|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
57936697|NCT03100799|PROCEDURE|Arthroscopy|Arthroscopy of the target knee
57936698|NCT03100799|PROCEDURE|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
57936699|NCT03100799|DIAGNOSTIC_TEST|MRI|MRI with and without a gadolinium-based contrast agent
57936700|NCT01537536|DRUG|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
57936701|NCT02838095|BEHAVIORAL|Nap|A 1-hour daytime nap opportunity
57936702|NCT03621527|OTHER|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
57936703|NCT03621527|OTHER|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
57936704|NCT03380351|BEHAVIORAL|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
58072958|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
58291958|NCT06144112|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
58291959|NCT05632263|DIAGNOSTIC_TEST|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
58291960|NCT03727841|DRUG|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
58404125|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
58404126|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
57936705|NCT02014740|DRUG|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
58291961|NCT03356600|COMBINATION_PRODUCT|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
58404127|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
58291962|NCT02606240|DEVICE|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
58291963|NCT00807365|DRUG|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
58291964|NCT00866957|PROCEDURE|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
58291965|NCT01523145|BEHAVIORAL|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
58291966|NCT01523145|OTHER|Control Group|usual follow-up Standard follow-up at the participating heart center
58291967|NCT04887350|BEHAVIORAL|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
58291968|NCT04887350|BEHAVIORAL|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
58291969|NCT04399369|DEVICE|SDF|38% silver diamine fluoride solution
58291970|NCT04399369|DEVICE|NaF|5% sodium fluoride varnish
58291971|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and dairy fat|12-weeks, 3x per day
58291972|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and plant fat|12-weeks, 3x per day
58404128|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
58404129|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
57936706|NCT02014740|DRUG|Metformin|
58072959|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening, lateral excursion, and range of motion of shoulder abduction, neck joint
58072960|NCT06602739|DRUG|REGN5713|Administered per protocol
58291973|NCT04397874|DIAGNOSTIC_TEST|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
58291974|NCT04799262|DRUG|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
58404130|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, ... \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
57936707|NCT05766709|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously once weekly.
57936708|NCT05766709|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
57936709|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/3.20 mg/mL)|NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
58072961|NCT06602739|DRUG|REGN5715|Administered per protocol
58072962|NCT06602739|DRUG|Placebo|Administered per protocol
58072963|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
57936710|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/0.33mg/mL)|NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
58404131|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
58404132|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
58072964|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
58095127|NCT05179655|OTHER|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
58291975|NCT03183115|PROCEDURE|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
57936711|NCT03306355|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
58291976|NCT03183115|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
57936712|NCT03306355|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
57936713|NCT05291442|OTHER|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
57936714|NCT04901481|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
57936715|NCT00393796|DRUG|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
57936716|NCT00393796|OTHER|Placebo|
58291977|NCT03183115|DRUG|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
58291978|NCT02824224|DRUG|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
58291979|NCT02824224|DRUG|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
57936717|NCT02281357|BIOLOGICAL|Tralokinumab|Tralokinumab dose
57936718|NCT02281357|OTHER|Placebo|Placebo dose
57936719|NCT05923021|OTHER|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
58072965|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
58095128|NCT02599610|OTHER|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
57730108|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
57936720|NCT04095780|OTHER|Advanced oral hygiene care programme|"1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education"
57936721|NCT04095780|OTHER|Oral hygiene instruction|Oral hygiene education
57936722|NCT04516707|OTHER|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
57936723|NCT01931748|DRUG|MELSMON|
57936724|NCT01931748|DRUG|UNCNT|
57936725|NCT02890758|BIOLOGICAL|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
57936726|NCT02890758|BIOLOGICAL|ALT803|given at 6mcg/kg weekly for four weeks
57936727|NCT04778345|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging after 18F-FDG PET/CT scan during 2 days and 1 week.
57936728|NCT03961971|DRUG|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
57936729|NCT00518427|DRUG|Insulin Glargine|"Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
57936730|NCT03228069|PROCEDURE|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
57936731|NCT05223114|OTHER|Not applicable (N/A)|Not applicable to this study
57936732|NCT06079944|PROCEDURE|Progressive resistance training|"* 6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~* 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~* Speed of movement will be 2 seconds for both the eccentric and concentric phases.~* To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
57936733|NCT06079944|PROCEDURE|Traditional physical therapy|"* TENS+ Hot pack~* Pendulum exercises and stretching exercises"
57936734|NCT04796922|DRUG|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
57936735|NCT04796922|DRUG|rituximab|rituximab will be administered intravenously on select days as per protocol.
57936736|NCT04796922|DRUG|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
58404133|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
58404134|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
58404135|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
58404136|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
57936737|NCT02906787|BEHAVIORAL|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
57936738|NCT02906787|BEHAVIORAL|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
57936739|NCT03340649|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
57936740|NCT05444842|OTHER|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
57936741|NCT05444842|OTHER|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
57936742|NCT05444842|OTHER|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
57936743|NCT05510765|BEHAVIORAL|Transportation service|Improved transportation assets applied to all aspects of subjects life
57936744|NCT00890253|DRUG|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
57936745|NCT00890253|DRUG|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
57936746|NCT00890253|DRUG|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
57936747|NCT00890253|DRUG|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
57936748|NCT02901496|BEHAVIORAL|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
58291980|NCT02899247|PROCEDURE|Surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
57936749|NCT02901496|BEHAVIORAL|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
57936750|NCT02901496|BEHAVIORAL|No Exercise|Control to exercise
57936751|NCT02901496|DRUG|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
57936752|NCT02901496|DRUG|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
58404137|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
57936753|NCT04876755|DRUG|MBM-02|MBM-02 is an HIF-1 and HIF-2 inhibitor.
57936754|NCT03846349|DEVICE|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
57936755|NCT03846349|DEVICE|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
57936756|NCT02637479|DEVICE|GammaKnife®|
58072966|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
57936757|NCT02637479|DEVICE|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
57936758|NCT02637479|DEVICE|MRI|
57936759|NCT00941668|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
57936760|NCT00941668|DRUG|sodium monofluorophosphate toothpaste|Twice daily usage
57936761|NCT05378841|PROCEDURE|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
57936762|NCT02677948|DRUG|Pacritinib|
58072967|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
57936763|NCT02677948|DRUG|Ibrutinib|
57936764|NCT00003111|DRUG|carboplatin|
57936765|NCT00003111|DRUG|cisplatin|
57936766|NCT00003111|DRUG|irinotecan hydrochloride|
57936767|NCT00003111|DRUG|paclitaxel|
57936768|NCT00003111|PROCEDURE|neoadjuvant therapy|
57936769|NCT00003111|PROCEDURE|surgical procedure|
57936770|NCT00003111|RADIATION|radiation therapy|
57936771|NCT06490302|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear
57936772|NCT06490302|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear
57936773|NCT04860375|PROCEDURE|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
57936774|NCT04860375|OTHER|Standard care|Standard care in Sweden
57936775|NCT01298583|BEHAVIORAL|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
57936776|NCT02810847|DEVICE|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
57936777|NCT04431336|BEHAVIORAL|movement|movement
58072968|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
58291981|NCT02899247|PROCEDURE|No surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
57730109|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
58404138|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
58404139|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
58404140|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
58404141|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
58404142|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
58404143|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
58072969|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
58291982|NCT04367662|PROCEDURE|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
58291983|NCT04819139|OTHER|Active Excersises|Active thumb exercises
58291984|NCT04819139|OTHER|Reeducation ADL|Reeducation in the activities daily life
58291985|NCT04819139|OTHER|Joint protection|Used of a thumb orthosis
58291986|NCT04819139|OTHER|Proprioception exercises|Specific proprioception exercises
58404144|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
58404145|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
58404146|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
58291987|NCT04000971|OTHER|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
58291988|NCT04000971|OTHER|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
58291989|NCT03679143|DRUG|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
58291990|NCT03679143|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
58291991|NCT03679143|DRUG|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
58291992|NCT03679143|DRUG|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
58404147|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
58404148|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
58404149|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
58404150|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
58291993|NCT03679143|DRUG|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
57936778|NCT05837520|DEVICE|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
58404151|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
57730110|NCT04833023|DRUG|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
57936779|NCT05837520|BEHAVIORAL|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
57936780|NCT04060563|DEVICE|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
57936781|NCT02078635|BEHAVIORAL|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
57936782|NCT02078635|BEHAVIORAL|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
58072970|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
58072971|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
58291994|NCT03679143|DRUG|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
58291995|NCT03679143|DRUG|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
58072972|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
58291996|NCT03679143|DRUG|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
58291997|NCT03679143|DRUG|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
58291998|NCT03679143|DRUG|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
58291999|NCT03679143|DRUG|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
58292000|NCT03679143|DRUG|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
58292001|NCT03679143|DRUG|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
58292002|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
58292003|NCT03679143|DRUG|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
58292004|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
58404152|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
58292005|NCT03679143|DRUG|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
58404153|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
58404154|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
58404155|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
58404156|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
58404157|NCT04022785|DRUG|Azacitidine|Given IV or SC
58404158|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
57730111|NCT04833023|DRUG|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
58404159|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
58404160|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
57936783|NCT02417155|BEHAVIORAL|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
58072973|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
58072974|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
58072975|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
58292006|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
58292007|NCT03679143|DRUG|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
58292008|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
58292009|NCT04156893|BIOLOGICAL|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
58292010|NCT01707628|BIOLOGICAL|influenza vaccination with influenza vaccine|
58292011|NCT03559283|DIAGNOSTIC_TEST|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
58292012|NCT03666247|BEHAVIORAL|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
58292013|NCT03666247|BEHAVIORAL|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
58404161|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
58404162|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
58404163|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
58404164|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
57730112|NCT05119959|OTHER|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
57730113|NCT05119959|OTHER|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
58072976|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
58072977|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
58072978|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
58404165|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
57936784|NCT02417155|BEHAVIORAL|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
57936785|NCT02088788|DEVICE|Board|Also has radio-dense pelvic shielding
58404166|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
58404167|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
58404168|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
58404169|NCT01338350|DRUG|AZD5423|Inhalation, suspension
58404170|NCT01338350|DRUG|Placebo|Inhalation, solution
58292014|NCT01718392|BEHAVIORAL|Training|
58292015|NCT06202703|DRUG|Pneumococcal Vaccine|vaccination with pneumococcal vaccine (PCV13)
58292016|NCT04356287|BIOLOGICAL|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
58292017|NCT04356287|OTHER|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
58292018|NCT01996111|PROCEDURE|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
58404171|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
58404172|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
58404173|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
58404174|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
58404175|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
58404176|NCT00129701|PROCEDURE|Telephone consultation|
58404177|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
58404178|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
58404179|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
58072979|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
58072980|NCT04692324|OTHER|Survey Administration|Ancillary studies
58292019|NCT01996111|PROCEDURE|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
58292020|NCT01996111|PROCEDURE|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
58292021|NCT01996111|PROCEDURE|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
58292022|NCT05748574|DIETARY_SUPPLEMENT|Sleep Well Sachet|Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
58292023|NCT04986774|PROCEDURE|Rescue intracranial stenting|Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
58292024|NCT06612411|DRUG|B. subtilis|2 capsules, 3 times a day, orally taken for one month
58292025|NCT06612411|DRUG|Dead B. subtilis|2 capsules, 3 times a day, orally taken for one month
58292026|NCT03166501|DRUG|Lanicemine|Three 60 min parenteral infusions over a 5 day period
57936786|NCT02088788|DEVICE|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
57936787|NCT02150499|DRUG|levalbuterol tartrate HFA inhalation aerosol|
57936788|NCT02150499|DRUG|placebo|
58072981|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
58292027|NCT03166501|DRUG|Placebo|Three 60 min parenteral infusions over a 5 day period
58292028|NCT02651844|DRUG|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
58292029|NCT05827692|BEHAVIORAL|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
58292030|NCT06358118|DRUG|Buyuan Zhixiao Formula|Buyuan Zhixiao Formula
58292031|NCT06358118|DRUG|Placebo|The placebo contains 10% of the active ingredients of the Chinese medicine group
58292032|NCT00254215|BEHAVIORAL|high protein & low glycemic index diets|
58072982|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
58072983|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
58292033|NCT06488898|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|"Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention."
58404180|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
58404181|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
58072984|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
58072985|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
58095129|NCT02599610|DEVICE|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
58095130|NCT06414265|DEVICE|Transcatheter mitral valve replacement|The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
58404182|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
58292034|NCT02801825|PROCEDURE|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
58404183|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
58404184|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
58404185|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
58292035|NCT02801825|PROCEDURE|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
58292036|NCT00357877|DRUG|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
58292037|NCT00357877|OTHER|Placebo|
58292038|NCT04750057|DRUG|Anifrolumab|Multi-centre, open-label, early access program (EAP) designed to provide access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard therapy.
58292039|NCT02309970|DRUG|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
58292040|NCT02309970|DRUG|alteplase|subject in this group will receive intravenous tPA
58292041|NCT02309970|PROCEDURE|endovascular|
58292042|NCT06611462|BEHAVIORAL|Prehabilitation (the STRONG programme)|Participants screened positive for one or more SNAP factors and randomised to the intervention group will receive an individualised plan for prehabilitation of their specific SNAP factors.
58292043|NCT00570336|DRUG|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
58292044|NCT00570336|OTHER|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
58292045|NCT02646683|DRUG|vedolizumab|
58404186|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
58404187|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
58292046|NCT04173416|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
58404188|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
58404189|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
58404190|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
58404191|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
58404192|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
58292047|NCT06133998|DEVICE|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire."
58404193|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
58404194|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
58404195|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
58095131|NCT05242146|DRUG|GB5121|Capsule containing GB5121
58292048|NCT06133998|DEVICE|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap."
58292049|NCT00264485|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
58404196|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
58404197|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
58404198|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
58404199|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
58404200|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
58404201|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
57730114|NCT05150730|OTHER|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
58095132|NCT06404931|PROCEDURE|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
58095133|NCT06404931|PROCEDURE|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
58095134|NCT06404931|PROCEDURE|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
58292050|NCT04784078|PROCEDURE|Coronary Angiography and Intervention|Transradial access puncture site
58292051|NCT05837286|DEVICE|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
58292052|NCT05837286|OTHER|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
58292053|NCT03793023|DRUG|Teneligliptin 20mg|
58292054|NCT06609200|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
58292055|NCT04837287|OTHER|Static Stretching Exercise for 10 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
58292056|NCT04837287|OTHER|Static Stretching Exercise for 30 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
58292057|NCT00182741|DIETARY_SUPPLEMENT|calcitriol|
58292058|NCT00182741|DRUG|mitoxantrone hydrochloride|
58292059|NCT00182741|DRUG|prednisone|
58292060|NCT03977987|DRUG|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
58292061|NCT04874818|DIAGNOSTIC_TEST|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
58292062|NCT04693780|OTHER|Structured guide|Structured guide
58292063|NCT04693780|OTHER|List|List
58292064|NCT05505383|OTHER|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
58292065|NCT01630018|DRUG|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
58292066|NCT01630018|DRUG|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
58404202|NCT03638908|DRUG|Fluoxetine|
58404203|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
58404204|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
58404205|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
57730115|NCT06635772|DRUG|HS-10390|HS-10390 will be administered daily
58292067|NCT04126044|DRUG|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
58292068|NCT04126044|DRUG|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
58404206|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
58404207|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
58095135|NCT04456764|BEHAVIORAL|SaFTiE|A multi-modal fatigue risk management program.
58095136|NCT04456764|BEHAVIORAL|Attention Placebo Control|A multi-modal teamwork assessment program.
58095137|NCT06433765|OTHER|No intervention|No intervention
58095138|NCT00858611|DRUG|VRC-FLUDNA047-00-VP|
58292069|NCT01898052|DRUG|single anaesthetic drug|inject periarticular tissue of the knee after implantation
58292070|NCT01898052|DRUG|multimodal drug injection|inject periarticular tissue of the knee
58292071|NCT03003169|OTHER|Medical questionnaire|"* quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)"
58292072|NCT00027885|BIOLOGICAL|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
58292073|NCT00027885|DRUG|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
58292074|NCT00027885|DRUG|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
58404208|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
58404209|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
58404210|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
58404211|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
57936789|NCT05039333|DEVICE|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
57936790|NCT03329196|DRUG|MT-6548|Oral tablet
57936791|NCT03329196|DRUG|Darbepoetin alfa|Subcutaneous
58292075|NCT00027885|DRUG|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
58292076|NCT00027885|PROCEDURE|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
58292077|NCT00027885|PROCEDURE|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
58292078|NCT00027885|PROCEDURE|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
58292079|NCT00027885|RADIATION|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
58292080|NCT05701280|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
58292081|NCT05701280|OTHER|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
58292082|NCT06360965|DRUG|Improved warm meridians and relieve pain plaster|Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
58292083|NCT06360965|DRUG|Traditional warm meridians and relieve pain plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
58292084|NCT06360965|DRUG|Placebo plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
58404212|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
58404213|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
58404214|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
58404215|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
58404216|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
58404217|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
58404218|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
58404219|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
58404220|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
58404221|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
58292085|NCT05203601|BIOLOGICAL|SIBP-03|"Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study."
58292086|NCT04130074|DEVICE|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
58292087|NCT01957423|DIETARY_SUPPLEMENT|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
58292088|NCT01957423|DIETARY_SUPPLEMENT|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
58292089|NCT02252302|OTHER|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
58404222|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
58404223|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
57936792|NCT04020939|DEVICE|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
58404224|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
58404225|NCT00001155|DRUG|cyclophosphamide|
57730116|NCT06635772|DRUG|Irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
57730117|NCT00399477|DRUG|rasagiline mesylate|Azilect®
57730118|NCT00399477|DRUG|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
57936793|NCT04020939|DRUG|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
57936794|NCT01248286|OTHER|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
57936795|NCT01248286|OTHER|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
57936796|NCT02265861|DRUG|HCG|
57936797|NCT02556996|BIOLOGICAL|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
57936798|NCT02556996|OTHER|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
57936799|NCT05973097|DRUG|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
57936800|NCT05973097|OTHER|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
57936801|NCT05973097|OTHER|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
57936802|NCT05942430|PROCEDURE|Autologous costal osteochondral transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Trim the autograft according to the size of the lesion;~5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
57936803|NCT05942430|PROCEDURE|Autologous iliac osteoperiosteal transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
57936804|NCT02678338|DRUG|Hu5F9-G4|
57936805|NCT01958723|OTHER|Hospitalists|Introduction of Problem Specific Templates
57936806|NCT06035796|DEVICE|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
57936807|NCT02765087|OTHER|Medical History|Oriented Survey and complete physical exam.
57936808|NCT02765087|DEVICE|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
57936809|NCT02765087|OTHER|Chest CT|
57936810|NCT02765087|OTHER|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
57936811|NCT00698204|DRUG|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
57936812|NCT00698204|DRUG|placebo|Subject was asked to take placebo each day that radiation therapy was given.
57936813|NCT06328998|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
58072986|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
57936814|NCT06328998|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
57936815|NCT06328998|DRUG|Lidocaine Hydrochloride|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
57936816|NCT00001181|DRUG|Testolactone|
57936817|NCT03085979|PROCEDURE|Burch Colposuspension|Anti-incontinent surgery
57936818|NCT03085979|PROCEDURE|trans obturator tape|Anti-incontinent surgery
57936819|NCT03085979|PROCEDURE|tension free vaginal tape|Anti-incontinent surgery
58072987|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
58072988|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
58072989|NCT06531798|DRUG|Breztri Aerosphere|Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
58095139|NCT00858611|DRUG|Flulaval (Registered) Seasonal Influenza Vaccine|
58072990|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
58072991|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
58072992|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
58072993|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
58072994|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
58072995|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
58072996|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
57936820|NCT05614687|BEHAVIORAL|Community-informed art-based programme|The Community-informed art-based programme is an intervention incorporating art in the form of for example poetry and drawings in addressing trauma and encouraging community attitudes towards the positive reintegration of ex-offenders.
57936821|NCT05614687|OTHER|Government Media Intervention|Government Media Intervention involving media content from the National Orientation Agency and other media sources
57936822|NCT00338663|DEVICE|knee immobilization splint|
58072997|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
58072998|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
58404226|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
57936823|NCT02438891|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
58072999|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
58073000|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
58073001|NCT00807768|DRUG|Carboplatin|Given IV
58073002|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
58073003|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
58073004|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
58073005|NCT00807768|DRUG|Paclitaxel|Given IV
58073006|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
58073007|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
57730119|NCT00399477|DRUG|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
58073008|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
58073009|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
58073010|NCT00157638|DRUG|optimizing therapeutic treatments|
58073011|NCT00157638|BEHAVIORAL|optimizing processes of care|
58073012|NCT04366869|DEVICE|overdenture|removal of overdenture at night
58073013|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
58073014|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
58073015|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
58073016|NCT00366665|DEVICE|Legacy 20000|
58073017|NCT00366665|DEVICE|Infinit system|
58073018|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
58404227|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
58404228|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
58404229|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
58292090|NCT02252302|OTHER|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
58404230|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
58404231|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
58404232|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
58404233|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
58404234|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
58404235|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
58404236|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
58404237|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
58404238|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
58404239|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
58404240|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
58404241|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
58404242|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
58292091|NCT02252302|DRUG|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
58404243|NCT02182206|DRUG|BIBF 1120|
58404244|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
58404245|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
58292092|NCT02252302|DRUG|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
58292093|NCT02252302|OTHER|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
58404246|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
58404247|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
58404248|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
57730120|NCT00399477|DRUG|Rasagiline mesylate with Requip|Azilect®, Requip
58095140|NCT04711850|DRUG|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
58292094|NCT02252302|OTHER|Filtered air|Participants will be breathing filtered air
58292095|NCT02022046|OTHER|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
58404249|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
58404250|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
58292096|NCT01707888|PROCEDURE|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
58292097|NCT00002479|DRUG|tretinoin|
58404251|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
58404252|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
58073019|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
58073020|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
58095141|NCT06702943|DRUG|Tigecycline (Tygacil)|tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
58292098|NCT06442722|PROCEDURE|DDH with capsulorrhaphy|group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,
58292099|NCT06442722|PROCEDURE|DDH without capsulorrhaphy|group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
58292100|NCT04646018|OTHER|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
58292101|NCT04646018|OTHER|Sham Manipulation|Lumbar non-thrust manipulation without force applied
58404253|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
58404254|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
58095142|NCT06702943|DRUG|Colistimethate sodium (CMS)|Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
58095143|NCT06703268|DRUG|HSK7653 10 mg|HSK7653 10 mg Q2W
58095144|NCT06703268|DRUG|Daily DPP-4 inhibitor|Daily DPP-4 inhibitor
58095145|NCT05116761|BIOLOGICAL|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
58095146|NCT05116761|OTHER|Saline|Placebo Saline
58292102|NCT05510414|BEHAVIORAL|psychological intervention based on psychological capital|Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
58073021|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
58073022|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
58073023|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
58292103|NCT03014271|BEHAVIORAL|Sources of Strength (SOS) Prevention Program|Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
58292104|NCT00190788|DRUG|Drotrecogin Alfa (Activated)|
57936824|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
57936825|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Control Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
57936826|NCT02389751|DRUG|Carboplatin|Given IV
57936827|NCT02389751|DRUG|Ganetespib|Given IV
57936828|NCT02389751|DRUG|Paclitaxel|Given IV
58073024|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
58073025|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
58073026|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
58073027|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
58292105|NCT00190788|DRUG|placebo|
58292106|NCT04203212|DRUG|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
57936829|NCT02389751|RADIATION|Radiation Therapy|Undergo radiation therapy
58073028|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
58073029|NCT03210909|DRUG|BMS-986231|BMS-986231
58095147|NCT01278446|OTHER|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
58292107|NCT00239473|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
58292108|NCT00239473|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
58292109|NCT05394285|DRUG|Hetrombopag|"The first chemotherapy cycle (single center, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
58292110|NCT05394285|DRUG|rh-TPO|"The first chemotherapy cycle (single center, open label, randomized controlled):~Start using rh-TPO 15000 units/day (subcutaneous injection) when platelets are less than 50\*109/L. When the platelet count is more than 100\*109/L, the administration is suspended.~2nd chemotherapy cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after chemotherapy for 14 days."
58292111|NCT00042055|DRUG|CP-461|
58292112|NCT02532257|DRUG|Ibrutinib|Given PO
57936830|NCT00375557|DRUG|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
58292113|NCT02532257|OTHER|Laboratory Biomarker Analysis|Correlative studies
58292114|NCT02532257|DRUG|Lenalidomide|Given PO
57936831|NCT00375557|DRUG|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
57936832|NCT00236925|DRUG|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
57936833|NCT00236925|DRUG|Placebo|Placebo
57936834|NCT04458103|DEVICE|Percutaneous RVAD|ProtekDuo or Impella RP
57936835|NCT03128476|DIETARY_SUPPLEMENT|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
57936836|NCT03128476|DIETARY_SUPPLEMENT|Placebo (Energy matched)|
57936837|NCT01820936|DRUG|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
57936838|NCT01820936|DRUG|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
57936839|NCT01820936|DRUG|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
57936840|NCT01820936|DRUG|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
58292115|NCT02532257|BIOLOGICAL|Rituximab|Given IV
57730121|NCT01088451|DRUG|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
57936841|NCT01820936|DRUG|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
57936842|NCT03966781|PROCEDURE|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
57936843|NCT03966781|PROCEDURE|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
57936844|NCT03966781|PROCEDURE|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
57936845|NCT03966781|PROCEDURE|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
57730122|NCT04054583|OTHER|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
57730123|NCT04076228|DRUG|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
57730124|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
57936846|NCT00294242|PROCEDURE|membrane sweeping|
57936847|NCT02274181|DRUG|Androxal|
58095148|NCT01278446|OTHER|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
58095149|NCT01534429|PROCEDURE|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
58292116|NCT01345656|DRUG|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
58095150|NCT02091388|DRUG|LY03004|
57730125|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
57730126|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
58095151|NCT02091388|DRUG|Risperdal® Consta®|
58292117|NCT01345656|DRUG|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
58292118|NCT01345656|DRUG|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
58292119|NCT01345656|DRUG|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
58292120|NCT01345656|DRUG|Placebo|Placebo tablets for duration of 4 weeks
58292121|NCT01345656|DRUG|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
58292122|NCT05680077|DIAGNOSTIC_TEST|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
58404255|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
58404256|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
58073030|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
58073031|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
58073032|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
58073033|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
58073034|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
58073035|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
58073036|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
58073037|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
58073038|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
58073039|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
58073040|NCT06268288|DEVICE|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
58292123|NCT01326247|OTHER|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
58292124|NCT02235181|DEVICE|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
58404257|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
58404258|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
58404259|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
57936848|NCT02650336|DRUG|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
57936849|NCT05495139|DEVICE|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
57936850|NCT00273936|DRUG|AVN-944 capsules for oral administration|
58404260|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
58404261|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
57936851|NCT03189862|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
57936852|NCT04249323|DRUG|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
58404262|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
58404263|NCT01953549|PROCEDURE|physical fitness training|
58404264|NCT01953549|PROCEDURE|relaxation|
58404265|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
58404266|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
58404267|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
58404268|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
58404269|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
58073041|NCT06268288|OTHER|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
58404270|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
58404271|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
58292125|NCT02879955|OTHER|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
58292126|NCT02879955|OTHER|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
58292127|NCT02879955|OTHER|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
58292128|NCT02879955|OTHER|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
58404272|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
58404273|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
58404274|NCT01118520|DRUG|placebo|one daily
58404275|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
58404276|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
58404277|NCT05827549|DRUG|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
58404278|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
58404279|NCT06315283|DRUG|Oral olanzapine|Administered orally
58404280|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
58404281|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
58404282|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
58073042|NCT03398759|DRUG|Butorphanol|IV injection during induction
58404283|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
58073043|NCT03398759|DRUG|Placebos|IV injection during induction
58073044|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
58073045|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
58073046|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
58292129|NCT03821766|DEVICE|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
58292130|NCT00334087|BEHAVIORAL|feeding habits|
58292131|NCT03131726|DRUG|Simvastatin 40mg|see arm description
58292132|NCT00734708|DRUG|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
58404284|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
57936853|NCT04249323|DRUG|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
57936854|NCT04249323|DRUG|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
57936855|NCT05107804|OTHER|Exercise+CR|Exercise with caloric-restriction
57936856|NCT05107804|OTHER|Light Conditioning|Light Conditioning Exercise
57936857|NCT05365555|PROCEDURE|Fascia Iliaca Compartment Block|Blind technique.
57936858|NCT05365555|PROCEDURE|Femoral Nerve Block|Ultrasound guided.
58073047|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
58073048|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
58404285|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
58404286|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
58404287|NCT01588314|DRUG|placebo|compounded placebo capsules
57730127|NCT04418882|OTHER|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
57936859|NCT05365555|DRUG|Ropivacaine|Ropivacaine dosed according to local guidelines.
57936860|NCT01924013|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
57936861|NCT01924013|DIETARY_SUPPLEMENT|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
57936862|NCT06316245|OTHER|DASI questionnaire|All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
57730128|NCT04686903|PROCEDURE|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
57936863|NCT04749966|OTHER|This is an observational study, there are no interventions|This is an observational study, there are no interventions
58073049|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
58073050|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
58292133|NCT00734708|DRUG|Placebo|Control
58404288|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
58404289|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
58404290|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
58073051|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
58073052|NCT02701933|DRUG|Saline|Saline, intravenous infusion
58073053|NCT05111652|OTHER|observational|observational electromiographic musculature activation
58073054|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
58404291|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
57936864|NCT03623451|DRUG|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
57936865|NCT04184492|DRUG|GP-40081|biphasic insulin aspart 30 in doses 0.4 IU/kg
57936866|NCT04184492|DRUG|NovoMix® 30 Penfill®|biphasic insulin aspart 30 in doses 0.4 IU/kg
57936867|NCT05740033|PROCEDURE|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
57936868|NCT05740033|PROCEDURE|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
57936869|NCT03694613|OTHER|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
57936870|NCT05458050|DEVICE|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
58073055|NCT04075903|BEHAVIORAL|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
58073056|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
58292134|NCT03212859|BEHAVIORAL|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
57936871|NCT03452293|DEVICE|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
58073057|NCT06677086|DEVICE|Treatment with BTL-899|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
58073058|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58073059|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
58073060|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
58073061|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
58073062|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
57936872|NCT01398865|PROCEDURE|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
57936873|NCT05867082|OTHER|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
57936874|NCT00625352|DRUG|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
57936875|NCT01851278|DRUG|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
57936876|NCT01851278|DRUG|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
57936877|NCT00119145|DRUG|artesunate-amodiaquine|
57936878|NCT00119145|DRUG|coartem|
57936879|NCT00119145|DRUG|artesunate-lapdap|
57936880|NCT03742635|OTHER|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
57936881|NCT01165372|DRUG|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
57936882|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
57936883|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
57936884|NCT03540082|OTHER|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
57936885|NCT03540082|OTHER|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
57936886|NCT04429906|DEVICE|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
57936887|NCT01347775|DEVICE|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
57936888|NCT01347775|DEVICE|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
57936889|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
57936890|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
57936891|NCT04374409|DIETARY_SUPPLEMENT|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
57936892|NCT04374409|DIETARY_SUPPLEMENT|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
58404292|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
57936893|NCT06241807|DRUG|Camrelizumab Plus Chemotherapy|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
57936894|NCT01627002|BIOLOGICAL|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
57936895|NCT01627002|OTHER|Placebo|Subcutaneous
58292135|NCT03212859|BEHAVIORAL|Usual Care|"Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context."
58404293|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
58404294|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
58073063|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
58073064|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
58073065|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
58073066|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
58073067|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
57730129|NCT04686903|PROCEDURE|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
57730130|NCT04686903|PROCEDURE|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
57730131|NCT05978882|PROCEDURE|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
58073068|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
58073069|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
58073070|NCT04362514|BEHAVIORAL|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
58292136|NCT02299388|DRUG|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
57730132|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
57936896|NCT02525250|PROCEDURE|Realization of 3 Blood samples during study during treatment with lenalidomide|
57936897|NCT00099996|DRUG|SCH-58235|
57730133|NCT05631795|DRUG|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
57936898|NCT00099996|DRUG|Ezetimibe|
57936899|NCT00789880|DRUG|Vitamin D3|Administration of oral vitamin D3 at 4000IU
57936900|NCT00789880|DRUG|Placebo|Administration of oral Vitamin D3 placebo
57936901|NCT02048618|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
57936902|NCT02048618|DRUG|Placebo|placebo oral tablets, intake once daily for 20 weeks
57936903|NCT01274936|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
57936904|NCT01274936|DRUG|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
57936905|NCT00188565|DRUG|Celecoxib|
57936906|NCT05793138|BEHAVIORAL|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
57936907|NCT05793138|BEHAVIORAL|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
57936908|NCT02231463|OTHER|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
57936909|NCT02231463|OTHER|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
57936910|NCT02231463|OTHER|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
57936911|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
57936912|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
57936913|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
57936914|NCT00061165|BEHAVIORAL|School + family changes promoting healthy eating + activity|
58073071|NCT04362514|OTHER|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
58073072|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
57936915|NCT01191372|DRUG|placebo control|sterile saline for injection
57936916|NCT01191372|DRUG|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
57936917|NCT00791258|DRUG|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
57936918|NCT00791258|DRUG|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
57936919|NCT02762279|OTHER|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
57936920|NCT04924712|OTHER|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
57936921|NCT03911973|DRUG|Gedatolisib|Gedatolisib, 150-180MG IV
57936922|NCT03911973|DRUG|Talazoparib|.75-1.00mg
57936923|NCT01212653|DRUG|Simponi|Golimumab 50mg monthly
58073073|NCT01304576|OTHER|MRI|Cerebral MRI
58073074|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
58073075|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
58073076|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
58073077|NCT01074320|OTHER|Other|Observational study
57936924|NCT01212653|OTHER|0.9ml sodium chloride|0.9ml sodium chloride
58073078|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
58404295|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
57936925|NCT03932734|OTHER|survey|Face-Q conversion table
57936926|NCT03601936|DEVICE|Evivo Infant Gut Bifidobacterium Screening Test|Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
58073079|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
58073080|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
58073081|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
58404296|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
57936927|NCT00245544|DRUG|MK0759|
57936928|NCT05525728|OTHER|Neurosensory|Physiological and neurophysiological investigations
57936929|NCT06424951|BEHAVIORAL|LKCM(Loving-kindness and Compassion Meditations)|Loving-kindness and Compassion Meditations
57936930|NCT01805960|BIOLOGICAL|Canakinumab|
57936931|NCT01805960|BIOLOGICAL|Placebo|
57936932|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
58292137|NCT00595543|DRUG|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
58404297|NCT05678205|DRUG|AB-201|NK Cell Therapy
58404298|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
57936933|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
58073082|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
58073083|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
58073084|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
58073085|NCT01974310|PROCEDURE|Postoperative face-down positioning|
58095152|NCT06702657|DEVICE|Intracranial stent|Group A: Subjects will be given direct balloon dilatation and stenting immediately plus medical therapy after randomization
58095153|NCT06702657|DRUG|Tirofiban and antiplatelet drug|Subjects will continue to use tirofiban after randomization, and changed to antiplatelet drug treatment after 24-36 hours
58073086|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
58073087|NCT00899327|GENETIC|DNA methylation analysis|
58073088|NCT00899327|GENETIC|RNA analysis|
58073089|NCT00899327|GENETIC|cytogenetic analysis|
58073090|NCT00899327|GENETIC|gene expression analysis|
58404299|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
57936934|NCT01648894|PROCEDURE|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
58404300|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
57936935|NCT01648894|PROCEDURE|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
57936936|NCT02638350|DEVICE|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
57936937|NCT02742753|OTHER|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
57936938|NCT00348920|PROCEDURE|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
57936939|NCT03497806|BIOLOGICAL|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
57936940|NCT00300768|DRUG|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
57936941|NCT00300768|DRUG|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
57936942|NCT00300768|DRUG|4 mg moxidectin|Single dose, tablets encapsulated for blinding
57936943|NCT00300768|DRUG|8 mg moxidectin|single dose, tablets encapsulated for blinding
57936944|NCT01773642|BEHAVIORAL|Cognitive behavioral intervention to support pediatric HIV disclosure|
57936945|NCT04215614|DRUG|Lidocaine and Bupivacaine solution|1:1 ratio 2% lidocaine, and 0.5% bupivacaine
58073091|NCT00899327|GENETIC|mutation analysis|
58292138|NCT00595543|DRUG|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
58292139|NCT00595543|DRUG|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
58292140|NCT00002295|DRUG|Inosine pranobex|
57936946|NCT04215614|DEVICE|Costoclavicular block|Ultrasound-guided costoclavicular brachial plexus block
57936947|NCT04215614|DEVICE|Lateral Sagittal block|Ultrasound-guided lateral sagittal brachial plexus block
57936948|NCT03217942|DRUG|NGF|Intramuscular injection
57936949|NCT05989698|DEVICE|C-mo System|Patients will use C-mo System for a period of 24h, to assess cough characteristics.
57936950|NCT05178550|DRUG|Heparin|intravenous \[iv\] injection
57936951|NCT04654481|DEVICE|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
57936952|NCT04654481|OTHER|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
57936953|NCT06363279|OTHER|Conducting questionnaires|The questionnaires will be administered online or in person.
57936954|NCT06252259|BEHAVIORAL|Choose to Move|As described under study arm description
57936955|NCT02822950|DRUG|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
57936956|NCT01657097|DRUG|INCS|
57936957|NCT01657097|DRUG|Placebo|
58073092|NCT00899327|GENETIC|polymerase chain reaction|
58073093|NCT00899327|GENETIC|protein expression analysis|
58073094|NCT00899327|OTHER|laboratory biomarker analysis|
58073095|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
58073096|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
58073097|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
57936958|NCT03752775|DEVICE|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
57936959|NCT04221698|OTHER|Gait retraining|5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
57936960|NCT06428487|DRUG|Prolgolimab|Prolgolimab infusions 1 mg/kg
57936961|NCT03391206|DIAGNOSTIC_TEST|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
57936962|NCT06417112|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|All participants have been referred for a transthoracic echocardiogram by a clinician.
57936963|NCT00757536|PROCEDURE|Encircling Band|ppVE and encircling band
57936964|NCT00757536|PROCEDURE|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
58073098|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
58073099|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
58073100|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
58073101|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
58073102|NCT06724003|OTHER|Computer-based virtual reality simulation|The computer-based virtual practice simulation was created as a single scenario for oral care practice in the unconscious patient. The scenario software was created and designed by the researcher who is an IT specialist. In the formation phase of the scenario, the software was realized by working together with the researcher, the expert faculty member, the nurse and the informatics specialist for the photographs required for the virtual reality application and the steps of the scenario software.
57936965|NCT05913310|DRUG|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
57936966|NCT05913310|DRUG|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
57936967|NCT01132612|DRUG|AIN457|AIN457A 150 mg powder for solution
58073103|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
58073104|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
58073105|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
57730134|NCT05631795|DRUG|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
57730135|NCT03815851|DEVICE|prophylactic drainage|place prophylactic drainage after surgery
57936968|NCT01132612|DRUG|Placebo|Placebo to AIN457A 150 mg powder for solution
57936969|NCT02801955|PROCEDURE|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
58073106|NCT00091039|DRUG|carboplatin|
58073107|NCT00091039|DRUG|paclitaxel|
58073108|NCT00091039|RADIATION|radiation therapy|
58073109|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
58073110|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
58073111|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
58073112|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
58073113|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
58073114|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
58073115|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
58095154|NCT06702657|DEVICE|Intracranial stent|Group B: Randomization is not required and the patient will be enrolled in a registered cohort study and given immediate balloon dilatation and stenting
57936970|NCT02801955|PROCEDURE|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
57936971|NCT01091584|DEVICE|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
58073116|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
58292141|NCT05704270|BEHAVIORAL|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
58404301|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
57936972|NCT05149027|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
57936973|NCT03873766|DRUG|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
58404302|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
57936974|NCT03873766|PROCEDURE|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
57936975|NCT03873766|PROCEDURE|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
58404303|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
58404304|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
57936976|NCT03873766|PROCEDURE|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (\>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
58073117|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
58073118|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
58073119|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
58073120|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
57730136|NCT03815851|DEVICE|no prophylactic drainage|Not place prophylactic drainage after surgery
57730137|NCT03704818|DRUG|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
58073121|NCT04676022|DEVICE|WaveWriter|To receive Spinal Cord Stimulation programming
58404305|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
58404306|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
58404307|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
58404308|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
58404309|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
58404310|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
57936977|NCT03873766|RADIATION|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
57936978|NCT03873766|OTHER|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
58292142|NCT05704270|BEHAVIORAL|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
58292143|NCT03225677|PROCEDURE|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
58292144|NCT04530669|DEVICE|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
58404311|NCT01818258|DRUG|ZDV+3TC+LPV/r|
58404312|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
58404313|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
57936979|NCT03873766|RADIATION|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
57936980|NCT03873766|BEHAVIORAL|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
57936981|NCT05010850|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
57936982|NCT05010850|PROCEDURE|Stoma Creation|Protective ileostomy
58073122|NCT04676022|OTHER|Conventional Medical Managament|To receive conventional medical management
58095155|NCT03237481|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
58095156|NCT03237481|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
58292145|NCT04530669|OTHER|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
58404314|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
58404315|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
58404316|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
57730138|NCT03704818|DRUG|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
58095157|NCT03237481|DRUG|Saline placebo|Saline placebo by instillation
58292146|NCT03580161|OTHER|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292147|NCT03580161|OTHER|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292148|NCT03580161|OTHER|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292149|NCT03580161|OTHER|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292150|NCT03580161|OTHER|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292151|NCT03580161|OTHER|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292152|NCT03580161|OTHER|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
58292153|NCT00532532|DRUG|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
58292154|NCT00532532|DRUG|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
58292155|NCT00532532|DRUG|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
58292156|NCT05646030|DIAGNOSTIC_TEST|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
58292157|NCT05646030|DIAGNOSTIC_TEST|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
58292158|NCT05646030|DIAGNOSTIC_TEST|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
58292159|NCT01588158|DRUG|Acetaminophen|325 mg
58292160|NCT01588158|DRUG|Vicodin|Vicodin 5/325 mg
58292161|NCT02454348|DRUG|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
58292162|NCT02454348|DRUG|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
58292163|NCT03503110|OTHER|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
57730139|NCT02320604|DRUG|Administration of study drug|i.v. administration of Ambisome in two different dossages
58095158|NCT03237481|DEVICE|Luer-lock applicator|Applicator for instillation
58292164|NCT03503110|OTHER|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
58292165|NCT05587894|DRUG|Paxlovid 5 days|"Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19."
58292166|NCT05587894|DRUG|Paxlovid 10 days|Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
58292167|NCT05587894|DRUG|Veklury|"Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound."
57730140|NCT05032703|DEVICE|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
57730141|NCT01617421|BEHAVIORAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
58095159|NCT03237481|DEVICE|Vial access device|Device for withdrawal of drug product
58095160|NCT06666517|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Routine surgery after neoadjuvant chemotherapy for breast cancer according to current guidelines.
58292168|NCT03576274|BEHAVIORAL|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
57936983|NCT01473342|BEHAVIORAL|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
57936984|NCT00411125|DRUG|Oral salmon calcitonin|
57936985|NCT04224844|OTHER|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
57936986|NCT04224844|OTHER|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
57936987|NCT05805943|DRUG|IMM0306|IMM0306 is an bi-specific antibody
57936988|NCT02934997|OTHER|Observational study|
57936989|NCT04636424|OTHER|assesment of gait|speed and weight distribution during gait
57936990|NCT01188720|BEHAVIORAL|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
57936991|NCT05571748|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
57936992|NCT05571748|OTHER|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
57936993|NCT05619302|DRUG|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
57936994|NCT02663050|OTHER|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
57936995|NCT02663050|DRUG|NSAID's|twice a daily
57936996|NCT01145716|PROCEDURE|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
57936997|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
57936998|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
57936999|NCT00909233|DRUG|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
57937000|NCT02361827|PROCEDURE|Embryo transfer|For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
57937001|NCT01377064|BEHAVIORAL|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
57937002|NCT01377064|OTHER|Standard Care Group|No intervention, the group will be followed under their standard medical care.
57937003|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions|Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.
57937004|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions using intraoral scanners|Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
57937005|NCT04299191|DRUG|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
57937006|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
57937007|NCT00393952|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
57937008|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
57937009|NCT00393952|DRUG|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
58292169|NCT03576274|BEHAVIORAL|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
58292170|NCT03576274|BEHAVIORAL|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
58292171|NCT00256009|DRUG|Cytotec|
58292172|NCT00540397|DRUG|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
58073123|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
58073124|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
58292173|NCT01265394|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
58292174|NCT01680809|DEVICE|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
58292175|NCT01680809|DEVICE|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
58292176|NCT03156257|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
58292177|NCT04265222|DEVICE|Hipcheck Software|Software
58292178|NCT04265222|OTHER|Conventional Fluoroscopy|Conventional Fluoroscopy
58490992|NCT03924167|BEHAVIORAL|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
58490993|NCT01885585|DRUG|Apixaban|
57937010|NCT00393952|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
57937011|NCT02308631|PROCEDURE|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
57937012|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Photon Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
57937013|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Proton Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).
57937014|NCT06392295|DRUG|Androgen Deprivation Therapy|Androgen deprivation therapy will be administered as per standard of care.
57937015|NCT06392295|DRUG|Androgen Receptor Signaling Inhibitor|Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
57937016|NCT06018818|DEVICE|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
57937017|NCT06116227|DEVICE|Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.|Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.
57937018|NCT06116227|OTHER|Conventional Physical Therapy Exercise Program.|The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
57937019|NCT03385720|PROCEDURE|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
57937020|NCT03385720|PROCEDURE|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
57937021|NCT03056560|BEHAVIORAL|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
57937022|NCT01145014|DRUG|BI 660848|2 mg oral drinking solution
57937023|NCT01145014|DRUG|BI 660848|10 mg oral drinking solution
57937024|NCT01145014|DRUG|BI 660848|20 mg oral drinking solution
57937025|NCT01145014|DRUG|BI 660848|50 mg oral drinking solution
57937026|NCT01145014|DRUG|BI 660848|100 mg oral drinking solution
57937027|NCT01145014|DRUG|BI 660848|150 mg oral drinking solution
57937028|NCT01145014|DRUG|BI 660848|200 mg oral drinking solution
57937029|NCT01145014|DRUG|BI 660848|400 mg oral drinking solution
57937030|NCT01145014|DRUG|BI 660848|600 mg oral drinking solution
57937031|NCT01145014|DRUG|BI 660848|10,0 mg immediate release tablet
57937032|NCT01145014|DRUG|BI 660848|50,0 mg immediate release tablet
57937033|NCT01145014|DRUG|Placebo|matching placebo (oral drinking solution and IR tablets)
57937034|NCT03812484|BEHAVIORAL|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
57937035|NCT03812484|BEHAVIORAL|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
57937036|NCT01321359|DRUG|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
58073125|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
58073126|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
58073127|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
58073128|NCT02833779|OTHER|Individual exercises|
58073129|NCT02833779|OTHER|Group exercises|
58073130|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
58073131|NCT02618681|OTHER||
58073132|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
58073133|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
58073134|NCT00133276|OTHER|Placebo|
58073135|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
58073136|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
58073137|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
58073138|NCT02224495|BEHAVIORAL|Structured exercise training|
58073139|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
58073140|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
58073141|NCT03276858|DRUG|CRN00808|Investigational drug
58073142|NCT03276858|DRUG|Placebo Oral Solution|Placebo
58073143|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
58073144|NCT03276858|DRUG|Placebo oral capsule|Placebo
58073145|NCT04001790|BEHAVIORAL|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
58073146|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
58073147|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
58073148|NCT01617161|RADIATION|Proton Beam Therapy|5 days per week up to 9 weeks
58073149|NCT01617161|RADIATION|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
58073150|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
58073151|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
58073152|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
58073153|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
58292179|NCT01104883|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
58490994|NCT06514495|OTHER|Therapy|Cognitive behavioral psychotherapy with exposure
58490995|NCT00704119|DRUG|RhuDex®|"* Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
58073154|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
58292180|NCT01104883|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
58404317|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
58292181|NCT03425318|DEVICE|CNAP|Application of CNAP in patients with ARDS
58292182|NCT02665819|OTHER|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
58292183|NCT05423457|BEHAVIORAL|Vegan diet|The participants were advised to eat foods in their original type.
58292184|NCT02370511|DEVICE|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
58292185|NCT02404402|OTHER|LED|Low Level Light Therapy
58292186|NCT02404402|OTHER|sham LED|Inactive (sham) LED treatment
58292187|NCT02576977|BIOLOGICAL|Pembrolizumab|pembrolizumab 200 mg IV infusion
58292188|NCT02576977|DRUG|Pomalidomide|pomalidomide 4 mg capsules
58292189|NCT02576977|DRUG|Dexamethasone|dexamethasone 40 mg tablets
58292190|NCT04298827|OTHER|Unimodal|Patients will receive physical therapy alone.
58404318|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
58404319|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
58404320|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
58404321|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
58292191|NCT04298827|OTHER|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
58292192|NCT04870021|BIOLOGICAL|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
58404322|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
58404323|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
58404324|NCT01858805|PROCEDURE|esophagectomy|
57730142|NCT03973190|PROCEDURE|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
58404325|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
58404326|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
58404327|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
58292193|NCT04870021|BEHAVIORAL|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
58292194|NCT00228839|DRUG|Infliximab|
58292195|NCT04655326|BIOLOGICAL|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
58292196|NCT05851573|BEHAVIORAL|Psychosocial intervention|an SLP-administered 5-week treatment focused on psychological well-being
58292197|NCT02633943|OTHER|Safety and efficacy assessments|"Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study."
58404328|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
58073155|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
58095161|NCT06666517|OTHER|Immunohistochemistry Analysis|Determination of breast cancer subtypes through immunohistochemical analysis, and selection of Luminal B, HER2-positive, and triple-negative groups.
58292198|NCT00787163|PROCEDURE|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
58404329|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
58404330|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
58404331|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
58404332|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
58404333|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
58404334|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
58404335|NCT04834154|BEHAVIORAL|Control group|Wait list control
58404336|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
58095162|NCT06666517|PROCEDURE|Second Biopsy|Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
58292199|NCT05661019|OTHER|Obtain Myotrace measurements|Myotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
58292200|NCT04398940|DRUG|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
58292201|NCT05205499|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
58292202|NCT02196298|DEVICE|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
58292203|NCT02196298|OTHER|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
58292204|NCT01218815|PROCEDURE|IRA stenting in culprit lesion only|stenting
58292205|NCT01218815|PROCEDURE|IRA stenting|Complete IRA revascularization
58292206|NCT03602716|DEVICE|HD-tDCS|HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
58292207|NCT03602716|DEVICE|Sham HD-tDCS|HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
58292208|NCT02503241|PROCEDURE|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
58292209|NCT02503241|PROCEDURE|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
58292210|NCT02933398|PROCEDURE|Robotic Assisted Nephrectomy|Robotic (Davinci)
58292211|NCT02933398|PROCEDURE|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
58292212|NCT03320265|DRUG|PC-mAb|Monthly treatment for 3 months (4 administrations)
58292213|NCT03320265|DRUG|Placebo|Monthly treatment for 3 months (4 administrations)
58292214|NCT01653457|DRUG|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily"
58292215|NCT01653457|DRUG|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
58404337|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
58404338|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
58404339|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
58404340|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
58292216|NCT04211012|DRUG|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
58292217|NCT05807035|BIOLOGICAL|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
58292218|NCT05572021|DEVICE|Propspective VHR with Fortiva|Ventral hernia repair using Fortiva biologic mesh
58292219|NCT05572021|DEVICE|RetroSpective VHR with Strattice|Retrospective cohort of ventral hernia repair patients using Strattice mesh
58073156|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
58073157|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
58073158|NCT02778477|OTHER|Placebo|Multiple dose of placebo
58073159|NCT05548582|DRUG|OxyCODONE 5 mg Oral Tablet|No opioid prescription after laparoscopic hysterectomy
58073160|NCT05548582|DRUG|Acetaminophen 500 mg Tab|Standard prescription
58292220|NCT00622102|BEHAVIORAL|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
58292221|NCT00622102|BEHAVIORAL|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
57937037|NCT06190236|BEHAVIORAL|Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder|CBT4CBT is a 7-module web-delivered program based on CBT, an evidence-based behavioral treatment for alcohol use disorder (AUD).
58073161|NCT05548582|DRUG|Ibuprofen 600 mg|Standard prescription
58073162|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
58073163|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
58073164|NCT01054443|DRUG|Placebo|Tablet
58073165|NCT01054443|DRUG|Lusutrombopag|Tablet
58292222|NCT00673257|OTHER|pharmacological study|pharmacological studies
58292223|NCT00673257|PROCEDURE|dual x-ray absorptimetry|
58292224|NCT00301457|DRUG|Anastrozole|1 mg once daily oral dose
58292225|NCT02141191|DRUG|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
58292226|NCT03030677|PROCEDURE|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
58073166|NCT03102541|OTHER|None intervention|
58073167|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
58073168|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
58073169|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
58073170|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
58073171|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
58073172|NCT00042575|DRUG|Duloxetine|
58073173|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
58404341|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
58404342|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
57937038|NCT03970850|DIAGNOSTIC_TEST|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
58073174|NCT02528149|OTHER|blood sample|
58490996|NCT02100696|DRUG|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
58292227|NCT03030677|PROCEDURE|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
58292228|NCT03030677|OTHER|catheter insertion|catheter insertion after Lidocaine dissection
58292229|NCT04959409|DRUG|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
58292230|NCT01945983|DRUG|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
58292231|NCT01945983|DRUG|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
58404343|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
58404344|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
58404345|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
58404346|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
58404347|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
58404348|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
58292232|NCT04407039|DEVICE|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
58292233|NCT00873717|OTHER|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
58292234|NCT00873717|OTHER|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
58292235|NCT00873717|OTHER|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
58292236|NCT02437994|BEHAVIORAL|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
58404349|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
58404350|NCT05419128|BEHAVIORAL|ACHESS|ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
58404351|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
58404352|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
58404353|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
58292237|NCT03560011|DRUG|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
58292238|NCT01673178|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
58292239|NCT01673178|DRUG|25 mg PF-05231023|25 mg IV once a week for 4 weeks
58292240|NCT01673178|DRUG|50 mg PF-05231023|50 mg IV once a week for 4 weeks
58292241|NCT01673178|DRUG|100 mg PF-05231023|100 mg IV once a week for 4 weeks
58292242|NCT01673178|DRUG|150 mg PF-05231023|150 mg IV once a week for 4 weeks
58404354|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
57937039|NCT03970850|DIAGNOSTIC_TEST|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
57937040|NCT03819036|OTHER|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
58292243|NCT03289988|OTHER|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
58292244|NCT00968955|DRUG|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
58292245|NCT06149572|PROCEDURE|lateral position procedure|Lateral positioning will be used as an intervention for spinal hypotension.
58292246|NCT06149572|PROCEDURE|sitting position porocedure|parturients will get spinal punctures in the sitting position
58292247|NCT01084057|DRUG|vorinostat|Given orally
58292248|NCT01084057|DRUG|ixabepilone|Given IV
58404355|NCT04363697|DRUG|Placebo|Matched placebo
58404356|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
58404357|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
58404358|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
58404359|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
58404360|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
58404361|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
58404362|NCT01183052|OTHER|Training|20 sessions of training
58404363|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
58073175|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
58073176|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
58073177|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
58073178|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
58073179|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
58404364|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
58404365|NCT00813865|DRUG|afegostat tartrate|
58404366|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
58404367|NCT02370485|DRUG|LY2801653|Administered orally
57937041|NCT00844207|DRUG|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
58073180|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
58073181|NCT03025295|DRUG|Saline|It is safe Placebo.
58073182|NCT00145080|BEHAVIORAL|Disease Management Assessment|
58404368|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
58404369|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
58404370|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
58404371|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
58404372|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
58404373|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
58490997|NCT02100696|DRUG|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
58292249|NCT01084057|OTHER|laboratory biomarker analysis|Correlative studies
58292250|NCT01084057|OTHER|pharmacological study|Correlative studies
58292251|NCT06092528|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
58292252|NCT06092528|OTHER|Upper extremity aerobic exercise training|Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
58292253|NCT06092528|OTHER|Lower extremity aerobic exercise training|Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
57937042|NCT00844207|DRUG|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
57937043|NCT05747508|COMBINATION_PRODUCT|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
57937044|NCT05747508|COMBINATION_PRODUCT|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
57937045|NCT05747508|COMBINATION_PRODUCT|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
58073183|NCT05602818|DRUG|Soticlestat 300 mg|Administered orally.
58073184|NCT05602818|DRUG|Soticlestat 600 mg|Administered orally.
58292254|NCT06092528|OTHER|Resistant exercise training|Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
58292255|NCT06092528|OTHER|Thoracic expansion exercises|The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
58292256|NCT00003197|DIETARY_SUPPLEMENT|green tea extract|
58292257|NCT00837967|DRUG|Symbicort Turbuhaler|160/4.5μg for 3 days
58292258|NCT00837967|DRUG|Terbutaline Turbuhaler|0.4 mg for 3 days
58292259|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
58292260|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
58292261|NCT04110314|BEHAVIORAL|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
58292262|NCT05844332|OTHER|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
58292263|NCT04959799|DRUG|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
58292264|NCT02872233|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58292265|NCT02872233|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58292266|NCT00463918|DRUG|varenicline|
58292267|NCT02477878|BIOLOGICAL|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
58292268|NCT02477878|DRUG|Rimiducid|Rimiducid administered to treat GVHD
58292269|NCT00292708|DRUG|Cefmetazole (drug)|
58292270|NCT04666545|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
58292271|NCT02546128|DEVICE|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
58292272|NCT02546128|OTHER|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
57937046|NCT04373681|OTHER|patient-administered questionnaires|patient-administered questionnaires
58073185|NCT05602818|DRUG|Soticlestat 900 mg|Administered orally.
58073186|NCT05602818|DRUG|Alprazolam|Administered orally.
58073187|NCT05602818|DRUG|Placebo|Administered orally.
58073188|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
58073189|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
58073190|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
58073191|NCT00212082|DRUG|doxorubicin, docetaxel|
58073192|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
58073193|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
58073194|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
57730143|NCT03973190|PROCEDURE|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
57937047|NCT00763230|DEVICE|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
57937048|NCT03341572|OTHER|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
58073195|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
58292273|NCT05116371|DRUG|150 mcg levonorgestrel/30 mcg ethinyl estradiol|concurrent use of COC with Nexplanon
57937049|NCT04114188|DRUG|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
58292274|NCT01566422|DRUG|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
58292275|NCT03507985|OTHER|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
58292276|NCT02227784|DRUG|Evacetrapib|Administered orally
58292277|NCT02227784|DRUG|Atorvastatin|Administered orally
58292278|NCT02227784|DRUG|Ezetimibe|Administered orally
58292279|NCT02227784|DRUG|Placebo|Administered orally
58292280|NCT05018416|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
58292281|NCT01137487|PROCEDURE|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
58292282|NCT01137487|PROCEDURE|not monitoring of residual gastric volume|no measurements of residual gastric volume
58292283|NCT01330550|DIETARY_SUPPLEMENT|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
58292284|NCT04473872|OTHER|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
58292285|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal brushing|Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.
58292286|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal biopsy|Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
58292287|NCT03762577|OTHER|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
58292288|NCT05359211|DRUG|Cyclophosphamide|Given IV
58292289|NCT05359211|DRUG|Fludarabine|Given IV
58292290|NCT05359211|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
58292291|NCT05359211|DRUG|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Given IV
58292292|NCT05359211|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
58292293|NCT05359211|PROCEDURE|Echocardiography|Undergo ECHO
58292294|NCT05359211|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58292295|NCT05359211|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
58292296|NCT05359211|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
58292297|NCT05359211|PROCEDURE|Lumbar Puncture|Undergo LP
58292298|NCT05359211|PROCEDURE|Computed Tomography|Undergo PET/CT
58292299|NCT05359211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58292300|NCT05359211|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
58292301|NCT05359211|PROCEDURE|Biopsy|Undergo tissue biopsy
58292302|NCT04232644|DRUG|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
58292303|NCT04232644|DRUG|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
58404374|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
58404375|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
57937050|NCT00910572|DEVICE|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
58404376|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
58404377|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
58404378|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
58404379|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
58404380|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
58404381|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
58404382|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
58404383|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
58404384|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
58490998|NCT06338137|DEVICE|Holmium Yag laser|Use two laser energy low and high to reach the optimal setting for stone dusting
58490999|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
57937051|NCT02256605|DIETARY_SUPPLEMENT|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
57937052|NCT00020618|DRUG|morphine sulfate|
57937053|NCT00020618|PROCEDURE|quality-of-life assessment|
57937054|NCT06272786|PROCEDURE|conventional physiotherapy program.|It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.
58292304|NCT04664101|BEHAVIORAL|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
58292305|NCT04664101|OTHER|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
58292306|NCT02565316|DRUG|Nepeta menthoides Boiss & Bohse freeze dried extract|
58292307|NCT02565316|DRUG|Sertraline|
58292308|NCT02047370|OTHER|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
58292309|NCT02047370|OTHER|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
58292310|NCT00719160|DRUG|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
58292311|NCT00719160|DRUG|Placebo|Placebo 20 mg twice a day for 9 days
58292312|NCT05122624|OTHER|PredicTB score|"This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score."
58292313|NCT04224025|OTHER|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
58292314|NCT03592836|DRUG|Loop Diuretics|intravenous administration of diuretics
58292315|NCT00810069|DRUG|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
58292316|NCT00810069|DRUG|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
58491000|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
57730144|NCT03973190|DEVICE|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
57937055|NCT06272786|PROCEDURE|Suprascapular nerve block|Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
58404385|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
58404386|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
58404387|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
58404388|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
58292317|NCT04881214|OTHER|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
58292318|NCT01562717|DRUG|Ibuprofen|3 times a day
58404389|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
58404390|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
58404391|NCT00348699|DRUG|AFP464|Given IV
58404392|NCT00348699|OTHER|pharmacological study|Correlative studies
58404393|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
58404394|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
58404395|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
57937056|NCT01085552|DRUG|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
58292319|NCT01562717|DRUG|Placebo|3 times a day
58404396|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
58404397|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
58404398|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
58404399|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
58404400|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
57937057|NCT00521924|BIOLOGICAL|infliximab|infliximab 3 mg/kg and basic treatment
57937058|NCT00521924|DRUG|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
57937059|NCT00522054|OTHER|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
58292320|NCT03519126|OTHER|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
58292321|NCT01457417|DRUG|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
58404401|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
58404402|NCT00646321|DRUG|budesonide|
58404403|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
58404404|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
58404405|NCT01425359|DRUG|Ranolazine|
58404406|NCT01425359|DRUG|Ranolazine placebo|
58404407|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
58073196|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
58073197|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
58073198|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
58073199|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
58073200|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
58073201|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
58073202|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
58404408|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
58491001|NCT03494504|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
58404409|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
58404410|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
58404411|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
58404412|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
58404413|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
58404414|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
58404415|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
58404416|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
58404417|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
58404418|NCT04200443|DRUG|Cabozantinib|Given PO
58404419|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
58404420|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
58404421|NCT04200443|DRUG|Temozolomide|Given PO
58404422|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
58404423|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
58404424|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
58404425|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
58404426|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
58404427|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
58404428|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
58404429|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
57730145|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
57730146|NCT03663751|DRUG|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
58404430|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
58404431|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
58404432|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
58404433|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
58404434|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
58404435|NCT00790868|DRUG|d-cycloserine|50mg
58404436|NCT00790868|DRUG|placebo|50mg
58404437|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
57730147|NCT04656158|OTHER|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
57730148|NCT04691869|DEVICE|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
57937060|NCT06348550|DIETARY_SUPPLEMENT|Berberol® K|Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®
57937061|NCT06348550|DIETARY_SUPPLEMENT|Placebo|Placebo
58404438|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
58404439|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
57937062|NCT03045783|DRUG|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
57937063|NCT01440868|PROCEDURE|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
58404440|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
58404441|NCT03215758|DRUG|QAW039|QAW039 once daily
58404442|NCT03215758|DRUG|Placebo|Placebo once daily
58404443|NCT02091531|DRUG|MLN0128|
58404444|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
58404445|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
58073203|NCT05468619|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
58073204|NCT06534580|DEVICE|Virtual Reality|"A range of virtual reality software, delivered through the DR.VR (TM) device."
58292322|NCT01560026|PROCEDURE|surgery|endometrial cancer with or without oophorectomy
58292323|NCT01409187|DRUG|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
58404446|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
58404447|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
58404448|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
58404449|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
58404450|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
58404451|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
58404452|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
58404453|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
58404454|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
58404455|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
58404456|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
57937064|NCT04234165|DEVICE|TURBT|different power sources ( bipolar vs monopolar)
58073205|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
58073206|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
58073207|NCT05999773|DRUG|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
58292324|NCT01409187|DRUG|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
58292325|NCT01409187|DRUG|Interleukin-2 (Aldesleukin)|9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
58292326|NCT03052569|DRUG|RXDX-105|Oral Capsules
58292327|NCT05242302|PROCEDURE|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
58292328|NCT00939926|DRUG|Risperidone|
58404457|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
58404458|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
58404459|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
58404460|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
58404461|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
58404462|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58404463|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58404464|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
58404465|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
58404466|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
57937065|NCT01905163|PROCEDURE|Tumor Debulking Surgery by laparoscopy|
57937066|NCT04311216|OTHER|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
58073208|NCT00266617|DRUG|epoetin alfa|
58073209|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
58292329|NCT04069676|OTHER|EEG|EEG, ECG and EDR record during a behavioral task
58292330|NCT03350490|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
58292331|NCT03350490|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
58073210|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
58404467|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57937067|NCT04601623|OTHER|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
57937068|NCT06359366|PROCEDURE|perineal massage combined hip joint training|pregnant women take the lithotomy position, disinfect the vulva, and wear sterile gloves. Then thumbs, forefingers, and middle fingers dip massage oil to do a 2 minutes pressurized dilatation massage from inside to outside gently to loosen the fascia. Then rest 30s. All steps need to be repeated 2 to 3 times. When the pregnant women feel a slight sense of acidity and tingling sensation disappears, researchers sterilize the perineal body again. left side pelvic floor receives the same intervention as right. The whole process takes 15-20min, 5 times a week until delivery. Additionally, while using the pelvic floor fascia manipulation, pregnant women are instructed to perform specific movements of internal and external hip rotation, adduction and abduction, upward and downward.
57937069|NCT00544648|DRUG|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
58073211|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
58073212|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
58073213|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
58073214|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
58073215|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
58073216|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
58095163|NCT06700707|OTHER|Survey using a questionnaire.|"Permission was obtained from the original owner of the Athlete Disability Index Questionnaire (ADI) for the Turkish cultural adaptation, validity and reliability study.~120 athletes, determined by the number of questions times the rule of 10, will be asked to fill out the ADI, Oswestry Disability Index (ODI), and Roland-Morris Disability (RMDQ) questionnaires and 60 athletes will be asked to fill out the ADI questionnaire again 7 days later for test-retest reliability."
58404468|NCT01572363|DRUG|Sildenafil|50 mg once
58404469|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
58404470|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
57937070|NCT00544648|DRUG|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
57937071|NCT00544648|RADIATION|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
57937072|NCT06267170|DRUG|Adebrelimab|Treatment with adbelizumab
58404471|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
58404472|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
58404473|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
58404474|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
58404475|NCT00656188|DRUG|Placebo|Matching placebo
58404476|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
58404477|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
58404478|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
58404479|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
58404480|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
58404481|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
58404482|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
58404483|NCT00168636|DRUG|Vitamin A|
58404484|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
58404485|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
58404486|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
58292332|NCT05194345|BEHAVIORAL|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
58292333|NCT05194345|BEHAVIORAL|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
57937073|NCT05728515|DRUG|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
58292334|NCT03842904|DRUG|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
58292335|NCT03842904|DRUG|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
58292336|NCT03560063|PROCEDURE|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
58292337|NCT03560063|PROCEDURE|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
58292338|NCT03701542|DIAGNOSTIC_TEST|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
58404487|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
58404488|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
58404489|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
58404490|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
58404491|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
58404492|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
58404493|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
58404494|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
58404495|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
58404496|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
58404497|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
58404498|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
58491002|NCT04564157|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
57937074|NCT04553848|BEHAVIORAL|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
58073217|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
58404499|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
58404500|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
58404501|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
58404502|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
58404503|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
58404504|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
58404505|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
58404506|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
58404507|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
58404508|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
58404509|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
58404510|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
58404511|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
58404512|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
58404513|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
58404514|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
58404515|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
58404516|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
58404517|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
58404518|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
58404519|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
58404520|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
58404521|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
58404522|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
58404523|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
57937075|NCT04553848|BEHAVIORAL|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
57937076|NCT04553848|BEHAVIORAL|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait"
57937077|NCT05788003|DIAGNOSTIC_TEST|self-collected and operator-collected swab followed by molecular analysis|A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples.
57937078|NCT06062745|DRUG|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
57937079|NCT06062745|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
57937080|NCT00515736|DRUG|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
57937081|NCT00515736|DRUG|Placebo|vehicle
57937082|NCT01007032|BIOLOGICAL|Cixutumumab|Cixutumumab intravenously
57937083|NCT05554796|PROCEDURE|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
57937084|NCT05554796|PROCEDURE|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
57937085|NCT02705521|DEVICE|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
57937086|NCT03244410|DIAGNOSTIC_TEST|complete blood picture|complete blood picture
58404524|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
58404525|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
58404526|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
58404527|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
58404528|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
58404529|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
57937087|NCT01031550|DRUG|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
57937088|NCT01031550|DRUG|propofol|standard of care
57937089|NCT05175313|RADIATION|transthoracic ultrasonography|"1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound"
57937090|NCT05175313|DEVICE|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
57937091|NCT03138187|BEHAVIORAL|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
58292339|NCT03701542|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
58292340|NCT00329693|DRUG|Norprolac|Placebo
58292341|NCT00329693|DRUG|Norprolac|Quinagolide
58404530|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
58292342|NCT00329693|DRUG|Norprolac|Quinagolide
58292343|NCT00329693|DRUG|Norprolac|Quinagolide
58292344|NCT00130689|DRUG|Cetuximab|
58292345|NCT02128659|BEHAVIORAL|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
58292346|NCT05186584|OTHER|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
58404531|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
58404532|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
58073218|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
58073219|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
58073220|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
58073221|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
58073222|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
58404533|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
57937092|NCT03138187|BEHAVIORAL|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
57937093|NCT03856307|DIAGNOSTIC_TEST|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
57937094|NCT05467215|DRUG|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
57937095|NCT05035576|DRUG|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
57937096|NCT02748330|DRUG|Ticagrelor|Ticagrelor
57937097|NCT02748330|DRUG|Clopidogrel|Clopidogrel
57937098|NCT02748330|DRUG|Aspirin|Acetylsalicylic acid
58292347|NCT05186584|OTHER|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
58292348|NCT05013957|DIAGNOSTIC_TEST|Methylation analysis|Methylation analysis
58292349|NCT01952418|DEVICE|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
58292350|NCT04041921|PROCEDURE|Percutaneous coronary intervention|
58292351|NCT04041921|PROCEDURE|Coronary Artery Bypass Grafting|
57937099|NCT03713749|DEVICE|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
57937100|NCT05589779|OTHER|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
57937101|NCT00000387|BEHAVIORAL|Self-management therapy|Behavioral
57937102|NCT00000387|BEHAVIORAL|Self-management therapy|
58292352|NCT04041921|DRUG|Medical treatment|
58292353|NCT06161714|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
58292354|NCT06161714|DRUG|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
58292355|NCT00305669|BIOLOGICAL|sargramostim|
58292356|NCT00305669|OTHER|immunohistochemistry staining method|
58292357|NCT00305669|OTHER|immunological diagnostic method|
58292358|NCT00305669|OTHER|laboratory biomarker analysis|
58292359|NCT00305669|PROCEDURE|conventional surgery|
58292360|NCT00305669|PROCEDURE|neoadjuvant therapy|
58073223|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
58073224|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
58292361|NCT02794688|PROCEDURE|Ductal lavage therapy|"1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (\>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
58292362|NCT04252885|DRUG|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
58292363|NCT04252885|DRUG|Arbidol|As indicated in arm/group descriptions
58491003|NCT04564157|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
57937103|NCT02380950|BEHAVIORAL|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
57937104|NCT06474910|OTHER|Connective tissue massage|In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
57937105|NCT06474910|OTHER|Exercise|Only exercise program will be applied to 15 patients in this group. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
57937106|NCT01704040|DRUG|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
57937107|NCT01704040|DRUG|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
57937108|NCT01704040|DRUG|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
58073225|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
58073226|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
58073227|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
58292364|NCT02187003|DRUG|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
58292365|NCT02187003|OTHER|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
58073228|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
58073229|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
58073230|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
58292366|NCT02962232|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
57937109|NCT01704040|DRUG|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
58292367|NCT02962232|DEVICE|PTA catheter|control group
58292368|NCT00720070|PROCEDURE|positron emission tomography/computed tomography|Patients undergo PET/CT scan
58292369|NCT00720070|PROCEDURE|therapeutic conventional surgery|Patients undergo neck dissection
57937110|NCT01704040|OTHER|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
58073231|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
58073232|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
57937111|NCT02163187|DEVICE|Implantation of the InterStimTM|
58073233|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
58292370|NCT06597292|DEVICE|Vision improvement|Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
58491142|NCT05904418|OTHER|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
57937112|NCT02163187|BEHAVIORAL|MSK BFI questionnaires|
57937113|NCT02163187|BEHAVIORAL|The Low Anterior Resection Score (LARS) questionnaires|
58073234|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
58073235|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
58073236|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
58073237|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
58073238|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
58073239|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
58073240|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
58292371|NCT00667485|DRUG|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
58292372|NCT00667485|DRUG|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
58292373|NCT00667485|DRUG|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
58292374|NCT02990130|OTHER|Observational|
58292375|NCT04351165|DRUG|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
58292376|NCT04366154|OTHER|Questionnaire|delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
58292377|NCT01407263|PROCEDURE|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.
58292378|NCT01407263|PROCEDURE|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
58292379|NCT01407263|DRUG|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
58292380|NCT01407263|DRUG|Hemostatic Agent|For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
57937114|NCT02163187|BEHAVIORAL|The EuroQOL5D questionnaires|
57937115|NCT02163187|BEHAVIORAL|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
57937116|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
57937117|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
57937118|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
57937119|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
57937120|NCT01540825|DRUG|Placebo|Powder for oral solution
57937121|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
57937122|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
57937123|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
57937124|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
57937125|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
57937126|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
57937127|NCT04475640|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
57937128|NCT04475640|OTHER|Genetic Testing|Undergo genetic testing
57937129|NCT03089242|OTHER|observation of microRNA expression|no intervention
58073241|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
58073242|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
58073243|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
58073244|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
57730149|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
58073245|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
58073246|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
58073247|NCT03642249|BEHAVIORAL|E-learning|delirium care video
58073248|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
58073249|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
58073250|NCT02442284|DRUG|Ribavirin|Tablet
58073251|NCT06065371|DRUG|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
58073252|NCT06065371|DRUG|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
57730150|NCT03873649|OTHER|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
57730151|NCT02667158|OTHER|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
58073253|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
58073254|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
58292381|NCT04888494|DEVICE|Transcranial Magnetic Stimulation|For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (\~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups
58292382|NCT04888494|DEVICE|Sham rTMS|Sham rTMS
58292383|NCT03002636|PROCEDURE|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
58292384|NCT02921945|BIOLOGICAL|SCT800|recombinant human coagulation factor VIII
58292385|NCT06473831|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
58292386|NCT01695005|DRUG|LY3039478|Administered orally
58292387|NCT01695005|DRUG|Prednisone|Administered orally
58292388|NCT04133597|DEVICE|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
58292389|NCT03364036|DRUG|Mavenclad®|Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
58292390|NCT03100656|OTHER|A breakfast sandwich|A meat-based breakfast sandwich
58292391|NCT05468983|PROCEDURE|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
58292392|NCT01909141|DRUG|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
57730152|NCT02078284|BIOLOGICAL|CPP|One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
57730153|NCT02078284|BIOLOGICAL|LSP|
57730154|NCT01140191|DRUG|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
57730155|NCT01055366|DRUG|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
57730156|NCT04986657|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
57730157|NCT00581529|RADIATION|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
57730158|NCT02106026|OTHER|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
58292393|NCT01909141|DRUG|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
57730159|NCT06496893|DIETARY_SUPPLEMENT|IP 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
57730160|NCT06496893|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
58292394|NCT01909141|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of \> 18 mm or till day 20 of the cycle
58292395|NCT01909141|OTHER|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
58292396|NCT01909141|OTHER|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
58292397|NCT01909141|OTHER|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
58292398|NCT01909141|OTHER|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
58292399|NCT01909141|OTHER|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
57730161|NCT02855099|OTHER|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
58292400|NCT01909141|OTHER|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
58292401|NCT01100723|OTHER|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
58404534|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
58404535|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
58404536|NCT05291988|OTHER|Educational Intervention|Receive S2S education
58404537|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
58073255|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
58073256|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
58404538|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
58404539|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
58404540|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
58404541|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
57730162|NCT06626191|PROCEDURE|Interscalene brachial plexus block|"Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
58073257|NCT00223158|DRUG|Liothyronine|
58073258|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
58073259|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
58073260|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
58073261|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
58073262|NCT05677373|DRUG|Trametinib|Given PO
58073263|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
58073264|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
58073265|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
58073266|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
58073267|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
58073268|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
58292402|NCT00289094|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
58292403|NCT00289094|DEVICE|Total knee replacement|Fixed Cruciate Retaining Knee System
58292404|NCT02719002|DEVICE|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
58292405|NCT01320241|DEVICE|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
58292406|NCT01320241|DEVICE|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
58073269|NCT03205605|DRUG|oxybutynin|patch
58073270|NCT03205605|DRUG|oxybutynin|gel
57937130|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
58404542|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
58404543|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
57937131|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
57937132|NCT03254654|DRUG|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
57937133|NCT03254654|DRUG|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
58292407|NCT05490355|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
58292408|NCT05490355|PROCEDURE|Perineural Steroid Injection|Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
58292409|NCT03520712|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
58292410|NCT04684563|BIOLOGICAL|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
58292411|NCT05027438|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
58292412|NCT05027438|BEHAVIORAL|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
58292413|NCT03189212|BEHAVIORAL|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
58292414|NCT03189212|BEHAVIORAL|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
58292415|NCT03072290|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
58292416|NCT03072290|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
58404544|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
58404545|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
58404546|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
58404547|NCT01606683|OTHER|No intervention|
57937134|NCT05782270|DRUG|Warfarin|dual antiplatelet therapy combined with warfarin
57937135|NCT05782270|DRUG|DAPT|Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
57937136|NCT05782270|OTHER|CE+CABG|Coronary endarterectomy combined with coronary artery bypass grafting
57937137|NCT01166503|PROCEDURE|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
58292417|NCT03540732|OTHER|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
58292418|NCT03540732|PROCEDURE|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
58292419|NCT01221558|DIETARY_SUPPLEMENT|lycopene|
58292420|NCT01745562|DRUG|Alprazolam 0.5 mg|Reference product
58292421|NCT01745562|DRUG|Alprazolam 0.5 mg|Test product
58404548|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
58404549|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
58404550|NCT02072460|OTHER|electromyography|
58404551|NCT02072460|OTHER|electroencephalography|
57937138|NCT01166503|PROCEDURE|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
57937139|NCT01166503|PROCEDURE|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
57937140|NCT01166503|PROCEDURE|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
57937141|NCT01166503|PROCEDURE|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
57937142|NCT06257771|DRUG|Alcohol (Ethanol)|Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
57937143|NCT03764371|DIAGNOSTIC_TEST|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
57937144|NCT04532736|DRUG|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
57937145|NCT04532736|DRUG|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
57730163|NCT06626191|PROCEDURE|Serratus posterior superior intercostal plane block|"Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
57730164|NCT06626191|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
58404552|NCT02072460|OTHER|approaches from psychophysics|
58404553|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
58404554|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
58404555|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
57937146|NCT04532736|DRUG|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
57937147|NCT04728022|BEHAVIORAL|Education program|Mentored high school summer research program
57937148|NCT02170779|BEHAVIORAL|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
57937149|NCT02170779|OTHER|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
57937150|NCT00972426|DRUG|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
57937151|NCT04823611|DRUG|Part A:Placebo|Placebo solution
57937152|NCT04823611|DRUG|Part A:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
58073271|NCT01977664|OTHER|no intervention|
58073272|NCT00755976|DRUG|epirubicin hydrochloride|
58073273|NCT00755976|DRUG|sulindac|
58292422|NCT04330417|DEVICE|Robot-Assisted Hand Training|Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles
58292423|NCT04330417|OTHER|Standard Hand Therapy|Stretching, Strengthening, Hand Functional Training
58292424|NCT04967105|DEVICE|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
58292425|NCT03096561|DIAGNOSTIC_TEST|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
58404556|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
58404557|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
58404558|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
58404559|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
58404560|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
58404561|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
58404562|NCT02186652|DRUG|Pantoprazole|
58404563|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
58404564|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
58404565|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
58404566|NCT01528891|OTHER|Placebo|
58404567|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
58404568|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
58404569|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
58404570|NCT06218251|DRUG|BOTOX|Intramuscular Injections
58404571|NCT04960930|DRUG|FMX101|topically once daily
58404572|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
58404573|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
58404574|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
58404575|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
58404576|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
58404577|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
58404578|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
57937153|NCT04823611|DRUG|Part B:Placebo|Placebo solution
57937154|NCT04823611|DRUG|Part B:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
57937155|NCT04823611|DRUG|Part C: Placebo|Placebo solution
58073274|NCT00755976|OTHER|immunologic technique|
58073275|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
58404579|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
58404580|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
58404581|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
57730165|NCT04108546|DEVICE|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
57730166|NCT04108546|DRUG|Epidural analgesia|Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
57730167|NCT00724347|BEHAVIORAL|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
57937156|NCT04823611|DRUG|Part C: AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
58073276|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
57937157|NCT04993794|DRUG|XueBiJing Injection|XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.
57937158|NCT04993794|DRUG|Normal saline|Same saline dose as XueBiJing injection is taken intravenously.
58073277|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
58073278|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
58073279|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
57937159|NCT00017121|BIOLOGICAL|sargramostim|
57937160|NCT04280445|OTHER|Psychological therapy|Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
57937161|NCT05148039|BEHAVIORAL|Dietician advice|Personalised dietetic advice
58073280|NCT06394414|DRUG|YL201|YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.
58073281|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
58073282|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
58073283|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
58073284|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
58292426|NCT00003471|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58073285|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
58292427|NCT05505292|DRUG|Lifitegrast 5% Ophthalmic Solution|Dosed twice a day for 8 weeks
58292428|NCT05505292|OTHER|Lifitegrast Ophthalmic Solution Vehicle|Dosed twice a day for 8 weeks
58073286|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
58073287|NCT06722729|DRUG|KDT-3594|Oral administration
58073288|NCT06722729|DRUG|Placebo|Oral administration
58404582|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
58404583|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
58404584|NCT00027365|BIOLOGICAL|NefTat|
58404585|NCT00027365|DRUG|AS02A Adjuvant|
57937162|NCT04048590|OTHER|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
57937163|NCT03617250|OTHER|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
57937164|NCT02412020|DRUG|PA101|
57937165|NCT02412020|DRUG|Placebo|
57937166|NCT01043679|DRUG|Utapine|Efficacy and Safety of Utapine
57937167|NCT01043679|DRUG|Seroquel|Efficacy and Safety of Seroquel
57937168|NCT04340557|DRUG|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
57937169|NCT04710953|DEVICE|Continuous positive airway pressure machine|CPAP device set at 6-8cmH2O for several hours
57937170|NCT00695851|DRUG|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
57937171|NCT00695851|DRUG|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
57937172|NCT01293968|DRUG|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
57937173|NCT01293968|DRUG|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
57937174|NCT04525339|PROCEDURE|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
58073289|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
58073290|NCT06510894|DRUG|Sotagliflozin|Sodium-glucose cotransporter-1/2 inhibitor
58073291|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
58292429|NCT01360346|PROCEDURE|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
58292430|NCT01360346|PROCEDURE|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
58292431|NCT06612164|OTHER|kefir|Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
58292432|NCT03407001|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
58404586|NCT00027365|BIOLOGICAL|gp120W61D|
58404587|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
58404588|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
58073292|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
58073293|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
58404589|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
58404590|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
58073294|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
58073295|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
58073296|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
58073297|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
57730168|NCT06045962|DEVICE|Ureteral stent|Used to open the ureter and help the kidney drain
58073298|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
58404591|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
58404592|NCT00537667|DRUG|anakinra|anakinra
58404593|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
58404594|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
58404595|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
58404596|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
58073299|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
58292433|NCT03407001|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
58404597|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
58404598|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
58404599|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
58404600|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
57730169|NCT05123365|DRUG|N-Acetylcysteine|Given PO
57730170|NCT00406575|DRUG|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
57730171|NCT00406575|DRUG|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
57730172|NCT02094703|DRUG|Levofloxacin|
57730173|NCT02094703|DRUG|Solifenacin succinate|
57730174|NCT02094703|DRUG|Placebo (for Solifenacin succinate)|
57730175|NCT02161744|BIOLOGICAL|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
58292434|NCT03407001|PROCEDURE|Ultrasound|Undergo non-contrast US
57937175|NCT03443128|DRUG|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
57937176|NCT00284206|DRUG|long-acting injectable risperidone|
57937177|NCT01131416|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
58292435|NCT03792334|DEVICE|depth of anesthesia|monitoring of depth of anesthesia
58292436|NCT04769232|DEVICE|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
57937178|NCT05524922|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
58292437|NCT05895357|OTHER|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
58292438|NCT00874315|OTHER|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
58292439|NCT00874315|DRUG|busulfan|0.8 mg/kg/dose for total of 8 doses.
58292440|NCT00874315|DRUG|cyclosporine|1.5 mg/kg/dose every 12 hours.
58292441|NCT00874315|DRUG|fludarabine phosphate|30 mg/m2/day for 5 days.
58292442|NCT00874315|DRUG|mycophenolate mofetil|15 mg/kg/dose every 8 hours
58404601|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
57937179|NCT03934606|BEHAVIORAL|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
57937180|NCT01091597|PROCEDURE|usual PV ablation|usual PV ablation, per above
58292443|NCT00874315|DRUG|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
58292444|NCT00874315|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
58292445|NCT00563615|DRUG|Tegaserod|
58404602|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
58404603|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
58404604|NCT06598072|DEVICE|Dental floss|Dental Floss
58404605|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
57937181|NCT01091597|PROCEDURE|Box isolation of pulmonary veins|as above
57937182|NCT01553175|GENETIC|DNA analysis|
58292446|NCT02318888|PROCEDURE|Surgery|
58292447|NCT02318888|DRUG|Icodextrin|
58404606|NCT01408550|DRUG|Placebo|Physiological saline
58404607|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
58404608|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
58404609|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
58404610|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
57937183|NCT01553175|GENETIC|gene expression analysis|
57937184|NCT01553175|GENETIC|mutation analysis|
57937185|NCT01553175|GENETIC|protein expression analysis|
57937186|NCT01553175|OTHER|immunohistochemistry staining method|
57937187|NCT01553175|OTHER|laboratory biomarker analysis|
58292448|NCT04097769|DRUG|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
58292449|NCT02983890|DRUG|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
58404611|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
57937188|NCT04139044|PROCEDURE|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
57937189|NCT04139044|PROCEDURE|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
57937190|NCT04107883|BIOLOGICAL|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
57937191|NCT04107883|DIAGNOSTIC_TEST|blood sample|get blood samples at several specific points in time during perioperation
57937192|NCT01131026|DRUG|Levofloxacin|tablet, 500 mg, once a day for ten days
57937193|NCT01131026|DRUG|Amoxicillin|tablet, 1000 mg, once a day for ten days
57937194|NCT01131026|DRUG|Lansoprazole|capsule, 30 mg, twice a day for ten days
57937195|NCT04280536|DRUG|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
57937196|NCT04280536|DRUG|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
57937197|NCT01899625|BEHAVIORAL|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
58292450|NCT02983890|DRUG|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
58292451|NCT05143632|DEVICE|ClearSight|The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
58404612|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
58292452|NCT03018275|BIOLOGICAL|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
58292453|NCT01146535|DRUG|Interferon-alpha|150 IU lozenges bid for 5 days
58404613|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
58404614|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
58404615|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
57937198|NCT01899625|BEHAVIORAL|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
57937199|NCT02636933|OTHER|Lung Function Assessment|Lung Function Assessment
58292454|NCT01146535|DRUG|Oseltamivir|75 mg capsules bid for 5 days
57937200|NCT05303870|OTHER|Improving access to psychological therapies (IAPT)|"IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles:~1. Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes.~2. Appropriately trained and supervised workforce.~3. Routine outcome monitoring."
58073300|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
58073301|NCT02204722|DRUG|600mg/day of Imatinib|
58073302|NCT02204722|DRUG|400mg/day of Imatinib|
58073303|NCT06125847|GENETIC|NGGT006|Single intravenous infusion of NGGT006 at dose 1 (7.5e12vg/kg), dose 2 (1.5e13vg/kg) , dose 3 (3e13vg/kg) and dose 4 (4e13vg/kg).
58073304|NCT00045565|DRUG|arsenic trioxide|Given IV
58073305|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
58073306|NCT06713746|DIAGNOSTIC_TEST|growth differentiation factor 15|rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
58073307|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
58292455|NCT01146535|OTHER|maltose|200 mg maltose lozenges bid for 5 days
58292456|NCT03973541|BEHAVIORAL|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
58292457|NCT03973541|BEHAVIORAL|Relaxation Therapy|Relaxation Therapy
58292458|NCT02196857|DRUG|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
58292459|NCT02196857|DRUG|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
58292460|NCT03002545|DIETARY_SUPPLEMENT|Magnesium citrate|
58292461|NCT03002545|DIETARY_SUPPLEMENT|Placebo|
58292462|NCT02038179|DRUG|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
58292463|NCT02038179|DRUG|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
58292464|NCT03106883|BEHAVIORAL|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
58073308|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
58073309|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
58292465|NCT03106883|BEHAVIORAL|Sham training|3 sessions of sham attention training using non-affective stimuli
58292466|NCT06477081|PROCEDURE|FS-LASIK procedure|For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion o
58404616|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
58404617|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
58404618|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
58404619|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
57937201|NCT02611804|DRUG|Diclofenac sodium|
57937202|NCT02611804|DRUG|Diclofenac sodium|
58073310|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
57937203|NCT02611804|DRUG|Placebo|
58404620|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
58404621|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
58404622|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
58404623|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
58404624|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
57937204|NCT03388918|DEVICE|Telerehabilitation|Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
57937205|NCT05891184|DEVICE|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
57937206|NCT01186900|PROCEDURE|ultrasound-guided needle aspiration|one time drainage at time of randomization
57937207|NCT02618005|DIETARY_SUPPLEMENT|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
57937208|NCT00195312|BIOLOGICAL|HIV-1 gag DNA (formulated with bupivacaine)|
57937209|NCT00195312|BIOLOGICAL|IL-15 DNA (formulated with bupivacaine)|
57937210|NCT00195312|BIOLOGICAL|IL-12 DNA (formulated with bupivacaine)|
57937211|NCT00195312|BIOLOGICAL|Sodium chloride injection USP (0.9%)|
57937212|NCT04538872|BEHAVIORAL|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
57937213|NCT04538872|BEHAVIORAL|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
57937214|NCT06472583|DRUG|Keytruda|Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
57937215|NCT06472583|RADIATION|Preoperative radiation therapy|Boost of preoperative robotic stereotactic radiotherapy
57937216|NCT06472583|DRUG|Placebo|0,9% NaCl in the volume 100 ml
57937217|NCT03662139|OTHER|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
57937218|NCT01283230|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
57937219|NCT04263350|DRUG|Atazanavir/Cobicistat|Specified Dose on Specified Days
57937220|NCT04263350|DRUG|Reyataz Atazanavir|Specified Dose on Specified Days
57937221|NCT04263350|DRUG|Cobicistat|Specified Dose on Specified Days
57937222|NCT00579683|OTHER|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
57937223|NCT00805025|DRUG|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
58404625|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
58404626|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
57937224|NCT02790138|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
57937225|NCT02790138|DRUG|Ciprofloxacin|Ciprofloxacin tablets
57937226|NCT02790138|DRUG|Vedolizumab|Vedolizumab IV infusion
57937227|NCT00779792|DRUG|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
57937228|NCT00779792|DRUG|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
58404627|NCT04975919|DRUG|Venetoclax|Given PO
58404628|NCT02446704|DRUG|Olaparib|
58404629|NCT02446704|DRUG|Temozolomide|
58404630|NCT02455661|DEVICE|TR Band (TM)|
58404631|NCT02455661|DEVICE|AngioSeal|
58404632|NCT02455661|DEVICE|StarClose|
58404633|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
58404634|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
57937229|NCT00779792|DRUG|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
58073311|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
58073312|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
58073313|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
58073314|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
58073315|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
58073316|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
58404635|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
58404636|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
58404637|NCT02873065|DRUG|Ilaprazole|
58404638|NCT02873065|DRUG|Esoprazole|
58404639|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
57937230|NCT00779792|DRUG|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
58073317|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
58073318|NCT03935074|DRUG|intra-arterial administration of melphalan|
58073319|NCT01973920|DRUG|Oshadi Icp|
58073320|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
58073321|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
58073322|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
58073323|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
58404640|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
58404641|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
58404642|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
57937231|NCT00779792|DRUG|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
57937232|NCT01956149|DRUG|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
57937233|NCT01406288|OTHER|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
57937234|NCT05869292|DEVICE|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
58073324|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
58073325|NCT01494753|DRUG|T2345|One drop at 8.00pm.
58073326|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
58073327|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
58073328|NCT00958282|OTHER|placebo|
58073329|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
57730176|NCT06483750|DEVICE|Systane iLux Treatment|The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
57937235|NCT05869292|DEVICE|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
58292467|NCT06477081|PROCEDURE|KLEx|For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complete
58292468|NCT00558012|DRUG|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
57730177|NCT06668974|OTHER|Mendelian Randomization|This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.
57730178|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
57730179|NCT05440864|DRUG|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
57730180|NCT03321981|DRUG|Zenocutuzumab|full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
57730181|NCT03321981|DRUG|Trastuzumab|humanised IgG1 monoclonal antibody
57937236|NCT03553914|DRUG|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
57937237|NCT05968599|DRUG|Enzalutamide|As provided in real-world setting
57937238|NCT05968599|DRUG|Abiraterone acetate|As provided in real-world setting
57937239|NCT00718549|DRUG|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
57937240|NCT00718549|DRUG|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
57937241|NCT00718549|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
57937242|NCT06182150|BEHAVIORAL|Moderate-Intensity Indoor Cycling Exercise|The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
57937243|NCT02785965|DEVICE|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
58073330|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
58073331|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
58292469|NCT00558012|DIETARY_SUPPLEMENT|Vitamin D 800 IU/daily|Daily divided dose
58292470|NCT00558012|DIETARY_SUPPLEMENT|Calcium 1200 mg/daily|supplement plus diet
58292471|NCT05677425|OTHER|Temperature measurement|Temperature measurement in the renal pelvis during ureteroscopic laser activation.
58292472|NCT04307862|DRUG|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
58404643|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
58404644|NCT00387179|DRUG|Melatonin|5mg, pill, once
58404645|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
58404646|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
58404647|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
57730182|NCT03321981|DRUG|Vinorelbine|antineoplastic drug of vinca alkaloid family
57730183|NCT03321981|DRUG|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
57730184|NCT00839072|DRUG|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
57730185|NCT00839072|DRUG|Trazodone HCl|300 mg extended-release caplet, single dose
57730186|NCT04595708|BEHAVIORAL|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
57730187|NCT05308862|BEHAVIORAL|Care process for assessements of risks|Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
57730188|NCT01429259|DRUG|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
57730189|NCT03844763|DRUG|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
58292473|NCT04307862|DRUG|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
58292474|NCT04307862|DRUG|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
58292475|NCT04403555|DRUG|Ivermectin|Ivermectin treatment
58292476|NCT03953521|DEVICE|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
58292477|NCT04037371|OTHER|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
58292478|NCT04659863|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
58292479|NCT04659863|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
58292480|NCT05128266|PROCEDURE|Endodontical Retreatment|"1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
57730190|NCT03844763|DRUG|CTX|CTX: 50 mg Daily untill PD or major toxicity
57730191|NCT03844763|RADIATION|RT|RT: 8 Gy single shot day 8
57730192|NCT01817049|BEHAVIORAL|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
57730193|NCT01817049|BEHAVIORAL|placebo attention control|
57730194|NCT01138332|GENETIC|western blotting|
58292481|NCT01967004|DEVICE|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
58404648|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
57730195|NCT01138332|OTHER|laboratory biomarker analysis|
57730196|NCT06040489|DRUG|Miltefosine 50mg|Oral Miltefosine 50mg bid
57730197|NCT06040489|DRUG|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
57730198|NCT06040489|DRUG|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
57730199|NCT03822299|DIETARY_SUPPLEMENT|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
58292482|NCT05737901|OTHER|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
57937244|NCT02785965|BEHAVIORAL|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
57937245|NCT05529056|DRUG|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
57937246|NCT05529056|DRUG|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
58073332|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
58292483|NCT05737901|OTHER|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
57937247|NCT05529056|DRUG|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
57937248|NCT05529056|DRUG|Placebo|Placebo ophthalmic solution
57937249|NCT02248259|DRUG|BI 409306|Oral single dose of BI 409306
57937250|NCT02248259|DRUG|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
57937251|NCT01195753|BIOLOGICAL|HHLivC|multiple infusion of liver cells
57937252|NCT04653168|DRUG|LY3041658|Administered SC
57937253|NCT03595319|DRUG|Sevoflurane|Inhaled sevoflurane until allocated dose (see adaptive protocol)
58292484|NCT04761757|OTHER|Booklet of Scripts of Doctors|"The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context."
58292485|NCT04761757|OTHER|Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)|"The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context."
58292486|NCT06412848|DRUG|Avelumab|This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
58292487|NCT02342392|DRUG|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
58292488|NCT00640939|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
57937254|NCT04401163|DIAGNOSTIC_TEST|Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.
57937255|NCT00687440|DRUG|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
58073333|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
58073334|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
58073335|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
58073336|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
57937256|NCT00687440|DRUG|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
57937257|NCT00687440|DRUG|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
57937258|NCT00745693|DRUG|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
57937259|NCT00745693|DRUG|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
57937260|NCT00832520|DRUG|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None"
58073337|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
58073338|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
58073339|NCT06566157|DIETARY_SUPPLEMENT|Prebiotic|WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
58073340|NCT06566157|DIETARY_SUPPLEMENT|Maltodextrin (Corn)|Placebo
58073341|NCT00185146|DRUG|Pactimibe|
58073342|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
58073343|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
57730200|NCT03535818|PROCEDURE|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
57730201|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
57730202|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
58073344|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
58073345|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
58073346|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
58073347|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
57730203|NCT01735123|DIETARY_SUPPLEMENT|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
57730204|NCT00000744|DRUG|Fluconazole|
57730205|NCT01686711|DRUG|AD-4833 15 mg|
57730206|NCT01686711|DRUG|AD-4833 30 mg|
57937261|NCT04110548|PROCEDURE|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
57937262|NCT04110548|PROCEDURE|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
57937263|NCT06270342|OTHER|dual task assessment|The Minnesota Manual Dexterity Test was used to evaluate the upper extremity function of the participants in single and dual task conditions, and the Dual Task Questionnaire was used to evaluate the difficulties experienced during dual tasks. In the dual-task turning test, in addition to the single-task turning test, they were given a cognitive task, the task of counting the months of the year backwards from December to January. The dual-task turning test was continued by changing hands at the end of each turn until the last disk was turned. Meanwhile, verbal fluency and hand errors made while spinning the disc were recorded.
57937264|NCT05658016|DRUG|TK-112690|TK112690 treatment Pre \& Post Radiation
57937265|NCT05658016|DRUG|Placebo|TK112690 Placebo treatment Pre \& Post Radiation
57937266|NCT04485273|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
57937267|NCT04485273|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
57937268|NCT04485273|PROCEDURE|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
57937269|NCT04485273|DRUG|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
57937270|NCT04485273|DRUG|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
58073348|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
58073349|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
58073350|NCT01786707|OTHER|Hyperbaric oxygen therapy|
58073351|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
58073352|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
58073353|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
58073354|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
58073355|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
58073356|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
57730207|NCT01686711|DRUG|Placebo|
58073357|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
58073358|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
57730208|NCT00371891|PROCEDURE|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
57730209|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
57730210|NCT04651023|DIETARY_SUPPLEMENT|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
58292489|NCT00640939|DRUG|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
57937271|NCT01951079|DRUG|Intra-amniotic injection of DIGOXIN|
57937272|NCT06235450|DEVICE|iLIDS100|Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
57937273|NCT04248309|DRUG|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
57937274|NCT06374472|PROCEDURE|Osteosynthesis|Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
58292490|NCT01675492|DEVICE|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
58292491|NCT05714540|DRUG|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
58292492|NCT05171114|DIAGNOSTIC_TEST|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
58292493|NCT01878318|DRUG|methotrexate|stable dose
58292494|NCT01878318|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
58292495|NCT05177146|DRUG|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
58292496|NCT05602506|DRUG|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
58292497|NCT04052321|OTHER|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
58292498|NCT05645042|BEHAVIORAL|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
58292499|NCT05645042|BEHAVIORAL|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
57937275|NCT04645043|OTHER|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
58292500|NCT05828953|DRUG|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
58292501|NCT05828953|DRUG|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
58073359|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
58292502|NCT01585246|DRUG|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
58292503|NCT01585246|DRUG|soybean oil soft gel|placebo (soybean oil soft gel)
58292504|NCT02360280|DRUG|ketamine|sedative
58404649|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
58404650|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
57730211|NCT04069975|OTHER|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
57730212|NCT03119766|DRUG|Kolofort|Oral administration
57730213|NCT03119766|DRUG|Placebo|Oral administration
57730214|NCT00519480|DRUG|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
57730215|NCT00519480|DRUG|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
57730216|NCT00519480|DRUG|Placebo|Placebo will be available as an oral tablets.
57730217|NCT00254254|DRUG|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
58292505|NCT02360280|DRUG|midazolam|sedative
58292506|NCT03718390|DRUG|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
58292507|NCT03718390|DRUG|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
58292508|NCT03718390|DRUG|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
57730218|NCT00254254|DRUG|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
57730219|NCT00254254|DRUG|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
57937276|NCT00006090|DRUG|arsenic trioxide|
58073360|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
58073361|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
58073362|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
58292509|NCT03718390|DRUG|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
58292510|NCT03718390|DRUG|Formulation E|Placebo Capsule containing microcrystalline cellulose
58292511|NCT03718390|PROCEDURE|Endoscopy|Endoscopy at 2 hours post dosing
58292512|NCT03718390|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
58292513|NCT04658979|OTHER|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
58404651|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
58404652|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
57730220|NCT05424419|PROCEDURE|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
58073363|NCT05642884|OTHER|Multi-modal Exercise Regimen|Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.
58073364|NCT05642884|BEHAVIORAL|Dietary Guidelines|Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
58073365|NCT03153436|BIOLOGICAL|Myoinositol|
58292514|NCT02412202|OTHER|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
57937277|NCT03031379|OTHER|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
57937278|NCT00502489|PROCEDURE|Closed-loop sytem for5 weaning from mechanical ventilation|
58073366|NCT04177940|DRUG|DMAB Discontinuation and Switching|"Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
58073367|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
58095478|NCT05664451|OTHER|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
58404653|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
58404654|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
58404655|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
57730221|NCT00966940|DRUG|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
58404656|NCT01280058|DRUG|Carboplatin|Given IV
57730222|NCT00966940|DRUG|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
57937279|NCT02371122|DEVICE|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
57937280|NCT02371122|DEVICE|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
57937281|NCT02371122|DEVICE|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
57937282|NCT02371122|DEVICE|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
57937283|NCT06033781|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
58404657|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
57937284|NCT06470399|OTHER|Standard therapy group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
57937285|NCT06470399|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
57937286|NCT01131351|DRUG|Delamanid|OPC-67683 film-coated tablets
57937287|NCT01131351|DRUG|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
57937288|NCT03779971|OTHER|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
57937289|NCT03779971|OTHER|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
57937290|NCT03779971|OTHER|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
57937291|NCT01958788|BEHAVIORAL|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
57937292|NCT02000427|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
57937293|NCT05924737|OTHER|Sleep deprivatin|40 hours of continuous awakening
57937294|NCT05924737|OTHER|Sleep recovery|sleep recovery after 40 hours of continuous awakening
57937295|NCT00464347|DRUG|Avastin|
58404658|NCT01280058|DRUG|Paclitaxel|Given IV
57937296|NCT00464347|PROCEDURE|Photodynamic Therapy (PDT)|
57937297|NCT00464347|DRUG|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
57937298|NCT01069172|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
57937299|NCT01069172|PROCEDURE|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
58095479|NCT06064500|DRUG|Tarlatamab|Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
58095480|NCT04192799|BEHAVIORAL|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
58095481|NCT04192799|BEHAVIORAL|ED admission|Process of pediatric admission is through the emergency department
58404659|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
58404660|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
57730223|NCT02323919|BEHAVIORAL|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
58073368|NCT05311631|BEHAVIORAL|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
57937300|NCT01794520|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
57937301|NCT01794520|DRUG|Dexamethasone|Tablets were administered by mouth per the dexamethasone prescribing information.
57937302|NCT03137186|DRUG|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
57937303|NCT05584254|DIETARY_SUPPLEMENT|yeast-beta glucan|
57937304|NCT01713270|PROCEDURE|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
57937305|NCT01713270|DRUG|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
57937306|NCT01713270|PROCEDURE|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
57937307|NCT02383290|OTHER|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
57937308|NCT00744133|BIOLOGICAL|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
57937309|NCT02463721|OTHER|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
57937310|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
57937311|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
57937312|NCT02529007|DEVICE|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
57937313|NCT02529007|OTHER|Standard colonoscopy|Standard colonoscopy without end-cuff
58404661|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
57937314|NCT05538520|OTHER|Traditional Pilates|This group will perform a traditional Pilates session, which consists of stretching exercises, followed by exercises to strengthen the core (trunk flexors and extensors), lower limbs and upper limbs. The total duration of the intervention in this group should be approximately 50 minutes.
57937315|NCT05538520|OTHER|Pilates without stretching|This group will conduct a non-traditional Pilates session. This is because stretching exercises will be excluded. The muscle strengthening exercises will be the same as in the TP group, so that it is possible to discuss the influence of the inclusion/exclusion of stretching for the considered outcomes. The total duration of the intervention in this group should be approximately 35 minutes.
57937316|NCT04509141|OTHER|acupuncture|acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
58073369|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
58073370|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
57937317|NCT04278300|BIOLOGICAL|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
58073371|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
58292515|NCT05217602|BEHAVIORAL|AC+ARwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
58292516|NCT05217602|BEHAVIORAL|AC+RwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
58404662|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
58292517|NCT05217602|BEHAVIORAL|Usual Calm Control (UC)|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
58404663|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
58404664|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
58404665|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
58404666|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
58404667|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
58404668|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
57937318|NCT04278300|BIOLOGICAL|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
57937319|NCT03325478|OTHER|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
58073372|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
57937320|NCT00495820|DRUG|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
57937321|NCT00495820|OTHER|Placebo|Standard inactive pill.
58073373|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
58073374|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
58073375|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
58073376|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
57937322|NCT00471900|DRUG|dehydroepiandrosterone (DHEA)|
57937323|NCT00000808|DRUG|Nevirapine|
57937324|NCT03126526|BEHAVIORAL|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
57937325|NCT03126526|BEHAVIORAL|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
58073377|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
58404669|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
58404670|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
58404671|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
58404672|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
58404673|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
58404674|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
58404675|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
58404676|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
58404677|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
57730224|NCT02323919|BEHAVIORAL|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
57730225|NCT02323919|BEHAVIORAL|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
58404678|NCT00489424|DRUG|Placebo|
57730226|NCT06264440|DRUG|BIIB122|Administered as specified in the treatment arm.
57730227|NCT06264440|DRUG|Rabeprazole|Administered as specified in the treatment arm.
57937326|NCT03126526|BEHAVIORAL|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
57730228|NCT02224729|DRUG|Bendamustine hydrochloride|Given IV
58404679|NCT00489424|DRUG|Acetaminophen|
58404680|NCT00489424|DRUG|Fluvastatin|
58404681|NCT03828422|DIAGNOSTIC_TEST|imaging|
58404682|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
58404683|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
58404684|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
58404685|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
58404686|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
57730229|NCT02224729|DRUG|Bortezomib|Given SC
57730230|NCT02224729|DRUG|Dexamethasone|Given PO
57730231|NCT02568527|DEVICE|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
57730232|NCT04171700|DRUG|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
57730233|NCT01357798|DRUG|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
57937327|NCT02053324|COMBINATION_PRODUCT|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
58073378|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
57730234|NCT01357798|DRUG|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
57730235|NCT06535750|OTHER|Exercise|Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
57730236|NCT01108653|OTHER|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
58292518|NCT02726789|DRUG|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
58292519|NCT02726789|DRUG|pegylated interferon|immunotherapy
58292520|NCT02726789|DRUG|entecavir|local generic entecavir
57730237|NCT01108653|OTHER|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
57730238|NCT00746837|DRUG|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
57730239|NCT00746837|DRUG|AZD5672|50 mg od, 12 days
58073379|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
58292521|NCT03839329|BEHAVIORAL|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
58292522|NCT01416545|BEHAVIORAL|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
58292523|NCT01416545|BEHAVIORAL|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
58292524|NCT03263715|DRUG|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
58292525|NCT03263715|DRUG|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
58292526|NCT03263715|DRUG|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
58292527|NCT06049446|DEVICE|Pintuition|Magnetic seed localization
58292528|NCT06469450|DRUG|Atorvastatin|one 40 mg atorvastatin tablet once daily for 28 days
57730240|NCT00746837|DRUG|AZD5672|150mg od, 12 days
58292529|NCT01030016|DRUG|atenolol|25 mg/day, twice a day for 6 weeks
58292530|NCT03442647|DIAGNOSTIC_TEST|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
58404687|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
58404688|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
57730241|NCT06137391|PROCEDURE|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
57730242|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
57937328|NCT02859376|DIETARY_SUPPLEMENT|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
58073380|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
58073381|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
58095482|NCT05617898|BEHAVIORAL|Motivational Interviewing|Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
58292531|NCT03939923|DRUG|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
58292532|NCT03939923|DRUG|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
58292533|NCT03939923|DRUG|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
58292534|NCT03939923|DRUG|Sugammadex|Reversal with Sugammadex (2mg/kg)
58292535|NCT02472886|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
58404689|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
58404690|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
58404691|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
58404692|NCT06439433|DRUG|Placebo|once a week for 6 weeks
58292536|NCT02472886|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58404693|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
58292537|NCT05010746|DEVICE|Innovalve TMVR system|Innovalve TMVR system
58292538|NCT00242697|PROCEDURE|spinal analgesia and anesthesia for coronary artery surgery|
58292539|NCT05745545|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
58292540|NCT05745545|DRUG|Saline solution|One dose was administered by intramuscular injection, 0.5ml/vial
58292541|NCT04255758|OTHER|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
58404694|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
58404695|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
58404696|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
58404697|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
58404698|NCT05285618|DEVICE|Argus II|In response to the stimulation/image on the monitor subjects will be asked to make perceptual judgments and complete simple behavioral tasks. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, reporting shape by selecting a tactile object of similar shape, or locating a target by moving around, rotating the head, and pointing. Sighted control subjects will perform similar tasks in virtual reality.
58404699|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
58404700|NCT03457142|DRUG|Dexamethasone|Given PO
58404701|NCT03457142|DRUG|Ixazomib Citrate|Given PO
58404702|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
58404703|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
58404704|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
58404705|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
58404706|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
58404707|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
58404708|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
58404709|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
58404710|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
58404711|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
58404712|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
58404713|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
58404714|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
58404715|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
58404716|NCT02727387|DRUG|BUMEL|Consolidation phase
58404717|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
58404718|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
58404719|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
58292542|NCT04655508|DRUG|Seretide|"For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
58292543|NCT04655508|DRUG|Placebo|For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
58292544|NCT05819372|PROCEDURE|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results"
58292545|NCT04852731|PROCEDURE|Cardiac MRI|Injected cardiac MRI
58292546|NCT04852731|OTHER|Blood collection|Blood collection (including genetics at the inclusion visit)
58292547|NCT04852731|PROCEDURE|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
58292548|NCT01939730|DRUG|Rituximab|375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
58404720|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
58404721|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
58292549|NCT01939730|DRUG|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
58292550|NCT04001803|DRUG|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
58292551|NCT06521190|DRUG|ACOU085 (bimokalner)|Transtympanic injection
58292552|NCT06521190|DRUG|Placebo|Transtympanic injection
58292553|NCT00540839|DRUG|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
58292554|NCT00540839|DRUG|Placebo to montelukast|Placebo OG or CT
58292555|NCT00540839|DRUG|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
58292556|NCT00540839|DRUG|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
58292557|NCT04272463|OTHER|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
58292558|NCT04780672|DRUG|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
58292559|NCT04780672|DRUG|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
58292560|NCT05851248|PROCEDURE|Buccal muco-gingival tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site."
58292561|NCT05851248|PROCEDURE|Palatal connective tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone."
58095483|NCT05617898|BEHAVIORAL|Nutrition Didactic Training|The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
58292562|NCT02412397|PROCEDURE|Total Shoulder Arthroplasty|
58292563|NCT04240951|OTHER|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
58292564|NCT00848900|BEHAVIORAL|Outdoor activity|Adding 1 hour outdoor time into school curricula
58292565|NCT06613295|RADIATION|SABR|SABR
58292566|NCT06613295|PROCEDURE|Separation surgery|Separation surgery
58292567|NCT05672316|BIOLOGICAL|Balstilimab|Given IV
58404722|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
58404723|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
58404724|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
58292568|NCT05672316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58404725|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
57937329|NCT04175106|OTHER|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
58404726|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
58404727|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
57937330|NCT04175106|OTHER|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
58073382|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
58073383|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
58095484|NCT05648968|BIOLOGICAL|Ianalumab|i.v. infusion, prepared from concentrate solution
58095485|NCT05648968|DRUG|Placebo|i.v. infusion, prepared from matching placebo
58095486|NCT06347003|DRUG|Plozasiran Injection|ARO-APOC3 Injection
58404728|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
58404729|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
58404730|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
58404731|NCT03147612|DRUG|Cyclophosphamide|Given IV
58404732|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
58404733|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
57937331|NCT04175106|OTHER|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
58292569|NCT05672316|BIOLOGICAL|Botensilimab|Given IV
58292570|NCT05672316|PROCEDURE|Computed Tomography|Undergo CT
57937332|NCT04175106|OTHER|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
57937333|NCT02753660|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
57937334|NCT02753660|PROCEDURE|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
58292571|NCT05672316|DRUG|Regorafenib|Given PO
58292572|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
58292573|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
58292574|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
58404734|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
58404735|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
58404736|NCT03147612|DRUG|Ponatinib|Given PO
57730243|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
57730244|NCT03145116|DEVICE|CT ASPHINA 509|Intraocular lens
57730245|NCT01248884|BIOLOGICAL|Infanrix hexa™|3 doses, intramuscular into left thigh
57730246|NCT01248884|BIOLOGICAL|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
57730247|NCT01248884|BIOLOGICAL|GSK217744|3 doses, intramuscular into left thigh
57937335|NCT04377711|DRUG|Ciclesonide|160mcg Inhaler
57937336|NCT04377711|DRUG|Placebo|Matching Placebo Inhaler
57937337|NCT00601705|DRUG|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
57937338|NCT00601705|DRUG|epirubicin hydrochloride|50 mg/m2 IV bolus
57937339|NCT00601705|DRUG|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
58404737|NCT03147612|BIOLOGICAL|Rituximab|Given IV
58404738|NCT03147612|DRUG|Vincristine|Given IV
58404739|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
57730248|NCT01761747|DRUG|ponatinib|
57937340|NCT00601705|DRUG|oxaliplatin|130 mg/m2 IV infusion over 2 hours
57937341|NCT00601705|PROCEDURE|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
58404740|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
58404741|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
58404742|NCT02346331|OTHER|Oxygen delivery|
58404743|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
58404744|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
58404745|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
58404746|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
58404747|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
58404748|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
58404749|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
58404750|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
58404751|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
58404752|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
58404753|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
58404754|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
57937342|NCT00601705|PROCEDURE|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
57937343|NCT00861913|OTHER|Laboratory Biomarker Analysis|Correlative studies
58095487|NCT06347003|DRUG|Placebo|sterile normal saline (0.9% NaCl)
58095488|NCT06404281|BIOLOGICAL|γδ T-PD-1 Ab cells|Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
57730249|NCT05978323|BEHAVIORAL|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
57730250|NCT01097135|DRUG|Duraprep Surgical Solution|
57730251|NCT06669247|DRUG|Linvoseltamab|Administered per protocol
57730252|NCT06669247|DRUG|REGN7945+Linvoseltamab|Administered per protocol
57937344|NCT00861913|DRUG|Pazopanib Hydrochloride|Given orally
57937345|NCT00861913|OTHER|Pharmacological Study|Correlative studies
57937346|NCT04946396|DRUG|dexmedetomidine intravenous infusion|Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
57937347|NCT04946396|DRUG|0.9%sodium chloride|0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
58404755|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
58404756|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
58404757|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
58404758|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
58404759|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
58404760|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
58404761|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
58404762|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
58404763|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
58404764|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
57730253|NCT03379025|OTHER|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
57730254|NCT05306327|DIAGNOSTIC_TEST|electroencephalography (EEG)|"1. brain cortical activity using full scalp~2. cerebral blood flow velocity~3. during the dying process following planned withdrawal of life sustaining measures (WLSM)"
57730255|NCT02188017|DRUG|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
57730256|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
57730257|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
57730258|NCT00000129|PROCEDURE|Radial Keratotomy|
57937348|NCT01458366|DRUG|Bendamustine|"Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
57937349|NCT01458366|DRUG|Ofatumumab|"Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1"
57937350|NCT01458366|DRUG|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
57937351|NCT01458366|DRUG|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
57937352|NCT01458366|PROCEDURE|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
57937353|NCT01458366|PROCEDURE|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
58404765|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
58404766|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
58404767|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
58404768|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
58404769|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
58404770|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
58404771|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
58404772|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
58404773|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
58404774|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
58404775|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
58404776|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
58404777|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
58404778|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
58404779|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
58404780|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
58404781|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
58404782|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
58404783|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
58404784|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
58404785|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
58404786|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
58404787|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
58404788|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
58404789|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
58404790|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
58404791|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
58404792|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
58404793|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
58404794|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
58404795|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
58404796|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
58404797|NCT00003603|DRUG|cyclophosphamide|
58404798|NCT00003603|DRUG|dexamethasone|
58404799|NCT00003603|DRUG|idarubicin|
58404800|NCT00003603|DRUG|lomustine|
58404801|NCT00003603|DRUG|melphalan|
58404802|NCT00003603|DRUG|prednisolone|
58404803|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
58404804|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
58404805|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
58404806|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
58404807|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
58404808|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
58404809|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
58404810|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
58404811|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
58404812|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
58404813|NCT01969383|OTHER|Heated pool training|
58404814|NCT02607917|OTHER|Mass Media plus clinic intervention.|
58404815|NCT02607917|OTHER|Media|
58404816|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
58404817|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
58404818|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
58404819|NCT05083546|OTHER|Placebo|sugar pill
58404820|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
58073384|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
58073385|NCT00118885|BEHAVIORAL|Tai Chi Chih|
58404821|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
58404822|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
58404823|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
58404824|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
58404825|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
58404826|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
58404827|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
58404828|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
58404829|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
58404830|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
58404831|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
58404832|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
58404833|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
58404834|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
58404835|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
58404836|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
58404837|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
58404838|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
58404839|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
58404840|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
58404841|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
58404842|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
58404843|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
58404844|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
58404845|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
58404846|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
58404847|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
58404848|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
58404849|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
58404850|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
58404851|NCT02968160|DRUG|Rosuvastatin 20mg|
58404852|NCT02654288|OTHER|gemcitabine-based chemotherapy|
58404853|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
58404854|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
58404855|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
58404856|NCT04172415|OTHER|Retrospective cohort|Chart Review
58404857|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
58404858|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
58404859|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
58292575|NCT05525546|OTHER|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
58292576|NCT01243515|DEVICE|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
58404860|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
58404861|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
58404862|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
58404863|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
58404864|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
58404865|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
58404866|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
58404867|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
58404868|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
58404869|NCT00620425|DRUG|Sumatriptan|injection
58404870|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
58292577|NCT01243515|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
58292578|NCT05654064|DRUG|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
58404871|NCT05731908|DRUG|BI 690517|BI 690517
58404872|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
58404873|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
58292579|NCT05654064|DRUG|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
58292580|NCT02749162|DRUG|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
58292581|NCT02749162|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
58292582|NCT02749162|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
58292583|NCT02749162|DRUG|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
58292584|NCT02749162|DRUG|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
58292585|NCT02030119|BEHAVIORAL|Financial Incentives|
58292586|NCT02030119|BEHAVIORAL|Daily feedback|
58073386|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
58404874|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
58073387|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
57730259|NCT01556113|OTHER|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
58073388|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
58073389|NCT00033683|DRUG|CMF regimen|
58073390|NCT00033683|DRUG|cyclophosphamide|
58073391|NCT00033683|DRUG|docetaxel|
58073392|NCT00033683|DRUG|epirubicin hydrochloride|
58404875|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
57730260|NCT00652665|DRUG|Leflunomide|Tablets, 20mg, single-dose
57730261|NCT00652665|DRUG|ARAVA|Tablets, 20mg,single-dose
57730262|NCT02081300|DRUG|Oral testosterone undecanoate, LPCN 1021|
57730263|NCT02081300|DRUG|Topical testosterone gel 1.62 %|
57730264|NCT01490346|DRUG|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
57730265|NCT05160922|DRUG|crizotinib|crizotinib oral treatment
57730266|NCT03448146|DRUG|Para-Toluenesulfonamide|
57730267|NCT00646802|DRUG|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
58073393|NCT00033683|DRUG|fluorouracil|
58073394|NCT00033683|DRUG|methotrexate|
57730268|NCT00646802|DRUG|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
57730269|NCT01127178|DRUG|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
57730270|NCT04614389|OTHER|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
58292587|NCT04360369|DEVICE|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (\>23 mmHg).
58292588|NCT04360369|DEVICE|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
58292589|NCT04360369|DEVICE|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
58292590|NCT02465164|DEVICE|Cook catheter|
58292591|NCT02465164|DRUG|Oxytocin|
58292592|NCT03209193|DRUG|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
58292593|NCT03209193|DRUG|Desflurane|Desflurane use as main anesthetic drug during the surgery
58292594|NCT03419117|PROCEDURE|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
58292595|NCT03419117|PROCEDURE|Placebo|A sham ESP block will be performed before surgery in the placebo group
58292596|NCT01581515|DEVICE|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
58292597|NCT01581515|DEVICE|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
58292598|NCT06170944|DEVICE|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
57730271|NCT04614389|OTHER|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
57730272|NCT04614389|DEVICE|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
58073395|NCT00033683|DRUG|tamoxifen citrate|
58292599|NCT03202446|DRUG|1% Glycated Chitosan|
58292600|NCT03202446|DEVICE|Photothermal Laser|
58292601|NCT03202446|DRUG|Placebo|
58292602|NCT03202446|DRUG|Cyclophosphamide|
58292603|NCT03202446|DRUG|Standard of Care|
58292604|NCT03283930|BEHAVIORAL|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
58292605|NCT03283930|BEHAVIORAL|Placebo Attention Bias Modification Training|
58292606|NCT01381926|DRUG|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
58292607|NCT01381926|DRUG|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
58292608|NCT00570960|DRUG|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
58292609|NCT00570960|BIOLOGICAL|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
58292610|NCT03723863|BEHAVIORAL|Occupational Therapy|Receive in-person occupational therapist-led work consultation
58292611|NCT06494501|DRUG|Inclisiran|Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
57730273|NCT05599529|OTHER|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
58404876|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
58292612|NCT02380404|PROCEDURE|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
58404877|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
58292613|NCT04546633|DRUG|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
58292614|NCT04546633|DRUG|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
58292615|NCT04546633|DRUG|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
58292616|NCT05118347|OTHER|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
58292617|NCT06075771|DRUG|Carbidopa Levodopa|Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
58292618|NCT06075771|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
58292619|NCT00102115|DRUG|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
58292620|NCT02768688|OTHER|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
58292621|NCT02768688|DRUG|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
58292622|NCT00934245|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
57730274|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
57937354|NCT01458366|GENETIC|Stem Cell Transplant (STC)|"For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
57937355|NCT04098042|DEVICE|Scaffold|implantation of a Magmaris scaffold
58292623|NCT00934245|BIOLOGICAL|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
58292624|NCT05502952|DRUG|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
58292625|NCT04826484|DRUG|Exparel 133 miligrams per 10 milliliter injection|Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
58292626|NCT04826484|DRUG|Bupivacaine Hydrochloride|Local wound infiltration with 0.25% bupivacaine.
58292627|NCT02633969|DRUG|Indomethacin Capsules low dose|
58292628|NCT02633969|DRUG|Indomethacin Capsules high dose|
58292629|NCT00826410|DEVICE|Redon drain|subcutaneous suction drain after laparotomy for two days
58292630|NCT00001296|DRUG|melphalan|
58404878|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
58404879|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
58404880|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
58404881|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
58292631|NCT00001296|DRUG|tumor necrosis factor|
58292632|NCT00001296|DRUG|interferon-gamma|
58292633|NCT00001296|PROCEDURE|hyperthermic isolated limb perfusion|
58292634|NCT02407847|OTHER|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
58292635|NCT03069534|DRUG|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
58292636|NCT01263717|DRUG|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
58292637|NCT01263717|DRUG|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
58292638|NCT03397121|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
58292639|NCT03397121|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
58404882|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
58404883|NCT02715882|DRUG|CBLB502|
58404884|NCT02715882|DRUG|Placebo|
58404885|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
58404886|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
58404887|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
58404888|NCT00378625|DRUG|Artesunate|
58404889|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
58404890|NCT04620382|DRUG|Placebo pill|single oral dose
58404891|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
57937356|NCT02675816|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
58073396|NCT00033683|PROCEDURE|adjuvant therapy|
58073397|NCT00033683|RADIATION|radiation therapy|
58292640|NCT04551664|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
58292641|NCT04551664|PROCEDURE|Endovascular therapy|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
58292642|NCT01986738|RADIATION|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
58292643|NCT01986738|DEVICE|Active Breathing Control Device (ABC)|
58404892|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
58404893|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
58404894|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
58404895|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
57937357|NCT00706550|BIOLOGICAL|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
57937358|NCT00706550|BIOLOGICAL|Placebo|Placebo
58073398|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
58073399|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
58073400|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
58073401|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
58073402|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
58073403|NCT01240629|OTHER|questionnaire administration|Correlative study
58073404|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
58095489|NCT05788237|BIOLOGICAL|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
58292644|NCT01986738|DEVICE|Computed Tomography Scan (CT)|
58292645|NCT04306497|DRUG|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
58292646|NCT03197467|DRUG|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
58292647|NCT02008136|DRUG|Botulinum Toxins|intramuscular injections
58404896|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
58404897|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
58404898|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
58404899|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
58404900|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
58404901|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
58404902|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
58404903|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
58292648|NCT02510612|DRUG|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
57937359|NCT01715753|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
57937360|NCT01715753|BEHAVIORAL|Diet counseling and group education lessons|Individual and group diet counseling to achieve a \>10% weight loss
57937361|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
57937362|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
57937363|NCT03520478|DRUG|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
57937364|NCT03520478|DRUG|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
57937365|NCT03712436|COMBINATION_PRODUCT|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
57937366|NCT03712436|COMBINATION_PRODUCT|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
57937367|NCT04820283|BEHAVIORAL|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
57937368|NCT04820283|BEHAVIORAL|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
57937369|NCT05590936|DRUG|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
57937370|NCT05590936|DRUG|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
57937371|NCT00395889|PROCEDURE|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
57937372|NCT00395889|PROCEDURE|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
57937373|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
57937374|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
57937375|NCT01028326|BIOLOGICAL|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
57937376|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
58292649|NCT02510612|DRUG|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
58292650|NCT05933330|OTHER|Brain MRI|All included patients receive an MRI of the brain
58292651|NCT02816073|DEVICE|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
57937377|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
57937378|NCT05552625|DRUG|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
57937379|NCT05552625|DRUG|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
57937380|NCT02224599|BIOLOGICAL|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
57937381|NCT02224599|DRUG|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
58095490|NCT05788237|BIOLOGICAL|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
58292652|NCT00431327|BEHAVIORAL|Peer coach phone call|
58292653|NCT02575196|DEVICE|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
58292654|NCT04784507|PROCEDURE|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
58292655|NCT04784507|PROCEDURE|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
58095491|NCT05788237|BIOLOGICAL|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
58404904|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
58073405|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
58095492|NCT05788237|DRUG|Placebo|0.9% saline for injection
58292656|NCT06259149|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
58292657|NCT02050139|DIETARY_SUPPLEMENT|L-cysteine|
58292658|NCT02050139|OTHER|Placebo|
58292659|NCT01655719|DRUG|Pioglitazone|
58292660|NCT02258659|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
58292661|NCT02258659|DRUG|carboplatin|Given IV
58292662|NCT02258659|RADIATION|radiation therapy|Undergo radiation therapy
58292663|NCT02258659|DRUG|paclitaxel|Given IV
58292664|NCT02258659|DRUG|fluorouracil|Given IV
58292665|NCT02258659|DRUG|hydroxyurea|Given PO
58292666|NCT02258659|DRUG|cisplatin|Given IV
58292667|NCT02258659|OTHER|laboratory biomarker analysis|Correlative studies
58292668|NCT02258659|PROCEDURE|quality-of-life assessment|Ancillary studies
58292669|NCT03638960|DRUG|Bupivacaine liposome|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
58292670|NCT03638960|DRUG|Bupivacaine Hydrochloride|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
58292671|NCT00868478|DRUG|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
58292672|NCT02356952|BEHAVIORAL|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
58292673|NCT02356952|BEHAVIORAL|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
58292674|NCT02356952|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
58292675|NCT03752879|PROCEDURE|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
58292676|NCT05018702|DRUG|ARX788|1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
58292677|NCT03746639|OTHER|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
58292678|NCT03168451|BEHAVIORAL|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
58292679|NCT03521869|DEVICE|Compression bandage|Compression bandage placed after total knee replacement
58292680|NCT03521869|DEVICE|Gauze dressing|standard of care gauze dressing placed after total knee replacement
58292681|NCT05934916|DEVICE|CPAP ( Continuous positive airway pressure)|The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
58292682|NCT05934916|DEVICE|oxygen therapy|both groups will receive oxygen
58292683|NCT05642104|DRUG|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
58292684|NCT01537848|PROCEDURE|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
58292685|NCT04865029|OTHER|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
58404905|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
58292686|NCT04865029|DRUG|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
58404906|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
58404907|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
58404908|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
58404909|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
58404910|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
58404911|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
57730275|NCT05658172|DIAGNOSTIC_TEST|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
57937382|NCT02224599|DRUG|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
58292687|NCT04865029|DRUG|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
58292688|NCT03824717|DRUG|Dose of ropivacaine|Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
58292689|NCT02078271|OTHER|FBDG group|The group received food based dietary guidelines for complementary feeding
58292690|NCT02078271|OTHER|Stimulation|The group received psychosocial stimulation
58292691|NCT02078271|OTHER|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
58404912|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
58404913|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
58404914|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
58073406|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
58073407|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
58095493|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
58292692|NCT02078271|OTHER|Control group|
58292693|NCT02781987|OTHER|chronic pancreatitis|patients with chronic pancreatitis
58292694|NCT05404711|DEVICE|CGM|Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
58292695|NCT05888480|OTHER|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
58292696|NCT05888480|OTHER|Routine training activity|Routine training activities arranged by relevant departments in hospitals
58292697|NCT02938338|PROCEDURE|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
58292698|NCT01639144|BIOLOGICAL|PRP and PPP|Autogenous PRP and PPP
57937383|NCT06235814|PROCEDURE|Molecular Analysis for Thyroid Resection|"Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care."
57937384|NCT01721057|DRUG|Placebo|Administered orally
58292699|NCT04563754|DIAGNOSTIC_TEST|mHRME (Mobile High resolution microendoscope)|"Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging."
58292700|NCT04563754|DRUG|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
58404915|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
58404916|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
58404917|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
58404918|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
58404919|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
58404920|NCT02359045|DRUG|D1400147|Treatment A
58404921|NCT02359045|DRUG|D14000136|Treatment B
58404922|NCT02359045|DRUG|D14000137|Treatment C
58404923|NCT02359045|DRUG|Epanova®|Treatment D
58404924|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
58404925|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
58404926|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
58404927|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
58404928|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
58404929|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
58404930|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
57937385|NCT01721057|DRUG|Baricitinib|Administered orally
57937386|NCT01721057|DRUG|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
57937387|NCT05995015|BIOLOGICAL|Universal CD19-specific CAR gene-engineered T cells|Infusion of 4SCAR19U cells
57937388|NCT06400342|PROCEDURE|TAVR-explant|Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.
57937389|NCT06400342|DEVICE|Redo-TAVR|Repeat transcatheter aortic valve implantation within a failed THV.
57937390|NCT00786565|DEVICE|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
57937391|NCT00786565|DEVICE|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
57937392|NCT05868551|PROCEDURE|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
57937393|NCT06343935|DRUG|Linperlisib|Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
58292701|NCT04563754|DIAGNOSTIC_TEST|High resolution anoscopy|Standard of care (SOC) HRA with Lugol's iodine will be performed.
57937394|NCT03366675|DRUG|AZD2811|AZD2811 100mg/vial
58292702|NCT05005936|PROCEDURE|Ultrasonography|Undergo ABUS
58292703|NCT05005936|PROCEDURE|Ultrasonography|Undergo WBUS
58292704|NCT03095352|BIOLOGICAL|Pembrolizumab|200 mg Given IV
58073408|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
57937395|NCT00591214|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
57937396|NCT02128451|DRUG|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
57937397|NCT02128451|DRUG|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
58073409|NCT06715891|DRUG|Raphamin|Tablet for oral use.
58073410|NCT06715891|DRUG|Placebo|Tablet for oral use.
58073411|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
58292705|NCT03095352|DRUG|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
58292706|NCT03095352|BIOLOGICAL|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
58292707|NCT02998996|BIOLOGICAL|15 µg HA/strain and 1% Endocine™|intranasal administration
58292708|NCT02998996|BIOLOGICAL|15 µg HA/strain and 2% Endocine™|intranasal administration
57937398|NCT00719550|DRUG|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
58292709|NCT02998996|BIOLOGICAL|15 µg HA/strain|intranasal administration
58292710|NCT02998996|BIOLOGICAL|intramuscular comparator|intramuscular administration
58292711|NCT02998996|BIOLOGICAL|intranasal comparator|intranasal administration
57937399|NCT00719550|DRUG|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
57937400|NCT00719550|DRUG|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
57937401|NCT00719550|DRUG|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
58292712|NCT02998996|BIOLOGICAL|Placebo, Saline|intranasal administration
57937402|NCT00719550|DRUG|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
57937403|NCT05830799|DRUG|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
57937404|NCT03294525|DRUG|Escitalopram Pill|escitalopram 10\~20mg/day
58404931|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
58404932|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
58292713|NCT05122689|DIETARY_SUPPLEMENT|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
58292714|NCT05122689|DIETARY_SUPPLEMENT|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
58292715|NCT00122525|PROCEDURE|Male Circumcision|
58292716|NCT04382716|OTHER|No intervention|No intervention; observation only
58292717|NCT01307059|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
58292718|NCT03189355|PROCEDURE|Blood sampling|"* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin"
58292719|NCT03189355|PROCEDURE|Bioelectrical impedance vector analysis|"* D1~* D4"
58292720|NCT03189355|PROCEDURE|Muscular echography|"* D1~* D4"
58292721|NCT04835064|DRUG|Nab paclitaxel|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15
58292722|NCT04835064|DRUG|Gemcitabine|Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks
58292723|NCT04835064|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
58292724|NCT01673984|DRUG|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
58404933|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
57730276|NCT05658172|DIAGNOSTIC_TEST|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
58292725|NCT01673984|DRUG|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
58292726|NCT05254899|DRUG|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
58292727|NCT05254899|DRUG|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
58292728|NCT05254899|DRUG|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
58292729|NCT05254899|DRUG|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
58292730|NCT05254899|RADIATION|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
58292731|NCT03072095|BEHAVIORAL|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
58292732|NCT03072095|BEHAVIORAL|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
58073412|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
58073413|NCT00405925|DRUG|Trizivir|
57937405|NCT03294525|DRUG|Duloxetine|duloxetine 30\~120mg/day
57937406|NCT03294525|DRUG|Mirtazapine Pill|Mirtazapine 15\~45mg/day
57937407|NCT03294525|DRUG|Other Antidepressants|
57937408|NCT01419782|OTHER|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
57937409|NCT06466785|DRUG|Efepoetin Alfa|Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
57937410|NCT06466785|DRUG|Darbepoetin Alfa|Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
57937411|NCT01294488|BEHAVIORAL|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
57937412|NCT04302584|DRUG|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
58073414|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
58073415|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
58073416|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
58292733|NCT01901016|BEHAVIORAL|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
58292734|NCT01901016|BEHAVIORAL|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
57730277|NCT05658172|DIAGNOSTIC_TEST|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
57730278|NCT05658172|OTHER|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
58095494|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
58095495|NCT06350266|BEHAVIORAL|Information about healthcare resources|Text messages will be sent following discharge from the emergency department; text may also be modified in the (online and/or printed) discharge summary packet.
58095496|NCT05125302|DRUG|Ubrogepant|Oral Tablet
58292735|NCT06004271|OTHER|exercise|"Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching"
58073417|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
58073418|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
57730279|NCT01324492|DRUG|RAD001|
57730280|NCT05035901|OTHER|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
57730281|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
57730282|NCT01897584|OTHER|inverse IE|in only one group changes of I:E ratio would be applied
57937413|NCT00619255|BEHAVIORAL|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
58073419|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
58073420|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
58073421|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
58073422|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
58073423|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
58073424|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
57730283|NCT02532218|DRUG|ARI-3037MO|Lipid lowering treatment Statins
57730284|NCT01477034|DIETARY_SUPPLEMENT|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
57730285|NCT00170118|BEHAVIORAL|motivational interviewing|
57730286|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
57730287|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
57730288|NCT03326999|DRUG|Saline|Saline as placebo comparator
57937414|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
57937415|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
58095497|NCT05125302|DRUG|Placebo-Matching Ubrogepant|Oral Tablet
57937416|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
58073425|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
57937417|NCT05295004|BEHAVIORAL|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
58073426|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
58073427|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
58073428|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
58073429|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
57937418|NCT01763151|DEVICE|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
57937419|NCT01763151|PROCEDURE|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
57937420|NCT02098642|OTHER|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
58073430|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
58292736|NCT06004271|OTHER|exercise and taping|When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
58292737|NCT06004271|OTHER|placebo|In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
58292738|NCT01267929|PROCEDURE|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
58292739|NCT01267929|PROCEDURE|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
57937421|NCT02098642|OTHER|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
57937422|NCT03135171|DRUG|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
58073431|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
58073432|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
57937423|NCT03135171|DRUG|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
57937424|NCT03135171|DRUG|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
57937425|NCT01118416|BEHAVIORAL|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
57937426|NCT00143091|DRUG|CP-316,311|
58073433|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
58073434|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
57937427|NCT00143091|DRUG|Placebo|
58073435|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
58073436|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
58073437|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
58073438|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
58404934|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
58404935|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
58404936|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
58073439|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
58073440|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
58073441|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
58073442|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
58073443|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
58292740|NCT00661635|DRUG|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
58292741|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
57937428|NCT00143091|DRUG|Sertraline|
58292742|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
58292743|NCT03280056|BIOLOGICAL|NurOwn® (MSC-NTF cells)|"NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors"
58292744|NCT03280056|OTHER|Placebo|"One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection"
57937429|NCT00290186|DEVICE|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
57937430|NCT00290186|DEVICE|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
58073444|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
58073445|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
58095498|NCT05199545|DIETARY_SUPPLEMENT|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
58095499|NCT05199545|OTHER|Placebo|Placebo of the dietary supplement
58292745|NCT03280056|OTHER|Bone Marrow aspiration|Bone Marrow aspiration
58292746|NCT00894088|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
58404937|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
58404938|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
58073446|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
58073447|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
58073448|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
58073449|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
58073450|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
58073451|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
58073452|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
58073453|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
58073454|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
58292747|NCT03446378|DEVICE|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
58404939|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
58404940|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
58404941|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
58073455|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
58073456|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
58073457|NCT06723223|DIAGNOSTIC_TEST|Traditional Peritoneal Equilibrium Test|The first day started with a traditional PET consisting of a 240-minutes dwell with 2.3% glucose PD solutions. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
58073458|NCT06723223|DIAGNOSTIC_TEST|Combined Peritoneal Equilibrium Test|The PET test on the first day (Day 1) was followed by a short (60 min) combined PET with 4.25% glucose solution. On the second day (Day 2), the combined PET was repeated. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
58292748|NCT03446378|BEHAVIORAL|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
58404942|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
58404943|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
58404944|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
58404945|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
58404946|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
57937431|NCT01490853|DRUG|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
58404947|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
58404948|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
58073459|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
58073460|NCT05986292|DRUG|LY3556050 ISA|Administered orally
58073461|NCT05986292|DRUG|LY3526318 ISA|Administered orally
58073462|NCT05986292|DRUG|LY3857210 ISA|Administered orally
58073463|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
58073464|NCT05986292|DRUG|Placebo|Placebo administered IV
58073465|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
58073466|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
58292749|NCT03446378|DEVICE|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
58404949|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
58404950|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
57937432|NCT02294084|DRUG|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
57937433|NCT02294084|DRUG|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
57937434|NCT04822610|PROCEDURE|interscalene block|peripheral nerve block
58073467|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
57937435|NCT04822610|PROCEDURE|suprascapular block + axillary block|peripheral nerve block
57937436|NCT02761395|PROCEDURE|Al-hijamah|"* Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
57937437|NCT02761395|DRUG|Deferasirox|20-40 mg/kg/day orally
57937438|NCT02257996|BEHAVIORAL|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
57937439|NCT00701090|DRUG|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
57937440|NCT00701090|DRUG|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
57937441|NCT00701090|DRUG|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
57937442|NCT01372722|DEVICE|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
58073468|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
58073469|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
58073470|NCT05704933|DRUG|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
58073471|NCT05704933|DRUG|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.\[18-20\] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
58095500|NCT05747261|GENETIC|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
58095501|NCT05747261|GENETIC|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
58095502|NCT05747261|GENETIC|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
57937443|NCT01372722|DEVICE|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
57937444|NCT01022502|DRUG|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
57937445|NCT01022502|DRUG|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
57937446|NCT02575404|DRUG|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
57937447|NCT02575404|DRUG|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
57937448|NCT04809311|DRUG|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
57937449|NCT04809311|DRUG|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
57937450|NCT04809311|DRUG|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
57937451|NCT03881384|OTHER|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
57937452|NCT00052039|DRUG|interferon-gamma 1b|This study was terminated prior to enrollment.
57937453|NCT00052039|DRUG|azathioprine|This study was terminated prior to enrollment.
57937454|NCT06489756|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
57937455|NCT00236860|DRUG|topiramate|
57937456|NCT02716675|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
57937457|NCT02716675|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
57937458|NCT04375787|DRUG|Atorvastatin|Patients received 80 mg atorvastatin before elective coronary angiography
57937459|NCT02901574|DEVICE|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
57937460|NCT02901574|DEVICE|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
57937461|NCT02901574|BEHAVIORAL|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
57937462|NCT00813332|DRUG|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
57937463|NCT00813332|DRUG|Placebo plus Docetaxel|Placebo plus Docetaxel
57937464|NCT03700151|BEHAVIORAL|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
57937465|NCT00237848|DRUG|D-serine|
57937466|NCT00237848|BEHAVIORAL|Cognitive retraining|
57937467|NCT06232512|DEVICE|Haptic Device|Provides sensory substitution by mapping pressure from the insole sensor onto a corresponding vibrating and heating patch to be worn where more sensation is present.
57937468|NCT02912299|PROCEDURE|Skin biopsies|2 3mm skin biopsies will be taken
57937469|NCT02912299|OTHER|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
57937470|NCT02912299|OTHER|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
57937471|NCT05406843|OTHER|Preoperative cognitive functions of participants undergoing open heart surgery|Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
57937472|NCT05406843|OTHER|Postoperative cognitive functions of particiants undergoing open heart surgery|Changes in mini mental test scores were recorded in the postoperative period.
57937473|NCT03274583|DIAGNOSTIC_TEST|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
57937474|NCT01931787|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
57937475|NCT04712396|DRUG|Capivasertib|Subects will be administered single doses of capiversatib on Day 1 and Day 6.
57937476|NCT04712396|DRUG|Itraconazole|Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
57937477|NCT00510991|DEVICE|nippv|
57937478|NCT00259779|DRUG|budesonide/formoterol|
57937479|NCT00259779|DRUG|Prednisolone|
57937480|NCT02029820|DEVICE|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
57937481|NCT01358760|DRUG|Placebo|Placebo vaginal suppository
57937482|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
58404951|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
57937483|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
57937484|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
58404952|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
58404953|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
57937485|NCT00594516|DRUG|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
57937486|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
57937487|NCT01524133|DRUG|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
57937488|NCT01524133|BEHAVIORAL|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
57937489|NCT04167748|PROCEDURE|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
57937490|NCT02194062|DRUG|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
58404954|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
58404955|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
57937491|NCT02194062|DRUG|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
57937492|NCT02194062|DRUG|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
57937493|NCT01761045|DIETARY_SUPPLEMENT|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
58073472|NCT05704933|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.\[6\] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
58073473|NCT05704933|PROCEDURE|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
58073474|NCT03023124|DRUG|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
57937494|NCT01761045|DIETARY_SUPPLEMENT|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
57937495|NCT01761045|DIETARY_SUPPLEMENT|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
57937496|NCT02170675|DRUG|Dabigatran etexilate|
57937497|NCT02170675|DRUG|Ketoconazole|
57937498|NCT02745366|PROCEDURE|BFPSC+FDBA+PRF|
57937499|NCT02745366|PROCEDURE|FDBA+PRF|
58073475|NCT03023124|DRUG|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
58073476|NCT03023124|DRUG|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
58404956|NCT01824823|DRUG|afatinib|Given PO
58404957|NCT01824823|OTHER|placebo|Given PO
57937500|NCT01817751|DRUG|sorafenib tosylate|Given by mouth
57937501|NCT01817751|DRUG|valproic acid|Given by mouth
57937502|NCT01817751|DRUG|sildenafil citrate|Given by mouth
57937503|NCT04360499|OTHER|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
57937504|NCT04360499|OTHER|Pilates training|Pilates style exercise training
57937505|NCT04678596|DEVICE|EonAligner|EonAligner system is one stage system.
57937506|NCT04678596|DEVICE|Clearfix|Clearfix system is three-stage system.
57937507|NCT03076931|PROCEDURE|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
57937508|NCT03076931|PROCEDURE|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
57937509|NCT03076931|PROCEDURE|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
58073477|NCT05171686|DRUG|Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
58073478|NCT06395441|DIETARY_SUPPLEMENT|American Ginseng|Given PO
58404958|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
57937510|NCT01279850|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
57937511|NCT03725514|PROCEDURE|Conventional|Conventional Blood Clot Technique
57937512|NCT03725514|PROCEDURE|PRF|Platelet Rich Fibrin Technique
57937513|NCT03890991|BEHAVIORAL|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
57937514|NCT03890991|BEHAVIORAL|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
57937515|NCT03890991|BEHAVIORAL|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
57937516|NCT06007365|DEVICE|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
57937517|NCT00447512|DRUG|ghrelin|acylated ghrelin
57937518|NCT00381563|DEVICE|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
57937519|NCT00381563|DEVICE|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
57937520|NCT05861687|DRUG|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
57937521|NCT05861687|DRUG|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg
57937522|NCT05861687|DRUG|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
57937523|NCT05861687|DRUG|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
58404959|NCT01345591|PROCEDURE|Fat Grafting|
58073479|NCT06395441|DRUG|Placebo Administration|Given PO
58404960|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
58404961|NCT00241631|DRUG|Fluticasone Propionate|500 u
57730289|NCT03998527|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
57937524|NCT06465719|PROCEDURE|Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System|Basal ganglion hemorrhage patients will be operated on hematoma puncture and aspiration with Tract-based AI Robot Guiding System
57937525|NCT06465719|DRUG|"Hemocoagulase Bothrops Atrox for Injection；Nicardipine"|"Basal ganglion hemorrhage patients will be managed with guideline-based medications without surgery. Hemocoagulase Bothrops Atrox for Injection belongs to the drug class of Hemostatic Agents. Nicardipine is a calcium channel blocker (CCB) drug to control blood pressure."
57937526|NCT02495220|DRUG|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
57937527|NCT02495220|DRUG|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
57937528|NCT04030039|DRUG|Interferon|chronic hepatitis B patients with interferon therapy
57937529|NCT04030039|DRUG|nucleoside analogues|chronic hepatitis B patients with interferon therapy
57937530|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
57937531|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
57937532|NCT04029181|OTHER|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
57937533|NCT00201669|DRUG|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
57937534|NCT01164566|PROCEDURE|endoscopic procedure|
57937535|NCT01164566|OTHER|questionnaire administration|Ancillary studies
57937536|NCT01454245|DRUG|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
57937537|NCT01454245|DRUG|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
57937538|NCT03923751|OTHER|Invitation to regional anesthesia survey|An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
57937539|NCT00068744|DRUG|cisplatin|
58073480|NCT06395441|OTHER|Questionnaire Administration|Ancillary studies
57937540|NCT00068744|DRUG|fluorouracil|
57937541|NCT00068744|DRUG|mitomycin C|
58073481|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
58404962|NCT00241631|DRUG|placebo|
58073482|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
58404963|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
58404964|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
58073483|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
58073484|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
58404965|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
58404966|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
58404967|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
57937542|NCT00068744|RADIATION|radiation therapy|
57937543|NCT02674698|OTHER|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
57937544|NCT02674698|OTHER|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
57937545|NCT02674698|OTHER|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
57937546|NCT02674698|OTHER|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
57937547|NCT04731038|DRUG|Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin|This is a single-arm study with all patients receiving these four drugs.
57937548|NCT02568475|BEHAVIORAL|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
58073485|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
58404968|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
57937549|NCT02109562|DRUG|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
57937550|NCT02109562|DRUG|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
57937551|NCT02109562|DRUG|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
57937552|NCT06401564|DEVICE|Virtual Reality Therapy|Each participant will receive one or two 20 minute VR sessions during their admission. Participants are able to pause or discontinue at any time. During each VR session, participants will use the REAL Immersive VR system and be equipped with a VR headset and 6 sensors attached to the torso, waist, and upper extremities. Patient will then undergo various virtual challenges guided by the physical or occupational therapist facilitating movements of the upper extremity, core, head, and neck.
57937553|NCT01460095|OTHER|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
57937554|NCT02024568|DRUG|Pregabalin|See arm description
58073486|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
58073487|NCT00121251|DRUG|Capecitabine|Given PO
58073488|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
58073489|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
58292750|NCT03446378|DEVICE|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
58292751|NCT03642535|DRUG|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
58404969|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
57730290|NCT05017740|PROCEDURE|ICSI|In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.
57730291|NCT05017740|PROCEDURE|PICSI|In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
57730292|NCT06081660|BEHAVIORAL|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
57730293|NCT01169870|DRUG|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
57730294|NCT01169870|DRUG|Paclitaxel|
57937555|NCT02024568|DRUG|Placebo|See arm description
57937556|NCT06345521|OTHER|No intervention|No intervention
57730295|NCT03221582|DRUG|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
57730296|NCT05114681|OTHER|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
58073490|NCT06580548|DEVICE|CHW-supported telerehabilitation|Participants will receive the Mobile Rehab mobile software, which allows participants to be prescribed personalized rehabilitation strengthening video regimens electronically based on respondent-indicated mobility and activities of daily living functionality
58073491|NCT06580548|OTHER|Usual Care|Participants will be provide a list of local social services resources, including mental health, that participants can use . A callback number will be provided if they have any questions about the services.
58073492|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
58073493|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
58073494|NCT06036407|DIAGNOSTIC_TEST|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
58095503|NCT06540924|OTHER|single nucleotide polymorphisms|The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
58292752|NCT04147247|DRUG|BI 905681|Infusion
58292753|NCT04821843|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
58292754|NCT04821843|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
58292755|NCT04821843|RADIATION|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
58292756|NCT04821843|PROCEDURE|Surgery|Radical esophagectomy
58292757|NCT04821843|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
58292758|NCT04821843|DRUG|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
57730297|NCT01889537|BEHAVIORAL|Virtual Reality|The patient will receive virtual reality during a burn care procedure
58404970|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
58404971|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
58404972|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
57937557|NCT06059924|OTHER|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
57937558|NCT06335810|BEHAVIORAL|Social Network Intervention|Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.
57937559|NCT06335810|BEHAVIORAL|Individual Lifestyle Intervention|The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.
57937560|NCT06335810|OTHER|Social Network Member|The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
57937561|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
57937562|NCT02661698|DIETARY_SUPPLEMENT|Placebo|3 x 1 g capsules Placebo: olive oil
58073495|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
58073496|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
58292759|NCT04821843|DRUG|Nimotuzumab|200-400mg, d1,qW
58292760|NCT05897515|DIAGNOSTIC_TEST|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
58292761|NCT03764514|DEVICE|Spinal Cord Stimulator|Permanent Implantation
58292762|NCT00624000|DRUG|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
58292763|NCT01908712|DRUG|Lamazym|ERT, i.v. infusions weekly
58292764|NCT05063578|DRUG|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
57937563|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
57937564|NCT05482074|DRUG|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
57937565|NCT05563675|DRUG|Long acting muscarinic antagonists (LAMAs) in the evening|LAMAs administered at bedtime (8pm - 2am)
57937566|NCT01363388|DRUG|Placebo|BID for 84 days
57937567|NCT01363388|DRUG|CCX168|BID for 84 days
58292765|NCT02810275|DRUG|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
58292766|NCT02810275|DRUG|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
57937568|NCT01053442|DIETARY_SUPPLEMENT|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
57937569|NCT01053442|DIETARY_SUPPLEMENT|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
57937570|NCT00003042|BIOLOGICAL|filgrastim|
57937571|NCT00003042|DRUG|cisplatin|
57937572|NCT00003042|DRUG|cyclophosphamide|
57937573|NCT00003042|DRUG|doxorubicin hydrochloride|
57937574|NCT00003042|DRUG|melphalan|
57937575|NCT00003042|DRUG|mesna|
57937576|NCT00003042|DRUG|paclitaxel|
57937577|NCT00003042|DRUG|tamoxifen citrate|
57937578|NCT00003042|PROCEDURE|bone marrow ablation with stem cell support|
57937579|NCT00003042|PROCEDURE|conventional surgery|
57937580|NCT00003042|PROCEDURE|peripheral blood stem cell transplantation|
57937581|NCT03353974|DEVICE|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
57937582|NCT03353974|DEVICE|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
57937583|NCT02830672|PROCEDURE|Surgical release A1 pulley for Trigger finger of the hand|
57937584|NCT02895503|BEHAVIORAL|Yoga|Participate in yoga
57937585|NCT02895503|BEHAVIORAL|Support Group Therapy|Participate in emotional support group therapy
57937586|NCT02895503|OTHER|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
57937587|NCT02895503|OTHER|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
57937588|NCT00545402|DRUG|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
57937589|NCT00545402|DRUG|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
57937590|NCT00545402|DRUG|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
57730298|NCT05430529|BEHAVIORAL|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
57937591|NCT00545402|DRUG|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
57937592|NCT00545402|DRUG|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
57937593|NCT01848886|PROCEDURE|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
57937594|NCT01848886|PROCEDURE|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
57937595|NCT01848886|PROCEDURE|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
57937596|NCT01848886|PROCEDURE|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
57937597|NCT00580372|DRUG|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
57937598|NCT00580372|DRUG|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
57937599|NCT00580372|PROCEDURE|Hemopoietic stem cell procurement|Collection target = 10 x 10\^6 cells/kg
57937600|NCT00580372|DRUG|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
57937601|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
57937602|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
57937603|NCT00580372|DRUG|Maintenance|3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
57937604|NCT01580865|DRUG|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
57937605|NCT01482585|OTHER|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
58404973|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
58404974|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
58404975|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
58404976|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
58404977|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
58404978|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
58404979|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
58404980|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
58404981|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
58404982|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
58404983|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
58404984|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
58404985|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
57730299|NCT05430529|BEHAVIORAL|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
57937606|NCT02046096|DEVICE|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
57937607|NCT02046096|DEVICE|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
57937608|NCT02248948|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
58404986|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
58404987|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
58404988|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
58404989|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
58404990|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
58404991|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
58404992|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
58404993|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
57937609|NCT02248948|DIETARY_SUPPLEMENT|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
57937610|NCT05147467|DRUG|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
58404994|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
58404995|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
57937611|NCT04766476|DRUG|BMS-963272|Specified dose on specified days
57937612|NCT04766476|OTHER|Placebo matching BMS-963272|Specified dose on specified days
57937613|NCT04513886|PROCEDURE|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
57937614|NCT04795726|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
57937615|NCT04795726|DRUG|Placebo|Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
57937616|NCT04262050|DEVICE|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
57937617|NCT05013645|OTHER|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
58292767|NCT06069739|BEHAVIORAL|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
58292768|NCT06069739|BEHAVIORAL|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
58292769|NCT03004768|DRUG|BMS-986165|Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
58292770|NCT02324361|OTHER|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
58292771|NCT02324361|BEHAVIORAL|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
58404996|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
58404997|NCT02808195|OTHER|Constraint-induced therapy|
58404998|NCT02808195|OTHER|kinect-based constraint-induced therapy|
58404999|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
58405000|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
57937618|NCT05013645|OTHER|Placebo|Gel control product
58405001|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
58405002|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
58405003|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
58405004|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
58405005|NCT02154620|DEVICE|Synthes TCP volar plate|
58405006|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
58405007|NCT00446953|OTHER|placebo|c-section at 39 weeks
58405008|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
57937619|NCT02726971|DRUG|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
57937620|NCT00660270|PROCEDURE|Pancreatic Surgery|
57937621|NCT00660270|RADIATION|Radiation therapy|
57937622|NCT00660270|DRUG|Cisplatin|
57937623|NCT00660270|DRUG|5-FU|
57937624|NCT00660270|DRUG|Alpha-interferon|
57937625|NCT00660270|DRUG|Gemcitabine|
57937626|NCT04142528|DEVICE|ParkinPal|Wear and periodic recording of motion data during daily wear
57937627|NCT02368067|PROCEDURE|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
57937628|NCT02368067|PROCEDURE|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
57937629|NCT03494751|DEVICE|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
57937630|NCT03494751|DEVICE|No heart monitor|Standard monitoring by nurses.
57937631|NCT04159597|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet.
57937632|NCT05893602|OTHER|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
58405009|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
58405010|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
58405011|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
58405012|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
58405013|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
58405014|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
58405015|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
57730300|NCT05430529|BEHAVIORAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
57730301|NCT06288984|DEVICE|active rTMS|The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks
57937633|NCT04312373|OTHER|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
58292772|NCT05002166|OTHER|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
58292773|NCT02959918|DRUG|SEL-212|SEL-212, biologic
58292774|NCT02959918|DRUG|SEL-037|SEL-037, biologic
58405016|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
58405017|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
58405018|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
58405019|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
58405020|NCT00521690|DRUG|insulin detemir|
58405021|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
58405022|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
58405023|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
58405024|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
58292775|NCT02959918|DRUG|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
58292776|NCT04512144|BEHAVIORAL|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
57937634|NCT00020579|DRUG|entinostat|
57937635|NCT04442191|BIOLOGICAL|Convalescent plasma|This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
57937636|NCT04442191|BIOLOGICAL|Placebo|The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
57937637|NCT04171518|DEVICE|Catalys Precision Laser System|Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
58292777|NCT05686863|DRUG|Remimazolam|Remazolam for sedation in children undergoing bidirectional endoscopy
58292778|NCT05686863|DRUG|Esketamine|Esketamine
58292779|NCT05686863|DRUG|Propofol|Propofol
58292780|NCT05686863|DRUG|remifentanil|remifentanil
58292781|NCT01383434|PROCEDURE|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
58292782|NCT00630799|DRUG|leuprolide acetate|17 mg i.m.
58292783|NCT04592549|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
58292784|NCT04592549|OTHER|Placebo|Placebo
58292785|NCT03677869|DEVICE|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
58292786|NCT00701688|DRUG|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
58292787|NCT04394156|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
58292788|NCT04964661|OTHER|Medical Imaging|MRI imaging
58292789|NCT00013871|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
58292790|NCT00013871|BIOLOGICAL|Measles-Mumps-Rubella Vaccine (Live)|
58292791|NCT00013871|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
58292792|NCT00013871|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
58292793|NCT00013871|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
58292794|NCT00022750|BEHAVIORAL|Nurse Case Manager and Community Health Worker Team|
58073497|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
58073498|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
58073499|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
58073500|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
58073501|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
58292795|NCT03934008|OTHER|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
58292796|NCT00953888|DRUG|AZD5069|Single dose of oral solution.
58292797|NCT00953888|DRUG|Placebo|Single dose of oral solution.
58292798|NCT05637307|PROCEDURE|Sentinel node procedure|Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
58292799|NCT00201344|DRUG|Cisplatin,5-FU,Leucovorin|
58292800|NCT01881607|BEHAVIORAL|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
58292801|NCT00331838|DRUG|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
58292802|NCT00331838|DRUG|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
58292803|NCT00331838|DRUG|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
58292804|NCT00331838|DRUG|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
58292805|NCT01427010|RADIATION|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
58292806|NCT00534248|BIOLOGICAL|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
58292807|NCT00534248|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
58405025|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
58405026|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
58073502|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
57730302|NCT06288984|DEVICE|sham rTMS|The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
58073503|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
58073504|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
58073505|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
58073506|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
58073507|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
58073508|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
58073509|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
58073510|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
58073511|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
58073512|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
58073513|NCT03050723|DEVICE|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
57730303|NCT06631586|BIOLOGICAL|MTP-101C|MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
58073514|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
58073515|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
58073516|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
58073517|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
58405027|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
57730304|NCT06631586|BIOLOGICAL|MTP-101S|MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
58405028|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
57730305|NCT00005633|BIOLOGICAL|OVA BiP peptide|
57730306|NCT00005633|BIOLOGICAL|gp209-2M antigen|
57730307|NCT00005633|BIOLOGICAL|recombinant 70-kD heat-shock protein|
57730308|NCT00005633|BIOLOGICAL|tyrosinase peptide|
57730309|NCT02984540|OTHER|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
57730310|NCT02984540|OTHER|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
57730311|NCT02759159|PROCEDURE|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
57730312|NCT02759159|PROCEDURE|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
57730313|NCT03609827|DRUG|Melphalan|
57730314|NCT03335553|DRUG|BMS-986235|Specified dose on specified days
58405029|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
58405030|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
58405031|NCT02300558|DRUG|Eleclazine|Tablets administered orally
58405032|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
58405033|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
58405034|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
58405035|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
58405036|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
58405037|NCT06327555|BEHAVIORAL|the traditional rehabilitation group|The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.
58405038|NCT06327555|DEVICE|the remote rehabilitation group|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform remote rehabilitation at home. At least twice a week, both sets of training sessions are identical.
58405039|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
58073518|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
58073519|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
58073520|NCT06724705|DIETARY_SUPPLEMENT|Lactose|Participants receive lactose to determine whether it changes gut microbial hydrogen production
57730315|NCT03335553|OTHER|Placebo|Specified dose on specified days
57730316|NCT04931511|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
58073521|NCT06724705|DIETARY_SUPPLEMENT|Sucrose|Participants will consume sucrose which they will consume as a placebo
58073522|NCT06724705|DEVICE|Wear smart underwear|Participants will wear the smart underwear device to measure the microbiome activity index
58405040|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
58073523|NCT00394862|DRUG|multivitamin|
58292808|NCT04017715|OTHER|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
58405041|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
58405042|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
58405043|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
57730317|NCT04931511|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
58405044|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
58405045|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
57730318|NCT04931511|BEHAVIORAL|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
57730319|NCT00648076|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
58073524|NCT05485961|DRUG|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
58073525|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
58073526|NCT05485961|DRUG|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
58073527|NCT06722742|DRUG|Ketamine only|Inj: Ketamine given to group K following spinal anesthesia
58073528|NCT06722742|DRUG|Tramadol|Inj Tramadol given to group T following spinal anesthesia
58073529|NCT04969653|OTHER|Exposure of venous thromboembolism|Composite of pulmonary embolism and deep vein thrombosis
58073530|NCT05024721|DRUG|HIP2101|Test drug
58073531|NCT05024721|DRUG|RLD2101|Reference drug
58073532|NCT05024721|DRUG|HPP2101|Placebo drug
58073533|NCT05024721|DRUG|HPP2102|Placebo drug
58073534|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
58073535|NCT06722651|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|"Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components:~* Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and~* Netrod™ Renal Denervation Radiofrequency Generator The catheter's electrodes deploy into a self-adaptive basket structure, optimizing contact with the vessel wall for effective ablation."
58073536|NCT06722651|DEVICE|Sham Procedure|Patients will be remained on the catheterization table for at least 20 min prior to sheath removal.
58073537|NCT00004219|DRUG|granisetron hydrochloride|
58073538|NCT00004219|DRUG|lerisetron|
58073539|NCT00004219|RADIATION|radiation therapy|
58073540|NCT05463731|DRUG|Remternetug (IV)|Administered IV
57937638|NCT00896779|DRUG|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
58073541|NCT05463731|DRUG|Remternetug (SC)|Administered SC
58292809|NCT04017715|OTHER|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
58292810|NCT04017715|OTHER|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
58073542|NCT05463731|DRUG|Placebo|Administered IV or SC
58073543|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
58073544|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
58292811|NCT03925129|DEVICE|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
57730320|NCT00648076|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fed
57730321|NCT03613857|DRUG|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
58292812|NCT03925129|DEVICE|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
58292813|NCT00635544|OTHER|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
58292814|NCT00635544|OTHER|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
58292815|NCT05391997|OTHER|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
57730322|NCT03613857|DRUG|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
57730323|NCT03066531|BEHAVIORAL|ACT-based intervention|
57937639|NCT03702751|PROCEDURE|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
57937640|NCT03702751|PROCEDURE|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
57937641|NCT05436769|DRUG|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
58073545|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
58073546|NCT05261126|DRUG|Enclitide Chloride|Enclitide Chloride administered orally
58073547|NCT05261126|DRUG|Placebo|Placebo matching enclitide chloride administered orally
58073548|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
58073549|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
58073550|NCT06724783|DEVICE|Collagen membrane|Implant placement with simultaneous GBR covered with a collagen membrane
58405046|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
58405047|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
58405048|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
58405049|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
58405050|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
58405051|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
58405052|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
58405053|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
58405054|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
58405055|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
58405056|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
58405057|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
58405058|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
58405059|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
58405060|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
58405061|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
58405062|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
58405063|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
58405064|NCT05611229|DRUG|Nivolumab|Nivolumab
58405065|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
58405066|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
58405067|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
58405068|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
58405069|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
58405070|NCT00234481|DRUG|XL844|
57730324|NCT03066531|BEHAVIORAL|CBT-based intervention|
57730325|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
58405071|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
58405072|NCT02673476|DRUG|Placebo|Identical placebo tablets
58405073|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
58405074|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
58405075|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
58405076|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
58405077|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
57730326|NCT00724282|DRUG|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
57730327|NCT00724282|DRUG|Placebo|Placebo by mouth daily at bedtime for 9 days
57730328|NCT04243876|DIAGNOSTIC_TEST|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
57937642|NCT05436769|DRUG|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
58405078|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
57937643|NCT03093753|OTHER|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
57937644|NCT03093753|OTHER|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
58073551|NCT06722066|DEVICE|Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves|Device: Edwards SAPIEN 3 valve, Medtronic Evolut valve, Boston Acurate Neo valve, or Abbott Navitor Access route: transfemorak, subclavian, transapical, transcarotid, or transcaval The use of balloon dilation will be left to the discretion of the operator.
58292816|NCT05391997|OTHER|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
58292817|NCT00603603|OTHER|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
58292818|NCT00603603|OTHER|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
58292819|NCT02983045|DRUG|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
58292820|NCT02983045|DRUG|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
58292821|NCT02983045|DRUG|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
58292822|NCT02983045|DRUG|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
58292823|NCT00812175|DRUG|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
58292824|NCT00766597|DRUG|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
58292825|NCT06254989|OTHER|Aerobic Exercise|"Participants will engage in aerobic exercise at HNH fitness at a minimum of 2 days a week for 12 weeks. Participants will have their daily step count collected via the Fitbit during this period. VO2 measurements will also be collected during active intervention using the UNCCRI protocol.~The structured aerobic exercise program (Weeks 3-14) will entail 30 minutes of aerobic activity, 3 days a week, on the treadmill, at a goal of between 50 to 70% of predicted VO2 maximum heart rate. All structured aerobic program sessions will take place at Holy Name Health (HNH) Fitness and will be overseen by our collaborator and Director of Human Performance (Reg Grant). Exercise data will be recorded in the Technogym MyWellness cloud. Participants who drop out or discontinue attendance (defined as 4 consecutive sessions missed without notification of absence) before completion of the 12-week study intervention period will be replaced."
58405079|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
58405080|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
57937645|NCT03093753|OTHER|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
57937646|NCT03093753|DIETARY_SUPPLEMENT|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
58405081|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
58405082|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
58405083|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
58405084|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
58405085|NCT00529126|DRUG|SKY0402|SKY0402
58405086|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
58405087|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
58405088|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
58405089|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
58405090|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
58405091|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
57937647|NCT03093753|OTHER|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
57937648|NCT03093753|DIETARY_SUPPLEMENT|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
57937649|NCT03093753|OTHER|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
57937650|NCT03093753|DIETARY_SUPPLEMENT|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
58405092|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
58405093|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
58405094|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
58405095|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
58292826|NCT04710004|DEVICE|Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device|Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
58292827|NCT03263026|DRUG|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
58292828|NCT03263026|OTHER|R-CHOP + placebo|R-CHOP + placebo
58292829|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
58405096|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
58405097|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
58405098|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
58405099|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
58405100|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
58405101|NCT00422149|DRUG|Placebo treatment|Placebo treatment
58405102|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
57937651|NCT03093753|OTHER|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
57937652|NCT03093753|OTHER|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
58405103|NCT00000467|BEHAVIORAL|diet|
57937653|NCT03093753|OTHER|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
58292830|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
58292831|NCT03619655|PROCEDURE|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
58292832|NCT03619655|DRUG|18F-DCFPyL PET/CT|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
58292833|NCT03619655|DRUG|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
58292834|NCT03619655|PROCEDURE|WB-MRI|Whole body MRI exam (total examination time \< 50 minutes)
58292835|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + resveravine|
58292836|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
58292837|NCT00303238|DRUG|Rose hips extract + resveravine + Aframomum melegueta extract|
58292838|NCT01421641|DRUG|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
58292839|NCT01421641|DRUG|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
58292840|NCT03321201|PROCEDURE|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
58405104|NCT00000467|BEHAVIORAL|exercise|
58405105|NCT00000467|BEHAVIORAL|smoking cessation|
58405106|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
58405107|NCT05019742|DRUG|Placebo|Placebo
58405108|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
58405109|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
58405110|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
58405111|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
58405112|NCT02362516|DRUG|BI 425809|
57937654|NCT03093753|OTHER|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
57937655|NCT03093753|OTHER|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
57937656|NCT03093753|OTHER|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
57937657|NCT01500850|DRUG|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
58292841|NCT03321201|PROCEDURE|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
58405113|NCT00004248|BIOLOGICAL|aldesleukin|
58405114|NCT00004248|DRUG|doxorubicin hydrochloride|
57937658|NCT01500850|DRUG|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
57937659|NCT01500850|DRUG|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
57937660|NCT01500850|DRUG|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
57937661|NCT03974334|BEHAVIORAL|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
57937662|NCT04349878|DIAGNOSTIC_TEST|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
57937663|NCT01587378|DRUG|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
57937664|NCT01587378|DRUG|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
57937665|NCT00053703|DRUG|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
57937666|NCT00053703|DRUG|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
57937667|NCT00053703|DRUG|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
57937668|NCT01903070|DRUG|Linagliptin|
57937669|NCT04713202|DRUG|Telotristat ethyl|Telotristat Ethyl, 250mg
57937670|NCT04713202|DRUG|Peptide Receptor Radionuclide Therapy|Peptide Receptor Radionuclide Therapy
57937671|NCT04713202|OTHER|Placebo|Placebo
57937672|NCT05740020|DEVICE|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
57937673|NCT05740020|OTHER|The traditional exercise program|"The selected physical therapy program:~1. Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~2. Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~3. Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~4. Strengthening exercise: aims to improve the functional ability (figure 7).~5. Spider suspension exercise for 30 minutes (figure 8).~5. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
57937674|NCT00077051|DRUG|cisplatin|
57937675|NCT00077051|DRUG|cytochlor|
57937676|NCT00077051|DRUG|tetrahydrouridine|
57937677|NCT00077051|RADIATION|radiation therapy|
57937678|NCT01643525|DEVICE|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
57937679|NCT00623974|DRUG|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
57937680|NCT00623974|DRUG|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
57937681|NCT00623974|DRUG|Calcitriol|0.25 micrograms PO Every 12 Hours
58292842|NCT04554602|DIAGNOSTIC_TEST|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
58292843|NCT02600611|DRUG|iclaprim|Experimental treatment
58292844|NCT02600611|DRUG|vancomycin|Active comparator
58292845|NCT00152113|PROCEDURE|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
58292846|NCT00152113|DEVICE|CliniMACS|
57937682|NCT05831826|BIOLOGICAL|the inactivated COVID-19 vaccines|receive the doses of inactivated COVID-19 vaccines
57937683|NCT00515255|DRUG|Minocycline|Capsules
57937684|NCT05697263|OTHER|Periodization of training|Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
57937685|NCT05668039|PROCEDURE|Enhanced external counterpulsation|15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
57937686|NCT02409290|DRUG|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
57937687|NCT02409290|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
58405115|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
58405116|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
58405117|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
58405118|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
58405119|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
58073552|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
58292847|NCT00152113|DRUG|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
58292848|NCT04710680|OTHER|no intervention|no intervention
58292849|NCT03162185|DRUG|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
58405120|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
57730329|NCT05305144|PROCEDURE|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam"
57937688|NCT02409290|DRUG|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
57937689|NCT02409290|DRUG|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
57937690|NCT02409290|DRUG|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
58292850|NCT03162185|DRUG|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
58292851|NCT05204147|DRUG|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
58292852|NCT05204147|PROCEDURE|Biospecimen Collection|Correlative studies
58292853|NCT03897569|OTHER|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
58292854|NCT05383417|DEVICE|EndoClip|Clip attached to mid portion of the endotracheal tube.
58292855|NCT05148637|DRUG|Maintenance of general anesthesia by Sevoflurane|Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
58405121|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
57937691|NCT02409290|DRUG|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
57937692|NCT02409290|DRUG|Prothionamide|Prothionamide has a bacteriostatic action.
57937693|NCT02409290|DRUG|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
57937694|NCT02409290|DRUG|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
58292856|NCT05148637|DRUG|Maintenance of general anesthesia by Desflurane|Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
58292857|NCT05148637|DRUG|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
58292858|NCT05603585|DIETARY_SUPPLEMENT|Optimal protein supplementation to achieve 80% protein adequacy.|Additional protein required and delivered by adding protein powder and given in bolus feeds
58292859|NCT06611891|DRUG|68Ga-DOTATOC|Slow direct intravenous injection
58292860|NCT01911754|BIOLOGICAL|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
58292861|NCT06285799|DRUG|Low Dose IHAT|Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)
58405122|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
58405123|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
58405124|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
58405125|NCT01382303|DRUG|Placebo|placebo tablet three times a day
58405126|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
58405127|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
58405128|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
57937695|NCT02409290|DRUG|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
57937696|NCT05953558|DEVICE|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
57937697|NCT03109548|OTHER|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
58292862|NCT06285799|DRUG|High Dose IHAT|Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)
58292863|NCT06285799|DRUG|Carob Flour|Twice daily dose of 1 placebo capsule (carob flour)
58292864|NCT00141414|DRUG|Pregabalin|
58292865|NCT04703010|DEVICE|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
58292866|NCT04703010|DEVICE|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
58292867|NCT04703010|BEHAVIORAL|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
58292868|NCT01433419|DRUG|TAK-875|
58292869|NCT01433419|DRUG|TAK-875|
58292870|NCT00361452|DRUG|nebulized epinephrine and nebulized albuterol|
58405129|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
58405130|NCT00349180|DRUG|Enoxaparin sodium|
57937698|NCT06070844|BEHAVIORAL|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
58073553|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
58292871|NCT00107562|BEHAVIORAL|Adolescent Safer Sex Social Network Intervention|
58405131|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
58405132|NCT00522314|DEVICE|NIV and ACBT|
58405133|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
58405134|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
58073554|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
58073555|NCT00561262|OTHER|questionnaire administration|
57937699|NCT01020591|OTHER|Osteopathic evaluation|evaluation of movement and tissue mobility
58073556|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
58073557|NCT00561262|PROCEDURE|quality-of-life assessment|
58292872|NCT03666416|BEHAVIORAL|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
58292873|NCT03735407|DEVICE|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
58292874|NCT05179746|DEVICE|Implants are decontaminated with electrolytic cleaning|Implants are decontaminated with electrolytic cleaning
58292875|NCT05179746|DEVICE|Implants are decontaminated without electrolytic cleaning|Implants are decontaminated without electrolytic cleaning
58292876|NCT04330144|DRUG|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
58292877|NCT04330144|OTHER|Others(No intervention)|No treatment. Close monitoring and quarantine.
58292878|NCT04701450|OTHER|digital consent|the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
58292879|NCT03703752|DIAGNOSTIC_TEST|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
58405135|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
58405136|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
58405137|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
58405138|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
58405139|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
58073558|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
58292880|NCT00914134|DRUG|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
58292881|NCT01967771|DRUG|DTG|DTG will be supplied as 50 mg tablet to be administered orally
58292882|NCT01967771|DRUG|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
58292883|NCT02166359|DRUG|Extraneal (Icodextrin)|
57937700|NCT01020591|OTHER|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
58292884|NCT02166359|DRUG|Glucose solution|
58292885|NCT03455712|BEHAVIORAL|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
58292886|NCT04167189|DRUG|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
58292887|NCT03533231|COMBINATION_PRODUCT|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
57730330|NCT00423124|GENETIC|HSV-TK|Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
57937701|NCT00074022|BIOLOGICAL|GTI-2040|Given IV
57937702|NCT00074022|DRUG|docetaxel|Given IV
57937703|NCT00074022|OTHER|laboratory biomarker analysis|Correlative studies
58073559|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
58292888|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Propolis Paste|
58292889|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Metronidazole Paste|
58292890|NCT03533231|COMBINATION_PRODUCT|Propolis + Metronidazole paste|
58292891|NCT03974282|BEHAVIORAL|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
57730331|NCT04952545|DRUG|ALXN2050|Oral tablet.
57730332|NCT04952545|DRUG|Placebo|Oral tablet.
57730333|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
57937704|NCT00074022|OTHER|pharmacological study|Correlative studies
57937705|NCT06155747|OTHER|Epidemiologic investigation|"Identification of:~1. overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~2. environmental NTM isolates that are highly related to respiratory isolates.~3. common water source exposure among subjects with clustered NTM infections via shared home of residence watershed."
57937706|NCT04879641|BEHAVIORAL|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
58292892|NCT00196105|DEVICE|6 mm Nitinol Zilver Stent|
58292893|NCT00196105|DEVICE|10 mm Nitinol Zilver Stent|
58292894|NCT00196105|DEVICE|10 mm Stainless Steel Wallstent|
58292895|NCT00697593|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
58292896|NCT00765739|OTHER|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
58292897|NCT00765739|OTHER|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
58292898|NCT06134661|DEVICE|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session."
57730334|NCT06486259|OTHER|Controlled mechanical ventilation|Patients were ventilated under similar tidal volume, respiratory rate, and plateau pressure. PEEP was the adjustment variable to reach a similar plateau pressure
57730335|NCT03380442|DRUG|Psilocybin|Psilocybin ingested orally
57730336|NCT03380442|DRUG|Ketamine (Ketalar)|Ketamine administered intranasally
57730337|NCT01479660|OTHER|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
58292899|NCT00685360|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
57937707|NCT04879641|BEHAVIORAL|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
57937708|NCT04879641|BEHAVIORAL|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
57937709|NCT04879641|BEHAVIORAL|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
58073560|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
58073561|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
58073562|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
58073563|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
58073564|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
58073565|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
58073566|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
58073567|NCT06723691|DRUG|Acetaminophen|Acetaminophen
58073568|NCT06723691|DRUG|Metformin|Metformin
58073569|NCT06723691|DRUG|Warfarin|Warfarin
58073570|NCT06723691|DRUG|Atorvastatin|Atorvastatin
58073571|NCT06723691|DRUG|Digoxin|Digoxin
58073572|NCT06723691|DRUG|HRS9531|HRS9531
58073573|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
58292900|NCT00685360|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
58292901|NCT00685360|DRUG|Placebo|Placebo tablets matching 50-mg tablets of delamanid
58292902|NCT00538226|DEVICE|External Electric Muscle Stimulation|
58292903|NCT02824146|OTHER|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
58292904|NCT05989204|BIOLOGICAL|TmCD19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
58292905|NCT05816382|DRUG|TAK-861|TAK-861 tablets
58292906|NCT06612814|DRUG|Fluzoparib|Parp inhibitor
58292907|NCT06612814|DRUG|Dalpiciclib|CDK4/6 inhibitor
58292908|NCT06612814|DRUG|Fulvestrant/AI|Endocrine therapy
58292909|NCT03959046|BEHAVIORAL|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
58073574|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
57937710|NCT03120806|PROCEDURE|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
58073575|NCT03844048|DRUG|Venetoclax|oral; film-coated tablets or tablets for oral suspension
58073576|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
58073577|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
58073578|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
58292910|NCT06611592|DRUG|Pramipexole 0.088mg/tid|Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).
58292911|NCT06611592|DRUG|Pramipexole 0.18 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt)."
58405140|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
57937711|NCT03120806|PROCEDURE|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
58405141|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
58405142|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
58405143|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
58405144|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
58405145|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
58405146|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
57937712|NCT01161602|DRUG|Pumosetrag|
58292912|NCT06611592|DRUG|Pramipexole 0.35 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt)."
58292913|NCT02340143|OTHER|Control|Marketed partially hydrolyzed cow's milk protein infant formula
58292914|NCT02340143|OTHER|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
58292915|NCT01252407|OTHER|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
58292916|NCT02554045|DRUG|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
58292917|NCT02554045|DRUG|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
58292918|NCT01941394|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells infusion
58292919|NCT04275258|OTHER|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
58292920|NCT04227418|DEVICE|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
58292921|NCT04227418|DEVICE|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
58292922|NCT04227418|DEVICE|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
58292923|NCT05395871|BEHAVIORAL|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
58292924|NCT05395871|BEHAVIORAL|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
58292925|NCT05395871|OTHER|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
58405147|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
58405148|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
58405149|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
58405150|NCT00897403|OTHER|biologic sample preservation procedure|
58405151|NCT00897403|PROCEDURE|diagnostic colonoscopy|
58405152|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
58405153|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
58405154|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
58405155|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
57937713|NCT01161602|DRUG|Pumosetrag|
57937714|NCT01161602|OTHER|Placebo|
57937715|NCT01161602|DRUG|Pumosetrag|
57937716|NCT03933384|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
57937717|NCT03933384|DRUG|Entecavir|Entecavir 0.5mg/tab once daily
57937718|NCT02486848|DRUG|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
58292926|NCT05117112|DIETARY_SUPPLEMENT|XS Muscle Multiplier|Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
58292927|NCT03743766|DRUG|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
58292928|NCT03743766|DRUG|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
58292929|NCT03743766|DRUG|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
58405156|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
58405157|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
58405158|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
57937719|NCT02486848|DRUG|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
57937720|NCT02202291|GENETIC|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
57937721|NCT02204384|OTHER|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
58073579|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
58073580|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
58073581|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
58073582|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
58292930|NCT02975817|OTHER|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
58405159|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
57937722|NCT02204384|DIETARY_SUPPLEMENT|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
57937723|NCT02204384|OTHER|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
57937724|NCT05449197|OTHER|HEMOPHAR e-learning program|training on professional practice by following HEMOPHAR e-learning program
57937725|NCT01704287|BIOLOGICAL|Pembrolizumab|IV infusion
57937726|NCT01704287|DRUG|Carboplatin|Carboplatin per institutional standard
57937727|NCT01704287|DRUG|Paclitaxel|Paclitaxel per institutional standard
57937728|NCT01704287|DRUG|Dacarbazine|Dacarbazine per institutional standard
57937729|NCT01704287|DRUG|Temozolomide|Temozolomide per institutional standard
58292931|NCT02975817|OTHER|Warm Air|Active, convective warming of patient using warm air blanket
58292932|NCT05728333|DRUG|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
58292933|NCT05728333|DRUG|Alteplase|Intravenous alteplase before endovascular thrombectomy.
58405160|NCT04158141|DRUG|Carboplatin|Given IV
58073583|NCT05534412|OTHER|Academic Detailing|"1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
58073584|NCT05534412|OTHER|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
58292934|NCT06024811|BEHAVIORAL|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
58292935|NCT06164938|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
58292936|NCT03143101|BIOLOGICAL|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
58405161|NCT04158141|DRUG|Cisplatin|Given IV
58073585|NCT05534412|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
58073586|NCT05534412|OTHER|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
58073587|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
58292937|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
58405162|NCT04158141|PROCEDURE|Decortication|Undergo decortication
58405163|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58405164|NCT04158141|DRUG|Pemetrexed|Given IV
58405165|NCT04158141|DRUG|Pemetrexed Disodium|Given IV
58405166|NCT04158141|RADIATION|Pencil Beam Scanning|Undergo PBS
58405167|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
58073588|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
58292938|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
58292939|NCT01766531|DEVICE|body bioelectrical impedance|
58292940|NCT04587141|DRUG|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
58292941|NCT04587141|DRUG|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
58405168|NCT04158141|OTHER|Quality-of-Life Assessment|Ancillary studies
58405169|NCT04158141|OTHER|Questionnaire Administration|Ancillary studies
58405170|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
58405171|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
58405172|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
57937730|NCT04157816|OTHER|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
57937731|NCT04157816|OTHER|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
58073589|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
58073590|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
58292942|NCT04587141|DRUG|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
58292943|NCT02223351|DRUG|ASP2151|
58292944|NCT02223351|DRUG|ritonavir|
58292945|NCT03092570|DEVICE|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
58292946|NCT03092570|DEVICE|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
58292947|NCT04814589|DRUG|ezetimibe tablets|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
58292948|NCT04814589|DRUG|ezetimibe tablets(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
58405173|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
58405174|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
58405175|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
58405176|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
58405177|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
58405178|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
58405179|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
58405180|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
58405181|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
58405182|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
58405183|NCT02937077|DEVICE|Medtronic Reveal LINQ|
58405184|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
58073591|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
58292949|NCT02759094|DEVICE|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
58405185|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
57937732|NCT04157816|OTHER|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
58073592|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
58073593|NCT06722703|PROCEDURE|shock wave lithotripsy|Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.
58292950|NCT01095627|OTHER|Metacholine challenge|Exhaled breath analysis following metacholine challenge
58292951|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
58292952|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
58292953|NCT00961779|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
58292954|NCT00961779|DRUG|Placebo|Normal saline infusion
58292955|NCT03020628|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
58292956|NCT03020628|BIOLOGICAL|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
58292957|NCT00254059|PROCEDURE|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
58292958|NCT00938665|DEVICE|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
58292959|NCT02186977|DEVICE|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
58292960|NCT02186977|DRUG|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
58292961|NCT02186977|DRUG|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
58292962|NCT01688323|OTHER|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
58292963|NCT02217111|BEHAVIORAL|Adventures in Voice: Pediatric Voice Therapy|
58405186|NCT00869804|BEHAVIORAL|Attention control|
58292964|NCT05262335|DRUG|Anlotinib + Oxaliplatin + Capecitabine|"1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
58292965|NCT05262335|DRUG|Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|"1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
58405187|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
58405188|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
58405189|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
57937733|NCT05485584|DRUG|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
58292966|NCT05262335|DRUG|Anlotinib + Standard first-line chemotherapy|"1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
58073594|NCT06722703|PROCEDURE|Flexible ureteroscope lithotripsy|All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
58073595|NCT03644862|DEVICE|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
58292967|NCT01431339|DRUG|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
58292968|NCT01431339|DRUG|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
58292969|NCT05302375|OTHER|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
58292970|NCT00002917|DRUG|paclitaxel|
58292971|NCT06484296|OTHER|Education|"Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test."
58292972|NCT03975504|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
58292973|NCT03975504|DEVICE|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
58292974|NCT03975504|DIAGNOSTIC_TEST|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
58292975|NCT04500301|OTHER|Preemptive Pharmacogenomic Testing|The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
58292976|NCT03339414|OTHER|collect blood|collect blood at different time point
58292977|NCT02988739|BIOLOGICAL|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
58292978|NCT02988739|DEVICE|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
58292979|NCT04988334|OTHER|Wait Control|usual activities
58292980|NCT00768690|DRUG|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
58292981|NCT00768690|DRUG|ketoconazole|Tablet, see arms for intervention description
58292982|NCT00768690|DRUG|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
58292983|NCT03068689|PROCEDURE|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is \> 185mm HG the cuffs are inflated to 15 mmHG above that level.
58292984|NCT03068689|OTHER|Placebo|Placebo
58292985|NCT06612138|OTHER|pilates exercises|the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises
58292986|NCT06612138|OTHER|yoga exercises|"the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing."
58292987|NCT06612138|OTHER|tai chi exercises|the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.
58292988|NCT06612138|OTHER|tradional physical therapy|Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
58292989|NCT02526160|BIOLOGICAL|burosumab|solution for SC injection
58292990|NCT02526160|OTHER|Placebo|saline solution for SC injection
58292991|NCT05371561|DEVICE|reusable respirators|Dentist wearing reusable respirator will examin the patient
58292992|NCT02465437|DRUG|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
58292993|NCT02465437|DRUG|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
58292994|NCT02465437|DRUG|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
58292995|NCT05182411|OTHER|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
58292996|NCT01972412|BEHAVIORAL|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
58292997|NCT00646373|OTHER|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
58292998|NCT00002071|DRUG|Epoetin alfa|
58405190|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
57937734|NCT05485584|DRUG|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
58073596|NCT06723119|OTHER|Resveratrol (VRES) 500 mg oral once daily.|Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
58073597|NCT06723119|OTHER|Placebo 500 mg oral once daily.|Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
58073598|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
58292999|NCT01290302|DRUG|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
58293000|NCT01290302|DRUG|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
57937735|NCT05485584|DRUG|Placebo Nasal Spray|Once daily
57937736|NCT05485584|DRUG|Placebo Nasal Spray|Twice daily
57937737|NCT04672265|OTHER|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
57937738|NCT04533087|OTHER|No intervention|No intervention
58073599|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
58073600|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
58073601|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
58073602|NCT06079879|DRUG|Bomedemstat|Oral Capsule
58073603|NCT06079879|DRUG|Anagrelide|Oral Capsule
58073604|NCT06079879|DRUG|Busulfan|Oral Tablet
58293001|NCT00094679|DEVICE|Eye patch|adhesive patch to cover the sound eye
58293002|NCT03783286|DRUG|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
58293003|NCT01124669|GENETIC|DNA analysis|
58293004|NCT01124669|GENETIC|mutation analysis|
58293005|NCT01124669|OTHER|laboratory biomarker analysis|
58293006|NCT02690272|BEHAVIORAL|Psychic processes|Quantitative and qualitative aprroche of the psychic process
58293007|NCT01963884|PROCEDURE|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
58293008|NCT01963884|RADIATION|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
58293009|NCT01963884|OTHER|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
58293010|NCT06347367|OTHER|Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)|Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
58293011|NCT06347367|OTHER|Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)|İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
58293012|NCT03923881|DEVICE|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
58293013|NCT00172445|PROCEDURE|blood sampling, neck lymph node biopsy|
58293014|NCT01517633|DEVICE|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
58293015|NCT02853045|DRUG|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
58293016|NCT02853045|DRUG|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
58405191|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
58405192|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
58073605|NCT06079879|DRUG|Interferon alfa/pegylated interferon alfa|Subcutaneous Solution
58073606|NCT06079879|DRUG|Ruxolitinib|Oral Tablet
58073607|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
58073608|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
58073609|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
58073610|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
58073611|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
58073612|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
58073613|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
57730338|NCT01479660|DRUG|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
57730339|NCT02742727|BIOLOGICAL|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
57937739|NCT02954146|BEHAVIORAL|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
57937740|NCT00804570|DRUG|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
57937741|NCT00804570|DRUG|placebo|once daily, orally, 16 weeks
57937742|NCT04253535|OTHER|questionnaries|Study on questionnaries
57937743|NCT01117454|DRUG|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
57937744|NCT01117454|DRUG|Placebo|placebo, similar in appearance to flecainide
57937745|NCT01117454|DRUG|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
57937746|NCT00492323|DRUG|placebo|twice daily for 4 weeks
57937747|NCT00492323|DRUG|carisbamate|200 mg tablet twice daily for 4 weeks
57937748|NCT03216811|DRUG|nutraceutical|8-week administration of nutraceutical compound
57937749|NCT00350168|DRUG|valsartan + amlodipine|
57937750|NCT04198454|OTHER|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
58073614|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
58073615|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
58073616|NCT04086745|DRUG|Baricitinib|Administered orally.
58073617|NCT04086745|DRUG|TNF Inhibitor|Administered SC
58073618|NCT06101381|BIOLOGICAL|CART-19|The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
58073619|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
58073620|NCT00079079|DRUG|carboplatin|
58073621|NCT00079079|DRUG|cisplatin|
58073622|NCT00079079|DRUG|gemcitabine hydrochloride|
57937751|NCT04198454|OTHER|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
57937752|NCT04198454|DEVICE|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
57937753|NCT01992120|OTHER|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
57937754|NCT01992120|OTHER|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
57937755|NCT03837704|OTHER|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
57937756|NCT03837704|OTHER|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
58073623|NCT03758612|DRUG|TBI-223 oral suspension|TBI-223 oral suspension, orally administered.
57730340|NCT06283979|COMBINATION_PRODUCT|STIMULAN VG|Insertion of STIMULAN VG into the ulcer cavity prior to flap closure.
57730341|NCT06283979|PROCEDURE|Standard of Care|Standard of Care. Ulcer bursectomy, debridement and flap closure. Peri-operative antibiotics.
57730342|NCT02328326|OTHER|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
57937757|NCT03837704|OTHER|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
57937758|NCT05902078|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
57937759|NCT05902078|DRUG|Calcitriol capsules|Oral calcitriol 0.5μg daily
58073624|NCT03758612|DRUG|TBI-223 enteric capsule|TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.
58073625|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 1|TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.
58073626|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 2|TBI-223 600 mg SR tablet Prototype 2, orally administered.
58073627|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 3|TBI-223 900 mg SR tablet Prototype 3, orally administered.
58073628|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet, orally administered
58073629|NCT03758612|DRUG|Placebo suspension|Placebo for TBI-223 oral Suspension; orally administered.
58073630|NCT03846310|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
58073631|NCT03846310|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
58073632|NCT03846310|DRUG|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
58073633|NCT03846310|DRUG|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
58073634|NCT03846310|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
58405193|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
58293017|NCT05074524|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
58293018|NCT05074524|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
58293019|NCT06221371|DRUG|rhTNK-tPA|rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.
58293020|NCT06221371|DEVICE|direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
58293021|NCT00338403|PROCEDURE|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
58293022|NCT02602314|DRUG|Imatinib|
58293023|NCT02602314|DRUG|Nilotinib|
58293024|NCT04220801|DRUG|ZM-H1505R|Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
58405194|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
58405195|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
58405196|NCT00549263|DRUG|SB797620|
58405197|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58405198|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
58405199|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
58405200|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
58405201|NCT00003914|DRUG|dolastatin 10|
58405202|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
58405203|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
58405204|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
57937760|NCT05106504|DRUG|Medical Cannabis|Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
57937761|NCT04054089|DRUG|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
58405205|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
58405206|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
58405207|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
58405208|NCT05385887|DRUG|Placebo|Placebo tablets
57937762|NCT04054089|DRUG|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
58405209|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
58073635|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
58073636|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
58405210|NCT01447485|DRUG|Valsartan (VAL489)|
58405211|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
58405212|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
58405213|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
58073637|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
58405214|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
58405215|NCT00182052|OTHER|Placebo|Given orally twice daily.
58405216|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
58405217|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
58405218|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
58405219|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
58405220|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
58405221|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
58405222|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
58405223|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
58405224|NCT01925495|OTHER|varied middle-ear pressure|
57937763|NCT04062526|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
58405225|NCT01925495|DRUG|varied middle-ear gas composition|
58405226|NCT01925495|OTHER|varied ear-canal pressure|
58405227|NCT00004552|DRUG|acamprosate (Campral)|
57937764|NCT06098898|DRUG|NK510|NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.
57937765|NCT06098898|DRUG|Tislelizumab，atezolizumab or Trastuzumab|Administer according to the instructions.
57937766|NCT05956145|DRUG|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
57937767|NCT05956145|OTHER|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
57937768|NCT03100071|DRUG|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
57937769|NCT02576444|DRUG|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
57937770|NCT02576444|DRUG|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
58293025|NCT04826159|DRUG|IMB-1018972|Modified release tablet for oral administration
58293026|NCT02137148|DEVICE|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
58405228|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
58405229|NCT02082457|DRUG|YKP10811 5mg|
58405230|NCT02082457|DRUG|YKP10811 20mg|
58405231|NCT02082457|DRUG|YKP10811 placebo|
58405232|NCT01657890|DRUG|isavuconazole|oral
58293027|NCT00874159|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
58293028|NCT05639218|DRUG|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
58405233|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
58405234|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
58405235|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
58293029|NCT02105233|BIOLOGICAL|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
58293030|NCT03113968|PROCEDURE|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
58293031|NCT03113968|DRUG|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
58293032|NCT03940196|DEVICE|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
58293033|NCT03940196|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
58293034|NCT00943397|DRUG|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
58293035|NCT00943397|DRUG|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
58293036|NCT05185466|BEHAVIORAL|Nurse-Supported Self Management Programme|Training and incentives to improve nutrition habits and sleep health.
58293037|NCT03438201|DIETARY_SUPPLEMENT|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
58293038|NCT03438201|DIETARY_SUPPLEMENT|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
58293039|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
58405236|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
58405237|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
57937771|NCT02576444|DRUG|AZD1775|The recommended dose will be available no earlier than March 2016.
57937772|NCT02576444|DRUG|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
57937773|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow oxygen
58293040|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
57937774|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow air
57937775|NCT02357134|OTHER|Quality-of-Life Assessment|Ancillary studies
57937776|NCT02357134|OTHER|Questionnaire Administration|Ancillary studies
57937777|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow oxygen
57937778|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow air
57937779|NCT03392272|DEVICE|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
58405238|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
58405239|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
58405240|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
58405241|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
58405242|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
58405243|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
58405244|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
58405245|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
58405246|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
58293041|NCT00438204|BIOLOGICAL|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
58405247|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
58405248|NCT01725230|DRUG|Fostamatinib|100-mg tablet
58405249|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
58405250|NCT01725230|DRUG|Simvastatin|40-mg tablet
58405251|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
58405252|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
58293042|NCT00438204|DRUG|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
58293043|NCT00438204|DRUG|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
58293044|NCT01793038|DRUG|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
58293045|NCT01793038|DRUG|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
58293046|NCT06331832|BIOLOGICAL|IGM2323|Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε.
58293047|NCT03159832|DRUG|SHR3824|All subjects were given SHR3824 20mg only one time.
58293048|NCT00712894|DRUG|Diltiazem|Intracoronary Infusion 400-2000ug
58293049|NCT00712894|DRUG|Verapamil|Intracoronary Infusion 200-1000ug
58293050|NCT00712894|DRUG|Nitroglycerin|Intracoronary Infusion 200-1000ug
58293051|NCT00073450|DRUG|Farnesyl Protein Transferase Inhibitor|
58293052|NCT04974892|DIAGNOSTIC_TEST|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
57730343|NCT02328326|OTHER|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
57730344|NCT02574546|PROCEDURE|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
58293053|NCT01918657|DRUG|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
58293054|NCT01918657|DRUG|walnut powder|escalating doses of walnut powder
58293055|NCT01945047|DRUG|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
58293056|NCT01945047|DRUG|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
58293057|NCT03452956|OTHER|None-Observation Only|No intervention-this is an observational study
58293058|NCT02608385|RADIATION|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
58293059|NCT02608385|DRUG|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
58293060|NCT04522557|DRUG|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
58293061|NCT03574974|DEVICE|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
57730345|NCT02048384|DRUG|metformin alone (Arm A)|metformin alone
57730346|NCT02048384|DRUG|metformin (Arm B)|rapamycin + metformin
57730347|NCT02048384|DRUG|rapamycin (Arm B)|rapamycin + metformin
57937780|NCT03392272|OTHER|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
57937781|NCT00951301|DRUG|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
58405253|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
58405254|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
58405255|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
58405256|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
58405257|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
58405258|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
57937782|NCT00951301|DRUG|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
58073638|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
58073639|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
58073640|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
58073641|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
58293062|NCT03574974|DEVICE|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
58293063|NCT05359614|DEVICE|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
58293064|NCT05359614|DEVICE|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
58293065|NCT02949882|DIETARY_SUPPLEMENT|Yakult|Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
58293066|NCT02949882|DIETARY_SUPPLEMENT|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
58293067|NCT04552561|BEHAVIORAL|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
58293068|NCT05278741|PROCEDURE|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months, six months and 12 months: 2 questionnaires + two tests will be perfomed"
58293069|NCT02052427|DEVICE|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
58293070|NCT02052427|DEVICE|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
58293071|NCT05433545|OTHER|Questionnaire|Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
58293072|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer only|classical arthrocentesis with lactate ringer only (control group).
58293073|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)|classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
58293074|NCT00202501|DEVICE|Nasal CPAP (Continuous Positive Airway Pressure)|
58293075|NCT02966847|PROCEDURE|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
58405259|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
58405260|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
57937783|NCT03882203|DRUG|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
57937784|NCT04795856|DRUG|[11C] acetate|PET Tracer
57937785|NCT00058552|DRUG|Pertuzumab (rhuMAb 2C4)|
57937786|NCT00490633|BEHAVIORAL|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
57937787|NCT00490633|BEHAVIORAL|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
57937788|NCT01553188|DRUG|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
58073642|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
58293076|NCT02966847|PROCEDURE|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
58293077|NCT03586050|DEVICE|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
57937789|NCT01553188|DRUG|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
58405261|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
57730348|NCT03575923|BEHAVIORAL|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
57730349|NCT02932618|BIOLOGICAL|von Willebrand factor (Recombinant)|Lyophilized powder and solvent to prepare solution for injection.
57937790|NCT01553188|DRUG|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
57937791|NCT06161662|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
57937792|NCT06161662|OTHER|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
57937793|NCT03589495|DRUG|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
57937794|NCT03589495|OTHER|dextrose 5%|
57937795|NCT03165435|BIOLOGICAL|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
57937796|NCT03165435|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
57937797|NCT01262937|DEVICE|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
57937798|NCT03483909|DEVICE|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
57937799|NCT03483909|DEVICE|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
57937800|NCT03483909|DEVICE|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
57937801|NCT00156351|BEHAVIORAL|Physical activity promotion|
57937802|NCT01091688|BEHAVIORAL|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
58293078|NCT05056402|BIOLOGICAL|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
58293079|NCT05056402|BIOLOGICAL|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
58293080|NCT05098327|DRUG|Pioglitazone 30 mg|pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
58293081|NCT05098327|DRUG|Placebo|placebo pills containing cellulose 1 pill daily will be given for 12 weeks
58293082|NCT00331539|DEVICE|Cochlear Implant|
58293083|NCT05717712|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
58405262|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
58405263|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
57937803|NCT03561792|OTHER|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
57937804|NCT02818166|PROCEDURE|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
57937805|NCT06227364|DIAGNOSTIC_TEST|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
58293084|NCT05586997|DEVICE|Bonded-Hyrax|The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
58293085|NCT05586997|COMBINATION_PRODUCT|Bonded Rapid Maxillary Expansion and low-Level Laser therapy|Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
58405264|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
58405265|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
58073643|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
58073644|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
58073645|NCT04152200|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
58073646|NCT03072927|DEVICE|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
58073647|NCT03072927|DEVICE|Interspinous Process Decompression|Interspinous Process Decompression
58293086|NCT02600923|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
58293087|NCT02600923|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
58293088|NCT03335813|DEVICE|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
58293089|NCT00642005|PROCEDURE|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
58405266|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
58405267|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
58405268|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
58405269|NCT01955434|DRUG|Cyclophosphamide|Given PO
58405270|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
58405271|NCT01955434|OTHER|Pharmacological Study|Correlative studies
58405272|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
58405273|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
58405274|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
58073648|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
58293090|NCT00642005|PROCEDURE|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
58293091|NCT00550797|BIOLOGICAL|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
58293092|NCT00550797|BIOLOGICAL|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
58293093|NCT06128421|DIETARY_SUPPLEMENT|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
58405275|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
58405276|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
58405277|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
58405278|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
58405279|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
58405280|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
58405281|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
58405282|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
58073649|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
57730350|NCT02932618|BIOLOGICAL|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
57937806|NCT06227364|DIAGNOSTIC_TEST|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
58073650|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
58073651|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
58073652|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
58073653|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
57937807|NCT00391664|BEHAVIORAL|Psychosocial|
57937808|NCT06426485|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablets|orally once a day
57937809|NCT06426485|DRUG|placebo|orally once a day
57937810|NCT03611621|DRUG|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
57937811|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
57937812|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FSPG PET/CT
58073654|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
58073655|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
58073656|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
58073657|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
57730351|NCT00700687|DRUG|PA32540|aspirin/omeprazole
57730352|NCT00700687|DRUG|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
57937813|NCT02448225|RADIATION|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
57937814|NCT02448225|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
57937815|NCT02448225|OTHER|Laboratory Biomarker Analysis|Correlative studies
57937816|NCT02448225|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
57937817|NCT02448225|PROCEDURE|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
58073658|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
58073659|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
57937818|NCT03901573|DRUG|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
57937819|NCT03901573|DRUG|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
57937820|NCT01086410|DRUG|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
58073660|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
58073661|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
58073662|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
58293094|NCT06014177|BEHAVIORAL|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
57937821|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
57730353|NCT00700687|DRUG|aspirin and [NSAID]|aspirin and \[NSAID\]
57730354|NCT06296719|OTHER|Chit-Chat|Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
57730355|NCT00679003|BEHAVIORAL|SLCBT|Social learning and cognitive behavioral therapy
57730356|NCT00679003|BEHAVIORAL|ES|Education and support (information about nutrition and gastrointestinal system)
58293095|NCT06014177|OTHER|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
58405283|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
58405284|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
58405285|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
58405286|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
57937822|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
58405287|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
57937823|NCT01086410|DRUG|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
58073663|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
58293096|NCT03146338|OTHER|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
58405288|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
58405289|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
57937824|NCT01086410|DRUG|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
57937825|NCT03914404|DRUG|γ-linoleic acid and placebo(Thioctic Acid)|"* γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
57937826|NCT03914404|DRUG|Thioctic Acid and placebo(γ-linoleic acid)|"* Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
58073664|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
58073665|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
58073666|NCT06724484|PROCEDURE|Surgical management of fracture|Surgical management of fracture
58293097|NCT02267070|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
58293098|NCT02267070|BEHAVIORAL|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
58293099|NCT02267070|BEHAVIORAL|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
58293100|NCT02267070|BEHAVIORAL|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
58293101|NCT00610181|PROCEDURE|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
58073667|NCT06724484|OTHER|No intervention|No intervention
58405290|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
58293102|NCT01341093|BEHAVIORAL|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
58293103|NCT01341093|BEHAVIORAL|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
58293104|NCT04002726|OTHER|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
58293105|NCT05701540|DRUG|Tegoprazan|Tegoprazan 50mg tablet
58293106|NCT05701540|DRUG|Esomeprazole|"Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet"
58293107|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
57937827|NCT06170905|DIETARY_SUPPLEMENT|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
57937828|NCT05198336|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
58073668|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
58293108|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
58293109|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
58293110|NCT00672568|DRUG|Placebo|Solution, single dose, injection
58405291|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
58405292|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
58293111|NCT00657800|BEHAVIORAL|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
58293112|NCT02371902|DEVICE|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
58293113|NCT02371902|DEVICE|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
58293114|NCT05920499|OTHER|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
58293115|NCT04659148|PROCEDURE|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
58293116|NCT00028262|DRUG|Cystagon|
58293117|NCT01001520|DRUG|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
58293118|NCT01001520|DRUG|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
58293119|NCT04020419|DRUG|PediaBerry|PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
58293120|NCT01405495|PROCEDURE|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
58405293|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
58405294|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
58405295|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
58405296|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
58405297|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
58405298|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
58405299|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
58405300|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
58405301|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
58405302|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
58405303|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
58405304|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
58405305|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
58405306|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
58405307|NCT05802706|OTHER|No intervention.|No intervention.
58405308|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
58405309|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
57730357|NCT00875680|DEVICE|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
58073669|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
58073670|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
58405310|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
58073671|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
58073672|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
58073673|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
58073674|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
58405311|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
58405312|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
58073675|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
58073676|NCT06037863|OTHER|Best Practice|Undergo bladder filling prior to CT
58073677|NCT06037863|PROCEDURE|Computed Tomography|Undergo CT
58073678|NCT06037863|OTHER|Electronic Health Record Review|Ancillary studies
58073679|NCT06037863|PROCEDURE|Imaging Procedure|Undergo bladder emptying prior to CT
58293121|NCT03145753|OTHER|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
58293122|NCT03145753|OTHER|HIV/HCV Education|Only education and support will be provided in this arm
58293123|NCT01307891|DRUG|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
58293124|NCT01307891|DRUG|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
58293125|NCT00526448|DRUG|ribavirin|2000 mg/day
58293126|NCT00526448|DRUG|ribavirin|1000-1200 mg/day
58293127|NCT00526448|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
58293128|NCT00526448|DRUG|epoetin beta|epoetin beta 450 UI/week
58293129|NCT01897051|DRUG|Rifaximin + propranolol|"1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
58293130|NCT01897051|DRUG|Propranolol + Placebo|"1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
58293131|NCT03566277|BEHAVIORAL|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
58293132|NCT03566277|BEHAVIORAL|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
58293133|NCT03566277|BEHAVIORAL|Feedback|Participants will receive text message feedback each day about progress towards their goal
58405313|NCT01083979|DRUG|Liposomes|Intravesical instillation
58405314|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
58405315|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
58405316|NCT02230761|DRUG|XOPH5 Ointment|
58405317|NCT02230761|DRUG|Placebo|
58073680|NCT06037863|OTHER|Questionnaire Administration|Ancillary studies
58073681|NCT06037863|RADIATION|Radiation Therapy|Undergo radiation therapy
58073682|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
58073683|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
58073684|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
58073685|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
57937829|NCT03311451|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
57937830|NCT02756351|DEVICE|CytaCoat Nasal Prong|
58073686|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
58073687|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
58073688|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
58073689|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
58073690|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
58073691|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
58073692|NCT03806166|OTHER|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
58073693|NCT03806166|OTHER|Standard treatment|Standard duration of systemic antibiotic treatment
58293134|NCT03197662|DRUG|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
58293135|NCT03197662|DRUG|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
58293136|NCT03671655|DEVICE|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
58293137|NCT03671655|DEVICE|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
58293138|NCT02111174|DEVICE|Scrambler Therapy|
58293139|NCT02111174|DEVICE|Sham Therapy|
58293140|NCT00777868|DRUG|Low Strength IDP-108|Topical application once a day for 9 months
58293141|NCT00777868|DRUG|High Strength IDP-108|Topical application once a day for 9 months
58293142|NCT00777868|DRUG|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
58293143|NCT00777868|DRUG|Vehicle|Topical application once a day for 9 months
58405318|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
58405319|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
57937831|NCT02756351|DEVICE|Inspiration Healthcare Inspire nCPAP Nasal Prong|
57937832|NCT04727203|BEHAVIORAL|AHAA|Multi-component healthy lifestyle program
57937833|NCT06061679|DEVICE|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
57937834|NCT05876091|OTHER|Vaping|Undergo vape puffing regimen
57937835|NCT05876091|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
58073694|NCT02852876|DRUG|ASP2151|Oral
58293144|NCT04283812|DEVICE|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
58293145|NCT03866421|DIAGNOSTIC_TEST|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
58293146|NCT03866421|DIAGNOSTIC_TEST|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
58293147|NCT03866421|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
58293148|NCT03866421|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
57937836|NCT05876091|OTHER|Questionnaire Administration|Administer Quesitonnaire
57937837|NCT01925898|DRUG|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
58073695|NCT02852876|DRUG|Placebo|Oral
58073696|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
58073697|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
58073698|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
58073699|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
58073700|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
58073701|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
58073702|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
58073703|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
58073704|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
58073705|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
58073706|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
58073707|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
58073708|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
58073709|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
58073710|NCT03007732|DRUG|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
58073711|NCT03007732|DRUG|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
58073712|NCT03007732|DRUG|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
58073713|NCT03007732|DRUG|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
58073714|NCT03007732|DRUG|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
58073715|NCT03007732|RADIATION|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
58073716|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
57937838|NCT01925898|DRUG|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
57937839|NCT02290626|DRUG|Elmental diet|elemental diet is administered using PEG.
57937840|NCT02290626|DRUG|Semi-solid diet|Semi-solid diet is administered using PEG.
57937841|NCT05622825|BIOLOGICAL|DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
57937842|NCT06494215|OTHER|Pressure Support Variation and Calculation of Respiratory Mechanics|Patients will be submitted to different levels of pressure support (PS) in a randomly assigned order. First 30 minutes shall be recorded at the clinical PS. Next, blood gas samples shall be collected. Subsequently, three inspiratory pauses of at least 2 seconds shall be performed with an interval of at least 8 respiratory cycles between them. The same shall be performed with three expiratory pauses. Next, the PS shall be varied to 50% less or 50% more than clinical PS (based on randomization) and the same procedures shall be performed after 30 minutes of data recording (blood gas sample collection, inspiratory and expiratory pauses). All data shall be analyzed offline using a software that will be able to compare three different methods to calculate Pendelluft magnitude based on the literature. After completion of the protocol, ventilatory parameters shall be returned to the original settings. If the patient becomes tachypneic during lower PS, the protocol shall be interrupted.
57937843|NCT02774616|DEVICE|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
58073717|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
58293149|NCT03866421|DIAGNOSTIC_TEST|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
58293150|NCT03866421|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
58073718|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
58293151|NCT03866421|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
58073719|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
58293152|NCT03866421|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
58293153|NCT00652704|DRUG|Doxycycline monohydrate|Capsules, 100 mg, fed
58293154|NCT00652704|DRUG|Monodox|Capsules, 100 mg, fed
58293155|NCT00652704|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, fasting
58293156|NCT03654703|DRUG|Cyclophosphamide|cyclophophamide
58293157|NCT03822260|DIAGNOSTIC_TEST|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
58293158|NCT05288946|OTHER|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
58293159|NCT05288946|OTHER|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
58405320|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
58073720|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
58293160|NCT05288946|OTHER|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
58293161|NCT06014086|DRUG|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
58293162|NCT04056949|DRUG|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
58293163|NCT04056949|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
58293164|NCT03975257|DEVICE|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
58293165|NCT04152291|DIETARY_SUPPLEMENT|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of EPA is added to participants' normal diet.
58405321|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
58073721|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
58073722|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
58293166|NCT06367946|PROCEDURE|mechanical ventilation|Mechanical ventilation is machine-delivered flow of gases to both oxygenate and ventilate a patient who is unable to maintain physiological gas exchange.
58293167|NCT05272553|OTHER|Narrative Exposure Therapy|NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
58293168|NCT03751475|OTHER|Nutritional Strategy - OptiMA|"All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
58293169|NCT03751475|OTHER|Effective nutritional standard strategy|"Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
58405322|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
58405323|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
58405324|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
58073723|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
58293170|NCT01869777|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
58293171|NCT00921661|DRUG|AVE0005 (aflibercept)|IV infusion
58293172|NCT06071117|DEVICE|Virtual Reality Glasses (VR)|Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
58293173|NCT06071117|OTHER|White noise|"Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter"
58293174|NCT06071117|BEHAVIORAL|Basic behavior management techniques|Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
58293175|NCT03936153|DRUG|abexinostat|abexinostat tablet
58293176|NCT01302418|DEVICE|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
58293177|NCT01733121|DRUG|NBI-98854|25 mg capsule
58293178|NCT01733121|DRUG|NBI-98854|50 mg capsule
58293179|NCT01733121|DRUG|Placebo|
58293180|NCT04720989|PROCEDURE|Bathing With Baby Cleanser and water|Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
58293181|NCT04720989|PROCEDURE|Bathing With only Water|Preterm infants will have their first baths only with water.
58293182|NCT05684289|DRUG|BMS-986278|Specified dose on specified days
58293183|NCT05684289|DRUG|Sildenafil|Specified dose on specified days
58293184|NCT05684289|DRUG|Placebo|Specified dose on specified days
58405325|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
58405326|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
58405327|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
58405328|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
58405329|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
58405330|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
58405331|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
58405332|NCT00322296|DRUG|Bexarotene 1% gel|
58405333|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
58073724|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
58073725|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
58073726|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
58293185|NCT00003205|DRUG|bryostatin 1|
58293186|NCT02378948|DIETARY_SUPPLEMENT|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
58293187|NCT06309823|DRUG|MAS825|MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
58293188|NCT00696735|PROCEDURE|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
58293189|NCT00696735|PROCEDURE|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
58405334|NCT02916641|DRUG|Fuzhenghuayu|
58405335|NCT02916641|DRUG|UDCA|
58073727|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
57730358|NCT03431077|DRUG|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
58073728|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
58073729|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
58073730|NCT06724211|OTHER|Treatment bundle of care|The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
58073731|NCT06724211|OTHER|Control Group|Routine clinical care for kidney transplant patients
58405336|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
58405337|NCT00003103|BIOLOGICAL|oblimersen sodium|
58405338|NCT00003103|DRUG|docetaxel|
58405339|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
58405340|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
58405341|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
58405342|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
58405343|NCT00369174|DRUG|rosiglitazone maleate|Given orally
58405344|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
58405345|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
57937844|NCT02774616|DEVICE|Plexa ICD lead|predefined follow-up schedule
58405346|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
58405347|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
57937845|NCT00731055|DRUG|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
57937846|NCT00731055|DRUG|Placebo|1 dose of placebo
57937847|NCT05320562|PROCEDURE|Kinesio taping|"Additionally, they received kinesio taping application for 7 days. Blue color kinesio tape (manufactured by Theraband®, USA) was used. Kinesio taping was done by experienced physiotherapist with 5 years of experience. Two Y shape bands were applied for lymphatic taping and to improve anterior upper leg muscle function (lymphatic correction and muscle correction techniques were integrated together).~Then two I shape bands (75-100% tension) were applied above the patella tendon and medial/lateral collateral ligaments in order to improve mechanoreceptor stimulation, proprioception and knee stability."
57937848|NCT05320562|PROCEDURE|Sham taping|Additionally, they received sham (placebo) taping: usual white patch was applied to the painful knee for 7 days. The technique of taping used was the same as in kinesiotaping group, but without stretching.
58073732|NCT06723145|DRUG|Aspirin|perioperative aspirin continuation
58073733|NCT06723145|DRUG|Aspirin interruption|Aspirin interruption 5-7 days before surgery
58073734|NCT05626751|DRUG|HZN-825|HZN-825 will be administered BID for 52 weeks
58073735|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
58073736|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
58073737|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
58073738|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
58405348|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
58405349|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
58405350|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
58405351|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
58405352|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
58073739|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
58073740|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
58073741|NCT05867875|OTHER|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
58073742|NCT05867875|OTHER|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
58073743|NCT06562192|DRUG|[68Ga]Ga-NNS309|Radioligand imaging agent
58073744|NCT06562192|DRUG|[177Lu]Lu-NNS309|Radioligand therapy
58073745|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
58073746|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
58073747|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
58073748|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
58073749|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
58073750|NCT04441619|BEHAVIORAL|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
58073751|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
58073752|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
58073753|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
58073754|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
58073755|NCT04300556|DRUG|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
58073756|NCT04300556|DRUG|Prednisone|Prednisone administered orally.
58073757|NCT04300556|DRUG|Prednisolone|Prednisolone administered orally.
58073758|NCT04300556|DRUG|Dexamethasone|Dexamethasone administered orally.
58073759|NCT01678287|DRUG|ASP1941|oral
58073760|NCT01678287|DRUG|Placebo|oral
58073761|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
58073762|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
58073763|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
58405353|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
58073764|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
58293190|NCT03341845|DRUG|Axitinib|axitinib in combination with avelumab
58293191|NCT03341845|DRUG|Avelumab|axitinib in combination with avelumab
58293192|NCT05323747|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
58405354|NCT06022965|OTHER|Best Practice|Receive SOC
58405355|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
58073765|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
58073766|NCT06580756|OTHER|Short training program|Training in the early identification of addictive disorders in primary care
58073767|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
58073768|NCT01197846|DRUG|Placebo|Placebo
58073769|NCT00230711|BEHAVIORAL|Physical activity counseling|
58293193|NCT06344975|BIOLOGICAL|STR-V003/Placebo|IM
58293194|NCT04612283|OTHER|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
58293195|NCT04612283|OTHER|Placebo|A Placebo with no active ingredients
58293196|NCT02256813|DRUG|BIRT 2584 XX|
58293197|NCT02256813|DRUG|Warfarin sodium|
58293198|NCT02256813|DRUG|Omeprazole|
58405356|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
58405357|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
58405358|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
58405359|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
58073770|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
58073771|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
58073772|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
58073773|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
58293199|NCT02256813|DRUG|Dextromethorphan hydrobromide|
58293200|NCT02256813|DRUG|Caffeine|
58293201|NCT02256813|DRUG|Midazolam hydrochloride|
58293202|NCT02256813|DRUG|Vitamin K1|
58293203|NCT01664702|DIETARY_SUPPLEMENT|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
58293204|NCT01664702|DIETARY_SUPPLEMENT|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
58293205|NCT00279383|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
58293206|NCT01388855|DRUG|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
58405360|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
58405361|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
58405362|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
58293207|NCT01388855|DRUG|Placebo|Pills made to look like vitamin D but have no medication in them
58405363|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
58293208|NCT04009187|BEHAVIORAL|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
58293209|NCT04009187|BEHAVIORAL|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
58293210|NCT04474561|OTHER|Reduced sulfur diet|A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., \> 4 g/d18).
58405364|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
58293211|NCT05118620|DRUG|Active bupivacaine 0.375% PENG block|A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
58293212|NCT05118620|DRUG|Placebo normal saline PENG block|A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
58293213|NCT01153607|DRUG|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
58293214|NCT01153607|DRUG|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
58293215|NCT01153607|DRUG|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
58405365|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
58293216|NCT02077686|BEHAVIORAL|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
58405366|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
57937849|NCT04444960|PROCEDURE|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
57937850|NCT05199675|BEHAVIORAL|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
58405367|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
58405368|NCT04750473|DRUG|Fluciclovine F18|Given IV
58405369|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
58405370|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
57937851|NCT04983368|DRUG|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
57937852|NCT04983368|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
57937853|NCT04983368|DRUG|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
57937854|NCT02937025|DEVICE|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
57937855|NCT03975270|DRUG|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
57937856|NCT02749032|OTHER|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
57937857|NCT02749032|DRUG|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
57937858|NCT02749032|DRUG|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
57937859|NCT02749032|DRUG|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
58073774|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
57937860|NCT02749032|DRUG|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
57937861|NCT02749032|OTHER|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
58293217|NCT03460873|PROCEDURE|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
58293218|NCT06612060|PROCEDURE|Cardiac surgery with the use of extracorporeal circulation|All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.
58293219|NCT03937544|BIOLOGICAL|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the chemotherapy.
58293220|NCT03937544|DRUG|Cyclophosphamide|Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
57937862|NCT03342313|OTHER|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
58405371|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
58405372|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
58405373|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
58405374|NCT02540330|DRUG|Fulvestrant|
58405375|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
58293221|NCT03937544|DRUG|Fludarabine|Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
58293222|NCT06611904|DRUG|Dulaglutide|Combined treatment with dulaglutide and dapagliflozin
58293223|NCT06611904|DRUG|DPP-4 Inhibitors|DPP-4i treatment as an add-on to metformin
58405376|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
58405377|NCT00620178|DRUG|Losartan|once daily oral dose
58405378|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
58405379|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
57937863|NCT02739620|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
57937864|NCT01727765|OTHER|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
57937865|NCT04869163|OTHER|Non-red meat|Red meat analogues and alternatives
58073775|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
58073776|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
58073777|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
58073778|NCT06724952|DRUG|MTX S.C or IM and Silymarin 140 mg tab|IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
58293224|NCT02762435|OTHER|sham|light touch at established points on hand and wrist
58293225|NCT02762435|OTHER|control|no contact with the subject
58293226|NCT02762435|OTHER|acupressure|moderate pressure at established points on hand and wrist
58293227|NCT04649879|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
58293228|NCT04649879|OTHER|Standard of care|Standard of care as determined by hospital practices for COVID-19 patients.
58293229|NCT00478270|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
58293230|NCT03409536|DEVICE|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
58293231|NCT00333710|BEHAVIORAL|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
58293232|NCT00333710|BEHAVIORAL|Telehealth Intervention|Individual telephone contact with educational and goal setting components
58293233|NCT01247350|DRUG|LY3009104|Administered orally
58293234|NCT01247350|DRUG|Placebo|Administered orally
58293235|NCT02653911|OTHER|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
58293236|NCT02653911|OTHER|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
58293237|NCT06338943|DIAGNOSTIC_TEST|Echocardiography|Echocardiography to diagnose HFpEF
58405380|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
57937866|NCT04673591|DRUG|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
58073779|NCT06724952|DRUG|MTX S.C or IM|IM or SC Methotrexate plus placebo tablet once daily for 3 months.
58073780|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
58073781|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
58073782|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
57937867|NCT04673591|OTHER|Placebo|Matched Placebo
58293238|NCT06338943|OTHER|Questionnaire|Questionnaire to determine the presence of adverse pregnancy outcomes history
57937868|NCT03122496|DRUG|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
57937869|NCT03122496|DRUG|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
57937870|NCT03122496|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
57937871|NCT02879604|OTHER|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
57937872|NCT02879604|OTHER|Usual|Usual care
57937873|NCT01821833|DIETARY_SUPPLEMENT|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
57937874|NCT01821833|DIETARY_SUPPLEMENT|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
58073783|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
58073784|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
58073785|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
58073786|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
58073787|NCT05628389|BEHAVIORAL|Educational materials|Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
58073788|NCT05628389|BEHAVIORAL|Phone counseling|Cessation counseling to address insufficient patient self-efficacy and motivation.
58073789|NCT05628389|DRUG|Nicotine Replacement Therapy|Nicotine patches to address nicotine withdrawal symptoms in patients.
58293239|NCT02014519|PROCEDURE|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
57937875|NCT01821833|DRUG|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
57937876|NCT04495855|DRUG|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
57937877|NCT03685864|OTHER|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
57937878|NCT03685864|OTHER|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
58293240|NCT02014519|OTHER|Data collection|Active questioning
58293241|NCT05704205|DEVICE|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
58293242|NCT05704205|COMBINATION_PRODUCT|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
58293243|NCT05136235|DIAGNOSTIC_TEST|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
58293244|NCT05136235|DIAGNOSTIC_TEST|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
58293245|NCT02597738|OTHER|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
58293246|NCT02597738|OTHER|Blood/Urine Sample Collection|A one time blood sample will be collected.
58293247|NCT03045653|DRUG|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
58293248|NCT03728439|DEVICE|LED before|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58073790|NCT05628389|BEHAVIORAL|Provider training|Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
57730359|NCT03563495|OTHER|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
58073791|NCT05628389|BEHAVIORAL|Electronic reminders|Electronic reminders to address the lack of integration of AAA/AAC into practice.
57730360|NCT03563495|PROCEDURE|autogenous bone graft group|
57730361|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
57730362|NCT05818735|OTHER|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
57937879|NCT01440842|OTHER|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
57937880|NCT01440842|OTHER|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
57937881|NCT03109158|DRUG|NC-6004|NC-6004 provided by NanoCarrier
57937882|NCT03109158|DRUG|Cetuximab|Commercially Available
57937883|NCT03109158|DRUG|5-FU|Commercially Available
57937884|NCT05803304|BEHAVIORAL|PATH Intervention|The PATH intervention guides participants in making changes in their lifestyle and PA habits to support long-term adherence to the minimum threshold of PA Guidelines (150 MVPA minutes per week). The health coach provides participants with access the PATH website and a detailed orientation on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA by about 10 minutes per week. The PA prescription process begins by identifying a suitable PATH level for each participant. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA).
57937885|NCT05803304|BEHAVIORAL|Attention Control Intervention|"A health coach will have a zoom meeting with each control group participant where they will be provided with an electronic copy of the Be Active Your Way booklet, developed by the Centers for Disease Control and Prevention (CDC) to help individuals integrate PA into their daily lives. The coach will orient the participant to the key strategies used in the booklet and encouraged them to use it regularly and to self-monitor PA using the Fitbit during the entire course of the study. In addition, the group will be introduced to www.health.com, a jargon free website that focuses on general health topics and latest medical news. At the end of the meeting, the participants will be asked to provide a schedule for zoom meetings the study team twice per month during the 6 month study. The meetings will focus on their progress in using the Be Active Your Way handout and the health.com website."
57937886|NCT05803304|OTHER|Physical activity tracker|Participants will be asked to wear Fitbit Charge 5 on their non-dominant hand for the entire duration of the study using a 24hr wear protocol.
58073792|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
58073793|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
58073794|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
58073795|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
58293249|NCT03728439|DEVICE|LED interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58293250|NCT03728439|DEVICE|LED after|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58073796|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
58073797|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
58073798|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
58073799|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
58073800|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
58405381|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
58405382|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
57937887|NCT05803304|BEHAVIORAL|Dietary education|Diet quality and barriers to healthy eating will be evaluated at baseline, and then all study participants will be provided with educational materials that are curated to promote diet quality. Participants will receive a monthly email with a brief PDF addressing a diet component focused on improving diet quality to reduce CVD risk and improve general health.
58405383|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
57937888|NCT06127927|DEVICE|Interventional Left Ventricular Assist System|Interventional left ventricular assist system for cardiogenic shock patients
57937889|NCT00715195|BEHAVIORAL|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
57937890|NCT02018406|DRUG|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
57937891|NCT02018406|DRUG|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
57937892|NCT01974089|OTHER|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
57937893|NCT01518283|DRUG|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
57937894|NCT06490393|OTHER|Questionnaires|EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department
57937895|NCT02218242|DEVICE|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
57937896|NCT04353596|DRUG|ACE inhibitor, angiotensin receptor blocker|In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
57937897|NCT02217436|DEVICE|iPad|iPad with age-appropriate applications, videos, and music
57937898|NCT02217436|OTHER|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
57937899|NCT03008954|DEVICE|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
57937900|NCT03008954|DIETARY_SUPPLEMENT|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
57937901|NCT01191866|BEHAVIORAL|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
57937902|NCT00670501|DRUG|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
57937903|NCT00670501|DRUG|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
57937904|NCT00670501|DRUG|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
57937905|NCT00670501|DRUG|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
58073801|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
58073802|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
58405384|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
58405385|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
57937906|NCT00670501|DRUG|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
57937907|NCT00636467|OTHER|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
58073803|NCT01659411|OTHER|Observational|Yearly clinical visits
58073804|NCT04522986|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
58073805|NCT06724640|DRUG|VH4011499 Injection|VH4011499 Injection will be administered either subcutaneously or intramuscularly.
57730363|NCT05818735|OTHER|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
57730364|NCT05818735|DRUG|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
58405386|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
57730365|NCT05818735|DRUG|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
57937908|NCT01865526|DIETARY_SUPPLEMENT|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
57937909|NCT01865526|DIETARY_SUPPLEMENT|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
57937910|NCT04680728|OTHER|collection of biological parameters|haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
57937911|NCT04680728|OTHER|collection of echographic parameters|echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
57937912|NCT04680728|OTHER|collection of clinical parameters|eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
58405387|NCT01783574|DRUG|Testosterone|
58405388|NCT01783574|DRUG|Placebo|
58405389|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
58405390|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
58405391|NCT02080039|DEVICE|Electrical Stimulation|
58405392|NCT01753219|PROCEDURE|Onstep|
58405393|NCT01753219|PROCEDURE|Lichtenstein|
58405394|NCT02802241|DRUG|placebo|
58405395|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
58405396|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
58405397|NCT00130143|DRUG|Ethyol (Amifostine)|
58405398|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
58073806|NCT06724640|DRUG|Placebo for VH4011499 Injection|Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
58073807|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
58073808|NCT06722989|BEHAVIORAL|mobile-guided exercise|"Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000."
58073809|NCT06722989|BEHAVIORAL|Unguided physical activity|In this group, pregnant women will be physically active at their discretion.
58073810|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
58073811|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
57730366|NCT05450874|PROCEDURE|hepatectomy|
57937913|NCT04714736|DEVICE|Coronary angiography using DyeVert system|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
57937914|NCT04714736|PROCEDURE|Coronary angiography using conventional manual injection syringe.|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
58293251|NCT06424561|BEHAVIORAL|Psychological Intervention Group|"The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers."
58293252|NCT06363019|BEHAVIORAL|Supporting at-risk Mothers Across perinatal period: a Randomized controlled Trial (SMART) mobile application|The intervention is delivered through the SMART mobile application. It contains educational information in audio, visual, article format; on parenting, pregnancy and managing emotional well-being. There is also a peer support feature where participants can speak to experienced mothers via the SMART app. There is also a forum feature where participants can interact with other mothers.
58293253|NCT00477802|BIOLOGICAL|Botulinum Toxin Type A|Injected once during the course of the study.
58293254|NCT00477802|BIOLOGICAL|Placebo|Injected once during the course of the study.
58293255|NCT00826059|DEVICE|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
58293256|NCT00826059|DEVICE|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
58293257|NCT02503163|DRUG|KCT-0809 ophthalmic solution|
58405399|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
57937915|NCT00048620|DRUG|N-acetylgalactosamine 4-sulfatase|
57937916|NCT01486797|DRUG|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~* 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
57730367|NCT02794493|DRUG|Traditional Chinese Medicine Formula LC09|
57730368|NCT02794493|OTHER|Placebo|
57730369|NCT03649022|DEVICE|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
57730370|NCT02246998|DRUG|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
57937917|NCT01338623|DRUG|Tansulosine|capsule 0,4 mg
58073812|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
58073813|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
58073814|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
58073815|NCT06598943|DRUG|Eltrekibart|Administered
58073816|NCT06598943|DRUG|Mirikizumab|Administered
58073817|NCT06598943|DRUG|Placebo|Administered
58073818|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
58073819|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
58073820|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
57937918|NCT04248582|DEVICE|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
57937919|NCT04977102|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
57937920|NCT04977102|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
57937921|NCT03332329|DRUG|Entecavir|Entecavir is used for 96 weeks
57937922|NCT03332329|DRUG|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
58073821|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
58073822|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
58073823|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
58073824|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
58073825|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
58073826|NCT05620849|BEHAVIORAL|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
58073827|NCT05372419|DRUG|Lebrikizumab|Administered SC
57730371|NCT02246998|DRUG|TVD|200/300 mg FDC tablet administered orally once daily with food
57937923|NCT03332329|DRUG|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
57937924|NCT03332329|DRUG|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
58073828|NCT06722625|OTHER|Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process|Receiving remote care facilitated by a specialized informatic system to support the physician
57730372|NCT02246998|DRUG|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
58073829|NCT06040437|BEHAVIORAL|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
58073830|NCT06724367|DEVICE|Transspinal direct current stimulation|Direct current electrical stimulation applied non-invasively to the spinal cord.
58073831|NCT06724367|DEVICE|Sham Comparator|transspinal direct current stimulation simulated
58293258|NCT00731796|DEVICE|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
58293259|NCT06050096|PROCEDURE|PCI|CTO patients treated by DCB
57730373|NCT02246998|DRUG|RTV|100 mg tablet administered orally once daily with food
58073832|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
58073833|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
58073834|NCT05275855|DRUG|EDI048|Oral Liquid
58073835|NCT05275855|OTHER|Placebo|Oral Liquid
57730374|NCT02246998|DRUG|ATV|300 mg capsule administered orally once daily with food
57730375|NCT02246998|DRUG|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
57730376|NCT02246998|DRUG|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
57730377|NCT04613414|OTHER|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
57730378|NCT00005854|DRUG|cyclophosphamide|
58073836|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
57730379|NCT00005854|DRUG|cyclosporine|
57730380|NCT00005854|DRUG|methotrexate|
57730381|NCT00005854|PROCEDURE|allogeneic bone marrow transplantation|
57730382|NCT00005854|PROCEDURE|in vitro-treated bone marrow transplantation|
57730383|NCT00005854|RADIATION|radiation therapy|
57730384|NCT03321019|DRUG|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
58293260|NCT00534872|DRUG|SB-649868|10 mg
58405400|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
58405401|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
58405402|NCT01133405|DRUG|LY2886721|Oral capsules
58405403|NCT01133405|DRUG|Placebo|Oral capsules
58405404|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
58405405|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
58405406|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
58405407|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
58405408|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
58405409|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
58405410|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
58405411|NCT04748757|DRUG|Placebo|Normal saline 50 ml
57937925|NCT06401122|PROCEDURE|haemodialysis|process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
57937926|NCT01881893|BEHAVIORAL|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
58405412|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
57730385|NCT03321019|DEVICE|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
57730386|NCT03321019|OTHER|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
58293261|NCT01867320|DRUG|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
58405413|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
58405414|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
58405415|NCT06029673|DRUG|Placebo|Placebo
58405416|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
58405417|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
57730387|NCT03321019|PROCEDURE|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
57730388|NCT01159938|DRUG|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
57730389|NCT00355082|DRUG|lamotrigine, 300 mg/day|300 mg/day
57937927|NCT01034592|DRUG|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
57937928|NCT00006345|BIOLOGICAL|denileukin diftitox|
57937929|NCT00006345|DRUG|dexamethasone|
57937930|NCT02423304|GENETIC|blood samples collected from all patients|blood samples collected from brachial pluxes
57937931|NCT03042182|BIOLOGICAL|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
58293262|NCT01355562|DRUG|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
58073837|NCT06722508|BEHAVIORAL|exercise and nutritional prehabilitation|The study involves a behavioral intervention (exercise and nutritional prehabilitation) designed to assess outcomes related to feasibility, acceptability, and safety in head and neck cancer patients. Outcomes are being measured following the intervention over a defined period (from diagnosis through 1-month post-surgery).
58073838|NCT06668584|DRUG|Olutasidenib|Given by mouth
58073839|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
58073840|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
58073841|NCT06533176|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
58073842|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
58073843|NCT06624839|BIOLOGICAL|Human papillomavirus (HPV) vaccine, 9-valent|0.5 ml intramuscular injection
58073844|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
58073845|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
58073846|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 700rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
58073847|NCT06546709|BIOLOGICAL|HDCV Comparator|Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M
58073848|NCT06546709|OTHER|Normal Saline Placebo|Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
58073849|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 1400rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
58073850|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
58073851|NCT01632007|DRUG|SYR-472|
58073852|NCT01632007|DRUG|Alogliptin 25 mg|
58073853|NCT01632007|DRUG|Placebo|
57937932|NCT05183113|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
58073854|NCT05391113|DIAGNOSTIC_TEST|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
58073855|NCT05391113|DIAGNOSTIC_TEST|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
58073856|NCT05464914|DRUG|CEO Pack|is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
57730390|NCT00355082|DRUG|lamotrigine, 250 mg/day|250 mg/day
58073857|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
57937933|NCT00605592|PROCEDURE|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
57937934|NCT01739569|OTHER|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
57730391|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
57937935|NCT01519765|DRUG|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
57937936|NCT01519765|DRUG|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
57937937|NCT01085786|DRUG|14-day sequential treatment|"* 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
58405418|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
58405419|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
58405420|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
58405421|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
58405422|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
58405423|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
58405424|NCT05118789|DRUG|NVL-520|Oral tablet of NVL-520
58405425|NCT01671501|BEHAVIORAL|Motivational Interviewing|
58405426|NCT01671501|BEHAVIORAL|Email Feedback|
57937938|NCT01085786|DRUG|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
57937939|NCT00432536|OTHER|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
57937940|NCT04582942|DRUG|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
57937941|NCT04582942|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
57937942|NCT01936909|DRUG|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
57937943|NCT01936909|DRUG|Anakinra (weeks 3-12)|
57937944|NCT01936909|DRUG|Placebo|
57937945|NCT00572962|PROCEDURE|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
57937946|NCT03773198|OTHER|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
57937947|NCT03773198|OTHER|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
57937948|NCT00283049|DRUG|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
58073858|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
58073859|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
58073860|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
58405427|NCT01671501|OTHER|Usual Care|
58405428|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
58405429|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
58405430|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
57937949|NCT00283049|DRUG|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
57937950|NCT01329887|DRUG|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
57937951|NCT00698451|DRUG|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
57937952|NCT00698997|BEHAVIORAL|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
57937953|NCT00698997|BEHAVIORAL|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
58073861|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
58405431|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
58405432|NCT06038526|OTHER|Survey Administration|Ancillary studies
58073862|NCT00863265|OTHER|Placebo|
58293263|NCT05352932|DIAGNOSTIC_TEST|pancreatic duct biopsy|"Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination."
57937954|NCT03662217|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
57937955|NCT03662217|OTHER|ADA- based diet|The American standard of care dietary guidelines for diabetes.
57937956|NCT00441181|DRUG|Travoprost|
57937957|NCT02232282|DEVICE|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
57937958|NCT02232282|DEVICE|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
57937959|NCT01087957|DEVICE|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
57937960|NCT01087957|OTHER|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
57937961|NCT02443649|BEHAVIORAL|Sleep hygiene program|Sleep hygiene program
57937962|NCT02443649|BEHAVIORAL|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
58073863|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
58073864|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
58073865|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
58073866|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
58073867|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
58293264|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
58293265|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
58293266|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
58293267|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
58293268|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
58293269|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
58293270|NCT03893955|DRUG|ABBV-927|Intravenous (IV) Infusion
58293271|NCT03893955|DRUG|ABBV-368|Intravenous (IV) Infusion
58405433|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
58405434|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
58405435|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
57730392|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
57730393|NCT05509829|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
58293272|NCT03893955|DRUG|ABBV-181|Intravenous (IV) Infusion
58293273|NCT03893955|DRUG|Carboplatin|Intravenous (IV) Infusion
58293274|NCT03893955|DRUG|Nab-paclitaxel|Intravenous (IV) Infusion
58293275|NCT04927897|DIAGNOSTIC_TEST|Ultrasound|3D endorectal ultrasound.
58293276|NCT04927897|DIAGNOSTIC_TEST|Rectoscopy|Rigid rectoscopy.
58293277|NCT04927897|OTHER|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
58293278|NCT01968187|DRUG|FE 992097|
58293279|NCT01968187|DRUG|Placebo|
58405436|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
57730394|NCT02308436|DEVICE|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries \& acidic challenges
57730395|NCT00822510|BEHAVIORAL|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
57730396|NCT00822510|BEHAVIORAL|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
57730397|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
58293280|NCT00753675|DRUG|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58293281|NCT00753675|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
57730398|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
57730399|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
58293282|NCT00753675|DRUG|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58293283|NCT00753675|DRUG|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58293284|NCT04912492|BEHAVIORAL|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
57937963|NCT01903642|OTHER|proteomic analysis|
57937964|NCT04170790|DRUG|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
57937965|NCT04170790|DRUG|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
57937966|NCT02910960|DEVICE|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
58293285|NCT04912492|BEHAVIORAL|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
58293286|NCT04912492|BEHAVIORAL|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
58293287|NCT04912492|BEHAVIORAL|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
58293288|NCT04912492|BEHAVIORAL|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
58293289|NCT01575756|BIOLOGICAL|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
58293290|NCT01575756|BIOLOGICAL|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
58293291|NCT05488951|OTHER|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
58293292|NCT03034837|DRUG|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
58293293|NCT03034837|DRUG|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
58405437|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
58293294|NCT03877146|BEHAVIORAL|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
58405438|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
57730400|NCT06152120|OTHER|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
57730401|NCT06261151|OTHER|Clinical data collection|Clinical data of elderly patients with gastric cancer who underwent open gastrectomy were collected and analyzed.
57730402|NCT04937374|OTHER|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
57730403|NCT04937374|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
57730404|NCT00390052|DRUG|triapine|Given IV and orally
57730405|NCT00390052|OTHER|pharmacological study|correlative study
57730406|NCT00390052|PROCEDURE|laboratory biomarker analysis|Correlative study
57937967|NCT02910960|DEVICE|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
57937968|NCT02126033|PROCEDURE|take blood samples|
57937969|NCT01507779|BIOLOGICAL|IVACFLU|IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
57937970|NCT01507779|OTHER|Placebo|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
57937971|NCT03143010|DRUG|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
57937972|NCT03143010|DRUG|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
57937973|NCT03143010|DRUG|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
57937974|NCT03143010|DRUG|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
57937975|NCT00744211|DRUG|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
57937976|NCT00744211|DRUG|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
57937977|NCT00744211|OTHER|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
57937978|NCT01587339|DRUG|retigabine/ezogabine|oral - all doses
57937979|NCT01587339|DRUG|lacosamide|oral - all doses
57937980|NCT01587339|DRUG|zonisamide|oral - all doses
57937981|NCT01587339|DRUG|pregabalin|oral - all doses
58293295|NCT01136252|DRUG|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
58293296|NCT00134966|DRUG|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
57730407|NCT02239887|DEVICE|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
57937982|NCT01587339|DRUG|eslicarbazepine|oral - all doses
57937983|NCT01069120|DRUG|Proellex|2, 25 mg capsules once per day
57937984|NCT01069120|DRUG|Proellex|1, 25 mg capsule once per day
57937985|NCT05843682|DEVICE|Using the Avatr App|The patients will use the mobile application called Avatr, which will monitor their health data, as well as provide individualized care and early intervention through alerts generated for the multidisciplinary team.
57937986|NCT03771586|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
57937987|NCT03771586|DRUG|Placebo|Placebo in combination with Ketamine
57937988|NCT06490432|DEVICE|Transient elastography|Device that measures stiffness of liver tissue
57937989|NCT06374875|PROCEDURE|Metabolic surgery|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure
58293297|NCT02145208|DEVICE|TIND System|An implant
58293298|NCT03011177|DRUG|Teneligliptin|teneligliptin 20mg qd
58293299|NCT03011177|DRUG|Linagliptin|linagliptin 5mg qd
58293300|NCT06180122|DIAGNOSTIC_TEST|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
58293301|NCT00888888|PROCEDURE|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
58293302|NCT05413915|DRUG|Asciminib|Tyrosine kinase inhibitor
58293303|NCT05413915|DRUG|Imatinib|Tyrosine kinase inhibitor
58293304|NCT01900041|DRUG|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
58293305|NCT01900041|DRUG|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
58293306|NCT02472158|DEVICE|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
58293307|NCT02472158|DEVICE|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
58293308|NCT06609278|BEHAVIORAL|harm reduction intervention|Each participant will complete a pre-test at Study Visit 1 prior to the intervention, participate in the intervention, then complete a post-test. After the intervention, participants will participate in a recorded focus group. Participants will be offered FTS, Narcan, first aid supplies at the study visit.
58293309|NCT02870192|PROCEDURE|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
58293310|NCT06515418|DRUG|Oral Azelaprag (BGE-105)|Capsules
58405439|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
57730408|NCT05391282|OTHER|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
58073868|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
58073869|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
58073870|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
58073871|NCT06628622|DRUG|BI 1356225|BI 1356225
58073872|NCT06628622|DRUG|Placebo|Placebo
58073873|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
58293311|NCT06515418|DRUG|Oral Placebo for Azelaprag (BGE-105)|Capsules
58293312|NCT06515418|DRUG|Tirzepatide|Subcutaneous Injection
58293313|NCT06515418|DRUG|Tirzepatide Placebo|Subcutaneous Injection
58293314|NCT01497548|DRUG|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
58293315|NCT01497548|DRUG|Placebo|Placebo given on morning (0800) and noon (1200)daily
58293316|NCT04785898|DIAGNOSTIC_TEST|ID Now™ COVID-19 Screening Test|"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
58405440|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
57937990|NCT06374875|DRUG|Incretin-Based Therapy|Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.
57937991|NCT00827684|DRUG|Irinotecan|
57937992|NCT00827684|DRUG|Temsirolimus|
57937993|NCT05030103|DEVICE|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
57937994|NCT00024050|DRUG|busulfan|
57937995|NCT00024050|DRUG|cyclophosphamide|
57937996|NCT00024050|DRUG|cyclosporine|
57937997|NCT00024050|DRUG|methotrexate|
57937998|NCT00024050|PROCEDURE|allogeneic bone marrow transplantation|
57937999|NCT00024050|PROCEDURE|peripheral blood stem cell transplantation|
57938000|NCT06143150|OTHER|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
57938001|NCT02941887|BEHAVIORAL|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
57938002|NCT06034535|BIOLOGICAL|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
57938003|NCT04596982|OTHER|Placement of IMPELLA®|ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
57938004|NCT00117507|DRUG|Deferasirox|
57938005|NCT02934308|DEVICE|Skin Conductance Monitor|
57938006|NCT03800888|OTHER|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
57938007|NCT03800888|OTHER|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
57938008|NCT03800888|OTHER|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
57938009|NCT01473563|DRUG|Pemetrexed|Administered intravenously
58073874|NCT03373916|BEHAVIORAL|Peer mentorship|The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
58293317|NCT02966132|BEHAVIORAL|iMD|Interactive video education delivered on a tablet computer
58293318|NCT02966132|BEHAVIORAL|NPA|
57938010|NCT04747093|BIOLOGICAL|CAR-ITNK cells|CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
58405441|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
58405442|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
57938011|NCT05606250|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
57938012|NCT00393809|DRUG|DTA-H19|
57938013|NCT01401842|OTHER|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
57938014|NCT01401842|OTHER|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
57938015|NCT03772470|OTHER|1X airtime incentive|An incentive given in the form of airtime
57938016|NCT03772470|OTHER|2X airtime incentive|An incentive given in the form of airtime
57938017|NCT03772470|OTHER|Lottery airtime incentive|An incentive given in the form of airtime
57938018|NCT03059927|PROCEDURE|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design
57938019|NCT03059927|PROCEDURE|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design
57938020|NCT03059927|PROCEDURE|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
58073875|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
58073876|NCT05959278|OTHER|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
58073877|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
58293319|NCT04016142|DRUG|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
58293320|NCT00943592|DRUG|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
58293321|NCT00943592|DRUG|Melphalan|Doses ranging from 100 to 140 mg/m2
58293322|NCT00943592|DRUG|Campath|20mg/d x5
58293323|NCT00943592|PROCEDURE|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
58293324|NCT05588752|OTHER|TAP block|TAP block under ultrasound
58293325|NCT04601168|DEVICE|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
58405443|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
58293326|NCT03790852|DRUG|KSI-301|Intravitreal injection
58293327|NCT02945735|BEHAVIORAL|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
58293328|NCT02007720|DRUG|Serelaxin|Intravenous infusion
58293329|NCT02007720|DRUG|Placebo|Intravenous infusion
58293330|NCT02007720|OTHER|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
58293331|NCT05339919|DIAGNOSTIC_TEST|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
58405444|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
58405445|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
58073878|NCT06724263|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
58073879|NCT03842228|PROCEDURE|Biopsy|Undergo tumor biopsy
58293332|NCT04406714|BEHAVIORAL|Trial Mailed FIT Intervention - Age Group 50-75|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
58293333|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|"Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call."
58293334|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
58293335|NCT02003755|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
58405446|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
58405447|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
58405448|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
57938021|NCT05688462|OTHER|Data Collection|This is an observational prospective cohort study. Children admitted to ten identified PICUs in the UK with severe TBI with a clinical need for ICP and ABP monitoring will be included for data collection. The database will contain routinely monitored physiological parameters during management of PTBI in PICU. Without disturbing the routine care and management of these patients, investigators aim to collect this data continuously in a bedside laptop equipped with the study software (ICM+, Cambridge Enterprise Ltd, Cambridge, UK). Alongside these physiological parameters, investigators will also collect relevant clinical and demographic data (details below) and follow these patients for up to 12 months post ictus to assess neuro-psychological outcome.
57938022|NCT02794467|DRUG|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
58293336|NCT05452915|DIAGNOSTIC_TEST|Neuropsychological (NPA)|"The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session"
58293337|NCT05452915|OTHER|Imaging|"Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR)."
57938023|NCT02794467|DRUG|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
58073880|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58293338|NCT05452915|DIAGNOSTIC_TEST|Inflammatory biomarkers|Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
58293339|NCT03170817|DIAGNOSTIC_TEST|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes."
57730409|NCT03913273|PROCEDURE|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
57730410|NCT03913273|PROCEDURE|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
58073881|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
57730411|NCT02106468|DRUG|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
58073882|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
58073883|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
58073884|NCT03842228|PROCEDURE|Echocardiography|Undergo ECHO
58073885|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58073886|NCT03842228|DRUG|Olaparib|Given PO
58073887|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
58073888|NCT04047472|DRUG|Brolucizumab 6mg|Intravitreal injection
58073889|NCT04047472|DRUG|Aflibercept 2 mg|Intravitreal injection
58073890|NCT06333613|DEVICE|ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY (AO1D)|Test Lens
58073891|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
58073892|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
58293340|NCT03170817|DRUG|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
58293341|NCT03170817|DRUG|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
58293342|NCT01794962|OTHER|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
58293343|NCT01794962|OTHER|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
58293344|NCT03459716|OTHER|No intervention|No intervention
58293345|NCT06612801|BEHAVIORAL|The REThink Game|REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
58293346|NCT03055247|DRUG|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
58293347|NCT03055247|DRUG|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
58293348|NCT03055247|DRUG|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
58293349|NCT00500578|DRUG|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
58293350|NCT00500578|DRUG|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
58293351|NCT02362893|OTHER|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
58293352|NCT03564769|BEHAVIORAL|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
58293353|NCT03564769|OTHER|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
58405449|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
58405450|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
58293354|NCT02360787|BEHAVIORAL|Energy restriction|
58293355|NCT02360787|BEHAVIORAL|Almonds (15% kcal/day)|
58293356|NCT00889655|DRUG|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
58293357|NCT00889655|DRUG|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
58293358|NCT00423280|DRUG|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
58293359|NCT01885832|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction|
58293360|NCT00197431|DRUG|S-1|
58293361|NCT00300222|DRUG|NGX-4010|
58293362|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
58293363|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
58293364|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
58293365|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
58293366|NCT01276912|DRUG|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
58293367|NCT01276912|BEHAVIORAL|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
57938024|NCT00227565|DRUG|carboplatin|
57938025|NCT00227565|DRUG|pemetrexed disodium|
58405451|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
57938026|NCT00227565|RADIATION|radiation|
57938027|NCT02454335|PROCEDURE|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
57730412|NCT02106468|DRUG|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
57938028|NCT01101438|DRUG|metformin hydrochloride|Given orally
58293368|NCT05453110|BEHAVIORAL|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
58293369|NCT03335319|OTHER|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or \> 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
57938029|NCT01101438|OTHER|placebo|Given orally
57938030|NCT02596243|BIOLOGICAL|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
57938031|NCT02596243|BIOLOGICAL|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
58405452|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
58405453|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
58405454|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
58405455|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
58405456|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
57730413|NCT00566228|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
57730414|NCT00566228|PROCEDURE|leukapheresis|Stem cells collected
57730415|NCT01211626|DRUG|ANA773|ANA773 Tosylate Capsule
57938032|NCT02478905|OTHER|Influenza|
57938033|NCT01444768|OTHER|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
57938034|NCT05014334|DRUG|Berberine|berberine 500 mg, twice daily for 14 days
57938035|NCT05014334|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
57730416|NCT01211626|DRUG|Placebo|Matching Placebo Capsule
57730417|NCT02758431|DRUG|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
57730418|NCT02758431|DRUG|Placebo Gel|Placebo gel packet applied daily for 28 days.
57938036|NCT05014334|DRUG|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
57938037|NCT05014334|DRUG|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
57938038|NCT05014334|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
57938039|NCT05014334|DRUG|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
57938040|NCT02320136|BEHAVIORAL|cognitive testing|patients perform simple tasks like watching a video or memorizing items
57938041|NCT01848353|BEHAVIORAL|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
58073893|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
58073894|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
58073895|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
58073896|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
58073897|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
58073898|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
58293370|NCT03335319|OTHER|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
58293371|NCT02690012|OTHER|Magnesium Oxide|Magnesium Oxide
58293372|NCT02690012|OTHER|Magnesium Citrate|Magnesium Citrate
58293373|NCT06117722|OTHER|Eplerenone torasemide in chronic heart failure|Heart Failure patients treated with eplerenone and torasemide
57730419|NCT02758431|DRUG|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
57938042|NCT05322928|BEHAVIORAL|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
57938043|NCT02448693|DEVICE|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
57938044|NCT02448693|DEVICE|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
58073899|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
58073900|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
58073901|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
58073902|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
58073903|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
58073904|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
58073905|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
58293374|NCT04270617|BEHAVIORAL|Yoga program|The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
58293375|NCT04530838|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
57938045|NCT04919291|DEVICE|Topoguided LASIK|Topoguided ablation profile on dominant eye
58293376|NCT04530838|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
57938046|NCT04919291|DEVICE|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
57938047|NCT01982721|DEVICE|Locking mechanism for prosthetic knee|
57938048|NCT04062019|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
57938049|NCT02558387|DRUG|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
57938050|NCT03708120|OTHER|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
57938051|NCT02700152|DEVICE|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
57938052|NCT01701076|DRUG|Bendamustine|"Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
57938053|NCT06493539|PROCEDURE|Standard of Care group|The control group will receive standard of care wound treatment
57938054|NCT06493539|DEVICE|CINPWT|Subject will receive CINPWT until discharged
57938055|NCT06150573|DRUG|Test Dentifrice|Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
57938056|NCT06150573|DRUG|Reference Dentifrice (Aquafresh Cavity Protection)|Dentifrice containing 1150 ppm fluoride as sodium fluoride.
57938057|NCT06474975|DEVICE|AURA 10 PET/CT|The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
57938058|NCT00761852|DRUG|Ruboxistaurin|32 mg daily for 2 weeks
57938059|NCT00761852|DRUG|Placebo|1 tab po QD for 2 weeks
57938060|NCT01812889|DRUG|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
57938061|NCT01812889|DRUG|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
58293377|NCT00666211|OTHER|educational intervention|Participants will be educated on pain management.
58293378|NCT00666211|OTHER|Titrated pain management|Pain will be Monitored and Medication Titrated
58293379|NCT00666211|OTHER|questionnaire administration|Participants will be given questionnaires to complete.
57938062|NCT01591967|DEVICE|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
57938063|NCT01017367|DRUG|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
57938064|NCT01017367|DRUG|Placebo|Placebo
57938065|NCT01295476|GENETIC|gene expression analysis|
57938066|NCT01295476|GENETIC|microarray analysis|
57938067|NCT01295476|OTHER|laboratory biomarker analysis|
57938068|NCT01864187|DRUG|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
57938069|NCT03654976|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
57938070|NCT03654976|OTHER|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
58293380|NCT06612359|BEHAVIORAL|BOOST GAIT Program|In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
58293381|NCT00075452|DRUG|gemcitabine hydrochloride|
58293382|NCT00075452|DRUG|oxaliplatin|
57938071|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
57938072|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
57938073|NCT00295633|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
57938074|NCT00295633|DRUG|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
57938075|NCT00295633|DRUG|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
57938076|NCT00295633|DRUG|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
57938077|NCT03809455|DRUG|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge...), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
57938078|NCT03809455|DRUG|Placebo|one intake of placebo (intranasal or buccal)
57938079|NCT04275141|OTHER|oral glucose load|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
58405457|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
58073906|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
58293383|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
58293384|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
58293385|NCT05113680|BEHAVIORAL|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
58293386|NCT05113680|BEHAVIORAL|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
58405458|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
58405459|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
57730420|NCT02758431|DRUG|Testosterone Gel|Testosterone Gel applied daily for 28 days
57938080|NCT04275141|OTHER|exercise test|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
57938081|NCT00075595|DRUG|FOLFIRI regimen|
57938082|NCT00075595|DRUG|fluorouracil|
57938083|NCT00075595|DRUG|irinotecan hydrochloride|
57938084|NCT00075595|DRUG|leucovorin calcium|
57938085|NCT00563628|DEVICE|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
57938086|NCT05169684|BIOLOGICAL|BMS-986218|Specified dose on specified days
57938087|NCT05169684|DRUG|Docetaxel|Specified dose on specified days
57938088|NCT05169684|BIOLOGICAL|Nivolumab|Specified dose on specified days
58293387|NCT03628378|DEVICE|Verasense|Ligamentous balancing device
57730421|NCT02758431|DRUG|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
57730422|NCT00741234|DRUG|SB939|SB939 taken orally in a 4-week cycle.
57938089|NCT02146599|OTHER|Administration of patient self-assessment|
57938090|NCT01010633|DRUG|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
57938091|NCT01010633|DRUG|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
57938092|NCT00141895|DRUG|Misoprostol|2 tablets 200 micrograms Vaginal route
57938093|NCT00141895|DRUG|Misoprostol|2 tablets of 200 micrograms Sublingual route
57938094|NCT04422548|PROCEDURE|AI-assisted Colonoscopy|This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
57938095|NCT04422548|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
57938096|NCT02794077|DRUG|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
57938097|NCT02091154|BEHAVIORAL|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim"
58073907|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
58293388|NCT06119165|BEHAVIORAL|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
58293389|NCT05556980|PROCEDURE|totally laparoscopic distal gastrectomy|all the surgical procedure would be finished under laparoscopy
58293390|NCT04658433|DIETARY_SUPPLEMENT|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
58293391|NCT01698970|OTHER|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
58293392|NCT01698970|OTHER|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
58073908|NCT00078663|BEHAVIORAL|Oral Care|
57730423|NCT00741234|DRUG|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
57938098|NCT02091154|BEHAVIORAL|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
57938099|NCT02091154|BEHAVIORAL|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
57938100|NCT00578136|DRUG|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
57938101|NCT03808389|OTHER|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
57938102|NCT03808389|OTHER|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
57938103|NCT04967222|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .
57938104|NCT04967222|BEHAVIORAL|Control Downregulate Condition|Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
57938105|NCT00714467|BEHAVIORAL|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
57938106|NCT00714467|BEHAVIORAL|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
57938107|NCT00234507|BIOLOGICAL|Botulinum toxin type A|
57938108|NCT05546450|BEHAVIORAL|Diet|"Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician."
57938109|NCT05546450|DIETARY_SUPPLEMENT|Cornus mas L.(Cornelian Cherry)|"Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement."
57938110|NCT05075837|BIOLOGICAL|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
57938111|NCT00036439|DRUG|Infliximab|
57938112|NCT00938717|DRUG|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
57938113|NCT05188820|PROCEDURE|PRP - platelet rich plasma injection|Facet block using PRP
57938114|NCT05188820|PROCEDURE|Cortisone injection|Facet block using cortisone
57938115|NCT02596620|DRUG|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
57938116|NCT02596620|DRUG|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
58293393|NCT02632006|BIOLOGICAL|PIK-PD-1 cells|"DC cell suspension (1×10\*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10\*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
58293394|NCT02632006|BIOLOGICAL|DC-PMAT|"DC cell suspension (1×10\*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10\*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
57730424|NCT03744156|BEHAVIORAL|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
57730425|NCT03744156|BEHAVIORAL|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
57938117|NCT02596620|DRUG|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
58405460|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
57730426|NCT05106257|BEHAVIORAL|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
57938118|NCT02596620|DRUG|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
57938119|NCT02463071|DRUG|AZD0585|1g soft capsule
57938120|NCT02463071|DRUG|AZD0585 placebo|1g soft capsule
57938121|NCT06388304|BEHAVIORAL|THRIVE Online PAT Program|Online program: behavioral intervention based on Positive Affect Training (PAT)
57938122|NCT00332839|DRUG|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
57938123|NCT00332839|DRUG|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
57938124|NCT00332839|DRUG|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
57938125|NCT00332839|DRUG|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
57938126|NCT00332839|DRUG|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
57938127|NCT02980120|OTHER|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig \& Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
57938128|NCT02980120|OTHER|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner \& Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
57938129|NCT02980120|OTHER|EDI-2|The Eating Disorder Inventory 2 (Paul \& Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
57938130|NCT02980120|OTHER|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig \& Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
58073909|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
58073910|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
58073911|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
58073912|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
58073913|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
58073914|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
58073915|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
58073916|NCT06723561|DRUG|4.5mg daily dose of naltrexone|Study subjects will take a daily 4.5mg dose of naltrexone.
58073917|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
58073918|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
58073919|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
58073920|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
58073921|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
58073922|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
58073923|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
58073924|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
58073925|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
58293395|NCT02948647|OTHER|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
58293396|NCT05221697|DEVICE|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
58293397|NCT01369459|BEHAVIORAL|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
58293398|NCT02533934|DRUG|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
58293399|NCT00608751|RADIATION|IMRT|
58293400|NCT01608464|DRUG|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
58293401|NCT01608464|DRUG|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
58293402|NCT05361967|DEVICE|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
58073926|NCT05108818|BIOLOGICAL|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
58073927|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
58073928|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
58073929|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
58073930|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
58073931|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
58073932|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
58073933|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
58073934|NCT06538610|DEVICE|Holter monitor|"Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours."
58073935|NCT06722352|BEHAVIORAL|Palliative Care Training|Teaching about caring for individuals with
58293403|NCT04781296|DEVICE|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
58293404|NCT02536105|DRUG|Methylphenidate HCl ER tablets 1|
58293405|NCT02536105|DRUG|Placebo|
58293406|NCT02536105|DRUG|Methylphenidate HCl ER tablets 2|
58293407|NCT02536105|DRUG|Methylphenidate HCl ER for suspension|
58293408|NCT00527280|PROCEDURE|Feasibility ot face transplantation|Feasibility ot face transplantation
58293409|NCT03861091|DRUG|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
58293410|NCT03861091|DRUG|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
58293411|NCT05163262|OTHER|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
57938131|NCT02980120|OTHER|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke \& Krischer, 2011).
58073936|NCT05689554|BEHAVIORAL|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
58073937|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
58073938|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
58073939|NCT05769777|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
58073940|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
58073941|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
58073942|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
58073943|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
58073944|NCT04190199|OTHER|Observational|Cross-sectional only
58073945|NCT01933269|DRUG|FACBC|
58073946|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
58073947|NCT04924608|DRUG|Selumetinib|Selumetinib oral capsules (10 mg and 25 mg)
58073948|NCT04924608|OTHER|Placebo|Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
58073949|NCT05692726|OTHER|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
58073950|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
58073951|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
58073952|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
58293412|NCT00760721|BEHAVIORAL|Educational Small Group Session|1 hour small group health-related discussion
58293413|NCT01944748|BEHAVIORAL|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
58293414|NCT04033146|DEVICE|Ankle Exoskeleton Assistance|The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.
58293415|NCT02571062|DRUG|Fexinidazole|
57938132|NCT02980120|OTHER|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann \& Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
58073953|NCT05289739|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
58073954|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
58073955|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
58073956|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
58293416|NCT01772927|DIETARY_SUPPLEMENT|Parenteral Nutrition|Protein and energy intakes
58073957|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
58293417|NCT04643327|DRUG|Levetiracetam|Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
57938133|NCT02980120|DEVICE|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
58293418|NCT04643327|DRUG|Placebo|Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
58293419|NCT03795337|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
57938134|NCT04042870|BEHAVIORAL|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
57938135|NCT02626481|DRUG|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
57938136|NCT02626481|DRUG|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
57938137|NCT02851420|OTHER|spectroscopy|
57938138|NCT04354220|DIAGNOSTIC_TEST|capnography monitoring|routinely used capnography monitoring
57938139|NCT04354220|DIAGNOSTIC_TEST|arterial blood gas|Routinely taken arterial blood gas values
57938140|NCT00237822|BEHAVIORAL|Adherence Feedback (AF)|
57938141|NCT00237822|BEHAVIORAL|AF + Contingency Management (AF + CM)|
57938142|NCT00237822|BEHAVIORAL|AF + Motivational Enhancement Therapy (AF + MET)|
57938143|NCT05080699|DIETARY_SUPPLEMENT|Peptamen Intense VHP, Nestlé Health Science, Switzerland|An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
58073958|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
58073959|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
58073960|NCT06724237|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
58073961|NCT06724237|OTHER|Best Practice|Receive standard of care observation
58073962|NCT06724237|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58073963|NCT06724237|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58073964|NCT06724237|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58073965|NCT06724237|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58073966|NCT06724237|DRUG|High Dose Chemotherapy|Receive high dose chemotherapy
57938144|NCT05197517|DRUG|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
57938145|NCT02795533|BEHAVIORAL|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
57938146|NCT00001990|DRUG|Atovaquone|
57938147|NCT04540770|DRUG|HuL001|Anti-ENO1 monoclonal antibody
57938148|NCT04353479|DRUG|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
57938149|NCT04353479|DRUG|Decitabine|A DNA methyltransferase inhibitor
57938150|NCT03001960|DRUG|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
58073967|NCT06724237|PROCEDURE|Leukapheresis|Undergo leukapheresis
58073968|NCT06724237|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57938151|NCT03001960|DRUG|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
57938152|NCT05916105|DRUG|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
58073969|NCT06724237|DRUG|Stem Cell Mobilization Therapy|Receive stem cell mobilization therapy
58073970|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
58073971|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
58293420|NCT01619878|DRUG|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
58293421|NCT03113110|DRUG|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
58293422|NCT01074177|DRUG|BIBW 2992|Taken orally once a day
58293423|NCT02954328|DEVICE|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
58293424|NCT04657263|OTHER|Vaccine coverage assessment|Vaccine coverage assessment
58293425|NCT01275443|DRUG|300mg TMC278LA|300mg TMC278LA intramuscular injection
58293426|NCT01275443|DRUG|150mg TMC278LA|150mg TMC278LA intramuscular injection
58293427|NCT01275443|DRUG|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
58293428|NCT01275443|DRUG|600mg TMC278LA|600mg TMC278LA intramuscular injection
58405461|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
58073972|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
58073973|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
58073974|NCT06722586|DRUG|Sirolimus|Sirolimus two pills (1mg) per day
58073975|NCT06722586|DRUG|Placebo|Placebo two pills per day
58073976|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
58073977|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
58073978|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
58073979|NCT03927209|DRUG|BI 1467335|tablet
58073980|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
58073981|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
58073982|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
58073983|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
58073984|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
58073985|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
58073986|NCT01288911|DRUG|enzalutamide|capsules
58073987|NCT01288911|DRUG|bicalutamide|tablets
58405462|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
58405463|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
58405464|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
58405465|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
58405466|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
58073988|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
58073989|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
58073990|NCT03880162|OTHER|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
58073991|NCT03880162|OTHER|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
58073992|NCT06722157|DRUG|BI 771716|BI 771716
58073993|NCT06722157|DRUG|Pegcetacoplan|Pegcetacoplan
58073994|NCT06722157|DRUG|Sham comparator to BI 771716|Sham comparator to BI 771716
58073995|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
58073996|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
58405467|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
57730427|NCT05106257|BEHAVIORAL|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
57730428|NCT05106257|BEHAVIORAL|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
58073997|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
58073998|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
58073999|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
58074000|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
58074001|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
58293429|NCT05364476|BEHAVIORAL|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
58293430|NCT05622461|BEHAVIORAL|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
58405468|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
58405469|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
58405470|NCT00346502|DRUG|20% betulinic acid ointment|
58405471|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
58405472|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
57938153|NCT06037603|BEHAVIORAL|Brain & Walk Exercise Every Day (BraW-Day)|The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
57938154|NCT05922657|DEVICE|Cerene|Real world use of Cerene.
57938155|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
57938156|NCT00449670|BIOLOGICAL|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
57938157|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
57938158|NCT02803528|DRUG|Biodentine|Biodentine is going to be used as the direct pulp capping material
57938159|NCT02803528|DRUG|MTA|MTA is going to be used as the direct pulp capping material in the second group
57938160|NCT00382018|DRUG|chemotherapy|No administration details available
57938161|NCT01114282|DRUG|velcade|
57938162|NCT01114282|DRUG|Pralatrexate|
57938163|NCT00450242|DRUG|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
57938164|NCT00450242|DRUG|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
57938165|NCT06025669|BEHAVIORAL|Nap restriction|There are 2 interventions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of nap intervention followed randomization.
57938166|NCT00610545|DRUG|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
57938167|NCT00610545|DRUG|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
57938168|NCT00780013|DRUG|metformin hydrochloride liquid 500 mg per 5 mL|
57938169|NCT03459599|DRUG|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
57938170|NCT03459599|OTHER|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
57938171|NCT02310776|DEVICE|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
58074002|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
58074003|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
58074004|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
58074005|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
58074006|NCT05766410|DRUG|Letrozole|Endocrine therapy
58074007|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
58074008|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
58074009|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
58074010|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
58074011|NCT04668157|DRUG|TAK-536|TAK-536 granule formulation
58074012|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
58074013|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,...) in order to strengthen the stretching."
58074014|NCT05574959|DEVICE|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
58074015|NCT05574959|DEVICE|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
58074016|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
58074017|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
58074018|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
58074019|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
58074020|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
58074021|NCT04738123|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
58074022|NCT04738123|DRUG|Placebo|Placebo Capsules
58074023|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
58074024|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
58074025|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
57938172|NCT02310776|DEVICE|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
57938173|NCT04841824|OTHER|Observational study|Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
57938174|NCT06231576|OTHER|Prehabilitation|"* Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention."
57938175|NCT06372951|DEVICE|Ultrasound|A device that use ultrasonic waves as a way to image the internal organs and tissues of the body in order to diagnose the different diseases.
57938176|NCT02667873|DRUG|SL-801|SL-801 is a small molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
57938177|NCT03843281|DRUG|Paracetamol|s. above
57938178|NCT03843281|DRUG|Placebo|s. above
57938179|NCT03843281|DRUG|Morphine|s. above
57938180|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
57938181|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
57938182|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
57938183|NCT01504165|DRUG|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
58074026|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
58074027|NCT06601478|BEHAVIORAL|The MedLIFE app|The intervention arm will receive the lifestyle counselling by the MEDLIFE app, and the control arm will go on with standard lifestyle recommendations in the form of a two-page written handout.
58074028|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
58074029|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
58074030|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
58074031|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
58074032|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
58074033|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
58074034|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
58074035|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
58074036|NCT04672200|OTHER|Group exercise|Weekly group exercises delivered online and face to face
58293431|NCT04485078|DIAGNOSTIC_TEST|Pressure pain threshold|The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
58293432|NCT04485078|DIAGNOSTIC_TEST|Temporal summation|TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
58293433|NCT04485078|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
58293434|NCT04485078|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
58293435|NCT04485078|OTHER|Bath Ankylosing Spondylitis Disease Activity Index|Standardized questionnaire to determine the level of disease activity in AxSpa patients
58293436|NCT04485078|OTHER|Ankylosing Spondylitis Quality of Life|Standardized questionnaire to investigate the quality of life in AxSpa patients
58293437|NCT04485078|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability
58293438|NCT04485078|OTHER|Beck Depression Inventory|Standardized questionnaire to investigate the depression
58293439|NCT04485078|OTHER|Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue
58293440|NCT04485078|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
58293441|NCT04485078|OTHER|Fibromyalgia Rapid Screening Tool|Standardized questionnaire to detect fibromyalgia
58293442|NCT04485078|OTHER|Visual analogue scale|global pain score on a 0 to 10
58293443|NCT06473207|OTHER|Remote ischemic post conditioning sessions|Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
58293444|NCT06473207|OTHER|Sham sessions|Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
58293445|NCT02931786|DRUG|propofol|propofol, midazolam and atropine administration via intravenous cannula.
57938184|NCT01504165|DRUG|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
58074037|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
57938185|NCT01555047|PROCEDURE|IUI|intrauterine insemination
57938186|NCT01555047|PROCEDURE|IUI|intrauterine insemination
57938187|NCT00003172|BIOLOGICAL|filgrastim|
57938188|NCT00003172|BIOLOGICAL|recombinant interferon alfa|
57938189|NCT00003172|DRUG|docetaxel|
57938190|NCT00003172|DRUG|doxorubicin hydrochloride|
57938191|NCT00003172|DRUG|fluorouracil|
57938192|NCT00003172|DRUG|hydroxyurea|
58074038|NCT06679920|DEVICE|Optical coherence tomography|Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
58293446|NCT02931786|DRUG|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
58293447|NCT02542397|GENETIC|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
58293448|NCT00762762|DRUG|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
58293449|NCT00762762|DRUG|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
58293450|NCT02997605|DRUG|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
58074039|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
58074040|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
58074041|NCT05115630|DRUG|Cyclophosphamide|Given by IV
58074042|NCT05115630|DRUG|Mesna|Given by IV
58074043|NCT05115630|DRUG|Filgrastim|Given by IV
58074044|NCT05115630|DRUG|Melphalan|Given by IV
58293451|NCT04010292|BEHAVIORAL|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
58293452|NCT04635930|OTHER|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
58293453|NCT04058197|DRUG|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
57938193|NCT05410613|COMBINATION_PRODUCT|electromagnetic field and a plantar resistance exercise|"Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening)."
58293454|NCT04058197|OTHER|Placebo|Placebo Patch
58074045|NCT05115630|DRUG|Fludarabine phosphate|Given by IV
58074046|NCT05115630|DRUG|Tacrolimus|Given by IV
58074047|NCT05115630|DRUG|Mycophenolate mofetil|Given by IV
58074048|NCT05115630|DRUG|Total Body Irradiation One Dose|Given by IV
58074049|NCT06286293|OTHER|Neuropsychological assessment, driving simulator task|Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
58293455|NCT01405898|DIETARY_SUPPLEMENT|beetroot juice|Beetroot juice 4 weeks 250ml daily
58293456|NCT01405898|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
58293457|NCT00214617|DRUG|Rosuvastatin at 5 mg/day and 40 mg/day|
58293458|NCT00653367|PROCEDURE|Nerve section|Intercostal nerve is divided during surgery
58293459|NCT03793647|DEVICE|Electrical muscle devise|evaluate two types of EMS stimulation of legs
58293460|NCT03212014|OTHER|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
57938194|NCT05410613|DEVICE|Pulsed electromagnetic field|Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
57938195|NCT05410613|OTHER|usual care|standard general advice according to hospital protocol
57938196|NCT00768326|DRUG|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
57938197|NCT00768326|DRUG|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
58293461|NCT03212014|OTHER|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
58293462|NCT03212014|OTHER|Traditional rehabilitation|traditional exercise models in currently clinical use
58293463|NCT00397605|DRUG|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
58074050|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
58074051|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
58074052|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
58074053|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
58074054|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
58293464|NCT03779347|DRUG|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
58293465|NCT03779347|DIAGNOSTIC_TEST|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
57938198|NCT00768326|DRUG|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
57938199|NCT00768326|DRUG|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
57938200|NCT00768326|DRUG|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
57938201|NCT00768326|DRUG|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
58074055|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
58074056|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
58074057|NCT02990273|BIOLOGICAL|Blood transfusion|
58074058|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
58074059|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
58074060|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
58074061|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
57938202|NCT05845658|DEVICE|Active VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
58074062|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
58074063|NCT06077760|BIOLOGICAL|V940|IM injection
58074064|NCT06077760|BIOLOGICAL|Pembrolizumab|IV infusion
58074065|NCT06077760|OTHER|Placebo|IM injection
57730429|NCT05106257|BEHAVIORAL|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
58074066|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
58074067|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
57938203|NCT05845658|DEVICE|Sham VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
57938204|NCT06429267|DEVICE|Bioabsorbable Screw|Bioabsorbable screw that redissolves into the bone. Mineral fibers are composed of Silicon Dioxide (SiO2), Sodium Oxide, Calcium Oxide, Magnesium Oxide, Boron Trioxide, and Phosphorous Pentoxide
57938205|NCT06429267|DEVICE|Metal/Titanium Screw|Traditional metal screw used in fracture fixation that requires hardware removal
58293466|NCT03779347|DIAGNOSTIC_TEST|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
58293467|NCT02455505|BEHAVIORAL|background questionnaire|
58293468|NCT02455505|BEHAVIORAL|bereavement risk screening tool|
57938206|NCT02042651|DEVICE|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
57938207|NCT02042651|DEVICE|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
57938208|NCT02284620|PROCEDURE|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
57938209|NCT02284620|PROCEDURE|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
57938210|NCT00478465|DRUG|valganciclovir|
57938211|NCT01806857|DRUG|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
58074068|NCT06722014|BEHAVIORAL|STAMP + CBT|A mobile health, smartphone application that provides tailored multi-media, cancer pain psycho-education and self-management advice to participants while facilitating clinician monitoring.
58074069|NCT06722014|BEHAVIORAL|Digital Cancer Pain Education Packet|Packet including Articles from the Association for Clinical Oncology and the National Cancer Institute and the pain and medication monitoring form.
58074070|NCT06580106|OTHER|Biospecimen samples|Buccal swabs and Blood samples will be collected throughout study.
58074071|NCT02425774|PROCEDURE|Vagus stimulation|
58293469|NCT01951417|DRUG|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
58293470|NCT01951417|OTHER|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
58293471|NCT01951417|OTHER|Foam Wash|Foam Wash (twice daily)
58293472|NCT00991289|DRUG|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
58293473|NCT00991289|DRUG|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
58293474|NCT00991289|DRUG|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
58293475|NCT05602740|DEVICE|Harmony|Passive recording of the head pulse
58293476|NCT00120705|DRUG|darbepoetin alfa|
58293477|NCT00254553|DRUG|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
58293478|NCT00254553|DRUG|Placebo|two tubes of placebo per day
58293479|NCT02440061|DRUG|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
58293480|NCT02440061|DRUG|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
58074072|NCT02425774|PROCEDURE|Sham stimulation|
58074073|NCT02425774|DRUG|Prucalopride|
58074074|NCT02425774|DRUG|Placebo|
58074075|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
58074076|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
58074077|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
58074078|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
58074079|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
58074080|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
58074081|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
58074082|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
58074083|NCT02496715|DRUG|Placebo|Placebo inhaler
58074084|NCT05814627|DRUG|Upadacitinib|Oral Tablets
58074085|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
58074086|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
58074087|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
58074088|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
58074089|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
58074090|NCT01694849|DRUG|GFT505 80mg|
58293481|NCT02440061|DRUG|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
58293482|NCT02051790|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
58293483|NCT03438084|DIETARY_SUPPLEMENT|Interesterified fat|50 g fat provided as commercially available interesterified fat.
58293484|NCT03438084|DIETARY_SUPPLEMENT|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
58293485|NCT03438084|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
58293486|NCT03438084|DIETARY_SUPPLEMENT|Butter|50g fat provided as commercially available spreadable butter
58293487|NCT00002182|DRUG|Megestrol acetate|
58405473|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
58074091|NCT01694849|DRUG|GFT505 120mg|
58074092|NCT01694849|DRUG|Placebo|
58074093|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
58074094|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
58074095|NCT06199479|PROCEDURE|MRI Scan|Performed by MRI Scan
58074096|NCT06199479|PROCEDURE|CT Scan|Performed by CT Scan
58074097|NCT06199479|PROCEDURE|Biopsy|Standard of Care Biopsy
58074098|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
58074099|NCT06445907|DRUG|Azacitidine|Given by IV
58074100|NCT06445907|DRUG|Venetoclax|Given by PO
58074101|NCT06445907|DRUG|Q702|Given by PO
58074102|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
58074103|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
58293488|NCT06171854|DRUG|Cabozantinib|cabozantinib in patients with refractory mCRC
58293489|NCT00118989|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
58293490|NCT01711983|DEVICE|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
58293491|NCT01289548|DEVICE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
58405474|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
57938212|NCT01806857|DRUG|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
58074104|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
58074105|NCT05429268|DRUG|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
58074106|NCT05429268|DRUG|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
58074107|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
58074108|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
58074109|NCT05968157|DIAGNOSTIC_TEST|Breast MRI|Supplemental MRI (in addition to standard of care MRI).
58074110|NCT05968157|DEVICE|MIRAI|Artificial intelligence software
58074111|NCT04446039|DRUG|Escitalopram|Treatment for depression
58074112|NCT04446039|DRUG|Paroxetine|Treatment for depression
58074113|NCT04446039|DRUG|Fluoxetine|Treatment for depression
58074114|NCT04446039|DRUG|Mirtazapine|Treatment for depression
58074115|NCT04446039|DRUG|Duloxetine|Treatment for depression
58074116|NCT04446039|DRUG|Sertraline|Treatment for depression
58074117|NCT04446039|DRUG|Venlafaxine|Treatment for depression
58074118|NCT04446039|DRUG|Tianeptine|Treatment for depression
58074119|NCT04446039|DRUG|Vortioxetine|Treatment for depression
58074120|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
58074121|NCT04446039|DRUG|Bupropion|Treatment for depression
58074122|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
58293492|NCT03414333|PROCEDURE|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
58293493|NCT03414333|DRUG|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
58405475|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
57938213|NCT01488279|DRUG|Dexamethasone 2.5 mg and Sitagliptin 100 mg|Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
57938214|NCT01488279|DRUG|Dexamethasone 2.5 mg and placebo tablet|Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
57938215|NCT03811457|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
58074123|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
58074124|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
58074125|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
58074126|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
58074127|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
58074128|NCT05275231|BEHAVIORAL|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
58293494|NCT03559543|DIETARY_SUPPLEMENT|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
58293495|NCT01867515|OTHER|Acoustic distortion of speech|
58074129|NCT03698825|DRUG|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
58074130|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
58074131|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
58074132|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
58074133|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
58293496|NCT05714696|BEHAVIORAL|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
57938216|NCT00161876|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
57938217|NCT00502346|DRUG|PM10|
57938218|NCT02767323|DEVICE|rTMS|excitatory 5Hz rTMS will be used
57938219|NCT02767323|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
57938220|NCT00978549|DRUG|docetaxel|
57938221|NCT00978549|DRUG|steroid therapy|
57938222|NCT00978549|OTHER|questionnaire administration|
57938223|NCT00978549|PROCEDURE|nausea and vomiting therapy|
57938224|NCT00978549|PROCEDURE|pain therapy|
57938225|NCT00978549|PROCEDURE|quality-of-life assessment|
57938226|NCT00978549|PROCEDURE|standard follow-up care|
57938227|NCT00978549|RADIATION|radiation therapy|
57938228|NCT00962442|DRUG|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
57938229|NCT00962442|DRUG|placebo|Glucosé 5% perfusion for 14 days, intravenously
57938230|NCT05659589|OTHER|blood sample|Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.
57938231|NCT02602912|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
57938232|NCT05024799|DRUG|Fentanyl, propofol|The patients in this group will be administered with fentanyl and propofol
57938233|NCT05024799|DRUG|fentanyl and dexmedetomindine|The patients in this group will be administered with fentanyl and dexmedetomindine
57938234|NCT05024799|DRUG|Butorphanol and propofol|The patients in this group will be administered with butorphanol and propofol
57938235|NCT05024799|DRUG|Butorphanol and dexmedetomindine|The patients in this group will be administered with butorphanol and dexmedetomindine
57938236|NCT02675842|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
57938237|NCT02675842|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
57938238|NCT03600064|DRUG|Misoprostol|the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
57938239|NCT00000180|DRUG|AIT-082|
57938240|NCT03926754|DRUG|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
57938241|NCT06209008|DRUG|Intravesical injection of Platlet Rich Plasma (PRP)|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
57938242|NCT02419326|BEHAVIORAL|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
57938243|NCT06475313|BEHAVIORAL|plaque index assessment, periodontal probing, Bleeding on probing (BOP), Prosthetic adjacency check, initial occlusal contact, maximum occlusal contact, and filling of the cusps.|oral panoramic radiograph
58074134|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
58074135|NCT02918968|DRUG|Enzalutamide|Oral Capsule
58074136|NCT02918968|DRUG|Flutamide|Oral tablet
58074137|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
58074138|NCT06508593|DIAGNOSTIC_TEST|Serum metabolic profile|Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques
58074139|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
58074140|NCT03542409|OTHER|MR Perfusion Scan|MR perfusion scan before and during surgery.
58074141|NCT03542409|OTHER|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
58293497|NCT05714696|BEHAVIORAL|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
58405476|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
58405477|NCT00002211|DRUG|Nelfinavir mesylate|
58405478|NCT00002211|DRUG|Delavirdine mesylate|
58405479|NCT00002211|DRUG|Stavudine|
57938244|NCT04541290|DRUG|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
57938245|NCT01671813|DRUG|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
57938246|NCT01740960|DRUG|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
57938247|NCT01740960|DRUG|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
57938248|NCT00142350|DRUG|continuous infusion of 5-fluorouracil|
57938249|NCT00142350|DRUG|combination of irinotecan and cisplatin|
57938250|NCT00142350|DRUG|oral administration of S-1|
57938251|NCT00156234|BEHAVIORAL|One-knee extension ergometer|
57938252|NCT00029913|OTHER|Observation|Observation of participants who received HIV preventive vaccine and became infected.
58293498|NCT06300099|DRUG|Dexamethasone|Dexamethasone as adjunct to serratus anterior plane block.
58293499|NCT06300099|DRUG|Dexmedetomidine|Dexmedetomidine as adjunct to serratus anterior plane block.
58405480|NCT00002211|DRUG|Didanosine|
58405481|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
57938253|NCT00267033|PROCEDURE|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
57938254|NCT05260905|BEHAVIORAL|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
57938255|NCT02000596|DRUG|Trastuzumab plus Pertuzumab|
57938256|NCT02000596|DRUG|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
57938257|NCT02000596|DRUG|Chemotherapy with Eribulin|
57938258|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
57938259|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
58405482|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
58405483|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
58405484|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
57938260|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
57938261|NCT00152282|DRUG|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
57938262|NCT03090087|BIOLOGICAL|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
58074142|NCT03542409|OTHER|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
58074143|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
58074144|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
58074145|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
58074146|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
58405485|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
58405486|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
57938263|NCT03090087|DRUG|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
57938264|NCT00118391|BEHAVIORAL|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
58405487|NCT03717792|OTHER|no intervention|no intervention
58405488|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
58405489|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
58405490|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
58405491|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
58074147|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
58074148|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
58074149|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
58293500|NCT04181671|OTHER|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
58405492|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
58405493|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
58405494|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
58405495|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
58405496|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
58405497|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
57938265|NCT00118391|BEHAVIORAL|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
58074150|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
58405498|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
58405499|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
58405500|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
58405501|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
58293501|NCT04181671|OTHER|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
58074151|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
58293502|NCT02408042|DRUG|Pembrolizumab|
57938266|NCT03366051|PROCEDURE|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
58074152|NCT04888507|DRUG|Cemdisiran|SC administration
58074153|NCT04039282|DEVICE|myfood24|online website for dietary analysis
58293503|NCT02408042|DRUG|Etoposide|
58293504|NCT02408042|DRUG|Ifosfamide|
57938267|NCT03366051|PROCEDURE|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
58074154|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
58074155|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
58293505|NCT02408042|DRUG|Mesna|
58293506|NCT02408042|DRUG|Carboplatin|
58293507|NCT02408042|DRUG|Brentuximab vedotin|
58293508|NCT02408042|DRUG|Rituximab|
58293509|NCT02541422|DIETARY_SUPPLEMENT|N Acetyl Cysteine|
58293510|NCT02541422|OTHER|placebo|
58074156|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
57730430|NCT05106257|BEHAVIORAL|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
57730431|NCT01332877|BEHAVIORAL|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
58074157|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
58074158|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
57730432|NCT01332877|BEHAVIORAL|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
57730433|NCT03749551|DIAGNOSTIC_TEST|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
58293511|NCT03574077|BEHAVIORAL|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
57730434|NCT03787368|DRUG|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
57730435|NCT03787368|DRUG|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
57730436|NCT04313634|DRUG|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
57730437|NCT04313634|DRUG|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
57730438|NCT04313634|DRUG|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
57730439|NCT02360709|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
57730440|NCT00436059|DRUG|bortezomib|
57730441|NCT02588391|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
57730442|NCT02588391|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
58074159|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
58074160|NCT06219499|OTHER|Placebo|Placebo
58074161|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
58074162|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
58074163|NCT05017116|DRUG|RBD1016|subcutaneous injection
58074164|NCT05017116|DRUG|Placebo|subcutaneous injection
58074165|NCT05017116|DRUG|Entecavir|Take orally.
58074166|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
58074167|NCT00272194|DEVICE|Ambu Laryngeal Mask|
58074168|NCT00272194|DEVICE|Aintree Exchange Catheter|
58074169|NCT00272194|DEVICE|Laryngeal Mask Airway|
58293512|NCT03574077|BEHAVIORAL|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
58293513|NCT03574077|BEHAVIORAL|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
58293514|NCT03574077|BEHAVIORAL|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
58293515|NCT03574077|BEHAVIORAL|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
58293516|NCT00181883|DRUG|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
58293517|NCT05084183|DEVICE|PermeaDerm®|Wound Management Device
58293518|NCT05084183|DEVICE|Mepilex Ag|Wound Dressing
58293519|NCT04487808|DRUG|Pecan|Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
58293520|NCT04487808|OTHER|Average American Diet devoid of nuts|Diet mimicking usual American intake
58293521|NCT00507260|BEHAVIORAL|Food Record|A record of the amount and kind of food and drink you intake will be completed.
58293522|NCT00507260|OTHER|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
57938268|NCT02019823|BEHAVIORAL|Informational SMS-text|
57938269|NCT02019823|BEHAVIORAL|Interactive SMS-text|
58074170|NCT06205225|BEHAVIORAL|Text4HF|Behavioral text messages about heart failure self-care
58074171|NCT06205225|BEHAVIORAL|MyApps|consumer mobile health apps and devices for heart failure self-care
58074172|NCT06205225|BEHAVIORAL|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
58074173|NCT06205225|BEHAVIORAL|Enhanced Usual Care|Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
58293523|NCT04338477|DRUG|Nephrosolid tablets|Adminstration of drug
57938270|NCT02019823|BEHAVIORAL|Enhanced usual care|
57938271|NCT04543058|DEVICE|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
57938272|NCT04543058|OTHER|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
57938273|NCT04543058|OTHER|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
57938274|NCT02866799|OTHER|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
57938275|NCT02866799|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
57938276|NCT04373954|OTHER|Forgiveness Therapy|The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.
58293524|NCT00933504|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks.
58074174|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
58405502|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
58405503|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
57730443|NCT02588391|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
57730444|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
57730445|NCT05147818|OTHER|CBC ,renal function tests , fundus Examination|Laboratory investigations
57730446|NCT02563912|OTHER|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
57730447|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
57938277|NCT04373954|OTHER|Carey Guides|The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
57938278|NCT04323085|BEHAVIORAL|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
57938279|NCT04323085|BEHAVIORAL|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
57938280|NCT01937598|DRUG|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
57938281|NCT01937598|OTHER|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
57938282|NCT01937598|DRUG|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
57938283|NCT01937598|DRUG|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
57938284|NCT00502073|DRUG|cyclosporine|
57938285|NCT01095406|DEVICE|S1 ventilation|Ventilation with a O2 and CO2 controller
57730448|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
57730449|NCT06244784|BEHAVIORAL|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
57938286|NCT04233164|DRUG|Solu-Medrol 1mg/kg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
57938287|NCT04233164|DRUG|Solu-Medrol 250 mg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
58074175|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
58293525|NCT05533489|OTHER|No intervention|No intervention This study is a retrospective descriptive study.
58293526|NCT06612242|PROCEDURE|early tracheostomy (less than 7 days from intubation)|Early tracheostomy (less than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
58405504|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
57730450|NCT06218017|DEVICE|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
57938288|NCT00848133|PROCEDURE|mini-midvastus surgical approach for total knee arthroplasty|
57938289|NCT00848133|PROCEDURE|mini-subvastus surgical approach for total knee arthroplasty|
57938290|NCT01421927|DRUG|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant"
58293527|NCT06612242|PROCEDURE|Late tracheostomy (more than 7 days from intubation)|Late tracheostomy (more than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
58293528|NCT02706080|OTHER|emergency|
57730451|NCT06218017|DEVICE|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
57730452|NCT01503905|DRUG|Docetaxel|75mg/m2, iv injection, day1, every 21 days
57730453|NCT01503905|DRUG|epirubicin|80mg/ m2, iv injection, day1, every 21 days
58293529|NCT04691219|DIETARY_SUPPLEMENT|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
57730454|NCT01503905|DRUG|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
57730455|NCT01503905|PROCEDURE|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
57938291|NCT01971983|OTHER|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
57938292|NCT01971983|OTHER|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
57938293|NCT01971983|OTHER|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
57938294|NCT04695067|BEHAVIORAL|Central fatigue group|a fatigue protocol that pitchers need to pitch 80 trials in a simulated game
57938295|NCT00445874|DRUG|Ketotifen with a Contact Lens (no generic name)|
57730456|NCT01503905|DRUG|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
57730457|NCT01503905|DRUG|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
57730458|NCT01503905|DRUG|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
57730459|NCT01503905|RADIATION|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
57730460|NCT01503905|DRUG|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
57938296|NCT03088475|BEHAVIORAL|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
57938297|NCT03088475|BEHAVIORAL|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
58293530|NCT04691219|BEHAVIORAL|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
58293531|NCT02454751|DRUG|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
58293532|NCT05748964|PROCEDURE|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
58405505|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
58405506|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
58405507|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
58405508|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
58405509|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
58405510|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
58405511|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
58405512|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
58405513|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
58405514|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
58405515|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
58405516|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
57730461|NCT01503905|DRUG|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
57730462|NCT05462366|OTHER|Sample collection|Collect breast-milk and feces from mother-infant-pairs.
57730463|NCT01793792|DEVICE|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
58293533|NCT03485794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58293534|NCT03485794|OTHER|Laboratory Biomarker Analysis|Correlative studies
58293535|NCT05940415|BEHAVIORAL|active surveillance|active surveillance without prostate biopsy
58293536|NCT05364788|OTHER|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
58293537|NCT05492149|OTHER|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
58293538|NCT03315845|OTHER|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
58293539|NCT01124318|DRUG|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
58293540|NCT01124318|DRUG|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
57730464|NCT02624804|BIOLOGICAL|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
58293541|NCT03153046|DIETARY_SUPPLEMENT|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
58293542|NCT03153046|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
58405517|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
58405518|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
58405519|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
58405520|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
57730465|NCT06495008|OTHER|no intervention, only questionnaires, saliva collection and taste/smell tests|no intervention, only questionnaires, saliva collection and taste/smell tests
57730466|NCT04242927|DRUG|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
57938298|NCT05824286|OTHER|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
57938299|NCT02584322|OTHER|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
57938300|NCT03476941|DRUG|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
57938301|NCT03476941|DRUG|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
58405521|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
58405522|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
58405523|NCT04362371|DEVICE|Ainara|1 g at each administration
58405524|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
58405525|NCT06605833|DIAGNOSTIC_TEST|Lead ECG|"Participants will undergo a standard 12 lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
58405526|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
58405527|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
58405528|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
58405529|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
57730467|NCT04242927|DRUG|Routine care|Routinely apply urea ointment and provide best supportive care.
57730468|NCT01018901|OTHER|Survey Administration|Patients complete survey
57938302|NCT03476941|OTHER|Placebo|The placebo group will receive drain irrigation twice/day
57938303|NCT05529459|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
57938304|NCT01092143|DRUG|BI 671800|BI 671800
58074176|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
58293543|NCT04767113|DRUG|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
58405530|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
58405531|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
58405532|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
57730469|NCT04680221|DRUG|Liposomal bupivacaine|Deposition of liposomal bupivacaine
57730470|NCT04680221|PROCEDURE|TAP block|Transversus abdominis plane block performed to deposit anesthetic
57938305|NCT01092143|DRUG|Fluticasone propionate placebo|Placebo matching Fluticasone propionate
57938306|NCT01092143|DRUG|Fluticasone propionate|Fluticasone propionate
57938307|NCT01092143|DRUG|BI 671800 Placebo|Placebo matching BI 671800
58293544|NCT04767113|DRUG|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
57730471|NCT04680221|DRUG|Deposition of saline|Deposition of saline
57730472|NCT06226376|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
57730473|NCT04269928|PROCEDURE|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
57938308|NCT03517891|BEHAVIORAL|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
57938309|NCT00971763|BIOLOGICAL|rituximab|
58074177|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
58293545|NCT02195635|DRUG|Telotristat etiprate|500 mg telotristat etiprate
57938310|NCT00971763|DRUG|cyclophosphamide|
57938311|NCT00971763|DRUG|gemcitabine hydrochloride|
57938312|NCT00971763|DRUG|prednisolone|
57938313|NCT00971763|DRUG|vincristine sulfate|
57938314|NCT03926845|OTHER|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
57938315|NCT03926845|OTHER|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
57938316|NCT01855763|DRUG|Metformin|
57938317|NCT01855763|DRUG|Insulin|
58293546|NCT02195635|DRUG|Octreotide acetate|200 µg octreotide acetate three times daily
58293547|NCT00156026|PROCEDURE|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
58293548|NCT00248157|DRUG|Octreotide acetate in microspheres|
57938318|NCT02772640|DRUG|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -\> evening evening -\> morning"
57938319|NCT00189072|DRUG|gabapentin|
57938320|NCT02931942|OTHER|blood withdrawn|venous blood sampling
57938321|NCT06281067|DIAGNOSTIC_TEST|"full-physiology approach arm"|"* All MB patients belonging to the full-physiology arm will undergo functional assessment of the intramural artery with basal Pd/Pa, FFR (after intravenous adenosine), RFR, CFR and IMR.~* In the presence of a negative functional assessment (Pd/Pa\> 0.92, FFR\> 0.80, RFR\> 0.89, CFR≥ 2.0 and IMR\< 25), FFR, CFR and IMR will be measured after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d) to exalt the epicardial hemodynamic significance of MB or its impact on structural microvascular remodelling (impaired endothelium-independent vasodilatation).~* In the absence of epicardial hemodynamic significance (FFR-d\> 0.75) and structural microvascular dysfunction (CFR≥ 2.0 and IMR\< 25), ACH provocative test will be performed to evaluate the presence of epicardial or microvascular spasm (impaired endothelium-dependent vasodilatation)."
57938322|NCT06281067|DIAGNOSTIC_TEST|"standard approach arm"|"In the standard approach arm patients will undergo an angiographic evaluation of the tunnelled artery"
57938323|NCT02553122|DRUG|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
57938324|NCT02553122|DEVICE|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
57938325|NCT00078325|DRUG|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
57938326|NCT00078325|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
57938327|NCT00078325|DRUG|Placebo|Matching placebo tablets once daily in the morning
57938328|NCT02289651|DEVICE|Venner|Video-laryngoscopy
57938329|NCT02289651|DEVICE|Miller|Direct-Laryngoscopy
57938330|NCT03989076|PROCEDURE|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
57938331|NCT03738878|DRUG|Valsartan|oral valsartan
57938332|NCT03738878|DRUG|LCZ696|oral LCZ696
57938333|NCT03738878|DRUG|Bradykinin|Intra-arterial bradykinin at three graded doses
57938334|NCT03738878|DRUG|Substance P|Intra-arterial substance P at three graded doses
57938335|NCT03738878|DRUG|BNP|Intra-arterial BNP at three graded doses
57938336|NCT03738878|DRUG|Sitagliptin|oral sitagliptin
57938337|NCT05998083|OTHER|exercise|"In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations."
57938338|NCT05998083|OTHER|control|The control group continued only the individual support education program.
57938339|NCT02179879|OTHER|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
58293549|NCT00447525|BIOLOGICAL|REVAXIS®|
58293550|NCT00447525|BIOLOGICAL|DT-Polio®|
57938340|NCT01033526|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
57938341|NCT01033526|DRUG|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
57938342|NCT05829642|BEHAVIORAL|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
58074178|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
57730474|NCT06634914|DIETARY_SUPPLEMENT|Moonbrew|A blend of adaptogens with Chamomile, Rose, and Magnesium in a powdered form, designed to be mixed in liquid and consumed 2-3 hours before bed.
58293551|NCT00718094|DRUG|Polyphenon E®|Oral capsules
58293552|NCT00718094|DRUG|Placebo Oral Tablet|Oral tablet: placebo
57938343|NCT03889665|OTHER|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
57938344|NCT04494230|BEHAVIORAL|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
58074179|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
58074180|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
58405533|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
57730475|NCT06670326|BEHAVIORAL|Imagery Rescripting|Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
57730476|NCT01815177|DEVICE|Arthroscopic transosseous fixation|
57730477|NCT01815177|DEVICE|Suture anchors|
57730478|NCT03398538|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
57938345|NCT04616391|DEVICE|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
57938346|NCT02116257|DRUG|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
57938347|NCT02116257|DRUG|PCA regimen|
57938348|NCT03988231|DRUG|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
57938349|NCT03988231|DRUG|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
57938350|NCT04828187|DIAGNOSTIC_TEST|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
57938351|NCT06306079|DEVICE|Lateral Wedge insole|Insoles with lateral wedges are placed in patients' shoes to control biomechanical knee loading on the medial side of the knee. Insoles with lateral wedges are designed to be thinner on the inside (medially of the foot) and thicker on the outside (laterally of the foot) to relieve knee biomechanical loading parameters.
57938352|NCT01788657|BEHAVIORAL|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
57938353|NCT01788657|BEHAVIORAL|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
58074181|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
58074182|NCT03737812|DRUG|elezanumab|solution for infusion
58293553|NCT05347810|OTHER|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
58293554|NCT06420817|BEHAVIORAL|Indian version of a 'Portfolio' diet|The participants will be required to follow the prescribed diet plan for 4 weeks
58074183|NCT03737812|DRUG|placebo|solution for infusion
58074184|NCT05926687|BEHAVIORAL|Social Communication|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
58074185|NCT05926687|BEHAVIORAL|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
58074186|NCT05926687|BEHAVIORAL|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour once/week
58074187|NCT05926687|BEHAVIORAL|Social Communication + Add Tools|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
58293555|NCT06420817|BEHAVIORAL|Physical Activity|"The participants will be required to join for an hour of group online exercise program 3 days a week for 4 weeks~• (Exercise Duration = 180 minutes per week including cardio, strength training and flexibility)"
57730479|NCT03398538|OTHER|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
58074188|NCT05926687|BEHAVIORAL|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour every other week
58074189|NCT05926687|BEHAVIORAL|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
58074190|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
57730480|NCT03398538|OTHER|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
58293556|NCT06420817|BEHAVIORAL|Intermittent fasting|The participants will be required to do intermittent fasting for 12 hours daily for 4 weeks
58405534|NCT03564964|DRUG|SUVN-502|Tablet
57730481|NCT03398538|OTHER|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
58293557|NCT06420817|BEHAVIORAL|Monitoring of sleep and stress levels|The participants will be required to monitor their sleep and stress levels
57730482|NCT00061295|PROCEDURE|Body weight support treadmill training|
57730483|NCT00774735|DRUG|GSK1349572|30 mg given in combination with lopinavir/ritonavir
57730484|NCT00774735|DRUG|GSK1349572|30 mg in combination with darunavir/ritonavir
57730485|NCT05582434|DRUG|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
57730486|NCT05582434|DRUG|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
57730487|NCT05582434|DRUG|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
57730488|NCT06348394|OTHER|Intracardiac Echocardiography|Transesophageal echocardiography will be performed under general anesthesia.
57730489|NCT02278601|DEVICE|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
57730490|NCT02278601|DRUG|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
57730491|NCT02278601|DRUG|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
57730492|NCT05469321|OTHER|None, pure observationnal study|None, pure observational study following the usual management of the patients
57730493|NCT03223298|DRUG|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
57730494|NCT03223298|DRUG|0.9% Sodium Chloride Injection|1cc syringe
57730495|NCT05911854|DEVICE|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
57730496|NCT05911854|DEVICE|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
57730497|NCT05911854|OTHER|complete decongestive therapy|"Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
57730498|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
57730499|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
57730500|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
57730501|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
57730502|NCT01101737|OTHER|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
57730503|NCT04745676|BEHAVIORAL|Telehealth|Telehealth ACP intervention advance care planning intervention
57730504|NCT05916508|DRUG|0.454% stannous fluoride|Brush two times daily
57730505|NCT05916508|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
57730506|NCT05916508|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
57938354|NCT02964299|DEVICE|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
57730507|NCT05639738|OTHER|Clinical and instrumental measurements|"* Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations"
57730508|NCT04307186|DRUG|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
57730509|NCT04307186|DRUG|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
57730510|NCT01367262|DRUG|LY2886721|Administered orally
57730511|NCT02919579|DRUG|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
57730512|NCT02919579|DRUG|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
57730513|NCT02919579|OTHER|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
57730514|NCT02919579|DRUG|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
57730515|NCT03678948|DEVICE|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
58293558|NCT01067534|DRUG|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
57730516|NCT03678948|DEVICE|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
57730517|NCT04712526|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
57730518|NCT03277222|BIOLOGICAL|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
57730519|NCT03277222|BIOLOGICAL|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
57730520|NCT00538161|OTHER|Ventilation strategy|
57730521|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
57730522|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
58074191|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
58405535|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
58405536|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
58405537|NCT00420615|DRUG|Patupilone and Omeprazole|
58405538|NCT00420615|DRUG|Patupilone + Midalzolam|
58405539|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
58405540|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
58405541|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
58405542|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
58405543|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
58405544|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
58405545|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
58405546|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
58074192|NCT05332912|BEHAVIORAL|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
58405547|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
58405548|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
58405549|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
58405550|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
58074193|NCT06297629|DRUG|ASTX727|Given by PO
58074194|NCT06297629|DRUG|Donor Lymphocyte Infusion|Given by Infusion
58405551|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
57730523|NCT00497380|DIETARY_SUPPLEMENT|Arginine|Oral nutritional supplement
57730524|NCT06422741|DIETARY_SUPPLEMENT|grape seed proanthocyanidin extract|250 mg of product presented in capsule form will be given.
57730525|NCT06422741|DIETARY_SUPPLEMENT|Placebo|165 mg of cellulose will be given presented in capsule form.
58074195|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
58074196|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
58293559|NCT01062893|OTHER|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
58405552|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
58405553|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
58405554|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
58405555|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
58074197|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
58074198|NCT06724549|DRUG|BN104|This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
58405556|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
57730526|NCT03631186|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
58293560|NCT01062893|OTHER|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
58293561|NCT05607316|DRUG|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study."
58293562|NCT02992028|DRUG|Intravenous Nutrition (Vitamins) injection|
58293563|NCT02992028|DRUG|Intravenous Saline injection|
58074199|NCT06011603|DEVICE|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
58095504|NCT06701292|DEVICE|PVS-PVI targeted ablation|"Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI."
58293564|NCT04875910|OTHER|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
58293565|NCT03576339|PROCEDURE|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
58293566|NCT03576339|DEVICE|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
58293567|NCT03576339|DEVICE|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
58293568|NCT00242515|PROCEDURE|CD8+ T-cell depleted donor lymphocyte infusion|
58293569|NCT04884646|OTHER|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
58293570|NCT04884646|OTHER|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
58293571|NCT04884646|OTHER|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
58293572|NCT02089802|DRUG|Pazopanib|
58293573|NCT06039319|OTHER|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
57730527|NCT03434119|DRUG|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
57730528|NCT03434119|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
58405557|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
58293574|NCT05886114|BEHAVIORAL|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
57938355|NCT01898936|PROCEDURE|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
57938356|NCT01898936|DEVICE|Only photodynamic therapy|
57938357|NCT00711425|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
57938358|NCT03329222|OTHER|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
58293575|NCT05886114|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
58293576|NCT04244617|BEHAVIORAL|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
58293577|NCT05641441|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery
58293578|NCT02775097|DEVICE|OCT|OCT for all Arms
58293579|NCT01945879|DRUG|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
58293580|NCT01373034|DIETARY_SUPPLEMENT|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
57938359|NCT03329222|OTHER|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
58293581|NCT01373034|DIETARY_SUPPLEMENT|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
58405558|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
58405559|NCT00137137|PROCEDURE|Placement of the mini-screw|
57938360|NCT03521830|DRUG|Nivolumab|480mg IV every 4 weeks
57938361|NCT03521830|DRUG|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
58405560|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
58405561|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
58405562|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
58405563|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
58405564|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
58405565|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
58405566|NCT02402894|OTHER|no intervention|
58405567|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
58405568|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
58405569|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
58405570|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
58405571|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
58405572|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
57938362|NCT03521830|DRUG|Relatlimab|480 mg IV q4wks
58405573|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
57730529|NCT03434119|DRUG|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
57730530|NCT03435393|PROCEDURE|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
58405574|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
58405575|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
58405576|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
58405577|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
57730531|NCT05200923|DEVICE|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
57730532|NCT03376321|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
57730533|NCT03376321|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
57938363|NCT06432088|DEVICE|Extended Magnetic Grasper Device|The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.
57938364|NCT05512793|DIAGNOSTIC_TEST|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
58405578|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
58405579|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
58405580|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
58293582|NCT06010212|DRUG|Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin|"Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled."
58293583|NCT03191565|OTHER|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
58293584|NCT03191565|DEVICE|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
58293585|NCT00727935|DRUG|Lidocaïne|
57938365|NCT05512793|DIAGNOSTIC_TEST|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
58293586|NCT00727935|DRUG|Ropivacaïne|
58293587|NCT00727935|DRUG|Placebo|
58405581|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
58405582|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
58405583|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
58405584|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
58405585|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
58293588|NCT00301912|BIOLOGICAL|filgrastim|
58293589|NCT00301912|DRUG|busulfan|
58293590|NCT00301912|DRUG|fludarabine phosphate|
58293591|NCT00301912|DRUG|methotrexate|
58293592|NCT00301912|DRUG|tacrolimus|
58293593|NCT00301912|PROCEDURE|allogeneic bone marrow transplantation|
58293594|NCT00301912|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
57938366|NCT03021395|DRUG|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
57938367|NCT02575248|DRUG|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
58293595|NCT00301912|PROCEDURE|peripheral blood stem cell transplantation|
58293596|NCT02090686|DEVICE|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
58293597|NCT02090686|DEVICE|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
58293598|NCT01697800|DRUG|Tadalafil|
58293599|NCT01697800|DRUG|Placebo|
58293600|NCT03988140|DEVICE|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
58293601|NCT00643019|BEHAVIORAL|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
57938368|NCT02575248|DRUG|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
57938369|NCT02689284|BIOLOGICAL|Margetuximab 10 mg/kg|Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
57938370|NCT02689284|BIOLOGICAL|Margetuximab 15 mg|Margetuximab treatment is administered IV once every 21-day cycle
57938371|NCT02689284|BIOLOGICAL|Pembrolizumab|Pembrolizumab treatment is administered IV once every 21-day cycle
57938372|NCT05794165|DRUG|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
57938373|NCT05794165|DRUG|Placebo|Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
57938374|NCT04942652|DRUG|Itraconazole 200 mg|Itraconazole 100 mg capsule x 2
58293602|NCT00643019|OTHER|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
57938375|NCT04942652|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet x 1
58293603|NCT02752360|PROCEDURE|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
58293604|NCT02752360|PROCEDURE|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
58293605|NCT01032447|BEHAVIORAL|Navigator Support|Standard of Care
58293606|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
57938376|NCT03275181|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
57938377|NCT03275181|DIAGNOSTIC_TEST|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
58293607|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
57938378|NCT03275181|DIAGNOSTIC_TEST|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
58293608|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
58293609|NCT00664352|DRUG|Mannose-6-Phophate (Juvidex)|"* 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
57938379|NCT03051282|DRUG|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
58293610|NCT00664352|DRUG|Placebo|"* 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
58293611|NCT00679848|DEVICE|RS2 (RESTORe Suturing System)|Suturing in stomach
58293612|NCT03452462|DEVICE|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
58293613|NCT00112918|BIOLOGICAL|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
58293614|NCT00112918|DRUG|Capecitabine|Film-coated tablets
58293615|NCT00112918|DRUG|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
57938380|NCT02985099|DRUG|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
57938381|NCT02985099|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
57938382|NCT02339064|DRUG|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
57938383|NCT04196803|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
57938384|NCT04196803|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
57938385|NCT05515861|PROCEDURE|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
58405586|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
57938386|NCT01120548|OTHER|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
57938387|NCT05214417|DRUG|Ketamine Injectable Solution|2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
57938388|NCT05214417|OTHER|Naturalistic Control|Continuation of pre-existing conventional treatment
58074200|NCT06412289|DIAGNOSTIC_TEST|US-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The ultrasound investigation will be conducted using the ultrasound machine supplied to the Center involved in the trial and usually used in eTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
58074201|NCT06412289|DIAGNOSTIC_TEST|CT-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The CT scan will be performed using the CT machinery equipped by the Center involved in the trial and usually used for the tTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
58293616|NCT00112918|DRUG|Leucovorin calcium|Administered as a 200 mg/m\^2 infusion over 2 hours.
58293617|NCT00112918|DRUG|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
58293618|NCT01329770|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
58293619|NCT01329770|DIETARY_SUPPLEMENT|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
58293620|NCT05005624|OTHER|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
58293621|NCT00871624|DRUG|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
58293622|NCT00871624|DRUG|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
58293623|NCT00537186|DRUG|Iron oligosaccharide|
58293624|NCT01299883|OTHER|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
58293625|NCT05545137|DRUG|Pivmecillinam hydrochloride tablets|400mg tablet
58405587|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
58405588|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
58405589|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
57938389|NCT01512602|BEHAVIORAL|DBT|16 weeks DBT treatment
58293626|NCT05545137|DRUG|Fosfomycin Tromethamine Granules|3g/pack
58405590|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
58405591|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
58405592|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
58405593|NCT02388035|DRUG|Cefotaxime|
58405594|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
58405595|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
58405596|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
58405597|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
58405598|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
58405599|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
58405600|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
58405601|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
58405602|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
58405603|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
58405604|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
58405605|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
57938390|NCT01512602|BEHAVIORAL|CAMS|CAMS-informed psychotherapy
57938391|NCT03146767|DEVICE|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
57938392|NCT06287814|BIOLOGICAL|Blood sample/lliquid biopsy|ctDNA analysis
57938393|NCT01678482|DEVICE|light based device for treatment of acne|
57938394|NCT05513625|DRUG|Pritelivir|oral administration
58405606|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
58405607|NCT00091130|BIOLOGICAL|HspE7|Given SC
58405608|NCT00091130|OTHER|placebo|Given SC
58405609|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
58293627|NCT04092530|BEHAVIORAL|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
57938395|NCT05513625|DRUG|ESO and pritelivir|oral administration
58293628|NCT04348097|DEVICE|Activator instrument|activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
57938396|NCT03126396|DEVICE|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
57938397|NCT06471426|OTHER|Osteopathic Manipulative Treatment|The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
57938398|NCT06115941|DEVICE|Pre-Op Incentive Spirometer|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
57938399|NCT01909648|OTHER|Blood withdrawal|
58405610|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
58405611|NCT00792662|DRUG|Placebo|Standard inactive pill.
58293629|NCT04348097|DEVICE|dry needle|By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
58293630|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
58293631|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
58293632|NCT05438238|DEVICE|Oncomfort|Virtual Reality
58293633|NCT04001556|DIAGNOSTIC_TEST|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
58293634|NCT04001556|DIAGNOSTIC_TEST|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
58293635|NCT04001556|DIAGNOSTIC_TEST|MSG US|Ultrasonography of Major Salivary Glands
58293636|NCT04269720|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
58405612|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
57938400|NCT01909648|GENETIC|Blood withdrawal|
57938401|NCT02460705|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
57938402|NCT03429439|OTHER|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
58293637|NCT02247739|BIOLOGICAL|Recombinant human C1 inhibitor|
58293638|NCT02247739|OTHER|Placebo|
58074202|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
58074203|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
58074204|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
58074205|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
58074206|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
58074207|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
58293639|NCT02453880|BEHAVIORAL|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
58293640|NCT03687866|GENETIC|non invasive prenatal testing|
58293641|NCT06432647|DRUG|ATH-1105|ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
58293642|NCT06432647|DRUG|Placebo|Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
58293643|NCT05495308|PROCEDURE|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
58293644|NCT04724603|OTHER|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
58293645|NCT03235466|BEHAVIORAL|Voice Therapy|See Arm 1 \& 2
58293646|NCT03235466|BEHAVIORAL|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 \& 3
58293647|NCT03235466|BEHAVIORAL|Heart Rate Variability Biofeedback|See Arm 2 \& 3
58293648|NCT00244153|DRUG|intraarticular morphine|
58293649|NCT00244153|DRUG|intraarticular dexamethasone|
58293650|NCT02490826|OTHER|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
57938403|NCT03429439|DRUG|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
57938404|NCT04347070|OTHER|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
58293651|NCT02490826|OTHER|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
58293652|NCT02677415|OTHER|Intravenous anesthetics|
58293653|NCT02677415|OTHER|local anesthesia|
58293654|NCT02677415|OTHER|Controlled ventilation|
57938405|NCT06071767|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
58074208|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
58405613|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58405614|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58074209|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
58074210|NCT06724822|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
58074211|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
58074212|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
58074213|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
58074214|NCT02335411|DRUG|cisplatin|IV infusion
58074215|NCT02335411|DRUG|5-FU|IV infusion
58293655|NCT02677415|OTHER|Spontaneous breathing|
58293656|NCT04474886|DIETARY_SUPPLEMENT|Fresubin® powder fibre|2 servings per day
58293657|NCT03301987|OTHER|Therapeutic exercise|30 minutes per day of therapeutic exercise
58293658|NCT03468725|DRUG|XPF-008|Capsule filled with XEN1101
58293659|NCT03468725|DRUG|Microcrystalline Cellulose|Placebo capsule
58293660|NCT04247165|DRUG|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
58293661|NCT04247165|DRUG|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
58293662|NCT04247165|DRUG|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
58293663|NCT04247165|DRUG|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
57938406|NCT06071767|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
57938407|NCT06071767|BIOLOGICAL|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
58074216|NCT02335411|DRUG|capecitabine|oral tablets
58293664|NCT04247165|RADIATION|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~* Prescription dose shall be according to the following specifications:~* A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~* Pauses are accepted but the treatment should be delivered within 10 calendar days.~* PTV should be covered by 95% isodose (PTV D99% \>95%)."
58293665|NCT01386931|PROCEDURE|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
58293666|NCT01386931|PROCEDURE|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
58293667|NCT06169306|PROCEDURE|throat pack|Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
58074217|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
58074218|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
58074219|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
58074220|NCT06723626|DRUG|ascorbic acid|Ascorbic acid group will receive intravenous vitamin C.
58074221|NCT06723626|DRUG|Placebo|Placebo group will receive intravenous NS or 5% GS.
58074222|NCT05722327|DRUG|MRTX849|Given by PO (mouth)
58074223|NCT05722327|DRUG|Irinotecan|Given by IV (vein)
57730534|NCT03376321|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
57730535|NCT05610553|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
57730536|NCT05610553|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
58074224|NCT05722327|DRUG|Cetuximab|Given by IV (vein)
58293668|NCT06251271|DEVICE|Point-of-Care Ultrasound|Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
57730537|NCT03002181|OTHER|Education|70 minute education session.
57730538|NCT06635252|DRUG|STA 4783|Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
58074225|NCT03265808|DRUG|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
58293669|NCT05199922|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
58293670|NCT03565874|DEVICE|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
58293671|NCT04398810|PROCEDURE|robotic single port cholecystectomy|"1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity"
58293672|NCT00006114|DRUG|mitoxantrone hydrochloride|
57730539|NCT02015897|PROCEDURE|Physical TherapyA|"Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity"
57730540|NCT02015897|PROCEDURE|Physical TherapyB|"Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity"
58074226|NCT03265808|DRUG|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
58074227|NCT05740982|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
58074228|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
58074229|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
58074230|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
57730541|NCT02116634|BIOLOGICAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
57938408|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
58074231|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
58074232|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
58074233|NCT05674461|OTHER|WhatsApp Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
58293673|NCT00006114|DRUG|vinorelbine tartrate|
58293674|NCT02982889|DRUG|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
58405615|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58074234|NCT05674461|OTHER|Face-to-face Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
58074235|NCT05674461|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
58074236|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
58293675|NCT02982889|DRUG|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
58293676|NCT02982889|DRUG|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
58293677|NCT02982889|DRUG|0.5% bupivacaine hydrochoride|single subcutaneous injection
58293678|NCT02061813|DRUG|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
58293679|NCT02061813|DRUG|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
58293680|NCT02061813|DRUG|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
58293681|NCT02061813|DRUG|Placebo|
58293682|NCT02459197|BEHAVIORAL|Heat Pain Stimuli A|
58293683|NCT02459197|BEHAVIORAL|Heat Pain Stimuli B|
58293684|NCT02459197|BEHAVIORAL|Positive Video|
58293685|NCT02459197|BEHAVIORAL|Neutral Video|
58074237|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
58074238|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
58293686|NCT02459197|DRUG|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
58293687|NCT02459197|DRUG|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
58293688|NCT00010504|PROCEDURE|Acupuncture|
58293689|NCT06612385|DEVICE|platelet indices|Significance of platelet indices and ratios in different degrees of burn
58293690|NCT02309957|DEVICE|BioMatrix CRD|
58293691|NCT03828955|DIETARY_SUPPLEMENT|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
58293692|NCT03828955|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
58293693|NCT03609814|DRUG|Clofarabine|Given IV
58293694|NCT03609814|DRUG|Fludarabine Injection|Given IV
58293695|NCT03060057|DEVICE|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
58293696|NCT03871530|OTHER|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
57730542|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
58293697|NCT03871530|OTHER|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
58293698|NCT03871530|OTHER|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
58293699|NCT03871530|OTHER|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
58293700|NCT03871530|OTHER|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
58293701|NCT03871530|OTHER|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
58293702|NCT03871530|OTHER|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
58293703|NCT03871530|OTHER|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
58293704|NCT03871530|OTHER|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
58293705|NCT03871530|OTHER|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
58293706|NCT03871530|OTHER|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
58293707|NCT03871530|OTHER|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
57938409|NCT06071767|DRUG|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
57938410|NCT06071767|DRUG|GS-5423|Administered via intravenous (IV) infusion at week 7
57938411|NCT06071767|DRUG|GS-2872|Administered via IV infusion at week 7
57938412|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
57938413|NCT06071767|BIOLOGICAL|Placebo|Placebos for vaccines, VES, and bnAbs
57938414|NCT01765842|BIOLOGICAL|Rituximab|Only one cycle of rituximab will be administered in this arm.
57938415|NCT02871804|PROCEDURE|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
57938416|NCT02871804|PROCEDURE|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
57938417|NCT00745199|DRUG|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
57938418|NCT00745199|DRUG|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
57938419|NCT01045798|DRUG|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
58074239|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
58293708|NCT03871530|OTHER|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
58293709|NCT03871530|OTHER|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
58293710|NCT05619315|OTHER|Charcoal -based whitening toothpaste|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
58293711|NCT05619315|OTHER|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
58293712|NCT05455151|PROCEDURE|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
58293713|NCT05455151|BIOLOGICAL|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
58293714|NCT05455151|BIOLOGICAL|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
58293715|NCT05455151|BIOLOGICAL|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
58293716|NCT02691390|DEVICE|Active dTMS|dTMS to ACC
58293717|NCT02691390|DEVICE|Sham dTMS|SHAM - no stimulation
58293718|NCT01787669|DRUG|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
58293719|NCT01787669|DRUG|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
57730543|NCT05267041|BIOLOGICAL|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
57730544|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
57730545|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire before second line treatment
57730546|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
57938420|NCT01045798|DRUG|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
57938421|NCT02126449|OTHER|Fasting mimicking diet|
57938422|NCT01817907|DRUG|Placebo pill|Subjects will receive a sugar pill during the placebo arm
57938423|NCT01817907|DRUG|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
57938424|NCT04719494|OTHER|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
57938425|NCT02140333|DRUG|Erlotinib|100mg vs. 150mg
57938426|NCT03660709|BEHAVIORAL|Intervention|"1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5."
57938427|NCT03660709|BEHAVIORAL|Control|Standard-of-care HIV testing and counseling
57938428|NCT03039166|DEVICE|MRI 7T|
57938429|NCT03039166|DEVICE|MRI 3 T|
57938430|NCT03039166|BIOLOGICAL|blood sample|
57938431|NCT04169022|OTHER|Sample collection|Sample collection blood and/or bone marrow
57938432|NCT04416347|OTHER|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
57938433|NCT00941161|DRUG|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
57938434|NCT00941161|DRUG|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
58293720|NCT00201019|BEHAVIORAL|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
58293721|NCT04608331|DRUG|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
58074240|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
58074241|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
58074242|NCT00967356|DRUG|Placebo|Oral suspension
58074243|NCT06722794|PROCEDURE|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene Suture|This novel technique of fixating the plate of Ahmed glaucoma valve to the sclera using a single flanged prolene suture is an efficient, safe, fast, and reproducible technique that combines the benefits of both fixing the plate providing excellent stability without the complications of free plate techniques and at the same time, minimizing both the risks of conventional old valve plate fixation techniques and the concerns of the relative technical difficulty of suturing due to the difficult access to the posterior globe
58074244|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
58074245|NCT06660420|DRUG|Cyclophosphamide|Given by IV
58074246|NCT06660420|DRUG|Fludarabine|Given by IV
58074247|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
58074248|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
58074249|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
58074250|NCT03173950|DRUG|Nivolumab|Participants will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
58293722|NCT04608331|DRUG|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
57938435|NCT00941161|DRUG|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
57938436|NCT02465983|BIOLOGICAL|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
58074251|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
58293723|NCT02440893|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
58293724|NCT04175275|OTHER|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
58293725|NCT04978272|DRUG|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
58293726|NCT04978272|OTHER|DP Placebo|Placebos will be identical appearance to DP.
58293727|NCT00387972|DRUG|denagliptin (GW823093)|
58293728|NCT02908152|DIETARY_SUPPLEMENT|curcumin|"1500 mg~1 capsule / day for 12 weeks"
57938437|NCT02465983|DRUG|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
58293729|NCT02908152|DIETARY_SUPPLEMENT|placebo|"1500 mg~1 capsule / day for 12 weeks"
58293730|NCT01429844|DRUG|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
57938438|NCT02263521|OTHER|No intervention employed. Study is based on a cross-sectional observational design.|
57938439|NCT03645265|BEHAVIORAL|Auditory|Use of auditory cues to improve speech production
57938440|NCT03645265|BEHAVIORAL|Gestures|Use of gestures to improve speech production
58293731|NCT01429844|DRUG|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
57938441|NCT02739750|OTHER|No intervention|There is no intervention for this study. It is a MRS.
57938442|NCT03535714|BEHAVIORAL|MANTR-a treatment|MANTR-a treatment
57938443|NCT02616744|DRUG|Ibandronic acid|150 mg per month oral ibandronate
57938444|NCT02616744|DRUG|Placebo|1 oral capsule of placebo per month
57938445|NCT00001096|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
57938446|NCT00001096|BIOLOGICAL|QS-21|
57938447|NCT00001096|BIOLOGICAL|rgp120/HIV-1MN|
57938448|NCT01202279|DRUG|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
57938449|NCT01202279|DEVICE|Placebo|Placebo bid for 7 days
57938450|NCT05349526|OTHER|None, pure observational study|None, pure observational study
57938451|NCT01835925|GENETIC|Tissue specimen|
57730547|NCT03958903|DEVICE|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
57938452|NCT02293850|BIOLOGICAL|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
58293732|NCT00816777|PROCEDURE|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
57730548|NCT03958903|BEHAVIORAL|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
57938453|NCT03129451|DIAGNOSTIC_TEST|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
57938454|NCT04022187|OTHER|Observational study : no intervention|Observational study : no intervention, only exporting data
57938455|NCT04843215|PROCEDURE|Type of omentectomy|Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
57938456|NCT03511534|BEHAVIORAL|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
57938457|NCT03511534|OTHER|Pharmacotherapy|Pharmacotherapy by a psychiatrist
57938458|NCT04427683|BEHAVIORAL|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
57938459|NCT01148849|BIOLOGICAL|margetuximab|margetuximab
57938460|NCT02748850|BIOLOGICAL|blood sample|a blood sample 20 milliliter
57938461|NCT02748850|BIOLOGICAL|Stem cell donation|The volume of stem cells remained in the tube is recovered
57938462|NCT05049980|DRUG|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
57938463|NCT05049980|PROCEDURE|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
57938464|NCT00314509|DRUG|Ciclesonide/Formoterol Combination|
57938465|NCT01536951|DRUG|LY3009104|administered orally
57938466|NCT01536951|DRUG|Placebo|Administered orally
57938467|NCT01536951|DRUG|moxifloxacin|Administered orally
57938468|NCT02630732|BEHAVIORAL|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
58293733|NCT00816777|DRUG|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
58074252|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
58074253|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
58074254|NCT03099434|BEHAVIORAL|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
58405616|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58405617|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58074255|NCT03099434|BEHAVIORAL|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
58074256|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
58074257|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
58074258|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
58074259|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
58074260|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
58293734|NCT01005576|DRUG|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
58293735|NCT04087837|DEVICE|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
58293736|NCT04087837|DEVICE|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
58293737|NCT02489448|DRUG|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
58293738|NCT00055445|DRUG|IdB 1016|
58293739|NCT06084702|OTHER|Rehydration with plain water|Plain water without calories, sweetener, or electolytes
58405618|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
57938469|NCT02630732|BEHAVIORAL|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
57938470|NCT02608060|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
58074261|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
58293740|NCT06084702|OTHER|Rehydration Drink|Roaring Water. An electrolyte drink with low Carbohydrate content
58293741|NCT03287076|DRUG|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
58293742|NCT02488018|BIOLOGICAL|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
58293743|NCT04579432|OTHER|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
58293744|NCT03996668|OTHER|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
58293745|NCT00614172|RADIATION|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
58405619|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58405620|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
58405621|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
58405622|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
58405623|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
58405624|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
58405625|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
58405626|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
58405627|NCT01559259|DRUG|Placebo|Two caplets of placebo
58293746|NCT04214366|RADIATION|Carbon ion irradiation|22 x 3 Gy(RBE) Carbon Ions
57730549|NCT02358577|DEVICE|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
58405628|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
58405629|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
58293747|NCT04214366|RADIATION|Bimodal irradiation|25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
58293748|NCT04256564|PROCEDURE|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
58405630|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
58405631|NCT02662153|OTHER|Observation only|No intervention.
58405632|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
58405633|NCT03284333|DEVICE|other|no arm
58405634|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
58293749|NCT02364297|DEVICE|Early TIPS|TIPS (first 5 days)
58293750|NCT06609122|OTHER|Animal Assisted Intervention|"Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support."
58405635|NCT00824551|OTHER|Standard care|Patient will undergo standard care
58405636|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
58405637|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
58074262|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
58074263|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
58074264|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
58074265|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
58074266|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
58074267|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
58074268|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
58074269|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
58074270|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
58074271|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
58074272|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
58074273|NCT04982224|DRUG|REGN5093-M114|Administered by intravenous (IV) infusion
58074274|NCT04982224|DRUG|Cemiplimab|Administered by IV infusion
58405638|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
58405639|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
57938471|NCT01504490|DRUG|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
58405640|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
58405641|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
57730550|NCT02358577|OTHER|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
57730551|NCT01415791|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
57730552|NCT03607305|PROCEDURE|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
57730553|NCT03607305|PROCEDURE|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
58074275|NCT06058039|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
58074276|NCT06058039|DRUG|Placebo|Placebo will be administered orally
58074277|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
58074278|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
58074279|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
58074280|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
58074281|NCT05643573|DRUG|Asundexian (BAY2433334)|Once a day
58074282|NCT05643573|DRUG|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
58074283|NCT05643573|DRUG|Asundexian matching placebo|Placebo to asundexian, once a day
58074284|NCT05643573|DRUG|Apixaban matching placebo|Placebo to apixaban, twice a day
58293751|NCT02584270|DEVICE|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
58405642|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
58405643|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
58405644|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
58405645|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
58405646|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
57938472|NCT03195751|DEVICE|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
57938473|NCT03195751|DEVICE|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
57938474|NCT00136409|DRUG|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
58095505|NCT06701292|DEVICE|Wide area circumferential ablation (WACA)|After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
58293752|NCT02584270|OTHER|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
58405647|NCT02493257|DRUG|Capsaicin|
58405648|NCT02493257|DRUG|Placebo|
58405649|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
58405650|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
58405651|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
58405652|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
58405653|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
58405654|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
58405655|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
58405656|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
58405657|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
58405658|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
58405659|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
58405660|NCT01989780|DRUG|Paclitaxel|
58405661|NCT01989780|DRUG|Bevacizumab|
58405662|NCT01989780|DRUG|Letrozole|
58405663|NCT01989780|DRUG|Anastrozole|
57730554|NCT04298567|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg \[BID\])
58405664|NCT01989780|DRUG|Exemestane|
58405665|NCT01989780|DRUG|Fulvestrant|
58405666|NCT01989780|DRUG|Goserelin|
58405667|NCT01989780|DRUG|leuprorelin|
58405668|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
58405669|NCT04671784|OTHER|EUS-E|EUS-E
58405670|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
58405671|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
58405672|NCT02359357|DRUG|FDL169|
58405673|NCT02359357|DRUG|Placebo|
58405674|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
58405675|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
58405676|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
58405677|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
58405678|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
58405679|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
58405680|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
58405681|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
58405682|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
58405683|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
58405684|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
58405685|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
58405686|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
58074285|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
58074286|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
57730555|NCT04298567|DRUG|Acetylsalicylic acid(ASA)|ASA (75mg \[QD\]; dose according to local label.
58074287|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
58074288|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
58074289|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
58074290|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
58074291|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
58074292|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
58293753|NCT02368132|BEHAVIORAL|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
58293754|NCT02368132|BEHAVIORAL|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
58293755|NCT03038529|PROCEDURE|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
58293756|NCT03038529|PROCEDURE|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
58293757|NCT00107757|DRUG|GW685698X|
58293758|NCT02770235|OTHER|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
58405687|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
58405688|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
58405689|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
58405690|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
57730556|NCT06092996|OTHER|Time of Sling Use|Standard sling worn for only three days post operatively
57730557|NCT00607451|DRUG|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
57730558|NCT00464542|DRUG|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
57730559|NCT01021969|OTHER|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
57730560|NCT00884429|PROCEDURE|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
58405691|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
58405692|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
58405693|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
58405694|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
58405695|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
57730561|NCT00884429|PROCEDURE|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
57730562|NCT00884429|PROCEDURE|3-Airway suction|Airway suction
58074293|NCT04963517|BEHAVIORAL|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
58074294|NCT04963517|OTHER|Information|"* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations."
58074295|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
58074296|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
58074297|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
58095506|NCT06061601|DEVICE|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
58074298|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
58074299|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
58074300|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
58074301|NCT06066359|DRUG|Fludarabine phosphate|Given by (IV) vein
58074302|NCT06066359|DRUG|Cyclophosphamide|Given by (IV) vein
58074303|NCT06066359|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
58074304|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
58074305|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
58074306|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
58074307|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
58074308|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
58074309|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
58074310|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
58074311|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
58074312|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
58074313|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
58074314|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
58293759|NCT02770235|OTHER|AGE measurement|By AGE-ReaderTM
58293760|NCT00092976|DRUG|ReFacto|
58293761|NCT03687723|DEVICE|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
58405696|NCT00380991|DRUG|lactoserum|
58074315|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
58293762|NCT06263647|BEHAVIORAL|Houston-HVIP treatment|Participants will be assigned a case manager provide a brief assessment of psychological and social needs and individualized discharge planning bedside and will receive coordinated referral, networking, and close follow-up with community-level violence outreach organizations from the City of Houston Mayor's Office and the Health Equity Collective and will be referred for program enrollment to the Forgotten Third for credible messenger intervention and concurrent tailored intervention programs based on individual needs. Trauma counseling and referrals to tailored social service programs based on the patient's needs and follow-up contacts and services from an assigned case manager over 12 months following discharge from the hospital to ensure continuity of care and services. This will include ongoing case coordination and motivational interviewing to promote successful community-based program integration and completion will also be provided.
58293763|NCT06263647|BEHAVIORAL|Enhanced Case Management|Participants will receive expanded case management services tailored to their personal needs and ongoing monitoring for three months for motivational interviewing, case coordination, social determinants of health referrals and referral for community-based resources. Based on each patient's needs, case managers will remain involved in the case past three months if needed.
58293764|NCT04793646|DRUG|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
58293765|NCT04793646|DRUG|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
58293766|NCT02380937|PROCEDURE|ablation for typical atrial flutter|ablation for typical atrial flutter
58405697|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject\&#39;s comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
58405698|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
57938475|NCT05718479|BEHAVIORAL|Trauma Informed Prenatal Intervention (TPI)|TPI is designed to foster behavior change and health coping by enhancing knowledge, beliefs, regulation skills and abilities. In the experimental group, a research staff member will meet with participants and help them to identify a health behavior they want to change, explore the pros and cons of making a change, create a behavior change plan, and learn several mindfulness meditation techniques. The facilitator will check-in with the participants about their behavior change plan in the subsequent sessions regarding progress made, barriers encountered, and changes in the plan and/or goal going forward. Participants will be instructed to implement an at-home mental wellness skills and provided with a tracking log to report the frequency and dose of daily/weekly practice.
57938476|NCT05718479|OTHER|Prenatal Education Topics|In the control group, a research staff member will provide participants with four different weekly prenatal education topics, including information on prenatal care, labor and delivery, postpartum care, and newborn care.
58074316|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
58074317|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
58074318|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
58074319|NCT05044143|OTHER|Monitoring the length of the uterine cervix using transvaginal ultrasound|Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
58074320|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
58074321|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
58074322|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
58074323|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
58405699|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
58405700|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
57730563|NCT03668145|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
57730564|NCT03043183|PROCEDURE|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
57730565|NCT04540107|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
58074324|NCT00847002|DEVICE|Standard Wound Care|
58074325|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
58074326|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
58074327|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
58074328|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
58074329|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
57730566|NCT04540107|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57730567|NCT04540107|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
58405701|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
58074330|NCT02530034|DRUG|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
58074331|NCT02530034|OTHER|Laboratory Biomarker Analysis|Correlative studies
58293767|NCT02380937|DEVICE|Vision Ablation Catheter|
58405702|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
58405703|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
58405704|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
58293768|NCT00198263|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
58293769|NCT05046015|OTHER|10% Urea foot lotion|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
58293770|NCT05046015|OTHER|10% Urea foot ointment|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves."
58074332|NCT02530034|OTHER|Pharmacological Study|Correlative studies
58405705|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
58405706|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
58405707|NCT01978249|PROCEDURE|Systemic chemotherapy|
58074333|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
58293771|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
58293772|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
58293773|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
58293774|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
58405708|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
58405709|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58405710|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58405711|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58405712|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58074334|NCT03373422|DRUG|Placebo|Matching placebo tablets
58074335|NCT01914289|PROCEDURE|Resection|
58074336|NCT01914289|RADIATION|Radiotherapy|
58074337|NCT06722313|DIAGNOSTIC_TEST|Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband|"1. Targeted deep sequencing for mosaicism detection for patients with suspected gonadal mosaicism, eg. Repeated similar abortion due to the same variant while the couple were tested negative for the variant in the peripheral blood.~2. Ovarian stimulation, embryo culture, biopsy and vitrification as routinely used in the IVF clinical practice.~3. Gametes and arrested embryo preservation by the embryo laboratory during embryo culture.~4. Genetic testing, including multiple displacement amplification for WGA, variant sequencing in WGA products and Infinium Chip protocol for amplified DNA and haplotype analysis"
58074338|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
58293775|NCT00784719|DRUG|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
58293776|NCT00784719|DRUG|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
58293777|NCT00447902|DRUG|tipranavir|
58074339|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
58074340|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
58074341|NCT05174013|DRUG|Placebo|Placebo will be administered
58074342|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
58074343|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
58074344|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
58074345|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
58074346|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
58405713|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58074347|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
58074348|NCT05915455|OTHER|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
58405714|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
58405715|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
58405716|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
58074349|NCT05915455|OTHER|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
58405717|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
58405718|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
57938477|NCT06473883|OTHER|Training recommendation|The players in the intervention group are also given specific training recommendations for the prevention of head injuries, which are compiled by experts (sports scientists, physiotherapists and neuroscientists). The exercise selection covers several areas that can be affected after a head injury. Each section contains 8 different exercises with increasing levels of difficulty (3x Basic-3x Intermediate-2x Advanced). The recommendations should be used as a warm-up program throughout the season before each training session. The coach or athletic coach will lead the warm-up program and ensure that each player follows the sequence and completes each phase according to the scheduled weeks. The warm-up program should be conducted as an 8-week cycle.
57938478|NCT03433495|OTHER|Melodic Intonation Therapy|
58074350|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
58074351|NCT04322929|DRUG|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
58074352|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
57938479|NCT00943709|BIOLOGICAL|insulin glargine recombinant|Given subcutaneously
57938480|NCT00943709|DRUG|therapeutic insulin|Given subcutaneously
58074353|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
58074354|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
58293778|NCT00447902|DRUG|ritonavir|
58405719|NCT00002114|DRUG|Procysteine|
58405720|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
58074355|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
58074356|NCT06502821|OTHER|questtionnaire|questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
58074357|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
58074358|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
58074359|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
58074360|NCT00036621|DRUG|BMS-275291|
58293779|NCT00160056|PROCEDURE|Hypoglycemia|
58405721|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
58405722|NCT00256815|DRUG|chemotherapy|
57938481|NCT03573609|DEVICE|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
57938482|NCT01772901|OTHER|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
58293780|NCT01706835|DRUG|aldoxorubicin|
58293781|NCT04189432|BIOLOGICAL|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
57938483|NCT02809014|OTHER|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
58405723|NCT00256815|PROCEDURE|Radiation|
58405724|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
57938484|NCT02809014|OTHER|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
57938485|NCT02809014|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
58074361|NCT00031616|DRUG|brivudine phosphoramidate|
58074362|NCT06112249|BEHAVIORAL|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
58074363|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
58074364|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
58293782|NCT04189432|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
58293783|NCT04788095|BEHAVIORAL|Behavioral Intervention|Participate in an app-based mindfulness program
58293784|NCT04788095|OTHER|Quality-of-Life Assessment|Ancillary studies
58405725|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
58293785|NCT04788095|OTHER|Questionnaire Administration|Ancillary studies
58293786|NCT00370591|DRUG|Salmeterol/fluticasone propionate and fluticasone propionate|
58293787|NCT03292185|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
58293788|NCT03292185|DRUG|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
58293789|NCT03292185|DRUG|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
58293790|NCT00455000|BIOLOGICAL|PF-04360365|Monoclonal antibody
58293791|NCT00455000|DRUG|Placebo|Placebo
58405726|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
57730568|NCT04122417|OTHER|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
57730569|NCT04198129|DRUG|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
58074365|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
58074366|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
58074367|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
58293792|NCT00707057|DRUG|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
58293793|NCT00707057|DRUG|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
58293794|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
58405727|NCT05848700|DRUG|Placebo|Placebo Tablet
58405728|NCT00123578|DRUG|Lorazepam|Lorazepam
58405729|NCT00123578|DRUG|Pentobarbital|Pentobarbital
58405730|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
58405731|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
58405732|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
58293795|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
57730570|NCT04198129|DRUG|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
57938486|NCT02809014|OTHER|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
57938487|NCT04615468|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
58293796|NCT02193750|DIETARY_SUPPLEMENT|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
58293797|NCT02193750|DIETARY_SUPPLEMENT|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
57938488|NCT00246909|DRUG|Pantoprazole|
58293798|NCT02193750|DIETARY_SUPPLEMENT|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
58293799|NCT04715282|PROCEDURE|Epley maneuver|Epley maneuver
58293800|NCT01472445|DRUG|Vitamin D|
58293801|NCT03012841|DEVICE|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
57938489|NCT06034171|DEVICE|dental implant|Dental implant surgery in the lower jawbone.
57938490|NCT00873366|DRUG|dextromethorphan hydrobromide|
57938491|NCT00873366|DRUG|tamoxifen citrate|
57938492|NCT00873366|OTHER|high performance liquid chromatography|
57938493|NCT00873366|OTHER|laboratory biomarker analysis|
58074368|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
58293802|NCT00086450|PROCEDURE|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
58293803|NCT00086450|DEVICE|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
57938494|NCT00873366|OTHER|pharmacogenomic studies|
57938495|NCT00873366|OTHER|pharmacological study|
57938496|NCT00873366|PROCEDURE|fluorescence imaging|
57938497|NCT04596020|OTHER|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
58293804|NCT04860479|DEVICE|ultrasound|ultrasonography to inguinal region
57938498|NCT01747967|OTHER|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
57938499|NCT04533282|DIAGNOSTIC_TEST|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
57938500|NCT04533282|DIAGNOSTIC_TEST|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
57938501|NCT04533282|DIAGNOSTIC_TEST|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
57938502|NCT04533282|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
57938503|NCT01891708|OTHER|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
58293805|NCT05897866|PROCEDURE|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
58293806|NCT05783947|DIAGNOSTIC_TEST|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
58405733|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
58405734|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
58405735|NCT02242435|DRUG|4 mL Injection of Placebo|
58405736|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
58405737|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
58405738|NCT00147862|DRUG|Tranexamic Acid|
58405739|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
58405740|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
58405741|NCT02783040|DRUG|Midazolam|
58405742|NCT02783040|DRUG|Warfarin|
58405743|NCT02783040|DRUG|Omeprazole|
58405744|NCT02783040|DRUG|Midazolam|
58293807|NCT00280592|DRUG|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
58293808|NCT00280592|DRUG|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
58293809|NCT03318003|DEVICE|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
58405745|NCT02783040|DRUG|Digoxin|
58405746|NCT02783040|DRUG|BI 425809|
58405747|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
57938504|NCT03453073|BEHAVIORAL|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
58405748|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
58405749|NCT01851486|DRUG|placebo|
58405750|NCT01851486|OTHER|saline|
57938505|NCT03453073|OTHER|physician diagnosis of first occurrence of serious chronic disease|
58405751|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
58405752|NCT02182661|DRUG|Ba253BINEB|
58405753|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
58405754|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
58405755|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
58405756|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
58405757|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
57938506|NCT00307333|DEVICE|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
57938507|NCT00454857|OTHER|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
58405758|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
58405759|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
58405760|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
58293810|NCT06337357|BEHAVIORAL|Progressive Resistance Training|"Progressive resistance training includes face-to-face education on resistance training:~Resistance exercises with elastic bands include 9 exercises for 1 course. During the first 4 weeks, the patient exercises twice a week with a level of exertion according to Borg's category-ratio 10 (CR10) scale of 4-5 points. For the next 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 6-7 points. In the last 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 8-9 points.~The three-month intervention involves twelve weekly calls, with a focus on building rapport (e.g. providing feedback on the baseline assessment); education reinforcement on resistance training; and skill-building (e.g. self-monitoring and resistance training diary). The emphasis is on helping participants to gain the knowledge and skills necessary to achieve targeted intensity. Every 4 weeks, all patients are re-visited by investigators in the hospital."
58405761|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
58405762|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
58405763|NCT01666535|BIOLOGICAL|Influenza vaccination|
58405764|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
58405765|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
58405766|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
58405767|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
58405768|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
58405769|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
58405770|NCT04453085|DRUG|JR-171 (lepunafusp alfa)|IV infusion
58405771|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
58405772|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
58405773|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
58405774|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
58405775|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
58405776|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
58405777|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
58405778|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
58405779|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
58405780|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
58405781|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
58405782|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
58405783|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
57730571|NCT04198129|OTHER|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
58095507|NCT06558630|PROCEDURE|Endotracheal intubation|Over the course of several years as many as possible ED centres in the Netherlands will be included in the collection of all data involving airway management. Airway management is defined as the process of planning, preparation and execution of endotracheal intubation.
58293811|NCT02895685|OTHER|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
58405784|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
58405785|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
58405786|NCT02196116|OTHER|MRI|
58405787|NCT02196116|OTHER|neuropsychological tests|
58405788|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
58405789|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
58405790|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
58405791|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
58405792|NCT02788773|DRUG|Durvalumab|
58405793|NCT02788773|DRUG|Tremelimumab|
58405794|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
58405795|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
58074369|NCT04408105|BEHAVIORAL|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
58074370|NCT04408105|BEHAVIORAL|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
58074371|NCT04408105|BEHAVIORAL|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
58074372|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
58074373|NCT02839213|DRUG|Hyoscine Butyl bromide|
58074374|NCT02839213|DRUG|Saline|
58074375|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
58074376|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
58074377|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
58293812|NCT03202290|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
58293813|NCT03340038|OTHER|Non-ICU Specialty ward|
58293814|NCT01757860|DRUG|CARD-024|Comparison of different dosages of drug
58293815|NCT01757860|OTHER|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
58293816|NCT00606749|DRUG|KC706|300 mg once daily (QD) for 12 weeks.
58293817|NCT04868773|DRUG|Cabozantinib|Oral cabozantinib
58293818|NCT04868773|DRUG|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
58293819|NCT02898233|OTHER|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
58293820|NCT02898233|DEVICE|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
58293821|NCT02898233|DEVICE|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
58293822|NCT04006470|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
58293823|NCT04006470|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
58293824|NCT04006470|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
58293825|NCT06612632|DRUG|research drug in combination with Toripalimab|research drug in combination with Toripalimab
58293826|NCT06612632|DRUG|Toripalimab|Toripalimab
58293827|NCT00780780|DRUG|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
58293828|NCT00780780|DRUG|triamcinolone intravitreal injection|triamcinolone intravitreal injection
58293829|NCT03682068|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
58293830|NCT03682068|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
57730572|NCT00388414|DRUG|duloxetine|30-60mg of duloxetine daily
57730573|NCT00388414|DRUG|Placebo|Placebo pill once daily
57730574|NCT02964845|BEHAVIORAL|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
58293831|NCT03682068|DRUG|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
58293832|NCT03682068|DRUG|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
58405796|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
58293833|NCT03954002|DIAGNOSTIC_TEST|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
58405797|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
58405798|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
58405799|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
57938508|NCT00454857|OTHER|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
57938509|NCT00454857|OTHER|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
57938510|NCT03364361|PROCEDURE|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
57938511|NCT00224094|DRUG|Premarin® (oral) vs. Alora® (transdermal)|
57938512|NCT03306082|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
57938513|NCT04195048|OTHER|Risk factors|Risk factors: modifiable and unmodifiable risk factors
58293834|NCT02674724|OTHER|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
58293835|NCT02674724|OTHER|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
58293836|NCT02674724|OTHER|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
58293837|NCT06152380|OTHER|Knee Care @Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
58405800|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
57938514|NCT03821818|BEHAVIORAL|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise \> 75% max heart rate, 5/day)
57938515|NCT04494139|BEHAVIORAL|Behavioral and Canteen intervention|Behavioral intervention: 16 weeks
58074378|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
58074379|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
58405801|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
57938516|NCT04494139|OTHER|Canteen|Canteen changes to introduce health foods
57938517|NCT04714528|OTHER|Physical Exercise|Physical exercise as described before.
57938518|NCT04714528|OTHER|Relaxation Therapy|Relaxation therapy as described before.
57938519|NCT00750971|PROCEDURE|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
58074380|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
58293838|NCT01918917|DRUG|Levobupivacaine|intraarticular
58293839|NCT01918917|DRUG|Dexmedetomidine|intraarticular 1 ml (100 mcg)
58293840|NCT01918917|DRUG|Morphine|intravenously, patient-controlled analgesia
58293841|NCT02356757|BEHAVIORAL|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
58293842|NCT02356757|BEHAVIORAL|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
58293843|NCT04803214|DEVICE|ReActiv8|Market-approved ReActiv8 device implanted
58293844|NCT06318403|DRUG|Transdermal estrogen|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
58293845|NCT06318403|PROCEDURE|Rotator Cuff Repair Surgery|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
58405802|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
57938520|NCT03496012|GENETIC|BIIB111|Administered as specified in the treatment arm.
57938521|NCT05707832|DRUG|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
58293846|NCT04147143|OTHER|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
58293847|NCT06422871|DEVICE|HeRO® Graft System or Super HeRO® System|Treatment attempted with the HeRO® or Super HeRO® device.
58293848|NCT00230789|DRUG|Tolterodine ER 4 mg QD|
58405803|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
58293849|NCT00230789|BEHAVIORAL|OAB Patient Behavioral Training Material|
58293850|NCT04718480|DRUG|Placebo|po placebo tablets
58293851|NCT04718480|DRUG|Fluvoxamine|po fluvoxamine tablets
58293852|NCT00970645|PROCEDURE|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
58293853|NCT00970645|PROCEDURE|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
58293854|NCT04734808|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
58293855|NCT04734808|DIAGNOSTIC_TEST|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
58293856|NCT05664308|OTHER|Clinical follow-up (ECG)|Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
58293857|NCT05664308|OTHER|Ongoing monitoring|"Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center."
58293858|NCT02598739|OTHER|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
58293859|NCT02598739|OTHER|Waiting list for the exercises|
58405804|NCT00159731|DRUG|Pregabalin|
58293860|NCT01214668|DRUG|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
58293861|NCT01214668|DRUG|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
58405805|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
58405806|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
58405807|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
58405808|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
58405809|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
58405810|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
58293862|NCT03513263|PROCEDURE|Scaling and polishing|An electronic scaler will be used to clean the gums
58293863|NCT03513263|OTHER|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
58293864|NCT03450577|PROCEDURE|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
58293865|NCT04491461|DIETARY_SUPPLEMENT|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
58293866|NCT04491461|DIETARY_SUPPLEMENT|Warm water|1 cup of warm water
58293867|NCT06420245|DEVICE|Orion TM Amniotic Membrane Allograft|The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
58293868|NCT06420245|PROCEDURE|Standard of Care (SOC)|Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
58293869|NCT04368507|DRUG|YYB101|"1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity"
58293870|NCT02571764|OTHER|Nutritional Oats Cookie|
58293871|NCT02740959|DRUG|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
58405811|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
58405812|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
58405813|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
58405814|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
58405815|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
58405816|NCT04051710|DRUG|Placebo|Placebo Product
58074381|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
58405817|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
58074382|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
58074383|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
58074384|NCT06724445|BEHAVIORAL|Thabo cartoon|The animated cartoon features Thabo, a Black South African man living with HIV. Through his narrative, viewers follow his daily experiences managing his condition and confronting societal stigma in a South African context. The story explores his interactions with family, friends, and community members, highlighting both challenges and moments of resilience. The animation concludes with Thabo delivering an anti-stigma message directly to viewers.
58293872|NCT02740959|DRUG|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
58293873|NCT03441685|BEHAVIORAL|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
58293874|NCT06336057|BEHAVIORAL|Mentalization|complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
58293875|NCT00074815|DRUG|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
58293876|NCT00074815|BEHAVIORAL|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
58293877|NCT00074815|BEHAVIORAL|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
58293878|NCT02303639|PROCEDURE|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
58293879|NCT02303639|DRUG|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
58293880|NCT04878120|DEVICE|Standard HCL System|Standard HCL system (USS Virginia)
58293881|NCT04878120|DEVICE|HCL System with Smart Bolus Calculator|HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
58405818|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
58405819|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
58405820|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
58405821|NCT03392389|OTHER|Placebo|Saline
58405822|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
58293882|NCT06612658|DIETARY_SUPPLEMENT|A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids|This study will investigate the effect of the supplement on exercise performance.
58405823|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
58405824|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
58293883|NCT05377112|DRUG|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
58293884|NCT05377112|OTHER|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
58293885|NCT06373341|BEHAVIORAL|VR training for arm and hand rehabilitation|The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
58293886|NCT02546869|DRUG|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
58293887|NCT02546869|DEVICE|Prefilled Syringes|
58293888|NCT01948921|DRUG|placebo|
58293889|NCT01948921|DRUG|Meperidine|
58293890|NCT01061541|BIOLOGICAL|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
58293891|NCT01061541|BIOLOGICAL|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
58293892|NCT01061541|BIOLOGICAL|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
58293893|NCT01061541|BIOLOGICAL|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
58293894|NCT01061541|BIOLOGICAL|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
58293895|NCT01750060|DRUG|Fentanyl|
58293896|NCT01750060|DRUG|Naltrexone|
58293897|NCT02553824|DRUG|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
58405825|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
57938522|NCT05638451|DRUG|Sintilimab plus Bevacizumab and Temozolomide|200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
57938523|NCT03677050|OTHER|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
57938524|NCT04162184|BEHAVIORAL|Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention|a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
57938525|NCT03086057|BEHAVIORAL|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
57938526|NCT03086057|BEHAVIORAL|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
57938527|NCT04973020|DRUG|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
57938528|NCT03084406|OTHER|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
57938529|NCT00004152|DRUG|iodinated contrast dye|
57938530|NCT00004152|PROCEDURE|computed tomography|
58293898|NCT02553824|DRUG|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
58293899|NCT04378686|OTHER|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
57938531|NCT00004152|PROCEDURE|positron emission tomography|
57938532|NCT00004152|RADIATION|fludeoxyglucose F 18|
58293900|NCT01803087|DRUG|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
58293901|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
58293902|NCT01803087|DRUG|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
58293903|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) (CTR)|
58293904|NCT04998890|OTHER|adventure-based cognitive behavioral intervention|"The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues."
58293905|NCT04143191|DRUG|Sorafenib|Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
58293906|NCT04143191|PROCEDURE|Transarterial chemoembolization|TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
57938533|NCT05048953|DIAGNOSTIC_TEST|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~1. Muscle thickness~2. Muscle echogenicity~3. Muscle fasciculations"
57938534|NCT00570973|PROCEDURE|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
58074385|NCT06724445|BEHAVIORAL|Steve cartoon|The animated cartoon follows Steve, a White man living with HIV. His narrative parallels Thabo's, showing his daily experiences managing HIV and facing societal stigma. The story depicts his interactions with family, friends, and community members, presenting the same situations and challenges as in Thabo's story. The animation ends with Steve delivering the same anti-stigma message to viewers.
58074386|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
58074387|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
58074388|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
58074389|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
58074390|NCT06641141|PROCEDURE|Induction of Labour|"Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a failed IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia."
58074391|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
58074392|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
58074393|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
58074394|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
58074395|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
58074396|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
58293907|NCT01751750|OTHER|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
58293908|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
58405826|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
57938535|NCT00570973|PROCEDURE|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
58293909|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
58293910|NCT01388153|DRUG|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
57938536|NCT06466538|DRUG|Calcium hydroxide|intracanal medicament
57938537|NCT06466538|DRUG|Leddermix|Leddermix
57938538|NCT06466538|DRUG|Boswellia|Boswellia
57938539|NCT01408433|OTHER|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
57938540|NCT01408433|OTHER|Double embryo transfer|two (2) embryo transfer of untested embryos
58293911|NCT04653831|DRUG|Pirfenidone|Treatment with Pirfenidone as mentioned in the experimental arm description.
58293912|NCT04653831|OTHER|Standard of care|Treatment with SoC as mentioned in the control arm description.
58293913|NCT02896569|OTHER|Topical combination therapy|
57938541|NCT00589498|DIETARY_SUPPLEMENT|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
58293914|NCT05463497|DRUG|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
58293915|NCT05463497|DRUG|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
58293916|NCT05463497|DRUG|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
58293917|NCT05463497|DRUG|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
58293918|NCT05463497|DRUG|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
58293919|NCT04998214|DIAGNOSTIC_TEST|liver function , prothrombin time , INR , US .|analytic
58293920|NCT03593954|DRUG|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
58293921|NCT03593954|DRUG|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
58293922|NCT01649362|OTHER|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
58293923|NCT06084910|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
58293924|NCT06084910|BEHAVIORAL|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
58293925|NCT06520527|DIETARY_SUPPLEMENT|Andrographis paniculata|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
58293926|NCT06520527|BEHAVIORAL|Brisk Walking Exercise|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
57730575|NCT02964845|OTHER|Enhanced Treatment as Usual|Linkage to Primary care.
57730576|NCT06669000|DIAGNOSTIC_TEST|Standard X-Rays|- Standard X-Rays: feet (Month 0)
57938542|NCT04962217|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
57730577|NCT06669000|DIAGNOSTIC_TEST|Ultrasound|- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
57938543|NCT03413852|DEVICE|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
57938544|NCT00102960|DRUG|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
57938545|NCT00102960|DRUG|Didanosine|Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
57938546|NCT00102960|DRUG|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
58293927|NCT06520527|OTHER|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
58293928|NCT05259163|DEVICE|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
58293929|NCT05259163|DEVICE|Traditional phoropter (SOC)|Standard unit for evaluating visual refractive state of the patient
58293930|NCT05130996|DEVICE|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
57730578|NCT06669000|DIAGNOSTIC_TEST|DECT of feet|DECT of feet: in tophaceous patients only (Month 0, Month 24)
57730579|NCT06669000|BIOLOGICAL|DNA sample|DNA will be collected at Month 0
58405827|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
57730580|NCT06669000|BIOLOGICAL|Serum collection|- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
57730581|NCT02854540|DEVICE|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
57730582|NCT03988179|DIAGNOSTIC_TEST|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
57938547|NCT00102960|DRUG|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
58074397|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
58074398|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
58074399|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
58074400|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
58074401|NCT03176979|OTHER|Contrast Agent|Given IV
58074402|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
58074403|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
58074404|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
58074405|NCT05300256|DEVICE|Sham|Sham
58074406|NCT06723847|PROCEDURE|Robotic pancreaticoduodenectomy|All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
58074407|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
58293931|NCT02475772|DRUG|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
58293932|NCT02475772|PROCEDURE|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
58293933|NCT00977912|DIETARY_SUPPLEMENT|Probiotic supplementation|one capsule containing probiotics per day added to milk
57730583|NCT03646513|DEVICE|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
57938548|NCT00102960|DRUG|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
58293934|NCT00977912|DIETARY_SUPPLEMENT|Milk containing placebo|one capsule containing placebo per day added to milk
58293935|NCT03649893|DEVICE|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
58293936|NCT06175208|BEHAVIORAL|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
58293937|NCT06175208|BEHAVIORAL|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
58293938|NCT00101868|DEVICE|Discharge communication software|Computerized physician order entry software used by discharging physician
58293939|NCT00101868|OTHER|Usual care discharge process|Handwritten
58405828|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
58405829|NCT00004480|DRUG|botulinum toxin type A|
57730584|NCT05354700|DRUG|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
57730585|NCT05354700|DRUG|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
57730586|NCT05354700|DRUG|carboplatin and etoposide|chemotherapeutics
57938549|NCT00102960|DRUG|Nevirapine|Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
57938550|NCT00102960|DRUG|Zidovudine|First Line Regimen: 240 mg/m\^2 taken orally twice daily
57938551|NCT06456528|DRUG|QL0911|QL0911
57938552|NCT06456528|DRUG|QL0911 plus Placebo|QL0911 plus Placebo
57938553|NCT06456528|DRUG|Placebo|Placebo
57938554|NCT00854698|OTHER|exercise training|subjects are asked to exercise 20 or 30 minutes.
57938555|NCT00854698|OTHER|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
58293940|NCT01273909|PROCEDURE|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
58293941|NCT01273909|PROCEDURE|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
58405830|NCT02518958|DRUG|RRx-001|
58405831|NCT02518958|DRUG|Nivolumab|
58405832|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
58293942|NCT00539071|DRUG|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
58293943|NCT00539071|DRUG|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
57730587|NCT06273852|DRUG|PBA-0405|Intratumoral microdose injection by the CIVO device.
57730588|NCT05255640|PROCEDURE|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
57938556|NCT01699542|DEVICE|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
58293944|NCT00539071|DRUG|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
58293945|NCT04655781|PROCEDURE|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
58293946|NCT00649077|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fasting
58293947|NCT00649077|DRUG|Mobic® Tablets 15 mg|15mg, single dose fasting
57938557|NCT01699542|DEVICE|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
57938558|NCT04045704|PROCEDURE|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
57938559|NCT05627544|PROCEDURE|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
57938560|NCT05627544|PROCEDURE|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
57938561|NCT05627544|PROCEDURE|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
57938562|NCT05627544|PROCEDURE|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
57938563|NCT03078712|OTHER|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
57938564|NCT03078712|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
57938565|NCT03161288|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
57938566|NCT03161288|DRUG|Placebo|Matched placebo
58293948|NCT04609423|DIETARY_SUPPLEMENT|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
58293949|NCT04609423|DIETARY_SUPPLEMENT|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
58293950|NCT02144038|DRUG|LGH447|pan-PIM inhibitor
58293951|NCT02144038|DRUG|BYL719|PI3K-alpha inhibitor
58293952|NCT03200210|DRUG|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
58293953|NCT03200210|DRUG|Placebo|Pills manufactured to mimic Febuxostat tablets
58293954|NCT02630810|OTHER|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
57730589|NCT04498650|DRUG|PQ912|PQ912 50 mg tablets and 150 mg tablets
57730590|NCT04498650|DRUG|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
57730591|NCT01303289|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
57938567|NCT02841202|DRUG|oral contraceptive pills|
57938568|NCT04434950|BEHAVIORAL|Promoting and implementing repeated HIV self-testing and online real-time counseling|At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
57938569|NCT06214247|DEVICE|Wedge NC Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
58293955|NCT02630810|OTHER|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
58293956|NCT02521792|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
58293957|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
58293958|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
58293959|NCT03624491|OTHER|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
58293960|NCT03860298|DEVICE|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
58405833|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
58074408|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
58074409|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
58293961|NCT00354965|DRUG|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
58293962|NCT06434675|OTHER|No intervention done|No intervention done
58405834|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
58405835|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
58405836|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
58405837|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
58405838|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
58405839|NCT05721937|DRUG|Abrocitinib|taken by mouth
58405840|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
58405841|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
58405842|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
58405843|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
58293963|NCT02132143|RADIATION|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
58293964|NCT02132143|RADIATION|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
58293965|NCT03249168|DRUG|Duloxetine 60mg|tablet
58293966|NCT03249168|DRUG|Placebo|Tablet
58405844|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
58405845|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
58405846|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
58405847|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
58405848|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
58405849|NCT03754582|DRUG|Perampanel|Oral tablets.
58074410|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
58405850|NCT03754582|DRUG|Perampanel|Intravenous infusion.
58405851|NCT02108717|DEVICE|Remote CT reading using the iPhone|
58405852|NCT02108717|DEVICE|CT reading using LCD monitor|
58405853|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
58405854|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
58074411|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
58293967|NCT03410992|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
58405855|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
58405856|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
58405857|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
58405858|NCT00096148|DRUG|idarubicin|Given IV
58405859|NCT00096148|DRUG|cytarabine|Given IV
58293968|NCT03410992|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
58293969|NCT00006029|DRUG|gemcitabine hydrochloride|
58293970|NCT00006029|DRUG|pegylated liposomal doxorubicin hydrochloride|
58293971|NCT00006029|DRUG|vinorelbine tartrate|
58405860|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
58293972|NCT05105672|DRUG|Sintilimab|IV infusion
58293973|NCT05105672|DRUG|Cisplatin|IV infusion
58293974|NCT05105672|RADIATION|External Beam Radiotherapy (EBRT)|Undergo pelvic EBRT
58293975|NCT05105672|RADIATION|brachytherapy|brachytherapy
58293976|NCT00379899|DRUG|cinacalcet|Low dose vitamin D with cinacalcet
58293977|NCT02100280|DRUG|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
58293978|NCT03783117|DEVICE|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
58293979|NCT05691413|OTHER|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
58293980|NCT02040753|BEHAVIORAL|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
58293981|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
58405861|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
58405862|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
58405863|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
58293982|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
58293983|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
58293984|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
58293985|NCT01236040|OTHER|Placebo|Intramuscular injection, two doses
58405864|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
58405865|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
58405866|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
58405867|NCT02578680|DRUG|Cisplatin|IV infusion
58405868|NCT02578680|DRUG|Carboplatin|IV infusion
58405869|NCT02578680|DRUG|Pemetrexed|IV infusion
58074412|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
58074413|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
58074414|NCT06722937|OTHER|Observation|Observe the clinical natural changes of eye parameters of the subjects.
58293986|NCT06106880|DRUG|Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
58293987|NCT06106880|DRUG|Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
58405870|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
58293988|NCT06106880|DIETARY_SUPPLEMENT|Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
58293989|NCT06106880|OTHER|Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
58293990|NCT04019145|DRUG|EverX Posterior|fiber reinforced bulk fill resin composite
58293991|NCT04019145|DRUG|Resins, Composite|incremental packing of Nanohybrid Resin composite
58293992|NCT04241770|OTHER|no intervention|no intervention
58293993|NCT05888298|PROCEDURE|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
58293994|NCT03343743|OTHER|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
58293995|NCT01491867|DRUG|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
58074415|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
58074416|NCT06472934|OTHER|Transcatheter aortic valve replacement in the absence of B-blocker treatment|Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.
58074417|NCT06472934|OTHER|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
58074418|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
58074419|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
58074420|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
58074421|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
58293996|NCT04279080|OTHER|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
58293997|NCT05930314|DRUG|CNCT19 cell injection|"Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells"
58074422|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
58074423|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
58074424|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
58074425|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
57938570|NCT06214247|DEVICE|Scoreflex Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
57938571|NCT01809132|DRUG|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
57938572|NCT01809132|DRUG|Pentoxifylline|Pentoxifylline, generic
57938573|NCT01809132|DRUG|Zinc Sulfate|Zinc Sulfate, nutritional supplement
57938574|NCT01809132|DRUG|Methylprednisolone|Methylprednisolone, corticosteroid
57938575|NCT04354909|OTHER|s-CD95-L|levels of s-CD95-L (ELISA test)
58074426|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
58074427|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
58074428|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
58293998|NCT02247882|OTHER|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
58405871|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
57730592|NCT01303289|DIETARY_SUPPLEMENT|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
57730593|NCT06007092|BIOLOGICAL|HPVDC injection level dose 1|patient receive 3 injections of vaccine at the same level dose
57730594|NCT06007092|BIOLOGICAL|placebo injection level dose 1|patient receive 3 injections of vaccine at the same level dose
57730595|NCT06007092|BIOLOGICAL|HPVDC injection level dose 2|patient receive 3 injections of vaccine at the same level dose
57730596|NCT06007092|BIOLOGICAL|placebo injection level dose 2|patient receive 3 injections of vaccine at the same level dose
57730597|NCT03788486|DEVICE|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
57730598|NCT04273633|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
57938576|NCT03101774|DEVICE|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
58074429|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
58074430|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
58074431|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
58074432|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
58074433|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
58074434|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
58074435|NCT05949177|BEHAVIORAL|Graded Exposure and Mindfulness Meditation|Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
58074436|NCT05949177|BEHAVIORAL|Waitlist Control|Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
58074437|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
58074438|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
58074439|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
57730599|NCT04273633|DEVICE|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
57938577|NCT03101774|DEVICE|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
57938578|NCT03101774|OTHER|Control group|Conventional therapy without any inspiratory muscle training program
57938579|NCT01161043|DEVICE|Sensor wear|All subjects to wear sensors
57938580|NCT05563519|PROCEDURE|I-PRF with collagen|The products will be applied to the sockets after tooth extractions
57938581|NCT05563519|PROCEDURE|L-PRF|The products will be applied to the sockets after tooth extractions
57938582|NCT02154542|DEVICE|Neurovent Monitor XIII|
57938583|NCT02616757|DEVICE|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
57938584|NCT05827055|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
57938585|NCT05827055|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
57938586|NCT05827055|DRUG|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
58405872|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
57938587|NCT05827055|DRUG|Placebo|Placebo given in vegan. capsules orally three times a day
57938588|NCT05166915|DEVICE|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
57938589|NCT05166915|DEVICE|Sham Control Catheter|Sham Control Device
57938590|NCT03618784|BIOLOGICAL|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals"
57938591|NCT03618784|OTHER|sterile saline|"sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
57938592|NCT00453648|OTHER|White-fleshed sweet potatoes|
57938593|NCT00453648|OTHER|Orange-fleshed sweet potatoes (boiled)|
58074440|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
58074441|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
58405873|NCT02578680|DRUG|Saline solution|IV infusion
58405874|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
58405875|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
58405876|NCT00307840|DRUG|paricalcitol|
58405877|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
57730600|NCT00443248|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
57730601|NCT04898153|DEVICE|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
57938594|NCT00453648|OTHER|Orange-fleshed sweet potatoes (fried)|
57938595|NCT00453648|OTHER|WFSP and capsule of retinyl palmitate|
57938596|NCT00193089|DRUG|Docetaxel|Docetaxel
57938597|NCT00193089|DRUG|Vinorelbine|Vinorelbine
57938598|NCT00193089|DRUG|Trastuzumab|Trastuzumab
57938599|NCT03868852|DRUG|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
57938600|NCT03868852|RADIATION|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
58074442|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
58074443|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
58074444|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
58074445|NCT05778617|DRUG|Ambroxol Hydrochloride (420mg)|Oral tablet
58074446|NCT05778617|DRUG|Placebo|Oral tablet
58074447|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
58074448|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
58074449|NCT06722950|DRUG|CAPEOX|CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
57730602|NCT00373789|DRUG|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
57938601|NCT04666350|OTHER|Direct Skin Feeding Assay (DSFA)|In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.
57938602|NCT04666350|DRUG|Primaquine|Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.
57938603|NCT04666350|DRUG|Artemether/Lumefantrine|Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
57938604|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
57938605|NCT01732796|DRUG|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
57938606|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
57938607|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
57938608|NCT01732796|DRUG|BI 201335 (Faldaprevir)|24 weeks of BI 201335
57938609|NCT01732796|DRUG|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
57938610|NCT01732796|DRUG|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
57938611|NCT01732796|DRUG|Faldaprevir (BI 201335)|24 weeks of 201335
57938612|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
57938613|NCT04243850|DRUG|Empagliflozin 10 MG|Jardiance
58074450|NCT06722950|DRUG|Placebo|Placebo：3 times a day (daily), taken with boiled water.
58074451|NCT06722950|DRUG|AC591|AC591 : 3 times a day (daily), taken with boiled water.
58074452|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
58074453|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
58074454|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
58074455|NCT06406452|DEVICE|Bioresorbable Tracheobronchial Splint|"Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires."
58074456|NCT03517150|DEVICE|mandibular advancement device|
58074457|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
58074458|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
58074459|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
58074460|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
58074461|NCT00883402|PROCEDURE|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
58074462|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
58074463|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
58074464|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
58074465|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
58074466|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
58074467|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
58074468|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
58074469|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
58074470|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
58074471|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
58074472|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
58074473|NCT05237804|OTHER|Patient component|Video, booklet, website
58074474|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
58405878|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
58405879|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
58405880|NCT02049827|OTHER|participation in the study|
57730603|NCT00373789|DRUG|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
57730604|NCT00299234|DRUG|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
57730605|NCT02493127|OTHER|Standard PCS|Subject completes the standard version of the PCS Questionnaire
57730606|NCT02493127|OTHER|Grip Strength|Research Assistant takes Grip Strength Measurements
57730607|NCT02493127|OTHER|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
57938614|NCT04243850|DRUG|Placebo oral tablet|Placebo
58074475|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
58074476|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
58405881|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
58405882|NCT06606860|DRUG|Placebo|Placebo tablet
58074477|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
58074478|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
58074479|NCT06326203|BIOLOGICAL|CELULAS TRONCO|Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
58405883|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
58074480|NCT06326203|DEVICE|CONVENTIONAL DRESSING|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
58074481|NCT06001177|DRUG|KAN-101|Dose KAN-101 Intravenous (IV) Infusion
58074482|NCT06001177|DRUG|Placebo|Placebo Intravenous (IV) Infusion
58405884|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
57938615|NCT04243850|DIAGNOSTIC_TEST|Caffeine|caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
58293999|NCT02247882|OTHER|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
57938616|NCT02958007|BEHAVIORAL|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
57938617|NCT02958007|BEHAVIORAL|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
57938618|NCT02560363|DRUG|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
57938619|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
57938620|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
57938621|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
57938622|NCT06493344|OTHER|Applying additional weight|Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
57938623|NCT00929604|OTHER|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
57938624|NCT05761054|RADIATION|RT|"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
57938625|NCT04352192|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
57938626|NCT01721876|DRUG|Placebo|Placebo matching Volasertib
57938627|NCT01721876|DRUG|Volasertib|Volasertib
57938628|NCT01721876|DRUG|Cytarabine|Cytarabine
57938629|NCT04180748|OTHER|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
57938630|NCT04543799|DEVICE|polysomnography, actigraphy, questionnaires|sleep quality recording
57938631|NCT04246801|DRUG|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
57938632|NCT04246801|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
57938633|NCT04468789|OTHER|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
58074483|NCT06525337|BEHAVIORAL|STANDARDCARE (STAND) group|Will receive a device and health coaching
58074484|NCT06525337|OTHER|CONTROL (CON) group|Will not use any devices or receive health coaching
58074485|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
57938634|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks"
57938635|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks"
57938636|NCT02479945|OTHER|Obtaining biospecimen|
57938637|NCT04726384|DEVICE|Assessment of physical activity level|Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (\>3MET) and moderate ( \>6MET) exercise.
57938638|NCT03372850|DRUG|HIP1601|Test Drug
57938639|NCT03372850|DRUG|HGP1705|Reference Drug
57938640|NCT01466530|DRUG|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
57938641|NCT01466530|DRUG|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
57938642|NCT01811784|BEHAVIORAL|Ask people not to drink raw sap|
57938643|NCT01811784|BEHAVIORAL|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
57938644|NCT01811784|OTHER|No Intervention|
58074486|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
58294000|NCT01085708|DRUG|rabeprazole|10 mg normal tablet
58294001|NCT01085708|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
58294002|NCT01085708|DRUG|rabeprazole|Type 2 granules containing rabeprazole 10 mg
58074487|NCT06427577|DRUG|ZhenQi FuZheng granules (ShiDaiYangGuang)|1 bag at a time, twice a day. Oral orally for 4 weeks.
58074488|NCT00756379|OTHER|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
58074489|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
58074490|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
58074491|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
58074492|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
58074493|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
58074494|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
58074495|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
58074496|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
58074497|NCT06666608|DEVICE|Bone Stimulator|Subjects will be asked to wear their device (if applicable) for a minimum of 30 minutes a day for 12 weeks with no maximum usage time. The device will track compliance. Bone stimulator should be worn at rest.
58294003|NCT01085708|DRUG|rabeprazole|Type 3 granules containing rabeprazole 10 mg
58294004|NCT02458560|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
58074498|NCT06666608|OTHER|Standard of Care Spondylolysis Treatment|Participants will follow the standard of care regimen for spondylolysis treatment at Houston Methodist which will involve physical therapy and wearing a back brace.
58294005|NCT02794298|DEVICE|Transcranial direct current stimulation (tDCS)|
58074499|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
58074500|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
58074501|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
58074502|NCT04726787|RADIATION|Bridging Radiotherapy|Bridging Radiotherapy will start immediately after leukapheresis and before Tisagenlecleucel treatment
57938645|NCT01811784|OTHER|No Intervention|
57938646|NCT02629796|OTHER|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
57938647|NCT03502239|OTHER|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
58074503|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
58074504|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
58294006|NCT02794298|DEVICE|sham-tDCS|
57938648|NCT01500122|DRUG|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
57938649|NCT00544050|DRUG|Levetiracetam|
58294007|NCT00650819|DRUG|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
58294008|NCT00650819|DRUG|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
58294009|NCT00650819|DRUG|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
58294010|NCT00500734|PROCEDURE|Blood Sample|One time blood draw of 2 teaspoons.
58294011|NCT04754646|DEVICE|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
57938650|NCT01971502|DRUG|Placebo to BI 1060469|single rising doses
57938651|NCT01971502|DRUG|BI 1060469|food effect
57938652|NCT01971502|DRUG|BI 1060469|single rising doses
58405885|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
58405886|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
58405887|NCT00664560|DRUG|Placebo|sugar pill bid
58294012|NCT04754646|DEVICE|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
58294013|NCT01023347|DRUG|Paclitaxel (Genexol®)|
58294014|NCT01023347|DRUG|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
58405888|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
58405889|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
58405890|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
57938653|NCT04700384|BEHAVIORAL|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
57938654|NCT04700384|BEHAVIORAL|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
57938655|NCT01172197|DRUG|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
57938656|NCT01172197|DRUG|Ropivacaine|Bolus and infusion
57938657|NCT02887014|PROCEDURE|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
57938658|NCT04115579|OTHER|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
57938659|NCT04115579|OTHER|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
57938660|NCT06417320|DRUG|ACEI, SGLT-2i|"Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)"
57938661|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - active|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
57938662|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - sham|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
57938663|NCT01728415|OTHER|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
57938664|NCT04146779|BEHAVIORAL|Yoga Video|A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
57938665|NCT04146779|BEHAVIORAL|Posture and Strengthening Video|The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
57938666|NCT04146779|BEHAVIORAL|Relaxation Video|The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
57938667|NCT04146779|BEHAVIORAL|Breath Work Video|The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
57730608|NCT00655187|OTHER|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
57938668|NCT04146779|BEHAVIORAL|Satisfaction Survey|Participants will complete a questionnaire addressing satisfaction with the yoga program.
57938669|NCT04146779|BEHAVIORAL|Guided Yoga Session|Instructor guided yoga session twice a week
57938670|NCT04146779|BEHAVIORAL|Written Yoga Instructions|Introduction to Yoga and Yoga poses
57938671|NCT03482557|DEVICE|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
58405891|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
58405892|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
58405893|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
58405894|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
58074505|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
58074506|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
58074507|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
58074508|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
58074509|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
58074510|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
58074511|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
58074512|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
58074513|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
58074514|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
58074515|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
58074516|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
58074517|NCT05852301|OTHER|no intervention|no intervention, observational study only
58074518|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
58074519|NCT04492514|DRUG|Mavrilimumab|Treatment infusion
58074520|NCT04492514|DRUG|Placebo|Placebo infusion
57938672|NCT03482557|DEVICE|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
58074521|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
58074522|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
58074523|NCT06012149|BEHAVIORAL|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
58074524|NCT06012149|BEHAVIORAL|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
57938673|NCT05508009|DRUG|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
57938674|NCT05508009|DRUG|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
57938675|NCT05508009|DRUG|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
57938676|NCT05508009|RADIATION|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
57938677|NCT05508009|DRUG|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
57938678|NCT05508009|DRUG|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
58405895|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
58294015|NCT02033707|DRUG|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
58294016|NCT00613366|DRUG|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
58294017|NCT00613366|DIETARY_SUPPLEMENT|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
57938679|NCT05508009|DRUG|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
57938680|NCT05508009|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
57938681|NCT05508009|PROCEDURE|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with \> 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI \>18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
57938682|NCT03537859|OTHER|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
57938683|NCT03537859|OTHER|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
57938684|NCT06144775|OTHER|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
57938685|NCT04722120|RADIATION|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
58405896|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
57938686|NCT04722120|RADIATION|Conventional CT (radiation)|Underwent liver CT without change of radiation.
57938687|NCT04722120|DRUG|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
57938688|NCT04722120|DRUG|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
57938689|NCT04722120|OTHER|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
57938690|NCT01735279|DRUG|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
57938691|NCT01735279|DRUG|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
57938692|NCT00959998|OTHER|Self-administered Acupressure|
57938693|NCT00243698|DRUG|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
57938694|NCT00021151|BIOLOGICAL|alemtuzumab|
58294018|NCT00535431|DRUG|AER 001|60 mg (in nebuliser), twice daily for 28 days
58294019|NCT00535431|DRUG|placebo|Sterile saline nebulised, twice daily for 28 days
58405897|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
57938695|NCT01689675|BEHAVIORAL|Computer based pain management|
57938696|NCT05586048|DRUG|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
57938697|NCT01961206|OTHER|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
57938698|NCT05439161|DEVICE|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
57938699|NCT05045898|OTHER|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
58405898|NCT01057225|DRUG|carfilzomib|Given IV
58405899|NCT01057225|DRUG|cyclophosphamide|Given orally
58405900|NCT01057225|DRUG|thalidomide|Given orally
58405901|NCT01057225|DRUG|dexamethasone|Given orally
57938700|NCT05045898|OTHER|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
57938701|NCT04960020|OTHER|Retrospective Data Review|Retrospective Data Review
57938702|NCT05204823|OTHER|Experimental product|Chocolate milk shakes
57938703|NCT05204823|OTHER|Control product|Glucose
57938704|NCT02116504|PROCEDURE|Sampling of blood|Sampling of blood for dosage of antibodies
57938705|NCT04213027|PROCEDURE|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
57938706|NCT01582295|DRUG|Cabozantinib|Starting dose 40 mg daily
57938707|NCT03712748|BEHAVIORAL|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
57938708|NCT06405711|DEVICE|frame lens|A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
57938709|NCT00504907|DRUG|BTA9881|Single oral escalating doses
57938710|NCT00504907|DRUG|Placebo|
57938711|NCT06216184|DIAGNOSTIC_TEST|Vortexing|use combined of vortexing and Maki techniques
57938712|NCT03083847|DRUG|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
57938713|NCT03083847|DRUG|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
57938714|NCT03083847|BIOLOGICAL|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
57938715|NCT04182633|COMBINATION_PRODUCT|vancomycin, Miralax, intestinal microbiota|vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
57938716|NCT04182633|COMBINATION_PRODUCT|placebo vancomycin, Miralax, placebo intestinal microbiota|placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
57938717|NCT05304650|DEVICE|iTEAR100|Controlled Stimulation External Nasal Nerve to stimulate tear production
58294020|NCT05083910|DRUG|I.V Oxytocin administration|Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
58294021|NCT02594917|PROCEDURE|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
58294022|NCT02594917|OTHER|Blood draw|Test and control group will be asked to give 20 ml of blood samples
58294023|NCT05275933|OTHER|TCM intervention|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
58294024|NCT05275933|OTHER|Placebo intervention|Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
58294025|NCT02077309|DRUG|Linagliptin|
58294026|NCT02077309|DRUG|Placebo|
57938718|NCT04838665|DRUG|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
57938719|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
57938720|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
57938721|NCT04807855|DEVICE|The cMLP device|There is only one medical device we are testing, so only one intervention.
57938722|NCT03611868|DRUG|Phase 1b: APG-115+pembrolizumab|"dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.~Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone."
57938723|NCT02485990|DRUG|Tremelimumab|
58294027|NCT05765357|DRUG|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
58294028|NCT05765357|DRUG|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
58294029|NCT00270296|DRUG|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
58405902|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
58405903|NCT01371253|OTHER|Nintendo wii balance training|
58405904|NCT01371253|OTHER|EVA-soles|
57938724|NCT02485990|DRUG|Olaparib|
57938725|NCT00117546|DRUG|alpha methyldopa|500 mg twice a day
57938726|NCT03109379|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
57938727|NCT03086395|DRUG|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
58294030|NCT00270296|DRUG|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
58405905|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
58405906|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
57938728|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
57938729|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
57938730|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
57938731|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
58294031|NCT00270296|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
58405907|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
58405908|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
58405909|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
58405910|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
58405911|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
58405912|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
57938732|NCT04824638|BIOLOGICAL|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
58294032|NCT00270296|DRUG|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
57938733|NCT04824638|BIOLOGICAL|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
58294033|NCT04849663|BIOLOGICAL|free fat graft|fat harvested from patient will be used to cover exposed root
58405913|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
57938734|NCT03194178|OTHER|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)"
58294034|NCT04849663|BIOLOGICAL|subepithelial graft|subepitheial graft harvested from palate
58405914|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
58405915|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
58294035|NCT03102957|OTHER|functional MRI|
58294036|NCT01243060|DRUG|Almorexant|100mg
58294037|NCT01243060|DRUG|Almorexant|200mg
58294038|NCT01243060|DRUG|Zolpidem 10mg|10mg
58405916|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
58405917|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
58294039|NCT01243060|DRUG|Placebo|One-time dose of Placebo
58294040|NCT02981199|PROCEDURE|stem cell transplantation|conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
58294041|NCT03695263|BEHAVIORAL|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
57730609|NCT00655187|PROCEDURE|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
57730610|NCT06497439|DRUG|Silfamin|2 tablets of Silfamin 150 mg twice daily
57938735|NCT00492830|DRUG|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
57938736|NCT03241199|DRUG|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
58294042|NCT04858308|DRUG|YYC506|YYC506
58294043|NCT04858308|DRUG|Control|Active control
58294044|NCT04858308|DRUG|YYC506 Placebo|Placebo
58294045|NCT04858308|DRUG|Control Placebo|Placebo
58294046|NCT01602796|BEHAVIORAL|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
58294047|NCT05220514|DRUG|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
58294048|NCT05220514|DRUG|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
58294049|NCT04986241|DRUG|Statin|Chronic use of statin prescribed previously by the assistant physician.
58294050|NCT04986241|OTHER|Physical activity|Physically active participants
58294051|NCT04986241|OTHER|Sedentary|Physically inactive or sedentary participants.
58294052|NCT03297229|BEHAVIORAL|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
58074525|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
58405918|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
57730611|NCT06497439|DRUG|Placebo tablet of Silfamin|2 tablets of Silfamin Placebo twice daily
57730612|NCT03538535|BEHAVIORAL|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
57730613|NCT02446132|DRUG|AVP-786|
57730614|NCT02443181|DEVICE|Activa PC+S|Implementation of closed loop DBS for essential tremor
57730615|NCT03666039|BEHAVIORAL|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
57730616|NCT04289857|OTHER|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
57730617|NCT05653505|OTHER|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
57938737|NCT02269787|BEHAVIORAL|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
57938738|NCT00041301|OTHER|QoL assessment|qol questionnaires
57938739|NCT02179671|DRUG|Gefitinib|Gefitinib once daily followed by MEDI4736
57938740|NCT02179671|DRUG|AZD9291|AZD9291 once daily followed by MEDI4736
57938741|NCT02179671|DRUG|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
57938742|NCT02179671|DRUG|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
57938743|NCT04635410|OTHER|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
57938744|NCT00897806|GENETIC|Microarray analysis|
57938745|NCT00897806|OTHER|Laboratory biomarker analysis|
57730618|NCT05811338|BEHAVIORAL|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
57730619|NCT05811338|BEHAVIORAL|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
57938746|NCT00112931|BIOLOGICAL|rituximab|
57938747|NCT00112931|OTHER|No treatment|
57938748|NCT02321930|DRUG|tofacitinib 5mg po bid|
57938749|NCT01653964|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
57938750|NCT00350584|BEHAVIORAL|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
57938751|NCT00350584|BEHAVIORAL|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
57938752|NCT02238951|OTHER|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
57938753|NCT02238951|OTHER|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
57938754|NCT00284323|DRUG|Adenosine|
57938755|NCT00291798|PROCEDURE|rate of remission|
57938756|NCT02849197|PROCEDURE|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
58294053|NCT03297229|BEHAVIORAL|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
58294054|NCT01971567|DEVICE|HIRREM|
58294055|NCT05409950|PROCEDURE|Immediate implant placement using socket shield technique|Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
58294056|NCT06503068|OTHER|Questionnaire|A questionnaire in both digital and written forms in both Arabic and English versions.
58294057|NCT04452851|DEVICE|BREATHE|The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
58294058|NCT04452851|DEVICE|BiPAP|BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
58294059|NCT04452851|DRUG|COPD Inhaler|Inhaler medication to support quick relief from COPD symptoms
57938757|NCT02780050|OTHER|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
57938758|NCT03929081|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
57938759|NCT03929081|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
57938760|NCT06041399|DRUG|hypoglycemic Agents(metformin)|patients treated with hypoglycemic Agents(metformin)
57938761|NCT06041399|DRUG|lipid-lowering drug(Statin)|patients treated with lipid-lowering drug(Statin)
57938762|NCT03588988|DRUG|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
57938763|NCT03588988|DRUG|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
57938764|NCT06455592|BEHAVIORAL|practice adapted physical activity|practice daily adapted physical activity during 4 days
57938765|NCT06455592|OTHER|control arm|practice once adapted physical activity during 4 days
57938766|NCT01743924|OTHER|raw broccoli|To eat this plant material
57938767|NCT02508051|BEHAVIORAL|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
58074526|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
58074527|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
58294060|NCT03245320|DEVICE|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
58294061|NCT00751140|PROCEDURE|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
58405919|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
58405920|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
58405921|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
57938768|NCT02508051|BEHAVIORAL|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
58405922|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
57938769|NCT05091749|BIOLOGICAL|blood samples|troponin measurement
57938770|NCT01660321|DRUG|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
57938771|NCT05983549|PROCEDURE|fluid balance|patients will receive fluids with the aim to achieve a neutral balance
57938772|NCT02401321|BEHAVIORAL|Telephone-Based Intervention|Complete Taking Care of Her program
57938773|NCT02401321|OTHER|Caregiver-Assisted Training|Complete Taking Care of Her program
57938774|NCT02401321|OTHER|Questionnaire Administration|Ancillary studies
57938775|NCT02401321|OTHER|Quality-of-Life Assessment|Ancillary studies
57938776|NCT03520959|BIOLOGICAL|LV305|Administered via subcutaneous (SC) injection.
57938777|NCT03520959|BIOLOGICAL|G305|Administered via intramuscular (IM) injection.
58074528|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
58294062|NCT06455852|BIOLOGICAL|oral cholera vaccine or typhoid conjugate vaccine|One group will receive a 2 dose oral cholera vaccine, the other a typhoid conjugate vaccine
58294063|NCT00763997|DRUG|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
58294064|NCT00763997|DRUG|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
58294065|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
57938778|NCT03520959|OTHER|LV305-matching placebo|Administered via SC injection.
58294066|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
57938779|NCT03520959|OTHER|G305-matching placebo|Administered via IM injection.
57938780|NCT02846350|BEHAVIORAL|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
58294067|NCT00763997|DRUG|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
58294068|NCT00763997|OTHER|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
58294069|NCT04485728|BEHAVIORAL|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
58294070|NCT00508911|DRUG|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
57938781|NCT00297635|DEVICE|GlucoDYNAMIX™ intervention system|
57938782|NCT00297635|DEVICE|GlucoMON™ telemetry device|
57938783|NCT05560282|DRUG|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
57938784|NCT01996813|DEVICE|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
57938785|NCT05222971|DRUG|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
57938786|NCT05222971|DRUG|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
57938787|NCT01637909|DRUG|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
57730620|NCT05811338|BEHAVIORAL|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
57730621|NCT00959023|OTHER|laboratory biomarker analysis|
57730622|NCT00959023|OTHER|medical chart review|
58294071|NCT00508911|DRUG|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
58405923|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
58294072|NCT00401128|DRUG|gemcitabine hydrochloride|
58294073|NCT00401128|DRUG|irinotecan hydrochloride|
58294074|NCT06604832|DRUG|PrabotulinumtoxinA-Xvfs|Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
58294075|NCT06604832|DRUG|IncobotulinumtoxinA|Each vial of incobotulinumtoxinA contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the right side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
58405924|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
58405925|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
57730623|NCT00959023|OTHER|questionnaire administration|
57730624|NCT05641688|DRUG|[18F]PI-2620|The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
58294076|NCT06604832|DRUG|saline solution (placebo)|As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
58405926|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
58405927|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
57730625|NCT00505739|DRUG|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
58405928|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
58405929|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
58405930|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
58405931|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
57730626|NCT01265329|OTHER|Negative selection|Sperm selection to continue the treatment with healthy sperm
57730627|NCT03701750|DRUG|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
57730628|NCT04642638|DRUG|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
57730629|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
57730630|NCT04642638|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
57730631|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
58074529|NCT06416462|PROCEDURE|antimicrobial photodynamic therapy|When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
58074530|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
58074531|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
58074532|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
58074533|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
58294077|NCT03675360|BEHAVIORAL|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
58294078|NCT05449171|OTHER|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
57938788|NCT01637909|DIETARY_SUPPLEMENT|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
58074534|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
58294079|NCT06612398|BEHAVIORAL|Preoperative preparation video|An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
58294080|NCT01863290|OTHER|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
58294081|NCT02688933|DRUG|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
58294082|NCT02688933|DRUG|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
58294083|NCT02688933|DRUG|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
58405932|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
58074535|NCT03159455|DRUG|BI 1467335|Duration - 28 days
58074536|NCT03159455|DRUG|Placebo|Duration - 28 days
58405933|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
58405934|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
58405935|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
57730632|NCT00986999|DRUG|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
57730633|NCT01934218|DEVICE|Gel-One|
57730634|NCT01934218|DEVICE|PBS|
58074537|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
58074538|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
58074539|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
58074540|NCT02058849|OTHER|Placebo|Placebo
58074541|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
57730635|NCT05846724|DRUG|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
58074542|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
58405936|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
57938789|NCT01637909|OTHER|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
57938790|NCT01766271|BEHAVIORAL|Health Coaching|biweekly health coaching for 5 months
58294084|NCT01342575|PROCEDURE|Intra-operative exposure maneuvers|"* Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
58294085|NCT00327717|DRUG|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
58294086|NCT00327717|DRUG|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
58294087|NCT06129383|PROCEDURE|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
58294088|NCT06612697|OTHER|Radiology|A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records.
58294089|NCT05923047|DRUG|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
58294090|NCT05923047|PROCEDURE|Polypeptomy|This group will undergone in-office nasal polypectomy.
58294091|NCT06246188|DIAGNOSTIC_TEST|Cardiac MRI using Regadenoson and GE-267|Performing stress-cardiac MRI for clinical diagnostic in adult patients with suspected coronary artery disease
58294092|NCT02447445|PROCEDURE|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men \< 27 kg and women \<16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
58294093|NCT02620787|DRUG|Tedizolid|
58294094|NCT02620787|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
58294095|NCT05127564|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
57730636|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
58074543|NCT06672445|DRUG|ARO-ATXN2 Injection|single dose of ARO-ATXN2 by intrathecal (IT) administration
58074544|NCT06672445|DRUG|Placebo|calculated volume to match active treatment by IT administration
58074545|NCT04920786|DRUG|TB006|TB006
58074546|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
58074547|NCT06269484|DRUG|Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
58074548|NCT06269484|DRUG|Zibotentan + placebo (placebo matching dapagliflozin tablet)|"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"
58294096|NCT02558764|DEVICE|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
58074549|NCT06269484|DRUG|Zibotentan + dapagliflozin|"zibotentan capsule~dapagliflozin 10 mg tablet"
58074550|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
58074551|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
58074552|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
58074553|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
58294097|NCT02193204|BEHAVIORAL|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
58294098|NCT02193204|BEHAVIORAL|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
58294099|NCT06065644|DEVICE|CTMA|Induced displacement of the Sacroiliac joint
57730637|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
57938791|NCT01766271|GENETIC|9p21|Genetic testing results of 9p21
57730638|NCT00427050|DRUG|PEP005|
57730639|NCT03874364|DEVICE|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
57730640|NCT03874364|OTHER|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
57730641|NCT03874364|OTHER|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
57730642|NCT03874364|DEVICE|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
57938792|NCT01766271|OTHER|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
57938793|NCT02713165|OTHER|Raisins|Participants will consume 84g of raisins per day for 14 days.
58405937|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
58405938|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
58405939|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
58405940|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
58405941|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
58405942|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
58405943|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
58405944|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
58405945|NCT06379958|DRUG|leramistat 40mg|Oral capsule
58405946|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
58405947|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
58405948|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
58405949|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
58405950|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
58294100|NCT05199792|DIAGNOSTIC_TEST|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
58294101|NCT06232967|PROCEDURE|Primary tumor resection or not|For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
58294102|NCT03746834|DEVICE|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
58294103|NCT03870334|DRUG|BT-11 880 mg|Oral once daily tablet
58294104|NCT03870334|DRUG|Placebo|Oral once daily tablet
58294105|NCT02027233|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
57730643|NCT03874364|OTHER|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
57938794|NCT04924569|DEVICE|Intermittent Catheter|Flexible tubular device used to drain urine from the bladder via the urethra by male, female, and pediatrics.
58294106|NCT05551390|OTHER|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
58294107|NCT05551390|OTHER|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
58294108|NCT03260608|BEHAVIORAL|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
58405951|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
58405952|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
58405953|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
58405954|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
58405955|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
58405956|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
58405957|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
58405958|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
58405959|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
58405960|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
58405961|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
58405962|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
58405963|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
58405964|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
58405965|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
58405966|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
58405967|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
58405968|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
58405969|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
58294109|NCT03747705|OTHER|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
58294110|NCT00353223|BEHAVIORAL|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
58294111|NCT00353223|BEHAVIORAL|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
58294112|NCT01158261|BIOLOGICAL|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
58294113|NCT01144455|DRUG|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
58294114|NCT01144455|DRUG|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
58294115|NCT01144455|DRUG|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
58294116|NCT05073419|OTHER|Standard of Care|Routine monitoring of post AMI patient with clinic visits
58294117|NCT05073419|DEVICE|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
58294118|NCT00803712|DRUG|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
58405970|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
57730644|NCT03874364|OTHER|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
58074554|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
58074555|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
58294119|NCT00803712|DRUG|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
58294120|NCT04716972|OTHER|survey|Online survey
58294121|NCT04716972|OTHER|Interview|Interview
58294122|NCT00954122|DRUG|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
58405971|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
58405972|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
58405973|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
58294123|NCT03169907|RADIATION|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
58405974|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
58405975|NCT00075946|BIOLOGICAL|rituximab|Given IV
58405976|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
58405977|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
57938795|NCT01473979|PROCEDURE|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
57938796|NCT01619111|DRUG|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
57938797|NCT01619111|DRUG|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib~+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
57938798|NCT06209554|DEVICE|ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser|diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
57938799|NCT02604953|DIAGNOSTIC_TEST|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
57938800|NCT02604953|DIAGNOSTIC_TEST|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
57938801|NCT04930809|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
57938802|NCT00784290|DRUG|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
57938803|NCT04503304|OTHER|Exercises|already included in arm/group descriptions.
57938804|NCT04122404|DIAGNOSTIC_TEST|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
57938805|NCT05057260|OTHER|No drug invervention|No clinical trial
57938806|NCT05831748|OTHER|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
57938807|NCT05831748|OTHER|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
57938808|NCT05926388|OTHER|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
57938809|NCT06429384|DRUG|Y-3 Injection/Y-3 blank injection|The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;
57938810|NCT00572026|DRUG|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
58074556|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
58074557|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
58294124|NCT02843126|DRUG|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
58405978|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol"
58074558|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
57730645|NCT05637138|DEVICE|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
57938811|NCT03571529|DEVICE|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
57938812|NCT03571529|OTHER|Conventional physiotherapy|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale"
57938813|NCT06372938|DIAGNOSTIC_TEST|Ultrasound measurement|The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).
57938814|NCT06372938|DIAGNOSTIC_TEST|Laboratory Tests and Inflammatory Markers|"The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL)."
57938815|NCT01444482|BIOLOGICAL|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
57938816|NCT01444482|BIOLOGICAL|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
57938817|NCT03054922|DRUG|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
57938818|NCT03054922|DRUG|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
57938819|NCT03054922|DRUG|Normosol-R Inj|IV infusion of Normosol throughout surgery.
58074559|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
58074560|NCT06723613|BEHAVIORAL|Exercise group|"Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.~Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH-Breastfeeding Record System, IMDAT: Breast milk intake level assessment tool scales will be applied to mothers before exercise (8th week after birth) and after exercise (14th week)."
58294125|NCT02843126|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
57730646|NCT05637138|DEVICE|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
57730647|NCT05637138|DEVICE|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
57938820|NCT00006392|DRUG|Vitamin E|400 IU daily by mouth for 7-12 years
57938821|NCT00006392|DRUG|Selenium|200 mcg daily for 7-12 years
57938822|NCT00006392|OTHER|Vitamin E placebo|daily for 7-12 years
57938823|NCT00006392|OTHER|selenium placebo|daily for 7-12 years
57938824|NCT00449384|BEHAVIORAL|Diagnostic Screening|
57938825|NCT00000536|BEHAVIORAL|sodium, dietary|
57938826|NCT04669340|OTHER|E-learning patient education|"The intervention implies patient education through an e-learning program. The program consists of three learning modules covering knowledge of rheumatoid arthritis, medication, examinations, complications and daily living with RA. Module 1 consists of 'need to know' information about disease management, symptoms and medication. Thus, it is mandatory and must be completed before entering module 2 and 3. In module 2 and 3, patients can move around on the basis of their individual needs.~The duration of the full program is approximately two hours, but may vary dependent on the individual user needs. The program may be used as much as needed throughout the study period."
57938827|NCT04669340|OTHER|Standard face-to-face patient education|The intervention implies usual care, i.e. face-to-face patient education in a one-hour session with a nurse at the hospital. This form of patient education is based on the patients individual need for information and guidance in relation to rheumatoid arthritis and medication. Thus, aspects of daily life with the disease is discussed at the beginning and forms the conversation. However, as a standard, information of the disease, disease management, symptoms and medication must be discussed with the patient and relatives.
57730648|NCT05637138|DEVICE|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
57730649|NCT00513669|BIOLOGICAL|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
57730650|NCT00513669|BIOLOGICAL|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
57730651|NCT06635447|DRUG|Capivasertib|400 mg, oral, twice daily; 4 days on and 3 days off
57730652|NCT06635447|DRUG|Fulvestrant|Fulvestrant IV
58405979|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
58405980|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
57938828|NCT01621542|BIOLOGICAL|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
58074561|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
58074562|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
58074563|NCT06672237|BIOLOGICAL|nexiguran ziclumeran|nexiguran ziclumeran 55 mg by single IV infusion
58074564|NCT06672237|DRUG|Normal Saline as Placebo|Normal saline (0.9% NaCl) by single IV infusion
58294126|NCT05746169|OTHER|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
58294127|NCT05746169|OTHER|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
58294128|NCT00945412|DEVICE|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
58294129|NCT00945412|DEVICE|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
58294130|NCT01129245|DRUG|Celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
58294131|NCT01129245|DRUG|Placebo|Placebo identical to celecoxib
58294132|NCT00705757|DRUG|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
58294133|NCT00705757|DRUG|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
58294134|NCT00705757|DRUG|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
58294135|NCT00816127|DRUG|Desmopressin|intranasal desmopressin (300μg)
58294136|NCT00816127|BIOLOGICAL|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
58294137|NCT02493517|DRUG|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
58294138|NCT02493517|DRUG|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
58294139|NCT03221998|DRUG|IV paracetamol|100 gram paracetamol infusion for moderate pain management
58405981|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
58405982|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
58405983|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
58405984|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
58405985|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
58405986|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
57938829|NCT06023316|DEVICE|mGain system|passive, noninvasive surface electromyography measurement device and gaming mobile application
57938830|NCT04048265|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
58294140|NCT03221998|DRUG|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
58294141|NCT06553690|OTHER|Brain Gym Therapy|Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
58405987|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
58405988|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
58405989|NCT00118313|BIOLOGICAL|sargramostim|
57938831|NCT04533490|DRUG|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
57938832|NCT01950247|DRUG|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
58074565|NCT05894070|OTHER|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~* Standardized, phonetically balanced text~* Sustained, modulated production of five vowels~* Picture description~* Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~* Health barometer~* Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
58074566|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
58074567|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
58074568|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
58074569|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
58074570|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
58074571|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
58074572|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
58074573|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
58074574|NCT00596466|DRUG|pregabalin|pregabalin
58074575|NCT06713928|OTHER|Oral hygiene with dog therapy|The DAT session is divided into two phases: a pre-sitting phase in which the patient could interact with the dog, touching, caressing and playing with him, under the supervision of the dog-trainer. This phase lasted about 15 minutes. The second phase was a during-sitting phase in which the dog was in the chair, next to the patient, during the entire oral hygiene procedure, under the supervision of the dog-trainer.
58074576|NCT04890054|OTHER|Fecal Immunochemical Test|Patients due for CRC screening are mailed a FIT test by the clinic or health plan
58074577|NCT04890054|OTHER|Interview|Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations
58074578|NCT04890054|BEHAVIORAL|Patient Navigation|Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
58074579|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
58074580|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
58074581|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
58074582|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
58074583|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
58074584|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
58074585|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
58074586|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
58074587|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
58074588|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
58074589|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
58074590|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
58405990|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
58405991|NCT00118313|DRUG|dimethyl sulfoxide|
58074591|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
58405992|NCT00118313|DRUG|imiquimod|
58405993|NCT00118313|PROCEDURE|adjuvant therapy|
57938833|NCT01950247|DRUG|SOC|
58294142|NCT01253096|DRUG|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
58405994|NCT00334997|PROCEDURE|endoscopic surgery|
58405995|NCT00334997|PROCEDURE|laser surgery|
58405996|NCT00334997|RADIATION|radiation therapy|
58405997|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
57938834|NCT00853749|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
57938835|NCT00853749|PROCEDURE|Blood draw|Collection of 10 mL of blood
58405998|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
58405999|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
58406000|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
58406001|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
58406002|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
58406003|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
58406004|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
58406005|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
58406006|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
58406007|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
58406008|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
58406009|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
58406010|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
58406011|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
58406012|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
58406013|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
58406014|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
58406015|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
57938836|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
58406016|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
58406017|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
58406018|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406019|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406020|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406021|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406022|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406023|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
58406024|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
57938837|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
57938838|NCT03522051|OTHER|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
57938839|NCT05699265|DIAGNOSTIC_TEST|Measures of arterial stiffness and endothelial function|baseline cMRI, vascular reactivity studies, and CPET
57938840|NCT05699265|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).
57938841|NCT05699265|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.
57938842|NCT05699265|DIAGNOSTIC_TEST|Serum and urine biomarkers|Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
57938843|NCT01810653|DRUG|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
57938844|NCT01810653|DRUG|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
57938845|NCT05573776|OTHER|Exercise Therapy, High Protein supplement|patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
57938846|NCT00227292|DRUG|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
57938847|NCT00227292|DRUG|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
57938848|NCT05082376|DRUG|CLM Original|Sunscreen lip balm.
57938849|NCT00946504|DRUG|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
57938850|NCT00946504|DRUG|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
57938851|NCT00278759|PROCEDURE|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
57938852|NCT03480568|DRUG|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
57938853|NCT03410459|DIAGNOSTIC_TEST|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
57938854|NCT06030336|BEHAVIORAL|Home Health Report|The Home Health Report has been described in the intervention arm description.
57938855|NCT05071365|OTHER|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
57938856|NCT00864890|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
57938857|NCT00864890|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
57938858|NCT00073528|DRUG|Lapatinib|1500 mg orally once a day
57938859|NCT00073528|DRUG|Letrozole|2.5 mg orally once a day
57938860|NCT00073528|DRUG|Placebo|Placebo (which matched with lapatinib tablet)
57938861|NCT06243731|OTHER|No Intervention|This is a non-interventional study.
57938862|NCT01079273|BIOLOGICAL|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
57938863|NCT04133454|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
57938864|NCT00681174|DRUG|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
57938865|NCT00681174|DRUG|oxycodone|20 mg p.o. 1 h before the start of anesthesia
57938866|NCT00681174|PROCEDURE|Paravertebral block|"* Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
57938867|NCT00681174|DRUG|Propofol|"* Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
57938868|NCT00681174|DRUG|Remifentanil|"* 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
57938869|NCT00681174|DRUG|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
57938870|NCT00681174|DRUG|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none"
57938871|NCT03426293|OTHER|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
58406025|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
57938872|NCT03777150|OTHER|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
57938873|NCT03777150|OTHER|Postoperative care in standard ward|Postoperative care in standard ward
57938874|NCT03707613|PROCEDURE|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
57938875|NCT03502291|BIOLOGICAL|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
58294143|NCT05488769|DEVICE|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
58294144|NCT04762199|DRUG|Flt3/MerTK Inhibitor MRX-2843|Given PO
58294145|NCT04762199|DRUG|Osimertinib|Given PO
58406026|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
58406027|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
58406028|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
58406029|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
58406030|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
58406031|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
58406032|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
58406033|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
58406034|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
58406035|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
58406036|NCT02045381|PROCEDURE|MRI Group|A single research MRI
57938876|NCT03502291|BIOLOGICAL|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
57938877|NCT03502291|BIOLOGICAL|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
57938878|NCT03502291|BIOLOGICAL|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
57938879|NCT02902081|DRUG|Cannabidiol|
57938880|NCT02902081|DRUG|Placebo|
57938881|NCT05962047|OTHER|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
57938882|NCT05962047|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
57938883|NCT01383980|DIETARY_SUPPLEMENT|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
57938884|NCT01322503|BIOLOGICAL|Norovirus|Norovirus challenge pool administered to each subject
57938885|NCT05234554|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
57938886|NCT05234554|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
57938887|NCT00360906|DRUG|Triomar™ (omega-3 fatty acids)|
58294146|NCT01366313|DRUG|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
58294147|NCT01366313|DRUG|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
57938888|NCT06478355|DRUG|Immunotherapy|Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
57938889|NCT06478355|DRUG|Chemotherapy drug|TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
57938890|NCT06478355|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
58294148|NCT01366313|DRUG|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
58406037|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
58406038|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
58406039|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
58406040|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
58406041|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
57938891|NCT01102348|OTHER|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
57938892|NCT04124484|DRUG|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
57938893|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
57938894|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
57938895|NCT04124484|DRUG|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
57938896|NCT04143360|DEVICE|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
57938897|NCT04143360|DEVICE|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
57938898|NCT04853836|COMBINATION_PRODUCT|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
57938899|NCT04853836|PROCEDURE|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
58406042|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
58406043|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
58406044|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
58406045|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
58406046|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
58406047|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
58406048|NCT03985410|DRUG|ETX2514|intravenous infusion
58406049|NCT03985410|DRUG|Placebo|intravenous infusion
58406050|NCT03985410|DRUG|moxifloxacin|oral tablet
58406051|NCT01760330|DRUG|IV acetaminophen|
58406052|NCT01760330|DRUG|Placebo|
58406053|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
58406054|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
58406055|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
58406056|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
58406057|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
57938900|NCT04853836|DRUG|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
57938901|NCT04853836|DRUG|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
57938902|NCT03874663|DEVICE|Directly assisted oral HIV self-testing (HIVST)|"1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
57938903|NCT02064920|DRUG|Placebo|Placebo for donepezil hydrochloride capsule
57938904|NCT02064920|DRUG|Donepezil|5 mg donepezil hydrochloride capsule.
57938905|NCT02064920|DRUG|Donepezil|10 mg donepezil hydrochloride capsule.
58406058|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
58406059|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
58406060|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
58406061|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
58406062|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
58406063|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
58074592|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
58074593|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
58074594|NCT02708524|DEVICE|Senofilcon C Contact Lens|
58074595|NCT02708524|DEVICE|Comfilcon A Contact Lens|
58406064|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
57938906|NCT06201247|DRUG|JD123 injection|JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
58406065|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
58406066|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
57938907|NCT01230281|OTHER|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
57938908|NCT01657474|OTHER|Weekly application of EpiFix plus standard of care|
57938909|NCT01657474|OTHER|Biweekly application of EpiFix plus standard of care|
57938910|NCT05050708|OTHER|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
57938911|NCT03470038|DRUG|NGF|Intramuscular injection
57938912|NCT03470038|DRUG|Isotonic saline|Intramuscular injection
58406067|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
58406068|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
57938913|NCT06414928|OTHER|Acute Heart Failure|Consecutive patients presented at Emergency Departement with Acute Heart Failure
57938914|NCT05164055|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
57938915|NCT02207998|DRUG|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
57938916|NCT02207998|DRUG|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
57938917|NCT03188562|OTHER|PET/CT|Positron Emission Tomography (PET/CT)
57938918|NCT03188562|PROCEDURE|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
57938919|NCT03188562|PROCEDURE|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
58074596|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
58074597|NCT02708524|DEVICE|Samfilcon A Contact Lens|
58074598|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
58074599|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
58074600|NCT04503655|OTHER|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
58074601|NCT00433368|DRUG|L-Ornithine L-Aspartate|
58406069|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
58406070|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
58074602|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
58074603|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
58074604|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
58074605|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
58074606|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
57938920|NCT02674542|OTHER|In-depth interviews|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
58406071|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
58406072|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
58406073|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
58406074|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
57938921|NCT02674542|OTHER|Focus Group|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
58406075|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
57730653|NCT04163302|BIOLOGICAL|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
57730654|NCT01525290|DRUG|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
57938922|NCT06438848|OTHER|Physical therapy program|group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions
57938923|NCT06438848|OTHER|Physical therapy program with lymphedema drainage|physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks
57938924|NCT05223660|DRUG|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
57938925|NCT05223660|DRUG|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
57938926|NCT05223660|DRUG|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
57938927|NCT05223660|DRUG|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
57938928|NCT03877978|BIOLOGICAL|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
58074607|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
58406076|NCT04092907|DRUG|placebo|Ophthalmic Solution
58406077|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
58406078|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
57730655|NCT01525290|DRUG|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
57730656|NCT06636435|DRUG|CBA-1205|CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
57730657|NCT06636435|DRUG|CBA-1205|CBA-1205 : 20 mg/kg and 30 mg/kg (Intravenous solution)
57730658|NCT06636435|DRUG|CBA-1205|CBA-1205: 30 mg/kg (Intravenous solution)
57730659|NCT06282627|OTHER|Observational study|No intervention. Observational study
58074608|NCT05885958|OTHER|Time|Patients will be given up to 30 minutes to void.
58074609|NCT05885958|OTHER|Time|Patients will be given up to 60 minutes to void.
58294149|NCT04613739|BEHAVIORAL|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
57938929|NCT00317720|DRUG|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
57938930|NCT00317720|DRUG|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
57938931|NCT02562079|BIOLOGICAL|Blood samples|"* biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)"
57938932|NCT02562079|BIOLOGICAL|Biopsy|Skin biopsies
57938933|NCT02375724|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
57938934|NCT02375724|DRUG|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
57938935|NCT04625842|OTHER|Focus group interview|Group interview with patients who received radiation treatment
57938936|NCT03921320|PROCEDURE|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
57938937|NCT03921320|PROCEDURE|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
57938938|NCT03921320|PROCEDURE|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
57938939|NCT01037491|DRUG|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
57938940|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
57938941|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
57938942|NCT00002117|DRUG|Zidovudine|
57938943|NCT00002117|DRUG|Zalcitabine|
58294150|NCT01060423|DRUG|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
58294151|NCT01060423|DRUG|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
58294152|NCT01060423|DEVICE|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
58294153|NCT04538469|OTHER|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
58294154|NCT04827979|BIOLOGICAL|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant"
58406079|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
58406080|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
57938944|NCT00759733|PROCEDURE|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
57938945|NCT00759733|PROCEDURE|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
57938946|NCT05570942|DIETARY_SUPPLEMENT|Oral Lactobacillus rhamnosus TCELL-1|A kind of probiotics which was isolated from the intestinal mucosa of health Taiwanese people
57938947|NCT06210750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57938948|NCT06210750|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
57938949|NCT06210750|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57938950|NCT06210750|DRUG|Calaspargase Pegol|Given IV
57938951|NCT06210750|PROCEDURE|Computed Tomography|Undergo CT
57938952|NCT06210750|DRUG|Cyclophosphamide|Given IV
57938953|NCT06210750|DRUG|Cytarabine|Given IT, IV or SC
57938954|NCT06210750|DRUG|Daunorubicin|Given IV
57938955|NCT06210750|DRUG|Dexamethasone|Given PO
57938956|NCT06210750|DRUG|Doxorubicin|Given IV
58294155|NCT04827979|BIOLOGICAL|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
58294156|NCT04827979|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
58406081|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
58406082|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
58406083|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
57938957|NCT06210750|PROCEDURE|Echocardiography|Undergo echocardiography
57938958|NCT06210750|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
57938959|NCT06210750|DRUG|Mercaptopurine|Given PO
57938960|NCT06210750|DRUG|Methotrexate|Given IT
57938961|NCT06210750|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
57938962|NCT06210750|BIOLOGICAL|Navitoclax|Given PO
57938963|NCT06210750|DRUG|Nelarabine|Given IV
57938964|NCT06210750|DRUG|Pegaspargase|Given IV
57938965|NCT06210750|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57938966|NCT06210750|DRUG|Thioguanine|Given PO
57938967|NCT06210750|DRUG|Venetoclax|Given PO
57938968|NCT06210750|DRUG|Vincristine|Given IV
57938969|NCT06210750|PROCEDURE|X-Ray Imaging|Undergo X-ray
57938970|NCT03057613|DRUG|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
57938971|NCT03057613|RADIATION|IMRT 60-66Gy|60-66Gy for 6 weeks
57938972|NCT02098265|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
57938973|NCT02098265|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
57938974|NCT02098265|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
57938975|NCT02098265|OTHER|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
57938976|NCT02098265|OTHER|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
57938977|NCT02098265|OTHER|Delay|10 week delay before intervention
57938978|NCT02098265|DEVICE|BCI-FES|
57938979|NCT02524548|OTHER|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
57938980|NCT05097144|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
58294157|NCT04806269|DEVICE|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
58294158|NCT00434772|DRUG|glucagon|
58406084|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
58406085|NCT02524015|OTHER|Novel physical therapy|
58406086|NCT02524015|OTHER|Standard physical therapy|
58406087|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
58074610|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
58074611|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
58406088|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
57938981|NCT05097144|DEVICE|Lens B (asmofilcon A)|Daily wear for one month
57938982|NCT04301232|OTHER|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg \> preanesthetic level, 20 - 50 mm Hg \> preanesthetic level, 50 mm Hg \> preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 \> 92% on room air, Supplemental O2 required to maintain SpO2 \> 90%,SpO2 \< 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
57938983|NCT04301232|OTHER|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)\<15%, Blood pressure 15-30%, Blood pressure\>30%, Level of consciousness,(Awake\&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value\>90% on room air, Requires supplemental oxygen, Saturation\<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea\&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score\<1 in any individual category)would be required for a patient after general anesthesia
57938984|NCT04301232|OTHER|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in room air Y/N, Pain Control (VAS \< 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
57938985|NCT01485341|DIETARY_SUPPLEMENT|gluten|gluten is administered once a day at 10g/day for 15 days
57938986|NCT01485341|DIETARY_SUPPLEMENT|rice starch|rice starch is administered once a day at 10 g/day for 15 days
57938987|NCT05526742|DRUG|CKD-510 capsule (reference)|Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
57938988|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
57938989|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fed state.
58074612|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
58074613|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
58074614|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
58074615|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
58074616|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
58074617|NCT05868187|BEHAVIORAL|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
57730660|NCT05226208|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
57938990|NCT00874445|DEVICE|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
57938991|NCT03406143|PROCEDURE|CGF injection|CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
57938992|NCT03406143|PROCEDURE|Control|Saline will be injected into expanded skin
57938993|NCT02452905|DRUG|Nitazoxanide|
57938994|NCT02452905|DRUG|Placebo (for Nitazoxanide)|
57938995|NCT05149183|OTHER|cervical stability training|cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
57938996|NCT05149183|OTHER|traditional treatment|TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
57938997|NCT01244295|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
57938998|NCT01244295|BEHAVIORAL|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
57938999|NCT03457545|BEHAVIORAL|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
57939000|NCT03457545|OTHER|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
57730661|NCT05226208|DIAGNOSTIC_TEST|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
57939001|NCT06025890|OTHER|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
58074618|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
58074619|NCT04530227|DRUG|Pemetrexed|chemotherapy
58074620|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
57730662|NCT06361082|PROCEDURE|ACL reconstruction|ACL reconstruction
57730663|NCT00725166|OTHER|Skeletal muscle aging|"W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
57730664|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
58074621|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
58074622|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
58074623|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
58074624|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
58074625|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
58074626|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
58074627|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
58074628|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
58074629|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
58074630|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
58074631|NCT06723782|BIOLOGICAL|AMTRIX-D|Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
58074632|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
58074633|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
58074634|NCT04393259|OTHER|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
58074635|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
58074636|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
58074637|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
58074638|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
58074639|NCT05638594|DRUG|Pyrotinib|320mg, qd
58074640|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
58074641|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
58074642|NCT05638594|DRUG|Letrozole|2.5mg，qd
58406089|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
57939002|NCT06025890|OTHER|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
57939003|NCT01877915|DRUG|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
58074643|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
58074644|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
58074645|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
58074646|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
58074647|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
58074648|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Sharkskin Forceps|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
58074649|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Standard Forceps|25g Grieshaber Standard ILM Forceps
58074650|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
58074651|NCT01143558|DEVICE|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
58074652|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
58074653|NCT02643992|OTHER|DOAC concentration measurement|
58074654|NCT03742895|DRUG|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
58406090|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
58074655|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
58074656|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
58074657|NCT06588855|DRUG|RO7790121|RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
58294159|NCT02259400|DEVICE|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.
58406091|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
58406092|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
58406093|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
58406094|NCT03280303|OTHER|non-interventional|
58406095|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
58406096|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
58074658|NCT06588855|DRUG|Placebo|Placebo matching IV RO7790121. Placebo matching SC RO7790121.
58074659|NCT05815758|DRUG|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
58074660|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
58074661|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
58074662|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
58074663|NCT06589271|BIOLOGICAL|human umbilical cord mesenchymal stem cell suspension|2 \* 10\^7 cells (2ml)
58074664|NCT06589271|PROCEDURE|total endoscopic extraction of lumbar nucleus pulposus|hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
58074665|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
58294160|NCT02259400|DEVICE|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
57939004|NCT01877915|DRUG|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
57939005|NCT01877915|OTHER|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
57939006|NCT03486886|DIAGNOSTIC_TEST|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
57939007|NCT05140122|DRUG|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
57939008|NCT05140122|OTHER|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
57939009|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
57939010|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
57939011|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
57939012|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
57939013|NCT03447938|PROCEDURE|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
57939014|NCT03447938|PROCEDURE|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
57939015|NCT00245310|PROCEDURE|Indocyangreen (ICG) clearance|
57939016|NCT00505596|BEHAVIORAL|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
58294161|NCT02716792|DRUG|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
58406097|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
58406098|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
57939017|NCT04825171|DRUG|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
57939018|NCT01667536|DRUG|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
57939019|NCT06469099|OTHER|excercises|exercises for strength and balance
57939020|NCT05242042|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
57939021|NCT05242042|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
57939022|NCT06065176|BIOLOGICAL|Novavax COVID-19 vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Novavax vaccine.
57939023|NCT06065176|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Pfizer vaccine.
58074666|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
58074667|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
58074668|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
58074669|NCT02426359|DRUG|Q301 Cream|
58074670|NCT02426359|DRUG|Placebo|
58074671|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
58074672|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
57730665|NCT02256462|DRUG|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
57730666|NCT03261518|PROCEDURE|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
57730667|NCT04820764|DEVICE|CardioMech MVRS|CardioMech MVRS
58074673|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
58074674|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
58074675|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
58074676|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
58294162|NCT00452660|DRUG|Exjade|
58294163|NCT00738634|BEHAVIORAL|Self-motivated physical activity|"Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
58294164|NCT00738634|BEHAVIORAL|Nutrition|"Components:~1. Nutrition education booklet (Double-sided A4 page)~2. Nutrition motivation tips (single-sided A4 page)~3. Nutrition monitoring chart~4. Online presentation of common obstacles and ways to overcome these obstacles"
58406099|NCT04188418|DRUG|Morphine|Given PO
58406100|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
58406101|NCT04188418|OTHER|Placebo Administration|Given PO
58406102|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
57730668|NCT01408160|DRUG|Cytarabine|Given IV
57730669|NCT01408160|BIOLOGICAL|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
58074677|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
58074678|NCT03007472|DEVICE|CI532|Cochlear implant
58406103|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
58074679|NCT03007472|DEVICE|Nucleus 7|Sound processor
58074680|NCT01224288|PROCEDURE|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
58074681|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
58294165|NCT00738634|BEHAVIORAL|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
58294166|NCT04168645|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
58294167|NCT04917614|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
58294168|NCT00522548|DRUG|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
58406104|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
58406105|NCT00063895|OTHER|pharmacological study|Correlative studies
58406106|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
58406107|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
58406108|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
58406109|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
58406110|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
58406111|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
58406112|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
57730670|NCT01408160|OTHER|Laboratory Biomarker Analysis|Correlative studies
57730671|NCT01408160|OTHER|Pharmacological Study|Correlative studies
57730672|NCT05644548|OTHER|No intervention|No intervention
57730673|NCT00524134|DRUG|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
57730674|NCT06634758|BEHAVIORAL|Nursing interventions based on the Watson Human Caring Model|In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
58294169|NCT00522548|DRUG|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
57730675|NCT05300724|OTHER|No intervention|No intervention will be administered in this study.
57730676|NCT01156753|DRUG|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
58294170|NCT00335517|DRUG|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
58406113|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
58406114|NCT02051153|DRUG|Placebo|
58406115|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
58406116|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
58294171|NCT05801861|DEVICE|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
58406117|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
58406118|NCT06589791|OTHER|No treatment given|Online self-completion survey
58406119|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
57730677|NCT01156753|DRUG|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
58294172|NCT05801861|DEVICE|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
58294173|NCT05801861|DEVICE|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
58294174|NCT05801861|DEVICE|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
58294175|NCT01242241|DRUG|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
58294176|NCT01242241|DRUG|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
58294177|NCT03854721|DRUG|VAX014|Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
58294178|NCT04032795|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
58294179|NCT04032795|DIETARY_SUPPLEMENT|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
58294180|NCT05435469|OTHER|Questionnaires|Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
58294181|NCT02868021|DEVICE|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
58294182|NCT02868021|BEHAVIORAL|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
58294183|NCT02868021|BEHAVIORAL|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
58294184|NCT02868021|BEHAVIORAL|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
57730678|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
57730679|NCT00137332|DRUG|GAP-486 (ZP-123)|
58294185|NCT02868021|BEHAVIORAL|Self-assessed function|Using the Late Life Function and Disability Instrument.
58406120|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
58406121|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
58406122|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
58406123|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
58406124|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
58406125|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
58294186|NCT02868021|PROCEDURE|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
58294187|NCT02868021|DEVICE|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
58294188|NCT02868021|DEVICE|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
58294189|NCT02868021|BEHAVIORAL|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
58294190|NCT01733745|OTHER|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
58294191|NCT01733745|OTHER|SYSTANE® BALANCE|Lubricant Eye Drops
58294192|NCT01733745|DIETARY_SUPPLEMENT|SYSTANE® Vitamins|
58294193|NCT01733745|OTHER|Microfiber towels (as warm compresses, with or without saline eye drops)|
58294194|NCT01992250|DEVICE|Visica 2 Treatment System|Cryoablation
58294195|NCT01051817|DRUG|AIN457|infusion 10 mg/Kg
58294196|NCT01051817|DRUG|Placebo|infusion
58294197|NCT01015716|BEHAVIORAL|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
58294198|NCT01015716|BEHAVIORAL|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
58294199|NCT04818073|DEVICE|New FINGER|New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
57730680|NCT00137332|DRUG|0.9% Sodium Chloride, USP|
58294200|NCT04917848|OTHER|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
58294201|NCT00260546|PROCEDURE|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
58294202|NCT01720316|DRUG|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
58294203|NCT01720316|DRUG|placebo|
58294204|NCT03735082|DRUG|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
58294205|NCT03735082|DRUG|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
58294206|NCT03735082|DRUG|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
58294207|NCT03464032|DRUG|BCD-135|Monoclonal anti-PD-L1 antibody
58294208|NCT01754324|DRUG|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
58294209|NCT00125060|DRUG|Simvastatin (20mg versus 80mg/day)|
58294210|NCT04380870|DIETARY_SUPPLEMENT|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
58294211|NCT04956510|OTHER|Evaluation|health status and quality of life were evaluated
58294212|NCT05497453|DRUG|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
58294213|NCT05497453|DRUG|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
58294214|NCT05497453|DRUG|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
58294215|NCT05497453|DRUG|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
58294216|NCT00237692|BEHAVIORAL|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
58294217|NCT00237692|BEHAVIORAL|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
57730681|NCT03007823|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
58294218|NCT00237692|BEHAVIORAL|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral \& medication management
58406126|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
58406127|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
58406128|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
58406129|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
58406130|NCT04899440|OTHER|Control|No Oral Irrigator Control
58406131|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
58406132|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
58406133|NCT03579472|DRUG|Eribulin Mesylate|Given IV
58406134|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
58406135|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
58406136|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
58406137|NCT01693874|BEHAVIORAL|control (health education)|health education
58406138|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
58406139|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
58406140|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
58406141|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
58406142|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
58406143|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
58406144|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
58406145|NCT03764631|DRUG|Empagliflozin|Drug
57730682|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
58406146|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
58406147|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
58406148|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
58406149|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
57730683|NCT03049046|DRUG|Placebos|Diluent
58406150|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
57730684|NCT01757769|DRUG|Silodosin|8 mg daily for 24 weeks
57730685|NCT00467870|DRUG|Testosterone Undecanoate 750 mg|
57939024|NCT01177436|BIOLOGICAL|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
57939025|NCT02729740|DEVICE|Penumbra Smart Coil|
57730686|NCT00467870|DRUG|Testosterone Undecanoate 1000 mg|
57939026|NCT02729740|DEVICE|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
58294219|NCT00850369|OTHER|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
58294220|NCT02307149|BIOLOGICAL|CAVATAK|CAVATAK is a preparation of CVA21
58294221|NCT02307149|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
58294222|NCT06357624|OTHER|Mulligan mobilization|The SNAGS technique was applied to 3 sets of 10 repetitions with 15-30 seconds rest between sets while the participants were in a sitting position. A physiotherapist applied passive motion to facet joints at each spinal level. The participant was questioned in which direction he/she felt pain during cervical ROM and the application was carried out in the painful/limited directions.
58294223|NCT06357624|OTHER|Self-Mobilization|For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.
58294224|NCT03832270|BEHAVIORAL|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
58294225|NCT03832270|BEHAVIORAL|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
58294226|NCT02012725|DRUG|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
58294227|NCT05074641|OTHER|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
58294228|NCT05074641|OTHER|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
58294229|NCT02288702|DEVICE|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
58294230|NCT04793984|DEVICE|Carragelose|inhalation 3 times a day
58294231|NCT04793984|DEVICE|NaCl|inhalation 3 times a day
58294232|NCT00725907|BIOLOGICAL|PGRF|injection of 6cc into injured area
58294233|NCT00725907|BIOLOGICAL|placebo saline|injection of 6cc into injured area
58294234|NCT05225545|DRUG|Sucrosomial Iron|Experimental Arm
58294235|NCT05225545|DRUG|Oral Iron|Active Comparator
58294236|NCT00447096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
58294237|NCT01825304|DEVICE|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
58294238|NCT02340377|DEVICE|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
58294239|NCT06380205|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
58294240|NCT06380205|DRUG|Levonorgestrel/Ethinyl estradiol|Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
58294241|NCT04249362|DRUG|Durvalumab|All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
58294242|NCT02264808|OTHER|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
58294243|NCT03151447|RADIATION|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
58294244|NCT05828459|DRUG|OT-A201|OT-A201 IV infusion qw or q2w
57939027|NCT06114277|OTHER|ETCO2 levels|Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in group 1.
57939028|NCT06114277|OTHER|Patients with high ETCO2 levels|Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
58294245|NCT05828459|DRUG|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
58294246|NCT05828459|DRUG|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
58294247|NCT05828459|DRUG|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
57939029|NCT02873936|DRUG|Filgotinib|Tablet(s) administered orally once daily
58074682|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
58406151|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
58406152|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
58406153|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
58406154|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
58406155|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
58406156|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
58406157|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
58406158|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
58406159|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
58406160|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
58406161|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
58406162|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
58406163|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
57939030|NCT02873936|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
58406164|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
58406165|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
58406166|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
58406167|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
57730687|NCT04458948|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
57939031|NCT02873936|DRUG|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
57939032|NCT04195035|DEVICE|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.
57939033|NCT04195035|DEVICE|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.
58406168|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
57939034|NCT06280222|DEVICE|The VR instrument - Oculus Quest 2|Patients in the interventional group will watch 20-minute scenery movies in the VR instrument before entering the oocyte retrieval procedure.
58406169|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
57939035|NCT02484326|OTHER|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
58294248|NCT05828459|DRUG|TBD Compound|Combination regimen for hematological malignancy
58294249|NCT02136459|OTHER|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
58294250|NCT02136459|OTHER|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
57730688|NCT04458948|DRUG|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
57939036|NCT06001996|PROCEDURE|Pericapsular nerve group (PENG) block|Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
57939037|NCT06001996|PROCEDURE|Suprainguinal fascia iliaca plane block|Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
58074683|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
57939038|NCT03104075|BIOLOGICAL|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
57939039|NCT03104075|BIOLOGICAL|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
57939040|NCT00955812|DRUG|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
57939041|NCT01062139|DRUG|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
57939042|NCT01062139|DRUG|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
57939043|NCT02219321|DRUG|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
57939044|NCT02219321|DRUG|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
57939045|NCT00537498|DRUG|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l"
57939046|NCT04012879|COMBINATION_PRODUCT|CD19 CART|CD19 CART
57939047|NCT00657865|DRUG|ramipril|oral intake
57939048|NCT00657865|DRUG|placebo|placebo
57939049|NCT04819256|OTHER|PACE-It mobile application|Care co-ordination platform
58294251|NCT02721056|RADIATION|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
58294252|NCT02479659|OTHER|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
58294253|NCT02479659|OTHER|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
58294254|NCT02479659|OTHER|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
58294255|NCT02479659|OTHER|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
58294256|NCT02479659|OTHER|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
58294257|NCT01025284|DRUG|LY2523355|Administered intravenously as a 1-hour infusion
58294258|NCT01025284|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
58294259|NCT00870467|BIOLOGICAL|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
58294260|NCT00870467|DRUG|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
58294261|NCT00870467|BIOLOGICAL|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
58294262|NCT00870467|BIOLOGICAL|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
58294263|NCT02250300|DRUG|MLN9708 (2.3 mg)|2.3 mg
58294264|NCT02250300|DRUG|MLN9708 (4.0 mg)|4.0 mg
58294265|NCT02250300|DRUG|MLN9708 (3.0 mg)|3.0 mg
58294266|NCT00294814|DEVICE|Proximal anastomosis using Heartstring anastomotic device|
58294267|NCT01503983|DRUG|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
58294268|NCT01503983|DRUG|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
58294269|NCT01503983|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
58294270|NCT04380376|DRUG|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
58294271|NCT04380376|OTHER|Standard of care|the patients will receive only SOC (standard of care) treatment
58294272|NCT06331663|DRUG|Remifentanil|first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
58294273|NCT04569175|OTHER|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
58294274|NCT02283658|DRUG|Everolimus|Given PO
58294275|NCT02283658|OTHER|Laboratory Biomarker Analysis|Correlative studies
58294276|NCT02283658|DRUG|Letrozole|Given PO
58294277|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
58074684|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
58074685|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
57939050|NCT02876120|OTHER|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
58074686|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
58074687|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
57939051|NCT05799599|BEHAVIORAL|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
58074688|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
58406170|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
57939052|NCT05799599|BEHAVIORAL|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
57939053|NCT05799599|BEHAVIORAL|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
57939054|NCT04557319|BIOLOGICAL|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
57939055|NCT04557319|BIOLOGICAL|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
58074689|NCT04790630|OTHER|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|computerized experimental brain-training treatment
58074690|NCT04790630|OTHER|Active Control|computerized intervention that follows recommendations for cognitive fitness
58074691|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
58074692|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
58074693|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
58074694|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
58074695|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
57939056|NCT04557319|BIOLOGICAL|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
57939057|NCT01433757|DRUG|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
58074696|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
58074697|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
58294278|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
58406171|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
58074698|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
58406172|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
58406173|NCT04527991|DRUG|Paclitaxel|Administered intravenously
58074699|NCT06576934|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
58074700|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
58074701|NCT06722287|BEHAVIORAL|Caregiver Mental Health Mobile Application Intervention|The mobile application includes self-care tools, caregiving management tools, and online support groups
58294279|NCT04493372|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
58406174|NCT04527991|DRUG|Docetaxel|Administered intravenously
58406175|NCT04527991|DRUG|Vinflunine|Administered intravenously
58074702|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
58406176|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
58406177|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
58406178|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
58406179|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
58406180|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
58406181|NCT02748434|OTHER|Lipohypertrophy|
58406182|NCT02748434|OTHER|Normal Subcutaneous Tissue|
58406183|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
57939058|NCT01433757|DRUG|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
57939059|NCT00378469|BEHAVIORAL|45 minute exercise on ergocycle|
57939060|NCT01881945|OTHER|Non-invasive physiological signal recording on healthy volunteer|
57939061|NCT01111942|OTHER|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)"
58074703|NCT01878708|DRUG|PEG-L-asparaginase|
58074704|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
58074705|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
58074706|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
58074707|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
58074708|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
58406184|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
58406185|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
58406186|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
58406187|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
58406188|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
58406189|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
58406190|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
58406191|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
58406192|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
58406193|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
58294280|NCT05562297|DRUG|sintilimab|Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
58406194|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
58406195|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
58406196|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
58406197|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
58406198|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
58406199|NCT02526524|DRUG|Placebo|
58406200|NCT00258232|DRUG|capecitabine|
57939062|NCT01111942|PROCEDURE|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
57939063|NCT03947450|BIOLOGICAL|Autologous Skin Fibroblasts|The site or whole stump will be injected with autologous fibroblasts
57939064|NCT03947450|BIOLOGICAL|Placebo|The site or whole stump will be injected medium only without autologous skin fibroblasts
57939065|NCT05738811|OTHER|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
58294281|NCT05562297|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
58294282|NCT05562297|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
58294283|NCT00873730|DRUG|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
58294284|NCT00873730|DRUG|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
58294285|NCT02761018|BEHAVIORAL|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
58406201|NCT00258232|DRUG|celecoxib|
58406202|NCT00258232|DRUG|irinotecan hydrochloride|
58406203|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
57939066|NCT05738811|OTHER|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
58294286|NCT02761018|BEHAVIORAL|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
58294287|NCT06517498|OTHER|No Intervention|No Intervention will be conducted
58294288|NCT03493438|OTHER|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
58294289|NCT05180162|DRUG|68Ga-FAP-2286|A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
58294290|NCT05180162|PROCEDURE|Positron Emission Tomography (PET)|Imaging will begin 50-100 minutes after injection and last about 45 minutes.
58294291|NCT02131064|DRUG|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w
58294292|NCT02131064|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infusion q3w
58294293|NCT02131064|DRUG|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
58294294|NCT02131064|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
58406204|NCT01656343|DRUG|Belatacept|No Intervention
58406205|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
58406206|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
58406207|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
58406208|NCT02123238|OTHER|bed positioning|
58406209|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
58406210|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
58074709|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
58074710|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
57730689|NCT03362554|BEHAVIORAL|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
57939067|NCT05738811|OTHER|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
57939068|NCT04786457|BIOLOGICAL|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
57939069|NCT01628107|BIOLOGICAL|Epoetin Hospira|Intravenous (IV) injection
57939070|NCT02741804|DIETARY_SUPPLEMENT|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
58074711|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
58074712|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
58294295|NCT02131064|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
58294296|NCT04712136|OTHER|MRI|MRI cardiac
58294297|NCT01492504|DRUG|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
58294298|NCT02791529|PROCEDURE|Electrocautery|Skin incision performed by electrocautery
58294299|NCT02791529|PROCEDURE|Scalpel|Skin incision performed by scalpel
58294300|NCT04474808|OTHER|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
58406211|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
58406212|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
58406213|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
58406214|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
57730690|NCT03375619|OTHER|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
57730691|NCT02858739|DEVICE|BIOFREEDOM STENT|
57939071|NCT02741804|OTHER|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
57939072|NCT02741804|DIETARY_SUPPLEMENT|Brain Health Placebo|Treatment with placebo consisting of soybean oil
57939073|NCT00058474|DRUG|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
57939074|NCT00058474|DRUG|fluorouracil|225 mg/m2 IV daily continuous infusion
57939075|NCT00058474|DRUG|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
58294301|NCT04474808|OTHER|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
58294302|NCT02480881|DRUG|BMS-663068|Investigational product
58294303|NCT02480881|DRUG|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
58294304|NCT02480881|DRUG|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
58294305|NCT01001312|OTHER|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
58294306|NCT01001312|OTHER|Clinical volume status assessment|Volume assessment based on history and physical examination
58294307|NCT04617119|DEVICE|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
58294308|NCT04617119|OTHER|Conventional physical therapy|daily
58294309|NCT03997097|DRUG|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
58294310|NCT03997097|DRUG|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
58294311|NCT05627050|DEVICE|An Online Augmented Reality (AR) Training Platform|The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
58294312|NCT01893697|OTHER|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
58294313|NCT01628848|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
58294314|NCT01628848|DRUG|Placebo|Placebo transdermal patch
58294315|NCT02777905|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
58294316|NCT01345812|DRUG|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
58294317|NCT01345812|DRUG|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
58406215|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
58074713|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
58074714|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
58074715|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
58294318|NCT04663685|OTHER|Exercise program|Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.
58294319|NCT04663685|OTHER|Nutrition education|Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
58406216|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
58406217|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
58406218|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
57730692|NCT02896855|DRUG|Docetaxel|Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
58074716|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
58074717|NCT00848965|DRUG|Placebo|Placebo comparator
58074718|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
58074719|NCT06063538|COMBINATION_PRODUCT|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
58074720|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
58074721|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
58406219|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
58074722|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
58074723|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
58074724|NCT06724120|OTHER|No interventions|No interventions
58406220|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
58074725|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
58074726|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
58074727|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
58074728|NCT00457951|DRUG|Open-Label|ODSH administered open-label
58074729|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
58074730|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
58406221|NCT04819438|DRUG|Riluzole 50 mg Oral Film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
58074731|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
57939076|NCT00058474|RADIATION|radiation therapy|Given 5 days a week for 5-6 weeks
57939077|NCT04654520|OTHER|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
58406222|NCT04819438|DRUG|Rilutek 50Mg Tablet|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
58406223|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
57730693|NCT02896855|DRUG|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
57939078|NCT04296279|DRUG|FMP014|Falciparum Malaria Protein-14
57939079|NCT04296279|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
57939080|NCT06188819|PROCEDURE|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
57939081|NCT01375257|DRUG|Oral treatment with antibiotics for endocarditis|
57939082|NCT01375257|DRUG|Guideline treatment with parenteral antibiotics|
58406224|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
58406225|NCT01974557|OTHER|Exercise|
58406226|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
58406227|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
58406228|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
58406229|NCT02745782|OTHER|Observational Study|Observational Study
58406230|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
58406231|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
58406232|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
57939083|NCT04888299|DEVICE|Raman spectroscopy (SPECTRA IMDx)|The SPECTRA IMDx comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx probe is connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal for diagnostic classification.
57939084|NCT01025596|DRUG|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
57939085|NCT05510921|OTHER|Minimalist music group|Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.
57939086|NCT05510921|OTHER|Minimalist music + birdsongs group|Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
58074732|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
58074733|NCT05788484|DRUG|CDX-585|CDX-585 is administered by infusion every 2 weeks
58406233|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
57939087|NCT05629429|DRUG|Olaparib|Olaparib 300mg BID PO
57939088|NCT05629429|DRUG|Chemotherapy drug|Continue platinum based chemotherapy
58074734|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
58074735|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
58074736|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
58406234|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
58406235|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
58406236|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
57730694|NCT02896855|DRUG|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
58406237|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
58406238|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
58406239|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
58406240|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
58406241|NCT01897753|DRUG|growth hormone|36 months
57939089|NCT05479279|OTHER|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
57939090|NCT05479279|OTHER|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
57939091|NCT00517322|DRUG|ramipril|ramipril 2.5- 5 mg once daily
57939092|NCT00517322|DRUG|irbesartan|irbesartan 150-300 mg once daily
57939093|NCT02903251|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
57939094|NCT02903251|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
57939095|NCT03662672|PROCEDURE|Rib raising and lumbar release|Rib raising per protocol described in arm description.
57939096|NCT03662672|PROCEDURE|Sham procedure|Sham procedure per protocol described in arm description
57939097|NCT01918423|BEHAVIORAL|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
57939098|NCT01887951|DRUG|Penthrox Inhaler|
57939099|NCT01887951|DRUG|Tramadol Injection|
57939100|NCT02960178|BEHAVIORAL|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
58294320|NCT03182790|BEHAVIORAL|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
58294321|NCT03182790|BEHAVIORAL|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
58294322|NCT03182790|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
58294323|NCT03182790|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
58406242|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
58406243|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
58406244|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
58294324|NCT03182790|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
58294325|NCT03182790|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
58406245|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
58294326|NCT03182790|BEHAVIORAL|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
58294327|NCT03182790|BEHAVIORAL|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
58294328|NCT05504837|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
58294329|NCT05470244|OTHER|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
58406246|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
58406247|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
58406248|NCT01626118|DRUG|Placebo|capsules
58406249|NCT02944357|DRUG|Cisplatin|Given IV
58406250|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
58406251|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
57939101|NCT02960178|BEHAVIORAL|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
58074737|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
58074738|NCT02461173|DEVICE|shepherd catheter|
58406252|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
58406253|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
58406254|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
58406255|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
58406256|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
58406257|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
58294330|NCT05470244|OTHER|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
57939102|NCT00797836|PROCEDURE|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods"
58406258|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
58406259|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
58406260|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
58406261|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
58406262|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
57939103|NCT01471314|BEHAVIORAL|Headache day versus non-headache day|
57939104|NCT01358890|OTHER|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
58406263|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
58406264|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
58406265|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
58406266|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
58406267|NCT06052826|OTHER|Best Practice|Undergo standard of care
58406268|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
58406269|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
58406270|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
58294331|NCT05030233|BEHAVIORAL|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
58294332|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
58294333|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
58294334|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
58294335|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
58294336|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
58294337|NCT03237897|BEHAVIORAL|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
58294338|NCT03237897|BEHAVIORAL|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
58294339|NCT03227731|DRUG|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
58294340|NCT05876429|OTHER|New Standardized Accept Note|A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.
58294341|NCT05876429|OTHER|Existing Transfer Patient Admission Process|Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
58294342|NCT04712409|PROCEDURE|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
58294343|NCT04712409|PROCEDURE|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
58294344|NCT04712409|PROCEDURE|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
58294345|NCT04712409|PROCEDURE|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
58294346|NCT01042821|PROCEDURE|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
58294347|NCT01042821|PROCEDURE|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
58294348|NCT04178408|OTHER|No intervention|No intervention
58294349|NCT00713271|DRUG|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
58294350|NCT00713271|DRUG|Placebo|
58294351|NCT00713271|DRUG|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
58294352|NCT00713271|DRUG|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
58074739|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
58074740|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
58074741|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
58074742|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
58074743|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
58294353|NCT04078971|OTHER|Western diet|Subjects in this intervention will follow a normal western diet
58294354|NCT04078971|OTHER|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
58294355|NCT02689804|DRUG|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
57730695|NCT02896855|DRUG|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
57939105|NCT01358890|OTHER|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
57939106|NCT06465251|DEVICE|Home-based CIMT|Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.
57939107|NCT06465251|DEVICE|Clinic-based CIMT|Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour. Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day
57939108|NCT06465251|DEVICE|Control|Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
57939109|NCT04612036|DEVICE|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
57939110|NCT04612036|DEVICE|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
58074744|NCT06724328|BEHAVIORAL|Gentle Human Touch|the trained NICU nurse will place one hand's fingertips on the baby's forehead along the brow line, while the other hand will be placed around the baby's lower abdomen
58294356|NCT02689804|DRUG|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
58294357|NCT05304988|OTHER|Testing of the EFT|A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.
58294358|NCT01971814|DRUG|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
58294359|NCT05924659|OTHER|Cerabral training|1 week of cerebral training (neurofeedback or sham)
58294360|NCT03331263|DRUG|Chlorhexidine Gluconate|2% CHG
58294361|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 16 weeks
58294362|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 8 weeks
58294363|NCT00920777|BEHAVIORAL|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
58294364|NCT03248648|DRUG|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
58294365|NCT03248648|DRUG|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
58294366|NCT00398216|DRUG|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
58294367|NCT02169505|DRUG|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
58294368|NCT02326272|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
58294369|NCT02326272|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
58294370|NCT04009304|BEHAVIORAL|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
58294371|NCT04217460|BEHAVIORAL|Intervention for fluency difficulty|Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
58294372|NCT04835727|OTHER|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
58294373|NCT03939442|PROCEDURE|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
58406271|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
58406272|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
58406273|NCT00004729|BEHAVIORAL|Ketogenic diet|
57730696|NCT03848533|DRUG|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
57939111|NCT04612036|DEVICE|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
58074745|NCT06724328|BEHAVIORAL|Maternal Heartbeat and Gentle Human Touch|maternal heartbeat will be played and GHT steps will be applied simultaneously at the designated times
58406274|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
58406275|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
58406276|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
57939112|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
58294374|NCT00288418|DEVICE|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
58074746|NCT06724328|BEHAVIORAL|Maternal Heartbeat|The recording of the mother's heartbeat will be done when the mother's mood is stable and the environment is quiet. A Doppler fetal heart monitor will be used to detect the mother's heartbeat. After ensuring a regular and stable heart rate, the mother's heartbeat will be recorded for 15 minutes using a recording device
58294375|NCT06117020|DRUG|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
58294376|NCT05919082|DRUG|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
58294377|NCT05919082|DRUG|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
58294378|NCT05276102|OTHER|Emollient cream|Commercially available emollient cream
58294379|NCT03141190|BEHAVIORAL|Mindfulness Based Stress Reduction - modified|already described
58294380|NCT03141190|BEHAVIORAL|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
58294381|NCT06525051|DRUG|Tiotropium|Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.
58294382|NCT04853823|DRUG|PDC-APB|PDC-APB Intra-muscular Injection
58294383|NCT04853823|OTHER|Placebo|Vehicle
58294384|NCT02308449|DRUG|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
58294385|NCT02308449|DRUG|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
58294386|NCT00198991|DRUG|Cyclophosphamide|Cytostatic drug
58294387|NCT00198991|DRUG|Dexamethasone|Antileukemic drug
58294388|NCT00198991|DRUG|Vincristine|Cytostatic drug
58294389|NCT00198991|DRUG|Daunorubicin|Cytostatic drug
58294390|NCT00198991|DRUG|Asparaginase|Cytostatic drug
58294391|NCT00198991|DRUG|Methotrexate|Cytostatic drug
58294392|NCT00198991|DRUG|Cytarabine|Cytostatic drug
57939113|NCT02114268|DRUG|Placebo|Participants received placebo on Day 1.
57939114|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
57939115|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
57939116|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
58294393|NCT00198991|DRUG|Mercaptopurine|Cytostatic drug
58294394|NCT00198991|DRUG|G-CSF|Growth factor
58294395|NCT00198991|DRUG|Vindesine|Cytostatic drug
58294396|NCT00198991|DRUG|Etoposide|Cytostatic drug
58294397|NCT00198991|DRUG|Prednisolone|Antileukemic drug
58294398|NCT00198991|DRUG|Adriamycin|Cytostatic drug
58294399|NCT00198991|DRUG|Thioguanine|Cytostatic drug
58294400|NCT00198991|DRUG|Teniposide|Cytostatic drug
58294401|NCT00198991|PROCEDURE|CNS irradiation|Cytostatic drug
58294402|NCT00198991|PROCEDURE|Mediastinal Irradiation|Irradiation
58294403|NCT00198991|PROCEDURE|Stem cell transplantation (SCT)|Stem cell transplantation
58294404|NCT00198991|DRUG|Idarubicin|Cytostatic drug
58294405|NCT00198991|DRUG|Fludarabine|Cytostatic drug
58294406|NCT00198991|DRUG|Cladribine|Cytostatic drug
58294407|NCT01702909|DRUG|Interleukin-2|Interleukin-2
58294408|NCT03157674|OTHER|Non-Interventional|Non-Interventional
58294409|NCT04726826|DIAGNOSTIC_TEST|Diagnostic and prognostic biomarkers|Observational study of biomarkers predictive of morbidity and mortality in febrile children
58294410|NCT03625739|DRUG|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
58294411|NCT04750018|OTHER|surgery|Patients were divided into surgery and no disease.
58294412|NCT01793753|DRUG|Propofol|
58294413|NCT03816553|DRUG|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
58294414|NCT03816553|DRUG|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
58294415|NCT06039644|DIETARY_SUPPLEMENT|Probiotic|Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
58294416|NCT06039644|OTHER|Placebo|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
58294417|NCT03782714|DEVICE|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
58294418|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
58294419|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of NHFOV|neonates assigned to NHFOV will be started with the following boundaries: a) Paw of 6 cmH2O (the range 6-10 cmH2O); b) frequency of 10 Hz (the range 8-12 Hz). c) Inspiratory time 50% (1:1). d) amplitude 15 cmH2O(the range 15-25 cmH2O) NHFOV will only be provided with piston/ membrane oscillators able to provide an active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A).
57730697|NCT03848533|DRUG|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
57730698|NCT03848533|DRUG|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
58294420|NCT04664257|BEHAVIORAL|e-CBT|e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
58294421|NCT00369343|DRUG|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
58294422|NCT00369343|DRUG|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
58294423|NCT00048035|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
58294424|NCT06324643|PROCEDURE|sensory motor integration training|one group treated by strengthening exercises , stretching ,and occupational therapy and other group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training
57730699|NCT03334123|OTHER|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
58294425|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
58294426|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
58294427|NCT05624411|DEVICE|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
58294428|NCT05624411|DEVICE|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
58294429|NCT05342753|DEVICE|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
58294430|NCT04612985|DEVICE|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
58294431|NCT03675568|PROCEDURE|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
58294432|NCT03675568|PROCEDURE|Split skin Graft|A traditional method for treatment of burn wounds
58294433|NCT04449289|DRUG|Intravenous lidocaine|Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
58294434|NCT04449289|DRUG|Epidural ropivacaine|Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
58294435|NCT02691546|OTHER|blood sample collection|
58294436|NCT02902042|DRUG|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
58294437|NCT02902042|DRUG|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
58294438|NCT02902042|DRUG|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
58294439|NCT02902042|DRUG|Pembrolizumab alone|200 mg q3w
58294440|NCT01138020|BEHAVIORAL|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
57730700|NCT03334123|OTHER|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
57730701|NCT03102398|DRUG|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
57730702|NCT05733988|PROCEDURE|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
58294441|NCT01138020|BEHAVIORAL|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
58294442|NCT00463801|DRUG|Daptomycin|
58294443|NCT01285869|OTHER|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
58294444|NCT03620188|OTHER|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
58294445|NCT04394702|OTHER|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
58294446|NCT04394702|OTHER|manual stainless steel K-file|sequential manual filing with stainless steel K-files
58294447|NCT05401721|DIAGNOSTIC_TEST|Serum copeptin|Blood test
58406277|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
58406278|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
57730703|NCT02860728|BEHAVIORAL|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
57730704|NCT02715128|DEVICE|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
57730705|NCT00006154|DRUG|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
57730706|NCT00006154|DRUG|Ritonavir|100 mg liquid capsules equaling 400 mg daily
57730707|NCT00006154|DRUG|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
57939117|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
57939118|NCT00488111|OTHER|Ringer's Lactate|Ringer's Lactate was used 15min before operation
57939119|NCT00488111|OTHER|6% Starch|6% Starch was used 15min before operation
57939120|NCT05147064|PROCEDURE|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
57939121|NCT05147064|PROCEDURE|conventional open surgery|open interlaminar lumbar decompression
57939122|NCT01873417|DRUG|BG00012 (DMF)|
57939123|NCT00904631|DEVICE|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
57939124|NCT00344565|DRUG|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
57939125|NCT00344565|BEHAVIORAL|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
57939126|NCT01038804|DRUG|YM155|intravenous infusion
57939127|NCT01038804|DRUG|Docetaxel|intravenous infusion
58406279|NCT02654431|PROCEDURE|Cancer patients|Samples
57730708|NCT00006154|DRUG|Efavirenz|200 mg capsules equaling 600 mg daily
57730709|NCT00006154|DRUG|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
57730710|NCT00006154|DRUG|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
57730711|NCT00006154|DRUG|Aldesleukin|Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
57939128|NCT05800340|BIOLOGICAL|Toripalimab|240mg Q3W
57939129|NCT05800340|DRUG|Nab paclitaxel|135 mg/m2, d1, 8 Q3W
57939130|NCT05800340|DRUG|Pemetrexed|500mg/m2, d1 Q3W
57939131|NCT05800340|DRUG|Carboplatin|AUC 5, d1 Q3W
57939132|NCT02221349|DEVICE|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
57939133|NCT02221349|DRUG|Sodium fluoride paste|Toothpaste used by subject
58074747|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
58074748|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
57939134|NCT02221349|DRUG|Stannous fluoride paste|Toothpaste used by subject
57939135|NCT03378323|DRUG|Multiple injection local anesthetic|Multiple injection local anesthetic
57939136|NCT03378323|DRUG|Single injection local anesthetic|Single injection local anesthetic
57939137|NCT04128345|DEVICE|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
57939138|NCT04349163|OTHER|Questionnaire|CD-RISC 25 questionnaire
58074749|NCT00193076|DRUG|Gemcitabine|Gemcitabine
58074750|NCT00193076|DRUG|Carboplatin|Carboplatin
58074751|NCT00193076|DRUG|Trastuzumab|Trastuzumab
58074752|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
58074753|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
58074754|NCT00158002|DRUG|Topiramate|
58074755|NCT05959551|DEVICE|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
58074756|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
58074757|NCT05882045|DRUG|Retatrutide|Administered SC
58074758|NCT05882045|DRUG|Placebo|Administered SC
58294448|NCT06008054|DRUG|SI-B003|Administered by intravenous infusion every 3 weeks (Q3W).
58294449|NCT06008054|DRUG|BL-B01D1|Administered by intravenous infusion for a cycle of 3 weeks.
58294450|NCT06008054|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
58294451|NCT00715234|OTHER|Reminder/recall notices for vaccines|"1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter."
58294452|NCT05076604|DRUG|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
58294453|NCT05076604|DRUG|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
58294454|NCT01411319|RADIATION|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
57939139|NCT03092206|DRUG|F/TAF|antiretroviral therapy
57939140|NCT03092206|DRUG|E/C/F/TAF|antiretroviral therapy
57939141|NCT03092206|DRUG|R/F/TAF|antiretroviral therapy
57939142|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice|Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.
57939143|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.
57939144|NCT01178320|DRUG|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
58406280|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
58406281|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
58406282|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
58406283|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
58406284|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
58406285|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
58406286|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
58406287|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
58406288|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
58406289|NCT04773782|DRUG|avapritinib|oral administration
58406290|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
58406291|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
58406292|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
58406293|NCT04075968|OTHER|Home exercise|Home exercise will be applied
58406294|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
58406295|NCT00631150|DRUG|Levetiracetam (Keppra)|
58406296|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
58406297|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
57939145|NCT00182832|BEHAVIORAL|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
58294455|NCT01411319|RADIATION|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
58294456|NCT04624048|DIAGNOSTIC_TEST|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
58294457|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
58294458|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
58294459|NCT05547256|DRUG|Placebo|Saline solution
58294460|NCT01688622|BEHAVIORAL|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
58294461|NCT03160040|DRUG|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
58294462|NCT05710328|DRUG|Chemotherapy|Receive standard of care chemotherapy
57939146|NCT00182832|BEHAVIORAL|Standard Care|Standard care for hospitalized older patients with cognitive impairment
57939147|NCT01457391|BEHAVIORAL|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
57939148|NCT01457391|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
58294463|NCT05710328|PROCEDURE|Computed Tomography|Undergo PET/CT
58294464|NCT05710328|OTHER|Fludeoxyglucose F-18|Given IV
58294465|NCT05710328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58294466|NCT05710328|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
58406298|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
58406299|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
58406300|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
58406301|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
58294467|NCT05679115|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
58294468|NCT04753957|DRUG|micronized Progesterone|200mg micronized progesterone placed vaginally
57939149|NCT01457391|BEHAVIORAL|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
58294469|NCT00174824|DRUG|Insulin glargine|
58294470|NCT01060189|DRUG|Ulinastatin|
58294471|NCT01060189|DRUG|Tranexamic Acid|
58294472|NCT01060189|DRUG|Saline Solution|
58294473|NCT05867667|OTHER|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
58294474|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
58294475|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
58294476|NCT02587767|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
58294477|NCT02587767|DEVICE|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
57939150|NCT04960540|OTHER|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
57939151|NCT02715336|DRUG|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
58074759|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
57939152|NCT01925352|DRUG|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
57939153|NCT00897143|GENETIC|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
57939154|NCT00897143|GENETIC|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
57939155|NCT00897143|OTHER|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
58074760|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
58406302|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
57939156|NCT00897143|OTHER|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
57939157|NCT00729378|OTHER|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
58406303|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
58294478|NCT06074783|BIOLOGICAL|Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)|50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
58294479|NCT05859607|PROCEDURE|laparoscopic cholecystectomy|conventional laparoscopic cholecystectomy with calculation of difficulty scorings
57939158|NCT01033552|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
58294480|NCT00174200|DRUG|Risperidone 2 mg|
57939159|NCT01033552|DRUG|Fludarabine|40 mg/m\^2/day intravenously on Days -6, -5, -4, -3 and -2.
58074761|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
58406304|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
58406305|NCT06011798|DRUG|foselutoclax|Experimental drug
57939160|NCT01033552|DRUG|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
57939161|NCT01033552|DRUG|Myeloablative Busulfan|Targeting AUC 1000 umol/min
57939162|NCT01033552|PROCEDURE|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
57939163|NCT01033552|RADIATION|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
57939164|NCT01033552|PROCEDURE|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
57939165|NCT00263029|DRUG|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
58074762|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
58074763|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
58074764|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
58074765|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
58074766|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
58074767|NCT03007680|OTHER|Core muscle activation|
58294481|NCT06167785|DRUG|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks
58294482|NCT06167785|DRUG|Zanubrutinib|Zanubrutinib 160 mg oral twice daily
58294483|NCT06167785|DRUG|Tislelizumab + Zanubrutinib|Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
58294484|NCT00941304|DRUG|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
58406306|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
58406307|NCT01691885|DRUG|Vilanterol|25mcg Once daily
58406308|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
57939166|NCT00263029|DRUG|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
57939167|NCT00263029|RADIATION|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
57939168|NCT00585611|DRUG|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
58074768|NCT04236986|DRUG|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
58074769|NCT00017108|DRUG|chlorambucil|
58294485|NCT00941304|DRUG|Buprenorphine|Single-dose of buprenorphine HCl buccal film
58406309|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
58406310|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
58406311|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
58074770|NCT00017108|DRUG|cyclophosphamide|
58074771|NCT00017108|DRUG|fludarabine phosphate|
58074772|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
58074773|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
58074774|NCT06209268|DRUG|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
58074775|NCT06209268|DRUG|Placebo|0.9% NaCl 1 ml per day in five consecutive days
58074776|NCT01992146|DRUG|Target-controlled naloxone-infusion|
58074777|NCT01992146|DRUG|Placebo|
58074778|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
58294486|NCT00941304|DRUG|Placebo Film|Single-dose of placebo buccal film
58294487|NCT00941304|DRUG|Placebo Capsule|Single-dose of oral placebo capsule
58294488|NCT05625724|DRUG|Aspirin|Experimental drug administrated orally
58294489|NCT05625724|DRUG|Placebo|Treatment for the control group
57939169|NCT00585611|OTHER|placebo|placebo
58294490|NCT02213315|DRUG|100mg Mavrilimumab|100mg Mavrilimumab
58294491|NCT02213315|DRUG|150mg mavrilimumab|150mg mavrilmumab
58294492|NCT02213315|OTHER|Placebo|Placebo
57939170|NCT02650999|DRUG|Pembrolizumab|200mg intravenously (IV)
57939171|NCT01688284|DEVICE|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
57939172|NCT02546765|DRUG|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
57939173|NCT02546765|DRUG|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
57939174|NCT02546765|DRUG|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
57939175|NCT02546765|DRUG|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
57939176|NCT03612362|DEVICE|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence \& HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements \& suitably short follow-up period to decrease attrition."
57939177|NCT03175354|DRUG|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
57939178|NCT03175354|DRUG|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
57939179|NCT05102578|BEHAVIORAL|Digital Decision Aid Tool|The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
57939180|NCT04667000|OTHER|Forced Air Warming|We will use Forced Air Warming for cesarean patient
57939181|NCT04785170|DRUG|Amino Acid|"A novel non-protein amino acid secreted by skeletal muscles which aids the cross-talk between skeletal muscles, liver, and adipose tissue at molecular levels. amino acid is generated by catabolism of the branched-chain amino acid valine. Existing literature states, amino acid induces body fat loss by increasing energy expenditure, stimulating free fatty acid (FFA) oxidation in the liver and skeletal muscle cell, and by enhancing oxygen consumption by adipose tissue and hepatocytes. It was observed that amino acid stimulated differentiation of energy storing white adipose tissue preadipocytes to an energy burning beige (brown to white) phenotype."
57939182|NCT01984164|DRUG|Candesartan|blinded
57939183|NCT01984164|DRUG|Lisinopril|Blinded
57939184|NCT03202823|PROCEDURE|blood samples|3 tubes (5 ml volume) collected during surgery
57939185|NCT03202823|PROCEDURE|recover samples of atheromatous plaque|a carotid sample collected during surgery
57939186|NCT02372565|BEHAVIORAL|Facebook and text Message|Culturally-relevant physical activity promotion program
57939187|NCT02372565|BEHAVIORAL|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
57939188|NCT02794142|PROCEDURE|renal transplantation|
57939189|NCT02794142|OTHER|No intervention|
58074779|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
57939190|NCT00305968|BEHAVIORAL|patient education|Patient education group
57939191|NCT01368536|DRUG|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
57939192|NCT01368536|DRUG|Amlodipine|Amlodipine 5 mg and 10 mg capsule
57939193|NCT01368536|DRUG|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
57939194|NCT01368536|DRUG|Placebo of Valturna Tablet|Matching placebo of valturna tablet
58294493|NCT03857698|OTHER|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~* Ice application for pain, edema control~* Patellar mobilization~* Three-way straight leg lifting exercises~* Isometric exercises around the hips and knees~* Active assisted, active, resistant knee range of motion exercises~* Heel shift exercises in supine and sitting~* Hip abduction on the side lying~* Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~* Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
58406312|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
58406313|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
58406314|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
57939195|NCT01368536|DRUG|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
57939196|NCT01129050|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
58406315|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
57939197|NCT01129050|DIETARY_SUPPLEMENT|Flaxseed Oil|Flaxseed oil capsule
57939198|NCT01129050|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule
57939199|NCT06476522|OTHER|Physiotherapy Program|In the first evaluation, 5 different exercises were shown and the patients were asked to do home exercises in accordance with the given program. The physiotherapist suggested starting with a 10-minute walk 5 times a week and then gradually increasing the walking time. The patients were given a program for balance and sensory training. They were asked to apply the physiotherapy program at least 3 days a week for 12 weeks. Weekly follow-up of the patients was carried out by the physiotherapist over the phone or face to face when they underwent routine treatment.
57939200|NCT06476522|OTHER|To Inform|The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.
57939201|NCT00501514|DRUG|Growth hormone|
57939202|NCT06441045|DRUG|Double Dose of Third-generation EGFR-TKI|Double Dose of Third-generation EGFR-TKI
57939203|NCT06441045|DRUG|Intrathecal Pemetrexed|Intrathecal Pemetrexed
57939204|NCT05708950|DRUG|KVA12123 - Dose Escalation|Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
57939205|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Escalation|Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
57939206|NCT05708950|DRUG|KVA12123 - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
58074780|NCT06234501|OTHER|Placebo|Placebo tablet once daily
58074781|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
58406316|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
58406317|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
58074782|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
58074783|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
58294494|NCT03857698|OTHER|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension"
58294495|NCT01000987|DRUG|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
58294496|NCT01000987|DRUG|placebo|placebo
58294497|NCT00242411|DRUG|Budesonide/Formoterol Turbuhaler|
58294498|NCT00242411|DRUG|Conventional Best Asthma Therapy|
57939207|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
57939208|NCT06396585|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
57939209|NCT06396585|DRUG|Anlotinib|Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
57939210|NCT06396585|DRUG|Oxaliplatin|Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
57939211|NCT06396585|DRUG|Tegafur|Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
57939212|NCT03747042|DRUG|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
58294499|NCT05221970|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
58294500|NCT05221970|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
58294501|NCT05221970|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
57939213|NCT04838223|OTHER|Hyperosmolar Response|A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.
57939214|NCT04838223|OTHER|Proparacaine Challenge Test|A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).
58294502|NCT02526485|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
58294503|NCT03058354|DRUG|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
58074784|NCT04291885|DRUG|Placebo|Placebo IV infusion
58074785|NCT06144229|DIAGNOSTIC_TEST|Self-Collection HPV testing kit from Abbott|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
58074786|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
58074787|NCT04338685|DRUG|RO7119929|RO7119929 will be administered orally as a capsule
58294504|NCT03058354|PROCEDURE|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
58406318|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
57730712|NCT06534476|OTHER|Education|"Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room."
57730713|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
57730714|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
57939215|NCT04838223|OTHER|Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers|The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.
58294505|NCT01795794|DRUG|omeprazole|
58294506|NCT03613714|OTHER|At-home Blood Pressure Monitoring|Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
58294507|NCT01583413|PROCEDURE|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
58294508|NCT03213847|DEVICE|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
57939216|NCT04838223|OTHER|Ocular Pain Assessment Survey (OPAS)|Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain \[18\]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.
57939217|NCT04838223|OTHER|Visual Analogue Questionnaire|Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.
58294509|NCT01185470|DEVICE|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
58294510|NCT06204770|OTHER|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
57939218|NCT04248387|DRUG|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
58294511|NCT03513679|PROCEDURE|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
58294512|NCT04999943|BIOLOGICAL|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
58294513|NCT01000974|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
58294514|NCT01000974|BIOLOGICAL|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
58294515|NCT01000974|BIOLOGICAL|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
57939219|NCT00376337|DRUG|Micafungin|IV
57939220|NCT00376337|DRUG|Systemic antifungal therapy|IV
57939221|NCT00794495|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
57939222|NCT00794495|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
57939223|NCT04646681|BEHAVIORAL|ConnectCare|increased monitoring between clinical mental health visits
57939224|NCT02887235|OTHER|Home Delivered, Medically Tailored Meals (HDTM)|
57939225|NCT02386748|DIETARY_SUPPLEMENT|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
58074788|NCT04338685|DRUG|Tocilizumab|"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV"
58074789|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
58074790|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
58074791|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
58294516|NCT01000974|BIOLOGICAL|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
58294517|NCT01000974|BIOLOGICAL|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
58406319|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
58406320|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
58294518|NCT01000974|BIOLOGICAL|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
57939226|NCT02386748|DIETARY_SUPPLEMENT|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
58406321|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
57939227|NCT02386748|OTHER|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
57939228|NCT01088464|BIOLOGICAL|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
57939229|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, every 2 weeks
57939230|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
57939231|NCT05392504|OTHER|Core stability exercise|The core stability training consist of three phases
57939232|NCT05392504|OTHER|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
57939233|NCT04643080|OTHER|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
57939234|NCT01505270|OTHER|Retrospective case study|Retrospective case study
57939235|NCT02020057|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
58074792|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
58074793|NCT06187064|OTHER|Mobile Van Clinic|The investigators will implement a pilot clinic one evening per week, with the primary goal of measuring a community-based extension of SHE Clinic's impact on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). The clinic will be dispatched with a driver, nurse, physician, and research assistant. The van clinic will be outfitted with space to obtain a confidential history and physical exam and include a space for sample collection. In addition to standard of care, the investigators will provide participants with rapid point-of-care HIV and STI testing, and HIV PrEP and MOUD counseling and prescriptions.
58074794|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
58074795|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
58074796|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
58074797|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
58294519|NCT01000974|BIOLOGICAL|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
58294520|NCT01000974|BIOLOGICAL|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
58406322|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
57939236|NCT01876251|DRUG|PF-03084014|Tablet, 10 mg, twice a day
57939237|NCT01876251|DRUG|PF-03084014|Tablet, 50 mg, twice a day
57939238|NCT01876251|DRUG|PF-03084014|Tablet, 100 mg, twice a day
58294521|NCT03628859|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib \[in France only\], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
57939239|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 75 mg/m\^2, every 3 weeks
57939240|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 100 mg/m\^2, every 3 weeks
57939241|NCT01998620|DRUG|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
57939242|NCT01998620|DRUG|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
57939243|NCT01998620|DRUG|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
57939244|NCT04032704|DRUG|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
57939245|NCT04032704|DRUG|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
57939246|NCT05435170|DRUG|linerixibat|linerixibat will be administered per the treatment sequence
57939247|NCT04450667|DIETARY_SUPPLEMENT|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
57939248|NCT06174051|BEHAVIORAL|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
57939249|NCT06174051|BEHAVIORAL|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
57939250|NCT04173884|OTHER|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
58406323|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
58406324|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
58406325|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
58406326|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
57730715|NCT04804358|BEHAVIORAL|Exposition Test|"During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system."
57939251|NCT04173884|OTHER|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
58074798|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
58074799|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
58074800|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
58074801|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
58406327|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
58406328|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
58406329|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
57730716|NCT04194190|DRUG|Individual Patient TCR-Transduced PBL|
57730717|NCT05282524|DEVICE|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
57939252|NCT02813278|DIETARY_SUPPLEMENT|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
58074802|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
58074803|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
58074804|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
58074805|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
58074806|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
58074807|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
58074808|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
58406330|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
58406331|NCT02118766|DRUG|Matching vehicle control|
58406332|NCT00092703|DRUG|MK0663, etoricoxib|
58406333|NCT00092703|DRUG|Comparator: Diclofenac sodium|
58406334|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
58406335|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
58406336|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
58406337|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
58406338|NCT00236496|DRUG|topiramate|
58406339|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
58406340|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
57730718|NCT05194397|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
57939253|NCT02813278|OTHER|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
57939254|NCT04607148|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
57730719|NCT05194397|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
57939255|NCT00841204|DRUG|sulindac|Given orally
57939256|NCT00841204|OTHER|placebo|Inactive agent
57939257|NCT00841204|OTHER|laboratory biomarker analysis|Correlative studies
57939258|NCT03032406|DRUG|Hydroxychloroquine|Hydroxychloroquine
57939259|NCT03032406|DRUG|Everolimus|Everolimus
57939260|NCT04143399|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
57939261|NCT04143399|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
57939262|NCT01882842|PROCEDURE|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
57939263|NCT01882842|DEVICE|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
57939264|NCT00077532|BIOLOGICAL|gp100 antigen|
57939265|NCT00077532|BIOLOGICAL|incomplete Freund's adjuvant|
57939266|NCT00077532|BIOLOGICAL|ipilimumab|
57939267|NCT00454038|DEVICE|HYPRO SORB F|resorbable, double layered, collagen membrane
57939268|NCT00277420|BEHAVIORAL|Comprehensive weight management|
57939269|NCT03035695|DEVICE|Axiostat®|
57939270|NCT03035695|DEVICE|Cotton Gauze|
57939271|NCT03163784|BIOLOGICAL|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
57939272|NCT03163784|BIOLOGICAL|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
57939273|NCT03163784|DRUG|Antibiotic|Antibiotic pre-treatment
57939274|NCT03163784|DRUG|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
57939275|NCT01535495|DRUG|Propranolol|Propranolol XL 120mg by mouth once daily
57939276|NCT04989426|OTHER|the state of health of newly arrived migrant patients in the year following their arrival in France|the state of health of newly arrived migrant patients in the year following their arrival in France
57939277|NCT02860195|OTHER|oral dose of alcohol|
58074809|NCT06709612|DRUG|AMT-143 hydrogel containing containing ropivacaine|AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine HCl equivalence basis). AMT-143 hydrogel will be provided as pre-filled syringes for administration via instillation into the surgical site after surgery and prior to suture.
58074810|NCT06709612|DRUG|Ropivacaine|5 mL Ropivacaine 10 mg/mL (1%) solution
58074811|NCT06709612|OTHER|Placebo|Saline Placebo
58074812|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
58294522|NCT02610517|BEHAVIORAL|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
58294523|NCT02610517|BEHAVIORAL|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
58406341|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
58406342|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
58406343|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
57939278|NCT02860195|DEVICE|alcotest|
57939279|NCT02860195|BIOLOGICAL|blood samples|
57939280|NCT02860195|DEVICE|Transdermal monitor|
57939281|NCT00290290|DRUG|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
57939282|NCT00290290|DRUG|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
57939283|NCT05518227|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
58074813|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
58074814|NCT01451203|DRUG|CZP|SC
58074815|NCT01451203|DRUG|methotrexate (MTX)|oral
58074816|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
58074817|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
58074818|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
57939284|NCT00189618|DRUG|Aspirin|100mg p.o. OD
57939285|NCT00189618|DRUG|Clopidogrel|75mg p.o. OD
57939286|NCT01978535|DRUG|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
57939287|NCT01978535|DRUG|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
57939288|NCT01411020|PROCEDURE|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
57939289|NCT06419192|OTHER|dietary advice|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
58074819|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
58074820|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
58074821|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
58074822|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
57939290|NCT06419192|OTHER|dietary advice alone|Advise to eat 7 dates a day from 37SA until delivery. The food will not be provided.
57939291|NCT06419192|OTHER|food supplied|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
57939292|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
58294524|NCT02404610|PROCEDURE|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
57939293|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
57939294|NCT03770091|DRUG|Theraworx|Theraworx foam applied to skin and/or compression wrap
57939295|NCT03770091|DRUG|Placebo|Placebo foam
57939296|NCT03569046|DRUG|local anaesthetic injection|ear block by 0.25% bupivacaine
57939297|NCT03569046|DRUG|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
57939298|NCT03569046|DRUG|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
57939299|NCT03569046|DRUG|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
57939300|NCT01200004|DRUG|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
57939301|NCT01200004|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
58074823|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
58074824|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
58294525|NCT02404610|PROCEDURE|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
58294526|NCT02404610|DRUG|propofol|
58294527|NCT04069884|RADIATION|regional nodal irradiation|external-beam radiotherapy (XRT)
58294528|NCT04069884|RADIATION|WBI|Whole Breast Irradiation
57939302|NCT01200004|DRUG|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
57939303|NCT01961375|DRUG|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
57939304|NCT01698866|BIOLOGICAL|Vaccin GenHevac B Pasteur|
57939305|NCT03043521|DRUG|Dexlansoprazole 60 MG|
57939306|NCT03043521|DRUG|CJ-12420 50mg|
57939307|NCT03043521|DRUG|CJ-12420 100mg|
57939308|NCT03043521|DRUG|CJ-12420 200mg|
57939309|NCT00467779|DRUG|cobimetinib|Repeating oral dose
57939310|NCT00467779|DRUG|dextromethorphan|In Stage III only: single dose of dextromethorphan
57939311|NCT00467779|DRUG|midazolam|In Stage III only: single dose of midazolam
57939312|NCT01611064|DRUG|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
58294529|NCT04069884|RADIATION|chestwall XRT|chestwall irradiation
57939313|NCT01611064|DRUG|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
57939314|NCT04643756|OTHER|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
57939315|NCT04643756|OTHER|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
57939316|NCT05126186|OTHER|haplo-SCT with PTCy|"Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic."
57939317|NCT02959528|OTHER|Working memory training|n-back training program
57939318|NCT02959528|OTHER|perceptual training|visual-perceptual training program
57939319|NCT00112775|DRUG|dasatinib|
57939320|NCT00112775|DRUG|imatinib mesylate|
57939321|NCT01353508|DRUG|LCZ696|200 mg and 400 mg tablets
58294530|NCT01255072|PROCEDURE|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
58294531|NCT01255072|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
57939322|NCT01353508|DRUG|Valsartan|160 mg tablets
57939323|NCT03755570|DIAGNOSTIC_TEST|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
57939324|NCT03755570|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
57939325|NCT03755570|DIAGNOSTIC_TEST|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
57939326|NCT03755570|DIAGNOSTIC_TEST|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
58294532|NCT06379373|OTHER|Spine manipulation; westren medicine|"First Cervical traction,than spine release method,Massage the neck for about 10 minutes to realease muscles.Doctor use his two hands work together to pull the neck forward and upward,meanwhile, the patient's head is passively rotated to the right to the maximum, being rotated slightly with appropriate force, Doctor's left thumb pushes the crooked spinous process to the right, and the reduction sound can be heard at this time.~If patient has upper thoracic spine misalignment, the dislocated segment needs to be adjusted.~If patient has scoliosis, the affected spine segment should also be adjusted. If patient's lumbar facet joints are misaligned, or one of the lumbar muscles is spasmal, also the disorder joints need to be adjusted."
58294533|NCT03362762|OTHER|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
58406344|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
58406345|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
58406346|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
58406347|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
58406348|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
58406349|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
58406350|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
58406351|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
57730720|NCT05194397|OTHER|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
57730721|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
57730722|NCT00936364|OTHER|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
57730723|NCT00936364|OTHER|Modified fast|Minimal caloric intake on days -2 and -1
57730724|NCT00936364|OTHER|Fasting|Day -1
57730725|NCT00936364|OTHER|Fasting|Days -2 and -1
58294534|NCT02864407|DRUG|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
58294535|NCT04235426|DRUG|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
58406352|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
57730726|NCT00936364|OTHER|Fasting|Days -3, -2, and -1
57730727|NCT00936364|OTHER|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
57730728|NCT04573920|DRUG|Atrasentan|Film-coated tablet
57730729|NCT05724797|DRUG|NRS-033|A single dose of NRS-033 will be administered
57730730|NCT05724797|DRUG|Placebo|A single dose of matching placebo will be administered
58074825|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
58074826|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
58074827|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
58074828|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
58074829|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
58074830|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
58074831|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
58074832|NCT06520046|OTHER|Experimental Group|Propioceptive exercises
58294536|NCT04235426|PROCEDURE|30 patients went to surgical procedure|30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
58406353|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
57730731|NCT03809182|DRUG|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
57730732|NCT03809182|DRUG|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
57730733|NCT03809182|DRUG|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
57939327|NCT03755570|DIAGNOSTIC_TEST|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
57939328|NCT04416399|DRUG|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
57939329|NCT03611283|OTHER|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
57939330|NCT03611283|OTHER|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
57939331|NCT03611283|OTHER|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
57939332|NCT03611283|OTHER|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
57939333|NCT02616614|DRUG|Onexton|Topical gel for treating acne
57939334|NCT02616614|DRUG|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
57939335|NCT02616614|DRUG|Placebo|Vehicle gel used as a placebo
57939336|NCT01538628|DEVICE|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
57939337|NCT02591381|PROCEDURE|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
58074833|NCT06520046|OTHER|Control Group|Usual exercises
58074834|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
57939338|NCT04506814|DEVICE|Endocardial PVI|Catheter based PVI
58074835|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
58294537|NCT04235426|OTHER|Injection|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
58294538|NCT04472897|DRUG|GSK2556286|GSK2556286 will be administered.
58294539|NCT04472897|DRUG|Placebo|Placebo will be administered
58294540|NCT05136677|BIOLOGICAL|Nivolumab|Specified dose on specified days
58294541|NCT05136677|BIOLOGICAL|Ipilimumab|Specified dose on specified days
57939339|NCT04506814|DEVICE|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
58074836|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
58074837|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
58074838|NCT00403429|DRUG|capecitabine|
58294542|NCT05136677|DRUG|Pemetrexed|Specified dose on specified days
58406354|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
57730734|NCT03809182|DRUG|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
57939340|NCT04862533|DRUG|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
57939341|NCT04862533|DRUG|Placebo|Participants will receive matching placebo three times a day
57939342|NCT04862533|PROCEDURE|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
57939343|NCT04532216|PROCEDURE|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
58074839|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
58074840|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
58074841|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
58074842|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
58074843|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
58074844|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
58074845|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
58074846|NCT06724874|OTHER|Web-Based Deep Relaxation Exercise|Web-based deep relaxation exercise videos have been prepared online. Each video lasts approximately 20-25 minutes. The 4-week applications will be sent to pregnant women one video each week and they will be asked to continue the exercises at home 4 times a week.
58074847|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
58074848|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
58406355|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
58074849|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
58074850|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
58074851|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
58074852|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
58074853|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
58074854|NCT03160131|DEVICE|Neuro Vision Technology|Training using Neuro Vision Technology
58294543|NCT05136677|DRUG|Cisplatin|Specified dose on specified days
58294544|NCT05136677|DRUG|Carboplatin|Specified dose on specified days
58294545|NCT00667992|DRUG|Budesonide HFA|standard daily inhaled dose
58406356|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
58406357|NCT01741142|DRUG|Placebo|Subject receiving placebo
57730735|NCT00814372|DRUG|MBX-102|capsule
57730736|NCT00814372|DRUG|Placebo|matching placebo
57939344|NCT04532216|PROCEDURE|Traditional surgery|Tendon transfer
57939345|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 200 mg"|"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
57939346|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 400 mg"|Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
57939347|NCT00372242|BEHAVIORAL|Prospective Longitudinal Interventional Stury|
57939348|NCT01837069|DRUG|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
57939349|NCT01837069|DRUG|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
57939350|NCT01837069|DRUG|Atorvastatin|80mg PO QD at preadmission testing
57939351|NCT01837069|BEHAVIORAL|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
58074855|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
58074856|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
58074857|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
58406358|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
57939352|NCT02867124|DRUG|XR-NTX|Vivitrol
57939353|NCT02867124|OTHER|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
57939354|NCT02867124|OTHER|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
57939355|NCT06537739|OTHER|Lumbar manipulation|Participant lies in the supine position, a physiotherapist faces the participant's side that will be manipulated. The participant interlocks their fingers behind their neck. Then the physiotherapist turns the participant on their side and performs a short thrust across the participant's pelvis in a posterior and inferior direction. The manipulation will be carried out on the symptomatic side, based on the participant's indication of the painful side. If the participant is unable to indicate the more symptomatic side, the physiotherapist performing the procedure will select the side. If no audible cavitation occurs during the manipulation, the physiotherapist will attempt to manipulate the opposite side. A maximum of 2 attempts per side will be allowed.
57939356|NCT06537739|OTHER|Positive communication - placebo|"Participants from Group A who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is a very effective method of treating spinal disorders, which will significantly reduce the low back pain you are experiencing (positive communication - placebo)."
57939357|NCT06537739|OTHER|Negative communication - nocebo|"Participants form Group B who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is not an effective method of treating spinal disorders, thus it may temporarily increase the low back pain you are experiencing (negative communication - nocebo)."
58074858|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
58074859|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
58406359|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
58406360|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
57730737|NCT00814372|DRUG|Actos|over-encapsulated to match MBX-102 and placebo
57730738|NCT00814372|DRUG|Metformin|greater than or equal to 1500 mg/kg day
57730739|NCT00563784|DRUG|Erlotinib|150 mg by mouth daily for 7 Weeks
58074860|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
58074861|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
58074862|NCT06724042|DRUG|ISM5939|ISM5939 tablets will be administered orally once daily (QD).
58074863|NCT06724042|DRUG|Cisplatin|Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
58074864|NCT06724042|DRUG|Docetaxel|Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
58294546|NCT00667992|DRUG|Budesonide CFC|standard daily inhaled dose
58406361|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
58406362|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
58406363|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
57730740|NCT00563784|DRUG|Carboplatin|2 AUC by vein weekly for 7 Weeks
57939358|NCT06537739|OTHER|Neutral communication|"Participants from Group C who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation has not been verified for its effectiveness in affecting your level of low back pain (neutral communication)."
57939359|NCT03128970|OTHER|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
57939360|NCT04346498|OTHER|Chest-to-back|
57939361|NCT06386965|OTHER|taking blood sample|A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
57939362|NCT02834169|OTHER|Non interventional|Data collection
57939363|NCT04630587|PROCEDURE|Indirect restorations|see the Arm description
57939364|NCT00630851|DRUG|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
57939365|NCT00630851|DRUG|Placebo|Matching placebo tablets orally once daily for 6 months
57939366|NCT06258889|BEHAVIORAL|reward-focused intervention|"Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session."
57939367|NCT06258889|BEHAVIORAL|cognitive flexibility intervention|"This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations."
58074865|NCT06724042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
58074866|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
58074867|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
58074868|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
58074869|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
58074870|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
58294547|NCT00292552|OTHER|Novel endpoint determination|Novel endpoint determination
58294548|NCT06380920|DEVICE|"AI Mindful Eating App"|"The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI."
58406364|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
58406365|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
58406366|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
58406367|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
58406368|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
58406369|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
58406370|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
58406371|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
58406372|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
57939368|NCT06258889|BEHAVIORAL|exposure|"All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions)."
57730741|NCT00563784|DRUG|Paclitaxel|45 mg/m\^2 by vein weekly for 7 Weeks
57730742|NCT00563784|RADIATION|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
57939369|NCT06258889|BEHAVIORAL|Psychoeducation|All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
57939370|NCT05232851|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
57939371|NCT05232851|BIOLOGICAL|Pembrolizumab|Given IV
57939372|NCT05232851|PROCEDURE|Computed Tomography|Undergo CT, FDG-PET/CT
57939373|NCT05232851|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
57939374|NCT05232851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57939375|NCT05232851|PROCEDURE|Biopsy|Undergo biopsy
57939376|NCT03017638|OTHER|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
57939377|NCT02730052|DEVICE|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
57939378|NCT02730052|DEVICE|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
57939379|NCT00316251|DEVICE|Vibration Plate Therapy|
58074871|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
58074872|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
58294549|NCT06380920|BEHAVIORAL|Outpatient regular follow-up|Outpatient regular follow-up
58406373|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
58406374|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
58406375|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
58406376|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
58406377|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
58406378|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
58406379|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
57939380|NCT02252536|DRUG|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
57939381|NCT02252536|DRUG|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
57939382|NCT00136526|DRUG|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
57939383|NCT04344301|OTHER|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
57939384|NCT00404820|DRUG|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
58074873|NCT01263652|DRUG|Tramadol|IM/PO tramadol
58074874|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
58074875|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
58074876|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
58074877|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
58294550|NCT05807971|DRUG|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
58406380|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
58406381|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
58406382|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
58406383|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
58406384|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
58406385|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
58406386|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
58406387|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
58406388|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
58074878|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
58074879|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
58074880|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
58074881|NCT05705310|BEHAVIORAL|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
58074882|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
57939385|NCT00404820|DRUG|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
57939386|NCT00404820|DRUG|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
57939387|NCT00806676|DRUG|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
57939388|NCT00497783|DRUG|Lactoserum|
57939389|NCT03947983|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
57939390|NCT03947983|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
57939391|NCT00842231|OTHER|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
57939392|NCT00646906|DRUG|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
57939393|NCT00646906|DRUG|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
57939394|NCT00646906|DRUG|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
58294551|NCT05807971|DRUG|Placebo|Identical capsule to the drug without the active ingredient.
58406389|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
57939395|NCT00646906|DRUG|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
57939396|NCT00646906|DRUG|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
57939397|NCT03244514|OTHER|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
57939398|NCT02692664|DEVICE|Endovascular aorto-iliac repair|
58074883|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
58074884|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
58294552|NCT03714477|PROCEDURE|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
58294553|NCT02959216|OTHER|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
58294554|NCT02959216|OTHER|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
58406390|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
58406391|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
58406392|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
58406393|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
58406394|NCT01317537|OTHER|Electronic personal health record|
58294555|NCT00931632|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
58406395|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
58406396|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
58406397|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
58406398|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
58406399|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
58406400|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
58406401|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
58406402|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
58406403|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
58406404|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
58294556|NCT00931632|DRUG|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
58406405|NCT04851210|OTHER|No intervention|No intervention
57939399|NCT00436618|DRUG|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
57939400|NCT01639768|DRUG|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
58074885|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
58074886|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
58294557|NCT03812900|DRUG|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
58294558|NCT05617807|PROCEDURE|Nanoscopic partial meniscectomy|Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
58294559|NCT05617807|PROCEDURE|Standard Partial Meniscectomy|Patients will have partial meniscectomy performed using standard arthroscopic equipment
58294560|NCT04257396|DEVICE|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
58294561|NCT03066830|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
58294562|NCT03066830|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
58294563|NCT03066830|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
58294564|NCT03066830|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
58406406|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
58406407|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
57939401|NCT02247960|DRUG|Ciprofloxacin|
57939402|NCT05948007|DEVICE|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
57939403|NCT05948007|DEVICE|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
58074887|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
58074888|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
58074889|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
58294565|NCT00004268|DRUG|midodrine|
58294566|NCT03852823|DRUG|SG001|Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
58294567|NCT06386380|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.
58294568|NCT06386380|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30
58406408|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
58406409|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
58406410|NCT06605105|DRUG|CYB003|CYB003 is a synthetic psilocybin analog
58406411|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
58406412|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
58406413|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
58406414|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
58406415|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
57939404|NCT05948007|BEHAVIORAL|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
57939405|NCT00502814|PROCEDURE|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
57939406|NCT00502814|PROCEDURE|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
57939407|NCT00502814|PROCEDURE|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
57939408|NCT00502814|PROCEDURE|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
58074890|NCT03911401|DRUG|1% OPA-15406|Twice daily
58406416|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
58406417|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
58406418|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
58406419|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
58406420|NCT00395291|DRUG|Placebo|Placebo
58406421|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
58406422|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
58406423|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
57939409|NCT03056950|DEVICE|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
57939410|NCT03130062|OTHER|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
58074891|NCT03911401|DRUG|Placebos|Twice daily
58074892|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
58074893|NCT02873806|DRUG|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
58074894|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
58074895|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
58074896|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
58074897|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
58074898|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
58406424|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
57939411|NCT00615472|DRUG|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
58074899|NCT06146010|OTHER|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
58074900|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
58074901|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
57939412|NCT00615472|DRUG|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
57939413|NCT00615472|DRUG|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
57939414|NCT06490705|OTHER|tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises|"6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board."
57939415|NCT05125094|DEVICE|TACE,Ablation|Transcatheter arterial chemoembolization
57939416|NCT00621751|DRUG|Carbamazepine|800 mg daily
57939417|NCT00621751|DRUG|Placebo|Placebo
57939418|NCT02809131|DRUG|polymixin/bacitracin|Antibacterial irrigation
58074902|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
58294569|NCT06386380|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.
57939419|NCT02809131|DRUG|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
57939420|NCT02809131|DRUG|Saline|Saline irrigation
57939421|NCT00528164|BEHAVIORAL|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
57939422|NCT01210170|DRUG|placebo|placebo inhalation before albuterol.
57939423|NCT01210170|DRUG|mometasone 400 mcg|mometasone inhalation before albuterol.
58074903|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
58074904|NCT01020812|PROCEDURE|TACE|Standard of Care
58074905|NCT01020812|PROCEDURE|SBRT|Standard of Care
58294570|NCT06386380|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
58406425|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
58406426|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
58406427|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
58406428|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
57939424|NCT01210170|DRUG|mometasone 200 mcg|200ug mometasone before albuterol.
57939425|NCT01089998|DRUG|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
57939426|NCT01089998|DRUG|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
58294571|NCT06386380|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.
58406429|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
58074906|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
58074907|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
58074908|NCT04276493|BIOLOGICAL|Zanidatamab|Administered intravenously
58074909|NCT04276493|DRUG|Docetaxel|Administered intravenously
58074910|NCT04276493|BIOLOGICAL|Tislelizumab|Administered intravenously
58074911|NCT04276493|DRUG|Capecitabine|Administered orally
58074912|NCT04276493|DRUG|Oxaliplatin|Administered intravenously
58074913|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
58074914|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
58074915|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
58074916|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
58074917|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
57939427|NCT01089998|DRUG|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
57939428|NCT01089998|DRUG|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
57939429|NCT03951051|DRUG|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
57939430|NCT03951051|DRUG|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
57939431|NCT01236105|DRUG|LY2624803|Administered orally (po), once.
58074918|NCT06623032|OTHER|Medium-Chain Fatty Acid (MCFA)|The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)
58074919|NCT06623032|OTHER|Long-Chain Fatty Acid (LCFA)|The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
57939432|NCT01236105|OTHER|Activated Charcoal|Administered po
57939433|NCT00486772|DRUG|Sevelamer (Renagel), calcium acetate (Phos-ex)|
57939434|NCT00151983|DRUG|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
57939435|NCT03877562|DRUG|Olanzapine|Olanzapine 10 mg oral tablet
57939436|NCT03877562|DRUG|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
57939437|NCT03877562|DRUG|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
57939438|NCT01624259|DRUG|LY2189265|Administered SC
57939439|NCT01624259|DRUG|Liraglutide|Administered SC
57939440|NCT01624259|DRUG|Metformin|
58074920|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
58074921|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
58074922|NCT06694935|DRUG|QX1206|QX1206 will be administered orally before bedtime
58074923|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
58074924|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
58074925|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
58074926|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
58074927|NCT03035331|PROCEDURE|Cryosurgery|Undergo cryosurgery
57939441|NCT02047539|DRUG|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
57939442|NCT02047539|DRUG|Placebo|
57939443|NCT01395251|DRUG|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
58074928|NCT03035331|BIOLOGICAL|Dendritic Cell Therapy|Given IT
58074929|NCT03035331|OTHER|Laboratory Biomarker Analysis|Correlative studies
58074930|NCT03035331|BIOLOGICAL|Pembrolizumab|Given IV
58074931|NCT03035331|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
58074932|NCT03035331|OTHER|Quality-of-Life Assessment|Ancillary studies
58074933|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
58074934|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
57730743|NCT03729219|BIOLOGICAL|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
57939444|NCT03347981|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
58406430|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
57730744|NCT03729219|OTHER|Placebo|Oral suspension
57939445|NCT03347981|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
58406431|NCT01904643|DRUG|lenalidomide|Given PO
57730745|NCT05794191|BIOLOGICAL|Vaccine Administration|PCV13 administration
57730746|NCT00818948|DRUG|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
57730747|NCT01773226|DEVICE|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
58406432|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
57939446|NCT00433680|BEHAVIORAL|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
58294572|NCT06386380|OTHER|Brief Resilient Coping Scale|The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.
58294573|NCT06386380|GENETIC|Expression of CDKN2A /p16INK4a|CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.
58294574|NCT06386380|OTHER|Immunophenotype of leukocyte subpopulations|CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).
58294575|NCT06386380|GENETIC|Telomere length|The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.
58294576|NCT06386380|OTHER|Cellular senescence|Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
58294577|NCT01618786|OTHER|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
58294578|NCT01618786|OTHER|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
58294579|NCT03717779|DIAGNOSTIC_TEST|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
58294580|NCT03216707|DEVICE|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
58294581|NCT03216707|DEVICE|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
58294582|NCT03216707|DEVICE|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
58406433|NCT01904643|DRUG|etoposide|Given IV
58406434|NCT01904643|DRUG|cytarabine|Given IV
57939447|NCT01723215|BEHAVIORAL|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
58294583|NCT03216707|OTHER|Capsaicin cream|Capsaicin cream
58294584|NCT01216878|DRUG|losartan potassium|100 mg tablet
58294585|NCT04072250|PROCEDURE|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
58294586|NCT06013449|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|Pulsed Electromagnetic Field (PEMF) Device BEMER Device consist of a total body mat (B. BODY) plus a targeted pelvic mat (B.PAD), and a Control Unit which powers the device and logs usage. Both B.BODY and B.PAD must be plugged into the Control Unit simultaneously and activated individually. B. Body must be placed on a flat surface (i.e. bed, floor, reclining chair etc.) for best results.
58294587|NCT06013449|DEVICE|Sham Pulsed Electromagnetic Feild (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
58406435|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
58406436|NCT01161550|DRUG|Cladribine|
58406437|NCT01161550|DRUG|Cytarabine|
57939448|NCT01723215|BEHAVIORAL|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
57939449|NCT01723215|BEHAVIORAL|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
57939450|NCT05281796|DIAGNOSTIC_TEST|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
58294588|NCT00000795|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
58406438|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
58406439|NCT01161550|DRUG|Midostaurin|
58406440|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
58406441|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
57939451|NCT05281796|DIAGNOSTIC_TEST|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
57939452|NCT05060705|DRUG|Efesovir|Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
57939453|NCT04903925|PROCEDURE|Impacted tooth extraction|All patients will undergo a surgical tooth extraction
58294589|NCT01899820|DRUG|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
58294590|NCT01899820|DRUG|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
58406442|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
58406443|NCT02103725|DRUG|Vehicle cream|
57939454|NCT03171844|OTHER|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
57939455|NCT05345535|OTHER|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
57939456|NCT05345535|OTHER|Walking|45 minutes of moderate tempo walking
57939457|NCT00049803|DRUG|sodium oxybate|
57939458|NCT04863079|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
57939459|NCT01700270|DRUG|dovitinib (TKI258)|
57939460|NCT01700270|DRUG|fluvoxamine|perpetrator drug; 7 days of dosing
58074935|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
58406444|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
58406445|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
57939461|NCT00002296|DRUG|Inosine pranobex|
58294591|NCT05157880|BEHAVIORAL|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
58406446|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
58406447|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
58406448|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
58406449|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
58406450|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
58406451|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
58406452|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
58406453|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
58074936|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
58294592|NCT05157880|BEHAVIORAL|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
58294593|NCT05554640|DEVICE|Acuvue® Oasys MAX 1-Day|TEST Lens
58294594|NCT05554640|DEVICE|Dailies Total 1|CONTROL Lens
58294595|NCT05860569|GENETIC|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
58294596|NCT00356161|DEVICE|interventionally implanted hepatic arterial port catheter|
57939462|NCT04973579|PROCEDURE|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
57939463|NCT00493090|BEHAVIORAL|modification of an interactive seminar|
57939464|NCT05328726|DRUG|GZR-18|As previously described in Arms
58294597|NCT05305859|DRUG|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
58294598|NCT00490347|DEVICE|VentrAssist Left Ventricular Assist Device|
58294599|NCT06523140|DEVICE|Boracare remote monitoring solution|Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
57939465|NCT05328726|OTHER|Placebo|Placebo will be dosed in an identical manner to active study drug.
57939466|NCT02019225|OTHER|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
57939467|NCT06194513|OTHER|Intervention 1: Twice a day for 1 week PIOMI|Preterm babies will receive two sessions of treatment every day for a week, for a total of 14 sessions. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
57939468|NCT06194513|OTHER|Intervention 2: Once a day for 2 weeks PIOMI|Preterm babies will receive a total of 14 sessions of treatment, one every day for two weeks. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
57939469|NCT01231256|BEHAVIORAL|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
57939470|NCT01460953|BEHAVIORAL|health literacy training video|participants will watch a training video
58294600|NCT02604030|OTHER|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
58294601|NCT06067867|OTHER|Data extraction from medical files|Data extraction from medical files
58294602|NCT03044847|OTHER|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
57939471|NCT01256151|DRUG|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
57939472|NCT01256151|DRUG|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
57939473|NCT02081404|DRUG|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
58294603|NCT00000962|DRUG|Nevirapine|
57939474|NCT02081404|DRUG|Placebo|placebo
58074937|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
58294604|NCT06613022|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
58294605|NCT06613022|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
58406454|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
58406455|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
58074938|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
58074939|NCT06297603|DRUG|Retatrutide|Administered SC
58074940|NCT06297603|DRUG|Placebo|Administered SC
58074941|NCT01406548|DRUG|BPS804 20mg/Kg|
58074942|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
58074943|NCT06058013|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
58074944|NCT06058013|DRUG|Placebo|Placebo will be administered orally
58074945|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
58074946|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
58074947|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
58074948|NCT05169567|DRUG|Abemaciclib|Administered orally.
58074949|NCT05169567|DRUG|Fulvestrant|Administered IM.
57939475|NCT04203745|DEVICE|Nonablative Fractional Diode Laser|The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
57939476|NCT01316185|DRUG|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
57939477|NCT00041925|DRUG|CGT003 (E2F Duplex Decoy)|
57939478|NCT04049955|PROCEDURE|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
57939479|NCT02882542|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
57939480|NCT05059158|RADIATION|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
57939481|NCT04609813|DIAGNOSTIC_TEST|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
57939482|NCT04588194|DRUG|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
57939483|NCT04588194|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
57939484|NCT04588194|DRUG|Dexamethasone|40 mg IV/PO days 1-4
58074950|NCT05169567|DRUG|Placebo|Administered orally.
58074951|NCT00261352|DRUG|Tesaglitazar|
58074952|NCT00261352|DRUG|Metformin|
58074953|NCT00261352|DRUG|Fenofibrate|
57939485|NCT04472143|DRUG|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
58074954|NCT06722105|BIOLOGICAL|2 infusions of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 MSC(AT) (2x10\^6 cells/kg) injection at M3
58074955|NCT06722105|BIOLOGICAL|1 infusion of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 placebo injection at M3
58074956|NCT06722105|OTHER|Placebo|Placebo at M0 and M3
58074957|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
58074958|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
58074959|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
58074960|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
58074961|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
58074962|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
58074963|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
58074964|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
57939486|NCT01715220|DRUG|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
58074965|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
58074966|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
58074967|NCT05231785|DRUG|Placebo|Placebo will be administered IT
58074968|NCT05962463|PROCEDURE|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
58074969|NCT05962463|PROCEDURE|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
58074970|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
58074971|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
57939487|NCT03961217|RADIATION|Radiotherapy|Radiotherapy as part of cancer treatment
58294606|NCT06517433|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
57939488|NCT01752660|BEHAVIORAL|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
58294607|NCT01264809|BEHAVIORAL|Specific consultation for physical activity counseling|Specific consultation
58294608|NCT01264809|BEHAVIORAL|Consultation for physical activity counseling|Specific consultation
57939489|NCT01752660|BEHAVIORAL|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
57939490|NCT01386918|DEVICE|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
57939491|NCT02607592|DRUG|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
57939492|NCT02607592|DRUG|nedaplatin+pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
58074972|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
58074973|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
58074974|NCT04116073|DRUG|INCMGA00012 (PD-1 antibody)|"1. Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~2. Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)"
58294609|NCT02202798|DEVICE|Syringe device|
58294610|NCT03952572|DRUG|Cyclophosphamide|750mg/m² ivgtt on day 1
58294611|NCT03952572|DRUG|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
57730748|NCT03085563|DRUG|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
57730749|NCT03085563|DRUG|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
57730750|NCT06496152|OTHER|questionnaire|online form used to collect all information used in questionnaire
57730751|NCT01800877|DRUG|Vasopressors|
57730752|NCT03401970|BEHAVIORAL|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
57730753|NCT03401970|BEHAVIORAL|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
57939493|NCT05997433|PROCEDURE|7days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days
57939494|NCT05997433|PROCEDURE|14 days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days
57939495|NCT01878526|DRUG|Alginic acid|Algycon 1 tab chew tid after meal
57939496|NCT01878526|DRUG|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
57939497|NCT01878526|DRUG|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
57939498|NCT01878526|DRUG|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
57939499|NCT03059095|BEHAVIORAL|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
57939500|NCT05731258|DRUG|Liposomal doxorubicin containing regimen|Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
57939501|NCT04637893|OTHER|Colonoscopy|Pt. underwent colonoscopy
57939502|NCT04206995|OTHER|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
57939503|NCT04206995|OTHER|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
57939504|NCT00943579|DRUG|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
57939505|NCT01410682|OTHER|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
58294612|NCT03952572|DRUG|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
58074975|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
58074976|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
57939506|NCT01410682|OTHER|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
57939507|NCT02600104|DEVICE|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
57939508|NCT03372928|DIETARY_SUPPLEMENT|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
57939509|NCT03372928|DIETARY_SUPPLEMENT|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
57939510|NCT02722382|OTHER|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
57939511|NCT06321289|BIOLOGICAL|Allogeneic CD19-STAR T cell|Phase 1 dose escalation (3+3): dose 1 (2×10\^6 cells/kg), dose 2 (6×10\^6 cells/kg), dose 3 (1.8×10\^7 cells/kg); Phase 2: dose of RP2D. No more than 5 × 10\^4 per kilogram of allogenic residual TCR-positive T cells harbouring in grafts can only be released for recipient infusion.
57939512|NCT06321289|DRUG|Fludarabine|Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.
57939513|NCT06321289|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
57939514|NCT05692856|DRUG|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
58074977|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
58074978|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
58074979|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
58074980|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
58074981|NCT02924922|DRUG|Mannitol|
58074982|NCT00014066|DRUG|hematoporphyrin derivative|
58074983|NCT00014066|RADIATION|brachytherapy|
58074984|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
58074985|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
58294613|NCT03952572|DRUG|Prednisone|Prednisone100mg/m² po on day1-5
58294614|NCT03952572|DRUG|Doxorubicin|50mg/m² ivgtt on day 1
58294615|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
58294616|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
58074986|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
57730754|NCT03401970|BEHAVIORAL|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
57939515|NCT05692856|DRUG|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
57939516|NCT04202523|RADIATION|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
57939517|NCT04202523|DEVICE|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
57939518|NCT06508918|DRUG|Betametasona|pressure pain threshold values of the most painful area will be recorded with a manual algometer
57939519|NCT04271085|OTHER|Observational study|No intervention involved
57939520|NCT00006254|BIOLOGICAL|salmonella VNP20009|
57939521|NCT03337542|BIOLOGICAL|AR101|AR101
57939522|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Monococcum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Monococcum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
57939523|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Aestivum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Aestivum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
57939524|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
57939525|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
57939526|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
58294617|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
58294618|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
57939527|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
57939528|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
57939529|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
57939530|NCT03827382|BEHAVIORAL|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
57939531|NCT03514030|DIAGNOSTIC_TEST|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
57939532|NCT05732662|RADIATION|SBRT|24-50Gy/8-12.5Gy/3-4f
57939533|NCT05732662|DRUG|Cadonilimab|10 mg/kg,q3w
57939534|NCT00329667|DEVICE|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
57939535|NCT02706704|DRUG|Adalimumab|
57939536|NCT05769023|BEHAVIORAL|Intervention test|behavioral sessions to promote vaccines
58074987|NCT06216600|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Participants will undergo ACT in combination with exercise and social support.
58074988|NCT06216600|BEHAVIORAL|Body weight circuit training|Participants will learn and undergo body weight circuit training in combination with ACT and social support.
58074989|NCT06216600|BEHAVIORAL|Empathetic social support|Study participants will participate in empathetic social support
58074990|NCT06216600|OTHER|Control - list of resources|A local list of resources to access exercise, therapy and social support will be provided.
58294619|NCT01290419|BIOLOGICAL|Placebo|Placebo; Day 0 and Day 30
58294620|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
58294621|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
57939537|NCT04762641|DRUG|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
58294622|NCT04824898|DRUG|Simvastatin|Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
57939538|NCT02575053|PROCEDURE|assessment of a new latex protocol|"1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,...) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol."
57939539|NCT03891342|DRUG|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
57939540|NCT00489814|BEHAVIORAL|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
57939541|NCT04297813|COMBINATION_PRODUCT|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
57939542|NCT04297813|PROCEDURE|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
58294623|NCT04824898|OTHER|injectable plasma rich fibrin|I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
57939543|NCT06048107|DRUG|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
57939544|NCT03021148|OTHER|Questionnaire|Administration of questionnaire.
57939545|NCT01814020|DRUG|MOB015B|
58074991|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
58294624|NCT04594655|PROCEDURE|surgery|colectomy
58294625|NCT04865588|PROCEDURE|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
58294626|NCT04865588|DEVICE|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
58294627|NCT04865588|DEVICE|plain old balloon|current standard treatment of stent placement
58294628|NCT02753816|DRUG|Tranexamic Acid|
58294629|NCT02753816|DRUG|Placebo Comparator|
58294630|NCT06337864|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.
58294631|NCT02106351|BIOLOGICAL|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
58406456|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
58406457|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
58406458|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
58406459|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
58406460|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
58406461|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
58406462|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
58074992|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
57939546|NCT05351983|PROCEDURE|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
57939547|NCT03649282|OTHER|HFNC|HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
58074993|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
58074994|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
58074995|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
58074996|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
58074997|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
58074998|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
58074999|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
58075000|NCT05620186|OTHER|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
58075001|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
58075002|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
58075003|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
58075004|NCT03982381|DRUG|Metformin|Active comparator
58075005|NCT03982381|DRUG|Dapagliflozin 10 MG|Experimental treatment
58075006|NCT05660070|BEHAVIORAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
58075007|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
58075008|NCT00489411|OTHER|placebo|Given orally
58294632|NCT03570775|DEVICE|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
58294633|NCT03570775|DEVICE|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
58294634|NCT02752438|DEVICE|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
58294635|NCT03630159|BIOLOGICAL|Tisagenlecleucel|Gene modified autologous T cells
58406463|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
58406464|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
57939548|NCT03649282|OTHER|NCPAP|NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
57939549|NCT00627783|OTHER|a bicycle exercise test|
57939550|NCT06010498|BEHAVIORAL|eye mask|"* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
57939551|NCT06010498|BEHAVIORAL|standart care|"Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
57939552|NCT05973552|OTHER|CO-rebreathing|In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
58075009|NCT01917396|DRUG|Fleet enema|
58075010|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
58075011|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
58075012|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
58075013|NCT05028569|DRUG|BOTOX|Intramuscular Injection
58075014|NCT05028569|DRUG|Placebo|Intramuscular Injection
58075015|NCT01958944|DRUG|Nitric oxide|
58075016|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
58075017|NCT02064491|DRUG|Erlotinib|
58075018|NCT02064491|DRUG|Chemotherapy|
58075019|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
58075020|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
58075021|NCT06445959|DRUG|Olutasidenib|Given by PO
58075022|NCT06445959|DRUG|Venetoclax|Given by PO
58294636|NCT03630159|DRUG|Pembrolizumab|anti PD-1
58294637|NCT05074134|DRUG|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
58294638|NCT05088499|GENETIC|DNA analysis|GWAS
58294639|NCT00437164|DRUG|Insulin|
58294640|NCT00437164|DRUG|Oral GW677954 Capsules (15 mg)|
57730755|NCT05197959|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
57730756|NCT05197959|OTHER|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take \~ 30 minutes to complete.
57730757|NCT03449602|DEVICE|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
57939553|NCT05973552|OTHER|Oral iron isotope administration (54Fe)|Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
57939554|NCT05973552|OTHER|Intravenous iron isotope administration (58Fe)|Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
57939555|NCT05040724|DRUG|Ivermectin|ivermectin placebo
58075023|NCT06445959|DRUG|Decitabine|Given by IV
57939556|NCT06423482|OTHER|PEEK bar|The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
57939557|NCT06423482|OTHER|Titanium bar|The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
57939558|NCT00087347|DRUG|ferumoxytol|
57939559|NCT00087347|PROCEDURE|magnetic resonance imaging|
57939560|NCT05022394|BIOLOGICAL|Nivolumab|Given IV
57939561|NCT05022394|DRUG|Sapanisertib|Given PO
57939562|NCT00346099|DRUG|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
58075024|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
58075025|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
58075026|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
58294641|NCT03923153|DEVICE|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
58294642|NCT03923153|DEVICE|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
58294643|NCT00000757|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
58075027|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
58075028|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
58075029|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
58075030|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
58294644|NCT01073826|BEHAVIORAL|Sport|
58294645|NCT01073826|DRUG|Tocilizumab|
58294646|NCT01073826|DRUG|Sitagliptin|
58294647|NCT06612476|DRUG|Interleukin 6-guided antibiotic therapy|In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
57939563|NCT00346099|DRUG|Panitumumab with capecitabine and radiation|
58294648|NCT06612476|DRUG|GOLD-guided antibiotic therapy|In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
57939564|NCT04759261|OTHER|SMAD4 expression and methylation|Effect of SMAD4 methylations on smad4 expression
57939565|NCT04163900|DRUG|NUC-1031|IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes
57939566|NCT04163900|DRUG|Gemcitabine|IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert
57939567|NCT04163900|DRUG|Cisplatin|IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol
57939568|NCT03723317|PROCEDURE|Liver transplantation|First deceased-donor liver transplantation
57939569|NCT04227886|RADIATION|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
57939570|NCT04227886|DRUG|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
57939571|NCT05635968|RADIATION|Low-dose whole brain irradiation|In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
57939572|NCT02777697|OTHER|chronic pain|
57939573|NCT03926715|OTHER|Nutritional status|
57939574|NCT01011439|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
57939575|NCT01112020|DEVICE|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
57939576|NCT01112020|DEVICE|Biopatch|Biopatch applied to 7 sites
57939577|NCT01112020|DEVICE|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
57939578|NCT02580942|DEVICE|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
57939579|NCT02580942|DEVICE|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
57939580|NCT02580942|DRUG|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
57939581|NCT01050452|DRUG|albendazole|albendazole (400 mg on dose)
57939582|NCT01050452|DRUG|mebendazole|mebendazole (500 mg one dose)
57939583|NCT01050452|DRUG|ivermectin|ivermectin (200 microgram/kg body weight)
57939584|NCT01050452|DRUG|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
58294649|NCT02923999|DRUG|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
58294650|NCT02923999|DRUG|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
57939585|NCT01050452|DRUG|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
57939586|NCT00162760|DRUG|Thalidomide|
57939587|NCT06021899|OTHER|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
57939588|NCT05296642|OTHER|Moderate Cycling|Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
57939589|NCT05296642|OTHER|Personalized Tourniquet System|An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
57939590|NCT02486653|DRUG|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
58294651|NCT02923999|DRUG|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
58294652|NCT04993209|BIOLOGICAL|NDV-HXP-S 1μg|NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
58294653|NCT04993209|BIOLOGICAL|NDV-HXP-S 3μg|NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
58294654|NCT04993209|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
58294655|NCT04993209|OTHER|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
58294656|NCT02249104|DRUG|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
58294657|NCT02249104|OTHER|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
58075031|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
58075032|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
58075033|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
58075034|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
58075035|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
58075036|NCT01390376|DRUG|placebo|starch pill
58075037|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
58075038|NCT02285582|OTHER|Registry study|No intervention.
58075039|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
58294658|NCT02686164|DRUG|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
58294659|NCT02686164|DRUG|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
58294660|NCT03851848|OTHER|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
58294661|NCT03851848|OTHER|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
58294662|NCT04024605|DIETARY_SUPPLEMENT|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
58294663|NCT04024605|DIETARY_SUPPLEMENT|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
58406465|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
57730758|NCT03449602|DEVICE|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
58406466|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
58406467|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
58406468|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
58406469|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
57939591|NCT02486653|DRUG|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
58406470|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
57730759|NCT02964936|DRUG|roxadustat|Oral administration
57730760|NCT04651452|BEHAVIORAL|Value Affirmation|Participants will complete writing tasks regarding their personal values.
57939592|NCT05916781|DRUG|Mycophenolate Mofetil|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
57939593|NCT05916781|DRUG|Tacrolimus|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
58294664|NCT04024605|DIETARY_SUPPLEMENT|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
58294665|NCT04024605|DIETARY_SUPPLEMENT|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
58294666|NCT01653145|OTHER|Diet A|Dietary
58294667|NCT01653145|OTHER|Diet B|Dietary
58294668|NCT01653145|OTHER|Diet C|Dietary
58294669|NCT00416819|BIOLOGICAL|filgrastim|
58294670|NCT00416819|BIOLOGICAL|rituximab|
58294671|NCT00416819|DRUG|cytarabine|
58294672|NCT00416819|DRUG|etoposide phosphate|
58294673|NCT00416819|DRUG|leucovorin calcium|
58294674|NCT00416819|DRUG|methotrexate|
58294675|NCT00416819|DRUG|temozolomide|
58294676|NCT04385433|DRUG|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
58294677|NCT04385433|OTHER|CONTROL GROUP|"Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
58406471|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
58406472|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
57939594|NCT05916781|DRUG|Glucocorticoid|"Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare."
57939595|NCT04434599|DEVICE|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
58294678|NCT04385433|RADIATION|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
57939596|NCT04434599|DEVICE|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
57939597|NCT04434599|DEVICE|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
57939598|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
57939599|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
58294679|NCT05441033|OTHER|Group-FHB|This is the group where pregnant women and their spouses listen to the fetal heartbeat.
58294680|NCT05441033|OTHER|Group-GIT|This is the group in which the guided imagery technique is applied to pregnant women and their spouses.
58294681|NCT06444503|OTHER|Biological samples|Blood and urine will be taken in larger quantity
58294682|NCT06444503|OTHER|Biological|Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
58294683|NCT05869669|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
58294684|NCT05869669|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
58294685|NCT03797898|OTHER|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
58294686|NCT03895359|RADIATION|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
58294687|NCT03895359|DRUG|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
58294688|NCT01676103|DIETARY_SUPPLEMENT|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
58294689|NCT01676103|OTHER|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
58294690|NCT01211756|DRUG|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
58294691|NCT01211756|DRUG|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
58294692|NCT06383026|DIAGNOSTIC_TEST|Breast Cancer Screening|Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
58294693|NCT06383026|OTHER|Survey/Interview|A mixed-methods approach including electronic surveys and one on one interviews.
57939600|NCT05872490|OTHER|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
57939601|NCT05872490|OTHER|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
57939602|NCT03726606|DEVICE|Intraocular lens|Bilateral implantation of the same intraocular lens.
57939603|NCT02508142|DRUG|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
58075040|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
58294694|NCT06383026|OTHER|Focus Group|A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for transgendered and nonbinary persons.
58294695|NCT03131115|PROCEDURE|Lateral Crural Strut Graft|surgical technique as described
58406473|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
58075041|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
58294696|NCT03131115|PROCEDURE|Bone Anchored Suspension|Surgical technique as described
58294697|NCT01158560|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
58294698|NCT01158560|BEHAVIORAL|Gargling|gargling with tap water, twice daily
58294699|NCT01158560|DIETARY_SUPPLEMENT|Placebo|matched placebo for active vitamin D
58294700|NCT02037815|DRUG|20% mannitol solution, 125 ml, IV infusion in 15 min|
58294701|NCT02037815|DRUG|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
58294702|NCT04508686|DRUG|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
58294703|NCT01050946|BIOLOGICAL|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
58294704|NCT03476057|DIAGNOSTIC_TEST|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
58294705|NCT05682833|PROCEDURE|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
58294706|NCT00571662|DRUG|Pentostatin|4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
57939604|NCT05544188|DIAGNOSTIC_TEST|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
57939605|NCT03229421|OTHER|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
57939606|NCT03590015|OTHER|Old invitation letter|Invitation Letter written by researchers/doctors
57939607|NCT03590015|OTHER|New invitation Letter|Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
57939608|NCT05608382|OTHER|sterile Phosphate Buffer Saline|control group
57939609|NCT05608382|OTHER|SGW13|active comparator
57939610|NCT03259750|OTHER|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
58294707|NCT00571662|RADIATION|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
58294708|NCT00571662|DRUG|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
58294709|NCT00571662|DRUG|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
58294710|NCT00571662|DRUG|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
58294711|NCT05722717|GENETIC|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
58294712|NCT03003247|DRUG|IDP-120 Gel|IDP-120 Gel is a combination product
57939611|NCT01329250|DRUG|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
58294713|NCT03003247|DRUG|IDP 120 Component A Gel|Monad of Component A
58294714|NCT03003247|DRUG|IDP 120 Component B Gel|Monad of Component B
58294715|NCT03003247|DRUG|IDP 120 Vehicle Gel|Vehicle
58294716|NCT00045799|DRUG|Omeprazole sodium bicarbonate immediate release PWD/FS|
58294717|NCT00045799|DRUG|Cimetidine IV|
58294718|NCT06612346|DEVICE|Minimally Invasive Micro Trabeculostomy|The MINT system is a surgical device designed to create a trabeculostomy within the eye.
58294719|NCT01834456|OTHER|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
58294720|NCT04878068|DEVICE|Theram COVID-19 Rapid Antigen Test|The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
58294721|NCT03184311|OTHER|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
58294722|NCT03184311|OTHER|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
58294723|NCT02630563|DRUG|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
58294724|NCT02630563|DRUG|Cyclosporine|Cyclosporine will be administered as per center practice.
58294725|NCT02630563|DRUG|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
58294726|NCT02829047|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
58294727|NCT03610074|OTHER|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
57939612|NCT02703415|DRUG|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
58294728|NCT03610074|PROCEDURE|Blood test|Additional blood test 5 min after mint ice cubes application
58294729|NCT03610074|OTHER|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
58294730|NCT05091983|OTHER|Sensory Processing Scale Inventory (SPSI)|The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire
58294731|NCT05091983|OTHER|Autism Spectrum Screening Quotient (ASSQ)|"The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents."
58294732|NCT05091983|OTHER|GAD 7|"The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire."
58294733|NCT05091983|OTHER|Conners abridged|"The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents."
58294734|NCT05091983|OTHER|EAT 26|"The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire."
57939613|NCT02703415|DRUG|Tramadol|caudal block with tramadol 1 mg/kg
57939614|NCT04666467|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
57939615|NCT01611948|DRUG|Aprepitant|125mg/day for 8 weeks
58294735|NCT04613518|DRUG|BMS-986165|Specified Dose on Specified Days
57939616|NCT01611948|DRUG|Placebo|125mg/d placebo pill for 8 weeks
57939617|NCT01611948|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
58294736|NCT04613518|OTHER|Placebo Comparator|Specified Dose on Specified Days
58294737|NCT00062348|DRUG|boronophenylalanine-fructose complex|
58294738|NCT00062348|DRUG|sodium borocaptate|
58294739|NCT00062348|PROCEDURE|conventional surgery|
58294740|NCT03035513|OTHER|Continuous spikes and waves during slow sleep (CSWS)|
58294741|NCT00707967|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
58294742|NCT00707967|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
58294743|NCT00707967|BIOLOGICAL|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
58294744|NCT02020369|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
58294745|NCT05854485|COMBINATION_PRODUCT|REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group|Participants in this group will receive multi-muscle FES during arm robotic training
58294746|NCT05854485|COMBINATION_PRODUCT|Robot only group|Participants in this group will receive arm robotic training only
58294747|NCT03668665|DRUG|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
58294748|NCT03668665|DEVICE|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
57730761|NCT04651452|BEHAVIORAL|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
57730762|NCT06029907|OTHER|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
57730763|NCT06029907|DRUG|Varenicline|Patients will receive varenicline prescribed by their oncologist
58294749|NCT02363387|BEHAVIORAL|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
58294750|NCT02363387|BEHAVIORAL|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
58294751|NCT06201039|DRUG|0.5% Lidocaine Hydrochloride|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
58294752|NCT06201039|DRUG|0.9% Normal Saline|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
58294753|NCT04710875|DRUG|Na-lactate|intravenous
58294754|NCT04710875|DRUG|Sodium chloride|Intravenous
58294755|NCT00974363|PROCEDURE|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
58294756|NCT02773095|OTHER|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
58294757|NCT03742986|DRUG|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
58294758|NCT03742986|DRUG|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
58294759|NCT03742986|DRUG|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
58294760|NCT03742986|DRUG|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
58294761|NCT03742986|DRUG|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
58294762|NCT03742986|DRUG|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
58294763|NCT03742986|DRUG|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
58294764|NCT01667445|DRUG|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
58294765|NCT01667445|DRUG|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
58294766|NCT03118817|DRUG|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
58294767|NCT06410651|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
58294768|NCT05855434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
58294769|NCT00149396|DRUG|NV1020|NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
58294770|NCT05868538|DIAGNOSTIC_TEST|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
58294771|NCT04019717|DRUG|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
58294772|NCT04019717|DRUG|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
58294773|NCT02871609|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
58294774|NCT01212094|DRUG|Rituximab|
58294775|NCT01212094|OTHER|normal saline|normal saline
58294776|NCT06301789|DRUG|Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries|Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
58294777|NCT05701254|PROCEDURE|Transilial bone biopsy|The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
58406474|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
58406475|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
58406476|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
58406477|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
58406478|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
58406479|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
58406480|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
58406481|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
58406482|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
58406483|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
58406484|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
58406485|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
58406486|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
58406487|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
58294778|NCT02154932|DRUG|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
58294779|NCT02154932|DRUG|single dose misoprostol|1 dose, 1 hours, prior surgery
58294780|NCT00229749|DRUG|AVI-4065 Injection|
58294781|NCT02958787|RADIATION|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
58294782|NCT04218721|OTHER|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
57730764|NCT02484794|BEHAVIORAL|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
57939618|NCT04006496|BEHAVIORAL|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
57939619|NCT03052504|OTHER|Registration of complications|Prospective registration
57939620|NCT03462420|OTHER|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
57939621|NCT05212506|BIOLOGICAL|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
57939622|NCT03920553|BIOLOGICAL|Hyaluronic acid|Topical application of hyaluronic acid following Laser assisted frenectomy
57939623|NCT01688128|DEVICE|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
57939624|NCT01688128|OTHER|Washout (2 wks)|2-weeks wash out period in both arms
58294783|NCT02431312|BIOLOGICAL|INO-1800|INO-1800 delivered by EP
57939625|NCT01688128|DEVICE|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
57939626|NCT04446962|DRUG|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
58294784|NCT02431312|BIOLOGICAL|INO-9112|INO-9112 delivered by EP
58294785|NCT02431312|DRUG|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
58294786|NCT06573229|DIETARY_SUPPLEMENT|Aminolife Plus by Piemme Pharmatech, Italy|A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)
58294787|NCT00024440|BIOLOGICAL|filgrastim|
58406488|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
58406489|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
58406490|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
58294788|NCT00024440|BIOLOGICAL|oblimersen sodium|
58294789|NCT00024440|DRUG|cyclophosphamide|
58406491|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
58406492|NCT03206632|DRUG|BI 690517|single dose
58294790|NCT00024440|DRUG|fludarabine phosphate|
58406493|NCT03206632|DRUG|Placebo|single dose
58406494|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
58406495|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
58406496|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
58406497|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
58406498|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
58406499|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
58406500|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
58406501|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
58406502|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
58406503|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
58406504|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
58294791|NCT02044757|BEHAVIORAL|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
58406505|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
58075042|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
58075043|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
58075044|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
58075045|NCT06403540|DIAGNOSTIC_TEST|ultrasonography|Using ultrasonography to measure diaphragm thickness
58075046|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
58075047|NCT06429722|DRUG|NMRA-335140 80 mg|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
58075048|NCT06429722|DRUG|Placebo|Placebo will be administered orally
58075049|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
58075050|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
58075051|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
58075052|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
57730765|NCT02484794|BEHAVIORAL|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
57730766|NCT03391479|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
57730767|NCT03391479|OTHER|Best Supportive Care|As required.
57939627|NCT04446962|DRUG|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
57939628|NCT05489692|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
57939629|NCT05058417|DRUG|Empagliflozin 10 MG|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
57939630|NCT05058417|DRUG|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
57939631|NCT03007979|DRUG|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
57939632|NCT03007979|DRUG|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
57939633|NCT03007979|DRUG|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
58075053|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
58075054|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
58075055|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
58075056|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
58075057|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
58075058|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
58075059|NCT01111058|OTHER|Placebo|
58075060|NCT06108531|OTHER||
58075061|NCT04056325|DRUG|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
58075062|NCT04056325|DRUG|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
58075063|NCT04056325|DRUG|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
58075064|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
57730768|NCT02165150|OTHER|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
57730769|NCT02361853|OTHER|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
57730770|NCT02361853|OTHER|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
57939634|NCT03007979|PROCEDURE|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
58075065|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
58075066|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
58075067|NCT05972681|DRUG|Bupivacaine|10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
58075068|NCT05972681|DRUG|Epinephrine|Epinephrine (1:200,000) injected to the vaginal laceration site.
57730771|NCT02361853|OTHER|Exposure: abundance of Immature monocytes counts in blood samples|
57730772|NCT02361853|OTHER|Exposure: abundance of Immature neutrophils counts in blood samples|
58075069|NCT05972681|OTHER|Sham normal saline arm|10 milliliter (ml) of normal saline injected to the vaginal laceration site.
57939635|NCT03007979|DRUG|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
58294792|NCT03962621|RADIATION|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
57730773|NCT04198662|DEVICE|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
57730774|NCT04198662|DRUG|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
57730775|NCT04198662|DEVICE|Sham cryoneurolysis with a Painblocker|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
57730776|NCT04198662|DRUG|Placebo intercostal nerve block with normal saline|3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
57730777|NCT00246636|DRUG|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
57730778|NCT00246636|DRUG|Antara (fenofibrate)|Antara (fenofibrate) + placebo
57730779|NCT05619614|DEVICE|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
57730780|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
57730781|NCT01306162|DRUG|Dabigatran etexilate|150 mg as single dose
57730782|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
57730783|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
57730784|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
57730785|NCT01116817|DRUG|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
57730786|NCT01116817|DRUG|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
57730787|NCT03130582|DRUG|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
57730788|NCT04271930|BEHAVIORAL|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
57730789|NCT04271930|BEHAVIORAL|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
57730790|NCT05679492|BIOLOGICAL|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
57730791|NCT05679492|OTHER|Normal saline|Normal saline
57730792|NCT06180564|OTHER|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
57939636|NCT03007979|PROCEDURE|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression"
57939637|NCT03007979|PROCEDURE|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
57939638|NCT03007979|PROCEDURE|Tumor biopsy (optional)|-Baseline and progression
57939639|NCT02277977|OTHER|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
57939640|NCT00809419|DEVICE|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
57939641|NCT02730273|DEVICE|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
58075070|NCT05489432|BEHAVIORAL|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
58294793|NCT03962621|RADIATION|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
57939642|NCT01687140|DRUG|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
57939643|NCT01687140|DRUG|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
58075071|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
58075072|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
58075073|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
58294794|NCT00818155|DRUG|desvenlafaxine succinate SR|desvenlafaxine succinate SR
58294795|NCT00818155|OTHER|Placebo|
58294796|NCT02155699|BEHAVIORAL|Exercise 1|65% of VO2max and 2 sessions per week
58294797|NCT02155699|BEHAVIORAL|Exercise 2|85% intensity and 3 sessions per peek
58294798|NCT03028675|OTHER|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
58294799|NCT02806856|DEVICE|tDCS neuroConn|Cathodal on M1
58294800|NCT02806856|DEVICE|Sham stimulation|Sham
58294801|NCT04242979|BEHAVIORAL|Questionnaire about albumin use in liver cirrhosis|"1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~3. A pilot study will be 10% done to test the clarity and feasibility of developed tool.~4. Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
58294802|NCT04312243|DRUG|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
58294803|NCT02106780|DRUG|14C-labeled ASP1707|oral
58294804|NCT02809924|OTHER|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
57939644|NCT02422342|DEVICE|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
58294805|NCT02809924|OTHER|Video training|Video describing endotracheal intubation
58294806|NCT01736735|DRUG|CLP|
58294807|NCT01736735|DRUG|placebo|
58294808|NCT00763789|OTHER|local anaesthesia and remifentanil sedation|
58294809|NCT00763789|OTHER|total intravenous anaesthesia|
58294810|NCT02408731|DRUG|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
58294811|NCT06579677|OTHER|Without any intervention|No interventions will be performed.
58294812|NCT02121171|DEVICE|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
58294813|NCT02121171|PROCEDURE|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
58406506|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
58294814|NCT02592941|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
58406507|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
58294815|NCT01678118|BEHAVIORAL|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
58294816|NCT06611943|BEHAVIORAL|DietCoach|Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
58294817|NCT01754064|DEVICE|Cardiac Rhythm Management device|
58294818|NCT04579003|OTHER|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
58294819|NCT04579003|OTHER|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
58294820|NCT05766774|OTHER|Low-added sugar, high-fat diet|Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
58294821|NCT05766774|OTHER|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be \>60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
58294822|NCT00649792|DRUG|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
58294823|NCT02413957|OTHER|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
58406508|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
58406509|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
58406510|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
58406511|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
58406512|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
58406513|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
58406514|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
57939645|NCT03805997|DEVICE|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
57939646|NCT03805997|OTHER|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
58406515|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
57939647|NCT03805997|OTHER|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
58075074|NCT06236373|OTHER|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
58075075|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
58075076|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
58075077|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
58075078|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
58075079|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
58075080|NCT00442741|DRUG|Patupilone|
58075081|NCT00442741|DRUG|Patupilone + Omeprazole|
58075082|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
58075083|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
58075084|NCT04544592|DRUG|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
58406516|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
58406517|NCT04201366|OTHER|No intervention|No intervention
58406518|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
58406519|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly.
58406520|NCT04986046|OTHER|Virtual Home Plate|Virtual Home Plate comprises two, 45-minute weekly sessions where parents work together with a study staff member to discuss the themes and prepare the components of a meal, including entrees, side dishes, and desserts.
58406521|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
58406522|NCT05385081|OTHER|genomic profiling|next generation sequencing
58406523|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
58406524|NCT04753658|DRUG|lorlatinib|Oral
58406525|NCT03085628|DRUG|Oxytocin|40IU
58406526|NCT03085628|DRUG|Placebo|40IU
58406527|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
58406528|NCT05247970|DRUG|S-309309|Capsule administered orally
58406529|NCT05247970|DRUG|Midazolam|Syrup administered orally
58406530|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
58406531|NCT05467761|DRUG|Oral Psilocybin|25mg orally
58406532|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
58406533|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
58406534|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
57939648|NCT03805997|BIOLOGICAL|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
57939649|NCT03805997|OTHER|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
58406535|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
58406536|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
58406537|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
58075085|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
57939650|NCT03805997|OTHER|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
57939651|NCT03805997|OTHER|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
58075086|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
58294824|NCT02413957|OTHER|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
58294825|NCT06608940|DRUG|BC3402|BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
58294826|NCT06608940|DRUG|Durvalumab|Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
58294827|NCT06608940|DRUG|Tremelimumab|Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
58294828|NCT02508376|OTHER|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
58294829|NCT02508376|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
58294830|NCT02508376|BIOLOGICAL|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
58294831|NCT01853293|DRUG|Kudzu extract|
58294832|NCT01853293|DRUG|Placebo|
58294833|NCT01853293|BEHAVIORAL|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
58294834|NCT00003925|DRUG|gemcitabine hydrochloride|
58294835|NCT00003925|DRUG|leucovorin calcium|
58294836|NCT00003925|DRUG|tegafur-uracil|
57939652|NCT03805997|OTHER|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
57939653|NCT03686098|DIETARY_SUPPLEMENT|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
57939654|NCT03686098|DIETARY_SUPPLEMENT|Soy Supplement|Soy isoflavones delivered in extracted form
57939655|NCT02124395|OTHER|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
58075087|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
58075088|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
58294837|NCT04494295|DEVICE|Aurora Surgiscope System|MIS evacuation of hematoma using the Aurora Surgiscope System
58294838|NCT01061697|DRUG|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
58294839|NCT02580253|DRUG|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
58294840|NCT02580253|DRUG|mFOLFOX6|Oxaliplatin,Fluorouracil
57939656|NCT02171273|BEHAVIORAL|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
57939657|NCT02171273|BEHAVIORAL|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
57939658|NCT02171273|BEHAVIORAL|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
57939659|NCT00534820|PROCEDURE|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
57939660|NCT00517153|DRUG|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
58075089|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
58075090|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
58075091|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
58075092|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
58075093|NCT04225117|DRUG|pembrolizumab|IV infusion
58075094|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
58075095|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
58075096|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
58294841|NCT06184009|DRUG|ALL, High risk|"Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
58294842|NCT02529254|BEHAVIORAL|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
58294843|NCT01973686|BEHAVIORAL|Physical activity|
58294844|NCT05886842|OTHER|Test-retest|Test-retest
58294845|NCT04328025|OTHER|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
58294846|NCT05439421|BEHAVIORAL|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
58294847|NCT05439421|BEHAVIORAL|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
58294848|NCT00014612|PROCEDURE|axillary lymph node dissection|
58294849|NCT00014612|PROCEDURE|lymphoscintigraphy|
58294850|NCT00014612|PROCEDURE|therapeutic conventional surgery|
58294851|NCT00014612|RADIATION|radiation therapy|
58406538|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
58406539|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
58406540|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
58406541|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
58294852|NCT01301300|DEVICE|Disinfecting Cap|Replace standard practice with using the disinfecting cap
58294853|NCT04464967|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
58294854|NCT04464967|DRUG|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
58294855|NCT04464967|DRUG|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
58294856|NCT01726062|BEHAVIORAL|Motivational Interviewing plus Incentives|"1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
58294857|NCT01726062|BEHAVIORAL|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
58294858|NCT02081378|DRUG|Asciminib (ABL001)|Asciminib was be administered orally in a dose escalation schedule.
58294859|NCT02081378|DRUG|Nilotinib|Asciminib and Nilotinib was administered orally in CML patients
58294860|NCT02081378|DRUG|Imatinib|Asciminib and imatinib was administered orally in CML patients
58406542|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
58406543|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
58294861|NCT02081378|DRUG|Dasatinib|Asciminib and dasatinib was administered orally in CML patients
58406544|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
58406545|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
58294862|NCT04633226|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
58294863|NCT03127319|DRUG|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
58294864|NCT03127319|DRUG|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
58294865|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
58406546|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
58406547|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
58294866|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
58406548|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
57730793|NCT04326491|DIAGNOSTIC_TEST|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
57730794|NCT01443962|OTHER|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
58294867|NCT01008865|PROCEDURE|Studer Pouch orthotopic urinary diversion|
58294868|NCT01008865|PROCEDURE|T-Pouch orthotopic urinary diversion|
58294869|NCT00151437|DRUG|Pegvisomant treatment|
58294870|NCT00151437|PROCEDURE|Medical History, demographics|
58294871|NCT00151437|PROCEDURE|Sign and symptoms: questionnaire|
58294872|NCT00151437|PROCEDURE|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
58294873|NCT00151437|PROCEDURE|MRI|
58294874|NCT01136577|DEVICE|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
58294875|NCT00994747|OTHER|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
58294876|NCT00994747|OTHER|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
58294877|NCT02871622|DEVICE|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
58294878|NCT06283953|BEHAVIORAL|Trach Plus|The Trach Plus program includes education, social support, and outreach to outpatient care team.
58294879|NCT06283953|BEHAVIORAL|Trach Me Home|The Trach Me Home discharge program includes caregiver education, skills training and case management.
58294880|NCT02019342|OTHER|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
58294881|NCT02019342|OTHER|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
58294882|NCT03875469|DEVICE|Centargo injector (BPI 1000045)|Contrast-enhanced computer tomography conducted with Centargo injector
58294883|NCT03875469|DEVICE|Stellant MP injector|Contrast-enhanced computer tomography conducted with Stellant MP injector
58294884|NCT00941200|BIOLOGICAL|Blood collection|
58294885|NCT02372344|DRUG|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
58294886|NCT03180203|DEVICE|INTELLiVENT-ASV|"After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if \>10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate \>35b/min or increases \>100% since start of SBT, FiO2 \>50%, PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
58406549|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
58406550|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
58406551|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
58406552|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
58406553|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
57730795|NCT01443962|OTHER|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
57730796|NCT05273710|OTHER|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
57730797|NCT05273710|OTHER|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
57730798|NCT05273710|OTHER|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
57939661|NCT04457180|DRUG|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
57939662|NCT04457180|DRUG|Repaglinide|Repaglinide will be administered daily on D1 and D12
57939663|NCT04457180|DRUG|Bupropion|Bupropion will be administered daily on D2 and D13
57939664|NCT05932836|OTHER|No interventions.|No interventions to be administered.
57939665|NCT01444742|DRUG|Clofarabine|"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
57939666|NCT01444742|DRUG|Cytarabine|"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"
57939667|NCT03382015|OTHER|BKR-013 or Placebo|Encapsulated L-glutamine
57939668|NCT05553483|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
57939669|NCT05553483|OTHER|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
57939670|NCT02669966|PROCEDURE|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
58406554|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
58406555|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
58406556|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
58406557|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
58406558|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
58406559|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
58406560|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
58406561|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
58406562|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
58406563|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
58406564|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
58406565|NCT04861467|DRUG|Camrelizumab|IV
58406566|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
58406567|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
58406568|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
58406569|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
58406570|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
57939671|NCT02432222|BEHAVIORAL|Visual Arts Training|Visual arts training
57939672|NCT02432222|BEHAVIORAL|Music Training|Music training
57939673|NCT01671020|DRUG|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
57939674|NCT01671020|DRUG|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
57939675|NCT00664495|BEHAVIORAL|Diet Weight Loss|
58075097|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
57730799|NCT01944046|DRUG|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
58294887|NCT03180203|DEVICE|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if \>10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate \>35b/min or increases \>100% since the start of SBT, saturation \<92% or the PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
58294888|NCT00203658|DRUG|Tinzaparin sodium|
58294889|NCT06240481|DRUG|Test Regimen|toothpaste \& mouthwash
58294890|NCT06240481|DRUG|Control Regimen|toothpaste
58294891|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
57939676|NCT00664495|BEHAVIORAL|Exercise Weight Loss|
58075098|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
58294892|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
57939677|NCT00664495|BEHAVIORAL|Exercise Without Weight Loss|
57939678|NCT04375579|OTHER|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
57939679|NCT03227471|DRUG|IVA|IVA tablet for oral administration
57939680|NCT03227471|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
57939681|NCT03227471|DRUG|VX-445|VX-445 tablet for oral administration.
58294893|NCT05028309|OTHER|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
58294894|NCT01801111|DRUG|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
58294895|NCT01801111|DRUG|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
58294896|NCT05319496|DEVICE|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
58406571|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
57939682|NCT03227471|DRUG|Matched Placebo|Matched placebo.
57939683|NCT03227471|DRUG|TEZ|Tablet for oral administration.
57939684|NCT03227471|DRUG|VX-561|Tablet for oral administration.
57939685|NCT03227471|DRUG|VX-445|VX-445 IV injection
57939686|NCT05133401|DEVICE|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
57939687|NCT05937308|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
57939688|NCT01040065|PROCEDURE|distal clavicle resection|Presence of tenderness at 2 years after surgery
57939689|NCT04103489|DRUG|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
57939690|NCT03151642|RADIATION|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
58406572|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
58406573|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
58406574|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
58406575|NCT02514694|DRUG|LEO32731|
58406576|NCT02514694|OTHER|Placebo|
58406577|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
58406578|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
58406579|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
58406580|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
58406581|NCT00000273|DRUG|opiates|prescription opioids
58406582|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
58406583|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
58406584|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
58406585|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
58406586|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
58406587|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
58406588|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
58406589|NCT06511739|DRUG|placebo|Oral tablet
58406590|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
58294897|NCT05319496|BEHAVIORAL|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
58294898|NCT00099164|DRUG|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
58294899|NCT01936363|DRUG|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
58406591|NCT02952963|DRUG|Chenodeoxycholic Acid|
58406592|NCT02952963|DRUG|Colesevelam|
58406593|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
58406594|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
58406595|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
58406596|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
58406597|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
58406598|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
58406599|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
58406600|NCT02198482|DRUG|Volasertib|
58406601|NCT02198482|DRUG|Cytarabine|
58406602|NCT02198482|DRUG|Daunorubicin|
58406603|NCT02198482|DRUG|Mitoxantrone|
58406604|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
58294900|NCT01936363|DRUG|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
58294901|NCT01936363|DRUG|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
58294902|NCT01936363|DRUG|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
58294903|NCT01936363|DRUG|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
58294904|NCT00181675|DRUG|galantamine HBr|
58294905|NCT06206512|DRUG|Extended release torsemide|This is an extended-release formulation of torsemide
58294906|NCT06206512|DRUG|Immediate release torsemide|This is the generic, immediate release formulation of torsemide
58294907|NCT06206512|DRUG|Extended release torsemide placebo|Placebo of extended release torsemide
58294908|NCT06206512|DRUG|Immediate release torsemide placebo|Placebo of immediate release torsemide
58294909|NCT04598217|OTHER|anesthesiologist|non-interventional observational
58294910|NCT01367249|DRUG|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
58294911|NCT01367249|DRUG|Placebo|Sterile ophthalmic solution
58294912|NCT03839394|BEHAVIORAL|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
58294913|NCT03839394|OTHER|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
58294914|NCT03172598|DRUG|MT-8554 low dose|Capsule
58294915|NCT03172598|DRUG|MT-8554 middle dose|Capsule
58294916|NCT03172598|DRUG|MT-8554 high dose|Capsule
58294917|NCT03172598|DRUG|Placebo|Capsule
58294918|NCT04610138|DRUG|CNM-ZnAg|ZnAg liquid solution
58294919|NCT04610138|DRUG|Placebo|Water
58294920|NCT01218542|RADIATION|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
58294921|NCT02210520|DEVICE|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
58294922|NCT02210520|DEVICE|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
58294923|NCT02210520|DEVICE|laser|1 W/cm², 2 minutes in 6 points around the back spine
58294924|NCT05713357|PROCEDURE|Catheter ablation|Endocardial catheter ablation
58294925|NCT03568578|DRUG|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
58294926|NCT03568578|DRUG|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
58294927|NCT02813928|GENETIC|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
58294928|NCT02574364|RADIATION|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
58294929|NCT02574364|OTHER|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
58294930|NCT04621032|DIAGNOSTIC_TEST|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
58294931|NCT04621032|DIAGNOSTIC_TEST|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
58294932|NCT04258124|OTHER|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
58294933|NCT02143219|DRUG|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
58294934|NCT02143219|DRUG|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
58294935|NCT02143219|DRUG|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
58294936|NCT02143219|DRUG|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
58294937|NCT05293522|COMBINATION_PRODUCT|NTX-001|2 solutions plus a delivery device; one time use surgical product
58406605|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
58075099|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
58075100|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
58075101|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
58075102|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
58075103|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
58075104|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
58075105|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
58075106|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
58075107|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
58075108|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
58075109|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
58075110|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
58294938|NCT05317429|OTHER|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
58406606|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
58075111|NCT06718413|DRUG|hyaluronidase plus saline|Injection of study drug with saline
58075112|NCT06718413|DRUG|saline|injection of normal saline and no study drug
58075113|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
58075114|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
58075115|NCT06724250|DEVICE|Biofeedback therapy|Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.
58075116|NCT06724250|DRUG|Botulinum Toxin A (Botox )|Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
58075117|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
58075118|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
58075119|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
58075120|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
58075121|NCT06722040|OTHER|Implementation of a pediatric triage track|In 2023, a pediatric triage track was implemented at MH1813 to route calls concerning children to specialists in pediatrics, ensuring better expertise.
58075122|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
58294939|NCT03423212|BEHAVIORAL|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
57939691|NCT03151642|RADIATION|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
57939692|NCT03151642|PROCEDURE|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
57939693|NCT03151642|DEVICE|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
57939694|NCT03151642|OTHER|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
57939695|NCT00282178|DRUG|Hydrochlorothiazide|25-50 mg once daily
57939696|NCT00282178|DRUG|Placebo|Once daily
57939697|NCT00282178|DRUG|Candesartan|16-32 mg once daily 12 weeks
57939698|NCT03042104|DEVICE|Edwards SAPIEN 3 / SAPIEN 3 Ultra THV|Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
57939699|NCT05895162|DRUG|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
57939700|NCT05895162|DRUG|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
57939701|NCT01825642|PROCEDURE|nerve-sparing radical prostatectomy|
57939702|NCT01825642|PROCEDURE|seminal vesicle-sparing radical prostatectomy|
57939703|NCT04326699|PROCEDURE|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
57939704|NCT03525106|BEHAVIORAL|Booklet|Receive positive psychology manual
57939705|NCT03525106|BEHAVIORAL|Exercise Intervention|Complete positive psychology exercises
57939706|NCT03525106|OTHER|Quality-of-Life Assessment|Ancillary studies
57939707|NCT03525106|OTHER|Survey Administration|Ancillary studies
57939708|NCT03525106|BEHAVIORAL|Telephone-Based Intervention|Participate in phone sessions
57939709|NCT02632396|DRUG|Ixazomib|Given PO
57939710|NCT02632396|BIOLOGICAL|Rituximab|Given IV
57939711|NCT05454436|PROCEDURE|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
57939712|NCT06026748|DRUG|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
57939713|NCT06026748|DRUG|Placebo|Placebo contains only excipients.
57939714|NCT05768581|OTHER|Concurrent Training|Participants should perform strength training and aerobic exercises
58075123|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
58294940|NCT03423212|BEHAVIORAL|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
57939715|NCT05768581|OTHER|Strength Training|Participants should perform strength exercises
57939716|NCT05768581|OTHER|Aerobic training|Participants should perform aerobic exercises
57939717|NCT06057584|BEHAVIORAL|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
57939718|NCT06057584|BEHAVIORAL|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
57939719|NCT06057584|BEHAVIORAL|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
58075124|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
58075125|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
58075126|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
58075127|NCT06722404|DIETARY_SUPPLEMENT|Standard therapeutic foods|All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days
58294941|NCT00003483|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
58294942|NCT05219968|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
58294943|NCT05219968|DRUG|Sham procedure control|Sham procedure control
58294944|NCT05219968|OTHER|Background Therapy|Daily Saline Irrigation
58294945|NCT06420037|DEVICE|Hearing aid feature adjustment (frequency compression) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely frequency compression turned off, to the basic setting.
58294946|NCT06420037|DEVICE|Hearing aid feature adjustment (noise reduction) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely noise reduction turned off, to the basic setting.
58294947|NCT06420037|BEHAVIORAL|Cognitive screening and vision screening|The Dutch Montreal Cognitive Assessment will be assessed. The Snellen Eye Test will be used to screen for normal or corrected-to-normal vision.
58294948|NCT06420037|BEHAVIORAL|Audiological Assessment|Three audiological tests are included: 1) Tympanometry to assess the middle ear status, 2) Pure-tone audiometry with headphone to evaluate the hearing thresholds, 3) Speech audiometry in free field to assess the ability to understand spoken sentences in quiet and in the presence of background noise.
58294949|NCT06420037|BEHAVIORAL|Questionnaires|"Three questionnaires are included:~1. The HAVICOP questionnaire to assess the hearing-related quality of life (Ceuleers, D., Baudonck, N., Keppler, H., Kestens, K., Dhooge, I., \& Degeest, S. (2023). Development of the hearing-related quality of life questionnaire for auditory-visual, cognitive and psychosocial functioning (hAVICOP). Journal of communication disorders, 101, 106291.)~2. the FAS (fatigue assessment scale) to assess how you usually feel~3. the EEAS (extended effort assessment scale) to assess how you experience listening in everyday life."
58294950|NCT06420037|BEHAVIORAL|Cognition|Four cognitive functions, important for speech understanding, will be assessed both audibly and visually: divided attention, working memory, processing speed, and cognitive flexibility and inhibition.
58294951|NCT06420037|OTHER|Real ear measurement|This test will give an objective assessment of the hearing aids' configuration.
58294952|NCT01935024|OTHER|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
58294953|NCT04576728|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days.
57939720|NCT05080972|BEHAVIORAL|in-the-kNOW mobile app|"in-the-kNOW is a mobile app with restricted access through a single-use registration code.~The app will be developed with regular input from Black women enrolled in Atlanta Healthy Start Initiative (AHSI).~The app will have culturally- and contextually targeted HIV prevention and optimal sexual health messaging.~Each participant will have 4 months to engage with the app, with e-reminders in time intervals preferred by the participants (a minimum of 3 times per week) via push notifications. During the 4-month study period, participants will receive push notifications to encourage the use of all app domains: My Logger, My Test, My Resources, and My Circle.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
57939721|NCT05080972|BEHAVIORAL|Control|"The control condition will be a one-time virtual women's health counseling session with a healthcare provider. Participants will get information on~1. Sexual Transmitted Infections (STI)/HIV prevention,~2. Family planning, and~3. General health promotion (e.g., exercise and diet).~The control condition provides access to HIV prevention materials that are publicly available but that do not offer the dynamic and individually customized features of the health communication/new media research approach proposed herein.~Control group participants will continue to receive the usual care associated with Atlanta Healthy Start Initiative (AHSI) enrollment.~The control group will not have access to intervention content (e.g. commodity ordering) until after the study has concluded.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
57939722|NCT00966420|DEVICE|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
58075128|NCT06722404|COMBINATION_PRODUCT|Therapeutic foods plus Synbiotics|the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
58075129|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
58075130|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
58075131|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
58075132|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
58075133|NCT06724562|OTHER|Anti-IL1 Therapy|Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients
58294954|NCT04576728|OTHER|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days.
58075134|NCT06722378|OTHER|Access to medical notes|Inpatient notes shared in real-time on a hospital-owned bedside tablet linked to their child's records.
58075135|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
58075136|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
58075137|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
58406607|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
58406608|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
58406609|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
58406610|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
58406611|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
58406612|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
58406613|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
58406614|NCT02073838|DRUG|Ribavirin|
57939723|NCT05102084|DEVICE|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
57939724|NCT01265615|DRUG|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
57939725|NCT01265615|DRUG|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
57939726|NCT01265615|DRUG|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
57939727|NCT01265615|DIETARY_SUPPLEMENT|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
57939728|NCT01187550|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.
57939729|NCT03636620|DEVICE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
57939730|NCT03636620|DEVICE|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
57939731|NCT01499784|BEHAVIORAL|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
57939732|NCT00932360|DEVICE|TENS|Active TENS, Placebo TENS and No Treatment TENS
57939733|NCT04000789|DRUG|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
57939734|NCT02685579|OTHER|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
57939735|NCT02782936|OTHER|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
58075138|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
58075139|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
58075140|NCT01405989|DRUG|darexaban|oral
58075141|NCT01405989|DRUG|ketoconazole|oral
58075142|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
58075143|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
58075144|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
58294955|NCT03421938|OTHER|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
58294956|NCT03339817|DIAGNOSTIC_TEST|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
58294957|NCT00080015|DRUG|Diflomotecan (BN80915)|
58294958|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
58294959|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
58294960|NCT00631254|PROCEDURE|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
58294961|NCT00631254|PROCEDURE|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
58294962|NCT05630443|PROCEDURE|prone position|Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
58294963|NCT01945346|DRUG|PRX167700|Oral capsule
58294964|NCT01945346|DRUG|Placebo|Oral capsule
58294965|NCT05501392|BEHAVIORAL|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
58294966|NCT01639612|BIOLOGICAL|ALD-451|ALD-451 iv
58294967|NCT01637714|DRUG|Multi-strain probiotics|"* B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
58294968|NCT01637714|DRUG|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
58294969|NCT02449421|BEHAVIORAL|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
58294970|NCT02449421|BEHAVIORAL|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
58294971|NCT01470703|DEVICE|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O
58294972|NCT01470703|OTHER|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for \>6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
58406615|NCT02073838|DRUG|Vismodegib|
58406616|NCT02073838|DRUG|Decitabine|
58406617|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
58406618|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
58406619|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
58406620|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
58406621|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
58406622|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
58406623|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
58075145|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
58406624|NCT01391572|DRUG|cisplatin|
58406625|NCT01391572|DRUG|fluorouracil|
57939736|NCT02782936|DEVICE|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
57939737|NCT02008279|BIOLOGICAL|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
57939738|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
57939739|NCT02008279|BIOLOGICAL|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
57939740|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
57939741|NCT02008279|DRUG|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
57939742|NCT04946279|OTHER|Best Practice|Receive usual/standard of care
57939743|NCT04946279|OTHER|Informational Intervention|Receive conversation tool
57939744|NCT04946279|OTHER|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
57939745|NCT01089920|OTHER|Green tea|Infusion (tea bags) from commercially available green tea
57939746|NCT01089920|OTHER|Coffee|Soluble coffee commercially available
57939747|NCT01462136|DRUG|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
57939748|NCT05803408|OTHER|gluten-free oats|Early vs late introduction of gluten free oats
57939749|NCT00780819|DEVICE|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
57939750|NCT02101021|DRUG|Momelotinib|Tablet (s) administered orally once or twice daily
58294973|NCT05382546|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
58294974|NCT03653845|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
58406626|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
57939751|NCT02101021|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
57939752|NCT02101021|DRUG|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
58075146|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
58075147|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
58406627|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
58406628|NCT04488159|DRUG|Capecitabine|Tablet
58406629|NCT04488159|DRUG|Oxaliplatin|Infusion
58406630|NCT04488159|DRUG|Fluorouracil|Infusion
58406631|NCT04488159|DRUG|Leucovorin|Infusion
57939753|NCT02101021|DRUG|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
57939754|NCT05287971|BEHAVIORAL|Lifestyle advice|Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.
57939755|NCT03838055|PROCEDURE|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
57939756|NCT04290520|OTHER|bioassay|Serum progesterone level (ng/ml)
57939757|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
57939758|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
57939759|NCT01516840|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
57939760|NCT01516840|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
57939761|NCT05615051|DEVICE|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
57939762|NCT02801136|BEHAVIORAL|ReACT|
57939763|NCT02801136|BEHAVIORAL|Supportive Therapy|
57939764|NCT03429881|PROCEDURE|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
57939765|NCT00005036|DRUG|irinotecan hydrochloride|Given IV
57939766|NCT00005036|DRUG|oxaliplatin|Given IV
57939767|NCT00005036|DRUG|leucovorin calcium|Given IV
57939768|NCT00005036|DRUG|fluorouracil|Given IV
57939769|NCT00005036|PROCEDURE|quality-of-life assessment|Ancillary studies
57939770|NCT02862405|OTHER|vision tests|
57939771|NCT04638959|OTHER|collect gastric tissue and stool samples|collect gastric tissue and stool samples
57939772|NCT01758458|BIOLOGICAL|Aldesleukin|Given SC
57939773|NCT01758458|OTHER|Laboratory Biomarker Analysis|Correlative studies
57939774|NCT01758458|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
57939775|NCT01758458|RADIATION|Radiation Therapy|Undergo radiation therapy
57939776|NCT01758458|BIOLOGICAL|Recombinant Interferon Beta|Given intralesionally
58406632|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
58406633|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
58406634|NCT01904916|PROCEDURE|Histological biopsy procedure|
58406635|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
58075148|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
58075149|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
58075150|NCT05219110|OTHER|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing \< 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
58075151|NCT05219110|OTHER|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
58075152|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
58075153|NCT05836649|BEHAVIORAL|Oculus Go headset without active intervention|VR software with non-interactive content.
58075154|NCT05836649|BEHAVIORAL|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
58075155|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
58075156|NCT06724354|OTHER|The Surgical Site Infections Precaution Package Form includes the parameters that should be applied to patients before, during and after surgery.|Surgical site infections are a preventable cause of morbidity following surgical procedures. Strategies to reduce SSI rates should address preoperative, perioperative and postoperative factors, and multiple interventions can be combined into 'bundles'. Adoption of these measures may reduce SSIs, but this is dependent on a high level of package compliance. The aim of this study was to evaluate the change in SSI rates after the implementation of the SSI prevention package after neurosurgical operations. It is thought that if the results of our study are positive, the package form created will be pioneered for use in other patient groups. In addition, reducing SSI rates will shorten the postoperative recovery time of patients and reduce hospital costs.
58075157|NCT00078689|DRUG|Daclizumab|
58075158|NCT06514170|OTHER|No intervention|No intervention
58075159|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
58075160|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
58075161|NCT06464081|OTHER|Sleep quality assessment|1. Pediatric Sleep Questionnaire.
58075162|NCT06464081|OTHER|Anthropometry|2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
58075163|NCT06464081|OTHER|Tongue strength assessment|3. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
58075164|NCT06464081|OTHER|Tongue endurance assessment|6. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
58075165|NCT06464081|OTHER|Orofacial praxis assessment|8. Motricité Bucco-Linguo-Faciale (MBLF) test.
58075166|NCT00004173|DRUG|oxaliplatin|
58075167|NCT00004173|DRUG|paclitaxel|
58075168|NCT05623319|DRUG|Pembrolizumab/Olaparib|Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
58075169|NCT00462501|BIOLOGICAL|bevacizumab|
58075170|NCT00462501|DRUG|fluorouracil|
58075171|NCT00462501|DRUG|leucovorin calcium|
58075172|NCT00462501|DRUG|oxaliplatin|
58075173|NCT00462501|PROCEDURE|conventional surgery|
58075174|NCT00462501|RADIATION|radiation therapy|
58075175|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
58075176|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
58075177|NCT06715761|OTHER|Myofascial release|The sequence of myofascial release is as follows: 30 seconds of contact between the therapist's hands and the entire region of the participant's spine, sliding with medium pressure in a caudocranial direction; palpation of the erector spinae, quadratus lumborum, gluteus and piriformis muscles bilaterally, to identify trigger points, marking each point of tension with a dermographic pencil for subsequent manipulation; 3 cycles of bilateral paravertebral release, by sustained pressure with crossed hands, until the restrictive tissue barrier is found, for 60 seconds; 90 seconds of the vertical rolling technique (superficial elevation of the skin and mobilisation of the tissue with the tips of all the fingers) on the bilateral paravertebrals and, at the end, sliding along the entire length of the bilateral multifidus, with the fingers flexed, using the bony prominence between the proximal and middle phalanges as contact with the skin, in a caudocranial direction and returning craniocaudal.
58294975|NCT03653845|DRUG|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
58294976|NCT05104073|BEHAVIORAL|Intervention|Provided with educational materials, guidelines and instructions.
58294977|NCT01747356|DEVICE|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
58294978|NCT06280898|PROCEDURE|Remote ischemic conditioning|Remote ischemic condition
58075178|NCT06715761|OTHER|Cupping therapy|The acrylic cups (DongBang®) will be placed on the meridional points, as Traditional Chinese Medicine calls them, 1 cup in the central region of each popliteal fossa, the so-called B40 or Wei Zhong point, 6 cups in the region of the quadratus lumborum muscles, more specifically on the BL23 or Shenshu points (approximately 5 centimetres lateral to the edge of the L2 spinous process), BL24 or Qihaishu (approximately 5 centimetres lateral to the edge of the spinous process of L3) and BL25 or Dachangshu (approximately 5 centimetres lateral to the edge of the spinous process of L4) bilaterally, as well as a cup on a single point of the participant's choice, where they report the most lower back pain (ashi point). The cups will be attached to the skin using a gun, applying two suction pressures, and the participant will be asked to signal whether the pressure is strong or weak. The cups will remain attached for 12 minutes on the B40 meridian and 15 minutes on the other meridians. If a cup lo
58075179|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
58075180|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
58075181|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
58075182|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
58075183|NCT00207831|DRUG|Tegafur and Uracil|
58075184|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
58075185|NCT06724744|OTHER|Aerobic training|For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.
58075186|NCT06724744|OTHER|Manual Diaphragm Release|The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
58075187|NCT05593185|BIOLOGICAL|Galinpepimut-S|
58075188|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
58075189|NCT05653388|OTHER|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
58075190|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
58075191|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
58075192|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
58075193|NCT05859334|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58075194|NCT05859334|DRUG|Erdafitinib|Given PO
58075195|NCT05859334|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58075196|NCT05859334|PROCEDURE|Optical Coherence Tomography|Undergo OCT
58075197|NCT05653882|BIOLOGICAL|AB248|Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug
58075198|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
58075199|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
58075200|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
58075201|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
58075202|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
58075203|NCT04881669|DEVICE|obturator|variable bulbs
58075204|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
58075205|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
58075206|NCT05372614|PROCEDURE|Biopsy|Correlative studies
58075207|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58075208|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
58075209|NCT05372614|PROCEDURE|Echocardiography|Undergo echocardiography
58075210|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
58075211|NCT05372614|DRUG|Neratinib Maleate|Given PO
58075212|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
58075213|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
58075214|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
58075215|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
57939777|NCT04196738|OTHER|ventilation strategy|Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
57939778|NCT00215124|DRUG|Filgrastim|
58294979|NCT01234597|DRUG|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
57939779|NCT00613444|DEVICE|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
57939780|NCT01128361|BEHAVIORAL|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
57939781|NCT01128361|BEHAVIORAL|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
57939782|NCT06292572|PROCEDURE|Retinal Detachment Surgery|Retinal Detachment Surgery that consists in either Pars Plana Vitrectomy or Scleral Buckling or a combination of both techniques, and with or without use of intraocular tamponade
57939783|NCT01805596|DRUG|clopidogrel|
57939784|NCT01805596|DRUG|Ticagrelor|
57939785|NCT00699803|DRUG|T-PRED|T-PRED sterile ophthalmic solution
57939786|NCT00699803|DRUG|Pred Forte|Pred Forte sterile ophthalmic solution
57939787|NCT04969445|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
57939788|NCT00943891|PROCEDURE|Tumor biopsies|
57939789|NCT05501145|PROCEDURE|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
57939790|NCT02941874|OTHER|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
57939791|NCT05380258|OTHER|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
57939792|NCT05380258|OTHER|chewing gum|Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
57939793|NCT01181076|DIETARY_SUPPLEMENT|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
57939794|NCT06072989|BIOLOGICAL|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
57939795|NCT03253757|OTHER|This study is non-interventional.|This study is non-interventional.
57939796|NCT03745833|DEVICE|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
57939797|NCT04042168|DIAGNOSTIC_TEST|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
57939798|NCT05464706|DIETARY_SUPPLEMENT|Synchrolevels|Supplement therapy to model the recovery after liver surgery
57939799|NCT00955279|DRUG|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
57939800|NCT00955279|DRUG|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
57939801|NCT00955279|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
58075216|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
58075217|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
58075218|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
58075219|NCT06722638|OTHER|Use of Virtual Reality Headset|Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
57939802|NCT05197348|BEHAVIORAL|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
58294980|NCT01234597|DRUG|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
58294981|NCT03462784|OTHER|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
58294982|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
58406636|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
58406637|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
58406638|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
58406639|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
58406640|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
58406641|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
58406642|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
58406643|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
58406644|NCT01602783|OTHER|11C Acetate Imaging|Single scan
57939803|NCT05197348|BEHAVIORAL|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
57939804|NCT02823795|BEHAVIORAL|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
57939805|NCT00998049|DRUG|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
57939806|NCT00998049|DRUG|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
58075220|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
58294983|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
58294984|NCT00402792|DRUG|Placebo|2 tablets q 12 hours
58406645|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
58406646|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
58406647|NCT02795507|BEHAVIORAL|conventional exercises|
58406648|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
58406649|NCT03848208|DRUG|placebo|matching placebo oral tablet
58406650|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
58406651|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
58406652|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
58406653|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
58406654|NCT05341895|OTHER|Kinesiotape|Taping
58406655|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
58406656|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
57939807|NCT05273879|PROCEDURE|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
57939808|NCT05273879|PROCEDURE|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
57939809|NCT02319668|DRUG|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
57939810|NCT02319668|DRUG|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
58075221|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
58075222|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
58075223|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
58075224|NCT05428176|OTHER|Best Practice|Receive usual care
58075225|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
58075226|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
58075227|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
58075228|NCT06723249|DIETARY_SUPPLEMENT|stingless bee honey|Participants under intervention group will receive 20g of stingless bee honey in a packet form but participants under control group will not receive any stingless bee honey
58406657|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
58075229|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
58075230|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
58075231|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
58075232|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
58406658|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
58406659|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
58406660|NCT06608901|DRUG|REGN7544|Administered per the protocol
58406661|NCT06608901|DRUG|PB|Administered per the protocol
58406662|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
58406663|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
58406664|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
58406665|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
58406666|NCT02068690|DRUG|Placebo|Placebo
58406667|NCT02068690|DRUG|Placebo|Placebo
58406668|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
58075233|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
58406669|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
58406670|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
58406671|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
58406672|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
58075234|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
58075235|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
58075236|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
58294985|NCT04300712|BEHAVIORAL|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
58294986|NCT04848636|DIAGNOSTIC_TEST|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
58294987|NCT00378885|BEHAVIORAL|Cognitive-behavioral tailored intervention|
58294988|NCT05679245|DIAGNOSTIC_TEST|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
57730800|NCT01944046|DRUG|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
57939811|NCT04502004|DEVICE|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
57939812|NCT00797875|PROCEDURE|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
57939813|NCT00797875|PROCEDURE|passive stretching|passive stretching x 5 repetitions continue 3 days
57939814|NCT02957591|DIETARY_SUPPLEMENT|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
58075237|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
58075238|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
58075239|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
58075240|NCT06083038|DRUG|Alpelisib|Patients will receive standard of care alpelisib
58075241|NCT06083038|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
57730801|NCT01944046|DRUG|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
58075242|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
58075243|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
57730802|NCT01870271|BEHAVIORAL|Developmentally adapted cognitive processing therapy|
58075244|NCT02040415|DRUG|Placebo drug of DW-1030|
57730803|NCT06365580|DRUG|Kylo-0603 capsule|Administrated orally.
57939815|NCT02957591|OTHER|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
57939816|NCT05575037|DRUG|Dupilumab|8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
57939817|NCT01039077|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
57939818|NCT06289322|OTHER|Digital toolkit for assessment|The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
57939819|NCT00122681|BIOLOGICAL|Cervarix™|Intramuscular injection, 3 doses
57939820|NCT00122681|BIOLOGICAL|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
57939821|NCT00110292|BEHAVIORAL|Age-specific parenting newsletters and developmental toys|
57939822|NCT00110292|BEHAVIORAL|Parent-completed Ages & Stages Questionnaires|
58075245|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
57939823|NCT00110292|BEHAVIORAL|Clinic-based distribution of children's books|
57939824|NCT04551222|DRUG|probenecid|1 gr. orally of probenecid twice daily for 180 days
58075246|NCT00175552|BEHAVIORAL|Psychotherapy Training|
58075247|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
58075248|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
58075249|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
58075250|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9\<5) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9\<5) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
58075251|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
58075252|NCT06665009|DEVICE|Manually Opened and Device-Opened Ampoules|this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
57730804|NCT06365580|DRUG|Placebo|Administrated orally.
57939825|NCT04551222|DRUG|Placebo|identical tablets to probenecid
57939826|NCT06460675|PROCEDURE|Autogenic Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
57939827|NCT06460675|PROCEDURE|Reciprocal Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
57939828|NCT00956774|PROCEDURE|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
57939829|NCT00956774|PROCEDURE|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
57939830|NCT00956774|PROCEDURE|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
57939831|NCT02967705|BEHAVIORAL|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
57939832|NCT02043548|DRUG|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
57939833|NCT02043548|DRUG|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
57939834|NCT02161575|DRUG|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
58075253|NCT06724393|OTHER|Blood flow restrictions in combination with low-intensity resistance training|Blood flow restrictions in combination with low-intensity resistance training to test if an online intervention (telehealth) can improve functional capacity and balance in older adults
58075254|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
58075255|NCT05056909|OTHER|Standard of care|Standard of care
58075256|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
58075257|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
58075258|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
58406673|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
58406674|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
58406675|NCT06303648|DRUG|Methylone|Oral dose of methylone
57939835|NCT00878111|DRUG|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
57939836|NCT06452966|OTHER|traditional Chinese medicine|"patients in the group will receive one of or a combination of the following interventions:~Oral Chinese medicine decoction:~The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs."
57939837|NCT06452966|OTHER|Routine ICU care|Patients will receive ICU care
57939838|NCT06452966|OTHER|historical Routine ICU care|Patients had received ICU care
57939839|NCT00856960|DRUG|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
57939840|NCT00856960|DRUG|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
57939841|NCT00856960|DRUG|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
58075259|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
58075260|NCT05078658|OTHER|Low-carbohydrate diet|The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
58075261|NCT05078658|OTHER|Recommended-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.
58406676|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
58406677|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
58406678|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
57939842|NCT00856960|DRUG|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
57939843|NCT00856960|DRUG|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
57939844|NCT01848184|DEVICE|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
57939845|NCT04651543|OTHER|X-Ray|X-ray obtained at one-week of the fracture
57939846|NCT01932242|BIOLOGICAL|ETI-204|Monoclonal Antibody
57939847|NCT01932242|OTHER|Placebo|Placebo for ETI-204
58075262|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
58075263|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
58075264|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
58075265|NCT04920097|OTHER|In-person training for seed placement and APA|In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
58075266|NCT04920097|OTHER|Virtual training for seed placement and APA|Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
58075267|NCT04920097|OTHER|Usual Care|Participants will continue with usual care from oncologist.
58294989|NCT04710069|BEHAVIORAL|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
58294990|NCT05177640|DRUG|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
58294991|NCT05549583|DRUG|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
58294992|NCT06453395|OTHER|Patients were grouped according to tumor location|Patients were grouped according to tumor location
58294993|NCT05627518|DRUG|Linaprazan glurate|100 mg
58294994|NCT05855837|OTHER|Ready to Eat Cereal|Cereal products available in retail stores
58294995|NCT06257056|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
58294996|NCT00461825|DRUG|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
58294997|NCT00461825|DRUG|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
58294998|NCT00461825|DRUG|Group B: CsA + CellCept(500 mg x 2/day)|
57939848|NCT00498160|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
57939849|NCT02841098|OTHER|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
57939850|NCT02841098|DRUG|Optimal medical therapy alone|Optimal medical therapy alone
57939851|NCT01415011|DRUG|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
57939852|NCT06091085|DRUG|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
57939853|NCT06091085|DRUG|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
57939854|NCT05520437|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
57939855|NCT05520437|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
58294999|NCT00461825|DRUG|Group C: CsAm|
58295000|NCT02872025|DRUG|Pembrolizumab|Injected intralesionally
58295001|NCT02872025|BIOLOGICAL|Intralesional mRNA 2752|Injected intralesionally
58295002|NCT01442012|OTHER|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
58406679|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
58406680|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
57939856|NCT02589496|DRUG|pembrolizumab|200 mg every 3 weeks
57939857|NCT00314626|DRUG|efavirenz|Efavirenz
57939858|NCT00314626|DRUG|Abacavir+lamivudine|Abacavir+lamivudine
57939859|NCT04564963|OTHER|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
57939860|NCT02036632|DEVICE|Eye Patching|
57939861|NCT03150862|DRUG|Pamiparib|Administered as specified in the treatment arm
57939862|NCT03150862|DRUG|TMZ|Administered as specified in the treatment arm
57939863|NCT03150862|RADIATION|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
58075268|NCT04920097|OTHER|Post-training zoom session for seed placement and APA coaching|Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
58075269|NCT06056505|PROCEDURE|partial kidney nephrectomy|surgery for partial nephrectomy
58075270|NCT06056505|DEVICE|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
58075271|NCT06056505|DEVICE|Innersight 3D software|investigational product to generate the 3D model
58295003|NCT00988000|OTHER|telephone consultation|alternative to face to face consultation for new referrals
58295004|NCT00988000|OTHER|No intervention|no alternative to face to face consultation
58295005|NCT05036798|DRUG|Tislelizumab|"Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD"
58295006|NCT05201612|DRUG|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
58295007|NCT05201612|DRUG|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
58295008|NCT02721615|PROCEDURE|Insertion of intra spinal sub dural pressure monitor|
58295009|NCT02721615|PROCEDURE|Insertion of sub dural microdialysis probe|
58295010|NCT01870986|BIOLOGICAL|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
58075272|NCT06722027|BEHAVIORAL|Compassion Centered Spiritual Health Team Intervention (CCSH-TI)|"Delivered to healthcare teams by spiritual health clinicians proficient in group facilitation. It is composed of 4 sessions delivered every other week and lasting 60 minutes each.~CCSH-TI sessions teach participants to attune to their interpersonal relationships; acknowledge and allow difficult emotions; and access compassion. It also provides psychoeducation about skillful coping strategies. Each session consists of didactic material about team norms and safety, a feeling check-in, facilitated group discussions about social connection and professional team building, and meditations to promote mindfulness, to cultivate a feeling of being nurtured, and to access compassion for self and others. CCSH-TI is delivered to healthcare teams by spiritual health clinicians proficient in group facilitation."
58075273|NCT06722027|BEHAVIORAL|Treatment as Usual|TAU refers to the current buffet of wellness and professional development activities that are available to employees at the Winship Cancer Institute.
58295011|NCT01870986|BIOLOGICAL|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
58295012|NCT01870986|BIOLOGICAL|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
58406681|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
58406682|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
58406683|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
57939864|NCT04662944|DRUG|brolucizumab|There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
57939865|NCT04662944|DRUG|ranibizumab|There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
57939866|NCT04662944|DRUG|aflibercept|There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
57939867|NCT02056054|OTHER|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
57939868|NCT02056054|OTHER|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
57939869|NCT02056054|OTHER|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
57939870|NCT02056054|OTHER|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
57939871|NCT02056054|OTHER|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
57939872|NCT02056054|OTHER|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
57939873|NCT02056054|OTHER|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
57939874|NCT00575536|PROCEDURE|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
58075274|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
58406684|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
58406685|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
58406686|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
58406687|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
58406688|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
58406689|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
58406690|NCT03259503|DRUG|Busulfan|Given IV
58406691|NCT03259503|DRUG|Gemcitabine|Given IV
58406692|NCT03259503|DRUG|Melphalan|Given IV
58406693|NCT03259503|DRUG|Olaparib|Given PO
58406694|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
58406695|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
58406696|NCT03259503|BIOLOGICAL|Rituximab|Given IV
58406697|NCT03259503|DRUG|Vorinostat|Given PO
58075275|NCT05028894|OTHER|No intervention|No intervention
58075276|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
58075277|NCT06068790|DEVICE|28 French sized rigid sheath|The 28Fr is the standard of care sheath size used at this site.
58295013|NCT05852314|BEHAVIORAL|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
58295014|NCT00351689|BEHAVIORAL|dietary supplement|
58295015|NCT05155748|OTHER|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
58295016|NCT00121719|DRUG|Lenvatinib|Lenvatinib tablets taken orally, once daily.
58295017|NCT03036371|BEHAVIORAL|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
58295018|NCT04677114|DRUG|Buprenorphine and Outpatient Parenteral Antibiotic Therapy|Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
58295019|NCT04677114|DRUG|Buprenorphine and standard of care antibiotic treatment|All participants will receive treatment of OUD and the infection per usual clinical care.
58295020|NCT03746925|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
58295021|NCT03746925|PROCEDURE|SuperPATH|SuperPATH approach surgery to replace the hip.
58406698|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
58075278|NCT06068790|DEVICE|22 French sized rigid sheath|The 22Fr is the smaller, investigational sheath size to be used in this study.
58075279|NCT04620005|OTHER|Observational|Survey
58075280|NCT05955651|DIAGNOSTIC_TEST|Peritoneal washings|"Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab.~1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus.~2. Second washing will be done after the hysterectomy and containment of the uterus in the bag.~3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff."
58295022|NCT00001577|PROCEDURE|double isolated limb perfusion with melphalan alone|
58406699|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
58406700|NCT00000419|DRUG|Premarin and Provera|
58406701|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
58406702|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
58406703|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
58406704|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
58406705|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
58406706|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
57939875|NCT04029220|BEHAVIORAL|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
58075281|NCT00384072|DRUG|bazedoxifene BZA-20|
58075282|NCT06616857|BEHAVIORAL|NUDGE|Individuals in this condition will receive intervention content to promote physical activity.
58075283|NCT06616857|OTHER|Education|Individuals will receive educational materials about how to increase physical activity
58075284|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
58075285|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
58295023|NCT04292067|BIOLOGICAL|Faecal sampling|Faecal sampling at baseline
57730805|NCT04731649|BEHAVIORAL|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
57939876|NCT00001764|DRUG|Mycophenolate Mofetil|
57939877|NCT02742597|BEHAVIORAL|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
57939878|NCT03568045|DEVICE|standard light|usual care
58075286|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
58295024|NCT05311826|PROCEDURE|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
58295025|NCT05311826|PROCEDURE|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
58295026|NCT02277275|DIETARY_SUPPLEMENT|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
58295027|NCT02277275|DIETARY_SUPPLEMENT|Placebo|Placebo will be provided to the other two arms for six months
58295028|NCT01693913|BEHAVIORAL|cognitive behavioral exercise and nutrition over|
58295029|NCT01693913|BEHAVIORAL|nutrition and exercise education|
57939879|NCT03568045|DEVICE|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
57939880|NCT03568045|DEVICE|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
58295030|NCT03683836|DIAGNOSTIC_TEST|No intervention|No intervention
58295031|NCT01476267|DRUG|dalcetrapib|Single oral radiolabeled dose
58295032|NCT01985100|OTHER|hyperbaric oxygen chamber|
57939881|NCT06141850|BEHAVIORAL|COVID-19 Test Reporting|Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.
58075287|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
58075288|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
58075289|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
58295033|NCT03200561|DRUG|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
58295034|NCT03200561|BIOLOGICAL|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
58295035|NCT03889249|DRUG|Tenecteplase|Stroke Thrombolytic
58295036|NCT03889249|DRUG|Alteplase|Stroke Thrombolytic
58295037|NCT05198856|DRUG|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
57730806|NCT00324623|BIOLOGICAL|Melan-A VLP vaccine, IMP321 adjuvant|
57730807|NCT00324623|BIOLOGICAL|adoptive immunotherapy|
57730808|NCT00324623|BIOLOGICAL|therapeutic autologous lymphocytes|
57730809|NCT00324623|DRUG|cyclophosphamide|
57730810|NCT00324623|DRUG|fludarabine phosphate|
57730811|NCT03813329|DIETARY_SUPPLEMENT|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
58295038|NCT04770506|OTHER|Data extraction from medical files|Data extraction from medical files
58295039|NCT04708080|PROCEDURE|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
57939882|NCT06141850|BEHAVIORAL|Personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.
57939883|NCT06141850|BEHAVIORAL|Non-personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
58295040|NCT03844425|DEVICE|Conventional VFR|Conventional retainers
57939884|NCT05104645|OTHER|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
57939885|NCT05104645|OTHER|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
58295041|NCT03844425|DEVICE|VFR from SLA|SLA has better finishing compared to FDM but it is more expensive.
57939886|NCT05104645|OTHER|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
58295042|NCT03844425|DEVICE|VFR from FDM|FDM has poorer finishing compared to SLA but it is cheaper.
57939887|NCT02728661|BEHAVIORAL|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
58295043|NCT05270980|OTHER|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
58295044|NCT04685252|OTHER|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
58295045|NCT04685252|OTHER|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
58295046|NCT03821987|DRUG|Fludarabine|Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
58295047|NCT06255080|OTHER|Training intervention|"The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared."
58295048|NCT00791219|DRUG|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
58295049|NCT00791219|DRUG|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
58295050|NCT00791219|DRUG|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
58295051|NCT04749095|DRUG|Erector spinae plane block|bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
58295052|NCT04749095|DRUG|sham subcutaneous infiltration|bilateral ESP block will be injected with 20 ml of normal saline
58295053|NCT01737307|DRUG|Fluoride varnish|Fluoride Varnish (NaF 5%)
58295054|NCT01737307|OTHER|Oral Hygiene|Oral hygiene followed.
58295055|NCT01737307|DRUG|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
58295056|NCT06132334|OTHER|Upper extremity aerobic exercise training|"Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points.~Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of \>300 mg/dL will not be allowed to exercise that day."
58295057|NCT06132334|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
58295058|NCT05897749|OTHER|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
58295059|NCT05897749|OTHER|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
58295060|NCT00625456|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
58295061|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
57939888|NCT02728661|BEHAVIORAL|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
57939889|NCT02510092|DEVICE|Percutaneous coronary intervention with new generation fully resorbable scaffold|
58295062|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
58295063|NCT01418911|OTHER|questionnaire|questionnaire only
58295064|NCT01158742|OTHER|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
58295065|NCT01158742|OTHER|Glomerular Filtration Rate with Iohexol|used to determine kidney function
58295066|NCT02256839|DEVICE|CST_001|
58295067|NCT04610710|PROCEDURE|Operation|Operation for deep infiltrating endometriosis
57730812|NCT03813329|DIETARY_SUPPLEMENT|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
57939890|NCT03045445|DIAGNOSTIC_TEST|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
57939891|NCT03045445|DIAGNOSTIC_TEST|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
57939892|NCT05520346|DEVICE|Electronic Device for Toilet|Device will be installed on toilet of patients will in hospital to measure all waste output.
57939893|NCT01854320|BEHAVIORAL|Acceptance-based treatment|
57939894|NCT01854320|BEHAVIORAL|Standard behavioral treatment|
57939895|NCT05452330|OTHER|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
57939896|NCT05452330|OTHER|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
57939897|NCT03633526|DRUG|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
57939898|NCT03633526|DRUG|IVA|IVA mono tablet.
57939899|NCT00187096|DRUG|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
57939900|NCT00187096|PROCEDURE|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
57939901|NCT00187096|DEVICE|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
57939902|NCT05765266|DEVICE|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
58295068|NCT04610710|PROCEDURE|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
58295069|NCT01845597|PROCEDURE|MAKOplasty® medial UKA|A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
58295070|NCT00078403|DRUG|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
58295071|NCT00078403|DRUG|Ribavirin|One tablet or capsule containing ribavirin 200 mg
57939903|NCT05765266|DEVICE|Depo-Medrol®|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
57939904|NCT02000076|BEHAVIORAL|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
57939905|NCT02000076|BEHAVIORAL|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
57939906|NCT04650282|COMBINATION_PRODUCT|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
57939907|NCT04650282|COMBINATION_PRODUCT|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
57939908|NCT03778567|DRUG|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
57939909|NCT04540549|BEHAVIORAL|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
57939910|NCT04677673|DRUG|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
57939911|NCT04677673|PROCEDURE|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
57939912|NCT05168748|DRUG|IMJ995 single agent|Single intravenous administration of IMJ995
58075290|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
58295072|NCT03060226|DIAGNOSTIC_TEST|blood sample|Search of blood predictive marker (s)
58295073|NCT05814315|BEHAVIORAL|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
58075291|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
58075292|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
58075293|NCT03158532|DRUG|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
58075294|NCT03158532|DRUG|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
58075295|NCT03158532|DRUG|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
58075296|NCT03158532|DRUG|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
58075297|NCT02502994|DRUG|GEN0101|
58075298|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
58075299|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
58075300|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
58075301|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
58075302|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
58075303|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
58075304|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
58075305|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
58075306|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
58075307|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
58075308|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
58075309|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
58075310|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
58075311|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
58075312|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
58075313|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
58075314|NCT02688881|DRUG|sirolimus|Rapamune
58075315|NCT04373720|PROCEDURE|Magnetic Resonance Elastography|Undergo MRE
58075316|NCT04373720|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
58075317|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
58075318|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
58075319|NCT00066274|DRUG|FOLFIRI regimen|
58075320|NCT00066274|DRUG|FOLFOX regimen|
58075321|NCT00066274|DRUG|fluorouracil|
58295074|NCT00809445|BEHAVIORAL|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
58075322|NCT00066274|DRUG|irinotecan hydrochloride|
58075323|NCT00066274|DRUG|leucovorin calcium|
58075324|NCT00066274|DRUG|oxaliplatin|
58075325|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
58075326|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
58075327|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
58075328|NCT00452166|DRUG|rosiglitazone|
58075329|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
58075330|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
58295075|NCT00809445|BEHAVIORAL|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
58295076|NCT00809445|BEHAVIORAL|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
58295077|NCT02607501|DEVICE|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
58295078|NCT00230334|DRUG|Gleevec|
58075331|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
58075332|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
58075333|NCT00551694|DRUG|GSK256073A tablets|
58075334|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
58075335|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
58075336|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
58075337|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
58075338|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
58075339|NCT06357832|DEVICE|Brainsway Deep TMS System|The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.
58075340|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
58075341|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
58075342|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
58075343|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
58075344|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
58075345|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
58075346|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
57939913|NCT03389295|RADIATION|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
58075347|NCT06199193|DIETARY_SUPPLEMENT|Personalized diet|Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets
58075348|NCT06199193|DIETARY_SUPPLEMENT|Dietary counseling|Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
58075349|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
58295079|NCT06128018|PROCEDURE|Surgical gastrojejunostomy (S-GJ)|Surgical gastro-jejunostomy
58295080|NCT06128018|PROCEDURE|EUS-guided gastrojejunostomy (EUS-GJ)|Endoscopic Ultrasound guided gastro-jejunostomy
58295081|NCT01829698|DRUG|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
58075350|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
58075351|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
58075352|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
58075353|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
58075354|NCT05587933|DRUG|Antispasmodic|Antispasmodic
58075355|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
58075356|NCT06161766|DRUG|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
58075357|NCT06456346|DRUG|Bomedemstat|Oral capsule
58075358|NCT06456346|DRUG|Hydroxyurea|Oral capsule
58295082|NCT01829698|DRUG|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
58075359|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
58075360|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
58075361|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
58075362|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
58075363|NCT05278663|DRUG|E6742|E6742 tablet.
58075364|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
58075365|NCT05642325|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
58075366|NCT05642325|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
58406707|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
57939914|NCT05520151|DIETARY_SUPPLEMENT|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
58075367|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
58075368|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
58075369|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
58075370|NCT05156749|DEVICE|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
57730813|NCT03813329|DIETARY_SUPPLEMENT|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
58075371|NCT05156749|DEVICE|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
58075372|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
58075373|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
58075374|NCT05167669|DEVICE|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
58075375|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
58075376|NCT02278042|OTHER|Beverage Consumption|
58075377|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
58075378|NCT03313297|DRUG|Placebo|Matching placebo
58075379|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
58075380|NCT03730051|DRUG|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
58406708|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
57730814|NCT02169674|BIOLOGICAL|EngerixB, GlaxoSmithKline Vaccines|
57730815|NCT00977262|OTHER|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
57730816|NCT00977262|OTHER|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
57730817|NCT00977262|OTHER|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
57730818|NCT06670690|DRUG|Atenolol 50 MG|patients will be premedicated with atenolol (50mg)
57939915|NCT05520151|OTHER|control|no intervention
57939916|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
57939917|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
57939918|NCT02495844|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
58075381|NCT03730051|DRUG|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
58075382|NCT03970603|OTHER|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
58075383|NCT03970603|OTHER|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
58295083|NCT02990013|DEVICE|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
58075384|NCT06724172|BEHAVIORAL|Self-Management|We will universally offer social needs supports (grocery, physical activity, transportation support) widely in use in clinical settings. Patients may elect to receive all, some, or none of the supports. The patient-directed, structured self-management intervention will be provided through mobile health technology (mHealth) and/or mailings, according to patient preference. Participants will receive health information to support health education and behavior change.
58075385|NCT06724172|BEHAVIORAL|Community-Based|As is currently in use broadly by community health workers, participants will complete a detailed social needs assessment and active assistance with referrals to evidence-based home visiting programs; maternal child health services to promote social support and resource access; and services to improve social determinants of health including active enrollment assistance for WIC, SNAP, healthcare and insurance, legal support, housing, job training, mental health and others. Community health workers will deliver group and individual physical activity support and assistance with behavioral goal setting.
58075386|NCT05672459|DRUG|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
58075387|NCT05672459|DRUG|Fludarabine phosphate|Given by IV (vein)
58075388|NCT05672459|DRUG|Cyclophosphamide|Given by IV (vein)
58075389|NCT05672459|PROCEDURE|leukapheresis|Given by IV (vein)
58295084|NCT02990013|DRUG|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
58295085|NCT02990013|DRUG|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
57939919|NCT03128398|DRUG|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
57939920|NCT02491957|OTHER|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
58295086|NCT02990013|DRUG|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
58295087|NCT05048043|BEHAVIORAL|Computer-assisted Behavior Intervention|"The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands."
58295088|NCT05048043|BEHAVIORAL|Challenging Horizons Program|The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
58295089|NCT05701358|PROCEDURE|Physiology-guided NCL PCI|For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
58295090|NCT05701358|PROCEDURE|Angiography-guided NCL PCI|PCI will be performed as per local practice
58295091|NCT03659123|BEHAVIORAL|standardized geriatric intervention|"Nutritional care is based on:~* A personalized evaluation of nutritional balance and nutritional needs of the patient~* A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~* 2 to 3 times a week: strength exercise~* 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~* 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
58295092|NCT05862051|PROCEDURE|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation \[radiofrequency ablation (RFA) or microwave ablation (MWA)\]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
58406709|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
58075390|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
58075391|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
58075392|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
58075393|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
58075394|NCT05635110|DRUG|VX-548|Tablets for oral administration.
58075395|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
58075396|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
58075397|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
58075398|NCT03165227|DRUG|BI 685509|Taken orally
58406710|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
58075399|NCT03165227|DRUG|Placebo|Taken orally
58295093|NCT05862051|PROCEDURE|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
58295094|NCT03362177|BIOLOGICAL|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
58295095|NCT03362177|OTHER|Placebo|Placebo Comparator
58406711|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
58406712|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
58406713|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
58406714|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
58406715|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
58406716|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
58406717|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
58406718|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
58406719|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
58406720|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
58406721|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
58406722|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
57939921|NCT03579420|BEHAVIORAL|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
57939922|NCT03579420|BEHAVIORAL|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
57939923|NCT00036751|DRUG|imatinib mesylate|Given orally
58406723|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
58406724|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
58406725|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
58406726|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
58406727|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
58406728|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
57939924|NCT00036751|OTHER|laboratory biomarker analysis|Correlative studies
57939925|NCT04311736|BEHAVIORAL|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
57939926|NCT04311736|BEHAVIORAL|Cycling|Cycling on a recumbent cycle ergometer
57939927|NCT04311736|BEHAVIORAL|Stretching|Stretching exercises
57939928|NCT03422679|DRUG|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
57939929|NCT00352287|DRUG|Recombinant human growth hormone; pioglitazone|
57939930|NCT01168973|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
58295096|NCT01664676|DRUG|Liraglutide|
58295097|NCT01664676|DRUG|Placebo-liraglutide|
58295098|NCT04156126|OTHER|Blood Collection|Blood Collection
58295099|NCT03485534|DRUG|Tenofovir Disoproxil Fumarate|Viread 300mg
58295100|NCT03485534|DRUG|Tenofovir Disoproxil|Virehepa 245mg
58295101|NCT05643989|PROCEDURE|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
58295102|NCT05643989|PROCEDURE|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
58295103|NCT00297700|BEHAVIORAL|Active referral|
58406729|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
57939931|NCT01168973|DRUG|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
58095164|NCT05961319|DEVICE|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
58295104|NCT04968093|BEHAVIORAL|Mindfulness-based therapy.|"Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts."
58295105|NCT04001192|BEHAVIORAL|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
58295106|NCT01016145|DRUG|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
58295107|NCT01016145|DRUG|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
58295108|NCT00901043|DIETARY_SUPPLEMENT|Walnut supplementation|Eight weeks of walnut supplementation
58295109|NCT00901043|DIETARY_SUPPLEMENT|Ad lib diet|Eight weeks without walnut supplementation
58295110|NCT04195724|OTHER|mNGS for pathogen detection|mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
58295111|NCT03404388|BEHAVIORAL|Balance Training|4 days of a challenging balance training task
58295112|NCT04794751|DEVICE|JJVC Investigational Multifocal Contact Lens|senofilcon A C3
58295113|NCT04794751|DEVICE|Dailies Total 1® Multifocal Contact Lens|delefilcon A
58295114|NCT00090909|DRUG|cisplatin|
58295115|NCT00090909|DRUG|dexamethasone|
58295116|NCT00090909|DRUG|gemcitabine hydrochloride|
58295117|NCT00920959|DRUG|FP 100mcg|Once-daily dosing
58406730|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
58406731|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
58406732|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
58406733|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
58406734|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
58406735|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
58406736|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
58406737|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
58406738|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
58406739|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
57730819|NCT06670690|DRUG|Propranolol Pill|patients will be premedicated with propranolol (10mg)
58406740|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
58406741|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
57939932|NCT01168973|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
57939933|NCT03281967|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
57939934|NCT02067195|DRUG|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
58075400|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
58295118|NCT00920959|DRUG|FSC 100/50mcg|Once-daily dosing
58295119|NCT00920959|DRUG|Placebo|Once-daily dosing
58295120|NCT05139355|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
58295121|NCT03847961|DEVICE|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
58295122|NCT03176719|OTHER|Venipuncture|"1. Full blood count and leukocyte differentiation.~2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~3. Detection of anemia, thallasemia and sickle cell anemia (XN-20)~4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~5. Circulating cytokines and inflammatory markers (ELIZA)~6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~7. pan-Salmonella PCR~8. Gametocyte PCR"
58406742|NCT00010387|DRUG|cyclophosphamide|
58406743|NCT00010387|DRUG|filgrastim|
57730820|NCT06670690|DRUG|Ivabradine|patients will be premedicated with Ivabradine (5mg)
57730821|NCT02907333|BEHAVIORAL|Advice to use condoms|
57730822|NCT02359526|DRUG|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
58295123|NCT00715299|BEHAVIORAL|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
57730823|NCT02520635|DRUG|supra-early TEMODAL® chemotherapy|
57730824|NCT02520635|DRUG|standard TEMODAL® chemotherapy|
57730825|NCT02520635|RADIATION|Radiotherapy 60Gy|
57730826|NCT02976766|DRUG|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
57730827|NCT02976766|DRUG|Placebo|Participants will receive placebo three times a day for 10 days.
58406744|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
58095165|NCT06701370|OTHER|Task Oriented Training|Task oriented training consists of opening the bottlecap, stacking cubes on different sizes, buttoning,screwing, wearing a coat.
58095166|NCT06701370|OTHER|Conventional Rehabilitation|Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.
58095167|NCT06701370|OTHER|Upper arm ergometer|The patients will be rode 5 minutes forwardly and 5 minutes backwardly
58406745|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
58406746|NCT02307097|OTHER|WAIT|
58406747|NCT06232148|DEVICE|Type of surgery|
58406748|NCT01110837|OTHER|Allergen|Allergen nasal challenge
58406749|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
58406750|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
58406751|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
58075401|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
58406752|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
58406753|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
58406754|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
58406755|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
57730828|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
57730829|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
58075402|NCT03234023|BEHAVIORAL|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
58075403|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
58406756|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
58406757|NCT02240823|OTHER|adipose derived stem cells|
58406758|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
57730830|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
57730831|NCT00748436|DRUG|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
57730832|NCT02648698|DRUG|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
57730833|NCT05540236|OTHER|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
57939935|NCT02067195|DRUG|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
57939936|NCT00812799|DRUG|Oralgen|19.000 BU daily
57939937|NCT00812799|OTHER|placebo control|placebo control
57939938|NCT03713034|OTHER|PlayTest!|Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
57939939|NCT03713034|OTHER|Control games|Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
57939940|NCT02067442|DRUG|oral acetaminophen|1000 milligrams given orally before surgery
58075404|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
58295124|NCT01676246|DRUG|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
57730834|NCT05540236|OTHER|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
57730835|NCT03850392|DEVICE|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
57939941|NCT02067442|DRUG|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
57939942|NCT02656459|OTHER|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
57939943|NCT06365866|DEVICE|"BRAXX Esophageal Brachytherapy Applicator."|The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.
57939944|NCT06365866|RADIATION|Add-on of intraluminal brachytherapy|Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
57939945|NCT05577286|OTHER|regular care|the regular medical treatment without change of their daily activity routine
57939946|NCT05577286|OTHER|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
57939947|NCT00356083|DRUG|Methadone|
57939948|NCT01640912|DRUG|RXI-109|Single intradermal injection of RXI-109 at incision sites
58075405|NCT04255433|DRUG|Tirzepatide|Administered SC
58075406|NCT04255433|DRUG|Dulaglutide|Administered SC
58095168|NCT00739206|DRUG|SAR97276A|Dose based on body weight
58295125|NCT01676246|DRUG|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
58295126|NCT01676246|DRUG|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
58406759|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
58406760|NCT00961246|BEHAVIORAL|general health information|participants received general health information
57730836|NCT03421925|PROCEDURE|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
57939949|NCT01640912|DRUG|Placebo|Single intradermal injection of placebo at incision sites
58295127|NCT01676246|PROCEDURE|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
58295128|NCT01676246|PROCEDURE|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
58295129|NCT06259214|OTHER|15% HCl gel|Icon , DMG, Hamburg, Germany
58295130|NCT06259214|OTHER|H3PO4 gel|Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
57939950|NCT04886648|BEHAVIORAL|Music Therapy|
58295131|NCT06259214|OTHER|Er:YAG laser|Fotona AT Fidelis III, Ljubljana, Slovenia
58295132|NCT02390089|DRUG|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
58406761|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
58406762|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
57730837|NCT03296995|DEVICE|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
57939951|NCT03528759|DIAGNOSTIC_TEST||phenotypic and genotypic Method
57730838|NCT02576574|DRUG|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
57939952|NCT00003765|DRUG|O6-benzylguanine|
57939953|NCT00003765|DRUG|carmustine|
57939954|NCT00321750|DRUG|1% pimecrolimus cream|
57939955|NCT03831061|OTHER|Cognitive stimulation|
57939956|NCT00217048|DRUG|Yohimbine, oral|
57939957|NCT03559036|PROCEDURE|Locomotor Training|Body-weight supported stepping on a treadmill.
58295133|NCT02390089|OTHER|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
57730839|NCT02576574|DRUG|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
57730840|NCT02576574|DRUG|Paclitaxel|Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
57939958|NCT06476574|DEVICE|Vacuum-formed retainer|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer)."
57939959|NCT06476574|DEVICE|Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.|"* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0."
57939960|NCT06476574|DEVICE|Lingual bonded retainer from canine-to-canine|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer)."
58075407|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
58075408|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
58075409|NCT02184312|DRUG|Nevirapine XR low dose|
58075410|NCT02184312|DRUG|Nevirapine XR medium dose|
58075411|NCT02184312|DRUG|Nevirapine XR high dose|
58075412|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
58075413|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
58075414|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
58075415|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
57939961|NCT02237963|PROCEDURE|Posterolateral thoracotomy|
58075416|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
57730841|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
58295134|NCT02390089|RADIATION|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
58295135|NCT02390089|DEVICE|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
58295136|NCT02815033|DRUG|Enzalutamide|
57730842|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
57730843|NCT02576574|DRUG|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
58295137|NCT02815033|PROCEDURE|11C or 18F-Choline PET/CT|
58295138|NCT02815033|PROCEDURE|Whole body MRI|
58295139|NCT02815033|PROCEDURE|Bone scan|
57939962|NCT02237963|PROCEDURE|Axillary thoracotomy|
57939963|NCT04647877|DRUG|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
57939964|NCT04647877|OTHER|Placebo cream|Placebo cream to be applied on the neuropathic pain area
57939965|NCT04885868|OTHER|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.
57939966|NCT00516048|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
57939967|NCT00134264|DRUG|torcetrapib/atorvastatin|
57939968|NCT00134264|DRUG|atorvastatin|
58075417|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
58075418|NCT00777582|DRUG|AZD2281|Oral single dose formulation
58295140|NCT04805138|OTHER|Spectrophotometer|To objectively measure the discoloration of the peri-implant mucosa, spectrophotometric measurements of the buccal mucosa will be performed at study implant and at control tooth.
58295141|NCT02619097|DRUG|Pegol-sihematide injection|single dose
58295142|NCT00003843|DRUG|irinotecan hydrochloride|
58295143|NCT00003843|GENETIC|mutation analysis|
58075419|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
58075420|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
58075421|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
58295144|NCT00003843|GENETIC|polymorphism analysis|
58295145|NCT04328909|DEVICE|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
58295146|NCT04328909|OTHER|Control Group|Usual care - No E-Care app will be provided
57939969|NCT03422419|DRUG|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
58075422|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
58075423|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
58295147|NCT01387178|DRUG|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
58295148|NCT01387178|DRUG|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
58295149|NCT02501746|OTHER|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
58295150|NCT02501746|OTHER|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
58406763|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
58406764|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
58406765|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
58406766|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
58406767|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
58406768|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
58406769|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
58406770|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
58406771|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
58406772|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
58406773|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
57730844|NCT02576574|DRUG|Cisplatin|Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
57730845|NCT02576574|DRUG|Carboplatin|Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
57939970|NCT03422419|DEVICE|TIPS|transjugular intrahepatic portosystemic shunt deployment
58075424|NCT05794204|DRUG|RMP-A03 - Dose 1|Patients will randomized to low dose of RMP-A03
58075425|NCT05794204|DRUG|RMP-A03 - Dose 2|Patients will be randomized to high dose of RMP-A03
58075426|NCT05794204|DRUG|RMP-A03 Placebo|Patients will be randomized to RMP-A03 Placebo
58295151|NCT02501746|OTHER|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
57730846|NCT02576574|DRUG|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
58295152|NCT04453761|DRUG|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
58295153|NCT04453761|DRUG|Placebo|Intravenous NaCl0.9%
58295154|NCT03446092|BEHAVIORAL|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
58295155|NCT01520207|DRUG|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
58406774|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
58406775|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
58406776|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
58406777|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
58406778|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
58406779|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
58406780|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
57730847|NCT06010589|DRUG|DWJ1558|DWJ1558
57939971|NCT04651621|DEVICE|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
58295156|NCT01520207|DRUG|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
58295157|NCT05922644|DEVICE|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
58406781|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
58406782|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
58406783|NCT01983722|DRUG|Stiripentol|
58406784|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
58406785|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
57730848|NCT06010589|DRUG|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
58295158|NCT05922644|OTHER|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
58406786|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
58406787|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
58406788|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
58406789|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
58406790|NCT02386891|OTHER|Thermal Environment|
57730849|NCT06499870|PROCEDURE|Biopsy|Undergo biopsy
57730850|NCT06499870|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58406791|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
58406792|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
58406793|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
58406794|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
58406795|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
58406796|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
58406797|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
58406798|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
58406799|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
58406800|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
58406801|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
58406802|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
58406803|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
58406804|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
58406805|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
57939972|NCT04651621|DEVICE|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
57939973|NCT06231420|OTHER|Encourage using pedometer|Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
58075427|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
58295159|NCT03950453|BEHAVIORAL|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
58295160|NCT03950453|BEHAVIORAL|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.
57939974|NCT06231420|DEVICE|pedometer|pedometer
57939975|NCT03677596|DRUG|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
58295161|NCT03950453|OTHER|Non-randomized historical control (WLC) assessment only|Non-randomized, historical control group with only assessments during intervention and follow-up period.
58295162|NCT00798941|BEHAVIORAL|mouth care|mouth spray, mouth swab, moisturizer
58295163|NCT00798941|BEHAVIORAL|pain intervention|music and massage
58295164|NCT01614015|BEHAVIORAL|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
58295165|NCT01614015|BEHAVIORAL|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
58295166|NCT04407676|OTHER|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
58295167|NCT04371055|OTHER|7-day Holter ECG|7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
58295168|NCT04371055|OTHER|Implantable cardiac monitor|Continuous rhythm monitoring using an implantable cardiac monitor
58295169|NCT04371055|OTHER|Standard of care|Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
58406806|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
58295170|NCT01715948|DEVICE|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
58295171|NCT01715948|DEVICE|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
58406807|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
58406808|NCT06194955|DRUG|GIP(1-42)|Infusion
57939976|NCT03677596|DRUG|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
58295172|NCT06080542|PROCEDURE|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
58295173|NCT06080542|PROCEDURE|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
58295174|NCT01579513|DRUG|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
58295175|NCT01579513|DRUG|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
58295176|NCT02855489|BEHAVIORAL|Attitudes Only|
58295177|NCT02855489|BEHAVIORAL|Norms Only|
58406809|NCT06194955|DRUG|GLP-1|Infusion
58406810|NCT06194955|DRUG|GLP-2|Infusion
58406811|NCT06194955|OTHER|Placebo|Saline
58406812|NCT06607393|DRUG|Pembrolizumab|
58406813|NCT06607393|DRUG|Pemetrexed|
57730851|NCT06499870|PROCEDURE|Computed Tomography|Undergo CT
57730852|NCT06499870|DRUG|Enzalutamide|Given PO
57939977|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
57939978|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
58295178|NCT02855489|BEHAVIORAL|Perceived Behavioral Control Only|
58295179|NCT02855489|BEHAVIORAL|Intentions Only|
58295180|NCT02855489|BEHAVIORAL|Three Constructs|
58406814|NCT06607393|DRUG|Cisplatin|
57730853|NCT06499870|OTHER|Fluorine F 18 Piflufolastat|Undergo fluorine F 18 piflufolastat PET/MRI
57730854|NCT06499870|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
57730855|NCT06499870|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
57730856|NCT06499870|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
57730857|NCT06499870|OTHER|Questionnaire Administration|Ancillary studies
57730858|NCT06499870|DRUG|Relugolix|Given PO
57730859|NCT01197079|OTHER|Survey|Self administered anonymous survey
57939979|NCT06171620|DEVICE|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
58295181|NCT02855489|BEHAVIORAL|Four Constructs|
58295182|NCT05763914|BEHAVIORAL|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
58295183|NCT05763914|BEHAVIORAL|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
58295184|NCT05763914|BEHAVIORAL|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
58295185|NCT05763914|BEHAVIORAL|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
58406815|NCT06607393|DRUG|Carboplatin|
58406816|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
58406817|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
58406818|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
58406819|NCT00102297|DRUG|FG-3019|
57939980|NCT06171620|OTHER|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
57939981|NCT00121836|DRUG|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
57939982|NCT00121836|DRUG|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
57939983|NCT03193762|OTHER|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
57939984|NCT04683978|OTHER|Position|Neck extension
57939985|NCT05865444|BEHAVIORAL|Values alignment wise intervention|"The intervention includes: (1) reading materials, such as recent journalistic works that expose the deceptive and manipulative marketing practices of food companies and the harmful effects of these practices on society, with particular emphasis on harm to young children and the economically disadvantaged. Stories from other young people will also be included in order to contribute to the perception of widespread outrage and to suggest how that outrage can be channeled into taking a stand against the injustice perpetrated by food companies by eating less unhealthy or healthier food; (2) writing exercises, such as a story with a brief statement of what the participants would tell a younger child about the ads; and (3) an interactive activity, called Make It Real in which they are shown pictures of food ads and allowed to write and draw about them, making whatever changes (e.g., crossing out and substituting words) they feel necessary to make the ad real (i.e., no longer misleading)."
57939986|NCT05865444|BEHAVIORAL|Educational traditional intervention|The educational intervention includes information on nutrition and physical exercise. It includes reading and writing exercises.
57939987|NCT00516542|DRUG|letrozole|A daily dose of 2.5 mg will be used throughout the study.
57939988|NCT00516542|DRUG|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
57939989|NCT00516542|OTHER|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
57939990|NCT02436564|GENETIC|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
58075428|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
58075429|NCT06526026|BEHAVIORAL|Virtual crisis stabilization support with a multi-disciplinary team|Daily 1:1 sessions with multidisciplinary team via a range of virtual modalities (videoconferencing, phone, text, email), group programming, self-management resources, remote home monitoring app, referrals and linkages to community programs.
58075430|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
58075431|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
58075432|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
58075433|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
57730860|NCT05909865|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
57730861|NCT05909865|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
57939991|NCT04868721|PROCEDURE|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
57730862|NCT04592367|PROCEDURE|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
57939992|NCT00005950|DRUG|nelarabine|Given IV
57939993|NCT00005641|BIOLOGICAL|anti-thymocyte globulin|
57939994|NCT00005641|DRUG|busulfan|
57939995|NCT00005641|DRUG|cyclophosphamide|
57939996|NCT00005641|DRUG|cyclosporine|
57939997|NCT00005641|DRUG|leucovorin calcium|
58075434|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
57939998|NCT00005641|DRUG|methotrexate|
57939999|NCT00005641|DRUG|methylprednisolone|
57940000|NCT00005641|PROCEDURE|allogeneic bone marrow transplantation|
57940001|NCT00005641|PROCEDURE|in vitro-treated bone marrow transplantation|
57940002|NCT00005641|RADIATION|radiation therapy|
58295186|NCT05763914|BEHAVIORAL|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
58295187|NCT05763914|BEHAVIORAL|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
57940003|NCT02536768|BEHAVIORAL|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
57940004|NCT00069732|BEHAVIORAL|qigong|
57940005|NCT00069732|BEHAVIORAL|acupressure-TAT|
57940006|NCT06186713|OTHER|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
58075435|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
58075436|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
58295188|NCT00218478|BEHAVIORAL|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
58406820|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
58406821|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
57940007|NCT03492528|BIOLOGICAL|blood samples|blood samples
58075437|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
58075438|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
58075439|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
58075440|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
58406822|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
58406823|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
58406824|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
58406825|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
58406826|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
58406827|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
57940008|NCT00492427|DRUG|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.
57940009|NCT00492427|DRUG|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
57940010|NCT00574145|PROCEDURE|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
57940011|NCT00574145|PROCEDURE|fatigue assessment and management|duration
57730863|NCT03694548|BEHAVIORAL|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
57940012|NCT00574145|PROCEDURE|psychosocial assessment and care|duration
57940013|NCT00574145|PROCEDURE|quality-of-life assessment|duration
57940014|NCT00574145|PROCEDURE|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
58075441|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
58075442|NCT03491384|DRUG|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
58295189|NCT03404986|PROCEDURE|ureteroscopy|The patients will be subjected to rigid ureteroscopy
58295190|NCT03404986|RADIATION|Ultrasonography|The patients will be subjected to Ultrasonography
57940015|NCT01184222|DEVICE|great occipital nerve stimulation|"* Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
57940016|NCT02131675|DIETARY_SUPPLEMENT|Boost shake|Blood draw after mixed-meal consumption
57940017|NCT05500820|DRUG|CIN-107|A repeat oral dose of CIN-107 once daily for 10 days.
58075443|NCT06094075|OTHER|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
58075444|NCT06094075|OTHER|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
58075445|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
58406828|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
58406829|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
57940018|NCT05500820|DRUG|Matching Placebo|A repeat oral dose of matching placebo once daily for 10 days.
57940019|NCT06354582|DRUG|Vitamin C Injection|Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.
58406830|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
58406831|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
58406832|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
57940020|NCT06354582|OTHER|Normal saline|The placebo comparator will receive normal saline with the same volume and be administered after the induction of epidural labor anesthesia.
57940021|NCT05726851|DRUG|E2025|E2025 IV infusion.
57940022|NCT05726851|DRUG|Placebo|E2025 matched placebo IV infusion.
57940023|NCT03851003|PROCEDURE|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
57940024|NCT03851003|PROCEDURE|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
57940025|NCT03851003|DEVICE|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
57940026|NCT03851003|OTHER|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
58406833|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
58406834|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
58406835|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
58406836|NCT00610441|DRUG|MK-8777|
58406837|NCT00610441|DRUG|Placebo|
58406838|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
58406839|NCT03648489|DRUG|TAK228|Please refer to arm/group description
57940027|NCT02613845|OTHER|no intervention|
57940028|NCT02224313|DRUG|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
57940029|NCT02224313|DRUG|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
57940030|NCT00403676|OTHER|Follow up bu a nurse|Follow up bu a nurse
57940031|NCT00403676|OTHER|Follow up by a medical doctor|Follow up by a medical doctor
57730864|NCT03694548|BEHAVIORAL|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
57730865|NCT02796339|DIETARY_SUPPLEMENT|Mastiha|
57730866|NCT02796339|DIETARY_SUPPLEMENT|Placebo|
58095169|NCT05330611|DEVICE|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
58295191|NCT03890458|DRUG|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
58406840|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
58406841|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
58406842|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
58406843|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
58406844|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
58406845|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
58406846|NCT02388594|DRUG|Cyclophosphamide|
58406847|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
58406848|NCT00379782|OTHER|Navigation|Navigation and escourt
58406849|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
58406850|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
58406851|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
58406852|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
58406853|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
58406854|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
58406855|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
58406856|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
58406857|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
58406858|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
58406859|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
58406860|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
58406861|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
58406862|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
57940032|NCT03975920|DEVICE|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
58075446|NCT06723977|OTHER|Auditory Hallucination Based Voice Hearing Simulation|"1. st stage: Preparation of the environment, introduction, providing information about the purpose, duration and content of the application, application of data collection tools and distribution of the information brochure were provided.~2. nd stage: Introducing the recording devices and headphones, performing the first task simultaneously while listening to the prepared three-dimensional sound recording (watching a city promotional film and answering verbal questions about this film), performing the second task simultaneously while listening to the prepared three-dimensional voice recording (telling a story). (reading the text and answering the questions about this story text in writing) were applied.~3. rd stage: Information about the next application time of the measurement tools was provided.~Additional stage: Data collection tools were reapplied."
58295192|NCT03414190|BEHAVIORAL|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
58295193|NCT00446017|DRUG|adrenaline|
58295194|NCT00446017|DRUG|milrinone|
58295195|NCT01817075|PROCEDURE|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
58295196|NCT01817075|OTHER|Laboratory Biomarker Analysis|Correlative studies
58295197|NCT01817075|PROCEDURE|Mild Soap Skin Cleanser|Given control cleansing
58295198|NCT01817075|OTHER|Questionnaire Administration|Ancillary studies
58295199|NCT02622243|DRUG|Tiotropium|long acting muscarinic antagonist
58295200|NCT02622243|DRUG|glycopyrronium|long acting muscarinic antagonist
57940033|NCT02663271|DRUG|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
57940034|NCT02663271|DEVICE|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
58295201|NCT02622243|DEVICE|Respimat|inhaler device used to deliver active tiotropium or placebo
58295202|NCT02622243|DEVICE|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
58295203|NCT02573259|DRUG|PF-06801591|IV every 21 days (Part 1)
58295204|NCT02573259|DRUG|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
58295205|NCT04260997|DIETARY_SUPPLEMENT|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
58295206|NCT04260997|OTHER|Placebo capsule|Once per day (QD), 12 weeks
58295207|NCT03756948|OTHER|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
58295208|NCT03756948|OTHER|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
58295209|NCT04784130|BEHAVIORAL|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
58406863|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
58406864|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
58295210|NCT04784130|BEHAVIORAL|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
58295211|NCT04784130|BEHAVIORAL|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
58295212|NCT04332068|DRUG|Oral ivermectin|Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
58295213|NCT04332068|DRUG|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
58295214|NCT04332068|OTHER|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
58295215|NCT04332068|OTHER|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
58295216|NCT04839718|BEHAVIORAL|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
58295217|NCT03436017|OTHER|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
58295218|NCT02589470|OTHER|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
58295219|NCT03981146|DRUG|Nivolumab|60 Minute IV Infusion
58295220|NCT00189163|DRUG|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
58295221|NCT00189163|DRUG|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
58295222|NCT02302846|DRUG|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
58295223|NCT00338546|DRUG|Cocaine hydrochloride|
58295224|NCT00338546|DRUG|Dexmedetomidine|
57940035|NCT02663271|OTHER|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
58295225|NCT00338546|PROCEDURE|Microneurography|
58295226|NCT00338546|PROCEDURE|Laser doppler velocimetry|
58295227|NCT02003144|BIOLOGICAL|eculizumab|
58295228|NCT01309321|BEHAVIORAL|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
58295229|NCT01309321|BEHAVIORAL|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
58406865|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
58075447|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
58075448|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
57940036|NCT02663271|OTHER|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
57940037|NCT03687645|DIAGNOSTIC_TEST|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
58075449|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
58075450|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
58075451|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
58075452|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
58075453|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
58075454|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
58075455|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
58406866|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
58406867|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
58406868|NCT04775927|OTHER|education|premarital education
57940038|NCT01087099|DRUG|Albendazole|Treatment with albendazole
57940039|NCT02198339|DRUG|BIBN 4096 BS|
58406869|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
58406870|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
58406871|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
58406872|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
58406873|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
58406874|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
58406875|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
58406876|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
58406877|NCT02842515|OTHER|teeth avulsion|
58406878|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
58406879|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
58406880|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
58406881|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
58406882|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
58406883|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
58406884|NCT00002522|DRUG|cisplatin|
58406885|NCT00002522|DRUG|cyclophosphamide|
58406886|NCT00002522|DRUG|etoposide|
58406887|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
58406888|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
58406889|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
58406890|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
58406891|NCT00002522|RADIATION|radiation therapy|
58406892|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
58406893|NCT01884558|DRUG|isavuconazole|oral
58406894|NCT01884558|DRUG|metformin|oral
58406895|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
58406896|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
58406897|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
57940040|NCT02198339|DRUG|Placebo|
58075456|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
58295230|NCT02589080|BEHAVIORAL|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
58075457|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
58075458|NCT04827992|DRUG|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
58295231|NCT01249417|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
58075459|NCT04827992|BEHAVIORAL|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
57940041|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
57940042|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Mini PCNL will be performed.
57940043|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
57940044|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
57940045|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
57940046|NCT02522676|PROCEDURE|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
58075460|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
58075461|NCT06722560|OTHER|GLP-1 hormone|s.c. continuous infusion for 72 hours using an insulin pump
58075462|NCT06722560|OTHER|Placebo|s.c. continuous infusion for 72 hours using an insulin pump
58295232|NCT01249417|DRUG|Placebo|I.M. injection on day 1 of a single treatment cycle.
58295233|NCT02171429|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
58295234|NCT02171429|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
58295235|NCT02171429|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
57940047|NCT00940381|DRUG|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
57940048|NCT00940381|DRUG|Cetuximab|Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
57940049|NCT04993534|BEHAVIORAL|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
57940050|NCT04993534|OTHER|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
57940051|NCT01068197|BEHAVIORAL|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
58075463|NCT06724926|DRUG|Azeliragon|"Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion."
58075464|NCT06724926|PROCEDURE|CSI|Patients will receive CSI.
58075465|NCT05847023|BEHAVIORAL|LUNA|see description above
58075466|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
58075467|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
58075468|NCT02763566|DRUG|Abemaciclib|Administered orally
57940052|NCT03366090|PROCEDURE|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
57940053|NCT00571844|BEHAVIORAL|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
57940054|NCT00571844|BEHAVIORAL|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
58075469|NCT02763566|DRUG|Anastrozole|Administered orally
58075470|NCT02763566|DRUG|Letrozole|Administered orally
58075471|NCT02763566|DRUG|Placebo|Administered orally
58075472|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
58075473|NCT06722820|DRUG|LPH-5|LPH-5
58075474|NCT06722820|DRUG|Placebo|Placebo
58075475|NCT01388946|DRUG|Ropivacaine 0.75|
58075476|NCT01388946|DRUG|Normal saline|
58075477|NCT06724913|OTHER|specialized food product based on ice cream|Day 1: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 3: standard ice cream (12% fat)
58295236|NCT02171429|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
58295237|NCT00336934|DIETARY_SUPPLEMENT|pomegranate juice|Given orally daily.
58295238|NCT00336934|OTHER|placebo|Given orally daily.
58406898|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
58406899|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
58406900|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
58406901|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
58406902|NCT00055354|PROCEDURE|Acupuncture|
58406903|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
58406904|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
58406905|NCT00024661|DRUG|LErafAON|
58406906|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
58406907|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
58406908|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
58406909|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
58406910|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
58406911|NCT02210689|OTHER|placebo|vehicle used as placebo
58406912|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
58406913|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
58406914|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
58406915|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
58406916|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
58406917|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
58406918|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
58406919|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
58406920|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
58406921|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
58295239|NCT05911477|DRUG|RhBMP-2|1mg RhBMP-2 for one fusion-level
58295240|NCT02720276|OTHER|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
57940055|NCT05298189|BEHAVIORAL|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
58075478|NCT06724913|OTHER|specialized food product based on ice cream 2|Day 1: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: standard ice cream (12% fat)
57940056|NCT05298189|BEHAVIORAL|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
58295241|NCT00970489|DRUG|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
57940057|NCT05298189|BEHAVIORAL|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
57940058|NCT04126083|DRUG|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
57940059|NCT04559191|DEVICE|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
57940060|NCT01583933|DEVICE|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
57940061|NCT01583933|DEVICE|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
57940062|NCT05514704|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
57940063|NCT05514704|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
57940064|NCT03469583|DRUG|EYP001|EYP001 self administered capsules, morning, with non carbonated water
57940065|NCT03469583|DRUG|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
57940066|NCT04537546|DEVICE|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
57940067|NCT04754750|DRUG|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
58075479|NCT06724913|OTHER|specialized food product based on ice cream 3|Day 1: standard ice cream (12% fat) Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin
57940068|NCT04754750|DRUG|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
57940069|NCT05289050|DRUG|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
57940070|NCT05289050|DRUG|S-ketamine|For patients in the s-ketamine group,anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
57940071|NCT00396994|DEVICE|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
57940072|NCT00396994|DEVICE|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
57940073|NCT03972579|BEHAVIORAL|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
57940074|NCT03972579|BEHAVIORAL|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
58075480|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
58295242|NCT00970489|DRUG|Placebo|Olive Oil capsules
58295243|NCT05468216|OTHER|MovIn-Lessons group|The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
58295244|NCT04164368|DRUG|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
58075481|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
58075482|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
58075483|NCT03921008|DRUG|Paclitaxel|-Commercial supply
58075484|NCT03921008|RADIATION|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
58075485|NCT03921008|PROCEDURE|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
58075486|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
58075487|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
58075488|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
58075489|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
58075490|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
58075491|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
58075492|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
58075493|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
58295245|NCT06439108|PROCEDURE|single symphyseal plating in management of vertically unsable open book pelvic ring injuries|open book pelvic ring injuries can be managed via the two techniques.
58295246|NCT00003494|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58295247|NCT05128591|DRUG|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
58295248|NCT05128591|DRUG|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
57730867|NCT03407638|OTHER|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
57730868|NCT01154166|DRUG|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
57730869|NCT01154166|DRUG|Placebo|Placebo
57940075|NCT01937936|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
58295249|NCT00053209|DRUG|gemcitabine hydrochloride|
57730870|NCT00455195|BIOLOGICAL|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
58295250|NCT00053209|DRUG|pemetrexed disodium|
58295251|NCT03175926|DEVICE|placebo Diskus®|device will be given daily for one week, two puffs per day
57730871|NCT03467659|OTHER|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
57730872|NCT03467659|OTHER|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
58075494|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
58075495|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
58075496|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
58075497|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
58295252|NCT03175926|DEVICE|placebo Ellipta®|device will be given daily for one week, one puff per day
58295253|NCT03175926|DEVICE|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
58295254|NCT04308863|DRUG|Chitosan scaffold/ MTA pulp dressing material|Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
58406922|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
57940076|NCT01937936|BEHAVIORAL|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
57940077|NCT03275571|BEHAVIORAL|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
57940078|NCT04623372|PROCEDURE|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
57940079|NCT04623372|PROCEDURE|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
58406923|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
58406924|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
58406925|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
58406926|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
58075498|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
58075499|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
58075500|NCT03319160|DEVICE|Wearable Cardioverter Defibrillator|A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
58075501|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
58075502|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
57730873|NCT03467659|OTHER|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
58075503|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
58075504|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
58075505|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
58075506|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
58295255|NCT04308863|DRUG|MTA pulp dressing material|MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
58295256|NCT05594147|DRUG|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
58295257|NCT05594147|DRUG|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
58295258|NCT05594147|DRUG|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
58406927|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
58295259|NCT05594147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
58295260|NCT01178125|DRUG|DR-102|
58295261|NCT03012932|BEHAVIORAL|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
58295262|NCT01566604|DRUG|NVA237|Delivered via a single dose dry powder inhaler
58295263|NCT01566604|DRUG|Placebo|Delivered via a single dose dry powder inhaler
58295264|NCT00944346|DRUG|Metformin HCl|
58295265|NCT01751321|DRUG|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
58295266|NCT04634188|DIAGNOSTIC_TEST|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
58295267|NCT03137277|PROCEDURE|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards."
58295268|NCT03059732|OTHER|Treatment|Observe the treatments of gastric cancer in each group
58295269|NCT06158204|BEHAVIORAL|Lifestyle Intervention|"Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day"
58295270|NCT04505852|DEVICE|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
58295271|NCT02938117|OTHER|cycling exercises|
58295272|NCT02824627|DRUG|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
58295273|NCT02824627|DRUG|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
58295274|NCT02862145|DRUG|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
58295275|NCT02862145|DRUG|Dexamethasone|Premedication during the week of treatment
58295276|NCT06298955|DRUG|OMS906 study drug|OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
58295277|NCT04754815|DRUG|Pembrolizumab|PD-L1 inhibitor administered as an intravenous (IV) infusion.
57730874|NCT03467659|OTHER|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
57730875|NCT03467659|OTHER|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
57730876|NCT03467659|OTHER|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
57730877|NCT06669897|OTHER|Questionnaire|Chronic cough questionnaire
58075507|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
58295278|NCT04754815|DRUG|Pemetrexed|Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
58295279|NCT04754815|DRUG|Paclitaxel|A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
58295280|NCT04754815|DRUG|Nab-paclitaxel|Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
58295281|NCT04754815|OTHER|Laboratory Biomarker Analysis|Correlative studies
58295282|NCT00441285|DRUG|Praziquantel|- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
58295283|NCT00441285|DRUG|Albendazole|"* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
58295284|NCT00441285|DRUG|ABZ Placebo|- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
58406928|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
58295285|NCT00441285|DRUG|PZQ Placebo|- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
58075508|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
58295286|NCT02212119|DRUG|Botulinum Toxin|
58295287|NCT02212119|DRUG|Saline|
58295288|NCT00849069|BIOLOGICAL|GSK2231395A|3 doses intramuscular injections
58295289|NCT00849069|BIOLOGICAL|TwinrixTM|3 doses intramuscular injections
58295290|NCT03932461|PROCEDURE|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
58295291|NCT03932461|PROCEDURE|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
58295292|NCT06086938|DEVICE|active cTBS combined with iTBS|"Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
58295293|NCT06086938|DEVICE|sham cTBS combined with iTBS|"Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
58295294|NCT01454011|DRUG|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
58295295|NCT01454011|DRUG|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
58295296|NCT06108908|BEHAVIORAL|Reminder|1. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
58295297|NCT02976610|DEVICE|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
58295298|NCT01704807|DEVICE|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
58295299|NCT01704807|DEVICE|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
58295300|NCT04531423|DRUG|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
58295301|NCT04531423|OTHER|SSRI + placebo|placebo
58295302|NCT03157076|DEVICE|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
58295303|NCT00889941|PROCEDURE|LASIK|laser-assisted in situ keratomileusis
58295304|NCT04273516|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
58295305|NCT04273516|DRUG|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
58295306|NCT01442662|DRUG|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
58295307|NCT03150329|OTHER|Laboratory Biomarker Analysis|Correlative studies
58295308|NCT03150329|BIOLOGICAL|Pembrolizumab|Given IV
58295309|NCT03150329|DRUG|Vorinostat|Given PO
57730878|NCT00547560|DRUG|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
58075509|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
58075510|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
58075511|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
58075512|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
58295310|NCT05686447|OTHER|Observational studies, no intervention|Observational studies, no intervention
58295311|NCT03035565|BEHAVIORAL|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
58295312|NCT03035565|BEHAVIORAL|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
58295313|NCT01932697|DRUG|Docetaxel|Given IV
58295314|NCT01932697|RADIATION|Hyperfractionation|Undergo hyperfractionated IMRT
58295315|NCT01932697|RADIATION|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
58295316|NCT01932697|OTHER|Laboratory Biomarker Analysis|Correlative studies
58295317|NCT01932697|OTHER|Quality-of-Life Assessment|Ancillary studies
58295318|NCT04990193|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
58295319|NCT04990193|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
58295320|NCT00347178|PROCEDURE|Laser Peripheral Iridotomy|
58295321|NCT00116961|DRUG|Velcade|
58295322|NCT00116961|DRUG|Doxil|
58295323|NCT00116961|DRUG|Dexamethasone|
58406929|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
58295324|NCT05002556|DIAGNOSTIC_TEST|Urinary Biomarkers|Prior to each examination, participating patients will produce a urine sample of approximately 20 to 40 ml in total dedicated to the determination of the marker proposed by your urologist, done by medical analysis laboratory. At each follow-up endoscopic examination scheduled in the patient's personalized care plan, the investigating urologist will record its date and endoscopic findings (white light bladder fibroscopy). The name and result of the urine test will also be recorded by the investigating urologist. The performance of the test will be evaluated from these data by calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and by means of an analysis of variance (ANOVA) to explore possible differences within the test by tumor grade and stage, and according to previous endovesical treatments received
58295325|NCT01116037|DEVICE|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
58406930|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
57940080|NCT02057796|DEVICE|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
57940081|NCT02057796|DRUG|ART (Atripla, Truvada, Efavirenz, Combivir)|"* ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
57940082|NCT02057796|DRUG|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
57940083|NCT04420611|OTHER|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
57940084|NCT04420611|OTHER|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
58075513|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
58295326|NCT04464746|OTHER|implementation of a specific program to improve therapeutic adherence|"1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
58295327|NCT01983215|DEVICE|Prevena vac|
58295328|NCT05758818|DRUG|Placebo|Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
58295329|NCT05758818|DRUG|Moxifloxacin (positive control)|Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
58295330|NCT05758818|DRUG|Milademetan|"Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2"
58295331|NCT00000173|DRUG|Donepezil|
58295332|NCT00000173|DRUG|Vitamin E|
58295333|NCT01563328|DRUG|DTG|50 mg q24h
58295334|NCT01563328|DRUG|BCV|800 mg q8h
58295335|NCT01563328|DRUG|TVR|750 mg q8h
58406931|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
58406932|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
58406933|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
58406934|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
58406935|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
58406936|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
58406937|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
58075514|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
57940085|NCT04420611|OTHER|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
58075515|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
58295336|NCT00919633|DRUG|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
58295337|NCT00919633|DRUG|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
58295338|NCT00919633|DRUG|ribavirin, USP|All patients will receive oral ribavirin
58295339|NCT00919633|DEVICE|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
58406938|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
58295340|NCT05460299|COMBINATION_PRODUCT|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
58295341|NCT04195061|PROCEDURE|Cardiopulmonary exercise test (CPET)|CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
58295342|NCT05890417|OTHER|questionnaire|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy
58295343|NCT05927168|DEVICE|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
58295344|NCT02133430|DEVICE|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
58406939|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
58490619|NCT05760469|OTHER|Screening|Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
57730879|NCT05942508|DRUG|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
57940086|NCT04420611|OTHER|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
57940087|NCT02522507|BEHAVIORAL|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
58075516|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
57940088|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp CBD|Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.
57940089|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp Placebo Capsule|Vantage Hemp Placebo Capsule Intervention
57940090|NCT04056481|DRUG|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
57940091|NCT02398448|DRUG|Zyloprim® 300 mg|
57940092|NCT02398448|DRUG|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
57940093|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
57940094|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 3|
57940095|NCT00698932|DRUG|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
57940096|NCT00698932|DRUG|Placebo|oral tablet, once daily for 24 weeks
57940097|NCT05950295|OTHER|Intranasal lavage with hypochlorous acid solution|intranasal lavage for ten days
57940098|NCT00884325|DRUG|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
57940099|NCT00884325|DRUG|placebo|One tablet taken orally at night for 28 days
57940100|NCT03974399|DIETARY_SUPPLEMENT|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
57940101|NCT05926154|PROCEDURE|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
57940102|NCT03228355|DRUG|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
57940103|NCT03228355|DRUG|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
57730880|NCT06635733|BEHAVIORAL|Rhapsode Capable™ Platform (Intervention Group)|Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
57940104|NCT02065167|BIOLOGICAL|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
57940105|NCT06303284|DRUG|subcutaneous Teriparatide injection|20 µg subcutaneous (SC) Teriparatide injection
58075517|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
58295345|NCT03134729|DRUG|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
58295346|NCT04085848|OTHER|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
57940106|NCT06303284|OTHER|placebo|placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
57940107|NCT00592033|OTHER|oxygen from a portable concentrator|2 l/minute during exercise
57940108|NCT01414699|BEHAVIORAL|Variety|These conditions will have snack served with an increase of fruit variety.
57940109|NCT01414699|BEHAVIORAL|Non-Variety|These conditions will receive a snack without a variety of fruit.
57940110|NCT02452281|DRUG|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
57940111|NCT02452281|DRUG|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
57940112|NCT01247987|PROCEDURE|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
57940113|NCT01247987|PROCEDURE|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
58075518|NCT06040905|OTHER|Placebo|Starch, dextrin
58295347|NCT02797028|DIETARY_SUPPLEMENT|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
58095170|NCT05330611|OTHER|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
58075519|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
58075520|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
58075521|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
58075522|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
58075523|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
58075524|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
58075525|NCT05216302|BEHAVIORAL|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
57940114|NCT02800408|OTHER|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
57940115|NCT02800408|OTHER|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
57940116|NCT02800408|OTHER|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
57940117|NCT00064220|DRUG|soblidotin|
57940118|NCT01468220|OTHER|Endurance training|Endurance training three times per week over six weeks
57940119|NCT05383404|DIAGNOSTIC_TEST|blood and urine samples|complete blood count, blood glucose, blood gases, serum bicarbonates, serum electrolytes, serum albumin ,serum creatinine. blood urea nitrogen, urine analysis.
57940120|NCT04016831|BEHAVIORAL|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
57940121|NCT04016831|OTHER|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
57940122|NCT03700580|DRUG|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
58075526|NCT00945815|BIOLOGICAL|epratuzumab|
58075527|NCT00945815|DRUG|clofarabine|
58075528|NCT00945815|DRUG|cytarabine|
57730881|NCT06635733|BEHAVIORAL|Paper-based ISP (Control Group)|Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
57730882|NCT00529828|PROCEDURE|Consumption of CLA enriched food|
57730883|NCT01823718|BIOLOGICAL|Injection of allogenic CTL EBV specific|
57730884|NCT03227770|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
57730885|NCT03227770|DEVICE|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
57730886|NCT02540200|DEVICE|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
58075529|NCT00945815|OTHER|laboratory biomarker analysis|
58075530|NCT06541665|DRUG|ONO-4059|Specified dose, once daily
58075531|NCT06541665|DRUG|Rituximab|Specified dose on specified days
58075532|NCT06541665|DRUG|Methotrexate|Specified dose on specified days
58075533|NCT06541665|DRUG|Procarbazine|Specified dose on specified days
58075534|NCT06541665|DRUG|Vincristine|Specified dose on specified days
58406940|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
58406941|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
58406942|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
58406943|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
58295348|NCT02797028|DIETARY_SUPPLEMENT|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
58295349|NCT02797028|DRUG|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
58406944|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
57730887|NCT02540200|PROCEDURE|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
57730888|NCT00201383|DRUG|cisplatin|
57940123|NCT03700580|DRUG|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
58295350|NCT06609486|DEVICE|Blood pressure measurement group|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."
58295351|NCT03916445|OTHER|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
58295352|NCT02848664|DEVICE|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
58295353|NCT05471388|DIAGNOSTIC_TEST|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
58406945|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
58406946|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
58406947|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
57940124|NCT01083524|DRUG|Dichloroacetate Sodium|3 mg po bid for 28 weeks
58406948|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
58406949|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
58406950|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
58295354|NCT03925337|DEVICE|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
58295355|NCT02907242|OTHER|Revealment|Cerebroplacental ratio revealment
58406951|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
58406952|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
57730889|NCT00561223|DRUG|iloprost Inhalation|inhale 2.5 mg, repeat times one
57730890|NCT00561223|DRUG|iloprost|inhaled 2.5 mg, repeat times one
57940125|NCT01083524|DRUG|Dichloroacetate Sodium|6.25 mg po bid
58075535|NCT06722807|PROCEDURE|sutureless, clampless partial nephrectomy|All subjects will undergo a clampless, sutureless robotic partial nephrectomy.
57940126|NCT01083524|DRUG|Dichloroacetate Sodium|12.5 mg po bid
57940127|NCT03621865|DIETARY_SUPPLEMENT|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
57940128|NCT03621865|DIETARY_SUPPLEMENT|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
57940129|NCT03621865|DIETARY_SUPPLEMENT|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
57940130|NCT03621865|DIETARY_SUPPLEMENT|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
57940131|NCT03621865|DIETARY_SUPPLEMENT|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
57940132|NCT00000787|BEHAVIORAL|Pre- and post-test counseling|
57940133|NCT00173745|DRUG|botulinum toxin A injection|
57940134|NCT03975101|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
57940135|NCT05273476|PROCEDURE|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
57940136|NCT01898897|PROCEDURE|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
57940137|NCT01898897|PROCEDURE|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
57940138|NCT02418780|OTHER|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
58075536|NCT02221882|DRUG|LY3164530|Administered IV.
58075537|NCT06722196|DRUG|topical amiodarone|amiodarone soaked patch placed on the left atrial roof at the end of surgery
57940139|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
57940140|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
57940141|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
57940142|NCT00382239|DRUG|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
57940143|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
57940144|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
57940145|NCT00807326|DRUG|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
57940146|NCT04357873|DRUG|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
57940147|NCT02991742|OTHER|contrast media|Compare 2 contrast media
57940148|NCT02241382|DEVICE|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
57940149|NCT02241382|DEVICE|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
57940150|NCT02267603|OTHER|Laboratory Biomarker Analysis|Ancillary studies
57940151|NCT02267603|BIOLOGICAL|Pembrolizumab|Given IV
57940152|NCT01366261|DEVICE|semirigid thoracoscopy|thoracoscopy with semirigid instrument
58075538|NCT06722196|OTHER|saline solution patch|saline solution soaked patch placed on left atrial roof at the end of surgery
58075539|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
57940153|NCT01366261|DEVICE|rigid thoracoscopy|thoracoscopy with rigid instrument
57940154|NCT04572880|PROCEDURE|Trabeculectomy|Trabeculectomy is performed
57940155|NCT04572880|DEVICE|XEN®|Microinvasive Surgery with XEN® is performed
57940156|NCT04572880|DEVICE|Preserflo®|Microinvasive Surgery with Preserflo® is performed
57940157|NCT03437564|DRUG|Vortioxetine|Vortioxetine tablet
57940158|NCT03584828|BEHAVIORAL|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
57940159|NCT04063241|OTHER|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
57940160|NCT04063241|OTHER|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
57940161|NCT03558165|DIAGNOSTIC_TEST|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
58075540|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
58075541|NCT00241566|DEVICE|implantation of stimulator|
58075542|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
58075543|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
58075544|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
58075545|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
58095171|NCT01516684|DRUG|placebo administration|Given topically
58295356|NCT04014010|OTHER|Blood pressure|"Systolic Blood Pressure (SBP)~1. Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative SBP~3. Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~4. Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~1. Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative MAP~3. Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~4. Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
58295357|NCT04014010|OTHER|Heart rate|"1. Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~2. Relative change (%) from preoperative heart rate (positive and negative)~3. Maximum pulse variation (maximum heart rate minus minimum heart rate)~4. Longest single episode (minutes) a) below 60, and b) above 100BPM~5. Cumulative duration (minutes) a) below 60, and b) above 100BPM"
58295358|NCT04014010|OTHER|Use of hemodynamic medications (i.e. special medications for blood pressure)|"1. Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~2. Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~3. Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~4. Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~5. Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
58295359|NCT04014010|OTHER|Oxygen saturation by pulse oximetry (SpO2)|"1. Longest single episode (minutes) below a) 88, and b) 90%~2. Cumulative duration (minutes) below a) 88, and b) 90%"
58295360|NCT04014010|OTHER|End-tidal Carbon dioxide (EtCO2)|"1. Longest single episode (minutes) a) below 30, and b) above 45mmHg~2. Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
58295361|NCT01820897|DRUG|Fosfomycin-Trometamol|
58295362|NCT01820897|DRUG|Sulfamethoxazole trimethoprim|
58295363|NCT01660867|DRUG|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
58295364|NCT01660867|DRUG|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
57940162|NCT04204863|OTHER|collection of patient data|Extract data from the digital medical records, the electroencephalographic and microbiologic database.
57940163|NCT00774280|DRUG|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
57940164|NCT00533143|OTHER|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
57940165|NCT01163812|PROCEDURE|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
57940166|NCT03228472|DEVICE|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
57940167|NCT03228472|DEVICE|sham stimulation|Placebo treatment
57940168|NCT04013789|DEVICE|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
57940169|NCT04013789|DEVICE|DACP contact lenses|Nelfilcon A soft contact lenses
57940170|NCT00814671|DRUG|Rifapentine 450|rifapentine 450 mg
57940171|NCT00814671|DRUG|Rifapentine 600|rifapentine 600 mg
57940172|NCT00814671|DRUG|Rifampin|rifampin 600 mg
58095172|NCT01516684|DRUG|EMLA|Given topically
58095173|NCT01516684|DRUG|propofol|Given IV
58095174|NCT01516684|DRUG|fentanyl citrate|Given IV
58295365|NCT02478515|DRUG|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
58295366|NCT06404619|BEHAVIORAL|Education program|The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
58295367|NCT03077893|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
58295368|NCT03077893|DEVICE|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
58295369|NCT02377856|DRUG|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
58295370|NCT02864732|OTHER|Rehabilitation exercises|
58295371|NCT02864732|DEVICE|Electrical Stimulation|
58295372|NCT00594893|PROCEDURE|Mini Incision Approach|Mini Incision Approach
58295373|NCT00594893|PROCEDURE|2 Incision Approach|2 Incision Approach
58295374|NCT05362370|DEVICE|Stryker's PEEK Customized Implant|The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
57730891|NCT03920917|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
57730892|NCT03920917|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
57730893|NCT03346629|DRUG|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
57940173|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
58295375|NCT01167400|BEHAVIORAL|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
57730894|NCT05504460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
57940174|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
57940175|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
58095175|NCT06336538|OTHER|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
58295376|NCT01167400|BEHAVIORAL|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
58295377|NCT04153474|PROCEDURE|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
58295378|NCT04153474|PROCEDURE|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
58295379|NCT01953042|BEHAVIORAL|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
57730895|NCT05504460|OTHER|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
58075546|NCT05346887|BEHAVIORAL|Home-based Therapy|The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
58295380|NCT04215562|COMBINATION_PRODUCT|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
57730896|NCT06634927|DRUG|Ozempic®|Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
57730897|NCT06634927|DRUG|HDG1901|Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
57730898|NCT03272438|DEVICE|Accelerometer|Participants use an accelerometer to monitor their steps activity
57940176|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
57940177|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
58406953|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
57730899|NCT03272438|BEHAVIORAL|Step goal|Participants are given a daily step goal to aim for
57940178|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
57730900|NCT03272438|BEHAVIORAL|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
57730901|NCT03272438|BEHAVIORAL|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
57940179|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
57940180|NCT03521050|DEVICE|defibrillator lead|observation of long-term performance of defibrillator leads
57940181|NCT00655954|PROCEDURE|Induced sputum|Used Ultrasonic nebuliser
57940182|NCT05242757|OTHER|Mixed-activated Killer Immune Cells|Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
57940183|NCT02717884|DRUG|tranylcypromine|"TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
57940184|NCT02717884|DRUG|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
57940185|NCT02717884|DRUG|cytarabine|40mg s.c. (days 1-10)
57940186|NCT04497116|DRUG|RP-3500 (camonsertib)|Oral ATR inhibitor
58295381|NCT01851655|BEHAVIORAL|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
58295382|NCT06008210|BEHAVIORAL|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
58295383|NCT06008210|BEHAVIORAL|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
58295384|NCT05709288|DRUG|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
58406954|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
58295385|NCT06407219|DEVICE|Robot Assisted Gait Training|The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
58295386|NCT02418793|DRUG|MOD-5014|Long Acting Factor VIIa
58295387|NCT00553488|DRUG|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
58295388|NCT00553488|DRUG|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
58295389|NCT00558987|BEHAVIORAL|Discipline Video|"1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
58406955|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
58406956|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
58406957|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
57730902|NCT04867577|DIAGNOSTIC_TEST|CT scan of lung and spine|Dual energy CT scan of thorax and spine
57730903|NCT01404312|DRUG|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
58075547|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
58075548|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
58406958|NCT01866423|DRUG|orteronel|Given PO
58406959|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
58406960|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
57730904|NCT01404312|DRUG|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
57730905|NCT01404312|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
57730906|NCT01412944|DRUG|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
57730907|NCT01412944|DRUG|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
57730908|NCT04799015|DRUG|Dexamethasone|Dexamethasone 10mg IV
57730909|NCT04799015|DRUG|Metoclopramide 10mg|Metoclopramide 10mg IV
58075549|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
58075550|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
58075551|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
58406961|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
58406962|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
58406963|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
58406964|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
57940187|NCT04497116|DRUG|Talazoparib|Oral PARP inhibitor
58295390|NCT00558987|BEHAVIORAL|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
58295391|NCT05816915|BEHAVIORAL|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
58295392|NCT01136018|PROCEDURE|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
58295393|NCT00105742|PROCEDURE|Diagnosis|
58295394|NCT00714974|DEVICE|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
58295395|NCT02855775|OTHER|additional blood sample|blood sample every 3 weeks
58295396|NCT03198858|PROCEDURE|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
58295397|NCT03198858|PROCEDURE|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
58295398|NCT03319433|DEVICE|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
58295399|NCT05946226|BIOLOGICAL|IMC002 injection|"three different IMC002 Doses will be escalated in 3+3 design"
58295400|NCT02701621|OTHER|MIRT-AT|Aquatic therapy
58295401|NCT02701621|OTHER|MIRT|Land-based Therapy
58406965|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
58406966|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
58406967|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
58406968|NCT06491290|OTHER|No intervention administered|NA (not applicable)
58406969|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
58406970|NCT04788797|OTHER|Placebo|Two capsules three times a day
58406971|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
57730910|NCT02167828|BEHAVIORAL|Social Support|
58406972|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
58406973|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
58406974|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
58406975|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
58406976|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
57940188|NCT04497116|DRUG|Gemcitabine Injection|Gemcitabine
58095176|NCT01874015|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
58295402|NCT01979874|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
58295403|NCT01979874|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
58295404|NCT00660296|OTHER|Air insufflation use in colonoscopy|Air insufflation for colonic distension
58295405|NCT00660296|OTHER|CO2 use in colonoscopy|Co2 insufflation for colonic distension
58295406|NCT02534597|BEHAVIORAL|Promotores Training|
58295407|NCT02534597|BEHAVIORAL|Delayed Promotores training|
58295408|NCT02534597|BEHAVIORAL|Caregiver training|
58295409|NCT02534597|BEHAVIORAL|Delayed caregiver training|
58295410|NCT02534597|BEHAVIORAL|Materials support|
58295411|NCT02534597|BEHAVIORAL|Delayed materials support|
58295412|NCT02534597|BEHAVIORAL|Technical assistance|
58295413|NCT02534597|BEHAVIORAL|Delayed technical assistance|
58295414|NCT03535857|DEVICE|PTNS|Use of PTNS on the ankle for 30 minutes
58295415|NCT04007965|PROCEDURE|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
58295416|NCT01510821|OTHER|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
58295417|NCT01510821|OTHER|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
58295418|NCT04252677|BEHAVIORAL|Obesity Prevention|This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
58295419|NCT04252677|BEHAVIORAL|Health Literacy|This intervention includes content specific to improving health literacy.
58295420|NCT06612970|DRUG|HB0056|HB0056 Injection
58295421|NCT06612970|DRUG|Placebo|Placebo
58075552|NCT06723028|BEHAVIORAL|Regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-T+ or mROC-Tc) will: 1. Read a brief essay about either the social justice benefits of eating healthy foods (POSITIVE, mROCT+) or critical of social justice aspects of unhealthy foods (CRITICAL, mROC-Tc). 2. Participants complete six free-response questions to ensure that they understood the essays.~3. Participants are instructed to use the information from the essay. They are shown a cue matching the essay they read either: Think Positive or Think Critically.~4. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat). 5. Finally, the participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
58075553|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
58095177|NCT01874015|BIOLOGICAL|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
58295422|NCT06561633|DRUG|Sugammadex administration|After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
58295423|NCT01526408|DRUG|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
58295424|NCT01526408|DRUG|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
58295425|NCT03522116|OTHER|No intervention|No intervention
58295426|NCT02636569|DRUG|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
58295427|NCT02636569|DRUG|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
58295428|NCT05535374|DEVICE|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
58295429|NCT03164447|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion
58295430|NCT03164447|DRUG|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
58295431|NCT00409279|BEHAVIORAL|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
58406977|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
58095178|NCT04498806|OTHER|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
58095179|NCT02235415|DRUG|Motens® (lacidipine)|
58095180|NCT01556464|DEVICE|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
58095181|NCT03173807|BEHAVIORAL|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
58295432|NCT04572828|PROCEDURE|Paracervical Block|Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
58295433|NCT04572828|DRUG|550 mg Naproxen Sodium 60 minutes before the procedure|550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
58295434|NCT04572828|PROCEDURE|The capped needle|The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
58406978|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
58406979|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
58406980|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
58406981|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
57730911|NCT04744480|PROCEDURE|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
57730912|NCT01998373|BEHAVIORAL|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
58295435|NCT01042834|OTHER|Air pollution study on healthy volunteers.|"The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air."
58295436|NCT00697853|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
58295437|NCT00697853|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
58295438|NCT00823238|DRUG|ceftazidime and tobramycin|
58406982|NCT03764917|OTHER|Time|Different detecting time
58406983|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
57730913|NCT02635815|PROCEDURE|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
57730914|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
57730915|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
57940189|NCT06397755|PROCEDURE|Prostate Biopsy and/or Radical Prostatectomy|Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
58095182|NCT01679418|DEVICE|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
58295439|NCT00823238|DRUG|inhaled tobramycin|
58295440|NCT02793765|DRUG|Docetaxel|
58295441|NCT02793765|BIOLOGICAL|Sipuleucel-T|
58295442|NCT04256759|DRUG|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
58295443|NCT04297202|DRUG|Apatinib Combined With SHR-1210 Injection|"3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;"
58295444|NCT05419297|DRUG|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
58295445|NCT05419297|OTHER|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
58295446|NCT05419297|DEVICE|actigraph|Subjects will wear this device to monitor sleep and activity
58295447|NCT05419297|BEHAVIORAL|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
58295448|NCT05419297|OTHER|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
58295449|NCT05419297|OTHER|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
58295450|NCT05419297|BEHAVIORAL|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
58406984|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
58406985|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
58406986|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
58406987|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
58406988|NCT00309712|DRUG|simvastatin 20 mg and placebo|
57730916|NCT02699177|DEVICE|CBF measurements|CBF measurements
57730917|NCT03793881|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
57730918|NCT03793881|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
57730919|NCT01273727|DRUG|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
57940190|NCT02996188|PROCEDURE|routine therapeutic paracentesis|
57940191|NCT04296877|DEVICE|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
58095183|NCT01679418|OTHER|No-drain after surgery|After surgery, no drain was put
58295451|NCT05419297|BEHAVIORAL|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
58295452|NCT03629769|DRUG|Proxelan|Administration of one suppository of proxelan once a day for 30 days
58295453|NCT02236312|DRUG|Botulinum Toxin Type A|
58295454|NCT02236312|DRUG|Placebo|
58295455|NCT05201846|DEVICE|DIA:CONN G8 insulin pump|Subjects on continuous subcutaneous insulin infusion system with CGM
58406989|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
58295456|NCT05201846|OTHER|Multiple daily insulin injection|Subjects on multiple daily insulin injection with CGM
58295457|NCT06273527|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
57730920|NCT01273727|DRUG|dexamethasone|intravitreal implant 0.7 mg duration 6 months
58295458|NCT06273527|OTHER|Sham Program|The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
57730921|NCT06635798|BIOLOGICAL|GR2001|The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
57730922|NCT06635798|BIOLOGICAL|HTIG|The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
57730923|NCT04586855|DIAGNOSTIC_TEST|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
57940192|NCT00890149|DRUG|Ondansetron|Ondansetron (4ug/kg bid),
58295459|NCT02764502|DEVICE|Pressure Gauge Manometer|Identification of epidural space
57730924|NCT04586855|DIAGNOSTIC_TEST|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
57730925|NCT02345057|DRUG|CS-3150|
57730926|NCT02345057|DRUG|placebo|
57730927|NCT03956017|DRUG|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
57730928|NCT03956017|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
57730929|NCT00216684|DRUG|fentanyl|
57730930|NCT02545673|BEHAVIORAL|Enhanced linkage to care|
57730931|NCT02545673|BEHAVIORAL|Standard-of-care plus|
58295460|NCT05871840|OTHER|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
58295461|NCT03021317|DRUG|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
58295462|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
58295463|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance elastography (MRE)|Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.
58295464|NCT04591106|DEVICE|Prototype MRE soft flexible passive transducer paddle|The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.
58295465|NCT01684514|DEVICE|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
58295466|NCT01676701|DRUG|Tabalumab Auto-Injector|Administered SC by auto-injector
58295467|NCT01676701|DRUG|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
58295468|NCT01814410|DRUG|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
58406990|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
58406991|NCT05154136|DRUG|Etrumadenant|Capsule
58406992|NCT05154136|DRUG|Itraconazole|Capsule
58406993|NCT00017589|BIOLOGICAL|oblimersen sodium|
58406994|NCT00017589|DRUG|gemtuzumab ozogamicin|
58406995|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
58406996|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
58406997|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
58406998|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
58406999|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
58407000|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
58407001|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
58407002|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
58407003|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
58407004|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
58407005|NCT00226408|DRUG|Interferon-alpha-2b|
58407006|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
58407007|NCT00822705|DRUG|Placebo tablet|Control arm
58407008|NCT03604874|DRUG|Oxytocin|intravenous infusion
57940193|NCT00890149|DRUG|Placebo|Placebo bid
58407009|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
58407010|NCT02956044|DRUG|Metformin|1000 mg metformin
58407011|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
58295469|NCT01814410|DRUG|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
58407012|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
58407013|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
58407014|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
58407015|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
58407016|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
58407017|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
58407018|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
58407019|NCT00525824|DRUG|Ezetimibe|10 mg
58407020|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
58407021|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
58407022|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
58407023|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
58407024|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
58407025|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
58407026|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
58295470|NCT01814410|DRUG|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
58407027|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
58407028|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
58407029|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
58407030|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
57940194|NCT00890149|BEHAVIORAL|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
58295471|NCT05747859|OTHER|teletherapy|speech therapy remotely delivered
58295472|NCT04846192|OTHER|Nutritional evaluation|Collecting existing data on pre operative nutritional status and outcomes after surgery
58295473|NCT01480388|DRUG|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
58407031|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
58407032|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
58407033|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
58407034|NCT00091338|BIOLOGICAL|MART-1 antigen|
58407035|NCT00091338|BIOLOGICAL|gp100 antigen|
58407036|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
58407037|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
58407038|NCT05432388|DRUG|remibrutinib|oral tablets
58407039|NCT05432388|DRUG|placebo|oral tablets
58295474|NCT01480388|DRUG|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
58295475|NCT01480388|DRUG|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
58295476|NCT01480388|DRUG|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
58407040|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
58407041|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
58407042|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
58407043|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
58407044|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
58407045|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
58407046|NCT00005631|BIOLOGICAL|filgrastim|
58407047|NCT00005631|BIOLOGICAL|rituximab|
58407048|NCT00005631|DRUG|carboplatin|
58407049|NCT00005631|DRUG|etoposide|
58407050|NCT00005631|DRUG|ifosfamide|
58295477|NCT01480388|DRUG|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
58295478|NCT04232020|DIAGNOSTIC_TEST|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
57730932|NCT05245864|OTHER|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
57730933|NCT05245864|OTHER|physical therapy standard of care|the current standard of care after surgery for ACL repair.
57730934|NCT01257295|DIETARY_SUPPLEMENT|control: no fiber addition|liquid breakfast without addition of fiber
58407051|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
58407052|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
58407053|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
57730935|NCT01257295|DIETARY_SUPPLEMENT|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
57730936|NCT01257295|DIETARY_SUPPLEMENT|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
57730937|NCT01257295|DIETARY_SUPPLEMENT|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
57730938|NCT01257295|DIETARY_SUPPLEMENT|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
58407054|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
57730939|NCT01257295|DIETARY_SUPPLEMENT|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
58095184|NCT00788008|DRUG|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
58295479|NCT00764569|DEVICE|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
58407055|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
58295480|NCT04358016|DRUG|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
58295481|NCT04358016|DRUG|Somatostatin|Somatostatin
58295482|NCT03000946|DRUG|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
58295483|NCT03000946|DRUG|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
58295484|NCT04396132|DIAGNOSTIC_TEST|Subjective Visual Vertical with Virtual SVV instrument|The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
58295485|NCT04157088|DRUG|Darolutamide (Nubeqa, BAY1841788)|600mg, twice daily
58407056|NCT00161577|OTHER|Placebo|Placebo Comparator
58295486|NCT04157088|DRUG|Enzalutamide|160mg, once daily
58407057|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
57730940|NCT05843942|OTHER|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
57730941|NCT04544462|OTHER|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
58407058|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
58407059|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
58407060|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
58407061|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
57940195|NCT02768233|BEHAVIORAL|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
58075554|NCT06453473|OTHER|TSBR|"The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to reach a training at 60%-80% of maximal pulse, including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling."
58075555|NCT06453473|OTHER|PerTSBR|Participants of the intervention group will receive a combination of lateral and medial tilting unannounced perturbations during stage 2 of the TSBR training. This will be provided by roll and pitch angles (tilt) balance perturbations that aim to evoke trunk and arm balance recovery responses.
58075556|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
58075557|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
58407062|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
58407063|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
58407064|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
58407065|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
58407066|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
57940196|NCT00573209|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
57940197|NCT03959124|DEVICE|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz
57940198|NCT03959124|DRUG|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
58075558|NCT06280079|DIETARY_SUPPLEMENT|Ultra-high-caloric fatty diet|100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g
58295487|NCT05828316|BEHAVIORAL|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
58295488|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
58295489|NCT02584478|DRUG|Paclitaxel|"Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week"
58407067|NCT03937648|DRUG|Placebo|Placebo
58407068|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
58407069|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
57730942|NCT03719456|PROCEDURE|Retrograde Intrarenal Surgery|
57940199|NCT06273007|OTHER|PartoMa intervention(Locally achievable intrapartum care guideline), in house LDHF trainings|We will implement PartoMa interventions: seminars, LDHF training, and supportive supervision
57940200|NCT04922463|DEVICE|PLASOMA|Treatment with cold plasma device
57940201|NCT00602095|DRUG|misoprostol|0.025mg tablet vaginally every 4 hour until progress
57940202|NCT00602095|DRUG|dinoprostone|2mg vaginal gel every 6 hours until progress
57940203|NCT00602095|DEVICE|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
58075559|NCT06280079|OTHER|Placebo|\<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g
58295490|NCT02584478|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard"
58407070|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
58407071|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
58407072|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
58407073|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
58407074|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
58407075|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
58407076|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
58407077|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
58407078|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
58407079|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
58407080|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
58407081|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
58407082|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
58407083|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
58075560|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
58295491|NCT02584478|DRUG|Topotecan|Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
58407084|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
58407085|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
58407086|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
58407087|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
58407088|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
57730943|NCT01365494|BIOLOGICAL|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
57730944|NCT03131648|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
57940204|NCT01617590|DRUG|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
58075561|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
58075562|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
58295492|NCT02584478|DRUG|Topotecan|Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard
58295493|NCT02584478|DRUG|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
58295494|NCT02584478|DRUG|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
58407089|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
57730945|NCT03131648|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
58075563|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
58295495|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
58295496|NCT05927792|DEVICE|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
58295497|NCT05927792|DEVICE|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
58295498|NCT02735980|DRUG|Prexasertib|Administered IV
58295499|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
58295500|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
58295501|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
58295502|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
58295503|NCT02937181|DRUG|Ceftaroline|IV Ceftaroline will be given for 72 hours
58295504|NCT01255904|DRUG|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
58295505|NCT01255904|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
58295506|NCT01255904|OTHER|Oral placebo|Oral saline administered
58295507|NCT01255904|OTHER|Intranasal placebo|Intranasal saline administered
58295508|NCT02635919|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
58295509|NCT04202497|DRUG|TAK-418|TAK-418 orally.
58295510|NCT04202497|DRUG|[18F]MNI-1054 (radiotracer)|\[18F\]MNI-1054 injection.
58295511|NCT06611709|DEVICE|sham taping (non-elastic medical cloth tape)|sham taping
58295512|NCT06611709|DEVICE|Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold|A standard 5-cm wide KinesioⓇ Tex Gold
58295513|NCT06611709|OTHER|exercises|home-based exercises
58295514|NCT02993198|DRUG|Carvedilol|
58295515|NCT01493050|DRUG|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
58295516|NCT01493050|DRUG|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
58295517|NCT02949947|DRUG|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
58407090|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
58407091|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
57940205|NCT01617590|DRUG|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
58295518|NCT02949947|DIETARY_SUPPLEMENT|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
58295519|NCT02949947|BEHAVIORAL|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
58295520|NCT04354415|PROCEDURE|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
58295521|NCT03319316|DRUG|Durvalumab|Combination of durvalumab + tremelimumab treatment
58295522|NCT03319316|DRUG|Tremelimumab|Combination of durvalumab + tremelimumab treatment
58295523|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
58295524|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
58295525|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
58295526|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
58295527|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
58295528|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
58295529|NCT02862964|OTHER|identify L4/L5|"* For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
58295530|NCT04560959|DEVICE|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
58295531|NCT04472546|OTHER|in-vivo mesure|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
58407092|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
58407093|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
57940206|NCT00319280|PROCEDURE|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
58075564|NCT06018389|BEHAVIORAL|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
58075565|NCT06018389|BEHAVIORAL|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
58075566|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
58075567|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
58075568|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
58075569|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
58075570|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
58295532|NCT04472546|OTHER|Scotch|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
58295533|NCT04472546|OTHER|Lipid index|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
58295534|NCT04472546|OTHER|Absorbant paper|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
58407094|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
58407095|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
58075571|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
58075572|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
58075573|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
58075574|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
58075575|NCT02062541|OTHER|usual assessment+fast rehabilitation|
58075576|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
58075577|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
58075578|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
58295535|NCT04472546|OTHER|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
58295536|NCT04472546|OTHER|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
58295537|NCT05282368|BEHAVIORAL|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
58295538|NCT01589419|DRUG|veliparib|see arm description
58295539|NCT01589419|DRUG|capecitabine|see arm description
58295540|NCT01589419|RADIATION|radiation|see arm description
58295541|NCT00490971|DRUG|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
58407096|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
58295542|NCT00490971|DRUG|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
58295543|NCT00490971|DRUG|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
58295544|NCT04401332|OTHER|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
58295545|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
57940207|NCT03337360|DIETARY_SUPPLEMENT|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
57940208|NCT03337360|OTHER|Placebo|Inactive ingredients, placebo
57940209|NCT03193645|DRUG|Degarelix|Injection
57940210|NCT00121784|DRUG|mycophenolate mofetil [CellCept]|1
57940211|NCT04223843|DRUG|Tiotropium + olodaterol|Oral Inhalation
57940212|NCT04223843|DRUG|Placebo|Oral Inhalation
57940213|NCT04047550|DIAGNOSTIC_TEST|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
57940214|NCT03965936|PROCEDURE|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
57940215|NCT03965936|PROCEDURE|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
58295546|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
58295547|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
58295548|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
58295549|NCT01725633|BEHAVIORAL|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
58295550|NCT01725633|BEHAVIORAL|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
58295551|NCT01725633|OTHER|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
58295552|NCT01725633|OTHER|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
57940216|NCT05092919|OTHER|Flavor|Sweet flavored vs. non-flavored cigarillos.
57940217|NCT00474708|DRUG|Effexor|
57940218|NCT00474708|DRUG|SSRI|
57940219|NCT00309465|DRUG|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
58295553|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia (TEA) group|Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
57940220|NCT00309465|OTHER|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
57940221|NCT00309465|DRUG|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
57940222|NCT03629236|OTHER|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
57940223|NCT03629236|OTHER|Control|Debridement, dressing application, standard compression therapy
57940224|NCT00468520|DRUG|low dose oxytocin|
57940225|NCT03592966|DIETARY_SUPPLEMENT|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
57940226|NCT03592966|DIETARY_SUPPLEMENT|Placebo|Freeze-dried placebo powder
58075579|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
58075580|NCT05602623|DEVICE|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
58075581|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
57940227|NCT01841463|DRUG|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
57940228|NCT01841463|DRUG|Vemurafenib (Zelboraf®)|"* In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
58075582|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
58295554|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
58295555|NCT05292261|OTHER|Recreational team handball|Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
58295556|NCT05136417|DEVICE|intra-procedural intracardiac echocardiography (ICE) probe|placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
58295557|NCT06600412|DRUG|R3R01|R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.
58295558|NCT06600412|DRUG|Placebo|Please refer to arm/group description for further information.
58295559|NCT05989932|OTHER|Upadacitinib|Real-world on the use of Upadacitinib
58295560|NCT03338764|DRUG|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
58295561|NCT03338764|DRUG|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
58295562|NCT04004312|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
58295563|NCT02017275|DEVICE|BuMA|This group will contain 1175 subjects.
58295564|NCT02017275|DEVICE|EXCEL|This group will contain 1175 subjects.
58295565|NCT05915273|OTHER|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group
58295566|NCT05915273|OTHER|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
58295567|NCT05915273|OTHER|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
58295568|NCT05183334|DRUG|Sildenafil 50 mg|PD5I
58295569|NCT05183334|DRUG|Placebo|placebo
58295570|NCT05183334|DRUG|Tramadol Hydrochloride 100 MG|opiod
58295571|NCT02683980|DEVICE|Lumenis Pulse P120H and Xpeeda side firing fiber|
58295572|NCT02351401|BEHAVIORAL|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
58295573|NCT04245592|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
58295574|NCT04245592|DIETARY_SUPPLEMENT|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
58295575|NCT01683604|OTHER|Observational study|
58295576|NCT01747499|DRUG|Azacitidine|
57940229|NCT05672511|BEHAVIORAL|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
57940230|NCT05260853|OTHER|Weaning Board|structured care concept
58295577|NCT01624480|DRUG|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
58295578|NCT05150665|PROCEDURE|En-masse retraction|"Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew"
58295579|NCT05150665|PROCEDURE|Two step Retraction|"Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw."
58295580|NCT04474262|BIOLOGICAL|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
58295581|NCT04474262|DRUG|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
58295582|NCT04474262|OTHER|Placebo|Placebo
58295583|NCT02896764|DEVICE|Cone-beam CT|
58295584|NCT02952690|DEVICE|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
58295585|NCT02952690|DEVICE|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
58295586|NCT04192240|OTHER|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
58295587|NCT04192240|OTHER|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
58407097|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
57940231|NCT02607683|DRUG|XAF5 (concentration A: 0.1%)|
57940232|NCT02607683|DRUG|XAF5 (concentration B: 0.035%)|
57940233|NCT02607683|DRUG|Matching placebo|
57940234|NCT02596802|DEVICE|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
57940235|NCT04415957|OTHER|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
57940236|NCT03969849|DRUG|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
57940237|NCT03969849|DRUG|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
57940238|NCT00446524|DRUG|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
58075583|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
58075584|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
58075585|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
58075586|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
58075587|NCT06008938|GENETIC|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
58075588|NCT06008938|BIOLOGICAL|Factor IX (FIX)|FIX prophylaxis therapy
58075589|NCT05685355|DIAGNOSTIC_TEST|Standardized intraoral photography|Mouth photos will be taken with a plastic retractor to retract the subject's cheek and lips. This is a standard clinical procedure that is non-invasive and does not cause any harm or adverse effect on subjects.
58075590|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
58075591|NCT01794221|PROCEDURE|stitches only|standard of care
58295588|NCT03003442|DIETARY_SUPPLEMENT|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
58295589|NCT03003442|DIETARY_SUPPLEMENT|Placebo|Placebo
58295590|NCT00036283|DRUG|Celecoxib|
58295591|NCT05694806|OTHER|analysis of thoracic scans|analysis of thoracic scans realised in standard care
58295592|NCT01815658|DEVICE|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
57940239|NCT05534906|OTHER|Blood & Urine Samples|Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
57940240|NCT05534906|OTHER|Imaging|MRI \& MRE Scans
58295593|NCT02517957|DRUG|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
58295594|NCT02517957|DRUG|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
57940241|NCT04355741|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
58295595|NCT02517957|DRUG|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
58075592|NCT02978625|PROCEDURE|Biopsy|Undergo tissue biopsy
58075593|NCT02978625|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58075594|NCT02978625|PROCEDURE|Computed Tomography|Undergo CT
58075595|NCT02978625|OTHER|Laboratory Biomarker Analysis|Correlative studies
58075596|NCT02978625|BIOLOGICAL|Nivolumab|Given IV
58075597|NCT02978625|PROCEDURE|Positron Emission Mammography|Undergo PET/CT
58075598|NCT02978625|BIOLOGICAL|Talimogene Laherparepvec|Given IT
58075599|NCT04463719|BEHAVIORAL|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
58075600|NCT04463719|BEHAVIORAL|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
58075601|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
58075602|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
58075603|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
58075604|NCT02645682|DEVICE|anti-infection CVC|
58075605|NCT02645682|DEVICE|normal CVC|
58295596|NCT02517957|DRUG|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
58295597|NCT05734820|DIAGNOSTIC_TEST|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
58407098|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
58407099|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
58407100|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
58407101|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
58407102|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
58407103|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
58075606|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
58075607|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
58075608|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
58295598|NCT05734820|DIAGNOSTIC_TEST|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
58075609|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
58075610|NCT04456816|DRUG|Placebo|Matching placebo tablet
58295599|NCT01726075|DRUG|COLIRIOBCN070660|One drop per eye twice a day during 24 months
58295600|NCT01726075|DRUG|Placebo|One drop per eye twice a day during 24 months
58295601|NCT01726075|DRUG|Brimonidine|One drop per eye twice a day during 24 months
58295602|NCT05896397|PROCEDURE|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
58295603|NCT02962310|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
58295604|NCT02962310|DRUG|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
58295605|NCT03506438|BEHAVIORAL|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
58295606|NCT03506438|OTHER|Usual care|Usual ICU care as per the standards of the ICU attending
58295607|NCT02090504|DRUG|Sodium Oxybate (SMO)|
58295608|NCT02090504|DRUG|Oxazepam|
58295609|NCT01852123|DEVICE|High-sensitivity troponin I assay|
58295610|NCT05793281|OTHER|No Drug|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
58295611|NCT03789097|DRUG|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
58295612|NCT03789097|DRUG|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
58075611|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
58075612|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
58075613|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
58075614|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
58295613|NCT03789097|RADIATION|Radiation|The target site will get 2 small treatments of radiation.
58295614|NCT03789097|DRUG|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
58295615|NCT03692637|BIOLOGICAL|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
58295616|NCT00733278|DEVICE|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
58295617|NCT02900248|OTHER|Provider determined|Provider will treat patient as he/she feels best
58075615|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
58075616|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
58075617|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
57940242|NCT03221738|BEHAVIORAL|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
57940243|NCT04668053|OTHER|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
57940244|NCT04668053|OTHER|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
57940245|NCT04006340|COMBINATION_PRODUCT|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
57940246|NCT04006340|COMBINATION_PRODUCT|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
57940247|NCT04006340|DIAGNOSTIC_TEST|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
58075618|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
58075619|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
58295618|NCT03801642|DRUG|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
57940248|NCT03111485|DRUG|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
57940249|NCT03111485|DRUG|Placebo oral capsule|Capsule taken at bedtime
57940250|NCT05187052|OTHER|Tracheal intubation|Video-assisted intubation technique
57940251|NCT00578110|DEVICE|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
57940252|NCT05988268|OTHER|Vibration Foam Rolling|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
57940253|NCT05988268|OTHER|Non-Vibration Foam Rolling|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
57940254|NCT02931136|DRUG|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
57940255|NCT02931136|DRUG|Placebo|The participants will treatment by the placebo in 52 weeks.
57940256|NCT04952103|OTHER|no intervention|The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
58075620|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
58075621|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
58075622|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
58075623|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
58295619|NCT03801642|OTHER|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
58295620|NCT03155555|OTHER|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
58295621|NCT01859182|DRUG|selumetinib|Given PO
58295622|NCT01859182|DRUG|Akt inhibitor MK2206|Given PO
58295623|NCT01859182|OTHER|laboratory biomarker analysis|Correlative studies
58295624|NCT01859182|OTHER|pharmacogenomic studies|Correlative studies
58295625|NCT01859182|PROCEDURE|quality-of-life assessment|Ancillary studies
58295626|NCT05130827|DRUG|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
58295627|NCT01889368|DIETARY_SUPPLEMENT|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
57940257|NCT04660526|OTHER|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
57940258|NCT04660526|OTHER|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
58407104|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
57940259|NCT04660526|OTHER|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
57940260|NCT04660526|OTHER|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
57940261|NCT01547585|OTHER|Standardized soy containing muffin|Standardized muffin containing two levels of soy
57940262|NCT04169087|OTHER|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
57940263|NCT01550861|PROCEDURE|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
57940264|NCT01550861|PROCEDURE|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
57940265|NCT05206409|DIAGNOSTIC_TEST|Ultrasound|Fetal head position determination using ultrasound
57940266|NCT04410588|DRUG|Fentanyl + Topical Levobupivacaine|in nasal packing
57940267|NCT04410588|DRUG|levobupivacaine|in nasal packing
57940268|NCT02047136|OTHER|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
57940269|NCT02047136|OTHER|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
57940270|NCT04981314|DRUG|Equinacea Arkopharma|Echinacea hard caplets
57940271|NCT04981314|OTHER|Placebo|Placebo hard caplets
57940272|NCT02132884|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
57940273|NCT02132884|PROCEDURE|therapeutic procedure|Receive standard of care treatment
57940274|NCT02132884|DRUG|targeted therapy|Receive specific targeted therapy
57940275|NCT02132884|OTHER|laboratory biomarker analysis|Correlative studies
57940276|NCT04825795|DRUG|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
57940277|NCT04825795|DRUG|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
58295628|NCT01889368|DIETARY_SUPPLEMENT|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
58295629|NCT02402946|BEHAVIORAL|Biofeedback|
58295630|NCT02402946|DRUG|Placebo|
57940278|NCT04570501|DRUG|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
57940279|NCT04570501|DRUG|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
57940280|NCT06343506|DEVICE|Grassroots Ankle Flex|This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The Ankle Flex device is used to stretch patients into a dorsiflexion position by securing the foot to the base of the device and the shin to the leg strap attached to the pulley system. The patients can then pull the handle of the pulley system, giving them the mechanical advantage to gently mobilize their ankle into dorsiflexion with their foot firmly secured to the base of the device. This can allow for a deeper and more controlled stretch than previous stretching methods done during at home care.
58295631|NCT02712957|DRUG|NEO6860|TRPV1 antagonist
58295632|NCT02712957|DRUG|NEO6860 placebo|Inactive substance
58295633|NCT02712957|DRUG|Naproxen|NSAID
58295634|NCT02712957|DRUG|Naproxen placebo|inactive substance
58295635|NCT01005862|BIOLOGICAL|PF-04360365|10 mg/kg, single dose administered intravenously
58295636|NCT01005862|DRUG|Placebo|Placebo
58295637|NCT01534117|BIOLOGICAL|Platelets|1 unit of platelets
58295638|NCT01534117|DRUG|DDAVP|Desmopressin 0.3mcg/kg IV x 1
57940281|NCT03420794|OTHER|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
57940282|NCT04613154|DIETARY_SUPPLEMENT|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
57940283|NCT04613154|DIETARY_SUPPLEMENT|Placebo|Ester-c
57940284|NCT06070077|PROCEDURE|Chest compressions|2 minutes of chest compressions
57940285|NCT00280306|OTHER|No interventions|No intervention
57940286|NCT04765475|BEHAVIORAL|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
57940287|NCT04765475|BEHAVIORAL|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
57940288|NCT04765475|BEHAVIORAL|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
57940289|NCT04765475|OTHER|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
57940290|NCT03819881|BIOLOGICAL|STMC-103H|Live bacterial product
57940291|NCT03819881|BIOLOGICAL|Placebo|Inactive placebo substance
57940292|NCT03289936|DEVICE|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
58295639|NCT03291821|DRUG|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
57730946|NCT00856583|DRUG|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
57940293|NCT03289936|DEVICE|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
57940294|NCT02844920|DEVICE|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
57940295|NCT01630655|DRUG|Torrent's Felodipine Extended-Release Tablets|
57940296|NCT01377025|DRUG|Placebo|two tablets in the morning and two in the evening.
58295640|NCT03291821|DRUG|GnRH antagonist|GnRH antagonist subcutaneously
57730947|NCT00856583|DRUG|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
57730948|NCT00389662|DEVICE|"Wearing the Nike Free shoe"|
57940297|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
58295641|NCT03291821|DRUG|GnRH analog|GnRH analog subcutaneously
58295642|NCT03291821|PROCEDURE|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
58295643|NCT03291821|DIAGNOSTIC_TEST|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
58295644|NCT03291821|PROCEDURE|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
58295645|NCT03291821|PROCEDURE|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
57940298|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
57940299|NCT04541979|DRUG|aerosolized DNase|DNase
57940300|NCT04541979|DRUG|NaCl|NaCl 0.9%, isotonic saline
57940301|NCT00713479|DRUG|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
57940302|NCT00713479|DRUG|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
58075624|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
58075625|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
58075626|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
58295646|NCT03291821|DIAGNOSTIC_TEST|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
58295647|NCT03291821|PROCEDURE|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
58295648|NCT03291821|DIAGNOSTIC_TEST|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
58295649|NCT03291821|PROCEDURE|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
58295650|NCT03291821|PROCEDURE|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
58295651|NCT03075267|DRUG|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
58295652|NCT03075267|DRUG|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
58295653|NCT03075267|DRUG|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
58295654|NCT03146741|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
58295655|NCT02627456|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
57730949|NCT04634604|DRUG|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
58295656|NCT02627456|BIOLOGICAL|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
58295657|NCT02627456|DRUG|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
58295658|NCT02627456|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
58407105|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
58407106|NCT00101764|DRUG|Triamcinolone Acetonide|
58407107|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
57940303|NCT06051032|DEVICE|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
58407108|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
58407109|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
58407110|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
57940304|NCT06051032|DEVICE|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
57940305|NCT05781230|BEHAVIORAL|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
58075627|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
58075628|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
58075629|NCT03326882|DEVICE|Endotracheal intubation|
58075630|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
58075631|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
58075632|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
58075633|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
58075634|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
58075635|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
58075636|NCT06522373|DRUG|MT-0169|Given by Vein (IV)
58075637|NCT06725004|DRUG|Oxytocin|Injection Oxytocin 10 mg intramuscular as trigger for ovulation induction
58075638|NCT06725004|DRUG|Human Chorionic Gonadotropin|Injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
58075639|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
58075640|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
58075641|NCT05534620|DRUG|Treosulfan|IV infusion
58075642|NCT05534620|DRUG|Fludarabine|IV infusion
58075643|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
58075644|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
58075645|NCT06165471|BEHAVIORAL|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
58075646|NCT06165471|BEHAVIORAL|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
58075647|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
58295659|NCT02627456|DRUG|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
58295660|NCT02627456|DRUG|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
57940306|NCT05781230|BEHAVIORAL|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity
57940307|NCT00003936|DRUG|bryostatin 1|
57940308|NCT02933099|DRUG|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
57940309|NCT02933099|DRUG|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
57940310|NCT00528515|DRUG|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
57940311|NCT00528515|DRUG|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
57940312|NCT04961268|DRUG|TraMADol 50 Mg Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
57940313|NCT04961268|DRUG|Tramadol 100 MG Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
57940314|NCT04961268|DRUG|Ibuprofen 600Mg Tab|The patients were randomly given the medication by mouth 60 min before administering IANB.
57940315|NCT04961268|DRUG|ibuprofen 600 mg/acetaminophen 1000 mg|The patients were randomly given the medication by mouth 60 min before administering IANB.
57940316|NCT04961268|DRUG|Placebo|The patients were randomly given the medication by mouth 60 min before administering IANB.
57940317|NCT00924105|DRUG|CYT013-IL1bQb|s.c. injection
57940318|NCT00924105|DRUG|Placebo|s.c. injection
57940319|NCT04641299|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
57940320|NCT04641299|DRUG|Placebo|Placebo solution
57940321|NCT01003210|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
58075648|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
58295661|NCT00785161|DEVICE|Penumbra System|Mechanical Thrombectomy in acute stroke
58295662|NCT04248946|OTHER|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
58295663|NCT03559504|DRUG|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
57940322|NCT04857996|DRUG|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
57940323|NCT04857996|OTHER|Sham|Sham procedure
57940324|NCT02372916|DRUG|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
57940325|NCT03685383|DEVICE|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
57940326|NCT03685383|DEVICE|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
57940327|NCT02443896|PROCEDURE|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
57940328|NCT02443896|PROCEDURE|No sealant of permanent molars|No sealant applied to permanent molars.
57940329|NCT06238674|OTHER|indirect calorimetry and nitrogen balance|"nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance"
57940330|NCT06238674|OTHER|Indirect calorimetry (Standard care nutrition arm)|indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
57940331|NCT00470054|DRUG|dasatinib|Given PO
57940332|NCT02895620|BIOLOGICAL|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
57940333|NCT05515705|DEVICE|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
58075649|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
58295664|NCT05610488|DRUG|FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]|Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
57940334|NCT04315194|DRUG|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
57940335|NCT04263064|DRUG|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
57940336|NCT04263064|DRUG|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
57940337|NCT05046847|DRUG|TQB3811|TQB3811 is a second-generation TrkA inhibitor.
57940338|NCT02198443|DRUG|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
57940339|NCT02198443|DRUG|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
57940340|NCT01194713|BEHAVIORAL|Sleep deprivation|subjects will undergo one night of full sleep deprivation
57940341|NCT03208764|DRUG|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
57940342|NCT00311376|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
57940343|NCT00311376|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval
57940344|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
57940345|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval
57940346|NCT03428022|DRUG|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
57940347|NCT01555567|DEVICE|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
57940348|NCT01555567|OTHER|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
58075650|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
58075651|NCT04985916|BIOLOGICAL|Vehicle|topical liniment without investigational product
58295665|NCT06521047|OTHER|NA - Observational study|Observational study, data collection only.
58295666|NCT03498313|DRUG|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
58075652|NCT04985916|BIOLOGICAL|botulinum toxin, Type A|ET-01 topical liniment
58075653|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
58075654|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
57940349|NCT01058070|DEVICE|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
57940350|NCT01021787|DRUG|Titanium dioxide|Topical cream
57940351|NCT05355272|DRUG|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
57940352|NCT00238173|BIOLOGICAL|filgrastim|
57940353|NCT00238173|DRUG|acetylcysteine|administered i.v. over 30 to 60 minutes
57940354|NCT00238173|DRUG|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
57940355|NCT00238173|DRUG|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
57940356|NCT00238173|DRUG|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
57940357|NCT00238173|DRUG|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
57940358|NCT00238173|DRUG|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
57940359|NCT00907751|DRUG|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
58295667|NCT03498313|DRUG|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
58407111|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
58407112|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
58407113|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
58407114|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
57940360|NCT02822885|RADIATION|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
57940361|NCT02282566|OTHER|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
57940362|NCT01761825|DRUG|ivabradine|
57940363|NCT00745407|DRUG|fenofibrate|
57940364|NCT03018587|DEVICE|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
57940365|NCT04018794|DEVICE|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
57940366|NCT02791282|OTHER|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
57940367|NCT02483559|OTHER|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (\~470 nm) to be worn prior to desired sleep onset time.
58295668|NCT03498313|DRUG|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
57940368|NCT02483559|OTHER|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
57940369|NCT02975427|OTHER|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
57940370|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
57940371|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
58295669|NCT00225186|DRUG|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
57730950|NCT04634604|PROCEDURE|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
57940372|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
57940373|NCT00310804|BIOLOGICAL|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
57940374|NCT00693914|BEHAVIORAL|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
57940375|NCT00865683|DIETARY_SUPPLEMENT|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
57940376|NCT00865683|DIETARY_SUPPLEMENT|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
57940377|NCT00192387|BIOLOGICAL|CAIV-T, Liquid|
57940378|NCT00163267|DRUG|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
57940379|NCT03442036|DEVICE|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
57940380|NCT03442036|DEVICE|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
57940381|NCT01456650|DRUG|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
57940382|NCT00068575|BIOLOGICAL|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
57940383|NCT00068575|DRUG|Cisplatin|30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
58075655|NCT05549804|DRUG|KL340399 Intratumoral|KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
58075656|NCT05999747|DRUG|pudexacianinium chloride|Intravenous
58295670|NCT01604889|DRUG|Epacadostat|
58075657|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
58295671|NCT01604889|DRUG|Placebo|Placebo
58295672|NCT01604889|DRUG|ipilimumab|ipilimumab 3 mg/kg IV
58295673|NCT01604889|DRUG|ipilimumab|Doses to be determined following the completion of Phase I of the study
58295674|NCT03110133|DRUG|Full Spectrum Microbiota|Orally administered donor derived microbiota
58295675|NCT03110133|DRUG|Placebo|Placebo for CP101
58075658|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
58075659|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
58075660|NCT01751490|OTHER|physiotherapy|physiotherapy
58075661|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
58075662|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
58295676|NCT01638715|DRUG|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
58295677|NCT01638715|DRUG|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
58295678|NCT01638715|DRUG|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
58295679|NCT01638715|DRUG|Mabthera|"- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
58295680|NCT00789620|DRUG|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
58295681|NCT00789620|DRUG|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
58295682|NCT05796700|PROCEDURE|Microwave Ablation|"Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation"
58295683|NCT03421379|DRUG|Glucagon Nasal Powder|Administered intranasally
57940384|NCT00068575|DRUG|Fluorouracil|175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
57940385|NCT00068575|RADIATION|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
57940386|NCT00299052|DEVICE|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
57940387|NCT00299052|BIOLOGICAL|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
58295684|NCT03421379|DRUG|Glucagon Hydrochloride Solution|Administered IM
58295685|NCT00887705|BEHAVIORAL|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
58407115|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
58407116|NCT00537732|DRUG|omeprazole|20 mg daily
58407117|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
57940388|NCT05932875|OTHER|Exercise Training|4 day per week concurrent exercise training program
58075663|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
58075664|NCT02369874|DRUG|Standard of Care|Standard of Care
58075665|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
58075666|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
58075667|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
58407118|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
58407119|NCT02563860|DRUG|Lovastatin|dose escallating
57730951|NCT06626828|DEVICE|Electroacupuncture|Disposable sterilized needles are inserted into selected acupoints at a depth of approximately 17-25 mm and an angle of 15-30° along the scalp. Acupoints are then stimulated by the SDZ-II electroacupuncture device, with a dilatational wave pattern at 4/20 Hz. The intensity of the stimulation was adjusted to the patient\&#39;s tolerance.
57940389|NCT01977820|DRUG|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
57940390|NCT01977820|DRUG|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
57940391|NCT01534013|DEVICE|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
58295686|NCT05569122|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
58295687|NCT05569122|DEVICE|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
58407120|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
58407121|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
58407122|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
58407123|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
58407124|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
58407125|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
58407126|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
58407127|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
58407128|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
58407129|NCT02202512|DRUG|Placebo|tablets
58407130|NCT02202512|DRUG|Cimetidine|
57940392|NCT01534013|DEVICE|Open loop|glucose sensor and pump
57940393|NCT03226314|PROCEDURE|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
58407131|NCT02202512|DRUG|Placebo|tablets
58407132|NCT02202512|DRUG|Placebo|tablets
58407133|NCT02202512|DRUG|BI 1060469 high dose|tablets
58407134|NCT02202512|DRUG|BI 1060469 low dose|tablets
58407135|NCT02202512|DRUG|Naproxen|
58407136|NCT02202512|DRUG|BI 1021958|tablets
57940394|NCT02773030|DRUG|CC-220|Specified dose on specified days
57940395|NCT02773030|DRUG|Dexamethasone|Specified dose on specified days
58295688|NCT05569122|DEVICE|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
58295689|NCT05569122|DEVICE|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
58295690|NCT05569122|DRUG|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
58295691|NCT05714787|OTHER|Chest CT Scan examination|Double examination of chest CT scan on sagittal section after multiplanar reconstruction
57730952|NCT06636240|DIETARY_SUPPLEMENT|Mulberry fruit juice|Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including Fluticasone and Prednisolone
57730953|NCT06636240|OTHER|Fluticasone|Standard therapy for atopic dermatitis including Fluticasone and Prednisolone
57730954|NCT06111950|OTHER|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
57940396|NCT02773030|DRUG|Daratumumab|Specified dose on specified days
57940397|NCT02773030|DRUG|Bortezomib|Specified dose on specified days
58295692|NCT02233699|DRUG|XEN-D0501|
58295693|NCT02233699|DRUG|Placebo|
58295694|NCT04985045|OTHER|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
58295695|NCT04978324|BIOLOGICAL|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
58407137|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
58407138|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
58407139|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
58407140|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
58407141|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
58407142|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
57940398|NCT02773030|DRUG|Carfilzomib|Specified dose on specified days
57940399|NCT03837782|PROCEDURE|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
57940400|NCT03410849|DIAGNOSTIC_TEST|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
58295696|NCT04978324|PROCEDURE|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
58407143|NCT00150358|DRUG|Sildenafil Citrate|
58407144|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
58407145|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
58407146|NCT01598883|DRUG|Heparin|150 U/kg
58407147|NCT01598883|DRUG|ATryn|1000 IU
58075668|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
58295697|NCT02750332|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
58295698|NCT03970525|DEVICE|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
58295699|NCT03970525|DEVICE|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
58407148|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
58407149|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
58407150|NCT02183337|DRUG|BI 1356|
58407151|NCT02183337|DRUG|BI 1356 + Pioglitazone|
58407152|NCT02183337|DRUG|Pioglitazone|
58407153|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
58407154|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
58407155|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
58407156|NCT00521430|DRUG|busulfan|
58407157|NCT00521430|DRUG|cyclosporine|
58407158|NCT00521430|DRUG|fludarabine phosphate|
58407159|NCT00521430|DRUG|methotrexate|
58407160|NCT00521430|DRUG|methylprednisolone|
58407161|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58407162|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
58407163|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
58407164|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
58407165|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
58407166|NCT02101801|OTHER|vegetables from fresh or recycled water|
58407167|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
58407168|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
58407169|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
58407170|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
58407171|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
58407172|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
58407173|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
58407174|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
58407175|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
58407176|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
58407177|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
58407178|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
58407179|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
58407180|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
58407181|NCT02879591|OTHER|Social Skills training with Avatar therapist|
58407182|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
58407183|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
57940401|NCT05195944|DRUG|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
58075669|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
58295700|NCT04777760|DRUG|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
58295701|NCT04777760|DRUG|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
58295702|NCT05057221|DRUG|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
58295703|NCT00311688|DRUG|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
58295704|NCT05216445|BEHAVIORAL|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
58295705|NCT04906226|BEHAVIORAL|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
57940402|NCT05195944|DRUG|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
58295706|NCT05688865|OTHER|urinary markers|urinary marker testing
58407184|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
58407185|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
58407186|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
58407187|NCT00025428|DRUG|carboplatin|
58095185|NCT05443503|OTHER|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
58407188|NCT00025428|DRUG|cyclophosphamide|
58407189|NCT00025428|DRUG|doxorubicin hydrochloride|
58407190|NCT00025428|DRUG|etoposide|
58407191|NCT00025428|DRUG|vincristine sulfate|
58407192|NCT00025428|PROCEDURE|adjuvant therapy|
58407193|NCT00025428|PROCEDURE|conventional surgery|
58407194|NCT00025428|PROCEDURE|neoadjuvant therapy|
58407195|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
58407196|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
58407197|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
58407198|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
58075670|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
58075671|NCT05696184|DIAGNOSTIC_TEST|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
58075672|NCT05696184|DIAGNOSTIC_TEST|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
58075673|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
58075674|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
58075675|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
58075676|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
58075677|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
57940403|NCT04582149|DEVICE|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
57940404|NCT05717842|RADIATION|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
57940405|NCT02247245|DRUG|Ivabradine|Ivabradine 7.5mg
57940406|NCT02247245|OTHER|Atrial fibrillation|Pacemaker base rate alteration
57940407|NCT02247245|DRUG|Placebo|Placebo
57940408|NCT05765006|BIOLOGICAL|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
57940409|NCT02018198|DIAGNOSTIC_TEST|FebriDx|Point of Care Host Immune Response Test
57940410|NCT02707380|OTHER|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
57940411|NCT02707380|OTHER|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
57940412|NCT03924336|PROCEDURE|Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
57940413|NCT03924336|PROCEDURE|Open flap debridement (OFD) alone|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
57940414|NCT02153554|BEHAVIORAL|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
57940415|NCT02538016|DRUG|Tolvaptan|
57940416|NCT03409848|DRUG|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
57940417|NCT03409848|DRUG|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
57940418|NCT03409848|DRUG|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
57940419|NCT01484977|DRUG|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
57940420|NCT05251740|DEVICE|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
58407199|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
57940421|NCT05427136|DIAGNOSTIC_TEST|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~* Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~* Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
58295707|NCT03927859|OTHER|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
58295708|NCT04296708|OTHER|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
58295709|NCT03461198|DEVICE|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
58295710|NCT06218615|OTHER|Educational Intervention (Video)|Watch video
58295711|NCT06218615|OTHER|Survey Administration|Answer survey questions
57940422|NCT05427136|DIAGNOSTIC_TEST|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
57940423|NCT05427136|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
57940424|NCT05427136|OTHER|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
57940425|NCT05427136|OTHER|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
57940426|NCT05427136|OTHER|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
57940427|NCT00931242|DRUG|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
57940428|NCT03687073|DRUG|Indole-3-Carbinol|Cohorts 2, 3, \& 4: 400 mg PO BID
57940429|NCT03687073|DRUG|Silibinin|Cohorts 1 \& 4: 720mg
57940430|NCT03687073|DRUG|Silibin|Cohort 3: 360mg
57940431|NCT03679611|DRUG|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
57940432|NCT03679611|DRUG|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
57940433|NCT06472154|OTHER|Experimental|The experimental group intervened based on the midnight-noon ebb-flow theory, listening to music corresponding to the five organs at different time periods.
57940434|NCT06472154|OTHER|Control|The control group listened to Chinese five elements music pieces from 13:00 to 18:00 p.m., each music piece for within 30 minutes for, 5 days per week, 4 weeks for a cycle, 3 cycles in total.
57940435|NCT01775332|OTHER|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
58295712|NCT06611618|OTHER|Muscle power assessment|Isokinetic dynamometry test Stair ascent/descent on instrumented stairs
58295713|NCT06611618|OTHER|Muscle force assessment|Isometric dynamometry (Maximal Voluntary Isometric Contraction)
58295714|NCT06611618|OTHER|Home-based mobility monitoring|Mobility monitoring with wearable sensors
58295715|NCT06611618|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Full lower limb MRI
58295716|NCT06611618|OTHER|Gait assessment|Motion capture, surface EMG and gorund reaction force data
58295717|NCT03185286|DEVICE|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
58295718|NCT02788643|BIOLOGICAL|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
58295719|NCT02923583|BIOLOGICAL|M834|
58407200|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
58407201|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
58407202|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
58407203|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
58295720|NCT02923583|BIOLOGICAL|US-Sourced Orencia®|
58407204|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
58407205|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
58407206|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
58407207|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
58295721|NCT02923583|BIOLOGICAL|EU-Sourced Orencia®|
58075678|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
58075679|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
57940436|NCT04442971|BEHAVIORAL|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
57940437|NCT04442971|BEHAVIORAL|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
57940438|NCT04442971|BEHAVIORAL|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
57940439|NCT00184626|DRUG|biphasic insulin aspart|
57940440|NCT00184626|DRUG|insulin glargine|
57940441|NCT00184626|DRUG|metformin|
58295722|NCT02953483|OTHER|Red blood cells|Packed red blood cells to final hematocrit of 14%
58295723|NCT05573451|DIAGNOSTIC_TEST|ultrasound - transvaginal/transrectal + transabdominal|Each patient undergoes at least ultrasound examination and PET-CT.
58295724|NCT03788161|OTHER|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
58295725|NCT03788161|OTHER|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
58295726|NCT06071741|PROCEDURE|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
58295727|NCT01947101|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
58295728|NCT04778839|DRUG|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
58295729|NCT04778839|DRUG|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
58295730|NCT04187443|DRUG|MS-553|MS-553
58407208|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
58407209|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
58407210|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
58407211|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
57940442|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
58075680|NCT04815005|OTHER|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
58095186|NCT04327609|DEVICE|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
58295731|NCT04789525|OTHER|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
58295732|NCT03215537|BEHAVIORAL|comprehensive intervention|preoperative and postoperative exercise program
58295733|NCT03863847|PROCEDURE|Neurofeedback|The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
58295734|NCT03863847|PROCEDURE|Sham|The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
57940443|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
58075681|NCT05715190|OTHER|Education|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment. Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
58075682|NCT06722963|DRUG|fentanyl|Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
58075683|NCT06722963|DRUG|Nalbuphine|Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
58075684|NCT02185443|RADIATION|SBRT|"* 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
58075685|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
57940444|NCT00771823|DRUG|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
57940445|NCT00771823|DRUG|Maraviroc|"* Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study."
57940446|NCT05161533|DRUG|Carboplatin|Given IV
58095187|NCT04327609|DEVICE|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
58295735|NCT05380154|DRUG|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
58295736|NCT05380154|DRUG|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
58295737|NCT00018642|DRUG|quetiapine|
58295738|NCT00018642|DRUG|haloperidol decanoate|
58295739|NCT00029393|PROCEDURE|Hematopoietic Stem Cell Transplantation|
58295740|NCT00029393|DRUG|Immunosuppression|
58407212|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
57940447|NCT05161533|DRUG|Cisplatin|Given IV
57940448|NCT05161533|BIOLOGICAL|Durvalumab|Given IV
58295741|NCT00828113|DRUG|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
58295742|NCT00828113|DRUG|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
58295743|NCT00828113|BEHAVIORAL|Individual smoking cessation counseling|Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
58295744|NCT04796766|DIAGNOSTIC_TEST|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
57940449|NCT05161533|DRUG|Etoposide|Given IV
57940450|NCT05161533|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
57940451|NCT05161533|OTHER|Quality-of-Life Assessment|Ancillary studies
57940452|NCT05161533|OTHER|Questionnaire Administration|Ancillary studies
57940453|NCT01177683|DRUG|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
58095188|NCT00830271|DEVICE|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
58095189|NCT00830271|DEVICE|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
58295745|NCT04796766|DIAGNOSTIC_TEST|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
58295746|NCT02084901|DEVICE|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
58295747|NCT02084901|DEVICE|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
58295748|NCT06518733|OTHER|appliance type|different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews
58095190|NCT04897334|DEVICE|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
58295749|NCT03967288|DRUG|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
57940454|NCT01177683|DRUG|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
57940455|NCT01177683|DRUG|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
58295750|NCT03967288|DRUG|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
58295751|NCT06408337|PROCEDURE|implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).|cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
58295752|NCT04226781|DIAGNOSTIC_TEST|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
58295753|NCT04226781|DIAGNOSTIC_TEST|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
58295754|NCT02240017|DRUG|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
58295755|NCT02240017|DRUG|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
57940456|NCT01177683|DRUG|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
57940457|NCT01177683|DRUG|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000"
57940458|NCT01483716|BEHAVIORAL|Rehabilitation|
57940459|NCT00888420|OTHER|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
57940460|NCT00626704|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
57940461|NCT00626704|OTHER|Placebo|Inactive dummy AMG 655 (to maintain blind)
57940462|NCT00626704|DRUG|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
57940463|NCT00922480|DRUG|Fimasartan|Fimasartan 60 \~ 120mg/po take one tablets once a day
57940464|NCT00922480|DRUG|Losartan (Control)|Losartan 50 mg \~ 100 mg/po, take one tablets once a day
57940465|NCT03040791|DRUG|Nivolumab|Nivolumab
57940466|NCT04354545|DRUG|Xiidra (Lifitegrast ophthalmic solution) 5%|FDA approved lifitegrast opthalmic solution eye drop
57940467|NCT00282295|BIOLOGICAL|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
57940468|NCT00282295|BIOLOGICAL|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
57940469|NCT02964026|DEVICE|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
57940470|NCT05981170|OTHER|Adapted physical activity at home|"The programme will take place over 6 months and will include :~1 consultation with the oncologist who will first assess the need for Adapted Physical Activity and then prescribe the APA with a certificate of no physical contraindication~1 consultation with the ICO's APA coach who will present the APA programme and assess the patient's physical capacity using the Short Physical Performance Battery (SPPB) test in order to adapt the programme to their needs.~13 home-based APA sessions (ideally one session per week) with the EAPA from Departmental Committee for Sport for All in 49~1 telephone call with the EAPA of the ICO to evaluate the programme 3 months after the last session.~Patients will also be asked to complete questionnaires at the first session (S1), halfway through the sessions (S6) and at the last session (S13).~These are FACIT-F 5Functional Assessment of Chronic Illness Therapy - Fatigue ; Ricci and L. Gagnon ; P-GIC (Patients' Global Impression of Change (PGIC) scale)"
57940471|NCT05106673|BEHAVIORAL|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
57940472|NCT05106673|BEHAVIORAL|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
58407213|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
58075686|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
58075687|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
58075688|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
58075689|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
58075690|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
58075691|NCT02919709|BIOLOGICAL|blood taking|
58075692|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
58075693|NCT05731726|DRUG|Serplilumab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits."
58075694|NCT05731726|DRUG|Capecitabine|Given PO
58075695|NCT05731726|DRUG|Oxaliplatin|Given IV
58075696|NCT05731726|DRUG|Celecoxib|celebrex
58295756|NCT02240017|DRUG|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
58075697|NCT01934842|DEVICE|TAP20-C|
58075698|NCT01934842|DEVICE|SAFE-T-FILL|
58075699|NCT06723067|DEVICE|Wearable wireless breast pump|As above
58295757|NCT03243825|RADIATION|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
57730955|NCT06111950|OTHER|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
58075700|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
58295758|NCT03243825|DRUG|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
58295759|NCT05710900|OTHER|Dietary intervention|Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
58295760|NCT02004938|DEVICE|Sonosite Titan Ultrasound Machine|
58075701|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
58075702|NCT03892967|OTHER|Interview|Participate in interview
57730956|NCT06111950|OTHER|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
58075703|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
58075704|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
58075705|NCT05656729|DIETARY_SUPPLEMENT|DefensePlus|Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
58075706|NCT05656729|DIETARY_SUPPLEMENT|Placebo|Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
58075707|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
58075708|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
57730957|NCT04848038|BEHAVIORAL|Exercise|Standard public health exercise recommendations
58075709|NCT03596645|DRUG|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
58075710|NCT03596645|DRUG|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
58075711|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
58075712|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
58075713|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
58075714|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
58075715|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
58075716|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
58075717|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
58075718|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
58075719|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
58075720|NCT06291909|BEHAVIORAL|Small Steps Program|Participants in the intervention group will be given access to the Small Steps website. Small Steps website provides a visual representation of the participant's current use of time and allows for manipulation to demonstrate how small lifestyle changes may improve sleep and physical activity needs. The personal outcome goals selected by the participant will also feature on participant's dashboard within the Small Steps website as a reminder. Participants will be prompted through the first 12 weeks to add a new behaviour change each week and will receive support phone calls weekly. During the 12-week Maintenance Phase participants will be guided to maintain their new behaviour, with supportive phone calls being progressively reduced from fortnightly to monthly. At the completion of the 12 weeks, investigator support will be withdrawn. Maintenance of the new behaviour without support will then be assessed over 12 additional weeks in the Follow-Up phase.
58075721|NCT06291909|BEHAVIORAL|Comparator Program|Participants will receive generic health advice only and it will not be individually tailored, nor will they receive weekly support phone calls during the first 12-weeks. Participants will receive no feedback or support in the Maintenance or Follow-Up phases.
58075722|NCT04142697|BEHAVIORAL|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
58075723|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
57940473|NCT05106673|BEHAVIORAL|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
58075724|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58295761|NCT05231343|PROCEDURE|Dual Mini-fragment Plating|Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.
58295762|NCT05231343|PROCEDURE|Single Precontoured Plating|Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
58295763|NCT02895347|BEHAVIORAL|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
58295764|NCT04739033|BEHAVIORAL|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
58295765|NCT02958579|OTHER|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
58295766|NCT00953290|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
58295767|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
58295768|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50
58407214|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
58407215|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
58295769|NCT00366782|BIOLOGICAL|Placebo|Placebo for rB/HPIV3 vaccine
58295770|NCT03064711|DIAGNOSTIC_TEST|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
58295771|NCT05618015|PROCEDURE|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
58295772|NCT05618015|PROCEDURE|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
58295773|NCT04038112|OTHER|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
58295774|NCT03363607|PROCEDURE|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
58295775|NCT03363607|PROCEDURE|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
58407216|NCT00875238|BIOLOGICAL|trastuzumab|
58407217|NCT00875238|DRUG|doxorubicin hydrochloride|
58407218|NCT00875238|GENETIC|polymorphism analysis|
57940474|NCT05106673|OTHER|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
57940475|NCT06417359|PROCEDURE|Mesh Fixation|That mesh will be fixation with three tackers.
57940476|NCT06417359|PROCEDURE|No Mesh Fixation|That mesh will not be fixation
57940477|NCT02319291|DEVICE|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
57940478|NCT03846570|DRUG|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
58295776|NCT03363607|PROCEDURE|Intraoral scanning|Intraoral Scanning of the bonded brackets
58407219|NCT00875238|OTHER|laboratory biomarker analysis|
58407220|NCT00875238|OTHER|questionnaire administration|
58407221|NCT00875238|PROCEDURE|assessment of therapy complications|
58407222|NCT00875238|PROCEDURE|magnetic resonance imaging|
58407223|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
57940479|NCT03846570|DRUG|Placebo|Matching placebo (identically package) administered BID
57940480|NCT00415506|DRUG|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
57940481|NCT03505047|DEVICE|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
57940482|NCT02428712|DRUG|FORE8394|
57940483|NCT04776473|PROCEDURE|Open treatment|Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
57940484|NCT04776473|OTHER|Closed treatment|Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
58075725|NCT06722001|BEHAVIORAL|"The Brief insomnia intervention interactive e-book"|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
58075726|NCT06722001|BEHAVIORAL|traditional paper handout|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
58075727|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
58075728|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
58075729|NCT06619587|DRUG|Phase I Arm A|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
58075730|NCT06619587|DRUG|Phase I Arm B|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
58295777|NCT03363607|PROCEDURE|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
58407224|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
58407225|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
58407226|NCT05363293|DRUG|AL 001|a crystal engineered lithium-salicylate-proline lithium delivery product
58407227|NCT05363293|DRUG|Placebo|matching placebo formulation
58407228|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
57940485|NCT05863975|DRUG|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
58075731|NCT06724458|OTHER|Resistance exercise|All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
58075732|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
58075733|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
58075734|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
58075735|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
58075736|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
57940486|NCT05311670|BEHAVIORAL|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
57940487|NCT03223870|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
57940488|NCT04275505|OTHER|shortwave diathermy treatment|shortwave diathermy is a deep heating physical therapy agent. It was found efficiaous in carpal tunnel syndrome which is an entrapment neuropathy like ulnar nerve entrapment so it was hypothesised that shortwave diathermy could be an effective treatment method in ulnar nerve entrapment.
57940489|NCT04275505|OTHER|placebo shortwave diathermy treatment|shortwave device was not turned on while participants were asked to put their elbow into the device
57940490|NCT03593850|BEHAVIORAL|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
57940491|NCT03593850|BEHAVIORAL|Silence Group|Audio file that contained no sounds.
57940492|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
57940493|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
57940494|NCT00047671|DRUG|Citalopram|PDA Approved antidepressant
57940495|NCT05316532|DEVICE|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
58295778|NCT01417975|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
58295779|NCT01417975|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
58407229|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
58075737|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
58075738|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
58075739|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
58075740|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
58075741|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
58075742|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
58075743|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
58075744|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
58407230|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
58407231|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
58075745|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
58075746|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58075747|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
58295780|NCT04391777|OTHER|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
58295781|NCT04391777|OTHER|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
57940496|NCT06537648|BEHAVIORAL|Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program|Adults with Down syndrome will be asked to attend 35 minute, remotely delivered (Zoom®) group dance sessions twice weekly across 12 weeks. All sessions will be directed by an instructor experienced in leading 35 minute, group remote exercise sessions for individuals with intellectual disability as part of the ongoing exercise program for individuals with intellectual disability offered by the Division for Physical Activity and Weight Management.
57940497|NCT03848754|DRUG|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
57940498|NCT03848754|DRUG|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
57940499|NCT03848754|DRUG|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
57940500|NCT03848754|DRUG|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
58075748|NCT06723795|OTHER|Cardiologist evaluation|The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.
58075749|NCT06723795|OTHER|Pulmonologist evaluation|optimize basic treatment, and recommend continued follow-up as needed.
58095191|NCT04897334|DEVICE|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
58295782|NCT04010461|DEVICE|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
57730958|NCT06573398|COMBINATION_PRODUCT|SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin|Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
57940501|NCT03260634|DRUG|Voriconazole|
57940502|NCT06110260|DIETARY_SUPPLEMENT|AstraGin (Ginseng and Astragalus Saponin Extract)|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
58075750|NCT06260995|OTHER|Social Prescribing Link Worker Intermediary Intervention|Social prescribing link workers \[SPLW\] receive referrals from healthcare professionals, community services, or through self-referral. Individuals are referred for social isolation or social needs, frequent healthcare attendance, or to address a pre-existing health issue. SPLW carry out an in-depth assessment of the individual's needs, and then work with the individual over weeks and months to connect them to community services and supports, which can include local physical activities. They use several strategies during this follow-up period, such as instrumental support (doing things for the individual), empowerment and motivation techniques and/or attending activities with the individual. After the SPLW establishes a connection to a local physical activity, the individual enrols and participates in the chosen activity. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi.
58075751|NCT06260995|OTHER|Local Sports Partnership Community Development Officer Intervention|Local sports partnership community development officers \[LSPO\] mainly receive self-referrals, or can receive referrals, to improve physical activity levels of individuals through participation in physical activity groups delivered by the partnership. LSPO do not carry out an in-depth assessment but may carry out screening before explaining/signposting to local physical activities. They use several strategies to connect the individual to local physical activities, such as attending the first session of the group, providing reassurance and practical support, and keeping the person updated and informed as to upcoming groups. After the LSPO establishes a connection to a local physical activity, the individual enrols and participated in the chosen activity. The LSPO continues to support this engagement during the follow-up period. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi amongst others.
58075752|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
58075753|NCT06724692|OTHER|Ultra-processed breakfast|With this intervention, participants will consume ultra-processed foods
58407232|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
58407233|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
58407234|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
57940503|NCT06110260|DIETARY_SUPPLEMENT|Placebo|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
57940504|NCT05006157|DEVICE|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
57940505|NCT04290338|OTHER|PIOMI|Intraoral and extraoral stimulation.
57940506|NCT01761279|PROCEDURE|High definition white light endoscopy|
58407235|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
58407236|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
57730959|NCT06086223|PROCEDURE|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
57730960|NCT06086223|PROCEDURE|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
57730961|NCT06442371|OTHER|High Intensity interval training + Quranic Listening|In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
57940507|NCT02551614|PROCEDURE|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
57940508|NCT02551614|PROCEDURE|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
57940509|NCT02551614|PROCEDURE|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
57940510|NCT05360173|BEHAVIORAL|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
57940511|NCT05360173|BEHAVIORAL|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
57940512|NCT03991000|DRUG|Ferric carboxymaltose|Intravenous iron
57940513|NCT03991000|DRUG|Saline|Saline application according to dosing rules of iron.
57940514|NCT02146742|DRUG|ASP1707|oral
57940515|NCT02146742|DRUG|Placebo|oral
57940516|NCT05009927|DRUG|Imatinib tablets|Imatinib interruption
57940517|NCT00228397|DRUG|CCI-779|
57940518|NCT02435108|DRUG|crizotinib|crizotinib 250mg bid daily
57940519|NCT03089775|DRUG|BBI-2000|Experimental
57940520|NCT03089775|DRUG|Vehicle|Vehicle Comparator
58407237|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
58407238|NCT03960580|DRUG|OPN-375|OPN-375, BID
58407239|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
58407240|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
58075754|NCT06724692|OTHER|Low-processed breakfast|With this intervention, participants will consume low-processed foods
57940521|NCT03089775|OTHER|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
57940522|NCT03269370|BEHAVIORAL|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
57940523|NCT03269370|BEHAVIORAL|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
58075755|NCT05805306|BEHAVIORAL|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
58075756|NCT05805306|BEHAVIORAL|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
58075757|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
58407241|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
58075758|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
58407242|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
57940524|NCT03269370|BEHAVIORAL|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)"
57940525|NCT00555477|DRUG|anastrozole|1 mg tablet by mouth once a day
58407243|NCT01825395|DRUG|3, 4-Diaminopyridine|
58407244|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
58407245|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
57940526|NCT02254577|DRUG|Endometrin® plus Progesterone in Oil (PIO)|
58407246|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
57940527|NCT02254577|DRUG|Progesterone in Oil (PIO) Only|
57940528|NCT03848689|OTHER|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
57940529|NCT03848689|OTHER|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
57940530|NCT01347424|DRUG|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
58075759|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
58075760|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
58075761|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
58075762|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
58075763|NCT06520865|OTHER|Acoustic paradigms|Acoustic oddball Gap detection
58295783|NCT04010461|BEHAVIORAL|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
58295784|NCT01096953|BEHAVIORAL|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
58295785|NCT01096953|BEHAVIORAL|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
58295786|NCT02942069|BEHAVIORAL|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
58295787|NCT02767778|DEVICE|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
58295788|NCT02767778|DEVICE|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
58295789|NCT01039766|DRUG|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
58407247|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
58407248|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
57940531|NCT01347424|DRUG|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
57940532|NCT04968041|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
57940533|NCT04153773|DIAGNOSTIC_TEST|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
57730962|NCT06442371|OTHER|High intensity interval training|In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
57940534|NCT02963038|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
57940535|NCT00916279|DEVICE|Lutonix Paclitaxel-Coated Balloon|PTCA
58075764|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
58075765|NCT06298721|BEHAVIORAL|Standard of Care TKA|- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
58075766|NCT03953300|BIOLOGICAL|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
58075767|NCT03953300|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
58075768|NCT03877484|DEVICE|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
58075769|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
58407249|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
57730963|NCT00497653|DRUG|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
58407250|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
58407251|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
58407252|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
57730964|NCT00497653|DRUG|Placebo|Placebo, twice daily for 6 weeks
57940536|NCT04844684|OTHER|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
57940537|NCT00000475|BEHAVIORAL|health education|
57940538|NCT04239105|DEVICE|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
57940539|NCT00613353|OTHER|Behavioral|Participants will be asked to wear an accelerometer
58075770|NCT05206305|DEVICE|GammaSense Stimulation device|Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
58407253|NCT00174681|DRUG|Insulin Glargine|
57940540|NCT00220168|DRUG|Irinotecan, Capecitabine|
57940541|NCT03420014|DRUG|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
57940542|NCT03420014|COMBINATION_PRODUCT|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
57940543|NCT00199446|DRUG|Istradefylline (KW-6002)|
57940544|NCT04291248|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
57940545|NCT04291248|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
57940546|NCT02336789|OTHER|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
57940547|NCT02336789|OTHER|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
57940548|NCT02026921|DRUG|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
58075771|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
58295790|NCT01039766|DRUG|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
58295791|NCT00424593|DRUG|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
58295792|NCT00424593|DRUG|Placebo|every day (QD), by mouth (PO), 13 weeks
58407254|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
58407255|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient\&#39;s arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
58407256|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient\&#39;s blood and analyzed to detect mutations in BRAF and other prognostic genes.
58407257|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
57730965|NCT00344682|DRUG|memantine|memantine 5mg - 20mg PO daily
57730966|NCT00344682|DRUG|Placebo|5mg - 20mg PO daily over 8 weeks
57940549|NCT02026921|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
58407258|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
57940550|NCT05896449|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
57940551|NCT02894710|DRUG|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
57940552|NCT02894710|DRUG|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
57940553|NCT05503784|OTHER|BITE Deodorant|BITE natural Deodorant
57940554|NCT03001973|OTHER|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
57940555|NCT06395233|DEVICE|BetterPoints App|The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
57940556|NCT03439436|DRUG|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
58075772|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
58075773|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
57940557|NCT03439436|DRUG|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
58075774|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
58075775|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
58075776|NCT06723093|BEHAVIORAL|Social Medicine Housing Initiative|"Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies."
58075777|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
58075778|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
57940558|NCT06238609|DEVICE|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
57940559|NCT06238609|DEVICE|Control Group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
57940560|NCT02504359|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
57940561|NCT02504359|DRUG|Carmustine|Given BEAM chemotherapy
57940562|NCT02504359|DRUG|Cytarabine|Given BEAM chemotherapy
57940563|NCT02504359|DRUG|Etoposide|Given BEAM chemotherapy
57940564|NCT02504359|DRUG|Ixazomib Citrate|Given PO
57940565|NCT02504359|DRUG|Melphalan|Given BEAM chemotherapy
57940566|NCT02504359|DRUG|Methotrexate|Given IV
57940567|NCT02504359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
57940568|NCT02504359|OTHER|Quality-of-Life Assessment|Ancillary studies
57940569|NCT02504359|DRUG|Tacrolimus|Given IV or PO
58075779|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
58075780|NCT00887562|OTHER|Placebo|Placebo - No idebenone
58075781|NCT05933057|DRUG|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
58075782|NCT05933057|DRUG|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
58075783|NCT06722209|OTHER|polyethylene glycol (Protocol I)|Intestinal preparation protocol with polyethylene glycol (Protocol I)
57940570|NCT03527082|OTHER|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
58075784|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
58407259|NCT02791191|DRUG|LY3202626|Administered orally
57940571|NCT00653042|DRUG|Nesiritide|
57940572|NCT03511053|PROCEDURE|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
57940573|NCT05353699|OTHER|Implementation strategies|We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
58075785|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
58075786|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
58075787|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
58407260|NCT02791191|DRUG|Placebo|Administered orally
58075788|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
58075789|NCT06722859|PROCEDURE|Open surgical decompression in degenerative lumbar canal stenosis|Open surgical decompression in degenerative lumbar canal stenosis
58075790|NCT06722859|PROCEDURE|Microsurgical decompression|Microsurgical decompression of degenerative lumbar canal stenosis
58075791|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
58075792|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
58075793|NCT02180659|DRUG|sublingual buprenorphine tablets|
58075794|NCT02180659|DRUG|Buprenorphine implant|
58075795|NCT02180659|DRUG|placebo implants|
58075796|NCT02180659|DRUG|sublingual placebo tablets|
58295793|NCT01495052|DIETARY_SUPPLEMENT|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
58295794|NCT01057667|DRUG|RO5024048|1000mg bid po, 24 weeks
58295795|NCT01057667|DRUG|Ribavirin [Copegus]|1000mg or 1200mg po daily
58295796|NCT01057667|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
58407261|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
58407262|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
58407263|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
58407264|NCT05699993|DRUG|IBI351|IBI351 was administered orally
58407265|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
58407266|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
58407267|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
58407268|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
58407269|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
58407270|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
58407271|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
58407272|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
57940574|NCT05069506|OTHER|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
57940575|NCT05069506|OTHER|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
57940576|NCT05069506|OTHER|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
57940577|NCT05069506|OTHER|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
58075797|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
58075798|NCT02259777|OTHER|high fat, high caloric meal|
58075799|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
58075800|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
58075801|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
58075802|NCT03380091|DRUG|Metformin|Oral medication daily
58295797|NCT01157611|BEHAVIORAL|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
58295798|NCT03588897|DIETARY_SUPPLEMENT|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
58295799|NCT04733586|PROCEDURE|Sonar guided fascia iliaca|Sonar guided fascia iliaca
58075803|NCT03380091|DRUG|Vitamin D|Oral medication daily
58295800|NCT04733586|PROCEDURE|Sonar guided quadratus lumborum block|Sonar guided quadratus lumborum block
58295801|NCT01986803|DEVICE|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
58295802|NCT00662077|DRUG|Ibandronate|Ibandronate endovenous 3 mg every 3 months
58295803|NCT00662077|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
57940578|NCT05069506|OTHER|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
58075804|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
58075805|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
57940579|NCT05069506|OTHER|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
57940580|NCT05069506|OTHER|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
57940581|NCT04118270|DEVICE|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
57940582|NCT01120392|OTHER|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
57940583|NCT01120392|OTHER|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
57940584|NCT05407597|DRUG|Icatibant|"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
57940585|NCT05407597|DRUG|0.9% Sodium Chloride Injection|"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
57940586|NCT00298129|DEVICE|Ambulatory blood pressure monitoring|
57940587|NCT04058925|DEVICE|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
58407273|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
57940588|NCT03945591|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
57940589|NCT03945591|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
57940590|NCT02113943|DRUG|Citalopram 30mg|
57940591|NCT06004648|PROCEDURE|Upper extremity surgery|Comparison of 2 different peripheral nerve blocks
57940592|NCT05704686|DEVICE|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
58075806|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
58075807|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
58295804|NCT04987866|DEVICE|vibration device , Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China|The vibration device is a reusable, handheld device with a battery-powered motor and a vibration frequency of approximately 6000 times per minute (Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China)
58295805|NCT03920358|DEVICE|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
58295806|NCT00099112|GENETIC|microarray analysis|
58295807|NCT00099112|PROCEDURE|biopsy|
58295808|NCT00099112|PROCEDURE|evaluation of cancer risk factors|
58407274|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
58407275|NCT06607068|OTHER|None (Observational study)|None (Observational study)
58407276|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
58295809|NCT01909804|DRUG|SOF|400 mg tablet administered orally once daily
58075808|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
58075809|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
58075810|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
58075811|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
58075812|NCT00439010|DRUG|[123I] AV 39|
58075813|NCT06272487|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
58407277|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
58407278|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
58407279|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
58407280|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
57940593|NCT04516317|OTHER|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
57940594|NCT04516317|OTHER|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
57940595|NCT05175573|DEVICE|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
57940596|NCT05175573|DEVICE|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
57940597|NCT06387173|OTHER|Non-Interventional Study|Non-interventional study
58075814|NCT06272487|DRUG|Placebo|Placebo administered by SC injection
58075815|NCT06522074|DIAGNOSTIC_TEST|Coronary angiography with OCT|Intravascular imaging with Optical Coherence Tomography (OCT) in patients with chronic coronary syndrome who have been indicated for coronary angiographic will be used at the operator's discretion, for diagnostic purposes and/or to guide possible coronary artery disease treatment.
58295810|NCT01909804|DRUG|VEL|Tablet administered orally once daily
58407281|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
57940598|NCT03582930|COMBINATION_PRODUCT|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
57940599|NCT00353834|DRUG|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
57940600|NCT00353834|DRUG|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
58295811|NCT01909804|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58407282|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
58295812|NCT03671876|DEVICE|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
58295813|NCT04611542|BEHAVIORAL|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
58295814|NCT03204643|BEHAVIORAL|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
58407283|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
58407284|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
58295815|NCT04361422|DRUG|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
57940601|NCT05259813|GENETIC|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
57940602|NCT04307160|PROCEDURE|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
57940603|NCT01406236|PROCEDURE|Transradial PCI|Transradial PCI
57940604|NCT01406236|PROCEDURE|Transfemoral PCI|Transfemoral PCI
57940605|NCT04862624|BEHAVIORAL|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
57940606|NCT04862624|BEHAVIORAL|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
57940607|NCT05317884|BEHAVIORAL|Reminder|Email
57940608|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
57940609|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
57940610|NCT00652730|DRUG|Buspar|Tablets, 30 mg, single-dose, fed conditions
57940611|NCT03276312|DEVICE|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
57940612|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
57940613|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
57940614|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
57940615|NCT04603131|BIOLOGICAL|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
57940616|NCT02413840|BEHAVIORAL|Baduanjin qigong|
57940617|NCT06449924|DEVICE|Endotracheal tube|Endotracheal Tube Inserted to the Level of the Hypopharynx
58075816|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
58075817|NCT02007798|DRUG|normal saline|100 ml per bag
58295816|NCT04884100|OTHER|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
57730967|NCT01230476|DRUG|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
57940618|NCT04979689|OTHER|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
57940619|NCT04979689|OTHER|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
57940620|NCT03339388|DEVICE|Enhanced Lithotripsy System|Stone treatment with the Enhanced Lithotripsy System
57940621|NCT03302975|DEVICE|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
57940622|NCT04069195|DIETARY_SUPPLEMENT|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
57940623|NCT04069195|DIETARY_SUPPLEMENT|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
57940624|NCT01847430|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
57940625|NCT03419039|DIETARY_SUPPLEMENT|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
57940626|NCT03419039|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules.
57940627|NCT00520455|DRUG|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
57940628|NCT01214863|DEVICE|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
57940629|NCT01214863|DEVICE|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
57940630|NCT01214863|DEVICE|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
57940631|NCT01766960|OTHER|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
57940632|NCT01766960|DRUG|Morphine|Five milligrams of intravenous morphine will be administered.
57940633|NCT05005455|DRUG|bevacizumab with new manufacturing process.|3mg/kg,I.V.,single dose
57940634|NCT05005455|DRUG|bevacizumab with old manufacturing process.|3mg/kg,I.V.,single dose
57940635|NCT00993265|DRUG|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
57940636|NCT00993265|DRUG|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
57940637|NCT01025960|PROCEDURE|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
57940638|NCT01025960|PROCEDURE|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
58295817|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
58295818|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
58407285|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
58407286|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
58075818|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
58075819|NCT00383344|PROCEDURE|FDG PET/CT|
58407287|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
58407288|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
58407289|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
58075820|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
58075821|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
58075822|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
58407290|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
57730968|NCT04111081|OTHER|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
57730969|NCT04111081|OTHER|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
57940639|NCT03069885|DEVICE|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
57940640|NCT03069885|OTHER|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
57940641|NCT01907542|PROCEDURE|stapled skin closure|as above
57940642|NCT01907542|PROCEDURE|monocryl skin suture|as above
57940643|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
57940644|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
57940645|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
58075823|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant chemotherapy prior to surgery or over 4-6 weeks if not receiving neoadjuvant chemotherapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant chemotherapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
58295819|NCT02851459|BEHAVIORAL|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
58295820|NCT02851459|BEHAVIORAL|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
58407291|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
57940646|NCT03632590|DRUG|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
57730970|NCT06636617|DRUG|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
57730971|NCT06636617|DRUG|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
58407292|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
57940647|NCT01371136|PROCEDURE|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
58407293|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
57940648|NCT02923661|DEVICE|CM LOC|
57940649|NCT02923661|DEVICE|ball attachment|
58407294|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
58407295|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
58407296|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
57940650|NCT00596661|DEVICE|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
57940651|NCT00688155|BEHAVIORAL|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
57940652|NCT00688155|BEHAVIORAL|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
57940653|NCT00688155|BEHAVIORAL|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
57940654|NCT01963429|PROCEDURE|radiofrequency ablation|"\* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min."
57940655|NCT01963429|RADIATION|Proton beam therapy|"\* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)"
57940656|NCT02476825|DRUG|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
58407297|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
58407298|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
58407299|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
58407300|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
58407301|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
57940657|NCT02476825|DEVICE|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
57940658|NCT00685880|DRUG|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
57940659|NCT00685880|DRUG|Betamethasone|CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
57940660|NCT02632721|DRUG|Decitabine|
57940661|NCT02632721|DRUG|BI 836858|
58295821|NCT02851459|BEHAVIORAL|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
58295822|NCT02851459|BEHAVIORAL|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
58295823|NCT02851459|BEHAVIORAL|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
58407302|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
57940662|NCT05494021|OTHER|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
57940663|NCT05494021|DEVICE|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
57940664|NCT02580851|OTHER|diagnostic test - cardiac magnetic resonance imaging|
57940665|NCT02580851|OTHER|diagnostic test - coronary angiography|
57940666|NCT00253643|DIETARY_SUPPLEMENT|green tea catechin extract|Given orally 2 times/day
57940667|NCT00253643|DIETARY_SUPPLEMENT|fish oil|Given orally 3 times/day
57940668|NCT00253643|OTHER|placebo|Given olive oil placebo orally 3 times/day
57940669|NCT00253643|OTHER|placebo|Given green tea placebo orally 2 times/day
57940670|NCT03269851|RADIATION|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
57940671|NCT03755791|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
57940672|NCT03755791|DRUG|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
57940673|NCT03755791|DRUG|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
57940674|NCT03755791|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
57940675|NCT02520895|BIOLOGICAL|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
57940676|NCT03956316|DEVICE|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
58295824|NCT02851459|BEHAVIORAL|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
58407303|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
58407304|NCT05452369|DRUG|Rhomboid intercostal plane block|- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
57940677|NCT01195090|DRUG|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
57940678|NCT01195090|DRUG|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
57940679|NCT00175214|BEHAVIORAL|Multifaceted intervention (patient education, physician guidelines, reminders)|
57940680|NCT05014360|DRUG|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
57940681|NCT00487136|DRUG|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
57940682|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
57940683|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
57940684|NCT00018551|DRUG|Folic Acid|
57940685|NCT01799187|PROCEDURE|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
57940686|NCT01799187|PROCEDURE|apexification|apexification uses calcium hydroxide as root medication
57940687|NCT03427567|PROCEDURE|Sublobar dissection|Sublobar dissection plus lymphadenectomy
58295825|NCT06288243|DIAGNOSTIC_TEST|Clinician-observed assessment tests|Turkish Modified Mann Swallowing Ability Test, which evaluates swallowing skills Standardized Mini-Mental Test assessing Cognitive Status Modified Rankin Scale to evaluate functionality
58295826|NCT04616716|DRUG|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
57940688|NCT05275348|BEHAVIORAL|Tele-Enhance Fitness|"Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode."
57940689|NCT05275348|BEHAVIORAL|In-person Enhance Fitness|Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
57940690|NCT05119608|BEHAVIORAL|CBT/ACT|10-session ACT-re-enforced CBT intervention.
57940691|NCT02529982|DIETARY_SUPPLEMENT|Curcumin|
57940692|NCT02529982|DIETARY_SUPPLEMENT|Placebo|
57940693|NCT02150148|BEHAVIORAL|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
57940694|NCT00037011|BIOLOGICAL|beta-glucan|
57940695|NCT00037011|BIOLOGICAL|monoclonal antibody 3F8|
57940696|NCT03882138|PROCEDURE|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
57940697|NCT05165355|DRUG|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
57940698|NCT03995732|DRUG|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
57940699|NCT03995732|DRUG|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
58295827|NCT03880552|OTHER|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
58295828|NCT01105312|DRUG|letrozole|
58295829|NCT01105312|DRUG|panobinostat|
58407305|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
58407306|NCT02227173|DRUG|BMS-986020|
58407307|NCT02227173|DRUG|Montelukast|
58407308|NCT02227173|DRUG|Flurbiprofen|
58407309|NCT02227173|DRUG|Digoxin|
58407310|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
57940700|NCT02114411|PROCEDURE|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
57940701|NCT02114411|PROCEDURE|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
57940702|NCT00175955|DRUG|Levetiracetam|
57940703|NCT03372109|DIETARY_SUPPLEMENT|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
57940704|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral capsules|Multivitamin/mineral supplement
57940705|NCT03372109|DIETARY_SUPPLEMENT|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
58295830|NCT01105312|GENETIC|RNA analysis|
58407311|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
57940706|NCT03372109|DIETARY_SUPPLEMENT|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
57940707|NCT03372109|DIETARY_SUPPLEMENT|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
58295831|NCT01105312|GENETIC|microarray analysis|
58407312|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
57940708|NCT03372109|DIETARY_SUPPLEMENT|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
58295832|NCT01105312|GENETIC|reverse transcriptase-polymerase chain reaction|
58295833|NCT01105312|OTHER|enzyme-linked immunosorbent assay|
58295834|NCT01105312|OTHER|immunohistochemistry staining method|
58295835|NCT01105312|OTHER|laboratory biomarker analysis|
58295836|NCT00102843|PROCEDURE|supplementation with folic acid and betaine|
58295837|NCT02999334|BEHAVIORAL|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
57940709|NCT03372109|DIETARY_SUPPLEMENT|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
57940710|NCT03372109|DIETARY_SUPPLEMENT|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
58295838|NCT01414478|OTHER|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
58295839|NCT04374370|BIOLOGICAL|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
57940711|NCT03372109|DIETARY_SUPPLEMENT|Saffron extract capsule|Saffron extract 88.25mg/capsule
58295840|NCT02826161|DRUG|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
58295841|NCT02826161|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
58295842|NCT01775007|DEVICE|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
57940712|NCT03372109|DIETARY_SUPPLEMENT|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
57940713|NCT03372109|DIETARY_SUPPLEMENT|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
57940714|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
57940715|NCT01489202|DEVICE|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
58295843|NCT02319252|DEVICE|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
58295844|NCT02319252|DEVICE|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
58075824|NCT05123482|DRUG|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers
58075825|NCT05123482|DRUG|AZD8205 and AZD2936 (Rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
58075826|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
58075827|NCT04796142|OTHER|medication reconciliation|medication reconciliation
58075828|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
58075829|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
58075830|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
58075831|NCT02118467|DRUG|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
58075832|NCT02118467|DRUG|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
58075833|NCT02118467|DRUG|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
58075834|NCT02118467|DRUG|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
57940716|NCT01489202|DEVICE|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
57940717|NCT03034460|DRUG|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
57940718|NCT03034460|DRUG|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
57940719|NCT03034460|DRUG|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
57940720|NCT03034460|DRUG|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
57940721|NCT05680571|DEVICE|BulbiCam|BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
57940722|NCT04402970|DRUG|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
57940723|NCT05284279|OTHER|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
57940724|NCT04777435|DIAGNOSTIC_TEST|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
58075835|NCT05733208|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
58075836|NCT05733208|PROCEDURE|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
58075837|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
58075838|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
58075839|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
58295845|NCT01407809|DEVICE|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
58295846|NCT05581823|DRUG|Tavapadon|Oral tablets
58295847|NCT05581823|DRUG|Carbamazepine|Extended-release oral tablets
58295848|NCT05987826|DRUG|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
58295849|NCT00171990|DRUG|Famciclovir|
58295850|NCT05636813|OTHER|Training|Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
57730972|NCT06636617|DRUG|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
57940725|NCT04801875|OTHER|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
58075840|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
58075841|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
58295851|NCT00235573|DIETARY_SUPPLEMENT|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
58295852|NCT01834170|DRUG|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
58407313|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
58407314|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
57940726|NCT03992664|OTHER|EDUCATION|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
58075842|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
58407315|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58075843|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
58075844|NCT05482646|BEHAVIORAL|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
58075845|NCT05482646|BEHAVIORAL|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
58075846|NCT05482646|BEHAVIORAL|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
58407316|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58075847|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
58075848|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
58407317|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58075849|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
58075850|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
58075851|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
58075852|NCT01256866|DRUG|Dexmedetomidine|
58075853|NCT01256866|DRUG|Midazolam|
58075854|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
58295853|NCT03463629|OTHER|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
58407318|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407319|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407320|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407321|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407322|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407323|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407324|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
58407325|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
58407326|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
57730973|NCT01201434|DIETARY_SUPPLEMENT|Bio-25 probiotic|2 tablets per day for 6 months
57730974|NCT02830594|RADIATION|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
58407327|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
58407328|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
58407329|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
58407330|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
58407331|NCT02337530|DRUG|Selumetinib|
58407332|NCT02337530|DRUG|Pemetrexed|
58407333|NCT02337530|DRUG|Cisplatin|
58407334|NCT02337530|DRUG|Carboplatin|
58407335|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
58295854|NCT03463629|OTHER|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
58295855|NCT02048124|DEVICE|25g standard needle|
58295856|NCT02048124|DEVICE|25d ProCor needle|
58295857|NCT06612775|DRUG|Test drug CB03-154 5mg group|CB03-154 tablet (5mg/tablet) once daily.
57730975|NCT02830594|OTHER|Laboratory Biomarker Analysis|Correlative studies
57730976|NCT02830594|BIOLOGICAL|Pembrolizumab|Given IV
57730977|NCT00120393|DRUG|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
57730978|NCT00120393|DRUG|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
58295858|NCT06612775|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
58295859|NCT06612775|DRUG|Test drug CB03-154 20mg group|Four CB03-154 tablets (5mg/tablet) once daily.
58295860|NCT06612775|DRUG|Placebo group|Four Placebo tablets once daily.
58295861|NCT01047280|DIETARY_SUPPLEMENT|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
58295862|NCT01047280|DIETARY_SUPPLEMENT|Safflower oil|3.5 g/d of safflower oil
58295863|NCT01047280|DIETARY_SUPPLEMENT|G-c9, t11|3.5 g/day of c9, t11 CLA
58295864|NCT05911126|DRUG|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
58295865|NCT02595502|DEVICE|JJVC Marketed Contact Lens (Test)|
58295866|NCT02595502|DEVICE|Competitor Marketed Contact Lens (Control)|
58295867|NCT04596969|OTHER|Soluble Fiber Dextrin|Ingredient based on resistant starch
58295868|NCT02381678|DEVICE|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
58295869|NCT00037063|DRUG|Thiamine hydrochloride|
58295870|NCT00037063|DRUG|Riboflavin|
58295871|NCT00037063|DRUG|Ascorbic acid|
58295872|NCT00037063|DRUG|Vitamin E|
58295873|NCT06150300|BEHAVIORAL|Pulmonary rehab program|Exercise videos, breathing exercises, and educational messages delivered virtually
58075855|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
57730979|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
57940727|NCT05353049|BEHAVIORAL|Bathing technique based on Basale Stimulation|"The relaxing somatic modelling technique will be applied, framed within the concept of Basal Stimulation®. To do this, the user remains seated and the parts of the body that are not being washed at that moment are covered with a towel, favouring the preservation of the user's privacy. The user is lathered up with soft mittens previously moistened with lukewarm water and lathered up. This process shall be carried out starting from the shoulder in a proximal to distal direction on the upper limbs, lower limbs and trunk (taking into account the sagittal anatomical plane) and in a cephalic to caudal direction (taking into account the transverse anatomical plane).~Subsequently, rinsing is carried out following the same guidelines as described above, using moistened soft mittens. Finally, intimate hygiene is performed with a disposable soapy sponge and the soap is rinsed off again with moistened soft terrycloth mittens. Throughout the whole process, the activity is explained to the user."
57940728|NCT03055754|PROCEDURE|Argon randomized arm|Endoscopic argon plasma coagulation
58075856|NCT06375044|DRUG|SIM0500|Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
58075857|NCT06566742|DRUG|Olutasidenib|Given by PO
58075858|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 1|Daplusiran/Tomligisiran dose level 1 will be administered
58075859|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 2|Daplusiran/Tomligisiran dose level 2 will be administered
58075860|NCT06537414|DRUG|Bepirovirsen|Bepirovirsen will be administered
58075861|NCT06537414|DRUG|Placebo|Placebo will be administered
58075862|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
58407336|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
58407337|NCT00000146|DRUG|Methylprednisolone|
57940729|NCT03055754|PROCEDURE|Control arm|No Endoscopic procedure
58075863|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
58407338|NCT00000146|DRUG|Prednisone|
57730980|NCT01610323|OTHER|Standard Care|
57940730|NCT03066908|DEVICE|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
57940731|NCT05505136|DEVICE|Arrhythmia Management System (AMS)|Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
57940732|NCT03451084|DRUG|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
58075864|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
58075865|NCT05819775|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
58075866|NCT06724939|OTHER|self-adhesive bulk-fill resin composite|surefil one self-adhesive bulk-fill composite
58075867|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
58295874|NCT06150300|BEHAVIORAL|Placebo|Breathing exercises and educational messages
58295875|NCT01976481|DEVICE|sunbed exposure|exposure to sunbed ultraviolet radiation
58407339|NCT02854488|DRUG|Yervoy|
58407340|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
58407341|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
58407342|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
58407343|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
57940733|NCT01093625|DEVICE|Narafilcon B Contact Lens|
57940734|NCT01093625|DEVICE|Spectacles|spectacle wearers
57940735|NCT01993212|DRUG|Androxal 12.5 mg or 25 mg|
57940736|NCT01993212|DRUG|AndroGel 1.62%|
57940737|NCT01993212|DRUG|Placebo Capsules|
57940738|NCT01993212|DRUG|Placebo Gel|
57940739|NCT00003757|BIOLOGICAL|rituximab|
57940740|NCT02090413|DRUG|dimethyl fumarate|
57940741|NCT02090413|DRUG|acetylsalicylic acid|enteric-coated capsule
58075868|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
58407344|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
58407345|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
58407346|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
57940742|NCT02090413|DRUG|ASA-Placebo|matched placebo
57940743|NCT02445625|DEVICE|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
57940744|NCT00777777|DEVICE|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
57940745|NCT00347334|BEHAVIORAL|infant home positioning|
57940746|NCT04824820|BEHAVIORAL|Vibrator|Clitoral stimulation
57940747|NCT04475575|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
57940748|NCT06470789|BEHAVIORAL|Shoulder blood restriction training|Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
57940749|NCT03180164|OTHER|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
58295876|NCT00485069|DRUG|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
58407347|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
58407348|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
58407349|NCT01688921|DEVICE|Needle-Syringe|
58407350|NCT01688921|DEVICE|Stratis needle-free injection device|
58407351|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
58407352|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
58407353|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
58407354|NCT06345794|DRUG|Itraconazole|Administered orally.
58407355|NCT06345794|DRUG|Fluconazole|Administered orally.
58407356|NCT06345794|DRUG|Carbamazepine|Administered orally.
58407357|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
58407358|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
58407359|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
58407360|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
58407361|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
58407362|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
58407363|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
58407364|NCT01868620|DEVICE|Iontophoretic CXL|
58407365|NCT01868620|DEVICE|Standard CXL|
58407366|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
58407367|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
58407368|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
58407369|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
58407370|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
57940750|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
57730981|NCT06175494|BIOLOGICAL|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
58075869|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
58407371|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
57730982|NCT06175494|BIOLOGICAL|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
57940751|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
57940752|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
57940753|NCT02147366|BEHAVIORAL|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
57940754|NCT02147366|BEHAVIORAL|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
57940755|NCT01073267|RADIATION|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
57940756|NCT05144113|BEHAVIORAL|Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.|"The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program."
57940757|NCT04595253|OTHER|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
57940758|NCT02295345|OTHER|Cognitive Behavioural Therapy for Insomnia|
57940759|NCT00224614|PROCEDURE|Allogenic transplantation|
57940760|NCT05728931|BIOLOGICAL|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
57940761|NCT02361450|DEVICE|Retrograde Colonic Irrigation|
57940762|NCT02361450|OTHER|Usual Care|
58075870|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
58075871|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
58407372|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
58407373|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
57940763|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
58075872|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
58075873|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
58407374|NCT05105841|DRUG|Venetoclax|Oral Tablet
58407375|NCT05105841|DRUG|Ibrutinib|Oral Capsule
58407376|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
58407377|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
58407378|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
58407379|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
58407380|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
57730983|NCT06175494|BIOLOGICAL|Placebo|boost with saline
57730984|NCT02393079|DEVICE|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
58295877|NCT00485069|DRUG|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
58407381|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
57940764|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
57940765|NCT01415128|DRUG|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
57730985|NCT02393079|DEVICE|Sham|A SHAM identical helmet will be used in the control group.
57730986|NCT03931577|DIAGNOSTIC_TEST|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
57940766|NCT01415128|DRUG|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
57940767|NCT01415128|DRUG|Desipramine|Single dose of Desipramine (50 mg) for 1 day
57940768|NCT06489639|BEHAVIORAL|DOCT-SAD|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder is a 10-session, combined individual/group clinical intervention for treating social anxiety in adolescents. It consists of four individual and six group sessions during ten weeks. DOCT-SAD groups are formed for 4-6 adolescnts. One parent or both parents attend two of the individual sessions.
57940769|NCT06489639|BEHAVIORAL|SC|Standard Counseling (SC) is a intervention consisting of counseling sessions delivered by a school health and welfare (SHWS) professional (i.e., school nurse, school social worker, or school psychologist) to support a student with social anxiety. The defined length of intervention is ten weeks, and number of sessions will be according to what is routinely agreed between the professional and the adolescent. In SC, routine professional working methods and procedures available to the SHWS professional delivering the intervention are used.
57940770|NCT05146245|OTHER|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
57940771|NCT05146245|OTHER|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
57940772|NCT02127671|OTHER|IDEAL intervention|
57940773|NCT02127671|OTHER|Control|
57940774|NCT05529849|DRUG|TCMCB07|Subcutaneous injection of TCMCB07
57940775|NCT05529849|DRUG|Placebo|Matching subcutaneous placebo
57940776|NCT06268171|OTHER|ultrasound measurement of the cross-sectional area of the rectus femoris|ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
57940777|NCT03349099|DEVICE|Cook Flexor|ureteral access sheath
57940778|NCT03349099|DEVICE|Boston Scientific Navigator|ureteral access sheath
58295878|NCT02211378|OTHER|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
57730987|NCT03931577|PROCEDURE|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
57730988|NCT06060171|PROCEDURE|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
57730989|NCT04898608|OTHER|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
57730990|NCT04450615|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
57940779|NCT05410444|DEVICE|Clean Intermittent Catheterization|Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.
57940780|NCT05410444|DEVICE|Indwelling catheterization|A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
57940781|NCT05069064|OTHER|music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
57940782|NCT05069064|OTHER|no music|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
58075874|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
58075875|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
58075876|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
58075877|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
58075878|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
58075879|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
58407382|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
58075880|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
58075881|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
58075882|NCT05952037|DRUG|BGB-11417|Administered orally as a tablet.
58075883|NCT05952037|DRUG|Zanubrutinib|Administered orally as a tablet.
58075884|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
58075885|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
58075886|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
58075887|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
58295879|NCT02211378|OTHER|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
58295880|NCT04131712|OTHER|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
58295881|NCT04214574|DEVICE|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
57940783|NCT03404284|BEHAVIORAL|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
57940784|NCT04345770|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
57940785|NCT04345770|DRUG|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
57940786|NCT04345770|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
57940787|NCT01878942|DRUG|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
57940788|NCT01878942|DRUG|LSD|200µg per os, single dose
57940789|NCT00930839|DRUG|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
57940790|NCT00510081|DEVICE|Calcium Hydroxylapatite injection|filler injection
58075888|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
58075889|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
58075890|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
58075891|NCT05539378|BEHAVIORAL|Auditory Stimulation|enhancement of sleep slow wave activity through acoustic stimulation
58075892|NCT05539378|BEHAVIORAL|Sham (no stimulation)|Playing no tones during sleep but still recording brain activity
58075893|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
58075894|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
58075895|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
58075896|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
58075897|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
58075898|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
58075899|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
58075900|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
58295882|NCT04214574|DEVICE|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
58295883|NCT00291369|DRUG|Interleukin-2|
58295884|NCT00291369|DRUG|Interferon alfa|
58407383|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
58407384|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
58407385|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
57940791|NCT02390479|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
58407386|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
58407387|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
58407388|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
58407389|NCT00492479|DRUG|LubriDerm|
58407390|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
58407391|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
58407392|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
58407393|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
58407394|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
58407395|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
58407396|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
58407397|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
57940792|NCT02840110|OTHER|ACTR T Cell Product|
57940793|NCT02228720|DEVICE|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
57940794|NCT00500630|DEVICE|Body fixed 3D sensors|
57940795|NCT01889082|BEHAVIORAL|Behavioral Weight Loss Intervention for Young Adults|
57940796|NCT03405805|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
57940797|NCT04532385|DIETARY_SUPPLEMENT|Green tea extract|400 mg capsule
58295885|NCT00291369|DRUG|medroxyprogesterone acetate|
58295886|NCT00627497|PROCEDURE|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
57940798|NCT04532385|DIETARY_SUPPLEMENT|Placebo|400 mg capsule
57940799|NCT04425603|DEVICE|Anthology Hip Replacement System|
57940800|NCT04336670|DEVICE|Immersive Virtual Reality exercise program|Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
57940801|NCT04336670|OTHER|Usual care|Usual center therapies (Physical therapy, occupational therapy..)
58075901|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
58295887|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
58295888|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
58295889|NCT00627497|DEVICE|Fusion|Posterolateral Interbody Fusion
57940802|NCT01310790|PROCEDURE|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was \>30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
57940803|NCT04387955|DIAGNOSTIC_TEST|Biological Sample Collection|"* Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2"
57940804|NCT06313450|RADIATION|de-escalated radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.
58075902|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
58295890|NCT01699334|BEHAVIORAL|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
58407398|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
58407399|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
58407400|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
58407401|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
58407402|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
58407403|NCT00900679|BEHAVIORAL|telephone-based intervention|
58407404|NCT00900679|OTHER|counseling intervention|
58407405|NCT00900679|OTHER|educational intervention|
58407406|NCT00900679|OTHER|medical chart review|
58407407|NCT00900679|OTHER|questionnaire administration|
58295891|NCT01699334|OTHER|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
58407408|NCT00900679|PROCEDURE|psychosocial assessment and care|
58407409|NCT00900679|PROCEDURE|quality-of-life assessment|
58407410|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
58407411|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
58407412|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
58407413|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
58407414|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
58407415|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
58407416|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
58407417|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
58407418|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
58407419|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
58407420|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
58407421|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
58407422|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
57940805|NCT06313450|RADIATION|conventional radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.
58075903|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
57940806|NCT03135275|PROCEDURE|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
57940807|NCT03135275|PROCEDURE|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
58075904|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
57940808|NCT03135275|DEVICE|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
57940809|NCT03484286|DEVICE|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
57940810|NCT03484286|OTHER|Standard care|Patients in the control group will be subject to standard heart failure care.
57940811|NCT00513110|GENETIC|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
57940812|NCT00513110|DRUG|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
57940813|NCT00513110|DRUG|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
57940814|NCT04530903|DRUG|Clonidine|75 µg (0.5mL) per injection site
57940815|NCT04530903|DRUG|Levobupivacaine|0.25% (10 ml) per injection site
57940816|NCT04530903|DRUG|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
57940817|NCT05407909|DRUG|SYHX2001|SYHX2001 tablets, oral
57940818|NCT04534491|DRUG|Oxybutynin (Oxytrol, BAY839380)|Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
57940819|NCT06098625|DRUG|Empagliflozin 25 MG|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
58075905|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
58075906|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
58295892|NCT06289439|DIETARY_SUPPLEMENT|Green tea (Camellia sinensis) 1000 mg as extract|Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
58407423|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
58407424|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
58407425|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
57940820|NCT06098625|DRUG|Linagliptin 5 mg Oral Tablet|linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
57940821|NCT05804643|PROCEDURE|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
57940822|NCT03351790|OTHER|Questionniare only|A pre-procedure questionnaire will be completed by all participants
57940823|NCT04012034|DEVICE|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
57940824|NCT04012034|DEVICE|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
57940825|NCT03179891|DRUG|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
57940826|NCT01888120|DRUG|Ziconotide|
57940827|NCT02642770|DEVICE|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
57940828|NCT03363750|BEHAVIORAL|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
57940829|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE NEO/TF|Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation
57940830|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro|Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
57940831|NCT05798130|OTHER|No intervention group.|No intervention group.
58075907|NCT05804669|DRUG|CRN04894|CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
58075908|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
58295893|NCT06289439|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
58075909|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
58295894|NCT03062215|BEHAVIORAL|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
58407426|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
58295895|NCT06145503|DEVICE|Dance Intervention Group|The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
58295896|NCT04705012|OTHER|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
58295897|NCT03374475|DRUG|JNJ-42847922 20mg|Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
58295898|NCT03374475|DRUG|JNJ-42847922 40mg|Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
58295899|NCT03374475|DRUG|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
58295900|NCT05283811|DEVICE|NEUROPACE RNS SYSTEM|This device is indicated as a therapy in reducing the frequency of seizures in individuals
58295901|NCT05283811|BEHAVIORAL|EMU|Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
58295902|NCT02789969|DRUG|Hydromorphone|Hydromorphone 15mcg/kg IV
58295903|NCT02789969|DRUG|Fentanyl|Fentanyl 1.5mcg/kg IV
58295904|NCT00305227|DRUG|Lactin-V|
58295905|NCT00305227|DRUG|Placebo|
58295906|NCT04435808|DRUG|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
58295907|NCT01673581|OTHER|Survey|
58295908|NCT01081626|DRUG|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
58295909|NCT04683796|DRUG|100% Autologous platelet rich plasma|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
58295910|NCT04683796|DRUG|100% Autologous serum|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
58295911|NCT03076112|DRUG|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
58295912|NCT03076112|DRUG|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
58295913|NCT01089842|BEHAVIORAL|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
58295914|NCT01089842|OTHER|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
58295915|NCT00526422|PROCEDURE|Dental Preventive|
58295916|NCT01029262|DRUG|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
58075910|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
58075911|NCT06724419|BEHAVIORAL|Nutrition education-based intervention|The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 120 minutes. Its aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational formats.intervention and will each be provided with The PMS Management Booklet.
58075912|NCT06722339|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|"Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects."
58075913|NCT06722469|OTHER|WCI|The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
58075914|NCT06724185|DIETARY_SUPPLEMENT|LP28 capsule|LP28 capsule : 5.0×10\^9 CFU/capsule
58075915|NCT06724185|DIETARY_SUPPLEMENT|Placebo Capsule|Maltodextrin
58075916|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
58075917|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
58075918|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
58075919|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
58075920|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
58075921|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58075922|NCT06206408|DRUG|Fezolinetant|oral
58075923|NCT06206408|DRUG|Placebo|oral
58075924|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
58075925|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
58075926|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
58295917|NCT01029262|OTHER|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
58295918|NCT04378569|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
58295919|NCT04378569|DRUG|ARQ-252 cream 0.1%|ARQ-252 cream 0.1%
58295920|NCT04378569|DRUG|ARQ-252 Vehicle Cream|ARQ-252 Vehicle Cream
58295921|NCT00687986|RADIATION|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
58295922|NCT00687986|PROCEDURE|primary surgery|an anatomical surgical resection with lymph node dissection
58295923|NCT06421701|DRUG|anti-CD19 CAR-NK cells|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the 3 + 3 dose-escalation strategy."
58075927|NCT03950531|OTHER|No intervention|
58075928|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
58075929|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
58075930|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
58075931|NCT00750061|DRUG|Placebo|Matching placebo
58295924|NCT06236321|OTHER|Fast Field Cycling MRI scan|Three scans to be done over the period of cancer treatment
58295925|NCT06236321|OTHER|Provision of saliva and faecal samples|Three times over the period of cancer treatment
58295926|NCT02537951|DEVICE|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
58295927|NCT02537951|DEVICE|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
58295928|NCT02537951|DEVICE|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
58295929|NCT01806168|DEVICE|rTMS|Magstim Super Rapid-2
58295930|NCT06444334|RADIATION|low level Diode Laser|Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device
57940832|NCT06306287|BEHAVIORAL|ePACE Personalized Intervention|The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.
58075932|NCT06715904|OTHER|Womens with Morton´s Extension|Morton extension application
58075933|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
58295931|NCT06444334|PROCEDURE|PRF platelet rich fibrin|The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
58295932|NCT04961164|DIETARY_SUPPLEMENT|Resistant Potato Starch, Corn Starch|Consume resistant potato starch at study period 1, then consume corn starch at study period 2.
58295933|NCT04961164|DIETARY_SUPPLEMENT|Corn Starch, Resistant Potato Starch|Consume corn starch at study period 1, then consume resistant starch at study period 2.
58295934|NCT02026765|DEVICE|traditional lens|A random eyes with traditional lens
58295935|NCT02026765|DEVICE|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
58295936|NCT03074877|BEHAVIORAL|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
58295937|NCT06312384|PROCEDURE|3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.
58407427|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
58407428|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
58407429|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
57940833|NCT06306287|BEHAVIORAL|eFACE Fixed Intervention|The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
58295938|NCT06312384|PROCEDURE|conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
58295939|NCT03193047|DRUG|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
58295940|NCT03193047|OTHER|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
58295941|NCT03193047|DRUG|evolocumab|Monthly PCSK9i (evolocumab) background therapy
58295942|NCT05909020|OTHER|No intervention.|No intervention.
58295943|NCT03539978|OTHER|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
58295944|NCT04494269|DRUG|Tegoprazan 50mg|Oral administration once daily
58295945|NCT03555487|DRUG|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
58295946|NCT00929838|BEHAVIORAL|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
58295947|NCT00929838|BEHAVIORAL|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
58295948|NCT00929838|BEHAVIORAL|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
58407430|NCT01701479|DRUG|ch14.18/CHO|
58407431|NCT01701479|DRUG|Aldesleukin|
58407432|NCT01701479|DRUG|Isotretinoin|
58295949|NCT00929838|BEHAVIORAL|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
58295950|NCT00320242|DEVICE|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
58295951|NCT04658797|DEVICE|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
58295952|NCT04658797|DEVICE|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
58295953|NCT04658797|OTHER|Personal Facemask|Personal Facemask
58295954|NCT00040599|DRUG|hMN14 (labetuzumab)|
58295955|NCT05411835|DIETARY_SUPPLEMENT|Nutritional Ketone Supplement|Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
58295956|NCT05411835|DIETARY_SUPPLEMENT|Isocaloric Placebo Supplement|Maltodextrin with flavors and stevia sweetener
58295957|NCT02805296|OTHER|Light irradiance|Comparison of double vs. single phototherapy
58295958|NCT00368303|DRUG|Paroxetine CR|
58295959|NCT00368303|DRUG|Paroxetine IR|
58075934|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
58295960|NCT02214342|OTHER|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
57940834|NCT04201990|DRUG|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
57940835|NCT05339581|RADIATION|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
58295961|NCT01189877|PROCEDURE|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
58295962|NCT00926757|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
58407433|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
58407434|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
58407435|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
58407436|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
57940836|NCT05339581|COMBINATION_PRODUCT|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.
57940837|NCT05339581|DRUG|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
57940838|NCT05339581|DRUG|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
57940839|NCT05339581|DRUG|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
57940840|NCT05339581|DRUG|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
58407437|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
57940841|NCT02705807|DRUG|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.
57940842|NCT02705807|DRUG|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
57940843|NCT04737408|DRUG|Rosuvastatin 40mg|Rosuvastatin 40 mg
57940844|NCT04656314|DIAGNOSTIC_TEST|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
57940845|NCT01865630|DRUG|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
57940846|NCT02445118|OTHER|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
57940847|NCT02097524|DRUG|Sarilumab|
57940848|NCT02097524|DRUG|Tocilizumab|
57940849|NCT06215521|DRUG|Pirtobrutinib|Administered orally
57940850|NCT06215521|DRUG|Placebo|Administered orally
57940851|NCT06215521|DRUG|Moxifloxacin|Administered orally
57940852|NCT05896514|DEVICE|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
58295963|NCT00926757|DRUG|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
58295964|NCT05022277|BEHAVIORAL|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
58295965|NCT05022277|BEHAVIORAL|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
58407438|NCT02609230|DRUG|ONC-201|
58407439|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
58407440|NCT00969761|DRUG|BI 6727|low to high dose
58407441|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
58407442|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
57940853|NCT05690282|DRUG|Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|Multimodal Pain Management to minimize patients' reliance on opioids.
58075935|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
58295966|NCT01261390|BEHAVIORAL|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
58295967|NCT01261390|DEVICE|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
58295968|NCT01261390|DEVICE|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
58295969|NCT01261390|DEVICE|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
58295970|NCT01468454|DRUG|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
58407443|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
58407444|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
58407445|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
58407446|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
58407447|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
58407448|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
58407449|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
58407450|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
58407451|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
58407452|NCT00273520|DRUG|Telithromycin|
58407453|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
58407454|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
58407455|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
58407456|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
58407457|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
58407458|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
58407459|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
58407460|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
58407461|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
58407462|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
58407463|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
58407464|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
58407465|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
58407466|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
58407467|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
58407468|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
58407469|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
58407470|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
58407471|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
58407472|NCT05151640|DRUG|Nintedanib|Nintedanib
58407473|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
58407474|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
58407475|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
58407476|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
58407477|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
58407478|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
58407479|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
58407480|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
58295971|NCT03654729|DRUG|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
58295972|NCT03654729|DRUG|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
58295973|NCT03654729|DRUG|Placebo|Solution in 20 mL single dose glass vials
58295974|NCT00800111|PROCEDURE|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
58295975|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
58295976|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
58295977|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
58295978|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
58295979|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
58295980|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
58295981|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
58295982|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58295983|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58295984|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58295985|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
58295986|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58407481|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
58407482|NCT00129870|DRUG|oxaliplatin|
58407483|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
58075936|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
58075937|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
58075938|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
58075939|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
58075940|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
58075941|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
58075942|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
58075943|NCT01779466|DRUG|Desmopressin|
58075944|NCT01779466|DRUG|Placebo (not active)|
58075945|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
58075946|NCT02596074|DRUG|Vehicle topical gel|
58075947|NCT06722547|OTHER|Standard PR|PLB, ACBT, Aerobic exercise, Education
58075948|NCT06722547|OTHER|Standard PR plus Respiratory Muscle Stretching|Standard PR plus Respiratory Muscle Stretching (RMS)
58075949|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
58075950|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
58295987|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
58295988|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
58295989|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
58075951|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
58295990|NCT04999761|DRUG|Ramucirumab|Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
58295991|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
57940854|NCT05610904|DIAGNOSTIC_TEST|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
58295992|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
58295993|NCT04999761|DRUG|Bevacizumab|Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
58407484|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
58295994|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
58295995|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58295996|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58295997|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
58295998|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
58075952|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
58295999|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58296000|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296001|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
58296002|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58296003|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296004|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
58296005|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
58296006|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
58407485|NCT06357871|OTHER|No intervention|No intervention
58407486|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
58095192|NCT04897334|BEHAVIORAL|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
58296007|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58296008|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296009|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
58296010|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58296011|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296012|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
58296013|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
58407487|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
58407488|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
58407489|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
58407490|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
58296014|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
58407491|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
58407492|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
58407493|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
58407494|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
58407495|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
58296015|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296016|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
58296017|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
58296018|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
58296019|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
58296020|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
58296021|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
58296022|NCT05044247|PROCEDURE|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
58296023|NCT00493012|DIETARY_SUPPLEMENT|vitamin D|6 drops of a vitamin D containing oil
58075953|NCT06724341|BEHAVIORAL|Distraction|"Control group: inferior alveolar nerve block will be administrated with passive behavior management (displaying animated movies directly on the screen of a mobile device).~Movies group: inferior alveolar nerve block will be administrated with displaying animated movies directly on the screen of a mobile device usage of the augmented reality glasses.~Video games group: Application of active behavior management by usage video games on the screen of a mobile device connected to augmented reality glasses before administration of inferior alveolar nerve block.~Movies and Video games group: An active and passive behavior management will be applied by usage video games before administration of inferior alveolar nerve block and animated movies during administration on the screen of a mobile device connected to augmented reality glasses."
58075954|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
58075955|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
58075956|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
58075957|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
58075958|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
58075959|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
58075960|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
58075961|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
58075962|NCT06185140|OTHER|TELEA platform|TELEA platform
58075963|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
58075964|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
58075965|NCT05934422|OTHER|Intervention (Study Nutritional Drink)|Study nutritional drink containing a mix of enriched micronutrients, probiotics and myo-inositol.
58296024|NCT00052078|DRUG|Sertraline (SRT)|Participants were treated with sertraline.
58296025|NCT00052078|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
58296026|NCT00052078|DRUG|Placebo|Participants were treated with a placebo pill.
58075966|NCT05934422|OTHER|Control (Standard Nutritional Drink)|Control nutritional drink containing a standard mix of micronutrients
58407496|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
57940855|NCT00241995|DRUG|Anticonvulsants|
58075967|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
58075968|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
58075969|NCT00016211|RADIATION|radiation therapy|
58095193|NCT06145880|DIAGNOSTIC_TEST|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
58296027|NCT03868189|OTHER|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
58296028|NCT03868189|OTHER|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
58296029|NCT01166750|BEHAVIORAL|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
58075970|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
58296030|NCT01166750|BEHAVIORAL|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
58296031|NCT01081782|DRUG|ONO-4641|0.15 mg once per day for 26 weeks
58407497|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
57940856|NCT02741869|DEVICE|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
57940857|NCT04144270|OTHER|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
57940858|NCT00021320|DRUG|cisplatin|
57940859|NCT00021320|DRUG|fluorouracil|
57940860|NCT00021320|DRUG|paclitaxel|
57940861|NCT00021320|PROCEDURE|conventional surgery|
57940862|NCT00021320|PROCEDURE|neoadjuvant therapy|
57940863|NCT00021320|RADIATION|radiation therapy|
57940864|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 30|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
57940865|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 90|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
58095194|NCT01217567|PROCEDURE|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
58296032|NCT01081782|DRUG|ONO-4641|0.1 mg once per day for 26 weeks
58296033|NCT01081782|DRUG|ONO-4641|0.05 mg once per day for 26 weeks
58296034|NCT01081782|DRUG|ONO-4641 placebo|Placebo once per day for 26 weeks
58296035|NCT04424147|COMBINATION_PRODUCT|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
58407498|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
58407499|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
58407500|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
57940866|NCT03922542|COMBINATION_PRODUCT|riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
57940867|NCT03922542|COMBINATION_PRODUCT|Riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
57940868|NCT02720770|DRUG|norditropine simplex|
57940869|NCT03461172|PROCEDURE|Surgery of breast cancer|Surgery of breast cancer
57940870|NCT03461172|OTHER|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
57940871|NCT00766090|DRUG|GW685698X|Inhaled Corticosteroid
57940872|NCT03623594|PROCEDURE|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
57940873|NCT01350921|DRUG|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
57940874|NCT01350921|DRUG|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
57940875|NCT04807699|OTHER|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
57940876|NCT03960073|DIETARY_SUPPLEMENT|MitoQ|4 week 20mg oral daily dose of Mito Q
57940877|NCT03960073|DIETARY_SUPPLEMENT|Placebo|4 week oral daily dose of TTP placebo
57940878|NCT02806089|DEVICE|Handheld dynamometer|Evaluation of muscle strength
57940879|NCT02806089|BIOLOGICAL|Creatinine index|Evaluation of muscle mass using plasma creatinine level
57940880|NCT02806089|DEVICE|Electrical bioimpedance analysis|Evaluation of lean body mass
57940881|NCT02806089|OTHER|"Voorrips score questionnaire"|Evaluation of physical activity
57940882|NCT02806089|BIOLOGICAL|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
57940883|NCT03453658|PROCEDURE|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
58296036|NCT00810199|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
58296037|NCT00810199|DRUG|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
58296038|NCT00810199|DRUG|placebo|Placebo matching methotrexate capsule taken orally once a week.
58296039|NCT00908414|DRUG|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
58296040|NCT00908414|DRUG|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
58075971|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
57730991|NCT05959850|DRUG|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
57940884|NCT03453658|PROCEDURE|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
57940885|NCT04841980|DRUG|Rifaximin|Administration route: PO Rifaximin 400mg TDS for 2 weeks
58075972|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
58075973|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
58407501|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
58407502|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
58407503|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
58407504|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
57940886|NCT04841980|OTHER|Low FODMAP diet|Low FODMAP diet under dietitian guidance for 4 weeks
57940887|NCT03200054|OTHER|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
58075974|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
58075975|NCT00100711|DRUG|Motexafin Gadolinium|
58075976|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
58075977|NCT02319265|DRUG|Melatonin|Oral liquid
58075978|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
58075979|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
58075980|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
58075981|NCT03115723|PROCEDURE|Coronary angiography|
58075982|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
58075983|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
58296041|NCT00908414|DRUG|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
58407505|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
57940888|NCT05353400|OTHER|Early urinary catheter removal|Early catheter removal
57940889|NCT05353400|OTHER|Urinary catheter removal on POD 3|Catheter removal on POD 3
57940890|NCT05744622|OTHER|KetacTM Universal AplicapTM|chemically cured conventional GICs
57940891|NCT05744622|OTHER|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
57940892|NCT05054647|OTHER|psychometric questionnaires|Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
57940893|NCT03154814|DRUG|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
57940894|NCT03154814|DRUG|control|conventional CPB was applied without ulinastatin treatment
57940895|NCT01906775|OTHER|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
57940896|NCT03013673|OTHER|No intervention|No intervention
57940897|NCT02900079|DEVICE|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
57940898|NCT06099899|OTHER|interview|conduct in-depth interviews
57940899|NCT01396226|DRUG|AZD2927|A single dose of AZD2927 administered as an iv infusion
57940900|NCT01396226|DRUG|Placebo|A single dose of placebo administered as an iv infusion
57940901|NCT01595984|DRUG|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
58075984|NCT06717256|BEHAVIORAL|training|The diabetes education booklet is a collection of information designed by the researcher. These interventions will continue for 1.5 months, with a total of 6 sessions for each type 2 DM individual, lasting approximately 120 minutes (2 hours per week and 12 hours in total after 6 weeks), and will be carried out as reminders afterwards. In these sessions, agendas will be created appropriately on regular eating habits, physical activity, regular monitoring of blood sugar, compliance with treatment, problem-solving ability, coping strategies and minimizing risks, conflicts regarding self-management and skin care behaviors of the patient will be tried to be resolved, the patient's suitability and adaptation to the change phase will be determined, their willingness to change will be questioned, and the change plan will be helped in the matters of care and self-management.
58075985|NCT05965089|BIOLOGICAL|Placebo|Placebo
58075986|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
58075987|NCT06526104|DRUG|Tremelimumab|Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
57940902|NCT01595984|DRUG|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
58075988|NCT06526104|DRUG|Durvalumab|Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
58075989|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
58095195|NCT01217567|PROCEDURE|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
58095196|NCT03259763|DEVICE|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
57940903|NCT01442194|DRUG|other disease-modifying therapy|
57940904|NCT01442194|DRUG|Fingolimod|
57940905|NCT03524885|PROCEDURE|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
57940906|NCT03524885|PROCEDURE|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
58296042|NCT00908414|DRUG|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
58296043|NCT00908414|DRUG|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
58296044|NCT00908414|DRUG|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
58296045|NCT00908414|DRUG|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
58296046|NCT00908414|DRUG|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
58075990|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
58075991|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
58075992|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
58075993|NCT06723236|BIOLOGICAL|MGC028|MGC028 is an antibody-drug conjugate targeted against ADAM9.
58075994|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
58296047|NCT00908414|DRUG|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
58075995|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
58075996|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
58296048|NCT00908414|DRUG|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
58296049|NCT00908414|DRUG|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
58296050|NCT00908414|DRUG|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
58296051|NCT00908414|DRUG|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
58296052|NCT00908414|DRUG|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
58296053|NCT00908414|DRUG|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
58296054|NCT00908414|DRUG|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
58296055|NCT00908414|DRUG|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
58296056|NCT05969990|OTHER|tryptophan metabolites in plasma|we will investigate the tryptophan metabolites in plasma of children with migraine
58296057|NCT05996939|OTHER|To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.|Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
58296058|NCT00992641|OTHER|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
58296059|NCT00992641|OTHER|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
58296060|NCT01587105|BEHAVIORAL|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
58296061|NCT04149717|DIETARY_SUPPLEMENT|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
58296062|NCT03158168|DRUG|Candida Antigen|Candida Albicans Antigen injection
58296063|NCT03158168|DRUG|Zinc Sulfate|Zinc Sulfate injection
58296064|NCT03235037|DRUG|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
58296065|NCT06179069|DRUG|ZL-1310|Drug: ZL-1310
58296066|NCT06179069|DRUG|Atezolizumab|Drug Atezolizumab
58296067|NCT04226300|PROCEDURE|Laparoscopic|A transversus abdominis nerve block will be placed laparoscopically.
58296068|NCT04226300|PROCEDURE|Ultrasound|A transversus abdominis nerve block will be place by ultrasound
58296069|NCT00184938|DRUG|morphine|
58296070|NCT00184938|DRUG|naloxone|
58296071|NCT00184938|DRUG|Technetium-TC99m-labeled Annexin A5|
58296072|NCT00184938|PROCEDURE|forearm ischemic exercise|
58296073|NCT00184938|PROCEDURE|ten minute forearm ischemia|
58296074|NCT00642226|PROCEDURE|Grid Laser|ETDRS Grid Laser
58296075|NCT00642226|PROCEDURE|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
58296076|NCT00122291|DRUG|Capecitabine|
58296077|NCT00122291|PROCEDURE|Pelvic radiation|
58075997|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
58075998|NCT05128656|OTHER|serology|serology at M3 and serology at M6
58075999|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
58076000|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
58076001|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
58076002|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
58076003|NCT05710848|DRUG|STM-416|STM-416 monotherapy
58076004|NCT06706999|OTHER|PREVAIL model of care|"Components 1, 2, and 3 are essential components that all participants will receive. Components 4 and 5 are based on the results of either the DAPS tool or the PT consultation call.~1. Screening tool (DAPS) completed at baseline to determine current level of limitation with valued life activities.~2. Recommendation to rheumatology clinician based on screening results to provide exercise resource and/or recommend a PT consult call during routine visit.~3. Exercise resource (PREVAIL website) provided to all participants by their rheumatology clinician at their routine visit.~4. Brief consultation call with a study physical therapist to determine level of priority for PT referral. Only applicable for those with/at risk for limitation with valued life activities.~5. Referral to PT. Only applicable if determined by study physical therapist to meet priority requirements."
58076005|NCT00000856|DRUG|Foscarnet sodium|
57730992|NCT05959850|DRUG|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
58076006|NCT00000856|DRUG|Ganciclovir|
58076007|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
57730993|NCT03016871|DRUG|Carboplatin|Given IV
58076008|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
57730994|NCT03016871|DRUG|Etoposide|Given IV
58296078|NCT03850834|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
58296079|NCT03850834|DRUG|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
58296080|NCT02638779|BIOLOGICAL|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
58076009|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
58296081|NCT00219947|OTHER|blood draw|"* T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing"
58296082|NCT00369915|DRUG|Scopolamine|
58296083|NCT00369915|DRUG|Scopolamine|
58296084|NCT04361799|DEVICE|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
58296085|NCT04361799|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
57730995|NCT03016871|DRUG|Ifosfamide|Given IV
57730996|NCT03016871|OTHER|Laboratory Biomarker Analysis|Correlative studies
57730997|NCT03016871|BIOLOGICAL|Nivolumab|Given IV
57730998|NCT06316843|DRUG|Valacyclovir celecoxib dose 1|1500 mg valacyclovir 200 mg celecoxib taken two times a day
57730999|NCT06316843|DRUG|Valacyclovir celecoxib dose 2|750 mg valacyclovir 200 celecoxib mg taken two times a day
57731000|NCT06316843|DRUG|Placebo|Placebo capsules colored matched to investigational product taken two times a day
57731001|NCT01194141|BEHAVIORAL|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
58076010|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
58076011|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
58095197|NCT03259763|DEVICE|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
58095198|NCT01783860|DRUG|Azithromycin|
58095199|NCT01783860|DRUG|Doxycycline|
58095200|NCT03428217|DRUG|CB-839|Oral glutaminase inhibitor
58095201|NCT03428217|DRUG|Cabozantinib|Oral receptor tyrosine kinase inhibitor
58095202|NCT03428217|DRUG|Placebo|Placebo tablets
58296086|NCT03161041|PROCEDURE|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
58296087|NCT03161041|DRUG|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
58296088|NCT01836562|BIOLOGICAL|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
58407506|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
58407507|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
57940907|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
58076012|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
58076013|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
58076014|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
58076015|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
58296089|NCT04525430|OTHER|childbirth education|"The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking."
58296090|NCT04525430|OTHER|childbirth education and was subjected to a birth plan|In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
58296091|NCT02248064|DEVICE|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
58407508|NCT01686750|BEHAVIORAL|Integrated care centers|
58407509|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
58407510|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
58407511|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
58407512|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
57940908|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
58076016|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
58076017|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
58076018|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
57940909|NCT03314077|OTHER|GOLD 2017|Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
58296092|NCT04232007|DEVICE|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
58296093|NCT02244047|DRUG|Bifidobacterium breve|
58296094|NCT02244047|DRUG|Placebo (for Bifidobacterium breve)|
58296095|NCT02198729|PROCEDURE|Endoscopic Submucosal Dissection|
58296096|NCT02198729|PROCEDURE|Endoscopic Mucosal Resection|
58296097|NCT02736448|DRUG|Capecitabine|oral low dose of capecitabine
57940910|NCT01733966|DRUG|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
57940911|NCT01733966|DRUG|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
57940912|NCT02470026|DRUG|yohimbine|single low dose treatment
57940913|NCT02470026|DRUG|placebo|single control treatment
57940914|NCT02023242|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
57940915|NCT02023242|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
57940916|NCT01299376|DRUG|L50/H12.5/A5|
57940917|NCT01299376|DRUG|L50/H12.5|
57940918|NCT01299376|DRUG|Placebo to L50/H12.5/A5|
57940919|NCT01299376|DRUG|Placebo to L50/H12.5|
58076019|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
58296098|NCT02736448|DRUG|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
58296099|NCT02736448|DRUG|SS-LAR|long acting octreotide or lanreotide
58296100|NCT06036394|DIAGNOSTIC_TEST|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
58296101|NCT06405178|DRUG|Metformin|Insulin Sensitizer
58296102|NCT06405178|DRUG|Dapagliflozin|Sodium-Glucose Co-transporter-2
58296103|NCT06405178|DRUG|Dapagliflozin/Metformin|Anti diabetic drug
58296104|NCT06405178|DRUG|Letrozole|Aromataze inhibitor
58296105|NCT01164150|RADIATION|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
58296106|NCT01266824|DRUG|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
58296107|NCT01884948|DRUG|Omegaven™|
58296108|NCT01779557|DRUG|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
58296109|NCT01779557|DRUG|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
58407513|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
57940920|NCT00161460|BEHAVIORAL|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
57940921|NCT03210350|DIAGNOSTIC_TEST|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
57940922|NCT03305289|PROCEDURE|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
57940923|NCT03305289|PROCEDURE|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
57940924|NCT06388850|BEHAVIORAL|Healthy Relationships Project|The Healthy Relationships Project (HRP), created by the community-based organization Prevent Child Abuse Vermont (PCAVT), will be the focus of this rigorous evaluation study. The program is fully manualized with a widely accepted curriculum designed for Pre-K to 2nd graders (Care for Kids) and 3rd to 6th graders (We Care Elementary, though implementation will stop at 5th grade for this study). The HRP uses an upstream universal public health approach for the primary prevention of child and youth perpetration of child sexual abuse with developmentally appropriate intervention elements for children, faculty and staff at their schools, and for their caregivers.
57940925|NCT03832803|BEHAVIORAL|Empty bladder|No drinking protocol.
58407514|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
57940926|NCT03832803|BEHAVIORAL|Full bladder|Followed drinking protocol
57940927|NCT04611971|DRUG|Benlysta|Benlysta injection will be administered subcutaneously.
57940928|NCT04611971|DRUG|Candin|Candin will be administered intradermally along with NaCl solution.
57940929|NCT05275075|OTHER|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
57940930|NCT01764542|PROCEDURE|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
57940931|NCT06037642|BEHAVIORAL|ABC 0-2 years|Four 1 hour meetings and homework
57940932|NCT06037642|OTHER|waiting list|Will be put on hold for four weeks
57940933|NCT00482703|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily
57940934|NCT00482703|DRUG|dasatinib|tablets, Oral, 50 mg, twice daily
58076020|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
58076021|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
57940935|NCT05038254|OTHER|Best Practice|Receive standard of care telemedicine
57940936|NCT05038254|PROCEDURE|Patient Monitoring|Undergo remote monitoring
57940937|NCT05038254|OTHER|Questionnaire Administration|Ancillary studies
57940938|NCT06432829|BEHAVIORAL|Unified Protocol for the transdiagnostic treatment of emotional disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
57940939|NCT00795249|BEHAVIORAL|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
57940940|NCT05445284|BEHAVIORAL|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
57731002|NCT06387563|PROCEDURE|Abdominal activation using pressure biofeedback|"PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
58076022|NCT02849873|DRUG|IDP-123 Lotion|Lotion
58076023|NCT02849873|DRUG|Tazorac Cream|Cream
58076024|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
58076025|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
58076026|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
58076027|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
57731003|NCT06387563|PROCEDURE|Abdominal activation using SEMG biofeedback|"SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
57731004|NCT04873375|DRUG|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
57731005|NCT01159496|DRUG|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
57731006|NCT01159496|DRUG|Placebo|Oral capsule, once daily for 14 days
57731007|NCT00645398|DRUG|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
57940941|NCT05445284|OTHER|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
58076028|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
58296110|NCT02574169|OTHER|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
58407515|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
58076029|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
58076030|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
58076031|NCT06445972|BIOLOGICAL|MK-2870|3 mg/kg or 4 mg/kg IV Infusion
58076032|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
58407516|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
58076033|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
58076034|NCT05665543|BEHAVIORAL|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
58076035|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
58076036|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
58076037|NCT05340842|OTHER|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
58076038|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
58076039|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
58076040|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
58076041|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
58076042|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
57940942|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
58076043|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
58076044|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
58296111|NCT02574169|OTHER|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
58296112|NCT04256980|DRUG|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
58076045|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
58407517|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
58407518|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
58407519|NCT02323204|OTHER|So you've been in an accident|Educational materials
58407520|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
58407521|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
57731008|NCT00645398|DRUG|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
57731009|NCT00645398|DRUG|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
57731010|NCT00645398|DRUG|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
57940943|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
58407522|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
57731011|NCT00941187|OTHER|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
57731012|NCT02978365|OTHER|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
57940944|NCT00312221|DRUG|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
57940945|NCT03715842|OTHER|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
57940946|NCT03715842|OTHER|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
57940947|NCT03555513|PROCEDURE|living kidney transplantation|receiving kidney transplantation from living donor
57940948|NCT00908024|DRUG|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
58076046|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
58076047|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
58076048|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
58076049|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
58076050|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
58095203|NCT01721824|BEHAVIORAL|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
58296113|NCT06107647|DEVICE|COVIDIEN WarmTouch|"COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia."
58296114|NCT03251157|OTHER|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
58296115|NCT05609396|BEHAVIORAL|Behaviorally enhanced reminder letter|Behavioral interventions to increase FIT-based colorectal cancer screening uptake
58296116|NCT02842476|DEVICE|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
58296117|NCT02842476|DEVICE|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
58296118|NCT02842476|DEVICE|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
58296119|NCT00002029|DRUG|Fat Emulsion 2%|
58296120|NCT00002029|DRUG|Fat Emulsion 20%|
58296121|NCT05039697|OTHER|oxygen|deliver high flow oxygen (10L/min)
58296122|NCT01275144|DRUG|LY2216684|Administered orally
58296123|NCT01275144|DRUG|Placebo|Administered orally
58296124|NCT01275144|DRUG|Lorazepam|Administered orally
58296125|NCT02668965|PROCEDURE|Intrauterine hCG (pregnyl)|
58296126|NCT05418439|DIETARY_SUPPLEMENT|Drink Poppi Soda|Drink Poppi Vinager Soda
58296127|NCT02675764|OTHER|Vibration|peripheral vibration at the wrist skin at an imperceptible level
58296128|NCT02675764|OTHER|Placebo (for vibration)|No peripheral vibration at the wrist skin
57731013|NCT02978365|DEVICE|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
57731014|NCT04862143|DRUG|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
58296129|NCT02675764|BEHAVIORAL|therapy|standardized hand therapy program
57731015|NCT04862143|DRUG|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
58076051|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
58076052|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
57731016|NCT04862143|DRUG|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
57940949|NCT00908024|DRUG|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
58296130|NCT05436561|DRUG|MBF-RIC|Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
58296131|NCT04907214|DRUG|Empagliflozin 25 MG|Oral empagliflozin daily
58296132|NCT05304845|DRUG|DWP14012|Potassium-competitive acid blocker
58296133|NCT05304845|DRUG|Aspirin|acetylsalicylic acid
58296134|NCT02232204|BEHAVIORAL|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
58296135|NCT04678843|BEHAVIORAL|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
58296136|NCT03972215|DRUG|Berberine Chloride|Traditional Chinese Medicine
58296137|NCT03972215|DRUG|Placebo|Placebo Control
58296138|NCT00379561|DRUG|PSA-Activated PSA-PAH1|
58296139|NCT01945944|DRUG|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
58296140|NCT01945944|DRUG|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
58296141|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
58296142|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
58407523|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
58407524|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
58407525|NCT00717522|DRUG|Pomalidomide|
58407526|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
58407527|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
58407528|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
58407529|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
58407530|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
58407531|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
58407532|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
58407533|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
58407534|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
58296143|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
58296144|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
58296145|NCT03513666|COMBINATION_PRODUCT|Drug intervention|anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
58296146|NCT00678015|DRUG|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
58296147|NCT02576262|PROCEDURE|TCT，HPV，colposcopic inspection|
58296148|NCT01131559|DRUG|Lisdexamfetamine|Oral; 20-70mg/day
58296149|NCT01131559|DRUG|Placebo control|Oral; 20-70mg/day
58407535|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
58407536|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
58407537|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
58407538|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
58407539|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
58407540|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
58407541|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
58407542|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
58407543|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
58076053|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
58076054|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
58296150|NCT03049228|DIAGNOSTIC_TEST|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
58296151|NCT03049228|DIAGNOSTIC_TEST|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
58296152|NCT03049228|DIAGNOSTIC_TEST|Blood analysis|To determine blood glucose metabolism and renal function.
58296153|NCT03049228|DIAGNOSTIC_TEST|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
57731017|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
57940950|NCT01672567|DIETARY_SUPPLEMENT|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
57940951|NCT01672567|DIETARY_SUPPLEMENT|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
57940952|NCT01672567|DIETARY_SUPPLEMENT|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
57940953|NCT04993235|BEHAVIORAL|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
57940954|NCT04993235|BEHAVIORAL|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
57940955|NCT04993235|BEHAVIORAL|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
57940956|NCT00659620|BIOLOGICAL|mesenchymal stem cell|transplantation of mesenchymal stem cell
57940957|NCT02289170|DEVICE|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
57940958|NCT02289170|DEVICE|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
57940959|NCT01129921|DEVICE|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
57940960|NCT01129921|DEVICE|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
57940961|NCT03071614|OTHER|News items with spin|Interpretation of news items with spin
58076055|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
58076056|NCT06597734|DRUG|Azacitidine (AZA)|Given by SC or IV
58076057|NCT06597734|DRUG|Decitabine|Given by IV
58076058|NCT06597734|DRUG|Olutasidenib|Given by PO
57940962|NCT03071614|OTHER|News items without spin|Interpretation of news items without spin
57940963|NCT03072784|PROCEDURE|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
57940964|NCT03360097|PROCEDURE|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
57940965|NCT05066321|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
58076059|NCT06597734|DRUG|Cedazuridine|Given by PO
58076060|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
58076061|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
58076062|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
58076063|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
58076064|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
58076065|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
58076066|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
58076067|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
58076068|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
58076069|NCT06235983|DRUG|LY3537982|Administered orally.
58076070|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.
58076071|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit through Week 48.
58076072|NCT06723106|DRUG|RAY121|Injection
58076073|NCT05535478|BEHAVIORAL|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
57731018|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
57940966|NCT04057534|BEHAVIORAL|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
57940967|NCT04057534|BEHAVIORAL|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
58076074|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
58076075|NCT01395420|DRUG|CAZ104|IV Infusion
58076076|NCT01395420|DRUG|CAZ104|IV Infusion
58076077|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
58076078|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
58076079|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
58076080|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
58076081|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
58076082|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
57731019|NCT00451854|PROCEDURE|Random, no advanced notice drug and alcohol testing|
58076083|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
58076084|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
58076085|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
58076086|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
58076087|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
58076088|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
58076089|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
58076090|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
57731020|NCT01640691|BIOLOGICAL|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
58076091|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
58076092|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
58076093|NCT06580002|DRUG|Riluzole|Given PO
58076094|NCT06580002|DRUG|Placebo|Given PO
58076095|NCT00509275|DRUG|W0027|capsule
58076096|NCT00509275|DRUG|Placebo|Placebo
58076097|NCT00009750|BIOLOGICAL|filgrastim|
58076098|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
58296154|NCT03049228|DIAGNOSTIC_TEST|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
58296155|NCT02415153|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58296156|NCT02415153|OTHER|Pharmacological Study|Correlative studies
58296157|NCT02415153|DRUG|Pomalidomide|Given PO
58296158|NCT00576862|DRUG|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
58296159|NCT03744637|DRUG|MK-5475|Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization
58296160|NCT03744637|DRUG|Placebo|Single inhaled dose of placebo to match MK-5475
57731021|NCT04247854|DIETARY_SUPPLEMENT|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
57731022|NCT04247854|OTHER|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
58076099|NCT00009750|DRUG|cyclosporine|
58076100|NCT00009750|DRUG|paclitaxel|
58076101|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
58076102|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
58076103|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
58076104|NCT05525559|DRUG|ET0038|ET0038 for oral administration
58076105|NCT06682494|BEHAVIORAL|Traditional Education|Participants will receive traditional educational handouts focusing on increasing awareness of oral cancer risks, preventive strategies, and the importance of regular dental check-ups. Participants will be provided time to read the handouts based on calculated reading time.
58076106|NCT06682494|BEHAVIORAL|AI-powered Chatbox|The chatbot interaction will be initiated through a provided link, allowing participants to access information and ask questions related to oral health and cancer prevention. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups. Participants will be encouraged to interact with the chatbot for a specified duration
58076107|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
58076108|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
58076109|NCT04920175|OTHER|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
58296161|NCT01528410|DEVICE|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
58296162|NCT01528410|PROCEDURE|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
58076110|NCT06724679|OTHER|Utilisability of an immersive VR device in a functional restoration program (FRP) for patients with chronic low back pain.|"Patients participating will engage in three 20-minute VR sessions per week, in addition to the standard FRP program, for a duration of four to five weeks. The sessions will consist of a series of pre-programmed exercises designed to facilitate various trunk movements (flexion, extension, inclination, rotation) through exergames. Each exercise will last an average of 5 to 7 minutes. These exercises have been developed in collaboration between the company providing the VR device and the rehabilitation teams. Patients will be set up by a healthcare provider in a dedicated room for VR use. The provider will configure the device, assist the patient in donning it, and initiate the program, will remain present throughout the session to monitor for any adverse effect~. While the specific exercises may vary, the total duration of the session will be 20 minutes, consisting of various exercises interspersed with breaks. The principal investigator will propose a standardized series of exercises,"
58076111|NCT02726997|DRUG|Carboplatin|Given IV
58076112|NCT02726997|BIOLOGICAL|Durvalumab|Given IV
58076113|NCT02726997|OTHER|Laboratory Biomarker Analysis|Correlative studies
57940968|NCT04057534|BEHAVIORAL|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
57940969|NCT04057534|BEHAVIORAL|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
57940970|NCT00003865|DRUG|toremifene|
57940971|NCT02098512|DRUG|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
57940972|NCT02098512|PROCEDURE|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
57940973|NCT02098512|DRUG|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
57940974|NCT02327052|OTHER|No intervention was performed.|No intervention was performed.
57940975|NCT04021199|GENETIC|Mody test|"Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test."
57940976|NCT00593944|BIOLOGICAL|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
57940977|NCT03540225|DRUG|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
57940978|NCT03543111|BEHAVIORAL|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
58076114|NCT02726997|DRUG|Paclitaxel|Given IV
58076115|NCT02726997|OTHER|Pharmacological Study|Correlative studies
58076116|NCT02726997|OTHER|Quality-of-Life Assessment|Ancillary studies
58076117|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
57940979|NCT00314353|DRUG|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
57940980|NCT00314353|DRUG|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
58076118|NCT05114031|OTHER|Placebo|Saline water
58076119|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
58076120|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
58076121|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
58076122|NCT02651662|DRUG|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
58076123|NCT02651662|DRUG|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
58076124|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
58076125|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
58296163|NCT01747096|DRUG|68-Ga-DOTANOC|
58296164|NCT03113370|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil capsules
58296165|NCT03113370|DIETARY_SUPPLEMENT|Placebo|Olive Oil
58296166|NCT03256019|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
57731023|NCT03089424|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
57731024|NCT03089424|DEVICE|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
57731025|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
57731026|NCT01511952|OTHER|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
57731027|NCT01511952|OTHER|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
57731028|NCT05827367|DEVICE|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
57731029|NCT05827367|OTHER|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
57731030|NCT05827367|OTHER|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
57731031|NCT06043921|OTHER|No intervention|There is no intervention associated with this observational study.
57940981|NCT00314353|DRUG|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
57940982|NCT00314353|DRUG|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
57731032|NCT02255175|DRUG|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
57940983|NCT01665547|DRUG|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
57940984|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II hemispherical cup
57940985|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II Tritanium cup
57940986|NCT05811715|OTHER|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
58076126|NCT06285890|DRUG|HC-7366|Given by PO
58296167|NCT02364687|RADIATION|Computed tomography late enhancement imaging|
58296168|NCT00593450|DRUG|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
58296169|NCT00593450|DRUG|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
58296170|NCT05438979|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to CFB
58296171|NCT05438979|DIETARY_SUPPLEMENT|Calcium Fructoborate|216mg CFB
58296172|NCT00509899|DRUG|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
58296173|NCT00234026|DRUG|gemcitabine hydrochloride|
58296174|NCT04559477|OTHER|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
58296175|NCT04559477|OTHER|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
58076127|NCT06285890|DRUG|Azacitidine|Given by IV or SC
58076128|NCT06285890|DRUG|Venetoclax|Given by PO
58076129|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
58076130|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
58076131|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
58076132|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
58076133|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
58076134|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
58076135|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
58076136|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
58076137|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
58076138|NCT03734874|OTHER|control|no supplementation
58076139|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
58076140|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
58076141|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
57940987|NCT05811715|OTHER|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
57940988|NCT01249820|DRUG|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
57940989|NCT01249820|DRUG|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
57940990|NCT01213875|BEHAVIORAL|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
57940991|NCT04285242|OTHER|Observational assessments|Clinical assessments
57940992|NCT02539420|DEVICE|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
58076142|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
58076143|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
58076144|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
58076145|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
58076146|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
58076147|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
58076148|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
58076149|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
58076150|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
58076151|NCT06400420|OTHER|Exercise|classic futsal training program
58076152|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
57940993|NCT03441334|DEVICE|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
58076153|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
58076154|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
58076155|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
58076156|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
58076157|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
58076158|NCT06722755|DEVICE|CPAP device|Eligible participants with OSA will be started on automatically-adjusting CPAP.
58076159|NCT06722755|BEHAVIORAL|CPAP technical support|Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.
58076160|NCT06722755|BEHAVIORAL|Phone follow-up for adherence feedback and self-management skills|The research coordinator will call participants approximately monthly to provide any needed support.
58076161|NCT06722755|BEHAVIORAL|myAir|Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.
58076162|NCT06722755|BEHAVIORAL|Tailored messages|Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.
57940994|NCT03441334|DEVICE|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
58076163|NCT06722755|BEHAVIORAL|Written Materials|A binder of written educational materials will be provided to participants.
57940995|NCT05968898|DEVICE|Optellum Virtual Nodule Clinic|The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
58076164|NCT06722755|BEHAVIORAL|Motivational Enhancement Therapy (MET)|A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
58076165|NCT00003695|DRUG|chemotherapy|
58076166|NCT00003695|PROCEDURE|surgical procedure|
58296176|NCT04501484|PROCEDURE|Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy|Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
58076167|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
58076168|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
58076169|NCT06722131|OTHER|Sampling|"Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)"
58076170|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
58076171|NCT06724471|DEVICE|Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials|Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).
58296177|NCT00002314|DRUG|Ro 24-7429|
58076172|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
58076173|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
58076174|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
58076175|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
57940996|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
57940997|NCT00063570|DRUG|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
58076176|NCT06623422|BIOLOGICAL|Pembrolizumab|IV Infusion
58076177|NCT06623422|DRUG|Cisplatin|IV infusion
58296178|NCT01570140|BEHAVIORAL|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
58407544|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
58076178|NCT06623422|DRUG|Carboplatin|IV infusion
58296179|NCT00929994|BEHAVIORAL|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
58296180|NCT00000887|DRUG|Nelfinavir mesylate|
57940998|NCT00063570|DRUG|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
57940999|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
57941000|NCT01683279|BIOLOGICAL|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
57941001|NCT02806128|DRUG|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
57941002|NCT00194181|DRUG|TPA Infusion|
57941003|NCT00136422|BIOLOGICAL|autologous tumor cells|
57941004|NCT04366050|DRUG|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
57941005|NCT04366050|DRUG|Placebo oral capsule|Placebo
57941006|NCT01342484|DRUG|placebo|comparison of different dosages of drug (low vs high) vs placebo
57941007|NCT01342484|DRUG|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
57941008|NCT01342484|DRUG|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
57941009|NCT02363348|DIETARY_SUPPLEMENT|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
57941010|NCT02363348|OTHER|Placebo|calcined magnesia
57941011|NCT04935398|OTHER|Physiotherapy|The aim is to test two treatment techniques against each other to see how effective they are.
57941012|NCT04622332|DRUG|SIR1-365|Route of administration: oral
57941013|NCT04622332|DRUG|Matching Placebo|Route of administration: oral
58076179|NCT06623422|DRUG|Pemetrexed|IV infusion
58076180|NCT06623422|DRUG|Gemcitabine|IV infusion
58076181|NCT06623422|DRUG|Paclitaxel|IV infusion
57731033|NCT02255175|DRUG|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
57941014|NCT00609193|DRUG|lithium|standard clinical care
57941015|NCT00609193|DRUG|quetiapine|standard clinical care
57941016|NCT02430350|DRUG|Compound Edaravone Injection|
57941017|NCT02430350|DRUG|Edaravone Injection|
57941018|NCT00649259|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
57941019|NCT00649259|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
57941020|NCT04288986|BEHAVIORAL|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
57941021|NCT04950179|OTHER|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
57941022|NCT04027699|PROCEDURE|Mini-bolus|"* First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)"
57941023|NCT01022996|DRUG|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
57941024|NCT00002128|DRUG|Adefovir dipivoxil|
57941025|NCT00823849|DRUG|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
57941026|NCT00823849|DRUG|Probucol|250 mg Bid, PO after breakfast and dinner.
57941027|NCT00823849|DRUG|Cilostazol+Probucol|
57941028|NCT00823849|OTHER|Control Group|Routine treatment
58076182|NCT06623422|BIOLOGICAL|V940|IM injection
58076183|NCT06623422|OTHER|Placebo|IM injection
57941029|NCT06450249|BEHAVIORAL|Humanitude® Care Methodology (HCM) training sessions|During a five-day training session healthcare professionals are trained to the HCM within their own care unit
57941030|NCT06450249|BEHAVIORAL|Self-administered questionnaire|The self-administered questionnaire will be completed before and after participation in Humanitude® Care Methodology training sessions
57941031|NCT02301663|OTHER|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
57941032|NCT02301663|OTHER|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
57941033|NCT02301663|OTHER|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
57941034|NCT00121108|BIOLOGICAL|Motavizumab|Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
57941035|NCT00121108|OTHER|Placebo|Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
57941036|NCT03953430|OTHER|Gait analysis|
57941037|NCT01520233|GENETIC|RNA analysis|
57941038|NCT01520233|GENETIC|gene expression analysis|
57941039|NCT01520233|OTHER|laboratory biomarker analysis|
57941040|NCT05065372|DRUG|Metformin Hcl 1000Mg Tab|Agent used to modify insulin sensitivity
57941041|NCT05065372|DRUG|Aminohippurate Sodium 20 % Injection|Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
58076184|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
58076185|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
58296181|NCT00000887|DRUG|Lamivudine|
58296182|NCT00000887|DRUG|Zidovudine|
58296183|NCT05231889|DEVICE|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
58076186|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
58296184|NCT05231889|DEVICE|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
58296185|NCT01724177|DRUG|Lenalidomide|25 mg of Lenalidomide administered orally once daily
58296186|NCT03461458|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
58296187|NCT06133140|DEVICE|Unblinded postoperative vital sign monitoring|Unblinded postoperative GE Portrait monitoring
58296188|NCT06133140|DEVICE|Blinded postoperative vital sign monitoring|Blinded postoperative GE Portrait monitoring
58296189|NCT06314217|DEVICE|Everads Injector|Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector
58296190|NCT06392464|DEVICE|Clinical decision support system (software)|"Use of a clinical decision support system. Naevia Medical is clinical decision support software (CDSS) that, based on clinical input data (patient history, symptoms, complementary test data, etc.) from adult patients with heart disease, provides healthcare professionals with prioritized, justified, and referenced recommendations and knowledge-related suggestions related to diagnosis, prognosis, and/or treatment (recommended tests, medications, alerts, etc.)"
57941042|NCT05065372|DRUG|Iohexol 300 Mg/mL Injectable Solution|Diagnostic aid/agent used to measure glomerular filtration rate
57941043|NCT05065372|DRUG|Placebo|Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
57941044|NCT03574753|DRUG|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
57941045|NCT06350838|DRUG|BCG for Therapeutic Use|Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
57941046|NCT02349594|DRUG|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
57941047|NCT02349594|DRUG|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
57941048|NCT01929239|DRUG|Anti-PSMA Designer T Cells|
57941049|NCT02131441|PROCEDURE|laparoscopic hepatectomy|
57941050|NCT02131441|PROCEDURE|open liver resection|
57941051|NCT03029741|DRUG|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
57941052|NCT03029741|DRUG|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
57941053|NCT03341975|BEHAVIORAL|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
57941054|NCT05476042|DRUG|Prescription of placebo|Normal saline
57941055|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
57941056|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
57941057|NCT03926689|BEHAVIORAL|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
58076187|NCT05846659|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
57941058|NCT03926689|BEHAVIORAL|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
57941059|NCT00998270|PROCEDURE|Autologous bone marrow transplantation|"Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
58076188|NCT05846659|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
58076189|NCT05846659|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
58076190|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
58296191|NCT01999647|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
57941060|NCT00998270|PROCEDURE|Allogeneic bone marrow transplantation|"Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
57941061|NCT03073668|PROCEDURE|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
57941062|NCT03073668|DRUG|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
57941063|NCT02831192|BIOLOGICAL|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
57941064|NCT01194453|DRUG|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
57941065|NCT01194453|DRUG|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
57941066|NCT04941066|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
58407545|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
58407546|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
58076191|NCT04446468|BEHAVIORAL|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
57731034|NCT01518205|DEVICE|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
57731035|NCT02601313|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
58407547|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
58407548|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
57731036|NCT02601313|DRUG|Cyclophosphamide|Administered intravenously
57941067|NCT04941066|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
57941068|NCT03786562|DRUG|Intrathecal Morphine|Group 1
57941069|NCT03786562|DRUG|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
57941070|NCT01898871|DIETARY_SUPPLEMENT|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
57941071|NCT01421940|DRUG|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
57941072|NCT01421940|DRUG|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
57941073|NCT02630342|BEHAVIORAL|Mock MRI scanner|Using a mock scanner for preparation for MRI
57941074|NCT02630342|BEHAVIORAL|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
57941075|NCT02630342|BEHAVIORAL|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
58095204|NCT06696729|PROCEDURE|Topical Mirabilite Application for Postoperative Gastrointestinal Patients|Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.
58407549|NCT04213703|OTHER|No intervention|There is no intervention for this study
58407550|NCT01054937|DRUG|4SC-203|i.v. administration
58407551|NCT01054937|DRUG|Placebo|i.v. administration
58407552|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
58407553|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
58407554|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
58407555|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
57731037|NCT02601313|DRUG|Fludarabine|Administered intravenously
58407556|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
57731038|NCT02601313|DRUG|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
57731039|NCT05695859|DRUG|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
57941076|NCT02630342|BEHAVIORAL|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
57941077|NCT05315050|OTHER|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
57941078|NCT05315050|OTHER|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
57941079|NCT04165226|DEVICE|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
57941080|NCT04165226|DEVICE|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
58076192|NCT04446468|OTHER|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
58076193|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
58076194|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
58076195|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
58076196|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
58076197|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
58076198|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
58076199|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
58095205|NCT06696729|PROCEDURE|Standard Postoperative Care for Gastrointestinal Patients|Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
58407557|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
57941081|NCT04165226|DEVICE|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
57941082|NCT01154244|OTHER|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
57941083|NCT06010771|OTHER|Listening to fairy tales|Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
57941084|NCT06010771|OTHER|Watching Cartoon Film|The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
57941085|NCT04026347|DEVICE|Vesair Balloon|Indwelling, intravesical balloon
57941086|NCT04026347|OTHER|Sham balloon placement|Sham balloon placement procedure
57941087|NCT03664154|BEHAVIORAL|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
57941088|NCT01839396|DEVICE|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
57941089|NCT04568278|OTHER|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
57941090|NCT06208384|DRUG|Statin eye drop|Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
57941091|NCT06208384|DRUG|Placebo|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
57941092|NCT00773721|DEVICE|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
57941093|NCT01776762|DIETARY_SUPPLEMENT|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
57941094|NCT03000179|DRUG|Avelumab|Avelumab through a vein once every 2 weeks
57941095|NCT02794818|BEHAVIORAL|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
58076200|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
58076201|NCT06724380|OTHER|unknown health risk situation|a unknown health risk situation detected at anestesiology consult
58076202|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
58076203|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
58076204|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
58076205|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
58076206|NCT06723990|DRUG|Neoadjuvant standard treatment for HER2+|NEOADJUVANT SETTING
58076207|NCT06723990|DRUG|Adjuvant standard treatment for HER2+|ADJUVANT SETTING
58076208|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
58076209|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
58076210|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
58076211|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
58076212|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
58076213|NCT06050928|DRUG|Oral EP262|Once daily
58076214|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
58076215|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
58296192|NCT01999647|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
58296193|NCT01999647|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
58296194|NCT01999647|PROCEDURE|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
58407558|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
58076216|NCT04856566|DRUG|Placebo|Placebo drug with no THC
58076217|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
58076218|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
58076219|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
58076220|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
58076221|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
58076222|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
58407559|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
58076223|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
58076224|NCT06723652|DRUG|SHR-1918|six administration
58076225|NCT06723652|DRUG|SHR-1918 placebo|SHR-1918 placebo three administration+SHR-1918 three administration
58076226|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
58076227|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
58076228|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
58076229|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
58296195|NCT01999647|DRUG|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
58407560|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
58407561|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
57941096|NCT05453032|DEVICE|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
58076230|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
58076231|NCT06724536|OTHER|non interventional study with the use of biological samples.|"Patients will undergo to the follow evaluations:~Gut microbiome on stool samples by NGS (16S rRNA gene amplicon sequencing); Markers of impaired intestinal permeability \[diaminoxidase (DAO), serum zonulin\], and markers of inflammation of the GI tract (fecal calprotectin); Plasma inflammatory indices, cytokines (by Luminex), markers of autoimmunity, and metabolic profile; Acquired and adaptive immunity by multiparametric flow cytometry on PB samples."
58296196|NCT03327389|DRUG|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
58076232|NCT05026866|DRUG|Donanemab|Administered intravenously
58076233|NCT05026866|DRUG|Placebo|Administered intravenously
58076234|NCT06443138|OTHER|Personalized pre-habilitation program|"Each patient will undergo 4 weeks of individualized pre-habilitation before surgery.~Each session (1 session per day) will be carried out autonomously by the patient at home, via a dedicated application (Activiti Pro) installed on their tablet or smartphone."
58095206|NCT04322383|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
58296197|NCT03327389|DRUG|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
58296198|NCT03361241|OTHER|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
58076235|NCT06619444|BEHAVIORAL|Aerobic exercise only|Aerobic exercise training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year trial
58076236|NCT06619444|BEHAVIORAL|30 min of resistance exercise|30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 15 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
58076237|NCT06619444|BEHAVIORAL|60 min of resistance exercise|60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
58076238|NCT06619444|BEHAVIORAL|120 min of resistance exercise|120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
58076239|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
58076240|NCT06709976|DEVICE|Vaginal microbiome swab|All swabs were collected using FLOQSwabs™ (Copan Italia SpA, Brescia, Italy). The patients were instructed to spread the labia with one hand, insert the swab 3-5 cm beyond the vaginal orifice with the other hand, and rotate the swab along the vaginal wall for 10-15 seconds.
58076241|NCT06709976|DEVICE|Menstrual Blood Collection via Menstrual Cup|Self-collect menstrual blood during 24 hours in 2 blocks of 12 hours
58076242|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
58076243|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
58076244|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
58076245|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
58407562|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
58407563|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
58407564|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
58407565|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
58407566|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
58407567|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
57941097|NCT04169490|OTHER|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
57941098|NCT04169490|OTHER|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
57941099|NCT04169490|OTHER|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
58076246|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
58076247|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
58076248|NCT04485104|DRUG|GWP42003-P|Oral Solution
58076249|NCT04227665|OTHER|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
58076250|NCT04227665|OTHER|Altitude|Altitude exposure / altitude exposure Iron metabolism
58076251|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
58296199|NCT03361241|OTHER|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
58296200|NCT01820247|DRUG|enteral nutrition|
58407568|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
58407569|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
58407570|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
58407571|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
57731040|NCT06205511|DIAGNOSTIC_TEST|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
58407572|NCT00617071|OTHER|medical chart review|
58407573|NCT00617071|OTHER|survey administration|
57731041|NCT03571061|PROCEDURE|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
58076252|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
58076253|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
58076254|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
58296201|NCT01820247|DRUG|Tripterygium glycosides|
58296202|NCT04997876|OTHER|Biomarker analysis|Biomarkers from presurgical OCTs are assessed
58407574|NCT00617071|PROCEDURE|fecal occult blood test|
58407575|NCT00617071|PROCEDURE|screening colonoscopy|
58296203|NCT05965596|OTHER|a psycho educational intervention program|The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.
58076255|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
58076256|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
58076257|NCT00439920|DRUG|High-dose anthracycline|
58076258|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
58076259|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
58076260|NCT05295810|DRUG|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
58407576|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
58407577|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
58407578|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
57731042|NCT04093622|GENETIC|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
57731043|NCT03701724|DEVICE|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
58076261|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
58076262|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
58296204|NCT05965596|OTHER|the routine care|the routine care provided for all gynecological cancer patients in the study setting
58296205|NCT01655225|DRUG|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
57731044|NCT03701724|DEVICE|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
58076263|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
58296206|NCT01655225|DRUG|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
58296207|NCT01655225|DRUG|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
58296208|NCT01655225|DRUG|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
58296209|NCT01655225|DRUG|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
58296210|NCT01655225|DRUG|Abemaciclib|Administered orally
58076264|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
58076265|NCT06724666|BEHAVIORAL|Transdiagnostic Internet-delivered intervention|The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
58296211|NCT01655225|DRUG|Letrozole|Administered orally
58296212|NCT05528172|DRUG|Ripasudil|K-321 ophthalmic solution
58296213|NCT05528172|DRUG|Placebo|Placebo ophthalmic solution
58296214|NCT00613821|DRUG|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
58296215|NCT00613821|DRUG|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
58407579|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
58076266|NCT06489041|GENETIC|"Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx"|Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
58076267|NCT02528643|DRUG|Enzalutamide|Oral capsule
58076268|NCT02528643|DRUG|Placebo|Oral capsule
58076269|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
58076270|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
58076271|NCT00184730|DRUG|somatropin|
58076272|NCT06716710|BEHAVIORAL|Art therapy group|In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, a mandala coloring session will be held 3 days a week, 2 times a week under the supervision of the researcher. In order to ensure standardization in the pregnant women included in the study group, each pregnant woman will be given the same mandala work box (36 colored coloring pencils, file, eraser, pencil sharpener and the same mandala prints for all pregnant women). The selection of mandala patterns will be determined by the researchers. In the second week of the training, the researcher will evaluate the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of birth scale. At the end of the four-week activity, the researcher will evaluate again.
57731045|NCT03701724|DEVICE|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
57731046|NCT01788683|PROCEDURE|Regenexx SD|stem cell treatment
57731047|NCT01788683|OTHER|Exercise Therapy|exercise therapy control
57941100|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
57941101|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
57941102|NCT04192851|PROCEDURE|Tent Pole Technique|"* All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material"
57941103|NCT03487809|DRUG|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
57941104|NCT00073151|DRUG|ABT-751|
57941105|NCT00535314|DRUG|RTA 402 Dose1|
58076273|NCT06716710|OTHER|Control group|In addition to the medical treatments that the pregnant women in the control group will receive in the clinic for 4 weeks, no other application will be made. After two weeks, the researcher will evaluate them using the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of childbirth scale. At the end of the fourth week, the researcher will evaluate them again.
58076274|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
58076275|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
58076276|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
58076277|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
58076278|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
57941106|NCT00535314|DRUG|RTA 402 Dose2|
57941107|NCT01751399|DRUG|LY2605541|
57941108|NCT03837626|DRUG|Placebo - Cap|6 months of 1 pill a day
57941109|NCT03837626|DRUG|Amiloride Pill|Max dose of 5 mg a day for 6 months
57941110|NCT03906383|OTHER|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
57941111|NCT03275220|DIAGNOSTIC_TEST|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
57941112|NCT02034630|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
57941113|NCT04095728|DIETARY_SUPPLEMENT|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
57941114|NCT04095728|OTHER|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
58076279|NCT05812183|DEVICE|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
58095207|NCT02184169|DEVICE|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
58095208|NCT02184169|DEVICE|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
58095209|NCT01518985|DRUG|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
58095210|NCT01518985|DRUG|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
58076280|NCT05812183|DRUG|Medical weight loss|The medical weight loss intervention will follow UCLA's RFO standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very low caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins. Some patients may recieve adjuvant drug therapy including Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), Naltrexone-bupropion (Contrave), Liraglutide (Saxenda), Semaglutide (Wegovy), Tirzepatide (Zepbound) or Setmelanotide (Imcivree).
57941115|NCT01054144|DRUG|Lenalidomide|"* Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~* Dose Level -4: Discontinue"
58407580|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
58407581|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
58407582|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
58407583|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
58407584|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
58407585|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
57941116|NCT01054144|DRUG|Prednisone|"* Starting Dose: 100 mg PO days 1-5 every 28 days;~* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~* Dose level -3: Discontinue"
57941117|NCT01054144|DRUG|Dexamethasone|"* Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~* Dose level -3: Discontinue"
57941118|NCT00037570|DRUG|Pantoprazole|
57941119|NCT04925167|DRUG|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
57941120|NCT04925167|DRUG|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
57941121|NCT02330822|DRUG|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
57941122|NCT02968069|DEVICE|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
57941123|NCT03648775|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
57941124|NCT00253396|DRUG|Unfractionated heparin|
58076281|NCT06484387|BEHAVIORAL|Social interaction|Participants are required to speak to one another. Participants are given various topics of conversation.
57941125|NCT00253396|DRUG|Enoxaparin|
57941126|NCT00183768|BEHAVIORAL|Cognitive Behavioral Therapy|
58076282|NCT06723496|BEHAVIORAL|Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.|is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.
58095211|NCT01518985|OTHER|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
58407586|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
58407587|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
58407588|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
58407589|NCT03645525|DRUG|placebo|saline
58407590|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
57941127|NCT00183768|BEHAVIORAL|Psychopharmacology|
57941128|NCT05239611|DIAGNOSTIC_TEST|Exercise|The intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
57941129|NCT00250653|DRUG|Saredutant succinate (SR48968C)|
57941130|NCT03947840|BEHAVIORAL|Physical activity|Se their physical activity level
57941131|NCT00947700|BEHAVIORAL|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
57941132|NCT02342496|DIETARY_SUPPLEMENT|Placebo|Powder
57941133|NCT02342496|DIETARY_SUPPLEMENT|Active, only probiotics|Powder
57941134|NCT02342496|DIETARY_SUPPLEMENT|Active, blend of berries and probiotics|Powder
58076283|NCT06723496|BEHAVIORAL|parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer|It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors
58076284|NCT06723496|BEHAVIORAL|Symptom Checklist -90- Revised (SCL-90-R) for parents|It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions
58076285|NCT06723496|BEHAVIORAL|posttraumatic stress disorders by posttraumatic check list -5 (PCL-5) for parents|It is a 20 -item measure that assess the 20 DSM-5 symptoms of PTSD.
58076286|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
58076287|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
58076288|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
58076289|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
58076290|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
58076291|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
58076292|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
58076293|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
58076294|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
58296216|NCT05562245|OTHER|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
57941135|NCT03897907|OTHER|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
57941136|NCT03897907|OTHER|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
58076295|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
58076296|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
58076297|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
58076298|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
58076299|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
58076300|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
58076301|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
58076302|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
58076303|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
58076304|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
58076305|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
58076306|NCT05524805|DEVICE|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
57731048|NCT05512494|BIOLOGICAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
57941137|NCT05052073|DIAGNOSTIC_TEST|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
58296217|NCT06415019|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
58296218|NCT06415019|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
57731049|NCT03057548|PROCEDURE|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
57941138|NCT05052073|DIAGNOSTIC_TEST|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
58076307|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
57941139|NCT03246139|BEHAVIORAL|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
57941140|NCT03246139|BEHAVIORAL|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
57941141|NCT03246139|BEHAVIORAL|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
57941142|NCT00362414|DRUG|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
57941143|NCT00829049|DRUG|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
57941144|NCT00829049|DRUG|Adapalene|1 pea-size amount, QD x 16 weeks
57941145|NCT01422148|DRUG|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
57941146|NCT01422148|DRUG|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
57941147|NCT01550250|BEHAVIORAL|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
57941148|NCT01550250|BEHAVIORAL|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
57941149|NCT06304077|OTHER|Forest|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
57941150|NCT06304077|OTHER|Urban|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
58076308|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
58076309|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
58076310|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
58076311|NCT05893160|OTHER|Placebo|Inert placebo formulation
58076312|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
58296219|NCT06415019|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch.
58296220|NCT01153217|DRUG|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
58407591|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
58407592|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
58407593|NCT02179736|DEVICE|Restylane|
57731050|NCT03057548|PROCEDURE|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
58296221|NCT05044429|DRUG|Intravenous Lidocaine|Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
57731051|NCT01276587|DRUG|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
57941151|NCT06304077|OTHER|Rural|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
57941152|NCT04661722|OTHER|No intervention|No intervention
58076313|NCT06722898|DIETARY_SUPPLEMENT|Supplement|Contains ingredients believed to reduce Blood Alcohol Concentration and symptoms of alcohol impairment.
58076314|NCT06722898|DIETARY_SUPPLEMENT|Placebo|Placebo
58076315|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
58076316|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
58076317|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
58076318|NCT05614544|DRUG|Placebo|Intralipid
58076319|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
58076320|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
58076321|NCT04179864|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
58296222|NCT05044429|DRUG|Transversus abdominis plane (TAP) block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
58296223|NCT05044429|DRUG|Quadratus Lumborum (QL) Block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
58076322|NCT04179864|DRUG|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
58076323|NCT04179864|DRUG|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
58076324|NCT06723080|DRUG|VC005 low dose group|VC005 low dose group repeat administration
58296224|NCT01617239|BIOLOGICAL|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
58296225|NCT03900208|DIAGNOSTIC_TEST|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
58296226|NCT04745741|RADIATION|IB-positive group|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
58407594|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
58407595|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
57941153|NCT03862144|DRUG|Netupitant/Palonosetron|
58076325|NCT06723080|DRUG|VC005 high dose group|VC005 high dose group repeat administration
58076326|NCT06723080|DRUG|VC005 Placebo group|VC005 Placebo group repeat administration
57941154|NCT01131520|BEHAVIORAL|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
57941155|NCT01131520|BEHAVIORAL|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
58076327|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
58076328|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
58076329|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
58076330|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
58076331|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
58076332|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
58296227|NCT02403011|OTHER|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
58407596|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
58407597|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
58296228|NCT02403011|OTHER|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
58296229|NCT02928796|BEHAVIORAL|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
58407598|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
58407599|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
57731052|NCT06035133|DRUG|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
57941156|NCT06247631|OTHER|STOP BANG|The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
57941157|NCT03184077|PROCEDURE|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
58407600|NCT02094742|PROCEDURE|biopsy|
58407601|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
58407602|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
58407603|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
58407604|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
57731053|NCT06035133|DRUG|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
57941158|NCT03184077|PROCEDURE|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
58296230|NCT05537311|BEHAVIORAL|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
57731054|NCT06035133|RADIATION|radiotherapy|radiotherapy
57731055|NCT04148248|OTHER|No intervention|There is no intervention for this study
58296231|NCT00473057|OTHER|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
58296232|NCT04892732|DRUG|Budesonide|Budesonide dispensing claim is used as the reference group.
58296233|NCT04892732|DRUG|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
58407605|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
58407606|NCT04659928|DEVICE|External evacuation device (EED)|Extraoral suction unit will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
58407607|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
57731056|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
57731057|NCT05234944|BEHAVIORAL|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
58296234|NCT05332041|OTHER|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
57731058|NCT05740462|BEHAVIORAL|Recipes consumption|Participants will eat two recipes a day for 17 weeks
57941159|NCT05701098|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
58296235|NCT04974229|OTHER|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
58407608|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
57941160|NCT03708549|DRUG|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
57941161|NCT03708549|DRUG|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
57731059|NCT05740462|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
57731060|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
57941162|NCT02937194|BEHAVIORAL|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
57941163|NCT02937194|BEHAVIORAL|Pamphlets distribution|Oral health pamphlets distribution
57941164|NCT02911506|OTHER|Polysomnography|
57941165|NCT00237575|DRUG|gemcitabine|
57941166|NCT00237575|DRUG|cisplatin|
57941167|NCT00237575|DRUG|sargramostim|
57941168|NCT00237575|DRUG|filgrastim|
57941169|NCT05337787|OTHER|flipped classroom approach|The students in the experimental group were trained using the flipped learning model.
57941170|NCT03268928|BEHAVIORAL|Story Starters Intervention|Shared reading intervention
58296236|NCT00447668|BEHAVIORAL|Yoga|Yoga for back pain
58296237|NCT00447668|BEHAVIORAL|Exercise|exercises for back pain
58296238|NCT00447668|BEHAVIORAL|Self-care book recommendations|Self-care book for back pain
57941171|NCT03268928|BEHAVIORAL|Wait-list Control|Wait-list control
57941172|NCT05051150|DRUG|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
57941173|NCT05051150|DRUG|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
57941174|NCT05051150|DRUG|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
57941175|NCT00656240|DRUG|DE-104 ophthalmic solution|
57941176|NCT00656240|DRUG|DE-104 vehicle|
58296239|NCT02768168|DRUG|dezocine|receive dezocine 0.1 mg/kg
58296240|NCT02768168|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
58296241|NCT00058071|DRUG|amifostine trihydrate|
58296242|NCT05550636|DRUG|BI 1015550|BI 1015550
58296243|NCT05550636|DRUG|midazolam|midazolam
58296244|NCT06131450|DRUG|BL-M07D1|Administration by intravenous infusion
58296245|NCT02434874|DEVICE|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
58296246|NCT00000694|DRUG|Interferon alfa-2b|
58076333|NCT05691530|DRUG|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
58076334|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Hydrogen-rich water|Hydrogen-rich water with 12 mg of hydrogen per serving
58296247|NCT00000694|DRUG|Zidovudine|
57731061|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
57731062|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
57731063|NCT02528214|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
57731064|NCT02528214|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
57941177|NCT04760951|DIETARY_SUPPLEMENT|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
57941178|NCT04760951|DIETARY_SUPPLEMENT|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
57941179|NCT01892592|BEHAVIORAL|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
57941180|NCT06210477|DRUG|medical treatment for lower urinary tract symptoms|The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
57941181|NCT04190979|DEVICE|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
57941182|NCT02941705|BIOLOGICAL|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
57941183|NCT02941705|BIOLOGICAL|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
57941184|NCT05149664|DEVICE|Therapeutic ultrasound (TUS)|As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
57941185|NCT00474110|DRUG|Ketamine & hydromorphone|See Detailed Description
57941186|NCT05712148|BIOLOGICAL|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
57941187|NCT05954923|OTHER|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
57941188|NCT05985148|RADIATION|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
57941189|NCT01953575|DEVICE|Mucosal Impedance|A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
58076335|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Control water|Control water with 0 mg of hydrogen per serving
58076336|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
58076337|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
58076338|NCT06717217|PROCEDURE|NURSING EDUCATION GIVEN BEFORE TYMPANOPLASTY SURGERY|EAR CARE TRAINING
57941190|NCT01953575|PROCEDURE|Upper Endoscopy|Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
58076339|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
58076340|NCT06722456|DIAGNOSTIC_TEST|Analysis of protein signatures in stool samples|Stool protein signatures are to be established in parallel to standard clinical evaluation of the intestinal inflammatory activity.
58076341|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
58076342|NCT00873496|DRUG|Hydroxychloroquine|
58296248|NCT00000694|DRUG|Sargramostim|
58076343|NCT06718348|OTHER|Use of the Exoskeleton JAPET.W|Phsysiotherapy sessions with the support of the Exoskeleton JAPET.W
58076344|NCT06487806|BEHAVIORAL|SmokefreeSGM|Participants will be asked to set a quit date within the next 15 days before being enrolled in the SmokefreeSGM Español text messaging program. They will be mailed a 6-week supply of nicotine patches. The participants will get daily text messages for 6 weeks that will encourage them to quit smoking.
58076345|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
58076346|NCT02649673|DRUG|LCL161|
58076347|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
58076348|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
58076349|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
58076350|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
58076351|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
57941191|NCT04568395|OTHER|TCIG|Use a TCIG
57941192|NCT04568395|OTHER|ECIG|Use an ECIG
57941193|NCT04568395|OTHER|sham control|Use a sham control (empty ECIG)
57941194|NCT04067479|DIETARY_SUPPLEMENT|Amino Acids|Oral bolus of essential amino acids
57941195|NCT00754351|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
57941196|NCT00754351|DRUG|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
57941197|NCT00754351|DRUG|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
57941198|NCT02205411|DEVICE|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
57941199|NCT02205411|DEVICE|Control VAD|The HeartMate II® VAD or HVAD®
57731065|NCT02528214|DRUG|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
57941200|NCT05040893|BEHAVIORAL|Physiotherapy|"Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
57941201|NCT03013283|OTHER|self questionnaire|"* Interface side effects and degree of satisfaction of the patients~* Technician evaluation and device measures."
57941202|NCT05080049|DRUG|Erythropoietin|"Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
57941203|NCT05080049|DRUG|Placebo|"In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
57941204|NCT00130702|DRUG|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
58076352|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
58076353|NCT00057642|DRUG|Sertraline|
58296249|NCT04557735|DRUG|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
58296250|NCT04557735|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
58296251|NCT06354218|DRUG|Serplulimab|Serplulimab （4.5mg/Kg every 3 weeks）
57941205|NCT04906356|GENETIC|Genetic sub-study|One time saliva sample collection
57941206|NCT05060120|DIAGNOSTIC_TEST|biomakers for ovarian torsion|Blood biomarkers analysis using multiplex ELISA: The Luminex system is a magnetic bead-based multiplex ELISA that enable to measure simultaneously multiple proteins within the same sample. Human magnetic Luminex assay will be used for the following analytes: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml). Plasma samples stored at -70°C will be sent to accredited lab at BioTest (Israel) for performing the multiplex ELISA readout assay test using MagPix system.
57941207|NCT05060120|DIAGNOSTIC_TEST|peritoneal fluid proteins analysis|"Western blot for peritoneal fluid proteins analysis~We will look for the relative abundance of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS) using western blot. Superoxide dismutase 1 (SOD1, 16kDa) scavenges superoxides (O-2) within cells. Catalase (60kDa) is hydrogen peroxide (H2O2) scavenging enzyme regulate ROS concentrations within cells by reducing H202 into O2 and water. Thioredoxin (12kDa) facilitates the reduction of proteins via cysteine thiol-disulfide exchange. Alpha smooth muscle actin (42kDa) will be used as a loading control. These four proteins will be resolved by western blot given their different molecular weights using western blot cocktail antibodies (abcam # ab179843)."
57941208|NCT03877536|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
57941209|NCT04755348|OTHER|Product A|A 4mg nicotine pouch product
57731066|NCT02528214|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
57941210|NCT04755348|OTHER|Product B|A 4mg nicotine pouch product
57941211|NCT04755348|OTHER|Product C|A 2mg nicotine lozenge product
57941212|NCT04755348|OTHER|Product D|A 2mg nicotine lozenge product
57941213|NCT04755348|OTHER|Product E|A 2mg nicotine lozenge product
57941214|NCT04755348|OTHER|Product F|A 2mg nicotine lozenge product
57941215|NCT05492734|DRUG|EDG-5506|single oral dose
57941216|NCT03087188|OTHER|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
58296252|NCT00675987|DRUG|losartan|losartan 100 mg tablets 1 tab po QD
58296253|NCT00675987|DRUG|Placebo control|Placebo 1 po QD
58296254|NCT01557478|DRUG|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
58296255|NCT01557478|DRUG|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
57941217|NCT02246582|DEVICE|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
57941218|NCT02246582|DEVICE|Guardian Mobile App|
57941219|NCT02246582|DEVICE|640G Insulin Pump|
58296256|NCT00983645|DRUG|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
58296257|NCT00983645|DRUG|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
58296258|NCT04058639|PROCEDURE|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
58296259|NCT04058639|PROCEDURE|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
58296260|NCT01240096|DRUG|Mirtazapine|Mirtazapine 15 mg daily
58296261|NCT01516138|DRUG|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
58407609|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
57941220|NCT05740085|OTHER|Patient information form|Patients will be asked to fill out a patient information form and an osteoporosis awareness form
57941221|NCT05510154|BEHAVIORAL|Brief advice|A single, brief advice session on switching to electronic cigarettes.
57941222|NCT05510154|BEHAVIORAL|Single Training|A single, in-depth training session on switching to electronic cigarettes.
57941223|NCT05510154|BEHAVIORAL|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
57941224|NCT01667081|DRUG|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
57941225|NCT03364582|OTHER|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
57941226|NCT03199664|RADIATION|NB-UVB|NB-UVB given twice weekly for 6 months
57941227|NCT03199664|COMBINATION_PRODUCT|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
57941228|NCT01829971|DRUG|MRX34|micro RNA therapy
57941229|NCT05111665|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|
57941230|NCT05111665|BEHAVIORAL|Relaxation Group Therapy (RGT)|
57941231|NCT05111665|BEHAVIORAL|Treatment as usual (TAU)|
57941232|NCT00618410|DEVICE|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
58076354|NCT00057642|DRUG|Venlafaxine Extended Release|
58296262|NCT01516138|DRUG|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
58407610|NCT02708849|DRUG|Placebo|oral dose placebo
58407611|NCT00427531|OTHER|physiologic testing|
58407612|NCT02269176|DRUG|Low dose of telmisartan|
58407613|NCT02269176|DRUG|High dose of telmisartan|
58407614|NCT02269176|DRUG|Low dose of losartan|
58407615|NCT02269176|DRUG|High dose of losartan|
57941233|NCT00618410|OTHER|Placebo|Nasal placebo
57941234|NCT02313298|RADIATION|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
57941235|NCT03157505|DRUG|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
57941236|NCT03157505|OTHER|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
57941237|NCT00164047|DRUG|Nitrous Oxide|
58407616|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
57941238|NCT03493087|DIETARY_SUPPLEMENT|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
57941239|NCT03493087|DIETARY_SUPPLEMENT|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
57941240|NCT00445224|OTHER|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
57941241|NCT00445224|OTHER|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
57941242|NCT05150600|PROCEDURE|Inverse Ratio Ventilation|The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
57941243|NCT02774447|PROCEDURE|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
57941244|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 1|Pharmaceutical form: suspension for injection Route of administration: intramuscular
57941245|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 2|Pharmaceutical form: suspension for injection Route of administration: intramuscular
57941246|NCT05608005|BIOLOGICAL|Unadjuvanted Panblok Dose 3|Pharmaceutical form: liquid for injection Route of administration: intramuscular
57941247|NCT00004172|BIOLOGICAL|filgrastim|
57941248|NCT00004172|DRUG|carboplatin|
57941249|NCT00004172|DRUG|cyclophosphamide|
58076355|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
58076356|NCT04816591|DEVICE|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
58076357|NCT04816591|OTHER|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only (Control)
58076358|NCT04816591|DEVICE|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
58076359|NCT04816591|OTHER|Active Comparator: Observational Cohort: Control Arm|Standard of Care Medical Management Only (Control)
58407617|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
58407618|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
58076360|NCT05659875|OTHER|Standard Occupational Therapy Arm Exercise Program|Standard exercise program will be provided addressing shoulder, elbow, forearm, wrist, and hand with expectation that participant will complete 3 times a week. Exercise program will be updated at assessment timepoints as needed with change in arm function.
58076361|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
58076362|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
58076363|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
58296263|NCT06320210|BEHAVIORAL|Multicomponent program|The intervention is a multi-component program that includes in-depth training for current school teachers/staff who are critical in asthma care, restructured processes to identify students with asthma, technological adaptations to support integrated systems for asthma care and absenteeism, strategies to enhance communication about asthma within school and between school and home, protocols for routine care (e.g., participation in gym/recess) and emergencies, and education for all students about asthma.
58296264|NCT02708550|BEHAVIORAL|Participatory Organizational Intervention|
58296265|NCT02620683|DRUG|Lidocaine|See above
58296266|NCT03562078|BEHAVIORAL|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
58296267|NCT03718715|DRUG|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
58407619|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
58407620|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
58407621|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
58407622|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
58407623|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
58407624|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
58407625|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
58407626|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
58407627|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
58407628|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
58407629|NCT00377546|DRUG|Nepafenac|
58407630|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
58407631|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
58407632|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
58407633|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
58407634|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
58407635|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
58407636|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
58407637|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
58407638|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
58407639|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
58076364|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
58076365|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
58076366|NCT00516698|GENETIC|polymorphism analysis|
58076367|NCT00516698|OTHER|high performance liquid chromatography|
58407640|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
58407641|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
57731067|NCT02528214|DRUG|Albuterol/Salbutamol|Oral inhalation as needed.
57941250|NCT00004172|DRUG|ifosfamide|
57941251|NCT00004172|DRUG|thiotepa|
57941252|NCT00004172|PROCEDURE|peripheral blood stem cell transplantation|
57941253|NCT00004172|RADIATION|radiation therapy|
57941254|NCT00110981|DEVICE|NB-UVB|Three times a week (TIW) for 12 weeks
57941255|NCT00110981|DRUG|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
57941256|NCT00110981|DRUG|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
57941257|NCT01686009|DRUG|Intra-nasal ketamine|
57941258|NCT06273670|OTHER|screening and data collection|"Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data."
57941259|NCT04353284|DRUG|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
57941260|NCT04353284|OTHER|Placebo|Placebo taken orally, 4 times daily, for 7 days.
57941261|NCT04994197|OTHER|Observational study only - no intervention|Observational study only - no intervention
57941262|NCT03857204|DEVICE|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
57941263|NCT05082584|DRUG|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
57941264|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
57941265|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
57941266|NCT03228303|DRUG|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
57941267|NCT03228303|DRUG|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
58076368|NCT00516698|OTHER|laboratory biomarker analysis|
58076369|NCT00516698|PROCEDURE|radiomammography|
58076370|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
58076371|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
58407642|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
57941268|NCT03625687|DRUG|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
57941269|NCT00000491|DRUG|aspirin|
57941270|NCT00135239|PROCEDURE|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
58076372|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
58407643|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
58407644|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
58407645|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
58407646|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
58407647|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
58407648|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
57731068|NCT02528214|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
57941271|NCT00135239|PROCEDURE|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
57941272|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
57941273|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
57941274|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
58076373|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
58076374|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
58407649|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
58407650|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
57941275|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
57941276|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
57941277|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
57941278|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
57941279|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
57941280|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
57941281|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
57941282|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
57941283|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
57941284|NCT01235559|DRUG|Placebo|Oral doses, once a day for 52 weeks
57941285|NCT01235559|DRUG|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
57941286|NCT01235559|DRUG|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
57941287|NCT01961401|BEHAVIORAL|exercise|
57941288|NCT03823404|DRUG|COR388 capsule|BID (twice daily)
57941289|NCT03823404|DRUG|Placebo capsule|BID
57941290|NCT04213105|DRUG|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
57941291|NCT04213105|DRUG|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
58076375|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
58407651|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
58407652|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
57941292|NCT00887120|DRUG|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"* BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
57941293|NCT00887120|DRUG|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"* BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
57941294|NCT00475722|BEHAVIORAL|1 Healthy Eating|6 months telephone counseling
57941295|NCT00475722|BEHAVIORAL|2 Mediterranean|6 months telephone counseling
57941296|NCT02558114|DRUG|Ribavirin|
57941297|NCT00698724|DRUG|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
57941298|NCT00698724|DRUG|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
57941299|NCT00790686|PROCEDURE|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
57941300|NCT06243406|OTHER|Intravitreal injection of anti-VEGF|Intravitreal injection of anti- vascular endothelial growth factor (VEGF) treatment
58407653|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
57941301|NCT00733954|DRUG|clobetasol propionate spray|Apply twice daily
57941302|NCT00733954|DRUG|clobetasol propionate ointment|Apply twice daily
57941303|NCT02613884|DRUG|Treatment|
58076376|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58407654|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
58076377|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58076378|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58076379|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
58076380|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
58076381|NCT06612645|BIOLOGICAL|B7H3-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
58076382|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
58076383|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
58076384|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
58076385|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
58076386|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
58076387|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
58076388|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
58076389|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
58076390|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
58076391|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
58076392|NCT06087822|DEVICE|IMD SiPore21®|The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c
58407655|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
58407656|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
57731069|NCT04090307|BEHAVIORAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
57731070|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
57731071|NCT03655158|DEVICE|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
57731072|NCT06634472|OTHER|AI|AI-enabled skin perforator segmentation tool
58076393|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
58407657|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
58407658|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
58076394|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
58076395|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
58076396|NCT06724627|DIAGNOSTIC_TEST|Dermatology/Skin - Other|Belle AI for skin image assessment.
58095212|NCT01810393|DRUG|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
58095213|NCT03860987|DRUG|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
58095214|NCT03860987|DRUG|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
58095215|NCT03860987|DRUG|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
57731073|NCT04867564|DIAGNOSTIC_TEST|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
58407659|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
58296268|NCT05467852|DRUG|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
58296269|NCT00000363|DRUG|Antihistamine|
58296270|NCT00000363|DRUG|Corticosteroid|
58296271|NCT00090896|BIOLOGICAL|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
58407660|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
58407661|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
58407662|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
58296272|NCT06085521|DRUG|LNK01001 Dose A|Capsules taken orally
58296273|NCT06085521|DRUG|LNK01001 Dose B|Capsules taken orally
58407663|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
58407664|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
57941304|NCT05247814|GENETIC|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
57941305|NCT05247814|OTHER|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
57941306|NCT05247814|OTHER|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
57941307|NCT02525055|OTHER|Infectious titre 1 (H3N2)|Infectious titre 1: 2.8 x 10\*3 TCID50/mL
57941308|NCT02525055|OTHER|Infectious titre 2 (H3N2)|Infectious titre 2: 2.5 x 10\*4 TCID50/mL
57941309|NCT02525055|OTHER|Infectious titre 3 (H3N2)|Infectious titre 3: 3.6 x 10\*5 TCID50/mL
58095216|NCT03860987|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
58095217|NCT03860987|DRUG|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
57941310|NCT02525055|OTHER|Infectious titre 4 (H3N2)|Infectious titre 4: 4.7 x 10\*6 TCID50/mL
57941311|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
58296274|NCT06085521|DRUG|placebo|Capsules taken orally
58296275|NCT01607593|DRUG|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
58296276|NCT02174224|BEHAVIORAL|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
58296277|NCT02174224|BEHAVIORAL|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
58407665|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
58407666|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
58407667|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
58407668|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
57941312|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
57941313|NCT03968107|OTHER|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
58095218|NCT03860987|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
58095219|NCT02449967|PROCEDURE|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
58296278|NCT02174224|BEHAVIORAL|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
58296279|NCT02915159|BIOLOGICAL|Abatacept|
58296280|NCT02915159|OTHER|Placebo|
58296281|NCT04758013|PROCEDURE|Epidural injection through thoracic epidural catheter|The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.
57941314|NCT05220397|BIOLOGICAL|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
57941315|NCT05220397|OTHER|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
57941316|NCT05220397|OTHER|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
57941317|NCT04077541|BEHAVIORAL|internet platform|The trauma care bundles combined with the internet platform.
57941318|NCT02451579|DRUG|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
57941319|NCT02451579|OTHER|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
57941320|NCT01624987|BEHAVIORAL|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
57941321|NCT01624987|OTHER|Control group|The control group receives no intervention.
57941322|NCT02016820|DRUG|Omeprazole (suspension)|1 mg/kg/day
58095220|NCT03549845|BEHAVIORAL|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
58095221|NCT01093365|DRUG|Varenicline|"* 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days"
58296282|NCT04758013|PROCEDURE|Without epidural injection|The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
57731074|NCT05655793|DIAGNOSTIC_TEST|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
57941323|NCT02016820|OTHER|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
57941324|NCT05741281|BEHAVIORAL|Physical exercises program|- Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
57941325|NCT00560742|PROCEDURE|Control|Coronary artery bypass grafting without bone marrow cells injection
57941326|NCT00560742|PROCEDURE|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
57941327|NCT00560742|PROCEDURE|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
58095222|NCT05543863|DIAGNOSTIC_TEST|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
58296283|NCT03722082|BEHAVIORAL|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
58296284|NCT03722082|BEHAVIORAL|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
58296285|NCT01040949|BEHAVIORAL|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
58296286|NCT01040949|BEHAVIORAL|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
58296287|NCT01119521|BIOLOGICAL|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
57731075|NCT05655793|DIAGNOSTIC_TEST|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
57731076|NCT01868581|DRUG|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
57731077|NCT01868581|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
57731078|NCT05493280|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
57731079|NCT02995603|DEVICE|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
57941328|NCT05891340|OTHER|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
57941329|NCT05891340|OTHER|Endurance exercise|walking exercise 5000 steps/day
57941330|NCT01671111|DRUG|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
57941331|NCT04092296|OTHER|resin infiltration|using infiltrant resin intervene proximal caries
57941332|NCT04092296|OTHER|remineralization|using fluoride to remineralize proximal caries
57941333|NCT04092296|OTHER|sham|replace resin with water
57941334|NCT04526743|BEHAVIORAL|Questionnaire|Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
57941335|NCT05424172|BEHAVIORAL|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
58095223|NCT05443009|DRUG|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
58296288|NCT01119521|DRUG|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
58296289|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by children preference
58407669|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
57731080|NCT05154864|PROCEDURE|SBUF-SMUF|Intra-operative continuous ultrafiltration
57731081|NCT06299501|PROCEDURE|Routine questions|The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
57731082|NCT06299501|PROCEDURE|Questions on evidence based indication|The group of nurses will receive training and supervision and will ask questions on evidence based indication
57731083|NCT06299501|PROCEDURE|Treatment as usual|The group of nurses will ask questions when suspecting ongoing violence in the family
57731084|NCT01651429|BEHAVIORAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
57941336|NCT05424172|BEHAVIORAL|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
57941337|NCT05424172|BEHAVIORAL|Stage-II, Groups 1a/2a: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
57941338|NCT05424172|BEHAVIORAL|Stage-II, Groups 1b/2b: E-Coaching 4x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
57941339|NCT01043276|DRUG|Treatment A|PF-00258210 220 µg using inhaler A
58296290|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to randomization|The parent who will accompany the child during the perioperative period will be determined by randomization.
57941340|NCT01043276|DRUG|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
57941341|NCT01043276|DRUG|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
57941342|NCT01043276|DRUG|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
57941343|NCT01043276|DRUG|Treatment E|PF-00258210 220 µg using inhaler B
58296291|NCT05074953|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
57731085|NCT06245785|PROCEDURE|transarterial chemoembolisation|Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
57731086|NCT05870280|BEHAVIORAL|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
57731087|NCT06167681|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
57731088|NCT01826591|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
58095224|NCT05443009|DRUG|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
57731089|NCT01826591|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
57731090|NCT01826591|BEHAVIORAL|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
57731091|NCT04025073|OTHER|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
57731092|NCT04025073|OTHER|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
57731093|NCT03451838|DIAGNOSTIC_TEST|Ultrasound|Ultrasound will be done to every pregnant lady
57731094|NCT03451838|DIAGNOSTIC_TEST|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
57731095|NCT03028168|OTHER|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
57731096|NCT03028168|OTHER|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
57731097|NCT03028168|OTHER|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
57731098|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
57941344|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
57941345|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
57941346|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
57941347|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
57731099|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
57731100|NCT05034003|DEVICE|Zirconia crown|Esthetic crowns for capping primary incisor with caries
57731101|NCT05034003|DEVICE|composite strip crown|Esthetic resin restoration for primary incisor with caries
57941348|NCT01423851|DRUG|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
57731102|NCT01197950|DEVICE|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
57941349|NCT00682448|DRUG|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
57941350|NCT00682448|DRUG|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
58296292|NCT00543114|DRUG|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
58296293|NCT00543114|DRUG|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
58296294|NCT00543114|DRUG|Rituximab|Given intravenously on Day 1 of each 28 day cycle
58296295|NCT02057263|DRUG|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
58296296|NCT02057263|DRUG|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
58296297|NCT02057263|DRUG|Placebo|Participants will receive 4 doses of placebo during the course of the study.
58296298|NCT04670120|DRUG|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
58407670|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
58407671|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
57941351|NCT01572675|DRUG|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
57941352|NCT01572675|DRUG|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
57941353|NCT01925924|OTHER|Resin-modified glass ionomer cement|This material contains fluoride
57941354|NCT01925924|OTHER|Composite resin|This material does not include fluoride
57941355|NCT00397033|DRUG|Paliperidone ER|6mg/day paliperidone er for 6 weeks
57941356|NCT00397033|DRUG|Paliperidone ER|12mg/day paliperidone er for 6 weeks
57941357|NCT00397033|DRUG|Placebo|Placebo for 6 weeks
57941358|NCT00786747|BEHAVIORAL|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
57941359|NCT00786747|BEHAVIORAL|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
58095225|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
58095226|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
58095227|NCT05346237|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires, measuring maximum phonation and diadochokinesis
58095228|NCT04595565|DRUG|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
58407672|NCT00373165|DRUG|Ganciclovir|
58407673|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
58076397|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
58076398|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
58076399|NCT05854719|BEHAVIORAL|Speechreading training with an application|The Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
58076400|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
58076401|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
58076402|NCT03486873|DRUG|Pembrolizumab|200 or 400 mg IV infusion
58076403|NCT03486873|DRUG|Standard of Care (SOC)|IV infusion or oral tablets
58076404|NCT03486873|DRUG|Lenvatinib|Oral capsules
58076405|NCT06723743|OTHER|Transcutaneous vagus nerve stimulation for attention in veterans with TBI|This study focuses on veterans with a history of traumatic brain injury (TBI) and co-occurring depression and/or posttraumatic stress disorder (PTSD), a population uniquely affected by attention and memory impairments. It evaluates the effects of transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive brain stimulation technique, on attention and memory performance, as well as physiological responses such as heart rate variability (HRV). Unlike other interventions, taVNS does not require surgery or medication, offering a safe and accessible treatment option. This study employs a randomized, blinded crossover design, where each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden. By
58076406|NCT06723743|DEVICE|Soterix Medical Vagus Nerve Stimulation mini-CT|Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.
58076407|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
58076408|NCT00010634|DRUG|Adaptogenic herbs|
58076409|NCT00010634|DRUG|glutamine|
58076410|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
58076411|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
58407674|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
58407675|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
58407676|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
57941360|NCT00272064|DRUG|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
58076412|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
57941361|NCT00272064|DRUG|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
57941362|NCT00272064|DRUG|Metformin|1000 mg b.i.d, since the qualification phase, oral
57941363|NCT00535275|DRUG|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
57941364|NCT00535275|DRUG|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
57941365|NCT02723695|OTHER|Evaluation of postural performances|Postural tests
58076413|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
58076414|NCT06723405|BIOLOGICAL|EVO301|Intravenous EVO301
58076415|NCT06723405|BIOLOGICAL|Placebo|Placebo
58076416|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
58076417|NCT02675660|DRUG|Placebo|placebo capsules once daily
58076418|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
58076419|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
58076420|NCT05730621|DRUG|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
58076421|NCT05730621|DRUG|Aspirin|Aspirin 100mg qd for 12 weeks
58076422|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
58076423|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
58407677|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
58407678|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
57941366|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone"
58076424|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
58076425|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
58076426|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
58076427|NCT02070718|DRUG|Standard Dose Kappa Agonist|
58076428|NCT02070718|DRUG|Half Dose Kappa Agonist|
58076429|NCT02070718|OTHER|Placebo|
58407679|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
58076430|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
58076431|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
58076432|NCT05433584|DRUG|Tirzepatide|Administered SC
58076433|NCT05433584|DRUG|Antihyperglycemic medication|As prescribed
58076434|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
58076435|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
58076436|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
58076437|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
58076438|NCT04089943|PROCEDURE|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
58076439|NCT04089943|OTHER|Control group|Healthy non-PAD participants will be recruited for the study.
58076440|NCT06724614|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
58407680|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
58407681|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
58407682|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
58407683|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
58076441|NCT06724614|DRUG|Placebo|Placebo
58095229|NCT04595565|DRUG|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
58095230|NCT04595565|DRUG|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
58095231|NCT04595565|DRUG|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
58076442|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
58076443|NCT02977741|DRUG|Olanzapine|
58076444|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
58076445|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
58076446|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
58076447|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
58076448|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
58076449|NCT02471898|DRUG|HTX-011|
58076450|NCT02471898|DRUG|Placebo|Saline
58296299|NCT05105347|DRUG|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
58296300|NCT03775083|DRUG|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
58296301|NCT00387322|DRUG|erlotinib hydrochloride|Given orally
58296302|NCT00387322|DRUG|pemetrexed disodium|Given IV
57731103|NCT01197950|DEVICE|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
57731104|NCT01311492|BEHAVIORAL|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
57731105|NCT01311492|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
57731106|NCT06425354|DEVICE|Mechanical ventilation|Mechanical ventilatiom
58076451|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
57731107|NCT06635395|OTHER|Scale validity and reliability|The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
57731108|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
58076452|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
58076453|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
58095232|NCT05469815|BEHAVIORAL|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
58095233|NCT04977388|DRUG|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
58095234|NCT04977388|OTHER|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
58296303|NCT05337865|OTHER|Aerobic exercise test.|Aerobic exercise test at a treadmill.
58296304|NCT04786691|OTHER|Addition of half and half to coffee|1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
58296305|NCT04786691|OTHER|Addition of non-dairy creamer to coffee|1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
58296306|NCT04786691|OTHER|Black|No Creamer
58296307|NCT05988762|OTHER|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
58407684|NCT01689714|DRUG|Tc 99m EC20|
58407685|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
58407686|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
58296308|NCT05988762|OTHER|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
58296309|NCT01807533|BEHAVIORAL|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
58296310|NCT01807533|BEHAVIORAL|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
58407687|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
58407688|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
58076454|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
58296311|NCT05041556|OTHER|Case-control study of clinical outcomes|A case-control questionnaire will be administered at the home of cases and controls
58296312|NCT05041556|OTHER|Case-control study of mortality outcome|A case-control questionnaire will be administered at the home of cases and controls
58296313|NCT03119948|DRUG|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
58296314|NCT03119948|DRUG|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
58407689|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
58407690|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
58407691|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
58407692|NCT02249299|DRUG|Placebo|
58407693|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
58407694|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
58407695|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
58407696|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
58407697|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
58407698|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
58407699|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
58407700|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
58407701|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
58076455|NCT06230523|DRUG|LY3841136|Administered SC.
58076456|NCT06230523|DRUG|Placebo|Administered SC.
58407702|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
58407703|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
58407704|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
58407705|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
57731109|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
58076457|NCT06721988|DRUG|oxycodone and parecoxib sodium combinations|Participants will receive 0.1ml/kg oxycodone (1mg/ml) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Oxycodone is administered 5 minutes after parecoxib sodium administration.
58076458|NCT06721988|DRUG|Placebo and parecoxib sodium combinations|Participants will receive 0.1ml/kg placebo (0.9% saline) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Placebo is administered 5 minutes after parecoxib sodium administration.
58076459|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
58407706|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
57731110|NCT05319691|BEHAVIORAL|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
58076460|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
58076461|NCT01952821|OTHER|Six-Minute Walk Test|
58076462|NCT01952821|OTHER|10-Meter Walk Test|
58296315|NCT03119948|DRUG|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
58296316|NCT00956839|DRUG|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
58407707|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
58407708|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
58407709|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
58407710|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
58407711|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
57731111|NCT01299246|PROCEDURE|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
57941367|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Indian Costus|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements"
57941368|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Quinine pills|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)"
58076463|NCT01952821|OTHER|30-Second Chair Stand|
58076464|NCT01952821|OTHER|Linear Analog Scale of Function|
58076465|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
58296317|NCT00148044|PROCEDURE|Blood sampling for determination of uremic toxins|
58296318|NCT02408198|BEHAVIORAL|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
58296319|NCT03358550|DIAGNOSTIC_TEST|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
58296320|NCT05388981|BIOLOGICAL|SBT115301|Immunomodulatory dimeric fusion protein
58296321|NCT05388981|BIOLOGICAL|Placebo|Matched placebo
58407712|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
58407713|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
58407714|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
57941369|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Anise seed capsule|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)"
58076466|NCT01952821|OTHER|FACIT-Fatigue|
58407715|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
58407716|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
58407717|NCT00000344|DRUG|Buprenorphine/naloxone|
58076467|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
58407718|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
58076468|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
58076469|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
58076470|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
58076471|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
58076472|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
58076473|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
58076474|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
58076475|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
58296322|NCT03225287|DRUG|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
58296323|NCT01834339|BIOLOGICAL|AlloDerm|
58296324|NCT01834339|BIOLOGICAL|EVPOME|
58296325|NCT03167554|OTHER|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
58296326|NCT03167554|OTHER|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
58296327|NCT03167554|OTHER|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
58296328|NCT01921517|DEVICE|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
58407719|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
58407720|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
58407721|NCT06361602|OTHER|inapplicable|inapplicable
58407722|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
57731112|NCT06534346|DRUG|15 mg DA-302168S tablet|"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
57941370|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg"
57941371|NCT04553705|DRUG|Active Comparator|Standard protocol care of COVID-19 infection
57941372|NCT04556396|DIAGNOSTIC_TEST|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
58076476|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
58076477|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
58095235|NCT03022929|BEHAVIORAL|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
58296329|NCT01921517|DEVICE|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
58407723|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
58407724|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
58407725|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
57731113|NCT04495673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
57731114|NCT04495673|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
58296330|NCT02558842|OTHER|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
58407726|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
58076478|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
58076479|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
58076480|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
58296331|NCT04633681|DIETARY_SUPPLEMENT|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
58296332|NCT01419314|DEVICE|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
58296333|NCT01419314|DEVICE|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
58296334|NCT00523770|PROCEDURE|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
58296335|NCT05856253|PROCEDURE|Enhanced recovery program|Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
58296336|NCT04862260|DRUG|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
58296337|NCT02574663|DRUG|TGR-1202|TGR-1202 oral daily dose
58296338|NCT02574663|DRUG|nab-paclitaxel + gemcitabine|IV infusion
58296339|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
58296340|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
58296341|NCT01101750|BIOLOGICAL|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
58296342|NCT00411450|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
58296343|NCT00411450|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
58296344|NCT02056418|DIETARY_SUPPLEMENT|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
58296345|NCT02056418|DRUG|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
58296346|NCT03529253|DRUG|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
58296347|NCT03529253|DRUG|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
58407727|NCT03691844|DRUG|AMZ001|diclofenac gel
58407728|NCT03691844|DRUG|Placebo|Placebo
58076481|NCT05337410|BEHAVIORAL|YES IDEAS|YES IDEAS is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES IDEAS curriculum empowers youth from diverse backgrounds to address racism and racial discrimination as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting inclusion, diversity, equity, appreciation, and solidarity in their community.
58076482|NCT05059444|DIAGNOSTIC_TEST|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
58296348|NCT03646968|DRUG|Anlotinib and Docetaxel|Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
58296349|NCT04979091|DIAGNOSTIC_TEST|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
58407729|NCT03691844|DRUG|Comparator|diclofenac gel
58407730|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
58407731|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
58407732|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
57941373|NCT02535715|DRUG|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
57941374|NCT02535715|DRUG|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
57941375|NCT02535715|DRUG|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
57941376|NCT05659784|OTHER|Telerehabilitation|Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
57941377|NCT00749476|BIOLOGICAL|Factor IX recovery|
58296350|NCT03590574|BIOLOGICAL|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
58296351|NCT06422169|DEVICE|ArToFILL|ArToFILL is an injectable medical device (class III) intended for use as a temporary filler in joints. It is a sterile, non-pyrogenic, colorless and transparent hyaluronic acid gel of non-animal origin. ArToFILL is a hydrogel consisting of a mixture of two different molecular weights of hyaluronic acid, for a total HA concentration of 2.7 %.
58296352|NCT06230731|OTHER|Oxygen saturation|Measure oxygen levels in 5 proximal colon mucosa locations.
57941378|NCT01655420|PROCEDURE|LASIK|Laser eye surgery
58296353|NCT01715701|PROCEDURE|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
58296354|NCT01715701|PROCEDURE|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
58296355|NCT01715701|PROCEDURE|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
58296356|NCT02167438|DEVICE|Hem-Avert Perianal Stabilizer|
58296357|NCT02874612|OTHER|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
58407733|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
57941379|NCT01372150|DRUG|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
57941380|NCT01372150|DRUG|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
57941381|NCT01372150|DRUG|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
57941382|NCT00943774|OTHER|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
57941383|NCT00068211|DRUG|ILX651|
57941384|NCT06226311|OTHER|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
57941385|NCT06226311|OTHER|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
57941386|NCT01943513|BIOLOGICAL|BIIB023|Intravenous (IV) infusions
57941387|NCT01943513|BIOLOGICAL|Placebo|Matched placebo
57941388|NCT01750320|DEVICE|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
58296358|NCT05558319|DRUG|Bortezomib|Bortezomib
58296359|NCT05558319|DRUG|Isatuximab|Isatuximab
58296360|NCT05558319|DRUG|Iberdomide|Iberdomide
58296361|NCT05558319|DRUG|Lenalidomide|Lenalidomide
58296362|NCT05558319|DRUG|Dexamethasone|Dexamethasone
58296363|NCT05944185|DRUG|αPD1-MSLN-CAR T Cells|αPD1-MSLN-CAR T Cells
58296364|NCT00892463|DRUG|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
58296365|NCT03679559|OTHER|Best Practice|Continue usual physical activity
58296366|NCT03679559|BEHAVIORAL|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
57941389|NCT04937244|DIAGNOSTIC_TEST|5ALA exoscopic fluorescence filter|Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
57941390|NCT05901493|BEHAVIORAL|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
57941391|NCT05161091|DEVICE|Topical application of Orosol®|Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
58076483|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
58076484|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
58076485|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
58076486|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
58407734|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
58407735|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
58296367|NCT03679559|BEHAVIORAL|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
58296368|NCT03679559|BEHAVIORAL|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
58296369|NCT03679559|OTHER|Informational Intervention|Watch video
58296370|NCT03679559|OTHER|Laboratory Biomarker Analysis|Correlative studies
58296371|NCT03679559|DEVICE|Monitoring Device|Wear Fitbit
58296372|NCT03679559|OTHER|Quality-of-Life Assessment|Ancillary studies
58296373|NCT03679559|OTHER|Questionnaire Administration|Ancillary studies
58407736|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
58407737|NCT02007057|PROCEDURE|Suprascapular nerve block|
58407738|NCT02007057|PROCEDURE|Interscalene nerve block|
58407739|NCT00801489|DRUG|Cytarabine|Given IV
58407740|NCT00801489|DRUG|Decitabine|Given IV
58407741|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
58407742|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
58407743|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
58407744|NCT00801489|DRUG|Idarubicin|Given IV
58407745|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
58407746|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
58407747|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
58407748|NCT04531358|DEVICE|nasal spray|application of nasal spray
58407749|NCT04531358|OTHER|no treatment|no treatment
58407750|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58407751|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58407752|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
58407753|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
58407754|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
57731115|NCT04495673|BEHAVIORAL|Cognitive Training|Executive functioning tasks
57731116|NCT02493361|DRUG|Pembrolizumab|
57731117|NCT02493361|DRUG|pIL-12|
57941392|NCT05161091|DEVICE|Topical application of Placebo comparator|Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
57941393|NCT00419146|DRUG|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
57941394|NCT00419146|DRUG|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
57941395|NCT00419146|OTHER|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
57941396|NCT00419146|OTHER|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
57941397|NCT02594969|OTHER|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
57941398|NCT01161355|DRUG|AZD9668|Tablets of AZD9668 and IV dose of \[C14\]AZD9668
57941399|NCT01245387|DRUG|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
57941400|NCT01345747|DEVICE|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
58076487|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
57941401|NCT05799079|DRUG|Venetoclax|Given by mouth
58076488|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
58076489|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
58076490|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
58076491|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
58076492|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
57941402|NCT05799079|DRUG|Decitabine|Given by mouth
57941403|NCT05799079|DRUG|Cedazuridine|Given by mouth
58076493|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
58076494|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
58076495|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
57941404|NCT05799079|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy
57941405|NCT05799079|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58076496|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
58076497|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
57731118|NCT04266028|BIOLOGICAL|DM-101|DM-101 administered by subcutaneous (SC) injection
57731119|NCT04266028|BIOLOGICAL|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
57941406|NCT04234672|DRUG|TAK-831 Oral Tablet|TAK-831 tablet.
57941407|NCT04234672|DRUG|[14C]TAK-831 IV Infusion|\[14C\]TAK-831 IV infusion.
57941408|NCT04234672|DRUG|[14C]TAK-831 Oral Suspension|\[14C\]TAK-831 oral suspension.
57941409|NCT06151912|OTHER|Postoperative Nausea and Vomiting scala|The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
57941410|NCT06151912|OTHER|Quality of life|The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
57941411|NCT05767554|BEHAVIORAL|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can begin a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
57941412|NCT02475226|OTHER|type of the brain injury|epidural hematoma
57941413|NCT02475226|OTHER|type of the brain injury|subdural hematoma
57941414|NCT02475226|OTHER|type of the brain injury|subarachnoid hematoma
57941415|NCT02475226|OTHER|type of the brain injury|intraparenchymal hematoma
57941416|NCT02475226|OTHER|type of the brain injury|scull fracture
57941417|NCT02475226|OTHER|type of the brain injury|brain contusion
57941418|NCT00616915|DRUG|Wellbutrin XL|Wellbutrin XL 300mg daily
58076498|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
58076499|NCT00469339|BEHAVIORAL|Family Health History|
58076500|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
58076501|NCT06690086|PROCEDURE|Lesion biopsy|Lesions enrolled in the study are biopsied to confirm histopathology
58076502|NCT06690086|DEVICE|DermaSensor Device Use|Users are blinded to the DermaSensor Device result
58076503|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
58095236|NCT00068653|DRUG|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
57941419|NCT05604495|DIAGNOSTIC_TEST|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
57941420|NCT03067571|BIOLOGICAL|Daratumumab|Given IV
58407755|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
58407756|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
58407757|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
58407758|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
58407759|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
58407760|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
58407761|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
58407762|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
58407763|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
57731120|NCT00506493|DEVICE|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
57941421|NCT06322836|PROCEDURE|Duble current electro cardioversion|Instead of the regular clinical treatment, in this study direct-current electrical cardioversion (DC-ECV) will be performed at the patient's home and will be carried out by well-trained and certified advanced practice providers (APP) on site, i.e. nurse practitioner or physician assistant, supported by an EMS ambulance team containing an ambulance nurse and ambulance driver, both trained advanced life-support (ALS) professionals.
57941422|NCT04458662|PROCEDURE|Interval running protocol / eccentric-based resistance exercise protocol|
57941423|NCT05484479|BEHAVIORAL|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
57941424|NCT04498208|BEHAVIORAL|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome \& Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
58076504|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
58076505|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
58076506|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
58076507|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
58076508|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
58076509|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
58407764|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
58407765|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
58407766|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
58407767|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
58407768|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
58407769|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
58407770|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
58407771|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
58407772|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
58407773|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
58407774|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
58296374|NCT06278948|OTHER|Group TP|Application full face, twice daily, in the morning and at bedtime for 4 months
58076510|NCT04830813|DRUG|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
58296375|NCT06278948|DRUG|Group CYS|Application short contact, of thin layer once daily at bedtime for 4 months
58296376|NCT01059773|DRUG|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
58407775|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
58076511|NCT04830813|DRUG|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
58095237|NCT00068653|DRUG|ZD1839|ZD1839 250 mg po every day, taken with or without food.
58095238|NCT04129515|DEVICE|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
58296377|NCT01059773|DRUG|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
58407776|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
58407777|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
57941425|NCT04498208|BEHAVIORAL|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
58076512|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
58076513|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
58076514|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
58076515|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
58076516|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
58076517|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
58296378|NCT01358292|PROCEDURE|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
58296379|NCT01358292|PROCEDURE|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
57941426|NCT04498208|BEHAVIORAL|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
58076518|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
58095239|NCT04129515|DRUG|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
58296380|NCT01161810|OTHER|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
58296381|NCT01514383|DEVICE|Cyanoacrylate (Octylseal )|surgical adhesive
58296382|NCT02021292|DRUG|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
58296383|NCT02021292|DRUG|Placebo|Matching placebo oral tablet, to be taken once daily.
57941427|NCT04498208|BEHAVIORAL|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
57941428|NCT03880032|BEHAVIORAL|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
57941429|NCT00844155|DRUG|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
57941430|NCT06181942|DEVICE|SP|English name: da Vinci SP Surgical System Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
57941431|NCT02512809|DRUG|Isoflurane|
58407778|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
57941432|NCT02512809|DRUG|Dexmedetomidine|
57941433|NCT01391403|DRUG|Artemisinin|400 mg/day
58076519|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
58296384|NCT03943914|COMBINATION_PRODUCT|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.
58407779|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
58407780|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
58407781|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
57941434|NCT01391403|OTHER|Placebo|400mg/day
58095240|NCT04406129|BIOLOGICAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool.
58296385|NCT03943914|COMBINATION_PRODUCT|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
58296386|NCT01912950|DEVICE|Prowave LX IPL|
58407782|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
58407783|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
58296387|NCT03050177|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
57731121|NCT00506493|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
57731122|NCT03793985|DRUG|T|CKD-391 40/10mg
57731123|NCT03793985|DRUG|R|D086 and D337 co-administration
57941435|NCT00747643|DRUG|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
58296388|NCT03050177|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
58296389|NCT05208996|DRUG|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
58296390|NCT00173628|PROCEDURE|blood drawing|
58296391|NCT04891302|DRUG|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
58296392|NCT04891302|DRUG|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
57941436|NCT00747643|DRUG|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
57941437|NCT05097521|OTHER|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
57941438|NCT05097521|OTHER|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
57941439|NCT05097521|OTHER|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
57941440|NCT05374382|BEHAVIORAL|Strengthening|3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery
57941441|NCT05374382|BEHAVIORAL|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
57941442|NCT04427150|BEHAVIORAL|Auditory Training|A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
57941443|NCT04427150|BEHAVIORAL|Non-auditory training|A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
57941444|NCT06132165|DRUG|Deoxycholic Acid|Injection into the cutaneous Neurofibromas lesion.
57941445|NCT06132165|DRUG|Polidocanol|Injection into the cutaneous Neurofibromas lesion.
57941446|NCT06132165|DEVICE|1064nm Nd:YAG laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.
57941447|NCT06132165|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
57941448|NCT01978782|DRUG|raltegravir|
57941449|NCT01978782|DRUG|citalopram|
57941450|NCT03256955|DEVICE|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
57941451|NCT03256955|DEVICE|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
57941452|NCT00338754|DRUG|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
57941453|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
58407784|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
57941454|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
57941455|NCT04957550|DRUG|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
57941456|NCT06254742|DRUG|HHPG-19K Injection|first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
57941457|NCT00050141|DRUG|ZARNESTRA, tipifarnib, R115777|
57941458|NCT01782573|DRUG|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
57941459|NCT01782573|DRUG|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
57941460|NCT01891500|DRUG|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
57941461|NCT01891500|DRUG|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
57941462|NCT01891500|DRUG|Crossover iNO|Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
57941463|NCT02512406|OTHER|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
57941464|NCT02512406|OTHER|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
57941465|NCT02512406|OTHER|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
57941466|NCT02512406|OTHER|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
58407785|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
58095241|NCT04406129|OTHER|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug.
57941467|NCT02512406|OTHER|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
57941468|NCT02512406|OTHER|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
57941469|NCT01811745|BEHAVIORAL|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
57941470|NCT01811745|BEHAVIORAL|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
57941471|NCT04747834|DEVICE|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
57941472|NCT04272840|BEHAVIORAL|Low Glycemic Index Education|Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
57941473|NCT03576599|DRUG|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
57941474|NCT03576599|DRUG|Placebo|Placebo
58095242|NCT05964361|BIOLOGICAL|IL15-transpresenting WT1-targeted Dendritic Cell Vaccine|IL15/IL15Ra/WT1 DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered every 2 weeks (+- 3 days) for a total of 6 administrations.
58296393|NCT00715559|DRUG|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
58296394|NCT03227393|BEHAVIORAL|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
58407786|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
57941475|NCT02244320|DRUG|Tamsulosin|
57941476|NCT03294226|DEVICE|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
57941477|NCT03294226|DEVICE|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
58296395|NCT05269368|PROCEDURE|Wicking|Absorbable or non-absorbable wicking
58296396|NCT05269368|PROCEDURE|No wicking|No wicking after surgery
57941478|NCT05875051|OTHER|Reduced-exertion high intensity training|The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
58296397|NCT04924634|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
58296398|NCT02336867|DEVICE|Closure clip (OTSC® Proctology)|
58296399|NCT06111768|DRUG|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
58296400|NCT03163407|DRUG|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
58296401|NCT03163407|DRUG|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
58296402|NCT04607902|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
58296403|NCT04607902|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
58296404|NCT04607902|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
58296405|NCT06143046|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
58296406|NCT06143046|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58095243|NCT05225428|BEHAVIORAL|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
58296407|NCT04893551|BIOLOGICAL|Tilvestamab|Tilvestamab will be administered as IV infusion.
58296408|NCT02047279|PROCEDURE|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
58407787|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
57941479|NCT05875051|OTHER|Short moderate intensity training|The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
57941480|NCT02013453|DRUG|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
58407788|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
58407789|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
58296409|NCT02047279|PROCEDURE|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
58407790|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
58407791|NCT00336011|DEVICE|Magnetic resonance imaging|
58407792|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
57941481|NCT02013453|DRUG|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
57941482|NCT02013453|DRUG|5FU|Administered by infusion.
57941483|NCT02013453|DRUG|Paclitaxel|Administered by infusion.
57941484|NCT02013453|DRUG|Pemetrexed|Administered by infusion.
57941485|NCT01622192|DEVICE|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
57941486|NCT03390543|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
57941487|NCT03390543|DEVICE|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
57941488|NCT05746299|BEHAVIORAL|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
57941489|NCT05746299|BEHAVIORAL|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
57941490|NCT05746299|BEHAVIORAL|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
57941491|NCT05015192|DRUG|NH102|tablets, orally
58296410|NCT02047279|PROCEDURE|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
58296411|NCT06435767|DRUG|Adjuvant chemotherapy|In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
58296412|NCT01441973|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|
58296413|NCT03836157|DRUG|Mirvetuximab Soravtansine|The dose will not be recalculated unless the patient has ±10% weight change.
58296414|NCT03836157|DRUG|Bevacizumab|Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
58296415|NCT04187833|DRUG|Nivolumab|480mg intravenously every 4 weeks (28 days)
58296416|NCT04187833|DRUG|Talazoparib|1mg orally daily
58296417|NCT06336317|BIOLOGICAL|Influenza vaccine|VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02
58296418|NCT06336317|BIOLOGICAL|Placebo|Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
57941492|NCT05015192|DRUG|Placebo|tablets, orally
57941493|NCT01217398|BIOLOGICAL|bevacizumab|
57941494|NCT01217398|DRUG|temozolomide|
57941495|NCT01217398|GENETIC|polymorphism analysis|
57941496|NCT01217398|OTHER|pharmacogenomic studies|
57941497|NCT01080248|DRUG|Gemcitabine|
57941498|NCT01080248|DRUG|Pazopanib|
58095244|NCT05225428|BEHAVIORAL|Genetic Counseling|Standard genetic counseling
58296419|NCT00459810|DRUG|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
58296420|NCT00459810|DRUG|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
58296421|NCT04771078|BIOLOGICAL|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
58296422|NCT04797988|DEVICE|eon® FR 1064 nm device|The subject will be treatment area - flanks, will be treated with the eon device.
58296423|NCT04007328|DRUG|Methylprednisolone Sodium Succinate|methylprednisolone vial
58296424|NCT04007328|DRUG|Placebo|Normal saline manufactured to mimic methylprednisolone vial
58296425|NCT05354518|BEHAVIORAL|gestational diabetes management of midwifery students|Gestational diabetes management of midwifery students with a simulator
58296426|NCT01448252|BIOLOGICAL|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
58296427|NCT01448252|BIOLOGICAL|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
58296428|NCT03808233|OTHER|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
58296429|NCT01898169|OTHER|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
58296430|NCT03063736|DRUG|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
58296431|NCT03063736|BIOLOGICAL|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
58296432|NCT00121706|BEHAVIORAL|Condition A (see detailed summary)|
58296433|NCT00121706|BEHAVIORAL|Condition B (see detailed summary)|
58296434|NCT00121706|BEHAVIORAL|Condition C (see detailed summary)|
58296435|NCT00817622|DIETARY_SUPPLEMENT|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
58296436|NCT03086629|OTHER|Patient Concerns Inventory|
58296437|NCT03086629|OTHER|No Patient Concerns Inventory|
58296438|NCT01776970|DRUG|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
57941499|NCT04202770|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
57941500|NCT03999723|DIETARY_SUPPLEMENT|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
57941501|NCT03999723|DIETARY_SUPPLEMENT|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
57941502|NCT00034710|DRUG|Capsaicin Patch|
57941503|NCT00002970|DRUG|nelarabine|Given IV
57941504|NCT00002970|DRUG|methotrexate|Given IT
57941505|NCT00002970|DRUG|cytarabine|Given IT
58296439|NCT04221919|DRUG|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
58296440|NCT01726296|OTHER|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
58296441|NCT01726296|OTHER|medical chart review|Complete patient medical chart audit
58296442|NCT04001088|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
58296443|NCT04001088|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
58296444|NCT05928039|BIOLOGICAL|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
57941506|NCT00002970|DRUG|therapeutic hydrocortisone|Given IT
58296445|NCT05928039|BIOLOGICAL|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
58296446|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
58296447|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
58296448|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
58296449|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
58296450|NCT04609657|OTHER|Flavored carbonated soft drink (CSD)|Beverage
57941507|NCT02704546|DRUG|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
57941508|NCT02704546|DRUG|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
57941509|NCT01614938|DRUG|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
57941510|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
58296451|NCT06612567|DIAGNOSTIC_TEST|PET/CT|is an imaging test that can help reveal the metabolic or biochemical function of your tissues and organs. The PET scan uses a radioactive drug called a tracer to show both typical and atypical metabolic activity. A PET scan can often detect the atypical metabolism of the tracer in diseases before the disease shows up on other imaging tests, such as computerized tomography (CT) and magnetic resonance imaging (MRI).
58296452|NCT05962112|OTHER|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
58296453|NCT00166868|DRUG|Lactobacillus casei rhamnosus (Lcr35)|
58076520|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
58076521|NCT05565950|BIOLOGICAL|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
58407793|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
58407794|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
58407795|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
58407796|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
58407797|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
58407798|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
58076522|NCT05565950|BIOLOGICAL|Vehicle|Vehicle Formulation
58076523|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
58076524|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
57941511|NCT01614938|DRUG|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
57941512|NCT01614938|RADIATION|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
57941513|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
58076525|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
58076526|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
58076527|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
58076528|NCT06715397|OTHER|No intervention|No intervention
58076529|NCT03473691|DRUG|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
58296454|NCT00166868|DRUG|Neomycin|
57941514|NCT04026178|DRUG|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
58076530|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
58076531|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
58296455|NCT04263246|DIETARY_SUPPLEMENT|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
58296456|NCT04263246|DIETARY_SUPPLEMENT|Inulin|Inulin (6 capsules per day)
58296457|NCT03193632|DIAGNOSTIC_TEST|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
58296458|NCT03193632|DIAGNOSTIC_TEST|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
58296459|NCT02751112|BIOLOGICAL|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
58296460|NCT05238636|PROCEDURE|Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication|This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
58296461|NCT02541331|BIOLOGICAL|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
58296462|NCT02541331|BIOLOGICAL|PLACEBO|Matched tablets without any active substance.
58296463|NCT05051046|PROCEDURE|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
58407799|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
57941515|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
58407800|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
58407801|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
58407802|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
57941516|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
57941517|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
57941518|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
57941519|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
57941520|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
57941521|NCT04206748|DEVICE|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
58407803|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
58407804|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
58407805|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
58407806|NCT06127043|DRUG|Placebo|Administered via SC
58407807|NCT00176176|DEVICE|EEG|
57941522|NCT04206748|DEVICE|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
57941523|NCT03625050|PROCEDURE|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
58076532|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
58076533|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
58076534|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
58076535|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
58076536|NCT00977600|DRUG|Ammonul|
58296464|NCT06018805|OTHER|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
58296465|NCT06018805|OTHER|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
58296466|NCT02843464|OTHER|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
58296467|NCT06418113|RADIATION|hypofractionated stereotactic radiotherapy|conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
58296468|NCT06418113|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy
58296469|NCT06418113|PROCEDURE|resection|supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
57941524|NCT03625050|DRUG|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
57941525|NCT01987960|DRUG|Placebo|Once daily, tablets, orally
57941526|NCT01987960|DRUG|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
57941527|NCT02171962|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
57941528|NCT05533879|OTHER|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
57941529|NCT03010306|OTHER|CASITA|
58407808|NCT05918653|OTHER|Home Healthcare|No intervention in this study
58407809|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
58407810|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
57941530|NCT05805384|DEVICE|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
57941531|NCT00151970|DRUG|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
58076537|NCT00977600|DRUG|Buphenyl|
58076538|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash without erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash without erythritol.
58076539|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash with erythritol.
58076540|NCT06723054|OTHER|high fluoride 500 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a high fluoride 500 ppm F mouthwash with erythritol.
58076541|NCT02185820|DRUG|Carfilzomib|
58076542|NCT02185820|DRUG|Pomalidomide|
58076543|NCT02185820|DRUG|Dexamethasone|
58296470|NCT06418113|DRUG|Chemotherapy|4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
58407811|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
58407812|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
58407813|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
57941532|NCT00151970|DRUG|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
57941533|NCT00151970|DRUG|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
57941534|NCT02798055|DRUG|Bosentan group|
57941535|NCT03044782|OTHER|53-Item Survey|
57941536|NCT03174418|PROCEDURE|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
57941537|NCT03779308|DEVICE|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
57941538|NCT03858842|OTHER|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
57941539|NCT01693354|DEVICE|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
57941540|NCT01693354|DEVICE|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
57941541|NCT00054704|DRUG|Riluzole|Riluzole
57941542|NCT00054704|DRUG|Placebo|Placebo
57941543|NCT00543075|DRUG|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
57941544|NCT00785044|DRUG|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
57941545|NCT00244270|DEVICE|totally implantable vascular access device|totally implantable vascular access device
57941546|NCT04209036|OTHER|0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)|total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
57941547|NCT00612170|DRUG|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
57941548|NCT00612170|DRUG|Placebo|0 mg oral tablet once a day dosing
57941549|NCT00612170|DRUG|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
57941550|NCT00612170|DRUG|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
57941551|NCT03662165|BEHAVIORAL|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
57941552|NCT03662165|BEHAVIORAL|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
57941553|NCT03662165|BEHAVIORAL|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
57941554|NCT05396079|OTHER|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
57941555|NCT05396079|OTHER|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
57941556|NCT06226350|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
57941557|NCT04237727|DEVICE|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
57941558|NCT04173689|DEVICE|Threshold IMT|7 days a week, 2 times a day 15 min each
57941559|NCT04173689|OTHER|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
57941560|NCT04188795|PROCEDURE|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
57941561|NCT00240981|DRUG|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
57941562|NCT00240981|DRUG|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
57941563|NCT00363324|PROCEDURE|intracoronary injection of bone marrow cells|
57941564|NCT02700997|DEVICE|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
58076544|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
58076545|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
58296471|NCT06418113|RADIATION|radiotherapy Stupp protocol|radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
58296472|NCT06418113|DRUG|Chemotherapy Stupp Protocol|temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
58407814|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
58407815|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
58407816|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
58407817|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
58407818|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
57731124|NCT06635421|OTHER|Model of care delivery for long-acting injectable ART|This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
57731125|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
57731126|NCT05847218|DRUG|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
57731127|NCT05847218|DRUG|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
57731128|NCT04414670|PROCEDURE|C/S|laparoscopic or robotic metroplasty
57731129|NCT02418325|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
58076546|NCT05869188|DRUG|Isotretinoin|"* Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients ."
58076547|NCT02977052|DRUG|Ipilimumab|
57731130|NCT02418325|OTHER|Liberation therapy|
57731131|NCT03633383|DEVICE|Transcatheter aortic valve|Self-expandable aortic valve prothesis
57731132|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
58076548|NCT02977052|DRUG|Nivolumab|
58076549|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
58076550|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
58076551|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
58076552|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
58296473|NCT02761590|OTHER|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
58076553|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
58076554|NCT06648408|PROCEDURE|Balett Training|The ballet training will happen twice a week for six weeks, with each session lasting 60 minutes, for a total of 12 sessions. These sessions will be held in groups of 10 to 12 children and led by experienced ballet teachers. The classes will follow a beginner-level ballet routine, introducing the kids to ballet techniques in a fun and playful way, making sure they learn the movements step by step. Each lesson will follow the same structure, allowing the children to improve their skills week after week. In addition to the group sessions, the children will be given a 10-minute daily home exercise program. This will include simple ballet exercises they learned in their first class, which they should practice on the five days when they don't have ballet sessions. The children will track their practice in a child-friendly diary designed just for them.
58296474|NCT05667662|DRUG|Itraconazole Powder|Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
58407819|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
57731133|NCT05614297|DIAGNOSTIC_TEST|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
57731134|NCT06284811|BEHAVIORAL|Exercise program focusing on quadriceps|Participants will be asked to perform the exercise program that focusing on quadriceps muscle
57941565|NCT06401824|DRUG|Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab|Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
57941566|NCT02214602|DRUG|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
57941567|NCT05501938|PROCEDURE|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
57941568|NCT04035018|PROCEDURE|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
57941569|NCT04035018|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
57941570|NCT03562572|PROCEDURE|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
57941571|NCT03562572|OTHER|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
57941572|NCT01788033|DRUG|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
57941573|NCT01788033|DRUG|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
57941574|NCT02709499|DEVICE|0J LLLT|perform with the machine off
58296475|NCT05667662|DRUG|Placebo|Capsules with 11.8 mg total powder (excipients only)
58407820|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
57731135|NCT05699434|BEHAVIORAL|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
57731136|NCT06636513|DIETARY_SUPPLEMENT|SMT04 (M3XTRA)|This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
57941575|NCT02709499|DEVICE|6J LLLT|irradiation will be perform with 4J
57941576|NCT04615754|DIETARY_SUPPLEMENT|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
57941577|NCT04615754|DIETARY_SUPPLEMENT|Placebo - use of saline infusion|Saline is infused as an comparator
58407821|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
57941578|NCT01378858|DRUG|Varenicline|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
57941579|NCT05151003|OTHER|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
57941580|NCT05376826|BEHAVIORAL|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
57941581|NCT00532181|BEHAVIORAL|Savings Behavior and Consumer's Approach to Risk|
58076555|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
58076556|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
58076557|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
58296476|NCT02871141|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy
58296477|NCT02871141|DRUG|Antidepressant|Antidepressant
58296478|NCT00965237|DEVICE|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
58296479|NCT00965237|DEVICE|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
58296480|NCT00965237|OTHER|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
58296481|NCT04790578|DEVICE|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
58296482|NCT04790578|BEHAVIORAL|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
58296483|NCT06436989|OTHER|hot purified water|Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
58296484|NCT03764280|OTHER|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
58296485|NCT04067869|PROCEDURE|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
58296486|NCT00055120|DRUG|Emtricitabine/tenofovir disoproxil fumarate|
58296487|NCT00055120|DRUG|Lopinavir/ritonavir|
58296488|NCT00055120|DRUG|Stavudine|
58407822|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
58076558|NCT02061293|DRUG|Psilocybin|
58076559|NCT02061293|DRUG|Diphenhydramine|
58076560|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
58296489|NCT05102669|OTHER|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
58407823|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
58296490|NCT05102669|DIAGNOSTIC_TEST|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
58296491|NCT06041906|PROCEDURE|Shunt Closure|Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
58407824|NCT00536874|GENETIC|protein expression analysis|
58407825|NCT00536874|GENETIC|proteomic profiling|
58076561|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
58076562|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
58076563|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
58076564|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
58296492|NCT02329327|BIOLOGICAL|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
58407826|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
58407827|NCT00536874|PROCEDURE|adjuvant therapy|
58407828|NCT00536874|PROCEDURE|neoadjuvant therapy|
58407829|NCT00536874|PROCEDURE|therapeutic conventional surgery|
58407830|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
57941582|NCT05281107|DIETARY_SUPPLEMENT|Placebo, 500 mg calcium|Berry flavoured sachet powder (500 mg calcium)
58076565|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
58076566|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
58076567|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
58076568|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
58076569|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
58076570|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
58076571|NCT06446427|OTHER|Acute high altitude exposure|"Thirty minutes after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 1, high altitude at 3450 masl) is performed."
58076572|NCT06446427|OTHER|Acute high altitude exposure, with supplementary oxygen|"4 hours after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 2, high altitude at 3450 masl) is performed, while the participants receive 4 litres / minute of oxygen via nasal route."
58296493|NCT04194489|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
58296494|NCT02392026|DRUG|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
57941583|NCT05281107|DIETARY_SUPPLEMENT|600 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
57941584|NCT05281107|DIETARY_SUPPLEMENT|1200 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
57941585|NCT05281107|DIETARY_SUPPLEMENT|4000 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
57941586|NCT03658265|OTHER|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
57941587|NCT03658265|OTHER|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
58076573|NCT06446427|OTHER|Subacute high altitude exposure, after having spent a night at high altitude|"After having spent a night at the Research Station Jungfraujoch, a simulated scenario of patient care (Intervention 3, high altitude at 3450 masl) is performed."
58076574|NCT00001426|DRUG|Cyclophosphamide|
58296495|NCT04302402|DRUG|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
58296496|NCT04302402|DRUG|Placebo|Similar looking placebo
58296497|NCT00467428|DRUG|NS2359|
58076575|NCT00001426|DRUG|Paclitaxel|
58076576|NCT00001426|DRUG|Cisplatin|
58076577|NCT00001426|DRUG|G-CSF|
58076578|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
58296498|NCT00467428|DRUG|Placebo|
58296499|NCT05053269|OTHER|good body weight growth|body weight growth after birth is consistent with the growth curve
58296500|NCT05053269|OTHER|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
57941588|NCT03658265|OTHER|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
57941589|NCT03658265|OTHER|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
57941590|NCT04404322|OTHER|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
57941591|NCT04404322|OTHER|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
57941592|NCT02867865|DRUG|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
57941593|NCT02867865|DRUG|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
57941594|NCT02867865|RADIATION|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
57941595|NCT02867865|PROCEDURE|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
58076579|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
58296501|NCT00678847|DEVICE|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
58296502|NCT00678847|DEVICE|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
58296503|NCT04052880|DRUG|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
58296504|NCT04052880|DRUG|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
58296505|NCT04052880|DRUG|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
58296506|NCT04052880|DRUG|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
58296507|NCT04052880|DRUG|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
58296508|NCT03907696|OTHER|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
58296509|NCT03967860|DIAGNOSTIC_TEST|CT scan|Post surgical standard CT Scan as predictor of complication
57731137|NCT06057350|PROCEDURE|Tumor removal|Removal of incompletely removed early-stage colon cancer
57941596|NCT02867865|PROCEDURE|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
57941597|NCT01429818|DRUG|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
57941598|NCT01429818|DRUG|Metformin|1000 mg tablets once daily for eight weeks
57941599|NCT00003073|DRUG|liposomal cytarabine|
58296510|NCT00943657|BIOLOGICAL|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
58407831|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
58407832|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
57941600|NCT00538330|DRUG|Tamoxifen|Tamoxifen
57941601|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
57941602|NCT01733979|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
57941603|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron|Heme-Iron (1g/day)
58076580|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
58407833|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
58076581|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
58296511|NCT04204161|BIOLOGICAL|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
58296512|NCT03094585|OTHER|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
58296513|NCT03094585|OTHER|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
58296514|NCT04214496|DEVICE|Sedline|Intraoperative EEG monitorization
58296515|NCT02097823|DRUG|Olanzapine|
58296516|NCT02097823|DRUG|Aprepitant|
58296517|NCT00333489|DRUG|valsartan|
58296518|NCT01246895|DEVICE|Microfracture with BST-CarGel|
58407834|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
58407835|NCT01513603|DRUG|CLAG-M|IV times 5 days
58296519|NCT01246895|DEVICE|Microfracture without BST-CarGel|
58296520|NCT02039778|RADIATION|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
58407836|NCT01513603|DRUG|CLAG-M|Chemotherapy
58407837|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
58407838|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
58296521|NCT05882500|OTHER|No intervention, observation|
58296522|NCT05719194|OTHER|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
58407839|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
58407840|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
58407841|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58407842|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
57731138|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
57731139|NCT01610700|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
57731140|NCT01610700|DRUG|Placebo|Each actuation of placebo delivered the excipients only.
58076582|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
58407843|NCT00903136|OTHER|questionnaire administration|
58407844|NCT00903136|PROCEDURE|comparison of screening methods|
58407845|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
58407846|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
58407847|NCT00903136|PROCEDURE|tethered capsule endoscopy|
58407848|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
58407849|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
58407850|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
58407851|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
58407852|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
57941604|NCT01733979|DIETARY_SUPPLEMENT|Organic Iron|Organic Iron (1g/day)
57941605|NCT02181816|DRUG|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD \& HD
57941606|NCT03215550|PROCEDURE|CEA|Carotid Endarterectomy
57941607|NCT03215550|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
57941608|NCT03215550|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
57941609|NCT00395863|DRUG|Multihance|0.5 M at a single injection
57941610|NCT00395863|DRUG|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
58076583|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
58076584|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
58076585|NCT05419765|DIAGNOSTIC_TEST|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
58076586|NCT06723548|DRUG|Telitacicept|Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
58076587|NCT00043134|DRUG|decitabine|
58076588|NCT00473187|DRUG|somatropin|
58407853|NCT00107315|BIOLOGICAL|bevacizumab|
58407854|NCT00107315|DRUG|capecitabine|
58407855|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
58407856|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
58407857|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
58407858|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
57941611|NCT03357315|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
57941612|NCT06372548|DEVICE|Find You! Cure My Animal Friends|Introduced cognitive evaluation theory combined with masking therapy to develop a gamified product that guides amblyopic children to develop habits for the purpose of rehabilitation training.
57941613|NCT06372548|DEVICE|DuoBao Vision Training System|This is a visual training app where participants are required to complete several training tasks.
57941614|NCT00137228|PROCEDURE|figure-of-eight hand measurements|
57941615|NCT00137228|PROCEDURE|water volumetry hand measurements|
57941616|NCT05132842|OTHER|Survey Administration|Complete a Survey
57941617|NCT02035085|DRUG|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
57941618|NCT04594382|DIAGNOSTIC_TEST|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
57941619|NCT04594382|DIAGNOSTIC_TEST|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
57941620|NCT01147744|DRUG|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
57941621|NCT01147744|DRUG|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
57941622|NCT01147744|DRUG|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
57941623|NCT01147744|DRUG|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
57941624|NCT01147744|DRUG|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
57941625|NCT01147744|DRUG|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
57941626|NCT01147744|DRUG|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
57941627|NCT01147744|DRUG|Placebo montelukast|Placebo capsule once daily in the evening
57941628|NCT01147744|DRUG|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
57941629|NCT01147744|DRUG|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
57941630|NCT00000570|DRUG|pulmonary surfactant|
57941631|NCT05956730|OTHER|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
58076589|NCT04914975|OTHER|Neuromuscular electrical stimulation|The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
57731141|NCT04847635|DEVICE|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
57731142|NCT04847635|DEVICE|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
57941632|NCT05956730|OTHER|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
57941633|NCT01568684|OTHER|Citalopram|Treatment
57941634|NCT03021499|DRUG|Voclosporin|calcineurin inhibitor
57941635|NCT03021499|DRUG|Placebo Oral Capsule|matching placebo capsule
57941636|NCT03211221|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
57941637|NCT00359138|DRUG|desloratadine|5 mg tablet once daily
57941638|NCT00359138|DRUG|levocetirizine|5 mg capsule once daily
57941639|NCT00359138|DRUG|Desloratadine placebo tablet|once daily
57941640|NCT00359138|DRUG|Levocetirizine placebo capsule|once daily
57941641|NCT06094751|BEHAVIORAL|ACT Guide for Insomnia|ACT Guide for Insomnia includes 2 modules. Module 1 will include sleep/insomnia education, ACT skills (acceptance, defusion), and behavioral change. Module 2 will include sleep restriction, sleep hygiene, ACT skills (values, committed action), and behavioral change.
57941642|NCT04244630|COMBINATION_PRODUCT|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
57941643|NCT04515225|OTHER|Blood Sample|Blood Sample
57941644|NCT05542550|BEHAVIORAL|Voice Rest|Voice rest restricting patient phonation
57941645|NCT05542550|BEHAVIORAL|No Voice Rest|No Voice rest
57731143|NCT05234294|OTHER|Survey|We will investigate symptoms through monthly surveys.
57731144|NCT05487508|DRUG|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
57731145|NCT05487508|DRUG|Normal saline|Placebo (NaCl 0.9%)
57731146|NCT05396586|BEHAVIORAL|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
58076590|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
57731147|NCT05396586|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
58076591|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
58076592|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
58296523|NCT05719194|OTHER|SBT with T-piece or PSV|"- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful."
58296524|NCT00000863|DRUG|Sitamaquine|
58296525|NCT00078286|DRUG|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
58296526|NCT00078286|DRUG|Placebo|Dosage ranging from 50 mg to 200 mg once a day
58296527|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
58296528|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
58296529|NCT04424225|DRUG|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
57941646|NCT04896047|PROCEDURE|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
57941647|NCT04341636|RADIATION|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
57941648|NCT01205828|DRUG|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
58076593|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
58076594|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
58296530|NCT04424225|DRUG|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
58296531|NCT06145126|OTHER|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
58296532|NCT06145126|OTHER|Placebo|Placebo to predinisolon
57941649|NCT01205828|DRUG|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
57941650|NCT04429165|OTHER|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
58296533|NCT05192317|DEVICE|Sollievo Fisiolax|Class IIb Medical Device
58296534|NCT05192317|OTHER|Sollievo Fisiolax Placebo|Placebo
58296535|NCT03082027|DIAGNOSTIC_TEST|ultrasonography|ultrasonography of median nerve
58076595|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
58407859|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
57941651|NCT04429165|OTHER|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
57941652|NCT04429165|OTHER|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
58296536|NCT05867056|DRUG|IMC-I109V Single Ascending Dose|Single dose administration of IMC-I109V
58296537|NCT05867056|DRUG|IMC-I109V Multiple Ascending Doses|Multidose administration of IMC-I109V
58296538|NCT05867056|DRUG|HBV HCC Module MAD|Multidose administration of IMC-I109V
58407860|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
58296539|NCT06344169|DRUG|Sebacoyl Dinalbuphine Ester|SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance
58296540|NCT06344169|DRUG|Morphine|A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
58296541|NCT00431093|DRUG|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
57951273|NCT04755361|BEHAVIORAL|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
58296542|NCT00431093|DRUG|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
58076596|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
58076597|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
58076598|NCT06722443|DIETARY_SUPPLEMENT|Probiotic|Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months
58076599|NCT06722443|DIETARY_SUPPLEMENT|Prebiotic|Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months
58296543|NCT05308290|OTHER|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
58296544|NCT05308290|OTHER|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
58296545|NCT04839172|DIAGNOSTIC_TEST|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
58296546|NCT04823312|DEVICE|Experimental prospective single arm evaluating the Medtronic Duo Extended Set|Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
58296547|NCT03920475|DRUG|Sertraline or venlafaxine|Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
58296548|NCT03920475|DIAGNOSTIC_TEST|Immune parameters|Serum was taken before, during an after treatment for measurement of different immune parameters.
57941653|NCT05341479|PROCEDURE|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
57941654|NCT05341479|RADIATION|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
57941655|NCT05341479|RADIATION|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
57941656|NCT05341479|OTHER|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
57941657|NCT05341479|PROCEDURE|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
57941658|NCT00290199|DEVICE|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
57941659|NCT00097773|DRUG|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
57941660|NCT00097773|DRUG|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
57941661|NCT00097773|DRUG|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
57941662|NCT02897492|OTHER|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
58076600|NCT06722443|DIETARY_SUPPLEMENT|Synbiotic|A pill with a combination of prebiotic and probiotic at the same doses during 6 months
58076601|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
58076602|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
58076603|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
58076604|NCT05835154|BEHAVIORAL|Assessment|Complete checklist
58076605|NCT05835154|OTHER|Questionnaire Administration|Complete questionnaires
58076606|NCT05835154|OTHER|Interview|Undergo semi-structured feedback interview
58076607|NCT05835154|OTHER|Electronic Health Record Review|Review of medical records
58076608|NCT04513015|DIETARY_SUPPLEMENT|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
58076609|NCT04513015|DIETARY_SUPPLEMENT|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
58296549|NCT00680329|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
58296550|NCT00680329|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
58296551|NCT02007317|DRUG|Oshadi D & Oshadi R|Anti tumor agents
58296552|NCT05699512|BEHAVIORAL|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
57941663|NCT06387654|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
57941664|NCT06387654|BIOLOGICAL|Remainders of samples taken as part of the treatment|blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
58076610|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
58296553|NCT05767853|OTHER|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
58296554|NCT01014598|DRUG|Cisplatin|Given intra-arterially via isolated lung suffusion
58296555|NCT01014598|OTHER|Pharmacological Study|Correlative studies
57941665|NCT04196075|DRUG|Andrographis Paniculata|AP as palliative treatment
58296556|NCT01886508|PROCEDURE|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
58296557|NCT01886508|PROCEDURE|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
58296558|NCT02760719|DRUG|nebulized 3% hypertonic solution|already described
58296559|NCT06073457|DEVICE|MagGJ System|Anastomoses achieved by magnetic compression.
58296560|NCT05419713|OTHER|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
58296561|NCT00105612|DEVICE|Memory and Organizational Aid|
58296562|NCT00105612|BEHAVIORAL|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
58296563|NCT03944772|DRUG|Osimertinib|Osimertinib given orally at 80 mg once daily
57941666|NCT01805167|OTHER|Electrophysiological study of the interindividual variability of vocal performance|
58296564|NCT03944772|DRUG|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
58407861|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
57941667|NCT04982757|DEVICE|MagVenture MagPro System with Brainsight neuronavigation device|10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
57941668|NCT03668600|DRUG|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
57941669|NCT04342286|GENETIC|Organoid culture|Organoid culture
57951274|NCT03268044|OTHER|Hospital admission and surgery|Hospital admission and noncardiac surgery
57951275|NCT03666455|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
58076611|NCT06716008|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
58296565|NCT03944772|DRUG|Gefitinib|Gefitinib given orally at 250 mg once daily
58296566|NCT03944772|DRUG|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
58296567|NCT03944772|DRUG|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
58296568|NCT03944772|DRUG|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
58296569|NCT03944772|DRUG|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
58296570|NCT03944772|DRUG|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
58296571|NCT03944772|DRUG|Selpercatinib|Selpercatinib given orally at 160mg twice daily
58296572|NCT03944772|DRUG|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
58296573|NCT03944772|DRUG|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
58296574|NCT03944772|DRUG|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
58296575|NCT03944772|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
58296576|NCT03054181|BIOLOGICAL|HyQvia|
58076612|NCT06716008|OTHER|Manual Diaphragm Release|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
58076613|NCT03650218|DEVICE|THIODERM STRONG|Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
58076614|NCT06722300|DEVICE|Ultrasonic teeth cleaning plus Tinidazole microneedle patches applying|After gargling with compound chlorhexidine rinse or 3% hydrogen peroxide rinse for 1 minute, ultrasonic teeth cleaning was performed. After teeth cleaning, the wound was rinsed with 3% hydrogen peroxide and bleeding was stopped. After ultrasonic teeth cleaning, two metronidazole oral composite microneedle patches were immediately applied to the upper and lower gums near the inner side of the first molar, especially where the teeth were lost or damaged. The mouth was kept closed for 15 minutes. After the microneedles were fully degraded, the patient could leave the clinic.
58076615|NCT06202079|DRUG|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
58076616|NCT06202079|DRUG|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
58076617|NCT06096532|OTHER|75 gm oral glucose load|Consumption of 75 gm oral glucose load in order to test nutrient responsiveness
58076618|NCT00021125|PROCEDURE|adjuvant therapy|
58076619|NCT00021125|RADIATION|radiation therapy|
58076620|NCT02390869|DRUG|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
58076621|NCT02390869|DRUG|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
58296577|NCT06117696|OTHER|Animated video|delivery of written and oral information, supported by animated videos.
58296578|NCT03894709|BEHAVIORAL|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
58407862|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
57731148|NCT05396586|BEHAVIORAL|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
57941670|NCT04514120|OTHER|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
57941671|NCT03803501|OTHER|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
58076622|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
58076623|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
58076624|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
58076625|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
58076626|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
58076627|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
58076628|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
58296579|NCT06394947|OTHER|Fluid administration (any type)|The fluid challenge (FC) (bolus) is defined as the administration of any bolus of fluid (crystalloid or colloid) which is expected to affect pressure/flow/perfusion variables. The FC is expected to be completed within 30 min.
58296580|NCT04061278|DRUG|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
58407863|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
58407864|NCT00031655|DRUG|cyclosporine|Given PO
58407865|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
58407866|NCT00031655|DRUG|fludarabine phosphate|Given IV
58407867|NCT00031655|DRUG|mycophenolate mofetil|Given PO
58407868|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
58407869|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
57941672|NCT06443164|BEHAVIORAL|Empowered Relief|Pain Management Course that has been used to treat pain in patients with different pain conditions.
57941673|NCT06443164|OTHER|Standard of Care|Gender Affirming surgery without any attention to pain conditions prior to surgery.
57941674|NCT03314740|DRUG|Paclitaxel|Comparator active compound
57941675|NCT03314740|DRUG|Cediranib|Experimental compound
57941676|NCT03314740|DRUG|Olaparib|Experimental compound
57941677|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
57941678|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
57941679|NCT03653130|BEHAVIORAL|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
57941680|NCT06490796|BEHAVIORAL|Expanded diaphragm exercise|Individuals will be instructed in 360-degree expansive diaphragm exercises using the Ohmbelt device (Nilus Medical LLC, OHMBELT, Redwood City, CA, USA). Two Ohmbelt devices will be used in this study. The placement of the devices will be as described in the literature (14,23,24): The patient will be in a seated position with hips and knees flexed at 90 degrees, both feet supported on the ground, and sitting upright on a chair without back support. In this position, the Ohmbelt devices will be secured to the patient's body. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes
57941681|NCT06490796|BEHAVIORAL|Standard diaphragm exercise|Individuals in this group will be instructed in standard diaphragm exercises. They will be asked to lie on their backs with their heads and knees supported by pillows, and to close their eyes to focus before starting. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes.
57941682|NCT02230254|DEVICE|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
57941683|NCT05903729|OTHER|Neurodevelopmental therapy treatment|The group will receive NDT therapy
57941684|NCT05903729|OTHER|conventional physiotherapy|conventional physiotherapy
57941685|NCT02899689|DEVICE|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
57941686|NCT02899689|DEVICE|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
57941687|NCT04316377|DRUG|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
57941688|NCT04096027|DRUG|Cabergoline Pill|0.5 mg cabergoline pill taken orally
57941689|NCT04750876|OTHER|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
57941690|NCT04750876|OTHER|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~* consultations with a psychologist~* The patient will also be cared for on a daily basis by a physical therapist."
57941691|NCT02243254|DRUG|high dose remifentanil|high dose remifentanil
57941692|NCT02243254|DRUG|Ibuprofen|intravenous ibuprofen
57941693|NCT02243254|DRUG|low dose remifentanil|low dose remifentanil
57941694|NCT05210283|DEVICE|MRD|ctDNA MRD test
57941695|NCT01094587|PROCEDURE|Gastroschisis closure with suture|
57941696|NCT01094587|PROCEDURE|Gastroschisis closure without suture|
57941697|NCT01628445|DRUG|liraglutide|liraglutide titrated to 1.8 mg sc daily
57941698|NCT01628445|DRUG|placebo injection|placebo injected sc daily volume equal to active comparator
57941699|NCT01133899|DIETARY_SUPPLEMENT|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
57941700|NCT01133899|DIETARY_SUPPLEMENT|GAA-4|4.8 grams of guanidinoacetic acid
57941701|NCT01133899|DIETARY_SUPPLEMENT|GAA-1|1.2 grams of guanidinoacetic acid
58076629|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
58076630|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
58296581|NCT04061278|DRUG|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
58296582|NCT01051479|DRUG|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
58296583|NCT03301662|DIAGNOSTIC_TEST|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
58296584|NCT04518618|DRUG|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
58076631|NCT06724198|DIETARY_SUPPLEMENT|Psyllium husk|3.66 gram Psyllium husk twice daily for 8 weeks
58076632|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
58076633|NCT06725030|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
58076634|NCT06723769|DEVICE|rTMS treatment|Repetitive transcranial magnetic stimulation (rTMS) is a new physiotherapy technique for the treatment of PSD Compared to other strategies, it has the advantages of simple operation, non-invasive, painless, and safe. Studies have comprehensively shown that rTMS can effectively improve depressive symptoms in PSD patients
58076635|NCT06723769|OTHER|conventional treatment|general treatment of stabilizing vital signs (such as antidepressants, stabilizing blood pressure, stabilizing blood sugar, etc. ) and conventional rehabilitation treatment (hemiplegic limb comprehensive training, swallowing speech training, cognitive perception training, etc. ).
58076636|NCT01150149|BEHAVIORAL|No face touch|
58076637|NCT01150149|DEVICE|Surgical face mask|
58076638|NCT01150149|DEVICE|Surgical face mask + no face touch|
58076639|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
58076640|NCT06713967|PROCEDURE|Metformin (Glucophage)|In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
58076641|NCT06713967|PROCEDURE|Standard Care (Diet and Exercise Only)|In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
58296585|NCT04518618|DRUG|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
58296586|NCT05506969|BIOLOGICAL|rF1V vaccine and CpG 1018® adjuvant|rF1V vaccine and CpG 1018® adjuvant
58296587|NCT05506969|BIOLOGICAL|rF1V vaccine|rF1V vaccine
58296588|NCT00610168|BIOLOGICAL|Boostrix TM|Single booster dose of vaccine
58296589|NCT01839916|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
58296590|NCT01839916|OTHER|laboratory biomarker analysis|Correlative studies
58296591|NCT02078193|DRUG|Belatacept|Patients will be converted from their MMF to Belatacept
58296592|NCT01116752|OTHER|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
58296593|NCT02843009|BEHAVIORAL|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
58296594|NCT02843009|DIETARY_SUPPLEMENT|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
58296595|NCT03784391|DRUG|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
58407870|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
58076642|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
58076643|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
58076644|NCT06125951|DRUG|Xanamem|Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
58076645|NCT06125951|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
58076646|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
58076647|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
58076648|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
58076649|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
58076650|NCT01069692|DRUG|SBR759A|9g daily
58076651|NCT01069692|DRUG|SBR759A|12g daily
58076652|NCT00577382|DRUG|Sunitinib|
58076653|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
58076654|NCT05879614|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
58076655|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
58407871|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
58407872|NCT02723006|DRUG|TAK-580|TAK-580 tablets
58407873|NCT02723006|DRUG|TAK-202|TAK-202 infusion
58407874|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
58407875|NCT02723006|DRUG|nivolumab|nivolumab infusion
58407876|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
58076656|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
58296596|NCT03113565|BEHAVIORAL|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
58296597|NCT05869071|DEVICE|Sensor analyzing software (own development)|A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
58296598|NCT05869071|DEVICE|Body plethysmograph|Body plethysmograph measures specific airway resistance
58407877|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
58407878|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
58407879|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
58407880|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
58407881|NCT00092872|DRUG|MK0557|
58407882|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
58407883|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
58407884|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
58407885|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
57941702|NCT01133899|DIETARY_SUPPLEMENT|PLACEBO|celulose
58076657|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
58076658|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
58407886|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
57941703|NCT00004047|DRUG|exatecan mesylate|
58076659|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
58076660|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
58076661|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
58076662|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
58076663|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
58296599|NCT01406119|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
58296600|NCT02149407|DRUG|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
58296601|NCT02149407|PROCEDURE|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
58407887|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
58407888|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
58407889|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
58407890|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
58407891|NCT02928029|DRUG|Placebo|Matching placebo
58407892|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
57941704|NCT00738153|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
57941705|NCT00692484|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
57941706|NCT00692484|DRUG|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
57941707|NCT00596947|DRUG|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
58076664|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
58076665|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
58296602|NCT02149407|OTHER|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
58296603|NCT04277780|DEVICE|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
58296604|NCT04277780|OTHER|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
58296605|NCT02092454|DRUG|Benzocaine|topical otic solution
58296606|NCT02092454|DRUG|Placebo|topical otic solution
58296607|NCT04331834|DRUG|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
58296608|NCT04331834|DRUG|Placebos|"Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
58296609|NCT00082212|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
58296610|NCT05286853|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.
58296611|NCT05286853|PROCEDURE|Sham Comparator|Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
58296612|NCT01720641|BEHAVIORAL|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
58296613|NCT01720641|BEHAVIORAL|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
58296614|NCT01720641|BEHAVIORAL|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
58296615|NCT00598065|OTHER|PET/CT|Synchronized PET/CT Imaging
58296616|NCT04780815|OTHER|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
58296617|NCT04780815|OTHER|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
58296618|NCT00492726|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
58296619|NCT00492726|DRUG|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
58296620|NCT05028764|DIAGNOSTIC_TEST|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
58296621|NCT01170325|DRUG|Divalproex Sodium|
58296622|NCT01170325|DRUG|Placebo Comparator|
58296623|NCT04868110|BEHAVIORAL|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
58296624|NCT00152607|PROCEDURE|donor right hepatic lobectomy|
58296625|NCT04533113|PROCEDURE|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
58296626|NCT02676557|DEVICE|Exposed to the high pressure during the surgery|
58296627|NCT00137345|DRUG|sirolimus|
58296628|NCT05748132|PROCEDURE|combined conventional and pulsed RF|"1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
58296629|NCT04383197|BEHAVIORAL|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
58296630|NCT04383197|DRUG|Semaglutide|3 months of therapeutic treatment with semaglutide
58296631|NCT06441318|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
58296632|NCT06441318|DRUG|Placebo|Placebo will be administered at protocol defined dose.
58296633|NCT06441318|DRUG|Moxifloxacin|Moxifloxacin will be administered at protocol defined dose.
58296634|NCT02296658|RADIATION|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
58296635|NCT02296658|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
58296636|NCT02292459|DRUG|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
58076666|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
58076667|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
58076668|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
58296637|NCT02292459|DRUG|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
58296638|NCT01687218|DRUG|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
58296639|NCT01687218|DRUG|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
57951276|NCT06250803|DEVICE|early pancreatic stent placement (EPSP)|In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.
58296640|NCT01687218|DRUG|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
58296641|NCT02038556|BEHAVIORAL|cognitive behaviorial therapy -Insomnia|
58296642|NCT05465369|OTHER|giomer|injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
58296643|NCT05465369|OTHER|high viscosity glass ionomer|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
58296644|NCT02835859|OTHER|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
58296645|NCT02835859|OTHER|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
58296646|NCT05780138|BEHAVIORAL|Parents Taking Action|Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
58296647|NCT05994547|DRUG|Byfavo|For induction and maintenance of sedation
58296648|NCT05994547|DRUG|Midazolam|For induction and maintenance of sedation
58407893|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
57951277|NCT03129659|DIAGNOSTIC_TEST|Coronary CT Angiography|Coronary CT angiography
58296649|NCT02543047|DEVICE|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
58296650|NCT06219863|BEHAVIORAL|Body weight supported harness|A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
58407894|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
58407895|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
58407896|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
58407897|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
58407898|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
58407899|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
58407900|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
58407901|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
57951278|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
57951279|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
57951280|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
57951281|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
57951282|NCT04289337|DIETARY_SUPPLEMENT|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
57951283|NCT04289337|DIETARY_SUPPLEMENT|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
57951284|NCT03254420|DEVICE|Calypso beacon implant|Calypso beacon implant before radiotherapy
57951285|NCT03254420|RADIATION|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
57951286|NCT00024115|DRUG|BL22 immunotoxin|
57951287|NCT00024115|PROCEDURE|antibody therapy|
57951288|NCT00024115|PROCEDURE|biological response modifier therapy|
57951289|NCT00024115|PROCEDURE|immunotoxin therapy|
58407902|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
58407903|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
58407904|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
58076669|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
58296651|NCT03867175|RADIATION|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
58296652|NCT03867175|BIOLOGICAL|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
58407905|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
58407906|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
58407907|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
58296653|NCT06203470|DRUG|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
58296654|NCT06203470|DRUG|Tacrolimus|topical Calcineurin inhibitor
58296655|NCT04951089|DEVICE|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
58407908|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
58407909|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
57731149|NCT06415682|DEVICE|SMA+M1 Transcranial Magnetic Stimulation|"The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA)."
57731150|NCT06415682|DEVICE|M1 Transcranial Magnetic Stimulation|The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
58076670|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
58076671|NCT00003401|DRUG|carmustine|
58296656|NCT04951089|DEVICE|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
58296657|NCT05710146|DRUG|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
58296658|NCT05710146|DRUG|Placebo|1 injection of 100mL of normal saline
58296659|NCT00417144|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
58296660|NCT00417144|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
58296661|NCT01173315|DIETARY_SUPPLEMENT|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
58296662|NCT05275465|DRUG|HH-006|Different dose levels of HH-006
58296663|NCT05275465|DRUG|Placebo|Different dose levels of placebo
58296664|NCT03289767|OTHER|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
58296665|NCT02467361|DRUG|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
58296666|NCT02467361|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
58296667|NCT02467361|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
58407910|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
58296668|NCT02467361|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
58296669|NCT02701725|DEVICE|CRI status|Measurement of CRI
58296670|NCT03773289|OTHER|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
58407911|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
58407912|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
58407913|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
58296671|NCT04687410|DEVICE|ProControl, MediGlobe|standard 22G FNA needle
58296672|NCT04687410|DEVICE|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
58296673|NCT01116947|OTHER|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
58296674|NCT02021214|DRUG|Methylphenidate|
58296675|NCT02021214|DRUG|Placebo|
58296676|NCT05826210|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
58296677|NCT04717258|OTHER|Fire and Rescue Service Safe and Well Visit|Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
58296678|NCT04717258|OTHER|Self-Determination Theory informed trial invitation letter|Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
58296679|NCT04717258|OTHER|Pen included with reminder questionaire|A pen will be included with the four-month reminder questionnaire.
58296680|NCT01693679|DRUG|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
58296681|NCT02176369|DRUG|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
58296682|NCT01340755|PROCEDURE|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
58296683|NCT02667301|DEVICE|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
58296684|NCT02667301|DEVICE|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
58296685|NCT02667301|DEVICE|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
58296686|NCT03459625|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
58296687|NCT03459625|BEHAVIORAL|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
58296688|NCT04990115|OTHER|root canal shaping|root canal treatment
58296689|NCT00655252|DRUG|Everolimus|
58296690|NCT04292210|DEVICE|Perisafe|A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
58296691|NCT05193513|DEVICE|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
58296692|NCT03899857|DRUG|Pembrolizumab|Pembrolizumab will be added to standard of care
57731151|NCT06415682|DEVICE|Sham Transcranial Magnetic Stimulation|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
58076672|NCT00003401|DRUG|cisplatin|
58296693|NCT03210493|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
58296694|NCT01835912|OTHER|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
58296695|NCT03471832|DEVICE|stenfilcon A lens|contact lens
58296696|NCT03471832|DEVICE|narafilcon A lens|contact lens
57951290|NCT03838302|PROCEDURE|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
57951291|NCT03838302|PROCEDURE|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
57951292|NCT03317938|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
57951293|NCT02785250|OTHER|DPX-Survivac|SubQ injection
57951294|NCT02785250|DRUG|Cyclophosphamide|PO BID
58076673|NCT00003401|DRUG|cyclophosphamide|
58296697|NCT01766908|OTHER|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
57731152|NCT03447418|PROCEDURE|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
57941708|NCT00596947|DRUG|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
57941709|NCT00596947|DRUG|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
57941710|NCT00596947|DRUG|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
58076674|NCT00003401|DRUG|dexamethasone|
58076675|NCT00003401|DRUG|etoposide|
58407914|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
58407915|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
58076676|NCT00003401|DRUG|gemcitabine hydrochloride|
58407916|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
58076677|NCT00003401|DRUG|melphalan|
58076678|NCT00003401|DRUG|paclitaxel|
58076679|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
58296698|NCT03719430|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
58296699|NCT03719430|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
58296700|NCT05199467|BEHAVIORAL|Health Coaching|Health coaches help people focus on goals, identify strengths and values, and work towards building the kind of life they wish to live.
57731153|NCT03506971|OTHER|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
57731154|NCT03506971|OTHER|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years"
58076680|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
58076681|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
58076682|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
58076683|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
58076684|NCT01889342|BEHAVIORAL|Metacognitive therapy|
58076685|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
58076686|NCT06109714|OTHER|Goal Directed Fluid Therapy|Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
58296701|NCT05199467|BEHAVIORAL|VA Benefits Information|Printed materials with information on VA benefits.
58296702|NCT01525966|DRUG|carboplatin|Given IV
58296703|NCT01525966|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
58296704|NCT01525966|OTHER|laboratory biomarker analysis|Correlative studies
58407917|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
58407918|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
58407919|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
58407920|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
58407921|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
58407922|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
58407923|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
58407924|NCT01696344|PROCEDURE|PVAI|
58407925|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
58407926|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
57941711|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
58296705|NCT01190813|DRUG|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
57951295|NCT02785250|DRUG|Epacadostat (INCB024360)|PO BID
57951296|NCT02424253|DRUG|ZPL-3893787|ZPL-3893787
57951297|NCT02424253|DRUG|Placebo|Matched Placebo
58296706|NCT01190813|DRUG|Placebo|Oral placebo tid
58296707|NCT01190813|OTHER|Patching|Two hours of daily patching
58296708|NCT01861769|OTHER|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
58296709|NCT01861769|OTHER|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
58296710|NCT04748289|DEVICE|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~1. ICU Cockpit COVID-19 for remote monitoring of isolated patients,~2. ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~3. ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
58296711|NCT03118518|DEVICE|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
58296712|NCT03118518|DRUG|Antiarrhythmic drug|Antiarrhythmic drug initiation
58296713|NCT03188055|OTHER|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
58296714|NCT05078203|BEHAVIORAL|Exercise|36 minutes of Exercise
58296715|NCT05761418|DRUG|Dinoprostone|prostaglandin (PG) E2 analog
58296716|NCT05761418|DRUG|Misoprostol|prostaglandin (PG) E1 analog
58296717|NCT04101383|DRUG|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
58296718|NCT04101383|DRUG|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
58296719|NCT00775762|DRUG|aspirin|Aspirin (75-100 mg)die for three months
58296720|NCT00775762|DRUG|clopidogrel|Clopidogrel (75mg) die for three months
58296721|NCT00775762|DRUG|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
58296722|NCT00541567|DRUG|ibipinabant|oral, tablet, once daily
58296723|NCT01398852|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
58296724|NCT01398852|DEVICE|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
58296725|NCT04907292|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
58296726|NCT03163719|DIAGNOSTIC_TEST|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
58296727|NCT05173077|PROCEDURE|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
57731155|NCT03506971|OTHER|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months"
57941712|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
58076687|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
58296728|NCT05173077|OTHER|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (\>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
58296729|NCT05173077|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
58296730|NCT05173077|OTHER|Blood sample collection|Serum, plasma sampling for group description and stratification.
58296731|NCT05173077|DIAGNOSTIC_TEST|Microbiota testing|Faecal samples for microbiota testing.
58296732|NCT05173077|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
57731156|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
57731157|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
57731158|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
57731159|NCT00760864|DRUG|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
57731160|NCT05531396|OTHER|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
57941713|NCT00906893|PROCEDURE|18F]-FMISO PET-CT|pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.
57941714|NCT06237543|OTHER|hypotension|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
58076688|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
58296733|NCT05545423|OTHER|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
58407927|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
58296734|NCT05545423|OTHER|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
58296735|NCT05985057|OTHER|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
58407928|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
58407929|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
58407930|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
58407931|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
58407932|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
58407933|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
58407934|NCT04857437|DRUG|Placebo|Matching Placebo
58407935|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
58407936|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
58407937|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
58076689|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
58296736|NCT02492893|OTHER|Hatha yoga|
58296737|NCT02104076|DEVICE|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
58407938|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
58407939|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
58407940|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
58407941|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
58407942|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
58407943|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
58407944|NCT00043108|DRUG|carboplatin|
58407945|NCT00043108|DRUG|paclitaxel|
58407946|NCT00043108|PROCEDURE|conventional surgery|
58407947|NCT00043108|RADIATION|radiation therapy|
58076690|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
58076691|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
58296738|NCT03534167|BEHAVIORAL|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
58407948|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
58407949|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
58407950|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
58407951|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
58407952|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
58407953|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
58407954|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
58407955|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
58407956|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
58407957|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
57941715|NCT00766948|OTHER|There is no intervention, this is a biorepository.|There are no interventions in this study.
57941716|NCT04703673|DRUG|Cineole|self administration according to directions for use
57941717|NCT04703673|DRUG|Nasal Decongestant|self administration according to directions for use
57941718|NCT04489251|DIAGNOSTIC_TEST|Protein Elisa analysis, microRNA analysis, whole exome sequencing|"ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing."
57941719|NCT06125769|PROCEDURE|Liver transplantation|Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
57941720|NCT06044064|PROCEDURE|A blood sample for CA 19-9 (cancer detection test)|"* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline.~* Contrast CT abdomen - Pancreas protocol will be done at baseline.~* EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you.~* If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done."
57941721|NCT02528370|DEVICE|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
57941722|NCT02879227|DRUG|Cisplatin|Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
58296739|NCT02348697|BIOLOGICAL|NOVOCART 3D|Autologous Chondrocyte Implantation
58296740|NCT02738359|PROCEDURE|optical colonoscopy|optical colonoscopy
58296741|NCT02738359|PROCEDURE|colon capsule endoscopy|colon capsule endoscopy
58407958|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
57731161|NCT05531396|OTHER|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
57731162|NCT06028269|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
57941723|NCT02879227|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
58076692|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
58296742|NCT02738359|DIAGNOSTIC_TEST|fecal immunological test (FIT)|fecal immunological test (FIT)
58296743|NCT03995888|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
57941724|NCT00805272|OTHER|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
57941725|NCT05568108|PROCEDURE|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
57941726|NCT05568108|PROCEDURE|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
57941727|NCT02524522|DEVICE|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
57941728|NCT02524522|DEVICE|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
57941729|NCT03932656|BEHAVIORAL|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
57941730|NCT03932656|DRUG|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
57941731|NCT04972474|OTHER|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
58076693|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
58076694|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
58076695|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
58076696|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
58076697|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
58076698|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
58076699|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
58076700|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
58076701|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
58076702|NCT02190994|DRUG|Hydrocortisone|used intravenously
58076703|NCT02190994|DRUG|Prednisone|used as tablet form
58296744|NCT01519011|DRUG|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
58407959|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
58407960|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
58076704|NCT05269225|OTHER|Organic diet|Organically produced foods.
58076705|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
58095245|NCT02969473|DRUG|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
58296745|NCT01519011|DRUG|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
58296746|NCT06406335|OTHER|Health education program|Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
58296747|NCT04632277|OTHER|Water|Participants will receive a tab water
58076706|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
58076707|NCT06509880|BIOLOGICAL|Placebo|Placebo
58076708|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
58076709|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
58076710|NCT06723639|PROCEDURE|A new two-layer surgical technique|A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
58076711|NCT06723639|OTHER|Standard non-surgical treatment|Standard non-surgical treatment
58296748|NCT04632277|DIETARY_SUPPLEMENT|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
58296749|NCT04632277|DIETARY_SUPPLEMENT|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
58296750|NCT01190085|DRUG|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
58296751|NCT01190085|DRUG|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
58296752|NCT01190085|DRUG|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
58296753|NCT05418803|DRUG|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
58296754|NCT05418803|DRUG|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
58296755|NCT04531748|DRUG|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
58296756|NCT04531748|DRUG|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
58296757|NCT04531748|OTHER|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
58296758|NCT04036721|DRUG|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
57941732|NCT01923142|BIOLOGICAL|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
57941733|NCT01923142|BIOLOGICAL|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
58296759|NCT04036721|DRUG|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
58296760|NCT04356469|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
58296761|NCT05653947|PROCEDURE|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
58296762|NCT04884347|DIETARY_SUPPLEMENT|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
58296763|NCT04884347|DIETARY_SUPPLEMENT|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
58296764|NCT02727738|DIETARY_SUPPLEMENT|Selenium|Selenium 80 mg bid for 90 days
58296765|NCT02727738|DRUG|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
58296766|NCT01789788|DRUG|Placebo|Matching placebo, multiple doses
58296767|NCT01789788|DRUG|RO6811135|multiple ascending doses
57941734|NCT00290342|BIOLOGICAL|DTPa-IPV|3 intramuscular injections
58296768|NCT02376504|BEHAVIORAL|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
57941735|NCT00290342|BIOLOGICAL|DTPa|3 intramuscular injections
57941736|NCT00290342|BIOLOGICAL|IMOVAX Polio®|3 intramuscular injections
57941737|NCT04981470|DEVICE|baroloop System|vagal nerve stimulation
57941738|NCT03371979|DRUG|Pegzilarginase|Administered IV
57941739|NCT03371979|DRUG|Pembrolizumab|Administered IV
58296769|NCT06195618|BIOLOGICAL|Peptide pulsed autologous Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
58296770|NCT04856111|DRUG|Pirfenidone|Same as arm description
58296771|NCT04856111|DRUG|Nintedanib|Same as arm description
58296772|NCT03424798|DEVICE|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
58296773|NCT04230369|BEHAVIORAL|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
58296774|NCT04230369|OTHER|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
58296775|NCT05862493|DIAGNOSTIC_TEST|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
58407961|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
58407962|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
58407963|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
57941740|NCT05549700|OTHER|Neuromodulation|Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
58076712|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
58296776|NCT04030598|DRUG|Donidalorsen|Donidalorsen administered SC
58296777|NCT04030598|DRUG|Placebo|Placebo matching solution administered SC
58296778|NCT00115778|DRUG|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
58296779|NCT00115778|OTHER|Placebo|0.1% Albumin in an equal volume to the investigational product
58296780|NCT02274597|DEVICE|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
58296781|NCT00572260|DRUG|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
58296782|NCT00612911|OTHER|Cell therapy|bone marrow mononuclear cell
58296783|NCT00959465|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
58296784|NCT00090727|DRUG|AQ4N|
58296785|NCT03805737|OTHER|Amulez and sunlight|Amulez and sun exposure for 2 hours
58296786|NCT03805737|OTHER|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
58296787|NCT02348229|PROCEDURE|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
58296788|NCT02348229|PROCEDURE|ERAS protocols|No bowel preparation
58296789|NCT02348229|PROCEDURE|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
58296790|NCT02348229|PROCEDURE|ERAS protocols|Vasoactive drugs used if need be
58296791|NCT02348229|PROCEDURE|ERAS protocols|Temperature management
58296792|NCT02348229|PROCEDURE|ERAS protocols|Intra-abdominal drains not to be used
58296793|NCT02348229|PROCEDURE|ERAS protocols|Intraperitoneal Ropivicaine infusion
58407964|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
58407965|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
58407966|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
58407967|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
58407968|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
58407969|NCT02417116|OTHER|Saline|Application as required to improve comfort
58407970|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
58407971|NCT01418131|DRUG|Placebo|Placebo
58076713|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
57731163|NCT04848025|DEVICE|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
57731164|NCT01141192|DIETARY_SUPPLEMENT|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
57731165|NCT01141192|DIETARY_SUPPLEMENT|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
57731166|NCT06635408|DIAGNOSTIC_TEST|cystatin c|a biomarker to assess renal function
57731167|NCT05812261|OTHER|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
57731168|NCT01490632|DRUG|Placebo|Administered orally
57731169|NCT01490632|DRUG|Baricitinib|Administered orally
57731170|NCT04973137|DRUG|Birtamimab|Intravenous administration of 24 mg/kg birtamimab every 28 days
57731171|NCT04973137|OTHER|Placebo|Intravenous 0.9% Saline administration as a placebo every 28 days
58076714|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
58296794|NCT02348229|PROCEDURE|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
58296795|NCT02348229|PROCEDURE|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
57731172|NCT04973137|DRUG|Standard of Care Chemotherapy|Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care
57731173|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
57731174|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
57731175|NCT05053087|DRUG|Placebo|Saline filled catheter
57731176|NCT04246034|PROCEDURE|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
57731177|NCT06459687|DRUG|Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
58076715|NCT00390676|DRUG|ADH -1 and carboplatin|
58076716|NCT00390676|DRUG|ADH -1 and docetaxel|
58076717|NCT00390676|DRUG|ADH -1 and capecitabine|
57941741|NCT01713621|DRUG|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
58076718|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
58076719|NCT05834244|DRUG|Azacitidine|Given by IV (vein)
58076720|NCT05834244|DRUG|Venetoclax|Given by PO
58076721|NCT05834244|DRUG|NK Cells|Given by IV (vein)
58296796|NCT02348229|PROCEDURE|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
58296797|NCT02348229|PROCEDURE|ERAS protocols|On the5-6th postoperative day Check discharge criteria
58296798|NCT02348229|PROCEDURE|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
58407972|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
57731178|NCT06459687|DRUG|Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
57731179|NCT06633640|COMBINATION_PRODUCT|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.|The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.
57941742|NCT02597569|BEHAVIORAL|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
57941743|NCT05496179|DRUG|Prucalopride|Prokinetic
57941744|NCT05496179|DRUG|Metoclopramide|Prokinetic
57941745|NCT02091778|DEVICE|Fast gelling dressing|
57941746|NCT06396078|DRUG|Ceftriaxone 1000 MG|Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
57941747|NCT06396078|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
57941748|NCT06396078|DRUG|Metronidazole 500 mg|Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
58076722|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
58076723|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
58076724|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
58076725|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
58076726|NCT05566795|DRUG|Tovorafenib|Oral type II RAF kinase inhibitor
58076727|NCT05566795|DRUG|Chemotherapeutic Agent|Intravenous solution for injection
57941749|NCT06396078|DRUG|Ampicillin 2 GM Injection|Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
57941750|NCT06396078|DRUG|Amoxicillin 250 MG|Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
57941751|NCT06396078|DRUG|Azithromycin|Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
57941752|NCT06396078|DRUG|Erythromycin|Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
57941753|NCT01688596|DRUG|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
57941754|NCT02875249|OTHER|patients stool collection|patients stool collection
57941755|NCT06317818|OTHER|Mesenchymal Stem Cells|Suspension of mesenchymal stromal cells for intratissular injection
57941756|NCT06317818|OTHER|Comparative placebo|Cell-free cell suspension solution devoid of cells for intratissular injection
58076728|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
58076729|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
58076730|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
58076731|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
58076732|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
58076733|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
58407973|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
58076734|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
58076735|NCT03451630|BEHAVIORAL|High-Touch|Intensive, in-person and/or telephonic support.
58076736|NCT03451630|BEHAVIORAL|High-Tech|Remote care management and self-directed digital tools.
58076737|NCT03451630|BEHAVIORAL|Optimal Discharge Planning|Transition to other Health Plan disease management programs and/or community resources.
58076738|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
58076739|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
58076740|NCT06284486|DRUG|Venetoclax|Given by PO
58076741|NCT06284486|DRUG|Revumenib|Given by PO
58296799|NCT02348229|PROCEDURE|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
58296800|NCT02348229|PROCEDURE|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
58296801|NCT02348229|PROCEDURE|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
58296802|NCT02348229|PROCEDURE|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
58296803|NCT02348229|PROCEDURE|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
58407974|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
58407975|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
58407976|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
58407977|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
58407978|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
58076742|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
58407979|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
58407980|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
58407981|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
58407982|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
58407983|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
58076743|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
58076744|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
58076745|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
58076746|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
58076747|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
58076748|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
58407984|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
58407985|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
58407986|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
58076749|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
58076750|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
58296804|NCT05308966|OTHER|Data collection|Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
58296805|NCT02361034|DRUG|GRC 27864|
58296806|NCT02361034|DRUG|Placebo|
58407987|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
57941757|NCT03583983|BEHAVIORAL|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
57941758|NCT03583983|BEHAVIORAL|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
57941759|NCT05439486|DEVICE|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
57941760|NCT01866384|PROCEDURE|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
57941761|NCT01866384|OTHER|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
57941762|NCT05147272|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 in combination with gemcitabine
57941763|NCT01753128|DRUG|imipramine|
57941764|NCT04521023|DRUG|Cantabell Tab|Patients assigned to experimental group are treated with Cantabell Tab
57941765|NCT04521023|DRUG|Candemore Plus Tab|Patients assigned to experimental group are treated with Candemore Plus Tab
57941766|NCT04350385|OTHER|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.
57941767|NCT04350385|OTHER|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week
57941768|NCT05207995|BIOLOGICAL|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
57941769|NCT05207995|OTHER|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
57941770|NCT04404998|OTHER|Lower Energy Density|Test meal with lower energy density
57941771|NCT04404998|OTHER|Higher Energy Density|Test meal with higher energy density
57941772|NCT04404998|OTHER|Lower Satiation|Information on lower satiation
57941773|NCT04404998|OTHER|Higher Satiation|Information on higher satiation
57941774|NCT03280875|OTHER|pedalling exercises|pedalling exercises on a bicycle ergometer
57941775|NCT04072289|DEVICE|Visumax spherocylindrical treatment|treatment of low cylinder (\<0.75D)
57941776|NCT04041986|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
57941777|NCT03016208|DRUG|Misoprostol vaginal insert|
57941778|NCT02355249|PROCEDURE|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
57941779|NCT02355249|PROCEDURE|OE|Patients will be treated with traditional three incisions esophagectomy.
58076751|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
58076752|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
58076753|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
58076754|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
58076755|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
58407988|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
57941780|NCT02743351|BIOLOGICAL|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
57941781|NCT02743351|BIOLOGICAL|Control Arm|Untreated mobilized peripheral blood (mPB) cells
57941782|NCT00268437|DRUG|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
57941783|NCT00268437|DRUG|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
57941784|NCT00268437|PROCEDURE|conventional surgery|
57941785|NCT00268437|PROCEDURE|neoadjuvant therapy|
57941786|NCT00268437|RADIATION|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
57941787|NCT03840512|DRUG|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
57941788|NCT03434340|BIOLOGICAL|Peppermint essential oil|2 drops applied on a nasal strip
58407989|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
58407990|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
58407991|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
58407992|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
58407993|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
58407994|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
57731180|NCT02959060|DRUG|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
57731181|NCT02959060|DRUG|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
57941789|NCT03434340|DRUG|Granisetron|1mg intravenous injection
57941790|NCT03434340|DRUG|Dexamethasone|4mg intravenous injection
57941791|NCT03292809|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
57731182|NCT04088097|BEHAVIORAL|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
57731183|NCT04088097|OTHER|Control Condition|Educational and informational materials on adolescent health and nutrition.
57731184|NCT00164437|BEHAVIORAL|educational CD-ROM|
57941792|NCT03292809|DRUG|Vehicle topical ocular, eye drops|Vehicle
57941793|NCT03104894|PROCEDURE|Meibomian Glands Massage|Meibomian gland expression
57941794|NCT03104894|PROCEDURE|Sham Meibomian Glands Massage|Touching the eyelids gently
57941795|NCT03104894|DEVICE|Meibomian Massage device|Meibomian glands expression with applicator
57941796|NCT06512012|BEHAVIORAL|yoga and exercise|Technology-Assisted Yoga and Exercise Intervention during 6 months
57941797|NCT02371226|DRUG|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
57941798|NCT02556502|DEVICE|18F-Florbetaben PET|
57941799|NCT01451008|DEVICE|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
57941800|NCT00530751|OTHER|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool \[GREAT\]) are explored.
58407995|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
57941801|NCT00577109|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
57941802|NCT00577109|DRUG|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
57941803|NCT00577109|DRUG|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
57941804|NCT00577109|DRUG|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
57941805|NCT00577109|DRUG|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
57941806|NCT01419951|BEHAVIORAL|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
57941807|NCT01419951|OTHER|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
57941808|NCT01419951|BEHAVIORAL|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
57941809|NCT00012220|DRUG|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
57941810|NCT00012220|DRUG|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
57941811|NCT00012220|DRUG|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle"
57941812|NCT00012220|DRUG|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
57941813|NCT05132374|OTHER|I-T CHILD|This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
57941814|NCT02782520|DRUG|Ringer Lactate (10ml/kg) fluid expansion|
57941815|NCT02782520|DRUG|Hypertonic saline (3ml/kg) fluid expansion|
57941816|NCT05246020|PROCEDURE|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
58407996|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
57941817|NCT05246020|PROCEDURE|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
57941818|NCT03048539|PROCEDURE|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
57941819|NCT01778439|DRUG|OMP-52M51|
57941820|NCT02166164|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
57941821|NCT02166164|OTHER|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
57941822|NCT02166164|OTHER|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
57941823|NCT01770470|DIETARY_SUPPLEMENT|Chitosan|The product chitosan is contained in a chewing gum formulation
57941824|NCT06148987|OTHER|Questionnaire|The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
57941825|NCT02982369|OTHER|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
58407997|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
58407998|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
58407999|NCT03626636|OTHER|Sham|Sham injection
57731185|NCT02633878|DRUG|Chinese Herbal Medicine plus Oral Micronized Progesterone|Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
57731186|NCT02633878|DRUG|Chinese Herbal Medicine plus Oral Micronized Progesterone Placebo|Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
58296807|NCT01096160|DRUG|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
58296808|NCT01096160|DRUG|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
58296809|NCT01096160|DRUG|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
58296810|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
58296811|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
58296812|NCT01096160|DRUG|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
58296813|NCT01096160|DRUG|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
58076756|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
58296814|NCT01096160|DRUG|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
58296815|NCT01096160|DRUG|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
58296816|NCT01096160|DRUG|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
58296817|NCT03607877|BEHAVIORAL|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
58296818|NCT03607877|BEHAVIORAL|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
58296819|NCT03607877|BEHAVIORAL|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
58296820|NCT05682417|DEVICE|Body Map Assessment Tool: MOVE Tool|"In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area."
58296821|NCT05682417|OTHER|PAQ questionnaire|This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
58296822|NCT05682417|OTHER|F-DFlex questionnaire|This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
58296823|NCT05682417|OTHER|BSQ questionnaire|"The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological."
58296824|NCT05682417|OTHER|Silhouette testing|Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
58076757|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
58076758|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
58076759|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
58076760|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
58408000|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
57941826|NCT02982369|OTHER|Pain Education|Subjects will receive pain education based in biopsychosocial approach
57941827|NCT02982369|OTHER|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
57941828|NCT05217121|OTHER|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
58408001|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
58408002|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
58408003|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
57941829|NCT05217121|OTHER|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
57941830|NCT02066311|DRUG|Nelfinavir|
57941831|NCT01650025|DIETARY_SUPPLEMENT|VSL#3 active probiotic|
57941832|NCT01650025|OTHER|VSL#3 placebo|
58408004|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
58408005|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
58408006|NCT01817673|DIETARY_SUPPLEMENT|placebo|
58408007|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
58408008|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
58408009|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
57941833|NCT05670769|OTHER|Education|The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
57941834|NCT02456597|DRUG|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
57941835|NCT02456597|DRUG|Isotonic Saline|Isotonic saline injected through the novel Catheter
57941836|NCT04673227|DIAGNOSTIC_TEST|Blood draw|Blood draw and the analysis of blood in laboratory
57941837|NCT02061670|BIOLOGICAL|Ragweed-SPIRE|Intradermal injection
57941838|NCT02061670|BIOLOGICAL|Placebo|
57941839|NCT05567575|BEHAVIORAL|Cognitive Behavioral Therapy,|TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
57941840|NCT00086970|DRUG|ifosfamide|Given IV
57941841|NCT00086970|DRUG|O6-benzylguanine|Given IV
58076761|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
58408010|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
58408011|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
57731187|NCT02633878|DRUG|Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone|Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
58408012|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
58408013|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
58408014|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
58408015|NCT05266183|OTHER|Single-Food|1 food served
58408016|NCT05266183|OTHER|Small Portion|Small meal portion size
58408017|NCT05266183|OTHER|Large Portion|Large meal portion size
57731188|NCT02633878|DRUG|Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone Placebo|Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
57941842|NCT00942175|DRUG|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
57941843|NCT00942175|DRUG|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
57941844|NCT00942175|DRUG|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
57941845|NCT00942175|DRUG|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
57941846|NCT00942175|DRUG|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
57941847|NCT00169689|PROCEDURE|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
57941848|NCT00169689|OTHER|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
57941849|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg once daily
57941850|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg bid
57941851|NCT01519596|PROCEDURE|quality-of-life assessment|Ancillary studies
57941852|NCT01519596|OTHER|counseling intervention|Receive lifestyle-related counseling
58408018|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
58408019|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
58408020|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
58408021|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
58408022|NCT02759107|DRUG|Tirzepatide|Administered SC
58408023|NCT02759107|DRUG|Placebo|Administered SC
58076762|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
58076763|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
58076764|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
58076765|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
58076766|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
58076767|NCT03308799|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
58076768|NCT03308799|DRUG|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
58076769|NCT03308799|DRUG|Cream vehicle|Vehicle Cream
58076770|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
57941853|NCT01519596|BEHAVIORAL|exercise intervention|Undergo physical activity intervention
57941854|NCT01519596|OTHER|educational intervention|Receive educational materials
58076771|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
58076772|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
58076773|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
58076774|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
58076775|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
58076776|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
58076777|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
58076778|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
58076779|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
58076780|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
58408024|NCT02759107|DRUG|Dulaglutide|Administered SC
57941855|NCT01519596|PROCEDURE|standard follow-up care|Undergo usual care
57941856|NCT06385730|DRUG|neoadjuvant anti-PD-1|PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
57941857|NCT06385730|DRUG|neoadjuvant anti-PD-1 with LDRT|"Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators"
57941858|NCT02307487|DRUG|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
58076781|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
58076782|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
58076783|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
58076784|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
58076785|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
58076786|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
58076787|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
58076788|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
58076789|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
58408025|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
58076790|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
58076791|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
58076792|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
58076793|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
58076794|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
58408026|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
57941859|NCT02307487|DRUG|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
58408027|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
58408028|NCT03553498|DRUG|IV placebo|given intravenously
58408029|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
57941860|NCT02307487|DRUG|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
57941861|NCT02307487|DRUG|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
57941862|NCT02307487|DRUG|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
57941863|NCT02307487|DRUG|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
57941864|NCT03278600|GENETIC|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
57941865|NCT02218957|PROCEDURE|Extended Pouch RYGB|
58076795|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
58076796|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
58076797|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
58076798|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
58408030|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
58408031|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
58408032|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
58408033|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
58408034|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
58076799|NCT02335359|DRUG|Placebo|Saline
58076800|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
58076801|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
58076802|NCT05680545|OTHER|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
58076803|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
58076804|NCT01704482|DRUG|placebo|
58408035|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
58408036|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
57941866|NCT02218957|PROCEDURE|Standard RYGB|
57941867|NCT06226909|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
57941868|NCT04624464|OTHER|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
57941869|NCT04624464|OTHER|Examination of patient room|Only performed for cohort 2
57941870|NCT06289244|DIAGNOSTIC_TEST|Ultrasound|"The thickness of the diaphragm and quadriceps will be assessed using bedside ultrasound, utilizing a 13-6 MHz cm linear probe. The measurement of the right hemidiaphragm's end-expiratory thickness will be conducted via diaphragm ultrasound. For accurate positioning, the ultrasound probe will be placed along the right anterior axillary line, specifically between the ninth and tenth intercostal spaces, in a sagittal oblique orientation. To enhance measurement consistency, the probe's position on the skin will be marked.~To ascertain accuracy, the operator will conduct each measurement three times, and the mean of these three values will be used for analysis. Similarly, for diaphragmatic assessment and peripheral assessments (Qthick and CSA) of the lower limbs, the examination areas will be demarcated on the skin with a dermatographic pen, ensuring measurement reproducibility over different timepoints."
58076805|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
58076806|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
58076807|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
58076808|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
58076809|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
58076810|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
58076811|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
58076812|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
58076813|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
58076814|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
58076815|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
58076816|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
58076817|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
58076818|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
58076819|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
58076820|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
58076821|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
58408037|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
58076822|NCT00045136|DRUG|melphalan|
58076823|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
58076824|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
58076825|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
58296825|NCT05682417|OTHER|Eating Disorder Inventory - 2|"Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)"
58408038|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
58408039|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
58076826|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
58076827|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
58408040|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
58076828|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
57941871|NCT06289244|DIAGNOSTIC_TEST|Muscle strength measurement|"The assessment of limb muscle strength in this study will be conducted using the Medical Research Council (MRC) Score. For a more precise evaluation of quadriceps strength, a dynamometer will be employed.~Furthermore, the study will incorporate an invasive method for gauging inspiratory muscle strength, utilizing the negative inspiratory force (NIF) metric. Post-extubation, the maximum inspiratory pressure (MIP) will be determined using an electronic manometer. Three separate MIP measurements will be executed, and the highest reading among these will be recorded as the definitive measurement."
57941872|NCT01969487|OTHER|Preoperative warm-up on simulator|
57941873|NCT05788744|DIAGNOSTIC_TEST|ctDNA|ctDNA guided surveillance
57941874|NCT03665389|DEVICE|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
57941875|NCT05771064|BEHAVIORAL|Gentle Moves|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
57941876|NCT03936283|BEHAVIORAL|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
57941877|NCT04703036|DIETARY_SUPPLEMENT|Glycine|Glycine is an amino-acid (protein)
58408041|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
57941878|NCT04703036|DIETARY_SUPPLEMENT|N-acetylcysteine|This is a donor of the amino-acid cysteine (protein)
57941879|NCT04703036|DIETARY_SUPPLEMENT|Alanine|Alanine is an amino-acid (protein)
57941880|NCT06011564|DEVICE|Reminder function on Android computer tablet|Computer tablet with reminder function
57941881|NCT00326742|BEHAVIORAL|Trier Social Stress Test|
57941882|NCT01978821|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
57941883|NCT01719315|OTHER|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
57941884|NCT06001112|OTHER|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
57941885|NCT06001112|DRUG|Etoricoxib|etoricoxib 120mg
57941886|NCT00703001|BEHAVIORAL|Educational Intervention|students in this arm will receive several oral health educational modules in class
58076829|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
58076830|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
58076831|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
58076832|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
58076833|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
58408042|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
58408043|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
58076834|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
58076835|NCT02550418|DRUG|Budesonide|
58076836|NCT04037579|OTHER|Survey|Non-randomised survey
58076837|NCT00000362|BEHAVIORAL|Chin-down position|
58076838|NCT00000362|BEHAVIORAL|Thickened liquid administration|
58076839|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
58076840|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
58076841|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
58076842|NCT00070070|BIOLOGICAL|sargramostim|
58076843|NCT01784094|DEVICE|StromaGlide|
58076844|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
58076845|NCT02042807|DRUG|Placebo|
58076846|NCT02042807|DRUG|MCS®|
58076847|NCT00359684|DRUG|Cysteamine|Cystine-depleting agent
57731189|NCT06538090|BEHAVIORAL|Early Movers|The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
57731190|NCT02276300|DRUG|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
57941887|NCT00703001|BEHAVIORAL|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
57941888|NCT00754481|OTHER|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
58296826|NCT05682417|OTHER|EDEQ questionnaire|"Or Eating Disorders Examination - Questionnaire (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days."
58408044|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
58408045|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
58408046|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
58408047|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
58408048|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
57731191|NCT02276300|DRUG|Sargramostim|Sargramostim is part of Her2 vaccination
57731192|NCT02276300|DRUG|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
57731193|NCT02276300|DRUG|Imiquimod|Imiquimod is part of Her2 vaccination
57731194|NCT01857544|DRUG|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
57941889|NCT00754481|OTHER|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
57731195|NCT04383912|DRUG|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
57731196|NCT04383912|OTHER|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
57731197|NCT06568692|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
57941890|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
57941891|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
57941892|NCT01034735|BIOLOGICAL|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
57941893|NCT03714191|OTHER|Patient Outcomes|The intervention includes different versions of the BPA design and message.
57941894|NCT03714191|OTHER|Billing documentation|The intervention includes different versions of the BPA design and message.
57941895|NCT03714191|OTHER|Regulatory|The intervention includes different versions of the BPA design and message.
57941896|NCT05259722|DRUG|Delgocitinib|Cream for topical application 20 mg/g
57941897|NCT05259722|DRUG|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
58408049|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
58076848|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
58076849|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
58076850|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
58408050|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
57731198|NCT06568692|DRUG|Capecitabine|Commercially available capecitabine is a commonly used oral fluoropyrimidine.
57941898|NCT05111262|DRUG|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
57941899|NCT00737191|DRUG|olanzapine|Given orally
57941900|NCT00737191|OTHER|placebo|Given orally
57941901|NCT05602038|PROCEDURE|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
57941902|NCT05602038|DRUG|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
57941903|NCT05602038|DRUG|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
57941904|NCT01575106|DEVICE|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
57941905|NCT05184673|OTHER|Behavioral and environmental|These are all active comparator yoga sequences
58076851|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
58076852|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
58076853|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
58076854|NCT06724809|DRUG|eculizumab|Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.
58076855|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
58408051|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
58408052|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
57731199|NCT01840423|DRUG|ODM-104|ODM-104
57731200|NCT01840423|DRUG|Placebo|Placebo
57731201|NCT01840423|DRUG|Entacapone|entacapone + levodopa/carbidopa
57941906|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
57941907|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
57941908|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
57941909|NCT01830855|BIOLOGICAL|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
57941910|NCT01830855|BIOLOGICAL|Saline|0.5 mL dose of sterile normal saline for injection.
57941911|NCT00966342|DRUG|Fluviral 2009/10|single dose given IM .05 mL
57941912|NCT03023930|OTHER|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
57941913|NCT03023930|OTHER|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
57941914|NCT04792567|DRUG|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
58076856|NCT02479594|OTHER|control|control group without competence-feedback
58076857|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
58076858|NCT05762276|BIOLOGICAL|Placebo|Normal saline
58076859|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
58076860|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
58076861|NCT06724289|DRUG|Psilocybin 25 mg|25 mg psilocybin administered to each participant in single arm, open-label trial
58076862|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
58076863|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
58076864|NCT02059473|PROCEDURE|Physiotherapy|
57731202|NCT01840423|DRUG|levodopa/carbidopa|entacapone + levodopa/carbidopa
57941915|NCT04792567|DRUG|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
57941916|NCT04792567|BIOLOGICAL|BNT162|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
57941917|NCT04792567|BIOLOGICAL|mRNA-1273|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
57941918|NCT03574857|DRUG|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
57941919|NCT03574857|DRUG|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
57941920|NCT02071212|DRUG|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
57941921|NCT03624933|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
57941922|NCT03624933|BEHAVIORAL|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
57941923|NCT03280654|OTHER|overactive bladder|Association between groups and over active bladder symptoms
57941924|NCT05704764|BEHAVIORAL|Ending Self Stigma for Persons living with HIV and Use Substances|Group-based intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
57941925|NCT03722342|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
57941926|NCT03456648|DRUG|apixaban|non-vitamin K oral anticoagulant (NOAC)
57941927|NCT04497896|OTHER|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
57941928|NCT04983173|DRUG|Ovarian Stimulation with CC+rFSH|: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
57941929|NCT04983173|DRUG|Ovarian Stimulation with rFSH|rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
57941930|NCT02130739|PROCEDURE|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
57941931|NCT02130739|PROCEDURE|mastectomy|mastectomy with/without breast reconstruction
57941932|NCT02130739|DRUG|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
57941933|NCT02130739|DRUG|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
57941934|NCT02130739|DRUG|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
57941935|NCT04492098|DIAGNOSTIC_TEST|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
57941936|NCT04745039|DEVICE|Endopatch System|The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
57941937|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
57941938|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
57941939|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
57941940|NCT05676684|DRUG|Dapagliflozin|A: Dapagliflozin 10 mg once daily
57941941|NCT05676684|DRUG|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)
57941942|NCT03932370|PROCEDURE|endoscopic surgery|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water
58408053|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
58408054|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
58408055|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
58408056|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
57731203|NCT00604253|DRUG|insulin detemir|
57731204|NCT00604253|DRUG|insulin NPH|
57731205|NCT00251810|DEVICE|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
58408057|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
58076865|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
58076866|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
58076867|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
58076868|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
58076869|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
58076870|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
58076871|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
58076872|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
58076873|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
58076874|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
58076875|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
58408058|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
58408059|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
58408060|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
58408061|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
58408062|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
58408063|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
58408064|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
58408065|NCT03970096|DRUG|Thiotepa|Given IV
58408066|NCT03970096|DRUG|Fludarabine|Given IV
58408067|NCT03970096|DRUG|Tacrolimus|Given IV
58408068|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
58408069|NCT03970096|DRUG|Methotrexate|Given IV
58076876|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
58076877|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
58076878|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
58076879|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
58076880|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
58408070|NCT03970096|DRUG|Cyclophosphamide|Given IV
58408071|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
58408072|NCT03970096|DRUG|Cyclosporine|Given IV
58408073|NCT03970096|DRUG|Sirolimus|Given IV
58076881|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
58076882|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
58408074|NCT03970096|DRUG|Busulfan|Given IV
58408075|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
58408076|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
58408077|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58408078|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58408079|NCT06608836|OTHER|an ice massage|an ice massage
58408080|NCT06608836|OTHER|the cold spray|the cold spray
58408081|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
58408082|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
58408083|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
57941943|NCT01040351|PROCEDURE|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
58076883|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
58076884|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
58076885|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
58076886|NCT01575158|DRUG|Citalopram|
58408084|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
57941944|NCT01966328|DRUG|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
58408085|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
58408086|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
58408087|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
57941945|NCT01966328|DRUG|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
58408088|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
58408089|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
58408090|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
58408091|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
58408092|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
58408093|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
58408094|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
58408095|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
57941946|NCT01015768|DEVICE|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
57941947|NCT01015768|DEVICE|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
57941948|NCT02509182|DRUG|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
58076887|NCT01575158|DRUG|Clomipramine|
58296827|NCT05682417|OTHER|STAI questionnaire|The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
58296828|NCT05682417|OTHER|BECK questionnaire|Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
58296829|NCT03768778|PROCEDURE|Debridement and dural repair|
57731206|NCT04959045|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
57941949|NCT02509182|DRUG|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
57941950|NCT03827824|DEVICE|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
57941951|NCT03827824|DEVICE|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
57941952|NCT01637220|BIOLOGICAL|Blood volume collected specifically for this study|"* case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection"
57941953|NCT04881071|DEVICE|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
57941954|NCT04881071|OTHER|Usual clinical practice|Participants will receive the usual clinical practice
57941955|NCT02431897|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
57941956|NCT02431897|DRUG|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
57941957|NCT03377842|DRUG|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
57731207|NCT02096653|PROCEDURE|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
57731208|NCT02096653|PROCEDURE|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
58076888|NCT01575158|DRUG|placebo|
57731209|NCT02508480|BEHAVIORAL|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
57941958|NCT03377842|DRUG|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
57941959|NCT03236220|DRUG|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
57941960|NCT03887533|DRUG|VTS-270|Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
57941961|NCT00829179|DRUG|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
57941962|NCT02887404|OTHER|Spine surgery analgesic pathway|Enhanced pain management care
57941963|NCT02887404|OTHER|Usual Care|Standard of pain management care
57941964|NCT03399981|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
57941965|NCT00838292|DIETARY_SUPPLEMENT|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
57941966|NCT00838292|OTHER|nutrition counseling|
58076889|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
58076890|NCT06240468|OTHER|not have|not have
58076891|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
58076892|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
58076893|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
58076894|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
58076895|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
57731210|NCT02508480|BEHAVIORAL|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
57731211|NCT04179032|COMBINATION_PRODUCT|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
57731212|NCT05403489|PROCEDURE|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
57731213|NCT05403489|PROCEDURE|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
57941967|NCT01567657|DRUG|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
57731214|NCT06042829|DEVICE|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
57731215|NCT06042829|DEVICE|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
57941968|NCT01567657|DRUG|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
58076896|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
58076897|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
58076898|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
57941969|NCT05279248|BIOLOGICAL|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
57941970|NCT05279248|BIOLOGICAL|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
58076899|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
58076900|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
58076901|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
58076902|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
58076903|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
58076904|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
58076905|NCT02928198|DEVICE|ABSORB BVS|
58076906|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
58076907|NCT06724653|DRUG|RAS blocker tapering group|RAS blocker tapering out
58076908|NCT06724653|DRUG|Beta blocker tapering out|Beta blocker tapering out group
58296830|NCT03752476|PROCEDURE|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
58296831|NCT02107846|DRUG|PRX-112|
58408096|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
58408097|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
58408098|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
58408099|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
57941971|NCT05279248|BIOLOGICAL|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
57941972|NCT02428543|DRUG|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
57941973|NCT05687747|DRUG|Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI|68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.
58408100|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
57941974|NCT00830245|DRUG|Erlotinib|Erlotinib 150mg/day
57941975|NCT01518881|DRUG|TKM-100201|IV Infusion
57941976|NCT01518881|DRUG|Placebo|IV infusion
57941977|NCT01524198|DRUG|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
57941978|NCT01524198|DRUG|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
57941979|NCT05506176|DRUG|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
57941980|NCT05506176|DRUG|Placebo|Placebo (tablet)
57941981|NCT01973374|BEHAVIORAL|Text Message Intervention|
57941982|NCT02441413|RADIATION|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
58408101|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
57941983|NCT01214694|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
57941984|NCT01214694|BEHAVIORAL|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
57941985|NCT01214694|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
57941986|NCT01651858|DRUG|Nurigra Chewable tablet|1 tablet of 100mg, once a day
57941987|NCT04183283|DRUG|LY3526318|Administered orally.
57941988|NCT04183283|DRUG|Placebo|Administered orally.
57941989|NCT04870411|BIOLOGICAL|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
57941990|NCT04725695|DRUG|Viscous Lidocaine|The patients will be randomized to either viscous lidocaine or placebo
58296832|NCT03941340|DRUG|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1
58408102|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
58408103|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
58408104|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
58408105|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
58408106|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
58408107|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
58408108|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
58408109|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
58408110|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
57731216|NCT04627766|DEVICE|Monitoring with VT-Patch (Connected device manufactured by VitalTracer)|Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
58296833|NCT04533789|OTHER|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
57731217|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
57941991|NCT02601677|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
57941992|NCT02601677|DRUG|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
57941993|NCT01767675|PROCEDURE|Secondary Cytoreductive Surgery|
57941994|NCT01767675|DRUG|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
57941995|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|5 cycles
57941996|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|6 cycles
57941997|NCT06216379|DIAGNOSTIC_TEST|Assessment|Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
57941998|NCT05774925|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
57941999|NCT01936636|DRUG|Fentanyl|
57942000|NCT05514990|DRUG|Bortezomib|Given SC or IV
57942001|NCT05514990|DRUG|Dexamethasone|Given PO, IV, or IM
58296834|NCT00209001|PROCEDURE|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
58296835|NCT00209001|PROCEDURE|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
57731218|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
57731219|NCT04543929|BEHAVIORAL|exercise|partially supervised and home-based exercise activity
57731220|NCT00649012|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
57731221|NCT00649012|DRUG|Actos® Tablets 45 mg|45mg, single dose fed
57731222|NCT05491473|DEVICE|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
58296836|NCT01701804|DRUG|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
57731223|NCT01707602|BIOLOGICAL|INTANZA® 15|intradermal vaccination
57731224|NCT01707602|BIOLOGICAL|Vaxigrip®|Intramuscular vaccination
57942002|NCT05514990|BIOLOGICAL|Pelareorep|Given IV
57942003|NCT05514990|BIOLOGICAL|Pembrolizumab|Given IV
57942004|NCT01979159|BEHAVIORAL|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
57951298|NCT05574595|OTHER|Music theraphy|In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
58296837|NCT01701804|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
58296838|NCT01701804|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.
58296839|NCT01701804|PROCEDURE|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
58296840|NCT03701880|DRUG|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
58296841|NCT03701880|DRUG|Bisoprolol|Bisoprolol is beta-blocker
58408111|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
57951299|NCT01136655|DRUG|80/2.25 μg Symbicort pMDI|inhalation
58076909|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
58076910|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
58076911|NCT03389633|OTHER|rehabilitation|
58076912|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
58076913|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
58076914|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
58076915|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
58076916|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
57942005|NCT02660203|PROCEDURE|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
58076917|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
58408112|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
57731225|NCT01707602|BIOLOGICAL|INTANZA® 15 T|transcutaneous vaccination
57942006|NCT05692492|DRUG|ZSP1601|50mg BID
57942007|NCT05692492|DRUG|ZSP1601|100mg BID
57942008|NCT05692492|DRUG|Placebo|Placebo
57942009|NCT02017353|DIETARY_SUPPLEMENT|Curcuphyt|
57942010|NCT01508104|DRUG|BEZ235|dose escalation 400mg- 1000mg per day
58076918|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
58076919|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
58076920|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
58408113|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
57942011|NCT01508104|DRUG|Everolimus|dose escalation 2.5 to 5 mg per day
57942012|NCT01434420|GENETIC|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
57942013|NCT04943081|PROCEDURE|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
57942014|NCT02009436|DRUG|Azacitidine|Given via nebulizer
57942015|NCT02009436|OTHER|Laboratory Biomarker Analysis|Correlative studies
57942016|NCT02009436|OTHER|Pharmacological Study|Correlative studies
57942017|NCT04195854|DEVICE|P4HB product|Retrospective use of P4HB in various anatomies
57942018|NCT03962738|DRUG|Lasmiditan|Administered orally
57942019|NCT03962738|DRUG|Placebo|Administered orally
57942020|NCT01018628|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
57942021|NCT01018628|DRUG|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
57942022|NCT00471705|DRUG|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
57942023|NCT00471705|DEVICE|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
57942024|NCT00471705|DRUG|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
58076921|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
58076922|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
58076923|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
58076924|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
58076925|NCT00399542|DRUG|Lubiprostone|
58076926|NCT00399542|DRUG|Placebo|
58076927|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
58076928|NCT06723730|PROCEDURE|Upper Quadrant Core Strengthening protocol|"Upper Quadrant Core Strengthening protocol Core strengthening protocol will comprise of following four week protocol.~1. Week one Scapular postural correction and shoulder shrugging exercises~2. Week two External rotation at 0 degree~3. Week three Internal rotation at 0 degree~4. Week four Standing row at 45 and 90 degree , Anterior shoulder stretch and Thoracic exercise in sitting"
58076929|NCT06723730|PROCEDURE|Mobilization with movement|"In addition to upper quadrant core strengthening protocol participants will also perform mobilization with movement.~Mobilization with movement protocol will comprise of following forms.~1. Acromioclavicular joint glides~2. Scapular glides~3. Glenohumeral joint glides ( inferior glides, postero-lateral glides, postero-inferior)"
58076930|NCT02046551|DRUG|Atomoxetine|
58076931|NCT02046551|DRUG|Placebo|
58076932|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
58076933|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
58076934|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
58296842|NCT05854420|PROCEDURE|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
57731226|NCT02535065|DEVICE|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
57731227|NCT05044572|OTHER|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
57731228|NCT05044572|OTHER|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
57731229|NCT03507166|DRUG|RC48-ADC|2 mg/kg IV every 2 weeks
57731230|NCT06024928|DEVICE|Control-IQ use in Type 2 Diabetes under basal insulin injections|Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
57942025|NCT05449990|OTHER|Participation in PFCC-IR|Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
57942026|NCT03082105|OTHER|Breathing in snow|Breathing in snow with different physical properties
57942027|NCT05561361|PROCEDURE|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
57942028|NCT05561361|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
58076935|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
58076936|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
58076937|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
58076938|NCT00334893|DRUG|eribulin mesylate|Given IV
58076939|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
58076940|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
58076941|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
58076942|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
58296843|NCT02219685|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
58296844|NCT02219685|DRUG|Placebo|Tablet administered orally once daily
58296845|NCT04214522|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
57731231|NCT04431323|BEHAVIORAL|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
57731232|NCT00783536|DRUG|Etanercept + Methotrexate|
57731233|NCT00783536|DRUG|DMARDS|
57731234|NCT04393545|DEVICE|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
57731235|NCT04393545|OTHER|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
57731236|NCT04393545|OTHER|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
57731237|NCT04450589|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
57731238|NCT04450589|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57731239|NCT04450589|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57731240|NCT04450589|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
57731241|NCT04450589|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
57731242|NCT04450589|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57731243|NCT04450589|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57942029|NCT04688151|DRUG|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
57942030|NCT00239811|DRUG|FTY720|
57942031|NCT01180478|DEVICE|White Light|White Light Cystoscopy
58296846|NCT02582333|OTHER|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
58296847|NCT04284683|OTHER|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
58296848|NCT00049725|DRUG|Daclizumab|
58296849|NCT00302536|DRUG|Tacrolimus|Tacrolimus
58296850|NCT01481558|DEVICE|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
58076943|NCT06722911|DRUG|Nimotuzumab|Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
58408114|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
58408115|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
58408116|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
58408117|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
58408118|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
58408119|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
58408120|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
58408121|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
58408122|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
58408123|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
58408124|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
58408125|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
58408126|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
58076944|NCT06722911|DRUG|AG|Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
58076945|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
58076946|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
58076947|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
58408127|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
58408128|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
58408129|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
58408130|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
58408131|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
58408132|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
58408133|NCT01820403|OTHER|portion size kcal of box lunch|
58408134|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
58408135|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
58408136|NCT00521599|DRUG|Placebo|
58408137|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
58408138|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
58408139|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
58076948|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
57731244|NCT04450589|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
58076949|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
58076950|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
58076951|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
58076952|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
58076953|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
58076954|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
58076955|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
58076956|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
58076957|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
58076958|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
58076959|NCT02010359|DRUG|Placebo|Placebo pill
58076960|NCT02641691|RADIATION|Radiation|
58076961|NCT02641691|DRUG|Oxaliplatin|
58076962|NCT02641691|DRUG|Leucovorin|
58076963|NCT02641691|DRUG|Fluorouracil|
58076964|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
58076965|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
58076966|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
58076967|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
58076968|NCT03539666|OTHER|diet|dietary patterns
58408140|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
58076969|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
58076970|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
58076971|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
58076972|NCT02190604|DRUG|Placebo|Capsule- oral dose
58076973|NCT02190604|DRUG|QBW251|Capsule - oral dose
58076974|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
58076975|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
58076976|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
58076977|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
58076978|NCT00012350|DRUG|FTI|
58076979|NCT06724835|DRUG|XKDCT293|Autologous targeted Nectin4 chimeric antigen receptor T cell injection
58076980|NCT06724835|OTHER|CAR-T cell|Nectin-4-CAR-T
58076981|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
58076982|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
58076983|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
58076984|NCT03401502|DRUG|Placebos|Oral, b.i.d
58076985|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
58076986|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
58076987|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
58076988|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
58076989|NCT00231621|DRUG|topiramate|
58076990|NCT06722092|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
58076991|NCT06722092|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and prerecorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
58076992|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
58076993|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
58076994|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
58076995|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
58076996|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
58076997|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
58296851|NCT06540560|BEHAVIORAL|My Pelvic Plan website|"Following the baseline interview, participants will receive a link to a web-based self-guided program and have access for two weeks My Pelvic Plan that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Subsequent to this, participants will then complete another brief questionnaire after a two-week interval. This questionnaire will focus on willingness to consider specific treatment modalities, credibility/expectancy for specific treatment modalities, and a brief measure assessing self-efficacy for managing symptoms."
57942032|NCT01180478|DEVICE|Narrow Band Imaging|Narrow Band Imaging
57942033|NCT00050154|DRUG|ZARNESTRA, tipifarnib, R115777|
57942034|NCT00120861|DRUG|valopicitabine|
57942035|NCT00120861|DRUG|pegylated interferon|
58076998|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
58076999|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
58296852|NCT01841970|DEVICE|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
58296853|NCT03281746|PROCEDURE|Dental Procedure|Undergo dental examination
58296854|NCT03281746|OTHER|Educational Intervention (prevention education)|Receive prevention education
58296855|NCT03281746|OTHER|Interview|Ancillary studies
57731245|NCT01224262|BIOLOGICAL|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
57942036|NCT00120861|DRUG|ribavirin|
57942037|NCT03537144|DRUG|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
57942038|NCT03537144|DRUG|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
57942039|NCT02726087|PROCEDURE|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
57942040|NCT02726087|PROCEDURE|Full sternotomy|Conventional full median sternotomy
57942041|NCT01687075|DEVICE|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
57942042|NCT04425720|DEVICE|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.
57942043|NCT04425720|OTHER|Standard of Care|This group will be treated based on standard of care at our institution.
57942044|NCT01129362|BIOLOGICAL|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
58077000|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
58077001|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
58296856|NCT03281746|OTHER|Survey Administration|Ancillary studies
57731246|NCT01224262|BIOLOGICAL|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
57731247|NCT01224262|BIOLOGICAL|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
57731248|NCT00146952|DEVICE|Vibrotactile feedback|
57942045|NCT01129362|BIOLOGICAL|Other Pertussis Vaccines|0.5 mL, Intramuscular
57942046|NCT00587002|PROCEDURE|IVUS|Intravascular ultrasound with virtual histology
57942047|NCT02751762|OTHER|Observation Only|No Intervention
57942048|NCT02984579|DEVICE|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
57951300|NCT01136655|DRUG|80/4.5 μg Symbicort pMDI|inhalation
57951301|NCT01136655|DRUG|Foradil Aerolizer 12 μg|inhalation
58077002|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
58077003|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
58077004|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
58077005|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
58077006|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
58296857|NCT03281746|OTHER|Educational Intervention (one-on one education)|Receive one-on-one education
58296858|NCT01705938|DRUG|SP-333|
58296859|NCT03625596|DIETARY_SUPPLEMENT|L-Arginine|Acute intervention (3 hours)
58296860|NCT03625596|DIETARY_SUPPLEMENT|Nitrate / Nitrite|Acute intervention (3 hours)
57942049|NCT02984579|DEVICE|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
57942050|NCT02984579|DEVICE|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
58408141|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
58408142|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
58408143|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
58408144|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
58408145|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
58408146|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
58408147|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
58408148|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
57731249|NCT04336254|BIOLOGICAL|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
57731250|NCT04336254|OTHER|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
57942051|NCT03885791|DEVICE|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
57942052|NCT05492695|DRUG|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
57942053|NCT05492695|OTHER|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
58296861|NCT03625596|DIETARY_SUPPLEMENT|Placebo|Acute intervention (3 hours)
58296862|NCT05384002|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)
58296863|NCT04078711|DRUG|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
58296864|NCT04078711|DRUG|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
58296865|NCT04078711|DRUG|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
58296866|NCT03748134|BIOLOGICAL|Sintilimab|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
58296867|NCT03748134|DRUG|Cisplatin|75mg/m\^2 IV Q3W day 1
58296868|NCT03748134|DRUG|Paclitaxel|87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
58296869|NCT03748134|DRUG|Fluorouracil|800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
58296870|NCT03748134|DRUG|Placebo|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
58296871|NCT03334357|OTHER|PAR|
58296872|NCT03334357|OTHER|HIIT|
58296873|NCT03334357|OTHER|WB-EMS|
58296874|NCT02915224|DRUG|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
58077007|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
58077008|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
58077009|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
58408149|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
58408150|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
58408151|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
58408152|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
58408153|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
58408154|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
57731251|NCT03634774|OTHER|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
57731252|NCT05477134|OTHER|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
57731253|NCT04387084|DRUG|Atezolizumab|Given IV
57942054|NCT02073175|DRUG|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
57942055|NCT05378997|DRUG|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
57942056|NCT05378997|DRUG|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
57942057|NCT05378997|DRUG|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
57942058|NCT01976520|BIOLOGICAL|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
57942059|NCT01686776|OTHER|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
57942060|NCT00381199|DRUG|Amitriptyline Hydrochloride|
57942061|NCT00381199|DRUG|Nabilone|
57942062|NCT01529177|DRUG|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
57942063|NCT01529177|DRUG|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
58408155|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
57942064|NCT04002037|DRUG|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
57942065|NCT04002037|DRUG|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
57942066|NCT04002037|DRUG|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
57942067|NCT00443807|DEVICE|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
57942068|NCT00443807|DEVICE|EEGo vs BIS|comparison of two processed EEG monitors.
57942069|NCT05571228|BEHAVIORAL|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
57942070|NCT00917527|DRUG|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
57942071|NCT02746133|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
57942072|NCT02032550|OTHER|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
57942073|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
57951302|NCT01136655|DRUG|40 μg budesonide HFA pMDI|inhalation
57951303|NCT01136655|DRUG|placebo HFA pMDI|inhalation
58077010|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
57731254|NCT04387084|DRUG|Avelumab|Given IV
58077011|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
58077012|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
58077013|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
58077014|NCT06136650|DRUG|Opevesostat|Administered orally
58077015|NCT06136650|DRUG|Dexamethasone|Administered orally
58077016|NCT06136650|DRUG|Fludrocortisone acetate|Administered orally
58077017|NCT06136650|DRUG|Hydrocortisone|Administered orally or IM as a rescue drug
58077018|NCT06136650|DRUG|Abiraterone acetate|Administered orally
58077019|NCT06136650|DRUG|Prednisone acetate|Administered orally
58077020|NCT06136650|DRUG|Enzalutamide|Administered orally
58296875|NCT02915224|DRUG|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
57942074|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
57942075|NCT03177616|OTHER|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports"
58077021|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
58077022|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
58077023|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
58077024|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
58077025|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
58077026|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
58296876|NCT00875563|DEVICE|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
58296877|NCT00514618|DRUG|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
58296878|NCT00514618|DIETARY_SUPPLEMENT|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
58296879|NCT05704400|DRUG|Rituximab Biosimilar ABP 798|Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
58408156|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
58077027|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
58077028|NCT03556202|DRUG|Mirikizumab|Administered SC
57731255|NCT04387084|BIOLOGICAL|Cemiplimab|Given IV
57942076|NCT02917681|OTHER|Two intrathecal MSC injections|
57731256|NCT04387084|BIOLOGICAL|Durvalumab|Given IV
58077029|NCT02257970|DRUG|Ketoprofen|
58077030|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
58077031|NCT00281736|DRUG|HPPH|Given IV
58077032|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
57731257|NCT04387084|BIOLOGICAL|Nivolumab|Given IV
57731258|NCT04387084|BIOLOGICAL|Pembrolizumab|Given IV
58077033|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
58077034|NCT00000658|DRUG|Bleomycin sulfate|
58077035|NCT00000658|DRUG|Vincristine sulfate|
58077036|NCT00000658|DRUG|Doxorubicin hydrochloride|
58077037|NCT00000658|DRUG|Cyclophosphamide|
58077038|NCT00000658|DRUG|Allopurinol|
58077039|NCT00000658|DRUG|Methotrexate|
58077040|NCT00000658|DRUG|Cytarabine|
58077041|NCT00000658|DRUG|Leucovorin calcium|
58296880|NCT05704400|DRUG|Daratumumab|Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
58296881|NCT04743934|DRUG|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
58296882|NCT04743934|DRUG|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
58408157|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
58408158|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
58408159|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
58408160|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
58408161|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
57942077|NCT05301868|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
57942078|NCT05604820|BEHAVIORAL|Progressive Muscle Relaxation Exercise|Training on progressive muscle relaxation exercises will be given to the experimental group in the chemotherapy unit. Before going to sleep in the evening and during the day, they will be asked to do progressive muscle relaxation exercises in line with the instruction of the video. They will be asked to do the application every day for 8 weeks. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. Only routine care will be applied to the control group and no intervention will be made. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. After the evaluations, information about progressive muscle relaxation exercises will be given.
58296883|NCT04743934|DRUG|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
58296884|NCT05682547|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
58296885|NCT05682547|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
58296886|NCT04528134|DEVICE|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
58408162|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
58408163|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
58408164|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
58296887|NCT04528134|DEVICE|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
58296888|NCT01124747|DRUG|ASP1585|Oral
58296889|NCT01124747|DRUG|14C-Labeled ASP1585|Oral
57731259|NCT04387084|OTHER|Quality-of-Life Assessment|Ancillary studies
57731260|NCT04387084|OTHER|Short-Term Fasting|Undergo STF
57942079|NCT00771134|DRUG|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
57942080|NCT00771134|DRUG|Placebo|B.I.D. for 8 weeks
57942081|NCT00771134|DRUG|Quetiapine|300mg/day for 8 weeks
57942082|NCT02403362|DRUG|EPO-018B|
57951304|NCT04212455|OTHER|Non-interventional study|This is an observational, non-interventional study
58077042|NCT00000658|DRUG|Sargramostim|
58077043|NCT00000658|DRUG|Dexamethasone|
58077044|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
58077045|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
57942083|NCT04168073|OTHER|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
57942084|NCT04168073|OTHER|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
57942085|NCT06002308|OTHER|Age|The retrospective study included 540 patients with primary ACL tears (71 pediatric patients and 469 adults) whose MRI examination and pivot-shift test were conducted within 14 days after injury. To detect concomitant KF and ALL injury in knees with ACL injury using MRI in both adult and pediatric patients and compare the effect of KF injury and multiple risk factors on anterolateral rotatory laxity as measured by the pivot-shift test in a clinical setting.
57942086|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
57942087|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
57942088|NCT01868256|OTHER|early discharge (<72 h)|
57942089|NCT01868256|OTHER|Conventional discharge|
57942090|NCT02383095|BEHAVIORAL|Art therapy|
57942091|NCT02383095|BEHAVIORAL|metacognitive therapy|
57942092|NCT04223895|DRUG|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
57942093|NCT04223895|DRUG|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
57942094|NCT04223895|DRUG|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
57942095|NCT01944683|OTHER|Placebo|
57942096|NCT01944683|DRUG|GGF2|
57942097|NCT01944683|DRUG|Midazolam|
57942098|NCT01543828|DRUG|indacaterol|delivered via single-dose dry-powder inhaler
57942099|NCT01543828|DRUG|placebo|delivered via single-dose dry-powder inhaler
57942100|NCT02554903|DRUG|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
57942101|NCT02554903|DRUG|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
57942102|NCT04857801|DRUG|Teduglutide|effect of teduglutide on intestinal rehabilitation
57942103|NCT04603885|BEHAVIORAL|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
57942104|NCT04603885|BEHAVIORAL|Stretching exercise|stretching exercise
57942105|NCT05772754|GENETIC|study of molecular and protein pathways|42 ml peripheral venous blood sample.
58077046|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
58296890|NCT03834025|BEHAVIORAL|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
57942106|NCT05823415|PROCEDURE|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
57942107|NCT05823415|PROCEDURE|CAF with CTG|Gold standard surgical technique
57942108|NCT04533555|GENETIC|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
57942109|NCT04533555|GENETIC|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
57942110|NCT00095875|DRUG|carboplatin|Given IV
57942111|NCT00095875|DRUG|cisplatin|Given IV
57942112|NCT00095875|DRUG|docetaxel|Given IV
57942113|NCT00095875|DRUG|fluorouracil|Given IV
57942114|NCT01369420|DEVICE|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
57942115|NCT04123236|OTHER|Age 0-18|Patients under 18 years of age
57942116|NCT04123236|OTHER|Age 18-26|Patients over18 years of age
57942117|NCT04123236|OTHER|Girls|Girls
57942118|NCT04123236|OTHER|Boys|Boys
57942119|NCT05606081|DEVICE|Logistic regression risk model|Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
58077047|NCT00000131|PROCEDURE|Photocoagulation Therapy|
58077048|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
58077049|NCT02691845|BEHAVIORAL|BA (brief advice)|
58077050|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
58077051|NCT02691845|BEHAVIORAL|HE (health education)|
58077052|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
58077053|NCT00004808|DRUG|fluconazole|
58077054|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
58077055|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
58077056|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
58296891|NCT03834025|BEHAVIORAL|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
58296892|NCT03834025|BEHAVIORAL|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
58408165|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
57942120|NCT03533972|DRUG|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
57942121|NCT03533972|OTHER|Placebo|placebo capsules given twice daily after meals for 1 month
57942122|NCT05560373|DRUG|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
58408166|NCT00221806|DEVICE|endothelialised prosthesis|
58408167|NCT00012129|DRUG|liposomal annamycin|
58408168|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
58408169|NCT01299857|DRUG|Rituximab|375mg/m2
58408170|NCT02924714|OTHER|Discontinuation of imatinib|
58408171|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
58408172|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
57942123|NCT05560373|OTHER|operational treatment, the best basic treatment|other
57942124|NCT05560373|DRUG|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
57942125|NCT05560373|OTHER|Interventional treatment, the best basic treatment|other
58296893|NCT03834025|BEHAVIORAL|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
57942126|NCT05895682|DEVICE|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70\~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
57942127|NCT03078374|DRUG|Warfarin|Reduced dosage to obtain lower INR range
57951305|NCT02560376|DRUG|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
58296894|NCT03834025|BEHAVIORAL|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
58296895|NCT03834025|BEHAVIORAL|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
58077057|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
57942128|NCT01380379|BEHAVIORAL|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
57942129|NCT01127659|DRUG|testosterone|intramuscular every 2 weeks
57942130|NCT01127659|DRUG|placebo|saline intramuscular every 2 weeks
57942131|NCT00520728|BEHAVIORAL|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
58077058|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
58077059|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
58077060|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
58077061|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
58077062|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
58077063|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
58077064|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
58077065|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
58077066|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
58077067|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
58077068|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
58408173|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
58408174|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
57942132|NCT03777540|PROCEDURE|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
57942133|NCT04060082|OTHER|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
57942134|NCT05417607|BEHAVIORAL|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
58077069|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
58077070|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
58077071|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
58408175|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
58408176|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
58408177|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
58408178|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
58408179|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
58296896|NCT03834025|BEHAVIORAL|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
57942135|NCT05340361|DEVICE|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
57942136|NCT05340361|DEVICE|Optical coherence tomography-guided Onyx family stent expansion|"1. Expansion of 2.25, 3.0, and 4.0 mm Onyx family stent@ nominal pressure~2. OCT pullback~3. Expansion with over 0.5mm sized non-compliant balloon of each stent~4. OCT pullback~5. Expansion with over 1.0mm sized non-compliant balloon of each stent~6. OCT pullback~7. Expansion with over 1.25\~1.5mm sized non-compliant balloon of each stent~8. OCT pullback~9. Evaluation of polymer status with overexpansion assessed by an electric microscope"
57942137|NCT02429726|DRUG|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
57942138|NCT02429726|DRUG|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
57942139|NCT02429726|DRUG|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
57942140|NCT04252053|OTHER|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
57731261|NCT05419648|BIOLOGICAL|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
57942141|NCT04252053|OTHER|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
57942142|NCT01788384|DRUG|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
57942143|NCT01788384|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
57942144|NCT01788384|DRUG|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
58296897|NCT05722262|DRUG|K-001|K-877-ER and CSG452 combination tablet
58296898|NCT05722262|DRUG|K-877-ER|K-877-ER tablet
58296899|NCT05722262|DRUG|CSG452|CSG452 tablet
58296900|NCT03307928|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
58296901|NCT03307928|DIAGNOSTIC_TEST|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
58408180|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
57942145|NCT02108860|DRUG|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
57942146|NCT02108860|DRUG|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
57942147|NCT03620890|DRUG|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
57731262|NCT05169359|BEHAVIORAL|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
57731263|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
58408181|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
58408182|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
58408183|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
58408184|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
58408185|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
57731264|NCT05477355|BEHAVIORAL|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
57731265|NCT02762526|PROCEDURE|Lipoabdominoplasty|
57731266|NCT05082090|PROCEDURE|Spinal Surgery|Implanted with Orthofix Spinal products
57731267|NCT00692172|DRUG|Alefacept|intramuscular injection (IM)
57731268|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
57731269|NCT06530407|OTHER|Static streching exercise|Static stretching exercises were applied to the M. Gastrocnemious and M. Hamstring muscle groups. The exercises were applied as a set, with three repetitions for 15 seconds on each leg, with a 20-second rest between repetitions. Static stretching was applied by slowly stretching the relevant muscle group to the point of sensitivity, without straining the pain threshold, and waiting in that position. All stretching exercises lasted an average of 6 minutes.
57731270|NCT03094572|OTHER|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
57731271|NCT03574168|BIOLOGICAL|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
57731272|NCT02568787|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
57731273|NCT02568787|DIETARY_SUPPLEMENT|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
57731274|NCT06357728|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
57942148|NCT03620890|DRUG|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
58408186|NCT00112411|DRUG|Bronchodilator|
58408187|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
58408188|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
58408189|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
58408190|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
58408191|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
57731275|NCT02997358|DRUG|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
57731276|NCT02997358|DRUG|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
57731277|NCT03177304|OTHER|Web based IPT Training|
57731278|NCT06152536|OTHER|Vegetarian Meal|"meal with vegetarian protein and meal with animal protein"
57942149|NCT00069927|DRUG|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
57942150|NCT00069927|DRUG|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
57942151|NCT05299775|DIAGNOSTIC_TEST|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
57942152|NCT00105248|BEHAVIORAL|patient-centered communication training|
57942153|NCT00129168|DRUG|Zosuquidar|
57942154|NCT00129168|DRUG|Daunorubicin|
57942155|NCT00129168|DRUG|Cytarabine|
57942156|NCT00101751|DRUG|biphasic insulin aspart|
57942157|NCT00101751|BEHAVIORAL|dietary regimen|
57942158|NCT06089148|DIAGNOSTIC_TEST|contrast enhanced digital mammography, tomosyntheis and MRI|
57942159|NCT02951286|DEVICE|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
57942160|NCT02951286|DEVICE|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
57942161|NCT02925702|DRUG|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
57942162|NCT03979690|DEVICE|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
57942163|NCT05899881|BEHAVIORAL|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
57942164|NCT04428463|PROCEDURE|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
57942165|NCT04428463|PROCEDURE|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
58408192|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
57942166|NCT04265716|OTHER|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
57942167|NCT06295367|OTHER|Best Practice|Receive PAF brochure describing financial navigation services
57942168|NCT06295367|OTHER|Financial Navigation|Receive CostCOM financial counseling
57942169|NCT06295367|OTHER|Interview|Participate in a 1 on 1 in-depth interview
57942170|NCT06295367|OTHER|Survey Administration|Ancillary studies
57942171|NCT03416270|DRUG|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
57942172|NCT03416270|DRUG|Placebo|Placebo once daily for 12 weeks
57942173|NCT01824511|BEHAVIORAL|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
57942174|NCT01966614|DRUG|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
57942175|NCT01966614|OTHER|Placebo|Single intraprostatic bilateral injection of vehicle only
57942176|NCT00458796|DRUG|zoledronic acid|
57942177|NCT00458796|PROCEDURE|quality-of-life assessment|
57942178|NCT01093274|DRUG|Sodium Picosulphate|2 Sachets
57942179|NCT01093274|DRUG|Polyethylene Glycol|3 Liters solution
57942180|NCT04898920|DRUG|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
57942181|NCT04898920|DRUG|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
57942182|NCT00545597|DRUG|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
57942183|NCT03850600|OTHER|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
57942184|NCT03134742|OTHER|Control Group|No interventions this is the control group-no additional scans
57942185|NCT03134742|DIAGNOSTIC_TEST|CT Scan|CT Scan of affected and contralateral limb
57942186|NCT03134742|DIAGNOSTIC_TEST|DEXA Scans|DEXA Scan of affected and contralateral limb
58077072|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
58296902|NCT03796312|BEHAVIORAL|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
58296903|NCT03796312|BEHAVIORAL|Sponge Bathing|Sponge bathing is routine care of the clinic
58296904|NCT02318849|BEHAVIORAL|Web intervention|interactive website using social media and gamification
58408193|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
57731279|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
57731280|NCT05360979|DRUG|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
57731281|NCT03859323|DRUG|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
57942187|NCT03134742|DIAGNOSTIC_TEST|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
57942188|NCT00051675|DRUG|ING-1(heMAb)|
58408194|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
58408195|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
57731282|NCT03859323|OTHER|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
57942189|NCT04358263|DEVICE|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
57942190|NCT04358263|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
57942191|NCT03754140|DRUG|Polidocanol Injection|Sclerotic agent
58077073|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
58077074|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
58077075|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
58077076|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
58077077|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
58077078|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
58077079|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
58077080|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
58077081|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
58077082|NCT04833465|OTHER|No Intervention|No Intervention
58077083|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
58296905|NCT01575171|BEHAVIORAL|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
58296906|NCT02513004|DRUG|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
58296907|NCT02513004|DRUG|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
58296908|NCT05983796|DIAGNOSTIC_TEST|18F-HER2 PET|18F-HER2 PET
58408196|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
58077084|NCT04707768|DRUG|Vadadustat|oral tablets
58077085|NCT04707768|DRUG|Mircera®|intravenous administration
58077086|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
58077087|NCT05483062|OTHER|galla chinensis|toothpaste
58077088|NCT05483062|OTHER|Stannous fluoride|Toothpaste
58077089|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
58077090|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
58077091|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
58077092|NCT02263976|DRUG|BEA 2180 BR|
58077093|NCT02263976|DRUG|Placebo|
57942192|NCT00527436|DIETARY_SUPPLEMENT|fish oil|Fish oil pills will be taken daily for 12 weeks
58077094|NCT02263976|DEVICE|Respimat® A 4|
58077095|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
58077096|NCT02263976|DRUG|Spiriva|
58077097|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
58077098|NCT03478982|DRUG|Placebos|single dose for inhalation
58077099|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
58077100|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
58077101|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
58077102|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
58296909|NCT04001010|DRUG|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
57731283|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
58296910|NCT04001010|DRUG|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
58296911|NCT05459909|DIETARY_SUPPLEMENT|Synbiotic supplementation|Daily supplementation of synbiotic
58296912|NCT05459909|BEHAVIORAL|Dietary intervention|Increased fruits and vegetables consumption
58296913|NCT05225025|BEHAVIORAL|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
58408197|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
58408198|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
58408199|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
57731284|NCT00326235|DRUG|Buspirone|
57731285|NCT01873794|DEVICE|Bright white light|
58077103|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
58077104|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
58296914|NCT05225025|OTHER|Standard of Care|Usual hospital care with no behavioral intervention
58296915|NCT00922116|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
58296916|NCT04630223|DIAGNOSTIC_TEST|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
58296917|NCT00437996|DRUG|Clonidine|
58296918|NCT00437996|DRUG|Levobupivacaine|
58296919|NCT00437996|DRUG|Sufentanil|
58408200|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
57731286|NCT01873794|DEVICE|Dim red light|
57731287|NCT00120172|DRUG|oxaliplatin, capecitabine, bevacizumab|
57731288|NCT05620758|OTHER|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
57731289|NCT05620758|OTHER|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
57731290|NCT05620758|OTHER|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
57731291|NCT05620758|OTHER|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
57731292|NCT05620758|OTHER|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
58296920|NCT00616746|DRUG|Nicotine|1.0 microg/kg/min IV x 10 minutes
58296921|NCT00616746|DRUG|Ethanol|IV
58296922|NCT05724342|DRUG|rhTNK-tPA Thrombolysis|rhTNK-tPA Thrombolysis
58408201|NCT00314717|BEHAVIORAL|Control diet|
58408202|NCT00314717|BEHAVIORAL|Low GI diet|
58408203|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
58408204|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
58408205|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
58408206|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
57731293|NCT03669029|DRUG|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
58077105|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
58408207|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
58408208|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
58408209|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
58408210|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
58408211|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
58408212|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
58408213|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
58408214|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
58408215|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
58408216|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
58408217|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
58408218|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
58408219|NCT02830347|DRUG|Amoxicillin|Extraction
58408220|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
58408221|NCT01869361|DRUG|Indomethacin|Study drug
58408222|NCT01869361|DRUG|Placebo|Control drug
57731294|NCT03669029|DRUG|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
57731295|NCT00601926|BIOLOGICAL|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
57731296|NCT05851404|PROCEDURE|Thyroidectomy|Total thyroidectomy or lobectomy
58077106|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
58077107|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
58077108|NCT00491595|DRUG|High Dose Soy isoflavones|
58408223|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
58408224|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
58408225|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
58408226|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
57731297|NCT03033303|BIOLOGICAL|Hu3F8|Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
57731298|NCT03033303|DRUG|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
58077109|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
58077110|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
58296923|NCT05411393|OTHER|ADL-enhanced program|The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.
58296924|NCT05411393|OTHER|Usual home health rehabilitation therapy|Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
58408227|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
58408228|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
58296925|NCT03019900|PROCEDURE|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
57731299|NCT03033303|DRUG|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
58077111|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
58296926|NCT01625871|DRUG|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
58296927|NCT02415192|DRUG|Levacalm|
58296928|NCT02415192|DRUG|Valsartan/amlodipine|
58296929|NCT06136468|BEHAVIORAL|Virtual coach|The virtual coch will be displayed to the participants using an optical see-through head-mounted display
58296930|NCT06239610|DEVICE|electromagnetic placement device|Daily use of an EMPD to verify FT position
58296931|NCT03905837|DRUG|Lidocaine|Intravenous or paravertebral lidocaine
58296932|NCT03905837|DRUG|Remifentanil|intravenous remifentanil
58296933|NCT00033319|DIETARY_SUPPLEMENT|folic acid|
58296934|NCT00033319|DRUG|acetylsalicylic acid|
58408229|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
58408230|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
58408231|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
58408232|NCT05617053|DEVICE|DAART|
58408233|NCT05617053|DEVICE|ATP/Supera stenting|
58296935|NCT02479074|DRUG|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
58296936|NCT02479074|DRUG|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
58296937|NCT02479074|DRUG|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
58077112|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
58077113|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
58077114|NCT02631434|PROCEDURE|sit-to-stand test|
58077115|NCT02631434|PROCEDURE|six-minutes walking test|
58408234|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
58408235|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
58408236|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
58408237|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
58408238|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
58077116|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
58296938|NCT03296969|PROCEDURE|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
58296939|NCT03296969|PROCEDURE|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
58296940|NCT02267915|DRUG|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
58296941|NCT00248651|DRUG|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
58296942|NCT00248651|DRUG|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
58296943|NCT00248651|DRUG|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
58296944|NCT02435303|DRUG|Sildenafil|
58408239|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
58408240|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
58408241|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
58296945|NCT02435303|DRUG|Placebo|
58296946|NCT03072667|DRUG|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
58296947|NCT01151345|DRUG|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
58296948|NCT01151345|DRUG|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
58408242|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
58408243|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
58408244|NCT01442506|OTHER|biopsies|taking biopsies
58408245|NCT01442506|OTHER|biopsy|biopsy
58408246|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
58408247|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
58408248|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
58408249|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
58408250|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
58296949|NCT02718911|DRUG|LY3022855|Administered IV
58296950|NCT02718911|DRUG|Durvalumab|Administered IV
58296951|NCT02718911|DRUG|Tremelimumab|Administered IV
58296952|NCT01450813|DRUG|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
58296953|NCT01450813|DRUG|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
58296954|NCT01450813|DRUG|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
58296955|NCT01450813|DRUG|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
58296956|NCT03043742|DRUG|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
57731300|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
57731301|NCT03721380|BEHAVIORAL|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
57942193|NCT00527436|DIETARY_SUPPLEMENT|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
57942194|NCT03422562|DIETARY_SUPPLEMENT|Florababy|Probiotic supplement
57942195|NCT05414981|DRUG|ABI-H3733|25 mg or 100 mg tablets for oral administration
58296957|NCT03639857|DEVICE|532nm laser|532nm laser will be used to treat the lesion in this study arm.
58408251|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
58408252|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
58408253|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
58408254|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
58408255|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
57942196|NCT05414981|DRUG|Placebo|25 mg or 100 mg tablets for oral administration
57942197|NCT00003440|DRUG|paclitaxel|Given IV over 1 hour or 3 hours
57942198|NCT00003440|BIOLOGICAL|trastuzumab|Given IV
57942199|NCT00003440|PROCEDURE|quality-of-life assessment|Ancillary studies
57942200|NCT00003440|OTHER|laboratory biomarker analysis|Correlative studies
57942201|NCT03361150|PROCEDURE|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
57942202|NCT03361150|PROCEDURE|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
57942203|NCT02988180|OTHER|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
57942204|NCT02988180|OTHER|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
57942205|NCT00806247|DRUG|tapentadol HCl|
57942206|NCT04186975|DEVICE|Non-Invasive fetal ECG|Non-Invasive fetal ECG
57942207|NCT04186975|DEVICE|Fetal heart rate monitor|Fetal heart rate monitor
57942208|NCT02559297|DRUG|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
57942209|NCT02559297|DRUG|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
57942210|NCT00277186|OTHER|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
57942211|NCT00665873|DEVICE|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
57942212|NCT00665873|DRUG|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
57942213|NCT02039804|DRUG|Corticosteroids|Intra-bursal injection
57942214|NCT02039804|DEVICE|Hyaluronic acid|Intra-bursal injection
58077117|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
58408256|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
58408257|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
57942215|NCT06389981|OTHER|Veterans peer connect Program|To assess outcomes of the Peer-led program, the study team will collect information from Veteran pilot test participants via surveys and data abstraction on healthcare utilization (Lung cancer screening completion, tobacco treatment) from the Veterans Affairs Corporate Data Warehouse. Survey data will be collected at 3 timepoints: baseline, post-Peer-led orientation, and 3-months post-enrollment. Healthcare utilization data will be abstracted from the corporate data warehouse to reflect the 3-month post-enrollment timepoint. Finally, interviews will be conducted with a subset of participants.
57942216|NCT06293248|OTHER|musical application|Rast, Acemasiran, and Huseyni from Classical Turkish Music modes were optionally offered to the patients in the music group, and the patient's preferred music was listened to through headphones for 15-20 minutes before the CAG procedure. Following the interviews, musical genres were arranged as instrumental, without words, at 70 decibels in terms of rhythm and duration, at approximately 60 metronomes per minute, and were played according to the person's preference. Instrumental music was loaded onto the portable MP3 player provided by the researchers.
57942217|NCT01771055|PROCEDURE|Galactose|Galactose dripped into the abdomen after surgery
57942218|NCT01771055|PROCEDURE|Standard surgical methods|
57942219|NCT01520311|DEVICE|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
58077118|NCT06722495|RADIATION|SBRT|Patient will receive SBRT (8Gy\*3F) in combination with the original regimen of neoadjuvant immunochemotherapy in course 3. Gross tumor target volume (GTV) based on the primary foci clearly identified by clinical and imaging examinations. The GTV was discharged 3 mm to generate a Planning target volume (PTV). the target area (PTV) was dosed accordingly to the PTV.
58077119|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
58296958|NCT03639857|DEVICE|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
58296959|NCT03639857|DRUG|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
58296960|NCT00437476|DRUG|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
58296961|NCT00437476|DRUG|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
58296962|NCT00437476|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
58296963|NCT00437476|DRUG|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
58296964|NCT03747848|BEHAVIORAL|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
58296965|NCT02511925|OTHER|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
58296966|NCT02511925|OTHER|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
58296967|NCT02511925|OTHER|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
58296968|NCT00095979|DRUG|ixabepilone|Given IV
58296969|NCT04331691|DRUG|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
58408258|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
58408259|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
58408260|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
58408261|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
58408262|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
58408263|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
58408264|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
58408265|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
58408266|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
58408267|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
58408268|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
58408269|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
58408270|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
58408271|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
58408272|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
57731302|NCT02609243|BEHAVIORAL|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
57731303|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
57942220|NCT02466867|DRUG|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
57942221|NCT02466867|DRUG|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
57942222|NCT01523496|DRUG|Vitamin D control dose|18,000 IU per month
57942223|NCT01523496|DRUG|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
57942224|NCT00750698|DRUG|Entinostat|Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
57942225|NCT00750698|DRUG|Erlotinib|Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
57942226|NCT01056510|DRUG|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
57942227|NCT01056510|DRUG|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
58296970|NCT04331691|DRUG|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
58296971|NCT06008119|DRUG|Tunlametinib plus Vemurafenib|12mg BID Tunlametinib+720mg BID Vemurafenib
58296972|NCT06008119|DRUG|Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab|According to investigators' suggestion
58296973|NCT04718870|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
58296974|NCT02548624|DEVICE|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
58296975|NCT04801251|DIAGNOSTIC_TEST|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
57942228|NCT01056510|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
57942229|NCT04416555|DEVICE|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
57942230|NCT04416555|DEVICE|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
58408273|NCT05785741|DRUG|DB-1310|Administered I.V.
57942231|NCT00121433|DRUG|leptin|
58408274|NCT05785741|DRUG|Trastuzumab|Administered I.V.
58408275|NCT05785741|DRUG|Osimertinib|Administered I.V.
57942232|NCT03804736|BIOLOGICAL|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
58408276|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
58408277|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
58408278|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
58408279|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
58408280|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
58408281|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
58408282|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
58408283|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
58408284|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
58408285|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
58408286|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
57942233|NCT03804736|BIOLOGICAL|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
58296976|NCT00516100|DRUG|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
58408287|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
58408288|NCT00825058|DRUG|paroxetine|oral 20 mg/day
58408289|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
58408290|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
58408291|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
58408292|NCT02229214|DRUG|Qsymia|
58408293|NCT02229214|DRUG|Placebo|
58408294|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
58408295|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
58408296|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
58408297|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
58408298|NCT01806025|OTHER|no intervention|
58408299|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
58408300|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
57731304|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
57731305|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
57942234|NCT00793260|BEHAVIORAL|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
57942235|NCT00793260|BEHAVIORAL|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
57942236|NCT04269148|OTHER|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
57942237|NCT06426251|DEVICE|Photobiomodulation|Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
57942238|NCT00928889|DRUG|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
58408301|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
58408302|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
58296977|NCT04614298|DRUG|KHK4827-Active|Single SC administration
58296978|NCT04614298|DRUG|KHK4827-Placebo|Single SC administration
57731306|NCT03674177|DRUG|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
57731307|NCT05738395|DIAGNOSTIC_TEST|Questions|Questions
57731308|NCT01437592|DRUG|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
57731309|NCT02460991|DEVICE|DEB-TACE|
57731310|NCT02460991|DRUG|Sorafenib|
58296979|NCT05235360|BEHAVIORAL|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
58296980|NCT05235360|BEHAVIORAL|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
58408303|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
58408304|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
58408305|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
58408306|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
58408307|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
58408308|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
58408309|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
58408310|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
58408311|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
58408312|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
58408313|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
58408314|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
57942239|NCT00928889|DRUG|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
58077120|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
58077121|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
58077122|NCT03628872|PROCEDURE|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
58408315|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
58408316|NCT02029716|DRUG|Lotion vehicle/placebo|
58408317|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
58077123|NCT03628872|DEVICE|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
58408318|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
58408319|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
58408320|NCT00000429|DRUG|Calcium carbonate|
58408321|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
58408322|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
58408323|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
58408324|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
57942240|NCT00089050|DRUG|cyclosporine|
57942241|NCT00089050|DRUG|gemtuzumab ozogamicin|
58296981|NCT05235360|BEHAVIORAL|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
57942242|NCT00196638|DRUG|Antiretroviral combination (drugs)|
57942243|NCT00196638|DRUG|Pegylated Interferon alpha (drug)|
57942244|NCT02554747|DEVICE|Navigated laser|Aflibercept, Navilas®
57942245|NCT02554747|DEVICE|Conventional laser|Aflibercept, Pascal
57942246|NCT04183816|OTHER|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
57942247|NCT04183816|OTHER|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
57942248|NCT06473311|DEVICE|whole bady vibration and virtual reality|study group I received a whole body vibration program in addition to a conventional physical therapy program, and study group II received a Wii-fit therapy program (a virtual reality treatment program) in addition to the same. A two-month treatment program was implemented for both groups. Every child in both groups had the same evaluation processes, which included using the Physical Self Maintenance Scale (PSMS) for daily living activities and a dynamometer to measure quadriceps muscular strength. Evaluation was done prior to the start of treatment and was done again after one month (post I) and two months (post II).
57942249|NCT00209014|DRUG|Thalidomide|
57942250|NCT00161187|BIOLOGICAL|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
57942251|NCT02341638|DRUG|BMS-986141|
57942252|NCT02341638|DRUG|Placebo|
57942253|NCT02341638|DRUG|Aspirin|
57942254|NCT02341638|DRUG|Itraconazole|
57942255|NCT02802748|DRUG|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
57942256|NCT02802748|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
58077124|NCT03628872|DEVICE|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
57942257|NCT01553136|DRUG|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
57942258|NCT05103878|DRUG|BT051 100mg|Single oral dose of 100mg BT051
57942259|NCT05103878|DRUG|BT051 300mg|Single oral dose of 300mg BT051
57942260|NCT05103878|DRUG|BT051 700mg|Single oral dose of 700mg BT051
57942261|NCT05103878|DRUG|BT051 1500mg|Single oral dose of 1500mg BT051
57942262|NCT05103878|DRUG|BT051 3500mg|Single oral dose of 3500mg BT051
58077125|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
58077126|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
57942263|NCT05103878|DRUG|Matching Placebo|Placebo Matching BT051
57942264|NCT01677156|DIAGNOSTIC_TEST|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
57942265|NCT04664361|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
57942266|NCT04664361|OTHER|Placebo|Daily supplementation with placebo for 38 days in total
57942267|NCT01864499|PROCEDURE|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
58077127|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
58077128|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
58296982|NCT05235360|BEHAVIORAL|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
57942268|NCT04137120|DRUG|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
57942269|NCT03450291|OTHER|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
57942270|NCT03913702|DRUG|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
57942271|NCT03913702|DRUG|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
57942272|NCT02386280|BEHAVIORAL|Motivational Interviewing for Change of Parenting Styles|
57942273|NCT02386280|BEHAVIORAL|Psicoeducation|
57942274|NCT02490475|DRUG|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
57942275|NCT02490475|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
57942276|NCT05125055|DRUG|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
57942277|NCT05125055|DRUG|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
57942278|NCT05125055|DRUG|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
57942279|NCT05125055|DRUG|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
57942280|NCT05125055|DRUG|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
57942281|NCT06149390|DRUG|consolidation with ASCT|high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
58077129|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
58077130|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
58077131|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
58077132|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
58077133|NCT00005990|DRUG|tipifarnib|
58077134|NCT00005990|DRUG|topotecan hydrochloride|
58077135|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
58077136|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
58077137|NCT00602082|DRUG|capecitabine|
58077138|NCT00602082|DRUG|cisplatin|
58296983|NCT05235360|BEHAVIORAL|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
58296984|NCT05235360|BEHAVIORAL|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
58296985|NCT05235360|BEHAVIORAL|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
58408325|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
58408326|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
58408327|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
57942282|NCT04577729|PROCEDURE|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
57942283|NCT04577729|PROCEDURE|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
57942284|NCT06189495|DRUG|GenSci048|1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
57942285|NCT06189495|DRUG|GenSci048 placebo|"1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
57942286|NCT02470468|BIOLOGICAL|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
57942287|NCT02470468|BIOLOGICAL|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
57942288|NCT02470468|OTHER|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
58077139|NCT00602082|DRUG|streptozocin|
58077140|NCT00602082|GENETIC|DNA analysis|
58077141|NCT00602082|GENETIC|RNA analysis|
58077142|NCT00602082|GENETIC|protein analysis|
58077143|NCT00602082|GENETIC|proteomic profiling|
58077144|NCT00602082|OTHER|laboratory biomarker analysis|
58077145|NCT00002600|BIOLOGICAL|filgrastim|
58077146|NCT00002600|DRUG|carboplatin|
58077147|NCT00002600|DRUG|cyclophosphamide|
58077148|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
58077149|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
58077150|NCT00138723|DRUG|SPM 907|
58077151|NCT00372658|DRUG|1% Lidocaine intracervical injection|
58296986|NCT03878823|DRUG|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
58408328|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
58077152|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
58077153|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
58077154|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
58408329|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
58408330|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
57942289|NCT05201027|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
57942290|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
57942291|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
57942292|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
57942293|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
57942294|NCT06428084|DRUG|Ondansetron|4 mg of ondansetron intravenously
57942295|NCT06428084|DRUG|Haloperidol|1 mg of Haloperidol intravenously
57942296|NCT06399523|DEVICE|VR therapy|Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.
57942297|NCT06399523|DEVICE|VR sham|Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
57942298|NCT03621332|OTHER|Questionnaire|Online/paper questionnaires
57942299|NCT00546299|DRUG|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
57942300|NCT06118151|BIOLOGICAL|Influenza Hemagglutinin mRNA vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
57942301|NCT06118151|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
58296987|NCT00984932|DRUG|Rosuvastatin|40 mg of rosuvastatin daily
58296988|NCT02899065|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
58296989|NCT02899065|OTHER|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
58296990|NCT02381613|OTHER|Baked beef|A meal based on baked beef
57942302|NCT06229106|DEVICE|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
57942303|NCT06229106|DEVICE|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
58077155|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
58296991|NCT02381613|OTHER|Baked herring|A meal based on baked herring
58296992|NCT02381613|OTHER|Pickled herring|A meal based on pickled herring
57942304|NCT04689204|DRUG|CTA30X|CTA30X cell injection by intravenous infusion
57942305|NCT04267770|DRUG|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
57942306|NCT04267770|DRUG|Insulin (flat rate)|Participant's own insulin set to flat basal rates
57942307|NCT06323603|OTHER|Micro and nanoplastic|Biological samples will be obtained to evaluate the different biomarkers selected
57942308|NCT01274819|OTHER|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
57942309|NCT04861675|PROCEDURE|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
57942310|NCT03991806|OTHER|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
58296993|NCT03060304|DRUG|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
58296994|NCT03060304|DRUG|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
58296995|NCT00005743|BEHAVIORAL|exercise|
58296996|NCT00005743|BEHAVIORAL|weight loss|
57942311|NCT00461344|DRUG|Docetaxel|
57942312|NCT00461344|DRUG|Doxorubicin|
57942313|NCT05675540|DEVICE|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
58296997|NCT04464291|OTHER|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
58296998|NCT00061841|BEHAVIORAL|exercise|
57942314|NCT04092348|OTHER|complete blood count|"1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
57942315|NCT00094692|DEVICE|Eye patch|
58077156|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
58077157|NCT01439308|DRUG|Placebo|SB-705498 placebo
58077158|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
58296999|NCT01877200|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
58408331|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
57942316|NCT00094692|DEVICE|spectacles|
58077159|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
58297000|NCT03450759|DRUG|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
58297001|NCT03450759|DRUG|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
58297002|NCT03450759|DRUG|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
58408332|NCT03054350|DRUG|Vadadustat|Daily oral dose
58408333|NCT03054350|DRUG|Placebo|Daily oral dose
58408334|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
57942317|NCT00094692|DRUG|atropine|
57942318|NCT03371433|OTHER|Soft drinks|Caffeine and Caffeine free soft drinks
57942319|NCT04171479|DEVICE|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
57942320|NCT00159757|DRUG|ziprazidone|
57942321|NCT00770770|DRUG|Fluocinolone Acetonide|0.2 µg/day
57942322|NCT00770770|DRUG|Fluocinolone Acetonide|0.5 µg/day
58077160|NCT02711085|OTHER|No intervention|No intervention - observational study
58408335|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
57942323|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
57942324|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
57942325|NCT03209206|DRUG|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
57942326|NCT03209206|DRUG|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
57942327|NCT01429584|DRUG|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
57942328|NCT01429584|DRUG|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
57942329|NCT03883191|OTHER|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
58077161|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
58077162|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
58077163|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every 3 weeks intravenously for 5 doses and then every 6 weeks thereafter.
58077164|NCT06373380|OTHER|Placebo|Patients in the placebo arm will be receiving vehicle on the same schedule. Patients will receive treatment with HB-200 alternating therapy or placebo until recurrence or for a total duration of 1 year.
58077165|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
58077166|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
58077167|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
58077168|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
58297003|NCT03450759|DRUG|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
58297004|NCT01997034|BEHAVIORAL|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
58297005|NCT06291766|DEVICE|FreeStyle Libre 2, continous glucose monitoring|The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
58408336|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
57731311|NCT04040803|DEVICE|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
57731312|NCT02747342|DRUG|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
58408337|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
57942330|NCT03883191|OTHER|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
58408338|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
58408339|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
58408340|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
57942331|NCT01329445|OTHER|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
57942332|NCT02106286|DRUG|Bisoprolol|
57942333|NCT03945357|DRUG|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
57942334|NCT03945357|DRUG|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
58077169|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
57942335|NCT03725579|DRUG|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
57942336|NCT03725579|DRUG|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
57942337|NCT05242731|DEVICE|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
57942338|NCT05242731|DEVICE|"Video calling program Better-close"|Video calling program.
57942339|NCT05242731|DEVICE|Researchmanager program|Case Report Form, Datamanagement program
58408341|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
58408342|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
58408343|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
58408344|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
58408345|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
58408346|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
57942340|NCT06043115|OTHER|covid-19 survival cohort|consists of surviving patients
57942341|NCT06043115|OTHER|covid-19 mortality cohort|consists of deceased patients
57942342|NCT03281668|BEHAVIORAL|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
57942343|NCT00742248|DRUG|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
57942344|NCT00742248|DRUG|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
58077170|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
58077171|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
58077172|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
58077173|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
58077174|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
58077175|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
58077176|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
58077177|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
58077178|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
58077179|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
58077180|NCT00116610|DRUG|picoplatin|
58077181|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
58077182|NCT02377258|OTHER|Non Interventional|
58408347|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
57731313|NCT06635967|DEVICE|frequency-specific rTMS|Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
58077183|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
58077184|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
58077185|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
58077186|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
58077187|NCT06062810|DRUG|Crizotinib - Usual|"* XALKORI - crizotinib capsule (high dose)~* XALKORI 250 mg taken orally twice daily"
58077188|NCT06062810|DRUG|Crizotinib - Study|"* XALKORI - crizotinib capsule (low dose)~* XALKORI 200 mg taken orally twice daily"
58077189|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
58077190|NCT06723483|PROCEDURE|Distraction Plate|This technique deals with comminuted distal radius fracture using a distraction plate. The plate was inserted by minimally invasive skin incisions, fixed from the 2end metacarpal distally to the 2end extensor compartment at intact radius proximally Spaning the comminution, Restoring the Radial Length, Radial Inclination, Volar Tilt
58077191|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
58408348|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
58408349|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
58408350|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
58408351|NCT00975104|DRUG|Placebo|Placebo IV QW
58408352|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
58077192|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
58077193|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
58408353|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
58408354|NCT00771732|DEVICE|light therapy|6 minute light therapy
58408355|NCT00771732|DEVICE|light therapy|combination of wavelengths
58408356|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
58408357|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
57731314|NCT06635967|DEVICE|1 Hz rTMS|Low-frequency rTMS will be performed at a frequency of 1Hz
57731315|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
57731316|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
57942345|NCT00742248|DRUG|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
58408358|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
58077194|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
58408359|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
58408360|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
58408361|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
58077195|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
58077196|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
58077197|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
57942346|NCT03350295|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
57942347|NCT00279019|DRUG|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
58077198|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
58077199|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
58408362|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
58408363|NCT02502669|DRUG|Placebo tablets|
58408364|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
58408365|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
58408366|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
58408367|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
58408368|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
58408369|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
58408370|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
58408371|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
58408372|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
58408373|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
58408374|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
58408375|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
57942348|NCT00279019|DRUG|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
58077200|NCT05403944|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
58408376|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
58408377|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
58408378|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
57942349|NCT00279019|DRUG|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
57942350|NCT04334707|PROCEDURE|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
57942351|NCT02484833|DRUG|Cetuximab|
57942352|NCT02484833|DRUG|FOLFIRI|
57942353|NCT00001520|DRUG|neostigmine|
57942354|NCT02193321|BIOLOGICAL|Amniotic Membrane Patch|
58408379|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
58408380|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
58408381|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
58408382|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
58408383|NCT00004206|DRUG|FOLFOX regimen|
58408384|NCT00004206|DRUG|fluorouracil|
58408385|NCT00004206|DRUG|leucovorin calcium|
58408386|NCT00004206|DRUG|oxaliplatin|
58408387|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
58408388|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
58408389|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
58408390|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
58408391|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
58408392|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
57942355|NCT02209298|DEVICE|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
57942356|NCT01565915|DEVICE|Perlane-L|Perlane-L Injection in the midface
57942357|NCT01565915|OTHER|Non-treatment|Non-treatment Arm
57942358|NCT01607424|BEHAVIORAL|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
57942359|NCT06000995|OTHER|Survey Questions|Thirty questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure.
57942360|NCT00263744|BIOLOGICAL|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
57942361|NCT00263744|OTHER|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
57942362|NCT05560542|DRUG|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
57942363|NCT03651453|BEHAVIORAL|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
58408393|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
58408394|NCT02427568|DRUG|MDMA (125 mg)|Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
58408395|NCT02427568|DRUG|Placebo|Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
58408396|NCT02427568|BEHAVIORAL|Therapy|Non-directive therapy
58408397|NCT00190138|DEVICE|Bi-ventricular pacing|
58408398|NCT00002955|DRUG|fluorouracil|
58408399|NCT00002955|DRUG|leucovorin calcium|
58408400|NCT00002955|DRUG|trimetrexate glucuronate|
58408401|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
58408402|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
58408403|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
58408404|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
58408405|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
58408406|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
58408407|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
58408408|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
58408409|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
58408410|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
57942364|NCT03651453|BEHAVIORAL|Standard care|Standard harm reduction information
57942365|NCT01666509|DEVICE|Rossoseq™|
57942366|NCT01666509|DEVICE|Placebo|
57942367|NCT01274715|BEHAVIORAL|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
57942368|NCT04417764|PROCEDURE|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
57942369|NCT04417764|BIOLOGICAL|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10\^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
57942370|NCT03782402|DRUG|Cannabinoids|Cannabinoids with THC and CBD versus placebo cannabinoids
57942371|NCT06155500|OTHER|OTQ923|There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
57942372|NCT03194386|OTHER|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
57942373|NCT03194386|OTHER|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
57942374|NCT03853811|DEVICE|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
57942375|NCT05058755|DRUG|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
57942376|NCT05058755|DRUG|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
57942377|NCT05546164|OTHER|Assessment of hand grip strength|Assessment of hand grip strength
57942378|NCT05546164|OTHER|Assessment of pinch strength|Assessment of pinch strength
57942379|NCT05546164|OTHER|Assessment of upper limb dexterity|Assessment of upper limb dexterity
57942380|NCT03184233|PROCEDURE|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
57942381|NCT03184233|PROCEDURE|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
57942382|NCT00321347|DRUG|Lidocaine|
57942383|NCT06476210|DRUG|BDL regimen|"Drug:bedaquiline 100mg tablets~Other Names:~Bdq TMC-207 bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week~Drug:delamanid 50mg tablets~Other Names:~Dlm OPC-67683 delamanid 100mg 2 times daily~Drug:linezolid Scored 600mg tablets~Other Names:~Lzd linezolid 600mg once daily"
57942384|NCT01997762|DIETARY_SUPPLEMENT|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
57942385|NCT01997762|DIETARY_SUPPLEMENT|Placebo|
57942386|NCT04290663|DRUG|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
57942387|NCT04290663|OTHER|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4\>1 ng/mL or rhTSH-sTg\>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
57942388|NCT04845321|DRUG|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
57942389|NCT04845321|DRUG|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
58408411|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
58408412|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
57942390|NCT02676999|PROCEDURE|Implantation of a Scheker total distal radioulnar joint prosthesis|
57942391|NCT05934747|DEVICE|DBS|Deep Brain Stimulation
57942392|NCT06245876|OTHER|Blood collection|Blood collection
57942393|NCT06410365|DRUG|Dexmedetomidine injection|Comparison of intravenous and intrathecal route of dexmedetomidine
57942394|NCT01150175|PROCEDURE|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
58408413|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
57942395|NCT01150175|PROCEDURE|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
58297006|NCT03414944|RADIATION|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
58297007|NCT04916717|OTHER|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
58297008|NCT03175614|OTHER|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
58408414|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
58297009|NCT03175614|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
58297010|NCT02930057|DRUG|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
58297011|NCT02930057|PROCEDURE|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
58297012|NCT02930057|DRUG|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
58297013|NCT03383991|PROCEDURE|Reverse Total Shoulder Arthroplasty|
58297014|NCT03383991|PROCEDURE|Hemiarthroplasty|
58297015|NCT04552132|DEVICE|Multisonic vs Sonic activation of irrigants|Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
58297016|NCT00327223|DRUG|imexon|
58297017|NCT01407991|OTHER|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
58297018|NCT01407991|OTHER|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
58297019|NCT00004102|DRUG|FOLFOX regimen|
58297020|NCT00004102|DRUG|fluorouracil|
58297021|NCT00004102|DRUG|leucovorin calcium|
58297022|NCT00004102|DRUG|oxaliplatin|
58297023|NCT05360407|OTHER|Using mobile information application about before and after surgery|"The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password."
58297024|NCT04190862|DRUG|E-CEL UVEC|Injection of E-CEL UVEC
58297025|NCT02762448|DRUG|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
58297026|NCT02361112|DRUG|pyrotinib combined with capecitabine|
58408415|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
57942396|NCT00113074|DRUG|Nicotine Replacement Therapy|Nicotine replacement therapy program
57942397|NCT00113074|BEHAVIORAL|Diet|Diet program
57942398|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
57942399|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
57942400|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
58297027|NCT00729716|BIOLOGICAL|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
58297028|NCT00729716|PROCEDURE|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
58297029|NCT06346847|DIETARY_SUPPLEMENT|Postbiotic|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
58297030|NCT06346847|DIETARY_SUPPLEMENT|Placebo|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
58077201|NCT05403944|BEHAVIORAL|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
58077202|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
58297031|NCT04250116|DRUG|NOAC monotherapy|Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
58297032|NCT04250116|DRUG|Dual antithrombotic therapy with NOAC and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
58297033|NCT03930095|BEHAVIORAL|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
58297034|NCT03930095|BEHAVIORAL|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
58297035|NCT02403050|DEVICE|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
58297036|NCT01858038|DEVICE|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
58297037|NCT00334789|DRUG|Belinostat|Given IV
57942401|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
57942402|NCT04312035|PROCEDURE|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
58408416|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
57942403|NCT04312035|PROCEDURE|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
58297038|NCT00334789|DRUG|Isotretinoin|Given orally
58297039|NCT00334789|OTHER|Pharmacological Study|Correlative studies
58408417|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
58408418|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
58077203|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
58077204|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
58077205|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
58297040|NCT05986981|DRUG|Vaccine|"Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects)."
58297041|NCT01265186|DEVICE|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
58297042|NCT01265186|DEVICE|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
57942404|NCT04312035|PROCEDURE|Control|hands-on cutaneous technique
57942405|NCT04187300|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
57942406|NCT05088642|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet
57942407|NCT06108713|OTHER|Addition of juggling|Participants will not change ther daily activities, and participate in juggling intervention lasted 4 weeks and consisted of 12 meetings (3 trainings per week), each lasting 45 minutes.
58297043|NCT05159557|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
58297044|NCT05159557|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
57942408|NCT02201121|OTHER|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
57942409|NCT06455917|DRUG|Combination of TIL Transfer and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses)."
58077206|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
58297045|NCT00238407|DRUG|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
58297046|NCT00238407|RADIATION|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
58297047|NCT01676051|OTHER|Skin culture|Culture swab used to culture skin adjacent to incision
57731317|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
58297048|NCT01804088|DEVICE|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
57731318|NCT04727866|DEVICE|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
58297049|NCT03961763|DIETARY_SUPPLEMENT|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
57731319|NCT00827034|DRUG|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
58297050|NCT03961763|OTHER|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
58297051|NCT06203509|BEHAVIORAL|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
58408419|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
57942410|NCT02107495|DEVICE|Samsung LABGEO IVD-A20 CHF Test|
57942411|NCT03761511|DRUG|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
57942412|NCT03761511|DRUG|Placebo|Matching Placebo (capsules) once daily
57942413|NCT03075813|OTHER|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
57942414|NCT03896542|DEVICE|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
58408420|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
57731320|NCT00827034|DRUG|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
57731321|NCT00827034|DRUG|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
57731322|NCT04936412|DEVICE|Rehabilitation brace|Rehabilitation brace
57942415|NCT03896542|DEVICE|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
57942416|NCT05187442|OTHER|questionnaire, interview|The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited.
57942417|NCT01149889|PROCEDURE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
58408421|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
58408422|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
58297052|NCT06262971|DEVICE|Percutaneous coronary intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
58297053|NCT03372798|PROCEDURE|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
57731323|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
57731324|NCT04768010|DRUG|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
57942418|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
58408423|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
57731325|NCT04578262|PROCEDURE|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
57942419|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
58077207|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
58077208|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
58408424|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
58077209|NCT00038428|DRUG|TLK286|
58077210|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
58297054|NCT01057355|PROCEDURE|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
58297055|NCT04074434|DEVICE|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
58297056|NCT00132080|DRUG|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
58297057|NCT00081887|DRUG|Clofarabine|Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
58297058|NCT01598610|DEVICE|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
58297059|NCT04753294|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
58297060|NCT04753294|DEVICE|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
58297061|NCT01703390|DRUG|FOLFIRI + Cetuximab|
58297062|NCT01703390|DRUG|modifiedFOLFOX6 + Cetuximab|
58297063|NCT04904471|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
58408425|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
58408426|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
58408427|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
58077211|NCT06713954|BEHAVIORAL|Dietary assessment|Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
57942420|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
57942421|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
57942422|NCT02423551|OTHER|MRE|MRE consumption
57942423|NCT05357690|PROCEDURE|Stellate ganglion block|Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
57942424|NCT05357690|DRUG|Bupivacaine|10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
57942425|NCT05357690|DRUG|Placebo|10 mL of saline injected in the plane of the right stellate ganglion
57942426|NCT05287945|DRUG|Orellanine|Orellanine administered intravenously
57942427|NCT02572674|OTHER|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
57942428|NCT02572674|GENETIC|Genetic sample|Blood samples
57942429|NCT02687542|DRUG|Placebo|Placebo
58077212|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
58077213|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
57942430|NCT02687542|DRUG|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
57942431|NCT02687542|DRUG|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
58077214|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
58077215|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
58077216|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
58077217|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
57942432|NCT02687542|DRUG|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
57942433|NCT02687542|DRUG|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
57942434|NCT00225979|DRUG|Octreotide LAR|
57942435|NCT05231499|OTHER|nasal irrigation|regular saline nasal rinse
58077218|NCT00277823|DRUG|DVS-SR 50 mg|
58077219|NCT00277823|DRUG|DVS-SR 100 mg|
58077220|NCT00277823|DRUG|Placebo|
58077221|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
58077222|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
58408428|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
58408429|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
57942436|NCT00333671|DRUG|Glycerol|
57942437|NCT05060263|DRUG|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
57942438|NCT04993040|DRUG|Oraxol|"* HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules"
57942439|NCT04791839|DRUG|Zimberelimab|Zimberelimab will be supplied by Arcus Biosciences.
57942440|NCT04791839|DRUG|Domvanalimab|Domvanalimab will be supplied by Arcus Biosciences.
58408430|NCT04946409|OTHER|no intervention|no intervention
57942441|NCT04791839|DRUG|Etrumadenant|Etrumadenant will be supplied by Arcus Biosciences.
57942442|NCT04310085|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
57942443|NCT04310085|BIOLOGICAL|PfSPZ-DVI Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
58408431|NCT01396265|DRUG|Afatinib|single dose
58408432|NCT01396265|DRUG|Afatinib|single dose
57942444|NCT00038727|BEHAVIORAL|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
57942445|NCT00038727|DRUG|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
57942446|NCT00038727|BEHAVIORAL|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
57942447|NCT00038727|BEHAVIORAL|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
57942448|NCT03345823|DRUG|Upadacitinib|Oral; Tablet
57942449|NCT03345823|DRUG|Placebo for Upadacitinib|Oral; Tablet
57942450|NCT04519411|DIAGNOSTIC_TEST|Transpulmonary pressure measurements|Transpulmonary pressure measurements
57942451|NCT04335942|OTHER|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
58408433|NCT01396265|DRUG|Rifampicin|multiple doses
58077223|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
57942452|NCT04335942|OTHER|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
57942453|NCT06402175|OTHER|follow up|follow up
57942454|NCT05111444|DRUG|Camrelizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion
58077224|NCT01830621|DRUG|BBI608|
58077225|NCT01830621|DRUG|Placebo|
58077226|NCT01830621|OTHER|Best Supportive Care|
58408434|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
58077227|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
58077228|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
58077229|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
58077230|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
58077231|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
58077232|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
58077233|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
58408435|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
58077234|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
58408436|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
58408437|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
58077235|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
58408438|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
58408439|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
58408440|NCT03158623|BIOLOGICAL|Cellerate|
58408441|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
58408442|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
58408443|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
58408444|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
57942455|NCT05111444|DRUG|Pyrotinib|320mg as continuous oral once daily on every 21 days
57942456|NCT05111444|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
57942457|NCT05111444|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
57942458|NCT05111444|DRUG|Paclitaxel|80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
57942459|NCT05111444|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
57942460|NCT00977236|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
57942461|NCT00977236|DEVICE|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
57942462|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
57942463|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
57942464|NCT02114164|DEVICE|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
57731326|NCT04578262|PROCEDURE|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
57942465|NCT02114164|DEVICE|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
58408445|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
58408446|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
58408447|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
58408448|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
57731327|NCT01343082|DRUG|DE-111 ophthalmic solution|
57731328|NCT02909777|DRUG|CUDC-907|
57731329|NCT05601479|DRUG|Acetyl-L-carnitine|At the beginning of the first chemotherapy of the oxaliplatin regimen, Acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks. If subjects discontinue oxaliplatin-containing chemotherapy for various reasons (e.g., allergy to oxaliplatin), they will continue taking acetyl-L-carnitine until 24 weeks (unless acetyl-L-carnitine intolerance or other conditions interfere with medication).
57942466|NCT03351751|DRUG|Placebo|Placebo
57942467|NCT03351751|DRUG|PF-06372865|PF-06372865
57731330|NCT05935345|BEHAVIORAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
57942468|NCT02285920|DRUG|Spironolactone|The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
57942469|NCT02665052|DEVICE|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
57942470|NCT02665052|DEVICE|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
57942471|NCT02665052|BEHAVIORAL|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
57942472|NCT05114395|OTHER|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
57942473|NCT05114395|OTHER|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
57942474|NCT02453373|DEVICE|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
57942475|NCT02453373|DRUG|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
57942476|NCT02453373|DRUG|tPA|tPA will be administered intravenously if indicated
57942477|NCT02453373|DRUG|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
57942478|NCT02453373|DRUG|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
58408449|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
58408450|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
58408451|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
58408452|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
58408453|NCT02256267|DRUG|LY2835219|Administered orally
58408454|NCT02256267|DRUG|Rifampin|Administered orally
58408455|NCT06608108|OTHER|Non-intervention|Non-intervention
58408456|NCT06608394|OTHER|no intervention|no intervention
58408457|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
58408458|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
58077236|NCT06722573|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
58077237|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
57942479|NCT02453373|PROCEDURE|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
57942480|NCT04756700|DIAGNOSTIC_TEST|DigiCog (BCCAMS app)|Administered as specified in the treatment arm.
57942481|NCT04756700|DIAGNOSTIC_TEST|Konectom Application|Administered as specified in the treatment arm.
57942482|NCT01552291|DIETARY_SUPPLEMENT|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
57942483|NCT01552291|DRUG|Placebo|30g oral maltodextrin / day for 5 days before surgery
58077238|NCT05423275|DEVICE|Negative ion therapy|Negative ion generator
57942484|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
57942485|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
57942486|NCT04641455|DRUG|Water|Administration of water before upper endoscopy
57942487|NCT04832958|DRUG|99m-TC-PSMA-I&S|"* 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
58077239|NCT05423275|DEVICE|Light therapy|Fluorescent light box
58077240|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
58077241|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58077242|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58077243|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58408459|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
58077244|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58408460|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
58408461|NCT03122353|DRUG|Placebo|vehicle used as placebo
58408462|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
58408463|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
58408464|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
58077245|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58408465|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
58408466|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
58408467|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
58077246|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58408468|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
57731331|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
57942488|NCT00113230|DRUG|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
57942489|NCT00113230|DRUG|Capecitabine|900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
57942490|NCT00113230|RADIATION|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
57942491|NCT05742997|DEVICE|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
57942492|NCT05742997|DEVICE|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
57942493|NCT05833048|PROCEDURE|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
58408469|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
57942494|NCT00753831|PROCEDURE|Aurosling|Silicon rod to be used in frontalis suspension surgery
57942495|NCT02640833|DRUG|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
57942496|NCT02640833|DRUG|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
57942497|NCT01376778|DRUG|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
57942498|NCT01376778|OTHER|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
57942499|NCT06319313|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.
57942500|NCT06319313|DRUG|docetaxel|50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.
57942501|NCT06319313|DRUG|HB1801|75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.
57942502|NCT02545621|OTHER|RAGE TXNIP Inflammasome axis|
57942503|NCT03598816|DRUG|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
57942504|NCT03598816|DRUG|Tremelimumab|-Tremelimumab will be administered first
57942505|NCT03598816|DEVICE|TDS-IM v1.0 System|-Integrated electroporation device
57942506|NCT03598816|BIOLOGICAL|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
58408470|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
58408471|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
58408472|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
57942507|NCT03598816|PROCEDURE|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
57942508|NCT04858750|DEVICE|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
57942509|NCT03883594|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
57942510|NCT01582022|DRUG|Bupivacaine|local application for 5 minutes
57942511|NCT01582022|DRUG|normal saline|local application for 5 minutes
57942512|NCT01460199|DRUG|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
57942513|NCT01460199|DRUG|placebo|tablets
57942514|NCT02760979|DRUG|Denosumab|Denosumab treatment one year after surgery
57942515|NCT02760979|DRUG|Placebo|Serum one year after surgery
57942516|NCT04492462|OTHER|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
57942517|NCT04492462|OTHER|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
57942518|NCT02709694|OTHER|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
57942519|NCT01786096|DRUG|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
57942520|NCT05856916|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
57942521|NCT05856916|DIETARY_SUPPLEMENT|Placebo|Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
58408473|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
58408474|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
58408475|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
58408476|NCT00241514|DRUG|Esomeprazole|
57942522|NCT03388242|OTHER|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
57942523|NCT04674475|DEVICE|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
57942524|NCT03210389|DRUG|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
58077247|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
58408477|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
58408478|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
58408479|NCT03670329|DEVICE|URGO2875|Dressing
58408480|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
58408481|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
58408482|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
58408483|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
58408484|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
58408485|NCT01065051|DRUG|Placebo|Single oral dose
58408486|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
58408487|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
57942525|NCT05837442|OTHER|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
57942526|NCT02999867|DIETARY_SUPPLEMENT|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
57942527|NCT02999867|DIETARY_SUPPLEMENT|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
57942528|NCT03041350|OTHER|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
58077248|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
58297064|NCT04904471|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
58297065|NCT05332314|DRUG|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
58297066|NCT02475434|DIETARY_SUPPLEMENT|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
58297067|NCT06017401|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
58408488|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
58408489|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
58408490|NCT00410319|BEHAVIORAL|Fear-reducing Information|
57731332|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
57731333|NCT01732393|DRUG|Placebo|
58408491|NCT00410319|BEHAVIORAL|Symptom-based exercise|
57731334|NCT00769366|BEHAVIORAL|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
57731335|NCT00769366|DRUG|Medical therapy|Optimal medical therapy after Acute myocardial infarction
57942529|NCT01048749|OTHER|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
58297068|NCT06017401|PROCEDURE|Transmuscular Quadratus Lumborum Block|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
58408492|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
58408493|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
58408494|NCT06463704|OTHER|There is no intervention|There is no intervention
58408495|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
58408496|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
58408497|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
58408498|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
58408499|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
58408500|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
58408501|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
57942530|NCT01048749|OTHER|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
58077249|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
57942531|NCT01357655|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
57942532|NCT01357655|DRUG|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
57942533|NCT00530283|OTHER|PET-CT|
57942534|NCT02712151|PROCEDURE|Abdominal Wall Block|bilateral TAP and RS blocks.
57942535|NCT02712151|PROCEDURE|Surgical infiltration|distributed between the 4 laparoscopic port sites.
57942536|NCT02712151|DRUG|Sterile saline|Placebo injection
57942537|NCT02712151|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
58077250|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
57942538|NCT02712151|DEVICE|Ultrasound|For nerve localization
57942539|NCT02712151|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
57942540|NCT03333642|PROCEDURE|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
57942541|NCT02171845|OTHER|surgical biopsies|
57942542|NCT02982590|DRUG|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
57942543|NCT02982590|DRUG|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
57942544|NCT05987059|BEHAVIORAL|SBIRT Intervention|"Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies."
57942545|NCT05171348|DRUG|CM326|a humanized monoclonal antibody
57942546|NCT05171348|DRUG|Placebo|Placebo
57942547|NCT00528580|DRUG|Simvastatin|80 mg once daily PO/NG x 4 days
57942548|NCT00528580|DRUG|Identical-appearing placebo|once daily x 4 days
57942549|NCT05486520|DEVICE|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
57942550|NCT01395875|DRUG|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
57942551|NCT01395875|DRUG|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
58077251|NCT00719706|DRUG|Placebo|Placebo
58077252|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
58077253|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
58077254|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
58077255|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
57942552|NCT04752176|DEVICE|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
57942553|NCT05784636|DEVICE|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
57942554|NCT05784636|DEVICE|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
57942555|NCT01208584|OTHER|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
57942556|NCT05888090|OTHER|Prone, right lateral, and semi-elevated supine positions|Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.
57942557|NCT05888090|OTHER|Semi-elevated supine, prone, and right lateral positions|Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.
57942558|NCT05888090|OTHER|Right lateral, semi-elevated supine, and prone positions|Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
57942559|NCT02771509|DRUG|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
57942560|NCT02771509|DRUG|Placebo|Normal saline
57942561|NCT01226459|DRUG|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
57942562|NCT01226459|DRUG|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
57942563|NCT04497129|DEVICE|ROMTech PortableConnect|ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.
57942564|NCT04497129|DEVICE|Traditional Rehabilitation and CPM Device|Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
57942565|NCT00025220|DRUG|Thalidomide|Given PO
58077256|NCT00371748|DEVICE|Express2|Coronary Stent System
58077257|NCT00003266|DRUG|methylphenidate hydrochloride|
57942566|NCT00025220|OTHER|Laboratory Biomarker Analysis|Correlative studies
57942567|NCT01886339|OTHER|SNIF test (Sniff Nasal Inspiratory Force)|
58077258|NCT00003266|PROCEDURE|quality-of-life assessment|
58077259|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
58077260|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
58077261|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
58297069|NCT00528307|DEVICE|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
58077262|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
58077263|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
58077264|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
58077265|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
58297070|NCT02985112|DEVICE|FFR and IVUS-NIRS|
58297071|NCT03050827|DRUG|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
58077266|NCT06724497|PROCEDURE|face scanning pre and post orthognathic surgery|patient will be scanned pre operative using both scanners and then undergo orthognathic surgery then will be rescanned again 6 montsh later
58077267|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
57942568|NCT01490450|BIOLOGICAL|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
57942569|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
57942570|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
57942571|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
57942572|NCT01830751|OTHER|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
57942573|NCT02665169|BEHAVIORAL|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
57942574|NCT02665169|OTHER|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
57942575|NCT01837030|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
57942576|NCT01837030|DEVICE|Capsule Endoscopy|GIVEN capsule
57942577|NCT05338177|OTHER|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
57942578|NCT05338177|OTHER|No immunosuppression reduction|participants do not alter immunosuppresion
57942579|NCT03163589|DRUG|Erythropoietin|injection
57942580|NCT03163589|DRUG|normal saline|injection
57942581|NCT04411420|BEHAVIORAL|Pain modulation with physical pain treatment|Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation
57942582|NCT04411420|BEHAVIORAL|Telephone delivered self-management counseling for increasing physical activity|Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient
58077268|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
58297072|NCT03050827|DRUG|Placebo|Non-active placebo for 3% oxybutynin
58297073|NCT00091468|DRUG|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
58297074|NCT00091468|DRUG|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
57942583|NCT04411420|BEHAVIORAL|Telephone delivered behavioral treatment for participants with high risk for continued disability|Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.
57942584|NCT04411420|BEHAVIORAL|Patient preference treatment protocol|the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol
58297075|NCT01348724|DRUG|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
58297076|NCT00570375|DRUG|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
58297077|NCT05738746|DIETARY_SUPPLEMENT|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
58297078|NCT05738746|DIETARY_SUPPLEMENT|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
58077269|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
58408502|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
58408503|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
57942585|NCT04411420|BEHAVIORAL|Nonpharmacological guideline adherent treatment protocol|the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient
57942586|NCT04411420|BEHAVIORAL|Facilitated referrals to existing VA or non-VA pain management resources|the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
57942587|NCT05102851|DIAGNOSTIC_TEST|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
57942588|NCT00383084|BEHAVIORAL|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
58408504|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
58408505|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
58408506|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
58408507|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
57942589|NCT00383084|BEHAVIORAL|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
57942590|NCT01713842|DRUG|TCZ|Tocilizumab at week 0, 4 and 8.
57942591|NCT05517395|BEHAVIORAL|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
57942592|NCT05517395|BEHAVIORAL|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
57942593|NCT05526690|DRUG|Metformin|1000 mg dose of immediate-release metformin
57942594|NCT05526690|DRUG|CIN-107|10 mg dose of CIN-107
57942595|NCT05349851|OTHER|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
57942596|NCT03218098|PROCEDURE|Lobectomy via UVATS|lobectomy with small skin access 4 cm
58408508|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
57942597|NCT01072305|DEVICE|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
57942598|NCT01072305|DEVICE|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
57942599|NCT00739011|DEVICE|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
57942600|NCT02536313|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
57942601|NCT02536313|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
57942602|NCT03761875|OTHER|blood sample CHB patients|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 1 dry tube per patient"
58297079|NCT02562586|DEVICE|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
58408509|NCT02073032|OTHER|No intervention, only observation|
58408510|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
58408511|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
58408512|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
58408513|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
57942603|NCT03761875|OTHER|boold sample Control group|"* 2 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 1 dry tube"
57942604|NCT02535884|DEVICE|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
57942605|NCT02375152|PROCEDURE|Anterior Capsulotomy|
57942606|NCT00006151|BEHAVIORAL|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
58297080|NCT02377869|OTHER|No intervantion|
58408514|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
58408515|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
57942607|NCT04207450|OTHER|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
57942608|NCT04207450|OTHER|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
57942609|NCT04207450|OTHER|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
57942610|NCT03215420|DIAGNOSTIC_TEST|MRI 3T|
57942611|NCT06243042|DIAGNOSTIC_TEST|serum vitamin D|blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.
57942612|NCT06243042|DIAGNOSTIC_TEST|urine osmolality|"nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg."
57942613|NCT06243042|OTHER|Frequency volume chart|volume and frequency from time of sleep till 8 am
57942614|NCT04007575|DIAGNOSTIC_TEST|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
57942615|NCT02171611|DRUG|Dabigatran etexilate pellets|
57942616|NCT02171611|DRUG|Dabigatran etexilate powder|
57942617|NCT02171611|DRUG|Dabigatran etexilate capsule|
57942618|NCT01252212|BEHAVIORAL|SMS medication adherence|SMS messages to cell phones.
57942619|NCT01252212|BEHAVIORAL|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
57942620|NCT01621230|DRUG|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
57942621|NCT01621230|DRUG|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
57942622|NCT03853720|PROCEDURE|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
57942623|NCT05641870|PROCEDURE|Sample collection|Tumor samples will be collected as standard diagnostic procedure at diagnosis. Plasma samples from whole blood extractions will also be collected at diagnosis, after chemoradiotherapy, and every 3 months from there until completing one year of follow-up.
58297081|NCT00777166|DRUG|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
58297082|NCT00777166|DRUG|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
58297083|NCT00808067|DRUG|dabigatran dose 1|dabigatran high dose twice daily
58297084|NCT00808067|DRUG|dabigatran dose 2|dabigatran low dose twice daily
58297085|NCT03621033|PROCEDURE|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
58297086|NCT01372631|DEVICE|miniature spectral imaging system|Use of miniature spectral imaging system
58297087|NCT01372631|DEVICE|Bench-top optical spectrometer|Use of bench-top optical spectrometer
58297088|NCT01372631|DEVICE|High resolution microendoscope|Use of high resolution microendoscope
58297089|NCT00183118|BEHAVIORAL|Adapted Enhanced-RESPECT (HIV prevention intervention)|
58297090|NCT02340000|DRUG|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
58077270|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
58077271|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
58408516|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
58408517|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
58408518|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
58408519|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
58408520|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
58408521|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
58408522|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
58408523|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
58408524|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
58408525|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
57942624|NCT05641870|DIAGNOSTIC_TEST|Characterization of the tumoral tissue genomic alterations|Genomic alterations of tumor tissue samples will be analyzed locally by next-generation sequencing when material is adequate, as standard diagnostic procedure.
57942625|NCT05641870|DRUG|Chemoradiation treatment regimen and maintenance (if amenable)|Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
57942626|NCT05641870|DIAGNOSTIC_TEST|Genomic and methylation analysis in liquid biopsy|"Blood samples for ctDNA genomic and methylation analysis (4 mL of plasma for each sample) will be sent to the Guardant Health Laboratories in the US and analyzed after Contractual Agreement signature, using the Guardant Reveal test.~This liquid biopsy test uses ctDNA to detect presence of MRD and monitor for recurrence after definitive surgical/systemic therapy for patients with cancer. It has been validated in early-stage colorectal cancer and integrates assessment of somatic alterations with an epigenomic cancer signature to identify the presence of methylation signatures associated with cancer versus normal DNA."
57942627|NCT01398020|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
57942628|NCT01398020|DRUG|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
57942629|NCT05043571|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
57942630|NCT03988530|DRUG|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
57942631|NCT03988530|OTHER|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
57942632|NCT01250340|DRUG|Aspirin|100 mg/day for 30 days
57942633|NCT01250340|DRUG|Placebo|1 cp day for 30 days
57942634|NCT01053299|OTHER|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
57942635|NCT01640652|BIOLOGICAL|MenPF-1.|A new vaccine against meningococcal disease.
57942636|NCT05911659|DRUG|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
57942637|NCT04623203|OTHER|No intervention|No intervention
57942638|NCT00164073|PROCEDURE|Liver biopsy|
57942639|NCT03975621|BEHAVIORAL|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
57942640|NCT03286686|BEHAVIORAL|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
57942641|NCT03286686|BEHAVIORAL|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
57942642|NCT03286686|BEHAVIORAL|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
57942643|NCT04933604|PROCEDURE|laparoscopic partial nephrectomy|Nephron sparing minimally invasive surgery
57942644|NCT04933604|PROCEDURE|Laparoscopic radical nephrectomy|Completely removal of kidney by using laparoscopic surgery
57942645|NCT02524821|DEVICE|Gelesis100|3 capsules each containing 0.75 mg
57942646|NCT02524821|DRUG|Metformin|1 tablet of 850 mg
57942647|NCT03320928|OTHER|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
58077272|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
58077273|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
58408526|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
57942648|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
57942649|NCT00820950|DRUG|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
57942650|NCT00820950|DRUG|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
57942651|NCT00820950|DRUG|Placebo cream|Cream applied once or twice daily for 56 days
57942652|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
57942653|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
58077274|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
58077275|NCT01716221|DRUG|bupropion & Citalopram|
58077276|NCT01716221|DRUG|Bupropion & Placebo|
58077277|NCT01716221|DRUG|Placebo & Citalopram|
58077278|NCT01716221|DRUG|Placebo & Placebo|
58077279|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
58077280|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
58077281|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
58408527|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
57942654|NCT03600142|BEHAVIORAL|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
57942655|NCT01568775|DRUG|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
57942656|NCT04637607|OTHER|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
57942657|NCT00940979|PROCEDURE|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
57942658|NCT03585218|BIOLOGICAL|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
57942659|NCT00053092|BIOLOGICAL|rituximab|
57942660|NCT00053092|DRUG|cyclophosphamide|
57942661|NCT00053092|DRUG|fludarabine phosphate|
58077282|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
58077283|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
58077284|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
57942662|NCT06295341|DRUG|Recombinant human growth hormone (only for children with growth hormone deficiency)|6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
57942663|NCT03764891|PROCEDURE|Uphold|Uphold system in treating women with cystocele
57942664|NCT03764891|PROCEDURE|Perigee|Perigee system in treating women with cystocele
57731336|NCT06635187|DIAGNOSTIC_TEST|Speech and swallowing assessment|This is an observational study in which post-stroke patients will undergo a series of assessments tapping oral-motor and speech functions. Both behavioral and instrumental examinations will be used. Their performance will be captured via an artificial intelligence(AI)-powered mobile health application. The relation between the oral/speech-motor movements captured by the app and their performance as measured via instruments/behavioral means will be investigated.
57731337|NCT04507191|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
57942665|NCT03648008|DRUG|Hydromorphone|0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
57942666|NCT03648008|DRUG|Morphine|0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
57942667|NCT04206020|DRUG|SkQ1 Vehicle Solution|SkQ1 Ophthalmic Solution Vehicle
57942668|NCT04206020|DRUG|SkQ1 Ophthalmic Solution|SkQ1 Ophthalmic Solution
57942669|NCT00398671|DEVICE|Application of cool cap after primary successful CPR|
57942670|NCT00642395|DRUG|Bortezomib|bortezomib-Melphalan
57942671|NCT05470920|BEHAVIORAL|Electronic Decision Aid|Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
58408528|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
58408529|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
57942672|NCT05470920|BEHAVIORAL|Pre-Test Genetic Counseling|Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
58077285|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
58408530|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
58408531|NCT03638869|DRUG|Placebo|
58408532|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
58408533|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
57951306|NCT01321710|BEHAVIORAL|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
57951307|NCT01321710|BEHAVIORAL|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
58077286|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
58077287|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
58408534|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
58408535|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
57731338|NCT04994626|DRUG|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
57731339|NCT00548769|DRUG|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
57731340|NCT00548769|DRUG|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
57731341|NCT00548769|DRUG|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
57731342|NCT00548769|DRUG|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
57942673|NCT05018039|OTHER|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
58077288|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
58077289|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
58408536|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
58408537|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
58408538|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
58408539|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
57942674|NCT03331861|DRUG|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
57942675|NCT03331861|DRUG|Placebo|Similar dosing regime as active comparator
57942676|NCT03609138|DEVICE|Spinal Hardware|Pedicle screws and patient specific rods
57942677|NCT05395611|OTHER|EBPcollected using the PExA device.|The PExA device is a non invasive device that collect particles in exhaled air
57942678|NCT04823572|PROCEDURE|A-PRF/OFD|Comparing healing effect of an autologous and open flap debridement
57942679|NCT03512795|BIOLOGICAL|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
57942680|NCT04298775|PROCEDURE|spinal anesthesia with morphine|
57942681|NCT04298775|PROCEDURE|spinal anesthesia without morphine + peripheral nerve block|
57942682|NCT04860271|PROCEDURE|Manual Acupuncture|Manual acupuncture treatment using different types of needle
57942683|NCT02251379|DRUG|Flovent Diskus|Inhaled corticosteroids
57942684|NCT02251379|OTHER|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
57942685|NCT02251379|DRUG|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
57942686|NCT02213575|DRUG|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
57942687|NCT05602662|BEHAVIORAL|Music|Music therapy during mechanical ventilation
57942688|NCT05043714|BIOLOGICAL|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
57942689|NCT01612468|DRUG|Liraglutide|1.8 mg/day subcutaneous
57942690|NCT01612468|DRUG|Placebo|1.8 mg/day subcutaneous
58077290|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
58077291|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
58077292|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
58408540|NCT00992381|DRUG|Naprosyn|500mg Naproxen
57942691|NCT02593162|DRUG|Faldaprevir|
57942692|NCT02593162|DRUG|TD-6450|
57942693|NCT02593162|DRUG|Ribavirin|
57942694|NCT05864742|DRUG|Ibrutinib|560 mg daily continuously
58077293|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
58077294|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
58077295|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
58077296|NCT04058665|DEVICE|Floseal|Hemostatic agent
58297091|NCT02340000|DRUG|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
58297092|NCT05564481|BEHAVIORAL|diabetes education and parent coaching support|Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
58077297|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
58077298|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
58077299|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
58077300|NCT06253507|BIOLOGICAL|Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47|"Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg."
58077301|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
58077302|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
58077303|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
58077304|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
58077305|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
58077306|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
58077307|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
58297093|NCT01649882|PROCEDURE|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
58297094|NCT00247520|DRUG|topical nasal rEV131|
58297095|NCT03656627|DRUG|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
58297096|NCT04413344|DRUG|Bromocriptine|TW-012R: Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
58297097|NCT04413344|DRUG|Placebos|Placebo: Identical tablets which contain no active ingredient
58408541|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
58408542|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
58408543|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
58408544|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
58408545|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
58077308|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
58077309|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
58077310|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
58077311|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
58077312|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
58077313|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
58077314|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
58297098|NCT05736328|PROCEDURE|Traction|Postoperative lower extremity traction
58297099|NCT00288652|DRUG|[S,S]-Reboxetine|
58297100|NCT04135482|OTHER|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
58297101|NCT01715233|DRUG|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
58297102|NCT01715233|DRUG|Leucovorin|Leucovorin 400mg/m2 on Day 1
58297103|NCT01715233|DRUG|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
58297104|NCT01715233|DRUG|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
58297105|NCT06607900|DRUG|hUC-MSC-sEV-001 nasal drops|hUC-MSC-sEV-001 nasal drops
58297106|NCT05137717|DRUG|Maribavir|Maribavir tablets
58297107|NCT02121860|DRUG|IDN-6556|
58297108|NCT02443831|PROCEDURE|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19/22 CAR T-cells
58077315|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
58077316|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
58077317|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
58077318|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
58077319|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
58077320|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
58077321|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
58077322|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
58077323|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
58408546|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
57942695|NCT05864742|DRUG|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
57942696|NCT05864742|DRUG|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
57942697|NCT05864742|DRUG|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
57942698|NCT03207711|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
57942699|NCT03207711|BEHAVIORAL|Mindfulness|Mindful eating app-use and instruction
57942700|NCT03029715|DRUG|Propofol|Total intravenous anaesthesia.
58077324|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
58077325|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
58297109|NCT02443831|DRUG|Lymphodepletion with fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19/22CAR T-cell infusion.
58408547|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
58408548|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
58408549|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
57942701|NCT03029715|DRUG|Remifentanil|Narcotics
57942702|NCT03029715|DRUG|Dexmedetomidine|Total intravenous anaesthesia
57942703|NCT03029715|DRUG|Desflurane|Inhalation anaesthesia.
57942704|NCT01129830|DIETARY_SUPPLEMENT|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
57942705|NCT05001984|DRUG|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
58077326|NCT00821847|OTHER|DEXA scan|DEXA scan
57942706|NCT03588182|OTHER|Virtual Reality Experience|Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
57942707|NCT03886311|DRUG|Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]|Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
57942708|NCT03886311|DRUG|Nivolumab IV Soln 100 MG/10ML|NIVOLUMAB 240 mg IV over 30 min q 2 weeks
57942709|NCT03886311|DRUG|Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution|TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
57942710|NCT02577744|OTHER|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
57942711|NCT02577744|OTHER|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
57942712|NCT06433830|DRUG|Hetrombopag Olamine|The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
58077327|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
58408550|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
58408551|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
57942713|NCT03422432|PROCEDURE|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
57942714|NCT00880659|BEHAVIORAL|Soap|Promotion of handwashing with soap
57942715|NCT04609228|OTHER|Non-acceptance of blood-transfusions|Patients who do not accept blood products transfusions
57942716|NCT04609228|OTHER|Acceptance of blood-transfusions|Patients who accept blood products transfusions
57942717|NCT00095082|DRUG|insulin detemir|
57942718|NCT00095082|DRUG|insulin glargine|
57942719|NCT00095082|DRUG|insulin aspart|
57942720|NCT00036075|DRUG|CP-461|
57942721|NCT05131984|DRUG|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
57942722|NCT04638972|DEVICE|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
58408552|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
58408553|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
58408554|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
58408555|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
57942723|NCT00003702|BIOLOGICAL|Dactinomycin|Given IV
57942724|NCT00003702|DRUG|Methotrexate|Given intramuscularly
57942725|NCT00003895|BIOLOGICAL|HPV 16 E7:12-20|Given SC
57942726|NCT00003895|BIOLOGICAL|gp100:209-217(210M)|Given SC
57942727|NCT00003895|OTHER|laboratory biomarker analysis|Correlative studies
57942728|NCT06082388|DRUG|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
57942729|NCT00175877|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
57942730|NCT02549430|DRUG|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
57942731|NCT02549430|DRUG|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
58077328|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
58408556|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
58408557|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
58408558|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
57942732|NCT02549430|DRUG|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
57942733|NCT02549430|DRUG|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
57942734|NCT02549430|DRUG|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
57942735|NCT04091490|DRUG|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
57942736|NCT02680132|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
57942737|NCT02680132|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
57942738|NCT02489643|PROCEDURE|Individualized practical training|
57942739|NCT00651417|DIETARY_SUPPLEMENT|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
57942740|NCT00651417|DIETARY_SUPPLEMENT|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
57942741|NCT00847145|BIOLOGICAL|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
57942742|NCT00847145|BIOLOGICAL|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
58077329|NCT00967889|GENETIC|gene expression analysis|
58077330|NCT00967889|GENETIC|protein analysis|
58077331|NCT00967889|OTHER|biologic sample preservation procedure|
58077332|NCT00967889|OTHER|laboratory biomarker analysis|
57942743|NCT00847145|BIOLOGICAL|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
57942744|NCT00847145|BIOLOGICAL|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
57942745|NCT00847145|BIOLOGICAL|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
57942746|NCT00847145|BIOLOGICAL|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
57942747|NCT00847145|BIOLOGICAL|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
57942748|NCT00847145|BIOLOGICAL|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
57942749|NCT04932850|BIOLOGICAL|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
57942750|NCT04932850|OTHER|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
57942751|NCT03670043|DRUG|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
57942752|NCT03670043|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
57942753|NCT00777621|OTHER|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
57942754|NCT00777621|OTHER|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
57942755|NCT00777621|OTHER|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
58408559|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
58408560|NCT03369041|DRUG|Irinotecan-Eluting Beads|
58408561|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
57731343|NCT02478294|PROCEDURE|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
57731344|NCT02478294|DRUG|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
57731345|NCT04196400|DRUG|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
57731346|NCT00407537|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
57731347|NCT03836287|DRUG|Sofpironium Bromide Gel, 15%|Active
57942756|NCT04046081|DRUG|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
58297110|NCT02443831|DRUG|Lymphodepletion with cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19/22CAR T-cell infusion.
58408562|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
57731348|NCT03836287|DRUG|Vehicle|Vehicle gel
57731349|NCT00958035|DRUG|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
57731350|NCT00958035|DRUG|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
57731351|NCT04797247|DRUG|lerodalcibep|PCSK9 inhibitor
57731352|NCT02958436|DRUG|REGN3500|
57731353|NCT02958436|DRUG|Placebo|
57731354|NCT01060215|PROCEDURE|Normal saline|20 cc normal saline injection into the knee joint
57731355|NCT05864794|DIAGNOSTIC_TEST|MRI|MRI scan of the brain
57731356|NCT06669975|DRUG|AP402 (Part 1 Dose esclation)|Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
57731357|NCT06669975|DRUG|AP402 (Part 2 Dose Expansion)|After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
57942757|NCT05755295|OTHER|horse therapy|equitherapy and hippotherapy once a week during 16 weeks
57942758|NCT02047253|DRUG|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
57942759|NCT02047253|DRUG|Dexamethasone|Administered prior to administration of Study drug
57942760|NCT02047253|DRUG|Acyclovir|Administered orally twice daily
57942761|NCT04666779|OTHER|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
57942762|NCT03901105|DRUG|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
57942763|NCT03901105|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
57942764|NCT02774512|DRUG|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
57731358|NCT03607448|DEVICE|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
57731359|NCT01218438|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
57942765|NCT05752877|BIOLOGICAL|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
57942766|NCT05752877|BIOLOGICAL|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
57942767|NCT04349982|DIAGNOSTIC_TEST|Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)|Factorial
57942768|NCT03526770|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
57942769|NCT03526770|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
57942770|NCT03526770|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
58077333|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
58077334|NCT00004058|DRUG|tetradecanoylphorbol acetate|
58077335|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
58077336|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
58077337|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
58297111|NCT02443831|BIOLOGICAL|CD19/22 CAR T-cells|A single dose of 1 x 10\^6/kg CD19/22CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
58297112|NCT04609683|DEVICE|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
58297113|NCT03685097|DIAGNOSTIC_TEST|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
58297114|NCT04092738|BEHAVIORAL|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
58408563|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
58408564|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
58408565|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
57951308|NCT01321710|DRUG|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
57731360|NCT01218438|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
57731361|NCT02654080|BIOLOGICAL|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
57731362|NCT02654080|BIOLOGICAL|rVSV HIV envC vaccine|1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
58077338|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
58077339|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
58077340|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
58077341|NCT05065151|OTHER|Stimulation on|Stimulation from Percept PC DBS will be on while the patient is playing a decision-making game on a computer-based application.
58077342|NCT05065151|OTHER|Stimulation off|Stimulation from Percept PC DBS will be off while the patient is playing a decision-making game on a computer-based application.
58077343|NCT05065151|BEHAVIORAL|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
58077344|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
58077345|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
58077346|NCT01866605|DEVICE|Bair Hugger|Forced air warming
58077347|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
58077348|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
57942771|NCT03526770|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
58077349|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
58077350|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
58077351|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
58077352|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
58077353|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
58077354|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
58408566|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
58408567|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
58408568|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
58408569|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
58077355|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
58077356|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
58077357|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
58077358|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
58408570|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
58408571|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
57942772|NCT03526770|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
58077359|NCT02059265|DRUG|Dasatinib|Given PO
58077360|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
58077361|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
58077362|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
58077363|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
58077364|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
58077365|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
58077366|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
58077367|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
58077368|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
58077369|NCT04098003|DRUG|Placebo|Matched placebo control
58077370|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
58077371|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
58077372|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
58077373|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
58077374|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
58408572|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
58408573|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
57942773|NCT03526770|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
57942774|NCT00729482|DRUG|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
57942775|NCT01037660|DRUG|Metformin|Metformin 1 gram per day
57942776|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFU IM, 1.0 mL
57942777|NCT00376090|BIOLOGICAL|Placebo|1.0 mL IM
57942778|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^6 PFU ID, 0.1 mL
57942779|NCT00376090|BIOLOGICAL|Placebo|0.1 mL ID
57942780|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^8 PFU IM, 1.0 mL
57942781|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFD ID, 0.1 mL
57942782|NCT04856930|BIOLOGICAL|Imsidolimab|Humanized Monoclonal Antibody
57942783|NCT04856930|BIOLOGICAL|Placebo Solution|Placebo
57942784|NCT02197338|OTHER|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
57942785|NCT00636675|BEHAVIORAL|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets."
57942786|NCT00636675|BEHAVIORAL|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
57942787|NCT01166100|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
57942788|NCT00542464|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
57942789|NCT01979536|DRUG|Brentuximab Vedotin|Given IV
57942790|NCT01979536|DRUG|Crizotinib|Given PO
57942791|NCT01979536|DRUG|Cyclophosphamide|Given IV
57942792|NCT01979536|DRUG|Cytarabine|Given IT and IV
57942793|NCT01979536|DRUG|Dexamethasone|Given PO or IV
57942794|NCT01979536|DRUG|Doxorubicin Hydrochloride|Given IV
57942795|NCT01979536|DRUG|Etoposide|Given IV
57942796|NCT01979536|DRUG|Ifosfamide|Given IV
57942797|NCT01979536|DRUG|Methotrexate|Given IT and IV
57942798|NCT05645614|OTHER|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
57942799|NCT06348485|OTHER|Patients without massive nasal bleeding|No event of massive nasal bleeding after curative radiotherapy
57942800|NCT06348485|OTHER|Patients with massive nasal bleeding|Any event of massive nasal bleeding after curative radiotherapy
57942801|NCT02430142|OTHER|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
57942802|NCT05038462|DIETARY_SUPPLEMENT|Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
57942803|NCT05038462|OTHER|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
58077375|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
58297115|NCT03323112|BIOLOGICAL|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
58297116|NCT02550743|DRUG|BYL719|
58408574|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
58408575|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
58408576|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
57942804|NCT04086004|OTHER|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
57942805|NCT04086004|OTHER|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
57942806|NCT06011343|DRUG|Oral tofacitinib|Association of tofacitinib and meglumine antimoniate
57942807|NCT06011343|DRUG|Parenteral meglumine antimoniate|Meglumine antimoniate
57942808|NCT00825279|DEVICE|Bare Metal Stent|Stainless steel stent
57942809|NCT00825279|DEVICE|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
57942810|NCT05310643|DRUG|Nivolumab|"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."
58297117|NCT02550743|DRUG|Capecitabine|
57942811|NCT05310643|DRUG|Ipilimumab|Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
57942812|NCT03198520|DEVICE|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
57942813|NCT00011908|DRUG|hLL2 (Epratuzumab)|
57942814|NCT04973982|DRUG|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
57942815|NCT04973982|DRUG|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
57942816|NCT04329351|PROCEDURE|Guided Bone regeneration|Guided bone regeneration to ridge preservation
57942817|NCT00725881|DRUG|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
57942818|NCT00725881|DRUG|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
57942819|NCT02742064|OTHER|Cogito Companion Mobile Phone Application|
57942820|NCT06038240|BEHAVIORAL|Savoring Meditation|Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).
57942821|NCT06038240|BEHAVIORAL|Pain Self-Management and Education|Participants will learn about the biopsychosocial drivers of chronic pain.
57942822|NCT00937261|DRUG|Risperidone|2mg - 8mg per day, for the duration of participation in the study
57942823|NCT00937261|DRUG|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
57942824|NCT00185952|DRUG|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
57942825|NCT05785468|DRUG|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
57942826|NCT05140512|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
57942827|NCT05140512|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
57942828|NCT03387436|BEHAVIORAL|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
57942829|NCT03387436|BEHAVIORAL|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
57942830|NCT00262210|DRUG|Cyclophosphamide Epirubicin Etoposide Prednisolone|
57942831|NCT00474396|BEHAVIORAL|Low fat dairy diet|
57942832|NCT01661855|DRUG|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
57942833|NCT01661855|DRUG|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
57942834|NCT05691998|OTHER|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
58408577|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
58408578|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
58408579|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
58408580|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
57942835|NCT03688399|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
57942836|NCT03688399|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
57942837|NCT00625495|DRUG|Esomeprazole|40mg Intravenous infusion over 3 minutes
57942838|NCT00625495|DRUG|Esomeprazole|40mg Oral
57942839|NCT04350528|DRUG|Chlorpromazine or Pentobarbital|Sedation
57942840|NCT00193869|DRUG|Dexamethasone|
57942841|NCT00236769|DRUG|norelgestromin + ethinyl estradiol|
57942842|NCT01640509|RADIATION|treated by synchrotron radiation|treated by synchrotron radiation
57942843|NCT05860842|OTHER|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
57942844|NCT06466031|OTHER|MRI & PET fusion|MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.
57942845|NCT06466031|OTHER|MRI+T1C|MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
57951309|NCT00475683|OTHER|Mouth wash|Mouth wash with chlorehexidin, three times a day
57951310|NCT00475683|DIETARY_SUPPLEMENT|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
58077376|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
58077377|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
58077378|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
58077379|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
58077380|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
57731363|NCT02654080|BIOLOGICAL|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
57942846|NCT03663426|PROCEDURE|study group|"1. High dose corticoids pre-operative and 24h postoperative~2. Opioid free general anesthesia~3. Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
57942847|NCT03663426|PROCEDURE|control|"1. No corticoids pre-operative.~2. Opioid anesthesia~3. Opioids post-operative after NSAID and paracetamol."
57942848|NCT01670539|DEVICE|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
58408581|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
58408582|NCT00888329|DRUG|Placebo|Placebo
57942849|NCT03094351|PROCEDURE|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
57942850|NCT03094351|PROCEDURE|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
58077381|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
58077382|NCT01215968|DRUG|Placebo|Administered subcutaneously
58077383|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
58077384|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
58077385|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
58077386|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
58077387|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
58077388|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
57942851|NCT05421312|DRUG|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
57942852|NCT05421312|DRUG|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
57942853|NCT05421312|DRUG|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
57942854|NCT00143195|DRUG|Amlodipine|
57942855|NCT00143195|DRUG|iso- 5 - mononitrate|
58077389|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
57942856|NCT00143195|PROCEDURE|Blood tests|
57942857|NCT00143195|PROCEDURE|Exercise Stress Test|
57942858|NCT01436084|DRUG|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
57942859|NCT01825291|PROCEDURE|CPAP treatment|
57942860|NCT06345430|DEVICE|Exopulse Molli-Suit (Wearable Technological Device)|After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
57942861|NCT00754793|DRUG|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
57942862|NCT00754793|DRUG|placebo|inactive comparator; titrated as per protocol over 12 weeks
57942863|NCT06446245|DRUG|Doxycycline|adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy
58077390|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
58077391|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
58077392|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
58077393|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
57731364|NCT01485510|BEHAVIORAL|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
57731365|NCT01485510|BEHAVIORAL|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
57731366|NCT05164822|OTHER|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
57731367|NCT06635096|DEVICE|Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)|These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
57731368|NCT03387852|DRUG|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
57942864|NCT06446245|DRUG|Placebo|Placebo
57942865|NCT06446245|DRUG|Anti Tuberculosis Drug|Standard anti-tuberculous therapy
57942866|NCT06446245|DRUG|Adjunctive corticosteroid|Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
57942867|NCT05974150|OTHER|Web based survey|online weekly survey
57942868|NCT04687332|OTHER|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
58077394|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
58077395|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
58077396|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
58408583|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
57942869|NCT02369107|OTHER|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
57942870|NCT02369107|OTHER|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
58077397|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
58077398|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
58077399|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
58077400|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
58408584|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
58408585|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
58077401|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
57942871|NCT02639572|BIOLOGICAL|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
57942872|NCT02639572|BIOLOGICAL|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
57942873|NCT04918745|DEVICE|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~* A - Baseline stimulation, no modulation stimulation~* B - Baseline stimulation, modulated stimulation~* C - Reduced baseline stimulation, modulated stimulation"
57942874|NCT03277742|BEHAVIORAL|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
57942875|NCT03277742|DRUG|Standard of care|DOTS plus standard DM2 care
57942876|NCT02512133|DEVICE|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
57942877|NCT02512133|PROCEDURE|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
57942878|NCT04972240|OTHER|customization of abutment|we will customize abutment for every patient not ready made
57942879|NCT05472467|DRUG|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
57942880|NCT05472467|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
57951311|NCT03413501|BEHAVIORAL|MUD-PI|
58077402|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
58077403|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
58077404|NCT00912756|DRUG|cilostazol|200 mg/day BID
58077405|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
58077406|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
58077407|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
58077408|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
58077409|NCT00066573|DRUG|anastrozole|Given orally
57731369|NCT03387852|DRUG|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
58077410|NCT00066573|DRUG|exemestane|Given orally
58077411|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
57942881|NCT05472467|DRUG|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
57942882|NCT06360250|DRUG|Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation|Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.
57942883|NCT06360250|DRUG|Tetanus human immunoglobulin (HTIG)|Tetanus human immunoglobulin (HTIG)
57942884|NCT06360250|DRUG|Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo|There were no active ingredients, and other ingredients were the same
57942885|NCT06360250|BIOLOGICAL|Adsorbed tetanus vaccine (TT)|containing tetanus toxoid titer not less than 40 IU
58408586|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
57731370|NCT03387852|DRUG|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
58077412|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
58077413|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
58077414|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
58077415|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
58077416|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
58408587|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
58408588|NCT00000224|DRUG|Buprenorphine|
58408589|NCT06087263|DRUG|Regorafenib|Given by PO
58408590|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
58408591|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
57942886|NCT03344952|DRUG|Botulinum toxin type A|Repeated injections to hypertonic muscles
58077417|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
58077418|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
57731371|NCT03387852|DRUG|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
57731372|NCT03387852|DRUG|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
57731373|NCT00413153|DRUG|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
57942887|NCT03344952|OTHER|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
57942888|NCT02821923|DIETARY_SUPPLEMENT|E967-Xylitol|24g xylitol/d
58077419|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
58077420|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
57942889|NCT02821923|DIETARY_SUPPLEMENT|E968-Erythritol|36g erythritol/d
57942890|NCT01554644|DEVICE|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
57942891|NCT01554644|DEVICE|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
58077421|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
58077422|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
58077423|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
58297118|NCT02550743|RADIATION|Radiation|
58408592|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
58408593|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
57942892|NCT03163251|BEHAVIORAL|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
57942893|NCT05897723|DEVICE|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
57942894|NCT03715894|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
57942895|NCT02779959|DRUG|Prochlorperazine|
57942896|NCT01490814|PROCEDURE|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
57942897|NCT01490814|PROCEDURE|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
57942898|NCT06299657|BEHAVIORAL|IMPROVE|"IMPROVE is an individual manualized intervention.~Session1 includes:~* psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations~* guided discussion of maladaptive thoughts about bodily sensations related to anxiety~* how to challenge bodily sensations cognitively~* generating three takeaways about the benign nature of anxiety~Session 2 includes:~* review of homework~* psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty.~* when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty.~Session 3 includes:~* review interoceptive exposure (IE) and behavioral exercises (BE) for progress~* revisit beliefs related to cognitive biases~* discuss areas where skills can be used moving forward"
57942899|NCT06299657|BEHAVIORAL|PHET|"Clinicians will administer PHET using a Powerpoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. PHET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
57942900|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
57942901|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
57942902|NCT01458912|DRUG|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
57942903|NCT01458912|DRUG|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
58077424|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
58077425|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
58077426|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
58077427|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
58077428|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
58297119|NCT01493895|DEVICE|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
58297120|NCT01493895|DEVICE|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
58408594|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
58408595|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
58408596|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
58408597|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
57942904|NCT04311892|DIAGNOSTIC_TEST|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
57942905|NCT00714675|DIETARY_SUPPLEMENT|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
57942906|NCT00714675|DIETARY_SUPPLEMENT|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
57942907|NCT05092542|BEHAVIORAL|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
57942908|NCT00474734|DEVICE|Intravascular ultrasound of the liver|
57942909|NCT05244291|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
57942910|NCT02354222|DRUG|Canagliflozin|
57942911|NCT02354222|DRUG|Teneligliptin|
57942912|NCT02354222|DRUG|Placebo|
57942913|NCT04100681|DEVICE|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
57942914|NCT04100681|DEVICE|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
57942915|NCT02724384|DEVICE|MOE Plasma Delivery System A|Plasma treatment
57942916|NCT02724384|DEVICE|MOE Plasma Delivery System B|Plasma treatment
57942917|NCT03062592|DIETARY_SUPPLEMENT|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
57942918|NCT04524702|DRUG|Gemcitabine|Given IV
58077429|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
58297121|NCT06344715|BIOLOGICAL|SL-T10|A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants
58408598|NCT00003946|DRUG|danazol|
58408599|NCT01466660|DRUG|Afatinib|afatinib once daily
58077430|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
58297122|NCT06344715|BIOLOGICAL|GX-I7|A T-cell growth factor
58297123|NCT06344715|BIOLOGICAL|Pembrolizumab|An immune check point inhibitor
58297124|NCT01699724|DRUG|JZoloft|50 mg tablet on Day 1 of each period
58297125|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
58297126|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
58297127|NCT02631317|BEHAVIORAL|Advance hospital notification by EMS|Advance hospital notification by EMS
58297128|NCT02631317|BEHAVIORAL|stroke team notification|stroke team notification
58297129|NCT02631317|BEHAVIORAL|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
58297130|NCT02631317|BEHAVIORAL|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
58408600|NCT01466660|DRUG|gefitinib|Gefitinib once daily
57942919|NCT04524702|DRUG|Hydroxychloroquine|Given PO
57942920|NCT04524702|DRUG|Nab-paclitaxel|Given IV
57942921|NCT04524702|DRUG|Paricalcitol|Given IV
57942922|NCT01529099|DEVICE|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
57942923|NCT02317211|DIETARY_SUPPLEMENT|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
57942924|NCT02317211|DIETARY_SUPPLEMENT|placebo|starch
57942925|NCT00080028|DRUG|Motexafin Gadolinium Injection|
57942926|NCT02472041|DEVICE|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
57942927|NCT02472041|DEVICE|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
57942928|NCT04154670|BIOLOGICAL|MGTA-145|MGTA-145 will be given intravenously
57942929|NCT00382720|DRUG|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
58297131|NCT02631317|BEHAVIORAL|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
58297132|NCT02884739|OTHER|Data collection|
58297133|NCT04213391|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane take 2550mg once a day.
58297134|NCT04213391|DIETARY_SUPPLEMENT|Placebo|Placebo take 2550mg once a day.
58408601|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
58408602|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
58408603|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
58408604|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
58408605|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
58408606|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
57731374|NCT00413153|DRUG|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
57731375|NCT00283504|DRUG|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
57731376|NCT03675386|OTHER|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
57942930|NCT00382720|DRUG|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
57942931|NCT00382720|DRUG|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
57942932|NCT02467283|GENETIC|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
57942933|NCT03406247|DRUG|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months"
57942934|NCT03406247|DRUG|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
57942935|NCT00123292|DRUG|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
58408607|NCT03602313|DEVICE|Body Weight Support Gait Training|
58408608|NCT03602313|OTHER|Traditional Gait Training|
57731377|NCT03675386|OTHER|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
57731378|NCT00329277|PROCEDURE|perimetry|
57731379|NCT04956393|BEHAVIORAL|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
57942936|NCT00123292|DRUG|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
57942937|NCT00123292|DRUG|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
57942938|NCT03868540|DRUG|BI 1291583|tablet
57942939|NCT03868540|DRUG|Placebo|tablet
58297135|NCT06151353|DIAGNOSTIC_TEST|REMS|Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation
58297136|NCT06434194|DEVICE|Serranator PTA Serration Catheter|The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
58297137|NCT06434194|DRUG|PTA (Standard of Care)|A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
58297138|NCT00302978|BEHAVIORAL|Behavior therapy|
58297139|NCT00427141|DRUG|GSK580416|
58408609|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
58408610|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
58408611|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
58408612|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
57942940|NCT00257166|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
57942941|NCT00257166|DRUG|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
57942942|NCT00424749|DRUG|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m\^2.
57942943|NCT00424749|DRUG|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
57942944|NCT04552275|DIAGNOSTIC_TEST|Proteomics Analysis|Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
57942945|NCT04957342|BIOLOGICAL|amnion-chorion membrane|allograft to be placed on palate
57942946|NCT04957342|PROCEDURE|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
57942947|NCT04424160|BIOLOGICAL|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
57942948|NCT04344340|DIAGNOSTIC_TEST|clinical examination|clinical examination
57942949|NCT01141114|OTHER|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
57942950|NCT01141114|OTHER|Usual care|Usual care
57942951|NCT01898572|OTHER|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
57942952|NCT00053924|DRUG|perifosine|
57942953|NCT03344419|DRUG|CI-581a|Medication infusion intravenously over 1 hour.
57942954|NCT03344419|DRUG|CI-581b|Medication infusion intravenously over 1 hour.
58297140|NCT00700375|DRUG|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
58297141|NCT00700375|DRUG|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
58297142|NCT03141112|PROCEDURE|renal replacement therapy|
58297143|NCT01961414|DRUG|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
58297144|NCT05893862|DRUG|MK-8189|Oral Tablet
58408613|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
57942955|NCT03344419|BEHAVIORAL|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
57942956|NCT03344419|BEHAVIORAL|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
57942957|NCT01205230|DRUG|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
57942958|NCT05780255|DEVICE|VV-ECMO|veno-venous extracorporeal membrane oxygenation
57942959|NCT05764382|BEHAVIORAL|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.
57942960|NCT05764382|OTHER|Usual care|Usual care as per primary care physican, physical therapist.
57942961|NCT02558920|OTHER|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
57942962|NCT01186796|DRUG|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
57942963|NCT01798368|DEVICE|PBASE system 2.0|
57942964|NCT05160155|PROCEDURE|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
57942965|NCT05160155|PROCEDURE|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
58297145|NCT05893862|DRUG|Moxifloxacin|Oral Tablet
58297146|NCT05893862|DRUG|Placebo|Oral Tablet
58297147|NCT00419757|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
58297148|NCT00419757|DRUG|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
58297149|NCT01439243|DRUG|Donepezil|10 mg Tablet
58297150|NCT01439243|DRUG|Aricept®|10 mg Tablet
57942966|NCT04383379|BEHAVIORAL|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
57942967|NCT01762215|BEHAVIORAL|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
57942968|NCT05842369|DEVICE|ADVOS|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
57942969|NCT05842369|DEVICE|CVVHD|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
57942970|NCT04193020|OTHER|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
58077431|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
58077432|NCT00381134|DRUG|losartan 100 mg orally once daily|
58077433|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
58077434|NCT00381134|DRUG|placebo once orally once daily|
58297151|NCT06258434|DIAGNOSTIC_TEST|multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)|Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
58297152|NCT01801709|GENETIC|intracerebral administration of AAVrh.10cuARSA|
58297153|NCT04953195|DRUG|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
57942971|NCT01353040|DRUG|AVI-6003|Single intravenous administration
58297154|NCT00227539|DRUG|cisplatin|
58297155|NCT00227539|DRUG|pemetrexed disodium|
58297156|NCT00227539|PROCEDURE|adjuvant therapy|
57942972|NCT01353040|DRUG|Placebo|Single intravenous administration
58297157|NCT00227539|PROCEDURE|therapeutic conventional surgery|
58297158|NCT00227539|RADIATION|fludeoxyglucose F 18|
58297159|NCT05943470|DRUG|Icodextrin Peritoneal Dialysis Solution|alternative day use of icodextrin comparing with daily use of icodextrin
58297160|NCT01944436|DRUG|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
58297161|NCT01519817|BIOLOGICAL|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
57942973|NCT05280028|DRUG|Tibolone 2.5 mg|Tibolone 2.5 mg per day
57942974|NCT05280028|DRUG|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
57942975|NCT05214612|COMBINATION_PRODUCT|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
57942976|NCT00670436|DEVICE|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
58297162|NCT05681013|BEHAVIORAL|Laughter Therapy|The effect of the Laughter Therapy on nursing students
57942977|NCT00670436|DEVICE|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
57942978|NCT02479100|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
57942979|NCT02146508|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
57942980|NCT02146508|DEVICE|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
58297163|NCT00429832|DRUG|Ondansetron|
58297164|NCT00429832|DRUG|promethazine|
58297165|NCT03172728|BEHAVIORAL|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
57942981|NCT03378804|PROCEDURE|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
58408614|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
58408615|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
58408616|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
58408617|NCT04755166|PROCEDURE|Lateral ridge augmentation|
58408618|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
58408619|NCT02032693|OTHER|Placebo|
58408620|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
57942982|NCT03378804|PROCEDURE|Continous epidural analgesia|
57942983|NCT05341362|PROCEDURE|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
57942984|NCT05739565|BEHAVIORAL|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
57942985|NCT05381142|DRUG|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
58408621|NCT01913665|OTHER|B.lactis|
57942986|NCT05381142|DRUG|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
57942987|NCT03099642|RADIATION|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
58408622|NCT01913665|OTHER|Inulin|
58408623|NCT01913665|OTHER|B.Lactis +Inulin|
58408624|NCT01913665|OTHER|Placebo|
58408625|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
58408626|NCT04573426|DRUG|Placebo|Liquid placebo solution
58408627|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
58408628|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
58408629|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
58408630|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
58408631|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
58408632|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
57942988|NCT00699465|DRUG|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
57942989|NCT00699465|DRUG|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
57942990|NCT05442151|DRUG|PET/CT ([F-18]FAPI-74)|PET/CT using \[18F\] FAPI-74 injection
57942991|NCT00304200|DRUG|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
58297166|NCT03912740|DRUG|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
57942992|NCT02863731|OTHER|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
57942993|NCT02863731|OTHER|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
57942994|NCT04328246|DEVICE|IES System|The IES system is composed of a stimulator and self-adhesive surface gel electrodes.
57942995|NCT04328246|OTHER|Standard of Care Therapy|Standard institutional practices for treating pressure injury.
58297167|NCT03912740|DRUG|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
58297168|NCT03912740|DRUG|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
58408633|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
58408634|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
58408635|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
58408636|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
58408637|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
57942996|NCT00603460|BIOLOGICAL|DCVax-L and T Cells|"Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit"
57942997|NCT04378816|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
57951312|NCT04001023|DEVICE|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
57951313|NCT01056627|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
57951314|NCT00239798|DRUG|FTY720|
57951315|NCT02728830|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
58297169|NCT03565757|BEHAVIORAL|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
58297170|NCT02752815|DRUG|Rituximab|
58297171|NCT02752815|DRUG|Cyclophosphamide|
58077435|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
57942998|NCT05710120|OTHER|Hepatitis C Screening Alerts in CHORUS™|"ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test."
58077436|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
58077437|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
58077438|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
57942999|NCT05710120|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
57943000|NCT00526409|DRUG|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
57943001|NCT00526409|DRUG|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
57943002|NCT00526409|DRUG|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
57943003|NCT00526409|DRUG|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
57943004|NCT00526409|DRUG|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
57943005|NCT00526409|DRUG|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
57943006|NCT00526409|DRUG|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
57943007|NCT02819635|DRUG|Placebo|Film-coated tablet for oral administration
57943008|NCT02819635|DRUG|Upadacitinib|Film-coated tablet for oral administration
58077439|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
58077440|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
58077441|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
57943009|NCT05838079|OTHER|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
57943010|NCT00689702|DRUG|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
57943011|NCT00364520|OTHER|Shanghai workers|
58077442|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
58077443|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
58077444|NCT06715709|DRUG|Dexamethasone IV|Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.
58077445|NCT06715709|DRUG|Dexamethasone IV+Oral|Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
58297172|NCT02752815|DRUG|Epirubicin|
58297173|NCT02752815|DRUG|Vincristine|
58077446|NCT06715709|DRUG|Dexamethasone IV+Oral 2 Day|Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
58297174|NCT02752815|DRUG|Prednisone|
58297175|NCT03575247|DRUG|Glucocorticoids|Long-term use of glucocorticoids
58297176|NCT02926105|BEHAVIORAL|T&E Home-based exercise programme|"T\&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
58297177|NCT02926105|BEHAVIORAL|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
58408638|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
58408639|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
58408640|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
58408641|NCT00336167|DRUG|bezafibrate (drug)|
58297178|NCT02926105|BEHAVIORAL|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
58297179|NCT05874102|OTHER|Sidelying|Position sidelying then Upright
58408642|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
58408643|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
58408644|NCT00497328|DRUG|N-acetylcysteine|
58408645|NCT00497328|DRUG|Sodium Bicarbonate|
58408646|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
58408647|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
58408648|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
58408649|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
58408650|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
58408651|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
58077447|NCT04784676|OTHER|restoration|indirect restoration
58077448|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
58077449|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
58297180|NCT05874102|OTHER|Upright|Position upright then sidelying
58297181|NCT03113669|BEHAVIORAL|CBT-GSH|
58297182|NCT01168921|DRUG|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
58297183|NCT03175081|DRUG|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
58297184|NCT03175081|DRUG|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
58297185|NCT00035178|DRUG|Argatroban|
57943012|NCT03974776|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
57943013|NCT03974776|OTHER|Placebo|Placebo administered subcutaneously
57943014|NCT00001075|DRUG|Ritonavir|
57943015|NCT00001075|DRUG|Lamivudine|
57943016|NCT00001075|DRUG|Zidovudine|
57943017|NCT01651104|BIOLOGICAL|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
57943018|NCT01121523|BEHAVIORAL|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
57943019|NCT02280395|DRUG|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
57943020|NCT02280395|DRUG|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
57943021|NCT03069352|DRUG|Placebo|tablet
57943022|NCT03069352|DRUG|Venetoclax|tablet
57943023|NCT03069352|DRUG|Cytarabine|Subcutaneous injection
57943024|NCT01792349|BEHAVIORAL|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
57943025|NCT03199040|DRUG|Durvalumab|-Human monoclonal antibody
58077450|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
58077451|NCT06722534|DRUG|Celecoxib 400mg|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
58297186|NCT02168491|DRUG|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
57943026|NCT03199040|BIOLOGICAL|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
58077452|NCT06722534|DRUG|Placebo|Participants in the control group receive identically appearing placebo twice daily for 6 months
58077453|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
58077454|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
58077455|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
58077456|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
58408652|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
57943027|NCT03199040|DEVICE|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
57943028|NCT03199040|PROCEDURE|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
57943029|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
57943030|NCT03083704|DRUG|Apixaban 5 MG|factor Xa inhibitor
57943031|NCT03083704|DRUG|Rivaroxaban 20 MG|factor Xa inhibitor
57943032|NCT03083704|DRUG|Enoxaparin sodium|low molecular weight heparin
57943033|NCT03083704|DRUG|Edoxaban 60 MG|factor Xa inhibitor
57943034|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
57943035|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
57943036|NCT03083704|DRUG|Apixaban 10 MG|factor Xa inhibitor
57943037|NCT03083704|DRUG|Rivaroxaban 10 MG|factor Xa inhibitor
57943038|NCT04602169|PROCEDURE|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise \>38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
57951316|NCT02389127|DEVICE|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
57951317|NCT05535348|BEHAVIORAL|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
58077457|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
58077458|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
57943039|NCT04602169|PROCEDURE|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
57943040|NCT04066036|OTHER|This is an observational study only.|This is an observational study only.
57943041|NCT02645760|OTHER|Core stabilization exercise|7-weeks of core stabilization exercise
57943042|NCT02645760|OTHER|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
57943043|NCT00843518|DRUG|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
57943044|NCT00843518|DRUG|Placebo|Placebo orally twice daily for 12 weeks
57943045|NCT04240015|OTHER|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
57943046|NCT04529681|DEVICE|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
57943047|NCT04529681|OTHER|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
57943048|NCT06076837|DRUG|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
57943049|NCT06076837|DRUG|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
57943050|NCT06076837|DRUG|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
57943051|NCT06076837|DRUG|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
57943052|NCT06240221|DEVICE|Elevation Spine Saber-C System|Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
57943053|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session.
57943054|NCT05418673|DRUG|BIIB122|Administered as specified in the treatment arm.
57943055|NCT05418673|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
57943056|NCT04474665|DEVICE|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
57943057|NCT05144750|BEHAVIORAL|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
58297187|NCT02168491|DRUG|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
58297188|NCT02076620|DRUG|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
57943058|NCT02791984|DEVICE|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
57943059|NCT03747211|BEHAVIORAL|Aerobic exercise|High Intensity Interval Training (HIIT)
58077459|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
58297189|NCT02076620|DRUG|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
58297190|NCT03983408|DIETARY_SUPPLEMENT|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
57943060|NCT01845012|OTHER|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
57943061|NCT01186575|OTHER|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
57943062|NCT05539768|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
58297191|NCT03983408|DIETARY_SUPPLEMENT|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
58297192|NCT04295798|OTHER|Traditional tDCS|The participant will receive a single-session of traditional tDCS for 20 minutes.
58297193|NCT04295798|OTHER|Traditional Sham|The participant will receive a single-session of traditional sham for 20 minutes.
58297194|NCT04295798|OTHER|Personalized tDCS|The participant will receive a single-session of personalized tDCS for 20 minutes.
58297195|NCT04295798|OTHER|Personalized Sham|The participant will receive a single-session of personalized sham for 20 minutes.
58408653|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
58297196|NCT04651998|DIAGNOSTIC_TEST|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
58297197|NCT04192721|BEHAVIORAL|Cognitive Behavioral Therapy-Based Group Counseling|"* Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents"
58297198|NCT01278602|DRUG|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
58297199|NCT01657162|DRUG|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
58297200|NCT00689689|DEVICE|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
58297201|NCT00689689|DEVICE|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
58297202|NCT05483868|DRUG|AU-011|Administration of AU-011 intratumorally and intramurally
58408654|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
58408655|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
58077460|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
58297203|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Adminstration|AU-011 Intratumorally and Intramurally
57943063|NCT00542295|DRUG|alverine citrate and simeticone|
57943064|NCT00542295|DRUG|placebo|
58077461|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
58077462|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
58077463|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
58297204|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Administration|AU-011 Intratumorally
58297205|NCT02316639|OTHER|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
58408656|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
58297206|NCT05236907|DRUG|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
58297207|NCT05236907|OTHER|No intervention|No intervention was used.
57943065|NCT03012087|BEHAVIORAL|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
57943066|NCT03012087|OTHER|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
57943067|NCT05362422|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
58297208|NCT05236907|DRUG|Midazolam|7.5 mg of Midazolam orally.
58297209|NCT02073526|DRUG|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
58077464|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
58408657|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
58408658|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
58408659|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
58408660|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
57943068|NCT05362422|DEVICE|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
57943069|NCT05802654|RADIATION|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
58077465|NCT06723002|DRUG|Atherolive 500mg/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
58297210|NCT01171157|OTHER|Routine sample collection|Collection of routine nasal/throat swab samples
58297211|NCT01781104|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
58297212|NCT01781104|DRUG|Placebo|Placebo delivered subcutaneously once daily for 14 days.
58297213|NCT02182401|DRUG|BI 207127 NA|Days 3-8 and days 25-30
58077466|NCT06723002|DRUG|Atherolive 1000/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
58077467|NCT06723002|DRUG|Placbo_Atherolive|"Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
58297214|NCT02182401|DRUG|BI 201335 NA|Days 15-30
58297215|NCT02182401|DRUG|Midazolam|Days 1, 7, 23 and 29
58297216|NCT02182401|DRUG|Tolbutamide|Days 1, 7, 23 and 29
58297217|NCT00631059|OTHER|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
58077468|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
58077469|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
58077470|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
58077471|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
57943070|NCT05342662|DEVICE|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
57943071|NCT05342662|DEVICE|Glasses with clear lenses|Non-blue light-blocking glasses
57943072|NCT03854929|DRUG|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
57943073|NCT03854929|DRUG|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
57943074|NCT01312038|DRUG|Simethicone|single 125 mg chewable tablet
57943075|NCT01312038|DRUG|Placebo|chewable calcium tablet
57943076|NCT05038020|DRUG|AKST4290|Oral AKST4290
57943077|NCT05038020|DRUG|Placebo|Oral Placebo
57943078|NCT00164112|DRUG|Cooperstown 5+1 alone|
57943079|NCT00164112|DRUG|Azithromycin plus Cooperstown 5+1|
57943080|NCT00164112|DRUG|Telithromycin plus Cooperstown 5+1|
57943081|NCT00164112|DRUG|Levofloxacin plus Cooperstown 5+1|
57943082|NCT05288218|DEVICE|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
57943083|NCT05288218|DEVICE|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
58077472|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
58077473|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
57943084|NCT02462668|PROCEDURE|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
57943085|NCT02462668|PROCEDURE|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
57943086|NCT02462668|PROCEDURE|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
58077474|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
58077475|NCT01510704|DRUG|APD421|IV
58408661|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
57943087|NCT01218464|DRUG|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
57943088|NCT01218464|DRUG|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
57943089|NCT01027819|DEVICE|Mobile bearing|Mobile bearing in total knee arthroplasty
57943090|NCT01027819|DEVICE|Fixed bearing|Fixed bearing in total knee arthroplasty
57943091|NCT01684072|BIOLOGICAL|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
57943092|NCT01684072|BIOLOGICAL|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
57943093|NCT02988570|BEHAVIORAL|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
58077476|NCT01510704|DRUG|Placebo|IV
58077477|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
58077478|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
58077479|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
58077480|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
58077481|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
58077482|NCT04371705|OTHER|control|placebo
58077483|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
58077484|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
58077485|NCT06243679|DRUG|Immunotherapy|Monotherapy with PD-1 inhibitors, up to 1 year.
57731380|NCT04956393|BEHAVIORAL|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
57943094|NCT06265857|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
57943095|NCT06265857|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
58077486|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
58077487|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
58077488|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
58077489|NCT06137040|DRUG|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg"
58408662|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
57731381|NCT05133557|OTHER|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
58077490|NCT06137040|OTHER|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
58077491|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
58077492|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
58077493|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
58077494|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
58077495|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
58077496|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
58077497|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
58297218|NCT03174015|BEHAVIORAL|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
58297219|NCT00407225|DRUG|Difluprednate Ophthalmic Emulsion|
58297220|NCT06203821|DRUG|NP137|NP137 for the Treatment of Resectable Pancreatic Cancer
58297221|NCT06202144|DEVICE|Noninvasive support|Noninvasive respiratory support delivered through a helmet
58408663|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
58408664|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
58408665|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
58297222|NCT03030625|RADIATION|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
58297223|NCT03534947|DRUG|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
58297224|NCT03534947|DRUG|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
58408666|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
58077498|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
58077499|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
58077500|NCT06724770|OTHER|Resilience training intervention|Training intervention on tools and strategies to strengthen the resilience of work teams in healthcare centres.
58077501|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
58297225|NCT03534947|PROCEDURE|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
58297226|NCT03534947|OTHER|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
58408667|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
58297227|NCT01575418|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
58408668|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
57943096|NCT06265857|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
57943097|NCT02439996|DRUG|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
57943098|NCT02439996|DRUG|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
58077502|NCT05361005|DRUG|Placebo|Intravenous injection
58077503|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
58077504|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
58077505|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
58077506|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
58077507|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
58297228|NCT01575418|DRUG|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
58408669|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
58408670|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
58408671|NCT01574898|DRUG|V0474 - A mg|Single oral administration
58408672|NCT01574898|DRUG|V0474 - B mg|Single oral administration
58408673|NCT01574898|DRUG|V0474 - C mg|Single oral administration
58408674|NCT01574898|DRUG|V0018 - B mg|Single oral administration
58408675|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
58408676|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
58077508|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
58077509|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
58077510|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
58077511|NCT05123703|DRUG|Ocrelizumab|Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
57731382|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
57731383|NCT04698980|DIAGNOSTIC_TEST|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
58077512|NCT05123703|OTHER|Ocrelizumab Placebo|Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.
58077513|NCT05123703|DRUG|Fingolimod|Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
58077514|NCT05123703|OTHER|Fingolimod Placebo|Fingolimod matching placebo will be administered daily as a capsule.
58297229|NCT01575418|DRUG|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
58297230|NCT01575418|RADIATION|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
58297231|NCT01121510|DEVICE|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
58297232|NCT06265090|OTHER|therapeutic exercises|Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.
58408677|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
58408678|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
58408679|NCT03359707|OTHER|survey|no intervention just survey
58408680|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
58408681|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
58408682|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
58408683|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
58408684|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
58408685|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
57943099|NCT02439996|DRUG|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
57943100|NCT03941678|DIETARY_SUPPLEMENT|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
58408686|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
58408687|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
58408688|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
58408689|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
58408690|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
57943101|NCT03941678|DIETARY_SUPPLEMENT|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
57943102|NCT05931796|OTHER|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
57943103|NCT05931796|OTHER|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
57943104|NCT05376215|DEVICE|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
57943105|NCT04106882|DRUG|Ketones|Supplement administered mid-scan.
57943106|NCT04106882|DRUG|Glucose|Supplement administered mid-scan.
57943107|NCT01236690|DRUG|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
57943108|NCT00228995|DRUG|epoetin alfa|
57943109|NCT05018247|PROCEDURE|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
57943110|NCT02685423|BEHAVIORAL|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
57943111|NCT02685423|BEHAVIORAL|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
58408691|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
58408692|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
57943112|NCT02679014|DRUG|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
57943113|NCT02679014|DRUG|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
58077515|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
58408693|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
58408694|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
58408695|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
58408696|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
58408697|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
58408698|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
58297233|NCT06265090|OTHER|exercises|"The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
57943114|NCT01797497|BEHAVIORAL|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
57943115|NCT01465100|RADIATION|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
58297234|NCT05083663|DRUG|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
58408699|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
58077516|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
58408700|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
58408701|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
58408702|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
58408703|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
58408704|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
58408705|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
58408706|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
58408707|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
58408708|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
58408709|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
58408710|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
58408711|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
58297235|NCT03639246|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
58297236|NCT03639246|DRUG|Paclitaxel (Pac)|Paclitaxel is active comparator
58297237|NCT03639246|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
58297238|NCT03639246|OTHER|Placebo|Placebo comparator
58297239|NCT04307134|DRUG|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
58408712|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
58408713|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
58408714|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
58408715|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
58408716|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
58408717|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
58408718|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
58297240|NCT05544591|DRUG|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
57943116|NCT01465100|PROCEDURE|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
57943117|NCT01465100|DRUG|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
57943118|NCT01465100|OTHER|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
57943119|NCT01465100|BEHAVIORAL|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
57943120|NCT01465100|DIAGNOSTIC_TEST|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
57943121|NCT01465100|PROCEDURE|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
57943122|NCT04858763|OTHER|No Intervention|There will be no intervention during this study.
57943123|NCT03440099|OTHER|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
57943124|NCT00479284|PROCEDURE|Average volume assured pressure support (AVAPS)|
57943125|NCT01534247|DRUG|CAZ-AVI|Infusion
57943126|NCT01534247|DRUG|metronidazole|Infusion
57943127|NCT01534247|DRUG|CAZ-AVI + metronidazole|Infusion
57943128|NCT00096785|DRUG|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
57943129|NCT00096785|DRUG|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
57943130|NCT01434589|BEHAVIORAL|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
57943131|NCT00923403|DIETARY_SUPPLEMENT|plant sterol enriched soymilk|plant sterol enriched soymilk
58297241|NCT05544591|DRUG|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
58297242|NCT05544591|DRUG|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
58297243|NCT03819413|DIAGNOSTIC_TEST|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
58297244|NCT03819413|DIAGNOSTIC_TEST|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
58408719|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
58408720|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
57943132|NCT00923403|DIETARY_SUPPLEMENT|control dairy milk|control dairy milk
57943133|NCT05837156|DRUG|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
57943134|NCT05837156|DRUG|Heptaflurane|Heptaflurane only
57943135|NCT05837156|DRUG|Cyclophenol|Cyclophenol only
58297245|NCT03819413|DIAGNOSTIC_TEST|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
58408721|NCT01028716|DRUG|Cyclophosphamide|Given IV
58408722|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
58408723|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
58408724|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
57731384|NCT03447769|DRUG|Canakinumab|200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
57943136|NCT05242055|OTHER|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
57943137|NCT03417908|PROCEDURE|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
57943138|NCT03417908|PROCEDURE|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
58077517|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
58077518|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
58297246|NCT03445000|DRUG|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
58297247|NCT05306717|OTHER|Questionnaire|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
58297248|NCT04633746|DIAGNOSTIC_TEST|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
58297249|NCT05701982|BEHAVIORAL|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
58297250|NCT05701982|OTHER|Usual Care|Usual Care
58297251|NCT05649670|OTHER|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
58077519|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
58077520|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
58297252|NCT01906242|OTHER|water|
58297253|NCT01906242|OTHER|sodium hypochlorite|
58297254|NCT01906242|OTHER|sodium bicarbonate|
58297255|NCT01906242|OTHER|chlorhexidine|
57731385|NCT03447769|DRUG|Placebo|Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
57731386|NCT02341716|PROCEDURE|WA|Walk advice with Nordic Poles and best medical treatment
57731387|NCT02341716|PROCEDURE|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
57731388|NCT02341716|PROCEDURE|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
57943139|NCT04881825|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
57943140|NCT04090710|DRUG|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
58077521|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
58408725|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
58408726|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
58408727|NCT01028716|DRUG|Tacrolimus|Given IV or PO
57731389|NCT04000906|DRUG|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
57731390|NCT04000906|DRUG|Cisplatin|10.5 mg/m2
57731391|NCT00402753|BEHAVIORAL|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
57731392|NCT00637221|DRUG|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
57943141|NCT04090710|RADIATION|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
57943142|NCT03533647|OTHER|Observational|none (observational study)
57943143|NCT03081442|DRUG|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
58077522|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
57943144|NCT03081442|DEVICE|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
57943145|NCT03105167|PROCEDURE|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
57943146|NCT03105167|PROCEDURE|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
57943147|NCT02265770|DRUG|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
57943148|NCT02265770|DRUG|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
57943149|NCT02265770|DRUG|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
57943150|NCT02265770|RADIATION|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
58077523|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
58297256|NCT00994110|DRUG|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
58408728|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
58408729|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
58408730|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
58408731|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
57731393|NCT00270543|DRUG|Taxotere, Fluorouracil, Leucovorin|
57731394|NCT03293823|BEHAVIORAL|VSOP training|a computerized cognitive training of attention and processing speed
57731395|NCT03293823|BEHAVIORAL|MLA control|a computerized cognitive intervention of multiple mental leisure activities
57731396|NCT03711981|PROCEDURE|TAP Block|
57943151|NCT02265770|DRUG|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
57943152|NCT02265770|DRUG|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
58408732|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
58408733|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
58408734|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
58408735|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
58408736|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
57943153|NCT02265770|RADIATION|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
58408737|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
58297257|NCT00994110|OTHER|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
57943154|NCT05888727|BEHAVIORAL|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
57943155|NCT05888727|BEHAVIORAL|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
57943156|NCT01541189|DRUG|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
58077524|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
58297258|NCT03112694|OTHER|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
58297259|NCT02130947|BEHAVIORAL|Exercise|
58297260|NCT06116578|DRUG|Pembrolizumab|cf Arm A
58297261|NCT06116578|DRUG|Pembrolizumab and Olaparib|cf Arm B
58297262|NCT06116578|DRUG|Pembrolizumab adjuvant|After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
58077525|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
58297263|NCT03225170|BEHAVIORAL|Self Affirmation (SA)|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
58297264|NCT03225170|BEHAVIORAL|Control|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
58297265|NCT00362947|DRUG|LMWH parnaparin subcutaneously|
58408738|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
58408739|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
58077526|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
57943157|NCT05427409|DIETARY_SUPPLEMENT|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
57943158|NCT00741247|PROCEDURE|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
57943159|NCT03789461|PROCEDURE|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
57943160|NCT00139282|DRUG|Squalamine Lactate|
57943161|NCT01656148|DRUG|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
57943162|NCT06462300|BEHAVIORAL|A meaning-centered intervention for young women with weight and shape concerns|"* adapted version of the manualized meaning-centered psychotherapy for cancer patients developed by van der Spek et al. (2017)~* six weekly individual online sessions, each lasting one hour~* sessions led by a certified trainer~* four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
58077527|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
58077528|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
58077529|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
58077530|NCT00475839|DEVICE|Tension-free Vaginal Tape|
58077531|NCT00475839|DEVICE|Monarc sub-fascial hammock|
58077532|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
58077533|NCT01487109|DRUG|Placebo|Matching placebo tablet
58077534|NCT01041027|DRUG|Paclitaxel|Given IV
58077535|NCT01041027|DRUG|Carboplatin|Given IV
58077536|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
58077537|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
58077538|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
58077539|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
58077540|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
57943163|NCT05182463|DRUG|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
57943164|NCT05182463|DRUG|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
57943165|NCT02013947|OTHER|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
57943166|NCT06292091|DRUG|Captopril 12.5 Mg|12.5 mg of captopril
57943167|NCT06292091|DRUG|Sodium bicarbonate 4 G|4 g of sodium bicarbonate
57943168|NCT06292091|DRUG|Torsemide 20 MG|20 mg of torsemide
57943169|NCT05678036|DRUG|Opioid maintenance treatment|A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
57943170|NCT00003004|DRUG|alvocidib|
57943171|NCT00003004|DRUG|cisplatin|
57943172|NCT00003004|DRUG|paclitaxel|
58297266|NCT01076543|OTHER|Laboratory Biomarker Analysis|Correlative studies
58297267|NCT01076543|DRUG|Lenalidomide|Given PO
58297268|NCT01076543|DRUG|Temsirolimus|Given IV
58408740|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
58408741|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
58408742|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
57943173|NCT04159142|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
58077541|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
58077542|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
58077543|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
58077544|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
58077545|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
58297269|NCT06175286|OTHER|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
58077546|NCT00197691|PROCEDURE|blood draws, etc.|
58297270|NCT02616783|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
58297271|NCT02616783|DRUG|TDF|300 mg tablet administered orally once daily
58077547|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
58077548|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
58297272|NCT02616783|DRUG|FTC|200 mg capsule administered orally once daily
58408743|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
58408744|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
58408745|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
58408746|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
57943174|NCT04159142|DRUG|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
57943175|NCT05784779|DRUG|GH509|Orally, once daily before bedtime (qhs)
57943176|NCT05784779|DRUG|Placebo|Orally, once daily before bedtime (qhs)
57943177|NCT01379469|DRUG|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
58297273|NCT02616783|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
58297274|NCT02616783|DRUG|3TC|Tablet administered orally
58297275|NCT02616783|DRUG|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
58408747|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
58408748|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
58408749|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
57943178|NCT01379469|DRUG|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
58077549|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
58077550|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
57943179|NCT05340894|PROCEDURE|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
57943180|NCT05340894|PROCEDURE|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
57943181|NCT04452474|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL
57943182|NCT04452474|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
57943183|NCT02177396|DRUG|Telmisartan|
57943184|NCT02177396|DRUG|Valsartan|
57943185|NCT02177396|DRUG|Placebo|
57943186|NCT00488722|DRUG|Zoladex|
57943187|NCT04667377|DRUG|BI 456906|BI 456906
57943188|NCT04667377|DRUG|Placebo|Placebo
57943189|NCT04305275|DRUG|SAGE-324|SAGE-324 oral tablet
57943190|NCT04305275|DRUG|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
57943191|NCT05422820|DIAGNOSTIC_TEST|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (\>150-400 or \>400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
57943192|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in PD|Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).
57943193|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in PD|STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).
58077551|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
58077552|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
58077553|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
58297276|NCT06390657|OTHER|Planning CT, MRI|"SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only."
57943194|NCT06323564|DEVICE|International Affective Picture System (IAPS)|Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).
57943195|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in AN|Verbal Fluencies, Tower of London, TMT-A \& B
57943196|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in AN|STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).
57943197|NCT06323564|DIAGNOSTIC_TEST|Analysis of bio-humoral parameters|the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1
58077554|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
58077555|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
58077556|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
58077557|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
58297277|NCT01562977|DRUG|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
58077558|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
58077559|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
58408750|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
58408751|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
58408752|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
57943198|NCT04452045|DEVICE|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
57943199|NCT04704830|BIOLOGICAL|R21/Matrix-M|Adjuvanted malaria vaccine
57943200|NCT04704830|BIOLOGICAL|Rabies vaccine or Hepatitis A vaccine|Placebo Comparator
57943201|NCT03926975|DEVICE|Scleral Lens|The contact lens will be worn on one eye.
57943202|NCT03926975|OTHER|No lens|No lens worn on the contralateral control eye
57943203|NCT05442099|BEHAVIORAL|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
57943204|NCT05442099|BEHAVIORAL|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
57943205|NCT02330575|BEHAVIORAL|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
57943206|NCT02330575|BEHAVIORAL|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
57943207|NCT00359021|DRUG|TMC125|200 mg twice daily until commercially available
57943208|NCT04327765|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
57943209|NCT04327765|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
58297278|NCT01635829|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
58297279|NCT01635829|DRUG|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
58297280|NCT01635829|DRUG|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
57943210|NCT04327765|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
57943211|NCT02942914|DRUG|LY3209590|Administered SC
57943212|NCT02942914|DRUG|Placebo|Administered SC
57943213|NCT02942914|DRUG|Insulin Glargine|Administered SC
57943214|NCT03690076|OTHER|Endocarditis|Comparison : Endocarditis vs. control
57943215|NCT03690076|OTHER|Obese vs. control|Comparisons : Obese vs. control
57943216|NCT02398708|OTHER|Questionnaires|Both groups will have questionnaires collected and compared.
57943217|NCT02398708|OTHER|Blood Sample|Both groups will have a blood sample collected and compared.
57943218|NCT02398708|OTHER|Stool Sample|Both groups will have a stool sample collected and compared.
57943219|NCT02398708|OTHER|Clinical data|Both groups will have clinical data collected and compared.
57943220|NCT06490549|OTHER|RSV infection observation cohort|No intervention; Epidemiological Study. Participants will receive standard care based on local clinical practice
57943221|NCT03924752|DEVICE|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
58077560|NCT00000172|DRUG|Galantamine|
58077561|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
58297281|NCT05739487|PROCEDURE|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
58077562|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
58077563|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
58077564|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
58077565|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
58077566|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
58297282|NCT00970905|DRUG|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
58408753|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
58408754|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
58408755|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
58077567|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
58077568|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
57943222|NCT04699019|OTHER|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
57943223|NCT04699019|OTHER|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
58077569|NCT06354660|DRUG|Retatrutide|Administered SC.
58077570|NCT06354660|DRUG|Placebo|Administered SC.
57943224|NCT04439604|OTHER|regional ventilation monitoring|regional ventilation monitoring
57943225|NCT04579562|OTHER|No intervention|This is observational, non-interventional study
57943226|NCT03974087|DEVICE|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
57943227|NCT03310450|OTHER|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
58077571|NCT01024270|DRUG|Misoprostol|
58077572|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
58077573|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
58077574|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
58077575|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
58077576|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
58077577|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
58077578|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
58077579|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
58077580|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
58077581|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
58297283|NCT00970905|DRUG|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
58297284|NCT00055341|DRUG|Peginterferon alfa-2a|
58297285|NCT00055341|DRUG|Ribavirin|
58297286|NCT06063928|PROCEDURE|Archive Sample Retrieval|Undergo collection of archival tumor tissue
58297287|NCT06063928|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
58408756|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
57943228|NCT02075242|DRUG|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
57943229|NCT02075242|DRUG|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
57943230|NCT02015442|DIETARY_SUPPLEMENT|Sucrose|
57943231|NCT00820911|DRUG|cyclosporine (reduced exposure) / everolimus|twice daily
57943232|NCT00820911|DRUG|AEB071 300 mg b.i.d. / everolimus|twice daily
57943233|NCT00820911|DRUG|AEB071 200 mg b.i.d. / everolimus|twice daily
57943234|NCT01892163|DEVICE|Ozurdex|Dexamethasone implant (Ozurdex)
57943235|NCT04662658|DRUG|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
57943236|NCT05149222|DEVICE|Digital ACT|This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
57943237|NCT01496729|PROCEDURE|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
57943238|NCT01496729|PROCEDURE|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
57943239|NCT05040802|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
57943240|NCT01440270|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
57943241|NCT01043341|BEHAVIORAL|educative folder|folder about HPV infection and vaccines
58297288|NCT06063928|OTHER|Electronic Health Record Review|Medical records reviewed
58297289|NCT06063928|OTHER|Genetic Testing|Undergo genetic testing
58408757|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
58077582|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
58077583|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
58077584|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
58077585|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
58077586|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
58077587|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
58077588|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
58077589|NCT02528331|DEVICE|Transcranial magnetic stimulation|
58077590|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
58077591|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
58408758|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
57943242|NCT03127839|PROCEDURE|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
58077592|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
58077593|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
58077594|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
58077595|NCT00242645|BEHAVIORAL|Health Information|
58077596|NCT00242645|BEHAVIORAL|Preventive Services|
58077597|NCT00242645|BEHAVIORAL|Computer tailored information|
58077598|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
58077599|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
57943243|NCT03127839|PROCEDURE|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
58077600|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
57943244|NCT03127839|BEHAVIORAL|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
58297290|NCT06063928|OTHER|Questionnaire Administration|Complete questionnaires
58297291|NCT05863650|DEVICE|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
58408759|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
57943245|NCT04134182|DRUG|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
58408760|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
58408761|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
58408762|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
57943246|NCT04134182|DRUG|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
57943247|NCT02329080|DRUG|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
57943248|NCT02329080|DRUG|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
57943249|NCT02329080|DRUG|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
57943250|NCT02329080|DRUG|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
57943251|NCT02329080|DRUG|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
57943252|NCT02329080|DRUG|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
57943253|NCT02329080|DRUG|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
57943254|NCT02329080|DRUG|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
57943255|NCT02329080|RADIATION|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
57943256|NCT06489600|OTHER|No Rays, Thanks Mineral sunscreen|"Wash your face with standard facewash and apply a pea size amount on the face in the morning.~Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical"
57943257|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation|Oral, encapsulated FMT
57943258|NCT02801656|DRUG|Vancomycin|Vancomycin po 125 mg qid x 10 days
57943259|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
57943260|NCT02801656|DRUG|Vancomycin Placebo|Matching placebo to Vancomycin
57943261|NCT02164175|DEVICE|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
57943262|NCT02075489|OTHER|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
57943263|NCT02075489|OTHER|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
57943264|NCT03908320|OTHER|Menstrual Cycle Timing|Quit date is set to menstrual phase.
57943265|NCT03908320|OTHER|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
58077601|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
58077602|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
58077603|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
58408763|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
57943266|NCT03908320|DRUG|NRT Patch|NRT patch is provided
57943267|NCT03908320|BEHAVIORAL|Cessation Counseling|Cessation counseling is provided
57943268|NCT03750578|BEHAVIORAL|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
57943269|NCT02681679|DRUG|0.1% bromfenac ophthalmic solution|
57943270|NCT02681679|PROCEDURE|femtosecond laser cataract surgery|
57943271|NCT06317675|OTHER|Osteopathic manipulative treatment (OMT)|Manual therapy on different area of the body.
57943272|NCT02219282|OTHER|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
57943273|NCT02426476|BEHAVIORAL|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
57943274|NCT02426476|BEHAVIORAL|sham HRVB training|passive relaxation
57943275|NCT05301920|DEVICE|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
57943276|NCT00053950|DRUG|pyrazoloacridine|Given IV
57943277|NCT00053950|BIOLOGICAL|filgrastim|Given IV or SC
57943278|NCT00053950|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
57943279|NCT00053950|PROCEDURE|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
57943280|NCT00053950|OTHER|laboratory biomarker analysis|Correlative studies
57943281|NCT00053950|OTHER|pharmacological study|Correlative studies
58297292|NCT05863650|OTHER|Face to face education|In the face-to-face education group, two case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
58297293|NCT02067520|DRUG|intrathecal hydromorphone (IT hydromorphone)|
58297294|NCT03489343|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
58077604|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
58077605|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
58077606|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
58077607|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
58077608|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
58077609|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
58077610|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
58077611|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
58297295|NCT02874313|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
58297296|NCT02874313|DRUG|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
58297297|NCT02874313|OTHER|Conventional anti-diabetic diet recommendations|
58297298|NCT02810418|DRUG|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
58408764|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
58408765|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
58408766|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
58408767|NCT05124587|OTHER|No intervention group|No intervention group
58408768|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
58077612|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
58077613|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
58077614|NCT02549391|DRUG|KHK7580|Oral administration
58077615|NCT02549391|DRUG|KRN1493|Oral administration
58077616|NCT01136317|DRUG|Omeprazole|
58077617|NCT01136317|DRUG|Rabeprazole|
58077618|NCT01136317|DRUG|Lactose|
57943282|NCT05897021|BEHAVIORAL|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
58077619|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
58077620|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077621|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
58077622|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077623|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077624|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077625|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077626|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
58077627|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
58077628|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
58077629|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
58297299|NCT02810418|DRUG|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
58297300|NCT02810418|DEVICE|Mesothelin Expression|Research blood test for Arm B1 eligibility
58297301|NCT02810418|DRUG|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
58297302|NCT05874362|OTHER|Diagnosis of depressive episode or post traumatic stress disorder|Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
58077630|NCT06716632|DEVICE|Using Ligasure for heamostasis|Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm.
58077631|NCT06716632|PROCEDURE|Use of conventional knot tying technique for heamostasis|Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers. While these techniques effectively control bleeding from vessels, they are time-consuming and carry the risk of harming adjacent structures like the recurrent and superior laryngeal nerves.
58077632|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
58077633|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
58077634|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
57943283|NCT05897021|BEHAVIORAL|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
57943284|NCT06159387|DRUG|Cannabis Extract Oil SR Capsule|"After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model"
58297303|NCT05874362|OTHER|No diagnosis of depressive episode or post traumatic stress disorder|No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
58297304|NCT00001322|DRUG|Leuprolide Acetate 3.75|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
58297305|NCT00001322|DRUG|Estradiol|Transdermal Estradiol, 100mcg/day by skin patch
58408769|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
57943285|NCT04828395|BIOLOGICAL|Camrelizumab|200mg iv Q3W
57943286|NCT04828395|DRUG|Fluzoparib|150mg bid
57943287|NCT04828395|DRUG|Cisplatin，Pemetrexed|Cisplatin 75mg/m2 IV and Pemetrexed 500mg/m2 IV Q3W (Day 1 of each cycle of cycles 1-3) (non-squamous cell carcinoma only)
57943288|NCT04828395|DRUG|Cisplatin，Etoposide|Cisplatin 50mg/m2 IV (the 1st and 8th days of the 1st cycle and the 2nd cycle; the 8th and 15th days of the 3rd cycle); Etoposide 50mg/m2 IV (the 1st cycle And the 1st to the 5th day of the 2nd cycle; the 8th to the 12th day of the 3rd cycle).
58297306|NCT00001322|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
58297307|NCT00001322|DRUG|Placebo suppository|Placebo suppository twice daily
58297308|NCT00001322|DRUG|Placebo patch|Placebo by skin patch
58297309|NCT04478565|OTHER|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
58297310|NCT03435588|PROCEDURE|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
58297311|NCT03435588|PROCEDURE|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
58297312|NCT03435588|PROCEDURE|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
58408770|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
58408771|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
58408772|NCT03397888|DRUG|Betrixaban|80 mg capsule
58408773|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
58297313|NCT01546051|DRUG|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
57943289|NCT04828395|DRUG|Carboplatin, Albumin Paclitaxel|Carboplatin AUC=6, Albumin Paclitaxel 100mg/m2 IV; Days 1, 8 and 15 of cycles 1, 2, and 3.
57943290|NCT04828395|RADIATION|Radiotherapy|60 Gy (total 6 weeks)
58408774|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
57943291|NCT05584982|DEVICE|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
57943292|NCT04483674|DRUG|50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide|"Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL"
57943293|NCT04312685|DEVICE|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
57943294|NCT01392677|DRUG|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
57943295|NCT01392677|DRUG|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
57943296|NCT04114292|DRUG|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
57943297|NCT05782400|RADIATION|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
57943298|NCT05782400|BIOLOGICAL|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
57943299|NCT02069470|BEHAVIORAL|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
57943300|NCT06064942|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
57943301|NCT06064942|BEHAVIORAL|School services for families of children with ADHD|Selected school social personnel will deliver services as usual for the control group.
58297314|NCT01546051|DRUG|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
58297315|NCT01546051|DRUG|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
58297316|NCT01546051|DRUG|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
58297317|NCT00844090|DRUG|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
58408775|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58408776|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
58408777|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
57943302|NCT05337579|OTHER|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
57943303|NCT05337579|PROCEDURE|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
58077635|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
58077636|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
58077637|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
58077638|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
58077639|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
58077640|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
58077641|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
58077642|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
57731397|NCT05393232|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
58077643|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
57731398|NCT05393232|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
57731399|NCT02342067|DRUG|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
58077644|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
58297318|NCT00533819|OTHER|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
58297319|NCT03204617|BIOLOGICAL|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
58297320|NCT03204617|BIOLOGICAL|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
58297321|NCT03204617|DRUG|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
58297322|NCT00120237|DRUG|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
58297323|NCT01316575|DEVICE|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
58408778|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
58408779|NCT06413420|OTHER|No treatment|No treatment
58408780|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
57731400|NCT02342067|DRUG|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
58077645|NCT02164058|DEVICE|TandemHeart System|
58077646|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
58408781|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
58408782|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
58408783|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
58077647|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
58077648|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
58077649|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
58077650|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
58077651|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
58077652|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
57943304|NCT04053647|OTHER|Non-interventional study|Non-interventional study
58077653|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. - Installation of a short stretch belt (urgo K2® kit)~2. - Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. - Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
57731401|NCT05321524|DRUG|OCA 0.1mg|Tablets administered orally once daily.
57731402|NCT05321524|DRUG|OCA 1.5mg|Tablets administered orally once daily.
57731403|NCT05321524|DRUG|OCA 5mg|Tablets administered orally once daily.
57943305|NCT04311697|DRUG|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
57943306|NCT04311697|DRUG|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
57943307|NCT04927286|BEHAVIORAL|Learning to Breathe|Learning to Breathe is an evidence-based mindfulness curriculum for adolescents
57943308|NCT04927286|BEHAVIORAL|Campus Connections|Campus Connections is a mentoring program for at-risk adolescents
57943309|NCT02142738|DRUG|Pembrolizumab|Pembrolizumab IV solution
57943310|NCT02142738|DRUG|Paclitaxel|Paclitaxel IV solution
57943311|NCT02142738|DRUG|Carboplatin|Carboplatin IV solution
57943312|NCT02142738|DRUG|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
57943313|NCT02142738|DRUG|Cisplatin|Cisplatin IV solution
57943314|NCT02142738|DRUG|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
58077654|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
58077655|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
58077656|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
58297324|NCT01316575|DEVICE|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
58297325|NCT01235065|DEVICE|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
57731404|NCT03524222|OTHER|Home Hospitalization|See above
57731405|NCT04933682|DRUG|ALXN2050|Oral tablet.
57943315|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
57943316|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
57943317|NCT02499861|DRUG|Decitabine and Genistein|intravenous Decitabine with oral genistein
57943318|NCT00130195|DRUG|imatinib|
57943319|NCT00130195|DRUG|cyclophosphamide|
57943320|NCT00130195|DRUG|daunorubicin|
57943321|NCT00130195|DRUG|vincristine|
57943322|NCT00130195|DRUG|prednisolone|
57731406|NCT04933682|DRUG|Fluconazole|Oral tablet.
57731407|NCT04933682|DRUG|Rifampin|Oral capsule.
57943323|NCT00130195|DRUG|methotrexate|
57943324|NCT00130195|DRUG|cytarabine|
57943325|NCT00130195|DRUG|dexamethasone|
57943326|NCT01105676|PROCEDURE|skin biopsy|Two skin biopsies will be taken one time
57943327|NCT02058030|DEVICE|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
57943328|NCT02135211|BEHAVIORAL|Lifestyle counseling|
57943329|NCT02282150|DRUG|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
57943330|NCT02282150|DRUG|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
57943331|NCT06174844|OTHER|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
57943332|NCT03691129|BEHAVIORAL|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
57943333|NCT05818553|DRUG|Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks|Once daily oral or G-tube treatment.
57943334|NCT05818553|DRUG|Part A: 0.5mg/kg/day PRAX-562 for 12 Weeks and Matching Placebo for 4 Weeks|Once daily oral or G-tube treatment with PRAX-562 for 12 weeks and matching placebo for 4 weeks.
57943335|NCT05818553|DRUG|Part B: 0.5mg/kg/day PRAX-562|Once daily oral or G-tube treatment.
57943336|NCT03514342|PROCEDURE|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
57943337|NCT03514342|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
57943338|NCT00268632|DRUG|risedronate|
57943339|NCT00001545|DEVICE|Magstim Super Rapid Magnetic Stimulator|
58077657|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
58077658|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
58077659|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
58077660|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
58077661|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
58077662|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
58077663|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
57943340|NCT00001545|DEVICE|Cadwell MES-10|
57943341|NCT04093843|DEVICE|TMS|NeuroStar TMS Therapy
57943342|NCT03251742|DEVICE|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
57943343|NCT03300895|OTHER|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
57943344|NCT03300895|OTHER|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
57943345|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
57943346|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
57943347|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
57943348|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
57943349|NCT01118273|DRUG|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
58297326|NCT05662748|DEVICE|Transfemoral aortic valve replacement|aortic valve replacement
58297327|NCT02922153|DEVICE|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
57731408|NCT02271386|BEHAVIORAL|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
57943350|NCT01118273|DRUG|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
57943351|NCT03349775|DRUG|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
57943352|NCT03349775|DRUG|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
57943353|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression.
57943354|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression and perinatal extra support.|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression. Additionally, up to three supportive contacts with a midwife or perinatal mental health nurse to support ICBT treatment and adress general pregnancy related health problems.
57943355|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by chance|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation by chance.
57943356|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by choice|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation based on patient preference.
58077664|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
58077665|NCT00117975|BIOLOGICAL|galiximab|given IV
58077666|NCT00117975|BIOLOGICAL|rituximab|Given IV
58077667|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
58077668|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
58077669|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
58077670|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
58077671|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
58077672|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
58077673|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
58077674|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
57943357|NCT00871845|BEHAVIORAL|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
58077675|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
58077676|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
58077677|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
58077678|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
58077679|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
58077680|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
58077681|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
58077682|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
57943358|NCT00267683|DRUG|insulin aspart|
57943359|NCT00267683|DRUG|glibenclamide|
57943360|NCT00029874|DRUG|Minocycline|
57943361|NCT00454259|DRUG|Fentanyl/Placebo injection|Ultra low dose intravenous injection
57943362|NCT05653622|PROCEDURE|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
57943363|NCT04037748|DRUG|Puran T4®|Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
57943364|NCT04037748|DRUG|Eutirox®|Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
57943365|NCT02691754|OTHER|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
57943366|NCT01912742|BEHAVIORAL|Very-low calorie diet (VLCD)|
57943367|NCT01912742|BEHAVIORAL|Low calorie diet (LCD)|
58077683|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
58297328|NCT02922153|DRUG|Standard of Care|Institutional SOC for pain management will be followed.
57943368|NCT02671357|PROCEDURE|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
57943369|NCT06331442|OTHER|Photodynamic therapy|Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
57943370|NCT06331442|OTHER|Tricalcium phosphate (TCP) varnish with 5% NaF|Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
57943371|NCT06331442|OTHER|Chlorhexidine varnish|Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
57943372|NCT03561103|BEHAVIORAL|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
57943373|NCT04869345|BEHAVIORAL|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
57943374|NCT00927654|DRUG|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
57943375|NCT00927654|DRUG|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
58077684|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
58297329|NCT00092924|DRUG|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
58297330|NCT03186144|GENETIC|Blodd punction for genetic analysis|
58297331|NCT06342713|DRUG|BGB-45035|Administered orally
58408784|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
57943376|NCT06118983|OTHER|I-TRANSFER-HF|"I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US."
57943377|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
57943378|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
57943379|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
57943380|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
57943381|NCT02680925|PROCEDURE|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
57943382|NCT02680925|PROCEDURE|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
57943383|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with web-based support|Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
57943384|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with standard support|Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
57943385|NCT03562130|DRUG|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
57943386|NCT00868348|DRUG|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
57943387|NCT00868348|DRUG|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
57943388|NCT06242379|BIOLOGICAL|GMP compliant-BM-MSC derived sEVs|The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
57943389|NCT03375398|DIETARY_SUPPLEMENT|Rice|Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water
57943390|NCT03375398|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
57943391|NCT01030159|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
57943392|NCT02623127|DRUG|Sunitinib|
57943393|NCT01922817|DRUG|Saxagliptin|5mg saxagliptin
57943394|NCT01469182|BIOLOGICAL|SCH 39641|Rapidly dissolving tablet sublingually once daily
58077685|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
58077686|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
58077687|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
58077688|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
58077689|NCT02319018|DRUG|Alisertib|Given PO
58077690|NCT02319018|DRUG|Fluorouracil|Given IV
57943395|NCT01469182|DRUG|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
57943396|NCT04860570|DEVICE|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
57943397|NCT05273034|PROCEDURE|1-hour sepsis bundle|"The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate \> 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (\> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation."
58077691|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
58077692|NCT02319018|DRUG|Leucovorin Calcium|Given IV
58077693|NCT02319018|DRUG|Oxaliplatin|Given IV
58297332|NCT06342713|DRUG|Placebo|Administered orally
57943398|NCT04743921|DEVICE|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
57943399|NCT01068691|PROCEDURE|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"* Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~* Blood pressure~* Obstructive sleep apnea syndrome (OSAS)~* Carotid-to-femoral pulse wave velocity (PWV)~* Biological parameters"
57943400|NCT04400370|DEVICE|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~1. At the entrance of the operating room before induction of anesthesia~2. 1 hour after surgery~3. 24 hours after surgery"
57943401|NCT03509142|DEVICE|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
57943402|NCT01471015|DRUG|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
57943403|NCT01471015|DRUG|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
57943404|NCT01471015|DRUG|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
57943405|NCT00674583|BIOLOGICAL|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
57943406|NCT00674583|BIOLOGICAL|Menjugate|Intramuscular administration, 1 dose
57943407|NCT04204733|BEHAVIORAL|Mobile application|Mobile application that incorporates biosensor feedback, teleconsultation, and online group physical activity classes
57943408|NCT00995475|DRUG|Fluticasone propionate|
57943409|NCT00995475|DRUG|Placebo|
57943410|NCT05376475|DEVICE|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
57943411|NCT05376475|DEVICE|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
57943412|NCT05376475|DEVICE|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
57943413|NCT05376475|DEVICE|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
57943414|NCT04204187|BEHAVIORAL|service learning|service learning for university students
57943415|NCT03070925|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
57943416|NCT03880487|DRUG|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
57943417|NCT03880487|DRUG|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
57943418|NCT03880487|DRUG|Oxycodone oral capsule|10 mg Oxycodone Capsules
57943419|NCT00006469|DRUG|carboplatin|
57943420|NCT00006469|DRUG|paclitaxel|
57943421|NCT00006469|PROCEDURE|conventional surgery|
57943422|NCT00006469|PROCEDURE|neoadjuvant therapy|
57943423|NCT00006469|RADIATION|radiation therapy|
57943424|NCT04778982|DRUG|KN026 combined with Palbociclib and Fulvestrant|HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
57943425|NCT02319187|DRUG|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
57943426|NCT02319187|DRUG|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
57943427|NCT02319187|DRUG|irinotecan|irinotecan 160mg/m2 d1, every 14 days
57943428|NCT00211848|DRUG|Polyenylphosphatidylcholine (PPC)|
57943429|NCT00211848|DRUG|Pegylated Interferon|
57943430|NCT00211848|DRUG|Ribavirin|
57943431|NCT00702754|BIOLOGICAL|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
57943432|NCT03697720|DRUG|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
57943433|NCT01710384|DRUG|betamethasone|
57943434|NCT00808236|DEVICE|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
57943435|NCT00808236|OTHER|Control|Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
58077694|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
58077695|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
58077696|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
58077697|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
58077698|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
58077699|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
58077700|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
58077701|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
58077702|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
58408785|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
57943436|NCT03735927|OTHER|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
57943437|NCT04267419|DIAGNOSTIC_TEST|salivary biomarker|MDA and NO as salivary biomarkers
57943438|NCT00427349|DRUG|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
57943439|NCT00427349|DRUG|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
57943440|NCT02667275|DRUG|A-101 Solution|
57943441|NCT02667275|OTHER|Vehicle Solution|Placebo
57943442|NCT06463691|DRUG|BGB-11417|Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule
58077703|NCT06724107|RADIATION|UVC|It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
58077704|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
58077705|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
58077706|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
58077707|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
58077708|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
57943443|NCT06463691|DRUG|BGB-3111|Zanubrutinib, orally, 320 mg total daily dose
57943444|NCT06463691|DRUG|CD20|CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
58077709|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
57943445|NCT04591730|OTHER|First time father questionnaire self-administration|The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
58297333|NCT01893112|BEHAVIORAL|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).
57943446|NCT05855057|PROCEDURE|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
57943447|NCT05855057|PROCEDURE|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
57943448|NCT05855057|PROCEDURE|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
57943449|NCT01824992|DRUG|Yallaferon®|
57943450|NCT03317470|OTHER|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
57943451|NCT03317470|BEHAVIORAL|Life Navigator|"* The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
57943452|NCT03317470|OTHER|Follow-up survey|-5 questions about the acceptability of the basic needs survey
57943453|NCT03317470|OTHER|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
57943454|NCT00415857|BIOLOGICAL|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
57943455|NCT00415857|DRUG|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
57943456|NCT00415857|DRUG|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
57943457|NCT00415857|DRUG|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
58077710|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
58297334|NCT01893112|BEHAVIORAL|Breast Cancer Screening|
58297335|NCT00268983|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
58297336|NCT00268983|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
58297337|NCT03588858|OTHER|structured interview questionnaires|"* Module (1): Socio-demographic characteristics~* Module (2) :Occupational history~* Module (3): Presence of work related injuries and diseases by history and observation.~* Module (4): Food frequency questionnaires (FFQ) during the past week.~* Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
57943458|NCT00238550|DRUG|Cannabis based medicine extract (CBME)|
57943459|NCT04810182|DRUG|Regorafenib 40 MG Oral Tablet [STIVARGA]|As per the treating physicians discretion
57943460|NCT05753267|DRUG|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
57943461|NCT05753267|DRUG|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
57943462|NCT05803200|DRUG|No intervention|No intervention was given as this is an observational study.
57943463|NCT05094791|DEVICE|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
57943464|NCT05094791|DEVICE|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
57943465|NCT05094791|DEVICE|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
57943466|NCT05261763|OTHER|Dry Needling|abc
58077711|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
58077712|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
58077713|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
58077714|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
58077715|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
58077716|NCT02231502|OTHER|Vegetable-based convenience food|
58077717|NCT02231502|OTHER|Vegetable meal|
58077718|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
58077719|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
58077720|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
58077721|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
58077722|NCT06722391|OTHER|Resistance Training|Group will receive exercise training.
58077723|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
58077724|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
58297338|NCT03166787|OTHER|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
58297339|NCT03166787|OTHER|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
57943467|NCT05261763|OTHER|Sham Dry Needing|xyz
57943468|NCT05166629|BEHAVIORAL|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
57943469|NCT05166629|BEHAVIORAL|Usual Care|Please see above description of usual care.
57943470|NCT02953639|DRUG|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
57943471|NCT02953639|DRUG|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
57943472|NCT00528021|DRUG|Placebo|Vehicle Only
57943473|NCT00528021|DRUG|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
57943474|NCT01961349|DRUG|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
57943475|NCT01961349|DRUG|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
57943476|NCT01961349|DRUG|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
57943477|NCT05584670|DRUG|SAR445877|Concentrate for solution for infusion
57943478|NCT05584670|DRUG|Cetuximab|Solution for infusion
57943479|NCT01304095|DRUG|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
57943480|NCT00299962|BIOLOGICAL|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
57943481|NCT00299962|BIOLOGICAL|SCH 721015|Comparison of different doses and frequency of investigational agent
57943482|NCT05801328|DEVICE|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
57943483|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
57943484|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
57943485|NCT04967079|DRUG|Trametinib|Trametinib 2 mg given orally, once daily
57943486|NCT04967079|DRUG|Anlotinib|Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle
58077725|NCT06724796|OTHER|Y4BI|"The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly."
58077726|NCT06724796|OTHER|ACTIVE|The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
58077727|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
58408786|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
57943487|NCT06453811|OTHER|Self-efficacy Theory-based Childbirth Preparation Program|Couples assigned to the experimental group will be included in a three-week program, attending a self-efficacy theory-based childbirth preparation program in groups of 4-5 couples, scheduled according to their availability. At the end of the sessions, brochures reflecting the educational content will be given to the couples to read at home. These couples will also receive routine care provided at the hospital, which includes standard antenatal follow-up and information about pregnancy and childbirth during physician visits. After the completion of the training, couples will receive weekly phone calls until their estimated due date to reinforce the educational content.
57943488|NCT01329679|DIETARY_SUPPLEMENT|Energy Drink|Energy drink, 2oz twice daily for 7 days
57943489|NCT01329679|OTHER|Placebo|Water, lime juice and cherry flavoring
57943490|NCT05788887|OTHER|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
57943491|NCT05788887|OTHER|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
57943492|NCT01086020|DRUG|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
57943493|NCT01086020|DRUG|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
57943494|NCT04536428|DEVICE|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops."
57943495|NCT03451786|DEVICE|IOL|Intraocular lens
58077728|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
58077729|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
58077730|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
58077731|NCT06724523|BEHAVIORAL|Business-as-usual instruction|Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
58077732|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
58077733|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
57943496|NCT03169764|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
57943497|NCT03169764|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
57943498|NCT03169764|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
57943499|NCT03169764|BIOLOGICAL|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
57943500|NCT03169764|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
57943501|NCT03169764|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
57943502|NCT03169764|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
57943503|NCT03169764|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
57943504|NCT03169764|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
57943505|NCT03169764|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
57943506|NCT03169764|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
57943507|NCT03169764|DRUG|Lovaza|Omega-3-acid ethyl esters
57943508|NCT03169764|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
58077734|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
58077735|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
58077736|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
58077737|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
58077738|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
58077739|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
58077740|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
58077741|NCT06723600|OTHER|Information|Nurse-led family member information
58077742|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
58077743|NCT06369402|DIAGNOSTIC_TEST|Cerebral haemodynamic testing using transcranial Doppler|Measurement of cerebral haemodynamics using transcranial Doppler to insonate the middle cerebral arteries bilaterally testing neurovascular coupling with selected domains from the Addenbrooks cognitive examination III and the digit span forward and backwards.
58077744|NCT06369402|DIAGNOSTIC_TEST|Ankle-brachial pressure index|Ratio of ankle to brachial blood pressure measured using handheld Doppler at rest and after exercise (six-minute walk test).
58077745|NCT06369402|DIAGNOSTIC_TEST|Six-minute walk test|Supervised brisk walk for six minutes. Time and distance to onset of claudication pain and total distance walked (and total time walked if did not complete the full six minutes).
58077746|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
58077747|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
58077748|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
58077749|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
58077750|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
58077751|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
58077752|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
58077753|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
58297340|NCT03166787|OTHER|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
58297341|NCT03166787|DRUG|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
58077754|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
58077755|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
58077756|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
58077757|NCT06136624|DRUG|Opevesostat|Administered orally
58077758|NCT06136624|DRUG|Abiraterone acetate|Administered orally
58077759|NCT06136624|DRUG|Enzalutamide|Administered orally
58077760|NCT06136624|DRUG|Hydrocortisone|Administered orally or IM as a rescue medication
58077761|NCT06136624|DRUG|Fludrocortisone acetate|Administered orally
58077762|NCT06136624|DRUG|Prednisone|Administered orally
58077763|NCT06136624|DRUG|Dexamethasone|Administered orally as rescue medication
58077764|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
58077765|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
58077766|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
58077767|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
58077768|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
58408787|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
58408788|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
58408789|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
58408790|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
58408791|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
58408792|NCT05868733|DRUG|Placebo|Placebo
58408793|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
58077769|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
58077770|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
58077771|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
58077772|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
58077773|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
58077774|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
58077775|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
58408794|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
58077776|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
58077777|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
58077778|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
58077779|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
58077780|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
58077781|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
58077782|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
58077783|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
58077784|NCT05276726|DRUG|JAB 21822|Administered orally
58077785|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
58077786|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
58077787|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
58077788|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
58077789|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
58077790|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
58077791|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
58077792|NCT02081352|OTHER|Standard care|
58077793|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
58077794|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
58077795|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
58077796|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
58077797|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
58077798|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
58077799|NCT00802295|DRUG|Low dosis Gonadotrophin|
58077800|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
58077801|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
58077802|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
58077803|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
58077804|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
58077805|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
58077806|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
58077807|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
58297342|NCT03166787|OTHER|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
58297343|NCT03166787|DRUG|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
58297344|NCT03166787|DRUG|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
58297345|NCT03328247|OTHER|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
58297346|NCT01018758|DRUG|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
58297347|NCT02288104|DEVICE|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
58408795|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
58077808|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
58077809|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
58077810|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
58408796|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
58408797|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
57943509|NCT03169764|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\]
57943510|NCT03169764|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen (CEA) vaccine
57943511|NCT03169764|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 (HER2) vaccine
57943512|NCT03169764|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
57943513|NCT03169764|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1) vaccine
57943514|NCT03169764|BIOLOGICAL|GI-4000|Ras yeast vaccine
57943515|NCT03169764|BIOLOGICAL|GI-6207|CEA yeast vaccine
57943516|NCT03169764|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
57943517|NCT03169764|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
57943518|NCT03146000|DRUG|lidocaine-prilocaine cream|topical cream
57943519|NCT03146000|DRUG|meloxicam rectal suppository|suppository
57943520|NCT02715375|DEVICE|CREON2000A|
57943521|NCT03698942|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
57943522|NCT02330887|OTHER|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
58077811|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
58077812|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
58077813|NCT06424756|DIETARY_SUPPLEMENT|MitoQ|MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
58077814|NCT06424756|DIETARY_SUPPLEMENT|Placebo|MitoQ matched Placebo
58077815|NCT06424756|DRUG|MitoTempo|During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
58408798|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
58408799|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
58408800|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
58408801|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
58408802|NCT06026371|DRUG|Placebo|Given PO
58408803|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
57943523|NCT02330887|OTHER|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
57943524|NCT04200053|OTHER|Reflexology massage|Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.
57943525|NCT04200053|OTHER|Reflexology massage and passive music|Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
57943526|NCT03791242|DEVICE|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
57943527|NCT03589599|OTHER|Flavored tobacco|Effects of flavored tobacco
57943528|NCT03589599|OTHER|Non-flavored tobacco|Effects of non-flavored tobacco
57943529|NCT01463670|DRUG|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
57943530|NCT04170803|DEVICE|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
57943531|NCT04170803|OTHER|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
58077816|NCT06424756|DRUG|Tempol|During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
58077817|NCT06424756|DRUG|L-NAME|During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
58408804|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
57943532|NCT02663453|DRUG|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
57943533|NCT02663453|DRUG|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
57943534|NCT05289570|DRUG|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
57943535|NCT03098849|OTHER|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
57943536|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
57943537|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
57943538|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
57943539|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
57943540|NCT03566355|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
57943541|NCT05777447|PROCEDURE|Mycotic aortic-iliac aneurysms and in situ reconstruction|Surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction
57943542|NCT02277015|DEVICE|Miller Laryngoscope|Direct Laryngoscopy
57943543|NCT02277015|DEVICE|The Berci-Kaplan DCI|Videolaryngoscope-1
57943544|NCT02277015|DEVICE|The AirTraq|Videolaryngoscope-2
57943545|NCT02277015|DEVICE|GlideScope GVL|Videolaryngoscope-3
57943546|NCT02277015|DEVICE|The Pentax AWS|Videolaryngoscope-4
57943547|NCT01971021|DEVICE|PICC or subcutaneous venous port|
57943548|NCT04300699|OTHER|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
57943549|NCT05539729|DRUG|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
57943550|NCT05539729|DRUG|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
57943551|NCT02681328|OTHER|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
58077818|NCT06424756|DRUG|SNP - Sodium Nitroprusside|At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
58408805|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
57731409|NCT01876173|BEHAVIORAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
57731410|NCT04112147|DRUG|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
57943552|NCT02681328|OTHER|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
57943553|NCT02681328|OTHER|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
57943554|NCT02681328|OTHER|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
57943555|NCT04530773|BEHAVIORAL|Watch VR movies/ Play VR games|The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
57943556|NCT02839057|PROCEDURE|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
57943557|NCT02839057|PROCEDURE|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
57943558|NCT04956003|BEHAVIORAL|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
57943559|NCT05687331|PROCEDURE|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
57943560|NCT05687331|PROCEDURE|venipuncture|Peripheral venipuncture to gather a blood sample
57943561|NCT05687331|DIAGNOSTIC_TEST|MRI-scan|MRI-scan of the knee
57943562|NCT05687331|DIAGNOSTIC_TEST|Physical examination|Physical examination of the injured knee
57943563|NCT05687331|OTHER|KOOS questionnaire|KOOS questionnaire of the injured knee
57943564|NCT04858451|DRUG|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
57943565|NCT05839275|DRUG|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
57943566|NCT05839275|DRUG|Sintilimab|200mg, d1, q3w
58077819|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
58077820|NCT00381602|OTHER|Placebo|
58077821|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
58077822|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
58077823|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
58077824|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
58077825|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
58077826|NCT05877508|OTHER|Placebo|Placebo infusion
58077827|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
57731411|NCT04112147|DRUG|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
57943567|NCT05839275|RADIATION|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
57943568|NCT03025230|OTHER|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
57943569|NCT03025230|OTHER|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
57943570|NCT00721370|DEVICE|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
57943571|NCT02285777|BIOLOGICAL|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
57943572|NCT02285777|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
57943573|NCT02385149|OTHER|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
57943574|NCT02385149|OTHER|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
57943575|NCT01806350|OTHER|questionnaire administration|Ancillary studies
57943576|NCT01806350|PROCEDURE|standard follow-up care|Receive usual care
57943577|NCT01806350|OTHER|educational intervention|Undergo PFMT
57943578|NCT01225731|BIOLOGICAL|tildrakizumab|SC administration of tildrakizumab at assigned dose
57943579|NCT01225731|DRUG|Placebo|SC administration of Placebo
58077828|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
58077829|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
58077830|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
58077831|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
58077832|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
57731412|NCT04112147|DRUG|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
57731413|NCT03869775|DEVICE|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
57731414|NCT03869775|DIAGNOSTIC_TEST|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
57943580|NCT00784381|DEVICE|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
57943581|NCT01981915|PROCEDURE|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
57943582|NCT01981915|PROCEDURE|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
57943583|NCT05369104|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
57943584|NCT02668874|DEVICE|Isolite System|
57943585|NCT02668874|OTHER|Cotton Roll Technique|
57943586|NCT04368572|BEHAVIORAL|Hypnosis|"An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase"
57943587|NCT02595671|OTHER|Digital Super Coach|Receive Digital Super Coach during 12 weeks
57943588|NCT02595671|OTHER|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
57943589|NCT02595671|OTHER|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
57943590|NCT02595671|OTHER|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
58077833|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
58077834|NCT02078557|DRUG|MK-8892|
58077835|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
58077836|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
57731415|NCT03124641|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
58077837|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
58408806|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
58408807|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
58408808|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
58408809|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
58408810|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
58408811|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
57731416|NCT03124641|PROCEDURE|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
57943591|NCT05382247|DEVICE|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
57731417|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
57731418|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
57731419|NCT00325793|DRUG|Nicardipine|
57731420|NCT02159482|DRUG|Interferon Alfa-2a|
57943592|NCT05735730|OTHER|Blood draw|The study intervention consists of a blood draw for genetic analysis.
57943593|NCT04519359|OTHER|Stop NAs therapy|Stop NAs therapy
57943594|NCT02604316|OTHER|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
57943595|NCT02604316|OTHER|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
57943596|NCT05376813|PROCEDURE|CT-Scan and MRI|CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
57943597|NCT03852862|DRUG|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
57943598|NCT03852862|DRUG|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
57943599|NCT02792270|OTHER|Caloric Restriction Diet|"Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein."
57943600|NCT01427998|DIETARY_SUPPLEMENT|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
57943601|NCT01427998|OTHER|placebo|placebo
57943602|NCT04298736|PROCEDURE|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
57943603|NCT04298736|BEHAVIORAL|Lifestyle modification|guided low-calorie diet and physical activity.
57943604|NCT05092178|BEHAVIORAL|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
57943605|NCT05092178|BEHAVIORAL|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
57943606|NCT02043821|DRUG|Capecitabine|14days
57943607|NCT02043821|OTHER|placebo|14 days
58077838|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
58077839|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
58077840|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
58077841|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
58077842|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
58077843|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
58077844|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
58077845|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
58077846|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
58077847|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
58077848|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
58077849|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
58077850|NCT03157804|DRUG|Plerixafor|Given SC
58077851|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
58077852|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
58077853|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
58077854|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
58077855|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
58077856|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
57943608|NCT00362349|DRUG|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
57943609|NCT05488600|BEHAVIORAL|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
57943610|NCT05787873|DRUG|SIPS-2209-1|QD, PO
57943611|NCT05787873|DRUG|SIPS-2209-2, SIPS-2209-3|QD, PO
57943612|NCT02997527|DEVICE|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
58077857|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
58077858|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
58077859|NCT06615245|BEHAVIORAL|No VR vs. immersive high tech VR|No VR vs. immersive High Tech VR
58077860|NCT06615245|BEHAVIORAL|Plausible control vs immersive High Tech VR|plausible control condition vs. immersive high tech VR
57943613|NCT04518215|PROCEDURE|Erector Spinae Plain Block|Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.
57943614|NCT04518215|PROCEDURE|Intra-Venous Analgesia|Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.
57943615|NCT03173131|BEHAVIORAL|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
58077861|NCT02910895|OTHER|tumor biopsy|biopsy
58077862|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
57943616|NCT00827606|DRUG|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
57943617|NCT05039450|DRUG|EFX|Investigational drug, Efruxifermin
57943618|NCT05039450|DRUG|Placebo|Placebo
57943619|NCT00050648|DRUG|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
57943620|NCT00050648|DRUG|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
57943621|NCT00050648|DRUG|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
57943622|NCT04232228|OTHER|No intervention|No intervention was used in this study.
57943623|NCT03725124|OTHER|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
57943624|NCT06497348|OTHER|manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder|They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
57943625|NCT04251910|DRUG|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
57943626|NCT04251910|DRUG|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
57943627|NCT04040075|DRUG|Biktarvy Tab|Antiretroviral drug
57943628|NCT01271192|PROCEDURE|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
57943629|NCT01271192|PROCEDURE|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
57943630|NCT03104699|DRUG|AGEN2034|Anti-PD-1 Monoclonal Antibody
58077863|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
57943631|NCT03388359|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
57943632|NCT03388359|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
57943633|NCT03388359|OTHER|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
58077864|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
58077865|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
57943634|NCT03388359|OTHER|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
58077866|NCT06367959|BEHAVIORAL|Esays|Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
58077867|NCT06367959|BEHAVIORAL|Questionnaires|"Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay."
58077868|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
57943635|NCT03388359|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
57943636|NCT03388359|DEVICE|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
57943637|NCT03388359|BIOLOGICAL|Eosinophils|Eosinophils are isolated from peripheral blood
57943638|NCT03388359|BIOLOGICAL|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
57943639|NCT03388359|BIOLOGICAL|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
57943640|NCT03271398|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing (intensive format)
57943641|NCT03271398|BEHAVIORAL|PC|Progressive counting (intensive format)
57943642|NCT03385603|DEVICE|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
57943643|NCT03385603|BEHAVIORAL|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
57943644|NCT00143663|DRUG|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
57943645|NCT00143663|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
57943646|NCT02203825|BIOLOGICAL|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
57943647|NCT05743738|DIAGNOSTIC_TEST|Doppler ultrasound|Control venous Doppler ultrasound
58077869|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
58077870|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
58408812|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
57943648|NCT04948775|OTHER|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
57943649|NCT04663789|PROCEDURE|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
57943650|NCT04663789|PROCEDURE|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
57943651|NCT01785459|DRUG|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
57943652|NCT01785459|DRUG|Standard Care|10 mg Intravenous injection of Prochlorperazine
57943653|NCT02905929|DEVICE|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
57943654|NCT02905929|BEHAVIORAL|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
57943655|NCT02905929|BEHAVIORAL|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
57943656|NCT02905929|BEHAVIORAL|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
57943657|NCT02905929|OTHER|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
57943658|NCT02905929|BEHAVIORAL|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
57943659|NCT04508400|DRUG|Fosaprepitant,ondansetron, dexamethasone|Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.
57943660|NCT04508400|DRUG|placebo ondansetron with dexamethasone|placebo plus ondansetron with dexamethasone
57943661|NCT03755895|OTHER|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
57943662|NCT03755895|DRUG|Kalinox|patients will have brachytherapy detachment under Kalinox
57943663|NCT01075412|DRUG|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
57943664|NCT03544372|OTHER|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
57943665|NCT01585272|DRUG|ENA713|
58077871|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
58077872|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
58077873|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
58077874|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
58077875|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
58077876|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
58408813|NCT02240849|DEVICE|Placebo general pillow|
58408814|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
58408815|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
58408816|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
58408817|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
58408818|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
58077877|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
58077878|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
58077879|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
58077880|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
58077881|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
58077882|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
58077883|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
58297348|NCT04198831|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
58297349|NCT04198831|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
58297350|NCT03065686|GENETIC|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
57943666|NCT03262454|DRUG|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
57943667|NCT01948336|DRUG|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
57943668|NCT01948336|DRUG|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
57943669|NCT01948336|DRUG|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
57943670|NCT04998838|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
57943671|NCT04998838|DRUG|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
57943672|NCT03226145|PROCEDURE|MRI Motility|MRI sequence to assess colonic motility
57943673|NCT03226145|PROCEDURE|High Resolution Manometry|HRM of colon to assess motility
57943674|NCT03226145|DRUG|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
58077884|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
57943675|NCT03226145|DRUG|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
57943676|NCT04973475|DRUG|Indocyanine Green|Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer
57943677|NCT01164774|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
57731421|NCT04890002|DEVICE|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
57943678|NCT01164774|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
57943679|NCT05331040|DIAGNOSTIC_TEST|MRI|Radiomic analysis of newly diagnosed rectal cancers
57943680|NCT00388973|DRUG|Quetiapine|
57943681|NCT03714321|DEVICE|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
58077885|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
58077886|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
58077887|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
58077888|NCT06722716|OTHER|Swab collection|Nasopharyngeal swab
58077889|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
58077890|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
58297351|NCT06323785|DEVICE|Active whole-body hyperthermia|Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
58297352|NCT06323785|DEVICE|Sham whole-body hyperthermia|Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
58297353|NCT00823264|DRUG|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
58408819|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
57943682|NCT03385811|OTHER|no intervention, only questionnaires survey|questionnaires survey
58077891|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
58077892|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
58408820|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
58408821|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
58408822|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
58408823|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
58408824|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
58408825|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
58408826|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
58408827|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
58408828|NCT03134365|OTHER|Combined meal|Combined meal.
57943683|NCT04001075|DRUG|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
57943684|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
57943685|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
57943686|NCT03880175|BEHAVIORAL|Anti Stigma Information|Adults in the households are provided anti-stigma information
57943687|NCT03880175|BEHAVIORAL|HIV/AIDS Information|The households receive information about HIV infection and AIDS
57943688|NCT03880175|BEHAVIORAL|ART Information|The households receive information about antiretroviral therapy.
57943689|NCT03880175|BEHAVIORAL|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
57943690|NCT03880175|BEHAVIORAL|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
57943691|NCT02698670|DEVICE|Rhythmia mapping system|A 3-D Cardiac Mapping system
57943692|NCT02698670|DEVICE|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
57943693|NCT04896554|BEHAVIORAL|Health literacy scale|"The Turkish version of The European Health Literacy Survey (HLS-EU) Health Literacy Questionnaire scale (ASOY-TR) was used to measure health literacy. This scale consists of 47 questions. Each item has 4 degrees such that 1 = Very difficult, 2 = Difficult, 3 = Easy, 4 = Very easy. Code 5 is used for the expression I don't know. The total score that can be obtained from the scale is between 47-188. For the sake of ease of calculation, the total score is standardized with the following formula to take a value between 0-50.~Formula = Index = (arithmetic mean-1) x \[50/3\] High score means better health literacy."
57943694|NCT02278562|DRUG|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
57943695|NCT02278562|DRUG|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
57943696|NCT02278562|OTHER|placebo|placebo capsules and injection
57943697|NCT01228370|DRUG|silodosin|silodosin 8mg once a day for 12 weeks
57943698|NCT04674514|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
57943699|NCT04674514|DRUG|Rd|Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
57943700|NCT04256460|BEHAVIORAL|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
57943701|NCT00163202|PROCEDURE|Blood samples|
58408829|NCT00196586|DRUG|Interleukin 2|
58408830|NCT00196586|DRUG|pegylated interferon alpha 2a|
58408831|NCT00196586|DRUG|ribavirin|
58408832|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
58408833|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
58077893|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
58077894|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
58077895|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
58077896|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
58077897|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
58077898|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
58077899|NCT04479696|OTHER|Educational Intervention|Receive standard of care verbal and written education materials
58077900|NCT04479696|OTHER|Questionnaire Administration|Ancillary studies
58077901|NCT04479696|OTHER|Survey Administration|Complete optional survey
57943702|NCT00163202|DRUG|Atorvastatin|
58408834|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
58408835|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
58408836|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
58408837|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
57943703|NCT02154360|DRUG|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
57943704|NCT04443543|DRUG|Capecitabine (Xeloda) Pharmacogenetic Test Reagents|CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
57943705|NCT04443543|DRUG|irinotecan|CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
57943706|NCT04443543|RADIATION|IMRT|Pelvic Radiation: 50Gy/25Fx
58077902|NCT04479696|OTHER|Video|Watch NIRS video
58077903|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
58408838|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
58408839|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
57731422|NCT04890002|DEVICE|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
57943707|NCT04443543|DRUG|Oxaliplatin|FOLFIRINOX: 85mg/m2 d1
57943708|NCT04443543|DRUG|5Fluorouracil|FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
57943709|NCT04443543|DRUG|Tislelizumab|200mg iv
57943710|NCT04417179|PROCEDURE|transversus abdominis block|transversus abdominis block
57943711|NCT04417179|PROCEDURE|Erector spinae block|Erector spinae block
57943712|NCT04417179|DRUG|Bupivacaine 0.25% Injectable Solution|Local Anesthetic used in both blocks
57943713|NCT04417179|DEVICE|Siemens Acuson x300 3-5MHz Ultrasound|Ultrasound used to aid in the blocks
57943714|NCT01871220|DEVICE|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
57943715|NCT01871220|DEVICE|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
57943716|NCT05304104|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
57943717|NCT02116777|OTHER|Laboratory Biomarker Analysis|Correlative studies
57943718|NCT02116777|OTHER|Pharmacological Study|Correlative studies
57943719|NCT02116777|DRUG|Talazoparib|Given PO
57943720|NCT02116777|DRUG|Temozolomide|Given PO
58077904|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
58077905|NCT05083975|DEVICE|Buzzy System|Vibrating Device
58077906|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
58077907|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
58077908|NCT01907373|DRUG|olmesartan medoxomil|
58077909|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
58077910|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
58077911|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
58077912|NCT04433858|DRUG|Psilocybin|open-label
57943721|NCT02281032|OTHER|interRAI PC|"PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results"
57943722|NCT05407233|DEVICE|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
58077913|NCT03054493|BEHAVIORAL|no intervention|no intervention
57943723|NCT05407233|DEVICE|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
57943724|NCT00004414|DRUG|sincalide|
58077914|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
58077915|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
58077916|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
58077917|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
58077918|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
58077919|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
58077920|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
58077921|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
58077922|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
58077923|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
58297354|NCT01222208|DIETARY_SUPPLEMENT|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
58077924|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
58077925|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
58077926|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
58297355|NCT01222208|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
58297356|NCT00179595|BEHAVIORAL|relaxation response- meditation|
58297357|NCT03983200|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
58297358|NCT03983200|DRUG|Mecobalamin|mecobalamine 0.5mg,tid
58297359|NCT03052881|DEVICE|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of \<10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
58297360|NCT00000237|DRUG|Buprenorphine|
58408840|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
57943725|NCT04097613|DRUG|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
57943726|NCT04097613|DRUG|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
57943727|NCT03221491|DEVICE|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
57943728|NCT00823628|DRUG|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
57943729|NCT00823628|DRUG|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
57943730|NCT03778528|PROCEDURE|cataract surgery|tissue collection.
57943731|NCT00683163|DRUG|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
57943732|NCT00683163|DRUG|Ibandronate|150mg by mouth once monthly
58077927|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
58077928|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
58077929|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
58077930|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
58297361|NCT05686655|OTHER|questionnaire about sleep quality in diabetic children|Pittsburgh sleep quality index
58297362|NCT05619471|DEVICE|VIO Imaging|Skin conditions that are candidates for skin biopsies
57943733|NCT00683163|OTHER|Placebo injection|Daily injections as placebo for PTS 1-84
57943734|NCT00683163|OTHER|Placebo pills|Monthly pills as placebo for oral ibandronate
57943735|NCT00278642|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
57943736|NCT04221763|DEVICE|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
58297363|NCT03426410|OTHER|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
58297364|NCT03310216|PROCEDURE|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
58297365|NCT03310216|PROCEDURE|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
58408841|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
58408842|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
57943737|NCT01819649|DIETARY_SUPPLEMENT|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
57943738|NCT01699477|DEVICE|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
58408843|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
58408844|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
57943739|NCT03945526|DRUG|Astaxanthine|
57943740|NCT03945526|DRUG|Placebo Oral Tablet|
57943741|NCT02354066|DEVICE|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
58297366|NCT01571960|BIOLOGICAL|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
58297367|NCT01571960|BIOLOGICAL|MVA/HIV62B (MVA62B) vaccine|1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
57943742|NCT02354066|DEVICE|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
58297368|NCT01571960|BIOLOGICAL|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
58297369|NCT01571960|BIOLOGICAL|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
58297370|NCT01552226|DEVICE|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
58297371|NCT01552226|DEVICE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
58297372|NCT06166017|OTHER|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
57943743|NCT02354066|DEVICE|Retail Shoe|Brake response time measurement before surgery (control run)
58297373|NCT04527029|OTHER|No interventions|It is an observational study. No interventions.
58297374|NCT02993861|OTHER|Anti-epileptics|
58297375|NCT02485327|DRUG|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
58408845|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
58408846|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
57943744|NCT00677651|PROCEDURE|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
57943745|NCT00677651|PROCEDURE|Blood sample|Blood will be sampled from an IV line
57943746|NCT00677651|RADIATION|CT Scan|Single image at the level of the liver
57943747|NCT00677651|RADIATION|DEXA|Whole body scan
57943748|NCT03669432|RADIATION|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
57943749|NCT03669432|PROCEDURE|Surgery alone|This intervention is of no interest
57943750|NCT02596477|DRUG|Vepoloxamer|
57943751|NCT02596477|OTHER|5% dextrose in water|
57943752|NCT05650489|OTHER|assessment|correlation between Autistic features, motor function and quality of life
57943753|NCT03870659|RADIATION|Breast MRI|Magnetic resonance imaging to the breast
58077931|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
58297376|NCT03714464|OTHER|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
58297377|NCT03714464|OTHER|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
58297378|NCT03714464|OTHER|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
58297379|NCT01309412|DRUG|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
58297380|NCT04166604|DRUG|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
58297381|NCT05761353|DEVICE|Endermologie|"Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
58297382|NCT05761353|DEVICE|Negative pressure therapy|"Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
58408847|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
58408848|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
58408849|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
58408850|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
58408851|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
57943754|NCT04229433|DRUG|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
57943755|NCT04229433|DRUG|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
57943756|NCT05596682|DEVICE|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
57943757|NCT04286087|PROCEDURE|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
57943758|NCT04286087|PROCEDURE|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
57943759|NCT06210698|DIAGNOSTIC_TEST|Venipuncture|venipuncture
57943760|NCT04485143|DEVICE|Wisdom bracelet|routine medical
57943761|NCT01944293|DRUG|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
57943762|NCT01944293|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
58408852|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
58408853|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
58408854|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
57943763|NCT05915689|OTHER|Myofascial arm pull technique|patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.
57943764|NCT05915689|OTHER|post isometric relaxation technique|The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
57943765|NCT05636592|DRUG|immunotherapy|statin combined with immunotherapy
57943766|NCT04436536|OTHER|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
57943767|NCT04436536|OTHER|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
57943768|NCT02858908|DRUG|Tideglusib|Tideglusib for oral suspension,
57943769|NCT05467956|OTHER|Covid-19|Covid-19 disease
57943770|NCT03536975|OTHER|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
57943771|NCT03880942|OTHER|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
57943772|NCT03880942|OTHER|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
58297383|NCT02298972|BEHAVIORAL|Nurse support and selfmanagement intervention|
58077932|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
58077933|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
58077934|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
57943773|NCT05679336|DRUG|Rituximab, Cyclophosphamide, and Corticosteroids|"1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count \>5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7)."
58077935|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
58077936|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
58077937|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
58077938|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
58077939|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
57943774|NCT06427928|BEHAVIORAL|Explains the perioperative process with pictures|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
57943775|NCT06427928|BEHAVIORAL|The perioperative process is only explained|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
57943776|NCT00595322|OTHER|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
57943777|NCT04035447|BEHAVIORAL|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
57943778|NCT02889406|BEHAVIORAL|Motivational intervention|motivational interviewing schema
57943779|NCT03126695|DRUG|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
57943780|NCT03126695|DRUG|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
58077940|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
58077941|NCT01700218|OTHER|telemonitoring|
58077942|NCT01700218|OTHER|control|
58077943|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
58077944|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
58077945|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
58077946|NCT02014428|DRUG|Placebo|
57731423|NCT04378244|DRUG|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
57731424|NCT03879798|DRUG|DS-3201b|100 mg daily
58077947|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
57943781|NCT03126695|DRUG|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
57943782|NCT03126695|DRUG|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
57943783|NCT03667534|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
57943784|NCT03622463|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
57943785|NCT03622463|OTHER|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
57943786|NCT04703556|DEVICE|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
57943787|NCT05097703|BEHAVIORAL|Sleep Resource|The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
57943788|NCT00022867|DRUG|Nondigestible oligosaccharide (NDO)|
57943789|NCT06474949|DRUG|Bupivacaine injection|Injection at end of Open Reduction Internal Fixation
57943790|NCT06474949|OTHER|Saline|Injection at end of Open Reduction Internal Fixation
57943791|NCT04276389|DEVICE|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
57943792|NCT04276389|DEVICE|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
57943793|NCT03556436|DRUG|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
57943794|NCT01750931|DRUG|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
57943795|NCT01750931|DRUG|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
57943796|NCT00904800|DRUG|AZD0837|tablet, oral, once daily, 1+5 days
57943797|NCT00904800|DRUG|Placebo|Placebo
58077948|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
58297384|NCT02939209|DRUG|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
58297385|NCT02939209|DRUG|Placebo|Patients may be randomized to placebo.
57731425|NCT03879798|DRUG|irinotecan|Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
57731426|NCT00021762|BIOLOGICAL|HIV-1 Immunogen|
57731427|NCT00021762|PROCEDURE|Structured Treatment Interruption|
57731428|NCT03786601|OTHER|Observation|The participants were assigned to different groups according to the results of HPV detection.
57731429|NCT04182425|OTHER|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
57731430|NCT00511004|DRUG|Albendazole|Comparing 400 mg to 800 mg dose
57943798|NCT02895880|BEHAVIORAL|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
57943799|NCT02895880|BEHAVIORAL|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
57943800|NCT04796051|DEVICE|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
57943801|NCT04796051|OTHER|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
57943802|NCT02245438|DRUG|Tipranavir low dose|
57943803|NCT02245438|DRUG|Tipranavir high dose|
57943804|NCT02245438|DRUG|Ritonavir low dose|
57943805|NCT02245438|DRUG|Ritonavir high dose|
57943806|NCT02245438|DRUG|Norethindrone-Ethinyl Estradiol|
57943807|NCT05075525|OTHER|High Intensity Laser Therapy Group|High Intensity Laser Therapy (HILT) and exercises will be used.
57943808|NCT05075525|OTHER|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Transcutaneous electrical nerve stimulation(TENS), ultrasound (US) will be applied.
57943809|NCT05075525|OTHER|Ultrasound and Interferential Current Stimulation Group|Ultrasound (US) ,interferential current stimulation and exercise will be used.
57943810|NCT02652338|DIETARY_SUPPLEMENT|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
57731431|NCT00511004|DRUG|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
57731432|NCT05742373|OTHER|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
57943811|NCT02652338|DIETARY_SUPPLEMENT|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
57943812|NCT02289430|DRUG|Crestor+Ezetrol|rosuvastatin+ezetimibe
57731433|NCT05742373|OTHER|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
57731434|NCT01891123|DEVICE|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
57731435|NCT01891123|DRUG|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
57943813|NCT02289430|DRUG|Ezetrol|ezetimibe
57943814|NCT02289430|DRUG|Crestor|rosuvastatin
57943815|NCT01314963|DEVICE|Prototype intraoperative handheld gamma camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
57943816|NCT01314963|DEVICE|Lymphoscintigraphy with intraoperative gamma probes (GP)|Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
57943817|NCT01314963|RADIATION|radioactive Tc99M|Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
58077949|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
58077950|NCT02144311|PROCEDURE|PET/CT Scan|
58077951|NCT02144311|PROCEDURE|MRI|
58077952|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
58297386|NCT03040401|DRUG|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
58408855|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
58408856|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
58077953|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
58297387|NCT03040401|DRUG|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
58077954|NCT01493791|DRUG|CDB-2914|
58077955|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
58297388|NCT03040401|DRUG|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
58297389|NCT06613204|BEHAVIORAL|STELLA-FTD Control|Participants receive information about FTD and support via weekly group video-conference-based meetings.
58297390|NCT06613204|BEHAVIORAL|STELLA-FTD Test|The test group receives a information and support, but with a focus that is different from the Control Group
58297391|NCT04235400|DIAGNOSTIC_TEST|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
58297392|NCT03107910|BEHAVIORAL|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
58297393|NCT03107910|BEHAVIORAL|Health Information Seeking|Seeking and evaluating online health information will be assessed.
58297394|NCT04088669|OTHER|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
58408857|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
58408858|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
58408859|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
58408860|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
58408861|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
58408862|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
58077956|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
58077957|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
58077958|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
58077959|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
58077960|NCT06557356|DRUG|LY3532226|Administered SC
58077961|NCT06557356|DRUG|Placebo|Administered SC
58077962|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
58077963|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
58077964|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
58077965|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
58077966|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
58077967|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
58077968|NCT06717321|PROCEDURE|(Arm 1): PEG|A 20-French pull type percutaneous endoscopic feeding tube placed into the stomach using endoscopic guidance
58077969|NCT06717321|PROCEDURE|(Arm 2): PEG-J|24-French pull type percutaneous endoscopic feeding tube placed into the stomach with a 12-French jejunal extension tube advanced through the PEG and positioned post-pyloric in the small bowel using endoscopic guidance
58077970|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
58077971|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
58077972|NCT04482894|OTHER|Palliative Care Visits|Regular visits with a palliative (supportive) care specialist
58077973|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
57943818|NCT05032625|PROCEDURE|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
58077974|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
58077975|NCT02337543|DRUG|Placebo|Placebo
58077976|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
58077977|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
58077978|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
58077979|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
58077980|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
58077981|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
58077982|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
58408863|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
58408864|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
58408865|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
58297395|NCT04088669|OTHER|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
58297396|NCT00372632|DRUG|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
57943819|NCT02877693|RADIATION|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
58297397|NCT00372632|DRUG|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
58077983|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
58077984|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
58077985|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
58297398|NCT02521363|DEVICE|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.
58297399|NCT02521363|DRUG|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
58297400|NCT03082729|DRUG|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
58297401|NCT06044818|DEVICE|Accexible|Speech Analysis
58297402|NCT02936375|DRUG|Iguratimod|25mg twice a day, orally administrated
58297403|NCT02936375|DRUG|Cyclophosphamide|1g/m², every 4 weeks, intravenous
58297404|NCT02936375|DRUG|Azathioprine|2mg/kg·d, once a day, orally administrated
58297405|NCT02936375|DRUG|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
58408866|NCT01696617|DRUG|Aripiprazole 6-week group|
58408867|NCT01696617|DRUG|Aripiprazole 8-week group|
58408868|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
57943820|NCT05513937|DRUG|Nebivolol|Tablets administered orally once daily according instructions provided by Principal Investigator.
57943821|NCT05513937|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
57943822|NCT00546767|BEHAVIORAL|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
58297406|NCT03073486|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
58297407|NCT03073486|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
58297408|NCT01023204|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
58297409|NCT04578171|DRUG|Mepolizumab|100 mg subcutaneous injections every four weeks
58297410|NCT00752089|DRUG|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
58297411|NCT00752089|DRUG|NaF/KNO3 Dentifrice|Experimental toothpaste
58297412|NCT00752089|DRUG|NaF Dentifrice|Active comparator
58408869|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
58408870|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
58408871|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
58408872|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
58408873|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
58077986|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
58077987|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
58077988|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
58077989|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
58077990|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
58077991|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
58077992|NCT03332225|DRUG|Anakinra|Treatment with anakinra
58077993|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
58077994|NCT03332225|DRUG|Placebo|Treatment with Placebo
58077995|NCT00395317|OTHER|Placebo|placebo tablet
58077996|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
58077997|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
58077998|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
58077999|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
58078000|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
58078001|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
58078002|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
58078003|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
58078004|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
58078005|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
58078006|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
58078007|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
58078008|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
58078009|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
57943823|NCT00546767|BEHAVIORAL|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
58078010|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
58078011|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
58078012|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
58078013|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
58078014|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
58078015|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
58078016|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
58078017|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
58297413|NCT00752089|OTHER|Placebo Dentifrice|Placebo comparator
58297414|NCT04122118|OTHER|Medical Chart Review|Review of medical chart
58297415|NCT04122118|OTHER|Educational Intervention|Receive pharmacist-led education
58078018|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
58078019|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
58078020|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
58078021|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
58078022|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
58078023|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
58078024|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
58297416|NCT04122118|OTHER|Survey Administration|Ancillary studies
58297417|NCT00269945|DRUG|epoetin alfa|
58297418|NCT05946200|PROCEDURE|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
58297419|NCT06612021|PROCEDURE|Beautibond universal adhesive|HEMA free universal adhesive
58297420|NCT06612021|PROCEDURE|Tetric N universal bond|HEMA containing universal bond
58297421|NCT05538013|OTHER|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
58297422|NCT00147706|PROCEDURE|Tailored Healthmedia programs on EHR Patient Portal|
58297423|NCT00954265|DRUG|10000 IU urinary HCG|ovulation triggering
57943824|NCT00546767|BEHAVIORAL|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
57943825|NCT00546767|BEHAVIORAL|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
58078025|NCT06724159|DRUG|darolutamide|Darolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice
58078026|NCT06724159|DRUG|Nivolumab monotherapy|Adjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice
58078027|NCT06724159|DRUG|enfortumab vedotin|Following the posology and administration details of its marketing authorization and standard clinical practice
58078028|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
58297424|NCT00954265|DRUG|250 mcg recombinant HCG|ovulation triggering
58297425|NCT00317915|DRUG|Irbesartan treatment|
58408874|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
58408875|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
58408876|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
57731436|NCT06055296|OTHER|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
57731437|NCT06582615|PROCEDURE|Biospecimen Collection|Undergo dried blood spot collection
57731438|NCT06582615|PROCEDURE|Cognitive Assessment|Ancillary studies
57943826|NCT00829075|DRUG|r-FSH|
57943827|NCT00829075|DRUG|HP-hMG|
57943828|NCT00829075|DRUG|r-FSH plus HP-hMG|
57943829|NCT05992870|RADIATION|Neoadjuvant radiotherapy|"In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment."
57943830|NCT06009003|DRUG|REL-1017|REL-1017 tablet
57943831|NCT04770389|DRUG|Obicetrapib 5mg|tablet
57943832|NCT04770389|DRUG|Ezetimibe 10mg|tablet
57943833|NCT04770389|OTHER|Placebo|tablet
57943834|NCT00273975|DRUG|Nevirapine|
57943835|NCT00273975|DRUG|Lamivudine|
57943836|NCT00273975|DRUG|Zidovudine|
57943837|NCT01301950|OTHER|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
58078029|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
58297426|NCT06548282|OTHER|Acceptance and commitment therapy|"Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude."
58297427|NCT03943498|DRUG|Fingolimod|Given PO daily for 4 weeks
58297428|NCT03943498|DRUG|Fingolimod Hydrochloride|Given PO
57731439|NCT06582615|OTHER|Dietary Intervention|Receive MIND counseling sessions
57731440|NCT06582615|OTHER|Dietary Intervention|Follow a personalized diet
57731441|NCT06582615|OTHER|Dietary Intervention|Receive general health recommendations counseling sessions
57731442|NCT06582615|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
57731443|NCT06582615|OTHER|Questionnaire Administration|Ancillary studies
57731444|NCT04001465|PROCEDURE|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
57731445|NCT04001465|PROCEDURE|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
57731446|NCT04144673|OTHER|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
57731447|NCT04144673|OTHER|Placebo|Placebo water with no active ingredients
57943838|NCT01301950|OTHER|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
57943839|NCT04173676|DRUG|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
57943840|NCT01391286|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
57943841|NCT01391286|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
57943842|NCT03418129|DEVICE|Mindfulness|Neuromodulatory intervention for pain management
57943843|NCT03418129|DEVICE|Neurofeedback|Neuromodulatory intervention for pain management
57943844|NCT03418129|DEVICE|Relaxation|Neuromodulatory intervention for pain management
57943845|NCT01210807|DEVICE|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
57943846|NCT01210807|DEVICE|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
57943847|NCT02884063|PROCEDURE|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
57943848|NCT05167682|OTHER|Prehabilitation program|Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
57943849|NCT00809666|DEVICE|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
57943850|NCT05172414|OTHER|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
57943851|NCT03370120|DRUG|Padsevonil|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
57943852|NCT02153528|DRUG|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
57731448|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
57731449|NCT02765932|PROCEDURE|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
57943853|NCT02153528|DRUG|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
58297429|NCT03943498|OTHER|Questionnaire Administration|Ancillary studies
58408877|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
58297430|NCT06034093|DEVICE|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
58297431|NCT03756415|DEVICE|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
58297432|NCT03756415|DEVICE|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
58297433|NCT01028729|DRUG|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
58297434|NCT01028729|DRUG|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
58297435|NCT04486508|DRUG|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
58297436|NCT04486508|DRUG|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
58297437|NCT04486508|DRUG|Atorvastatin 20mg|Statin
58297438|NCT04486508|DRUG|Matched placebo|Matched placebo to atorvastatin 20 mg
58297439|NCT04743089|DEVICE|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
58297440|NCT04743089|OTHER|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
58297441|NCT03798418|BEHAVIORAL|elastic band strengthening exercise|2-3days per week(150min per week)
58408878|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
58408879|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
58408880|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
58408881|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
58408882|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
58408883|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
58408884|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
58408885|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
58408886|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
58408887|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
58408888|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
58408889|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
58408890|NCT01967017|DRUG|Lidocaine|
58408891|NCT01967017|DRUG|Placebo|
58297442|NCT03798418|DIETARY_SUPPLEMENT|diet counseling|each patients in this group will receive4-5times diet counseling
58297443|NCT03569098|BIOLOGICAL|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
58297444|NCT03569098|DRUG|Placebo|Investigators will inject the reconstituted solution into foot muscles.
58078030|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
58078031|NCT02137473|OTHER|Human milk-based fortifier|
58078032|NCT02137473|OTHER|Bovine protein-based fortifier|
58078033|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
58297445|NCT03871153|DEVICE|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
58408892|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
58408893|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
58408894|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
58408895|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
57943854|NCT02447055|BIOLOGICAL|Tocilizumab|
58078034|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
58078035|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
58297446|NCT03871153|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
58297447|NCT03871153|DRUG|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
58408896|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
58408897|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
58408898|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
58408899|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
57943855|NCT02447055|DRUG|Melphalan|
57943856|NCT02447055|DRUG|Fludarabine|
57943857|NCT02447055|DRUG|Cyclophosphamide|
57943858|NCT02447055|DRUG|Tacrolimus|
57943859|NCT02447055|DRUG|Mycophenolate mofetil|
57943860|NCT02447055|DRUG|Filgrastim|
58078036|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
58078037|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
58078038|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
58078039|NCT04804319|OTHER|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
58078040|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
58078041|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
58078042|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
58078043|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
58078044|NCT00953576|DRUG|ketoconazole|
58078045|NCT00953576|DRUG|hydrocortisone|
58078046|NCT00953576|DRUG|dutasteride|
58078047|NCT00953576|DRUG|lapatinib|
58078048|NCT06551467|BEHAVIORAL|Online Ayurveda Program for Detox and Lifestyle|The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
58078049|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
58078050|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
58078051|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
58078052|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
58078053|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
58078054|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
58078055|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
58408900|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
58408901|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
58408902|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
58408903|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
58408904|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
58408905|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
58078056|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
58408906|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
58408907|NCT06216782|OTHER|Non-intervention|Non-intervention
58078057|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
58078058|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
58078059|NCT00001256|DRUG|prednisone and methotrexate|
58078060|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
58297448|NCT03871153|RADIATION|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
58297449|NCT03871153|PROCEDURE|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
58297450|NCT03861780|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
58297451|NCT03861780|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
58297452|NCT03861780|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
58297453|NCT01819727|DRUG|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
58297454|NCT01823471|OTHER|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
58297455|NCT01557673|DIETARY_SUPPLEMENT|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
58297456|NCT01557673|DIETARY_SUPPLEMENT|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
58297457|NCT06011694|OTHER|MERCURY test, health questionnaires and annual routine physical exams|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
58297458|NCT04771013|BIOLOGICAL|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
58297459|NCT06398236|DIETARY_SUPPLEMENT|SE5-OH tablets|SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
58297460|NCT04899115|DRUG|Placebo|Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
58297461|NCT04899115|DRUG|VE303|"Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules."
58297462|NCT04899115|DRUG|oral vancomycin|All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
58408908|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
58408909|NCT00657839|DRUG|Placebo|Matching placebo
58408910|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
58408911|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
58408912|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
58078061|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
57943861|NCT06264882|DRUG|Degarelix|After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.
57943862|NCT06264882|DRUG|Transdermal Estradiol Patch|Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
57943863|NCT06264882|DRUG|Transdermal Placebo Patch|Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
57943864|NCT05087355|DIAGNOSTIC_TEST|PCR or antigen test for Covid 19 or Inluenza|PCR or antigen test for Covid 19 or Inluenza
58078062|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
58078063|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
58078064|NCT04009122|OTHER|Placebo|Group B
58078065|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
58078066|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
58078067|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
58078068|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
58078069|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
58078070|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
58078071|NCT06450990|OTHER|PLACEBO|Placebo
58078072|NCT06704516|DRUG|Menopausal hormone therapy|"Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)"
58078073|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
58297463|NCT00222703|BEHAVIORAL|Smoking relapse prevention|
57943865|NCT01664988|BEHAVIORAL|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
58297464|NCT00053885|DRUG|PTK787/ZK 222584|oral
58408913|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
57943866|NCT01664988|BEHAVIORAL|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
57943867|NCT01664988|OTHER|control (routine care)|received routine care of clinic or health center and use drugs if necessary
57943868|NCT06340048|DRUG|HiCM-188 therapy|Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
57943869|NCT01232543|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
57943870|NCT04405687|PROCEDURE|Severe head and face deformity reconstructive surgery|Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
58078074|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
58078075|NCT06723535|DRUG|BMS-986278|Specified dose on specified days
58078076|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
58078077|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
58078078|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
58078079|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
58078080|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
58078081|NCT02477319|OTHER|Observational|
58078082|NCT06058572|DRUG|Rifaximin with allogeneic stem cell transplant|Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
58078083|NCT06058572|PROCEDURE|Allogeneic stem cell transplant|Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
58078084|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
58408914|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
58408915|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
57943871|NCT05403320|DEVICE|Continuous cuff pressure regulation|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)
57943872|NCT05403320|DEVICE|Intermittent cuff pressure regulation|ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O
57943873|NCT05403320|DEVICE|Automatic subglottic secretion drainage|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)
57943874|NCT05403320|DEVICE|Manual subglottic secretion drainage|Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen
58078085|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
58078086|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
58078087|NCT00020995|PROCEDURE|therapeutic dietary intervention|
58078088|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
58078089|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
58078090|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
58078091|NCT04717310|DRUG|Vehicle|Twice a day (BID)
58078092|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
58078093|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
58078094|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
58078095|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
58078096|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
58078097|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
58078098|NCT06722690|BEHAVIORAL|eTSF|eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
58078099|NCT06722690|BEHAVIORAL|Educational materials|Educational materials on drinking problems and a list of local/online AA meetings.
58078100|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
58078101|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
58078102|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
58078103|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
58078104|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
58078105|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
58078106|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
58078107|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
58408916|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
58078108|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
58408917|NCT05967546|OTHER|Observational|No interventions will be given to patients.
58408918|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
58408919|NCT03153644|BEHAVIORAL|Observation|Field Observation
58408920|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
57943875|NCT05403320|DIAGNOSTIC_TEST|Tracheobronchial colonization assessment|Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture
58297465|NCT02732808|DRUG|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
58297466|NCT00295165|DRUG|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
58297467|NCT00295165|DRUG|Placebo|Placebo subcutaneously once daily
58408921|NCT00074529|DRUG|MK0677|
58297468|NCT04951908|DIAGNOSTIC_TEST|MRI|MRI of TMJ
58408922|NCT00174863|DRUG|SR31747A|
58297469|NCT00124891|DRUG|Double-blind investigational anti-arrhythmic|
57943876|NCT05403320|DIAGNOSTIC_TEST|Microaspiration assessment|Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase
58297470|NCT00124891|DRUG|GAP-486|
58297471|NCT05563545|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.
58297472|NCT01735318|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
58297473|NCT01735318|DRUG|Lisinopril|40 mg tablet once a day
58297474|NCT05209230|PROCEDURE|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
58297475|NCT05209230|OTHER|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
58297476|NCT03247777|OTHER|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
58297477|NCT03247777|OTHER|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
58297478|NCT02162160|DEVICE|probiotic creme|Probiotic creme applied
58297479|NCT02162160|DRUG|Placebo|Creme without probiotics applied in same manner
58297480|NCT00157768|DEVICE|Implantable cardioverter defibrillator|
58297481|NCT00814138|DRUG|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
58297482|NCT00814138|OTHER|Placebo|Weekly
58297483|NCT03874013|DRUG|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
58408923|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
58408924|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
58408925|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
58408926|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
58408927|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
58408928|NCT05319483|OTHER|No intervention|No intervention.
58408929|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
58078109|NCT03252808|BIOLOGICAL|TBI-1401(HF10)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
58078110|NCT03252808|DRUG|Gemcitabine|1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
58078111|NCT03252808|DRUG|Nab-paclitaxel|125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
58078112|NCT03252808|DRUG|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
57943877|NCT05403320|DIAGNOSTIC_TEST|VAP assessment|Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
57943878|NCT03597230|OTHER|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
57943879|NCT02883023|OTHER|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
57943880|NCT02883023|DRUG|Intralesional bleomycin injection|Local intralesional injections with bleomycin
57943881|NCT03327012|DRUG|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
57943882|NCT03327012|DRUG|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
57943883|NCT06422975|DRUG|Vasopressin|Patients treated with vasopressin
57943884|NCT00063141|DRUG|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
57943885|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
57943886|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
57943887|NCT05319184|OTHER|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
57943888|NCT02861768|BIOLOGICAL|Pharyngeal swab|
57943889|NCT03778411|DEVICE|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
57943890|NCT01671540|DEVICE|intrapulmonary percussive ventilation|
57943891|NCT01671540|OTHER|standard treatment|breathing control exercises
57943892|NCT01943526|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
57943893|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
57943894|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
58408930|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
58408931|NCT00441649|DRUG|Methylphenidate|
57943895|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
57943896|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
57943897|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
57943898|NCT06360991|DEVICE|Deep brain stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (vALIC, BNST, amSTN, VC/VS, or NAc) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
57943899|NCT01704586|RADIATION|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
58408932|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
58408933|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
58408934|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
58408935|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
58408936|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
58408937|NCT05293444|OTHER|overnight fasting|no intervention
58408938|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
58408939|NCT02029183|DEVICE|bi-level positive airway pressure|
58408940|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
58408941|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
58408942|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
57943900|NCT01704586|RADIATION|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
57943901|NCT01223170|BEHAVIORAL|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
57943902|NCT01223170|BEHAVIORAL|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
57943903|NCT01223170|BEHAVIORAL|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
57943904|NCT01223170|BEHAVIORAL|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
57943905|NCT02495155|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
57943906|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
57943907|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
57943908|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
57943909|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
57943910|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
57943911|NCT00653614|DRUG|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
57943912|NCT00653614|DRUG|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
57943913|NCT00653614|DRUG|Placebo|Placebo administration in each arm
57943914|NCT03803072|BEHAVIORAL|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
57943915|NCT04697238|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
58078113|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
58078114|NCT04691674|PROCEDURE|Endoscopy|Endoscopic removal of the pancreatic stent
58078115|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
57943916|NCT06256315|PROCEDURE|Hyper-ERAS Program|Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.
58408943|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
57943917|NCT02921074|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
57943918|NCT02921074|OTHER|Commercially available computerized training|
57943919|NCT00331695|DRUG|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
57943920|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
57943921|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
57943922|NCT01010698|DRUG|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
57943923|NCT01439542|RADIATION|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
57943924|NCT01439542|DRUG|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
57943925|NCT05905120|DRUG|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
57943926|NCT05498350|PROCEDURE|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
57943927|NCT05691374|PROCEDURE|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes \| no), Signs of anchor displacement and location (lateral\|medial row), Location of defect (at the foot print\|medial cuff failure), Status of long biceps tendon (intact\|in continuity\|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
57943928|NCT05691374|PROCEDURE|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
57943929|NCT04974554|BEHAVIORAL|FIT|FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
57943930|NCT04974554|BEHAVIORAL|Home-Based Family Support|Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
57943931|NCT02198625|OTHER|Moderate FiO2 and Protective Lung Ventilation Using|
57943932|NCT03181230|OTHER|No intervention|No intervention
57943933|NCT05836142|PROCEDURE|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
58078116|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
58078117|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
58408944|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
58408945|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
58408946|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
57943934|NCT05026281|DEVICE|Quantra analyzer|one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
57943935|NCT05947994|PROCEDURE|Intracranial stenting with Credo® stent|Symptomatic ischemic stroke patients were treated with Credo® Stent
57943936|NCT03839173|OTHER|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
57943937|NCT05377268|PROCEDURE|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy
57943938|NCT05307484|OTHER|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
57943939|NCT05307484|OTHER|Dengue prevention website|This is a website containing information regarding dengue prevention.
57943940|NCT00900354|GENETIC|molecular genetic technique|
57943941|NCT00900354|OTHER|mass spectrometry|
57943942|NCT00900354|OTHER|pharmacological study|
57943943|NCT00018655|BEHAVIORAL|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
57943944|NCT00018655|BEHAVIORAL|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
57943945|NCT03454802|DIAGNOSTIC_TEST|Passive Leg Raising|See above
57943946|NCT00538798|DRUG|[18F]SP203|
57943947|NCT02783443|OTHER|General anesthesia|General anesthesia
58408947|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
58408948|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
57943948|NCT02783443|OTHER|Regional anesthesia|Regional anesthesia
57943949|NCT04526236|DRUG|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
57943950|NCT06400173|BEHAVIORAL|Cognitive screening|The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
57943951|NCT06400173|BEHAVIORAL|Audiological Assessment|"Four audiological tests are included in the audiological assessment~1. Tympanometry to assss the middle ear status~2. Pure-tone audiometry with headphone to evaluate the hearing thresholds~3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise~4. The hAVICOP questionnaire to assess the hearing-related quality of life"
57943952|NCT01999569|DRUG|Letrozole|Letrozole administered daily through the time of ovulation.
57943953|NCT04717518|OTHER|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
57943954|NCT00988143|BIOLOGICAL|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
57943955|NCT00988143|BIOLOGICAL|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
57943956|NCT00988143|BIOLOGICAL|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
57943957|NCT01496131|RADIATION|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
58408949|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
58408950|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
57943958|NCT01496131|DRUG|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
57943959|NCT01496131|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
57943960|NCT01496131|DRUG|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
57943961|NCT00376116|DEVICE|Cardiac resynchronisation therapy|
57943962|NCT00376116|DEVICE|Implantable cardioverter-defibrillator|
57943963|NCT06414525|OTHER|abdominal massage|It will include patients that will receive abdominal massage; the frequency and duration of the massage will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
57943964|NCT06414525|OTHER|visceral manipulation|It will include patients that will receive visceral manipulation; the frequency and duration of the technique will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
58078118|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
58078119|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
58078120|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
57943965|NCT06414525|OTHER|instructions on daily, dietary , toilet , and physical activity habits|It will include patients that will receive behavioral therapy: defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advice (diet, water consumption, fiber food, etc.), teaching effective defecation posture, and timed toilet training.
58078121|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
58078122|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
58078123|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
57943966|NCT00182312|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
58078124|NCT00811499|DRUG|Placebo; oral|matching placebo
58078125|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
58078126|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
58078127|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
58078128|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
58078129|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
58078130|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
58408951|NCT04814368|BIOLOGICAL|canakinumab|intra-articular injection (into the knee)
58408952|NCT04814368|BIOLOGICAL|LNA043|intra-articular injection (into the knee)
58408953|NCT04814368|OTHER|Placebo to canakinumab|intra-articular injection (into the knee)
58408954|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
58408955|NCT05519501|PROCEDURE|Standard of Care|Offloading
58408956|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
58408957|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
58408958|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
58408959|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
58408960|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
58078131|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
58078132|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
58078133|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
58078134|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
58078135|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
58078136|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
58078137|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
58078138|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
58078139|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
58078140|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
58078141|NCT02190162|DRUG|Tantum Verde® mouthwash|
58078142|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
58078143|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
58078144|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
58078145|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
58078146|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
58408961|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
58408962|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
58408963|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
58408964|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
58408965|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
58408966|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
58408967|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
58408968|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
58078147|NCT02043002|PROCEDURE|18F-FDG-PET scan|
58078148|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
58078149|NCT02583854|DEVICE|RY-STOP hemostasis device|
58078150|NCT02583854|DEVICE|TR-Band, Terumo|
58078151|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
58078152|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
58078153|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
58408969|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
58408970|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
58408971|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
58408972|NCT00003136|BIOLOGICAL|filgrastim|
58408973|NCT00003136|DRUG|amifostine trihydrate|
58408974|NCT00003136|DRUG|carboplatin|
58078154|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
58078155|NCT00364338|BEHAVIORAL|gourment cooking workshop|
58078156|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
58078157|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
58078158|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
58078159|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
58078160|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
58408975|NCT00003136|DRUG|cyclophosphamide|
58408976|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
58408977|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
58408978|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
58408979|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
58408980|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
58078161|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
58297484|NCT03874013|DRUG|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
58408981|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
58408982|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
58408983|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
58408984|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
58408985|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
58408986|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
58408987|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
58408988|NCT00075387|DRUG|Carboplatin|Given IA
58408989|NCT00075387|DRUG|Cyclophosphamide|Given IV
58078162|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
58078163|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
58078164|NCT02501642|OTHER|Treatment as usual|Treatment as usual
58078165|NCT02184234|DRUG|Antistax film coated tablets|
58297485|NCT02228005|DRUG|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
58408990|NCT00075387|DRUG|Etoposide Phosphate|Given IV
58408991|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
58408992|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
58408993|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
58078166|NCT06723353|OTHER|Visceral Manipulation Therapy|Visceral Manipulation (VM) is a manual therapy consisting of gentle, specifically placed manipulations that encourage normal mobility, tone, and inherent tissue motion of the viscera and their connective tissues. These manipulations can potentially improve the structural integrity of the abdominal cavity and enhance the physiological functioning of the organs. VM will be administered by certified therapists trained in this specialized technique, focusing on reducing the Inter-Recti Distance (IRD) and associated symptoms of DRA.
58297486|NCT01296412|DRUG|sitagliptin|100 mg tablet, orally, once daily.
58297487|NCT01296412|DRUG|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
58297488|NCT01296412|DRUG|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
58297489|NCT01296412|DRUG|metformin|metformin tablets at a dose of ≥1500 mg per day
58408994|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
57943967|NCT04474795|BEHAVIORAL|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
57943968|NCT00004754|DRUG|epoprostenol|
57943969|NCT02302352|OTHER|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
57943970|NCT02302352|OTHER|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
57943971|NCT03719690|DRUG|Tipifarnib|Tablet for oral administration
57943972|NCT03719690|DEVICE|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
57943973|NCT04512053|DRUG|TAS-303 18 mg/day|Oral administration for 12 weeks, once daily
57943974|NCT04512053|DRUG|Placebo|Oral administration for 12 weeks, once daily
57943975|NCT06006234|OTHER|questionnaire survey|questionnaire survey
58297490|NCT00924846|PROCEDURE|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
58408995|NCT01498627|OTHER|Data collection|PGRx information system
58408996|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
58408997|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
58408998|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
58408999|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
57943976|NCT00530985|BEHAVIORAL|Benefits Counseling|Help deciding whether to work
57943977|NCT00530985|BEHAVIORAL|VA Orientation|Orientation to services available at VA
57943978|NCT03434171|BEHAVIORAL|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
57943979|NCT03434171|DIETARY_SUPPLEMENT|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
57943980|NCT04532476|DEVICE|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
58297491|NCT05042817|DRUG|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
58297492|NCT05042817|DRUG|0.9% NaCl|NaCl 0.9%
58297493|NCT05042817|DRUG|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
58297494|NCT05042817|PROCEDURE|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
58409000|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
58409001|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
58409002|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
58409003|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
58078167|NCT06723353|OTHER|Abdominal Kinesio Taping|Kinesio Taping (KT) involves the application of a thin, stretchable tape over and around muscles to enhance function, reduce inflammation, and support muscles in movement on a 24hr/day basis. It is non-restrictive, allowing for full range of motion. In this study, KT will be applied in a crisscross pattern across the abdomen to support the abdominal muscles affected by DRA, potentially aiding in muscle function and reducing pain and discomfort.
58078168|NCT06723353|OTHER|Combined Visceral Manipulation and Kinesio Taping|This intervention combines Visceral Manipulation and Kinesio Taping to leverage the benefits of both modalities. The combination aims to enhance the functional and structural support of the abdominal region by improving organ function through VM and providing muscular support through KT. This dual approach is hypothesized to offer a synergistic benefit, potentially providing a more effective treatment for reducing IRD and improving overall abdominal function.
58078169|NCT06723353|OTHER|Postpartum Core Strengthening Program|The Core Strengthening Program is designed to strengthen the deep core muscles, including the transverse abdominis, multifidus, and the pelvic floor muscles. Exercises will be tailored to accommodate postpartum women and will be progressively adjusted to match improvements in strength and endurance. The program includes supervised training sessions focusing on enhancing core stability, which is crucial for postpartum recovery and long-term spinal and pelvic health.
57731450|NCT02765932|PROCEDURE|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
57943981|NCT04660513|PROCEDURE|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
57943982|NCT06367075|DRUG|Cadonilimab|injectable solution
57943983|NCT06367075|DRUG|Adriamycin|injectable solution
57943984|NCT01884259|DRUG|Docetaxel|75 mg/m² on day 1 of 21-days cycle
58078170|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
58078171|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
57731451|NCT04195503|PROCEDURE|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
57731452|NCT04846504|BEHAVIORAL|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
57731453|NCT04846504|BEHAVIORAL|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
57731454|NCT04846504|BEHAVIORAL|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
57731455|NCT04846504|BEHAVIORAL|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
57731456|NCT00274534|DRUG|Tiotropium|
57731457|NCT00274534|DRUG|Salmeterol|
57943985|NCT01884259|DRUG|Cisplatin|75 mg/m² on day 1 of 21-days cycle
57943986|NCT01884259|DRUG|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
57943987|NCT01884259|BIOLOGICAL|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
57943988|NCT01884259|BIOLOGICAL|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
58078172|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
57943989|NCT01884259|RADIATION|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
57943990|NCT00005798|DRUG|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
57943991|NCT00005798|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
57943992|NCT00005798|DRUG|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
57943993|NCT02422888|DRUG|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
57943994|NCT02422888|DRUG|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
57943995|NCT02971631|OTHER|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
57943996|NCT02971631|OTHER|Placebo|Infusion of 1% human albumin in normal saline
57943997|NCT02241369|BIOLOGICAL|INO-3106, INO-9012|
57943998|NCT06044207|DIAGNOSTIC_TEST|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
57943999|NCT06044207|DIAGNOSTIC_TEST|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
57944000|NCT06044207|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
57944001|NCT02910947|PROCEDURE|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
57944002|NCT01534312|DRUG|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
57944003|NCT01534312|DRUG|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
57944004|NCT06024395|BEHAVIORAL|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
57944005|NCT03331055|DEVICE|PENS|percutaneous electrical nerve stimulation
58078173|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
57944006|NCT03331055|DEVICE|TENS|transcutaneous electrical nerve stimulation
57944007|NCT02963116|DRUG|AZD5718 IR tablet|
57944008|NCT02963116|DRUG|AZD5718 oral suspension|
57944009|NCT02963116|DRUG|Rosuvastatin tablet|
57944010|NCT00399789|DRUG|Perifosine|Perifosine will be tested in 3 dose forms
57944011|NCT05122884|DRUG|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
57944012|NCT06029075|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
57944013|NCT06029075|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
57944014|NCT06029075|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
57944015|NCT02768090|DEVICE|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
57944016|NCT02441049|BEHAVIORAL|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
57944017|NCT00082524|DRUG|caspofungin acetate|Duration of Treatment - 7-90 days
57944018|NCT00002364|DRUG|Abacavir sulfate|
57944019|NCT03683277|DRUG|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
57944020|NCT00077363|DRUG|tipifarnib|Given PO
57944021|NCT00077363|DRUG|capecitabine|Given PO
57944022|NCT03640598|PROCEDURE|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
57944023|NCT03640598|PROCEDURE|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
57944024|NCT02330978|PROCEDURE|Intravitreal transplantation of mesenchymal stem cell|
58078174|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
58078175|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
58409004|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
57944025|NCT02330978|BIOLOGICAL|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
57944026|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
57944027|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
57944028|NCT01033825|DRUG|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
57944029|NCT01033825|DRUG|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
57944030|NCT01033825|DRUG|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
57944031|NCT01033825|DRUG|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
57944032|NCT01033825|DRUG|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
57944033|NCT02618655|OTHER|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
57944034|NCT05429788|DRUG|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
57944035|NCT05429788|DRUG|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
57944036|NCT05429788|DRUG|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
57944037|NCT01059110|DRUG|Salicylate ointment|cream, one application every night, for 90 days
57944038|NCT01059110|DRUG|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
57944039|NCT01059110|DRUG|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
57944040|NCT01059110|DRUG|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
58409005|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
58409006|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
58409007|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
57944041|NCT03939845|RADIATION|RT|external- beam radiotherapy (EBRT)
57944042|NCT03939845|PROCEDURE|TACE|transarterial chemoembolization (TACE)
58409008|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
58409009|NCT01151735|DRUG|placebo|placebo
58409010|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
57944043|NCT02366559|DEVICE|Hyfrecator|
58409011|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
58409012|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
58409013|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
57944044|NCT02366559|DEVICE|532 nm Q-switched Nd:YAG laser|
57944045|NCT00802204|RADIATION|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
57944046|NCT00802204|PROCEDURE|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
57944047|NCT00802204|PROCEDURE|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
57944048|NCT00802204|BEHAVIORAL|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
57944049|NCT00802204|OTHER|Caloric Restriction|Obese participants only complete a short-term (\~10days) very low calorie diet
57944050|NCT01396174|BEHAVIORAL|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
57944051|NCT01396174|BEHAVIORAL|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
57944052|NCT04146740|OTHER|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
57944053|NCT04146740|BEHAVIORAL|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
57944054|NCT00654914|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
58409014|NCT05752227|RADIATION|CT chest|Computed tomography
58409015|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
58409016|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
58409017|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
58409018|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
58409019|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
58409020|NCT00792025|DRUG|sunitinib malate|
58409021|NCT02636244|DRUG|SHAPE Gel|
58297495|NCT04211350|DEVICE|NightBalance Sleep Position Trainer (SPT)|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
57944055|NCT01023867|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
58297496|NCT04211350|DEVICE|Automatic Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
57944056|NCT03889275|BIOLOGICAL|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
57944057|NCT03889275|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
57944058|NCT03283124|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
57944059|NCT02594423|DEVICE|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
58078176|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
58297497|NCT03771963|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
58297498|NCT00405418|DRUG|Insulin glargine|Subcutaneous injection, once a day in the evening
58297499|NCT00405418|DRUG|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
58297500|NCT01602991|PROCEDURE|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
57944060|NCT02594423|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
57944061|NCT02047682|BEHAVIORAL|Biopsychosocial|
57944062|NCT02047682|BEHAVIORAL|Reference|
58078177|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
58078178|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
58078179|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
57944063|NCT01838616|DRUG|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
57944064|NCT01838616|DRUG|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
57944065|NCT05458765|DRUG|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
57944066|NCT05458765|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
57944067|NCT04942795|DEVICE|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
57944068|NCT03085524|DIAGNOSTIC_TEST|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
57944069|NCT03085524|DIAGNOSTIC_TEST|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
57944070|NCT05627414|DRUG|Disitamab Vedotin|2.5mg/kg，IV，Q3W
57944071|NCT05627414|DRUG|Sintilimab|200 mg，IV，Q3W
57944072|NCT05627414|DRUG|S-1|40\~60mg / m2, bid, d1-14, repeated every 3 weeks.
58078180|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
58078181|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
58078182|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
58297501|NCT01602991|PROCEDURE|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
58297502|NCT00180908|DRUG|Etoposide, Ifosfamide, Methotrexate|
58297503|NCT00180908|DRUG|Doxorubicin, Methotrexate|
58297504|NCT03200353|DEVICE|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
58297505|NCT03498729|OTHER|Peripheral Blood Sample|30mL peripheral whole blood sample
58409022|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
57944073|NCT05627414|PROCEDURE|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
57944074|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
57944075|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
58078183|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
58078184|NCT06722118|DRUG|Dexamethasone IV|IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
58078185|NCT06722118|OTHER|Placebo|Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
58078186|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
58078187|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
58297506|NCT02622152|PROCEDURE|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
58297507|NCT02622152|PROCEDURE|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
58078188|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
58078189|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
58409023|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
57944076|NCT02384902|OTHER|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
57944077|NCT05511974|DIAGNOSTIC_TEST|BASET score|The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
57944078|NCT00319150|DRUG|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
57944079|NCT06261073|DIAGNOSTIC_TEST|blood sample and tissue biopsy|Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
57944080|NCT05704894|BIOLOGICAL|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between \<12g/dL
57944081|NCT05919654|DEVICE|MyoCare|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
58078190|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
58078191|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
58078192|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
58078193|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 5|The number of family skills training sessions administered: 5 sessions
58078194|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: In-person|The mode of administration of family skills training sessions: in person or online
58078195|NCT06724406|BEHAVIORAL|Family Skills Training Content: Communication|The content of family skills training sessions administered focused on communication and conflict resolution : communication and conflict resolution
58078196|NCT06724406|BEHAVIORAL|Family Skills Training Content: Cohesion|The content of family skills training sessions administered focused on cohesion: cohesion or no cohesion
58078197|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 10|The number of family skills training sessions administered: 10 sessions
58078198|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: Online|The mode of administration of family skills training sessions: online
58078199|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Communication|The content of family skills training sessions administered focused on communication and conflict resolution : no communication and conflict resolution
58078200|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Cohesion|The content of family skills training sessions administered focused on cohesion: no cohesion
58297508|NCT02622152|PROCEDURE|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
58297509|NCT02622152|PROCEDURE|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
58297510|NCT02622152|PROCEDURE|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
58297511|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
58297512|NCT00299819|BIOLOGICAL|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
58409024|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
58409025|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
58078201|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
58297513|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
58297514|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
58297515|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
58297516|NCT00657423|DRUG|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
58297517|NCT00657423|DRUG|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
58297518|NCT03383224|OTHER|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
58297519|NCT03383224|DRUG|Nicotine patch|
58297520|NCT03383224|BEHAVIORAL|Smoking cessation counseling|
58297521|NCT00445471|BEHAVIORAL|Mifne Approach to PDD|
58297522|NCT00445471|BEHAVIORAL|Treatment as usual|
58297523|NCT00988104|BEHAVIORAL|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
58297524|NCT00988104|BEHAVIORAL|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
58297525|NCT02227277|DRUG|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
58297526|NCT05597995|DRUG|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
58297527|NCT04574453|DEVICE|Iracross|Administration of max 2ml of Iracross at first visit
58297528|NCT04574453|DEVICE|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
58297529|NCT02876796|DRUG|GS-0976|Capsule(s) administered orally
58297530|NCT02876796|DRUG|Placebo|Capsule(s) administered orally
58297531|NCT02876796|OTHER|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
58297532|NCT02876796|OTHER|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
58297533|NCT00545623|PROCEDURE|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
58297534|NCT00545623|BEHAVIORAL|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
58297535|NCT00545623|OTHER|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
58297536|NCT03007355|OTHER|peripheral perfusion index measurement|
58297537|NCT01167569|DRUG|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
58297538|NCT01167569|OTHER|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
58297539|NCT05252741|OTHER|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
58297540|NCT00588146|DRUG|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
58297541|NCT00588146|OTHER|Standard care|Standard care
58297542|NCT00249873|DRUG|clopidogrel (SR25990C)|oral administration (tablets)
58297543|NCT00249873|DRUG|placebo|oral administration (tablets)
58297544|NCT00145769|DRUG|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
58297545|NCT00145769|DRUG|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
58297546|NCT00145769|RADIATION|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
58297547|NCT00145769|RADIATION|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
58297548|NCT00145769|DRUG|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
58297549|NCT00145769|PROCEDURE|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
58297550|NCT05370898|DRUG|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
58297551|NCT05370898|DRUG|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
58297552|NCT05370898|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
58297553|NCT03847740|DEVICE|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
58297554|NCT04288934|BIOLOGICAL|Collection and expansion of BM-MSC|MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
58409026|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
58409027|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
58409028|NCT00182780|OTHER|Placebo|
58409029|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
58409030|NCT05884112|DEVICE|sham control|sham control
58409031|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
58409032|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
58409033|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
58409034|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
58409035|NCT00302276|DRUG|Metobes-compound|
58409036|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
58297555|NCT04288934|DIAGNOSTIC_TEST|VI-SCI evaluation and patients' follow up|"* At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection."
58297556|NCT05375500|DEVICE|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
58297557|NCT02123719|OTHER|Surgery|
58297558|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus plantarum strain 299v|Given PO
58297559|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus acidophilus probiotic|Given PO
58297560|NCT01644097|DIETARY_SUPPLEMENT|placebo|Given PO
58297561|NCT01644097|OTHER|laboratory biomarker analysis|Correlative studies
58297562|NCT01644097|OTHER|questionnaire administration|Ancillary studies
58297563|NCT01644097|PROCEDURE|quality-of-life assessment|Ancillary studies
58297564|NCT01644097|DIETARY_SUPPLEMENT|Bifidobacterium lactis probiotic supplement|Given PO
58297565|NCT00827710|BEHAVIORAL|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
58297566|NCT00827710|BEHAVIORAL|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
58297567|NCT03957486|OTHER|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
58297568|NCT03957486|OTHER|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
58297569|NCT02601079|DEVICE|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
58297570|NCT02601079|DEVICE|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
58297571|NCT05052853|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
58297572|NCT05052853|DRUG|Placebo Cap|Use of placebo as a comparator
58297573|NCT01156688|DRUG|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
58297574|NCT01156688|DRUG|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
58409037|NCT04253899|OTHER|Observation|observation and follow up
58297575|NCT05469529|DRUG|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
58409038|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
58409039|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
58078202|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
58297576|NCT06377293|OTHER|Dialysis-specific therapeutic diet|A healthy diet for dialysis patients
58297577|NCT02224612|DEVICE|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
58409040|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
58409041|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
58409042|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
58409043|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
57731458|NCT04469179|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
57731459|NCT04469179|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
58297578|NCT02224612|DEVICE|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
57944082|NCT05919654|DEVICE|ClearView|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
58297579|NCT01496313|DRUG|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
58297580|NCT01496313|DRUG|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
58297581|NCT01542138|DRUG|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
58297582|NCT01542138|DRUG|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
58297583|NCT01542138|DRUG|Placebo|Humectant placebo cream
58297584|NCT00325819|DRUG|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
58297585|NCT00325819|OTHER|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
57731460|NCT05807711|DRUG|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
57944083|NCT03944226|DIETARY_SUPPLEMENT|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
57944084|NCT01825057|BEHAVIORAL|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
58078203|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
58297586|NCT05908396|DRUG|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
58297587|NCT02581683|DRUG|Magnesium Sulfate|Given via adductor canal block
58078204|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
58297588|NCT02581683|DRUG|Ropivacaine|Given via adductor canal block
58297589|NCT02581683|OTHER|Sham|Sham adductor canal block
58297590|NCT00113295|DRUG|Continued Paroxetine CR|
58297591|NCT00113295|DRUG|Quetiapine|
58297592|NCT00113295|DRUG|Placebo|
58078205|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
58078206|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
57731461|NCT00744653|PROCEDURE|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
58078207|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
58078208|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
58078209|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
58078210|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
58078211|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
58078212|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
58078213|NCT03096899|OTHER|Observational|Best Supportive Care
58297593|NCT06203535|OTHER|Aerobic training|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
58297594|NCT01712828|DRUG|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
58297595|NCT01712828|DRUG|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
58297596|NCT01712828|DRUG|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
58078214|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
58297597|NCT01712828|DRUG|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
58297598|NCT03643510|DRUG|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
58297599|NCT03643510|DRUG|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
58297600|NCT00281697|DRUG|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
58297601|NCT00281697|DRUG|Placebo|
58297602|NCT00281697|DRUG|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle."
58409044|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
57731462|NCT00360308|DRUG|Placebo|
57731463|NCT00360308|DRUG|E2007|
57731464|NCT00360308|DRUG|E2007|
57731465|NCT03845348|OTHER|TD03|Shampoo TD 3 days
57731466|NCT03845348|OTHER|TD07|Shampoo TD 7 days
57731467|NCT03845348|DRUG|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
57731468|NCT04619641|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
58078215|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
58078216|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
58078217|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
58078218|NCT03914456|OTHER|rehabilitation treatment|
57944085|NCT01825057|BEHAVIORAL|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
57944086|NCT01825057|BEHAVIORAL|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
57944087|NCT05230589|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
57944088|NCT03849417|OTHER|ECT|ECT administered as part of normal clinical management
57944089|NCT02486978|OTHER|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
57944090|NCT02486978|DIETARY_SUPPLEMENT|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
57944091|NCT02486978|DIETARY_SUPPLEMENT|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
57944092|NCT05891925|OTHER|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~* older adult id,~* date, hour and time that the older adult listened to each poem,~* poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
57944093|NCT00538395|DRUG|Adriamycin, Taxol and Cytoxan|Chemotherapy
57944094|NCT03700281|BEHAVIORAL|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
57944095|NCT03700281|BEHAVIORAL|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
57944096|NCT05459454|DEVICE|A digital health program for patients with Breast Cancer|A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
57944097|NCT01186120|DEVICE|Biolimus A9-eluting stent|drug-eluting stent
57944098|NCT01186120|DEVICE|Everolimus-eluting stent|drug-eluting stent
58078219|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
58078220|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
58297603|NCT03644771|DRUG|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
58409045|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
57944099|NCT03675035|DEVICE|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
57944100|NCT02605187|OTHER|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
58297604|NCT00727129|DRUG|Divigel|
58297605|NCT03278496|BEHAVIORAL|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
58409046|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
58297606|NCT03278496|BEHAVIORAL|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
57944101|NCT02605187|OTHER|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
57944102|NCT02605187|DRUG|Ibuprofen|Ibuprofen 600mg po q6h
57944103|NCT02605187|DRUG|Acetaminophen|Acetaminophen 650mg po q6h
57944104|NCT02605187|DRUG|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
57944105|NCT02605187|DRUG|Morphine (low)|Intrathecal morphine dose 50mcg
57944106|NCT02605187|DRUG|Morphine (med)|Intrathecal morphine dose 150mcg
57944107|NCT02605187|DRUG|Morphine (high)|Intrathecal morphine 300mcg
57944108|NCT02056197|OTHER|Placebo|Shortwave
57944109|NCT02056197|OTHER|Stable surface exercises|Stable surface exercises
57944110|NCT02056197|OTHER|Unstable surface exercises|
58297607|NCT03278496|BEHAVIORAL|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
58297608|NCT03280485|OTHER|no intervention|no intervention validation of guidelines via database
58297609|NCT06436079|BEHAVIORAL|Intervention group|Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.
58297610|NCT00698815|OTHER|Laboratory Biomarker Analysis|Correlative studies
58297611|NCT00698815|DRUG|Pemetrexed Disodium|Given IV
58297612|NCT00698815|DRUG|Sunitinib Malate|Given PO
58297613|NCT00583908|DEVICE|senofilcon A|toric contact lens
58297614|NCT00583908|DEVICE|balafilcon A toric|toric contact lens
58297615|NCT00583908|DEVICE|lotrafilcon B toric|toric contact lens
57944111|NCT02700412|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
57944112|NCT00071942|BIOLOGICAL|recombinant vaccinia-MUC1 vaccine|Given intradermally
57944113|NCT00071942|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|Given intradermally
57944114|NCT00071942|OTHER|laboratory biomarker analysis|Correlative studies
57944115|NCT00071942|PROCEDURE|quality-of-life assessment|Ancillary studies
57944116|NCT00222170|DRUG|Rabeprazole|
57944117|NCT05796908|DEVICE|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
57944118|NCT02691208|OTHER|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
57944119|NCT02691208|OTHER|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
58297616|NCT00583908|DEVICE|omafilcon A|toric contact lens
58297617|NCT01559805|BEHAVIORAL|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
58297618|NCT01559805|BEHAVIORAL|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
58297619|NCT06148103|DRUG|Patients who received Dexmedetomodine|1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
58297620|NCT06148103|DRUG|patients who received propofol-fentanyl|Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
57944120|NCT00215995|DRUG|Cisplatin|As outlined in Detailed Description
57944121|NCT00215995|DRUG|Irinotecan|As outlined in Detailed Description
57944122|NCT00215995|DRUG|ZD 1839|As outlined in Detailed Description
57944123|NCT01382797|DRUG|ALKS 37|Capsules for oral administration
57944124|NCT01382797|DRUG|Placebo|Capsules for oral administration
57944125|NCT03271814|BIOLOGICAL|LPS|0.6 by/kg LPS single dose iv
57944126|NCT03271814|OTHER|Placebo|Sterile Water
57944127|NCT02664272|PROCEDURE|Total Hip Arthroplasty|
57944128|NCT02799407|OTHER|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
57944129|NCT02427451|DRUG|Bcl-2 Inhibitor GDC-0199|Given PO
57944130|NCT02427451|BIOLOGICAL|Obinutuzumab|Given IV
57944131|NCT02427451|DRUG|Ibrutinib|Given PO
57944132|NCT02427451|OTHER|Pharmacological Study|Correlative studies
57944133|NCT02427451|OTHER|Laboratory Biomarker Analysis|Correlative studies
57944134|NCT02427451|OTHER|Quality-of-Life Assessment|Ancillary studies
57944135|NCT03364244|DRUG|Sildenafil|"\[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
58297621|NCT05210439|DRUG|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment for BSI-PA
58297622|NCT05210439|DRUG|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment for BSI-PA
58297623|NCT02764437|BIOLOGICAL|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
58409047|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
58409048|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
57944136|NCT05069883|DRUG|Steroid Drug|In this group Oral steroid medication after Direct Vision Internal Urethrotomy
58078221|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
58078222|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
58078223|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
58078224|NCT04550143|OTHER|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
58078225|NCT04550143|OTHER|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
58078226|NCT04550143|OTHER|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
57944137|NCT05069883|DRUG|No steroid|In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
57944138|NCT03358199|PROCEDURE|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
57944139|NCT03173859|DRUG|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
57944140|NCT03173859|DRUG|Apalutamide|apalutamide 240mg qD orally
58297624|NCT01810562|OTHER|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
57944141|NCT01795885|BEHAVIORAL|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
57944142|NCT01365039|DEVICE|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
57944143|NCT01365039|DEVICE|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
57944144|NCT00545298|DRUG|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
57944145|NCT00545298|DRUG|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
57944146|NCT02371239|BEHAVIORAL|Physical activity intervention|
57944147|NCT01699945|OTHER|This is an observational study being conducted as a substudy of antoher trial.|
57944148|NCT03022695|DEVICE|High Intensity Focused Ultrasound|
57944149|NCT03078075|DRUG|Naltrexone: Vivitrol®|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
57944150|NCT03078075|DRUG|Placebo (PLB) Injectable|Placebo: 4 intramuscular injections administered every 3 weeks
57944151|NCT03078075|DRUG|Bupropion: Wellbutrin XL®|Bupropion: 450 mg oral dose daily
58078227|NCT04550143|OTHER|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness."
58078228|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
58078229|NCT06426680|BIOLOGICAL|ILB-3101|There are eight escalating dose cohorts.
58078230|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
58078231|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
58297625|NCT00631982|PROCEDURE|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
57944152|NCT03078075|DRUG|Placebo (PLB) Oral|Placebo: once-daily oral placebo tablets
57944153|NCT04804514|DRUG|KH001|The study drug is applied to teeth
57944154|NCT04804514|DRUG|Placebo|The placebo is applied to teeth
57944155|NCT00097747|DRUG|Placebo|
57944156|NCT00097747|DRUG|peginesatide|
58078232|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
58078233|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
58078234|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
58078235|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
58078236|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
58078237|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
58078238|NCT06518616|BEHAVIORAL|10-day meditation intervention|prerecorded meditation units delivered by smartphone app
58297626|NCT03967067|PROCEDURE|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
58297627|NCT04158219|BEHAVIORAL|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
57944157|NCT02870049|BEHAVIORAL|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
58078239|NCT06518616|BEHAVIORAL|10-day health education intervention|prerecorded health education units delivered by smartphone app
58078240|NCT06713460|BEHAVIORAL|BEAM|Multicomponent intervention
58297628|NCT02956538|DRUG|Thalidomide|
57944158|NCT02870049|BEHAVIORAL|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
57944159|NCT02870049|BEHAVIORAL|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
57944160|NCT02870049|BEHAVIORAL|Usual care|Usual care: FIT kit delivery as part of usual care
57944161|NCT00554359|DRUG|I5NP (a small interfering RNA)|Single IV injection of experimental drug
57944162|NCT00554359|DRUG|placebo|Single IV injection of saline
57944163|NCT04142775|OTHER|complication versus no complication|development of ICH
57944164|NCT05404399|BEHAVIORAL|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
57944165|NCT05404399|BEHAVIORAL|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
57944166|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
57944167|NCT01119742|DRUG|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
57944168|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
57944169|NCT01119742|DRUG|Vehicle A|Twice daily application for 7 days
57944170|NCT01119742|DRUG|Vehicle B|Twice daily application for 7 days
58078241|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
58078242|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
58078243|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
58078244|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
58078245|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
58078246|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
58078247|NCT05921851|OTHER|no intervention|no intervention
58078248|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
58078249|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
58078250|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
58078251|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
58078252|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
58078253|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
58078254|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
58078255|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
58078256|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
58078257|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
58078258|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
58078259|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
58078260|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
58078261|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
58078262|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
58078263|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
57944171|NCT02834221|DEVICE|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
57944172|NCT02834221|OTHER|Anatomical landmark guided puncture|Anatomical landmark puncture
58078264|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
58297629|NCT02956538|DRUG|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
58078265|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
58078266|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
58078267|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
58078268|NCT00053911|DRUG|anastrozole|
58078269|NCT00053911|DRUG|cyclophosphamide|
58078270|NCT00053911|DRUG|docetaxel|
58078271|NCT00053911|DRUG|epirubicin hydrochloride|
58078272|NCT00053911|DRUG|fluorouracil|
57731469|NCT04619641|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
58078273|NCT00053911|DRUG|goserelin acetate|
58078274|NCT00053911|DRUG|tamoxifen citrate|
58078275|NCT00053911|PROCEDURE|adjuvant therapy|
58078276|NCT00618046|DRUG|Oxcarbazepine|
58078277|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
58078278|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
58078279|NCT06724861|OTHER|Explicit Sensory Retraining for the lower extremities|Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.
58078280|NCT06724861|OTHER|no treatment|Usual care
58078281|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
58078282|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
58078283|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
58078284|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
58297630|NCT04435938|RADIATION|Stereotactic Body Radiotherapy (SBRT)|45 Gy in 5 fractions delivered once every 3-4 days
58297631|NCT01038687|DRUG|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
57731470|NCT04880759|OTHER|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
58078285|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
58078286|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
58078287|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
58078288|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
58078289|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
58078290|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
58078291|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
58078292|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
58078293|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58297632|NCT01038687|DRUG|placebo|placebo
57731471|NCT01056224|DRUG|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
57731472|NCT05802459|OTHER|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
58078294|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
58078295|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
58297633|NCT02154438|DRUG|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
58078296|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
58078297|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
58297634|NCT04221269|BEHAVIORAL|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
58297635|NCT04221269|BEHAVIORAL|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
58078298|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
58078299|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
58078300|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
57944173|NCT02220842|DRUG|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
57944174|NCT02220842|DRUG|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
57944175|NCT02220842|DRUG|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
57944176|NCT03397004|DRUG|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
57944177|NCT03397004|DRUG|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
57944178|NCT05961995|BEHAVIORAL|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart.
57944179|NCT06124625|PROCEDURE|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
57944180|NCT06124625|PROCEDURE|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
57944181|NCT02437864|DEVICE|Supplemental oxygen via nasal cannula|
57944182|NCT00565253|DRUG|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
57944183|NCT00710879|DEVICE|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
57944184|NCT02769663|BEHAVIORAL|questionnaires and neuropsychological assessments|
57944185|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
57944186|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
58078301|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
58078302|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
58078303|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
58078304|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
58078305|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
57731473|NCT05802459|OTHER|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
57944187|NCT03871322|DIETARY_SUPPLEMENT|Placebo|Placebo control group
57944188|NCT05402475|BEHAVIORAL|CBT + Mindfulness|Eight weeks of online CBT intervention combined with mindfulness
57944189|NCT01141036|DRUG|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
57944190|NCT01141036|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
57944191|NCT03317041|OTHER|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
58078306|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
58078307|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
58078308|NCT03406780|DRUG|Placebo|Placebo
58078309|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
58297636|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
58297637|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
58078310|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58078311|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
58078312|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
58078313|NCT01869959|DRUG|LY2405319|Administered SC
58078314|NCT01869959|DRUG|Placebo|Administered SC
58078315|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
57944192|NCT00866450|DIETARY_SUPPLEMENT|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
57944193|NCT00866450|DIETARY_SUPPLEMENT|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
57944194|NCT05774730|OTHER|Emphysema quantitative analysis software based on chest image AI technology|The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.
57944195|NCT05774730|OTHER|artificial analysis of chest image|The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.
57944196|NCT05774730|PROCEDURE|imported Chartis detection system|The participants would undergo imported Chartis detection system.
57944197|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
57944198|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
57944199|NCT03366688|DRUG|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
57944200|NCT03366688|DRUG|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
57944201|NCT04244526|OTHER|Talking a urine sample|Just taking a urine sample
57944202|NCT04811404|DRUG|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
57944203|NCT01612182|OTHER|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
57944204|NCT02433197|DEVICE|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
57944205|NCT05357443|PROCEDURE|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
57944206|NCT05357443|PROCEDURE|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
57944207|NCT00449683|DRUG|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
57944208|NCT03159091|DRUG|Rengalin|Oral administration.
57944209|NCT03159091|DRUG|Placebo|Oral administration.
57944210|NCT00105716|BEHAVIORAL|Telephone behavioral education|
57944211|NCT00105716|BEHAVIORAL|Computer behavioral education|
57944212|NCT04778436|DIETARY_SUPPLEMENT|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
57944213|NCT02950090|BEHAVIORAL|MobilWise|see arm description for MobilWise above
57944214|NCT02950090|BEHAVIORAL|Fitbit Only|see arm description for Fitbit above
58078316|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
58078317|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
57731474|NCT05802459|OTHER|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
58078318|NCT00107601|DRUG|Insulin|
58078319|NCT05455294|DRUG|Navitoclax|See Arm Description
58078320|NCT05455294|DRUG|Venetoclax|See Arm Description
58297638|NCT04819165|OTHER|COVID-19|Impact of covid-19 on infections associated with health care devices.
58297639|NCT00596102|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
58297640|NCT01540513|DRUG|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
58297641|NCT01540513|DRUG|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
58409049|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
58409050|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
58409051|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
58409052|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
58409053|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
58409054|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
58409055|NCT02337283|DRUG|BI 425809|Tablets
57731475|NCT05802459|OTHER|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
58078321|NCT05455294|DRUG|Decitabine|See Arm Description
58297642|NCT06431334|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.5 to 2.8 g/kg/d
58409056|NCT02337283|DRUG|Placebo|Tablets
58409057|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
58409058|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
58078322|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
58297643|NCT01438112|BIOLOGICAL|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
58297644|NCT01438112|OTHER|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
58297645|NCT03175887|DEVICE|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
58297646|NCT02438189|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
58297647|NCT05947604|DRUG|Acoziborole|Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
58297648|NCT05947604|DRUG|Midazolam|• Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
58297649|NCT05947604|DRUG|Dextromethorphan|• Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
58297650|NCT02025283|PROCEDURE|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
58297651|NCT05105191|DIAGNOSTIC_TEST|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
58409059|NCT00099242|DRUG|rivastigmine transdermal patch|
58409060|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
58409061|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
58078323|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
58078324|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
58409062|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
58078325|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
58078326|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
58078327|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
58078328|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
58078329|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
58078330|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
58078331|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
58078332|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
58078333|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
58409063|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
58409064|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
58409065|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
58409066|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
58409067|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
57731476|NCT05802459|PROCEDURE|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
58409068|NCT03469830|OTHER|SSCP|Insert
58409069|NCT03469830|OTHER|SPMS|Pressure therapy
57731477|NCT04071938|OTHER|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
58409070|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
58409071|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
58078334|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
58409072|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
58409073|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
58409074|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
57731478|NCT04071938|OTHER|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
58078335|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
58078336|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
58078337|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
58078338|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
58078339|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
58078340|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
58078341|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
58078342|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
58078343|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
58078344|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
58078345|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
58297652|NCT06240117|PROCEDURE|Intraoperative cellular salvage|When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If \>100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
58297653|NCT04346199|DRUG|Acalabrutinib|Acalabrutinib- administered orally
58297654|NCT01114009|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
58409075|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
57731479|NCT03887377|DRUG|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
57731480|NCT03887377|OTHER|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
58078346|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
58078347|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
58078348|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
58078349|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
58078350|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
58078351|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
58078352|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
58078353|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
58078354|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
58078355|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
58078356|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
58078357|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
58078358|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
58078359|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
58078360|NCT01917149|DRUG|Benazepril|
57731481|NCT03894449|COMBINATION_PRODUCT|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
57731482|NCT04172792|DIETARY_SUPPLEMENT|high-caloric fatty diet|see arm/group description
57731483|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric fatty diet|see arm/group description
57731484|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric carbohydrate-rich diet|see arm/group description
57731485|NCT01968213|DRUG|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
57731486|NCT01968213|DRUG|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
57944215|NCT04511832|DRUG|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
57944216|NCT04790136|DRUG|GLA-015|administration followed by PK blood sampling
58409076|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
57731487|NCT06636344|OTHER|Pseudoxanthoma Elasticum|Answer to the PSQ-18, patient care confidence score (likert scale) and SF-12 questionaries at each visit, for an estimated duration of 15 minutes.
57731488|NCT00003011|DRUG|marimastat|10 mg PO BID
57731489|NCT00003011|DRUG|Placebo|10 mg PO BID
57944217|NCT04790136|DRUG|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|administration followed by PK blood sampling
57944218|NCT00316355|BEHAVIORAL|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
57944219|NCT00316355|BEHAVIORAL|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
57944220|NCT02403336|OTHER|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
58297655|NCT01114009|PROCEDURE|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
58297656|NCT02511327|DRUG|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
58297657|NCT03069235|BEHAVIORAL|Family member / peer support|supplemental individualized counselling
58297658|NCT03069235|BEHAVIORAL|Enhanced intervention with counselor support|"hands on EBF demonstrations"
58297659|NCT03069235|BEHAVIORAL|standard of care|one on one and in-group counselling
58409077|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
58409078|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
57731490|NCT04733560|PROCEDURE|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
57731491|NCT04733560|PROCEDURE|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
57731492|NCT04733560|DRUG|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
57731493|NCT01437449|DRUG|Docetaxel|30 mg/m² by intravenous (IV) administration
57944221|NCT02403336|BEHAVIORAL|Behavioral group intervention|Intervention on patients (educational workshop).
58078361|NCT01917149|DRUG|Valsartan|
58078362|NCT01917149|DRUG|Metoprolol|
58409079|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
57944222|NCT02403336|OTHER|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
57944223|NCT04966520|OTHER|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
57944224|NCT04341220|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
57944225|NCT04341220|OTHER|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
57944226|NCT04700527|DRUG|Short Chain Fatty Acid|Participants will take the supplement as prescribed to determine if it can help with GI toxicity
57944227|NCT04700527|DRUG|Tapioca Flour|Participants taking this will be used as a control group compared to those receiving the SCFA supplement
57944228|NCT02947672|DRUG|Intravenous Dexamethasone|
57944229|NCT02947672|DRUG|Intraperitoneal Dexamesathone|
57944230|NCT01417598|OTHER|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
57944231|NCT01417598|OTHER|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
57944232|NCT01766128|DRUG|Zonisamide|The first arm will be treated by zonisamide
57944233|NCT01766128|DRUG|Placebo|The second arm will receive placebo
57944234|NCT04712721|DRUG|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
57944235|NCT04935892|BEHAVIORAL|Slippers|Patients in the intervention group wear slippers when out of bed
57944236|NCT03118700|OTHER|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
57944237|NCT03118700|OTHER|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
57944238|NCT02021084|DIETARY_SUPPLEMENT|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
57944239|NCT02021084|DIETARY_SUPPLEMENT|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
57944240|NCT05543577|OTHER|Questionnaire|Questionnaire
57944241|NCT03680911|DRUG|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
57944242|NCT03680911|DRUG|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
57944243|NCT05790382|DRUG|NM-101|"In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts)."
57944244|NCT05790382|DRUG|Placebo|Placebo solution for infusion
57944245|NCT06490341|DRUG|GP Regimen, Nimotuzumab, Sintilimab|gemcitabine,ciplatin, nimotuzumab, sintilimab
58078363|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
58078364|NCT03950947|DEVICE|Amplatzer vascular plug|See above
58078365|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
57731494|NCT01437449|DRUG|Cisplatin|30 mg/m² by intravenous (IV) administration
58078366|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
58297660|NCT05722730|PROCEDURE|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
58297661|NCT03614403|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
58297662|NCT00976326|DRUG|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
58297663|NCT05995938|BEHAVIORAL|Mindfullnes-Based Cognitive Therapy|Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
57944246|NCT01001468|DRUG|VB-201|Single daily dose of oral VB-201 20 mg
57944247|NCT01001468|DRUG|VB-201|Single daily dose or oral VB-201 80 mg
57944248|NCT01001468|OTHER|Placebo|Single daily dose of oral placebo
57944249|NCT03137589|OTHER|Telemedical support|Participating sites will be advised by telemedicine support.
57944250|NCT04296214|DRUG|5-azacitidine|Cycles of 28 days
57944251|NCT04578860|OTHER|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
57944252|NCT04578860|OTHER|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
57944253|NCT04578860|OTHER|Treatment as usual for sleep disorders|No intervention
57944254|NCT02227732|DEVICE|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
57944255|NCT01886573|DRUG|Azacitidine|Given SC
57944256|NCT01886573|DRUG|Entinostat|Given PO
57944257|NCT01886573|OTHER|Laboratory Biomarker Analysis|Correlative studies
57944258|NCT01886573|OTHER|Pharmacological Study|Correlative studies
57944259|NCT01886573|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57944260|NCT04227366|BIOLOGICAL|BCD-089|BCD-089 162 mg SC
58078367|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
57944261|NCT04227366|BIOLOGICAL|Placebo|Placebo
57944262|NCT04227366|DRUG|Methotrexat|15 to 25 mg/week
57944263|NCT01124903|PROCEDURE|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
57944264|NCT02121600|OTHER|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.
57944265|NCT02121600|RADIATION|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
57944266|NCT02121600|RADIATION|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
57944267|NCT05060653|OTHER|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
57944268|NCT03650920|PROCEDURE|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
57944269|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
57944270|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
57944271|NCT00456105|BEHAVIORAL|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
58078368|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
58078369|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
57944272|NCT01593293|DRUG|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
57944273|NCT01593293|DRUG|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
57944274|NCT03606993|OTHER|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one \~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
57944275|NCT05755841|OTHER|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~* Twice weekly fetal cardiotocography.~* Complete blood count once a week.~* A weekly clinical and ultrasound examination."
57944276|NCT05755841|OTHER|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
57944277|NCT03700320|DRUG|Standard of Care (SOC) Migraine Preventive Medication|Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
57944278|NCT03700320|DRUG|Atogepant|Atogepant tablets taken orally, once daily for 52 weeks.
58297664|NCT06608121|OTHER|Upper limb isokinetic forces measurements|The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.
58297665|NCT01241708|DRUG|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
58297666|NCT04313517|OTHER|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
57731495|NCT01437449|DRUG|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
57731496|NCT01437449|DRUG|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
57731497|NCT02103439|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
57944279|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
57944280|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
57944281|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
57944282|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
57944283|NCT03213964|BIOLOGICAL|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)"
57944284|NCT03213964|DRUG|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
57944285|NCT05445401|BEHAVIORAL|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
57944286|NCT05445401|BEHAVIORAL|Standard medical care|Traditional care
58078370|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
58078371|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
58078372|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
58078373|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
58297667|NCT04406922|PROCEDURE|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
58297668|NCT02126215|PROCEDURE|MRI CO2 and O2 stress testing|Pre and post operatively
58297669|NCT05914818|DEVICE|EXPLORER V2|4 sessions of use of the exoskeleton, 1 in a laboratory of gait analysis and 3 in the home and the community of the participants
57944287|NCT03946137|OTHER|Chest Therapy|The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
57944288|NCT03946137|OTHER|Postural Hygiene|Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
57944289|NCT03856853|DRUG|Pirfenidone|pirfenidone for SSc-ILD treatment
57944290|NCT03856853|OTHER|placebo|as control
57944291|NCT04308070|DEVICE|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
57944292|NCT04308070|DEVICE|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
57944293|NCT05462964|BEHAVIORAL|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
58078374|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
57944294|NCT05462964|BEHAVIORAL|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
58078375|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
58078376|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
58078377|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
58078378|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
58078379|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
58078380|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
58078381|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
58297670|NCT04572776|DRUG|Resiniferatoxin|Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
58297671|NCT04572776|OTHER|Standard of Care|Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
58078382|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
58078383|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
58409080|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
58409081|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
58297672|NCT04639557|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
58409082|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
58409083|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
58409084|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
58409085|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
58409086|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
58409087|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
57944295|NCT05988450|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
57944296|NCT03231046|DEVICE|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
57944297|NCT03231046|PROCEDURE|Hepatic Biopsy or Ablation|Standard of Care
57944298|NCT00006448|BEHAVIORAL|cognitive therapy|
57944299|NCT00006448|PROCEDURE|Physical Therapy|
57944300|NCT00006448|DRUG|Methadone|
57944301|NCT04185753|DIAGNOSTIC_TEST|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
57944302|NCT02566291|DEVICE|Success|Success rate and time for insertion
57944303|NCT06466304|BEHAVIORAL|inspiratory muscle training|children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
57944304|NCT04326712|OTHER|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
58297673|NCT02958371|PROCEDURE|fMRI|
58297674|NCT02958371|BEHAVIORAL|fruit-flavored drink ingestion|
57944305|NCT04326712|OTHER|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
57944306|NCT00552175|DRUG|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
57944307|NCT00552175|DRUG|placebo|placebo taken orally every day
57944308|NCT00552175|DRUG|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
57944309|NCT02506595|BEHAVIORAL|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
57944310|NCT03359291|DRUG|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
57944311|NCT03359291|DRUG|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
57944312|NCT03739905|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
57944313|NCT01994382|DRUG|Cerdulatinib|Oral capsule
57944314|NCT01994382|BIOLOGICAL|Rituximab|IV infusion
57944315|NCT01490099|DRUG|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
57944316|NCT04777136|OTHER|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
57944317|NCT04777136|OTHER|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
58297675|NCT02187549|DEVICE|HYMOVIS|Intra-articular injection
57731498|NCT02103439|DRUG|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
57731499|NCT05542355|DRUG|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
57944318|NCT06443918|BEHAVIORAL|A Just-in-Time Adaptive Intervention for Child and Family Mental Health|Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
57944319|NCT05548348|DRUG|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
57944320|NCT03862352|DEVICE|Covered coronary stent|Insertion of covered coronary stent as part of standard care
57944321|NCT06489496|DIAGNOSTIC_TEST|18F-1007 PSMA PSMA PET/CT|"Each patient will receive an IV injection 18F-PSMA-1007 PET/CT.~PET/CT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq/kg (max 400 MBq +/- 15%) 18F-PSMA-1007 in patients."
57944322|NCT02713542|DEVICE|ACP|Autologous Conditioned Plasma
57944323|NCT02713542|OTHER|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
57944324|NCT03242265|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
57944325|NCT02657161|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
57944326|NCT02657161|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
57944327|NCT02657161|BIOLOGICAL|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
57944328|NCT00139347|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
58297676|NCT02187549|DEVICE|Placebo|Intra-Articular Injection
58297677|NCT01533116|DRUG|BIA 9-1067|
57731500|NCT05542355|DRUG|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
57731501|NCT05542355|OTHER|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
57944329|NCT02365220|BEHAVIORAL|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
58297678|NCT01533116|DRUG|Placebo|
57944330|NCT02365220|BEHAVIORAL|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
57944331|NCT02365220|BEHAVIORAL|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
58297679|NCT01533116|DRUG|levodopa/carbidopa|
57731502|NCT05542355|OTHER|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
57731503|NCT05108337|PROCEDURE|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
57731504|NCT05108337|OTHER|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
57731505|NCT00935025|DRUG|AZD1305|single and multiple oral doses, extended-release capsule
57731506|NCT00935025|DRUG|Placebo|single and multiple oral doses, capsule
57731507|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
57731508|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
57731509|NCT04034433|PROCEDURE|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
57731510|NCT03478891|BIOLOGICAL|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
57731511|NCT04445818|BEHAVIORAL|More appreciation|
57731512|NCT04445818|BEHAVIORAL|Less criticism|
57731513|NCT04445818|BEHAVIORAL|More Fruit and Vegetable|
58297680|NCT01533116|DRUG|levodopa/benserazide|
58297681|NCT02288819|DEVICE|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
58297682|NCT02288819|DRUG|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved."
58297683|NCT03718429|DRUG|Rivaroxaban 2.5 mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
58297684|NCT05515133|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
58078384|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
58078385|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
58078386|NCT01781130|PROCEDURE|Steroid injection|
58297685|NCT01063855|DRUG|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
58297686|NCT01063855|DRUG|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
58297687|NCT01063855|DRUG|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
58297688|NCT00076037|BIOLOGICAL|HIV CTL MEP administered with RC529-SE adjuvant|
58409088|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
57944332|NCT02365220|BEHAVIORAL|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
57944333|NCT01711411|DEVICE|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
57944334|NCT04646785|BEHAVIORAL|Mindfulness-based cognitive therapy + TAU|The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).
57944335|NCT04646785|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
58078387|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
58078388|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
58078389|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
58078390|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
58078391|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
58297689|NCT00076037|DRUG|GM-CSF|
58297690|NCT00004002|DRUG|bortezomib|
58306874|NCT03238417|OTHER|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
58409089|NCT03596073|OTHER|Topical Vaseline|Placebo
58409090|NCT00164385|BEHAVIORAL|Adolescent Impact|
58409091|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
58409092|NCT06606067|DRUG|Placebo|Placebo tablet daily
58409093|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
58409094|NCT05976503|DRUG|Placebo|Placebo
58409095|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
58409096|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
58409097|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
58409098|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
58078392|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
58078393|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
58078394|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
58078395|NCT02182726|DRUG|MOBEC|
58078396|NCT02472600|DRUG|Colistin|
58078397|NCT02472600|DRUG|Neomycin|
58078398|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
58078399|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
58078400|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
58078401|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
58078402|NCT04648943|PROCEDURE|Trabeculectomy|
58078403|NCT03783026|DRUG|Apremilast|Tablets for oral administration
58078404|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
58078405|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
58078406|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
58078407|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
58078408|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
58078409|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
58297691|NCT04578704|OTHER|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
57731514|NCT04950699|GENETIC|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
58078410|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
58078411|NCT01048710|OTHER|No intervention|
57731515|NCT03851653|BEHAVIORAL|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
58078412|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
58078413|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
58078414|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
58078415|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
58078416|NCT03406286|DRUG|Tolvaptan|
57944336|NCT00859599|DEVICE|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
57944337|NCT00859599|DEVICE|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
57944338|NCT01967355|OTHER|lipid apheresis|
57944339|NCT04512443|DRUG|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
57944340|NCT04140656|OTHER|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
57944341|NCT04140656|OTHER|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
57944342|NCT04828070|OTHER|Observation|all participants followed for clinical data for one year, vital status check at 5 years
57944343|NCT02306109|PROCEDURE|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
57944344|NCT02306109|PROCEDURE|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
57944345|NCT00066768|DRUG|suramin|Given IV
57944346|NCT00066768|DRUG|docetaxel|Given IV
57944347|NCT00066768|DRUG|gemcitabine hydrochloride|Given IV
57944348|NCT00066768|OTHER|laboratory biomarker analysis|Correlative studies
57944349|NCT00066768|OTHER|pharmacological study|Correlative studies
57944350|NCT00003784|DRUG|CHOP regimen|
57944351|NCT00003784|DRUG|cyclophosphamide|
57944352|NCT00003784|DRUG|doxorubicin hydrochloride|
57944353|NCT00003784|DRUG|prednisone|
57944354|NCT00003784|DRUG|vincristine sulfate|
57944355|NCT00003784|RADIATION|tositumomab and iodine I 131 tositumomab|
57944356|NCT06448702|PROCEDURE|wet wrap therapy|Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect
58078417|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
57731516|NCT04145752|PROCEDURE|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
57944357|NCT06448702|DEVICE|External compression counter-pulsation (EECP)|External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
57944358|NCT02477657|PROCEDURE|Paracentesis|Paracentesis
57944359|NCT02477657|DEVICE|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
57944360|NCT02477657|DEVICE|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
57944361|NCT05005806|DRUG|Omega 3 fatty acid|omega 3 fatty acid soft gel
57944362|NCT05005806|DRUG|Placebo|placebo soft gel
57944363|NCT03565575|BEHAVIORAL|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~1. Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~2. Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
57944364|NCT00111280|DRUG|TMC125|
58078418|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
58078419|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
58078420|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
58297692|NCT01062308|PROCEDURE|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique"
58297693|NCT01062308|PROCEDURE|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
57944365|NCT00861250|DRUG|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
57944366|NCT00002142|DRUG|Cidofovir|
57944367|NCT00002142|DRUG|Probenecid|
57944368|NCT00974675|BIOLOGICAL|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
57944369|NCT00974675|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
57944370|NCT00974675|BIOLOGICAL|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
57944371|NCT00974675|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
58078421|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
58078422|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
58078423|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
58078424|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
58078425|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
58078426|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
58078427|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
58078428|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
58078429|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
58078430|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
58078431|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
58078432|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
57731517|NCT04321720|OTHER|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
58078433|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
58078434|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
58297694|NCT01328470|DRUG|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
58297695|NCT03380871|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
58297696|NCT03380871|BIOLOGICAL|Pembrolizumab|monoclonal antibody against PDL1
58297697|NCT03380871|OTHER|Adjuvant|immune adjuvant
58297698|NCT03380871|DRUG|Carboplatin|chemotherapy
57944372|NCT00619970|PROCEDURE|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
57944373|NCT00619970|DRUG|xifaxan|xifaxan 550mg TID x10days
57944374|NCT00619970|DRUG|placebo|placebo TID x 10days
57944375|NCT00619970|PROCEDURE|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
57944376|NCT00997451|BEHAVIORAL|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
57944377|NCT00997451|BEHAVIORAL|Symptom monitoring|Daily symptom via web diary
57944378|NCT05192356|DRUG|CKD-348(3)|QD, PO
57944379|NCT05192356|DRUG|CKD-828, D097, D337|QD, PO
57944380|NCT03010969|PROCEDURE|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
57944381|NCT03817554|DRUG|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
57944382|NCT03817554|OTHER|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
57944383|NCT02403570|OTHER|Brain MRI|
57944384|NCT01242267|DRUG|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
57944385|NCT06541067|DRUG|Posaconazole|"Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose"
57944386|NCT05798676|OTHER|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
58078435|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
58078436|NCT02430064|OTHER|Low PAMP diet|
58297699|NCT03380871|DRUG|Pemetrexed|chemotherapy
58297700|NCT03573596|DRUG|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
58297701|NCT04030169|DRUG|MDMA|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
58297702|NCT03414853|DIAGNOSTIC_TEST|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
58297703|NCT00908271|DRUG|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
58297704|NCT00689338|DRUG|Anidulafungin|Anidulafungin Intravenous Administration
57944387|NCT03173729|DIAGNOSTIC_TEST|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
57944388|NCT01395199|DRUG|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
58078437|NCT01813162|DRUG|Tenofovir 1% gel|
58297705|NCT00689338|DRUG|Fluconazole|Oral Administration of Fluconazole
58297706|NCT00689338|DRUG|Voriconazole|Oral Administration of Voriconazole
57944389|NCT02285998|BIOLOGICAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
58078438|NCT01813162|DRUG|Vaginal product|
58297707|NCT05119127|DEVICE|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
58306875|NCT02674516|DEVICE|Transcranial direct current stimulation|
58306876|NCT02674516|DEVICE|Sham transcranial direct current stimulation|
58306877|NCT00818935|DIETARY_SUPPLEMENT|Low-Intermediate-Glycemic Index diets|
58306878|NCT00818935|DIETARY_SUPPLEMENT|High GI diet|
58306879|NCT05402956|BEHAVIORAL|Aerobic exercise|Moderate aerobic exercise training
58306880|NCT02879292|OTHER|Spinal anesthesia|Spinal Anesthesia
58306881|NCT04014530|DRUG|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
58306882|NCT05475522|DEVICE|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
58409099|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
58409100|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
58409101|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
58409102|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
58409103|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
58409104|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
58409105|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
58409106|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
58409107|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
58409108|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
58409109|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
58409110|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
58409111|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
58409112|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
58409113|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
57731518|NCT04321720|OTHER|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
58306883|NCT05475522|DEVICE|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
58306884|NCT05836480|PROCEDURE|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
57731519|NCT04321720|OTHER|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
57731520|NCT04321720|OTHER|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
57731521|NCT02423473|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
57731522|NCT02423473|PROCEDURE|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
57944390|NCT02285998|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
58306885|NCT05207865|DRUG|Rimegepant|rimegepant ODT 75mg daily
57731523|NCT03984669|DIAGNOSTIC_TEST|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
58078439|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
57731524|NCT03984669|BIOLOGICAL|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
57731525|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
57731526|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
57731527|NCT04478279|DRUG|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
57731528|NCT04478279|DRUG|Temozolomide|Temozolomide
57731529|NCT04478279|RADIATION|Radiation|Radiation
57731530|NCT05202561|BIOLOGICAL|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
57731531|NCT05202561|BIOLOGICAL|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
57731532|NCT04399629|BEHAVIORAL|PCIT-ED|12 sessions of PCIT-ED therapy
57731533|NCT04399629|BEHAVIORAL|Parenting Wisely|Teaches parents how to set more effective limits
57731534|NCT04898335|DEVICE|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
57731535|NCT03348891|OTHER|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
57731536|NCT01343368|DRUG|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
57731537|NCT01343368|BIOLOGICAL|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
57731538|NCT01343368|BIOLOGICAL|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
57731539|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
57731540|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
57731541|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
57731542|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
57731543|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
57731544|NCT06183801|DIETARY_SUPPLEMENT|Placebo 1|Subjects take capsule three times a day before meal.
57731545|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
57731546|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
57731547|NCT06183801|DIETARY_SUPPLEMENT|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
57731548|NCT00793416|DEVICE|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
57731549|NCT06106477|BEHAVIORAL|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
58306886|NCT04343183|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
57731550|NCT01465893|DRUG|Vitamin D|vitamin D ,50000 unit /week
57731551|NCT01465893|DRUG|Vitamin D withheld|do not receive anything
57731552|NCT06669988|DEVICE|VR|VR - Immersive instruction using virtual reality.
57731553|NCT06669988|DEVICE|Video|Video - Educational content presented through video.
57731554|NCT06669988|DEVICE|written materials|Written Materials - Instruction using text and images.
57731555|NCT02171468|DRUG|Dabigatran high dose|
57731556|NCT02171468|DRUG|Dabigatran low dose|
57944391|NCT04897477|DRUG|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
57944392|NCT00645814|DRUG|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
57944393|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
57944394|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
58078440|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
57944395|NCT02603367|OTHER|Communication Intervention|Undergo communication coaching
57944396|NCT02603367|OTHER|Educational Intervention|Receive COMFORT communication curriculum
57944397|NCT02603367|OTHER|Psychosocial Support for Caregiver|Undergo communication coaching
57944398|NCT02603367|OTHER|Questionnaire Administration|Complete questionnaires
57944399|NCT02408705|DRUG|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
57944400|NCT02408705|DRUG|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
57944401|NCT02408705|DRUG|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
57944402|NCT02349399|DRUG|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
57944403|NCT01673711|DRUG|deuterated phenanthrene tetraol|Given PO
57944404|NCT01673711|DRUG|pharmacological study|Correlative studies
57944405|NCT01673711|DRUG|laboratory biomarker analysis|Correlative studies
58078441|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
58306887|NCT03519009|BEHAVIORAL|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
58409114|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
57944406|NCT06039462|BEHAVIORAL|Application of a virtual reality headset|Use of a headset to experience a different reality
57944407|NCT02867176|DRUG|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
57944408|NCT02867176|DRUG|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
57944409|NCT00589420|DRUG|docetaxel|
57944410|NCT00589420|DRUG|sorafenib tosylate|
57944411|NCT01362361|DRUG|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
57944412|NCT01362361|DRUG|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
57944413|NCT02558673|OTHER|TMAO dietary precursors|
57944414|NCT02558673|OTHER|Control (or active comparator)|
57944415|NCT00507949|DRUG|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
57944416|NCT00507949|DRUG|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
57944417|NCT04086082|DEVICE|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
57944418|NCT04750759|DRUG|Niclosamide + Camostat|Niclosamide will be applied in combination with camostat.
57944419|NCT04750759|OTHER|Placebo|Placebo to interventional drug
57944420|NCT03741114|PROCEDURE|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
57944421|NCT03741114|DRUG|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
57944422|NCT03741114|DRUG|Placebo|patients received 100 ml saline just before skin incision
57944423|NCT03295877|DRUG|RO7171009|Patients will receive RO7171009 via ITV injection.
57944424|NCT04170439|DRUG|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
58078442|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
58409115|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
58409116|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
58409117|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
58409118|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
58409119|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
58409120|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
58409121|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
58409122|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
58409123|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
58409124|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
58409125|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
58409126|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
58409127|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
58409128|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
58409129|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
58409130|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
58409131|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
58409132|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
58409133|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
57731557|NCT04589923|DEVICE|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
57944425|NCT04170439|DRUG|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
58078443|NCT00482976|DRUG|Ruboxistaurin|
58078444|NCT00482976|DRUG|Placebo|
58078445|NCT02101957|DRUG|RP103|
58078446|NCT02101957|DRUG|Placebo|
58078447|NCT06003283|DRUG|Rituximab|IV rituximab
58078448|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
58078449|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
58078450|NCT05160766|BIOLOGICAL|Comirnaty(BTN162b2)|Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
58297708|NCT00861666|BEHAVIORAL|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
58297709|NCT05184348|RADIATION|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
58409134|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
58409135|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
58409136|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
57731558|NCT04589923|DEVICE|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
57944426|NCT04170439|DRUG|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
57944427|NCT02458521|DEVICE|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
57944428|NCT02458521|DEVICE|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
57944429|NCT01512836|BEHAVIORAL|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching"
57944430|NCT05957250|DIAGNOSTIC_TEST|[68Ga]Ga-FAPI-46 PET/CT|one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
57944431|NCT01328951|DRUG|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
57944432|NCT01328951|DRUG|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
58078451|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
58078452|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
58078453|NCT00082134|DRUG|ILX651|
58409137|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
58409138|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
58409139|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
58078454|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
58078455|NCT04155567|DRUG|TAK-123|TAK-123 infusion
58409140|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
58297710|NCT05184348|DRUG|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
57731559|NCT00142480|DRUG|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
57731560|NCT00142480|DRUG|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
57944433|NCT01328951|DRUG|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
57944434|NCT01841502|DRUG|Paroxetine|paroxetine 20 mg once daily
57944435|NCT01841502|DRUG|telaprevir|telaprevir 1125 mg twice daily
57944436|NCT02324855|OTHER|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
57944437|NCT02781142|OTHER|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
57944438|NCT01561950|DRUG|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
57944439|NCT01561950|DRUG|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
57944440|NCT01561950|DRUG|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
57731561|NCT00142480|DRUG|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
57731562|NCT00142480|PROCEDURE|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
57731563|NCT04279249|OTHER|HEPA Air Filtration|2 HEPA air filters placed in home (one in bedroom, one in living room) for 30 days
57731564|NCT04279249|OTHER|Sham HEPA Air Filtration|2 HEPA air filter devices with filter removed placed in home (one in bedroom, one in living room) for 30 days
57731565|NCT00206648|DRUG|Betaferon/Betaseron|Betaseron 250 µg SC every other day
57731566|NCT00206648|DRUG|Betaferon/Betaseron|Avonex 30 µg IM once per week
57731567|NCT00982462|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
57731568|NCT00982462|DIETARY_SUPPLEMENT|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
57944441|NCT02459327|BEHAVIORAL|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
58078456|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
57731569|NCT04608474|DRUG|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
57731570|NCT04608474|DRUG|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
57731571|NCT02945085|OTHER|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
57731572|NCT02945085|OTHER|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
57731573|NCT06588491|BIOLOGICAL|Standard lymphodepletion regimen|Standard lymphodepletion regimen
57731574|NCT03360461|DRUG|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
57731575|NCT06052501|PROCEDURE|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
57731576|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
57731577|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
57731578|NCT04939480|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenous solution
57731579|NCT03738540|BEHAVIORAL|TALK study group|Telephone Delivered Intervention
58297711|NCT05184348|COMBINATION_PRODUCT|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
58297712|NCT03161730|OTHER|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
58297713|NCT03161730|OTHER|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
58297714|NCT03161730|OTHER|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
58297715|NCT02315144|DRUG|TV48108|TV48108 15, 60, 120 μg
58297716|NCT02315144|DRUG|Placebo|Placebo Comparator
57731580|NCT03738540|BEHAVIORAL|TALK control group|Telephone Delivered Intervention
57944442|NCT02459327|BEHAVIORAL|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
57944443|NCT01258244|OTHER|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
57944444|NCT02114320|DEVICE|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
57944445|NCT02670070|DRUG|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
57944446|NCT04450680|OTHER|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
57944447|NCT05929716|DRUG|Magrolimab|Given by IV (vein)
57944448|NCT05929716|DRUG|Rituximab|Given by IV (vein)
57944449|NCT05929716|DRUG|CAR T leukapheresis|Given by IV (vein)
57944450|NCT05929716|DRUG|Radiation|Given by IV (vein)
58297717|NCT03327324|BEHAVIORAL|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
58297718|NCT00448214|DRUG|YM150|Oral
58297719|NCT00448214|DRUG|warfarin|Oral
58297720|NCT04654715|PROCEDURE|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
58297721|NCT04033978|BEHAVIORAL|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
58297722|NCT04033978|BEHAVIORAL|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
58297723|NCT00765856|DRUG|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
57731581|NCT04377646|DRUG|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
57731582|NCT04377646|DRUG|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
57731583|NCT04377646|DRUG|Zinc|15 mg per day up to 2 months
57731584|NCT04377646|DRUG|Zinc (Placebo)|1 pill per day up to 2 months
57731585|NCT06163755|DRUG|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
57731586|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
57944451|NCT02639611|OTHER|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
57944452|NCT02639611|OTHER|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
57944453|NCT04363528|OTHER|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
57944454|NCT03639103|PROCEDURE|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
57944455|NCT02839408|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
57944456|NCT02839408|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn
57944457|NCT02839408|OTHER|Talc powder|Sachet containing talc powder and tablet containing talc powder
57944458|NCT02839408|PROCEDURE|Periodontal treatment Scaling and root planning|
57944459|NCT05327413|OTHER|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
57944460|NCT02865018|DRUG|cetirizine|
57944461|NCT02571127|DRUG|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
58297724|NCT00205114|BEHAVIORAL|Individualized multifactorial intervention for community-living high-risk older adults|
58297725|NCT00205114|BEHAVIORAL|Health professional education program about fall prevention|
58297726|NCT01999985|DRUG|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
58297727|NCT01999985|DRUG|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
58078457|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
58078458|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
58078459|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
58078460|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
58078461|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
58078462|NCT02120456|DRUG|LEO 43204|
58078463|NCT02120456|DRUG|Placebo|
58078464|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
58078465|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
58078466|NCT03023358|DRUG|chidamide|30mg po twice a week
58078467|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
58078468|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
58078469|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
58078470|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
58078471|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
58078472|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
58078473|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
58078474|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
58078475|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
58078476|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
58409141|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
57731587|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
57731588|NCT01435577|DRUG|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
57731589|NCT01435577|DRUG|Matching Placebo|Maximum 12 administrations over 48 hours
57731590|NCT04265755|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
57731591|NCT04974216|DRUG|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
58078477|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
58078478|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
57944462|NCT05401084|OTHER|Diet|Macronutrient diet changes.
57944463|NCT01846728|DRUG|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
58297728|NCT01999985|DRUG|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
58409142|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
57731592|NCT04974216|DRUG|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
57731593|NCT04974216|DRUG|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
57731594|NCT02244944|DRUG|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
57731595|NCT00189631|PROCEDURE|UFT/LV|
57731596|NCT00189631|PROCEDURE|Observation|
57944464|NCT02836028|DRUG|Talazoparib|Talazoparib monotherapy 1mg/day orally
57944465|NCT02836028|DRUG|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
58078479|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
58078480|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
58078481|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
58409143|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
57944466|NCT00836043|DRUG|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
57944467|NCT01887236|BEHAVIORAL|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
57944468|NCT01887236|BEHAVIORAL|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
57944469|NCT05664542|OTHER|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
57944470|NCT05664542|DRUG|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
57944471|NCT01877187|DRUG|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
57944472|NCT00612950|DRUG|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
57944473|NCT00612950|DRUG|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
57944474|NCT00612950|DRUG|Saline|continuous infusion of Saline for 120 min
57944475|NCT00337909|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
57944476|NCT00337909|OTHER|Educational DVDs|
57944477|NCT04563780|DEVICE|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
57944478|NCT00217204|DRUG|Pancrelipase microtablets|
58078482|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
58078483|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
58297729|NCT01999985|DRUG|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
58297730|NCT00228228|BIOLOGICAL|T cell vaccination|
58409144|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
58409145|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
58409146|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
57944479|NCT02513849|DRUG|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
57944480|NCT01436136|OTHER|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
57944481|NCT01436136|OTHER|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
57944482|NCT00548015|BEHAVIORAL|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
57944483|NCT06341530|DRUG|anlotinib combined with penpulimab|single arm
57944484|NCT00993642|DRUG|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
57944485|NCT05015075|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
58078484|NCT01973673|BEHAVIORAL|Bone health educational materials|
58078485|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
58078486|NCT05110118|DRUG|LY01008|Single intravenous injection
58297731|NCT00002293|DRUG|Nystatin|
58297732|NCT04967807|DIAGNOSTIC_TEST|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
58078487|NCT05110118|DRUG|Avastin|Single intravenous injection
58078488|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
58297733|NCT04967807|DIAGNOSTIC_TEST|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
58409147|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
58409148|NCT00097162|PROCEDURE|Anodal stimulation|
58409149|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
58409150|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
58078489|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
58078490|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
58078491|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
57944486|NCT00625209|DRUG|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
57944487|NCT00625209|DRUG|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
58078492|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
58078493|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
58297734|NCT02830412|OTHER|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
58297735|NCT03669549|DRUG|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
58297736|NCT03924388|DEVICE|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
57944488|NCT00625209|DRUG|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
57944489|NCT00625209|DRUG|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
57944490|NCT05949619|DRUG|BL-M02D1|Administration by intravenous infusion
58078494|NCT01700894|BEHAVIORAL|Walking Program|
58078495|NCT02708576|BIOLOGICAL|NGM313|
58078496|NCT02708576|OTHER|Placebo|
58078497|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
58078498|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
58078499|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
58078500|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
58078501|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
58078502|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
58078503|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
58078504|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
58078505|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
58078506|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
58078507|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
58078508|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
58297737|NCT03924388|DEVICE|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
58297738|NCT03832647|COMBINATION_PRODUCT|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
58297739|NCT03832647|DRUG|Salicylic Acid|Salicylic Acid
58297740|NCT03832647|OTHER|Hydréane légère|moisturizer
58297741|NCT05704855|BEHAVIORAL|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
58078509|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
58078510|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
57944491|NCT05929898|BEHAVIORAL|Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback|fMRI neurofeedback training of sustained midbrain/VTA activation via motivational imagery.
57944492|NCT02100436|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
57944493|NCT04278963|DRUG|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
57944494|NCT04278963|DRUG|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
57944495|NCT04278963|OTHER|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
57944496|NCT04278963|OTHER|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
57944497|NCT04030221|OTHER|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
57944498|NCT05217485|DEVICE|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
57944499|NCT05335499|DRUG|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
57944500|NCT05335499|DRUG|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
57944501|NCT05335499|DRUG|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
57944502|NCT05335499|DRUG|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
57944503|NCT05335499|DRUG|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
57944504|NCT05335499|DRUG|Placebo|"* Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD"
57944505|NCT00002400|DRUG|Indinavir sulfate|
57944506|NCT00002400|DRUG|Delavirdine mesylate|
57944507|NCT00002400|DRUG|Lamivudine|
58078511|NCT02463500|OTHER|DFU|Standard care.
58078512|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
58078513|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
57944508|NCT00002400|DRUG|Zidovudine|
57944509|NCT00657813|DRUG|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
57944510|NCT06125912|OTHER|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
57944511|NCT06125912|OTHER|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
57944512|NCT03836495|DIETARY_SUPPLEMENT|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
57944513|NCT06547658|OTHER|Mouth closure|Closing the mouth during sleep by applying pressure to the mentum until the teeth were in occlusion, without altering the head position.
58078514|NCT02042573|DEVICE|rTMS|
58078515|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
58078516|NCT02042573|OTHER|Genetic samples|
58078517|NCT01302366|DRUG|TBL12|
58078518|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
58078519|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
58078520|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
58078521|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
58078522|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
58078523|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
58078524|NCT02791906|DRUG|ISMN|
58409151|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
57944514|NCT04774731|OTHER|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
58409152|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
57944515|NCT04871269|DRUG|Dronabinol|Dronabinol
57944516|NCT04871269|DRUG|Placebo|Placebo
57944517|NCT04144374|DRUG|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
57944518|NCT04144374|PROCEDURE|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
58409153|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
58409154|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
58078525|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
58078526|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
58078527|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
58078528|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
58078529|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
58078530|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
58078531|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
58078532|NCT00106717|PROCEDURE|Narrative medicine|
58297742|NCT05704855|BEHAVIORAL|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
58297743|NCT03217552|DIAGNOSTIC_TEST|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
58297744|NCT02727049|OTHER|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
58297745|NCT05237115|DRUG|Clostridium butyricum capsule|Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
58297746|NCT05237115|DRUG|esomeprazole|Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
57731597|NCT02594891|DEVICE|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
58297747|NCT05237115|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
58409155|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
57731598|NCT02594891|DEVICE|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
57731599|NCT05006625|OTHER|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
57731600|NCT05353335|OTHER|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
57731601|NCT05353335|OTHER|Current regimen|The participants will begin on their current regimen.
57731602|NCT05688904|DRUG|Imipramine|Topical 4% Imipramine
57731603|NCT05688904|OTHER|Vehicle|Vehicle
57731604|NCT02590718|PROCEDURE|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
57731605|NCT04895267|DEVICE|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
57731606|NCT00096135|BIOLOGICAL|filgrastim|given subcutaneously (SC)
58078533|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
58078534|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
58078535|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
57731607|NCT00096135|DRUG|cyclophosphamide|IV over 15-30 minutes
58078536|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
58078537|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
58078538|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
58078539|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
58078540|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
58078541|NCT01196754|OTHER|sevoflurane|
58078542|NCT02444676|OTHER|Stratification and outcomes|No necessary
58078543|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
58078544|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
58078545|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
58078546|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
58078547|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
58078548|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
58078549|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
57731608|NCT00096135|DRUG|cytarabine|IV over 3 hours twice daily
58078550|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
58078551|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
58078552|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
57731609|NCT00096135|DRUG|daunorubicin hydrochloride|IV over 15 minutes
58078553|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
58078554|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
58078555|NCT00722618|OTHER|Written materials|2 written materials available on public website
58078556|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
58078557|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
58078558|NCT02112565|OTHER|pharmacological study|Correlative studies
57731610|NCT00096135|DRUG|dexamethasone|oral twice daily
58078559|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
57731611|NCT00096135|DRUG|etoposide|IV over 1 hour
57731612|NCT00096135|DRUG|leucovorin calcium|rescue IV over 24 hours
57731613|NCT00096135|DRUG|mercaptopurine|oral
57731614|NCT00096135|DRUG|methotrexate|intramuscularly (IM)
57731615|NCT00096135|DRUG|pegaspargase|intramuscularly (IM)
57731616|NCT00096135|DRUG|therapeutic hydrocortisone|
57731617|NCT00096135|DRUG|vincristine sulfate|given IV
57731618|NCT00096135|RADIATION|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
57731619|NCT04464564|DRUG|AVP-786|oral capsules
57731620|NCT04464564|DRUG|Placebo|oral capsules
57731621|NCT01660906|DRUG|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
57731622|NCT02345512|DEVICE|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
57731623|NCT02508311|DRUG|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
57731624|NCT02508311|DRUG|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
57731625|NCT06613347|OTHER|whitening maintenance|whitening maintenance regimen
57731626|NCT06613347|OTHER|whitening maintenance MW|maintenance MW
57731627|NCT06613347|OTHER|negative control|negative control
57731628|NCT00235794|DRUG|temsirolimus|
58078560|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
58078561|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
58078562|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
58078563|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
58078564|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
58078565|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
58078566|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
58078567|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
58078568|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
58078569|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
58078570|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
58078571|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
58078572|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
58078573|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
58078574|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
58078575|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
58078576|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
58078577|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
58078578|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
58078579|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
58078580|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
58078581|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
58078582|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
58078583|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
58409156|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
58409157|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
58409158|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
58409159|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
57944519|NCT04658901|DEVICE|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
58409160|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
58409161|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
58409162|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
58409163|NCT00061074|DRUG|Nicotrol|
58409164|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
58409165|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
58409166|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
57731629|NCT06536114|OTHER|CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.
57944520|NCT04658901|DEVICE|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
57944521|NCT01213420|OTHER|Nivea Cream for scar hydration|3 applications per day during 6 months
57944522|NCT01213420|OTHER|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
57944523|NCT01213420|OTHER|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
57944524|NCT01213420|OTHER|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
57944525|NCT06178445|DRUG|SOC plus trastuzumab and pembrolizumab|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
57944526|NCT04472520|DEVICE|AliveCor Heart Monitor|Records single-channel ECG rhythms
57944527|NCT00210392|DRUG|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
58409167|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
58409168|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
58409169|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
58409170|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
58409171|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
58409172|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
58409173|NCT00387374|DRUG|paclitaxel|Given IV
57731630|NCT06536114|OTHER|Standard of Care|The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
57731631|NCT06515912|OTHER|Ketogenic Diet|A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
57731632|NCT00659633|DRUG|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
57944528|NCT04672564|DRUG|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
57944529|NCT04672564|DRUG|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
57944530|NCT00332254|DRUG|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
57944531|NCT00464321|BIOLOGICAL|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
57944532|NCT00464321|BIOLOGICAL|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
57944533|NCT00464321|BIOLOGICAL|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
58078584|NCT02087865|DRUG|donepezil HCL|
58409174|NCT00387374|DRUG|carboplatin|Given IV
58409175|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
57731633|NCT06636552|DRUG|Daratumumab (Subcutaneously)|"D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1"
58409176|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
58409177|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
58409178|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
58409179|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
58409180|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
58409181|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
57731634|NCT02393495|DEVICE|intrauterine device TCu 380A|
57731635|NCT00022568|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|
57731636|NCT00518947|DRUG|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
58409182|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
58409183|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
58409184|NCT04214483|OTHER|No intervention|There is no intervention for this study.
58409185|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
58409186|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
58409187|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
57731637|NCT00518947|DRUG|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
58078585|NCT02087865|DRUG|Placebo|
58078586|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
58409188|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
58409189|NCT02144506|OTHER|T&E|
57731638|NCT00518947|DRUG|verapamil plus lithium|
58409190|NCT02144506|OTHER|OTAGO|
58409191|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
58409192|NCT00445848|BIOLOGICAL|bevacizumab|
58409193|NCT00445848|DRUG|erlotinib hydrochloride|
57731639|NCT01941862|BEHAVIORAL|Psychoeducation and Cognitive Bias Modification|
57731640|NCT04039113|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
57731641|NCT04039113|OTHER|Placebo|Placebo subcutaneous injection
57731642|NCT00990652|DRUG|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
57731643|NCT00990652|DRUG|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
57731644|NCT00052065|DRUG|TLK286|
57731645|NCT04480294|DRUG|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
57944534|NCT00464321|BIOLOGICAL|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
57944535|NCT02701452|OTHER|COAGO|blood samples for haemostasis and hormonal data
58078587|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
58078588|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
58078589|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
58409194|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
58409195|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
58409196|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
58409197|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
58409198|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
58409199|NCT02111135|BIOLOGICAL|b-OPV|
58409200|NCT02111135|BIOLOGICAL|m-OPV2|
58409201|NCT02111135|BIOLOGICAL|m-IPV HD|
58409202|NCT02111135|BIOLOGICAL|t-IPV|
57731646|NCT06438861|DRUG|Vibegron 75mg|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
57731647|NCT06438861|DRUG|Placebo|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
57731648|NCT02777593|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
57731649|NCT06065072|DEVICE|Optical measurement|Optical measurements by optical biometers and an OCT
57731650|NCT02221206|DEVICE|Mini-Screw implant|Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
57731651|NCT05481762|DEVICE|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
57731652|NCT01930773|DEVICE|Genotyping|Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
57731653|NCT01930773|DEVICE|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
57731654|NCT02182193|DRUG|BIBF 1120 capsules charge 1|
57731655|NCT02182193|DRUG|BIBF 1120 capsules charge 2|
57731656|NCT02182193|DRUG|BIBF 1120 drinking solution|
58078590|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58409203|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
58409204|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
58409205|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
57731657|NCT02980367|OTHER|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
58078591|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58409206|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
58409207|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
58409208|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
57944536|NCT03399136|BEHAVIORAL|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
57944537|NCT03800784|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
57944538|NCT05688878|DEVICE|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
57944539|NCT04563273|BIOLOGICAL|BCG vaccine 1（0.025mg/0.1ml/person）|Intradermal injection of 0.025mg/0.1ml/person dose BCG.
57944540|NCT04563273|BIOLOGICAL|BCG vaccine 2 （0.05mg/0.1ml/person）|Intradermal injection of 0.05mg/0.1ml/person dose BCG.
58297748|NCT05237115|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
58409209|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
58409210|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
58409211|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
58409212|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
58409213|NCT03436641|OTHER|No intervention|No intervention
58409214|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
58409215|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
58409216|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
58409217|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
58409218|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
58409219|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
58409220|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
57944541|NCT04563273|BIOLOGICAL|BCG vaccine 3（0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
57944542|NCT04563273|BIOLOGICAL|BCG vaccine 4 （0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
57944543|NCT04563273|BIOLOGICAL|Placebo of BCG vaccine （0.1ml/person）|Intradermal injection of 0.1ml/person dose Placebo.
58078592|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58078593|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58078594|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58078595|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58078596|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
57731658|NCT02980367|PROCEDURE|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
57731659|NCT02415400|DRUG|Apixaban|
58297749|NCT05237115|DRUG|Bacillus clotting|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
57731660|NCT02415400|DRUG|vitamin K antagonist|
57731661|NCT02415400|DRUG|Acetylsalicylic acid|
57731662|NCT02415400|OTHER|Acetylsalicylic acid placebo|
57731663|NCT02951325|OTHER|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
57731664|NCT01458574|DRUG|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
57944544|NCT00867789|DRUG|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
57944545|NCT00867789|DRUG|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
57944546|NCT04931784|DRUG|Nitrate|Administration of intra-coronary nitrate before percutaneous coronary intervention
57944547|NCT02079857|OTHER|Standard protocol|Subjects will receive a standard treatment
57944548|NCT02079857|OTHER|Individualized protocol|Subjects will receive an individualized treatment
57944549|NCT02079857|OTHER|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
57944550|NCT02036242|DRUG|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
57944551|NCT02036242|DRUG|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
57944552|NCT02036242|DRUG|Ropivacaine|
57944553|NCT04521829|OTHER|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
57944554|NCT03079206|DIAGNOSTIC_TEST|Food challenge|food challenge with hazelnut
58078597|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
58297750|NCT05237115|DRUG|Bismuth|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
58297751|NCT03502538|DEVICE|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
58297752|NCT03502538|DEVICE|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
57731665|NCT01458574|DRUG|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
57731666|NCT01458574|DRUG|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
57731667|NCT01093352|PROCEDURE|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
57731668|NCT03353818|BEHAVIORAL|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
57944555|NCT03079206|DIAGNOSTIC_TEST|skin testing|Skin testing with hazelnut extract
57944556|NCT03079206|DIAGNOSTIC_TEST|blood sampling|blood sampling to perform basophile activation tests
57944557|NCT00454103|DRUG|123I-Iodometomidate|
57944558|NCT00906802|PROCEDURE|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
57944559|NCT03938779|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
57944560|NCT03938779|DIAGNOSTIC_TEST|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
58078598|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
58078599|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
58078600|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
58078601|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
58078602|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
58078603|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
58078604|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
58078605|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
58078606|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
58297753|NCT01142934|DEVICE|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
58297754|NCT05636709|DEVICE|Adacolumn|Non interventional study
58409221|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
57944561|NCT03598647|BEHAVIORAL|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
57944562|NCT03598647|BEHAVIORAL|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
57944563|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline and at follow up|Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
57944564|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline|Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
57944565|NCT05656768|OTHER|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
58078607|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
58078608|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
58078609|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
58078610|NCT02701907|OTHER|Blood sampling|
58078611|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
58078612|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
58078613|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
58078614|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
58078615|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
58078616|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
58297755|NCT03898193|DRUG|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
58409222|NCT05084560|DRUG|Placebo|Placebo
58409223|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
58297756|NCT03898193|DRUG|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
58297757|NCT02089048|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
58297758|NCT03590171|DRUG|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
58297759|NCT00938353|DRUG|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
57731669|NCT03353818|BEHAVIORAL|No intervention|Patients acting as controls will not be restricted in any ways.
57731670|NCT06152224|DEVICE|The Leva Pelvic Health System|The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
57944566|NCT02389023|OTHER|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
57944567|NCT02389023|OTHER|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
58297760|NCT00938353|DRUG|Placebo solution for nebulisation 2 ml|single dose: 4 ml
58297761|NCT05794815|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
57944568|NCT01472770|DRUG|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
57944569|NCT03558984|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
57944570|NCT03558984|OTHER|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
57944571|NCT00254501|BEHAVIORAL|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
58297762|NCT05794815|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
58297763|NCT00606307|DRUG|ITF2357|50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
58297764|NCT00308789|PROCEDURE|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
58297765|NCT00308789|PROCEDURE|CPAP|Continuous positive airway pressure
58297766|NCT06467604|BEHAVIORAL|Surveys|Participants will be provided electronic surveys at 3 timepoints throughout study.
58297767|NCT06467604|OTHER|Indirect Calorimetry|Participants will receive indirect calorimetry at 3 time points throughout the study.
58297768|NCT06467604|OTHER|Body composition|Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.
58297769|NCT06467604|OTHER|Anthropometrics|Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.
58297770|NCT04144959|DEVICE|Indigo Aspiration System|Indigo Aspiration System
58297771|NCT05429671|PROCEDURE|total knee arthroplasty|Participants will have total knee arthroplasty
58297772|NCT05429671|DRUG|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
58297773|NCT05429671|DRUG|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
57731671|NCT05008679|DRUG|Oseltamivir|at a dose of 75 mg twice daily
57731672|NCT06634628|RADIATION|Radioligand [11C]CHDI-00491009|Intravenous injection of radioligand in the arm with PET imaging of the brain.
57731673|NCT05499975|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
57944572|NCT00254501|BEHAVIORAL|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
57944573|NCT00587548|OTHER|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
57944574|NCT05281133|OTHER|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
58297774|NCT05429671|DEVICE|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
58297775|NCT06090968|PROCEDURE|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
58297776|NCT06090968|PROCEDURE|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
58297777|NCT01591798|PROCEDURE|Robotic surgery|Robotic assisted rectal resection
58297778|NCT01591798|PROCEDURE|Laparoscopic surgery|Laparoscopic assisted rectal resection
57731674|NCT06247306|BEHAVIORAL|ScanSTRESS fMRI-paradigm (Streit et al., 2014)|The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
57731675|NCT06247306|BEHAVIORAL|real-time fMRI neurofeedback|"Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination."
58078617|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
58078618|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
58078619|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
58078620|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
58297779|NCT04483466|DRUG|Methotrexate|Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
58297780|NCT04483466|DRUG|Placebo|Placebo
57944575|NCT00013208|BEHAVIORAL|Case Management|
57944576|NCT02023775|DEVICE|Melody valve implantation|
57944577|NCT03568591|PROCEDURE|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
57944578|NCT01626898|BEHAVIORAL|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
57944579|NCT01626898|BEHAVIORAL|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
57944580|NCT02937012|DRUG|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
58297781|NCT00877318|DEVICE|SCAD information system|Cardiac rehabilitation at home by telemedicine
58297782|NCT04987463|DRUG|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
58297783|NCT04987463|DRUG|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
58297784|NCT04987463|DRUG|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
58297785|NCT04987463|DRUG|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
58297786|NCT03800316|DEVICE|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
58297787|NCT00632567|PROCEDURE|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
58297788|NCT00632567|PROCEDURE|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
58078621|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
58078622|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
58078623|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
58078624|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
58297789|NCT05923918|DRUG|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
58297790|NCT05923918|DRUG|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
58078625|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
58297791|NCT05923918|DRUG|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
58409224|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
57731676|NCT05938634|BEHAVIORAL|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
57731677|NCT01757964|BIOLOGICAL|Bacteriotherapy|
57731678|NCT04759820|DRUG|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
57944581|NCT02937012|DRUG|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
57944582|NCT02937012|DRUG|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
57944583|NCT05003947|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57731679|NCT04759820|DRUG|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
57731680|NCT00344123|DRUG|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
57944584|NCT04059172|DRUG|Ibuprofen 200 mg and acetaminphen 650 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
57944585|NCT04059172|DRUG|Ibuprofen 200 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
58078626|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
58078627|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
58078628|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
58078629|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
58078630|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
57731681|NCT00344123|DRUG|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
58297792|NCT02221648|DRUG|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
58297793|NCT02221648|DRUG|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
58409225|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
58409226|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
58409227|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
58409228|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
58409229|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
58409230|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
58078631|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
58078632|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
57731682|NCT06310161|DEVICE|Bright light|Bright light treatment will consist of using the Re-timer device 3 times per week during dialysis sessions for 4 weeks. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Participants will be instructed to use the device for 60 minutes at the beginning of each dialysis session.
57731683|NCT06310161|DEVICE|Dim Light|Dim light treatment will use non-light emitting glasses that look identical to Re-Timer for 4 weeks at each dialysis session following baseline assessments. Participants will use the device for 60 minutes at the beginning of their dialysis session.
57731684|NCT00345904|BIOLOGICAL|Fluarix|
57944586|NCT04059172|DRUG|Placebo oral tablet|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
57944587|NCT05105464|DRUG|SYHA1815|Subjects will receive SYHA1815 orally.
57944588|NCT04041089|BEHAVIORAL|Recognition of objects|"* Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects"
57944589|NCT04041089|BEHAVIORAL|Location of objects|"* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible"
57944590|NCT04041089|BEHAVIORAL|Manipulation of objects|"* Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)"
57944591|NCT05530720|OTHER|Cross-sectional survey|No intervention.
57944592|NCT00627887|PROCEDURE|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
57944593|NCT00627887|DRUG|venlafaxine|extended release target dose of 300mg/day duration of one year
57944594|NCT00627887|DRUG|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
57944595|NCT00147056|DEVICE|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
57944596|NCT03527134|DRUG|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
57944597|NCT03890783|OTHER|Evaluation of phonation quality|"Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
57944598|NCT03890783|OTHER|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
57944599|NCT03890783|OTHER|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
57944600|NCT04756505|DRUG|Bintrafusp Alfa|Given IV
58078633|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
58078634|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
57944601|NCT04756505|BIOLOGICAL|Immunocytokine NHS-IL12|Given SC
57944602|NCT04756505|RADIATION|Radiation Therapy|Undergo radiation therapy
57944603|NCT02583906|DEVICE|CPAP|Treatment with CPAP for six months in the CPAP arm.
58078635|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
58078636|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
58409231|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
57731685|NCT05773859|BIOLOGICAL|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
57731686|NCT03305016|DRUG|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
57731687|NCT01829412|OTHER|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
57944604|NCT03821740|OTHER|Kinesiotaping|Mc Connel taping and another kinesiotaping technique
57944605|NCT02688491|DRUG|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
58078637|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
58078638|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
58078639|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
58078640|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
58078641|NCT01872832|DRUG|RDEA3170 and Placebo|
58078642|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
58297794|NCT01252771|OTHER|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
58297795|NCT06122389|DRUG|SHR2554; Chidamide analog tablets|SHR2554 + Chidamide analog tablets
58297796|NCT06122389|DRUG|SHR2554 analog tablets; Chidamide|SHR2554 analog tablets + Chidamide
58297797|NCT00006329|PROCEDURE|Minimally invasive radioguided parathyroidectomy|
58297798|NCT05861414|BEHAVIORAL|EWM-T|"This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials."
58297799|NCT02365935|PROCEDURE|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
57731688|NCT06670066|BEHAVIORAL|Let's Talk Birth Control|Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
57944606|NCT06239337|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra in stools and urine|All children with presumptive TB had at least 1 sample collected of respiratory or extrapulmonary specimen (considered as gold standard) and 1 sample of stools and 1 sample of urine. All of them were analyzed with Xpert MTB/RIF Ultra.
57944607|NCT04158076|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
58297800|NCT02365935|PROCEDURE|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
58297801|NCT02365935|DRUG|Cisplatin|
58297802|NCT02365935|DRUG|Paclitaxel|
58409232|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
58409233|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
58409234|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
58409235|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
58409236|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
58409237|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
58409238|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
58409239|NCT01919047|DRUG|Betanis|Oral
58078643|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
57731689|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
58409240|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
58409241|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
58409242|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
58409243|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
58409244|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
58409245|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
57731690|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
57731691|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
57731692|NCT03590301|BEHAVIORAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
57944608|NCT04158076|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
57944609|NCT04158076|DRUG|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
57944610|NCT03581266|OTHER|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
57944611|NCT00303147|BEHAVIORAL|Expressive Writing|
57944612|NCT00219284|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
57944613|NCT02201420|DRUG|Tc 99m tilmanocept|
57944614|NCT02705924|BEHAVIORAL|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
57944615|NCT04544475|DEVICE|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
57944616|NCT04544475|DRUG|Estrace|Vaginal estrogen cream, estradiol: 100mcg
57944617|NCT01648790|DRUG|Prasugrel ODT1 - Tablet|Administered orally as tablet.
57944618|NCT01648790|DRUG|Prasugrel ODT2 - Tablet|Administered orally as tablet.
57944619|NCT01648790|DRUG|Prasugrel ODT2 - Suspension|Administered orally as suspension.
57944620|NCT00659568|DRUG|metformin hydrochloride|
57944621|NCT00659568|DRUG|temsirolimus|
57944622|NCT00761306|DRUG|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
57944623|NCT04026698|BEHAVIORAL|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months."
57944624|NCT02258789|OTHER|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
57944625|NCT02359630|DEVICE|EasyTube|Insertion for ventilation
57944626|NCT02359630|DEVICE|Endotracheal tube|Insertion for ventilation
57944627|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
57944628|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC)|See above in arm/group description
57944629|NCT04417634|DIAGNOSTIC_TEST|RFR|Measurement of resting flow ratio
57944630|NCT04417634|DIAGNOSTIC_TEST|FFR|Measurement of fractional flow reserve
57944631|NCT03854136|PROCEDURE|Excision of tumor|Wide margin excision of tumors +/- limb preservation
57944632|NCT01312454|DRUG|AL-59412C injectable solution|Concentration 1 and Concentration 2
58078644|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
58078645|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
58078646|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
58078647|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
58297803|NCT02717728|PROCEDURE|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
58409246|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
57731693|NCT03590301|BEHAVIORAL|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
57944633|NCT01312454|DRUG|Travoprost injectable solution|
57944634|NCT01312454|DRUG|AL-59412C Vehicle|Inactive ingredients used as placebo
57944635|NCT00374686|DRUG|Valganciclovir|
57944636|NCT00480181|DRUG|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
57944637|NCT00480181|OTHER|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
57944638|NCT03679533|DIETARY_SUPPLEMENT|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
57944639|NCT03679533|DIETARY_SUPPLEMENT|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
57944640|NCT05162027|DRUG|Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
57944641|NCT05162027|DRUG|Placebo|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
58409247|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
58409248|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
58409249|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
58409250|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
58409251|NCT05013918|OTHER|Observational study|No intervention
58409252|NCT04059523|DRUG|S6G5T-3|once daily
58409253|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
58409254|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
57944642|NCT03216096|DRUG|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
58409255|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
57731694|NCT06276855|OTHER|Sleep hygiene education|The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
57944643|NCT04489745|RADIATION|SBRT|
58409256|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
58409257|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
57731695|NCT06031246|PROCEDURE|Selective Lymph Node Dissection|For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
57944644|NCT04489745|DRUG|Androgen deprivation therapy (ADT)|
57944645|NCT04245514|DRUG|Durvalumab|Immunotherapy
57944646|NCT04245514|RADIATION|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
58297804|NCT02717728|PROCEDURE|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
58409258|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
58409259|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
58409260|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
58409261|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
57731696|NCT06464393|DRUG|ketamine-lidocaine-dexmedetomidine|Patients will be administered 0,8 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations just before induction of anesthesia.
57731697|NCT06464393|DRUG|fentanyl|Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
57731698|NCT03725982|DEVICE|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
57944647|NCT04493021|DEVICE|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
58297805|NCT01223404|DRUG|Placebo|Participants are administered a placebo patch and a placebo capsule
58409262|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
57944648|NCT00956397|DRUG|Rifaximin|rifaximin 550 mg TID PO x 10 days
57944649|NCT00956397|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
57944650|NCT00956397|DRUG|Placebo|placebo TID x 10 days
57944651|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
57944652|NCT04735445|DIAGNOSTIC_TEST|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
57944653|NCT04735445|DIAGNOSTIC_TEST|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
57944654|NCT04735445|DIAGNOSTIC_TEST|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
57944655|NCT04735445|DIAGNOSTIC_TEST|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
57944656|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
57944657|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~* Asian male\> 40 years old~* Asian woman\> 50 years old~* African man or woman~* HCC family history"
58297806|NCT01223404|DRUG|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
58297807|NCT01223404|DRUG|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
58297808|NCT03198845|OTHER|video game|20-min per session for 3 times per week for a 4-week duration
58297809|NCT03198845|OTHER|exercise|20-min per session for 3 times per week for a 4-week duration
58297810|NCT00510341|BEHAVIORAL|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
58297811|NCT00914225|OTHER|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
58409263|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
58409264|NCT02089464|DEVICE|NBS-guided rTMS|
58409265|NCT02089464|DEVICE|Sham rTMS|
58409266|NCT02089464|PROCEDURE|Task oriented rehabilitation|
58409267|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
57731699|NCT03725982|DEVICE|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
57944658|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
57944659|NCT04735445|DIAGNOSTIC_TEST|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
57944660|NCT04735445|DIAGNOSTIC_TEST|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
57944661|NCT04735445|DIAGNOSTIC_TEST|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
57944662|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
57944663|NCT04735445|DIAGNOSTIC_TEST|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
58078648|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
57944664|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~* Age \> 40 years~* Active smoker or former smoker\<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~* No contraindications for thoracic surgery~* No lung infection in the last 2 months"
58078649|NCT02875743|DRUG|Posaconazole|
57944665|NCT04735445|DIAGNOSTIC_TEST|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
58078650|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
58078651|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
58078652|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
58078653|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
58078654|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
58078655|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
58078656|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
58078657|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
58078658|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
57944666|NCT02124278|DRUG|PUL-042 Inhalation Solution|
57944667|NCT05795686|OTHER|"Evaluation of program AVanCer"|Evaluation of program AVanCer with quantitative and qualitative approaches
57944668|NCT03491007|DRUG|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
57944669|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
57944670|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
57944671|NCT01816061|BEHAVIORAL|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
57944672|NCT01816061|BEHAVIORAL|Control - COMPASS|Increased hours of patient-provider interactions Group.
58078659|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
58297812|NCT04009603|DRUG|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
57944673|NCT01475175|DEVICE|CRT pacing at rest and during exercise|CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
57944674|NCT01143727|DRUG|Santyl|Apply one 24-hr period sufficient to cover the wound.
57944675|NCT01143727|DRUG|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
58078660|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
58078661|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
57944676|NCT01599520|BEHAVIORAL|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
57944677|NCT01599520|BEHAVIORAL|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
57944678|NCT02999542|OTHER|Music|Children will be randomised to receive either music via headphones or silence via headphones
57944679|NCT02999542|OTHER|No music|Children will be randomised to receive either music via headphones or silence via headphones
57944680|NCT04224675|DRUG|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
58078662|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
58078663|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
58078664|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
58078665|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
58078666|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
58297813|NCT04009603|DRUG|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
58297814|NCT01056393|DRUG|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
58297815|NCT01056393|DRUG|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
57944681|NCT06189807|BEHAVIORAL|Decision aid|Enrolled participants will be sent the novel educational decision aid about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment, study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
58297816|NCT01701544|DEVICE|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
58297817|NCT04754893|DEVICE|Healthdot application|Healthdot device is applied on subject's chest after surgery
58297818|NCT00947310|DEVICE|Standard ICD programming|Standard ICD programming
58297819|NCT00947310|DEVICE|High rate cutoff|Programming of a high rate cutoff
58078667|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
58078668|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
58297820|NCT00947310|DEVICE|Long delay|Programming of a prolonged delay
58297821|NCT04113941|DRUG|Neuronox|intradetrusor injection
58297822|NCT04113941|DRUG|Placebo|intradetrusor injection
58297823|NCT04520217|DRUG|4% Imipramine Cream|4% Imipramine Cream
58297824|NCT04520217|DRUG|Base Cream|Base Cream
58297825|NCT02571556|DRUG|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
58297826|NCT00358696|DRUG|tenofovir|See Detailed Description.
58078669|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
58078670|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
58078671|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
58078672|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
58078673|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
58078674|NCT00538434|BIOLOGICAL|Reslizumab|
58078675|NCT00538434|OTHER|Saline|
58078676|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
58297827|NCT01214993|DRUG|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
58297828|NCT01214993|DRUG|Placebo|Placebo is a tablet with no drug in it.
58297829|NCT01214993|DRUG|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
58297830|NCT01214993|DRUG|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
57731700|NCT04287374|BEHAVIORAL|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
57731701|NCT04287374|BEHAVIORAL|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
58078677|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
58078678|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
58078679|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
58297831|NCT06378424|OTHER|Cold Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
58078680|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
58078681|NCT01001091|DRUG|AL-38583 ophthalmic solution|
58078682|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
58078683|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
58078684|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
58078685|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
58078686|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
58078687|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
58078688|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
58078689|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
58078690|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
58078691|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
58078692|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
57731702|NCT01753024|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
57944682|NCT06189807|OTHER|Standard handout|Enrolled participants will be sent the standard information about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment, the participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
57944683|NCT00933179|DRUG|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
57944684|NCT00933179|DRUG|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
57944685|NCT03279614|DRUG|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
57944686|NCT00806195|BIOLOGICAL|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
57944687|NCT00806195|BIOLOGICAL|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
57944688|NCT00806195|BIOLOGICAL|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
57731703|NCT05627128|OTHER|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
57731704|NCT05319327|OTHER|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
57944689|NCT00806195|BIOLOGICAL|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
57944690|NCT00806195|BIOLOGICAL|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
57944691|NCT00806195|BIOLOGICAL|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
57944692|NCT00806195|BIOLOGICAL|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
58297832|NCT06378424|OTHER|Heat Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
57731705|NCT05319327|OTHER|Control|General counseling to adhere to a healthy Mediterranean diet
58297833|NCT06378424|OTHER|Vibration Application|With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
57731706|NCT01369342|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
57731707|NCT01369342|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
57944693|NCT00806195|BIOLOGICAL|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
57731708|NCT01369342|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
57731709|NCT00365859|DRUG|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
57731710|NCT06577532|DRUG|ABO2102|mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
57944694|NCT04644939|OTHER|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
57944695|NCT04644939|OTHER|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
57944696|NCT04644939|OTHER|Colonoscopy|Patients will undergo colonoscopy
57944697|NCT04272671|OTHER|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
58078693|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
58297834|NCT04608071|PROCEDURE|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
58297835|NCT05897671|OTHER|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
58297836|NCT02972983|DRUG|Daptomycin|Adjuvant therapy for up to five days
58297837|NCT02972983|OTHER|Placebo|Placebo
58297838|NCT02317991|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV
58297839|NCT02317991|BIOLOGICAL|ramucirumab|Ramucirumab 8 mg/kg IV
57731711|NCT06577532|DRUG|Toripalimab|Anti-PD-1 antibody, administered intravenously
58297840|NCT03006237|DRUG|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
58297841|NCT03006237|DEVICE|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
58297842|NCT01878903|OTHER|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
58297843|NCT06332196|OTHER|Analysis of biological sample and clinical data|Analysis of biological sample and clinical data
58297844|NCT03041662|DIAGNOSTIC_TEST|MR/MRCP|MR/MRCP
58297845|NCT04776928|BEHAVIORAL|Push reports|"Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc."
58297846|NCT03108612|DIAGNOSTIC_TEST|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
58297847|NCT03228641|DEVICE|micro-excisional skin removal with coring needle|
57731712|NCT04215029|BEHAVIORAL|Exercise Intervention|Receive exercise plan
57944698|NCT01616420|OTHER|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
58297848|NCT04064203|OTHER|Oral glucose tolerance test|50 grams OGTT
58297849|NCT04064203|OTHER|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
57731713|NCT04215029|OTHER|Informational Intervention|Receive printed exercise materials
57731714|NCT04215029|OTHER|Informational Intervention|Receive physical activity and healthy eating information/materials
57731715|NCT04215029|OTHER|Interview|Participate in interview
57731716|NCT04215029|OTHER|Nutritional Assessment|Complete nutrition counseling sessions
57731717|NCT04215029|OTHER|Questionnaire Administration|Ancillary studies
57731718|NCT04215029|BEHAVIORAL|Telephone-Based Intervention|Receive coaching calls
57944699|NCT02381405|DIETARY_SUPPLEMENT|Enterade beverage|
58297850|NCT03487770|DRUG|Aripiprazole Oral Solution|Aripiprazole 2\~15 mg/day (2\~15 mL/day)
58297851|NCT03487770|DRUG|Placebo Oral Solution|Placebo 2\~15 mg/day (2\~15 mL/day)
58297852|NCT03328234|RADIATION|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
57731719|NCT04032847|BIOLOGICAL|ATL001|ATL001 infusion
57731720|NCT04032847|DRUG|Pembrolizumab|Checkpoint inhibitor
57731721|NCT02353923|DIETARY_SUPPLEMENT|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
57731722|NCT01631032|DRUG|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
57731723|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Human Milk|Comparing formula and human milk
57731724|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Formula|Comparing formula and human milk
57731725|NCT04593888|BEHAVIORAL|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
57731726|NCT00644722|DEVICE|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
57731727|NCT00644722|DEVICE|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
57731728|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
57731729|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
57944700|NCT01349868|DRUG|PT005 MDI|PT005 MDI taken as two inhalations
58297853|NCT03328234|DRUG|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
58297854|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
58297855|NCT03328234|DRUG|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
58297856|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
58297857|NCT03328234|OTHER|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
58297858|NCT00035269|DRUG|Antibiotic|
58297859|NCT03281941|OTHER|Inhaled capsaicin cough challenge|
58297860|NCT05833126|DRUG|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
58297861|NCT05569798|DIAGNOSTIC_TEST|Whole body point of care ultrasound scan|"The INSIGHT Scan is a whole-body PoCUS scan which comprises imaging the following windows:~1. subcostal~2. inferior vena cava cardiac view~3. left hemidiaphragm~4. bladder~5. right hemidiaphragm~6. six major central veins (left/right internal jugular/ subclavian/ femoral veins)~The scan should take no more than 10 minutes to perform. Simple yes/no questions are asked for each window to identify any significant abnormalities. For example, is the left ventricle bigger than the right ventricle; is there a pleural effusion; is the bladder distended etc.~The scan is reported in the intensive care online medical notes and reviewed by the clinical team as soon as possible."
58078694|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
58297862|NCT02199769|OTHER|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
57944701|NCT01349868|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
57944702|NCT01349868|DRUG|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
57944703|NCT01349868|OTHER|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
57944704|NCT01454375|BEHAVIORAL|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
57944705|NCT04222673|BEHAVIORAL|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
57944706|NCT02516787|OTHER|Parabolic flight|
57944707|NCT02516787|OTHER|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
57944708|NCT02516787|OTHER|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
58297863|NCT04812184|DEVICE|Tape Face Mask|Adding tape to face mask
57944709|NCT01847482|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
57944710|NCT05085639|BIOLOGICAL|GLS-5130|GLS-5310 DNA plasmid vaccine
58078695|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
58078696|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
58078697|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
58078698|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
58078699|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
58078700|NCT00094146|DRUG|Sandostatin LAR Depot|
58297864|NCT01368510|BEHAVIORAL|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
57944711|NCT05085639|BIOLOGICAL|Placebo|Placebo
58297865|NCT01368510|BEHAVIORAL|Waitlist|Minimal contact waitlist weekly for 4 weeks
58409268|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
58409269|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
57944712|NCT04643028|OTHER|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
57944713|NCT04643028|OTHER|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
57944714|NCT04643028|OTHER|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
57944715|NCT04277520|PROCEDURE|Root canal therapy|Different types of instrumentation motions during root canal therapy
57944716|NCT00259155|DRUG|Rifaximin|
57944717|NCT04020601|DRUG|Ropivacaine|Local anesthetic injection
58409270|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
58409271|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
57944718|NCT04020601|DRUG|Dextrose|Sham injection
57944719|NCT01981655|DRUG|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
57944720|NCT01981655|DRUG|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
57944721|NCT01188200|OTHER|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
57944722|NCT01188200|OTHER|Standard food|Standard meal prior to test time
57944723|NCT04262687|DRUG|Capecitabine|2000 mg/m²/day, from day 1 to 14 of each cycle
57944724|NCT04262687|DRUG|Oxaliplatin|130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle
57944725|NCT04262687|DRUG|Bevacizumab|7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle
57944726|NCT04262687|DRUG|Pembrolizumab|200 mg by IV infusion over 30 minutes, on day 1 of each cycle
57944727|NCT01793142|DRUG|Viviant|Viviant (Bazedoxifene) 20mg once daily
57944728|NCT03497481|BIOLOGICAL|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
58078701|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
58078702|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
58078703|NCT02358707|OTHER|Ibuprofen phonophoresis|
58078704|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
58297866|NCT03368313|DEVICE|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
58409272|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
57944729|NCT06451445|DEVICE|Irreversible Electroporation (NanoKnife)|Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
57944730|NCT02414399|DRUG|Azithromycin|oral administration of Azithromycin
57944731|NCT02414399|DRUG|Placebo|5 days of taste/appearance/bottle-matched inactive substance
57944732|NCT00146315|BEHAVIORAL|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
57944733|NCT00146315|BEHAVIORAL|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
57944734|NCT01989403|OTHER|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
57944735|NCT04206605|OTHER|Placebo|Placebo-matching lanadelumab SC injection.
57944736|NCT04206605|DRUG|Lanadelumab|Lanadelumab solution in a PFS for injection.
57944737|NCT00836628|DRUG|Busulfan|
57944738|NCT02878538|DRUG|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
57944739|NCT02878538|OTHER|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
57944740|NCT04501770|DRUG|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
57944741|NCT04501770|DRUG|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
57944742|NCT04501770|DRUG|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
57944743|NCT04501770|DRUG|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
57944744|NCT04501770|DRUG|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
57944745|NCT04501770|DRUG|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
57944746|NCT04501770|DRUG|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
57944747|NCT04501770|DRUG|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
57944748|NCT02977650|PROCEDURE|Endoscopic ultrasonography-guided fine needle aspiration|
57944749|NCT00501371|DRUG|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
57944750|NCT00501371|DRUG|Placebo|soft-gel capsule, Qd, 12 weeks
57944751|NCT01017003|DRUG|colchicine tablets|0.6mg colchicine tablet
58078705|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
58409273|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
58297867|NCT04017767|PROCEDURE|Induced Acute Intermittent Hypoxia (AIH)|AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).
58409274|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
57944752|NCT01017003|DRUG|colchicine tablets|0.6mg q12 hours for 10 days
58409275|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
58078706|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
58078707|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
58078708|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
58078709|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
58078710|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
58409276|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
57731730|NCT04711564|OTHER|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
57944753|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
57731731|NCT04711564|OTHER|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
57944754|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
58078711|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
58078712|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
58078713|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
58078714|NCT02331680|DRUG|OPC-41061|
58297868|NCT04017767|DEVICE|AIH mask|Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
58297869|NCT02974933|DRUG|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
58297870|NCT00887614|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
58409277|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
58409278|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
57731732|NCT04325659|DEVICE|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
57944755|NCT00929877|DRUG|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
57944756|NCT02428855|DRUG|Dasatinib|
58409279|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
58297871|NCT05299684|OTHER|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
58297872|NCT00160108|BEHAVIORAL|dietary intervention|
58297873|NCT00231790|DRUG|MK-0634 50 mg|one capsule orally, once daily in morning
58297874|NCT00231790|DRUG|MK-0634 125 mg|one or three capsules orally, once daily in morning
58297875|NCT00231790|DRUG|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
57944757|NCT00871182|DRUG|Inhaled PT001|single dose, inhaled
57944758|NCT00871182|DRUG|Inhaled Placebo|single dose, inhaled
57944759|NCT00871182|DRUG|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
58078715|NCT02331680|DRUG|OPC-41061|
58078716|NCT02331680|DRUG|Placebo|
58078717|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
58078718|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
58409280|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
58409281|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
58078719|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
57944760|NCT03963414|COMBINATION_PRODUCT|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
57944761|NCT03963414|COMBINATION_PRODUCT|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
57944762|NCT01908270|BEHAVIORAL|Yoga|
57944763|NCT01908270|OTHER|Usual care|
57944764|NCT05937178|DRUG|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
57944765|NCT05937178|DRUG|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
57944766|NCT00127725|DEVICE|Pulsed electromagnetic field stimulation|
57944767|NCT06354114|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
57944768|NCT00881127|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
57944769|NCT00881127|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
57944770|NCT06240000|PROCEDURE|Radiofrequency ablation|Firstly, the posterior superior iliac spine was showed in the transverse plane, and it was gradually moved proximally until gluteus maximus muscle disappears and gluteus medius arises. Medial branch of the SCN is seen between iliac crest and thoracolumbar fascia as an ovoid structure. Radiofrequency device was utilized with 22-gauge 10-cm, 5 mm RF cannulas for all procedures. Cannula was placed thorough the SCN area and Sensory fiber stimulation was started between 0.3 and 0.5 V. The patient was asked for feedback on symptoms such as numbness, paresthesia or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was given up to 1.5 V and it was checked whether there was any contraction or not. If there is no contraction detected, the SCN was ablated at 42° degrees centigrade for 240 seconds.
57944771|NCT02830776|DRUG|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
57944772|NCT04101565|BEHAVIORAL|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
57944773|NCT05262699|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
58078720|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
58078721|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
58078722|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
58078723|NCT00243620|DEVICE|Vacuum therapy (device)|
58409282|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
58409283|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
58409284|NCT03257163|DRUG|Capecitabine|Given PO
57944774|NCT05262699|OTHER|Placebo Control|Devices mounted, no stimulation
57944775|NCT00336219|DRUG|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
57944776|NCT05141370|DEVICE|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
57944777|NCT06538948|PROCEDURE|Bariatric Surgery|The intervention is not assigned to the participant after recruitment in the study, rather the intervention is an inclusion criteria for participation in the study.
57944778|NCT06156683|OTHER|Multiple sclerosis disease modifying drug|There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.
57944779|NCT06061315|DIETARY_SUPPLEMENT|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
57944780|NCT06061315|DIETARY_SUPPLEMENT|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
57944781|NCT03863600|BEHAVIORAL|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
58078724|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
58409285|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
58409286|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
58409287|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
58409288|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
58409289|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
58409290|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
57944782|NCT02592551|DRUG|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
57944783|NCT02592551|DRUG|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
57944784|NCT02592551|OTHER|no other name|Neither MEDI4736 nor Tremelimumab will be used.
57944785|NCT04996173|DEVICE|Spray cryotherapy|A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
57944786|NCT04996173|DEVICE|Ballon Dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.
57944787|NCT04996173|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
57944788|NCT03793465|DIETARY_SUPPLEMENT|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
57944789|NCT04327687|DEVICE|Remote ischaemic conditioning|5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
57944790|NCT04327687|OTHER|conventional therapy|conventional therapy
57944791|NCT06072521|DRUG|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
57944792|NCT01641328|BEHAVIORAL|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
58078725|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
58297876|NCT00356447|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
58297877|NCT00356447|DRUG|Placebo|Same administration.
58297878|NCT03647566|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
58409291|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
58409292|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
58409293|NCT01778049|DRUG|BI 10773|Empagliflozin active
58409294|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
57944793|NCT01641328|BEHAVIORAL|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
57944794|NCT01298752|DRUG|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
57944795|NCT01298752|DRUG|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
57944796|NCT00362934|DRUG|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
57944797|NCT00362934|DRUG|Atorvastatin|Atorvastatin 10 mg and 20mg
58078726|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
58078727|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
58078728|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
58078729|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
58078730|NCT02679300|OTHER|Virtual reality exercise group|
58078731|NCT02679300|OTHER|Conventional exercise group (control group)|
58297879|NCT03647566|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
58297880|NCT03647566|DIAGNOSTIC_TEST|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
58297881|NCT01935089|DRUG|Pegylated Interferon alpha 2b|1µg/kg/week
58297882|NCT00469222|PROCEDURE|hypofractionated external beam|
58297883|NCT00394186|DRUG|GW427353|
58297884|NCT00394186|DRUG|Placebo|
58297885|NCT02912221|OTHER|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
58297886|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
58409295|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
58409296|NCT01778049|DRUG|BI 10773|Empagliflozin active
58409297|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
58409298|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
58409299|NCT01778049|DRUG|BI 10773|Empagliflozin active
58409300|NCT01778049|DRUG|BI 10773|Empagliflozin active
58078732|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
58078733|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
58297887|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
58297888|NCT00732069|DRUG|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
57731733|NCT04325659|DRUG|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
57731734|NCT04325659|DRUG|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
58297889|NCT00732069|DRUG|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
58297890|NCT00732069|DRUG|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
58297891|NCT00802646|DRUG|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
58297892|NCT00802646|DRUG|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
58297893|NCT01789047|DRUG|Topiramate|Topiramate as adjunct to amantadine
58297894|NCT01789047|DRUG|Placebo|Placebo control
58297895|NCT01789047|DRUG|Amantadine|Existing treatment for all participants
58297896|NCT00484471|DRUG|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
58297897|NCT00484471|DRUG|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
58297898|NCT00484471|DRUG|placebo|placebo to aripiprazole, 22 weeks
58409301|NCT01778049|DRUG|BI 10773|Empagliflozin active
58078734|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
58297899|NCT00913081|DIETARY_SUPPLEMENT|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
58297900|NCT00913081|DIETARY_SUPPLEMENT|Placebo|Placebo PO one time
58297901|NCT05657366|PROCEDURE|Peritoneal lavage|Continuous abdominal flushing with normal saline
58297902|NCT05628246|OTHER|Telemedicine|Telemedicine
58297903|NCT05628246|OTHER|In-person|In-person
58409302|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
58409303|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
57731735|NCT04325659|DEVICE|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
58409304|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
58078735|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
58078736|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
58078737|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
58078738|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
58078739|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
58078740|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
58078741|NCT05011357|DRUG|Saline Control|Saline infusion
58078742|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
58078743|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
58078744|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
58078745|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
58078746|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
58078747|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
58078748|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
58297904|NCT00185315|DRUG|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
58297905|NCT03045939|DEVICE|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
58078749|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
58078750|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
58078751|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
58078752|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
58078753|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
58078754|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
58078755|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
58078756|NCT00281931|BIOLOGICAL|rituximab|
58078757|NCT00281931|DRUG|cyclophosphamide|
58078758|NCT00281931|DRUG|fludarabine phosphate|
58078759|NCT04054531|BIOLOGICAL|KN046|IV infusion
58078760|NCT04054531|DRUG|Paclitaxel|IV infusion
58078761|NCT04054531|DRUG|Pemetrexed|IV infusion
58078762|NCT04054531|DRUG|Carboplatin|IV infusion
58078763|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
58297906|NCT00712257|DEVICE|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
58297907|NCT03139734|DEVICE|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
58297908|NCT00910598|DRUG|glatiramer acetate|20 mg daily s.c. for 1 year
58297909|NCT00398944|DEVICE|Evaluation of the impact of a guideline based computerized decision support system.|
58297910|NCT02762084|DRUG|Patidegib|
58297911|NCT02762084|DRUG|Vehicle gel|
58078764|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
58078765|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
58078766|NCT00396357|DRUG|Vildagliptin|
58078767|NCT00396357|DRUG|metformin|
58078768|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
58078769|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
58078770|NCT02183948|DRUG|Oxytocin|
58078771|NCT02183948|DRUG|Placebo|
58078772|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
58078773|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
58297912|NCT01714544|DRUG|Cloderm Cream|
58297913|NCT00744718|DRUG|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
58297914|NCT00744718|DRUG|Carboplatin|Carboplatin AUC 5 every 5 weeks
58409305|NCT01778049|DRUG|BI 10773|Empagliflozin active
58078774|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
58078775|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
58078776|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
58297915|NCT03615261|BEHAVIORAL|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
58297916|NCT05191719|PROCEDURE|Botox injection|Comparator, current gold standard
58297917|NCT05191719|PROCEDURE|Neurotomy|Surgical procedure
58297918|NCT04037124|PROCEDURE|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
58297919|NCT05582278|DRUG|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
58297920|NCT05582278|DRUG|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
57944798|NCT00870220|DRUG|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
58297921|NCT05582278|DRUG|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg
58078777|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
58078778|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
58078779|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
58078780|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
58078781|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
58078782|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
58078783|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
58297922|NCT05582278|DRUG|tislelizumab|tislelizumab 200 mg, every 3 weeks.
58297923|NCT01348139|DRUG|AZD3199|Inhaled via single inhaler device (SID)
58297924|NCT01348139|DRUG|AZD3199|Inhaled via Turbuhaler inhaler
58297925|NCT01348139|OTHER|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
58297926|NCT02849743|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
58297927|NCT02849743|DRUG|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
58297928|NCT00006320|PROCEDURE|determine blood levels of anti-HIV drugs|
58297929|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
58078784|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
58297930|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
58297931|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
58297932|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
58409306|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
58409307|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
58409308|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
58078785|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
58297933|NCT01914237|DEVICE|Castor Stent Graft|Endovascular Repair of Aortic Dissection
58297934|NCT02157519|OTHER|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
58297935|NCT02699996|OTHER|Questionnaire Administration|Complete interview
58297936|NCT02699996|BEHAVIORAL|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
58297937|NCT01475903|PROCEDURE|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
58297938|NCT05863819|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
58409309|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
58409310|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
58409311|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
58409312|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
58409313|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
58409314|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
57944799|NCT01378234|BEHAVIORAL|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~1. Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~2. Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~3. Supporting caregivers to reduce stress and burden"
58409315|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
57944800|NCT01722175|PROCEDURE|ALPPS surgery|
58297939|NCT02463669|DEVICE|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
58297940|NCT00525837|DRUG|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
57944801|NCT01722175|PROCEDURE|PVO surgery|
58297941|NCT00525837|DRUG|varenicline|up to 1 mg twice daily
58297942|NCT03018314|OTHER|Blood sample|Serum analysis
58297943|NCT00738647|PROCEDURE|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
58297944|NCT06331507|DEVICE|CMR patch|The Cardiac Magnetic Resonance (MR) patch is a sequence modification for enhancing the images in patients with devices (CIED) for assessing heart muscle scar. The Philips tested patch supports multiple cardiac MR imaging enhancements compiled from several individual patches generated by multiple Philips MR research collaborators for use on 1.5 Tesla Philips scanners.
57944802|NCT05863104|DRUG|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
57944803|NCT00554567|BEHAVIORAL|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
57944804|NCT02712476|DRUG|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
57944805|NCT02712476|DRUG|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
57944806|NCT02712476|DRUG|placebo|mannitol alone is compared with placebo
58297945|NCT02068911|DEVICE|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
58297946|NCT04632459|DRUG|pembrolizumab plus ramucirumab|"Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles."
58297947|NCT00750802|DRUG|AZD6280|10mg Capsule, oral, single-dose
58297948|NCT00750802|DRUG|AZD6280|40mg Capsule, oral, single-dose
58297949|NCT00750802|DRUG|Lorazepam|2mg tablet, oral single-dose
58297950|NCT00750802|DRUG|Placebo|
58297951|NCT00263198|DRUG|PTK787/ZK222584|
58297952|NCT00263198|DRUG|Letrozole|
58297953|NCT03031717|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
58297954|NCT00524251|DRUG|esomeprazole|
58297955|NCT04329429|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
58409316|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
58409317|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
57944807|NCT00199836|BIOLOGICAL|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
57944808|NCT04202679|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
58409318|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
57944809|NCT04202679|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
57944810|NCT04202679|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
57944811|NCT04202679|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
57944812|NCT04202679|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
57944813|NCT05376358|DEVICE|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
57944814|NCT05376358|OTHER|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
57944815|NCT02569814|DRUG|Fimasartan/Amlodipine/Rosuvastatin|
57944816|NCT02569814|DRUG|Fimasartan/Amlodipine|
58409319|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
57944817|NCT02569814|DRUG|Rosuvastatin|
58297956|NCT01773083|DRUG|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
58297957|NCT01773083|DRUG|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
58409320|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
58409321|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
58409322|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
58409323|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
58409324|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
58409325|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
58409326|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
58409327|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
58409328|NCT05854576|PROCEDURE|vascular acess|AVF
58078786|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
58078787|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
58297958|NCT02864069|BEHAVIORAL|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
58297959|NCT02864069|BEHAVIORAL|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
58297960|NCT02864069|BEHAVIORAL|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
58297961|NCT01023594|PROCEDURE|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
58297962|NCT05931536|OTHER|Dietary fibre|Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
58409329|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
58409330|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
57944818|NCT05280184|BEHAVIORAL|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
57944819|NCT01187966|DRUG|Safinamide|
57944820|NCT01187966|DRUG|Safinamide|
57944821|NCT01187966|DRUG|Placebo|
58078788|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
57944822|NCT04459052|DIETARY_SUPPLEMENT|N acetyl cysteine|Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
58078789|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
58078790|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
58409331|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
58409332|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
57731736|NCT05191576|OTHER|Children's sleep habits questionnaire (CSHQ)|"1. Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~2. DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~3. DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~   SDQ).is used to screen emotional and behavioral problems in children.~4. SDQ is used to screen emotional and behavioral problems in children."
57944823|NCT04459052|DRUG|[F-18] Fluorodopa Positron Emission Tomography|FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
58078791|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
58078792|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
58078793|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
58297963|NCT06492447|DRUG|Against HER 2-ADC Drug|Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
58409333|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
58409334|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
58409335|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
58409336|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
58409337|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
58078794|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
58409338|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
58409339|NCT02676336|OTHER|Placebo|
58409340|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
58409341|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
58409342|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
58409343|NCT03087942|DRUG|QAW039|450 mg
58409344|NCT03087942|DRUG|QAW39A|450 mg
57731737|NCT02983734|DRUG|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
57731738|NCT02983734|DRUG|Placebos|Sugar pill
57731739|NCT01410448|DRUG|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
57731740|NCT01410448|DRUG|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
57731741|NCT01410448|DRUG|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
58078795|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
58409345|NCT03087942|DRUG|QAW39A2107|450 mg
58409346|NCT03087942|DRUG|QAW39A2107|450 mg
58409347|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
57731742|NCT01410448|DRUG|Steroids|Steroids were administered according to local clinical practice.
57944824|NCT03039231|DEVICE|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
57944825|NCT02853448|DEVICE|Novel Blood Drawing Apparatus|
57944826|NCT05885867|BEHAVIORAL|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
57944827|NCT03610724|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel was infused once as an intravenous infustion at a dose of either 0.2 to 5 x 106 CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 108 CAR-positive viable T cells for subjects \> 50 kg.
57944828|NCT03610724|DRUG|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
57944829|NCT03610724|DRUG|Bridging Therapy|Pre-treatment phase could also include bridging therapy of investigator's choice
57944830|NCT01269762|DRUG|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
57944831|NCT04968977|PROCEDURE|PCI vs. CABG|PCI vs. CABG
57944832|NCT02462356|PROCEDURE|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
57944833|NCT02462356|PROCEDURE|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
57944834|NCT06083441|DIAGNOSTIC_TEST|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
57944835|NCT06083441|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score \>2, or an arousal score \> 0 means that a subject is responding to commands
57944836|NCT03590730|DEVICE|ICD implantation|ICD will be implanted according to current guidelines recommendations.
57944837|NCT00318214|DRUG|MRE0094|Gel, 500 mcg/g once each day
57944838|NCT00318214|DRUG|Vehicle gel|Gel administered once per day
57944839|NCT04523636|DEVICE|Splinting|Pre-fabricated or custom resting hand splints
57944840|NCT04060420|OTHER|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
58078796|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
58078797|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
58078798|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
58078799|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
58297964|NCT05687097|DEVICE|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
58297965|NCT05687097|DEVICE|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
58297966|NCT05687097|DEVICE|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
58297967|NCT01289327|DRUG|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
58297968|NCT00456872|DRUG|lidocaine|
58297969|NCT01441128|DRUG|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
58297970|NCT01441128|DRUG|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
58297971|NCT00692380|RADIATION|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
58409348|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
57944841|NCT01605279|DRUG|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
57944842|NCT01605279|DRUG|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
57944843|NCT02384668|DIETARY_SUPPLEMENT|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
57944844|NCT02384668|DIETARY_SUPPLEMENT|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
57944845|NCT04550104|RADIATION|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
57944846|NCT04550104|DRUG|Olaparib Oral Tablet [Lynparza]|Oral tablet
58409349|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
57731743|NCT02494791|BEHAVIORAL|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
57944847|NCT04550104|DRUG|AZD1390|Oral tablet
57944848|NCT04550104|DRUG|Ceralasertib|Oral Tablet
57944849|NCT04550104|DRUG|AZD5305|Oral Tablet
57944850|NCT04550104|DRUG|Durvalumab|1500mg iv infusion
58297972|NCT04426097|PROCEDURE|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
58297973|NCT04426097|PROCEDURE|Without Blockade|Without Blockade
58297974|NCT02383069|OTHER|Intervention Group|Aerobic training
58297975|NCT02383069|OTHER|Control Group|Chest physiotherapy: Flutter and muscle stretching
58297976|NCT01991353|PROCEDURE|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
58297977|NCT01991353|PROCEDURE|Without PRP|Standard of care meniscal repair without augmentation.
58297978|NCT04994561|DRUG|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
57944851|NCT00715026|DEVICE|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
58297979|NCT00944710|DRUG|Atropine|Weekend atropine 1%
58297980|NCT00944710|DEVICE|Plano lens|plano lens over the sound eye
58297981|NCT00944710|DRUG|Atropine|Weekend atropine 1%
58297982|NCT02852460|OTHER|rapid recovery|
57731744|NCT04141306|OTHER|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
57944852|NCT04822649|DIAGNOSTIC_TEST|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
58409350|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
57944853|NCT04214379|PROCEDURE|Ptosis surgery|Frontalis sling surgery using pose-up and Wright's fascia-lata needle
57944854|NCT00839384|DEVICE|Advisa IPG|Implantable Pulse Generator will be implanted
57944855|NCT03172832|PROCEDURE|PTBD|Percutaneous access and tube placement into the bile duct
58409351|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
58297983|NCT03482271|OTHER|No intervention - data collection only|No intervention - data collection only
57944856|NCT03172832|PROCEDURE|ERC|Endoscopic access and stent placement in the bile duct
57944857|NCT02409849|DRUG|Octreotide lar|
57944858|NCT02992340|DRUG|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
57944859|NCT02992340|DRUG|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
58409352|NCT00309699|DRUG|Placebo|Daily for 3 weeks
58409353|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
57944860|NCT02992340|DRUG|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
58078800|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
58409354|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
58409355|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
58409356|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
58409357|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
57731745|NCT04141306|OTHER|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
57731746|NCT04141306|OTHER|Histological data|Evaluation of Pathology report of thyroid surgery
57731747|NCT04141306|OTHER|Imaging data|Evaluation of scintigraphy, MRI, scan
57731748|NCT04141306|OTHER|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
57731749|NCT04141306|OTHER|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
57944861|NCT02970604|DRUG|Aspirin|Non enteric coated aspirin
57944862|NCT06156436|DEVICE|ResAppDx v.20|Software application used to aid diagnosis of respiratory disorders
57944863|NCT01652742|DRUG|BI 135585 XX|one single dose
57944864|NCT01651351|BIOLOGICAL|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
57944865|NCT01651351|BIOLOGICAL|Placebo: Human albumin 2.5%|Intravenous administration
57944866|NCT04912245|BEHAVIORAL|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
57944867|NCT05151081|OTHER|basicly|Do not repeat information already included in arm/group descriptions.
58297984|NCT00168948|DRUG|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
58297985|NCT00666107|BIOLOGICAL|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
58297986|NCT01749956|RADIATION|Radiation|
58297987|NCT01749956|DRUG|Aflibercept|
58297988|NCT01749956|PROCEDURE|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
58297989|NCT01749956|DRUG|FOLFOX6|
58297990|NCT03289247|DEVICE|tissue adhesive (Leukosan®)|Tissue ahaesive
58078801|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
58078802|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
58078803|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
58078804|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
58297991|NCT03099460|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
57731750|NCT06486740|DEVICE|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
58078805|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
58078806|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
58078807|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
58078808|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
58297992|NCT03099460|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
57731751|NCT05853913|BEHAVIORAL|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
57731752|NCT01813799|DRUG|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
57731753|NCT01813799|DRUG|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
57731754|NCT01813799|DRUG|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
57731755|NCT01813799|DRUG|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
57731756|NCT03408912|DIAGNOSTIC_TEST|FFR|FFR from CMR compared to invasive FFR
58078809|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
58078810|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
58078811|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
58078812|NCT01065662|DRUG|cediranib|Taken orally daily
58078813|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
57731757|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
57731758|NCT05685108|DEVICE|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
57731759|NCT05685108|DEVICE|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
57731760|NCT00044382|DRUG|CC-5013|
57944868|NCT01450449|RADIATION|Radiotherapy|25 Gy in 5 daily fractions over 1 week
57944869|NCT01450449|RADIATION|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
57944870|NCT04822051|OTHER|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
57944871|NCT04885803|DIETARY_SUPPLEMENT|Softgel Vitamin D3|5000IU vitamin D3 taken as single oral softgel once daily for 30 days
57944872|NCT04885803|DIETARY_SUPPLEMENT|Nano Liquid Vitamin D3|5000IU vitamin D3 taken as liquid oral spray once daily for 30 days
57944873|NCT04885803|DIAGNOSTIC_TEST|25(OH)D Blood Serum Test|A sample of blood is drawn off and processed for 25(OH)D levels at baseline, after 15 days of supplementation, and after 30 days of supplementation
58078814|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
57944874|NCT04885803|OTHER|Placebo Control|Liquid oral spray once daily for 30 days. Solution identical in smell, taste, color, and production process to Nano Liquid D3, but containing no Vitamin D3.
57944875|NCT03147781|DEVICE|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
57944876|NCT03147781|DEVICE|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
57944877|NCT01840579|BIOLOGICAL|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
58078815|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
58078816|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
58078817|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
58078818|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
57731761|NCT06669130|DEVICE|Xiangtong TM full degradation sinus drug stent system|use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus
57731762|NCT06669130|DEVICE|nasopore|use nasopore to protect the post-operative sinus
57731763|NCT05234892|DEVICE|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
57731764|NCT04078282|BEHAVIORAL|Intervention group|see above
57731765|NCT02282501|OTHER|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
57944878|NCT01840579|BIOLOGICAL|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
57944879|NCT01840579|BIOLOGICAL|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
58409358|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
58078819|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
58078820|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
58078821|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
58078822|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
58409359|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
57944880|NCT01840579|DRUG|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
57944881|NCT01840579|DRUG|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
57944882|NCT01840579|DRUG|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
57944883|NCT01840579|DRUG|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
57944884|NCT01840579|DRUG|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
57944885|NCT01840579|DRUG|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
58078823|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078824|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
57731766|NCT06393452|DRUG|PP405 0.05% Topical Gel|PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)
57944886|NCT01840579|BIOLOGICAL|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
58078825|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
57944887|NCT01840579|DRUG|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
57944888|NCT01840579|DRUG|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
57944889|NCT02775084|DIETARY_SUPPLEMENT|Fish Oil|4 capsules twice daily with food for 6 weeks
58078826|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078827|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
57944890|NCT02775084|DIETARY_SUPPLEMENT|Olive Oil|4 capsules twice daily with food for 6 weeks
57944891|NCT02751593|DRUG|Dexamethasone|dexamethasone 40mg/d for 4 days
57944892|NCT00113776|DRUG|ABX-EGF|
57944893|NCT01414881|DRUG|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
57944894|NCT01414881|DRUG|Placebo|Placebo administered subcutaneously (SC) once weekly
57944895|NCT04116996|DEVICE|DEEP BRAIN STIMULATION|NEUROMODULATION
58078828|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078829|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078830|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078831|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
58078832|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
58078833|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
58078834|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
58409360|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
58409361|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
58409362|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
58078835|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
58078836|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
58078837|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
58078838|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
58078839|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
58078840|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
58078841|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
58078842|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if... then.... This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
58297993|NCT03099460|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
58297994|NCT06366646|OTHER|Competency-based intervention|90 head nurses and their assistants received the competency-based intervention program
58078843|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
58078844|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
58409363|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
58297995|NCT01589367|DRUG|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
58409364|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
58409365|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
57731767|NCT06393452|DRUG|PP405 Topical Vehicle Gel|PP405 Vehicle = placebo
57731768|NCT05251753|DEVICE|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
57944896|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
58078845|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
58078846|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
58078847|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
58078848|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
58078849|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
57944897|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
57731769|NCT01407185|OTHER|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
58297996|NCT01589367|DRUG|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
58297997|NCT04778852|DEVICE|Experimental: EksoGT|EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
58409366|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
58409367|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
58409368|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
58409369|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
58409370|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
57731770|NCT05854381|BIOLOGICAL|VIR-1388|VIR-1388 is given by subcutaneous injection
58409371|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
57731771|NCT05854381|BIOLOGICAL|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
57731772|NCT03538626|BIOLOGICAL|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
57731773|NCT03538626|BIOLOGICAL|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
57731774|NCT03165526|DEVICE|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
57731775|NCT06669598|OTHER|Whole Body Electromyostimulation|The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
57731776|NCT06669598|BEHAVIORAL|control group|The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
57731777|NCT02486224|DIETARY_SUPPLEMENT|Kona Deep|Subjects will receive Kona Deep post exercise
57731778|NCT02486224|DIETARY_SUPPLEMENT|Spring Water|Subjects will receive Spring Water post exercise
57731779|NCT02486224|DIETARY_SUPPLEMENT|Sports Drink|Subjects will receive Sports Drink post exercise
57944898|NCT04798937|OTHER|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
57944899|NCT04341441|DRUG|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
57731780|NCT06465420|BIOLOGICAL|Haemophilus influenzae type a (Hia) glycoconjugate vaccine|0.5 mL intramuscular injection, given on days 0 and 28
57944900|NCT04341441|DRUG|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
57944901|NCT04341441|OTHER|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
58078850|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
58078851|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
58409372|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
57731781|NCT00243373|DEVICE|Barcode technology/eMAR|
58297998|NCT04778852|OTHER|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
58297999|NCT00689962|DEVICE|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
58298000|NCT00689962|DEVICE|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
58409373|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
58409374|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
57731782|NCT00748046|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
57731783|NCT06634550|OTHER|Mulligan technique|The participants will receive Mulligan technique (modified SNAGs) (10 rep. / 3 sets with 5 min rest in between) for 30 minutes, 3 sessions / week in addition to lifestyle modification advice for 4 weeks.
57731784|NCT06634550|OTHER|Core stability exercise|The participants will perform core stability exercises (spinus multifiduse ex, diaphragmatic strengthening ex, frontal plank, pelvic floor ex,) 3 sessions / week for 30 min each session in addition to lifestyle modification advice for 4 weeks
57731785|NCT06634550|OTHER|Lifestyle modification advice|The participants will receive lifestyle modification advice only for 4 weeks
57731786|NCT06635031|PROCEDURE|Oral surgery|The patients were undergone routine oral surgeries. Surgical procedures included an incision on the oral mucosa and full-thickness flap reflection, and the primary wound closure was achieved by polyglactin absorbable sutures.
58409375|NCT02072135|DRUG|Exparel|
58409376|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
58409377|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
58409378|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
58409379|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
57944902|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
57944903|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
57944904|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
57944905|NCT04341441|OTHER|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 \&7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
57944906|NCT03574675|DEVICE|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
57944907|NCT03574675|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
57944908|NCT02332499|DRUG|Anlotinib|Anlotinib p.o. qd
58078852|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
58078853|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
58078854|NCT00242840|DRUG|No intervention; Observational study|
58078855|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
58409380|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
58409381|NCT00177567|DRUG|lithium carbonate|
58409382|NCT00177567|DRUG|Depakote-ER|
58409383|NCT00177567|DRUG|risperidone|
58409384|NCT00177567|DRUG|olanzapine|
58409385|NCT00177567|DRUG|paroxetine|
58409386|NCT00177567|DRUG|bupropion|
58409387|NCT00177567|DRUG|lamotrigine|
58409388|NCT00177567|DRUG|venlafaxine|
58409389|NCT00177567|DRUG|tranylcypromine|
58409390|NCT00177567|DRUG|mirtazapine|
58409391|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
57944909|NCT02332499|DRUG|Placebo|Placebo p.o. qd
57944910|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Consult
57944911|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Control - Standard of Care
57944912|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Newsletter
57944913|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Parent Letter
57944914|NCT04080947|DRUG|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
57944915|NCT04080947|DRUG|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
57944916|NCT04292808|DRUG|Methoxyflurane|Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
57944917|NCT00006047|DRUG|Oral Etoposide|
57944918|NCT00006047|DRUG|Oral 9-Nitrocamptothecin|
57944919|NCT05945186|DEVICE|Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)|External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
57944920|NCT01850485|DEVICE|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
57944921|NCT04670497|PROCEDURE|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
57944922|NCT03096951|BEHAVIORAL|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
57944923|NCT03096951|OTHER|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
57944924|NCT04689581|OTHER|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
57944925|NCT04689581|OTHER|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
57944926|NCT06031649|DEVICE|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
57944927|NCT00907348|DRUG|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
57944928|NCT00577642|DRUG|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
57944929|NCT01199588|DRUG|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
57944930|NCT01199588|DRUG|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
57944931|NCT01199588|DRUG|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
57944932|NCT06017570|DIAGNOSTIC_TEST|Radiologic examination on orthopantomogram|Caries examination on the distal side of the adjacent second molar in the orthopantomogram of patients with an appointment for the extraction of mesioangular or horizontal partially impacted third molars
57944933|NCT06017570|DIAGNOSTIC_TEST|Clinical examination after surgery|İnspectional caries examination on the distal side of the adjacent second molar after surgery of patients with mesioangular or horizontal partially impacted third molars
57944934|NCT00767052|DRUG|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
57944935|NCT00767052|DRUG|Placebo|Placebo tablet matching to the active in multiple dose part.
57944936|NCT00767052|DRUG|AZD1236|75mg single dose will be administered in relative bioavailability part.
57944937|NCT00767052|DRUG|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
57944938|NCT04638348|DEVICE|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
57944939|NCT03335163|DRUG|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
57944940|NCT04957576|BEHAVIORAL|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
58078856|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
58078857|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
58078858|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
58078859|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
58078860|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
58078861|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
58078862|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
58078863|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
58078864|NCT00563927|PROCEDURE|Conventional RT|
58078865|NCT00563927|DRUG|Cisplatin|
58078866|NCT00563927|DRUG|5-fluorouracil|
58078867|NCT04619043|DEVICE|Ankle Orthotic|
58078868|NCT03045926|DRUG|Diosmectite (Smecta®)|
58078869|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
58078870|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
58078871|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
58078872|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
58078873|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
58078874|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
58078875|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
58078876|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
58078877|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
58078878|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
58078879|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
58078880|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
58078881|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
58078882|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
58078883|NCT00313716|OTHER|placebo|an inactive substance
58078884|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
58078885|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
58409392|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
58409393|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
58078886|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
58078887|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
58078888|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
57944941|NCT01858532|DRUG|Atrasentan|Film-coated tablet
57944942|NCT01858532|DRUG|Placebo|Film-coated tablet
57944943|NCT01027611|DRUG|proparacaine HCL 0.5%|
58078889|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
58078890|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
58078891|NCT00116246|PROCEDURE|McRobert's manoeuvre|
58078892|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
58078893|NCT01520038|RADIATION|Proton therapy|
58078894|NCT01520038|RADIATION|IMRT|
58078895|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
58298001|NCT03547024|DRUG|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
57944944|NCT01027611|DRUG|proparacaine HCL 0.5% + 4% lidocaine solution|
58078896|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
58078897|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
58078898|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
58078899|NCT03454191|PROCEDURE|No injection|No injection
58078900|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
58078901|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
57944945|NCT01027611|DRUG|3.5% viscous lidocaine gel|
57944946|NCT01483742|DRUG|RO5024048|1000 mg orally bid, 24 weeks
58078902|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
58078903|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
58078904|NCT00406939|GENETIC|IL-12 gene|
58078905|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
58078906|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
58078907|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
58078908|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
58078909|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
58078910|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
58078911|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
58078912|NCT00201630|DRUG|Uroxatrol (drug)|
57944947|NCT01483742|DRUG|danoprevir|100 mg orally bid, 24 weeks
57944948|NCT01483742|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
57944949|NCT01483742|DRUG|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
57944950|NCT01483742|DRUG|ritonavir|100 mg orally bid, 24 weeks
58078913|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
58298002|NCT03547024|DRUG|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
58298003|NCT03547024|DRUG|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
58298004|NCT03547024|DRUG|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
58298005|NCT00713843|OTHER|Manual Therapy Utrecht|Manual Therapy (6 weeks).
58298006|NCT00713843|OTHER|Physical Therapy|Physical Therapy (six weeks).
58298007|NCT02298348|DRUG|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
58078914|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
58078915|NCT03562676|OTHER|weightlessness|parabolic flight
58078916|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
58078917|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
57944951|NCT04127253|DEVICE|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
58078918|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
58078919|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
58078920|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
58078921|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
58078922|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
58078923|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
58078924|NCT00060320|OTHER|placebo|
58078925|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
58078926|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
58078927|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
58078928|NCT02352831|DRUG|Tosedostat|
58078929|NCT02352831|DRUG|Capecitabine|
58078930|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
58078931|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
58078932|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
57944952|NCT04127253|DEVICE|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
58078933|NCT00202254|BEHAVIORAL|Physiotherapy|
57944953|NCT04127253|BEHAVIORAL|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
58078934|NCT00202254|BEHAVIORAL|Occupational therapy|
58298008|NCT02298348|DRUG|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
58078935|NCT00202254|BEHAVIORAL|Speech pathology|
58078936|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
58078937|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
58078938|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
58078939|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
58298009|NCT02298348|DRUG|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
58409394|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
57944954|NCT02475070|DRUG|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
58078940|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
58078941|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
58078942|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
58078943|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
58078944|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
58078945|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
58078946|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
58078947|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
58298010|NCT05991011|OTHER|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
58298011|NCT05991011|OTHER|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
58298012|NCT05991011|OTHER|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
58298013|NCT05991011|OTHER|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
58298014|NCT05991011|OTHER|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
58298015|NCT05991011|OTHER|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
58298016|NCT01178905|PROCEDURE|ultrashort heat inactivation|
58298017|NCT05417412|BEHAVIORAL|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
58298018|NCT04054544|DIETARY_SUPPLEMENT|Gluten powder 4g|Gluten powder 4g oral BID
57944955|NCT02475070|DRUG|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
57944956|NCT01505790|DRUG|PRASUGREL|60 mg the first day then 10 mg per day during one month
58298019|NCT04961437|OTHER|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
58298020|NCT05545176|OTHER|termination of resuscitation rules|Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
58298021|NCT06519838|OTHER|Local anesthesia solution at room temperature|The local anesthesia cartridge is used at room temperature (average of 21 °C)
57944957|NCT01505790|DRUG|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
58078948|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
58078949|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
58078950|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
58298022|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 37°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 37°C at 120 seconds."
58298023|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 40°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 40°C at 130 seconds."
58298024|NCT06519838|OTHER|Maxillary infiltration technique|A 30 gauge short needle is oriented so that the bevel is facing the bone. The syringe is held parallel to the long axis of the tooth and the needle is inserted into the height of the mucobuccal fold over the offending tooth. The needle is advanced to a depth of 1 millimeter into the tissues. Aspiration is done, and once it is negative then 0.6 ml (nearly one third of the cartridge) of the anesthetic solution is injected slowly without permitting the tissues to balloon.
58409395|NCT01846195|DEVICE|CM 1500|
58409396|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
58298025|NCT06519838|OTHER|Inferior alveolar nerve block technique|While the mouth is opened as wide as possible, the index finger palpates the external oblique ridge reaching the Coronoid notch. A 27-gauge long dental needle will be used for injection. The needle will be directed between the two primary molars on the opposing side of the arch, penetrating the tissues at the point halfway between coronoid notch and the pterygomandibular raphe at the occlusal plane level or slightly lower.The needle is withdrawn 2mm to aspirate. Once negative aspiration is checked, the remainder of the solution is deposited slowly. Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. The average depth of insertion is about 15mm, which is nearly two-thirds the needle length.
58409397|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
58409398|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
58409399|NCT02504112|OTHER|there is no intervention|
58078951|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
58409400|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
58409401|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
58409402|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
58409403|NCT01445522|DRUG|ABT-888|
58409404|NCT01445522|DRUG|Cyclophosphamide|
58409405|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
58409406|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
58409407|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
58409408|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
58409409|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
58409410|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
58409411|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
58409412|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
58409413|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
58409414|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
58298026|NCT04693429|DRUG|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
58298027|NCT01781208|DEVICE|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
58409415|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
58409416|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
58409417|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
58409418|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
58409419|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
58409420|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
58409421|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
58409422|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
58409423|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
58298028|NCT02320708|DRUG|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
58298029|NCT02320708|DRUG|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
58409424|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
58409425|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
58409426|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
58409427|NCT04443517|BEHAVIORAL|Emergence from anesthesia with propofol|Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
58409428|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
58409429|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
58409430|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
58409431|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
58409432|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
58298030|NCT02320708|DRUG|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
58298031|NCT02320708|DRUG|Placebo|2 placebo caplets for acetaminophen taken orally one time
58298032|NCT02320708|DRUG|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
58298033|NCT02320708|DRUG|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
58298034|NCT02104024|OTHER|Contrast Enhanced Ultrasound Scanning|
58298035|NCT00503893|BEHAVIORAL|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
58298036|NCT00503893|OTHER|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
58298037|NCT00334412|DRUG|Ambisome|
58298038|NCT00334412|DRUG|caspofungin|
58298039|NCT05978518|DEVICE|CPM Device + Monitoring|Daily device use \& data monitoring leading to symptomology assessment and notification to provider.
58298040|NCT05978518|DRUG|CPM Device|Daily device use
58078952|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
57731787|NCT06457009|COMBINATION_PRODUCT|Multi-component Intervention Package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
57731788|NCT04612361|OTHER|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
57731789|NCT00880932|BEHAVIORAL|Electronic Alert|
58078953|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
58078954|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
58078955|NCT00077896|PROCEDURE|Direct Current Polarization|
58078956|NCT03143933|DRUG|Propofol|I.V propofol
58078957|NCT03143933|DRUG|Fentanyl|
58078958|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
58078959|NCT04014556|DRUG|Aflibercept|Aflibercept
58078960|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
58078961|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
58409433|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
57731790|NCT05916742|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions
57731791|NCT05916742|PROCEDURE|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
57731792|NCT05916742|DEVICE|VCMX|Porcine derived collagen matrix.
57731793|NCT05916742|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
58078962|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
57731794|NCT05916742|DRUG|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
57731795|NCT05916742|DRUG|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
57731796|NCT00784043|DEVICE|Cochlear Implant|Bilateral Implantation in children
58078963|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
58078964|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
58078965|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
58298041|NCT01429662|BEHAVIORAL|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
57944958|NCT03497585|BEHAVIORAL|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
58409434|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
58409435|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
57731797|NCT05156138|OTHER|no interventions as it is a case control observational study|no interventions as it is a case control observational study
57944959|NCT00177749|DRUG|Posaconazole|
57944960|NCT01102075|DEVICE|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
58298042|NCT01429662|BEHAVIORAL|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
57944961|NCT01102075|DEVICE|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
57944962|NCT00803699|DIETARY_SUPPLEMENT|placebo|daily placebo capsules for 12 months
57944963|NCT00803699|DIETARY_SUPPLEMENT|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
57944964|NCT00496730|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
57944965|NCT00496730|DRUG|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
57944966|NCT03382977|BIOLOGICAL|VBI-1901|The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
57944967|NCT03382977|DRUG|Carmustine|Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
57944968|NCT03382977|DRUG|Lomustine|Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
57944969|NCT00639691|BIOLOGICAL|omalizumab|sc
57944970|NCT01710995|DRUG|Zegerid|
57944971|NCT01710995|DRUG|Losec|
57944972|NCT04266184|OTHER|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
58298043|NCT02694133|PROCEDURE|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
58298044|NCT02694133|PROCEDURE|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
58409436|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
58409437|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
58409438|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
58409439|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
58409440|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
57731798|NCT03806985|DRUG|Placebo oral capsule|microcrystalline cellulose capsule
57731799|NCT03806985|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
57731800|NCT03806985|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
57731801|NCT02138591|PROCEDURE|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
57944973|NCT04266184|OTHER|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
58298045|NCT02353026|DRUG|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
58298046|NCT03593499|DRUG|omaveloxolone|
58298047|NCT02993848|OTHER|No intervention|
58298048|NCT01656395|DRUG|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
58078966|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
58078967|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
57944974|NCT04266184|OTHER|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
57944975|NCT01323725|BEHAVIORAL|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
57944976|NCT01239095|DRUG|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
57944977|NCT05233020|DEVICE|robotic|fifteen patients undergo robotic operation
57944978|NCT05233020|DEVICE|hybrid|fifteen patients undergo hybrid operation
57944979|NCT04754360|OTHER|Evaluation of functional impairment|Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test
57944980|NCT04754360|OTHER|Evaluation of pulmonary function|Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.
57944981|NCT04754360|OTHER|Evaluation of quality of life|Quality of life will be evaluated using Short Form-36 Questionnaire.
57944982|NCT04754360|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form
57944983|NCT04640272|DRUG|RBM-007|Intravitreal injection
57944984|NCT05267275|PROCEDURE|extended resection with splenic flexure mobilization|During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
57944985|NCT01483781|DRUG|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
57944986|NCT01483781|DRUG|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
57944987|NCT01388660|DRUG|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)
57944988|NCT01388660|DRUG|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
57944989|NCT05613764|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
58298049|NCT01656395|DRUG|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
58298050|NCT01656395|DRUG|Placebo|Parts I-II: Participants will receive Placebo tablets QD
57944990|NCT01330134|DRUG|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
57944991|NCT01330134|DRUG|lidocaine|1% lidocaine subcutaneous injection alone
58298051|NCT05798715|DRUG|Gleptomet 50/1000(Metformin HCl & Sitagliptin)|Test drug
57944992|NCT00912028|DEVICE|senofilcon A|contact lens
57944993|NCT00912028|DEVICE|lotrafilcon B|contact lens
57944994|NCT00912028|DEVICE|balafilcon A|contact lens
57944995|NCT00912028|DEVICE|methafilcon A|contact lens
57944996|NCT00912028|DEVICE|vifilcon A|contact lens
57944997|NCT05068466|DRUG|INCB054707|Administered Orally
57944998|NCT05068466|DRUG|Placebo|Administered Orally
57944999|NCT04898075|BEHAVIORAL|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
58078968|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
58298052|NCT05798715|DRUG|Janumet 50/1000(Metformin HCl & Sitagliptin)|Reference drug
58298053|NCT00333567|DRUG|Lumiracoxib|
58298054|NCT04571047|OTHER|Time to treatment|Treatment before or after 4 weeks after diagnosis
58298055|NCT01421498|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
58298056|NCT01421498|DRUG|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
57945000|NCT04898075|OTHER|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
57945001|NCT01247636|OTHER|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
57945002|NCT01247636|OTHER|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
58078969|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
58298057|NCT01298700|DRUG|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
58298058|NCT01298700|DRUG|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
58298059|NCT05555238|DRUG|single arm, single group(No interventional)|(Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
57945003|NCT03819348|OTHER|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
57945004|NCT05235945|BEHAVIORAL|Online exercise intervention|Described in arm descriptions
57945005|NCT01933633|BEHAVIORAL|Exercise|
57945006|NCT03886753|OTHER|Registry|Collect data on subjects
58298060|NCT01214889|BIOLOGICAL|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
58298061|NCT01214889|BIOLOGICAL|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
58298062|NCT06018155|OTHER|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
57945007|NCT03886753|OTHER|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
57945008|NCT06166420|OTHER|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
57945009|NCT06166420|OTHER|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
58298063|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
58298064|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
58298065|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
57731802|NCT02138591|PROCEDURE|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
57945010|NCT03439475|BIOLOGICAL|AMG 714|
58078970|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
58298066|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
58298067|NCT01301261|DRUG|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
58298068|NCT01301261|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
58298069|NCT01301261|DRUG|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
57945011|NCT00349167|DRUG|PR-104|
58298070|NCT04458675|DEVICE|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
58298071|NCT04458675|DRUG|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
58298072|NCT03717103|DRUG|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
58298073|NCT04184557|BEHAVIORAL|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
57731803|NCT02138591|PROCEDURE|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
57945012|NCT00349167|OTHER|laboratory biomarker analysis|
57945013|NCT00349167|OTHER|pharmacological study|
58298074|NCT00443222|DRUG|Infliximab|
58298075|NCT05441228|DEVICE|Oculus Quest 2|Oculus Quest 2 is virtual reality headset with 2 hand control remotes. Beat Saber application will be used on Oculus Quest 2.
57731804|NCT00936390|DRUG|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
57945014|NCT02847455|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
57945015|NCT02847455|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
57945016|NCT02847455|DRUG|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
57945017|NCT06490276|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
57945018|NCT06490276|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
57945019|NCT02456844|DRUG|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12."
57945020|NCT02456844|DRUG|Methotrexate, Leucovorin and BMS-986142|"1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10."
58298076|NCT05441228|DEVICE|Mirror therapy box|Mirror therapy is provided by mirror therapy box by placing it in sagittal plane of patient.
58298077|NCT00846053|DIAGNOSTIC_TEST|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
58298078|NCT03351543|BIOLOGICAL|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
58298079|NCT05658471|OTHER|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
58298080|NCT05658471|OTHER|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
58298081|NCT05658471|BEHAVIORAL|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
58298082|NCT05658471|OTHER|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
58298083|NCT02416232|DRUG|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
57945021|NCT03118232|DRUG|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
58409441|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
58409442|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
58409443|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
58409444|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
58409445|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
57731805|NCT00936390|DRUG|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
57731806|NCT00936390|DRUG|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
57945022|NCT03118232|DRUG|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
58298084|NCT02416232|DRUG|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
58298085|NCT05002595|DRUG|H. pylori eradication|Antimicrobial agents for H. pylori eradication
57945023|NCT04501068|DEVICE|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
58298086|NCT03268343|DRUG|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
58298087|NCT00015002|DRUG|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
58298088|NCT04081675|DEVICE|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
58298089|NCT04715464|OTHER|review of surveillance cultures within the past year|"ASC results are reported as positive or negative based on the culture source. Antimicrobial susceptibility testing is performed but not reported; however, physicians may obtain susceptibility information for MDR GNB only if clinically indicated through the microbiology department.~1. Nasal swab for MRSA~2. Respiratory specimens~i. Sputum for MRSA, VRE, and Multi Drug Resistant gram-negative Bacteria (MDR GNB) (if not intubated but with productive cough) ii. Endotracheal aspirate for MRSA, VRE, and MDR GNB (if intubated) c. Drainage from any wounds for MRSA, VRE, and MDR GNB d. Rectal/ perianal swab for VRE, and MDR GNB e. Urine for MRSA, VRE, and MDR GNB (from patients catheterized prior to admission only)"
58298090|NCT03724357|DRUG|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
58298091|NCT03432481|PROCEDURE|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
57945024|NCT02614365|BEHAVIORAL|Aerobic exercise|Cardiovascular fitness
57945025|NCT02614365|BEHAVIORAL|Stretch exercise|Muscle stretch
58409446|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
58409447|NCT04579302|DRUG|Bupivacaine|bupivacaine
58409448|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
58409449|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
58409450|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
57945026|NCT02753322|OTHER|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
57945027|NCT02753322|OTHER|Single-task training|Balance and walking exercises and and attention demanding task performed separately
57945028|NCT02753322|OTHER|Limbs exercise|Stretching and strengthening exercises
58409451|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
57945029|NCT04922840|BEHAVIORAL|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
58298092|NCT03432481|DEVICE|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
58298093|NCT00054496|DRUG|erlotinib hydrochloride|
57731807|NCT00936390|RADIATION|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
57731808|NCT04065438|DEVICE|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
57731809|NCT06074666|BEHAVIORAL|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
57945030|NCT06014892|DEVICE|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
57945031|NCT06014892|DEVICE|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
57945032|NCT06014892|BEHAVIORAL|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
57945033|NCT06014892|BEHAVIORAL|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
57945034|NCT01875783|DEVICE|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
57945035|NCT04688775|DRUG|Eptinezumab|Eptinezumab - concentrate for solution for infusion, intravenously
57945036|NCT04688775|DRUG|Placebo|Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
57945037|NCT02537886|DEVICE|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
57945038|NCT01257815|DRUG|Ranibizumab|
57945039|NCT01987687|BEHAVIORAL|Exercise|Exercise at 55% of maximum power output for 30 min.
57945040|NCT01987687|BEHAVIORAL|Rest|Rest for 30 min
57945041|NCT01987687|BEHAVIORAL|Delay|Delay between exercise and OGTT
58078971|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
58078972|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
58078973|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
57945042|NCT00833053|DRUG|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
57945043|NCT00833053|DRUG|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
57945044|NCT04309942|OTHER|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
57945045|NCT03402984|DRUG|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
57945046|NCT03402984|DRUG|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
57945047|NCT00810004|DRUG|Ferinject|Intravenous infusion of iron
57945048|NCT02716051|DEVICE|MRI|Whole body MRI with cardiac and pulmonary synchronization
58078974|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
58078975|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
57945049|NCT02716051|DEVICE|PET|
57945050|NCT06097000|DEVICE|powered exoskeletons|Whether to use powered exoskeletons for exercise rehabilitation
57945051|NCT02916849|OTHER|Safe Step|Strength and balance exercise-digital version
57945052|NCT02916849|OTHER|OEP|Strength and balance exercise -paper version
57945053|NCT03070470|DRUG|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
58078976|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
58078977|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
58078978|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
58298094|NCT03569397|OTHER|Music Therapy|Patients will be administered music therapy during the operation.
58298095|NCT00958854|DRUG|cyclophosphamide|
58298096|NCT00958854|DRUG|fludarabine phosphate|
58298097|NCT00958854|DRUG|thalidomide|
58298098|NCT00958854|OTHER|laboratory biomarker analysis|
58298099|NCT03124160|DRUG|Mona Lisa® NT Cu380 Mini|copper intrauterine device
58298100|NCT03124160|DRUG|ParaGard® TCu380A|copper intrauterine device
58409452|NCT00054951|DRUG|MTC-DOX for Injection|
58409453|NCT02115750|DRUG|Etanercept|Head-to-head comparison
58409454|NCT02115750|DRUG|CHS-0214|
58078979|NCT04938869|OTHER|Survey Administration|Ancillary studies
58078980|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
58078981|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
58078982|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
58078983|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
58298101|NCT03255694|DRUG|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
58409455|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
58409456|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
58409457|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
58409458|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
58409459|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
58078984|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
58298102|NCT04492423|DIAGNOSTIC_TEST|VerifyNow PRUTest|VerifyNow PRUTest for platelet aggregation
58298103|NCT01542450|DRUG|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
58298104|NCT01542450|DRUG|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
58298105|NCT02359110|DRUG|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
58409460|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
58409461|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
58409462|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
58409463|NCT00989521|DRUG|PUR003|PUR003 for inhalation
58078985|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
58078986|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
58078987|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
58078988|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
58409464|NCT00989521|DRUG|Placebo|Normal saline for inhalation
58409465|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
58078989|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
58298106|NCT02359110|OTHER|Placebo|Patient will receive placebo tab less than 1 hour before surgery
58298107|NCT02948712|BEHAVIORAL|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
58298108|NCT02948712|BEHAVIORAL|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
58298109|NCT06010797|DEVICE|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
58409466|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
58409467|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
58409468|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
58409469|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
58409470|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
58078990|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
58298110|NCT03633604|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
58409471|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
58409472|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
58409473|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
58409474|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
58078991|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
58078992|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
58078993|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
58409475|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
58078994|NCT04162756|DRUG|Fludarabine|Administered per package insert
58409476|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
58409477|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
58409478|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
58409479|NCT00328653|DRUG|Vehicle|
58409480|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
58298111|NCT05849038|DRUG|Baricitinib|Patients will receive baricitinib at a dose of 2 mg oral daily.
58298112|NCT05849038|OTHER|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
58409481|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58409482|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
58409483|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
58409484|NCT05941520|DRUG|Tamoxifen|Given PO
58409485|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
58078995|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
58078996|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
58078997|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
58078998|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
58078999|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
58079000|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
58409486|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
58079001|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
58079002|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
58079003|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
58298113|NCT00811694|OTHER|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
58298114|NCT01429467|DEVICE|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
58298115|NCT00849563|OTHER|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
58298116|NCT04856332|OTHER|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
58298117|NCT00078013|DRUG|MCC-135|
58298118|NCT06064058|DIETARY_SUPPLEMENT|Ghazwan program|6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
58298119|NCT06064058|DRUG|Standard management|Standard care with NSAIDs and acetaminophen for pain management
58298120|NCT04350268|DEVICE|Wearable sensor|Wireless sensor
58298121|NCT05252715|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
58298122|NCT05252715|BIOLOGICAL|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
58298123|NCT04078009|DIAGNOSTIC_TEST|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
58298124|NCT04078009|DIAGNOSTIC_TEST|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
58298125|NCT06209073|OTHER|Virtual Reality exercise|after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
58298126|NCT06209073|OTHER|conventional treatment|the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
58079004|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
57731810|NCT06074666|BEHAVIORAL|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
57945054|NCT03070470|DRUG|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
57945055|NCT03070470|DRUG|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
57945056|NCT03070470|DRUG|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
58079005|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
58079006|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
58079007|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
58298127|NCT00846586|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
58409487|NCT04289077|OTHER|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
58409488|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
58409489|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
58409490|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
58409491|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
58409492|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
57945057|NCT03070470|DRUG|Placebo|Placebo (administered orally)
57945058|NCT03070470|DRUG|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
57945059|NCT01487642|DEVICE|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
57945060|NCT01487642|DEVICE|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
58079008|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
58079009|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
58079010|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
58409493|NCT02508740|DRUG|bevenopran|Single oral dose
58409494|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
58409495|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
58409496|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
58409497|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
58079011|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
58079012|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
58079013|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
58079014|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
58079015|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
58079016|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
58079017|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
58298128|NCT00846586|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
58298129|NCT00846586|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
58298130|NCT02532335|DRUG|Obeticholic acid|active drug
58409498|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
58409499|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
58409500|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
58079018|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
58079019|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
58079020|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
57731811|NCT04617028|DRUG|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
57945061|NCT01487642|DEVICE|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
57945062|NCT01487642|DEVICE|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
57945063|NCT02308982|DRUG|Immunoglobulins, Intravenous (Privigen)|
57945064|NCT02308982|DRUG|Placebo|
57945065|NCT01815749|BIOLOGICAL|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
57945066|NCT01815749|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
57945067|NCT01815749|OTHER|laboratory biomarker analysis|Correlative studies
57945068|NCT01014325|BIOLOGICAL|Allergen extract|sublingual application
57945069|NCT01014325|BIOLOGICAL|Placebo|sublingual application
57945070|NCT01730508|DRUG|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
57945071|NCT02518997|OTHER|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
57945072|NCT00389792|DRUG|ATI-2042|no intervention
57945073|NCT00389792|DRUG|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
58298131|NCT02532335|DRUG|Obeticholic acid placebo|matching placebo
58298132|NCT00251134|DRUG|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
58298133|NCT00251134|DRUG|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
58298134|NCT03502499|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
58298135|NCT03502499|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
58298136|NCT00633607|OTHER|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
57945074|NCT03807349|DEVICE|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
58298137|NCT05702437|OTHER|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
57731812|NCT04617028|DRUG|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
57731813|NCT04617028|DRUG|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
57731814|NCT04617028|DRUG|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
57731815|NCT01899976|DEVICE|X-Suit NIR Covered Biliary Stent|
57945075|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
57731816|NCT04015648|BIOLOGICAL|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
57945076|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
57945077|NCT01397799|DRUG|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
57945078|NCT02631525|DRUG|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
57945079|NCT02631525|DRUG|Propofol|Total intravenous anesthesia based on propofol
57945080|NCT03630211|DRUG|Cyclophosphamide|Stem Cell Mobilization
57945081|NCT03630211|DRUG|Mesna|Stem Cell Mobilization
57945082|NCT03630211|DRUG|Rituximab|Transplantation Conditioning
57945083|NCT03630211|DRUG|Alemtuzumab|Transplantation Conditioning
57945084|NCT03630211|DRUG|Thiotepa|Transplantation Conditioning
57945085|NCT03630211|DRUG|GM-CSF|Transplantation Conditioning
57945086|NCT03630211|DRUG|Intravenous immunoglobulin|Transplantation Conditioning
58079021|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
57945087|NCT03630211|RADIATION|Total Body Irradiation|Transplantation Conditioning
57945088|NCT03630211|DRUG|Anti Thymocyte Globulin|Transplantation Conditioning
57945089|NCT03762369|DRUG|CKD-351|twice a day
57945090|NCT03762369|DRUG|Latanoprost|once a day
57945091|NCT03762369|DRUG|D930|three times a day
57945092|NCT03762369|DRUG|Placebo of CKD-351|once a day
57945093|NCT03762369|DRUG|Placebo of CKD-351|twice a day
57945094|NCT03762369|DRUG|Placebo of D930|three times a day
57945095|NCT01241799|PROCEDURE|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
57945096|NCT01241799|PROCEDURE|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
57945097|NCT06158542|PROCEDURE|Spinal Anesthesia|After standard monitoring, the patient is placed in a sitting position for site marking and administration of anesthesia. The line connecting the upper border of the right and left iliac crests through conventional palpation of anatomical landmarks (Tuffier line) is identified as the entry point at the L3-L4 interspinous space or L2-L3 interspace. For patients in whom spinal entry is successful, spinal anesthesia is provided with the appropriate dose and types of local anesthetics (intrathecal 10-12 mg bupivacaine with the addition of 15-25 mcg fentanyl). After completing the procedure and placing the patient in the supine position, the block level is determined 10 minutes post-procedure using the ice test/pinprick test. Blocks reaching the T4-T6 level are considered successful.
57945098|NCT06158542|DIAGNOSTIC_TEST|Blood Sampling|Preoperatively, syndecan-1 serum levels will be investigated from the blood sample taken before cesarean section.
57945099|NCT04721470|PROCEDURE|Combined therapy|Patients undergoing combined therapy
57945100|NCT04721470|PROCEDURE|Microwave ablation|Patients undergoing Microwave ablation
57945101|NCT04721470|PROCEDURE|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
57945102|NCT02567253|PROCEDURE|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
57945103|NCT02567253|DRUG|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
57945104|NCT02567253|DRUG|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
57945105|NCT02567253|DRUG|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
57945106|NCT02567253|DRUG|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
57945107|NCT06002399|DEVICE|cataract surgery|cataract surgery
57945108|NCT01397370|DRUG|GLPG0492|Oral solution
58079022|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
58409501|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
58409502|NCT02242981|DRUG|LY2623091|Administered orally
57945109|NCT01397370|DRUG|Placebo|Oral solution
57945110|NCT06476418|BEHAVIORAL|distraction|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
57945111|NCT05992103|PROCEDURE|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
57945112|NCT05992103|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
57945113|NCT05992103|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
57945114|NCT00627653|DRUG|fenofibrate|148mg daily for 30 days
57945115|NCT02817971|BEHAVIORAL|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
57945116|NCT02817971|BEHAVIORAL|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
57945117|NCT03789942|PROCEDURE|Oral surgery|Oral surgery procedures
57945118|NCT02938884|DEVICE|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
57945119|NCT06047652|DEVICE|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
57945120|NCT04820972|DRUG|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
57945121|NCT03044249|DRUG|MP-101|Capsules
57945122|NCT03044249|DRUG|Placebo|Capsules
57945123|NCT02625233|DEVICE|senofilcon C|
57945124|NCT02625233|DEVICE|comfilcon A|
58079023|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
58079024|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
58079025|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
58079026|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
58079027|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
58079028|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
58079029|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
58079030|NCT01727804|OTHER|Laser in caries prevention|
58079031|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
58079032|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
57945125|NCT05689970|DIAGNOSTIC_TEST|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
57945126|NCT03763071|OTHER|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
57945127|NCT00974246|DRUG|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
57945128|NCT06438484|BEHAVIORAL|multimodal prehabilitation program|"Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience). The physical exercise training consisted of high-intensity interval training (HIIT) three times a week and functional strengthening exercises. Patients visited the hospital two times a week and performed home exercise training five times a week on a stationary cycle ergometer (Corival Home+, Lode BV, Groningen, The Netherlands).~The dietary intervention consisted of optimization of energy and protein intake, optimization of timing of eating protein-rich products, and if necessary additional protein and vitamin supplements. Individual protein requirements were set at 1.5-1.9 g/kg fat free mass. Patients used the eiFIT-application or a food diary to track their protein intake."
57945129|NCT00344721|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
58079033|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
58079034|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
58079035|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
58079036|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
58079037|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
58079038|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
58079039|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
58079040|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
58079041|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
58079042|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
58079043|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
57945130|NCT00344721|DIETARY_SUPPLEMENT|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
58079044|NCT02504099|DRUG|ribavirin|Tablet
58079045|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
58079046|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
58079047|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
58079048|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
58079049|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
58079050|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
57945131|NCT06489587|DIETARY_SUPPLEMENT|Placebo|Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
58079051|NCT03127267|DRUG|Placebo|treatment per os
58079052|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
58079053|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
57945132|NCT06489587|DIETARY_SUPPLEMENT|Creatine|Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
58079054|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
58079055|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
57945133|NCT00853320|DRUG|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
57945134|NCT00853320|DRUG|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
57945135|NCT00984971|DRUG|Tenofovir|Topical gel applied rectally
57945136|NCT00984971|DRUG|HEC Placebo|Placebo gel applied rectally
57945137|NCT00984971|DRUG|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
57945138|NCT06445946|DRUG|Metformin|Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
57731817|NCT05383248|BEHAVIORAL|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
57945139|NCT06445946|DRUG|Insulin|Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
57945140|NCT04203732|PROCEDURE|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
57945141|NCT01984372|DRUG|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
57945142|NCT05840926|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12|Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
57945143|NCT05840926|OTHER|No probiotic supplementation|Children who did not receive any probiotic supplementation
58079056|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
58079057|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
58079058|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
58079059|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
58079060|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
58079061|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
58079062|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
57731818|NCT05383248|BEHAVIORAL|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
57731819|NCT03188939|PROCEDURE|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
57731820|NCT03188939|PROCEDURE|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
57945144|NCT02032563|DRUG|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
57945145|NCT02833012|DRUG|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
57945146|NCT02833012|DRUG|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
57945147|NCT02833012|DRUG|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
57945148|NCT02833012|DRUG|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
57945149|NCT04080570|OTHER|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
58079063|NCT00040209|DRUG|JP 1730|
58079064|NCT00040209|DRUG|IV Levodopa|
58079065|NCT00040209|DRUG|IV Apomorphine|
58079066|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
58079067|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
58079068|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
58079069|NCT02071472|OTHER|DP medication reconciliation|
58079070|NCT04651569|OTHER|Observational study|none, Observational study
58079071|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
58079072|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
57945150|NCT01301443|DRUG|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
58079073|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
58079074|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
57945151|NCT04178759|PROCEDURE|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
57945152|NCT05534425|BEHAVIORAL|GenX intergenerational mentoring program|GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
58079075|NCT04567849|BEHAVIORAL|message|patient portal message
58079076|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
58079077|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
58079078|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
58079079|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
58079080|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
58079081|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
58079082|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
58079083|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
58079084|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
58409503|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
58079085|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
58079086|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
58079087|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
58079088|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
58079089|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
58409504|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
58409505|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
58409506|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
58409507|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
58409508|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
58079090|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
58079091|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
58079092|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
58079093|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
58409509|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
57945153|NCT01972620|DRUG|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
58079094|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
58079095|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
58079096|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
58079097|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
58079098|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
58079099|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
58079100|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
58079101|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
58079102|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
58079103|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
58079104|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58079105|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58079106|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58079107|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
58079108|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
58079109|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
58079110|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
58079111|NCT02191033|BEHAVIORAL|Smoking counseling|
58079112|NCT02191033|BEHAVIORAL|Text messaging|
58079113|NCT02191033|DRUG|Nicotine patch|
58079114|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
58079115|NCT00031902|BIOLOGICAL|bleomycin sulfate|
58079116|NCT00031902|BIOLOGICAL|rituximab|
58079117|NCT00031902|DRUG|prednisolone|
58079118|NCT00031902|DRUG|vincristine sulfate|
57945154|NCT05878457|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
58079119|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
58079120|NCT06502002|DRUG|Placebo|normal saline infusion
58079121|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
58079122|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
58079123|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
58079124|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
58079125|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
58079126|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
58409510|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
58409511|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
58409512|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
58409513|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
58409514|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
57945155|NCT02286414|DRUG|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
57945156|NCT02286414|DRUG|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
57945157|NCT03693625|DRUG|GDC-0853|Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
57945158|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
57945159|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
57945160|NCT00333398|BIOLOGICAL|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
57945161|NCT02776189|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
58079127|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
58079128|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
58079129|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
58079130|NCT00058097|DRUG|tipifarnib|Given orally
58079131|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
58079132|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
58079133|NCT02208518|DEVICE|EUS-elastography|
58298138|NCT04797507|DRUG|SHR-1210 plus Anlotinib|SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
57945162|NCT02776189|DRUG|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
58409515|NCT02241057|OTHER|Temperature Probe|
58409516|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
58409517|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
58409518|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
58409519|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
58409520|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
58409521|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
58079134|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
58079135|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
58298139|NCT03627793|OTHER|resistance training|Moving muscles against loads with the purpose of increasing strength.
58298140|NCT04420728|COMBINATION_PRODUCT|Early auto-mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
58298141|NCT04420728|COMBINATION_PRODUCT|Delayed auto mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
58409522|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
58409523|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
58409524|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
58409525|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
58409526|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
58409527|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
58409528|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
58409529|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
57945163|NCT02776189|DRUG|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
57945164|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
57945165|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
57945166|NCT03919279|DEVICE|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
57945167|NCT01708070|BEHAVIORAL|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
58079136|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
58298142|NCT06499194|OTHER|DASH diet|The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
58298143|NCT03566095|BEHAVIORAL|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
58298144|NCT03566095|BEHAVIORAL|Voices for Food Kit|Voices for Food Kit
58298145|NCT01796028|DRUG|METFORMIN|
58409530|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
58409531|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
58409532|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
58409533|NCT02521233|DRUG|losartan+hydrochlorothiazide|
58409534|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
58409535|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
58409536|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
58409537|NCT00589056|DRUG|cisplatin|
58409538|NCT00589056|DRUG|etoposide|
58409539|NCT00589056|DRUG|nelfinavir mesylate|
58409540|NCT00589056|GENETIC|protein expression analysis|
57945168|NCT00250250|DRUG|ZOMACTON|
57945169|NCT06042400|BEHAVIORAL|Written Exposure Therapy|An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
58079137|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
58079138|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
58079139|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
58079140|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
58298146|NCT01796028|DRUG|Placebo|
58298147|NCT01796028|DRUG|TAXOTERE®|
58298148|NCT04035824|DRUG|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
58409541|NCT00589056|OTHER|immunohistochemistry staining method|
58409542|NCT00589056|OTHER|laboratory biomarker analysis|
58409543|NCT00589056|PROCEDURE|biopsy|
57945170|NCT03196076|DRUG|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
57945171|NCT03471975|PROCEDURE|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
57945172|NCT03471975|PROCEDURE|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
58298149|NCT04035824|DRUG|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
58298150|NCT03983954|COMBINATION_PRODUCT|Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion.~NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days."
58298151|NCT03983954|COMBINATION_PRODUCT|Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)|NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
57945173|NCT03108547|OTHER|Determination of scalp hair steroids|
58298152|NCT02380365|DEVICE|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
58298153|NCT01463787|PROCEDURE|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
58298154|NCT01463787|PROCEDURE|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
58298155|NCT02246738|OTHER|Blood Collection|
57945174|NCT00992940|PROCEDURE|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
58079141|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
58298156|NCT02216383|DRUG|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
58298157|NCT02216383|DRUG|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
58298158|NCT02216383|DRUG|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
58079142|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
58079143|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
58079144|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
58298159|NCT05668897|DRUG|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
58298160|NCT05668897|DRUG|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
58298161|NCT02821429|OTHER|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
57945175|NCT00992940|PROCEDURE|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
57945176|NCT04879667|PROCEDURE|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
57945177|NCT04831489|RADIATION|Imaging|pre and postoperative CT scan of lung
57945178|NCT06042777|BEHAVIORAL|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
58079145|NCT06101940|DIAGNOSTIC_TEST|Brain MRI scan|Normal brain MRI scan to evaluate the integrity of the nervous system
58079146|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
58079147|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
58298162|NCT01844037|DEVICE|OneShot Ablation System|Renal denervation
58298163|NCT03708445|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases"
58409544|NCT00589056|RADIATION|radiation therapy|
58298164|NCT01055015|DRUG|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
58298165|NCT01055015|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
58298166|NCT03660748|BIOLOGICAL|MET-2|Ingestion of a novel human microbiome preparation
58409545|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
57945179|NCT00873340|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
58298167|NCT05430425|OTHER|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
58298168|NCT00500448|DEVICE|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
57731821|NCT03188939|PROCEDURE|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
57731822|NCT04667117|BIOLOGICAL|Quadrivalent influenza vaccine|2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
57945180|NCT05738473|DRUG|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
58079148|NCT00021554|DRUG|Enfuvirtide|
58298169|NCT06324877|DRUG|Nicotinamide riboside|Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
58079149|NCT00001422|DRUG|fludarabine|
58298170|NCT03507855|OTHER|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
58298171|NCT03507855|OTHER|Normal|No change in the normal operating room environment.
58079150|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
58079151|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
58079152|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
58298172|NCT00299065|DRUG|Zileuton injection|
58298173|NCT00508950|PROCEDURE|Large volume blood draw|Large volume blood draw
58298174|NCT03007303|DRUG|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
58409546|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
58409547|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
58409548|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
58079153|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
58079154|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
58298175|NCT03007303|OTHER|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
58298176|NCT05914350|PROCEDURE|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
58298177|NCT05914350|DRUG|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
58298178|NCT05914350|DRUG|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
58298179|NCT05914350|DRUG|medical ozone|10 ml of medical ozone
58298180|NCT04656613|BIOLOGICAL|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
58298181|NCT04656613|OTHER|placebo|Placebo Comparator
57945181|NCT02997735|BEHAVIORAL|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
58079155|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
58079156|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
58298182|NCT05591157|DEVICE|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
58298183|NCT02529930|BIOLOGICAL|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
58298184|NCT03740763|DEVICE|Spinal Cord Stimulation (SCS)|SCS for treatment of neuropathic pain
58298185|NCT03740763|OTHER|Physiotherapy|Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
58298186|NCT05121610|PROCEDURE|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
58298187|NCT04504110|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
58298188|NCT04575220|OTHER|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
57945182|NCT01063075|DRUG|Cetuximab|Administered Intravenously
57945183|NCT01063075|DRUG|Carboplatin|Administered Intravenously
57945184|NCT01063075|DRUG|5 - FU|Administered Intravenously
58079157|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
58298189|NCT00483535|DRUG|GW273225|GW273225 will be available as 25 milligram tablets.
57945185|NCT02616549|BEHAVIORAL|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
58298190|NCT00483535|DRUG|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
58298191|NCT05756881|OTHER|Cosmetic product|Apply on the face twice a day
58298192|NCT02975180|DEVICE|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
58298193|NCT02975180|BEHAVIORAL|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
58298194|NCT04851132|RADIATION|Radiotherapy|IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.
57945186|NCT02292030|DRUG|HTEA|usually high thoracic epidural anesthesia
57945187|NCT04342754|DEVICE|Deep Brain Stimulation (DBS)|The device will be ON
57945188|NCT04342754|DEVICE|Sham Stimulation|The device will be OFF
57945189|NCT00150826|DRUG|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
57945190|NCT00150826|DRUG|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
57945191|NCT01439555|DRUG|Simvastatin|Simvastatin, 40 mg per day orally
57945192|NCT01439555|DRUG|L-Arginine|L-Arginine, 2 Gm four times per day orally;
57945193|NCT01439555|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
57945194|NCT03044938|DRUG|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
58079158|NCT01953380|BEHAVIORAL|extended information|
58079159|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
57945195|NCT03044938|DRUG|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
58079160|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
58079161|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
58079162|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
57945196|NCT01128127|BEHAVIORAL|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
58079163|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
58079164|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
58079165|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
58079166|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
58298195|NCT04851132|DRUG|Durvalumab|Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
58298196|NCT06102317|OTHER|nursing consultancy with smartphone support|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
58298197|NCT02050334|DRUG|CC100|CC100 reconstituted in diluent
58298198|NCT02050334|DRUG|Placebo|Diluent. Amount to match CC100 dose.
57945197|NCT01128127|BEHAVIORAL|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
58409549|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
58079167|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
58079168|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
58079169|NCT00544570|BIOLOGICAL|filgrastim|
58079170|NCT00544570|DRUG|carmustine|
58079171|NCT00544570|DRUG|cyclophosphamide|
58079172|NCT00544570|DRUG|etoposide|
58298199|NCT01839747|PROCEDURE|PET-MRI|Imaging
58298200|NCT01839747|PROCEDURE|PET-CT|Imaging
58079173|NCT00544570|DRUG|melphalan|
58298201|NCT05200273|DRUG|AK114|AK114 administered by subcutaneous injection
58079174|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
58079175|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
58079176|NCT00544570|RADIATION|radiation therapy|
58079177|NCT00544570|RADIATION|total-body irradiation|
58079178|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
58409550|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
58409551|NCT00232388|PROCEDURE|Blood draw|
58409552|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
58079179|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
58079180|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
58409553|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
58409554|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
58409555|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
58409556|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
58409557|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
57945198|NCT01128127|BEHAVIORAL|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
57945199|NCT00733148|DRUG|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
57945200|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
57945201|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
57945202|NCT04943575|DIETARY_SUPPLEMENT|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
57945203|NCT00631020|BEHAVIORAL|CBME|6 weeks of once a week one-on-one CBME
57945204|NCT00631020|DRUG|Optional NRT|NicoDerm CQ nicotine transdermal patch
57945205|NCT02527369|DEVICE|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
57945206|NCT02055651|BEHAVIORAL|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
57945207|NCT06265675|DRUG|Phenol|Chemical neurolysis
57945208|NCT06265675|DRUG|Celestone|Chemical neurolysis with corticosteroid
58079181|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
58079182|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
58079183|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
58079184|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
58298202|NCT02214030|DEVICE|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
58298203|NCT02575417|BEHAVIORAL|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
58298204|NCT00975377|PROCEDURE|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
58298205|NCT03925142|OTHER|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
57945209|NCT06265675|DRUG|Lidocain|Chemical neurolysis with local anesthetic
57945210|NCT04586543|DRUG|Selegiline|10 mg selegiline tablet per day
57945211|NCT04586543|DRUG|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
57945212|NCT01792921|BEHAVIORAL|COG - FUN|
57945213|NCT04918277|DEVICE|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
57945214|NCT02533063|DEVICE|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
57945215|NCT01147328|OTHER|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
57945216|NCT00483301|DRUG|Sorafenib (BAY 43-9006)|dosage
57945217|NCT00483301|DRUG|ABI-007(Abraxane)|dosage
58298206|NCT03925142|OTHER|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
57945218|NCT05726799|PROCEDURE|Cryo myectomy|Extended septal myecotmy using cryo energy
57945219|NCT05726799|PROCEDURE|Myectomy|Classic surgical myectomy
57945220|NCT02571296|DRUG|micronized progesterone|Oral
57945221|NCT02571296|DRUG|Placebo|Oral
57945222|NCT02221531|DRUG|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
57945223|NCT02221531|DRUG|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
57945224|NCT06310681|BEHAVIORAL|"Encompass group programme"|"* Groups will take place over ten modules~* They will take place in-person at a local community venue~* The groups will be two hours long, with a break for refreshments in the middle. They will take place every fortnight in term-time only over approximately 6 months.~* The groups predominantly follow a participatory learning approach and although the facilitators have manuals, the activities tend to include some imparting of information, key points for discussion, examples from other settings and activities for the group to practice.~* They are run by two facilitators - one parent with lived experience and one healthcare professional"
57945225|NCT04160455|BIOLOGICAL|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
57945226|NCT05786079|BEHAVIORAL|Footstrike modification|
57945227|NCT05786079|BEHAVIORAL|Control|
57945228|NCT06490588|OTHER|sevoflurane|No intervention
57945229|NCT06052163|DRUG|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
58079185|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
58079186|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
58079187|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
58409558|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
58079188|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
57945230|NCT06052163|DRUG|Placebo|A placebo has no active properties and is taken orally.
57945231|NCT05699889|OTHER|Data collection|acute kidney injury and tubular dysfunction
58079189|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
58079190|NCT02129257|DRUG|AFLIBERCEPT|
58079191|NCT02129257|DRUG|Irinotecan|
58079192|NCT02129257|DRUG|5-Fluorouracil|
58298207|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
58298208|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
58298209|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
58409559|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
57945232|NCT01786200|DRUG|Aspirin|
57945233|NCT01786200|DRUG|Ibuprofen|
57945234|NCT06243874|PROCEDURE|greater occipital nerve block|greater occipital nerve block
58079193|NCT02129257|DRUG|Folinic Acid|
58079194|NCT00274573|DRUG|Tiotropium bromide|
58079195|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
58079196|NCT00389766|DRUG|topotecan hydrochloride|
58079197|NCT00389766|PROCEDURE|chemotherapy|
58079198|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
58409560|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
58409561|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
58409562|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
58409563|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
58409564|NCT02280824|DEVICE|Amplatzer Duct Occluder|
58298210|NCT06305975|PROCEDURE|Blunt fascial abdominal entry|Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
58409565|NCT04920721|OTHER|no intervention|no intervention descriptiv study
58409566|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
58409567|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
58409568|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
57731823|NCT04667117|DRUG|Ofatumumab|"Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab."
57731824|NCT04667117|DRUG|iDMT|Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
57731825|NCT03790176|DRUG|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
58298211|NCT06305975|PROCEDURE|Veress needle abdominal entry|Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
58298212|NCT00676403|DRUG|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
58298213|NCT00676403|DRUG|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
58409569|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
57731826|NCT00000893|DRUG|Nelfinavir mesylate|
58298214|NCT00676403|DRUG|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
58298215|NCT00676403|DRUG|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
58298216|NCT00676403|DRUG|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
58298217|NCT00676403|DRUG|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
58298218|NCT01825200|BIOLOGICAL|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
58409570|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
58409571|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
58409572|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
58409573|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
58409574|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
57731827|NCT00000893|DRUG|Efavirenz|
57945235|NCT06243874|PROCEDURE|transnasal sphenopalatine ganglion block|transnasal sphenopalatine ganglion block
57945236|NCT03955302|BEHAVIORAL|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
58298219|NCT01825200|BIOLOGICAL|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
58298220|NCT00510614|DRUG|tinidazole|1 gram twice weekly for 12 weeks
58409575|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
58409576|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
58409577|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
58079199|NCT00389766|PROCEDURE|radioisotope therapy|
58409578|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
58409579|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
58409580|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
58409581|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
58409582|NCT01230515|OTHER|interview, focus group and structured survey|
58409583|NCT01230515|OTHER|interview, focus group and structured survey|
58409584|NCT01230515|OTHER|interview, focus group and structured survey|
58409585|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
58409586|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
58409587|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
58409588|NCT00267605|BEHAVIORAL|ADHD Standard Care|
58409589|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
58409590|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
58409591|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
57731828|NCT04667455|DIAGNOSTIC_TEST|Biomarker analysis at enrolment|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
57945237|NCT02691975|DRUG|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
57945238|NCT00625469|DRUG|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
58079200|NCT00389766|PROCEDURE|radionuclide imaging|
58079201|NCT00389766|PROCEDURE|radiosensitization|
58079202|NCT00389766|PROCEDURE|total-body irradiation|
58079203|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
58079204|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
58079205|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
58079206|NCT00240331|DRUG|10mg Rosuvastatin|
58079207|NCT00240331|DRUG|Placebo|
58298221|NCT00510614|DRUG|Placebo|one pill twice weekly for 12 weeks
58298222|NCT01001910|DRUG|Carboplatin|Given IV
58298223|NCT01001910|OTHER|Laboratory Biomarker Analysis|Correlative studies
58298224|NCT01001910|DRUG|Pemetrexed Disodium|Given IV
58298225|NCT01877161|DEVICE|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
58298226|NCT01877161|DEVICE|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
58298227|NCT01877161|DEVICE|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
58409592|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
57731829|NCT04667455|DIAGNOSTIC_TEST|Biomarker analyses throughout the study|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
57945239|NCT00711620|DRUG|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
57945240|NCT00039585|DRUG|imatinib mesylate|
57945241|NCT03333720|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
57945242|NCT04162964|BEHAVIORAL|Chair Yoga|8-week dyadic chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead by a certified instructor and will include 4-10 participants (or 2-5 patient-caregiver dyads).
57945243|NCT00530270|DRUG|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
57945244|NCT00530270|DRUG|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
57945245|NCT01169298|DRUG|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
57945246|NCT06277895|DIAGNOSTIC_TEST|VOCs|test the end-expiratory gas
57945247|NCT01125150|DRUG|Metformin|Dosage to be determined by Endocrinologist
57945248|NCT01125150|BEHAVIORAL|Dietary Modification|To be determined by Endocrinologist
58298228|NCT00142649|BEHAVIORAL|diet|
57945249|NCT03234244|DRUG|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
57945250|NCT03234244|DRUG|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
57945251|NCT03234244|DRUG|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
57945252|NCT04646096|DEVICE|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
57945253|NCT01934686|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
57945254|NCT02446314|DIETARY_SUPPLEMENT|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
57945255|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
57945256|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
57945257|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
57945258|NCT01473238|OTHER|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
57945259|NCT02440360|BEHAVIORAL|PSH|Please see arm description.
58298229|NCT00142649|BEHAVIORAL|physical activity|
58298230|NCT05208333|DRUG|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
58409593|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
58409594|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
58079208|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
57945260|NCT02440360|BEHAVIORAL|Usual Care|Please see arm description.
58079209|NCT02147015|DRUG|Glucocorticoids|
58079210|NCT02147015|DRUG|Antibiotics|
58079211|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
58079212|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
58079213|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
58079214|NCT02147015|OTHER|Physical treatments|
58079215|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
58079216|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
58079217|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
58079218|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
58079219|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
58079220|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
58079221|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
58079222|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
58079223|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
58079224|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
57945261|NCT02777268|DRUG|Infacort|Multi-particulate granules
57945262|NCT02777268|DRUG|Hydrocortisone|Tablet
58079225|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
58079226|NCT04056650|DRUG|L-theanine|up to 250 mg
58079227|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
58409595|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
58079228|NCT04056650|DEVICE|N1 app|N1 App on mobile device
58079229|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
58079230|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
58298231|NCT04565548|OTHER|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
58298232|NCT04565548|OTHER|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
58298233|NCT00002223|DRUG|Indinavir sulfate|
58298234|NCT00002223|DRUG|Ritonavir|
58298235|NCT04474964|RADIATION|Low dose Craniospinal Irradiation plus Focal Radiotherapy|The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
58298236|NCT03546712|OTHER|Tactile Localization|tactile localization is help to assess touch sensation
58409596|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
57731830|NCT04635722|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
58298237|NCT04243629|DRUG|Rapid-Acting Insulin|Novorapid or Humalog insulin delivered in a basal-bolus manner.
58298238|NCT04243629|DRUG|Placebo|Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
58298239|NCT04243629|DRUG|Pramlintide Acetate|Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
58298240|NCT04243629|DEVICE|Artificial Pancreas|Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
57731831|NCT04294810|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
58298241|NCT02590055|DRUG|gemcitabine/docetaxel combination|
58298242|NCT01105520|PROCEDURE|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
58298243|NCT03040167|PROCEDURE|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
58298244|NCT03040167|DRUG|Bupivacaine with epinephrine|Treatment group
58298245|NCT03040167|DRUG|Normal saline|Placebo group
58298246|NCT05592938|RADIATION|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
58298247|NCT04009265|COMBINATION_PRODUCT|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
58298248|NCT05399199|PROCEDURE|virtual reality distraction|study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
58298249|NCT02539017|DRUG|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
58409597|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
58409598|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
58409599|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
58409600|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
57945263|NCT06335095|OTHER|Kinematic sensors|Comparative analysis of kinematic data acquired in supervised and unsupervised environment
58409601|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
58409602|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
58409603|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
58409604|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
58409605|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
58409606|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
58409607|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
58409608|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
58409609|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
57945264|NCT05687968|BEHAVIORAL|"3D/AR MetaFood  nutrition education, and receive instant feedback from the nutritionists or AI after recording their dietary food image."|"The participants record diet images by using Taiwan FoodAPP and receive instant feedback from the nutritionists or AI after recording their dietary food image. The dietitian will use 3D/AR MetaFood food nutrition education platform to do nutrition education for patients."
57945265|NCT05687968|BEHAVIORAL|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
57945266|NCT01498198|PROCEDURE|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
58079231|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
58409610|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
58409611|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
58409612|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
58409613|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
58409614|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
58409615|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
58409616|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
57945267|NCT01498198|OTHER|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
57945268|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
57945269|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
57945270|NCT00003281|DRUG|paclitaxel|
57945271|NCT00003281|DRUG|topotecan hydrochloride|
57945272|NCT00003281|RADIATION|radiation therapy|
58079232|NCT06323655|DRUG|Tasimelteon|oral capsule
58079233|NCT06323655|DRUG|Active Control Placebo|oral capsule
58079234|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
58079235|NCT06323655|DRUG|Active Control|oral capsule
58079236|NCT03315780|DRUG|Dulaglutide|Administered SC
58079237|NCT03315780|DRUG|Placebo|Administered SC
57945273|NCT03707548|BEHAVIORAL|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
57945274|NCT03707548|BEHAVIORAL|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
57945275|NCT03707548|BEHAVIORAL|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
57945276|NCT05851742|DEVICE|TENS|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
57945277|NCT05851742|OTHER|Myofascial trigger point release|Release of trigger points
57945278|NCT00478582|PROCEDURE|Estimation of Hb concentrations with the HemoHue card|
57945279|NCT05004636|DRUG|Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
57945280|NCT06219265|BEHAVIORAL|Dance Therapy|"A single-centre prospective randomised controlled trial will be conducted with a minimum of 48 patients with severe mental disorder (SMD) who will be randomised into two groups, 1 intervention group receiving dance therapy (n=24) and 1 control group receiving no intervention or treatment (n=24).~In addition, there will be an intervention group of healthy people who will receive dance therapy (n=20).~All the tests, will be carried out with patients with SMD and only the EEG for healthy people, in order to determine their baseline state. The dance therapy program will last for 20 sessions over 10 weeks.~The 44 people in the two experimental groups will participate in a 10-week intervention program with 2 sessions per week in which they will work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.~The 24 people in the control group will not receive any type of intervention."
57945281|NCT03672409|BEHAVIORAL|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
57945282|NCT04405115|BEHAVIORAL|Geriatric Assessment|Geriatric Assessment Visit
58298250|NCT02539017|BIOLOGICAL|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
58298251|NCT03255356|OTHER|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
58409617|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
57945283|NCT02781909|DRUG|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
58409618|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
57945284|NCT02781909|DRUG|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
58079238|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
58079239|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
58079240|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
58079241|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
58079242|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
58298252|NCT03618446|OTHER|The presence of a pelvic fracture|
58298253|NCT06086379|BEHAVIORAL|Compensatory Cognitive Training for COVID-19|CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
58298254|NCT06086379|BEHAVIORAL|Holistic Cognitive Education|HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
58079243|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
58298255|NCT03852589|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
58298256|NCT03852589|DEVICE|Blind|PLMA will inserted by anesthesiologist with digital finger.
58298257|NCT05577728|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
57731832|NCT04294810|DRUG|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
57731833|NCT04294810|DRUG|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
57731834|NCT05867446|BEHAVIORAL|pecha kucha|pecha kucha training
58079244|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
58079245|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
58079246|NCT04173520|DRUG|DDA|Follow up after SVR
58079247|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
58298258|NCT05577728|DRUG|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
58298259|NCT02373150|DRUG|Imeglimin|
58298260|NCT02373150|DRUG|Placebo|
58298261|NCT02185417|DRUG|Hydrochlorothiazide (HCTZ)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
58298262|NCT02185417|DRUG|Chlorthalidone (CTD)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
58409619|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
58409620|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
58079248|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
58409621|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
57731835|NCT06205524|BIOLOGICAL|TI-0010|Sterile liquid for injection
57731836|NCT06205524|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58298263|NCT05007119|PROCEDURE|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
58298264|NCT05007119|PROCEDURE|Cupping|Cupping with blood letting
57731837|NCT01834417|DEVICE|TexiMat|
57731838|NCT01289912|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
58298265|NCT04206345|OTHER|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
58298266|NCT04206345|OTHER|exercise|Elbow bending exercises
58298267|NCT02104895|RADIATION|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
58298268|NCT02104895|RADIATION|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
58409622|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
58409623|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
58079249|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
57945285|NCT03853239|PROCEDURE|face mask ventilation crossover nasal ventilation|Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.
58079250|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
58079251|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
58079252|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
58409624|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
58409625|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
57945286|NCT03853239|PROCEDURE|nasal ventilation crossover face mask ventilation|Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
57945287|NCT00986544|PROCEDURE|no drain|drain positioned on the skin
57945288|NCT00986544|PROCEDURE|drain positioned|drain positioned in the subhepatic space
58079253|NCT00591552|DEVICE|Electrocautery|
58079254|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
58079255|NCT02651246|OTHER|data collection|
58079256|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
58079257|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
58079258|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
58079259|NCT02219477|DRUG|dasabuvir|tablet
58079260|NCT02219477|DRUG|ribavirin|tablet
58079261|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
57945289|NCT00986544|PROCEDURE|drain not positioned|Drain positioned in the abdominal wall
58079262|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
58079263|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
58079264|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
58409626|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
58409627|NCT00793429|DRUG|Prucalopride|
58409628|NCT00793429|OTHER|Placebo|
58409629|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
57731839|NCT01289912|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
57731840|NCT01636882|BIOLOGICAL|CVA21|
57731841|NCT04412395|DIETARY_SUPPLEMENT|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
57731842|NCT04412395|DRUG|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
57731843|NCT02116465|DRUG|Levodopa Carbidopa immediate release tablets|oral administration
57731844|NCT02579642|DRUG|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
57731845|NCT02579642|DRUG|Placebo|Normal saline administered with usual induction drugs for ECT
57731846|NCT04481048|DRUG|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
57945290|NCT03540784|OTHER|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
57945291|NCT03540784|OTHER|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
57945292|NCT00481286|BEHAVIORAL|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
57945293|NCT00481286|BEHAVIORAL|Standard of Care|Standard of care for diabetes patients
57945294|NCT05780775|OTHER|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
57945295|NCT01737918|PROCEDURE|TOT|
57945296|NCT01737918|DRUG|solifenacin|
57945297|NCT01390766|DRUG|Azathioprine|
57945298|NCT06032780|OTHER|Eccentric Resistive Training + Aerobic training Group|"Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
57945299|NCT06032780|OTHER|Resistance Training + Aerobic training Group|"Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
58079265|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
58079266|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
58409630|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
58409631|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
58409632|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
58409633|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
57731847|NCT04481048|OTHER|Placebo|Eight (8) weeks of treatment with placebo.
57731848|NCT00380068|DRUG|Ambrisentan|Oral tablets taken once daily.
58079267|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
58079268|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
58079269|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
58079270|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
58079271|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
58079272|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
58079273|NCT04731740|DRUG|Lenvatinib|PO
58079274|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
58079275|NCT04731740|DRUG|Chemotherapy|Investigators' choice
58079276|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
58079277|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
58079278|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
58079279|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
57731849|NCT00033254|RADIATION|radiation therapy|Undergo conventional radiation therapy
58079280|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
58079281|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
58079282|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
58079283|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
57945300|NCT06032780|OTHER|Aerobic training Group|Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
57945301|NCT04808570|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
57945302|NCT00012779|BEHAVIORAL|Health Education Program|
58079284|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
58079285|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
58079286|NCT06091826|DRUG|NFL-101|Subcutaneous injections
58079287|NCT06091826|DRUG|Placebo|Subcutaneous injections
58079288|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
57731850|NCT00033254|DRUG|thalidomide|Given orally
58079289|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
58298269|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
58298270|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
58298271|NCT01425736|DRUG|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
58298272|NCT01425736|DRUG|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
57731851|NCT00033254|PROCEDURE|quality-of-life assessment|Ancillary studies
57945303|NCT03215771|DEVICE|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
58298273|NCT02436863|PROCEDURE|Surgical performance|Two different surgical performances
58409634|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
58298274|NCT04845997|BIOLOGICAL|COVID-19 Vaccine|Patients with rheumatic diseases who have been vaccinated for COVID-19
57731852|NCT03263377|DIETARY_SUPPLEMENT|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
57731853|NCT04601155|DEVICE|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
57731854|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
57731855|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
57731856|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
57731857|NCT01761435|BIOLOGICAL|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
57731858|NCT00620477|DRUG|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
58298275|NCT03166020|OTHER|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
58298276|NCT06223295|PROCEDURE|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
57731859|NCT00620477|DRUG|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
58298277|NCT06223295|PROCEDURE|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
58298278|NCT00763360|DEVICE|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
58298279|NCT00763360|DRUG|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
58298280|NCT00763360|DRUG|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
58298281|NCT03041389|BEHAVIORAL|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
58298282|NCT03041389|BEHAVIORAL|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
58298283|NCT05056961|OTHER|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
58298284|NCT02490774|DRUG|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
58298285|NCT02490774|DRUG|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
58298286|NCT02490774|DRUG|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
58298287|NCT01023607|DRUG|Atorvastatin|Atorvastatin 20mg/day
58298288|NCT01023607|DRUG|Atorvastatin|Atorvastatin, 60mg/day
58298289|NCT01023607|DRUG|Rosuvastatin|Rosuvastatin,10mg/day
58298290|NCT01783743|OTHER|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
58298291|NCT01048541|DEVICE|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
58298292|NCT01048541|DEVICE|SpeediCath|Catheter for intermittent catheterisation
58298293|NCT00732927|DRUG|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
58298294|NCT00732927|DRUG|aspirin|tablets, 100 mg for 3 months
58298295|NCT05013216|DRUG|Cohort A: Patients at high risk of developing pancreatic cancer.|"1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
58298296|NCT05013216|DRUG|Cohort B: Patients must have evidence of a pancreatic cystic neoplasm|Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
58409635|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
58409636|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
58298297|NCT06522815|DEVICE|CART-I plus|"CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method."
58409637|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
57731860|NCT03914157|DEVICE|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
57731861|NCT00823082|DRUG|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
57945304|NCT03215771|OTHER|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
57945305|NCT00677820|BIOLOGICAL|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
57945306|NCT00677820|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
57945307|NCT01071538|DRUG|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
57945308|NCT02484976|BEHAVIORAL|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
57945309|NCT00839670|OTHER|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
57945310|NCT00839670|OTHER|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
58298298|NCT06522815|DEVICE|Polysomnography|"In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring"
58298299|NCT04438408|OTHER|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
58298300|NCT04178304|DRUG|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
58298301|NCT03345381|OTHER|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
58298302|NCT03345381|OTHER|Usual care|Treatment as usual
58409638|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
58409639|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
57945311|NCT06090370|DEVICE|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
58409640|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
58409641|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
58409642|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
58409643|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
58409644|NCT00416156|BEHAVIORAL|Lifestyle modification|
57731862|NCT02953626|BEHAVIORAL|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
57945312|NCT06090370|DEVICE|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
57945313|NCT06090370|OTHER|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
57945314|NCT06090370|OTHER|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
58298303|NCT03936088|DEVICE|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
58298304|NCT03936088|DEVICE|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
58409645|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
58298305|NCT01824888|DRUG|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
58298306|NCT01824888|DRUG|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
58409646|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
58409647|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
58409648|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
58298307|NCT00607776|DRUG|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
58298308|NCT00607776|DRUG|Systane|Drops
58298309|NCT03202420|OTHER|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
58298310|NCT04564001|DRUG|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
58298311|NCT04564001|DRUG|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
58298312|NCT00001989|DRUG|Trichosanthin|
58298313|NCT00001989|DRUG|Zidovudine|
58409649|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
58409650|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
58409651|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
58409652|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
58409653|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
57945315|NCT06090370|OTHER|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
57945316|NCT00971165|DRUG|losartan|Oral losartan up to 100 mg daily fo 18 months
57945317|NCT00971165|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
57945318|NCT01446406|DEVICE|MONARCA|Monitoring affective symptoms entered by the patient every day.
57945319|NCT01446406|DEVICE|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
57945320|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
57945321|NCT04305522|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
57945322|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
57945323|NCT01370720|DIETARY_SUPPLEMENT|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
57945324|NCT01370720|OTHER|Placebo|tablets, 2tablets/day, 12 weeks
58298314|NCT05554497|BEHAVIORAL|Mindfulness-based stress reduction curriculum|Standard 8-week mindfulness-based stress reduction curriculum
57945325|NCT05514379|BEHAVIORAL|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
57945326|NCT00808795|DRUG|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
57945327|NCT00808795|DRUG|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
57945328|NCT00772486|BIOLOGICAL|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
58298315|NCT06047639|DEVICE|Bone-anchored hearing implants|surgically placed hearing device
58298316|NCT00973258|DIETARY_SUPPLEMENT|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
57945329|NCT01758796|PROCEDURE|Non-operative treatment|Below-the-knee cast for six weeks.
57945330|NCT01758796|PROCEDURE|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
57945331|NCT03151720|DRUG|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
57945332|NCT03151720|DRUG|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
57945333|NCT02122198|DRUG|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
57945334|NCT02122198|DRUG|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
58298317|NCT00973258|OTHER|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
58079290|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
58079291|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
58079292|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
58079293|NCT01934101|DRUG|CHR-5154|CHR-5154
58079294|NCT01934101|DRUG|Placebo|Placebo
58298318|NCT00973258|OTHER|Cognitive Training|"The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
58079295|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
58298319|NCT00973258|OTHER|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
58079296|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
58079297|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
58079298|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
58079299|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
58079300|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
58079301|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
58079302|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
58298320|NCT00973258|OTHER|Placebo|Participants will receive their usual diet and placeboes.
58298321|NCT06235112|DEVICE|Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment|The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
57945335|NCT02122198|DRUG|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
57945336|NCT02122198|DRUG|Placebo|placebo
57945337|NCT01481051|DRUG|Latanoprost-PPDS|Sustained delivery for 12 weeks
58079303|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
58298322|NCT03224793|DRUG|BIIB059|Administered as specified in the treatment arm
58298323|NCT03224793|DRUG|Placebo|Administered as specified in the treatment arm
58298324|NCT01045005|OTHER|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
57731863|NCT01006044|BIOLOGICAL|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
57731864|NCT06558318|OTHER|Assessment of temporomandibular dysfunction|TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
57731865|NCT06114823|PROCEDURE|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
57731866|NCT06114823|PROCEDURE|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
57945338|NCT06316700|DIETARY_SUPPLEMENT|Nutritional supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
58079304|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
58079305|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
58079306|NCT00470301|DRUG|tipifarnib|Given orally
58079307|NCT00470301|DRUG|paclitaxel|Given IV
58079308|NCT00470301|DRUG|doxorubicin|Given IV
57731867|NCT05889247|OTHER|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
57731868|NCT06081309|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
57945339|NCT06316700|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
57945340|NCT06389864|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
57945341|NCT02876588|OTHER|Unrestricted|Users may open up to 4 patient records at a time.
57945342|NCT02876588|OTHER|Restricted|Users are restricted to open 1 patient record at a time.
57945343|NCT00162864|DRUG|montelukast sodium|
57945344|NCT01857284|DRUG|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
58079309|NCT00470301|DRUG|cyclophosphamide|Given IV
58409654|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
57945345|NCT01857284|DRUG|Ursodeoxycholic Acid Capsules|250mg.tid.po
58079310|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
58079311|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
58079312|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
58079313|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
58079314|NCT00823875|DRUG|control group|routine treatment
58079315|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
58079316|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
58079317|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
58079318|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
58079319|NCT00270400|DRUG|nesiritide|
58409655|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
58409656|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
58409657|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
58079320|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
58298325|NCT01045005|OTHER|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
58298326|NCT05885451|DRUG|AMG 592|Administered as SC injection
58409658|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
58409659|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
58409660|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
58409661|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
58409662|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
58409663|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
58409664|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
57945346|NCT04207801|DRUG|AUR101|Inhibitor of RORγ
58079321|NCT00752427|DRUG|Paliperidone ER OROS®|
58079322|NCT05665257|DEVICE|Inspiratory muscle training|
58079323|NCT05665257|DEVICE|Mini-PEP|
58079324|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
58409665|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
58409666|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
58079325|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
58298327|NCT05885451|OTHER|Placebo|Administered as SC injection
58298328|NCT01119690|DIETARY_SUPPLEMENT|Cold-pressed turnip rapeseed oil (CTPRO)|"1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
58409667|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
58298329|NCT01119690|DIETARY_SUPPLEMENT|milk fat|"1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.~2. In the 5-hour oral glucose and fat tolerance test: glucose and cream"
58298330|NCT01622933|BIOLOGICAL|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
58409668|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
58409669|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
57731869|NCT02044510|DRUG|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
57731870|NCT02044510|DRUG|Placebo|Matched placebo capsules to the intervention arm
57945347|NCT04207801|DRUG|Matching Placebo|Drug-Placebo of AUR101 tablet
57945348|NCT03936621|DRUG|Omega 3 fatty acid|To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
57945349|NCT04961151|OTHER|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
58079326|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
58079327|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
58079328|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
58079329|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
58079330|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
58079331|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
58409670|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
58409671|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
58409672|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
58409673|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
58409674|NCT00127283|DRUG|eptacog alfa (activated)|
58409675|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
58409676|NCT02177643|DRUG|Placebo|Placebo oral capsules
58409677|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
58409678|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
58409679|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
58409680|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
58409681|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
57945350|NCT04961151|OTHER|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
57731871|NCT05935540|OTHER|ACP-Family|"It consists of two sessions (45-60 mins) to be delivered within one month in a face-to-face format as long as the patient is still in the hospital. The treatment will be continued in the patient's home if he/she is discharged before the two sessions are completed.~The treatment will cover five elements in ACP, namely (1) patients' understanding of their illness, (2) patients' values and beliefs underpinning care preferences, (3) possible health conditions in the future, (4) introducing the idea of AD and its arrangement, and (5) construction of the role of substituted decision maker. A 3-min video on end-of-life treatment options will be shown to help patients and family members to clearly understand the related topic. However, there will be no restriction on the order of the five topics to be discussed during the intervention."
57945351|NCT02698267|DRUG|BIIB074|Administered as specified in the treatment arm
57945352|NCT02698267|DRUG|Itraconazole|200 mg twice daily \[BID\] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
57945353|NCT03837639|OTHER|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
57945354|NCT03837639|OTHER|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
57945355|NCT03837639|OTHER|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
58079332|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
58079333|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
58079334|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
58079335|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
58298331|NCT01622933|BIOLOGICAL|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
58298332|NCT02277327|BEHAVIORAL|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
58298333|NCT02277327|BEHAVIORAL|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
58298334|NCT04428385|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
58298335|NCT04428385|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
58298336|NCT02507492|DRUG|RM-493|
58298337|NCT03698292|DRUG|Itopride|Prokinetic Drug
58298338|NCT03698292|DRUG|Metoclopramide 10mg|Prokinetic Drug
58298339|NCT06397430|DIETARY_SUPPLEMENT|parenteral nutrition supplements|parenteral nutrition
58298340|NCT06397430|DIETARY_SUPPLEMENT|enteral nutrition supplements|enteral nutrition
58298341|NCT06397430|DIETARY_SUPPLEMENT|mixed nutrition supplements|mixed nutrition
58298342|NCT01904890|BEHAVIORAL|CRC Prevention and Screening Education|Refer to Arm Description
57945356|NCT04066491|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
57945357|NCT04066491|DRUG|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
57945358|NCT04066491|DRUG|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
57945359|NCT04066491|DRUG|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
57945360|NCT03702764|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
57945361|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
58079336|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
58079337|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
58079338|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
58079339|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
58079340|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
58079341|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
58298343|NCT01904890|BEHAVIORAL|Nutrition Education|Refer to Arm Description
58298344|NCT03485599|DIAGNOSTIC_TEST|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
58298345|NCT04512807|DIAGNOSTIC_TEST|AMH|AMH \& PREGNANCY
58298346|NCT03902613|DRUG|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
58298347|NCT01982695|DRUG|Losartan|
58298348|NCT01982695|DRUG|Lisinopril|
58298349|NCT00345917|DEVICE|Retinal transplantation instrument|
58298350|NCT00345917|DEVICE|Fetal tissue.|
58298351|NCT03278821|BEHAVIORAL|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
58298352|NCT03278821|BEHAVIORAL|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
57945362|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
57945363|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
58298353|NCT04318704|DRUG|Ifenprodil|Ifenprodil 20 mg TID
58298354|NCT00370617|DRUG|metformin|
58298355|NCT06070090|PROCEDURE|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
58298356|NCT02029131|BEHAVIORAL|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
58298357|NCT05975814|DEVICE|dental implant|dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
58409682|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
57945364|NCT05002270|DRUG|Cetuximab (EGFR inhibitor)|Administered IV
57945365|NCT04821037|BEHAVIORAL|ACT|Acceptance and Commitment Therapy
58079342|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
58409683|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
58409684|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
58409685|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
58409686|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
58409687|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
58298358|NCT05235152|OTHER|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~* Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~* Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~* Individual proprioceptive training."
58298359|NCT05235152|OTHER|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
58409688|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
58409689|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
58409690|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
58409691|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
58409692|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
58409693|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
58409694|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
58409695|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
58409696|NCT02436668|DRUG|Ibrutinib|
57945366|NCT00609986|DRUG|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
58298360|NCT00666302|DRUG|tacrolimus ointment|topical
58298361|NCT00666302|DRUG|pimecrolimus cream|topical
58298362|NCT00902577|DRUG|FMISO|FMISO PET scans
58298363|NCT00902577|OTHER|MRI|Undergo MRI
58298364|NCT00902577|OTHER|PET|Undergo FMISO PET scan
58298365|NCT00902577|OTHER|MRS|
58298366|NCT03557593|OTHER|Educational|Multi component educational intervention in long-term care
58409697|NCT02436668|DRUG|Gemcitabine|
58409698|NCT02436668|DRUG|Nab-paclitaxel|
58298367|NCT04110431|PROCEDURE|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
58409699|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
57731872|NCT04954339|DRUG|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
57731873|NCT01953926|DRUG|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
57731874|NCT01953926|DRUG|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
57731875|NCT01953926|DRUG|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
58298368|NCT04110431|PROCEDURE|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
58409700|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
58409701|NCT00810485|DRUG|ADX10059|oral administration
58409702|NCT00810485|DRUG|ADX10059|oral administration
58079343|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
58298369|NCT05782803|BEHAVIORAL|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
58298370|NCT05670743|DRUG|38% silver diamine fluoride|Topical application of 38% silver diamine fluoride to dental caries lesions
58298371|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
58409703|NCT00810485|DRUG|ADX10059|oral administration
58409704|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
58409705|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
58409706|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
58409707|NCT01287221|DRUG|placebo|placebo
58079344|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
58079345|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
58298372|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
58298373|NCT04528316|BEHAVIORAL|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:"
58298374|NCT04528316|BEHAVIORAL|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
58409708|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
57731876|NCT01953926|DRUG|Paclitaxel|80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
57731877|NCT01764984|DEVICE|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
58079346|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
58079347|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
58079348|NCT05146999|BIOLOGICAL|Placebo|Placebo
58409709|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
58409710|NCT00343369|DRUG|asparaginase|
58409711|NCT00343369|DRUG|cyclophosphamide|
58409712|NCT00343369|DRUG|cytarabine|
58409713|NCT00343369|DRUG|daunorubicin hydrochloride|
58409714|NCT00343369|DRUG|dexamethasone|
58409715|NCT00343369|DRUG|doxorubicin hydrochloride|
58409716|NCT00343369|DRUG|mercaptopurine|
57731878|NCT00158379|DRUG|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
57731879|NCT02522533|OTHER|Physical Therapy|6 weeks of an exercise program.
57731880|NCT05806801|BEHAVIORAL|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
58079349|NCT00139269|DRUG|Docetaxel|
58079350|NCT00139269|DRUG|Cisplatin|
57731881|NCT05806801|BEHAVIORAL|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
57731882|NCT00354705|BEHAVIORAL|Questionnaire|Two questionnaires taking 30 minutes to complete.
58079351|NCT00139269|DRUG|5-Fluorouracil|
58409717|NCT00343369|DRUG|methotrexate|
58409718|NCT00343369|DRUG|pegaspargase|
58409719|NCT00343369|DRUG|prednisolone|
58409720|NCT00343369|DRUG|teniposide|
58409721|NCT00343369|DRUG|thioguanine|
58409722|NCT00343369|DRUG|vincristine sulfate|
58409723|NCT00343369|RADIATION|radiation therapy|
58409724|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
58409725|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
58409726|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
58409727|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
58409728|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
57945367|NCT00609986|DRUG|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
58409729|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
58409730|NCT02825420|DRUG|trabectedin|
58409731|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
58409732|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
58409733|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
58409734|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
58409735|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
58409736|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
58409737|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
58409738|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
58409739|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
58409740|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
58409741|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
57945368|NCT04024033|DIETARY_SUPPLEMENT|pine cone extract|pine cone extract capsule
57945369|NCT04024033|OTHER|placebo|placebo capsule
57945370|NCT03831971|DRUG|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
57945371|NCT04597983|DIETARY_SUPPLEMENT|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
57945372|NCT04597983|DIETARY_SUPPLEMENT|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
57945373|NCT04032600|PROCEDURE|Paracentesis|Full versus partial paracentesis (3 liters)
57945374|NCT05773521|PROCEDURE|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
57945375|NCT04474769|OTHER|Educational intervention for preceptors|
57945376|NCT03924349|DEVICE|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
57945377|NCT05681000|DRUG|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
57731883|NCT04657146|OTHER|Biorepository|"Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)"
58409742|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
57945378|NCT00388700|DRUG|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
58409743|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
57945379|NCT00388700|DRUG|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
57945380|NCT01295528|DEVICE|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
58298375|NCT04528316|BEHAVIORAL|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
58409744|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
58409745|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
57731884|NCT04536636|DRUG|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
58079352|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
58409746|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
58409747|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
58409748|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
58409749|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
58409750|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
58079353|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
58079354|NCT02177370|DRUG|Fenoterol MDI|
58298376|NCT04161235|DEVICE|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
58298377|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
58298378|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
58298379|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
58298380|NCT01686945|DRUG|placebo|Placebo semaglutide. For oral administration.
58298381|NCT01686945|DRUG|placebo|Placebo semaglutide with carrier. For oral administration.
58409751|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
58409752|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
58409753|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
57731885|NCT04536636|DRUG|Control-No drug|Patients received usual medical care with no DHA
57731886|NCT00891566|PROCEDURE|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
57731887|NCT04225208|DRUG|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
58079355|NCT02177370|DRUG|DSCG MDI|
58298382|NCT04213664|OTHER|prognosis|cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
58298383|NCT00319709|DRUG|SR58611A|
58079356|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
58079357|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
58298384|NCT05060575|OTHER|Education and Telephone Counceling|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
57945381|NCT02347098|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
58298385|NCT01122069|OTHER|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
58298386|NCT05865223|OTHER|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
58298387|NCT05865223|OTHER|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
58298388|NCT03119597|DIETARY_SUPPLEMENT|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
58298389|NCT03119597|DIETARY_SUPPLEMENT|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
58298390|NCT00917826|DRUG|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
57945382|NCT02347098|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
57945383|NCT02651584|DRUG|CAM2038 SC injection|
57945384|NCT02651584|DRUG|SL BPN/NX tabs|
58079358|NCT01578109|DRUG|Sorafenib|Given PO
58079359|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
58079360|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
58298391|NCT00917826|DRUG|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
58298392|NCT00917826|DRUG|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
58298393|NCT01754519|PROCEDURE|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
58298394|NCT01754519|RADIATION|Radiation Therapy|Undergo SFRT
58298395|NCT01754519|OTHER|Laboratory Biomarker Analysis|Correlative studies
58298396|NCT01754519|OTHER|Quality-of-Life Assessment|Ancillary studies
58298397|NCT03977012|DRUG|Buprenorphine|5\~20 mcg
58298398|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
58298399|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (The Upjohn Company)|
58298400|NCT03641261|OTHER|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
58298401|NCT05178823|DRUG|Chlorhexidine mouthwash|Comparison of oral rinses
58298402|NCT04375163|OTHER|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
58298403|NCT04375163|OTHER|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
58298404|NCT05293782|OTHER|Kinesitaping|Kinesiotaping - muscle facilitation technique
57945385|NCT02651584|DRUG|placebo SC injections|
57945386|NCT02651584|DRUG|SL placebo tablets|
58079361|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
57945387|NCT02829242|DEVICE|NIRS Monitoring (SenSmart Monitor)|
58079362|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
57945388|NCT05316402|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
57945389|NCT05316402|OTHER|dosimetry|dosimetry
58298405|NCT04022317|BIOLOGICAL|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
58298406|NCT04022317|BIOLOGICAL|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
58298407|NCT04851106|DIAGNOSTIC_TEST|Endoscopic ultrasound|Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
58298408|NCT01681758|OTHER|IV fluid according to PPV|intravenous fluids
58298409|NCT01681758|OTHER|fluids according to standard care|
58409754|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
58079363|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
58298410|NCT03478371|DEVICE|tampon D|regular absorbency tampon
58298411|NCT03478371|DEVICE|tampon M|regular absorbency tampon
58298412|NCT03478371|DEVICE|tampon T|regular absorbency tampon
58409755|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
58409756|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
58409757|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
58409758|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
58298413|NCT03478371|DEVICE|tampon V|regular absorbency tampon
58298414|NCT00103285|RADIATION|3-Dimensional Conformal Radiation Therapy|Some patients undergo cranial radiotherapy
58298415|NCT00103285|DRUG|Cyclophosphamide|Given IV
58298416|NCT00103285|DRUG|Cytarabine|Given IV or SC
58409759|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
58409760|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
58409761|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
58409762|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
58298417|NCT00103285|DRUG|Dexamethasone|Given IV or PO
58409763|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
57945390|NCT04178694|DEVICE|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
57945391|NCT04082403|PROCEDURE|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
57945392|NCT04082403|PROCEDURE|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
58298418|NCT00103285|DRUG|Doxorubicin Hydrochloride|Given IV or IT
58298419|NCT00103285|DRUG|Leucovorin Calcium|Given PO
58298420|NCT00103285|DRUG|Mercaptopurine|Given PO
58298421|NCT00103285|DRUG|Methotrexate|Given IM or IT
58298422|NCT00103285|DRUG|Pegaspargase|Given IM
58298423|NCT00103285|DRUG|Thioguanine|Given PO
58298424|NCT00103285|DRUG|Vincristine Sulfate|Given IV
58298425|NCT00059228|DRUG|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
58298426|NCT00059228|DRUG|Placebos|Placebo skin patch for 6 weeks
58298427|NCT03513016|DRUG|UBX0101|Investigational drug intra-articular injection
58409764|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
58409765|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
58409766|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
58409767|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
58409768|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
58409769|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
58409770|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
58409771|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
58409772|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
58409773|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
58409774|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
57945393|NCT02520687|DIETARY_SUPPLEMENT|Beetroot juice|200mls daily for seven days
57945394|NCT02520687|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|200mls daily for seven days
58298428|NCT03513016|OTHER|Placebo|Diluent intra-articular injection
58079364|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
58079365|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
58298429|NCT01828970|DRUG|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
58298430|NCT04758195|PROCEDURE|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
58298431|NCT04758195|OTHER|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
58298432|NCT05934474|BIOLOGICAL|Peripheral venipuncture blood sampling, as part of standard care procedures|Collection of 36 mL of blood
58298433|NCT05934474|OTHER|Interview with a psychiatrist|Research project data collection
58298434|NCT01716663|DEVICE|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
58298435|NCT02665247|BEHAVIORAL|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
58298436|NCT02665247|OTHER|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
58409775|NCT00085254|DRUG|cilengitide|Given IV
57945395|NCT06075342|BEHAVIORAL|exercise|Exercise intervention according to the training program
57945396|NCT04673292|BEHAVIORAL|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
58079366|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
58079367|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
58079368|NCT00314275|DEVICE|Endeavor|Drug eluting stent
58409776|NCT00085254|DRUG|temozolomide|Given orally
58409777|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
58409778|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
58409779|NCT00085254|OTHER|pharmacological study|Correlative studies
58409780|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
58409781|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
58409782|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
58409783|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
58409784|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
58409785|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
58409786|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
58409787|NCT02100163|OTHER|Standard treatment|
58409788|NCT05523596|DRUG|ICM20|small molecules
58409789|NCT05523596|DRUG|Benznidazole|small molecule
58409790|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
58409791|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
58409792|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
58079369|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
58079370|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
58079371|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
57945397|NCT04673292|BEHAVIORAL|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
57945398|NCT04673292|BEHAVIORAL|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
57945399|NCT04026724|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
57945400|NCT03351920|OTHER|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
58079372|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
58298437|NCT05778474|OTHER|Healthy subjects|"Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~1. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~3. Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section."
58298438|NCT05778474|OTHER|Pathologic group|"Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning."
57945401|NCT01636973|PROCEDURE|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
57945402|NCT02170883|OTHER|Interactive SMS|
58298439|NCT05659147|DIAGNOSTIC_TEST|Research MRI without administration of intravenous secretin|Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
58409793|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
58409794|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
57945403|NCT02170883|OTHER|Usual care|
57731888|NCT01597544|PROCEDURE|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
57731889|NCT06326606|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
57731890|NCT06326606|DRUG|Placebo|Capsule with no active ingredients
58079373|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
58079374|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
58079375|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
58079376|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
58298440|NCT05659147|DIAGNOSTIC_TEST|Research MRI with administration of intravenous secretin|Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
58298441|NCT05659147|GENETIC|Genetic Sequencing|Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
57945404|NCT04468542|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
57945405|NCT04468542|DRUG|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
57945406|NCT00111800|DRUG|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
58079377|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
58079378|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
58079379|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
58079380|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
58079381|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
58079382|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
58079383|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
58298442|NCT05659147|DIAGNOSTIC_TEST|Blood Tests|Research blood draw (for markers of pancreatic endocrine insufficiency)
58298443|NCT05659147|DIAGNOSTIC_TEST|Stool Tests|Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
57731891|NCT04058769|DEVICE|Premedication Guide|Software with guidelines recommendations for preoperative assessment
57945407|NCT00111800|DRUG|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
57945408|NCT00111800|DRUG|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
57945409|NCT00111800|DRUG|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
57945410|NCT00111800|DRUG|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
57945411|NCT00111800|DRUG|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
58079384|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
58079385|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
58079386|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
58079387|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
58079388|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
58079389|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
58079390|NCT02881866|DRUG|Furosemide|
58079391|NCT02881866|DRUG|Saline|
58079392|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
58079393|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
58079394|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
58079395|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
58079396|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
58079397|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
58079398|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
58079399|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
58079400|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
58079401|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
58079402|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
58079403|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
58079404|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
57731892|NCT04465006|OTHER|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
57731893|NCT04465006|OTHER|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
57731894|NCT02684422|OTHER|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
58079405|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
58079406|NCT02391194|DRUG|AVB-620|
58079407|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
58079408|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
58079409|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
58079410|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
57731895|NCT03989804|BEHAVIORAL|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
58079411|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
58079412|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
58079413|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
58079414|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
58079415|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
58079416|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
58079417|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
58298444|NCT05659147|OTHER|Survey Completion|Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
58298445|NCT05659147|DIAGNOSTIC_TEST|Endoscopic pancreatic function tests (ePFTs)|At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
58409795|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
58079418|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
58079419|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
58409796|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
57731896|NCT01792089|OTHER|fat+protein meal|cream+ whey protein
57731897|NCT01792089|OTHER|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
57731898|NCT01792089|OTHER|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
58298446|NCT05659147|DRUG|Secretin|"Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study."
58298447|NCT00037986|DEVICE|Hearing Aids|Hearing aid use
57731899|NCT01792089|OTHER|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
57945412|NCT00883662|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
57731900|NCT01792089|OTHER|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
57731901|NCT00475059|DRUG|cimetidine arrow|patients who received cimétidine
57731902|NCT02511431|DRUG|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
57731903|NCT02511431|DRUG|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
57731904|NCT02511431|OTHER|Placebo|Placebo
57731905|NCT06669793|DEVICE|biolimus-coated balloon|238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.
57731906|NCT06669793|DEVICE|paclitaxel-coated balloon|237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
58079420|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
58079421|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
57731907|NCT03037385|DRUG|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
57731908|NCT01803997|BEHAVIORAL|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
57731909|NCT04579263|OTHER|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
58079422|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
58079423|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
58079424|NCT02116374|OTHER|Physiopathology study|
58298448|NCT02996071|PROCEDURE|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
58298449|NCT02881658|DIETARY_SUPPLEMENT|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
58298450|NCT02881658|DIETARY_SUPPLEMENT|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
58298451|NCT03154580|DRUG|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
58298452|NCT00002935|DRUG|porfimer sodium|
57731910|NCT00492349|DRUG|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
57945413|NCT01306448|DEVICE|Vibrant capsule|vibrating capsule
57945414|NCT00503594|DRUG|Methotrexate and temozolomide|Methotrexate and temozolomide
57945415|NCT00503594|DRUG|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
57945416|NCT01127685|DEVICE|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
58298453|NCT02955953|DRUG|LY2963016|Administered SC
58298454|NCT01464190|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
58298455|NCT01464190|DRUG|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
58298456|NCT02052986|OTHER|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
58409797|NCT04610892|BIOLOGICAL|Placebo|Buffer
57945417|NCT04605302|DEVICE|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
58409798|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
58409799|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
57945418|NCT04605302|DEVICE|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
57945419|NCT06211894|PROCEDURE|transobturator tape|transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
57945420|NCT04107415|OTHER|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
57731911|NCT00492349|DRUG|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
57731912|NCT01689116|DRUG|Bardoxolone Methyl 20mg|Oral
58298457|NCT00608400|DIETARY_SUPPLEMENT|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
58298458|NCT02209363|DEVICE|auto-adjusting positive airway pressure|nightly use for 6 months
58298459|NCT02209363|OTHER|Nasal dilator strips|nightly use for 6 months
58298460|NCT02137941|BEHAVIORAL|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
58409800|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
58409801|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
57945421|NCT03525717|DIETARY_SUPPLEMENT|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
57945422|NCT03525717|DIETARY_SUPPLEMENT|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
57945423|NCT00843388|DRUG|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
58298461|NCT02137941|BEHAVIORAL|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
58409802|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
58409803|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
58298462|NCT01549665|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
58409804|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
58409805|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
58409806|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
58409807|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
58409808|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
58409809|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
58409810|NCT01833260|BEHAVIORAL|Music|
57945424|NCT00843388|DRUG|placebo tablet|placebo tablet 25 mg OD
57945425|NCT03008642|OTHER|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
57945426|NCT05099627|OTHER|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
58079425|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
58079426|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
58079427|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
57945427|NCT05099627|OTHER|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
57945428|NCT05099627|OTHER|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
57945429|NCT04021836|OTHER|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
57945430|NCT04331795|DRUG|Tocilizumab|"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
58079428|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
58079429|NCT06723964|DRUG|AP505|AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
58079430|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
58079431|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
58079432|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
58079433|NCT01995656|DRUG|Placebo - Capsule|Administered orally
58079434|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
58079435|NCT01995656|DRUG|Placebo - Solution|Administered orally
58298463|NCT05943353|OTHER|Pentoxifylline|Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
58298464|NCT05418465|DRUG|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
58409811|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
58079436|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
58079437|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
58079438|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
58079439|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
58079440|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
58079441|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
58079442|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
58409812|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
58409813|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
58409814|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
58409815|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
58409816|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
58409817|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
58409818|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
58409819|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
58409820|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
57731913|NCT01689116|DRUG|Bardoxolone Methyl 80mg|Oral
57731914|NCT01689116|DRUG|Bardoxolone Methyl Placebo|Oral
57731915|NCT01689116|DRUG|Moxifloxacin 400mg|Oral
57731916|NCT01689116|DRUG|Moxifloxacin Placebo|Oral
57731917|NCT06534515|DEVICE|Tomatis auditory stimulation|Traditional Tomatis Method Protocol
58298465|NCT05418465|DRUG|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
58298466|NCT01608880|DRUG|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
58298467|NCT01608880|DRUG|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
58409821|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
58409822|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
58409823|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
58409824|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
58409825|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
58409826|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
58409827|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
58409828|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
58409829|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
58409830|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
58409831|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
58409832|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
58409833|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
58409834|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
58409835|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
58409836|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
58409837|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
58079443|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
58079444|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
58079445|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
58079446|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
58079447|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
58079448|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
57945431|NCT04331795|DRUG|Tocilizumab|"Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
57945432|NCT03124771|DEVICE|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
57945433|NCT04649255|DEVICE|Liquid Embolic|Lava Liquid Embolic System (LES)
57945434|NCT03556553|DEVICE|Vertise Flow|Composite resin
57945435|NCT03556553|DEVICE|LuxaFlow|Composite resin
57945436|NCT03556553|DEVICE|Teco Adhesive|Adhesive system
58079449|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
58298468|NCT06080516|OTHER|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
58298469|NCT03936569|DRUG|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
58409838|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
58409839|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
58409840|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
58409841|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
57945437|NCT01937533|PROCEDURE|Magnetic Resonance Imaging using an endovaginal receiver coil|
57945438|NCT02025868|BEHAVIORAL|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
57945439|NCT02025868|DRUG|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
57945440|NCT02348775|DIETARY_SUPPLEMENT|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
57945441|NCT05578859|DRUG|AMG 510|Single oral dose of AMG510.
57945442|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
57945443|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
58079450|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
58079451|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
58079452|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
58079453|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
58298470|NCT03936569|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
58298471|NCT02115100|PROCEDURE|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
58409842|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
58409843|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
57945444|NCT02231164|DRUG|placebo|oral placebo
57945445|NCT02231164|DRUG|nintedanib|oral experimental therapy
57945446|NCT06369103|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
58298472|NCT01707641|DIETARY_SUPPLEMENT|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
58298473|NCT01707641|OTHER|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
57731918|NCT06530953|BEHAVIORAL|Patient Navigator Model|The patient navigator model is an evidence-based intervention to improve access to healthcare services.
57731919|NCT00690521|DRUG|Treatment of Furosemide + Hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
57731920|NCT00690521|DRUG|Treatment of Furosemide + Metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
57945447|NCT06369103|DRUG|Propofol|Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
57945448|NCT02152085|DEVICE|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
57945449|NCT02152085|DEVICE|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
57945450|NCT02731261|OTHER|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
57945451|NCT04701671|BEHAVIORAL|Observational (not including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
57945452|NCT04701671|BEHAVIORAL|Observational (including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
57945453|NCT05258773|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
57945454|NCT03119961|DEVICE|SONOCLOUD®|BBB opening by ultrasound
57945455|NCT03426956|DIETARY_SUPPLEMENT|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
58298474|NCT05857722|BEHAVIORAL|Jóvenes Capibara|Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
57731921|NCT01985126|DRUG|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
57945456|NCT03426956|DIETARY_SUPPLEMENT|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
57945457|NCT05997862|DEVICE|HFFS|This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
57731922|NCT01985126|DRUG|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
57945458|NCT03321227|OTHER|Snack skipping|No snack provided
57945459|NCT03321227|OTHER|Whole eggs|2 whole large eggs scrambled, provided as a snack
57945460|NCT03321227|OTHER|Egg whites|2 egg whites scrambled, provided as a snack
57945461|NCT03321227|OTHER|Egg yolks|2 egg yolks scrambled, provided as a snack
57945462|NCT03321227|OTHER|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
58298475|NCT02300623|DRUG|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
58298476|NCT02300623|DRUG|Antiretroviral therapy alone|Standard antiretroviral therapy
58409844|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
57945463|NCT03506321|DIAGNOSTIC_TEST|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
57945464|NCT05565716|OTHER|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
57945465|NCT05565716|OTHER|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
57945466|NCT01787942|DEVICE|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
57945467|NCT05723185|OTHER|Outpatient visit|Patients will be seen and treated at the outpatient clinic like in the usual care
57945468|NCT00668070|DRUG|ASP9831|Oral
57945469|NCT00668070|DRUG|Placebo|Oral
57945470|NCT04066270|DIAGNOSTIC_TEST|video nystagmography|routine test battery applied to all cochlear implant candidates
57945471|NCT01735253|PROCEDURE|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
57945472|NCT01534104|PROCEDURE|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI \& DSI, neurological/physical testing \& brain MRI showing tumor \&/or edema located in or near (\<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), \&/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately \<48 hours before surgery\*) fMRI to localize gray matter DTI, DSI \& tractography to localize white matter, DSI \& updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray \&/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (\<48 hours after surgery)
57945473|NCT04071847|DEVICE|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
58079454|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
58079455|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
58079456|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
58079457|NCT00013910|DRUG|NNC 90-1170|
58409845|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
58409846|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
58409847|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
57731923|NCT01985126|DRUG|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
57731924|NCT01985126|DRUG|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
57731925|NCT01985126|DRUG|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
57731926|NCT01985126|DRUG|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
57731927|NCT03080129|DIETARY_SUPPLEMENT|Fresubin energy|dietary protein energy supplement
58409848|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
58409849|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
58409850|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
58409851|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
57945474|NCT02667210|OTHER|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
57945475|NCT05467475|DRUG|BI 1819479|BI 1819479
58079458|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
58409852|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
57731928|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
58079459|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
58079460|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
58079461|NCT06397248|OTHER|No intervention|No intervention
57731929|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
57731930|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
57731931|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
57731932|NCT03140436|DRUG|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
57731933|NCT03140436|DRUG|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
58079462|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
57731934|NCT06197893|PROCEDURE|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
57731935|NCT06197893|PROCEDURE|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
58079463|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
58079464|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
57945476|NCT05467475|DRUG|Esomeprazole|Esomeprazole
57945477|NCT02230384|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
57945478|NCT02230384|DRUG|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
57945479|NCT05224063|DEVICE|Individualized CEN-targeted rTMS|Delivers patterned magnetic stimulation based on individualized CEN targeting
57945480|NCT05224063|DEVICE|Neuronavigated rTMS|Delivers patterned magnetic stimulation based on MRI images
57945481|NCT05224063|DEVICE|Scalp-targeted rTMS|Delivers patterned magnetic stimulation based on BEAM F3 targeting
57945482|NCT05224063|DEVICE|Sham rTMS|Delivers placebo magnetic stimulation
57945483|NCT03677258|DEVICE|Collagen for injections 7%|Injection of medical device
58079465|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
58079466|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
58409853|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
58079467|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
58298477|NCT01759706|BEHAVIORAL|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
58298478|NCT01759706|PROCEDURE|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
57945484|NCT03677258|DEVICE|Hyaluronic acid for injections 2%|Injection of medical device
57945485|NCT02997904|DEVICE|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
57945486|NCT01835015|DRUG|CLG561|Administered by intravitreal injection, Day 1
57945487|NCT00763750|DRUG|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
57945488|NCT05610033|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
57945489|NCT00102011|PROCEDURE|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
57945490|NCT00102011|PROCEDURE|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
57945491|NCT00102011|PROCEDURE|screening colonoscopy|Patients undergo baseline screening colonoscopy
57945492|NCT00102011|PROCEDURE|standard follow-up care|Standard care
57945493|NCT00090194|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
57945494|NCT04899271|DRUG|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
57945495|NCT04899271|OTHER|Placebo|Placebo will be administered orally with the same scheme of administration of LDX to preserve blinding
57945496|NCT05554484|BIOLOGICAL|Autologous peripheral blood-derived tolerogenic dendritic cells|AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1\~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
58298479|NCT01759706|DRUG|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
57731936|NCT06197893|PROCEDURE|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
57945497|NCT04712877|DIAGNOSTIC_TEST|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
57945498|NCT01252745|DRUG|10.0 mg of Testosterone, 4.0% TID|
57945499|NCT01252745|DRUG|13.5 mg of Testosterone, 4.5% B.I.D|
57731937|NCT06197893|PROCEDURE|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
57945500|NCT01252745|DRUG|11.25 mg of Testosterone, 4.5% T.I.D|
57945501|NCT01856244|BEHAVIORAL|treadmill walking|
57945502|NCT01856244|DEVICE|Treadmill|
57945503|NCT00665899|BEHAVIORAL|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
57945504|NCT00665899|BEHAVIORAL|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
57945505|NCT03011268|OTHER|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
57945506|NCT03011268|OTHER|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
57945507|NCT04031911|DEVICE|Hydroposturotherapy|"Hydroposturotherapy combines:~* posturotherapy (patient placed upside down with water jets sent to the kidneys)~* lumbar percussion~* hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
57945508|NCT04031911|DEVICE|Standard support in urology|Dispensing of AFU plugs Dietary advice
57945509|NCT00938808|DIETARY_SUPPLEMENT|day formula diet|The Cambridge Programme. Formula diet
57945510|NCT02710838|DEVICE|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
58079468|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
58079469|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
58079470|NCT03333564|OTHER|Control|No intervention was given
58079471|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
58079472|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
58079473|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
58079474|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
57945511|NCT02340338|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
57945512|NCT02727985|PROCEDURE|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
58298480|NCT01759706|OTHER|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
57945513|NCT03528343|DRUG|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
58079475|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
58409854|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
57731938|NCT02543346|DRUG|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
58079476|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
58079477|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
58079478|NCT02027831|DRUG|Indocyanine Green|
58079479|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
58079480|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
58298481|NCT01759706|DRUG|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
58298482|NCT01759706|DRUG|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
58298483|NCT01759706|BEHAVIORAL|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
58409855|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
57731939|NCT02543346|OTHER|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
58079481|NCT00000147|DRUG|Methylprednisolone|
58079482|NCT00000147|DRUG|Prednisone|
58079483|NCT00138281|BIOLOGICAL|FluMist|
58298484|NCT01759706|DRUG|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
57731940|NCT00288587|DRUG|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
57731941|NCT00288587|DEVICE|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
58298485|NCT03434210|OTHER|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
58298486|NCT03434210|OTHER|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
57731942|NCT06270823|PROCEDURE|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
57945514|NCT01110616|DRUG|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
57945515|NCT01110616|DRUG|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
58079484|NCT00138281|BIOLOGICAL|Fluzone|
58079485|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
58298487|NCT00371956|DRUG|raloxifene|60mg/day
58298488|NCT00371956|DRUG|placebo|tab 1 daily
58409856|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
58079486|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
58079487|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
58079488|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
58409857|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
57731943|NCT03447782|DRUG|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
57945516|NCT01110616|DRUG|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
57945517|NCT06186076|DRUG|TRX-221|TRX-221 oral dose as defined
57945518|NCT01239550|DRUG|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
58079489|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
58298489|NCT01307813|DEVICE|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
57731944|NCT04053764|DRUG|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
57731945|NCT04053764|DRUG|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
57731946|NCT05605119|DRUG|AUR105|Once daily
57945519|NCT03625167|OTHER|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
57945520|NCT06466148|DEVICE|JessieHug|Assessment of JessieHug device when placed on infants.
58079490|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
58079491|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
58079492|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
58079493|NCT00005874|DRUG|rubitecan|
58079494|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
58079495|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
58079496|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
58079497|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
58079498|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
58079499|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
58079500|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
58079501|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
58079502|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
58079503|NCT00006049|DRUG|carboplatin|
58079504|NCT00006049|DRUG|gefitinib|
58079505|NCT00006049|DRUG|paclitaxel|
58409858|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
58409859|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
58079506|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
58079507|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
58079508|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
58409860|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
58409861|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
58409862|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
58409863|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
58409864|NCT06214052|DRUG|VH4524184|VH4524184 will be administered.
58409865|NCT06214052|DRUG|Placebo|Placebo will be administered.
58409866|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
58409867|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
58409868|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
58409869|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
58409870|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
58298490|NCT01374022|OTHER|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
57731947|NCT04709536|DRUG|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
57731948|NCT04709536|DRUG|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
57945521|NCT05422560|PROCEDURE|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
57945522|NCT02800889|DRUG|Pixantrone|Pixantrone
57945523|NCT06198803|DRUG|L Carnitine|The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
57945524|NCT02969187|DRUG|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
57945525|NCT02969187|DRUG|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
57945526|NCT02969187|DRUG|Saline|
57945527|NCT01136135|OTHER|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
57945528|NCT04282395|BEHAVIORAL|Resilience-Based Diabetes Self-Management Education|"During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~* the location in community-based church settings,~* recognition of cultural dietary preferences, and~* emphasis on cultural/historical significance of resilience in AAs."
58298491|NCT01374022|OTHER|ARDSNet Strategy|Conventional mechanical ventilation strategy.
58298492|NCT03286218|DRUG|Lasmiditan|Administered orally
58298493|NCT03286218|DRUG|Alprazolam|Administered orally
58298494|NCT03286218|DRUG|Placebo|Administered orally
58298495|NCT04071782|DEVICE|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
58298496|NCT03669601|DRUG|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
58298497|NCT03669601|DRUG|Gemcitabine|Nucleoside metabolic inhibitor.
58298498|NCT01393145|DRUG|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
58298499|NCT01393145|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
58298500|NCT05468255|OTHER|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
58298501|NCT02823353|DRUG|Fenofibrate|Fenofibrate 200mg/day
58298502|NCT02823353|DRUG|UDCA|UDCA 13-15mg/kg/day
58298503|NCT06301919|OTHER|Clinical data|Collecting data from the medical record.
58298504|NCT06301919|OTHER|Imaging data|Collecting data from the medical record.
58298505|NCT06301919|OTHER|Biological data|Collecting data from the medical record.
58298506|NCT02118103|PROCEDURE|Spinal Manipulation|Lumbar spinal manipulation
57945529|NCT04282395|BEHAVIORAL|Standard Diabetes Self-Management Education|"Control group sessions, led by professional nurses, cover topics such as:~* causes and symptoms of type 2 diabetes,~* glucose self-monitoring,~* models for and principles of healthy eating, grocery shopping and dining out,~* physical activity,~* diabetes medications,~* managing sick days and stress, and~* community resources."
57945530|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler|
57945531|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
57945532|NCT03060044|DRUG|Seretide Diskus|
57731949|NCT04304833|OTHER|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
57945533|NCT03060044|DRUG|Seretide Diskus with charcoal|
57945534|NCT04763642|PROCEDURE|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
57945535|NCT06147479|BEHAVIORAL|CS-ADL (Cognitive stimulation in Activities of Daily Living)|CS-ADL sessions are delivered once weekly, for seven weeks. Sessions last approximately 2 hours. Sessions are themed around domains of everyday activities, for example 'Morning routine', ' Domestic Activities', 'Leisure'. Activities in each session follow this theme. A typical session begins with introductions, reality orientation, a group song and discussion of the news of the week. This is followed by a physical activity/game and ADL-focused cognitive stimulation activities. These activities include the identification and categorization of everyday items, discussion, reminiscence, planning and sequencing of ADLs and the completion of everyday writing/calculation tasks. This is followed by practice of an ADL. Examples of activities include making a breakfast, a simple gardening activity or sorting laundry. The session then ends with a summary and repeat of the group song, and a plan for the next session.
57945536|NCT04076514|PROCEDURE|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
57945537|NCT05988788|OTHER|Epigallocatechin-3-gallate|to be used as a root canal irrigant
57945538|NCT05988788|OTHER|sodium hypochlorite|to be used as a root canal irrigant
57945539|NCT02305095|DRUG|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
57945540|NCT00861120|DRUG|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
57945541|NCT00861120|DRUG|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
57945542|NCT03715699|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
57945543|NCT03715699|DRUG|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
57945544|NCT00547872|PROCEDURE|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
57945545|NCT03112889|DRUG|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
57945546|NCT02553265|DRUG|Carbidopa Low-Dose|300 mg/day
57731950|NCT04304833|BEHAVIORAL|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
57945547|NCT02553265|OTHER|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
57945548|NCT02553265|DRUG|Carbidopa High-Dose|600 mg/day
57945549|NCT03960775|DRUG|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
57945550|NCT03960775|DRUG|saline|Saline infusion during same time period.
57945551|NCT01245504|OTHER|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
57945552|NCT04188574|DRUG|BB2603-1|Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
57945553|NCT04188574|DRUG|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
57945554|NCT04188574|DRUG|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
57945555|NCT04188574|OTHER|Vehicle|Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
57945556|NCT00820495|BEHAVIORAL|Web + Phone|Web + Phone
57945557|NCT00820495|BEHAVIORAL|Web Only|Web Only
57945558|NCT00820495|BEHAVIORAL|Phone Only|Phone Only
57945559|NCT00820495|BEHAVIORAL|Usual Care|Usual Care
57945560|NCT01590550|PROCEDURE|Use of citrate based dialysate|Use of heparin free citrate based dialysate
58079509|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
58079510|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
58079511|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
58079512|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
57731951|NCT03176680|PROCEDURE|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
58079513|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
58079514|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
57945561|NCT02300948|DRUG|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
58079515|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
58079516|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
58079517|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
58079518|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
58298507|NCT02488226|OTHER|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
58298508|NCT03993483|BEHAVIORAL|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
58298509|NCT06278805|OTHER|The reliability and validity study of the T-LUNS|To test the reliability and validity of the T-LUNS, 110 chronic stroke survivors fulfilling the inclusion / exclusion criteria at the 3 study sites will be assessed. The assessment of each patient will include recording of the demographic and clinical characteristics and administration of the T-LUNS as well as the Turkish version of the Stroke Impact Scale 3.0 (SIS). For the assessment of test-retest reliability of the T-LUNS, half of the participants (n= 55) will fill in the T-LUNS again, 2 weeks after the first administration.
58298510|NCT00735345|DRUG|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
58298511|NCT00735345|DRUG|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
58298512|NCT00735345|DRUG|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
58409871|NCT02403635|DRUG|Midazolam|
58409872|NCT02403635|DRUG|ASP2151|
58079519|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
58079520|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
58079521|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
58079522|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
58079523|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
58079524|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
58079525|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
57731952|NCT06636097|DEVICE|Full arch|design
57731953|NCT00438386|DRUG|Aripiprazole|
57731954|NCT01664845|DRUG|metformin|metformin 500mg tid
57731955|NCT01664845|DRUG|pegylated-IFN|pegasys 180 mcg qw
57731956|NCT01664845|DRUG|ribavirin|ribavirin 800-1200 mg qd according to BW
58079526|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
58079527|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
58079528|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
58298513|NCT00735345|BIOLOGICAL|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
58298514|NCT00735345|RADIATION|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
58298515|NCT03472131|PROCEDURE|Unilateral Posterolateral Approach and Debridement|
58409873|NCT00002839|DRUG|cisplatin|
58409874|NCT00002839|DRUG|fluorouracil|
58409875|NCT00002839|PROCEDURE|conventional surgery|
58409876|NCT00002839|PROCEDURE|neoadjuvant therapy|
58409877|NCT00002839|RADIATION|radiation therapy|
58409878|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
58409879|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
58409880|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
58409881|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
58409882|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
57945562|NCT02300948|DRUG|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
58409883|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
57945563|NCT06491056|DEVICE|Focal Therapy for Prostate Cancer|Ablation of \<75% of the prostate gland for limited volume prostate cancer
57945564|NCT03683940|DIAGNOSTIC_TEST|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
57945565|NCT05145998|DIETARY_SUPPLEMENT|Glucola|50 grams of Glucola sugar beverage
57945566|NCT05145998|DIETARY_SUPPLEMENT|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
58298516|NCT03472131|OTHER|Titanium cage insertion supplemented by screw fixation|
58298517|NCT03262779|BIOLOGICAL|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
58298518|NCT02048150|BIOLOGICAL|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
58298519|NCT02048150|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
58298520|NCT02048150|OTHER|diffuse optical imaging|Undergo IOOI
58079529|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
58079530|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
58298521|NCT02048150|OTHER|pharmacological study|Correlative studies
58298522|NCT02048150|OTHER|Laboratory Biomarker|Correlative studies
58298523|NCT02048150|OTHER|Questionnaire|Ancillary studies
58298524|NCT04912843|DRUG|NR082 injection|Intravitreal injection（IVT）
57945567|NCT05145998|DIETARY_SUPPLEMENT|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
57945568|NCT05145998|DIETARY_SUPPLEMENT|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
57945569|NCT05145998|DIETARY_SUPPLEMENT|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
57945570|NCT00708123|DRUG|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
57945571|NCT00708123|DRUG|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
58079531|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
58298525|NCT04912843|DEVICE|Sham Injection|Sham Intravitreal Injection
58298526|NCT00980824|BEHAVIORAL|Cognitive behavioural therapy|Six sessions brief CBT.
58298527|NCT00980824|OTHER|Standard treatment|Referral to NHS services appropriate to patient's needs
58298528|NCT00433550|DRUG|capecitabine|given orally
58298529|NCT00433550|DRUG|irinotecan hydrochloride|given IV
58298530|NCT00433550|DRUG|oxaliplatin|given IV
58298531|NCT05434455|DEVICE|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
58298532|NCT01200706|DRUG|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
58298533|NCT02244671|PROCEDURE|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
58298534|NCT02244671|DRUG|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
58298535|NCT02244671|DEVICE|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
58298536|NCT04987112|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
58298537|NCT05511298|BEHAVIORAL|Relationship Smarts Combo|The intervention is a combination of Mind Matters, Relationship Smarts 4.0, and Money Habitudes curricula, developed by the Dibble Institute
58298538|NCT00746226|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
58298539|NCT00746226|BIOLOGICAL|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
58298540|NCT02262910|BIOLOGICAL|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
58409884|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
58409885|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
58409886|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
58409887|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
58409888|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
58079532|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
58079533|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
58079534|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
58079535|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
58079536|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
58079537|NCT02440490|BEHAVIORAL|Computerised cognitive training|
58079538|NCT02440490|BEHAVIORAL|Video watching|
58079539|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
58409889|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
58409890|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
58409891|NCT02387801|DRUG|Ixekizumab|Administered SC
58409892|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
58409893|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
58409894|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
58409895|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
57731957|NCT01311102|DRUG|Lidocaine|1.33 cc 2% liquid lidocaine
57945572|NCT04072055|DEVICE|MOTO Medial|MOTO medial unicompartmental knee system
57945573|NCT01035099|DRUG|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;"
57945574|NCT01035099|DRUG|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
58409896|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
57731958|NCT01311102|DRUG|Normal Saline|1.33cc normal saline
57731959|NCT06568302|DRUG|SerpinPC|Administered as SC injection.
57731960|NCT04686448|DRUG|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
57731961|NCT04686448|DRUG|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
57731962|NCT03116594|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
57731963|NCT03116594|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
57945575|NCT03182647|PROCEDURE|Surgically treatment of the ACL|Surgical initial ACL treatment
57945576|NCT03182647|OTHER|Non surgical initial ACL treatment|Non surgical initial ACL treatment
57945577|NCT06082141|PROCEDURE|Transversus thoracis plane block combined with serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance
57945578|NCT06082141|PROCEDURE|Serratus anterior plan block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
58079540|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
58079541|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
58079542|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
58079543|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
58079544|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
58079545|NCT04918186|DRUG|BA3011|IV
58079546|NCT04918186|DRUG|BA3021|IV
58079547|NCT04918186|DRUG|To be determined|To be determined
58079548|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
58409897|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
57731964|NCT03652311|DEVICE|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
57731965|NCT03273439|DEVICE|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
57731966|NCT03273439|DEVICE|Sham rTMS|Sham rTMS, without stimulation
57731967|NCT01737112|DRUG|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
58409898|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
58409899|NCT00003825|DRUG|pentosan polysulfate sodium|
58409900|NCT00003825|PROCEDURE|quality-of-life assessment|
58409901|NCT00315107|DRUG|Alesse|
58409902|NCT02241876|DRUG|N-acetylcysteine|
58409903|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
58079549|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
58079550|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
57731968|NCT02504658|BEHAVIORAL|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
57945579|NCT05623930|DEVICE|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
57945580|NCT05623930|OTHER|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
57945581|NCT00948363|OTHER|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
57945582|NCT00948363|OTHER|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
57945583|NCT01222455|DRUG|Fostamatinib|Oral tablets, single dose
58079551|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
58079552|NCT02531074|BEHAVIORAL|Mobile Application|
58079553|NCT02531074|BEHAVIORAL|Food Journal|
58079554|NCT02531074|BEHAVIORAL|Usual Care|
58079555|NCT00267917|DEVICE|Berodual Respimat|
58079556|NCT00267917|DEVICE|Berodual HFA-MDI|
58079557|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
58079558|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
58079559|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
57731969|NCT02504658|BEHAVIORAL|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
57731970|NCT05316038|DIAGNOSTIC_TEST|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
57731971|NCT04986553|DEVICE|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
57731972|NCT02794402|DRUG|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
57731973|NCT02794402|BEHAVIORAL|Placebo|Placebo once weekly injections sc
57731974|NCT04941755|DRUG|BMS-986256|Specified dose on specified days
57731975|NCT04941755|DRUG|Famotidine|Specified dose on specified days
57731976|NCT02630667|OTHER|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
57731977|NCT02630667|OTHER|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
57731978|NCT02630667|OTHER|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
58079560|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
58079561|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
58079562|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
57731979|NCT04139317|DRUG|Capmatinib|INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
57731980|NCT04139317|BIOLOGICAL|Pembrolizumab|Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
58079563|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
58079564|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
58079565|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
58298541|NCT05656170|PROCEDURE|Stellate ganglion block|"Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total)."
58298542|NCT05656170|DRUG|Bupivacain|The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
58298543|NCT05656170|DRUG|Saline|The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
58298544|NCT06428266|DEVICE|Bicanalicular intubation|Placement of the bicanalicular intubation set at each lacrimal point and fixed by means of its flaps at the level of the opening of the lacrimal sac.
58298545|NCT06428266|PROCEDURE|Closed dacryointubation|Placement of dacryointubation tube through the canaliculus until it reaches the medial wall of the lacrimal sac and then passed the nasolacrimal duct until it empties out at the level of the inferior meatus.
57945584|NCT00434421|DRUG|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
57945585|NCT00434421|DRUG|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
57945586|NCT01540253|DRUG|PI3K inhibitor BKM120|Given PO
57945587|NCT01540253|DRUG|docetaxel|Given IV
57945588|NCT01540253|OTHER|pharmacological study|Correlative studies
57945589|NCT01540253|OTHER|questionnaire administration|Ancillary studies
57945590|NCT01540253|OTHER|laboratory biomarker analysis|Correlative studies
57945591|NCT04935099|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
57945592|NCT04935099|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
58079566|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
58079567|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
58079568|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
58079569|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
58079570|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
58079571|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
58079572|NCT02646566|DRUG|APD421|
58079573|NCT02646566|DRUG|Placebo|
58079574|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
58079575|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
58079576|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
58298546|NCT01439113|PROCEDURE|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
58079577|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
58079578|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
58079579|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
58298547|NCT03273959|OTHER|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
58298548|NCT04362202|OTHER|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
58409904|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
58409905|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
58409906|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
57945593|NCT00932204|DEVICE|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
58079580|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
58079581|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
58079582|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
58079583|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
58079584|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
58079585|NCT02277665|BEHAVIORAL|CUD Treatment|
58079586|NCT02277665|BEHAVIORAL|Tobacco Treatment|
58298549|NCT06122402|OTHER|SECURE Care Bundle|The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including 2-octyl-cyanoacrylate tissue adhesive, CHG dressing and silicone based remover.
58298550|NCT06122402|PROCEDURE|Standart Care|It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
58298551|NCT03838939|OTHER|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
57945594|NCT04424654|DRUG|Testosterone cypionate|Testosterone cypionate 400 mg IM
57731981|NCT06457542|OTHER|Active Release Technique|Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.
57731982|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
58079587|NCT00390338|BIOLOGICAL|polarized dendritic cells|
58079588|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
58079589|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
58079590|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
58079591|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
58079592|NCT02553486|OTHER|quality of life evaluation|
58079593|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
58079594|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
58079595|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
58079596|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
58298552|NCT03249428|DEVICE|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
58298553|NCT04043429|BEHAVIORAL|Vision Restoration Training (VRT)|
58409907|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
58409908|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
58409909|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
58409910|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
58409911|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
58409912|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
57731983|NCT01529957|DRUG|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
57731984|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
57731985|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
57945595|NCT05070975|OTHER|Epidemiology|Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
57945596|NCT01159028|DRUG|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
57945597|NCT01159028|DRUG|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
57945598|NCT05063721|BIOLOGICAL|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
57945599|NCT02946242|DEVICE|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
57945600|NCT02255409|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
58079597|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
58079598|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
57945601|NCT02255409|BIOLOGICAL|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
57945602|NCT02859181|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
58079599|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
58079600|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
58079601|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
58079602|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
57945603|NCT02672436|DRUG|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
57945604|NCT02672436|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
57945605|NCT05894174|BEHAVIORAL|Board Game|Food Hunter board game intervention, which includes various nutrient cards and question cards and is played with pawns and dice, will be played with children for approximately 4 weeks, one day a week and one session (40 minutes) with the researcher dietitian. By talking about the nutrients in the game on the game cards, children will be able to recognize the nutrients and important points will be emphasized for the participants with the answers to the cards containing various questions about healthy nutrition.
57945606|NCT01645189|BIOLOGICAL|Hunterase|once weekly, 0.5mg/kg IV infusion
57945607|NCT04266262|BEHAVIORAL|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
58079603|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
58079604|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
58079605|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
58079606|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
58079607|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
58079608|NCT05950529|OTHER|No product|no product
57945608|NCT04266262|BEHAVIORAL|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
58079609|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
58298554|NCT04043429|BEHAVIORAL|Vision Exploration Training (VET)|
58409913|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
58409914|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
58409915|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
58409916|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
58409917|NCT02549222|OTHER|Standard of Care|
57945609|NCT01438489|BIOLOGICAL|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
57945610|NCT01438489|BIOLOGICAL|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
58298555|NCT03981016|OTHER|Biological collection|"* blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
58409918|NCT00505037|DRUG|ASP1585|Oral
58409919|NCT00505037|DRUG|Placebo|Oral
58409920|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
58409921|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
58409922|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
58079610|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
58298556|NCT06100536|BEHAVIORAL|Music-with-movement|The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
57731986|NCT06328647|DEVICE|POC Quantra QPlus System|The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
58079611|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
58079612|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
58079613|NCT03006042|DRUG|Bupivacaine|
58298557|NCT02260960|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
58298558|NCT00484770|DEVICE|Brain Natriuretic Peptide Levels -- Diagnostic testing|
58298559|NCT00484770|OTHER|clinical assessment|
58298560|NCT03128450|BIOLOGICAL|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
58298561|NCT05259826|OTHER|biopsy sampling|"1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression."
58298562|NCT01484080|DRUG|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
58298563|NCT01484080|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
58298564|NCT03854331|BEHAVIORAL|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
58298565|NCT04652557|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
58409923|NCT05460598|OTHER|commonly used bedding|commonly used bedding
58298566|NCT04652557|DRUG|Placebo|no active component
58298567|NCT01328639|OTHER|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
58298568|NCT01328639|OTHER|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
58298569|NCT01838239|DIETARY_SUPPLEMENT|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
58298570|NCT04534517|DEVICE|JJV Investigational Multifocal Contact Lens|TEST Lens
58298571|NCT04534517|DEVICE|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
58298572|NCT04249947|BIOLOGICAL|P-PSMA-101 CAR-T cells|P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).
58298573|NCT04249947|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated
58298574|NCT04852250|OTHER|Virtual centralized multidisciplinary tumour board|Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
58298575|NCT00480090|DRUG|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
58298576|NCT00098241|DRUG|Certican|
57945611|NCT01438489|OTHER|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
58298577|NCT02948829|BIOLOGICAL|TDV|TDV SC injection.
58298578|NCT04106908|BIOLOGICAL|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
58298579|NCT01676493|DRUG|Codeine|
58298580|NCT06455657|OTHER|breast cancer education|Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
58298581|NCT05947253|OTHER|Buyteko breathing technique|group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
58298582|NCT05947253|OTHER|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
58298583|NCT03293745|BEHAVIORAL|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
58298584|NCT03293745|BEHAVIORAL|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
58298585|NCT05529537|OTHER|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
58298586|NCT05529537|OTHER|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
57945612|NCT01986920|DRUG|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
57945613|NCT01986920|DRUG|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
57945614|NCT01986920|DRUG|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
57945615|NCT01986920|DRUG|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
57945616|NCT00215800|DRUG|Ampligen|
58298587|NCT06523959|DRUG|Apixaban 2.5 MG|To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
58298588|NCT05239663|DRUG|Ganglioside-Monosialic Acid|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
57945617|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
57945618|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
57945619|NCT04856787|DRUG|placebo、 BP102、 XELOX|"Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
57945620|NCT03982836|DIETARY_SUPPLEMENT|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
57945621|NCT04391036|DEVICE|High Eudragit® Content Vaginal Film|High (12.8%) Eudragit® Content Vaginal Film
57945622|NCT04391036|DEVICE|Low Eudragit® Content Vaginal Film|Low (6.4%) Eudragit® Content Vaginal Film
57945623|NCT01089348|DRUG|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
57945624|NCT01089348|DRUG|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
57945625|NCT02681536|DRUG|Triptorelin|
58298589|NCT05239663|DRUG|250ml normal saline (NS)|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
58298590|NCT06311058|DIETARY_SUPPLEMENT|Whey protein isolate|25g of whey protein isolate
58298591|NCT06311058|DIETARY_SUPPLEMENT|Protein + BAA|"* Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)"
58298592|NCT06311058|DIETARY_SUPPLEMENT|Placebo|• isocaloric-matched (25g) maltodextrin supplement
58298593|NCT02260817|DRUG|11C-choline Injection|"1. Choline C11 Injection for PET/CT Imaging Protocol:~   * 15 - millicuries (mCi) 11C-choline IV Injection~  * PET images skull base to mid thigh with 3 min per bed position~  * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~  * Fusion of PET and CT images~2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~   * No IV contrast~  * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~  * Fusion of coronal and PET images"
58298594|NCT06474156|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
58298595|NCT01090180|DRUG|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
58298596|NCT01090180|DRUG|Placebo (sugar pill)|inactive
57945626|NCT02681536|DRUG|Combined oral contraceptive pills|
57945627|NCT02681536|DRUG|HMG|
57945628|NCT01262768|BEHAVIORAL|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
57945629|NCT05223634|OTHER|Collection of oral and/or nasal samples|Collection of oral and/or nasal samples after SOC test performed
57945630|NCT06311045|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Participants will take two NAC 600mg capsules daily for four weeks.
57945631|NCT06311045|DIETARY_SUPPLEMENT|Placebo|Participants will take two placebo 600mg capsules daily for four weeks.
57945632|NCT06311045|PROCEDURE|Positive Airway Pressure (PAP) Therapy|All participants will receive PAP therapy per standard of care for OSA.
58079614|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
57945633|NCT00801645|BEHAVIORAL|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
57945634|NCT05177653|OTHER|Intravenous infusion|GIP receptor antagonist (GIP(3-30)NH2)
57945635|NCT05177653|OTHER|Intravenous infusion|GLP-1 receptor antagonist (exendin(9-39)NH2)
57945636|NCT05177653|OTHER|Intravenous infusion|GIP(3-30)NH2 and exendin(9-39)NH2
57945637|NCT05177653|OTHER|Intravenous infusion|Saline
58298597|NCT03024983|OTHER|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
58298598|NCT03024983|OTHER|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
58298599|NCT03024983|OTHER|Bread|Bread (122 g) eaten with 500 mL of water
58298600|NCT03024983|OTHER|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
57945638|NCT03485248|DIETARY_SUPPLEMENT|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
58298601|NCT03024983|OTHER|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
58298602|NCT03024983|OTHER|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
58298603|NCT04416997|PROCEDURE|Blood and serum samples|The blood and serum samples will taken from RA patients
58298604|NCT00097214|DRUG|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
58298605|NCT00097214|BIOLOGICAL|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
58298606|NCT01445249|PROCEDURE|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
58298607|NCT01445249|PROCEDURE|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
58298608|NCT05881655|DEVICE|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
57945639|NCT03485248|DIETARY_SUPPLEMENT|Placebo|140ml of Beetroot Juice (nitrate free)
57945640|NCT06264427|GENETIC|Whole genome sequencing|Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
57945641|NCT06264427|DIAGNOSTIC_TEST|VAGUS|To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
57945642|NCT06264427|DIAGNOSTIC_TEST|NightOwl|Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
58079615|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
58079616|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
58298609|NCT05881655|DEVICE|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
58298610|NCT00102596|DRUG|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
58298611|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery -\> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
58409924|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
57945643|NCT06264427|DEVICE|CPAP|Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
58409925|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
57945644|NCT06491108|DRUG|Vardenafil 5 Mg Oral Tablet|Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
58298612|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
58298613|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
58298614|NCT00818584|DRUG|Micafungin|IV Administration
58298615|NCT04659707|DRUG|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
58298616|NCT01845779|DRUG|DCF regimen|
58298617|NCT01553565|PROCEDURE|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
58298618|NCT01655316|DRUG|Verapamil|
58298619|NCT04131920|DEVICE|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
58298620|NCT02053493|DRUG|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
58298621|NCT02053493|DRUG|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
58298622|NCT03999502|DEVICE|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
58298623|NCT01474850|PROCEDURE|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
58298624|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
58298625|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 472 mg QD|SFC 118 mg capsules will be given to the patients as 472 mg QD
58298626|NCT04020653|DRUG|Artemisinin-based combination (ACT)|Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
57945645|NCT02324959|DEVICE|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
57945646|NCT02324959|DEVICE|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
58298627|NCT04020653|DRUG|Placebo|Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
58298628|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
58409926|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
57945647|NCT03599128|OTHER|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
57945648|NCT03599128|OTHER|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
58298629|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 236 mg BID|SFC 118 mg capsules will be given to the patients as 236 mg BID
58298630|NCT03234036|DRUG|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
57945649|NCT03599128|OTHER|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
58298631|NCT03234036|DRUG|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
58298632|NCT03234036|DRUG|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
58409927|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
58298633|NCT03234036|DRUG|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
58298634|NCT06611982|OTHER|Unconditional cash transfer|$1000/month for 12 months
58298635|NCT06611982|OTHER|Contact information for social worker and financial counselor|Information on financial toxicity and contact information for social worker and financial counselor
58298636|NCT06446414|BEHAVIORAL|Choose to Move|As described under study arm description
58298637|NCT02584283|PROCEDURE|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
58409928|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
58409929|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
58079617|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
58079618|NCT03580746|PROCEDURE|Taping and posteromedial release|
58079619|NCT03580746|PROCEDURE|Ponseti|
58298638|NCT02584283|DEVICE|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
58298639|NCT02584283|PROCEDURE|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
58298640|NCT02584283|DRUG|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
58298641|NCT03041636|DRUG|Ruxolitinib|Given PO
58298642|NCT03041636|DRUG|Ruxolitinib Phosphate|Given PO
58298643|NCT04662112|DRUG|NASOX|Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
58409930|NCT01480518|GENETIC|DNA analysis|
58409931|NCT01480518|GENETIC|comparative genomic hybridization|
58409932|NCT01480518|GENETIC|gene expression analysis|
58409933|NCT01480518|GENETIC|mutation analysis|
58409934|NCT01480518|GENETIC|polymerase chain reaction|
58298644|NCT02782741|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
58298645|NCT02782741|DRUG|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
58298646|NCT01274351|DRUG|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
58409935|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
58409936|NCT01480518|OTHER|laboratory biomarker analysis|
58409937|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
58409938|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
58079620|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
58079621|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
58079622|NCT00594334|DRUG|Risedronate|Weekly Risedronate
58298647|NCT04622917|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
58298648|NCT04622917|DRUG|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
58298649|NCT01372046|BEHAVIORAL|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
58298650|NCT01372046|BEHAVIORAL|Training|memorandums, staff meetings
58298651|NCT01756989|DRUG|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
58298652|NCT06310811|DRUG|RD06-04 Cells injection|Patient will be treated with RD06-04 cells when enrolled in the study
58298653|NCT01437618|DRUG|FOLFOXIRI plus bevacizumab|"* BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
58409939|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
58409940|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
58409941|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
58409942|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
58409943|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
58409944|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
58409945|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
58409946|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
58409947|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
58409948|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
58409949|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
58409950|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
58409951|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
57945650|NCT03599128|OTHER|Placebo|Reconstituted in water and given to subjects
57945651|NCT04347915|DRUG|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
57945652|NCT04347915|DRUG|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
57731987|NCT06328647|OTHER|Routine care|Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
57945653|NCT01578408|PROCEDURE|Total Hip Arthroplasty|
57945654|NCT01578408|DEVICE|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
57945655|NCT01578408|DEVICE|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
57945656|NCT02374099|DRUG|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
57945657|NCT02374099|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
57945658|NCT01066585|DRUG|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
58298654|NCT00971867|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
57945659|NCT01066585|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
57945660|NCT00213187|BEHAVIORAL|Aerobic and Qi gong Exercise|
57945661|NCT05635799|OTHER|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
57945662|NCT05635799|OTHER|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
57945663|NCT05635799|OTHER|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
57945664|NCT05635799|OTHER|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
57945665|NCT04620551|DEVICE|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
57945666|NCT00625989|DRUG|Aeroallergen|
57945667|NCT01334151|DRUG|Insulin LISPRO|Single doses of: 0.15 U/kg
57945668|NCT01334151|DRUG|recombinant human insulin|Single doses of: 0.15 U/kg
58298655|NCT04936503|DIAGNOSTIC_TEST|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
58298656|NCT04936503|DIAGNOSTIC_TEST|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
57945669|NCT02800070|BIOLOGICAL|Lentivirus Alpha-gal A transduced stem cells|
57945670|NCT01064674|OTHER|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
57945671|NCT05872802|OTHER|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
57945672|NCT05872802|OTHER|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
57945673|NCT00258011|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
58079623|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
58409952|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
58409953|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
58409954|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
58409955|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
58409956|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
58409957|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
58409958|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
57731988|NCT05659290|DRUG|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
57945674|NCT05138042|OTHER|Cryotherapy (frozen glove)|"In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes."
57945675|NCT02080442|OTHER|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
57945676|NCT00006507|BEHAVIORAL|Occupational Therapy|
57945677|NCT03250260|OTHER|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
57945678|NCT03250260|OTHER|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
57945679|NCT06247436|DIETARY_SUPPLEMENT|Branch Chained Amino Acids|postoperative BCAA consumption
57945680|NCT00851201|BEHAVIORAL|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
57945681|NCT00851201|BEHAVIORAL|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
57945682|NCT00585000|DRUG|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
58409959|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
58409960|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
57945683|NCT03829657|DRUG|ampreloxetine|Oral tablet, QD (Daily)
57731989|NCT05659290|DRUG|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
57945684|NCT03829657|DRUG|Placebo|Oral tablet, QD
57945685|NCT00007839|DRUG|beta alethine|
58079624|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
58079625|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
58298657|NCT04936503|DIAGNOSTIC_TEST|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
57945686|NCT04491539|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
58298658|NCT04936503|DIAGNOSTIC_TEST|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
58409961|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
58409962|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
57945687|NCT02524470|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
57945688|NCT02524470|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
57945689|NCT04599322|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
57945690|NCT04111640|OTHER|CoRe software|Computer-supported cognitive training (CT)
57945691|NCT04111640|OTHER|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
57945692|NCT03428763|DEVICE|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~* Joint score by the patient~* Patient global disease activity measured on a 0-100 mm visual analogue scale.~* CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
58079626|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
58298659|NCT04936503|OTHER|Questionnaire|To determine the rhythmic risk of athletes
58298660|NCT04936503|DEVICE|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~* 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~* 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
58409963|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
58409964|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
58409965|NCT02159222|PROCEDURE|Additional physical therapy|
58409966|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
58409967|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
58079627|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
58298661|NCT04936503|BIOLOGICAL|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
58298662|NCT02049736|DRUG|Telbivudine|
58298663|NCT04253340|DIAGNOSTIC_TEST|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
58298664|NCT00346749|DRUG|Salmeterol|
58409968|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
58409969|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
58409970|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
57945693|NCT03428763|OTHER|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
57945694|NCT04338009|OTHER|Discontinuation of ARB/ACEI|The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
57945695|NCT04338009|OTHER|Continuation of ARB/ACEI|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
58298665|NCT00346749|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
58298666|NCT03239678|DRUG|100% Oxygen|Conventional preoxygenation with 100% oxygen
58298667|NCT03239678|DRUG|30% Oxygen|preoxygenation with 30% oxygen
58298668|NCT03239678|DRUG|21% Oxygen|preoxygenation with 21% oxygen
58298669|NCT03239678|DRUG|40% Oxygen|preoxygenation with 40% oxygen
58409971|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
58409972|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
58409973|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
58409974|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
58298670|NCT03239678|DRUG|60% Oxygen|preoxygenation with 60% oxygen
57945696|NCT00865397|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
57945697|NCT02256514|BIOLOGICAL|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
58298671|NCT03239678|DRUG|80% Oxygen|preoxygenation with 80% oxygen
58298672|NCT05919550|DRUG|search for a clozapine intake|search for a clozapine intake
58298673|NCT01081613|OTHER|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
58298674|NCT02554760|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
58298675|NCT06173479|BEHAVIORAL|HeBSaPU|HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
58298676|NCT04153279|BIOLOGICAL|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
57945698|NCT00277511|DRUG|Levofloxacin|
57945699|NCT05086536|OTHER|no intervention|This is a retrospective and observational study.
58298677|NCT05720559|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
58298678|NCT05720559|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
58079628|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
58079629|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
58079630|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
58079631|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
58079632|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
58079633|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
58079634|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
58079635|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
58079636|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
58409975|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
58409976|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
58409977|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
58409978|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
58079637|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
58409979|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
58079638|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
58079639|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
58079640|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
58079641|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
58409980|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
58079642|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
58079643|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
58079644|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
58079645|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
58079646|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
58079647|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
58079648|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
58409981|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
58409982|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
57945700|NCT03045679|OTHER|RYGB|laparoscopic RYGB
57945701|NCT03045679|OTHER|OAGB/MGB|laparoscopic OAGB/MGB
57945702|NCT02187172|DRUG|Ustekinumab|
57945703|NCT02187172|DRUG|Placebo|
57945704|NCT02820155|DRUG|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
58298679|NCT05720559|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
57945705|NCT02820155|DRUG|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
57945706|NCT06489483|BEHAVIORAL|Action Regulation Movement Task|A joystick is utilized to trace the movement of a visual stimulus on a computer screen. In stop signal task, the subjects are required to move a reference dot to reach to a target dot by controlling a joystick and stop their movements when the target turns red. During the switch task, subjects will be required to switch their joystick movement trajectory when the target location is switched to one of the other target locations.
57945707|NCT03425214|OTHER|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
57945708|NCT03425214|OTHER|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
57945709|NCT03425214|OTHER|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
57945710|NCT01843842|DRUG|Ergoferon|Safety and Efficiency of liquid dosage form
57945711|NCT01843842|DRUG|Placebo|Safety and Efficiency of liquid dosage form
57945712|NCT00638001|DEVICE|custom-molded insoles and custom-molded shoes|"* custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~* custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
58079649|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
58298680|NCT05720559|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
58298681|NCT05720559|DRUG|Vitamin A|Vitamin A 25,000 units/time, qd
58298682|NCT05720559|DRUG|Folic acid|Folic acid 0.4 mg/time, qd
58298683|NCT05720559|DRUG|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
57945713|NCT05344794|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-6 and NE levels were detected.
57945714|NCT05160961|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
57945715|NCT05160961|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
57945716|NCT04090008|DRUG|PRP gel|The PRP gel is applied on the ulcer twice per week
57945717|NCT04090008|DRUG|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
57945718|NCT03357731|DRUG|HNO Donor|Infusion
57945719|NCT03357731|DRUG|Nitroglycerin (NTG)|Infusion
57945720|NCT03357731|OTHER|Placebo|Infusion
57945721|NCT02366442|OTHER|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
57945722|NCT03221751|DRUG|prazosin hydrochloride|Prazosin is an oral capsule. It is an alpha-1 antagonists.
57945723|NCT03221751|DRUG|placebo|Placebo is an inert oral capsule identical in appearance to prazosin capsules.
58079650|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
58079651|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
58079652|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
58079653|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
58079654|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
58079655|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
58298684|NCT03103191|DIAGNOSTIC_TEST|KL-6 levels|Measure of KL-6 in serum
58298685|NCT04838847|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection
58298686|NCT04691128|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
58298687|NCT04691128|DRUG|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
58409983|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
58409984|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
58409985|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
58298688|NCT01124812|OTHER|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~1. Cohorts 1, 2 \& 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 \& 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 \& 3. Treatment cycles will be repeated every 28 days.~2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~   * Total treatment duration is 8-16 weeks"
58298689|NCT00498680|DRUG|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
58298690|NCT00498680|DRUG|Sildenafil|100mg
58298691|NCT00498680|DRUG|Vardenafil|20mg
58298692|NCT00498680|DRUG|Sildenafil & Vardenafil|50mg \& 10 mg
58298693|NCT00019461|DRUG|carboxyamidotriazole|
58298694|NCT00019461|DRUG|chemotherapy|
58298695|NCT00616551|DRUG|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
58298696|NCT00616551|DRUG|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
58298697|NCT02700048|DRUG|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
58298698|NCT02700048|DRUG|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
58409986|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
57945724|NCT04168866|PROCEDURE|Operative management|Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
57945725|NCT04168866|OTHER|Drainage or antibiotics|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
57945726|NCT04878770|DRUG|Topical corticosteroids|Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
57945727|NCT04878770|DRUG|Systemic cyclosporine|"Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months."
58079656|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
58079657|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
58079658|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
58079659|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
58298699|NCT03335800|DEVICE|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
58298700|NCT04567940|BEHAVIORAL|ENRED@TE: Behavioural multicomponent intervention|Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
58298701|NCT02671253|PROCEDURE|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
58298702|NCT01368263|DRUG|goserelin acetate|Given SC
58298703|NCT01368263|DRUG|letrozole|Given PO
58298704|NCT01368263|DRUG|anastrozole|Given PO
58298705|NCT01368263|DRUG|chemotherapy|Standard chemotherapy
58298706|NCT01368263|PROCEDURE|Surgery|
58298707|NCT05353088|OTHER|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
58409987|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
58409988|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
58409989|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
58409990|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
58409991|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
58079660|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
58079661|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
58409992|NCT01113489|DRUG|placebo|1 ml b.i.d.
57945728|NCT04878770|DRUG|Systemic dupilumab|Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
58079662|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
58079663|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
58298708|NCT05353088|OTHER|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
58409993|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
57945729|NCT02694770|BIOLOGICAL|Neihulizumab Treatment|Monoclonal antibody
57945730|NCT02694770|BIOLOGICAL|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
57945731|NCT02615483|OTHER|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
57945732|NCT03672279|DIAGNOSTIC_TEST|CogCheck|Novel self-administered cognitive assessment tool
57945733|NCT03784547|DRUG|Ocrelizumab|already described
58079664|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
58079665|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
58298709|NCT03721224|DIAGNOSTIC_TEST|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
58298710|NCT03686072|PROCEDURE|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
58298711|NCT01439646|OTHER|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
58298712|NCT05093556|BEHAVIORAL|iCHART - Interactive CBT for Headache And Relaxation Training|IVR based cognitive behavioral therapy for headache
58298713|NCT02322749|DRUG|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
58298714|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
58298715|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
58409994|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
58409995|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
58409996|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
58298716|NCT05133323|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm.
58298717|NCT05133323|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
58298718|NCT02653157|OTHER|MDR-GNB|
58409997|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
58409998|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
58298719|NCT00186342|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
58298720|NCT01409239|DRUG|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
58298721|NCT01409239|DRUG|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
58409999|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
58410000|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
58410001|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
58079666|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
58079667|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
58079668|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
58079669|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
58079670|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
58079671|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
58079672|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
58079673|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
58079674|NCT04964076|OTHER|No intervention|No intervention
58079675|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
58079676|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
58298722|NCT06193174|DRUG|C134 Re-Administration|Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
58298723|NCT00002610|BIOLOGICAL|dactinomycin|
58410002|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
58410003|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
57945734|NCT05735691|PROCEDURE|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
57945735|NCT05735691|PROCEDURE|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
57945736|NCT05735691|PROCEDURE|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
57945737|NCT00234468|DRUG|Iressa (Gefitinib)|
57945738|NCT01722604|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
57945739|NCT01722604|DRUG|Azopt 1%|Azopt 1%, RLD
58410004|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
57945740|NCT06015139|DEVICE|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
57945741|NCT06015139|DEVICE|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
57945742|NCT05651165|DEVICE|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
58079677|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
58079678|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
58079679|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
58079680|NCT00210366|DRUG|Idarubicin|
58079681|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
58079682|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
58079683|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
58079684|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
58079685|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
58298724|NCT00002610|BIOLOGICAL|filgrastim|
58298725|NCT00002610|DRUG|carboplatin|
58298726|NCT00002610|DRUG|cyclophosphamide|
58298727|NCT00002610|DRUG|doxorubicin hydrochloride|
58298728|NCT00002610|DRUG|etoposide|
58298729|NCT00002610|DRUG|vincristine sulfate|IV
58298730|NCT00002610|PROCEDURE|conventional surgery|
58298731|NCT00002610|RADIATION|radiation therapy|
58410005|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
58410006|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
58410007|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
58410008|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
57945743|NCT05651165|DEVICE|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
57945744|NCT04344470|DEVICE|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
57945745|NCT04344470|DEVICE|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
57945746|NCT00702364|DRUG|atomoxetine|
57945747|NCT00702364|DRUG|placebo|
57945748|NCT01989312|PROCEDURE|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
58298732|NCT01882296|DRUG|AGSPT_10|AGSPT 10mg for 7days administration
58298733|NCT01882296|DRUG|AGSPT_20|AGSPT 20mg for 7days administration
57945749|NCT01989312|PROCEDURE|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
57945750|NCT01989312|DEVICE|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
57945751|NCT01989312|DEVICE|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
57945752|NCT01989312|DRUG|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
57945753|NCT01989312|DRUG|Lidocaine|
57945754|NCT01989312|DRUG|Epinephrine|
57945755|NCT01989312|DRUG|Levobupivacaine|
57945756|NCT03180099|DRUG|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
58079686|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
58298734|NCT01882296|DRUG|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
58079687|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
58079688|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
58079689|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
58298735|NCT01882296|DRUG|Pantoprazole_20|Pantoprazole 20mg for 7days administration
58298736|NCT01882296|DRUG|Pantoprazole_40|Pantoprazole 40mg for 7days administration
58298737|NCT04710719|DRUG|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
58298738|NCT04710719|DRUG|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
58298739|NCT01239394|DRUG|ofatumumab|Weekly infusion for 8 weeks
58298740|NCT04536662|DRUG|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
58298741|NCT04536662|DRUG|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
58410009|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
58410010|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
58410011|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
58079690|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
58410012|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
58410013|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
58410014|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
58079691|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
58298742|NCT04536662|DRUG|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
58298743|NCT06376487|DEVICE|Flow rate evaluation|Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
58410015|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
58410016|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
57945757|NCT03180099|DRUG|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
57945758|NCT06208787|BEHAVIORAL|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
57945759|NCT06208787|BEHAVIORAL|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
57945760|NCT00652366|DRUG|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
57945761|NCT00652366|DRUG|Erlotinib, standard dose|100mg, PO, once daily
58079692|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
58079693|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
58079694|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
58079695|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
58079696|NCT00048438|DRUG|paricalcitol|
58079697|NCT01671462|DEVICE|BD HPV assay on Viper LT|
58298744|NCT06612008|DEVICE|Mandibular Advancement Device|MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
58298745|NCT01803659|DIETARY_SUPPLEMENT|b-carotene|
58298746|NCT01803659|DIETARY_SUPPLEMENT|retinyl palmitate|
58298747|NCT01803659|DIETARY_SUPPLEMENT|placebo|
58410017|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
58410018|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
58410019|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
58410020|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
58410021|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
58410022|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
58410023|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
58410024|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
58410025|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
58410026|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
58410027|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
58410028|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
58079698|NCT02405182|OTHER|Magnetic Resonance Imaging|
58410029|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
58079699|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
58079700|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
58079701|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
58079702|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
58079703|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
58079704|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
58079705|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
58079706|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
58079707|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
58079708|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
58079709|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
58079710|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
58298748|NCT00710255|PROCEDURE|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
58298749|NCT03492437|DRUG|Dabigatran Etexilate|Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
58298750|NCT03492437|DRUG|Tepotinib|Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
57945762|NCT00652366|DRUG|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
57945763|NCT00927290|DRUG|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
58079711|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
58298751|NCT02871674|BEHAVIORAL|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
58298752|NCT00248469|BEHAVIORAL|In-school Sexual Health Education|
58298753|NCT00248469|BEHAVIORAL|Youth-friendly health services|
57945764|NCT00927290|DRUG|Placebo|Placebo 45 mg QD (30 mg QD the first month)
57945765|NCT03268434|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
58079712|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
58079713|NCT03804554|OTHER|Non-Interventional|Non-Interventional
58079714|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
58079715|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
58079716|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
58079717|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
58079718|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
58079719|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
58298754|NCT00248469|BEHAVIORAL|Youth condom promotion & distribution|
58298755|NCT00248469|BEHAVIORAL|Community activities related to adolescent sexual health|
58410030|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
58410031|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
58410032|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
58410033|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
58410034|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
58410035|NCT04410666|OTHER|Placebo Mouthwash|distilled water
58079720|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
58079721|NCT03133429|DEVICE|MER|carotid artery stenting
58079722|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
58079723|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
57945766|NCT03268434|BEHAVIORAL|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
58298756|NCT03169478|PROCEDURE|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
57945767|NCT04885088|DEVICE|Wisdom bracelet|Wisdom bracelet
57945768|NCT02200354|DRUG|pemetrexed with bevacizumab|
57945769|NCT04675164|DEVICE|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
57945770|NCT04675164|PROCEDURE|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
57945771|NCT01756040|DRUG|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
57945772|NCT00440479|DRUG|Bortezomib|dose as determined (observational study) by treating physician
58298757|NCT00356109|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
58298758|NCT00356109|DRUG|Injectable insulin|patient specific dose, injected, before meals, 6 months
58298759|NCT00356109|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
58298760|NCT02151617|DRUG|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
57945773|NCT02582606|OTHER|Regular meal pattern|a 14-day period of eating 6 meal per day
58298761|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
57945774|NCT02582606|OTHER|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
57945775|NCT01707043|DRUG|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
57945776|NCT01224626|DRUG|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
57945777|NCT02737852|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
57945778|NCT02087956|BEHAVIORAL|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
57945779|NCT02087956|BEHAVIORAL|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
57945780|NCT05095870|OTHER|No intervention|Pure observational study
57945781|NCT00433914|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
58079724|NCT06309069|OTHER|None, purely observational study|None, purely observational study
58079725|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
58079726|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
58079727|NCT02672475|DRUG|Galunisertib|Given PO
58079728|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
58079729|NCT02672475|DRUG|Paclitaxel|Given IV
58079730|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
58079731|NCT05534958|DEVICE|Accexible|Speech Analysis
58079732|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
58079733|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
58079734|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
58079735|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
58079736|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
58298762|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
58298763|NCT02151617|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
58298764|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
58298765|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
58298766|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
58298767|NCT02151617|DRUG|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
57731990|NCT06467045|OTHER|Pediatric patients who received sedation for magnetic resonance imaging|Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
58079737|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
58079738|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
57731991|NCT04419493|DRUG|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
57945782|NCT00433914|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
58079739|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
58079740|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
58298768|NCT02151617|DRUG|PF-06743649|Tablet, to be decided dose, once daily, 14 days
58410036|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
58079741|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
57945783|NCT02821611|BEHAVIORAL|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
57945784|NCT01792804|DRUG|Trimethoprim-Sulfamethoxazole|study drug 1
57945785|NCT01792804|DRUG|Clindamycin|study drug 2
57945786|NCT01792804|DRUG|Linezolid|study drug 3
57945787|NCT01792804|DRUG|Flucloxacillin|study drug 4
58410037|NCT01878110|BEHAVIORAL|COMB|
58079742|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
58079743|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
57731992|NCT04419493|DRUG|Alteplase (from current manufacturing process)|Alteplase, TPA-02
58079744|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
57731993|NCT04419493|DRUG|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
57731994|NCT03778294|PROCEDURE|Computed Tomography|Undergo PET/CT
58079745|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
58298769|NCT02151617|DRUG|Placebo|Tablet, once daily, 14 days
58298770|NCT00601315|DRUG|Clarithromycin|
58298771|NCT02410863|DRUG|Dabrafenib|150 mg twice daily
57731995|NCT03778294|OTHER|Fluorodopa F 18|Given IV
57731996|NCT03778294|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
57731997|NCT03778294|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
57731998|NCT03778294|RADIATION|Proton Beam Radiation Therapy|Receive proton beam RT
57731999|NCT03778294|OTHER|Quality-of-Life Assessment|Ancillary studies
58298772|NCT02410863|DRUG|Trametinib|2 mg daily
58410038|NCT03080883|DRUG|Apixaban|Given PO
57732000|NCT03778294|OTHER|Questionnaire Administration|Ancillary studies
57732001|NCT03778294|DRUG|Temozolomide|Drug
57945788|NCT01792804|DRUG|Cloxacillin|study drug 5
57945789|NCT01792804|DRUG|Vancomycin|study drug 6
57945790|NCT01792804|DRUG|Daptomycin|study drug 7
57945791|NCT01792804|DRUG|Cefazolin|study drug 8
57945792|NCT02328651|DRUG|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg,iv, Bid\~tid）"
58298773|NCT01569126|DRUG|LY110140|Administered orally as capsules
58298774|NCT01569126|DRUG|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
58298775|NCT06249516|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
58410039|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
58410040|NCT00004564|DRUG|Clopidogrel|
58410041|NCT00004564|DRUG|Atorvastatin|
58410042|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
58410043|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
58079746|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
58079747|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
58079748|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
58079749|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
58079750|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
58079751|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
58079752|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
57945793|NCT02328651|DRUG|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）"
57945794|NCT06248164|OTHER|No intervention|We will not carry out any type of intervention, just observe the behaviors and health parameters of parents and children.
57945795|NCT00891982|DRUG|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
57945796|NCT00891982|DRUG|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
57945797|NCT04329702|BEHAVIORAL|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
57945798|NCT04329702|BEHAVIORAL|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
58079753|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
58079754|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
58410044|NCT01878669|DRUG|N-acetyl cysteine|
58410045|NCT01878669|DRUG|Saline|
58410046|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
58410047|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
58410048|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
57732002|NCT01673139|BEHAVIORAL|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
57732003|NCT01673139|BEHAVIORAL|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
58079755|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
58079756|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
58079757|NCT02730832|OTHER|Questionnaires completed at D0|
58079758|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
58079759|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
58079760|NCT03172910|DRUG|Placebo|Saline for injection
58079761|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
58079762|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
58410049|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
58410050|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
57945799|NCT05993936|DEVICE|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
57945800|NCT05774236|DEVICE|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
58079763|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
58079764|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
58079765|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
58079766|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
58079767|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
58079768|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
58079769|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
58079770|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
58079771|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
58079772|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
58079773|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
58079774|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
58079775|NCT00828009|BIOLOGICAL|bevacizumab|IV
58079776|NCT00828009|BIOLOGICAL|Tecemotide|
58298776|NCT06249516|BIOLOGICAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
58410051|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
58410052|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
58410053|NCT00477269|DRUG|Imatinib mesylate|
58410054|NCT00477269|DRUG|Placebo|
58410055|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
58410056|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
58410057|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
58410058|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
57945801|NCT05774236|DRUG|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
57945802|NCT04926051|DRUG|BMS-986172|Specified dose on specified days
57945803|NCT04926051|OTHER|Placebo|Specified dose on specified days
57945804|NCT03631030|DEVICE|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
58079777|NCT00828009|DRUG|carboplatin|IV
58079778|NCT00828009|DRUG|cyclophosphamide|IV
58410059|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
58079779|NCT00828009|DRUG|paclitaxel|IV
58079780|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
58079781|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
58079782|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
58079783|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
58079784|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
58079785|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
58079786|NCT03772210|OTHER|Sham|Apparent Stimulation administered
58079787|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
58079788|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
58410060|NCT00459693|DRUG|[11C]PBR28|
58298777|NCT06080009|GENETIC|exome sequencing (retrospective) and exome and methylome sequencing (prospective)|"Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed."
58079789|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
58079790|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
58298778|NCT02464137|RADIATION|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
58298779|NCT01145664|DRUG|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
58298780|NCT01145664|DRUG|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
58298781|NCT01145664|DRUG|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
58298782|NCT02427854|BEHAVIORAL|Education by animated training video|Training performed by watching an animated educational video.
58298783|NCT02427854|PROCEDURE|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
58298784|NCT02935569|DEVICE|Compression HeadBand|"* commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
58298785|NCT06225973|DRUG|TL-925|TL-925 is an eye drop.
58298786|NCT06225973|OTHER|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
58298787|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(montly)|once a month
58298788|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(weekly)|once a week
58298789|NCT02000050|DRUG|FOLFOX4|FOLFOX4
58298790|NCT02000050|RADIATION|Tomotherapy|Tomotherapy
58298791|NCT02000050|PROCEDURE|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
58298792|NCT01654770|DEVICE|video capsule endoscopy|
58079791|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
58298793|NCT01654770|DEVICE|double balloon enteroscopy|
58298794|NCT01505413|DRUG|Erlotinib|Erlotinib 100 mg po qd daily
58298795|NCT01505413|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
58298796|NCT01505413|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
58079792|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
58079793|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
58079794|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
58079795|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
58298797|NCT00898066|GENETIC|cytogenetic analysis|marrow and peripheral blood
58298798|NCT00898066|GENETIC|fluorescence in situ hybridization|marrow and peripheral blood
58298799|NCT01162889|DRUG|Placebo SC Injection|Single injection
58298800|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
58298801|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
58298802|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
58410061|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
58298803|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
58298804|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
58298805|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
58298806|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
58298807|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
58298808|NCT01162889|DRUG|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
58298809|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
58298810|NCT05995834|OTHER|Research questions|"Stage 1: Secondary analysis of a previous international survey to identify items~Stage 2: Cognitive debriefing interviews with about 10 people living with iMCD to assess the content validity of the items~Stage 3: Completion of questionnaire to finalise scale~Stage 4a: Re-administering of follow-up questionnaire to Stage 3 patients to assess minimally important clinical difference. Test-retest will be calculated only in patients exhibiting no change.~Stage 4b: Qualitative interviews with a subset of participants from Stages and 4 to help with interpretation of meaningful difference from their perspective"
58298811|NCT02214940|DRUG|BI 11634|
58298812|NCT02214940|DRUG|Placebo|
58079796|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
58079797|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
58079798|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
58079799|NCT01896518|DRUG|Nicotine polacrilex|
58079800|NCT01896518|DRUG|Tobacco lozenge|
58079801|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
58079802|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
58079803|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
58079804|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
58079805|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
58079806|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
58079807|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
58079808|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
58079809|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
58079810|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
58079811|NCT00742404|DRUG|bortezomib|
58079812|NCT00742404|DRUG|dexamethasone|
58079813|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
58079814|NCT00742404|GENETIC|protein analysis|
58079815|NCT00742404|OTHER|immunologic technique|
58079816|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
58298813|NCT04583007|DRUG|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
58298814|NCT04583007|DRUG|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
58298815|NCT01014247|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
58298816|NCT01014247|DRUG|Placebo|Single dose of matching tablet
58079817|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
58079818|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
58079819|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
58079820|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
58079821|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
58298817|NCT00239070|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
58079822|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
58079823|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
58079824|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
58079825|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
58079826|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO_QOL.
58079827|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
58079828|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
58079829|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
58079830|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
58079831|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
58079832|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
58079833|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
58079834|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
58079835|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
58079836|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
58079837|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
58079838|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
58079839|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
58410062|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
58410063|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
58079840|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
58079841|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
58079842|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
58079843|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
58079844|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
58079845|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
58410064|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
58079846|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
58079847|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
58079848|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
58079849|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
58079850|NCT05623189|DRUG|Placebo|Placebo, BID
58079851|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
57945805|NCT03166566|DEVICE|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
57945806|NCT04172714|DEVICE|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
57945807|NCT04660461|DRUG|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
57945808|NCT04660461|DRUG|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
57945809|NCT01786603|DRUG|Rasagiline|Rasagiline 2mg once a day for 12 months.
57945810|NCT01786603|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
57945811|NCT05193253|PROCEDURE|Radiofrequency ablation|Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
57945812|NCT05193253|PROCEDURE|Liver resection|Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
57945813|NCT05193253|PROCEDURE|Liver transplantation|Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
58079852|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
58079853|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
58079854|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
58079855|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
58079856|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
58410065|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
58410066|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
57732004|NCT01673139|BEHAVIORAL|Control|Given information on recommendations for physical activity.
57732005|NCT01847846|DEVICE|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
57732006|NCT02599792|DRUG|CTP-656|
58079857|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
58079858|NCT01869231|DIETARY_SUPPLEMENT|water|
58079859|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
58079860|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
58079861|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
58079862|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
58410067|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
58410068|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
58079863|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
57945814|NCT04143009|BEHAVIORAL|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
58079864|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
58079865|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
58079866|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
58079867|NCT00286936|DRUG|Zolpidem|
58079868|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
58079869|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
58079870|NCT01946295|DRUG|Placebo|
58079871|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
58079872|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
58410069|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
58410070|NCT02252549|DEVICE|WLI assisted TURB|
58410071|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
58410072|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
58410073|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
58079873|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
58079874|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
58079875|NCT05333861|DRUG|hetrombopag|According to prescription
58079876|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
58079877|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
58079878|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
58079879|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
58410074|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
58079880|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
58079881|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
58410075|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
58410076|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
58410077|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
58410078|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
58410079|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
58410080|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
58298818|NCT04013295|OTHER|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
58298819|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
58298820|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
58298821|NCT06229223|BEHAVIORAL|PALOMA|Partnering with Parents of Adolescent Latinos on Mental Health Assistance
58298822|NCT02412124|PROCEDURE|Supportive Care|Complete W2W mentoring program
58298823|NCT02412124|OTHER|Quality-of-Life Assessment|Complete the FACT-G
58298824|NCT02412124|OTHER|Questionnaire Administration|Complete the W2W Patient Survey
58298825|NCT04838002|DEVICE|Extracorporeal shock wave|Focus and Radial types Extracorporeal shock wave therapy
58298826|NCT05864534|DRUG|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
58298827|NCT05864534|DRUG|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
58298828|NCT05864534|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
58298829|NCT05864534|DEVICE|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
58298830|NCT05458986|OTHER|Media Intervention|Watch an educational video
58298831|NCT05458986|OTHER|Best Practice|Receive usual care
58298832|NCT05458986|OTHER|Questionnaire Administration|Ancillary studies
58298833|NCT05694858|COMBINATION_PRODUCT|Lignocaine-loaded maltose microneedle array patch|A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to intravenous cannulation
58298834|NCT05694858|DRUG|EMLA 5% patch|EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to intravenous cannulation
58298835|NCT02571140|DRUG|Teriparatide|subcutaneous standard injection
58298836|NCT02571140|DRUG|Oral PTH (1-34)|Different optimization of API
58298837|NCT00087100|DRUG|pemetrexed disodium|
58298838|NCT01026948|DRUG|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
58298839|NCT01026948|DEVICE|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
58298840|NCT06523010|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
58079882|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
58298841|NCT06523010|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
58298842|NCT05499884|PROCEDURE|Endovaginal ultrasound|"Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion"
58298843|NCT04868019|DRUG|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
58298844|NCT01921803|RADIATION|hypofractionation|
58298845|NCT04965181|BEHAVIORAL|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
58298846|NCT04965181|DRUG|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
57732007|NCT02599792|DRUG|Placebo for CTP-656|
57732008|NCT02599792|DRUG|Kalydeco|
57732009|NCT02025777|DEVICE|Capsule Endoscopy|
58079883|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
58410081|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
58410082|NCT02261129|DRUG|Telmisartan film-coated tablet|
57945815|NCT04143009|OTHER|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
57945816|NCT04143009|BEHAVIORAL|Adapted Friendship Bench|Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
58079884|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
58079885|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
58079886|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
57945817|NCT02695992|DRUG|Metoprolol|Dosage 100 mg o.d.
58079887|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
58079888|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
58079889|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
58079890|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
58079891|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
58079892|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
58410083|NCT02261129|DRUG|Telmisartan uncoated tablet|
58410084|NCT00330044|DRUG|Premetrexed (Alimta)|
58079893|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
58079894|NCT00039429|DRUG|atrasentan hydrochloride|
58079895|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
58079896|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
58079897|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
58079898|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
58079899|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
58079900|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
58410085|NCT00330044|DRUG|Carboplatin|
58410086|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
58410087|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
58410088|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
58410089|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
58410090|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
58410091|NCT00257595|DRUG|Cetirizine Dry Syrup|
58410092|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
58410093|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
58410094|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
58410095|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
58410096|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
58410097|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
58298847|NCT04965181|BEHAVIORAL|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
58298848|NCT04965181|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
58298849|NCT01573000|BIOLOGICAL|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
58298850|NCT02903342|OTHER|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
58298851|NCT04260516|DRUG|N-acetyl cysteine|Mucolytic and antioxidant drug
58298852|NCT02405767|OTHER|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
58298853|NCT02085200|OTHER|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
58298854|NCT02085200|OTHER|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
57945818|NCT02695992|DRUG|Diltiazem|Dosage 360 mg o.d.
57945819|NCT06427200|DRUG|oral Iron|oral iron once daily during or after meals as add-on therapy for 12 weeks.
58298855|NCT06158217|PROCEDURE|ultrasound combined with microbubbles|IBC tumors were treated with microbubbles (MBs) stimulated by ultrasound
58410098|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
58410099|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
57945820|NCT06427200|DRUG|Lactoferrin|lactoferrin twice daily before meals as add-on therapy for 12 weeks.
57945821|NCT06427200|DRUG|lactoferrin and oral iron|lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
57945822|NCT04972396|DRUG|ALT-801|Injected subcutaneously (SC)
57945823|NCT04972396|DRUG|Metformin|Taken by mouth (PO)
57945824|NCT04972396|DRUG|Atorvastatin|Taken by mouth (PO)
57945825|NCT04972396|DRUG|Warfarin|Taken by mouth (PO)
57945826|NCT04972396|DRUG|Digoxin|Taken by mouth (PO)
57945827|NCT04972396|DRUG|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
57945828|NCT01977599|OTHER|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
57945829|NCT04880785|DRUG|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
58079901|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
57945830|NCT02833922|BEHAVIORAL|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
57945831|NCT06246565|DRUG|HS-10383|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
58410100|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
58410101|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
57945832|NCT06246565|DRUG|HS-10383 Placebo|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
57945833|NCT05507775|DRUG|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
57945834|NCT02904915|DRUG|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
57945835|NCT02904915|OTHER|No analgesia|IUD placement without analgesia.
57945836|NCT02904915|DEVICE|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
57945837|NCT00130585|BEHAVIORAL|Controlled diet|
57945838|NCT00130585|BEHAVIORAL|folic acid supplement|
57945839|NCT00130585|BEHAVIORAL|13C11-labelled folic acid supplement|
57945840|NCT02963545|OTHER|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
58079902|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
58079903|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
58079904|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
58298856|NCT02725658|DEVICE|DOSI|Breast tissue properties scanning
58298857|NCT01759953|OTHER|Game|InsuOnline game, on the web, in the player´s own time and rhythm
58298858|NCT01759953|OTHER|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
58298859|NCT00874913|DEVICE|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
58298860|NCT00298064|GENETIC|Tissue Repository|
58410102|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
58410103|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
58410104|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
58079905|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
58079906|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
58410105|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
58410106|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
58410107|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
57945841|NCT02963545|BIOLOGICAL|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
57945842|NCT02963545|PROCEDURE|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
57945843|NCT01833611|DRUG|Entecavir|entecavir 0.5mg qd
57945844|NCT01833611|DRUG|placebo|placebo qd
57945845|NCT02004262|BIOLOGICAL|GVAX Pancreas Vaccine|
57945846|NCT02004262|BIOLOGICAL|CRS-207|
58410108|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
57945847|NCT02004262|DRUG|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
58410109|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
58410110|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
57945848|NCT02004262|DRUG|cyclophosphamide|
57945849|NCT05074251|DIAGNOSTIC_TEST|HIV self test|For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).
57945850|NCT05074251|BEHAVIORAL|Counseling and referral for partner testing|Counseling and refer participant's partner for facility based HIV testing
57945851|NCT05964374|DEVICE|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
57945852|NCT02072408|DRUG|aflibercept|"1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~   * Loss of five ETDRS letters or one Snellen line of vision from baseline~  * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~  * Presence of active polyp on indocyanine green angiography"
57945853|NCT03587662|DRUG|Doxorubicin|Given IV
57945854|NCT03587662|DRUG|Doxorubicin Hydrochloride|Given IV
57945855|NCT03587662|DRUG|Gemcitabine|Given IV
57945856|NCT03587662|DRUG|Gemcitabine Hydrochloride|Given IV
57945857|NCT03587662|DRUG|Ixazomib|Given PO
57945858|NCT03587662|DRUG|Ixazomib Citrate|Given PO
57945859|NCT04781621|OTHER|Robotic Gait Training|Participants will wear an exoskeleton suit and receive robotic gait training with a physical therapist for 90 minutes each week. Robot gait training will include standing and walking activities while wearing a robot suit. Participants will be asked to completed questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor.
57945860|NCT04781621|OTHER|Usual Care Gait Training|Participants receive usual care gait training with a physical therapist for 90 minutes each week. Usual care gait training may include standing and walking activities while using a treadmill or walker. Participants will be asked to completed questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor and number of steps.
57945861|NCT02336659|DRUG|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
57945862|NCT02336659|DRUG|sitagliptin|DPP-4 Inhibition
58079907|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
58079908|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
58079909|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
58079910|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58079911|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
58079912|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58079913|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
58079914|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58410111|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
58410112|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
57945863|NCT02336659|OTHER|Placebo|Saline
57945864|NCT05390112|BIOLOGICAL|DNA|ctDNA; cfDNA
58298861|NCT00917124|DEVICE|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
58298862|NCT01898247|OTHER|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
58298863|NCT01132183|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
58298864|NCT01507116|OTHER|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
58298865|NCT06410716|DEVICE|Valve-regulated pleural drainage system|Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
58410113|NCT02743780|DRUG|MGV354 ophthalmic suspension|
57945865|NCT01990638|OTHER|exercise capacity test|
58298866|NCT05200585|BEHAVIORAL|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
58410114|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
58410115|NCT00004664|DRUG|megestrol|
58410116|NCT00004664|BEHAVIORAL|Exercise|
58410117|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
57945866|NCT04391348|RADIATION|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
57945867|NCT00411359|BEHAVIORAL|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
57945868|NCT00888550|PROCEDURE|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
57945869|NCT00888550|PROCEDURE|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
57945870|NCT05560256|OTHER|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
57945871|NCT01669161|DEVICE|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
57945872|NCT01669161|OTHER|Rehab Only|Rehabilitation without device implant and VNS
57945873|NCT01156272|DEVICE|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
57945874|NCT01041482|DRUG|sorafenib|sorafenib 400mg twice daily
58410118|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
57945875|NCT00870402|DRUG|Spironolactone|25 mg per day for 9 months
58079915|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
58079916|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58298867|NCT05200585|BEHAVIORAL|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
58298868|NCT00224302|DRUG|Duloxetine|
58298869|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
58410119|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
58410120|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
58410121|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
58410122|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
58410123|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
58410124|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
58410125|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
58410126|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
58410127|NCT00304018|BIOLOGICAL|sargramostim|
58410128|NCT00304018|DRUG|busulfan|
57945876|NCT00870402|DRUG|Placebo|Placebo 1 tablet per day for nine months
57945877|NCT01130285|GENETIC|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
58410129|NCT00304018|DRUG|etoposide|
58410130|NCT00304018|DRUG|fludarabine phosphate|
58079917|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
58079918|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58410131|NCT00304018|DRUG|prednisone|
58079919|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
58079920|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
58079921|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
58079922|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
58079923|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
58079924|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
58079925|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
58079926|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
58079927|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
58079928|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
58298870|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
58298871|NCT01494805|OTHER|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
58298872|NCT05460546|DRUG|Jincaopian Tablets high dose|Jincaopian Tablets 0.2g tid p.o.
58298873|NCT05460546|DRUG|Jincaopian Tablets low dose|Jincaopian Tablets 0.1g tid p.o.
58298874|NCT05460546|OTHER|Placebo|Placebo tid p.o.
58298875|NCT03955510|OTHER|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
58410132|NCT00304018|DRUG|tacrolimus|
58410133|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58410134|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
58410135|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
58410136|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
58410137|NCT00072891|BEHAVIORAL|telephone counseling|
58079929|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
58079930|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
58079931|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
58079932|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
58298876|NCT03955510|OTHER|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
58298877|NCT03955510|PROCEDURE|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
58298878|NCT03955510|PROCEDURE|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
57945878|NCT05997329|OTHER|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
57945879|NCT05787080|OTHER|Massage|In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
57945880|NCT00145028|DRUG|Carboplatin|
57945881|NCT05023408|DRUG|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
57945882|NCT05023408|PROCEDURE|Cryotherapy|Cryotherapy used for comparison of efficacy.
58079933|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
58079934|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
58079935|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
58079936|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
58079937|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
58079938|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
58079939|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
58079940|NCT01569321|DEVICE|MRI|
58079941|NCT01569321|DEVICE|PET-CT scan|
58079942|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
58079943|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
58079944|NCT00150137|DRUG|Methimazole|
58079945|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
58079946|NCT02268214|DRUG|Dapagliflozin|Tablets
58079947|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
58079948|NCT01229865|DRUG|VB-111|
58079949|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
58410138|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
58410139|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
58298879|NCT03955510|OTHER|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
58298880|NCT05767489|COMBINATION_PRODUCT|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
58079950|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
58079951|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
58079952|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
58079953|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
58079954|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
58079955|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
58079956|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
58079957|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
58079958|NCT02334891|OTHER|Standard|Standard management
58079959|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
58079960|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
58298881|NCT05288114|DEVICE|Signal Relief Patch|Eligible subjects will be provided a Signal Relief patch, the instructions for use, and patch placement materials (adhesive, athletic tape, or wrap as applicable for the location of the pain). Subjects will be instructed to use the patch daily for seven days. The patch must be worn constantly except when showing or swimming.
58079961|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
58079962|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
58079963|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
58079964|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
58079965|NCT01411124|DRUG|placebo|placebo
58079966|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
58079967|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
58079968|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
58079969|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
58079970|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
58079971|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
58079972|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
58079973|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
58079974|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
58079975|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
58079976|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
58079977|NCT04128059|OTHER|placebo|placebo
58079978|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
58079979|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
58298882|NCT02262650|DRUG|Telmisartan|
58298883|NCT02262650|DRUG|Clopidogrel|
58079980|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
58079981|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
58298884|NCT02825914|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|
58079982|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
58079983|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
58298885|NCT02825914|DIETARY_SUPPLEMENT|Placebo|
58298886|NCT02480738|BEHAVIORAL|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
58298887|NCT02552108|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|
58079984|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
58079985|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
58079986|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
58298888|NCT03578627|BEHAVIORAL|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
58298889|NCT03207191|DRUG|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
58298890|NCT03207191|DRUG|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
58298891|NCT04694001|DEVICE|Use of the Atalante exoskeleton|A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
58298892|NCT00577772|DRUG|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
58298893|NCT00577772|DEVICE|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
58298894|NCT00577772|PROCEDURE|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
58298895|NCT04253158|BEHAVIORAL|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
58298896|NCT04253158|BEHAVIORAL|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
58079987|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
57732010|NCT06636058|BEHAVIORAL|vCare Intervention (6-month active treatment followed by 6-month maintenance)|"During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks."
58079988|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
58079989|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
58079990|NCT03085940|DRUG|Placebo|Placebo
58079991|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
58079992|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
58079993|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
58079994|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
58079995|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
58079996|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
57732011|NCT06636058|BEHAVIORAL|vCare Intervention (active treatment after 6 months)|During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
57732012|NCT00936858|DRUG|RAD001|
57945883|NCT00788372|DRUG|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
57945884|NCT02023645|DIETARY_SUPPLEMENT|active supplement|tablet
57945885|NCT02023645|OTHER|placebo|tablet
57945886|NCT03545763|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
57945887|NCT00432042|BIOLOGICAL|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
57945888|NCT00432042|BIOLOGICAL|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
57945889|NCT05947487|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"
58298897|NCT04253158|BEHAVIORAL|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
58298898|NCT04253158|BEHAVIORAL|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
58298899|NCT04253158|BEHAVIORAL|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
57945890|NCT01289236|DRUG|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
57945891|NCT01289236|DRUG|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
58079997|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
58079998|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
58079999|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
58080000|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
58080001|NCT00473928|DRUG|POT-4|Single intravitreal injection.
58080002|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
58080003|NCT02122874|OTHER|1200 Kcal diet|
58080004|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
58080005|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
58080006|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
58298900|NCT04253158|BEHAVIORAL|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
58080007|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
58080008|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
58080009|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
58298901|NCT04253158|BEHAVIORAL|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
58080010|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
58080011|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
58080012|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
58080013|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
58080014|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
58095508|NCT06702046|DEVICE|transcutaneous pulsed radiofrequency acupuncture|For the TCPRF acupuncture group, we choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
58298902|NCT04253158|BEHAVIORAL|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
58298903|NCT03871036|DRUG|Tremelimumab|See experimental arm description for more details.
58298904|NCT03871036|DRUG|Durvalumab|See experimental arm description for more details.
58298905|NCT03871036|DRUG|Paclitaxel|See experimental arm description for more details.
57945892|NCT01289236|DRUG|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
57945893|NCT03913052|PROCEDURE|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
57945894|NCT05843084|PROCEDURE|7T MRI network analysis for deep brain stimulation in Parkinson's disease|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in PD patients.
57945895|NCT03127384|DEVICE|Restylane Lidocaine|Hyaluronic acid based filler
57945896|NCT03127384|OTHER|No-treatment control|No-treatment control
57945897|NCT03788720|PROCEDURE|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
57945898|NCT03788720|PROCEDURE|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
57945899|NCT05685875|OTHER|diabetes|Diabetes and metabolic syndrome defined using criteria by IDF. Obesity defined as BMI\>=30
57945900|NCT03000907|OTHER|Intervention|Diet and physical exercises
57945901|NCT01422915|DRUG|Colestipol|2 grams morning and bedtime for 90 days.
57945902|NCT02613650|DRUG|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
57945903|NCT00002243|DRUG|Calanolide A|
57945904|NCT03588351|DRUG|chitosan nanoparticles gel|intracanal medicament
57945905|NCT03588351|DRUG|chitosan gel|intracanal medicament
57945906|NCT03588351|DRUG|chlorhexidine gluconate|intracanal medicament
57945907|NCT04267341|OTHER|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
57945908|NCT04267341|OTHER|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
57945909|NCT04267341|OTHER|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
57945910|NCT01160757|DEVICE|ultrasound|ultrasound exposure on acute acne lesions
57945911|NCT05442255|OTHER|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
57945912|NCT04227314|DRUG|Apremilast|Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
57945913|NCT04227314|DRUG|Placebo oral tablet|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
57945914|NCT02913690|DIETARY_SUPPLEMENT|Placebo|2 x 150mg capsules daily
57945915|NCT02913690|DIETARY_SUPPLEMENT|TRF|2 x 150mg capsules daily
58298906|NCT03664115|DRUG|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
58298907|NCT03664115|DRUG|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
58298908|NCT06234540|PROCEDURE|PRP|a-PRP intrauterine instillation before frozen-thawed embryo transfer cycle
58298909|NCT06234540|OTHER|Standard treatment|Standard treatment
57945916|NCT03998111|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
57945917|NCT03574870|DEVICE|wearable sensor|A commercially-available wearable fitness sensor
57945918|NCT04784728|DRUG|Lidocaine topical system 1.8%|lidocaine patch
57945919|NCT02582320|DRUG|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
57945920|NCT01355484|DRUG|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
57945921|NCT01355484|DRUG|placebo|subject will receive placebo for the duration of the trial
57945922|NCT02116556|DRUG|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
57945923|NCT02116556|DRUG|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
57945924|NCT05970341|BEHAVIORAL|1. Welcome package|"At the end of the baseline data collection visit at the clinic, the Research Staff will hand the participant a welcome packet that includes:~* educational and motivational written materials (about such topics as CKD and healthy eating for early CKD stages)~* a collection of recipes featuring kidney-friendly vegetables"
57945925|NCT05970341|BEHAVIORAL|2. Welcome information (phone or text)|"Those allocated to the intervention arm will receive a welcome call from the Program Staff to provide further details and expectations about the program (such as delivery details and schedule).~Those allocated to the control arm will receive an SMS text that informs them of their arm allocation, what to expect and a phone number to call for questions."
58095509|NCT06702046|DEVICE|Sham Comparison|same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
58095510|NCT01146886|DRUG|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
58298910|NCT02955303|OTHER|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
58298911|NCT00922870|DEVICE|Cascade|Cascade treatment over 48h
58298912|NCT00922870|OTHER|Standard treatment|Standard therapy
58298913|NCT01705977|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
58080015|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
58298914|NCT01705977|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
58298915|NCT01705977|OTHER|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
58410140|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
58410141|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
58410142|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
58410143|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
58080016|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
58080017|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
58298916|NCT04608045|DRUG|CPX-POM|CPX-POM
58298917|NCT04809441|OTHER|Diet change|A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
58298918|NCT02634073|DRUG|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
58298919|NCT02634073|DRUG|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
58298920|NCT00991081|BEHAVIORAL|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD"
58298921|NCT00991081|BEHAVIORAL|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
58298922|NCT00991081|DRUG|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion"
58410144|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
58410145|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
58410146|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
57732013|NCT06513897|OTHER|Acupressure|Acupressure will be applied to the foreheads of the babies in this group starting two minutes before the heel prick. Acupressure application will be finished when heel prick blood collection is finished.
57732014|NCT06513897|OTHER|Father's Lap|Infants in this group will be placed on the father's lap two minutes before heel prick blood collection. They will remain on the father's lap during the heel prick procedure.
58410147|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
58080018|NCT00003701|DRUG|carboplatin|
58080019|NCT00003701|DRUG|cisplatin|
58410148|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
58410149|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
58410150|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
58410151|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
57732015|NCT00875836|DRUG|Buspirone|Flexible dose, up to 60 mg daily
57732016|NCT00875836|DRUG|Placebo|Flexible dose, up to 60 mg daily
58080020|NCT00003701|DRUG|doxorubicin hydrochloride|
58080021|NCT00003701|DRUG|methotrexate|
58080022|NCT00003701|DRUG|paclitaxel|
58080023|NCT00003701|DRUG|vinblastine sulfate|
58080024|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
58080025|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
58080026|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
58298923|NCT00991081|BEHAVIORAL|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
58298924|NCT00991081|BEHAVIORAL|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
58298925|NCT01204203|DRUG|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
57732017|NCT05457946|BIOLOGICAL|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
57732018|NCT05457946|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
58080027|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
58080028|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
58080029|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
58080030|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
58080031|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
58080032|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
58080033|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
58080034|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
58080035|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
58298926|NCT00324922|DRUG|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
58298927|NCT00324922|DRUG|vancomycin|1g iv bid
58298928|NCT03541291|DEVICE|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
58298929|NCT04804176|DEVICE|Ultra-low frequency repetitive transcranial magnetic stimulation|Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
58298930|NCT06387758|BEHAVIORAL|Low systemic strength training|Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.
58298931|NCT06387758|BEHAVIORAL|Moderate systemic exercise|Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
57945926|NCT05970341|BEHAVIORAL|3. Produce delivery + Recipes customized to produce|"* Content: Bags with kidney-friendly produce will include 2 vegetables sufficient for 2 meals for 4 people, 1 type of fruit, and 1 dried fruit. The total cost is estimated at USD 20, excluding delivery, for prices in June 2022.~* Delivery: Bags will be delivered to the participant's preferred location (e.g. home or work) and period of the day (e.g., morning, evening).~* Recipes: SMS texts will precede each delivery to share an URL to recipes customized to the items being delivered, and to inform of an upcoming produce bag, its content.~* Frequency:~  1. Weeks 1-2 (2 weeks): No bags delivered.~ 2. Weeks 3-10 (8 weeks): Delivered weekly, for a total of 8 bags.~ 3. Weeks 11-18 (8 weeks): Delivered every two weeks, for a total of 4 bags.~ 4. Weeks 19-26 (8 weeks): No bags delivered."
58080036|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
58080037|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
58080038|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
58080039|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
58080040|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
58080041|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
58080042|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
58080043|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
58080044|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
58080045|NCT00037908|PROCEDURE|Strength training|
58080046|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
58080047|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
58080048|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
58080049|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
58080050|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
58080051|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
58080052|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
58080053|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
58080054|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
58080055|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
58080056|NCT02681991|DRUG|Renamezin capsule|
58080057|NCT03174457|DRUG|Micafungin|Intravenous
58080058|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
58080059|NCT00118209|BIOLOGICAL|rituximab|IV
58080060|NCT00118209|DRUG|cyclophosphamide|IV
58080061|NCT00118209|DRUG|doxorubicin|IV or CIVI
58298932|NCT01973218|BIOLOGICAL|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
58298933|NCT01973218|BIOLOGICAL|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
58298934|NCT01973218|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
58298935|NCT03353324|DRUG|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
58410152|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
58410153|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
58410154|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
58080062|NCT00118209|DRUG|vincristine|IV or CIVI
58080063|NCT00118209|DRUG|prednisone|oral
58080064|NCT00118209|DRUG|etoposide|CIVI
58080065|NCT00118209|DRUG|filgrastim|IV
58080066|NCT00118209|DRUG|pegfilgrastim|IV
58080067|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
58410155|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
58080068|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
58080069|NCT06439186|DRUG|Lidocain|Local anesthesia
58080070|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
58080071|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
58410156|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
58410157|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
57945927|NCT05970341|BEHAVIORAL|4. E-gift cards to a grocery store of choice|"Five (5) e-gift cards to a major local grocery retailer chosen by the participant (from 3 options) at the following frequency:~1. Weeks 1-6: No e-gift card.~2. Week 7: One card of USD 30.00 value.~3. Week 11 \& 15: One card of USD 40.00, for a total of USD 80.00.~4. Week 19 \& 23: One card of USD 60.00, for a total of USD 120.00."
57945928|NCT05970341|BEHAVIORAL|5. Personalized practical & emotional support through a dedicated health partner|"* Each participant is assigned a program staff (dedicated health partner) who call them briefly (15 min or so) over the phone for empathy-based support on the participant's health journey, and practical suggestions for shopping and food preparation.~* The Health Partner will share periodically via SMS text a curated list of evidence-based, trustworthy online educational resources.~* Health partners are not trained to answer medical or health-related questions and will not provide medical guidance or advice of any kind. For such questions, they will encourage participants to contact the clinic or physician.~* Frequency:~  1. Weeks 1-2 (2 weeks): No calls.~ 2. Weeks 3-7 (4 weeks): 2 calls a week, for a total of 8 calls.~ 3. Weeks 8-26 (18 weeks): 1 call every 2 weeks, for a total of 10. But during weeks 7, 11, and 19, participants will be given the choice to keep at 1x/week or decrease to 1x every 4 weeks."
57945929|NCT06159920|DIAGNOSTIC_TEST|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
57945930|NCT00000225|DRUG|Buprenorphine|
57945931|NCT00550680|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
57945932|NCT03861936|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
57945933|NCT03861936|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
57945934|NCT03117075|DEVICE|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
57945935|NCT03410433|DEVICE|Silk 4.0|Silk suture 4.0
57945936|NCT03410433|DEVICE|PG 910 4.0|PG 910 4.0
58080072|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
58080073|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
58080074|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
58080075|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
58095511|NCT01146886|DRUG|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
58080076|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
58080077|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
58080078|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
58080079|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
58080080|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
58080081|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
58080082|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
58080083|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
58080084|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
58080085|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
58410158|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
58080086|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
58080087|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
58080088|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
58080089|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
58080090|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
58080091|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
58080092|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
58080093|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
58080094|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
58080095|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
58080096|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
58080097|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
58080098|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
58080099|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
58080100|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
58080101|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
57945937|NCT03410433|DEVICE|PP 4.0|PP 4.0
58080102|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
58080103|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
58410159|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
57945938|NCT03410433|DEVICE|Silk 5.0|Silk 5.0
57945939|NCT03410433|DEVICE|PG910 5.0|PG910 5.0
57945940|NCT03410433|DEVICE|PP 5.0|PP 5.0
57945941|NCT03410433|DEVICE|APG 5.0|APG 5.0
57945942|NCT03410433|DEVICE|ePTFE 5.0|ePTFE 5.0
57945943|NCT04918030|PROCEDURE|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
57945944|NCT04918030|PROCEDURE|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
57945945|NCT01449461|DRUG|Brigatinib|Brigatinib tablets and capsules.
57945946|NCT02908256|DRUG|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
57945947|NCT02908256|DRUG|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
57945948|NCT03015675|DRUG|ascorbic acid|20g/day, D1-3, every 2 weeks
57945949|NCT03015675|DRUG|mFOLFOX6|"mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
57945950|NCT02676089|DRUG|CHF 5993 200/6/12.5 µg|
58080104|NCT02223624|OTHER|walking and light weights|
58298936|NCT03353324|RADIATION|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
58298937|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
58410160|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
58410161|NCT00481312|DRUG|Midazolam|Continuous Infusion
58410162|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
58410163|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
57945951|NCT02676089|DRUG|CHF 1535 200/6 µg|
57945952|NCT02676089|DRUG|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
57945953|NCT06290349|DRUG|DA5221-T1|DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
57945954|NCT06290349|DRUG|DA5221-T2|DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
57945955|NCT06290349|DRUG|Placebo|DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
57945956|NCT06290349|DRUG|DA5221-B1|DA5221-B1, orally, daily for background therapy
57945957|NCT06290349|DRUG|DA5221-B2|DA5221-B2, orally, daily for background therapy
57945958|NCT03478553|OTHER|Blood draw|Blood draw
57945959|NCT03478553|OTHER|Questionnaire|Pulmonary Fibrosis Questionnaire
57945960|NCT06385249|DEVICE|Navina Mini|Trans-anal irrigation (TAI) with a new CE-marked device, Navina Mini
57945961|NCT02921191|DRUG|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
58080105|NCT02223624|OTHER|eccentric aerobic exercise|
58080106|NCT02223624|OTHER|concentric aerobic exercise|
58080107|NCT00131937|DRUG|sorafenib tosylate|Given orally
58080108|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
58080109|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
58080110|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
58080111|NCT01454037|PROCEDURE|Radiation|Radiate prostate
58080112|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
58080113|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
58080114|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
58080115|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
58095512|NCT05192954|DEVICE|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
58095513|NCT00759759|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
58298938|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
58298939|NCT01950299|DRUG|Placebo|Placebo 0.67 ml injections twice daily
58298940|NCT04619784|OTHER|Pilates Exercises|Patients will receive 12 sessions of pilates.
58298941|NCT04619784|OTHER|control|Their routine medical treatments were continued
58298942|NCT03902769|PROCEDURE|Prescribing conventional chemotherapy while with holding allo-SCT|Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
58080116|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
58080117|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
58410164|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
58410165|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
58410166|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
58410167|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
58410168|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
57945962|NCT04461262|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
57945963|NCT04461262|DEVICE|Standard Care|Uncoated Foley catheter
57945964|NCT05211336|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
57945965|NCT05211336|DRUG|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
57945966|NCT05211336|DRUG|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
57945967|NCT05211336|DRUG|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
57945968|NCT05211336|DRUG|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
57945969|NCT05449626|DIAGNOSTIC_TEST|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
57945970|NCT02767440|BEHAVIORAL|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
57945971|NCT01815047|DIETARY_SUPPLEMENT|Vitamin D3 Supplementation|
58080118|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
58080119|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
58095514|NCT00759759|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
58410169|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
58410170|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
58410171|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
58410172|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
58410173|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
58410174|NCT00004446|DRUG|fluoxetine|
58410175|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
58410176|NCT00717587|DRUG|motexafin gadolinium|
58410177|NCT00717587|DRUG|sunitinib malate|
58410178|NCT00717587|GENETIC|comparative genomic hybridization|
58410179|NCT00717587|GENETIC|gene expression analysis|
58298943|NCT04386902|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
58410180|NCT00717587|GENETIC|mutation analysis|
58080120|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
58080121|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
58080122|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
58080123|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
58080124|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
58080125|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
58080126|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
58080127|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
58080128|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
58080129|NCT02547064|PROCEDURE|Glidescope guided intubation|
58080130|NCT02547064|DEVICE|GlideScope®|
58080131|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
58298944|NCT03158961|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
58298945|NCT03017222|DRUG|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
58410181|NCT00717587|GENETIC|polymorphism analysis|
58410182|NCT00717587|OTHER|immunohistochemistry staining method|
58410183|NCT00717587|OTHER|iodine I-124 girentuximab|
58410184|NCT00717587|OTHER|laboratory biomarker analysis|
58410185|NCT00717587|OTHER|pharmacological study|
58410186|NCT00717587|PROCEDURE|adjuvant therapy|
58410187|NCT00717587|PROCEDURE|neoadjuvant therapy|
58410188|NCT00717587|PROCEDURE|therapeutic conventional surgery|
58410189|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
57732019|NCT05834608|BEHAVIORAL|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
58080132|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
58080133|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
58080134|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
58080135|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
58080136|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
58080137|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
58080138|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
58080139|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
58080140|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
58080141|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
58080142|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
58080143|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
58080144|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
58080145|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
58080146|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
58080147|NCT01716546|DRUG|Pazopanib|
58080148|NCT02623569|DRUG|Ivabradine|Not Provided
58080149|NCT02623569|DRUG|Atenolol|Not Provided
58080150|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
58080151|NCT03605277|DRUG|Asciminib|40 mg single dose
58080152|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
58080153|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
58080154|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
58080155|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
58080156|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
58080157|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
58080158|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
58410190|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
57732020|NCT04291963|PROCEDURE|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
58080159|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
58080160|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
58298946|NCT03017222|DRUG|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
58080161|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
58080162|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
58080163|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
58080164|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
58080165|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
58080166|NCT02584972|OTHER|no intervention required|no intervention required
58080167|NCT00542165|DRUG|Alfuzosin|
58080168|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
58080169|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
58080170|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
58080171|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
58080172|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
58080173|NCT00181051|DEVICE|Alaris AEP monitor|
58080174|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
58080175|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
58080176|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
58080177|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
58080178|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
58410191|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
58080179|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
58080180|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
58080181|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
58298947|NCT00468117|PROCEDURE|Islet transplantation|
58298948|NCT00468117|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
58298949|NCT00468117|BIOLOGICAL|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
58298950|NCT00468117|BIOLOGICAL|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
58080182|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
58080183|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
58080184|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
58080185|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
58080186|NCT00036868|BIOLOGICAL|trastuzumab|
58080187|NCT00036868|DRUG|CMF regimen|
58080188|NCT00036868|DRUG|cyclophosphamide|
58080189|NCT00036868|DRUG|fluorouracil|
58080190|NCT00036868|DRUG|methotrexate|
58080191|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
58298951|NCT00468117|BIOLOGICAL|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
58298952|NCT00003677|DRUG|Dolastatin 10|IV bolus once every 21 days.
58298953|NCT05398406|OTHER|TAP Block group|TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
58298954|NCT05398406|OTHER|Paravertebral block group|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
58298955|NCT05398406|OTHER|Erector spinae block group|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
58298956|NCT03547323|DEVICE|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
58298957|NCT03547323|DEVICE|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
58410192|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
58080192|NCT00471237|DRUG|Teriparatide|PTH (1-34)
58298958|NCT04414852|DRUG|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
58298959|NCT04281082|DRUG|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
58298960|NCT00269152|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
58298961|NCT00269152|DRUG|cisplatin|75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
58298962|NCT00269152|DRUG|carboplatin|area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
58298963|NCT01837251|DRUG|Carboplatin|
58298964|NCT01837251|DRUG|PLD|
58298965|NCT01837251|BIOLOGICAL|Bevacizumab|
58298966|NCT02114619|DRUG|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
58080193|NCT00471237|DRUG|Alendronate|Bisphosphonate
58080194|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
58080195|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
58080196|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
58080197|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
58080198|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
58080199|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
58298967|NCT02114619|DRUG|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
58410193|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
58080200|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
58080201|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
58080202|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
58080203|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
58298968|NCT02114619|DRUG|High dose|We will administer 200 micro currie of iodine per thyroid gram
58298969|NCT02025192|DRUG|Tucatinib|Administered twice per day, orally.
58298970|NCT02025192|DRUG|Capecitabine|1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
58298971|NCT02025192|DRUG|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
58298972|NCT04182958|DRUG|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
57945972|NCT05796102|PROCEDURE|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
57945973|NCT03309085|PROCEDURE|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
57945974|NCT03309085|DEVICE|CT scan|CT scan
57945975|NCT05914636|BIOLOGICAL|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
58298973|NCT02077998|RADIATION|carbon C 14 oxaliplatin|Given IV
58298974|NCT02077998|DRUG|oxaliplatin|Given IV
58298975|NCT02077998|OTHER|laboratory biomarker analysis|Correlative studies
58298976|NCT00857662|DEVICE|Onyx|Embolization
58298977|NCT00857662|DEVICE|TRUFILL|Embolization
58298978|NCT04086810|DRUG|DCCR|Once daily oral administration
58298979|NCT05943366|DEVICE|Keep-on-Keep-Up Nutrition (KOKU-Nut)|Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
58298980|NCT06432478|DEVICE|3D-printed custom applicator|3D-printed custom applicator
58298981|NCT04390646|DRUG|GnRH, gonadorelin acetate|Drug administered by a subcutaneous pump
58298982|NCT04390646|DRUG|0.9% NaCl|Drug administered by a subcutaneous pump
58410194|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
58410195|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
57732021|NCT04291963|PROCEDURE|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
57945976|NCT05598593|DRUG|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
57945977|NCT03716271|DEVICE|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
57945978|NCT06470113|DEVICE|simultaneous cognitive training with transcranial magnetic stimulation|simultaneous cognitive training with transcranial magnetic stimulation can enhance the therapeutic effect and improve brain function non-invasively.
58298983|NCT04441346|RADIATION|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
58298984|NCT00914407|DRUG|Oxygen|100% Oxygen inhalation for 30 minutes
58298985|NCT04915560|DEVICE|Connected T-shirt|Ware of a connected T-shirt
58410196|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
58410197|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
58410198|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
58410199|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
58080204|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
57945979|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
58080205|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
58410200|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
57945980|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
58080206|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
58080207|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
58080208|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
58080209|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
58080210|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
58080211|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
58080212|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
58080213|NCT05931601|DRUG|Noradrenaline|See arm description
58080214|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
58410201|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
58410202|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
58410203|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
58410204|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
58410205|NCT00150228|DRUG|CP-526,555 (varenicline)|
58410206|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
58080215|NCT01280305|DRUG|placebo|Placebo bid
58410207|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
58410208|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
58410209|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
58410210|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
57945981|NCT03370536|DEVICE|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
58080216|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
58080217|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
58080218|NCT02618096|DRUG|Oxytocin|
58080219|NCT02618096|DRUG|Dinoprostone|
58080220|NCT02618096|PROCEDURE|Membrane sweeping|
58080221|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
58080222|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
58080223|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
58080224|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
57945982|NCT03370536|PROCEDURE|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
58080225|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
58080226|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
58080227|NCT01301157|DRUG|M518101|Proper quantity twice a day
58298986|NCT01369264|DEVICE|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
58298987|NCT01369264|DEVICE|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
58080228|NCT01301157|DRUG|placebo|Proper quantity twice a day
58080229|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
58080230|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
58298988|NCT00789503|DIETARY_SUPPLEMENT|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
58080231|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
58080232|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
58080233|NCT02978729|OTHER|Telephone remote genetic counseling|
58298989|NCT04321577|PROCEDURE|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
58298990|NCT05476393|OTHER|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
58298991|NCT03427710|DRUG|CiVi007|cholesterol lowering drug
58298992|NCT03427710|OTHER|Placebo|matching placebo to CiVi007
58298993|NCT04149444|DRUG|Trifluridine/Tipiracil|Oral medication
58298994|NCT05916898|DEVICE|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
58298995|NCT01064271|DRUG|Risperidone|Risperidone Tablets 1 mg
58298996|NCT04645563|OTHER|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
58410211|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
57945983|NCT03370536|DRUG|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
58080234|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
58080235|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
58080236|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
58080237|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
58080238|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
58080239|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
58080240|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
58080241|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
58080242|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
58410212|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
58410213|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
58410214|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
58410215|NCT02238314|DRUG|Tipranavir low dose|
58410216|NCT02238314|DRUG|Tipranavir high dose|
58298997|NCT05867758|OTHER|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer \& Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
58298998|NCT06312865|DEVICE|Ophthalmic exam|include best corrected visual acuity and cycloplegic refraction data
58298999|NCT03933449|BIOLOGICAL|pembrolizumab|IV infusion
58410217|NCT02238314|DRUG|Ritonavir|
58410218|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
57945984|NCT05763797|BEHAVIORAL|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
57945985|NCT05763797|BEHAVIORAL|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
57945986|NCT03120221|DIAGNOSTIC_TEST|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
57945987|NCT03834467|OTHER|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
57945988|NCT03834467|OTHER|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
57945989|NCT02614859|DRUG|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
57945990|NCT02614859|DRUG|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
57945991|NCT04654442|DIAGNOSTIC_TEST|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
57945992|NCT00281645|DRUG|Bicifadine|
57945993|NCT00281645|DRUG|Standard of Care (pharmacological analgesic treatment)|
57945994|NCT04360980|DRUG|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
57945995|NCT00951847|DRUG|oxcarbazepine 300 mg/5 mL oral suspension|
57945996|NCT02888015|OTHER|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
57945997|NCT02263274|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
57945998|NCT05283759|OTHER|No intervention because it is a patient registry|
57945999|NCT03761095|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
57946000|NCT03761095|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
57946001|NCT02088970|DEVICE|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
57946002|NCT02088970|DRUG|antibiotic treatment|"If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone"
57946003|NCT03592706|BIOLOGICAL|IKC (Immune Killer Cells)|
57946004|NCT03592706|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization)|
57946005|NCT02589899|OTHER|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
57946006|NCT04116086|DIAGNOSTIC_TEST|Prostate Biopsy Test|see earlier information
57946007|NCT03518593|OTHER|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
57946008|NCT02110368|DRUG|Testosterone Topical Gel, 1.62% Metered Pump|
57946009|NCT02110368|DRUG|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
57946010|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily
57946011|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
57946012|NCT01197521|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
57946013|NCT06018415|BEHAVIORAL|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
58410219|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
58410220|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
58410221|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
57946014|NCT06018415|BEHAVIORAL|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
57732022|NCT01658787|DEVICE|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
58080243|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
57732023|NCT02079805|DRUG|Azilsartan|Azilsartan tablets
57732024|NCT02079805|DRUG|Telmisartan|Telmisartan tablets
58080244|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
58080245|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
58080246|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
58080247|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
58080248|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
58080249|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
58080250|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
58080251|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
58080252|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
58080253|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
58080254|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
58080255|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
57732025|NCT01316926|DRUG|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
57732026|NCT01316926|DRUG|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
57732027|NCT00823719|DRUG|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle."
58080256|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
58080257|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
58080258|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
58080259|NCT01636011|OTHER|Light Touch sham|Light Touch sham
58080260|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
58299000|NCT03933449|DRUG|paclitaxel|IV infusion
58410222|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
57732028|NCT00823719|DRUG|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle."
57732029|NCT05617716|RADIATION|Conventional external beam radiation therapy dose (EBRT)|Participants will undergo 8 Gray in 1 fraction of EBRT
57732030|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy standard dose|Participants will undergo 24 Gray in 2 fractions of SBRT
58080261|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
58080262|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
58080263|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
58080264|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
58080265|NCT00796367|DRUG|Placebo|placebo
58080266|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
58080267|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
58080268|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
58080269|NCT04864704|OTHER|dry needling|Physical therapy
58080270|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
58080271|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
58299001|NCT03933449|DRUG|docetaxel|IV infusion
58299002|NCT03933449|DRUG|irinotecan|IV infusion
58299003|NCT06140433|DEVICE|VSC-MEDlib|VSC-MEDlib will be used for post-processing
58080272|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
58080273|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
58080274|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
58080275|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
58080276|NCT04435431|DRUG|Mesdopetam|Oral use
58080277|NCT04435431|DRUG|Placebo|Oral use
57732031|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy high dose|Participants will undergo 19 Gray in 1 fraction of SBRT
58080278|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
58080279|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
58080280|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
58080281|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
58080282|NCT01821131|OTHER|muffin|
58080283|NCT00103389|DRUG|PI-88|PI-88+docetaxel
58080284|NCT00103389|DRUG|docetaxel|docetaxel only
58080285|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
58080286|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
58080287|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
58080288|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
58299004|NCT05329857|DRUG|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
58299005|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
58299006|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
58299007|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
58299008|NCT04902781|DRUG|AT-007|Treatment with AT-007 given orally
58299009|NCT04902781|OTHER|Placebo|Placebo given orally
58299010|NCT02970383|BEHAVIORAL|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
58299011|NCT02970383|BEHAVIORAL|Inital prescription for 30 narcotic tabs|
58299012|NCT00315445|DRUG|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
58410223|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
58410224|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
57732032|NCT00742703|OTHER|Mineralized water|
57732033|NCT00742703|OTHER|Low mineralized water|
57732034|NCT02541929|DIETARY_SUPPLEMENT|Docosahexaenoic acid|
58080289|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
58080290|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
58080291|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
58080292|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
58080293|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
58080294|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
58080295|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
58080296|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
58080297|NCT01441882|DRUG|Dasatinib|Given PO
58080298|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
58080299|NCT01441882|OTHER|Pharmacological Study|Correlative studies
58080300|NCT00227591|DRUG|lenalidomide|Given orally (PO)
58080301|NCT00227591|DRUG|prednisone|Given PO
58080302|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
58080303|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
58080304|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
58080305|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
58080306|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
58080307|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
58080308|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
58080309|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
58080310|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
58080311|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
58080312|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
58080313|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
58080314|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
58080315|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
58080316|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
58080317|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
58080318|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
58080319|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
58080320|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
58080321|NCT05018533|DRUG|TAKC-02|Inhalation Solution
57732035|NCT00628771|BEHAVIORAL|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
58080322|NCT05018533|DRUG|Placebo|Inhalation Solution
58299013|NCT00315445|DRUG|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
58299014|NCT00315445|DRUG|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
58299015|NCT00315445|DRUG|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
57732036|NCT00628771|BEHAVIORAL|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
57732037|NCT04236349|GENETIC|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
58080323|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
58080324|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
58080325|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
58080326|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
58299016|NCT00757393|DIETARY_SUPPLEMENT|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
58299017|NCT00757393|DRUG|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
58299018|NCT02346708|DEVICE|Real TMS|real treatment
58299019|NCT02346708|DEVICE|Sham TMS|placebo treatment
58299020|NCT01621386|DRUG|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
58299021|NCT01621386|DRUG|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
58299022|NCT00523913|DRUG|rosiglitazone|
58299023|NCT01808274|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
58410225|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
58080327|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
58080328|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
58080329|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
58080330|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
58080331|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
58080332|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
58080333|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
58080334|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
58080335|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
58410226|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
57732038|NCT04842955|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
57732039|NCT04842955|DEVICE|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
57946015|NCT05642455|GENETIC|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
58080336|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
58080337|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
58080338|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
58080339|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
58080340|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
58080341|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
58080342|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
58080343|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
58080344|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
58080345|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
58080346|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
58080347|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
58080348|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
58080349|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
58080350|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
58080351|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
57732040|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
57946016|NCT04628637|OTHER|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
58080352|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
58080353|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
58080354|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
58080355|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
58080356|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
58080357|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
58080358|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
58080359|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
58080360|NCT00683670|DRUG|cyclophosphamide|
58080361|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
58080362|NCT02213627|DRUG|Corifollitropin alfa|
58080363|NCT02213627|DRUG|Recombinant FSH|
58080364|NCT02213627|DRUG|HP-hMG|
58080365|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
58080366|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
57946017|NCT02634151|DRUG|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
58080367|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58080368|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58080369|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
58080370|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
58080371|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
58410227|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
58410228|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
58410229|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
57946018|NCT02634151|DRUG|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
57946019|NCT01345136|DRUG|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
57946020|NCT00253175|DRUG|topiramate|
57946021|NCT05558475|BEHAVIORAL|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
57946022|NCT01519804|DRUG|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
57946023|NCT01519804|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
57946024|NCT01519804|DRUG|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
57946025|NCT01519804|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
57946026|NCT01380730|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
57946027|NCT01380730|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
57946028|NCT06338904|BEHAVIORAL|Problem-solving-based psychological intervention|The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).
57946029|NCT02956954|DRUG|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
57946030|NCT02956954|PROCEDURE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
57946031|NCT01425827|DRUG|duloxetine HCL|60 mg/day duloxetine for 16 weeks
57946032|NCT01425827|DRUG|placebo|similar looking tablets to the active agent for 16 weeks
57946033|NCT05470751|DEVICE|Intermittent self-catheterisation|Self-catheterising with GC Male and Glide Male with Feelclean technology
57946034|NCT00595556|DRUG|zonisamide|flexible dosages of 100-500mg/day
57946035|NCT00595556|DRUG|Placebo|Placebo
57946036|NCT01476475|DRUG|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
57946037|NCT01476475|DRUG|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
57946038|NCT01476475|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
57946039|NCT05912777|RADIATION|Scanner|Scanner to be performed by patients
57946040|NCT05019898|DIAGNOSTIC_TEST|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~* The quantification of their anxiety~* An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
57946041|NCT02113085|BEHAVIORAL|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
57946042|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
58410230|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
57946043|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
57946044|NCT02214966|DRUG|Telmisartan/Ramipril, fixed dose combination tablet|
57946045|NCT02214966|OTHER|high fat, high caloric meal|
57946046|NCT01702714|DRUG|RO5083945|multiple ascending doses
57946047|NCT01702714|DRUG|carboplatin|up to 6 cycles
57946048|NCT01702714|DRUG|cisplatin|up to 6 cycles
57946049|NCT01702714|DRUG|gemcitabine|up to 6 cycles
57946050|NCT01702714|DRUG|paclitaxel|up to 6 cycles
57946051|NCT03028870|DRUG|V120083|Capsules
57946052|NCT03028870|DRUG|Naproxen|Capsules
57946053|NCT03028870|DRUG|Placebo|Capsules to match V120083 and/or naproxen
57946054|NCT01867060|DEVICE|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
58080372|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
58080373|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
58080374|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
58080375|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
58080376|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
58080377|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
58080378|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
58080379|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
58080380|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
58080381|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
58080382|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
58410231|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
58410232|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
58410233|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
58410234|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
58410235|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
58410236|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
58410237|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
58410238|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
58410239|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
58410240|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
58080383|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
58080384|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
58080385|NCT04943627|DRUG|Topotecan|Chemotherapy
58080386|NCT04943627|DRUG|Vinorelbine|Chemotherapy
57946055|NCT01867060|DEVICE|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
57946056|NCT05246436|PROCEDURE|warming saline media|use warm saline as a distention media in office hysteroscopy
57946057|NCT05246436|PROCEDURE|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
57946058|NCT02284789|OTHER|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
57946059|NCT00418990|DRUG|Multivitamin/Mineral supplements|
58080387|NCT04943627|DRUG|Gemcitabine|Chemotherapy
58080388|NCT04943627|DRUG|Irinotecan|Chemotherapy
58080389|NCT04943627|DRUG|Pemetrexed|Chemotherapy
58080390|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
58080391|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
58080392|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
58080393|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
58080394|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
58080395|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
58080396|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
58080397|NCT00763126|BEHAVIORAL|stress level|Stress levels
58080398|NCT02305069|DRUG|Pioglitazone|Described elsewhere
58080399|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
58080400|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
58080401|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
58080402|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
58080403|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
58080404|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
58410241|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
58080405|NCT01695707|DRUG|Pioglitazone|see Arm Description
58080406|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
58080407|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
58410242|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
58080408|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
58080409|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
58410243|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
58080410|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
58080411|NCT01399619|DRUG|BI201335|BI201335 for 12w
58080412|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
58080413|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
58080414|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
58080415|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
58080416|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
58080417|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
58080418|NCT00002110|DRUG|Cysteamine|
58080419|NCT00002110|DRUG|Zidovudine|
58080420|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
58080421|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
58080422|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
58080423|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
58410244|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
58080424|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
58410245|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
58410246|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
58410247|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
58410248|NCT04533542|OTHER|Measurement|Undergo sensory measurements
58410249|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
58410250|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
58080425|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
58080426|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
58410251|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
58410252|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
58410253|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
58410254|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
58410255|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
58410256|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
57946060|NCT01021956|DRUG|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
58080427|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
58299024|NCT04522648|OTHER|Prospective surveillance|A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
58080428|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
58299025|NCT02391025|DRUG|Gallium-68 citrate|Given via IV at time of imaging
58299026|NCT02391025|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
58410257|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
58410258|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
58410259|NCT05535738|DRUG|Dupilumab|300mg
58410260|NCT05535738|DRUG|Adalimumab|40mg
58410261|NCT05535738|DRUG|Ustekinumab|45mg
58410262|NCT05535738|DRUG|Guselkumab|100mg
58410263|NCT05535738|DRUG|Canakinumab|150mg
57946061|NCT00312624|PROCEDURE|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
57946062|NCT00234936|DRUG|Adalimumab|
57946063|NCT00234936|DRUG|Methotrexate|
57946064|NCT05140655|DRUG|Fulvestrant|Medicine for Advanced breast cancer
58410264|NCT05535738|DRUG|Sarilumab|200mg
57946065|NCT04135339|OTHER|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
57946066|NCT04135339|OTHER|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
58410265|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
58410266|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
58410267|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
58410268|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
58410269|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
58080429|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
58080430|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
58410270|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
58410271|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
58410272|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
58410273|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
57732041|NCT04800029|OTHER|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
57946067|NCT04135339|OTHER|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
58299027|NCT05150431|DRUG|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
58299028|NCT05150431|DRUG|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
58410274|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
58410275|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
58410276|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
58410277|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
57946068|NCT03060135|BEHAVIORAL|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
57946069|NCT03060135|BEHAVIORAL|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
57946070|NCT05666336|BIOLOGICAL|Telitacicept|It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
57946071|NCT05666336|DRUG|Hydroxychloroquine|It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
57946072|NCT05666336|DRUG|Prednisone|It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
57946073|NCT05666336|DRUG|Methylprednisolone|It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
57946074|NCT05666336|DRUG|Cyclophosphamide|It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
57946075|NCT05666336|DRUG|Mycophenolate Mofetil|It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
57946076|NCT05666336|DRUG|Tacrolimus|It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
57946077|NCT05415475|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
57946078|NCT04898270|DRUG|Flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."
57946079|NCT04898270|DRUG|Multi-acting receptor-targeted antipsychotics (MARTAs)|Multi-acting receptor-targeted antipsychotics (MARTAs)
57946080|NCT03870984|DIETARY_SUPPLEMENT|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
57946081|NCT03870984|OTHER|w/oNUTS, low-caloric diet without nuts|low caloric diet
57946082|NCT01423162|OTHER|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
57946083|NCT01423162|OTHER|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
57946084|NCT01439321|BIOLOGICAL|Eltrombopag|Switched to Eltrombopag
57946085|NCT01439321|BIOLOGICAL|Romiplostim|Switched to Romiplostim
57946086|NCT00503646|OTHER|communication intervention|
57946087|NCT00503646|OTHER|counseling intervention|
57946088|NCT00503646|OTHER|questionnaire administration|
57946089|NCT00503646|PROCEDURE|psychosocial assessment and care|
58080431|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
58080432|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
58080433|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
58080434|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
58080435|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
58080436|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
58410278|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
58410279|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
58410280|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
58410281|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
58410282|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
58410283|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
58410284|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
58410285|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
58410286|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
58410287|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
58410288|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
58410289|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
58080437|NCT00003576|DRUG|cisplatin|
58080438|NCT00003576|DRUG|fluorouracil|
58080439|NCT00003576|PROCEDURE|surgical procedure|
58080440|NCT00003576|RADIATION|radiation therapy|
58080441|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
58080442|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
58299029|NCT02965404|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
58299030|NCT02965404|BIOLOGICAL|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
58299031|NCT02965404|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
58410290|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
58080443|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
58410291|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
58410292|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
58410293|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
58410294|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
58410295|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
58410296|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
58410297|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
58410298|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
58410299|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
58410300|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
58410301|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
58080444|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
58080445|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
58080446|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
58080447|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
58080448|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
58299032|NCT01601769|DEVICE|Vitom|Patients treated and diagnosed by vitom
58299033|NCT01601769|DEVICE|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
58299034|NCT00262652|DRUG|sodium pyruvate|
58299035|NCT01605864|DRUG|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
58299036|NCT05486416|DRUG|HSK3486|HSK3486 for induction of general anesthesia
58299037|NCT05486416|DRUG|Propofol|Propofol for induction of general anesthesia
58299038|NCT00902070|DRUG|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
58299039|NCT04751695|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
58299040|NCT01666561|OTHER|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
58410302|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
58410303|NCT02404922|DRUG|CTP-730|
58410304|NCT02404922|DRUG|Placebo for CTP-730|
58410305|NCT02435680|DRUG|MCS110|taken by I.V
58410306|NCT02435680|DRUG|carboplatin|taken by I.V
58410307|NCT02435680|DRUG|gemcitabine|taken by I.V
58410308|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
58410309|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
58410310|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
58410311|NCT04332471|OTHER|Home therapy|Stretching and ice massage
58410312|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
58410313|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
58410314|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
58410315|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
58410316|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
58410317|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
58080449|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
58080450|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
58410318|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
57946090|NCT04303130|DRUG|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
57946091|NCT04167046|PROCEDURE|Erector spinae block|Preoperative erector spinae block.
57946092|NCT06185829|DRUG|Neurloeptanalgesic treatment|Usual neuroleptanalgesic treatment
57946093|NCT06185829|OTHER|Hypnoanalgesia|Hypnoanalgesia
57946094|NCT02386436|DRUG|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
57946095|NCT02386436|DRUG|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
57946096|NCT02322125|DEVICE|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
57946097|NCT05487898|DEVICE|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
57946098|NCT02450175|DRUG|Everolimus|10 mg of Everolimus daily (by mouth)
57946099|NCT02450175|DRUG|Letrozole|2.5mg taken daily (by mouth)
57946100|NCT04050670|DRUG|Tirzepatide|Tirzepatide administered SC
57946101|NCT01617070|DRUG|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
57946102|NCT01617070|DIETARY_SUPPLEMENT|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
57946103|NCT06367231|OTHER|VibrantMinds|We are exploring the potential of computer games to reveal insights into the cognitive abilities of older adults. We developed the VibrantMinds (https://vibrant-minds.org/vibrantminds2/start) platform, featuring five games: Whack-a-Mole, Bejeweled, Mahjong Solitaire, Word Search, and Memory Game. Our evaluation focused on the usability of these games, their appeal to users, and their effectiveness in enhancing cognitive functions. The next phase of our study aims to determine whether these games can offer meaningful data on the cognitive skills of older adults.
57946104|NCT00455390|PROCEDURE|Post-immediate Psychotherapeutic Intervention|
57946105|NCT03184961|DIAGNOSTIC_TEST|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
57946106|NCT00349856|DEVICE|Biofinity|Soft contact lens
57946107|NCT00330876|DRUG|Pitavastatin|
57946108|NCT04164836|DIAGNOSTIC_TEST|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
57946109|NCT04802525|OTHER|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
57946110|NCT00880399|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
57946111|NCT00880399|OTHER|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
57946112|NCT01924182|DEVICE|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
57946113|NCT01924182|OTHER|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
57946114|NCT03437382|DEVICE|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
57946115|NCT01399554|BEHAVIORAL|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
57946116|NCT05555043|DEVICE|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
57946117|NCT05555043|DEVICE|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
57946118|NCT05555043|DEVICE|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
57946119|NCT00634634|DRUG|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
57946120|NCT00634634|DRUG|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
58080451|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
58299041|NCT01666561|OTHER|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
58410319|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
57732042|NCT04800029|OTHER|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
58080452|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
58080453|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
58080454|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
58080455|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
58080456|NCT01014104|DRUG|Control|Normal salin injection
58080457|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
58080458|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
58080459|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
58080460|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
58080461|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
58080462|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
58080463|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
58299042|NCT01666561|OTHER|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
58299043|NCT04008225|PROCEDURE|Bronchoalveolar lavage|
58299044|NCT06135844|DRUG|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
58299045|NCT06135844|DRUG|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
58299046|NCT06163001|BEHAVIORAL|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
58410320|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
57732043|NCT04800029|OTHER|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
57732044|NCT04985591|PROCEDURE|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
57732045|NCT04985591|PROCEDURE|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
57732046|NCT01318187|DRUG|paracetamol|1 gr
57732047|NCT01318187|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
57732048|NCT01318187|DRUG|Paracetamol|1 gr intravenous
57732049|NCT01318187|DRUG|Paracetamol|intravenous 1 gr
57732050|NCT01318187|DRUG|Morphine|0.1 mg/kg intravenous
57732051|NCT01427075|PROCEDURE|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
57946121|NCT02520375|OTHER|Prebiotic|
57946122|NCT02520375|OTHER|Control|
57946123|NCT05773794|DIETARY_SUPPLEMENT|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
57946124|NCT05773794|DIETARY_SUPPLEMENT|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
57946125|NCT02701387|DEVICE|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
57946126|NCT02701387|DEVICE|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
57946127|NCT03785925|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
57946128|NCT03785925|BIOLOGICAL|Nivolumab|Specified dose on specified days
57946129|NCT01573871|OTHER|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
57946130|NCT02603770|DRUG|XueZhiKang|
57946131|NCT02603770|DRUG|Lovastatin|
57946132|NCT04045288|BEHAVIORAL|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
57946133|NCT04045288|BEHAVIORAL|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
58410321|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
57732052|NCT01752192|DEVICE|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
57732053|NCT05132699|DRUG|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
58410322|NCT04972227|DRUG|CY6463|oral tablets
58410323|NCT04972227|DRUG|Placebo|oral tablets
57732054|NCT05132699|DRUG|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
57732055|NCT05132699|BEHAVIORAL|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
57732056|NCT06279221|DRUG|LITFULO|as provided in real world practice
57732057|NCT03861962|OTHER|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
58080464|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
58080465|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
58410324|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
57946134|NCT05675878|BEHAVIORAL|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
57946135|NCT03668886|OTHER|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
58080466|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
58080467|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
58080468|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
58080469|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
58080470|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
58410325|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
58410326|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
58080471|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
58410327|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
58410328|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
58410329|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
58410330|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
58410331|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
58410332|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
58410333|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
58080472|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
58080473|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
58080474|NCT00100282|DRUG|PPI-1019 (APAN)|
58080475|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
58080476|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
58080477|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
58080478|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
58080479|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
58080480|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
58080481|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
58080482|NCT00006292|DRUG|Infliximab|
58080483|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
58080484|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
58080485|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
58080486|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
58080487|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
58080488|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
58080489|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
58299047|NCT06163001|DIETARY_SUPPLEMENT|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
58080490|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
58080491|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
58080492|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
58299048|NCT03589807|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
58299049|NCT03589807|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
58299050|NCT03589807|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
58299051|NCT03589807|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
58080493|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
58080494|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
58080495|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
57946136|NCT03870438|DRUG|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
57946137|NCT03831867|OTHER|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
57946138|NCT01157754|DRUG|levonorgestrel and ethynilestradiol|
57946139|NCT05963958|COMBINATION_PRODUCT|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
57946140|NCT05963958|COMBINATION_PRODUCT|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
57946141|NCT03689153|DRUG|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
57946142|NCT03689153|DRUG|Placebo|Participants will receive matching placebo intravenously.
57946143|NCT05377788|DRUG|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
57946144|NCT01592253|DRUG|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
57946145|NCT00865059|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
57946146|NCT00865059|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
57946147|NCT04185103|DRUG|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
57946148|NCT03395548|DRUG|Macrogol|Used drug: Macrogol (osmotic laxative)
57946149|NCT01108146|DRUG|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
57946150|NCT01108146|DRUG|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
57946151|NCT01147289|DRUG|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
57946152|NCT01147289|DRUG|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
57946153|NCT00817232|DEVICE|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
57946154|NCT02524574|PROCEDURE|cardiac Rehabilitation|
58080496|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
58080497|NCT00145795|DRUG|Current Regimen|
58080498|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
58080499|NCT02353234|OTHER|Bread|In each arm subjects consume bread
58080500|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
58080501|NCT00812045|DRUG|Placebo|
58299052|NCT04958876|DRUG|SP-104|oral capsule once daily
58410334|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
58299053|NCT04958876|DRUG|Naltrexone immediate release oral capsules|oral capsule once daily
57946155|NCT02524574|OTHER|Tomography Positron Emission|
57946156|NCT01845922|DIETARY_SUPPLEMENT|Low sodium diet|Low sodium diet
57946157|NCT00182195|PROCEDURE|Control Ventilation Strategy|
58299054|NCT04449965|DRUG|Povidone-iodine|This will be performed twice daily for two weeks.
58410335|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
57946158|NCT04376320|DEVICE|customised ceramic sheets (Group 1)|guided bone regeneration
57946159|NCT04376320|COMBINATION_PRODUCT|modified sausage technique (Group 2)|guided bone regeneration
57946160|NCT04531696|PROCEDURE|Blood draw|Blood draw at inclusion
57946161|NCT04531696|PROCEDURE|Post-mortem tissue collection|Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
57946162|NCT03495258|PROCEDURE|Clarion Evolve Laser Vaporization System|
57946163|NCT03495258|PROCEDURE|Olympus TURis Plasma Vaporization|
57946164|NCT03324906|DEVICE|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
58299055|NCT04449965|DRUG|Placebo|This will be performed twice daily for two weeks.
58410336|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
58080502|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
58080503|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
58080504|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
58080505|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
58080506|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
58080507|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
58080508|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
58080509|NCT01882166|DRUG|fostimon|
58080510|NCT01882166|DRUG|puregon|
58080511|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
57946165|NCT00396201|DRUG|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
57946166|NCT00370227|BIOLOGICAL|10 valent pneumococcal conjugate (vaccine)|
58080512|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
58080513|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
58080514|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
58080515|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
58080516|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
58080517|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
58080518|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
58299056|NCT04776408|DEVICE|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
58080519|NCT01674010|DRUG|ELND005|
58080520|NCT01674010|DRUG|Lamotrigine|
58080521|NCT01674010|DRUG|Valproic acid|
58080522|NCT01674010|DRUG|Placebo|
58080523|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
58080524|NCT05182840|DRUG|BI 690517|Film-coated tablets
58080525|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
58080526|NCT05182840|DRUG|Empagliflozin|Empagliflozin
58080527|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
58080528|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
58080529|NCT00002037|DRUG|Trifluridine|
58299057|NCT04776408|DEVICE|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
58080530|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
58080531|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
58080532|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
58299058|NCT03736655|DEVICE|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
58080533|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
58080534|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
58080535|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
58080536|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
58410337|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
58410338|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
58410339|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
57946167|NCT02221453|DRUG|Triamcinolone Acetonide|
58080537|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
58080538|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
58080539|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
58080540|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
58080541|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
58080542|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
58299059|NCT04789408|DRUG|Cyclophosphamide|Administered intravenously
58299060|NCT04789408|DRUG|Fludarabine|Administered intravenously
58410340|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
58410341|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
58410342|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
58410343|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
58410344|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
58410345|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
58410346|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
58410347|NCT01389349|OTHER|Sham Control|Sham control acupuncture
58080543|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
58299061|NCT04789408|BIOLOGICAL|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
58299062|NCT03810157|DEVICE|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
58410348|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
58410349|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
58080544|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
58080545|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
58299063|NCT01105104|DEVICE|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
58299064|NCT01105104|DEVICE|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
58299065|NCT05447065|DIETARY_SUPPLEMENT|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
58299066|NCT00001475|DRUG|IL-2 plus Anti-TNF or Thalidomide|
58299067|NCT00215891|DRUG|PEG-Interferon a-2b + Ribavirin|
58299068|NCT05554029|DIAGNOSTIC_TEST|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
58299069|NCT03666442|DRUG|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
57946168|NCT03885427|DRUG|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
57946169|NCT05113160|BEHAVIORAL|Conversation Treatment for Aphasia|Conversation treatment is a theoretically motivated approach in which a speech language pathologist facilitates discourse about topics of interest to the client using individualized, multi-modal supports. Treatment occurs either in groups of 6-8 people with aphasia or 2 people with aphasia. Individual communication goals are targeted for each group member within the context of naturalistic conversations.
58080546|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
58080547|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
58080548|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
58080549|NCT03484858|OTHER|High glycaemic index meal and exercise|
58080550|NCT03484858|OTHER|High glycaemic index meal and rest|
58080551|NCT03484858|OTHER|Low glycaemic index meal and exercise|
58080552|NCT03484858|OTHER|Low glycaemic index meal and rest|
58080553|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
58080554|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
58080555|NCT00347776|DRUG|azithromycin|oral antibiotic
58299070|NCT04152681|DRUG|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
58299071|NCT02479555|DRUG|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
58299072|NCT01299350|OTHER|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
58299073|NCT06276374|DRUG|Patients who are scheduled to undergo carotid artery stenting|"* Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)"
58299074|NCT04018495|DEVICE|Fitbit Tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
58410350|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
57946170|NCT01024010|DRUG|Cyclophosphamide|Given IV
57946171|NCT01024010|OTHER|Laboratory Biomarker Analysis|Correlative studies
58080556|NCT00347776|DRUG|topical tetracycline|
58080557|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
58080558|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
58080559|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
58080560|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
57946172|NCT01024010|BIOLOGICAL|Ofatumumab|Given IV
57946173|NCT01024010|DRUG|Pentostatin|Given IV
57946174|NCT05244759|DRUG|[14C]-BLU-5937|Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
57946175|NCT02718781|BEHAVIORAL|Health talk|Health talk on zero-time exercise.
58080561|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
58080562|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
58080563|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
58080564|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
58080565|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
58080566|NCT04836832|DRUG|Acalabrutinib|Given PO
58080567|NCT04836832|DRUG|Duvelisib|Given PO
58080568|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
58080569|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
58080570|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
58080571|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
58080572|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
58080573|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
58080574|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
58299075|NCT01598805|BEHAVIORAL|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
58410351|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
58410352|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
57946176|NCT02718781|BEHAVIORAL|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
58080575|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
58080576|NCT05059470|DRUG|Pembrolizumab|Given by IV
58299076|NCT00856791|DRUG|ON 01910.Na|
58299077|NCT04620577|OTHER|antibiotic|normal saline
58299078|NCT05010213|OTHER|Educational intervention|Educational intervention
58299079|NCT04362124|BIOLOGICAL|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
58299080|NCT04362124|OTHER|Placebo|A single dose intradermal application of normal saline solution.
58299081|NCT05660096|DEVICE|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
57946177|NCT02718781|DEVICE|Handgrip|This is a home-based equipment
57946178|NCT04264403|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
58080577|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
58080578|NCT00051766|BEHAVIORAL|Computer-based Intervention|
58080579|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
58080580|NCT02189928|OTHER|Usual care|
58080581|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
58080582|NCT00674440|RADIATION|PET scan|
58080583|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
58080584|NCT02279082|DRUG|DFN-02|Active Experimental Drug
58080585|NCT03005717|DRUG|LIPO-202|
58080586|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
58080587|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
58080588|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
58080589|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
58080590|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
58080591|NCT01800500|OTHER|questionnaire administration|Ancillary studies
58080592|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
58080593|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
58080594|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
58080595|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
58080596|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
58080597|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
58080598|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
58080599|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
58299082|NCT05362708|DEVICE|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
58299083|NCT00987168|DRUG|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
57732058|NCT05168241|OTHER|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
58080600|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
58080601|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
58080602|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
58080603|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
58410353|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
58080604|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
58080605|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
58080606|NCT01934777|DRUG|placebo pearls|placebo
58080607|NCT00003758|DRUG|cytarabine|
58080608|NCT00003758|DRUG|idarubicin|
58080609|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
58080610|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
58080611|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
58080612|NCT00594568|DRUG|LY450139|Administered orally once daily
58080613|NCT00594568|DRUG|Placebo|Administered orally once daily
58080614|NCT00006001|DRUG|semaxanib|
58080615|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
58299084|NCT05707416|DEVICE|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
58299085|NCT05707416|OTHER|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
58410354|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
58410355|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
57732059|NCT05168241|OTHER|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
57732060|NCT03411655|DEVICE|Ambu Aura GainTM|Time and success rate
58299086|NCT02926963|OTHER|samples collection : hair and skin biopsy|
58299087|NCT00989222|PROCEDURE|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
58299088|NCT00989222|PROCEDURE|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
57732061|NCT03411655|DEVICE|Ambu® Aura-ITM|Time and success rate
57946179|NCT02874456|OTHER|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
57946180|NCT02724254|DRUG|AP611074 5% gel|
57946181|NCT02724254|DRUG|AP611074 matching placebo|
57946182|NCT02961621|BEHAVIORAL|Stress Reduction Training for 9-1-1 Telecommunicators|
57946183|NCT01516970|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
57946184|NCT01516970|DRUG|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
57946185|NCT01516970|DRUG|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
57946186|NCT01516970|DRUG|NRTIs|The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
57946187|NCT01516970|DRUG|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
57946188|NCT06477874|PROCEDURE|Dental implants placement|implants placed in consolidated bone grafts
57946189|NCT02348892|OTHER|Coordinator|Patients in complex situation taken care by coordinator
57946190|NCT02348892|OTHER|Classic plan|Patients in complex situation taken care by classic plan
57946191|NCT01853995|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
57946192|NCT06137924|DRUG|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
57946193|NCT06137924|DRUG|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
57946194|NCT06137924|DRUG|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
57946195|NCT02266667|DEVICE|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
58080616|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
58080617|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
58410356|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
58410357|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
58410358|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
58410359|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
58410360|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
58299089|NCT02136537|DEVICE|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
58299090|NCT02136537|OTHER|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
58299091|NCT05743153|BEHAVIORAL|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
58299092|NCT03280407|DRUG|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
58299093|NCT03280407|DRUG|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
58299094|NCT03280407|DRUG|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
58299095|NCT02709148|DEVICE|Activa PC+S|DBS
58299096|NCT02582476|DRUG|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
58410361|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
58410362|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
58410363|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
58410364|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
58410365|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
58410366|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
57946196|NCT02266667|DEVICE|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
58410367|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
58410368|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
58410369|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
58410370|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
57946197|NCT01231594|DRUG|GSK2118436|Study Drug
57946198|NCT01231594|DRUG|GSK1120212|Study Drug
57946199|NCT01231594|DRUG|Other approved anti-cancer agent|Study Drug
57946200|NCT06482736|DEVICE|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy could reduce the pain of myofascial pain syndrome by pain signal alteration, promoting angiogenesis and increasing perfusion in ischemic tissues induced by sensitization of nociceptors and muscle ischemia.
57946201|NCT03804203|RADIATION|standard treatment|3000 cGy in 10 daily fractions
57946202|NCT03804203|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
57946203|NCT06185621|DRUG|100mg aspirin|Patients received oral 100mg aspirin, one tablet daily for 2 years
57946204|NCT01859832|OTHER|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
57946205|NCT02871778|DRUG|VX-371|
57732062|NCT04084808|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
58410371|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
57946206|NCT02871778|DRUG|Hypertonic Saline|
57946207|NCT02871778|DRUG|Placebo (0.17% saline)|
57946208|NCT02871778|DRUG|VX-371 + HS|
58299097|NCT02582476|DRUG|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
57946209|NCT02871778|DRUG|Ivacaftor|
57946210|NCT00914251|DRUG|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
57946211|NCT00914251|DRUG|Placebo|Administration of oral Placebo, 500 mg/daily
57946212|NCT02331433|DRUG|APN1125|APN1125 orally at ascending doses
57946213|NCT02331433|DRUG|Placebo|Matching Placebo
57946214|NCT05564143|PROCEDURE|EUS-guided gastroenterostomy (EUS-GE)|Treatment
57946215|NCT05564143|PROCEDURE|Laparoscopic gastroenterostomy (LGE)|Treatment
57946216|NCT05426889|PROCEDURE|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
57946217|NCT05426889|DRUG|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
57946218|NCT03724188|PROCEDURE|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
57946219|NCT06068270|PROCEDURE|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
57946220|NCT05776121|DRUG|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
58299098|NCT01268852|DEVICE|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
58299099|NCT01268852|DEVICE|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
57946221|NCT05776121|DRUG|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
57946222|NCT06060964|OTHER|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
57946223|NCT01517893|DRUG|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
57946224|NCT01517893|DRUG|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
57946225|NCT02854514|PROCEDURE|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
57946226|NCT03569579|DRUG|Memantine Tab. 10mg|Memantine Tab. 10mg\* 2T/day, QD, PO
57946227|NCT03569579|DRUG|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
57946228|NCT01999465|DEVICE|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)"
58299100|NCT06426667|PROCEDURE|posterior tibial nerve radiofrequency|pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.
58299101|NCT06426667|PROCEDURE|plantar fasciitis radiofrequency|the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.
58080618|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
58080619|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
58080620|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
58080621|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
58080622|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
58080623|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
58080624|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
58080625|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
57946229|NCT01999465|DEVICE|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)"
58080626|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
57946230|NCT00436800|DRUG|Gemcitabine|1000mg/m² over 10mg/m²/min
58080627|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58080628|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
58299102|NCT02396225|DRUG|Voriconazole|
58299103|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - ULTRASOUND|At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
57946231|NCT00436800|DRUG|Oxaliplatin|100 mg/m² over 2 hours.
57946232|NCT02034942|OTHER|Non-sedation|
57946233|NCT02034942|OTHER|Sedation, control|
57946234|NCT01974492|PROCEDURE|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
58080629|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
58080630|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
58080631|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
58299104|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - SURGERY|Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
58299105|NCT02894333|BEHAVIORAL|behavioral observation|
58299106|NCT02314858|BEHAVIORAL|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
58299107|NCT02314858|BEHAVIORAL|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
57946235|NCT01974492|PROCEDURE|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
57946236|NCT01489670|DRUG|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
58080632|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
58080633|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
58080634|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
58080635|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
58080636|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
58080637|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
58080638|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
58299108|NCT02314858|BEHAVIORAL|Treatment as Usual (TAU)|The TAU group will not watch a video.
58299109|NCT06238024|DRUG|Tocilizumab|Single dose intravenous application
58299110|NCT06238024|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
58299111|NCT02233218|DRUG|Telmisartan|
58410372|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
58410373|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
58410374|NCT00549185|DRUG|SAR3419|Intravenous infusion
57946237|NCT03377530|DIAGNOSTIC_TEST|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
58299112|NCT02233218|DRUG|Amlodipine|
58299113|NCT02233218|DRUG|Rosuvastatin|
57946238|NCT05467514|DRUG|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
57946239|NCT05843851|DIAGNOSTIC_TEST|Diagnostic test|Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
58080639|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
58080640|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
58080641|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
58080642|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
58080643|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
58080644|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
58299114|NCT05901337|COMBINATION_PRODUCT|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin c~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
58299115|NCT05901337|DRUG|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
58299116|NCT05726487|BEHAVIORAL|ACTION Intervention|Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
58410375|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
58410376|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
58410377|NCT05685732|OTHER|placebo|matching placebo
58410378|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
57946240|NCT03972787|DEVICE|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
57946241|NCT02231151|BEHAVIORAL|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
57946242|NCT00876187|BIOLOGICAL|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
57946243|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
57946244|NCT00876187|BIOLOGICAL|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
57946245|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
57946246|NCT00876187|BIOLOGICAL|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
57946247|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
58299117|NCT05726487|OTHER|Education Control|Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
58299118|NCT01981668|DRUG|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
58410379|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
58410380|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
58410381|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
58080645|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
58410382|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
57946248|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
57946249|NCT00876187|DRUG|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
57946250|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
57946251|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
57946252|NCT04345289|BIOLOGICAL|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
57946253|NCT04345289|OTHER|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
57946254|NCT04268251|DIAGNOSTIC_TEST|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
58080646|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
58299119|NCT05344222|DEVICE|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
58299120|NCT05344222|DEVICE|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
57946255|NCT02215876|DRUG|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
57946256|NCT02215876|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
57946257|NCT02215876|DRUG|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
57946258|NCT05750875|DRUG|Loratadine|Participants were given loratadine 10mg, oral, daily, for 4 weeks
57946259|NCT05750875|DRUG|Gabapentin|Participants were given gabapentin 100mg, oral, daily, for 4 weeks
57946260|NCT03633175|DRUG|Vaginal progesterone|400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
57946261|NCT02730585|BIOLOGICAL|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
57946262|NCT06296186|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy for PTSD
57946263|NCT03789851|DEVICE|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
58080647|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
58080648|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
58080649|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
58080650|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
58080651|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
58080652|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
58299121|NCT00799084|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
57946264|NCT02722538|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
58299122|NCT00799084|BEHAVIORAL|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
58299123|NCT02481076|DEVICE|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
58299124|NCT02481076|OTHER|Braun frame|The leg is elevated on a Braun frame
58299125|NCT02481076|DEVICE|compression bandage|application of flowtron hydroven boot and compression bandage
58410383|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
58410384|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
57946265|NCT05993624|DEVICE|virtual reality|The BeCure Balance Assessment System protocol used in this study; It was planned to determine the amount of change in the center of gravity in the x and y axes and the position of the center of gravity of the body with images during standing and balancing for 15 seconds on the board with eyes open. In order to support the balanced development of the participants with the Becure system; Balance surfing, balance adventure, balance bowling and traffic games were played. uBall, gates, smartclean and SmartBubblePop games with Kinect for the upper extremity; KneeUp game was played on the lower extremity.
57946266|NCT04265885|OTHER|collection of testimonies from transgender people|guided interview
57946267|NCT01833442|BEHAVIORAL|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
58299126|NCT03690713|DIAGNOSTIC_TEST|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
58299127|NCT05988567|DIETARY_SUPPLEMENT|Placebo candy|consume 2 tablets per day
58299128|NCT05988567|DIETARY_SUPPLEMENT|melon and oil olive pressed candy|consume 2 tablets per day
58299129|NCT04226417|DEVICE|Transcranial direct current stimulation|Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
58299130|NCT05959265|BEHAVIORAL|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
58410385|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
58410386|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
58410387|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
58410388|NCT00823992|DRUG|placebo|sc once weekly
58299131|NCT04191889|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
58299132|NCT01289886|DRUG|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
58299133|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
58410389|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
58410390|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
58410391|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
57946268|NCT01833442|BEHAVIORAL|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
57946269|NCT06461975|DRUG|Benoxinate Hydrochloride|"The first group had the first examination done using the tear substitute Polyfresh ® eye drops and the second using the Benoxinate HCL drops Benox ® given just before the ROP screening."
57946270|NCT06461975|DRUG|artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.|"The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening."
57946271|NCT00855985|PROCEDURE|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
58410392|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
58410393|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
58410394|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
58410395|NCT03834506|DRUG|Docetaxel|IV infusion
58410396|NCT03834506|DRUG|Prednisone|Oral tablets
58410397|NCT03834506|DRUG|Placebo|IV infusion
58410398|NCT03834506|DRUG|Dexamethasone|Oral tablets
58410399|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
58410400|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
58410401|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
58410402|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
58410403|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
58299134|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
58410404|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
58299135|NCT03988933|DRUG|Rifampin double dose|Double dose of rifampin for 2 months.
58299136|NCT03988933|DRUG|Rifampin triple dose|Triple dose of rifampin for 2 months.
58299137|NCT03988933|DRUG|Rifampin standard dose|Standard dose of rifampin for 4 months.
58299138|NCT02546648|DRUG|Tranexamic Acid|
58299139|NCT02546648|DRUG|Tranexamic Acid Placebo|
58410405|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
58410406|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
58410407|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
57946272|NCT03200366|BEHAVIORAL|Tailored DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
57946273|NCT03200366|BEHAVIORAL|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
57946274|NCT05016115|BEHAVIORAL|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
58080653|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
58299140|NCT02546648|DRUG|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
58299141|NCT05998681|OTHER|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages|"Participants in the experimental group were provided with education on Breastfeeding and Basic Maternal-Neonatal Care at the hospital and mobile messages were sent with the same content as education program for 6 weeks after discharge."
58299142|NCT02557399|DRUG|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
58299143|NCT02557399|DRUG|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
58410408|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
58410409|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
57946275|NCT05895942|DRUG|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
57946276|NCT05514314|DRUG|Icotinib|Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
58299144|NCT02557399|DRUG|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
58299145|NCT03934671|DEVICE|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
58299146|NCT03934671|DEVICE|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
58299147|NCT02043288|DRUG|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
58080654|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
58080655|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
58080656|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
58080657|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
58080658|NCT02489682|OTHER|Long-form written Informed consent information|
58080659|NCT02489682|OTHER|Short-form written Informed consent information|
58080660|NCT02489682|OTHER|Video Informed consent information|
58080661|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
57946277|NCT03449498|OTHER|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
57946278|NCT03449498|OTHER|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
57946279|NCT05440162|DIAGNOSTIC_TEST|electrolyte|follow up NA
57946280|NCT06135649|PROCEDURE|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
57946281|NCT05091463|DEVICE|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
58080662|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
58080663|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
58080664|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
58080665|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
58410410|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
57946282|NCT01361243|BEHAVIORAL|NOURISH+|6 week face-to-face parent intervention.
57946283|NCT01361243|BEHAVIORAL|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
57946284|NCT03691233|DRUG|Clinical audit on diagnosis and management of neonatal shock|intervenous
58080666|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
58080667|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
58080668|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
58080669|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
58080670|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
58080671|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
58410411|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
57946285|NCT02887287|DRUG|EEN|
57946286|NCT02319421|OTHER|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
57946287|NCT04374760|BEHAVIORAL|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
57946288|NCT05520697|BEHAVIORAL|Nutritional intervention|Nutritional treatment with caloric restriction.
58080672|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
58080673|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
58080674|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
58080675|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
58299148|NCT02043288|DRUG|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
58410412|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
58410413|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
58410414|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
57946289|NCT05520697|BEHAVIORAL|Mental exercise.|Mental exercise.
57946290|NCT05520697|BEHAVIORAL|Physical training.|Exercise.
57946291|NCT06310486|OTHER|Drowning-related OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
57946292|NCT06310486|OTHER|Drowning-related non-OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
57946293|NCT00800436|DRUG|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
57946294|NCT00787462|DRUG|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
57946295|NCT00787462|DRUG|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
57946296|NCT04245475|BEHAVIORAL|Virtual Reality psychological pain reduction|attention distraction
58080676|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
58299149|NCT04025541|BIOLOGICAL|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
58299150|NCT04145856|DIETARY_SUPPLEMENT|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
58299151|NCT04145856|COMBINATION_PRODUCT|I31 probiotic combined to Alverine/Simethicone|"* I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
58299152|NCT04145856|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
58410415|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
58410416|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
58410417|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
58410418|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
58080677|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
58410419|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
57946297|NCT00841568|DRUG|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
57946298|NCT04906980|DRUG|JNJ-64281802|JNJ-64281802 will be administered orally.
58080678|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
58080679|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
58080680|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
58080681|NCT01994369|DRUG|EC17|
58080682|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
58080683|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
58299153|NCT06492434|BEHAVIORAL|Peer decision coaching|Peer Decision Coaching is a brief, personalized intervention grounded in evidence-based decision- and peer support principles. During the intervention, a trained peer specialist supports the young person in identifying a decision related to community participation that they need to make, such as whether to work or go to school, helping them address decision-making needs, and assisting them with developing and implementing a decision-making plan. Ultimately, the intervention aims to support young people in pursuing their community participation interests and goals.
58299154|NCT04637841|OTHER|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
58410420|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
58410421|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
57946299|NCT04906980|DRUG|Placebo|Matching placebo (PEG400) will be administered orally.
57946300|NCT02086786|DRUG|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
57946301|NCT00863200|BEHAVIORAL|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
58080684|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
57732063|NCT04084808|BEHAVIORAL|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
58080685|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
58080686|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
58080687|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
58080688|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
58080689|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
58080690|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
58080691|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
58080692|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
58080693|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
58080694|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
58080695|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
58080696|NCT04149366|DEVICE|Retainer|Orthodontic retainer
58410422|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
58080697|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
58080698|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
58080699|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
58080700|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
58080701|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
58299155|NCT04637841|OTHER|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
58299156|NCT01854749|DRUG|S1 combined with cisplatin|
58299157|NCT03744442|PROCEDURE|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
58410423|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
58410424|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
58410425|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
58080702|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
58080703|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
58080704|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
58080705|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
58080706|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
58410426|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
58410427|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
57732064|NCT04084808|PROCEDURE|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS)."
57946302|NCT00863200|BEHAVIORAL|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
57946303|NCT04240444|DEVICE|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
57946304|NCT00117429|BIOLOGICAL|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
57946305|NCT00632099|DRUG|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
57946306|NCT00632099|DRUG|Placebo|matched placebo
57946307|NCT00002284|DRUG|Zidovudine|
57946308|NCT04793542|PROCEDURE|lower-limb hot water immersion|For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
57946309|NCT01987206|DEVICE|MPC control algorithm|
57946310|NCT01987206|DEVICE|PID control algorithm|
57946311|NCT04340713|OTHER|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
57946312|NCT06490913|DRUG|Capecitabine|1000mg/m2, bid, d1-d14，q3w，1cycle
57946313|NCT06490913|DRUG|oxaliplatin|130mg/m2, ivgtt, d1，q3w，1cycle
57946314|NCT06490913|DRUG|Cetuximab|cetuximab 500mg/m2, q2w
57946315|NCT06490913|DRUG|Oxaliplatin|85mg/m2, d1,q2w
57946316|NCT06490913|DRUG|Leucovorin|400mg/m2, d1,q2w
57946317|NCT06490913|DRUG|5-FU|400mg/m2，d1,q2w
57946318|NCT03658382|OTHER|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
57946319|NCT03185364|DRUG|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
57946320|NCT03185364|DRUG|Placebo Oral Tablet|placebos treatment for 12 weeks
57946321|NCT02598375|OTHER|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
57946322|NCT03885310|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
57946323|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
57946324|NCT01260012|OTHER|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
57946325|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
57946326|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
57946327|NCT03089593|OTHER|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
57946328|NCT03089593|OTHER|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
58080707|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
57732065|NCT04084808|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
58080708|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
58080709|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
58080710|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
58080711|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
58080712|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
58080713|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
58080714|NCT06021769|OTHER|Observational only|No intervention
58080715|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
58080716|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
58080717|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
58299158|NCT03744442|PROCEDURE|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
57732066|NCT04084808|PROCEDURE|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
58080718|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
58080719|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
58080720|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
58080721|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
58080722|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
58080723|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
57732067|NCT04084808|BEHAVIORAL|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
58080724|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
58080725|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
58080726|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
58080727|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
58299159|NCT03744442|PROCEDURE|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
58080728|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
58410428|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
58410429|NCT00359944|DRUG|AC-3933|5mg twice daily
58410430|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
58410431|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
58080729|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
58080730|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
58410432|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
58410433|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
58410434|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
58410435|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
58410436|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
58410437|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
58410438|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
58410439|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
58410440|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
57732068|NCT04084808|BEHAVIORAL|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
57732069|NCT01638923|DRUG|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
58410441|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
58410442|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
58410443|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
58410444|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
58410445|NCT00444704|DRUG|PRA-027|
57732070|NCT01638923|DRUG|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
58410446|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
58080731|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
58080732|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
58080733|NCT01863394|OTHER|Screening by mothers|
58080734|NCT01863394|OTHER|Active comparator: Screening by community health workers|
58080735|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
58080736|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
58080737|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
58080738|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
58299160|NCT01896193|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
58080739|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
58080740|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
58080741|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
58080742|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
58080743|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
58080744|NCT05116410|DRUG|HS-20094|Administrated SC
58080745|NCT05116410|DRUG|Placebo|Administrated SC
58080746|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
58080747|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
58080748|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
58080749|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
58299161|NCT01896193|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58080750|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
58080751|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
58080752|NCT00161148|DRUG|Probiotics|
58299162|NCT03049878|DRUG|Paracetamol Codeine|preoperative administration
58299163|NCT03049878|DRUG|Placebo Oral Tablet|preoperative administration
58080753|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
58080754|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
58080755|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
58080756|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
58080757|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
58080758|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
58080759|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
58080760|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
58080761|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
58080762|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
58080763|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
58299164|NCT02417753|DRUG|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
58299165|NCT03904420|OTHER|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
58299166|NCT03904420|OTHER|Traditional Model|Standard clinical practice and education
58299167|NCT02738112|DEVICE|Encore System|Hyo-mandibular suspension
58299168|NCT03136718|OTHER|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
58299169|NCT02862080|DEVICE|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
58299170|NCT02862080|DEVICE|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
58299171|NCT02862080|DEVICE|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
58299172|NCT04381780|DIETARY_SUPPLEMENT|Recovery Factors|A unique porcine serum based polypeptide nutritional support
58299173|NCT01361750|PROCEDURE|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
58299174|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Gadovist for MRI investigation|Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis
58299175|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Imeron for B-CT investigation|Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
58299176|NCT02175225|DRUG|Deferoxamine Mesylate|
58299177|NCT02175225|DRUG|Placebo (for Deferoxamine Mesylate)|
58299178|NCT00526318|BIOLOGICAL|filgrastim|
58410447|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
58410448|NCT00005764|DRUG|Lamivudine/Zidovudine|
58410449|NCT00005764|DRUG|Abacavir sulfate|
58410450|NCT00005764|DRUG|Lamivudine|
57946329|NCT02137512|DEVICE|Closed-Loop Control System|"This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
57946330|NCT02137512|DEVICE|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump"
57946331|NCT06236295|DRUG|SHR6508|SHR6508 will be administered to all the eligible subjects
57946332|NCT04043325|DIAGNOSTIC_TEST|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
57946333|NCT01908023|BEHAVIORAL|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
57946334|NCT02690857|DRUG|Docosahexaenoic acid|
57946335|NCT02690857|DRUG|Sunflower Oil|
58080764|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
58299179|NCT00526318|DRUG|carboplatin|
58299180|NCT00526318|DRUG|cisplatin|
58299181|NCT00526318|DRUG|cyclophosphamide|
58299182|NCT00526318|DRUG|dacarbazine|
58299183|NCT00526318|DRUG|doxorubicin hydrochloride|
58299184|NCT00526318|DRUG|etoposide phosphate|
58299185|NCT00526318|DRUG|ifosfamide|
58299186|NCT00526318|DRUG|isotretinoin|
58299187|NCT00526318|DRUG|melphalan|
58299188|NCT00526318|DRUG|topotecan hydrochloride|
58299189|NCT00526318|DRUG|vincristine sulfate|
58299190|NCT00526318|DRUG|vindesine|
58299191|NCT00526318|PROCEDURE|autologous hematopoietic stem cell transplantation|
58299192|NCT00526318|RADIATION|iobenguane I 131|
57946336|NCT05999370|BEHAVIORAL|Nutrition|"The nutrition intervention will be based on needs assessed by indirect calorimetry, patient-generated subjective global assessment, and 24hr recall conducted at baseline, enabling individualized caloric and protein targets.~Deficits in nutrient intake will be addressed with one-on-one dietary counselling and supplementation at baseline in a quantity that matches the estimated deficit in intake. Adherence will be monitored using 24-hr recalls and weight status by the dietitian weekly."
57946337|NCT05999370|BEHAVIORAL|Exercise|The exercise intervention will include both a resistance and an aerobic component to be performed a total of 5 times a day, 5 times per week, 5 minutes each session, totaling 125 minutes per week. The ability to perform exercises as prescribed will be monitored with a weekly in-person or virtual supervised session.
57946338|NCT02971579|PROCEDURE|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
58299193|NCT00526318|RADIATION|radiation therapy|
58299194|NCT00432900|RADIATION|[(11)C]PBR28|PET Ligand
58299195|NCT03658551|DIAGNOSTIC_TEST|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
58299196|NCT03740269|OTHER|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
58299197|NCT00028717|BIOLOGICAL|filgrastim|
58299198|NCT00028717|BIOLOGICAL|rituximab|
58299199|NCT00028717|DRUG|cyclophosphamide|
58299200|NCT00028717|DRUG|doxorubicin hydrochloride|
58299201|NCT00028717|DRUG|prednisone|
58410451|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
58410452|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
58410453|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
58410454|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
58080765|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
58410455|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
58080766|NCT01987570|DRUG|Allopurinol|
58410456|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
57732071|NCT02084966|PROCEDURE|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
58080767|NCT01987570|DRUG|Placebo|
58080768|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
58080769|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
58080770|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
58080771|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
58080772|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
58299202|NCT00028717|DRUG|vincristine sulfate|
58299203|NCT04657939|DRUG|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
58299204|NCT04657939|DRUG|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
58299205|NCT01623921|DRUG|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
58299206|NCT01623921|DRUG|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
58299207|NCT01623921|DRUG|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
58299208|NCT01623921|DRUG|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
58299209|NCT05421065|DRUG|Psilocybin|1 25mg oral dose
58299210|NCT05421065|DRUG|Ketamine|1 200mg oral dose
58299211|NCT06514079|PROCEDURE|Esophageal dilatation with steroids injection|Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
58299212|NCT04148547|DEVICE|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
58410457|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
58410458|NCT02834585|OTHER|Ultrasound|
58410459|NCT02887053|DEVICE|MRI|
58410460|NCT02818036|DRUG|Naltrexone|
58410461|NCT02818036|DRUG|Placebo|
58410462|NCT04429581|OTHER|Anthropometry|
57732072|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
58410463|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
57732073|NCT00158743|OTHER|sodium chloride|
57732074|NCT05062928|OTHER|Virtual coach|This group will be trained and assessed by the virtual coach.
57732075|NCT01130766|PROCEDURE|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
57732076|NCT04740294|DRUG|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
57732077|NCT03619733|OTHER|no intervention|this is an observational study. no intervention is planned
58080773|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
58080774|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
58080775|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
58080776|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
58080777|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
58080778|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
58080779|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
58080780|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
58080781|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
58080782|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
58080783|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
58080784|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
58080785|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
58080786|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
58080787|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
58080788|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
58080789|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
58299213|NCT04148547|DEVICE|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
58410464|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
58410465|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
58410466|NCT00793572|DRUG|Bortezomib|Given SC
58410467|NCT00793572|DRUG|Cyclosporine|Given IV
58410468|NCT00793572|DRUG|Cyclosporine|Given PO
58410469|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
58410470|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
57732078|NCT04729855|DIAGNOSTIC_TEST|PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample, normal and CRC tissue
58410471|NCT00793572|DRUG|Melphalan|Given IV
58410472|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
58080790|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
58080791|NCT03621566|OTHER|No intervention|Routine care (registry)
58080792|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
58080793|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
58080794|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
58080795|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
58299214|NCT05343663|BEHAVIORAL|Education|Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
58080796|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
58080797|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
58080798|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
58080799|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
58080800|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
58080801|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
58080802|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
58080803|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
58080804|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
58080805|NCT00280839|DRUG|Topiramate|
58080806|NCT00280839|DRUG|Placebo|
58080807|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
58080808|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
58080809|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
58080810|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
58299215|NCT02291029|DRUG|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
58080811|NCT02119858|DRUG|indocyanine green solution|Given transperineally
58080812|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
58080813|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
58299216|NCT02291029|DRUG|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
57732079|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
58299217|NCT02291029|DRUG|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
58299218|NCT02291029|DRUG|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
58299219|NCT02291029|DRUG|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
58299220|NCT02291029|DRUG|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
58299221|NCT05029687|BEHAVIORAL|Youth-Led Hypertension Education Digital Intervention|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
58080814|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
58080815|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
58080816|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
58080817|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
58080818|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
58080819|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
58080820|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
58080821|NCT05375942|DRUG|Inflectra|1. To describe the characteristics of patients newly initiated on Inflectra.
58080822|NCT05375942|DRUG|Inflectra|2. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
58080823|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
58080824|NCT00003876|PROCEDURE|surgical procedure|
58080825|NCT00003876|RADIATION|iodine I 125|
58080826|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
58080827|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
58299222|NCT03049826|OTHER|Nutritional status|Body composition and nutrient status
58299223|NCT04073719|DIETARY_SUPPLEMENT|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
58299224|NCT04073719|DIETARY_SUPPLEMENT|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
58299225|NCT02361775|DEVICE|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
58299226|NCT02361775|DEVICE|opioid iv pca|opioid pca consisting of hydromorphone
58410473|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
58410474|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
57732080|NCT05641493|COMBINATION_PRODUCT|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
58080828|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
58299227|NCT02361775|DRUG|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
58299228|NCT02361775|DEVICE|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
58299229|NCT03492229|OTHER|tDCS|1 mA of tDCS
58299230|NCT03492229|OTHER|AMT|Ankle motor training
58299231|NCT03492229|BEHAVIORAL|Treadmill training|High intensity treadmill training
58299232|NCT00317746|DRUG|Citalopram|
58299233|NCT00317746|DRUG|Placebos|
58410475|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
58410476|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
58410477|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
58410478|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
58410479|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
58080829|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
58299234|NCT02121795|DRUG|FTC/TDF|200/300 mg FDC tablets administered orally once daily
58299235|NCT02121795|DRUG|F/TAF|Tablets administered orally once daily
58299236|NCT02121795|DRUG|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
58299237|NCT02121795|DRUG|FTC/TDF Placebo|Tablets administered orally once daily
58410480|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
58410481|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
58410482|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
58299238|NCT02121795|DRUG|F/TAF Placebo|Tablets administered orally once daily
57732081|NCT01470755|DRUG|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
57732082|NCT01470755|DRUG|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
57732083|NCT01470755|DRUG|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
57732084|NCT01470755|DRUG|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
57732085|NCT05591352|DIETARY_SUPPLEMENT|Chenopodium formosanum extracts sachet|consume 1 sachet per day
58299239|NCT06109389|DRUG|Lidocaine IV|LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
58299240|NCT05426408|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging to study coronary microvascular dysfunction|Myocardial perfusion mapping will be investigated after administration of adenosine
58299241|NCT03179735|DRUG|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
58299242|NCT03179735|DRUG|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
58410483|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
58080830|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
58080831|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
58080832|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
58080833|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
57946339|NCT00159991|PROCEDURE|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
58080834|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
58080835|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
57946340|NCT00159991|PROCEDURE|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
57946341|NCT01182402|DEVICE|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
57946342|NCT04161820|BEHAVIORAL|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
57946343|NCT04631575|DRUG|SHR6390|SHR6390, PO,single-dose
57946344|NCT03641872|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
57946345|NCT02092012|DRUG|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
57946346|NCT02092012|DRUG|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
57946347|NCT00473343|DRUG|Metvix® cream|
57946348|NCT06306625|DEVICE|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.
57946349|NCT06306625|DEVICE|No remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
58080836|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
58080837|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
57946350|NCT03383484|OTHER|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
57946351|NCT03383484|OTHER|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
58080838|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
58299243|NCT03179735|DRUG|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
57946352|NCT01034007|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
57946353|NCT06116500|DEVICE|Modified twin block appliance with expander|These appliances are myofunctional appliance used for treating class II division growing adolescents.
57946354|NCT06116500|DEVICE|Conventional twin block appliance with expander|These appliances are myofunctional appliances used for treating class II division growing adolescents.
57946355|NCT00019188|DRUG|interleukin-12|
58080839|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
57946356|NCT01317862|DEVICE|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
57946357|NCT04518462|DRUG|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
57946358|NCT04518462|DRUG|Bupivacaine Hydrochloride|0.25% bupivacaine
57946359|NCT02373059|OTHER|Diabetes Issue Cards Decision Aids|
57946360|NCT02373059|OTHER|Usual Pharmaceutical Care|
57946361|NCT02841397|DEVICE|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
58080840|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
58080841|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
58080842|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
58299244|NCT04321902|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
58410484|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
58410485|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
57732086|NCT05591352|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
58080843|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
58080844|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
58299245|NCT05628701|PROCEDURE|Ileorectal anastomosis (IRA)|After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
58299246|NCT05628701|PROCEDURE|Ileal pouch anal anastomosis (IPAA)|The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
58299247|NCT05628701|PROCEDURE|ileostomy|no reconstruction is performed and the patient is left with his/her ileostomy
58299248|NCT04294537|PROCEDURE|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
58299249|NCT04294537|PROCEDURE|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
58299250|NCT04294537|PROCEDURE|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
58299251|NCT04294537|DRUG|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
58299252|NCT06449469|DRUG|Rivaroxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
58410486|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
58410487|NCT00096499|DRUG|ispinesib|Given IV
58410488|NCT00096499|OTHER|pharmacological study|Correlative studies
58410489|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
58410490|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
58410491|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
58080845|NCT02095834|DRUG|Carfilzomib|Given IV
58080846|NCT02095834|DRUG|Dexamethasone|Given PO or IV
58080847|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
58080848|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
57946362|NCT02613962|PROCEDURE|biopsy or surgical resection of tumor and blood sampling|
57946363|NCT00402649|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
57946364|NCT02839265|DRUG|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
57946365|NCT02839265|RADIATION|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
57946366|NCT02076997|DRUG|Methotrexate|"Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
57946367|NCT01737385|PROCEDURE|Measurement with O2C|Measurement of microcirculation using O2C light probes.
57946368|NCT03947489|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
58080849|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
58080850|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
58299253|NCT06449469|DRUG|Acetylsalicylic acid|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
58299254|NCT06449469|DRUG|Clopidogrel|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
58299255|NCT06449469|DRUG|Edoxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
58299256|NCT06449469|DRUG|Dabigatran|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
58299257|NCT06449469|DRUG|Apixaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
58299258|NCT05588986|OTHER|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
58299259|NCT03603197|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
58299260|NCT03603197|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
58299261|NCT06383611|COMBINATION_PRODUCT|VT-X7 Treatment System|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
58299262|NCT06524986|BEHAVIORAL|Self-efficacy promoting program using computer game|The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment
58299263|NCT06524986|BEHAVIORAL|Standard nursing care|The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
58299264|NCT05510258|OTHER|Physiotherapy|TWO GROUPS CONTROL ND EXPERIMENTAL
58080851|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
58080852|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
58080853|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
58080854|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
58080855|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
58080856|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
58080857|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
58080858|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
58080859|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
58080860|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
58080861|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
58080862|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
58080863|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
58299265|NCT06359262|OTHER|Hope@School|A digital platform aimed at promoting student mental health in schools
57946369|NCT05767177|OTHER|Glucemia following Mixed Meal Test|On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.
57946370|NCT05767177|OTHER|Enteroscopy - mucosal ketogenic activity as well as glucose transport|On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
57946371|NCT03027362|OTHER|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
57946372|NCT03027362|OTHER|Psychoeducation and medication|
58080864|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
58080865|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
58299266|NCT06359262|OTHER|Treatment as usual|Regular student health care in schools
57946373|NCT00393887|DEVICE|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
57946374|NCT00393887|DEVICE|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
57946375|NCT01991990|DRUG|placebo|Single i.v. infusion
57946376|NCT01991990|DRUG|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
58080866|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
58299267|NCT00245024|DRUG|sulindac|
58299268|NCT00245024|OTHER|laboratory biomarker analysis|
58299269|NCT01102712|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
58299270|NCT04891666|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 12 weeks
58299271|NCT04891666|DIETARY_SUPPLEMENT|Placebo|1 sachet of placebo per day for 12 weeks
58299272|NCT03286387|OTHER|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
57946377|NCT00210093|DRUG|denufosol tetrasodium (INS37217)|
57946378|NCT01049685|DRUG|First-line Antiretroviral Therapy|"* Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background"
57946379|NCT05883462|COMBINATION_PRODUCT|Airiver Nasal Drug Coated Balloon (DCB) Catheter.|The balloon is coated with a paclitaxel drug (3.5ug/mm2).
57946380|NCT04986306|PROCEDURE|SLNB + ALND|Patients who received neoadjuvant chemotherapy will undergo SLNB+ALND to evaluate the feasibility of SLNB
57946381|NCT00071695|DRUG|Duloxetine Hydrochloride|
57946382|NCT00071695|DRUG|Venlafaxine Extended Release|
58299273|NCT00144599|DRUG|MRA(Tocilizumab)|
58299274|NCT00144599|DRUG|placebo|
58080867|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
58080868|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
58299275|NCT02597517|DEVICE|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
58299276|NCT03901846|DEVICE|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
58299277|NCT03310242|BEHAVIORAL|Sunlight Exposure|"* Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~* Completing a Sun Diary after sunlight exposure"
58299278|NCT03310242|DIETARY_SUPPLEMENT|Vitamin D Supplementation|- Supplementation of vitamin D3 500 IU/day for 8 weeks
58299279|NCT03310242|OTHER|Placebo|- Intake of placebo for 8 weeks
58299280|NCT02133391|OTHER|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
58299281|NCT02133391|OTHER|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
58299282|NCT04030741|DRUG|Meronem and flagyl|meronem and flagy
58299283|NCT04030741|PROCEDURE|Appendectomy|Appendectomy as treatment for acute appendicitis
58299284|NCT00165503|DRUG|Cisplatin|
58080869|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
58080870|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
58080871|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
58299285|NCT00165503|DRUG|Sodium Thiosulfate|
58299286|NCT00165503|DRUG|ALIMTA|
58299287|NCT04121338|PROCEDURE|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
58299288|NCT04121338|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
58080872|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
58080873|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
58410492|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
58410493|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
58080874|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
58080875|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
58080876|NCT01564680|OTHER|placebo|normal saline
58080877|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
58080878|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
58080879|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
58080880|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
58080881|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
58080882|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
58080883|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
58080884|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
58080885|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
58080886|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
58080887|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
58080888|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
58080889|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
58080890|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
58080891|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
58080892|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
58080893|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
58080894|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
58080895|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
58410494|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
58410495|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
58410496|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
58410497|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
58410498|NCT05933642|DRUG|Frusemide|frusemide 120mg
58410499|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
58410500|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
58080896|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
58410501|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58410502|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
58410503|NCT05074888|DRUG|Prospekta|Oral administration.
58410504|NCT05074888|DRUG|Placebo|Oral administration.
58410505|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
57946383|NCT01402609|DEVICE|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
58080897|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
58080898|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
58080899|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
58080900|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
58080901|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
58080902|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
58080903|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
58080904|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
57946384|NCT01402609|DEVICE|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
57946385|NCT03631784|DRUG|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
57946386|NCT03631784|DRUG|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
57946387|NCT03631784|DRUG|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
57946388|NCT03631784|DRUG|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
57946389|NCT03631784|DRUG|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
57946390|NCT03631784|RADIATION|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
57946391|NCT03631784|DRUG|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
57946392|NCT03631784|DRUG|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
57946393|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
57946394|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
57946395|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
57946396|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
57946397|NCT03203044|OTHER|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
57946398|NCT06087796|DRUG|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
57946399|NCT06087796|DRUG|Pentoxifylline|Topical treatment modality for alopecia areata.
57946400|NCT06087796|DRUG|Metformin|Topical treatment modality for alopecia areata.
58080905|NCT01367626|DRUG|letrozole|2.5 mg tablet
58080906|NCT01367626|DRUG|letrozole|2.5 mg tablet
58080907|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
58080908|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
58080909|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
58080910|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
58080911|NCT02780180|DRUG|QGC001|
58080912|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
58080913|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
58080914|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
58080915|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
58080916|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
57732087|NCT06669260|PROCEDURE|TEThA technique|Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
57732088|NCT05499741|DEVICE|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
57732089|NCT02194049|DRUG|BKM120|Given PO
57946401|NCT00800293|DRUG|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
58080917|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
58080918|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
58410506|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
58410507|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
58410508|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
58080919|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
57732090|NCT02194049|DRUG|cisplatin|Given IV
58080920|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
58410509|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
58410510|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
58410511|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
58410512|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
58410513|NCT00162279|DRUG|Abatacept|
58410514|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
58410515|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
58410516|NCT00642369|DRUG|haloperidol|6-40mg/day
57732091|NCT02194049|DRUG|etoposide|Given IV
58080921|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
58080922|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
58080923|NCT01927159|OTHER|Placebo|
58410517|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
57732092|NCT02662842|DEVICE|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
57732093|NCT02662842|DEVICE|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
57732094|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
58080924|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
58080925|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
58080926|NCT01103375|DRUG|isotretinoin|Given PO
58080927|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
58080928|NCT01103375|GENETIC|protein expression analysis|Correlative study
58080929|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
58080930|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
58080931|NCT02492152|DEVICE|Study group|Dianatal
58299289|NCT00129441|DRUG|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
58080932|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
58080933|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
58080934|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
58080935|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
58080936|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
58080937|NCT02052206|PROCEDURE|Shoulder replacement surgery|
58080938|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
58080939|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
58080940|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
57732095|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
57732096|NCT00870805|PROCEDURE|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
57732097|NCT00870805|PROCEDURE|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
57732098|NCT00870805|PROCEDURE|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
57732099|NCT00870805|PROCEDURE|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
58080941|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
58080942|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
58080943|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
58080944|NCT00330772|DRUG|Aspirin|
58080945|NCT00330772|DRUG|Clopidogrel|
58080946|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
58080947|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
58080948|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
58080949|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
58080950|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
58080951|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
58080952|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
58080953|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
58080954|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
58080955|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
58080956|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
58080957|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
58080958|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
58080959|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
58080960|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
58080961|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
58080962|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
58080963|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
58080964|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
58080965|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
58080966|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
58080967|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
58080968|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
58080969|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
58080970|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
58299290|NCT00129441|DRUG|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
58299291|NCT00741312|BEHAVIORAL|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
58299292|NCT00741312|BEHAVIORAL|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
58299293|NCT03572673|DEVICE|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
58299294|NCT03572673|DEVICE|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
58299295|NCT00379145|DRUG|trabectedin|
57732100|NCT03152552|DRUG|LIK066|LIK066 was supplied in different doses as tablets taken orally.
58080971|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
58080972|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
58080973|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
58080974|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
58080975|NCT02392377|DRUG|Oxaliplatin|Given IV
58299296|NCT00964028|BIOLOGICAL|Infanrix™-IPV/Hib|Intramuscular, three doses
58299297|NCT05728138|BEHAVIORAL|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
57946402|NCT02835001|PROCEDURE|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
58080976|NCT02392377|DRUG|Leucovorin Calcium|Given IV
58080977|NCT02392377|DRUG|Fluorouracil|Given IV
58080978|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
58080979|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
58080980|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
58080981|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
58080982|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
57732101|NCT03152552|DRUG|Placebo|Placebo was supplied as tablets and capsules taken orally.
57732102|NCT03152552|DRUG|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
57946403|NCT02835001|DEVICE|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
57946404|NCT00923130|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
58080983|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
58299298|NCT01428843|DRUG|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
57732103|NCT01184066|BEHAVIORAL|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
57946405|NCT00923130|DRUG|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
57946406|NCT04819152|BEHAVIORAL|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
57946407|NCT03380455|DRUG|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
57946408|NCT03380455|DRUG|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
57946409|NCT00139945|DRUG|Human acylated ghrelin|5 pmol/kg body weight per min
57946410|NCT01217632|DRUG|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
57946411|NCT01217632|DRUG|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
57946412|NCT01217632|DRUG|Entecavir|
57946413|NCT04623684|DRUG|Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
57946414|NCT04623684|DRUG|Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]|1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
57946415|NCT01666431|DRUG|Lapatinib|
57946416|NCT00816426|DRUG|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
57946417|NCT00816426|DRUG|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
57946418|NCT00816426|DRUG|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
57946419|NCT00816426|DRUG|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
57946420|NCT00816426|DRUG|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
57946421|NCT01485939|OTHER|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
57946422|NCT01485939|OTHER|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
57946423|NCT05478798|OTHER|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
58080984|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
57946424|NCT05478798|OTHER|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
57946425|NCT05478798|OTHER|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
57946426|NCT02278900|OTHER|Communication aids|Question Prompt list Audiofile
57946427|NCT00257725|DRUG|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
57946428|NCT01403818|DRUG|ASP1941|oral
57946429|NCT01403818|DRUG|Mitiglinide calcium hydrate|oral
57946430|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using locator attachment|
57946431|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using ball attachment|
58080985|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
58080986|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
58299299|NCT01428843|DRUG|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
58299300|NCT00750763|DRUG|Colonlytely|Bowel preparation
58299301|NCT00750763|DRUG|Picolax/Picoprep|Bowel preparation
58410518|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
58410519|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
58410520|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
58410521|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
58410522|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
58410523|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
58410524|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
58410525|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
58410526|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
58410527|NCT00096525|DRUG|lenalidomide|
58299302|NCT00750763|DRUG|Fleet|Bowel preparation
58299303|NCT02743364|OTHER|Laboratory Biomarker Analysis|Correlative studies
58080987|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
58299304|NCT02743364|OTHER|Placebo Administration|Given PO
58299305|NCT02743364|OTHER|Quality-of-Life Assessment|Ancillary studies
58299306|NCT02743364|OTHER|Questionnaire Administration|Ancillary studies
58299307|NCT02743364|DRUG|Simvastatin|Given PO
58299308|NCT02343367|BEHAVIORAL|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
58299309|NCT02343367|OTHER|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
58299310|NCT02343367|BEHAVIORAL|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
58080988|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
58080989|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
58080990|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
58080991|NCT01970423|DEVICE|conventional right ventricular stimulation|
58080992|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
58080993|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
58080994|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
58080995|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
58080996|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
58299311|NCT02343367|BEHAVIORAL|Text messages|regularly scheduled cell phone text messages for 12 months
58299312|NCT02343367|BEHAVIORAL|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
58299313|NCT02343367|BEHAVIORAL|Newsletters|12 monthly newsletters mailed to participant homes
57732104|NCT01184066|BEHAVIORAL|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
58080997|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
58299314|NCT02770911|PROCEDURE|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
58299315|NCT02770911|PROCEDURE|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
58299316|NCT00241007|DRUG|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
58410528|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
58410529|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
58410530|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
58410531|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
58410532|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
58080998|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
58080999|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
58081000|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
58081001|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
58299317|NCT01098084|DRUG|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
58299318|NCT02104427|DRUG|TG-0054 combined with G-CSF|
58299319|NCT02397941|OTHER|Ultrasound|ultrasound measures
58299320|NCT00000399|DRUG|Hormone replacement therapy|
58081002|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
58081003|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
58081004|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
58081005|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
58299321|NCT00000399|PROCEDURE|Strength training|
58299322|NCT05618314|DRUG|AT-527|single dose AT-527
58299323|NCT05618314|DRUG|AT-527|Single dose of AT-527 pre- and post-dialysis
58299324|NCT05618314|DRUG|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
58299325|NCT00039624|RADIATION|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
58410533|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
58081006|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
58081007|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
58081008|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
58081009|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
58081010|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
58081011|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
57732105|NCT01032967|PROCEDURE|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
57732106|NCT01032967|RADIATION|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
57732107|NCT04587440|OTHER|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
57732108|NCT00220194|DRUG|leuprolide acetate|
58081012|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
58081013|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
58299326|NCT03139552|OTHER|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
58410534|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
58410535|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
58410536|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
58410537|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
58410538|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
58410539|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
58410540|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
58081014|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
58081015|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
58081016|NCT00283621|DRUG|Adriamycin|
58081017|NCT00283621|DRUG|Ifosfamide|
58081018|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
58081019|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
58081020|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
58081021|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
58081022|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
58081023|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
58081024|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
58081025|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
58081026|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
58081027|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
58081028|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
58081029|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
58081030|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
58081031|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
58081032|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
58299327|NCT03139552|OTHER|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
58410541|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
57946432|NCT06092554|DIETARY_SUPPLEMENT|LactoLevure|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
58081033|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
58081034|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
58081035|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
58081036|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
58081037|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
58081038|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
58081039|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
58081040|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
58081041|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
58081042|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
58081043|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
58410542|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
58081044|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
58081045|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
58410543|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
58081046|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
58410544|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
58299328|NCT03139552|OTHER|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
58299329|NCT00180089|DRUG|Budesonide|
57946433|NCT06092554|OTHER|Placebo|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The placebo capsules contain a powdered glucose polymer that is unharmful for the patient and will be provided by the sponsor. The placebo capsules look identical to the probiotic capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
57946434|NCT02716987|DRUG|TAK-831|TAK-831 oral suspension.
57946435|NCT02716987|DRUG|[18F]PGM299|\[18F\]PGM299 injection
57946436|NCT04928859|DRUG|Albumin|"At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group."
57946437|NCT02011282|OTHER|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
58410545|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
58410546|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
57946438|NCT00099970|DRUG|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
57946439|NCT03329911|DRUG|EU Avastin®|100 mg/4 mL
57946440|NCT03329911|DRUG|BAT1706|100 mg/4 mL
57946441|NCT03329911|DRUG|Paclitaxel|200 mg/m²
57946442|NCT03329911|DRUG|carboplatin|target area under the curve \[AUC\] 6 mg/mL•minute
57946443|NCT00737256|DRUG|Aripiprazole|15-30 mg
57946444|NCT00737256|DRUG|Perphenazine|8-16 mg
57946445|NCT04973436|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
57946446|NCT05486351|OTHER|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
57946447|NCT00354770|DRUG|Placebo|daily
57946448|NCT00354770|DRUG|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
57946449|NCT00823498|BEHAVIORAL|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
57946450|NCT00823498|BEHAVIORAL|Interview|Interview with a member of study staff at housing development site.
57946451|NCT00823498|OTHER|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
57946452|NCT03436459|DEVICE|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
57946453|NCT03436459|DEVICE|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
57946454|NCT05068570|OTHER|ARMEROMTERY|ARMERGOMTERY TRAINING FOR UPPERLIMB
57946455|NCT03260088|DIAGNOSTIC_TEST|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
58081047|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
58299330|NCT04823780|DIETARY_SUPPLEMENT|nutrient solution|For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
58299331|NCT02812589|OTHER|Diffusion tensor imaging (DTI) in Breast MRI|
57946456|NCT01560780|DRUG|Prasugrel|one 10 mg tablet by mouth daily
57946457|NCT01560780|DRUG|Placebo|placebo similar in appearance to prasugrel
57946458|NCT00534339|DEVICE|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
57946459|NCT03339206|BEHAVIORAL|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
58081048|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
58081049|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
58081050|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
58081051|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
58081052|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
57946460|NCT03339206|BEHAVIORAL|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
57946461|NCT03339206|BEHAVIORAL|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
57946462|NCT04558411|BEHAVIORAL|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
57946463|NCT01389375|DEVICE|FemoSeal®|Closure device for femoral artery access closure
57946464|NCT01389375|DEVICE|ExoSeal®|Closure device for femoral artery access closure
57946465|NCT01389375|OTHER|Manual compression|Conventional manual compression
57946466|NCT04349774|DRUG|Control Group - ESP block with SAP block|None - Control Group
57946467|NCT04349774|DRUG|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
57946468|NCT05325151|OTHER|Educational Intervention|Receive GCPP intervention videos
57946469|NCT05325151|OTHER|Genetic Counseling|Receive genetic counseling
57946470|NCT05325151|OTHER|Survey Administration|Ancillary studies
58081053|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
58081054|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
58081055|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
58299332|NCT01331369|BEHAVIORAL|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
57946471|NCT05489731|DRUG|VIC-1911|VIC-1911 tablets for oral administration
57946472|NCT05489731|DRUG|Osimertinib Mesylate Tablets|Osimertinib tablets for oral administration
57946473|NCT05739786|DRUG|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
57946474|NCT05739786|DRUG|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
57946475|NCT05455112|BIOLOGICAL|RUTI® Vaccine|One subcutaneous injection of RUTI 25µg FCMtb
57946476|NCT05455112|BIOLOGICAL|Placebo|One subcutaneous injection of saline
57946477|NCT03483142|DRUG|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
57946478|NCT03483142|DRUG|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
57946479|NCT00112671|DRUG|sorafenib tosylate|Given orally 400mg orally twice daily
57946480|NCT00112671|OTHER|laboratory biomarker analysis|Correlative studies
57946481|NCT05847101|PROCEDURE|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
57946482|NCT06343948|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
57946483|NCT06343948|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
57946484|NCT06343948|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
57946485|NCT06343948|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
57946486|NCT06343948|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
57946487|NCT03982004|DEVICE|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
58081056|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
58081057|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
58081058|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
58299333|NCT01331369|OTHER|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
58299334|NCT01938196|DRUG|KWA-0711|
58299335|NCT01938196|DRUG|Placebo|
58299336|NCT02410447|DEVICE|Defocused shock wave therapy (DUOLITH® SD1)|
58299337|NCT06350734|OTHER|Non-Interventional Study|Non-Interventional Study
58299338|NCT01031303|BIOLOGICAL|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
58299339|NCT02731378|DRUG|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
57732109|NCT02411721|BEHAVIORAL|Animal Assisted Intervention|"1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
57946488|NCT03982004|DRUG|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
57946489|NCT03982004|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
57946490|NCT03982004|OTHER|Dermatologic Quality of Life Index|"* 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
57946491|NCT03982004|OTHER|Functional Assessment of Cancer Therapy|"* 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
57946492|NCT03982004|DRUG|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
58299340|NCT02731378|DRUG|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
57946493|NCT03982004|DEVICE|Cry-AC|-Device used to give the cryoimmunotherapy
58299341|NCT02731378|DRUG|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
57732110|NCT00002334|DRUG|Saquinavir|
57732111|NCT00002334|DRUG|Zidovudine|
57732112|NCT00002334|DRUG|Zalcitabine|
57732113|NCT04032899|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
57732114|NCT04032899|DIETARY_SUPPLEMENT|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
57732115|NCT02960529|PROCEDURE|extra-peritoneal high ligation of hernia|
57732116|NCT02960529|PROCEDURE|intraabdominal high ligation of hernia|
57732117|NCT00740545|DRUG|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
57946494|NCT03982004|PROCEDURE|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
57946495|NCT03982004|PROCEDURE|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
57946496|NCT01230242|DEVICE|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
57946497|NCT05109065|DIAGNOSTIC_TEST|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
58299342|NCT02731378|DRUG|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
58299343|NCT00524524|DRUG|ARQ 501|Weekly IV Infusion; 450 mg/m2
57732118|NCT00740545|DRUG|placebo|Women inject ourselves every days with placebo
58081059|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
58081060|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
58081061|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
58081062|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
58081063|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
58081064|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
58081065|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
58081066|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
58081067|NCT02951182|DRUG|TEZ|
57732119|NCT04838301|DRUG|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
57946498|NCT05109065|DIAGNOSTIC_TEST|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
57946499|NCT05109065|DIAGNOSTIC_TEST|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
57946500|NCT05109065|DIAGNOSTIC_TEST|Vitals|Height and weight will be measured in order to calculate BMI.
58081068|NCT02951182|DRUG|IVA|
58081069|NCT02951182|DRUG|VX-440|
57946501|NCT05109065|DIAGNOSTIC_TEST|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
57946502|NCT05109065|DIAGNOSTIC_TEST|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
58081070|NCT02951182|DRUG|Matched Placebo|
57946503|NCT05109065|DIAGNOSTIC_TEST|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
58081071|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
58081072|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
58081073|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
58081074|NCT00246675|DRUG|Frusemide|
58081075|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
58081076|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
58299344|NCT03573037|DRUG|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
58299345|NCT05262816|OTHER|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
58299346|NCT05251350|PROCEDURE|surgery|our study is observational and we use secondary data
57732120|NCT04838301|OTHER|Placebo|Normal saline solution IV via 30-minute infusion, once per week
57732121|NCT00490646|DRUG|ixabepilone|"Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
57946504|NCT05109065|DIAGNOSTIC_TEST|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
57946505|NCT06113900|DRUG|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
57946506|NCT00389428|DRUG|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
57946507|NCT03988348|PROCEDURE|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
57946508|NCT03988348|PROCEDURE|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
57946509|NCT04729985|DEVICE|CGM device with diabetic education, CGM education and a follow up protocol.|Blind CGM placed and recorded for 14 days after discharge and data downloaded
57946510|NCT01090466|DRUG|cisplatin|
58081077|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
58081078|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
58081079|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
58081080|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
58081081|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
58081082|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
58081083|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
58081084|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
58081085|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
58081086|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
58081087|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
57946511|NCT01090466|DRUG|gemcitabine hydrochloride|
57946512|NCT01090466|DRUG|temsirolimus|
58081088|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
58299347|NCT01491425|DEVICE|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
58299348|NCT01491425|DEVICE|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
58299349|NCT01099358|DRUG|Cetuximab|Administered Intravenously
58299350|NCT01099358|DRUG|Cisplatin|Administered Intravenously
58299351|NCT01099358|DRUG|5 - Fluorouracil|Administered Intravenously
58299352|NCT05313724|OTHER|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
58299353|NCT00750113|DRUG|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
58299354|NCT00750113|DRUG|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
58299355|NCT00750113|DRUG|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
58299356|NCT00667329|DRUG|2CdA|1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
58299357|NCT00667329|DRUG|Cyclophosphamide|40 mg/m\^2 PO twice daily x 7 days.
58299358|NCT00667329|DRUG|Rituximab|375 mg/m\^2 IV once weekly x 4 weeks.
58299359|NCT00012025|DRUG|fulvestrant|
57946513|NCT01090466|OTHER|pharmacological study|
58299360|NCT01149655|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
58299361|NCT01149655|DRUG|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
57946514|NCT06068712|BEHAVIORAL|Attentional Cue Type|Positive cue (target), negative cue (distractor), or neutral cue (baseline)
57946515|NCT05218512|OTHER|WB-EMS|"The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS."
57946516|NCT03769246|DEVICE|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
58081089|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
58299362|NCT01610037|DRUG|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
58299363|NCT01610037|DRUG|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
58299364|NCT01610037|DRUG|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
58299365|NCT05108701|BEHAVIORAL|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
57946517|NCT03769246|OTHER|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
57946518|NCT05421936|DRUG|Osimertinib|Treatment as the first EGFR-TKI
57946519|NCT02369848|DEVICE|Shockwave Lithoplasty System|
58081090|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
58081091|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
58081092|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
58081093|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
57732122|NCT00490646|DRUG|docetaxel|Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
57946520|NCT02329964|DRUG|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
58081094|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
58081095|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
58299366|NCT01102309|DEVICE|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
58299367|NCT01102309|OTHER|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
58299368|NCT00652912|DRUG|Clonazepam|ODT, 1 mg
58299369|NCT00652912|DRUG|Klonopin Wafers|ODT, 1 mg
58299370|NCT01367015|OTHER|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
58299371|NCT01367015|OTHER|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
58299372|NCT03255369|OTHER|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
58299373|NCT04232930|OTHER|Music|Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
58299374|NCT05246891|OTHER|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
58299375|NCT00243763|DRUG|TKI258|
58299376|NCT04936516|DEVICE|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
57946521|NCT02329964|DRUG|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
57946522|NCT06468397|DEVICE|iSeelr™|The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear
57946523|NCT05785156|OTHER|quick tests|"New quick tests are~* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
57946524|NCT03178760|DIAGNOSTIC_TEST|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~1. Age~2. Gender~3. Weight~4. Length~5. Waist Circumference~6. Body mass index"
57946525|NCT05821764|OTHER|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~* Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~* The cord blood sample (10 mL) immediately after delivery.~Data collection :~* A data collection sheet for the attention of the investigator (doctor or midwife) ;~* Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
58081096|NCT00083226|DRUG|doxorubicin|Given IV
58081097|NCT00083226|DRUG|bortezomib|Given IV
58299377|NCT03205293|BEHAVIORAL|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
58299378|NCT04845334|BEHAVIORAL|RR intervention|"The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain"
58299379|NCT05474183|DRUG|Ketamine|drug
58299380|NCT03902093|DIAGNOSTIC_TEST|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
58081098|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
58299381|NCT00564941|DRUG|deferasirox|
58081099|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
58081100|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
58081101|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
58081102|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
57732123|NCT00490646|DRUG|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
57732124|NCT05222230|OTHER|FFP3 Mask|Participans will wear FFP3 respirators during the study.
57946526|NCT05217199|OTHER|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
57946527|NCT02960230|BIOLOGICAL|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
57946528|NCT02960230|DRUG|Nivolumab|anti-PD1 monoclonal antibody
57946529|NCT05984342|DRUG|Tislelizumab|Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
58081103|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
58081104|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
58081105|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
58410547|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
57732125|NCT04820673|DRUG|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
57946530|NCT02159729|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
57946531|NCT02159729|DRUG|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
58081106|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
58081107|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
58081108|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
58081109|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
57732126|NCT01220557|BEHAVIORAL|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
57732127|NCT01220557|BEHAVIORAL|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
57732128|NCT02000245|BEHAVIORAL|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
58081110|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
58081111|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
58081112|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
58081113|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
58081114|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
58081115|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
58299382|NCT04503967|DRUG|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
57732129|NCT02000245|BEHAVIORAL|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
58081116|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
58081117|NCT00752206|DRUG|Saracatinib|Oral Agent
58299383|NCT05282628|BEHAVIORAL|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
58299384|NCT05837273|DEVICE|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
58299385|NCT05837273|BEHAVIORAL|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
58081118|NCT00752206|DRUG|Placebo|Oral Agent
58081119|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
57732130|NCT03882684|DIAGNOSTIC_TEST|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
57732131|NCT04584112|DRUG|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
57732132|NCT04584112|DRUG|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
57732133|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
57732134|NCT04584112|DRUG|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
58081120|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
58081121|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
58081122|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
58081123|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
58081124|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
58081125|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
58081126|NCT00236730|DRUG|topiramate|
58081127|NCT01826929|OTHER|Therapeutic education|
58081128|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
58081129|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
58081130|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
58081131|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
58081132|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
57732135|NCT04584112|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
57732136|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
57732137|NCT04584112|DRUG|Carboplatin|Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
57732138|NCT04584112|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
58081133|NCT00346775|DRUG|Flunisolide|Flunisolide
58081134|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
58081135|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
58081136|NCT00005658|DRUG|Glycine|
58081137|NCT01298362|DRUG|Aromatase Inhibitors|
58081138|NCT01298362|DRUG|Chemotherapy|
58081139|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
58081140|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
58081141|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
58081142|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
58081143|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
58081144|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
58081145|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
58081146|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
58081147|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
58081148|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
58081149|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
58081150|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
58081151|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
58081152|NCT00252668|DRUG|Etanercept|
57732139|NCT04584112|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
57732140|NCT04584112|DRUG|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
57732141|NCT04584112|DRUG|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
57732142|NCT06636032|DRUG|AdMSC (CellReady®)|At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
57732143|NCT04236557|BEHAVIORAL|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
57732144|NCT04236557|BEHAVIORAL|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
57946532|NCT02159729|DRUG|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
57946533|NCT02159729|DRUG|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
57946534|NCT01407770|GENETIC|DNA analysis|Genetic
57946535|NCT01407770|GENETIC|gene expression analysis|Genetic
57946536|NCT01407770|OTHER|enzyme-linked immunosorbent assay|Genetic
57946537|NCT01407770|OTHER|flow cytometry|Genetic
57946538|NCT01407770|OTHER|laboratory biomarker analysis|Genetic
57946539|NCT01407770|OTHER|questionnaire administration|Genetic
57946540|NCT01407770|PROCEDURE|adjuvant therapy|Genetic
57946541|NCT01407770|PROCEDURE|assessment of therapy complications|Genetic
57946542|NCT01407770|PROCEDURE|quality-of-life assessment|Genetic
57946543|NCT01407770|RADIATION|3-dimensional conformal radiation therapy|Genetic
57946544|NCT01407770|RADIATION|breast irradiation|Genetic
57946545|NCT01407770|RADIATION|external beam radiation therapy|Genetic
57946546|NCT01407770|RADIATION|hypofractionated radiation therapy|Genetic
57946547|NCT01407770|RADIATION|intensity-modulated radiation therapy|Genetic
57946548|NCT01407770|RADIATION|whole breast irradiation|Genetic
57946549|NCT05360459|RADIATION|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
57946550|NCT02085889|OTHER|no intervention: observational study|observational
57946551|NCT06073015|DRUG|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
57946552|NCT00248755|PROCEDURE|mucociliary clearance scan|
57946553|NCT03662880|RADIATION|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
57946554|NCT03662880|RADIATION|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
58081153|NCT00252668|DRUG|Methotrexate|
58081154|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
58081155|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
58410548|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
58081156|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
58081157|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
57946555|NCT01643629|BIOLOGICAL|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
57946556|NCT01643629|OTHER|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
57946557|NCT00603109|DRUG|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
57946558|NCT00603109|DRUG|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
58081158|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
58081159|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
58081160|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
58081161|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
58081162|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
58410549|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
57946559|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
57946560|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
57946561|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
58081163|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
58081164|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
58081165|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
58410550|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
58410551|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
58410552|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
58410553|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
58410554|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
58410555|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
58410556|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
58410557|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
57946562|NCT02712567|DRUG|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
57946563|NCT04047810|BIOLOGICAL|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
57946564|NCT04841707|DEVICE|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
57946565|NCT04013529|BEHAVIORAL|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
57946566|NCT04013529|BEHAVIORAL|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
57946567|NCT01547169|DRUG|Placebo Comparator|saline, taken twice per day for a 3 week duration
57946568|NCT01547169|DRUG|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
57946569|NCT01547169|DRUG|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
58299386|NCT04810988|BEHAVIORAL|Unified Protocol|The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.
58299387|NCT04810988|BEHAVIORAL|Therapist Support|4 video calls with study therapists
58299388|NCT00737100|DRUG|Placebo Respimat|patient to receive placebo matching active drug once daily
58410558|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
58410559|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
58410560|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
58410561|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
58410562|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
58410563|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
58410564|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
58410565|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
58410566|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
58410567|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
57946570|NCT05679128|DIAGNOSTIC_TEST|identification of the cricothyroid membrane using Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
58410568|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
58410569|NCT01448824|DRUG|LY2484595|Administered orally
58410570|NCT01448824|DRUG|Placebo|Administered orally
58410571|NCT01448824|DRUG|Ketoconazole|Administered orally
58410572|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
58410573|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
58410574|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
57946571|NCT05679128|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane using ultrasonography|identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
57946572|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage survival cohort|consists of surviving patients
57946573|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage mortality cohort|consists of deceased patients
58081166|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
58081167|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
58299389|NCT00737100|DRUG|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
58299390|NCT00737100|DRUG|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
58410575|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
58410576|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
58410577|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
58410578|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
58410579|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
58410580|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
58410581|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
58410582|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
58410583|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
58410584|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
58299391|NCT01137513|DEVICE|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
58410585|NCT03770494|DRUG|LY3405105|Administered orally.
58299392|NCT01137513|DEVICE|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
58299393|NCT06119230|BEHAVIORAL|Activity Counselling|Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
58299394|NCT02245815|DIETARY_SUPPLEMENT|use probiotics boucardii|group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
58410586|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
58410587|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
58410588|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
58410589|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
58410590|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
58410591|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
58410592|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
58299395|NCT02245815|DIETARY_SUPPLEMENT|use probiotics Multi-species|Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
58299396|NCT04511897|DRUG|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
58299397|NCT02895269|BEHAVIORAL|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
58299398|NCT05550350|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
58299399|NCT05550350|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
58299400|NCT04980014|DRUG|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
58299401|NCT06336421|OTHER|Virtual Reality|"VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes."
58299402|NCT03159936|BIOLOGICAL|Tofacitinib citrate|10 mg daily by mouth
58299403|NCT04423471|DIAGNOSTIC_TEST|Sociodemographic variables|"* Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~* General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~* Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~* Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~* Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~* Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~* Result variables: Changes in PASI or MADRS scores"
58299404|NCT02498678|PROCEDURE|Tetanus|tetanic electric stimulation
58299405|NCT00275522|DRUG|Sirolimus|
58299406|NCT03804268|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
58299407|NCT03804268|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
58299408|NCT03741374|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
58299409|NCT06469957|OTHER|Questionnaires and data collection sheet|Questionnaires
58410593|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
58410594|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
58410595|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
58410596|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
58410597|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
58410598|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
58410599|NCT01175200|DRUG|Prasugrel|antiplatelet agent
58299410|NCT03539094|OTHER|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
58299411|NCT05598060|RADIATION|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
58299412|NCT00821275|PROCEDURE|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
58299413|NCT03366857|DRUG|Oxygen 30 %|The oxygen concentration will be set at 30%.
58299414|NCT03366857|DRUG|Oxygen 80 %|The oxygen concentration will be set at 80%.
58299415|NCT02886923|DEVICE|Hioxifilcon A Test|contact lens made with hioxifilcon A material
58410600|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
58299416|NCT02886923|DEVICE|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
58299417|NCT02532374|OTHER|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
58410601|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
58299418|NCT02532374|OTHER|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
58410602|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
58410603|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
58410604|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
58410605|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
58410606|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
58410607|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
58410608|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
58410609|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
58410610|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
58410611|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
58410612|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
58081168|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
57732145|NCT05253625|OTHER|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
57732146|NCT00991250|BIOLOGICAL|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
58081169|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
58299419|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
58410613|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
58410614|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
58410615|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
58410616|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
58410617|NCT04766385|DRUG|KHK7791|oral administration
58410618|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
58410619|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
58410620|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
58410621|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
58410622|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
58410623|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
58410624|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
58081170|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
58081171|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
58299420|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
58299421|NCT00216593|DRUG|galantamine hydrobromide|
58299422|NCT02245165|BIOLOGICAL|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
58299423|NCT02245165|BIOLOGICAL|saline|
58299424|NCT03330509|OTHER|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
58299425|NCT03395626|DIETARY_SUPPLEMENT|ID-JPL934|probiotics
58299426|NCT03395626|DIETARY_SUPPLEMENT|Placebo|corn starch
58299427|NCT05530772|DEVICE|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
58299428|NCT03580070|BIOLOGICAL|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
58299429|NCT00270452|DRUG|WT1 and PR1 Peptide Vaccine|
58299430|NCT05968144|BEHAVIORAL|Dietary recommendations|One-on-one meeting with a nutritionist to discuss and personalize dietary recommendations for patients with prostate cancer undergoing ADT.
58299431|NCT05968144|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
58299432|NCT00345267|DEVICE|Integrated Care Pathway|
58299433|NCT03606564|OTHER|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
58299434|NCT00962312|DRUG|capecitabine|
58299435|NCT00962312|DRUG|lapatinib ditosylate|
58299436|NCT00866905|DRUG|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
58299437|NCT00866905|DRUG|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
58299438|NCT02421692|OTHER|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
58299439|NCT00791999|DRUG|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
58299440|NCT00791999|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
58299441|NCT00791999|DRUG|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
58299442|NCT00791999|DRUG|Placebo of CDP870|given every 2 weeks until Week22 (SC)
58299443|NCT05194462|DEVICE|Pericoach® by Analytica|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback .
58299444|NCT05194462|OTHER|Pelvic Floor Physical Therapy|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of PFPT.
58299445|NCT03275207|DRUG|saline|an equal volume of saline
58299446|NCT03275207|DRUG|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
58299447|NCT04414007|BEHAVIORAL|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
58410625|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
58410626|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
58410627|NCT00383643|DRUG|zolpidem tartrate|
58081172|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
58081173|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
58081174|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
58081175|NCT05294133|BEHAVIORAL|physical activity|physical activity
58081176|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
58081177|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
58299448|NCT04414007|BEHAVIORAL|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
58081178|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
58081179|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
58299449|NCT06442605|DEVICE|single-channel uterine fibroid morcellation system|Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.
58299450|NCT06442605|DEVICE|Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator|In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
58299451|NCT03008811|PROCEDURE|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
58081180|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
58081181|NCT02389621|DRUG|Placebo|Tablets for oral administration
58081182|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
58081183|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
58081184|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
58081185|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
58081186|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
58081187|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
58081188|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
58081189|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
58081190|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
58081191|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
58299452|NCT03008811|PROCEDURE|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
58299453|NCT01587885|DRUG|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
58299454|NCT01587885|DRUG|Omeprazole 20 mg|Tablets, orally
58299455|NCT02357225|DRUG|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
58299456|NCT01417468|BEHAVIORAL|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
58410628|NCT00383643|DRUG|sodium oxybate|
58410629|NCT00383643|DRUG|Matching Placebos|
58081192|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
58299457|NCT01417468|BEHAVIORAL|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
58299458|NCT00956085|DRUG|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
58299459|NCT05580484|PROCEDURE|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
58299460|NCT00535652|DRUG|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
58299461|NCT04825665|OTHER|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
58299462|NCT04825665|OTHER|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
58299463|NCT02492802|DRUG|posaconazole|collection plasma samples for measuring posaconazole drug concentration
58299464|NCT05733663|DIAGNOSTIC_TEST|Endoscopic procedure with duodenal biopsy|"* In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
58299465|NCT04102293|PROCEDURE|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
58299466|NCT04102293|PROCEDURE|manual K-files|manual instrumentation used in pulp therapy
58299467|NCT00715403|DRUG|BIBF 1120|
58299468|NCT05684341|COMBINATION_PRODUCT|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
58299469|NCT03495063|DIETARY_SUPPLEMENT|Natural Caffeine|Consumption of 400mg of natural caffeine
58299470|NCT03495063|DIETARY_SUPPLEMENT|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
58299471|NCT03905083|OTHER|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
58410630|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
58410631|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
58410632|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
58410633|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
58410634|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
58410635|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
58410636|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
58410637|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
58410638|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
58410639|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
58410640|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
58410641|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
58410642|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
58410643|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
58410644|NCT00454753|DRUG|Dasatinib|
58410645|NCT01960543|DRUG|fentanyl 15 microg|
58081193|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
58081194|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
58410646|NCT01960543|DRUG|Bupivacaine 7 mg|
58410647|NCT01960543|DRUG|Bupivacaine 9 mg|
58410648|NCT01960543|DRUG|Levobupivacaine 7 mg|
58410649|NCT01960543|DRUG|Levobupivacaine 9 mg|
58410650|NCT00088283|DRUG|pegaptanib sodium|
58410651|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
58410652|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
58410653|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
58410654|NCT01477463|DRUG|placebo and vitamin D|
58410655|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
58410656|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
57946574|NCT04597736|BIOLOGICAL|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
57946575|NCT04226690|DRUG|Active CBD/THC Dose 1|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
58081195|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
58299472|NCT02937480|OTHER|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
58299473|NCT02937480|OTHER|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
58410657|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
58410658|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
58410659|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
58410660|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
58410661|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
57946576|NCT04226690|DRUG|Active CBD/THC Dose 2|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
57946577|NCT04226690|DRUG|matched placebo comparator|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
57946578|NCT03194282|OTHER|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
57946579|NCT01325922|PROCEDURE|DFT Testing with a 50/50% tilt|
58299474|NCT02828488|OTHER|No intervention|It is a descriptive study. No intervention
58299475|NCT02713178|DRUG|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
58299476|NCT02713178|DRUG|Placebo|Normal saline.
58410662|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
58410663|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
58410664|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
58410665|NCT02961790|OTHER|Placebo|Given PO
58410666|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
57946580|NCT03016325|DRUG|HNO Donor|Infusion
57946581|NCT03016325|DRUG|Placebo|Infusion
57946582|NCT04163796|DEVICE|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
58410667|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
57732147|NCT00991250|DRUG|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
58299477|NCT05681117|OTHER|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
58299478|NCT00350883|BEHAVIORAL|Cognitive Therapy|Goal-oriented talk therapy
58299479|NCT00350883|OTHER|Treatment as Usual|Keep getting usual care
58410668|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
57732148|NCT00650832|DRUG|TMC114; darunavir; Prezista|
57732149|NCT06162520|OTHER|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
57732150|NCT01947946|BIOLOGICAL|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
58299480|NCT04737525|DEVICE|Dental implant placement, bone and soft tissue augmentation on buccal site|"1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray"
58299481|NCT05358899|DEVICE|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
58299482|NCT05358899|DEVICE|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
58299483|NCT00327340|DRUG|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
58299484|NCT00327340|DRUG|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
58299485|NCT05001607|DEVICE|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
58299486|NCT01997008|BEHAVIORAL|Intervention|Positive Affect Skills Training
58410669|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
58410670|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
57732151|NCT01947946|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
57732152|NCT02078323|DRUG|Linaclotide|
57732153|NCT02078323|DRUG|Placebo|
57732154|NCT01308216|PROCEDURE|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
58299487|NCT04327921|BEHAVIORAL|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
57732155|NCT05427786|DRUG|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
57732156|NCT00598689|DRUG|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
57732157|NCT03579563|OTHER|AUD fitting|Prescription hearing aids will be fitted by audiologists using established procedures.
57732158|NCT03579563|OTHER|OTC+ fitting|Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
57732159|NCT03579563|OTHER|OTC fitting|In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
57946583|NCT03443076|DIETARY_SUPPLEMENT|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
57946584|NCT03443076|OTHER|Lovaza (active comparator; already FDA approved)|A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
57946585|NCT00003351|DRUG|irinotecan hydrochloride|
57946586|NCT04592640|OTHER|Human amniotic mesenchymal stem cells|"1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
57946587|NCT05380011|OTHER|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
57946588|NCT05380011|OTHER|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
57946589|NCT04790877|OTHER|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
57946590|NCT04790877|OTHER|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
57946591|NCT04146194|OTHER|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
57946592|NCT03283826|BIOLOGICAL|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
57946593|NCT03283826|DRUG|Placebo|Placebo matching to ATA188
57946594|NCT02238704|DIETARY_SUPPLEMENT|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
57946595|NCT02238704|DIETARY_SUPPLEMENT|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
57946596|NCT05936684|BEHAVIORAL|Breathing with prolonged exhalation (ProlEx) during risky decision-making|20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
57946597|NCT05936684|BEHAVIORAL|Normal breathing (Eupnea/Control) during risky decision-making|20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
58299488|NCT04327921|BEHAVIORAL|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
57732160|NCT03579563|DEVICE|High-end HA|High-end hearing aids will be used.
57732161|NCT03579563|DEVICE|Low-end HA|Low-end hearing aids will be used.
57732162|NCT05739747|OTHER|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~* Patient registration.~* Complete medical history.~* Gendolcat scale (including the Spanish version of the SF-12 scale).~* Spanish version of the catastrophizing scale."
57732163|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
57732164|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
57732165|NCT05739747|OTHER|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
58299489|NCT01127100|DRUG|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
58299490|NCT04321772|OTHER|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
58299491|NCT04321772|OTHER|Traditional Resistance Training|Subjects trained the other leg with HIIRT
58299492|NCT05245383|OTHER|ten products (S01~S10) and two blank (BK1, BK2)|"S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back."
58299493|NCT05684848|DEVICE|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
57732166|NCT05739747|OTHER|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
57732167|NCT05169658|BIOLOGICAL|Mosunetuzumab|Given SC
57732168|NCT05169658|BIOLOGICAL|Obinutuzumab|Given IV
57732169|NCT05169658|DRUG|Polatuzumab Vedotin|Given IV
57946598|NCT04496622|OTHER|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
57946599|NCT04496622|OTHER|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
57946600|NCT01255644|DRUG|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
57946601|NCT00732277|DRUG|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
57946602|NCT03402529|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammography|Pilot study
57946603|NCT05957666|DRUG|Misoprostol Oral Tablet|oral misoprostol 50 microgram repeated after 6 hours if required
57946604|NCT05957666|DRUG|vaginal misoprostol|vaginal misoprostol 50 microgram repeated after 6 hours if required
57946605|NCT03187431|BIOLOGICAL|autologous bone marrow mesenchymal stem cells|intravenous infusion
57946606|NCT01294202|DRUG|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
57946607|NCT02159703|PROCEDURE|TORS|
57946608|NCT02159703|RADIATION|Adjuvant Radiation Therapy|
57946609|NCT03847129|OTHER|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
57946610|NCT03847129|OTHER|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
57946611|NCT03411720|OTHER|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
57946612|NCT00050609|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
57946613|NCT00050609|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
57946614|NCT00050609|DRUG|placebo|Placebo tablet taken by mouth once a day for 8 weeks
57946615|NCT00900458|BEHAVIORAL|Aerobic Exercise training|aerobic exercise training (cycling)
57732170|NCT05169658|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET and FDG-PET/CT
57732171|NCT05169658|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
57732172|NCT05169658|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and FDG-PET/CT
57732173|NCT05169658|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58081196|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
58081197|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58081198|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
58081199|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
58081200|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
58081201|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
58081202|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
58081203|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58081204|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
58081205|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
58081206|NCT06129851|DRUG|Relugolix|Given PO
58081207|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
58081208|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
58081209|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
58081210|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
58081211|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
58081212|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
58081213|NCT00050050|DRUG|Drug therapy|
58081214|NCT00283517|DRUG|antipsychotics|as prescribed
58081215|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
58081216|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
58081217|NCT00295256|BEHAVIORAL|nurse case manager|
58081218|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
58081219|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
58299494|NCT05684848|DEVICE|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
58299495|NCT05357846|DRUG|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
58081220|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
58081221|NCT00373282|DRUG|Triamcinolone acetonide|
58081222|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
58081223|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
58081224|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
58081225|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
58081226|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
58081227|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
58081228|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
58081229|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
58081230|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
58081231|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
58081232|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
58081233|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
58081234|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
58081235|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
58081236|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
58081237|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
57732174|NCT05169658|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58081238|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
58081239|NCT00021476|BEHAVIORAL|Behavioral treatments|
58081240|NCT00021476|BEHAVIORAL|Physical therapy|
58081241|NCT06008015|DRUG|BR1015|One tablet administered alone
58081242|NCT06008015|DRUG|BR1015-1|One tablet administered alone
58081243|NCT06008015|DRUG|BR1015-2|One tablet administered alone
58081244|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
58081245|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
58081246|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
58081247|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
58410671|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
58410672|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
57732175|NCT05169658|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57946616|NCT04992819|PROCEDURE|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
57946617|NCT04564742|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
57946618|NCT04564742|DRUG|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
58081248|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
57732176|NCT01714219|PROCEDURE|Posterior reconstruction|
57732177|NCT04381026|DIETARY_SUPPLEMENT|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
57732178|NCT04381026|DIETARY_SUPPLEMENT|Placebo|Filler agent
57732179|NCT05741125|BEHAVIORAL|DSME + ASE intervention (Centering Appetite)|The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
58081249|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
58410673|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
57946619|NCT03821025|DEVICE|Biliary stent|Palliation of malignant biliary obstruction
58081250|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
58081251|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
58081252|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
58081253|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
58081254|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
58081255|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
58081256|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
58081257|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
58299496|NCT05357846|RADIATION|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
57732180|NCT04495374|DRUG|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
57732181|NCT04495374|OTHER|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
58081258|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
58081259|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
58410674|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
57946620|NCT03255681|PROCEDURE|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
58081260|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
58299497|NCT05357846|DRUG|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
58299498|NCT05357846|DRUG|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
58410675|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
57732182|NCT03834064|BEHAVIORAL|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
58299499|NCT05357846|PROCEDURE|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
58410676|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
58410677|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
58081261|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
58081262|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
58081263|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
58081264|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
58081265|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
58081266|NCT00734318|DRUG|Flutiform 250/10 micrograms|
58081267|NCT00734318|DRUG|Flutiform 50/5 micrograms|
57732183|NCT00832923|BEHAVIORAL|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
57732184|NCT01602848|OTHER|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
57732185|NCT03821376|DRUG|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
57946621|NCT03757286|PROCEDURE|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
58081268|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
58081269|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
58081270|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
58081271|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
58081272|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
58081273|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
58081274|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
58081275|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
58081276|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
58081277|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
58081278|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
58081279|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
58081280|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
58081281|NCT05417373|OTHER|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
58081282|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
58081283|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
58081284|NCT02223520|DRUG|Placebo ointment and placebo cloths|
58081285|NCT01984840|DEVICE|Telemedicine|
58081286|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
58081287|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
58081288|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
58081289|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
57732186|NCT03473886|BEHAVIORAL|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
58081290|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
58081291|NCT00131027|DRUG|Cyclophosphamide|
58081292|NCT00131027|DRUG|Daunorubicin|
58081293|NCT00131027|DRUG|Vincristine|
58081294|NCT00131027|DRUG|Prednisolone|
58081295|NCT00131027|DRUG|L-asparaginase|
57732187|NCT04166019|BEHAVIORAL|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
58081296|NCT00131027|DRUG|Cytarabine|
58081297|NCT00131027|DRUG|Etoposide|
58081298|NCT00131027|DRUG|Dexamethasone|
58081299|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
58081300|NCT00131027|DRUG|Mercaptopurine|
58081301|NCT00131027|DRUG|Doxorubicin|
58081302|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
58081303|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
58081304|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
58081305|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
58081306|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
58081307|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
58081308|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
58081309|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
58081310|NCT01283659|OTHER|Standard Imaging|
58081311|NCT01283659|OTHER|Advanced Imaging|
58081312|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
58081313|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
58081314|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
58081315|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
58081316|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
58081317|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
57732188|NCT04166019|BEHAVIORAL|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
57732189|NCT04166019|BEHAVIORAL|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
58081318|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
58081319|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
58299500|NCT00924924|BEHAVIORAL|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
57732190|NCT05266911|BEHAVIORAL|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
57732191|NCT05266911|BEHAVIORAL|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
58081320|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
57732192|NCT04464304|DEVICE|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
58299501|NCT00924924|BEHAVIORAL|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
58299502|NCT05909540|PROCEDURE|Posterior facet distraction and fusion|With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.
58299503|NCT02063113|OTHER|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
57732193|NCT04464304|DEVICE|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
58081321|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
58081322|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
58081323|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
58081324|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
58299504|NCT01089127|DRUG|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
57732194|NCT04968938|DRUG|midomafetamine|80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
58299505|NCT01089127|DRUG|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
58299506|NCT01089127|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
57732195|NCT04968938|BEHAVIORAL|Therapy|Manualized therapy
57732196|NCT00022464|DRUG|temsirolimus|
58299507|NCT01089127|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
58299508|NCT02619617|DRUG|SOM230|The study evaluated SOM230 vs Placebo
58299509|NCT02619617|DRUG|Placebo|The study evaluated SOM230 vs Placebo
57732197|NCT00562159|DRUG|Placebo|Placebo sublingual tablet
58299510|NCT05235932|PROCEDURE|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
58299511|NCT05235932|PROCEDURE|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
58299512|NCT00275171|DRUG|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
58299513|NCT00275171|DRUG|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
58299514|NCT00275171|OTHER|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
58299515|NCT05178472|OTHER|Immunotherapy|Receive SOC immunotherapy
58081325|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
58081326|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
58081327|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
58081328|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
58081329|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
58081330|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
58081331|NCT05354349|DRUG|PRA023 SC|Drug
58299516|NCT05178472|RADIATION|Stereotactic Radiosurgery|Undergo SRS
58299517|NCT05178472|PROCEDURE|Vertebroplasty|Undergo vertebroplasty
58299518|NCT04113291|OTHER|DASH Diet|12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
58299519|NCT04113291|OTHER|Usual diet|12 weeks usual diet \<2300 mg Na/day
58299520|NCT01333423|DRUG|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
58299521|NCT01333423|DRUG|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
58299522|NCT01324947|DRUG|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
58299523|NCT02276963|DRUG|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
58299524|NCT02557724|PROCEDURE|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
58299525|NCT02557724|PROCEDURE|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
58299526|NCT01753713|DRUG|dovitinib|Given PO
58299527|NCT01753713|OTHER|laboratory biomarker analysis|Correlative studies
58410678|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
58410679|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
58081332|NCT05354349|DRUG|Placebo IV|Placebo
58081333|NCT05354349|DRUG|Placebo SC|Placebo
58081334|NCT05354349|DRUG|PRA023 IV High Dose|Drug
58299528|NCT01551966|DEVICE|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
58299529|NCT05406700|DRUG|Niraparib|Oral, daily, dosage per protocol,4 Weeks
58299530|NCT05406700|DRUG|Resection/Treatment with Niraparib|"The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent."
58299531|NCT03880136|DRUG|CTP-543|Once daily dosing
58410680|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
58410681|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
58410682|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
58081335|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
58081336|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
58081337|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
57732198|NCT00562159|BIOLOGICAL|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
57946622|NCT03757286|PROCEDURE|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
57946623|NCT04758442|OTHER|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
57946624|NCT01732302|OTHER|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
57946625|NCT04283136|DRUG|Padsevonil type 1 Tablet 200 mg|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
58299532|NCT06420388|DRUG|2% Lidocaine Gel|"The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications."
58299533|NCT06420388|DRUG|Water-based Lubricant Gel (K-Y Gel)|The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
57946626|NCT04283136|DRUG|Padsevonil type 2 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
57946627|NCT04283136|DRUG|Padsevonil type 3 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
57946628|NCT04283136|DRUG|Padsevonil type 4 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
57946629|NCT04283136|DRUG|Padsevonil type 5 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
57946630|NCT05917561|DRUG|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
57946631|NCT05917561|DRUG|Placebo|Placebo once a month, infusion for 36 weeks
57732199|NCT00562159|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
57946632|NCT03113656|OTHER|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
57946633|NCT03113656|OTHER|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
57946634|NCT06153875|OTHER|Sensory Thresold, Burst High Frecuency|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 5 trains of 5 seconds, 55 seconds apart, at a frequency of 100Hz, making 5 minutes of total treatment. The intensity will be set 200 microamperes (μA) above the detection threshold for each patient, guaranteeing a sensitive but not painful perception.
57946635|NCT06153875|OTHER|Theta-Burst Stimulation|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 40 trains separated by 7 seconds from each other, where each train contains 5 trains separated by 200ms, at a frequency of 5Hz, resulting in 6 minutes and 45 seconds of total treatment. The intensity will be set at the motor threshold of the patient, ensuring a non-painful stimulation.
58299534|NCT06420388|DRUG|Standard Postoperative Analgesics|"Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous"
58299535|NCT05459415|PROCEDURE|Reducing Excision Margins|Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
58299536|NCT01677741|DRUG|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
58299537|NCT03984344|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
58299538|NCT03984344|DEVICE|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
57732200|NCT00562159|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
57946636|NCT06153875|OTHER|Transcutaneous Electrical Nerve Stimulation|The transcutaneous electrical nerve stimulation will be applied on the trapezius or low back and internal calf muscles at a frequency of 80Hz and a pulse width of 250 microseconds, for 15 minutes. The intensity will be set at the detection threshold of each patient generating a sensitive but non-painful perception.
57946637|NCT03200132|DIAGNOSTIC_TEST|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
57946638|NCT04707742|DRUG|Betadine© bucal 100 mg/ml|15 ml 2% povidone-iodine, one minute rinse.
57946639|NCT04707742|DRUG|Oximen® 3%|15 ml 1% hydrogen peroxide, one minute rinse.
57946640|NCT04707742|DRUG|Clorhexidine Dental PHB©|15 ml 0,12% clorhexidine, one minute rinse.
57946641|NCT04707742|DRUG|Vitis Xtra Forte©|15 ml 0,07% cetylpyridinium chloride, one minute rinse.
57946642|NCT04707742|DRUG|Distilled Water|15 ml distilled water, one minute rinse.
58299539|NCT03984344|DEVICE|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
58299540|NCT01691378|OTHER|Window to Hope|Psychotherapy - Group
58299541|NCT01691378|OTHER|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
58299542|NCT00032448|PROCEDURE|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
58299543|NCT03281772|OTHER|Clinical Decision Software - provider portal|As noted in Arms
58299544|NCT03281772|OTHER|Clinical Decision Software - patient portal|As noted in Arms
58299545|NCT03361852|DRUG|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
58299546|NCT03361852|BIOLOGICAL|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
57732201|NCT00562159|DRUG|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
57732202|NCT00562159|DRUG|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
57946643|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
57946644|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Hard Capsule-Route of administration:Oral
57946645|NCT02768337|DRUG|Afatinib|
57946646|NCT02768337|RADIATION|2 Gy targeted radiotherapy|
57946647|NCT02768337|RADIATION|4 Gy targeted radiotherapy|
57946648|NCT00842738|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
57946649|NCT00842738|OTHER|No meditation|Health care services as usual
57946650|NCT00842738|OTHER|Controls|No intervention
57946651|NCT05021250|PROCEDURE|Lipiodol marking|HCC patients treated with TACE and the tumor marked with lipiodol.
58081338|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
58081339|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
58081340|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
58081341|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
58081342|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
58299547|NCT03361852|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
58299548|NCT00360425|DRUG|ferumoxytol|
58299549|NCT00360425|DRUG|moxifloxacin|
58299550|NCT00360425|DRUG|placebo|
58299551|NCT04214210|OTHER|Adapted Family Gene Toolkit|Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
58299552|NCT04214210|OTHER|Targeted intervention|The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
58299553|NCT02766348|DRUG|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
58081343|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
58081344|NCT00488098|DRUG|GSK372475|
58081345|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
58081346|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
58081347|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
57732203|NCT00562159|DRUG|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
58081348|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
58081349|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
58081350|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
58081351|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
58299554|NCT02766348|BIOLOGICAL|DC-CTL|8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
58299555|NCT02766348|DRUG|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
58299556|NCT04179877|BEHAVIORAL|IPS|Occupational rehabilitation and support Integrated with clinical treatment
58299557|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
58299558|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
58299559|NCT00577317|OTHER|Quality-of-Life Assessment|Ancillary studies
58299560|NCT05357534|OTHER|Physical activity|Physical activity: 10 km run on a treadmill
58081352|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
58081353|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
58081354|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
58081355|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
58081356|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
58081357|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
58081358|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
58299561|NCT02692807|PROCEDURE|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
58081359|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
58081360|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
58081361|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
58081362|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
58081363|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
58081364|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
58081365|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
58081366|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
58081367|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
58081368|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
58081369|NCT00350935|PROCEDURE|fMRI|One 30 minute session
58081370|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
58081371|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
58081372|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
58081373|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
58299562|NCT04866966|BEHAVIORAL|Shared medical appointments for weight loss|Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
58081374|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
58081375|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
58081376|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
58081377|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
58299563|NCT01908868|OTHER|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
58299564|NCT01908868|OTHER|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
58299565|NCT01908868|OTHER|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
58299566|NCT02155192|DRUG|No Intervention|
58299567|NCT05989555|OTHER|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
58081378|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
58081379|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
58081380|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
58081381|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
58081382|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
58081383|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
58081384|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
58081385|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
58081386|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
58081387|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
58081388|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
58081389|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
58081390|NCT01800812|BIOLOGICAL|Injections of OM-174|
58081391|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
58081392|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
58081393|NCT02888782|OTHER|Pharmacist Consultation|
58081394|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
58299568|NCT04758728|PROCEDURE|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
58299569|NCT04758728|DRUG|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
58299570|NCT04758728|DRUG|normal saline|Use of normal saline solution NaCl 0,9% topically
58299571|NCT05355285|PROCEDURE|Glucose Clamp|Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
58299572|NCT00846144|DIETARY_SUPPLEMENT|copper sulfate|copper sulfate 3mg/d for a period of 6 months
58299573|NCT04195711|DIAGNOSTIC_TEST|"objective pediatric vision screen, blinq,"|hand-held birefringent screener for simultaneous foveation
58299574|NCT03587064|DEVICE|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
58299575|NCT03587064|DEVICE|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
58299576|NCT05739604|DIAGNOSTIC_TEST|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
58299577|NCT05757817|PROCEDURE|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
58081395|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
58081396|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
58081397|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
58081398|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
58081399|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
58081400|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
58081401|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
58081402|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
57732204|NCT00562159|DRUG|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
58081403|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
58081404|NCT00329225|DRUG|rosiglitazone|
58081405|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
58081406|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
58081407|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
58081408|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
58081409|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
58081410|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
58081411|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
58081412|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
58299578|NCT03686553|OTHER|laboratory-based data collection|laboratory-based surveillance of SSI
58299579|NCT03980262|BEHAVIORAL|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
58299580|NCT03980262|BEHAVIORAL|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
58299581|NCT03776474|BIOLOGICAL|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
58299582|NCT01466738|BIOLOGICAL|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
58081413|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
58081414|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
58081415|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
58081416|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
58299583|NCT01466738|BIOLOGICAL|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
58081417|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
58081418|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
58299584|NCT04028726|OTHER|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
57946652|NCT04788251|OTHER|Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)|"The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31)."
57946653|NCT04788251|OTHER|Wait-list control|To receive fall prevention resources while waiting for their programme to start
57946654|NCT05023096|OTHER|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
58081419|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
58081420|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
58081421|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
58081422|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
58081423|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
58081424|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
58081425|NCT00093327|PROCEDURE|Acupuncture|
58299585|NCT00006877|DRUG|temozolomide|
58299586|NCT02882126|DRUG|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
58299587|NCT03021811|DEVICE|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
58299588|NCT03464435|DRUG|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
58299589|NCT05876325|OTHER|FINassist Patient|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
58299590|NCT05876325|OTHER|FINassist Caregiver|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
58299591|NCT06489912|DIAGNOSTIC_TEST|WAIS IV|Psychological assessement
58299592|NCT02844166|OTHER|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
58299593|NCT02844166|OTHER|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
58299594|NCT01028781|DRUG|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
58299595|NCT05568134|DIAGNOSTIC_TEST|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
58081426|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
58081427|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
58410683|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
58410684|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
58081428|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
58081429|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
58081430|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
58081431|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
58081432|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
58081433|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
58081434|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
58081435|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
58081436|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
58081437|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
58081438|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
58081439|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
58081440|NCT01913613|DEVICE|IASD|IASD device implantation
58081441|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
58081442|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
58081443|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
58081444|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
58081445|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
58299596|NCT05460949|OTHER|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
58410685|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
57946655|NCT00549939|DRUG|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
58081446|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
58081447|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
58081448|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
58081449|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
58081450|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
58081451|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
58081452|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
58081453|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
58081454|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
58081455|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
58081456|NCT01473602|DRUG|Teriparatide|Administered by SC injection
58081457|NCT01473602|DRUG|Placebo|Administered by SC injection
58081458|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
58081459|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
58299597|NCT05460949|OTHER|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
58299598|NCT03514719|DIAGNOSTIC_TEST|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
58081460|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
58081461|NCT01159652|DRUG|zaleplon|10 mg
58081462|NCT01159652|DRUG|zolpidem extended release|12.5 mg
58081463|NCT01159652|DRUG|bedtime placebo|placebo
58081464|NCT01159652|DRUG|middle of the night placebo|placebo
58081465|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
57732205|NCT00562159|DRUG|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
57732206|NCT02828111|DRUG|Patidegib|
57732207|NCT02828111|DRUG|Vehicle gel|
57732208|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
58081466|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
58081467|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
58081468|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
58081469|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
58081470|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
58081471|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
58081472|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
58081473|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
58081474|NCT00497822|PROCEDURE|Aerobic exercise training|
58081475|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
58081476|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
58081477|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
58081478|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
58081479|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
58081480|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
58081481|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
58081482|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
58081483|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
58081484|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
58081485|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
58081486|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
58299599|NCT03514719|DRUG|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
58081487|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
58081488|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
58299600|NCT02938572|DRUG|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
58299601|NCT02938572|DRUG|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
58299602|NCT02364388|DEVICE|Imagio IUS|Imagio diagnostic gray-scale ultrasound
57732209|NCT00317239|DRUG|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
58299603|NCT02364388|DEVICE|Imagio OA/US|Diagnostic opto-acoustic +gray-scale ultrasound
58299604|NCT03535363|DRUG|Osimertinib|Drug: Osimertinib 80mg or 40mg
58299605|NCT03940872|DIAGNOSTIC_TEST|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
58081489|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
58081490|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
58081491|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
58081492|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
58081493|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
58081494|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
58081495|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
58081496|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
58081497|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
58081498|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
57946656|NCT00549939|DRUG|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
57946657|NCT01576770|DEVICE|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
58081499|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
58081500|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
58081501|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
58081502|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
58081503|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
58299606|NCT03191552|DEVICE|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
57946658|NCT01576770|DRUG|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
58299607|NCT03191552|OTHER|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
58299608|NCT00306046|DRUG|Bisphosphonate treatment|
58299609|NCT02892617|OTHER|Bacteriological analysis of disc|
57946659|NCT03823066|DEVICE|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
57946660|NCT02238873|DRUG|Pegfilgrastim|
57946661|NCT03901079|OTHER|single-arm study|single-arm study
58081504|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
58081505|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
58081506|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
58081507|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
58299610|NCT05055726|DRUG|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
58299611|NCT03551847|DRUG|Antibiotic|The intervention involves giving an infected patient antibiotics.
58299612|NCT03551847|DRUG|No antibiotics|The intervention involves not giving an infected patient antibiotics.
57946662|NCT00366964|DEVICE|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
58299613|NCT04916652|RADIATION|MRI|MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).
58299614|NCT02339103|OTHER|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
58299615|NCT02339103|OTHER|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
58299616|NCT05796713|OTHER|Hydrocephalus|Interview
58299617|NCT00109993|BIOLOGICAL|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
58299618|NCT00109993|DRUG|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
58299619|NCT00109993|DRUG|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
58299620|NCT03442725|DRUG|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
58299621|NCT04477369|DRUG|DWJ1439|300mg single dose
58299622|NCT04477369|DRUG|DWJ1464|300mg single dose
58299623|NCT04477369|DRUG|DWC202003|300mg single dose
57946663|NCT00366964|DEVICE|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
58081508|NCT05385783|DRUG|Placebo|Placebo
58081509|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
58081510|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
58081511|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
58081512|NCT04689334|OTHER|Outcome|The number of surgeries
58081513|NCT06652971|DRUG|CKD-379|QD, PO
58299624|NCT04477369|DRUG|DWC202004|300mg single dose
58299625|NCT04266899|DEVICE|Foot Drop Stimulator - Neuro Orthosis|The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
58299626|NCT04266899|DEVICE|Treadmill|Gait training on a treadmill
58299627|NCT05775601|DRUG|18F-LY3950321|3 millicuries (±1 mCi)
58299628|NCT05775601|PROCEDURE|PET Scan|positron emission tomography (PET) scan
58299629|NCT04915235|BEHAVIORAL|Algorithm|Algorithm
57732210|NCT00317239|DRUG|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
57732211|NCT00618475|BEHAVIORAL|Cognitive behavioral therapy|"10 sessions~1 hour per week"
57732212|NCT03696121|DRUG|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
57732213|NCT03696121|DRUG|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
58081514|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
58299630|NCT01351818|DRUG|Growth Hormone|
58299631|NCT00006015|BIOLOGICAL|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)
57732214|NCT00869232|DRUG|Velcade|1.0mg/m2 days 1, 5, 8, \& 11
57732215|NCT00869232|DRUG|Melphalan|10 mg/m2 day 3
57732216|NCT00869232|DRUG|Thalidomide|200 mg days 5-8
57732217|NCT00869232|DRUG|Dexamethasone|40 mg day 5-8
58299632|NCT00006015|DRUG|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
58299633|NCT00006015|DRUG|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
58299634|NCT00006015|DRUG|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
58299635|NCT03760224|OTHER|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
57946664|NCT03705637|DRUG|Exparel|"* Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
58081515|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
57732218|NCT00869232|DRUG|Cisplatin|10 mg/m2 day 5-8
58081516|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
58081517|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
58081518|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
58081519|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
58081520|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
58081521|NCT00578448|DRUG|Belatacept|IV infusion
58081522|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
58081523|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
58081524|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
58081525|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
58081526|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
58410686|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
57732219|NCT00869232|DRUG|Adriamycin|10 mg/m2 day 5-8
57732220|NCT00869232|DRUG|Cyclophosphamide|400 mg/m2 day 5-8
57732221|NCT00869232|DRUG|Etoposide|40 mg/m2 day 5-8
58081527|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
58081528|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
58081529|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
58299636|NCT03760224|OTHER|SMS group|SMS group for 8 weeks
58081530|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
58081531|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
58081532|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
58081533|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
58081534|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
58081535|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
58081536|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
58081537|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
58081538|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
58081539|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
58081540|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
58081541|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
58081542|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
57946665|NCT04219176|DIAGNOSTIC_TEST|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
58081543|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
58299637|NCT03723434|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
58299638|NCT03723434|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
58299639|NCT03723434|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
58299640|NCT06107998|OTHER|stethoscope|endotracheal tube cuff will be inflated via stethoscope guidance
58299641|NCT06107998|OTHER|Audible leak/Balloon palpation|endotracheal tube cuff will be inflated via audible leak/balloon palpation method
58299642|NCT01219712|PROCEDURE|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
58299643|NCT01484951|DRUG|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
58299644|NCT00766324|DRUG|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
58299645|NCT00766324|DRUG|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
58299646|NCT06326190|DRUG|Local standard of Care|According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.
58299647|NCT06326190|DRUG|177Lu-DOTATATE|Intravenous injection of 177Lu-DOTATATE
58299648|NCT00887484|DRUG|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
58299649|NCT00887484|DRUG|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
58081544|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
58081545|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
58081546|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
58081547|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
58081548|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
58081549|NCT00161031|DRUG|Atomoxetine|
58081550|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
57732222|NCT06457750|BEHAVIORAL|Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application|Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
57732223|NCT03523533|PROCEDURE|Angiocatheter|Placement of angiocatheter in internal jugular vein
57732224|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
57732225|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
57732226|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
58081551|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
58081552|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
58081553|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
58081554|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
58081555|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
58081556|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
58410687|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
57732227|NCT02247505|DRUG|Harnal-D Cap. 0.2mg|
57732228|NCT02247505|DRUG|Cialis Tab. 5mg|
57946666|NCT00524342|DRUG|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
57946667|NCT04441268|PROCEDURE|primary IOL implantation|implant IOL in capsular bag after cataract extraction
57946668|NCT00833950|DEVICE|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
58081557|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
58081558|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
58081559|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
58081560|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
58081561|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
58081562|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
58410688|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
58410689|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
57732229|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
57732230|NCT05509972|DEVICE|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
57732231|NCT03726346|DEVICE|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
58081563|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
57732232|NCT05520905|OTHER|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
57732233|NCT04792346|RADIATION|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
57732234|NCT02883725|OTHER|data collection|
57732235|NCT03080519|PROCEDURE|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
58081564|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
58410690|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
58410691|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
58081565|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
58081566|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
58081567|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
58081568|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
58081569|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
58081570|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
58081571|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
58081572|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
58081573|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
58299650|NCT00505050|OTHER|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
58299651|NCT05781867|OTHER|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
58081574|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
58081575|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
58081576|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
58299652|NCT00465517|DRUG|Ganaxolone|Oral suspension 200-500 mg 3x/day
58299653|NCT00465517|OTHER|Placebo|non-active placebo
58299654|NCT04378712|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
58299655|NCT04378712|OTHER|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
58410692|NCT00349687|BEHAVIORAL|self-control practice|
58410693|NCT02157792|DRUG|M6620|
58410694|NCT02157792|DRUG|Gemcitabine|
58410695|NCT02157792|DRUG|Cisplatin|
58410696|NCT02157792|DRUG|Etoposide|
58410697|NCT02157792|DRUG|Carboplatin|
58081577|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
58081578|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
58081579|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
58081580|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
58081581|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
58081582|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
58081583|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
58081584|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
58081585|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
58081586|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
58081587|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
57732236|NCT00428454|DEVICE|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
58081588|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
58081589|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
58081590|NCT04722627|DRUG|AT-752|Parallel Assignment
58081591|NCT04722627|DRUG|Placebo|Parallel Assignment
58081592|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
58081593|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
58081594|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
58081595|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
58081596|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
58081597|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
58081598|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
58081599|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
58299656|NCT04789382|DEVICE|LID018869+RepleniSH|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
58081600|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
58081601|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
58081602|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
58081603|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
58081604|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
58299657|NCT04789382|DEVICE|LID018869+Biotrue|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
58299658|NCT04789382|DEVICE|Biofinity+RepleniSH|Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
57732237|NCT04757753|DEVICE|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
57732238|NCT04757753|DEVICE|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
57732239|NCT04598477|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
58081605|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
58081606|NCT00008034|DRUG|capecitabine|
58299659|NCT04789382|DEVICE|PV+Biotrue|Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
58299660|NCT02702089|PROCEDURE|Rectal cancer surgery|Rectal cancer resection
58299661|NCT03759080|PROCEDURE|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
58081607|NCT00008034|DRUG|cyclophosphamide|
58081608|NCT00008034|DRUG|epirubicin hydrochloride|
58081609|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
58081610|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
58081611|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
58081612|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
58299662|NCT03759080|PROCEDURE|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
58410698|NCT02157792|DRUG|Irinotecan|
57946669|NCT05988775|BEHAVIORAL|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
57946670|NCT05988775|BEHAVIORAL|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
57946671|NCT05988775|OTHER|Nature movie watching|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
57946672|NCT04800562|DRUG|PCS499|PCS499 900mg twice a day with food
57946673|NCT04800562|OTHER|placebo|placebo comparator
57946674|NCT02771704|OTHER|Silver Diamine fluoride|
57946675|NCT02771704|OTHER|Potassium iodide|
57946676|NCT02771704|OTHER|Chlorhexidine|
57946677|NCT02771704|OTHER|Silver diamine fluoride and potassium iodide|
57946678|NCT02771704|OTHER|Physiological saline|
57946679|NCT00975299|DRUG|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
57946680|NCT00975299|DRUG|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
57946681|NCT03290833|DEVICE|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
57946682|NCT03290833|OTHER|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
57946683|NCT00108394|DRUG|pamidronate|
57946684|NCT02324920|DEVICE|DDD-CLS|
57946685|NCT02324920|DEVICE|ODO|
58081613|NCT00910000|DRUG|Vorinostat|
58081614|NCT00910000|DRUG|Carboplatin|
57946686|NCT00817882|OTHER|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
57946687|NCT00817882|OTHER|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
57946688|NCT00247000|DEVICE|Routine Care in a HF clinic vs Home Telehealth Care for HF|
57946689|NCT02317861|DRUG|RDEA3170|Oral Treatment
57946690|NCT02317861|DRUG|Febuxostat|Oral Treatment
57946691|NCT02317861|DRUG|Benzbromarone|Oral Treatment
57946692|NCT03536988|PROCEDURE|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
58081615|NCT00910000|DRUG|Gemcitabine|
58081616|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
58410699|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
57732240|NCT04598477|DRUG|prednisone|Oral prednisone tablets
57946693|NCT03536988|PROCEDURE|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
57946694|NCT05270070|OTHER|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
58081617|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
58081618|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
58081619|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
58081620|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
58081621|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
58081622|NCT02763410|OTHER|PRBC transfusion|
58081623|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
58081624|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
58081625|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
58081626|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
58081627|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
58081628|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
58081629|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
58299663|NCT03169569|PROCEDURE|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
58299664|NCT03169569|PROCEDURE|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
58299665|NCT03227718|BEHAVIORAL|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
58299666|NCT01403558|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
58299667|NCT04478318|DEVICE|uEXPLORER/mCT|Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
58299668|NCT04478318|DEVICE|mCT/uEXPLORER|Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
58299669|NCT02068638|PROCEDURE|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
58410700|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
58081630|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
58081631|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
58081632|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
58081633|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
58081634|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
58081635|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
58081636|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
58081637|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
58299670|NCT02068638|PROCEDURE|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
58299671|NCT02068638|PROCEDURE|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
58410701|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
58410702|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
58410703|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
57732241|NCT06551519|OTHER|ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
57946695|NCT04858230|DEVICE|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
58299672|NCT02068638|PROCEDURE|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
58299673|NCT05031442|DEVICE|RH1 (low waist)|Investigational product variant 1 low waist
58299674|NCT05031442|DEVICE|Reference variant 1 (low waist)|Reference product variant 1
58299675|NCT05031442|DEVICE|RC2 (high waist)|Investigational product variant 2 high waist
58410704|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
57946696|NCT00507390|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
58299676|NCT05031442|DEVICE|Reference variant 2 (high waist)|Reference product variant 2
58410705|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
57946697|NCT00507390|DIETARY_SUPPLEMENT|olive oil|1 capsule day
57946698|NCT05949775|BIOLOGICAL|Neoantigen mRNA Personalised Cancer vaccine|Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection
57946699|NCT04241211|DRUG|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
57946700|NCT04241211|DRUG|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
58299677|NCT04222816|DRUG|Lithium Carbonate|Lithium carbonate 800-900 mg orally daily for 12 weeks
58299678|NCT04222816|DRUG|Sodium chloride|Sodium chloride 1gm daily per orally for 12 weeks
58299679|NCT00537888|DRUG|fluconazole|Intravenous or oral 400 md/d
58410706|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
58410707|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
58410708|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
58410709|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
58410710|NCT01386541|DRUG|BYK324677|capsules, administered orally
58410711|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
58410712|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
58410713|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
58410714|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
58410715|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
58410716|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
58410717|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
57732242|NCT06551519|OTHER|DMT category 1|This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
57732243|NCT01380483|DRUG|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
57732244|NCT01380483|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
57732245|NCT02084953|DRUG|BMS-791325|
57732246|NCT02084953|DRUG|Moxifloxacin|
57732247|NCT02084953|DRUG|Placebo matching BMS-791325|
58410718|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
58410719|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
58410720|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
58410721|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
58081638|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
58081639|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
58299680|NCT06106230|COMBINATION_PRODUCT|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
58299681|NCT01162044|OTHER|Computer game|Playing with specially designed computer game while in emergency room
58299682|NCT04425070|COMBINATION_PRODUCT|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
58299683|NCT04425070|COMBINATION_PRODUCT|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
58299684|NCT04425070|COMBINATION_PRODUCT|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
58410722|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
58410723|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
58299685|NCT02979782|PROCEDURE|Endo-CABG|minimal invasive cardiac intervention
58299686|NCT02979782|PROCEDURE|PCI|stenting procedure
58410724|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
57946701|NCT04581564|DEVICE|Rhythm-based speech therapy app (i.e., Speech Hero)|Patients with non-fluent aphasia will practice speech production during the intervention period.
58299687|NCT04058509|COMBINATION_PRODUCT|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
58299688|NCT00144443|BEHAVIORAL|Basic home repair|
58299689|NCT00144443|BEHAVIORAL|Asthma Trigger Education|
58299690|NCT00248209|DRUG|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
58299691|NCT01534273|DRUG|LY2886721|Administered orally.
58299692|NCT01534273|DRUG|Placebo|Administered orally.
58299693|NCT03011866|DRUG|Wound topically irrigated with 500mg TXA|
58410725|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
58410726|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
58410727|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
58299694|NCT03011866|DRUG|1mg/kg/hr TXA intravenous infusion till the last suture|
58410728|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
58410729|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
58410730|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
58410731|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
58299695|NCT05390008|OTHER|Pelvic Floor Muscle Training|"In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased."
58299696|NCT05390008|OTHER|Modified Pilates Exercise|"Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching."
58410732|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
58410733|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
58410734|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
58410735|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
58410736|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
58410737|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
58410738|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
58410739|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
58410740|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
58410741|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
58081640|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
57946702|NCT03770949|DEVICE|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
58299697|NCT02626598|DEVICE|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
57946703|NCT02820792|PROCEDURE|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
57946704|NCT02820792|DEVICE|LMA ProtectorTM|
57946705|NCT02820792|DEVICE|Ambu AuraGainTM|
57946706|NCT06115772|OTHER|Non-Interventional Study|Non-interventional study
58299698|NCT00621101|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
58299699|NCT00621101|DRUG|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
58299700|NCT00621101|DRUG|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
58299701|NCT00734292|DRUG|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
58299702|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
58299703|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
58299704|NCT00767572|DRUG|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
58299705|NCT00767572|DRUG|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
58299706|NCT06164977|PROCEDURE|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
58299707|NCT00338091|DRUG|Benazepril|
58299708|NCT00338091|DRUG|Losartan|
58299709|NCT02515903|PROCEDURE|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
58081641|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
58410742|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
58410743|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
57946707|NCT05895149|OTHER|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
57946708|NCT05895149|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
57946709|NCT05993650|OTHER|Inspiratuar Muscle Training Group|Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks
57946710|NCT05993650|OTHER|Thoracic Expansion Exercise Group|"Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
57946711|NCT06261398|BEHAVIORAL|BETTER: motivational interviewing and text messaging|Motivational interviewing to encourage individuals to address their social needs and engage with text messages that allow individuals to connect to their care team, a local organization that can help them address their social needs, and/or a resource that enables them to find help to address their needs based on their zip code.
57946712|NCT06261398|BEHAVIORAL|Standard of care|No motivational interviewing or text messages will be provided.
57946713|NCT04960982|DIAGNOSTIC_TEST|blood test|blood sample is taken in first, second and third trimester of pregnancy
57946714|NCT04944212|DIAGNOSTIC_TEST|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
57946715|NCT01168648|BEHAVIORAL|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
57946716|NCT01168648|OTHER|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
57946717|NCT03427047|DEVICE|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
58081642|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
58081643|NCT02543918|DRUG|Boostrix®|Administered by IM injection
58410744|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
58410745|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
58410746|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
58410747|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
58410748|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
58410749|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
57732248|NCT06388577|OTHER|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
58299710|NCT02515903|PROCEDURE|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
58299711|NCT05225948|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
58299712|NCT05225948|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
58081644|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
58081645|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
58299713|NCT05337176|OTHER|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
58299714|NCT02786992|DRUG|Misoprostol|
58299715|NCT02786992|DRUG|Oxytocin|
58299716|NCT02786992|DRUG|Carbetocin|
58081646|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
58081647|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
58081648|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
58081649|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
58299717|NCT02786992|DRUG|Placebo|
58299718|NCT05660278|OTHER|Milk containing A1 and A2 beta-casein|Single dose of milk
58299719|NCT05660278|OTHER|Milk containing only A2 beta-casein|Single dose of milk
58299720|NCT02672176|BEHAVIORAL|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
58299721|NCT02672176|BEHAVIORAL|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
58299722|NCT02269839|DEVICE|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
58299723|NCT01436487|BIOLOGICAL|MultiStem|single infusion 1-2 days following ischemic stroke
58299724|NCT01436487|BIOLOGICAL|Placebo|single infusion 1-2 days following ischemic stroke
58081650|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
58081651|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
58081652|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
58299725|NCT00057291|BEHAVIORAL|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
58299726|NCT01082744|DRUG|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
58299727|NCT01082744|DRUG|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
58299728|NCT04554589|DRUG|Glycopyrrolate 0.2 MG|injections
58299729|NCT04554589|DRUG|normal saline|normal saline
58410750|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
58410751|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
58410752|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
58410753|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
58410754|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
58081653|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
58081654|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
58299730|NCT02937623|DEVICE|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
58299731|NCT06141785|OTHER|Nutritional intervention|An individually targeted nutritional intervention, and a simple home-based physical exercise program. The Nutritional intervention will be delivered by a clinical dietitian, from treatment initiation and throughout the treatment trajectory
58299732|NCT01217827|BEHAVIORAL|Clinical Reminder|
58081655|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
57946718|NCT03427047|DEVICE|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
58299733|NCT00159315|PROCEDURE|Inhalation Challenge with ATP|
57946719|NCT01087775|BEHAVIORAL|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
57946720|NCT01018433|BEHAVIORAL|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
57946721|NCT01018433|OTHER|Treatment as usual|Can include other psychotherapy and pharmacotherapy
57946722|NCT00124059|DRUG|Seroquel|400mg/day quetiapine
57946723|NCT00124059|DRUG|Placebo|400mg/day placebo
57946724|NCT04562207|DIAGNOSTIC_TEST|Screening for respiratory virus infection|Nasopharyngeal swab for screening for respiratory virus infection before surgery
57946725|NCT03737383|BEHAVIORAL|Narrative Exposure Therapy|brief, trauma-focused treatment.
57946726|NCT06190652|DRUG|Chemotherapy combined with immunotherapy|chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
57946727|NCT06190652|RADIATION|radiotherapy|Intensity-modulated radiation therapy
57946728|NCT05858021|DIAGNOSTIC_TEST|Physical examination|"Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA."
58081656|NCT03194165|BIOLOGICAL|Darunavir|Dosage
58081657|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
58081658|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
58081659|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
58299734|NCT00159315|PROCEDURE|Inhalation Challenge with AMP|
58299735|NCT05355467|DRUG|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
58299736|NCT05355467|OTHER|Historical Data|Historical Data
57946729|NCT03542006|DRUG|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
57946730|NCT01572116|DRUG|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
57946731|NCT01572116|DRUG|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
57946732|NCT01353820|DIETARY_SUPPLEMENT|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( \>10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )
57946733|NCT01353820|DIETARY_SUPPLEMENT|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
57946734|NCT02151955|BEHAVIORAL|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
58081660|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
58081661|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
58081662|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
58081663|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
58081664|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
58081665|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
58081666|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
58081667|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
58081668|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
58081669|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
58081670|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
58299737|NCT03337815|DRUG|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
58081671|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
58299738|NCT03337815|DRUG|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
58081672|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
58081673|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
58081674|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
58081675|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
58081676|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
58081677|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
58081678|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
58081679|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
58081680|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
58081681|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
58081682|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
58081683|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
58081684|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
58081685|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
58081686|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
58081687|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58081688|NCT06538389|DRUG|BRC-001|Given PO
58081689|NCT06538389|DRUG|Placebo Administration|Given PO
58081690|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
58081691|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
58081692|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
57732249|NCT02938416|DEVICE|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
58081693|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
58081694|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
58081695|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
58081696|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
58081697|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
58081698|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
58081699|NCT00381680|DRUG|vincristine sulfate|Given IV
58081700|NCT00381680|DRUG|prednisone|Given PO
58299739|NCT04264780|OTHER|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
58299740|NCT00203801|DRUG|Sulfadoxine-pyrimethamine|
58299741|NCT00203801|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
58299742|NCT00203801|DRUG|Artemether-lumefantrine|
58081701|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
58081702|NCT00381680|DRUG|pegaspargase|Given IM
58081703|NCT00381680|DRUG|cytarabine|Given IT or IV
58081704|NCT00381680|DRUG|methotrexate|Given IT or IV
58299743|NCT03123081|PROCEDURE|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
58299744|NCT06244368|DRUG|GVM±R regimen|"Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
58299745|NCT03957785|DEVICE|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
58299746|NCT03318198|OTHER|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
58299747|NCT03318198|OTHER|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
58299748|NCT03429101|DRUG|Poziotinib|Poziotinib is a tablet for oral administration.
58299749|NCT03429101|DRUG|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
58410755|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
58410756|NCT01839240|DRUG|azacitidine|Given IV or SC
58299750|NCT06160336|OTHER|Transcutaneous Electrical Nerve Stimulation|"Phase 1: Participants undergo a comprehensive assessment in a single experimental session (mapping session) aimed at mapping the regions and sensations that can be electrically stimulated. This mapping protocol is conducted on both the intact and amputated limbs.~Phase 2: This phase comprises a 4-week experimental protocol, including:~1. four mapping sessions conducted at the onset of each week, where the protocol is randomly applied to the participant's intact and amputated limb.~2. three stimulation sessions held over three consecutive days in the initial week to assess the participant's ability to discern stimuli of varying intensities.~3. ten sessions utilizing an end-effector gait rehabilitation robot, aiming to train the participant in walking using the proposed sensory feedback restoration system based on TENS under controlled and repeatable experimental conditions."
58299751|NCT01560247|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
58410757|NCT01839240|DRUG|cytarabine|Given IV
58081705|NCT00381680|DRUG|dexamethasone|Given PO
58081706|NCT00381680|DRUG|etoposide|Given IV
58081707|NCT00381680|DRUG|cyclophosphamide|Given IV
58299752|NCT02208076|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
58081708|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
58299753|NCT00467519|BIOLOGICAL|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
58299754|NCT00467519|BIOLOGICAL|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
58081709|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
58410758|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
58410759|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
58410760|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
58410761|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
58410762|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
58410763|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
58410764|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
58410765|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
58410766|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
58081710|NCT00381680|DRUG|asparaginase|Given IM
58081711|NCT00381680|DRUG|mercaptopurine|Given PO
58081712|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
58081713|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
58410767|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
58410768|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58410769|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
58081714|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
58081715|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
58081716|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
58081717|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
58081718|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
57732250|NCT02938416|DEVICE|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
58081719|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
58081720|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
58081721|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
58081722|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
58081723|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
58081724|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
58081725|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
58081726|NCT02743182|DRUG|Pegylated interferon alfa-2a|
58081727|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
58081728|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
58081729|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
58299755|NCT02783612|OTHER|glucose buddy application|
58299756|NCT04743622|DRUG|Monoprost|preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
58299757|NCT04743622|DRUG|Xalatan|preserved latanoprost 1 drop once a day for 12 weeks to target eyes
57732251|NCT02938416|BEHAVIORAL|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
58299758|NCT00426881|BEHAVIORAL|Exercise Training|Twice weekly resistance training for 52 weeks.
58299759|NCT00426881|BEHAVIORAL|Exercise training|Once weekly resistance training for 52 weeks.
58299760|NCT00426881|BEHAVIORAL|Exercise training|Twice weekly resistance training for 52 weeks.
58299761|NCT05648799|DRUG|GP30341 capsules 200 mg|orall take of capsules twice a day
58299762|NCT05648799|DRUG|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
58299763|NCT03279809|DRUG|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
58410770|NCT02253823|DRUG|EFV|
58410771|NCT02253823|DRUG|TPV/RTV - low dose|
58410772|NCT02253823|DRUG|TPV/RTV - high dose|
58410773|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
58299764|NCT03279809|DRUG|Placebo|Case with placebo medication for 6 months after stenting
58081730|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
58081731|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
58081732|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
58081733|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
58081734|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
58081735|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
58081736|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
58081737|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
58081738|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
58081739|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
58081740|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
58081741|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
58081742|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
58299765|NCT05401565|DRUG|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
58299766|NCT05401565|DRUG|Placebo|Matching placebo
58299767|NCT03241095|PROCEDURE|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
58299768|NCT03241095|PROCEDURE|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
58299769|NCT02909790|DEVICE|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
58299770|NCT05090202|DIAGNOSTIC_TEST|hbA1C|hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
58299771|NCT03025113|DRUG|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
58081743|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
58081744|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
58081745|NCT00482664|DRUG|Placebo|Tablets for oral administration
58081746|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
58081747|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
58081748|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
58081749|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
58081750|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
58081751|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
58081752|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
58299772|NCT03025113|DRUG|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
58299773|NCT06046677|OTHER|No intervention|No intervention
58299774|NCT00260013|PROCEDURE|program of care delivery|
58299775|NCT06211556|BEHAVIORAL|Very-low calorie diet|\~800 kcal/day delivered via commercially available diet plan (NUPO).
58299776|NCT01145365|PROCEDURE|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
58299777|NCT03973580|BEHAVIORAL|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
58299778|NCT03973580|BEHAVIORAL|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
58410774|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
58410775|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
58410776|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
58410777|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
58410778|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
57732252|NCT00426504|PROCEDURE|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
57732253|NCT01637012|PROCEDURE|Implantation|index angioplasty with ALEX stent implatation
57732254|NCT05106231|BEHAVIORAL|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
57732255|NCT05106231|BEHAVIORAL|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
57732256|NCT02920905|DRUG|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
58299779|NCT02576392|BEHAVIORAL|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
58299780|NCT04723459|OTHER|ivermectin impregnated mask|mask with ivermectin nano solution
58299781|NCT01848574|OTHER|standardized multifaceted information procedure to improve patients' comprehension|
58299782|NCT02447419|DRUG|Gefitinib|Gefitinib 250mg will be administered orally daily
58299783|NCT03744897|BEHAVIORAL|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
58410779|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
58410780|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
57732257|NCT02920905|DRUG|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
58410781|NCT00450671|PROCEDURE|Collagen Plug Placement|
58410782|NCT00450671|PROCEDURE|Seton placement|
58410783|NCT00199316|DRUG|spinal morphine|
58410784|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
58410785|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
58410786|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
58410787|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
58299784|NCT03744897|DEVICE|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
57732258|NCT02920905|DRUG|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
57732259|NCT04445805|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
58081753|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
58081754|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
58081755|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
58081756|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
58081757|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
58081758|NCT00939861|PROCEDURE|laparotomy|colorectal resection
58081759|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
58081760|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
58081761|NCT02826005|DEVICE|MRI|
58081762|NCT00403962|DRUG|vestipitant/paroxetine|
58081763|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
58081764|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
58081765|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
58081766|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
58081767|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
58081768|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
58081769|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
58299785|NCT03744897|OTHER|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
58081770|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
58081771|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
58081772|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
58081773|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
58299786|NCT03744897|DEVICE|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
58299787|NCT01493245|DRUG|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
57732260|NCT04445805|BEHAVIORAL|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
58081774|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
57732261|NCT04445805|BEHAVIORAL|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
57732262|NCT05126797|OTHER|Questionnaire Administration|Ancillary studies
58081775|NCT03417245|DRUG|fitusiran|by SC injection
58081776|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
58081777|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
58081778|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
58081779|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
58410788|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
58410789|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
58081780|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
58081781|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
58410790|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
58081782|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
58081783|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
58410791|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
58410792|NCT01215110|DRUG|TMC207|
58410793|NCT01215110|DRUG|Rifafour e-275 mg|
58410794|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study.
58410795|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
58410796|NCT05518773|OTHER|Observational|Observational
58410797|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
58081784|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
58081785|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
58081786|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
58081787|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
58081788|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
58081789|NCT01761461|DRUG|TS-1, oxaliplatin|
58081790|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
58299788|NCT06392035|OTHER|health education, web-based education|Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
58299789|NCT01800045|DRUG|Pitolisant|1 capsule in the morning before breakfast
58299790|NCT01800045|DRUG|Placebo|1 capsule in the morning before breakfast
58410798|NCT00110071|DRUG|fludarabine phosphate|Given IV
58410799|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
58410800|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
58410801|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
58410802|NCT00110071|OTHER|flow cytometry|Correlative studies
58410803|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
58410804|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
58410805|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
57732263|NCT05126797|DEVICE|Stent Device|Wear customized 3D printed oral stent
58081791|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
58081792|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
58081793|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
58081794|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
58081795|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
58081796|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
58410806|NCT01012921|DEVICE|MembraGel|Device application at surgery
58410807|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
58081797|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
58081798|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
58081799|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
58081800|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
58081801|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
58081802|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
58081803|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
58081804|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
58081805|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
58081806|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
58081807|NCT01166126|DRUG|temsirolimus|Given IV
58081808|NCT01166126|DRUG|selumetinib|Given orally
58081809|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
58081810|NCT00003104|RADIATION|radiation therapy|
58081811|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
58081812|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
58081813|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
58081814|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
58081815|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
58081816|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
58081817|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
58081818|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
58299791|NCT05970250|OTHER|Whole body vibration group|Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
58410808|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
58081819|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
58081820|NCT02010671|OTHER|Survey|Survey
58081821|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
58081822|NCT05932979|OTHER|Placebo|Starch
58081823|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
58081824|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
58081825|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
58081826|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
58081827|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
58081828|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
58081829|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
58081830|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
58081831|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
58081832|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
58081833|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
58410809|NCT03040869|OTHER||
58410810|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
58410811|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
58410812|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
58410813|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
58410814|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
58410815|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
58081834|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
58081835|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
58081836|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
58081837|NCT02246244|DRUG|Escitalopram|
58081838|NCT02246244|OTHER|Placebo|
58081839|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
58081840|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
58081841|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
58081842|NCT03418025|OTHER|Survey Administration|Ancillary studies
58081843|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
58081844|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
58410816|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
58410817|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
58410818|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
58410819|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
58410820|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
58410821|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
58410822|NCT01244789|OTHER|observation|active observation
58081845|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
58081846|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
58081847|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
58081848|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
58081849|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
58081850|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
58081851|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
58410823|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
58299792|NCT05970250|OTHER|Weight bearing exercises|Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
58299793|NCT05970250|DRUG|vitamin D supplements and calcium|vitamin D supplements and calcium
58410824|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
58410825|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
58410826|NCT00003044|DRUG|cisplatin-e therapeutic implant|
58081852|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
58081853|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
58410827|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
58081854|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
58081855|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
58081856|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
58081857|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
58081858|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
58081859|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
58081860|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
58081861|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
58081862|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
58081863|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
58081864|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
58081865|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
58081866|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
58081867|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
58081868|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
58081869|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
58081870|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
58410828|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
58410829|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
58410830|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
58410831|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
58081871|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
58081872|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
58081873|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58081874|NCT05756166|DRUG|Celecoxib|Given PO
58081875|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
58081876|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
58081877|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58410832|NCT02220023|DRUG|INOmax Inhalation|
58081878|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
58299794|NCT03160391|BEHAVIORAL|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
58299795|NCT03160391|BEHAVIORAL|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
58299796|NCT02799147|PROCEDURE|Allogeneic stem cell transplantation|
58299797|NCT02799147|DRUG|Fludarabine monophosphate|
58299798|NCT02799147|DRUG|Busulfan|
58081879|NCT05756166|DRUG|Rintatolimod|Given IV
58081880|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
58081881|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
58081882|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
58081883|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
58081884|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
58081885|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
58081886|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
58081887|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
58081888|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
58081889|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
58081890|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
58081891|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
58410833|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
58410834|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
58410835|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
58410836|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
58410837|NCT04371822|OTHER|placebo|No Intervention
58081892|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
58081893|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
58081894|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
58081895|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
58081896|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
58081897|NCT00307775|DRUG|oestradiol|
58081898|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
58081899|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
58081900|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
58081901|NCT00351611|DRUG|placebo|Twice a day, oral administration
58081902|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
58081903|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
58081904|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
58299799|NCT02799147|DRUG|Bendamustine|
58299800|NCT02731300|DEVICE|tDCS|brain stimulation by cathodal electrode at motor cortex
58299801|NCT04295577|OTHER|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
58081905|NCT05295459|DRUG|Sham procedure control|Sham procedure control
58081906|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
58081907|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
58081908|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
58081909|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
58081910|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
58081911|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
58081912|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
58081913|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
58081914|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
57732264|NCT05369650|DRUG|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
58081915|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
58081916|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
58081917|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
57732265|NCT02521090|BIOLOGICAL|EGFRBi-Armed Autologous T Cells|Given IT and IV
58081918|NCT01358266|DRUG|DE-109 44 ug|Low dose
58081919|NCT01358266|DRUG|DE-109 440 ug|Medium dose
58081920|NCT01358266|DRUG|DE-109 880 ug|High dose
58081921|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
58081922|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
58081923|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
58299802|NCT02931760|DEVICE|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
58299803|NCT02931760|DEVICE|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
58299804|NCT03984084|OTHER|no intervention|no intervention
57732266|NCT02521090|OTHER|Laboratory Biomarker Analysis|Correlative studies
58081924|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
58081925|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
58299805|NCT04534998|PROCEDURE|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
58299806|NCT04010409|OTHER|no intervention|no intervention
58299807|NCT05835141|OTHER|OCT Imaging|Each participant will receive imaging of the inferior sectors of the iridocorneal angle at 150°, and 180°, and 210° with the swept-source ANTERION AS-OCT system under standardized light and dark lighting conditions by a trained research technician
58299808|NCT03215069|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
58299809|NCT03215069|DRUG|Placebo oral capsule|Placebo PO daily
58410838|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
58410839|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
57784872|NCT05424861|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
58081926|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
58081927|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
58081928|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
58081929|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
58081930|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
58081931|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
58081932|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
58081933|NCT06127862|OTHER|No training was given|No training was given
58081934|NCT00138866|DRUG|Risedronate|
58081935|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
58081936|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
58081937|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
58081938|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
58081939|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
58081940|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
58081941|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
58081942|NCT00421746|DRUG|Piboserod|
58081943|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
58081944|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
58081945|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
58299810|NCT00619788|DEVICE|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
58081946|NCT00065169|DRUG|Celecoxib|
58081947|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
58081948|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
58081949|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
58299811|NCT03212040|DIAGNOSTIC_TEST|needle biopsy|breast biopsy using different needle gauges
58299812|NCT03428334|DRUG|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
58299813|NCT01151306|DRUG|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
58299814|NCT01151306|DRUG|Lactose tablet|One tablet taken each evening for 6 weeks
58081950|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
58081951|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
58081952|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
58081953|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
58081954|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
58081955|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
58081956|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
58081957|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
58081958|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
58081959|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
58081960|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
58081961|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
58081962|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
58081963|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
58081964|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
58081965|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
58081966|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
58081967|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
58081968|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
58081969|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
58081970|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
58081971|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
58081972|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
58081973|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
58299815|NCT04022330|OTHER|Blood sampling|The blood sampling will be done just before surgery
57784873|NCT05424861|OTHER|Control group|No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
58081974|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
58081975|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
58081976|NCT03907111|DEVICE|placebo|traditional gauze
58081977|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
58081978|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
58081979|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
58081980|NCT04260594|OTHER|basic treatment|basic treatment
58081981|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
58081982|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
58081983|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
58081984|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
58081985|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
57784874|NCT02420327|DRUG|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
57784875|NCT02420327|DRUG|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
57784876|NCT02420327|DRUG|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
58081986|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
58410840|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
58081987|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
58081988|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
58081989|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
58081990|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
58081991|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
58081992|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
58081993|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
58081994|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
58081995|NCT03755856|OTHER|Questionnaire|Health-related quality of life
58081996|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
58081997|NCT02027766|OTHER|Calf muscle stretching|
58081998|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
58081999|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
58082000|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
58082001|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
58410841|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
58410842|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
58410843|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
58410844|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
58082002|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
58082003|NCT05841862|DEVICE|2C-QD|Quantum Dot
58082004|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
58082005|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
58299816|NCT03612466|DRUG|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
58082006|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
58082007|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
58082008|NCT02822729|DRUG|DE-117 ophthalmic solution|
58082009|NCT02822729|DRUG|Timolol ophthalmic solution|
58082010|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
58082011|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
58082012|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
58082013|NCT01716442|DRUG|Placebo|
58082014|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
58082015|NCT03542864|OTHER|Control|Progress registration of body composition values
58082016|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
58082017|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
58082018|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
58082019|NCT01334502|BIOLOGICAL|rituximab|PO
58410845|NCT02387125|BIOLOGICAL|CMB305|
58082020|NCT01334502|DRUG|cyclophosphamide|IV
58082021|NCT01334502|DRUG|doxorubicin hydrochloride|IV
58082022|NCT01334502|DRUG|everolimus|PO
58410846|NCT02387125|BIOLOGICAL|G100|
58410847|NCT02387125|DRUG|Metronomic CPA|
58410848|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
58410849|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
58410850|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
58082023|NCT01334502|DRUG|prednisone|PO
58410851|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
58082024|NCT01334502|DRUG|vincristine sulfate|IV
58082025|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
58082026|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
58082027|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
58299817|NCT03612466|RADIATION|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
58410852|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
58410853|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
58410854|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
58410855|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
58410856|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
57784877|NCT02420327|DRUG|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
58082028|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
58299818|NCT03612466|DRUG|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
58410857|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
58410858|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
58410859|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
58410860|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
58410861|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
58410862|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
58410863|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
58082029|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
58082030|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
58082031|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
58082032|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
58082033|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
58082034|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
58299819|NCT03612466|DRUG|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
58410864|NCT02980146|OTHER|Non interventional study|
58410865|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
58410866|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
58410867|NCT01977443|DRUG|APD-209 Eye drops|
58410868|NCT01977443|DRUG|APD-209 Placebo Eye drops|
58082035|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
57784959|NCT04318964|BIOLOGICAL|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
58082036|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
58082037|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
58082038|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
58082039|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
58082040|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
58082041|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
58082042|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
58082043|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
58082044|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
58082045|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
58082046|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
58082047|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
58082048|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
58082049|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
58082050|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
58082051|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
58082052|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
58082053|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
58082054|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
58082055|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
58082056|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
58082057|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
58299820|NCT03612466|DRUG|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
58299821|NCT03117634|DRUG|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
58299822|NCT03117634|DRUG|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
58299823|NCT04065243|OTHER|Overfeeding diet|Two weeks of overfeeding
58299824|NCT04065243|OTHER|Isocaloric diet|Two weeks of isocaloric weight maintenance
58299825|NCT01635660|DEVICE|Intubation|Tracheal Intubation with the assigned video laryngoscope
58410869|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
58410870|NCT06495840|OTHER|no intervention|no intervention
58082058|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
58082059|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
58082060|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
58082061|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
58082062|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
58082063|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
58299826|NCT00941850|PROCEDURE|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
58299827|NCT04685993|DRUG|LPCN 1144|Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
58299828|NCT04583605|DEVICE|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
58299829|NCT05897242|BEHAVIORAL|Smartphone app|Use ACT on Vaping smartphone app
58299830|NCT05897242|OTHER|Text Message|Receive text messages
58410871|NCT02590562|OTHER|Routine clinical practice|
58410872|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
58410873|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
57784960|NCT00799071|DRUG|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
58082064|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
58082065|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
58299831|NCT05897242|OTHER|Survey Administration|Ancillary studies
58299832|NCT05800756|DRUG|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
58299833|NCT00168571|BIOLOGICAL|Measles vaccine|
58299834|NCT03303495|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
58299835|NCT03303495|DRUG|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
58299836|NCT03303495|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
58299837|NCT03303495|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
58299838|NCT03303495|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
58299839|NCT04089254|BEHAVIORAL|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
58410874|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
58410875|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
58410876|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
58410877|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
58410878|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
58082066|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
58082067|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
58082068|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
58082069|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
58082070|NCT05141110|DRUG|NVP-1705|NVP-1705
58082071|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
58082072|NCT00002738|DRUG|leucovorin calcium|
58299840|NCT04089254|BEHAVIORAL|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
57784961|NCT01182922|BEHAVIORAL|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
58082073|NCT00002738|DRUG|trimetrexate glucuronate|
58082074|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
58082075|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
58082076|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
58082077|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
57784962|NCT02403531|DRUG|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
57784963|NCT02403531|DRUG|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
58082078|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
58082079|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
58082080|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
58082081|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
58082082|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
58082083|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
58082084|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
58082085|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
58082086|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
58082087|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
58082088|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
58082089|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
58082090|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
58082091|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
58082092|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
58082093|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
58299841|NCT03906812|OTHER|Telemetry|Bed type assignment
58299842|NCT03906812|OTHER|Unmonitored|Bed type assignment
57784964|NCT02403531|RADIATION|Radiotherapy|definitive radiotherapy
58082094|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
58082095|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
58082096|NCT00805857|DRUG|Tipranavir|
58082097|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
58082098|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
58082099|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
58082100|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
58082101|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
58082102|NCT00544778|BIOLOGICAL|filgrastim|
58082103|NCT00544778|DRUG|dexrazoxane hydrochloride|
58082104|NCT00544778|DRUG|doxorubicin hydrochloride|
58082105|NCT00544778|DRUG|ifosfamide|
58082106|NCT00544778|DRUG|irinotecan hydrochloride|
58082107|NCT00544778|GENETIC|protein expression analysis|
58082108|NCT00544778|OTHER|immunoenzyme technique|
58299843|NCT03177148|BEHAVIORAL|Intervention by Clinicians|"•Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone."
58299844|NCT03177148|BEHAVIORAL|Usual Care|Pediatric clinicians provide care as normal
58299845|NCT04767464|OTHER|Compass Course|The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer. Enrollment in this arm will involve participation in the Compass Course virtually.
58299846|NCT04828031|DRUG|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
58299847|NCT02277028|BEHAVIORAL|priming and task specific training|This task specific training protocol has been used in several clinical trials.
57784965|NCT03263351|BEHAVIORAL|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
58082109|NCT00544778|PROCEDURE|adjuvant therapy|
58082110|NCT00544778|PROCEDURE|conventional surgery|
58299848|NCT03535961|DRUG|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
58299849|NCT02500316|DRUG|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
58299850|NCT02374320|DRUG|liposomal bupivacaine|injected as an axillary block
58299851|NCT05695742|OTHER|Active Smoking|Being active smoker
58299852|NCT05695742|OTHER|Passive smoker|Being exposed to secondhand smoke
58299853|NCT05695742|OTHER|Non-smoker|Not being an active or passive smoker.
58299854|NCT04238377|PROCEDURE|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
58082111|NCT00544778|PROCEDURE|neoadjuvant therapy|
58082112|NCT00544778|RADIATION|radiation therapy|
58082113|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
58082114|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
58082115|NCT06230705|OTHER|Guided management|Guided Management
58082116|NCT06230705|OTHER|Self management|Self management
58082117|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
58082118|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
58082119|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
58082120|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
58082121|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
58082122|NCT01955824|DRUG|1% lignocaine|
58082123|NCT01955824|DRUG|2% lignocaine|
58082124|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
58082125|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
58082126|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
58082127|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
58082128|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
58082129|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
58299855|NCT04238377|DRUG|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
58299856|NCT04419857|DIETARY_SUPPLEMENT|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
58299857|NCT00452439|DRUG|Actonel (Risedronate)|35 mg (pill) by mouth weekly
58299858|NCT00452439|DIETARY_SUPPLEMENT|Calcium|500 mg by mouth twice a day for a total of 24 months.
58299859|NCT00452439|DIETARY_SUPPLEMENT|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
58082130|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
58082131|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
58082132|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
58082133|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
58082134|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
58299860|NCT04846270|DEVICE|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
58299861|NCT00289276|DEVICE|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
58299862|NCT02418234|OTHER|mutation detection|
58299863|NCT02418234|OTHER|ARMS and ddPCR|
58299864|NCT02418234|GENETIC|ctDNA analysis|
58299865|NCT00140062|DRUG|latanoprost 0.005% (Xalatan)|
58299866|NCT02371681|DRUG|Treatment|Different Drug combinations
58299867|NCT02371681|RADIATION|PET/CT Scan|PET/CT Scans
58299868|NCT02371681|PROCEDURE|Sample Collection|Sample Collection
58299869|NCT05504096|DEVICE|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
58299870|NCT05504096|DEVICE|SVT In-Ear Prototype (IEP)|In-Ear wearable
58299871|NCT00575354|DRUG|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
58299872|NCT00575354|DRUG|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
58299873|NCT02525016|BIOLOGICAL|Blood sampling|
58299874|NCT02525016|DRUG|Lidocaine|
58299875|NCT01919164|DRUG|Sprifermin|Participants received Sprifermin as intra-articular injection.
58299876|NCT01919164|DRUG|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
58299877|NCT00563121|PROCEDURE|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
58299878|NCT04751760|BIOLOGICAL|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
57784966|NCT03263351|BEHAVIORAL|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
58082135|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
58082136|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
58082137|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
58082138|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
58082139|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
58299879|NCT02821494|BIOLOGICAL|Hespecta|A dose escalation of Amplivant® conjugated peptide
58299880|NCT03533218|DEVICE|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
58299881|NCT02204670|OTHER|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
58299882|NCT05271565|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral formula
58299883|NCT05271565|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
58410879|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
58410880|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
57784967|NCT00059254|DIETARY_SUPPLEMENT|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
58082140|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
58082141|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
58299884|NCT02457195|DRUG|granisetron|Application granisetron transdermal patch preoperatively
58299885|NCT03248869|OTHER|Current Daily Survey|need description
58299886|NCT03248869|OTHER|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
58299887|NCT05385198|BEHAVIORAL|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
57784968|NCT00059254|DIETARY_SUPPLEMENT|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
57784969|NCT06157775|DIAGNOSTIC_TEST|Shear-wave elastography|Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
57784970|NCT03554161|BIOLOGICAL|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
58082142|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
58082143|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
58082144|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
58082145|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
58082146|NCT00076544|DRUG|Ziconotide|
58082147|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
58082148|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
58082149|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
58082150|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
58082151|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
58082152|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
58082153|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
58082154|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
58082155|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
58082156|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
58299888|NCT04422938|OTHER|Manuel chest compressions handled by clinicians|Compressions will be handled by human efforts
58410881|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
58410882|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
57784971|NCT01907152|OTHER|Protein enriched yoghurt drink and bread|
57784972|NCT02129569|OTHER|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
58082157|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
58082158|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
58082159|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
58082160|NCT01722058|DRUG|Peptide application|
58082161|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
58082162|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
58082163|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
58082164|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
58299889|NCT04422938|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
58410883|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
58410884|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
58410885|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
58410886|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
58410887|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
58410888|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
58410889|NCT02275117|BIOLOGICAL|ALD403|
58410890|NCT02275117|BIOLOGICAL|Placebo|
58299890|NCT05026944|OTHER|Percussive massage and static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
58299891|NCT05026944|OTHER|static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
58082165|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
58410891|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
58410892|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
58410893|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
58410894|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
57732267|NCT05207059|BEHAVIORAL|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
58410895|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
58082166|NCT00353392|DEVICE|Laser Therapy|
58082167|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
58082168|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
58082169|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
58082170|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
58410896|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
58410897|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
58410898|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
58410899|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
58410900|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
58410901|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
58410902|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
58410903|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
58082171|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
58082172|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
58082173|NCT00465322|DRUG|fluvastatin|
58410904|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
58410905|NCT05857449|DRUG|LPM3480392|Intravenous infusion
58410906|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
58410907|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
58410908|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
58410909|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
58410910|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
58410911|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
58082174|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
58082175|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
58082176|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
58082177|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
58082178|NCT02905695|DRUG|Chirocaine|
58082179|NCT02905695|OTHER|Placebo|
58082180|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
58299892|NCT03964389|OTHER|"Pain Neuroscience Education (PNE)"|A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
58299893|NCT00969228|BIOLOGICAL|Rotarix ™|Two oral doses
57732268|NCT05860322|DIETARY_SUPPLEMENT|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
58082181|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
58082182|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
58082183|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
58082184|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
58082185|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
58299894|NCT00969228|BIOLOGICAL|Placebo|Two oral doses
58299895|NCT00994942|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
58299896|NCT01832337|PROCEDURE|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
58082186|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
58299897|NCT00780975|DRUG|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
58299898|NCT01328964|DRUG|Fluticasone propionate|fluticasone propionate 44 mcg
58299899|NCT01328964|DRUG|Budesonide|budesonide
58299900|NCT01328964|DRUG|Montelukast|montelukast
58082187|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
58299901|NCT04833777|DRUG|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
57732269|NCT05860322|OTHER|Placebo|Placebo control
57732270|NCT01923727|BIOLOGICAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
58082188|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
58082189|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
58082190|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
58299902|NCT04833777|DRUG|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
58299903|NCT04502446|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
58299904|NCT00002535|BIOLOGICAL|aldesleukin|
58299905|NCT00002535|BIOLOGICAL|lymphokine-activated killer cells|
58299906|NCT00002535|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58299907|NCT00002535|DRUG|cyclophosphamide|
58299908|NCT00002535|DRUG|indomethacin|
58299909|NCT00002192|DRUG|Rifapentine|
58299910|NCT00002192|DRUG|Ethambutol hydrochloride|
58299911|NCT00002192|DRUG|Clarithromycin|
58299912|NCT00002192|DRUG|Azithromycin|
58299913|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
58299914|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
58299915|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
58410912|NCT04811443|DRUG|Empegfilgrastim|Extimia®
58082191|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
58082192|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
58082193|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
58082194|NCT00101140|DRUG|anti-thymocyte globulin|
58299916|NCT05628753|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
58082195|NCT00101140|DRUG|fludarabine phosphate|
58082196|NCT00101140|DRUG|thiotepa|
58082197|NCT00101140|PROCEDURE|biological therapy|
58082198|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
58082199|NCT00101140|PROCEDURE|chemotherapy|
58082200|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
58082201|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
58082202|NCT00101140|PROCEDURE|radiation therapy|
58299917|NCT05190874|DEVICE|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
58299918|NCT03984396|OTHER|Educational Materials - Patient & Clinician|deprescribing information for patient \& clinician
58299919|NCT00781053|DRUG|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
58299920|NCT02779569|DRUG|decitabine|
58299921|NCT02757729|DRUG|PAC-14028 cream 0.1%|Topical application
58299922|NCT02757729|DRUG|PAC-14028 cream 0.3%|Topical application
58299923|NCT02757729|DRUG|PAC-14028 cream 1.0%|Topical application
58299924|NCT02757729|DRUG|PAC-14028 cream vehicle|Topical application
58299925|NCT01077323|DRUG|exenatide|subcutaneous injection, dosing according to normal clinical practice
58299926|NCT01077323|DRUG|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
57732271|NCT03151265|DEVICE|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
57732272|NCT03676062|OTHER|exercise|All exercises programs applied three sessions per week, totally six week.
58082203|NCT00359866|RADIATION|IMRT with tomotherapy|
58082204|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
58082205|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
58082206|NCT04440761|OTHER|Observation only|Observation only
58082207|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
58082208|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
58082209|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
58082210|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
58082211|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
58082212|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
58082213|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
58299927|NCT01077323|OTHER|No diabetes therapy|Subjects not diagnosed with diabetes
58299928|NCT01259947|DRUG|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
58299929|NCT00487903|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
58299930|NCT00377637|DRUG|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
58299931|NCT00377637|DRUG|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3."
58299932|NCT00377637|DRUG|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
58299933|NCT00377637|DRUG|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
58299934|NCT00377637|DRUG|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
58082214|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
58082215|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
58082216|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
58082217|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
58082218|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
58082219|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
58082220|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
58082221|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
58082222|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
58082223|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
58082224|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
58082225|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
58082226|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
57784973|NCT02129569|BEHAVIORAL|behavioral intervention|Receive individualized walking prescription and wear pedometer
57784974|NCT02129569|OTHER|counseling intervention|Receive supplemental counseling support over the phone
57784975|NCT02129569|OTHER|educational intervention|Receive NCI educational booklets and a link to the ACS website
58082227|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
58082228|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
58082229|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
58299935|NCT00377637|DRUG|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
58299936|NCT02667340|DIETARY_SUPPLEMENT|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game \& at halftime)
58410913|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
58082230|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
58082231|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
58082232|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
58082233|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
58082234|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
58082235|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
57784976|NCT02129569|OTHER|telephone-based intervention|Receive calls that are primarily social in nature
57784977|NCT02129569|OTHER|questionnaire administration|Ancillary studies
57784978|NCT02129569|OTHER|quality-of-life assessment|Ancillary studies
57784979|NCT00191048|DRUG|Atomoxetine|
58082236|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
58082237|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
58299937|NCT02667340|OTHER|Placebo|0.7 g glucose per kg body mass in two ingestions (before game \& at halftime)
58299938|NCT00480571|DRUG|BL-1020|BL-1020 Low Dose
58299939|NCT00480571|DRUG|BL 1020 High Dose|BL 1020 High Dose
58299940|NCT06293274|PROCEDURE|Discharge training|What is motherhood blues? Why does it occur? What are its symptoms? How to deal with it? What is postpartum depression? What causes postpartum depression? Information is provided on this topic.
58299941|NCT02667925|DRUG|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
58410914|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
58410915|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
58410916|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
58410917|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
58410918|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
58410919|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
58410920|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
58410921|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
58410922|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
58410923|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
58410924|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
58410925|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
58410926|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
58082238|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
58082239|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
58082240|NCT02070367|OTHER|Somatosensory rehabilitation|
58082241|NCT02070367|OTHER|Usual treatment: physiotherapy|
58410927|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
58410928|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
58410929|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
57732273|NCT05558059|DEVICE|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
58082242|NCT01970280|DRUG|Enoxaparin|
58082243|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
58299942|NCT03001947|OTHER|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
58410930|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
58299943|NCT03280459|PROCEDURE|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
58410931|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
58410932|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
58410933|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
58082244|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
58082245|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
58082246|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
58082247|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
58082248|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
58299944|NCT04448119|DRUG|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
57732274|NCT05057533|OTHER|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~1. Related to defecation (may be increased or unchanged by defecation)~2. Associated with a change in stool frequency~3. Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. \[2\] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
58082249|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
58082250|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
58299945|NCT04448119|DRUG|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
58299946|NCT03040271|OTHER|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
58299947|NCT03851770|OTHER|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
58299948|NCT05735704|DIAGNOSTIC_TEST|Blood sampling for HemaChip screening/diagnostic testing|"Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed."
58299949|NCT05735704|DIAGNOSTIC_TEST|Bone marrow sampling|as part of the discovery stage, bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure. Additionally, up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery.
57732275|NCT04055948|BEHAVIORAL|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)
57732276|NCT04055948|BEHAVIORAL|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
58299950|NCT05673447|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10\^8, 1×10\^9, 1.5×10\^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
58299951|NCT00094991|DRUG|Muraglitazar|
58299952|NCT00847600|DIETARY_SUPPLEMENT|Pregnenolone|50 mg, caps.
58299953|NCT00847600|DIETARY_SUPPLEMENT|Placebo|caps
58299954|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
58299955|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
58299956|NCT03512522|BEHAVIORAL|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
58299957|NCT03512522|BEHAVIORAL|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
58299958|NCT05793021|DIAGNOSTIC_TEST|Blood sample|Blood sample pre and post surgery to determine the level of FKBP51s protein
58299959|NCT03308422|BEHAVIORAL|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
58299960|NCT04773223|PROCEDURE|Open surgery and complex EVAR due to AAA|"There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)"
57732277|NCT00803647|BIOLOGICAL|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
58299961|NCT00827788|DRUG|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
58299962|NCT00827788|DRUG|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
58299963|NCT01334294|DEVICE|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
58410934|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
58410935|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
57946735|NCT04243590|BEHAVIORAL|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
58082251|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
58410936|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
58082252|NCT00856570|DRUG|warfarin|Oral
58082253|NCT00856570|DRUG|YM178|Oral
58299964|NCT02605200|BEHAVIORAL|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
58299965|NCT02605200|BEHAVIORAL|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
58299966|NCT00170209|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
58299967|NCT00170209|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
58299968|NCT02861508|OTHER|Point-of-care ultrasound|
58299969|NCT02861508|OTHER|Usual care|
58410937|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
57732278|NCT00803647|DRUG|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
58082254|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
58082255|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
58082256|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
58082257|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
58299970|NCT04039620|OTHER|Observational study, no interventions expected|No interventions are planned
58299971|NCT05556148|DRUG|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
58299972|NCT04454359|DIETARY_SUPPLEMENT|Multi-nutrient supplement|
58299973|NCT04454359|DIETARY_SUPPLEMENT|Placebo|
58299974|NCT03006536|DEVICE|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
58299975|NCT00831116|DEVICE|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
58299976|NCT03320707|DRUG|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
58299977|NCT03320707|DRUG|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
58299978|NCT03320707|DRUG|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
58299979|NCT00631293|DIETARY_SUPPLEMENT|lactisole|administration of lactisole followed by placebo
58299980|NCT00631293|OTHER|placebo|administration of placebo followed by lactisole
58299981|NCT04060953|OTHER|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
58299982|NCT02907567|DRUG|CT1812|Active study drug
57732279|NCT00803647|DRUG|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
57732280|NCT00803647|DRUG|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
57732281|NCT02239718|PROCEDURE|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
58082258|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
58082259|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
58082260|NCT04855201|DRUG|Bocidelpar|Oral
58299983|NCT02907567|DRUG|Placebo|non-active study drug
58299984|NCT03511677|DEVICE|Insole|Customized insole
58299985|NCT03511677|DEVICE|Placebo Insole|Placebo flat insole
58299986|NCT01061606|DRUG|temsirolimus|Given IV
58299987|NCT03983538|OTHER|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
58299988|NCT01460732|DEVICE|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
58299989|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)
58299990|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
57732282|NCT02239718|PROCEDURE|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
58299991|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)
58299992|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)
58299993|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
58299994|NCT01159574|DRUG|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
58082261|NCT04855201|DRUG|Placebo|Oral
58082262|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
58082263|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
58299995|NCT01159574|DRUG|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
58299996|NCT01159574|DRUG|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
58299997|NCT06402383|BIOLOGICAL|Vaccination Provision|HPV vaccination #1 will be offered by provider at the first visit when the HPV self-sample is collected. HPV Vaccination #2 will be offered at 6 months for HPV negative women and at 12 months for HPV positive women.
58410938|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
57732283|NCT02961140|OTHER|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
57732284|NCT02961140|OTHER|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
57732285|NCT00747799|DRUG|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
58082264|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
57732286|NCT06360835|PROCEDURE|total hip arthroplasty|
57732287|NCT01953796|DRUG|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
57732288|NCT05078944|DEVICE|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
57732289|NCT05078944|DEVICE|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
58299998|NCT06402383|BIOLOGICAL|Vaccination Provision 2|"HPV vaccination #1 will be offered by the provider after an HPV negative result is received with vaccine #2 given at 3 months after negative test results obtained.~For HPV positive women - vaccination #1 will be offered at 12 months and vaccination #2 will be offered at the 15 month mark."
57732290|NCT05078944|DRUG|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
58299999|NCT05415189|OTHER|Not relevant|This is a non-intervention cohort study
57732291|NCT05094960|DIAGNOSTIC_TEST|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
57784980|NCT04689022|BEHAVIORAL|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
58082265|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
58082266|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
58082267|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
58300000|NCT02819570|DRUG|I.V cefuroxime 750 mg*3/d for 2 days|
58300001|NCT02819570|DRUG|I.V ampicillin 2 gram x4/d for 2 days|
58300002|NCT02819570|DRUG|P.O cefuroxime 500 mgx2/d for 5 days|
58300003|NCT02819570|DRUG|P.O roxithromycin 150 mg*2/d for 7 days|
58300004|NCT02819570|DRUG|P.O moxypen 500 mgx3/d for 5 days|
58300005|NCT03539276|BEHAVIORAL|Knowledge exchange|OptimaMed
58300006|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-High（Combined Vaccine）|
58300007|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-Low（Combined Vaccine）|
58300008|NCT02992925|BIOLOGICAL|Hib vaccine|
58300009|NCT02992925|BIOLOGICAL|DPT-IPV|
58082268|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
58082269|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
58082270|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
58082271|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
58300010|NCT00151333|DRUG|SRA-333|
58300011|NCT00703235|DRUG|Bevacizumab|
58082272|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
58082273|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
58300012|NCT03200548|BEHAVIORAL|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
58300013|NCT03200548|BEHAVIORAL|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
58300014|NCT03200548|BEHAVIORAL|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
58300015|NCT03200548|BEHAVIORAL|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
58300016|NCT00209391|DRUG|Gadodiamide Injection|
58300017|NCT00634478|RADIATION|Pre-lemniscal Radiation Deep Brain Stimulation|
58300018|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
58300019|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
58300020|NCT01321671|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
57732292|NCT04305613|OTHER|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
57732293|NCT03125304|OTHER|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
57732294|NCT04156308|OTHER|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
57784981|NCT04689022|DIAGNOSTIC_TEST|visual analogue scale (VAS)|pain intensity
57784982|NCT04689022|DIAGNOSTIC_TEST|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
58300021|NCT04606303|DRUG|Toripalimab combination with platinum-containing dual-drug chemotherapy.|"cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician."
58410939|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
58410940|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
58082274|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
58082275|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
58082276|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
58082277|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
58082278|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
58082279|NCT00094900|DRUG|IL-1 Trap|
58082280|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
58082281|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
58082282|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
58082283|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
58082284|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
58082285|NCT00308555|DRUG|Cannabis|
58082286|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
58300022|NCT02717195|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
57732295|NCT04156308|OTHER|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
57732296|NCT00778466|DRUG|metformin hydrochloride 1000 mg tablets|
57732297|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
57732298|NCT03285282|PROCEDURE|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
58300023|NCT02717195|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
57732299|NCT01745861|DIETARY_SUPPLEMENT|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
57732300|NCT01745861|DIETARY_SUPPLEMENT|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
57732301|NCT04597320|DRUG|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
57732302|NCT04597320|DRUG|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
57784983|NCT00442286|DEVICE|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
57784984|NCT00780442|DRUG|D-cycloserine|50 mg DCS
58082287|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
58082288|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
58082289|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
58082290|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
58082291|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
58082292|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
58082293|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
58082294|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
58410941|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
58410942|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
58410943|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
58410944|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
58410945|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
58300024|NCT02717195|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
58082295|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
58082296|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
58300025|NCT02717195|DRUG|Lu AF35700|20 mg/day, encapsulated tablets, orally
58410946|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
58410947|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
58082297|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
58082298|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
58300026|NCT06508086|PROCEDURE|laser ablation technique in the treatment of pilonidal sinus|group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser
58300027|NCT06508086|PROCEDURE|Karydakis technique in the treatment of pilonidal sinus|group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
58300028|NCT05759637|DIAGNOSTIC_TEST|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
58300029|NCT02837926|OTHER|questionnaire|
58300030|NCT02837926|BIOLOGICAL|Gardasil vaccine|
58300031|NCT02837926|BIOLOGICAL|Cervarix®|
58300032|NCT03110354|DRUG|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
58300033|NCT02737761|BEHAVIORAL|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
58300034|NCT00255619|DEVICE|Baxter's UltraBag® and FMC Andy·Disc®|
58410948|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
58410949|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
58410950|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
57732303|NCT04597320|DRUG|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
58300035|NCT01559662|DIETARY_SUPPLEMENT|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
58300036|NCT02329847|DRUG|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
58300037|NCT02329847|DRUG|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
58300038|NCT04020211|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
58082299|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
57732304|NCT03521635|DRUG|Pramipexole SR|Tablets
57732305|NCT03521635|DRUG|Pramipexole IR|Tablets
58300039|NCT00842634|BIOLOGICAL|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
58300040|NCT00842634|OTHER|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
58300041|NCT03262077|DRUG|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
58300042|NCT03262077|DRUG|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
58300043|NCT01810224|PROCEDURE|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
57732306|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
57732307|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
57784985|NCT00780442|DRUG|Placebo|Placebo
58082300|NCT02163746|PROCEDURE|Surgical Deroofing|
58300044|NCT00614874|DRUG|rosiglitazone|2mg, 4mg, 8mg
58300045|NCT04212767|PROCEDURE|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
58300046|NCT02147613|OTHER|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
57784986|NCT01609153|DRUG|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
58082301|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
58082302|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
58300047|NCT02147613|OTHER|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
58300048|NCT04190355|OTHER|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
58300049|NCT04190355|DRUG|5.25% NaOCl|5.25% NaOCl solution
58300050|NCT04190355|DRUG|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
58300051|NCT02977793|DEVICE|Tomey EM-4000 Specular Microscope|
58300052|NCT02977793|DEVICE|Konan CellChek XL Specular Microscope|
58300053|NCT02723188|DEVICE|Sham stimulation (1.5 milliampere,30 seconds)|
58300054|NCT02723188|DEVICE|DC stimulation (1.5 milliampere, 20 minutes)|
57732308|NCT03477448|DRUG|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
57732309|NCT03477448|DRUG|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
57784987|NCT01609153|DRUG|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
57784988|NCT01609153|DRUG|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
58300055|NCT02723188|DEVICE|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
58300056|NCT02083796|PROCEDURE|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
58300057|NCT02083796|PROCEDURE|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
58300058|NCT02083796|PROCEDURE|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
58300059|NCT02083796|PROCEDURE|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
58300060|NCT00871156|DRUG|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
58300061|NCT00871156|DRUG|Placebo|Placebo
58300062|NCT02471573|PROCEDURE|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
58300063|NCT02471573|PROCEDURE|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
58410951|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
58082303|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
57732310|NCT04297540|DEVICE|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
57732311|NCT04297540|DEVICE|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
57732312|NCT03727750|DRUG|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
58082304|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
58082305|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
58082306|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
58082307|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
58082308|NCT01977703|OTHER|Ultra Conservative ICD Programming|
58082309|NCT01977703|OTHER|Traditional ICD Programming|
58082310|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
58410952|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
57732313|NCT00798798|DEVICE|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
57732314|NCT00332748|DRUG|Oral Taxane|
58082311|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
58082312|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
58082313|NCT00012766|BEHAVIORAL|Integrated team care|
58082314|NCT00004646|DRUG|prednisone|
58082315|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
58410953|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
58410954|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
58082316|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
58082317|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
58410955|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
58082318|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
58082319|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
58082320|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
58300064|NCT01331811|OTHER|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~* interview on anamnesis~* clinical examination~* evaluation of HIV infection stage~* hematology and biochemistry tests~* CD4 count~* HIV viral load~* IGRA~* chest radiograph~* Abdominal ultrasonograph to detect abdominal lymphadenopathy~* Tuberculin skin test~* gastric aspirates, sputum and string tests according to the age of children~* nasopharyngeal aspirate~* stool sample~* lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
58300065|NCT00707044|PROCEDURE|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
58300066|NCT00707044|PROCEDURE|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
58300067|NCT04052607|DRUG|LH Suppression|Stimulation protocols
58300068|NCT05702580|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
58300069|NCT04385498|BEHAVIORAL|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
58082321|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
58300070|NCT04385498|BEHAVIORAL|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
58300071|NCT02993835|OTHER|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
58300072|NCT02993835|OTHER|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
58300073|NCT02993835|OTHER|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
58300074|NCT06433167|OTHER|Pedobarographic analysis|During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
58300075|NCT04470973|DRUG|Cefuroxime|Patients receive cefuroxime as part of standard care.
58300076|NCT04470973|DRUG|Amikacin|Patients receive amikacin as part of standard care.
58300077|NCT01088633|OTHER|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
58410956|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
58410957|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
58410958|NCT02046174|BIOLOGICAL|RENCA macrobeads|
58410959|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
58410960|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
58410961|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
58082322|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
58300078|NCT01660009|OTHER|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
58410962|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
58410963|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
58410964|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
58410965|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
58410966|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
58410967|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
58410968|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
58300079|NCT01630135|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
58410969|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
58410970|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
58410971|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
58300080|NCT01630135|DRUG|Placebo|Placebo, intranasal, 2 weeks
58300081|NCT06431464|OTHER|picosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
58300082|NCT06431464|OTHER|nanosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
58300083|NCT04771845|DEVICE|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
58300084|NCT05171010|OTHER|no study-based therapeutic interventions|no study-based therapeutic interventions
58300085|NCT02365350|PROCEDURE|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
58300086|NCT02365350|PROCEDURE|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
58300087|NCT03806543|DRUG|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
58300088|NCT04601740|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
58300089|NCT01766362|PROCEDURE|PRPC using Pascal laser|
58300090|NCT02012400|OTHER|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
58410972|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
58410973|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
58410974|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
58410975|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
57732315|NCT05459844|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
58082323|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
58082324|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
58082325|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
58082326|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
58082327|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
58082328|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
58082329|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
58082330|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
58082331|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
58082332|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
58082333|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
58082334|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
58082335|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
58300091|NCT01699048|PROCEDURE|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
57732316|NCT05459844|DRUG|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
57732317|NCT03682094|DRUG|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
57732318|NCT00113438|DRUG|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
58082336|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
58082337|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
58082338|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
58082339|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
58300092|NCT01699048|PROCEDURE|PCI|Multi-vessel PCI with DES
58300093|NCT01699048|PROCEDURE|CABG|Coronary artery bypass graft (CABG) treatment
58300094|NCT01513993|PROCEDURE|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
58300095|NCT02530112|OTHER|Survey|
58300096|NCT03505372|DEVICE|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
58300097|NCT04552600|DRUG|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
58300098|NCT04552600|OTHER|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
58300099|NCT05793749|BEHAVIORAL|Prophylactic lymphedema treatment|1. perform manual lymphatic drainage twice a week after the start of radiotherapy for a total of 10 times, and wear lymphedema compression stockings after each manual lymphatic drainage, 2. teach patients how to care for their skin. 3. perform functional exercises for lymphedema of the lower extremities twice a day for 15 \~ 20 minutes each time. 4. follow up observation: before the start of radiotherapy, every Friday during radiotherapy, and every 3 months after the end of radiotherapy, the occurrence of lymphedema and related symptoms and quality of life were evaluated.
58300100|NCT04438525|DIAGNOSTIC_TEST|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
58410976|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
58410977|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
58410978|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
58410979|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
58410980|NCT01742910|PROCEDURE|intraocular lens implantation|
58410981|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
58410982|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
58410983|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
58410984|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
58410985|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
58410986|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
58410987|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
58410988|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
58410989|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
58410990|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
58410991|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
58410992|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
58410993|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
58410994|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
58410995|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
58410996|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
58410997|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
58410998|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
58410999|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
58411000|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
57784989|NCT05269511|DRUG|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
57732319|NCT06349161|PROCEDURE|One-trocar-assisted pyeloplasty|Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
57732320|NCT02416791|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
57732321|NCT02416791|DEVICE|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
58082340|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
57732322|NCT02416791|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
58300101|NCT04438525|OTHER|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
58300102|NCT00260988|DRUG|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
58300103|NCT00260988|DRUG|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
58411001|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
58411002|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
57732323|NCT02416791|OTHER|Physical Therapy|Physical therapy will be administered for 40 minutes.
57732324|NCT02416791|OTHER|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
58082341|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
58082342|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
58300104|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 60 mg iron sulfate|control agent
58300105|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (60 mg iron)|contains 60 mg of iron
58300106|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (10 mg iron)|contains 10 mg iron
58300107|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 10 mg iron sulfate|control agent
58411003|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
58411004|NCT01510015|DRUG|Risperidone|variable dose
58411005|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
58411006|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
58411007|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
58411008|NCT04525924|DEVICE|bright light therapy|please see arm description
58411009|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
58411010|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
58082343|NCT02689505|DRUG|BI 836880|
58082344|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
58082345|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
58082346|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
58300108|NCT00918983|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
58300109|NCT00918983|DRUG|Placebo|Single intraprostatic injection of placebo
58300110|NCT02254772|BIOLOGICAL|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
58300111|NCT02254772|DRUG|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
58300112|NCT02254772|RADIATION|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
58300113|NCT01406535|DRUG|Vardenafil|5 mg vardenafil per os twice daily
58300114|NCT01406535|OTHER|Placebo|5 mg placebo per os twice daily
58300115|NCT06164457|OTHER|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,\[4\] the EuroQol EQ5D-5L,\[5\] the Medical Outcomes Study Social Support Scale (8 item version),\[6\] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools\[7\], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).\[8\]
58300116|NCT04103190|DEVICE|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
58300117|NCT03708263|DEVICE|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
58082347|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
58300118|NCT03708263|DEVICE|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
58300119|NCT03734393|OTHER|HIVD+/R+|Liver from an HIV-infected deceased donor
57732325|NCT00448539|DRUG|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
57732326|NCT06138574|DRUG|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
57732327|NCT06138574|DRUG|Remifentanil|Remifentanil
57732328|NCT04413890|DRUG|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
58082348|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
58082349|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
58300120|NCT01827969|PROCEDURE|ablathermy focused ultrasound|ablathermy focused ultrasound
58300121|NCT03787823|PROCEDURE|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
58300122|NCT05344846|OTHER|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
58300123|NCT03457389|DRUG|Cabergoline|Cabergoline tablet
58300124|NCT00596271|BIOLOGICAL|IC51|
58300125|NCT00596271|BIOLOGICAL|HAVRIX|
58300126|NCT00596271|OTHER|Placebo|
57732329|NCT02875587|DRUG|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
58082350|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
58082351|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
58082352|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
58082353|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
58082354|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
57732330|NCT02875587|DRUG|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
58082355|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
58082356|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
58082357|NCT00179101|PROCEDURE|Deep Brain Stimulation|
58300127|NCT00003740|BIOLOGICAL|trastuzumab|
58300128|NCT04105179|DEVICE|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
58300129|NCT04105179|DEVICE|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
58300130|NCT00270101|DRUG|epoetin alfa|
58300131|NCT04847024|DRUG|Parecoxib|40 mg IV
58300132|NCT04847024|DRUG|Dexketoprofen|50 mg IV
58300133|NCT00261105|DRUG|telithromycin|
58300134|NCT00380536|BEHAVIORAL|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
58300135|NCT00179140|DRUG|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
58300136|NCT00179140|BEHAVIORAL|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
58300137|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
57732331|NCT03153280|DRUG|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
57732332|NCT03153280|DRUG|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
57732333|NCT03153280|DRUG|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
57732334|NCT01866410|DRUG|Cabozantinib S-malate|Given PO
57732335|NCT01866410|DRUG|Erlotinib Hydrochloride|Given PO
57732336|NCT01866410|OTHER|Laboratory Biomarker Analysis|Correlative studies
58300138|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
58300139|NCT00230048|BEHAVIORAL|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
58300140|NCT06274970|OTHER|Enhanced recovery protocols|Enhanced recovery Protocol with Recommendations Preoperative Consideration-Preadmission education, nutritional assessment, Peri operative Calcium and Vitamin D supplementation, Reduce preoperative fasting Preoperative fasting, Precarb drink (250ml= 1glass) administered to the patient at 6:00 AM, Nutrition interventions individualized, Antibiotic prophylaxis, Postoperative nausea and vomiting prophylaxis, Patients should receive short acting anxiolytics Operative Considerations-Hypothermia prevention, Goal-directed fluid management,Nerve monitoring can prevent nerve injuries, may be useful Dressings and drain use -individualized Postoperative Considerations- No post operative antibiotics in clean surgery, Pain management Opioid-sparing, multimodal analgesia, Postoperative Early mobilization, Urinary catheters should be removed less than 24 hours after completion of surgery Perioperative pulmonary physical therapy Steam Inhalation Incentive spirometry Chest Physiotherapy
58411011|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
58082358|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
58082359|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
58082360|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
58082361|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
58300141|NCT06274970|OTHER|Conventional Protocols|Preoperative- Antibiotic prophylaxis, short or long-acting anxiolytics, no post operative nausea and vomiting, no Serum vitamin D correction Operative-Hypothermia prevention, Postoperative- Routine use of post operative prophylactic antibiotics, pain management multimodal analgesia, urinary catheters maybe be removed less than 24 hours after completion of surgery, Perioperative pulmonary physical therapy Steam Inhalation Incentive spirometry Chest Physiotherapy
58082362|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
58082363|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
58082364|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
58082365|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
58082366|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
58082367|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
58300142|NCT01042418|OTHER|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
58300143|NCT02842047|BEHAVIORAL|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
58300144|NCT02842047|BEHAVIORAL|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
58300145|NCT02842047|BEHAVIORAL|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
58300146|NCT02614989|PROCEDURE|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
58300147|NCT06165211|OTHER|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
58300148|NCT06165211|OTHER|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
58300149|NCT05038930|DEVICE|Mobilisation using the Sara Combilizer|The mobilisation with the Sara Combilizer, will be done one time either 24 or 48 hours after stable intracranial pressure
58300150|NCT01228591|DEVICE|Acuvue Advance Plus|Silicone hydrogel contact lens.
58300151|NCT01228591|DEVICE|Acuvue Advance|Silicone hydrogel contact lens
58300152|NCT02456194|DEVICE|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
58300153|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve preservation|In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
58300154|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve is not preserved|In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
57732337|NCT06635473|BEHAVIORAL|Information support|The experimental group was given intervention measures. According to the general data survey, discharge readiness and self-efficacy assessment, parents were divided into low, middle and high discharge readiness groups and low, middle and high self-efficacy groups, respectively, using WeChat mini programs to push different content.
57784990|NCT00926965|DRUG|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
57732338|NCT06635473|BEHAVIORAL|Stress and coping|According to the results of self-efficacy and anxiety assessment, different interventions were based on different scores. Give encouragement and affirmation to parents with low anxiety and high self-efficacy. Parents with high anxiety and low self-efficacy should push stress relief methods such as mindfulness relaxation therapy in time. And through the wechat mini program to provide parents to respond to the pressure of the problem, the medical staff to give timely feedback.
58082368|NCT03964896|OTHER|Survey|Complete survey
58082369|NCT03964896|OTHER|Survey Administration|Ancillary studies
58082370|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
58082371|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
58082372|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
58082373|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
58300155|NCT06396949|DIAGNOSTIC_TEST|Fibromyalgia study form|Fibromyalgia study form, consisting of clinical measurement, Fibromyalgia impact questionnaire (FIQ), Beck Anxiety Questionnaire and Beck Depression Questionnaire, Short-Form (SF)-36, who applied to the outpatient clinic with fibromyalgia will be filled in detail.
58300156|NCT06396949|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
58300157|NCT06396949|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity) (millimeter-mm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
58300158|NCT05868590|OTHER|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
58300159|NCT03658291|DRUG|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
58300160|NCT03658291|DRUG|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
58300161|NCT03658291|DRUG|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
58300162|NCT02567383|RADIATION|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
58300163|NCT02567383|DEVICE|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
58300164|NCT02567383|DRUG|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
57732339|NCT06635473|BEHAVIORAL|Specialist guidance|Carry out offline science popularization education and specialized training, and highly qualified specialist doctors and nurses will train parents, and parents will be assessed after training, and personalized guidance will be given according to the weak points of each parent\&#39;s assessment.
57732340|NCT06635473|OTHER|Social support and interaction|Support and encouragement for parents continue from admission to discharge, so that parents feel that even after discharge, there are people to accompany and support them.
57732341|NCT06635473|BEHAVIORAL|Parentage development|Since parents and children are separated during the hospitalization of preterm infants, we will create an environment where parents still play the role of parents, and stimulate parental competence through kangaroo care, parental touch, and breastfeeding.
57732342|NCT02026700|DEVICE|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
57732343|NCT02864082|DRUG|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
57732344|NCT02864082|DRUG|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
58082374|NCT01961778|DEVICE|Radio-Frequency Ablation|
58082375|NCT01961778|DEVICE|Cryotherapy|
58082376|NCT00026156|DRUG|docetaxel|
58082377|NCT00026156|DRUG|vinorelbine tartrate|
58082378|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
58082379|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
58082380|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
58300165|NCT02567383|DRUG|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
58300166|NCT03021746|BEHAVIORAL|Diabetes Self Management Support (DSMS)|
58082381|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
58082382|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
58082383|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
58082384|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
58082385|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
58082386|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
58082387|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
58082388|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
58082389|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
58411012|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
58411013|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
58411014|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
58411015|NCT05006209|OTHER|One visit root canal treatment|
58411016|NCT05006209|OTHER|Two visit root canal treatment|
58082390|NCT00775827|DRUG|fenofibrate 160 mg tablets|
58082391|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
58082392|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
58082393|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
58082394|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
58082395|NCT05798325|OTHER|2MWT|Two minutes walk tests.
58411017|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
58411018|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
58411019|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
58411020|NCT00346489|DRUG|5-fluorouracil|
58411021|NCT00346489|DRUG|Mitomycin C|
58411022|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
58411023|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
58411024|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
58411025|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
58411026|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
58411027|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
58411028|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
58411029|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
58411030|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
58411031|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
58082396|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
58082397|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
58082398|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
58082399|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
58082400|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
58082401|NCT05798325|OTHER|10mWT|10 meters walking Test.
58082402|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
58082403|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
58082404|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
58082405|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
58082406|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
58082407|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
58082408|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
58082409|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
58082410|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
57732345|NCT02864082|DRUG|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
57732346|NCT02864082|DRUG|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
58082411|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
58082412|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
58082413|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
57732347|NCT02693873|BEHAVIORAL|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
57732348|NCT02795442|OTHER|Even protein|5 day intake of even protein 3 day rotating menu.
57732349|NCT02795442|OTHER|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
57732350|NCT03567538|PROCEDURE|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
57946736|NCT04243590|BEHAVIORAL|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
58300167|NCT03714763|DRUG|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
57732351|NCT03408158|PROCEDURE|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
57732352|NCT00116805|DRUG|TDF|300 mg tablet administered orally once daily
57732353|NCT00116805|DRUG|ADV|10 mg tablet administered orally once daily
58082414|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
58300168|NCT03714763|OTHER|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
58300169|NCT03065647|DEVICE|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
58082415|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
58082416|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
58082417|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
58082418|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
58082419|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
57732354|NCT00116805|DRUG|TDF placebo|Tablet administered orally once daily
58082420|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
58082421|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
58082422|NCT02966366|DEVICE|Cochlear implant|
58082423|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
58082424|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
58082425|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
58082426|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
58082427|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
58082428|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
58082429|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
58082430|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
58082431|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
58082432|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
58082433|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
58082434|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
58082435|NCT03441373|DRUG|Placebo|once daily during 5 days.
58082436|NCT00937859|DRUG|SER120|SER120
58082437|NCT00937859|DRUG|Placebo|Placebo
57732355|NCT00116805|DRUG|ADV placebo|Tablet administered orally once daily
58300170|NCT04155463|OTHER|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
58300171|NCT04155463|OTHER|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
58300172|NCT05677711|DEVICE|ultimaster|Subjects who received Ultimaster stent will be included.
57732356|NCT00116805|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
57732357|NCT02543359|BEHAVIORAL|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
57732358|NCT02543359|BEHAVIORAL|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
58300173|NCT04036487|DRUG|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
57732359|NCT02543359|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
57732360|NCT04408755|DRUG|AVP-786|oral capsules
58082438|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
58082439|NCT02433522|DRUG|Placebo|
58082440|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
58082441|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
58300174|NCT04036487|DRUG|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
58300175|NCT02168959|DRUG|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
58300176|NCT01394289|BIOLOGICAL|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
58300177|NCT05116917|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
58300178|NCT05116917|DRUG|Ipilimumab|1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
58300179|NCT05116917|BIOLOGICAL|Influenza vaccine|Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
58300180|NCT05116917|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
58300181|NCT04822714|BEHAVIORAL|Mobile Career Competencies Intervention|Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
57732361|NCT04408755|DRUG|Placebo|oral capsules
57732362|NCT05085600|OTHER|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
57946737|NCT04243590|BEHAVIORAL|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study."
57946738|NCT00094770|DRUG|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
57946739|NCT00094770|DRUG|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
57946740|NCT05688436|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
57946741|NCT05688436|BIOLOGICAL|Alemtuzumab|Administered as specified in the treatment arm.
57946742|NCT05688436|DRUG|Fingolimod|Administered as specified in the treatment arm.
57946743|NCT05688436|DRUG|Glatiramer acetate|Administered as specified in the treatment arm.
57946744|NCT05688436|BIOLOGICAL|Interferon beta|Administered as specified in the treatment arm.
57946745|NCT05688436|BIOLOGICAL|Natalizumab|Administered as specified in the treatment arm.
57946746|NCT05688436|BIOLOGICAL|Ocrelizumab|Administered as specified in the treatment arm.
57946747|NCT05688436|BIOLOGICAL|Ofatumumab|Administered as specified in the treatment arm.
57946748|NCT05688436|DRUG|Ozanimod|Administered as specified in the treatment arm.
57946749|NCT05688436|BIOLOGICAL|Peginterferon beta-1a|Administered as specified in the treatment arm.
57946750|NCT05688436|DRUG|Ponesimod|Administered as specified in the treatment arm.
57946751|NCT05688436|DRUG|Siponimod|Administered as specified in the treatment arm.
57946752|NCT05293834|BEHAVIORAL|Virtual Reality Aggression Prevention Training (VRAPT)|"VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)"
57946753|NCT03615677|DRUG|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
57946754|NCT03615677|DRUG|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
57946755|NCT03186677|BIOLOGICAL|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous
58300182|NCT00274742|BIOLOGICAL|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
58300183|NCT03118934|DEVICE|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
58300184|NCT03118934|DEVICE|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
58300185|NCT03118934|DEVICE|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
57946756|NCT03186677|BIOLOGICAL|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
58411032|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
57946757|NCT06119490|DRUG|Abrocitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks
58300186|NCT00116948|DEVICE|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
58300187|NCT01956890|DRUG|PET|18F-FLT PET and MRI of the breast
58300188|NCT03898622|DRUG|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
58300189|NCT01590108|DRUG|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
58300190|NCT01590108|DRUG|Saline|Saline
58300191|NCT03131167|DRUG|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
58300192|NCT03131167|DRUG|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
58300193|NCT06160089|OTHER|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
58411033|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
58411034|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
58411035|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
57732363|NCT05085600|OTHER|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
57732364|NCT05501860|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
58300194|NCT06160089|OTHER|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
58300195|NCT04577989|OTHER|data collection|data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.
58300196|NCT04479839|DIAGNOSTIC_TEST|Ultrasound of the airway|Placing ultrasound on the neck after intubation
58300197|NCT04996420|DEVICE|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
58300198|NCT04619017|BIOLOGICAL|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
58300199|NCT00967577|DRUG|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
58300200|NCT02438280|DEVICE|AcceleDent, Vibrational Device|20 minutes of vibration each day
58300201|NCT03403907|OTHER|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
58411036|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
58411037|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
58411038|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
57732365|NCT05501860|DRUG|Placebo|Placebo Sterile Topical Ophthalmic Solution
57946758|NCT06119490|DRUG|Tofacitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
58300202|NCT04052646|OTHER|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
58300203|NCT01093846|DRUG|AIN457|300mg every 4 weeks
58300204|NCT01093846|DRUG|AIN457|300mg every 2 weeks
58300205|NCT01093846|DRUG|Placebo AIN457|Placebo to AIN457
58300206|NCT03769649|DEVICE|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
58300207|NCT01704755|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
57732366|NCT01703455|DRUG|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
57732367|NCT06350903|OTHER|Fast + High-fat low-carbohydrate diet|Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
57784991|NCT00926965|DRUG|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
57784992|NCT00926965|DRUG|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
57946759|NCT00129324|PROCEDURE|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
58300208|NCT01704755|DRUG|Ribavirin (RBV)|Capsule
58300209|NCT00971477|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
58411039|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58411040|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58411041|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58411042|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
58411043|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58411044|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
58411045|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58411046|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58411047|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58411048|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
58411049|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
57946760|NCT00129324|PROCEDURE|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
58300210|NCT00971477|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
58300211|NCT01768325|DEVICE|EUS-TCB needle (QuickCore) standard of care|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
58300212|NCT01768325|DEVICE|EUS-Guided biopsy needle (ProCore)|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
58300213|NCT04988204|BEHAVIORAL|Diabetes Prevention Program|The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
58300214|NCT06195436|BEHAVIORAL|Acceptance and Commitment Therapy for people with and without depression|Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
58300215|NCT02164955|DRUG|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
58300216|NCT03022591|OTHER|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
57946761|NCT00272142|DRUG|Zinc|
57946762|NCT00272142|DRUG|Placebo|
58300217|NCT02102048|DRUG|Atazanavir|
58300218|NCT04046068|PROCEDURE|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
58300219|NCT05366595|DRUG|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
58300220|NCT04545450|DRUG|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
58411050|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
58411051|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
58411052|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
57946763|NCT02547350|DRUG|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
58411053|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
58411054|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
58411055|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
58411056|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
58411057|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
58411058|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
58411059|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
58411060|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
58082442|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
58082443|NCT00625768|DRUG|AS1409|Study drug
58082444|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
58082445|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
58300221|NCT04545450|DRUG|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
58082446|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
58082447|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
58082448|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
58082449|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
58082450|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
58082451|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
58082452|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
58082453|NCT00190476|DRUG|Weekly docetaxel alone|
58082454|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
58082455|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
58300222|NCT00972959|DRUG|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
58082456|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
58300223|NCT00972959|DRUG|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
57784993|NCT05956977|DEVICE|resection with help of 3D ultrasound|see above
57784994|NCT02100618|PROCEDURE|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
58082457|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
58082458|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
58082459|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
58082460|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
58082461|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
58082462|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
58082463|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
58082464|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
58082465|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
58082466|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
58082467|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
58082468|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
58082469|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
58082470|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
58082471|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
58300224|NCT00972959|DRUG|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
58082472|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
58300225|NCT03705702|OTHER|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
58411061|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
58411062|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
58411063|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
58411064|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
58411065|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
58411066|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
58411067|NCT00118352|DRUG|fludarabine phosphate|Given IV
58411068|NCT00118352|DRUG|cyclosporine|Given PO or IV
58411069|NCT00118352|DRUG|mycophenolate mofetil|Given PO
58411070|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
58082473|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
58082474|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
58411071|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
58411072|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
58082475|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
58411073|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
58411074|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
58411075|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
58411076|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
57784995|NCT03254693|COMBINATION_PRODUCT|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
57946764|NCT04882306|DEVICE|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
58082476|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
58082477|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
58411077|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
58411078|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
58411079|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
58411080|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
58411081|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
58082478|NCT02867748|PROCEDURE|TVT-Abbrevo|
58082479|NCT02867748|PROCEDURE|Serasis|
58082480|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
58082481|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
58300226|NCT03705702|BEHAVIORAL|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
58300227|NCT01799447|BEHAVIORAL|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
58300228|NCT06225492|DRUG|DaxibotulinumtoxinA 15 units|Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band
58300229|NCT06225492|DRUG|DaxibotulinumtoxinA 20 units|Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band
58082482|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
58300230|NCT02553343|BIOLOGICAL|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
58300231|NCT02553343|BIOLOGICAL|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
58300232|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
58300233|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
58082483|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
58082484|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
58082485|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
58300234|NCT02309086|BIOLOGICAL|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
58411082|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
58411083|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
58300235|NCT03795480|BEHAVIORAL|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
58411084|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
58411085|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
58411086|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
58411087|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
58411088|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
58411089|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
58411090|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
58411091|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
57732368|NCT06350903|COMBINATION_PRODUCT|Fast + Empagliflozin|Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
57732369|NCT02359396|DRUG|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
58300236|NCT01032564|OTHER|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
58300237|NCT01350817|DRUG|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
58300238|NCT01350817|DRUG|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
58300239|NCT03765060|PROCEDURE|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
58300240|NCT03765060|PROCEDURE|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
58300241|NCT02148393|PROCEDURE|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
58300242|NCT02148393|PROCEDURE|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
58300243|NCT02148393|DRUG|Pregnyl®|1500 IU
58300244|NCT02148393|DRUG|Utrogestan®|200 mg tid
58300245|NCT02148393|DRUG|Progynova®|2 mg bid
58300246|NCT02148393|DEVICE|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
58082486|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
58082487|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
58082488|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
58082489|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
58082490|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
57732370|NCT06429020|BIOLOGICAL|the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.|record the condition of vaccination
58082491|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
58082492|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
58082493|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
58082494|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
58082495|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
58082496|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
58082497|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
58082498|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
58082499|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
58082500|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
58082501|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
58082502|NCT03066011|DRUG|Posaconazole|Oral and intravenous
58082503|NCT06116799|DEVICE|Orthotic|Arch support orthotic
58082504|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
58300247|NCT02491138|BEHAVIORAL|Appearance-based intervention|
58300248|NCT02491138|OTHER|Pamphlets|
58300249|NCT03194009|DRUG|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
58411092|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
58411093|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
58411094|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
58411095|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
58411096|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
58411097|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
58411098|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
58082505|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
58082506|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
58411099|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
58411100|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
58411101|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
58411102|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
58411103|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
58411104|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
57732371|NCT04596254|OTHER|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
57732372|NCT02202473|DRUG|Lamivudine|
57732373|NCT02202473|DRUG|Lamivudine+Oxymatrine Capsules|
58082507|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
58082508|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
58082509|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
58411105|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
58411106|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
58082510|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
58082511|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
58082512|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
58300250|NCT03194009|BEHAVIORAL|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
58300251|NCT03577249|DRUG|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
58300252|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
58300253|NCT05032144|DRUG|Placebo|Intravenous injection
58300254|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
58300255|NCT05032144|DRUG|Placebo|Intravenous injection
58300256|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
58300257|NCT05032144|DRUG|Placebo|Intravenous injection
58300258|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
58300259|NCT05032144|DRUG|Placebo|Intravenous injection
58300260|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
57732374|NCT05853250|OTHER|Reiki/manual therapy|Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
57784996|NCT03254693|COMBINATION_PRODUCT|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
57946765|NCT06042218|BEHAVIORAL|Xiaxi intervention program|The Xiaxi sessions will follow the same structure in both intervention groups. First of all, 8-minute warm-up where the participants will work on: postural awareness; active static stretching of the pectoral, hamstring and psoas muscles; and mobility. The main part will include the following blocks of content during the 12 weeks of intervention (46 minutes will be spent on this part in each session): breathing; mobility; active and dynamic static stretching of the tonic muscles with effects on the spine dynamic; strength of the phasic muscles with effects on the spine dynamic, alternating upper limb, lower limb and core; postural awareness; and passive static stretching of the tonic muscles with effects on the spine dynamic. The cool down will be similar in each session (6 minutes) and will focus on: postural awareness and passive static stretching of the pectoral, hamstring and psoas muscles.
57946766|NCT03814486|OTHER|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
57946767|NCT04247061|OTHER|Educational video|One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
57946768|NCT04247061|OTHER|Text-message program|A one-month text message program to motivate and facilitate contact with smoking cessation resources.
57946769|NCT01805531|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
58082513|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
58082514|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
58082515|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
58300261|NCT05032144|DRUG|Placebo|Intravenous injection
58300262|NCT00583310|BEHAVIORAL|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
58300263|NCT03934216|DRUG|BMS-986165|Specified Dose on Specified Days
58300264|NCT03934216|OTHER|Placebo|Specified Dose on Specified Days
58300265|NCT05358691|DRUG|AN0025|To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
58300266|NCT04880109|DRUG|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
58300267|NCT04880109|DRUG|Placebo|Oral administration of placebo capsule once daily for 14 days
58300268|NCT04861844|BEHAVIORAL|mindfulness training|phone based mindfulness training on 4 consecutive days
58300269|NCT04861844|BEHAVIORAL|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
58300270|NCT02570347|DRUG|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
58300271|NCT02570347|BIOLOGICAL|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
58411107|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
57946770|NCT03481114|COMBINATION_PRODUCT|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
58300272|NCT06522464|OTHER|Group A: mCIMT with cross-education|"For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands (18). We'll utilize weight cuffs for every activity."
58082516|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
58082517|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
58082518|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
58082519|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
58300273|NCT06522464|OTHER|Group B: mCIMT without cross-education|For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
58300274|NCT06385171|DRUG|Botulinum toxin type A|The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
58300275|NCT02016768|PROCEDURE|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
58411108|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
58411109|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
57946771|NCT03481114|COMBINATION_PRODUCT|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
58082520|NCT02401724|OTHER|Transcranial direct current stimulation|
58300276|NCT03301402|DEVICE|Air purifier|Air purifier with filter at automatic mode on all time
58300277|NCT00349141|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
58411110|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
58411111|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
58411112|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
57946772|NCT00003737|DRUG|becatecarin|
58082521|NCT02401724|OTHER|Action Training|
57946773|NCT00889265|DEVICE|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
58411113|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
58082522|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
58082523|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
58082524|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
58082525|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
58082526|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
58082527|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
58082528|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
58082529|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
58411114|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
58300278|NCT02567188|OTHER|MIRCERA|
58300279|NCT00380263|DRUG|PACAP38|10 pmol/kg/min given one time
58300280|NCT03064113|DRUG|Placebo|
58300281|NCT03064113|DRUG|TD-4208 700 μg|
58300282|NCT03064113|DRUG|TD-4208 350 μg|
58300283|NCT03064113|DRUG|Ipratropium 500 μg|
58300284|NCT05952921|OTHER|Mouthwash|Concentration rinse with 0.05% HOCl
58300285|NCT05952921|OTHER|Chlorhexidine|A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
58300286|NCT03663296|OTHER|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
58411115|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
58411116|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
58411117|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
57732375|NCT03921268|DRUG|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
57732376|NCT00407992|DEVICE|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
57732377|NCT00407992|DEVICE|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
57732378|NCT05014165|OTHER|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
58300287|NCT05534139|DIAGNOSTIC_TEST|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
58300288|NCT05534139|DIAGNOSTIC_TEST|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
58300289|NCT05534139|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
58300290|NCT05534139|DIAGNOSTIC_TEST|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
58082530|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
58082531|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
58411118|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
58082532|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
58082533|NCT05865002|DRUG|AUR107|Once daily
58082534|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
58082535|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
58082536|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
58082537|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
58082538|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
58082539|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
58082540|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
58082541|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
58082542|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
58300291|NCT01769677|DRUG|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
58411119|NCT03584191|OTHER|No treatment given|Completion of a survey
57732379|NCT05014165|OTHER|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
57732380|NCT05014165|OTHER|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
57732381|NCT05635123|OTHER|No intervention|This is a prospective observational study with no intervention.
57732382|NCT04391049|DRUG|Carboplatin|Given IV
57732383|NCT04391049|DRUG|Paclitaxel|Given IV
58082543|NCT02029729|DRUG|omaveloxolone|
58082544|NCT03733301|DRUG|Baricitinib|Administered orally.
58082545|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
58082546|NCT03733301|DRUG|Placebo|Administered orally.
58082547|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
58082548|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
58411120|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
58411121|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
58082549|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
58082550|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
58411122|NCT00002598|BIOLOGICAL|sargramostim|
58411123|NCT00002598|DRUG|cyclophosphamide|
58411124|NCT00002598|DRUG|cytarabine|
58411125|NCT00002598|DRUG|etoposide|
58411126|NCT00002598|DRUG|methotrexate|
58411127|NCT00002598|DRUG|mitoxantrone hydrochloride|
58411128|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
58411129|NCT00002598|RADIATION|radiation therapy|
58411130|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
58411131|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
58411132|NCT02727556|BEHAVIORAL|visual images|
58411133|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
58411134|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
58411135|NCT02442791|OTHER|20% Human Albumin|See description of Arms
57732384|NCT04391049|RADIATION|Radiation Therapy|Undergo radiation therapy
57946774|NCT04049838|PROCEDURE|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
57946775|NCT00002106|DRUG|Ranitidine hydrochloride|
58411136|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
58411137|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
57946776|NCT03753646|OTHER|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
57946777|NCT05744765|OTHER|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
57946778|NCT05768451|OTHER|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
57946779|NCT05468554|DRUG|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
57946780|NCT05468554|RADIATION|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
57946781|NCT00822731|DRUG|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
57946782|NCT04056572|DRUG|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
57946783|NCT04694664|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
57946784|NCT03844984|DRUG|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
57946785|NCT03844984|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
57946786|NCT03844984|DRUG|Normal saline|This group will receive normal saline 10 mL
57946787|NCT03844984|DRUG|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
57946788|NCT03844984|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
57946789|NCT02735395|PROCEDURE|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
58411138|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
58411139|NCT04371640|DRUG|Placebo|Oral solution
58411140|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
58411141|NCT05602675|DRUG|LY3871801|Administered orally.
58082551|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
58082552|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
58082553|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
58082554|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
58082555|NCT02515175|DRUG|Placebo|0.9% Normal Saline
58082556|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
58082557|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
58082558|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
58082559|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
58082560|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
58082561|NCT02984904|OTHER|survey|survey
58082562|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
58082563|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
58082564|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
58082565|NCT02249065|DRUG|Brimonidine|
58082566|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
58082567|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
58082568|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
58082569|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
58082570|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
58082571|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
57732385|NCT04391049|BIOLOGICAL|Telomerase-specific Type 5 Adenovirus OBP-301|Given by intratumoral injection
57732386|NCT00122018|DRUG|N-acetylcysteine|
57946790|NCT02735395|DRUG|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
58082572|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
58300292|NCT01305564|DEVICE|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
58411142|NCT05602675|DRUG|Methotrexate|Administered orally.
58411143|NCT05602675|DRUG|Warfarin|Administered orally.
58082573|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
58082574|NCT02900508|OTHER|Exergaming training|
58082575|NCT02900508|OTHER|Physical therapy intervention|
58082576|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
58082577|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
58082578|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
58082579|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
58082580|NCT04865536|DRUG|1800 mg TBI-223|3 x 600 mg SR1 tablets
58082581|NCT04865536|DRUG|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
58082582|NCT04865536|DRUG|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
58082583|NCT04865536|DRUG|TBI-223 Placebo|3 x Placebo tablets
58082584|NCT04865536|DRUG|TBI-223 Placebo|4 x Placebo tablets
58082585|NCT04865536|DRUG|TBI-223 Placebo|5 x Placebo tablets
58082586|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
58082587|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
58300293|NCT00713804|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
58300294|NCT00713804|BEHAVIORAL|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
58300295|NCT04518917|BEHAVIORAL|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
58411144|NCT05602675|DRUG|Dextromethorphan|Administered orally.
58411145|NCT05602675|DRUG|Midazolam|Administered orally.
58411146|NCT05602675|DRUG|Repaglinide|Administered orally.
58411147|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
58082588|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
58082589|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
58082590|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
58082591|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
58082592|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
58082593|NCT00104858|DRUG|Cyclosporine|Given PO
58082594|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
58082595|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
58082596|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
58082597|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
58411148|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
58411149|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
58411150|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
58082598|NCT00104858|OTHER|Pharmacological Study|Correlative studies
58082599|NCT00104858|BIOLOGICAL|Rituximab|Given IV
58300296|NCT04518917|BEHAVIORAL|Listening to music|Participants listen to their song and match their footfalls to the beat.
57732387|NCT00122018|DRUG|fenoldopam|
58082600|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
58082601|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
58082602|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
58082603|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
58082604|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
58082605|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
58082606|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
58082607|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
58082608|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
58082609|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
58082610|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
58082611|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
58300297|NCT04518917|BEHAVIORAL|Singing|Participants will sing their song out loud and match their footfalls to the beat.
58411151|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
58411152|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
58411153|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
57732388|NCT03137147|BEHAVIORAL|Intervention for Sleep and Pain in Youth|See arm description.
57732389|NCT04842357|OTHER|standardised video concerning clinical skill|watching a video concerning clinical skills.
57732390|NCT03483636|DRUG|Lemborexant|Film-coated oral tablet
57732391|NCT03483636|DRUG|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
58082612|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
58082613|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
58082614|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
58300298|NCT05990725|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
58300299|NCT01491022|DRUG|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
58300300|NCT01491022|DRUG|placebo first, then Ampyra|placebo
58300301|NCT04826627|OTHER|glycemia|capillary glycemia
58300302|NCT01811537|DEVICE|Artificial Chordae|
58300303|NCT05486884|PROCEDURE|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
58300304|NCT05486884|PROCEDURE|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
58411154|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
58411155|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
58300305|NCT01043978|BEHAVIORAL|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
58411156|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
58411157|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
57732392|NCT03483636|DRUG|Placebo|Film-coated oral tablet
57784997|NCT03254693|OTHER|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
58082615|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
58082616|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
58082617|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
58082618|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
58082619|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
58300306|NCT04536714|BEHAVIORAL|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
57732393|NCT06583096|BEHAVIORAL|Surveys|Participants (in both arms) will complete surveys once per week and participants in the intervention arm will also complete additional 1-minute surveys daily. Study participation will be completed at the conclusion of the final follow-up survey administered 6-weeks after study enrollment.
58082620|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
58082621|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
58082622|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
58082623|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
58082624|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
58082625|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
58082626|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
58082627|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
58082628|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
58082629|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
58082630|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
57732394|NCT06583096|BEHAVIORAL|Supportive Text messages|Text messages will be sent Mondays-Sunday if participants are randomized to receive them in a given week, with a daily 50:50 send/no-send randomization. A bank of 25 text messages will be used for the study, providing tips/strategies across a range of topics, including managing time and academic stressors, recommendations for self-care and mood management, and messages geared towards fostering social connections and support. Some messages will contain links to videos, websites, or articles for more information on a topic.
58082631|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
58300307|NCT02605759|DEVICE|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
57784998|NCT03254693|OTHER|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
57784999|NCT00126204|DRUG|Doxycycline|
57946791|NCT02735395|DRUG|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
58082632|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
58411158|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
58411159|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
58082633|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
58082634|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
58082635|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
58082636|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
57732395|NCT06583096|BEHAVIORAL|Personalized Feedback (PF) Report|For individuals that are randomized to receive a Personalized Feedback Report, the study team will send participants a text on a Monday with the feedback from the prior survey (baseline survey in the first week, weekly survey in the next five weeks). There will be graphs for depression, anxiety, stress, and flourishing.
57732396|NCT04626791|DRUG|Acalabrutinib|Given PO
57732397|NCT04626791|DRUG|Bortezomib|Given SC
58082637|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
58082638|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
58300308|NCT04996966|BIOLOGICAL|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
58300309|NCT04996966|OTHER|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
58082639|NCT03323021|OTHER|Standard of Care|Standard of Care
58082640|NCT05173025|DRUG|Fimasartan|- Fimasartan group: fimasartan, 60 mg once a day, oral administration
58082641|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
58300310|NCT04561648|DRUG|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
58300311|NCT00667641|DRUG|bortezomib|Starting dose level 0.70mg/m2
58300312|NCT00667641|DRUG|paclitaxel|Starting dose level 40mg/m2
58300313|NCT04752371|DRUG|Camoteskimab (CERC-007, AVTX-007, AEVI-007)|Intravenous (IV) Infusion
58300314|NCT00232557|DEVICE|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
58300315|NCT00232557|DEVICE|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
58300316|NCT00993551|PROCEDURE|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
57732398|NCT04626791|DRUG|Cyclophosphamide|Given IV
57732399|NCT04626791|DRUG|Cytarabine|Given IV
57732400|NCT04626791|DRUG|Doxorubicin Hydrochloride|Given IV
57732401|NCT04626791|DRUG|Prednisone|Given PO
57732402|NCT04626791|BIOLOGICAL|Rituximab|Given IV
57732403|NCT04626791|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV
58300317|NCT00661089|DRUG|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
58300318|NCT00661089|DRUG|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
58300319|NCT02033759|DEVICE|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
58300320|NCT02033759|OTHER|Anxiety Questionnaire|21 item questionnaire
58300321|NCT02033759|OTHER|Traditional Circumferential Measurements|
58300322|NCT01619865|DRUG|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
58300323|NCT04486118|DRUG|Lisinopril Pills|Tablets will be taken by oral administration daily, based on titration
58300324|NCT04486118|DRUG|Benazepril Pill|Tablets will be taken by oral administration daily, based on titration
58300325|NCT06413966|PROCEDURE|Partially absorbable mesh|- In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).
58300326|NCT06413966|PROCEDURE|Apical pleurectomy|- In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
58300327|NCT02349035|DEVICE|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
58300328|NCT02349035|PROCEDURE|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
58300329|NCT00006193|BEHAVIORAL|diet|
58300330|NCT01508988|DRUG|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
58300331|NCT01508988|DRUG|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
58300332|NCT01508988|DRUG|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
58300333|NCT01508988|DRUG|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
58300334|NCT01508988|DRUG|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
58300335|NCT01508988|DRUG|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
58300336|NCT01508988|DRUG|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
58300337|NCT00789321|DRUG|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
58082642|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
58082643|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
58300338|NCT00789321|DRUG|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
58300339|NCT03643718|PROCEDURE|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
58300340|NCT06529341|OTHER|High-definition transcranial direct current stimulation|HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
58300341|NCT06529341|OTHER|High-definition transcranial direct current stimulation pseudo-stimulation control group|The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
58411160|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
58082644|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
58082645|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
58082646|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
58082647|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
58082648|NCT04979325|OTHER||
58300342|NCT01682824|OTHER|Nutritional Assessment|Complete dietary intake assessment
58300343|NCT01682824|OTHER|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
58300344|NCT01682824|OTHER|Questionnaire Administration|Complete EQ-EMA questionnaire
58300345|NCT02671851|DRUG|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
58300346|NCT02671851|DRUG|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
58300347|NCT00141518|DRUG|Levodopa-carbidopa intestinal gel (LCIG)|
58411161|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
58300348|NCT00141518|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
58411162|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
58411163|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
58411164|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
58411165|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
58411166|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
58411167|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
58411168|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
58411169|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
58411170|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
58411171|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
58411172|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
58411173|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
58411174|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
58411175|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
58411176|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
58411177|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
58411178|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
58411179|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
58411180|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
58411181|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
57732404|NCT05043649|DRUG|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
58300349|NCT00141518|DEVICE|percutaneous endoscopic gastrostomy tube (PEG tube)|
58300350|NCT00141518|DEVICE|jejunal extension tube (J-tube)|
58411182|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
58411183|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
58411184|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
58411185|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
57732405|NCT03136614|DEVICE|Arteriograph|
57732406|NCT03808506|DIAGNOSTIC_TEST|Fecal calprotectin|Stool test to look at baseline burden of inflammation
58300351|NCT05003544|PROCEDURE|Group A|PENG BLOCK
58300352|NCT05003544|PROCEDURE|Group B|Intra-articular
58411186|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
57732407|NCT06374602|DRUG|Pembrolizumab + Lenvatinib|Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
58300353|NCT05003544|PROCEDURE|Group C|Quadratus lumborum block
58300354|NCT03735823|OTHER|No intervention, just collect blood samples and CSF samples|No intervention
58300355|NCT02354612|DRUG|TRC105|
58300356|NCT02354612|DRUG|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
58300357|NCT02354612|DRUG|Axitinib|companion therapy selection depends on companion therapy used in the parent study
58300358|NCT02354612|DRUG|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
58300359|NCT02354612|DRUG|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
58082649|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
58082650|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
58082651|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
58082652|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
58082653|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
58082654|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
58082655|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
58082656|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
58082657|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
58082658|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
58082659|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
58082660|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
58082661|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
58082662|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
58082663|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
58082664|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
58082665|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
58082666|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
58082667|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
58082668|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
58082669|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
58082670|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
58082671|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
58082672|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
58082673|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
57732408|NCT00648908|DRUG|Fampridine-SR|Tablets, 10 mg, BID
57732409|NCT02585895|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once every 2 weeks
58082674|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
58082675|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
58082676|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
58082677|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
58082678|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
58082679|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
58082680|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
58082681|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
58082682|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
58300360|NCT02787577|BEHAVIORAL|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
58300361|NCT04350827|DEVICE|Platelet Rich Plasma|Platelet rich plasma injection into patellar tendon
58300362|NCT04350827|DEVICE|Platelet Rich Plasma plus IGF|Platelet rich plasma plus IGF injection into patellar tendon
58300363|NCT00296855|DRUG|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
58300364|NCT06139172|BEHAVIORAL|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
58411187|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
57732410|NCT02585895|PROCEDURE|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
57946792|NCT02735395|DRUG|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
57946793|NCT02735395|DRUG|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
57946794|NCT02735395|DRUG|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
57946795|NCT02735395|OTHER|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
57946796|NCT02735395|OTHER|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
57946797|NCT02735395|OTHER|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
57946798|NCT02735395|OTHER|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
57946799|NCT01940471|DRUG|TAF|25 mg tablet administered orally once daily
57946800|NCT01940471|DRUG|TDF|300 mg tablet administered orally once daily
58082683|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
58082684|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
57946801|NCT01940471|DRUG|TAF Placebo|Tablet administered orally once daily
58082685|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
58082686|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
58082687|NCT01528839|DRUG|Placebo|
58082688|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
58082689|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
58300365|NCT06139172|OTHER|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
58300366|NCT03301636|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
58300367|NCT03301636|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
58300368|NCT03301636|DRUG|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
58300369|NCT04623866|DRUG|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
58300370|NCT04623866|DRUG|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
58411188|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
58411189|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
58411190|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
57732411|NCT05230524|DEVICE|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
57732412|NCT02873611|DEVICE|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
58082690|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
58082691|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
58300371|NCT00194129|DRUG|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
58300372|NCT00194129|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
58300373|NCT00194129|DRUG|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
58082692|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
58082693|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
58300374|NCT05186129|DRUG|Clopid® 75 mg Tablet|Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
58411191|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
58411192|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
58411193|NCT02154048|DRUG|Ropivacaine|
58082694|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
58300375|NCT05186129|DRUG|Plavix® 75mg Tablet|Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
58300376|NCT03567473|DRUG|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
58300377|NCT03567473|DRUG|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
58411194|NCT02154048|DRUG|Dexamethasone|
58411195|NCT02154048|OTHER|Placebo|
58411196|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
58411197|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
58411198|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
57732413|NCT02873611|PROCEDURE|genicular ablation procedure|
57732414|NCT01178151|DRUG|Everolimus|10mg daily orally
57946802|NCT01940471|DRUG|TDF Placebo|Tablet administered orally once daily
57946803|NCT02349048|DRUG|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
58082695|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
58082696|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
58082697|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
58082698|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
58082699|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
58082700|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
58300378|NCT03567473|DRUG|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
58082701|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
58082702|NCT00084188|BEHAVIORAL|Behavior Therapy|
58082703|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
58082704|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
58082705|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
58082706|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
58082707|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
58082708|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
58082709|NCT03486015|DRUG|Sterile water|2 ml of sterile water
58082710|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
58082711|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
58082712|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
58082713|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
58300379|NCT03567473|DRUG|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
58300380|NCT03567473|DRUG|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
58300381|NCT03567473|DRUG|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
58300382|NCT06401707|DRUG|Perampanel|Perampanel is a non-competitive AMPA glutamate receptor antagonist.
58300383|NCT06401707|DRUG|Placebo|Placebo
58300384|NCT01702467|DRUG|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
58300385|NCT01702467|DRUG|Placebo|Matching placebo capsules.
58300386|NCT05532215|DRUG|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
58300387|NCT05532215|DRUG|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
58300388|NCT00374478|DRUG|Scopolamine|
58300389|NCT03400527|OTHER|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
58300390|NCT00388791|DRUG|Systane Free|
58411199|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
58411200|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
57946804|NCT02349048|DRUG|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
57946805|NCT02349048|DRUG|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
57732415|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
57732416|NCT04818346|DRUG|INCB054707|INCB054707 will be administered once daily
58300391|NCT06086990|DEVICE|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
58300392|NCT02361866|BIOLOGICAL|GC1107|0.5 ml, Intramuscular, single dose(day0)
58082714|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
58082715|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
58082716|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
58082717|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
58082718|NCT00002329|DRUG|Celgosivir hydrochloride|
58082719|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
58082720|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
58082721|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
58082722|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
58082723|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
58300393|NCT02361866|BIOLOGICAL|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
58300394|NCT02238730|DEVICE|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
58300395|NCT02238730|DEVICE|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
58300396|NCT05036941|DEVICE|Acteev™ Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
58300397|NCT05036941|DEVICE|Comparison Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
58300398|NCT03999255|PROCEDURE|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
58300399|NCT03159585|DRUG|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
58300400|NCT01914393|DRUG|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
58300401|NCT04157010|DRUG|Tocilizumab|
58300402|NCT04157010|DRUG|Methotrexate|
57732417|NCT04818346|DRUG|Placebo|Placebo or INCB054707 will be administered once daily
58082724|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
58300403|NCT04735705|DEVICE|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
58300404|NCT00003039|DRUG|alvocidib|
57732418|NCT01432366|OTHER|SC anti-TNF|Subcutaneous (SC) anti-TNF
57946806|NCT02943564|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
58082725|NCT00363272|DRUG|ispinesib|Given IV
58082726|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
58082727|NCT00363272|OTHER|pharmacological study|Correlative studies
58082728|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
58082729|NCT01826006|DEVICE|Excimer laser|
58082730|NCT01826006|DEVICE|Manual Thrombus Aspiration|
58082731|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
58082732|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
58082733|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
58082734|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
58082735|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
58082736|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
58082737|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
58082738|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
58082739|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
58082740|NCT00003582|DRUG|amifostine trihydrate|
58082741|NCT00003582|DRUG|cisplatin|
58082742|NCT00003582|DRUG|fluorouracil|
58082743|NCT00003582|DRUG|paclitaxel|
58082744|NCT00003582|PROCEDURE|quality-of-life assessment|
58082745|NCT00003582|RADIATION|radiation therapy|
58082746|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
58082747|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
58082748|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
58082749|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
58082750|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
58300405|NCT05324319|DRUG|Ad26COVS1|Heterologous vaccination
58411201|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
57732419|NCT05067491|BEHAVIORAL|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
57732420|NCT03389802|BIOLOGICAL|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
57732421|NCT03389802|BIOLOGICAL|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
57732422|NCT01495767|OTHER|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
57732423|NCT02129738|DEVICE|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
57946807|NCT02943564|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
57946808|NCT00502138|DRUG|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
57946809|NCT02725983|BEHAVIORAL|SPT consultation|
57946810|NCT02725983|DEVICE|SOPROCARE®|
57946811|NCT02404623|DIETARY_SUPPLEMENT|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
57946812|NCT02446431|DRUG|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
57946813|NCT02446431|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
58082751|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
58300406|NCT05324319|DRUG|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
58411202|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
58411203|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
58411204|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
58411205|NCT00889889|BIOLOGICAL|Placebo|Placebo
58411206|NCT01063491|PROCEDURE|bypass graft angiography|
58411207|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
57732424|NCT04323436|DRUG|Spartalizumab|Concentrate for solution for infusion
58082752|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
58082753|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
58082754|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
58082755|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
58082756|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
58082757|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
58411208|NCT00701298|DRUG|decitabine|Given IV
57732425|NCT04323436|DRUG|Capmatinib|Film-coated tablet
57732426|NCT04323436|DRUG|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
57732427|NCT06465147|BIOLOGICAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
57732428|NCT06040866|OTHER|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
58082758|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
58082759|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
58082760|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
58082761|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
58082762|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
58082763|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
58411209|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
58411210|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
58411211|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
57732429|NCT06040866|OTHER|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
57732430|NCT06040866|OTHER|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
57732431|NCT02977624|BEHAVIORAL|The Cognitive Orientation to daily Occupational Performance|
57732432|NCT02243033|DEVICE|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
58300407|NCT05324319|DRUG|BNT162B2|Homologous vaccination
58300408|NCT05324319|DRUG|mRNA-1273|Homologous vaccination
58300409|NCT03308669|DRUG|Lasmiditan|Administered orally
58300410|NCT03308669|DRUG|Placebo|Administered orally
58300411|NCT03308669|DRUG|Topiramate|Administered orally
58300412|NCT04045756|DEVICE|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
58300413|NCT02564276|PROCEDURE|Sentinel lymph node biopsy|
58300414|NCT02391051|RADIATION|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
57732433|NCT06543979|DRUG|lubiprostone , single arm|laxative
57732434|NCT06543979|PROCEDURE|biofeed back sessions|Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
57732435|NCT06543979|PROCEDURE|botox injection|Botulinum toxin injection for participants suffering from elevated anal canal pressure
57732436|NCT00006127|DRUG|amifostine|
57732437|NCT03916003|DRUG|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
57732438|NCT01823848|DRUG|Sodium phosphate enema|Rectally administered medication to treat constipation
57732439|NCT01823848|DRUG|Normal saline enema|Rectally administered medication to treat constipation
57732440|NCT01823848|DRUG|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
57732441|NCT04331600|DRUG|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
58082764|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
58300415|NCT05485922|DEVICE|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
58411212|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
58082765|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
58082766|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
58082767|NCT00101374|DRUG|Leflunomide|
58082768|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
58082769|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
58082770|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
58082771|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
58082772|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
58082773|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
58082774|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
58082775|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
58082776|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
58082777|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
58082778|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
58082779|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
58082780|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
58082781|NCT00077870|DRUG|ocrelizumab|
58082782|NCT02557191|OTHER|Observational study|
58082783|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
58082784|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
58082785|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
58082786|NCT02253849|DRUG|Carbamazepine|
58411213|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
58411214|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
58300416|NCT05485922|DEVICE|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
58300417|NCT05554107|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
57732442|NCT04331600|OTHER|Telemedicine|Telemedical supervision for 42 days
58300418|NCT03908788|DEVICE|Intplex test|Blood sample at each tumor assessment
58411215|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
58411216|NCT00297102|DRUG|Placebo|once daily
58411217|NCT00494377|DRUG|duloxetine|
58411218|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
58411219|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
58411220|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
58082787|NCT02253849|DRUG|Tipranavir|
58411221|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
58082788|NCT02253849|DRUG|Ritonavir|
58082789|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
58082790|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
58082791|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
58300419|NCT06338306|DRUG|Tacrolimus（FK506）|Prograf
58082792|NCT02665858|OTHER|OCT Imaging|
58082793|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
58082794|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
58082795|NCT06647862|DRUG|IMM01|IV infusion
58082796|NCT06647862|DRUG|Azacitidine|subcutaneous injection
58082797|NCT06647862|DRUG|Placebo|IV infusion
58082798|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
58300420|NCT04604834|OTHER|PFAT first|Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
58300421|NCT04604834|OTHER|APRP first|Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
58082799|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
58082800|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
58082801|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
58082802|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
58082803|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
58082804|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
58082805|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
58082806|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
58082807|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
58300422|NCT04797208|DEVICE|Real-Time CGM|Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
58300423|NCT04797208|DEVICE|Capillary blood glucose testing with masked CGM|Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
58300424|NCT03988153|COMBINATION_PRODUCT|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
58300425|NCT06360328|DEVICE|video laryngoscopy|The residents used video laryngoscopy for endotracheal intubation
58411222|NCT02081638|DRUG|Aspirin|Daily Asprin daily
58411223|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
58411224|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
58300426|NCT05237726|DRUG|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
58300427|NCT05237726|DRUG|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
58082808|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
58300428|NCT05237726|DRUG|Unfractionated heparin 5000 U q8 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
58300429|NCT02946359|DRUG|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
58300430|NCT03087734|DEVICE|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
58300431|NCT03087734|DEVICE|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
58300432|NCT02296489|DEVICE|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
58300433|NCT01705080|DEVICE|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
58300434|NCT00190424|DRUG|CpG-ODN|
58300435|NCT00756626|BEHAVIORAL|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
58300436|NCT00826553|DRUG|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
58300437|NCT00826553|DRUG|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
58300438|NCT01518647|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
58300439|NCT05251272|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
58300440|NCT05030649|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
58300441|NCT05030649|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
58300442|NCT06297512|DRUG|Radiotherapy, Temozolomide, Doxorubicin|"Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);"
58300443|NCT01219543|DRUG|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
58300444|NCT01219543|DRUG|AZD1480 BID|Oral Dose, Capsule, BID Dosing
58300445|NCT05089578|OTHER|focus interview|"The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes."
58300446|NCT00372424|DRUG|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
58300447|NCT00372424|DRUG|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
58300448|NCT00372424|DRUG|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
58300449|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
58300450|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
58300451|NCT00928434|DRUG|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
58300452|NCT04864743|DRUG|ADVATE|a single dose.
58300453|NCT04864743|DRUG|FRSW117|a single dose.
58082809|NCT00062075|DRUG|romidepsin|Given IV
58082810|NCT00165191|DRUG|Doxorubicin|
58082811|NCT00165191|DRUG|Cisplatin|
58082812|NCT00165191|DRUG|5-fluorouracil|
58082813|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
58300454|NCT02664142|PROCEDURE|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
58411225|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
58082814|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
58082815|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
58082816|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
58082817|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
58300455|NCT02664142|PROCEDURE|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
58300456|NCT02664142|DRUG|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
58300457|NCT00163566|DRUG|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
58300458|NCT03565354|DRUG|iron isomaltoside(Monofer®)|intravenous iron isomaltoside
58411226|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
58411227|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
57732443|NCT03972488|DRUG|Lutathera|Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
57732444|NCT03972488|DRUG|30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
58300459|NCT01500798|DRUG|20 mg bardoxolone methyl|20 mg, oral, once daily
58300460|NCT01500798|DRUG|Placebo|Oral, once daily
58300461|NCT05743530|DEVICE|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
58411228|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
58411229|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
58300462|NCT05743530|OTHER|Placebo|Pre-operative day 1 till postoperative day 14.
58300463|NCT01091922|DIETARY_SUPPLEMENT|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
58300464|NCT01091922|DIETARY_SUPPLEMENT|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
58300465|NCT05705830|DEVICE|Pulse magnetic therapy|Pulse magnetic therapy SM-II (2019102133903)
58300466|NCT05705830|DRUG|Selective serotonin reuptake inhibitors （SSRI）|Anti-anxiety Drugs
58300467|NCT05705830|DEVICE|Shame magnetic therapy|Shame magnetic therapy
58411230|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
58411231|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
58411232|NCT00612859|DRUG|levetiracetam|
58411233|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
58411234|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
58411235|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
58411236|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
58411237|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
58411238|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
58411239|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
58300468|NCT04040517|DIAGNOSTIC_TEST|Evoked potential audiometer|The ASSR \[ steady state response\] test stimuli are modulated pure tones with insert earphone..
58300469|NCT03781466|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
58300470|NCT03781466|DRUG|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
58411240|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
58411241|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
58411242|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
58411243|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
57732445|NCT03972488|DRUG|2.5% Lys-Arg sterile amino acid solution|Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
57732446|NCT03972488|DRUG|High dose 60 mg octreotide long-acting repeatable|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
58300471|NCT03013400|DRUG|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
58300472|NCT03013400|DRUG|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
58300473|NCT03191851|DEVICE|standard device|paracentesis using standard
58300474|NCT03191851|DEVICE|Melody Device|paracentesis using Melody Device
58300475|NCT03191851|DEVICE|Melody Device with Pump|paracentesis using Melody Device with Pump
58300476|NCT00120692|DRUG|Darbepoetin Alfa|
58300477|NCT00120692|DRUG|Recombinant Human Erythropoietin|
58300478|NCT05822817|DRUG|sevoflurane|Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
58300479|NCT05822817|DRUG|propofol|Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
58082818|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
58082819|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
58082820|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
58082821|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
58082822|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
58082823|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
58082824|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
58082825|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
58082826|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
57732447|NCT04073043|BEHAVIORAL|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
58082827|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
58082828|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
58082829|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
58082830|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
58082831|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
58082832|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
57732448|NCT05997004|DRUG|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
57732449|NCT05997004|DRUG|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
57732450|NCT02811029|BEHAVIORAL|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
57732451|NCT06287359|OTHER|individual interviews|Qualitative research with individual interviews
57732452|NCT00599326|DRUG|Deferasirox|250 mg of deferasirox once daily for 6 months
57732453|NCT04955639|OTHER|Control|Standard of Care - Control Smoking Cessation Program
57732454|NCT04955639|OTHER|Pivot|Pivot Program Smoking Cessation Program
57732455|NCT00320658|BIOLOGICAL|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
58411244|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
58411245|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
58411246|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
58411247|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
58082833|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
58082834|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
58082835|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
58082836|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
58082837|NCT06522828|DRUG|carboplatin|chemotherapy
58082838|NCT06522828|DRUG|paclitaxel|chemotherapy
58082839|NCT00182208|DEVICE|Veno-device (Venowave)|
58082840|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
58082841|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
58082842|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
58082843|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
58411248|NCT00777530|DRUG|Bosutinib (SKI-606)|
58411249|NCT06360081|DRUG|Zongertinib|Zongertinib
58082844|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
58082845|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
58411250|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
58411251|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
58411252|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
58411253|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
58082846|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
58082847|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
58082848|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
58082849|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
58082850|NCT05725642|OTHER|Polysomnography|Polysomnography
58082851|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
58082852|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
58082853|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
58411254|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
58411255|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
58411256|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
57732456|NCT00320658|BIOLOGICAL|CPG 7909|Adjuvant
58082854|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
58411257|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
58411258|NCT00004174|BIOLOGICAL|filgrastim|
58411259|NCT00004174|DRUG|cyclophosphamide|
58411260|NCT00004174|DRUG|paclitaxel|
58411261|NCT00004174|DRUG|thiotepa|
58411262|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
58082855|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
58082856|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
58082857|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
58300480|NCT05648903|OTHER|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
58300481|NCT05648903|OTHER|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
58300482|NCT05648903|OTHER|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
58082858|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
58082859|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
58300483|NCT03080740|DRUG|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
58300484|NCT03080740|DRUG|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
58300485|NCT02981940|DRUG|Abemaciclib|Abemaciclib capsule
58300486|NCT02981940|PROCEDURE|Surgery|Surgery
58411263|NCT00004174|RADIATION|radiation therapy|
58411264|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
58411265|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
58411266|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
58411267|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
58411268|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
58411269|NCT00902993|DRUG|Placebo|Placebo
58411270|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
58082860|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
58082861|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
58082862|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
58082863|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
58082864|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
58082865|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
58082866|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
58082867|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
58300487|NCT03065491|DIETARY_SUPPLEMENT|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
58300488|NCT03065491|OTHER|Placebo|Oral administration: 1 tablet per day
58411271|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
58411272|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
58411273|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
58411274|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
58411275|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
58411276|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
58411277|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
58411278|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
57732457|NCT06293235|OTHER|Lifestyle and metabolic indicators|Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
57732458|NCT05827978|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
57732459|NCT05827978|BIOLOGICAL|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
58082868|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
58411279|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
58411280|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
58411281|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
58411282|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
58411283|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
58411284|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
58411285|NCT04965961|DRUG|EPO|Please refer to the arm description
58082869|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
58082870|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
58082871|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
58082872|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
58082873|NCT03938454|DRUG|crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
58082874|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
58082875|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
58082876|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
58082877|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
58082878|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
58082879|NCT02183168|DRUG|Meloxicam suppository|
58082880|NCT02183168|DRUG|Meloxicam tablet|
58082881|NCT02183168|DRUG|Indomethacin|
58082882|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
58082883|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
58082884|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
58082885|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
58082886|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
58082887|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
58082888|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
58300489|NCT05406414|BEHAVIORAL|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems"
58082889|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
58411286|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
58082890|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
58082891|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
58411287|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
58411288|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
58411289|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
58411290|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
58411291|NCT04104685|OTHER|Vehicle Foam|Placebo
58411292|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
58082892|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
58082893|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
58082894|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
58082895|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
58082896|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
58082897|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
58082898|NCT04592666|DRUG|Pemetrexed|standard dose
58082899|NCT04592666|DRUG|Carboplatin|AUC=5
58082900|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
58082901|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
58082902|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
58082903|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
58411293|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
58411294|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
58411295|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
58411296|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
58411297|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
58411298|NCT01431937|DRUG|GSK2018682|Active Drug
58411299|NCT01431937|DRUG|Placebo|Placebo
58411300|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
58411301|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
58411302|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
58411303|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
58411304|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
58082904|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
58411305|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
58411306|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
58082905|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
58082906|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
58411307|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
58411308|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
58411309|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
58411310|NCT01956045|OTHER|Patient's capacity|
58082907|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
58082908|NCT05978375|PROCEDURE|TARP|Using TARP technique.
58300490|NCT05406414|BEHAVIORAL|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
58300491|NCT03648788|OTHER|NA (Observation study)|NA (Observation study)
58411311|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
58411312|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
58411313|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
58411314|NCT04881500|OTHER|Routine Care|Patients will follow routine care
58411315|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
57732460|NCT00633321|BIOLOGICAL|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
57732461|NCT00633321|BIOLOGICAL|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
57732462|NCT00153049|DRUG|Telmisartan|
57732463|NCT00153049|DRUG|Hydrochlorothiazide|
57732464|NCT00153049|DRUG|Telmisartan + Hydrochlorothiazide|
57732465|NCT00384228|DRUG|Nilotinib|
58082909|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
58082910|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
58082911|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
58082912|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
58082913|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
58082914|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
58082915|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
58082916|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
58082917|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
58082918|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
58082919|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
58082920|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
58082921|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
58082922|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
58082923|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
58082924|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
58082925|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
58082926|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
58082927|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
58082928|NCT02726516|OTHER|Placebo|1 sachet per day
58082929|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
58082930|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
58082931|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
58082932|NCT00346970|DRUG|Placebo|Placebo tablets
58082933|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
58082934|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
58082935|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
58082936|NCT01969201|DRUG|Urofollitrophin|
58082937|NCT01969201|DRUG|Follitrophin alpha|
58082938|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
58082939|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
58082940|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
58082941|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
58082942|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
58082943|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
58082944|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
58082945|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
58082946|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
58082947|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
58300492|NCT04460326|DRUG|Insulin glargine|Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%
58300493|NCT04460326|DRUG|NovoLog|Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
58300494|NCT04460326|DRUG|Insulin Fiasp|Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
57946814|NCT02446431|DRUG|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
57946815|NCT02446431|DRUG|Temsirolimus|Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
57946816|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
57946817|NCT03015571|DEVICE|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
57946818|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
57946819|NCT03015571|DEVICE|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
57946820|NCT02240979|DEVICE|cardiac MRI|cardiac MRI
57946821|NCT01231659|DRUG|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
57946822|NCT01231659|DRUG|Letrozole|Letrozole 2.5 mg once daily
57946823|NCT04744207|DRUG|GS-248|120 mg, capsule, once daily for 4 weeks
57946824|NCT04744207|DRUG|Placebo|capsule, once daily for 4 weeks
57946825|NCT00721474|DRUG|Bosutinib|Bosutinib fasting
57946826|NCT00721474|DRUG|Bosutinib|Bosutinib fed
57946827|NCT04247958|PROCEDURE|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
57946828|NCT02670824|DRUG|CN-105|Single and multiple intravenous (IV) doses of CN-105
58082948|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
58082949|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
58082950|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
58300495|NCT04460326|OTHER|Standard carbohydrate diet|Standard carbohydrate diet as per usual hospital care (75g with each meal)
58411316|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
58411317|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
57946829|NCT02670824|DRUG|Placebo|Normal Saline
57946830|NCT04686175|DRUG|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
57946831|NCT01262378|PROCEDURE|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
57946832|NCT05023759|DIETARY_SUPPLEMENT|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
57946833|NCT00792194|OTHER|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
57946834|NCT06307821|DIETARY_SUPPLEMENT|Probiotic|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
57946835|NCT01214928|DRUG|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
57946836|NCT04507542|BEHAVIORAL|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
57946837|NCT04507542|BEHAVIORAL|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
58300496|NCT02076204|BEHAVIORAL|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
58300497|NCT04817332|DRUG|Brensocatib|Selective, competitive, and reversible inhibitor of DPP1
58082951|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
58082952|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
58082953|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
58082954|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
58082955|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
58082956|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
58300498|NCT04817332|DRUG|Placebo|Matched placebo
58300499|NCT02048722|DRUG|regorafenib|Given PO
58300500|NCT05525351|DEVICE|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
58300501|NCT05525351|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
58300502|NCT05525351|DRUG|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
58411318|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
58411319|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
57946838|NCT02976714|OTHER|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
58082957|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
57785000|NCT04573231|DRUG|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
57785001|NCT01780493|PROCEDURE|The Direct Nipple Ureteroneocystostomy Technique|
57785002|NCT02873286|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
58082958|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
58082959|NCT02160054|DRUG|Graceptor®|oral
58082960|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
58082961|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
58082962|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
58082963|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
58082964|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
58082965|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
58082966|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
58411320|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
58082967|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
58082968|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
58082969|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
58411321|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
58411322|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
58411323|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
58082970|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
58082971|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
58082972|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
58082973|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
58082974|NCT02466191|DRUG|Memantine|
57785003|NCT02873286|OTHER|Placebo|Tris Buffered Saline, sterile
57785004|NCT04796935|DEVICE|Tactile Imaging (VerTouch)|VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
57946839|NCT01650961|DRUG|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
57946840|NCT01650961|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
57946841|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
57946842|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
57946843|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
57946844|NCT05567497|PROCEDURE|trigeminal nerve block|ultrasound guided trigeminal nerve block
57946845|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
58082975|NCT02466191|DRUG|Gabapentin|
58082976|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
58082977|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
58082978|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
57732466|NCT03517774|DEVICE|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
57946846|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
57946847|NCT04776733|OTHER|prepackaged semisolid nutritional formulations|"The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast."
58082979|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
58411324|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
58082980|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
58411325|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
58411326|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
58411327|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
58411328|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
58411329|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
58411330|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
57785005|NCT04796935|OTHER|Control (palpation)|Control, palpation used to identify and mark an insertion site.
57946848|NCT04776733|OTHER|restricted diet|"The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast."
57946849|NCT01439464|DEVICE|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
57946850|NCT01439464|DEVICE|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
57946851|NCT02902354|OTHER|Nifedipine for tocolysis|observational
57946852|NCT02361541|PROCEDURE|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
57946853|NCT04449770|DEVICE|double lumen tube|prospective cohort study
58082981|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
58082982|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
58082983|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
58082984|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
58411331|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
58411332|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
58411333|NCT00463983|DRUG|octreotide|
58411334|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
57785006|NCT06012838|BEHAVIORAL|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
57785007|NCT04849728|DRUG|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
58082985|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
58411335|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
58411336|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
57732467|NCT03293940|PROCEDURE|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
57732468|NCT03293940|PROCEDURE|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
57732469|NCT01659723|DRUG|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
57732470|NCT05808725|DRUG|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
57732471|NCT05808725|DRUG|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
58082986|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
58082987|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
58082988|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
58082989|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
58082990|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
58300503|NCT05525351|DRUG|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
58300504|NCT01935999|DEVICE|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
58300505|NCT04625335|OTHER|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
58411337|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
58411338|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
57732472|NCT02869217|DRUG|Cyclophosphamide|
57732473|NCT02869217|BIOLOGICAL|TBI-1301|
57732474|NCT02869217|DRUG|Fludarabine|
58082991|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
58082992|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
58082993|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
58082994|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
58082995|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
58082996|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
58300506|NCT04625335|OTHER|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
58411339|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
57732475|NCT00110617|DRUG|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
58082997|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
58082998|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
58082999|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
58083000|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
58300507|NCT02986464|DEVICE|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
58300508|NCT02986464|OTHER|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
58411340|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
58411341|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
58411342|NCT02823132|BIOLOGICAL|blood sample|
57732476|NCT00110617|DRUG|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
57732477|NCT05997693|DRUG|Ticagrelor 90 MG|Ticagrelor 90 mg twice daily taken orally for one month
57732478|NCT05997693|DRUG|Low-dose aspirin|75-150 mg once daily taken orally
57732479|NCT03425149|BIOLOGICAL|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
58083001|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
58083002|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
58083003|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
58083004|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
58083005|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
58083006|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
58083007|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
58083008|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
58083009|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
58083010|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
58083011|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
58411343|NCT02340182|DRUG|Vancomycin|250mg 3dd2
58411344|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
58411345|NCT02340182|DRUG|Metronidazole|500mg 3dd1
58411346|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
58411347|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
58411348|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
58083012|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
58083013|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
58083014|NCT02553291|BEHAVIORAL|SystemCHANGE|
58083015|NCT02553291|BEHAVIORAL|Control|
58411349|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
58411350|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
58083016|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
58083017|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
58083018|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
58083019|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
58083020|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
58083021|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
58083022|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
58083023|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
58083024|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
58083025|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
58083026|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
58411351|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
58411352|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
58411353|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
58411354|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
58411355|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
58411356|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
58411357|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
57732480|NCT03425149|BIOLOGICAL|Placebo|Phosphate buffered saline (PBS)
58083027|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
58083028|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
58083029|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
58083030|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
58083031|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
58083032|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
58083033|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
58083034|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
58083035|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
58411358|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
57732481|NCT06130059|DRUG|Low Dose Colchicine|Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
57732482|NCT06130059|DRUG|Placebo|Placebo
57946854|NCT03739398|DEVICE|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
58411359|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
58411360|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
58411361|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
57732483|NCT00035438|DRUG|St. John's Wort|
58083036|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
58411362|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
58411363|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
58411364|NCT02436408|DRUG|Vismodegib|
58411365|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
57732484|NCT06635265|DEVICE|Target Stimulation (HGN, AC, GG, Strap muscles)|Simulation of a combination of: HGN, AC, GG or strap muscles
57785008|NCT04849728|DRUG|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
57785009|NCT00739635|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
58411366|NCT00002427|DRUG|Hydroxyurea|
58411367|NCT00002427|DRUG|Stavudine|
58411368|NCT00002427|DRUG|Didanosine|
58411369|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
58411370|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
58411371|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
58411372|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
58411373|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
58411374|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
58083037|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
58083038|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
58083039|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
58083040|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
58083041|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
58083042|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
58083043|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
58083044|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
58083045|NCT00000518|PROCEDURE|electrophysiology|
58411375|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
58411376|NCT00642148|DRUG|GW856553|Active tablet
58411377|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
58411378|NCT00642148|DRUG|Seretide|Active comparator inhaler
58411379|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
58083046|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
58083047|NCT00000518|DRUG|imipramine|
58083048|NCT00000518|DRUG|mexiletine|
58083049|NCT00000518|DRUG|procainamide|
58083050|NCT00000518|DRUG|quinidine|
58411380|NCT04205851|DRUG|Placebo|Saline
58411381|NCT02209948|DRUG|Temozolomide|
58411382|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
58411383|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
58411384|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
58411385|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
58083051|NCT00000518|DRUG|sotalol|
58083052|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
58083053|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
58083054|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
58083055|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
58083056|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
58083057|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
58083058|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
58083059|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
58083060|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
58083061|NCT00363935|DRUG|Dexmedetomidine|
58411386|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
58411387|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
58083062|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
58083063|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
58083064|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
58083065|NCT05450900|OTHER|Microcellulose filler|supplement, oral
58083066|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
58083067|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
58083068|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
58083069|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
58083070|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
58083071|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
58083072|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
58083073|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
58083074|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
58083075|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
58083076|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
58083077|NCT06311981|OTHER|targeted therapy|targeted therapy
58083078|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
58083079|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
58083080|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
58083081|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
58083082|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
58411388|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
57785010|NCT00739635|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo
58083083|NCT02866201|OTHER|Rectal swab|
58083084|NCT01654211|DRUG|danoprevir|single iv infusion
58083085|NCT01654211|DRUG|danoprevir|single oral dose
58083086|NCT01654211|DRUG|placebo|single iv infusion
58083087|NCT01654211|DRUG|ritonavir|oral doses
58083088|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
58083089|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
58083090|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
58083091|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
58083092|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
58083093|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
58083094|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
58083095|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
58083096|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
58083097|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
58083098|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
58083099|NCT00083356|PROCEDURE|Wisdom tooth extraction|
58083100|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
58083101|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
58083102|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
58083103|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
58083104|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
58411389|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
58083105|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
58083106|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
58083107|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
58083108|NCT06355180|DRUG|Subanesthetic dose intravenous esketamine|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Esketamine (0.2mg/kg) is given intravenously three times a week for two weeks. Dosage and sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
58083109|NCT06355180|DEVICE|Modified electroconvulsive therapy|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Modified electroconvulsive therapy (MECT) is given three times a week for two weeks. Sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
58411390|NCT06108648|OTHER|Control|Standard care according to national standards.
58411391|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
58083110|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
58411392|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
58411393|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
58083111|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
58083112|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
58083113|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
58083114|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
58083115|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
58083116|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
58083117|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
58083118|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
58083119|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
58083120|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
58083121|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
58083122|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
58411394|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
58411395|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
58083123|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
58083124|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
58083125|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
58083126|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
58083127|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
58083128|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
58083129|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
58411396|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
58411397|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
58083130|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
57785011|NCT02093143|DRUG|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
57946855|NCT03739398|DEVICE|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
58083131|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
58083132|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
58083133|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
57946856|NCT03328702|DEVICE|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
58083134|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
57946857|NCT04467944|OTHER|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
57946858|NCT04055714|DEVICE|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
57946859|NCT00662402|OTHER|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
57946860|NCT06535243|BEHAVIORAL|Lifespan Integration Therapy (LI)|same as above
57946861|NCT05886790|BIOLOGICAL|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
57946862|NCT05886790|BIOLOGICAL|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
57946863|NCT05886790|BIOLOGICAL|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
57946864|NCT00644774|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
57946865|NCT00644774|DRUG|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
57946866|NCT00616122|DRUG|cyclophosphamide|
57946867|NCT00616122|DRUG|methotrexate|
57946868|NCT00616122|DRUG|sunitinib malate|
57946869|NCT00616122|OTHER|laboratory biomarker analysis|
57946870|NCT00939783|DRUG|Dimebon|Tablet for oral administration
58083135|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
58083136|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain...~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA...)"
58411398|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
58411399|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
58411400|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
57946871|NCT03766529|PROCEDURE|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
57946872|NCT04782544|OTHER|Buttermilk Powder|Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
57946873|NCT04782544|OTHER|Anhydrous Milk Fat|Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
57946874|NCT05645874|DIAGNOSTIC_TEST|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
57946875|NCT00606203|DRUG|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
58411401|NCT04736953|DRUG|Sirolimus|Sirolimus
58411402|NCT04736953|OTHER|Placebo|Placebo
58411403|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
58411404|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
58411405|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
58411406|NCT00384423|DRUG|PRX-03140|
58083137|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
58083138|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
57785012|NCT05731375|DIAGNOSTIC_TEST|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
57785013|NCT03501238|OTHER|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
57785014|NCT03501238|OTHER|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
57785015|NCT03501238|OTHER|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
57946876|NCT00606203|DRUG|placebo|placebo
57946877|NCT00052351|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
57946878|NCT00052351|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
57946879|NCT00052351|BIOLOGICAL|sargramostim|
57946880|NCT00052351|DRUG|cyclophosphamide|
57946881|NCT00052351|DRUG|doxorubicin hydrochloride|
57946882|NCT00052351|DRUG|paclitaxel|
57946883|NCT00052351|RADIATION|radiation therapy|
57946884|NCT05074264|PROCEDURE|Biopsy|Undergo biopsy
57946885|NCT05074264|PROCEDURE|Biospecimen Collection - Anal|Undergo collection of anal swabs
57946886|NCT05074264|PROCEDURE|Biospecimen Collection - Cervical|Undergo collection of cervical swabs
57946887|NCT05074264|PROCEDURE|Colposcopy|Undergo colposcopy
57946888|NCT05074264|PROCEDURE|High Resolution Anoscopy|Undergo high-resolution anoscopy
57946889|NCT05074264|PROCEDURE|Imaging Technique|Undergo cervical imaging
57946890|NCT03523728|DRUG|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
57946891|NCT03523728|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
57946892|NCT00441974|DRUG|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
57946893|NCT04688736|DRUG|Placebo|The tablet resembles chlorpheniramine but has no therapeutic value.
57946894|NCT04688736|DRUG|Chlorpheniramine|An antihistamine that reduces the natural chemical histamine in the body.
57946895|NCT01606267|OTHER|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
57946896|NCT05623579|BEHAVIORAL|Pain Neuroscience Education|8 Sessions of different pain education interventions
57946897|NCT05623579|BEHAVIORAL|Exercise|12 Sessions of Aerobic Exercise
57946898|NCT00645593|DRUG|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
57946899|NCT00645593|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
57946900|NCT00645593|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
57946901|NCT04187638|DIETARY_SUPPLEMENT|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
57946902|NCT04187638|DIETARY_SUPPLEMENT|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
58083139|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
58083140|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
58083141|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
58411407|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
58411408|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
58411409|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
57946903|NCT05502042|BEHAVIORAL|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
57946904|NCT04821466|DEVICE|Virtual Reality Headset to provide a Virtual Reality Experience|Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
57946905|NCT02989831|DEVICE|Vibrating insoles 'on'|Duration: 30-60 seconds
57946906|NCT00959036|DRUG|ATN-103|10 mg every 4 weeks until week 12
57946907|NCT00959036|DRUG|ATN-103|10 mg every 8 weeks until week 12
57946908|NCT00959036|DRUG|ATN-103|30 mg every 4 weeks until week 12
57946909|NCT00959036|DRUG|ATN-103|80 mg every 4 weeks until week 12
57946910|NCT00959036|DRUG|ATN-103|80 mg every 8 weeks until week 12
57946911|NCT00959036|DRUG|Placebo|Placebo every 4 weeks
57946912|NCT00959036|DRUG|Methotrexate|
58083142|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
58083143|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
58083144|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
58083145|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
58300509|NCT05209659|OTHER|Pragmatic Mobilization|"The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)"
58300510|NCT04839744|DRUG|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
58300511|NCT04839744|DRUG|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
58300512|NCT02643641|BIOLOGICAL|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
58300513|NCT02643641|BIOLOGICAL|Placebo|Placebo contains aluminum hydroxide only
58300514|NCT03250689|DRUG|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
58083146|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
58083147|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
58300515|NCT03250689|DRUG|Placebo|Placebo will be available as oval shaped, white film coated tablets.
58083148|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
58083149|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
58083150|NCT01761123|BIOLOGICAL|VXA-A1.1|
58300516|NCT03250689|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
58300517|NCT03250689|DRUG|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
58300518|NCT01288599|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
58300519|NCT03529500|DIAGNOSTIC_TEST|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
57946913|NCT03970694|RADIATION|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
57946914|NCT03970694|DRUG|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
57946915|NCT03912142|DIAGNOSTIC_TEST|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
57946916|NCT04169750|BEHAVIORAL|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
57946917|NCT04169750|BEHAVIORAL|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
57946918|NCT04169750|BEHAVIORAL|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
57946919|NCT02644564|OTHER|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
58083151|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
58083152|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
58083153|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
58083154|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
58083155|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
58083156|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
58083157|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
57946920|NCT00734799|BEHAVIORAL|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
58411410|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
58411411|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
58083158|NCT03229902|BEHAVIORAL|mantra meditation|see study description
58411412|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
58083159|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
58083160|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
58083161|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
58083162|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
58083163|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
58083164|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
58083165|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
58083166|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
58083167|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
58083168|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
58083169|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
58083170|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
58083171|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
58083172|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
58411413|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
58083173|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
58083174|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
58411414|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
58083175|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
58083176|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
58083177|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
58300520|NCT03529500|DIAGNOSTIC_TEST|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: \< 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and \> 2.0 ml/min = high flow.
58300521|NCT03529500|DIAGNOSTIC_TEST|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
58411415|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
58411416|NCT03332719|BIOLOGICAL|Etanercept|
58083178|NCT01587807|DRUG|LPS|50 μg
58083179|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
58411417|NCT03332719|DRUG|Methotrexate|
58411418|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
58411419|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
57946921|NCT04782362|OTHER|Brace Treatment|Body image and quality of life of individuals who have used brace will be evaluated
57946922|NCT01969994|OTHER|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
57946923|NCT01969994|OTHER|(-)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.
58083180|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
58083181|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
58083182|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
58083183|NCT01713374|OTHER|no intervention|control visit
58411420|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
58411421|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
58083184|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
58083185|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
58083186|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
58083187|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
58083188|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
58411422|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
58411423|NCT02119039|DEVICE|Genteal HA eye drops|
58411424|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
58083189|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
58083190|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
58083191|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
58083192|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
58083193|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
58083194|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
58083195|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
58083196|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
58083197|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
58083198|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
58083199|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
58300522|NCT05430165|OTHER|Standard mHealth screening (triage) tool|"Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey."
58300523|NCT00194935|DRUG|Topotecan|
58300524|NCT01848106|DRUG|pegnivacogin/anivamersen|
58300525|NCT01848106|DRUG|Bivalirudin|
58411425|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
58300526|NCT03592888|DRUG|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
58411426|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
58411427|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
57946924|NCT01563770|DIETARY_SUPPLEMENT|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
57946925|NCT01563770|DIETARY_SUPPLEMENT|Placebo|3 placebo capsules, twice daily for four consecutive weeks
57946926|NCT01505348|OTHER|Overnight fast|Overnight fast from 21:00 h
57946927|NCT04629820|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
57946928|NCT03650816|OTHER|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
57946929|NCT03650816|OTHER|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
57946930|NCT02094456|PROCEDURE|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
57946931|NCT02094456|PROCEDURE|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
57946932|NCT04125550|DRUG|Propofol|2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
57946933|NCT04125550|DRUG|Sevoflurane|sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
57946934|NCT04540146|DIAGNOSTIC_TEST|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
57946935|NCT05597475|DIAGNOSTIC_TEST|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
58083200|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
58300527|NCT01492348|BEHAVIORAL|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
58083201|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
58083202|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
58083203|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
58083204|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
58083205|NCT02378870|DRUG|Placebo|
58083206|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
58083207|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
58083208|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
58083209|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
58083210|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
58083211|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
58083212|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
58083213|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
58083214|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
58083215|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
58083216|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
58083217|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
58083218|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
58083219|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
58083220|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
58083221|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
57946936|NCT06022731|DIAGNOSTIC_TEST|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
57946937|NCT04572984|PROCEDURE|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
58083222|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
58083223|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
58083224|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
58083225|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
58083226|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
58083227|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
58083228|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
58083229|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
58083230|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
58083231|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
58083232|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
57946938|NCT02897700|DRUG|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
57946939|NCT02897700|DRUG|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
57946940|NCT02897700|DRUG|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
57946941|NCT01361035|OTHER|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
57946942|NCT02121262|DRUG|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
57946943|NCT02121262|PROCEDURE|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
57946944|NCT04462562|DIAGNOSTIC_TEST|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
57946945|NCT01189188|PROCEDURE|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
57946946|NCT01189188|PROCEDURE|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
57946947|NCT04221932|DEVICE|CRRT KPI Reports|This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
57946948|NCT04001621|DRUG|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
57946949|NCT04113200|DIETARY_SUPPLEMENT|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
57946950|NCT04113200|DIETARY_SUPPLEMENT|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
57946951|NCT06020586|OTHER|hair lotion|ECOHAIR
57946952|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
57946953|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
57946954|NCT03331770|DRUG|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
57946955|NCT00320008|BEHAVIORAL|Diet|
57946956|NCT00320008|BEHAVIORAL|Exercise|
57946957|NCT00320008|BEHAVIORAL|Stop smoking|
57946958|NCT00320008|DRUG|Glucose lowering therapy|
57946959|NCT00320008|DRUG|Blood pressure lowering therapy|
57946960|NCT00320008|DRUG|Lipid lowering therapy|
57946961|NCT04342000|OTHER|Movement education workshop|"30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form."
57946962|NCT04342000|OTHER|Sham Education Workshop|"30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)"
57946963|NCT06037733|RADIATION|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
57946964|NCT01035775|PROCEDURE|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
58083233|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
58083234|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
58083235|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
58083236|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
58083237|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
58083238|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
58083239|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
58083240|NCT03290131|DRUG|Placebo|Placebo comparator
58083241|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
58083242|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
58083243|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
58083244|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
58083245|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
57946965|NCT01035775|PROCEDURE|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
57946966|NCT01361776|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 4 arms
57946967|NCT02690662|BEHAVIORAL|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
57946968|NCT03728075|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
57946969|NCT00365456|DRUG|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
57946970|NCT00365456|DRUG|Risedronate|Orally once weekly as one 35 mg tablet.
57946971|NCT02287389|DEVICE|balloon dilation|
57946972|NCT02287389|PROCEDURE|cryotherapy|
57946973|NCT02287389|PROCEDURE|spiculiform electrosurgery|
57946974|NCT02287389|DRUG|mitomycin C|
57946975|NCT02515110|RADIATION|External Beam Radiation Therapy|Undergo hypofractionated RNI
57946976|NCT02515110|OTHER|Questionnaire Administration|Ancillary studies
57946977|NCT02515110|OTHER|Laboratory Biomarker Analysis|Correlative studies
57946978|NCT01659242|DRUG|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
57946979|NCT01659242|DRUG|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
57946980|NCT02407262|DIETARY_SUPPLEMENT|Black seed oil|
57946981|NCT02407262|OTHER|Placebo|vegetable oil
57946982|NCT01756534|DEVICE|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
57946983|NCT06098612|DRUG|C11-SY08|a PET imaging agent
57946984|NCT06120400|DRUG|Whole Egg|Whole Large, Grade A Egg
57946985|NCT03653273|OTHER|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
57946986|NCT03653273|DRUG|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
57946987|NCT02301182|DEVICE|ADM X3-MoP Cup|
57946988|NCT02301182|DEVICE|CoC Cup|
57946989|NCT02754895|OTHER|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
57946990|NCT02754895|OTHER|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
57946991|NCT04411485|OTHER|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
57946992|NCT05502575|BEHAVIORAL|Self-monitoring and personalized stress management|Self-monitoring and personalized stress management education and materials.
57946993|NCT05502575|BEHAVIORAL|Self-monitoring and general stress management|Self-monitoring and general stress management education and materials.
57946994|NCT00356850|DRUG|Azithromycin|
58083246|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
58083247|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
58083248|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
58083249|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
58083250|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
58083251|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
58083252|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
58083253|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
58083254|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
58083255|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
58083256|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
58083257|NCT00138827|DRUG|Biotene (mouth care)|
58083258|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
58083259|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
58083260|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
58083261|NCT01947010|BIOLOGICAL|Prevenar 13|
57946995|NCT03121911|OTHER|Interval Training (IT)|"Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
58083262|NCT01947010|BIOLOGICAL|Pneumovax|
57946996|NCT03121911|OTHER|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
58083263|NCT01756586|DRUG|Dexamethasone|
58083264|NCT01756586|DRUG|Bupivacaine|Control
58083265|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
58083266|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
58083267|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
58083268|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
58083269|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
58083270|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
58083271|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
58300528|NCT01492348|BEHAVIORAL|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
58300529|NCT05447143|OTHER|Fatigue Severity Scale|Evaluation for severity of fatigue
58300530|NCT05447143|OTHER|Berg Balance Test|Evaluation of balance
58300531|NCT05447143|OTHER|Time up and go- 25 steps walking test|Evaluation for walking
58300532|NCT05447143|OTHER|Multiple Sclerosis Quality of Life|Evaluation of quality of life
58300533|NCT05447143|OTHER|Brief International Cognitive Assessment for MS (BICAMS)|Evaluation of cognitive functions
58300534|NCT05447143|OTHER|Beck Depression and Anxiety Scale|Evaluation of depression and anxiety
58300535|NCT03869372|DEVICE|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
58411428|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
57946997|NCT05953142|DRUG|Dobutamine|Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
57946998|NCT03959332|DRUG|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
57946999|NCT02441465|DRUG|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
57947000|NCT02441465|DRUG|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
57947001|NCT04945668|PROCEDURE|Modified technique for pericapsular nerve group block|with the patient in the supine position, ultrasound probe in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus. In this view, the ilio pubic eminence (IPE), the iliopsoas muscle and tendon will be observed. A spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip between the psoas tendon and the pubic ramus. Fluoroscopic image will be taken to confirm the needle tip position in the target site. Following negative aspiration, 15 ml dye will be injected in 5-mL increments while observing for adequate spread using fluoroscopy followed by 15ml local anesthetic
57947002|NCT01916876|OTHER|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice"
57947003|NCT05970198|RADIATION|Total Marrow irradiation，TMI|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min."
58083272|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
58083273|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
58083274|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
58083275|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
58083276|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
58083277|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
58083278|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
58083279|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
58083280|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
58083281|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
58083282|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
58083283|NCT00998166|DRUG|Cisplatin|4. Cisplatin 75mg/m2 IV over 60-120 minutes
58083284|NCT00998166|DRUG|Bevacizumab|5. Bevacizumab 15mg/kg IV over 90 minutes
58083285|NCT03022526|PROCEDURE|CSE|
58083286|NCT03022526|PROCEDURE|Epidural|
58083287|NCT03022526|DRUG|Bupivacaine / fentaNYL|
57947004|NCT05970198|PROCEDURE|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation;Porting method melphalan
58083288|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
58083289|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
58083290|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
58083291|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
58083292|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida \[UCF\]; Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
58083293|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
58083294|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
57947005|NCT06494696|DIAGNOSTIC_TEST|Ga-68 PSMA PET/MRI|The participant will undergo a Ga-68 PSMA PET/MRI scan, and then be followed up for 2 years to see if prostate cancer is diagnosed.
57947006|NCT02216864|PROCEDURE|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
57947007|NCT02745587|RADIATION|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
57947008|NCT04716452|DRUG|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
57947009|NCT03641963|DEVICE|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
57947010|NCT05515250|DEVICE|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
57947011|NCT00019708|DRUG|tanespimycin|Given IV
57947012|NCT02340585|DEVICE|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
58083295|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
58083296|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
58083297|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
58083298|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
58083299|NCT02267343|DRUG|ONO-4538|
58083300|NCT02267343|DRUG|Placebo|
58083301|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
58083302|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
58083303|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
58083304|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
58083305|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
58083306|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
58083307|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
58083308|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
58083309|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
58300536|NCT04577105|DIAGNOSTIC_TEST|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
58300537|NCT04938076|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
58083310|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
58083311|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
58083312|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
58083313|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
58083314|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
58083315|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
58083316|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
58300538|NCT04938076|DEVICE|sham control|sham control
58300539|NCT02745652|DEVICE|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
58300540|NCT02745652|DEVICE|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
58083317|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
58083318|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
58083319|NCT02046655|DRUG|Corifollitropin alfa|
58083320|NCT02046655|DRUG|rFSH|
58083321|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
58083322|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
58083323|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
58083324|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
58083325|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
58083326|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
58083327|NCT02974270|DRUG|Leuprolide|
58083328|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
58083329|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
58083330|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
58083331|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
58083332|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
58083333|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
58083334|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
58083335|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
58083336|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
58083337|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
58083338|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
58300541|NCT02534168|DEVICE|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
58083339|NCT03651440|OTHER|PNF|PNF
58083340|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
58083341|NCT03651440|OTHER|Physical Therapy|Physical Therapy
58083342|NCT03651440|OTHER|Control|Control group
58083343|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
58083344|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
58083345|NCT05538039|OTHER|Distract with play dough|Distract with play dough
58083346|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
58300542|NCT01634646|DIETARY_SUPPLEMENT|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
58083347|NCT05538039|OTHER|Control group|Routine nursing care
58083348|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
58083349|NCT00785252|DEVICE|standard central line|placement of a central line
58083350|NCT01458535|DRUG|ABT-450|tablets
58083351|NCT01458535|DRUG|ABT-267|tablets
58083352|NCT01458535|DRUG|ribavirin|tablets
58083353|NCT01458535|DRUG|ritonavir|capsules
58083354|NCT00552422|DRUG|domperidone|10mg orally four times per day
58083355|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
58083356|NCT03291249|OTHER|placebo|Placebo oral solution
58083357|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
58083358|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
58083359|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
58083360|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
58083361|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
58083362|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
58083363|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
58083364|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
58083365|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
58083366|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
58083367|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
58083368|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
58083369|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
58083370|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
58083371|NCT06566729|OTHER|Peripheral blood sample collection|In this study, peripheral blood samples would be collected before adjuvant chemotherapy, after adjuvant chemotherapy and every 3 months thereafter until 2 years after surgery.
58300543|NCT03070795|PROCEDURE|early feeding|start oral sips four hours after cesarean section
58083372|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
58083373|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
58083374|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
58300544|NCT03070795|PROCEDURE|delayed feeding|start oral feeding on post operation day 1 (\>12hours) after surgery
58083375|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
58300545|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
58083376|NCT03384576|OTHER|No music|No music played in emergency waiting room
58083377|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
58083378|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
58083379|NCT01890876|OTHER|Walking uphill|ascending about 500 m
58083380|NCT01890876|OTHER|Walking downhill|descending about 500 m
58083381|NCT04683874|DEVICE|3D printed tray|3D printed tray
58083382|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
58083383|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
58083384|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
58083385|NCT05925036|OTHER|Placebo|Controls
58083386|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
58300546|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
58300547|NCT00904007|OTHER|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
58083387|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
58083388|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
58083389|NCT00014300|DRUG|glufosfamide|
58083390|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
58083391|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
58083392|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
58083393|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
58083394|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
58083395|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
57947013|NCT06540781|PROCEDURE|wet cupping therapy|"The cupping (WCT) procedure consists of five phases:~Primary suction: Using a manual suction pump, air was drawn from glass cups that were positioned on the chosen locations. The skin and subcutaneous tissue swelled as a result of the cups' five minutes of skin contact.~Area disinfection: After disinfecting the cupped areas with povidone-iodine, they were wiped with sterile gauze.~Scarification: Using a sterile number 11 surgical blade, superficial incisions measuring 20-30 gauge in length and 1-2 mm in depth were made on the skin.~Bloodletting and secondary suction: Once again applied to the scarified areas, the previously removed cups created suction using the manual pump which was previously mentioned. In order to fill the cups, blood was drawn from the skin's and subcutaneous tissue's capillaries.~Removing and dressing: After 10 minutes, the cups filled with blood were removed. The application areas were wiped with sterile gauze, and dressings were applied."
58083396|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
58083397|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
58083398|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
57947014|NCT05654597|OTHER|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
57947015|NCT05654597|OTHER|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
57947016|NCT05896254|DRUG|MAR001|Subcutaneous injection
57947017|NCT05896254|DRUG|Placebo|Subcutaneous injection
57947018|NCT04648605|OTHER|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
57947019|NCT02088112|DRUG|Gefitinib|Gefitinib QD
57947020|NCT02088112|DRUG|MEDI4736|MEDI4736 IV Q2W
57947021|NCT05241392|BIOLOGICAL|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
57947022|NCT02988453|OTHER|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
57947023|NCT01432873|DRUG|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
57947024|NCT01432873|DRUG|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
57947025|NCT06096402|PROCEDURE|no intervention, but surgical practice as usual is continued. Its a pragmatic study|no intervention
57947026|NCT01545479|DRUG|captopril 25mg|renal blood oxygenation after captopril
57947027|NCT01870427|DRUG|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
57947028|NCT02068742|OTHER|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
57947029|NCT02866279|DEVICE|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
57947030|NCT02113436|DRUG|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
58083399|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
58083400|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
58083401|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
58083402|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
58083403|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
58083404|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
58083405|NCT01042379|DRUG|Ganetespib|Arm is closed.
58083406|NCT01042379|DRUG|ABT-888|Arm is closed.
58083407|NCT01042379|DRUG|Neratinib|Arm is closed.
58083408|NCT01042379|DRUG|PLX3397|Arm is closed.
58083409|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
58083410|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
58083411|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
58083412|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
58083413|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
58083414|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
58083415|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
58083416|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
58083417|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
58083418|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
58083419|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
58083420|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
58083421|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
57947031|NCT02113436|DRUG|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
58300548|NCT00678418|DRUG|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
58300549|NCT00678418|DRUG|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
58300550|NCT00778596|DRUG|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
58300551|NCT00778596|DRUG|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
58411429|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
58411430|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
57947032|NCT04967300|PROCEDURE|Dental treatment|bilateral restorative treatment on the mandibular primary first molars
57947033|NCT02877368|OTHER|Computed tomography|
57947034|NCT00428909|DRUG|Imatinib/Acetaminophen|
57947035|NCT04231149|DEVICE|Test product 2|Test catheter 2
57947036|NCT04231149|DEVICE|Test product 3|Test catheter 3
57947037|NCT04231149|DEVICE|Comparator|SpeediCath Flex
57947038|NCT05275374|DRUG|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
57947039|NCT05275374|DRUG|Trametinib|Trametinib will be administered 2mg orally once a day.
57947040|NCT00562952|DRUG|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
57947041|NCT00562952|DRUG|placebo|no intervention
57947042|NCT04944511|DRUG|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
57947043|NCT01012375|DRUG|AZD1446|10 mg capsule, oral dose
57947044|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
57947045|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
58083422|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
58083423|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
58083424|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
58083425|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
58083426|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
58083427|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
58083428|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
58083429|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
58083430|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
58083431|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
58083432|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
58083433|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
58083434|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
58083435|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
58083436|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
58083437|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
58083438|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
58083439|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
58083440|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
58083441|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
58083442|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
58083443|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
58083444|NCT02206984|DRUG|Tamoxifen|
58083445|NCT02206984|DRUG|Anastrozole|
58083446|NCT02206984|DRUG|Fulvestrant|
58083447|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
58083448|NCT00066417|DRUG|cyclophosphamide|
58083449|NCT00066417|DRUG|cyclosporine|
58083450|NCT00066417|DRUG|fludarabine phosphate|
57947046|NCT01012375|DRUG|Placebo|Matching capsule, oral dose
58083451|NCT00066417|DRUG|methylprednisolone|
58083452|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
58083453|NCT00066417|DRUG|thiotepa|
58083454|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
58083455|NCT00066417|PROCEDURE|biological therapy|
58083456|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
58083457|NCT00066417|PROCEDURE|bone marrow transplantation|
58083458|NCT00066417|PROCEDURE|chemotherapy|
58083459|NCT00066417|PROCEDURE|leukocyte therapy|
58083460|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
58083461|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
58083462|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
58083463|NCT00066417|PROCEDURE|radiation therapy|
58083464|NCT01335620|DRUG|Raltegravir|400 mg twice daily
58083465|NCT01335620|DRUG|Tenofovir|245 mg once daily
58083466|NCT01335620|DRUG|Emtricitabine|200mg once daily
58083467|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
58083468|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
58083469|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
58083470|NCT03223506|DRUG|Paracetamol|
58083471|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
58083472|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
58411431|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
58411432|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
58083473|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
58083474|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
58083475|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
58083476|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
58083477|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
58083478|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
58083479|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
58083480|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
58083481|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
58083482|NCT03563729|DRUG|Trametinib|In combination with trametinib
58083483|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
58083484|NCT03204006|DRUG|sterile saline|normal saline preinduction
58411433|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
58411434|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
58083485|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
58300552|NCT00580957|DRUG|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
58411435|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
58411436|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
57947047|NCT05120895|DRUG|Mevalotin|Oral tablets (starting dose 5 mg)
57947048|NCT04449055|DEVICE|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
58083486|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
58083487|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
58083488|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
58083489|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
58083490|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
58083491|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
58083492|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
58300553|NCT00580957|DRUG|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
58300554|NCT01954849|DIETARY_SUPPLEMENT|Probiotic formulation|
58300555|NCT02379013|PROCEDURE|Volunteer with MRI|functional MRI
58300556|NCT01943487|DRUG|EC905|Oral
58083493|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
58083494|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
58083495|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
58083496|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
58083497|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
58083498|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
57947049|NCT02242578|DEVICE|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
57947050|NCT02242578|DEVICE|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
58083499|NCT02696837|DEVICE|ETT|
58083500|NCT02696837|DEVICE|Proseal LMA|
58083501|NCT02696837|DRUG|Rocuronium|
58083502|NCT02696837|OTHER|No Muscle Relaxant|
58083503|NCT02696837|DRUG|Rocuronium|
58083504|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
57947051|NCT04096209|DEVICE|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
58300557|NCT01943487|DRUG|verapamil|Oral
58300558|NCT05673356|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
58300559|NCT03308240|BEHAVIORAL|Magic Therapy|As described in the arm description
58300560|NCT02672098|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
57947052|NCT01996475|DRUG|Escitalopram Oxalate Tablets|
58083505|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
57947053|NCT02385981|DEVICE|Stivax|
57947054|NCT05775640|BEHAVIORAL|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
58083506|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
58083507|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
58300561|NCT02672098|DRUG|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
58300562|NCT04369833|DEVICE|continuous glucose monitoring system|wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
58300563|NCT04661293|BIOLOGICAL|Autologous Muscle Derived Cells (AMDCs)|
58083508|NCT02058264|DRUG|BBI-4000|
58083509|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
58083510|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
58083511|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
58083512|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
58083513|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
58083514|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
58083515|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
58083516|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
58083517|NCT04342130|DRUG|Morphine|30 mg oral tablet
58083518|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
58083519|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
58083520|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
58083521|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
58411437|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
58083522|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
58411438|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
58411439|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
57732485|NCT04942106|OTHER|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
58083523|NCT00536991|DRUG|Ketoconazole|Given PO
58083524|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
58083525|NCT00536991|OTHER|Pharmacological Study|Correlative studies
58083526|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
58300564|NCT05222555|DRUG|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
58300565|NCT05222555|DRUG|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
58300566|NCT01781962|OTHER|No Treatment|No Treatment was given in this study.
58300567|NCT05563337|PROCEDURE|Arteriography and renal denervation|Diagnostic renal Arteriography - Randomization - Renal denervation
58300568|NCT05563337|PROCEDURE|Arteriography without renal denervation|Diagnostic renal Arteriography - Randomization
58083527|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
58083528|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
58083529|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
58083530|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
58300569|NCT02749344|OTHER|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
58300570|NCT03148262|DEVICE|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
58300571|NCT03148262|DEVICE|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
58300572|NCT05175781|DRUG|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
58300573|NCT05175781|DRUG|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
58300574|NCT05175781|DRUG|Placebo|Normal saline
58300575|NCT01508247|BIOLOGICAL|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
58300576|NCT01508247|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
58300577|NCT01414998|BEHAVIORAL|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
58300578|NCT01414998|BEHAVIORAL|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
58300579|NCT06076031|BEHAVIORAL|Streaming Media|The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
58300580|NCT05232552|DRUG|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
58300581|NCT05232552|DRUG|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
58300582|NCT05232552|RADIATION|concurrent chemoradiation|definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
58083531|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
58083532|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
58083533|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
58083534|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
58083535|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
58083536|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
58083537|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
58083538|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
58083539|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
58083540|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
58083541|NCT00206037|DEVICE|COLLOSS E|
58083542|NCT00206037|DEVICE|TomoFix Plate|
58083543|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
58300583|NCT01232790|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
58300584|NCT01232790|DRUG|Placebo|Placebo
58300585|NCT05481801|BIOLOGICAL|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
58300586|NCT05481801|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
58300587|NCT05481801|BIOLOGICAL|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
58300588|NCT05481801|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
58411440|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
58411441|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
58300589|NCT05763927|DRUG|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
58300590|NCT05763927|DRUG|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
58411442|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
58411443|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
58411444|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
58411445|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
58411446|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
58083544|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
58083545|NCT03309072|DEVICE|tDCS|active tDCS
58083546|NCT03309072|DEVICE|sham tDCS|sham tDCS
58083547|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
58083548|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
58083549|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
58083550|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
58083551|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
58083552|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
58300591|NCT05763927|RADIATION|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
58300592|NCT05763927|PROCEDURE|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
58083553|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
58083554|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
58083555|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
58300593|NCT00183651|BEHAVIORAL|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
58300594|NCT00183651|BEHAVIORAL|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
58300595|NCT00183651|BEHAVIORAL|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
58411447|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
57947055|NCT03529721|OTHER|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
57947056|NCT03529721|OTHER|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
58083556|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
58083557|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
58083558|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
58083559|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
58083560|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
57947057|NCT02014350|DEVICE|DePuy Delta Xtend Reverse TSA|
58083561|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
58083562|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
58083563|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
58083564|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
58083565|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
58300596|NCT04687852|OTHER|Conservative and Non-conservative treatments|This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
58300597|NCT04521556|PROCEDURE|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
58300598|NCT04521556|PROCEDURE|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
58300599|NCT04521556|PROCEDURE|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
58300600|NCT04521556|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
58411448|NCT02851407|DRUG|Defibrotide|
58411449|NCT02851407|OTHER|Best Supportive Care|
58411450|NCT04218357|DRUG|Probenecid|safety
58411451|NCT04218357|DRUG|Matching placebo|Placebo
58411452|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
58411453|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
58411454|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
58083566|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
58300601|NCT00417664|DRUG|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
57947058|NCT02534688|DRUG|LNG-IUS|
58083567|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
58083568|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
58083569|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
58083570|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
58083571|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
58083572|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
58083573|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
58083574|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
58083575|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
58083576|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
58083577|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
58083578|NCT02116309|DRUG|Rectal Indomethacin|
58083579|NCT02116309|DRUG|Epinephrine|
58083580|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
58083581|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
58300602|NCT00417664|DRUG|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
58300603|NCT00417664|DRUG|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
58300604|NCT01339039|DRUG|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
58300605|NCT01339039|DRUG|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
57947059|NCT02534688|DRUG|DMPA|
58083582|NCT02325206|DRUG|dapagliflozin|one administration in the morning
58083583|NCT02325206|DRUG|Placebo|one administration in the morning
58300606|NCT01339039|DRUG|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
58083584|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
58083585|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
58083586|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
58083587|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
58083588|NCT03673111|DRUG|Y14|Gut hormone analogue
58083589|NCT03673111|DRUG|Placebo|0.9% saline
58083590|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
58083591|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
58083592|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
58083593|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
58083594|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
58083595|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
58300607|NCT01339039|DRUG|Plerixafor|Daily administration for 5-9 days prior to surgery
58300608|NCT01339039|PROCEDURE|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
57947060|NCT04103684|DRUG|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
57947061|NCT04103684|DRUG|Dexamethasone|0.6mg per kg perday for 5 days
57947062|NCT00282334|DEVICE|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
58083596|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
58083597|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
58083598|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
58411455|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
58411456|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
57732486|NCT04942106|OTHER|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
58083599|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
58083600|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
58083601|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
58083602|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
58083603|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
58083604|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
58083605|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
58083606|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
58083607|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
58083608|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
58083609|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
58083610|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
58083611|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
58083612|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
58083613|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
58083614|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
58083615|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
58083616|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
58083617|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
58083618|NCT02332044|DRUG|Erdos|capsule, 300mg
58083619|NCT02332044|DRUG|Talion|tablet, 10mg
58083620|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
58083621|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
58300609|NCT00250822|DRUG|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16"
57732487|NCT00093769|DRUG|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
57732488|NCT06322472|OTHER|The Turkish Early Language Development Test (TEDIL)|The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
57732489|NCT06322472|OTHER|The Family Literacy Scale|The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.
58300610|NCT00667563|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
58300611|NCT00667563|GENETIC|DNA analysis|Weeks 0, 2, 10, 26, and 52.
58411457|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
57947063|NCT04503499|OTHER|Manuel Therapy|"The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times."
57947064|NCT01982474|BIOLOGICAL|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
57947065|NCT01982474|OTHER|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
58083622|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
58083623|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
58083624|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
58083625|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
58083626|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
58083627|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
58083628|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
58300612|NCT00667563|GENETIC|polymerase chain reaction|Screening, week 36, and week 52.
58300613|NCT00667563|OTHER|cytology specimen collection procedure|Screening, week 36, and week 52.
58300614|NCT00667563|PROCEDURE|colposcopic biopsy|Screening, week 36, and week 52.
58300615|NCT00405171|DRUG|Nevirapine|
58300616|NCT03025633|OTHER|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
58083629|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
58411458|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
58411459|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
58411460|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
58411461|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
58411462|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
58411463|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
58411464|NCT05869422|DIETARY_SUPPLEMENT|Iron|90 ± 5 days of daily oral iron supplementation.
58411465|NCT05869422|OTHER|Placebo|90 ± 5 days of daily oral placebo intake.
58411466|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
57947066|NCT02302976|DRUG|cocaine hydrochloride|
58083630|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
58083631|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
58083632|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
58083633|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
58083634|NCT01177865|OTHER|informational intervention|
58083635|NCT01177865|OTHER|questionnaire administration|
58083636|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
58083637|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
58083638|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
58083639|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
57947067|NCT02302976|DRUG|exenatide|
57947068|NCT02302976|DRUG|placebo|
58083640|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
58083641|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
58083642|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
58083643|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
58083644|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
58083645|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
58083646|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
58411467|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
58411468|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
58411469|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
58411470|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
58411471|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
58411472|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
58411473|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
58411474|NCT03294096|OTHER|Routine care|Routine post-op care
58411475|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
58411476|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
58083647|NCT01725204|DRUG|Dasatinib + PegIFN|
58411477|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
58411478|NCT00977938|DRUG|Placebo & Aspirin|
58411479|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
58411480|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
58411481|NCT04023357|OTHER|PEEK|New polyetheretherketones material
58083648|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
58083649|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
57947069|NCT03156920|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
57947070|NCT03156920|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58083650|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
58083651|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
58083652|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
58083653|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
58083654|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
58083655|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
58083656|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
58083657|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
58083658|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
58083659|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
58083660|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
58083661|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
57947071|NCT04854434|DRUG|Selinexor|Participants will receive selinexor oral tablets.
57947072|NCT04854434|DRUG|Pembrolizumab|Participants will receive pembrolizumab intravenously.
58083662|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
58083663|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
58083664|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
58411482|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
58411483|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
58411484|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
57947073|NCT04854434|DRUG|Trifluridine|Participants will receive trifluridine oral tablets as SOC.
57947074|NCT04854434|DRUG|Tipiracil|Participants will receive tipiracil oral tablets as SOC.
57947075|NCT01417195|DRUG|Bravelle|
57947076|NCT01417195|DRUG|Menopur|
57947077|NCT00871520|OTHER|no specific interventions|There are no specific interventions in this observational study
57947078|NCT00545727|BEHAVIORAL|Diet|Whole-foods, low glycemic index diet
57947079|NCT00545727|OTHER|Standard diet|Standard diet meeting American Diabetes Association guidelines
58411485|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
58411486|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
58411487|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
58411488|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
58411489|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
58411490|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
58411491|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
58411492|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
58411493|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
58411494|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
58411495|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
58411496|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
58411497|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
58411498|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
58411499|NCT00188851|DRUG|therapeutic management strategy|
58411500|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
58411501|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
58411502|NCT02109523|BEHAVIORAL|Routine discharge counseling|
58411503|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
58411504|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
58411505|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
58411506|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
58411507|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
58411508|NCT00070252|DRUG|Capecitabine|Given PO
58411509|NCT00070252|DRUG|Docetaxel|Given IV
58411510|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
58411511|NCT00070252|OTHER|Pharmacological Study|Correlative studies
58411512|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
58411513|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
58411514|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
57947080|NCT00198380|DRUG|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
58411515|NCT03783741|BEHAVIORAL|Questionnaire|Interview
58411516|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
58411517|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
58411518|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
58411519|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
58411520|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
58411521|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
58411522|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
57947081|NCT03193697|DEVICE|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
57947082|NCT03193697|DEVICE|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
58411523|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
58411524|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
58411525|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
58411526|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
58411527|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
58411528|NCT04688541|DEVICE|Foley catheter|Foley catheter
58411529|NCT02093988|DRUG|Topical TXA|
58411530|NCT02093988|DRUG|Intravenous TXA|
58411531|NCT02549352|DRUG|LEO43204 gel|
58411532|NCT02549352|DRUG|Vehicle gel|
58411533|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
58411534|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
57947083|NCT06398548|OTHER|Control Group|Participants continue with their lifestyle as usual, with no modification to lifestyle, or exercise habits.
58411535|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
58411536|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
57947084|NCT06398548|OTHER|Moderate Intensity Continuous Training|This group cycles at 70% of the resistance associated with their first lactate threshold.
57947085|NCT06398548|OTHER|Heavy Intensity Continuous Training|This group cycles at 10% of the difference between the resistance associated with their lactate threshold, and maximal achieved watts, added to the resistance associated with their lactate threshold.
57947086|NCT01922687|DRUG|amlodipine plus atorvastatin (Caduet)|
57947087|NCT01922687|DRUG|amlodipine (Norvasc)|
57947088|NCT01424111|DRUG|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
57947089|NCT01424111|OTHER|Healthy Control|No Treatment
57947090|NCT05521230|DRUG|Placebo Mouthwash|Application of mouthwashes
57947091|NCT05521230|DRUG|Cymenol mouthwash|Application of mouthwashes
57947092|NCT01251848|DRUG|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
57947093|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
57947094|NCT01251848|DRUG|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
57947095|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
57947096|NCT05216679|DEVICE|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
57947097|NCT05216679|DEVICE|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
57947098|NCT03704142|DEVICE|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
57947099|NCT03704142|DEVICE|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
57947100|NCT03704142|DEVICE|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
57947101|NCT03704142|DEVICE|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
57947102|NCT05067322|DEVICE|Minecraft|A game played within the videogame Minecraft
57947103|NCT02004496|DEVICE|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
57947104|NCT01104038|BEHAVIORAL|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
57947105|NCT01104038|BEHAVIORAL|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
57947106|NCT01104038|BEHAVIORAL|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
58411537|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
58411538|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
58411539|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
57732490|NCT06322472|OTHER|The Early Childhood Phonological Sensitivity Scale (PASECP)|The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).
57947107|NCT03642756|DEVICE|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
57947108|NCT01131533|PROCEDURE|Vitrectomy|vitrectomy following intravitreal erythropoietin
57947109|NCT05505162|DRUG|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
57947110|NCT05505162|DRUG|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
58411540|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
58411541|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
58300617|NCT05456204|DRUG|Pharmacological cardioversion with Refralon|"1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
58300618|NCT02060500|PROCEDURE|Cardiaplication|
58300619|NCT01611623|DRUG|SNX-5422|Tablets dose every other day; dose escalation based on safety
58300620|NCT06172231|PROCEDURE|Instrument Assisted Soft tissue mobilization|The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific. Frequency: 4 sessions in 4-week period. Duration: 15_35 min each session.
58300621|NCT06172231|PROCEDURE|Conventional therapy|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15_ 35 min each session.
58300622|NCT00454961|DRUG|artemether-lumefantrine|
58300623|NCT01438138|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
58300624|NCT00072410|BIOLOGICAL|90Y-hu3S193|Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
58300625|NCT00072410|BIOLOGICAL|111In-hu3S193|Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
58300626|NCT01967680|PROCEDURE|Non-sedation for intubated, mechanically ventilated patients|
58300627|NCT01967680|PROCEDURE|Controlgroup, sedation with daily wake-up trial|
58300628|NCT02355717|OTHER|Observational Study|
58300629|NCT04348708|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
58300630|NCT03994978|PROCEDURE|elective sigmoidectomy|elective sigmoidectomy
58300631|NCT03615313|BIOLOGICAL|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
58300632|NCT02697643|BEHAVIORAL|BHCDS-based recommendations|
58300633|NCT02697643|BEHAVIORAL|Non-tailored recommendations|
58411542|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
58300634|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
58300635|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
57732491|NCT06322472|OTHER|The Early Literacy Home Environment Scale (ELHES)|The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)
58300636|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
58300637|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
57732492|NCT06322472|OTHER|Demographic Questionaries|The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
57732493|NCT01413451|DRUG|Amatuximab (MORab-009)|
57732494|NCT05797285|DEVICE|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
58300638|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
58300639|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
57732495|NCT04980053|OTHER|massage|Intervention group Control group
58411543|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
58411544|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
57732496|NCT03722160|DEVICE|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
57732497|NCT04471818|DRUG|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
57732498|NCT04471818|OTHER|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
57732499|NCT01793064|BEHAVIORAL|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
58083665|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
58083666|NCT01738282|DRUG|Baclofen|
58300640|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
58300641|NCT05721664|OTHER|Trianing program for nurse in how to provide evidence based practices for mechanically Ventilated Patients|"Short Name: (EBNPTP) for Caring of Mechanically Ventilated Patients in terms of standardized care.~Duration: Two weeks A number of Contact Hours: 30 hrs. associated arm (interventional arm): for study group of ICU Nurses working at National Hepatology and Tropical Medicine Research Institute (NHTMRI)"
58300642|NCT03949595|OTHER|Data collection|
58411545|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
58411546|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
58411547|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
58411548|NCT02282371|DRUG|Cetuximab|
57732500|NCT01793064|BEHAVIORAL|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
57732501|NCT00974857|DEVICE|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
58300643|NCT05222165|DRUG|Infigratinib|Hard gelatin capsules for oral use
58300644|NCT04530045|OTHER|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
58300645|NCT04488445|BEHAVIORAL|Strength training|3 sets of 3 to 5 repetitions with 4 minutes of rest between sets. 90% load of 1 maximum repetition of a resistance exercise
58411549|NCT02282371|DRUG|BYL719|
58411550|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
57947111|NCT06490458|COMBINATION_PRODUCT|Balance Training|Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.
57947112|NCT03189823|DEVICE|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
58300646|NCT04488445|BEHAVIORAL|Stretch and balance training|3 sets of 3 exercises of stretching and balance of one minute each. One minute of resting time between sets.
58300647|NCT03794492|DRUG|Mycophenolate mofetil 500mg Tab. or 250mg Cap.|- Orally, up to 1g BID(total 2g daily)
58300648|NCT03794492|DRUG|Tacrolimus|- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
58411551|NCT00051467|GENETIC|TNFerade|
58411552|NCT00168077|DRUG|Prothrombin Complex Concentrate|
58411553|NCT02295007|BEHAVIORAL|text message|
58411554|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
58411555|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
58411556|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
57732502|NCT00974857|OTHER|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
57947113|NCT03115736|DRUG|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
57947114|NCT00480818|DRUG|SAM-531|
57947115|NCT02793440|OTHER|cortivazol treatment|
57947116|NCT02793440|OTHER|lumbar traction|
58083667|NCT01738282|DRUG|Placebo (for baclofen)|
58083668|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
58300649|NCT03794492|DRUG|Methylprednisolone/prednisolone|- Methyprednisolone 500mg / Prednisolone 5mg
58300650|NCT03794492|DRUG|Basiliximab|- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
58411557|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
58083669|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
58083670|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
58083671|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
58083672|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
58083673|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
58083674|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
58083675|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
58300651|NCT01241422|DRUG|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
58411558|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
58411559|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
58411560|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
58411561|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
58411562|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
58083676|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
58083677|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
58300652|NCT01241422|DRUG|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
57947117|NCT06503575|OTHER|Assesment|All assessments will be made
58083678|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
58083679|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
58083680|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
58300653|NCT01241422|DRUG|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
58300654|NCT01716806|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
58300655|NCT01716806|DRUG|bendamustine|70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
58083681|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
58083682|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
57947118|NCT04383873|DEVICE|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
58083683|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
58083684|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
58083685|NCT01387958|DRUG|LCQ908|
58083686|NCT01387958|DRUG|Placebo|
58300656|NCT01716806|DRUG|dacarbazine|375 mg/m\^2 every 3 weeks by IV infusion
58300657|NCT01716806|DRUG|nivolumab|3 mg/kg every 3 weeks by IV infusion
58300658|NCT00197093|DRUG|SB773812|
58411563|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
58411564|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
58411565|NCT00393302|PROCEDURE|HIV screening in pregnancy|
58411566|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
58411567|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
58411568|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
58411569|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
58411570|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
58411571|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
58300659|NCT06237933|BEHAVIORAL|Enhanced intervention via social networking site (SNS)|We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
58300660|NCT06237933|BEHAVIORAL|Standard intervention|In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
58300661|NCT02461537|DRUG|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
58300662|NCT02461537|DRUG|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
58300663|NCT05162443|DRUG|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
57732503|NCT05585424|OTHER|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
58300664|NCT03645642|DRUG|Midodrine|Midodrine 5 mg thrice daily
58300665|NCT03645642|BIOLOGICAL|Albumin|Albumin 20g/l
58300666|NCT03645642|DRUG|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
58083687|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
57732504|NCT00550225|DRUG|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
57732505|NCT00550225|DRUG|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
58300667|NCT00532545|DRUG|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
58300668|NCT01816321|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
58300669|NCT01816321|DRUG|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
57732506|NCT02014857|PROCEDURE|Gingival Crevicular Fluid Sampling|
58300670|NCT01816321|DRUG|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
57732507|NCT04618354|OTHER|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
57732508|NCT06046573|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
57732509|NCT06046573|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
57732510|NCT06046573|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
57732511|NCT06046573|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
58083688|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
58083689|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
58083690|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
58083691|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
58083692|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
58300671|NCT01816321|DRUG|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
58300672|NCT03786900|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727|
58083693|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
58300673|NCT02404051|DRUG|Everolimus|10 mg daily tablets
58300674|NCT02404051|DRUG|Exemestane|25 mg daily tablets
58300675|NCT02404051|DRUG|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
58300676|NCT02378389|DRUG|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
58300677|NCT06459310|DRUG|Metformin Hydrochloride tablet|Extended release oral tablets, 1000 mg/day, single dose
58300678|NCT06459310|DRUG|Placebo|Oral tablets, 1000 mg/day, single dose
58300679|NCT01462630|DRUG|pazopanib hydrochloride|Given PO
58300680|NCT01462630|OTHER|laboratory biomarker analysis|Correlative studies
58083694|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
58083695|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
58083696|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
58411572|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
58411573|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
58411574|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
58411575|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
58411576|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
57732512|NCT03537924|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
57732513|NCT03537924|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
57732514|NCT04287049|DRUG|Azithromycin|Azithromycin 250 mg PO daily
57732515|NCT01634698|DIETARY_SUPPLEMENT|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
57947119|NCT04383873|OTHER|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
58300681|NCT01462630|PROCEDURE|positron emission tomography|Correlative studies
58300682|NCT01462630|PROCEDURE|computed tomography|Correlative studies
58300683|NCT01462630|RADIATION|fludeoxyglucose F 18|Correlative studies
58300684|NCT00261755|PROCEDURE|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
58300685|NCT00261755|OTHER|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
58300686|NCT00261755|OTHER|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
58300687|NCT06044103|DRUG|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
58300688|NCT02898857|OTHER|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
58411577|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
58411578|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
58083697|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
58083698|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
58083699|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
58411579|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
58411580|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
58411581|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
58083700|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
58083701|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
58083702|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
58083703|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
58083704|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
58411582|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
58411583|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
58411584|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
58411585|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
58083705|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
58083706|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
58083707|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
58083708|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
58300689|NCT02306369|BEHAVIORAL|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
58300690|NCT01439035|DEVICE|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
58300691|NCT01960101|OTHER|LactoXeros|
58300692|NCT01960101|DEVICE|Aequasyal|
58300693|NCT04581434|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
58083709|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58083710|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
58083711|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
58083712|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
58083713|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
58083714|NCT01153971|DRUG|rituximab|1
58083715|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
58083716|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
58083717|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
58083718|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
58300694|NCT04581434|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
58300695|NCT04581434|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation"
58300696|NCT05751798|DRUG|OSE-279 100mg|Human IgG4 mAb against PD-1
58300697|NCT05751798|DRUG|OSE-279 300mg|Human IgG4 mAb against PD-1
58300698|NCT05751798|DRUG|OSE-279 500mg|Human IgG4 mAb against PD-1
58411586|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
58411587|NCT01663428|OTHER|Sup-ER Splint|
58411588|NCT01663428|OTHER|Currently accepted treatment|
58411589|NCT00006799|DRUG|megestrol acetate|
58411590|NCT00006799|PROCEDURE|quality-of-life assessment|
58411591|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
58411592|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
58411593|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
58411594|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
58411595|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
58300699|NCT03865030|DEVICE|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
57732516|NCT04433767|DRUG|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
57732517|NCT00706121|DRUG|Vitamin E|400 IU daily by mouth for 7 - 12 years
58083719|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
58083720|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
58083721|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
58083722|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
58083723|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
58083724|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
58083725|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
58300700|NCT05817162|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
58300701|NCT05817162|PROCEDURE|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
58300702|NCT05817162|DRUG|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
58300703|NCT05817162|DRUG|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
58300704|NCT03561896|RADIATION|IGRT|Image-Guided Radiation Therapy
58300705|NCT03561896|RADIATION|SRS|stereotactic radiation therapy
58300706|NCT04881344|PROCEDURE|laser hemorrhoidoplasty|"* Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able."
57732518|NCT00706121|DRUG|Selenium|200 mcg daily for 7 - 12 years
57732519|NCT00706121|DRUG|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
57732520|NCT00706121|DRUG|selenium placebo|1 pill by mouth daily for 7 - 12 years
58083726|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
58083727|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
58300707|NCT04881344|PROCEDURE|mucopexy|"* Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention)."
57732521|NCT03727191|OTHER|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
57947120|NCT04383873|OTHER|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
58083728|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
58083729|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
57732522|NCT03727191|OTHER|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
58083730|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
58083731|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
58083732|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
58083733|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
58083734|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
58300708|NCT02548377|PROCEDURE|Remote ischemic preconditioning|
58300709|NCT02548377|PROCEDURE|Sham|
58300710|NCT00457730|DRUG|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
57732523|NCT05700682|DEVICE|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
57947121|NCT01352832|OTHER|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
57947122|NCT01352832|OTHER|Usual Care|Usual Care
58083735|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
58083736|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
58300711|NCT00457730|DRUG|Placebo|Subjects are randomized to either Duloxetine or Placebo
58300712|NCT05192265|DRUG|Antimalarials, pyronaridine-artesunate|The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.
58300713|NCT05192265|DRUG|Antimalarials, Artemether + Lumefantrine|Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
58083737|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
58083738|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
58083739|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
58083740|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
58083741|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
58083742|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
58083743|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
58083744|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
57732524|NCT03400540|DIAGNOSTIC_TEST|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
57947123|NCT05540002|DEVICE|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
58083745|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
58083746|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
58083747|NCT02863874|DEVICE|VicrylPlus®|Suture
58083748|NCT02863874|DEVICE|Vicryl®|Suture
58083749|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
58083750|NCT00467051|DRUG|Carboplatin|Given IV
58083751|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
58083752|NCT00467051|DRUG|Ifosfamide|Given IV
58083753|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58083754|NCT00467051|DRUG|Paclitaxel|Given IV
58083755|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
58083756|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
57947124|NCT05540002|DEVICE|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
57947125|NCT00017342|DRUG|bryostatin 1|
58083757|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
58083758|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
58083759|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
57947126|NCT00017342|DRUG|cytarabine|
57947127|NCT00607386|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
58083760|NCT01406327|DRUG|Ambrisentan|Ambrisentan
58300714|NCT02670369|BEHAVIORAL|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
58300715|NCT03440619|DEVICE|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
58300716|NCT00164138|PROCEDURE|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
57947128|NCT06469996|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.
57947129|NCT06469996|OTHER|Self myofascial relaxation|Self myofascial relaxation will be practiced with foam roller in patients with Fibromyalgia.
57947130|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
57947131|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
57947132|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
58083761|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
58083762|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 1
58083763|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 2
58300717|NCT03498521|DRUG|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
57947133|NCT04719650|DRUG|Placebo|Infusion normal saline once.
58300718|NCT03498521|DRUG|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
58300719|NCT03498521|DRUG|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
58083764|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 at the selected dose
58083765|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
58083766|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
58300720|NCT03498521|DRUG|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
58300721|NCT03498521|DRUG|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
58300722|NCT03498521|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
58300723|NCT03498521|DRUG|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
58300724|NCT03498521|DRUG|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
58300725|NCT03498521|DRUG|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
57732525|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
57947134|NCT02218281|BEHAVIORAL|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
57947135|NCT02218281|BEHAVIORAL|NCI's QuitSTART app|NCI's smoking cessation app
57947136|NCT02218281|BEHAVIORAL|Written smoking cessation materials only|Receipt of written smoking cessation materials
57732526|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
57947137|NCT03549156|DIETARY_SUPPLEMENT|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
57947138|NCT03549156|DIETARY_SUPPLEMENT|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
57947139|NCT05725070|DRUG|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
57947140|NCT00272909|DRUG|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
57947141|NCT00272909|DRUG|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
57947142|NCT00272909|DRUG|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
58083767|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
58083768|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
58083769|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
58083770|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
58083771|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
58083772|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
58083773|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
58083774|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
58083775|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
58083776|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
58083777|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
58083778|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
58083779|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
58083780|NCT02844231|OTHER|Single-photon emission computed tomography|
58083781|NCT01961765|DRUG|cabozantinib|
58083782|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
58083783|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
58083784|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
58083785|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
58083786|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
58083787|NCT02158949|BEHAVIORAL|mROAD|
58083788|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
58083789|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
58083790|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
58083791|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
58083792|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
58083793|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
58083794|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
58083795|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
58300726|NCT03498521|DRUG|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
58300727|NCT03498521|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
58411596|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
58411597|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
58083796|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
58083797|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
58083798|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous or intravenous injection
58083799|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous or intravenous injection
58083800|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
58083801|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
58083802|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
58083803|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
58083804|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
58083805|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
58083806|NCT02209272|DRUG|bacteriostatic saline|
57732527|NCT04661995|DEVICE|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
58083807|NCT02209272|DRUG|buffered lidocaine|
58083808|NCT03323034|DRUG|Irinotecan|Given IV
58083809|NCT03323034|DRUG|Pevonedistat|Given IV
58083810|NCT03323034|DRUG|Temozolomide|Given PO
58083811|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
57732528|NCT01040104|OTHER|Skin sample|Taken from regularly discarded tissue during routine operation
57732529|NCT01040104|OTHER|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
58083812|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
58083813|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
58083814|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
58083815|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
58300728|NCT03498521|DRUG|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
57732530|NCT01040104|OTHER|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
57732531|NCT01040104|OTHER|Blood taking|Blood taking on day 0
58083816|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
58300729|NCT03498521|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
58300730|NCT03498521|DRUG|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
57732532|NCT01040104|OTHER|Blood taking|Blood taking on day 90
57732533|NCT04477980|OTHER|Disease outcome (mortality)|Mortality rate between the two groups
58083817|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
58083818|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
58083819|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
58083820|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
58083821|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
58083822|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
58083823|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
58411598|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
58083824|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
58411599|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
58411600|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
57732534|NCT04743908|OTHER|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
58083825|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
58083826|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
58083827|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
58083828|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
58083829|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
58083830|NCT00762073|DRUG|budesonide|oral suspension
58083831|NCT00762073|DRUG|placebo|oral suspension matching budesonide
58083832|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
58083833|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
58083834|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
57732535|NCT04411108|OTHER|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
57732536|NCT04411108|OTHER|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
58083835|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
58083836|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
58083837|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
58083838|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
58083839|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
58083840|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
58411601|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
58411602|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
58411603|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
58411604|NCT02744612|DRUG|Ibrutinib|Given PO
57732537|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
57732538|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
57732539|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
58083841|NCT03818542|DRUG|ABBV-181|intravenous infusion
58083842|NCT03818542|DRUG|ABBV-368|intravenous infusion
58083843|NCT03818542|DRUG|ABBV-927|intravenous infusion
58083844|NCT03818542|DRUG|ABBV-927|intratumoral injection
58083845|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
58083846|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
58083847|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
58083848|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
58083849|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
58083850|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
58083851|NCT02231606|OTHER|Free Glasses|Provide free glasses
58083852|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
57732540|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
57732541|NCT05958342|DRUG|Calcium Gluconate|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
57947143|NCT04719143|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Subjects receive 6-8 CBT-I sessions in an individual format.
58083853|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
58083854|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
58083855|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
58083856|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
58083857|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
58300731|NCT03498521|DRUG|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
58300732|NCT03498521|DRUG|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
58300733|NCT03498521|DRUG|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
58300734|NCT03498521|DRUG|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
58300735|NCT03165773|OTHER|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
58300736|NCT03165773|OTHER|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
58300737|NCT02885038|OTHER|Platelet concentrate transfusion|
57732542|NCT05958342|DRUG|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
57732543|NCT05958342|DRUG|saline placebo|saline placebo volume matched to prehospital or in hospital phase
57947144|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
57947145|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
57947146|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
57947147|NCT00917150|DRUG|placebo|oral administration of placebo, once daily for 24months
57947148|NCT03956914|OTHER|Placebo|Placeob water 440 ml/day for 8 weeks
57947149|NCT03956914|OTHER|Deep sea water|Deep sea water 440 ml/day for 8 weeks
57947150|NCT02173860|PROCEDURE|FFR-guided surgical revascularization|
57947151|NCT02173860|PROCEDURE|Angio-guided surgical revascularization|
57947152|NCT02692365|PROCEDURE|Magnetic Resonance + hemodynamic + infusion of gadolinium|
57947153|NCT03187938|DIAGNOSTIC_TEST|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
57947154|NCT06281470|DRUG|WS016 Single Dose(6g)|WS016 6g, to be administered orally as a single dose.
57947155|NCT06281470|DRUG|WS016 Single Dose(12g)|WS016 12g, to be administered orally as a single dose.
57947156|NCT06281470|DRUG|WS016 Single Dose(24g)|WS016 24g, to be administered orally as a single dose.
57947157|NCT06281470|DRUG|WS016 Single Dose(36g)|WS016 36g, to be administered orally as a single dose.
57947158|NCT06281470|DRUG|WS016 Single Dose(48g)|WS016 48g, to be administered orally as a single dose.
57947159|NCT06281470|DRUG|SAD matching placebo|Matching placebo, to be administered orally as a single dose.
57947160|NCT06281470|DRUG|WS016 Multiple Dose(12g)|WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
57947161|NCT06281470|DRUG|WS016 Multiple Dose(24g)|WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
57947162|NCT06281470|DRUG|WS016 Multiple Dose(48g)|WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
57947163|NCT06281470|DRUG|MAD matching placebo|Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
57947164|NCT01975740|OTHER|Sham manual diaphragm release technique|
57947165|NCT01975740|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
58411605|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
57947166|NCT06320691|PROCEDURE|Total Hip Arthroplasty|Patients that underwent direct anterior approach total hip arthroplasty
57947167|NCT06320691|PROCEDURE|General Anesthesia|Patients that underwent general/systemic anesthesia before surgery
57947168|NCT06320691|PROCEDURE|Spinal Anesthesia|Patients that underwent spinal/neuraxial anesthesia before surgery
57947169|NCT05003622|DRUG|Encorafenib|oral capsule
57947170|NCT05086328|BEHAVIORAL|Nonviolent Resistance|Six two weekly sessions of two hours, based on nonviolent resistance Questionnaires pre and post intervention
58083858|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
58083859|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
58083860|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
58083861|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
58083862|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
58083863|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
58083864|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
58083865|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
58083866|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58083867|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
58083868|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
58083869|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
58300738|NCT05191966|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|"S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
57947171|NCT00141024|BIOLOGICAL|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
57947172|NCT00141024|BIOLOGICAL|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
57947173|NCT01785160|DRUG|Raltegravir|low dose oral administration
57947174|NCT01785160|DRUG|Raltegravir|low dose oral administration
57947175|NCT01785160|DRUG|Faldaprevir|medium dose oral administration
58083870|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
58083871|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
58083872|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
58083873|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
58083874|NCT01748162|DRUG|Prednisolone IF needed|
58083875|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
58083876|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
58083877|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
58300739|NCT05191966|PROCEDURE|Thoracic Paravertebral Block|"TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
58300740|NCT01205347|DRUG|Simvastatin 80mg|Simvastatin 80mg once a day
58300741|NCT01205347|DRUG|Simvastatin 10mg|Simvastatin 10mg once a day
58300742|NCT05181098|PROCEDURE|Robotic-guided spine surgery|The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
58300743|NCT04940156|DEVICE|Confirm Rx (Implantable Cardiac Monitor)|Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
58300744|NCT04940156|DEVICE|Reveal LINQ (Implantable Cardiac Monitor)|Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
58300745|NCT03946059|DEVICE|iTBS then cTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
58300746|NCT03946059|DEVICE|cTBS then iTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
58300747|NCT03374839|DRUG|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
58083878|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
58083879|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
57732544|NCT02005471|DRUG|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
58083880|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
58083881|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
58411606|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
58411607|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
58411608|NCT02174523|DRUG|40mg lurasidone|
58300748|NCT04703985|DIETARY_SUPPLEMENT|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
58411609|NCT02174523|DRUG|placebo|
58411610|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
58411611|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
58411612|NCT01649544|DRUG|Amiodarone|
58411613|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
58411614|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
57732545|NCT02005471|DRUG|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
57732546|NCT02005471|DRUG|Rituximab|"Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
57732547|NCT02649868|PROCEDURE|Transarterial embolization (TAE)|Transarterial embolization
57732548|NCT02649868|DEVICE|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
58411615|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
58411616|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
58411617|NCT00195520|DRUG|Totelle®|
58411618|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
58411619|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
58411620|NCT02288962|DRUG|cabergoline|
58411621|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
58411622|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
57947176|NCT05046405|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
57947177|NCT04438083|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
57947178|NCT00131469|DRUG|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
57947179|NCT00131469|DRUG|Placebos|
57947180|NCT03709238|BEHAVIORAL|Thermal stimulation|Thermal stimulation
57947181|NCT02572726|DEVICE|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
57947182|NCT02572726|DEVICE|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
57947183|NCT02947152|DRUG|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
57947184|NCT02869282|OTHER|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
57947185|NCT02869282|OTHER|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
57947186|NCT02794324|PROCEDURE|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
57947187|NCT02794324|PROCEDURE|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
57947188|NCT02794324|PROCEDURE|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
57947189|NCT02794324|DEVICE|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
57947190|NCT05693636|PROCEDURE|Total wrist arthroplasty|Two different surgical interventions for treatment of end-stage arthritis are compared
57947191|NCT05877053|DRUG|CK-4021586|CK-4021586
58411623|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
58411624|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
58411625|NCT01716338|DRUG|Glyburide|
58411626|NCT01716338|DRUG|Placebo|
57947192|NCT05877053|DRUG|Placebo for CK-4021586|Placebo for CK-4021586
57947193|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice1|Apple Juice1
57947194|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
57947195|NCT03846986|DIETARY_SUPPLEMENT|Raw Apple|Raw Apple
58083882|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
58411627|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
58411628|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
58411629|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
58411630|NCT02187523|DRUG|Hydrochlorothiazide|
58411631|NCT02187523|DRUG|Telmisartan|
58411632|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
58411633|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
58411634|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
58411635|NCT00000357|DRUG|Buprenorphine|
58411636|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
58411637|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
58411638|NCT02110888|OTHER|SCS Only|
58411639|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
58411640|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
58411641|NCT00048815|DRUG|Placebos|Placebo pill
58411642|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
58411643|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
58411644|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
57732549|NCT03179839|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
58411645|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
58411646|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
58411647|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
58411648|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
58411649|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
57947196|NCT03095794|OTHER|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
58411650|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
58411651|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
58411652|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
58411653|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
58411654|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
58411655|NCT02390674|DRUG|Saline|
58411656|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
58411657|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
58411658|NCT01963013|DEVICE|Non-returning catheter valve|
58411659|NCT01963013|DEVICE|Conventional urine bag|
58411660|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
58411661|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
58411662|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
58411663|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
58411664|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
58411665|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
58411666|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
58411667|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
58411668|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
58411669|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
58411670|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
58411671|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
58411672|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
58411673|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
58411674|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
57947197|NCT03095794|OTHER|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
57947198|NCT03095794|OTHER|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
57947199|NCT03095794|OTHER|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
57947200|NCT02290873|DRUG|Remimazolam|For induction and maintenance of sedation
57947201|NCT02290873|DRUG|Midazolam|For induction of maintenance and sedation
58300749|NCT02740842|BEHAVIORAL|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
58300750|NCT02740842|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
58300751|NCT04265521|DEVICE|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
58300752|NCT02410408|DEVICE|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
58300753|NCT02410408|OTHER|information package|Information on PSC and RCA
58300754|NCT01153919|BIOLOGICAL|romiplostim|Given subcutaneously
58300755|NCT01153919|DRUG|ribavirin|Given orally
58300756|NCT01153919|OTHER|placebo|Given subcutaneously
58300757|NCT01153919|BIOLOGICAL|PEG-interferon alfa-2a|Given subcutaneously
58300758|NCT01153919|OTHER|laboratory biomarker analysis|Correlative studies
58300759|NCT04096846|DIAGNOSTIC_TEST|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
58300760|NCT03856372|RADIATION|Hypofractionated|daily fractions, five fractions per week.
58300761|NCT03856372|RADIATION|Conventional|daily fractions, five fractions per week.
58300762|NCT00898430|GENETIC|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
58300763|NCT00898430|GENETIC|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
58300764|NCT00898430|GENETIC|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
58300765|NCT05944575|DEVICE|active taVNS|The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.
58300766|NCT05944575|DEVICE|sham-taVNS|The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
58300767|NCT01991964|OTHER|laryngeal ultrasound|
58300768|NCT04622566|DRUG|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
58300769|NCT04817306|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
58300770|NCT04421040|DEVICE|Biotronik Biomonitor 3 implant of device|The Biotronik Biomonitor 3 device will be implanted by the research team physician.
58300771|NCT04421040|DEVICE|Biotronik Biomonitor 3 explant of device|The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
57732550|NCT03179839|BEHAVIORAL|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
58083883|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
58300772|NCT01721538|OTHER|Weight reduction program|
58300773|NCT01721538|OTHER|Lecture on healthy nutrition|
58300774|NCT00246584|DRUG|SPP100|
58300775|NCT02299440|OTHER|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
58300776|NCT02299440|DRUG|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
58300777|NCT02299440|DRUG|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
58300778|NCT02299440|OTHER|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
58300779|NCT02299440|DRUG|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
58300780|NCT02299440|DRUG|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
58300781|NCT01505777|DRUG|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
58411675|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
57947202|NCT02290873|DRUG|Placebo|Inactive control arm
57947203|NCT00573989|DRUG|erlotinib hydrochloride|
57947204|NCT00573989|DRUG|pemetrexed disodium|
57947205|NCT00573989|PROCEDURE|quality-of-life assessment|
57947206|NCT00573989|RADIATION|intensity-modulated radiation therapy|
57947207|NCT04095650|BEHAVIORAL|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
57947208|NCT01268358|DRUG|Lamazym|Lamazym, ERT, infusion weekly
57947209|NCT05645497|PROCEDURE|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
57947210|NCT05645497|PROCEDURE|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
57947211|NCT02164929|PROCEDURE|TAP block|
57947212|NCT02164929|PROCEDURE|Epidural|
57947213|NCT02164929|PROCEDURE|Paravertebral block|
57947214|NCT02164929|DRUG|Acetaminophen 1g IV|
57947215|NCT02164929|DRUG|Dexamethasone 4mg|
58300782|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
58300783|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
58300784|NCT01505777|DRUG|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
58300785|NCT01505777|DRUG|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
58300786|NCT01765296|DRUG|CG100649|2 mg capsule
58300787|NCT01765296|DRUG|Celecoxib|200 mg capsule
58300788|NCT01765296|DRUG|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
58300789|NCT04210986|DIETARY_SUPPLEMENT|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
58300790|NCT04210986|DRUG|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
58300791|NCT06470490|BEHAVIORAL|psychoeducational|educational program
58411676|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
58083884|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
58083885|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
58083886|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
58083887|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
58083888|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
58083889|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
58083890|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
57947216|NCT02164929|DRUG|Midazolam up to 2mg|
58083891|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
58083892|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
58083893|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
58083894|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
58083895|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
58411677|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
58411678|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
58411679|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
58411680|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
58411681|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
58411682|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
57732551|NCT03179839|DRUG|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
57732552|NCT06635174|OTHER|Dextrose|we are using 2ml of 50% dextrose
57732553|NCT06635174|OTHER|normal water|patient will receive 2ml of normal water
57947217|NCT02164929|DRUG|Propofol 1-2.5 mg/kg|
57947218|NCT02164929|DRUG|Sevoflurane to keep a bispectral index of between 40-60|
57947219|NCT02164929|DRUG|Local infiltration with 10 mL of plain ropivacaine 0.25%|
57947220|NCT02164929|DRUG|Lidocaine|1.5% lidocaine
57947221|NCT02164929|DRUG|Epinephrine|1:200,000 epinephrine
57947222|NCT02164929|DRUG|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
57947223|NCT00254462|DRUG|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
57947224|NCT00254462|DRUG|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
57947225|NCT00254462|BEHAVIORAL|Parent Training|All children will receive parent training for the duration of the study.
57947226|NCT06379737|BEHAVIORAL|Multi-systemic Rehabilitation|"Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit"
57947227|NCT02672670|BEHAVIORAL|Experimental: Intervention group---coping-oriented supportive programme|
57947228|NCT02672670|BEHAVIORAL|Active Comparator: Comparison group---a didactic talk (usual care)|
58083896|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
58083897|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
58083898|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
58083899|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
58300792|NCT03028142|DRUG|1.5 mg RPL554 plus tiotropium|
58300793|NCT03028142|DRUG|6 mg RPL554 plus tiotropium|
58300794|NCT03028142|DRUG|Placebo plus tiotropium|
58411683|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
58411684|NCT01889134|DRUG|Sedron (alendronate)|
58411685|NCT01889134|PROCEDURE|Parathyroidectomy|
57732554|NCT01352598|RADIATION|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
57947229|NCT05259865|DIAGNOSTIC_TEST|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
57947230|NCT03803462|OTHER|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
58300795|NCT03160716|DEVICE|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
58300796|NCT00870454|DRUG|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
58300797|NCT00870454|DRUG|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
58300798|NCT00870454|DRUG|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
58300799|NCT00870454|DRUG|Placebo|Placebo capsules twice daily
58300800|NCT00999505|DRUG|Amantadine|Amantadine 200mg twice a day over 12 weeks
58300801|NCT00999505|DRUG|Placebo|Placebo capsules twice a day over 12 weeks
58300802|NCT01150630|DRUG|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
58300803|NCT01150630|DRUG|cisplatin|30 mg/mq every 14 days for 6 months
58411686|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
57947231|NCT00091104|BIOLOGICAL|MART-1:27-35 peptide vaccine|
58300804|NCT01150630|DRUG|epirubicin|30 mg/mq every 14 days for 6 months
58300805|NCT01150630|DRUG|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
58300806|NCT02360514|DRUG|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
58300807|NCT04241549|DRUG|Cusatuzumab|Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
58300808|NCT04241549|DRUG|Azacitidine|Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
58300809|NCT03151850|OTHER|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
58300810|NCT03151850|OTHER|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
58300811|NCT04263259|BEHAVIORAL|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
58300812|NCT05023122|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3 (cholecalciferol) 800 IU QD
58411687|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
58300813|NCT05023122|DIETARY_SUPPLEMENT|calcium|calcium citrate 600 mg QD
58300814|NCT01316718|DRUG|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
58300815|NCT01316718|DRUG|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
58300816|NCT03147872|OTHER|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
58411688|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
58083900|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
58083901|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
58300817|NCT00314158|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
57732555|NCT03422003|RADIATION|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
57732556|NCT03719105|DRUG|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
58083902|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
58083903|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
58083904|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
58083905|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
58083906|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
58083907|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
58083908|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
58083909|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
58083910|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
58083911|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
58300818|NCT00314158|DRUG|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
58300819|NCT00314158|DRUG|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
57732557|NCT03719105|DRUG|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
58300820|NCT03798743|DRUG|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
58300821|NCT05070013|DEVICE|Deep Brain Stimulation|All subjects will undergo three 1-week conditions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
58300822|NCT05954052|DRUG|Glutathione|Giving supplement orally
58300823|NCT04448275|OTHER|Neurodynamics Nerve flossing|"Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique"
58300824|NCT04448275|OTHER|conventional selected exercise program|Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
58300825|NCT03197948|OTHER|Internet-Based Intervention|Complete questionnaire via a smartphone application
58300826|NCT00709332|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
57732558|NCT03719105|DRUG|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732559|NCT03719105|DRUG|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732560|NCT03719105|DRUG|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732561|NCT03719105|DRUG|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
58411689|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
58411690|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
58411691|NCT00236418|DRUG|topiramate|
58411692|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
58411693|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
58411694|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
58411695|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
58411696|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
57947232|NCT00091104|BIOLOGICAL|aldesleukin|
57947233|NCT00091104|BIOLOGICAL|filgrastim|
58300827|NCT00773357|DRUG|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
58300828|NCT00773357|DRUG|placebo|placebo
58300829|NCT00013507|PROCEDURE|Falls|
58300830|NCT02779491|BEHAVIORAL|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
58300831|NCT02395068|DRUG|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
58300832|NCT02395068|DRUG|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
58300833|NCT00434031|DRUG|docetaxel|
58300834|NCT00434031|DRUG|cyclophosphamide|
58300835|NCT00434031|DRUG|trastuzumab|
58300836|NCT00434031|DRUG|liposomal doxorubicin|
58300837|NCT03361462|BEHAVIORAL|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
58300838|NCT00948090|DRUG|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
58300839|NCT05781672|DIAGNOSTIC_TEST|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
58300840|NCT01157845|DEVICE|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
58300841|NCT04549662|DIETARY_SUPPLEMENT|Active A|Powdered formula containing whey protein and arginine
58300842|NCT04549662|DIETARY_SUPPLEMENT|Active B|Powdered formula containing whey protein
58411697|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
58411698|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
58411699|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
58411700|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
57947234|NCT00091104|BIOLOGICAL|incomplete Freund's adjuvant|
57947235|NCT00091104|BIOLOGICAL|therapeutic autologous lymphocytes|
57947236|NCT00091104|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
57947237|NCT00091104|DRUG|cyclophosphamide|
57947238|NCT00091104|DRUG|fludarabine phosphate|
57947239|NCT00091104|PROCEDURE|autologous hematopoietic stem cell transplantation|
57947240|NCT00091104|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58300843|NCT04549662|DIETARY_SUPPLEMENT|Lipid bolus|Omega-3 fatty acids
58083912|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
58083913|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
58411701|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
57732562|NCT03719105|DRUG|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
58083914|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
58083915|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
58300844|NCT04549662|DIETARY_SUPPLEMENT|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
58300845|NCT05824013|DIAGNOSTIC_TEST|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
58300846|NCT02177929|OTHER|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
58300847|NCT00952666|DEVICE|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
58300848|NCT01820663|OTHER|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
58300849|NCT01820663|OTHER|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
58300850|NCT01661738|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
58300851|NCT05626309|DRUG|Qizhu Yuling Prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
58300852|NCT05626309|DRUG|Placebo|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
58411702|NCT04671082|DRUG|Placebo|TID
58411703|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
58411704|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
58411705|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
58411706|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
58411707|NCT02385916|OTHER|Placebo|Placebo
58411708|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
58411709|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
58083916|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
57732563|NCT03719105|DRUG|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732564|NCT03719105|DRUG|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732565|NCT03719105|DRUG|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
57732566|NCT06636214|BEHAVIORAL|CHATO-I|Online communication education program
57732567|NCT05684965|DRUG|XTX301|XTX301 monotherapy
57947241|NCT00091104|RADIATION|total-body irradiation|
58083917|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
58083918|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
58083919|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
58300853|NCT04998864|DEVICE|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
58300854|NCT02198846|DEVICE|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
58300855|NCT02198846|DRUG|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
58411710|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
58411711|NCT05944562|DRUG|Tulmimetostat|Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
58411712|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
58411713|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
58411714|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
58411715|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
58411716|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
58411717|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
58411718|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
58411719|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
57732568|NCT03088384|DRUG|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
58300856|NCT02432885|DRUG|Enalapril|up to 20mg bid
58300857|NCT03476421|PROCEDURE|Hepatic resection|Surgery of the liver; removal of a part of the liver
58300858|NCT02597777|OTHER|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
58300859|NCT02597777|OTHER|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
58300860|NCT00347750|DRUG|Lopinavir pharmacokinetic/pharmacodynamic analysis|
58300861|NCT00901342|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
57732569|NCT05028660|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
58300862|NCT00555074|DRUG|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
58300863|NCT00555074|DRUG|Placebo|Placebo, BID, oral route during 6 weeks
58300864|NCT04958070|OTHER|MPS I|MPS I, symptoms of disease onset , ERT
58300865|NCT06215235|OTHER|Bright light therapy|for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.
58411720|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
58411721|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
58411722|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
58411723|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
58411724|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
58411725|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
58411726|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
57732570|NCT06636448|PROCEDURE|the effect of body mass index during low-flow anesthesia|The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
58083920|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
57732571|NCT01073618|DRUG|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
58300866|NCT03434639|DIAGNOSTIC_TEST|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
58300867|NCT00221013|PROCEDURE|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
57732572|NCT04105023|DIETARY_SUPPLEMENT|genistein|Administered orally once every 12 hours
58300868|NCT03976752|DRUG|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
58300869|NCT02473185|DRUG|Methylphenidate|Cross-over
57732573|NCT04105023|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
57732574|NCT03205995|BIOLOGICAL|OMS721|Intravenous loading dose followed by daily subcutaneous injections
57732575|NCT03239379|DRUG|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
57732576|NCT03239379|DRUG|Placebo|Normal Saline
57732577|NCT01999504|OTHER|PAL-2|meal
58300870|NCT03793569|BEHAVIORAL|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
57732578|NCT01999504|OTHER|TFH-1|Meal
57732579|NCT01999504|OTHER|Reference|Meal
57732580|NCT03551938|BEHAVIORAL|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
58300871|NCT04163848|OTHER|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
58300872|NCT05397197|OTHER|Electroencephalography|experimental task, neuropsychological evaluation, clinical exam
58300873|NCT01477762|DRUG|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
57732581|NCT01989650|OTHER|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
57732582|NCT01989650|OTHER|No break|No break will be provided
57732583|NCT06451068|DEVICE|Peripheral retina robotically aligned optical coherence tomography (OCT) system|To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
57732584|NCT06451068|OTHER|Likert Scales|Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
57732585|NCT00647712|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
57732586|NCT00647712|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fasting
57732587|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
57732588|NCT01093794|DRUG|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
57732589|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
57732590|NCT01093794|DRUG|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
58300874|NCT01477762|DRUG|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
58300875|NCT01010737|BIOLOGICAL|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
58300876|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
58300877|NCT01010737|BIOLOGICAL|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
58300878|NCT01010737|BIOLOGICAL|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
58300879|NCT01010737|BIOLOGICAL|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
57732591|NCT05472714|OTHER|Educational Video|We will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
57732592|NCT04191057|DEVICE|Free light chains|Blood samples will be collected and analyzed
57732593|NCT05343702|DRUG|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
57732594|NCT04962464|DIETARY_SUPPLEMENT|Peak Human Labs calorie mimetic supplement|Supplement
57732595|NCT04962464|BEHAVIORAL|Fasting Mimicking Diet|Diet
57732596|NCT02096900|DRUG|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
57732597|NCT02096900|DRUG|Midazolam|
57732598|NCT05556408|DRUG|Succinylcholine|1.5mg/kg was given intravenously
57947242|NCT01035385|DRUG|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
58083921|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
58300880|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
58300881|NCT01010737|BIOLOGICAL|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
58300882|NCT02799563|OTHER|Coach, Preselected number of cases|
58300883|NCT02799563|OTHER|Coach, Self-selected number of cases|
58300884|NCT02799563|OTHER|No coach, Preselected number of cases|
58300885|NCT02799563|OTHER|No coach, Self-selected number of cases|
58300886|NCT03788694|DRUG|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
58300887|NCT04360460|OTHER|Immersive virtual reality + related functional translation into real-life|The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.
57947243|NCT02589691|DRUG|Rocuronium|
57947244|NCT02589691|OTHER|Sodium chloride 0.9%|
57947245|NCT00185744|RADIATION|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
58300888|NCT04360460|OTHER|Immersive virtual reality + non-related translation into real-life|The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
58300889|NCT00433472|DEVICE|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI
58300890|NCT00143338|DRUG|Inhaled insulin|
58300891|NCT06213558|DEVICE|Rectangular and square striaght archwire technique|The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
58300892|NCT01826942|DEVICE|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
58300893|NCT01826942|DEVICE|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
58300894|NCT01276158|PROCEDURE|Ultrasound|Ultrasound used to place arterial line
58300895|NCT01276158|PROCEDURE|Doppler|Doppler used to place arterial line
57732599|NCT06469320|OTHER|Online questionnaire|Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel
57732600|NCT04104581|OTHER|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
57732601|NCT04104581|OTHER|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
57732602|NCT04104581|OTHER|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
57732603|NCT04104581|OTHER|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
57732604|NCT04104581|OTHER|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
57732605|NCT01571362|DRUG|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
57732606|NCT01571362|DRUG|Placebo|oral placebo, divided into symmetric doses and administered twice daily
57947246|NCT00185744|PROCEDURE|Lumpectomy|
57947247|NCT00185744|RADIATION|Whole Breast Radiotherapy|six and a half week treatment
57947248|NCT00185744|RADIATION|Intracavitary Brachytherapy|5 day treatment
58083922|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
58300896|NCT05782075|OTHER|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
58300897|NCT03912038|OTHER|No intervention.|No intervention
58300898|NCT05638282|DRUG|Cendakimab|Specified dose on specified days
58300899|NCT05638282|DRUG|Placebo|Specified dose on specified days
58300900|NCT00804453|DEVICE|Cartridge blood set|Once a week
57947249|NCT00185744|RADIATION|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
58083923|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
58083924|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
58083925|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
58083926|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
58083927|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
58300901|NCT00804453|DEVICE|Standard blood line|Once a week
58411727|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
58411728|NCT01887119|DRUG|Eplerenone|
58300902|NCT03920085|DEVICE|OneTouch Verio|OneTouch Verio Blood Glucose Monitoring System.
58411729|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
58411730|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
58300903|NCT03920085|DEVICE|OneTouch Select Plus|OneTouch Select Plus Blood Glucose Monitoring System.
58300904|NCT03920085|DEVICE|OneTouch Ultra|OneTouch Ultra Blood Glucose Monitoring System.
58300905|NCT04956471|OTHER|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
58411731|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
58411732|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
58411733|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
58411734|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
57947250|NCT00185744|RADIATION|Stereotactic APBI|4 day treatment
58411735|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
58411736|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
57947251|NCT00960843|DEVICE|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
57947252|NCT00960843|OTHER|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
57947253|NCT05138016|DEVICE|Soft exosuit|Progressive cardiovascular exercise testing with soft exosuit assistance.
57947254|NCT05138016|BEHAVIORAL|No Soft exosuit|Progressive cardiovascular exercise testing.
57947255|NCT01001000|PROCEDURE|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
57947256|NCT02060682|DEVICE|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
57947257|NCT00641550|OTHER|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
57947258|NCT03300674|DRUG|Hydromorphone|Hydromorphone intravenous infusion
57947259|NCT03300674|DRUG|Lidocaine|Lidocaine intravenous infusion
57947260|NCT05018832|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57947261|NCT02227602|DRUG|Mango polyphenolics|Frozen mango pack will be provided (200\~400g per day).
57947262|NCT00670670|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
57947263|NCT00670670|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
57947264|NCT04050982|DEVICE|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
57947265|NCT04050982|BEHAVIORAL|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
57947266|NCT03096730|DRUG|Normal saline|Normal saline is intravenously administrated before anesthesia induction
57947267|NCT03096730|DRUG|Remifentanil|Remifentanil is intravenously administrated
57947268|NCT03096730|DRUG|Sufentanil|Sufentanil is intravenously administrated
57947269|NCT03096730|DRUG|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
57947270|NCT03096730|DRUG|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
58083928|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
58083929|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
58083930|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
58083931|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
58083932|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
58083933|NCT02230332|DRUG|Alendronate|
58083934|NCT02230332|DRUG|Placebo|
58083935|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
58083936|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
58083937|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
58083938|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
58083939|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
58083940|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
58083941|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
58083942|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
58083943|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
58083944|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
58083945|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
58083946|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
58083947|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
58083948|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
58083949|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
58083950|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
58083951|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
58083952|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
58083953|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
58083954|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
58083955|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
58083956|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
58083957|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
58083958|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
58083959|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
58083960|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
58300906|NCT02635308|BEHAVIORAL|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
58300907|NCT04798157|RADIATION|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
58083961|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
58083962|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
57732607|NCT06054724|OTHER|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
57947271|NCT01868880|DRUG|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
58083963|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
58083964|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
58083965|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
58083966|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
58083967|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
58083968|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
58083969|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
58083970|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
58083971|NCT02585375|DRUG|Preserved latanoprost 0.005%|
58083972|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
58300908|NCT03173417|BIOLOGICAL|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
58083973|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
58083974|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
58411737|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
58083975|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
58083976|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
58083977|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
58300909|NCT03173417|DRUG|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
58411738|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
58411739|NCT04963530|PROCEDURE|No intervention|No intervention.
58083978|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
58083979|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
58300910|NCT05665868|DEVICE|integrated care mode|The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model
58300911|NCT05665868|DEVICE|conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
58300912|NCT05078983|DIAGNOSTIC_TEST|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
58411740|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
57947272|NCT01868880|DRUG|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
57947273|NCT00004138|PROCEDURE|positron emission tomography|
58083980|NCT00061568|DRUG|Sirolimus|Sirolimus
58083981|NCT00058994|DRUG|anecortave acetate|
58083982|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
57947274|NCT00004138|PROCEDURE|radionuclide imaging|
58083983|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
57947275|NCT00004138|RADIATION|fludeoxyglucose F 18|
58083984|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
58083985|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
58300913|NCT02849587|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
58300914|NCT00930462|DEVICE|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
58300915|NCT00370500|DRUG|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
58300916|NCT02651870|DRUG|Candesartan 16mg|
58300917|NCT02651870|DRUG|Amlodipine 5mg|
58300918|NCT02651870|DRUG|Amlodipine 10mg|
58300919|NCT05306847|DRUG|Sintilimab|Sintilimab will be given intravenously at a dose of 200mg every 21 days.
58411741|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
58411742|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
58083986|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
58083987|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
58300920|NCT05306847|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
58411743|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
58411744|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411745|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411746|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
58083988|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
58300921|NCT04577638|COMBINATION_PRODUCT|Nivolumab and Intensity Modulated Radiotherapy (IMRT)|"Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption."
58300922|NCT05282147|DEVICE|Neocam|Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
58300923|NCT02869763|DIETARY_SUPPLEMENT|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
58411747|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
58411748|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
58411749|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
58411750|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
57947276|NCT01556139|DEVICE|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
58411751|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
58411752|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411753|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
57947277|NCT04714242|DRUG|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
57947278|NCT04936360|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
58083989|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
58083990|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
58083991|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
58083992|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
58083993|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
58083994|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
58300924|NCT02869763|DIETARY_SUPPLEMENT|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
58300925|NCT02869763|DIETARY_SUPPLEMENT|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
58300926|NCT03506048|DRUG|Lenvatinib|Given orally once daily continuously
58411754|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411755|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411756|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411757|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
58411758|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
58411759|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
58411760|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
58411761|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
58411762|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
58411763|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
58411764|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
58411765|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
58411766|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
58411767|NCT00767234|PROCEDURE|Observation|Standard of Care
58300927|NCT00241202|BEHAVIORAL|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
58300928|NCT01507181|DRUG|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
58300929|NCT01507181|DRUG|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
58300930|NCT03563573|DRUG|Potassium Gluconate Oral Capsule|Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
58300931|NCT03563573|DRUG|Placebo oral capsule|Each subject will receive a dose of \~8 mg/kg of a placebo capsule
58300932|NCT02765152|OTHER|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
58300933|NCT02765152|OTHER|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
58300934|NCT02765152|OTHER|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
58300935|NCT00042913|BIOLOGICAL|epratuzumab|
58300936|NCT06022328|BIOLOGICAL|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
58411768|NCT00040807|DRUG|docetaxel|
58083995|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
58411769|NCT00040807|DRUG|irinotecan hydrochloride|
58411770|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
57947279|NCT02953353|DEVICE|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
58083996|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
58083997|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
58300937|NCT00026091|DRUG|fenretinide|Given orally
58300938|NCT00026091|OTHER|laboratory biomarker analysis|Correlative studies
58300939|NCT00026091|OTHER|pharmacological study|Correlative studies
58300940|NCT05662020|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.
58300941|NCT05662020|BIOLOGICAL|GARDASIL® 9|20-26 years possitive control group will be vaccinated at months 0, 2 and 6
58300942|NCT05401994|PROCEDURE|screw retained arch bar|maxillomandibular fixation with bone screwed arch bar
58300943|NCT05401994|PROCEDURE|conventional Erich's Arch Bar|maxillomandibular fixation with conventional arch bar fixed to the teeth
58300944|NCT01758497|PROCEDURE|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
58083998|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
58083999|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
58300945|NCT01758497|PROCEDURE|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
58300946|NCT01711112|DRUG|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
58300947|NCT02569892|DEVICE|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
58300948|NCT03875001|DRUG|BI 1358894|tablet
57947280|NCT02953353|OTHER|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
57947281|NCT02953353|OTHER|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
57947282|NCT02799823|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
57947283|NCT01048762|OTHER|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
57947284|NCT01048762|OTHER|home training|one instruction in home based exercise training
57947285|NCT03805945|DRUG|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
57947286|NCT03805945|DRUG|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
57947287|NCT01607736|BEHAVIORAL|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
57947288|NCT04438161|BEHAVIORAL|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
57947289|NCT00932347|DRUG|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
57947290|NCT00932347|DRUG|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
57947291|NCT02075372|OTHER|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
57947292|NCT02734836|DEVICE|Balloon Angioplasty|
57947293|NCT02734836|OTHER|Optical Coherence Tomography|
57947294|NCT00382746|DEVICE|EarlySense monitoring device|
58300949|NCT03875001|DRUG|Placebo|tablet
58300950|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
58300951|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
57947295|NCT05437003|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients
57947296|NCT01349465|DRUG|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
57947297|NCT01587911|OTHER|Whey|Preload containing complete whey protein.
57947298|NCT01587911|OTHER|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
57947299|NCT01587911|OTHER|Control|Preload control matched for energy to the other 5 preloads.
57947300|NCT01587911|OTHER|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
58084000|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
58084001|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
58084002|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
58084003|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
58084004|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
58084005|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
58300952|NCT06444750|OTHER|Blood sample collection|Blood sample collection of maximum 70 ml
58300953|NCT00412841|DRUG|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
58300954|NCT00412841|PROCEDURE|MRI, Venipuncture|MRIs done baseline, four and nine months
58411771|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
58411772|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
58411773|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
58411774|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
58084006|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
58084007|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
58300955|NCT00412841|DRUG|Placebo|Tablets identical to atorvastatin 40mg
58300956|NCT03016169|DEVICE|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
58411775|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
58411776|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
58411777|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
58411778|NCT00545220|BEHAVIORAL|problem-solving training|
58411779|NCT00545220|BEHAVIORAL|sham intervention|
58411780|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
58084008|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
58084009|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
58084010|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
58084011|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
58084012|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
58300957|NCT01876108|DRUG|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
58084013|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
58084014|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
57947301|NCT01587911|OTHER|MPI|Preload containing whole milk protein.
58084015|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
58084016|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
58084017|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
58084018|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
58084019|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
57947302|NCT01587911|OTHER|CPI|Preload containing sodium caseinate.
58084020|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
58084021|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
58084022|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
58084023|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
58084024|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
58084025|NCT02894541|DRUG|CKD-519 100mg|
58084026|NCT02894541|DRUG|CKD-519 200mg|
58084027|NCT02894541|DRUG|CKD-519 100mg|
58084028|NCT02894541|DRUG|CKD-519 200mg|
58084029|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
58084030|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
58084031|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
58300958|NCT00458003|DRUG|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
57947303|NCT04046432|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
57947304|NCT04046432|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo.
57947305|NCT01077648|DRUG|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
57947306|NCT05371977|PROCEDURE|Trabeculectomy|trabeculectomy glaucoma surgery
57947307|NCT05371977|PROCEDURE|Deep Sclerectomy|deep sclerectomy glaucoma surgery
57947308|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
57947309|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
57947310|NCT00349375|DRUG|Simvastatin|Simvastatin 40 mg
58084032|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
58300959|NCT00458003|DRUG|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
58300960|NCT03885414|BEHAVIORAL|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
58300961|NCT03885414|BEHAVIORAL|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
58300962|NCT05157659|DIAGNOSTIC_TEST|[18F]F-AraG PET-scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
58300963|NCT04718597|PROCEDURE|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
58300964|NCT04718597|PROCEDURE|Open inguinal hernia repair|Classical approach (open repair)
58300965|NCT04268407|DRUG|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
58300966|NCT06205784|OTHER|Prehabilitative exercise|3-4 weeks of heavy resistance exercise
58300967|NCT01911416|DRUG|LDE225|
58300968|NCT03100409|OTHER|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
58300969|NCT05218200|OTHER|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
58300970|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch|NSAIDs+narcotic analgesics
58300971|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
58300972|NCT06448962|DRUG|AD-2021|PO, Once daily(QD), 8weeks
58300973|NCT06448962|DRUG|AD-2022|PO, Once daily(QD), 8weeks
58300974|NCT06448962|DRUG|AD-2021 Placebo|PO, Once daily(QD), 8weeks
58300975|NCT06448962|DRUG|AD-2022 Placebo|PO, Once daily(QD), 8weeks
58300976|NCT06355661|DIETARY_SUPPLEMENT|ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
58300977|NCT06355661|DIETARY_SUPPLEMENT|MCC: 400 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
58300978|NCT03720678|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
58300979|NCT03720678|DRUG|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
58300980|NCT00937963|DIETARY_SUPPLEMENT|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
58300981|NCT04028362|DRUG|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
58300982|NCT05583097|DIAGNOSTIC_TEST|Non-selective cytology|All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
58300983|NCT03151382|DRUG|Tandospirone Citrate|Tandospirone, 30-60 mg/d
58300984|NCT03151382|DRUG|Donepezil Hydrochloride|Donepezil, 10 mg/d
58300985|NCT03924323|DRUG|Escitalopram|8-weeks of treatment followed by 1-week taper down period
58300986|NCT03924323|OTHER|Placebo|Matching oral administration of inactive substance once daily
58300987|NCT03003234|PROCEDURE|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
58300988|NCT03003234|DEVICE|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
58300989|NCT03003234|DIETARY_SUPPLEMENT|Nutri drink|Liquid meal of 200 ml.
58300990|NCT06195644|DEVICE|Galvanic vestibular stimulation|galvanic current generated by Gymna DUO 200 and delivered through conductive medium (electrode gel) by two small carbon rubber electrodes 3 cm 2 each bilaterally over two mastoid processes for 30 minutes, two times per week for 12 weeks .
58300991|NCT06195644|DEVICE|MovAlyzeR® software from Neuroscript|MovAlyzeR® movement analysis software from Neuroscript turns a pen tablet or mouse into a high-quality system for examining movements by a pen, mouse or finger. Hence, it can train and analyze hand dexterity and handwriting using pen tablets such as sentence parameters.
58300992|NCT06195644|DEVICE|BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)|stationary upper body pedaling as a moderate intensity aerobic training
58300993|NCT01359930|OTHER|placebo|matching placebo
58300994|NCT01359930|DRUG|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
58300995|NCT06225843|BIOLOGICAL|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
58411781|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
58411782|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
58084033|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
58084034|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
58084035|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
58084036|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
58084037|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
58084038|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
58084039|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
58300996|NCT06225843|COMBINATION_PRODUCT|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
58300997|NCT05821387|DRUG|Lucid-21-302|A small molecule inhibitor of hypercitrullination
58300998|NCT05821387|DRUG|Placebo|Product containing excipients with no active ingredients
58300999|NCT02763774|OTHER|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
58301000|NCT02763774|OTHER|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
58301001|NCT02763774|OTHER|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
58301002|NCT04042571|DEVICE|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
58301003|NCT00739648|DRUG|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
58301004|NCT00739648|DRUG|Placebo|same frequency as study drug using the same method of delivery
58301005|NCT03332186|DRUG|BMS-986231|Intravenous infusion administration
58301006|NCT03504618|DRUG|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
58301007|NCT06367088|DRUG|Cadonilimab|Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
58301008|NCT01645150|BEHAVIORAL|Progressive strength training|12 weeks of supervised progressive strength training
58301009|NCT00692575|BEHAVIORAL|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
58301010|NCT00692575|OTHER|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
58301011|NCT04995068|RADIATION|Head CT to determine presence of traumatic intracranial lesion|Head CT to determine presence of traumatic intracranial lesion
58301012|NCT02779140|BIOLOGICAL|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
58084040|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
58084041|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
58084042|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
58084043|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
58084044|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
58084045|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
58084046|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
58301013|NCT02779140|OTHER|Placebo|Placebo
58301014|NCT05719896|DRUG|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
58411783|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
58411784|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
58411785|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
58084047|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
58301015|NCT05719896|DRUG|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
58301016|NCT05719896|DRUG|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
58301017|NCT02553642|DRUG|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
58301018|NCT02553642|DRUG|Nivolumab plus Ipilimumab|"Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
58301019|NCT04542980|DIAGNOSTIC_TEST|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
58301020|NCT06410300|RADIATION|Curative Radiotherapy|Radiation dose of 45 Gy or higher
58301021|NCT06410300|DRUG|Immunotherapy|checkpoint inhibitor per PI discretion
58301022|NCT05124522|BEHAVIORAL|MSPA eClass|An 8-week MS-HAPA Internet-based intervention
58301023|NCT00311493|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
58301024|NCT04151069|OTHER|Procedure A|Up-dosing nut drink at home
58301025|NCT04151069|OTHER|Procedure B|Up-dosing nut drink at the hospital
58301026|NCT04151069|OTHER|Control group|Strict avoidance of tree nut consumption
58301027|NCT03533751|BIOLOGICAL|Etokimab|Humanized monoclonal antibody, administered by subcutaneous injection
58411786|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
58301028|NCT03533751|DRUG|Placebo|Administered by subcutaneous injection
58301029|NCT01526785|DRUG|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
58411787|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
58084048|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
58084049|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
58084050|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
57732608|NCT06054724|OTHER|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
57732609|NCT03044067|OTHER|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
57732610|NCT03044067|OTHER|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
58084051|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
58084052|NCT00054639|BIOLOGICAL|rituximab|Given IV
58084053|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
58084054|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
58084055|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
58084056|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
58084057|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
58084058|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
58084059|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
58084060|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
58084061|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
58084062|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
58084063|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
58084064|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
58084065|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
58084066|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
58084067|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
58084068|NCT06405152|OTHER|Chart review|Retrospective Chart Review
58301030|NCT05701813|DIETARY_SUPPLEMENT|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
58301031|NCT05701813|DIETARY_SUPPLEMENT|CELLULOSE|4.3 grams of cellulose once a day for 90 days.
58301032|NCT03276598|DRUG|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
58411788|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
58084069|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
57947311|NCT04701138|DIETARY_SUPPLEMENT|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
57947312|NCT02428842|PROCEDURE|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
57947313|NCT02428842|PROCEDURE|Blood sampling|Blood sampling will be performed before and after treatment.
57947314|NCT04456179|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
57947315|NCT04456179|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
57947316|NCT05245331|DEVICE|Peristeen® Transanal irrigation system with the conic catheter|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
57947317|NCT05245331|DEVICE|Standard reusable enema|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
57947318|NCT02031497|DIETARY_SUPPLEMENT|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
57947319|NCT02031497|DIETARY_SUPPLEMENT|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
57947320|NCT00029692|DRUG|Ginseng|
57947321|NCT00029692|DRUG|Ginkgo|
58301033|NCT03276598|DRUG|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
58301034|NCT03276598|DRUG|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
57732611|NCT06088654|DRUG|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
57947322|NCT00103974|BIOLOGICAL|BHT-3009-01|
58084070|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
58084071|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
58084072|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
58084073|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
58084074|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
58084075|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
58301035|NCT03276598|DRUG|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
57732612|NCT02132611|DEVICE|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
57732613|NCT06516757|DIETARY_SUPPLEMENT|Boric Acid Suppository|Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
58301036|NCT03276598|DRUG|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
58301037|NCT05350020|DRUG|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
58301038|NCT05350020|DRUG|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
58301039|NCT01831895|DEVICE|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
58301040|NCT02174757|DRUG|Inersan|Probiotic
58084076|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
58084077|NCT05340049|DIAGNOSTIC_TEST|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
58084078|NCT05340049|OTHER|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
58301041|NCT02174757|DRUG|Doxycycline|Antibiotic
58301042|NCT01518569|DRUG|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
58301043|NCT01518569|DRUG|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
58301044|NCT03515863|GENETIC|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
58301045|NCT03515863|DEVICE|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
58301046|NCT03515863|OTHER|Collection of life style data|Collection of life style data using quality of life questionnaire
58301047|NCT03790410|OTHER|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
58301048|NCT03790410|OTHER|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
58411789|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
58411790|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
58411791|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
58084079|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
58084080|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
58084081|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
58084082|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
58084083|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
58084084|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
58084085|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
58084086|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
58084087|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
57732614|NCT02152267|DEVICE|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
57732615|NCT02264067|DRUG|Talsaclidine|
57732616|NCT02264067|DRUG|Placebo|
57732617|NCT05023252|OTHER|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
57947323|NCT05354011|OTHER|Kinesiotape|Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain
57947324|NCT05354011|OTHER|Active Release Technique|This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
57947325|NCT01244555|OTHER|ultrasound|Twice weekly ultrasound sessions for 6 weeks
57947326|NCT01244555|OTHER|massage|Twice weekly massage sessions for 6 weeks
57947327|NCT01971073|DEVICE|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
57947328|NCT01971073|DEVICE|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
57947329|NCT04077307|DRUG|Karonudib|First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
57947330|NCT01529437|DRUG|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
57947331|NCT01529437|DRUG|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
57947332|NCT03677830|DRUG|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
57947333|NCT03677830|DRUG|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
57947334|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
57947335|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
57947336|NCT02355899|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
57947337|NCT06238167|DRUG|Tislelizumab|Tislelizumab, 200mg Q3W, max 16 cycles.
57947338|NCT06238167|DRUG|S-1 therapy|S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).
57947339|NCT06238167|DRUG|low dose SOX therapy|Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
57947340|NCT02411162|DRUG|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
57947341|NCT02411162|DRUG|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
58084088|NCT05493683|DRUG|Tislelizumab|400mg，q6w
58301049|NCT03883243|DEVICE|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
58411792|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
58411793|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
57732618|NCT02709954|DRUG|Active inhaled delta-9-THC|"Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
57732619|NCT02709954|DRUG|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
57732620|NCT02709954|DRUG|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
57732621|NCT02709954|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
57947342|NCT06179758|DEVICE|icompanion app|use of the icompanion app as a digital telemonitoring solution
57947343|NCT05587855|OTHER|E-group|Participants with Hypertension will be assigned to eCulinary medicine
57947344|NCT01342835|DRUG|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
57947345|NCT06148376|OTHER|Personalized treatment|Discontinue prandial insulin treatment
57947346|NCT00351013|OTHER|Malaria Tropica Nosode D200|5 pellets every four months
57947347|NCT01431196|BIOLOGICAL|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
57947348|NCT04983407|DRUG|batiraxcept|Batiraxcept is experimental drug
57947349|NCT04983407|DRUG|Nab paclitaxel|Nab paclitaxel is active comparator
57947350|NCT04983407|DRUG|Gemcitabine|Gemcitabine is active comparator
57947351|NCT05489835|BEHAVIORAL|Nutritional counseling|Nutritional counseling
57947352|NCT00455689|DRUG|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
57947353|NCT01509495|DEVICE|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
57947354|NCT02311153|DEVICE|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
57947355|NCT02311153|DEVICE|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
57947356|NCT04095364|PROCEDURE|Biopsy|Undergo tumor biopsy
57947357|NCT04095364|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57947358|NCT04095364|DRUG|Carboplatin|Given IV
57947359|NCT04095364|PROCEDURE|Imaging Technique|Undergo medical imaging
57947360|NCT04095364|DRUG|Letrozole|Given PO
57947361|NCT04095364|DRUG|Paclitaxel|Given IV
57947362|NCT06075836|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
58084089|NCT00002074|DRUG|Fluconazole|
58084090|NCT00002074|DRUG|Amphotericin B|
58084091|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
58084092|NCT05774080|OTHER|Observational|Observational
58084093|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
58084094|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
58411794|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
58084095|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
58084096|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
58084097|NCT03522506|DRUG|Modafinil|Modafinil tablets.
58084098|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
58084099|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
58084100|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
58084101|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
58084102|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
58084103|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
58084104|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
58084105|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
58084106|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
58084107|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
58084108|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
58084109|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
58084110|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
58084111|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
58084112|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
58084113|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
58084114|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
58084115|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
58084116|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
57732622|NCT04697758|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
58084117|NCT02074982|DRUG|AIN457 300 mg|
58084118|NCT02074982|DRUG|ustekinumab 45/90 mg|
58084119|NCT02074982|DRUG|placebo secukinumab|Placebo
58084120|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
58084121|NCT06651242|OTHER|Routine care|Routine care
58084122|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
58084123|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
58084124|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
58084125|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
58084126|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
58084127|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
57732623|NCT04697758|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
57732624|NCT04697758|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
58084128|NCT03933709|OTHER|recommended diet|WHO Diet
58084129|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
58084130|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
58084131|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
58084132|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
58411795|NCT03035253|DRUG|OMP-305B83|
58084133|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
58084134|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
58301050|NCT03026946|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
57732625|NCT05309161|DIETARY_SUPPLEMENT|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
57732626|NCT02808455|DRUG|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
57732627|NCT02808455|DRUG|(Treatment B)|A single 80-mg oral solution dose of pacritinib
57732628|NCT04156607|OTHER|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
57732629|NCT04156607|OTHER|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
58301051|NCT03026946|DRUG|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
58301052|NCT02310074|DRUG|Pulsatile Gonadotropin Releasing Hormone|
58301053|NCT02310074|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
58301054|NCT02310074|DRUG|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
58301055|NCT03545945|PROCEDURE|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
58301056|NCT03545945|PROCEDURE|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
58301057|NCT03020485|OTHER|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
58301058|NCT03020485|OTHER|Sucrose|Sucrose is normal table sugar
58301059|NCT04805671|DRUG|ADG20|Single dose of ADG20
58301060|NCT04805671|DRUG|Normal saline|Single dose of normal saline
58301061|NCT02144701|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given PO
58411796|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
57732630|NCT01627249|DRUG|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
57732631|NCT01627249|DRUG|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
58301062|NCT02144701|OTHER|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
58301063|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
58411797|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
58411798|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
57732632|NCT01627249|DRUG|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
57732633|NCT03178357|OTHER|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
58084135|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
58084136|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
58084137|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
58084138|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
58301064|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
58301065|NCT05006378|DIETARY_SUPPLEMENT|Placebo Capsule|"Placebo capsules consumed by subjects as described in Placebo Comparator study arms section."
58301066|NCT02314728|DRUG|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
58301067|NCT02314728|DRUG|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
58411799|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
58411800|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
58084139|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
57732634|NCT03178357|OTHER|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
57732635|NCT03969069|DEVICE|MAPLe|Additional assessment with MAPLe
58084140|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
58084141|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
58084142|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
58084143|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
58084144|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
58084145|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
58084146|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
58084147|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
58084148|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
58084149|NCT00721513|BIOLOGICAL|cetuximab|
58084150|NCT00721513|DRUG|cisplatin|
58084151|NCT00721513|DRUG|docetaxel|
58084152|NCT00721513|DRUG|fluorouracil|
58411801|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
58084153|NCT00721513|PROCEDURE|computed tomography|
58084154|NCT00721513|PROCEDURE|positron emission tomography|
58084155|NCT00721513|PROCEDURE|quality-of-life assessment|
58084156|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
58084157|NCT00721513|RADIATION|intensity-modulated radiation therapy|
58084158|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
58084159|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
58084160|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
58084161|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
58411802|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
58411803|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
58411804|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
57732636|NCT04837482|DRUG|AGN-190584|Topical eyedrop
57732637|NCT04837482|DRUG|Vehicle|Topical eyedrop
57732638|NCT03820661|DEVICE|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
57732639|NCT04725721|BEHAVIORAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
57732640|NCT04725721|BEHAVIORAL|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
58084162|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
58084163|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
58084164|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
58084165|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
58084166|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
58084167|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
58084168|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
58084169|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
58411805|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
58411806|NCT02798770|OTHER|No Intervention Foreseen|
58411807|NCT00074373|OTHER|No intervention; observational|
57947363|NCT06075836|OTHER|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
58084170|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
58084171|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
58301068|NCT01262144|RADIATION|Radiotherapy|Radiotherapy for cervical cancer
58301069|NCT00297648|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
58301070|NCT03772808|DIETARY_SUPPLEMENT|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
58301071|NCT06077344|PROCEDURE|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation
58301072|NCT06077344|PROCEDURE|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment
58411808|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
58084172|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
58084173|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
58084174|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
58084175|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
58301073|NCT04214587|DIAGNOSTIC_TEST|tissue and blood sampling|only diagnostics will be peformed
58301074|NCT02100046|DRUG|Zarontin® (ethosuximide) and Stodal®|
58084176|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
58084177|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
58301075|NCT04727957|OTHER|Diagnostic and prognostic models for VA-LRTIs|Diagnostic and prognostic models for VA-LRTIs
58301076|NCT00313729|DRUG|temozolomide|Chemotherapy
57947364|NCT01528111|DRUG|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
57947365|NCT01528111|DRUG|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
58084178|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
58301077|NCT00629031|DRUG|Paromomycin|11 mg/kg for 14 days
58301078|NCT00629031|DRUG|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
58411809|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
58411810|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
58411811|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
58411812|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
58411813|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
58084179|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
58084180|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
58084181|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
58411814|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
57947366|NCT01528111|DRUG|LX7101 Vehicle|Subjects will receive vehicle
58411815|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
58411816|NCT01971216|BEHAVIORAL|Relaxation|
58084182|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
58084183|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
58411817|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
58084184|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
58084185|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
58084186|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
58084187|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
58084188|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
58084189|NCT04389008|OTHER|no interventions|no interventions
58084190|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
58084191|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
58084192|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
58084193|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
58084194|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
58084195|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
58084196|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
58084197|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
58084198|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
58084199|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
58084200|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
58084201|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
58084202|NCT01977131|OTHER|Cells|
58084203|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
58084204|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
58084205|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
58084206|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
57947367|NCT02438514|OTHER|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
58084207|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
58084208|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
58084209|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
58084210|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
58084211|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
58084212|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
58084213|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
58084214|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
58084215|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
58084216|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
58084217|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
58084218|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
58084219|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
58084220|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
58084221|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
57947368|NCT00779480|DRUG|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
58301079|NCT02365662|DRUG|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
58301080|NCT01022333|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
58301081|NCT04584515|DRUG|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
58301082|NCT04584515|DRUG|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
58301083|NCT04708158|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
58301084|NCT04708158|BIOLOGICAL|Placebo|Saline
58301085|NCT02823470|DRUG|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
58301086|NCT02823470|DEVICE|activated smart device|
58301087|NCT02823470|DEVICE|de-activated smart device|
58301088|NCT01613261|DRUG|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
58301089|NCT05057689|DRUG|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
58301090|NCT05057689|DRUG|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
58301091|NCT05057689|DRUG|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
57732641|NCT04947111|DIAGNOSTIC_TEST|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
58301092|NCT05830760|BIOLOGICAL|Myocardium biopsy|The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
58301093|NCT05874232|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
58301094|NCT01719549|DRUG|Dovitinib|"* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks"
58301095|NCT02992119|BIOLOGICAL|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
58301096|NCT02992119|BIOLOGICAL|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
58301097|NCT02992119|BIOLOGICAL|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
58301098|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
58301099|NCT02992119|BIOLOGICAL|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
58301100|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
58084222|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
57732642|NCT02126293|DRUG|Zinc Supplement|
57732643|NCT02126293|PROCEDURE|Repeat blood and urine tests|
57732644|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
57732645|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
58301101|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
58301102|NCT02421354|OTHER|Laboratory Biomarker Analysis|Correlative studies
58301103|NCT02421354|BIOLOGICAL|Nivolumab|Given IV
58301104|NCT02421354|OTHER|Quality-of-Life Assessment|Ancillary studies
58301105|NCT05341024|OTHER|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
58301106|NCT05455827|OTHER|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
58301107|NCT05455827|OTHER|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
58301108|NCT02486692|OTHER|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
58301109|NCT01730807|DEVICE|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
58301110|NCT04238936|DIAGNOSTIC_TEST|Serum amyloid A values|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
57732646|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
57732647|NCT04883671|OTHER|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
57732648|NCT04883671|RADIATION|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
58084223|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
58084224|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
58301111|NCT04238936|DIAGNOSTIC_TEST|Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
58084225|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
58084226|NCT00005607|DRUG|FOLFIRI regimen|
58084227|NCT00005607|DRUG|fluorouracil|
57732649|NCT03689010|DRUG|Azelaic acid foam 15%|Azelaic acid foam 15%
58301112|NCT00890448|OTHER|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
58301113|NCT03154086|DRUG|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
58301114|NCT03154086|DRUG|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
58301115|NCT02589145|DRUG|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
58301116|NCT02589145|DRUG|Vorinostat|1000 mg by mouth on Days -9 to -2.
57732650|NCT03689010|DRUG|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
58084228|NCT00005607|DRUG|irinotecan hydrochloride|
58084229|NCT00005607|DRUG|leucovorin calcium|
58084230|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
58084231|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
58084232|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
58084233|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
58084234|NCT00900276|OTHER|immunologic technique|
58084235|NCT00900276|OTHER|laboratory biomarker analysis|
58084236|NCT00900276|OTHER|mass spectrometry|
58084237|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
58084238|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
58301117|NCT02589145|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
58301118|NCT02589145|DRUG|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
58301119|NCT02589145|DRUG|Melphalan|60 mg/m2 by vein on days -3 and -2.
57732651|NCT03689010|DRUG|Vehicle of the test product|Vehicle of the test product
57732652|NCT06507566|DEVICE|Tasso+™|The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.
58084239|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
58084240|NCT03659032|PROCEDURE|Educational Physical Therapy|
58084241|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
58084242|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
58084243|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
58084244|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
58084245|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
58084246|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
58084247|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
58084248|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
58084249|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
58084250|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
58084251|NCT00000549|DRUG|estrogen replacement therapy|
58301120|NCT02589145|DRUG|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
58301121|NCT02589145|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
57732653|NCT00193700|DRUG|Testosterone Gel (1%)|
58084252|NCT00000549|DRUG|hormone replacement therapy|
58084253|NCT00000549|DRUG|estrogens|
58084254|NCT00000549|DRUG|progestins|
58301122|NCT02589145|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
58301123|NCT02589145|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
58084255|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
58084256|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
58084257|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
58084258|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
58301124|NCT02589145|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
58301125|NCT02589145|DRUG|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
58301126|NCT02589145|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
58084259|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
58084260|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
58084261|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
58084262|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
58084263|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
58084264|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
58084265|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
58084266|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
58084267|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
58301127|NCT02589145|DRUG|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
58301128|NCT00455169|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
58411818|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
57732654|NCT02612402|DEVICE|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
57732655|NCT02612402|DEVICE|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
58301129|NCT00001512|DRUG|Id-KLH Vaccine|
58301130|NCT00001512|DRUG|GM-CSF|
58301131|NCT04549493|BEHAVIORAL|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
58411819|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
58411820|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
57732656|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
58084268|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
58084269|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
58084270|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
58084271|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
58084272|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
58084273|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
58084274|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
58084275|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
58084276|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
58084277|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
58084278|NCT02575807|DRUG|Epacadostat|PO BID
58084279|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
58411821|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
58411822|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
58411823|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
58411824|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
58411825|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
57732657|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
58411826|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
58411827|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
58411828|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
58411829|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
58411830|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
58411831|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
58411832|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
57732658|NCT06486168|PROCEDURE|NIVATS|Non-Intubated Video-Assisted Thoracic Surgery (NIVATS) is the least invasive approach available. It is part of an optimal Enhanced Recovery After Surgery (ERAS) pathway and allows for expanding surgical indications in patients with poor cardio-pulmonary function.
58084280|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be used as an intervention to help manage stress, worry, and sadness. It is grounded on evidence-based cognitive behavioral therapy and acceptance and commitment therapy techniques, including psychoeducation, mindfulness, behavioral activation through values clarification and goal setting, and cognitive reframing to identify and reframe cognitive distortions.
58084281|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
58084282|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
58084283|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
58084284|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
58084285|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
58084286|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
58084287|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
58084288|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
58301132|NCT04353726|OTHER|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
58301133|NCT01535924|DRUG|gemcitabine hydrochloride|Given IV
58301134|NCT01535924|DRUG|bendamustine hydrochloride|Given IV
58301135|NCT01401595|DRUG|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
58301136|NCT04381078|OTHER|ACE - AudioVisual Guide|Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
58301137|NCT00954681|DRUG|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
58301138|NCT05514730|BEHAVIORAL|Phase-based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children|PBT is a skills-based protocol that primarily works with caregivers to manage problematic behavior and to teach children healthy information about sex and sexuality. It was designed based on the current empirical knowledge regarding the etiology and treatment of childhood problematic sexual behavior. It is delivered in 12 weekly sessions, with each session lasting approximately 50 minutes.
58301139|NCT05514730|BEHAVIORAL|Treatment-as-Usual (TAU)|The TAU intervention designed for this trial relies largely on the delivery of child-focused treatment techniques, particularly on the development of therapeutic rapport through the utilization of non-directive techniques. These sessions are supplemented with educational materials for the caregiver on child behavior and parenting recommendations. This treatment is designed to be administered over 12 weekly sessions, with each session lasting approximately 50 minutes.
58301140|NCT02833896|GENETIC|surgery|
58411833|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
58411834|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
58411835|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
58411836|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
57732659|NCT00765193|OTHER|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
58084289|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
58084290|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
58084291|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
58084292|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
58411837|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
58084293|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
58084294|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
58084295|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
58084296|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
58084297|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
58084298|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
58084299|NCT03005262|DRUG|MLN8237|
58084300|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
58084301|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
58084302|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
58084303|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
58084304|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
58084305|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
58084306|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
58084307|NCT05858515|DRUG|Placebo|Placebo
58084308|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
58084309|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
58084310|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
57732660|NCT06670352|DRUG|Placebo|QD or BID, 24-weeks fixed dose.
57732661|NCT06670352|DRUG|HSK39297 50mgBID|24-weeks fixed dose.
57732662|NCT06670352|DRUG|HSK39297 100mgBID|24-weeks fixed dose.
57732663|NCT06670352|DRUG|HSK39297 200mgQD|24-weeks fixed dose.
58084311|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
58084312|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
58084313|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
58084314|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
58084315|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
58084316|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
58084317|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
58411838|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
58411839|NCT05250050|DRUG|Esomeprazole|20mg bid
58411840|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
58084318|NCT04406363|OTHER|non interventional|non interventional
58084319|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
58084320|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
58084321|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
58084322|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
58084323|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
58084324|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
58084325|NCT00152594|DRUG|voriconazole|
58301141|NCT02001701|PROCEDURE|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
58301142|NCT05117060|DRUG|LEO 152020 tablet|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
58411841|NCT05250050|DRUG|Metronidazole|0.4g qid
58411842|NCT05250050|DRUG|Clarithromycin|0.5g bid
58411843|NCT05250050|DRUG|Levofloxacin|0.5g qd
58411844|NCT05250050|DRUG|Amoxicillin|1g bid
58411845|NCT05250050|DRUG|Tetracycline|0.5g qid
58411846|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
58411847|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
58411848|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
58411849|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
58084326|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
58084327|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
58084328|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
58411850|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
58411851|NCT05544942|OTHER|maltodextrin|1 capsule once a day
58411852|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
58411853|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
58411854|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
58411855|NCT00262678|DRUG|EN3267|
58411856|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
58084329|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
58411857|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
58411858|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
58411859|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
58084330|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
58084331|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
58084332|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
58084333|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
58084334|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
58084335|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
58084336|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
58084337|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
58084338|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
58084339|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
58084340|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
58084341|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
58084342|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
58084343|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
58084344|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
58084345|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
58084346|NCT01463631|DRUG|LY3007113|Administered orally
58084347|NCT04793958|DRUG|MRTX849|28 Day Cycle
58084348|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
58084349|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
58084350|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
58084351|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
58301143|NCT05117060|DRUG|LEO 152020 placebo tablet|LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
58411860|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
58411861|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
58411862|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
58411863|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
58411864|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
58084352|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
58084353|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
58084354|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
58084355|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
58084356|NCT01572610|DRUG|RTA 402|once a day, oral administration
58411865|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
58084357|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
58084358|NCT02524366|DEVICE|Artificial Urinary Sphincter|
58084359|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
58084360|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
58084361|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
58084362|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
58084363|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
58084364|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
58084365|NCT01422876|DRUG|high dose FDC|once daily
58411866|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
58411867|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
58084366|NCT01422876|DRUG|BI 10773 high dose|once daily
58084367|NCT01422876|DRUG|high dose FDC placebo|once daily
57732664|NCT02848417|DRUG|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
57732665|NCT02848417|DRUG|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
58084368|NCT01422876|DRUG|low dose FDC placebo|once daily
58084369|NCT01422876|DRUG|high dose FDC placebo|once daily
58084370|NCT01422876|DRUG|high dose FDC placebo|once daily
58084371|NCT01422876|DRUG|low dose FDC placebo|once daily
58084372|NCT01422876|DRUG|low dose FDC placebo|once daily
58084373|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
58084374|NCT01422876|DRUG|low dose FDC|once daily
58084375|NCT01422876|DRUG|high dose FDC placebo|once daily
58084376|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
58084377|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
58084378|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
58084379|NCT01422876|DRUG|linagliptin|once daily
58084380|NCT01422876|DRUG|low dose FDC placebo|once daily
58084381|NCT01422876|DRUG|linagliptin placebo|once daily
58084382|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
58084383|NCT01422876|DRUG|linagliptin placebo|once daily
58084384|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
58084385|NCT01422876|DRUG|linagliptin placebo|once daily
58084386|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
58084387|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
58084388|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
58084389|NCT01422876|DRUG|linagliptin placebo|once daily
58084390|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
58084391|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days."
58084392|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days."
58084393|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
58411868|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
58084394|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
58084395|NCT00139243|DRUG|Taxotere|
58084396|NCT00139243|DRUG|Cisplatin|
58084397|NCT00139243|DRUG|5-Fluorouracil|
58084398|NCT00139243|DRUG|Leucovorin|
58084399|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
58084400|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
58084401|NCT02965027|DRUG|Prazosin|
57947369|NCT04565886|DEVICE|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
57947370|NCT04565886|DEVICE|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
57947371|NCT03203057|OTHER|coronary occlusion|percutaneous coronary intervention
57947372|NCT04114149|DEVICE|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
57947373|NCT04114149|DRUG|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
57947374|NCT04464395|DRUG|CPI-006|Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
57947375|NCT04464395|OTHER|Standard of Care|Participants will receive standard of care treatment only.
57947376|NCT00844753|DRUG|atomoxetine|atomoxetine
57947377|NCT00844753|DRUG|Placebo|Placebo + parent management treatment
57947378|NCT00844753|BEHAVIORAL|Parent Management Training|
57947379|NCT06119867|PROCEDURE|Japanese pathological investigation|Japanese pathological investigation
57947380|NCT06119867|PROCEDURE|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
57947381|NCT00331045|DRUG|alvimopan|0.25 mg/day
57947382|NCT00331045|DRUG|Placebo|
57947383|NCT00331045|DRUG|Alvimopan 0.5 mg/day|
57947384|NCT00331045|DRUG|Alvimopan 1 mg/day|
57947385|NCT06098365|OTHER|segmental cervical stabilization exercises|Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
57947386|NCT06098365|OTHER|cervical isometric exercises|Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
57947387|NCT01378507|BEHAVIORAL|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
57947388|NCT02039375|OTHER|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
58084402|NCT02965027|DRUG|Placebo|
58084403|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
58084404|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
58084405|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
58084406|NCT00163527|DRUG|Roflumilast|
58084407|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
57732666|NCT02848417|OTHER|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
57732667|NCT00386906|PROCEDURE|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
58084408|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
58084409|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
58084410|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
57732668|NCT02727101|DRUG|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
57732669|NCT06030726|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
57732670|NCT03551015|OTHER|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
57732671|NCT05956340|BEHAVIORAL|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
57732672|NCT04402177|DRUG|Methyl Prednisolonate|Corticosteroid treatment
57732673|NCT04833647|DIAGNOSTIC_TEST|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
57732674|NCT04777565|OTHER|Robotic surgery|Cochlear implant surgery with HEARO procedure
57732675|NCT06262529|OTHER|Cerebral MRI|Cerebral MRI at 72h / 3 months / 12 months
57732676|NCT05283174|OTHER|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
57732677|NCT05064969|BEHAVIORAL|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
58084411|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
58084412|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
58084413|NCT03488537|DEVICE|AeonoseTM|Breath test
58084414|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
58084415|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
58084416|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
58084417|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
58084418|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
58084419|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
57732678|NCT05282381|BEHAVIORAL|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
57732679|NCT06328361|PROCEDURE|Nonoperative surveillance|Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
57732680|NCT01248650|DRUG|nalfurafine hydrochloride|
57732681|NCT02785406|DRUG|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
57732682|NCT02785406|DRUG|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
57732683|NCT05014594|DRUG|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
57732684|NCT05014594|DRUG|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
57732685|NCT00026533|DRUG|thalidomide|
57732686|NCT05680103|RADIATION|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
58084420|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
58084421|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
58084422|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
58084423|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
58084424|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
58084425|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
58084426|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
58084427|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
58084428|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
58084429|NCT00153751|DRUG|Holopon|holopon
58084430|NCT00153751|OTHER|placebo|placebo
58084431|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
58411869|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
58301144|NCT05433467|PROCEDURE|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
57947389|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg"
57947390|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg"
57947391|NCT01057407|DRUG|ASP1585|oral
57947392|NCT01057407|DRUG|Sevelamer hydrochloride|oral
57947393|NCT05884203|DEVICE|Caregiver socket|A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
57947394|NCT05884203|DEVICE|Prosthetist socket|A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
57947395|NCT01833637|OTHER|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
57947396|NCT00533832|DEVICE|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
57947397|NCT05732090|OTHER|therapeutic exercise program|therapeutic exercise program (3 sessions/week/two months).
58411870|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
58084432|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
58084433|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
58084434|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
58084435|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
58084436|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
58084437|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
58084438|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
58084439|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
58084440|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
58084441|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
58084442|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
58084443|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
58084444|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
58301145|NCT02509377|PROCEDURE|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
58301146|NCT04085601|DRUG|APL-2|Complement (C3) Inhibitor
57947398|NCT05732090|OTHER|diaphragmatic myofascial release|therapeutic exercise program in addition to diaphragmatic myofascial release (3 sessions/week/two months).
57947399|NCT03614754|DIAGNOSTIC_TEST|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
58084445|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
58084446|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
58084447|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
58301147|NCT03745053|DEVICE|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
58301148|NCT03745053|DEVICE|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
58301149|NCT04772066|OTHER|Measure of medication adherence|Measure of medication adherence
58301150|NCT00313690|DRUG|Bortezomib, Docetaxel and Cisplatin|
58301151|NCT00699777|DRUG|Risedronate|1 risedronate 150 mg tablet administered orally
58301152|NCT00699777|DRUG|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
58411871|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
58411872|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
58411873|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
58084448|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
58301153|NCT03708471|PROCEDURE|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
58301154|NCT03708471|PROCEDURE|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
58301155|NCT02599532|DRUG|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
58301156|NCT04247516|BEHAVIORAL|Online-intervention group I (IGI)|Narrative-based online intervention program to promote self-regulatory competences.
58301157|NCT04247516|BEHAVIORAL|Online-intervention group II (IGII)|Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
58411874|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
58411875|NCT00361699|DRUG|Statin|
58411876|NCT01747200|PROCEDURE|Sham rTMS|
58411877|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
58411878|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
58411879|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
58411880|NCT01747200|PROCEDURE|rTMS over TP8|
58411881|NCT01747200|PROCEDURE|rTMS over TP7|
58411882|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
58411883|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
57947400|NCT00867321|BIOLOGICAL|bevacizumab|Given IV
57947401|NCT00867321|DRUG|sorafenib tosylate|Given orally
57947402|NCT03535467|OTHER|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
57947403|NCT03077685|DRUG|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
57947404|NCT01982032|PROCEDURE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
57947405|NCT01982032|DEVICE|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
57947406|NCT01982032|DEVICE|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
57947407|NCT03007368|OTHER|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
57947408|NCT03007368|OTHER|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
57947409|NCT03007368|OTHER|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
57947410|NCT03007368|OTHER|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
57947411|NCT03007368|OTHER|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
58084449|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
58084450|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
58084451|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
58084452|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
58084453|NCT00052507|DRUG|bortezomib|
58084454|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
58084455|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
58084456|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
58084457|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
58084458|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
58084459|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
58084460|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
58084461|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
58084462|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
58084463|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
58084464|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
58084465|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
58084466|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
58084467|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
58084468|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
58301158|NCT04954521|DRUG|Anlotinib|This is an observational study
58301159|NCT02307227|DRUG|Trastuzumab|
58301160|NCT02307227|DRUG|Paclitaxel|
58301161|NCT02307227|DRUG|Epirubicin|
58411884|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
58084469|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
58084470|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
58084471|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
58084472|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
58084473|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
58084474|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
58084475|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
58084476|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
58084477|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
58084478|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
58301162|NCT02307227|DRUG|Docetaxel|
58301163|NCT05438277|DRUG|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
58301164|NCT05438277|DRUG|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
58301165|NCT05775627|BEHAVIORAL|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
58084479|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
58411885|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
58084480|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
58084481|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
58084482|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
58084483|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
58084484|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
58084485|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
58084486|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
58084487|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
58084488|NCT05340309|OTHER|Survey Administration|Ancillary studies
58084489|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
58084490|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
58084491|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
58084492|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
58411886|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
58411887|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
58411888|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
58411889|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
58411890|NCT03132103|RADIATION|Placebo SSR|
58411891|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
58411892|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
58411893|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
58084493|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
58084494|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
58084495|NCT04707612|OTHER|No intervention.|No intervention.
58084496|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
58084497|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
58084498|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
58084499|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
58084500|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
58084501|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
58084502|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
58084503|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
58084504|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
58084505|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
58084506|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
58411894|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
58411895|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
58411896|NCT01735708|BEHAVIORAL|HIVPASS|
58084507|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
58084508|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
58084509|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
58084510|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
58084511|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
58084512|NCT00956813|OTHER|placebo|Given orally
58084513|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
58084514|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
58084515|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
58084516|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
58084517|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
58084518|NCT01898884|DRUG|VP 20629|
58084519|NCT01898884|DRUG|Placebo|
58084520|NCT00407966|DRUG|alvocidib|Given IV
57947412|NCT03007368|OTHER|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
58084521|NCT00407966|DRUG|cytarabine|Given IV
58084522|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
58301166|NCT03722706|OTHER|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
58301167|NCT01690507|DRUG|Decitabine|20 mg/m²/day for 5 days
58301168|NCT01690507|DRUG|Cytarabine|
58411897|NCT01735708|OTHER|Health Education|
58301169|NCT01690507|DRUG|aclacinomycin|
58301170|NCT01690507|DRUG|Granulocyte colony-stimulating factor|
58301171|NCT01690507|OTHER|HLA haploidentical mononuclear cells infusion|
58301172|NCT02586376|DEVICE|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
58301173|NCT02586376|DEVICE|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
58301174|NCT02586376|DEVICE|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
58301175|NCT02586376|DEVICE|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
57947413|NCT03007368|OTHER|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
57947414|NCT03007368|OTHER|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
57947415|NCT00456352|PROCEDURE|duodenal exclusion|
57947416|NCT03257670|DRUG|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
57947417|NCT03257670|DEVICE|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
57947418|NCT03029143|DRUG|Vedolizumab IV|Vedolizumab intravenous infusion.
57947419|NCT00889148|DRUG|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
57947420|NCT00889148|OTHER|Placebo|Half the patients will be randomized to placebo
57947421|NCT01315860|OTHER|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
57947422|NCT03628053|BIOLOGICAL|Tisagenlecleucel|autologous cellular immunotherapy product
57947423|NCT03628053|DRUG|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
57947424|NCT03628053|DRUG|Inotuzumab|CD22-directed antibody-drug conjugate
57947425|NCT03186690|OTHER|Biodentine|
57947426|NCT03186690|OTHER|Mineral Trioxide Aggregate|
58301176|NCT00424281|DRUG|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
58301177|NCT01753609|DEVICE|Tulip capsule|swallowing Tulip capsule for up to 29 days
58411898|NCT00212199|DRUG|orlistat|
58411899|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
58084523|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
58084524|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
58084525|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
58084526|NCT02494882|DRUG|Ruxolitinib|
58084527|NCT02494882|DRUG|Dasatinib|
58084528|NCT02494882|DRUG|Dexamethasone|
58084529|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
58084530|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
58084531|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
58084532|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
58084533|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
58084534|NCT00138801|DRUG|Ceftriaxone|
58084535|NCT00138801|DRUG|Doxycycline|
58084536|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
58084537|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
58084538|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
58084539|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
58084540|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
58084541|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
58084542|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
58084543|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
58084544|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
58084545|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
58084546|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
58084547|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
58084548|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
58084549|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
58411900|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
58084550|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
58084551|NCT01754805|DRUG|peficitinib|oral
58084552|NCT01754805|DRUG|methotrexate|oral
58084553|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
58084554|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
58084555|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
58301178|NCT05932758|PROCEDURE|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
58301179|NCT05932758|PROCEDURE|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
58411901|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
58301180|NCT00852813|DIETARY_SUPPLEMENT|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
58084556|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
58084557|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
58084558|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
58084559|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
58084560|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
58084561|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
58084562|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
58411902|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
58084563|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
58084564|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
58084565|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
58084566|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
58084567|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
58084568|NCT04909879|DRUG|Placebo|Excipient solution
58084569|NCT01010724|DRUG|bIAP|
58084570|NCT01010724|DRUG|Placebo|
58084571|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
58084572|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
58084573|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
58084574|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
58084575|NCT02647632|DRUG|Grazoprevir/Elbasvir|
58084576|NCT02647632|DRUG|Sofosbuvir|
58084577|NCT02647632|DRUG|Ribavirin|
58084578|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
58084579|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
58084580|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
58084581|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
58084582|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
58084583|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
58411903|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
58411904|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
58411905|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
58411906|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
58084584|NCT05518058|OTHER|device and exercises|device and exercises
58084585|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
58084586|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
58084587|NCT02127788|DRUG|Micafungin|intravenous
58084588|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
58084589|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
58084590|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
58084591|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
58084592|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
58084593|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
58084594|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
58084595|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
58084596|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
58084597|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
58084598|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
58084599|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
58084600|NCT01292291|OTHER|biologic sample preservation procedure|
58084601|NCT01292291|OTHER|laboratory biomarker analysis|
58084602|NCT01292291|OTHER|study of socioeconomic and demographic variables|
58084603|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
58084604|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
58411907|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
58411908|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
58084605|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
58084606|NCT01292291|PROCEDURE|quality-of-life assessment|
58084607|NCT01292291|PROCEDURE|transperineal prostate biopsy|
58084608|NCT01292291|PROCEDURE|transrectal prostate biopsy|
58084609|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
58084610|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
58084611|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
58084612|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
58084613|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
58084614|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
58084615|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
58084616|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
58084617|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
58084618|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
58084619|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
58084620|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
58084621|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
58084622|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
58084623|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
58084624|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
58084625|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
58084626|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
58084627|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
58084628|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
58301181|NCT01128296|DRUG|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
58301182|NCT01128296|DRUG|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
58411909|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
58411910|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
58411911|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
58411912|NCT02668861|OTHER|placebo|placebo for 8 weeks
58411913|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
58411914|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
58084629|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
58084630|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
58084631|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
58084632|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
58084633|NCT04150107|OTHER|Placebo|Fish oil capsule
58084634|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
58084635|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
58084636|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
58084637|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
58084638|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
58084639|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
58084640|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
58301183|NCT01663402|DRUG|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
58301184|NCT01663402|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
58301185|NCT01663402|DRUG|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
58301186|NCT00742911|DRUG|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
58301187|NCT00742911|DRUG|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
58301188|NCT04787367|PROCEDURE|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
58301189|NCT06330376|OTHER|Usual care of traditional treatment|Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated
58301190|NCT06330376|OTHER|Specific DB program/Diaphragmatic manipulation program|12 weeks of 2 sessions/week: one session will be remote and one in-person
58301191|NCT01450319|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
58301192|NCT05229328|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
58301193|NCT02692586|DEVICE|FlowTriever System|
58301194|NCT02644278|DRUG|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
58301195|NCT02644278|DRUG|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
58411915|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
58084641|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
58084642|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
58084643|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
58084644|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
58084645|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
58084646|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
58084647|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
58084648|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
58084649|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
58084650|NCT00335816|DRUG|fluorouracil|Given IV
58411916|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
58411917|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
58411918|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
58411919|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
58084651|NCT00335816|DRUG|leucovorin calcium|Given IV
58084652|NCT00335816|DRUG|oxaliplatin|Given IV
58084653|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
58084654|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
58084655|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
58084656|NCT00335816|GENETIC|DNA analysis|Correlative studies
58084657|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
58301196|NCT02644278|DRUG|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
58301197|NCT02644278|DRUG|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
58301198|NCT05397353|OTHER|Sleepio (TM)|Sleepio is a mobile Digital Cognitive Behavior Therapy for Insomnia (dCBT-I) app.
58301199|NCT05731700|DEVICE|Drug Eluting Balloon|PCI of in-stent restenosis
58301200|NCT03573635|DEVICE|Supratube|Aspiration of orotracheal secretions with supratube device
58301201|NCT03573635|OTHER|Reference|Usual aspiration with any other device
58411920|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
58411921|NCT02466074|DRUG|Acetazolamide|see arm description
58411922|NCT02466074|DRUG|Placebo|Placebo arm
58084658|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
58084659|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
58084660|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
58084661|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
58084662|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
58301202|NCT03503279|DEVICE|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
57732687|NCT02529774|DRUG|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
57947427|NCT06255704|DRUG|Zanubrutinib and RCHOP/RDHAP|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。"
58084663|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
58084664|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
58411923|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
57947428|NCT02410668|DIETARY_SUPPLEMENT|flaxseed|
57947429|NCT02410668|DIETARY_SUPPLEMENT|Placebo|
57947430|NCT02410668|BEHAVIORAL|Exercise recommendation|
57947431|NCT01718561|PROCEDURE|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
58084665|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
58084666|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
58084667|NCT00292006|DEVICE|Computerized tomography|
57947432|NCT01230541|DRUG|Placebo|Daily, oral tablet
57947433|NCT01230541|DRUG|Udenafil|Daily tablet
57947434|NCT05896085|OTHER|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
57947435|NCT01731379|PROCEDURE|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
57947436|NCT06005870|DRUG|Zanubrutinib plus RCHOP|Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21
58084668|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
58084669|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
58084670|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
58411924|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
57947437|NCT00061542|DRUG|BETOPTIC S (betaxolol HCl)|betaxolol HC)
57947438|NCT00061542|DRUG|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
57947439|NCT00351832|DRUG|Vildagliptin|
57947440|NCT01887067|PROCEDURE|Renal denervation therapy|
57947441|NCT03820414|BIOLOGICAL|CRV 101|(Different formulations)
57947442|NCT03820414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
58084671|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
58084672|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
58084673|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
58084674|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
58084675|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
58084676|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
58301203|NCT03863860|DRUG|Fluzoparib capsules|Fluzoparib capsules
58084677|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
58084678|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
58084679|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
58084680|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site and isolated with cotton rolls (not to contaminate the medication with saliva) Patients were recalled after a week for refrained from using any other oral hygiene measures in the observation period, recalled after a month for follow-up.
58084681|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
58084682|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
58084683|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
58084684|NCT00262483|DRUG|VX-950|
58084685|NCT00262483|DRUG|ribavirin|
58084686|NCT00262483|DRUG|peginterferon alfa-2a|
57732688|NCT02529774|DRUG|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
58084687|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
58084688|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
58084689|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
58084690|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
58084691|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
58084692|NCT00207025|DRUG|BMS-275183|
58084693|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
58084694|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
58084695|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
58084696|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
58084697|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
58084698|NCT04029766|DRUG|HSK3486|
58084699|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
57732689|NCT04790981|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
58084700|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
58084701|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
58084702|NCT00144859|DRUG|SB681323|
58084703|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
57732690|NCT04790981|OTHER|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
57947443|NCT02751203|BEHAVIORAL|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
58084704|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
58084705|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
58301204|NCT03863860|DRUG|Placebo capsules|Placebo capsule
57732691|NCT04201548|OTHER|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
57732692|NCT04201548|OTHER|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
57732693|NCT04201548|OTHER|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
57732694|NCT06670274|DRUG|HC002 SAD|"Part 1 will enroll 40 participants across 5 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 5 cohorts."
57732695|NCT06670274|DRUG|HC002 MAD|"Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days"
57732696|NCT06670274|DRUG|Placebo|Matching placebo will be administered across SAD and MAD
57732697|NCT05209282|OTHER|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
57732698|NCT05209282|OTHER|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
57732699|NCT05209282|OTHER|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
57947444|NCT02431702|DRUG|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
57947445|NCT02431702|DRUG|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
57947446|NCT02431702|DRUG|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
57947447|NCT02431702|DRUG|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
58084706|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
58084707|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
58084708|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
58084709|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
58084710|NCT04621227|DRUG|Midazolam|2mg single dose
58084711|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
58301205|NCT03429348|OTHER|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
58084712|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
58084713|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
58084714|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
58084715|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
58084716|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
58084717|NCT04492488|DRUG|MRG002|Administrated intravenously
58084718|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
58084719|NCT01782638|BEHAVIORAL|deep brain stimulation|
57947448|NCT02431702|DRUG|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
58084720|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
58084721|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
58084722|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
58084723|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
57947449|NCT02431702|DRUG|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
57947450|NCT02431702|DRUG|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
57947451|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
57947452|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
58084724|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
58084725|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
58084726|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
58084727|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
58084728|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
58084729|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
58084730|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
58084731|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
58084732|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
58084733|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
58084734|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
58084735|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
58084736|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
58301206|NCT05390606|COMBINATION_PRODUCT|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
58411925|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
57947453|NCT03433872|OTHER|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
57947454|NCT05676359|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
57947455|NCT05676359|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
57947456|NCT05676359|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
57947457|NCT05676359|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
57947458|NCT05676359|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
57947459|NCT05676359|OTHER|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
57947460|NCT05676359|OTHER|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
57947461|NCT05676359|OTHER|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
57947462|NCT02164695|PROCEDURE|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
57947463|NCT02164695|PROCEDURE|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
58084737|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
58084738|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
58411926|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
58411927|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
58411928|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
58084739|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
58084740|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
58084741|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
58084742|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
58084743|NCT02500173|RADIATION|Radiation|Radiation therapy
58084744|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58084745|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
58084746|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
58084747|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
58084748|NCT03583801|OTHER|without aromatherapy|no intervention
58084749|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
58084750|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
58084751|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
58084752|NCT00226447|DRUG|Pegylated Interferon|
58084753|NCT00226447|DRUG|Lamivudine|
58084754|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
58084755|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
58084756|NCT00288782|DRUG|Mirtazapine|
58084757|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
58084758|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
58084759|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
58084760|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
58084761|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
58084762|NCT02452775|BIOLOGICAL|OC-L|
58084763|NCT02452775|OTHER|Montanide|
58301207|NCT05868317|DRUG|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
58301208|NCT05868317|RADIATION|Radiotherapy|Short Course Radiotherapy
58084764|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
58084765|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
58084766|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
58084767|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
58084768|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
58084769|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
58084770|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
58084771|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
58084772|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
58084773|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
58084774|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
58084775|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
58084776|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
58084777|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
58301209|NCT02652637|DRUG|neomycin, metronidazole, polyethylene glycol (PEG)|
58411929|NCT01229943|DRUG|Everolimus|Given PO
58411930|NCT01229943|DRUG|Octreotide Acetate|Given IM
58084778|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
58084779|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
58084780|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
58084781|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
58084782|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
58084783|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
58084784|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
58084785|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
57947464|NCT05771220|OTHER|radial extracorporeal shockwave therapy+ evidence-based physical therapy|The experimental group received six sessions of rESWT over six weeks in addition to an EBPT program. The rESWT procedure involved applying shockwaves to the affected area using a radial probe, with sessions lasting 10-15 minutes and consisting of up to 2000 impulses delivered at a frequency of 3-6 pulses per second and an energy intensity level of 1.8 bar, based on patient tolerance. Patients were seated or lying down during the rESWT procedure, with gel or oil applied to facilitate shockwave transmission through the skin. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
57947465|NCT05771220|OTHER|sham radial extracorporeal shockwave therapy+ evidence-based physical therapy|The participants in the control group received six weeks of sham rESWT (radial extracorporeal shock wave therapy) combined with the EBPT (evidence-based physical therapy) program. The sham rESWT involved six sessions with a maximum of 200 impulses delivered at a low intensity, with the applicator placed on the affected area for the same duration as the experimental group. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
57947466|NCT03270189|DEVICE|prism glasses|orthoptic treatment by wearing prisms when writing
57947467|NCT05248568|DEVICE|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
57947468|NCT01023633|DRUG|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
57947469|NCT02424032|BEHAVIORAL|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
57947470|NCT02424032|BEHAVIORAL|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
57947471|NCT00894062|DEVICE|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
57947472|NCT00894062|DEVICE|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
58084786|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
58084787|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
58084788|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
58084789|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
58084790|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
58084791|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
58084792|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
58084793|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
58411931|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
58084794|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
58084795|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
58084796|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
58084797|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
58301210|NCT05704868|BEHAVIORAL|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
57947473|NCT05700305|OTHER|12-week, low threshold physical rehabilitation intervention with protein supplementation|12 week, low threshold, rolling exercise intervention with protein supplementation
57947474|NCT06148688|OTHER|Digital Story|"Digital storytelling; It is used in education and training, business marketing, non-profit organizations such as libraries, community centers and museums, and health sciences education. Digital storytelling in health sciences can be a tool for patients and health science professionals to share their experiences, cope with diseases, and add a human element to health problems.~In the study, digital stories were created to increase the self-management of pregnant women with gestational diabetes. In creating a digital story; Qualitative studies involving the self-management experiences of women with gestational diabetes have been examined in the literature. Using the results of the studies, scenarios were created that included factors that facilitate and complicate diabetes self-management. The created scenarios were used in the digital storytelling initiative. A total of four long and four short digital story videos were prepared."
57947475|NCT01486849|DRUG|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
57947476|NCT01486849|DRUG|Placebo|Matching placebo tablets BID for 21 days
57947477|NCT01486849|DRUG|Riluzole 50 MG|
57947478|NCT04455763|PROCEDURE|SVF|Adipose-derived stromal vascular fraction
57947479|NCT04455763|OTHER|Splint|Thumb brace (Actimove® Rhizo Forte)
57947480|NCT04944654|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
57947481|NCT03144245|BIOLOGICAL|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
57947482|NCT03144245|COMBINATION_PRODUCT|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
57947483|NCT06114784|DIAGNOSTIC_TEST|metagenomics|Perform metagenomic analysis on balf, feces, and blood
57947484|NCT05630248|DIAGNOSTIC_TEST|Recurrent Neural Network|it is to classify pulse types by using specialized pulse measuring instruments.
57947485|NCT00294359|DRUG|Mitomycin C; Capecitabine; Bevacizumab|
57947486|NCT05963789|OTHER|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
57947487|NCT05963789|OTHER|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
57947488|NCT05404464|OTHER|Different baseline characteristics and clinical management|Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
58411932|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
58411933|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
57947489|NCT05576389|DRUG|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
57947490|NCT00861068|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
57947491|NCT00861068|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
57947492|NCT03817775|OTHER|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
57947493|NCT02993874|DIETARY_SUPPLEMENT|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
58084798|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
58084799|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
58084800|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
58084801|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
58084802|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
58084803|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
58084804|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
57732700|NCT06630871|DRUG|Distitamab Vedotin in combination with Tislelizumab|On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
57732701|NCT00549926|DRUG|Fluvastatin|
57947494|NCT02993874|DIETARY_SUPPLEMENT|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
57732702|NCT00549926|DRUG|Pravastatin|
57732703|NCT00549926|DRUG|Pitavastatin|
57732704|NCT00549926|DRUG|Atorvastatin|
57947495|NCT00472264|PROCEDURE|PET imaging|Medical imaging assessment
58084805|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
58084806|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
58084807|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
58084808|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
58084809|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
58084810|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
58084811|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
58301211|NCT02437760|OTHER|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~* at time of diagnosis~* every 3 month during treatment~* stop at the progression or after 12 months"
58411934|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
58411935|NCT05388773|DRUG|Cisplatin|Given IV.
58084812|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
58411936|NCT05388773|DRUG|Carboplatin|Given IV
58411937|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
58411938|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
58411939|NCT00041171|DRUG|Hypericum perforatum|
58411940|NCT00041171|DRUG|docetaxel|
58411941|NCT00041171|OTHER|placebo|
58084813|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
58084814|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
58411942|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
58411943|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
58411944|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
58411945|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
58411946|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
58411947|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
58411948|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
58411949|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
58411950|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
58411951|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
58301212|NCT03962608|DEVICE|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
58301213|NCT03962608|DEVICE|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
58411952|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
58411953|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
58411954|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
58411955|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
58411956|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
58411957|NCT00197145|DRUG|GW873140|400 mg twice daily
58411958|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
58084815|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
58084816|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
58411959|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
58411960|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
58411961|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
58411962|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
58411963|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
58411964|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
58411965|NCT05026892|OTHER|no intervention|no intervention, only collection of data
58411966|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
58411967|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
58411968|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
58411969|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
58411970|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
58411971|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
58411972|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
58411973|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
58411974|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
58411975|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
58411976|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
58411977|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
58411978|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
58411979|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
58411980|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
58411981|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
58411982|NCT00084019|DRUG|Atazanavir|
58411983|NCT00084019|DRUG|Ritonavir|
58411984|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
57732705|NCT04506970|DIAGNOSTIC_TEST|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
57732706|NCT04506970|OTHER|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
58411985|NCT03024138|RADIATION|Repeat CT scan|
58411986|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
58411987|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
57732707|NCT02091999|DRUG|enfortumab vedotin|intravenous (IV) infusion
58084817|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
58084818|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
58084819|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
58084820|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
58084821|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
58084822|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
58084823|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
58084824|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
57732708|NCT05553691|DRUG|SPL026|Intravenous
58084825|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
58084826|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
58084827|NCT05726110|DRUG|Selinexor|Given PO
58084828|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
58084829|NCT05726110|DRUG|Daunorubicin|Given per standard of care
58301214|NCT00916552|DRUG|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
58411988|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
58411989|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
58411990|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
58411991|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
58411992|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
57732709|NCT02870790|DRUG|TDF/FTC|one pill daily
58084830|NCT05726110|DRUG|Cytarabine|Given per standard of care
58084831|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
58084832|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
58084833|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
58084834|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
58084835|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
58084836|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
58301215|NCT00974311|DRUG|Enzalutamide|MDV3100, 160 mg orally per day
57732710|NCT01107574|DRUG|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
58084837|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
58084838|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
58084839|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
58084840|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
58084841|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
58084842|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
58084843|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
58084844|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
58084845|NCT01894542|DIETARY_SUPPLEMENT|Control|
58084846|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
58084847|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
58301216|NCT00974311|DRUG|Placebo|Placebo comparator
58301217|NCT05793515|DIAGNOSTIC_TEST|whole genome sequencing|Whole genome sequencing will be performed in patients whose test was negative for the targeted resequencing and/or clinical exome sequencing.
58301218|NCT03240419|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
58301219|NCT03240419|DIETARY_SUPPLEMENT|Placebo|capsule manufactured to mimic probiotic capsules.
58301220|NCT02975401|PROCEDURE|rTAPP technique|robot-assisted rTAPP technique
58301221|NCT00115310|DRUG|NGX-4010|
58084848|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
58301222|NCT03179358|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
58301223|NCT02031523|DRUG|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
58301224|NCT02031523|DRUG|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
58411993|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
58411994|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
58411995|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
58411996|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
58411997|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
58411998|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
58411999|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
58412000|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
58412001|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
58412002|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
58412003|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
58084849|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
58301225|NCT00165126|PROCEDURE|Radiation therapy|Given as standard therapy
58412004|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
58412005|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
58084850|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
58084851|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
58084852|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
58301226|NCT01975558|BIOLOGICAL|Sampling at baseline, one week after baseline, two weeks after baseline|
58084853|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
58084854|NCT00566397|DRUG|Placebo|Placebo
58301227|NCT01975558|BIOLOGICAL|Sampling at baseline, during radiotherapy and after|
58301228|NCT03472911|OTHER|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
58301229|NCT05211440|DIETARY_SUPPLEMENT|Placebo + Meal|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a placebo capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
58412006|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
58412007|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
58412008|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
58412009|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
58412010|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
58412011|NCT00898924|GENETIC|molecular diagnostic method|
58412012|NCT00898924|GENETIC|mutation analysis|
58412013|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
58412014|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
58301230|NCT05211440|DIETARY_SUPPLEMENT|BC-006 + Meal|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a BC-006 capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
58084855|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
58084856|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
58084857|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
58084858|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
58084859|NCT06018363|BIOLOGICAL|Allogenic B7H3 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^7 cells) , dose 2 (3 × 10\^7 cells), dose 3 (1× 10\^8 cells); Phase 2 : dose of RP2D.
58084860|NCT02702375|OTHER|Fructose-containing Sugars|
58084861|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
58084862|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
58084863|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
58084864|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
58084865|NCT06537336|DEVICE|lung function|lung function tests using spirometry
58084866|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
58084867|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
58084868|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
58084869|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
58084870|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
58084871|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
58301231|NCT03114293|BEHAVIORAL|Smartphone App|The app includes an EBPI and physical activity feedback
58301232|NCT01775670|DEVICE|Off-the-shelf splint|Subjects will use an off-the-shelf splint
58084872|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
58084873|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
58084874|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
58084875|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
58084876|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
58301233|NCT01775670|DEVICE|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
58301234|NCT00502567|DRUG|AZD2171|oral tablet once daily
58301235|NCT00502567|DRUG|FOLFOX|intravenous infusion
58301236|NCT00502567|DRUG|Pemetrexed|intravenous infusion
58301237|NCT00502567|DRUG|Irinotecan (administered with & without Cetuximab)|intravenous injection
58301238|NCT00502567|DRUG|Docetaxel|intravenous infusion
58301239|NCT00965107|DRUG|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
58301240|NCT00965107|DRUG|Propofol|Propofol given as a bolus dose of 1 mg/kg.
58301241|NCT01558219|DRUG|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
58412015|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
58084877|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
58084878|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
58084879|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
58084880|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
58084881|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
58084882|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
58084883|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
58084884|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
58084885|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
58084886|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
58084887|NCT03948646|DRUG|Vehicle|Vehicle gel
58084888|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
58084889|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
58084890|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
58084891|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
58084892|NCT03197506|DRUG|Temozolomide|Given PO
58084893|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58084894|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
58301242|NCT02311829|OTHER|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
58301243|NCT04831034|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
58301244|NCT05439746|DEVICE|Microlyte® Matrix|Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
58412016|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
58084895|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
58084896|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
58084897|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
58084898|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
58084899|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
58084900|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
58301245|NCT05793593|OTHER|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
58301246|NCT05793593|OTHER|Colorectal Cancer (CRC) education alone|CRC education alone.
58301247|NCT06040359|OTHER|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
58301248|NCT06040359|OTHER|Usual care|Usual perinatal care
58412017|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
57947496|NCT01347554|DEVICE|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
58301249|NCT05310669|DEVICE|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose).
58301250|NCT04799925|DRUG|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
58301251|NCT05728736|DRUG|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
58301252|NCT05728736|DRUG|Placebo|Placebo will be taken nightly for two consecutive nights
58301253|NCT01461642|OTHER|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
58301254|NCT00458315|DRUG|Cisplatin|
58301255|NCT00458315|DRUG|Paclitaxel|
57947497|NCT01347554|DEVICE|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
57947498|NCT00169455|BIOLOGICAL|Live attenuated human rotavirus vaccine|
57947499|NCT04046107|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
57947500|NCT03413189|OTHER|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
57947501|NCT03413189|OTHER|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
57947502|NCT03413189|OTHER|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
57947503|NCT04194528|DRUG|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
57947504|NCT04194528|DEVICE|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
57947505|NCT02431091|OTHER|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
57947506|NCT04852328|DRUG|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
58084901|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
58084902|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
58084903|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
58084904|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
58301256|NCT00458315|DRUG|Gemcitabine|
58301257|NCT00458315|DRUG|Avastin (Bevacizumab)|
58301258|NCT02224625|DRUG|2% CHG Cloth solution|Investigational CHG
58301259|NCT02224625|DEVICE|Vehicle Cloth|Excipients from CHG cloth only
58301260|NCT02224625|DRUG|Active Comparator|Active comparator
58301261|NCT02224625|OTHER|Saline|Negative control
58301262|NCT02224625|OTHER|SLS|Provides a slight irritation for a positive control
58301263|NCT05945238|OTHER|Thrower's Ten Exercise Program|T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
58301264|NCT04966286|OTHER|multimedia education|The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
58301265|NCT02923765|OTHER|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
58301266|NCT03259152|DRUG|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
58412018|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
58412019|NCT02608580|OTHER|Survey|
58412020|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
58412021|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
58412022|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
58084905|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
58084906|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
58084907|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
58084908|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
58084909|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
58084910|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
58084911|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
58301267|NCT02570386|PROCEDURE|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
58301268|NCT02570386|PROCEDURE|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
58301269|NCT02230891|DRUG|Carvedilol|Carvedilol is a non selective beta blocker
58301270|NCT02230891|DRUG|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
58301271|NCT02230891|OTHER|Usual care|standard care as per primary care provider
58301272|NCT06524388|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
58301273|NCT06524388|DEVICE|placebo cognitive training|Participants received cognitive training tasks of fixed difficulty.
58301274|NCT02733718|DEVICE|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
58301275|NCT02655003|OTHER|TIME|
58412023|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
57732711|NCT01107574|PROCEDURE|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
58084912|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
58084913|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
58084914|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
58084915|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
58084916|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
58084917|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
58084918|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
58084919|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
58084920|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
58084921|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
58084922|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
58084923|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
58301276|NCT02655003|OTHER|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
58301277|NCT01937897|OTHER|Bi-lateral massage|Unilateral massage on the left side of the body.
58301278|NCT00128661|BIOLOGICAL|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
58301279|NCT00128661|BIOLOGICAL|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
58412024|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
58412025|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
58412026|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
58412027|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
58412028|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
58084924|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
58084925|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
58084926|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
58301280|NCT03479112|BEHAVIORAL|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
58301281|NCT03479112|BEHAVIORAL|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
58301282|NCT03479112|BEHAVIORAL|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
58301283|NCT03479112|BEHAVIORAL|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
58301284|NCT03540693|PROCEDURE|RYGB|RYGB-weight loss surgery
58301285|NCT03540693|PROCEDURE|SG|SG- weight loss surgery
58301286|NCT03540693|PROCEDURE|LAGB|LAGB- weight loss surgery
58301287|NCT04062695|DRUG|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
58301288|NCT04062695|DRUG|Placebo oral tablet|tablets containing placebo
58301289|NCT03319771|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
58301290|NCT03319771|BEHAVIORAL|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
58301291|NCT06550843|PROCEDURE|mesentery-guided division|In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
58301292|NCT04249427|DRUG|Erenumab Prefilled Syringe|140mg Erenumab, pre-filled syringe given by subcutaneous injection
58301293|NCT04249427|OTHER|Placebo|Placebo, pre-filled syringe given by subcutaneous injection
58412029|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
58412030|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
58084927|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
58301294|NCT02262897|DRUG|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
58301295|NCT01155817|DRUG|Nilotinib|200, 400, 800, oral
58301296|NCT04389528|OTHER|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
58301297|NCT03685604|DRUG|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
58301298|NCT03685604|DRUG|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
58412031|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
58412032|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
58084928|NCT05584202|OTHER|Placebo|0.9% sodium chloride
58084929|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
58084930|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
58084931|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
58084932|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
58084933|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
58084934|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
58084935|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
58084936|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
58084937|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
58084938|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
58084939|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
58084940|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
58084941|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
58084942|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
58084943|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
58084944|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
58084945|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
58084946|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
58084947|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
58084948|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
58301299|NCT01537224|OTHER|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
58301300|NCT02099513|DEVICE|The Mobile Health Platform|
58301301|NCT03691636|DEVICE|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
58301302|NCT03691636|DEVICE|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
58412033|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
58084949|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
58084950|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
58084951|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
58084952|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
58084953|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
58084954|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
58084955|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
58084956|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
58084957|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
58084958|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
58301303|NCT02895035|DRUG|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
58301304|NCT02895035|DRUG|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
58301305|NCT02405819|OTHER|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
58301306|NCT02405819|OTHER|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
58412034|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
57732712|NCT01107574|OTHER|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
57732713|NCT04763122|OTHER|not applicable as it is a retrospective study|It is a retrospective study
58084959|NCT00981565|OTHER|Night-cast|individual night time splinting
58301307|NCT02295072|BEHAVIORAL|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
58301308|NCT02974868|DRUG|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
58301309|NCT02974868|DRUG|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
58412035|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
58412036|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
57732714|NCT06352853|OTHER|Skin incision in Cesarean Section by Diathermy|Skin incision by diathermy
57732715|NCT06352853|OTHER|Skin incision in Cesarean Section by Scalpel|Skin incision by scalpel
57732716|NCT02487563|DRUG|Decitabine|Decitabine
58301310|NCT02974868|DRUG|Placebo|Placebo
58301311|NCT00132535|DRUG|sulfadoxine-pyrimethamine intermittent preventive treatment|
58301312|NCT00132535|DRUG|chloroquine|
58301313|NCT05327582|DRUG|Durvalumab|Administered intravenously, 1000 mg on day 1 in a 3-week cycle
57732717|NCT02487563|DRUG|rhTPO|rhTPO
58412037|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
58412038|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
58412039|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
57732718|NCT02487563|OTHER|Conventional Treatment|immunoglobulin, glucocorticoid etc
57732719|NCT00959517|DRUG|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
57732720|NCT00959517|DRUG|sulphadoxine-pyrimethamine (SP)|
57732721|NCT00959517|DRUG|Chloroquine (CQ)|
57732722|NCT00959517|DRUG|primaquine (PQ)|
58301314|NCT05327582|DRUG|Lenvatinib|Administered orally, 8mg/d once daily in a 3-week cycle
58301315|NCT05327582|DRUG|Nab paclitaxel|Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
58301316|NCT06268834|DIAGNOSTIC_TEST|Blood for zonulin level was drawn from the group.|Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
57732723|NCT04514315|PROCEDURE|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
57732724|NCT04514315|PROCEDURE|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
57732725|NCT03266250|PROCEDURE|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
57732726|NCT00311272|BIOLOGICAL|MelCancerVac|
57732727|NCT04821596|OTHER|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
57732728|NCT01693432|DRUG|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
57732729|NCT03539562|DRUG|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
57732730|NCT00372463|BEHAVIORAL|6-week Online Diabetes Self-Management Educational Program|
57732731|NCT05982522|DRUG|IN10018|orally taken once daily
58301317|NCT05296707|OTHER|Inspiratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
58301318|NCT05296707|OTHER|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
58301319|NCT05296707|OTHER|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
58301320|NCT05107219|PROCEDURE|Biopsy|Undergo biopsy
58301321|NCT05107219|PROCEDURE|Biospecimen Collection|Undergo collection of luminal fluid
58301322|NCT05107219|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
58412040|NCT05675267|OTHER|data collection|HEART score calculation
58412041|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
58412042|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
57732732|NCT05982522|DRUG|Nab-paclitaxel|125 mg/m2 D1, 8 Q3W, Intravenously
58084960|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
58301323|NCT05107219|DRUG|Linaclotide|Given PO
58301324|NCT05107219|DRUG|Plecanatide|Given PO
58301325|NCT02344316|DRUG|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
58412043|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
58412044|NCT05118984|DRUG|Placebo|A treatment that has no active properties
58412045|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
57732733|NCT05982522|DRUG|Tislelizumab|200mg Q3W, Intravenously
57732734|NCT00000974|DRUG|Pentamidine isethionate|
57947507|NCT06475833|DIAGNOSTIC_TEST|Prone plank test, Side plank test, The Awareness of Sports Injuries Scales|"Prone Plank Test: For the prone bridge test, athletes will position themselves in a plank position with their elbows shoulder-width apart and directly under their shoulders. Using a stopwatch, the duration for which they can maintain this position without breaking form will be recorded.~Side Plank Tests: For the side bridge test, athletes will position themselves in a side plank position, ensuring that the shoulder is directly above the elbow. The duration for which they can maintain this position will be recorded using a stopwatch.~The Injury Prevention Awareness Scale for Athletes will be used to evaluate athletes' awareness and attitudes towards preventing sports injuries. A high score indicates a good level of awareness of injury prevention in sports."
57947508|NCT01530204|PROCEDURE|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
57947509|NCT01530204|BEHAVIORAL|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
57947510|NCT01530204|OTHER|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
57947511|NCT02225470|DRUG|E7389 (Eribulin Mesylate)|
57947512|NCT02225470|DRUG|Vinorelbine injection|
57947513|NCT02498015|DRUG|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
57947514|NCT02498015|DRUG|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
57947515|NCT02031562|OTHER|chiropractic|chiropractic
57947516|NCT02031562|OTHER|physical therapy|physical therapy
57947517|NCT00954720|OTHER|No Intervention|There is no intervention on this trial
57947518|NCT05626998|DRUG|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
57947519|NCT05626998|DRUG|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
57947520|NCT00143312|DRUG|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
57947521|NCT06170138|OTHER|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
57947522|NCT03860675|DIAGNOSTIC_TEST|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
58301326|NCT02344316|OTHER|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
58301327|NCT03477292|DRUG|Duration of antibiotic|Duration of antibiotic for treatment of VAP
58301328|NCT05240235|OTHER|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
58301329|NCT05240235|OTHER|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
58301330|NCT03171259|OTHER|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
57947523|NCT02461550|DEVICE|Irreversible Electroporation Ablation|
57947524|NCT06453096|OTHER|prevalence of personality disorders|the prevalence of personality disorders will be investigated with a retrospective study
58301331|NCT04426942|OTHER|survey|survey on sexuality during pregnancy
58301332|NCT06167941|BIOLOGICAL|Lung cancer types|Cancer tissue matched to normal tissue, all from the same patient
58301333|NCT05493293|DRUG|NBI-921352|Tablets for oral administration
58301334|NCT06223230|OTHER|Nutritional psychological interventions and vomit-free management|Nutritional psychological interventions and vomit-free management
58301335|NCT06125093|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
58301336|NCT05032014|OTHER|M9|one times a day during the whole treatment
58301337|NCT05032014|OTHER|placebo|placebo
58301338|NCT04054401|DEVICE|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
57947525|NCT02838966|DIETARY_SUPPLEMENT|Nestle IMPACT Advanced Recovery|
57947526|NCT02838966|DIETARY_SUPPLEMENT|Nestle Boost High Protein Drink|
57947527|NCT05425615|DEVICE|Transcranial Magnetic Stimulation|Deymed DuoMag XT-100 rTMS
57947528|NCT01508702|DRUG|lesinurad|Tablets, 400 mg QD
57947529|NCT01508702|DRUG|Placebo|Tablets, Placebo QD
57947530|NCT05110703|DIETARY_SUPPLEMENT|Supergut|Meal replacement shake
57947531|NCT05110703|DIETARY_SUPPLEMENT|Placebo|Placebo
58084961|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
58084962|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
58084963|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
58084964|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
58084965|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
58084966|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
58084967|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
58084968|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
58412046|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
58412047|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
58412048|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
58412049|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
57947532|NCT05110703|OTHER|Dietary guidelines|Dietary guidelines
57947533|NCT03134599|DEVICE|etafilcon A|contact lens
57947534|NCT03134599|DEVICE|methafilcon A - Interozzo|contact lens
57947535|NCT03134599|DEVICE|methafilcon A - CVI (CooperVision)|contact lens
57947536|NCT00766038|DRUG|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
57947537|NCT00766038|DRUG|Placebo|SC injection daily
57947538|NCT04636827|BIOLOGICAL|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
57947539|NCT04636827|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
58084969|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
58084970|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
58084971|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
58084972|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
58084973|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
58301339|NCT02527629|OTHER|Decellularized human heart valves|Decellularized human aortic heart valves
57947540|NCT04636827|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
57947541|NCT04636827|BIOLOGICAL|HepA|HepA at the age of 18 month old
57947542|NCT01923285|DEVICE|AXIUM Neurostimulator System|
57947543|NCT01923285|DEVICE|Control Spinal Cord Stimulation Device|
58412050|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
57947544|NCT04628338|DRUG|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
57947545|NCT06001658|DRUG|Gemcitabine|Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
57947546|NCT06001658|DRUG|Cisplatin|Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
58412051|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
58412052|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
58412053|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
57947547|NCT06001658|DRUG|Pembrolizumab|Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
58084974|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
58301340|NCT05407285|DRUG|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
58301341|NCT05407285|DRUG|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
58301342|NCT05407285|DRUG|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
58301343|NCT05407285|DRUG|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
58301344|NCT05407285|DRUG|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
58301345|NCT00003713|DRUG|intoplicine|
58301346|NCT01209403|DRUG|Glucose-infusion|Continuous iv infusion of glucose
58301347|NCT01209403|DRUG|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
58301348|NCT00863915|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
58301349|NCT00863915|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
58412054|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
58412055|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
57947548|NCT03516526|DRUG|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
58084975|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
58084976|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
58084977|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
58084978|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
58301350|NCT04042584|PROCEDURE|Visio conference device evaluation (DVCM)|Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
58301351|NCT01396083|DRUG|Ranibizumab|
58301352|NCT01396083|DRUG|Dexamethasone implant and sham injections|
58301353|NCT00243009|DRUG|cyclosporine|
58301354|NCT00243009|DRUG|fludarabine phosphate|
58301355|NCT00243009|DRUG|mycophenolate mofetil|
57947549|NCT01236573|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
57947550|NCT01236573|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
58084979|NCT05259059|OTHER|No intervention is involved|No intervention is involved
58084980|NCT00040001|DRUG|DTI-0009|
58301356|NCT00243009|PROCEDURE|allogeneic bone marrow transplantation|
58301357|NCT00243009|PROCEDURE|peripheral blood stem cell transplantation|
58301358|NCT00243009|RADIATION|radiation therapy|
58301359|NCT03081247|DRUG|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
58301360|NCT03081247|DRUG|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
58301361|NCT00913549|DRUG|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
58301362|NCT00913549|DRUG|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
58301363|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
58412056|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
58412057|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
58084981|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
58301364|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
58301365|NCT03187743|OTHER|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
58301366|NCT03825588|BEHAVIORAL|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
58301367|NCT03825588|BEHAVIORAL|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
58301368|NCT03825588|BEHAVIORAL|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
58301369|NCT04756622|DRUG|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
58301370|NCT00303030|PROCEDURE|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
58301371|NCT00303030|PROCEDURE|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
58301372|NCT02144870|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
58301373|NCT02144870|BEHAVIORAL|Resources activation|
58301374|NCT04929899|BEHAVIORAL|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
58301375|NCT06139926|DRUG|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
58301376|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
58301377|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
58301378|NCT00910234|DRUG|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
58301379|NCT00960193|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
58301380|NCT00960193|OTHER|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
58301381|NCT03692429|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
58301382|NCT03692429|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
58301383|NCT03692429|DRUG|FOLFIRI|5-FU, leucovorin and irinotecan
58301384|NCT01555658|DRUG|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
58301385|NCT01555658|DRUG|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
58301386|NCT02897557|DEVICE|Insulet Artificial Pancreas (AP) System|
58301387|NCT01940965|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
58301388|NCT01940965|DRUG|biguanide|Pharmaceutical form:tablet Route of administration: oral
58301389|NCT01940965|DRUG|TZD|Pharmaceutical form:tablet Route of administration: oral
57947551|NCT01236573|BIOLOGICAL|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
57732735|NCT04482751|DRUG|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
58084982|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
58084983|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
58084984|NCT02632448|DRUG|LY2880070|Capsules
58084985|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
58084986|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
58084987|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
58084988|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
58084989|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
58084990|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
58084991|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
58084992|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
58084993|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
58084994|NCT04798430|DRUG|lerodalcibep|PCSK9 inhibitor
58084995|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
58084996|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
58084997|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
57732736|NCT01193803|PROCEDURE|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
57947552|NCT03765138|COMBINATION_PRODUCT|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
57947553|NCT05397626|BEHAVIORAL|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome
58084998|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
58084999|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
58085000|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
58085001|NCT02364882|DRUG|Sildenafil|
58085002|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
58301390|NCT01940965|DRUG|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
58301391|NCT01940965|DRUG|glinide|Pharmaceutical form:tablet Route of administration: oral
58301392|NCT00669318|BIOLOGICAL|alemtuzumab|
58301393|NCT00669318|BIOLOGICAL|rituximab|
58412058|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
58412059|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
57947554|NCT05397626|DIETARY_SUPPLEMENT|Hydrogen Water|Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome
58085003|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
58085004|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
58085005|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
58085006|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
58412060|NCT00598078|DRUG|Sodium Oxybate|Dose 1
58412061|NCT00598078|DRUG|Sodium Oxybate|Dose 2
58412062|NCT00598078|OTHER|Placebo|Dose 3
58301394|NCT00669318|DRUG|pentostatin|
58301395|NCT00669318|DRUG|sargramostim|
58301396|NCT05775419|COMBINATION_PRODUCT|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
58301397|NCT05775419|COMBINATION_PRODUCT|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
58301398|NCT02419807|DRUG|Indocyanine Green Solution|Given subdermally
58301399|NCT02419807|RADIATION|Technetium Tc-99m Sulfur Colloid|Given via injection
58301400|NCT02419807|PROCEDURE|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
58301401|NCT02419807|PROCEDURE|Axillary Lymph Node Biopsy|Undergo biopsy
58412063|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
58412064|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
58301402|NCT02945826|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
58301403|NCT02945826|DEVICE|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
58301404|NCT05062096|OTHER|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
58301405|NCT05062096|OTHER|Skin biopsy|Biopsy of the skin lesion (optional)
58301406|NCT02909010|DEVICE|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
58301407|NCT02909010|OTHER|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
58301408|NCT04830566|OTHER|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
58301409|NCT04830566|OTHER|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
58301410|NCT06338566|OTHER|Follow-up|Follow-up at D45, 3 months and 6 months, with scoring, radiological monitoring and assessment of wound healing
58301411|NCT03163641|DEVICE|Acuvue Oasys|Bandage Contact Lens
58301412|NCT03163641|DEVICE|Ocular Bandage Gel|0.75% crosslinked HA
58301413|NCT02171546|DRUG|Dabigatran etexilate capsules|
58412065|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
58412066|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
57732737|NCT00672048|OTHER|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
58301414|NCT02171546|DRUG|Quinidine sulfate tablets|
58301415|NCT02171546|DRUG|Fexofenadine tablets|
58301416|NCT06448052|BIOLOGICAL|umbilical cord mesenchymal stem cell|A total of 100 million single cells were suspended in 0.9% sterile saline solution and given intravenously at a 5-ml/min rate for 45 min. All patients will get two intravenous autologous infusions on days 0 (D0) and 90 (D90).
58301417|NCT03570216|OTHER|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
58301418|NCT03570216|OTHER|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
58412067|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
58412068|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
58412069|NCT01794741|DRUG|Dymista Nasal Spray|
58412070|NCT01794741|DRUG|Fluticasone propionate nasal spray|
58412071|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
58412072|NCT04333953|OTHER|No intervention|No intervention, observational study
57732738|NCT00672048|OTHER|Continuing Education Course|Annual standard continuing education
57732739|NCT00672048|OTHER|Continuing education|Annual standard continuing education materials
57732740|NCT06495801|BEHAVIORAL|Frendie PRO mobile application|Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
58301419|NCT03570216|OTHER|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
58301420|NCT04997603|OTHER|Accelerometer|Fitbit brand
58301421|NCT01706562|DRUG|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
58301422|NCT00001057|DRUG|Zidovudine|
58301423|NCT00001057|DRUG|Didanosine|
58301424|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
58301425|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
58301426|NCT01362764|DRUG|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
58301427|NCT01996371|DEVICE|Pedicle Screw|
58301428|NCT04471701|BEHAVIORAL|Environmental exposure and clinical features|Environmental exposures and clinical features are measured by means of a self-administered 38-item on-line questionnaire containing mainly mandatory and closed questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the lockdown.
58301429|NCT00953030|BEHAVIORAL|COACH|
58301430|NCT00953030|BEHAVIORAL|RealAge|
58301431|NCT04517292|DRUG|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
58301432|NCT04517292|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
58085007|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
58085008|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
58085009|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
58301433|NCT06368310|DEVICE|INBRAIN Graphene Cortical Interface|Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.
57947555|NCT05397626|COMBINATION_PRODUCT|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
58301434|NCT02731196|BEHAVIORAL|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
58301435|NCT04454008|BEHAVIORAL|executive function family training|Intervention programs include executive function training for children with ADHD and parenting guidance for parents
58301436|NCT04454008|BEHAVIORAL|treat as usual|Outpatient routine health education, behavioral guidance and family support
58412073|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
58412074|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
58412075|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
57947556|NCT00957528|DRUG|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
57947557|NCT00957528|DRUG|Placebo|Weekly IM injections of sesame oil.
57947558|NCT04591275|DRUG|CMAB807 Injection|mAb targeting RANKL, human monoclonal antibody targeting RANKL
57947559|NCT04591275|DRUG|Prolia®|mAb targeting RANKL, human monoclonal antibody targeting RANKL
58301437|NCT02189668|DRUG|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
58301438|NCT00229671|OTHER|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
58301439|NCT00229671|OTHER|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
58301440|NCT05716347|BIOLOGICAL|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
58301441|NCT05815134|BIOLOGICAL|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
58301442|NCT00572091|DEVICE|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
58301443|NCT02981030|DRUG|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
58301444|NCT02981030|DRUG|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
58301445|NCT01346865|DRUG|Cilostazol|Cilostazol 100mg bid
58301446|NCT01346865|DRUG|Placebo|Placebo 1tablet bid
58301447|NCT00254514|DRUG|somatropin|
58301448|NCT03603522|DIETARY_SUPPLEMENT|BioGaia-DSM17938|2mL per day (1x10\^9 CFU) per day taken orally for 28 days
57947560|NCT02250274|BIOLOGICAL|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
58301449|NCT03603522|OTHER|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
58085010|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
58085011|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
58085012|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
58085013|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
58085014|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
58301450|NCT04806022|OTHER|Fatigability assessment|Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
58301451|NCT04658264|DIETARY_SUPPLEMENT|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
58301452|NCT06029881|DEVICE|Movesense MD|This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
58301453|NCT06139848|OTHER|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
58301454|NCT06139848|OTHER|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
58301455|NCT01086670|OTHER|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
58301456|NCT01909700|DEVICE|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
58412076|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
58412077|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
58412078|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
58412079|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
58412080|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
58412081|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
58412082|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
58412083|NCT00034229|DRUG|Felbamate|
58412084|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
58412085|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
58412086|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
58412087|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
58412088|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
58412089|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
58412090|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
58412091|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
58085015|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
58085016|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
58301457|NCT05340335|DRUG|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
58301458|NCT06327412|OTHER|Aerobic exercise on the treadmill|According to the cardiopulmonary exercise (CPET) test, 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level recorded individually in patients, 5 days a week for 4 weeks.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily
58412092|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
58412093|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
58412094|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
57947561|NCT02250274|BIOLOGICAL|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]"
58301459|NCT06327412|OTHER|Walking between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg Scale|He/she will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE according to the Modified Borg scale.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily.Treatment compliance will be increased by making weekly phone calls to patients in order to increase treatment compliance and evaluate compliance.
58412095|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
58412096|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
58412097|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
58085017|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
58085018|NCT02738606|DRUG|Chemotherapy|
58085019|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
58301460|NCT05562869|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
58301461|NCT02718664|OTHER|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
58301462|NCT00226369|DRUG|CY-1503|
58301463|NCT05813418|BIOLOGICAL|blood retriewal|blood retriewal for cytokine concentration measurement
58301464|NCT00239148|DRUG|E1 and G1|
58301465|NCT04486261|OTHER|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
58301466|NCT06417970|DIAGNOSTIC_TEST|Shoulder Proprioception, Palmar Touch Sensation and Psychometric Parameters|"Shoulder Proprioception: Proprioception will be measured with isokinetic device. The measurement reference angles are 30° and 60°.~Palmar Touch Sensation: Palmar tactile sensation will be measured with the Semmes-Weinstein Monofilament.~Psychometric Parameters: Athlete Psychological Strain Questionnaire, Tampa kinesiophobia questionnaire"
58301467|NCT00683423|DRUG|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
58301468|NCT00683423|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
58301469|NCT02976311|PROCEDURE|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
58301470|NCT02976311|PROCEDURE|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
58301471|NCT03101150|DRUG|400 IU Vitamin D3|Antenatal multivitamin
57732741|NCT00889213|PROCEDURE|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
57732742|NCT00889213|PROCEDURE|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
57732743|NCT05623150|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
57732744|NCT00967850|DRUG|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
58085020|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
58301472|NCT03101150|DRUG|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
58301473|NCT01265498|DRUG|obeticholic acid|25 mg daily for 72 weeks
58412098|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
58085021|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
58085022|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
58085023|NCT04279483|BEHAVIORAL|7-11|Assigned to make a small (\~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
58412099|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
58085024|NCT04279483|BEHAVIORAL|CVS|Assigned to make a small (\~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
58301474|NCT01265498|DRUG|placebo|placebo capsule, 25 mg daily for 72 weeks
58301475|NCT00236054|DRUG|Gabitril|
58301476|NCT04240808|BIOLOGICAL|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)
58412100|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
58412101|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
58412102|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
58412103|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
58412104|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
58412105|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
58412106|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
58412107|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
58412108|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
58412109|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
58412110|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
58412111|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
58412112|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
58412113|NCT00162240|DRUG|Muraglitazar|
58412114|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
58412115|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
58412116|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
58412117|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
58412118|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
58412119|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
58412120|NCT04272008|OTHER|Tampon|Annovera with tampon use
58412121|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
58412122|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
58412123|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
58412124|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
58412125|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
58412126|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
58412127|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
58412128|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
58412129|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
58412130|NCT02312219|DRUG|Placebo|placebo once weekly
57732745|NCT00967850|DRUG|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
57732746|NCT01434602|DRUG|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
57732747|NCT01434602|DRUG|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
58412131|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
58412132|NCT04401956|OTHER|bread|Different types of bread
58412133|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
58412134|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
58412135|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
58412136|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
58412137|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
58412138|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
58412139|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
58412140|NCT00227318|DRUG|ATACAND|
58412141|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
57732748|NCT04353869|BIOLOGICAL|Bio collection|venous blood sampling and collection of urine
58412142|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
58412143|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
58412144|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
58412145|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
57732749|NCT03318575|DEVICE|autoRIC|Automated Remote Ischemic Conditioning
58412146|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
57732750|NCT03318575|DEVICE|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
57732751|NCT03140748|OTHER|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
58412147|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
58412148|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
58412149|NCT05180318|DRUG|0.9% saline|0.9% saline
58412150|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
58412151|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
58412152|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
58412153|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
58412154|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
58412155|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
58412156|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
58412157|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
58412158|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
58412159|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
58412160|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
58412161|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
58412162|NCT00058149|DRUG|gemcitabine hydrochloride|
58301477|NCT03137810|PROCEDURE|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
58412163|NCT00058149|DRUG|oxaliplatin|
58412164|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
58412165|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
58412166|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
58301478|NCT03137810|PROCEDURE|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
58412167|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
58301479|NCT03474796|BEHAVIORAL|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
58301480|NCT05572645|DRUG|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
58085025|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
58085026|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites... (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
58301481|NCT05572645|DRUG|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
58301482|NCT02266446|BEHAVIORAL|Attention & Interpretation Modification|
58301483|NCT00236002|DRUG|Alendronate|Alendronate 70mgm once a week for one year
58301484|NCT03059914|DEVICE|InterOss|Anorganic bovine bone mineral - Xenograft
58301485|NCT03059914|DEVICE|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
58301486|NCT02900352|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
58301487|NCT02900352|DRUG|Placebo|Placebo
58301488|NCT01703494|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
57947562|NCT04152577|DRUG|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
57947563|NCT04152577|DRUG|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
57947564|NCT03075800|BEHAVIORAL|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
57947565|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
57947566|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
57947567|NCT00788281|PROCEDURE|laparoscopic surgery|surgery would be performed by laparoscope
57947568|NCT00788281|PROCEDURE|open surgery|surgery would be performed by traditional surgery.
57947569|NCT01131676|DRUG|BI 10773 low dose|BI 10773 tablets once daily
57947570|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
58301489|NCT01703494|BIOLOGICAL|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
58301490|NCT04928781|BEHAVIORAL|Smoking Cessation Counseling|Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
58412168|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
57947571|NCT01131676|DRUG|BI 10773 high dose|BI 10773 tablets once daily
57947572|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
57947573|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
57947574|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
58301491|NCT03799614|DEVICE|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
58301492|NCT03799614|DEVICE|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
58301493|NCT01401322|DRUG|Lenalidomide|50 mg; po
58412169|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
57732752|NCT04481347|DEVICE|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
57732753|NCT04481347|OTHER|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
57732754|NCT04481347|DEVICE|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
58085027|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
58085028|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
58085029|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
58085030|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
58301494|NCT01100853|DRUG|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
58301495|NCT06251141|PROCEDURE|Gum Health gel|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel
57732755|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
58412170|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
57732756|NCT01962493|OTHER|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
57732757|NCT01962493|DRUG|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
57732758|NCT05794464|PROCEDURE|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
58085031|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
58301496|NCT06251141|PROCEDURE|Gel foam|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
58301497|NCT01129401|BEHAVIORAL|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
58301498|NCT04779424|OTHER|POCT|Capillary blood sample antibody point of care test
58301499|NCT06087770|DRUG|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
58301500|NCT03365661|BIOLOGICAL|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains \> 2 x 105 α/β T cells/kg recipient weight.
57732759|NCT00305058|DRUG|Morphine|0.05 mg/kg Intravenous
57732760|NCT00305058|DRUG|Hydromorphone|0.0075 mg/kg intravenous
57732761|NCT06634706|DEVICE|RefleXion X1 Radiotherapy System [Imaging Only]|kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
57732762|NCT00586105|DRUG|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
57732763|NCT03432624|DIAGNOSTIC_TEST|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
57732764|NCT06528119|OTHER|COVID 19 pandemic|Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).
57732765|NCT03498248|DRUG|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
58085032|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
58301501|NCT01543568|DRUG|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
58301502|NCT04591639|DRUG|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
58301503|NCT04591639|DRUG|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
58301504|NCT03874832|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
58412171|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
57732766|NCT06143215|BEHAVIORAL|2 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.
58085033|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
58085034|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
58085035|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
58085036|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
58085037|NCT02594254|OTHER|Placebo|Placebo
58085038|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
58085039|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
58085040|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
58085041|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
58085042|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
58085043|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
58085044|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
58085045|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
58085046|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
58085047|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
58301505|NCT01341015|OTHER|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
58412172|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
58412173|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
58412174|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
57732767|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
57732768|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
58085048|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
58085049|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
58085050|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
58085051|NCT05186974|DRUG|Carboplatin|Administered intravenously
58085052|NCT05186974|DRUG|Cisplatin|Administered intravenously
58085053|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
58085054|NCT00024557|DRUG|IL13-PE38QQR|
58085055|NCT00024557|PROCEDURE|targeted fusion protein therapy|
58085056|NCT00024557|PROCEDURE|surgery|
58085057|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
58085058|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
58085059|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
58085060|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
58085061|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
58085062|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
58085063|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
58085064|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
58085065|NCT00870415|PROCEDURE|quality-of-life assessment|
58085066|NCT00870415|PROCEDURE|therapeutic conventional surgery|
58085067|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
58412175|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
58085068|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
58085069|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
58085070|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
58085071|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
58085072|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
58085073|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
58085074|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
58085075|NCT00004454|GENETIC|lymphocyte gene therapy|
58085076|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
58085077|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
58085078|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
58412176|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
57732769|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
57732770|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
57947575|NCT00574288|DRUG|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
58085079|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
58085080|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
58085081|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
57732771|NCT00144339|DRUG|tiotropium|
57732772|NCT00144339|DRUG|placebo|
58085082|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
58085083|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
58085084|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
58085085|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
58412177|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
58412178|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
58412179|NCT02106247|DRUG|BI 1181181 high dose|two tablet
58412180|NCT02106247|DRUG|BI 1181181 low dose|one tablet
58412181|NCT02106247|DRUG|Placebo|tablet
58085086|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
58085087|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
58085088|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
58085089|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
58085090|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
58085091|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
58085092|NCT03564678|DRUG|Vitamin B Complex|Given PO
58085093|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
58085094|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
58085095|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
58085096|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
58085097|NCT00370929|BEHAVIORAL|Meditation|
58085098|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
58085099|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
58085100|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
58085101|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
58085102|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
57947576|NCT00574288|DRUG|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
58085103|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
58085104|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
58085105|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
58085106|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
58085107|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
58085108|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
58085109|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
57732773|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
57732774|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
57732775|NCT03020420|OTHER|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
58085110|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
58085111|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
58085112|NCT03660059|DRUG|Peficitinib|Oral
58085113|NCT03660059|DRUG|Plaebo|Oral
58085114|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
58085115|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
58085116|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
58085117|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
57947577|NCT00574288|OTHER|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
57947578|NCT00574288|OTHER|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
57947579|NCT05169151|OTHER|Smartphone Application|Utilize smartphone application
57947580|NCT00006451|DRUG|anti-thymocyte globulin|
57947581|NCT00006451|DRUG|cyclophosphamide|
57947582|NCT00006451|DRUG|cyclosporine|
57947583|NCT00006451|DRUG|methotrexate|
57947584|NCT00006451|DRUG|methylprednisolone|
57947585|NCT00006451|PROCEDURE|allogeneic bone marrow transplantation|
57947586|NCT00006451|PROCEDURE|in vitro-treated bone marrow transplantation|
57947587|NCT00006451|PROCEDURE|radiation therapy|
57947588|NCT01497470|DRUG|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
57947589|NCT01651624|OTHER|Invitation to screening|
57947590|NCT00633906|BEHAVIORAL|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
57947591|NCT00633906|BEHAVIORAL|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
57947592|NCT02505503|DEVICE|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
57947593|NCT02505503|DEVICE|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
57947594|NCT04354480|BIOLOGICAL|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
57947595|NCT04354480|OTHER|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
57947596|NCT06275763|DRUG|Phase C: Eplerenone|Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
57947597|NCT06275763|DRUG|Phase C: Spironolactone|Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
57947598|NCT06275763|DRUG|Phase C: Torasemide|Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
57947599|NCT06275763|DRUG|Phase B: Triplixam / Elestar HCT|Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
57947600|NCT06275763|DIAGNOSTIC_TEST|Phase A: Confirmation of uncontrolled hypertension|Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
57947601|NCT01863940|DEVICE|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
57947602|NCT00840086|DRUG|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
57947603|NCT02718742|OTHER|Laboratory Biomarker Analysis|Correlative studies
57947604|NCT02718742|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
57947605|NCT02718742|OTHER|Quality-of-Life Assessment|Ancillary studies
57947606|NCT03129087|BEHAVIORAL|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
57947607|NCT06254911|BIOLOGICAL|Atezolizumab|Given IV
57947608|NCT06254911|PROCEDURE|Transoral Surgery with cervical lymphadenctomy (neck dissection)|Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck
57947609|NCT06254911|PROCEDURE|Computed Tomography|Undergo CT scan
57947610|NCT06254911|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57947611|NCT02097615|PROCEDURE|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
58085118|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
57732776|NCT04349787|OTHER|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
57947612|NCT02097615|OTHER|deionized water|application every 24 hours six weeks
57947613|NCT03300999|DIETARY_SUPPLEMENT|ginger tea|"1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
57947614|NCT02346032|DRUG|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
57947615|NCT00079404|DRUG|tanespimycin|Given IV
57947616|NCT01193855|DRUG|dutasteride|
57947617|NCT01193855|DRUG|gadolinium-chelate|
57947618|NCT01193855|OTHER|active surveillance|
57947619|NCT01193855|PROCEDURE|diffusion-weighted magnetic resonance imaging|
57947620|NCT01193855|PROCEDURE|functional magnetic resonance imaging|
57947621|NCT01193855|PROCEDURE|prostate biopsy|
57947622|NCT01193855|PROCEDURE|ultrasound imaging|
57947623|NCT04702776|DRUG|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
57947624|NCT04702776|DRUG|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
57947625|NCT04702776|DRUG|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
57947626|NCT04244656|BIOLOGICAL|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
57947627|NCT00236015|DRUG|Gabitril|
57947628|NCT05479253|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
57947629|NCT05649085|DEVICE|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
57947630|NCT03234387|OTHER|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
57947631|NCT00490451|DRUG|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
57947632|NCT06201897|DRUG|ACTH/Oral Steroids|Injection ACTH or Oral Steroids in children with West Syndrome
57947633|NCT03426371|DRUG|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
57947634|NCT03426371|DRUG|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
57947635|NCT04186494|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
57947636|NCT04186494|DEVICE|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
57947637|NCT04186494|COMBINATION_PRODUCT|Liraglutide and CPAP|Combination of both treatments
57947638|NCT01467843|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
57732777|NCT04349787|OTHER|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
57732778|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
57947639|NCT01467843|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
58085119|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
57732779|NCT05300308|OTHER|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
58085120|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
58085121|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
58085122|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
58085123|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
58085124|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
58085125|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
58085126|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
58085127|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
58085128|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
58085129|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
58085130|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
58085131|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
58085132|NCT01977482|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
58085133|NCT01977482|DRUG|Placebo|Matching placebo tablet for GSK1278863
58085134|NCT01977482|DRUG|rhEPO|rhEPO will be procured from local market
58085135|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
58085136|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
58085137|NCT00761085|DRUG|Morphine|Standard of care for pain management of acute episode of pain
58085138|NCT00761085|DRUG|Methadone|Compare to standard of care for pain management of acute episode of pain
58085139|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
58085140|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
58301506|NCT02150928|DRUG|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"* Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
58301507|NCT01056692|DRUG|OC000459|Capsules twice daily for 15 days
58301508|NCT01056692|DRUG|Placebo|Capsules twice daily for 15 days
58301509|NCT04478058|BEHAVIORAL|Live CBT|Weekly in-person Cognitive Behavioural Therapy
57732780|NCT01517698|DRUG|Placebo|placebo to RO4917523 orally once a day for 12 weeks
57732781|NCT01517698|DRUG|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
57732782|NCT01517698|DRUG|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
57732783|NCT04216108|DEVICE|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
57732784|NCT04216108|DEVICE|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
58085141|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
58085142|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
58085143|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
58085144|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
58085145|NCT00683462|DRUG|Placebo|
58085146|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
58085147|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
58085148|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
58085149|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
58085150|NCT01075126|DRUG|Depakote|
58085151|NCT01075126|DRUG|Lithium|
58301510|NCT04478058|BEHAVIORAL|e-CBT|Weekly online Cognitive Behavioural Therapy
58412182|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
58085152|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
58085153|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
58085154|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
58085155|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
58085156|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
58085157|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
58085158|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
58085159|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
58085160|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
58085161|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
58085162|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
58085163|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
58085164|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
58085165|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
58085166|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
58085167|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
58085168|NCT02244385|OTHER|no intervention|
57732785|NCT03994627|DRUG|Olaratumab|Administered intravenously (IV)
57732786|NCT02706158|DIETARY_SUPPLEMENT|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
57732787|NCT02706158|BEHAVIORAL|balanced diet|participants will get a balanced diet according to pregnancy stage
58085169|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
58085170|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
58085171|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
58085172|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
58085173|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
58085174|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
58085175|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
58085176|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
58412183|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
57732788|NCT00098124|DRUG|milnacipran hydrochloride|
58412184|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
58412185|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
58412186|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
58412187|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
58412188|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
58412189|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
58085177|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
58085178|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
58085179|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
58085180|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
58085181|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
58085182|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
58085183|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
58085184|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
58085185|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
58085186|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
58085187|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
58085188|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
58301511|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
58301512|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
58301513|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
58412190|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
57732789|NCT05741736|BEHAVIORAL|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
57732790|NCT01431677|PROCEDURE|Muscle Biopsy|
57732791|NCT02575092|DRUG|Enalapril Maleate Tablets(as the program-based antihypertension)|
57732792|NCT02575092|DRUG|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
57732793|NCT02575092|DRUG|Placebo|
57732794|NCT02462876|DEVICE|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
57732795|NCT02446561|DRUG|MRXXX|
57947640|NCT04835636|BEHAVIORAL|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
57947641|NCT06290375|DRUG|HSK21542 tablet|once-daily
57947642|NCT06290375|DRUG|Placebo|once-daily
57947643|NCT04423874|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
58085189|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
58085190|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
58085191|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
58085192|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
58085193|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
58085194|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
58085195|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
58085196|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
58085197|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
58085198|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
58085199|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
57732796|NCT02446561|DRUG|MR1XXX|
57732797|NCT02446561|DRUG|MR2XXX|
57732798|NCT02446561|DRUG|MR3XXX|
57732799|NCT05893654|DRUG|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
58085200|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
58085201|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
58301514|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
58301515|NCT05718349|OTHER|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
58412191|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
58412192|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
58085202|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
58085203|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
58085204|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
58085205|NCT02495974|DRUG|enzalutamide|oral
58412193|NCT00934947|DRUG|Propranolol|40 mg
58412194|NCT00934947|DRUG|Placebo|sugar pill
58412195|NCT00934947|DRUG|Propanolol|120 mg twice per day
58412196|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
58412197|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
58412198|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
58085206|NCT06491719|OTHER|NCR300（Allogenic Ipsc-derived Natural Killer cells ）|"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."
58085207|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
58085208|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
58301516|NCT03836027|OTHER|No intervention|No intervention
58085209|NCT00001080|DRUG|Lamivudine|
58085210|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
58085211|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
58085212|NCT01067729|DEVICE|AWBAT Wound Dressing|
58085213|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
58085214|NCT01711814|DRUG|peficitinib|oral
58301517|NCT03713684|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
57732800|NCT05893654|RADIATION|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
57947644|NCT04423874|DIAGNOSTIC_TEST|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
58085215|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
58301518|NCT03713684|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58301519|NCT03713684|DRUG|Background therapy|Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
58085216|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
58085217|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
58085218|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
58085219|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
58085220|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
58085221|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
58085222|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
58085223|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
58085224|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
58085225|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
58085226|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
58085227|NCT06170528|DEVICE|AURA_ALZ|AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
58085228|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
58085229|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
58085230|NCT00449761|DRUG|LBH589|
58085231|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
58085232|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
58085233|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
58085234|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
57732801|NCT06635993|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\&#39;s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
58085235|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
58085236|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
58085237|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
58085238|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
58085239|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
58085240|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
58301520|NCT02626416|DEVICE|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
58301521|NCT02754232|OTHER|Telemedical training|Intervention will involve resistance training and anaerobic training
58301522|NCT00351585|DRUG|Vildagliptin|
58301523|NCT00247468|PROCEDURE|Strict Glucose Control|
58301524|NCT02484144|OTHER|modern information|information by video for coronarography
58301525|NCT02484144|OTHER|usual information|usual information for coronarography
58301526|NCT03933163|DRUG|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
58301527|NCT05442060|BIOLOGICAL|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
58301528|NCT05442060|DRUG|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
58412199|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
58412200|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
58412201|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
58412202|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
58412203|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
58412204|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
58412205|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
57947645|NCT04423874|BEHAVIORAL|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
57947646|NCT04423874|DIAGNOSTIC_TEST|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
57947647|NCT01737476|PROCEDURE|Transcranial Magnetic Stimulation. PFC|
57947648|NCT00929175|DEVICE|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
57947649|NCT00929175|DEVICE|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
57947650|NCT03957265|PROCEDURE|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
57947651|NCT02887664|PROCEDURE|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
57947652|NCT03898375|OTHER|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
57947653|NCT05445375|OTHER|PAD education video|20-min online multi-media video
58085241|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
58412206|NCT00199225|DRUG|Rupatadine|
58412207|NCT00199225|DRUG|moxifloxacin|
58412208|NCT00199225|PROCEDURE|Continous electrocardiographic register|
58412209|NCT00199225|PROCEDURE|Pharmacokinetic profile|
58085242|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
58085243|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
58085244|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
58085245|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
58301529|NCT03150082|DRUG|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
57732802|NCT05934734|OTHER|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
57947654|NCT04700839|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
57947655|NCT04700839|DRUG|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
57947656|NCT02898532|BEHAVIORAL|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
57947657|NCT00127738|PROCEDURE|Angiographic renal revascularization|
57947658|NCT02808000|DEVICE|BIP Foley (latex) or BIP Foley -silicone|
57947659|NCT02808000|DEVICE|Standard catheter|
57947660|NCT04053868|OTHER|JUUL|Electronic Cigarette
57947661|NCT04053868|OTHER|Tobacco|Tobacco Cigarette
57947662|NCT04738812|DRUG|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
57947663|NCT04738812|DRUG|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
57947664|NCT06170424|PROCEDURE|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
57947665|NCT06170424|PROCEDURE|Control group|The patients who used skin grafting.
57947666|NCT04754880|DIAGNOSTIC_TEST|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
57947667|NCT01967628|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
57947668|NCT01967628|DIETARY_SUPPLEMENT|Placebo Sugar Pill|
57947669|NCT01439672|DIETARY_SUPPLEMENT|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \~100mg/dl at 1100.
57947670|NCT03807804|BIOLOGICAL|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
57947671|NCT03761615|DEVICE|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
57947672|NCT04500782|OTHER|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
57947673|NCT01022242|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
57947674|NCT01022242|DRUG|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
57947675|NCT03518879|OTHER|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
58085246|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
58085247|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
58085248|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
58085249|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
58085250|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
58085251|NCT06147856|DRUG|mRNA-3210|IV infusion
58301530|NCT03150082|DRUG|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
58085252|NCT01554696|DRUG|peficitinib|oral
58085253|NCT01554696|DRUG|Placebo|oral
58085254|NCT01554696|DRUG|methotrexate|oral
58301531|NCT04630977|DIETARY_SUPPLEMENT|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
58085255|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
58301532|NCT04630977|OTHER|Progressive Resistance Training|The information about it has been detailed in advance.
58301533|NCT04630977|BEHAVIORAL|Nutritional Patterns Guideline|This intervention has also been described in advance.
58085256|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
58085257|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
58085258|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
58085259|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
57947676|NCT03688880|DEVICE|MAR-CUTIS|MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds \>8 cm, 2 syringes were required.
57947677|NCT03688880|DEVICE|Dermabond Advanced|Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
57947678|NCT01430455|DRUG|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
58085260|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
58085261|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
58301534|NCT02433847|DRUG|Mosapride|
58301535|NCT06200935|DIETARY_SUPPLEMENT|Probiotic blend|Administration of one stick of combined probiotics per day for 5 months
58301536|NCT06177288|COMBINATION_PRODUCT|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
58301537|NCT00507936|DRUG|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
58301538|NCT00507936|DRUG|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
58301539|NCT00507936|DRUG|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
57732803|NCT03516318|BEHAVIORAL|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
57947679|NCT05312177|OTHER|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
57947680|NCT05312177|OTHER|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
57947681|NCT05312177|OTHER|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
57947682|NCT05312177|OTHER|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
57947683|NCT05312177|OTHER|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
58085262|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
58085263|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
58301540|NCT00507936|DRUG|placebo|placebo capsule BID throughout the treatment period
58301541|NCT00507936|DRUG|Duloxetine|Duloxetine 60 mg QD throughout treatment period
58301542|NCT03031340|DRUG|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
58301543|NCT03031340|OTHER|placebo|placebo
58301544|NCT02337491|DRUG|Pembrolizumab|
58301545|NCT02337491|DRUG|Bevacizumab|
58301546|NCT04611100|DEVICE|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
58301547|NCT02256696|DRUG|PA-824|200 mg QD
58301548|NCT02256696|DRUG|Rifampin|600 mg QD
58301549|NCT02256696|DRUG|Rifabutin|300 mg QD
58301550|NCT02256696|DRUG|Pyrazinamide|25mg/kg QD
58301551|NCT02256696|DRUG|Ethambutol|15mg/kg QD
58301552|NCT02256696|DRUG|Isoniazid|300 mg QD
58301553|NCT01644721|BIOLOGICAL|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
58301554|NCT02308800|DEVICE|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
58301555|NCT02308800|DEVICE|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
58301556|NCT01139996|DRUG|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
58301557|NCT01139996|DRUG|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
58301558|NCT00313846|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
57732804|NCT06436053|DEVICE|LBBAP with SyncAV|Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.
57947684|NCT05312177|OTHER|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
58085264|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
58301559|NCT00313846|DRUG|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
58301560|NCT01586234|PROCEDURE|DSAEK with graft shaping and smoothing|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
58301561|NCT01586234|PROCEDURE|Standard DSAEK|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
58301562|NCT06321822|DIAGNOSTIC_TEST|Whole exome sequencing (WES)|Patient selected for genetic study will undergo blood sample collection for DNA estraction, biobank storage and WES study
58301563|NCT06434935|COMBINATION_PRODUCT|CABA|Coronary Bypass
58301564|NCT02200146|DRUG|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
58301565|NCT02200146|DRUG|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
58301566|NCT02597309|DRUG|Canagliflozin|
58301567|NCT05742334|PROCEDURE|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
57947685|NCT05312177|OTHER|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
57947686|NCT05312177|OTHER|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
58085265|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
58301568|NCT05742334|DEVICE|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
58301569|NCT03781726|DRUG|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
58301570|NCT04512963|DRUG|Progerinin|100 mg/g nano-suspension for oral use
58301571|NCT04512963|DRUG|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
57732805|NCT05497284|DRUG|LTP001|LTP001 will be administered once daily in the morning
58301572|NCT03814564|DEVICE|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
58301573|NCT03322293|DRUG|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
58301574|NCT03322293|DEVICE|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
58301575|NCT03834363|DRUG|Fentanyl|Fentanylpatch 12 mcg/hr, change patch every three days.
58301576|NCT03834363|DRUG|Morphine Retard|Morphine retard capsules 10 mg bid.
58301577|NCT03834363|DRUG|Placebo patch|Placebo patch, change patch every three days.
58301578|NCT03834363|DRUG|Placebo oral capsule|Placebo oral capsule bid
58085266|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
58085267|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
58085268|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
58085269|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
58085270|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
58301579|NCT04391478|DRUG|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
58412210|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
58412211|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
58412212|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
57947687|NCT04484298|DIAGNOSTIC_TEST|Reference position patient is put in a 30 degree supine position during 5 minutes|Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
57947688|NCT04484298|DIAGNOSTIC_TEST|nitroglucerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
57947689|NCT04049591|DRUG|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
57947690|NCT04049591|DRUG|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
57947691|NCT03707067|DEVICE|Compression garments|Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)
58085271|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
58085272|NCT03207607|OTHER|Snack skipping|no snack
58085273|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
58085274|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
57947692|NCT03707067|OTHER|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
58301580|NCT04391478|DRUG|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
58301581|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
58301582|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
58301583|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
58301584|NCT03583658|DRUG|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
58301585|NCT03583658|DRUG|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
57947693|NCT05083728|DIAGNOSTIC_TEST|CT|Clinicians are free to choose the adult subjects in whom a non-contrast calibrated CT-scan will be performed as a part of routine clinical care. The decision to order a noncontrast CT-scan of the shoulder must be made prior to, and independently from, the decision to enroll the patient.
57947694|NCT04674020|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
57947695|NCT05758519|DRUG|QLS1128|QLS1128
57947696|NCT05758519|DRUG|Placebo|Placebo
57947697|NCT05798442|OTHER|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
58085275|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
58085276|NCT00843739|DEVICE|sham EMST|Four week sham device training program
58085277|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
58301586|NCT02392078|DEVICE|NeuroBlate System|
58301587|NCT00788385|DEVICE|ShuntCheck test|
58301588|NCT05562752|DIETARY_SUPPLEMENT|Probiotic|multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.
58301589|NCT05562752|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 12 weeks.
58412213|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
57732806|NCT05497284|DRUG|Placebo|Placebo to LTP001 will be administered once daily in the morning
58412214|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
58412215|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
58412216|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
58412217|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
58412218|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
58085278|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
58085279|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
58085280|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
57732807|NCT05497284|DRUG|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
57732808|NCT00346008|GENETIC|mutation analysis|
57732809|NCT00346008|OTHER|high performance liquid chromatography|
57732810|NCT00346008|OTHER|laboratory biomarker analysis|
57732811|NCT00346008|OTHER|questionnaire administration|
58301590|NCT00243919|BEHAVIORAL|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
57732812|NCT02755987|DRUG|ANG1005|
57732813|NCT06669065|DEVICE|extraoral versus intraoral scanning techniques|different data acquisition techniques for full-arch dental implants
57732814|NCT01972516|DRUG|Tivozanib|
57732815|NCT04458584|PROCEDURE|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
57732816|NCT04458584|PROCEDURE|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
58301591|NCT00243919|BEHAVIORAL|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
57732817|NCT04458584|PROCEDURE|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
57732818|NCT06316986|DIAGNOSTIC_TEST|pH indication with NGPOD|"The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach."
57732819|NCT01023100|DRUG|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
57732820|NCT01361412|BIOLOGICAL|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
58085281|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
58085282|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
58301592|NCT00243919|BEHAVIORAL|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
58301593|NCT02559037|DEVICE|Acupuncture and moxibustion|"Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
58301594|NCT02559037|DEVICE|Sham acupuncture and moxibustion|"The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
58085283|NCT02303977|DRUG|Abraxane|
58085284|NCT02303977|DRUG|Gemcitabine|
58085285|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
58085286|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
58085287|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
58085288|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
58085289|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
58085290|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
58301595|NCT02996916|DRUG|Olmesartan|10-40mg daily
58301596|NCT02996916|DRUG|Amlodipine|2.5-10mg daily
58301597|NCT03921736|DRUG|Perindopril|4 mg/day p.o. for 12 months
57732821|NCT01361412|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
57732822|NCT01739829|DEVICE|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
57732823|NCT01739829|DEVICE|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
57732824|NCT05734846|DEVICE|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
57732825|NCT05734846|DEVICE|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
57732826|NCT04331366|DEVICE|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
57732827|NCT00114374|DRUG|Escitalopram|
57732828|NCT00290940|DRUG|CS-917|
57732829|NCT00290940|DRUG|metformin hydrochloride|
57732830|NCT00290940|DRUG|pioglitazone|
57732831|NCT03671603|DRUG|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
57947698|NCT05254431|BEHAVIORAL|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
57732832|NCT05709743|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
58085291|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
58085292|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
58412219|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
58412220|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
58412221|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
58412222|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
57732833|NCT01260233|OTHER|Smoking cessation program|"Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
57947699|NCT04278339|OTHER|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
57947700|NCT02512224|DEVICE|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
57947701|NCT02512224|DEVICE|Enteral nutrition|Participants are retrospectively selected with propensity score matching
57947702|NCT05536310|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|TAVI with the JenaValve Trilogy Heart Valve System
57947703|NCT06084520|DIAGNOSTIC_TEST|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
57947704|NCT06084520|DIAGNOSTIC_TEST|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
58085293|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
58085294|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
57947705|NCT06084520|DIAGNOSTIC_TEST|PETh|Alcohol use detection
57947706|NCT06084520|DIAGNOSTIC_TEST|ASI-SR|Cross-validation form
57947707|NCT06084520|DIAGNOSTIC_TEST|AUDIT|Cross-validation form
57947708|NCT06084520|DIAGNOSTIC_TEST|DUDIT|Cross-validation form
57947709|NCT06084520|DIAGNOSTIC_TEST|Brief Pain Inventory - BPI|Cross-validation form
57947710|NCT06084520|DIAGNOSTIC_TEST|Patient Global Impression of Change PGIC|Cross-validation form
57947711|NCT06084520|DIAGNOSTIC_TEST|GAD-7|Cross-validation form
58085295|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
57732834|NCT05577429|OTHER|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
57732835|NCT05577429|OTHER|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
57732836|NCT05577429|OTHER|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
57947712|NCT06084520|DIAGNOSTIC_TEST|Patient Health questionnaire (PHQ9)|Cross-validation form
58085296|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
58085297|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
58301598|NCT03921736|DRUG|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
58301599|NCT03921736|DRUG|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
58301600|NCT06100796|COMBINATION_PRODUCT|Pembrolizumab|Immune check inhibitor with OHA
58085298|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
58085299|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
58085300|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
58085301|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
58085302|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
58085303|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
58085304|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
58085305|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
58301601|NCT00452374|DRUG|Cytarabine|1 g/m\^2 given IV for two days (Days 2 and 3).
58085306|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
58085307|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
58085308|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
58085309|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
58301602|NCT00452374|DRUG|Fludarabine|30 mg/m\^2 given IV for two days (Days 2 and 3).
58301603|NCT00452374|DRUG|Oxaliplatin|Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).
58301604|NCT00452374|DRUG|Rituximab|375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
58301605|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
57732837|NCT02268838|DRUG|E6007|
57732838|NCT02268838|DRUG|E6007 matching placebo|
57732839|NCT06442553|DEVICE|GRR laser|A total of 15 sessions were applied to each patient for three weeks, five times per week.
57732840|NCT06442553|DEVICE|Nd:YAG laser|A total of 10 sessions, five sessions per week, were applied
57947713|NCT06084520|DIAGNOSTIC_TEST|DBS - cannabis test|cross-validation form
57947714|NCT06084520|OTHER|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
58085310|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
58412223|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
58412224|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
58085311|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
58301606|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
58301607|NCT03025321|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
58301608|NCT02815306|DEVICE|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
58301609|NCT03261076|BEHAVIORAL|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
58301610|NCT04726735|BIOLOGICAL|Samples of bladder tissue|Samples of bladder tissue collected between 2007 and 2011.
58301611|NCT00249834|DRUG|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
58301612|NCT00249834|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
58412225|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
58412226|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
58412227|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
58412228|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
57732841|NCT03589456|OTHER|No intervention|There are no interventions associated with this registry as it is purely observational.
57947715|NCT00794599|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
57947716|NCT00794599|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
58301613|NCT03640169|OTHER|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
58301614|NCT03132545|DIAGNOSTIC_TEST|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
58301615|NCT03132545|DIAGNOSTIC_TEST|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
57947717|NCT04228042|DRUG|Infigratinib|Given PO
58301616|NCT00909064|DRUG|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
58301617|NCT01891214|OTHER|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
58301618|NCT01663389|DRUG|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
58301619|NCT01663389|DRUG|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
58301620|NCT05545475|DRUG|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
57947718|NCT04228042|OTHER|Quality-of-Life Assessment|Ancillary studies
57947719|NCT04228042|OTHER|Questionnaire Administration|Ancillary studies
57732842|NCT04240821|DRUG|Theophylline ER|Oral theophylline
57732843|NCT04210687|PROCEDURE|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
57732844|NCT04210687|PROCEDURE|Trapeziectomy|Simple trapeziectomy
57947720|NCT04228042|PROCEDURE|Surgical Procedure|Undergo surgery
58301621|NCT04918862|DRUG|Granisetron|210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
58301622|NCT02889068|OTHER|Blood sample|
58301623|NCT03309553|OTHER|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
58412229|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
58412230|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
58412231|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
58412232|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
58412233|NCT01024582|RADIATION|accelerated partial breast irradiation|
58412234|NCT01024582|RADIATION|image-guided radiation therapy|
58412235|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
58412236|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
58412237|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
58085312|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
58412238|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
58412239|NCT00070681|PROCEDURE|Polysomnography|
57947721|NCT06478069|DIAGNOSTIC_TEST|Group A|Group A was treated with Ibuprofen Dosage After breakfast and after dinner for 6 weeks.
57947722|NCT06478069|BEHAVIORAL|Group B|Group B was treated with physical therapy; (Upper limb: The stroke patient warmed up with some gentle stretches for the wrist and fingers to get the muscles ready. They subsequently engaged in resistance training using dumbbells or resistance bands to increase the strength of their upper limbs. Bicep curls, tricep extensions, and shoulder presses were some of these exercises. They tried to complete two to three sets of ten to fifteen repetitions for each exercise, progressively increasing the resistance as their strength increased. Then, to improve dexterity and coordination in daily tasks, functional exercises were included.
57947723|NCT01669070|DRUG|FF, 50 mcg|Novel dry powder inhaler
57947724|NCT01669070|DRUG|FF, 100 mcg|Novel dry powder inhaler
57947725|NCT01669070|DRUG|FF, 200 mcg|Novel dry powder inhaler
58412240|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
58412241|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
58412242|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
58412243|NCT02903758|OTHER|cross sectional|
58412244|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
57947726|NCT01669070|DRUG|FF, 250 mcg|Intravenous
58412245|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
58412246|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
58412247|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
58412248|NCT01355263|DRUG|iron and vitamin a|
58412249|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
58412250|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
58412251|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
58412252|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
58085313|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
58085314|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
58301624|NCT03309553|OTHER|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
58301625|NCT00683228|BEHAVIORAL|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
58412253|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
58412254|NCT01228994|DRUG|placebo pill|placebo pill
58412255|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
57947727|NCT05754385|BEHAVIORAL|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
57947728|NCT05754385|BEHAVIORAL|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
57947729|NCT05703971|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
57947730|NCT05703971|BIOLOGICAL|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
57947731|NCT05548621|OTHER|Decision aid|Online interactive decision aid for RCC
58085315|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
58085316|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
58085317|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
58085318|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
58085319|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
58085320|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
58085321|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
58301626|NCT00532909|DRUG|Vandetanib|100mg or 300mg By mouth every day continuous
58301627|NCT00532909|DRUG|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
58301628|NCT00532909|DRUG|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
58301629|NCT00532909|DRUG|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
58301630|NCT05974254|DEVICE|Acupuncture|Electroacupuncture
58412256|NCT02590601|DRUG|Bromocriptine|
58412257|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
58412258|NCT00000262|DRUG|30% Nitrous oxide|
58412259|NCT00000262|DRUG|0.4% Sevoflurane|
58412260|NCT00000262|DRUG|0.2% sevoflurane|
58412261|NCT00000262|OTHER|Placebo|
58412262|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
58412263|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
58085322|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
57947732|NCT06398847|DEVICE|Virtual Reality headset|Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.
58085323|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
58085324|NCT00209560|DRUG|fospropofol disodium|
58085325|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
58085326|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
58085327|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
58085328|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
58085329|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
58301631|NCT02345005|DEVICE|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
57947733|NCT02054897|DRUG|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
57947734|NCT02054897|DRUG|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
57947735|NCT05073614|GENETIC|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
57947736|NCT01518218|BEHAVIORAL|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
57947737|NCT03220542|DRUG|Probiotics|Saccharomyces boulardii
57947738|NCT03220542|DIETARY_SUPPLEMENT|Broccoli|Broccoli sprouts extract
57947739|NCT03220542|DRUG|Esomeprazole|Esomeprazole
57947740|NCT03220542|DRUG|Amoxicillin|Amoxicillin
57947741|NCT03220542|DRUG|Clarithromycin|Clarithromycin
57947742|NCT01418807|PROCEDURE|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
57947743|NCT01418807|PROCEDURE|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
58301632|NCT05573763|DEVICE|F&P Toffee|Nasal pillows mask
58301633|NCT03272243|PROCEDURE|short segment posterior spine fixation|
58301634|NCT03272243|PROCEDURE|long segment posterior spine fixation|
58301635|NCT02283879|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
58301636|NCT02914834|OTHER|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
57947744|NCT06047340|DEVICE|G:DATA, dementia screen videogame|A videogame for screening
57947745|NCT04425291|BIOLOGICAL|4-valent HPV Vaccine|Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
57947746|NCT04425291|BIOLOGICAL|9-valent HPV Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
57947747|NCT04425291|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
57947748|NCT06100822|DRUG|Metformin|500 mg capsules of Metformin Extended Release
57947749|NCT06100822|DRUG|Placebo|500 mg capsules of placebo pills
57947750|NCT01035554|OTHER|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
57947751|NCT01035554|OTHER|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
57947752|NCT01035554|OTHER|Usual Care|Standard care
57947753|NCT01035554|OTHER|Printed Materials|National Institutes of Health Printed Materials on hypertension
57947754|NCT03113240|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
57947755|NCT03113240|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
57947756|NCT00838773|BEHAVIORAL|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
58412264|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
57947757|NCT00838773|BEHAVIORAL|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
58085330|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
58085331|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
58085332|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
58085333|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
58085334|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
58085335|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
58301637|NCT02914834|OTHER|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
58301638|NCT06245642|DRUG|Compound Xiwujia granule + Guipi granule|Experimental group: Basic treatment + compound Xiwujia granules + Guipi granules simulator orally for 6 weeks Positive drug control group: basic treatment + Guipi granule + compound Xiwujia granule simulant Koufu for 6 weeks
58412265|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
58412266|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
58412267|NCT00000627|DRUG|Fluconazole|
58412268|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
58412269|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
57947758|NCT00838773|BEHAVIORAL|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
57947759|NCT02827864|BEHAVIORAL|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
58085336|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
58085337|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
58412270|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
58412271|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
58301639|NCT03131284|BEHAVIORAL|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
58412272|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
58412273|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
57732845|NCT05408494|BEHAVIORAL|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
58085338|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
58301640|NCT00232700|DRUG|Escitalopram|
58301641|NCT01861067|PROCEDURE|LESS-TLH|
58301642|NCT01861067|PROCEDURE|LESS-LAVH|
58301643|NCT01302405|DRUG|PRI-724|Dose escalation
58301644|NCT03087305|DIAGNOSTIC_TEST|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
57732846|NCT05408494|BEHAVIORAL|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
58085339|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
58301645|NCT05261165|PROCEDURE|hysterectomy|Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
58301646|NCT00021723|BIOLOGICAL|AN-1792 also known as AIP-001|
58301647|NCT00331565|PROCEDURE|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
58412274|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
58412275|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
58412276|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
58412277|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
58412278|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
58412279|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
57947760|NCT02827864|BEHAVIORAL|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
57947761|NCT02827864|BEHAVIORAL|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
58301648|NCT03428100|DRUG|Baricitinib|Administered orally.
58301649|NCT03428100|DRUG|Placebo|Administered orally.
58301650|NCT03428100|DRUG|Topical corticosteroid|Administered as standard-of-care.
58301651|NCT03627325|OTHER|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
58301652|NCT02899611|DRUG|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
58412280|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
58412281|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
57732847|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
57947762|NCT00058812|BIOLOGICAL|EBV specific T cells|One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
58085340|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
58085341|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
58085342|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
58085343|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
58412282|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
58412283|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
58412284|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
58412285|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
58412286|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
58412287|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
58085344|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
58085345|NCT00231530|DRUG|topiramate|
58085346|NCT00718809|DRUG|saracatinib|Given orally
58085347|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
58085348|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
58301653|NCT00905242|DRUG|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
58301654|NCT04600869|OTHER|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
58085349|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
58085350|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
58301655|NCT04270461|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
58301656|NCT03556995|OTHER|bariatric surgery patients|
58301657|NCT02911649|OTHER|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
58301658|NCT02911649|OTHER|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
58301659|NCT02911649|OTHER|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
58301660|NCT02911649|OTHER|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
58301661|NCT00511810|DRUG|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
58301662|NCT00511810|DRUG|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
58085351|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
58085352|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
58085353|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
58085354|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
58085355|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
58085356|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
58085357|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
58085358|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
58085359|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
57947763|NCT04428021|DRUG|Standard Therapy Protocol (STP)|Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee
58085360|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
58085361|NCT01058707|DRUG|MLN0128|MLN0128 capsules
58085362|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
58085363|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
58085364|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
58085365|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
58085366|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
58085367|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
58085368|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
58085369|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
58301663|NCT06410664|OTHER|72-hour HME exchange interval group|All patients in the experimental arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 72 hours. At the exchange point, both outlets of the HME filter will be swabbed.
58412288|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
57947764|NCT04428021|OTHER|STP + Standard Plasma (SP)|Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP
57947765|NCT04428021|OTHER|STP + COVID-19 Convalescent Plasma (CP)|Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
58085370|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
58412289|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
57947766|NCT02941016|DRUG|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
57947767|NCT06043232|BIOLOGICAL|DC vaccine|DC vaccine produced by the Team
57947768|NCT01911442|DRUG|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
57947769|NCT01911442|DRUG|Lurasidone|Lurasidone 60 mg once daily
58085371|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
58085372|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
58085373|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
58085374|NCT00139802|DEVICE|Coronary Stent Implantation|
58085375|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
58085376|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
58085377|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
58085378|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
58412290|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
58412291|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
58412292|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
58412293|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
58412294|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
58412295|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
58412296|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
57732848|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
58085379|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
58085380|NCT02468167|DRUG|Lauromacrogol|
58085381|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
58085382|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
58085383|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
58085384|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
58085385|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
58085386|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
58085387|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
58085388|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
58412297|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
58412298|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
58412299|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
58412300|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
58412301|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
58412302|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
58412303|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
58412304|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
58412305|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
58412306|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
58412307|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
58412308|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
58412309|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
58412310|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
57732849|NCT01949480|PROCEDURE|Thoracotomy|
57732850|NCT01949480|PROCEDURE|Video-Assisted Thoracoscopic Surgery (VATS)|
58412311|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
58412312|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
58412313|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
58301664|NCT06410664|OTHER|24-hour HME exchange interval group|All patients in the control arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 24 hours. At the exchange point, both outlets of the HME filter will be swabbed.
58412314|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
58412315|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
58301665|NCT02728232|PROCEDURE|internal iliac artery ligation|
58301666|NCT02728232|PROCEDURE|Cesarean Hysterectomy|
58301667|NCT03499808|BIOLOGICAL|Isatuximab|Given IV
58301668|NCT03499808|OTHER|Laboratory Biomarker Analysis|Correlative studies
57947770|NCT01911442|DRUG|Placebo|Placebo
58301669|NCT00710931|DEVICE|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
58301670|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
58301671|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
57947771|NCT06466915|DRUG|Dexmedetomidine|Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
57947772|NCT06466915|DRUG|Propofol|Group Pofol received 1 mg/kg propofol IV before the extubation.
57947773|NCT02242084|DRUG|Intravenuse Alteplase|
57947774|NCT04620044|OTHER|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
57947775|NCT04620044|OTHER|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
58301672|NCT01734447|DRUG|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
58301673|NCT04500444|OTHER|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
58301674|NCT04406467|DEVICE|Xen Gel Stent|Ab-interno or Ab-Externa Xen with closed or open conjunctiva.
58301675|NCT02499107|DIETARY_SUPPLEMENT|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
58301676|NCT02499107|DIETARY_SUPPLEMENT|Pasta treatment|
58301677|NCT02499107|DIETARY_SUPPLEMENT|Boiled and mashed potato treatment|
58301678|NCT02499107|DIETARY_SUPPLEMENT|Baked french fries treatment|
58301679|NCT02499107|DIETARY_SUPPLEMENT|Fried french fries treatment|
58301680|NCT03167242|DRUG|KAF156|KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
58301681|NCT03167242|DRUG|Coartem|Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
58412316|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
58412317|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
58412318|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
58412319|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
58412320|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
58412321|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
58412322|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
58412323|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
58412324|NCT02691403|DRUG|levo-bupivacaine|
58412325|NCT02691403|DRUG|normal saline|
58412326|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
58412327|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
58085389|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
58085390|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
58085391|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
58085392|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
58085393|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
58085394|NCT06326476|DRUG|Siplizumab|40 mg doses
58085395|NCT00333437|DRUG|Mycophenolate mofetil|
58085396|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
58085397|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
58085398|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
58085399|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
58085400|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
58085401|NCT02195271|DRUG|Melatonin|
58085402|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
58085403|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
58085404|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
58085405|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
58085406|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
58412328|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
58412329|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
58412330|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
58085407|NCT00211575|BEHAVIORAL|Disease Management Assessment|
58085408|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
58412331|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
58085409|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
58085410|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
58085411|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
58085412|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
58085413|NCT05595460|DRUG|Atezolizumab|Atezolizumab
58085414|NCT05595460|DRUG|Carboplatin|Carboplatin
58085415|NCT05595460|DRUG|Etoposide|Etoposide
58085416|NCT04753606|DRUG|Obicetrapib|tablets
58085417|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
58412332|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
58412333|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
58412334|NCT00274560|DRUG|Tiotropium|
58412335|NCT00274560|DRUG|Salmeterol|
58085418|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
58085419|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
58085420|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
58085421|NCT00474994|DRUG|sunitinib malate|
58085422|NCT02222168|DRUG|BI 409306|film-coated tablet
58085423|NCT04928625|DRUG|SHR-A1904|SHR-A1904
58301682|NCT03167242|DRUG|Lumefantrine Solid Dispersion Formulation|LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
58301683|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
58301684|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
58301685|NCT00743756|BEHAVIORAL|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
58412336|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
58412337|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
58412338|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
58412339|NCT01269385|BIOLOGICAL|rituximab|Given IV
58412340|NCT01269385|DRUG|PGG beta-glucan|Given IV
58412341|NCT01269385|OTHER|flow cytometry|Correlative studies
58412342|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
58412343|NCT01269385|GENETIC|DNA analysis|Correlative studies
58301686|NCT04472221|PROCEDURE|Arterioarterial synthetic graft|Synthetic poly tetraflouroethylene graft
58301687|NCT03444844|DRUG|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
58301688|NCT00596219|DRUG|celecoxib|celecoxib
58301689|NCT02964130|OTHER|No name|
58301690|NCT03994913|BIOLOGICAL|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
58301691|NCT04348526|PROCEDURE|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
58301692|NCT04348526|PROCEDURE|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
58301693|NCT01656044|PROCEDURE|wound care management|Receive SSD
58301694|NCT01656044|PROCEDURE|wound care management|Receive NPT
58301695|NCT02592447|OTHER|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
58412344|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
58412345|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
58412346|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
58412347|NCT01269385|GENETIC|mutation analysis|Correlative studies
57732851|NCT03116139|DIAGNOSTIC_TEST|V/Q imaging|Standard of care
57732852|NCT03116139|DIAGNOSTIC_TEST|Computed tomography scan|Standard of care
58412348|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
58412349|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
58412350|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
58412351|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
58412352|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
58085424|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab. The samples will be then stored at -70°C until analysis."
58085425|NCT02187406|PROCEDURE|Modified ankle athletic taping|
58085426|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
58085427|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
58085428|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
58085429|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
58085430|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
58085431|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
58085432|NCT05079204|OTHER|No intervention|No intervention
58085433|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
58085434|NCT05703009|DRUG|Placebo|Placebo
58301696|NCT02592447|OTHER|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
57732853|NCT05218005|DIAGNOSTIC_TEST|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
58085435|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
58085436|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
58301697|NCT02661230|DEVICE|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
58301698|NCT05724303|OTHER|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
58301699|NCT00146562|DRUG|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
58301700|NCT00146562|DRUG|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
58301701|NCT00146562|DRUG|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
58301702|NCT00146562|DRUG|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
58301703|NCT00146562|DRUG|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
58301704|NCT03391102|OTHER|Observational study|
58301705|NCT05619731|OTHER|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
58301706|NCT01015326|OTHER|Questionnaire|Administered questionnaire
58301707|NCT01015326|OTHER|Questionnaire|Administered questionnaire
58301708|NCT05700734|DRUG|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
58301709|NCT01251042|DEVICE|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
58301710|NCT01447407|BIOLOGICAL|NDV-3 vaccine with alum IM|One dose administered IM
58301711|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum IM|One dose administered IM
58301712|NCT01447407|BIOLOGICAL|Placebo with alum IM|One dose administered ID
58301713|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum ID|One dose administered ID
58301714|NCT03321721|PROCEDURE|Suture for wound repair|Repair of wound with suture
58301715|NCT03321721|DEVICE|Suture for wound repair|Repair of wound with suture
58301716|NCT01687114|OTHER|cranberry juice|27% cranberry juice
58085437|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
58085438|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
57947776|NCT04620044|OTHER|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
57947777|NCT00621478|DRUG|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
58085439|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
58085440|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
58085441|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
58085442|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
58085443|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
57947778|NCT02532894|DEVICE|Electronic cigarette|Inhaling e-cigarette vapor
57947779|NCT02227628|DIETARY_SUPPLEMENT|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
58301717|NCT05259488|DIETARY_SUPPLEMENT|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
58412353|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
58412354|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
58412355|NCT01223898|DRUG|Tasigna|
58412356|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
58412357|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
57947780|NCT02227628|DIETARY_SUPPLEMENT|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
58412358|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
58412359|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
58412360|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
57947781|NCT05617833|COMBINATION_PRODUCT|MLT+EPO|Melatonin component will be a single daily dose of 30 mg/kg enteral administered in the evening. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr IV) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday IV/SC) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.
57947782|NCT05617833|OTHER|Placebo|Placebo enteral and IV
57947783|NCT03247270|BEHAVIORAL|Intervention I|Low intensive physical exercise
57947784|NCT03247270|BEHAVIORAL|Intervention II|High intensive physical exercise
58085444|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
58085445|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
58085446|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
58085447|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
58085448|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
58085449|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
58301718|NCT00004547|PROCEDURE|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
58085450|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
58085451|NCT04827576|DRUG|Magrolimab|Administered intravenously
58085452|NCT04827576|DRUG|Docetaxel|Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
58085453|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
58085454|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
58301719|NCT00004547|PROCEDURE|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
58085455|NCT00029159|OTHER|placebo|an inactive substance
58085456|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
58412361|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
57947785|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
58085457|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
58085458|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
58085459|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
58301720|NCT00004547|DRUG|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M\^2) and 1 L of normal saline containing paclitaxel (125 mg/M\^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
57947786|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
58301721|NCT05469126|DRUG|LY3502970|Administered orally.
58412362|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
58412363|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
57732854|NCT05035719|DEVICE|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
57947787|NCT02851381|DRUG|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~* Dose: 35 mg/kg~* Route: IV over one hour following completion of gemcitabine infusion~* Schedule:~  * Days 1, 8, and 15~ * Please note that Day 8 infusion will on be completed during the first treatment cycle"
57947788|NCT06356298|OTHER|Airway Management: Flexible Reinforced Laryngeal Mask Airway|In the FLMA group, a FLMA was applied according to the manufacturer's recommendations. After lubrication of the posterior surface with oxybuprocaine hydrochloride gel, the FLMA was inserted after propping the shoulders. Its cuff was fully deflated before insertion, and the pressure was adjusted to 40 cm H2O with a manometer after insertion.
57947789|NCT06356298|OTHER|Airway Management: Endotracheal Tube|In the ETT group, guided by a visual laryngoscope, a ETT was intubated after lubrication of the surface with oxybuprocaine hydrochloride gel: endotracheal tube size = (16+ age) /4. The cuff pressure of ETT was adjusted to 20 cm H2O with a handheld manometer after inflation.
57947790|NCT04016480|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
57947791|NCT04016480|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
57947792|NCT06395831|DIAGNOSTIC_TEST|BREF,ADL,AIS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
57947793|NCT05970874|DEVICE|Hand grip strength measureme|Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).
57947794|NCT06295939|OTHER|social support program|"Group 2, the experimental group, will receive routine nursing care from the assigned nurse and a social support program provided by the researcher, as follows:~Phase 1 (Before Pregnancy Termination)~Phase 2 (After Pregnancy Termination, Before Returning Home):"
57947795|NCT06295939|OTHER|Routine nursing care|The sample group will receive routine nursing care from the assigned nurse.
57947796|NCT02093806|OTHER|measurment|
58301722|NCT05469126|DRUG|Clarithromycin|Administered orally.
58085460|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
58085461|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
58085462|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
58301723|NCT01039467|DEVICE|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
58301724|NCT00782197|DEVICE|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
58412364|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
58412365|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
58412366|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
58412367|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
58412368|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
58412369|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
58412370|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
57947797|NCT02140697|DIETARY_SUPPLEMENT|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
58412371|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
58412372|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
58412373|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
57947798|NCT02140697|DIETARY_SUPPLEMENT|Placebo (3g/day)|Placebo (3g/day), parallel design
57947799|NCT00128479|DRUG|mifepristone|mifepristone 300 mg daily for 7 dats
57947800|NCT00128479|DRUG|mifepristone matched placebo|daily for 7 days
57947801|NCT00128479|DRUG|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
57947802|NCT00128479|DRUG|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
58085463|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
58301725|NCT00782197|DEVICE|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
58301726|NCT02397616|OTHER|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
58412374|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
58412375|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
58412376|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
57947803|NCT05362903|OTHER|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
57947804|NCT02520323|OTHER|Blood draw|
57947805|NCT02520323|PROCEDURE|Bronchoscopy|
57947806|NCT02520323|BEHAVIORAL|Questionnaires|
57947807|NCT03745274|BIOLOGICAL|GHB04L1|Solution
57947808|NCT03745274|OTHER|Placebo|Buffer solution
57947809|NCT04933331|DRUG|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
58301727|NCT04566068|BEHAVIORAL|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.
58085464|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
58085465|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
58085466|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
58085467|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
58085468|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
58085469|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
58085470|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
58085471|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
58085472|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
58085473|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
58085474|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
58085475|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
58085476|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
58085477|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
58085478|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
58085479|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
58085480|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
58085481|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
58085482|NCT05527301|DRUG|Placebo|Placebo
58085483|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
58085484|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
58085485|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
58085486|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
58085487|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
58085488|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
58085489|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
58085490|NCT00540735|PROCEDURE|photodynamic therapy|
58085491|NCT02753777|OTHER|Questionnaires|
58085492|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
58085493|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
58085494|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
58085495|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
58085496|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
58085497|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
58085498|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
58085499|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
58412377|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
57732855|NCT05518929|DRUG|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
57732856|NCT05518929|DRUG|Propofol|The sedation of gastrointestinal endoscopy with Propofol
57732857|NCT03564379|DRUG|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
58085500|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
58085501|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
58085502|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
58085503|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
58085504|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
58301728|NCT04566068|BEHAVIORAL|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
58301729|NCT03991390|OTHER|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
58412378|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
57732858|NCT03564379|DRUG|Placebo|Matching placebo tablet will be administered orally.
58085505|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
58085506|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
58301730|NCT03991390|OTHER|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
58301731|NCT00955500|DIETARY_SUPPLEMENT|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
58085507|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
58085508|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
58085509|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
58085510|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
58085511|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
58085512|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
58085513|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
58085514|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
58085515|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
58085516|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
58085517|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
58085518|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
58085519|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
58085520|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
58085521|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
58085522|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
58085523|NCT02351206|RADIATION|x-ray, MRI|
58085524|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
58301732|NCT00955500|DIETARY_SUPPLEMENT|Maltodextrin|30 grams of oral maltodextrin daily
58301733|NCT01619852|DRUG|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
58301734|NCT01619852|DRUG|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
57732859|NCT02824913|DRUG|P-321 Ophthalmic Solution|
57732860|NCT02824913|DRUG|P-321 Ophthalmic Solution placebo|
58412379|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
58412380|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
57732861|NCT02872259|DRUG|BGB324+pembrolizumab|Combination
58412381|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
58085525|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
58412382|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
57732862|NCT02872259|DRUG|BGB324+dabrafenib and trametinib|Combination
58085526|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
58085527|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
58085528|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
58085529|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
58085530|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
58085531|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
58085532|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
58085533|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
58085534|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
58085535|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
58085536|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
58085537|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
58085538|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
58085539|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
58412383|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
58412384|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
58412385|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
58085540|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
58085541|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
58085542|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
58412386|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
58412387|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
58412388|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
58085543|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
58412389|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
57732863|NCT02872259|DRUG|pembrolizumab|Monotherapy
57732864|NCT02872259|DRUG|dabrafenib and trametinib|Combination
57732865|NCT05625906|OTHER|Multi-media experiential training programme|"1. Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~2. A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~3. Writing a reflective journal after the role play with standardised patients"
58085544|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
58412390|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
58085545|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
58085546|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
58085547|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
58085548|NCT02604849|DRUG|Neomycin|
58085549|NCT02604849|DRUG|Streptomycin|
58085550|NCT02604849|DRUG|Gentamicins|
58085551|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
58085552|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
57732866|NCT05881668|BIOLOGICAL|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
58085553|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
58085554|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
58085555|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
58085556|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
58085557|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
58085558|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
58412391|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
58412392|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
58412393|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
57732867|NCT03421691|DEVICE|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
57947810|NCT04933331|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
57947811|NCT04933331|DEVICE|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
57947812|NCT04933331|DEVICE|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
57947813|NCT04933331|DRUG|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
57947814|NCT00521261|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
58085559|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
57732868|NCT00583726|BEHAVIORAL|motivational interviewing|telephone counseling
57732869|NCT00583726|BEHAVIORAL|written materials only|dietary guidance materials and pedometers
58085560|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
58085561|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
58085562|NCT00584831|DEVICE|senofilcon A|toric contact lens
58085563|NCT00584831|DEVICE|balafilcon A|toric contact lens
58085564|NCT00584831|DEVICE|omafilcon A|toric contact lens
58085565|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
58085566|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
58085567|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
57732870|NCT06636539|DEVICE|CEM Exam in Investigational Device|All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
57732871|NCT03146169|BEHAVIORAL|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
58085568|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
58085569|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
58085570|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
58085571|NCT02743598|DRUG|Liraglutide|
58085572|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
58085573|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
58085574|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
58085575|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
58085576|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
58085577|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
58085578|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
58085579|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
58085580|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
58085581|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
58085582|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
58085583|NCT03707938|DRUG|Brigatinib|Given PO
58301735|NCT04126304|DRUG|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
58412394|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
58301736|NCT04126304|DRUG|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
58412395|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
58412396|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
57732872|NCT02053350|DRUG|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
57732873|NCT04972513|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57732874|NCT04972513|PROCEDURE|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
57732875|NCT04972513|PROCEDURE|Oscillometry|Undergo airwave oscillometry
57732876|NCT04972513|PROCEDURE|Spirometry|Undergo spirometry
57732877|NCT04972513|OTHER|Survey Administration|Complete survey
57732878|NCT04972513|PROCEDURE|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
58085584|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
58085585|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
58085586|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
58085587|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
58085588|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
58085589|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
58085590|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
58085591|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
58085592|NCT00117013|DRUG|Topotecan|
58085593|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
58085594|NCT06540352|DRUG|Mannitol|Placebo in tablets
57732879|NCT02431039|DEVICE|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
57732880|NCT02431039|DEVICE|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
57732881|NCT06668987|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
57732882|NCT03077724|DRUG|Fish oil|Fish oil supplementation
57732883|NCT03077724|DRUG|Placebos|Olive Oil capsules
57732884|NCT00971048|DEVICE|HP828-101|Topical test article applied once daily
57732885|NCT00971048|DEVICE|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
57732886|NCT04639453|DIAGNOSTIC_TEST|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
57732887|NCT04639453|DIAGNOSTIC_TEST|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
57732888|NCT04639453|DIAGNOSTIC_TEST|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
57732889|NCT04639453|DIAGNOSTIC_TEST|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
57732890|NCT04639453|DIAGNOSTIC_TEST|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
57732891|NCT04639453|DIAGNOSTIC_TEST|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
57732892|NCT02169687|DEVICE|HIFU|High Intensity focalized Ultrasounds
57732893|NCT06670547|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Endoscopic retrograde cholangiopancreatography (ERCP)
57732894|NCT06380231|OTHER|kangaroo mother care (KMC)|"Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index."
57732895|NCT04458350|BEHAVIORAL|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
57732896|NCT04271709|BEHAVIORAL|Enhanced Intervention Using Patient Navigators|Enhanced support includes patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
57732897|NCT04271709|OTHER|Usual Care|Usual Care subjects who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
57732898|NCT03149783|DRUG|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
57732899|NCT03149783|DRUG|sodium chloride|Placebo
57732900|NCT04643444|DIAGNOSTIC_TEST|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
57732901|NCT04643444|OTHER|Online Questionnaire|Questions on working place, risk profiles and PPE
57732902|NCT01335243|PROCEDURE|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
57732903|NCT01872169|OTHER|Disordered eating screening questionnaire|
57732904|NCT03380962|DRUG|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
57732905|NCT05219240|OTHER|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
58085595|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
58301737|NCT04126304|DIAGNOSTIC_TEST|Mycoplasma detection|"1. common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~2. community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
57732906|NCT00346060|DEVICE|Retinal transplantation instrument|
57732907|NCT00346060|DEVICE|Fetal tissue.|
57732908|NCT01257867|DIETARY_SUPPLEMENT|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
57732909|NCT01257867|DIETARY_SUPPLEMENT|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
57732910|NCT01917526|DEVICE|oxygen mask|
57732911|NCT01917526|DEVICE|oxygen cannula|
57732912|NCT02357628|DEVICE|Wound treatment with RO-NPT|
57732913|NCT02357628|DEVICE|Wound Irrigation|
57732914|NCT03904472|BEHAVIORAL|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
57947815|NCT02905370|BEHAVIORAL|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
57947816|NCT02905370|BEHAVIORAL|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
57947817|NCT01070732|DRUG|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
57947818|NCT03990064|OTHER|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
57947819|NCT01148199|DEVICE|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
57947820|NCT01148199|DEVICE|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
57947821|NCT00867399|DRUG|ABT-126|See arm for details
57947822|NCT01880671|DEVICE|Inactive Migraine Medical Device|
57947823|NCT01880671|DEVICE|Migraine Medical Device|
57947824|NCT05913570|DRUG|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
57947825|NCT04194359|DRUG|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
57947826|NCT01357096|BEHAVIORAL|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
57947827|NCT01357096|OTHER|Traditional group|CAD education fryers
57947828|NCT04339907|OTHER|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
57947829|NCT04339907|OTHER|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
58085596|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
58085597|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
58085598|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
58085599|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
58085600|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~--------------------------------------------------------------------------------"
58085601|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
58085602|NCT01060007|RADIATION|External beam radiation|
58301738|NCT04126304|OTHER|Data collection|"1. Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~2. Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~3. Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
57732915|NCT06164262|OTHER|Individuals with CSVD|This does not entail the application of interventions.
57732916|NCT01495065|DRUG|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
57732917|NCT01495065|DRUG|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
57732918|NCT01495065|DRUG|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
58085603|NCT01060007|DRUG|Oxaliplatin|
58085604|NCT01060007|DRUG|Leucovorin|
58085605|NCT01060007|DRUG|5-FU|
58085606|NCT01060007|DRUG|Capecitabine|
58085607|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
58085608|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
58085609|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
58085610|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
58085611|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
58085612|NCT05349760|DRUG|Placebo|Saline/D5W
58085613|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
58085614|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
58085615|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
58085616|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
57732919|NCT01495065|DRUG|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
58085617|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
58085618|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
58085619|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
58085620|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
58085621|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
58085622|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
58085623|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
58085624|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
58085625|NCT06648226|BEHAVIORAL|Environment swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more environmentally sustainable products (e.g., with a A or B climate label)."
57732920|NCT01495065|DRUG|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
57732921|NCT01495065|DRUG|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
57732922|NCT04785404|PROCEDURE|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
57732923|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
58085626|NCT06648226|BEHAVIORAL|Combined health and environment swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or environmental sustainability) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
58085627|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
58085628|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
58085629|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
58085630|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
58085631|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
58085632|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
58085633|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
58085634|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
58085635|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
58085636|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
58085637|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
58412397|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
58412398|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
58085638|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
58085639|NCT00369798|PROCEDURE|PET scan|
58085640|NCT00369798|DRUG|Rolipram|
58085641|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
58085642|NCT02448212|DRUG|TS-121|Oral
58085643|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
58085644|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
58085645|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
58085646|NCT00327080|PROCEDURE|MRI|
57732924|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
57732925|NCT03712917|PROCEDURE|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
58085647|NCT00327080|DRUG|L-NMMA|
58085648|NCT00327080|DRUG|Acetylcholine|
58085649|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
58085650|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
58085651|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
58412399|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
57732926|NCT03712917|DRUG|Topiramate|An antiepileptic agent used for migraine prophylaxis.
57732927|NCT03712917|DRUG|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
58085652|NCT02612649|DRUG|Ramosetron|Oral
58085653|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
58085654|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
58085655|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
58085656|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
58085657|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
58085658|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
58085659|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
58085660|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
58085661|NCT00219024|DRUG|aliskiren|
58085662|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
58085663|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
58085664|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
58085665|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
58412400|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
58412401|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
58412402|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
58412403|NCT03026478|DRUG|Betamethasone Dipropionate|
58412404|NCT03026478|DRUG|Clobetasol Propionate|
57732928|NCT05935501|DEVICE|Formaderm Young|Dermal filler injection to facial areas.
57732929|NCT05935501|DEVICE|Restylane|Dermal filler injection to facial areas.
58085666|NCT01019746|DRUG|propofol|propofol administration
58085667|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
58085668|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
58085669|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
58085670|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
58085671|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
58085672|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
58085673|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
58085674|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
58085675|NCT05181553|OTHER|Canada's Food Guide principles (CFG diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
58085676|NCT05181553|OTHER|Standard North American diet (NAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
58085677|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
58085678|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
58085679|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
58301739|NCT04126304|OTHER|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
58301740|NCT02427841|DRUG|Fluorouracil|Given IV
58301741|NCT02427841|DRUG|Gemcitabine|Given IV
58301742|NCT02427841|RADIATION|Image Guided Radiation Therapy|Undergo IG-IMRT
58301743|NCT02427841|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
58301744|NCT02427841|OTHER|Laboratory Biomarker Analysis|Correlative studies
58412405|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
57732930|NCT02797925|OTHER|Training|Long slow strength training of the tendon for 3 months to improve function
57732931|NCT05924919|PROCEDURE|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
57732932|NCT05924919|PROCEDURE|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
58301745|NCT02427841|DRUG|Nab-paclitaxel|Given IV
58412406|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
58412407|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
57732933|NCT04488536|DIAGNOSTIC_TEST|Clinical Frailty Scale|Frailty assessment
57732934|NCT04897893|OTHER|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
57732935|NCT06196762|DRUG|XKH002 Injection|240 mg/4 mL/vial（60 mg/mL）
57732936|NCT04826354|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
57732937|NCT04826354|DRUG|Rosuvastatin|Rosuvastatin
57732938|NCT00064727|DRUG|Avandia (Rosiglitazone)|
57732939|NCT00064727|DRUG|Avanclia (Rosiqlitazone)|
57732940|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
57732941|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
58085680|NCT02797951|DRUG|Galcanezumab|Administered SC
58085681|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
58085682|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
58085683|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
58085684|NCT02504463|DRUG|Samidorphan IV|Single IV administration
58301746|NCT02427841|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58301747|NCT00421278|DRUG|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
58301748|NCT00026247|PROCEDURE|pain therapy|
58085685|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
58085686|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
58085687|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
58301749|NCT00026247|PROCEDURE|radiofrequency ablation|
58301750|NCT00742794|OTHER|Observation|Observation of sting frequency
58412408|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
58412409|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
58301751|NCT05623410|BIOLOGICAL|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
58301752|NCT05623410|BIOLOGICAL|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
58301753|NCT04488913|OTHER|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
58301754|NCT04488913|OTHER|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
58412410|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
58301755|NCT06115174|DRUG|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\]."
58301756|NCT06115174|RADIATION|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
58412411|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
58412412|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
58412413|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
58412414|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
58085688|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
58085689|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
58085690|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
58085691|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
58085692|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
58085693|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
58085694|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
58412415|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
58412416|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
57732942|NCT01714128|DRUG|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
58085695|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
58085696|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
58301757|NCT06115174|RADIATION|XELOX|(oxaliplatin + capecitabine)
58301758|NCT06115174|DRUG|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
58412417|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
58412418|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
58412419|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
58301759|NCT03625726|BIOLOGICAL|Thrombin generation assay (in vitro)|One blood sample.
58301760|NCT02959502|OTHER|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
58301761|NCT02959502|OTHER|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
58301762|NCT00430846|DRUG|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
58301763|NCT00447772|BIOLOGICAL|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
58301764|NCT00065299|BEHAVIORAL|Restricted phenylalanine diet|
58301765|NCT04309032|PROCEDURE|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
58301766|NCT05848037|DEVICE|cymactiv catheter device|A new type of catheter has recently been submitted for CE marking as a Class IIb device and will soon be available in the UK market. Ingenion Medical's cymactive™ Catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body and has an integral, magnetically controlled valve that allows the user to control their own urination. The patient will be supplied with their own magnet so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items.
58301767|NCT05848037|DEVICE|Foley-type catheter device|Routine standard of care
58301768|NCT06109012|PROCEDURE|duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
58301769|NCT03175497|DRUG|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
58301770|NCT04083560|DRUG|Vit B12|Vitamin B12 250mcg
58301771|NCT05541939|DRUG|Mizagliflozin|Encapsulated or Liquid Formulation
58301772|NCT06437925|DIETARY_SUPPLEMENT|probiotic ayran drink|The test group has received probiotic ayran drink for 6 weeks
58301773|NCT06437925|DIETARY_SUPPLEMENT|Placebo ayran drink|The control group has received placebo ayran drink for 6 weeks
58301774|NCT02016443|DRUG|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
58301775|NCT02016443|DRUG|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
58301776|NCT02250339|OTHER|LAKU family program|Multi-systemic and multicomponent family-based intervention program
58301777|NCT02250339|OTHER|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
58301778|NCT02250339|OTHER|Family therapy|Treatment as usual (TAU)
58301779|NCT02925858|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
58301780|NCT02925858|DRUG|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
58301781|NCT02594319|BEHAVIORAL|Monetary incentives|
58301782|NCT02594319|BEHAVIORAL|Self monitoring|
58301783|NCT01837836|BEHAVIORAL|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
58301784|NCT03257436|DEVICE|CRT-D|Left Ventricular MultiSite Pacing
58301785|NCT01365130|DRUG|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
58301786|NCT03588130|DRUG|EscharEx (5% EX-02 formulation)|Active arm
58301787|NCT03588130|DRUG|Gel Vehicle|Control arm
58412420|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
58412421|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
58301788|NCT03588130|DRUG|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
58085697|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
58085698|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
58085699|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
58085700|NCT02975882|OTHER|Pharmacological Study|Correlative studies
58085701|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
58085702|NCT02975882|DRUG|Temozolomide|Given PO
58085703|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
58085704|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
58085705|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
58085706|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
58085707|NCT03725436|DRUG|Paclitaxel|Given IV
58085708|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
58085709|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
58085710|NCT06564961|DRUG|Placebo|1 tab once daily
58085711|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
58085712|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
58085713|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
58301789|NCT03765606|DIETARY_SUPPLEMENT|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
58085714|NCT05424939|PROCEDURE|Colectomy|Colon resection
58085715|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
58085716|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
58085717|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
58085718|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
58085719|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
58301790|NCT03765606|DIETARY_SUPPLEMENT|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
58085720|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
58085721|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
58085722|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
58085723|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
57732943|NCT03351374|OTHER|Software|multi-module system of web software tools
58085724|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
58085725|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
58085726|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
58085727|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
58085728|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
58085729|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
58085730|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
58085731|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
58085732|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
58085733|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
58085734|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
58085735|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
58085736|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
58301791|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
58301792|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
57732944|NCT02194426|DRUG|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
57732945|NCT03577002|OTHER|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
58085737|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
58085738|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
58085739|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
58085740|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
58085741|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
58085742|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
58301793|NCT03416348|DRUG|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
58301794|NCT03416348|DRUG|Alcohol|Placebo
58301795|NCT02347046|DRUG|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
58085743|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
58085744|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
58085745|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
58085746|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
58085747|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
58085748|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
58085749|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
58085750|NCT04754529|OTHER|Survey Administration|Ancillary studies
58085751|NCT04754529|OTHER|Yoga|Receive yoga intervention
58085752|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
58085753|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
58085754|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
58412422|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
58085755|NCT03814213|OTHER|CGA|Multi-level Health assessment
58085756|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
58085757|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
58085758|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
58085759|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
58085760|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
58085761|NCT01764776|DRUG|LDE225|LDE225
58085762|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
58085763|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
58085764|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
58085765|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
58085766|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
58085767|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
58085768|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
58085769|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
58085770|NCT02217397|DEVICE|OA, CPAP, combination therapy|
58301796|NCT05387876|DIETARY_SUPPLEMENT|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
58301797|NCT05387876|DIETARY_SUPPLEMENT|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
58301798|NCT01087164|BEHAVIORAL|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
58301799|NCT01087164|BEHAVIORAL|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
58301800|NCT02483884|DRUG|[68Ga]RM2|\[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
58301801|NCT02483884|PROCEDURE|PET/CT|Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min
58085771|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
58085772|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
58412423|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
58412424|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
58412425|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
58412426|NCT01901965|BEHAVIORAL|eccentric training|
58412427|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
58085773|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
58085774|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
58085775|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
58085776|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
58085777|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
58085778|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
58085779|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
58085780|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
58085781|NCT01701180|DRUG|Placebo|
58085782|NCT02660489|DRUG|OC459|
58085783|NCT02660489|DRUG|Placebo|
58085784|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
58301802|NCT03283735|BEHAVIORAL|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
58301803|NCT00570401|DRUG|dasatinib|
58085785|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
58085786|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
58085787|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
58412428|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
58085788|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
58085789|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
58085790|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
58412429|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
58412430|NCT02088502|DRUG|N-acetylcysteine|
58412431|NCT02088502|DRUG|Theophylline|
58412432|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
58412433|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
58412434|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
58085791|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
58085792|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
58085793|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
58085794|NCT00554788|DRUG|Carboplatin|Given IV
58085795|NCT00554788|DRUG|Cisplatin|Given IV
58085796|NCT00554788|DRUG|Cyclophosphamide|Given IV
58085797|NCT00554788|DRUG|Etoposide|Given IV
58085798|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
58085799|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
58085800|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
58085801|NCT00554788|DRUG|Thiotepa|Given IV
58085802|NCT00554788|DRUG|Vincristine Sulfate|Given IV
58085803|NCT03007615|OTHER|Intimate Lubricant Gel|
58085804|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
58301804|NCT04784234|DIETARY_SUPPLEMENT|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
58301805|NCT04784234|OTHER|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
58085805|NCT05117294|DRUG|Bocidelpar|Oral
58085806|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
58085807|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
58085808|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
58085809|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
58085810|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
58301806|NCT00643760|DRUG|Placebo|placebo
58301807|NCT00643760|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
58301808|NCT00643760|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
58301809|NCT00643760|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
58301810|NCT00643760|DRUG|Pregabalin|pregabalin 300mg/day
58301811|NCT05427435|DEVICE|Marshall ethanolisation|Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
58301812|NCT02915146|RADIATION|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
58301813|NCT02882334|DEVICE|Finger Force Manipulandum|
58412435|NCT01887821|DRUG|Chloroquine|
58412436|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
58412437|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
58412438|NCT03366103|DRUG|Vistusertib|Given PO
58085811|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
58085812|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
58301814|NCT02882334|OTHER|Conventional physiotherapy|
58301815|NCT00965133|OTHER|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
58301816|NCT03732027|PROCEDURE|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
58412439|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
58412440|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
57947830|NCT00933673|DRUG|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
57947831|NCT06475066|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|"After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline."
58301817|NCT03732027|PROCEDURE|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
58301818|NCT00955799|DRUG|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
58301819|NCT00955799|DRUG|Placebo|Double-blind treatment period of 29 weeks placebo
58301820|NCT02028598|DRUG|Treatment 1|An oral single dose administration
58301821|NCT02028598|DRUG|Treatment 2|An oral single dose administration
58301822|NCT02028598|DRUG|Treatment 3|Co-administration of oral single doses
58301823|NCT01905618|BEHAVIORAL|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
57947832|NCT00128856|DRUG|Gemcitabine|
57947833|NCT00128856|DRUG|Adriamycine|
57947834|NCT00128856|DRUG|Paclitaxel|
58412441|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
57947835|NCT02234479|BIOLOGICAL|Hydrophor (Group A)|"* Rehydrates dry, chapped or chafed skin~* May be used alone as a skin lubricant or protectant"
57947836|NCT02234479|BIOLOGICAL|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~* Maintain a balanced environment for healing.~* Aids in reducing dermatitis.~* Reduce affected area pH.2-3"
57947837|NCT04272658|DIAGNOSTIC_TEST|value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI"
57947838|NCT00015054|DRUG|Methylphenidate|
57947839|NCT00679510|DRUG|rosuvastatin|tablet 10 mgs once daily
57947840|NCT00679510|DRUG|placebo|placebo
57947841|NCT02628236|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
57947842|NCT02628236|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
57947843|NCT05592912|DRUG|HydroLenz Injection|The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
58085813|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
58412442|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
58085814|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
58085815|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
58085816|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
58085817|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
58085818|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
58085819|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
58085820|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
58085821|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
58085822|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
58085823|NCT01998659|DRUG|Placebo|Oral drinking solution
58085824|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
58085825|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
58085826|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
58085827|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
58085828|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
58085829|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
58085830|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
58085831|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
58085832|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
58085833|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
58085834|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
58085835|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
58085836|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
58085837|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
58301824|NCT01905618|BEHAVIORAL|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
57732946|NCT03006250|DRUG|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
58085838|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
58085839|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
58085840|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
58085841|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
58085842|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
58085843|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
58085844|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
58085845|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
58085846|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
58085847|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
58085848|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
58085849|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
58085850|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
58085851|NCT00399204|DRUG|Pioglitazone vs Metformin|
58085852|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures
58085853|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files
58085854|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
58085855|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
58085856|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
58085857|NCT00088504|DRUG|Merimepodib|
58085858|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
57947844|NCT05592912|OTHER|No HydroLenz Injection|No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
57947845|NCT04133792|DRUG|Simvastatin 40mg|40 mg orally daily for 5 years.
57947846|NCT04133792|DRUG|Placebo oral tablet|40 mg orally daily for 5 years.
57947847|NCT02471703|DEVICE|Total hip arthroplasty|Total hip arthroplasty
57947848|NCT01305642|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
57947849|NCT03686436|DEVICE|ocular coherence tomography|imaging by ocular coherence tomography
57947850|NCT04723121|DIAGNOSTIC_TEST|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
57947851|NCT04723121|DIAGNOSTIC_TEST|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
57947852|NCT04462094|DRUG|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
57947853|NCT04462094|DRUG|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
57947854|NCT02195024|PROCEDURE|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
57947855|NCT05554419|DRUG|Azacitidine|Given IV or SC
57947856|NCT05554419|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
57947857|NCT05554419|DRUG|Cytarabine|Given IV
57947858|NCT05554419|PROCEDURE|Echocardiography|Undergo ECHO
57947859|NCT05554419|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
57947860|NCT05554419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57947861|NCT05554419|DRUG|Venetoclax|Given PO
58085859|NCT00088504|DRUG|Ribavirin (Copegus®)|
58085860|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
58085861|NCT04143477|DRUG|peficitinib|Oral
58085862|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
58085863|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
58085864|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
58085865|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
58085866|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
58085867|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
58085868|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
58085869|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
58085870|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
58085871|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
58085872|NCT04926857|OTHER|Non-Interventional|Non-Interventional
58085873|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
58085874|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
58085875|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
57732947|NCT03006250|DRUG|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
57732948|NCT02516618|DRUG|Fasinumab|
57732949|NCT02516618|DRUG|Placebo|
57732950|NCT04094454|DEVICE|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
57732951|NCT04094454|DEVICE|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
58301825|NCT01905618|BEHAVIORAL|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
58412443|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
57732952|NCT05544994|OTHER|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
57732953|NCT05544994|OTHER|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
58412444|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
58412445|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
57732954|NCT01316133|DRUG|tacrolimus|oral
57732955|NCT04719793|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
57732956|NCT04691765|DRUG|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
57732957|NCT02269293|DRUG|Paclitaxel|
58412446|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
57732958|NCT02269293|DRUG|Carboplatin|
57732959|NCT02269293|DRUG|Selinexor|
57732960|NCT00124527|DRUG|Irofulven + capecitabine|
57947862|NCT00524602|PROCEDURE|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
57947863|NCT06218095|OTHER|Simulation application|Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
57732961|NCT05975190|OTHER|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R\&R training provided on an MP3-player for daily practice
57732962|NCT06635512|OTHER|The Effect of Stress Ball Application After Transurethral Resection of the Prostate on Patients' Recovery Quality and Hospital Discharge Time|The effect of the stress ball applied after surgery on patients' recovery quality will be evaluated.
57732963|NCT06031701|BEHAVIORAL|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
57732964|NCT02180646|OTHER|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
57732965|NCT02180646|OTHER|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
58085876|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
58085877|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
58085878|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
57732966|NCT05088213|PROCEDURE|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
57732967|NCT05088213|PROCEDURE|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
57732968|NCT02105363|OTHER|measure of skin movement on surface of the back|
57732969|NCT02105363|OTHER|Measurement of skin movement on surface of back|
57732970|NCT01719952|DRUG|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
57732971|NCT01719952|DRUG|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
57732972|NCT04789421|DEVICE|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
57732973|NCT04789421|DEVICE|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
57732974|NCT06315218|BEHAVIORAL|iTHRIVE 365 HIV care intervention|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
57732975|NCT01314118|DRUG|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
57732976|NCT03453606|OTHER|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
57732977|NCT03453606|OTHER|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
57732978|NCT05515159|OTHER|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
57732979|NCT05204355|DIAGNOSTIC_TEST|MRI|Patients will be imaged using MRI
57732980|NCT05204355|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
57947864|NCT00821639|BEHAVIORAL|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
58085879|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
58085880|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
58085881|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
58085882|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
58085883|NCT02765958|DEVICE|portable ECG devise|
58085884|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
58085885|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
58085886|NCT00326625|DRUG|Placebo|
58085887|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
58085888|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
58085889|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
58085890|NCT05855967|DRUG|Ixekizumab|Administered SC
58085891|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
58085892|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
58085893|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
58085894|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
58085895|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
58085896|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
58085897|NCT05392920|OTHER|assessment study|there is no intervention in this study
58085898|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
58085899|NCT02084329|DEVICE|Weighted Compression Vest|
58085900|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
58085901|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
58085902|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
58085903|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
58085904|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
58085905|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58085906|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
58085907|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
58085908|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
58085909|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
58085910|NCT04158739|DRUG|Cytarabine|Given IT
58085911|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
58085912|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
58412447|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
58085913|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
58085914|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
58085915|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
58085916|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
58085917|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
58085918|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
58085919|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
58412448|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
58412449|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
58085920|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
58085921|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
58085922|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
58085923|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
58085924|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
58085925|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
58085926|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
58085927|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
58412450|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
58412451|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
58412452|NCT05244460|DRUG|Diphenhydramine|Treatment
58412453|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
58412454|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
58412455|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
58412456|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
58412457|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
57947865|NCT00366275|PROCEDURE|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes \>1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
58412458|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
58412459|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
58412460|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
57732981|NCT05204355|DIAGNOSTIC_TEST|HRCT|High Resolution Computer Tomography
57732982|NCT00593372|BEHAVIORAL|Spaced Retrieval Training|Increasing time to remember important information.
57947866|NCT05453058|DIAGNOSTIC_TEST|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
57947867|NCT00309309|DRUG|Rosiglitazone|
57947868|NCT03539055|DRUG|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
57947869|NCT01270308|DRUG|Lansoprazole|Lansoprazole DR Capsules 30 mg
57947870|NCT00405067|DRUG|BMS-201038 (AEGR-733)|
57947871|NCT00405067|DRUG|Ezetimibe|
57947872|NCT05291676|BIOLOGICAL|Fluzone|Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
57947873|NCT05291676|BIOLOGICAL|Fluad|Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
57947874|NCT03804333|RADIATION|standard treatment|3000 cGy in 10 daily fractions
57947875|NCT03804333|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
57947876|NCT06190067|DRUG|Azacitidine Plus PD-1 therapy|Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
57947877|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
57947878|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
58085928|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
58085929|NCT02392312|DRUG|ATF-Fresenius S|intravenous
58301826|NCT01905618|BEHAVIORAL|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
58301827|NCT01187732|DEVICE|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
58412461|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
58412462|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
58412463|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
58412464|NCT00182767|DRUG|ixabepilone|Given IV
58412465|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
58301828|NCT01026025|DEVICE|Duet TRS|This is a single arm study.
58301829|NCT02493972|PROCEDURE|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
58301830|NCT02493972|PROCEDURE|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
58301831|NCT03199352|OTHER|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
58301832|NCT03199352|OTHER|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
58301833|NCT01620645|RADIATION|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
58412466|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
58301834|NCT02172027|DEVICE|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
58301835|NCT00509717|OTHER|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
58301836|NCT00509717|OTHER|control|educational manual
58301837|NCT04744818|DIETARY_SUPPLEMENT|Iron syrup|Daily supplementation with iron
58301838|NCT04744818|DIETARY_SUPPLEMENT|Multivitamin syrup|Daily supplementation with multivitamins
58301839|NCT00861133|DEVICE|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
58301840|NCT03634943|OTHER|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
58301841|NCT05289700|DEVICE|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
58412467|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
58412468|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
58412469|NCT02542891|OTHER|Blended CBT|
58412470|NCT02542891|OTHER|Treatment as Usual (TAU)|
58412471|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
58412472|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
58085930|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
58085931|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
58301842|NCT05289700|DEVICE|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
58301843|NCT01065818|DRUG|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
58412473|NCT02658747|OTHER|No intervention|No intervention administered in this study
58412474|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
58412475|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
58412476|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
58085932|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
58085933|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
58085934|NCT02416505|BEHAVIORAL|Verbal+Video|
58085935|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
58085936|NCT02736669|BEHAVIORAL|Energy Reduction|
58085937|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
58085938|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
58085939|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
58085940|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
58085941|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
58085942|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
58085943|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
58085944|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
58085945|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
58085946|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
58085947|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
58085948|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
58085949|NCT00213486|DRUG|irinotecan|
58085950|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.
58301844|NCT02351947|OTHER|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
58301845|NCT03467451|PROCEDURE|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
58085951|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
58085952|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
58085953|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
58085954|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
58301846|NCT05104385|OTHER|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
58301847|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
58301848|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
57947879|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
58301849|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
58085955|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
58085956|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
58085957|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
58085958|NCT06110338|DRUG|placebo|placebo iv. once.
58085959|NCT06110338|DRUG|IBI355|IBI355 iv. once.
58085960|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
58085961|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
58301850|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
58301851|NCT03830268|DIETARY_SUPPLEMENT|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
58301852|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
58301853|NCT01164202|DRUG|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
58301854|NCT01164202|DRUG|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
58301855|NCT01164202|PROCEDURE|transarterial chemoembolization|Chimioembolisation
58301856|NCT06204497|PROCEDURE|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
58301857|NCT02515630|DRUG|MMB|Momelotinib (MMB) tablet administered orally once daily
58301858|NCT00032591|PROCEDURE|Weekly patient self-testing of prothrombin time|
58301859|NCT00032591|OTHER|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
58301860|NCT05179304|PROCEDURE|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
58301861|NCT03205150|DRUG|LIK066|Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
58301862|NCT03205150|DRUG|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
58301863|NCT04102618|BIOLOGICAL|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
58301864|NCT04102618|DRUG|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
58301865|NCT04102618|DRUG|Atezolizumab|1200 mg administered intravenously on Day 3
58301866|NCT04102618|DRUG|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
58301867|NCT01586052|DRUG|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
58301868|NCT02511301|DEVICE|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
58085962|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
58085963|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
58085964|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
58085965|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
58085966|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
58085967|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
58085968|NCT00018343|DRUG|estrogen|
58085969|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
58085970|NCT02992808|DRUG|recombinant gonadotropins|
58085971|NCT02992808|DRUG|HP-HMG|
58085972|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
58085973|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
58085974|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
58085975|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
58085976|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
58085977|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
58085978|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
58085979|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
58085980|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
58085981|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58301869|NCT06425796|DIETARY_SUPPLEMENT|Adiposity and Iron Requirements in Pregnancy (ADIPREG)|"Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered."
58301870|NCT01838538|DRUG|Bevacizumab|
58301871|NCT01838538|DRUG|TC:paclitaxel + carboplatin|
58301872|NCT03981471|BEHAVIORAL|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
58301873|NCT02271113|DRUG|GMI-1271|
58085982|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
58085983|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
58085984|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
58085985|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
58085986|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
58085987|NCT02873195|DRUG|Atezolizumab|Given IV
58085988|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
58085989|NCT02873195|DRUG|Capecitabine|Given PO
58085990|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
58085991|NCT02873195|OTHER|Placebo|Given IV
58085992|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
58085993|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
58085994|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
58085995|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
58085996|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
58085997|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
58085998|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
58085999|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
58086000|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
58301874|NCT02271113|DRUG|Placebo|
58301875|NCT02271113|DRUG|Enoxaparin Sodium (Lovenox®)|
58301876|NCT01939314|DRUG|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
58301877|NCT01939314|DRUG|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
58301878|NCT01502085|DRUG|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
58301879|NCT05619666|PROCEDURE|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
58301880|NCT02573714|DRUG|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
58301881|NCT02573714|DRUG|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
58301882|NCT02573714|OTHER|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
58301883|NCT02573714|OTHER|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
58301884|NCT02573714|OTHER|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
58301885|NCT00691522|DRUG|Xerecept|
58301886|NCT02990403|DRUG|Aspirin|
58301887|NCT02990403|DRUG|Heparin|
58301888|NCT02990403|DRUG|Prednisone|
58301889|NCT02990403|DRUG|Immunoglobulin|
58301890|NCT02990403|DRUG|Dydrogesterone|
58301891|NCT05720416|DIETARY_SUPPLEMENT|protein supplementation|protein supplementation for 16 weeks
58301892|NCT05720416|BEHAVIORAL|muscle strength training|muscle strength training for 16 weeks
58301893|NCT05720416|OTHER|usual care|no intervention
58301894|NCT01926028|BIOLOGICAL|NDV-3A|0.5mL injection IM
58301895|NCT01926028|BIOLOGICAL|NDV-3|0.5mL injection IM
58301896|NCT01926028|BIOLOGICAL|Placebo|aluminum hydroxide and buffered saline
58301897|NCT02653365|DEVICE|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
58301898|NCT02151357|DRUG|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
58301899|NCT06435975|OTHER|Physical Activity|Participants will perform a baseline +4000 steps/day for the duration of the study. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
58301900|NCT06435975|OTHER|Survey|Participants will complete a series of survey at multiple points throughout this study to assess quality of life issues. Questionnaires may be completed via paper forms with prepaid postage envelopes or using a REDCap online survey.
58301901|NCT06435975|BEHAVIORAL|Telehealth Lifestyle Coaching|Participants will meet with a health coach, the Principal Investigator, to review baseline bowel habits and symptoms as well as discuss physical activity and potential strategies to achieve this goal, on a weekly basis for 12 weeks.
58301902|NCT02539992|DEVICE|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
58412477|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
58086001|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
58086002|NCT00295919|DRUG|fenretinide lipid matrix|
58086003|NCT00295919|DRUG|ketoconazole|
58301903|NCT02539992|DEVICE|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
58301904|NCT02539992|DEVICE|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
58301905|NCT04000178|DEVICE|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
58301906|NCT04000178|DEVICE|silicone stent|silicone stent
58086004|NCT00295919|OTHER|laboratory biomarker analysis|
58301907|NCT00072384|DRUG|liposomal vincristine sulfate|Given IV
58301908|NCT00072384|PROCEDURE|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
58301909|NCT00072384|PROCEDURE|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
58301910|NCT00072384|DRUG|carboplatin|Given IV
58301911|NCT00072384|DRUG|etoposide|Given IV
58301912|NCT00072384|BIOLOGICAL|filgrastim|Given subcutaneously
58301913|NCT05689359|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
58301914|NCT05757414|DEVICE|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
58301915|NCT05757414|DEVICE|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
58086005|NCT00295919|OTHER|pharmacological study|
58086006|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
58086007|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
58086008|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
58086009|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
58301916|NCT05646368|DIETARY_SUPPLEMENT|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
58301917|NCT05646368|DIETARY_SUPPLEMENT|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
58301918|NCT04650074|DRUG|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
58412478|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
58412479|NCT02238340|DRUG|Extended- release Oxycodone|
58412480|NCT02238340|DRUG|ketoprofen|
58412481|NCT02238340|DRUG|dipirone|
58412482|NCT02238340|DRUG|dexametasone|
58412483|NCT02238340|DRUG|Morphine IV (rescue)|
58412484|NCT04394273|OTHER|Exercise|stabilization exercise
58086010|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
58086011|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
58086012|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
58086013|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
58086014|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
58086015|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
58086016|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
58086017|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
58086018|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
58086019|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
58086020|NCT05309993|DEVICE|PTNS|See arm description
58086021|NCT05309993|DEVICE|TENS|See arm description
58086022|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
58086023|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
58086024|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
58086025|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
58301919|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
58301920|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
58301921|NCT03069872|DIAGNOSTIC_TEST|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
58301922|NCT02664077|DRUG|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
58301923|NCT02664077|DRUG|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
58301924|NCT02037672|DRUG|metformin|
58412485|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
58301925|NCT02037672|DRUG|metformin and roflumilast|
58301926|NCT00471497|DRUG|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
58301927|NCT00471497|DRUG|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
58301928|NCT04463134|DRUG|NTM drug treatment|NTM drug treatment according to guideline and sensitivity test results
58086026|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
58086027|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
58086028|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
58086029|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
58086030|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
58301929|NCT04873089|OTHER|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product"
58086031|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
58086032|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
58086033|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
58086034|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
58301930|NCT01116921|DEVICE|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
58301931|NCT01116921|DEVICE|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
58301932|NCT01116921|DRUG|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
58301933|NCT05812950|BEHAVIORAL|GST|Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
58301934|NCT05812950|BEHAVIORAL|CBT-E|Outpatient eating disorder treatment (20-40 weekly individual sessions)
58301935|NCT05669118|PROCEDURE|Tooth Autotransplantation|Place another tooth in the place of the newly extracted tooth in the same patient.
58301936|NCT05669118|PROCEDURE|Immediate implant|Place a dental implant immediately after tooth extraction.
58301937|NCT00471484|BIOLOGICAL|recombinant interferon alfa-2b|
58301938|NCT00471484|DRUG|doxorubicin hydrochloride|
58301939|NCT00471484|DRUG|fluorouracil|
58301940|NCT00471484|DRUG|oxaliplatin|
58301941|NCT00471484|OTHER|diagnostic laboratory biomarker analysis|
58301942|NCT00471484|OTHER|immunoenzyme technique|
58301943|NCT00471484|OTHER|immunohistochemistry staining method|
58301944|NCT00471484|PROCEDURE|adjuvant therapy|
58301945|NCT00471484|PROCEDURE|biopsy|
58301946|NCT00471484|PROCEDURE|neoadjuvant therapy|
58301947|NCT00471484|PROCEDURE|therapeutic conventional surgery|
58301948|NCT01487083|DRUG|Pomaglumetad methionil|Administered orally
58301949|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
58301950|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
58301951|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
58301952|NCT02923700|BIOLOGICAL|Leukocyte-rich PRP intra-articular injections|
58301953|NCT02923700|BIOLOGICAL|Leukocyte-poor PRP intra-articular injections|
58301954|NCT03937115|DEVICE|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
58301955|NCT03937115|DEVICE|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
58301956|NCT03937115|DEVICE|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
58301957|NCT03937115|DEVICE|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
58301958|NCT02411240|DEVICE|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
58301959|NCT00995839|DRUG|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
58301960|NCT00995839|DRUG|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
58301961|NCT00995839|DRUG|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
58301962|NCT02390154|DRUG|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution
58301963|NCT02390154|DRUG|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
58301964|NCT02728063|DIETARY_SUPPLEMENT|Lactibiane Tolerance|probiotics
58301965|NCT06459713|DIAGNOSTIC_TEST|multiplex respiratory polymerase chain reaction test|According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
58301966|NCT03511768|DRUG|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
58301967|NCT03511768|DEVICE|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
58301968|NCT01046864|DRUG|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
58086035|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
58086036|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
58086037|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
58086038|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
58086039|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
58086040|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
58086041|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
58086042|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
58086043|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
58086044|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
58086045|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
58086046|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
58086047|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
58301969|NCT01046864|DRUG|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
58301970|NCT01046864|DRUG|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
58301971|NCT01046864|DRUG|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
58412486|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
58086048|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
58086049|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
58086050|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
58086051|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
58301972|NCT01046864|DRUG|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
58301973|NCT01046864|DRUG|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
58301974|NCT01046864|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
58301975|NCT05385146|OTHER|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
58301976|NCT00018317|BEHAVIORAL|low protein diet|
58301977|NCT00018317|BEHAVIORAL|resistance training|
58301978|NCT00018317|BEHAVIORAL|combination of diet control and exercise|
58301979|NCT03598400|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
58301980|NCT03598400|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
58412487|NCT04029389|DEVICE|Injection|Local corticosteroid injection
58412488|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
58086052|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
58086053|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
58086054|NCT02141373|DEVICE|Glubran 2|
58086055|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
58086056|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
58086057|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
58086058|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
58086059|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
58086060|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
58086061|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
58086062|NCT02615652|OTHER|no intervention|no intervention, observational study
58086063|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
58086064|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
58086065|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
58086066|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
58086067|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
58086068|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
58412489|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
57732983|NCT04254900|OTHER|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
57732984|NCT05624242|PROCEDURE|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
58086069|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
58412490|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
58412491|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
58412492|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
58412493|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
58412494|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
57732985|NCT02059694|DRUG|Hyaluronidase|
57732986|NCT02059694|OTHER|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
57732987|NCT00919243|DRUG|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
57732988|NCT00919243|DRUG|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
57732989|NCT04452708|DEVICE|HFNC|HFNV vs NIV vs conventional nasal cannula
58086070|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
58086071|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
58086072|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
58086073|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
58086074|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
58086075|NCT00798902|OTHER|Iliac crest autograft|autograft
58086076|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
58086077|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
58086078|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
58086079|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
58301981|NCT00729521|OTHER|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
58301982|NCT00729521|OTHER|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
58301983|NCT01285661|DRUG|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
58412495|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
57732990|NCT05672992|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
58086080|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
58086081|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
58086082|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
58086083|NCT02820324|DRUG|Oliceridine|
58086084|NCT02820324|DRUG|Placebo|
58086085|NCT02820324|DRUG|Morphine|
58086086|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
58086087|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
58086088|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
58086089|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
58086090|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
58086091|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
58301984|NCT04331288|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
58301985|NCT04331288|OTHER|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
58412496|NCT04699292|PROCEDURE|Surgery|Surgery
58412497|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
57732991|NCT03862404|DRUG|Bupivacaine-epinephrine|See previous description
58086092|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
58086093|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
58086094|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
58086095|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
58086096|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
58086097|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
58086098|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
58086099|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
58086100|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
58086101|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
58086102|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
58301986|NCT02178904|PROCEDURE|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
58301987|NCT05020041|BEHAVIORAL|Physical activity|"The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance."
58301988|NCT05762367|DIAGNOSTIC_TEST|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
58412498|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
58412499|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
58412500|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
58412501|NCT01777555|DRUG|CVT-301|
58412502|NCT01777555|DRUG|Placebo|
58086103|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
58086104|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
58086105|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
58086106|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
58086107|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
58086108|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
58086109|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
58086110|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
58412503|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
58412504|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
58412505|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
58412506|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
58412507|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
58412508|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
58086111|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58086112|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
58086113|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
58086114|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
58086115|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
58301989|NCT05029908|DIAGNOSTIC_TEST|Jaw Functional Limitation Scale|DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
58301990|NCT05105074|DRUG|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
58301991|NCT05105074|DRUG|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
58412509|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
58412510|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
58412511|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
58086116|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
58086117|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
58086118|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
58086119|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
58301992|NCT03393182|PROCEDURE|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
58301993|NCT03393182|PROCEDURE|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
58301994|NCT00383201|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
58301995|NCT03462810|DRUG|cabotegravir, CAB|open label investigational product
58301996|NCT01088971|DIETARY_SUPPLEMENT|Duolac7S|1 capsule two times everyday for 6 weeks
58301997|NCT01088971|DIETARY_SUPPLEMENT|starch|1capsule two times everyday for 6 weeks
58301998|NCT01885013|DRUG|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
58301999|NCT01885013|DRUG|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
58302000|NCT04710212|OTHER|No intervention.|Observational study with no intervention.
58302001|NCT06005363|DRUG|Dexmedetomidine|dexmedetomidine infusion
58302002|NCT06005363|DEVICE|anesthesia depth monitoring|intraoperative anesthesia depth monitoring to keep BIS 40-60
58302003|NCT03388424|DIAGNOSTIC_TEST|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
58412512|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
58412513|NCT01234805|OTHER|questionnaire administration|Ancillary studies
58412514|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
58412515|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
58412516|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
58086120|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
58086121|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
58086122|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
58086123|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
58086124|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
58412517|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
58412518|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
58086125|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
58086126|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
58086127|NCT03014427|OTHER|Biological Database|Biological Database
58302004|NCT03323593|DRUG|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
58302005|NCT05976789|DEVICE|Sound therapy using low-level background sound|"This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief."
58302006|NCT05976789|BEHAVIORAL|Remote counseling using HAT-Online|This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
58302007|NCT05976789|OTHER|Sound therapy using successive approximations|This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
58302008|NCT03451981|PROCEDURE|mechanical debridement and chemical decontamination|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.
58302009|NCT03451981|PROCEDURE|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
57732992|NCT03862404|DRUG|Normal saline|See previous descreption
57947880|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
58086128|NCT02073591|OTHER|Ceradan Cream|
58086129|NCT02073591|OTHER|Ceradan Wash|
58086130|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
58086131|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
58086132|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
58086133|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
58086134|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
58302010|NCT03451981|PROCEDURE|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
58302011|NCT04378335|OTHER|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
58086135|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
58086136|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
58086137|NCT02048059|DRUG|ANG1005|
58086138|NCT01410747|DRUG|Tacrolimus|oral
58086139|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
58086140|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
58412519|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
58086141|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
58086142|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
58086143|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
58086144|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
58086145|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
58086146|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
58086147|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
58086148|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
58086149|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
58302012|NCT03003910|BEHAVIORAL|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
58412520|NCT02868450|BIOLOGICAL|Blood Sample|
58412521|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
58086150|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
58086151|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
58086152|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
58086153|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
58086154|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
58086155|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
58086156|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
57732993|NCT00782340|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
57947881|NCT00601536|DRUG|Lithium|
58302013|NCT03003910|BEHAVIORAL|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
58302014|NCT01207947|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
58302015|NCT01662544|PROCEDURE|Oxygen delivery|
58302016|NCT04020367|PROCEDURE|biopsy of mucosa's olfactory|intervention under general or local anesthesia
58302017|NCT00036764|DRUG|ixabepilone|Given IV
58302018|NCT00036764|OTHER|pharmacogenomic studies|Correlative studies
58302019|NCT00036764|OTHER|laboratory biomarker analysis|Correlative studies
58302020|NCT03363971|DRUG|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
58412522|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
58412523|NCT02120170|PROCEDURE|Colon polypectomy|
57947882|NCT00490178|DRUG|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
57947883|NCT05931237|DIETARY_SUPPLEMENT|Cranberry extract capsules|Cranberry extract capsules (Prebiocran(TM))
57947884|NCT03521375|PROCEDURE|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
58412524|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
58412525|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
58412526|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
58412527|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
58086157|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
58086158|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
58086159|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
58302021|NCT03363971|DRUG|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
58412528|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
58412529|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
58412530|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
58302022|NCT04071379|BIOLOGICAL|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
58302023|NCT04071379|BIOLOGICAL|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
58302024|NCT06394583|PROCEDURE|Lung ultrasound|We will perform a LU at birth to all infants, before the first dose of surfactant.
58302025|NCT03547609|OTHER|No arm intervention|No arm intervention
58302026|NCT01241279|DEVICE|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
58302027|NCT01241279|DEVICE|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
58302028|NCT00002424|DRUG|L-756423|
58302029|NCT00002424|DRUG|Indinavir sulfate|
58302030|NCT00002424|DRUG|Lamivudine|
58302031|NCT00002424|DRUG|Stavudine|
58302032|NCT02359461|DEVICE|Combination pulsatile Stendo3|
58302033|NCT04283786|OTHER|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
58302034|NCT01883895|DEVICE|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
58302035|NCT01883895|OTHER|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
58302036|NCT01883895|OTHER|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
58302037|NCT00838071|DRUG|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
58302038|NCT04601727|DIAGNOSTIC_TEST|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
58302039|NCT04100616|OTHER|No intervention|There is no intervention for this study
58086160|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
58086161|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
58086162|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
58302040|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
58302041|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
58302042|NCT01095835|DRUG|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
58302043|NCT01051921|DRUG|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
58412531|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
58412532|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
58412533|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
58412534|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
58086163|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
58302044|NCT01051921|DRUG|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
58412535|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
58412536|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
58412537|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
58412538|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
58412539|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
58412540|NCT01657136|DRUG|Ivabradine|comparison of different drugs
58412541|NCT01657136|DRUG|Beta blocker|comparison of different drugs
58412542|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
58412543|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
58412544|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
58412545|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
58412546|NCT00023686|PROCEDURE|surgery|
58412547|NCT00023686|RADIATION|radiation|
58412548|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
58086164|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
58086165|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
58412549|NCT00458042|DRUG|treprostinil sodium|
58412550|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
58086166|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
58086167|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
58086168|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
58086169|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
58412551|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
58412552|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
57732994|NCT00782340|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
57732995|NCT01704092|DRUG|Dexmedetomidine|
58086170|NCT01771627|DRUG|varenicline|Given PO
58086171|NCT01771627|DRUG|nicotine patch|
58086172|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
58086173|NCT01764594|OTHER|Placebo|Placebo comparator
58086174|NCT06566053|OTHER|Observation|Observation
58086175|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
58086176|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
58086177|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
58086178|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
58086179|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
58086180|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
58086181|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
58086182|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
58086183|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
58086184|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
58086185|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
58086186|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
58086187|NCT01511562|DRUG|carmustine|Given IV
58086188|NCT01511562|DRUG|cytarabine|Given IV
58086189|NCT01511562|DRUG|etoposide|Given IV
58086190|NCT01511562|DRUG|thiotepa|Given IV
58086191|NCT01511562|PROCEDURE|stem cell transplant|
58086192|NCT01511562|DRUG|G-CSF|
58086193|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
58086194|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
58086195|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
58086196|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
58086197|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
58086198|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
58412553|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
58412554|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
58412555|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
58412556|NCT00170196|DRUG|prednisone|
58412557|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
58412558|NCT00114023|DRUG|Imiquimod 5% cream|
58412559|NCT04526873|BEHAVIORAL|Postcard|Mailed
58412560|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
58086199|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
58412561|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
58412562|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
58412563|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
58412564|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
58412565|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
57732996|NCT03631979|OTHER|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
57732997|NCT05445427|DEVICE|vagal nerve stimulator|Non-invasive vagus nerve stimulator
58086200|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
58086201|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
58086202|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
58086203|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
58086204|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
58086205|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
58086206|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
58086207|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
58086208|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
58412566|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
58412567|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
58412568|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
58412569|NCT01873729|DRUG|Naltrexone|Adults with ADHD
58412570|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
58086209|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
58086210|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
58086211|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
58412571|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
58086212|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
58086213|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
57732998|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
58086214|NCT01157065|DRUG|AL-78898A|Investigational treatment
58086215|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
58086216|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
58086217|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
58086218|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
58086219|NCT03300804|DRUG|Placebo|Placebo herb formulation
58086220|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
58086221|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
58086222|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
58086223|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
58086224|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
58086225|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
58086226|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
58086227|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
58086228|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
58086229|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
58302045|NCT01051921|DRUG|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
58302046|NCT06363643|DEVICE|ELECTROSTIMULATION (ES)|ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.
58302047|NCT06363643|OTHER|EXERCISE (C)|C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
58302048|NCT03671070|DRUG|Epinephrine|IV Low dose Boluses
58302049|NCT03671070|DRUG|Traditional management of shock|"1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
58302050|NCT00735007|DRUG|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
58302051|NCT01304797|DRUG|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
58302052|NCT01304797|DRUG|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
58302053|NCT01304797|DRUG|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
58302054|NCT01304797|DRUG|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
58086230|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
58086231|NCT02959398|DEVICE|Standard mammography|Standard mammography
58086232|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
58086233|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
58086234|NCT06060717|DEVICE|F&P Caramel|Nasal mask
58086235|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
58086236|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
58086237|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
58086238|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
58086239|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
58086240|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
58302055|NCT01341496|BIOLOGICAL|Epigenetically Modified Autologous Tumor|5x 10\^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
58302056|NCT01341496|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
58302057|NCT01341496|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
58302058|NCT04064112|PROCEDURE|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
58302059|NCT04064112|PROCEDURE|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
58302060|NCT03786380|DRUG|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
58302061|NCT02208544|PROCEDURE|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
58302062|NCT02208544|DEVICE|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
58302063|NCT02208544|RADIATION|FDG-PET/CT|Head and Neck FDG-PET/CT
58086241|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
58086242|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
58302064|NCT03273478|DEVICE|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~* The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~* The patients will only be enrolled in the study if they give their written consent.~* If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
58412572|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
58412573|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
58412574|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
58412575|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
58412576|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
58412577|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
58412578|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
58412579|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
58412580|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
58412581|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
58412582|NCT00005636|DRUG|cisplatin|
58412583|NCT00005636|DRUG|pemetrexed disodium|
57732999|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
58086243|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
58086244|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
58086245|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
58086246|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
58412584|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
58412585|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
58412586|NCT02066506|OTHER|symptomatic group|2 visits with MRI
58412587|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
58412588|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
58086247|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58086248|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58086249|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
57733000|NCT05399953|OTHER|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
58086250|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
58086251|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
58302065|NCT00449163|BIOLOGICAL|Bevacizumab|
58302066|NCT00449163|DRUG|Floxuridine|
58302067|NCT00449163|DRUG|Irinotecan|
58302068|NCT00449163|DRUG|Leucovorin|
58302069|NCT02182310|DRUG|BI 201335 low dose|
58086252|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
58086253|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
58086254|NCT02730039|BEHAVIORAL|workshop|
58086255|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
58086256|NCT02730039|BEHAVIORAL|assessments|
58086257|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
58086258|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
58302070|NCT02182310|DRUG|BI 201335 placebo|
58412589|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
58412590|NCT02954419|OTHER|No intervention|No intervention
58302071|NCT02182310|DRUG|Moxifloxacin|
58302072|NCT02182310|DRUG|BI 201335 high dose|
57733001|NCT05399953|OTHER|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
57947885|NCT03521375|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
57947886|NCT06033573|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
57947887|NCT02316340|DRUG|Vorinostat|400mg by mouth daily
57947888|NCT02316340|DRUG|Hydroxychloroquine|600mg by mouth daily
57947889|NCT02316340|DRUG|Regorafenib|160 mg by mouth daily
57947890|NCT03503877|DEVICE|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
57947891|NCT03503877|OTHER|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
57947892|NCT03503877|OTHER|SAGE MEDIA|Embryos will be cultured in SAGE media
58086259|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
58302073|NCT02564367|DRUG|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks"
58302074|NCT01954589|DRUG|ACT-462206 5 mg|
57733002|NCT05399953|OTHER|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
57947893|NCT02603120|DRUG|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
57947894|NCT02603120|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
57947895|NCT02603120|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
57947896|NCT02603120|DRUG|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
57947897|NCT03317795|DRUG|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
57947898|NCT03317795|DRUG|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
57947899|NCT04543071|DRUG|Motixafortide|1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
58302075|NCT01954589|DRUG|ACT-462206 25 mg|
58302076|NCT01954589|DRUG|ACT-462206 100mg|
58302077|NCT01954589|DRUG|ACT-462206 200mg|
58302078|NCT01954589|DRUG|ACT-462206 400mg|
58302079|NCT01954589|DRUG|ACT-462206 1000 mg|
58302080|NCT01954589|DRUG|ACT-462206 1500mg|
58302081|NCT01954589|DRUG|Almorexant 400mg|
58302082|NCT01954589|DRUG|Placebo|
58086260|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
58086261|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
58086262|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
58086263|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
58086264|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
58086265|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
58086266|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
58412591|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
57733003|NCT04230408|DRUG|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
57733004|NCT02626715|DRUG|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
57733005|NCT02626715|DRUG|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
57733006|NCT06034405|DIAGNOSTIC_TEST|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
57733007|NCT05996159|DEVICE|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
58086267|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
58412592|NCT00146185|DRUG|ALGRX 3268|
58412593|NCT01371643|DRUG|Octreotide LAR|
58412594|NCT01371643|PROCEDURE|transsphenoidal surgery|
57733008|NCT05996159|DEVICE|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
57733009|NCT00062933|PROCEDURE|Laparotomy|
57733010|NCT00175682|DRUG|Prazosin HCL|See Detailed Description
58086268|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
58086269|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
58086270|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
58086271|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
58086272|NCT00000459|BEHAVIORAL|diet, fat-restricted|
58302083|NCT05839717|PROCEDURE|Blood sampling|A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
58302084|NCT02215850|DRUG|SLC-0111|
58302085|NCT01339871|DRUG|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
58302086|NCT01339871|DRUG|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
58302087|NCT04363060|COMBINATION_PRODUCT|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
58412595|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
58412596|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
57733011|NCT01965834|DRUG|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
57733012|NCT00250887|DRUG|Gefitnib|
57733013|NCT00484705|PROCEDURE|Electroacupuncture|
57733014|NCT00484705|PROCEDURE|Physical exercise|
57733015|NCT00484705|PROCEDURE|Untreated control|
58412597|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
58412598|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
57733016|NCT06635746|DRUG|Vinpocetine|Increasing doses of vinpocetine to assess tolerability.
58086273|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
58086274|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
58086275|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
58086276|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
58086277|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
58086278|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
58302088|NCT04363060|DRUG|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
58302089|NCT04790695|DRUG|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
58302090|NCT04609514|DEVICE|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
58302091|NCT04609514|BEHAVIORAL|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
58302092|NCT04609514|DRUG|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
58302093|NCT04609514|BEHAVIORAL|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
58302094|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
58302095|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
58412599|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
58412600|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
58412601|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
58412602|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
58412603|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
58412604|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
58412605|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
58412606|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
58412607|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
57733017|NCT02816671|DEVICE|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
58086279|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
58412608|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
58412609|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
58412610|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
58412611|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
58412612|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
58412613|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
58412614|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
58412615|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58086280|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
58086281|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
58086282|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
58086283|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58086284|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
58086285|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
58086286|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
58086287|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
58086288|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
58086289|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
57733018|NCT02658643|PROCEDURE|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
57733019|NCT02658643|PROCEDURE|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
57733020|NCT00252642|DRUG|Peginterferon Alpha-2a|
57733021|NCT03034577|DRUG|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
57733022|NCT03034577|DRUG|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
57733023|NCT06634979|PROCEDURE|Selective lymph node dissection|For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
57733024|NCT02365467|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|
57733025|NCT04023695|DRUG|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
57733026|NCT04023695|DRUG|Corticosteroid with normal saline|Trigger finger injection
57733027|NCT04050293|DRUG|SPN-538|Patients will receive SPN-538
58086290|NCT02916056|DRUG|Azeliragon 5mg|
57733028|NCT04050293|DRUG|Placebo|Patients will receive Placebo
58086291|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
58086292|NCT03166969|PROCEDURE|Holter 21 days|
58086293|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
58086294|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
58086295|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
58086296|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
58412616|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
57733029|NCT03181360|DRUG|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
57733030|NCT03181360|OTHER|Control|Best standard treatment
57733031|NCT01659021|DRUG|Idelalisib|150 mg tablets administered orally twice daily
57733032|NCT01659021|DRUG|Ofatumumab|Administered intravenously
57733033|NCT01404572|DRUG|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
57733034|NCT01404572|DRUG|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
57733035|NCT01404572|DRUG|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
58302096|NCT05252403|GENETIC|PTG-CARCIK-CD19|PTG-CARCIK-CD19 cells is a gene therapy medicinal product (GTMP) composed of genetically modified allogeneic T lymphocytes formulated as cell suspension in normal saline solution and freezing media
58302097|NCT04271124|OTHER|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
58412617|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
58412618|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
58412619|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
58412620|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
58412621|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
58412622|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
58412623|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
58086297|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
58086298|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
58412624|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
58412625|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
58412626|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
58086299|NCT02988310|OTHER|No intervention|
58086300|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
58302098|NCT05645926|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
58302099|NCT05645926|PROCEDURE|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
58302100|NCT05543538|OTHER|multimedia audio-visual program|Participants in the control group will receive teaching method with multimedia audio-visual material.
58302101|NCT05543538|OTHER|experiential learning programmes|Participants in the experimental group will receive teaching method with experiential learning.
58302102|NCT05543538|OTHER|teachers' personal demonstration|Participants in the experience group will receive teachers' personal demonstration.
58302103|NCT00920153|BIOLOGICAL|bleomycin sulfate|Given IV
58302104|NCT00920153|DRUG|ABVD regimen|Given IV
58302105|NCT00920153|DRUG|carmustine|Given IV
58412627|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58412628|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
57733036|NCT02254447|DRUG|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
58302106|NCT00920153|DRUG|cisplatin|Given IV
58302107|NCT00920153|DRUG|cytarabine|Given IV
58302108|NCT00920153|DRUG|dacarbazine|Given IV
58302109|NCT00920153|DRUG|dexamethasone|Given orally
58302110|NCT00920153|DRUG|doxorubicin hydrochloride|Given IV
58302111|NCT00920153|DRUG|etoposide|Given IV
58412629|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
58086301|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
58086302|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
58086303|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
58412630|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
58412631|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
58086304|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
57947900|NCT04543071|DRUG|Cemiplimab|350 mg intravenous (IV) once every 21 days
58412632|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
58412633|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
58412634|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
58412635|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
57733037|NCT02254447|DRUG|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
57733038|NCT02254447|DRUG|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
57733039|NCT03024073|PROCEDURE|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
57733040|NCT02848508|DRUG|Metformin|
57733041|NCT04672304|OTHER|Al-Husban University Naser|filling a questionnaire
57733042|NCT02722746|DRUG|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
57733043|NCT02722746|DRUG|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
57733044|NCT03667053|DRUG|dasiglucagon|glucagon analog
57733045|NCT03667053|DRUG|placebo|placebo for dasiglucagon
57733046|NCT03667053|DRUG|GlucaGen HypoKit|native glucagon
57947901|NCT04543071|DRUG|Gemcitabine|1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
57947902|NCT04543071|DRUG|Nab paclitaxel|125 mg/m2 IV on days 1, 8, 14 (every 28 days)
57947903|NCT02363140|OTHER|Will undergo a single MRI assessment with intravenous dye|
57947904|NCT02363140|OTHER|pre and post surgery MRI scan|
58086305|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
58086306|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
58086307|NCT00116545|DRUG|troglitazone|
58086308|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
58086309|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
58086310|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
58086311|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
58086312|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
58412636|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
58412637|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
58412638|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
58412639|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
58412640|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
58412641|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
58412642|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
58412643|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
58086313|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
58412644|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
58412645|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
58412646|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
58412647|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
58412648|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
58412649|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
58412650|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
58412651|NCT05606419|DIETARY_SUPPLEMENT|PEN+usual care|Liquid food replacement intervention and regular diet. Focus on 24 hour diet recalls and FFQ to asses dietary habits.
58412652|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
58412653|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
58086314|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
58086315|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
58086316|NCT00991146|DRUG|canakinumab|canakinumab
58086317|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
58086318|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
58086319|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
58086320|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
58086321|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
58086322|NCT05355506|DEVICE|Application|Knowledge \& record
58302112|NCT00920153|DRUG|gemcitabine hydrochloride|Given IV
58302113|NCT00920153|DRUG|ifosfamide|Given IV
58302114|NCT00920153|DRUG|melphalan|Given IV
58302115|NCT00920153|DRUG|methylprednisolone|Given IV
58086323|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
58302116|NCT00920153|DRUG|mitoguazone|Given IV
58302117|NCT00920153|DRUG|vincristine sulfate|Given IV
58302118|NCT00920153|DRUG|vindesine|Given IV
58302119|NCT00920153|DRUG|vinorelbine tartrate|Given IV
58302120|NCT00920153|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
58302121|NCT00920153|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
57947905|NCT03506711|DIAGNOSTIC_TEST|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
57947906|NCT00507299|BEHAVIORAL|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
57947907|NCT00507299|BEHAVIORAL|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
57947908|NCT03173794|OTHER|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
57947909|NCT00970853|BEHAVIORAL|MOM Program home visiting|Mixed professional home visiting program.
57947910|NCT00970853|OTHER|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
57947911|NCT01170520|DEVICE|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
57947912|NCT01303042|DRUG|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
57947913|NCT02655965|DRUG|Ropivacaine|Ropivacaine 3.5 mg/ml
57947914|NCT02655965|DRUG|Clonidine|Clonidine 5µg/ml
57947915|NCT02655965|DRUG|Sodium Chloride|Sodium Chloride 0.9 %
58086324|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
58086325|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
58086326|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
58086327|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
58302122|NCT02577536|OTHER|No Interventions|No Interventions will be conducted under this study.
58302123|NCT03843372|DEVICE|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
58302124|NCT06479382|DEVICE|ETX-4143 2.0|Treatment of the eye with the ETX-4143 2.0 device
58302125|NCT01224275|OTHER|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
58086328|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
58086329|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
58086330|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
58086331|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
58086332|NCT01495104|DRUG|RO4917838|Multiple doses
58086333|NCT01495104|DRUG|valproate|Multiple doses
58086334|NCT04034875|OTHER|Questionnaire|questionnaire
58086335|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
57947916|NCT02847195|DEVICE|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
57947917|NCT00901771|DEVICE|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
57947918|NCT03230552|OTHER|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
57947919|NCT00814892|BIOLOGICAL|allogeneic tumor cell vaccine|Given intradermally
57947920|NCT00814892|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
57947921|NCT03501667|OTHER|Use of decision support tool|use of a decision support software during clinical assessment of a case
57947922|NCT03501667|OTHER|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
57947923|NCT01392911|DRUG|Rifampicin|High dose rifampicin
57947924|NCT04818736|BIOLOGICAL|COVID-19 Vaccination|Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28
57947925|NCT04818736|OTHER|Usual care|Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
57947926|NCT06094634|BEHAVIORAL|The Brief Alcohol Intervention (BAI): Behavioral|The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.
57947927|NCT04216459|DRUG|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
57947928|NCT04216459|DRUG|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
57947929|NCT02947035|PROCEDURE|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
57947930|NCT02947035|PROCEDURE|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
57947931|NCT00906087|DRUG|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
57947932|NCT02025907|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
57947933|NCT02025907|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
57947934|NCT02025907|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily.
57947935|NCT04694495|DIAGNOSTIC_TEST|16S rRNA gene sequencing of cervical secretions|"1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
57947936|NCT00575198|OTHER|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
57947937|NCT00575198|OTHER|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
57947938|NCT03624699|DEVICE|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
57947939|NCT02424942|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
58086336|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
58086337|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
58086338|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
57947940|NCT02424942|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
57947941|NCT05823675|DRUG|Itolizumab|Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
57947942|NCT05823675|DRUG|Methylprednisolone|Methylprednisolone will be taperred as required
57947943|NCT02244567|DRUG|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
57947944|NCT02244567|PROCEDURE|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
57947945|NCT02244567|OTHER|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
57947946|NCT03172845|PROCEDURE|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
57947947|NCT00350948|DRUG|Telcyta|Day 1 of 28 day Cycle.
57947948|NCT00350948|DRUG|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
57947949|NCT02325284|DEVICE|Pressure Algometer Testing|
57947950|NCT03535259|RADIATION|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
57947951|NCT02953340|DRUG|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
57947952|NCT02953340|DRUG|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
57947953|NCT02953340|DRUG|Docetaxel|75mg/m\^2 IV infusion administered on Day 1 of each cycle
57947954|NCT02953340|DRUG|Cyclophosphamide|600mg/m\^2 IV infusion administered on Day 1 of each cycle
57947955|NCT02422420|BEHAVIORAL|Financial Incentives|Use of financial incentives to promote health behaviors.
57947956|NCT01931657|DRUG|Mifepristone prior to Mirena|
57947957|NCT01931657|DRUG|Placebo prior to Mirena insertion|
57947958|NCT05086731|OTHER|Best Practice|Receive standard of care
57947959|NCT05086731|OTHER|Informational Intervention|Receive reminders
57947960|NCT05086731|OTHER|Medical Device Usage and Evaluation|Receive a SMRxT smart pill bottle
57947961|NCT05086731|OTHER|Quality-of-Life Assessment|Ancillary studies
57947962|NCT05086731|OTHER|Survey Administration|Ancillary studies
57947963|NCT04442945|DRUG|ANAVEX3-71|Active oral dose of ANAVEX3-71
57947964|NCT04442945|DRUG|Placebo|Oral placebo
57947965|NCT00748280|PROCEDURE|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
57947966|NCT00748280|PROCEDURE|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
57947967|NCT00210808|DRUG|topiramate|
57947968|NCT03711656|DEVICE|isCGM (intermittently scanned Continuous Glucose Monitoring)|Data collection
57947969|NCT03711656|DEVICE|Physical exercise tracker|Data collection
57947970|NCT05957991|DRUG|Metformin Hydrochloride tablet|Treatment with metformin
57947971|NCT05957991|DRUG|Placebo|Treatment with placebo
57733047|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
57733048|NCT01910129|DEVICE|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
57733049|NCT04060394|DRUG|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
57733050|NCT02457221|DRUG|Tacrolimus capsules|oral
57733051|NCT02457221|DRUG|Cyclophosphamide injections|intravenous injection
57733052|NCT02457221|DRUG|Prednisone|oral
57733053|NCT01710072|DRUG|aspirin|
57733054|NCT03460223|BIOLOGICAL|MSC|conventional plus MSC or placebo treatment
57733055|NCT05981443|DEVICE|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
57733056|NCT05981443|OTHER|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
57733057|NCT03185975|BEHAVIORAL|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
57733058|NCT03185975|BEHAVIORAL|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
57733059|NCT05568888|DRUG|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
57733060|NCT05568888|DRUG|Placebo|Administered by IV infusion
57733061|NCT03238937|DEVICE|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
57733062|NCT03879720|PROCEDURE|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
57733063|NCT03955393|OTHER|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
57733064|NCT00354523|DRUG|Capecitabine (Xeloda)|Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
58086339|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
57733065|NCT00354523|DRUG|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
57733066|NCT00354523|DRUG|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
57733067|NCT00709280|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
57733068|NCT00709280|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
57733069|NCT00655980|DRUG|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
57733070|NCT00655980|DRUG|Nitrous oxide and placebo|
57733071|NCT00655980|OTHER|standard of care|
57733072|NCT00249951|DRUG|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
57733073|NCT03009526|DRUG|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
57733074|NCT03009526|DRUG|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
57733075|NCT02790853|PROCEDURE|Biopsy|Undergo brush biopsy and incisional biopsy
57733076|NCT02790853|PROCEDURE|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
57733077|NCT02790853|PROCEDURE|High-Resolution Microendoscopy|Undergo HRME imaging
57733078|NCT02790853|DRUG|Proflavine Hemisulfate|Applied on mucosa
57733079|NCT01494402|DRUG|D961S|Oral gelatine capsule
57733080|NCT01494402|DRUG|Esomeprazole|Oral HPMC capsule
57733081|NCT01494402|DRUG|Buffered acetylsalicylic acid|Tablet
57733082|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
57947972|NCT05957991|BEHAVIORAL|Lifestyle intervention|Changing behaviour on diet and excersise
57947973|NCT05957991|BEHAVIORAL|No lifestyle intervention|No changes in behaviou on diet and excersise
57947974|NCT00524407|DRUG|Epoetin alfa|
57947975|NCT01741675|BEHAVIORAL|Questionnaire and monetary incentive|
57947976|NCT01741675|BEHAVIORAL|Questionnaire only|
57947977|NCT05944315|BEHAVIORAL|Education session|Classroom Education session appropriate for elementary school children
57947978|NCT04302194|DIETARY_SUPPLEMENT|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
58086340|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
58086341|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
58086342|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
58086343|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
58086344|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
58086345|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
57733083|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
57733084|NCT01713218|DRUG|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
57733085|NCT01713218|DRUG|Vismodegib|150 mg capsule, oral, once daily
57733086|NCT01713218|PROCEDURE|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
57733087|NCT02832323|BIOLOGICAL|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
57733088|NCT02638662|OTHER|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
57733089|NCT03419169|DEVICE|Light load BFR resistance training|A novel training light load resistance training modality.
57733090|NCT03419169|PROCEDURE|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
57733091|NCT00833989|DRUG|GSK249320|I.V. infusion
57733092|NCT00833989|DRUG|PLACEBO|Placebo
57733093|NCT04571619|BEHAVIORAL|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
58302126|NCT06333730|PROCEDURE|inferior alveolar nerve block|After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.
58302127|NCT06333730|PROCEDURE|mental nerve block|After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
58302128|NCT03728062|BEHAVIORAL|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
58302129|NCT03728062|BEHAVIORAL|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
58302130|NCT02016989|DEVICE|RGTA OTR4120 (CACICOL20)|
57733094|NCT04571619|DRUG|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
58086346|NCT03677973|OTHER|Placebo|Matching Placebo
58086347|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
58086348|NCT01856348|DRUG|Vitamin D|
57733095|NCT03057119|BEHAVIORAL|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
57733096|NCT03057119|BEHAVIORAL|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
58086349|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
58086350|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
57733097|NCT03057119|BEHAVIORAL|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
57733098|NCT03057119|BEHAVIORAL|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
57733099|NCT03057119|BEHAVIORAL|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
58086351|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
58086352|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
58086353|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
58086354|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
58086355|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
58086356|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
58086357|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
57733100|NCT00783744|DRUG|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
57733101|NCT00783744|DRUG|Glimepiride|Glimepiride 3 or 4 mg
58302131|NCT02016989|DEVICE|physiological salt solution|
58302132|NCT04669431|OTHER|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
58302133|NCT04669431|OTHER|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
58302134|NCT03849534|DEVICE|Soft occlusal appliance|According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition
58302135|NCT03849534|BEHAVIORAL|Jaw exercises|The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch
57733102|NCT00783744|DRUG|Metformin|At least 850 mg od
57733103|NCT00783744|DRUG|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
57733104|NCT02417038|DEVICE|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
57947979|NCT04070859|PROCEDURE|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes \& Screws, Tension bands. etc)
57947980|NCT03573427|DEVICE|Trans-atrial septal placement LV lead for CRT|
57947981|NCT00576459|DRUG|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
57947982|NCT00576459|DRUG|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
57947983|NCT00576459|PROCEDURE|standard of care laser photocoagulation|standard of care laser photocoagulation
57947984|NCT06037798|OTHER|cranio-cervical flexion test with NOD|testing the anterior neck muscles during a nodding movement and by using a dynamometer
58302136|NCT03849534|BEHAVIORAL|Counseling|The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
58302137|NCT02059837|PROCEDURE|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
58302138|NCT04356937|DRUG|Tocilizumab|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
58302139|NCT04356937|DRUG|Placebos|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
57947985|NCT06407167|DIAGNOSTIC_TEST|DN4 (Douleur Neuropathique 4 Questions) questionnaire|DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination
57947986|NCT00176605|DRUG|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
57947987|NCT00176605|DRUG|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
57733105|NCT02486926|OTHER|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
58086358|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
57947988|NCT04412850|DRUG|Magnesium Sulfate|"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge."
58086359|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
58086360|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
58086361|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
58086362|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
58086363|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
58086364|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
58086365|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
58086366|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
58086367|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
58086368|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
58086369|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
58302140|NCT03538080|DEVICE|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
58302141|NCT03538080|DEVICE|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
58302142|NCT00652444|DRUG|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
58302143|NCT00652444|DRUG|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
57733106|NCT02486926|DRUG|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
57947989|NCT00244387|DRUG|SPM 962|
57947990|NCT06266728|DEVICE|Total30 for Astigmatism Contact Lenses|Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
57947991|NCT00960336|DRUG|pegylated liposomal doxorubicin hydrochloride|
57947992|NCT04848558|DRUG|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
57947993|NCT04848558|OTHER|Placebo|Participants will receive IV infusion or SC injection of placebo.
57947994|NCT02749773|DEVICE|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
57947995|NCT01290874|DRUG|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
57947996|NCT01290874|DRUG|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
58086370|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
58086371|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
58086372|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
58086373|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
58086374|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
57733107|NCT02486926|DRUG|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
58086375|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
58086376|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
58086377|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
58086378|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
57733108|NCT02486926|DRUG|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
58086379|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
57947997|NCT01290874|DRUG|Formoterol|Formoterol 12 mcg twice daily for one year
58086380|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
58086381|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
58302144|NCT00652444|DRUG|Placebo (Unspecified)|Matching ezetimibe placebo
57947998|NCT00520884|DRUG|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
58302145|NCT00659087|PROCEDURE|Femoral Block|Those receiving femoral block postoperatively
57947999|NCT00520884|DRUG|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
58302146|NCT00659087|OTHER|Usual Care|Those receiving only usual pain management postoperatively
58302147|NCT02419599|OTHER|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
57733109|NCT02486926|DRUG|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
57733110|NCT05603273|BEHAVIORAL|non-weight bearing exercise|exercise on a non-weight bearing device at 50% of peak capacity, 3 days per week for 6 weeks
57948000|NCT00520884|OTHER|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
57948001|NCT00520884|OTHER|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
57948002|NCT02458963|PROCEDURE|IVF|Women will undergo one IVF cycle
57948003|NCT02458963|DRUG|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
58086382|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
58086383|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
58086384|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
58086385|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
58086386|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
58086387|NCT05549986|OTHER|Observational|Observational
58086388|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
58086389|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
58302148|NCT02419599|OTHER|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
58302149|NCT04343352|OTHER|implementation of mobile epilepsy training program|"Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied."
58302150|NCT03880747|PROCEDURE|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
58302151|NCT03669588|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
58302152|NCT03669588|BIOLOGICAL|Placebo|Intravenous administration of placebo
58412654|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
57733111|NCT04679467|DIETARY_SUPPLEMENT|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
58086390|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
58086391|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
58086392|NCT00023426|DRUG|rifapentine|
58086393|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
58086394|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
58086395|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
58086396|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
58086397|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
58086398|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
58086399|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
58302153|NCT00908765|BEHAVIORAL|Exercise|"1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
58302154|NCT02785393|DRUG|Sugar Pill|The administration of a sugar pill
58302155|NCT02785393|DRUG|Doxazosin|The administration of the Doxazosin medication
58302156|NCT06433128|DRUG|Fosmanogepix solution for infusion|Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
58302157|NCT06433128|DRUG|Fosmanogepix 400 mg tablets|Fosmanogepix 400 mg tablets for oral administration
58302158|NCT01325350|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
58302159|NCT01325350|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
58302160|NCT01325350|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
58302161|NCT01325350|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
57733112|NCT01090804|DEVICE|BreatheMAX breathing device|secretion clearance, breathing exercise
58086400|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
58302162|NCT01325350|DRUG|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
58302163|NCT03456466|DRUG|TQB2303|375mg/m2 ，iv
58086401|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
58086402|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
58086403|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
58086404|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
58086405|NCT00798161|DRUG|matching placebo|matching placebo
58086406|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
58086407|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
58086408|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
58302164|NCT03456466|DRUG|Rituximab|375mg/m2 ，iv
58302165|NCT03601169|DIETARY_SUPPLEMENT|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
58302166|NCT03601169|DIETARY_SUPPLEMENT|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
58412655|NCT00001065|DRUG|Amphotericin B|
58412656|NCT02488291|DRUG|0.25 sufentanil|with different dosage
58412657|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
58412658|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
58412659|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
58412660|NCT05128162|BEHAVIORAL|Psychotherapy|1. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
58302167|NCT03601169|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
58412661|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
58412662|NCT00413920|DRUG|Prednisone|Oral tablets
58412663|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
58412664|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
58412665|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
58412666|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
58412667|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
58412668|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
58412669|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
58302168|NCT02104661|DRUG|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
58302169|NCT02104661|DRUG|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
58302170|NCT03918811|PROCEDURE|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
58302171|NCT03918811|PROCEDURE|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
58302172|NCT02324751|BIOLOGICAL|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
58302173|NCT02324751|BIOLOGICAL|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
58302174|NCT02324751|BIOLOGICAL|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
58302175|NCT02145455|DEVICE|Unity Total Knee Replacement System|
58302176|NCT02145455|DEVICE|Unity Total Knee Replacement System|
58302177|NCT00545025|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
58412670|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
58412671|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
58412672|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
58412673|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
58412674|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
57733113|NCT02529319|PROCEDURE|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
57733114|NCT02529319|PROCEDURE|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
58302178|NCT00545025|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
58302179|NCT06461169|OTHER|stress ball|Patients squeeze the stress ball
58302180|NCT02312960|OTHER|Data Collection|No study treatment will be provided in this long term follow up study.
58302181|NCT05222880|DEVICE|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
58302182|NCT05810701|OTHER|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
58302183|NCT01684176|BEHAVIORAL|Complex tailored intervention|
58302184|NCT01684176|BEHAVIORAL|Usual care|
57733115|NCT03248739|DEVICE|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
57733116|NCT03248739|DEVICE|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
57733117|NCT06188364|OTHER|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
57733118|NCT06188364|OTHER|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
57733119|NCT02951104|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM) system|
58086409|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
58086410|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
58086411|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
58086412|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
58086413|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
58086414|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
58086415|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
58086416|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
58302185|NCT01274533|DRUG|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
58302186|NCT06339190|DIAGNOSTIC_TEST|Venepuncture|A single blood draw at the time of presentation to clinic or whilst an inpatient.
57733120|NCT02365051|BEHAVIORAL|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
57733121|NCT02494284|DRUG|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
57733122|NCT02494284|DRUG|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
57733123|NCT00851214|DEVICE|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
57733124|NCT01951430|DRUG|Antibiotic and antifungal drugs|
57733125|NCT05268666|DRUG|JBI-802|LSD1/HDAC6 inhibitor
57733126|NCT04070573|DRUG|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
57733127|NCT03297840|BEHAVIORAL|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
57733128|NCT05190393|PROCEDURE|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
57733129|NCT05190393|PROCEDURE|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
57733130|NCT00413504|DRUG|Fondaparinux|
57733131|NCT01278277|DIETARY_SUPPLEMENT|Saffron supplementation|Saffron supplementation 20 mg
57733132|NCT01278277|OTHER|placebo|placebo supplementation
58086417|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
58086418|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
58302187|NCT05446961|DIETARY_SUPPLEMENT|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
58302188|NCT05446961|DRUG|Placebo|orally capsules
58302189|NCT02164292|PROCEDURE|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
58302190|NCT03352076|DRUG|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
58302191|NCT03352076|DRUG|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
58302192|NCT06233786|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
58302193|NCT05412004|DRUG|Tirzepatide|Administered SC
58302194|NCT05412004|DRUG|Placebo|Administered SC
58086419|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
58086420|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
58086421|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
58302195|NCT06204562|BEHAVIORAL|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
58302196|NCT06006156|PROCEDURE|Dental implants placement|surgery for placement of two one-piece trans gingival implants
57733133|NCT05302466|DEVICE|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
57733134|NCT05302466|OTHER|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
57948004|NCT02234284|BEHAVIORAL|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
57948005|NCT04964427|DRUG|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
57948006|NCT04964427|DEVICE|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
57948007|NCT04964427|DEVICE|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
57948008|NCT00912002|DRUG|MK-0941|A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
57948009|NCT00400881|OTHER|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
57948010|NCT03278184|DEVICE|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
58302197|NCT03546673|BEHAVIORAL|Self-Regulation Condition|
58302198|NCT03546673|BEHAVIORAL|Emotional Disclosure Condition|
58302199|NCT05892237|PROCEDURE|bronchial artery interventional therapy|After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
58302200|NCT05892237|DRUG|Chemotherapy drug|Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
58302201|NCT05892237|RADIATION|IMRT|60Gy/2Gy/30f
58302202|NCT05892237|DRUG|Immunotherapy|PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
58302203|NCT02472730|DEVICE|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
58302204|NCT01666483|PROCEDURE|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
58412675|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
58412676|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
58412677|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
58412678|NCT03535662|DRUG|Orvepitant|Single oral dose
58412679|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
58412680|NCT02737644|OTHER|observation|This is an observational study
58412681|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
58412682|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
58412683|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
58412684|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
58412685|NCT01684644|BEHAVIORAL|Treatment as usual|
57733135|NCT03958344|DRUG|Prednisolone|Oral Tablet
57733136|NCT03958344|DRUG|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
58086422|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
58086423|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
58086424|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
58412686|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
57733137|NCT02086357|PROCEDURE|SWUE|
58412687|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
58412688|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
58412689|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
58412690|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
58412691|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
58412692|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
58412693|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
58412694|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
58412695|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
58412696|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
58412697|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
58412698|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
57948011|NCT03278184|DEVICE|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
57733138|NCT06479629|DRUG|Piracetam|800mg oral tablet of Piracetam three times every day for 3 months
57733139|NCT06479629|DRUG|Placebo|starch tablet
57948012|NCT03278184|DEVICE|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
57948013|NCT01781715|DEVICE|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
57948014|NCT00385957|DRUG|AZT+3TC+IDV+RTV|
57948015|NCT00385957|DRUG|AZT+3TC+EFV|
57733140|NCT06059196|BEHAVIORAL|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
57733141|NCT06059196|BEHAVIORAL|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
57733142|NCT06389604|OTHER|Heat acclimation|Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
57948016|NCT04320732|BEHAVIORAL|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
58302205|NCT01666483|PROCEDURE|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
58302206|NCT02204943|DEVICE|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
58302207|NCT02204943|DRUG|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
58302208|NCT03098680|DRUG|Albuterol Sulfate|see arm/group descriptions
58302209|NCT03098680|DRUG|Nicardipine Hydrochloride|see arm/group descriptions
58302210|NCT03098680|DRUG|Dobutamine Hydrochloride|see arm/group descriptions
58302211|NCT03098680|DRUG|Phenylephrine Hydrochloride|see arm/group descriptions
58302212|NCT03098680|DRUG|Verapamil Hydrochloride|see arm/group descriptions
58302213|NCT03098680|DRUG|Phentolamine Mesylate|see arm/group descriptions
58302214|NCT03098680|DRUG|Placebo|see arm/group descriptions
58302215|NCT00617357|DEVICE|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
58302216|NCT06154304|DRUG|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
58412699|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
57948017|NCT01794611|DEVICE|laryngoscopy|
58086425|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
58302217|NCT06154304|DRUG|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
58302218|NCT06154304|DRUG|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
58302219|NCT06154304|DRUG|Placebo|Placebo
58302220|NCT00435617|DEVICE|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
58412700|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
58302221|NCT02729337|BEHAVIORAL|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
58302222|NCT03048045|PROCEDURE|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD \>/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
58302223|NCT02184104|DIETARY_SUPPLEMENT|Caffeine|
58302224|NCT01545388|DRUG|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
58302225|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
58302226|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
58302227|NCT01545388|DRUG|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
58412701|NCT02049190|DRUG|onapristone|
58412702|NCT02049190|DRUG|abiraterone|
58412703|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
58412704|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
58086426|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
58086427|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
58086428|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
58086429|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
58412705|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
58412706|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
58412707|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
57948018|NCT03462576|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
58086430|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
58086431|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
58086432|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
58302228|NCT05660629|OTHER|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
58302229|NCT03918057|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
58302230|NCT03918057|OTHER|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
58412708|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
57948019|NCT03462576|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
57948020|NCT03462576|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
57948021|NCT00950768|PROCEDURE|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
58086433|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
58086434|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
58302231|NCT02429050|DRUG|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
58086435|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
58086436|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
58086437|NCT06522360|DRUG|Brigatinib|Given by mouth
58086438|NCT06522360|DRUG|Carboplatin|Given by mouth
58086439|NCT06522360|DRUG|Pemetrexed|Given by vein
58086440|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
58086441|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
58086442|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
58086443|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
58086444|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
58086445|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
58086446|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
58086447|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
58086448|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
58302232|NCT02429050|DRUG|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
58302233|NCT03497871|DEVICE|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
58302234|NCT04383301|PROCEDURE|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
58302235|NCT04383301|PROCEDURE|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
58086449|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
58086450|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
58086451|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
58086452|NCT00514501|DRUG|Iodofiltic acid I 123|
58086453|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
58086454|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
58086455|NCT01687777|BIOLOGICAL|OrthADAPT|
58086456|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
58086457|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
58086458|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
58086459|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
58086460|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
58086461|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
58086462|NCT00259311|DRUG|LY2422347|
58086463|NCT00259311|DRUG|placebo|
58086464|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
58086465|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
58086466|NCT02614352|DRUG|Atorvastatin + Candesartan|
58086467|NCT02614352|DRUG|AG1502|
58086468|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
58412709|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
58302236|NCT04827277|PROCEDURE|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
58302237|NCT04827277|PROCEDURE|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
58412710|NCT01053013|BIOLOGICAL|RENCA macrobeads|
58412711|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
58412712|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
58412713|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
58412714|NCT01084278|DRUG|Colchicine|Colchicine tablets
58412715|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
58412716|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
58412717|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
58412718|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
57733143|NCT06529679|BEHAVIORAL|Split-belt Training|Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.
58302238|NCT01278342|DRUG|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
58302239|NCT01278342|DRUG|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
57733144|NCT06529679|BEHAVIORAL|Tied-Belt Training|Walking on a split-belt treadmill in which the speed of both belts is the same.
58412719|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
58412720|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
58412721|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
57733145|NCT05711524|BIOLOGICAL|Traditional Cryoprecipitate|This is the cryoprecipitate already currently being given to patients with a cryo order.
57733146|NCT05711524|BIOLOGICAL|Pathogen-Reduced Cryoprecipitate|This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
57733147|NCT05307055|DEVICE|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
57733148|NCT05307055|DEVICE|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
57733149|NCT01906294|DRUG|antidiabetic treatment (ATC A10B)|
57733150|NCT01063257|DRUG|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
58086469|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
58086470|NCT04045405|DRUG|CDR132L|i.v. administration
58412722|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
58412723|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
58412724|NCT00140699|BEHAVIORAL|Balance|
58412725|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
58412726|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
58412727|NCT02124512|OTHER|Placebo|80 mg placebo once daily
58412728|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
58412729|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
58412730|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
58412731|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
57733151|NCT03806829|OTHER|Water|250 ml
57733152|NCT03806829|OTHER|Red Wine|250 ml
57733153|NCT03806829|OTHER|Green Tea|250 ml
57733154|NCT03806829|OTHER|Orange Juice|250 ml
57733155|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
57733156|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
57733157|NCT06529588|RADIATION|Radiation|HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
57733158|NCT00605241|DRUG|GSK598809|Drug
57733159|NCT06636045|OTHER|Not applicable- observational study|No intervention. Observational study.
57733160|NCT06502171|DRUG|Cabozantinib Oral Tablet|"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."
57733161|NCT06502171|DRUG|Selumetinib Oral Capsule|"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."
57733162|NCT01517451|RADIATION|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
57733163|NCT01517451|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
57948022|NCT04123782|DEVICE|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
58302240|NCT01278342|DRUG|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
58302241|NCT04869592|BIOLOGICAL|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
58302242|NCT04869592|BIOLOGICAL|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
58302243|NCT04869592|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
58302244|NCT05203640|BEHAVIORAL|High repetition (HI)|Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum
58302245|NCT05203640|BEHAVIORAL|Moderate repetition (MOD)|Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
58412732|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
58412733|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
57733164|NCT03347500|OTHER|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
57733165|NCT02233829|DRUG|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
57733166|NCT02233829|RADIATION|Brain Dopamine Receptor|The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
57733167|NCT01204151|BEHAVIORAL|discrete-trial training|
57733168|NCT00153764|DRUG|Cooper Complete One-A-Day Vitamin Supplement|
57733169|NCT06218667|DRUG|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
57733170|NCT06218667|DRUG|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
57733171|NCT06218667|PROCEDURE|Radical Prostatectomy|Standard treatment
57948023|NCT04123782|DEVICE|Placebo F-ESW Treatment|Very low concentration of F-ESW.
57948024|NCT05358756|DRUG|SACT-1|Single administartion of 150mg SACT-1
58412734|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
58412735|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
58412736|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
58302246|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
58412737|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
58412738|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
58412739|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
58412740|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
58412741|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
58412742|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
57733172|NCT03910257|BEHAVIORAL|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
57733173|NCT03722251|BEHAVIORAL|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
57733174|NCT01351285|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
57733175|NCT06104215|BIOLOGICAL|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
57733176|NCT02038673|DRUG|ASP5878|oral
57948025|NCT05358756|DRUG|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
58086471|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
58086472|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
58086473|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
58086474|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
58412743|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
57733177|NCT03216876|DRUG|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
57733178|NCT04233099|PROCEDURE|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
58086475|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
58086476|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
58086477|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
57733179|NCT03689322|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
57733180|NCT03689322|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
57733181|NCT03689322|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
57733182|NCT00360529|DRUG|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
58302247|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
58302248|NCT03928054|OTHER|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
58302249|NCT01270035|DRUG|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
58302250|NCT05869370|OTHER|High intensity resistance training|Twelve weeks of resistance training twice a week.
58302251|NCT05869370|OTHER|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
58412744|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58412745|NCT01011933|DRUG|Selumetinib|Given PO
58412746|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
58412747|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
58412748|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
57948026|NCT04030923|DEVICE|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
57948027|NCT02860364|PROCEDURE|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
57948028|NCT05352204|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
57948029|NCT02103998|DRUG|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
57948030|NCT02103998|DRUG|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
57948031|NCT04639856|PROCEDURE|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
57948032|NCT01439282|DRUG|eribulin mesylate|Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
57948033|NCT01439282|DRUG|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
57948034|NCT05156970|DRUG|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
57948035|NCT05156970|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
57948036|NCT05156970|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
57948037|NCT05156970|DRUG|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
57948038|NCT05156970|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
57948039|NCT01386359|DRUG|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
57948040|NCT00527475|DRUG|ranibizumab|0.5 mg. given as an intraocular injection
57948041|NCT00527475|DRUG|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
57948042|NCT00199550|PROCEDURE|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
57948043|NCT00199550|PROCEDURE|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
57948044|NCT02826642|DRUG|IDH305|
57948045|NCT00143715|DRUG|Phytonadione (Vitamin K1)|1.25 mg given orally
57948046|NCT05551715|DEVICE|Software development for individualized refractive surgery|Software development for individualized refractive surgery
57948047|NCT06054191|DRUG|Dabrafenib + Trametinib|Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
58086478|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
58086479|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
58302252|NCT06021327|PROCEDURE|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
58302253|NCT06021327|PROCEDURE|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
58302254|NCT03044314|DRUG|Iloprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
58302255|NCT01851941|DRUG|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
58086480|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
58086481|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
58086482|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
58086483|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
58086484|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
58086485|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
58086486|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
58086487|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
58086488|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
58086489|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
58412749|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
58412750|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
58412751|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
58412752|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
58412753|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
57948048|NCT06054191|DRUG|Capmatinib|Capmatinib 400mg BID/（2 cycles）
57948049|NCT04216277|DIAGNOSTIC_TEST|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
57948050|NCT05023356|DEVICE|Non-contact vital signs monitoring with camera|Monitor patients face image by non-contact vital signs monitoring with camera
57948051|NCT02538874|DRUG|BMS-986171|
58086490|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
57733183|NCT04992260|BIOLOGICAL|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
58086491|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
58086492|NCT00301925|BIOLOGICAL|pegfilgrastim|
58086493|NCT00301925|DRUG|capecitabine|
58086494|NCT00301925|DRUG|cyclophosphamide|
58086495|NCT00301925|DRUG|epirubicin hydrochloride|
58086496|NCT00301925|DRUG|fluorouracil|
58086497|NCT00301925|DRUG|methotrexate|
58086498|NCT00301925|PROCEDURE|adjuvant therapy|
58302256|NCT04322032|DRUG|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
58302257|NCT04322032|DRUG|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
57733184|NCT04992260|BIOLOGICAL|Controlled vaccine|The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
57733185|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
57948052|NCT02538874|OTHER|Placebo|
57948053|NCT02268279|DRUG|solithromycin|
58086499|NCT01371981|DRUG|Asparaginase|Given IM
58086500|NCT01371981|DRUG|Bortezomib|Given IV
58086501|NCT01371981|DRUG|Cytarabine|Given IT or IV
58086502|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
58086503|NCT01371981|DRUG|Etoposide|Given IV
58086504|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
58086505|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
58086506|NCT01371981|OTHER|Pharmacological Study|Correlative studies
58302258|NCT01251952|DRUG|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
58302259|NCT05266469|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
58302260|NCT05266469|OTHER|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
58302261|NCT01876524|DEVICE|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
58302262|NCT01585883|BEHAVIORAL|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
58302263|NCT01518803|DIETARY_SUPPLEMENT|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
58086507|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
58302264|NCT01518803|DIETARY_SUPPLEMENT|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
58412754|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
57733186|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
57733187|NCT00821418|DEVICE|PulseHaler treatment|treatment is for two weeks, 3 times per day
57733188|NCT00821418|DEVICE|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
57948054|NCT04863846|OTHER|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
58086508|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
58086509|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
58302265|NCT00126919|DEVICE|SonoPrep|
58302266|NCT04319393|BEHAVIORAL|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
58302267|NCT02889224|OTHER|Obese|
57948055|NCT04276428|DRUG|LY3209590|Administered SC.
57948056|NCT04276428|DRUG|Insulin Degludec|Administered SC.
57948057|NCT02861209|OTHER|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
57948058|NCT01030770|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
57948059|NCT01030770|DRUG|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
57948060|NCT01511276|BEHAVIORAL|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
57948061|NCT01511276|BEHAVIORAL|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
57948062|NCT06324006|DRUG|LIB-01|LIB-01 oral suspension
57948063|NCT06324006|OTHER|Placebo|Placebo oral suspension
57948064|NCT03119714|DRUG|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
57948065|NCT03119714|DRUG|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
57948066|NCT02989415|OTHER|Mechanical Ventilation|Mechanical ventilation during robotic surgery
58086510|NCT06067191|DRUG|RV299|Oral Suspension
58086511|NCT06067191|DRUG|Placebo|matching placebo
58086512|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
58086513|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
58302268|NCT02889224|PROCEDURE|Hypercortisolism|
58302269|NCT02889224|OTHER|Hydrocortisone|
58086514|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
58086515|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
58086516|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
58086517|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
58086518|NCT00026312|DRUG|Isotretinoin|Given PO
58086519|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
58086520|NCT00026312|OTHER|Pharmacological Study|Correlative studies
58086521|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
58086522|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
58086523|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
58302270|NCT02889224|OTHER|Control|
58302271|NCT02072642|DEVICE|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
58302272|NCT02072642|DEVICE|Placebo light therapy|4 weeks with Placebo light therapy
58302273|NCT05633433|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
58412755|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
58412756|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
58412757|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
58412758|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
58412759|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
57733189|NCT01258114|OTHER|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
57733190|NCT01258114|OTHER|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
57948067|NCT05270590|PROCEDURE|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
58086524|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
58086525|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
58086526|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
58302274|NCT05633433|DRUG|Placebo|Placebo
58302275|NCT05720637|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
58302276|NCT05720637|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
58302277|NCT05720637|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
58302278|NCT03490955|OTHER|salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning
58302279|NCT03490955|OTHER|salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
58412760|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
58412761|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
58412762|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
58412763|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
58412764|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
58086527|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
58086528|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
58086529|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
58302280|NCT03490955|OTHER|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
58302281|NCT03490955|OTHER|salad|Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning
58302282|NCT03490955|OTHER|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning
58412765|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
58412766|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
58086530|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
58086531|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
58086532|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
58086533|NCT03363724|OTHER|HaGuide version 1.0 software module|
58086534|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
58086535|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
58086536|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
58086537|NCT02018601|PROCEDURE|BRILMA|
58086538|NCT02018601|PROCEDURE|paravertebral block|
58086539|NCT02018601|DRUG|dexketoprofen|
58086540|NCT02018601|DRUG|paracetamol|
58302283|NCT03490955|OTHER|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning
58302284|NCT03490955|OTHER|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning
58302285|NCT03490955|OTHER|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
58302286|NCT00130507|DRUG|Vinorelbine|
58412767|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
58412768|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
58412769|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
58412770|NCT00145691|DRUG|Oxcarbazepine|
58412771|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
58412772|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
58086541|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
58086542|NCT04038307|DRUG|paracetamol|1gm
58086543|NCT04038307|DRUG|Saline Solution|100ml
58086544|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
58086545|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
58086546|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
58086547|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
58086548|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
58086549|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
58302287|NCT00130507|DRUG|Capecitabine|
58302288|NCT00130507|DRUG|Trastuzumab|
58302289|NCT01711697|RADIATION|stereotactic body radiation therapy|Undergo SBRT
58302290|NCT01711697|DRUG|carboplatin|
58302291|NCT01711697|DRUG|paclitaxel|
58302292|NCT01711697|RADIATION|radiation therapy|Undergo radiation therapy
58302293|NCT05253014|PROCEDURE|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
58302294|NCT05253014|DRUG|paracetamol|intravenous paracetamol every 8 hours
58412773|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
58412774|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
58412775|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
58412776|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
58412777|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
58412778|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
58086550|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
58086551|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
58086552|NCT02159651|DRUG|tacrolimus|oral
58086553|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
58086554|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
58302295|NCT05336266|DRUG|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
58302296|NCT02563899|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
58302297|NCT02563899|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
58302298|NCT04069715|DIETARY_SUPPLEMENT|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
58302299|NCT04069715|OTHER|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
58302300|NCT06286917|OTHER|NIV initiation in patients with ALS|NIV initiation according to standard care
58302301|NCT01483638|DRUG|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
58302302|NCT01483638|DRUG|placebo|will be administered orally with the same schedule of axitinib
58302303|NCT02704312|RADIATION|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
58412779|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
58412780|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
57733191|NCT02740127|PROCEDURE|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
57733192|NCT02740127|DRUG|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
57733193|NCT02740127|DRUG|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
57733194|NCT02740127|DRUG|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
57733195|NCT02740127|DRUG|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
57733196|NCT02740127|DRUG|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
57733197|NCT02740127|BEHAVIORAL|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
57733198|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
57733199|NCT04295733|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
57733200|NCT02412930|PROCEDURE|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
57733201|NCT02412930|DRUG|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
58302304|NCT00488423|PROCEDURE|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
58302305|NCT04481139|DRUG|SHR0302|SHR0302, oral, once daily
58302306|NCT04481139|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
57948068|NCT03147716|OTHER|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
58302307|NCT05938218|DEVICE|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
58302308|NCT03299101|OTHER|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
57733202|NCT02412930|DRUG|Bupivacaine|
57733203|NCT02412930|DEVICE|Ultrasound|
57733204|NCT05618353|DRUG|Colchicine|0.6 mg tablets
57733205|NCT05618353|DRUG|Placebo|Matching placebo
57733206|NCT04829344|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
57733207|NCT04829344|DRUG|Placebo|Placebo Topical Ophthalmic Solution
57733208|NCT02277782|DRUG|Hydromorphone|
57733209|NCT02277782|DRUG|Hyperbaric bupivacaine|
57733210|NCT02277782|DRUG|Fentanyl|
57733211|NCT03550313|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
57733212|NCT03550313|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
57733213|NCT02020954|PROCEDURE|ECG, echocardiography, cardiac MRI, sera biomarkers|
57733214|NCT04226924|DRUG|Trehalose|90 mg/ml trehalose solution for IV infusion
57948069|NCT03147716|OTHER|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
58086555|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
58086556|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
58086557|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
58086558|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
58086559|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
58086560|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
58086561|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
58086562|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
58086563|NCT04800159|DRUG|Placebo|Vaporization of placebo
58086564|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
58086565|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
58086566|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
58086567|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
58086568|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
58086569|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
58086570|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
58086571|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
58086572|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
58086573|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
58086574|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
58086575|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
58086576|NCT01920698|OTHER|control|
58086577|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
58086578|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
57733215|NCT03272633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
58302309|NCT01834547|DRUG|Drugs use: methylphenidate|40 mg tablets
58302310|NCT01834547|DRUG|Drug use: modafinil|40 mg tablets
58302311|NCT01834547|DRUG|caffeine|400 mg
58302312|NCT01834547|DRUG|placebo|placebo
57733216|NCT03272633|BIOLOGICAL|Irradiated Allogeneic Cells|Correlative studies
57733217|NCT05677334|DRUG|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
57733218|NCT05677334|DEVICE|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
57733219|NCT04183322|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
57733220|NCT00004129|RADIATION|brachytherapy|
57733221|NCT00004129|RADIATION|phosphorus P32|
58086579|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
58086580|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
58086581|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
57948070|NCT03147716|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
58086582|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
58086583|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
58086584|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
58086585|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
58086586|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
58086587|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
58086588|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
58086589|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
58086590|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
58086591|NCT03562923|DRUG|Placebo|Placebo Product
58086592|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
58086593|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
58086594|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
58086595|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
58086596|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
58086597|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
58086598|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
58086599|NCT01439776|DRUG|Vit D|800IU/day
58086600|NCT00032825|DRUG|Ketaconazole|
58086601|NCT00032825|DRUG|Docetaxel|
58086602|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
57948071|NCT03147716|OTHER|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
58086603|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
58086604|NCT05303844|DRUG|H101|H101 intratumorally injection starts at day 0.
58086605|NCT05303844|DRUG|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
58086606|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
58086607|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
58302313|NCT06555445|OTHER|BREATHING EXERCISE|Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
58302314|NCT06555445|OTHER|BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE|The resistance on the BREATHER device will be adjusted to match each participant's abilities and progression. The resistance level will be challenging yet manageable, ensuring participant comfort. Each daily session will consist of 15-30 minutes with the BREATHER device and can be split into two shorter sessions if necessary. The total duration of this treatment protocol will span 2 months. The BREATHER device will be employed for both inspiratory and expiratory muscle training. Alongside the device usage, specific breathing exercises, such as diaphragmatic and pursed lip breathing, will be performed
58412781|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
58412782|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
58412783|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
58086608|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
58086609|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
58086610|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
58086611|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
58086612|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
58302315|NCT01616043|PROCEDURE|Glyaderm|acellular dermis
58412784|NCT00005574|DRUG|Gentamicin|
58412785|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
58412786|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
58412787|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
58412788|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
58086613|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
58086614|NCT00608075|DRUG|Lithium|600 - 1800 mg
58086615|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
58086616|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
58086617|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
58086618|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
58086619|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
58086620|NCT04782258|DRUG|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
58412789|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
58412790|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
58412791|NCT00042068|DRUG|Meloxicam|
58412792|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
58412793|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
58086621|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
58086622|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
58086623|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
58086624|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
58086625|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
58086626|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
58086627|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
58086628|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
58086629|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
58086630|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
57948072|NCT02693561|BEHAVIORAL|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
58086631|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
58086632|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
58086633|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
58086634|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
58086635|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
58086636|NCT06650605|DRUG|123I-ATT001|123I-ATT001
58086637|NCT00985127|DRUG|placebo|administered daily for 21 days
57948073|NCT02693561|BEHAVIORAL|Self-Help Book|Reading the self-help book.
57948074|NCT01234974|DRUG|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
57948075|NCT01234974|DRUG|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
57948076|NCT00002375|DRUG|Indinavir sulfate|
57948077|NCT00002375|DRUG|Nelfinavir mesylate|
58086638|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
58086639|NCT00127296|DEVICE|FlexPen®|
58086640|NCT00127296|DEVICE|vial and syringe|
58086641|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
58086642|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
58086643|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
58302316|NCT01616043|PROCEDURE|STSG|autologous split skin only
57948078|NCT02084303|OTHER|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
57948079|NCT02690870|DRUG|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
57948080|NCT02690870|DRUG|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
58086644|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
58412794|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
57733222|NCT05320822|OTHER|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
58412795|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
57733223|NCT05320822|OTHER|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
57733224|NCT01436903|DEVICE|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
57733225|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
58412796|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
57733226|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
57948081|NCT02226107|BEHAVIORAL|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
57948082|NCT02226107|BEHAVIORAL|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
57948083|NCT02613936|DEVICE|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
57948084|NCT02613936|BEHAVIORAL|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
57948085|NCT01443520|DRUG|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
57948086|NCT01443520|DRUG|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
57948087|NCT01443520|DRUG|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
57948088|NCT06039124|OTHER|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
58086645|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
58086646|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
58302317|NCT02696395|DEVICE|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
58302318|NCT02696395|DEVICE|DePuy Corail® femoral stem + Deltamotion® acetabular component|
58302319|NCT02236000|DRUG|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
58302320|NCT02236000|DRUG|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
58302321|NCT04887649|DRUG|Morphine|morphine 3 mg
58302322|NCT04887649|DRUG|saline solution|4 cc of saline solution in epidural cateter in postpartum
57948089|NCT03362970|DEVICE|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
58086647|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
58086648|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
57733227|NCT03230916|DRUG|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
57948090|NCT03362970|OTHER|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
57948091|NCT02409589|DEVICE|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
57948092|NCT02409589|PROCEDURE|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
57948093|NCT01514487|DRUG|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
57948094|NCT03371615|OTHER|Anti-regurgitation infant formula|Anti regurgitation infant formula
57948095|NCT02808754|PROCEDURE|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic \> 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
57948096|NCT02104986|DRUG|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
57948097|NCT02104986|DRUG|Vepeside-ifosfamide-Cisplatin|
57948098|NCT02998775|DRUG|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
57948099|NCT01631136|DRUG|Cisplatin|75 mg/m²
57948100|NCT01631136|DRUG|Pemetrexed|500 mg/m²
57948101|NCT01631136|DRUG|Cisplatin|80 mg/m²
57948102|NCT01631136|DRUG|Gemcitabine|1250 mg/m²
57948103|NCT04071574|DRUG|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
57948104|NCT04071574|DRUG|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
57948105|NCT04071574|DRUG|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
57948106|NCT04071574|DRUG|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
57948107|NCT02742428|DEVICE|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
57948108|NCT02742428|PROCEDURE|Acute paracentesis.|Evacuation of a large (\>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
58086649|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
58086650|NCT00530621|DRUG|placebo|oral, daily
58086651|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
58086652|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
58412797|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
58412798|NCT01165320|DRUG|Caspofungin|
58412799|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
58412800|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
58412801|NCT04224272|DRUG|Palbociclib|Administered orally
58412802|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
57733228|NCT03456908|COMBINATION_PRODUCT|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
57733229|NCT05435612|DEVICE|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
57733230|NCT01600157|PROCEDURE|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
57948109|NCT02742428|BEHAVIORAL|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
57948110|NCT02742428|BEHAVIORAL|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
58086653|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
58086654|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
58086655|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
58086656|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
58086657|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
58086658|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
58086659|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
58086660|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
58086661|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
58086662|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
58086663|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
58086664|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
58412803|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
58412804|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
58412805|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
58412806|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
58412807|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
58412808|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
58412809|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
58412810|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
57948111|NCT02742428|BEHAVIORAL|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
57948112|NCT02902250|PROCEDURE|Decompression|vertebral body decompression in compression fracture
57948113|NCT02902250|PROCEDURE|Conservative Treatment|Conservative Treatment in vertebral compression fracture
57948114|NCT01432249|DRUG|Enbrel group|will be decided by treating physicians
57733231|NCT05904847|BEHAVIORAL|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
57733232|NCT00604981|BEHAVIORAL|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
57733233|NCT00604981|BEHAVIORAL|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
57733234|NCT01781572|DRUG|LEE011|LEE011 will be administered orally once daily
57733235|NCT01781572|DRUG|MEK162|MEK162 will be administered orally twice daily
58086665|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
57948115|NCT05354583|DRUG|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
58302323|NCT04887649|DRUG|Morphine|morphine 2 mg for epidural cateter in postpartum
58302324|NCT03469115|DIAGNOSTIC_TEST|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
57948116|NCT00376870|DRUG|Pioglitazone|pioglitazone 30 mg/d
57948117|NCT00376870|DRUG|Placebo|Placebo 30 mg/d
57948118|NCT03891264|DRUG|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
57948119|NCT01439204|BIOLOGICAL|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
57948120|NCT04712110|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
57948121|NCT04712110|BIOLOGICAL|Placebo|Placebo intramuscular injection
57948122|NCT00918034|DRUG|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
57948123|NCT00918034|DEVICE|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
57948124|NCT00918034|PROCEDURE|Placement|Placement of device in prostate urethra
57948125|NCT00631774|DIETARY_SUPPLEMENT|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
57948126|NCT04530942|DEVICE|Deep brain stimulation(Active)|DBS On with the optiomal parameters
57948127|NCT04530942|DEVICE|Deep brain stimulation(Sham)|DBS On with 0V Amplitude
57948128|NCT02703311|DEVICE|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
57948129|NCT00691002|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
57948130|NCT00691002|DRUG|LEO 80190 Vehicle|
57948131|NCT00691002|DRUG|Hydrocortisone|
57948132|NCT00691002|DRUG|Calcipotriol|
57948133|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
57948134|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
58086666|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
58086667|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
58086668|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
58086669|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
58086670|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
58302325|NCT04254510|OTHER|Myofascial relaxation technique|"* Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
58302326|NCT04310722|OTHER|None intervention. This is an observational study.|None intervention. This is an observational study.
58086671|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
58086672|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
58086673|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
58086674|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
58086675|NCT00608127|DEVICE|LupusorbTM|Single treatment
58086676|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
58086677|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
58086678|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
58086679|NCT00305331|DRUG|Domperidone (drug)|
58086680|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
58086681|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
58086682|NCT00685763|RADIATION|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
58086683|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
58086684|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
58086685|NCT01392469|DRUG|Sildenafil|Oral Administration
58086686|NCT01392469|DRUG|Bosentan|Oral Administration
58086687|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
58086688|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
58086689|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
58086690|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
58086691|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
58086692|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
58086693|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
58302327|NCT02354287|PROCEDURE|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
58302328|NCT01071174|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
58086694|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
58086695|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
58086696|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
58086697|NCT03907709|BEHAVIORAL|In-Home Addiction Treatment Program|"* Treatment was delivered per treatment protocol~* Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~* Urine drug screens administered randomly~* Appointments were scheduled per protocol for 52 weeks~* Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
58302329|NCT01071174|OTHER|Placebo|Vaginal Ring containing no drug substance
58086698|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
58086699|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
58086700|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
58086701|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
58086702|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
58086703|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
58086704|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
58302330|NCT03826017|DIETARY_SUPPLEMENT|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
58302331|NCT03826017|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
58302332|NCT04345276|DRUG|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
58302333|NCT05750758|DRUG|rivaroxaban|rivaroxaban 2.5mg bid for 1m
58302334|NCT01239797|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
58412811|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
58412812|NCT01363180|OTHER|No stress condition|
58412813|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
58412814|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
58412815|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
58412816|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
58412817|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
58412818|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
58412819|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
58302335|NCT01239797|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
58302336|NCT01239797|DRUG|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
58412820|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
58412821|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
58086705|NCT03184402|DRUG|DWJ1252|tablet
58302337|NCT01239797|DRUG|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
58302338|NCT01239797|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
57733236|NCT00826891|DRUG|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
57948135|NCT02810665|BEHAVIORAL|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
58302339|NCT04722029|BIOLOGICAL|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
58302340|NCT02991365|OTHER|nasal insulin|
58302341|NCT02991365|OTHER|placebo spray|
58302342|NCT00000638|DRUG|Isoniazid|
58302343|NCT00000638|DRUG|Pyrazinamide|
57948136|NCT03516682|BEHAVIORAL|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
57948137|NCT03009032|DIETARY_SUPPLEMENT|PMT25341|
58302344|NCT00000638|DRUG|Pyridoxine hydrochloride|
57948138|NCT03009032|DIETARY_SUPPLEMENT|Placebo|Lactose
57948139|NCT00449462|PROCEDURE|consumption of CLA enriched food|
57948140|NCT03059238|DRUG|Celecoxib 200mg oral capsule|
58086706|NCT03184402|DRUG|Gasmotin|tablet
58302345|NCT00000638|DRUG|Rifampin|
58412822|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
58412823|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
57948141|NCT03059238|DRUG|parecoxib sodium|
57948142|NCT03059238|DRUG|controlled-release oxycodone|
57948143|NCT01879995|PROCEDURE||
57948144|NCT04444999|PROCEDURE|Carbon Dioxide Angiography|• Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
57948145|NCT05709964|OTHER|Self-reported|Self-reported height, weight, and neck circumference
57948146|NCT05709964|OTHER|Measured|Height, weight, and neck circumference measured by the investigator.
57948147|NCT03705728|DRUG|Propofol|"Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
57948148|NCT03705728|DRUG|Sevoflurane|Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval
58086707|NCT03184402|DRUG|Placebo of Gasmotin|tablet
58086708|NCT03184402|DRUG|Placebo of DWJ1252|tablet
58086709|NCT03940742|DRUG|Tirzepatide|Administered SC
58086710|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
58302346|NCT04824807|OTHER|Yoga|"The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana."
58302347|NCT04824807|OTHER|Clinical Pilates|"before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge."
58302348|NCT04824807|OTHER|An educational booklet|Only educational booklets will be given to the control group
58302349|NCT02404545|DEVICE|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
58086711|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
58086712|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
58302350|NCT00395993|DRUG|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
58302351|NCT00395993|DRUG|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
58302352|NCT04946812|OTHER|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
58302353|NCT04418362|OTHER|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
58302354|NCT06323759|OTHER|educational intervention|In antenatal breastfeeding education: Theoretical contributions on BF (physiology of lactation, frequency complications), hands-on workshop, Provision of educational tools to promote the learning environment: breastfeeding booklet, educational video on breastfeeding, link to a BF specific platform, access to a telephone platform. In short-term postnatal breastfeeding education: Three systematic fallow-up at home or at midwives' office are planned. During these visits, a time of systematic discussion is planned with the nursing mothers. Their knowledge and ability to manage their breastfeeding are checked. The physiology of lactation, the gestures of breastfeeding and the occurrence of common complications are systematically recalled by the liberal midwife. In long-term postnatal breastfeeding education: Invitation of nursing mothers to breastfeeding information meetings at 2nd and 4th month after birth. These meetings will be facilitated either by the liberal midwives.
58302355|NCT03266900|PROCEDURE|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
58302356|NCT03266900|DRUG|6 weeks BCG instillation|standard 6 weeks of BCG induction
58412824|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
58412825|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
57733237|NCT03859843|COMBINATION_PRODUCT|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
58086713|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
58086714|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
57948149|NCT03705728|DRUG|Remifentanil automatic|"Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
58086715|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
57948150|NCT03705728|DRUG|Remifentanil manual|Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
58086716|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
58086717|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
58086718|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
58086719|NCT00560573|DRUG|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
58086720|NCT00560573|DRUG|Cisplatin|"Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
58302357|NCT02818855|PROCEDURE|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
58302358|NCT02818855|DRUG|Collagen Matrix|A new collagen membrane
58302359|NCT02818855|PROCEDURE|Subepithelial connective tissue graft|Connective tissue graft
58302360|NCT02071459|DRUG|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
58302361|NCT02071459|DRUG|placebo|initial period (4 weeks) followed by 8 weeks
58302362|NCT01651364|DRUG|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
58302363|NCT01651364|DRUG|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
58302364|NCT01614470|DRUG|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
58302365|NCT01614470|DRUG|Placebo|oral use, administered twice a day (q12h)
58302366|NCT04100928|OTHER|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
58302367|NCT02001571|DRUG|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
57948151|NCT04750642|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
57948152|NCT04750642|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
58086721|NCT00560573|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
58086722|NCT00560573|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
58086723|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
58086724|NCT00003652|DRUG|cisplatin|
58302368|NCT01022203|BEHAVIORAL|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
58302369|NCT01022203|OTHER|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
58302370|NCT00600093|DRUG|Amantadine|IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
58302371|NCT05934006|BIOLOGICAL|spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples
58302372|NCT00749398|BIOLOGICAL|Infliximab|According to local country regulations.
58302373|NCT00225745|PROCEDURE|Blood draw|One blood draw prior to first treatment
58086725|NCT00003652|DRUG|fluorouracil|
58302374|NCT00346957|DRUG|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
58302375|NCT00346957|DRUG|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
58302376|NCT00346957|DRUG|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
58302377|NCT00346957|OTHER|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
58086726|NCT00003652|PROCEDURE|neoadjuvant therapy|
58302378|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
58302379|NCT03351712|BEHAVIORAL|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
58302380|NCT03351712|BEHAVIORAL|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
58302381|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
57948153|NCT03496428|DEVICE|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
58302382|NCT03251365|DRUG|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
58412826|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
58412827|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
58412828|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
58412829|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
58412830|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
58412831|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
58412832|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
58412833|NCT02130336|BEHAVIORAL|Aerobic interval training|
58412834|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
58412835|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
58412836|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
58412837|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
58412838|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
57733238|NCT03859843|OTHER|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
57733239|NCT03859843|OTHER|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
57733240|NCT03877523|DIETARY_SUPPLEMENT|Cocarnit|a metabolic complex
57733241|NCT00321854|DRUG|pramipexole|
57733242|NCT01012869|DEVICE|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
57733243|NCT03297268|OTHER|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
57733244|NCT06383975|PROCEDURE|Pulsed field ablation with posterior wall isolation|Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
57733245|NCT06383975|PROCEDURE|Radiofrequency ablation and vein of Marshall ethanolization|Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
58302383|NCT00264147|DRUG|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
58302384|NCT00264147|DRUG|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
58302385|NCT00264147|DRUG|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
58302386|NCT00264147|DRUG|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
58302387|NCT00264147|DRUG|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
58302388|NCT00264147|DRUG|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
57733246|NCT06370598|BIOLOGICAL|TP-122A|Bacteriophage cocktail targeting Psa
57733247|NCT04604587|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
57733248|NCT03690869|DRUG|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
58086727|NCT00003652|RADIATION|radiation therapy|
58412839|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
57733249|NCT03690869|DRUG|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
58412840|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
58412841|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
58412842|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
58412843|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
58412844|NCT06455410|DRUG|GP|gemcitabine + cisplatin
58412845|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
58412846|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
58412847|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
58412848|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
58412849|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
57733250|NCT03690869|RADIATION|Conventional or hypofractionated|Combined with cemiplimab IV administration
57733251|NCT03690869|RADIATION|Re-irradiation|Combined with cemiplimab IV administration
57733252|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
57733253|NCT06635902|OTHER|Placebo|Isotonic normal saline
57733254|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
57733255|NCT00933231|DRUG|tacrolimus|Standard dose, Oral
57733256|NCT00933231|DRUG|tacrolimus|Low dose, Oral
57733257|NCT00933231|BIOLOGICAL|Simulect|IV
57733258|NCT00933231|DRUG|Cellcept|Oral
57733259|NCT00933231|DRUG|Corticosteroids|IV and Oral
57733260|NCT00933231|DRUG|Ramipril|Oral
57733261|NCT00933231|DRUG|Irbesartan|Oral
57733262|NCT04002934|DRUG|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
58086728|NCT01975129|DRUG|Vagitocin|
58302389|NCT00264147|DRUG|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
58412850|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
58412851|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
58412852|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
58412853|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
58412854|NCT00024310|DRUG|lometrexol|
58412855|NCT00024310|DRUG|paclitaxel|
58412856|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
58412857|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
58412858|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
58412859|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
58412860|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
57733263|NCT04885829|DRUG|Tocilizumab Prefilled Syringe|0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
58086729|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
57733264|NCT00393926|DEVICE|TheraDrive Assistive Device|
57733265|NCT00393926|PROCEDURE|Rote Therapy versus Fun Therapy|
57733266|NCT03849755|DEVICE|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
57733267|NCT05131100|DRUG|Somavert|As provided in real world practice
57733268|NCT02401191|DRUG|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
58086730|NCT01710007|DRUG|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
58086731|NCT01710007|DRUG|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
57733269|NCT00244504|DRUG|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
57733270|NCT04208022|OTHER|Respiratory evaluation|Hypermobility and Respiratory evaluation
57733271|NCT00863096|BIOLOGICAL|Gardasil|HPV vaccine
57733272|NCT06395350|DEVICE|Spire Health Monitor|Use of Health Monitor is Assessed
57948154|NCT03478514|DRUG|Palbociclib|Taken at 100 mg once daily for 21 days, followed by 7 days off
58412861|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
58412862|NCT00504790|DRUG|GSK923295|anti-mitotic compound
58412863|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
58412864|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
58412865|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
58412866|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
58412867|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
58412868|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
58412869|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
58412870|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
57948155|NCT03478514|DRUG|Ibrutinib|560 mg taken orally all patients throughout the study
58086732|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
58086733|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
58086734|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
58086735|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
58086736|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
58086737|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
58086738|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
58086739|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
58086740|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
58086741|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
58086742|NCT02493023|DEVICE|navigated bronchoscopy|
58086743|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
58086744|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
57948156|NCT04804787|DIAGNOSTIC_TEST|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
58302390|NCT02735031|DRUG|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
58302391|NCT02735031|DRUG|Placebo|6 weeks treatment with placebo on top of insulin treatment
58302392|NCT03667768|PROCEDURE|Glass ionomer sealant|
58302393|NCT03667768|BEHAVIORAL|Non-sealant (toothbrushing)|
58302394|NCT02697214|DEVICE|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
58086745|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
58086746|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
58086747|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
58086748|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
58086749|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
58086750|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
58086751|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
58086752|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
58086753|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
58086754|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
58086755|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
58086756|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
58412871|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
58086757|NCT04028570|RADIATION|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
58412872|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
58412873|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
58086758|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
58086759|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
58086760|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
58086761|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
58086762|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
58086763|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
58086764|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
58412874|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
58412875|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
58412876|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
58412877|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
58086765|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
58086766|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
58086767|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
58086768|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
58086769|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
58086770|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
58086771|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
58086772|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
58086773|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
58086774|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
58086775|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
58086776|NCT00249600|BEHAVIORAL|Contingency management|
58086777|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
58086778|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
58086779|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
58086780|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
58412878|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
57733273|NCT03753165|OTHER|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
58086781|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
58086782|NCT00374465|DRUG|Verapamil|
58086783|NCT00374465|DRUG|Carvedilol|
58086784|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
58086785|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
58086786|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
58086787|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
58086788|NCT02908191|DRUG|ABI-H0731|
58412879|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
58086789|NCT02908191|DRUG|Placebo for ABI-H0731|
58086790|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
58086791|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
58086792|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
58086793|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
58412880|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
58412881|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
58086794|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
58086795|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
58086796|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
58086797|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
58412882|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
58412883|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
58412884|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
58412885|NCT06120595|OTHER|Standard follow-up|Standard follow-up
58412886|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
58412887|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
58412888|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
57948157|NCT04555824|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
58086798|NCT03793309|DRUG|Vitamin D|Oral vitamin D
58086799|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
58086800|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
58086801|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
58086802|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
58086803|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
58086804|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
58086805|NCT03861533|OTHER|survey|Cross-Reference
57948158|NCT04555824|OTHER|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
58086806|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
58086807|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
58412889|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
58412890|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
58086808|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
58086809|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
58086810|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
58086811|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
58086812|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
58086813|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
58086814|NCT01856296|PROCEDURE|Biopsy|
58412891|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
58412892|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
58412893|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
58412894|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
58412895|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
58412896|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
58086815|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
58086816|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
58086817|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
58086818|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
58086819|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
58086820|NCT01937546|PROCEDURE|Primary delivery of anterior shoulder|
58086821|NCT01937546|PROCEDURE|Primary delivery posterior shoulder|
58086822|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
58086823|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
58086824|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
58086825|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
58086826|NCT06538961|OTHER|Collection of blood samples|the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).
58086827|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
57733274|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
57948159|NCT05386901|PROCEDURE|Conventional positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.
58086828|NCT06538961|OTHER|Urine Sample|Post-transplant monthly urine sample collection for 6 months
58086829|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
58086830|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
58086831|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
58086832|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
58086833|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
58086834|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
58086835|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
58086836|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
58086837|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
58086838|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
58086839|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
58302395|NCT02697214|DEVICE|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
58302396|NCT02697214|DEVICE|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
58302397|NCT02697214|DEVICE|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
58302398|NCT05829499|DEVICE|HPMC-HA eyedrops|Ocular drops based upon HPMC and HA
58302399|NCT04804761|OTHER|Electroacupuncture|Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
58302400|NCT03632564|DEVICE|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
58086840|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
58086841|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
58086842|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
58086843|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
58086844|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
58086845|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
58086846|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
58086847|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
58086848|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
58086849|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
58086850|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
58086851|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
58086852|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
58086853|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
58086854|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
58086855|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
58086856|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
58086857|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
58086858|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally."
58086859|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally."
58086860|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
58086861|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
58086862|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
58086863|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
58086864|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
58086865|NCT01541410|DEVICE|Vascutek Hybrid Graft|Single Group Assignment
58086866|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
58086867|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
58086868|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
58086869|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
58086870|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
58086871|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
58086872|NCT06056323|DRUG|HB0045 Drug Product|Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
58086873|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
58086874|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
58086875|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
58086876|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
58086877|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
58086878|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
58086879|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
58086880|NCT06048198|OTHER|No intervention|No intervention
58086881|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
58412897|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
58412898|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
58412899|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
58412900|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
58412901|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
58412902|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
58412903|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
58412904|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
58086882|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
58086883|NCT00210925|DRUG|topiramate|
58086884|NCT00488007|DEVICE|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
58086885|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
58086886|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
58086887|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
58086888|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
58302401|NCT02048800|DRUG|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)
58302402|NCT02198638|BIOLOGICAL|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
58302403|NCT02590666|PROCEDURE|Bipolar Polypectomy|Polyps resection with bipolar electrode
58302404|NCT02590666|PROCEDURE|Mechanical Polypectomy|Polyps resection with microscissors or graspers
58412905|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
58412906|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
58412907|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
58412908|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
58412909|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
57948160|NCT05386901|PROCEDURE|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
57948161|NCT02162836|DRUG|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
57948162|NCT04117243|DRUG|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
57948163|NCT04117243|DRUG|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
57948164|NCT04117243|DRUG|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
57948165|NCT01513538|DEVICE|TherapyGuide|Use of TherapyGuide function to help programming the device
57948166|NCT02467738|RADIATION|Brachytherapy|Undergo brachytherapy with Cesium-131
57948167|NCT02467738|DRUG|Cesium-131|Undergo brachytherapy with Cesium-131
57948168|NCT02467738|PROCEDURE|Conventional surgery|Undergo surgical resection
57948169|NCT02975895|DEVICE|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
57948170|NCT02975895|DEVICE|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
57948171|NCT03053700|DRUG|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
57948172|NCT03053700|DEVICE|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
57948173|NCT04094753|DIAGNOSTIC_TEST|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
57948174|NCT04094753|DIAGNOSTIC_TEST|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
57948175|NCT04094753|DIAGNOSTIC_TEST|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
57948176|NCT04094753|DIAGNOSTIC_TEST|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
57948177|NCT04094753|DIAGNOSTIC_TEST|Questionaires|"Patients have to fulfill the following questionaires~* ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~* TILBURG FRAILTY INDICATOR~* SF-36 Quality of Life score~* N- QOL"
57948178|NCT04094753|DIAGNOSTIC_TEST|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
57948179|NCT04094753|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
57948180|NCT05650814|DEVICE|ButterfLife|On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.
57948181|NCT05650814|OTHER|Control|Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
58086889|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
58086890|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
58086891|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
58412910|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
58412911|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
58412912|NCT00303446|DRUG|Placebo|Matched placebo
58412913|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
58412914|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
58412915|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
58412916|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
58412917|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
58412918|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
58412919|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
58412920|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
58412921|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
58412922|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
58412923|NCT00354107|DRUG|ifosfamide|Given IV
58412924|NCT00354107|DRUG|carboplatin|Given IV
58412925|NCT00354107|DRUG|etoposide|Given IV
58412926|NCT00354107|DRUG|methotrexate|Given IT
58412927|NCT00354107|DRUG|cytarabine|Given IT
58412928|NCT00354107|OTHER|pharmacological study|Correlative studies
58412929|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
57948182|NCT04798599|OTHER|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
57948183|NCT04798599|OTHER|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
57948184|NCT02371447|DRUG|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
58086892|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
58086893|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
58086894|NCT05879796|DRUG|cis-platinum|chemotherapeutics
58302405|NCT02590666|DEVICE|Bipolar electrode|Bipolar electrode used to performs polypectomy
58302406|NCT02590666|DEVICE|Microscissors or graspers|Mechanical instruments used to performs polypectomy
58302407|NCT00100399|BIOLOGICAL|Fluarix|
58302408|NCT03308552|RADIATION|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
58302409|NCT03308552|DRUG|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
58302410|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
58412930|NCT01839019|DRUG|ODM-102|Single dose escalation
58412931|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
58412932|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
58412933|NCT03243578|OTHER|None as this is an observational study|
58412934|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
58412935|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
58412936|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
58412937|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
58412938|NCT04589351|DRUG|Placebo|Matching placebo
58412939|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
58412940|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
58412941|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
58412942|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
58412943|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
58412944|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
58412945|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
58412946|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
58412947|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
58412948|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
58302411|NCT03308552|DRUG|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
58302412|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
58302413|NCT02862301|BIOLOGICAL|blood sample|
58302414|NCT00933725|OTHER|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
58302415|NCT00933725|OTHER|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
58412949|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
58412950|NCT00123773|PROCEDURE|Positron Emission Tomography|
58412951|NCT02523768|DRUG|ATG-F|
58412952|NCT02523768|DRUG|Simulect|
57733275|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
57733276|NCT04724655|OTHER|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
57948185|NCT01152320|BEHAVIORAL|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
57948186|NCT03962101|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
58302416|NCT05726435|DIETARY_SUPPLEMENT|Soluble dietary fiber with prebiotic properties|14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
58412953|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
58412954|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
58412955|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
57948187|NCT00525993|DRUG|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
57948188|NCT00525993|DRUG|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
58412956|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
58412957|NCT00739180|OTHER|Control|Standard care control (no exercise)
58412958|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
58412959|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
58412960|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
58412961|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
58412962|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
58086895|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
58086896|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
58086897|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
58086898|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
58086899|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
58086900|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
58086901|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
58086902|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
58086903|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
58086904|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
58086905|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
58086906|NCT04962815|DEVICE|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
58086907|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
58086908|NCT02139969|DEVICE|GreenLight XPS Laser System|
58086909|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
58302417|NCT05726435|DIETARY_SUPPLEMENT|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
58302418|NCT05067166|DRUG|Ansuvimab|single infusion 50 mg/kg IV
58412963|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
58086910|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
58086911|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
58302419|NCT02460289|DRUG|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
58302420|NCT03729050|BEHAVIORAL|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
58302421|NCT06369558|OTHER|PLYOMETRIC TRAINING|A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
58302422|NCT06369558|OTHER|CLASSIC PHYSIOTHERAPY PROGRAM|HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
58302423|NCT02890316|OTHER|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
58302424|NCT02890316|RADIATION|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
58412964|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
58086912|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
58302425|NCT04705818|DRUG|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
58302426|NCT04705818|DRUG|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
58302427|NCT05971771|OTHER|Placebo|Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
58302428|NCT05971771|DIETARY_SUPPLEMENT|Treatment|14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
58412965|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
58302429|NCT05606861|OTHER|Mindfulness Based Interventions in Pediatric Nurses|This intervention are structured mindfulness program including meditation and breathing techniques .
58412966|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
58412967|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
58412968|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
58412969|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
58412970|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
58412971|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
58412972|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
58412973|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
58412974|NCT01958021|DRUG|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
58412975|NCT01958021|DRUG|Letrozole|Letrozole 2.5 mg tablets taken orally.
58412976|NCT01958021|DRUG|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
58412977|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
58412978|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
58412979|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
58412980|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
58412981|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
58412982|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
58302430|NCT05637034|DIAGNOSTIC_TEST|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
58302431|NCT04640922|DEVICE|Gedea Pessary pHyph|Vaginal tablet
58412983|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
58412984|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
58412985|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
58412986|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
58412987|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
58412988|NCT02621398|DRUG|Carboplatin|Given IV
58412989|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
58412990|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
58412991|NCT02621398|DRUG|Paclitaxel|Given IV
58302432|NCT04640922|DEVICE|Placebo|Vaginal tablet
58302433|NCT01210794|PROCEDURE||The influence of different food components on zinc absorption in young adults consuming zinc fortified porridges prepared from maize, beans and sorghum
58302434|NCT04361084|OTHER|traditional simulated training|traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
58412992|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
57733277|NCT04724655|OTHER|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
57733278|NCT04724655|DRUG|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
58302435|NCT04361084|OTHER|mixed reality simulation|using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
58302436|NCT03831776|DRUG|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
58302437|NCT03831776|DRUG|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
58302438|NCT00973583|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 400 IU daily
58086913|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
58086914|NCT01850901|PROCEDURE|Renal sympathetic denervation|
58086915|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
58412993|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
58412994|NCT03749096|DRUG|Placebos|Normal Saline
58412995|NCT04656795|DRUG|MT-7117|MT-7117
58412996|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
58412997|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
58412998|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
58412999|NCT02361424|DRUG|placebo|
58413000|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
58413001|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
58413002|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
58413003|NCT00047333|OTHER|pharmacological study|Correlative studies
58413004|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
58413005|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
58413006|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
58413007|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
58413008|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
58413009|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
58413010|NCT03691350|DRUG|Cigarette|Smoke usual brand
58413011|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
58413012|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
58413013|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
58413014|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
58086916|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
58086917|NCT00307138|DRUG|hetastarch|
58086918|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
58413015|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
58413016|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
58413017|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
58413018|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
58413019|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
58413020|NCT04026360|OTHER|no intervention|
58413021|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
58413022|NCT02024022|DRUG|Individualized approach|
58413023|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
58413024|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
58413025|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
58413026|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
58413027|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
58413028|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
57733279|NCT04724655|OTHER|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
57948189|NCT03820648|DEVICE|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
58302439|NCT00973583|DIETARY_SUPPLEMENT|placebo|placebo
58413029|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
58413030|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
58413031|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
57948190|NCT03820648|DEVICE|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
58302440|NCT04458519|OTHER|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
58302441|NCT04458519|OTHER|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
58302442|NCT02815085|OTHER|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
58413032|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
58413033|NCT04634708|OTHER|No intervention|No intervention due to observational design
58413034|NCT04750980|OTHER|food allergy|food allergy
57948191|NCT05533528|PROCEDURE|periodontal surgery|A sulcular incision will be made in the affected teeth, followed by an incision from the buccal aspect in the mid-portion of the interproximal tissues The buccal and lingual flaps will be elevated. For periodontal granulation tissue preservation group, the soft tissues covering the alveolar crest will be prepared. A third incision will separate the pocket epithelium from the soft tissue (granulation tissue) attached to the bone. The pocket epithelium will be removed. The root surfaces will be carefully scaled and planed in both groups. Ethylenediaminetetraacetic acid (24%) will be applied to the root surfaces and removed after 2 minutes with abundant saline solution. In the experimental group, the preserved attached soft tissue and the space between it and the root surface will be irrigated with 10% polyvinylpyrrolidone-iodine. Finally, the flaps will be positioned and sutured.
58302443|NCT02017301|OTHER|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
58302444|NCT01927094|DIETARY_SUPPLEMENT|Probiotic|Comparison of probiotics vs. ORS
58302445|NCT01927094|DIETARY_SUPPLEMENT|ORS|ORS ad libitum
58413035|NCT04750980|OTHER|respiratory allergy|respiratory allergy
58413036|NCT04750980|OTHER|healthy controls|healthy controls
58413037|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
58413038|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
58413039|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
58413040|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
58413041|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
58413042|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
58413043|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
58413044|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
58413045|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
58413046|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
58302446|NCT00002125|DRUG|Foscarnet sodium|
57948192|NCT00133991|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
57948193|NCT00133991|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
58302447|NCT05653232|OTHER|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
58302448|NCT05653232|OTHER|Transmit and Treat (T&T)|For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
58302449|NCT04702464|DRUG|Fedratinib|Fedratinib
57948194|NCT00133991|DRUG|Cyclophosphamide|1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
58302450|NCT04702464|DRUG|Fluconazole|Fluconazole
58302451|NCT04881812|DEVICE|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
58413047|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
58302452|NCT04881812|DEVICE|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
58302453|NCT04967053|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy gives long-standing improvement or resolution of obesity-related conditions and also survival benefit. It is highly cost-effective. Surgical procedures for the treatment of obesity.
58302454|NCT01855958|PROCEDURE|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
58302455|NCT01855958|PROCEDURE|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
58302456|NCT00871234|DRUG|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
58302457|NCT02820077|DEVICE|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
58413048|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
58413049|NCT00283972|DEVICE|LAP-BAND System|
58413050|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
58413051|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
58413052|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
58413053|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
58413054|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
57948195|NCT00133991|DRUG|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
57948196|NCT00133991|DRUG|Methotrexate|3 g/m\^2 on Day 8 of each cycle of R-CVP.
57948197|NCT00133991|DRUG|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
57948198|NCT00133991|DRUG|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
57948199|NCT00133991|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
57948200|NCT00133991|DRUG|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
58302458|NCT02174107|RADIATION|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1\*8 Gy; 5\*4 Gy and 10\*3 Gy
58302459|NCT02174107|PROCEDURE|Percutaneous vertebroplasty|
58302460|NCT02831582|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO.
58413055|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
58413056|NCT02582281|DEVICE|intrauterine device TCu 380A|
58413057|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
58413058|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
57948201|NCT04858477|OTHER|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
58302461|NCT02831582|OTHER|Placebo|Given PO.
58413059|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
58413060|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
58413061|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
58413062|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
57948202|NCT04858477|OTHER|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
58413063|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
58302462|NCT06465017|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG and 68Ga-FAPI PET/CT), 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG and 68Ga-FAPI) and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
58086919|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
58086920|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
58086921|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
58086922|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
58302463|NCT01890655|DRUG|MT-1303-Low|
58302464|NCT01890655|DRUG|MT-1303-Middle|
58302465|NCT01890655|DRUG|MT-1303-High|
58302466|NCT01405560|DRUG|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
58302467|NCT01405560|BIOLOGICAL|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
58302468|NCT01405560|DRUG|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
58413064|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
58413065|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
58413066|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
58413067|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
58413068|NCT05743075|DRUG|Placebo|Placebo solution
58413069|NCT00174174|DRUG|Modafinil|
57948203|NCT03921424|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
58086923|NCT05963022|DRUG|Tirzepatide|Administered SC
58086924|NCT05963022|DRUG|Placebo|Administered SC
58413070|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
57948204|NCT03921424|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
57948205|NCT03921424|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
57948206|NCT02483663|DEVICE|Functional Magnetic Resonance Imaging|Measure brain activity.
58086925|NCT06232135|OTHER|CBCT scan|analysis of the CBCT scan to assign a calcification stage to the subject's lower left third molar and accordingly calculate the estimated age of each subject
58086926|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
58086927|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
58086928|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
58086929|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
58302469|NCT03851263|BIOLOGICAL|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
58302470|NCT03733366|OTHER|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
58302471|NCT03604939|DIAGNOSTIC_TEST|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
58413071|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
58413072|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
58413073|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
57948207|NCT02483663|RADIATION|Dual Energy X-ray absorptiometry|Body composition measurements.
58086930|NCT02269800|DRUG|Normal saline|Tid, 7 days
58086931|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
58086932|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
58086933|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
58413074|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
57733280|NCT03726034|BEHAVIORAL|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
58086934|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
58086935|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
58086936|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
58086937|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
58302472|NCT03604939|DIAGNOSTIC_TEST|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
58302473|NCT04754997|OTHER|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
58302474|NCT04754997|OTHER|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
58302475|NCT04356157|BEHAVIORAL|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
58302476|NCT03504215|OTHER|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
58302477|NCT03242941|PROCEDURE|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
58302478|NCT05859568|DEVICE|Pinna-located microphone|Sound processors using a pinna-located microphone
58302479|NCT05859568|DEVICE|Pinna-simulated microphone algorithm|Sound processors using a pinna-simulated algorithm
58302480|NCT02739217|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
58302481|NCT03819517|DRUG|Resveratrol|Over the counter supplementation
58302482|NCT03819517|OTHER|Placebo|Empty white colored soft vegetarian capsule
58302483|NCT03959007|OTHER|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
58302484|NCT03959007|OTHER|Questionnaire|Both arm at 3 times during hospitalization
58302485|NCT02523430|PROCEDURE|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
58302486|NCT01064479|DRUG|Carboplatin|Given IV
58302487|NCT01064479|DRUG|Cisplatin|Given IV
58413075|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
58302488|NCT01064479|DRUG|Docetaxel|Given IV
58302489|NCT01064479|DRUG|Erlotinib Hydrochloride|Given PO
58302490|NCT01064479|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58302491|NCT01064479|OTHER|Pharmacological Study|Optional correlative studies
58302492|NCT01064479|OTHER|Placebo|Given PO
58302493|NCT01064479|OTHER|Quality-of-Life Assessment|Ancillary studies
58302494|NCT06515756|OTHER|Post operative pain assessment after root canal treatment|the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
58302495|NCT03446040|BIOLOGICAL|BMS-986258|Specified dose on specified days
58302496|NCT03446040|BIOLOGICAL|Nivolumab|Specified dose on specified days
58302497|NCT03446040|DRUG|rHuPH20|Specified dose on specified days
58413076|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
57733281|NCT03726034|BEHAVIORAL|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
57948208|NCT02483663|OTHER|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
58086938|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
58086939|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
58086940|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
58086941|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
58086942|NCT06567171|PROCEDURE|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures.|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures. Parental use of pain relief strategies (PURPS) and parental postoperative pain management (PPPM) tools were used to collect data on the adequacy of knowledge of the use of different pain relief strategies and the skill of parental pain assessment, respectively. We used Spearman's rank correlation coefficient was used to determine the relationships between pain score given by parents and nurses. The statistical tests were performed at a 95% confidence interval and a 5% significance level.
58302498|NCT06197360|BEHAVIORAL|Based on BCW Theory of Health Education|Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.
58302499|NCT06197360|BEHAVIORAL|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
58302500|NCT02163161|DRUG|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
57948209|NCT02483663|OTHER|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
58302501|NCT02163161|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
58302502|NCT02163161|DRUG|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
58302503|NCT04521595|BEHAVIORAL|Weigh Smart Telehealth intervention|Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
58302504|NCT01095497|BIOLOGICAL|CINRYZE|C1 esterase inhibitor (human)
58302505|NCT06183034|OTHER|Very Low Calorie Diet|Participants will receive a very low calorie diet as described in the arm/group
58302506|NCT02499016|PROCEDURE|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
57948210|NCT02483663|OTHER|Test Meals|Breakfast, a snack, and lunch provided during study visit.
57948211|NCT02483663|OTHER|Computer Tests|Perform a series of computer tests to determine reaction time.
57948212|NCT02483663|PROCEDURE|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
58302507|NCT03451396|DRUG|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
58302508|NCT03482050|BIOLOGICAL|AstroRx|Astrocytes derived from human embryonic stem cells
58302509|NCT02770638|DEVICE|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
58413077|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
58413078|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
58413079|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
58413080|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
58302510|NCT02770638|DEVICE|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
58302511|NCT06192940|BEHAVIORAL|Counseling home caregivers|Advice on the proper use of insulin therapy will be given, if necessary, to caregivers. Patients are reviewed at 1 month of this first visit with a collection of the same data
57948213|NCT03592940|DIETARY_SUPPLEMENT|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
58413081|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
58413082|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
58413083|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
58413084|NCT00637637|DRUG|indinavir sulfate|
58413085|NCT00637637|DRUG|ritonavir|
57948214|NCT04539210|DEVICE|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
57948215|NCT05379348|OTHER|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
57948216|NCT02431065|PROCEDURE|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
58302512|NCT00584584|DRUG|QAX576|
58302513|NCT00584584|DRUG|Placebo|
58413086|NCT00637637|RADIATION|radiation therapy|
58413087|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
58413088|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
58302514|NCT05731310|DRUG|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
58302515|NCT02039258|DRUG|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
58302516|NCT00117169|PROCEDURE|multi-detector helical computed tomography|
58302517|NCT03610893|DRUG|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
58302518|NCT03610893|DRUG|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
58302519|NCT04284254|DRUG|Autologous Plasmablasts|"Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~- Maximum Tolerated Dose (MTD) established in Phase I"
58413089|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
58413090|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
58413091|NCT02257177|DRUG|Placebo|DPI placebo
58413092|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
58413093|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
58413094|NCT00410826|DRUG|cisplatin|Given IV
58413095|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
58413096|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
58413097|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
57733282|NCT05295498|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
57733283|NCT05295498|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
57733284|NCT02291614|DRUG|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
58086943|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
58086944|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
58086945|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
58086946|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
58086947|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
58086948|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
58086949|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
58086950|NCT00761761|DRUG|Sensoril|
58086951|NCT00761761|OTHER|Placebo|
58086952|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
58086953|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
58086954|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
57733285|NCT04388020|DEVICE|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
58086955|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
58086956|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
58086957|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
58086958|NCT06135129|DEVICE|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
58086959|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
58086960|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
58086961|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
58086962|NCT04607265|DIAGNOSTIC_TEST|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
58086963|NCT01068093|DRUG|Ezetimibe|10mg daily
58086964|NCT00232778|DEVICE|GAMMA-Iridium-192 catheter|
58086965|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
58086966|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
58086967|NCT02792400|DRUG|LY2403021 placebo|
58413098|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
58413099|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
58413100|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
58413101|NCT01256463|BEHAVIORAL|HIV prevention intervention|
58413102|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
58413103|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
58413104|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
58413105|NCT00570934|DRUG|Placebo|Placebo
58413106|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
58413107|NCT02031224|BEHAVIORAL|Conventional low protein diet|
58413108|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
58413109|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
58413110|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
58413111|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
58413112|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
58413113|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
57733286|NCT04388020|DEVICE|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
58086968|NCT02792400|PROCEDURE|Standardised liquid meal|
58086969|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
58413114|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
58086970|NCT02792400|DRUG|Linagliptin placebo|
58086971|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
58086972|NCT02792400|DRUG|Empagliflozin placebo|
58086973|NCT02404675|DRUG|icotinib|
58086974|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
58413115|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
58413116|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
58413117|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
58413118|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
58413119|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
58413120|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
58413121|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
58413122|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
58413123|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
58413124|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
58413125|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
58086975|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
58302520|NCT00217282|DRUG|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
58302521|NCT04354935|DEVICE|rTMS basic|1 session per day, for 4 or 6 weeks.
58302522|NCT04354935|DEVICE|rTMS VIIT|5 sessions per day, for 2 weeks.
58302523|NCT04354935|DEVICE|rTMS SAINT modified|8 sessions per day, for 1 week.
58302524|NCT04354935|DEVICE|rTMS SAINT|10 sessions per day, for 1 week.
58302525|NCT04140409|DRUG|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
58302526|NCT05414851|OTHER|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
58302527|NCT00000798|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
57733287|NCT03339050|BEHAVIORAL|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
57948217|NCT02431065|DRUG|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
58413126|NCT02248207|DRUG|Pramipexole|
58413127|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
58413128|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
58413129|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
58413130|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
58413131|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
58413132|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
58086976|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
58086977|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
58086978|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
58086979|NCT00096317|DRUG|ixabepilone|
58086980|NCT00096317|DRUG|ketoconazole|
58086981|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
58086982|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
58086983|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
58086984|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
58086985|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
58086986|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
58086987|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
58086988|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
58086989|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
57948218|NCT02431065|OTHER|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
58086990|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
58086991|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
58086992|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
58086993|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
58086994|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
58086995|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
58086996|NCT05514496|DRUG|NX-019|NX-019 will be administered orally.
58086997|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
58086998|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
58086999|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
58087000|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
58087001|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
58087002|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
58087003|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
58087004|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
58087005|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
58087006|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
58087007|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
58087008|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
57948219|NCT04548726|DEVICE|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
58087009|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
57948220|NCT04548726|DEVICE|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
57948221|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
58087010|NCT01035112|PROCEDURE|MRI|
58087011|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
58087012|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
58087013|NCT00490399|DRUG|gemcitabine|
58087014|NCT00490399|DRUG|cisplatin|
58302528|NCT05643391|RADIATION|Radioembolization using Holmium-166|This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
58302529|NCT00572845|OTHER|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
58302530|NCT00350441|DRUG|Sildenafil Citrate|
57733288|NCT06635720|DRUG|Prednisone|This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.
57733289|NCT06670443|DEVICE|experimental group|Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
58413133|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
58413134|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
58413135|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
58413136|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
58413137|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
58413138|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
57948222|NCT04539639|DRUG|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
57948223|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
57948224|NCT04539639|DRUG|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
57948225|NCT04040894|BIOLOGICAL|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
57948226|NCT03015259|DRUG|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
58302531|NCT03328481|PROCEDURE|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
58302532|NCT03328481|PROCEDURE|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
57948227|NCT03015259|DRUG|Symbicort|Active Comparator: Treatment 2
57948228|NCT03015259|DRUG|Placebo|Placebo Comparator: Treatment 3
57733290|NCT06670443|DEVICE|control group|Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
57733291|NCT01621217|DRUG|Cetuximab|Will be given weekly intravenously during study treatment.
58413139|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
58413140|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
58413141|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
58413142|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
58413143|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
58413144|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
58413145|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
58413146|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
58413147|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
58413148|NCT02787590|DRUG|Simvastatin|
58413149|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
58413150|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
58413151|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
58413152|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
58413153|NCT00088790|DRUG|AZD5438|
58413154|NCT00205842|DRUG|alvimopan|
58413155|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
58413156|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
58302533|NCT03328481|PROCEDURE|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
58302534|NCT05426590|DEVICE|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
58302535|NCT06252935|DEVICE|FormaAid|FormaAid is mainly composed of pure collagen extracted from bovine tendon, it is fabricated in the form of highly dense collagen matrix without chemical cross-linking to act as a barrier excluding epithelium.
58302536|NCT06252935|DEVICE|Bio-Gide|Bio-Gide is a bilayer collagen membrane made of porcine collagen, permits prompt and homogeneous vascularization and so brings about optimal tissue integration and wound stabilization.
58302537|NCT00496340|DRUG|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3."
58302538|NCT00496340|DRUG|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
58302539|NCT00496340|DRUG|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines."
58302540|NCT00496340|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
58413157|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
58413158|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
58413159|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
58413160|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
58413161|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
58413162|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
58413163|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
58413164|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
58087015|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
58087016|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
58087017|NCT01923207|DRUG|DX-2930|
58087018|NCT01923207|DRUG|Placebo|placebo, subcutaneous administration
58087019|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
58087020|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
58087021|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
58087022|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
58087023|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
58087024|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
58087025|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
58087026|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
58087027|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
58087028|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
58087029|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
58087030|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
58087031|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
57948229|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
58087032|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
58087033|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
58087034|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
58087035|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
58087036|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
58087037|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
58087038|NCT00034593|DRUG|ALIMTA|
58087039|NCT00034593|DRUG|gemcitabine|
58087040|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
58087041|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
58087042|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
58302541|NCT00706680|DRUG|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
58302542|NCT04811157|DIETARY_SUPPLEMENT|Test product|200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
58302543|NCT04811157|DIETARY_SUPPLEMENT|Control product|200 g/day of unsweetened yogurt
58302544|NCT04979481|BEHAVIORAL|BRAVE|The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.
58302545|NCT04979481|BEHAVIORAL|STEM|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
58302546|NCT04494646|DRUG|Bardoxolone Methyl|Once-daily administration of bardoxolone methyl (20mg)
57948230|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
57948231|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
57948232|NCT01199029|DRUG|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
57948233|NCT01199029|DRUG|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
58302547|NCT04494646|DRUG|Placebo|Once-daily administration of matching placebo
58302548|NCT01753349|BIOLOGICAL|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
57948234|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
57948235|NCT01199029|DRUG|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
57948236|NCT05206942|DIAGNOSTIC_TEST|Doppler ultrasound|Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
57948237|NCT05206942|DIAGNOSTIC_TEST|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
57948238|NCT05206942|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
57948239|NCT00707928|DRUG|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
57948240|NCT00707928|OTHER|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
58302549|NCT02615886|OTHER|Observational Control|Participants will be observed and not provided any dietary supplementation.
58302550|NCT02615886|DIETARY_SUPPLEMENT|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
58302551|NCT03884335|PROCEDURE|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
57733292|NCT01621217|DRUG|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
57733293|NCT01621217|DRUG|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
57733294|NCT01621217|RADIATION|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
57733295|NCT02501304|DEVICE|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
58087043|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
58087044|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
58087045|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
58087046|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
58302552|NCT04207905|OTHER|Healthy Michigan Plan (HMP) coverage with work requirements|For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
58302553|NCT05868135|BEHAVIORAL|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
58413165|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
58413166|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
58413167|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
58413168|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
58302554|NCT02718872|BEHAVIORAL|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
58302555|NCT05447273|DIAGNOSTIC_TEST|Multi-parametric, functional magnetic resonance imaging (MRI)|Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
58302556|NCT00764101|BEHAVIORAL|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
58302557|NCT03606811|PROCEDURE|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
58302558|NCT03606811|PROCEDURE|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
58302559|NCT02420535|BEHAVIORAL|Immediately Receive Tool|
58302560|NCT02420535|BEHAVIORAL|One Month Delay|
58302561|NCT01918501|PROCEDURE|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
58302562|NCT05128838|OTHER|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
58302563|NCT04527042|DRUG|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
58302564|NCT06040814|BEHAVIORAL|Rehabilitation Training|12 week Rehabilitation Training course
58302565|NCT03695146|BEHAVIORAL|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
58302566|NCT03695146|BEHAVIORAL|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
58302567|NCT01753882|DRUG|Lexapro|Agent + training vs Placebo + training
58413169|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
58413170|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
58413171|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
58413172|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
58302568|NCT01753882|DRUG|Placebo|Agent + training vs Placebo + training
58302569|NCT04524689|DRUG|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
58302570|NCT04524689|DRUG|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
57948241|NCT01127568|DRUG|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
58087047|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
57948242|NCT00709982|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
58087048|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
58087049|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
58302571|NCT04524689|DRUG|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
57948243|NCT04739254|DIAGNOSTIC_TEST|CardioFlux|Magnetocardiography
57948244|NCT01119300|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
57948245|NCT01119300|OTHER|Standard care|Standard care
57948246|NCT06175403|DRUG|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
57948247|NCT05203497|DRUG|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
57948248|NCT02963389|DRUG|Tripegfilgrastim|
57948249|NCT00505440|BEHAVIORAL|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
57948250|NCT00505440|BEHAVIORAL|Usual care|Usual care with mailed screening results
57948251|NCT00449501|DRUG|Budesonide/formoterol pMDI|
57948252|NCT00449501|DRUG|Budesonide HFA pMDI|
57948253|NCT04989114|DEVICE|nasal continuous positive airway pressure|positive end expiratory pressure will be applied by nasal continuous positive airway pressure
57948254|NCT03212053|BIOLOGICAL|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
58087050|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
58087051|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
58087052|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
58087053|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
58087054|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
58302572|NCT04524689|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
58302573|NCT04524689|DRUG|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
58302574|NCT02228252|OTHER|Whey protein|
58302575|NCT02228252|OTHER|Casein|
58302576|NCT02228252|OTHER|Gluten protein|
58302577|NCT02917174|BEHAVIORAL|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
58087055|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
58087056|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
58087057|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
58087058|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
58087059|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
58087060|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
58413173|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
58413174|NCT00220493|DRUG|Ritalin|
58413175|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
58413176|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
58413177|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
58413178|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
58413179|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
58413180|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
58413181|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
58413182|NCT00020462|BIOLOGICAL|aldesleukin|
58413183|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
58413184|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
58413185|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
58413186|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
57948255|NCT01326182|BEHAVIORAL|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
58087061|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
58087062|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
57948256|NCT01326182|BEHAVIORAL|MAAS|Group-based intervention including asthma education and education regarding general child health
57948257|NCT06050174|DRUG|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
57948258|NCT06050174|PROCEDURE|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
57948259|NCT04340375|DIETARY_SUPPLEMENT|AP green tea extracts|AP green tea extracts
57948260|NCT03532594|PROCEDURE|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
57948261|NCT03532594|PROCEDURE|Standard Care|Protamine administered according to Standard Care
57948262|NCT02193399|OTHER|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
57948263|NCT02666339|OTHER|Usual care|Usual care : drug therapy, nurse and physician consultations.
58087063|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
58087064|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
58087065|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
58087066|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04_0 Page 45-46)"
58302578|NCT02917174|BEHAVIORAL|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
57948264|NCT02666339|BEHAVIORAL|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
57948265|NCT04117971|OTHER|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
57948266|NCT03962374|DEVICE|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
57948267|NCT03962374|DEVICE|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
57948268|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
57948269|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
57948270|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
57948271|NCT00761007|DRUG|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
57948272|NCT03488173|DRUG|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
57948273|NCT03371446|GENETIC|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
57948274|NCT01577901|OTHER|Clearblue Advanced|Pregnancy test
58302579|NCT02510937|DRUG|CC-90001|
58302580|NCT00945646|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
58302581|NCT00945646|DRUG|Vehicle|Instill four times two times a day
58302582|NCT03903263|DIAGNOSTIC_TEST|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
57948275|NCT01300169|BEHAVIORAL|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
57948276|NCT01300169|BEHAVIORAL|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
57948277|NCT02304107|DRUG|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
57948278|NCT02304107|DRUG|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
57948279|NCT04278209|OTHER|Breakfast 1|Participant will receive Breakfast 1
57948280|NCT04278209|OTHER|Breakfast 2|Participant will receive Breakfast 2
57948281|NCT04278209|OTHER|Water|Participant will receive water
57948282|NCT00708149|DRUG|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
57948283|NCT00708149|DRUG|placebo|takepron placebo
57948284|NCT04772040|DIETARY_SUPPLEMENT|Fish oil supplementation|Fish oil capsules.
58302583|NCT06216418|DEVICE|BRFS-18G-S100WH|A facial tissue fixation material made of polydioxanone (PDO).
58302584|NCT06216418|DEVICE|MINT Lift FINE+|A facial tissue fixation material made of polydioxanone (PDO).
58302585|NCT04702360|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
58302586|NCT04702360|DRUG|IVA|IVA monotablet for oral administration.
58302587|NCT05437601|DRUG|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
58302588|NCT05437601|OTHER|Placebo|Oral placebo identical to astaxanthin
58302589|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
58087067|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
58087068|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
58087069|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
58087070|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
58087071|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
58087072|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
58302590|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
58302591|NCT03832283|OTHER|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.
58413187|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
57948285|NCT05155202|DRUG|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
57948286|NCT06466447|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
57948287|NCT03076385|BIOLOGICAL|VAL-506440|Escalating dose levels
57948288|NCT03076385|OTHER|Placebo|
57948289|NCT00996268|DRUG|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
57948290|NCT00996268|DRUG|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
57948291|NCT06394011|DRUG|venetoclax, azacitidine and HAAG regimen|Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
57948292|NCT04405154|BIOLOGICAL|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
57948293|NCT04405154|DRUG|Cisplatin|75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
57948294|NCT04405154|RADIATION|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
57948295|NCT02718755|DRUG|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
57948296|NCT02718755|DRUG|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
57948297|NCT02718755|DRUG|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
57948298|NCT01925690|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
58087073|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
58087074|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
58087075|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
58087076|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
58087077|NCT00256841|DRUG|Chemotherapy|
58087078|NCT00256841|PROCEDURE|Radiation Therapy|
58087079|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
58087080|NCT03529539|DRUG|PSV|
57733296|NCT05403723|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
57948299|NCT01925690|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
58087081|NCT02930538|OTHER|Survey|Completing a survey on RedCap
58087082|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
58087083|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
58087084|NCT06288490|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
58087085|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
58087086|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
58302592|NCT03832283|OTHER|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
58302593|NCT00703300|DRUG|bortezomib|Given IV
57733297|NCT05403723|DRUG|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
58087087|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
58087088|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
58087089|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
58087090|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58087091|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
58302594|NCT00703300|DRUG|decitabine|Given IV
58302595|NCT00703300|OTHER|pharmacological study|Correlative studies
58302596|NCT00703300|OTHER|laboratory biomarker analysis|Optional correlative studies
58302597|NCT03988361|DIAGNOSTIC_TEST|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
58302598|NCT01719380|DRUG|LGX818|
58302599|NCT01719380|DRUG|Cetuximab|
58087092|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
57733298|NCT05403723|DRUG|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
58087093|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
58087094|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
58302600|NCT01719380|DRUG|BYL719|
58302601|NCT03398473|DRUG|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
58302602|NCT03398473|DRUG|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
58302603|NCT00723229|DRUG|acyclovir|Acyclovir 400 mg PO BID for 28 days
57733299|NCT05403723|DRUG|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
58302604|NCT04270812|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
58302605|NCT03675646|DRUG|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
58302606|NCT06308471|OTHER|Baby massage was applied to the intervention group (n=20) of the study|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
57733300|NCT05403723|DEVICE|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
57733301|NCT03719872|DIAGNOSTIC_TEST|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
57733302|NCT03719872|DIAGNOSTIC_TEST|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
57948300|NCT04998435|PROCEDURE|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
58087095|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
58087096|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
58302607|NCT06308471|OTHER|Oral stimulation|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
58302608|NCT05211934|OTHER|No intervention|No intervention
58413188|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
58302609|NCT01710020|DRUG|CP-690,550|CP-690,550 10 mg oral powder for constitution
57733303|NCT06186648|DRUG|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
57733304|NCT02319499|DIETARY_SUPPLEMENT|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
58087097|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
58087098|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
58087099|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
58087100|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
58087101|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
58087102|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
58413189|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
58413190|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
57948301|NCT04998435|PROCEDURE|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
58087103|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
58087104|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
58087105|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
58087106|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
58087107|NCT06537505|DRUG|Adebrelimab|Q3W,IV
58087108|NCT06537505|DRUG|Apatinib|QoD
58087109|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
58302610|NCT05991310|OTHER|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
58302611|NCT05991310|OTHER|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
58302612|NCT04995913|OTHER|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
58413191|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
58413192|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
58413193|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
58413194|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
58413195|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
58413196|NCT03554772|DRUG|Placebo|Oral Solution
58413197|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
58413198|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
58413199|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
58087110|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
58087111|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
58087112|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
58087113|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
58087114|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
58413200|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
58413201|NCT00200538|DRUG|memantine|
58413202|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
57733305|NCT02319499|DIETARY_SUPPLEMENT|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
58087115|NCT00632138|BEHAVIORAL|exercise intervention|
58087116|NCT00632138|OTHER|questionnaire administration|
58302613|NCT02287038|DRUG|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
58413203|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
58413204|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
57733306|NCT02319499|DIETARY_SUPPLEMENT|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
57733307|NCT02319499|OTHER|Placebo|Placebo group received no minerals/vitamin
57733308|NCT02039050|DRUG|Tiotropium|
57733309|NCT02039050|DRUG|Aclidinium|
57733310|NCT04442217|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
57733311|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
57733312|NCT00838110|DRUG|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
57733313|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
57733314|NCT00838110|DRUG|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
57733315|NCT02935062|BEHAVIORAL|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
57733316|NCT02935062|BEHAVIORAL|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
57733317|NCT02935062|BEHAVIORAL|Placebo Therapy|No intervention to improve speech.
57733318|NCT06435871|BEHAVIORAL|Expanded Prostate Cancer Index Composite and Decision Regret Scale|This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
57733319|NCT02628054|BIOLOGICAL|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
57733320|NCT02628054|BIOLOGICAL|Placebo|Saline injection given 7 days apart
57733321|NCT01308749|DRUG|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
58087117|NCT00632138|PROCEDURE|biofeedback|
58087118|NCT00632138|PROCEDURE|management of therapy complications|
58087119|NCT00632138|PROCEDURE|psychosocial assessment and care|
58087120|NCT00632138|PROCEDURE|quality-of-life assessment|
58087121|NCT06543251|OTHER|High-intensity interval training group (HIIT)|The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
58413205|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
58087122|NCT06543251|OTHER|Moderate continuous training group (MCT)|Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
58087123|NCT06543251|OTHER|Sedentary control group (CON)|The control group had normal daily life.
58087124|NCT01902992|DRUG|Depiquick Birch (DPG103)|
58087125|NCT01902992|DRUG|Placebo|
58087126|NCT02288650|OTHER|early refeeding|
58302614|NCT03940833|BIOLOGICAL|BCMA CAR-NK 92 cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
57948302|NCT05214859|BEHAVIORAL|The Dyadic Expressive Arts Group Therapy|This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
58302615|NCT03561454|DEVICE|IORT|Intra-Operative Radiation Therapy
58413206|NCT06115694|DEVICE|TCI Articulating Introducer|use
57733322|NCT01308749|DRUG|Placebo|Placebo Nasal Spray
57733323|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
57948303|NCT06042153|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
57948304|NCT06042153|DRUG|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
57948305|NCT03514628|OTHER|Standard Care|The Valsalva strain will be produced using Standard Care techniques
57948306|NCT03514628|DEVICE|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
57948307|NCT00268489|BIOLOGICAL|bevacizumab|
57948308|NCT00268489|DRUG|pemetrexed disodium|
57948309|NCT00491348|DRUG|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
57948310|NCT01246570|BEHAVIORAL|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
57948311|NCT01246570|OTHER|Control|The patients will receive the usual care provided by the hospitals and the community health services
57948312|NCT05959395|DEVICE|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
57948313|NCT05259371|DRUG|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
58087127|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
58087128|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
58087129|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
58087130|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
58302616|NCT05584995|PROCEDURE|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
58413207|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
58087131|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
58413208|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
58413209|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
58413210|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
58413211|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
58413212|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
58413213|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
58413214|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
57948314|NCT00483561|DRUG|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
57948315|NCT02729142|PROCEDURE|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
57948316|NCT01662674|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
57948317|NCT01662674|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
57948318|NCT03019042|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
57948319|NCT03019042|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
57948320|NCT02334449|DRUG|LML134|LML134 will be administered first as single doses and then as multiple doses
57948321|NCT02334449|DRUG|Placebo|All study cohorts (except food effect cohort) are placebo controlled
57948322|NCT06504537|OTHER|THERAGUN PERCUSSION THERAPY|In Group A, Patients will receive Theragun Percussion therapy along with routine Physical Therapy Treatment. The range of motion of lateral flexion and forward flexion will take by using a bubble inclinometer. Then the patient will place in a sitting position with the shoulder area exposed. Percussion therapy by using the Theragun device will give by a specific order. Treatment will start with the percussion head applied at the origin and insertion heads of the trapezius, Rhomboid and scalene muscle for 3-4 minutes each. Following this the percussive Theragun applicator will applied with circular strokes along the length of the muscle for 3 minutes. The pressure of application will adjust to the subject's tolerance.
57948323|NCT06504537|OTHER|COMPRESSION THERAPY|In Group B, Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks. The cap will store in a freezer (15-18°C). At the onset of the migraine attacks, patients wore the cap and used it. We will choose 25 minutes as the time for application of the gel cap based on the results of two published studies.(23) Headache severity will measured by Visual Analogue Scale and pain relief will measured on a similar scale. Analgesic treatment will not take within 25 minutes after the onset of cold therapy. If patients did not experience adequate relief from the headache, we will allow them to use analgesics 25 minutes after the onset of cold therapy. The routine physical treatment will be same as in group A.
57948324|NCT05648994|BIOLOGICAL|TCR-T cells|patients will be administration of TCR-T cells
57948325|NCT05648994|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
57948326|NCT05648994|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
57948327|NCT05648994|DRUG|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
57948328|NCT05648994|DRUG|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
58087132|NCT02491086|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT
58087133|NCT02491086|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling
58413215|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
58413216|NCT06053957|PROCEDURE|early mobilization|early mobilization program
58413217|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
58413218|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
58413219|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
58413220|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
58413221|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
58087134|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
58087135|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
57948329|NCT00842426|BEHAVIORAL|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
58087136|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
58087137|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
58087138|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
58087139|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
58087140|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
58087141|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
58087142|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
58413222|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
58087143|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
58413223|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
58413224|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
58413225|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
58413226|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
58413227|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
58413228|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
58413229|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
58087144|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
58302617|NCT05584995|PROCEDURE|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
58413230|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
58413231|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
58413232|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
58413233|NCT00081315|DRUG|Amifostine|
58413234|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
58413235|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
57733324|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement + Whey Protein Hydrolysate|Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
58302618|NCT02484014|OTHER|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
57733325|NCT06478147|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate + still water|Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
57948330|NCT00842426|BEHAVIORAL|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
57948331|NCT01775735|DEVICE|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
57948332|NCT02081040|OTHER|Not applicable (observational study with no active intervention)|
57948333|NCT02595476|DRUG|Remifentanil|
57948334|NCT02595476|DRUG|propofol|
57948335|NCT02595476|DEVICE|TCI|
57948336|NCT02595476|PROCEDURE|Tetanic stimulation|
57948337|NCT02595476|DEVICE|Algiscan|Pupillometry
57948338|NCT03886051|PROCEDURE|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
57948339|NCT03886051|PROCEDURE|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
57948340|NCT04168944|DRUG|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
57948341|NCT04168944|DRUG|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
57948342|NCT04168944|DRUG|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
57948343|NCT01227044|DRUG|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
57948344|NCT01227044|OTHER|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
58087145|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
58087146|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
58302619|NCT02484014|OTHER|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
58302620|NCT05325996|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
58302621|NCT05325996|DIAGNOSTIC_TEST|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
58302622|NCT05325996|DIAGNOSTIC_TEST|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
58302623|NCT05325996|DIAGNOSTIC_TEST|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
57733326|NCT02738177|DRUG|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
57733327|NCT02738177|DRUG|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
58302624|NCT03292510|OTHER|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
58087147|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
57948345|NCT05348148|DRUG|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
57948346|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
57948347|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
57948348|NCT06141369|BIOLOGICAL|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
57948349|NCT01443104|DEVICE|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
57948350|NCT01443104|DEVICE|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
57948351|NCT06174623|DEVICE|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
57948352|NCT05290155|DRUG|anti-CD7 CAR-T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
57948353|NCT05699161|GENETIC|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
57948354|NCT06442579|OTHER|Walking on a treadmill|Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.
57948355|NCT01502709|DEVICE|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
57948356|NCT01502709|DEVICE|placebo|Matching placebo device
57948357|NCT03381716|DRUG|drug|Application bracket
57948358|NCT03381716|PROCEDURE|Surgery|Surgery
57948359|NCT01433575|DRUG|RO4917838|10 mg single oral dose
57948360|NCT01433575|DRUG|RO4917838|20 mg single oral dose
57948361|NCT04395664|DEVICE|C3+ Holter Monitor|ECG monitoring
58087148|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
58087149|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
58087150|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
58087151|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
58087152|NCT02776215|DRUG|tasimelteon|Melatonin receptor agonist
58087153|NCT00381667|DRUG|GW642444M|M salt
58087154|NCT00381667|DRUG|GW642444H|H salt
58087155|NCT00381667|OTHER|placebo|placebo
58302625|NCT03292510|OTHER|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
58302626|NCT06059040|PROCEDURE|eliminating gastric residual volume monitoring|eliminating gastric residual volume monitoring from routine care
58413236|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
58413237|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
58413238|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
58413239|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
58413240|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
58413241|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
58413242|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
58413243|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
58087156|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
58087157|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
58087158|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
58087159|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
58087160|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
58087161|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
58087162|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
58087163|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
58087164|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
58087165|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
58087166|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
58087167|NCT04120701|DRUG|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
58087168|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
58087169|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
58087170|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
58087171|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
58087172|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
58087173|NCT00011999|DRUG|cisplatin|
58087174|NCT00011999|DRUG|paclitaxel|
58087175|NCT00011999|PROCEDURE|conventional surgery|
58087176|NCT00011999|RADIATION|radiation therapy|
58087177|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
58087178|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
58087179|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
58087180|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
58087181|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
58087182|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
58087183|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
58087184|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
58087185|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
58087186|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
58087187|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
58087188|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
58087189|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
58087190|NCT06487182|OTHER|reiki|reiki
58087191|NCT06487182|OTHER|placebo reiki|placebo reiki
58087192|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
58087193|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
58087194|NCT02122939|DRUG|Escitalopram|
58087195|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
58087196|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
58087197|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
58087198|NCT06565871|DRUG|Placebo Injection|SC
58087199|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
58413244|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
58413245|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
58413246|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
58413247|NCT00089986|OTHER|Placebo|
58413248|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
58413249|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
58413250|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
58413251|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
58413252|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
58413253|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab：1200mg, iv, q3w capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
57948362|NCT06480916|PROCEDURE|Maternal-fetal transfers|Prospective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for.
57948363|NCT01823042|DRUG|azathioprine+enteral nutrition|
58413254|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
57948364|NCT01823042|DRUG|Azathioprine|
57948365|NCT06306521|GENETIC|BeginNGS Test|Genomic sequencing that screens for over 400 genetic diseases.
57948366|NCT05454371|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
58413255|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
58413256|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
58413257|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
57948367|NCT03723083|DRUG|CC-2001|CC-2001 will be administered orally
57948368|NCT06433609|DRUG|SHR-A1811|Via intravenous infusion
57948369|NCT06433609|DRUG|SHR-A1921|Via intravenous infusion
57948370|NCT06433609|DRUG|Adebrelimab|Via intravenous infusion
57948371|NCT05473403|OTHER|Corticosteroid therapy|Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
57948372|NCT04400812|OTHER|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
57948373|NCT04851587|BEHAVIORAL|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
57948374|NCT01063374|DIETARY_SUPPLEMENT|low glycemic diet instruction|
57948375|NCT01063374|DIETARY_SUPPLEMENT|high cereal fibre diet instruction|
57948376|NCT05144035|DRUG|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
57948377|NCT01952561|DRUG|dapivirine ring|
57948378|NCT02832973|DRUG|Spironolactone|Spironolactone 25 mg
57948379|NCT02832973|DRUG|Furosemide,|Furosemide 20-40 mg
57948380|NCT02832973|DRUG|Amiloride|Amiloride 5 mg
57948381|NCT02832973|DRUG|Ramipril|Ramipril 5-10 mg
57948382|NCT02832973|DRUG|Bisoprolol|Bisoprolol 5-10 mg
58413258|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
58087200|NCT03869905|DRUG|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
58087201|NCT03869905|DRUG|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
58413259|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
58413260|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
58413261|NCT00099229|DRUG|Licarbazepine|
58413262|NCT00297973|PROCEDURE|Blood pressure measurements|
58413263|NCT00297973|PROCEDURE|Blood samples|
58413264|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
58087202|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
58087203|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
58087204|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
58413265|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
58087205|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
58087206|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
58087207|NCT03833934|DIAGNOSTIC_TEST|Plasma Next Generation Sequencing (NGS)|Liquid biospys
58413266|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
58413267|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
58413268|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
58413269|NCT00906451|DRUG|Simvastatin|Simvastatin
58413270|NCT01357876|OTHER|Metformin|withdrawral
58413271|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
58413272|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
58413273|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
58087208|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
58087209|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
58087210|NCT00886873|DRUG|Mifepristone|
58087211|NCT02157181|DRUG|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
58087212|NCT06159699|OTHER|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
58087213|NCT06159699|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
58413274|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
58413275|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
58413276|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
58413277|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
58413278|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
58413279|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
58087214|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
58087215|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
58087216|NCT00163371|DRUG|Ciclesonide|
58087217|NCT04512105|DRUG|Pitavastatin|Given PO
58087218|NCT04512105|DRUG|Venetoclax|Given PO
58087219|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
58413280|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
57733328|NCT02738177|DRUG|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
57733329|NCT00157326|DRUG|tadalafil|
57948383|NCT06090214|DIAGNOSTIC_TEST|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
57948384|NCT02909075|DEVICE|PET/CT scans|
57948385|NCT02909075|DEVICE|MRI|
57948386|NCT02093013|OTHER|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
57948387|NCT01441479|DEVICE|In Vitro Diagnostic Device aid in diagnosing|
57948388|NCT04075474|DEVICE|silver diamine fluoride|38% SDF on primary upper anterior teeth
57948389|NCT04075474|DEVICE|sodium fluoride|5% NaF on primary upper anterior teeth
57948390|NCT00120991|PROCEDURE|Coronary artery bypass grafting|
57948391|NCT02813694|DRUG|lefamulin|antibacterial agent
57948392|NCT02813694|DRUG|Moxifloxacin|antibacterial agent
58087220|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
58087221|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
58087222|NCT03606109|DRUG|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
57948393|NCT00442780|DRUG|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
57948394|NCT00442780|DRUG|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
57948395|NCT03832491|OTHER|Home based therapy|Airway clearence techniques
57948396|NCT03832491|OTHER|Game and home based therapy|Game based approach programme and airway clearence techniques
57948397|NCT03912675|PROCEDURE|Integra® dermal substitute and RigeneraTM protocol|Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
57948398|NCT06072326|DRUG|Sotagliflozin|200 mg/day as a tablet
57948399|NCT06072326|DRUG|Ambrisentan|2.5 mg/day as a tablet
58413281|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
58413282|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
58413283|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
58413284|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
58087223|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
58087224|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
58413285|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
58413286|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
58413287|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
58413288|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
58413289|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
58087225|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
58087226|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
58087227|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
58087228|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
58087229|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
58087230|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
58087231|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
58087232|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
58087233|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
58087234|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
58087235|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
58087236|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
58087237|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
58087238|NCT00682097|DRUG|RO4998452|Escalating oral doses
58087239|NCT00682097|DRUG|placebo|Oral doses
58087240|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
58087241|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
58087242|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
58413290|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
58413291|NCT00183963|DRUG|Tamoxifen|20mg
58413292|NCT00183963|DRUG|Fulvestrant|250mg
58413293|NCT00183963|DRUG|Fulvestrant|500 mg IM
58413294|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
58087243|NCT00036556|DRUG|Atrasentan|
58087244|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
58087245|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
58087246|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
58087247|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
58413295|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
58087248|NCT00423501|DRUG|Placebo|sc weekly
58087249|NCT00423501|DRUG|taspoglutide|20mg sc weekly
58413296|NCT02372708|DRUG|dinitrophenyl(DNP)|
57948400|NCT06072326|DRUG|Ambrisentan and Sotagliflozin|2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet
58087250|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
58087251|NCT00423501|DRUG|taspoglutide|5mg sc weekly
58087252|NCT00423501|DRUG|taspoglutide|10mg sc weekly
57948401|NCT05279144|OTHER|Ventroguleal|Vastus Lateralis
57948402|NCT03521024|OTHER|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
58087253|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
57948403|NCT03521024|OTHER|lithium disilicate|well documented in the literatures as successful restoration modality.
57948404|NCT02511730|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
58087254|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
58302627|NCT03220308|OTHER|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
58413297|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
58413298|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
57948405|NCT02511730|DEVICE|FFDM|FujiFilm Aspire Cristalle System
58087255|NCT06450522|OTHER|Usual care|Usual care
58087256|NCT02353572|DRUG|Melphalan|Given IV
58087257|NCT02353572|DRUG|Bortezomib|Given IV
58087258|NCT02353572|DRUG|Dexamethasone|Given IV
58087259|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
58087260|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
58087261|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
58413299|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
58413300|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
58413301|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
58087262|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
58087263|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
58302628|NCT03220308|OTHER|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
58302629|NCT01668836|DRUG|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
58302630|NCT01668836|BEHAVIORAL|Caloric restriction|Diet of 1000kcal per day for 30 days
58413302|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
58413303|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
58413304|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
58087264|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
58087265|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
58087266|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
58087267|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
57733330|NCT05116163|BEHAVIORAL|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
58087268|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
58087269|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
58087270|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
58087271|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
58302631|NCT02970955|PROCEDURE|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
58087272|NCT05372211|OTHER|not use of any intervention|not use of any intervention
58302632|NCT00903643|OTHER|Physical examination|Physical examination and multiple questionnaires will be administered
58302633|NCT05022498|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
58302634|NCT04541355|DRUG|Cisplatin|Given IV
58302635|NCT04541355|OTHER|Hearing Handicap Inventory for Adults - Screening|Patient self-assessment questionnaire to measure probability of hearing impairment
58302636|NCT04541355|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to the standard of care
58302637|NCT04541355|DRUG|Sodium Thiosulfate|Given IV
58302638|NCT03485443|DRUG|%0.9 NaCl 10ml/kg|Fluid administration
58302639|NCT03485443|DRUG|%0.9 NaCl 20ml/kg|Fluid administration
58302640|NCT03854578|DRUG|BI 1358894|Film-coated tablet
58302641|NCT03854578|DRUG|Placebo matching BI 1358894|Film-coated tablet
58302642|NCT03854578|DRUG|Citalopram|Film-coated tablet
58302643|NCT01455870|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
58302644|NCT01455870|DRUG|sitagliptin|oral sitagliptin 100 mg/day
58302645|NCT03904823|DRUG|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
58302646|NCT03904823|DRUG|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
58302647|NCT06279078|DRUG|Corticosteroid|oral/inhaled corticosteroid
58413305|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
58413306|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
58413307|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
58413308|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
58413309|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
58413310|NCT00000630|BIOLOGICAL|HIVAC-1e|
58413311|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
58413312|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
58413313|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
58413314|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
58413315|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
58413316|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
58413317|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
58413318|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
58413319|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
58413320|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
58413321|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
58087273|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
58087274|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
58302648|NCT02603198|DRUG|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
58413322|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
58413323|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
58413324|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
58087275|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
58302649|NCT02603198|DRUG|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
58302650|NCT06404437|DIAGNOSTIC_TEST|Auscultation|Auscultation at five auscultation points using a digital stethoscope and a smartphone
58413325|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
58413326|NCT00099294|DRUG|Glufosfamide|
58413327|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
58302651|NCT02505958|OTHER|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.
58087276|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
58087277|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
58302652|NCT02505958|OTHER|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
58302653|NCT01739140|BEHAVIORAL|Yoga|
58413328|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
58413329|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
58413330|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
58413331|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
58413332|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
58413333|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
58413334|NCT02001896|DRUG|erlotinib|
58413335|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
58413336|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
58413337|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
58087278|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
58413338|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
58413339|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
58413340|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
58413341|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
58413342|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
58413343|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
58413344|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
58413345|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
58413346|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
58413347|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
58413348|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
58413349|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
58413350|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
58413351|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
58413352|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
58413353|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
58413354|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
58413355|NCT00533650|DRUG|MK0429|
58413356|NCT00000504|DRUG|encainide|
58413357|NCT00000504|DRUG|moricizine|
58413358|NCT00000504|DRUG|flecainide|
58413359|NCT00000504|DRUG|imipramine|
58413360|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
58413361|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
58413362|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
58413363|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
58413364|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
58413365|NCT02270762|OTHER|Rest in bed|
58413366|NCT02270762|OTHER|Passive verticalization|
58413367|NCT02270762|OTHER|Rest in bed|
58413368|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
58413369|NCT00912080|GENETIC|genomic signature|genomic signature analysis
58413370|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
58413371|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
58413372|NCT03254277|DRUG|Placebo|Placebo
58413373|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
58413374|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
58413375|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
58413376|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
58413377|NCT04218162|DRUG|Placebo|Placebo
58413378|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
58413379|NCT02010736|OTHER|Single treadmill gait training with additional loading|
58413380|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
58413381|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
58087279|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
58302654|NCT05846750|DRUG|Obinutuzumab|"Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression"
58413382|NCT04194918|OTHER|Text Message|Receive text messages
58413383|NCT04194918|OTHER|Handout|Receive handouts via email
58413384|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
58302655|NCT05846750|DRUG|lenalidomide|"Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression"
58413385|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
58413386|NCT04194918|OTHER|Survey Administration|Ancillary studies
58413387|NCT03270267|OTHER|Questionnaires|
58413388|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
58413389|NCT01289223|DRUG|Bendamustine IV|
58413390|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
58413391|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
58413392|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
58413393|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
58413394|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
58413395|NCT05962034|OTHER|Placebo|placebo capsule
58413396|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
58413397|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
58413398|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
58413399|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
58413400|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
58413401|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
58413402|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
58302656|NCT01836068|DRUG|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
58302657|NCT01100502|DRUG|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
58302658|NCT01100502|DRUG|placebo|Every 21 days by IV infusion
58302659|NCT01738100|DRUG|Ticagrelor|
58302660|NCT01738100|DRUG|Clopidogrel|
58302661|NCT01738100|DRUG|Morphine Sulfate|
58302662|NCT01738100|DRUG|Saline|
58302663|NCT04346953|BEHAVIORAL|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
58413403|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
58413404|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
58413405|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
58413406|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
58413407|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
58302664|NCT03687983|DEVICE|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
58302665|NCT03042845|DEVICE|Tiger cardiac catheter|Tiger cardiac catheter
58302666|NCT03042845|DEVICE|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
58302667|NCT06138197|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted hysterectomy following usual surgical technique
58302668|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
58302669|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
58302670|NCT00413023|DRUG|GW679769|
58302671|NCT01418339|DRUG|Aripiprazole|Aripiprazole tablet administered orally once a week.
58302672|NCT01418339|DRUG|Placebo|Aripiprazole-matching placebo tablet administered orally once a week.
58302673|NCT06138210|DRUG|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
58302674|NCT06138210|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
58302675|NCT01019161|DRUG|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
58413408|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
58413409|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
58413410|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
58302676|NCT01019161|DRUG|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
58302677|NCT06282991|DRUG|Lorlatinib|ALK/ROS1 tyrosine kinase inhibitor
58302678|NCT03037515|DRUG|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
58302679|NCT04217291|DRUG|SY-004|Take orally once a day
58302680|NCT04217291|OTHER|SY-004 matching placebo|Take orally once a day
58302681|NCT00125450|PROCEDURE|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
58302682|NCT00125450|PROCEDURE|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
58413411|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
58413412|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
57733331|NCT05116163|OTHER|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
58302683|NCT02207062|DRUG|Ibrutinib|Given PO
58302684|NCT02207062|OTHER|Laboratory Biomarker Analysis|Correlative studies
58302685|NCT03481452|BEHAVIORAL|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
58302686|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
58302687|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
58302688|NCT01195779|BIOLOGICAL|Fluarix™|Intramuscular injections
58302689|NCT01256528|PROCEDURE|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
58413413|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
58413414|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
58087280|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
58087281|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
58087282|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
58087283|NCT01915485|RADIATION|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
58087284|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
58087285|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
58087286|NCT02504060|DRUG|Starch Placebo|
58087287|NCT02504060|DRUG|N-acetyl-D-glucosamine|
58302690|NCT04125069|PROCEDURE|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
58302691|NCT01746719|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
58302692|NCT01746719|DRUG|Etodolac|500 mg tablet once a day
58302693|NCT06424808|OTHER|Consolidating content on a single website and providing access to it via QR codes in a brochure format|The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
58302694|NCT02147171|DIETARY_SUPPLEMENT|VisionAce|
58302695|NCT02147171|DIETARY_SUPPLEMENT|Placebo|
58302696|NCT01320397|DRUG|Rostafuroxin|6 microgram capsules
58302697|NCT01320397|DRUG|Rostafuroxin|50 micrograms capsules
58302698|NCT01320397|DRUG|Rostafuroxin|500 micrograms capsules
58302699|NCT01320397|DRUG|Losartan|Losartan 50 mg once a day
58302700|NCT05146752|DEVICE|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
58302701|NCT05146752|OTHER|routine care|routine care
58302702|NCT00215917|DRUG|D-serine 2100 mg daily|
58302703|NCT06122350|BEHAVIORAL|Earthquake preparedness training|Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
58302704|NCT03874793|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
57733332|NCT01713413|DEVICE|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
57733333|NCT01713413|DEVICE|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
58087288|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
58087289|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
58087290|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
58302705|NCT03874793|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
58087291|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
58087292|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
58087293|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
58087294|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
58413415|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
58413416|NCT01617135|DRUG|CVT-301|
58413417|NCT01617135|DRUG|Placebo|
58413418|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
58413419|NCT01617135|DRUG|CVT-301|
58413420|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
58413421|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
58413422|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
58413423|NCT05551975|OTHER|Control Product|Fed from Study Day 1
58413424|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
58413425|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
58413426|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
58413427|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
58413428|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
58413429|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
58413430|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
58413431|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
58087295|NCT00000868|BIOLOGICAL|MF59|
58087296|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
58413432|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
58087297|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
58087298|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
58087299|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
58087300|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
58087301|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
58087302|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58413433|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
58413434|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
58413435|NCT05786339|DRUG|Tested Irbesartan Tablet|T
58413436|NCT05786339|DRUG|Reference Irbesartan Tablet|R
58413437|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
58413438|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
58413439|NCT00137696|PROCEDURE|Collection of serum|
57948406|NCT06475417|DRUG|Adebrelimab combined with DOS|After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR
58302706|NCT06144515|PROCEDURE|Blood test|"Blood is collected in order to perform in vitro research:~1. If a routine blood test is performed for clinical tests, the sponsor will receive the results of the Complete blood count (CBC) and an additional blood sample from the same puncture of 20ml to maximum 40ml will be collected for this study.~2. If no routine blood test is performed for clinical tests, a CBC will be performed for the study and an additional blood sample of 20ml to maximum 40ml will be collected.~Additional Bone marrow (BM) material will be obtained from the same puncture performed for routine clinical tests:"
58302707|NCT01348126|DRUG|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
58302708|NCT01348126|DRUG|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
58302709|NCT04587817|COMBINATION_PRODUCT|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
58302710|NCT03767842|DEVICE|Visor System|Subjects are monitored one time with the Visor System.
58302711|NCT02280330|DIETARY_SUPPLEMENT|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
58302712|NCT02280330|OTHER|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
58302713|NCT06114680|DEVICE|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
58302714|NCT06114680|DEVICE|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
58302715|NCT06420531|BIOLOGICAL|Human milk|maternal breastmilk or donor breastmilk
58302716|NCT01611675|DRUG|Vemurafenib|take orally, twice daily
58302717|NCT01611675|DRUG|Leflunomide|take orally, once daily
58302718|NCT04794257|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
58302719|NCT01285843|PROCEDURE|Anterior Minimally Invasive Approach (AMIS)|
58302720|NCT05324306|DEVICE|combat application tourniquets (CAT)|"CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities."
58302721|NCT01719250|DRUG|Buparlisib|Given PO
58302722|NCT01719250|OTHER|Laboratory Biomarker Analysis|Correlative studies
58302723|NCT01719250|OTHER|Questionnaire Administration|Ancillary studies
58302724|NCT05558397|DEVICE|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
58302725|NCT05558397|DRUG|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
58302726|NCT01143285|OTHER|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
58302727|NCT02991391|OTHER|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
58302728|NCT05747066|OTHER|No intervention|No intervention
58413440|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
58413441|NCT00321997|DRUG|Pegaptanib sodium|
58413442|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
58413443|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
58413444|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
58413445|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
58087303|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
58087304|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
58087305|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
58087306|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
58087307|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
58087308|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
58413446|NCT04840563|DEVICE|Precision1|Precision1
58413447|NCT02252601|OTHER|HFDT test|
58413448|NCT02252601|OTHER|Pure tone Audiogram|
58413449|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
57948407|NCT03227900|DRUG|Lidocaine|Intragastric infusion of lidocain
57948408|NCT03227900|DRUG|Placebos|Intragastric infusion of water for injections
57948409|NCT05959135|DEVICE|Gastric ultrasonography|"It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies"
57948410|NCT04751890|BEHAVIORAL|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
57948411|NCT04751890|BEHAVIORAL|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
57948412|NCT05501561|BIOLOGICAL|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57948413|NCT05501561|BIOLOGICAL|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
58087309|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
58087310|NCT00408135|DRUG|telithromycin (HMR3647)|
58087311|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
58087312|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
58087313|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
58087314|NCT01924572|PROCEDURE|cord milking|
58413450|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
57948414|NCT05501561|BIOLOGICAL|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57948415|NCT05501561|BIOLOGICAL|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57948416|NCT01246583|DRUG|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
58087315|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
58087316|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
58087317|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
58087318|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
58087319|NCT00075465|DRUG|docetaxel|
58087320|NCT00075465|DRUG|epirubicin hydrochloride|
58087321|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
58087322|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
58413451|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
58413452|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
58413453|NCT02146677|OTHER|Osteopathic manipulative treatment|
58413454|NCT02146677|OTHER|Sham therapy|
58413455|NCT02146677|OTHER|Usual care|
58413456|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
58413457|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
58413458|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
58087323|NCT00448110|DRUG|placebo|placebo
58087324|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
58087325|NCT01901393|DRUG|IV ibuprofen|
58413459|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
58413460|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
58413461|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
57733334|NCT06204549|OTHER|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
57948417|NCT01246583|DRUG|Vehicle 1|Vehicle 1 twice daily for 4 weeks
58087326|NCT01901393|DRUG|Ketorolac|
58087327|NCT00245258|DRUG|Sildenafil Citrate|
58087328|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
58087329|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
58087330|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
58087331|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
58087332|NCT00170898|DRUG|Lumiracoxib|
58302729|NCT04503317|DEVICE|active acupuncture low level laser in addition to nasal laser irradiation|laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
58302730|NCT04503317|OTHER|treadmill exercise|aerobic exercise once per day, 3 times per week for three months
58413462|NCT01650714|OTHER|Full thickness gastric biopsy|
58413463|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
58413464|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
58413465|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
58413466|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
58413467|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
58413468|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
58413469|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
58087333|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
58087334|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
58087335|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
58413470|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
58413471|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
58413472|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
58413473|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
58413474|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
58413475|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
58413476|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
57948418|NCT01246583|DRUG|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
57948419|NCT01246583|DRUG|Vehicle 2|Vehicle 2 twice daily for 4 weeks
58413477|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
58413478|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
58413479|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
58413480|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
58413481|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
58413482|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
58413483|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
58413484|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
58413485|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
58413486|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
58413487|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
58413488|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
58413489|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
58413490|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
58413491|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
58413492|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
58413493|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
58413494|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
58413495|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
58413496|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
58413497|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
58413498|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
58413499|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
58087336|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
58413500|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
58413501|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
58413502|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
58413503|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
58413504|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
58413505|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
58087337|NCT00745459|DRUG|NPO-11|20 mL NPO-11
58087338|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
58087339|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
58087340|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
58087341|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
58087342|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
58087343|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
58087344|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
58087345|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
58413506|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
58413507|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
58413508|NCT03417596|OTHER|Control|Routine treatment
58413509|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
58413510|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
58413511|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
57733335|NCT06000046|DEVICE|Automatic image analysis|After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).
58087346|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
58413512|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
58413513|NCT01041443|DRUG|tetrahydrouridine|Given IV
58413514|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
58087347|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
58087348|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
58087349|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
58087350|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
58087351|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
58087352|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
58087353|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
58087354|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
58087355|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
58087356|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
58087357|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
58087358|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
58087359|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
58087360|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
58087361|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
58087362|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
58087363|NCT04611152|DRUG|KSI-301|Intravitreal Injection
58087364|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
58087365|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
58087366|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
58087367|NCT04450316|DRUG|Placebo|1 tab nightly
58087368|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
58087369|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
58087370|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
58087371|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
58087372|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
58087373|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
58087374|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
58087375|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
58087376|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
58087377|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
58087378|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
58087379|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
58087380|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
58087381|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
58302731|NCT04091165|OTHER|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
58087382|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
58087383|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
58087384|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
58087385|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
58087386|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
58413515|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
58413516|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
58087387|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
58087388|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
58087389|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
58087390|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
58087391|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
58413517|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
58087392|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
58087393|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
58087394|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
58087395|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
58087396|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
58087397|NCT02902107|DEVICE|CivaSheet|
58087398|NCT02902107|RADIATION|Brachytherapy|
58087399|NCT02902107|PROCEDURE|surgical resection|
58087400|NCT00171080|DRUG|valsartan|
58087401|NCT00171080|DRUG|irbesartan|
58087402|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
58087403|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
58087404|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
58087405|NCT00306124|DRUG|Levodopa|
58087406|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
58302732|NCT05030844|BEHAVIORAL|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
58302733|NCT00644761|DRUG|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
58302734|NCT03092752|DRUG|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
58302735|NCT04474340|DRUG|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
58413518|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
58087407|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
58087408|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
58087409|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
58087410|NCT01615822|DRUG|Placebo|
58087411|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
58413519|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
58413520|NCT00221624|DRUG|Peginterferon alfa-2a|
58413521|NCT00221624|DRUG|ribavirin|
58413522|NCT00221624|DRUG|amantadine|
58087412|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
58087413|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
58087414|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
58087415|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
58087416|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
58087417|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
58302736|NCT02873767|DRUG|PR1|"* Active substance: UCB4019~* Route of Administration: subcutaneously"
58413523|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
58413524|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
58413525|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
58413526|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
58413527|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
58413528|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
58413529|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
58413530|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
58413531|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
58413532|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
58413533|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
58413534|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
58413535|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
58413536|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
58413537|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
58413538|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
58413539|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
57733336|NCT04485962|BIOLOGICAL|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
57733337|NCT00328419|DEVICE|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
57733338|NCT00328419|DEVICE|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
58087418|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
58087419|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
58302737|NCT02873767|OTHER|PL1|"* Active substance: Placebo~* Concentration: 0.9 % saline~* Route of Administration: subcutaneously"
58302738|NCT02976519|DRUG|BI 443651|twice daily
58302739|NCT02976519|DRUG|Placebo|twice daily
58302740|NCT02267941|OTHER|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
58302741|NCT02464124|DRUG|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
58302742|NCT02464124|DRUG|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
58302743|NCT02501824|OTHER|anthroposophic therapeutic speech|anthroposophic therapeutic speech
58413540|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
58413541|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
58413542|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
58413543|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
58413544|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
58413545|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
58413546|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
58413547|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
58413548|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
58413549|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
58413550|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
58413551|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
58302744|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
58413552|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
58413553|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
58087420|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
58302745|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
58413554|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
58413555|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
58413556|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
57948420|NCT02577146|DEVICE|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
57948421|NCT00476411|BIOLOGICAL|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
57948422|NCT02448602|OTHER|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
57948423|NCT02448602|OTHER|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
57948424|NCT02448602|OTHER|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
57948425|NCT02167750|OTHER|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
57948426|NCT02255422|DRUG|Omaveloxolone capsules, 2.5 mg|
57948427|NCT02255422|DRUG|omaveloxolone capsules, 5 mg|
57948428|NCT02255422|DRUG|omaveloxolone capsules, 10 mg|
57948429|NCT02255422|DRUG|Placebo capsules|
57948430|NCT02255422|DRUG|omaveloxolone capsules, 20 mg|
57948431|NCT02255422|DRUG|omaveloxolone capsules, 40 mg|
57948432|NCT02255422|DRUG|omaveloxolone capsules, 80 mg|
57948433|NCT02255422|DRUG|omaveloxolone capsules, 160 mg|
58413557|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
58413558|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
57948434|NCT02238275|DRUG|Micardis® plus|
57948435|NCT01392534|DRUG|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
57948436|NCT01389167|DRUG|Vivitrol|An extended release naltrexone formulation for intramuscular injection
57948437|NCT01389167|DRUG|Naltrexone (oral)|Naltrexone 50 mg pills, daily
57948438|NCT01389167|BEHAVIORAL|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
57948439|NCT01389167|BEHAVIORAL|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
58413559|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
58413560|NCT01829282|BEHAVIORAL|Risk Reduction|
58413561|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
58087421|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
58087422|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
58087423|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
58087424|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
58087425|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
58413562|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
57733339|NCT03065894|OTHER|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
57733340|NCT03065894|OTHER|Current Care in Family Medicine|Patient education, medication management
57733341|NCT06503276|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm
57733342|NCT06503276|RADIATION|Ultra-low dose radiotherapy|2 Gy radiotherapy will be administerd twice in the first cycle
57733343|NCT01304836|DRUG|Advagraf|oral
57733344|NCT01304836|DRUG|Mycophenolate Mofetil|oral
57733345|NCT01304836|DRUG|Simulect|IV
57733346|NCT01304836|DRUG|Corticosteroids|IV \& oral
57948440|NCT00234689|DRUG|Naltrexone|
57948441|NCT03910829|BEHAVIORAL|Action Observation|Action observation training
57948442|NCT03910829|BEHAVIORAL|Motor Imagery|Motor imagery protocol
57948443|NCT03910829|BEHAVIORAL|Placebo Action Observation|Placebo Action Observation
57948444|NCT04156971|DIETARY_SUPPLEMENT|Omega 3|
57948445|NCT04156971|BEHAVIORAL|stage-based lifestyle modification intervention|
57948446|NCT03332823|BEHAVIORAL|SME Ambassadors training & program|"* Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
57948447|NCT01079897|DEVICE|Atopiclair|topical applied cream, twice daily
57948448|NCT01079897|DEVICE|EHK02-01|topical applied cream containing 7% ectoine
58087426|NCT02423564|OTHER|Placebo|
58087427|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
58087428|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
58087429|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
57733347|NCT04045392|BEHAVIORAL|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
57733348|NCT02374827|PROCEDURE|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
57733349|NCT02374827|PROCEDURE|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
57733350|NCT02539264|OTHER|Smoking|Influence of smoking on parameters derived from overnight PSG
58087430|NCT00989365|OTHER|Aerobic training|Treadmill training
58087431|NCT01903213|DRUG|bixalomer|Oral
58087432|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
58087433|NCT02753608|OTHER|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
58087434|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
58302746|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
58302747|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
58302748|NCT05116436|PROCEDURE|Blood sample|It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
58302749|NCT05116436|PROCEDURE|Spine X-ray|To determine the scoliosis
58302750|NCT04355364|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
58302751|NCT04355364|PROCEDURE|standard procedure|Patients will receive the usual care in accordance with good practice.
58302752|NCT05918536|DIAGNOSTIC_TEST|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
58302753|NCT00344058|DRUG|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
58302754|NCT05676229|DIETARY_SUPPLEMENT|Probiotic blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
58302755|NCT05676229|DIETARY_SUPPLEMENT|Placebo|Maltodextrin only (vehicle)
58302756|NCT03113045|OTHER|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
58302757|NCT03017092|BEHAVIORAL|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
58302758|NCT01582113|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
57733351|NCT02539264|OTHER|Obesity|Influence of obesity on parameters derived from overnight PSG
57733352|NCT02539264|OTHER|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
57733353|NCT01664078|DEVICE|Endovascular AAA repair with InCraft®|
58302759|NCT01582113|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
58302760|NCT04643132|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
58302761|NCT04643132|DRUG|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
58302762|NCT04643132|DRUG|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
58302763|NCT04722107|DRUG|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
58302764|NCT05883696|OTHER|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~1. Assessments of palliative care needs~2. Initiating palliative care 2D. End of life care.~3. After death. In this study only the first part of the S-PCG will be used."
58302765|NCT01541709|DRUG|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
57948449|NCT03045770|DRUG|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
57948450|NCT03045770|DRUG|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
58302766|NCT03663270|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
58302767|NCT05911217|DRUG|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
58302768|NCT06107114|DRUG|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
58302769|NCT06107114|DRUG|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
58302770|NCT06107114|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
58302771|NCT06107114|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
58302772|NCT00617552|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
58302773|NCT00617552|DRUG|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
58302774|NCT00617552|DRUG|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
58302775|NCT00617552|DRUG|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
58302776|NCT00617552|DRUG|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
58302777|NCT00617552|DRUG|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
58302778|NCT00617552|DRUG|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
58302779|NCT00617552|DRUG|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
58302780|NCT02408848|OTHER|Observational|This is an observational study. There is no intervention.
58302781|NCT03017807|BIOLOGICAL|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
58302782|NCT04500808|DRUG|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
58413563|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
57948451|NCT03045770|DRUG|Irinotecan|Irinotecan was used as first line treatment with AGC.
57948452|NCT03045770|DRUG|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
57948453|NCT03045770|DRUG|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
57948454|NCT03891173|DRUG|L-DOS47|L-DOS47 lyophilized powder reconstituted and diluted for iv injection
57948455|NCT03891173|DRUG|Cisplatin|Cisplatin concentrate for solution for iv infusion
57948456|NCT03891173|DRUG|Vinorelbine|Vinorelbine concentrate for solution for iv infusion
57948457|NCT02281643|DRUG|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
57948458|NCT01841242|DRUG|alcoholic povidone iodine|
57948459|NCT01841242|DRUG|alcoholic chlorhexidine|
58302783|NCT04500808|DRUG|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
58302784|NCT04500808|DRUG|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
58302785|NCT04500808|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
58302786|NCT03209479|DRUG|Glatiramer acetate|Copaxone subcutaneous injection syringe
58413564|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
58413565|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
58413566|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
57948460|NCT03831841|BEHAVIORAL|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
58413567|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
58413568|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
58413569|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
58413570|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
58413571|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
58413572|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
57948461|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
57948462|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
57948463|NCT00695448|DRUG|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
58302787|NCT03939104|DRUG|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
58413573|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
58413574|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
58413575|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
58413576|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
58413577|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
58413578|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
58413579|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
58413580|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
58413581|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
58413582|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
58413583|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
58413584|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
58413585|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
58413586|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
58413587|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
58413588|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
58413589|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
58413590|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
58413591|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
58413592|NCT04720768|DRUG|Binimetinib|MEK inhibitor
58413593|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
58413594|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
58413595|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
58413596|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
58302788|NCT03939104|DRUG|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
58087435|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
58302789|NCT03939104|DRUG|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
58302790|NCT03939104|DRUG|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
58302791|NCT01284894|DEVICE|Conventional manometry|Conventional esophageal manometry
58302792|NCT01284894|DEVICE|High resolution manometry|High resolution esophageal manometry
58302793|NCT04654741|DRUG|Medroxyprogesterone Acetate|1 pill per day
58302794|NCT04654741|DRUG|Ganirelix Acetate|1 injection per day
58302795|NCT02062138|OTHER|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
58302796|NCT02062138|OTHER|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
58302797|NCT02062138|OTHER|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
58302798|NCT00738712|PROCEDURE|MRI Magnetic Resonance Imaging|MRI
58302799|NCT03619473|BEHAVIORAL|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~* proper helmet wearing~* how to differentiate non-standard and standard helmets~* how to keep motorcycle safe using ABCD concept~* importance of wearing bright clothes~* police summon for not wearing helmets~* live demo on poor performance of non-standard helmet~* giving away standard motorcycle child safety helmets~* oath taking by parents and children~* distribution and placement of VEM on parents' motorcycles"
58302800|NCT01618968|DRUG|MTX|"* Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
58302801|NCT00828711|DRUG|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
58302802|NCT00828711|DRUG|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
58302803|NCT00828711|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
58413597|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
58413598|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
58413599|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
58413600|NCT00334906|DRUG|memantine HCl|
58413601|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
58413602|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
58413603|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
58413604|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
57948464|NCT04577950|PROCEDURE|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
58302804|NCT04264572|OTHER|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
58302805|NCT04264572|BEHAVIORAL|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
58302806|NCT03817606|DEVICE|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
58302807|NCT03817606|DEVICE|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
58302808|NCT05898035|PROCEDURE|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
58302809|NCT03961867|DRUG|Docetaxel|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
58302810|NCT03961867|DRUG|Oxaliplatin|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
58302811|NCT01856738|DRUG|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
58302812|NCT01856738|DRUG|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
58302813|NCT05015036|PROCEDURE|ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
58302814|NCT05015036|PROCEDURE|Minimally invasive surgery|Classic Minimally invasive surgery of the lumbar spine
58302815|NCT02630862|DRUG|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
58302816|NCT02630862|DRUG|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
58302817|NCT05294861|OTHER|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
58302818|NCT05294861|OTHER|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
58302819|NCT03508778|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
58302820|NCT03508778|DEVICE|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
58302821|NCT03508778|PROCEDURE|Cataract surgery|Cataract surgery per investigator's standard practice
58302822|NCT02097498|OTHER|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
58302823|NCT02097498|OTHER|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
58413605|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
58413606|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
58413607|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
58413608|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
58413609|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
58413610|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
58413611|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
58413612|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
58413613|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
58413614|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
58413615|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
58413616|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
58413617|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
58413618|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
58413619|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
58413620|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
58413621|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
58413622|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
58413623|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
58413624|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
58413625|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
58413626|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors... Endoscopy 2012; 44: 231-235)"
58413627|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
58413628|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
58413629|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
57785016|NCT02694003|BEHAVIORAL|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
58413630|NCT01341301|DRUG|Cyclophosphamide|Given IV
58413631|NCT01341301|DRUG|Tacrolimus|Given IV or PO
58413632|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
58413633|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
58087436|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
58087437|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
58413634|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
58413635|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
58413636|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
58413637|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
58413638|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
58413639|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
58413640|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
58413641|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
58413642|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
58413643|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
58413644|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
58413645|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
58413646|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
58413647|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
58413648|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
58413649|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
58413650|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
57785017|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
57785018|NCT01033396|DRUG|Allegra|Fexofenadine single dose 60 mg
57785019|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
58413651|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
58413652|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
58413653|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
58413654|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
58413655|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
58413656|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
58413657|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
58413658|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
58413659|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
58413660|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
58413661|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
58413662|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
58413663|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
58413664|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
58413665|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
58413666|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
58413667|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
58413668|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
58413669|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
58413670|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
58413671|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
58413672|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
58413673|NCT03224403|DRUG|Placebo|2 placebo caplets
58413674|NCT00050973|DRUG|bexarotene|
58087438|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
58087439|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
58413675|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
58413676|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
57785020|NCT01033396|DRUG|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
57785021|NCT01033396|DRUG|Placebo|Placebo single dose
57785022|NCT02239653|BEHAVIORAL|Physician communication|
57785023|NCT04349111|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
57948465|NCT03199820|DEVICE|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
57948466|NCT03199820|DRUG|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
57948467|NCT03119909|OTHER|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
57948468|NCT03119909|OTHER|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
57948469|NCT03119909|OTHER|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
57948470|NCT03119909|OTHER|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
57948471|NCT03119909|OTHER|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
57948472|NCT03119909|OTHER|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
57948473|NCT04234906|DRUG|Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
58087440|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
58087441|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
57785024|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
57785025|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
57948474|NCT04234906|DRUG|Magnesium Sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
57948475|NCT04234906|DRUG|Amiodarone|I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
57948476|NCT04234906|DRUG|Procainamide|IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
57948477|NCT02817321|PROCEDURE|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
57948478|NCT02817321|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
57948479|NCT02817321|DEVICE|PAJUNK Contiplex S Catheter|
57948480|NCT02817321|DRUG|single dose ropivacaine|"* 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed"
57948481|NCT02817321|DRUG|continuously infusion of ropivacaine|"* 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose"
57948482|NCT02817321|DRUG|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
58087442|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
58087443|NCT00568516|DRUG|ASP3550|subcutaneous administration
58087444|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
58087445|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
58087446|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
58087447|NCT04420000|OTHER|Control|Treatment as usual
58413677|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
58087448|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
58087449|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
58413678|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
58413679|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
57785026|NCT03100838|DRUG|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
57785027|NCT03100838|DEVICE|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
58087450|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
58087451|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
58087452|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
58087453|NCT03311386|DRUG|Actilyse|thrombolytic therapy
58087454|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
58087455|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
58087456|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
58087457|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
58087458|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
58087459|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
58087460|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
58413680|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
58413681|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
58413682|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
58413683|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
58413684|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
58413685|NCT01933126|DRUG|HCG injection|
58413686|NCT01933126|DRUG|Placebo|
58087461|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
58087462|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
58302824|NCT03776448|DIETARY_SUPPLEMENT|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
58302825|NCT03776448|DIETARY_SUPPLEMENT|Activated Charcoal Softgels|This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
58302826|NCT04892069|DRUG|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
58302827|NCT00598728|BEHAVIORAL|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
58413687|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
58413688|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
57733354|NCT04219748|BEHAVIORAL|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
57733355|NCT02037347|DRUG|Palifermin|
57733356|NCT03529604|OTHER|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
57948483|NCT00202787|DRUG|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
57948484|NCT00202787|DRUG|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
58087463|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
58302828|NCT04849793|OTHER|Acupressure|Before starting the application, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. . The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes
58413689|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
58413690|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
58413691|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
58413692|NCT04575818|DRUG|Placebo|Placebo oral suspension
58413693|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
58413694|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
58413695|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
58413696|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
58087464|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
58087465|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
58413697|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
58413698|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
58413699|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
58087466|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
58087467|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
58413700|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
58413701|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
57733357|NCT03529604|DIAGNOSTIC_TEST|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
58087468|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
58087469|NCT03666819|DEVICE|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
58087470|NCT03666819|OTHER|Questionnaire Administration|Ancillary studies
58087471|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
58413702|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
58413703|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
58413704|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
58413705|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
58413706|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
58413707|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
58413708|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
58413709|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
58087472|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
58087473|NCT01847625|OTHER|simulator|
58302829|NCT03638128|DRUG|Denosumab|Solution for injection
58413710|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
58413711|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
58413712|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
58413713|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
58413714|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
58413715|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
57733358|NCT03529604|DIAGNOSTIC_TEST|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
57733359|NCT04956718|OTHER|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
57733360|NCT04956718|OTHER|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
58413716|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
57733361|NCT02080026|BIOLOGICAL|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
58413717|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
58413718|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
58413719|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
58413720|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
58413721|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
58413722|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
58413723|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
58413724|NCT05564884|OTHER|no intervantion|no intervention
58413725|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
57733362|NCT02080026|BIOLOGICAL|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
57733363|NCT02080026|DRUG|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
57733364|NCT02080026|DRUG|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
57785028|NCT00906880|DRUG|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
58413726|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
57785029|NCT01987375|DRUG|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
57785030|NCT00958529|DIETARY_SUPPLEMENT|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
58413727|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
58413728|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
58413729|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
58413730|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
58413731|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
57785031|NCT03693261|PROCEDURE|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
57785032|NCT03693261|PROCEDURE|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
58087474|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
58087475|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
58087476|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
58087477|NCT00611780|RADIATION|tube voltage|standard 120 kV
58087478|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
58413732|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
58413733|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
58413734|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
58413735|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
58413736|NCT02635334|DRUG|Montelukast 10 mg orally|
58413737|NCT02635334|OTHER|Placebo|
58413738|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
58413739|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
58413740|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
58413741|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
58413742|NCT01188148|DRUG|Memantine|5 mg per day of memantine
58413743|NCT01188148|DRUG|Placebo|
58413744|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
58413745|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
58413746|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
58413747|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
58413748|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
58413749|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
58413750|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
58413751|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
58413752|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
58413753|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
57733365|NCT01544868|OTHER|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
57733366|NCT03832127|DRUG|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
57733367|NCT02076152|DEVICE|FMISO PET|
57733368|NCT02076152|DEVICE|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
57733369|NCT02076152|DRUG|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
57733370|NCT02076152|DRUG|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
58413754|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
58413755|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
58413756|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
58413757|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
58413758|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
58413759|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
58413760|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
58087479|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
58087480|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
58087481|NCT05494723|DRUG|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
58413761|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
58413762|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
58413763|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
58413764|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
58413765|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
58413766|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
58413767|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
58413768|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
58413769|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
58413770|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
58413771|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
58413772|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
58413773|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
58413774|NCT02253056|OTHER|Fasting / Caloric Restriction|
58413775|NCT02253056|OTHER|Healthy Diet|
58413776|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
58087482|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
58087483|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
58413777|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
58413778|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
58413779|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
58413780|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
58413781|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
58413782|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
58087484|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
58087485|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
58087486|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
58087487|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
58413783|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
58087488|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
58087489|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
58087490|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
58087491|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
58087492|NCT06557473|DRUG|Lidocaine IV|1.5mg/kg IV for induction of GA
58087493|NCT06557473|DRUG|Fentanyl|Fentanyl IV 2 µg/kg for GA induction
58087494|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
58087495|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
58087496|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
58087497|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
58087498|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
58087499|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
58087500|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
58087501|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
58087502|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
58087503|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
58087504|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
58087505|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
58087506|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
57785033|NCT05030935|DEVICE|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
58302830|NCT03638128|DRUG|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
58302831|NCT00524927|DRUG|Methoxyflurane|
58302832|NCT00524927|DRUG|Normal Saline|
58302833|NCT00308945|DRUG|travoprost 0.004% (drug)|local drop application
58302834|NCT00308945|DRUG|latanoprost 0.005% (drug)|local drop application
58302835|NCT01959113|BIOLOGICAL|Autologous Microbiome Transplant|
58302836|NCT01959113|OTHER|Placebo Arm|
58302837|NCT00967304|OTHER|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
58302838|NCT02344329|DEVICE|Topical wound dressing|Topical Wound Dressing
58302839|NCT02344329|BIOLOGICAL|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
58302840|NCT02344329|OTHER|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
58302841|NCT00380172|DEVICE|Rheopheresis blood filtration|
58302842|NCT01307787|OTHER|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
58302843|NCT01307787|OTHER|no intervention|waiting list control group with no intervention
58302844|NCT02324686|DRUG|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
58302845|NCT01980433|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
58302846|NCT01980433|OTHER|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
57948485|NCT06460402|OTHER|Ice packing|For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.
58413784|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
58087507|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
58087508|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
58087509|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
57785034|NCT03013699|BEHAVIORAL|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
58302847|NCT01980433|OTHER|WCRS|Writer's cramp rating scale
58302848|NCT01980433|OTHER|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
58302849|NCT01980433|OTHER|visual analog scale of discomfort writing and parameters collected on touchpad|
58302850|NCT04835545|OTHER|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
58302851|NCT04078464|OTHER|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
58302852|NCT04078464|OTHER|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
58302853|NCT04078464|OTHER|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
58302854|NCT04606693|OTHER|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
58302855|NCT04531865|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
58302856|NCT04531865|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
58302857|NCT04531865|DRUG|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
58302858|NCT01179607|DRUG|M0002|
58302859|NCT01179607|DRUG|Placebo|
58302860|NCT00144677|DRUG|sirolimus|
58302861|NCT00144677|DRUG|tacrolimus|
58302862|NCT01831869|DRUG|L-thyroxine|
58302863|NCT02631447|DRUG|LGX818|LGX818 450 mg p.o. od
58302864|NCT02631447|DRUG|MEK162|MEK162 45 mg p.o. bid
58302865|NCT02631447|DRUG|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
58302866|NCT02631447|DRUG|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
58302867|NCT00126594|DRUG|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
58302868|NCT00126594|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10\^6 international units twice daily
58302869|NCT00126594|OTHER|Laboratory Biomarker Analysis|Correlative studies
58302870|NCT01842269|DRUG|Mycophenolate Mofetil 500mg|
58302871|NCT01842269|DRUG|Mycophenolate Mofetil 250mg|
58302872|NCT03909048|BEHAVIORAL|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
58302873|NCT03909048|BEHAVIORAL|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
58302874|NCT01805895|DRUG|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
58302875|NCT03583957|DEVICE|Observational only|Device is only observational and used to record EEG.
58302876|NCT03583957|BEHAVIORAL|Psychological and Behavioral interaction with a seizure forecasting mobile app|Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
58302877|NCT03583957|COMBINATION_PRODUCT|Seizure Alerting and Prediction System|The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
58087510|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
58302878|NCT01774591|DRUG|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
58087511|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
58302879|NCT01774591|DRUG|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
58087512|NCT06638866|DIAGNOSTIC_TEST|Pancreatic imaging AI model|Subjects identified with pancreatic lesions by the AI model, which include PDAC and non-PDAC subtypes, will be required to undergo questionnaire, blood tests (including CA19-9, CA125, CEA, etc.) and further imaging examinations (including contrast CT, MRI, EUS, etc.) to confirm the final status of the pancreatic lesion.
58302880|NCT03856697|DRUG|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
58413785|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
58413786|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
58413787|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
58413788|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
58413789|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
58413790|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
58413791|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
58413792|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
58413793|NCT00970450|DRUG|Placebo|Saline
58413794|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
58413795|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
58413796|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
58413797|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
57733371|NCT01810588|DEVICE|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
57733372|NCT01810588|DRUG|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
57733373|NCT01810588|DRUG|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
58413798|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
57733374|NCT01810588|DRUG|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
57733375|NCT01810588|DRUG|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
58087513|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
58413799|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
58413800|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
58413801|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
58413802|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
58413803|NCT00378937|DRUG|acetaminophen|
58413804|NCT00378937|DRUG|codeine phosphate|
58413805|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
58413806|NCT00378937|DRUG|morphine sulfate|
58413807|NCT00378937|DRUG|oxycodone hydrochloride|
58413808|NCT00378937|PROCEDURE|management of therapy complications|
58413809|NCT00378937|PROCEDURE|quality-of-life assessment|
58413810|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
58413811|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
58413812|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
58413813|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
58413814|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
58413815|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
58413816|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
58413817|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
58413818|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
58413819|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
58413820|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
58413821|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
58413822|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
58413823|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
58413824|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
58413825|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
58413826|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
58413827|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
58413828|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
58413829|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
58413830|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
58413831|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
58413832|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
58413833|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
58413834|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
58413835|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
58413836|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
58413837|NCT02819960|DRUG|Placebo|Maltodextrin
58413838|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
58413839|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
58413840|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
58413841|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
58413842|NCT03983772|OTHER|Placebo|The placebo is starch.
58413843|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
58413844|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
58413845|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
58413846|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
58413847|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
58413848|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
58413849|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
58413850|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
58413851|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
58413852|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
58413853|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
58413854|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
58413855|NCT01061047|DRUG|Ertapeneme|
58413856|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
58413857|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
58413858|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
58413859|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
58413860|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
58413861|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
58413862|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
58413863|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
58413864|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
58413865|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
58413866|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
58413867|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
58413868|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
58413869|NCT00003671|DRUG|asparaginase|
58087514|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
58087515|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
58087516|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
58413870|NCT00003671|DRUG|cyclophosphamide|
58413871|NCT00003671|DRUG|cytarabine|
58413872|NCT00003671|DRUG|daunorubicin hydrochloride|
58413873|NCT00003671|DRUG|dexamethasone|
58413874|NCT00003671|DRUG|leucovorin calcium|
58413875|NCT00003671|DRUG|mercaptopurine|
58413876|NCT00003671|DRUG|methotrexate|
58413877|NCT00003671|DRUG|thioguanine|
58413878|NCT00003671|DRUG|vincristine sulfate|
58413879|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
58413880|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
58413881|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
58413882|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
58413883|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
58413884|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
58413885|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
58413886|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
57733376|NCT01810588|RADIATION|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
58413887|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
57733377|NCT01810588|DRUG|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
58087517|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
58087518|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
58087519|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
58087520|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
58087521|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
58087522|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
58087523|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
58087524|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
58413888|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
58413889|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
58413890|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
58413891|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
58413892|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
58413893|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
58413894|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
58413895|NCT02716701|BEHAVIORAL|Exercise Group|
58413896|NCT02716701|OTHER|Control Group|
58413897|NCT02716701|OTHER|wristband activity tracker|
58413898|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
58413899|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
58413900|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
58413901|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
58413902|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
58413903|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
58413904|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
58413905|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
58413906|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
58413907|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
58413908|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
58413909|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
58413910|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
58413911|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
58413912|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
58413913|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
58413914|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
58413915|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
58413916|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
58413917|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
57733378|NCT01810588|DRUG|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
58413918|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
58413919|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
58413920|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
58413921|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
58413922|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
58413923|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
58413924|NCT00252226|DRUG|Quetiapine|
58413925|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
58413926|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
58413927|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
58413928|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
58413929|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
58413930|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
58413931|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
58413932|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
58413933|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
58413934|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
58413935|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
58413936|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
58413937|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
58413938|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
58413939|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
57733379|NCT03776136|DRUG|lenvatinib|Administered orally once a day during each 21-day cycle.
58087525|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
58087526|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
58087527|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
58087528|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
58087529|NCT05263869|DRUG|MRG002|Administrated intravenously
58413940|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
58087530|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
58087531|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
58087532|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
58087533|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
58087534|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
58087535|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
58087536|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
58413941|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
58413942|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
57733380|NCT03776136|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
58087537|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
58087538|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
58087539|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
58413943|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
58413944|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
58413945|NCT00520013|DRUG|bevacizumab|
58413946|NCT00520013|DRUG|erlotinib|
58413947|NCT00520013|DRUG|paclitaxel|
58413948|NCT00520013|DRUG|carboplatin|
58413949|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
58413950|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
58413951|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
58413952|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
58413953|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
58413954|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
58087540|NCT00002680|BIOLOGICAL|filgrastim|
58087541|NCT00002680|DRUG|cyclophosphamide|
58087542|NCT00002680|DRUG|megestrol acetate|
58087543|NCT00002680|DRUG|melphalan|
58413955|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
58413956|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
58413957|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
58413958|NCT02741570|BIOLOGICAL|Nivolumab|
58413959|NCT02741570|BIOLOGICAL|Ipilimumab|
58413960|NCT02741570|DRUG|Cetuximab/Erbitux|
58413961|NCT02741570|DRUG|Cisplatin/Platinol|
58413962|NCT02741570|DRUG|Carboplatin/Paraplatin|
58413963|NCT02741570|DRUG|Fluorouracil/Adrucil|
58413964|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
58413965|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
58087544|NCT00002680|DRUG|tamoxifen citrate|
58087545|NCT00002680|DRUG|thiotepa|
58413966|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
58413967|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
58413968|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
57733381|NCT04480112|BEHAVIORAL|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
57733382|NCT04480112|OTHER|No research related technology based social interactions|No technology based social interactions with the research team.
57733383|NCT01865591|DEVICE|Ultrasound-based Renal Denervation|
57733384|NCT05734508|BIOLOGICAL|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
58087546|NCT00002680|PROCEDURE|conventional surgery|
58087547|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
58087548|NCT00002680|RADIATION|radiation therapy|
58413969|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
58413970|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
58413971|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
58413972|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
58413973|NCT01811576|DRUG|TV-1106|
58413974|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
58413975|NCT00493519|PROCEDURE|chocolate cake|
58413976|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
58413977|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
58087549|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
58087550|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
58087551|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
58413978|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
58302881|NCT03856697|DRUG|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
58413979|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
58087552|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
58087553|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
58087554|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
58087555|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
58087556|NCT05611372|DRUG|Rasagiline|1 mg rasagiline
58087557|NCT04980417|PROCEDURE|concomitant cholecystectomy|delayed cholecystectomy
58087558|NCT00104962|DRUG|lenalidomide|Given orally
58087559|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
58302882|NCT03856697|DRUG|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
58302883|NCT03856697|DRUG|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
58302884|NCT03521557|BEHAVIORAL|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
58087560|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
58302885|NCT03521557|BEHAVIORAL|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
58302886|NCT03509168|DRUG|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
58413980|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
58087561|NCT02903095|DRUG|TD-1439|
58087562|NCT02903095|DRUG|Placebo|
58087563|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
58087564|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
58087565|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
57733385|NCT01765634|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.
57733386|NCT01765634|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
58087566|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
58087567|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
58087568|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
58087569|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
58087570|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
58087571|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
58087572|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
58087573|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
58087574|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
58087575|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
57733387|NCT03750318|DEVICE|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
57733388|NCT04211714|BIOLOGICAL|EXG34217|Single infusion
57785035|NCT03013699|BEHAVIORAL|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
58087576|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
58087577|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
58087578|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
58087579|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
58087580|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
58087581|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
58087582|NCT03299088|DRUG|Trametinib|Given PO
58302887|NCT03509168|OTHER|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
58302888|NCT05535608|DIETARY_SUPPLEMENT|SRW Cel System|Dietary supplement
58302889|NCT03848559|DEVICE|Airway management with a submerged model|Airway management with a submerged manikin using different airway devices in randomized order
58302890|NCT01768780|DEVICE|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
57948486|NCT06460402|OTHER|Warm sitz bath|Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
57948487|NCT04417036|DRUG|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
57948488|NCT04417036|OTHER|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
57948489|NCT04417036|DRUG|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
57948490|NCT02987036|DEVICE|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
57948491|NCT02987036|DEVICE|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
57948492|NCT04279275|OTHER|SURVEY|QUESTIONAIRRE
57948493|NCT01549002|DRUG|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
57948494|NCT01549002|DRUG|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
57948495|NCT03831594|DEVICE|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
57948496|NCT03831594|OTHER|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
57948497|NCT02431936|DRUG|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
58413981|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
57948498|NCT02431936|DRUG|Placebo|Sugar pill made to look identical to Prazosin intervention.
57948499|NCT00676390|OTHER|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
57948500|NCT03978507|BEHAVIORAL|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
58087583|NCT00568464|DRUG|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
58087584|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
58413982|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
58413983|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
58413984|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
57948501|NCT03978507|BEHAVIORAL|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
57948502|NCT06494293|OTHER|Data Collection|Collection of medical data from MICU intervention file and patient medical files from participating centres
58413985|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
57948503|NCT02670863|OTHER|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
58087585|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
58087586|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
58087587|NCT02626273|RADIATION|weight loss|
58087588|NCT00027573|BIOLOGICAL|filgrastim|
58087589|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58087590|NCT00027573|DRUG|cyclophosphamide|
58087591|NCT00027573|DRUG|fludarabine phosphate|
58087592|NCT00027573|DRUG|methotrexate|
58087593|NCT00027573|DRUG|tacrolimus|
58413986|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
58413987|NCT00227513|DRUG|bortezomib|Given IV
58413988|NCT00227513|DRUG|vorinostat|Given orally
57948504|NCT02670863|OTHER|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
57948505|NCT00635479|DEVICE|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
57948506|NCT00635479|OTHER|Gauze dressing|Gauze dressing for surgical incision
57948507|NCT02860312|BEHAVIORAL|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
57948508|NCT02860312|BEHAVIORAL|Non-exercising group|Patients are having their usual physical activity
57948509|NCT00330395|DRUG|caspofungin acetate|Duration of Treatment 28 Days
57948510|NCT03066128|DIAGNOSTIC_TEST|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
57948511|NCT03066128|OTHER|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
57948512|NCT01100515|OTHER|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
58087594|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
58087595|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
58087596|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
58087597|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
58087598|NCT00980460|DRUG|Cisplatin|Given IV
58087599|NCT00980460|DRUG|Dexrazoxane|Given IV
58087600|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
58087601|NCT00980460|DRUG|Fluorouracil|Given IV
58087602|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
58087603|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
58413989|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
58087604|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
57948513|NCT01100515|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
58087605|NCT00980460|DRUG|Temsirolimus|Given IV
58087606|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58413990|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
58413991|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
57948514|NCT02263079|DRUG|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
57948515|NCT02263079|DRUG|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
57948516|NCT02263079|DRUG|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
57948517|NCT04162821|DRUG|Hydronidone|Take hydroxynitone capsule
57948518|NCT02474212|DRUG|Enoxaparin|
57948519|NCT00714285|BIOLOGICAL|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
57948520|NCT00714285|BIOLOGICAL|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
57948521|NCT01140451|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
57948522|NCT00319774|DEVICE|Hemocontrol Biofeedback System|
57948523|NCT05559489|DRUG|Oral Rehydration Solution|Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
57948524|NCT05559489|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
57948525|NCT00873977|DEVICE|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
57948526|NCT03095742|DIAGNOSTIC_TEST|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
57948527|NCT03095742|DIAGNOSTIC_TEST|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
57948528|NCT03412175|BEHAVIORAL|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
57948529|NCT05062876|DRUG|AD-214|1 tablet administered before the breakfast during 7 days
57948530|NCT05062876|DRUG|AD-2141|1 tablet administered before the breakfast during 7 days
57948531|NCT01142401|DRUG|Bortezomib|Given IV
58087607|NCT00980460|DRUG|Vincristine Sulfate|Given IV
58087608|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
58087609|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
58087610|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
58087611|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
58087612|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
58087613|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
57948532|NCT01142401|DRUG|Fulvestrant|Given IM
57948533|NCT01142401|OTHER|Laboratory Biomarker Analysis|Correlative studies
57948534|NCT00002152|DRUG|WF10|
57948535|NCT05288738|DRUG|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
57948536|NCT05288738|DRUG|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
57948537|NCT06171451|DIAGNOSTIC_TEST|PET with 11C-Fe-CIT|Use of the PET11C-Fe_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
57948538|NCT04046003|BEHAVIORAL|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
58087614|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
58087615|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
58087616|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
58087617|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
58087618|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
58413992|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
58413993|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
58413994|NCT03313284|PROCEDURE|Control|No intervention
58413995|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
58413996|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
58413997|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
58087619|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
58087620|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
58087621|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
58087622|NCT00390091|DRUG|abetimus sodium (LJP 394)|
58302891|NCT00179855|PROCEDURE|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
58302892|NCT05570552|BEHAVIORAL|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
58302893|NCT00169676|OTHER|observation|registry and database for surgery outcomes
58302894|NCT02778217|PROCEDURE|Culture media renwal|
58302895|NCT02125890|DRUG|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
58302896|NCT04911348|OTHER|none (observational)|no intervention
58302897|NCT01639352|BIOLOGICAL|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
58302898|NCT05316064|BIOLOGICAL|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
58413998|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
58413999|NCT00151034|DRUG|Trastuzumab|
58414000|NCT00151034|DRUG|Paclitaxel|
58414001|NCT00151034|DRUG|Carboplatin|
57948539|NCT02289742|DEVICE|Nelfilcon A multifocal contact lenses|
57948540|NCT02289742|DEVICE|Nelfilcon A toric contact lenses|
57948541|NCT02289742|DEVICE|Nelfilcon A sphere contact lenses|
58302899|NCT05316064|OTHER|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
58302900|NCT02187783|DRUG|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
58302901|NCT02142816|DEVICE|Doppler|Fluid therapy guided by doppler
58302902|NCT02142816|OTHER|PVI'|Fluid therapy guided by PVI
58414002|NCT00151034|DRUG|Gemcitabine|
58414003|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
58087623|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
58087624|NCT05480488|DRUG|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
58087625|NCT05480488|DRUG|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
58087626|NCT05480488|DRUG|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
58087627|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
58087628|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
58087629|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
58414004|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
58414005|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
58414006|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
58087630|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
58087631|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
58087632|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
58087633|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
58087634|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
58087635|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
58087636|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
58087637|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
58087638|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
58087639|NCT06250660|DIETARY_SUPPLEMENT|Strawberry Intervention|"This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries."
58087640|NCT01265875|DRUG|Human Secretin|Dose Escalation
58087641|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
58087642|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
58414007|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
58414008|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
58414009|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
58087643|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
58087644|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
58414010|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
58414011|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
58414012|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
58414013|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
58414014|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
58414015|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
57733389|NCT02356380|OTHER|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
57733390|NCT03950765|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
58087645|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
58087646|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
58302903|NCT03893578|DEVICE|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
58302904|NCT01030146|DRUG|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
58302905|NCT03159598|DEVICE|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
58302906|NCT03159598|DEVICE|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
58302907|NCT03159598|OTHER|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
58414016|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
58414017|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
58414018|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
57733391|NCT01026974|BIOLOGICAL|rMenB|
57733392|NCT01026974|BIOLOGICAL|rMenB+OMV NZ|
58414019|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
58414020|NCT00378911|DRUG|sunitinib malate|Given orally
57733393|NCT03152747|DEVICE|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
57733394|NCT00059800|RADIATION|boron neutron capture therapy|
57733395|NCT06630299|DRUG|ISL/LEN|Tablet administered orally
58414021|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
58414022|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
58414023|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
58087647|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
58087648|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
58414024|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
58414025|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
58414026|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
58414027|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
58087649|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
58087650|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
58087651|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
58087652|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
58087653|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
58414028|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
58414029|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
58414030|NCT01068782|DRUG|XL184|given orally as capsules
58414031|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
58414032|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
58414033|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
58414034|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
58414035|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
58414036|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule (2 taken once daily)
58414037|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
58087654|NCT04387227|DRUG|Carboplatin|Given IV
58087655|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
58087656|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
58087657|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58087658|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58414038|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
58414039|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
58414040|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
58302908|NCT06028789|DIAGNOSTIC_TEST|Blood sample test|"The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)"
58414041|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
57948542|NCT04044300|PROCEDURE|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
57948543|NCT04044300|OTHER|Conservative|Continued pain management and physical therapy.
57948544|NCT03024970|DEVICE|stenfilcon A lens with solution additive (test)|silicone hydrogel lens
57948545|NCT03024970|DEVICE|stenfilcon A lens (control)|contact lens
57948546|NCT00002279|DRUG|Zalcitabine|
57948547|NCT03894670|OTHER|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
57948548|NCT03894670|OTHER|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
57948549|NCT02011659|DRUG|Ramosetron|
57948550|NCT05311124|DEVICE|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
57948551|NCT05285241|OTHER|Multidirectional stepping exercises|These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).
57948552|NCT05285241|OTHER|Conventional physiotherapy group|Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)
57948553|NCT04266275|DRUG|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
57948554|NCT04266275|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
57948555|NCT03459911|DRUG|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)
57948556|NCT03459911|DRUG|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
58087659|NCT06649812|PROCEDURE|Biopsy|Undergo optional tumor biopsy
58087660|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58087661|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58087662|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58087663|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
58087664|NCT06649812|DRUG|Ibrutinib|Given PO
58414042|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
58414043|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
58414044|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
58414045|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
58414046|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
58414047|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
58414048|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
58414049|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
58414050|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
58414051|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
58414052|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
58414053|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
57733396|NCT06630299|DRUG|Antiretroviral Combinations|2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
57733397|NCT02188433|BEHAVIORAL|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
57733398|NCT00611143|DRUG|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
58087665|NCT06649812|DRUG|Lenalidomide|Given PO
58087666|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58087667|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
58087668|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
58087669|NCT06649812|DRUG|Prednisone|Given PO
58087670|NCT06649812|DRUG|Venetoclax|Given PO
58087671|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
58087672|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
58087673|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
58087674|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
58302909|NCT06028789|PROCEDURE|Thoracic Aortic Surgery|Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
58414054|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
58414055|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
58414056|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
58414057|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
58414058|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
58414059|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
58414060|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
58414061|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
58414062|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
58414063|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
58414064|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
58087675|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
58087676|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
58087677|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
58087678|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
58087679|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
58087680|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
58087681|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
58087682|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
58087683|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
58087684|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
58087685|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
58302910|NCT01243918|OTHER|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
58302911|NCT05511857|BEHAVIORAL|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
58302912|NCT05511857|BEHAVIORAL|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
58302913|NCT05511857|BEHAVIORAL|Distraction|The participants will engage in a distraction task.
58302914|NCT03531723|OTHER|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
58302915|NCT03318263|DIAGNOSTIC_TEST|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
58302916|NCT02783170|BIOLOGICAL|Tetanus, Diphtheria, and Pertussis Vaccine|
58302917|NCT02783170|BIOLOGICAL|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
58302918|NCT02783170|BIOLOGICAL|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
58302919|NCT04935203|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take \~2 min.
58414065|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
58414066|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
58414067|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
58414068|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
58087686|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
58087687|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
58087688|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
58087689|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
58087690|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
58087691|NCT04907994|OTHER|Cohort|Nothing. Only implementation of a cohort with data collection via the SNDS.
58087692|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
58087693|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
58087694|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
58087695|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
58087696|NCT00848666|DRUG|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
58087697|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
58087698|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
58087699|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
58087700|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
58087701|NCT00030849|DRUG|bexarotene|
58087702|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
58302920|NCT02179125|DEVICE|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
58414069|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
58414070|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
58414071|NCT02060994|OTHER|No intervention|No intervention
58414072|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
58087703|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
58087704|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
58087705|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
58087706|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
58087707|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
58087708|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
58087709|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
58087710|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
58087711|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
58087712|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
58087713|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
58087714|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
58302921|NCT00409981|DEVICE|paclitaxel coated balloon catheter (device with drug)|
58302922|NCT04670536|DEVICE|PASS LP implants|Thoraco lumbar arthrodesis
58302923|NCT04670536|DEVICE|PASS DEGEN|Thoraco lumbar arthrodesis
58302924|NCT04670536|DEVICE|PASS TULIP PRIME|Thoraco lumbar arthrodesis
58302925|NCT05337761|BEHAVIORAL|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
58302926|NCT03674268|DIAGNOSTIC_TEST|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
58414073|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
58414074|NCT02366767|DEVICE|Control|Threshold suspend
58414075|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
57733399|NCT03540927|BEHAVIORAL|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
57733400|NCT03540927|OTHER|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
57733401|NCT05930327|OTHER|Unconditional Cash Transfer (High-Value)|Monthly, Unconditional Cash Transfer ($325) for 4-months
58087715|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
58087716|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
58087717|NCT02263222|DRUG|MDT-10013|
58087718|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
58414076|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
58414077|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
58414078|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
57733402|NCT05930327|OTHER|Unconditional Cash Transfer (Low-Value)|Monthly, Unconditional Cash Transfer ($25) for 4-months
57733403|NCT05225818|BEHAVIORAL|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
57733404|NCT05754450|DRUG|AVTX-803|L-fucose crystalline powder
58087719|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
58087720|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
57733405|NCT06028230|DRUG|SAR444656 (KT-474)|Oral Tablet
57733406|NCT06028230|DRUG|Placebo|Oral Tablet
57733407|NCT00264615|DRUG|lamotrigine extended-release|
57733408|NCT04479618|DEVICE|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
58087721|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
58087722|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
58087723|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
58087724|NCT00088400|DRUG|TransMID|
58087725|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
58087726|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
58087727|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
58087728|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
58302927|NCT02624999|BIOLOGICAL|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
58414079|NCT00033709|DRUG|temozolomide|
58414080|NCT00033709|DRUG|thalidomide|
58414081|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
58414082|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
58414083|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
58414084|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
58414085|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
58414086|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
58087729|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
58087730|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
58087731|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
58087732|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
58087733|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
58087734|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
58087735|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
58087736|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
58087737|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
58087738|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
58087739|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
58087740|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
58087741|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
58087742|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
58087743|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
58087744|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
58087745|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
58302928|NCT02624999|DRUG|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
58414087|NCT02182908|OTHER|PET-Scan|PET-Scan
58414088|NCT00787137|DRUG|PG102|A single intravenous infusion
58414089|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
58414090|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
58414091|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
58414092|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
58414093|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
58414094|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
58087746|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
58087747|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
58087748|NCT02016027|DRUG|Carica folia|
58087749|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
58087750|NCT06313697|BIOLOGICAL|placebo|single dose
58087751|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
58087752|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
58087753|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure with information about mental health problems. Additionally, participants will receive a set of 5 educational mental health videos regarding depression. Each of these videos is 15 minutes long.
58087754|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
58087755|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
58302929|NCT02358057|DRUG|Dexmedetomidine|
58302930|NCT02358057|DRUG|Alfentanil|
58302931|NCT02773498|PROCEDURE|conventional TESE|usual procedure for sperm extraction
58302932|NCT02773498|PROCEDURE|Micro TESE|procedure of extraction is performed under the operating microscope
58414095|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
58087756|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
58087757|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
58302933|NCT01255215|DRUG|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
58414096|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
58414097|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
58414098|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
58414099|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
58414100|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
58414101|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
58414102|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
58414103|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
58414104|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
58414105|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
58414106|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
58414107|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
58414108|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
58414109|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
58414110|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
58414111|NCT00990145|DRUG|EDP-322|
58087758|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
58414112|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
58414113|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
58414114|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
58414115|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
58414116|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
58414117|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
58414118|NCT00002342|DRUG|Tecogalan sodium|
58087759|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
58087760|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
58087761|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
58087762|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
58087763|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
58414119|NCT03778320|DRUG|CTP-692|Single oral dose
58414120|NCT03778320|DRUG|D-Serine|Single oral dose
58414121|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
58414122|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
58414123|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
58414124|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
58414125|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
58414126|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
58414127|NCT00003787|BEHAVIORAL|educational/counseling intervention|
58414128|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
58414129|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
58414130|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
58414131|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
58414132|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
58414133|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
58414134|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
58414135|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
58414136|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
58414137|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
58414138|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
58414139|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
58414140|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
58414141|NCT01735669|DRUG|Remifentanil|
58414142|NCT01735669|DRUG|Nitrous Oxide|
58087764|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
58087765|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
58087766|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
58087767|NCT00577031|DRUG|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
58087768|NCT00577031|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
58087769|NCT00577031|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
58087770|NCT00417820|DRUG|BCT194|
58087771|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
58087772|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
58087773|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
58414143|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
58414144|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
58087774|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
58087775|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
58087776|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
58087777|NCT05384119|DRUG|TTI-101|Oral tablet
58414145|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
58087778|NCT05384119|DRUG|Palbociclib|Oral capsule
58087779|NCT05384119|DRUG|Aromatase inhibitor (AI)|Oral tablet
58087780|NCT05384119|DRUG|fulvestrant|Oral tablet
58087781|NCT05384119|DRUG|ribociclib|Oral tablet
58087782|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
58414146|NCT00289198|DRUG|Placebo|placebo nasal spray
58414147|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
58414148|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
58414149|NCT01563289|DRUG|Ibuprofen|3 times a day
58414150|NCT01563289|DRUG|Placebo|3 times a day
58414151|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
58087783|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
58087784|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
58087785|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
58087786|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
58302934|NCT05570448|PROCEDURE|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
58302935|NCT05570448|PROCEDURE|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
58302936|NCT00860275|DRUG|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
58302937|NCT00860275|DRUG|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
58302938|NCT00860275|DRUG|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
58302939|NCT00860275|DRUG|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
58302940|NCT00860275|DRUG|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
58302941|NCT00528424|BIOLOGICAL|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
58302942|NCT02935556|OTHER|no intervention|database and epigenetic study
58302943|NCT00004244|BIOLOGICAL|recombinant interferon alfa|
58302944|NCT00004244|BIOLOGICAL|recombinant interleukin-12|
58302945|NCT03472638|DEVICE|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
58302946|NCT03594929|DEVICE|Active RIC|
58414152|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
58087787|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
58087788|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
58302947|NCT03594929|DEVICE|Sham Control|
58302948|NCT00103454|DRUG|GW685698X|
58302949|NCT00374010|BEHAVIORAL|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~1. Representational assessment (10 - 15 minutes);~2. Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~3. Creating conditions for conceptual change (5 minutes);~4. Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~5. Summary (3 - 5 minutes)"
58302950|NCT01682980|OTHER|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
58302951|NCT01682980|OTHER|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
58302952|NCT00350077|DRUG|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
58302953|NCT00350077|DRUG|Vitamin C|IV vitamin C
58302954|NCT02938364|OTHER|Earplugs|Plastic earplugs on both ears
58302955|NCT02938364|OTHER|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
58302956|NCT02938364|OTHER|Placebo|Non pressure bands put on the wrists of the participant
58302957|NCT00802711|RADIATION|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
58302958|NCT00802711|RADIATION|brachytherapy|Given twice a day for 10 fractions
58414153|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
58414154|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
58414155|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
58414156|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
58414157|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
58087789|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
58087790|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
58414158|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
58087791|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
58087792|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
58087793|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
58087794|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
58087795|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
58087796|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
58087797|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
57733409|NCT04479618|DEVICE|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
58414159|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
58414160|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
58414161|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
58414162|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
58414163|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
58414164|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
58414165|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
57733410|NCT04479618|DEVICE|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
57948557|NCT01206062|DRUG|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
57948558|NCT01206062|DRUG|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
58087798|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
58414166|NCT02606760|DRUG|P-3073|
58414167|NCT02606760|DRUG|Vehicle of P-3073|
58414168|NCT02072187|DIETARY_SUPPLEMENT|Active|
58414169|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
58414170|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
58414171|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
58414172|NCT02516826|DRUG|Rosuvastatin|
58414173|NCT02516826|DRUG|Olmesartan|
58414174|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
57733411|NCT05832437|BEHAVIORAL|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
57948559|NCT03716401|DIAGNOSTIC_TEST|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
57948560|NCT03716401|DIAGNOSTIC_TEST|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
57948561|NCT03716401|PROCEDURE|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
57948562|NCT03716401|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
57948563|NCT03716401|DIAGNOSTIC_TEST|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
57948564|NCT00073723|DRUG|ABI-007|
58087799|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
58087800|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
58087801|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
58414175|NCT02516826|DRUG|Placebo of Rosuvastatin|
58414176|NCT02516826|DRUG|Placebo of Olmesartan|
58414177|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
58414178|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
58414179|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
58414180|NCT00491660|BEHAVIORAL|supine positioning|
58414181|NCT00491660|BEHAVIORAL|lateral positioning|
58414182|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
58414183|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
58414184|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
58414185|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
58414186|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
57733412|NCT05832437|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
57733413|NCT01734681|DRUG|G-202|
57733414|NCT04831736|DRUG|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
58087802|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
58414187|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
58414188|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
58414189|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
58414190|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
58414191|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
58414192|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
58414193|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
58414194|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
58414195|NCT04069247|BEHAVIORAL|ECBT-I|The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
58414196|NCT04069247|BEHAVIORAL|HE|The HE will be delivered in control though a mobile application (eSleep) with a personal password.
58414197|NCT00700102|DRUG|Chemotherapy|As prescribed
57733415|NCT04831736|DRUG|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
57733416|NCT06108622|DIAGNOSTIC_TEST|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
57733417|NCT04134442|DRUG|Bupivacaine Liposome Injection|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
58414198|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
58414199|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
58414200|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
58414201|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
58414202|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
58414203|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
58414204|NCT01898104|DRUG|Valproic Acid|
58414205|NCT01898104|DRUG|Capecitabine|
58414206|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
58414207|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
58414208|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
58414209|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
58414210|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
58414211|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
58414212|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
58414213|NCT00461994|BEHAVIORAL|diet|
58414214|NCT00461994|BEHAVIORAL|exercise|
58414215|NCT00461994|BEHAVIORAL|diet and exercise|
58414216|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
57733418|NCT04134442|OTHER|Standard Therapy|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
57733419|NCT06184984|DIETARY_SUPPLEMENT|Metabolic availability of methionine in mung beans|Each participant will randomly receive 7 different levels of methionine provided as free amino acids and cooked mung beans.
58414217|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
58414218|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
58414219|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
58414220|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
58414221|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
58414222|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
58414223|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
58414224|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
57733420|NCT02156674|DRUG|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
58087803|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
58087804|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
58087805|NCT00902486|DRUG|INCB028050|4 mg capsules QD
58087806|NCT00902486|DRUG|INCB028050|7 mg capsules QD
58087807|NCT00902486|DRUG|INCB028050|10 mg capsule QD
58087808|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
58087809|NCT06568718|DRUG|bovhyaluronidase azoximer|Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
58087810|NCT06568718|DRUG|tamsulosin|Tamsulosin 0.4mg per os every day
58087811|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
58414225|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
58414226|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
58414227|NCT01845584|DRUG|NPB-01|
58414228|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
58414229|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
58414230|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
58414231|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
58414232|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
58414233|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
58414234|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
58414235|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
57733421|NCT00392561|DIETARY_SUPPLEMENT|Selenium|200 ug Selenium daily
57948565|NCT03286062|COMBINATION_PRODUCT|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
58302959|NCT03735615|BEHAVIORAL|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
58414236|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
58414237|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
57948566|NCT02738983|DRUG|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
57948567|NCT02738983|RADIATION|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
58302960|NCT04637243|OTHER|Treatment of Benign or Malignant Liver and Bile Duct Diseases|Available treatment of Benign or Malignant Liver and Bile Duct Diseases
58414238|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
58414239|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
58414240|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
57733422|NCT00392561|DIETARY_SUPPLEMENT|vitamin E|100 mg Vitamin E daily
57733423|NCT06634589|DRUG|BGB-16673|Administered orally
57733424|NCT06634589|DRUG|sonrotoclax|Administered orally
57733425|NCT06634589|DRUG|Zanubrutinib|Administered orally
57733426|NCT01562756|OTHER|HVLA-SM|High velocity, low amplitude spinal manipulation
57733427|NCT02451800|OTHER|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
57733428|NCT02451800|OTHER|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
57733429|NCT02451800|OTHER|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
58302961|NCT00388648|DRUG|mixture of amino and keto acids|
58414241|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
58414242|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
58414243|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
58414244|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
58414245|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
58414246|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
57733430|NCT01126593|DRUG|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
58302962|NCT05471011|OTHER|Blood and nasal swab sampling|Blood and nasal swab sampling
58302963|NCT06454474|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states.
58302964|NCT02456727|PROCEDURE|Group/Community Acupuncture|Acupuncture treatment in a group setting.
58302965|NCT02456727|PROCEDURE|Individual Acupuncture|Acupuncture treatment in an individual setting.
58302966|NCT02533700|DRUG|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
58302967|NCT02533700|DRUG|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
58302968|NCT04872088|BEHAVIORAL|Strengthened SBCC|Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
58302969|NCT04872088|DIETARY_SUPPLEMENT|Preventive nutritional supplement|"Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~- \[6-17\]months old children diagnosed as non-wasted (MUAC\>=125mm)"
58302970|NCT04872088|BEHAVIORAL|Family MUAC|"MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family."
58302971|NCT04872088|BEHAVIORAL|Active screening by NASGs|"Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled."
58302972|NCT04872088|BEHAVIORAL|Intensified followup of children with wasting referred to and enrolled in CMAM treatment|NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
58302973|NCT04872088|BEHAVIORAL|Relapse prevention|NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
58302974|NCT04872088|BEHAVIORAL|Cooking demonstrations|NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
58302975|NCT00104936|PROCEDURE|adjuvant therapy|
58302976|NCT00104936|RADIATION|radiation therapy|
58302977|NCT00104936|RADIATION|stereotactic radiosurgery|
58302978|NCT03080935|DRUG|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
58302979|NCT04514900|BEHAVIORAL|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
58302980|NCT04514900|BEHAVIORAL|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
58302981|NCT04514900|BEHAVIORAL|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
57733431|NCT01126593|DRUG|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
57733432|NCT02501343|DRUG|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
57733433|NCT02501343|DRUG|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
57733434|NCT01899846|DRUG|Hydroxyprogesterone caproate 250 mg/ml|
57733435|NCT04781153|PROCEDURE|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
57733436|NCT03579745|PROCEDURE|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
58302982|NCT04514900|BEHAVIORAL|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
58302983|NCT03846934|DEVICE|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
58302984|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
58087812|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
58087813|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
58087814|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
58087815|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
58302985|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
58302986|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
58302987|NCT05465902|BIOLOGICAL|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
58302988|NCT05465902|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
58302989|NCT05465902|BIOLOGICAL|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
57733437|NCT00547391|PROCEDURE|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
57733438|NCT00547391|OTHER|no intervention|No intervention (controls). Follow up started from the day of randomization.
58302990|NCT05465902|BIOLOGICAL|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
58302991|NCT00016536|DRUG|Naphthalene 2-sulfonate polymer|
58302992|NCT00016536|DRUG|Carbopol polymer|
58302993|NCT02112942|DRUG|IDX21459|
58414247|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
58414248|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
58414249|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
58414250|NCT00049777|DRUG|Unfractionated heparin|
58414251|NCT00049777|DRUG|Low molecular weight heparin|
58414252|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
58414253|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
58414254|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
58414255|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
58414256|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
58414257|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
58414258|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
58414259|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
57733439|NCT04302857|OTHER|routine MRI|MRI with routine DTI sequence
57733440|NCT02544243|DRUG|Vinorelbine|
57733441|NCT02544243|DRUG|Gemcitabine|
57733442|NCT02544243|DRUG|Cisplatin|
58414260|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
58414261|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
58414262|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
58414263|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
58414264|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
58414265|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
58414266|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
58414267|NCT01024491|DRUG|placebo|active daily treatment with placebo
58414268|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
58414269|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
58414270|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
58414271|NCT00189943|BIOLOGICAL|MVA-BN|
58302994|NCT02112942|DRUG|Matching Placebo|
58302995|NCT03552991|DRUG|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
58414272|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
58414273|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
58414274|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
58414275|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
58414276|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
57733443|NCT06161844|DRUG|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
57948568|NCT04261790|DRUG|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
57948569|NCT05482464|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
58302996|NCT00671788|DRUG|Dasatinib|Given orally
58414277|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
57948570|NCT05060822|DRUG|HEC585|HEC585 Tablets，once daily
57948571|NCT05060822|DRUG|Pirfenidone|Pirfenidone，three times a day
57948572|NCT05060822|DRUG|Placebo|Placebo，once daily
58302997|NCT00671788|OTHER|Laboratory Biomarker Analysis|Correlative studies
58302998|NCT05508373|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
58302999|NCT02755506|DEVICE|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
58303000|NCT00037050|DRUG|Linezolid|
58303001|NCT00037050|DRUG|Vancomycin|
58303002|NCT00037050|DRUG|Oxacillin|
58303003|NCT00037050|DRUG|Dicloxacillin|
58414278|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
58414279|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
58414280|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
58414281|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
58414282|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
58414283|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
58414284|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
58414285|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
58414286|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
58414287|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
58414288|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
58414289|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
57733444|NCT06161844|DRUG|Ozempic®|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
57733445|NCT04976738|DRUG|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
58087816|NCT03632798|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
58087817|NCT03632798|DRUG|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel."
58303004|NCT05900375|BEHAVIORAL|Parent Decision Aid|A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
58303005|NCT01061996|DRUG|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
58303006|NCT04394598|DRUG|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
58303007|NCT04394598|RADIATION|Pelvic Radiation|50Gy/25Fx
58303008|NCT04394598|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
58414290|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
58414291|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
58414292|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
58414293|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
58414294|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
58414295|NCT00002824|BIOLOGICAL|gene therapy|
58414296|NCT00002824|DRUG|chemotherapy|
58414297|NCT00002824|DRUG|ganciclovir|
58414298|NCT00002824|PROCEDURE|conventional surgery|
58414299|NCT01688843|DEVICE|INGEVITY lead|
58414300|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
58414301|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
58414302|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
58414303|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
58414304|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
58414305|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
58414306|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
58414307|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
58414308|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
58414309|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
58414310|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
58414311|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
58414312|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
58414313|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
58414314|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
58414315|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
57733446|NCT03506516|DIETARY_SUPPLEMENT|Mixing alcohol|Alcoholic beverages, different types
57733447|NCT03506516|DIETARY_SUPPLEMENT|Single type alcohol|Alcoholic beverages, different types
58087818|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
58414316|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
58414317|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
58414318|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
58414319|NCT03745352|DRUG|Azacitidine|Given IV or SC
58414320|NCT03745352|DRUG|Pevonedistat|Given IV
58414321|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
57948573|NCT02600832|BEHAVIORAL|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
58087819|NCT00268385|OTHER|Pharmacological Study|Correlative studies
58414322|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
58087820|NCT00268385|DRUG|Temozolomide|Given orally
58087821|NCT00268385|DRUG|Vorinostat|Given orally
58414323|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
58414324|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
58087822|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
58087823|NCT00960232|DRUG|placebo|placebo
58087824|NCT00087763|DRUG|Macugen ™ (pegaptanib sodium injection)|
58087825|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
58087826|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 to 18 years old.
58087827|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
58087828|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
58414325|NCT00301548|DRUG|perioperative chemotherapy|
58414326|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
58087829|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
58087830|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
58087831|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
58303009|NCT04394598|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
58303010|NCT04394598|OTHER|Placebo|3g tid per day for 5weeks
58303011|NCT03466632|DRUG|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
58303012|NCT03466632|DRUG|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
58303013|NCT05797025|OTHER|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
58303014|NCT01505283|DRUG|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
58303015|NCT01505283|DRUG|Sufentanil|epidural administration of sufentanil 10 µg
58414327|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
58414328|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
58414329|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
58414330|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
58414331|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
58414332|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
58414333|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
58414334|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
57948574|NCT02600832|BEHAVIORAL|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
57948575|NCT01720342|PROCEDURE|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
58303016|NCT01505283|DRUG|lidocaine|epidural administration of lidocaine 50 mg
57948576|NCT06223659|DRUG|Eutectic Mixture of Local Anesthetics|Apply topically to skin
58087832|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
58087833|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
58414335|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
57948577|NCT06223659|DRUG|Placebo Administration|Apply topically to skin
58414336|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
58414337|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
58414338|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
58414339|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
58414340|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
58414341|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
58414342|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
58414343|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
58414344|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
58414345|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
58414346|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
58414347|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
58414348|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
57948578|NCT06223659|OTHER|Questionnaire Administration|Ancillary studies
57948579|NCT00562354|BIOLOGICAL|13vPnC|13vPnC for both stratum
57948580|NCT00522353|DIETARY_SUPPLEMENT|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
57948581|NCT00522353|DIETARY_SUPPLEMENT|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
57948582|NCT04571411|OTHER|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
58414349|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
58414350|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
58414351|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
58414352|NCT04415879|DEVICE|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
58414353|NCT04415879|DEVICE|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
58414354|NCT04415879|DIAGNOSTIC_TEST|Graded exercise test|No personal protective equipment during a graded exercise test
58414355|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
58414356|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
58414357|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
58087834|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
58087835|NCT02959372|OTHER|lung ultrasound|
58087836|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
58303017|NCT05502770|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
58414358|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
58414359|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
58414360|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
58414361|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
58414362|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
58414363|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
58414364|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
58414365|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
58414366|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
58414367|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
58414368|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
58414369|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
58414370|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
58414371|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
58414372|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
58414373|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
58414374|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
58414375|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
57948583|NCT02189161|DEVICE|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
57948584|NCT03853681|DIAGNOSTIC_TEST|additional blood sampling|additional blood sampling
58303018|NCT05502770|OTHER|Physical development and General Health|Physical development and General health examination
58303019|NCT05502770|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
58303020|NCT01085643|DRUG|Lubiprostone|24mcg PO taken once
58303021|NCT01085643|DRUG|Placebo|24mcg placebo capsule taken once
58303022|NCT01738945|DRUG|Amlodipine|10 mg/day for 12 weeks
58414376|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
58414377|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
58414378|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
58414379|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
58414380|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
58414381|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
57948585|NCT05227638|OTHER|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
58303023|NCT01053741|BIOLOGICAL|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
58303024|NCT01053741|BIOLOGICAL|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
58303025|NCT00029822|DRUG|Alfuzosin (SL770499)|
58303026|NCT05469945|DEVICE|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
57733448|NCT05983601|DEVICE|Transcranial Direct Current Stimulation|The anode electrode will be placed at the midline of the Cz according to international 10-20 EEG system, and the cathode electrode will be placed at the midline of forehead. In this way, both hemisphere of motor cortex can be stimulated which is used as protocol in various balance studies (Siedel-Marzi and Ragert, 2020b; Saruco et al., 2017). Participants will continue their training with tDCS (2mA) for 20 minutes. This application will continue three times a week for four weeks. In the end of the study, participants will be asked to guess which group they were in (active or sham).
58303027|NCT03514550|DRUG|Propofol|Propofol will be used for anesthesia during surgery
58303028|NCT03514550|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
58303029|NCT03514550|PROCEDURE|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
58303030|NCT00534027|DRUG|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
58303031|NCT00534027|OTHER|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
58303032|NCT05441800|OTHER|Observational Study|observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases
58303033|NCT00004293|DRUG|glucocerebrosidase|
58303034|NCT00653393|DRUG|Tranylcypromine|Tablets, 10 mg, single-dose
58303035|NCT00653393|DRUG|Parnate|Tablets, 10 mg, single-dose
58303036|NCT02238808|DRUG|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
58303037|NCT05654571|DIAGNOSTIC_TEST|mammography|All patients are checked for mammography every year after surgery.
57733449|NCT06448871|DIAGNOSTIC_TEST|Ultrasound assessment of the right lower extremity muscles|Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.
58303038|NCT04541563|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
58414382|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
58414383|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
58414384|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
58414385|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
58414386|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
58414387|NCT00103519|DRUG|Placebo|Placebo
58414388|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
58414389|NCT01891344|DRUG|Oral rucaparib|600 mg BID
58414390|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
57733450|NCT06448871|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA) scan|skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
57733451|NCT05932069|BEHAVIORAL|SPIN|Stationary cycling
57733452|NCT05932069|BEHAVIORAL|Non-aerobic, stretching/balance intervention Control|Balance and stretching exercise
57733453|NCT01863277|DRUG|Melatonin|
57733454|NCT01863277|DRUG|placebo|
57948586|NCT02707783|DEVICE|Bioresorbable vascular scaffold (BVS) implantation|
58303039|NCT02643875|DEVICE|Orthokeratology|It is a kind of rigid permeable lens.
58303040|NCT02110979|BEHAVIORAL|Use of a PDA to assist shared decision making|
58303041|NCT05235438|DRUG|IMM27M|IMM27M injection
58303042|NCT01499810|PROCEDURE|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
58414391|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
58303043|NCT04080726|DRUG|HIP1601|Oral esomeprazole
58303044|NCT04080726|DRUG|HGP1705|Oral Nexium Tab
58303045|NCT04080726|DRUG|HIP1601 Placebo|Oral Placebo
58303046|NCT04080726|DRUG|HGP1705 Placebo|Oral Placebo
57948587|NCT00007085|DEVICE|Tomography, X-ray Computed|
57948588|NCT02288936|DRUG|Enzalutamide|Enzalutamide 160 mg/day
57948589|NCT03076203|DRUG|Niraparib|Given orally
58303047|NCT02541617|PROCEDURE|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
58303048|NCT02541617|PROCEDURE|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
58303049|NCT06182059|PROCEDURE|continuous peripheral nerve block|continuous regional anesthesia in total knee replacement
58303050|NCT02175121|DRUG|Placebo|Tablet, once daily for 28 days
58303051|NCT02175121|DRUG|PF-06291874|Tablet, 15 mg, once daily for 28 days
58303052|NCT02175121|DRUG|PF-06291874|Tablet, 35 mg, once daily for 28 days
58303053|NCT02175121|DRUG|PF-06291874|Tablet, 75 mg, once daily for 28 days
58303054|NCT02175121|DRUG|PF-06291874|Tablet, 150 mg, once daily for 28 days
58303055|NCT05905432|DRUG|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
58303056|NCT00823134|DEVICE|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
58414392|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
58414393|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
58414394|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
58414395|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
58414396|NCT00029458|DRUG|Clozapine|
58414397|NCT04879849|DRUG|Pembrolizumab|IV infusion.
58414398|NCT04879849|DRUG|TAK-676|IV infusion.
58414399|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
58414400|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
58414401|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
58414402|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
58414403|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
58303057|NCT00558545|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
58303058|NCT05871307|RADIATION|Preoperative Radiotherapy|Resection of brain mestases following
57785036|NCT05290103|BEHAVIORAL|Game intervention|"Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations."
58303059|NCT05871307|RADIATION|Intraoperative Radiation|While Resection
58303060|NCT05871307|RADIATION|Postoperative Radiotherapy|After resection
58303061|NCT02373865|DRUG|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
58303062|NCT02373865|DRUG|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
58303063|NCT02373865|DRUG|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
58303064|NCT02373865|DRUG|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
58303065|NCT03217591|DRUG|IW-1973|Oral Tablet
58414404|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
58414405|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
58414406|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
58414407|NCT02494089|OTHER|distress analysis|
58414408|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
58414409|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
58414410|NCT03172065|DRUG|Normal saline|intravenous flluid
58414411|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
58087837|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
58303066|NCT03217591|DRUG|IW-1973|Oral Tablet
58303067|NCT03217591|DRUG|Placebo|Oral Tablet
58414412|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
58414413|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
58414414|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
57948590|NCT03076203|RADIATION|Radium Ra 223 Dichloride|Given intravenously
57948591|NCT02738970|DRUG|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
58087838|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
58087839|NCT00711165|DRUG|Placebo|2 puffs, qd
58087840|NCT00711165|DRUG|Mometasone Furoate|400 mcg, qd for 8 weeks
58087841|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
58087842|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
58087843|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
58087844|NCT00299546|DRUG|Placebo|SC injections
58087845|NCT00299546|BIOLOGICAL|Golimumab 50 mg|SC injections
58303068|NCT02163395|DEVICE|FullCeram implant|FullCeram implantation
58303069|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
58303070|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
58303071|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
58303072|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
58303073|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
58303074|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
58414415|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
58414416|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol (10 mL. or 8 g of pure ethanol)) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
58414417|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
58414418|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
58414419|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
58414420|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
58414421|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
58414422|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
58414423|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
58414424|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
58414425|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
58414426|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
58414427|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
57948592|NCT02738970|DRUG|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
57948593|NCT03023527|DRUG|Nivolumab|
57948594|NCT03023527|DRUG|Pomalidomide|
58087846|NCT00299546|BIOLOGICAL|Golimumab 100 mg|SC injections
58087847|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
58087848|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
58087849|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
58303075|NCT06429865|DIAGNOSTIC_TEST|cytosponge|Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
58303076|NCT01952652|DRUG|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
58303077|NCT01952652|DRUG|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
58303078|NCT00520143|BIOLOGICAL|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
58303079|NCT04702152|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
58303080|NCT01494818|DEVICE|Hydrogen peroxide-based contact lens care system|
58303081|NCT01494818|DEVICE|PHMB-containing contact lens solution|
58303082|NCT01494818|DEVICE|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
57948595|NCT03023527|DRUG|Dexamethasone|
57948596|NCT03023527|DRUG|Elotuzumab|
57948597|NCT01556425|DRUG|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
57948598|NCT01556425|BEHAVIORAL|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
57948599|NCT01556425|OTHER|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
57948600|NCT01265797|DEVICE|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
57948601|NCT01265797|DEVICE|Sham Device|participant wears sham device for 20 minutes daily for 28 days
57948602|NCT04291443|PROCEDURE|Heavy Force (225g)|Orthodontic Force
58087850|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
58087851|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
58087852|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
58087853|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
58087854|NCT01829659|DRUG|Ticagrelor|
58303083|NCT01460303|DEVICE|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
58414428|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
58414429|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
58414430|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
58303084|NCT01460303|DEVICE|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
58303085|NCT01033500|DRUG|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
58303086|NCT01249911|DIETARY_SUPPLEMENT|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
58303087|NCT01249911|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
58414431|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
58414432|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
58414433|NCT05960305|OTHER|P1213416|Tobacco Flavor
58414434|NCT05960305|OTHER|P1213422|Tobacco Flavor
58414435|NCT05960305|OTHER|P1213716|Tobacco Flavor
58414436|NCT05960305|OTHER|P1213722|Tobacco Flavor
57948603|NCT04291443|PROCEDURE|Light Force (25g)|Orthodontic Force
57948604|NCT03882970|DRUG|Tirzepatide|Administered SC
57948605|NCT03882970|DRUG|Insulin Degludec|Administered SC
57948606|NCT02594306|DEVICE|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
57948607|NCT02594306|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
57948608|NCT02594306|PROCEDURE|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
57948609|NCT02594306|PROCEDURE|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
57948610|NCT01311050|DRUG|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
58087855|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
58087856|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
58414437|NCT05960305|OTHER|P1211216|Menthol Flavor
58414438|NCT05960305|OTHER|P1211222|Menthol Flavor
58414439|NCT05960305|OTHER|P1213616|Menthol Flavor
58414440|NCT05960305|OTHER|P1213622|Menthol Flavor
58414441|NCT05960305|OTHER|P1213816|NTNM Flavor
58414442|NCT05960305|OTHER|P1213822|NTNM Flavor
58414443|NCT05960305|OTHER|P1211916|NTNM Flavor
58414444|NCT05960305|OTHER|P1211922|NTNM Flavor
58414445|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
58087857|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
58087858|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
58303088|NCT02499055|BEHAVIORAL|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
58414446|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
58414447|NCT00002368|DRUG|Nevirapine|
58414448|NCT00002368|DRUG|Lamivudine|
58414449|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
58414450|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
58414451|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
58414452|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
57948611|NCT00326352|DRUG|Sedation with propofol and remifentanil|
57948612|NCT00919100|DEVICE|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
58303089|NCT05867381|DEVICE|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
57948613|NCT00919100|OTHER|vapocoolant|venipuncture with vapocoolant spray offered
57948614|NCT00823407|DRUG|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
57948615|NCT00823407|DRUG|Placebo|Subjects will receive a single oral dose of placebo
58303090|NCT05867381|DEVICE|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
58303091|NCT02294279|DRUG|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
58414453|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
58414454|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
58414455|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
57948616|NCT01852994|DRUG|Testosterone replacement|Application quarterly of Testosterone Undecylate
57948617|NCT01852994|OTHER|Exercise training|Aerobic and strength exercise training
57948618|NCT02170285|DEVICE|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
57948619|NCT02170285|DEVICE|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
57948620|NCT02797340|OTHER|Blood draws and urine samples for metformin concentration measurements|
57948621|NCT02797340|DRUG|Metformin|
57948622|NCT03134170|OTHER|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
58087859|NCT05032183|DRUG|Cyclophosphamide|Given IV
58087860|NCT05032183|DRUG|Cytarabine|Given IT
58087861|NCT05032183|DRUG|Dexamethasone|Given IV or PO
58087862|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
58087863|NCT05032183|DRUG|Leucovorin|Given IV
58087864|NCT05032183|DRUG|Mercaptopurine|Given PO
58087865|NCT05032183|DRUG|Mesna|Give IV
58303092|NCT01198002|DRUG|LY2127399|Administered Subcutaneously (SC)
58303093|NCT01198002|DRUG|Placebo Q2W|Administered SC
58303094|NCT01198002|DRUG|Placebo Q4W|Administered SC
58303095|NCT01198002|DRUG|Methotrexate|Methotrexate is a background therapy.
58303096|NCT02171000|DRUG|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
58303097|NCT05098080|BIOLOGICAL|Hutrukin|Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
58303098|NCT05098080|BIOLOGICAL|Placebo|Placebo control for Hutrukin IV push.
58087866|NCT05032183|DRUG|Methotrexate|Given IT
58087867|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
58087868|NCT05032183|DRUG|Prednisone|Given PO
58303099|NCT04746638|DIAGNOSTIC_TEST|whole body study and SPECT with 99mTc-RM26|One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
58303100|NCT04065490|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System
58303101|NCT04065490|DEVICE|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
57948623|NCT05065502|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.\[practice\]."
58303102|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
58303103|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
58303104|NCT03518359|BEHAVIORAL|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
58303105|NCT03518359|BEHAVIORAL|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
58303106|NCT01037426|OTHER|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information"
58303107|NCT04737733|OTHER|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
58303108|NCT03657069|DEVICE|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
58303109|NCT03657069|OTHER|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
58303110|NCT04237948|DEVICE|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
58303111|NCT04237948|BEHAVIORAL|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
58303112|NCT00477763|DRUG|Restasis, Refresh Endura|"1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
58303113|NCT00018824|DRUG|NALTREXONE|
58303114|NCT00018824|DRUG|Placebo|
57948624|NCT05065502|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
57948625|NCT02232373|BEHAVIORAL|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
57948626|NCT02232373|DIETARY_SUPPLEMENT|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
57948627|NCT02232373|DIETARY_SUPPLEMENT|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
57948628|NCT01359709|DRUG|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
57948629|NCT06177964|DRUG|Lerapolturev|"Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor."
57948630|NCT06177964|DRUG|Lomustine Pill|Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
57948631|NCT00760019|DRUG|salsalate|1.5 grams orally 3 times daily
58087869|NCT05032183|BIOLOGICAL|Rituximab|Given IV
58087870|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
58414456|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
58414457|NCT03207945|OTHER|Placebo|Placebo
58414458|NCT04243395|OTHER|Pork|1 oz lean pork
57948632|NCT00760019|DRUG|placebo|matching placebo
58087871|NCT05032183|DRUG|Vincristine|Given IV
58414459|NCT04243395|OTHER|Egg|1 large whole egg
58414460|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
58414461|NCT04243395|OTHER|Almonds|0.5 oz almonds
57948633|NCT02554019|BIOLOGICAL|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
57948634|NCT02554019|BIOLOGICAL|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
57948635|NCT04124913|DRUG|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
57948636|NCT04124913|DRUG|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
57948637|NCT03831074|DEVICE|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
58087872|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
58414462|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
58414463|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
58414464|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
57948638|NCT01848288|DEVICE|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
57948639|NCT01848288|DEVICE|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
57948640|NCT01925573|DEVICE|Optune(NOVOTTF-100A)|
57948641|NCT01203540|DRUG|NAABAK eyedrops|
57948642|NCT01203540|DRUG|Saline eyedrops|
57948643|NCT04841421|DRUG|89Zr-CD147|The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
58087873|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
58087874|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
58087875|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
58087876|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
58087877|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
58087878|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
57948644|NCT04542759|DRUG|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
57948645|NCT04542759|DRUG|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
57948646|NCT05127837|BEHAVIORAL|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
57948647|NCT01908764|DRUG|AL-60371 otic suspension|
57948648|NCT04866693|OTHER|None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.|Qualitative study
57948649|NCT03986385|DRUG|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
57948650|NCT03986385|DRUG|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
57948651|NCT00606320|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
58087879|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
58087880|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
58087881|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
58087882|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
57785037|NCT05398354|BEHAVIORAL|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
58087883|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
58087884|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
58087885|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
58087886|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
58087887|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
58087888|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
57948652|NCT00058786|BIOLOGICAL|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
57948653|NCT03459209|OTHER|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
57948654|NCT00004998|DRUG|Lamivudine/Zidovudine|
57948655|NCT00004998|DRUG|Capravirine|
57948656|NCT00004998|DRUG|Nelfinavir mesylate|
57948657|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
57948658|NCT04988412|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
57948659|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
57948660|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
57948661|NCT01086462|DRUG|GSK2239633|100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
57948662|NCT04092712|DRUG|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
57948663|NCT05352126|OTHER|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
57948664|NCT01309542|DRUG|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
58087889|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
58087890|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
58087891|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
58087892|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
58087893|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
58087894|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
58414465|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
58414466|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
58414467|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
58414468|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
58414469|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
58414470|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
58414471|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
58414472|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
58414473|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
58414474|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
58414475|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
58087895|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
58414476|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
58414477|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
58414478|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
58414479|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
58414480|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
58087896|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
57733455|NCT04348604|BEHAVIORAL|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
58087897|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
58087898|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
58087899|NCT05218096|DRUG|ALXN2050|Oral tablet.
58087900|NCT05218096|DRUG|Placebo|Oral tablet.
58087901|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
58087902|NCT00329758|DRUG|Placebo|
58303115|NCT03089463|DIAGNOSTIC_TEST|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
58303116|NCT03401047|DRUG|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
58414481|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
58087903|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
58087904|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
58087905|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
58087906|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
58087907|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
58087908|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
58087909|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
58087910|NCT03035500|OTHER|Educational Intervention|Receive health education
58087911|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
58087912|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
58087913|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
58087914|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
57948665|NCT03784079|DRUG|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
58087915|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
58087916|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
58087917|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
58087918|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
58087919|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
58087920|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
58087921|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
58303117|NCT04777981|DIETARY_SUPPLEMENT|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
58303118|NCT04777981|DIETARY_SUPPLEMENT|Placebo|Placebo
58303119|NCT01561937|DRUG|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
58303120|NCT01561937|DRUG|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
58303121|NCT01561937|DRUG|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
58303122|NCT00119574|PROCEDURE|Collaborative Chronic Illness Model|
58303123|NCT06446934|DEVICE|CPAP|Initial CPAP titration and subsequent CPAP therapy for 12 weeks
58303124|NCT04553666|DRUG|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
58087922|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
58087923|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
57948666|NCT03784079|DRUG|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
58087924|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|"Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient."
58087925|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
58414482|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
58414483|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
58414484|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
58414485|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
57733456|NCT04348604|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
57733457|NCT05135910|DRUG|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
57948667|NCT05921994|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
57948668|NCT03676621|DRUG|Misoprostol|buccal tablets
57948669|NCT03676621|DRUG|Oxytocin|intravenous drip
57948670|NCT05149898|DRUG|ZYN002|"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."
57948671|NCT06241092|OTHER||
57948672|NCT04191330|DEVICE|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
57948673|NCT00255970|OTHER|DFDBA|Demineralized Freeze Dried Allograft bone
57948674|NCT00255970|DEVICE|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
57948675|NCT03235648|PROCEDURE|cardiophrenic lymph nodes resection|surgical resection
57948676|NCT02970825|OTHER|Exercise|Moderate to high intensity physical training
57948677|NCT02970825|OTHER|Relaxation|Low intensity physical activity and relaxation
57948678|NCT00837941|DRUG|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
57948679|NCT00837941|DRUG|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
57948680|NCT00837941|DRUG|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
57948681|NCT01222676|DRUG|cisplatin|
57948682|NCT01222676|DRUG|gemcitabine hydrochloride|
57948683|NCT01222676|DRUG|sorafenib tosylate|
57948684|NCT01222676|OTHER|imaging biomarker analysis|
57948685|NCT01222676|OTHER|laboratory biomarker analysis|
57948686|NCT01222676|PROCEDURE|computed tomography|
57948687|NCT01222676|PROCEDURE|neoadjuvant therapy|
57948688|NCT01222676|RADIATION|fludeoxyglucose F 18|
57948689|NCT01821651|DEVICE|HeartNavigator|Procedure with software
57948690|NCT01821651|DEVICE|EchoNav|Procedure with software
57948691|NCT01821651|OTHER|Control-Group EN|Procedure without software
57948692|NCT01821651|OTHER|Control-group HN|Procedure without software
57948693|NCT05914142|DEVICE|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
57948694|NCT04384562|DRUG|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
57948695|NCT04384562|DRUG|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
57948696|NCT04384562|DRUG|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
57948697|NCT04384562|DRUG|Placebo pill|A placebo pill is administered only once.
57948698|NCT04384562|DRUG|Placebo gum|A placebo gum is administered only once.
57948699|NCT02094690|DEVICE|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
58414486|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
58414487|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
58087926|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
58087927|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
58087928|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
58087929|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
58087930|NCT03412448|OTHER|observation|Observation,
58087931|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
58303125|NCT02706288|OTHER|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose \~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
58414488|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
58414489|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
58414490|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
57733458|NCT05078190|OTHER|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
57733459|NCT03892772|DRUG|SAS0421a|treatment will be given for 3 days
57733460|NCT03892772|DRUG|SAS0421b|treatment will be given for 3 days
58414491|NCT05270291|PROCEDURE|rectal swab|rectal swab
58414492|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
58414493|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
58087932|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
58087933|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
58087934|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
58087935|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
58087936|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
58087937|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
58087938|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
58087939|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
58087940|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
58087941|NCT03415412|DEVICE|IBond Universal|Adhesive systems
58087942|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
58414494|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
58414495|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
58414496|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
58414497|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
58414498|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
57733461|NCT03892772|DRUG|SAS0421c|treatment will be given for 3 days
58087943|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
58087944|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
58087945|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
58087946|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
58087947|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
58087948|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
58087949|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
58087950|NCT01526707|DRUG|inhaled steroid|inhaled budesonide for 7 days
58414499|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
58414500|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
58414501|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
58414502|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
58414503|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
58414504|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
58414505|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
58414506|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
58087951|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
58303126|NCT05524064|RADIATION|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (\>40 Gy/s).
58303127|NCT01897337|DRUG|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
58303128|NCT01897337|DRUG|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
58303129|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
58303130|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
58303131|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
58303132|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
58303133|NCT03854942|DRUG|Placebo|Placebo oral tablet daily
58414507|NCT01376375|PROCEDURE|Acupuncture|
58414508|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
58414509|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
58414510|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
58414511|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
57733462|NCT03892772|DRUG|placebo|placebo will be given for 3 days
58087952|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
58303134|NCT03854942|DRUG|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
58303135|NCT01064414|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
58303136|NCT01064414|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
58303137|NCT00808223|BIOLOGICAL|alefacept|IM injection
58303138|NCT02194972|DRUG|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
58414512|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
58414513|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
58414514|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
58414515|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
58414516|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
58087953|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
58087954|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
58087955|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
58087956|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
58303139|NCT05436990|DRUG|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
58414517|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
58414518|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
58303140|NCT00254865|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
58414519|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
58414520|NCT00001812|DRUG|Nystatin|
58414521|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
58414522|NCT02688088|DRUG|Drug Cocktail|Administered orally
58414523|NCT02688088|DRUG|Abemaciclib|Administered orally
58303141|NCT05696067|BIOLOGICAL|Corfluvec component 1 low dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
58303142|NCT05696067|BIOLOGICAL|Corfluvec component 2 low dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
58303143|NCT05696067|BIOLOGICAL|Corfluvec component 1 high dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
58303144|NCT05696067|BIOLOGICAL|Corfluvec component 2 high dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
58303145|NCT05696067|BIOLOGICAL|Corfluvec low dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
58303146|NCT05696067|BIOLOGICAL|Corfluvec high dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
58303147|NCT05696067|BIOLOGICAL|Placebo|Participants will receive two intranasal injections of placebo three weeks apart
58303148|NCT01241474|DIETARY_SUPPLEMENT|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
58414524|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
58414525|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
58087957|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
58087958|NCT01650142|OTHER|No intervention|No intervention
58087959|NCT03868176|OTHER|short message service|short message service
58303149|NCT01241474|DIETARY_SUPPLEMENT|Maize (corn) oil|6 x 1g capsules per day for 9 months
58303150|NCT02390271|OTHER|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
58303151|NCT05801003|DEVICE|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
58303152|NCT05801003|DEVICE|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
58303153|NCT03662126|DRUG|KRT-232|KRT-232, administered by mouth
58303154|NCT03662126|DRUG|Best Available Therapy (BAT)|"Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed)."
58303155|NCT04536363|DRUG|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
58303156|NCT04536363|DRUG|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
58303157|NCT01705041|DEVICE|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
58303158|NCT05444699|DRUG|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
58303159|NCT05444699|DRUG|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
58303160|NCT00145886|DRUG|rhPTH|Subjects will be treated with rhPTH for 12 months.
58303161|NCT04284865|OTHER|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
58087960|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
58087961|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
58087962|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
57785038|NCT04017741|DRUG|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
58414526|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
58414527|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
58414528|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
58414529|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
58414530|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
58414531|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
58414532|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
58414533|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
58414534|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
58414535|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
58414536|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
58414537|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
58414538|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
58414539|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
58414540|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
57948700|NCT02094690|DEVICE|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
57948701|NCT03638154|PROCEDURE|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
57948702|NCT03638154|PROCEDURE|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
57948703|NCT01336582|DRUG|taxotere|70 mg/m2 for age of ≥ 65
57948704|NCT04319575|DRUG|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
58087963|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
58087964|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
58087965|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
58303162|NCT02415543|PROCEDURE|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
58303163|NCT02415543|PROCEDURE|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
58087966|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
58303164|NCT03846869|DIAGNOSTIC_TEST|major cations|blood sample
58087967|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
58087968|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
58087969|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
58087970|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
58087971|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
58303165|NCT04112576|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
58087972|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
58087973|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
58087974|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
58087975|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
58087976|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
58087977|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
58087978|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
58303166|NCT04398680|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered
58087979|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
58087980|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
58087981|NCT00359073|DRUG|montelukast|10 mg everyday
58087982|NCT00359073|DRUG|placebo|like placebo
58087983|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
58087984|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
58087985|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
58303167|NCT00374348|DRUG|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
58303168|NCT02900742|DRUG|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
58087986|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
58087987|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
58087988|NCT05898009|GENETIC|blood sample for BRCA2 mutation detection|blood sample
58087989|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
58414541|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
58414542|NCT00022724|DRUG|temsirolimus|
58414543|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
58414544|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
58414545|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
58414546|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
58414547|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
58414548|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
58414549|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
58414550|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
58414551|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
58414552|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
58414553|NCT00532571|DRUG|CoQ10|
58414554|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
58414555|NCT02576860|DRUG|Vehicle|Vehicle gel
58414556|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
57785039|NCT04017741|DRUG|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
58414557|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
58414558|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
58414559|NCT04233658|DRUG|Placebo|3x2 capsules / day
58414560|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
58414561|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
58414562|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
58414563|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
58414564|NCT00474864|DRUG|GW856553|
58414565|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
58087990|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
57733463|NCT05409014|OTHER|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
58303169|NCT02900742|DRUG|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
58303170|NCT02900742|DRUG|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
58414566|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
58414567|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
58414568|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
58414569|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
58414570|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
58414571|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
58414572|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
58303171|NCT02900742|DRUG|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
58303172|NCT02900742|DRUG|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
58303173|NCT02900742|DRUG|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
58303174|NCT02900742|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
57733464|NCT02535208|OTHER|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
58087991|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
58087992|NCT02152631|DRUG|Abemaciclib|Administered orally
58303175|NCT06460259|BEHAVIORAL|Breathing Exercise|He individual will be seated in a quiet environment in a semi-fowler or fowler position with their feet pointing forward. Then, they will be asked to join their hands on their abdomen and breathe normally while focusing on their breath. They will ensure their shoulders are relaxed, their body is loose, and they will inhale and exhale slowly and deeply through the nose without rushing.Next, while sitting upright with relaxed muscles, they will close their eyes, block their right nostril with their thumb or ring finger, inhale as much air as possible through the left nostril, and hold their breath. Then, they will block the left nostril with their ring finger or thumb and exhale slowly through the right nostril. The same process will be repeated for the left nostril. They will continue this process for approximately 2 minutes.
58414573|NCT00136968|DRUG|Voriconazole|
57733465|NCT02535208|OTHER|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
57733466|NCT03487835|OTHER|Kinesiotape|
57733467|NCT03487835|OTHER|No application|This group have no application during study time
58087993|NCT02152631|DRUG|Erlotinib|Administered orally
58087994|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
58087995|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
58303176|NCT06165432|DRUG|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
58303177|NCT06165432|OTHER|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
58303178|NCT05366166|BIOLOGICAL|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
58303179|NCT05366166|DRUG|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
58303180|NCT05366166|DRUG|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
58303181|NCT05366166|RADIATION|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
58303182|NCT05081388|DRUG|REGN14256|Sub-cutaneous (SC) single dose
58303183|NCT05081388|DRUG|imdevimab|SC single dose
58087996|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
58087997|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
58087998|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
58087999|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58088000|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
58088001|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
58088002|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
58088003|NCT02461407|DRUG|Anlotinib|Anlotinib p.o. qd
58088004|NCT02461407|DRUG|Placebo|Placebo p.o. qd
58088005|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
58414574|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
58088006|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
58088007|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
58414575|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
58414576|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
58414577|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
58414578|NCT01989702|OTHER|Fermented blueberry drink|
58088008|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
58088009|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
58088010|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
58414579|NCT01989702|OTHER|Placebo drink|
58088011|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
58088012|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
58088013|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
58303184|NCT05081388|DRUG|casirivimab + imdevimab|SC single dose
58303185|NCT05081388|DRUG|Placebo|SC single dose
58303186|NCT04576650|DEVICE|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
58303187|NCT01516723|DEVICE|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
58414580|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
58414581|NCT01989702|OTHER|Sachets with placebo powder|
58414582|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
58414583|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
58088014|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
58414584|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
58088015|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
58414585|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
58414586|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
58414587|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
57785040|NCT05468671|DRUG|Remimazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
58088016|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
58088017|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
58088018|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
58088019|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
58088020|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
58088021|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
58088022|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
58088023|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
58088024|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
58088025|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
58088026|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
58088027|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
58088028|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
58088029|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
58088030|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
57785041|NCT05468671|DRUG|Propofol|Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
58088031|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
58088032|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
58088033|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
58088034|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
58088035|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
58088036|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
58088037|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
58088038|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
58088039|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
58088040|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
58088041|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
58088042|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
57785042|NCT05468671|DRUG|Rocuronium|Rocuronium is a non-depolarizing neuromuscular blocker
57948705|NCT01109914|BIOLOGICAL|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
57948706|NCT02529787|DRUG|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
57948707|NCT02529787|DRUG|Dexilant|1 capsule contains 60 mg Dexlansoprazole
57948708|NCT02894853|GENETIC|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
57948709|NCT01550146|DRUG|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
57948710|NCT01550146|DRUG|Placebo|iv. Normal Saline 0.1 ml/kg
57948711|NCT06363214|PROCEDURE|Patient blood management|Perioperative optimization of hemoglobin level, perioperative minimization of blood loss, increase of anemia tolerance
57948712|NCT03743311|PROCEDURE|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
57948713|NCT03743311|DRUG|Detralex|Conservative treatment of Hemorhoid
57948714|NCT03743311|OTHER|Combined therapy|Surgical + conservative treatment of Hemorhoid
57948715|NCT00621699|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
57948716|NCT00621699|DRUG|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
57948717|NCT00621699|DRUG|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
57948718|NCT02331082|OTHER|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
58088043|NCT02999646|OTHER|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
58088044|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
58088045|NCT03753893|OTHER|No intervention used|no intervention used
58088046|NCT02508649|DRUG|selepressin|
58088047|NCT02508649|DRUG|placebo|
58088048|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
58088049|NCT05744219|DRUG|Placebo|Placebo
58414588|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
57785043|NCT05468671|DRUG|Remifentanil|Remifentanil is an esterase-metabolized opioid
57785044|NCT05468671|DRUG|oxycodone|Oxycodone is an opiate painkiller.
57785045|NCT05468671|DRUG|Sugammadex Sodium|Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
57785046|NCT05468671|DRUG|Flumazenil|Flumazenil is used to reverse the effects of a benzodiazepine
57785047|NCT00217100|DIETARY_SUPPLEMENT|Multivitamin|1 tablet a day
57785048|NCT00217100|DIETARY_SUPPLEMENT|Placebo|1 tablet a day
57785049|NCT00170911|DRUG|AAE581|
57785050|NCT06270290|OTHER|Exposure to contact sports or history of concussions|History of contact sports practices or of concussions
57785051|NCT01719120|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
57785052|NCT00739193|DRUG|amiodarone|
57785053|NCT04640480|DRUG|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
57785054|NCT05498766|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
57785055|NCT05498766|DRUG|Oxaliplatin|Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
58088050|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
58088051|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
58088052|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
58088053|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
58414589|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
58414590|NCT00000729|DRUG|Foscarnet sodium|
57948719|NCT02331082|OTHER|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
57948720|NCT02331082|DEVICE|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
58088054|NCT01565655|DRUG|peficitinib|oral
58088055|NCT01565655|DRUG|Placebo|oral
58088056|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
58088057|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
58088058|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
58088059|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
58088060|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
58303188|NCT05625685|OTHER|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
58414591|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
58414592|NCT02252809|DRUG|adalimumab|
58414593|NCT02252809|DRUG|methylprednisolone|
58414594|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
58414595|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
58414596|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
57948721|NCT02331082|DEVICE|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
57948722|NCT02331082|BEHAVIORAL|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
58414597|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
58088061|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
57948723|NCT02331082|OTHER|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
57948724|NCT00846300|BEHAVIORAL|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
58088062|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
58088063|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
58414598|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
58414599|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
58088064|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088065|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088066|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088067|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088068|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088069|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
57948725|NCT00972673|DRUG|Placebo|comparator
57948726|NCT00972673|DRUG|GW685698X|Inhaled steroid
57948727|NCT04501185|DEVICE|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
57948728|NCT05546125|OTHER|as per Physician's prescription|Participants need to take the Revatio as per Physician's prescription
57948729|NCT00761514|DRUG|Humira (adalimumab)|40 mg eow
57948730|NCT00397813|DRUG|Cyclosporine|Given PO
57948731|NCT00397813|DRUG|Fludarabine Phosphate|Given IV
57948732|NCT00397813|OTHER|Laboratory Biomarker Analysis|Correlative studies
57948733|NCT00397813|DRUG|Mycophenolate Mofetil|Given PO
57948734|NCT00397813|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
57948735|NCT00397813|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
57948736|NCT00397813|RADIATION|Total-Body Irradiation|Undergo TBI
57948737|NCT03546530|DRUG|Interferon|Interferon
57948738|NCT03546530|DRUG|Interferon+resveratrol|Interferon+resveratrol
57948739|NCT05054114|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
57948740|NCT05774379|DEVICE|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
57948741|NCT05774379|BEHAVIORAL|fatigue education|fatigue education for children
58088070|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088071|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58088072|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
58088073|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
58088074|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
58088075|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
58088076|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
58088077|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
58088078|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
58088079|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
58088080|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
58088081|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
58088082|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
58088083|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
58088084|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
58088085|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
58088086|NCT06315530|DRUG|Telitacicept|160mg once a week for 48 weeks
58088087|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
58088088|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
58088089|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
58088090|NCT02151565|DEVICE|HTEMS|
58088091|NCT02151565|DEVICE|TENS|
58088092|NCT00142961|DRUG|Atomoxetine|atomoxetine
58088093|NCT00142961|OTHER|placebo|
58088094|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
58088095|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
58088096|NCT02823782|OTHER|neuropsychological assessment|
58088097|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
58088098|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
58088099|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
58088100|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
58088101|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
58088102|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
58088103|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
58088104|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
58414600|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
58088105|NCT06055894|DIETARY_SUPPLEMENT|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
58088106|NCT06055894|DIETARY_SUPPLEMENT|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
58088107|NCT06055894|DIETARY_SUPPLEMENT|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
58088108|NCT06055894|OTHER|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
58414601|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
58088109|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
58088110|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
58088111|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
58088112|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
58088113|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
58088114|NCT00563706|DRUG|risperidone|
58088115|NCT00563706|OTHER|placebo|
58088116|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
58088117|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
58303189|NCT05625685|OTHER|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
58088118|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
58088119|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
58088120|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
58303190|NCT05625685|OTHER|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
58303191|NCT05625685|OTHER|SDoH Control|No SDoH intervention
58303192|NCT02614638|OTHER|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
58303193|NCT02614638|OTHER|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
58414602|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
58414603|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
58414604|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
58088121|NCT04911075|DRUG|85% TCA Solution|"* TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
58088122|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
58088123|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
58088124|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
58088125|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
58088126|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
58088127|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
58088128|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
58088129|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
58088130|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
58088131|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
58088132|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
58088133|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
58088134|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
58088135|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
58088136|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
58088137|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
58088138|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
58088139|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
58088140|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
58088141|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
58088142|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
58088143|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
58088144|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
58088145|NCT00297063|DRUG|Rosiglitazone|
58088146|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
58088147|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
58303194|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
58303195|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
58088148|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
58303196|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
58088149|NCT00421369|DRUG|sertraline|
58088150|NCT00421369|DRUG|triiodothyronine (T3)|
58088151|NCT00421369|DRUG|reboxetine|
58088152|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
58088153|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
58088154|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
58088155|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
58088156|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
58303197|NCT01951144|DRUG|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
58303198|NCT02158689|DRUG|Letrozole|
58303199|NCT02158689|DRUG|human menopausal gonadotropin (hMG)|
58303200|NCT01248897|OTHER|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
57948742|NCT04075838|OTHER|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
57948743|NCT03014778|DRUG|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
57948744|NCT03014778|DRUG|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
57948745|NCT02075099|OTHER|tensing exercises|Donors will do tensing exercises during blood donation
57948746|NCT02075099|OTHER|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
57948747|NCT02192203|DRUG|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
57948748|NCT02192203|DRUG|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
57948749|NCT02192203|DRUG|Menthol Only Gel|3% menthol
57948750|NCT02192203|DRUG|Placebo Only Gel|0.09% menthol
57948751|NCT04035070|COMBINATION_PRODUCT|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
57948752|NCT04035070|COMBINATION_PRODUCT|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
57948753|NCT04035070|COMBINATION_PRODUCT|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
57948754|NCT04782271|DRUG|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
57948755|NCT04782271|DRUG|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
57948756|NCT04782271|DRUG|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
57948757|NCT04782271|DRUG|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
57948758|NCT01161264|BIOLOGICAL|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
57948759|NCT05447468|OTHER|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
57948760|NCT05447468|OTHER|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
57948761|NCT05447468|OTHER|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
57948762|NCT05447468|OTHER|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
57948763|NCT05447468|OTHER|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
57948764|NCT05447468|OTHER|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
57948765|NCT04248101|PROCEDURE|Double Ligation|
57948766|NCT04248101|DRUG|Topical Silver Nitrate|
57948767|NCT02921620|BIOLOGICAL|PRX-102|Intravenous
57948768|NCT02921620|OTHER|Placebo|Intravenous
57948769|NCT01767454|DRUG|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
57948770|NCT01767454|DRUG|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
57948771|NCT01767454|DRUG|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
57948772|NCT01187186|DRUG|ASP1941|oral
57948773|NCT00812058|DRUG|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
57948774|NCT00812058|DRUG|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
57948775|NCT03812640|DEVICE|Vicryl suture|Corneal suture with Vicryl suture
58303201|NCT05013411|OTHER|Qualitative study|Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
58088157|NCT03099265|DRUG|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
58088158|NCT03099265|DRUG|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
58088159|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
58088160|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
58088161|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
58088162|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
58088163|NCT01649999|DRUG|peficitinib|oral
58088164|NCT01649999|DRUG|Placebo|oral
58088165|NCT04483570|PROCEDURE|Redo-tethering operation|
58088166|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
58088167|NCT03125564|PROCEDURE|Sham|Infusion of sham
58088168|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
58088169|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
58088170|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
58088171|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
58088172|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
58088173|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
58088174|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
58414605|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
58414606|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
57785056|NCT05498766|DRUG|Tegafur, Gimeracil and Oteracil Potassium|Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
58088175|NCT04190056|DRUG|Tamoxifen|Given PO
58088176|NCT04190056|DRUG|Vorinostat|Given PO
58088177|NCT05137639|PROCEDURE|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
58088178|NCT05273554|DRUG|Pembrolizumab|Given by IV
58088179|NCT05273554|DRUG|lenvatinib|Given by PO
58088180|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
58088181|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
58088182|NCT03970252|DRUG|Fluorouracil|Given IV
58088183|NCT03970252|DRUG|Irinotecan|Given IV
58088184|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
58088185|NCT03970252|DRUG|Leucovorin|Given IV
58088186|NCT03970252|DRUG|Leucovorin Calcium|Given IV
58088187|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
58088188|NCT03970252|DRUG|Oxaliplatin|Given IV
58088189|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58088190|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
58088191|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
58088192|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
58088193|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
58088194|NCT02519582|DRUG|Niclosamide|2 g per day orally
58088195|NCT02784002|DRUG|Ridinilazole|
58088196|NCT02784002|DRUG|Fidaxomicin|
58088197|NCT03176953|DRUG|topiramate|active medication
58088198|NCT03176953|BEHAVIORAL|prolonged exposure|psychotherapy
58088199|NCT03176953|DRUG|placebo|non-active medication
58088200|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
58088201|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
58303202|NCT05720598|PROCEDURE|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (\>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
58414607|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
57948776|NCT03812640|DEVICE|Nylon suture|Corneal suture with Nylon suture
57948777|NCT00005039|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|Given IM
57948778|NCT00005039|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
57948779|NCT00005039|OTHER|laboratory biomarker analysis|Correlative studies
57948780|NCT04171375|DEVICE|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
57948781|NCT00547170|DRUG|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
57948782|NCT00547170|DRUG|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
58088202|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
58088203|NCT02286284|DEVICE|Apheresis for extracorporal removal of sFlt-1|
58088204|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
58088205|NCT05894668|OTHER|ECIRS|Endoscopic Combined Intrarenal Surgery
58088206|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
58088207|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
58088208|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
58088209|NCT00000254|DRUG|0.2% isoflurane|
58088210|NCT00000254|DRUG|0.4% isoflurane|
58088211|NCT00000254|DRUG|0.6% isoflurane|
58088212|NCT00792142|DRUG|bortezomib|Given IV
58088213|NCT00792142|DRUG|dexamethasone|Given orally
58088214|NCT00792142|DRUG|melphalan|Given IV
58088215|NCT00792142|DRUG|thalidomide|Given orally
58088216|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
58088217|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
58088218|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
58088219|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
58088220|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
58088221|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
58414608|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
58414609|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
58088222|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
58414610|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
58414611|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
58414612|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
58088223|NCT05418517|PROCEDURE|Tracheostomy|temporary tracheostomy insertion
58088224|NCT05418517|PROCEDURE|Overnight intubation|Patient who had overnight intubation
58088225|NCT00240786|DRUG|acetaminophen extended release|
58088226|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
58088227|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
58088228|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
58088229|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
58088230|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
58303203|NCT05720598|PROCEDURE|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
58414613|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
58414614|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
58414615|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
58414616|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
58088231|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
58088232|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
58088233|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
58088234|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
58088235|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
58088236|NCT01853969|OTHER|Typing assessment|
58088237|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
58088238|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
58088239|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
58088240|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
58088241|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
58088242|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
58088243|NCT06346080|OTHER|Survey|Discrete choice survey
58088244|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
58088245|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
58088246|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
58088247|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
58088248|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
58088249|NCT00243672|DRUG|Atorvastatin|
58088250|NCT00243672|DRUG|Gemfibrozil|
58088251|NCT03046966|PROCEDURE|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds"
58088252|NCT03046966|OTHER|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
58088253|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
58088254|NCT05881863|OTHER|No intervention|This is an observational study
58088255|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
58088256|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
58088257|NCT05550259|PROCEDURE|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
58088258|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
58088259|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
58088260|NCT05327803|DRUG|Epetraborole|500 mg taken orally QD
58088261|NCT05327803|DRUG|Placebo|Placebo taken orally QD
58414617|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
58088262|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
58088263|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
58088264|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
58088265|NCT05060913|DRUG|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
58088266|NCT05060913|DRUG|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
58088267|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
58088268|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
58088269|NCT05864287|BEHAVIORAL|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
58088270|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
58088271|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
58088272|NCT00811031|DRUG|Taxotere|75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
58088273|NCT00811031|DRUG|Prednisone|5 mg twice a day by mouth.
58088274|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
58303204|NCT05720598|PROCEDURE|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
58303205|NCT00101244|DRUG|ispinesib|Given IV
57948783|NCT03554876|DEVICE|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
58088275|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
58088276|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
58088277|NCT06415279|DRUG|Winlevi (clascoterone) 1% cream|Twice daily (BID) dosing
58088278|NCT05329155|DRUG|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
58088279|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
58088280|NCT05525429|BEHAVIORAL|Nutrition Education|Multidimensional nutrition education will be provided.
58303206|NCT00101244|OTHER|laboratory biomarker analysis|Correlative studies
58303207|NCT00101244|OTHER|pharmacological study|Correlative studies
58303208|NCT05328427|OTHER|Stopping|Discontinuation of nucleoside analogue
58303209|NCT00761228|DRUG|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
58414618|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
58303210|NCT00761228|DRUG|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
58303211|NCT02674139|DEVICE|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
58414619|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
58303212|NCT05497752|OTHER|cervical rehabilitation program|"(Positional release technique on trapezius muscle): The subject was supine The therapist applied Pressure by pinching the trapezius muscle between the thumb and fingers.~Suboccipital muscle release):~The patient will be in a Supine lying position therapist places both his palms at suboccipital region with upward pressure causing a stretch and distraction for 30 seconds. This technique was performed 3 times in one session with a rest interval of 1 minute after each time.~(Stretching of pectoralis muscle):. once daily Stretching with repetition of five, three times a day for 1week"
58414620|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
58414621|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
58414622|NCT00003772|PROCEDURE|quality-of-life assessment|
58303213|NCT05497752|OTHER|control group|Relax shoulders and neck sufficiently look down turn face to the right turn face to the left incline head to the right incline head to the left turn shoulders round and round slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening).
58303214|NCT01994213|DRUG|Famitinib|Famitinib 25 mg p.o. qd
58303215|NCT03559634|DIAGNOSTIC_TEST|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
58303216|NCT03559634|OTHER|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
58303217|NCT03539107|PROCEDURE|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
58303218|NCT03539107|OTHER|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
58303219|NCT00726609|DRUG|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
58303220|NCT01791985|DRUG|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
58303221|NCT01477307|OTHER|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
58303222|NCT02389959|DRUG|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
58303223|NCT02389959|DRUG|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
58303224|NCT04088162|DEVICE|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
58303225|NCT03102762|DRUG|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
58303226|NCT03102762|DRUG|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
58303227|NCT00863707|DRUG|Regadenoson|IV
58303228|NCT00863707|DRUG|Placebo|IV
58303229|NCT02512887|DRUG|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
58303230|NCT02512887|DRUG|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
58414623|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
58414624|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
58414625|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
57948784|NCT03554876|DEVICE|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
58088281|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
58088282|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
58414626|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
58303231|NCT04054830|DRUG|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
58414627|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
58303232|NCT04054830|DRUG|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
32848985|NCT05549440|DEVICE|Orsiro Mission|Percutaneous intervention using Orsiro Mission stent
32848986|NCT05549440|DEVICE|Resolute Onyx|Percutaneous intervention using Resolute Onyx stent
57733468|NCT04728243|OTHER|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
58303233|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Auto-Injector (AI).
58303234|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
58303235|NCT04188600|DIETARY_SUPPLEMENT|Libicare|"The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)"
58303236|NCT04188600|DIETARY_SUPPLEMENT|active control|Selenium and vitamins B complex
58303237|NCT02888834|OTHER|Adverse drug reaction|
58303238|NCT05200169|DRUG|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
58303239|NCT03369574|DRUG|Reslizumab|reslizumab administration
58303240|NCT01198912|DRUG|placebo|during 56 days
58303241|NCT01198912|DRUG|doxycycline 100 mg|during 56 days
58303242|NCT05810896|OTHER|AF at Home|The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q\&A. Supplementary educations materials will be made available to participants.
57733469|NCT04728243|OTHER|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
57733470|NCT00982358|DRUG|Valsartan|
58303243|NCT02532504|OTHER|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets"
58303244|NCT00004862|BIOLOGICAL|filgrastim|
58303245|NCT00004862|BIOLOGICAL|oblimersen sodium|
58303246|NCT00004862|DRUG|cytarabine|
58303247|NCT00004862|DRUG|fludarabine phosphate|
58303248|NCT05084976|BEHAVIORAL|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
58303249|NCT01021397|DRUG|rHPIV3cp45|10\^5 TCID50 nasal drops
58414628|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
58414629|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
58414630|NCT00005013|DRUG|Sertraline|
58414631|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
58414632|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
57733471|NCT00982358|OTHER|Placebo|
58303250|NCT01021397|DRUG|rHPIV3cp45 placebo|1X-L15 nasal drops
58303251|NCT03455517|DRUG|Venetoclax|Venetoclax and rituximab association
58303252|NCT03455517|DRUG|Rituximab|Venetoclax and rituximab association
58303253|NCT00541242|DRUG|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
58088283|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
58088284|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58088285|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
58088286|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
58088287|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
58088288|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
58088289|NCT06560255|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
58088290|NCT06560255|OTHER|Rape seed oil|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
58088291|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
58088292|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
58088293|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
58088294|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
58088295|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
58088296|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
58088297|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
58088298|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
58088299|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
58088300|NCT01101269|DRUG|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
58088301|NCT01101269|DRUG|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
58088302|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
58088303|NCT05378269|OTHER|Placebo|Placebo vaginal insert
58088304|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
58088305|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
58088306|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
58088307|NCT02729350|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
58088308|NCT02729350|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
57733472|NCT05892354|DIETARY_SUPPLEMENT|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
58088309|NCT04182386|PROCEDURE|Portal vein embolization|Selective preoperative portal vein embolization
58088310|NCT03858998|OTHER|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
58088311|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
58088312|NCT06126770|BEHAVIORAL|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
58088313|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
58088314|NCT03030638|DRUG|Olodaterol|Drug
58414633|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
57733473|NCT05892354|DIETARY_SUPPLEMENT|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
57733474|NCT04223193|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
57733475|NCT04223193|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
57733476|NCT06312839|OTHER|Collecting data from the medical record|"Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay"
58088315|NCT03030638|DRUG|Indacaterol|Drug
58088316|NCT06264141|DRUG|Nitric Oxide Releasing Solution|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
58088317|NCT06264141|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
58088318|NCT01096862|DRUG|peficitinib|oral
58088319|NCT01096862|DRUG|Placebo|oral
58088320|NCT05518565|OTHER|No intervention|No intervention
58088321|NCT02801201|DRUG|Midazolam|
58088322|NCT02801201|DRUG|Bupivacaine|
58088323|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
58414634|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
58414635|NCT03444766|DRUG|Nivolumab|specified dose on specified days
58088324|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
58088325|NCT06700460|DEVICE|Laser-assisted in Situ Keratomileusis|LASIK
58088326|NCT06700460|DEVICE|Implantable Collamer Lens placement|EVO ICL
58088327|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
58088328|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
58414636|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
58088329|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
58088330|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
58088331|NCT06156046|DIAGNOSTIC_TEST|skin prick test|Skin prick test for bee venom
58088332|NCT06156046|DIAGNOSTIC_TEST|Blood tests|IgE/G and T cell tolerance studies
58088333|NCT04485624|OTHER|No intervention|Observational study
58088334|NCT04317547|BEHAVIORAL|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
58088335|NCT04317547|BEHAVIORAL|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
58088336|NCT02237768|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
58088337|NCT02237768|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
58414637|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
58414638|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
58414639|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
58414640|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
58414641|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
58088338|NCT05150197|DEVICE|VisuALL|Virtual Reality Visual Field Device
58414642|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
58088339|NCT05150197|DEVICE|Humphrey Visual Field|Standard of care Visual Field test
58088340|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
58088341|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
58088342|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches...) will not be forbidden or contra-indicated."
57733477|NCT03222518|DRUG|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
58088343|NCT03224234|DEVICE|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
58088344|NCT03224234|DEVICE|Insulclock without feedback|Not feedback on insulin administration.
58088345|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
58088346|NCT00007735|DRUG|Doxycycline (200mg/day) or Placebo|
58303254|NCT00541242|DRUG|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
58303255|NCT01126099|DRUG|Prazosin|4 mg capsules twice daily for 12 weeks
58303256|NCT01126099|DRUG|Placebo|Placebo capsules twice daily for 12 weeks
58303257|NCT06438211|PROCEDURE|superficial or deep serratus anterior plane block for mastectomy|group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy
58303258|NCT02539251|BEHAVIORAL|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
57733478|NCT03222518|DRUG|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
57733479|NCT03222518|DRUG|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
57733480|NCT04006977|DIETARY_SUPPLEMENT|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
58303259|NCT04072029|PROCEDURE|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
58303260|NCT06316635|PROCEDURE|ventilation tube insertion|a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
58303261|NCT03135314|DIETARY_SUPPLEMENT|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
58303262|NCT03135314|DIETARY_SUPPLEMENT|placebo|7 days of placebo intake
58303263|NCT00747916|DEVICE|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
58303264|NCT05306990|DRUG|Atorvastatin 40 Mg Oral Tablet|patients followed up for 3 months
58303265|NCT05306990|DRUG|Rosuvastatin 20 Mg Oral Tablet|patients followed up for 3 months
58303266|NCT06521970|DIAGNOSTIC_TEST|The kyphosis angle|The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.
58303267|NCT06521970|DIAGNOSTIC_TEST|dynamic postural performance|The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
58303268|NCT06521970|DIAGNOSTIC_TEST|forward head position|The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (\>8 cm)
58303269|NCT04610229|RADIATION|Hypofractionation guioded by dose painting|1
58303270|NCT02479750|DEVICE|ColdZyme® mouth spray|
58303271|NCT02479750|DEVICE|Placebo|
58303272|NCT02112695|OTHER|[11C]diprenorphine|3 micrograms \[11C\]diprenorphine - intravenous use - 1 time
58303273|NCT00735709|DRUG|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
58303274|NCT00735709|DRUG|Placebo|Vortioxetine placebo-matching capsules
58303275|NCT03834311|DEVICE|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
58303276|NCT03834311|OTHER|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
58303277|NCT02746835|OTHER|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
57733481|NCT04006977|DIETARY_SUPPLEMENT|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
57733482|NCT01417312|DIETARY_SUPPLEMENT|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
58414643|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
58414644|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
58414645|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
58414646|NCT00900185|GENETIC|mutation analysis|
58414647|NCT00900185|GENETIC|polymerase chain reaction|
58414648|NCT00900185|GENETIC|polymorphism analysis|
58414649|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
58414650|NCT01328041|DRUG|dolutegravir|50 mg twice daily
58414651|NCT01718249|OTHER|Implantable neurostimulation system|
58414652|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
58414653|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
57733483|NCT01417312|DIETARY_SUPPLEMENT|Placebo|Daily intake of placebo capsules for 3 months
57733484|NCT04846608|OTHER|Observation|Observation
57733485|NCT00546728|DRUG|Exenatide|exenatide 10 mcg twice daily
57733486|NCT00546728|DRUG|Metformin|metformin 500 twice daily
58088347|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
58414654|NCT02907853|BEHAVIORAL|Contingency Management|as described above
58414655|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
58414656|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
58414657|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
57733487|NCT04561479|OTHER|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
58088348|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
58414658|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
58414659|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
58414660|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
58414661|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
58414662|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
57733488|NCT04561479|OTHER|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
57948785|NCT03554876|DEVICE|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
58088349|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
58414663|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
58414664|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
58414665|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
58414666|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
58414667|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
58414668|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
58414669|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
58414670|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
58414671|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
58414672|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
58414673|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
58414674|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
58414675|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
58414676|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
58414677|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
58414678|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
58414679|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
58414680|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
58414681|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
58414682|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
58414683|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
58414684|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
58414685|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
58414686|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
58414687|NCT00044187|DRUG|Sibutramine|
57733489|NCT03929146|DRUG|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
57948786|NCT05753072|OTHER|Carer Support Nurse|Specialist community nursing role to support unpaid family/carers with complex health-related support needs or unresolved health-related support needs that cannot be met by their usual health care team
57948787|NCT03045861|DRUG|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
58303278|NCT02781324|PROCEDURE|Posterior Spinal Fusion|
58303279|NCT02781324|DEVICE|Ultrasonic Bone Scalpel|
58303280|NCT06424522|DIETARY_SUPPLEMENT|Dietary Fiber|Receive dietary fiber
57948788|NCT03045861|DRUG|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
58303281|NCT06424522|PROCEDURE|Enema Administration|Undergo RRE
58303282|NCT06424522|DRUG|Loperamide Hydrochloride|Receive loperamide hydrochloride
58414688|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
58414689|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
58414690|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
58414691|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
58414692|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
58414693|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
58303283|NCT06424522|PROCEDURE|Physical Therapy|Undergo pelvic floor physical therapy
58414694|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
58303284|NCT06424522|OTHER|Questionnaire Administration|Ancillary studies
58414695|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
58414696|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
58414697|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
58414698|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
58414699|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
58414700|NCT02606227|OTHER|No financial incentive|No financial intervention
58414701|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
58414702|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
58414703|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
58414704|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
58414705|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
58414706|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
58414707|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
58303285|NCT06424522|PROCEDURE|X-Ray Imaging|Undergo abdominal film x-ray
58303286|NCT04221334|DEVICE|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
58303287|NCT04221334|OTHER|oral health care application|phone application that shows the user brushing efficiency real time
58414708|NCT03579446|DRUG|Hydrocodone|Given by PO
58414709|NCT03579446|DRUG|Hydromorphone|Given by PO
58414710|NCT03579446|DRUG|Levorphanol|Given PO
58414711|NCT03579446|DRUG|Morphine|Given by PO
58414712|NCT03579446|DRUG|Oxycodone|Given by PO
58414713|NCT03579446|DRUG|Oxymorphone|Given by PO
57948789|NCT00617500|OTHER|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
57948790|NCT00617500|OTHER|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
57948791|NCT00617500|OTHER|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
58303288|NCT01321034|DRUG|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
58303289|NCT00001104|DRUG|Zidovudine|
58303290|NCT00746551|DRUG|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
58303291|NCT00746551|DRUG|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
57948792|NCT00617500|DRUG|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
57948793|NCT03024554|DEVICE|Implantation of the Bifurcated Multilayer Flow Modulator|
57948794|NCT01914874|BEHAVIORAL|Mindfulness Meditation|
58414714|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
57948795|NCT04647591|OTHER|Questionnaires|Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
58088350|NCT05355194|OTHER|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
58303292|NCT03548077|BEHAVIORAL|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
58303293|NCT02988700|DRUG|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
58303294|NCT02988700|DRUG|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
58303295|NCT00005868|DRUG|cisplatin|
58303296|NCT00005868|DRUG|docetaxel|
58303297|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2321138A|One intramuscular injection
58303298|NCT01204671|BIOLOGICAL|FluarixTM|One intramuscular injection
58303299|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2604409A|One intramuscular injection
58303300|NCT04245969|DEVICE|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
58303301|NCT04245969|OTHER|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
58303302|NCT04245969|OTHER|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
58303303|NCT03345641|OTHER|describe precocious maternal impressions when confronting the premature birth of her infant|
58303304|NCT05246657|PROCEDURE|EUS-guided Entero-biliary Anastomosis|EUS-guided Entero-biliary Anastomosis
58303305|NCT05704816|OTHER|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
58303306|NCT02572453|DRUG|Onalespib|Given IV
58303307|NCT06485960|OTHER|ESDAM validation|"* 3\* 24-Hour Dietary Recalls~* Experience Sampling Dietary Assessment Method (mobile application)~* Continuous Blood Glucose Monitoring~* Doubly-labeled water administration~* Blood drawings (Erythrocyte Membrane Fatty Acid composition, Carotenoids)~* Urine sampling (Doubly-labeled water, urinary nitrogen)"
58303308|NCT04925557|DRUG|Mayzent|PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
58303309|NCT04925557|DRUG|Ocrevus|PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
58303310|NCT04844216|DEVICE|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
58303311|NCT04844216|DEVICE|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
58303312|NCT05356221|DEVICE|Ponto Sound processor|Bone Anchored Hearing solution fitted to compensate for the subjects hearing loss
58303313|NCT05986123|OTHER|Topical cream Z for PIH|The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
58303314|NCT02007902|OTHER|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"* Patient inclusion at birth~* Total plasma protein values measurement on cord blood sample at birth~* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth."
58303315|NCT00552695|DEVICE|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
58303316|NCT00552695|DEVICE|Placebo|Placebo patch identical in appearance to Synera
58303317|NCT04564911|COMBINATION_PRODUCT|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
58303318|NCT04564911|COMBINATION_PRODUCT|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
58303319|NCT01809756|OTHER|Caphosol|Caphosol 4 times a day
58303320|NCT02244983|OTHER|Patients History|History taking and drawing of a blood sample
58414715|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
58414716|NCT00149994|DRUG|Cyclosporine A|
58414717|NCT00149994|DRUG|Tacrolimus|
58414718|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
58088351|NCT05355194|OTHER|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
58088352|NCT05035706|PROCEDURE|Biopsy|Undergo biopsy
58088353|NCT05035706|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
58088354|NCT05035706|OTHER|Electronic Health Record Review|Medical records reviewed
58088355|NCT05035706|OTHER|Photography|Photographs taken
58303321|NCT01575080|DEVICE|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
58088356|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
58088357|NCT01016925|PROCEDURE|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
58088358|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
58088359|NCT00058045|BIOLOGICAL|aldesleukin|
58088360|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
58303322|NCT02124824|DRUG|BQ-123|Endothelin subtype A antagonist
58303323|NCT00103948|DRUG|Aricept|
58303324|NCT02247466|DRUG|Rocuronium and Sugammadex|
58303325|NCT03528148|BEHAVIORAL|cycling|Active cycling
58414719|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
58414720|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
58414721|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
58414722|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
58414723|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
58414724|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
58414725|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
58414726|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
58414727|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
58414728|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
58088361|NCT04645732|BEHAVIORAL|Personalized exercise therapy and self-management support program|See description under Arms
58088362|NCT04645732|OTHER|Usual care|See description under Arms
58088363|NCT04121169|DRUG|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
58303326|NCT03528148|BEHAVIORAL|Physical therapy|Conventional physical therapy
58303327|NCT05799846|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention
58303328|NCT05799846|BEHAVIORAL|PREVENT Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
58303329|NCT05799846|BEHAVIORAL|PROMOTE Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
58088364|NCT03824483|DRUG|Zanubrutinib|zanubrutinib (160mg by mouth BID)
58303330|NCT04925102|OTHER|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
58303331|NCT01944657|DEVICE|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
58414729|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
58414730|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
58414731|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
58414732|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
58414733|NCT00035360|DRUG|PEG-Intron|
58414734|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
57733490|NCT03929146|PROCEDURE|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
58088365|NCT03824483|DRUG|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter)."
58088366|NCT03824483|DRUG|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
58088367|NCT02427425|DEVICE|TENS|
58303332|NCT01944657|DRUG|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
58303333|NCT02373267|BIOLOGICAL|Technozyme|determination of ADAMTS13 activity
58303334|NCT05197816|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that adapts to patient activity and/or physiology
58414735|NCT00915668|DRUG|JNJ-31001074|
58414736|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
58414737|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
57733491|NCT01774565|DEVICE|Fully Automated Closed-Loop Insulin Delivery|
57733492|NCT01774565|DEVICE|Conventional insulin therapy|
57733493|NCT00848679|DRUG|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
58088368|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
58414738|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
58414739|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
58414740|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
57733494|NCT00848679|DRUG|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
57733495|NCT05969067|PROCEDURE|Tunneling Technique during RA SCP|As described in the intervention arm above
58088369|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
58414741|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
58414742|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
58414743|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
58414744|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
58414745|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
58414746|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
58414747|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
58414748|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
58414749|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
58414750|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
58303335|NCT04693793|OTHER|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
58303336|NCT02988011|PROCEDURE|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
58303337|NCT02988011|DIETARY_SUPPLEMENT|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
58303338|NCT04400461|OTHER|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
58303339|NCT03585270|DRUG|Clazosentan|Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
58303340|NCT03585270|DRUG|Placebo|Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
58303341|NCT03551795|BIOLOGICAL|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) in one course of treatment.
58303342|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
58303343|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
58303344|NCT01035749|BIOLOGICAL|Placebo (saline)|One dose intramuscularly
58303345|NCT00518570|DRUG|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
58303346|NCT04184401|DRUG|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution"
58303347|NCT04184401|DRUG|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~- 70% of ascites: replacement with Hartmann's solution"
58303348|NCT06482164|DIAGNOSTIC_TEST|Dry Eye Disease|Corneal sensitivity in patients who also have dry eye.
58303349|NCT02084511|DRUG|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
58303350|NCT02084511|DRUG|BI 1026706|BI 1026706
58414751|NCT01826266|DRUG|PER977, Placebo|
58414752|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
58414753|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
58414754|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
58414755|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
58414756|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
58414757|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
57733496|NCT05969067|PROCEDURE|Dissection Technique during RA SCP|As described in the intervention arm above
57733497|NCT00407446|DRUG|sildenafil|
58414758|NCT00219037|DRUG|aliskiren|
58414759|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
57948796|NCT04427007|DEVICE|Moisture Management Liner|A prototype liner designed to reduce and/or remove moisture and heat that builds up on the limb.
57948797|NCT04427007|DEVICE|ICE Socket Cooling System|The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.
58088370|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
58303351|NCT02084511|DRUG|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
58303352|NCT02084511|DRUG|Celecoxib|Celecoxib capsule
58414760|NCT02753127|DRUG|Fluorouracil|
58303353|NCT05982327|PROCEDURE|ORIF|fixation of scapular fractures by plate and screws
58414761|NCT02753127|DRUG|Leucovorin|
58414762|NCT02753127|DRUG|Irinotecan|
58414763|NCT02753127|DRUG|Bevacizumab|
58414764|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
57948798|NCT03731650|PROCEDURE|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
58088371|NCT02234427|DRUG|Aspirin|2-week aspirin therapy (81mg/day)
58303354|NCT01187316|DEVICE|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
58303355|NCT01187316|OTHER|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
58303356|NCT01418443|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
58303357|NCT03297190|BEHAVIORAL|SMS|Receipt of SMS messages on nutrition and health topics
57948799|NCT05020171|DEVICE|Group of strength training|2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
58303358|NCT03297190|BEHAVIORAL|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
58303359|NCT03313739|OTHER|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
58414765|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
58414766|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
58414767|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
58088372|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
58088373|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
58088374|NCT05097066|PROCEDURE|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
58303360|NCT00517608|DEVICE|Laparoscopic colectomy|
58303361|NCT02115984|DRUG|Panagen|
58414768|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
58414769|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
58414770|NCT00269503|PROCEDURE|Prone Distraction|
58414771|NCT00269503|PROCEDURE|Side-Posture Manipulation|
58414772|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
58414773|NCT00269503|PROCEDURE|Usual Care (Control Group)|
58414774|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
58414775|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
58414776|NCT02443493|RADIATION|radiotherapy|
58414777|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
58414778|NCT03801746|DRUG|Rifampin|IV Rifampin
58414779|NCT03801746|DRUG|Probenecid|Oral Probenecid
58414780|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
58414781|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
58414782|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
58414783|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
58414784|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
58414785|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
58414786|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
58414787|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
58414788|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
58414789|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
58414790|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
58303362|NCT02115984|DRUG|Placebo|
58303363|NCT02115984|PROCEDURE|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
58303364|NCT05334667|OTHER|Routine management|Routine management
58303365|NCT05334667|DEVICE|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
58303366|NCT05334667|DEVICE|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
58414791|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
58414792|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
58414793|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
58414794|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
58414795|NCT02251132|DRUG|TPV low 1|
58414796|NCT02251132|DRUG|TPV low 2|
58414797|NCT02251132|DRUG|TPV medium|
58414798|NCT02251132|DRUG|TPV high 1|
58414799|NCT02251132|DRUG|TPV high 2|
58088375|NCT04222218|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
58088376|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
58088377|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
58088378|NCT02296671|DRUG|Pemetrexed|
58088379|NCT02296671|DRUG|Oxaliplatin|
58088380|NCT02296671|DRUG|Leucovorin|
58414800|NCT02251132|DRUG|RTV low|
58414801|NCT02251132|DRUG|Ritonavir high|
58414802|NCT02251132|DRUG|Radiolabelled erythromycin|
58414803|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
58414804|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
58414805|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
57733498|NCT00845572|BEHAVIORAL|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
58088381|NCT02296671|DRUG|Fluorouracil|
58088382|NCT02296671|GENETIC|Germline genotyping analyses for TSER|
58414806|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
58414807|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
58414808|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
57733499|NCT04695834|PROCEDURE|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
58414809|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
57948800|NCT05020171|OTHER|Group of physiotherapy not focus on strength training|2x a week during 5 weeks, active physical therapy treatment based on movement
58088383|NCT01130805|DRUG|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
58088384|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
58088385|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
58088386|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
58414810|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
58414811|NCT04261959|OTHER|Physiotherapy|Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
58414812|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
58414813|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
58414814|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
58088387|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
57733500|NCT04695834|OTHER|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
58088388|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
58088389|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
58088390|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
58088391|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
58088392|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
58303367|NCT00465530|DRUG|Saline|Intranasal Saline
58303368|NCT00465530|DRUG|Gentamycin|Intranasal irrigation
58303369|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 2 mA|
58303370|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 3 mA|
58303371|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 2 mA|
58303372|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 3 mA|
58303373|NCT02112253|DEVICE|Deep brain stimulator empirical programming|
58303374|NCT03434483|PROCEDURE|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
58303375|NCT03434483|GENETIC|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
58303376|NCT03434483|OTHER|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
58303377|NCT03434483|OTHER|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
58303378|NCT03434483|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
58303379|NCT04879017|DRUG|FHD-286|FHD-286 as a single agent
58303380|NCT01988467|OTHER|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
58303381|NCT04602286|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
57733501|NCT00749151|BEHAVIORAL|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
57948801|NCT01590940|PROCEDURE|Open inguinal hernia repair with mesh|
57948802|NCT06236477|BEHAVIORAL|Personalized Music|Music that is familiar to the child will be played via bluetooth speaker throughout their immediate perioperative care
58303382|NCT06527690|DRUG|Niraparib/Abirate rone acetate fixed-dose combination|Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.
57948803|NCT06236477|BEHAVIORAL|No Music|Participants will receive standard care without music.
58303383|NCT06527690|DRUG|Prednisone|Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.
58303384|NCT06257732|OTHER|Exercise|The exercise interventions in this study include High-Intensity Interval Training (HIIT), involving brief bursts of intense exercise; Resistance Exercise, focusing on strength and muscle endurance; and Fatmax Exercise, tailored to optimize fat oxidation during aerobic activity.
58303385|NCT06257732|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will be employed as a counseling technique to elicit behavior change by fostering collaborative and empathetic conversations, enhancing motivation for positive lifestyle modifications in individuals with liver fat accumulation.
58303386|NCT05299866|DRUG|S-ketamine|After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
58303387|NCT05299866|DRUG|Placebo|After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
58303388|NCT02436824|DRUG|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
58303389|NCT02436824|OTHER|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
58414815|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
58414816|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
58414817|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
58414818|NCT02840786|DEVICE|plaque excision system|
58414819|NCT02840786|DEVICE|balloon and Stent|
58414820|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
57733502|NCT02700282|BEHAVIORAL|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
57733503|NCT06636305|BEHAVIORAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
57733504|NCT06223828|DRUG|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
58088393|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
58088394|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
58303390|NCT02943772|OTHER|Local hypothermia|Cooled brick
58303391|NCT02943772|OTHER|Control|Control brick
58303392|NCT05453851|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
58303393|NCT05453851|OTHER|Quality-of-Life Assessment|Ancillary studies
58303394|NCT05453851|OTHER|Treatment Planning|Undergo IV autologous islet cell transplant
58303395|NCT00825123|DRUG|Ivabradine|Ivabradine 10 mg once
58303396|NCT00825123|DRUG|Metoprolol|Metoprolol 50 mg once
57733505|NCT06470529|DEVICE|drug eluting stents|different types of drug eluting stents
58088395|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
58088396|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
58088397|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
58303397|NCT00825123|DRUG|Placebo|Lactose powder
58303398|NCT04204005|DIETARY_SUPPLEMENT|Probiotics|"Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively."
58414821|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
58414822|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
58414823|NCT02568449|DRUG|Nintedanib|Given PO
58414824|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
58414825|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
58414826|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
58088398|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
58303399|NCT02536937|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
58303400|NCT02087774|BEHAVIORAL|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
58303401|NCT05861830|DRUG|The combination of Dalpiciclib with physician-selected endocrine therapy|"* Dalpiciclib: 150 mg, orally, once daily, on days 1-21, every 28 days (3 weeks on, 1 week off)~* Letrozole: 2.5 mg, orally, once daily (continuous), every 28 days OR Anastrozole: 1.0 mg, orally, once daily (continuous), every 28 days OR Exemestane: 25 mg, orally, once daily (continuous), every 28 days OR Fulvestrant: 500 mg, intramuscular injection on day 1/15 of the first cycle, then on day 1 of each subsequent cycle, every 28 days OR Tamoxifen: 10-20 mg, orally, twice daily (continuous), every 28 days~* Pre/perimenopausal women also require ovarian function suppression (OFS), which can be achieved through bilateral oophorectomy or the use of gonadotropin-releasing hormone (GnRH) analog drugs"
58303402|NCT05861830|DRUG|Chemotherapy selected by the physician|The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
58303403|NCT04630184|BEHAVIORAL|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
58303404|NCT04630184|BEHAVIORAL|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
58303405|NCT04630184|BEHAVIORAL|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
58303406|NCT03582384|DRUG|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
58303407|NCT05383378|DRUG|si-544|Subcutaneous injection in the abdomen
58303408|NCT05383378|DRUG|Placebo|Subcutaneous injection in the abdomen
58303409|NCT03440476|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
58303410|NCT03440476|BEHAVIORAL|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
58303411|NCT03440476|BEHAVIORAL|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
58303412|NCT00372138|PROCEDURE|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
58303413|NCT03208816|BEHAVIORAL|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
58303414|NCT04974073|DRUG|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
58303415|NCT05098873|OTHER|psychodynamic|intervention with adolescents through the presentation of questions to be completed
58303416|NCT05924165|DRUG|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
58303417|NCT05924165|DRUG|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
58303418|NCT00566085|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
58303419|NCT00984412|PROCEDURE|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
58303420|NCT04655417|DRUG|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
58303421|NCT01200329|DRUG|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
58303422|NCT01200329|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
58303423|NCT01200329|DRUG|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
58303424|NCT01200329|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
58303425|NCT01200329|DRUG|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
58414827|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
58414828|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
58414829|NCT01969877|DRUG|cetuximab|
58414830|NCT01969877|DRUG|cisplatin|
58414831|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
58414832|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
58414833|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
58088399|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
58088400|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
58088401|NCT04625907|RADIATION|radiotherapy|Ionising radiation
58088402|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
58088403|NCT02396238|DEVICE|Celution Device|ADRCs prepared using the investigational Celution Device
58088404|NCT02396238|OTHER|Placebo|Placebo
58088405|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
58088406|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
58088407|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
58088408|NCT02191969|BEHAVIORAL|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
58414834|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
58414835|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
58088409|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
58088410|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
58088411|NCT02831686|DRUG|Selinexor|
58088412|NCT02831686|DRUG|Ixazomib|
58414836|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
58414837|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
58414838|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
58414839|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
58414840|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
58088413|NCT02831686|DRUG|Dexamethasone|
58088414|NCT03653637|BEHAVIORAL|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
58088415|NCT03653637|BEHAVIORAL|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
58414841|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
58414842|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
58414843|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
58414844|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
58414845|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
57733506|NCT06530017|DEVICE|Ingested, Space Occupying hydrogel capsules|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
58088416|NCT04662424|OTHER|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
58088417|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
58088418|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
58088419|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
58088420|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
58414846|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
58088421|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
58088422|NCT05604209|BIOLOGICAL|C62|C62 administered at Day 0 and M4 on Day 28
58303426|NCT01088555|DRUG|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
58303427|NCT01657396|PROCEDURE|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
58303428|NCT01657396|PROCEDURE|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
58414847|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
58414848|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
58414849|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
58414850|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
58414851|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
58414852|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
58414853|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
58414854|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
58414855|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
58414856|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
58414857|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
58414858|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
58414859|NCT04546295|OTHER|Water-flosser|Water-flosser
58414860|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
58414861|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
58414862|NCT00025168|DRUG|gemcitabine hydrochloride|
57733507|NCT06530017|DEVICE|placebo|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
57785057|NCT01330121|OTHER|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity"
58088423|NCT05604209|BIOLOGICAL|C1C62|C1C62 administered at Day 0 and M3M4 on Day 28
58088424|NCT05604209|OTHER|Placebo|Placebo administered on Day 0 and 28
58088425|NCT05604209|BIOLOGICAL|M4|M4 administered at Day 28
58414863|NCT00025168|DRUG|irinotecan hydrochloride|
58414864|NCT00025168|RADIATION|radiation therapy|
58088426|NCT05604209|BIOLOGICAL|M3M4|M3M4 administered on Day 28
58088427|NCT00000847|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
58088428|NCT00000847|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
58088429|NCT00000847|BIOLOGICAL|rgp120/HIV-1 SF-2|
58088430|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
58088431|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
57733508|NCT05493553|DIETARY_SUPPLEMENT|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
58088432|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
58088433|NCT06701526|DRUG|Eptinezumab|Solution for infusion
58088434|NCT06253520|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
58088435|NCT06253520|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
57733509|NCT05493553|OTHER|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
57733510|NCT04993326|BEHAVIORAL|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
57733511|NCT05061264|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
57733512|NCT01412723|OTHER|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
57733513|NCT01412723|OTHER|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
58088436|NCT06253520|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
58088437|NCT06253520|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
58088438|NCT06253520|BIOLOGICAL|GRT-C903/GRT-R904|Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
58303429|NCT01657396|PROCEDURE|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
58303430|NCT03368807|DEVICE|Continuous Glucose Monitoring|Commercially available
58303431|NCT03368807|DRUG|Insulin Lispro|As prescribed.
58303432|NCT05604365|BEHAVIORAL|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
57733514|NCT06535594|OTHER|Laser acupuncture|Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
58303433|NCT04512989|DIAGNOSTIC_TEST|Cognitive assesment using MOCA test|Cognitive assesment using MOCA test
58303434|NCT00221819|DEVICE|heated humidifier (device)|
58303435|NCT00221819|DEVICE|Heat and moisture exchanger (device)|
58303436|NCT06037317|DRUG|SY-3505|LTK tyrosine kinase inhibitor
58303437|NCT03600831|DRUG|Docetaxel plus cisplatin|cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
58088439|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
58088440|NCT02712736|OTHER|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
58303438|NCT03600831|RADIATION|radiotherapy|radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
58303439|NCT01208272|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
58303440|NCT01208272|BEHAVIORAL|Interpersonal Therapy (IPT)|
58303441|NCT03384589|BIOLOGICAL|PCV13|Vaccine against pneumococcal disease
58303442|NCT05567081|DRUG|Triamcinolone Acetonide 40mg/mL|Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
58303443|NCT05567081|DRUG|PRP|Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
58088441|NCT00444665|DRUG|Travatan-Z|
58088442|NCT00238108|DRUG|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
58088443|NCT00238108|DRUG|Placebo|Placebo
57733515|NCT06535594|OTHER|Physical therapy|Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
57948804|NCT02427074|PROCEDURE|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
57948805|NCT02427074|PROCEDURE|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
58414865|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
58414866|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
58414867|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
58414868|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
58414869|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
58414870|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
57733516|NCT03081455|DIAGNOSTIC_TEST|Diagnostic Test|Genetic Diagnostic Testing
57948806|NCT02548325|OTHER|Not apply|None. Just registration epidemiology dates
58088444|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
58088445|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
58414871|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
58414872|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
58414873|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
58414874|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
58414875|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
58088446|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
58414876|NCT00064766|DRUG|doxycycline|
58414877|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
58414878|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
58414879|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
58414880|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
57733517|NCT05253898|PROCEDURE|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
58088447|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
58088448|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
58088449|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
57733518|NCT05253898|PROCEDURE|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
57733519|NCT04274608|DRUG|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
57733520|NCT04274608|BEHAVIORAL|Weight Management Program|12 week weight management program
57733521|NCT02352948|DRUG|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
57733522|NCT02352948|DRUG|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
58088450|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
57733523|NCT02352948|DRUG|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
58088451|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
58088452|NCT06555952|DRUG|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
58088453|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
58088454|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
58088455|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
58414881|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
57733524|NCT02352948|DRUG|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
57733525|NCT02352948|DRUG|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
57785058|NCT01198925|DRUG|piperacillin continuous infusion|piperacillin continuous infusion
58088456|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
58088457|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
58088458|NCT01977560|BEHAVIORAL|Intensive Lifestyle Intervention|Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
58414882|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
58414883|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
58414884|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
58414885|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
58414886|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
58414887|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
58414888|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
58414889|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
58414890|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
58414891|NCT02605811|DRUG|temozolomide|
58414892|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
58414893|NCT00002440|DRUG|Indinavir sulfate|
58414894|NCT00002440|DRUG|Ritonavir|
58414895|NCT00002440|DRUG|Abacavir sulfate|
58088459|NCT01977560|BEHAVIORAL|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
57733526|NCT02352948|DRUG|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
57733527|NCT00060450|DRUG|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
58088460|NCT00557830|DRUG|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
58303444|NCT05133115|BEHAVIORAL|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
58303445|NCT04332263|OTHER|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
58303446|NCT01307956|DRUG|Fluorouracil|Given IV
58303447|NCT01307956|OTHER|Laboratory Biomarker Analysis|Correlative studies
58414896|NCT00002440|DRUG|Amprenavir|
58414897|NCT00002440|DRUG|Nelfinavir mesylate|
58414898|NCT00002440|DRUG|Saquinavir|
58414899|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
57733528|NCT00060450|DRUG|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
57948807|NCT04514523|OTHER|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
58414900|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
58414901|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
58414902|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
58414903|NCT01004016|DRUG|KPS-0373|
58414904|NCT01004016|DRUG|Placebo|
58414905|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
58088461|NCT00557830|DRUG|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
58088462|NCT06703515|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
58088463|NCT06703515|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
58088464|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
58088465|NCT04278872|DRUG|SJX-653|administered orally once daily
58088466|NCT04278872|DRUG|Placebo|administered orally once daily
58414906|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
58414907|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
58414908|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
57948808|NCT01748175|DRUG|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
58088467|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
58088468|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
58088469|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
58088470|NCT04857879|OTHER|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
58303448|NCT01307956|DRUG|Leucovorin Calcium|Given IV
58414909|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
58414910|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
58088471|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
58088472|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
58088473|NCT01436942|BEHAVIORAL|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
58303449|NCT01307956|DRUG|Oxaliplatin|Given IV
58303450|NCT01307956|BIOLOGICAL|Panitumumab|Given IV
58303451|NCT01307956|OTHER|Pharmacological Study|Correlative studies
58303452|NCT01307956|RADIATION|Radiation Therapy|Undergo radiation therapy
58303453|NCT01307956|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
58303454|NCT04545801|DRUG|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
58303455|NCT04545801|DRUG|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
58303456|NCT03398694|PROCEDURE|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
58303457|NCT04102137|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
58303458|NCT04102137|BIOLOGICAL|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
58303459|NCT04102137|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
58303460|NCT02386852|DRUG|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
58303461|NCT02386852|DRUG|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
58303462|NCT02386852|DRUG|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
57948809|NCT03107520|DIAGNOSTIC_TEST|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
58088474|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
58088475|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
58303463|NCT02812186|PROCEDURE|Deep to Moderate NMB|"Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
58303464|NCT02812186|PROCEDURE|Moderate to Deep NMB|"Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
58303465|NCT02812186|DRUG|Rocuronium|
58303466|NCT00800358|DRUG|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
58303467|NCT00800358|DRUG|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
58303468|NCT02654639|DRUG|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
58303469|NCT02654639|DRUG|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
58303470|NCT02203266|DEVICE|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
58303471|NCT02203266|BEHAVIORAL|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
58303472|NCT01689597|DRUG|Morphine|Comparison of different dosages of drug
58303473|NCT01689597|DRUG|Placebo|
58303474|NCT05130437|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
58303475|NCT01565213|BEHAVIORAL|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
58414911|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
57733529|NCT04724317|PROCEDURE|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
57733530|NCT04724317|PROCEDURE|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
58303476|NCT01565213|BEHAVIORAL|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
58303477|NCT01565213|BEHAVIORAL|CAU|Care as usual by the GPs
58303478|NCT00994305|DRUG|N-acetylcysteine|600 mg bid po 0-7 PO
58303479|NCT00994305|DRUG|control|No treatment: standard care provided. No N-acetylcysteine administration.
58303480|NCT00068276|DIETARY_SUPPLEMENT|cholecalciferol|
58303481|NCT02806713|DRUG|Phenazopyridine|
58303482|NCT02806713|OTHER|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
57733531|NCT04724317|PROCEDURE|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
57733532|NCT00626522|DRUG|Aclidinium bromide and formoterol|once daily
57733533|NCT00626522|DRUG|Aclidinium bromide and formoterol placebo|once daily
57733534|NCT05424068|BEHAVIORAL|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
57733535|NCT05424068|BEHAVIORAL|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
57733536|NCT01606449|PROCEDURE|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
57733537|NCT06316362|DRUG|SMOF lipid 20%|SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
57785059|NCT01198925|DRUG|piperacillin extended infusion|piperacillin extended infusion
58414912|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
58414913|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
58414914|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
58414915|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
58414916|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
57785060|NCT03302806|OTHER|Non interventional Study|
57785061|NCT00467142|BIOLOGICAL|bevacizumab|
58303483|NCT04741438|DRUG|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~* Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~* Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
58303484|NCT04741438|DRUG|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
58414917|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
58303485|NCT06151808|DRUG|XTR006|All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
57785062|NCT00467142|DRUG|fluorouracil|
57785063|NCT00467142|DRUG|irinotecan hydrochloride|
58303486|NCT05435547|DRUG|Dexamethasone|Will take Dexamethasone pre-operatively
58303487|NCT05435547|DRUG|Placebo|Will take Placebo pre-operatively
58303488|NCT02280252|DRUG|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
58303489|NCT02280252|RADIATION|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
58303490|NCT03035448|BEHAVIORAL|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
58303491|NCT03035448|OTHER|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
58303492|NCT05322096|DRUG|RGH-706|"Capsules~Oral administration"
58303493|NCT05322096|DRUG|Placebo|"Capsules~Oral administration"
58414918|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
58414919|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
58414920|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
58414921|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
58414922|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
58414923|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
58414924|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
58414925|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
58414926|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
58414927|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
58414928|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
57948810|NCT03107520|DRUG|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
57948811|NCT05627375|DRUG|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
58303494|NCT03043196|DRUG|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
58303495|NCT03043196|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
58303496|NCT00468585|DRUG|Capecitabine|
58303497|NCT00468585|DRUG|Bevacizumab|
58303498|NCT02979821|DRUG|Poziotinib|A cycle of study treatment is defined as 28 days.
58303499|NCT03177395|DRUG|PP100-01 (calmangafodipir)|PP100-01
58303500|NCT03177395|DRUG|Acetylcysteine|NAC
58303501|NCT04328337|DRUG|Intralipid, 20% Intravenous Emulsion|Infusion of Intralipid 20%
58303502|NCT04328337|DRUG|Placebos|saline 30 ml/hr for 12 hours through an IV
58414929|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
58414930|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
58414931|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
58303503|NCT04621331|DRUG|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
58303504|NCT06108999|DEVICE|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
57948812|NCT05627375|DRUG|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
57948813|NCT01515761|PROCEDURE|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
57948814|NCT01515761|PROCEDURE|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
58303505|NCT00945841|BIOLOGICAL|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
58303506|NCT03641508|DRUG|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
58303507|NCT03641508|DRUG|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
57785064|NCT00467142|DRUG|leucovorin calcium|
57785065|NCT00467142|GENETIC|polymorphism analysis|
58303508|NCT06265831|OTHER|Hand-fan application to the face|Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
58303509|NCT02772666|DEVICE|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
58303510|NCT02772666|OTHER|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
58303511|NCT01995669|OTHER|Laboratory Biomarker Analysis|Correlative studies
58303512|NCT01995669|DRUG|Lenalidomide|Given PO
58303513|NCT01995669|BIOLOGICAL|Obinutuzumab|Given IV
58303514|NCT06522750|OTHER|7-day ambulatory caloric restriction intervention using the Buchinger-Wilhelmi method|Buchinger-Wilhelmi method, will be administered in an ambulatory setting under physician guidance. It involves an initial bowel cleanse followed by 7-day fasting period. The initial bowel cleanse will be performed according to the standard procedure commonly used for colonoscopy preparation. During the fasting period, subjects will be provided with a dietary energy supply of a maximum of 350 kcal per day, primarily consisting of vegetable broths as well as fresh vegetable juices. Patients will only be allowed to consume calorie-free and unsweetened water or tea in addition to the prescribed diet.
58303515|NCT01443858|DRUG|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
58303516|NCT01443858|DRUG|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
58303517|NCT01443858|DRUG|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
58303518|NCT06144255|DRUG|Intranasal insulin|"Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken."
58303519|NCT00863382|DEVICE|Standard Event Monitor|Standard Event Monitor
58303520|NCT00863382|DEVICE|Sleuth Monitor|Implantable Sleuth Recorder
58303521|NCT02642705|OTHER|High intensity interval training N|Exercise training and ambient air breathing
58303522|NCT02642705|OTHER|High intensity interval training H|Exercise training and hypoxic breathing
58088476|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
58088477|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
58088478|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
58088479|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
58088480|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
58088481|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
58088482|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
58088483|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
58088484|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
58088485|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of low-fat milk (fat <1.5%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
58088486|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
58088487|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
58088488|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
58088489|NCT03258515|DRUG|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
58088490|NCT03258515|OTHER|Placebo|AZD6094 matching placebo without any pharmacological activity.
58088491|NCT03258515|DRUG|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
58088492|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
58088493|NCT04362761|DRUG|IVA|Tablet for oral administration.
58088494|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
57733538|NCT06316362|OTHER|Standard treatment for carbamazepine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
57733539|NCT01310036|DRUG|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
57733540|NCT06670014|DEVICE|repeech|Participants in this group will use the repeech application for a period of 4 weeks, with recommended usage of 5 days per week for 30 to 60 minutes per session. A designated speech-language pathologist (SLP) will set individualized treatment goals and customize the content of the therapy sessions based on each participant's baseline assessment. The repeech intervention will be tailored to meet the specific needs of each participant to improve speech intelligibility and communication abilities.
58088495|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
58088496|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
58414932|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
58414933|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
58303523|NCT02642705|OTHER|Constant load exercise training N|Exercise training and ambient air breathing
58303524|NCT02642705|OTHER|Constant load exercise training H|Exercise training and hypoxic breathing
58303525|NCT02642705|OTHER|Hypoxic conditioning at rest|Hypoxic breathing at rest
58303526|NCT02642705|OTHER|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
58303527|NCT01283100|DRUG|GSK1349572|50mg once every 24 hours for 7 days
58303528|NCT01283100|DRUG|GSK2248761|200 mg once every 24 hours for 7 days
58303529|NCT06053385|OTHER|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
58303530|NCT06053385|OTHER|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
58303531|NCT00926250|DIETARY_SUPPLEMENT|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
58303532|NCT00926250|DIETARY_SUPPLEMENT|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
58414934|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
58414935|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
58414936|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
58303533|NCT02765737|OTHER|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
58303534|NCT02765737|DEVICE|Mepilex Ag|
58303535|NCT01755507|DRUG|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
58303536|NCT01755507|DRUG|Placebo|
58303537|NCT00218751|BEHAVIORAL|Home Visiting|
58303538|NCT03301389|OTHER|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
58303539|NCT04233853|BEHAVIORAL|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
58303540|NCT04233853|OTHER|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
58414937|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
58414938|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
58414939|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
58414940|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
58414941|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
58303541|NCT00109863|BIOLOGICAL|hu14.18-IL2 fusion protein|
58303542|NCT01596569|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
58414942|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
58088497|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
58088498|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
58088499|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
58088500|NCT03480165|DRUG|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
58088501|NCT03480165|DRUG|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
57948815|NCT04720235|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
58088502|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
58088503|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
58088504|NCT04047459|OTHER|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
58088505|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
58088506|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
58303543|NCT01596569|BEHAVIORAL|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
58303544|NCT01270477|OTHER|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
58303545|NCT05033626|PROCEDURE|Simultaneous thyroidectomy and hyoid suspension|Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.
58303546|NCT05033626|PROCEDURE|Thyroidectomy|The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
58303547|NCT03850717|DEVICE|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
58303548|NCT04964115|OTHER|Cohort study|This cohort study does not involve an intervention
58414943|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
58414944|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
58414945|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
58414946|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
58088507|NCT02384200|DRUG|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
58088508|NCT02384200|DRUG|ampicillin|IV (2 g)
58088509|NCT02384200|DRUG|gentamicin|IV (5 mg/kg)
58088510|NCT02384200|DRUG|vancomycin|IV (1 g)
58088511|NCT02384200|DRUG|ceftriaxone|IV (2 g)
58088512|NCT01603927|DEVICE|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
58088513|NCT02250157|DRUG|Oratecan|
58303549|NCT06336785|DEVICE|Restylane line of soft tissue fillers and Dysport neuromodulator|Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
58303550|NCT05701709|DRUG|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
58303551|NCT00434824|DRUG|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
58303552|NCT00434824|DRUG|Placebo|treatment for 12 months with placebo in divided doses
58303553|NCT00843141|BEHAVIORAL|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
58414947|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
58088514|NCT05028881|OTHER|blood sampling|blood sampling for determining antibody responses
58088515|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
58088516|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
58088517|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
58088518|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
58088519|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
58088520|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
58088521|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
58088522|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
58088523|NCT05517746|DRUG|BAY2395840 tablet|tablets, oral administration
58088524|NCT05517746|DRUG|BAY2395840 oral solution|solution, oral administration
58088525|NCT05517746|DRUG|Placebo oral solution|Placebo matching BAY2395840, oral administration
58088526|NCT05517746|DRUG|Placebo tablet|Placebo matching BAY2395840, oral administration
58088527|NCT02290782|RADIATION|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
58088528|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
57948816|NCT05790109|DEVICE|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
57948817|NCT04490863|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
57948818|NCT02134483|BIOLOGICAL|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
57948819|NCT04344938|OTHER|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality|Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
57948820|NCT02350972|BIOLOGICAL|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
57948821|NCT03034564|DRUG|Northera|
57948822|NCT03034564|DRUG|Placebo Oral Tablet|
57948823|NCT04451577|OTHER|No intervention|No intervention, analysis of biological samples
57948824|NCT05382650|BIOLOGICAL|Human rabies immune globulin 300 IU/mL|All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
57948825|NCT04830202|DRUG|Telisotuzumab vedotin|Intravenous Infusion
57948826|NCT06020677|OTHER|L-WebTIPS|This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
58088529|NCT04914559|OTHER|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
58088530|NCT04914559|OTHER|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
58088531|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
58088532|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
58088533|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
58088534|NCT06515665|BEHAVIORAL|therapeutic foot orthosis|They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
58088535|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
58088536|NCT04141085|OTHER|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
58088537|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
58088538|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
58088539|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
58088540|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
58414948|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
58088541|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
58088542|NCT04928599|OTHER|Interview|Complete interview
58088543|NCT04928599|OTHER|Survey Administration|Complete survey
58088544|NCT04975113|OTHER|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
58088545|NCT04975113|OTHER|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
58088546|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
58088547|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
58088548|NCT05415618|OTHER|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
58088549|NCT05415618|DEVICE|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
58088550|NCT05415618|OTHER|Nerve gliding|Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
58088551|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
58088552|NCT05672225|DRUG|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
58088553|NCT05672225|DRUG|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
58088554|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
58088555|NCT04074122|DIAGNOSTIC_TEST|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
58088556|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
58088557|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
58088558|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
58303554|NCT00843141|BEHAVIORAL|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
58303555|NCT03245281|DRUG|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
58303556|NCT03245281|DRUG|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
58303557|NCT03245281|DRUG|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
58303558|NCT02952651|PROCEDURE|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
58303559|NCT03101306|OTHER|MR scans|Additional imaging using MR scans.
58088559|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
58088560|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
58088561|NCT06562582|DRUG|Bisoprolol Oral Tablet|Timing of drug intervention after PCI
58088562|NCT06562582|DRUG|Ramipril Oral Product|Timing of drug intervention after PCI
58088563|NCT06562582|DRUG|Dapagliflozin Oral Product|Timing of drug intervention after PCI
58088564|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
58088565|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
58088566|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
58088567|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
58088568|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
58088569|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
58303560|NCT05088772|DEVICE|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
58303561|NCT00224263|DRUG|Lingzhi (Ganoderma)|
58303562|NCT01338324|DRUG|Simvastatin|Simvastatin 20 mg single dose on day 1
58088570|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
58088571|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
58088572|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
58088573|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
58088574|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
58088575|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
58088576|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
58088577|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
58088578|NCT00003861|OTHER|laboratory biomarker analysis|
58088579|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
58088580|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
58088581|NCT02902757|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
58088582|NCT02902757|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
58088583|NCT02902757|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
58088584|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
58088585|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
58088586|NCT01125358|DRUG|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
58088587|NCT01125358|DRUG|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
58088588|NCT06565611|DRUG|Bremelanotide|Bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
58088589|NCT06565611|DRUG|Tirzepatide|Tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
58088590|NCT02788955|BEHAVIORAL|Dietary counselling|
58088591|NCT02788955|OTHER|Dietary Protein|
58088592|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
58088593|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
58088594|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
58088595|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
58088596|NCT01326611|DRUG|Clarithromycin|
58088597|NCT01326611|DRUG|Dextrose|
58088598|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
58088599|NCT04341727|DRUG|Azithromycin|Antibiotic
58088600|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
58088601|NCT01666067|DRUG|placebo|
58088602|NCT01666067|DRUG|vytorin|
58088603|NCT01666067|DRUG|simvastatin|
58088604|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
58088605|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
58088606|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
58088607|NCT05967767|DEVICE|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
58303563|NCT04023396|DRUG|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
58088608|NCT05967767|DEVICE|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
58088609|NCT02850783|PROCEDURE|89Zr-nanocoll and Indocyanine Green|
58414949|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
58414950|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
58414951|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
58414952|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
58088610|NCT04458428|OTHER|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
58088611|NCT01816334|DRUG|methylprednisolone|
58414953|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
58414954|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
58414955|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
58088612|NCT01816334|DRUG|Ketoprofen|
58414956|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
58414957|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
58414958|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
58414959|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
58088613|NCT01816334|DRUG|Sodium Chloride|
57733541|NCT06670014|OTHER|Workbook|Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria, due to the lack of a standardized care protocol for this condition. The recommended usage is the same as the treatment group: 5 days per week, for 30 to 60 minutes per session over a period of 4 weeks. After each self-treatment session, participants will record their activities on a checklist to monitor adherence and ensure compliance with the study protocol.
57733542|NCT05584215|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
58303564|NCT01219023|DRUG|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
58303565|NCT03477578|OTHER|freezers|neuropsychological evaluation
57733543|NCT03082963|DEVICE|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
58088614|NCT02766959|OTHER|Observational study|
58303566|NCT03477578|OTHER|non freezers|neuropsychological evaluation
58414960|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
58414961|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
58088615|NCT00879762|BIOLOGICAL|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
58088616|NCT00879762|DRUG|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
58088617|NCT00879762|BIOLOGICAL|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10\^8 tissue culture infectious dose 50 \[TCID50\] per 0.5 mL dose)
58088618|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
58088619|NCT00823680|DRUG|Placebo|po bid for 4 weeks
58088620|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
58088621|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
58088622|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
58088623|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
58088624|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
58088625|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
58088626|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
58088627|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
58088628|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
58088629|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
58088630|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
57733544|NCT04965844|DEVICE|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
57733545|NCT04965844|DEVICE|No intervention|Manual FiO2 adjustment according to SpO2 values
57733546|NCT02599194|DRUG|18F-FSPG|Administered intravenously (IV)
57733547|NCT02599194|DRUG|18F-FDG|Administered intravenously (IV)
58414962|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
57733548|NCT01573845|BEHAVIORAL|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
57733549|NCT01573845|BEHAVIORAL|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
57733550|NCT05665777|DRUG|Qingyan Lihou Decoction|Chinese medicine granules
57733551|NCT05665777|OTHER|Placebo|Placebo granules
57733552|NCT05642390|DEVICE|Breast implant|Patients operated for breast augmentation or reconstruction.
57733553|NCT05985486|BEHAVIORAL|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
57733554|NCT05985486|BEHAVIORAL|Health Education|Monthly health education sessions delivered remotely.
57733555|NCT06239168|DIETARY_SUPPLEMENT|Citrus extract|As described in experimental arm
58088631|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
57733556|NCT06239168|DIETARY_SUPPLEMENT|Maltodextrin|As described in comparator arm
57733557|NCT02370602|DRUG|TAK-063|TAK-063 tablets
58088632|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
58414963|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
58414964|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
58414965|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
58088633|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
58088634|NCT05475535|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
58088635|NCT05475535|BEHAVIORAL|Self-Compassion|Self-Compassion focused exercises
58088636|NCT05475535|BEHAVIORAL|Active Control|Engagement in a mobile application (Cooperation skills)
58088637|NCT01411475|OTHER|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
58088638|NCT02416089|DEVICE|Tampostat|
58088639|NCT02416089|DEVICE|Condom catheter tamponade|
58088640|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
58088641|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
58088642|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
58088643|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
58088644|NCT00061958|DRUG|arsenic trioxide|Given IV
58088645|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
58088646|NCT06500026|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
57733558|NCT02370602|DRUG|[^11C]T-773|\[\^11C\]T-773 IV solution
57733559|NCT01718769|OTHER|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
57733560|NCT04099069|PROCEDURE|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
57733561|NCT03249922|DEVICE|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
57733562|NCT01028573|DRUG|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
58088647|NCT06500026|DRUG|Topotecan|Administration by intravenous infusion for a cycle of 3 weeks.
58414966|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
58414967|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
58414968|NCT03165214|DEVICE|coil|microcoils
58414969|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
58414970|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
58414971|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
58414972|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
58414973|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
57733563|NCT01028573|DRUG|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
57733564|NCT01028573|DRUG|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
58088648|NCT05256940|BEHAVIORAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
58088649|NCT05256940|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
58088650|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
58088651|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
58088652|NCT00558831|DRUG|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
58088653|NCT00558831|DRUG|Moisturizing Lotion|
58088654|NCT04060979|DRUG|Nitric Oxide|Nitric Oxide given intermittently via inhalation
58414974|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
58414975|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
58414976|NCT00247442|BEHAVIORAL|Decision aid|
58414977|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
58414978|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
58088655|NCT04060979|OTHER|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
58088656|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
58088657|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
58088658|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
58088659|NCT05268003|DRUG|Ponatinib|Given by PO
58088660|NCT05268003|DRUG|Venetoclax|Given by PO
58088661|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
58088662|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
58414979|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
58414980|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
58414981|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
58414982|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
57733565|NCT01028573|DRUG|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
58088663|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
58088664|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
58088665|NCT06023511|DEVICE|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
57733566|NCT03822013|DRUG|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
58088666|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
58088667|NCT05832242|OTHER|Ultrasound|Point-of-care ultrasound in the emergency department
58088668|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
58088669|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
58088670|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
58088671|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
58088672|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
58088673|NCT05645263|OTHER|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
58088674|NCT04342390|OTHER|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
58088675|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
58088676|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
58088677|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
58088678|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
58088679|NCT04061655|DRUG|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
58088680|NCT04061655|OTHER|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
58088681|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
58088682|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
58088683|NCT05672394|DRUG|Bupivacaine|bupivacaine
58088684|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
58088685|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
58088686|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
58088687|NCT00910065|DRUG|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
58088688|NCT06565065|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant
58088689|NCT06565065|OTHER|Sham Light Touch|A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.
58088690|NCT06565065|OTHER|Exercise Protocol|A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.
58088691|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
58414983|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
58088692|NCT06277466|DRUG|Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs|Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
58088693|NCT06277466|DRUG|Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs|"The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing."
57733567|NCT03405870|DRUG|Smoflipid|Administration of lipid injectable emulsion
58088694|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
58088695|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
58088696|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
58088697|NCT01145872|BEHAVIORAL|Health Enhancement Program|
58088698|NCT03370627|BIOLOGICAL|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
58088699|NCT04102514|BEHAVIORAL|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
58088700|NCT04102514|BEHAVIORAL|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
58088701|NCT06695910|DIETARY_SUPPLEMENT|Monoglyceride Eicosapentaenoic acid (omega-3)|515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.
58088702|NCT06695910|OTHER|Sunflower Oil|698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 56 days followed by a wash-out period of 28 days.
58088703|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
58088704|NCT05455593|BEHAVIORAL|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
58088705|NCT05455593|BEHAVIORAL|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
58088706|NCT05455593|BEHAVIORAL|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
58088707|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
58088708|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
58088709|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
57733568|NCT00071487|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
57733569|NCT00071487|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
57733570|NCT00071487|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
58088710|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
58088711|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
58088712|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
58414984|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
58414985|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
58414986|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
58414987|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
58414988|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
58088713|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
58088714|NCT00308230|PROCEDURE|Six minute walk test|
58088715|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
58088716|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
58088717|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
58088718|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
58088719|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
58088720|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
58088721|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
58088722|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
58088723|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
58414989|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
58088724|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
58088725|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
58088726|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
58088727|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
58088728|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
58088729|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
58088730|NCT06540807|DEVICE|Colovac Colorectal Anastomosis Protection Device|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
58088731|NCT06540807|PROCEDURE|Stoma creation|Diverting loop ileostomy
58088732|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
58088733|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
58088734|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
58088735|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
58088736|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
58088737|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
58088738|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
58088739|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
58088740|NCT05021315|DRUG|10% povidone iodine|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
58088741|NCT03162120|DRUG|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
58088742|NCT03162120|DRUG|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
58088743|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
58088744|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
58088745|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
58088746|NCT05451849|BIOLOGICAL|TC-510|TC-510
58088747|NCT05451849|DRUG|Fludarabine|Fludarabine
58088748|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
58088749|NCT03840031|OTHER|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
57733571|NCT00071487|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
57733572|NCT01360151|DRUG|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
57733573|NCT06202378|DRUG|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
58088750|NCT03840031|OTHER|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
58088751|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
58088752|NCT01527942|DRUG|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
58088753|NCT01527942|DRUG|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
58088754|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
58088755|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
58088756|NCT01734421|OTHER|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
58088757|NCT01734421|DEVICE|Cell phone Aplication for Smarth Phone|
58088758|NCT06703177|DRUG|SHR-1826|SHR-1826
58088759|NCT06703177|DRUG|SHR-4642|SHR-4642
58088760|NCT06703177|DRUG|SHR-9839|SHR-9839
58088761|NCT06703177|DRUG|SHR-8068|SHR-8068
58088762|NCT06703177|DRUG|Bevacizumab Injection|Bevacizumab Injection
58088763|NCT06703177|DRUG|Fluorouracil Injection|Fluorouracil Injection
58088764|NCT06703177|DRUG|Calcium Folinate Injection|Calcium Folinate Injection
58088765|NCT06703177|DRUG|Adebrelimab Injection|Adebrelimab Injection
58088766|NCT06530706|DRUG|Esketamine|Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
58088767|NCT06530706|DRUG|normal saline|Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
58414990|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
58414991|NCT01460407|DRUG|LY2216684|Administered orally
58088768|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
58088769|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
58414992|NCT01460407|DRUG|Clarithromycin|Administered orally
57733574|NCT06202378|DRUG|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
57733575|NCT06202378|DRUG|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
57733576|NCT05972720|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
58088770|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
58088771|NCT03501017|OTHER|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
58088772|NCT03501017|OTHER|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
58088773|NCT01826032|DEVICE|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
58088774|NCT01826032|OTHER|Standard care for OSA|sleep higiene and dietary counseling
57733577|NCT05972720|DRUG|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
58088775|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
58088776|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
58088777|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
58088778|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
58088779|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
58088780|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
58088781|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
58088782|NCT01683331|DRUG|Insulin treatment for hyperglycemia|
57733578|NCT05972720|DRUG|firi-cel (Experimental drug)|Investigational agent
58088783|NCT00004199|DRUG|cisplatin|
58088784|NCT00004199|DRUG|gemcitabine hydrochloride|
58088785|NCT00004199|DRUG|prinomastat|
58414993|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
58414994|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
58414995|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
57733579|NCT00243724|DRUG|Esomeprazole|
57733580|NCT00694317|DRUG|Zaleplon|Short term treatment of insomnia
57733581|NCT01060761|BEHAVIORAL|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
57733582|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
57733583|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
58414996|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
58088786|NCT05859893|BEHAVIORAL|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
58088787|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
58088788|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
58088789|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
58088790|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
57733584|NCT00295750|DRUG|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
58088791|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
58088792|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
58088793|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
58088794|NCT02097966|DRUG|Daclatasvir|
58088795|NCT02097966|DRUG|Sofosbuvir|
58088796|NCT02097966|DRUG|Ribavirin|
58088797|NCT04509596|DRUG|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
58088798|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
58088799|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
58088800|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
58088801|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
57733585|NCT03099850|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
58088802|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
58088803|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
58088804|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
58088805|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
58088806|NCT04172727|DRUG|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
58088807|NCT04172727|DRUG|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
58088808|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
58414997|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
58414998|NCT04827797|DEVICE|balls|Birth balls to exercise
58414999|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
58415000|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
58415001|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
58415002|NCT03974672|PROCEDURE|Re-laparotomy|
58415003|NCT02437786|DRUG|GRAZAX|GRAZAX
58415004|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
58415005|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
58415006|NCT02833792|OTHER|Placebo|Intravenous administration
58415007|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
58415008|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
58415009|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
58415010|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
58415011|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
58415012|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
58415013|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
58415014|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
58415015|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
58415016|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
58415017|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
58415018|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
58415019|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
57733586|NCT04942171|PROCEDURE|Atrial fibrillation catheter ablation group|"1. Pulmonary vein isolation~2. Additional treatment for lesions caused by non-pulmonary veins~3. Esophageal temperature monitoring to prevent damage to the esophagus~4. Evaluation of procedure time and radiofrequency ablation time~5. Evaluation of complications after the procedure~6. Rhythm follow-up after the procedure is conducted in accordance with the above study design.~7. Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
58415020|NCT05531721|OTHER|Observation|Observation and retrospective data collection
58415021|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
58415022|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
58415023|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
58415024|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
58415025|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
58415026|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
58415027|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
58415028|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
58415029|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
58415030|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
58415031|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
58415032|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
58415033|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
58415034|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
58415035|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
58415036|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
58415037|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
58415038|NCT03738007|DEVICE|Perlane|Treatment with Perlane
58415039|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
58415040|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
58415041|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
58415042|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
58088809|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
58303567|NCT03846401|DEVICE|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate \& BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~1. Direct smear by Gram stain and ZeihlNelseen stain~2. Samples culturedinBact/alert bottle(BioMérieux, France).~3. Isolation of causative organism from positive cases by:~   Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~4. Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~5. Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
58303568|NCT02824445|DEVICE|individualized Transcranial Magnetic Stimulation|
58303569|NCT05913362|BEHAVIORAL|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
58303570|NCT05199246|DEVICE|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
58303571|NCT01126216|DRUG|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,
58303572|NCT01126216|RADIATION|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
58415043|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
58415044|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
58415045|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
58415046|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
58088810|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
58088811|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
58415047|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
58415048|NCT05407961|DRUG|LY3532226|Administered SC.
58415049|NCT05407961|DRUG|Placebo|Administered SC.
58088812|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
58415050|NCT05407961|DRUG|Dulaglutide|Administered SC.
58415051|NCT04139278|OTHER|Observational|Observational retrospective study
58415052|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
58415053|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
58088813|NCT05095896|OTHER|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
58415054|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
58415055|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
58088814|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
58303573|NCT01126216|DRUG|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33
57733587|NCT04942171|DRUG|Medical therapy group|"1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
57733588|NCT06560970|BEHAVIORAL|COPPEhR Intervention|Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
57733589|NCT06560970|BEHAVIORAL|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
57733590|NCT05580991|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
57733591|NCT02763527|BEHAVIORAL|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
57733592|NCT02763527|BEHAVIORAL|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
57733593|NCT04327466|DEVICE|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
58088815|NCT04130594|OTHER|placebo|placebo
58088816|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
58303574|NCT01126216|RADIATION|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
58303575|NCT03813862|OTHER|Non-interventional (observational only)|
58303576|NCT01062191|DEVICE|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
58303577|NCT01062191|DEVICE|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
58303578|NCT00496769|DRUG|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
58415056|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
58415057|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
58415058|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
58415059|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
58415060|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
58415061|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
58088817|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
58088818|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
58088819|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
58088820|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
58088821|NCT00000423|BEHAVIORAL|Social support group|
58088822|NCT00000423|BEHAVIORAL|Social support and education group|
58088823|NCT04730973|DRUG|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
58088824|NCT04730973|OTHER|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
58088825|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
58088826|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
58088827|NCT01550354|DRUG|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
58088828|NCT01550354|DRUG|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
58088829|NCT01550354|DRUG|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
58088830|NCT05174273|BIOLOGICAL|Fecal Microbiota Transplantation|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
58088831|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
58088832|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
58088833|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
58088834|NCT00096473|DRUG|Donepezil hydrochloride|
58088835|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
58088836|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
58088837|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
58088838|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
58088839|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
58088840|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
58088841|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
58088842|NCT04551027|BEHAVIORAL|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
58088843|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
58088844|NCT04185207|OTHER|no intervention|There is no intervention.
58088845|NCT04995302|PROCEDURE|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
58088846|NCT04995302|PROCEDURE|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
58088847|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
58088848|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
58303579|NCT00496769|DRUG|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
58088849|NCT05945849|BIOLOGICAL|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
58415062|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
58088850|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program
58088851|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58088852|NCT06049355|OTHER|Educational Intervention|Receive educational materials
58088853|NCT00391092|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
58088854|NCT00391092|DRUG|Docetaxel|100mg/m2 iv every 3 weeks
58088855|NCT00391092|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
58088856|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
58088857|NCT06004700|OTHER|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
58088858|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
58415063|NCT01550393|GENETIC|proteomic profiling|
58415064|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
58088859|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
58088860|NCT00249327|BEHAVIORAL|education|
58088861|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
58088862|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
58088863|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
58088864|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
58088865|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
58088866|NCT01598740|DRUG|CLP|Oral administration
58088867|NCT01598740|DRUG|Spironolactone|oral administration
58088868|NCT00006014|DRUG|semaxanib|
58088869|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
58088870|NCT05205824|OTHER|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
58088871|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
58088872|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
58088873|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
58303580|NCT05380245|DRUG|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
58303581|NCT05380245|DRUG|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
58088874|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
58088875|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
58088876|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
58415065|NCT01550393|OTHER|laboratory biomarker analysis|
58415066|NCT01550393|OTHER|medical chart review|
58415067|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
58415068|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
58415069|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
58303582|NCT04418947|OTHER|Communication type|Control letter vs. intervention letter
57733594|NCT04327466|DEVICE|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
58088877|NCT02424799|DRUG|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
58088878|NCT02424799|DRUG|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
58088879|NCT02424799|DRUG|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
58088880|NCT03144115|DRUG|Oxytocin|
58088881|NCT03144115|DRUG|Placebos|
58088882|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
58088883|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
58088884|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
58088885|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
58088886|NCT04379102|OTHER|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
58088887|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
58088888|NCT02799485|OTHER|Pharmacological Study|Correlative studies
58088889|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
58088890|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
58088891|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
58088892|NCT05917314|OTHER|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~* Limosilactobacillus fermentum K7-Lb1~* Limosilactobacillus fermentum K8-Lb1~* Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
58088893|NCT05917314|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
58088894|NCT03725267|DRUG|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
58088895|NCT03725267|DRUG|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
58088896|NCT03121560|DEVICE|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
58088897|NCT03121560|DEVICE|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
58303583|NCT03944616|BEHAVIORAL|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
58303584|NCT03944616|BEHAVIORAL|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
58303585|NCT01733277|OTHER|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
58088898|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
58088899|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
58088900|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
58088901|NCT01995058|DRUG|cabozantinib|Tablets taken orally
58088902|NCT01995058|DRUG|abiraterone|Tablets taken orally daily
58088903|NCT01995058|DRUG|prednisone|Tablets taken orally twice daily
58415070|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
58415071|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
58415072|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
58415073|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
58415074|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
58415075|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
58088904|NCT06703827|BEHAVIORAL|The metacognitive training group|The MCT will consist of spending 90 minutes a week in a small online group setting working through a series of workshops. Participants will also be asked to complete homework each week and they will be supported with this. Interviews and questionnaires regarding symptoms and thinking errors will be used before and immediately after the intervention. The participants who attended the group and improved in their symptoms and thinking errors will be invited to an interview asking them what worked for them and how they found the group.
58088905|NCT02215434|DRUG|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
57733595|NCT05887193|DEVICE|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
57733596|NCT05887193|DEVICE|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
58088906|NCT02215434|DRUG|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
58088907|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
58088908|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
58415076|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
58415077|NCT02337699|PROCEDURE|QST Testing|
58415078|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
58415079|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
58415080|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
58415081|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
58415082|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
58415083|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
58415084|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
57733597|NCT05887193|DEVICE|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
57733598|NCT05887193|DEVICE|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
57733599|NCT05369585|DIETARY_SUPPLEMENT|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
58415085|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
58415086|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
58415087|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
58415088|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
58415089|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
58415090|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
58415091|NCT02156544|DRUG|CKD-519|
58415092|NCT02156544|DRUG|placebo|
57948827|NCT05898100|DEVICE|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
57948828|NCT05898100|BEHAVIORAL|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
57948829|NCT01209650|DRUG|BIBW 2992|tablets
57948830|NCT03126942|DEVICE|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
57948831|NCT03126942|DEVICE|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
58415093|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
58415094|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
57733600|NCT00710047|DRUG|ZD4054|one single 10mg dose
57948832|NCT04941950|BEHAVIORAL|PlaySmart|PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.
57948833|NCT04941950|OTHER|Video Game Control|Participants in the control group will play another video game with no intended effect similar to PlaySmart.
57948834|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
57948835|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
57948836|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
58303586|NCT01106131|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
58415095|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
58415096|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
57733601|NCT03341390|DRUG|Aspirin|1 x 325 mg tablet of aspirin administered once daily
58303587|NCT01106131|DRUG|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
58303588|NCT00702780|DRUG|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
58415097|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
58415098|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
57733602|NCT03341390|DRUG|BMS-986177|200 mg of BMS-986177 administered twice daily
57733603|NCT03341390|DRUG|Placebo|200 mg of Placebo administered twice daily
57733604|NCT03812796|DRUG|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
57733605|NCT03812796|DRUG|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
57733606|NCT03332862|PROCEDURE|catheter ablation|catheter ablation for atrial fibrillation treatment
57733607|NCT00566267|DRUG|simvastatin 20 mg/ezetimibe|see protocol
57733608|NCT03105362|DIETARY_SUPPLEMENT|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
58415099|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
58415100|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
58415101|NCT02317952|OTHER|Active Comparator Formula|
58415102|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
57785066|NCT03403933|DRUG|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
57785067|NCT06034574|DEVICE|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
57785068|NCT03565861|DRUG|Placebo|Intravenous vehicle
57785069|NCT03565861|DRUG|NP10679|NP10679
58415103|NCT00437450|DRUG|Epoetin/Atra|
58415104|NCT00693004|DRUG|PRX-03140|
58415105|NCT00693004|DRUG|Donepezil|
58415106|NCT00693004|DRUG|Placebo|
58415107|NCT04015869|DRUG|Allopregnanolone|neurosteroid
58415108|NCT04015869|DRUG|Placebos|placebo
58415109|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
58415110|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
58415111|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
57733609|NCT06109038|OTHER|Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions)."
57733610|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).
57733611|NCT01109992|DRUG|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
57733612|NCT01109992|DRUG|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
57733613|NCT05465889|DRUG|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
57785070|NCT01593735|DRUG|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
58415112|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
58415113|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
58415114|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
58415115|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
58415116|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
58415117|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
58415118|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
58415119|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
58415120|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
58415121|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
58415122|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
58415123|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
58415124|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
58415125|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
58415126|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
58415127|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
58415128|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
58415129|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
58415130|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
58415131|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
58415132|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
58415133|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
58415134|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
58415135|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
58088909|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
58088910|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
58303589|NCT00702780|DRUG|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
58303590|NCT02477592|PROCEDURE|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
58303591|NCT02477592|PROCEDURE|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
58303592|NCT04787848|DRUG|Relistor Injectable Product|Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
58303593|NCT04027088|DIETARY_SUPPLEMENT|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
58303594|NCT04027088|DIETARY_SUPPLEMENT|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
58303595|NCT03368664|DRUG|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
58303596|NCT03368664|DRUG|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
58303597|NCT03368664|DRUG|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
58303598|NCT03368664|DRUG|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
58303599|NCT03368664|DRUG|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
58303600|NCT03368664|DRUG|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
58303601|NCT03368664|DRUG|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
58303602|NCT03368664|DRUG|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
58303603|NCT03368664|DRUG|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
58303604|NCT03368664|DRUG|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
58303605|NCT03368664|DRUG|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
58303606|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
58303607|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
58303608|NCT03654417|DRUG|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
58303609|NCT03654417|DRUG|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
58415136|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
58415137|NCT02581930|DRUG|Ibrutinib|Given PO
58415138|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
58415139|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
58415140|NCT02581930|OTHER|Pharmacological Study|Correlative studies
58415141|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
58415142|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
58415143|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
58415144|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
58415145|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
58415146|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
58415147|NCT01400243|DRUG|Placebo Patch|Placebo patch
58415148|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
58415149|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
58415150|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
57733614|NCT05465889|DRUG|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
57948837|NCT06194136|DEVICE|PBM light therapy|The PBM machine consists of a dual light emitting diode (LED) cluster array with 105 light diodes within the 660 nanometer (nm) red light wavelength and the 850 nm near-infrared light wavelength. These wavelengths are both within the ranges noted in previous literature for neuropathic pain (1) and are within the World Association for Photobiomodulation (Laser) Therapy (WALT) guidelines for PBM therapy (2). Dosage will be determined according to the following equation: Laser output Power (Watts) x Time (seconds) divided by Beam Area (cm2)= J/cm2 (1). The PBM unit generates energy equal to 115 mW/cm2 with a surface area of 54.6 cm x 17 cm. Thus, for a target power output of 3.45 J, the participant will have a continuous irradiation duration of 30 seconds for each application (1). The participant will be asked to utilize the PBM device on breast tissue post-mastectomy for 30 seconds 3 times per week with at least 24 hours between each session. The duration of treatment will be 6 weeks.
57948838|NCT00822757|BIOLOGICAL|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
58088911|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
58088912|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
58303610|NCT04339049|DRUG|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
58415151|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
57733615|NCT01015989|OTHER|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
57785071|NCT01593735|DRUG|Placebo|Placebo tablets, orally, once daily for 7 days
57785072|NCT00107380|BIOLOGICAL|rituximab|
57785073|NCT00107380|DRUG|cyclophosphamide|
57785074|NCT00107380|DRUG|doxorubicin hydrochloride|
57785075|NCT00107380|DRUG|prednisone|
57785076|NCT00107380|DRUG|vincristine sulfate|
57785077|NCT00107380|RADIATION|tositumomab and iodine I 131 tositumomab|
58088913|NCT00679094|OTHER|placebo|Given orally
58088914|NCT00679094|OTHER|pharmacological study|Correlative studies
58303611|NCT04339049|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
58415152|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
58415153|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
58415154|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
58415155|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
58415156|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
58415157|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
58415158|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
58415159|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
58415160|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
58415161|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
57785078|NCT05489029|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
57785079|NCT04137510|DEVICE|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
58415162|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
57785080|NCT02764775|DEVICE|Headpod|Adaptive equipment to assist with active head movements
57948839|NCT00822757|BIOLOGICAL|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
57948840|NCT04624711|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
58415163|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
58415164|NCT00023751|DRUG|fluorouracil|
58415165|NCT00023751|DRUG|leucovorin calcium|
58415166|NCT00023751|PROCEDURE|conventional surgery|
58415167|NCT00023751|RADIATION|radiation therapy|
57948841|NCT04624711|DRUG|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
58088915|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
58088916|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
58415168|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
58415169|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
58415170|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
58415171|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
58088917|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
58088918|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
58088919|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
58088920|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
58088921|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
58088922|NCT00216424|DRUG|Capecitabine (Xeloda)|
58088923|NCT02414490|DRUG|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
58088924|NCT06079437|PROCEDURE|Cheer|Maximum isometric contraction was performed with cheering.
58088925|NCT06079437|PROCEDURE|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
58088926|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
58088927|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
58088928|NCT00080925|BIOLOGICAL|filgrastim|
58415172|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
58415173|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
58415174|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
58415175|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
58415176|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
58415177|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
57948842|NCT05705609|OTHER|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
57948843|NCT00634309|DRUG|Candesartan|
58088929|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
58415178|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
57948844|NCT00634309|DRUG|Placebo|
57948845|NCT01724840|PROCEDURE|GraftJacket|Interposition with GraftJacket
57948846|NCT01724840|PROCEDURE|Tendon Interposition|Tendon Interposition with the FCR tendon
57948847|NCT04632758|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, QD
57948848|NCT04632758|DRUG|crizotinib|Capsules, 250mg, BID
58088930|NCT00080925|BIOLOGICAL|rituximab|
58088931|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58415179|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
58415180|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
58415181|NCT00690287|DRUG|Placebo|Placebo
58415182|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
58415183|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
58415184|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
58415185|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
58088932|NCT00080925|DRUG|cyclophosphamide|
58088933|NCT00080925|DRUG|cyclosporine|
58088934|NCT00080925|DRUG|cytarabine|
58088935|NCT00080925|DRUG|doxorubicin hydrochloride|
58088936|NCT00080925|DRUG|etoposide|
58088937|NCT00080925|DRUG|fludarabine phosphate|
58088938|NCT00080925|DRUG|prednisone|
58088939|NCT00080925|DRUG|vincristine sulfate|
58088940|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
58088941|NCT00391118|DRUG|enzastaurin|
58088942|NCT00391118|DRUG|carboplatin|
58088943|NCT00391118|DRUG|paclitaxel|
58088944|NCT00391118|DRUG|placebo|
58088945|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
58303612|NCT04339049|DRUG|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
58303613|NCT04686916|DRUG|IP2018|Test drug
58303614|NCT04686916|DRUG|Placebo|Placebo
58303615|NCT04627688|BEHAVIORAL|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
58303616|NCT04627688|BEHAVIORAL|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
58303617|NCT03894995|OTHER|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
58303618|NCT00368251|OTHER|Placebo|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use"
58303619|NCT00368251|DRUG|BRV 2.5 mg|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
58303620|NCT00368251|DRUG|BRV 25 mg|"* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
58303621|NCT00368251|DRUG|BRV 50 mg|"* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
58303622|NCT02794129|OTHER|Functional Magnetic Resonance Imaging|
58303623|NCT01776554|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
58303624|NCT06127277|BEHAVIORAL|Next4You|Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
58303625|NCT02828865|DEVICE|Irreversible Electroporation (IRE) System|
58303626|NCT02455128|OTHER|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
58303627|NCT02991274|PROCEDURE|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
58303628|NCT05985746|OTHER|Augmented reality group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
58303629|NCT05985746|OTHER|Traditional learning group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
58303630|NCT06422728|OTHER|Unified Protocol for Anxiety Disorders|"The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later."
58303631|NCT06422728|OTHER|Client-centered Supportive Therapy|Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
58303632|NCT00072449|BIOLOGICAL|rituximab|
58303633|NCT00003012|DRUG|CMF regimen|
58303634|NCT00003012|DRUG|cyclophosphamide|
58303635|NCT00003012|DRUG|epirubicin hydrochloride|
58303636|NCT00003012|DRUG|fluorouracil|
58088946|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
58088947|NCT00397904|BIOLOGICAL|cetuximab|
58088948|NCT00397904|DRUG|cisplatin|
58088949|NCT00397904|DRUG|irinotecan hydrochloride|
58088950|NCT00397904|OTHER|immunohistochemistry staining method|
58088951|NCT00397904|OTHER|laboratory biomarker analysis|
58088952|NCT00397904|PROCEDURE|biopsy|
58088953|NCT05968924|DEVICE|Podimetrics SmartMat|Participants receive training for stepping on SmartMat each day for 6 months. Monthly phone calls will be conducted to assess foot health and mat.
58088954|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
58088955|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
58088956|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
58088957|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
58088958|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
58088959|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
58088960|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
58088961|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
58088962|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
58088963|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
58088964|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
58415186|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
58415187|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
58415188|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
58415189|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
58415190|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
58088965|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
58088966|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
58088967|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
58088968|NCT00606996|BEHAVIORAL|Group interpersonal psychotherapy (IPT-G)|
58088969|NCT00606996|BEHAVIORAL|Psychoeducation on co-occurring disorders (PSYCHOED)|
58088970|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)|
57948849|NCT04039893|DIAGNOSTIC_TEST|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
58088971|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)+Tremelimumab|
58088972|NCT02453282|DRUG|Paclitaxel + Carboplatin|Chemotherapy Agents
58088973|NCT02453282|DRUG|Gemcitabine + Cisplatin|Chemotherapy Agents
58088974|NCT02453282|DRUG|Gemcitabine + Carboplatin|Chemotherapy Agents
58088975|NCT02453282|DRUG|Pemetrexed + Cisplatin|Chemotherapy Agents
58088976|NCT02453282|DRUG|Pemetrexed + Carboplatin|Chemotherapy Agents
58088977|NCT02453282|BIOLOGICAL|Tremelimumab|
58088978|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
58303637|NCT00003012|DRUG|methotrexate|
58303638|NCT02306889|DRUG|Fenofibrate|130mg Capsules
58415191|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
58088979|NCT02133911|DRUG|Ranolazine|
58088980|NCT01396499|DRUG|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
58088981|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
58088982|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
58088983|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
58088984|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
58088985|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088986|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088987|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58303639|NCT02306889|DRUG|ANTARA® (fenofibrate)|130mg Capsules
58303640|NCT01115452|DRUG|5% Potassium nitrate|5% potassium nitrate solution
58303641|NCT01115452|DRUG|2.5% Potassium nitrate|2.5% potassium nitrate solution
58303642|NCT01115452|OTHER|Sterile water|Sterile water
58303643|NCT03053882|OTHER|mouthwash|mouthwash containing herbal peppermint or green tea
58415192|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
58415193|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
58415194|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
58303644|NCT03366662|DEVICE|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
58415195|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
58415196|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
58415197|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
58415198|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
58415199|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
58415200|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
58415201|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
58415202|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
58415203|NCT01726673|DEVICE|Placebo sham|
58415204|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
58415205|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
58415206|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
58415207|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
58415208|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
58088988|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088989|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088990|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088991|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58088992|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
58303645|NCT06514287|BEHAVIORAL|Individualized intervention|It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
58415209|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
58415210|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
58415211|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
58303646|NCT04393649|OTHER|ESOGER|Questionnaire
58303647|NCT01814007|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
58303648|NCT00325169|DRUG|Tiotropium + SERETIDE 50/500|
58303649|NCT00100906|DRUG|IL-2|Immunotherapy with interleukin-2
58303650|NCT00100906|DRUG|ATRA|
58415212|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
58415213|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
58415214|NCT06294938|OTHER|Dextrose|Dextrose beverage
58415215|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
58415216|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
58415217|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
58303651|NCT02184819|DRUG|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
57948850|NCT04039893|DIAGNOSTIC_TEST|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
58303652|NCT02184819|DRUG|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
58303653|NCT00583648|OTHER|Urinanlysis|sending a Urine sample to the laboratory for processing
58415218|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
58415219|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
58415220|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
58415221|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
58415222|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
58415223|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
58415224|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
58415225|NCT02152514|DEVICE|PCA|
58415226|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
58415227|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
58415228|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
58415229|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
58415230|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
58415231|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
58415232|NCT02008513|BIOLOGICAL|Placebo|
58415233|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
58415234|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
58415235|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
58415236|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
58415237|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
58415238|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
58415239|NCT02673567|DRUG|Placebo|Matching Placebo
58415240|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
57948851|NCT04039893|PROCEDURE|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
57948852|NCT04039893|PROCEDURE|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
58303654|NCT05883865|DRUG|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
58303655|NCT04746469|BEHAVIORAL|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
57733616|NCT01015989|OTHER|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
58088993|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
58088994|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
58088995|NCT05260307|OTHER|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
58088996|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
58088997|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
57733617|NCT06454357|DRUG|B007|B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
58088998|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
58088999|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
58089000|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
58089001|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
58089002|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
58089003|NCT04942964|DRUG|Bocidelpar|Oral
58089004|NCT05535842|OTHER|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
58089005|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
58089006|NCT03114527|DRUG|Everolimus|mTOR inhibitor
58303656|NCT05606601|BEHAVIORAL|Minder|"There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support."
58303657|NCT01298947|DEVICE|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
58303658|NCT03534661|DRUG|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
58303659|NCT03534661|DRUG|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
58303660|NCT03534661|DRUG|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
57733618|NCT06042647|DRUG|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
57733619|NCT06042647|DRUG|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
57733620|NCT06042647|DRUG|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
57785081|NCT01723553|DRUG|C-11 PiB|One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
58089007|NCT05217901|DRUG|14C-labeled ASP0367|Oral
58089008|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
58089009|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
58089010|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
58089011|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
57733621|NCT03322865|DRUG|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
57733622|NCT04230473|BIOLOGICAL|single dose of CNCT19|"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
57733623|NCT05918094|DRUG|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
58089012|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
58089013|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
58089014|NCT04776135|DRUG|MT-1186|Suspension
58089015|NCT04132102|DRUG|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
58089016|NCT00367601|DRUG|Erlotinib|Erlotinib 150 mg qd days 1-21
58089017|NCT00367601|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
58303661|NCT02785198|DEVICE|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
58303662|NCT05564572|OTHER|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
58303663|NCT01434446|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
58415241|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
58415242|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
58415243|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
58415244|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
58415245|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
58415246|NCT03964753|PROCEDURE|surgery|surgery
58415247|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
58415248|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
58415249|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
58415250|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
58303664|NCT02134093|DRUG|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
58303665|NCT02134093|DRUG|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
58303666|NCT02134093|DRUG|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
58303667|NCT02134093|DRUG|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
58303668|NCT02585453|DEVICE|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
58303669|NCT02585453|DEVICE|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
58303670|NCT02585453|DEVICE|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
58303671|NCT00728494|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
58303672|NCT00728494|DRUG|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
58303673|NCT00728494|BEHAVIORAL|Patient Assistance Program|"The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects."
58303674|NCT01876095|PROCEDURE|Multidisciplinary medication review|"Consists of the following steps:~* 1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~* 2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~* 3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~* 5. Execution of pharmaceutical care plan according to agreed schedule."
58303675|NCT00944918|DRUG|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
58303676|NCT00944918|DRUG|anastrozole|Tablet, oral, once daily until disease progression.
58303677|NCT00944918|DRUG|exemestane|Tablet, oral, once daily until disease progression.
58303678|NCT02192671|PROCEDURE|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
58303679|NCT02192671|PROCEDURE|Radiofrequency Ablation|
58303680|NCT02109757|OTHER|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
58303681|NCT02109757|OTHER|Education only|
58303682|NCT05303116|DIAGNOSTIC_TEST|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
58303683|NCT04113044|OTHER|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
58303684|NCT00144430|DRUG|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
58303685|NCT00792285|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
58303686|NCT05410678|DRUG|Renal stent|renal stent implantation in ectatic/aneurysmatic coronary arteries
58303687|NCT02617615|DRUG|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
58303688|NCT02617615|DRUG|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
58303689|NCT00716456|DRUG|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
58303690|NCT02652169|DRUG|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
58303691|NCT02652169|DRUG|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
58303692|NCT02652169|DRUG|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
58303693|NCT02652169|OTHER|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
58303694|NCT01268163|DRUG|European Taxotere®|60-100 mg/m\^2 IV
58303695|NCT01268163|DRUG|American Taxotere®|60-100 mg/m\^2 IV
58303696|NCT01268163|DRUG|Hospira Docetaxel Injection|60-100 mg/m\^2 IV
58303697|NCT02076386|DRUG|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
58303698|NCT04805268|DIAGNOSTIC_TEST|18F FDG PET/CT|18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
58303699|NCT03622762|DRUG|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
58303700|NCT03622762|DRUG|Placebo|Placebo capsules, 400 mg twice daily fasting
58303701|NCT01423825|BIOLOGICAL|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
58303702|NCT01423825|BIOLOGICAL|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
58303703|NCT01423825|OTHER|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
58303704|NCT05021640|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
58303705|NCT05021640|DRUG|Placebo for DCR-AUD|0.9% saline for injection
58303706|NCT05021653|OTHER|no intervention|No intervention involved
58303707|NCT04347408|DIAGNOSTIC_TEST|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
58303708|NCT04347408|OTHER|Blood Storage|Storage of blood for multi-omics analysis
58303709|NCT00400075|DRUG|azathioprine|
58303710|NCT00400075|DRUG|cyclophosphamide|
58303711|NCT05784051|DRUG|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
58303712|NCT05784051|DRUG|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
58303713|NCT01162733|DRUG|Vancomycin|15mg/kg
58303714|NCT01162733|DRUG|Vancomycin|30mg/kg
58303715|NCT03818152|OTHER|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
58303716|NCT06521177|OTHER|Hand Serum and Glove|Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
58303717|NCT00419536|DRUG|LBH589|
58303718|NCT01625468|BEHAVIORAL|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
58303719|NCT05733897|DRUG|hydroxychloroquine|Using hydroxychloroquine to treat nonalcoholic steatohepatitis
58303720|NCT01183364|DRUG|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
58303721|NCT01811732|DRUG|Delafloxacin|Delafloxacin
57733624|NCT05918094|DRUG|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
58303722|NCT01811732|DRUG|Vancomycin|Vancomycin
58303723|NCT01811732|DRUG|Aztreonam|Aztreonam
58303724|NCT01811732|DRUG|Placebo|Placebo
57733625|NCT05403762|OTHER|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
58303725|NCT03347383|DEVICE|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
58303726|NCT02074202|DRUG|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
58303727|NCT02074202|DRUG|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
57733626|NCT05403762|OTHER|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
57733627|NCT06177340|DEVICE|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
58303728|NCT04968678|DIAGNOSTIC_TEST|P-wave duration measurement on 12 lead ECG with standard parameters|Hospital records will be used in order to obtain baseline characteristics and the most recent 12-lead ECG in sinus rhythm prior to ablation will be used to calculate PWD. Measurement of the PWD will be obtained at standard surface ECG recording settings of 25mm/s and 10mm/mV and measured accordingly to our previous protocol. In brief, all ECGs obtained will subsequently be anonymised and randomised by an Independent Clinical Investigator (ICI) before measured by the main clinical investigators blinded to initial results. If a dispute of the measurements arouse, consensus will be used to resolve it after consulting the Chief Investigator (CI) blinded to the results. Bland-Altman plots to minimise bias will be used
58303729|NCT01102023|OTHER|ordinary salt based- diet|
58303730|NCT03540264|DEVICE|Clearfil Majesty TM|Tooth wear - composite resin
58303731|NCT03540264|DEVICE|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
58303732|NCT05802017|OTHER|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
58303733|NCT02832778|DRUG|Efavirenz|Efavirenz 400mg
58303734|NCT02832778|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
58303735|NCT02832778|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
58415251|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
58415252|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
58089018|NCT05104268|DEVICE|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
58415253|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
57733628|NCT06308159|DRUG|Vebeglogene autotemcel|Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
58089019|NCT05187507|OTHER|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
58089020|NCT05187507|OTHER|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
58089021|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
57733629|NCT00820768|DRUG|ABI-010|17-AAG and ABI-007
58089022|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
58089023|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
58089024|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
58415254|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
58415255|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
58415256|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
58415257|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
57733630|NCT00898118|GENETIC|polymerase chain reaction|
57733631|NCT00898118|OTHER|flow cytometry|
57733632|NCT00898118|OTHER|laboratory biomarker analysis|
57733633|NCT00898118|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
57733634|NCT06230757|DRUG|Psilocybin 25mg|25mg psilocybin capsule
57733635|NCT06230757|DRUG|Placebo (active placebo)|1mg psilocybin capsule
57733636|NCT00208793|DIETARY_SUPPLEMENT|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
57733637|NCT00208793|DRUG|Placebo|Placebo
57733638|NCT00208793|DIETARY_SUPPLEMENT|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
58089025|NCT01544374|OTHER|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
58089026|NCT01900353|OTHER|brushing methods|
58303736|NCT02832778|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
58303737|NCT02832778|DRUG|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
58303738|NCT00155714|DRUG|type-5 phosphodiesterase Inhibitor (Sildenafil)|
58303739|NCT01126892|DRUG|Nilotinib|
57733639|NCT00208793|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
57733640|NCT06578234|DRUG|Adenosine|Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
58415258|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
58415259|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
58415260|NCT01133015|DEVICE|IVUS|intravascular ultrasound
58415261|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
58415262|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
58303740|NCT04870996|DEVICE|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
58415263|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
58415264|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
58415265|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
58415266|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
58415267|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
58415268|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
58415269|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
58415270|NCT04676867|OTHER|Placebo|Placebo Tablets
58415271|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
58415272|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
58415273|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
58415274|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
58415275|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
58415276|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
58415277|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
58415278|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
57948853|NCT01692275|OTHER|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
57948854|NCT01692275|OTHER|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
57948855|NCT01236300|DEVICE|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
57948856|NCT01628471|DRUG|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
57948857|NCT00073216|BIOLOGICAL|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
57948858|NCT00073216|BIOLOGICAL|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
57948859|NCT02443363|OTHER|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
57948860|NCT02443363|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
57948861|NCT00767091|DRUG|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
57948862|NCT00767091|DRUG|placebo|transdermal patch of placebo
57948863|NCT01076049|DEVICE|Standard of Care (SoC)|The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.
57948864|NCT01076049|DEVICE|Irrisept Delivery System|"Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression.~Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits."
58415279|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
58415280|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
58415281|NCT00031980|DRUG|cyclosporine|
58415282|NCT02159677|DEVICE|EIM Measurements|
58415283|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
58415284|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
58303741|NCT04870996|BEHAVIORAL|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
58303742|NCT03905733|DEVICE|Optiflow|supply of oxygen at 2 L / min/ kg through Optiflow
58303743|NCT05374447|PROCEDURE|Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy|Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
58303744|NCT00305162|DRUG|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
58303745|NCT00305162|DRUG|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
58303746|NCT00305162|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
58303747|NCT00305162|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
58303748|NCT00305162|DRUG|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
58415285|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
58415286|NCT01960088|DRUG|HPV vaccine|
58415287|NCT02960646|DRUG|Cyclophosphamide|Given IV
58415288|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
58415289|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
58415290|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
58415291|NCT02960646|DRUG|Melphalan|Given IV
58415292|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
58415293|NCT02960646|BIOLOGICAL|Rituximab|Given IV
58415294|NCT02960646|DRUG|Tacrolimus|Given IV or PO
58415295|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
58415296|NCT00115999|DRUG|alfimeprase|
58415297|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
58415298|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
57785082|NCT04436003|BEHAVIORAL|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
58303749|NCT00025389|BIOLOGICAL|bevacizumab|
58415299|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
58415300|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
58415301|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
57785083|NCT01290094|DRUG|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
57948865|NCT00868062|OTHER|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
58415302|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
58415303|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
58415304|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
58415305|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
58415306|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
58415307|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
58415308|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
58415309|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
58415310|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
58089027|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
58303750|NCT00025389|DRUG|carboplatin|
58303751|NCT00025389|DRUG|paclitaxel|
57785084|NCT05640739|BEHAVIORAL|Demonstration method for the use of the Metered Dose Inhaler|The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
57948866|NCT05073107|OTHER|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
57948867|NCT05142475|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
57948868|NCT03023020|DRUG|Aspirin|Dosing per current guidelines and local practice
58303752|NCT00025389|PROCEDURE|conventional surgery|
58303753|NCT00025389|PROCEDURE|neoadjuvant therapy|
58303754|NCT02539069|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
58303755|NCT05932888|DRUG|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
58303756|NCT05932888|DRUG|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
58303757|NCT01162616|DIETARY_SUPPLEMENT|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
58303758|NCT05058989|DIAGNOSTIC_TEST|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
57785085|NCT05640739|BEHAVIORAL|Video watching method for the use of the Metered Dose Inhaler|The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
58415311|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
58415312|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
58415313|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
58415314|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
58415315|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
58415316|NCT02351687|DRUG|Albendazole|
58415317|NCT02351687|DRUG|Zinc|
57733641|NCT06252129|OTHER|Subjects undergoing a lung specimen lymph node dissection|"A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging."
57733642|NCT06252129|OTHER|Control group|Control group
57733643|NCT03953027|OTHER|Survey Administration|Ancillary studies
57733644|NCT01821664|DEVICE|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
57733645|NCT01875926|BIOLOGICAL|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
57733646|NCT01875926|BIOLOGICAL|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
58303759|NCT05058989|OTHER|Clinical interventions and procedures|"First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
58303760|NCT03949881|BIOLOGICAL|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
58303761|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
58303762|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
58303763|NCT06135181|DRUG|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
58303764|NCT05859217|DRUG|Cabozantinib|Oral once per day, Days 1 - 21 every 21 days
58303765|NCT05859217|DRUG|Atezolizumab|Intravenous (IV) once every 21 days
58303766|NCT01202500|PROCEDURE|reducing treatment to 3 months|The treatment will be stopped after 3 months
58303767|NCT01202500|PROCEDURE|registered length of treatment|The treatment procedure will follow the actual recommandation
58303768|NCT03106688|DIAGNOSTIC_TEST|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
58303769|NCT03106688|DIAGNOSTIC_TEST|[11C]carfentanil PET scan|\[11C\]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
58303770|NCT03106688|DIAGNOSTIC_TEST|[18F]FMPEP-d2 PET scan|\[18F\]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
58303771|NCT03106688|DIAGNOSTIC_TEST|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand \[18F\]-FDG.
58303772|NCT03106688|DIAGNOSTIC_TEST|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
58303773|NCT03106688|DIAGNOSTIC_TEST|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
58415318|NCT02351687|OTHER|Insecticide-treated bednet|
58415319|NCT01790555|DRUG|Namisol|
58415320|NCT01790555|DRUG|Diazepam/placebo|
57733647|NCT01875926|BIOLOGICAL|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
58415321|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
58415322|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
58415323|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
58415324|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
58415325|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
58415326|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
58415327|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
58415328|NCT00349258|DRUG|Leuprolide acetate|
58415329|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
58415330|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
58415331|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
58415332|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
58415333|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
58415334|NCT00539929|DRUG|E6201 0.005%|
58415335|NCT00539929|DRUG|E6201 0.01%|
58415336|NCT00539929|DRUG|E6201 0.03%|
58415337|NCT00539929|DRUG|Placebo|
58415338|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
58415339|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
58415340|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
58415341|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
57733648|NCT06170008|DEVICE|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
57948869|NCT03023020|DRUG|P2Y12 inhibitor|Dosing per current guidelines and local practice
57948870|NCT00442052|DRUG|aspirin|
58303774|NCT03106688|DIAGNOSTIC_TEST|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
58415342|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
58415343|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
57948871|NCT00442052|DRUG|omeprazole|
58415344|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
58415345|NCT05853315|PROCEDURE|Surgery|Surgical Excision
58415346|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
58415347|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
58415348|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
58415349|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
58415350|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
58415351|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
58415352|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
58415353|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
57948872|NCT05779137|BEHAVIORAL|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
57948873|NCT00985803|OTHER|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
58089028|NCT05420636|DRUG|Iadademstat|Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
58415354|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
58415355|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
58415356|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
57948874|NCT00985803|OTHER|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
57948875|NCT02967081|PROCEDURE|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
57948876|NCT05106322|OTHER|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
57948877|NCT04419610|BIOLOGICAL|TRV027|peptide for infusion
57948878|NCT04419610|OTHER|sodium chloride 0.9%|placebo comparator for infusion
57948879|NCT04994951|DRUG|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
57948880|NCT04994951|DRUG|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
57948881|NCT05706896|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
57948882|NCT06438978|BIOLOGICAL|Tuberculosis Vaccine|"1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain~2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate~3. Lyophilized pellet in vials (10doses)~4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)"
57948883|NCT05222373|BEHAVIORAL|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
57948884|NCT05930600|DEVICE|Ultrasonography of Internal Jugular Vein|Non invasive monitoring of fluid responsiveness
57785086|NCT05157685|DRUG|Azithromycin Oral Tablet|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
57948885|NCT05930600|DEVICE|Doppler Echocardiograhy|Non invasive monitoring of fluid responsiveness
57948886|NCT05775185|RADIATION|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
57948887|NCT06030388|OTHER|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
58089029|NCT05420636|DRUG|Paclitaxel|Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
58089030|NCT04187469|DRUG|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
58089031|NCT04187469|DRUG|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
58415357|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
58415358|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
58415359|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
58415360|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
58415361|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
58415362|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
58415363|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
58415364|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
58415365|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
58415366|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
58415367|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
58415368|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
58415369|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
58415370|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
58415371|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
57733649|NCT06170008|DEVICE|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
57733650|NCT06170008|DEVICE|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
57733651|NCT02934373|DEVICE|A New Sound Processor|
58303775|NCT03106688|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
58303776|NCT00909168|DRUG|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
58303777|NCT03885908|OTHER|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
58415372|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
58415373|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
58415374|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
58415375|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
58415376|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
58415377|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
58415378|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
58415379|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
58415380|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
58415381|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
58415382|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
58415383|NCT01983280|OTHER|Healing Touch|
58415384|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
58415385|NCT02291393|DEVICE|80 lead ECG|
58415386|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
58089032|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
58089033|NCT00317031|DRUG|Acamprosate or Naltrexone|mg\&d 90 days
58089034|NCT03915041|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
58303778|NCT03885908|OTHER|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
58303779|NCT03143257|DEVICE|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
58303780|NCT04621799|DRUG|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
58303781|NCT03181152|DIAGNOSTIC_TEST|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
57948888|NCT06030388|OTHER|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
57948889|NCT01294579|BIOLOGICAL|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
57948890|NCT01294579|DRUG|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
57948891|NCT04375202|DRUG|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
58303782|NCT00764790|BIOLOGICAL|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
58303783|NCT00764790|BIOLOGICAL|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
57948892|NCT06132386|OTHER|biopsy|colorectal biopsy for tissue acquisition
57948893|NCT00355173|DEVICE|Lubo cervical collar|
57948894|NCT04652323|DRUG|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
57948895|NCT06159868|OTHER|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
58089035|NCT03915041|DEVICE|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
58089036|NCT05883527|OTHER|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
58089037|NCT05883527|OTHER|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
58089038|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
57733652|NCT04153266|OTHER|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
57733653|NCT00352729|DEVICE|ACell dressing|dressing
57948896|NCT06159868|OTHER|Standard care|Standard ward based care provided by usual care teams
57948897|NCT05241730|OTHER|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
58089039|NCT05581797|OTHER|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
58089040|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
57948898|NCT05241730|OTHER|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
57948899|NCT05241730|OTHER|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
58089041|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
58415387|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
58415388|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
58415389|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
58415390|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
58415391|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
58415392|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
58415393|NCT00057434|DRUG|multivitamin|
58415394|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
58415395|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
57733654|NCT06199921|DRUG|Atorvastatin 20mg|Participants will receive oral atorvastatin 20mg daily for 16 weeks
58089042|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
58303784|NCT03467074|BIOLOGICAL|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
58303785|NCT02383524|PROCEDURE|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
58303786|NCT01739881|DEVICE|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
58303787|NCT00512590|BEHAVIORAL|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
58415396|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
58415397|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
58415398|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
58415399|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
58415400|NCT05840692|DRUG|Placebo|
58415401|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
58415402|NCT00229580|OTHER|treatment as usual|
57733655|NCT06199921|DRUG|Atorvastatin 40mg|Participants will receive oral atorvastatin 40mg daily for 16 weeks
57948900|NCT05241730|OTHER|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
58089043|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
58089044|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
58089045|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
58089046|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
57948901|NCT02657395|DEVICE|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
58089047|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
58089048|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
58303788|NCT01012427|PROCEDURE|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase \> 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
58303789|NCT04816916|DRUG|AXA1665|AXA1665 administered TID with food
58303790|NCT04816916|DRUG|Placebo|Matching placebo administered TID with food
58303791|NCT05108766|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
58303792|NCT05108766|DRUG|Placebo|Matching placebo to tildrakizumab administered SC
58303793|NCT00652847|DRUG|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
58303794|NCT00652847|DRUG|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
58303795|NCT02169440|DRUG|BIA 9-1067|BIA 9-1067 25 mg
58303796|NCT02169440|DRUG|Warfarin|Warfarin 25 mg
58303797|NCT04126434|DEVICE|mask|facemask
58303798|NCT00560365|OTHER|laboratory biomarker analysis|
58303799|NCT00560365|PROCEDURE|computed tomography|
57733656|NCT06199921|DRUG|Atorvastatin 60mg|Participants will receive oral atorvastatin 60 mg daily for 16 weeks
57733657|NCT04590703|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
57948902|NCT05115838|DRUG|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
58303800|NCT00560365|PROCEDURE|magnetic resonance imaging|
58303801|NCT00560365|PROCEDURE|quality-of-life assessment|
57948903|NCT05115838|DRUG|Placebo|Placebo implantable rod placed subdermally on the upper arm.
57948904|NCT02281370|DRUG|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
57948905|NCT02281370|DRUG|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
57733658|NCT04590703|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
58415403|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
57733659|NCT05846594|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
58089049|NCT02866695|DRUG|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
58089050|NCT03855462|DEVICE|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months."
58089051|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
58303802|NCT04771910|OTHER|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
58303803|NCT04771910|OTHER|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
58415404|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58415405|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
58089052|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
58089053|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
58089054|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
58089055|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
58089056|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
58303804|NCT02154139|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
58303805|NCT02852421|PROCEDURE|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
58303806|NCT02852421|PROCEDURE|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
58303807|NCT02427009|OTHER|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
58415406|NCT00012090|DRUG|bicalutamide|
58415407|NCT00012090|DRUG|goserelin acetate|
58415408|NCT00722202|DRUG|ERB-257|
58415409|NCT00722202|OTHER|placebo|
57733660|NCT05846594|DIAGNOSTIC_TEST|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
58303808|NCT02427009|PROCEDURE|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
58415410|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
58415411|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
58415412|NCT05027932|OTHER|IN Placebo|The placebo will be normal saline in two syringes administered IN.
58415413|NCT05027932|OTHER|IM Placebo|The placebo will be normal saline in a syringe administered IM.
58415414|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
58415415|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
58415416|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
57733661|NCT06305572|DIAGNOSTIC_TEST|QFR|Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
58415417|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
58089057|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
57733662|NCT03449030|DRUG|TAK-164|TAK-164 intravenous infusion.
57733663|NCT03449030|DRUG|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
57733664|NCT00675740|DRUG|rosiglitazone|tablets 4 mg daily
57733665|NCT00675740|BEHAVIORAL|physical exercise|stationary bike 5-6 times a week
57733666|NCT00675740|OTHER|control|control without intervention
57733667|NCT03179228|DEVICE|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
57733668|NCT05660265|DRUG|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
58089058|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
58303809|NCT03954093|DEVICE|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
58303810|NCT00020657|DRUG|dolasetron mesylate|
58303811|NCT00020657|DRUG|granisetron hydrochloride|
58303812|NCT00020657|DRUG|ondansetron|
58303813|NCT00020657|DRUG|prochlorperazine|
58415418|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
57733669|NCT05660265|OTHER|Placebo|Matching placebo will be administered.
57733670|NCT06356610|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
57733671|NCT06356610|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
58303814|NCT00020657|PROCEDURE|quality-of-life assessment|
58303815|NCT01257347|BEHAVIORAL|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.
58303816|NCT01257347|DEVICE|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
57733672|NCT06356610|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
57733673|NCT06356610|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
57733674|NCT06356610|OTHER|Reference Product E|Use of Reference Product E in controlled use and ad libitum use sessions
58089059|NCT01626794|BIOLOGICAL|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
58089060|NCT01626794|BIOLOGICAL|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
58089061|NCT01626794|BIOLOGICAL|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
57733675|NCT06356610|OTHER|Reference Product F|Use of Reference Product F in controlled use and ad libitum use sessions
58415419|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
58415420|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
58415421|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
58415422|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
57733676|NCT03149094|BEHAVIORAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
57733677|NCT03149094|BEHAVIORAL|CBSM-SMI control|this group will receive the LifeSum app.
58303817|NCT05093582|DRUG|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
58415423|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
58415424|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
58415425|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
58415426|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
58415427|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
57733678|NCT06006520|OTHER|control|No exercises will be given.
57733679|NCT06006520|OTHER|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
57733680|NCT06006520|OTHER|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
58415428|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
58415429|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
58089062|NCT01591499|DEVICE|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
58089063|NCT01591499|DEVICE|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
58089064|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
58089065|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
58089066|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
58089067|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
58089068|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
58089069|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
58303818|NCT05093582|DRUG|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
58303819|NCT03035162|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
58415430|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
58089070|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
58089071|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
58089072|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
58303820|NCT05387616|DRUG|Copanlisib|"Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle."
58415431|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
57733681|NCT01726192|PROCEDURE|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
57733682|NCT01726192|PROCEDURE|Placement of a femoral neurostimulating catheter|
57733683|NCT06670898|DRUG|[14C] NS-580|Oral suspension
58089073|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
58089074|NCT05351437|DRUG|Placebo|0.9% saline
58089075|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
58089076|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
58415432|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
58415433|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
58415434|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
58415435|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
58415436|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
58415437|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
58415438|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
58415439|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
58415440|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
58415441|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
58415442|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
58415443|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
58415444|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
58415445|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
58415446|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
58415447|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
58415448|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
58415449|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
58415450|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
58089077|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
58089078|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
58089079|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
58415451|NCT05008757|OTHER|no drug|no intervention
58415452|NCT06244836|OTHER|Implementation of a bundle of care|
58089080|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
57733684|NCT00277264|DRUG|Tiotropium (Spiriva®)|
58089081|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
58415453|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
58089082|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
58089083|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
58089084|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
58089085|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
58089086|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
58089087|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
58089088|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
58089089|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
58089090|NCT05080218|DRUG|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
58089091|NCT05080218|DRUG|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
58415454|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
58415455|NCT00138112|DRUG|Empirical Vancomycin|
58415456|NCT00138112|DRUG|Prophylactic Vancomycin|
58089092|NCT05080218|DRUG|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
58089093|NCT05080218|DRUG|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
58089094|NCT05080218|DRUG|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
58089095|NCT05080218|DRUG|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
58089096|NCT05080218|DRUG|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
58089097|NCT05080218|DRUG|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
58415457|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
58089098|NCT00000705|DRUG|Zidovudine|
58089099|NCT06436469|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) Program|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
58089100|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
58089101|NCT02379650|DRUG|Hydroxychloroquine (HCQ)|
58089102|NCT02379650|DRUG|Placebo|
58089103|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
58089104|NCT00120380|DRUG|Aerosolized iloprost|
58415458|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
58415459|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
58415460|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
58089105|NCT00120380|DRUG|Placebo|
58089106|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
58415461|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
58415462|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
58415463|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
58415464|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
58415465|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
58415466|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
57733685|NCT00493766|DRUG|LBH589|
58089107|NCT05474794|DIAGNOSTIC_TEST|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
58415467|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
58415468|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
57733686|NCT02313142|BEHAVIORAL|Leg exercises|
58089108|NCT05474794|DIAGNOSTIC_TEST|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
58415469|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
58415470|NCT01900977|OTHER|Standard of Care|
58415471|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
58415472|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
57733687|NCT06636162|DRUG|DSP-0390|DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
57733688|NCT04607967|DEVICE|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
58089109|NCT06247579|OTHER|Dietary polystyrene microplastics from disposable plastic tableware|Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
58089110|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
58089111|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
58089112|NCT03914469|BEHAVIORAL|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
58089113|NCT04686968|PROCEDURE|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
58089114|NCT04686968|PROCEDURE|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
58089115|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
57733689|NCT00001048|DRUG|Filgrastim|
57733690|NCT00001048|DRUG|Cytarabine|
57733691|NCT00001048|DRUG|Zidovudine|
58089116|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
58089117|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
58415473|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
57733692|NCT00001048|DRUG|Zalcitabine|
57733693|NCT00001048|DRUG|Didanosine|
57733694|NCT06417099|DRUG|Dihydroartemisinin|dihydroartemisinin 40mg tid po for 90 consecutive days
57733695|NCT03399734|DRUG|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
58415474|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
58415475|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
58415476|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
58415477|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
58415478|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
58415479|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
58089118|NCT00755573|DRUG|placebo|Regime as described for pregabalin
58089119|NCT03958877|DRUG|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
58089120|NCT03958877|DRUG|Interferon beta type 1a|Administered as specified in the treatment arm
58303821|NCT05387616|DRUG|Obinutuzumab|"Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks."
58303822|NCT03874442|OTHER|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
58415480|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
58415481|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
58415482|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
58415483|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
58415484|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
58415485|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
58415486|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
58415487|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
57733696|NCT03399734|DRUG|Perampanel|Single 4-mg dose of perampanel fine granules
57733697|NCT02053948|PROCEDURE|Pursestring Wound Closure|
57733698|NCT02053948|PROCEDURE|Gunsight Skin Incision and Closure Technique|
58415488|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
58089121|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
58089122|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
58089123|NCT04268394|DRUG|CC-99677|CC-99677
58089124|NCT04268394|DRUG|Methotrexate|Methotrexate
58089125|NCT04268394|DRUG|Sulfasalazine|Sulfasalazine
58089126|NCT04268394|DRUG|Itraconazole|Itraconazole
58089127|NCT04268394|DRUG|Rifampin|Rifampin
58089128|NCT04268394|DRUG|Midazolam|Midazolam
58089129|NCT04268394|DRUG|Digoxin|Digoxin
57733699|NCT02866253|DRUG|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
58089130|NCT04268394|DRUG|Metformin|Metformin
58089131|NCT04268394|DRUG|Rosuvastatin|Rosuvastatin
58089132|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
58415489|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
57733700|NCT05712291|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
57733701|NCT05712291|DEVICE|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
58089133|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
58089134|NCT06402890|DIETARY_SUPPLEMENT|Resistance training with collagen supplementation|"Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week."
58089135|NCT04071457|DRUG|Lenalidomide|Commercially available intervention
58089136|NCT04071457|DRUG|Daratumumab/rHuPH20|SWOG-Held IND
58089137|NCT02766686|RADIATION|Radiotherapy with protons|
58089138|NCT02766686|RADIATION|Radiotherapy with photons|
58089139|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
58089140|NCT03980561|DRUG|Varenicline|Active medication
58415490|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
58415491|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
58089141|NCT03980561|DRUG|Placebo|Inactive medication
57733702|NCT05712291|PROCEDURE|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
57733703|NCT02334800|DRUG|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
58089142|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
58089143|NCT00199095|DRUG|Adriamycin|
58089144|NCT00199095|DRUG|Cyclophosphamide|
58089145|NCT00199095|DRUG|Cytarabine|
58089146|NCT00199095|DRUG|Dexamethasone|
58089147|NCT00199095|DRUG|Idarubicin|
58089148|NCT00199095|DRUG|Ifosfamide|
58089149|NCT00199095|DRUG|Methotrexate|
58089150|NCT00199095|DRUG|Mercaptopurine|
58089151|NCT00199095|DRUG|VM26|
58089152|NCT00199095|DRUG|Vincristine|
58089153|NCT05286931|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
58089154|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
58089155|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
58089156|NCT05665712|PROCEDURE|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
58089157|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
58089158|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
58089159|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
58089160|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
58303823|NCT03102502|DEVICE|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
58303824|NCT03102502|DRUG|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
58415492|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
58089161|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
58089162|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
58089163|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
58089164|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
58089165|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
58089166|NCT04469868|BEHAVIORAL|No opioids at discharge|"Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues."
58303825|NCT02100839|DRUG|AEM-28|Solution for injection
58303826|NCT02100839|DRUG|Normal Saline|0.9% saline for injection
57733704|NCT02610062|DRUG|AGS67E|Intravenous (IV) infusion
57733705|NCT06019468|OTHER|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
57733706|NCT02378168|OTHER|no intervention; retrospective study|
57733707|NCT05771753|OTHER|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
58303827|NCT00830765|DRUG|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
58303828|NCT00830765|DRUG|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
58303829|NCT01058447|DRUG|AZD1981|Oral tablet, 250 mg, single dose
58303830|NCT03373214|BIOLOGICAL|Na-GST-1|Na-GST-1/Alhydrogel®
58415493|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
58415494|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
58415495|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
57733708|NCT05771753|OTHER|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
57733709|NCT03743038|DRUG|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
57948906|NCT01667770|PROCEDURE|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
57948907|NCT05559190|OTHER|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
57948908|NCT05559190|OTHER|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
57948909|NCT05035615|DIAGNOSTIC_TEST|IUO Acute Leukemia Panel|This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
58415496|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
58415497|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
58415498|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
57948910|NCT05564975|OTHER||
58089167|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
58303831|NCT03373214|BIOLOGICAL|CPG 10104|CPG 10104
58303832|NCT04122261|DEVICE|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
58303833|NCT04122261|DEVICE|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
58303834|NCT00003062|DRUG|temozolomide|
58303835|NCT02459522|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
58303836|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
58303837|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
58303838|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
57733710|NCT03743038|OTHER|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
57733711|NCT02534857|PROCEDURE|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
57733712|NCT01820676|DEVICE|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
58303839|NCT03278574|PROCEDURE|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
58303840|NCT03278574|DEVICE|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
58303841|NCT03278574|DEVICE|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
58089168|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
58089169|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
58089170|NCT03252015|DRUG|Probe Drug Cocktail|Administered orally
58089171|NCT03252015|DRUG|Lasmiditan|Administered orally
58089172|NCT03252015|DRUG|Placebo|Administered orally
58415499|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
58415500|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
58415501|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
58415502|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
58089173|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
58089174|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
58089175|NCT00444873|DRUG|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
58415503|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
57948911|NCT06210074|DEVICE|Daye Diagnostic Tampon|"The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746).~The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. The DDT needs to be worn for 20 minutes then when removed should be placed immediately in the sterile container."
57948912|NCT01555528|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
57948913|NCT02648802|PROCEDURE|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
57948914|NCT02648802|PROCEDURE|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
57948915|NCT02700724|OTHER|Immediate Surgery|
57948916|NCT02700724|OTHER|Observation|
57948917|NCT02700724|PROCEDURE|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
58089176|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
58089177|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
58089178|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
58089179|NCT02218515|PROCEDURE|Open Flap Debridement|Open Flap Debridement (Control Group)
58089180|NCT02218515|BIOLOGICAL|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
58089181|NCT02218515|BIOLOGICAL|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
58089182|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
58089183|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
58415504|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
58415505|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
58415506|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
58415507|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
58415508|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
58415509|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
57733713|NCT05004623|DEVICE|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
57733714|NCT01873365|OTHER|Data collection|Case report forms (CRFs), logbooks and booklets.
58089184|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
58415510|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
58415511|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
58415512|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
58089185|NCT06702267|DEVICE|arterial blood samplers with needles PICO70 and safePICO syringes.|"PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation.~safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle."
58089186|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
58089187|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
58089188|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
58089189|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
58089190|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
58415513|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
58415514|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
57733715|NCT05956964|BEHAVIORAL|Sleep Restriction|5 hours of sleep for 3 days
57733716|NCT05956964|BEHAVIORAL|Sleep Adequate|9 hours of sleep for 3 days
57733717|NCT03808675|BEHAVIORAL|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
57733718|NCT03808675|BEHAVIORAL|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
58089191|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
58089192|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
58089193|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
58089194|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
58415515|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
58415516|NCT00791401|DRUG|ER OROS Paliperidone|
57733719|NCT06191926|DIAGNOSTIC_TEST|ultrasound|Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer
57733720|NCT00553267|DRUG|fixed dose combination of telmisartan+amlodipine|
57733721|NCT00553267|DRUG|amlodipine|
58415517|NCT02772796|DRUG|SENS-218|Oral Administration
58415518|NCT00139763|PROCEDURE|Educational Materials|
58415519|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
58415520|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
58415521|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
58415522|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
58415523|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
58415524|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
58415525|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
58415526|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
58415527|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
58415528|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
57733722|NCT04817280|OTHER|Ice Swimming|The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
57733723|NCT04433169|DRUG|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
57733724|NCT04433169|DRUG|VEGFR inhibitor|VEGFR inhibitor
57733725|NCT04433169|DRUG|Chemotherapy|chemotherapy
57733726|NCT05772793|DEVICE|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
57733727|NCT01265069|DRUG|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
57733728|NCT01265069|DRUG|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
57733729|NCT04320069|DEVICE|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
57733730|NCT00485485|DRUG|Imatinib Mesylate|400 mg by mouth daily
57733731|NCT00485485|DRUG|Docetaxel|60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
57733732|NCT01091311|DEVICE|Blephasteam|Eye lid warming goggles
57733733|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
57733734|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
57733735|NCT02047019|DRUG|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
57948918|NCT06359873|DIAGNOSTIC_TEST|CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)|"CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\].~C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\].~LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database."
57948919|NCT06287970|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.
57948920|NCT06287970|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
58415529|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
57733736|NCT02047019|DRUG|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
57733737|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
57733738|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
57733739|NCT06039020|DRUG|Anti-human thymocyte immunoglobulin, equine|Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
57733740|NCT05897099|BEHAVIORAL|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
57733741|NCT05897099|BEHAVIORAL|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
57733742|NCT02107521|OTHER|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
58415530|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
58415531|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
57733743|NCT02107521|OTHER|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
57733744|NCT01674036|DRUG|Genz-682452|Capsules for oral administration.
57733745|NCT01674036|DRUG|Placebo|Placebo to Genz-682452
57733746|NCT03385876|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
57733747|NCT05829902|OTHER|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
57733748|NCT05829902|OTHER|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
58089195|NCT03244722|DIETARY_SUPPLEMENT|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
58089196|NCT03244722|OTHER|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
58089197|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
58089198|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
58089199|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
58089200|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
58089201|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
58089202|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
58089203|NCT06568406|PROCEDURE|Physiotherapy|Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
58089204|NCT06568406|DIAGNOSTIC_TEST|Urogynaecology|Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
58089205|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
58089206|NCT00795379|BEHAVIORAL|Interoceptive Exposure|Exposure to internal stimuli.
58089207|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
58089208|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
58089209|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy SHAM|"Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application."
58089210|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
58089211|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
58089212|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
58089213|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
58089214|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
58089215|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
58089216|NCT03313401|DRUG|Aflibercept|Intravitreal aflibercept injection
58089217|NCT03313401|DEVICE|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
58089218|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
58089219|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
58089220|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
58303842|NCT05650203|DRUG|JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006|"1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w)."
58089221|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
58089222|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
58089223|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
58089224|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
58089225|NCT06652594|BEHAVIORAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to theirchild's myopia progression at baseline, 1 month, 3 months, 6 months.
58089226|NCT06652594|BEHAVIORAL|Control|Parents in the control group will not receive eye health education informationfrom doctors and nurses.
58089227|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
58089228|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
58089229|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
58089230|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
58089231|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
58089232|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
58089233|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
58089234|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
58089235|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
58089236|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
58089237|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
58089238|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
58089239|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
58089240|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
58089241|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
58089242|NCT05428059|OTHER|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
58089243|NCT03323359|DEVICE|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
58089244|NCT03323359|PROCEDURE|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
58089245|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
58089246|NCT01836094|DRUG|Placebo|oral, one time
58089247|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
58089248|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
58089249|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
58089250|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
58089251|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
58089252|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
58303843|NCT04227912|OTHER|Transversus abdominis plane block|Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
58303844|NCT04227912|OTHER|Local anesthetic infiltration|Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
57733749|NCT03821311|RADIATION|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
57733750|NCT06669052|DIETARY_SUPPLEMENT|30 mg liposomal iron, capsules|a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule
57948921|NCT05413486|OTHER|Observational|"Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups."
57948922|NCT04565964|OTHER|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
57948923|NCT03260504|BIOLOGICAL|Aldesleukin|Given SC or IV
57948924|NCT03260504|BIOLOGICAL|Pembrolizumab|Given IV
57948925|NCT04006886|DIETARY_SUPPLEMENT|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
57948926|NCT04169880|DEVICE|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
57948927|NCT04169880|COMBINATION_PRODUCT|HILT & EXERCISE|HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
57948928|NCT03591640|DIAGNOSTIC_TEST|Blood test|Standard blood test
57948929|NCT05513989|DEVICE|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
57948930|NCT05513989|DEVICE|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
57948931|NCT01579448|BIOLOGICAL|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
57948932|NCT01579448|BIOLOGICAL|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
57948933|NCT01579448|OTHER|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
57948934|NCT01632995|DRUG|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
58089253|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
58089254|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
58089255|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
58089256|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
58089257|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
58089258|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
58089259|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
58089260|NCT00513578|BIOLOGICAL|sargramostim|
58415532|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
58415533|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
58415534|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
58415535|NCT02322294|OTHER|Placebo|
57733751|NCT03843918|DRUG|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
57733752|NCT03278665|DRUG|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
57733753|NCT03266588|DRUG|Rimegepant|75 mg oral tablet
57733754|NCT00000216|DRUG|Buprenorphine|
57948935|NCT05265312|OTHER|START diabetes prevention clinical pathway|"The diabetes prevention clinical pathway will focus on the following steps:~1. Screen/test - testing of eligible patients for prediabetes/diabetes~2. Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~3. Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~4. Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~5. Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes."
57948936|NCT06294886|DIAGNOSTIC_TEST|Screening test to detect endometrial cancer and precancer|The device is designed to detect DNA biomarkers for cancer in cells shed from the lining of the uterus into vaginal fluid
57948937|NCT05595187|DEVICE|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
57948938|NCT00413647|DRUG|CardioPET|
57948939|NCT00554242|DIETARY_SUPPLEMENT|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
57948940|NCT05601375|OTHER|Echocardiography|Fetal echocardiography (ultrasound)
57948941|NCT04457050|DRUG|Sofosbuvir 400 milligram|single daily dose of 400 milligrams
57948942|NCT04457050|DRUG|Daclatasvir 60 milligram|single daily dose of 60 milligrams for 12 weeks
57948943|NCT04457050|DRUG|Ribavirin 400 milligram|weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks
57948944|NCT04457050|DRUG|Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab|single daily dose for 12 weeks
57948945|NCT02820285|OTHER|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
57733755|NCT05850689|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
57948946|NCT02820285|OTHER|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
57948947|NCT02820285|OTHER|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
58089261|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
58089262|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
58089263|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
58089264|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
58089265|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
58089266|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
58089267|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
58089268|NCT00544349|BIOLOGICAL|cetuximab|
58089269|NCT00544349|DRUG|fluorouracil|
58089270|NCT00544349|DRUG|leucovorin calcium|
58089271|NCT00544349|DRUG|oxaliplatin|
58089272|NCT02384837|DEVICE|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
58089273|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
58089274|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
58089275|NCT02773641|DRUG|Botulinum Toxin Type A|
58089276|NCT02773641|DRUG|Sterile Saline Solution|
58089277|NCT05925309|DRUG|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
58089278|NCT05925309|DRUG|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
58089279|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
58089280|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
58089281|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
58089282|NCT06650241|OTHER|Behavioral therapy|
58089283|NCT06650241|OTHER|Lip Bumper Therapy|
58089284|NCT06650241|OTHER|Modified Twin-Block Therapy|
58089285|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
58089286|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
58089287|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
58089288|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
58089289|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
58089290|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
58089291|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
58089292|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
58089293|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
58089294|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
58089295|NCT04338256|BEHAVIORAL|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
57733756|NCT05850689|DRUG|Placebo|Matching capsules administered orally, once daily
58089296|NCT06358157|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
58089297|NCT06150872|DEVICE|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
58089298|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
58089299|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
58089300|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
58089301|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
58089302|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
58089303|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
58089304|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
58303845|NCT04227912|OTHER|Intravenous dexketoprofen|Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
58303846|NCT04829071|BEHAVIORAL|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
58303847|NCT04829071|BEHAVIORAL|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
58303848|NCT02577640|DIETARY_SUPPLEMENT|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
58415536|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
58415537|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
58415538|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
57733757|NCT04152733|DEVICE|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
57948948|NCT05251181|DRUG|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
57948949|NCT05251181|DRUG|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
57948950|NCT05698082|DIAGNOSTIC_TEST|Immunohistochemical staining with anti-FOS|The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
57948951|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 1 - Gluteal|Dose level 1
57948952|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 2 - Gluteal|Dose level 2
57948953|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Gluteal|Dose level 3
57948954|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Deltoids|Dose level 3
57948955|NCT04550091|DEVICE|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
57948956|NCT03295370|PROCEDURE|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
57948957|NCT05404620|OTHER|Schroth exercises|9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.
57948958|NCT05404620|OTHER|PNF technique|9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
57948959|NCT04754698|BIOLOGICAL|CoronaVac|CoronaVac (Sinovac Biotech Ltd., Beijing, China)
58303849|NCT00121056|DRUG|Enbrel®|
57948960|NCT04933851|BEHAVIORAL|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
58303850|NCT00121056|DRUG|Kineret®|
58303851|NCT02191488|DRUG|5-aminolevulinic acid|
58303852|NCT00176046|DRUG|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
58303853|NCT00176046|DRUG|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
58303854|NCT00563771|DRUG|Rasburicase|
58303855|NCT04102826|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
58415539|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
58415540|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
58415541|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
58415542|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
58415543|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
58303856|NCT03524716|BEHAVIORAL|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
58303857|NCT00897117|GENETIC|gene expression analysis|Blood and lung tissue collection
58303858|NCT00897117|GENETIC|microarray analysis|Blood and lung tissue collection
58415544|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
58415545|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
58415546|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
58415547|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
58415548|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
58089305|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
58089306|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
58089307|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
58089308|NCT00244881|DRUG|cediranib maleate|Given orally
58089309|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
58089310|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
58089311|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
58303859|NCT00897117|GENETIC|protein expression analysis|Blood and lung tissue collection
58303860|NCT00897117|OTHER|biologic sample preservation procedure|Blood and lung tissue collection
58303861|NCT00897117|OTHER|laboratory biomarker analysis|Blood and lung tissue collection
58303862|NCT00897117|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
58303863|NCT02558049|OTHER|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
58303864|NCT00270673|PROCEDURE|Early lactate-directed therapy|
58303865|NCT04745728|DRUG|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
58303866|NCT04745728|DRUG|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
58303867|NCT04745728|DRUG|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
57948961|NCT04933851|BEHAVIORAL|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
58303868|NCT00196703|DRUG|memantine|
58303869|NCT00196703|PROCEDURE|constraint-induced language therapy|
57948962|NCT01515137|DRUG|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
57948963|NCT01515137|DRUG|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
57948964|NCT01515137|DRUG|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
57948965|NCT01921751|RADIATION|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
57948966|NCT01921751|DRUG|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
57948967|NCT01921751|DRUG|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]
57948968|NCT01921751|RADIATION|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
57948969|NCT01921751|DRUG|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]
57948970|NCT05768945|DRUG|Semaglutide|Semaglutide claim is used as the exposure group.
58089312|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
58089313|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
58089314|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
58303870|NCT01121471|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
58303871|NCT01121471|DIETARY_SUPPLEMENT|Safflower OIl|8.0g/day safflower oil
58303872|NCT04682899|DRUG|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
58303873|NCT04682899|DRUG|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
58303874|NCT04140773|DIETARY_SUPPLEMENT|D-serine|Capsule D-serine
58303875|NCT04140773|OTHER|Placebo|Capsule D-serine
58303876|NCT02037893|DRUG|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
57948971|NCT05768945|DRUG|DPP-4 inhibitor|DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
57733758|NCT03664713|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
58089315|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
57948972|NCT00823355|DRUG|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
58089316|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
58089317|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
58089318|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
58303877|NCT02037893|DRUG|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
58303878|NCT02037893|DRUG|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
58303879|NCT02037893|DRUG|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
58303880|NCT06143397|DEVICE|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
58303881|NCT06143397|DEVICE|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
58303882|NCT06143397|DEVICE|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
58303883|NCT06143397|BEHAVIORAL|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
58303884|NCT02004223|RADIATION|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
58303885|NCT01331317|DRUG|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
58303886|NCT04850651|DRUG|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
58303887|NCT02389660|BEHAVIORAL|Blended Cognitive Behavioural Therapy (CBT)|
58303888|NCT02389660|BEHAVIORAL|Treatment as usual|
57733759|NCT04181554|OTHER|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
57733760|NCT02007577|DRUG|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
58089319|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
58089320|NCT04955210|OTHER|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
58089321|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
58089322|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
58089323|NCT03998774|BEHAVIORAL|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
58089324|NCT06652425|OTHER|Low temperature (16°C) group|The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
58089325|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
58089326|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
58089327|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
58303889|NCT06134635|DRUG|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
58303890|NCT06134635|DRUG|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
58303891|NCT02728908|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
58303892|NCT00104052|BIOLOGICAL|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
58303893|NCT00104052|DRUG|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
58303894|NCT05190796|OTHER|platelet indices|One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
58303895|NCT03400449|OTHER|Video counseling|Video counseling
58303896|NCT03400449|OTHER|Conversational counseling|Conversational counseling
58303897|NCT01190891|PROCEDURE|Manual Physical Therapy|Same as arm description
58303898|NCT01190891|PROCEDURE|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
58303899|NCT01041859|DRUG|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
58303900|NCT01041859|DRUG|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
58303901|NCT02446691|BIOLOGICAL|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
58303902|NCT03115034|DRUG|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
58303903|NCT03115034|DRUG|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
58303904|NCT03115034|OTHER|blank|Patients under CEA without taking melatonin or placebo
57733761|NCT02007577|DRUG|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
57733762|NCT02221934|DEVICE|Altius|Electrical signal
57733763|NCT05905952|DIAGNOSTIC_TEST|balance and ROM assessment|assessment of postural stability and ankle range of motion
57733764|NCT02367911|DRUG|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
57733765|NCT02367911|DRUG|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
57733766|NCT02220972|DRUG|Perampanel|
57733767|NCT02220972|DRUG|Placebo|
57948973|NCT00823355|DRUG|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
58089328|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
57785087|NCT05157685|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
58089329|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
58089330|NCT01205373|DRUG|BI 671800|High dose oral drinking solution
58089331|NCT02238639|PROCEDURE|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
58089332|NCT03779282|DRUG|Dexmedetomidine|see descriptions
58089333|NCT03311217|BEHAVIORAL|Healthy retail strategies|
58089334|NCT06111131|DEVICE|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
58089335|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
58089336|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
58089337|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
58089338|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
58089339|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
58089340|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
58089341|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
58303905|NCT04288947|OTHER|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
58303906|NCT03837717|BEHAVIORAL|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
58303907|NCT03837717|OTHER|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
57785088|NCT00791622|DRUG|Paliperidone ER|
57948974|NCT00823355|DRUG|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
57948975|NCT00823355|DRUG|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
57948976|NCT05153083|PROCEDURE|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
57948977|NCT03339011|BEHAVIORAL|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
57948978|NCT03222206|DRUG|Salsalate|"1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
57948979|NCT03222206|OTHER|Placebo|"1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
57948980|NCT01419912|DIETARY_SUPPLEMENT|soy milk|
57948981|NCT01419912|DIETARY_SUPPLEMENT|cow's milk|
57948982|NCT00577785|OTHER|tissue procurement|No intervention. Tissue procurement study.
57948983|NCT00950664|DRUG|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
57948984|NCT00950664|DRUG|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
57948985|NCT04149015|DRUG|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
57948986|NCT02184195|DRUG|Olaparib|Tablet -100mg
57948987|NCT02184195|DRUG|Olaparib|Tablet-150mg
57948988|NCT02184195|DRUG|Placebo|Match Olaparib 100mg placebo
57948989|NCT02184195|DRUG|Placebo|Match Olaparib 150mg placebo
58089342|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
58303908|NCT03837717|BEHAVIORAL|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
58303909|NCT02870647|OTHER|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
58303910|NCT04331626|DRUG|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
57948990|NCT05179447|RADIATION|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
57948991|NCT05179447|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
57948992|NCT05179447|OTHER|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
57948993|NCT05179447|COMBINATION_PRODUCT|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
57948994|NCT04315675|BEHAVIORAL|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
57948995|NCT04315675|BEHAVIORAL|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
57948996|NCT04315675|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
57948997|NCT06459154|OTHER|Mixed Reality|The experimental group MR will use the mixed reality project involving activities in a supermarket. MR HoloLens2 glasses will be used to conduct the program. The technological equipment that will be used will allow the provision of visual and auditory stimuli. The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment. This program offers coordination activities, posture, cognitive activities and balance exercises. The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
57948998|NCT06459154|OTHER|Traditional Physiotherapy|The group of traditional physiotherapy follows the guidelines of EPDA. Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks. The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
57948999|NCT06353828|DRUG|CBD, synthetic form|Cannabidiol enema
57949000|NCT06353828|DRUG|Placebo|placebo enema
57949001|NCT03435848|DRUG|BST-236|1 to 4 courses
57949002|NCT06272474|OTHER|CAD-CAM zirconia crowns using buccal interocclusal record.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record.~First, scanning the buccal interocclusal record for each patient with the two arches in maximum intercuspation position (MIP) will be performed. The IOS will immediately reproduce the occlusal state of the digital casts; this method is called the buccal bite registration method (BBR)."
57949003|NCT06272474|OTHER|CAD-CAM zirconia crowns using lateral interocclusal records.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using lateral interocclusal record.~A second scan will be performed for each patient to record lateral mandibular excursion. Then, three STL files will be exported; maxillary arch, mandibular arch at MIP and lateral mandibular excursion"
57949004|NCT04238975|BIOLOGICAL|GC3111 vaccine|0.5mL, Intramuscular
57949005|NCT04238975|BIOLOGICAL|Boostrix® vaccine|0.5mL, Intramuscular
57949006|NCT03312959|DRUG|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
57949007|NCT03312959|DRUG|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
57949008|NCT05503173|BEHAVIORAL|MCBMAP|MCBMAP integrates motivational interviewing (MI) and cognitive-behavioral skill training interventions for unhealthy drinking with cognitive-behavioral and self- management approaches for chronic pain. The intervention is delivered through internet-based videoconferencing and supplemented with web-based content to support the intervention. The initial treatment session provides a rationale for addressing alcohol and pain together in the context of HIV management, and initiates MI related to alcohol use. Participants receive 6 additional treatment sessions over the subsequent weeks.
57949009|NCT05503173|OTHER|Brief Advice and Information|Through videoconferencing an interventionist will provide participants psychoeducation about the effects of alcohol and pain on HIV symptoms, advice/recommendations to reduce alcohol use, and a list of local treatment resources for alcohol and chronic pain.
57949010|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
57949011|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
57949012|NCT01390272|BEHAVIORAL|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
57949013|NCT01390272|BEHAVIORAL|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
58089343|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
58089344|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
58089345|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
58089346|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
58089347|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
58303911|NCT02367300|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
58415549|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
58303912|NCT02611882|DRUG|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
58415550|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
58415551|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
58415552|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
58415553|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
58415554|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
58415555|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
57949014|NCT01274975|OTHER|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
57949015|NCT03803059|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
57949016|NCT02064530|DRUG|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
57949017|NCT02064530|DRUG|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
57949018|NCT02064530|DRUG|serum physiologic|21 ml serum physiologic is applied interfasially
57949019|NCT00807742|DRUG|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
57949020|NCT00807742|BEHAVIORAL|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
57949021|NCT00807742|BEHAVIORAL|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
57949022|NCT00807742|BEHAVIORAL|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
57949023|NCT00964743|DRUG|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
57949024|NCT00964743|DRUG|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
57949025|NCT02029859|PROCEDURE|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
57949026|NCT02107638|PROCEDURE|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
58089348|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
58089349|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
58089350|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
58089351|NCT03140527|DRUG|PTI-801|Active
58089352|NCT03140527|DRUG|Placebo|Placebo
58089353|NCT03140527|DRUG|PTI-808|Active
58089354|NCT03140527|DRUG|Placebo|Placebo
58089355|NCT04116359|DRUG|Cisplatin|Given IV
58089356|NCT04116359|DRUG|Etoposide|Given IV
58089357|NCT04116359|DRUG|Etoposide Phosphate|Given IV
58089358|NCT04116359|DRUG|Molibresib|Given PO
58089359|NCT04116359|DRUG|Molibresib Besylate|Given PO
58089360|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
58089361|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
58089362|NCT02536625|OTHER|prospective study|
58089363|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
58089364|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
58089365|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
58415556|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
58415557|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
58089366|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
57785089|NCT02155582|DRUG|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
57785090|NCT01782326|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
58089367|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
58089368|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
58089369|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
58303913|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
58415558|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
58415559|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
58415560|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
58415561|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
58415562|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
58415563|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
58415564|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
58415565|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
58415566|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
58303914|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
58303915|NCT04405752|DEVICE|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
58303916|NCT04405752|DEVICE|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
58415567|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
58415568|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
58415569|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
58415570|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
58415571|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
58415572|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
58415573|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
58415574|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
58415575|NCT04337736|OTHER|Physical exercise|
58415576|NCT00180167|DRUG|randomization between two established Chemotherapies|
58415577|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
58415578|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
58415579|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
58415580|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
58415581|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
58415582|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
58415583|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
58415584|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
57949027|NCT02107638|OTHER|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
57949028|NCT03710174|RADIATION|Infrared LED photobiomodulation|Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
58303917|NCT04451772|DRUG|Elsubrutinib|Oral; Capsule
58303918|NCT04451772|DRUG|Placebo for Elsubrutinib|Oral; Capsule
58303919|NCT04451772|DRUG|Upadacitinib|Oral; Tablet
58303920|NCT04451772|DRUG|Placebo for Upadacitinib|Oral; Tablet
58303921|NCT03943628|BEHAVIORAL|Familias Unidas|
58303922|NCT05517629|OTHER|It is an observational cross-sectional study|It is an observational cross-sectional study
58303923|NCT02945436|BEHAVIORAL|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
58303924|NCT02945436|BEHAVIORAL|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
58303925|NCT01116336|DRUG|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
58303926|NCT01116336|DIETARY_SUPPLEMENT|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
58303927|NCT04228484|OTHER|Placebo|Placebo infusion
58303928|NCT04228484|OTHER|GIP receptor antagonization|GIP(3-30)NH2 infusion
58303929|NCT05696964|BEHAVIORAL|Motivational interviewing training enhanced with artificial intelligence|The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
58303930|NCT03093922|DRUG|Atezolizumab|1200 mg/m\^2
58303931|NCT03093922|DRUG|Gemcitabine|1000 mg/m\^2
58303932|NCT03093922|DRUG|Cisplatin|70 mg/m\^2
58303933|NCT04868669|BEHAVIORAL|In-home, intensive nutrition counseling|"* Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress"
58303934|NCT02338817|DEVICE|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
58303935|NCT05171322|DEVICE|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
58303936|NCT03567408|PROCEDURE|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
58303937|NCT03567408|DRUG|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
58303938|NCT03468842|BIOLOGICAL|Probiotic|Already described
58303939|NCT03468842|BIOLOGICAL|Placebo|Placebo
58303940|NCT03586310|DEVICE|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
58303941|NCT01271647|DRUG|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
58303942|NCT01271647|DRUG|placebo|granules,18g per time,two times per day,six months
58303943|NCT00001781|DRUG|CGP 77116|
58415585|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
58415586|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
58415587|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
58415588|NCT00302016|DRUG|AMN107|
58303944|NCT03106116|DEVICE|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
58303945|NCT03106116|DRUG|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
57733768|NCT05289804|DEVICE|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
57785091|NCT01782326|DRUG|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
57785092|NCT02727868|GENETIC|blood samples|
58303946|NCT00542893|DRUG|Genasense® (G3139, oblimersen sodium)|
58303947|NCT00542893|DRUG|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
58303948|NCT00542893|DRUG|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
58303949|NCT01054963|BEHAVIORAL|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
58303950|NCT03984708|OTHER|Samples|Blood sample, skin biopsy
58303951|NCT03984708|OTHER|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
58303952|NCT03984708|OTHER|Electrical bioimpedance|Measurement of electrical bioimpedance
58303953|NCT04758806|BIOLOGICAL|Fecal microbial transplantation|Procured faeces procured from unrelated donor
58303954|NCT06496451|OTHER|Spinal tap for CSF collection|"A spinal tap will be done on you by your choice of bedside or in the interventional radiology (IR) suite in the Shands (Neuromedicine) hospital. This procedure will be done by trained technicians under medical supervision or the principal investigator. Local anesthesia will be used to numb the site of injection on your back. We plan to collect about 4 tablespoons of spinal fluid."
58303955|NCT06496451|OTHER|Venipuncture for blood sample|a sample of blood (approximately 4-5 tablespoonfuls) will be collected
58303956|NCT01309386|DRUG|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
58303957|NCT01309386|DRUG|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
58303958|NCT03387605|DRUG|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
58303959|NCT03387605|DRUG|Placebo|matching placebo given 2 times daily for 72 hours
58303960|NCT01163552|PROCEDURE|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
58303961|NCT01725685|DRUG|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
58303962|NCT01725685|DRUG|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
58303963|NCT01725685|DRUG|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
58415589|NCT00048750|DRUG|Micafungin|IV
58415590|NCT00048750|DRUG|Placebo|IV
58415591|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
58415592|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
58415593|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
58415594|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
58415595|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
58415596|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
58089370|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
58089371|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
58303964|NCT05683106|DEVICE|Custom silicone digital orthosis (CSDO)|Custom silicone digital orthosis (CSDO) will be made under mold to provide realignment of toes, protection or replacement of a segment that was amputated.They will be indicated for corrections of rigid/fixed or flexible toes deformities.CSDO will be constructed using different types of silicone and different hardness considering whether the deformities are rigid or flexible and,when necessary,these components of the orthoses will be merged.Intervention participants will be asked to clean the CSDO and interdigital spaces with soap and water;adequate drying of the fingers and interdigital region;always wear the CSDO with appropriate footwear and socks;keep monitoring the integrity of the CSDO and always communicate any identification of changes in the feet or CSDO.Adverse effects will be evaluated, such as:possible skin irritation; discomfort or pain;contractures;trauma due to friction.Adherence will be verified every 3 months and via telephone contact,monthly.
58303965|NCT03257748|RADIATION|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
58303966|NCT03257748|RADIATION|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
58303967|NCT00010257|DRUG|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
58303968|NCT00010257|DRUG|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
58303969|NCT01572402|OTHER|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
58303970|NCT01572402|OTHER|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
58303971|NCT01572402|OTHER|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
58303972|NCT02627079|OTHER|Daily SMS text messaging|
58415597|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
58415598|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
58415599|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
58415600|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
57733769|NCT05289804|DRUG|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
58415601|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
58415602|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
57733770|NCT05289804|DEVICE|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
57733771|NCT05289804|DEVICE|Sham NITESGON|Sham NITESGON
57733772|NCT01730937|DRUG|Sorafenib|By mouth (PO)
58303973|NCT00122434|DRUG|BEA 2180 BR|
58303974|NCT00122434|DRUG|tiotropium|
58303975|NCT00992862|DRUG|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
58303976|NCT00992862|DRUG|Univasc® 15mg Tablets|
58303977|NCT03407313|DEVICE|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
58303978|NCT05213299|PROCEDURE|AURICULAR ACUPUNCTURE|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.
58303979|NCT05213299|OTHER|PLACEBO|For this intervention, instead of needles, the investigators use four pieces of tape.
58303980|NCT03423043|RADIATION|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
58303981|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
58303982|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at HCG|Ultrasound
58303983|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
58303984|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
58303985|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at HCG|Ultrasound
58303986|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at TVOR|Ultrasound
58303987|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at ET|Ultrasound scan
58303988|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at coordination scan|Ultrasound scan
58303989|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at HCG|Ultrasound scan
58303990|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at TVOR|Ultrasound scan
57733773|NCT01730937|RADIATION|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
57733774|NCT03832010|DRUG|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
57733775|NCT03832010|DRUG|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
58303991|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at ET|Ultrasound scan
58303992|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at coordination scan|Ultrasound scan
58303993|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at HCG|Blood test
58303994|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at TVOR|Blood test
58303995|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at ET|Blood test
58303996|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at coordination scan|Blood test
58303997|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between TVOR and ET|Ultrasound scan
58303998|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at HCG|Blood test
58303999|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at TVOR|Blood test
57733776|NCT03832010|DRUG|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
57733777|NCT03832010|DRUG|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
57733778|NCT02091726|PROCEDURE|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
57733779|NCT06227585|DEVICE|REVEAL 475 System|The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
58304000|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at ET|Blood test
58304001|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at coordination scan|Blood test
58304002|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at HCG|Ultrasound scan
58304003|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
58304004|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at ET|Ultrasound scan
58304005|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
58304006|NCT03860636|DIAGNOSTIC_TEST|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
58304007|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
58304008|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between HCG and ET|Ultrasound scan
58304009|NCT04576013|DEVICE|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
58304010|NCT04576013|BEHAVIORAL|Intensive upper extremity motor training|
58304011|NCT02524639|DRUG|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
58304012|NCT00061789|DRUG|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
58415603|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
58415604|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
57733780|NCT06227585|DRUG|Bevonescein|All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
58089372|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
58089373|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
58089374|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
58089375|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
58089376|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
58089377|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
58089378|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
58089379|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
58089380|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
58089381|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
58089382|NCT00185107|DRUG|Colesevelam Hydrochloride|
58089383|NCT00185107|DRUG|Ezetimibe|
58089384|NCT00185107|DRUG|Simvastatin|
58089385|NCT00662974|OTHER|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
58089386|NCT00662974|OTHER|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
58089387|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
58089388|NCT06689917|DRUG|JY231 Injection|Upon enrolment, leukapheresis will be performed and patients will receive 3-5 days of fludarabine and cyclophosphamide lymphodepleting therapy followed by an intravenous infusion of the JY231.
57733781|NCT05054790|BIOLOGICAL|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
57733782|NCT06489613|DIAGNOSTIC_TEST|M protein detection by iMS-LC Assay|"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput."
58089389|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
58089390|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
58089391|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
58089392|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
58089393|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
58089394|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
58089395|NCT01638260|DRUG|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
58089396|NCT01638260|BEHAVIORAL|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
58089397|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
58089398|NCT01940276|DRUG|Abiraterone acetate|
58089399|NCT01940276|DRUG|Prednisone|
58089400|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
58089401|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
58089402|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
58089403|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
58089404|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
58089405|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
58089406|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
58089407|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
58089408|NCT05193435|OTHER|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
57733783|NCT05522803|DEVICE|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
58089409|NCT05193435|OTHER|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
58415605|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
58415606|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
58089410|NCT06537583|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
58089411|NCT06537583|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
58089412|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
58089413|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
58304013|NCT06471439|OTHER|single leg exercise intervantion in COPD|"single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training"
58304014|NCT00455286|DRUG|Methotrexate|
58304015|NCT00455286|DRUG|Methylprednisolone|
58304016|NCT00455286|DRUG|Temozolomide|
58304017|NCT06212011|OTHER|Superimposed Neuromuscular Electrical Stimulation|The superimposed technique involves the application of electrical stimulation during voluntary muscle contraction. In our study, in the superimposed neuromuscular electrical simulation group, neuromuscular electrical stimulation will be applied to the lumbar multifidus muscle while individuals perform the activity of standing up from sitting.
58304018|NCT06212011|OTHER|Conventional Neuromuscular Electrical Stimulation|The conventional neuromuscular electrical simulation technique, electrical stimulation is applied without the individual performing voluntary contractions. In our study, conventional NMES will be applied to the lumbar multifidus muscle with the individual lying in the prone position and the individual will not elicit any voluntary contractions during the simulation.
58304019|NCT02999789|DEVICE|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
58304020|NCT02999789|DEVICE|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
58304021|NCT05719181|BIOLOGICAL|rhBMP-2|Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
58304022|NCT00023868|DRUG|FOLFIRI regimen|
57733784|NCT05522803|DEVICE|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
57733785|NCT02703883|DEVICE|BWST|BWST (six weeks, 3 times/week)
57733786|NCT03497923|DRUG|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
57733787|NCT03811067|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
58304023|NCT00023868|DRUG|cisplatin|
58304024|NCT00023868|DRUG|doxorubicin hydrochloride|
58304025|NCT00023868|DRUG|fluorouracil|
58304026|NCT00023868|DRUG|irinotecan hydrochloride|
58304027|NCT00023868|DRUG|leucovorin calcium|
58304028|NCT00023868|DRUG|mitomycin C|
58304029|NCT00869869|DRUG|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
58304030|NCT00869869|DRUG|placebo|placebo
58304031|NCT00485862|DRUG|Atomoxetine Hydrochloride|
57733788|NCT03811067|PROCEDURE|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
58304032|NCT00485862|DRUG|Sertraline|
58304033|NCT00485862|DRUG|Placebo|
58304034|NCT01449565|DRUG|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
58304035|NCT01449565|DRUG|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
58304036|NCT06043466|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
58304037|NCT06343116|DRUG|Nimotuzumab injection|Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
58415607|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
58415608|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
58415609|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
58415610|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
58415611|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
58415612|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
58304038|NCT06343116|DRUG|Placebo|Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
58304039|NCT06343116|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
58304040|NCT01564004|OTHER|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
58304041|NCT04887467|DRUG|Apomorphine|"Assigned Interventions:~* blood sampling~* blood collection~* systolic, diastolic, mean blood pressure and heart rate measure"
58304042|NCT05560620|BEHAVIORAL|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
58304043|NCT05560620|OTHER|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
58415613|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
58415614|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
58415615|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
58415616|NCT01943019|DRUG|Linagliptin|
58415617|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
58415618|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
58304044|NCT05560620|OTHER|No Caffeine|De-caffeinated coffee
58415619|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
57733789|NCT02011438|BEHAVIORAL|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
58304045|NCT06328972|BEHAVIORAL|systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.
58304046|NCT06328972|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
58415620|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
58415621|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
58304047|NCT06328972|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
58304048|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
58304049|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
58304050|NCT06047977|BIOLOGICAL|Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2|Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
58304051|NCT02789501|DEVICE|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
58304052|NCT02789501|DEVICE|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
58304053|NCT03555149|DRUG|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
58415622|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
58415623|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
58415624|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
58089414|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
58089415|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
58304054|NCT03555149|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
58304055|NCT03555149|DRUG|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
58304056|NCT03555149|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
58304057|NCT03555149|DRUG|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
58304058|NCT03555149|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
58304059|NCT03555149|DRUG|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
58304060|NCT03555149|DRUG|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
58304061|NCT03555149|GENETIC|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
57949029|NCT03710174|DEVICE|Occlusal splint|After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
58304062|NCT00965614|OTHER|MCG|Cardiac Arrhythmia,Heart Disease
58304063|NCT00521365|DRUG|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
58304064|NCT02116868|DEVICE|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
58304065|NCT02116868|DRUG|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
58304066|NCT02116868|DRUG|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
58304067|NCT01858870|DRUG|lacosamide|routine clinical practice
58304068|NCT03073928|PROCEDURE|Interscalene Block|Regional Anesthesia procedure in the neck
57949030|NCT03710174|RADIATION|Placebo LED photobiomodulation|The same procedure as LED group with the device turned off.
57949031|NCT00676676|DRUG|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
57949032|NCT02151474|DRUG|INCB047986|
57949033|NCT02151474|DRUG|Placebo|
57949034|NCT01787682|DIETARY_SUPPLEMENT|BOOST High Protein|
57949035|NCT02994433|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
57949036|NCT02994433|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
57949037|NCT02994433|DEVICE|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
57949038|NCT01305538|DRUG|BMS-954561|
57949039|NCT01305538|DRUG|BMS-954561|
57949040|NCT01305538|DRUG|Placebo|
57949041|NCT03519763|DIAGNOSTIC_TEST|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
57949042|NCT06360263|COMBINATION_PRODUCT|Densah bur in combination with activated plasma albumin gel|Simultaneous implant placement after transcrestal maxillary sinus lifting using densah burs in combination with activated plasma albumin gel.(APAG). A full mucoperiosteal flap will be elevated, and then reflected with periosteal elevator application of first densah bur (the narrowest) with densifying mood (reverse) counterclockwise, 800-1500 revolutions per minute with copious irrigation until the sinus is reached confirm bur position with a radiograph. Then a wider densah bur (3.0) is used with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.The sequential densah bur will be used with the same mode and bouncing motion to elevate the the sinus floor 3 mm maximum. After achieving the final planned osteotomy diameter, the osteotomy will be filled with APAG. Then, the desired implant length is inserted.
57949043|NCT01973712|PROCEDURE|Locked Compression Plating|
57949044|NCT01973712|PROCEDURE|Retrograde Intramedullary Nailing (RIMN)|
58304069|NCT03073928|PROCEDURE|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
58304070|NCT03073928|DRUG|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
57949045|NCT00810056|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
57733790|NCT02734342|OTHER|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
58089416|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
58089417|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
58089418|NCT03972709|DRUG|Sham Control|Sham control
58304071|NCT01687634|BEHAVIORAL|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
58304072|NCT01687634|BEHAVIORAL|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
58304073|NCT03959657|OTHER|No intervention performed by authors|Observational and retrospective study, no intervention performed
58304074|NCT04132037|OTHER|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
58304075|NCT05758896|DRUG|Isuzinaxib (APX-115)|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
58304076|NCT05758896|DRUG|Placebo|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
58304077|NCT03575702|DRUG|Uritos®|film-coated tablets 0.1 mg
58304078|NCT03575702|DRUG|Urotol®|film coated tablets, 2 mg
58304079|NCT04076241|OTHER|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
57949046|NCT00810056|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
57949047|NCT05988658|DEVICE|ESTOP - AKI 2.0|Medical software as a Noninvasive medical device, which at the time of the project will not implement directly into subject/clinical care.
57949048|NCT06220370|OTHER|Observational|There is no clinical intervention as part of this study. Participants will receive treatment as per their clinical treating team.
57949049|NCT03868592|PROCEDURE|Gastric sleeve/bariatric surgery|weight loss
57949050|NCT02774382|DRUG|Vancomycin|Already incl. in arm description
57949051|NCT02774382|DRUG|Fecal microbiota transplantation|Already incl. in arm description
57949052|NCT02774382|DRUG|Rectal bacteriotherapy|Already incl. in arm description
57949053|NCT03297736|DEVICE|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
57949054|NCT03297736|DEVICE|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
57949055|NCT03139812|DRUG|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
57949056|NCT03139812|DEVICE|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
57949057|NCT00622674|BIOLOGICAL|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
57949058|NCT00622674|DRUG|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
57949059|NCT03200327|PROCEDURE|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
57949060|NCT03200327|PROCEDURE|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
57949061|NCT03040375|BEHAVIORAL|Peer counselling|
57949062|NCT06363721|DIETARY_SUPPLEMENT|PerioPull™|PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
57949063|NCT00806936|DRUG|human insulin|Any kind of human insulin administered at the discretion of the physician
58304080|NCT04076241|OTHER|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
58304081|NCT02334163|DRUG|Nitazoxanide|500 mg nitazoxanide tablets twice daily
58304082|NCT02334163|DRUG|Oral lactulose|Oral lactulose (65%)
58304083|NCT02334163|DRUG|Metronidazole|250 mg metronidazole tablets every 8 hours
58304084|NCT02334163|DRUG|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
58304085|NCT00244179|DRUG|interferon-gamma|
58415625|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
58415626|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
58415627|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
58415628|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
58415629|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
58415630|NCT05162742|DRUG|Colchicine|ATC: M04AC01
58415631|NCT05162742|DRUG|Placebo|Placebo tablets
58415632|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
58415633|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
58415634|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
58415635|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
58415636|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
58415637|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
58415638|NCT01420627|BIOLOGICAL|Adagen|
58415639|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
58415640|NCT03036462|DRUG|Iron|i.v. iron administration
58415641|NCT03036462|DRUG|Saline|i.v. NaCl administration
58415642|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
58415643|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
58415644|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
57949064|NCT00806936|DRUG|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
58304086|NCT00244179|DRUG|infliximab|
58304087|NCT00244179|DRUG|dmard|
58304088|NCT05257317|OTHER|Osteopathic Medicine|"Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones."
58304089|NCT05257317|OTHER|Placebo therapy|Circular movements will be induced in a frontal and parietal bones
58304090|NCT05294120|DEVICE|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
58304091|NCT05294120|RADIATION|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
58304092|NCT01799759|BEHAVIORAL|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
58304093|NCT01799759|OTHER|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
58304094|NCT02217748|OTHER|Survey questionnaire|
58415645|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
58415646|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
58415647|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
58304095|NCT02766647|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
58304096|NCT02766647|BIOLOGICAL|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
58304097|NCT00249704|DRUG|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
58304098|NCT00249704|PROCEDURE|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
58415648|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
58415649|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
58415650|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
58089419|NCT05910580|BEHAVIORAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
58089420|NCT00668369|PROCEDURE|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
58304099|NCT00249704|PROCEDURE|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
58304100|NCT00249704|DRUG|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
57733791|NCT06635707|DRUG|Urapidil|"1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
57949065|NCT05925296|DEVICE|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
57949066|NCT02124564|DRUG|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
57949067|NCT06384209|BEHAVIORAL|Friendship Bench intervention|Trained Lay Health Workers (LHWs) deliver six weekly sessions of the Problem Solving Therapy on a bench in a discreet area on the premises of the PHC. Each session consists of four stages, namely opening the mind, uplifting, strengthening and re-strengthening. Opening up the mind includes psychoeducation and normalizing depression as a mental health condition. The aim of uplifting is to identify and formulate the problems that could contribute to depressed mood. Patients categorize and rate each problem in terms of its importance and potential solvability and brainstorm lists of possible solutions. In the next stage, strengthening, clients are encouraged to consider the pros and cons of potential solutions. The LHW helps them recognize potentially dysfunctional problem-solving and develop a realistic plan to resolve the prioritized problem. In the final stage, further strengthening, participants are reassured and encouraged that the goals they set can be achieved.
57949068|NCT06384209|DRUG|Antidepressants -Fluoxetine|If randomised to the intervention arm, participants will be prescribed the first dose of Fluoxetine 20mg or Sertraline 50mg if breastfeeding. They will receive weekly Friendship Bench sessions as in the control arm. The antidepressants will be tapered on the third study visit to Fluoxetine 40mg or Sertraline 100mg.The next tapering will be done on the sixth study visit. The general nurse will be informed on the treatment response and increase Fluoxetine to 60mg and Sertraline to 150mg in patients of the intervention arm without partial response defined as \<30% improvement in PHQ-9 as compared to baseline.
57949069|NCT06066827|DRUG|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
57949070|NCT06066827|OTHER|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
57949071|NCT06066827|COMBINATION_PRODUCT|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
57949072|NCT06537713|DIAGNOSTIC_TEST|Testican-1|Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
57949073|NCT04383860|PROCEDURE|5-0 suture|5-0 suture administration during surgery
57949074|NCT04383860|PROCEDURE|4-0 suture|4-0 suture administration during surgery
57949075|NCT04155255|OTHER|MyBFF@school|
57949076|NCT06379386|PROCEDURE|Transcatheter aortic valve replacement|A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
57949077|NCT05319171|DEVICE|TAVR|TAVR
57949078|NCT06494852|DIAGNOSTIC_TEST|investigations|laboratory assesment Kidney function test, Urine analysis, Arterial blood gases ,Electrolytes (Na,K,Cl,Ca,phosphorus) and Calcium/creatinine ratio , Total serum IgE Radiological assessment Abdominal ultrasonography
57949079|NCT03650842|DEVICE|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
57949080|NCT03332498|DRUG|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
58415651|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
58415652|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
58415653|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
58415654|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
58415655|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
58415656|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
58415657|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
58415658|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
58415659|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
58415660|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
58415661|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
58415662|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
58415663|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
58415664|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
58415665|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
58415666|NCT01247363|DRUG|LY2608204|Administered orally.
58415667|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
58415668|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
58415669|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
58415670|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
58415671|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
58415672|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
58415673|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
57785093|NCT05973890|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
57949081|NCT03332498|DRUG|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
58089421|NCT06653790|BEHAVIORAL|Psychosocial stimulations|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
58089422|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
58089423|NCT02677337|OTHER|Educational Program|
58089424|NCT05373017|OTHER|DANE Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
58089425|NCT05373017|OTHER|Questionnaires|Physical, cognitive, and psychological assessments
58089426|NCT02952300|PROCEDURE|neolix|single rotation file
58415674|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
58415675|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
58415676|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
58415677|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
58415678|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
58415679|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
58415680|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
58415681|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
58415682|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
58415683|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
58415684|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
58415685|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
58415686|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
58415687|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
58415688|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
58415689|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
58415690|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
58415691|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
58415692|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
58415693|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
58415694|NCT02857192|BIOLOGICAL|Blood samples|
58415695|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
58415696|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
58415697|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
57785094|NCT05973890|BEHAVIORAL|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
58415698|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
58415699|NCT00225589|DRUG|Rosuvastatin calcium|
58415700|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
58415701|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
57785095|NCT04544007|DRUG|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
58089427|NCT02952300|PROCEDURE|wave one|single reciprocation file
58089428|NCT02245997|RADIATION|External beam radiotherapy|
58089429|NCT02245997|RADIATION|proton beam RT|
58304101|NCT06342947|DRUG|ALG-055009|Softgel Capsule
57733792|NCT06635707|DRUG|Urapidil and Esmolol|"1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
58089430|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
58415702|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
58415703|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
58415704|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
58415705|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
58089431|NCT05567562|DRUG|Placebo|Placebo
58089432|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
58089433|NCT03335839|DRUG|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
58089434|NCT03335839|OTHER|Saline|Placebo
58089435|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
58089436|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
58089437|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
58089438|NCT00665366|DRUG|Lithium|Participant's ongoing dose
58089439|NCT00665366|DRUG|Valproate|Participant's ongoing dose
58089440|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
58089441|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
58089442|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
58089443|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
58089444|NCT05471518|OTHER|No intervention|No intervention
58089445|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
58089446|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
58089447|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
58089448|NCT05419635|DRUG|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
58089449|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
58089450|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
58089451|NCT04962958|DRUG|Donafenib|administration of Donafenib
58089452|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
58089453|NCT00857922|OTHER|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
58089454|NCT06568588|DRUG|S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745|250 mg three times a day for 4 months
58089455|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
58415706|NCT00044889|DRUG|clofarabine (IV formulation)|
58415707|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
58415708|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
58415709|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
58089456|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
58089457|NCT05359341|DRUG|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
58089458|NCT05359341|DRUG|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
58089459|NCT05359341|DRUG|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
57785096|NCT06115278|OTHER|survey|survey
57949082|NCT06436651|OTHER|Digital Storytelling|4 stages of digital storytelling will be implemented.
58089460|NCT05359341|DRUG|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
58089461|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
58089462|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
57733793|NCT01657422|BEHAVIORAL|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
57733794|NCT06295562|DRUG|Atomoxetine 80mg combined with oxybutynin 5mg|Atomoxetine 80mg combined with oxybutynin 5mg
58089463|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
58304102|NCT06342947|DRUG|Placebo|Softgel Capsule
58304103|NCT02623712|OTHER|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
58304104|NCT02623712|OTHER|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
58304105|NCT05367245|DRUG|Cal-Mag Butyrate|Supplements
58304106|NCT05367245|DRUG|Placebo|Only Cal-Mag but no Butyric acid
58415710|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
57733795|NCT06295562|DRUG|Venlafaxine 37.5mg|Venlafaxine 37.5mg
57733796|NCT06295562|DRUG|Atomoxetine 80mg combined with trazodone 100mg|Atomoxetine 80mg combined with trazodone 100mg
57733797|NCT06295562|DRUG|Placebo|Placebo tablet
57949083|NCT03081520|BEHAVIORAL|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
57949084|NCT03081520|BEHAVIORAL|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
57949085|NCT03081520|BEHAVIORAL|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
57949086|NCT06126302|OTHER|Birth year|we divided the patients according to patients' birth year
57949087|NCT04179734|DRUG|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
57949088|NCT04179734|DRUG|Placebo|Placebo subcutaenous injection.
57949089|NCT05241990|BEHAVIORAL|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
57949090|NCT05241990|BEHAVIORAL|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
57949091|NCT05995288|DRUG|Homeopathic Globule|Homeopathic globules were administered after careful anamnesis
57949092|NCT05418400|OTHER|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
57949093|NCT00522145|DRUG|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
57949094|NCT00540137|DRUG|nevirapine|400mg once daily
57949095|NCT00540137|DRUG|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
57949096|NCT04832997|DIAGNOSTIC_TEST|Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)|Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS \>= 3 and PRI-MUS \>= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
57949097|NCT02393638|OTHER|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
57949098|NCT02393638|OTHER|Lecture|Lecture
57949099|NCT02455570|OTHER|No intervention|No intervention
57949100|NCT05063227|DIAGNOSTIC_TEST|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
57949101|NCT04507685|OTHER|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
57733798|NCT05734118|DEVICE|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
57733799|NCT01592032|DRUG|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
58415711|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
58089464|NCT00242567|DRUG|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
58089465|NCT00242567|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
58089466|NCT06537778|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 21 h.
58089467|NCT06537778|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
58089468|NCT05800327|DRUG|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
58089469|NCT00402207|DRUG|extrafine HFA-beclomethasone|
58089470|NCT00402207|DRUG|HFA-fluticasone|
57733800|NCT01592032|DRUG|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
57733801|NCT01592032|DRUG|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
58089471|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
58089472|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
58089473|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
58089474|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
58089475|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
58089476|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
58089477|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
58089478|NCT01444469|DRUG|Placebo|Lactose powder
58089479|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
58089480|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
58089481|NCT06568471|DRUG|Lerodalcibep|PCSK9 inhibitor
58304107|NCT06523712|BEHAVIORAL|Smile Smarts|The interactive oral health care lessons provided to participants in Arm 1 would involve activities and discussions aimed at changing behaviors such as tooth brushing frequency, brushing techniques, and the use of interdental aids. The intervention aims to educate and motivate participants to adopt and maintain optimal oral hygiene habits through behavioral change strategies.
58304108|NCT00171093|DRUG|valsartan + simvastatin|
58304109|NCT04350463|DRUG|CC-90011|CC-90011
58089482|NCT06568471|DRUG|matching placebo|placebo
58304110|NCT04350463|DRUG|Nivolumab|Nivolumab
58304111|NCT01172873|DRUG|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
58089483|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
57733802|NCT01592032|DRUG|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
58089484|NCT05736809|OTHER|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
58089485|NCT05736809|OTHER|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
58089486|NCT05736809|OTHER|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
58089487|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
58089488|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
58089489|NCT02960724|OTHER|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
57733803|NCT01592032|DRUG|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
57733804|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
58089490|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
58089491|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
58089492|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
58089493|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
58089494|NCT04551859|OTHER|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
58089495|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
58089496|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
58089497|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
58089498|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
58304112|NCT01172873|BEHAVIORAL|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
58304113|NCT02672241|DRUG|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
57733805|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
57733806|NCT02653482|DRUG|Dapagliflozin|
57733807|NCT02653482|DRUG|Dapagliflozin matching placebo|
58089499|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
58089500|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
58089501|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
58089502|NCT00143416|DRUG|Pegvisomant|
58089503|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
58089504|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
58089505|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
58089506|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
58089507|NCT00580931|DRUG|Nicotinamide|1500 mg twice a day for 6 months
58089508|NCT00580931|DRUG|Enduramide placebo|1 tab twice a day
58089509|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
58089510|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
58089511|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
58089512|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
58089513|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
58089514|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
58089515|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
58089516|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
58089517|NCT03365869|DRUG|Sirolimus|Sirolimus or placebo were added to patients every day
58089518|NCT03901352|DRUG|Placebo|Matching placebo tablets for oral administration
58089519|NCT03901352|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
58089520|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
58089521|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
58089522|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
58089523|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
58089524|NCT05910840|OTHER|Support-t|Support-t plus usual diabetes care for 18 months
58089525|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
58089526|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
58089527|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
58415712|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
58415713|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
58415714|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
58415715|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58415716|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
57949102|NCT01388673|PROCEDURE|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
58089528|NCT03902249|DRUG|Dexamethasone|
58089529|NCT06501131|OTHER|full-spectrum light exposure|Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
58089530|NCT06501131|OTHER|specific spectrum absence light exposure|Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
58089531|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
58089532|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
58089533|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
58089534|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
58089535|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
58089536|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
58089537|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
58089538|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
58089539|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
58089540|NCT03819465|DRUG|AZD2936|AZD2936 IV
58089541|NCT03447470|DRUG|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
58089542|NCT03447470|DRUG|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
58089543|NCT02173132|DRUG|Acetyl-L-carnitine|
58089544|NCT02173132|OTHER|Placebo|
58089545|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
58089546|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
58089547|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
58089548|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
58089549|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
58415717|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
57949103|NCT06420778|OTHER|electroacupuncture|The patient takes the supine position, the whole body relaxes, the facial skin is routinely sterilized. Local acupuncture points along the head and face herpes zoster lesion branches with 0.18 × 25 mm millimetre needle series of shallow stabbing method row stabbing method.Han's Acupoint Neurostimulator (model HANS-200) was selected, local acupoints were chosen as Xiaguan+Quanliao or Xiaguan+Jiache, and distal acupoints were chosen as Hegu+Waiguan connected with electroacupuncture, sparse and dense wave 2/100 Hz was selected, and the treatment time was 60 minutes, and the intensity of the current was all to the extent that the patient could tolerate it. The needles were left in place for 60 minutes each time, once every other day, and the treatment was performed 3 times a week for 4 weeks, for a total of 12 treatments.
58089550|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
58089551|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
58089552|NCT02591602|OTHER|Teleradiology Service|Teleradiology Service at home or in nursing homes
58089553|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
58089554|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
58089555|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
58089556|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
58304114|NCT02672241|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
58304115|NCT04802499|PROCEDURE|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
58304116|NCT04993573|OTHER|Questionnaire|Questions about the impact of COVID-19 in their works
58415718|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
58089557|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
58089558|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
58304117|NCT04993573|OTHER|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
58304118|NCT03709251|BEHAVIORAL|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
58304119|NCT03709251|BEHAVIORAL|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
58089559|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
58089560|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
58089561|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
58089562|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
58089563|NCT00024271|BIOLOGICAL|recombinant interferon gamma|
58089564|NCT00024271|DRUG|cisplatin|
58089565|NCT00024271|DRUG|doxorubicin hydrochloride|
58089566|NCT00024271|DRUG|gemcitabine hydrochloride|
58089567|NCT00024271|DRUG|mitomycin C|
58089568|NCT00024271|PROCEDURE|conventional surgery|
58089569|NCT00024271|PROCEDURE|hyperthermia treatment|
58089570|NCT00024271|RADIATION|radiation therapy|
58089571|NCT06453707|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
58089572|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
58089573|NCT01371006|DRUG|normal dose|efavirenz once daily
58089574|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
58089575|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
58089576|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
58089577|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
58089578|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
58089579|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
58089580|NCT03549143|OTHER|IBS|No intervention, description of routine practice only
58089581|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
58089582|NCT05054621|BIOLOGICAL|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
58089583|NCT05054621|BIOLOGICAL|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
58089584|NCT02395601|DRUG|CPI-1205|Small molecule inhibitor of the enzyme EZH2
58089585|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
58089586|NCT06568627|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
58089587|NCT06568627|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
57733808|NCT03812146|BEHAVIORAL|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
58415719|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
58415720|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
58415721|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
58415722|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
58415723|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
58415724|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
58415725|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
58415726|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
58415727|NCT00000916|DRUG|Indinavir sulfate|
58415728|NCT00000916|DRUG|Lamivudine/Zidovudine|
58415729|NCT00000916|DRUG|Hydroxyurea|
57733809|NCT03812146|BEHAVIORAL|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
57733810|NCT05720806|OTHER|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
58415730|NCT00000916|DRUG|Lamivudine|
58415731|NCT00000916|DRUG|Stavudine|
58415732|NCT00000916|DRUG|Zidovudine|
58415733|NCT00000916|DRUG|Didanosine|
58415734|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
58415735|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
58415736|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
58415737|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
58415738|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
58415739|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
58415740|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
58089588|NCT03141346|BEHAVIORAL|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
58089589|NCT03141346|BEHAVIORAL|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
58089590|NCT03141346|OTHER|Home water delivery|Home delivery of bottled water administered over 24 months
58089591|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
58089592|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
58089593|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
58089594|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
58089595|NCT06380101|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
58089596|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
58089597|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
58089598|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
58415741|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
58415742|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
58415743|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
58415744|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
58415745|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
58415746|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
58415747|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
58089599|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58089600|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
58089601|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
58089602|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
58089603|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
58089604|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
58089605|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
58089606|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
57733811|NCT05720806|OTHER|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
57733812|NCT01612403|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
58089607|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
58089608|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
58089609|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
58089610|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
57733813|NCT06532708|OTHER|5x Oxycodone Oral Tablets|Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
57733814|NCT06532708|OTHER|16x Oxycodone Oral Tablets|Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
57733815|NCT06082050|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1。
57733816|NCT04154124|DIAGNOSTIC_TEST|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
57733817|NCT01844804|BIOLOGICAL|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
57733818|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
57733819|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
57733820|NCT06171945|BEHAVIORAL|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
57733821|NCT06171945|BEHAVIORAL|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
57733822|NCT06171945|BEHAVIORAL|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
57733823|NCT01494051|BEHAVIORAL|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
57733824|NCT02624973|DRUG|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
57733825|NCT02624973|DRUG|Neoadjuvant letrozole (postmenopausal women)|
57733826|NCT02624973|DRUG|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
57733827|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide|
57733828|NCT02624973|DRUG|Neoadjuvant docetaxel|
57733829|NCT02624973|DRUG|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
57733830|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
57733831|NCT02624973|DRUG|Neoadjuvant olaparib|
57733832|NCT02624973|DRUG|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
57733833|NCT02624973|PROCEDURE|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
57733834|NCT02624973|RADIATION|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
57733835|NCT02624973|DRUG|Adjuvant trastuzumab|
57733836|NCT02624973|DRUG|Adjuvant letrozole (postmenopausal women)|
57733837|NCT02624973|DRUG|Adjuvant tamoxifen + goserelin (premenopausal women)|
57733838|NCT02624973|DRUG|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
57733839|NCT02624973|DRUG|Adjuvant Epirubicin+ Cyclophosphamide|
57733840|NCT00153777|DRUG|Cellulose Sulfate gel (6%)|
57733841|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU +PD 1|Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
58304120|NCT04066933|COMBINATION_PRODUCT|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
57733842|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU|Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
57733843|NCT02647658|BEHAVIORAL|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
57733844|NCT02647658|BEHAVIORAL|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
57733845|NCT04401579|OTHER|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
57733846|NCT04401579|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
57733847|NCT04401579|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
57733848|NCT02812810|DEVICE|active rTMS|
57733849|NCT02812810|DEVICE|sham rTMS|
58089611|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
58089612|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
58089613|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
58089614|NCT04995510|OTHER|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
58089615|NCT00631709|OTHER|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
58415748|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
58415749|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
58415750|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
57949104|NCT06420778|DRUG|Pregabalin|Subjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
58089616|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
58089617|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
58089618|NCT04795973|BEHAVIORAL|time-restricted fasting for 4 weeks|eat ad libitum from 7am to 5pm and fast in other time
58415751|NCT05607329|DRUG|Chemotherapy|chemotherapy
58415752|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
58415753|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
58415754|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
58415755|NCT00973102|DRUG|Placebo|One time dose of placebo.
57785097|NCT04218136|BIOLOGICAL|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
57949105|NCT00885274|DRUG|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
57949106|NCT00885274|DRUG|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
57949107|NCT02431351|DRUG|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
57949108|NCT03703102|DRUG|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
57949109|NCT03703102|DRUG|Placebo|Matching placebo
57949110|NCT00514514|DRUG|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
57949111|NCT00514514|DRUG|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
58089619|NCT04795973|BEHAVIORAL|5:2 regimen for 4 weeks|chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week
58415756|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
58415757|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
58415758|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
58415759|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
58415760|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
58415761|NCT00206284|DRUG|AZD0865|
58415762|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
58089620|NCT01407107|DRUG|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
58089621|NCT01407107|DRUG|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
58089622|NCT01407107|DRUG|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
58415763|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
58415764|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
58415765|NCT03288194|BEHAVIORAL|Time Management|
58415766|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
58415767|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
58415768|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
58415769|NCT04836416|OTHER|Observational|Observational
58415770|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
58415771|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
58415772|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
57733850|NCT06198569|OTHER|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
58089623|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
58304121|NCT00413543|OTHER|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
58304122|NCT06277674|DRUG|Cadonilimab plus Pemetrexed and Anlotinib|Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
58304123|NCT00003146|DRUG|busulfan|
58304124|NCT00003146|DRUG|melphalan|
58304125|NCT00003146|DRUG|thiotepa|
58304126|NCT00003146|PROCEDURE|bone marrow transplantation|
58304127|NCT00003146|PROCEDURE|peripheral blood stem cell transplantation|
58304128|NCT05415306|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
58304129|NCT05415306|BEHAVIORAL|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
58415773|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
58415774|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
58415775|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
58415776|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
58415777|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
58415778|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
58415779|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
58089624|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
58089625|NCT01231880|DRUG|Monthly IPT using DP|Given every month
58089626|NCT01231880|DRUG|Placebo given every month|No active ingredient
58304130|NCT05415306|BEHAVIORAL|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
58304131|NCT00975936|DRUG|[14C]-GSK706769|50µg \[14C\]-GSK706769 containing 250 nCi
58304132|NCT00975936|DRUG|Ketoconazole|200 mg Ketoconazole (Q12)
58089627|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
58415780|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
58415781|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
58415782|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
58415783|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
58415784|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
58415785|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
58415786|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
58415787|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
58415788|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
58415789|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
58089628|NCT02161939|DRUG|Daclatasvir (BMS-790052)|
58089629|NCT02161939|DRUG|Sofosbuvir|
58304133|NCT04712292|PROCEDURE|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~* any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~* surgery for radicalization of cancer polyps previously removed endoscopically~* surgery for excision of large polyps which are not removable endoscopically~* staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~* palliative surgery (defined as any surgery with no curative intent)"
58304134|NCT00254436|DRUG|Procrit (epoetin alfa)|Weekly dose
58304135|NCT05343325|DRUG|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
58415790|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
58415791|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
58415792|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
58415793|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
58415794|NCT02818439|OTHER|evaluation of frailty|
58415795|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
58415796|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
58415797|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
58415798|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
58415799|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
58304136|NCT05343325|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
58304137|NCT03433235|DRUG|Edoxaban|"1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~- NIHSS: National Institute of Health Stroke Scales"
58304138|NCT01443169|DRUG|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304139|NCT01443169|DRUG|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304140|NCT01443169|DRUG|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304141|NCT01443169|DRUG|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
58304142|NCT01443169|DRUG|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
58304143|NCT01443169|DRUG|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304144|NCT01443169|DRUG|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
58304145|NCT01443169|DRUG|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304146|NCT01443169|DRUG|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304147|NCT01443169|DRUG|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
58304148|NCT01443169|DRUG|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304149|NCT01443169|DRUG|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304150|NCT01443169|DRUG|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
58304151|NCT01443169|DRUG|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304152|NCT01443169|DRUG|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
58304153|NCT01443169|DRUG|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
58304154|NCT01443169|DRUG|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304155|NCT01443169|DRUG|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304156|NCT01443169|DRUG|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
58304157|NCT01443169|DRUG|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
58304158|NCT00482937|DRUG|CD-NP|
58304159|NCT03593200|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
58304160|NCT00137709|DRUG|Sodium valproate|Week 1 \& 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
58304161|NCT00137709|DRUG|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
58304162|NCT01576575|DRUG|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
58304163|NCT01576575|DRUG|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
58304164|NCT01576575|DRUG|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
58304165|NCT01576575|DRUG|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
58304166|NCT04757155|BEHAVIORAL|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
58304167|NCT03564470|DRUG|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
58304168|NCT03564470|DRUG|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
58304169|NCT00571623|OTHER|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
58304170|NCT05466721|DEVICE|Hydrustoma C3|The participant will use the device for 14 days.
58304171|NCT05466721|DEVICE|Coloplast Alterna|The participant will use the device for 14 days.
58304172|NCT02205372|DRUG|MT-3995|
58304173|NCT02205372|DRUG|Placebo|
58304174|NCT05827276|OTHER|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
58304175|NCT00244049|BEHAVIORAL|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
58304176|NCT00244049|OTHER|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
58304177|NCT02400801|DRUG|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
58304178|NCT02400801|DRUG|ethinylestradiol + dienogest|oral oestroprogestogen
58304179|NCT05983952|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
58304180|NCT02728323|DRUG|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
58304181|NCT02728323|DRUG|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
58304182|NCT06319027|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
58304183|NCT06319027|OTHER|Fluciclovine F18|Given IV
58304184|NCT06319027|DRUG|Gadolinium-Chelate|Receive gadolinium-based contrast agent
58304185|NCT06319027|PROCEDURE|Magnetic Resonance Spectroscopy|Undergo MR spectroscopy
58304186|NCT06319027|PROCEDURE|Positron Emission Tomography|Undergo PET scan
58304187|NCT03457857|OTHER|Cleanser|Cosmetic Baby Cleanser/Shampoo
58304188|NCT03457857|OTHER|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
58304189|NCT02432339|DRUG|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
58304190|NCT02432339|DRUG|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
58304191|NCT02277483|DRUG|LAIS®|10 X 1,000 / twice a week
58304192|NCT04195594|OTHER|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
58304193|NCT01053156|DRUG|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
58304194|NCT01053156|DRUG|Placebo|Placebo will be given daily for 3 months.
58304195|NCT05276791|OTHER|EMR|Endoscopic mucosal resection, according to standard care
58415800|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
58304196|NCT05276791|OTHER|ESD|Endoscopic submucosal dissection, according to standard care
58304197|NCT06123702|BEHAVIORAL|Fear extinction|Extinction of conditioned fear response
58304198|NCT06123702|DRUG|Cannabidiol Cap/Tab|12 50-mg capsules
58304199|NCT06123702|DRUG|Placebo|12 placebo capsules
58304200|NCT00860639|DRUG|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
58304201|NCT04301856|DRUG|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
58304202|NCT04387123|PROCEDURE|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
58304203|NCT01643330|GENETIC|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
58304204|NCT01643330|GENETIC|Placebo|Single intracoronary infusion
58304205|NCT02276469|BEHAVIORAL|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
58304206|NCT05502627|DRUG|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
58089630|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
58089631|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
58089632|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
58089633|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
58089634|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
58089635|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
58089636|NCT06702098|DRUG|iNK cells|Induced pluripotent stem cells derived NK cells.
58089637|NCT03328286|BEHAVIORAL|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
58089638|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
58089639|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
58089640|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
58415801|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
58089641|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
58089642|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
58089643|NCT04935931|DRUG|Naltrexone|naltrexone 50 mg PO x 1
58415802|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
58415803|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
58415804|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
58415805|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
58415806|NCT01439074|DEVICE|Mepilex Ag|Dressing
58415807|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
58415808|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
58089644|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
58089645|NCT05880537|OTHER|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
58304207|NCT02415530|BEHAVIORAL|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months
58304208|NCT02415530|OTHER|No intervention|No intervention
58304209|NCT01536210|DRUG|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
58304210|NCT01536210|DRUG|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
58304211|NCT00057135|BEHAVIORAL|Unit of use medication packaging|
58304212|NCT00057135|BEHAVIORAL|Mailed reminders to patient when medication refills are due|
58304213|NCT00057135|BEHAVIORAL|Note to Mental Health Provider when refill is overdue|
58304214|NCT00057135|PROCEDURE|Aligning all prescriptions to fall due on same date|
58304215|NCT03569501|DIETARY_SUPPLEMENT|DHA|500 mg DHA tablets
58304216|NCT03569501|DIETARY_SUPPLEMENT|oat grains|90 mg oat, containing 4.05 mg β-glucan
58304217|NCT04229043|DIETARY_SUPPLEMENT|Sports drink|Drink that will be ingested
58304218|NCT04229043|DIETARY_SUPPLEMENT|Water|Drink that will be ingested
58304219|NCT02343224|DRUG|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
58304220|NCT05777421|PROCEDURE|Conventional Physical Therapy for Knee Osteoarthriths|Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week
58304221|NCT05777421|PROCEDURE|Virtual Reality-Based Therapeutic Exercise regimes|"* Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~* Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total."
58304222|NCT02306876|DRUG|PF-06412562 3mg BID|PF-06412562
58304223|NCT02306876|DRUG|PF-06412562 15mg BID|PF-06412562
57785098|NCT02139982|PROCEDURE|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
57785099|NCT02139982|DRUG|ropivacaine|Different concentration of ropivacaine
58304224|NCT02306876|OTHER|Placebo|Placebo
58089646|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
58089647|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
58415809|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
58415810|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
58415811|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
58415812|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
58415813|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
58415814|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
58415815|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
57949112|NCT00514514|DRUG|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
58415816|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
58415817|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
58415818|NCT03817294|OTHER|Comparison of exercise training modalities|As above
58415819|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
58415820|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
58415821|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58415822|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
58415823|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
58415824|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
58415825|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
58415826|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
58415827|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
58415828|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
57949113|NCT00514514|DRUG|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
57949114|NCT04080193|BEHAVIORAL|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
57949115|NCT04539561|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
58089648|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
58089649|NCT01759056|DRUG|AVX 470|active comparator
58089650|NCT01759056|DRUG|Placebo|
58089651|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
58089652|NCT01814917|DRUG|CBPB|
58089653|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
58089654|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
58089655|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
58415829|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
58415830|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
58415831|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
58415832|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
58415833|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
58415834|NCT03883334|DRUG|Metisoprinol|Immunodulator
58415835|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
58415836|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
58089656|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
58089657|NCT05555745|DEVICE|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
58415837|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
58415838|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
58415839|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
58415840|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
58415841|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
58415842|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
58415843|NCT04132492|OTHER|no intervention|there is no intervention
58415844|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
58415845|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
58415846|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
58415847|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
58415848|NCT02893826|DRUG|Enteral Nimodipine|
58415849|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
58415850|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
57949116|NCT06136377|RADIATION|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
57949117|NCT05759754|DRUG|TCM+ Routine Therapy|"TCM：The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued."
57949118|NCT05759754|DRUG|Routine Therapy|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
57949119|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
58415851|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
58415852|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
58415853|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
57949120|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
57949121|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
57949122|NCT01763619|DEVICE|Freedom Cervical Disc|
57949123|NCT01473082|DEVICE|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
58415854|NCT05305547|DRUG|S-217622|Administered as a round tablet.
58415855|NCT05305547|DRUG|Placebo|Administered as a round tablet.
58415856|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
58415857|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
58415858|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
58415859|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
58415860|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
58415861|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
58415862|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
58415863|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
58415864|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
58415865|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
58415866|NCT02067325|OTHER|Thai massage|
58415867|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
58089658|NCT05555745|DEVICE|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
58415868|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
58415869|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
58415870|NCT01797848|DRUG|Peginterferon alfa 2a|
58415871|NCT01797848|DRUG|Ribavirin|
58415872|NCT01797848|DRUG|Placebo matching Daclatasvir|
58089659|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
58089660|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
58089661|NCT04220073|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
58089662|NCT04220073|DRUG|placebo|placebo
58415873|NCT01797848|DRUG|Daclatasvir|
58415874|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
58089663|NCT04257773|BEHAVIORAL|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
58089664|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
58089665|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
58089666|NCT04736316|BEHAVIORAL|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
58089667|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
58089668|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
58089669|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
58089670|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
58089671|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
58089672|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
58089673|NCT01382680|DEVICE|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
58089674|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
58089675|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
58089676|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
58089677|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
58089678|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
58089679|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
58089680|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
57949124|NCT01473082|DEVICE|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
58089681|NCT02192307|DEVICE|Potassium oxalate|
58089682|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
58089683|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
58089684|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
58089685|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
58089686|NCT03724591|PROCEDURE|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
58089687|NCT03724591|PROCEDURE|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
58089688|NCT05598619|DIETARY_SUPPLEMENT|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
58089689|NCT05598619|OTHER|placebo|Colon delivered placebo once a day for 12 weeks
58089690|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
58089691|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
58089692|NCT05366725|DRUG|Avelumab|As provided in real world practice
58089693|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
58089694|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
58089695|NCT00576849|DRUG|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
57733851|NCT06198569|OTHER|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
57785100|NCT02025205|DEVICE|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
57949125|NCT00404690|PROCEDURE|Bedside Silo|silo placed at bedside on admission
58089696|NCT00576849|DRUG|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
58089697|NCT00576849|DRUG|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
58089698|NCT01845181|DRUG|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
58089699|NCT01845181|DRUG|Placebo|1 or 2 or 3 capsules of placebo.
58089700|NCT06701916|BEHAVIORAL|Intervention group.|The intervention will be carried out by a multidisciplinary team composed of nurses, doctors, social workers, and psychologists from each hospital. Through this intervention, a narrative from the patients will be obtained regarding their goals, desires, capabilities, and resources related to their health situation. A health plan will be jointly created, reflecting both short- and long-term objectives, identifying the resources available to the person and within their immediate environment, and outlining how they want and expect to receive support from healthcare professionals.
58089701|NCT06701916|BEHAVIORAL|Usual care|Usual care for the outpatient management of Chronic Heart Failure.
58089702|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
58089703|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
58089704|NCT02973178|DEVICE|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
58089705|NCT01131208|GENETIC|gene expression analysis|
58089706|NCT01131208|OTHER|laboratory biomarker analysis|
58089707|NCT03828344|BIOLOGICAL|hUC-MSC suspension|Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
58089708|NCT03828344|BIOLOGICAL|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
58089709|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
58089710|NCT05692739|DRUG|Insulin|see arm description
58089711|NCT05692739|DRUG|Cyclosporins|see arm description
58089712|NCT05692739|DRUG|Artificial tears|see arm description
58089713|NCT03896373|OTHER|Blood samples|Blood samples
57733852|NCT02999776|DEVICE|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
57733853|NCT02999776|DRUG|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
57949126|NCT00404690|PROCEDURE|Operative attempt at closure|go the operating room to attempt closure
57949127|NCT04878003|DRUG|KRT-232|KRT-232, administration by mouth
57949128|NCT04878003|DRUG|TL-895|TL-895, administration by mouth
57949129|NCT03325725|DEVICE|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
57949130|NCT03046485|BEHAVIORAL|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
57949131|NCT04687579|OTHER|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
57949132|NCT04687579|PROCEDURE|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
57949133|NCT04687579|PROCEDURE|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
58089714|NCT01260194|DRUG|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
58089715|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
58089716|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
58089717|NCT00924573|DRUG|Metformin|oral administration
58089718|NCT00924573|DRUG|placebo|oral administration
58089719|NCT00924573|DRUG|Glimepiride (HOE490)|oral administration
58089720|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
57785101|NCT00004225|BIOLOGICAL|Ad5CMV-p53 gene|
57785102|NCT00004225|RADIATION|radiation therapy|
58089721|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
58304225|NCT01614301|DRUG|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
58304226|NCT04605900|DEVICE|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
58415875|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
58415876|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
58415877|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
58415878|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
58415879|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
58415880|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
57949134|NCT04697459|OTHER|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
57949135|NCT04697459|OTHER|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
57949136|NCT01765920|DRUG|Ergoferon|5 ml 3 times a day
57949137|NCT01765920|DRUG|Placebo|5 ml 3 times a day
57949138|NCT03458221|DRUG|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
58415881|NCT04332614|BEHAVIORAL|Less-is-better|Email
58415882|NCT04332614|BEHAVIORAL|Social proof|Email
58415883|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
58415884|NCT04332614|BEHAVIORAL|Standard email|Email
57949139|NCT03458221|DRUG|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
57949140|NCT03458221|DRUG|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
57949141|NCT03458221|DRUG|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
57949142|NCT01469338|DRUG|cabazitaxel|Given IV
57949143|NCT01469338|DRUG|prednisone|Given PO
57949144|NCT01469338|DRUG|octreotide pamoate|Given IM
57785103|NCT00506285|DRUG|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
57949145|NCT01469338|OTHER|questionnaire administration|Ancillary studies
58089722|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
58415885|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
58415886|NCT03454867|DEVICE|Hemofiltration|
58415887|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
58415888|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
58415889|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
58304227|NCT04605900|DEVICE|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
58304228|NCT04605900|DEVICE|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
58415890|NCT05118815|OTHER|Standard abutment|Use a standard abutment
58415891|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
58415892|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
58415893|NCT00784732|DRUG|QAV680|
58415894|NCT00784732|DRUG|QAV680|
58415895|NCT00784732|DRUG|Mometasone Furoate|
58415896|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
58415897|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
58415898|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
58415899|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
58415900|NCT02754583|DRUG|Azithromycin|20mg/kg
58415901|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
58415902|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
58415903|NCT01023386|DRUG|YM155|I.V.
58415904|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
58415905|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
58415906|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
58415907|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
58415908|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
58415909|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
58415910|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
58415911|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
58415912|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
58415913|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
58415914|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
58415915|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
58415916|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
57949146|NCT01469338|DRUG|octreotide acetate|Given SC
57949147|NCT00025051|DRUG|celecoxib|
58304229|NCT04605900|BEHAVIORAL|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
58304230|NCT00073918|DRUG|cyclophosphamide|Given IV
58304231|NCT00073918|DRUG|etoposide|Given IV
58304232|NCT00073918|RADIATION|iodine I 131 tositumomab|Given IV
58415917|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
58415918|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
58415919|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
58415920|NCT02017145|DRUG|Chloraprep|
58415921|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
57733854|NCT02999776|DRUG|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
57733855|NCT04082065|OTHER|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
57733856|NCT04082065|OTHER|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
57733857|NCT03301051|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
57733858|NCT03301051|BIOLOGICAL|Placebo|Single dose of a Placebo
57733859|NCT06535451|OTHER|Screening|Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
57733860|NCT01278329|OTHER|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
57733861|NCT01192906|DRUG|Placebo|Oral doses, once a day for 52 weeks
57733862|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
57949148|NCT00025051|PROCEDURE|anti-cytokine therapy|
57949149|NCT00025051|PROCEDURE|antiangiogenesis therapy|
57949150|NCT00025051|PROCEDURE|biological therapy|
57949151|NCT00025051|PROCEDURE|cancer prevention intervention|
57949152|NCT00025051|PROCEDURE|chemoprevention of cancer|
57949153|NCT00025051|PROCEDURE|growth factor antagonist therapy|
57949154|NCT01717209|DRUG|Nitric Oxide|inhaled nitric oxide
57949155|NCT01717209|DRUG|Prostacyclin|inhaled prostacyclin
57949156|NCT01408992|PROCEDURE|Audiometry|Standard hearing test performed by audiologists
57949157|NCT01408992|OTHER|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
57949158|NCT01527864|DRUG|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
57949159|NCT01527864|DRUG|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
57949160|NCT01582425|DRUG|Isavuconazole|oral
57949161|NCT01582425|DRUG|Methadone|oral
57949162|NCT05041751|PROCEDURE|Acupuncture Point Injection|Receive trigger point injections
57949163|NCT05041751|PROCEDURE|Massage Therapy|Perform myofascial release
57949164|NCT05041751|OTHER|Quality-of-Life Assessment|Ancillary studies
57949165|NCT05041751|OTHER|Questionnaire Administration|Ancillary studies
57949166|NCT04445675|OTHER|Support for breastfeeding and the feeding of infants' with breast milk|The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
57949167|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
57949168|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
57949169|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
57949170|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
57949171|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
57949172|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
57733863|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
58304233|NCT00073918|PROCEDURE|quality-of-life assessment|Ancillary study
58304234|NCT00073918|PROCEDURE|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
57733864|NCT02124967|OTHER|Exercise|A one hour exercise class including both aerobic activity and resistance training
57733865|NCT06670534|DRUG|JMKX003142 tablets|JMKX003142 tablets for expermental groups
57733866|NCT06670534|DRUG|Torasemide tablets|Torasemide tablets for active comparator group
58304235|NCT03537066|DEVICE|CPAP|All patients included will be treated by CPAP
58304236|NCT01510405|OTHER|Tissue Collection|Tissue sample collection
58304237|NCT04056208|DRUG|Pistachio|Unsalted pistachios
58304238|NCT04056208|OTHER|Usual care|Advice and resources will be provided
57733867|NCT06670807|DIETARY_SUPPLEMENT|Probiotic Arm|Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.
57733868|NCT06670807|OTHER|Placebo|Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
57733869|NCT01914926|DRUG|Metoprolol|
57949173|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
58304239|NCT00566488|BIOLOGICAL|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
58304240|NCT03391752|COMBINATION_PRODUCT|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
58304241|NCT01471977|OTHER|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
58304242|NCT03541837|DRUG|Ropivacaine|ESP catheter
58304243|NCT03405727|DIETARY_SUPPLEMENT|Oral dietary supplements|Protein enriched diet
58304244|NCT04970212|DEVICE|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
58304245|NCT05807867|BEHAVIORAL|WMM-based intersectional stigma intervention|"Intervention components consist of:~1. psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~2. cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~3. Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
58304246|NCT05807867|BEHAVIORAL|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
58304247|NCT01368419|DRUG|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
58304248|NCT01368419|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
57733870|NCT01914926|DRUG|Diltiazem|
57733871|NCT03257462|DRUG|SPR001|SPR001 Capsules
57733872|NCT06313762|DEVICE|Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet|They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
57785104|NCT00506285|OTHER|placebo patch|This patch is designed to appear identical to the actual intervention patch
57949174|NCT00361270|BEHAVIORAL|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
58415922|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
58304249|NCT04077892|DRUG|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
58415923|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
58415924|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
57733873|NCT06313762|BEHAVIORAL|Traditional Distractors|The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
57949175|NCT00811616|DEVICE|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
57733874|NCT06313762|BIOLOGICAL|Triple Viral + Varicella Vaccine at 3 years of age|Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
58415925|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
58415926|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
58415927|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
58415928|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
58415929|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
58415930|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
58415931|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
58415932|NCT00430001|DRUG|docetaxel|
58415933|NCT00430001|DRUG|vinorelbine|
58415934|NCT00430001|DRUG|trastuzumab|
58415935|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
58415936|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
58415937|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
57949176|NCT01586884|PROCEDURE|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
57949177|NCT05009771|DRUG|Intravenous patient-control analgesia|At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
58304250|NCT01989858|OTHER|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
58415938|NCT00287937|DRUG|vorinostat|Given orally
58415939|NCT00287937|DRUG|paclitaxel|Given IV
58415940|NCT00287937|DRUG|carboplatin|Given IV
58415941|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
58415942|NCT00287937|OTHER|pharmacological study|Correlative studies
58415943|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
58415944|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
58415945|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
58415946|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
58415947|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
58415948|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
58415949|NCT00524589|DRUG|dexamethasone|Oral
58415950|NCT00524589|GENETIC|protein expression analysis|Correlative Study
58415951|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
58415952|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
58415953|NCT00002055|DRUG|Pentamidine isethionate|
58415954|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
58415955|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
58415956|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
58415957|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
57733875|NCT06313762|BIOLOGICAL|Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.|Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
58415958|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
58415959|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
58415960|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
58415961|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
58415962|NCT06299722|OTHER|STEEL|Relatively heavy strength training
58415963|NCT06299722|OTHER|Circuit training|Circuit training
58415964|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
58415965|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
58415966|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
58415967|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
58415968|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
58415969|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
58415970|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
58415971|NCT05586958|DRUG|Placebo|Matching placebo
58415972|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
58415973|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
58415974|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
58415975|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
58415976|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
58415977|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
58415978|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
58415979|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
58415980|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
58415981|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
58415982|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
58415983|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
58415984|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
58415985|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
58415986|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
57733876|NCT00925158|PROCEDURE|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
57733877|NCT03772080|OTHER|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
58415987|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
58415988|NCT02225912|OTHER|PrevinC|
58415989|NCT02225912|DRUG|placebo|
58415990|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
58415991|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
58415992|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
58415993|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
58415994|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
58415995|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
58415996|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
58415997|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
58415998|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
57949178|NCT05009771|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
57949179|NCT00885703|DRUG|Fluconazole|"Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
57949180|NCT00885703|DRUG|Amphotericin B|Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
57949181|NCT01827670|DRUG|Stannous fluoride|Test dentifrice containing 0.454% SnF
57949182|NCT01827670|DRUG|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
57949183|NCT00407095|DRUG|Pardoprunox|12-42 mg/day
58415999|NCT04665115|DRUG|Ibrutinib|Given PO
58416000|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
58416001|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
58416002|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
58416003|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
57949184|NCT06470256|PROCEDURE|Palliative Hepatectomy|"Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection."
57949185|NCT06470256|DRUG|Durvalumab|Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
57949186|NCT06470256|DRUG|Lenvatinib|Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
57949187|NCT03560856|DRUG|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
57949188|NCT00781911|BIOLOGICAL|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
57949189|NCT00781911|DRUG|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
57949190|NCT05443841|OTHER|pleural lavage|pleural lavages before tumor resection and after tumor resecion, respectively
57949191|NCT02351505|DRUG|Selinexor|Given PO
58089723|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
58089724|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
58089725|NCT00559975|BIOLOGICAL|Subunit influenza vaccine|0.5 mL single dose vaccine
58089726|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
58089727|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
58089728|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
58089729|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
58416004|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
58089730|NCT00049010|GENETIC|comparative genomic hybridization|
58089731|NCT00049010|GENETIC|cytogenetic analysis|
58089732|NCT00049010|GENETIC|fluorescence in situ hybridization|
58089733|NCT00049010|OTHER|immunohistochemistry staining method|
58416005|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
58416006|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
58416007|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
58416008|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
58416009|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
58416010|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
58416011|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
58089734|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
58416012|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
57733878|NCT00810134|PROCEDURE|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
58089735|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
58089736|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 3.
58089737|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
58089738|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
57733879|NCT00810134|PROCEDURE|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
57949192|NCT02351505|OTHER|Laboratory Biomarker Analysis|Correlative studies
58089739|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
58089740|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
58089741|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
58089742|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
58089743|NCT00274807|BIOLOGICAL|filgrastim|
58089744|NCT00274807|DRUG|cytarabine|
58089745|NCT00274807|DRUG|etoposide|
58089746|NCT00274807|DRUG|mitoxantrone hydrochloride|
58089747|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
58089748|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
58089749|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
58416013|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
58416014|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
58416015|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
58416016|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
58416017|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
57949193|NCT02351505|OTHER|Pharmacological Study|Correlative studies
57949194|NCT03949933|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
57949195|NCT01796587|DEVICE|LoFric Origo|
57949196|NCT00113828|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
57949197|NCT00113828|PROCEDURE|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
57949198|NCT03695575|DEVICE|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
57949199|NCT05170906|OTHER|Reflex locomotion stimulus|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
58416018|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
57949200|NCT05170906|OTHER|sham stimulus|The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
57949201|NCT00350142|RADIATION|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
57949202|NCT00350142|DRUG|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
57949203|NCT00350142|OTHER|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
57949204|NCT00350142|RADIATION|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
58089750|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
58089751|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
58089752|NCT02871336|OTHER|Data collection|
58089753|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
58089754|NCT05925049|DRUG|Natalizumab|Administered as specified in the treatment arm.
58089755|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
58089756|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
58416019|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
58416020|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
58416021|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
58416022|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
58416023|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
58416024|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
58416025|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
58416026|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
58416027|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
58416028|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
58416029|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
58416030|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
58416031|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
58416032|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
58416033|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
58416034|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
58416035|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
58416036|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
58416037|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
58416038|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
57949205|NCT00883207|BEHAVIORAL|Psychotherapy|Narrative and dialogical approach for couples
57949206|NCT04343625|BEHAVIORAL|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
57949207|NCT00715585|BEHAVIORAL|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
57949208|NCT00715585|BEHAVIORAL|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
57949209|NCT00715585|BEHAVIORAL|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
57949210|NCT03446222|PROCEDURE|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
58416039|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
58416040|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
58416041|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
58416042|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
58416043|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
58416044|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
58416045|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
58416046|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
58089757|NCT05761522|OTHER|transthoracic echocardiography|"* Concerning the main judgment criterion and the secondary judgment criteria:~  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~ * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~ * Tricuspid Annular Systolic Excursion (TAPSE) (mm)~ * S wave at the tricuspid ring (cm/s)~* Other parameters collected systematically:~  * Surface of the left ventricle (end-systolic and end-diastolic),~ * Global strain of the left ventricle~ * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~ * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~ * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
58089758|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
58089759|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
57949211|NCT03446222|PROCEDURE|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
58089760|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
58089761|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
58089762|NCT05121688|OTHER|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
58089763|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
58089764|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
58089765|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
58416047|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
58416048|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
58416049|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
58416050|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
58416051|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
58416052|NCT02726191|BEHAVIORAL|Token Task Exercise|
57733880|NCT03196648|OTHER|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
57949212|NCT04086394|PROCEDURE|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
57949213|NCT04086394|PROCEDURE|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
58089766|NCT06279273|DEVICE|Transcranial direct current stimulation|Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
57949214|NCT05123833|PROCEDURE|Hypospadias repair|surgical repair of hypospadias
57949215|NCT04722575|DRUG|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
58089767|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
58089768|NCT05691218|DEVICE|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
58416053|NCT02726191|BEHAVIORAL|Story Recall Exercise|
58416054|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
58416055|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
58416056|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
58416057|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
58416058|NCT02726191|BEHAVIORAL|Memory Match Exercise|
58416059|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
58416060|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
58416061|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
58416062|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
58416063|NCT02020772|OTHER|coordinating primary health care|
58416064|NCT02020772|OTHER|usual primary health care|
58416065|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
58416066|NCT00601913|DRUG|erlotinib hydrochloride|
58416067|NCT00601913|GENETIC|protein analysis|
58416068|NCT00601913|GENETIC|western blotting|
58416069|NCT00601913|OTHER|immunohistochemistry staining method|
58089769|NCT05691218|DEVICE|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
58304251|NCT01989858|OTHER|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
58304252|NCT01989858|OTHER|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
58304253|NCT01989858|OTHER|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
58304254|NCT01746862|DRUG|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
57733881|NCT03196648|OTHER|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
58304255|NCT01746862|DRUG|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
58304256|NCT05595135|OTHER|Text Message-Based Navigation Intervention|Receive interactive text messaging.
58304257|NCT05595135|OTHER|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
58304258|NCT05595135|OTHER|Survey Administration|Ancillary studies
58304259|NCT05595135|OTHER|Quality-of-Life Assessment|Ancillary studies
58304260|NCT00524433|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
58304261|NCT00524433|DRUG|placebo|
58304262|NCT01563523|DRUG|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
58304263|NCT01563523|DRUG|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
58304264|NCT02869789|DRUG|Nivolumab in combination with Ipilimumab|Specified dose on specified days
58304265|NCT06017245|DEVICE|whole-body vibration to Control|Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
57733882|NCT03196648|OTHER|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
57733883|NCT03721991|DIETARY_SUPPLEMENT|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
57733884|NCT03721991|DIETARY_SUPPLEMENT|placebo|matching placebo
57949216|NCT04722575|DRUG|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
58304266|NCT01290718|DRUG|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
58304267|NCT01290718|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
58304268|NCT02121210|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
58304269|NCT04149418|OTHER|Yogurt|Low-fat flavored yogurt
58304270|NCT04149418|OTHER|Control food|Low-fat flavored soy pudding
58416070|NCT00601913|OTHER|laboratory biomarker analysis|
58416071|NCT00601913|OTHER|liquid chromatography|
58416072|NCT00601913|OTHER|mass spectrometry|
57949217|NCT04722575|DRUG|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
58416073|NCT00601913|PROCEDURE|neoadjuvant therapy|
57949218|NCT02853942|BIOLOGICAL|Autologous adipose stem cell therapy|
57949219|NCT02853942|DRUG|Mecobalamin|
57949220|NCT04451356|DEVICE|Bioimpedance Spectroscopy|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device (BCM®Body Composition Monitor - Fresenius Medical Care D GmbH). The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. In addition, this analysis will provide the LTI and FTI for the included patients.
57949221|NCT04451356|DEVICE|Arterial Stiffness|Arterial stiffness assessment will be performed by applanation tonometry (SphygmoCorTM; PWV Inc., Westmead, Sydney, Australia) with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
57949222|NCT04451356|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic evaluations will be made in each patient at baseline. All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
57949223|NCT04451356|DIAGNOSTIC_TEST|Lung ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
57949224|NCT00314184|DRUG|quetiapine fumarate|
57949225|NCT03550482|DIETARY_SUPPLEMENT|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
58089770|NCT05691218|DEVICE|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
58304271|NCT06273761|BEHAVIORAL|Medication Management Service (MMS)|Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
58416074|NCT00601913|PROCEDURE|therapeutic conventional surgery|
58416075|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
58416076|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
58416077|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
57733885|NCT01178853|DRUG|Warfarin|Warfarin 5 mg once daily
57949226|NCT04426877|BEHAVIORAL|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
57949227|NCT04426877|BEHAVIORAL|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
57949228|NCT03734835|DIETARY_SUPPLEMENT|hesperidin|1000 mg hesperidin as two capsules
57949229|NCT03734835|DIETARY_SUPPLEMENT|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
57949230|NCT03734835|DIETARY_SUPPLEMENT|flaxseed|30 grams flaxseed
57949231|NCT03734835|OTHER|control|no supplementation
57949232|NCT03103802|DEVICE|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
57949233|NCT04763577|OTHER|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
57949234|NCT01888029|DEVICE|transcranial direct current stimulation|
57949235|NCT01888029|DEVICE|sham stimulation|
58089771|NCT03088280|DRUG|Thymoglobulin|reduced dose (3mg/Kg)
57733886|NCT01178853|DRUG|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
57733887|NCT01178853|DRUG|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
58089772|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
58089773|NCT04285736|DRUG|Conventional Treatment|
58089774|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
58089775|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
58089776|NCT05801094|DRUG|QL1604|QL1604 3 mg/kg Q3W
58304272|NCT01595373|DRUG|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
58304273|NCT01595373|DRUG|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
58304274|NCT03305718|OTHER|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
58304275|NCT03305718|OTHER|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
58304276|NCT03305718|OTHER|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
57733888|NCT06534151|DEVICE|CRT implantation|A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
57733889|NCT02105948|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
57733890|NCT02105948|DRUG|Placebo|Sterile 0.9% sodium chloride solution
58304277|NCT03305718|OTHER|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
58304278|NCT03305718|OTHER|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
58304279|NCT03305718|OTHER|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
58304280|NCT03305718|OTHER|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
58304281|NCT03305718|OTHER|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
58304282|NCT03305718|OTHER|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
58304283|NCT03305718|OTHER|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
58304284|NCT03305718|OTHER|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
58304285|NCT03305718|OTHER|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
58304286|NCT00888875|DEVICE|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
58304287|NCT00888875|DEVICE|ILMA|Insertion after Induction. Insertion of tracheal tube over device
58304288|NCT02668640|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
58304289|NCT02351934|DRUG|Furosemide|
58089777|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
58416078|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
58416079|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
58416080|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
58416081|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
58416082|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
58416083|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
58416084|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
58416085|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
58416086|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
58416087|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
58416088|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
58416089|NCT01752400|DRUG|AUY922|
58416090|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
58416091|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
58416092|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
58416093|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
58416094|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
58416095|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
58416096|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
58304290|NCT02351934|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
58416097|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
58416098|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
57733891|NCT06100497|DRUG|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
58304291|NCT02351934|DRUG|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
57733892|NCT06100497|DRUG|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
57733893|NCT06100497|DRUG|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
57733894|NCT02682264|DRUG|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
57733895|NCT02264795|DRUG|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
58304292|NCT01219582|DRUG|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
58304293|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
57733896|NCT02264795|DRUG|Placebo|0.9% Sodium Chloride Solution
57733897|NCT04044677|DEVICE|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
57733898|NCT04044677|DEVICE|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
58089778|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
58089779|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
58089780|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
58089781|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
58089782|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
58089783|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
58089784|NCT00103155|PROCEDURE|conventional surgery|
58089785|NCT00103155|PROCEDURE|radiofrequency ablation|
58089786|NCT04800822|DRUG|PF-07284892|PF-07284892
58089787|NCT04800822|DRUG|lorlatinib|lorlatinib
58089788|NCT04800822|DRUG|binimetinib|binimetinib
58089789|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
58089790|NCT04800822|DRUG|encorafenib|encorafenib
58089791|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
58089792|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
58304294|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
58304295|NCT02051296|DRUG|Minocycline|RCT blinded placebo trial
58416099|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
57733899|NCT02057822|PROCEDURE|Cytokins assay in tears|
57733900|NCT06630455|DIETARY_SUPPLEMENT|Meu-cinn|Meu-cinn 250 mg/day for 8 weeks
57733901|NCT06630455|DIETARY_SUPPLEMENT|Placebo|Placebo 250 mg/day for 8 weeks
57733902|NCT05734794|DRUG|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
57733903|NCT05734794|DRUG|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
57733904|NCT00907673|DEVICE|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
58416100|NCT04600336|DRUG|Placebo Administration|Given PO
57733905|NCT03720704|DEVICE|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
58089793|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
58089794|NCT05923333|DIETARY_SUPPLEMENT|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
58089795|NCT05923333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58416101|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
58416102|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
58416103|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
58416104|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
58416105|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
58416106|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
58416107|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
58416108|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
58416109|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
58089796|NCT06039007|DIETARY_SUPPLEMENT|7-day Fasting-Mimicking Diet (7-DAY FMD)|This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
58089797|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
58089798|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
58089799|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
57733906|NCT06019312|DIETARY_SUPPLEMENT|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
58304296|NCT02051296|DRUG|placebo|RCT blinded placebo trial
58304297|NCT01299558|DRUG|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
58304298|NCT01299558|DRUG|fluticasone furoate|Single IV dose of FF (250mcg)
58304299|NCT01299558|DRUG|GW642444|Single IV dose of GW642444 (55mcg)
58304300|NCT00191243|DRUG|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
58304301|NCT00191243|DRUG|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
58304302|NCT04131296|DIAGNOSTIC_TEST|influenza screening|positive influenza screening
58304303|NCT03110107|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58304304|NCT03110107|BIOLOGICAL|BMS-986218|Specified dose on specified days
58304305|NCT03110107|BIOLOGICAL|Nivolumab|Specified dose on specified days
58089800|NCT04951817|DRUG|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
57733907|NCT03302962|BEHAVIORAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
57733908|NCT01748929|DRUG|Albendazole|
57733909|NCT01748929|DRUG|Placebo|
57733910|NCT06670833|OTHER|Lung ultrasound|Portable lung ultrasound
57733911|NCT06670833|OTHER|Standard of Care (SOC)|SOC antibiotic treatment
58089801|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
58089802|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
58089803|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
58304306|NCT06221176|BEHAVIORAL|Being Brave|Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
58304307|NCT03759925|OTHER|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
58304308|NCT00001567|DRUG|Roferon-A|
58304309|NCT05870852|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
58304310|NCT05870852|OTHER|PNF|PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
58304311|NCT00927875|DRUG|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
58304312|NCT00927875|DRUG|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
58304313|NCT00927875|DRUG|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
58304314|NCT03034369|OTHER|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
58304315|NCT03034369|OTHER|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
58304316|NCT03034369|OTHER|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
58304317|NCT03034369|OTHER|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
58304318|NCT03034369|OTHER|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
58304319|NCT03034369|OTHER|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
58304320|NCT03034369|OTHER|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
58304321|NCT03034369|OTHER|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
58304322|NCT03034369|OTHER|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
58304323|NCT03034369|OTHER|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
58304324|NCT03034369|OTHER|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
58304325|NCT03034369|OTHER|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
58089804|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
58089805|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
58089806|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
58089807|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
58089808|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
58089809|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
58089810|NCT00463385|DRUG|Pomalidomide|
58416110|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
58416111|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
58089811|NCT00463385|DRUG|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
58416112|NCT02275728|OTHER|Eletromyography Biofeedback|
58416113|NCT02899923|OTHER|Data collection|
57733912|NCT02399579|OTHER|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
57733913|NCT02032472|OTHER|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
58089812|NCT00463385|DRUG|Placebo to pomalidomide|Matching pomalidomide placebo tablets
58089813|NCT00463385|DRUG|Placebo to prednisone|Matching prednisone placebo tablets
58089814|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
58089815|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
58089816|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
58304326|NCT03034369|OTHER|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
58304327|NCT05507099|BIOLOGICAL|Bone Marrow Aspirate, Lipoaspirate Concentrate|Autologous Cell Therapy.
58304328|NCT02962427|DRUG|Sphenopalatine ganglion Block|
57733914|NCT04945174|BEHAVIORAL|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
57733915|NCT02459574|PROCEDURE|AVATAR-AF ablation|Experimental ablation protocol
57785105|NCT00946647|DRUG|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
57785106|NCT00946647|DRUG|5-Azacytidine|
58304329|NCT02962427|PROCEDURE|Epidural blood patch|
58304330|NCT01111565|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
58304331|NCT01111565|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
58304332|NCT04554472|DIAGNOSTIC_TEST|Intraoperative ultrasound|During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
58304333|NCT03111524|OTHER|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
58304334|NCT03111524|OTHER|No intervention|No intervention is administered in this group as these are control groups
58304335|NCT00483652|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
58304336|NCT00483652|DRUG|Placebo|placebo (sugar pill)
58304337|NCT04861142|DRUG|Anti-osteoporotic medication( alendronate or denosumab)|Initiation of anti-osteoporotic medication (alendronate or denosumab)
58304338|NCT06163118|DIAGNOSTIC_TEST|Deglut'G test|"Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal."
58304339|NCT06163118|DIAGNOSTIC_TEST|SLP swallowing test|"At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient."
58089817|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
58089818|NCT06136676|BEHAVIORAL|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
58089819|NCT00006092|DRUG|Arsenic Trioxide|
58089820|NCT02392559|DRUG|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
58089821|NCT02392559|DRUG|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
58089822|NCT02578043|DRUG|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
58089823|NCT02578043|DRUG|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
58089824|NCT02578043|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
58089825|NCT00390572|BEHAVIORAL|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
58304340|NCT06163118|DIAGNOSTIC_TEST|ENT doctor swallowing test|"At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient."
58416114|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
58416115|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
58416116|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
58416117|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
58416118|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
58416119|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
58416120|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
58416121|NCT02552251|BIOLOGICAL|metabolic balance measurements|
58416122|NCT02552251|BIOLOGICAL|bone balance measurements|
58416123|NCT02552251|BEHAVIORAL|quality of life assessment|
58416124|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
57785107|NCT02555007|DRUG|Vinorelbine|
57785108|NCT00085059|DRUG|boronophenylalanine-fructose complex|
57785109|NCT01759875|DRUG|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
58304341|NCT03425669|DEVICE|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
58304342|NCT03425669|DEVICE|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
58304343|NCT03425669|DRUG|Active medication|Patients will be examined with and without medication.
58304344|NCT00643201|DRUG|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
58304345|NCT00643201|DRUG|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
58416125|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
58416126|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
58304346|NCT00643201|DRUG|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
58416127|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
58416128|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
58416129|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
58416130|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
58416131|NCT02714270|PROCEDURE|modified partograph|
58416132|NCT02714270|PROCEDURE|paperless partograph|
58089826|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
58304347|NCT00643201|DRUG|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
58304348|NCT00643201|DRUG|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
58304349|NCT00643201|DRUG|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
58416133|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
58416134|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
58416135|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
58416136|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
58416137|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
58416138|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
58416139|NCT04103463|OTHER|Home exercise|Home exercise
58416140|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
58416141|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
58416142|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
58416143|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
58416144|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
58416145|NCT00554099|OTHER|Dietary Advice|Dietary advice
58416146|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
58416147|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
58416148|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
58416149|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
58304350|NCT02851602|BIOLOGICAL|Blood sample|
58416150|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
58416151|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
58416152|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
58416153|NCT01150201|DRUG|Aliskiren|For CKD treatment
58416154|NCT01150201|DRUG|Losartan|Control
58089827|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
58416155|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
58416156|NCT00040508|DRUG|Sirolimus|
58416157|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
58304351|NCT02398110|PROCEDURE|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
58416158|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
58416159|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
58416160|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
58416161|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
58416162|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
58416163|NCT00002460|DRUG|goserelin acetate|
57733916|NCT02459574|DRUG|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
58416164|NCT00002460|DRUG|tamoxifen citrate|
58416165|NCT00002460|PROCEDURE|ablative endocrine surgery|
57733917|NCT02459574|PROCEDURE|Conventional AF ablation|Conventional ablation procedure
57733918|NCT00077025|DRUG|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
57733919|NCT00077025|DRUG|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
57733920|NCT03183427|DIAGNOSTIC_TEST|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
57733921|NCT00866840|DRUG|riluzole|100 mg orally twice daily
57733922|NCT06627933|OTHER|No intervention|No intervention
57733923|NCT01201629|DEVICE|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
58416166|NCT00002460|PROCEDURE|oophorectomy|
58416167|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
58416168|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
57733924|NCT01201629|DEVICE|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
58089828|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
58089829|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
58089830|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
57733925|NCT06636565|OTHER|No intervention|No intervention
57733926|NCT02166008|DRUG|Repamipide|
57733927|NCT02166008|DRUG|Placebo|
58089831|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
58089832|NCT02384239|DRUG|Palbociclib|Given orally (PO)
58089833|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
58089834|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
57733928|NCT01786967|DRUG|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
58089835|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
58304352|NCT02398110|PROCEDURE|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
57733929|NCT04732403|OTHER|Patient Position|The patient will be placed in an angle on the surgical table during cystoscopy.
57733930|NCT03981458|DEVICE|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
57733931|NCT03981458|DEVICE|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
57733932|NCT02012491|DRUG|Misoprostol|
57733933|NCT02012491|DRUG|Mifepristone|
57733934|NCT04654416|DRUG|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
57733935|NCT05437380|DIAGNOSTIC_TEST|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
57733936|NCT04207723|OTHER|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
57733937|NCT04207723|DRUG|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
58304353|NCT02425306|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
58304354|NCT02425306|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
58304355|NCT02425306|DRUG|polyICLC|polyICLC, local adjuvant
58089836|NCT04591327|PROCEDURE|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
58416169|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
58416170|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
58416171|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
58416172|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
58416173|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
58089837|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
58416174|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
57733938|NCT02564575|BIOLOGICAL|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
57949236|NCT01539967|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
57949237|NCT05182775|PROCEDURE|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
57949238|NCT01594515|DRUG|BI 1015550|High dose powder for oral solution
58089838|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
58089839|NCT01017731|DRUG|Moxifloxacin|Administered orally
58089840|NCT01017731|DRUG|Diphenhydramine|Administered IV
58089841|NCT06566248|DRUG|TQA3810 tablets+NUC|TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
58416175|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
58089842|NCT06566248|DRUG|Placebo+NUC|"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."
58089843|NCT00171899|DRUG|imatinib mesylate|
58089844|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
58416176|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
58416177|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
57733939|NCT05952141|BEHAVIORAL|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
57733940|NCT05952141|BEHAVIORAL|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
57733941|NCT05952141|BEHAVIORAL|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
57949239|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
57949240|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
57949241|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
57949242|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
57949243|NCT01594515|DRUG|Placebo|Solution for oral administration
57949244|NCT01594515|DRUG|BI 101550|High dose powder for oral solution
58089845|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
58089846|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
58416178|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
58416179|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
58416180|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
58416181|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
58416182|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
57733942|NCT05952141|BEHAVIORAL|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
57733943|NCT00762125|BEHAVIORAL|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
57949245|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
57949246|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
57949247|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
57949248|NCT01088776|DIETARY_SUPPLEMENT|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
57949249|NCT01088776|DIETARY_SUPPLEMENT|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
57949250|NCT03151863|DRUG|Opioids|The usual opioid treatment used for nursing care
57949251|NCT03151863|DRUG|Dexmedetomidine|Dexmedetomidine is provided intranasally
57949252|NCT03151863|DRUG|Placebo|Normal saline is either given subcutaneously or intranasally
57949253|NCT01166022|OTHER|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
57949254|NCT03455491|DRUG|XC221 100 mg|once daily during 3 days.
57949255|NCT03455491|DRUG|XC221 200 mg|once daily during 3 days.
57949256|NCT03455491|DRUG|Placebo|once daily during 3 days.
58089847|NCT06651177|DRUG|Tirzepatide|Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
58089848|NCT06651177|OTHER|Placebo|"A matched placebo (containing saline) will be created for use in the trial. A study MC will administer the once-weekly SQ dose of saline. The process for deciding on dose increases will be the same for placebo and tirzepatide."
58089849|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
58089850|NCT02704988|PROCEDURE|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
58089851|NCT02704988|PROCEDURE|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
58089852|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
58089853|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
57949257|NCT00567970|PROCEDURE|quality-of-life assessment|
57949258|NCT00567970|RADIATION|stereotactic body radiation therapy|
57949259|NCT04389762|DIETARY_SUPPLEMENT|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
57949260|NCT04979442|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
57949261|NCT04979442|DRUG|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
57949262|NCT02211729|DRUG|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
57949263|NCT02211729|DRUG|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
57949264|NCT06443866|DIAGNOSTIC_TEST|Disease status detection|RAI dose determination
57949265|NCT06443866|DIAGNOSTIC_TEST|Theranostic dosimetry|Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer
57949266|NCT06443866|DRUG|I-124 PET/CT imaging|Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer
58089854|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
58416183|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
58416184|NCT00314301|DEVICE|loaded sit-to-stand training|
58416185|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
58416186|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
58416187|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
58416188|NCT02002468|OTHER|Test result sent by letter|
58416189|NCT02002468|OTHER|Test result conveyed by general practitioners|
58416190|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
58416191|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
58416192|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
58416193|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
58416194|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
58416195|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
58416196|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
58416197|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
58416198|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
58416199|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
58416200|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
57949267|NCT06414811|OTHER|HYPOTENSİON|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
58089855|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
58304356|NCT02425306|DRUG|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
58304357|NCT00293553|PROCEDURE|Electronic Barostat|
58304358|NCT02980081|OTHER|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
58416201|NCT01789528|DRUG|CAZ-AVI|IV infusion
58416202|NCT01789528|DRUG|CXL|IV infusion
58416203|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
58416204|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
58416205|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
58416206|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
58416207|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
57949268|NCT01833286|PROCEDURE|TACE+RFA|TACE first, followed by RFA within 2 months
58089856|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
58089857|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
58089858|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
58089859|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
58304359|NCT06147934|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Liver biopsy will be conducted by experienced interventionists and reported by pathologists. There should be a maximum interval of no more than 1 month between the liver biopsy and ultrasound examination, and the length of specimen should be more than 1.0cm."
58416208|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
58416209|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
58416210|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
58416211|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
58416212|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
58416213|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
58416214|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
58416215|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
58416216|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
58416217|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
58416218|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
57733944|NCT00762125|BEHAVIORAL|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
57733945|NCT00762125|BEHAVIORAL|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
58416219|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
58416220|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
58416221|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
58416222|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
58416223|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
58416224|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
58416225|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
58416226|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
58416227|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
58416228|NCT00000765|DRUG|Zidovudine|
58416229|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
58416230|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
58416231|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
58416232|NCT00612625|DRUG|Saline|continuous infusion of saline
58416233|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
58416234|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
57733946|NCT03837652|OTHER|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
57733947|NCT05495854|DIAGNOSTIC_TEST|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
58416235|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
58416236|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
58416237|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
58416238|NCT00456976|DRUG|Selegiline|
58416239|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
58416240|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
58416241|NCT00428220|DRUG|sunitinib|sunitinib
58416242|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
58416243|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
58416244|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
57785110|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
57785111|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
57733948|NCT04386681|BEHAVIORAL|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
58416245|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
58416246|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
58416247|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
58416248|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
58416249|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
57949269|NCT01833286|PROCEDURE|re-resection|repeat hepatectomy for recurrent small HCC
58416250|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
58416251|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
58416252|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
58416253|NCT02127034|DRUG|Mirabegron|oral
58416254|NCT02127034|DRUG|Solifenacin|oral
58416255|NCT02127034|DRUG|Digoxin|oral
57733949|NCT04669704|OTHER|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
57733950|NCT04669704|OTHER|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
57733951|NCT01360606|RADIATION|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
58089860|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
58089861|NCT06541691|DRUG|Enteric-coated aspirin|Enteric-coated aspirin tablet 81 mg, once daily
58089862|NCT06541691|DRUG|Plain aspirin|Plain aspirin tablet 81 mg, once daily
58416256|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
58416257|NCT01500369|OTHER|standard of care|Placebo Comparator
58416258|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
58416259|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
58416260|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
58416261|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
58416262|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
58416263|NCT02922166|DRUG|SRX246|oral capsule
58416264|NCT02922166|DRUG|Placebo|oral capsule
58416265|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
58416266|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
58416267|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
58416268|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
57733952|NCT00463190|DRUG|Biothree|
57733953|NCT01915134|DRUG|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
57733954|NCT01915134|DRUG|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
57785112|NCT00280449|BEHAVIORAL|strengths-based case managed proactive service model|
57785113|NCT00002087|DRUG|Alvircept sudotox|
57785114|NCT00870025|BIOLOGICAL|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
58089863|NCT06541691|OTHER|Hybrid strategy|"A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days"
58416269|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
58416270|NCT01706042|OTHER|legume meal|
58416271|NCT01706042|OTHER|white bread|
58416272|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
58416273|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
58416274|NCT02492074|DRUG|Placebo|oral administration of placebo
58416275|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
58416276|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
58089864|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
58089865|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
58089866|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
58304360|NCT02964624|OTHER|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
58304361|NCT05858983|GENETIC|FT-001 Low Dose|Comparison of different dosages of FT-001
58416277|NCT01668641|DRUG|GLPG0634|
58416278|NCT01668641|DRUG|Placebo|
58416279|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
58416280|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
58416281|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
58416282|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
58416283|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
58416284|NCT05158985|OTHER|phonophoresis|treatment
58416285|NCT05158985|OTHER|exercises|treatment
58416286|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
58416287|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
58416288|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
57733955|NCT04315389|DEVICE|(1) Mobile Assistant Balance Robot|MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.
57733956|NCT04315389|DEVICE|(2) Transfer Assistive Cobot|TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
58416289|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
58416290|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
58416291|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
58416292|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
58416293|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
57949270|NCT03742180|DRUG|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
57949271|NCT03742180|DRUG|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
57949272|NCT01178450|PROCEDURE|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
57949273|NCT01178450|DRUG|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
57949274|NCT05377047|RADIATION|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
57949275|NCT01322464|DRUG|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
57949276|NCT01322464|DRUG|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
58304362|NCT05858983|GENETIC|FT-001 Mid Dose|Comparison of different dosages of FT-001
58304363|NCT05858983|GENETIC|FT-001 High Dose|Comparison of different dosages of FT-001
58304364|NCT02356120|OTHER|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
58304365|NCT01099046|BEHAVIORAL|Lifestyle|water intake, tympanic tubing, regular sleep
58416294|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
58304366|NCT03142945|OTHER|Traditional Physical Therapy|Physical therapy-based interventions
58416295|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
58416296|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
58416297|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
58416298|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
58416299|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
58416300|NCT01873053|DRUG|Placebo|
58416301|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
58416302|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
58416303|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
58416304|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
58416305|NCT00315770|PROCEDURE|weight loss diets for young adults|
58416306|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
58416307|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
58416308|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
58416309|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
58416310|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
58416311|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
57733957|NCT03520634|OTHER|PD-L1 PET imaging|PD-L1 PET imaging
57785115|NCT00870025|BIOLOGICAL|placebo|diluent, every 5 days, s.c., 4 doses
58416312|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
58416313|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
58416314|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
58416315|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
58304367|NCT03142945|OTHER|MDT based physical therapy|MDT based physical therapy
57949277|NCT01322464|DRUG|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
58416316|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
58416317|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
58416318|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
58416319|NCT02177409|DRUG|Telmisartan|
58416320|NCT02177409|DEVICE|Amlodipine|
58416321|NCT02177409|DRUG|Placebo|
58416322|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
58416323|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
58416324|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
58416325|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
58416326|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
58416327|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
58416328|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
58416329|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
58416330|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
58416331|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
58416332|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
58416333|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
58416334|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
58416335|NCT01604655|PROCEDURE|Stress Test|Stress Test
58304368|NCT00731822|DRUG|GW685698/GW642444|GW685698/GW642444
58304369|NCT00529711|DRUG|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
58416336|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
58416337|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
58416338|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
58416339|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
57733958|NCT01134029|BEHAVIORAL|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
57949278|NCT01322464|DRUG|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
57949279|NCT03448068|DRUG|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
58304370|NCT00529711|DRUG|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
58304371|NCT00059553|BEHAVIORAL|Locomotor treadmill training with body weight support|
58304372|NCT02273401|DRUG|BI 11054 CL|
58304373|NCT02273401|DRUG|Placebo|
58304374|NCT04216147|OTHER|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
58304375|NCT04216147|PROCEDURE|Surgery for CTS|Median nerve release
58416340|NCT05618782|DRUG|LEVI-04|Intravenous infusion
58416341|NCT05618782|OTHER|Placebo:|Placebo dose intravenous infusion
58416342|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
58416343|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
58416344|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
58416345|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
58416346|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
58416347|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
58304376|NCT04222920|OTHER|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
58416348|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
58416349|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
58416350|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
58416351|NCT00003358|DRUG|chemotherapy|
58416352|NCT00003358|DRUG|cisplatin|
58416353|NCT00003358|DRUG|gemcitabine hydrochloride|
58416354|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
58416355|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
58416356|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
58416357|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
58416358|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
58416359|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
58416360|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
58416361|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
58416362|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
58304377|NCT04222920|OTHER|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
58304378|NCT04222920|DRUG|Adalimumab|Adalimumab
58304379|NCT03620513|DRUG|Decongestant (oxymetazoline 0.05%)|As described in arm/group
58304380|NCT03620513|DRUG|Anesthesia (Lidocaine 15%)|As described in arm/group
58416363|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
58416364|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
58416365|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
58416366|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
58416367|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
58416368|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
58416369|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
58416370|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
58416371|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
58416372|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
58416373|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
58416374|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
58416375|NCT04291794|DRUG|Propofol|2mg/kg single bolus
58416376|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
58416377|NCT01863134|DRUG|Eptifibatide|
58416378|NCT01863134|DRUG|Placebo|
58089867|NCT04747912|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
58089868|NCT04747912|DRUG|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
58089869|NCT04747912|DRUG|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
58416379|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
58416380|NCT00244348|DRUG|Oxaliplatin (via HAI)|
58416381|NCT00244348|DRUG|5 Fluorouracil (systemic)|
58416382|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
58416383|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
58416384|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
58416385|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
58416386|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
58416387|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
58416388|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
58416389|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
58416390|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
58416391|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
58089870|NCT04747912|DRUG|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
58089871|NCT04747912|DRUG|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
58089872|NCT04747912|DRUG|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
58416392|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
58416393|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
58416394|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
58416395|NCT03054597|PROCEDURE|Exercise|
58416396|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
58416397|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
58416398|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
58416399|NCT03508323|DRUG|Teneligliptin|20mg/qd
58416400|NCT03508323|DRUG|Placebo|1T/qd
58416401|NCT02183129|DRUG|Diclofenac|
58416402|NCT02183129|DRUG|Meloxicam|
58416403|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
58416404|NCT01107119|OTHER|usual care|
58416405|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
58416406|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
58416407|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
58416408|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
58416409|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
57733959|NCT00873795|DRUG|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
58304381|NCT03620513|DRUG|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
58304382|NCT03620513|DRUG|Normal saline|Spray of normal saline as premedication
58304383|NCT04144192|DRUG|Lidocaine patch 1.8%|
58304384|NCT04144192|DRUG|Lidocaine 5% patch|
58304385|NCT04144192|DRUG|Lidocaine 2% Injectable Solution|
58304386|NCT03602105|BEHAVIORAL|Exercise|Exercises in group and/or individually
58304387|NCT00607243|BIOLOGICAL|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
58304388|NCT04858152|PROCEDURE|Follicular Unit Extraction via punch biopsy|Follicular unit extraction will be performed using standard 0.7mm - 1mm punch biopsies. The donor site, which will be selected as a vitiligo-free, hair-bearing area that is not visible per patient's preference, will be harvested via punch biopsies and transplanted to the recipient site, which will be the glabrous skin of the hands or feet.
58304389|NCT03041441|DEVICE|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
58304390|NCT03041441|PROCEDURE|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
58304391|NCT03041441|PROCEDURE|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
58304392|NCT01748370|DRUG|Vitamin D supplementation in hypogonadal men|
58304393|NCT01748370|DRUG|Vitamin D supplementation in eugonadal men|
58304394|NCT01748370|DRUG|Placebo hypogonadal|
58304395|NCT01748370|DRUG|Placebo eugonadal|
58304396|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
58304397|NCT00983372|DRUG|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
58304398|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
58304399|NCT03006562|DRUG|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
58304400|NCT02662569|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
58304401|NCT02662569|DRUG|Atorvastatin|Administered orally once a day
58304402|NCT02662569|OTHER|Placebo|Placebo to evolocumab administered by subcutaneous injection
58304403|NCT05749016|DRUG|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
58304404|NCT03072550|DEVICE|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
58304405|NCT00004246|DRUG|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
58304406|NCT00004246|RADIATION|Radiation Therapy (RT)|Days 1-5 for 7 weeks
58304407|NCT01317563|DIETARY_SUPPLEMENT|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
58304408|NCT01317563|DIETARY_SUPPLEMENT|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
58416410|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
57733960|NCT00986167|DRUG|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
57733961|NCT02629510|DRUG|Tachosil|
57733962|NCT03745664|DRUG|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
57733963|NCT03745664|DRUG|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
58304409|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
58304410|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
58304411|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
58304412|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
58304413|NCT01317147|PROCEDURE|Roux-en-Y gastric bypass (RYGBP)|
58304414|NCT02089347|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
58304415|NCT02089347|BIOLOGICAL|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
58304416|NCT05251584|DRUG|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
58304417|NCT05251584|DRUG|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
58304418|NCT02598453|DRUG|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
58416411|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
58416412|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
57733964|NCT05820724|DIAGNOSTIC_TEST|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
57733965|NCT05820724|OTHER|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
57785116|NCT00743522|DEVICE|ICD/ CRT-D|Cardiac device
58304419|NCT06443294|BEHAVIORAL|Smoking cessation video series.|The intervention in this study is a series of six videos totally approximately 40 minutes. These videos are led by a doctoral psychology student with experience in working with tobacco smokers. Videos utilize empirically-supported strategies for smoking cessation.
58304420|NCT00889629|DRUG|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
58304421|NCT00889629|DRUG|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
58304422|NCT00889629|DRUG|25-OH Vitamin D3|All groups received cholecalciferol
58304423|NCT03860740|OTHER|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
58304424|NCT03860740|OTHER|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
58304425|NCT01178294|BIOLOGICAL|OBI-1|Intravenous infusion
58304426|NCT00286182|DRUG|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
58304427|NCT00286182|DRUG|Placebo|Placebo
58304428|NCT03025373|OTHER|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
58304429|NCT01784874|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
58304430|NCT01784874|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
58304431|NCT00086671|DRUG|ABT-874/Human monoclonal antibody against IL-12|
58304432|NCT00086671|DRUG|Placebo|
58304433|NCT02683629|BIOLOGICAL|NTCELL Implantation|NTCELL Implantation
58304434|NCT02683629|OTHER|Sham Surgery|Sham Surgery
58304435|NCT02687854|DRUG|Apixaban|As prescribed by treating physicians
58304436|NCT02687854|DRUG|Vitamin K antagonist|As prescribed by treating physicians
58304437|NCT03212716|DRUG|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
58304438|NCT03212716|DRUG|Diltiazem|60 mgx3 per day during 10 days.
58304439|NCT03212716|DRUG|Placebos|Placebo of diltiazem
58304440|NCT00230035|PROCEDURE|Leukapheresis|
58304441|NCT00230035|PROCEDURE|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
58304442|NCT00230035|PROCEDURE|Autologous CD34+HPC transplantation (HSCT)|
58304443|NCT00230035|PROCEDURE|Plasmapheresis|
58304444|NCT00230035|DRUG|Rabbit anti-thymocyte globulin|
58416413|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
58416414|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
58304445|NCT00230035|DRUG|Methylprednisolone|
58304446|NCT00230035|DRUG|Growth colony stimulating factor (G-CSF)|
58304447|NCT00230035|DRUG|Corticosteroids|
58304448|NCT00230035|DRUG|Mycophenolate mofetil|
58304449|NCT00230035|DRUG|Azathioprine|
58304450|NCT00230035|DRUG|Intravenous immunoglobulin|
58304451|NCT00230035|DRUG|Methotrexate|
58304452|NCT00230035|DRUG|Rituximab|
58304453|NCT00230035|DRUG|Leflunomide|
58304454|NCT02516072|OTHER|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
58304455|NCT04367298|BEHAVIORAL|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
58304456|NCT04478617|DRUG|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
58304457|NCT03068104|OTHER|No intervention|
58304458|NCT04895917|DRUG|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
58304459|NCT05493566|BIOLOGICAL|Aldesleukin|Given SC
58304460|NCT05493566|BIOLOGICAL|Pembrolizumab|Given IV
58304461|NCT06003036|DEVICE|sham stimulation|sham delivery of transcranial magnetic stimulation
58304462|NCT06003036|DEVICE|transcranial magnetic stimulation|accelerated intermittent theta burst stimulation
58304463|NCT02816294|BEHAVIORAL|Housing Prescription|
58304464|NCT04547855|DRUG|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
58089873|NCT04747912|DRUG|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
58089874|NCT04747912|PROCEDURE|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
58089875|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
58416415|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58416416|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58416417|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58416418|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
58416419|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
58416420|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
58416421|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
58416422|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
58416423|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
58089876|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
58089877|NCT01708694|DIETARY_SUPPLEMENT|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
58089878|NCT01708694|DIETARY_SUPPLEMENT|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
58089879|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
58089880|NCT02751372|DRUG|BAY 987517|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
58416424|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
58416425|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
58416426|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
58416427|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
58416428|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
58089881|NCT02751372|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
58089882|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
58089883|NCT02972086|BEHAVIORAL|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
58089884|NCT03530007|DRUG|Normal saline|normal saline used for prevention of spinal shivering
58416429|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
58089885|NCT03530007|DRUG|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
58416430|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
58416431|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
58416432|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
58416433|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
58416434|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
58416435|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
58416436|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
58416437|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
58416438|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
58416439|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
57733966|NCT05820724|DRUG|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
57733967|NCT02252211|DRUG|DS-8895a 1 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
57733968|NCT02252211|DRUG|DS-8895a 3 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
58089886|NCT03530007|DRUG|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
58089887|NCT05428267|OTHER|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
58089888|NCT05428267|OTHER|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
58089889|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
58089890|NCT01009073|DRUG|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
58089891|NCT01009073|DRUG|erlotinib|150 mg of erlotinib is taken orally once daily.
58416440|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
58416441|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
58416442|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
58416443|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
58416444|NCT05053841|DRUG|Metformin|
58416445|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
58089892|NCT01009073|DRUG|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
57733969|NCT02252211|DRUG|DS-8895a 10 mg/kg|Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
57733970|NCT06156930|OTHER|Intervention group lavender oil|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
58089893|NCT01009073|DRUG|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
57733971|NCT06156930|OTHER|Placebo group sesame oil|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
57733972|NCT06670430|DEVICE|experimental group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
58089894|NCT02024386|DRUG|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
58089895|NCT06632990|DRUG|BMS-984923|oral capsules once or twice daily
58089896|NCT06632990|DRUG|Midazolam|midazolam, oral, 2mg administered before study drug and after study drug
58416446|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
58416447|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
58416448|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
58416449|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
58416450|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
58416451|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
58416452|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
58416453|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
58089897|NCT06632990|DRUG|Caffeine|Caffeine, oral, 100mg administered before study drug and after study drug
58416454|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
58416455|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
58089898|NCT06632990|DRUG|dextromethorphan|dextromethorphan, oral, 30mg administered before study drug and after study drug
58089899|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
58089900|NCT01525407|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
58089901|NCT01525407|DRUG|Atorvastatin Calcium|Given PO
58416456|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
58416457|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
58416458|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
58416459|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
58416460|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
58416461|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
58416462|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
58416463|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
58416464|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
58416465|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
58416466|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
58089902|NCT01525407|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
58089903|NCT02496442|DEVICE|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
58089904|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
58416467|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
58416468|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
57733973|NCT06670430|DEVICE|control group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
58089905|NCT02148835|OTHER|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
58089906|NCT02148835|OTHER|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
58416469|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
58089907|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
58089908|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
57733974|NCT03171298|PROCEDURE|Laparoscopic Assisted Transanal Total Mesorectal Excision|"* Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally"
57733975|NCT00981591|DRUG|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
57733976|NCT00981591|DRUG|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
57733977|NCT00864448|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
57733978|NCT00864448|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
57733979|NCT03418454|DIAGNOSTIC_TEST|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
57733980|NCT06634745|PROCEDURE|Standard Needle Irrigation (SNI)|"Standard Needle Irrigation (SNI):~Utilizes standard needle irrigation techniques for activating the antimicrobial solution within the root canal."
58089909|NCT06700538|DRUG|ARO-INHBE|SC injection
57733981|NCT06634745|PROCEDURE|Passive Ultrasonic Irrigation (PUI|"Passive Ultrasonic Irrigation (PUI):~Employs ultrasonic energy to enhance the activation and effectiveness of the antimicrobial solution in the root canal."
58089910|NCT06700538|DRUG|Placebo|calculated volume to match active treatment by SC injection
58089911|NCT06700538|DRUG|Tirzepatide|SC injection
58089912|NCT05550025|DRUG|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
58089913|NCT06540820|DIAGNOSTIC_TEST|Dexa or Biompedance analysis with clinical and biochemical evaluations|All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
58089914|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
58416470|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
58416471|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
58089915|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
58089916|NCT06344858|DRUG|Ketamine|One bolus of ketammine
58089917|NCT00567086|DRUG|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
58089918|NCT02051673|BIOLOGICAL|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
58089919|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
58089920|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
58089921|NCT05950828|BEHAVIORAL|SkillTalk|A subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
58089922|NCT04999592|DRUG|Standard of care without prophylaxis|Administer antibiotics in response to infection
58089923|NCT04999592|DRUG|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
58089924|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
58416472|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
57733982|NCT06634745|PROCEDURE|EndoActivator (EA)|"EndoActivator (EA):~Uses a sonic activation device to facilitate the distribution and activation of the antimicrobial solution in the root canal."
57733983|NCT06634745|PROCEDURE|EDDY|"EDDY:~Involves the use of a sonic activation device that operates at high frequency to activate the antimicrobial solution within the root canal.~These descriptions focus on the general method and purpose of each intervention without delving into the specific procedural details already covered in the arm/group descriptions."
57733984|NCT00005776|DRUG|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
58089925|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
58089926|NCT06244095|OTHER|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
58089927|NCT06244095|OTHER|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
58089928|NCT01097759|PROCEDURE|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
58089929|NCT01965431|DRUG|BI 207127|Medium dose oral administration
58089930|NCT01965431|DRUG|BI 207127 placebo|
58089931|NCT01965431|DRUG|Faldaprevir placebo|
58089932|NCT01965431|DRUG|Faldaprevir|Medium dose oral administration
58089933|NCT01965431|DRUG|Moxifloxacin (Avalox®)|
58089934|NCT02472431|OTHER|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
58089935|NCT02472431|PROCEDURE|Liposuction|
58089936|NCT02472431|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
58089937|NCT03231423|OTHER|Drainage|Using drain after operation
58089938|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
58304465|NCT00439972|DRUG|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
58416473|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
58416474|NCT00138047|DRUG|zinc supplementation|
57733985|NCT00005776|DRUG|Placebo|100% Oxygen
57733986|NCT05916690|DRUG|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
57733987|NCT03750201|DEVICE|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
57733988|NCT03750201|DEVICE|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
58089939|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
58089940|NCT02662556|DRUG|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
58089941|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
58089942|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
58089943|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
58089944|NCT04764669|DRUG|E2027|Oral hypromellose capsules.
58089945|NCT01410565|DRUG|Apaziquone|Apaziquone 4 mg in 40 mL diluent
58089946|NCT01410565|DRUG|Placebo|Placebo for Double Blind Phase
58089947|NCT06576830|DRUG|Methadone|Single-dose intraoperative intravenous methadone with initial dose at 0.15 mg/kg in children and 0.2 mg/kg in adolescents.
58416475|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
58416476|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
58416477|NCT03395561|OTHER|control|2 capsuls
58416478|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
58416479|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
58416480|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
58416481|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
58416482|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
58416483|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
58416484|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
58416485|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
58416486|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
58416487|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
58089948|NCT06576830|DRUG|Fentanyl/Hydromorphone|Per routine care, given as needed
58089949|NCT06648473|DIAGNOSTIC_TEST|MRI Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
58089950|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
58089951|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
58089952|NCT00187174|DRUG|Everolimus|The drug is given orally in 28 day courses.
58416488|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
58416489|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
57733989|NCT06299397|BEHAVIORAL|breastfeeding - humor training|Breastfeeding and humor-based practice will continue for 35-45 minutes, once a week for 2 weeks.
57733990|NCT06299397|OTHER|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
57733991|NCT06235216|DRUG|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
57733992|NCT02123693|OTHER|Osteopathic manipulative treatment|
57733993|NCT02123693|OTHER|Sham Therapy|
58089953|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
58089954|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
58089955|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
58416490|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
58416491|NCT06279793|DRUG|Long-chain n-3 fatty acids|"Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d"
58416492|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
57733994|NCT02123693|OTHER|No Intervention|
58089956|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
58089957|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
58416493|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
58416494|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
58304466|NCT00439972|DRUG|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
58304467|NCT00439972|DRUG|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
58304468|NCT06339775|DRUG|Blinatumomab|"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
58304469|NCT02328612|OTHER|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
58416495|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
58304470|NCT03226444|DRUG|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
58416496|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
58416497|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
58416498|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
58304471|NCT03226444|DRUG|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
58304472|NCT03226444|DRUG|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
58304473|NCT01930591|DRUG|Ticagrelor|180 mg bolus followed by 90 mg BID
58304474|NCT01930591|DRUG|Clopidogrel|300 mg bolus followed by 75 mg OD
58304475|NCT05190627|DRUG|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
58304476|NCT05190627|DRUG|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
58304477|NCT02659943|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
58304478|NCT02659943|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
58089958|NCT04292756|PROCEDURE|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
58416499|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
58089959|NCT04292756|PROCEDURE|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
58089960|NCT04292756|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
58416500|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
58416501|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
58416502|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
58416503|NCT04355858|DRUG|SHR3162|PARP inhibitor
58416504|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
58416505|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
58416506|NCT04355858|DRUG|SHR1210|PD-1 antibody
58416507|NCT04355858|DRUG|Everolimus|mTOR inhibitor
58416508|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
58089961|NCT04292756|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
58089962|NCT04292756|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
58416509|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
58416510|NCT04355858|DRUG|SHR3680|AR inhibitor
58416511|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
58416512|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
58416513|NCT04355858|DRUG|SERD|Fulvestrant
58416514|NCT04355858|DRUG|AI|aromatase inhibitor
58416515|NCT04355858|DRUG|VEGFi|Bevacizumab
58416516|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
58416517|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
58416518|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
57733995|NCT03355079|DRUG|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
57733996|NCT05411965|DRUG|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
58089963|NCT04292756|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
58089964|NCT04292756|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
58089965|NCT04292756|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
58416519|NCT02990195|OTHER|Chyme reinfusion|
58416520|NCT00316888|BIOLOGICAL|cetuximab|Given IV
58416521|NCT00316888|DRUG|cisplatin|Given IV
58416522|NCT00316888|DRUG|fluorouracil|Given IV
58416523|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
58416524|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
58416525|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
58416526|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
58416527|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
58416528|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
58416529|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
58416530|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
58416531|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
58416532|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
58416533|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
58416534|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
58416535|NCT04564248|OTHER|Website access|website access will be provide to families
58416536|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
58416537|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
58416538|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
58416539|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
58416540|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
58416541|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
58416542|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
58416543|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
58416544|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
58416545|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
58416546|NCT02335632|DRUG|Placebo|For probiotics
58089966|NCT04292756|DIAGNOSTIC_TEST|IOP|Ophthalmic examination
58089967|NCT03889197|DRUG|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
58089968|NCT02352207|OTHER|identification of a pulmonary malformation in the fetus|
58089969|NCT04376073|DRUG|Niraparib|Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
58089970|NCT04376073|DRUG|Anlotinib|Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
58089971|NCT06701903|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
58089972|NCT06701903|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
58089973|NCT06701903|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
58089974|NCT00232245|DRUG|Fish oil|
58089975|NCT00124579|DRUG|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
58416547|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
57733997|NCT05411965|DRUG|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
58089976|NCT00124579|DRUG|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
58089977|NCT00124579|DRUG|thalidomide|100 mg/d PO days 1-21 every 21 days
58089978|NCT00672308|OTHER|Benefiber|
58089979|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
58416548|NCT01863251|DRUG|Atomoxetine|
58416549|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
58416550|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
58416551|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
57733998|NCT05411965|DRUG|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
58089980|NCT00672308|OTHER|Benefiber with ORS|
58089981|NCT00672308|OTHER|Benefiber with ORS|
58089982|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
58089983|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
58089984|NCT00551473|DRUG|Lavoltidine|
58089985|NCT00552812|DEVICE|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
58089986|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
58089987|NCT05516498|DRUG|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
58416552|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
58416553|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
58416554|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
58416555|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
58089988|NCT05516498|DRUG|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
58416556|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
58089989|NCT05516498|DRUG|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
58089990|NCT05516498|DRUG|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
58089991|NCT05516498|DRUG|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
58089992|NCT05516498|DRUG|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
58089993|NCT05516498|DRUG|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
58089994|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
58089995|NCT06499935|OTHER|Rigid Taping|It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
58089996|NCT06499935|OTHER|Kinesio-Taping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
58089997|NCT06499935|OTHER|Sham Taping|Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
58089998|NCT04166877|DRUG|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
58089999|NCT04166877|DRUG|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
58090000|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
58090001|NCT06281522|OTHER|Operated patients with hydatid cyst of the lung|File screening and blood test results will be evaluated
58090002|NCT05648097|DEVICE|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
58090003|NCT02186470|RADIATION|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
58416557|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
58416558|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
58090004|NCT02186470|RADIATION|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
58090005|NCT02186470|RADIATION|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
58090006|NCT02186470|PROCEDURE|therapeutic conventional surgery|Lumpectomy
58090007|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/vilanterol
58090008|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium
58090009|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol
58090010|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium/vilanterol
58090011|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone propionate/salmeterol
58090012|NCT03662711|DRUG|Bronchodilator Agents|Beclometasone dipropionate/formoterol
58090013|NCT03662711|DRUG|Bronchodilator Agents|Budesonide formoterol
58090014|NCT03662711|DRUG|Bronchodilator Agents|Glycopyrronium
58090015|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium
58090016|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium
58090017|NCT03662711|DRUG|Bronchodilator Agents|Formoterol
58090018|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol glycopyrronium
58090019|NCT03662711|DRUG|Bronchodilator Agents|Salmeterol
58090020|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium olodaterol
58090021|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium/formoterol
58090022|NCT03662711|DRUG|Bronchodilator Agents|Olodaterol
58090023|NCT03662711|DRUG|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
58090024|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
58090025|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
58090026|NCT05458895|OTHER|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090027|NCT05458895|OTHER|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090028|NCT05458895|OTHER|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090029|NCT05458895|OTHER|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090030|NCT05458895|OTHER|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090031|NCT05458895|OTHER|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090032|NCT05458895|OTHER|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090033|NCT05458895|OTHER|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
58090034|NCT04037683|DRUG|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
58090035|NCT04037683|DRUG|Oxytocin|Oxytocin infusion
58090036|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
58090037|NCT03724422|RADIATION|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
58090038|NCT00511329|DRUG|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
58090039|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
58416559|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
58416560|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
58090040|NCT02919033|OTHER|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
58090041|NCT02919033|DEVICE|Self-management|"* Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App."
58090042|NCT02919033|OTHER|PCTM intervention|"* Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website."
58090043|NCT00633295|DRUG|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
58090044|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
58416561|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
58416562|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
58416563|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
58416564|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
57733999|NCT05834504|OTHER|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
58416565|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
58416566|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
58416567|NCT00449449|DRUG|Pertubation with Lidocain Solution|
58416568|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
58416569|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
58416570|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
58416571|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
58416572|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
58416573|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
58416574|NCT02804308|BEHAVIORAL|Combined Training|
58416575|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
58416576|NCT00018382|DRUG|rosiglitazone|
58416577|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
58416578|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
58416579|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
58416580|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
58416581|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
58090045|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
58090046|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
57734000|NCT04278144|DRUG|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
58090047|NCT06167798|OTHER|biopsy|two 2 mm gingival biopsies were obtained.
58090048|NCT03387267|DEVICE|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
58090049|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
58090050|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
58090051|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
58090052|NCT00915980|PROCEDURE|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
58090053|NCT05286580|BEHAVIORAL|Morbidity and mortality conference toolkit|"* Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form"
58090054|NCT06260007|DRUG|Tribulus terrestris|Tribulus terrestris
58090055|NCT06260007|OTHER|Placebo|Placebo
58090056|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
58090057|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
58090058|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
58090059|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
58090060|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
58090061|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
58090062|NCT05511805|OTHER|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
58090063|NCT05511805|OTHER|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
58090064|NCT05511805|OTHER|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
58304479|NCT02659943|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
58416582|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
57734001|NCT04278144|DRUG|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
57734002|NCT00497302|BEHAVIORAL|RBT|Contingency management and behavioral counseling including motivational interviewing
57734003|NCT00497302|BEHAVIORAL|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
57734004|NCT06670742|DEVICE|running|Running 10 kilometers on a treadmill
57734005|NCT06304233|DIAGNOSTIC_TEST|Echocardiography|ultrasound assessment of heart structure, volume and function
58090065|NCT05511805|DEVICE|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
58090066|NCT05511805|DEVICE|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
58090067|NCT05511805|DEVICE|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
58090068|NCT05511805|DEVICE|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
58090069|NCT03763708|DEVICE|Spinal Cord Stimulation|Programming
58090070|NCT05025774|OTHER|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
58090071|NCT02463058|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
58090072|NCT01806259|DRUG|Ketorolac 30 mg IV|Active drug
58090073|NCT01806259|DRUG|Placebos|Placebo looking like the Active drug
58090074|NCT06128278|DRUG|S-equol|Oral supplementation of S-equol
58090075|NCT04443231|DEVICE|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
58090076|NCT06395584|DEVICE|White Light LED|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
58090077|NCT06395584|DEVICE|Green Light LED|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
58090078|NCT06317870|PROCEDURE|Intrathecal morphine|"Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding."
58304480|NCT02850094|BEHAVIORAL|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
58304481|NCT03353376|BEHAVIORAL|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
58304482|NCT01976000|PROCEDURE|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
58304483|NCT05882929|OTHER|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
58416583|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
58416584|NCT01730404|DRUG|CHF6001 DPI|
58090079|NCT06317870|PROCEDURE|Pericapsular nerve group block (PENG)|"Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected."
57734006|NCT06304233|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|MRI assessment of heart structure, volume, function and tissue characteristics
57734007|NCT06304233|DIAGNOSTIC_TEST|Electrocardiography|Assessment of cardiac rhythm and electrical activity
58090080|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
58090081|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
58090082|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
58090083|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
58090084|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
58090085|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
58090086|NCT05784363|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
58416585|NCT01730404|DRUG|Roflumilast|
57734008|NCT06304233|OTHER|Blood sampling|To measure DISC1 mRNA expression and other potential biomarkers
57734009|NCT03553589|OTHER|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
57734010|NCT05291208|COMBINATION_PRODUCT|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
57734011|NCT05291208|BEHAVIORAL|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
58090087|NCT05784363|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
58416586|NCT01730404|DRUG|Placebo|
58416587|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
58416588|NCT00240110|DRUG|Placebo|Control arm
58416589|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
58416590|NCT03084042|DEVICE|fMRI|
58416591|NCT01756859|PROCEDURE|MRI Scan|
58416592|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
58416593|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
57734012|NCT01244048|DIETARY_SUPPLEMENT|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
57734013|NCT03782155|DRUG|glutamine supplementation|powder 14g
57734014|NCT03782155|DRUG|HMB|powder 3g
57734015|NCT03782155|DRUG|Placebo|powder 17g
58090088|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
58090089|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
58416594|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
58416595|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
58416596|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
58416597|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
58416598|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
58416599|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
58416600|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
58416601|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
58416602|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
58416603|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
58090090|NCT01502800|DRUG|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
58090091|NCT01502800|DRUG|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
58090092|NCT01502800|DRUG|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
58090093|NCT01502800|DRUG|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
58090094|NCT03334942|BEHAVIORAL|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
58090095|NCT01224769|DRUG|bendamustine +/- rituximab|
58090096|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
58304484|NCT05882929|OTHER|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
58416604|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
58416605|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
58416606|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
58416607|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
58416608|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
58416609|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
58416610|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
58416611|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
58416612|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
58416613|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
58416614|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
58416615|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
58416616|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
58416617|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
58416618|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
58416619|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
57785117|NCT02410161|DIETARY_SUPPLEMENT|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
58416620|NCT02501564|DRUG|Placebo|One tablet twice a day
58416621|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
58416622|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
58416623|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
58416624|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
58416625|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
58416626|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
58090097|NCT04138173|BEHAVIORAL|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
58090098|NCT04471792|DRUG|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
58090099|NCT04471792|DIETARY_SUPPLEMENT|Cellulose|Cellulose will be used in combination with muscle stretching.
58090100|NCT02342574|DRUG|F901318|Administration of active compound
58090101|NCT02342574|DRUG|Placebo|Administration of placebo
58416627|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
58090102|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
58090103|NCT03632837|DEVICE|Hemoadsorption|see arm description
58090104|NCT01281176|DRUG|Carboplatin|Given IV
58416628|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
57734016|NCT00634608|OTHER|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
57734017|NCT01007591|DRUG|LEO 80190|Applied once daily
57734018|NCT01007591|DRUG|Hydrocortisone|Applied once daily
57734019|NCT00201006|BEHAVIORAL|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
57734020|NCT00201006|BEHAVIORAL|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
57734021|NCT00201006|OTHER|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
57734022|NCT00896168|DRUG|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
57734023|NCT00896168|DRUG|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
57734024|NCT01477827|OTHER|None - observational study|
57734025|NCT03114254|DRUG|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
57785118|NCT03913728|OTHER|Drug level blood tests|All information included previously.
57785119|NCT03913728|OTHER|Telephone Interview|All information included previously.
57785120|NCT00097370|DRUG|mepolizumab|Study Drug
58090105|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
58090106|NCT01281176|DRUG|Paclitaxel|Given IV
58090107|NCT01281176|OTHER|Pharmacological Study|Correlative studies
58090108|NCT01281176|DRUG|Vorinostat|Given PO
58090109|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
58090110|NCT01912547|PROCEDURE|Blood draw for TEG analysis|Blood drawn for TEG analysis
58090111|NCT00081978|DRUG|TMC125|
58090112|NCT01311505|DRUG|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
58090113|NCT01311505|DRUG|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
58090114|NCT06412666|DRUG|Aficamten|Oral Tablet
58090115|NCT06412666|DRUG|Placebo|Oral Tablet
58090116|NCT03360721|DRUG|Abiraterone Acetate|Given PO
58090117|NCT03360721|DRUG|Apalutamide|Given PO
58090118|NCT03360721|DRUG|Prednisone|Given PO
58090119|NCT01555242|DRUG|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
58090120|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
58090121|NCT04873830|BIOLOGICAL|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
58090122|NCT04873830|PROCEDURE|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
58090123|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
58090124|NCT04387487|BEHAVIORAL|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
58090125|NCT00557700|DRUG|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
58090126|NCT00557700|DRUG|Administration of placebo|Administration of placebo
58090127|NCT06701123|DEVICE|uMAT-R mobile app with coaching component|uMAT-R recovery mobile app with coaching component
58090128|NCT02030509|OTHER|Quick diagnosis program|
58090129|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
57734026|NCT06484244|OTHER|5 Sessions of Split-belt Treadmill-based Locomotor Adaptation|Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
58090130|NCT03529045|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
58090131|NCT01876082|DRUG|PAZOPANIB treatment|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
58090132|NCT01876082|DRUG|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
58090133|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
58090134|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
58090135|NCT05058027|DEVICE|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
58090136|NCT05058027|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
58090137|NCT03813160|DRUG|Lenabasum 20 mg|oral capsule
58090138|NCT03813160|DRUG|Lenabasum 5 mg|oral capsule
58090139|NCT03813160|DRUG|Placebo|oral capsule
58090140|NCT05924464|OTHER|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
58090141|NCT05335096|BEHAVIORAL|An AI-chatbot-based mHealth intervention|The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
57734027|NCT01155947|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
58090142|NCT05335096|BEHAVIORAL|An attention-chatbot-based mHealth intervention|The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
58090143|NCT05335096|BEHAVIORAL|Educational materials|the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
58416629|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
58416630|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
58416631|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
58416632|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
58416633|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
58416634|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
58416635|NCT00136825|DRUG|N-Acetylcysteine|
58416636|NCT00136825|DRUG|Placebo|
58416637|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
58416638|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
58090144|NCT02216214|DRUG|Mirabegron|oral tablet
58090145|NCT02216214|DRUG|Placebo|oral tablet
58090146|NCT06531109|DRUG|Ritlecitinib|As provided in the real world practice.
58090147|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
58090148|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
58090149|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
58090150|NCT01807910|DRUG|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
58090151|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
58416639|NCT05394532|OTHER|Education|Common Education
58416640|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
58416641|NCT00581867|DRUG|Placebo|Placebo
58090152|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
58090153|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
58090154|NCT03029559|OTHER|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
57734028|NCT01182753|RADIATION|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
57949280|NCT03448068|DRUG|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
58090155|NCT03029559|OTHER|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
58090156|NCT03029559|OTHER|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
58090157|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
58090158|NCT05292339|DRUG|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
58090159|NCT05292339|DRUG|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
58090160|NCT05358795|BEHAVIORAL|Family Connections|Family Connections is based on the WHO endorsed Positive Connections manual.
58090161|NCT02230228|DRUG|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
58090162|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
58090163|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
58090164|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
57949281|NCT03359512|DEVICE|qCON monitor|supervision by qCON monitor of the depth of anesthesia
57949282|NCT02626897|DEVICE|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
57949283|NCT02626897|DEVICE|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
57949284|NCT03652038|DRUG|TD-8236|Study drug to be administered via inhaler device
57949285|NCT03652038|DRUG|Placebo|Placebo to be administered via inhaler device
57949286|NCT05650801|OTHER|Music Therapy|Therapy using a traditional music originally from Indonesian culture
57949287|NCT04227262|OTHER|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
58090165|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
58090166|NCT02206100|DRUG|enoxaparin|
58090167|NCT06541002|BEHAVIORAL|SHIFT Intervention Group|Participants assigned to SHIFT will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and start using SHIFT at their desired pace over 8 weeks to complete five modules.
58304485|NCT02891473|OTHER|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
58416642|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
58416643|NCT00613080|DRUG|oxaliplatin|
57949288|NCT05599542|OTHER|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
57949289|NCT05599542|OTHER|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
58090168|NCT06541002|BEHAVIORAL|Enhanced Usual Care Group|Participants assigned to the enhanced usual care group will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and maybe referred to a psychologist, urologist, or gynecologist at the participants' request or at the discretion of the HCT clinician.
58090169|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
58090170|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
58090171|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
58090172|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
58090173|NCT02251431|DRUG|BYDUREON|Exenatide-extended release, Cohorts A and B
58090174|NCT02251431|DRUG|Placebo|Cohort A only
58090175|NCT00005009|BIOLOGICAL|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
58090176|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
58090177|NCT06568848|COMBINATION_PRODUCT|EKKO therapy|In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
58090178|NCT06568848|DIAGNOSTIC_TEST|Conservative Treatment|In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
58090179|NCT05292781|OTHER|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
58416644|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
58416645|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
57734029|NCT01182753|RADIATION|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
57949290|NCT00916188|DIETARY_SUPPLEMENT|Black Tea Extract|Amount/dose depends on Arm assignment.
57949291|NCT04639973|DIAGNOSTIC_TEST|Group 1 (First trimester ultrasound)|A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
57949292|NCT04639973|DIAGNOSTIC_TEST|Group 2 (Second trimester anatomy ultrasound)|Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
57949293|NCT03092102|DRUG|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
57949294|NCT01903707|OTHER|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
57949295|NCT01903707|OTHER|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
57949296|NCT04729673|DEVICE|Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
57949297|NCT02970214|OTHER|no intervention, only observational|no intervention, only observational
57949298|NCT00720603|DRUG|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
57949299|NCT01826110|DRUG|[11C]PIB|Approximately 15 mCI \[11C\]PIB IV x1
57949300|NCT03087630|BEHAVIORAL|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
57949301|NCT03087630|BEHAVIORAL|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
58090180|NCT05292781|OTHER|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
58090181|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
58304486|NCT02891473|OTHER|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
58304487|NCT02355678|DRUG|dexamethasone|IV 0.5 mg/kg
58304488|NCT02355678|DRUG|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
58416646|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
58416647|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
58416648|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
58416649|NCT00228046|DRUG|Divalproex Sodium|
58416650|NCT00228046|DRUG|Methylphenidate|
58416651|NCT00228046|DRUG|Dextroamphetamine|
58416652|NCT00228046|DRUG|Mixed Amphetamine Salts|
57785121|NCT00813410|PROCEDURE|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
57949302|NCT03087630|BEHAVIORAL|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
58304489|NCT02355678|DRUG|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
58416653|NCT00228046|BEHAVIORAL|Family Counseling|
58416654|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
58416655|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
57949303|NCT03087630|BEHAVIORAL|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
57949304|NCT00279825|DRUG|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
57949305|NCT00279825|DRUG|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
57949306|NCT00279825|DRUG|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
57949307|NCT00279825|DRUG|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
57949308|NCT00279825|DRUG|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
57949309|NCT00279825|DRUG|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
57949310|NCT00279825|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
57949311|NCT00279825|DRUG|CD-LD CR Placebo|Placebo to match CD-LD CR
57949312|NCT04808531|DRUG|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
57949313|NCT04808531|DRUG|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
57949314|NCT04808531|DRUG|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
57949315|NCT04808531|DRUG|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
57949316|NCT04808531|DRUG|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
57949317|NCT05277545|BEHAVIORAL|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
58090182|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
57949318|NCT03723707|BEHAVIORAL|EQUIPED-ADRD Intervention|(10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
58090183|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
58090184|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
58304490|NCT02355678|PROCEDURE|Tonsillectomy|Mono-polar electrocautery or cold dissection
57949319|NCT03723707|BEHAVIORAL|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
57949320|NCT04851028|BEHAVIORAL|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
57949321|NCT06466629|BIOLOGICAL|Triaxis, Sanofi Pasteur|tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine
58090185|NCT02886494|DRUG|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
58090186|NCT02886494|DRUG|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
58090187|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
58304491|NCT02355678|PROCEDURE|gastric content suction|By orogastric tube
57949322|NCT04136873|DRUG|CVL-231|CVL-231
57949323|NCT04136873|DRUG|Matching Placebo|Placebo matching CVL-231
57949324|NCT02275078|BEHAVIORAL|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
57949325|NCT02275078|DEVICE|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
57949326|NCT02275078|OTHER|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
58090188|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
58090189|NCT04461431|PROCEDURE|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
58304492|NCT02355678|DRUG|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
58304493|NCT02355678|DRUG|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
58304494|NCT02355678|DRUG|Paracetamol Suppository|If Visual Analogue Scale was less than 4
58304495|NCT04549194|BIOLOGICAL|Blood collection|A blood sample will be collected before during and after the treatment.
58304496|NCT04549194|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
58304497|NCT04549194|BEHAVIORAL|Psychological questionnaires|"The participants will fill in several psychological questionnaires before, during and after treatment administration:~* Life Event Checklist~* Moral injury~* Posttraumatic Checklist~* Burnout Assessment Tool~* State-Trait Anger Expression Inventory-2~* Ruminative Response Scale - Reconsidered~* Deployment Risk and Resilience Inventory-2~* Questionnaire about tobacco use"
58304498|NCT04549194|DEVICE|Photoplethysmography|Photoplethysmography recording will be performed before during and after the treatment.
58304499|NCT04549194|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
58090190|NCT04622540|PROCEDURE|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
58090191|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
58416656|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
58416657|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
58416658|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
58416659|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
58416660|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
58416661|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
58416662|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
57734030|NCT03998618|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
58090192|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
58090193|NCT05752344|OTHER|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
58090194|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
58090195|NCT00626574|DRUG|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
58090196|NCT00626574|DRUG|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
58304500|NCT02607813|DRUG|LXH254|pan-RAF inhibitor
58304501|NCT02607813|DRUG|PDR001|Biological: PDR001 anti-PD1 antibody
58304502|NCT00746005|DIETARY_SUPPLEMENT|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
58304503|NCT00746005|DIETARY_SUPPLEMENT|placebo, sunflower oil|3 g of sunflower oil
58304504|NCT04624763|PROCEDURE|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met:~   1. Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~  2. If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~  3. LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is \< 10ms;~  4. A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
58304505|NCT04624763|PROCEDURE|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
58304506|NCT00015704|DRUG|Aldesleukin|
58416663|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
58416664|NCT01253265|DRUG|LY2439821|Administered subcutaneously
58416665|NCT01253265|DRUG|Placebo|Administered subcutaneously
58416666|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
58416667|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
57734031|NCT03998618|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
57734032|NCT00890955|DRUG|Amrubicin|"* Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
57734033|NCT00890955|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
57949327|NCT03621514|PROCEDURE|painless indwelling catheter|Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).
58304507|NCT02139540|DRUG|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
58304508|NCT02139540|DRUG|Placebo|50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
58304509|NCT00354315|BEHAVIORAL|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
58304510|NCT00902655|DRUG|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
58304511|NCT01692119|BEHAVIORAL|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
58090197|NCT06702150|BEHAVIORAL|Changing the nursing care model to the primary nursing model|The nurses received training in primary nursing care before the start of the intervention. The model was tested and implemented in early April 2022. Since then, all patients admitted to the unit have been assigned to a primary nurse within the first 48 hours. This nurse is responsible for developing and monitoring the patient's care plan, assessing care needs, implementing the care plan and evaluating the outcomes. This nurse is also responsible for coordinating care needs and discharge planning with other healthcare professionals. When the primary nurse is not working, another nurse from his or her team continues the care plan that he or she has defined. All patients admitted to the unit who met the selection criteria were informed about the study and, if they agreed to take part, completed a self-care competence questionnaire at admission (baseline), at discharge and one month after discharge. They also completed a questionnaire on satisfaction with nursing care at discharge.
58090198|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
58090199|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
58416668|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
58416669|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
58416670|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
58416671|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
58416672|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
58416673|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
58416674|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
58090200|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
58090201|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
58416675|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
58416676|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
58416677|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
58416678|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
58416679|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
58416680|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
58416681|NCT01724424|DRUG|Melatonin|20 mg oral single dose
58416682|NCT01724424|DRUG|Melatonin|30 mg oral single dose
58416683|NCT01724424|DRUG|Melatonin|50mg oral single dose
58416684|NCT01724424|DRUG|Melatonin|100mg oral single dose
58416685|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
58416686|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
58416687|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
58416688|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
58416689|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
58416690|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
58416691|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
58416692|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
58416693|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58416694|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
58416695|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
58416696|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58304512|NCT01165307|DRUG|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
58416697|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
58416698|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
57734034|NCT02469194|OTHER|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
57734035|NCT00121238|DRUG|cilengitide|Given IV
57734036|NCT05566301|DRUG|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
57734037|NCT05566301|DRUG|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
57734038|NCT05758064|DRUG|Duphaston|10 mg tablet will be given twice
58304513|NCT01165307|DRUG|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
58304514|NCT01165307|DEVICE|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
58304515|NCT03839134|DEVICE|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
58304516|NCT03839134|DRUG|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
58304517|NCT00217035|DIETARY_SUPPLEMENT|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
58304518|NCT00885118|DRUG|Placebo (middle dose)|Placebo tablets once a day
58304519|NCT00885118|DRUG|Placebo|Placebo tablets once a day
58304520|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
58304521|NCT00885118|DRUG|BI 10773|BI 10773 high dose tablets once a day
58304522|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
58304523|NCT00885118|DRUG|Placebo (high dose)|Placebo tablets once a day
58304524|NCT00885118|DRUG|BI 10773|BI 10773 low dose tablets once a day
58304525|NCT00885118|DRUG|Placebo (low dose)|Placebo tablets once a day
58304526|NCT04844320|DIAGNOSTIC_TEST|Cobb angle measurements|PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
58304527|NCT02866656|OTHER|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
58304528|NCT02866656|DEVICE|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
58304529|NCT02675205|DRUG|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
58304530|NCT02675205|DRUG|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
58304531|NCT02675205|DRUG|aspirin|
58304532|NCT04133948|DRUG|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
58304533|NCT04133948|DRUG|Nivolumab|2 courses nivolumab 240 mg q3weeks
58304534|NCT04133948|DRUG|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
58304535|NCT00624793|OTHER|Acupuncture|Standard Acup point protocol for treating nausea
58304536|NCT00624793|OTHER|Individualized Acup based on TCM diagnosis|Acup
58304537|NCT00624793|OTHER|Sham Acup|Sham Acup - Non-Active
58304538|NCT06183138|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
58304539|NCT02740816|OTHER|Comparative blood analysis|Collection of menstrual blood and systemic blood
58304540|NCT00290563|DRUG|MK0594|
58304541|NCT05002972|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
58304542|NCT01884883|DEVICE|PROTEOR Internal unicompartmental knee brace|
58304543|NCT01009853|DRUG|Codeine Sulfate|15 mg tablet
58304544|NCT03597737|DEVICE|Pain APP|pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
58416699|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
58416700|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
58416701|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
58416702|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
58416703|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
58416704|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
58416705|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
57734039|NCT05758064|DRUG|prolutex|subcutaneous injection daily
58304545|NCT00975416|BEHAVIORAL|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
58304546|NCT00975416|DRUG|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
58304547|NCT00975416|DRUG|Placebo|Placebo given in the context of cognitive behavioral therapy
58304548|NCT01118052|OTHER|Laboratory Biomarker Analysis|Correlative studies
58304549|NCT01118052|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
58304550|NCT04471961|GENETIC|Exome sequencing in pediatrics cancers|This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
58304551|NCT06427499|DRUG|Stannous fluoride toothpaste|brush 2 min morning \& night daily
58416706|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
58416707|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
58416708|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
58416709|NCT01434329|GENETIC|DNA methylation analysis|
58416710|NCT01434329|GENETIC|gene expression analysis|
58416711|NCT01434329|GENETIC|microarray analysis|
58416712|NCT01434329|OTHER|laboratory biomarker analysis|
58416713|NCT01434329|OTHER|medical chart review|
58416714|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
58416715|NCT03797092|OTHER|Control group|No treatment
57734040|NCT00846664|PROCEDURE|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
57734041|NCT03157986|OTHER|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
58304552|NCT06427499|DRUG|Colgate Cavity Protection Toothpaste|brush 2 min morning \& night daily
58304553|NCT05589896|OTHER|Ossium HPC Marrow, Bone Marrow Transplant|Hematopoetic Cell Transplantation
58304554|NCT05589896|OTHER|Pre-transplant conditioning - Myeloablative (MAC)|Regimen A or Regimen B
58304555|NCT05589896|OTHER|Pre-transplant conditioning - Reduced Intensity (RIC)|Regimen C
58304556|NCT05589896|OTHER|Post-transplant treatment|Post-transplant treatment
58304557|NCT03464760|DIETARY_SUPPLEMENT|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
58304558|NCT03464760|DIETARY_SUPPLEMENT|placebo|5 tablets per day of potato-based placebo
58304559|NCT01340690|DIETARY_SUPPLEMENT|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
57734042|NCT03157986|OTHER|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
57734043|NCT06635330|BIOLOGICAL|anti-CD19 CAR T cell therapy|Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
57734044|NCT05695183|DEVICE|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
57734045|NCT02001480|DEVICE|12 lead Holter|12 lead Holter measurements will be performed for 7 days
58090202|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
58090203|NCT03759301|DRUG|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
58090204|NCT03759301|DRUG|Placebo saline solution|same volume as growth hormone ampule used
58304560|NCT01340690|DIETARY_SUPPLEMENT|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
58416716|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
57734046|NCT02001480|DEVICE|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
57734047|NCT06518577|BIOLOGICAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4)
57734048|NCT06518577|BIOLOGICAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV)
57949328|NCT03621514|PROCEDURE|indwelling catheter|The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
57949329|NCT02662621|OTHER|blood samples|
57949330|NCT02662621|OTHER|Urine samples|
58090205|NCT02380716|DEVICE|GORE® Ascending Stent Graft|
58304561|NCT04644029|DRUG|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
58304562|NCT04644029|DRUG|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
58304563|NCT04644029|DRUG|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
58304564|NCT04644029|DRUG|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
58304565|NCT03566225|DRUG|Pioglitazone|Insulin sensitizing agents
58304566|NCT03566225|DRUG|Metformin|Insulin sensitizing agent
58416717|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
57734049|NCT00987467|DRUG|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
57734050|NCT03652753|DRUG|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
57734051|NCT03652753|DRUG|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
57734052|NCT01585103|DEVICE|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
57734053|NCT01277965|OTHER|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
57734054|NCT01277965|OTHER|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
57734055|NCT01277965|OTHER|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
58090206|NCT06538571|DIAGNOSTIC_TEST|Near infrared spectroscopy|Noninvasive monitor for venous saturation
58304567|NCT03566225|DRUG|Clomiphene Citrate|Induction drug
58304568|NCT04897386|DRUG|Duvalizumab|Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
58304569|NCT03290430|BEHAVIORAL|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
58304570|NCT03290430|BEHAVIORAL|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
58304571|NCT03290430|BEHAVIORAL|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
58304572|NCT03290430|BEHAVIORAL|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
58304573|NCT03290430|BEHAVIORAL|Texting support|Texts with smoking cessation support throughout the program
58416718|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
58416719|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
58416720|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
58416721|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
58090207|NCT06298487|OTHER|Patient questionnaires|Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
58416722|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
57734056|NCT01277965|OTHER|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
58090208|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
58416723|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
58416724|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
58416725|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
57734057|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change
58416726|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
58416727|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
57949331|NCT06005727|DEVICE|Transanal ice pack|A condom is filled with 100ml of water and frozen to serve as a transanal ice pack. It is covered by sterile plastic dressing and applied to the hemorrhoidectomy wound for 1 minute after surgery is completed.
58304574|NCT03290430|DRUG|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
58304575|NCT03263455|OTHER|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
58416728|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
58416729|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
58416730|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
58416731|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
58416732|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
58416733|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
58416734|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
58416735|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
58416736|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
58416737|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
58304576|NCT03263455|OTHER|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
58416738|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
58416739|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
58416740|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
58416741|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
58416742|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
58416743|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
58416744|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
58416745|NCT00711802|DRUG|Daptomycin|
58416746|NCT00711802|DRUG|Standard of Care (SOC)|
58416747|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
58416748|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
58416749|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
58416750|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
58416751|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
58416752|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
58416753|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
58416754|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
58416755|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
58090209|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
58416756|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
58416757|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
58416758|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
58416759|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
58416760|NCT02316210|DEVICE|electrical stimulation|
58416761|NCT00003252|DRUG|amifostine trihydrate|
58416762|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
58416763|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
58416764|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
58416765|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
58416766|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
58416767|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
58416768|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
58416769|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
58416770|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
58416771|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
58416772|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
58416773|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
58416774|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
58416775|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
58416776|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
57949332|NCT06392568|OTHER|epidemiological records|Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
58416777|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
58416778|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
58416779|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
58416780|NCT02267304|DRUG|Morphine 0,05mg/kg|
58416781|NCT02267304|DRUG|Naloxone 10mg|
58416782|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
58416783|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
58416784|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
58416785|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
58416786|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
58416787|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
58416788|NCT00002652|DRUG|suramin|
58416789|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
58416790|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
58416791|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
58416792|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
58416793|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
58416794|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
58416795|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
58416796|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
58416797|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
58416798|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
58416799|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
58416800|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
58416801|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
58416802|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
58416803|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
58416804|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
58416805|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
58416806|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
58416807|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
58416808|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
58416809|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
58416810|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
58416811|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
58416812|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
58416813|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
58416814|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
58416815|NCT00084175|BEHAVIORAL|Behavior Therapy|
58416816|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
58416817|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
58416818|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
58416819|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
57949333|NCT03639870|DEVICE|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
58090210|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
57949334|NCT06288620|PROCEDURE|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
58090211|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
58416820|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
58416821|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
58416822|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
58416823|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
58416824|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
58416825|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
58416826|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
58416827|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
58416828|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
58416829|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
58416830|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
58416831|NCT00099281|DRUG|YMB 1002|
58090212|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
58090213|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
58090214|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
58416832|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
58416833|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
57734058|NCT02504294|BIOLOGICAL|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
57734059|NCT02504294|OTHER|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
58090215|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
58090216|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
58090217|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
58090218|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
58090219|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
58090220|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
58304577|NCT05145985|DIAGNOSTIC_TEST|Senior Fitness Test|"Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)"
58304578|NCT05696951|OTHER|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
58304579|NCT03022006|DRUG|elbasvir, grazoprevir|
58304580|NCT06241911|DEVICE|transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
58416834|NCT01838785|DRUG|18F-DTBZ AV-133|
58416835|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
57734060|NCT02504294|DRUG|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
58090221|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
58090222|NCT06371911|OTHER|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
58090223|NCT06371911|OTHER|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
58090224|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin|
58090225|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
58090226|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
58090227|NCT02758509|DRUG|Ledipasvir/Sofosbuvir|
58090228|NCT02758509|DRUG|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
57734061|NCT03019536|DRUG|LY3303560 - IV|Administered IV
57734062|NCT03019536|DRUG|Placebo - IV|Administered IV
58090229|NCT02758509|DRUG|Daclatasvir+Sofosbuvir|
58090230|NCT02758509|DRUG|Simeprevir+Sofosbuvir|
58416836|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
58416837|NCT02241187|DRUG|PEGPH20|
58416838|NCT02241187|DRUG|Cetuximab|
58416839|NCT02241187|DEVICE|DW & DCE-MRI|
58416840|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
58416841|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
57949335|NCT03149081|DRUG|Boswellia|Boswellia is an extract from frankincense
58090231|NCT01166074|BIOLOGICAL|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
58090232|NCT00519948|DRUG|new MPS, opti-free express no rub MPS|
58090233|NCT02208934|DRUG|PBF-999|5, 10, 20 and 40 mg of PBF-999
58090234|NCT02208934|DRUG|Placebo|Placebo for all dosis of PBF-999
58090235|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
58090236|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
58090237|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
58090238|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
58090239|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
58090240|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
58090241|NCT04556877|PROCEDURE|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
58090242|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
58090243|NCT03829527|BEHAVIORAL|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
58090244|NCT00003786|DRUG|irofulven|
58090245|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
57734063|NCT03019536|DRUG|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
57734064|NCT03019536|DRUG|Flortaucipir F18|Administered IV during the PET scan performed during the study.
57734065|NCT05645588|BEHAVIORAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
57949336|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
58090246|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
58304581|NCT00160511|DRUG|Levetiracetam|
57949337|NCT02395926|DRUG|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
58090247|NCT05297149|BEHAVIORAL|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
58090248|NCT05297149|BEHAVIORAL|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
58090249|NCT03545360|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-703 device
58304582|NCT02672072|OTHER|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
58304583|NCT02672072|OTHER|questionnaire to define the presence of job strain at 6 months|
58304584|NCT02672072|OTHER|questionnaire to define the presence of job strain at 12 months|
58304585|NCT04773028|OTHER|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
58416842|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
58416843|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
58416844|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
57734066|NCT05645588|BEHAVIORAL|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
57949338|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
58304586|NCT01626066|DRUG|LUM015|LUM015 assigned dose given once by IV push
58416845|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
58416846|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
58416847|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
58416848|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
58416849|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
58416850|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
58416851|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
58304587|NCT04795063|PROCEDURE|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
58416852|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
58416853|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
58416854|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
58416855|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
58416856|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
58416857|NCT01151761|DRUG|5FU|200 mg/m2
58416858|NCT01151761|PROCEDURE|Liver transplantation|
57734067|NCT01561248|DRUG|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
57734068|NCT02837341|DEVICE|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
57734069|NCT05553808|DRUG|Docetaxel|Docetaxel was administered as IV infusion.
57949339|NCT04170322|DEVICE|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
58304588|NCT04795063|PROCEDURE|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
58304589|NCT04718922|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
58304590|NCT03835039|DEVICE|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
58304591|NCT04168034|BEHAVIORAL|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
58304592|NCT04168034|BEHAVIORAL|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
58416859|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
58416860|NCT06233864|DRUG|Gemcitabine|Gemcitabine
58416861|NCT00186537|DRUG|Rosiglitazone|
58416862|NCT00186537|DRUG|Fenofibrate|
58416863|NCT00186537|BEHAVIORAL|Weight Loss|
58416864|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
58416865|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
58416866|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
58416867|NCT00403533|DRUG|20 mg of atorvastatin daily|
58416868|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
57734070|NCT05553808|DRUG|Feladilimab|Feladilimab was administered as IV infusion.
57734071|NCT02987413|BIOLOGICAL|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
57734072|NCT06669858|OTHER|manual therapy|"In first session 6 techniques were applied to favorise fluids circulation, respiratory mecanism end equilibration of pressions (all were external soft tissue techniques, without manipulation): on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on liver and spleen organ, on lumbar fasciae.~In second session 6 techniques were applied in order to improve quality and quantity of legs and pelvis mobility (all were external sof tissue techniques, without manipulation) : on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on pubic symphysis, on legs and pelvis and on lumbar fasciae"
58090250|NCT03494673|DIAGNOSTIC_TEST|BOLD MRI|"1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
57734073|NCT06669858|OTHER|Sham|Wide ligth touch pressure applied with the 2 hand at day 2-4 and day 90
57734074|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
58090251|NCT03780452|DEVICE|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
58304593|NCT04768088|OTHER|Falling Training|For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
58304594|NCT02477176|OTHER|Discectomy|Lumbar discectomy
58304595|NCT01819714|OTHER|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
58304596|NCT01100424|DEVICE|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
58416869|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
58416870|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
58416871|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
58416872|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
58416873|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
58416874|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
58416875|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
58416876|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
58416877|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
57734075|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
57734076|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
57734077|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
57734078|NCT04969250|BIOLOGICAL|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
57734079|NCT04969250|BIOLOGICAL|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
57734080|NCT04019847|DEVICE|STAK Tool|Medical stretching device
57734081|NCT04019847|OTHER|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
57734082|NCT04298541|DRUG|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
57734083|NCT04298541|DRUG|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
57949340|NCT04170322|DEVICE|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
58416878|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
58416879|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
58416880|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
58416881|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
57734084|NCT03400891|BEHAVIORAL|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
57734085|NCT05328531|DRUG|Genakumab for Injection|150 mg/1ml/bottle
57734086|NCT05328531|DRUG|Placebo for Genakumab for Injection|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
57949341|NCT02512471|DRUG|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
57949342|NCT03439202|OTHER|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
57949343|NCT02866474|DIETARY_SUPPLEMENT|population living at home with meals on wheels|
58304597|NCT01100424|DEVICE|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
58304598|NCT01100424|DEVICE|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
58304599|NCT01100424|OTHER|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
58304600|NCT04574089|DRUG|Experimental: Baofukang Suppository 7 days|Experimental: Baofukang Suppository 7 days
57949344|NCT02866474|DIETARY_SUPPLEMENT|population living in an EHPAD|
58304601|NCT04574089|DRUG|Experimental: Baofukang Suppository 14 days|Experimental: Baofukang Suppository 14 days
58304602|NCT02816723|BEHAVIORAL|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
57949345|NCT03568474|DRUG|Silver Diamine Fluoride|Indirect pulp capping material
58304603|NCT02816723|BEHAVIORAL|Brain Health|Brain Health Education
57949346|NCT03568474|DRUG|Glass Ionomer|Indirect pulp capping material
58304604|NCT01947348|PROCEDURE|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
57949347|NCT00630656|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
57734087|NCT00906672|DEVICE|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
57949348|NCT00630656|DRUG|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
57949349|NCT05329376|DEVICE|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine"
57949350|NCT05329376|OTHER|Usual Care|Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
58304605|NCT04335435|DIETARY_SUPPLEMENT|Oat Bran Consumption|Oat bran (120 g), single dose.
58304606|NCT00766766|BEHAVIORAL|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
57734088|NCT00906672|PROCEDURE|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
57734089|NCT00048516|DRUG|paricalcitol capsule|
58304607|NCT00766766|BEHAVIORAL|Telephone Coaching Sessions|Telephone Coaching Sessions
58304608|NCT00766766|BEHAVIORAL|Physician Feedback Letter|Physician Feedback Letter
58304609|NCT02649010|DEVICE|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
58304610|NCT04497285|OTHER|blood sample collection and collection of tumor tissue block|blood sample collection and collection of tumor tissue block
58416882|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
58416883|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
58416884|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
58416885|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
58416886|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
58304611|NCT02414698|PROCEDURE|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
58416887|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
58416888|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
58416889|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
58416890|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
58416891|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
58416892|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
58416893|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
58416894|NCT02593708|DRUG|Neratinib|
58304612|NCT02414698|DRUG|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
58304613|NCT06333639|OTHER|orthopaedic surgery|usual procedures for an orthopaedic surgery
58304614|NCT06333639|OTHER|orthopaedic surgery and fitted with a virtual reality headset|usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
58416895|NCT02593708|DRUG|Paclitaxel|
58416896|NCT02593708|DRUG|Pertuzumab|
58416897|NCT02593708|DRUG|Trastuzumab|
58416898|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
58416899|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
58416900|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
58416901|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
58416902|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
58416903|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
57734090|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
57734091|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
57734092|NCT01098006|OTHER|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
57949351|NCT03978455|BEHAVIORAL|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
58416904|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
58416905|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
58416906|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
58416907|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
58416908|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
57734093|NCT02315157|DRUG|Bendamustine|Given IV
57949352|NCT00976222|DRUG|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
57949353|NCT03040440|DEVICE|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
58304615|NCT04214743|DEVICE|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
58416909|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
58416910|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
58416911|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
58416912|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
57949354|NCT03040440|DEVICE|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
58090252|NCT01615900|OTHER|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
58090253|NCT05244109|OTHER|Blood sample|Blood samples (2 times; 21mL per visit)
58090254|NCT05244109|DRUG|anti-TNF antibody administration|Anti-TNF antibody administration, according to current recommendations and randomization results
58090255|NCT05244109|DRUG|anti-IL-17 antibody administration|Anti-IL-17 antibody administration, according to current recommendations and randomization results
58090256|NCT00532779|DRUG|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
58090257|NCT00532779|DRUG|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
58090258|NCT00532779|DRUG|Placebo|
58090259|NCT00532779|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
58090260|NCT01074853|DRUG|propranolol|10mg twice daily escalated to 80mg once daily
58090261|NCT01074853|DRUG|placebo|Matched placebo
58090262|NCT02991651|DRUG|IRX4204|RXR agonist
58090263|NCT02991651|DRUG|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
58090264|NCT00572468|DRUG|Simvastatin|40 mg of simvastatin
58416913|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
57949355|NCT06097117|DIAGNOSTIC_TEST|MultiplexPCR|PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.
57949356|NCT03587714|DIAGNOSTIC_TEST|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
58090265|NCT00572468|OTHER|Placebo|placebo
58090266|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
58090267|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
58090268|NCT00713830|DEVICE|Pen auto-injector|
58090269|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
58090270|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
58090271|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
58090272|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
58304616|NCT04214743|DEVICE|Fundus camera from Optomed|It allows to monitor retinal microvasculature
58304617|NCT03342001|DRUG|Calcitonin|calcitonin nasal spray
58304618|NCT00998569|BEHAVIORAL|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
58416914|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
58416915|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
58416916|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
58304619|NCT00998569|BEHAVIORAL|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
58416917|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
58416918|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
58416919|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
58416920|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
58416921|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
58416922|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
58416923|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
58416924|NCT02303899|DRUG|Gemcitabine|infusion drug
58416925|NCT02303899|DRUG|Imatinib mesylate|oral drug
58416926|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
58304620|NCT06465472|DRUG|Stiripentol Oral Capsule|The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
57734094|NCT05978765|DEVICE|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
58304621|NCT06465472|DRUG|Placebo Oral Capsule|Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
58304622|NCT06465472|BIOLOGICAL|Urine samples collect|Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
58304623|NCT06465472|BIOLOGICAL|Blood samples collect|Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
58304624|NCT06465472|OTHER|Kidney imaging|Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
58304625|NCT06465472|OTHER|Quality of Life questionnaires|"Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available."
58304626|NCT02979964|BEHAVIORAL|Audit and Feedback|
58304627|NCT00807066|DRUG|Gefitinib|Gefitinib 250 mg/day
58304628|NCT00807066|DRUG|Platinum|Platinum based chemotherapy with cycles every 21 days
58304629|NCT01193946|DIETARY_SUPPLEMENT|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
58304630|NCT00084240|DRUG|Azithromycin/Chloroquine|
58416927|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
58304631|NCT00084240|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
58304632|NCT00914147|PROCEDURE|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
58304633|NCT00685516|DIETARY_SUPPLEMENT|green tea|6 cups of green tea daily for 2-8 weeks
58304634|NCT00685516|DIETARY_SUPPLEMENT|placebo|6 cups of water daily for 2-8 weeks
58304635|NCT00685516|DIETARY_SUPPLEMENT|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
58304636|NCT04064268|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
58304637|NCT04064268|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
58304638|NCT02530437|DRUG|Carboplatin|Given IV
58416928|NCT02230683|DRUG|IDN-6556|25 mg BID
58416929|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
58416930|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
58416931|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
58416932|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
58416933|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
57734095|NCT05978765|OTHER|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
57734096|NCT01666002|DEVICE|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
58304639|NCT02530437|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
58304640|NCT02530437|OTHER|Laboratory Biomarker Analysis|Correlative studies
58304641|NCT02530437|DRUG|Paclitaxel|Given IV
58304642|NCT02530437|DRUG|Taladegib|Given PO
58304643|NCT00005998|DRUG|carmustine|
58304644|NCT00005998|DRUG|cyclophosphamide|
58304645|NCT00005998|DRUG|cytarabine|
58304646|NCT00005998|DRUG|dexamethasone|
58304647|NCT00005998|DRUG|etoposide|
58304648|NCT00005998|DRUG|filgrastim|
58304649|NCT00005998|DRUG|mitoxantrone hydrochloride|
58304650|NCT00005998|DRUG|retrovirus vector LN|
58304651|NCT00005998|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58304652|NCT00005998|PROCEDURE|peripheral blood stem cell transplantation|
58304653|NCT00005998|PROCEDURE|radiation therapy|
58304654|NCT04531124|OTHER|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
58304655|NCT00379834|DRUG|Cosopt|Cosopt twice daily in both eyes
58304656|NCT03071211|DEVICE|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
58304657|NCT03071211|DEVICE|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
58304658|NCT06525116|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
58304659|NCT00231023|DRUG|Peribulbar Triamcinolone Acetonide|
58304660|NCT02358122|OTHER|Wholegrain rye|A variety of cereal foods providing \>100g/day wholegrain from rye
58304661|NCT02358122|OTHER|Wholegrain wheat|A variety of cereal foods providing \>100g/day wholegrain from wheat
58304662|NCT02358122|OTHER|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
58304663|NCT05328960|OTHER|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
58304664|NCT02791256|DRUG|Ribavirin|
58304665|NCT02791256|DRUG|peginterferon alfa-2a|
58304666|NCT02736617|DRUG|Ibrutinib|Given PO
58304667|NCT02736617|BIOLOGICAL|Obinutuzumab|Given IV
58304668|NCT01229878|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
58304669|NCT04258072|DRUG|Vactosertib|Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
58304670|NCT01015027|BIOLOGICAL|REGN668|4 IV Cohorts (Dose 1, 2, 3, \& 4)
58304671|NCT04550078|DIETARY_SUPPLEMENT|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
58304672|NCT04550078|DIETARY_SUPPLEMENT|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
58304673|NCT04550078|DIETARY_SUPPLEMENT|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
58304674|NCT02546011|OTHER|Fetal Heart Rate Monitor|Standard of care, not part of research
58304675|NCT02143817|DIETARY_SUPPLEMENT|L-citrulline supplementation|
58304676|NCT02143817|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
58304677|NCT06078215|COMBINATION_PRODUCT|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
58416934|NCT02616393|DRUG|Tesevatinib|
58416935|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
58416936|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
57734097|NCT06201182|DRUG|FMT via rectal enema|50 grams of FMT via rectal enema
58416937|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
58416938|NCT02144155|DRUG|Placebo|placebo drug
58416939|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
58416940|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
57949357|NCT03381235|OTHER|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
57949358|NCT00159900|DRUG|Sildenafil Citrate|
57949359|NCT05309798|BEHAVIORAL|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
57949360|NCT05309798|BEHAVIORAL|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
57949361|NCT05309798|BEHAVIORAL|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
57949362|NCT00431340|DRUG|PXD101|
57949363|NCT02573870|DRUG|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
57949364|NCT02573870|DRUG|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
57949365|NCT02573870|DRUG|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
57949366|NCT03413111|PROCEDURE|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
57949367|NCT04816929|OTHER|Bobath Method|Neurodevelopmental Treatment
57949368|NCT04816929|OTHER|Task-Oriented Approach|Task-Oriented Treatment
57949369|NCT04980482|DRUG|AB-729|subcutaneous injection
57949370|NCT04980482|DRUG|Peg-IFNα-2a|subcutaneous injection
57949371|NCT04225130|BEHAVIORAL|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
57949372|NCT04225130|BEHAVIORAL|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
57949373|NCT05240911|DRUG|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
57734098|NCT06201182|DRUG|FMT capsules|FMT capsules given twice daily for 2 consecutive days
57949374|NCT00507559|DEVICE|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
57949375|NCT04169360|DRUG|ANS-6637|White, oblong 300 mg tablet
57949376|NCT04169360|DRUG|Placebo oral tablet|White, oblong 300 mg tablet
57949377|NCT03583151|BIOLOGICAL|Amniotic fluid injection|Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
57949378|NCT03583151|BIOLOGICAL|Steroid injection|Solu-medrol
57949379|NCT05915572|OTHER|Mulligan Mobilization Technique|The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation
57949380|NCT05915572|OTHER|Traditional Physical Therapy Program|Myofascial release and ROM ex. 3 sessions per week for 6 weeks.
57949381|NCT03594227|DRUG|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
57734099|NCT06201182|DRUG|Placebo via rectal enema|Placebo via rectal enema
58090273|NCT04431622|DEVICE|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
58090274|NCT05610813|DRUG|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
58416941|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
58416942|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
58090275|NCT05610813|DRUG|Opioid therapy|The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
58416943|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
58416944|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
58416945|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
58416946|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
58416947|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
58416948|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
58416949|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
58416950|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
58416951|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
58090276|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
58090277|NCT06649799|DEVICE|LenSx|The patients in Group 1 conduct FLACS under LenSx
58090278|NCT06649799|DEVICE|Z8|The patients in Group 1 conducted FLACS using Z8
58090279|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
58416952|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
58416953|NCT01557959|DRUG|cisplatin|Given IV
58416954|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
58416955|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
58416956|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
58416957|NCT01557959|GENETIC|polymorphism analysis|Correlative study
58090280|NCT02001038|OTHER|Survey|
58416958|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
58416959|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
58416960|NCT01557959|DRUG|docetaxel|Given IV
57734100|NCT06201182|DRUG|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
58304678|NCT04443335|BEHAVIORAL|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
58416961|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
58416962|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
58416963|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
58304679|NCT04443335|BEHAVIORAL|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
58304680|NCT03010072|DRUG|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
58304681|NCT03010072|DRUG|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
58416964|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
58416965|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
58416966|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
58416967|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
58416968|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
58416969|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
58416970|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
58416971|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
58416972|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
57734101|NCT05921877|DIAGNOSTIC_TEST|venous sampling|venous sampling
57734102|NCT02938000|DEVICE|Theraband with exercise video|Theraband exercise band for resistance training
57734103|NCT02938000|OTHER|usual care with advice to exercise|advice to exercise
57734104|NCT02127801|DRUG|REGN1908-1909|
57734105|NCT02127801|DRUG|placebo|
57734106|NCT05268146|BEHAVIORAL|Lifestyles|Co-creation process and participatory research; lifestyles
57734107|NCT06146348|BEHAVIORAL|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
58304682|NCT00327483|BEHAVIORAL|Internet based education software|
58304683|NCT00617279|DEVICE|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
58304684|NCT00617279|PROCEDURE|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
58304685|NCT05641571|BEHAVIORAL|The home-based extremity exercise program|Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
58416973|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
58416974|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
58416975|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
58416976|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
58416977|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
57734108|NCT01597687|PROCEDURE|Blood collection|1 blood sample will be collected from each subject.
57734109|NCT01597687|OTHER|Data collection|Quality of Life and HE questionnaires.
57734110|NCT01669122|DRUG|nicotine|4 mg nicotine lozenge experimental
58304686|NCT03884881|DIAGNOSTIC_TEST|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
58304687|NCT03884881|DIAGNOSTIC_TEST|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
58304688|NCT03884881|DRUG|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
58304689|NCT03221114|BEHAVIORAL|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
58304690|NCT04573660|DEVICE|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
58416978|NCT02930408|PROCEDURE|electrocardiogram|
58416979|NCT02930408|PROCEDURE|Echocardiography|
58416980|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
58416981|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
58416982|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
58416983|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
58416984|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
58416985|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
58416986|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
58416987|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
58416988|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
58416989|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
58416990|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
58416991|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
58416992|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
58416993|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
58416994|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
58416995|NCT03266913|DRUG|Probiotic|Probiotics drop
58416996|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
58416997|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
58416998|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
58416999|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
58417000|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
58417001|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
58417002|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
58417003|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
58417004|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
57734111|NCT05542576|DRUG|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
58417005|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
58417006|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
58417007|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
58090281|NCT02815189|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
58090282|NCT02815189|DRUG|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
58090283|NCT03920527|DRUG|Itraconazole 400 mg|Duration of itraconazole
58417008|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
58417009|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
58417010|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
58417011|NCT04126889|OTHER|questionnaire survey|questionnaire survey
58417012|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
58417013|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
58304691|NCT04573660|DEVICE|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
58304692|NCT04573660|DEVICE|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
58304693|NCT04573660|DEVICE|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
58417014|NCT00248430|BIOLOGICAL|aldesleukin|
58417015|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58417016|NCT00248430|DRUG|melphalan|
58417017|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
58090284|NCT03916692|DIETARY_SUPPLEMENT|Carbohydrate drink|Meal replacement drink containing 200 kcal
58090285|NCT03916692|DIETARY_SUPPLEMENT|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
58090286|NCT03916692|DIETARY_SUPPLEMENT|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
58090287|NCT00345969|DRUG|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
58304694|NCT04573660|DEVICE|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
58304695|NCT04573660|DEVICE|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
58304696|NCT04573660|DEVICE|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
58304697|NCT04573660|DEVICE|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
58304698|NCT04573660|DEVICE|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
58304699|NCT05073705|BEHAVIORAL|Empowerment and personal transformation intervention|The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
58417018|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
58417019|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
58417020|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
58417021|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
58417022|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
58417023|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
58417024|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
58417025|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
58417026|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
58417027|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
58417028|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
57949382|NCT03594227|DRUG|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
58090288|NCT00345969|BEHAVIORAL|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
58417029|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
58417030|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
58417031|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
58417032|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
58090289|NCT06701084|GENETIC|Genomic Sequencing|Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.
58417033|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
58090290|NCT05742607|DRUG|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
58090291|NCT01135316|DRUG|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
58090292|NCT06566625|DIAGNOSTIC_TEST|Cardiac MRI (CMR) examination|"An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)"
58090293|NCT04040738|PROCEDURE|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
58090294|NCT04040738|PROCEDURE|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
58090295|NCT05887518|DEVICE|Socks Developed with Wearable Technology|This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
58304700|NCT06141252|DEVICE|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
58304701|NCT00646724|BIOLOGICAL|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
58304702|NCT04500574|DRUG|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
58304703|NCT04500574|DRUG|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
58417034|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
58417035|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
58417036|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
58417037|NCT02675335|DRUG|Sitagliptin|
58417038|NCT02675335|DRUG|Placebo|
58417039|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
58417040|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
58417041|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
58417042|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
58417043|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
58417044|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
58417045|NCT00489736|DRUG|amiodarone|oral administration
58417046|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
58417047|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
58417048|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
58417049|NCT00004864|DRUG|GEM 231|
58417050|NCT00004864|DRUG|docetaxel|
58417051|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
58417052|NCT02707393|DRUG|Fludarabine|infusion
58417053|NCT02707393|DRUG|Thiotepa|infusion
58417054|NCT02707393|DRUG|Melphalan|infusion
58417055|NCT02707393|DRUG|ATG|infusion
58417056|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
58417057|NCT02707393|DRUG|Mycophenolate mofetil|infusion
58417058|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
58304704|NCT00325741|DRUG|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
58304705|NCT00687934|DRUG|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
58304706|NCT00006032|DRUG|etoposide|
58304707|NCT00006032|DRUG|ifosfamide|
58304708|NCT00006032|DRUG|topotecan hydrochloride|
58417059|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
58417060|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
58417061|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
58417062|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
58417063|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
58417064|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
58417065|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
58417066|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
58417067|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
58417068|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
58417069|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
58417070|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
58417071|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
58417072|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
58417073|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
58417074|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
57949383|NCT03594227|DRUG|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
58417075|NCT05665699|DRUG|D-0120|increasing dose of D-0120
58417076|NCT05665699|DRUG|Allopurinol|standard dosing
58417077|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
58417078|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
58417079|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
58417080|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
57949384|NCT03594227|DRUG|Placebo|Placebo - oral administration
57949385|NCT03080298|DRUG|BP101|
57949386|NCT03080298|DRUG|Placebo|
58304709|NCT00006032|PROCEDURE|peripheral blood stem cell transplantation|
58304710|NCT04025216|BIOLOGICAL|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
57949387|NCT00736255|DRUG|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
58417081|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
58090296|NCT05635760|BEHAVIORAL|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
58090297|NCT05635760|BEHAVIORAL|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
58090298|NCT01742390|DRUG|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
58090299|NCT01742390|DRUG|risperidone or paliperidone|
58090300|NCT04602208|PROCEDURE|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
58090301|NCT00447265|DRUG|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
58090302|NCT00447265|DRUG|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
58090303|NCT00447265|DRUG|Placebo|
58090304|NCT04793152|DRUG|Vancomycin|Administration as outlined
58090305|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
58090306|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
58090307|NCT06566430|BEHAVIORAL|PrEP My Way intervention|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
58417082|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
58417083|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
58417084|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
58417085|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
58417086|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
58417087|NCT00241098|DRUG|valsartan|
58417088|NCT03262207|OTHER|Extraction genomic DNA|
58417089|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
58417090|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
58417091|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
58417092|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
58417093|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
58417094|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
58417095|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
58417096|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
58417097|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
58417098|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
58090308|NCT06566430|BEHAVIORAL|PrEP My Way intervention without STI testing|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
57734112|NCT04695171|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
57734113|NCT04695171|PROCEDURE|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
58090309|NCT06566430|BEHAVIORAL|Enhanced standard of care|These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
57734114|NCT03992755|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
58090310|NCT05276869|OTHER|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
57734115|NCT01059760|BEHAVIORAL|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
57734116|NCT01059760|BEHAVIORAL|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
57734117|NCT06609239|DRUG|Lunsekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
57734118|NCT05593835|DEVICE|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
57734119|NCT05593835|OTHER|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
57734120|NCT04189562|OTHER|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
58417099|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
58417100|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
57734121|NCT02721238|BIOLOGICAL|20% Albumin|
58417101|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
58417102|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
57734122|NCT02721238|OTHER|Plasmalyte|
58417103|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
58417104|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
58417105|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
58417106|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
57734123|NCT00058838|DRUG|sumanirole|
57734124|NCT01319448|DRUG|Proguanil|Proguanil tablets, 1.5mg/kg/day
58090311|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
57734125|NCT01319448|DRUG|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
57734126|NCT01319448|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
57734127|NCT06634992|OTHER|Oral immunotherapy|Clinical Follow up
57734128|NCT00175851|DRUG|Seletracetam (ucb 44212)|
57734129|NCT06634641|BIOLOGICAL|blood test|Only carrying out additional immunological assays during blood tests before initiation of treatment, six months after initiation of treatment and then one year after initiation of treatment.
57734130|NCT04313803|DEVICE|CGM|Dexcom CGM system
58417107|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
58090312|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
58090313|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
58417108|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
58417109|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
57734131|NCT01060228|DRUG|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
58090314|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
57949388|NCT00736255|DRUG|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
58090315|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
58090316|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
58090317|NCT02143479|DRUG|Tacrolimus|oral
58304711|NCT04025216|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
58304712|NCT04025216|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
58417110|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
58417111|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
58417112|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
58417113|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
58417114|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
58417115|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
57734132|NCT01060228|DRUG|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
57734133|NCT02907346|BEHAVIORAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
57734134|NCT00089440|DRUG|Aripiprazole|
57734135|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
57734136|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
57734137|NCT05608629|DEVICE|Transcutaneous Non-Invasive Vagus Nerve Stimulation|The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
58304713|NCT06209632|BEHAVIORAL|mirror therapy|30 minutes of intervention, twice a week, and a total of 12 weeks
58304714|NCT06209632|DEVICE|contralaterally controlled functional electrical stimulation|30 minutes of intervention, twice a week, and a total of 12 weeks
58304715|NCT06209632|BEHAVIORAL|conventional physiotherapy|50 minutes of intervention, twice a week, and a total of 12 weeks
58304716|NCT06416631|PROCEDURE|artificial intelligence based screw planning|artificial intelligence technology helps to plan screws in robot assisted spinal surgery
58304717|NCT06416631|PROCEDURE|manually screw planning|the screw trajcetories are manually planned
58304718|NCT04781712|BEHAVIORAL|Modular mHealth for Tailored Rehabilitation|an individually tailored self-management through the mHealth app with a smart band worn on the wrist
58304719|NCT01210638|DRUG|Oxymorphone|10 mg tablet
58304720|NCT05885932|PROCEDURE|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
58304721|NCT05885932|DRUG|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
58304722|NCT05885932|PROCEDURE|mono anti-platelet therapy|mono anti-platelet therapy
58304723|NCT00745303|PROCEDURE|Tai Chi Cuan|Tai Chi Cuan training for 3 months
57949389|NCT00736255|DRUG|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
58304724|NCT05497323|DRUG|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
58304725|NCT05497323|DRUG|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
58304726|NCT03190824|DRUG|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
58304727|NCT00125008|BIOLOGICAL|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
58417116|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
58417117|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
58417118|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
58417119|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
58417120|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
58417121|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
58304728|NCT00125008|BIOLOGICAL|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
58304729|NCT00000320|DRUG|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
57734138|NCT03649828|DIETARY_SUPPLEMENT|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
57949390|NCT02936583|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
58417122|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
57734139|NCT03649828|DIETARY_SUPPLEMENT|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
57949391|NCT00247026|DRUG|curcumin; coenzyme q10|
57949392|NCT01155362|BIOLOGICAL|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
57949393|NCT01155362|DRUG|Vehice Control|
57949394|NCT04058340|DIETARY_SUPPLEMENT|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
57949395|NCT04058340|OTHER|Placebo|0.9% NaCl solution in nebulization
57949396|NCT04911036|OTHER|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
57949397|NCT05145907|BIOLOGICAL|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
57949398|NCT03394144|DRUG|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
57949399|NCT02434848|DRUG|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
58304730|NCT05185063|DIAGNOSTIC_TEST|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
58304731|NCT01338896|DRUG|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
58304732|NCT05656300|DIAGNOSTIC_TEST|MRI scan using USPIO particles|Diagnostic imaging
58417123|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
58417124|NCT01304329|DRUG|BI 10773|Medium dose oral administration
58417125|NCT01304329|DRUG|simvastatin|Medium dose oral administration
58417126|NCT01304329|DRUG|simvastatin|Medium dose oral administration
58417127|NCT01304329|DRUG|BI 10773|Medium dose oral administration
58417128|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
58417129|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
58417130|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
57734140|NCT04158375|BEHAVIORAL|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
57734141|NCT00715429|DRUG|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
57734142|NCT00715429|DRUG|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
57734143|NCT03699943|PROCEDURE|CaverStem|
57734144|NCT05831332|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
58417131|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
58417132|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
58417133|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
58417134|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
58417135|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
58417136|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
58417137|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
58417138|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
58417139|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
58417140|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
58417141|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
58417142|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
58417143|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
58417144|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
58417145|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
58417146|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
58417147|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
58417148|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
58417149|NCT02182674|DRUG|Placebo Combivent HFA|
58417150|NCT02182674|DRUG|Combivent HFA|
58417151|NCT02182674|DRUG|Combivent (CFC)|
58417152|NCT02182674|DRUG|Placebo Combivent (CFC)|
58417153|NCT02087813|DRUG|Alpha1-antitrypsin|
58417154|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
58417155|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
58417156|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
58417157|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
58417158|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
58417159|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
58417160|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
58417161|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
58417162|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
58417163|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
58090318|NCT05718505|DEVICE|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
58090319|NCT05718505|DEVICE|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
58090320|NCT02670356|DIETARY_SUPPLEMENT|Fish oil|two 750 mg/capsules/day
58090321|NCT02670356|DIETARY_SUPPLEMENT|Krill oil|one 300 mg capsule/day
58090322|NCT02708940|OTHER|Participatory technology development|Creating mobile support tools by patients and their therapists
58090323|NCT02708940|OTHER|Usual Care|Usual care as part of the UCLA PHP and IOP programs
58090324|NCT00005886|DRUG|arzoxifene hydrochloride|
58090325|NCT00005886|DRUG|tamoxifen citrate|
58090326|NCT04624256|PROCEDURE|Discussion|Patients and physicians engage in discussion
58090327|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
58090328|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
58090329|NCT04624256|OTHER|Laboratory Biomarker Analysis|Correlative studies
58090330|NCT04624256|OTHER|Quality-of-Life Assessment|Ancillary studies
58090331|NCT04624256|OTHER|Questionnaire Administration|Ancillary studies
58090332|NCT04624256|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58417164|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
58417165|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
58417166|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
57734145|NCT01432119|DEVICE|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
57734146|NCT01432119|DRUG|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
58090333|NCT03574623|DEVICE|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
58090334|NCT03574623|BEHAVIORAL|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
58090335|NCT03032575|BEHAVIORAL|SEARCH010/RV254|
58090336|NCT01177735|DRUG|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
58090337|NCT06701513|DRUG|Deucravacitinib|As prescribed by treating clinician
58090338|NCT00213629|OTHER|transcriptome analysis|transcriptome analysis from muscle biopsy
58090339|NCT00213629|OTHER|T cell repertoire analysis|blood T cell repertoire analysis
58090340|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
58304733|NCT01382550|DRUG|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
58417167|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
58417168|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
58417169|NCT00106600|DRUG|Pixantrone IV infusion|
58417170|NCT02994368|OTHER|Observation|
58417171|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
58417172|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
58417173|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
58417174|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
58417175|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
58417176|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
58417177|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
58417178|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
58417179|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
57734147|NCT01432119|DRUG|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
57734148|NCT01432119|PROCEDURE|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
57734149|NCT04440553|BEHAVIORAL|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
57734150|NCT04440553|BEHAVIORAL|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
57734151|NCT06569056|DRUG|HRS-8427|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
58090341|NCT03259646|BEHAVIORAL|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
58090342|NCT03190707|BEHAVIORAL|Intervention|"1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed."
58090343|NCT04874311|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
58304734|NCT01764841|DRUG|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
57734152|NCT06569056|DRUG|Imipenem and Cilastatin Sodium|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
58090344|NCT04874311|DRUG|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
58304735|NCT01764841|DRUG|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
58417180|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
58417181|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
58417182|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
58417183|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
58417184|NCT01310959|OTHER|Database|Database
58417185|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
58417186|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
58417187|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
58417188|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
58417189|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
58417190|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
58417191|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
58417192|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
58417193|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
58417194|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
58417195|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
58417196|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
58417197|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
58417198|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
58417199|NCT01727011|RADIATION|IPAS|
58417200|NCT00025116|DRUG|gefitinib|
57734153|NCT06569056|DRUG|HRS-8427 placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
57734154|NCT06569056|DRUG|Imipenem and Cilastatin Sodium placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
57734155|NCT04625543|DRUG|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
58090345|NCT03584035|BEHAVIORAL|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
58090346|NCT03584035|BEHAVIORAL|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
58090347|NCT06115707|OTHER|The lying flat (0°-10°) head position for 72 hours|The lying flat (0°-10°) head position for 72 hours after endovascular therapy.
57734156|NCT04625543|DRUG|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
58090348|NCT06115707|OTHER|The The head elevation (30°-40°) position for 72 hours|The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
58090349|NCT03356834|DRUG|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
58090350|NCT03356834|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
58090351|NCT01518465|DRUG|dalteparin|Given SC
58090352|NCT01518465|DRUG|lenalidomide|Given PO
58090353|NCT01518465|DRUG|dexamethasone|Given PO
58090354|NCT01518465|OTHER|laboratory biomarker analysis|Correlative studies
58090355|NCT04918095|DEVICE|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
58090356|NCT01418534|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
58090357|NCT02705417|PROCEDURE|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
58090358|NCT02705417|PROCEDURE|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
58090359|NCT02705417|PROCEDURE|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
58090360|NCT02705417|PROCEDURE|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
58090361|NCT02705417|PROCEDURE|arteriovenous graft placement|surgical placement of arteriovenous graft
58090362|NCT04779242|DRUG|Omadacycline|IV for injection, oral tablets
58417201|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
58417202|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
58417203|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
57734157|NCT03900260|DEVICE|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
57734158|NCT05457608|DEVICE|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
57734159|NCT05457608|DEVICE|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
57734160|NCT06486753|PROCEDURE|Chevron osteotomy bunion surgery with lateral soft tissue release|Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
57734161|NCT02421614|OTHER|high-protein low-carbohydrate diet with high olive oil|
58090363|NCT04779242|DRUG|Moxifloxacin|IV solution, oral tablets
58090364|NCT05438199|DEVICE|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
58090365|NCT02141438|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
58090366|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
58090367|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
58090368|NCT03125707|OTHER|Registry study|
58090369|NCT05891496|DRUG|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
58090370|NCT05891496|DRUG|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
58304736|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
58304737|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
58304738|NCT03894358|DIETARY_SUPPLEMENT|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
58304739|NCT04142333|GENETIC|GIA|Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
58304740|NCT04854239|PROCEDURE|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
58304741|NCT04149340|DRUG|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
58304742|NCT02291978|DEVICE|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
58304743|NCT03225365|BIOLOGICAL|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
58304744|NCT00603031|OTHER|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
58304745|NCT00603031|OTHER|NaCl|infusion with NaCl for 120 minutes as placebo-arm
58304746|NCT00603031|OTHER|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
58304747|NCT03530891|PROCEDURE|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
58304748|NCT03530891|PROCEDURE|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
58304749|NCT01332825|OTHER|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
58304750|NCT01057836|BEHAVIORAL|Neck endurance training|
58417204|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
58417205|NCT03211026|OTHER|No intervention|No intervention
58417206|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
58417207|NCT05323123|BEHAVIORAL|PrEP Romania|Enrolled participants will receive PrEP education and adherence counseling from trained counselors, and have a medical evaluation from a physician, who will prescribe PrEP.
57734162|NCT02421614|OTHER|high-protein low-carbohydrate diet with high sunflower oil|
58090371|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
58090372|NCT04243005|PROCEDURE|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
58090373|NCT04243005|PROCEDURE|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
58304751|NCT01057836|BEHAVIORAL|Stretching|
58304752|NCT06088589|BEHAVIORAL|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
58304753|NCT01095172|DRUG|Rituximab|375mg/m\^2, single dose given 2-4 weeks prior to transplantation
58304754|NCT01095172|DRUG|Tacrolimus|dose calculated to give levels of 3-7ng/ml
58304755|NCT01095172|DRUG|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
58304756|NCT01095172|DRUG|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
58304757|NCT01095172|DRUG|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
58304758|NCT01095172|DRUG|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
58417208|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
58304759|NCT04680832|DIAGNOSTIC_TEST|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
58417209|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
58304760|NCT00800046|DEVICE|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
58304761|NCT01334086|DRUG|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
58304762|NCT04119934|BEHAVIORAL|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
58304763|NCT00176449|DRUG|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
58304764|NCT00176449|DRUG|Placebo Oral Tablet|Comparable placebo
58304765|NCT02344823|DRUG|Vardenafil|per oral intake of 10mg Vardenafil once daily
58417210|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
58417211|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
58417212|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
58417213|NCT02680210|OTHER|Questionnaires and cognitive measures|
58417214|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
58417215|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
58417216|NCT00892203|DRUG|BGG492|
58417217|NCT00892203|DRUG|Sumatriptan|
58304766|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
58304767|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
58304768|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
58304769|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
58304770|NCT02344823|DRUG|Placebo intake once daily|
58304771|NCT03289338|DRUG|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
58304772|NCT03289338|DRUG|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
58304773|NCT03289338|DRUG|Placebos|Normal saline intravenous once a month for 3 months
58304774|NCT02697071|DRUG|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
58304775|NCT02697071|DRUG|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
58304776|NCT01286129|PROCEDURE|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
58304777|NCT00072111|BIOLOGICAL|anakinra|
58304778|NCT01408706|DEVICE|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
58417218|NCT00892203|DRUG|Placebo|
58417219|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
58417220|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
58417221|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
58417222|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
58417223|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
58090374|NCT04469322|DIAGNOSTIC_TEST|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
58090375|NCT04469322|DIAGNOSTIC_TEST|Sham Test|"Names of 53 medications listed with use as directed"
58090376|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy|"Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;"
58090377|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based.
58090378|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy|"Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller."
58090379|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based
58090380|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
57734163|NCT02352558|DRUG|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
58090381|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
58090382|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
58090383|NCT03785652|DRUG|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
57734164|NCT02352558|DRUG|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
57734165|NCT02352558|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
58090384|NCT03785652|DRUG|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
58090385|NCT03785652|DRUG|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
58090386|NCT03785652|DRUG|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
58090387|NCT03785652|DRUG|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
58304779|NCT01408706|DEVICE|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
58304780|NCT04135404|OTHER|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
58304781|NCT04545073|DEVICE|PanOptix|Trifocal IOL with ORA in post refractive patients
58304782|NCT00986414|DRUG|AFQ056|
58304783|NCT00986414|DRUG|AFQ056|
58090388|NCT00903409|DRUG|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
58090389|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
58090390|NCT03465072|OTHER|Exercise training|8 weeks, 3 times per week, 30-40 minutes
58090391|NCT02484131|BEHAVIORAL|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
58304784|NCT00986414|DRUG|AFQ056|
58304785|NCT00986414|DRUG|AFQ056|
58304786|NCT00986414|DRUG|AFQ056|
58304787|NCT00986414|DRUG|Placebo|
58090392|NCT02484131|BEHAVIORAL|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
58417224|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
58417225|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
58417226|NCT00272324|DRUG|Aspirin|
58417227|NCT00272324|DRUG|Folate|
58417228|NCT01167868|DRUG|FosD|oral tablet
58417229|NCT01167868|DRUG|Placebo|oral tablet
57734166|NCT02352558|DRUG|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
57734167|NCT02352558|DRUG|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
58090393|NCT04356196|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
58090394|NCT04356196|DRUG|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
58090395|NCT04356196|DRUG|Placebo oral tablet|Placebo oral tablet
58090396|NCT06565377|BEHAVIORAL|Multimodal biopsychosocial teleprehabilitation|"Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet."
58090397|NCT06565377|OTHER|Best-evidence prehabilitation advice|Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
58090398|NCT00518011|DRUG|Erlotinib|150 mg po daily
58090399|NCT00518011|DRUG|Gemcitabine|As prescribed
58090400|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
58304788|NCT00975728|DIETARY_SUPPLEMENT|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
58304789|NCT04285463|DIAGNOSTIC_TEST|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
58304790|NCT02423226|PROCEDURE|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
58304791|NCT02423226|DRUG|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
58304792|NCT05444790|DIAGNOSTIC_TEST|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
58304793|NCT00163059|DRUG|NMDA Antagonist, CP-101,606 (traxoprodil)|
58304794|NCT00111761|DRUG|Irinotecan|Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
58417230|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
58417231|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
58417232|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
58090401|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
57734168|NCT04207190|DRUG|Gemtuzumab Ozogamicin|Given IV
58090402|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
58090403|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
58090404|NCT06098131|OTHER|Neurodynamic|Neurodynamic Slider and Tensioner Technique
58090405|NCT04574037|OTHER|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
58090406|NCT03889925|DRUG|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
58090407|NCT03889925|BIOLOGICAL|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
58090408|NCT04522271|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
58090409|NCT04522271|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
58090410|NCT04640701|OTHER||
58090411|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
58090412|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
58090413|NCT06561334|PROCEDURE|Botulinum toxin injections|Botulinum toxin injection to ease spasms of vocal cord
58090414|NCT06124534|DEVICE|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
58090415|NCT06537531|OTHER|Compare VCI scale|Compare VCI scale
58090416|NCT03992261|DRUG|Halobetasol Topical Foam|Foam
58090417|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
58090418|NCT06627894|BEHAVIORAL|Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression|Good Days Ahead (MindStreet, Inc.)
58090419|NCT06627894|BEHAVIORAL|Active Control|Depression education, symptom monitoring, and standard depression care
58090420|NCT03026842|DRUG|Decitabine|20 mg/m2/day for 5 days
58090421|NCT03026842|DRUG|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
58090422|NCT03026842|DRUG|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
57734169|NCT04207190|OTHER|Quality-of-Life Assessment|Ancillary studies
58090423|NCT03026842|DRUG|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
58090424|NCT05026749|DRUG|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
58090425|NCT05026749|OTHER|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
58090426|NCT06409325|DEVICE|MST|MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
58090427|NCT06409325|DEVICE|ECT|The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
58090428|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
58090429|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
58090430|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
58090431|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
58090432|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
58090433|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
58090434|NCT01301378|PROCEDURE|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
58090435|NCT03925116|OTHER|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
57734170|NCT04207190|OTHER|Questionnaire Administration|Ancillary studies
57734171|NCT04207190|DRUG|Talazoparib|Given PO
57734172|NCT04207190|DRUG|Talazoparib Tosylate|Given PO
58090436|NCT02815540|PROCEDURE|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
58090437|NCT02815540|DRUG|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
58090438|NCT02694393|DRUG|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
58090439|NCT01953731|DRUG|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
58090440|NCT01953731|DRUG|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
58090441|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
58090442|NCT01002118|DRUG|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
58090443|NCT01002118|DRUG|Placebo|4 capsules each day for 16 weeks
58090444|NCT04062643|DIAGNOSTIC_TEST|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
58090445|NCT01923961|PROCEDURE|HDF NaCl|
58090446|NCT01923961|PROCEDURE|Hemodialysis|
58090447|NCT01923961|PROCEDURE|Standard Predilution Hemodiafiltration|
58090448|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
58304795|NCT00111761|BIOLOGICAL|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
58417233|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
58417234|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
58417235|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
58417236|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
58417237|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
58417238|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
58417239|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
58417240|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
58417241|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
58417242|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
58417243|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
58417244|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
58090449|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
58090450|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
58090451|NCT02152930|DRUG|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
58304796|NCT00111761|DRUG|5-Fluorouracil|Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
58304797|NCT00111761|DRUG|Leucovorin|Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
58304798|NCT04599231|DIAGNOSTIC_TEST|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
58417245|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
58090452|NCT01248000|PROCEDURE|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
58090453|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
58090454|NCT05927207|OTHER|TRIP|TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
58090455|NCT04469465|DRUG|Danicopan|Oral tablet
58090456|NCT04469465|DRUG|Placebo|Oral tablet
58090457|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
58090458|NCT06650293|DRUG|Vitamin D|Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
58090459|NCT06523400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
58090460|NCT06523400|DRUG|Placebo|Matching Placebo
58090461|NCT06652347|OTHER|Cancer care delivery|Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
58090462|NCT03004963|DEVICE|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
58304799|NCT03504800|DEVICE|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
58304800|NCT02337062|DRUG|APD421|
57734173|NCT05804877|BEHAVIORAL|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
58090463|NCT03004963|DEVICE|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
58090464|NCT03956901|OTHER|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
58090465|NCT06346197|DRUG|Balstilimab|Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
58090466|NCT06346197|DRUG|Botensilimab|Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
58090467|NCT06346197|DRUG|Folfox Protocol|oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
58090468|NCT06346197|DRUG|XELOX|Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
58090469|NCT06346197|DRUG|Nivolumab|240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
58090470|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
58304801|NCT02337062|DRUG|Placebo|
58304802|NCT00134134|DRUG|efalizumab|
58304803|NCT03636399|BEHAVIORAL|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
58304804|NCT03636399|BEHAVIORAL|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
58304805|NCT00121004|BEHAVIORAL|Advance Directive Selection|
58304806|NCT05656196|OTHER|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
58304807|NCT02402517|OTHER|Control|Non pulse extruded snack
58304808|NCT02402517|OTHER|Small particle size pea flour|Pulse extruded snack
58304809|NCT02402517|OTHER|Large particle size pea flour|Pulse extruded snack
58304810|NCT02402517|OTHER|Lentil flour|Pulse extruded snack
58304811|NCT02402517|OTHER|Navy bean flour|Pulse extruded snack
58304812|NCT02402517|OTHER|Pinto bean flour|Pulse extruded snack
58304813|NCT04976816|PROCEDURE|peri-levator betamethasone injection|The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
58304814|NCT04976816|PROCEDURE|peri-levator triamcinolone injection|The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
58417246|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
58417247|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
58417248|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
58417249|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
58417250|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
58417251|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
58417252|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
58417253|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
58417254|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
58417255|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
58417256|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
58417257|NCT01680627|BEHAVIORAL|CASI|
58417258|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
58417259|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
58417260|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
58417261|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
58417262|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
58417263|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
58417264|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
57734174|NCT05804877|OTHER|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
58417265|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
58417266|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
58417267|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
58417268|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
58417269|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
58417270|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
58417271|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
58417272|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
58417273|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
57734175|NCT01270451|OTHER|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
58417274|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
58417275|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
58417276|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
58417277|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
58417278|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
58417279|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
58090471|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
58090472|NCT01700907|DRUG|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
58090473|NCT01700907|DRUG|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
58090474|NCT02350439|DRUG|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
58090475|NCT05553028|PROCEDURE|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
58090476|NCT06696534|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
58090477|NCT06696534|OTHER|Survey using a questionnaire.|Experience questionnaire into colorectal cancer screening programme
58090478|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
58090479|NCT01487018|PROCEDURE|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
58090480|NCT01487018|PROCEDURE|Traditional Surgery|To compare with the experamental group.
58090481|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
58090482|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
58304815|NCT04976816|PROCEDURE|peri-levator and retrobulbar betamethasone injection|In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
58304816|NCT04976816|PROCEDURE|peri-levator and retrobulbar triamcinolone injection|In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
58304817|NCT02172976|DRUG|Gemcitabine|
58304818|NCT02172976|DRUG|Oxaliplatin|
58304819|NCT02172976|DRUG|5-Fluorouracil|
58304820|NCT02172976|DRUG|Irinotecan|
58304821|NCT02172976|DRUG|Natriumfolinate|
58304822|NCT04522219|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
58304823|NCT03158207|DEVICE|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
58417280|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
58417281|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
58304824|NCT03158207|OTHER|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
58417282|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
58417283|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
58417284|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
58417285|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
57949400|NCT02434848|DRUG|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
58090483|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
58090484|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
58090485|NCT02989259|DRUG|Apatinib|apatinib 500mg p.o. qd
58090486|NCT03449420|DIAGNOSTIC_TEST|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
58090487|NCT00632476|OTHER|Placebo|Placebo capsule once a day
58090488|NCT00632476|DIETARY_SUPPLEMENT|Vitamin C|A 500-mg vitamin C capsule once a day
58090489|NCT03701516|DEVICE|etafilcon A with novel molding process|TEST Lens
58090490|NCT03701516|DEVICE|etafilcon A with current molding process|CONTROL Lens
58090491|NCT00958698|OTHER|Communication Intervention|Ancillary studies
58090492|NCT00958698|OTHER|Educational Intervention|Ancillary studies
58090493|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
58090494|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
58090495|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
58090496|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
58417286|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
58417287|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
58090497|NCT03347786|DRUG|Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure
58090498|NCT05071235|DEVICE|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
58417288|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
58417289|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
58417290|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
58417291|NCT03033953|DIETARY_SUPPLEMENT|Milk|
58417292|NCT03033953|OTHER|Strength training|
58417293|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
58417294|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
57949401|NCT03448250|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
57949402|NCT03448250|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
57949403|NCT01356082|DEVICE|CNAP|Non-invasive blood pressure monitor
58090499|NCT05071235|DEVICE|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
58090500|NCT05071235|DEVICE|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
58090501|NCT05071235|DEVICE|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
58090502|NCT05071235|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
58090503|NCT04167839|OTHER|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
58090504|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
58090505|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
58090506|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
58090507|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
58090508|NCT06566222|PROCEDURE|chemoradiotherapy after surgery|chemoradiotherapy after surgery vs preoperative chemoradiotherapy
58090509|NCT06566222|OTHER|High-risk Factors|High-risk Factors vs low-risk Factors
58090510|NCT05343247|DIAGNOSTIC_TEST|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
58090511|NCT05343247|DIAGNOSTIC_TEST|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
58090512|NCT00396318|DRUG|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
58090513|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
57949404|NCT04549870|DRUG|Roflumilast|Treatment according to national roflumilast guidelines
57949405|NCT05776836|DEVICE|Dermal filler|Subjects will be consecutively included to receive FASY F in nasolabial folds and cheeks and FASY P in periorbital areas.
57949406|NCT00081237|DRUG|OSI-7904L|
57949407|NCT00081237|DRUG|oxaliplatin|
57949408|NCT02247895|DEVICE|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
57949409|NCT02247895|DEVICE|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
57949410|NCT01087905|DRUG|Nicotine patch|"If \> 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day"
57949411|NCT01087905|DRUG|Nicotine gum|"If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
57949412|NCT01087905|BEHAVIORAL|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
57949413|NCT03058042|OTHER|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
57949414|NCT03058042|OTHER|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
58090514|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
58304825|NCT02776566|OTHER|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
58304826|NCT06435013|DRUG|Lenvatinib|Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
58304827|NCT02121197|DRUG|Ozurdex|
58304828|NCT01213381|DRUG|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
58304829|NCT01213381|DRUG|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
58304830|NCT01213381|DRUG|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
58304831|NCT04593381|RADIATION|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
58304832|NCT05938712|DRUG|Dapagliflozin 10 MG|Semaglutide subcutaneous once weekly for 12 weeks.
58304833|NCT05938712|DRUG|Semaglutide, 1.0 mg/mL|Dapagliflozin oral once daily for 12 weeks.
58304834|NCT05194514|DEVICE|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
58304835|NCT05194514|OTHER|Cold Storage|FDA-approved method for organ procurement
57949415|NCT03930719|DIAGNOSTIC_TEST|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
57949416|NCT02587650|DRUG|Capmatinib|Given PO
57949417|NCT02587650|DRUG|Ceritinib|Given PO
57949418|NCT02587650|DRUG|Entrectinib|Given PO
57949419|NCT02587650|OTHER|Laboratory Biomarker Analysis|Correlative studies
57949420|NCT02587650|DRUG|Regorafenib|Given PO
57949421|NCT02345954|PROCEDURE|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
58090515|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
58090516|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
58090517|NCT06347549|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|"Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest."
58090518|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
58090519|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
58090520|NCT00742859|DRUG|betrixaban|orally, once daily for at least 3 months
58304836|NCT05283434|DRUG|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
58304837|NCT05283434|DRUG|Placebo|Sugar pill placebo
58304838|NCT01542762|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
58304839|NCT05415293|DIETARY_SUPPLEMENT|Expecta 200mg DHA|
58304840|NCT05415293|DIETARY_SUPPLEMENT|Promise 275mg DHA|
58304841|NCT03294642|DIETARY_SUPPLEMENT|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
58090521|NCT00742859|DRUG|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
58304842|NCT03294642|DIETARY_SUPPLEMENT|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
58304843|NCT03294642|DIETARY_SUPPLEMENT|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
58304844|NCT05944835|OTHER|Analyzed on the post-operative scanner|Analyzed on the post-operative scanner
58304845|NCT03019848|DIETARY_SUPPLEMENT|Curcumin|
58304846|NCT03019848|OTHER|Placebo|
58304847|NCT01441986|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
58304848|NCT01441986|DRUG|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
58304849|NCT01441986|DRUG|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
58304850|NCT01441986|DRUG|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
58304851|NCT02941315|DRUG|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
58304852|NCT02941315|DRUG|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
58304853|NCT02941315|DRUG|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
58304854|NCT02941315|DRUG|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
58304855|NCT02079662|OTHER|Behavioral, Psychological or Informational Intervention|Undergo IO intervention
58304856|NCT02079662|OTHER|Best Practice|Undergo standard of care
58304857|NCT02079662|OTHER|Cognitive Intervention|Undergo IO intervention
58304858|NCT02079662|OTHER|Computer-Assisted Intervention|Undergo IO intervention
58304859|NCT02079662|OTHER|Counseling|Undergo counseling
58304860|NCT02079662|BEHAVIORAL|Exercise Intervention|Undergo IO intervention
57949422|NCT02345954|PROCEDURE|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
57949423|NCT00074321|DRUG|irinotecan hydrochloride|Given IV
57949424|NCT00074321|DRUG|oxaliplatin|Given IV
57949425|NCT00074321|DRUG|capecitabine|Given PO
57949426|NCT00074321|OTHER|laboratory biomarker analysis|Correlative studies
58304861|NCT02079662|OTHER|Laboratory Biomarker Analysis|Correlative studies
58304862|NCT02079662|OTHER|Quality-of-Life Assessment|Ancillary studies
58304863|NCT02079662|OTHER|Questionnaire Administration|Ancillary studies
58090522|NCT04762771|DRUG|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
57734176|NCT03830034|DRUG|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
57949427|NCT00074321|OTHER|pharmacological study|Correlative studies
58090523|NCT02566967|DRUG|tofacitinib|oral tofacitinib will be taken 2 times daily
58090524|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
58090525|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
58090526|NCT01570998|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
58090527|NCT01570998|OTHER|Laboratory Biomarker Analysis|Correlative studies
58090528|NCT03778190|PROCEDURE|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
58090529|NCT00090337|PROCEDURE|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
58090530|NCT00090337|PROCEDURE|standard follow-up care|Patients undergo standard care
57734177|NCT03830034|DRUG|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
58090531|NCT06218030|DRUG|L-methylfolate|Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
58090532|NCT00447694|DRUG|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
58090533|NCT06652048|DRUG|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
57734178|NCT01054820|DRUG|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
57734179|NCT01333124|RADIATION|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
57734180|NCT01333124|RADIATION|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
57734181|NCT03546244|BEHAVIORAL|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
57734182|NCT03546244|BEHAVIORAL|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
57734183|NCT05805397|BEHAVIORAL|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
57734184|NCT05805397|BEHAVIORAL|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
57734185|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
57734186|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
57949428|NCT03080844|BEHAVIORAL|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
57949429|NCT03080844|BEHAVIORAL|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
58090534|NCT06652048|DRUG|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
58090535|NCT06652048|DRUG|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
58090536|NCT04803773|DEVICE|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
58417295|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
58417296|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
58417297|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
58417298|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
58417299|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
58090537|NCT06346756|OTHER|Treatment of dental caries.|The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
58090538|NCT06236334|BEHAVIORAL|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
58090539|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
58090540|NCT02556528|BEHAVIORAL|Health Coaching|
58417300|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
58417301|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
58417302|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
58417303|NCT03449433|DRUG|LY900014|Administered SC
58417304|NCT03449433|DRUG|Insulin Lispro|Administered SC
58417305|NCT03449433|DRUG|Insulin Aspart|Administered SC
58417306|NCT03449433|DRUG|Insulin Aspart|Administered SC
58417307|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
58417308|NCT00003847|DRUG|biricodar dicitrate|
58090541|NCT02079389|DEVICE|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
58417309|NCT00003847|DRUG|doxorubicin hydrochloride|
58417310|NCT00003847|DRUG|vincristine sulfate|
58090542|NCT06574997|DRUG|OCU400|Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
58090543|NCT06248671|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
58090544|NCT06248671|DRUG|Placebo|Each tablet will be taken once daily for 84 days
58090545|NCT06248671|DRUG|Atorvastatin 20mg|Each tablet will be taken once daily for 84 days.
58417311|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
58417312|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
58417313|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
58417314|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
58417315|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
58417316|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
58417317|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
58417318|NCT02973191|DRUG|JCAR015|
58417319|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
58417320|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
58417321|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
58417322|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
58417323|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
58417324|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
58417325|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
58417326|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
58417327|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
58417328|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
58417329|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
58417330|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
58417331|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
58417332|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
58417333|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
58417334|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
58417335|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
58417336|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
58417337|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
58417338|NCT05886530|OTHER|No intervention|Observational data collection only.
57949430|NCT05916027|BEHAVIORAL|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
58090546|NCT06410859|DRUG|"Botulinum Toxin Type A for Injection,also known as HengLi®"|This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
58417339|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
58417340|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
58090547|NCT05681104|DIAGNOSTIC_TEST|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
58417341|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
58090548|NCT05681104|DIAGNOSTIC_TEST|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
58417342|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
58417343|NCT00239954|DRUG|Escitalopram|
58417344|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
58417345|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
58417346|NCT03418558|DRUG|Trastuzumab emtansine|
58417347|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
58417348|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
58417349|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
58417350|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
58417351|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
57949431|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-experimental treatment
58417352|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
58417353|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
57949432|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-placebo
58417354|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
58417355|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
58417356|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
58417357|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
58417358|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
58417359|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
58417360|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
58417361|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
58417362|NCT01007422|BEHAVIORAL|telephone-based intervention|
57949433|NCT03061175|OTHER|Internet-Based Intervention|Receive web-based CPM-DA
58417363|NCT01007422|OTHER|communication intervention|
58417364|NCT01007422|OTHER|intervention by caregiver|
58417365|NCT01007422|OTHER|medical chart review|
57949434|NCT03061175|OTHER|Survey Administration|Ancillary studies
57949435|NCT03957772|PROCEDURE|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
58090549|NCT05681104|DIAGNOSTIC_TEST|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
58417366|NCT01007422|OTHER|survey administration|
57734187|NCT02573519|RADIATION|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
57734188|NCT02573519|DEVICE|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data"
57949436|NCT03957772|PROCEDURE|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
57949437|NCT01471782|BIOLOGICAL|Blinatumomab|Administered by continuous intravenous infusion
57949438|NCT06199609|PROCEDURE|Hemodialysis pathway|AVF and TCC are two different vascular pathways for hemodialysis
57949439|NCT06199609|PROCEDURE|AVF|Left atrial changes caused by AVF establishment
57949440|NCT06199609|PROCEDURE|AVF|New onset atrial fibrillation caused by AVF establishment
58090550|NCT03348501|OTHER|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
58090551|NCT06567665|DIETARY_SUPPLEMENT|Leucine|Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
58304864|NCT04549181|BEHAVIORAL|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
58304865|NCT04588974|DEVICE|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
58304866|NCT03490617|DRUG|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
58417367|NCT01007422|PROCEDURE|end-of-life treatment/management|
57949441|NCT02267694|DRUG|Freeze-dried black raspberry powder|
57949442|NCT03295162|DRUG|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
58417368|NCT01007422|PROCEDURE|pain therapy|
58417369|NCT01007422|PROCEDURE|psychosocial assessment and care|
58090552|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
58090553|NCT01527786|DRUG|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
58417370|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
57949443|NCT03295162|COMBINATION_PRODUCT|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
57949444|NCT00177775|DRUG|MucoMilk product|
58090554|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
58090555|NCT01327989|DEVICE|Solitaire™ FR device|Mechanical Thrombectomy
58417371|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
58417372|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
58417373|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
58417374|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
58417375|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
58417376|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
58417377|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
58417378|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
58417379|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
58417380|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
58417381|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
58417382|NCT02794389|DRUG|N-acetyl cysteine|
58417383|NCT02794389|DRUG|Placebo|
58090556|NCT04051840|DRUG|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
58090557|NCT03246321|COMBINATION_PRODUCT|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
58090558|NCT03883789|DIAGNOSTIC_TEST|FibroScan|FibroScan will be used to assess liver stiffness
58304867|NCT04015739|DRUG|Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination|"Patients will receive a combination of these 3 drugs :~Bevacizumab 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w"
58417384|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
58417385|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
58417386|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
58417387|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
58417388|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
58417389|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
58417390|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
58417391|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
57949445|NCT04227509|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
57949446|NCT04227509|DRUG|Placebo|normal saline will be administered as a 30 minute IV infusion every 3 weeks.
57949447|NCT01664559|DRUG|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
57949448|NCT01664559|DRUG|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
57949449|NCT06496282|DRUG|Lemborexant|The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
58417392|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
58417393|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
58417394|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
58417395|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
58417396|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
58090559|NCT03107442|BEHAVIORAL|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
58090560|NCT05501002|DEVICE|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
58090561|NCT03310606|OTHER|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
58417397|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
58417398|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
58417399|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
58417400|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
58417401|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
58417402|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
58417403|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
58417404|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
58417405|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
58417406|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
58090562|NCT03112707|DRUG|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
58417407|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
58417408|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
58417409|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
58090563|NCT03112707|DRUG|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
58090564|NCT01224418|DRUG|Tacrolimus|oral
58090565|NCT00265239|DRUG|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
58090566|NCT06389240|OTHER|6 weeks post-operatively early weight bearing|Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
58304868|NCT05866913|PROCEDURE|Sciatic nerve slippage.|Sciatic nerve slippage.
58417410|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
58417411|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
58417412|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
58417413|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
58304869|NCT05866913|PROCEDURE|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
58090567|NCT06389240|OTHER|10 weeks post-operatively weight bearing (standard of care)|Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
58090568|NCT00638118|DRUG|Fexofenadine|
58090569|NCT05770219|DRUG|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
58090570|NCT04256135|OTHER|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
58090571|NCT04256135|OTHER|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
58090572|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
58417414|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
58417415|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
58417416|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
58417417|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
58417418|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
58417419|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
58417420|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
58417421|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
58417422|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
58090573|NCT01591902|DRUG|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
58090574|NCT01591902|DRUG|Placebo-Control|3.0 mL vials
58090575|NCT05559242|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
58304870|NCT05866913|PROCEDURE|passive shoulder mobilization.|passive shoulder mobilization.
58304871|NCT02481050|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
58417423|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
58417424|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
58417425|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
58417426|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
58417427|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
58417428|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
58090576|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
58090577|NCT01807780|BIOLOGICAL|biological monitoring|
58090578|NCT00363428|BEHAVIORAL|exercise intervention|life style
58090579|NCT00363428|BEHAVIORAL|smoking cessation intervention|Life style
58090580|NCT00363428|OTHER|counseling intervention|life style
58090581|NCT00363428|OTHER|educational intervention|life style
58090582|NCT00363428|PROCEDURE|conventional surgery|life style
58090583|NCT00363428|PROCEDURE|pulmonary complications management/prevention|life style
58090584|NCT00241319|DRUG|R89674 (generic name not yet established)|
58090585|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
58090586|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
58090587|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
58304872|NCT01583881|PROCEDURE|renal denervation|Renal denervation
58304873|NCT00584389|DRUG|rimonabant|20mg/d (oral) once daily for 12 weeks
58417429|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
58417430|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
58417431|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
58417432|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
58417433|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
58417434|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
58417435|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
58417436|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
58417437|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
58417438|NCT02598128|DEVICE|Placebo|Sham device
57949450|NCT06496282|DRUG|Placebo|The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
57949451|NCT01173224|DRUG|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
58417439|NCT02973776|DRUG|LEO 90100 aerosol foam|
58417440|NCT02973776|DRUG|Dermoval®/Dermovate®|
57949452|NCT01173224|DRUG|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
58417441|NCT02973776|DRUG|Diprosone|
58417442|NCT02973776|DRUG|Elocon|
58417443|NCT02973776|DRUG|Locoid|
58417444|NCT02973776|OTHER|LEO 90100 foam vehicle|
58090588|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
58090589|NCT03540446|DEVICE|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
58090590|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
58090591|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
58090592|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
58090593|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
58090594|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
58090595|NCT03872622|OTHER|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
58090596|NCT03507608|DRUG|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
58090597|NCT03507608|OTHER|Placebo|placebo prior to brachytherapy and prostatic biopsy
58090598|NCT04361552|OTHER|Best Practice|Receive standard of care
58090599|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
58304874|NCT00584389|BEHAVIORAL|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
57949453|NCT00823823|OTHER|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
57949454|NCT00823823|OTHER|Circumferential cast|Circumferential cast will be applied following closed reduction
58090600|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
58090601|NCT06565520|DEVICE|transcranial direct current stimulator|"The total amount of participation time per qualified subject will be approximately 150 minutes over two sessions. The participant screening session will take approximately 30 minutes, which is an appropriate amount of time to complete all screening tasks. The tDCS and sham sessions will take approximately a total of 120 minutes over two sessions.~The first session will include a screening (30 minutes) to ensure they qualify for the study, followed by a treatment session (60 minutes): including non-invasive brain stimulation combined with hip strengthening exercises and functional movement testing at UNLV Maryland Campus. Subjects will return for a second treatment session (60 minutes) 2 weeks after the first."
58090602|NCT04736576|DEVICE|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
58090603|NCT02393066|DRUG|Propofol|Sedation
58090604|NCT02393066|DRUG|Dexmedetomidine|Sedation
57949455|NCT03527121|OTHER|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
58090605|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
58090606|NCT02015286|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
58090607|NCT06700902|BEHAVIORAL|Taking Action|Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
58090608|NCT01033175|PROCEDURE|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
58090609|NCT01033175|PROCEDURE|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
58090610|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
58090611|NCT03829020|DRUG|Bortezomib|Given SC
58090612|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
58090613|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
58090614|NCT03022799|DRUG|KM-819|
58090615|NCT03022799|DRUG|Placebo|
58090616|NCT03853980|DEVICE|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
57949456|NCT03527121|OTHER|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
57734189|NCT02573519|DRUG|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
58090617|NCT00836238|BEHAVIORAL|Interview|Physical Function and Symptom Assessment Interviews
58090618|NCT00836238|OTHER|Physical Function Tests|3 physical function tests.
58090619|NCT03823859|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
58417445|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
58417446|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
58417447|NCT02403895|DRUG|paclitaxel|Taxane
58417448|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
58417449|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
58417450|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
58417451|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
58417452|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
58417453|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
58417454|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
57734190|NCT02573519|DEVICE|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
58090620|NCT03823859|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
58417455|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
57734191|NCT04494152|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
57734192|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
57734193|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
57734194|NCT00737087|DEVICE|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
57734195|NCT00433069|DRUG|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
57734196|NCT00433069|DRUG|Interferon Alfa-2a|Standard of care for chronic hepatitis C
58090621|NCT03823859|DIAGNOSTIC_TEST|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
58090622|NCT06703437|DRUG|Dehydrated alcohol|Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
57734197|NCT00433069|DRUG|Ribavirin|Standard of care for chronic hepatitis C
57949457|NCT04995055|DEVICE|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
57949458|NCT04995055|DEVICE|ACUVUE® OASYS Multifocal|CONTROL Lens
58090623|NCT06703437|DRUG|Lidocaine IV|By periprostatic injection, 2mL
58304875|NCT02658266|BEHAVIORAL|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
58417456|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
58417457|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
58417458|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
58417459|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
58090624|NCT06529250|DRUG|HAD|"Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
58417460|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
58417461|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
58417462|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
58417463|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
58417464|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
58417465|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
58417466|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
57734198|NCT06670911|DRUG|Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)|Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
58417467|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
58417468|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
58417469|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
58417470|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
58417471|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
58417472|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
58417473|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
58417474|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
58417475|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
58417476|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
58417477|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
58417478|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
57949459|NCT03479996|DRUG|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
57949460|NCT03489408|DEVICE|Conventus Cage™ PH|Proximal humeral fracture fixation
57949461|NCT01810185|DRUG|Low dose naltrexone|4.5 mg daily for 12 weeeks
58304876|NCT03531866|BEHAVIORAL|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
58417479|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
58417480|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
58417481|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
58417482|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
58417483|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
58417484|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
57734199|NCT06669182|DEVICE|Intermittent Theta-Burst Transcranial Magnetic Stimulation|50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.
58304877|NCT05267210|OTHER|Questionnaire|"1. Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~2. Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
58304878|NCT00706004|DRUG|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
58304879|NCT03122171|OTHER|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
58304880|NCT04483414|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
58304881|NCT04483414|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
58304882|NCT05041400|OTHER|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
58417485|NCT00657150|DRUG|Enoxaparin|40 mg once daily
58417486|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
58417487|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
57734200|NCT00651508|DRUG|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
57734201|NCT04564833|DRUG|Low Dose RBT-1|intravenous administration
57734202|NCT04564833|DRUG|High Dose RBT-1|intravenous administration
57734203|NCT04564833|DRUG|Placebo|intravenous administration
57734204|NCT03215446|DRUG|maintenance of anaesthesia with propofol|
57734205|NCT03215446|DRUG|maintenance of anaesthesia with sevoflurane|
57949462|NCT01810185|DRUG|Placebo|
58417488|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
58417489|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
58417490|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
58417491|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
58417492|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
58417493|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
58417494|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
58417495|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
58417496|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
58417497|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
57734206|NCT06077227|DEVICE|virtual reality therapy|6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
58304883|NCT06514352|OTHER|Skin contact immediately after birth|In the immediate skin-to-skin contact group after birth, if the newborn does not need any intervention, he will be placed on the mother's chest immediately (without cord clamping) and skin-to-skin contact will begin. An average of 60 minutes of skin contact will be made until the first breastfeeding occurs. All routine practices for the newborn in the delivery room (except weight measurement) will be performed on the mother's chest. (n=48)
58304884|NCT06514352|OTHER|Very Early Skin contact|In the very early skin-to-skin contact group, skin-to-skin contact will begin within the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, and skin-to-skin contact will be carried out for an average of 60 minutes until the first breastfeeding occurs.(n=48)
58304885|NCT06514352|OTHER|Early Skin contact|For newborns who need intervention after birth and whose skin-to-skin contact cannot be started in the delivery room, skin-to-skin contact will begin within the first 24 hours after birth, after the newborn becomes stable.(n=48)
58304886|NCT04321928|BEHAVIORAL|Personalized health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
58304887|NCT04321928|BEHAVIORAL|General health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
58304888|NCT00006152|DRUG|Ritonavir|
58304889|NCT00006152|DRUG|Abacavir sulfate|
58304890|NCT00006152|DRUG|Amprenavir|
58304891|NCT00269724|DRUG|OROS® oxybutynin|
58304892|NCT05588531|DRUG|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
58304893|NCT05588531|DRUG|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
58417498|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
58417499|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
58304894|NCT05588531|DRUG|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
58417500|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
58417501|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
58417502|NCT01314560|OTHER|Blood sample|Blood sample
58417503|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
58417504|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
57949463|NCT02550184|OTHER|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
58090625|NCT06529250|DRUG|Daunorubicin+Cytarabine|"Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
58304895|NCT05588531|DRUG|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
58304896|NCT05588531|DRUG|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
58304897|NCT05588531|DRUG|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
58304898|NCT00267436|BEHAVIORAL|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
58304899|NCT02696824|BEHAVIORAL|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
58304900|NCT04534751|BIOLOGICAL|Fibrinogen + PCC|"Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units)."
57734207|NCT06077227|OTHER|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
57734208|NCT05544799|OTHER|No intervention|No intervension
57949464|NCT01918007|PROCEDURE|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
58090626|NCT02539979|DRUG|Paracetamol|
58090627|NCT02539979|DRUG|Placebo - Normal Saline|Normal Saline 100cc
58090628|NCT04078893|OTHER|telephone recruitment|using telephone to recruit inactive donors on two different methods
58090629|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
58090630|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
58417505|NCT04317157|OTHER|Placebo|Placebo pill.
58417506|NCT02706561|BEHAVIORAL|questionnaires|
58417507|NCT02706561|BEHAVIORAL|three in-person sessions|
58417508|NCT02706561|BEHAVIORAL|monthly phone calls|
58417509|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
58417510|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
58417511|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
58090631|NCT04708782|DRUG|Placebo|Placebo administered QID
58417512|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
58417513|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
58090632|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
57734209|NCT04405700|OTHER|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
58090633|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
58090634|NCT03911882|DIETARY_SUPPLEMENT|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
58304901|NCT04534751|BIOLOGICAL|Frozen Plasma|"4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician."
58417514|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
58417515|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
58417516|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
58417517|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
58417518|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
58304902|NCT06227650|DEVICE|hybrid closed loop insulin delivery system|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
57734210|NCT03800823|BEHAVIORAL|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
58090635|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
58304903|NCT00371735|DRUG|chlorproguanil-dapsone-artesunate|
58304904|NCT00371735|DRUG|chlorproguanil-dapsone|
58417519|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
58417520|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
58417521|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
58417522|NCT00069524|DRUG|oyster mushroom|
58417523|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
58417524|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
58417525|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
58417526|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
58417527|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
58417528|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
58417529|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
58417530|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
58417531|NCT04713618|OTHER|Survey|Complete surveys
58417532|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
58090636|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
58090637|NCT05673915|DEVICE|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
58090638|NCT05673915|DEVICE|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
58090639|NCT06406894|OTHER|Conventional physical therapy|"lower limb muscle stretching ( pelvic bridging, Knee to chest,cat and camel stretch) (30 seconds hold and 3 sets of 5 repetitions with 1 min rest interval in between each set, per session on daily basis for only one week for immediate results and for long term effect on alternate 3 days in remaining 2nd ,3rd week).~Treatment protocol will be given on daily basis to check immediate effect and for long term effect treatment will be given in alternating 3 days for remaining 2 weeks. Total 12 session were given (3 weeks)."
58090640|NCT06406894|OTHER|Superficial back line relaxation (SMIT & CCFE)|Experimental group was given superficial back line relaxation includes SMIT \& CCFE along with conventional therapy includes lower limb muscle stretching. SMIT For short term effect 10-12 repetitions per session, on daily basis for 1st week. For long term effect 10-12 repetitions per session, for 3 alternate days in remaining 2nd\&3rd week. CCFE For short term effect 3 sets of 10 reps , 10 sec hold , 1 min rest after each set, on daily basis for 1st week. For long term effect 3 sets of 10 reps, 10 sec hold , 1 min rest after each set, for 3 alternate days , remaining 2nd \& 3rd week. Conventional therapy lower limb muscle stretching ( For short term effect 30 seconds hold , 3 sets of 5 repetitions , 1 min rest after each set, per session on daily basis for 1st week , for long term effect on alternate 3 days in remaining 2nd ,3rd week). Total 12 sessions were given (3 weeks).
58090641|NCT04671329|DEVICE|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
58090642|NCT01169831|OTHER|Exercise Training|2 weeks of daily aerobic exercise training
58090643|NCT01169831|OTHER|Exercise Cessation|Stopping all exercise for 2 weeks
58090644|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
58090645|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
58417533|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
58090646|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
58090647|NCT03862807|DRUG|Patisiran|Patisiran was administered via IV infusion.
58090648|NCT03296059|OTHER|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
58090649|NCT03296059|OTHER|conventional treatment|neonates is treated with conventional treatment.
58090650|NCT05907044|BIOLOGICAL|RQ3013|0.15mL/dose containing mRNA 30μg
58090651|NCT05907044|BIOLOGICAL|RQ3025|0.15mL/dose containing mRNA 30μg
58090652|NCT05907044|BIOLOGICAL|RQ3027|0.15mL/dose containing mRNA 30μg
58090653|NCT06567730|OTHER|Ni-ti Closed-coil Spring|Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.
58090654|NCT06567730|OTHER|Elastomeric Power chain|Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
58417534|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
58417535|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
58417536|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
58417537|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
58417538|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
58417539|NCT00436254|OTHER|flow cytometry|Correlative studies
58417540|NCT00436254|OTHER|immunologic technique|Correlative studies
58417541|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
58417542|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
58417543|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
58417544|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
58417545|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
58090655|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
58417546|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider
57734211|NCT03800823|BEHAVIORAL|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
57734212|NCT03800823|BEHAVIORAL|Standard care|Standard care for overweight and obesity.
57734213|NCT04837248|OTHER|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
57734214|NCT04837248|OTHER|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
57734215|NCT01893242|DRUG|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
58090656|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
58417547|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
58417548|NCT00093886|DRUG|clevidipine|
58417549|NCT00093886|DRUG|nitroglycerin|
58090657|NCT01155258|DRUG|temsirolimus|Given IV
58090658|NCT01155258|DRUG|vinorelbine ditartrate|Given IV
58417550|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
58417551|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
57734216|NCT01893242|DRUG|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
57734217|NCT03446443|DRUG|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
58090659|NCT05682352|DRUG|LEO 158968|IV infusion or SC injection
58090660|NCT05682352|DRUG|Placebo|IV infusion or SC injection
58090661|NCT05682352|DRUG|LEO 158968|SC injection
58090662|NCT05682352|DRUG|Placebo|SC injection
58090663|NCT03538314|DRUG|UV1|UV1 (300 microgram)
58090664|NCT03538314|DRUG|GM-CSF|GM-CSF (37,5 or 75 microgram)
58090665|NCT01637207|OTHER|Palpation|Group A: Palpation Group
58090666|NCT01637207|OTHER|Ultrasound|Group B: Ultrasound Group
58417552|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
58417553|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
58090667|NCT04708626|OTHER|Description and analysis|Collection of clinical, laboratory and radiological data from medical records.
58304905|NCT03398096|DEVICE|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
58304906|NCT01802385|DRUG|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
58304907|NCT04021966|PROCEDURE|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
58304908|NCT03864081|DEVICE|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
58304909|NCT03821129|DEVICE|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
58304910|NCT01042340|OTHER|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
58304911|NCT05146778|PROCEDURE|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
58304912|NCT05146778|PROCEDURE|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
58304913|NCT02127658|OTHER|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
58417554|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
58304914|NCT02127658|OTHER|Sodium Hypochlorite|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
58304915|NCT02127658|DRUG|Mupirocin ointment|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
58304916|NCT00453375|DRUG|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
58304917|NCT00453375|DRUG|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
58304918|NCT00614510|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
58417555|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
58304919|NCT05577416|PROCEDURE|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
57734218|NCT03446443|DRUG|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
57734219|NCT05051566|DRUG|LY3502970|Administered orally.
58304920|NCT05577416|DRUG|Part A: Safusidenib Erbumine|Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
57734220|NCT05051566|DRUG|Esomeprazole|Administered orally.
58090668|NCT04708626|OTHER|Description and analysis|Collection of laboratory data.
58090669|NCT06219135|OTHER|no intervention - Contamination group|there is no intervention for this group of patients
58417556|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
58417557|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
58417558|NCT01102894|DEVICE|SmartPill|SmartPill
58090670|NCT06219135|BIOLOGICAL|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
58090671|NCT02191930|DRUG|B-CAP|
58090672|NCT02191930|DRUG|Brentuximab Vedotin|
58090673|NCT04924738|BEHAVIORAL|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
58090674|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
58090675|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
58090676|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
58304921|NCT05577416|PROCEDURE|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
57734221|NCT00938873|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
57949465|NCT06248281|OTHER|combination of different rehabilitation strategies|"The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos."
57949466|NCT04509375|DEVICE|Cranial Doppler Ultrasonography|Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.
57949467|NCT04509375|DEVICE|Near-Infrared Spectroscopy|Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
57949468|NCT01589471|DRUG|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
57949469|NCT02012985|BIOLOGICAL|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
57949470|NCT02012985|DRUG|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
58090677|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
58090678|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
58090679|NCT05918952|DIAGNOSTIC_TEST|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
58090680|NCT05918952|OTHER|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
58090681|NCT05655494|BEHAVIORAL|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
58090682|NCT05655494|BEHAVIORAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
58304922|NCT05577416|DRUG|Part B: Safusidenib Erbumine|Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
58304923|NCT02842528|BEHAVIORAL|Diagnostic Interview for Genetic Studies|
58304924|NCT02842528|BEHAVIORAL|Family Informant Schedule and Criteria|
58304925|NCT02842528|BEHAVIORAL|Temperament and Character Inventory|
58304926|NCT02842528|BEHAVIORAL|Barratt Impulsiveness Scale|
58304927|NCT02842528|BEHAVIORAL|Wisconsin Card Sorting Test|
58304928|NCT02842528|GENETIC|blood sample withdrawn|
58304929|NCT01166919|DEVICE|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
58304930|NCT05333211|DRUG|Ortho-R/PRP|Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
58304931|NCT02118285|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion
58304932|NCT02118285|DRUG|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
58417559|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
58090683|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
58090684|NCT02783508|DRUG|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
58090685|NCT02783508|DRUG|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
58090686|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
58090687|NCT05460377|BIOLOGICAL|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
58090688|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
58090689|NCT05460377|BIOLOGICAL|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
58304933|NCT02118285|BIOLOGICAL|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
58304934|NCT02118285|BIOLOGICAL|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
58304935|NCT02118285|DRUG|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
58304936|NCT00368108|DRUG|2 mg perampanel|2 mg perampanel
58417560|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
57949471|NCT04012554|PROCEDURE|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
57949472|NCT04012554|PROCEDURE|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
58090690|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
58090691|NCT03273010|PROCEDURE|Free gingival graft|Free gingival graft was harvested from palatal donor site
58090692|NCT03273010|PROCEDURE|Cyanoacrylate application|Periacyrl was applied on palatal wounds
58090693|NCT05131282|DIAGNOSTIC_TEST|Blood test of PE risk|A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE
58090694|NCT05131282|DIAGNOSTIC_TEST|Blood test of Preterm PE risk|A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE
58090695|NCT03761121|OTHER|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
58090696|NCT03286595|OTHER|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
58090697|NCT04907916|OTHER|SIRTUIN1|The NAD dependent deacetylase activity of Sirtuin1
58090698|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
58304937|NCT00368108|DRUG|4 mg perampanel|4 mg perampanel
58090699|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
58304938|NCT00368108|DRUG|placebo comparator|placebo comparator
58304939|NCT02376686|OTHER|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
58304940|NCT02114021|DRUG|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
58304941|NCT02114021|DRUG|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
58304942|NCT02114021|DRUG|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
58304943|NCT01963702|DRUG|Docetaxol|
57734222|NCT05727605|BEHAVIORAL|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
57734223|NCT05727605|DIAGNOSTIC_TEST|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
57949473|NCT02971462|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
58090700|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
58090701|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
58304944|NCT01963702|DRUG|Oxaliplatin|
58304945|NCT01963702|DRUG|Capecitabine|
58304946|NCT03918265|DRUG|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
58304947|NCT05813756|OTHER|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+\~2.5 months), at the end of the intervention (T2 : T0+\~5 months) and 3 months after the intervention (T3 : T0+\~8 months). At the same time psychological questionnaires and scales will be completed
58304948|NCT05469646|DRUG|BI 1819479|BI 1819479
58304949|NCT05469646|DRUG|Matching placebo|Matching placebo
58417561|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
58417562|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
58417563|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
58417564|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
58417565|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
58417566|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
58417567|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
58304950|NCT05540704|BEHAVIORAL|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
58304951|NCT05540704|OTHER|Usual Care|Usual care for problems in Type 1 diabetes management
58417568|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
58090702|NCT00537056|DRUG|Sunitinib|50 mg/day po
58090703|NCT06567405|PROCEDURE|mechanical periodontal treatment|Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.
57734224|NCT05727605|BEHAVIORAL|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
57734225|NCT05727605|OTHER|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
57949474|NCT04081636|PROCEDURE|Systematic Transrectal biopsy (TR-Bx)|Through the rectum
57949475|NCT04081636|PROCEDURE|Targeted Transrectal biopsy (TR-Bx)|Through the rectum
58304952|NCT01041222|DRUG|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
58304953|NCT04119648|BEHAVIORAL|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
58304954|NCT03915834|DEVICE|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
58304955|NCT01723072|BIOLOGICAL|Omalizumab|Humanized monoclonal antibody against human IgE
58304956|NCT01723072|DRUG|Placebo|Placebo to omalizumab
58304957|NCT01065753|BEHAVIORAL|Lifestyle Counseling|Diet control with exercise
58304958|NCT04440501|DEVICE|Virtual Reality Goggles to provide education a regarding the gluten free diet.|To watch and participate in a virtual reality educational experience regarding the gluten free diet.
58304959|NCT00004700|DRUG|insulin-like growth factor I|
58304960|NCT01735604|BIOLOGICAL|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
58304961|NCT01735604|OTHER|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
58304962|NCT00171249|DRUG|STI571 400 mg|STI571 capsules and tablets
58304963|NCT00171249|DRUG|STI571 600 mg|STI571 capsules and tablets
58304964|NCT02797834|PROCEDURE|Endometrial fluid collection|
58304965|NCT02607631|DRUG|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
58304966|NCT02414282|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
58417569|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
58090704|NCT06567405|DEVICE|Derma pen with topical ascorbic Acid|local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
58090705|NCT00880867|DRUG|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
58417570|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
58417571|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
58090706|NCT01870921|DRUG|Ticagrelor|90mg/tablet, 1 tablet bid
58304967|NCT01053455|DEVICE|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
58304968|NCT01629550|PROCEDURE|skin disinfection prior catheter insertion|
58304969|NCT00949442|DRUG|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
58304970|NCT00949442|DRUG|Glimepiride|tablets of 1 and 2 mg
58304971|NCT00949442|DRUG|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
58304972|NCT02227095|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
58304973|NCT02227095|BEHAVIORAL|After-school program|Supervised recreational program with token economy
58304974|NCT00203515|DEVICE|Standard Latex Foley Catheter|
58304975|NCT00203515|DEVICE|Silver Coated Latex Foley Catheter|
58304976|NCT02342626|BEHAVIORAL|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
58304977|NCT06552117|OTHER|an elastoMRI sequence|Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
58304978|NCT05380765|BEHAVIORAL|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
58304979|NCT04745117|BEHAVIORAL|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
58304980|NCT05821049|OTHER|UPI65 (Low Dose)|Red colored Capsules
57949476|NCT04081636|PROCEDURE|Systematic Transperineal biopsy (TP-Bx)|Through the perineal skin
58304981|NCT05821049|OTHER|UP165 (High Dose)|Red colored Capsules
58304982|NCT05821049|OTHER|Placebo|Red colored Capsules
58304983|NCT04197271|PROCEDURE|Emergency Hernia Repair|Emergency repair of hernia using method selected by treating surgeon.
58304984|NCT04197271|OTHER|Conservative management|Treatment of hernia without resort to surgery
58304985|NCT05107661|BEHAVIORAL|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
58304986|NCT00349336|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
58304987|NCT00349336|DRUG|XELOX|As prescribed
58304988|NCT00349336|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
58304989|NCT00349336|DRUG|FOLFOX-4|As prescribed
58304990|NCT01278758|DRUG|ASA404, DMXAA or DXAA|
58304991|NCT06148870|DEVICE|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
58417572|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
58090707|NCT04479943|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
58090708|NCT04479943|OTHER|Surveys and Focus groups|Nurses will answer surveys about nurse behavior, changes in self-efficacy, frequency and distance of patient ambulation, documentation of ambulation, qualitative data collected to determine barriers to implementation
58090709|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
58090710|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
58090711|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
58090712|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
58090713|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
58090714|NCT05193331|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
58304992|NCT06148870|DEVICE|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
58304993|NCT02517658|OTHER|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
58304994|NCT02517658|OTHER|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
58304995|NCT02880254|DEVICE|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
58304996|NCT02880254|DEVICE|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
58304997|NCT01690663|DRUG|Bupivacaine 0.25%|
58304998|NCT01690663|DRUG|Dexamethasone|
58417573|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
58417574|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
58417575|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
58417576|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
58417577|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
58417578|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
58417579|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
58417580|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
58417581|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
58417582|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
58417583|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
58417584|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
58417585|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
58417586|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
58304999|NCT01690663|DRUG|normal saline|placebo
58305000|NCT02133157|DRUG|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
58305001|NCT00598091|DRUG|gemcitabine|1000mg/m2, Days 1, 8, 15
58305002|NCT00598091|DRUG|dasatinib|50mg, PO, QD
58305003|NCT00598091|DRUG|gemcitabine|1000mg/m2, days 1, 8, 15
58305004|NCT00598091|DRUG|dasatinib|50mg, PO, BID
58417587|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
58417588|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
58417589|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
58417590|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
58090715|NCT04229758|DRUG|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
58305005|NCT05265702|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
58305006|NCT02966834|DRUG|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
58417591|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
58417592|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
58417593|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
58417594|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
58417595|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
58417596|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
58417597|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
58305007|NCT02966834|DRUG|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
58305008|NCT04630678|OTHER|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
58305009|NCT04630678|OTHER|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
58417598|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
57949477|NCT04081636|PROCEDURE|Targeted Transperineal biopsy (TP-Bx)|Through the perineal skin
57949478|NCT00089362|DRUG|alvespimycin hydrochloride|Given IV
57949479|NCT00089362|OTHER|laboratory biomarker analysis|Correlative studies
57949480|NCT00089362|OTHER|pharmacological study|Correlative studies
57949481|NCT02642445|DEVICE|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
58090716|NCT06538714|OTHER|MIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling."
58305010|NCT04630678|OTHER|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
58305011|NCT01146847|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
58305012|NCT00785356|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
58305013|NCT00785356|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
58305014|NCT00785356|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
58305015|NCT02920190|DRUG|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
58417599|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
58417600|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
58417601|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
58417602|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
57734226|NCT06264050|DIAGNOSTIC_TEST|evalutaion scales|four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
58305016|NCT02528448|DRUG|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
58305017|NCT02528448|DRUG|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
58305018|NCT03627832|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
58305019|NCT03627832|BEHAVIORAL|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
58305020|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
58305021|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
58305022|NCT04556760|DRUG|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
58305023|NCT04556760|DRUG|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
58305024|NCT04556760|OTHER|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
58305025|NCT00771368|DRUG|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
58305026|NCT02860936|DRUG|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
58305027|NCT05789966|GENETIC|Genetic Risk Estimate+Health Coaching|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
58305028|NCT05789966|DEVICE|Genetic Risk Estimate + Fitbit Functions+Health Coaching|"Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well"
58305029|NCT05256823|DRUG|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
58305030|NCT05256823|DRUG|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
58305031|NCT05355558|DIAGNOSTIC_TEST|[18F]FLT-PET/MRI body scan|"\[18F\]FLT-PET/MRI body scan will be done at~* Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~* Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~* Obtain vital signs and weight in kg before FLT administration.~* Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.)~* Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~* Perform a saline flush following the FLT injection.~* Body PET/MRI will be performed after FLT injection.~* Time of injection of FLT and time of scan will need to be recorded."
58305032|NCT03259958|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
58305033|NCT03259958|DRUG|Aricept|Aricept Tablet
58090717|NCT06538714|OTHER|MIIT + HIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling."
58305034|NCT00905996|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
58305035|NCT00905996|DRUG|Beta-blocker (propranolol)|
58305036|NCT03523156|DRUG|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
58417603|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
58417604|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
57949482|NCT05195294|BIOLOGICAL|LioCyx-M|HBV antigen specific TCR redirected T cells
57734227|NCT05083247|DRUG|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
57734228|NCT05083247|RADIATION|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
57734229|NCT05083247|PROCEDURE|Surgery|Surgery
57734230|NCT00124904|BEHAVIORAL|Biofeedback|
57949483|NCT05195294|DRUG|Lenvatinib|12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
57949484|NCT04507555|PROCEDURE|Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing|"The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist."
57949485|NCT04507555|PROCEDURE|Standard care antidepressant selection and dosing|Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
57949486|NCT05088486|GENETIC|DNA analysis|GWAS
57949487|NCT02886143|PROCEDURE|Active Voiding Trial|"Nursing protocol:~1. Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~2. Clamp the Foley~3. Deflate the catheter balloon and remove the catheter from the bladder.~4. Record the amount of saline that was instilled into the bladder.~5. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
58305037|NCT03523156|DRUG|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
58305038|NCT05202834|DEVICE|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
58305039|NCT01811238|DRUG|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
58305040|NCT00830128|DRUG|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
58305041|NCT04654013|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
58305042|NCT06380062|OTHER|Plasma concentration of choline|The exposure in this observational study is plasma concentrations of choline
58305043|NCT03614104|BEHAVIORAL|Mobile Health Technology (short message service)|Health education through mobile technology with Short Message Service (SMS)
58305044|NCT04388410|BIOLOGICAL|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
58305045|NCT06293742|DRUG|ECC5004|ECC5004 tablet will be administered orally.
58305046|NCT06293742|DRUG|Midazolam|Midazolam will be administered orally.
58305047|NCT06293742|DRUG|Rosuvastatin|Rosuvastatin will be administered orally.
58305048|NCT06293742|DRUG|Digoxin|Digoxin will be administered orally.
58305049|NCT06293742|DRUG|Atorvastatin|Atorvastatin will be administered orally.
58305050|NCT05861375|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
58305051|NCT04415346|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
58305052|NCT00568971|DRUG|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
58090718|NCT06538714|OTHER|Control group|"Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling."
58417605|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
58305053|NCT03447548|BEHAVIORAL|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
58305054|NCT03447548|BEHAVIORAL|Active control|Commercially available games on tablet
58417606|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
58090719|NCT05416125|DRUG|Lisdexamfetamine Dimesylate|Vyvanse treatment
58090720|NCT05416125|BEHAVIORAL|Lifestyle therapy|Lifestyle treatment
58305055|NCT02402374|DEVICE|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
58305056|NCT02402374|DEVICE|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
58305057|NCT03060473|DRUG|Azithromycin|Azithromycin 1 gm PO once
58305058|NCT03060473|DRUG|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
58305059|NCT03060473|DRUG|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
58305060|NCT03060473|DRUG|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
58090721|NCT06460298|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
58417607|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
58090722|NCT06460298|DRUG|ProAgio Dose Expansion|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
58090723|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
58090724|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
58090725|NCT02093650|DRUG|black cohosh extract|Black cohosh extract 80 mg
58090726|NCT02093650|DRUG|Placebo|Soy bean oil
58090727|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
58305061|NCT05224700|BEHAVIORAL|JAPI|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. All the activities are games with the following structure: an introduction with instructions and protagonist selection, followed by a practice exercise to ensure that the children understand what they have to do (the exercise is repeated until the child performs it correctly), and, finally, the activity itself (4 different activities with 5 tries each). The first 10 sessions jointly stimulate working memory and emotion knowledge (4 activities focused on each skill per session), while the 10 remaining sessions stimulate inhibitory control and the selection of prosocial behaviours. In the inhibitory control activities, they must suppress automatic stimuli and processes; in the emotion recognition activities, they must identify basic emotions; and in the selection of prosocial behaviours, they must choose an option to deal with a social problem.
58090728|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
58417608|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
58417609|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
58090729|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
58090730|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
58090731|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
58090732|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
58305062|NCT05224700|BEHAVIORAL|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
58305063|NCT04175171|DRUG|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
58305064|NCT04175171|DRUG|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
58305065|NCT03644017|DEVICE|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
58417610|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
58417611|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
58090733|NCT06567184|BEHAVIORAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
58090734|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
58090735|NCT04499391|OTHER|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
58090736|NCT02397083|DRUG|Everolimus|Given PO
58090737|NCT02397083|OTHER|Laboratory Biomarker Analysis|Correlative studies
57734231|NCT00124904|BEHAVIORAL|Kegel exercises|
57734232|NCT04788667|OTHER|A health education programme using a telerehabilitation platform|All patients enrolled in the study will receive information through the tele rehabilitation platform, although the experimental group will have specific training/education whereas the control group will only receive some general recommendations as control/sham
57734233|NCT01694537|DRUG|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
57734234|NCT01694537|DRUG|placebo|Placebo is made with same size and shape with study drug.
57734235|NCT00433784|DRUG|Clopidogrel|
57734236|NCT00433784|PROCEDURE|Blood sampling - platelet aggregation|
57734237|NCT00433784|PROCEDURE|Blood sampling - genotyping|
57734238|NCT05947344|DRUG|STI-8591|Seven dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg,80mg,120mg, 160mg, 200mg, 240mg.Expansion is planned in three dose groups of 120mg, 160mg, and 200mg.
57734239|NCT00293839|DRUG|oxybutynin chloride|
57734240|NCT02937545|OTHER|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
57734241|NCT02937545|OTHER|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
58417612|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
58417613|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
58090738|NCT02397083|DEVICE|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
58305066|NCT05405790|PROCEDURE|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
58305067|NCT04044118|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet consisted of \~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
58305068|NCT00239720|DRUG|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
58305069|NCT00239720|DRUG|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
58417614|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
58417615|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
58417616|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
58417617|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
58417618|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
58417619|NCT01964599|DIETARY_SUPPLEMENT|Control|
58417620|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
58417621|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
58417622|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
58417623|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
58417624|NCT02303782|DRUG|OTX015|
58417625|NCT02303782|DRUG|Vidaza (azacitidine)|
58417626|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
57734242|NCT06058156|DRUG|SAR444656 (KT-474)|Oral Tablet
57734243|NCT06058156|DRUG|Placebo|Oral Tablet
57734244|NCT03166618|DEVICE|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
57734245|NCT01445899|DRUG|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
57734246|NCT01445899|DRUG|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
57734247|NCT01445899|DRUG|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
57734248|NCT04490746|OTHER|with no intervention, Collect samples|only with observation,there is no need to intervene
57734249|NCT00354874|DRUG|GW642444|drug
57734250|NCT00354874|DRUG|Placebo|placebo
57734251|NCT00354874|DRUG|salmeterol 50mcg|salmeterol
57734252|NCT02898974|BEHAVIORAL|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
57734253|NCT04885686|DEVICE|Endomethasone N RCS|Root canal sealer
57734254|NCT04885686|DEVICE|Endomethasone SP RCS|Root canal sealer
57734255|NCT00122512|DRUG|Tenofovir Disoproxil Fumarate|
57734256|NCT00158938|DEVICE|EASYTRAK 3 left ventricular pacing lead|
58417627|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
58090739|NCT03427788|DRUG|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
58417628|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
58417629|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
58417630|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
58090740|NCT03427788|DRUG|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
58417631|NCT02358655|OTHER|Retrospective review of OAC prescription|
58090741|NCT03992612|OTHER|control group: usual medical care|The patients received usual medical care.
58090742|NCT03992612|BEHAVIORAL|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
58090743|NCT05036447|OTHER|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
58090744|NCT05157529|DEVICE|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
58417632|NCT02358655|OTHER|Prescription of OAC in ED|
58417633|NCT02358655|OTHER|Community AF clinic|
58417634|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
58417635|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
58417636|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
58417637|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
58417638|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
58417639|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
58417640|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
58417641|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
58417642|NCT03384823|DRUG|Placebo|placebo to match EDP-938
58090745|NCT05157529|DEVICE|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
58417643|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
58417644|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
58417645|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
58417646|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
58417647|NCT02631733|DRUG|Ferumoxytol|Given IV
58417648|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
58090746|NCT06568445|DRUG|Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）|one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
58417649|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
58417650|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58417651|NCT02631733|DRUG|Veliparib|Given PO
58417652|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
58090747|NCT06568445|DRUG|as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）|as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
58090748|NCT01184781|DEVICE|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
58090749|NCT05860049|OTHER|Conventional physiotherapy|All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.
58090750|NCT05860049|OTHER|Core stability|All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.
58090751|NCT05860049|DEVICE|Instrument assisted soft tissue mobilization|Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
58090752|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
58417653|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
58417654|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
58090753|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
58090754|NCT01757873|DRUG|Z160|
57734257|NCT03643952|DRUG|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
57734258|NCT05317468|OTHER|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
57734259|NCT05558657|OTHER|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
57734260|NCT05558657|OTHER|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
57734261|NCT05554237|DRUG|Placebo|Placebo
58090755|NCT01757873|DRUG|Placebo|
58090756|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
58090757|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
58090758|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
58417655|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
57734262|NCT05554237|DRUG|PF-07612577|PF-07612577
57734263|NCT05554237|DRUG|PF-06264006|PF-06264006
57949488|NCT02886143|PROCEDURE|Passive Voiding Trial|"Nursing protocol:~1. Deflate the catheter balloon and remove the catheter from the bladder.~2. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~3. 5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
57949489|NCT00494611|DRUG|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
57949490|NCT03672019|BEHAVIORAL|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
57949491|NCT00005832|DRUG|R115777|300mg/dose BID, PO, Days 1-21, q 28days
57949492|NCT05079945|PROCEDURE|Spinal cord Tractography in order to differentiate spinal tracts.|Spinal cord tractography using DTI MRI sequences of the brain and spinal cord, in order to differentiate tracts at the spinal cord level; and by performing a stitching process between Brain and Spinal cord DTI sequences.
57949493|NCT00579371|DRUG|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
57949494|NCT03711578|DRUG|Tenalisib,|BID, Orally
57949495|NCT05374252|DRUG|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
57949496|NCT05374252|RADIATION|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
57949497|NCT01372384|DRUG|erlotinib [Tarceva]|150 mg orally daily
57949498|NCT04966377|BEHAVIORAL|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS), increasing awareness of Syrian women under temporary protection against breast cancer, decreasing their perception of barriers to screening tests, developing early diagnosis behaviors (such as BSE, CBE and mammography), increasing their self-efficacy and breast cancer fears are expected to be reduced.
57949499|NCT02230059|OTHER|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
57949500|NCT03321136|DRUG|LSD|0.025 mg LSD per os, single dose
57949501|NCT03321136|DRUG|LSD|0.05 mg LSD per os, single dose
57949502|NCT03321136|DRUG|LSD|0.1 mg LSD per os, single dose
57949503|NCT03321136|DRUG|LSD|0.2 mg LSD per os, single dose
57949504|NCT03321136|DRUG|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
57949505|NCT03321136|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
57949506|NCT00492752|DRUG|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
57949507|NCT00492752|DRUG|Placebo|Matching placebo (orally) twice daily
58090759|NCT05013749|PROCEDURE|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
58090760|NCT05013749|PROCEDURE|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
58090761|NCT02392975|PROCEDURE|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
58090762|NCT02392975|PROCEDURE|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
58090763|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
58090764|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
58090765|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
58090766|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
58090767|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
58417656|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
57734264|NCT03570294|DRUG|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
57734265|NCT00003269|BIOLOGICAL|sargramostim|
57734266|NCT00003269|DRUG|amifostine trihydrate|
57734267|NCT00003269|DRUG|cisplatin|
57734268|NCT00003269|DRUG|cyclophosphamide|
57734269|NCT00003269|DRUG|etoposide|
57734270|NCT05748405|DRUG|Placebo|Matching Tablets
57734271|NCT05748405|DRUG|AEF0217|Tablets of 100 mcg AEF0217
58090768|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
58417657|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
58417658|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
58417659|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
58417660|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
58417661|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
58417662|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
58417663|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
58417664|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
58417665|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
58417666|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
58417667|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
58417668|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
57949508|NCT05326945|OTHER|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
58417669|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
57734272|NCT05369052|DRUG|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
58417670|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
58417671|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
58417672|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
57949509|NCT00492167|BIOLOGICAL|beta-glucan|
57949510|NCT00492167|BIOLOGICAL|monoclonal antibody 3F8|
57734273|NCT05369052|DRUG|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
57949511|NCT00492167|OTHER|immunohistochemistry staining method|
57949512|NCT00492167|OTHER|laboratory biomarker analysis|
58090769|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
58090770|NCT06362369|DRUG|Alintegimod|Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
58090771|NCT06362369|DRUG|Ipilimumab|Ipilimumab (Yervoy) will be administered via IV
58090772|NCT06362369|DRUG|Nivolumab|Nivolumab (Opdivo) will be administered via IV
57734274|NCT01895166|PROCEDURE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
57949513|NCT03992508|DEVICE|intermittent pneumatic compression|
58417673|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
57734275|NCT01895166|PROCEDURE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
58417674|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
58417675|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
58417676|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
58417677|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
58417678|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
58417679|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
58417680|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
58417681|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
58417682|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
58417683|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
58417684|NCT01988545|OTHER|saline|
58417685|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
57734276|NCT01625429|DRUG|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
57734277|NCT05661331|DEVICE|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
58417686|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
58417687|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
58417688|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
58417689|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
58417690|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
58090773|NCT05760924|DEVICE|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
58095246|NCT02969473|DRUG|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
58417691|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
58417692|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
58417693|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
58417694|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
58417695|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
58417696|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
58417697|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
58417698|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
57734278|NCT06393465|DRUG|Tafamidis|61 milligrams under real world conditions
58417699|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
58417700|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
58417701|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
58417702|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
57734279|NCT02804542|OTHER|Observational|
57734280|NCT02804542|OTHER|Retrospective review|
57734281|NCT03839953|BEHAVIORAL|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
57949514|NCT03992508|PROCEDURE|complex decongestive therapy|
57949515|NCT00035022|DRUG|BCX-1777|
58090774|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
58090775|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
58090776|NCT03026868|PROCEDURE|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
58090777|NCT01388101|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
58090778|NCT05339542|OTHER|platelet rich plasma|derived from patient own blood
58090779|NCT05339542|DRUG|MethylPREDNISolone 40 MG|active comparative intervention
58305070|NCT00481884|OTHER|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
58305071|NCT00481884|OTHER|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
58417703|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
58417704|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
58417705|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
58417706|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
58417707|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
58417708|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
58417709|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
58417710|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
58417711|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
58417712|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
58417713|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
58417714|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
58417715|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
58417716|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
57949516|NCT00766532|DRUG|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
57949517|NCT01867281|DRUG|aspirin|
57949518|NCT01238016|DEVICE|experimental|
57949519|NCT03861754|BEHAVIORAL|Lifestyle modification|
58090780|NCT06253585|OTHER|Algorithm Alarm- Crystalloids|"The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution)."
58090781|NCT06253585|OTHER|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
58417717|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
58417718|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
58417719|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
58417720|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
58417721|NCT03504566|DRUG|Linagliptin|Linagliptin
58417722|NCT03504566|DRUG|Empagliflozin|Empagliflozin
58417723|NCT03504566|DRUG|Telmisartan|Telmisartan
58417724|NCT03504566|DRUG|Sulodexide|Sulodexide
58417725|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
58417726|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
58417727|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
58417728|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
58090782|NCT06702475|DIAGNOSTIC_TEST|Home Sleep Test with Watch PAT-one|Each participant will have a Watch-PAT one home sleep test, recording pulse oximetry, pulse tonometry, wrist actigraphy, snoring (by microphone), and chest motion by accelerometer.
58090783|NCT06319573|OTHER|Counseling Supported by Univfy® Report|The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
58090784|NCT06319573|OTHER|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
58090785|NCT02046239|PROCEDURE|Suture Group|
58417729|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
58417730|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
58090786|NCT02046239|BIOLOGICAL|Staple Group (control)|
58417731|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
58417732|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
58090787|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
58417733|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
58417734|NCT00000120|DRUG|Erythromycin Ointment|
58417735|NCT00000120|DRUG|Silver Nitrate Drops|
58417736|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
58417737|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
57949520|NCT04905121|DRUG|Psilocybin|Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
57734282|NCT03839953|OTHER|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
58090788|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
58090789|NCT01016158|DRUG|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
58090790|NCT04294290|BIOLOGICAL|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
58090791|NCT05774769|PROCEDURE|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
58090792|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
58090793|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
57949521|NCT03923426|OTHER|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
58090794|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
58090795|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
58090796|NCT05589649|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block
58090797|NCT05589649|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block
58090798|NCT05141045|DIETARY_SUPPLEMENT|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
58090799|NCT05141045|DIETARY_SUPPLEMENT|placebo|placebo
58090800|NCT06702280|DIETARY_SUPPLEMENT|IgY supplement|Ingesting the immune supplement over the experimental period
58090801|NCT03827460|BEHAVIORAL|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
58090802|NCT03827460|BEHAVIORAL|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
58090803|NCT03827460|DRUG|Intravenous Alcohol|During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
58417738|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
58417739|NCT00031018|DRUG|Aricept|
58090804|NCT06184373|DEVICE|Dexcom G6/G7 CGM|CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
58090805|NCT06184373|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
58305072|NCT02806440|DRUG|Low dose naltrexone|Active comparator
58305073|NCT02806440|DRUG|Placebo|Placebo comparator
58417740|NCT00031018|DRUG|IFN-alpha2A|
58090806|NCT06184373|DIAGNOSTIC_TEST|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
58090807|NCT05775341|OTHER|No Intervention|This is purely an observational study.
58090808|NCT04473339|PROCEDURE|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
58090809|NCT04473339|PROCEDURE|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
58090810|NCT03843307|DEVICE|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
58090811|NCT02926053|PROCEDURE|Surgical removal of tumor tissue for T cell production|Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
58090812|NCT02926053|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
58090813|NCT02926053|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
58090814|NCT02926053|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
58417741|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
58090815|NCT02926053|DRUG|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
58090816|NCT06568497|OTHER|Food|Food
58417742|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
57734283|NCT00439907|PROCEDURE|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
57734284|NCT00439907|PROCEDURE|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
57734285|NCT06476717|PROCEDURE|Biopsy|Kidney allograft biopsy
58417743|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
58417744|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
58417745|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
58417746|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
58417747|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
58417748|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
58417749|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
58417750|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
58417751|NCT02227823|DRUG|Pyridostigmine Bromide|
58417752|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
58417753|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
58417754|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
58417755|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
58417756|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
58417757|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
57734286|NCT06476717|DIAGNOSTIC_TEST|Blood Biomarkers - cfDNA|dd-cfDNA
57734287|NCT06476717|DRUG|Antirejection therapy|Patients will receive standard antirejection therapy according to center protocol.
58090817|NCT04645927|DIETARY_SUPPLEMENT|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
58090818|NCT04645927|DIETARY_SUPPLEMENT|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
58090819|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
57734288|NCT02179112|PROCEDURE|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
57734289|NCT06058832|DEVICE|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
57734290|NCT06058832|OTHER|Kegel Exercises|"* The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening"
58090820|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
58090821|NCT04527549|DRUG|Hydroxychloroquine|Given PO
58090822|NCT04527549|DRUG|Placebo Administration|Given PO
58090823|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
58090824|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
58090825|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
58417758|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
58417759|NCT02920957|DEVICE|comfilcon A|contact lens
58417760|NCT02920957|DEVICE|senofilcon C|contact lens
58417761|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
58417762|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
58417763|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
58417764|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
57734291|NCT01024322|DRUG|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
57734292|NCT01024322|DRUG|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
57734293|NCT01024322|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
57734294|NCT03895424|DIETARY_SUPPLEMENT|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
57734295|NCT03895424|DIETARY_SUPPLEMENT|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
57734296|NCT03895424|DIETARY_SUPPLEMENT|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
58090826|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
58090827|NCT03803514|DRUG|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
58090828|NCT02560207|DRUG|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
58095247|NCT04512391|PROCEDURE|Ultrasound guided Erector Spinae Plane Block (ESPB)|Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
58095248|NCT00872573|DEVICE|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
58417765|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
58417766|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
58417767|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
58417768|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
58417769|NCT01969500|BEHAVIORAL|Mobile Application|
58417770|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
58417771|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
58417772|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
58417773|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
58417774|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
58417775|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
58417776|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
58417777|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
57734297|NCT06326801|OTHER|Resistive Diaphragmatic breathing exercise|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
57734298|NCT06326801|OTHER|Diaphragmatic breathing exercise|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
57734299|NCT06326801|OTHER|Conventional stroke physiotherapy|Conventional stroke physiotherapy
57734300|NCT02040480|DRUG|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
57734301|NCT02040480|DRUG|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
57734302|NCT02388386|DEVICE|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
58090829|NCT03009591|OTHER|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver."
58090830|NCT04645342|DEVICE|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
58090831|NCT04645342|DEVICE|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
58090832|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
58090833|NCT06321042|DEVICE|Knee arthroplasty|Knee arthroplasty surgery with perseus orthokey alignment device
58090834|NCT02657746|OTHER|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
58095249|NCT05674721|DRUG|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
58417778|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
58417779|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
58417780|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
58417781|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
58417782|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
57734303|NCT02368353|OTHER|Cognitive behavioral therapy|
58417783|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
58417784|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
58417785|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
58417786|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
58417787|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
58417788|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
58417789|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
57734304|NCT02368353|OTHER|Supportive therapy|
57734305|NCT06516588|DEVICE|Transcranial Dirrect Current Stimulation|tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
58417790|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
58090835|NCT03049371|OTHER|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
58090836|NCT05572814|BEHAVIORAL|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
58090837|NCT05572814|BEHAVIORAL|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
58090838|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
58090839|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
58090840|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
58417791|NCT02427724|DRUG|placebo vehicle|
58417792|NCT02427724|DEVICE|Q-switched 532nm Laser|
58417793|NCT00450736|DRUG|celecoxib|
58417794|NCT00450736|PROCEDURE|adjuvant therapy|
58417795|NCT00450736|RADIATION|radiation therapy|
58417796|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
58417797|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
58417798|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
58417799|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
58417800|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
58417801|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
58090841|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
58417802|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
58090842|NCT02242331|DRUG|Micardis®|
58090843|NCT00138658|DRUG|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
58090844|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
58090845|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
58090846|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
58090847|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
58090848|NCT03586986|DIAGNOSTIC_TEST|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
58095250|NCT05674721|DRUG|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
58305074|NCT00405301|DRUG|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
58305075|NCT05899530|DEVICE|Invisalign|Expansion using Invisalign versus conventional expander
58305076|NCT05899530|DEVICE|Conventional expander|conventional expander
58305077|NCT05549596|DEVICE|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2\~L3
58305078|NCT05549596|DEVICE|Physical therapy with standard traction device|Physical therapy with standard traction device
58090849|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
58090850|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
58090851|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
58090852|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
58305079|NCT06011863|PROCEDURE|Thoracic Epidural Analgesia|Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
58417803|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
58417804|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
58417805|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
58417806|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
58417807|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
58417808|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
58417809|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
58417810|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
58417811|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
58417812|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
58417813|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
58417814|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
58417815|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
58417816|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
58417817|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
58417818|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
58417819|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
58090853|NCT06568770|DRUG|USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK|"With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected"
58090854|NCT06568770|DRUG|PERICAPSULAR NERVE BLOCK|"an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected."
58090855|NCT06670105|DRUG|Glofitamab|Given by vein
58090856|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
58090857|NCT04181697|DEVICE|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
58090858|NCT04181697|DEVICE|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
58417820|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
58417821|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
58417822|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
58417823|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
58417824|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
58417825|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
58417826|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
58417827|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
58090859|NCT03800134|DRUG|Durvalumab|1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
58090860|NCT03800134|OTHER|Placebo|Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
58090861|NCT03800134|DRUG|Carboplatin|Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
58417828|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
58417829|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
58417830|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
58417831|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
58090862|NCT03800134|DRUG|Cisplatin|75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
58090863|NCT03800134|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
58090864|NCT03800134|DRUG|Paclitaxel|200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
58090865|NCT03800134|DRUG|Gemcitabine|1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
58090866|NCT03800134|PROCEDURE|Surgery|Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
58417832|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
58417833|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
58417834|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
58417835|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
58090867|NCT02790619|DEVICE|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
58090868|NCT02790619|DEVICE|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
58090869|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
58090870|NCT03278639|BEHAVIORAL|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
58090871|NCT03278639|BEHAVIORAL|Kinesiology|Training will be directed to ameliorate gait and balance
58090872|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
58090873|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
58090874|NCT02550509|DEVICE|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
58417836|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
58417837|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
57949522|NCT03930654|BEHAVIORAL|iPrEP|"* iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women"
58090875|NCT02550509|DEVICE|elastography|elastography to patient with stoke
58090876|NCT03033069|DRUG|Brexpiprazole|Brexpiprazole oral tablets.
58090877|NCT03033069|DRUG|Sertraline|Sertraline oral capsules.
58090878|NCT03033069|DRUG|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
58090879|NCT03033069|DRUG|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
58090880|NCT00132600|DRUG|bacitracin (allergen)|
58090881|NCT06146543|OTHER|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
58090882|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine (IIV) at baseline|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
58090883|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 3-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
58090884|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine at Month 1|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
58090885|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 6-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
58090886|NCT00868816|DRUG|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
58090887|NCT00868816|DRUG|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
58090888|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
58417838|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
58417839|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
58417840|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
58417841|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
58417842|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
58090889|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
58090890|NCT06204848|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
58090891|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
58417843|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
57734306|NCT05358444|BEHAVIORAL|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
58090892|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
58090893|NCT02446496|DRUG|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
58417844|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
58417845|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
58417846|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
58417847|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
57734307|NCT05358444|BEHAVIORAL|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
57734308|NCT05616533|OTHER|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
57734309|NCT05062239|DRUG|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
57734310|NCT05062239|DRUG|No-intervention.|Continuance of prior statin therapy
57949523|NCT03930654|BEHAVIORAL|Usual Care|"* Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies"
57949524|NCT00894556|DRUG|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
57949525|NCT00894556|DRUG|Comparator: Placebo|Placebo to Rizatriptan
58417848|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
58417849|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
58417850|NCT02679820|DEVICE|Copper T intrauterine device|
57734311|NCT06669403|DRUG|OPT101|OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
58417851|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
58417852|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
57734312|NCT06669403|OTHER|Placebo|0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
57949526|NCT00894556|DRUG|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
57949527|NCT04511247|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
57949528|NCT04511247|DEVICE|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
57949529|NCT00782951|DRUG|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
57949530|NCT00782951|DRUG|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
57949531|NCT00782951|DRUG|Placebo|single IV dose of placebo after dental impaction surgery
57949532|NCT06012370|PROCEDURE|PRP injection|Injection of PRP and hyaluronic acid
57949533|NCT05140538|OTHER|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
57949534|NCT05140538|OTHER|SRP + toothpaste|Use of domiciliary products twice a day
57949535|NCT01834274|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
57949536|NCT01834274|DRUG|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
57734313|NCT05008354|DRUG|Pyridoxine|Pyridoxine tablet 40mg once daily
57734314|NCT05008354|DRUG|Placebo|Placebo tablet once daily
57949537|NCT01834274|DRUG|Sitagliptin|Sitagliptin tablets
57949538|NCT01834274|DRUG|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
57949539|NCT01834274|DRUG|Metformin|Metformin tablets
57949540|NCT01708642|DRUG|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
57949541|NCT01708642|DRUG|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
57949542|NCT06252064|OTHER|Rehabilitation + Drug therapy|Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.
57949543|NCT06252064|OTHER|Rehabilitation|Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.
57949544|NCT06252064|OTHER|Drug therapy|The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
57949545|NCT00769184|DRUG|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
57949546|NCT00769184|OTHER|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
57949547|NCT00769184|DRUG|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
57949548|NCT02956603|OTHER|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
57949549|NCT05158738|OTHER|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
57949550|NCT02381639|BEHAVIORAL|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
58090894|NCT02446496|DRUG|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
58090895|NCT04372810|PROCEDURE|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
57949551|NCT00712699|DRUG|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
58090896|NCT04372810|PROCEDURE|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
58090897|NCT06439316|BEHAVIORAL|Sedentary behavior|Total sedentary time was assessed by self-reported daily hours of sitting
58090898|NCT06439316|BEHAVIORAL|Depressive symptoms|depressive symptoms were assessed by Patient Health Questionnaire 9 scale
58090899|NCT05166369|BEHAVIORAL|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
58417853|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
57949552|NCT00712699|DRUG|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
58090900|NCT05166369|BEHAVIORAL|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
58090901|NCT06701877|BEHAVIORAL|Circle of security Parenting (COS-P)|The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).
58090902|NCT06701877|BEHAVIORAL|Traitement as usual (TAU)|TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
58090903|NCT06313294|OTHER|Tracking application app|An app will be implemented for mobile monitoring in patients who use continuous postoperative ambulatory regional analgesia.
58090904|NCT06313294|OTHER|Telephone interview|Patients who use continuous postoperative outpatient regional analgesia will be followed up using the current traditional method of post-discharge telephone call.
58090905|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
58090906|NCT02611531|BEHAVIORAL|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
58417854|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
58417855|NCT00225342|DRUG|Rosiglitazone|
58417856|NCT00225342|DRUG|Gliclazide (Comparison drug)|
58417857|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
58417858|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
58417859|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
58417860|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
57949553|NCT05486559|OTHER|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
57949554|NCT05486559|OTHER|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
57949555|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 2 dose efficacy|Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
57949556|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|Will be comparison group for 2 dose efficacy group.
57949557|NCT01920880|OTHER|Quantitative Sensory Testing analysis|
57949558|NCT06216639|DRUG|Bismuth Subcitrate|Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
57949559|NCT06216639|DRUG|Esomeprazole|Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
57949560|NCT06216639|DRUG|Metronidazole|Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
57949561|NCT06216639|DRUG|Amoxicillin|Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
57949562|NCT06216639|DRUG|Clarithromycin|Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
58090907|NCT02611531|BEHAVIORAL|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
58090908|NCT05984329|OTHER|Retrospective analysis of patients' choice|Retrospective analysis of patients' choice of tonic or Burst DR(TM) waves for their analgesic effect.
58305080|NCT06011863|PROCEDURE|Erector spinae plane block|Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
57949563|NCT06216639|DRUG|Levofloxacin|Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
57949564|NCT02541279|PROCEDURE|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
57949565|NCT00356928|DRUG|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
57949566|NCT00356928|BIOLOGICAL|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
57949567|NCT02681172|DRUG|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
57949568|NCT02681172|PROCEDURE|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
57949569|NCT02404259|DRUG|TDF (Tenofovir)|
57949570|NCT02404259|DRUG|Efavirenz|
57949571|NCT02404259|DRUG|lopinavir/ritonavir, atazanavir/ritonavir|
57949572|NCT05137548|DRUG|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
57949573|NCT05137548|DRUG|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
57949574|NCT00982865|DRUG|MSC1936369B|
57949575|NCT00982865|DRUG|MSC1936369B|
57949576|NCT00982865|DRUG|MSC1936369B|
57949577|NCT00982865|DRUG|MSC1936369B|
57949578|NCT00554502|DRUG|supportive therapy with: ACE-inhibitor / ARB / Statin|"* Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
57949579|NCT00554502|DRUG|supportive and immunosuppressive therapy|"* supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice"
57949580|NCT04594967|OTHER|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
57949581|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
57949582|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
57949583|NCT05815407|OTHER|No intervention|No intervention
57949584|NCT02124239|DRUG|Ingenol mebutate|
57949585|NCT03910907|DRUG|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
57949586|NCT02081534|DRUG|AZD1722|AZD1722, oral tablet
57949587|NCT02081534|DRUG|Placebo|Placebo bid, double dummy technique
57949588|NCT05012956|PROCEDURE|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
57949589|NCT05012956|PROCEDURE|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
57949590|NCT02807480|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy
57949591|NCT02807480|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
57949592|NCT02807480|BEHAVIORAL|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
57949593|NCT02807480|BEHAVIORAL|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
57949594|NCT02807480|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
57949595|NCT02807480|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
57949596|NCT02829307|DRUG|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
58090909|NCT02341872|OTHER|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
58090910|NCT02341872|OTHER|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
58090911|NCT05645016|BEHAVIORAL|COEST|Adapted version of our COEST training, targeting Black church members.
58305081|NCT01658280|DEVICE|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
57734315|NCT03069222|OTHER|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
57734316|NCT06557265|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
58090912|NCT03387735|OTHER|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
58090913|NCT03387735|BEHAVIORAL|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
58090914|NCT01735864|DRUG|Indirubin 200μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
58090915|NCT01735864|DRUG|Indirubin 100 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
58090916|NCT01735864|DRUG|Indirubin 50 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
58090917|NCT01735864|DRUG|Indirubin 10 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
58090918|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
58305082|NCT00416273|DRUG|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
58305083|NCT00416273|DRUG|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
58305084|NCT02035540|OTHER|Decellularized human valves|
58305085|NCT06458348|BEHAVIORAL|Local opera appreciating and Medical gymnastics training|To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
58305086|NCT00743210|DRUG|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
58305087|NCT00743210|DRUG|Placebo|Placebo, 3 grams once per day for 3 weeks.
58305088|NCT04773275|DEVICE|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
58305089|NCT00259935|DRUG|topotecan|topotecan
58090919|NCT00107809|DRUG|Modafinil|
58090920|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
58090921|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
58090922|NCT05287802|OTHER|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
58090923|NCT05287802|OTHER|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
58090924|NCT05814510|BEHAVIORAL|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
58090925|NCT05814510|BEHAVIORAL|Asthma CHAMPS Wait List Control|Stepped wedge design
58090926|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
58090927|NCT04959708|OTHER|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
58305090|NCT00133198|DRUG|Pramipexole|
58305091|NCT02625701|PROCEDURE|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
58305092|NCT02625701|PROCEDURE|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
57734317|NCT06557265|DRUG|Cyclophosphamide|Lymphodepletion
57734318|NCT02479412|DRUG|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
57949597|NCT00518037|BEHAVIORAL|surveys|anxiety surveys
58090928|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
58090929|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
58090930|NCT06496711|OTHER|Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients|The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
58090931|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
58090932|NCT04839133|DEVICE|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
58090933|NCT06519266|DEVICE|PHP|Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
58090934|NCT06519266|DRUG|IPI1/NIVO3|Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
58090935|NCT06519266|DRUG|IPI3/NIVO1|Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
58090936|NCT00000227|DRUG|Buprenorphine|
58090937|NCT04921384|DRUG|Placebo|0.9% normal saline, intravenously
58090938|NCT04921384|DRUG|Eptinezumab|Solution for infusion, intravenously
58090939|NCT03372395|OTHER|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
58090940|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
58090941|NCT03001427|BEHAVIORAL|Structured center-based lifestyle intervention|
58090942|NCT03001427|BEHAVIORAL|Standard education and physician advice|
58090943|NCT05922592|PROCEDURE|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
58090944|NCT05922592|PROCEDURE|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
58090945|NCT06537323|DRUG|Femoral nerve block with0.25% bupivacaine guided by ultrasound.|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
58090946|NCT06537323|DRUG|PENG block with0.25% bupivacaine guided by ultrasound.|PENG block with0.25% bupivacaine guided by ultrasound.
58090947|NCT06537323|DRUG|Preoperative IV fentanyl 100microgram|Preoperative IV fentanyl 100microgram
58090948|NCT02414165|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
58090949|NCT02414165|DRUG|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
58090950|NCT02414165|DRUG|Lomustine|
58090951|NCT02414165|DRUG|Temozolomide|
58090952|NCT02414165|BIOLOGICAL|Bevacizumab|
58090953|NCT06567275|PROCEDURE|block|ultrasound guided nerve block
58090954|NCT01658215|DRUG|V0116 transdermal patch (Test treatment )|
58090955|NCT01658215|DRUG|Nicotine transdermal patch (Reference treatment )|
58090956|NCT05872451|DRUG|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
58090957|NCT05872451|DIAGNOSTIC_TEST|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
58090958|NCT00896038|DRUG|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
58090959|NCT00896038|DRUG|Placebo|Non-active placebo
58090960|NCT02822612|DEVICE|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
58090961|NCT03533335|OTHER|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
58090962|NCT01164137|BEHAVIORAL|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
58090963|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
58090964|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
58090965|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
58090966|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
58090967|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58305093|NCT05117853|DRUG|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized"
58305094|NCT05117853|PROCEDURE|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
58417861|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
57734319|NCT02479412|DRUG|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
57734320|NCT02479412|DRUG|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
57949598|NCT00379652|BEHAVIORAL|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
57949599|NCT00379652|BEHAVIORAL|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
57949600|NCT00379652|OTHER|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
57949601|NCT01675635|DRUG|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
57949602|NCT01675635|OTHER|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
57949603|NCT03724071|BIOLOGICAL|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
57949604|NCT03724071|DRUG|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
57949605|NCT05809414|DEVICE|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
57949606|NCT05809414|DRUG|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
57949607|NCT02031770|DRUG|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
57949608|NCT02031770|OTHER|Control|subjects will receive no treatment
57949609|NCT04346589|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
57949610|NCT05254184|DRUG|Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides|administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
57949611|NCT04350775|OTHER|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
58090968|NCT00986609|OTHER|flow cytometry|Correlative studies
58090969|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
58090970|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
58417862|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
58417863|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
58417864|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
58417865|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
58417866|NCT02677844|DRUG|Abemaciclib|Administered orally
58090971|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
58090972|NCT02334839|OTHER|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
58090973|NCT00897039|OTHER|flow cytometry|
58090974|NCT00897039|OTHER|immunohistochemistry staining method|
58090975|NCT06704139|DRUG|Morphine - .25 mg|Fifty patients will receive intrathecal morphine
58090976|NCT06704139|DRUG|fentanyl + morphine|Fifty patients will receive intrathecal morphine and fentanyl
58305095|NCT06171893|BEHAVIORAL|Wavy stress application|"The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively."
58305096|NCT02143232|DEVICE|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
58305097|NCT05010278|PROCEDURE|Latarjet|Patients followed up 6 months after a Latarjet procedure
58305098|NCT00781846|DRUG|ridaforolimus|oral tablets, daily for 5 days/week
58305099|NCT00781846|DRUG|bevacizumab|IV infusion
58417867|NCT02677844|DRUG|Placebo|Administered orally
58417868|NCT02677844|DRUG|Loperamide|Administered orally
58417869|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
58417870|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
58417871|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
58417872|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
58417873|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
57734321|NCT02479412|DRUG|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
57734322|NCT02479412|DRUG|Salbutamol|Inhalation as needed
57734323|NCT03392311|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
58090977|NCT06704139|DRUG|Ondansetron + Dexamethasone|All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
58090978|NCT00806416|DRUG|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
58090979|NCT00806416|DRUG|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
58090980|NCT00806416|DIETARY_SUPPLEMENT|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
58090981|NCT01294709|DRUG|telcagepant|
58090982|NCT01294709|DRUG|Placebo to telcagepant|
58090983|NCT05724875|DEVICE|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
58305100|NCT00915174|DRUG|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
58305101|NCT02686853|DRUG|Liposomal amphotericin B|
58305102|NCT03805594|DRUG|Lutetium Lu 177-PSMA-617|Given IV
58305103|NCT03805594|BIOLOGICAL|Pembrolizumab|Given IV
58305104|NCT01288690|BEHAVIORAL|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
58090984|NCT05724875|DEVICE|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
58090985|NCT05905809|DEVICE|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
58090986|NCT05905809|DEVICE|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
58090987|NCT04425642|DRUG|Glucose/Amino acids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
58090988|NCT04425642|DRUG|Glucose/Amino acids/Lipids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
58090989|NCT03054168|DRUG|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
58090990|NCT03054168|DRUG|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
58090991|NCT03054168|OTHER|Placebo|
58090992|NCT05520060|OTHER|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
58090993|NCT05520060|OTHER|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
58090994|NCT05520060|OTHER|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
58090995|NCT05520060|OTHER|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
58090996|NCT04041063|DEVICE|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
58090997|NCT04041063|PROCEDURE|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
58090998|NCT00002066|DRUG|Thymopentin|
58090999|NCT02107768|OTHER|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
58091000|NCT06196970|OTHER|Pilate exercises|After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
57734324|NCT03392311|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
58091001|NCT06196970|OTHER|Burpees exercises|"After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set."
57734325|NCT02921997|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
57734326|NCT02921997|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
58417874|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
58091002|NCT05813275|DRUG|AD109|Oral administration at bedtime
58091003|NCT05813275|DRUG|Placebo|Oral administration at bedtime
58091004|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|This clinical trial is divided into three stages: the screening phase, the treatment phase, and the follow-up phase. During the screening phase, patient enrollment must be completed, and baseline conditions must be recorded. In the treatment phase, the transplantation treatment process for patients in the HLA-matched HSCT group and the umbilical cord blood-supported haplo-HSCT group must be completed, and treatment conditions must be recorded. In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
58091005|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
58091006|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
58095251|NCT03187288|DRUG|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
58095252|NCT04656782|OTHER|Imaging survey|Participation as expert panelist in the imaging survey.
58305105|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
58305106|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
58305107|NCT01329198|DEVICE|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
58305108|NCT02560168|DEVICE|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
58305109|NCT02560168|DEVICE|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
58305110|NCT02560168|DEVICE|Transthoracic Echocardiography|
58305111|NCT00368628|PROCEDURE|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
58305112|NCT03087864|DRUG|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
58305113|NCT03087864|DRUG|Carboplatin|Chemotherapy
58417875|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
57734327|NCT02921997|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
57949612|NCT04350775|OTHER|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
58305114|NCT03087864|DRUG|Paclitaxel|Chemotherapy
58305115|NCT03087864|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy
58305116|NCT03286920|DIETARY_SUPPLEMENT|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
58417876|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
58417877|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
58091007|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
58091008|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
58091009|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
58091010|NCT00457431|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
58091011|NCT06393907|DEVICE|Hemostatic Forceps|The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.
58091012|NCT06393907|DEVICE|Bipolar Electrocautery Probes|The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.
58091013|NCT01267968|DRUG|GSK2251052|1500 mg (dosing detailed in Arm description)
58091014|NCT03299218|DIETARY_SUPPLEMENT|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
58091015|NCT03299218|BEHAVIORAL|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
58417878|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
57949613|NCT02176473|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
57949614|NCT02757599|OTHER|Ultrasound training|Training on the transvaginal ultrasound simulator.
58091016|NCT03299218|OTHER|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
58091017|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
58091018|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
58091019|NCT04651673|OTHER|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
58091020|NCT06060496|DEVICE|Active cTBS|Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
58091021|NCT06060496|DEVICE|Sham cTBS|Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
58417879|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
58417880|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
58417881|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
58417882|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
58417883|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
57734328|NCT04287023|OTHER|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
58417884|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
58417885|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
58417886|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
57734329|NCT04287023|OTHER|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
57734330|NCT03021226|BEHAVIORAL|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
57734331|NCT03021226|BEHAVIORAL|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
58417887|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
58417888|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
58417889|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
58417890|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
58417891|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
58417892|NCT01610596|DRUG|Placebo|
58417893|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
58417894|NCT01064687|DRUG|LY2189265|
58417895|NCT01064687|DRUG|Exenatide|
58417896|NCT01064687|DRUG|Placebo|
57734332|NCT03021226|BEHAVIORAL|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
57734333|NCT06670976|PROCEDURE|Biopsy|Undergo tissue biopsy sample collection
57734334|NCT06670976|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57734335|NCT06670976|PROCEDURE|Computed Tomography|Undergo CT scan
57734336|NCT06670976|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57734337|NCT06670976|DRUG|Propranolol|Given PO
57734338|NCT06670976|RADIATION|Radiation Therapy|Undergo RT
57734339|NCT06670976|PROCEDURE|Surgical Procedure|Undergo surgery
57734340|NCT02978274|DRUG|MMF|MMF withdrawal by engraftment post haplo-SCT
57734341|NCT02978274|DRUG|MMF|MMF withdrawal by 2 month post haplo-SCT
57734342|NCT00149058|DRUG|Erythropoietin|
57734343|NCT05975268|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
57734344|NCT05625048|OTHER|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
57734345|NCT06635382|OTHER|Universal single bond adhesive|Will be applied and light cured for 20 seconds.
57734346|NCT06635382|OTHER|DMSO|DMSO application on tooth followed by active application of universal single bond adhesive and light cured for 20 seconds.
57734347|NCT04913363|OTHER|Green space|Green space in which activities take place
57734348|NCT02279758|DRUG|Metformin|
57734349|NCT03089086|BIOLOGICAL|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
57734350|NCT06369350|DRUG|Vitamin B6 25 MG|Vitamin B6 25 mg/day will be given for up to 31 days.
58417897|NCT01064687|DRUG|Metformin|
57734351|NCT06369350|DRUG|Vitamin B6 50 MG|Vitamin B6 50 mg/day will be given for up to 31 days.
57734352|NCT06369350|DRUG|Vitamin B6 100 MG|Vitamin B6 100 mg/day will be given for up to 31 days.
57734353|NCT06369350|DRUG|Placebo|Placebo capsule will be given for up to 31 days.
58417898|NCT01064687|DRUG|Pioglitazone|
58417899|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
58417900|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
58417901|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
58417902|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
58417903|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
58417904|NCT01883011|DRUG|Piracetam|
58417905|NCT01883011|OTHER|Placebo|
58417906|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
58417907|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
58417908|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
58417909|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
58091022|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
58091023|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
58417910|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
58091024|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
58091025|NCT02086968|DRUG|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
58091026|NCT02086968|DRUG|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
58091027|NCT01347983|DRUG|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
58091028|NCT02998645|DRUG|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
58091029|NCT02998645|DRUG|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained"
58091030|NCT03969979|DIAGNOSTIC_TEST|Shear wave elastography|shear wave elastogrophy will be performed
58091031|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
58091032|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
58091033|NCT03086642|DRUG|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
58417911|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
58417912|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
58417913|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
58417914|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
58417915|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
58417916|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
58417917|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
58417918|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
58417919|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
58417920|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
57734354|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
57734355|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
58091034|NCT01291186|DRUG|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
58091035|NCT01291186|DRUG|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
58091036|NCT01291186|DRUG|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
58091037|NCT01291186|DRUG|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
58091038|NCT01291186|DRUG|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
58091039|NCT01291186|DRUG|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
58417921|NCT00764907|DRUG|asparaginase|Given IV during reinduction
57734356|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
58091040|NCT01291186|DRUG|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
58091041|NCT01291186|DRUG|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
58091042|NCT01291186|DRUG|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
58091043|NCT01291186|DRUG|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
58091044|NCT01291186|DRUG|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
58091045|NCT01291186|DRUG|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
58091046|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
58091047|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
58091048|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
57734357|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
57734358|NCT00868023|DRUG|Placebo|Placebo
58091049|NCT06316960|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
58091050|NCT06316960|DRUG|Azacitidine Injection|75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
57734359|NCT05005975|DRUG|MT-7117|MT-7117
57734360|NCT01742767|DRUG|Cisplatinum|
57734361|NCT01742767|DRUG|Pemetrexed|
58091051|NCT06316960|DRUG|Decitabine Injection|20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
57734362|NCT04137380|DRUG|Mirikizumab - IV|Administered IV
57734363|NCT04137380|DRUG|Mirikizumab - SC|Administered SC
58091052|NCT06316960|DRUG|Idarubicin Hydrochloride|5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
58417922|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
58305117|NCT03286920|DIETARY_SUPPLEMENT|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
58417923|NCT00764907|DRUG|cytarabine|Given IV during reinduction
58417924|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
58417925|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
58417926|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
58417927|NCT00764907|DRUG|etoposide|Given IV during reinduction
58417928|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
58417929|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
58417930|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
58417931|NCT00764907|DRUG|methotrexate|Given orally during reinduction
58305118|NCT03073772|BEHAVIORAL|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
58305119|NCT03073772|BEHAVIORAL|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
58417932|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
58417933|NCT00764907|DRUG|thioguanine|Given orally during reinduction
58417934|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
58417935|NCT00764907|DRUG|vindesine|Given IV during reinduction
58417936|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
58417937|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
58417938|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
58417939|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
58417940|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
58417941|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
58417942|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
58417943|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
58417944|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
58417945|NCT01922375|DRUG|Naftopidil|
58417946|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
58417947|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
57949615|NCT05347186|OTHER|Systematic corrective exercises and non-biomechanical functional exercises|"1. Restraint exercise or self-release: will involve the gastrocnemius muscle, soleus muscle, fibula, knee compressor muscles, adductors of the thighs, the short head of the biceps femoris, and iliotibial band for 30 seconds, using a foam roller.~2. Static stretching drills: involving the soleus and gastrocnemius muscles on an inclined plane, tensor fasciae latae muscle, short head of the biceps femoris, and ilio- psoas muscle;~3. Resistance exercises: will consist of strengthening the eccentric muscles of the feet including dorsiflexion and knee inversion, adduction, and extension, external rotation of the hip joint with TheraBand exercise band, and strengthening the intrinsic muscles of the foot.~4. Integrative exercises: including the star balance test on all planes and resistive exercises."
57949616|NCT05347186|OTHER|Non biomechanical functional exercises|Conventional treatment involved Non biomechanical Functional exercises (NBF), these exercises indicated for the control group consists of dorsal and plantar flexion of the metatarsophalangeal joints in unloading of the subject in a long sitting position on a chair or couch with the knee at 90◦ for a period of eight weeks. Feet will be in hanging position to allow plantar flexion smoothly. The exercises will carry out daily without any kind of resistance for a period of 30s. A total of five series will be completed for each foot. These exercises will be considered as non-therapeutic which might have affected the foot's posture.
57949617|NCT04116385|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
57949618|NCT05049096|DEVICE|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
57949619|NCT05049096|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
57734364|NCT04137380|DRUG|Placebo - IV|Administered IV
57949620|NCT03737058|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
57949621|NCT00042887|DRUG|mitomycin C|
57949622|NCT00042887|PROCEDURE|conventional surgery|
57949623|NCT00777101|DRUG|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
57949624|NCT00777101|DRUG|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
57949625|NCT00777101|DRUG|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
57949626|NCT03068442|DRUG|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
57949627|NCT02149940|OTHER|heart-failure related pharmaceutical intervention|
57949628|NCT00961220|DRUG|Carmustine|Applied topically
57949629|NCT00961220|OTHER|Laboratory Biomarker Analysis|Correlative studies
57949630|NCT00961220|DRUG|O6-Benzylguanine|Given IV
57949631|NCT06365203|PROCEDURE|Through knee amputation|Amputation Technique
57949632|NCT06365203|PROCEDURE|Above knee Amputation|Amputation Technique
57949633|NCT04893642|PROCEDURE|Suture rectopexy|
57949634|NCT04893642|PROCEDURE|resection rectopexy|
57949635|NCT04893642|PROCEDURE|Delorme's operation|
57949636|NCT04893642|PROCEDURE|Altemeier's operation|
57949637|NCT02257372|DRUG|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
57949638|NCT02257372|DRUG|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
57949639|NCT02257372|DRUG|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
58417948|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
58091053|NCT06316960|DRUG|Cytarabine|10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
58091054|NCT06316960|DRUG|Granulocyte Colony-Stimulating Factor|300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
58091055|NCT04559373|OTHER|Virtual Reality and Field Training (VRFT)|The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
58091056|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
57734365|NCT04137380|DRUG|Placebo - SC|Administered SC
57949640|NCT02257372|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
57949641|NCT02522702|OTHER|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
58091057|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
58091058|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
58091059|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
58417949|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
58417950|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
58417951|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
57949642|NCT02534402|DRUG|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
58091060|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
58091061|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
58091062|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
58091063|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
58417952|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
58417953|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
58417954|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
58417955|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
58417956|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
58091064|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
58417957|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
58417958|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
58417959|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
58091065|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
57734366|NCT05892679|OTHER|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
58091066|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
58091067|NCT05939713|DEVICE|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
58091068|NCT01243866|OTHER|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
58091069|NCT01243866|OTHER|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
58091070|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
58091071|NCT03474952|PROCEDURE|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
58091072|NCT03474952|PROCEDURE|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
58417960|NCT00797238|OTHER||No intervention in this study
58417961|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
58095253|NCT04656782|OTHER|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
58417962|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
58417963|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
58417964|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
58417965|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
58417966|NCT00029757|DRUG|Estrogen|
58417967|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
58417968|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
58305120|NCT00535613|DRUG|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
58305121|NCT00001328|DRUG|Cytovene (Ganciclovir Sodium)|
58305122|NCT00001328|DEVICE|G1TKSVNa.53 Producer Cell Line|
58305123|NCT02513550|DRUG|Ixekizumab|Administered SQ
58305124|NCT02513550|DRUG|Placebo|Administered SQ
58305125|NCT00213681|DEVICE|Boussignac CPAP - bilevel ventilation support|
58305126|NCT05590169|OTHER|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
57734367|NCT05475418|PROCEDURE|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
58305127|NCT00086190|DRUG|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
58305128|NCT00086190|DRUG|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
58305129|NCT00086190|OTHER|placebo|an inactive substance
58305130|NCT02431689|PROCEDURE|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
58305131|NCT03246464|DEVICE|Orthokeratology lenses|Rigid gas permeable contact lenses
57949643|NCT04445571|PROCEDURE|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
57949644|NCT04812132|PROCEDURE|One-anastomosis gastric bypass|One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)
58305132|NCT03246464|DEVICE|Single-vision spectacles|Regular single vision spectacles
58305133|NCT02112214|DRUG|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
57949645|NCT04812132|PROCEDURE|Long biliary limb Roux gastric bypass|Other group is planned to receive a long biliary limb Roux gastric bypass
57734368|NCT05795595|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
57949646|NCT01245582|DRUG|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
57949647|NCT01245582|DRUG|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
58305134|NCT02112214|OTHER|Placebo|Placebo for bismuth-based quadruple therapy
58305135|NCT05734261|PROCEDURE|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
57734369|NCT03752229|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58417969|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
58417970|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
58417971|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
58417972|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
57734370|NCT03752229|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734371|NCT03752229|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949648|NCT01245582|DRUG|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
57949649|NCT01263821|PROCEDURE|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
58417973|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
58417974|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
57734372|NCT03752229|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58417975|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
58417976|NCT04041427|OTHER|High fat content diet|High fat content diet
58417977|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
58417978|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
58417979|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
58417980|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
58417981|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
57949650|NCT01263821|PROCEDURE|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
57949651|NCT01263821|PROCEDURE|Functional magnetic resonance imaging|Undergo functional MRI
57949652|NCT01263821|PROCEDURE|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
57949653|NCT01263821|PROCEDURE|Therapeutic conventional surgery|Undergo maximal surgical resection
58305136|NCT05862935|OTHER|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
58417982|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
58417983|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
58417984|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
58417985|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
58417986|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
58417987|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
58417988|NCT02783378|DRUG|Gaviscon Syrup|
58417989|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
58417990|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
58417991|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
58417992|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
58417993|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
58417994|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
58417995|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
58417996|NCT02071186|OTHER|Standard of care|
58417997|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
57949654|NCT01263821|PROCEDURE|Quality-of-life assessment|Ancillary studies
58305137|NCT05862935|OTHER|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
58305138|NCT00402831|BIOLOGICAL|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
58305139|NCT00626288|DRUG|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
58305140|NCT00626288|DRUG|Placebo|Placebo cpr, t.i.d. 12 weeks
58305141|NCT02065180|DIETARY_SUPPLEMENT|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
58305142|NCT02065180|DIETARY_SUPPLEMENT|placebo|
57949655|NCT01263821|PROCEDURE|Radiation therapy treatment planning/simulation|Undergo IMRT planning
58305143|NCT01549145|DEVICE|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
58305144|NCT06325163|DIAGNOSTIC_TEST|CBCT|Mandibular molar indicated for retreatment will be scanned using limited field of view CBCT to examine the number of canals
58305145|NCT06325163|DIAGNOSTIC_TEST|clinical examination under dental operating microscope|the number of canals will be examined by an a randomly assigned operator following gutta percha removal under dental operating microscope
58305146|NCT06325163|DIAGNOSTIC_TEST|canal detection AI software (diagnocat)|software used to analyze CBCT images and report the number of canals
58417998|NCT00276614|DRUG|bortezomib|
58417999|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
57949656|NCT01263821|PROCEDURE|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
57949657|NCT01263821|OTHER|Questionnaire administration|Ancillary studies
57949658|NCT05500209|BEHAVIORAL|Personal resources' enhancement: self-efficacy|Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
58305147|NCT00344695|DRUG|bupropion SR|
58305148|NCT01376869|DIETARY_SUPPLEMENT|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
58418000|NCT02532712|DRUG|Placebo|Placebo with same shape and size
58091073|NCT04682977|OTHER|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
58091074|NCT04682977|OTHER|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
58305149|NCT01376869|OTHER|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
58305150|NCT00611585|DEVICE|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
58305151|NCT05426746|DRUG|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
58305152|NCT05426746|OTHER|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
58305153|NCT03820401|DEVICE|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
58305154|NCT03820401|OTHER|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
57949659|NCT05973929|OTHER|Screen for movement disorder and correlates it with MRI findings.|"* To determine the prevalence of movement disorders in MS patients.~* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~* To find the correlation between the movement disorder and the different types of MS."
57949660|NCT02662257|DRUG|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
57949661|NCT02662257|DRUG|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
58305155|NCT03820401|OTHER|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
58305156|NCT03820401|OTHER|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
58418001|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
57949662|NCT01157975|DRUG|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
57949663|NCT01157975|DRUG|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
57949664|NCT05017207|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
57949665|NCT02641145|RADIATION|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
57949666|NCT02641145|DEVICE|MRI|Cardiac MRI with gadolinium contrast.
57949667|NCT02641145|RADIATION|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
58091075|NCT00518531|DRUG|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
58095254|NCT05040035|DIAGNOSTIC_TEST|ACT measurement|Measurement of active clotting time (ACT)
58418002|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
58418003|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
58418004|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
58418005|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
58418006|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
58418007|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
58418008|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
58418009|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
58418010|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
58418011|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
58418012|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
57949668|NCT03048903|DRUG|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
58305157|NCT05956041|DRUG|Pembrolizumab|400mg Intravenously
57949669|NCT03048903|DRUG|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
57949670|NCT01565733|DRUG|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
57949671|NCT03858673|PROCEDURE|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
57949672|NCT00002753|RADIATION|iodine I 131 monoclonal antibody 81C6|
57949673|NCT01901575|DRUG|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
58091076|NCT00518531|DRUG|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
58091077|NCT00197561|DIETARY_SUPPLEMENT|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
58091078|NCT00197561|DIETARY_SUPPLEMENT|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
58305158|NCT05956041|DRUG|Mogamulizumab|1mg/kg Intravenously
58305159|NCT06405919|DIAGNOSTIC_TEST|Histopathology|Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
58305160|NCT03319498|OTHER|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
58418013|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
58418014|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
58418015|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
58418016|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
58418017|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
58418018|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
58418019|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
58418020|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
58418021|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
58418022|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
58418023|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
58418024|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
58091079|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
58091080|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
58418025|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
58418026|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
58418027|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
58418028|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
58418029|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
58091081|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
58091082|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
58091083|NCT06341413|DEVICE|SmartSleep device|Device worn during sleep
58418030|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
58418031|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
58418032|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
58418033|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
58418034|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
58418035|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
58091084|NCT01570127|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
58418036|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
58418037|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
58418038|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
58418039|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
58418040|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
58418041|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
58091085|NCT01570127|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
58418042|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
57949674|NCT04481984|OTHER|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
58305161|NCT03319498|OTHER|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
58305162|NCT03156075|BEHAVIORAL|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
58305163|NCT01525589|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
58305164|NCT03256617|OTHER|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
58418043|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
58418044|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
58305165|NCT05287789|OTHER|Squatting position by footstool|"Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation."
58418045|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
58418046|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
58418047|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
58418048|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
58418049|NCT02177019|OTHER|Personalized health plan|
58418050|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
57949675|NCT04481984|OTHER|Care advice|Patients received care advice including avoiding cold exposure and trauma.
58091086|NCT01570127|PROCEDURE|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
58091087|NCT01570127|OTHER|Waiting|No interventions were applied to the patients in this group.
58091088|NCT00002373|DRUG|Maribavir|
58091089|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
58418051|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
58305166|NCT04074265|DRUG|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
58305167|NCT04074265|DRUG|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
58418052|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
58418053|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
58418054|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
58418055|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
58418056|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
58305168|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 125 mg|One capsule before breakfast for 84 days
58418057|NCT04527419|PROCEDURE|Systematically mediastinal lymph node dissection|Systematically mediastinal lymph node dissection will be performed.
58305169|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 250 mg|One capsule before breakfast for 84 days
58305170|NCT04733924|OTHER|Microcrystalline Cellulose|One capsule before breakfast for 84 days
58418058|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
58418059|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
58305171|NCT04577066|OTHER|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
58418060|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
58418061|NCT00174538|DRUG|Codeine (30 mg)|
58418062|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
58418063|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
58418064|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
58418065|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
58418066|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
58418067|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
58418068|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
58418069|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
58091090|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
58091091|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
58418070|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
58418071|NCT02102126|PROCEDURE|Renal denervation|
58418072|NCT00137189|PROCEDURE|Resource-oriented music therapy|
58418073|NCT00137189|PROCEDURE|Standard care|
58305172|NCT04577066|OTHER|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
58305173|NCT04577066|OTHER|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
58418074|NCT02170766|DRUG|BIBR 1048 low1|
58418075|NCT02170766|DRUG|BIBR 1048 low2|
58418076|NCT02170766|DRUG|BIBR 1048 medium|
58418077|NCT02170766|DRUG|BIBR 1048 high|
58418078|NCT02170766|DRUG|Pantoprazole|
58091092|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
58091093|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
58091094|NCT06109402|DRUG|TQB2450|Specified dose on specified days
58091095|NCT06109402|DRUG|Carboplatin|Specified dose on specified days
58091096|NCT06109402|DRUG|Pemetrexed|Specified dose on specified days
58091097|NCT06109402|DRUG|Nab-paclitaxel|Specified dose on specified days
58091098|NCT06109402|PROCEDURE|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
58091099|NCT06373978|DRUG|Diclofenac|50mg every 8hours as needed for pain
58091100|NCT06373978|DRUG|Tramadol|50mg every 8hours as needed for pain
58091101|NCT06373978|OTHER|Acetaminophen|1000mg every 8hours as needed for pain
58091102|NCT03101215|DIETARY_SUPPLEMENT|phosphorus|adding of phosphorus to high carbohydrate meal
58091103|NCT06702826|DRUG|Cadonilimab combined with SRS|Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
58091104|NCT02830724|DRUG|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
58091105|NCT02830724|DRUG|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
58091106|NCT02830724|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
58091107|NCT02830724|BIOLOGICAL|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
58091108|NCT00544713|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
58091109|NCT00544713|DRUG|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
58091110|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
58091111|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
58091112|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
58091113|NCT04395040|OTHER|Semi-structured interview|Semi-structured interview
58091114|NCT04770194|DRUG|SP-8008 Prototype Capsule A|Oral
58091115|NCT04770194|DRUG|SP-8008 Prototype Capsule B|Oral
57949676|NCT02651168|BIOLOGICAL|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
57949677|NCT04085679|OTHER|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
57949678|NCT05120479|PROCEDURE|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
57949679|NCT05120479|PROCEDURE|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
57949680|NCT02679898|OTHER|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
57949681|NCT02679898|OTHER|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
57949682|NCT02270619|BIOLOGICAL|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
57949683|NCT02270619|BEHAVIORAL|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
58091116|NCT04770194|DRUG|Placebo|Oral
58095255|NCT04177745|OTHER|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
58095256|NCT04177745|OTHER|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
58095257|NCT01247207|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
58095258|NCT02379338|DRUG|[18F]Fluortriopride|All subjects will receive a \[18F\]Fluortriopride PET/CT scan
58305174|NCT05572203|DIETARY_SUPPLEMENT|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
58305175|NCT03092427|DIETARY_SUPPLEMENT|VSL#3|Dietary Supplement
58305176|NCT03092427|OTHER|Placebo|Placebo
58305177|NCT02027025|DRUG|SPARC1103 low dose|once daily
58305178|NCT02027025|DRUG|SPARC1103 high dose|once daily
58305179|NCT02027025|DRUG|SPARC Placebo|
58305180|NCT03802552|DRUG|Cefadroxil|oral one-time dose of cefadroxil
58305181|NCT03802552|DRUG|Cephalexin|oral one-time dose of cephalexin
58305182|NCT01763541|DRUG|leuprolide acetate|Given to both arms to induce hypogonadism
58305183|NCT01763541|DRUG|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
58305184|NCT00310986|BEHAVIORAL|Breathing Meditation|
58305185|NCT01171378|DRUG|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
58305186|NCT03634319|DEVICE|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
58305187|NCT03516565|OTHER|Saliva collection|
58305188|NCT03516565|OTHER|GCF collection|
58305189|NCT00177125|DEVICE|ErectAid|
58305190|NCT04895501|OTHER|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
58305191|NCT00463645|PROCEDURE|microdialysis|
58305192|NCT00463645|PROCEDURE|microperfusion|
58305193|NCT04789304|DRUG|BI 1595043|BI 1595043
58305194|NCT04789304|DRUG|Placebo|Placebo
58305195|NCT04789304|DRUG|Midazolam|Midazolam
58305196|NCT06429904|DRUG|Nimotuzumab+ NALIRIFOX|"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"
58305197|NCT04802447|DRUG|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
58305198|NCT03043456|DEVICE|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
57949684|NCT02270619|OTHER|Placebo|0.9% saline as IV bolus
57949685|NCT02270619|OTHER|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
57949686|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
57949687|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
57949688|NCT01251653|DRUG|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
57949689|NCT01251653|DRUG|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
57949690|NCT04933175|DRUG|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
57949691|NCT04933175|DRUG|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
57949692|NCT05349929|DRUG|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
57949693|NCT05349929|DRUG|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
57949694|NCT05349929|PROCEDURE|Root Canal Therapy|all the participants go under RCT.
57949695|NCT01324258|DRUG|GSK1120212|Part1 and Part2
57949696|NCT01324258|DRUG|Gemcitabine|Part2
57949697|NCT04233697|DRUG|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
58305199|NCT03043456|DEVICE|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
58305200|NCT02515435|DRUG|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
58418079|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
58418080|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
57949698|NCT04233697|DRUG|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
57949699|NCT03666832|DRUG|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
57949700|NCT06281860|DRUG|Cisplatine Teva®|PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C
57949701|NCT01500278|BIOLOGICAL|Certolizumab Pegol (CZP)|"* Active substance: an injectable volume of 1 ml solution for injection CZP~* Pharmaceutical form: prefilled syringes CZP~* Concentration: 200 mg/ml CZP~* Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
57949702|NCT01500278|BIOLOGICAL|Adalimumab (ADA)|"* Active substance: an injectable volume of 0.8 ml solution for injection ADA~* Pharmaceutical form: prefilled syringes ADA~* Concentration: 40 mg/0.8 ml ADA~* Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
57949703|NCT01500278|DRUG|Methotrexate (MTX)|"* Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally"
58418081|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
58418082|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
58418083|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
58418084|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
58418085|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
58418086|NCT00933920|DRUG|Aliskiren|
58418087|NCT00933920|DRUG|Aliskiren|
58418088|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
58418089|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
58418090|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
58418091|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
58418092|NCT03275948|OTHER|whole grain|whole grain rye
58418093|NCT03275948|OTHER|reference|white wheat bread
58091117|NCT04843501|BEHAVIORAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
58091118|NCT04843501|BEHAVIORAL|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
58091119|NCT06181136|DRUG|DNL126|intravenous repeating dose
58091120|NCT00527527|PROCEDURE|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
58091121|NCT00527527|OTHER|placebo control|Placebo for comparison with flexion distraction treatment
58091122|NCT00380575|DRUG|YM087|
58091123|NCT04853888|BEHAVIORAL|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
58418094|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
58418095|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
58418096|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
58418097|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
58418098|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
58418099|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
58418100|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
58418101|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
58091124|NCT06593366|BIOLOGICAL|Fecal Microbiota Transplant|An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
58091125|NCT06593366|DRUG|Placebo|Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
58091126|NCT03348319|OTHER|radiation|Scanning cadaver organs
58091127|NCT02594384|DRUG|LAM-002A|25 mg capsules or 50 mg capsules
58091128|NCT02594384|DRUG|Rituximab|375 mg/m2 by vein
58091129|NCT02594384|DRUG|Atezolizumab|1200 mg by vein
58091130|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
58091131|NCT00326339|DRUG|Placebo|Placebo PO bid
58418102|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
58418103|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
58418104|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
58418105|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
58091132|NCT02619370|BEHAVIORAL|Conversation card game|
58091133|NCT02619370|BEHAVIORAL|Active Control|
58091134|NCT06184659|DRUG|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
58091135|NCT06184659|DRUG|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
58418106|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
58418107|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
58418108|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
58418109|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
58091136|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
58091137|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
58091138|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
58091139|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
58091140|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
58418110|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
58418111|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
57949704|NCT05818592|OTHER|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
57949705|NCT06152445|OTHER|Wheat bread|Different wheat breads
57949706|NCT05791500|BEHAVIORAL|lifestyle intervention|dietary behavior interventions:through a couple of dietary health education lectures physical activity interventions:through at least an offline teaching and jump rope or jog regularly and quantitatively life schedule and habits intervention group: live in a regular and healthy life habit and last at least 4 months
57949707|NCT03173833|OTHER|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
57949708|NCT03363321|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous injection
57949709|NCT04940104|DRUG|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
58091141|NCT06423937|DRUG|combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab|"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
58091142|NCT02949219|OTHER|Laboratory Biomarker Analysis|Correlative studies
58418112|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
58418113|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
58418114|NCT00003231|DRUG|cisplatin|
58091143|NCT02949219|BIOLOGICAL|Pembrolizumab|Given IV
58091144|NCT06594289|PROCEDURE|In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake|"The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake)."
58418115|NCT00003231|DRUG|docetaxel|
57949710|NCT02120014|PROCEDURE|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
58418116|NCT00003231|PROCEDURE|surgical procedure|
58418117|NCT00003231|RADIATION|radiation therapy|
58418118|NCT00299780|DRUG|Stem cell mobilization|
58418119|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
58418120|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
58418121|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
58418122|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
57949711|NCT02120014|PROCEDURE|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
57949712|NCT05428891|PROCEDURE|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
58418123|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
57949713|NCT00427076|DRUG|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
57949714|NCT00427076|DRUG|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
58091145|NCT04125160|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
58091146|NCT04125160|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
58091147|NCT04344782|DRUG|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
58305201|NCT01305811|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
58418124|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
58418125|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
58418126|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
58418127|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
58091148|NCT04056091|PROCEDURE|Back rub stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
58091149|NCT04056091|PROCEDURE|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
58091150|NCT02394379|DEVICE|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
58091151|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
58091152|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
58305202|NCT04261140|OTHER|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
58305203|NCT04261140|OTHER|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
58305204|NCT04261140|OTHER|NexComp Flow|Apply in 2-mm increment light cure for 20 s
58305205|NCT04261140|OTHER|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
58305206|NCT00225875|DRUG|Mabthéra|
58305207|NCT05446285|OTHER|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
58305208|NCT02092753|OTHER|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
58305209|NCT02092753|OTHER|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
58305210|NCT02092753|OTHER|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
58305211|NCT02198534|DEVICE|Methodology of visual acuity assessment|
58418128|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
57949715|NCT06080828|DEVICE|Percutaneous Posterior Tibial Nerve Stimulation|20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
57949716|NCT06080828|DEVICE|Placebo Percutaneous Posterior Tibial Nerve Stimulation|placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
57949717|NCT06080828|BEHAVIORAL|Home instructions|they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
57949718|NCT05513248|PROCEDURE|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
57949719|NCT01783080|BEHAVIORAL|Behavioral Activation for return to work|See Arm Description
57949720|NCT05470127|DEVICE|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
57949721|NCT02514616|PROCEDURE|Laparoscopic IPG and lead implant procedure|EST placement
57949722|NCT02514616|DEVICE|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
58305212|NCT04535427|DRUG|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58305213|NCT04535427|DRUG|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58305214|NCT02814071|OTHER|Early enteral feeding|Early enteral feeding as per description
58305215|NCT02669706|DRUG|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
58091153|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
58091154|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
58091155|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
58091156|NCT06653478|OTHER|No Intervention|No Intervention
58091157|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
58091158|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
58091159|NCT02263677|DRUG|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
58091160|NCT05844826|DEVICE|SIMBA Capsule|Participants will swallow capsule
58091161|NCT00216073|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
58091162|NCT00216073|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
58091163|NCT00216073|DRUG|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
58091164|NCT05165173|DIETARY_SUPPLEMENT|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
58091165|NCT05165173|DIETARY_SUPPLEMENT|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
58091166|NCT01125007|DEVICE|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
58091167|NCT06173713|DEVICE|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
58305216|NCT05985863|DRUG|standard medical treatment|standard medical treatment for ACLF
57949723|NCT02514616|DEVICE|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
57949724|NCT05348174|BEHAVIORAL|Virtual Reality Assisted Guided Imagery (VRAGI)|The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
58091168|NCT04475536|DEVICE|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
58091169|NCT00178763|DEVICE|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
58091170|NCT00178763|OTHER|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
58091171|NCT00178763|OTHER|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
58091172|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
58305217|NCT05985863|DRUG|Placebo|5% human serum albumin in 0.9% saline (at week0, week1 and week2)
58305218|NCT05985863|DRUG|hUC-MSC|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
58305219|NCT05985863|DRUG|hUC-MSC_Prolonged|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
58305220|NCT01548807|DRUG|Everolimus (RAD001)|
58305221|NCT05847608|DIETARY_SUPPLEMENT|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
58305222|NCT05847608|DIETARY_SUPPLEMENT|Placebo|Oleic Acid, Linoleic Acid
58091173|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
58091174|NCT02183701|DRUG|Telmisartan|
58091175|NCT02183701|DRUG|Losartan + Hydrochlorothiazide|
58091176|NCT02183701|DRUG|Placebo|
58091177|NCT02934568|DRUG|LEE011|Single agent LEE011 or in combination with other treatments
58091178|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
58091179|NCT05015803|COMBINATION_PRODUCT|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
58091180|NCT05015803|BEHAVIORAL|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
58091181|NCT05015803|BEHAVIORAL|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
58091182|NCT06405087|DRUG|Vedolizumab SC|Vedolizumab subcutaneous injection.
58091183|NCT06405087|OTHER|No Intervention|As this is an observational cohort, no intervention will be administered.
58091184|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
58091185|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
57949725|NCT04535349|DIAGNOSTIC_TEST|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
57949726|NCT05873582|DEVICE|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
57949727|NCT01531309|DRUG|AGO178|AGO178 is administered as a sublingual tablet.
58091186|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
58091187|NCT05634629|PROCEDURE|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
58091188|NCT05634629|PROCEDURE|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
58091189|NCT03015207|DRUG|NNC0194-0499|
58091190|NCT03015207|DRUG|Placebo|
58091191|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
58305223|NCT04420091|DIETARY_SUPPLEMENT|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
57949728|NCT06466226|PROCEDURE|Multiple central venous lines in two sites separately|Patients with two central venous lines in two sites separately (two central venous sites).
57949729|NCT06466226|PROCEDURE|Multiple central venous lines in one site (internal jugular vein)|Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).
57949730|NCT01505634|DRUG|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
58091192|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
58091193|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
58091194|NCT00834288|DRUG|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
58091195|NCT00834288|DRUG|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
58091196|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
58091197|NCT06452797|BEHAVIORAL|ProVent-14 score|A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
58091198|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
58091199|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
57949731|NCT01505634|DRUG|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
58091200|NCT01268683|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
58091201|NCT04881331|OTHER|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
58305224|NCT01521000|DEVICE|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
58305225|NCT00612820|DRUG|GSK256066|200mcg bd,
58305226|NCT00612820|DRUG|fluticasone propionate|200mcg od,100mcg bd
58305227|NCT05880706|DRUG|BL-B01D1|Administration by intravenous infusion
58305228|NCT05880706|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
58305229|NCT02976883|OTHER|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of \[18F\]HX4 and PET/CT scan
58305230|NCT01206465|DRUG|pralatrexate|Given IV
58305231|NCT01206465|DRUG|fluorouracil|Given IV
58418129|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
57734373|NCT03752229|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091202|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
58305232|NCT01206465|OTHER|laboratory biomarker analysis|Correlative studies
58418130|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
58418131|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
58418132|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
58418133|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
58418134|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
58418135|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
58418136|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
58418137|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
58418138|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
57734374|NCT03752229|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949732|NCT01505634|DRUG|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
58305233|NCT01206465|GENETIC|DNA analysis|Correlative studies
58305234|NCT01206465|OTHER|high performance liquid chromatography|Correlative studies
58305235|NCT01206465|GENETIC|polymerase chain reaction|Correlative studies
58305236|NCT01206465|GENETIC|nucleic acid sequencing|Correlative studies
58305237|NCT01206465|OTHER|pharmacological study|Correlative studies
58305238|NCT01206465|OTHER|pharmacogenomic studies|Correlative studies
58305239|NCT01206465|GENETIC|polymorphism analysis|Correlative studies
58305240|NCT03292016|DRUG|APL-130277|APL-130277 sublingual thin film
58305241|NCT03292016|DRUG|APO-go|Subcutaneous APO-go
58305242|NCT03292016|DRUG|Apokyn|Subcutaneous APOKYN
58305243|NCT02138565|PROCEDURE|Gastric by-pass surgery|
58418139|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
58418140|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
58418141|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
58418142|NCT01958892|PROCEDURE|TURP, TUERP|
57734375|NCT03752229|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58305244|NCT06273488|OTHER|Auriculotherapy|Treatment of pain, drug addictions, or other ailments by stimulating the various points on the external ear (EAR AURICLES). It is based on the ancient Chinese practices of EAR ACUPUNCTURE, but sometimes magnets and other modes of stimulation are used.
58305245|NCT04176224|DRUG|MT-1186|Suspension
58305246|NCT04166071|DRUG|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
58305247|NCT04166071|DRUG|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
58305248|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
58305249|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Dasatanib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
58305250|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
58418143|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
58418144|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
58418145|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
58418146|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
58418147|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
58418148|NCT03755232|OTHER|Control|water or dextrose or white bread
58418149|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
57734376|NCT03752229|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734377|NCT03752229|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58305251|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
58305252|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
58305253|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
58305254|NCT03899727|DEVICE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
58305255|NCT02902835|BEHAVIORAL|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
57734378|NCT03752229|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949733|NCT01505634|DRUG|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
57949734|NCT01505634|DRUG|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
58305256|NCT02902835|BEHAVIORAL|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
58305257|NCT04724746|BEHAVIORAL|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
58418150|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
57734379|NCT03752229|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949735|NCT01897285|DEVICE|AQUACEL® foam adhesive dressing|
57949736|NCT04314921|OTHER|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
57949737|NCT01199042|DEVICE|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
57949738|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
57949739|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
58418151|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
58091203|NCT01910701|BEHAVIORAL|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
58305258|NCT05768646|BEHAVIORAL|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
57734380|NCT03752229|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734381|NCT03752229|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734382|NCT03752229|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949740|NCT00914927|DRUG|Placebo|Placebo or inactive substance once a day for up to 7 days
57949741|NCT04759976|BEHAVIORAL|Robotic motor training|The experiments consist in performing motor tasks with upper-limb robotic devices.
57949742|NCT05073497|OTHER|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
57949743|NCT01748279|DRUG|Atorvastatin|
57949744|NCT01748279|DRUG|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
57949745|NCT01748279|DRUG|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
57949746|NCT04066582|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
57949747|NCT02965521|BEHAVIORAL|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
57949748|NCT03341962|DRUG|IMU-838|IMU-838 tablet
57949749|NCT03341962|DRUG|Placebo|Tablets manufactured to mimic IMU-838 tablets
57949750|NCT00911352|DEVICE|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for \> 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
57949751|NCT05530265|DEVICE|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
57949752|NCT05530603|BEHAVIORAL|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
57949753|NCT02845570|OTHER|68Ga-DOTANOC PET/MRI|
58091204|NCT01609127|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
58091205|NCT01609127|DRUG|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
58091206|NCT01609127|DRUG|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
58305259|NCT01805661|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
57734383|NCT03752229|DEVICE|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091207|NCT04476459|DRUG|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
58091208|NCT04476459|DRUG|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
58091209|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
58091210|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
57734384|NCT03752229|DEVICE|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734385|NCT03752229|DEVICE|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58418152|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
57734386|NCT03752229|DEVICE|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091211|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
58091212|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
58305260|NCT01805661|PROCEDURE|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
58305261|NCT01833676|DRUG|Sevoflurane|
58418153|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
57734387|NCT03752229|DEVICE|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734388|NCT03752229|DEVICE|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949754|NCT02845570|OTHER|18F-FDG PET/MRI|
58091213|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
58091214|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
58305262|NCT01833676|DRUG|Desflurane|
58091215|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
58091216|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
58091217|NCT01889927|OTHER|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
58091218|NCT02502084|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
58091219|NCT00684437|BEHAVIORAL|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
58091220|NCT00684437|BEHAVIORAL|Questionnaire|Questionnaires taking 15-30 minutes to complete.
58305263|NCT02858466|RADIATION|MRI scan|
58418154|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
58418155|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
58418156|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
58418157|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
57734389|NCT03752229|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734390|NCT03752229|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734391|NCT03752229|DEVICE|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734392|NCT03752229|DEVICE|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734393|NCT03752229|DEVICE|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091221|NCT01972607|OTHER|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
58091222|NCT06124326|DIETARY_SUPPLEMENT|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
57734394|NCT03752229|DEVICE|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091223|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
58091224|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
58305264|NCT03463083|DRUG|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
58418158|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
58418159|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
58418160|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
58418161|NCT01009346|DRUG|Cetuximab|250mg/m2/week
58418162|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
58418163|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
58418164|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
58418165|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
57734395|NCT03752229|DEVICE|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734396|NCT03752229|DEVICE|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734397|NCT03752229|DEVICE|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58418166|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
58418167|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
58418168|NCT00408590|OTHER|laboratory biomarker analysis|
58418169|NCT04124614|DRUG|Brexpiprazole|Up to 3 mg pill
58418170|NCT04124614|DRUG|Sertraline|Up to 150 mg pill
58418171|NCT04124614|OTHER|Placebo|Pill
58091225|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy with MediNiK|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
58091226|NCT01277107|DRUG|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
58305265|NCT03463083|DRUG|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
58305266|NCT03463083|DRUG|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
58305267|NCT04282174|DEVICE|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
58418172|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
58418173|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
58418174|NCT02784015|DRUG|Cisplatin|
58418175|NCT02784015|DRUG|Etoposide|
58418176|NCT02784015|DRUG|Doxorubicin|
58305268|NCT04282174|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
57949755|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
57949756|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
57949757|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
58091227|NCT01277107|DRUG|Placebo capsule|Identical placebo capsule
58095259|NCT04486807|DIAGNOSTIC_TEST|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
58095260|NCT06083883|DRUG|Fludarabine phosphate|Given by IV (vein)
58418177|NCT02784015|DRUG|Cyclophosphamide|
58418178|NCT02784015|DRUG|Ifosfamide|
58418179|NCT02784015|DRUG|Carboplatin|
58418180|NCT02784015|RADIATION|Radiotherapy|
58418181|NCT02784015|DRUG|Thiotepa|
58418182|NCT02784015|DRUG|Melphalan|
58418183|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
58418184|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
58418185|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
58418186|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
58418187|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
58418188|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
57734398|NCT03752229|DEVICE|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58418189|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
58418190|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
58418191|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
58418192|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
58418193|NCT04728594|BEHAVIORAL|Social Proof|Email
58418194|NCT04728594|BEHAVIORAL|Reframing|Email
58418195|NCT04728594|BEHAVIORAL|Scarcity Message|Email
58418196|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
58418197|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
58418198|NCT00226863|BEHAVIORAL|meditation plus education|
57949758|NCT04788121|DRUG|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
57949759|NCT04788121|OTHER|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
57949760|NCT04618159|OTHER|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
57734399|NCT03752229|DEVICE|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949761|NCT00075400|DRUG|imatinib mesylate|Given PO
58418199|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
58418200|NCT00226863|BEHAVIORAL|education|
58418201|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
58418202|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
58418203|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
58418204|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
58418205|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
58418206|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
58091228|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
58091229|NCT05186727|OTHER|Family History education|The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
58091230|NCT05186727|OTHER|Patient Ambassador|The support of a Patient Ambassador in addition to the education is also tested.
58091231|NCT02995928|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
58305269|NCT04282174|DRUG|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
57949762|NCT00075400|OTHER|laboratory biomarker analysis|Correlative studies
57949763|NCT00542256|DEVICE|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
57949764|NCT00542256|DEVICE|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
58095261|NCT06083883|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by IV (vein)
58095262|NCT06083883|DRUG|Cyclophosphamide|Given by IV (vein)
58305270|NCT04282174|DRUG|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
58305271|NCT04282174|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
58305272|NCT04282174|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
58305273|NCT04282174|DRUG|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
58305274|NCT04282174|DRUG|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
58305275|NCT02683109|DRUG|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
58305276|NCT02683109|DRUG|Placebo|
58305277|NCT02683109|DRUG|Tiotropium|
58305278|NCT02683109|DRUG|Olodaterol|
58418207|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
58418208|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
57949765|NCT05432882|BIOLOGICAL|bi-4SCAR CD19/22 T cells|Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
57949766|NCT01250600|BEHAVIORAL|Home exercise|Daily home exercise for 3 months
58091232|NCT02995928|PROCEDURE|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
58418209|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
58418210|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
58091233|NCT06567782|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
58091234|NCT06567782|DRUG|CAPEOX|CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
58091235|NCT00123110|DRUG|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
58091236|NCT00123110|DRUG|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
58091237|NCT00123110|DRUG|placebo pill|matching pill twice a day for 12 weeks
58091238|NCT00123110|DRUG|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
58091239|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
58091240|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
58091241|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
58091242|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
58091243|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
58418211|NCT00707746|DRUG|mipomersen|
58418212|NCT00707746|DRUG|placebo|
58418213|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
58091244|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
58091245|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
58091246|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
58091247|NCT01827085|DEVICE|Conventional Macintosh laryngoscope|
58091248|NCT01827085|DEVICE|Stortz videolaryngoscope|
58305279|NCT03704064|BEHAVIORAL|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
58305280|NCT03704064|BEHAVIORAL|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are \>10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
58305281|NCT06473441|BEHAVIORAL|Tele-Rehabilitation Therapy|Twice-weekly sessions with remote supervision and guidance from therapists.
58305282|NCT06473441|BEHAVIORAL|Health Education|Health education based on individual assessments.
58305283|NCT06473441|BEHAVIORAL|Exercise Prescription|Exercise prescription tailored to individual needs.
58305284|NCT06473441|BEHAVIORAL|Home Exercise Equipment Use|Use of a home exercise bike, resistance bands, respiratory muscle training device, and a portable heart rate monitor.
58305285|NCT06473441|BEHAVIORAL|Exercise Log|Logging daily exercise intensity and duration in a rehabilitation diary
58305286|NCT06473441|BEHAVIORAL|Follow-Up Calls|Regular follow-up calls to monitor progress and address any issues.
58305287|NCT02321852|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
58305288|NCT02321852|DRUG|Placebo|Once daily oral administration of placebo mannitol for 7 days
58305289|NCT05438563|PROCEDURE|MRI-Guided Transurethral Ultrasound Ablation|Undergo MRI-Guided TULSA
58305290|NCT05438563|OTHER|Quality-of-Life Assessment|Ancillary studies
58305291|NCT05438563|OTHER|Questionnaire Administration|Ancillary studies
58305292|NCT05438563|PROCEDURE|Digital Rectal Examination|Undergo DRE
58305293|NCT05438563|PROCEDURE|Cystoscopy|Undergo cystoscopy
58091249|NCT06652386|OTHER|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
58091250|NCT06269965|DEVICE|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
58091251|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
58091252|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
58091253|NCT06318091|BIOLOGICAL|platelet poor plasma gel|injection of platelet poor plasma gel in the dark circles around the eye to rejuvenate and improve pigmentation
58305294|NCT05438563|PROCEDURE|Biopsy|Undergo biopsy
58305295|NCT05438563|PROCEDURE|Bone Scan|Undergo bone scan
58305296|NCT05438563|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
58305297|NCT05438563|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
58305298|NCT03609463|BEHAVIORAL|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
58418214|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
58091254|NCT06318091|BIOLOGICAL|nanofat|injection of nanofat in the dark circles around the eye to rejuvenate and improve pigmentation
58091255|NCT04317664|COMBINATION_PRODUCT|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
58091256|NCT04317664|BEHAVIORAL|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
58091257|NCT03458910|BEHAVIORAL|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
58091258|NCT03840473|BEHAVIORAL|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
58091259|NCT03840473|BEHAVIORAL|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
58091260|NCT03840473|BEHAVIORAL|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
58091261|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
58091262|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
58091263|NCT05136859|PROCEDURE|preserve|preserve the perivascular fat of the target cephalic vein
58091264|NCT00935415|DRUG|Montelukast|Montelukast 5 mg
58091265|NCT00935415|DRUG|Placebo|capsules of matching placebo
58091266|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (active)|"This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function."
58091267|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
58091268|NCT03486327|DRUG|BR55|A novel targeted ultrasound contrast agent
57734400|NCT03752229|DEVICE|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091269|NCT06014359|DRUG|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
57734401|NCT03752229|DEVICE|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091270|NCT06014359|DRUG|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
58091271|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
58095263|NCT05338437|DEVICE|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
58095264|NCT00006096|DRUG|cisplatin|
58418215|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
58418216|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
58418217|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
58418218|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
58418219|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
58418220|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
57734402|NCT03752229|DEVICE|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734403|NCT03752229|DEVICE|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091272|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
58305299|NCT03609463|BEHAVIORAL|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
58305300|NCT03609463|OTHER|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
58305301|NCT04971499|DRUG|Dapansutrile|500 mg tablet
58305302|NCT04971499|DRUG|Pembrolizumab|Single-use vial containing 100 mg/4 mL of pembrolizumab
58305303|NCT04690465|BEHAVIORAL|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
58305304|NCT04690465|BEHAVIORAL|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
58305305|NCT03049501|BEHAVIORAL|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
58305306|NCT03049501|BEHAVIORAL|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
58305307|NCT02704767|DRUG|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
58305308|NCT02704767|DRUG|Tarceva|
58305309|NCT02704767|DRUG|Placebo|
58305310|NCT03070873|DEVICE|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
58305311|NCT03070873|DEVICE|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
58305312|NCT03070873|PROCEDURE|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
58418221|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
58418222|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
58418223|NCT00844805|DRUG|Infliximab|
58418224|NCT00844805|DRUG|Placebo|
58418225|NCT00844805|DRUG|Naproxen|
58418226|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
58418227|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
58418228|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
58418229|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
58091273|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
58418230|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
58418231|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
58418232|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
58418233|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
57734404|NCT03752229|DEVICE|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734405|NCT03752229|DEVICE|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091274|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
58091275|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
58091276|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
58091277|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
58091278|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
58091279|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
58305313|NCT05480124|DEVICE|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
57734406|NCT03752229|DEVICE|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734407|NCT03752229|DEVICE|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091280|NCT06193044|DRUG|Amlodipine/Valsartan|Amlodipine 10 mg \&valsartan 160 mg
58091281|NCT06193044|DRUG|Amlodipine 10 mg &valsartan 160 mg (Exforge)|Amlodipine 10 mg \&valsartan 160 mg
58091282|NCT05565105|RADIATION|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.
58091283|NCT05565105|DRUG|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
58091284|NCT05565105|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
58418234|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
58418235|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
58418236|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
58418237|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
58418238|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
58418239|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
58418240|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
58091285|NCT05565105|DRUG|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
58418241|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
57734408|NCT03752229|DEVICE|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734409|NCT03752229|DEVICE|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091286|NCT05565105|DRUG|Melphalan|Melphalan: 70 mg/m\^2/day x 2
58091287|NCT05565105|DRUG|Fludarabine|Fludarabine: 25 mg/m\^2/day x 5
58091288|NCT03255226|DRUG|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
58091289|NCT03278483|DRUG|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
58091290|NCT03278483|DRUG|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
58091291|NCT02516917|BEHAVIORAL|Attention Training Technique|
58091292|NCT00730067|DRUG|sildenafil|Sildenafil 50 mg three times daily
58305314|NCT05480124|DEVICE|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
58418242|NCT02082106|OTHER|Alpine skiing|
58418243|NCT02082106|OTHER|cross country skiing|
58091293|NCT00730067|DRUG|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
58091294|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
58091295|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
58091296|NCT04718727|DRUG|Placebo|oral Placebo tablets one-hour preoperatively
58091297|NCT04718727|DRUG|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
58091298|NCT04718727|DRUG|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
58091299|NCT06700577|DIAGNOSTIC_TEST|Gene expert|Gene expert and XDR to detect multidrug resistance between tb patient
58091300|NCT06700577|GENETIC|Ultra xpert and xdr xpert|Detect resistance between tyberculous patient
58095265|NCT00006096|RADIATION|radiation therapy|
58305315|NCT00094445|DRUG|Curcumin|Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
58418244|NCT02082106|OTHER|Indoor training (cycling)|
58418245|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
58091301|NCT04332874|PROCEDURE|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
58091302|NCT04332874|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
58091303|NCT04332874|DRUG|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
58091304|NCT05759988|DEVICE|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
58091305|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
58091306|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
58091307|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
58091308|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
58091309|NCT00461396|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
58091310|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
58091311|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
58091312|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
58091313|NCT01402193|DRUG|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
58091314|NCT01402193|DRUG|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
58091315|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
58418246|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
58091316|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
58091317|NCT01071083|DRUG|natalizumab|300 mg intravenous every 4 weeks
58091318|NCT01071083|DRUG|interferon beta 1-a|30 ug intramuscular once per week
58091319|NCT01071083|DRUG|methylprednisolone|1000 mg intravenous every 4 weeks
58091320|NCT01071083|OTHER|IV placebo|placebo intravenous every 4 weeks
58091321|NCT01071083|DRUG|glatiramer acetate|20 mg subcutaneous once daily
58091322|NCT00572169|DRUG|Velcade|Will be given in central venous catheter
58418247|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
58418248|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
57734410|NCT03752229|DEVICE|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091323|NCT00572169|DRUG|Thalidomide|Capsule taken by mouth
58091324|NCT00572169|DRUG|Dexamethasone|A pill taken by mouth
58091325|NCT00572169|DRUG|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
58091326|NCT00572169|DRUG|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
58091327|NCT00572169|DRUG|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
58091328|NCT00572169|DRUG|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
58091329|NCT05954611|BIOLOGICAL|GR2002 injection|one single dose of GR2002 injection
58091330|NCT05954611|BIOLOGICAL|Placebo|one single dose of placebo
58091331|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
58091332|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
58418249|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
58418250|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
58305316|NCT01208285|DRUG|VX-770|150 mg oral tablet
58418251|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
58418252|NCT02189408|BIOLOGICAL|Platelet rich plasma|
58418253|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
58091333|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
58091334|NCT01743664|BEHAVIORAL|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
58091335|NCT01743664|BEHAVIORAL|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
58305317|NCT05661448|BEHAVIORAL|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
58305318|NCT05661448|BEHAVIORAL|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
58305319|NCT03011203|OTHER|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
58305320|NCT05765877|DRUG|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
58305321|NCT06207409|BEHAVIORAL|PARTS-SUD|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
58305322|NCT02735564|PROCEDURE|Bariatric Surgery|
58305323|NCT05690880|DEVICE|Foresee Home|The ForeseeHome Monitoring System, a non-significant risk device, is prescribed by eye care providers to patients as part of their clinical care. Notal Vision Monitoring Center (NVMC) is an independent diagnostic testing facility responsible for clinical monitoring of FSH data. The NVMC communicates with the patients (for training on the use of the device, troubleshooting of device issues, adherence monitoring, etc.) and with the patients' eyecare providers (for reporting FSH alerts, monitoring of clinical outcomes to assess device functionality and ongoing need for the device, etc.).
58305324|NCT03416439|OTHER|lifestyle intervention|lifestyle intervention program carried out by trained professionals
58305325|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 1|
58305326|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 2|
58305327|NCT01458067|DRUG|GSK2636771|Oral capsules
58305328|NCT04433104|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
58305329|NCT04433104|DRUG|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
58305330|NCT04501250|DRUG|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
58305331|NCT04501250|DRUG|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
58305332|NCT01917279|DRUG|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
58305333|NCT01917279|DRUG|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
58305334|NCT01917279|DRUG|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
58305335|NCT02204917|DRUG|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
58305336|NCT02366416|BEHAVIORAL|Exercise training|Physical activity
58305337|NCT01741077|DIETARY_SUPPLEMENT|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
58305338|NCT03460678|DRUG|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
58305339|NCT03460678|DRUG|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
58305340|NCT02221752|DIETARY_SUPPLEMENT|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
58305341|NCT02221752|DIETARY_SUPPLEMENT|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
58091336|NCT05264623|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
58091337|NCT05285943|DRUG|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
58305342|NCT03415152|DRUG|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
58305343|NCT05260814|DEVICE|Electric toothbrush with smart phone app|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
58305344|NCT03052777|BEHAVIORAL|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
58418254|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
58418255|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
58418256|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
58418257|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
58418258|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
58418259|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
58418260|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
58418261|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
58418262|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
58418263|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
58418264|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
58418265|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
58418266|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
58418267|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
58418268|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
58418269|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
58418270|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
58418271|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
58418272|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
58418273|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
58418274|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
58091338|NCT05285943|DRUG|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
58091339|NCT05285943|OTHER|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
58091340|NCT02741609|DEVICE|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
58091341|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
58091342|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
58091343|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
58091344|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
58091345|NCT03401762|BEHAVIORAL|MCI|EMG-controlled game
58091346|NCT03401762|BEHAVIORAL|Sham MCI|Sham control game
58091347|NCT05949658|DRUG|Sirolimus|5mg, 10mg, or 15mg once weekly sirolimus
58091348|NCT05949658|DRUG|Everolimus|5mg, 10mg, or 15mg once weekly everolimus
57949767|NCT01610180|DRUG|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
58418275|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
58418276|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
57949768|NCT00821080|DRUG|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
58305345|NCT02915939|BEHAVIORAL|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
58305346|NCT05702008|OTHER|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
58305347|NCT04595058|DEVICE|Double pigtail plastic stent through lumen-apposing metal stent|Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent
58305348|NCT04595058|DEVICE|Lumen-apposing metal stent without double pigtail plastic stent|Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
58305349|NCT04646382|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
58305350|NCT04646382|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
58305351|NCT03980548|PROCEDURE|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
58305352|NCT03220841|DRUG|Adalimumab Injection|Standard dose adalimumab induction and maintenance
58305353|NCT03220841|DRUG|Thiopurine|Dose optimized thiopurine
58305354|NCT03220841|PROCEDURE|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
58418277|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
58418278|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
58418279|NCT03990805|DRUG|saline|saline, 1 time injection
57949769|NCT00821080|DRUG|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
57949770|NCT05775471|PROCEDURE|Biopsy|Undergo tissue biopsy
57949771|NCT05775471|PROCEDURE|Biospecimen Collection|Undergo blood and urine collection
57949772|NCT05775471|DRUG|Enfortumab Vedotin|Given IV
58091349|NCT01098058|OTHER|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
58091350|NCT01098058|OTHER|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
57734411|NCT03752229|DEVICE|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949773|NCT05775471|PROCEDURE|MR Urography|Undergo MRU
58305355|NCT02793986|DRUG|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
58418280|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
58418281|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
58418282|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
58418283|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
58418284|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
58418285|NCT01801852|BIOLOGICAL|NKT cells|
58418286|NCT01950585|DRUG|Hydroxyurea|
57949774|NCT05775471|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy
57949775|NCT05775471|BIOLOGICAL|Pembrolizumab|Given IV
57949776|NCT03284671|OTHER|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
57949777|NCT02263898|DRUG|Raf kinase inhibitor LGX818|Given PO
57949778|NCT02263898|DRUG|binimetinib|Given PO
57949779|NCT02263898|OTHER|laboratory biomarker analysis|Correlative studies
57949780|NCT00377377|DRUG|EP1572 (ghrelin agonist) oral and duodenal application|
58418287|NCT02227836|DEVICE|Allergy Patch Testing|
58418288|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
58418289|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
58418290|NCT01694277|DRUG|Masitinib|12 mg/kg/day
58418291|NCT01694277|DRUG|Sunitinib|50 mg/day
58418292|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
58418293|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
58418294|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
58418295|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
57949781|NCT03615196|DRUG|USB005 (aclerastide) Ophthalmic Solution|Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
57949782|NCT03615196|DRUG|USB005 Ophthalmic Solution Placebo|A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
57949783|NCT01278745|BIOLOGICAL|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
57949784|NCT01278745|DRUG|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
57949785|NCT04458298|DRUG|OP-101|OP-101 infusion will be administered intravenously.
57949786|NCT04458298|DRUG|Placebo|Matching placebo infusion will be administered intravenously.
57949787|NCT05412056|DRUG|Metformin|as in arm/group description
57949788|NCT05412056|DRUG|Placebo oral tablet|as in arm/group description
57949789|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
57949790|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
57949791|NCT00381342|DRUG|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
57949792|NCT00731575|DRUG|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
57949793|NCT03007056|OTHER|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
57949794|NCT05020873|OTHER|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
57949795|NCT01803984|DEVICE|MRI|
57949796|NCT01803984|DEVICE|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
57949797|NCT01803984|OTHER|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
58091351|NCT05482438|DEVICE|Polyethylene|Wear measurement
58091352|NCT05354336|DRUG|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
58091353|NCT05354336|DRUG|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
58091354|NCT05354336|DRUG|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
57949798|NCT01602770|DRUG|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
58418296|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
58418297|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
58418298|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
58418299|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
58418300|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
58091355|NCT04203758|OTHER|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
58418301|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
58418302|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
58418303|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
58418304|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
58418305|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
58418306|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
57949799|NCT03799250|DRUG|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
57949800|NCT03799250|OTHER|standard care|standard care
57949801|NCT04670614|PROCEDURE|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
57949802|NCT04670614|PROCEDURE|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
58305356|NCT02793986|DRUG|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
58305357|NCT01577797|BEHAVIORAL|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
58091356|NCT04203758|OTHER|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
58305358|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|One basal rate
58305359|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|Multiple basal rates
58305360|NCT00717145|DRUG|risedronate|one risedronate 20 mg DR tablet
58305361|NCT00717145|DRUG|risedronate|One risedronate 20 mg DR tablet
58305362|NCT00717145|DRUG|risedronate|One risedronate 35 mg DR tablet
58305363|NCT00717145|DRUG|risedronate|One risedronate 35 mg IR tablet
58305364|NCT01204034|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
58305365|NCT02749409|DRUG|Parecoxib|
58418307|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
58418308|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
58418309|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
58418310|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
58418311|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
58418312|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
58418313|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
58418314|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
58418315|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
58418316|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
58418317|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
58305366|NCT02749409|DRUG|Morphine|
58305367|NCT03717597|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
58305368|NCT03226795|OTHER|" Information-Motivation-Behavioral skills  intervention."|"* information -\> Reminders of medication: mobile application~* Motivation -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~* Behavioral skills -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
58418318|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
58418319|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
58418320|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
57949803|NCT02676492|OTHER|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
58418321|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
58418322|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
58418323|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
58418324|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
58418325|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
58418326|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
58418327|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
58091357|NCT01230502|DRUG|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
58418328|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
58418329|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
58418330|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
58418331|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
58091358|NCT01230502|OTHER|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
58305369|NCT05182944|DRUG|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
58305370|NCT05182944|DRUG|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
58418332|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
58418333|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
58418334|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
58418335|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
57734412|NCT03752229|DEVICE|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091359|NCT01230502|OTHER|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
58091360|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
58091361|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
58091362|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
58091363|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
57734413|NCT03752229|DEVICE|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
58091364|NCT04070534|OTHER|PALS|patient activated learning system
58091365|NCT06514586|DRUG|Oxytocin|Oxytocin gel 600 IU . 1mg/g
58091366|NCT06514586|OTHER|Hydroxypropyl methylcellulose|Placebo
58091367|NCT06236126|PROCEDURE|1% Lidocaine Injection|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal) or subcutaneously (Group Subcutaneous).
58091368|NCT02672488|DRUG|Sorafenib|Standard treatment for advanced HCC
58091369|NCT02672488|DRUG|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
58091370|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
58091371|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
58091372|NCT00798707|DRUG|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
58091373|NCT02507271|OTHER|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
58091374|NCT02507271|OTHER|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
58091375|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
57734414|NCT03752229|DEVICE|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734415|NCT03752229|DEVICE|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57949804|NCT02676492|OTHER|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
57949805|NCT00407524|DRUG|AKL 1|
57949806|NCT01568398|DRUG|TAK-438|
57949807|NCT04398875|OTHER|Acupuncture and standard care (ASC)|A semi-standardized treatment protocol and standard care will be employed.
57949808|NCT04398875|OTHER|Sham acupuncture and standard care (SSC)|Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.
57949809|NCT04398875|OTHER|Standard care (SC)|Standard care will be employed.
57949810|NCT06439212|DRUG|Ginger powder capsule|Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
57949811|NCT06439212|DRUG|Placebo|Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
57949812|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
57949813|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
57949814|NCT00962572|BEHAVIORAL|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
57949815|NCT04413253|DRUG|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
57949816|NCT04413253|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
57949817|NCT00433108|DRUG|Mitoquinone mesylate (MitoQ)|
57949818|NCT00947180|BEHAVIORAL|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
57949819|NCT00947180|OTHER|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
58418336|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
58418337|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
58305371|NCT05182944|DRUG|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
58418338|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
58418339|NCT03556098|DRUG|Saline Solution|Infusion of Saline
58418340|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
58418341|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
58418342|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
58418343|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
58418344|NCT01532544|DRUG|low molecular weight heparin.|
58418345|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
58418346|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
58418347|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
58418348|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
58418349|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
58418350|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
58418351|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
58418352|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
58418353|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
58418354|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
58418355|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
58418356|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
58418357|NCT00052312|DRUG|cisplatin|
58418358|NCT00052312|DRUG|doxorubicin hydrochloride|
58418359|NCT00052312|DRUG|paclitaxel|
58418360|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
58418361|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
57949820|NCT00947180|BEHAVIORAL|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
58418362|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
58418363|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
57949821|NCT04425187|DRUG|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
58418364|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
58418365|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
58418366|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
58418367|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
58305372|NCT05182944|DRUG|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
58305373|NCT04788134|DIAGNOSTIC_TEST|Post-rotatory nystagmus test|The test is administrated with the person sit down with cross legs at a rotatory board, with the head positioned by the examiner in 30° of forward flexion. The position was maintained by the administration of the test. The administration consist in two administrations separate by one minute. Each administration consist in rotate the person 10 times in 20 seconds (the first 10 rotations in a counterclockwise direction in 20 s and the second 10 rotations in a clockwise direction in 20 s). After each administration the examiner counts the duration of the reflex in seconds.
58418368|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
58418369|NCT03632603|RADIATION|No intervention|No intervention during study period.
58418370|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
58418371|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
58418372|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
58418373|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
58418374|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
58418375|NCT02804750|DRUG|CORT125134|
58418376|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
57949822|NCT04425187|DRUG|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
58418377|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
58305374|NCT04950400|DRUG|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
57734416|NCT03752229|DEVICE|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
57734417|NCT02644460|DRUG|Abemaciclib|
57734418|NCT01939028|PROCEDURE|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
58418378|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
58418379|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
58418380|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
58418381|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
58418382|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
58418383|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
58418384|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
58418385|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
58418386|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
58418387|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
58418388|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
57734419|NCT01939028|PROCEDURE|sentinel lymph node biopsy|Undergo SLN biopsy
57734420|NCT01939028|DRUG|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
57949823|NCT00626691|BEHAVIORAL|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
57734421|NCT01939028|DRUG|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
57734422|NCT01939028|PROCEDURE|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
57734423|NCT01939028|PROCEDURE|lymphadenectomy|Undergo para-aortic lymphadenectomy
57734424|NCT06114446|OTHER|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
58091376|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
58091377|NCT06059547|DRUG|Placebo|Placebo for Visugromab (CTL-002)
58305375|NCT01669434|DRUG|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
58305376|NCT01669434|DRUG|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
57734425|NCT06114446|OTHER|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
57734426|NCT06114446|OTHER|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
57949824|NCT02019576|RADIATION|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
58305377|NCT00697099|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
58305378|NCT00697099|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
58305379|NCT00697099|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
58305380|NCT00869960|DRUG|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
58305381|NCT00869960|DRUG|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
58305382|NCT00869960|DRUG|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
58305383|NCT00869960|DRUG|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
58305384|NCT03244488|DRUG|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
58305385|NCT03244488|DRUG|Mecamylamine Pill|10 or 20mg of mecamylamine orally
58305386|NCT02801331|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
58305387|NCT01762488|PROCEDURE|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
58305388|NCT01762488|PROCEDURE|Renal angiography|Renal angiography by femoral access
58305389|NCT04650737|DRUG|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
58305390|NCT04650737|DRUG|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
58305391|NCT02280434|DRUG|CBP-307|
58305392|NCT02280434|DRUG|Placebo|
58305393|NCT04644406|OTHER|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
58305394|NCT01326871|DRUG|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
58305395|NCT01326871|DRUG|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
58305396|NCT01326871|BIOLOGICAL|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
58305397|NCT00546442|DRUG|Metformine|850-2550 mg/daily for 48 weeks
58305398|NCT00546442|OTHER|Placebo of metformine|850-2550 mg/daily for 48 weeks
58305399|NCT05423834|DRUG|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
58305400|NCT05423834|DRUG|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
57734427|NCT01042457|DRUG|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
57734428|NCT06433180|DRUG|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
57949825|NCT01367535|DRUG|SC Methylnaltrexone (MNTX)|
57949826|NCT01367535|DRUG|IV Methylnaltrexone (MNTX)|
57949827|NCT01367535|DRUG|Oral Paroxetine|
57949828|NCT01367535|DRUG|SC Placebo|
57949829|NCT01811875|BIOLOGICAL|Optivate 500IU|
57949830|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
58305401|NCT01364155|DRUG|LIM-0705|
58305402|NCT01364155|DRUG|Placebo capsules|
58305403|NCT06202846|GENETIC|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
58305404|NCT04862338|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
58305405|NCT05100888|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
58305406|NCT04836741|DEVICE|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
58091378|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
58091379|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
58091380|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
58091381|NCT04222478|OTHER|Specific auriculotherapy|"3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
58091382|NCT04222478|OTHER|Non-specific auriculotherapy|3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
58418389|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
58091383|NCT02603536|OTHER|WelTel|An evidence-based, text messaging solution for improving patient adherence.
58091384|NCT01652482|DRUG|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
58091385|NCT01652482|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
58091386|NCT01652482|DRUG|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
58418390|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
58418391|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
58091387|NCT01652482|DRUG|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
58091388|NCT01652482|DRUG|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
58091389|NCT06566560|OTHER|redispensing oral anticancer drugs|"Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy."
58091390|NCT00832286|DRUG|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
58305407|NCT04836741|DEVICE|Laparoscope|The surgeries are performed with the laparoscope
57949831|NCT00531752|DRUG|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
57949832|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
58418392|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
58091391|NCT04509440|DRUG|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
58418393|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
57734429|NCT06433180|DRUG|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
57734430|NCT00578994|DEVICE|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
58091392|NCT04509440|DRUG|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
58091393|NCT03706209|DRUG|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
58091394|NCT03706209|DRUG|Placebo|hard gelatin capsules containing no active ingredient
58091395|NCT05131893|DRUG|Tamoxifen|endocrine therapy
58091396|NCT05131893|DRUG|Goserelin|endocrine therapy
58091397|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
58091398|NCT05131893|DRUG|Epirubicin|chemotherapy
58091399|NCT05131893|DRUG|cyclophosphamide|chemotherapy
58091400|NCT05131893|DRUG|Docetaxel|chemotherapy
58091401|NCT05131893|DRUG|paclitaxel|chemotherapy
58091402|NCT05131893|DRUG|trastuzumab|biological treatment
58091403|NCT05131893|DRUG|pertuzumab|biological treatment
58091404|NCT05131893|DRUG|Capecitabine|chemotherapy
58091405|NCT05308654|DRUG|ABBV-453|Oral; Tablet
58091406|NCT05308654|DRUG|Dexamethasone|Oral Tablet
58091407|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
58091408|NCT05308654|DRUG|Lenalidomide|Oral Capsule
58091409|NCT04749121|DEVICE|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
58091410|NCT04749121|DRUG|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
58091411|NCT04749121|DEVICE|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
58091412|NCT04749121|DEVICE|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
58305408|NCT03474224|DEVICE|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
57734431|NCT05637021|OTHER|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
57734432|NCT03337529|OTHER|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
57734433|NCT03337529|OTHER|Placebo|200 mg placebo will be given on daily basis for 8 weeks
57734434|NCT03135951|DRUG|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
57949833|NCT02145286|RADIATION|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
58091413|NCT01307488|DRUG|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
58305409|NCT04126200|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
58418394|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d"
58418395|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
58418396|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
58418397|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
58418398|NCT00762996|DEVICE|etafilcon A|contact lens
58418399|NCT00762996|DEVICE|omafilcon A|contact lens
58418400|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
58091414|NCT01307488|DRUG|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
58418401|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
57734435|NCT01436994|PROCEDURE|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
57734436|NCT01436994|PROCEDURE|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
58418402|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
57734437|NCT01436994|DRUG|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
57734438|NCT01436994|DRUG|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
58091415|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
58091416|NCT01506986|DRUG|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
58091417|NCT01506986|DRUG|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
58091418|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
58091419|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
58091420|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
58091421|NCT06540040|DEVICE|Aquacel Ag|Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.
58091422|NCT06540040|DEVICE|OPSITE|OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.
58418403|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
58418404|NCT02800590|DRUG|ABP-700|
58418405|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
57734439|NCT01436994|DRUG|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
57949834|NCT05928195|DIETARY_SUPPLEMENT|Acute Moderate-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
57949835|NCT05928195|DIETARY_SUPPLEMENT|Acute High-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
57949836|NCT05928195|DIETARY_SUPPLEMENT|Placebo|Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
57949837|NCT05617976|PROCEDURE|caudal block|caudal block
57949838|NCT00530894|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|
57949839|NCT00530894|DEVICE|Surgical Valve Replacement|
57949840|NCT00530894|OTHER|medical management and/or balloon aortic valvuloplasty|
57949841|NCT03010124|PROCEDURE|Blood sample|
57949842|NCT01290380|DRUG|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
58305410|NCT04126200|DRUG|GSK3174998|GSK3174998 will be administered.
58305411|NCT04126200|DRUG|Feladilimab|feladilimab will be administered.
58305412|NCT04126200|DRUG|Nirogacestat|Nirogacestat will be administered.
57734440|NCT01613248|DRUG|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
57734441|NCT01613248|DRUG|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
58091423|NCT06540040|DEVICE|MEPILEX POST OP BORDER|MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
58091424|NCT06540040|DEVICE|Traditional Dressing|Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
58091425|NCT00203892|BIOLOGICAL|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
58091426|NCT00203892|BIOLOGICAL|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
58091427|NCT00203892|BIOLOGICAL|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
58091428|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
58091429|NCT06446193|DEVICE|NDTx-01|NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
57734442|NCT01613248|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded."
58091430|NCT06446193|BEHAVIORAL|TAU|TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
58091431|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
58091432|NCT05037409|DRUG|Placebo|Intravenous infusion
57734443|NCT03671330|DRUG|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
57734444|NCT03671330|DRUG|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
58305413|NCT04126200|DRUG|Dostarlimab|Dostarlimab will be administered.
58305414|NCT04126200|DRUG|Isatuximab|Isatuximab will be administered.
58305415|NCT04126200|DRUG|Lenalidomide|Lenalidomide will be administered.
58305416|NCT04126200|DRUG|Dexamethasone|Dexamethasone will be administered.
58305417|NCT04126200|DRUG|Pomalidomide|Pomalidomide will be administered.
58305418|NCT04267497|DRUG|Amphotericin B Liposomal 50 MG|Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.
58305419|NCT04267497|OTHER|Placebo|Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
58305420|NCT00733967|DRUG|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
58305421|NCT00733967|DRUG|Placebo|Matching oral placebo capsules as control.
58305422|NCT05804812|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
58305423|NCT06012136|DRUG|VH4004280|VH4004280 will be administered.
57949843|NCT01445821|BIOLOGICAL|Peripheral Blood Stem Cells|Mobilized leukapheresis product
57949844|NCT01445821|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
58305424|NCT06012136|DRUG|Placebo|Placebo will be administered.
58305425|NCT06012136|DRUG|VH4011499|VH4011499 will be administered.
58305426|NCT03639168|DRUG|Chidamide combined with cisplatin|Chidamide combined with cisplatin
58305427|NCT02631005|OTHER|"Walk With Ease"|Six-week walking program
58418406|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
58418407|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
58418408|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
57734445|NCT03671330|DRUG|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
58418409|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
57734446|NCT03671330|DRUG|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
57949845|NCT01445821|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
57949846|NCT01445821|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
57949847|NCT01445821|DRUG|Methylprednisolone|Steroid
57949848|NCT01445821|DRUG|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
57949849|NCT01445821|DRUG|Fludarabine|Purine analog which inhibits DNA synthesis or repair
57949850|NCT03424785|OTHER|drug, stent, surgical treatment|drug, stent, surgical treatment
57949851|NCT02775396|DEVICE|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
57949852|NCT05069181|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
57949853|NCT05069181|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
57949854|NCT05069181|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
57949855|NCT01497639|DEVICE|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
57949856|NCT01497639|DEVICE|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
57949857|NCT02509806|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
57949858|NCT02734160|DRUG|Galunisertib|Administered orally
57949859|NCT02734160|DRUG|Durvalumab|Administered IV
58418410|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
58418411|NCT02159378|OTHER|Fructosamines|
58418412|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
58418413|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
58418414|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
57734447|NCT03671330|DRUG|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
57734448|NCT06099613|BIOLOGICAL|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
57949860|NCT00485602|PROCEDURE|"orthodontic treatment with Rafenalign appliance"|
57949861|NCT05464303|DRUG|Intravenous Antibodies|Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
57949862|NCT01462435|DRUG|Diclofenac Test (lower dose)|Capsules
57949863|NCT01462435|DRUG|Diclofenac Test (upper dose)|Capsules
57949864|NCT01462435|DRUG|Celecoxib|200 mg Capsules
57949865|NCT01462435|DRUG|Placebo|Capsules
57949866|NCT03578471|DEVICE|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
57949867|NCT03578471|DEVICE|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
57949868|NCT03578471|DEVICE|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
57949869|NCT01950000|DRUG|Fentanyl|
57949870|NCT01950000|OTHER|Placebo|
57949871|NCT05365542|OTHER|Hemodialyzer scanning|After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.
57949872|NCT05365542|OTHER|Bleeding Questionnaires|The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked
57949873|NCT05365542|OTHER|Quality of life questionnaire|The EQ5D questionnaire is asked.
58418415|NCT00788580|DRUG|pazopanib hydrochloride|
58418416|NCT00788580|DRUG|temsirolimus|
57949874|NCT05365542|OTHER|Visual inspection of the limbs|Visual inspection is done of the patient's limbs in order to quantify bruising.
58418417|NCT00788580|PROCEDURE|immunoenzyme technique|
58418418|NCT00788580|PROCEDURE|laboratory biomarker analysis|
58418419|NCT00788580|PROCEDURE|pharmacological study|
58418420|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
58091433|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
58091434|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
58091435|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
58091436|NCT06048718|DRUG|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
58091437|NCT06073873|DRUG|Ozanimod|According to local product label
58091438|NCT05972954|DRUG|OMT-28|once daily
58091439|NCT04432129|BEHAVIORAL|IBBIS II|"The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support."
58305428|NCT06029764|PROCEDURE|extended one-level interbody fusion|For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
58305429|NCT05828992|OTHER|No intervention administered|Survey only to gather people's experiences, opinions and needs.
57949875|NCT04031651|DRUG|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
57949876|NCT05677555|DRUG|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
57949877|NCT05677555|DRUG|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
58305430|NCT00721799|DRUG|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
58305431|NCT02930785|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)"
58305432|NCT03925896|DRUG|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
58305433|NCT02551458|OTHER|Systematic surgery|
58305434|NCT02551458|OTHER|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
58305435|NCT03961399|DEVICE|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
58305436|NCT03961399|DEVICE|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
58305437|NCT03037840|DEVICE|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
58305438|NCT02381236|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
58305439|NCT01631448|BIOLOGICAL|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
58305440|NCT02281617|BEHAVIORAL|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
57949878|NCT05872750|DEVICE|theta burst stimulation|Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)
57949879|NCT05872750|DEVICE|sham stimulation|sham stimulation
57949880|NCT03865173|OTHER|Telephone Interview|Telephone Interview
57949881|NCT03255707|DEVICE|eye patch|Occluding the better seeing eye for a given number of hours daily
57949882|NCT03255707|DEVICE|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
58418421|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
58418422|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
57734449|NCT01169467|DRUG|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
58091440|NCT04432129|BEHAVIORAL|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
58091441|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
58091442|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
58091443|NCT05367934|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch for stress
58091444|NCT05063318|DRUG|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
57734450|NCT01169467|OTHER|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
58091445|NCT05063318|DRUG|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
58091446|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
58091447|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
58091448|NCT01500434|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
58091449|NCT01500434|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
58091450|NCT01500434|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
58305441|NCT05489575|DEVICE|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
57734451|NCT04894604|DEVICE|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
57734452|NCT04696731|GENETIC|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
57734453|NCT04696731|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
57734454|NCT04696731|DRUG|Fludarabine|Chemotherapy for lymphodepletion
57734455|NCT04696731|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
57734456|NCT04775680|BIOLOGICAL|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
57734457|NCT04775680|BIOLOGICAL|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
57734458|NCT02495753|PROCEDURE|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
57734459|NCT02495753|PROCEDURE|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
57734460|NCT00074035|DRUG|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
58091451|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
58091452|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
58091453|NCT05385276|PROCEDURE|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
58091454|NCT05385276|PROCEDURE|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
58091455|NCT01596088|DRUG|Dexrazoxane|
58091456|NCT01974869|DRUG|Anti-tumor necrosis factor alpha agents|Treatment with biologics
58305442|NCT05489575|DEVICE|Sham CPAP|Sham continuous positive airway pressure applied at \<4 cm H2O
57734461|NCT03675022|DRUG|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
58091457|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 1|Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
58091458|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 2|Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
58091459|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 1|Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
58091460|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 2|Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
58091461|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 1|Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
58091462|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 2|Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
58091463|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine HTD formulation 2|Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
58091464|NCT06702449|COMBINATION_PRODUCT|Placebo|Placebo administered intramuscularly according to a 0, 2 months administration schedule.
58091465|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
58305443|NCT05489575|OTHER|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
57734462|NCT04838574|OTHER|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
57734463|NCT03932643|DRUG|ONC-201|"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
58091466|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
58091467|NCT05044637|DRUG|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
58091468|NCT04925479|DRUG|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: Mini-tablets will be supplied as size 0 capsules containing 1 mg mini-tablets, taken orally:~10 mg (10x 1 mg tablets in capsule) 15 mg (15x 1 mg tablets in capsule) 20 mg (20x 1 mg tablets in capsule) 30 mg (30x 1 mg tablets in capsule)"
58091469|NCT04925479|DRUG|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
58091470|NCT06697483|DRUG|Daratumumab|Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.
58091471|NCT06697483|DRUG|Lenalidomide|"Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance."
58091472|NCT03356366|OTHER|MRI 3T|Magnetic Resonance Imaging 3 Tesla
57734464|NCT03975348|DEVICE|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
57734465|NCT03975348|DEVICE|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
57949883|NCT00003535|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
58305444|NCT05334862|PROCEDURE|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and fixation by usuing 8 plate and screws.
58305445|NCT03471052|PROCEDURE|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
58091473|NCT03356366|OTHER|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
58091474|NCT03356366|OTHER|MRI 7T|Magnetic Resonance Imaging 7 Tesla
58091475|NCT01341158|DRUG|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
58091476|NCT04946474|DRUG|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
58305446|NCT03684408|DEVICE|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
58418423|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
58418424|NCT02674425|DEVICE|Dark Adaptometer|
57734466|NCT03975348|DEVICE|Facemask|Oxygen therapy through a conventional facemask
57734467|NCT02310750|DRUG|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
57734468|NCT02310750|OTHER|Placebo|Matching placebo given during the single ascending and multiple dose periods
57734469|NCT02310750|DRUG|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
57949884|NCT02758340|DRUG|Misoprostol|Women would be given misoprostol tablet by mouth
57949885|NCT02758340|DEVICE|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
58091477|NCT04375735|DRUG|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
58091478|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
58091479|NCT02058368|DRUG|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
58091480|NCT02058368|DRUG|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
58091481|NCT02058368|DRUG|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
57734470|NCT04786444|BIOLOGICAL|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
57734471|NCT06285812|DEVICE|OtoSight Middle Ear Scope|Subjects will be evaluated with the OtoSight Middle Ear Scope
58091482|NCT02058368|DRUG|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
58091483|NCT02512991|OTHER|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
58091484|NCT02800278|OTHER|observational|describe bone status and outcome of odontoid fracture
58091485|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
58091486|NCT06505213|OTHER|no intervention|no intervention
58091487|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
58091488|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
58305447|NCT03684408|DEVICE|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
58418425|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
57949886|NCT06320587|OTHER|Kangaroo care practice by both mother and father|In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.
57949887|NCT06320587|OTHER|Kangaroo care practice only mother|In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
57949888|NCT02838498|DEVICE|ERCP Mechanical Simulator (EMS)|Hands on EMS training
57949889|NCT04554160|DEVICE|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
57949890|NCT04554160|DEVICE|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
57949891|NCT02289950|DRUG|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
57949892|NCT02289950|DRUG|Placebo|Placebo will be administered intravenously (IV) weekly
57949893|NCT01053390|DRUG|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
57949894|NCT01053390|DRUG|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
57949895|NCT04162574|OTHER|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
57949896|NCT05909982|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
57949897|NCT06011148|DEVICE|Perceval S sutureless heart valve|Aortic Valve Replacement with Perceval S sutureless heart valve
57949898|NCT04777487|DIAGNOSTIC_TEST|GCF obtaining|4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
57949899|NCT06024642|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
57949900|NCT06024642|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
58091489|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
58091490|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
58091491|NCT01777191|DRUG|Ixekizumab Auto-Injector|Administered SC by auto-injector
58091492|NCT01777191|DRUG|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
58091493|NCT06195267|DRUG|Sivelestat|The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
57949901|NCT00715832|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
57949902|NCT05827939|OTHER|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
58091494|NCT06195267|DRUG|Blank control|Patients only received standard treatment and care.
58091495|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
58305448|NCT03684408|DEVICE|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
58305449|NCT05715619|BIOLOGICAL|VRELysin™|A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
57734472|NCT01572727|DRUG|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
57734473|NCT01572727|DRUG|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
57949903|NCT02846532|DRUG|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
57949904|NCT02846532|DRUG|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
57949905|NCT05121480|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
57949906|NCT05121480|DRUG|Placebo|Placebo oral capsule
57949907|NCT06268743|OTHER|High intensity|High intensity exercise
57949908|NCT06268743|OTHER|Moderate intensity|Moderate intensity exercise
57949909|NCT01651715|DRUG|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
57949910|NCT00453726|PROCEDURE|Non invasive mechanical ventilation|
57949911|NCT00718276|DRUG|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
57949912|NCT00718276|DIETARY_SUPPLEMENT|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
57949913|NCT00258336|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
57949914|NCT00258336|BIOLOGICAL|rituximab|
57949915|NCT00258336|BIOLOGICAL|sargramostim|
57949916|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
57949917|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.25mL dose for intramuscular injection
57949918|NCT05671432|BIOLOGICAL|CM326|CM326 injection
57949919|NCT05671432|OTHER|Placebo|Placebo
57949920|NCT00236808|DRUG|levofloxacin|
57949921|NCT02244216|DRUG|Berotec® N 100 µg Metered-dose Inhaler|
57949922|NCT02854423|DEVICE|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
58305450|NCT05715619|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
58305451|NCT02791269|DRUG|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
57949923|NCT02109900|OTHER|Serum Progesterone Levels|
57949924|NCT04451421|BEHAVIORAL|Change of standing Angle|Change the patient's standing Angle by using an electric bed
57949925|NCT06082700|DIAGNOSTIC_TEST|imaging|clinical examination to see missing posterior teeth \& vertical measurements by lateral cephalometric x-ray
57949926|NCT03051360|DRUG|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
57949927|NCT03051360|DRUG|Placebos|Patients will receive Placebo by a biweekly injection
57949928|NCT00675922|DRUG|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
57949929|NCT03669458|DEVICE|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
57949930|NCT01783275|BEHAVIORAL|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
58305452|NCT00909844|DRUG|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
58305453|NCT01848171|DRUG|L-thyroxine|
58305454|NCT00716612|DRUG|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
58305455|NCT00716612|DRUG|Placebo control|po Placebo QD
58305456|NCT04785417|OTHER|touch screen tablet|traditional occupational therapy in addition to games on tablet
58305457|NCT05685121|DEVICE|Apollo Neuro|The device is a wearable nerve stimulator.
58305458|NCT01386606|DRUG|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
58305459|NCT01386606|DRUG|Testosterone|"topical gel~1X a day 6 weeks"
58305460|NCT04267978|DRUG|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
58305461|NCT02067858|RADIATION|Stereotactic Radiosurgery|
58305462|NCT01911949|DRUG|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
58305463|NCT01899911|DEVICE|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
58305464|NCT05359471|DEVICE|Bone densitometry|It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
58305465|NCT05359471|OTHER|Questionnaires|Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
58418426|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
58418427|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
58418428|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
58418429|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
58418430|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
57734474|NCT01572727|DRUG|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
58091496|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
57734475|NCT02590354|OTHER|ART interruption|
57734476|NCT03759873|BEHAVIORAL|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
58305466|NCT05359471|DEVICE|Review of medical chart|History of previous liver diseases including hepatitis B, C, and HIV
58305467|NCT05619328|DRUG|Vitamin B combination tablet|Once daily, with some liquid with or after a meal
58305468|NCT05619328|DRUG|Placebo Tablet|Once daily, with some liquid with or after a meal
58305469|NCT02960412|DRUG|furosemide|10mg lasix given intraoperatively
58305470|NCT02960412|DRUG|Normal Saline|Normal saline given intraoperatively as placebo
58305471|NCT00348400|DRUG|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
58305472|NCT00516971|DRUG|Esomeprazole 20mg once daily|
57734477|NCT03759873|BEHAVIORAL|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
57734478|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
57734479|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
58305473|NCT03242317|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
58305474|NCT03242317|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
58305475|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
58305476|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
58305477|NCT04968236|OTHER|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
58305478|NCT04968236|OTHER|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
58305479|NCT04968236|OTHER|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
58305480|NCT00758446|DRUG|BLX-028914|50 mg capsules, p.o, daily, 14 days
58305481|NCT00758446|DRUG|BLX-028914|15 mg capsules, p.o, daily, 14 days
58305482|NCT00758446|DRUG|placebo|capsules, p.o, daily, 14 days
58305483|NCT02739126|PROCEDURE|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
58305484|NCT02739126|DEVICE|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
58305485|NCT00217945|BEHAVIORAL|Shared-Decision Making|
58418431|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
58418432|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
58418433|NCT00311116|DRUG|Vitamin E|
58418434|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
58418435|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
58418436|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
58091497|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
58091498|NCT05647694|OTHER|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
58091499|NCT04196699|BEHAVIORAL|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
58305486|NCT02932436|DRUG|Empagliflozin|10 mg per os daily for 12 weeks
58305487|NCT02932436|DRUG|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
58305488|NCT05540145|DRUG|SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
58305489|NCT00161655|DRUG|Etanercept|
58305490|NCT00161655|DRUG|Methotrexate|
58305491|NCT00171535|DRUG|valsartan/amlodipine|
58305492|NCT04735614|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
58305493|NCT05601349|BEHAVIORAL|Telehealth-based strategy|Teleducation course, based on the CPG recommendations
58305494|NCT06472947|DEVICE|ULM and MSOT|transplanted kidney will be examined non-invasively with ULM and MSOT
58305495|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
58305496|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
58305497|NCT02762032|DRUG|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
58305498|NCT01268995|DRUG|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
58305499|NCT01268995|DRUG|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
58305500|NCT03712280|DRUG|MNK6106|1 gram tablet of MNK6106 for oral administration
58305501|NCT03712280|DRUG|Rifaximin|550 mg tablet of rifaximin for oral administration
57734480|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
58305502|NCT04447716|DRUG|Venetoclax|Given PO
58305503|NCT04447716|DRUG|Lenalidomide|Given PO
58305504|NCT04447716|BIOLOGICAL|Rituximab|Given IV
58418437|NCT00004751|PROCEDURE|Surgery|
58418438|NCT00004751|PROCEDURE|Physical therapy|
58418439|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
58418440|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
58418441|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
58418442|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
57734481|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
57734482|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
58418443|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
58418444|NCT02333890|DRUG|Placebo|
58418445|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
57949931|NCT06076421|OTHER|Fact box|Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
58418446|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
58418447|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
58418448|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
58418449|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
58418450|NCT00000652|DRUG|Zidovudine|
58418451|NCT00000652|DRUG|Didanosine|
58418452|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
58418453|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
58418454|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
58418455|NCT00044824|DRUG|Fexofenadine|
57949932|NCT04512040|BEHAVIORAL|At-Home Yoga|At-home yoga practice over 12 weeks.
57734483|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
57734484|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
57949933|NCT02411539|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
57949934|NCT02411539|BIOLOGICAL|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
57949935|NCT01576549|DRUG|LY2127399|Administered subcutaneously
57949936|NCT03319875|DEVICE|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
57949937|NCT05497596|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
57949938|NCT05497596|OTHER|Placebo|Placebo
57949939|NCT05931887|DEVICE|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|A foley catheter is assigned and used according to regular standard of care
57949940|NCT03496220|DEVICE|Angulus|Feedback on patient recumbency
57949941|NCT02300701|DRUG|Xolair|According to manufacturer's instructions
58091500|NCT02145000|BIOLOGICAL|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
58091501|NCT02145000|BIOLOGICAL|Placebo|
58418456|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
58418457|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
58418458|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
57949942|NCT02300701|DRUG|Placebo|Placebo
57949943|NCT02055820|DRUG|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
57949944|NCT02055820|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
57734485|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
57949945|NCT02055820|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
57949946|NCT02055820|DRUG|Rituximab|Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
57949947|NCT02055820|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
57949948|NCT02055820|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
57949949|NCT02055820|DRUG|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
58091502|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
58305505|NCT04447716|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
58418459|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
58418460|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
58418461|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
58418462|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
57734486|NCT01325168|DRUG|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
57734487|NCT01325168|DRUG|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
57734488|NCT01973127|OTHER|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
57949950|NCT06494670|OTHER|No intervention|This study was a cross-sectional study with no intervention for participants
57949951|NCT02037295|DRUG|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
58305506|NCT00308867|PROCEDURE|Photodynamic Therapy|
58305507|NCT00308867|PROCEDURE|Cryosurgery|
57949952|NCT02037295|DRUG|Placebo oral tablet|Placebo pills orally four times per day for 12 days
57949953|NCT02037295|OTHER|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
57949954|NCT02037295|OTHER|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
58305508|NCT05263362|OTHER|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
58305509|NCT02666222|DEVICE|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
58305510|NCT03581006|DIETARY_SUPPLEMENT|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
58305511|NCT03581006|COMBINATION_PRODUCT|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
58305512|NCT03581006|OTHER|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
58305513|NCT04176913|DRUG|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
58305514|NCT03122795|PROCEDURE|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
58305515|NCT04161391|DRUG|TPX-0046|Oral TPX-0046 capsules
58305516|NCT03821961|PROCEDURE|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
58305517|NCT05034549|DEVICE|Noninvasive ventilation|The non-invasive ventilator at home (≥5h/ night)
58305518|NCT04082052|BEHAVIORAL|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
58305519|NCT03348605|DEVICE|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
58305520|NCT05626569|DRUG|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
58305521|NCT00117234|DRUG|darbepoetin alfa|
58305522|NCT04189016|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
58305523|NCT04391257|DEVICE|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
58418463|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
58418464|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
58418465|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
58091503|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
57734489|NCT01973127|OTHER|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
57949955|NCT04141384|DEVICE|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
58305524|NCT04882696|OTHER|Non-slip socks|Patients will wear non-slip socks during their hospitalization
58305525|NCT00492297|DRUG|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
58305526|NCT01483118|DRUG|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
58305527|NCT01483118|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing ground cereal.
58305528|NCT02984982|DRUG|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
58418466|NCT02122809|DRUG|Chiauranib|Take orally
58305529|NCT02984982|DRUG|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
58305530|NCT02984982|DRUG|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
57949956|NCT03915015|DIAGNOSTIC_TEST|MRI|MRI
57949957|NCT05865236|PROCEDURE|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
57949958|NCT05865236|PROCEDURE|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
57949959|NCT02142777|DRUG|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
57949960|NCT02142777|DRUG|Placebo|The placebo has no active ingredients but is made to look like the study drug.
57949961|NCT01756131|DRUG|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
57949962|NCT01756131|OTHER|Placebo to match injectable suspension|placebo
57949963|NCT05752253|OTHER|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
58305531|NCT02984982|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
58305532|NCT02984982|DRUG|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
58305533|NCT02984982|DRUG|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
58305534|NCT02984982|DRUG|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
58305535|NCT02984982|DRUG|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
58305536|NCT02048423|DRUG|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
58418467|NCT02723890|DEVICE|Tyto Device|
58418468|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
58418469|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
57949964|NCT03373097|BIOLOGICAL|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
58418470|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
58418471|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
58418472|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
58418473|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
58418474|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
58418475|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
58418476|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
58418477|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
58091504|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
58091505|NCT05008419|BEHAVIORAL|Narrative discourse treatment|The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
58091506|NCT05113277|BEHAVIORAL|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
58091507|NCT05113277|BEHAVIORAL|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
58418478|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
58418479|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
58418480|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
57949965|NCT06183840|DEVICE|Glutack|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
58305537|NCT04566107|BEHAVIORAL|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
58418481|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
58418482|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
58418483|NCT02984059|GENETIC|Genomic DNA|blood draw
58418484|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
58418485|NCT02984059|GENETIC|Microbiome|Stool microbiome
58418486|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
58418487|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
58418488|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
57734490|NCT00579917|BEHAVIORAL|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
58091508|NCT01062022|BEHAVIORAL|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
57734491|NCT00579917|BEHAVIORAL|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
57734492|NCT04805125|BIOLOGICAL|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
57734493|NCT04805125|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
57734494|NCT03349450|BIOLOGICAL|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
57734495|NCT03349450|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
57734496|NCT03349450|DRUG|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
57734497|NCT01237639|OTHER|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
57734498|NCT00352365|DRUG|lenalidomide|Given orally
57734499|NCT02345031|DRUG|AUT00063|600 mg, orally, once a day, for 4 weeks
57949966|NCT06183840|DEVICE|Conventional|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
58091509|NCT01062022|BEHAVIORAL|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
58305538|NCT04566107|BEHAVIORAL|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
58305539|NCT01244074|BEHAVIORAL|biofeedback training|
58305540|NCT03143361|PROCEDURE|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
58305541|NCT06516575|BEHAVIORAL|sentence manipulations|Auditory stimuli (sentences) are manipulated to have key words masked by noise, or to have prosody (pitch contour) manipulated to be consistent or inconsistent with a specific inferred meaning. Participants repeat the sentences while a camera tracks changes in their eye movements and changes in pupil dilation.
58305542|NCT04987047|BIOLOGICAL|Blood collection|A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
58305543|NCT04987047|OTHER|Questionnaires|Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
58305544|NCT04987047|OTHER|Cognitive test battery (optional)|"For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French)."
58305545|NCT01668420|OTHER|thermal stimulation|hot and cold/warm and cool pads applying.
58305546|NCT04587804|DEVICE|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
58305547|NCT01880827|PROCEDURE|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
58305548|NCT01880827|DRUG|GIP-infusion|Blood flow and volume during infusion
58305549|NCT01880827|DRUG|GLP-1|Blood flow and volume during infusion
58305550|NCT01880827|DRUG|MMS|Blood flow and volume after meal solution
58305551|NCT01880827|PROCEDURE|Sleeve gastrectomy|as in RYGS group
58418489|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
58418490|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
58418491|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
58418492|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
58418493|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
57734500|NCT02345031|DRUG|Placebo|orally, once a day, for 4 weeks
57734501|NCT00006325|DRUG|Peginterferon alfa-2b|
57734502|NCT04749420|OTHER|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
57949967|NCT00746980|DRUG|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
58418494|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
58418495|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
58418496|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
57949968|NCT00784654|DRUG|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
58091510|NCT06172361|DRUG|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
58091511|NCT06172361|DRUG|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
58091512|NCT06566287|OTHER|Immediate implant|Immediate Implant with Socket Shield Group
58091513|NCT06566287|OTHER|Delayed implant|Delayed Implant with Socket preserved with socket Shield and dentin graft Group
58091514|NCT06082609|PROCEDURE|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
58091515|NCT05439291|PROCEDURE|Regular Epilation Regimen|Epilation using laser device
58091516|NCT05439291|PROCEDURE|Surgical excision|Excision of pilonidal pit with trephine
58091517|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
58091518|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
58091519|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
58091520|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
58091521|NCT02179385|BEHAVIORAL|Health Coaching|
58305552|NCT06115018|PROCEDURE|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
58305553|NCT06115018|BEHAVIORAL|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
58418497|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
58418498|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
58418499|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
57949969|NCT00784654|DRUG|Placebo|Placebo capsule once per day (double-blind period)
57949970|NCT04455646|BEHAVIORAL|CBT-based, mobile-delivered, intervention platform|App of this platform have been shown to be associated with reduced psychopathology symptoms,including depressive symptoms, following treatment (i.e., relapse prevention). GGDE, which was specifically designed to address MDD related maladaptive beliefs and symptoms,includes different CBT-based intervention modules (nine active and one sham), as well as means for data collection and response monitoring. The active treatment modules will differ in the proportion of adaptive vs. maladaptive statements and the emphasis on particular content (e.g loneliness vs. hopelessness).
57949971|NCT05352815|DRUG|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
57949972|NCT05352815|DRUG|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
57949973|NCT00884273|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
57949974|NCT00884273|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
58418500|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
57949975|NCT00884273|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
57734503|NCT01309620|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
57734504|NCT01309620|DIETARY_SUPPLEMENT|Placebo|Placebo, Twice Daily
57734505|NCT02034578|DRUG|Apixaban|
57734506|NCT03560427|DRUG|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
57734507|NCT03560427|DRUG|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
57734508|NCT01943201|DEVICE|new bedsheet|sleeping 5 nights on the new bedsheet
57734509|NCT01943201|DEVICE|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
57734510|NCT03872349|OTHER|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
58091522|NCT05537246|PROCEDURE|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
58091523|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
58091524|NCT01247753|BEHAVIORAL|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
58305554|NCT06115018|COMBINATION_PRODUCT|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
58418501|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
57734511|NCT03872349|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
58418502|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
58418503|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
58418504|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
58418505|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
58418506|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
58418507|NCT00002762|PROCEDURE|blood sampling|
57949976|NCT02228291|DIETARY_SUPPLEMENT|Capsule containing citrus flavonoid|
57949977|NCT02228291|DIETARY_SUPPLEMENT|Placebo|
57949978|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
57949979|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
58418508|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
58418509|NCT00457444|DRUG|Pollen|
58418510|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
58418511|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
58418512|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
58418513|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
58418514|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
58091525|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
58418515|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
58418516|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
58418517|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
58305555|NCT06270641|OTHER|ExerciseRx intervention|ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
58418518|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
58418519|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
58418520|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
58418521|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
58418522|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
58418523|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
58418524|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
58418525|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
58418526|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
58418527|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
58418528|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
58091526|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
58305556|NCT01645436|OTHER|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
58305557|NCT02987010|DRUG|IDH305|Isocitrate Dehydrogenase 1 inhibitor
58418529|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
58418530|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
58418531|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
58418532|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
58418533|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
58418534|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
58418535|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
58418536|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
58418537|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
58418538|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
58418539|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
58418540|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
58418541|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
58418542|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
58418543|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
58418544|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
58418545|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
57734512|NCT06668311|OTHER|play dough|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
58091527|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
58305558|NCT05609669|OTHER|CADENCE program|The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
58418546|NCT02089113|DRUG|Dexamethasone|
58418547|NCT02089113|PROCEDURE|Placebo Vehicle|
58418548|NCT02525913|DEVICE|RFA Applicator|
58418549|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
58418550|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
58418551|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
58091528|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
58305559|NCT01674725|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
58305560|NCT01674725|DRUG|Ribavirin|Tablet
57949980|NCT01032915|BIOLOGICAL|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
58091529|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
58091530|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
58091531|NCT01064830|DRUG|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
58091532|NCT01064830|DRUG|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
58091533|NCT00318409|DRUG|Bupropion|
58091534|NCT00318409|DRUG|Placebo|
58091535|NCT01898624|DRUG|mirabegron|oral
58091536|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
58091537|NCT00281827|DRUG|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
57949981|NCT01032915|DRUG|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
57949982|NCT00625833|DRUG|Placebo|Oral tablet once a day dosing for 10 weeks.
57949983|NCT00625833|DRUG|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
58091538|NCT00281827|DRUG|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
58091539|NCT00281827|DRUG|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
58091540|NCT00281827|PROCEDURE|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
58091541|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
58091542|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58091543|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
58091544|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
58305561|NCT01867008|DEVICE|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
58305562|NCT01328938|BIOLOGICAL|GCPGC 3.6mg|Stage I:Single blinded
57734513|NCT06668311|OTHER|picture book reading|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
58091545|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
58418552|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
58418553|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
58418554|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
58418555|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
58418556|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
58418557|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
58418558|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
58418559|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
58418560|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
57734514|NCT05331352|BEHAVIORAL|Semi-structured interviews|Interview
58091546|NCT05204849|DEVICE|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
58418561|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
58418562|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
58418563|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
58418564|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
58418565|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
58418566|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
57734515|NCT05331352|BEHAVIORAL|Projective methode|Rorschach + thematic aperception test
57734516|NCT05331352|BEHAVIORAL|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
57734517|NCT01168817|DRUG|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
57734518|NCT01168817|DRUG|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
58091547|NCT05204849|PROCEDURE|Standard ventriculostomy|Standard passive external ventricular drainage
58305563|NCT01328938|BIOLOGICAL|GCPGC 6mg|Stage I: Single blinded;
58305564|NCT01328938|BIOLOGICAL|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
58305565|NCT01328938|BIOLOGICAL|GCPGC 6mg|Experimental: Stage II
58418567|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
58418568|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
57734519|NCT01168817|DRUG|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
57734520|NCT03966976|DEVICE|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
57734521|NCT03966976|OTHER|Conventional follow-up|Conventional follow-up
57734522|NCT01305967|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, Intravenous route, 16times for 2.5 months
58305566|NCT05709665|OTHER|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
58305567|NCT04260620|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
58305568|NCT03778008|DRUG|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
58305569|NCT03778008|COMBINATION_PRODUCT|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
58305570|NCT06151379|OTHER|Neoadjuvant therapy|To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
58305571|NCT06184048|PROCEDURE|Intra-Articular knee injection of LC-PRP|Blood Collection 45mL, Processed Neutrophil-Poor PRP, 2 Injections at day 0 and 3 weeks.
58305572|NCT03652818|DRUG|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
58305573|NCT03652818|DRUG|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
58305574|NCT03652818|DRUG|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
58305575|NCT03652818|DRUG|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
58305576|NCT03652818|DRUG|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
58305577|NCT03652818|DRUG|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
58305578|NCT04572373|DIETARY_SUPPLEMENT|SMOFlipid|
58305579|NCT00713076|OTHER|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
58305580|NCT00988702|BEHAVIORAL|Dan Tian Breathing|Dan Tian Breathing for one month
58418569|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
57734523|NCT01221597|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
57734524|NCT01221597|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
57785122|NCT05104411|OTHER|Rehabilitative intervention|Active rehabilitation programs were done for all patients. Participants were asked to attend exercise program at PT room or bedside. Exercise program was offered once or twice daily on weekdays, by trained kinesiologists. In PT programs, most patients performed strengthening exercise of lower extremities, balance training, sit-up training, sit-to-stand training and gait training for about 30 minutes. Each program was individualized to participants' current physical function. In bedside programs, patients also underwent strengthening exercise and balance training without gait training for about 10 minutes. The duration of exercise program at PT room depends on the patient's condition(upto 1 month).
58091548|NCT06652230|OTHER|Smile Arc Marginal Ridge Approach (SAMRA)|Smile Arc Marginal Ridge Approach (SAMRA) is a new orthodontic bonding technique proposed by Dr. Dalia El Bokle where she stated that it provides more accurate orthodontic results and less time and effort needed during finished. No randomized clinical trials are done on this new approach yet so our study is the first one to test it. 0.018-inch MBT brackets will be used in our study.
58091549|NCT06652230|OTHER|MBT Chart Method|For our comparator group MBT Chart Method will be used. Using charts during orthodontic bonding procedures is considered the gold standard. 0.018-inch brackets will be used.
58418570|NCT00120055|DRUG|Atorvastatin (Lipitor)|
58418571|NCT01995552|DEVICE|External Loop Recorder|
58418572|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
58418573|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
58091550|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
58091551|NCT06550180|DRUG|Spinal anaesthesia group (S)|Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
58091552|NCT06550180|DRUG|Subcostal TAP block and spinal anesthesia group (STAP)|patient receive Subcostal TAP block before spinal anesthesia. Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anesthesia
58091553|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
58091554|NCT03490539|DRUG|Mycophenolate Mofetil|oral tablets
58091555|NCT03490539|DRUG|Azathioprine|oral tablet
58091556|NCT03032237|OTHER|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
58091557|NCT03032237|OTHER|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
58091558|NCT00357708|DRUG|decitabine|Given IV
58091559|NCT00357708|DRUG|vorinostat|Given orally
58091560|NCT00357708|OTHER|laboratory biomarker analysis|Correlative studies
58091561|NCT00357708|OTHER|pharmacological study|Correlative studies
58091562|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
58305581|NCT00988702|BEHAVIORAL|Progressive muscle training|Progressive muscle training for one month
58305582|NCT03343548|DRUG|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
58305583|NCT03343548|DRUG|normal saline|2cc of normal saline will be administered epidurally
58305584|NCT05783934|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
58305585|NCT03416959|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
58305586|NCT06193772|BEHAVIORAL|Internet-delivered psychodynamic therapy (IPDT)|"IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions."
58091563|NCT06395389|BEHAVIORAL|Values in Action (VIA)|VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
58091564|NCT06280066|OTHER|Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers|The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
58091565|NCT02725840|RADIATION|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
58091566|NCT02725840|RADIATION|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
58091567|NCT02725840|PROCEDURE|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
58091568|NCT02725840|PROCEDURE|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
58418574|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
58418575|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
58418576|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
58418577|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
58418578|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
57949984|NCT05606367|DEVICE|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
58305587|NCT01928771|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
58418579|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
58091569|NCT06652555|OTHER|Group 1|without Intervention
58091570|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
58305588|NCT01928771|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
58305589|NCT00052104|BEHAVIORAL|Cognitive-Behavioral Family Systems Intervention|
58305590|NCT04232631|DEVICE|SnapshotNIR, Kent Imaging|Vascular imaging device
58305591|NCT04882371|DRUG|Chemotherapy|Neoadjuvant Chemotherapy for Breast Cancer
58305592|NCT04882371|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
58305593|NCT04882371|DIAGNOSTIC_TEST|Positron emission tomography - Copmputer Tomography (PET-CT)|Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
58305594|NCT01232283|DRUG|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
58305595|NCT01232283|DRUG|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
58305596|NCT01232283|OTHER|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
58305597|NCT03201991|OTHER|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
58305598|NCT02202304|DRUG|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
58305599|NCT01797393|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
58305600|NCT01797393|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
58305601|NCT01797393|OTHER|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
58305602|NCT01123655|DRUG|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
58305603|NCT01123655|DRUG|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
58305604|NCT06149702|OTHER|Keep-on-Keep-Up|Keep-On-Keep-Up (KOKU) programme in the app will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use
58305605|NCT00956436|DRUG|BIIB022|IV Q3W
58305606|NCT00956436|DRUG|Sorafenib|Standard dosing of Sorafenib
58305607|NCT03817281|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
58305608|NCT03311867|OTHER|Ethibond Suture|Cerclage placement with ethibond
58305609|NCT03311867|OTHER|Prolene Suture|Cerclage placement with prolene
58305610|NCT02510339|OTHER|Observation|Administration of two questionnairs during post operative visits.
58305611|NCT02821533|PROCEDURE|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
58418580|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
58418581|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
58418582|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
58418583|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
57785123|NCT03327675|OTHER|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
58418584|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
58418585|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
57734525|NCT04729803|BEHAVIORAL|Experimental: Attention Guidance + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
57734526|NCT04729803|BEHAVIORAL|Active Comparator: Exposure Alone|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
57785124|NCT00790829|DRUG|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
57785125|NCT05115656|BEHAVIORAL|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
57949985|NCT05606367|DEVICE|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
58305612|NCT02821533|DRUG|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
58418586|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
58418587|NCT00849602|DRUG|Placebo|Placebo bid for three days
58418588|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
58418589|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
58418590|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
58418591|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
58418592|NCT02195804|DRUG|Ranitidine hydrochloride|
58418593|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
58418594|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
58418595|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
57785126|NCT05115656|BEHAVIORAL|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
58091571|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
58305613|NCT01082029|DRUG|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
58305614|NCT01082029|DRUG|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
58305615|NCT05130424|DRUG|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
58305616|NCT04371016|OTHER|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
58305617|NCT03129932|DIETARY_SUPPLEMENT|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
58305618|NCT03129932|DIETARY_SUPPLEMENT|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
58305619|NCT00001305|DRUG|Humatrope|Patients receive a subcutaneous injection.
58305620|NCT04411615|DRUG|Omega 3|rTG form Omega-3
58305621|NCT06313463|DRUG|Carrellizumab + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
58305622|NCT06313463|DRUG|Placebo + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
58305623|NCT05414214|PROCEDURE|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
58305624|NCT05414214|PROCEDURE|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
58305625|NCT05414214|PROCEDURE|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
58305626|NCT04550117|PROCEDURE|Insertion of Intraspinal pressure monitor|A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
58305627|NCT02047578|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
58305628|NCT06100952|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
58305629|NCT06100952|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
58418596|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
58091572|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
57949986|NCT01157312|DRUG|clomiphene citrate +highly purified uFSH|
57949987|NCT01157312|DRUG|clomiphene citrate|
58091573|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
58091574|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
58091575|NCT05998031|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
58091576|NCT05998031|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
58091577|NCT06461897|DRUG|Upadacitinib|Oral Tablet or Oral Solution
58091578|NCT06461897|DRUG|Dupilumab|Subcutaneous Injection
58091579|NCT04461626|DEVICE|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
58091580|NCT00327652|DRUG|CRS-100|Live-attenuated Listeria monocytogenes
58091581|NCT06701500|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
58305630|NCT01825824|RADIATION|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
57949988|NCT00708500|DRUG|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
57949989|NCT00708500|BIOLOGICAL|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
57949990|NCT00708500|DRUG|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
57949991|NCT00708500|DRUG|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
58305631|NCT01700803|DRUG|Povidone Iodine 10% vand cesarean section wound infections|
58305632|NCT01700803|DRUG|Povidone Iodine 7.5% vand cesarean section wound infections|
58305633|NCT01608165|PROCEDURE|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
58305634|NCT01608165|PROCEDURE|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
58418597|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
57949992|NCT01097278|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
57949993|NCT01097278|OTHER|placebo|Given orally
57949994|NCT05348057|DRUG|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
57949995|NCT04360551|DRUG|Telmisartan 40mg|Angiotensin Receptor Blocker (ARB)
57949996|NCT04360551|DRUG|Placebo|Placebo once daily
57949997|NCT02085382|PROCEDURE|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
58091582|NCT06701500|BEHAVIORAL|Action Sequence Task (AST)|Participants need to press four keys according to the cue location; two keys are associated with high reward, while the other two are associated with low reward in case of correct and timely responses. The explicit goal is to maximize the reward. While in half of the trials the cues are presented in a random order, in the other half of the trials, participants repeatedly perform a fixed action sequence of 12 elements (habit condition). The degree of action sequence chunking (i.e. automation) is assessed via the differences in error rates and reaction times between the random and fixed order condition (habit parameter). Importantly, 15% of all trials are dual- target trials. In these the goal-directed system (press high reward key) and the action sequence (press sequence key) can either be in line (congruent trials) or in conflict (incongruent trials) with each other, thus the interference between goal-directed and habitual control can be tested.
58091583|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Structured Clinical Interview for DSM Disorders (SCID) Current Depression:~  * SCID Mania~ * SCID alcohol use disorder (AUD)~ * SCID tobacco use disorder (TUD)~* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Alcohol quantity-frequency~* Tobacco quantity-frequency~* Cannabis and other substances quantity-frequency"
58091584|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorders Identification Test (CUDIT)~* Adult ADHD Self-Report Scale (ASRS)"
57785127|NCT02916082|PROCEDURE|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
58091585|NCT06701500|BEHAVIORAL|Neuropsychology tests|"* Digit-Symbol-Test (DST)~* Go/Nogo Simon task~* Counting Stroop Task~* Value-based decision-making task (VBDM)"
58091586|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
58305635|NCT01608165|PROCEDURE|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
58305636|NCT03217409|DRUG|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
58305637|NCT03217409|DRUG|Rosuvastatin|Rosuvastatin 5Mg Tablet
58305638|NCT03620448|DEVICE|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
58305639|NCT03620448|OTHER|Oxygen Arm|Oxygen therapy from oxygen cylinders
58305640|NCT03307174|DRUG|Bupivacaine|
58305641|NCT03307174|DRUG|Fentanyl|
58305642|NCT04361656|DRUG|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
58305643|NCT04361656|DRUG|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
58305644|NCT04222543|COMBINATION_PRODUCT|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
58418598|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
58418599|NCT00764257|DEVICE|PREVELLE Shape|
57734527|NCT04729803|BEHAVIORAL|Experimental: Attention Control + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
58091587|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
58091588|NCT06398561|BEHAVIORAL|Active Patient Program|"The Active Patient Program is a peer-leader intervention that consist of training patients with a chronic disease or mental health illness for improve the symptoms of that pathology.~Training is carried out in groups of about 12-15 patients and usually has 2 patient trainers. These patients lead the sessions through the theoretical content they have integrated, motivation, group leadership, exchange of experiences and promotion of communication. In this way they favor problem-solving by the patients who attend the sessions, thus improving their self-management and self-efficacy.~In the group formed by patients who are trainers and patients who benefit from the sessions, a climate of trust is created that favors the expression of emotions on both sides, empathy and assertiveness. In addition to fostering socio-affective bonds between the participants and increasing perceived social and emotional support."
58091589|NCT05469854|DRUG|Linaprazan glurate|"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."
58091590|NCT05469854|DRUG|Placebo|Single dose, oral tablets
58091591|NCT04381468|DRUG|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
57734528|NCT04936022|OTHER|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
57734529|NCT04936022|BEHAVIORAL|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
58091592|NCT04381468|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
58091593|NCT06565845|PROCEDURE|Surgery|patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
58091594|NCT06565845|DRUG|triple anti-tuberculosis drug|Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
58418600|NCT00764257|DEVICE|Restylane|
58418601|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
58418602|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
58418603|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
58418604|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
58418605|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
58418606|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
58418607|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
58418608|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
58091595|NCT00297882|DRUG|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
58091596|NCT00297882|DRUG|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
58091597|NCT06700408|DRUG|Dachaihu Decoction combined Erzhiwan with variation|Chinese medicine granules
58091598|NCT06700408|OTHER|Placebo granules|Placebo granules
58091599|NCT01977625|DRUG|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
58091600|NCT01977625|OTHER|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
58091601|NCT04280939|PROCEDURE|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
58418609|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
58091602|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
58091603|NCT03773393|BIOLOGICAL|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
58091604|NCT05310578|PROCEDURE|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
58091605|NCT01104935|DRUG|trastuzumab monotherapy|
58091606|NCT01104935|DRUG|trastuzumab and chemotherapy|
58091607|NCT05910450|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
58091608|NCT05910450|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
58091609|NCT04846920|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
58091610|NCT05519527|DRUG|Part 1 (STI-6129)|Given by vein (IV)
58091611|NCT05519527|DRUG|Part 2 (STI-6129)|Given by vein (IV)
58091612|NCT05557968|OTHER|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
58091613|NCT05557968|OTHER|Action Observation Therapy (AO)|"The video consists of :~1. Ascending and descending the step box.~2. Ascending and descending the stairs in the treatment room.~3. Holding the handrails to climb and descend the stairs inside and outside the building.~4. Climbing and descending the stairs inside and outside the building without holding the handle.~5. Climbing and descending the sidewalk block"
58418610|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
58418611|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
58418612|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
58418613|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
58091614|NCT05484830|PROCEDURE|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
58418614|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
58418615|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
58418616|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
58418617|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
58418618|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
58418619|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
58418620|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
58418621|NCT00053807|BIOLOGICAL|aldesleukin|
58418622|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
58418623|NCT00053807|DRUG|fluorouracil|
58418624|NCT00053807|PROCEDURE|adjuvant therapy|
57734530|NCT03525353|OTHER|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
58091615|NCT05484830|PROCEDURE|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.)."
58091616|NCT00722007|DEVICE|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
58091617|NCT06700382|DRUG|capecitabine|different methods of treatment for capecitabine
58091618|NCT05638607|BEHAVIORAL|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
58091619|NCT00131573|DEVICE|bion|battery powered bion microstimulator
58418625|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
58418626|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
58418627|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
58418628|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
58418629|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
58418630|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
58418631|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
58418632|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
58418633|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
58418634|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
58418635|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
58418636|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
58418637|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
58418638|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
58418639|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
58418640|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
58418641|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
57734531|NCT05764850|GENETIC|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
58091620|NCT04661163|OTHER|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
58091621|NCT01876628|DRUG|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
57734532|NCT00035126|DRUG|epothilone b|
57734533|NCT02186119|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
57734534|NCT02186119|DRUG|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
58091622|NCT01876628|DRUG|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
58091623|NCT01876628|DRUG|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
58091624|NCT05149807|DRUG|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
58305645|NCT04493606|OTHER|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
58418642|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
58418643|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
58418644|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
58418645|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
57734535|NCT02186119|OTHER|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
57734536|NCT04747977|DRUG|OTX-DED|0.2mg dexamethasone ophthalmic insert
57734537|NCT04747977|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
57734538|NCT04747977|DRUG|OTX-DED|Hydrogel vehicle ophthalmic insert
57734539|NCT05893342|DIAGNOSTIC_TEST|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
58091625|NCT05149807|DRUG|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
58091626|NCT02827188|OTHER|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
58091627|NCT03113201|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
58091628|NCT03113201|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
58091629|NCT06566924|OTHER|Control|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'.
58091630|NCT06566924|OTHER|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made availa
58091631|NCT05179434|PROCEDURE|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
58091632|NCT05179434|PROCEDURE|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
58091633|NCT04840628|OTHER|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
58091634|NCT06701162|PROCEDURE|Ultrasoud-guided TAP block|the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.
58091635|NCT06701162|PROCEDURE|Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block|the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
58091636|NCT01048411|DRUG|Naja-comp.|homeopathic remedy
58091637|NCT01048411|DRUG|Placebo|s.c. injection of NaCl-solution three times a week
58091638|NCT03847428|DRUG|Durvalumab|Durvalumab IV (intravenous)
58091639|NCT03847428|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
58305646|NCT04493606|BEHAVIORAL|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
58305647|NCT02018133|DRUG|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
58305648|NCT02018133|DRUG|Placebo|placebo 2 capsule daily
58305649|NCT01493713|OTHER|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
58305650|NCT03353792|DEVICE|CL/AP system|CL/AP system enabled insulin pump/CGM combination
58305651|NCT03353792|DEVICE|usual diabetic care|usual diabetic care (insulin pump therapy) along with CGM recording
58305652|NCT04139252|OTHER|No intervention|No intervention
58305653|NCT01408069|DRUG|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
58305654|NCT01408069|DRUG|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
58091640|NCT03847428|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
58305655|NCT03628651|OTHER|Blood Sample Collection|HCC subjects will have one blood sample collected.
58305656|NCT03628651|OTHER|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
58305657|NCT01584713|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
58305658|NCT04128917|DRUG|Tegoprazan|Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
58305659|NCT04128917|DRUG|RAPAE01|RAPAE01/Clarithromycin/Amoxicillin BID peroral
58305660|NCT02123381|RADIATION|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
57734540|NCT06532175|DEVICE|Su-Jok|Su-jok seed therapy
58418646|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
58418647|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
58418648|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
58418649|NCT00002239|DRUG|Enfuvirtide|
58418650|NCT00002239|DRUG|Ritonavir|
58418651|NCT00002239|DRUG|Abacavir sulfate|
58418652|NCT00002239|DRUG|Amprenavir|
58418653|NCT00002239|DRUG|Efavirenz|
58418654|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
58418655|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
58418656|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
58418657|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
58418658|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
58418659|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
58418660|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
58418661|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
58418662|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
58418663|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
58418664|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
58418665|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
58418666|NCT00298493|PROCEDURE|Sedation management strategy|
58418667|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
58418668|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
58418669|NCT00005079|PROCEDURE|conventional surgery|
58418670|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
58305661|NCT02123381|DRUG|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
58418671|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
58418672|NCT02410577|DEVICE|PET/CT Scan|
58418673|NCT02410577|DEVICE|MRI|
58418674|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
58418675|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
58418676|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
58418677|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
58418678|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
58418679|NCT02666794|DRUG|Epidural sufentanil|20 mcg
58418680|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
58418681|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
58418682|NCT02666794|DRUG|Intrathecal morphine|60 mcg
58418683|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
58418684|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
58418685|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
58418686|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
58418687|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
58418688|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
58418689|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
58418690|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
58418691|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
58418692|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
58418693|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
58418694|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
58418695|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
58418696|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
58418697|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
58418698|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
58418699|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
58418700|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
58418701|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
58418702|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
57734541|NCT06171685|DRUG|Teclistamab|Comparing treatment regimens
57734542|NCT06171685|DRUG|Investigational Agent|Comparing Treatment Regimens
58418703|NCT00003447|DRUG|gemcitabine hydrochloride|
58418704|NCT00003447|DRUG|vinorelbine tartrate|
58418705|NCT05995197|OTHER|action observation|cartoon observation
58418706|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
58418707|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
57734543|NCT04802733|BIOLOGICAL|MSK-DA01|MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
57734544|NCT04802733|DEVICE|MSK-DA01 Cell Delivery Device|A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
57734545|NCT04992767|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
57734546|NCT04992767|BEHAVIORAL|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
57734547|NCT04566029|BIOLOGICAL|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
57734548|NCT04566029|BIOLOGICAL|Stool sample|The patients' stools will be collected at home
58418708|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
58418709|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
58418710|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
58418711|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
58418712|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
58418713|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
58418714|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
58418715|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
58418716|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
58418717|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
58418718|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
58418719|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
58418720|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
58418721|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
58418722|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
58418723|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
58418724|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
58418725|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
57734549|NCT04566029|OTHER|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
57734550|NCT00911872|DEVICE|collagen (EVOLENCE)|injectable collagen
57734551|NCT03923959|DRUG|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
58091641|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
58418726|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
58418727|NCT00416715|DRUG|letrozole|Given PO
58418728|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
57734552|NCT03923959|OTHER|Placebo|100 cc normal saline
57734553|NCT05947474|DRUG|ORB-011|Drug: ORB-011 is dosed via IV infusion
58418729|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
57734554|NCT01811550|OTHER|Glycemic Control|
57734555|NCT01725646|DRUG|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
57734556|NCT01725646|DRUG|Placebo|Subjects in placebo group will take this drug
57949998|NCT02085382|PROCEDURE|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
57949999|NCT03992976|OTHER|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
57950000|NCT02148965|BEHAVIORAL|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
57734557|NCT05359523|DEVICE|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
57950001|NCT00635037|DRUG|bupivacaine and acupuncture|"* trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week"
58091642|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
58418730|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
58418731|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
58418732|NCT00416715|DRUG|calcium gluconate|Given PO
58418733|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
58418734|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
57734558|NCT01792011|DEVICE|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
57734559|NCT05042219|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
57734560|NCT00377819|DRUG|alendronate|70 mg oral QW
57734561|NCT00377819|DRUG|Denosumab (AMG 162)|60 mg SC q 6 mos
57734562|NCT06316427|DRUG|Autologous CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
58418735|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
58418736|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
58418737|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
58418738|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
58418739|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
58418740|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
58091643|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
58418741|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
58418742|NCT00034879|DRUG|ZD1839 (Gefitinib)|
58091644|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
58091645|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
58418743|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
58091646|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
58091647|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
58091648|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
58091649|NCT03857945|OTHER|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
58091650|NCT06562673|DRUG|intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)|After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
58091651|NCT06535347|BEHAVIORAL|Information about scheduling a follow-up appointment|Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
58091652|NCT03159000|DRUG|Saline|1ml of 1/3 saline
58091653|NCT03159000|COMBINATION_PRODUCT|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
58091654|NCT03208218|DRUG|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
58091655|NCT03208218|DRUG|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
58091656|NCT06581250|BEHAVIORAL|Reminder Messages|Dental clinic staff will use scripts to contact patients 24 and 48 hours before appointments. These scripts will guide staff in confirming the patient will appear for their appointment.
58091657|NCT06581250|BEHAVIORAL|Walk-in Visits|When contacting patients to schedule an appointment (by phone, email, text, or other methods), dental clinic staff will notify patients of times during which patients can walk-in for a dental visit, if convenient for them; otherwise, a regular appointment will be arranged. Scheduled appointments will continue to be available in addition to the walk-in hours.
57734563|NCT06316427|DRUG|Prior-HSCT donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
57734564|NCT06316427|DRUG|New donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
57734565|NCT03434925|GENETIC|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
58305662|NCT06080477|BEHAVIORAL|Enhanced Usual Care|Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.
57734566|NCT04851613|DRUG|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
58418744|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
58418745|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
58418746|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
58418747|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
58418748|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
58418749|NCT00002177|DRUG|Hydroxyurea|
58418750|NCT00002177|DRUG|Nelfinavir mesylate|
58418751|NCT00002177|DRUG|Stavudine|
58418752|NCT00002177|DRUG|Didanosine|
58418753|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
58418754|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
58418755|NCT01932775|DEVICE|GlucoTab System|
58418756|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
58418757|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
58091658|NCT06581250|BEHAVIORAL|Motivation-enhanced Communication|Participating clinic site staff will be trained in motivation-enhanced communication techniques using the guide for dental clinic sites and coaching. Topics to be included in the motivation-enhanced communication training are a) to determine what patients hope to gain from their dental care, steps needed to succeed, how the agency and client will work together to attain the goals, and b) to identify patient barriers to attending their visit (e.g., transportation, payment, do not understand need for visit, etc.), and what the agency and patient will do to overcome those barriers. Staff will be instructed to use these techniques with patients at every contact about an upcoming appointment.
58418758|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
58418759|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
58418760|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
58418761|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
58418762|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
58418763|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
57950002|NCT03816930|PROCEDURE|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
58091659|NCT06180174|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
57950003|NCT02907385|DEVICE|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
57950004|NCT04522089|BIOLOGICAL|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
58091660|NCT02272972|OTHER|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
58091661|NCT05410769|BEHAVIORAL|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
58418764|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
58418765|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
57734567|NCT04851613|DRUG|Afuresertib/placebo|afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
58091662|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
58418766|NCT04485260|DRUG|KRT-232|administered by mouth
58418767|NCT04485260|DRUG|Ruxolitinib|administered by mouth
58418768|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
58418769|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
58418770|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
58418771|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
58418772|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
58418773|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
58418774|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
58418775|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
58418776|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
58418777|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
58418778|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
58418779|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
58418780|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
58418781|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
58418782|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
58418783|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
58418784|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
57785128|NCT00939796|DEVICE|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
57785129|NCT00518505|OTHER|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
58418785|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
58418786|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
58091663|NCT03257774|OTHER|Adhesive strip A|Strip consisting of a newly developed adhesive
58091664|NCT03257774|OTHER|Adhesive strip B|Strip consisting of a newly developed adhesive
58091665|NCT03257774|OTHER|Adhesive strip C|Strip consisting of a newly developed adhesive
58091666|NCT06150001|DRUG|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
58091667|NCT06150001|DRUG|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
58091668|NCT06150001|DRUG|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
58091669|NCT03039517|DEVICE|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
58091670|NCT03039517|DEVICE|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
58418787|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
58418788|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
58418789|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
58418790|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
58091671|NCT04208165|OTHER|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
58091672|NCT04208165|OTHER|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
58091673|NCT01909752|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
58091674|NCT01909752|BIOLOGICAL|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
58091675|NCT01909752|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
58091676|NCT01909752|DRUG|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
58418791|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
58418792|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
58418793|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
58418794|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
58418795|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
58418796|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
58091677|NCT01909752|BIOLOGICAL|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
58418797|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
58418798|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
58418799|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
58418800|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
58418801|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
58418802|NCT04316156|OTHER|Brochure|Brochure
58418803|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
58418804|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
58091678|NCT05425823|OTHER|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
58091679|NCT00795483|DRUG|Zoledronic acid|Zoledronic Acid 5mg/year
58091680|NCT00795483|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications
58091681|NCT00795483|DRUG|Zoledronic acid|Zoledronic acid (5mg/2years)
58091682|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
58418805|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
58418806|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
58091683|NCT05088382|DEVICE|LH Urine Test|Test for the qualitative measurement of LH in urine
58091684|NCT04184882|DRUG|Bocidelpar|Oral
58091685|NCT04184882|DRUG|Placebo|Oral
58091686|NCT03712046|DIAGNOSTIC_TEST|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
58091687|NCT05492877|DRUG|Mitiperstat (AZD4831)|Oral dosage, once daily.
58091688|NCT05492877|OTHER|Placebo|Oral dosage, once daily.
58091689|NCT02292407|DEVICE|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
58305663|NCT06080477|BEHAVIORAL|Adapted ENHANCE Intervention|Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
58418807|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
58418808|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
58418809|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
58418810|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
58418811|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
58418812|NCT02698904|OTHER|Documentary Movie|
58418813|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
58418814|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
58418815|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
58418816|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
58418817|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
58418818|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
58091690|NCT02502565|OTHER|Uric acid level|
58091691|NCT02204449|BEHAVIORAL|Cardiac Rehabilitation Peer Mentorship|
58091692|NCT00480363|PROCEDURE|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
58091693|NCT05631652|DEVICE|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
58091694|NCT01244516|DEVICE|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
58305664|NCT05428956|PROCEDURE|Single Inhalation technique|Single maximal inhalation with breath hold technique
58305665|NCT05428956|PROCEDURE|Tidal inhalation technique|5 tidal breaths technique
58418819|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
58418820|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
58418821|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
58091695|NCT01244516|DEVICE|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
58091696|NCT01244516|DEVICE|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
58091697|NCT05083559|DEVICE|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
58305666|NCT00461734|OTHER|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
58305667|NCT01542008|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
58091698|NCT05083559|DEVICE|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
58091699|NCT06701032|OTHER|Cardiovascular rehabilitation program|The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)
58305668|NCT01542008|BEHAVIORAL|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
58418822|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
58091700|NCT05065957|DRUG|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
58091701|NCT05065957|DRUG|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
58418823|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
58418824|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
58091702|NCT05302037|BIOLOGICAL|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
58091703|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
58091704|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
58091705|NCT06146517|OTHER|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
58091706|NCT06146517|OTHER|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
58091707|NCT06146517|OTHER|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
58091708|NCT06536868|DRUG|Tislelizumab|Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
58091709|NCT06536868|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
58091710|NCT06536868|DRUG|Carboplatin or Cisplatin|Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
58091711|NCT06536868|RADIATION|Thoracic radiotherapy|IMRT 30-45Gy/10-15f
58091712|NCT06701942|OTHER|Multiple family group intervention therapy|"Overview The intervention will be implemented at designated clinics where adolescents living with HIV/AIDS (ALHIV) and their families currently receive care. These sites will provide the MFG intervention alongside standard care services. All eligible adolescents and their family members who consent to participate will be included in the intervention group.~Program Structure The MFG intervention consists of 16 structured sessions, each running for 90 minutes. Sessions will be scheduled to coincide with clinic days over a 14-week period to maximize accessibility and attendance. Parent peers and community health workers, trained by the research team, will facilitate these group sessions.~Session Format Sessions on the MFGT will begin with introducing participants to one another, the facilitators, and the program curriculum. Subsequent sessions will concentrate on areas such as respectful communication, support, resilience building, problem-solving, conflict resolution, stress management"
58091713|NCT04666012|BIOLOGICAL|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
58091714|NCT06290622|DRUG|Retifanlimab, INCAGN02385, INCAGN02390|"Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles."
58418825|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
58418826|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
58418827|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
58418828|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
58418829|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
58418830|NCT00343863|DRUG|cyclophosphamide|Given orally
58418831|NCT00343863|DRUG|dexamethasone|Given orally or IV
57734568|NCT04256551|OTHER|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
58418832|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
58091715|NCT05595161|BEHAVIORAL|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
58091716|NCT06703008|OTHER|TEE hemodynamic monitoring|Transesophageal echocardiography monitoring to guide administration of fluids, vasopressor and inotropes during liver transplantation in order to avoid hypotension.
58091717|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
58305669|NCT06019572|PROCEDURE|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
58305670|NCT05843409|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
58305671|NCT03367000|DIETARY_SUPPLEMENT|Ceprolac|The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
58305672|NCT03367000|OTHER|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
58305673|NCT02664675|PROCEDURE|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
58305674|NCT02664675|PROCEDURE|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
58305675|NCT00300157|DEVICE|Percutaneous coronary intervention with Taxus stent|
58305676|NCT04724135|OTHER|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
58305677|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
58418833|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
58418834|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
58418835|NCT00343863|PROCEDURE|management of therapy complications|Given IV
58418836|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
58418837|NCT00343863|OTHER|survey administration|Ancillary studies
58418838|NCT00078065|DRUG|Xcellerated T Cells|
58418839|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
58418840|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
58418841|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
58418842|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
58418843|NCT00841048|DRUG|Placebo|
58091718|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
58418844|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
58418845|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
58418846|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
58418847|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
58418848|NCT03597282|OTHER|Adjuvant|immune adjuvant
58418849|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
58418850|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
58418851|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
58418852|NCT00166491|DRUG|Insulin|
58418853|NCT02577185|DRUG|Botulinum Toxin Type A|
58418854|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
58418855|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
58418856|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
58418857|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
58418858|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
58418859|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
58418860|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
58418861|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
58418862|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
58418863|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
58418864|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
58418865|NCT00381875|BIOLOGICAL|sargramostim|
58418866|NCT00381875|OTHER|immunoenzyme technique|
58418867|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
58418868|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
58418869|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
58418870|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
58418871|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
57785130|NCT01300793|DRUG|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 \& 11 q. 28 days.
58418872|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
58418873|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
58418874|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
58418875|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
58418876|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
57785131|NCT00459511|PROCEDURE|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
58091719|NCT04311359|DRUG|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
58091720|NCT04546126|DRUG|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
58418877|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
58418878|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
58418879|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
58418880|NCT03659058|DRUG|Colchicine|Colchicine 0.6
58418881|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
58418882|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
58418883|NCT00499655|DRUG|celecoxib|Given orally
58418884|NCT00499655|OTHER|placebo|Given orally
58418885|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
58418886|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
58418887|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
58418888|NCT00499655|GENETIC|mutation analysis|Correlative studies
58418889|NCT00499655|GENETIC|protein expression analysis|Correlative studies
58418890|NCT00499655|GENETIC|gene expression analysis|Correlative studies
58418891|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
58418892|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
58418893|NCT02559414|DRUG|Aspirin|
58418894|NCT02559414|DRUG|Clopidogrel|
58418895|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
58418896|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
58418897|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
58418898|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
58418899|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
58418900|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
58418901|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
58418902|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
58418903|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
57734569|NCT04256551|OTHER|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
58091721|NCT04546126|DRUG|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
58091722|NCT04546126|COMBINATION_PRODUCT|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
58091723|NCT06653686|OTHER|Hyperthermia combined with oral febuxostat.|Extracorporeal high-frequency hyperthermia combined with oral febuxostat
58091724|NCT06653686|DRUG|Febuxostat|The control group subjects were administered oral febuxostat.
58091725|NCT06070701|PROCEDURE|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
58091726|NCT06070701|PROCEDURE|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
58091727|NCT06070701|DRUG|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
58091728|NCT06070701|DRUG|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
58305678|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
58418904|NCT05644093|DRUG|SPL026 IV|IV dosing
58418905|NCT05644093|DRUG|SPL026 IM|IM dosing
58418906|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
58418907|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
58418908|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
58418909|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
58418910|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
58418911|NCT01747252|DIETARY_SUPPLEMENT|RGC|
58418912|NCT01747252|DIETARY_SUPPLEMENT|RGC|
58418913|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
58418914|NCT06103487|GENETIC|No Intervention|Observational study
58418915|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
58418916|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
58091729|NCT06701214|OTHER|Blood collection|Blood will be taken from participants already undergoing blood collection
58091730|NCT06701214|OTHER|Saliva collection|Undergo saliva collection
58091731|NCT06701214|OTHER|Bone marrow collection|Bone marrow will be taken from participants already undergoing bone marrow collection
58091732|NCT03943407|DRUG|Zyclara 3.75 % Topical Cream|The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
58091733|NCT03943407|DRUG|Prudoxin|The anti-histamine cream Prudoxin, containing 5% doxepin hydrochloride (1 g contains 50 mg of doxepin) (Healthpoint, San Antonio, TX) will be applied on the volar forearm. Two adhesive patches 4×4 cm (1mm thick, 3M foam adhesive tape, 3M, St. Paul, MN) each with a 3.5×3.5 cm center cut out (to deposit 1.2 grams of cream) will be each placed 3 cm distal and 3 cm proximal to the center of the volar aspect of each arm. Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1 h and 30 minutes.
58418917|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
58418918|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
58418919|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
58418920|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
58418921|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
58418922|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
58418923|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
58418924|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
58418925|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
58091734|NCT03943407|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction. . A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
58091735|NCT03943407|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip. The active substance delivered (mucunain) has been calculated to be in the nanogram range. The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
58091736|NCT03943407|OTHER|L-menthol|L-menthol (≥99.9%, TRPM8 agonist; (Sigma Aldrich, Broendby, Denmark) is dissolved in 96% ethanol at concentrations of 40%(w/v) L-menthol. A 1 mL aliquot is dispensed onto a 3 × 3 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape. In between the cotton pad and the medical tape, a layer of parafilm will be added to avoid evaporation. This configuration was subsequently applied for 1 h.
58091737|NCT03943407|OTHER|Trans-cinnamaldehyde (CA)|CA will be obtained from Sigma Aldrich (Brøndby, Denmark) and dissolved in 90% ethanol at a concentration of 10% (vol/vol) CA. One ml aliquot of CA is dispensed onto a 3x3 cm cotton pad and placed on a 5x5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic film will be added to inhibit the evaporation of the solutions. This configuration will be applied for 1 h.
58091738|NCT06703580|DRUG|Hyperbaric prilocaine 2% 40 mg|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
58091739|NCT06703580|DRUG|hyperbaric prilocaine 2% 50 mg|comparison of 3 different doses of prilocaine
58091740|NCT06703580|DRUG|hyperbaric prilocaine 2% 60 mg|this study compare 3 different doses of prilocaine
58091741|NCT04419428|DEVICE|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
58091742|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
58091743|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
58091744|NCT04669756|PROCEDURE|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
58418926|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
58418927|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
58418928|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
58418929|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
58418930|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
58418931|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
58418932|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
57734570|NCT04256551|OTHER|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
57734571|NCT05210192|DRUG|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
58091745|NCT04669756|PROCEDURE|placebo operation|in arm D sutures are transabdominal only
58091746|NCT05576597|DRUG|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
58091747|NCT06702397|DEVICE|Microscope|The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.
58091748|NCT06702397|DEVICE|Surgical loupes|Surgical loupes offer magnification of 3.5-5x.
58091749|NCT00228878|PROCEDURE|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
58091750|NCT05072145|OTHER|Telemedicine|Receiving care in a tele-ED hospital
58418933|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
58091751|NCT06023680|BEHAVIORAL|Continuous sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days."
58418934|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
58418935|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
58418936|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
58418937|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
58418938|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
58091752|NCT06023680|BEHAVIORAL|Bouted sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days."
57734572|NCT05210192|DRUG|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
57734573|NCT01750268|BEHAVIORAL|Medical Management Counseling|Brief alcohol and medication counseling
57734574|NCT01750268|DRUG|Topiramate|Experimental medication
58091753|NCT04797637|DEVICE|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
58091754|NCT00903942|RADIATION|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
58091755|NCT00903942|DRUG|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
58091756|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
58091757|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
58091758|NCT04657458|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
58091759|NCT04782687|DRUG|Selinexor|oral drug that comes in 20 mg tablets
58091760|NCT04782687|DRUG|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.
58091761|NCT04782687|DRUG|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
58418939|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
57734575|NCT01750268|DRUG|Placebo|Placebo comparator
57734576|NCT02363738|DRUG|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
57734577|NCT02363738|OTHER|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
57734578|NCT03646786|DEVICE|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
57734579|NCT00572234|DRUG|bupropion SR|12 week course of bupropion SR 150 mg, BID
57734580|NCT06565507|DRUG|Oxfendazole single dose|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
57734581|NCT06565507|DRUG|Oxfendazole three doses|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
58091762|NCT04782687|DRUG|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
58091763|NCT04390100|DRUG|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
58091764|NCT04390100|OTHER|Platelet rich fibrin|coverage of the free gingival graft area in the palate
58091765|NCT04390100|OTHER|Gel foam|coverage of the free gingival graft area in the palate
58091766|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
58091767|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
58091768|NCT06388265|OTHER|Trifold information|Additional detailed and written information about the procedure will be given to the participants
58418940|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
58418941|NCT00313547|DRUG|Quinapril 40 mg|
58091769|NCT02704130|DEVICE|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
58091770|NCT02704130|PROCEDURE|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
57734582|NCT06565507|DRUG|albendazole plus praziquantel regime|Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
58091771|NCT06384898|OTHER|Remote Tai Chi|Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
57734583|NCT00615966|DRUG|Diannexin|single dose, 200 µg/kg IV
58091772|NCT03020966|DRUG|Acetaminophen|Oral acetaminophen, intravenous placebo
58091773|NCT03020966|DRUG|Acetaminophen|Intravenous acetaminophen, oral placebo
58091774|NCT03284515|BIOLOGICAL|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
58091775|NCT06703047|DRUG|ATRA+pd-1+chemo|All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
57734584|NCT00615966|DRUG|Placebo|Single dose, IV
57734585|NCT00615966|DRUG|Diannexin|Single dose, 400 µg/kg IV
58091776|NCT06703047|DRUG|placebo+PD-1+chemo|Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
58091777|NCT06596382|DIETARY_SUPPLEMENT|Tocotrienol rich-vitamin E|Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome
58091778|NCT06596382|DIETARY_SUPPLEMENT|Placebo|Replicate for tocotrienol rich-vitamin E without any active ingredients
58091779|NCT02267759|DEVICE|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
58091780|NCT02267759|DEVICE|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
58091781|NCT06116994|OTHER|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
58091782|NCT06116994|OTHER|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
58091783|NCT06056063|DEVICE|Halcyon 4.0|This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
58091784|NCT05354141|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
58091785|NCT05354141|OTHER|Intravenous normal saline|Placebo
58091786|NCT06543498|DIAGNOSTIC_TEST|Lactulose/Mannitol Ratio Test|To test for gut permeability, Urine collected over 8hrs after ingestion of lactulose/mannitol drink.
58091787|NCT06543498|DIAGNOSTIC_TEST|Serum biomarkers of intestinal permeability|Phlebotomy and subsequent lab tests to analyse concentration of LPS, LPB, sCD14, Zonulin and Occludin.
57734586|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
57734587|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
57734588|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
57734589|NCT04333394|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
57734590|NCT04333394|OTHER|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
58091788|NCT06543498|OTHER|Rome IV questionnaire|Diagnositic questionnaire for IBS-D
58091789|NCT06543498|OTHER|Irritable bowel severity scoring system|Questionnaire to determine severity of abdominal and bowel symptoms
58091790|NCT06543498|OTHER|Bowel Habit diary|Assess bowel habit at baseline and changes in bowel habit over the study
58091791|NCT06543498|OTHER|3 day dietary record|Used to verify compliance to exclusion criteria #5.
58091792|NCT06543498|DIETARY_SUPPLEMENT|NCT and NFT|N-transcaffeoyltyramine and N-transferuloyltyramine supplement taken once per day.
58091793|NCT06543498|OTHER|Placebo|Placebo supplement taken once per day.
58091794|NCT00939965|DRUG|isotretinoin|
58091795|NCT00939965|GENETIC|DNA analysis|
57785132|NCT01442974|DRUG|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
58091796|NCT00939965|GENETIC|polymerase chain reaction|
58091797|NCT00939965|OTHER|laboratory biomarker analysis|
58091798|NCT00939965|OTHER|pharmacological study|
58418942|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
58091799|NCT03315871|BIOLOGICAL|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
58091800|NCT03315871|BIOLOGICAL|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
58091801|NCT03315871|DRUG|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
58091802|NCT03315871|BIOLOGICAL|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
58091803|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
58091804|NCT01246297|OTHER|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
58091805|NCT01246297|OTHER|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
58091806|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
58091807|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
58091808|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
58091809|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
58091810|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
58091811|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
58091812|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
58091813|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
58091814|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
58091815|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
58091816|NCT03121664|DRUG|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
57734591|NCT05859204|BEHAVIORAL|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
57785133|NCT00288197|DRUG|voriconazole|
57785134|NCT00309920|BIOLOGICAL|darbepoetin alfa|
57785135|NCT00309920|DRUG|cyclophosphamide|
57785136|NCT00309920|DRUG|docetaxel|
57785137|NCT00309920|DRUG|doxorubicin hydrochloride|
57785138|NCT00309920|DRUG|epirubicin hydrochloride|
58091817|NCT02618772|DRUG|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
58091818|NCT02618772|DRUG|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
58091819|NCT02553005|PROCEDURE|Acupuncture|
58091820|NCT06701448|DIAGNOSTIC_TEST|robotic bronchosopy|robotic bronchoscopy
58091821|NCT06701448|DIAGNOSTIC_TEST|Electromagnetic Navigation Bronchoscopy|Electromagnetic Navigation Bronchoscopy
58091822|NCT06701448|DIAGNOSTIC_TEST|Fluoroscopy bronchoscopy|Fluoroscopy bronchoscopy
58091823|NCT00571909|PROCEDURE|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
58091824|NCT03444909|DEVICE|cardiotocograph|Monitoring of 20 min with the cardiotocograph
58091825|NCT03444909|DEVICE|Toconaute|Monitoring of 20 min withToconaute
58091826|NCT03444909|DEVICE|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
58091827|NCT06569004|DEVICE|randomised study, two group (experimental and control)|Use of IR beam before peripheral intravenous catheter application
58091828|NCT04141670|DRUG|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
58091829|NCT04983095|RADIATION|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
58091830|NCT04983095|COMBINATION_PRODUCT|androgen deprivation therapy|Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
58091831|NCT04983095|RADIATION|Radiotherapy|RT to the prostate for de novo patients
58091832|NCT06471738|DRUG|Zanubrutinib|BTK inhibitor
58091833|NCT06471738|BIOLOGICAL|Rituximab|Monoclonal antibody to CD20
58091834|NCT06471738|DRUG|Venetoclax|BCL-2 inhibitor
58091835|NCT04437407|DEVICE|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
58091836|NCT04437407|DEVICE|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
58091837|NCT04437407|DEVICE|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
58091838|NCT04437407|DEVICE|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
58091839|NCT04437407|DEVICE|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
58091840|NCT04437407|DEVICE|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
58091841|NCT04437407|DEVICE|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
58091842|NCT04686500|DEVICE|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
58091843|NCT04965896|OTHER|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
58091844|NCT04965896|OTHER|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
58091845|NCT04225416|OTHER|Questionnaire/Structured Interview|No intervention
58091846|NCT06332209|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT; Cohen et al., 2017) is an evidence-based, manualized treatment protocol designed to treat posttraumatic stress and co-occurring symptoms such as depression and anxiety in trauma-exposed children and youth and their supportive and non-offending caregivers. TF-CBT is divided into nine cognitive and behavioral components, all of which incorporate gradual exposure to trauma memories and reminders
58091847|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
58305679|NCT00846365|DRUG|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
58305680|NCT01832766|DRUG|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
58418943|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
57734592|NCT05859204|BEHAVIORAL|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
57734593|NCT00001601|PROCEDURE|Electrocardiogram|
57734594|NCT00001601|PROCEDURE|Biopsies|
57734595|NCT00001601|PROCEDURE|Diagnostic imaging|
57785139|NCT00309920|DRUG|fluorouracil|
58091848|NCT06565754|OTHER|BFR|"Blood flow restriction training is an accessory to a variety of different exercise modes (e.g., resistance exercise, walking, cycling) has recently become a popular research topic. It involves the application of pressurized cuffs to the proximal portion of each lower extremity or upper extremity. It enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet or cuff.~The 3rd Generation SmartCuffs® pump (SmartCuffs® 3.0 PRO) is Personalized Pressure feature which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it is calculate arterial occlusion pressure and set the optimal pressure for patient's body. There is no need for an external doppler probe or hand pump. This unit will do everything for patient. Smart Cuffs 3rd generation is FDA Approved Listed Class 1 device.~The automatized tourniquet (Smart Tools) contains a ring-shaped single- chamber"
58091849|NCT06565754|OTHER|strengthening exercise|Quadriceps strengthening exercises are part of the treatment of PFPS, but the heavy resistance exercises may aggravate knee pain. Blood flow restriction training (BFRT) provides a low-load quadriceps strengthening method to treat PFPS (Giles et al., 2017).
58091850|NCT01551329|DRUG|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
58091851|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
58091852|NCT01188759|DRUG|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
58091853|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
58091854|NCT06023953|DEVICE|Nerivio device|REN treatment with Nerivio device
58091855|NCT04269746|DIAGNOSTIC_TEST|CCAT1|Long Non coding RNA
58091856|NCT02487979|DRUG|Glembatumumab Vedotin|Given IV
58091857|NCT02487979|OTHER|Laboratory Biomarker Analysis|Correlative studies
58091858|NCT02487979|OTHER|Pharmacological Study|Correlative studies
58091859|NCT05471063|DRUG|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
58091860|NCT05471063|DRUG|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
58091861|NCT05471063|DRUG|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
58091862|NCT06564155|DEVICE|carotid duplex|measure Carotid intima media thickness
58091863|NCT02232685|DEVICE|18F-Choline PET/CT|18F-Choline PET/CT
58091864|NCT04482101|OTHER|Root canal obturation|Root canal filling
58091865|NCT04764825|DRUG|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
58091866|NCT04764825|DRUG|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
57734596|NCT06129669|DRUG|Indocyanine green|Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
57734597|NCT05246423|DIAGNOSTIC_TEST|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
57734598|NCT04447404|DRUG|DUR-928|IV infusion
57734599|NCT04447404|DRUG|Placebo|IV infusion
57734600|NCT04701398|OTHER|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
57734601|NCT02501460|OTHER|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
57785140|NCT02006043|DRUG|Erlotinib 150mg|
57785141|NCT02353117|BEHAVIORAL|Congenital Syphilis Intervention Group|
58091867|NCT03491800|BEHAVIORAL|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
58091868|NCT03417674|COMBINATION_PRODUCT|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
58091869|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
58091870|NCT03686124|BIOLOGICAL|IMA203 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
58091871|NCT03686124|BIOLOGICAL|IMA203 product- flat dose|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
58091872|NCT03686124|BIOLOGICAL|IMA203CD8 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
58091873|NCT03686124|DRUG|nivolumab (Opdivo®)|Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
58091874|NCT03686124|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics
58305681|NCT01832766|OTHER|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
58091875|NCT01238523|PROCEDURE|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
58418944|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
58418945|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
57734602|NCT02501460|OTHER|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
58418946|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
58418947|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
58418948|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
58418949|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
58418950|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
57734603|NCT02501460|DIETARY_SUPPLEMENT|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
57734604|NCT02501460|OTHER|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
57785142|NCT02150044|DEVICE|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
58091876|NCT01238523|PROCEDURE|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
58305682|NCT06473350|OTHER|The application of right lateral, supine, and prone positions to preterm infants after feeding|Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
58305683|NCT01850641|DRUG|PA21|
58305684|NCT01079780|BIOLOGICAL|cetuximab|Given IV
58305685|NCT01079780|BIOLOGICAL|ramucirumab|Given IV
58418951|NCT04838704|DRUG|Ruxolitinib+Calcineurin +Methotrexate|low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
58418952|NCT04838704|DRUG|Calcineurin +Methotrexate+Mycophenolate mofetil|calcineurin and short course of methotrexate and mycophenolate mofetil
58418953|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
58418954|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
58305686|NCT01079780|DRUG|irinotecan hydrochloride|Given IV
58305687|NCT01042795|DRUG|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
58305688|NCT05959928|DEVICE|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
58305689|NCT04811196|DRUG|Selinexor|Selinexor
58305690|NCT04632004|OTHER|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
58305691|NCT00116688|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
58418955|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
58418956|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
58418957|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
58418958|NCT03715192|DRUG|Placebo|Administered IV
58418959|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
58418960|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
58418961|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
58418962|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
58418963|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
58418964|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
58418965|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
58418966|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
58418967|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
58418968|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
58091877|NCT04032522|OTHER|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
58091878|NCT03176511|BEHAVIORAL|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
58091879|NCT03176511|BEHAVIORAL|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
58305692|NCT00315341|DRUG|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
58418969|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
58418970|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
58418971|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
58418972|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
58418973|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
58418974|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
58418975|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
58418976|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
58418977|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
58418978|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
58418979|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
58418980|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
58418981|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
58418982|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
58418983|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
58418984|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
58091880|NCT06542354|BEHAVIORAL|Physical exercise|Physical exercises personally scheduled consisting of daily aerobic exercise(30mins) of fast walking(≥5km) and resisitance training.
57734605|NCT05240014|DEVICE|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
57950005|NCT01888640|DEVICE|TENS|"TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
57950006|NCT06356961|BEHAVIORAL|(Feedback Informed Therapy) with Clinical Support Tools and ah hoc training|Therapists in the condition (OPM-F) will receive specific training on the procedures and techniques inherent in feedback informed therapy (FIT); during the intervention phase (lasting 15 sessions) the Clinical Support System in FIT will guide them in the clinical application of the procedures. In addition, they will receive monthly supervision (for three months) apt to provide on-going clinical support on FIT and ROM, with practical discussion of the most difficult clinical cases and possible solutions to be implemented in therapy.
57950007|NCT06356961|BEHAVIORAL|Feedback and ROM (basic)|Process and outcome monitoring (OPM) in which patients will complete process and outcome measures related to each psychotherapy session but therapists will receive basic feedback on these measures
57950008|NCT03853603|DIETARY_SUPPLEMENT|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
57950009|NCT03853603|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
57950010|NCT01422122|DRUG|Vitamin D3|4000 mg per day, one tablespoon syrup per day
57950011|NCT01422122|DRUG|Placebo|one table spoon Syrup per day
57950012|NCT05348512|OTHER|spectral imaging|non-contact, non-invasive hyperspectral and multispectral imaging without a diagnostic test
57950013|NCT05348512|OTHER|photoplethysmography|non-invasive pulse oximetry without a diagnostic test
57950014|NCT03084536|DRUG|Bupivacaine|-Given after general anesthesia
57950015|NCT03084536|DRUG|Gabapentin|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
57950016|NCT03084536|DRUG|Celecoxib|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies."
57950017|NCT03084536|DRUG|Acetaminophen|-As per routine care
57950018|NCT03084536|DRUG|Midazolam|-As per routine care
57950019|NCT03084536|DRUG|Fentanyl|-As per routine care
58091881|NCT06542354|DIETARY_SUPPLEMENT|Nutrition supplement|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Oral nutrition supplement (ENSURE) is provided daily seperated in 2 doses
58305693|NCT00315341|DRUG|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
58091882|NCT06542354|BEHAVIORAL|Mental support|Relaxation exercise and psychological counselling delivered by weekly telephone follow-up
58091883|NCT05517005|DIETARY_SUPPLEMENT|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
58091884|NCT04095546|OTHER|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
57950020|NCT02831413|BEHAVIORAL|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
57950021|NCT02831413|BEHAVIORAL|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
57950022|NCT00085956|DRUG|Arzoxifene|
57950023|NCT00085956|DRUG|Placebo|
57950024|NCT06104852|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
57950025|NCT06104852|OTHER|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
58418985|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
57734606|NCT04154787|DRUG|LNP023|Investigation of LNP023
57734607|NCT04154787|DRUG|Rituximab|Comparison of rituximab dose
57734608|NCT03103555|DRUG|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
57950026|NCT05234970|OTHER|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
57950027|NCT05234970|OTHER|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
57950028|NCT01997736|DEVICE|Ablation|
57950029|NCT03473574|BIOLOGICAL|Durvalumab|immune checkpoint inhibitor
57950030|NCT03473574|DRUG|Gemcitabine|standard chemotherapy
57950031|NCT03473574|DRUG|Cisplatin|standard chemotherapy
57950032|NCT03473574|BIOLOGICAL|Tremelimumab|immune checkpoint inhibitor
57950033|NCT03168880|DRUG|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
57950034|NCT03168880|DRUG|Paclitaxel only|
57950035|NCT05591664|DIAGNOSTIC_TEST|eicosapentaenoic acid|eicosapentaenoic acid levels of the groups will be monitored
57950036|NCT02936427|DRUG|Dexamethasone|perineural infiltration of dexamethasone
57950037|NCT03570931|DRUG|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
57950038|NCT01479179|DRUG|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
57950039|NCT01479179|DRUG|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
57950040|NCT03057106|DRUG|Durvalumab|MEDI4736
57950041|NCT03057106|DRUG|Tremelimumab|Tremelimumab
57950042|NCT03057106|DRUG|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
58305694|NCT06407817|PROCEDURE|Spencer technique|No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)
58305695|NCT06407817|PROCEDURE|reverse distraction technique|No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)
57950043|NCT00123006|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
58305696|NCT00158808|BIOLOGICAL|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
58418986|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
57734609|NCT03103555|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
57734610|NCT01715805|DRUG|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
57734611|NCT01715805|DRUG|Placebo|Dose-matched placebo capsule once per day
57950044|NCT00123006|BEHAVIORAL|Control Diet|4 week feeding intervention
57950045|NCT00450723|DRUG|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
57950046|NCT00450723|PROCEDURE|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
57950047|NCT00450723|PROCEDURE|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
57950048|NCT00450723|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
57950049|NCT00450723|PROCEDURE|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
57950050|NCT00450723|RADIATION|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
57950051|NCT00541320|DRUG|GW813893|
58305697|NCT02051868|DRUG|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
58305698|NCT02051868|DRUG|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
58305699|NCT02051868|DRUG|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
57734612|NCT01715805|DRUG|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
57950052|NCT01745770|DRUG|Mesalazine - TID 1000 mg|
57950053|NCT01745770|DRUG|Mesalazine - TID 2x 500 mg|
57950054|NCT02590120|DIETARY_SUPPLEMENT|Enteral nutrition|
57950055|NCT00001288|DRUG|15 O Water|
57950056|NCT00001288|DRUG|FDG|
57950057|NCT04788979|DRUG|Melatonin 5Mg Oral Tablet|"1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
58418987|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
58418988|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
58418989|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
58418990|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
58305700|NCT02051868|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
58418991|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
58418992|NCT00004705|DRUG|amiloride|
58418993|NCT00004705|DRUG|uridine|
58418994|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
58418995|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
58418996|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
58418997|NCT00110487|DRUG|ERB-041|
58418998|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
58418999|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
58419000|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
57785143|NCT02116140|OTHER|[C11]Acetate and HED PET|
57785144|NCT05351736|DRUG|Lurasidone|Treatment with lurasidone
57785145|NCT01942655|OTHER|Blood sample and recto-colic biopsies|
57785146|NCT04055506|DRUG|BMS-986165|Dose 1
57785147|NCT04055506|DRUG|Ritonavir|100 mg
57950058|NCT03412656|DEVICE|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
58305701|NCT04264208|DRUG|68-Ga RM2.|PET radiopharmaceutical
58305702|NCT04264208|DRUG|68-Ga PSMA11|PET radiopharmaceutical
58305703|NCT04264208|DEVICE|PET/MRI|PET/MR scanner by GE healthcare
58305704|NCT00435071|PROCEDURE|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
58305705|NCT00435071|PROCEDURE|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
58305706|NCT02981511|DEVICE|optiflow|Optiflow device used for preoxygenation
58305707|NCT01792739|DRUG|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
58305708|NCT01792739|DRUG|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
58419001|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
58419002|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
58419003|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
58419004|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
58419005|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
58419006|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
58419007|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
58419008|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
58419009|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
58419010|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
58419011|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
58419012|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
57734613|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
57734614|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
57734615|NCT06073574|DIAGNOSTIC_TEST|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
57734616|NCT04020991|DIAGNOSTIC_TEST|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
57734617|NCT01479920|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
57734618|NCT01479920|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
58419013|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
58419014|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
58419015|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
58419016|NCT02535416|DRUG|ARC-520|
58419017|NCT02535416|DRUG|cetirizine|
58419018|NCT02535416|DRUG|diphenhydramine|
58419019|NCT02830204|DEVICE|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
58419020|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
58419021|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
58419022|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
58419023|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
58419024|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
58419025|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
58419026|NCT00424268|DRUG|Placebo|once daily
58419027|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
58419028|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
58419029|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
58419030|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
58419031|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
58419032|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
58419033|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
58419034|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
58419035|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
58419036|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
58419037|NCT06243055|OTHER|questionnare|laval questionnare
58419038|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
58419039|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
58419040|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
58419041|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
58419042|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
57734619|NCT01479920|PROCEDURE|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
58095266|NCT03851107|BEHAVIORAL|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
58419043|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
57734620|NCT00540280|RADIATION|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
57785148|NCT05914428|OTHER|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
57734621|NCT06589648|OTHER|mandala painting|Mandala coloring creates a relaxing effect on individuals because it starts with a pattern that develops like a flower around a point; it allows the individual to stay in the moment, to get away from stress, anxiety and worries, and it relaxes the mind.
58091885|NCT04036786|BEHAVIORAL|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
58091886|NCT04036786|BEHAVIORAL|standard care|standard pregnancy follow up
57734622|NCT00922493|OTHER|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
57785149|NCT01545362|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
57785150|NCT06242197|OTHER|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
58091887|NCT00901420|PROCEDURE|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
58091888|NCT00901420|BEHAVIORAL|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
58091889|NCT04598009|DRUG|Binimetinib|Taken orally (PO) twice a day (BID)
58091890|NCT04598009|DRUG|Imatinib|Taken orally (PO) once a day (QD)
58091891|NCT05760638|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
58091892|NCT03065517|DEVICE|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
58091893|NCT03065517|DEVICE|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
58091894|NCT02989467|DRUG|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
58091895|NCT02989467|DRUG|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
58091896|NCT02755727|PROCEDURE|Platelet Rich Plasma Injection|See Arms
58091897|NCT02755727|PROCEDURE|Open Surgical Release|See arms
58305709|NCT04592016|DRUG|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
58305710|NCT04592016|DRUG|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
58305711|NCT04592016|DRUG|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
58091898|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
58091899|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
58095267|NCT06107127|PROCEDURE|STOP|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
58419044|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
58419045|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
58091900|NCT04925622|DIAGNOSTIC_TEST|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
58091901|NCT06597006|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \<16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
58091902|NCT06597006|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
58091903|NCT04578548|DRUG|GLPG2737|Capsules administered orally
58091904|NCT04578548|DRUG|Placebo|Matching placebo capsules administered orally
58091905|NCT01273584|DRUG|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
58091906|NCT01273584|DRUG|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
58091907|NCT00698607|DEVICE|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
58419046|NCT00997399|DRUG|panobinostat (LBH589)|
57785151|NCT02064725|DRUG|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
57785152|NCT04463615|DRUG|Leflunomide|Given PO
57950059|NCT00363948|DRUG|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
57950060|NCT00363948|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
57950061|NCT03518788|PROCEDURE|Pleur-X|Permanent drainage
57950062|NCT03518788|PROCEDURE|Pleurodesis|Pleurodesis with talc in permanent VATS
57950063|NCT02636582|OTHER|Laboratory Biomarker Analysis|Correlative studies
57950064|NCT02636582|DRUG|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
57950065|NCT02636582|BIOLOGICAL|Sargramostim|Given ID
57950066|NCT02636582|PROCEDURE|Surgical Procedure|Undergo surgery
58091908|NCT00698607|DEVICE|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
58091909|NCT00698607|DRUG|6-month clopidogrel therapy|Use clopidogrel for 6 months
58091910|NCT00698607|DRUG|12-month clopidogrel therapy|Use clopidogrel for 12 months
58091911|NCT05503160|BEHAVIORAL|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
58419047|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
58419048|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
58419049|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
57950067|NCT03322189|GENETIC|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
57950068|NCT05335460|DRUG|Envafolimab|300mg,sc,d1,Q3W
57950069|NCT03917823|DEVICE|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
57950070|NCT03917823|DEVICE|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
57950071|NCT02336490|OTHER|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
57950072|NCT03223480|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
57950073|NCT02761304|PROCEDURE|Ultrasound|
57950074|NCT04022915|DRUG|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
57950075|NCT04022915|DIAGNOSTIC_TEST|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
57950076|NCT04759651|OTHER|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
57950077|NCT04759651|OTHER|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
57950078|NCT04759651|OTHER|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
58091912|NCT00552682|DRUG|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
58091913|NCT00535873|DRUG|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
58091914|NCT01904084|DEVICE|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
58091915|NCT01904084|DEVICE|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
58091916|NCT04635631|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
58091917|NCT01162993|PROCEDURE|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
58091918|NCT05144477|BEHAVIORAL|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
57734623|NCT04568538|OTHER|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
57734624|NCT03457532|DRUG|Gumarontinib Tablets|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
58091919|NCT02341794|DRUG|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
58091920|NCT05237687|DRUG|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
58091921|NCT03300882|OTHER|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
58091922|NCT01387672|DRUG|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
58091923|NCT01387672|OTHER|Placebo|Placebo ointment
58091924|NCT06511167|DEVICE|TIGR® Matrix|bioresorbable, synthetic, surgical mesh
58091925|NCT06446154|DRUG|Fruquintinib|Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
58091926|NCT05437718|OTHER|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
58091927|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
58091928|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
58091929|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
58091930|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
58091931|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
58091932|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
58091933|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
58091934|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil + boswellic acid supplement|This supplement contains frankincense essential oil and boswellic acid as its active ingredients.
58091935|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil supplement|This supplement contains frankincense essential oil as its active ingredient.
57734625|NCT05118854|DRUG|AMG 510|Given by IV
57734626|NCT05118854|DRUG|Cisplatin|Given by IV
57734627|NCT05118854|DRUG|Carboplatin|Given by IV
57734628|NCT05118854|DRUG|Pemetrexed|Given by IV
57734629|NCT00127075|DRUG|nomegestrol acetate|10 mg/day
58095268|NCT01531062|DRUG|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
58305712|NCT04592016|DEVICE|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
58305713|NCT04592016|DEVICE|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
58419050|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
58419051|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
58419052|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
58419053|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
58419054|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
58419055|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
58419056|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
58419057|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
58419058|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
58419059|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
58419060|NCT00001724|DRUG|Flurbiprofen|
58419061|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
58419062|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
58419063|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
58305714|NCT04592016|PROCEDURE|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
58305715|NCT04592016|PROCEDURE|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
58419064|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
58419065|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
58419066|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
57734630|NCT00127075|DRUG|estradiol|75 mcg, once a week
57734631|NCT00127075|DRUG|placebo|matching placebo treatments
57734632|NCT03858205|OTHER|Quality-of-Life Assessment|Ancillary studies
58305716|NCT06388772|DRUG|QHRD106 Injection|250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
58305717|NCT06388772|DRUG|placebo|placebo
58305718|NCT00087178|DRUG|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
58305719|NCT00087178|DRUG|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
57734633|NCT03858205|OTHER|Questionnaire Administration|Ancillary studies
57734634|NCT03858205|RADIATION|Radiation Therapy|Receive low-dose radiation therapy
57785153|NCT06160713|DRUG|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
58305720|NCT00087178|DRUG|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
58305721|NCT00087178|DRUG|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
58305722|NCT04320498|BIOLOGICAL|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
58305723|NCT04320498|DRUG|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
58305724|NCT04320498|BEHAVIORAL|sitz bath|participants were told to take a hot water sitz bath once a day
58305725|NCT04320498|DIETARY_SUPPLEMENT|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
58305726|NCT02206347|BEHAVIORAL|attention focus|
58305727|NCT00821535|DRUG|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
58305728|NCT03191799|DRUG|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
58419067|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
58419068|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
58419069|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
58419070|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
58419071|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
58091936|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
58419072|NCT00468845|DRUG|matched placebo|matched placebo
58419073|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
58419074|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
58419075|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
58419076|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
58419077|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
58419078|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
58419079|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
58419080|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
58419081|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
58091937|NCT00142324|DRUG|Donepezil|
58091938|NCT00460421|DRUG|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
58091939|NCT00460421|RADIATION|Total Body irradiation|
58305729|NCT01107925|DRUG|prasugrel|Administered orally, daily for 12 days
58305730|NCT01107925|DRUG|clopidogrel|Administered orally, daily for 12 days
57734635|NCT06635018|OTHER|Resting conditions|The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
57734636|NCT06635018|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
57785154|NCT06160713|OTHER|Standard care|Standard care for bronchiectasis
58305731|NCT04478838|DRUG|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
58305732|NCT04478838|DRUG|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
58419082|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
58419083|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
58419084|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
58419085|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
57785155|NCT02887560|PROCEDURE|transoesophageal echocardiography|
58091940|NCT00460421|DRUG|Chemotherapy|High dose etoposide, Cyclophosphamide
58091941|NCT00335985|DRUG|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
58091942|NCT00335985|DRUG|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
58091943|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.
58091944|NCT06700655|PROCEDURE|Corneal transplantation|The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.
58091945|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation combined corneal stromal stem cell group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
58305733|NCT03289078|OTHER|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
58305734|NCT02732639|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
57734637|NCT06635018|OTHER|Circulation constriction|The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
58091946|NCT04177173|DRUG|Simvastatin 20 mg|improvement of disease activity
58091947|NCT04177173|DRUG|Methotrexate 10 mg|improvement of disease activity
58091948|NCT05801107|DRUG|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
58091949|NCT01314859|DRUG|Nifedipine|"* Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
58091950|NCT01314859|DRUG|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
58091951|NCT05243134|OTHER|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
58419086|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
58419087|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
58419088|NCT01292083|DRUG|azacitidine|Given IV
58419089|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
58419090|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
58419091|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
58419092|NCT01292083|GENETIC|western blotting|Correlative studies
58419093|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
58419094|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
58419095|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
58419096|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
58419097|NCT02525939|DRUG|Placebo|matching placebo tablets
58419098|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
58419099|NCT01350115|DRUG|Placebo|supplied in capsules
58419100|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
58419101|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
58419102|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
58419103|NCT03271047|DRUG|binimetinib|Orally, twice daily.
58419104|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
58419105|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
57734638|NCT02656797|DRUG|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
57734639|NCT02952924|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
57734640|NCT02952924|OTHER|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
57734641|NCT02952924|DRUG|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
58091952|NCT04311411|DRUG|Tirzepatide|Administered SC.
58091953|NCT04311411|DRUG|Placebo|Administered SC.
58091954|NCT04311411|DRUG|Liraglutide|Administered SC.
58091955|NCT02405494|DIETARY_SUPPLEMENT|Beverage 1|
58091956|NCT02405494|DIETARY_SUPPLEMENT|Beverage 2|
58091957|NCT02405494|DIETARY_SUPPLEMENT|Beverage 3|
58091958|NCT02405494|DIETARY_SUPPLEMENT|Beverage 4|
58091959|NCT02405494|DIETARY_SUPPLEMENT|Beverage 5|
58091960|NCT02405494|DIETARY_SUPPLEMENT|Beverage 6|
58091961|NCT02405494|DIETARY_SUPPLEMENT|Beverage 7|
58091962|NCT02405494|DIETARY_SUPPLEMENT|Beverage 8|
58091963|NCT02405494|DIETARY_SUPPLEMENT|Beverage 9|
58091964|NCT06702527|PROCEDURE|Mitral transcatheter edge-to-edge repair|Mitral transcatheter edge-to-edge repair with the PASCAL system
58091965|NCT04731909|DRUG|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
58091966|NCT04731909|DRUG|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
58091967|NCT04731909|DRUG|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
58091968|NCT04731909|DRUG|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
58091969|NCT04923607|DRUG|TQC2731|TQC2731 injection
58091970|NCT04923607|DRUG|Placebo|Matching placebo with no active ingredients
58419106|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
58419107|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
58419108|NCT03689244|DRUG|Placebo|Oral tablets without active compound
58419109|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
57785156|NCT04218643|OTHER|Ultrasound-guided technique|IV inserted via ultrasound guidance
57785157|NCT04218643|OTHER|Standard technique|IV inserted via standard technique
57785158|NCT05677867|DRUG|Formulation A (PF-07081532 20 mg plus 60 mg)|Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
58091971|NCT03770182|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
58091972|NCT05362955|DRUG|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
58091973|NCT04672824|BIOLOGICAL|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
58419110|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
58091974|NCT04672824|OTHER|Saline|0.5ml saline placebo
58091975|NCT00713765|DRUG|AZD3480|18 total doses of 40 mg, on days 1-18
58091976|NCT00713765|DRUG|Donepezil|One single dose of mg on day 5
58091977|NCT04992897|DEVICE|Remote Electrical Neuromodulation (REN)|Acute migraine treament
58091978|NCT06703775|OTHER|Low level laser therapy (LLLT)|The first experimental will receive LLLT using the Fisioline Lumix 2 (Italy). Participants will be placed in a comfortable, supported sitting position and will wear protective eyeglasses to prevent retinal damage. The LLLT (GaAs type, 1-10 mW, 904 nm) will be applied to the most painful points on the deltoid and/or upper trapezius muscles. Treatment will target a minimum of two and a maximum of four painful points, with each point irradiated for 3-4 minutes, for a total session duration of up to 15 minutes.
58419111|NCT01459913|DRUG|Telaprevir|Tablet
58419112|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
58419113|NCT01459913|DRUG|Ribavirin|Tablet
58419114|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
58419115|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
58419116|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
58091979|NCT06703775|OTHER|Neural mobilization techniques|The second experimental will receive Neural Mobilization Therapy (NMT). The procedure will begin by positioning the patient in a sitting position. The initial positioning will involve placing the patient's arm at their side with the elbow bent at 90 degrees. The therapist will gently extend the patient's shoulder (moving the arm backward) while keeping the elbow bent, creating tension on the axillary nerve. This tension will be held for a few seconds, ensuring it remains within the patient's tolerance and does not cause discomfort or pain. The shoulder will then be slowly returned to the initial position, releasing the tension on the nerve. This sequence of tension and release will be repeated, gradually increasing the range of motion as tolerated. The treatment will consist of three sets of 10 repetitions, with a one-minute rest between sets, performed three times per week for a total of 12 sessions over four weeks.
58095269|NCT01531062|DIETARY_SUPPLEMENT|black sticky rice|300 mg capsule bid, 56 days
58095270|NCT05408910|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
58305735|NCT05110508|BEHAVIORAL|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
58419117|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
58419118|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
58419119|NCT01694719|BEHAVIORAL|Cognitive Control Training|
58419120|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
58419121|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
57785159|NCT05677867|DRUG|Formulation B (PF-07081532 80 mg)|Formulation B: administered as a 80 mg immediate release tablet
57785160|NCT05530954|OTHER|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
57785161|NCT05530954|OTHER|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
57785162|NCT03044093|DRUG|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
58091980|NCT06703775|OTHER|Conventional physical therapy program|The following exercises will be performed by the patients of three groups. Pendulum exercise, Isometric Scapular Retraction, Rotator cuff exercise, Wall creeping exercise, Active assisted ROM exercises, Codman exercises. Each exercise will be performed for all movements namely flexion extension and abduction-adduction, one sets of each 10-15 repetitions within pain-free range and instructed to carry out their activities of daily living.
58419122|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
58091981|NCT05641246|DRUG|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
57785163|NCT03044093|DRUG|Placebo|The group that will only get Misoprostol
58091982|NCT05641246|DRUG|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
58091983|NCT06095362|DRUG|Bevacizumab-IRDye800CW|All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
58091984|NCT04916067|DEVICE|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
58091985|NCT05986565|BEHAVIORAL|Families Moving Forward (FMF) Teacher adapted training|The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
58091986|NCT05161546|DEVICE|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
58095271|NCT05408910|DRUG|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
58419123|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
58419124|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
58419125|NCT04366557|OTHER|Education program|education about pelvic floor
57785164|NCT03044093|DRUG|Misoprostol|Both groups will get think drug
57950079|NCT04759651|OTHER|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
57950080|NCT04759651|OTHER|Insomnia Questionnaire|Subjective evaluation of insomnia.
57950081|NCT04759651|OTHER|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
57950082|NCT04759651|OTHER|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
57950083|NCT04759651|OTHER|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
57950084|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
57950085|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
57950086|NCT01263483|DRUG|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
57950087|NCT03219242|DEVICE|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
57950088|NCT01188889|DRUG|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
57950089|NCT01188889|DRUG|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
57950090|NCT04378530|BEHAVIORAL|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
58091987|NCT05161546|DEVICE|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
58091988|NCT05161546|BEHAVIORAL|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
58091989|NCT05161546|DEVICE|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
58091990|NCT03069365|DRUG|Glecaprevir/pibrentasvir|Film-coated tablet
57785302|NCT02006303|PROCEDURE|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
58091991|NCT01054469|PROCEDURE|TAP block placement with placebo|20 ml of normal saline (placebo)
58091992|NCT01054469|PROCEDURE|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
58091993|NCT02871466|DRUG|stem cells infusion|
58091994|NCT06539949|BEHAVIORAL|Rapid Planning Method (RPM)|RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
58091995|NCT06539949|BEHAVIORAL|Journaling|Subjects will be keeping a weekly to-do list.
58091996|NCT06260683|DRUG|Nicotine Replacement|Given nicotine patches and nicotine lozenges
58091997|NCT06260683|OTHER|Questionnaire Administration|Ancillary studies
58091998|NCT06260683|DEVICE|Vaping|Given Preferred Flavor e-liquid
58091999|NCT06260683|DEVICE|Vaping|Given Tobacco flavored e-liquid
58092000|NCT04846049|OTHER|Comprehensive Care|"1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration"
58092001|NCT04846049|OTHER|Standard Care|No intervention or treatment will be provided.
58092002|NCT04141839|BEHAVIORAL|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
58092003|NCT05873075|OTHER|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
58092004|NCT04425954|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
58092005|NCT00503035|DRUG|Celecoxib|400 mg by mouth twice daily x 6 months
58092006|NCT00503035|PROCEDURE|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
58092007|NCT06349408|DRUG|IBI3001|"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"
58092008|NCT04719728|DIAGNOSTIC_TEST|Aided pure tone audiometry|aided response, speech, evoked potential
58419126|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
58419127|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
57734642|NCT05967572|OTHER|Research processes;|"1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values."
57734643|NCT01227681|DRUG|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
57734644|NCT01227681|DRUG|Placebo|Sodium Chloride (NaCl) 0.9 %
58092009|NCT03415139|DRUG|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
58092010|NCT03415139|DRUG|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
58092011|NCT03415139|DRUG|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
58419128|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
58419129|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
58419130|NCT02383433|DRUG|Regorafenib|Given PO
58419131|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
58092012|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
58092013|NCT03327532|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
58092014|NCT03327532|PROCEDURE|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
58419132|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
58419133|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
58419134|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
58419135|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
58419136|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
58092015|NCT03327532|BIOLOGICAL|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
58092016|NCT03327532|OTHER|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
58092017|NCT03327532|BIOLOGICAL|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
58092018|NCT03327532|PROCEDURE|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
58092019|NCT00826865|DRUG|Levetiracetam|750 mg tablet
58095272|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
58419137|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
58095273|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
58419138|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
57734645|NCT06270901|OTHER|High Protein Planetary Health Diet|Planetary Health Diet Meal with 62 g of protein primarily from plant origin
57734646|NCT06270901|OTHER|Low Protein Planetary Health Diet|Planetary Health Diet Meal with 36 g of protein primarily from plant origin
57734647|NCT06270901|OTHER|High Protein Western Diet|Western Diet Meal with 62 g of protein primarily from animal origin
57734648|NCT06270901|OTHER|Low Protein Western Diet|Western Diet Meal with 36 g of protein primarily from animal origin
57734649|NCT00168025|DRUG|Immunoglobulins Intravenous (Human)|
58092020|NCT02306174|BEHAVIORAL|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
58092021|NCT05573555|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
57734650|NCT02907021|DRUG|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
57734651|NCT03339986|BEHAVIORAL|Reduction or Replacement|
58092022|NCT05573555|DRUG|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
58092023|NCT05968482|DRUG|Diclofenac Sodium Gel|Topical application on both knees
58092024|NCT06704048|OTHER|Cardiac rehabilitation|Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
58092025|NCT06363591|PROCEDURE|Wise vs wide|Wise vs wide excisions for thin melanoma
57734652|NCT05308251|PROCEDURE|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
57734653|NCT00052468|DRUG|TCG|
57734654|NCT00052468|DRUG|TC|
58092026|NCT03378999|DIETARY_SUPPLEMENT|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
58092027|NCT03378999|DIETARY_SUPPLEMENT|Control|Capsules containing microcrystalline cellulose
58092028|NCT05429632|DRUG|mocravimod|S1PR modulator
58092029|NCT04497571|PROCEDURE|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
58092030|NCT04497571|PROCEDURE|Conventional drilling|Implants placed using drilling technique
58092031|NCT06650254|OTHER|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed."
57734655|NCT03408717|OTHER|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
57734656|NCT03408717|OTHER|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
58092032|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
58092033|NCT06650397|OTHER|Placebo|Traditional maize
58092034|NCT01644461|OTHER|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
58092035|NCT02922036|DEVICE|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
58092036|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
58092037|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
58092038|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
58092039|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
58092040|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
58092041|NCT01132170|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
58092042|NCT01887366|DRUG|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
58092043|NCT01887366|DRUG|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
58092044|NCT01887366|DRUG|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
58092045|NCT02623530|OTHER|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
58419139|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
57734657|NCT03408717|OTHER|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
57734658|NCT04003649|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
57734659|NCT04003649|BIOLOGICAL|Ipilimumab|Given IV
57734660|NCT04003649|BIOLOGICAL|Nivolumab|Given IV
57734661|NCT04003649|OTHER|Quality-of-Life Assessment|Ancillary studies
57734662|NCT04003649|OTHER|Questionnaire Administration|Ancillary studies
57734663|NCT01251003|BIOLOGICAL|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
58092046|NCT06013423|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57734664|NCT03926091|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
57734665|NCT03926091|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
57734666|NCT04066114|BIOLOGICAL|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
57734667|NCT04066114|BIOLOGICAL|antithymocyte globulin (rabbit)|Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
57734668|NCT04066114|DRUG|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
57734669|NCT04066114|BIOLOGICAL|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
57734670|NCT04066114|DRUG|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
57734671|NCT04066114|DRUG|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
57734672|NCT04066114|BIOLOGICAL|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
58092047|NCT06013423|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
58092048|NCT06013423|DRUG|Cyclophosphamide|Receive IV
58092049|NCT06013423|DRUG|Cyclosporine|Receive IV or PO
58092050|NCT06013423|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
58419140|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
58419141|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
58419142|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
58419143|NCT00113750|BIOLOGICAL|TreeMATA MPL|
58092051|NCT06013423|PROCEDURE|Echocardiography|Undergo ECHO
58092052|NCT06013423|DRUG|Fludarabine Phosphate|Receive IV
58092053|NCT06013423|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58092054|NCT06013423|DRUG|Mycophenolate Mofetil|Receive IV
58092055|NCT06013423|OTHER|Survey Administration|Ancillary studies
58092056|NCT06013423|DRUG|Thiotepa|Receive IV
58092057|NCT06013423|RADIATION|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
58092058|NCT06013423|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
58092059|NCT00003769|DRUG|perillyl alcohol|
57734673|NCT04066114|DRUG|mycophenolate mofetil|mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
57734674|NCT04066114|DRUG|mycophenolic acid|mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
57734675|NCT00728819|DEVICE|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
57734676|NCT00728819|DEVICE|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
57734677|NCT03013114|DRUG|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
58092060|NCT00003769|PROCEDURE|surgical procedure|
58092061|NCT06212375|BEHAVIORAL|Vegetable variety|Either children are offered a variety of three vegetables or a single vegetable.
58092062|NCT06212375|BEHAVIORAL|Vegetable offering strategy|Either children can decide when to eat their vegetables or parents initiate a moment.
57734678|NCT04732962|DEVICE|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
57734679|NCT04732962|PROCEDURE|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
57734680|NCT05685615|DRUG|BV100 plus Polymyxin B|Rifabutin for Infusion plus Polymyxin B for Injection
57734681|NCT05685615|DRUG|BAT|The best avaialble antibiotic therapy to treat CRAB
57734682|NCT02615223|PROCEDURE|cryoablation|Cryoablation therapy
58092063|NCT01875419|DEVICE|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
58092064|NCT01875419|BEHAVIORAL|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
58092065|NCT03515889|BEHAVIORAL|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
58095274|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
58095275|NCT01226615|DRUG|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
58419144|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
58419145|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
58419146|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
58092066|NCT03515889|BEHAVIORAL|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
58419147|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
58419148|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
58419149|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
58419150|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
58092067|NCT02547779|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
58092068|NCT02547779|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
58419151|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
58419152|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
58419153|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
58419154|NCT00567918|DRUG|FK506|Ophthalmic suspension
58419155|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
58419156|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
57734683|NCT02615223|DRUG|Bicalutamide|bicalutamide
57734684|NCT02615223|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
58092069|NCT04592731|DRUG|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
58092070|NCT04592731|DRUG|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
58092071|NCT03109613|DEVICE|Positive end-expiratory pressure (PEEP)|level changes as per arm description
58095276|NCT01226615|DRUG|Placebo|Two placebo capsules taken once a day for four months.
58419157|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
58419158|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
58419159|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
58419160|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
58419161|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
58419162|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
58419163|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
58419164|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
58419165|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
58419166|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
58419167|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
58419168|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
58419169|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
58305736|NCT05342896|BEHAVIORAL|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
58305737|NCT05342896|BEHAVIORAL|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
58305738|NCT05228067|DEVICE|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
58305739|NCT05228067|DEVICE|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
58305740|NCT05228067|DEVICE|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
58305741|NCT02644018|DRUG|Imidazolyl ethanamide pentandioic acid|
58305742|NCT02644018|DRUG|placebo|
58305743|NCT04268693|OTHER|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
58305744|NCT02783638|DRUG|YHD1119|2 by 2
58305745|NCT02783638|DRUG|Lyrica|2 by 2
58305746|NCT02938468|DRUG|Dexamethasone|
58305747|NCT02938468|PROCEDURE|Any surgical intervention aim at treating chronic subdural hematoma|
58305748|NCT02035566|OTHER|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
58305749|NCT05576064|DIAGNOSTIC_TEST|Gait analysis|Analysis of gait profile and measures by gait laboratory on patients with suspected lower limb rotational deformities and anterior knee pain
58305750|NCT04437758|DIETARY_SUPPLEMENT|Collagen and Vitamin C powder mix nutritional intervention|20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
58305751|NCT04437758|OTHER|Maltodextrin placebo powder|20 g maltodextrin placebo daily, 60 min prior to exercise
58305752|NCT04437758|OTHER|Maximum power training exercise|Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
58305753|NCT01981616|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
58305754|NCT01981616|DRUG|Placebo|Placebo intravenous infusion
58305755|NCT01981616|BIOLOGICAL|Hepatitis B vaccine|
58305756|NCT01981616|BIOLOGICAL|Oral cholera vaccine|
58305757|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A|TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
58305758|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin|TMJ Arthrocentesis I-PRF Intra-articular Injection
58305759|NCT06207955|DRUG|TMJ Arthrocentesis|TMJ Arthrocentesis By Saline
58305760|NCT03012269|BEHAVIORAL|Working memory training|
58419170|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
58092072|NCT04285892|DEVICE|CAPA-IVM|"CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house."
58092073|NCT06425419|DRUG|Topotecan|20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
58305761|NCT02349555|DIETARY_SUPPLEMENT|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
58305762|NCT01429090|PROCEDURE|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
58305763|NCT01429090|DRUG|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
58305764|NCT01429090|DRUG|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
58419171|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
58419172|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
58419173|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
58419174|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
58419175|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
58419176|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
58419177|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
58419178|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
57734685|NCT06634966|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
58092074|NCT02374008|DRUG|Ropivacaine|
58092075|NCT04365829|DEVICE|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
58305765|NCT01429090|PROCEDURE|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
58305766|NCT01429090|PROCEDURE|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
58305767|NCT01429090|PROCEDURE|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
58305768|NCT01474395|DRUG|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
58305769|NCT01474395|DRUG|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
58419179|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
58419180|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
58419181|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
58419182|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
58419183|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
58419184|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
58419185|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
58419186|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
58419187|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
58419188|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
58095277|NCT06574217|BEHAVIORAL|Stepping Stones (StSt)|StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.
58305770|NCT01474395|BEHAVIORAL|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
58305771|NCT03011996|DRUG|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
58305772|NCT03011996|DRUG|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
58305773|NCT03011996|DRUG|CJ-12420 50mg|Cohort 2: bid for 7 days
58305774|NCT03011996|DRUG|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
58305775|NCT03011996|DRUG|Pantoprazole 40mg|Cohort 2: bid for 7 days
58419189|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
58419190|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
58419191|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
58419192|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
58419193|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
58419194|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
58419195|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
58419196|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
58419197|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
58419198|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
58419199|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
58419200|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
58419201|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
58419202|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
58419203|NCT03109691|DRUG|bupivacaine|group 1
58419204|NCT03109691|DRUG|Dexamethasone|group 2
58419205|NCT03109691|DEVICE|ultrasound|in all groups
58419206|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
58419207|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
58419208|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
58305776|NCT03499795|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid \[DNA\] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
58419209|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
57785303|NCT02006303|PROCEDURE|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
58305777|NCT03499795|DEVICE|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
58305778|NCT02522117|DRUG|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
58305779|NCT02522117|DRUG|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
58305780|NCT03572712|OTHER|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
58305781|NCT05596071|DRUG|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
58305782|NCT05596071|DRUG|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
58305783|NCT05596071|PROCEDURE|Epidural catheter|Intraoperative and postoperative analgesia
58305784|NCT04624113|DRUG|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
58305785|NCT04624113|DRUG|Pembrolizumab|Pembrolizumab is commercially available
58305786|NCT05547958|OTHER|Focus group and online survey|"Focus group with parents of children with disabilities or chronic condition will be organized to identify hypotheses regarding their needs in terms of informations exchange with pediatric rehabilitation professionals about the rehabilitation care of their children.~Then, an online survey will be proposed to parents of children with disabilities or chronic condition in France to identify their needs regarding the development of apps that offer the feature to share informations with rehabilitation professionals."
58305787|NCT02611947|RADIATION|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
58305788|NCT04165122|BIOLOGICAL|HDIT101|i.v. Infusion
58305789|NCT04165122|DRUG|Valaciclovir|oral application of encapsulated Valaciclovir tablets
58305790|NCT04165122|BIOLOGICAL|HDIT101 placebo|i.v. Infusion
58419210|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
57785304|NCT05415059|DEVICE|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
58305791|NCT04165122|DRUG|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
58305792|NCT02830568|PROCEDURE|open donor nephrectomy|open donor nephrectomy
58305793|NCT02830568|PROCEDURE|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
58305794|NCT02830568|PROCEDURE|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
58305795|NCT00972621|DEVICE|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
58305796|NCT00972621|DEVICE|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
58419211|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
58092076|NCT06696170|DEVICE|CellFX nano-pFA 360 Endocardial Ablation Catheter System|The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
58092077|NCT06319339|DRUG|Vumerity|diroximal fumarate 462 mg (2 capsules)
58092078|NCT06319339|OTHER|Placebo|Microcrystalline cellulose 462 mg (2 capsules)
58092079|NCT04305184|DRUG|ASP0598|ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
58092080|NCT04305184|OTHER|Placebo|Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
58305797|NCT03732378|DIETARY_SUPPLEMENT|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
58305798|NCT02756702|DEVICE|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
58419212|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
58419213|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
58419214|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
58419215|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
58419216|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
58419217|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
58419218|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
58419219|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
58419220|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
58092081|NCT04987307|DRUG|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
58092082|NCT04987307|DRUG|Placebo|Placebo will be administered by SC injection.
58092083|NCT04619472|DEVICE|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
58092084|NCT03717298|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
58305799|NCT06235671|PROCEDURE|Chiropractic care|6 weeks of chiropractic care
58419221|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
58419222|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
58419223|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
58305800|NCT03335345|OTHER|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
58305801|NCT03335345|OTHER|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
58305802|NCT03520452|OTHER|Green coffee extract|Reconstituted in water and given to subjects
58419224|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
58419225|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
58419226|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
57734686|NCT06669546|OTHER|Phase-locked auditory stimulation (PLAS)|"Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation."
58092085|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
58092086|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
58092087|NCT02297607|DIETARY_SUPPLEMENT|Tube Feeding|
58092088|NCT06565910|DRUG|Liposomal bupivacaine plus bupivacaine|Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.
58092089|NCT06565910|DRUG|Ropivacaine|Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.
57734687|NCT06669546|OTHER|Sham Phase-Locked Auditory Stimulation|Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.
58092090|NCT04093479|OTHER|blood samples|blood samples will be taken repeatedly
57785305|NCT00156338|PROCEDURE|fluid management|volume and sodium restriction
57785306|NCT00156338|PROCEDURE|fluid management|volume restriction
58092091|NCT04835207|OTHER|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
58092092|NCT06567366|BIOLOGICAL|CAR T-cell therapy|Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
58092093|NCT06567366|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."
58092094|NCT06567366|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
58092095|NCT05347407|PROCEDURE|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
58092096|NCT01830257|OTHER|sending message|Sending the suggestive short message
58092097|NCT04754425|PROCEDURE|Biopsy|Undergo biopsy
58092098|NCT04754425|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow
58092099|NCT04754425|DRUG|Erdafitinib|Given PO
58092100|NCT03165630|BEHAVIORAL|Transportation incentives|Free transportation only for the first 3 months post-discharge.
58092101|NCT03165630|BEHAVIORAL|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
58092102|NCT03642886|BEHAVIORAL|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
58419227|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
58092103|NCT03747094|DRUG|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
58092104|NCT03747094|DRUG|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
58092105|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
58095278|NCT06574217|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
58095279|NCT04303117|DRUG|NHS-IL12|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
58092106|NCT04075656|BEHAVIORAL|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
58092107|NCT04075656|BEHAVIORAL|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
58092108|NCT04369885|DEVICE|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
58092109|NCT03877848|DEVICE|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
58092110|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
58092111|NCT05657964|DEVICE|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
58092112|NCT06651788|OTHER|Ethyl Chloride|Topical anesthetic that rapidly cools the skin and underlying tissues
58092113|NCT06651788|OTHER|Cold Saline Spray|placebo application of cold saline spray
58092114|NCT00001001|DRUG|Zidovudine|
58092115|NCT03079739|DIAGNOSTIC_TEST|fractional flow reserve|assessment with FFR in at least one coronary lesion
58092116|NCT05529641|OTHER|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
58092117|NCT05529641|OTHER|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
58092118|NCT06568835|BEHAVIORAL|exercise|such as walking, jogging, swimming, Tai Chi, etc. It needs to be at a certain frequency and intensity
58419228|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
57734688|NCT04980833|DRUG|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
58092119|NCT06138548|DEVICE|Ossiofiber® Trimmable Fixation Nail|OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*
58092120|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
58092121|NCT01906801|DRUG|Glucosamine sulfate|
58092122|NCT01906801|DRUG|Diacerein|
58305803|NCT03520452|OTHER|Placebo|Placebo
58305804|NCT00193375|DRUG|Irinotecan|50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
58305805|NCT00193375|DRUG|Carboplatin|AUC 5
58305806|NCT00193375|DRUG|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
58305807|NCT00193375|RADIATION|Radiation|
58305808|NCT06519916|BEHAVIORAL|Assessment of mental performance|There was no intervention, the mental performance was assessed
58419229|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
58419230|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
58419231|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
58419232|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
58419233|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
57734689|NCT01015742|DRUG|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
57785307|NCT00156338|PROCEDURE|fluid management|liberal fluid management
57785308|NCT04643249|DRUG|KL1333|Tablet
58092123|NCT01906801|DRUG|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
58092124|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
58092125|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
58092126|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
58092127|NCT06700551|OTHER|Psychoeducation|Each week, the investigator will send participants one topic through the chat function on the Zalo app. Before receiving the topic, participants will vote on which topic they would like to learn about. The topics will be presented as videos and will cover the following seven areas: providing everyday care, being a caregiver, self-care, knowledge about dementia, fall prevention, pressure injury prevention and care, and managing behavior changes.They may ask questions related to providing dementia care or share their feelings via the chat on the Zalo app.
58092128|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
58092129|NCT03890835|PROCEDURE|MTA Pulpotomy.|Pulpotomy using MTA.
58092130|NCT03890835|PROCEDURE|Biodentine Pulpotomy|Pulpotomy using Biodentine
58092131|NCT02204839|DRUG|Basal insulin dose|
58092132|NCT06703255|DRUG|HX301+/Temozolomide|"Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each."
58092133|NCT03089931|PROCEDURE|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
57734690|NCT01138904|DRUG|irinotecan, oxaliplatin|"OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
58092134|NCT03791255|DRUG|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
58092135|NCT03791255|DRUG|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
58095280|NCT04303117|DRUG|M7824|1200 mg administered IV every two weeks while on NHS-IL12.
58419234|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
58419235|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
58419236|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
58419237|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
57785309|NCT04643249|DRUG|Flurbiprofen|Tablet
57785310|NCT04643249|DRUG|Dextromethorphan|Syrap
57950091|NCT04378530|BEHAVIORAL|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
57785311|NCT04643249|DRUG|Bupropion|Tablet
57785312|NCT04643249|DRUG|Midazolam injection|solution for injection
57785313|NCT04643249|DRUG|Omeprazole|Capsule
57785314|NCT04643249|DRUG|Caffeine|Tablet or capsule
57785315|NCT04643249|DRUG|Repaglinide|Tablet
57785316|NCT00189176|DRUG|Tetrathiomolybdate|
57785317|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (5)|5 mg of THC
57785318|NCT06471647|DRUG|Placebo|Placebo - dextrose
57785319|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (10)|10 mg of THC
58092136|NCT04889794|OTHER|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
58092137|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
58092138|NCT02980029|OTHER|Placebo|Placebo
58092139|NCT00291356|DRUG|GSK189075 oral tablets|
58092140|NCT00291356|DRUG|GW869682 oral tablets|
58092141|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
58092142|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
58092143|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
58092144|NCT06353113|BEHAVIORAL|Down Dog Prenatal Yoga App|"The Down Dog prenatal yoga app launched in 2015 and was designed to align with the changes a pregnant body goes through in each trimester. Users can select a practice by trimester, which will offer modification cues to work with a changing body during pregnancy. Users can also customize their experience by boosting things like Heartburn or Pubic Symphysis so they can continue to practice yoga and omit poses that might be uncomfortable. The app also utilizes user feedback, to continuously implement new practices to better their app for user interface.~All of the prenatal yoga classes were created by a certified and experienced prenatal yoga instructor who has a 200hr yoga certification through Pure Yoga (New York), 80hr prenatal yoga certification through Prenatal Yoga Center (New Yoga), and is Trauma Informed Yoga certified through Exhale to Inhale (New York)."
58092145|NCT06063291|DRUG|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
58092146|NCT06063291|DRUG|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
58092147|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
58092148|NCT05198349|DRUG|M1069|Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
58092149|NCT06702228|DIAGNOSTIC_TEST|Six minute walk test (6MWT)|Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
58092150|NCT06702228|DIAGNOSTIC_TEST|Computer-tomography of the thorax (CT Thorax)|Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
58092151|NCT06702228|OTHER|Quality of life questionnaires.|Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
58092152|NCT06702228|DIAGNOSTIC_TEST|Genetic Testing|10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
58092153|NCT06702228|DIAGNOSTIC_TEST|Spirometry|We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
58095281|NCT03667586|BEHAVIORAL|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
58419238|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
57734691|NCT01138904|DRUG|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
57734692|NCT05735951|DRUG|STIRIPENTOL oral administration|"Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
57734693|NCT01973933|DRUG|Metformin and Pyrimethamine|
57734694|NCT02242747|DRUG|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
57734695|NCT02242747|DRUG|5% 5-FU|two applications a day for four weeks in a pre-determined area
58092154|NCT06702228|DIAGNOSTIC_TEST|Serology|Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
58092155|NCT06702228|OTHER|Other Quality of Life Questionnaires|Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months
58092156|NCT06702228|OTHER|PatientMPower Home Monitoring App|Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
58419239|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
58419240|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
58419241|NCT02342379|DRUG|Bevacizumab|10mg/kg
58092157|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
58092158|NCT06569160|DEVICE|UVGI (Ultra-Violet Germicidal Irradiation Device)|Retirement homes are equipped with numerous airborne pathogen inactivation devices using UVGI.
58092159|NCT06426186|PROCEDURE|Right-stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia
58419242|NCT02342379|DRUG|TH-302|670mg/m2
58419243|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
58419244|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
58419245|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
58419246|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
58419247|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
58419248|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
58419249|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
58419250|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
58419251|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
58419252|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
58419253|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
58419254|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
57734696|NCT06424249|OTHER|Virtual Reality|A progressive rehabilitation protocol (different levels according to success scores) consisting of several exercises using virtual and augmented reality with mechanical perturbations (pitching of the treadmill), interaction with the virtual environment, interaction with the virtual environment and augmented reality (projection of obstacles on the treadmill), and modification of the gait pattern with visual and/or audio biofeedback
58092160|NCT05632757|BEHAVIORAL|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
58092161|NCT00424632|DRUG|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
58095282|NCT06414954|DRUG|NMD670|Tablets taken twice a day for 21 days
58095283|NCT06414954|DRUG|Placebo|Tablets taken twice a day for 21 days
58092162|NCT06700642|OTHER|Educational intervention|"In this study, 3 intervention tools were developed by the researchers. The first of these, 'Rational Drug Use Trainer Guide', was used for trainer training and standardisation of the education given to patients. The sample rational drug use presentations prepared by the Ministry of Health, Turkiye Medicines and Medical Devices Agency, Department of Rational Drug Use were combined in terms of content, enriched with information obtained from the literature and developed for the use of family physicians working in primary health care institutions in their clinical practices.~'Rational Drug Use Individual Education Presentation' was prepared by the researchers in line with the 'Rational Drug Use Trainer Guide'. It has been prepared in a format suitable for individual education presentation with the most concise and understandable content suitable for use during primary healthcare service delivery.~'Rational Drug Use Patient Brochure' was prepared by the researchers in a similar content."
58092163|NCT02618252|DEVICE|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
58092164|NCT02618252|DEVICE|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
58092165|NCT02525627|DEVICE|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
58092166|NCT02525627|DEVICE|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
58092167|NCT02525627|DEVICE|Symax stem|Orthopaedic implant
58419255|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
58419256|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
58092168|NCT02525627|DEVICE|Accolade TMZF stem|Orthopaedic implant
58092169|NCT04751435|OTHER|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
58092170|NCT02255773|BEHAVIORAL|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
58092171|NCT02255773|BEHAVIORAL|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
58092172|NCT05794386|PROCEDURE|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
58092173|NCT04934969|DIETARY_SUPPLEMENT|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
58092174|NCT06703684|OTHER|Cross-sectional observational study|This is a cross-sectional observational study. No intervention will be given.
58092175|NCT05031286|OTHER|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
58419257|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
58419258|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
57950092|NCT04378530|BEHAVIORAL|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
58419259|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
58092176|NCT05484622|DRUG|Vorasidenib|Administered orally as tablets.
58092177|NCT05484622|DRUG|Pembrolizumab|Administered as IV infusion.
58095284|NCT05523310|OTHER|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
58095285|NCT02094573|DRUG|Brigatinib|Brigatinib tablets
58095286|NCT03514121|BIOLOGICAL|FPA150|A monoclonal antibody against B7-H4
58092178|NCT03847532|GENETIC|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
58092179|NCT02277548|DRUG|Lyrica 300 mg|Lyrica 300 mg per day
58092180|NCT02277548|DRUG|Placebo|
58092181|NCT05564494|PROCEDURE|Bankart Repair|Patients Randomized to Bankart Repair Group
58092182|NCT05564494|PROCEDURE|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
58305809|NCT03768713|DRUG|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
58419260|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
58419261|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
58419262|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
58092183|NCT05782478|DIAGNOSTIC_TEST|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
58092184|NCT05388201|OTHER|N95|3M N95 Respirator
58092185|NCT05388201|OTHER|KN95|KN95 Mask (with and without clip)
58092186|NCT05388201|OTHER|KF94|KF94 Mask (with and without clip)
58092187|NCT05388201|OTHER|Surgical|Surgical Mask (with and without clip)
58092188|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
58305810|NCT03768713|DRUG|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
58305811|NCT02023489|DEVICE|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
58305812|NCT02023489|OTHER|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
58419263|NCT06507839|OTHER|Placebo|Matching placebo
58419264|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
58419265|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
58419266|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
58419267|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
58419268|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
58419269|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
57734697|NCT06424249|OTHER|Standard rehabilitation|A treadmill walking protocol with virtual reality to immerse the patient in a 3 x 5-minute walking session, without visual, mechanical or auditory disturbances, and without prompting the patient to modify their walking pattern.
58092189|NCT03899545|OTHER|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
58092190|NCT03899545|OTHER|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
58095287|NCT03514121|BIOLOGICAL|Pembrolizumab|An anti-PD1 antibody
58419270|NCT01703065|DRUG|Cabozantinib|Given orally once a day
58419271|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
58419272|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
58419273|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
58419274|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
58419275|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
58419276|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
58419277|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
57734698|NCT03200938|DEVICE|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
58092191|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
58092192|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
58092193|NCT05853237|DEVICE|laser therapy for wound management|comparison between laser effect on post median sternotomy incision compared to traditional wound care
58092194|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
58092195|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
58092196|NCT06694857|DRUG|HA filler|patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. Patients are limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
58095288|NCT03983369|DEVICE|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
58305813|NCT02023489|OTHER|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at \~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with \[1-13C\]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
58305814|NCT06258850|DRUG|Calcifediol Oral Capsule|One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
58419278|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
58419279|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
57734699|NCT03200938|DEVICE|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
58305815|NCT06258850|DRUG|Placebo|One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
58305816|NCT00364065|DEVICE|Ferris PainWrap|
58419280|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
58419281|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
57734700|NCT02273141|DRUG|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
57734701|NCT02273141|DRUG|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
57734702|NCT03386123|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
57734703|NCT03386123|BEHAVIORAL|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
58095289|NCT03983369|OTHER|Placebo|Placebo
58095290|NCT00486213|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
58095291|NCT00486213|OTHER|Placebo|
57734704|NCT03386123|BEHAVIORAL|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
57734705|NCT02243553|DRUG|Tipranavir capsule|
57734706|NCT02243553|DRUG|Tipranavir solution|
57734707|NCT02243553|DRUG|Ritonavir capsule|
57734708|NCT02243553|DRUG|Caffeine|
58419282|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
58419283|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
58419284|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
58419285|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
58419286|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
57734709|NCT02243553|DRUG|Warfarin sodium|
57734710|NCT02243553|DRUG|Vitamin K|
58419287|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
58419288|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
58419289|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
58419290|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
58419291|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
58419292|NCT03773107|DRUG|Dexamethasone|glucocorticoid
58419293|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
58419294|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
58419295|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
58419296|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
58419297|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
58419298|NCT02916147|DRUG|Sevoflurane|
58419299|NCT02916147|DRUG|Propofol|
57734711|NCT02243553|DRUG|Omeprazole|
57734712|NCT02243553|DRUG|Dextromethorphan hydrobromide|
57734713|NCT02243553|DRUG|Midazolam injection|
57734714|NCT02243553|DRUG|Midazolam oral solution|
57734715|NCT02243553|DRUG|Digoxin tablet|
57734716|NCT02243553|DRUG|Digoxin injection|
57734717|NCT04214132|OTHER|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
57734718|NCT04535401|PROCEDURE|Biopsy|Undergo tumor biopsy
57734719|NCT04535401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57950093|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
57734720|NCT04535401|PROCEDURE|Diagnostic Imaging|Undergo imaging
57734721|NCT04535401|DRUG|Elimusertib|Given PO
58092197|NCT06566950|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
58092198|NCT06566950|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
58092199|NCT06566950|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as stairs, single leg squat, and single leg deadlift.
58419300|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
58419301|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
57950094|NCT02868073|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
58305817|NCT02125552|PROCEDURE|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
58419302|NCT02124954|DRUG|TA-8995|
58419303|NCT02124954|DRUG|Midazolam|
58419304|NCT02124954|DRUG|Digoxin|
58419305|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
57950095|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
58092200|NCT01922973|OTHER|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
58092201|NCT02501655|DEVICE|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
57734722|NCT04535401|DRUG|Fluorouracil|Given IV
57734723|NCT04535401|DRUG|Irinotecan Hydrochloride|Given IV
57734724|NCT04535401|DRUG|Leucovorin Calcium|Given IV
58305818|NCT02125552|PROCEDURE|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
58305819|NCT00891280|DRUG|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
58419306|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
58419307|NCT02223416|DRUG|RGB-10|
58419308|NCT02223416|DRUG|Teriparatide|
58419309|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
58419310|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
58419311|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
58419312|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58419313|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
58419314|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
58419315|NCT02038660|DEVICE|Balloon angioplasty|
58419316|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
58419317|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
58419318|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
58419319|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
58419320|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
58419321|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
58419322|NCT00624780|DRUG|Placebo|Placebo
58419323|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
58419324|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
58419325|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
58419326|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
58419327|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
58419328|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
58419329|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
58419330|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
58419331|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
58419332|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
58419333|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
58419334|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
58419335|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
58419336|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
58419337|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
58419338|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
58419339|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
58419340|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
58419341|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
57734725|NCT00472095|OTHER|Fotonovela|
57950096|NCT01081912|DRUG|Placebo|Capsules, no active substance, shells identical to active comparator capsules
58419342|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
57734726|NCT00472095|OTHER|Placebo Fotonovela|
57950097|NCT01081912|DRUG|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
58419343|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
58419344|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
58419345|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
58419346|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
58419347|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
58419348|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
58419349|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
58419350|NCT04835168|DRUG|BT-11 low|Oral
58419351|NCT04835168|DRUG|BT-11 high|Oral
58419352|NCT04835168|DRUG|Placebo|Oral
58419353|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
58419354|NCT00342706|PROCEDURE|Community based intervention|
58419355|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
58419356|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
58419357|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
58419358|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
58419359|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
58419360|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
58092202|NCT02501655|DEVICE|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
58305820|NCT06333691|DRUG|Calcium Gluconate|to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
58305821|NCT04489342|DEVICE|IMU sensor test|Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
58305822|NCT03195439|DEVICE|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
58419361|NCT04093336|BIOLOGICAL|Placebo|Placebo
58419362|NCT04093336|OTHER|standardized treatment|standardized treatment
58419363|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
58419364|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
58419365|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
58419366|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
58419367|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
58419368|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
58419369|NCT00005976|DRUG|carboplatin|
58419370|NCT00005976|DRUG|pyrazoloacridine|
58419371|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
58092203|NCT06422832|OTHER|HeartLogic or TriageHF Algorithms for implantable devices|Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
58305823|NCT03844659|OTHER|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
58419372|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
57734727|NCT06636604|OTHER|DSA(Decision Support Algorithm)|Intramuscular injection will be given to 30 volunteer patients using the decision support algorithm.
57734728|NCT06412120|DRUG|Niraparib|Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
58419373|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
57734729|NCT01142557|DRUG|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
57734730|NCT05516797|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
57734731|NCT06155968|PROCEDURE|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
57734732|NCT06155968|DRUG|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
58419374|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
57734733|NCT05110196|DRUG|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
57950098|NCT01285115|DRUG|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
58419375|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
58419376|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
58092204|NCT00555399|DRUG|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
58092205|NCT00555399|DRUG|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days."
58419377|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
58419378|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
58419379|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
58419380|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
58419381|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
58419382|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
58419383|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
58419384|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
58419385|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
58419386|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
58419387|NCT01561963|DRUG|Apremilast|Tablets for oral administration
58419388|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
58092206|NCT00555399|PROCEDURE|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
58305824|NCT03844659|OTHER|No Song|No song will be played during subjects labor epidural placement.
58305825|NCT03844906|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
58419389|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
58419390|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
58419391|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
57734734|NCT05110196|DRUG|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
57734735|NCT02268552|DRUG|branaplam|
57734736|NCT05146674|DRUG|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
58305826|NCT03844906|DRUG|Placebo|Placebo in combination with Ketamine
58305827|NCT04108078|BEHAVIORAL|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
58305828|NCT04108078|BEHAVIORAL|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
58305829|NCT04108078|BEHAVIORAL|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
58419392|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
57734737|NCT06669273|OTHER|CEST MRI sequence at 3T|"The MRI will be performed at the Clermont Ferrand University Hospital on the 3T research MRI on a Siemens MRI system (MAGNETOM VIDA, Siemens Healthcare, Erlangen, Germany), the emission of the radiofrequency pulses and the reception of the signal will be done using a coil dedicated to the abdo-pelvic region. The images will be analyzed by the radiologist.~MRI is non-irradiating medical imaging. It is practiced according to good practices and the recommendations of the French Society of Radiology.~* Acquisition of morphological T1, T2 sequences for the identification of areas of interest on the pelvic area.~* Acquisition of the CEST MRI sequence (acquisition time 5 min)~* Acquisition of functional sequences, DWI diffusion-weighted images and dynamic DCE sequence after injection of a single dose of non-linear gadolinum.~The imaging report will reveal the presence or absence of tumor lesions in the prostate and their location. Data will then be compared to the histopathological analysis."
57734738|NCT01602536|BEHAVIORAL|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
57734739|NCT01602536|BEHAVIORAL|Twitter|Twitter quit-smoking group
58305830|NCT03155711|PROCEDURE|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
58305831|NCT03155711|PROCEDURE|Standard group|Supplemental oxygen through venturi mask
58419393|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
58419394|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
58419395|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
58419396|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
58419397|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
58419398|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
58419399|NCT00097890|DRUG|Replagal|
58419400|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
58419401|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
58419402|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
58419403|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
58419404|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
58419405|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
58419406|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
58419407|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
58419408|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
58419409|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
58092207|NCT00555399|DRUG|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
58092208|NCT00274664|DEVICE|6 hours occlusion by patching|
58092209|NCT00274664|DEVICE|12 hours occlusion by patching|
58092210|NCT03981315|DIAGNOSTIC_TEST|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
58092211|NCT03981315|DIAGNOSTIC_TEST|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
58419410|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
58419411|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
58419412|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
58419413|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
58419414|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
58419415|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
58419416|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
58419417|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
58419418|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
58419419|NCT03542435|DRUG|SXC-2023|Oral capsule
58419420|NCT03542435|DRUG|Placebo|Placebo
58419421|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
58419422|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
58092212|NCT03981315|DIAGNOSTIC_TEST|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
58092213|NCT03981315|DIAGNOSTIC_TEST|Microbiological bile test|Determination of the microbiological composition of the bile
58092214|NCT03332212|DRUG|Empagliflozin|12 weeks
58092215|NCT03332212|DRUG|Placebo|12 Weeks
58092216|NCT01215955|DRUG|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
58092217|NCT01215955|DRUG|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
58092218|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
58092219|NCT02641730|DRUG|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
58419423|NCT00077844|DRUG|Enoxaparin sodium|
58419424|NCT03859921|DRUG|Dydrogesterone|Progesterone
58419425|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
58419426|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
58419427|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
58419428|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
58419429|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
58419430|NCT02099201|DRUG|ACT-389949 40 mg|
58419431|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
57734740|NCT06634576|DEVICE|Smooth pursuit neck torsion test|Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
58092220|NCT02641730|DRUG|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
58092221|NCT06566807|DRUG|Orelabrutinib, obinutuzumab|orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
58092222|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
58092223|NCT05584839|OTHER|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
58419432|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
58419433|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
58419434|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
58419435|NCT02099201|DRUG|Placebo|
58419436|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
58419437|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
58419438|NCT04218071|DRUG|9-ING-41|9-
58419439|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
58419440|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
58419441|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
58419442|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
58419443|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
58419444|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
58419445|NCT00236392|DRUG|rabeprazole|
58419446|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
57734741|NCT02877290|DEVICE|non-invasive ventilation (NIV)|
57734742|NCT05178082|BEHAVIORAL|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
58419447|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
58092224|NCT02878239|OTHER|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
58092225|NCT02878239|OTHER|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
58092226|NCT06399276|BEHAVIORAL|Weight Loss|Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
58092227|NCT06442826|OTHER|Non-invasive auricular stimulation|"Single session TniAS stimulation will be achieved by applying four stimulation patches. These patches consist of stainless steel spheres with a diameter of 1.2 mm, covered with adhesive circular paper measuring 8 mm in diameter.~Point 1. Located in the Triangular Fossa, upper and central level at the vertex of the Fossa, at junction between the upper root and the lower root of the Antihelix.~Point 2. Located in the inner part of the Cymba (upper) conchae, in the angle formed by the lower root of the antihelix and the ascending branch of the Helix.~Point 3. Located in the middle depression of the Cavum (lower) conchae.~Poinit 4. It is located at the inner superior quadrant of Lobe, below the external curve of the Intertragus notch, in a depression 3-4 mm from the insertion of the lobe to the face."
58092228|NCT06442826|OTHER|Sham auricular stimulation (SAS)|"Sham intervention will be conducted following the exact same procedure as the TniAS group, with the only difference being the use of sham stimulation patches. These sham patches will consist of the same patches utilized in the TniAS group, except for the absence of the stainless steel spheres. During the application of these sham patches, the investigator will adhere to the identical process as in the TniAS group, with the exception that no palpation will be performed to locate the exact points, and only minimal pressure required for patch adherence will be applied to minimize any substantial stimulation. Participants in the SAS group will also be explicitly instructed not to stimulate the points until the removal of the patches.~The removal of the sham stimulation patches will follow the precise protocol applied in the TniAS group, ensuring consistency in the study procedures across both groups."
58092229|NCT00595127|DRUG|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
58092230|NCT00595127|DRUG|Fludarabine|Fludarabine (30mg/m\^2/day x 5 days)
58092231|NCT00595127|RADIATION|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
58419448|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
58092232|NCT03230695|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
58092233|NCT03230695|DEVICE|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
58092234|NCT03230695|DEVICE|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
58092235|NCT05311215|DRUG|SL-1002|SL-1002 injectable solution
58092236|NCT05311215|DRUG|Placebo|Matching placebo injectable solution
58092237|NCT05510856|OTHER|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
58092238|NCT05510856|OTHER|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
58092239|NCT05510856|OTHER|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
58095292|NCT06111313|RADIATION|FTLEAD|In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.
58419449|NCT03168100|DRUG|Lenalidomide|taken by mouth
58419450|NCT03168100|DRUG|Dexamethasone|taken by mouth
58419451|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
58092240|NCT06701968|OTHER|Healthy Nordic Diet|Oral and written dietary advice during the course of the interventiuon period of 18months. Participants will also receive some key food items representative for a Healthy nordic diet, e.g. whole grain rye and oats and rapeseed oil. Overall the diet is a high-fibre, moderate low-fat diet with moderate to high amounts of high-quality carbohydrates and unsaturated fats, low-fat fermented dairy products. Overall the diet is high in local fruits, legumes and vegetables and is to a large extent plant-based.
58092241|NCT06121661|DEVICE|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
58092242|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
58305832|NCT05598970|OTHER|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
58305833|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
58419452|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
58092243|NCT03384407|DEVICE|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
58092244|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
58092245|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
57734743|NCT05178082|BEHAVIORAL|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
57734744|NCT04674358|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
58305834|NCT05598970|OTHER|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
58305835|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
58305836|NCT03641976|DRUG|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
58305837|NCT03641976|DRUG|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
58305838|NCT02150941|DEVICE|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
58305839|NCT02150941|DEVICE|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
58305840|NCT02938780|OTHER|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
58305841|NCT02938780|OTHER|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
58305842|NCT01336725|BEHAVIORAL|Teaching life style changes|Single group: Teaching, group sessions, physical activity
58305843|NCT01336725|OTHER|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
58305844|NCT01336725|OTHER|Teaching|Morbid obesity group attend 40 hours of group sessions
58305845|NCT03277937|PROCEDURE|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
58305846|NCT00875316|DRUG|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
58305847|NCT01894906|DRUG|Soluble Ferric Pyrophosphate|
58305848|NCT01894906|OTHER|Placebo|
58305849|NCT03406520|DEVICE|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
58305850|NCT03945513|DRUG|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
58305851|NCT00048152|DRUG|Corticosteroids|As prescribed
58305852|NCT00048152|DRUG|Neoral|Low dose (target trough level 50-100ng/mL)
58305853|NCT00048152|DRUG|Neoral|Standard dose (target trough level 150-300ng/mL)
58305854|NCT00048152|DRUG|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
58305855|NCT00048152|DRUG|mycophenolate mofetil [CellCept]|1g po bid
58305856|NCT05939908|OTHER|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
58305857|NCT03095807|DRUG|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
58305858|NCT03095807|DRUG|Placebo|Administered subcutaneously (s.c., under the skin)
58305859|NCT05481710|DIAGNOSTIC_TEST|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
58305860|NCT02453607|DRUG|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
58305861|NCT02453607|DRUG|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
57734745|NCT04674358|DRUG|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
57734746|NCT05996003|DRUG|NS-089/NCNP-02|"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
57734747|NCT06470217|DRUG|tirilizumab with albumin-bound paclitaxel and cisplatin|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
57734748|NCT06470217|PROCEDURE|surgery|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
58092246|NCT04221204|DRUG|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
57734749|NCT04357028|DRUG|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
57734750|NCT04357028|DRUG|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
57734751|NCT03274843|OTHER|Activity of everyday life|Kitchen workshop
57734752|NCT02818881|OTHER|High-speed yoga|
58419453|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
57734753|NCT02818881|OTHER|Low-speed yoga|
57734754|NCT00108225|OTHER|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
57734755|NCT00108225|OTHER|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
58092247|NCT04727580|DRUG|HSK7653 10mg Q2W|HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
58092248|NCT04727580|DRUG|HSK7653 25mg Q2W|HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
58092249|NCT04727580|DRUG|Placebo|Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
58092250|NCT02023723|DIETARY_SUPPLEMENT|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
58092251|NCT02023723|DIETARY_SUPPLEMENT|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
57734756|NCT02943148|OTHER|Davey score for striae gravidarum|
57734757|NCT04586101|DEVICE|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
57734758|NCT04376021|BEHAVIORAL|Babywearing|Increase mother-infant physical contact through babywearing
57734759|NCT05086367|OTHER|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
57734760|NCT05086367|OTHER|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
57734761|NCT03618238|DRUG|Anlotinib|12 mg daily for continus 14 days every 21 days
58092252|NCT04657978|PROCEDURE|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
58305862|NCT01392599|PROCEDURE|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
58305863|NCT02460016|DRUG|AK0529|AK0529 pellets for oral administration
58305864|NCT03511703|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
58305865|NCT03511703|DRUG|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
58305866|NCT00601055|BEHAVIORAL|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
58305867|NCT00601055|BEHAVIORAL|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
58305868|NCT02091700|OTHER|Indocyanine Green ICG|
58305869|NCT01226329|BEHAVIORAL|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
58305870|NCT01226329|BEHAVIORAL|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
58305871|NCT01404910|DEVICE|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
58305872|NCT06290986|PROCEDURE|Pyrocardan® implant|Biconcave-shaped CMC-1 interposition implant
58305873|NCT06290986|PROCEDURE|Ligament reconstruction and tendon interposition (LRTI)|Weilby slightly modified as described by Burton and Pellegrini
58305874|NCT00284921|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
58305875|NCT03458377|OTHER|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
57734762|NCT06439563|DRUG|JP-1366 10 mg|JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
57734763|NCT06439563|DRUG|Lanston Capsule 15 mg|Lanston Capsule 15 mg orally once a day for up to 24 weeks
57734764|NCT06439563|DRUG|JP-1366 10 mg placebo|JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
57734765|NCT06439563|DRUG|Lanston Capsule 15 mg placebo|Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
57734766|NCT05970861|DIETARY_SUPPLEMENT|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
57734767|NCT05073133|GENETIC|OAV101|A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
58092253|NCT02475161|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
58092254|NCT02475161|DRUG|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
58419454|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
58419455|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
58419456|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
58419457|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
58092255|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
58092256|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
58092257|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
58092258|NCT04439097|OTHER|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
58092259|NCT04439097|OTHER|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
58419458|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
58092260|NCT02060227|PROCEDURE|Open Latarjet procedure|
58092261|NCT02060227|PROCEDURE|Arthroscopic Bankart repair|
58092262|NCT05303727|DRUG|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
58092263|NCT05303727|DRUG|Fludarabine|30 mg/m2/day for 5 days
58092264|NCT05303727|DRUG|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
58092265|NCT05303727|DRUG|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
58305876|NCT02995993|DRUG|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
58305877|NCT02425137|DRUG|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
58305878|NCT05556655|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
58305879|NCT03687632|BIOLOGICAL|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
58305880|NCT01929889|DRUG|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
58305881|NCT01078493|DEVICE|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
58305882|NCT05567536|DRUG|Antiplatelet Agents|Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
58419459|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
58419460|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
58419461|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
57734768|NCT02485470|OTHER|MPACT|Maintaining Physical Activity during Cancer Treatment
58419462|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
58419463|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
58419464|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
58419465|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
58419466|NCT02916459|DEVICE|21G EBUS-TBNA needle|
58419467|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
58419468|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
58419469|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
58419470|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
58419471|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
58305883|NCT04710121|OTHER|Virtual Reality Glasses|Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
58305884|NCT00447408|BEHAVIORAL|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
58419472|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
58419473|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
58419474|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
58419475|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
58419476|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
58419477|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
58419478|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
58419479|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
58419480|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
58419481|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
58419482|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
58419483|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
58419484|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
58419485|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
58419486|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
58419487|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
58419488|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
58419489|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
58419490|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
58419491|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
58419492|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
58419493|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
58419494|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
58419495|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
58419496|NCT00131456|DRUG|Venlafaxine|375mg/day
58419497|NCT00131456|DRUG|Placebo|Placebo
57734769|NCT02010060|BEHAVIORAL|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
57734770|NCT02010060|BEHAVIORAL|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
57734771|NCT03604081|OTHER|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
57734772|NCT03604081|OTHER|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
57734773|NCT04717596|OTHER|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
57734774|NCT05480566|OTHER|Functional strength training|Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.
57785320|NCT05092360|BIOLOGICAL|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
58092266|NCT05303727|DRUG|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
58092267|NCT05303727|DRUG|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
58092268|NCT05303727|DRUG|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
58092269|NCT05303727|DRUG|Cyclosporine|2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
58092270|NCT05303727|DRUG|Tacrolimus|0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
58305885|NCT00447408|BEHAVIORAL|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
58419498|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
58419499|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
58419500|NCT02844283|DRUG|Ad-HGF|
58419501|NCT02844283|OTHER|0.9% NaCl|
58419502|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
58419503|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
58419504|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
58419505|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
58419506|NCT00025623|DRUG|carboplatin|
58419507|NCT00025623|DRUG|cyclophosphamide|
58419508|NCT00025623|DRUG|doxorubicin hydrochloride|
58419509|NCT00025623|DRUG|etoposide|
58419510|NCT00025623|DRUG|vincristine sulfate|
58419511|NCT00025623|PROCEDURE|conventional surgery|
58419512|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
58419513|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
58092271|NCT05303727|DRUG|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
58092272|NCT05303727|DRUG|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
58092273|NCT04533165|BEHAVIORAL|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
58419514|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
58092274|NCT03056716|PROCEDURE|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
58092275|NCT02061709|BIOLOGICAL|Ragweed-SPIRE|
58092276|NCT02061709|BIOLOGICAL|Placebo|
58092277|NCT05066347|DEVICE|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
58419515|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
58419516|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
58419517|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
58419518|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
58419519|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
58419520|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
58419521|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
58092278|NCT06497101|BEHAVIORAL|Temperament Based Therapy with Support (TBT-S)|Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
58092279|NCT00152386|DRUG|Certolizumab pegol (CDP870)|
58092280|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
58419522|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
58419523|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
58419524|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
58419525|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
58419526|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
58419527|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
58419528|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
58419529|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
58092281|NCT01135901|BEHAVIORAL|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
58092282|NCT04383769|OTHER|questionnaires survey|data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
58092283|NCT05991492|DEVICE|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I|Digital insomnia treatment
58092284|NCT02561728|DEVICE|Hangar Helmet|Child will be fitted with the Hangar Helmet
58419530|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
58419531|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
57734775|NCT05480566|DEVICE|NMES|For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
58092285|NCT02561728|DEVICE|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
58092286|NCT02032823|DRUG|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
58092287|NCT02032823|DRUG|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
58092288|NCT06703151|BEHAVIORAL|CMDs (Cardiometabolic Diseases) Self-Care Manual|1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
58092289|NCT04452097|BIOLOGICAL|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
58092290|NCT04452097|OTHER|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
58092291|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
58092292|NCT06251024|BIOLOGICAL|RSV vaccine candidate|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58092293|NCT06251024|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
58305886|NCT05988372|DRUG|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
58419532|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
58419533|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
57734776|NCT05480566|DRUG|Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)|Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
57734777|NCT05480566|OTHER|Routine physiotherapy|Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
57785321|NCT05092360|BIOLOGICAL|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
58092294|NCT04579367|DRUG|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
58305887|NCT05988372|DRUG|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
58419534|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
58419535|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
58419536|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
57734778|NCT03340051|BEHAVIORAL|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
57950099|NCT01285115|DRUG|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
57950100|NCT01285115|DRUG|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
57950101|NCT04216745|DIAGNOSTIC_TEST|bile culture|Bile samples will be collected for microbial cultures and antimicrobial susceptibility testing using COMPACT-15 automated system (Bio Merieux, Marcy I'Etoile, France) for bacteria and saboroud's agar for fungal culture.
57950102|NCT06518122|DRUG|HCP1306|Take it once a day per period.
57950103|NCT06518122|DRUG|RLD2302|Take it once a day per period.
57950104|NCT06518122|DRUG|RLD2102|Take it once a day per period
57950105|NCT04916509|DRUG|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
57950106|NCT04916509|DRUG|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
57950107|NCT04261075|BIOLOGICAL|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
57950108|NCT04261075|BIOLOGICAL|durvalumab|Durvalumab Q3W for a maximum of 2 years
57950109|NCT04261075|BIOLOGICAL|oleclumab|Oleclumab Q3W for a maximum of 2 years
57950110|NCT02327637|BEHAVIORAL|Moderate Activity|Ambulation 150 feet, two times per day
58419537|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
58419538|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
58419539|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
58419540|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
58419541|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
57950111|NCT00376610|DEVICE|ASR/Re-cap|
57950112|NCT04327583|BEHAVIORAL|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
57950113|NCT01055600|DRUG|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
58092295|NCT06703203|BIOLOGICAL|26-Valent pneumococcal conjugate vaccine|As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
58092296|NCT06703203|BIOLOGICAL|23-Valent pneumococcal polysaccharide vaccine|As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.
57950114|NCT04249687|BIOLOGICAL|botulinum toxin|neuromodulator
58092297|NCT06703203|BIOLOGICAL|13-Valent pneumococcal conjugate vaccine|As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
58092298|NCT02810496|GENETIC|blood collection for mutation characterization|
58092299|NCT00364416|OTHER|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
58092300|NCT05455411|BEHAVIORAL|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
58092301|NCT05455411|BEHAVIORAL|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
58092302|NCT05314413|PROCEDURE|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
58092303|NCT03664024|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
58092304|NCT03664024|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
58092305|NCT03664024|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
58305888|NCT03728569|OTHER|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
58305889|NCT03728569|OTHER|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
58305890|NCT00597259|DRUG|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
58305891|NCT00597259|DRUG|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
57785322|NCT05092360|BIOLOGICAL|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
58092306|NCT03664024|DRUG|Cisplatin|Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
58092307|NCT04007406|DRUG|dexfadrostat phosphate|DP13 systemic administration
58092308|NCT06041516|DRUG|ADCT-701|ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
58092309|NCT04777591|DRUG|Liposomal bupivacaine TAP block|Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
58419542|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
57950115|NCT04249687|BIOLOGICAL|Placebo|placebo
57950116|NCT00983177|DRUG|Colchicine|0.5 mg twice daily for 4 months
57950117|NCT00983177|DRUG|lactose|lactose capsules twice daily
58092310|NCT04777591|DRUG|Bupivacain|Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
58092311|NCT02132936|DRUG|LEO 90100 aerosol foam|
58092312|NCT02132936|DRUG|Aerosol foam vehicle|
58092313|NCT02132936|DRUG|Calcipotriol BDP gel|
58305892|NCT00161213|DRUG|gemcitabine hydrochloride|
58305893|NCT00161213|DRUG|imatinib mesylate|
58305894|NCT03560908|DRUG|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
58419543|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
58419544|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
58419545|NCT04494724|DRUG|Clazakizumab|Infusion
58092314|NCT02132936|DRUG|Gel vehicle|
58092315|NCT03286426|DIAGNOSTIC_TEST|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
57950118|NCT04273828|PROCEDURE|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
58092316|NCT06632509|DEVICE|BD SiteRite(TM) 9|Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
58092317|NCT05346939|DEVICE|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
58092318|NCT01548573|DRUG|Dexamethasone|Given PO
58092319|NCT01548573|PROCEDURE|Tandem autologous stem cell transplant|
58092320|NCT01548573|DRUG|Cisplatin|Given IV
58092321|NCT01548573|DRUG|Doxorubicin|Given IV
58092322|NCT01548573|DRUG|Cyclophosphamide|Given IV or PO
58092323|NCT01548573|DRUG|Etoposide|Given IV
58092324|NCT01548573|DRUG|Bortezomib|Given IV
58092325|NCT01548573|DRUG|Thalidomide|Given PO
58092326|NCT01548573|DRUG|Melphalan|Given IV
58092327|NCT01788163|GENETIC|EGFR mutation test|EGFR mutation being tested in tissue and blood
58092328|NCT06489847|DIAGNOSTIC_TEST|SPPB++ Application|Participants will have video data collected as they perform the SPPB test one time.
58092329|NCT00006397|DRUG|Indinavir sulfate|
58092330|NCT00006397|DRUG|Ritonavir|
58092331|NCT00006397|DRUG|Stavudine|
58092332|NCT00006397|DRUG|Didanosine|
58092333|NCT02636166|OTHER|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
58092334|NCT02636166|OTHER|Professional pregnancy test|Alere Professional use pregnancy test
58092335|NCT02636166|OTHER|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
58092336|NCT03475186|DRUG|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
58092337|NCT01139801|DRUG|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
58092338|NCT01139801|DRUG|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
58092339|NCT05409664|BEHAVIORAL|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
58092340|NCT05409664|BEHAVIORAL|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
58092341|NCT06542887|DRUG|Atomoxetine|Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
58092342|NCT06542887|DRUG|Black Seed Oil Cap/Tab|Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
58092343|NCT06702605|DRUG|XNW5004 tablets|XNW5004 will be administered orally as tablets.
58092344|NCT06262490|DEVICE|Traditional ultrasound therapy|Ultrasound therapy for 2 session per week for until completing 12 treatment sessions (six weeks) with frequencies up to 3 MHz are used clinically to promote healing
58092345|NCT06262490|OTHER|Pelvic floor rehabilitation|Pelvic floor rehabilitation for 3 sessions per week for (six weeks) until completing 18 sessions with sessions lasting between 30-45 minutes
58092346|NCT06701487|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of Pavlovian-to-instrumental transfer (PIT) effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
58092347|NCT06701487|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
58092348|NCT06701487|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
58092349|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Quantity Frequency: Alcohol, Cannabis, (Meth-) Amphetamine, Cocaine)~* SCID: AUD and SUD (Cannabis, Methamphetamine, Amphetamine, Cocaine) criteria and last year \& depressive symptoms \& symptoms for Mania and psychotic disorder (acute and lifetime) MiniDIPS psychotic disorders"
58092350|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T and STAI-S)~* Adult ADHD Self-Report Scale (ASRS)~* Alcohol Use Disorders Identification Test (AUDIT)~* CAS -A (Alkohol)~* Cannabis Use Disorders Identification Test (CUDIT)~* Fragebogen zu Gedanken und Gefühle 14 Items (FGG-14)~* Fragebogen zur Sozialen Unterstützung (F-SozU-K14)~* Trierer Inventar zum chronischen Stress (TICS)~* Oslo 3-Items-Social-Support Scale (Oslo-3)~* Social Readjustment Rating Scale (SRRS)~* International Trauma Questionnaire (ITQ)~* Positive and Negative Affect Schedule (PANAS)"
58092351|NCT06701487|BEHAVIORAL|Neuropsychological tests|"* Digit-Symbol-Test (DST)~* Digit Span Task~* Value-based decision-making task (VBDM)"
58419546|NCT04494724|DRUG|Placebo|Infusion
58419547|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
58419548|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
58419549|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
58419550|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
58419551|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
57734779|NCT03340051|BEHAVIORAL|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
57734780|NCT06669923|BEHAVIORAL|iSIPsmarter Program|web-based behavioral intervention to reduce sugary drink intake
58092352|NCT00306137|DRUG|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach"
58092353|NCT00306137|DRUG|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
58092354|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
58092355|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
58092356|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
58419552|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
58419553|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
58092357|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
58092358|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
58092359|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
58092360|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
58092361|NCT05968300|BEHAVIORAL|INFORMED-Living Well|1) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging
58305895|NCT06106750|DEVICE|Endoscopic nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.
58419554|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
58419555|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
58419556|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
58419557|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
58419558|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
58419559|NCT02194322|DRUG|Placebo|
58419560|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
58419561|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
58419562|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
57734781|NCT06669923|BEHAVIORAL|Patient Education|website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)
57734782|NCT02241967|DEVICE|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
58092362|NCT05968300|BEHAVIORAL|Text Messaging Only|A 6-week automated SMS text messaging
58092363|NCT03925025|DRUG|Magnesium Sulfate|Treatment in addition to standard therapy
58092364|NCT03925025|DRUG|Nimodipine|Treatment in addition to standard therapy
58092365|NCT03681769|DEVICE|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
58092366|NCT03681769|DEVICE|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
58092367|NCT03681769|DEVICE|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
57734783|NCT02241967|DEVICE|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
57734784|NCT02241967|DEVICE|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
57734785|NCT02241967|DEVICE|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
57734786|NCT03835377|OTHER|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
57734787|NCT03835377|OTHER|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
58092368|NCT03681769|DEVICE|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
58092369|NCT05328167|DRUG|Perflutren Protein-Type A Microspheres|Given IV
58092370|NCT05328167|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
57734788|NCT02967302|DRUG|Morphine Sulfate|active intervention
58092371|NCT00185731|DRUG|Atorvastatin|80 mg orally once daily
58092372|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
58092373|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
58092374|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
57734789|NCT02967302|DRUG|Triamcinolone|active control
57734790|NCT02967302|DRUG|placebo|placebo control
57734791|NCT04398524|DRUG|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
57734792|NCT02562755|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
57734793|NCT02562755|DRUG|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
57734794|NCT02723838|BIOLOGICAL|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
57734795|NCT02723838|DRUG|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
57734796|NCT02723838|DRUG|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
58305896|NCT06106750|DEVICE|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
58092375|NCT05443659|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
58092376|NCT03667742|DIAGNOSTIC_TEST|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
58092377|NCT06703814|OTHER|Intraoperative flow-controlled ventilation strategy|"In the FCV group, intraoperative ventilation will be provided with the EVONE (IES Ventinova Medical).PEEP and Ppeak are titrated guided by dynamic compliance, as follows: Starting from a default setting of 5 cmH2O of PEEP and 15 cmH2O of Ppeak, PEEP and Ppeak are equally increased by 1 cmH2O steps and the PEEP value with the highest VT and thus highest dynamic compliance is defined as best PEEP. Subsequently, Ppeak is stepwise (+1 cmH2O) increased until there is no further over-proportional increase in tidal volume (VT) (i.e. measured VT \> expected VT according to measured dynamic compliance), defined as best driving pressure. No recruitment maneuvers are carried out during FCV. With the I:E ratio set to 1:1, flow is adjusted to establish normocapnia (target etCO2 4.5 to 5.8 kPa). FiO2 is adjusted to maintain oxygen saturation (SpO2) \> 92%."
58419563|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
58419564|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
58419565|NCT04679909|OTHER|Placebo|Administered intranasally
58095293|NCT06111313|DRUG|Ultra-Short-Term Androgen Deprivation Therapy with Relugolix|Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.
58419566|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
58419567|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
58419568|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
58305897|NCT06450769|OTHER|Aronia juice|100% aronia juice, 100 mL/day, twelve-week follow-up
58305898|NCT06450769|OTHER|Mediterranean diet|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet
58305899|NCT06450769|OTHER|Low-fat diet|An individually planned nutrition program suitable for the energy-restricted low-fat diet
58305900|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
58305901|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
58305902|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
58419569|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
57734797|NCT05709730|DIAGNOSTIC_TEST|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
57734798|NCT05530135|OTHER|Exercise program|Exercise program
58305903|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
58305904|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
58419570|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
57734799|NCT05530135|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy
57734800|NCT05530135|OTHER|Standard clinical care|Standard clinical care
57734801|NCT06495775|DEVICE|quickfact|fecal sampling
58092378|NCT06703814|OTHER|Intraoperative pressure-controlled ventilation strategy|In the PCV group, intraoperative ventilation will be provided by a standard anesthesia ventilator in use in the respective participating centers. Patients will be ventilated in PCV mode, at the lowest inspired oxygen fraction (FiO2), to maintain oxygen saturation (SpO2) \> 92%. It is left to the discretion of the attending anesthesiologist to use a higher fraction of FiO2. Inspiratory to expiratory ratio is set at 1:1 to 1:2, respiratory rate will be adjusted to target normocapnia (target etCO2 4.5 to 5.8 kPa. VT will be set at 7 to 9 ml/kg predicted body weight (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. Ventilation starts with 5 cm H2O PEEP, and can be increased to 10 cm H2O PEEP.
58092379|NCT00018174|DRUG|Fluoxetine|
58092380|NCT00018174|BEHAVIORAL|Behavioral group smoking cessation treatment|
58092381|NCT00018174|DRUG|Placebo|
58092382|NCT01306968|DRUG|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
58092383|NCT01306968|OTHER|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
58092384|NCT02935946|OTHER|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
58092385|NCT06282523|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
58092386|NCT06282523|BEHAVIORAL|HMRP web app|The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
58092387|NCT06024785|PROCEDURE|Vertebropexy|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side. Additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
58305905|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
58305906|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
58305907|NCT04232839|DRUG|BI 894416 Reference Formulation|R1 - 60 milligram (6 x 10 milligram tablets) BI 894416 Reference Formulation, immediate release (IR) tablets taken orally with 240 mL of water after an overnight fast of at least 10 hours.
58419571|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
58419572|NCT02411786|BIOLOGICAL|gm-csf|Given ID
58419573|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
57734802|NCT05503108|OTHER|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
58419574|NCT04831099|DRUG|Placebo|The route of administration is transdermal
58419575|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
58419576|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
58419577|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
58419578|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
58419579|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
58419580|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
57734803|NCT01904812|OTHER|Questionnaire about quality of life and satisfaction|
58419581|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
58419582|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
58419583|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
58419584|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
58419585|NCT00581451|DRUG|bifeprunox|oral tablet once daily
58419586|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
58419587|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
58419588|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
57734804|NCT05981274|DIAGNOSTIC_TEST|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
57734805|NCT04501315|DIAGNOSTIC_TEST|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
58419589|NCT02964832|DEVICE|Grasp method|
58419590|NCT02964832|DEVICE|Armband-in-hand method|
57734806|NCT04523545|DEVICE|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
57785323|NCT05092360|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
58092388|NCT06567821|DEVICE|RELIEVA SPINPLUS® NAV Balloon Sinusplasty System|The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
58419591|NCT02964832|DEVICE|Armband-on-arm method|
58419592|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
58419593|NCT04790487|DRUG|Placebo|Saline
58419594|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
58419595|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
58419596|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
58419597|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
58419598|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
58419599|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
58419600|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
58419601|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
58419602|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
58092389|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
58092390|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
58092391|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
58092392|NCT02531698|BIOLOGICAL|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
58419603|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
57785324|NCT05092360|DRUG|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
57785325|NCT05092360|DRUG|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
58092393|NCT02531698|BIOLOGICAL|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
57785326|NCT05092360|DRUG|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
57785327|NCT02273505|DRUG|Asasantin (ER)|
57785328|NCT02273505|DRUG|Persantin|
58092394|NCT02531698|OTHER|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
58092395|NCT06702423|BEHAVIORAL|AI-based chatbot|A tailored Japanese HPV vaccination chatbot.
58092396|NCT06702423|BEHAVIORAL|Leaflet|A publicly accessible HPV vaccination leaflet prepared by the Ministry of Health, Labour, and Welfare.
58092397|NCT00759668|DEVICE|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
58092398|NCT00759668|DEVICE|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
58305908|NCT04232839|DRUG|BI 894416 Formulation A2|T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
57734807|NCT02206503|DRUG|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
57734808|NCT02206503|DRUG|Lenalidomide|
57734809|NCT02206503|DRUG|Dexamethasone|
57734810|NCT02715921|OTHER|Tele-exercise|
57734811|NCT06669780|DEVICE|AMMO PTH DTx|An online cognitive behavioral therapy program accessed through a online program.
57734812|NCT06669780|DEVICE|AMMO SHAM|Online activities not including CBT in the AMMO online program.
58092399|NCT02487407|DRUG|ODM-109|ODM-109 1 mg capsule for oral administration.
58092400|NCT02487407|DRUG|Placebo for ODM-109|Placebo capsule for oral administration.
58092401|NCT05918055|DRUG|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
58092402|NCT05918055|DRUG|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
58092403|NCT06381401|DRUG|bupivacaine 0.25%|superficial cervical plexus block using 10 ml of bupivacaine 0.25%
58092404|NCT06381401|DRUG|bupivacaine 0.125%|superficial cervical plexus block using 10 ml of bupivacaine 0.125%
58092405|NCT06594445|DRUG|GTB-360|"GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day"
58092406|NCT06372834|DEVICE|piTBS being delivered using the Magstim Rapid2 stimulator|Magstim Rapid2 stimulator (Magstim Company, Ltd, Whitland, Wales, UK, SA340HR). See detail in arm/group descriptions regarding the intervention.
58419604|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation|Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.
58092407|NCT06480383|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
58092408|NCT06480383|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
58092409|NCT06480383|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
58092410|NCT05134727|DRUG|AZD5055|Healthy participants will receive AZD5055
58092411|NCT05134727|DRUG|Placebo|Healthy participants will receive placebo
58092412|NCT06317337|OTHER|focused ultrasound cavitation augmented with aerobic exercises|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
58092413|NCT06277778|OTHER|Taekwondo training with music therapy|Taekwondo training with music therapy
58092414|NCT06277778|OTHER|Taekwondo training alone|Taekwondo training without music therapy
58092415|NCT06703710|DRUG|JW2286|a single administration of JW2286 per dose
58092416|NCT06703710|DRUG|Placebo of JW2286|a single administration of Placebo of JW2286 per dose
58092417|NCT06701344|DRUG|Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)|"Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days"
58092418|NCT06701344|DRUG|Golidocitinib|"Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT."
58092419|NCT00975338|OTHER|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
58419605|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
57734813|NCT01692535|PROCEDURE|Intubation|Intubation with one of the six videolaryngoscopes
57734814|NCT03562000|DEVICE|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
57785329|NCT02273505|DRUG|Acetyl salicylic acid (ASA)|
57785330|NCT03264196|PROCEDURE|Open Reduction and Internal Fixation|Surgical treatment of fracture
58092420|NCT00975338|OTHER|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
58092421|NCT00716027|BEHAVIORAL|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
58419606|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
58419607|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
58092422|NCT00716027|BEHAVIORAL|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
58092423|NCT03801395|OTHER|There is no intervention|No intervention
58419608|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
58092424|NCT02790372|OTHER|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
58092425|NCT00720304|DRUG|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
58092426|NCT00720304|DRUG|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
57734815|NCT03562000|PROCEDURE|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
57734816|NCT01328574|DRUG|TRC105|15 mg/kg intravenously
57950119|NCT06490016|DEVICE|web based education|"The web page will be prepared with professional support in line with the guidelines of the Web Content Accessibility Guide (WCAG / WIEK 2.1) developed by W3C.~1. st meeting: online Informed Consent will be obtained. After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out online.~2. nd interview: Module 1-2.~3. rd interview: Module 3 -4.~4. th meeting: Module 5.They will be asked to fill out the System Usability Scale.~5. th interview: During the first menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online.~6. th interview: During the second menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online."
58092427|NCT00720304|GENETIC|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
57950120|NCT06490016|BEHAVIORAL|Face to face|"In face-to-face training, female internal reproductive organ models, female external reproductive organ models, training content prepared with Braille alphabet, menstrual hygiene management kit (underwear, pads, napkins, calendar) materials will be used. Pictures and audio descriptions will be used in web-based training.~1. st interview: Informed Consent . After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out.~2. nd meeting: Module 1-2~3. rd meeting: Module 3- 4~4. th meeting: Module 5.~5. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed.~6. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed."
57950121|NCT04322851|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
57950122|NCT00947336|DRUG|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
57950123|NCT00947336|DRUG|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
57950124|NCT03152019|DRUG|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
57950125|NCT03152019|DRUG|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
57950126|NCT02919878|DRUG|Gemcitabine|Nucleoside analog- Chemotherapy
57950127|NCT02919878|RADIATION|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
57950128|NCT02919878|DRUG|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
58092428|NCT00720304|GENETIC|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
58092429|NCT00720304|OTHER|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
57734817|NCT01662882|DRUG|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
57950129|NCT02244502|DEVICE|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
58092430|NCT00720304|OTHER|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
58092431|NCT00720304|OTHER|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
58092432|NCT00720304|OTHER|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
58419609|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
58419610|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
58419611|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
57734818|NCT05221164|DRUG|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
57734819|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program.|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
57734820|NCT05913622|DEVICE|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
57734821|NCT00628732|DRUG|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
57734822|NCT03332524|DRUG|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
57734823|NCT03332524|DRUG|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
57950130|NCT02244502|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
57950131|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
57734824|NCT03332524|DRUG|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
57734825|NCT01367327|BEHAVIORAL|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
58419612|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
58419613|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
58419614|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
57734826|NCT01367327|BEHAVIORAL|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
58092433|NCT00720304|PROCEDURE|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
58419615|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
58419616|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
58092434|NCT00720304|RADIATION|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
58092435|NCT00720304|RADIATION|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
58419617|NCT04670393|OTHER|Placebo|400 mcg folic acid
58419618|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
58419619|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
58092436|NCT05780515|BIOLOGICAL|ANX009|ANX009 will be administered per schedule specified in the arm description.
58419620|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
58419621|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
58419622|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
57734827|NCT04372966|DEVICE|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
58092437|NCT05700942|DEVICE|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
58092438|NCT05700942|DEVICE|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
57734828|NCT05570526|DIETARY_SUPPLEMENT|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
57734829|NCT05570526|OTHER|Placebo|Placebo tablet once daily.
57734830|NCT05462626|BEHAVIORAL|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
58092439|NCT05341583|DRUG|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
57734831|NCT00496665|DRUG|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
57734832|NCT00496665|DRUG|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
57734833|NCT00496665|DRUG|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
57950132|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
58092440|NCT05341583|DRUG|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
58419623|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
58419624|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
58419625|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
58419626|NCT03159104|DRUG|Placebo|Tablet for oral use.
58419627|NCT00357383|DRUG|Azithromycin (T1225)|
58419628|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
58419629|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
58419630|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
58419631|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
58419632|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
58419633|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
58419634|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
58419635|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
58419636|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
58419637|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
58419638|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
57734834|NCT04317820|BEHAVIORAL|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
58419639|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
58419640|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
58419641|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
58419642|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
58419643|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
58419644|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
58419645|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
58419646|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
58419647|NCT01071616|DRUG|Cannabis Cigarette|
58419648|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
58419649|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
58419650|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
58419651|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
58419652|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
58419653|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
58419654|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
58419655|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
58419656|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
58419657|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
58419658|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
58419659|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
58095294|NCT06111313|RADIATION|HypoLEAD|In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.
58095295|NCT06111313|DRUG|ADT Standard of Care|Participants will receive ADT as per standard of care (SOC).
58419660|NCT02652416|DRUG|BI 1026706|oral administration
58419661|NCT02652416|DRUG|Placebo|placebo
58419662|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
58419663|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
58419664|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
58419665|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
58419666|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
58419667|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
58419668|NCT04334213|DRUG|CKD-501|QD, PO
57734835|NCT05403008|OTHER|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
57734836|NCT01850680|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
58095296|NCT02088294|BEHAVIORAL|Lifestyle Education (LS)|See arm description
58095297|NCT02088294|BEHAVIORAL|LS + Stress Reduction Guided Imagery|See Arm Description
58419669|NCT04334213|DRUG|D745, D150|QD, PO
58419670|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
58419671|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
58419672|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
57734837|NCT01850680|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
58095298|NCT02088294|BEHAVIORAL|LS + Activity/Eating Guided Imagery|See arm description
58419673|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
57734838|NCT01850680|DRUG|methotrexate|Pharmaceutical form:capsule Route of administration: oral
58419674|NCT00329615|DRUG|Insulatard, flexpen|
58419675|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
58419676|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
58419677|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
58419678|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
58419679|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
58419680|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
58419681|NCT00278330|DRUG|alvocidib|Given by infusion
58419682|NCT00278330|DRUG|vorinostat|Given orally
58419683|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
58419684|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
58419685|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
58419686|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
58092441|NCT05552092|DEVICE|Esophageal temperature monitoring according to the depth|"Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured."
58092442|NCT05552092|OTHER|Anatomical landmark|For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
58092443|NCT03858920|DEVICE|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
58092444|NCT03858920|PROCEDURE|Low-dose non-contrast CT|CT scan as part of routine research care
58092445|NCT06125886|DIAGNOSTIC_TEST|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
58419687|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
58419688|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
58419689|NCT00473525|DRUG|Placebo|Placebo QD
58419690|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
58419691|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
58419692|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
58419693|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
58419694|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
58419695|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
58419696|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
58419697|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
58419698|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
58419699|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
58419700|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
58305909|NCT04232839|DRUG|BI 894416 Formulation C2|"T2 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T5 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
58419701|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
58419702|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
58419703|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
57734839|NCT01850680|DRUG|folic acid|Pharmaceutical form:tablet Route of administration: oral
57734840|NCT04477603|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
58092446|NCT04818060|OTHER|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
58305910|NCT04232839|DRUG|BI 894416 Formulation D2|T3 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation D2, extended release (ER) capsule (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
58419704|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
58419705|NCT02506660|DRUG|Bupivacaine|
58419706|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
58419707|NCT02506660|DRUG|Intravenous dexamethasone|
58419708|NCT02506660|DRUG|Intravenous saline|
58419709|NCT02506660|DRUG|Perineural saline|Saline in nerve block
58419710|NCT06135363|DRUG|SC1011|SC1011 tablet
58419711|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
58419712|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
58419713|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
58419714|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
57734841|NCT02003001|DRUG|Botulinum Toxin|
57734842|NCT01629004|OTHER|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
57734843|NCT01629004|OTHER|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
57734844|NCT06636136|DEVICE|OPRA|Surgery
58419715|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
58419716|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
58419717|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
58092447|NCT04818060|DIAGNOSTIC_TEST|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
58092448|NCT04818060|DIAGNOSTIC_TEST|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
58092449|NCT02001285|DRUG|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
57950133|NCT00117598|DRUG|Investigator's choice|"Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
57950134|NCT03217006|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
58092450|NCT04800913|DIAGNOSTIC_TEST|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
58092451|NCT04800913|DIAGNOSTIC_TEST|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
58092452|NCT05680727|PROCEDURE|transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
58092453|NCT04441203|DEVICE|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
58092454|NCT01819389|DRUG|Imatinib and Nilotinib|
58092455|NCT06542003|BEHAVIORAL|Movin' and Groovin' for Wellness|Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
58092456|NCT05188287|BEHAVIORAL|HealthyCells|Smoking cessation smartphone app
58092457|NCT06649591|BEHAVIORAL|Survey|The intervention is an email based survey as described in the study description.
58092458|NCT02469675|DEVICE|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
58092459|NCT02469675|DEVICE|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
58092460|NCT02469675|DEVICE|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
58092461|NCT05681039|DRUG|Tiragolumab|Given by IV (vein)
58092462|NCT05681039|DRUG|Atezolizumab|Given by IV (vein)
58092463|NCT05681039|BEHAVIORAL|Standard of Care|after care from surgery
58092464|NCT05681039|BEHAVIORAL|Questionnaires|Quality of life
58092465|NCT05681039|RADIATION|Cisplatin|Given by IV (vein)
58092466|NCT05681039|RADIATION|Carboplatin|Given by IV (vein)
58092467|NCT05521958|PROCEDURE|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
58092468|NCT05521958|PROCEDURE|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
58092469|NCT05521958|PROCEDURE|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
58092470|NCT06123897|OTHER|Regular follow-up assessments without intervention.|Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.
58092471|NCT06123897|OTHER|Cross-sectional assessment|Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
58305911|NCT04232839|DRUG|BI 894416 Formulation F2|"T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
57734845|NCT06113627|OTHER|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
58305912|NCT06194916|OTHER|Education|A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.
58419718|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
57734846|NCT02267382|DRUG|VT-1161|
57734847|NCT02267382|DRUG|Placebo|
57734848|NCT03411967|DRUG|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
57950135|NCT03217006|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
57950136|NCT00309543|DRUG|Fluorouracil|
58092472|NCT06359964|PROCEDURE|Transperineal Biopsy without antibiotics prophylaxis|Transperineal Biopsy without antibiotics prophylaxis
58092473|NCT06359964|PROCEDURE|Transperineal Biopsy with antibiotics prophylaxis|Transperineal Biopsy with antibiotics prophylaxis
58092474|NCT03308123|OTHER|Observational study, not interventional|Not an intervention study
58092475|NCT06117111|DEVICE|PaMo monitoring device|Comparison of the device to standard monitoring
58092476|NCT04484987|OTHER|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
58305913|NCT06194916|OTHER|CONTROL GROUP|THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
58305914|NCT03106077|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
58305915|NCT02647138|OTHER|white noise|exposure to white noise
58305916|NCT05178017|DIAGNOSTIC_TEST|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
57950137|NCT00309543|DRUG|Leucovorin|
57950138|NCT05793671|DEVICE|PPCI in heavy thrombus burden STEMI patients|minimally invasive procedures used to open clogged coronary arteries
57950139|NCT04659265|OTHER|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
58305917|NCT00967122|PROCEDURE|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
57734849|NCT03411967|DRUG|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
57734850|NCT03591341|DIAGNOSTIC_TEST|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
58419719|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
58419720|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
58419721|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
58419722|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
58419723|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
58419724|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
58419725|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
57950140|NCT01059669|OTHER|diagnostic test|
57950141|NCT02089399|DRUG|Sevikar(amlodipne/olmesartan)|Treatment AB
58305918|NCT04368169|DIETARY_SUPPLEMENT|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
58305919|NCT04368169|OTHER|Placebo|Emulsifier carrier without active supplement ingredients.
58305920|NCT01195649|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
58305921|NCT00499811|DRUG|vorinostat|Given orally
58305922|NCT00499811|OTHER|pharmacological study|Correlative studies
58305923|NCT03609047|DRUG|Palbociclib|CDK4/6 inhibitor
58305924|NCT03609047|DRUG|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
58419726|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
58419727|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
58419728|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
58419729|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
58419730|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
57950142|NCT02089399|DRUG|crestor(Rosuvastatin)|Treatment AB/Treatment C
58419731|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
58419732|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
58419733|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
58419734|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
58419735|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
58419736|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
58419737|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
58419738|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
58419739|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
58419740|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
57950143|NCT02410304|DEVICE|Xrays|Clinical evaluation
57950144|NCT02410304|DEVICE|Ultrasound (B mode )|
58305925|NCT03609047|DRUG|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
58305926|NCT03609047|DRUG|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
58305927|NCT03609047|DRUG|paclitaxel|Adjuvant Chemotherapy
58305928|NCT03783637|OTHER|Whole grain oats|A meal containing whole grain oats
58305929|NCT03783637|OTHER|Whole grain wheat|A meal containing whole grain wheat
58305930|NCT03484169|OTHER|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
58305931|NCT03316586|DRUG|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
58305932|NCT03316586|DRUG|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
58305933|NCT01380236|DRUG|ASM8|
58305934|NCT03928457|OTHER|Parental questionnaire|Parental questionnaire on pregnancy history and environmental exposure
58305935|NCT03928457|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
58419741|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
58419742|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
58419743|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
57950145|NCT02410304|DEVICE|Ultrasound (D mode)|
57734851|NCT02313012|DRUG|CC-90003|CC-90003 PO once daily
58419744|NCT00139256|DRUG|Betamethasone|Betamethasone injection
57734852|NCT03516331|DRUG|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
57734853|NCT04454411|DRUG|Brixadi|Extended release injectable Buprenorphine
57734854|NCT04454411|DRUG|Vivitrol|Extended release injectable Naltrexone
57734855|NCT05802238|DRUG|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
57734856|NCT05802238|OTHER|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
57734857|NCT06388525|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|
57950146|NCT05347888|OTHER|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
57950147|NCT04944160|OTHER|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
57950148|NCT04944160|OTHER|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
57950149|NCT03001089|DRUG|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
57950150|NCT03001089|DRUG|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
58092477|NCT04484987|OTHER|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
58305936|NCT03928457|OTHER|Follow-up of daily infants environmental and clinical parameters|Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures...)
58305937|NCT03928457|OTHER|Nocturnal polysomnography|Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
57734858|NCT03496038|PROCEDURE|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
57734859|NCT03496038|PROCEDURE|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
57950151|NCT02514915|RADIATION|Stereotactic Radiosurgery|Radiation therapy
57950152|NCT05601648|DRUG|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
57950153|NCT02714920|OTHER|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
57950154|NCT04098770|BIOLOGICAL|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
58095299|NCT02618707|OTHER|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
58095300|NCT05123586|DRUG|LY3361237|Administered SC
58095301|NCT05123586|DRUG|Placebo|Administered SC
58095302|NCT04113564|DRUG|Remimazolam|
58095303|NCT03944798|OTHER|Frequency: Every 3 Months|every 3 months
58095304|NCT03944798|OTHER|Frequency: Every 6 Months|every 6 months
58095305|NCT03944798|OTHER|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
58095306|NCT03944798|OTHER|Imaging Modality: Chest CT|Chest computed tomography (CT)
58305938|NCT03928457|DIAGNOSTIC_TEST|cerebral hemodynamics|cerebral hemodynamics (near infrared spectroscopy)
58305939|NCT03928457|DIAGNOSTIC_TEST|activity of the autonomic nervous system|activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
58305940|NCT03234465|BIOLOGICAL|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
57785331|NCT03487003|DRUG|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
57785332|NCT03487003|DRUG|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
57785333|NCT04766502|OTHER|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
57785334|NCT01498913|DRUG|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
57785335|NCT00000736|DRUG|Zidovudine|
57785336|NCT03113162|BIOLOGICAL|Autologous Hematopoietic Stem Cell|
57785337|NCT03113162|DRUG|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
57785338|NCT03724461|BEHAVIORAL|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
57785339|NCT03724461|BEHAVIORAL|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
57785340|NCT03724461|BEHAVIORAL|Control (12 weeks)|No resistance training during the intervention period.
57785341|NCT03724461|BEHAVIORAL|One High Intensity resistance training session|High intensity resistance training, 1 training session
57785342|NCT03724461|BEHAVIORAL|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
57785343|NCT03807505|PROCEDURE|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
57785344|NCT03807505|PROCEDURE|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
57785345|NCT02209207|DEVICE|Treadmill|
57785346|NCT02209207|OTHER|walking training|
57785347|NCT02004860|DRUG|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
57785348|NCT02004860|DRUG|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
57785349|NCT01734837|DEVICE|DS-Ligature Clip|
57785350|NCT04005547|BEHAVIORAL|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up
58092478|NCT04449354|DEVICE|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
58092479|NCT04265209|DRUG|SPECT|\[123I\]-FP-CIT SPECT imaging procedure
58092480|NCT04265209|DRUG|PET|\[18F\] LBT-999 PET imaging procedure
58092481|NCT06520358|OTHER|Acute Intermittent Hypoxia (AIH)|Acute intermittent hypoxia refers to brief (acute), repetitive (intermittent) episodes of breathing oxygen-deprived air (hypoxia) alternating with breathing ambient room air.
58305941|NCT03234465|OTHER|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
57950155|NCT04352959|DEVICE|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
57950156|NCT04352959|DEVICE|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
57950157|NCT02907294|DRUG|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
57950158|NCT02907294|DRUG|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
57950159|NCT02907294|DRUG|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
57950160|NCT00001014|DRUG|Trimetrexate glucuronate|
57950161|NCT00001014|DRUG|Sulfamethoxazole-Trimethoprim|
57950162|NCT00001014|DRUG|Leucovorin calcium|
57950163|NCT02318862|PROCEDURE|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
57950164|NCT00004420|DRUG|gamma-Linolenic acid|
57950165|NCT03155581|BEHAVIORAL|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
58419745|NCT02642146|DRUG|Calcium Channel Blockers|
58419746|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
58419747|NCT02642146|DRUG|Endothelin receptor blocker|
58419748|NCT02642146|DRUG|Prostanoids|
58419749|NCT02642146|DRUG|Other vasodilator|
58419750|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
58419751|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
58419752|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
58419753|NCT04149678|DRUG|Ozanimod|Ozanimod
58419754|NCT04149678|DRUG|Cyclosporine|Cyclosporine
58419755|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
57950166|NCT03155581|BEHAVIORAL|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
57950167|NCT00406510|DRUG|Optive, Systane|
57950168|NCT00087828|DRUG|Cranberry juice cocktail|
57950169|NCT01227486|DEVICE|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
58092482|NCT06520358|BEHAVIORAL|Task specific Airway Protection Training|The vLVC maneuver involves training participants to volitionally prolong closure of the laryngeal vestibule during swallowing, beginning with swallow onset and sustaining closure for at least 2 seconds.
58092483|NCT06520358|OTHER|Sham AIH|Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
58419756|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
58419757|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
58419758|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
58419759|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
57950170|NCT02709564|DRUG|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
57950171|NCT02709564|DRUG|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
57950172|NCT00265538|BEHAVIORAL|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
58092484|NCT06354959|BEHAVIORAL|Prehabilitation|8-week community based prehab program
58092485|NCT01991184|DRUG|GDC-0853|Multiple escalating doses
58419760|NCT05810714|OTHER|Best Practice|Receive usual care
58419761|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
58419762|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
58419763|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
58419764|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
58419765|NCT05810714|OTHER|Survey Administration|Ancillary studies
58419766|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
58419767|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
58419768|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
58419769|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
58419770|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
58419771|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
58419772|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
58419773|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
58419774|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
58419775|NCT05996809|DEVICE|Coseal|Adhesion reduction
57950173|NCT00265538|BEHAVIORAL|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
57950174|NCT01918839|DEVICE|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
58092486|NCT01861717|DRUG|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
58092487|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
57950175|NCT01918839|DEVICE|Restylane-L|Restylane-L injected into wrinkle treatment area
57950176|NCT01487252|BEHAVIORAL|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
57950177|NCT02575768|OTHER|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
58419776|NCT05733728|OTHER|any therapy suitable|any therapy suitable
58419777|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
57950178|NCT03972969|BEHAVIORAL|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
57950179|NCT03972969|BEHAVIORAL|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
57950180|NCT03972969|BEHAVIORAL|Health education|Provision of general information about a variety of topics
57950181|NCT04678570|OTHER|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
57950182|NCT04678570|OTHER|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
57950183|NCT01676675|BIOLOGICAL|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
58092488|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
58092489|NCT06539143|DRUG|Lidocaine|The Paracervical Block with lidocaine for manual vacuum aspiration
58092490|NCT05643027|BEHAVIORAL|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
58305942|NCT00798005|DRUG|XRP0038 (NV1FGF)|
58305943|NCT02981979|DRUG|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
58305944|NCT02981979|DRUG|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
58305945|NCT02981979|DRUG|Placebos|used in control group during the induced remission therapy for 24 weeks.
58305946|NCT02799927|PROCEDURE|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
58305947|NCT02799927|PROCEDURE|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
58305948|NCT01266616|BIOLOGICAL|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
57950184|NCT01676675|BIOLOGICAL|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
58092491|NCT03881722|DIETARY_SUPPLEMENT|Mg alginate|Mg alginate after feedings
58092492|NCT05790200|DRUG|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
58305949|NCT01266616|BIOLOGICAL|IL-12|Administered at Weeks 0, 4, and 12
58419778|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
58419779|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
58419780|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
58419781|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
58419782|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
58419783|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
58419784|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
57950185|NCT01676675|BIOLOGICAL|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
58095307|NCT03079869|DRUG|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
58305950|NCT01266616|OTHER|Placebo|Saline injections at Weeks 0, 4, and 12
58305951|NCT00971217|OTHER|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
58305952|NCT00971217|BEHAVIORAL|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
58095308|NCT01238172|OTHER|dietary education and counseling|
58095309|NCT01238172|OTHER|prostate cancer foundation booklet|
58305953|NCT00253136|DRUG|risperidone|
57950186|NCT01676675|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
58419785|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
58419786|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
58419787|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
58419788|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
58419789|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
58419790|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
58419791|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
58419792|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
58419793|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
58419794|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
58419795|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
58419796|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
57950187|NCT02840695|DRUG|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
57950188|NCT01339806|BEHAVIORAL|Cognitive Rehab|APT-III, Other standard individual and group interventions.
58092493|NCT04464382|PROCEDURE|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
57950189|NCT01339806|BEHAVIORAL|Brainworks|POSIT
57950190|NCT01339806|BEHAVIORAL|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
58095310|NCT06568913|DIAGNOSTIC_TEST|CBC|Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
57950191|NCT06548256|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|probiotics
57950192|NCT05462847|DRUG|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
57950193|NCT04200729|DRUG|Irrigation with PVI|The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
58092494|NCT04464382|PROCEDURE|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
58092495|NCT03406611|DRUG|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
58305954|NCT03832556|OTHER|CT scan|CT scan with biphasic injection of contrast product
58305955|NCT03832556|OTHER|MRI examination|MRI with injection of contrast
58305956|NCT01550133|BEHAVIORAL|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
58305957|NCT01550133|BEHAVIORAL|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
58305958|NCT01550133|BEHAVIORAL|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
58305959|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
58305960|NCT01550133|BEHAVIORAL|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
58305961|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
58305962|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
58305963|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
58305964|NCT03656341|BEHAVIORAL|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
58305965|NCT02739893|PROCEDURE|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
58305966|NCT02739893|PROCEDURE|Standard procedure for colonoscopy|
58305967|NCT02193841|PROCEDURE|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
58305968|NCT02193841|DEVICE|Curette|A small surgical instrument with a rounded edge designed for scraping
58305969|NCT02193841|DEVICE|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
58305970|NCT02908139|DEVICE|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
58305971|NCT02908139|DEVICE|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
58305972|NCT01494636|DRUG|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
58419797|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
58092496|NCT03406611|DRUG|Placebo|Normal saline for subcutaneous injection
57734860|NCT05406687|OTHER|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
57734861|NCT05499429|DEVICE|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
57734862|NCT05752123|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
57734863|NCT06574867|DEVICE|viQtor Wearable Monitoring Device|The viQtor device is a wearable medical device designed for continuous monitoring of vital signs, including heart rate (PR), respiratory rate (RR), and blood oxygen saturation (SpO2). It is worn on the upper arm and transmits data wirelessly to a cloud-based platform. This device is being evaluated as part of the standard monitoring protocol for post-operative patients in a surgical ward setting.
57734864|NCT03564912|DRUG|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
57950194|NCT04200729|PROCEDURE|Usual care|The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (\> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
57950195|NCT03581227|OTHER|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
58092497|NCT05948917|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
58092498|NCT06372145|DRUG|Tolebrutinib|Pharmaceutical form:Tablet-Route of administration:oral
58092499|NCT06372145|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:oral
58092500|NCT06372145|DRUG|Teriflunomide|Pharmaceutical form:Tablet-Route of administration:oral
58092501|NCT00003892|DRUG|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
58092502|NCT06081946|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
58305973|NCT01494636|DRUG|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
58305974|NCT01494636|DRUG|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
57734865|NCT06087601|DRUG|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
57950196|NCT02410135|DRUG|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
57950197|NCT00971451|OTHER|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
58092503|NCT06081946|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
58305975|NCT01494636|DRUG|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
58305976|NCT03228030|DIETARY_SUPPLEMENT|Thiamine|Capsules
58305977|NCT03228030|DIETARY_SUPPLEMENT|Placebo|Identical capsules
58305978|NCT01447888|DRUG|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
57734866|NCT06087601|DRUG|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
57950198|NCT00971451|OTHER|TENS|continuous use of TENS during the exercise session
57950199|NCT02849561|OTHER|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
58092504|NCT04519294|DEVICE|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
58305979|NCT01447888|OTHER|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
58305980|NCT00896493|DRUG|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
58305981|NCT00896493|DRUG|cyclosporine|5 mg/kg PO or IV
58305982|NCT00896493|RADIATION|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
57734867|NCT03001648|PROCEDURE|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
57734868|NCT06060691|DRUG|Kaempferol|Kaempferol
57734869|NCT00957502|DEVICE|ENTact™ Septal Stapler|1 year aged septal staples
58092505|NCT04519294|DEVICE|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
58305983|NCT04072874|DRUG|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
58305984|NCT02627560|DRUG|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
58305985|NCT02627560|DRUG|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
58305986|NCT05849077|OTHER|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
58305987|NCT05849077|OTHER|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
58305988|NCT01317940|DIETARY_SUPPLEMENT|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
58305989|NCT04827862|DRUG|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
58305990|NCT00900939|BEHAVIORAL|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
58305991|NCT00900939|BEHAVIORAL|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
58305992|NCT05706324|BIOLOGICAL|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
58305993|NCT04309331|DIETARY_SUPPLEMENT|Motion|Amino acid based protein substitute
58305994|NCT04831710|DRUG|Sintilimab|Sintilimab,200mg, ivd, d1
58305995|NCT04831710|DRUG|Chidamide|Chidamide,30mg,po,biw,d1-21
57734870|NCT00957502|DEVICE|ENTact™ Septal Stapler|18 Month Aged Staples
57734871|NCT03669848|OTHER|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
57734872|NCT01785238|OTHER|renal echography|renal echography to analyse the kidney
57734873|NCT01785238|OTHER|Blood sampling|Blood sampling to analyse different parameters of renal function
58092506|NCT03534635|DRUG|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
57734874|NCT01785238|OTHER|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
57734875|NCT01785238|OTHER|Blood pressure measurement|
57734876|NCT00920426|DRUG|GSK1265744 30mg|GSK1265744 30 mg
57734877|NCT00920426|DRUG|Placebo|Placebo to match GSK1265744
57734878|NCT00920426|DRUG|GSK1265744 5mg|GSK1265744 5mg
57734879|NCT02534909|BIOLOGICAL|LFG316|"LFG316 20 mg/kg was administered to all patients enrolled in the study:~* Treatment Periods 1 to 3: LFG316 20 mg/kg as i.v. infusion every 2 weeks~* Treatment Period 4: LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions)."
58092507|NCT03534635|DRUG|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
58092508|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
58092509|NCT06682949|BEHAVIORAL|Sleep Extension|Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.
58092510|NCT06682949|BEHAVIORAL|Daytime Routine|Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
58092511|NCT00038467|DRUG|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
58305996|NCT05074875|OTHER|Questionnaires and Patient Reported Outcomes (PROs)|"* EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~* St. George's Respiratory Questionnaire (SGRQ)~* Impact of Events Scale Revised (IES-R)~* Generalized Anxiety Disorder 7-Item (GAD-7)~* Patient Health Questionnaire (PHQ-9)"
58305997|NCT05074875|DIAGNOSTIC_TEST|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
58419798|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
58419799|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
58419800|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
58419801|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
58419802|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
58092512|NCT00038467|DRUG|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
58092513|NCT02957461|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
58092514|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
58092515|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
58092516|NCT01652872|BIOLOGICAL|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
58092517|NCT01652872|OTHER|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
58092518|NCT00262184|DRUG|Soy Isoflavone|
58092519|NCT02306018|DEVICE|EV1000™/volumeView™|
58305998|NCT05074875|GENETIC|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
58305999|NCT05074875|DIAGNOSTIC_TEST|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
58419803|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
58419804|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
57950200|NCT02849561|DEVICE|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
57950201|NCT02849561|OTHER|Electroencephalography|
57950202|NCT02849561|DEVICE|Pupillary light reflex surveillance|With Neurolight® device.
57950203|NCT02849561|DEVICE|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
58092520|NCT05905874|OTHER|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
58306000|NCT05074875|DIAGNOSTIC_TEST|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
58306001|NCT05074875|DIAGNOSTIC_TEST|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
58306002|NCT05074875|DIAGNOSTIC_TEST|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
58419805|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
58419806|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
58419807|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
58306003|NCT05074875|DIAGNOSTIC_TEST|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
57950204|NCT02205203|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
57950205|NCT02205203|OTHER|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
57950206|NCT03175900|DRUG|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
57950207|NCT03175900|DRUG|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
57950208|NCT00350051|DRUG|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
58092521|NCT00499252|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
58306004|NCT05074875|DIAGNOSTIC_TEST|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
58306005|NCT05074875|DIAGNOSTIC_TEST|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
58306006|NCT05074875|DIAGNOSTIC_TEST|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
58306007|NCT02966704|DIETARY_SUPPLEMENT|intrinsically labeled milk protein|
58306008|NCT01001429|DRUG|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
58306009|NCT01001429|DRUG|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
58419808|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
58419809|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
58419810|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
58419811|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
58419812|NCT02042313|OTHER|continuous epidural infusion|
58306010|NCT00663650|PROCEDURE|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
58419813|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
58419814|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
58419815|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
58419816|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
58419817|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
58419818|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
58419819|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
58419820|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
58419821|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
58419822|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
58419823|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
58419824|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
58419825|NCT00487448|DRUG|Fludarabine|
58419826|NCT00487448|DRUG|Cytarabine|
58419827|NCT00487448|DRUG|G-CSF|
58419828|NCT00487448|DRUG|Idarubicin|
58419829|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
58419830|NCT00487448|PROCEDURE|Bone marrow transplantation|
58419831|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
58419832|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
57950209|NCT02389803|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
57950210|NCT02389803|DIETARY_SUPPLEMENT|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
57950211|NCT06534450|DEVICE|Sham|The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.
57950212|NCT06534450|DEVICE|Therapeutic Plasma Exchange|Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.
57950213|NCT06534450|DRUG|IVIG|Intravenous Immunoglobulin
57950214|NCT06154369|BEHAVIORAL|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
57950215|NCT01441531|DRUG|gabapentin 600 mg po|Given one hour before surgery
57950216|NCT01441531|DRUG|Placebo pill given one hour before surgery|Placebo pill given
57950217|NCT03893968|BEHAVIORAL|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
57950218|NCT03893968|BEHAVIORAL|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
57950219|NCT02026895|GENETIC|Genetic blood sample|
57950220|NCT00267137|DEVICE|Pacing Algorithms|
57950221|NCT00295711|DRUG|Bicifadine|
58419833|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
57950222|NCT02189213|DRUG|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
57950223|NCT00208221|DRUG|ramipril|
57950224|NCT00208221|DRUG|ramipril-telmisartan|
57950225|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
58306011|NCT00663650|PROCEDURE|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
58419834|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
58419835|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
58419836|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
58419837|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
58419838|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
58306012|NCT04890808|DIETARY_SUPPLEMENT|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
58306013|NCT04890808|DIETARY_SUPPLEMENT|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
58419839|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
58419840|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
58419841|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
58419842|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
58419843|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
58419844|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
58419845|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
57734880|NCT02534909|DRUG|LNP023|Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.
57950226|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
57950227|NCT03415295|OTHER|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
57950228|NCT00346073|BIOLOGICAL|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
57950229|NCT00346073|BIOLOGICAL|ADACEL®|Sanofi Pasteur
57950230|NCT01097746|BIOLOGICAL|Bevacizumab|Given IV
57950231|NCT01097746|DRUG|Carboplatin|Given IV
58306014|NCT01103323|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
58306015|NCT01103323|DRUG|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
58306016|NCT01103323|OTHER|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
58419846|NCT00151788|DRUG|Pactimibe sulfate|
58419847|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
58419848|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
58419849|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
58419850|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
58419851|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
58419852|NCT01035346|DRUG|Placebo|Single dose of a placebo
58419853|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
58419854|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
58419855|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
58419856|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
58419857|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
58419858|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
58419859|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
58419860|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
58419861|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
58419862|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
58419863|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
58419864|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
58419865|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
58419866|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
58419867|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
58419868|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
58419869|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
58419870|NCT04932291|DRUG|vafidemstat|1.2mg capsule
58419871|NCT04932291|DRUG|Placebo|placebo capsule
58419872|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
58419873|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
58419874|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
58419875|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, ...). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
58419876|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
58419877|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
57734881|NCT03775239|BEHAVIORAL|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
57950232|NCT01097746|DRUG|Paclitaxel|Given IV
57950233|NCT03269045|DRUG|ORL-1B|Oral ORL-1B
57950234|NCT03574090|DRUG|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
57950235|NCT03574090|DRUG|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
57950236|NCT05433571|DEVICE|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
57950237|NCT00003283|DRUG|octreotide acetate|
57950238|NCT00003283|DRUG|prednisone|
57950239|NCT06361732|OTHER|No intervention|No intervention
58092522|NCT00433771|DEVICE|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
58092523|NCT05831787|OTHER|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
58419878|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
57950240|NCT04867473|BEHAVIORAL|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
57950241|NCT00997100|DRUG|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
57950242|NCT00177333|DRUG|Doxycycline|
57950243|NCT05590286|DRUG|Vonoprazan Tablets|Vonoprazan 20 mg, tablets, orally，QD
57950244|NCT05590286|DRUG|Amoxicillin Capsules|Amoxicillin 750mg, Capsules ,orally，QID
58092524|NCT00693056|DRUG|Placebo|Placebo (w/o API)
58092525|NCT00693056|DRUG|RX-10100 5mg|5 mg/dose of RX-10100
58306017|NCT01884597|DRUG|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
58306018|NCT01884597|DRUG|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
58306019|NCT01978457|DRUG|cocaine hydrochloride|
58306020|NCT01978457|DRUG|propranolol|
58306021|NCT01978457|DRUG|placebo|
58419879|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
57950245|NCT05590286|DRUG|Esomeprazole|Esomeprazole 20mg, Capsules ,orally，BID
57950246|NCT03115567|DRUG|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
57950247|NCT05972200|DEVICE|Active HD-tDCS over V5/MT|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V5/MT, whereas the other 4 electrodes return electrical currents that flow away from that area. V5/MT will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
57950248|NCT05972200|DEVICE|Active HD-tDCS over V1|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V1, whereas the other 4 electrodes return electrical currents that flow away from that area. V1 will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
57950249|NCT05972200|DEVICE|Sham HD-tDCS over V5/MT or V1|Sham HD-tDCS will be delivered over left V5/MT or left V1. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. .
58092526|NCT00693056|DRUG|RX-10100 10mg|10 mg/dose of RX-10100
58092527|NCT00693056|DRUG|RX-10100 15mg|15 mg/dose of RX-10100
58092528|NCT03138135|BEHAVIORAL|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
58092529|NCT03138135|BEHAVIORAL|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
58092530|NCT06703749|DEVICE|Treatment with BTL-899M|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.
58092531|NCT06703749|DEVICE|Treatment with BTL-899M with intensities below therapeutic threshold|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
58306022|NCT00032773|DRUG|pentostatin for injection|
58306023|NCT02771275|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
58419880|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
58419881|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
58419882|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
58419883|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
58419884|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
58419885|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
58419886|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
57950250|NCT03027531|BEHAVIORAL|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
58092532|NCT01491737|DRUG|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
58419887|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
58419888|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
58419889|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
58419890|NCT00002514|BIOLOGICAL|sargramostim|
58419891|NCT00002514|DRUG|asparaginase|
58419892|NCT00002514|DRUG|cyclophosphamide|
57950251|NCT01394042|DEVICE|Proxiscan device|All patients will be imaged with the device
58306024|NCT04458896|BEHAVIORAL|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~* Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, \& the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~* Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~* An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
58306025|NCT04012528|OTHER|ERAS program|ERAS program
58306026|NCT04621721|BEHAVIORAL|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
58419893|NCT00002514|DRUG|cytarabine|
58419894|NCT00002514|DRUG|daunorubicin hydrochloride|
58419895|NCT00002514|DRUG|dexamethasone|
58419896|NCT00002514|DRUG|etoposide|
58419897|NCT00002514|DRUG|imatinib mesylate|
58419898|NCT00002514|DRUG|leucovorin calcium|
58419899|NCT00002514|DRUG|mercaptopurine|
58419900|NCT00002514|DRUG|methotrexate|
58419901|NCT00002514|DRUG|prednisone|
58419902|NCT00002514|DRUG|thioguanine|
58419903|NCT00002514|DRUG|vincristine sulfate|
58419904|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
58419905|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
58419906|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
58419907|NCT00002514|RADIATION|radiation therapy|
58419908|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
58419909|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
58419910|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
58419911|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
58306027|NCT01201642|DRUG|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
58306028|NCT01201642|DEVICE|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
58306029|NCT01201642|OTHER|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
57950252|NCT03536871|DIETARY_SUPPLEMENT|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
57950253|NCT03536871|OTHER|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
57950254|NCT05219942|DRUG|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
57950255|NCT05219942|OTHER|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
57950256|NCT04500977|BEHAVIORAL|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
57950257|NCT01114503|DRUG|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
57950258|NCT01114503|DRUG|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
57950259|NCT01114503|DRUG|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
57950260|NCT01114503|DRUG|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
57950261|NCT01114503|DRUG|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
57950262|NCT01114503|DRUG|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
57950263|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
57950264|NCT01028092|DRUG|Thymoglobulin + Everolimus|"* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
57950265|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine then Everolimus|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
57950266|NCT05989906|BEHAVIORAL|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
57950267|NCT05989906|BEHAVIORAL|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
58092533|NCT01491737|DRUG|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
58092534|NCT01491737|DRUG|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
58306030|NCT02548936|DRUG|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
58419912|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
58419913|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
58419914|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
58306031|NCT04315441|DIAGNOSTIC_TEST|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
58419915|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
58419916|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
58419917|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
58419918|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
58419919|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
58419920|NCT00002465|DRUG|megestrol acetate|
58419921|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
57950268|NCT05989906|BEHAVIORAL|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
57950269|NCT05989906|BEHAVIORAL|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
57950270|NCT04706676|BEHAVIORAL|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
57950271|NCT04706676|BEHAVIORAL|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
57950272|NCT04706676|BEHAVIORAL|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
58092535|NCT01491737|DRUG|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
58092536|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
58306032|NCT02737722|DRUG|Bisphosphocin Nu-3|
58306033|NCT02737722|DRUG|Placebo|
58306034|NCT00055562|DRUG|CC 5013|
58306035|NCT00594776|DEVICE|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
58306036|NCT02679664|DRUG|Rosuvastatin|20 mg tablet of rosuvastatin
58306037|NCT05025930|DEVICE|endoscopic surgical instrument control system (SP1000: single-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
58306038|NCT05025930|DEVICE|endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
58306039|NCT03880474|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
58306040|NCT03880474|DRUG|Saline|Sodium Chloride Placebo
58092537|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
58092538|NCT06651255|PROCEDURE|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
58306041|NCT01192321|DEVICE|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
58419922|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
57734882|NCT03775239|BEHAVIORAL|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
57734883|NCT06670950|DRUG|SYT-510|Oral formulation A fasted
57734884|NCT06670950|DRUG|SYT-510|Oral formulation B fasted
57734885|NCT06670950|DRUG|SYT-510|Oral formulation A fed
57734886|NCT06670950|DRUG|Placebo|Oral formulation
57734887|NCT06364189|BEHAVIORAL|Music|Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
57950273|NCT03065907|OTHER|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
57950274|NCT02445807|DRUG|DFD06-Cream|Twice daily topical application for 14 days.
57950275|NCT02445807|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
57950276|NCT00226109|DRUG|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
57950277|NCT00271596|DRUG|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
57950278|NCT00271596|DRUG|Placebo|a daily matching placebo administered over 16 weeks
57950279|NCT01599403|PROCEDURE|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
57950280|NCT01599403|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
58092539|NCT06651255|PROCEDURE|Standard of care management|Standard of care management
58092540|NCT04720885|PROCEDURE|kind of surgery|hysteroscopy, curettage, other
58092541|NCT06703606|DRUG|MARSTACIMAB|Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
57950281|NCT01599403|PROCEDURE|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
57950282|NCT06156982|DRUG|Evusheld|Administration of Evusheld 600 mg
58092542|NCT02621021|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
58092543|NCT02621021|DRUG|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
58092544|NCT02621021|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
58306042|NCT01192321|DEVICE|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
58306043|NCT01854814|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
58306044|NCT01854814|DRUG|Losartan|Maximum tolerated labeled dose of Losartan
58419923|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
58419924|NCT03675516|OTHER|No specific intervention|Usual care
57734888|NCT06364189|BEHAVIORAL|Exercise|"The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
58092545|NCT02621021|DRUG|Pembrolizumab|(Cohort 1, Arm 2 and Cohort 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes. (Cohort 1, Arm 1 Retreatment) 4 doses every 3 weeks (+/- 2 days): Pembrolizumab 2mg/kg IV over approximately 30 minutes.
58092546|NCT02621021|BIOLOGICAL|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
58092547|NCT06362304|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
58092548|NCT05597514|OTHER|3D printed educational model|Slide-based presention plus 3D printed airway suction model
58419925|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
58419926|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
58419927|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
58419928|NCT04602026|OTHER|Best Practice|Receive standard of care
58419929|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
58419930|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
57734889|NCT06636461|PROCEDURE|microfragmented adipose tissue loaded on allograft|microfragmented adipose tissue loaded on allograft on ridge preservation
57950283|NCT05927051|OTHER|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
57950284|NCT05927051|OTHER|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
58419931|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
58419932|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
58419933|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
58419934|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
57950285|NCT05927051|OTHER|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
57950286|NCT05745220|OTHER|Device: silicone hydrogel contact lens|Silicone hydrogel contact lens
57950287|NCT03314974|BIOLOGICAL|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
57950288|NCT03314974|BIOLOGICAL|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
58092549|NCT05597514|OTHER|Tranditional model education|Slide-based presention plus tranditional model
58092550|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
58092551|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
58419935|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
58419936|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
58419937|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
58092552|NCT01473589|DRUG|Teriparatide|Administered by SC injection
58092553|NCT01473589|DRUG|Placebo|Administered by SC injection
58092554|NCT01473589|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
58092555|NCT01473589|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
58092556|NCT02405351|BEHAVIORAL|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
58092557|NCT06470737|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
58092558|NCT06470737|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
58092559|NCT06470737|OTHER|Cowhage|This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
58092560|NCT06470737|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
58092561|NCT00137462|DRUG|torcetrapib/atorvastatin|
58092562|NCT00137462|DRUG|atorvastatin|
58092563|NCT00003273|BIOLOGICAL|filgrastim|
58092564|NCT00003273|DRUG|carboplatin|
58092565|NCT00003273|DRUG|cisplatin|
58419938|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
58419939|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
58419940|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
58419941|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
58419942|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
58419943|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
58419944|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
58092566|NCT00003273|DRUG|cyclophosphamide|
58092567|NCT00003273|DRUG|etoposide|
58092568|NCT00003273|DRUG|leucovorin calcium|
58092569|NCT00003273|DRUG|methotrexate|
58092570|NCT00003273|DRUG|temozolomide|
58092571|NCT00003273|DRUG|thiotepa|
58092572|NCT00003273|DRUG|vincristine sulfate|
58092573|NCT00003273|PROCEDURE|autologous bone marrow transplantation|
58092574|NCT00003273|PROCEDURE|peripheral blood stem cell transplantation|
58092575|NCT00003273|RADIATION|radiation therapy|
58092576|NCT06025786|COMBINATION_PRODUCT|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
58092577|NCT01016431|OTHER|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
58092578|NCT01016431|OTHER|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
58092579|NCT03637270|DIETARY_SUPPLEMENT|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
58092580|NCT03637270|OTHER|Exercise training|Including aerobic cycling training and progressive resisted exercise
58095311|NCT00179218|DRUG|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
58419945|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
58419946|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
58419947|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
58419948|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
58092581|NCT03695042|OTHER|Blood Flow Restriction Training with Exercise|The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
58092582|NCT05795062|DRUG|apixaban|patients treated with apixaban
58092583|NCT05795062|DRUG|warfarin|patients treated with warfarin
58419949|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
58419950|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
58419951|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
58419952|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
58419953|NCT02857101|OTHER|dosage of calprotectin|
58092584|NCT06701851|BEHAVIORAL|Voluntary and involuntary conditions|"An task fMRI/EEG acquisition during the prodromal phase preceding the episode of abnormal movements.~A task fMRI/EEG acquisition the episode of abnormal movements A task fMRI/EEG acquisition when the subject voluntary mimics the sequence of events (prdrosomal phase + episode of dyskinesia)"
58092585|NCT04904588|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
58092586|NCT04904588|DRUG|Busulfan|Given IV pre-transplant as part of conditioning regimen
58092587|NCT04904588|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
58092588|NCT04904588|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
58092589|NCT04904588|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
58092590|NCT04904588|DRUG|Melphalan|Given IV pre-transplant as part of conditioning regimen
58092591|NCT04904588|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
58419954|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
58419955|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
58419956|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
58419957|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
58419958|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
58419959|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
58092592|NCT04904588|PROCEDURE|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
58092593|NCT04904588|DRUG|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
58092594|NCT04904588|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
58092595|NCT04904588|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
58092596|NCT04904588|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
58092597|NCT04904588|OTHER|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
58092598|NCT06047249|BEHAVIORAL|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
58092599|NCT06047249|BEHAVIORAL|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
58419960|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
58095312|NCT00179218|BEHAVIORAL|exercise|leg press exercise; every other day, 3 days per week, for 6 months
58095313|NCT02093468|DRUG|MST-188|
58095314|NCT02093468|DRUG|Saline|
58095315|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
58092600|NCT03361332|OTHER|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
58092601|NCT06319963|DRUG|Two IM injections Lenti-HPV-07|two Lenti-HPV-07 intramuscular injections one month apart
58306045|NCT02585869|DRUG|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
58419961|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
58092602|NCT06319963|DRUG|One IM injection Lenti-HPV-07|a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
58092603|NCT00960687|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
58306046|NCT02585869|DRUG|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
58306047|NCT02585869|DRUG|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
58306048|NCT02585869|DRUG|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
58306049|NCT02585869|DRUG|Placebo|Blinded capsule and tablets, once daily, 84 days
58419962|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
57734890|NCT05373394|OTHER|Test battery|motor and neuropsychological test battery
57734891|NCT02732925|DEVICE|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy"
58092604|NCT00960687|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
58092605|NCT05824975|DRUG|GI-102 subcutaneous (SC)|0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
58092606|NCT05824975|DRUG|GI-102|Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
58306050|NCT00547144|DRUG|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
58306051|NCT00547144|PROCEDURE|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
58306052|NCT04044105|OTHER|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
58092607|NCT05824975|DRUG|doxorubicin|Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
58092608|NCT05824975|DRUG|paclitaxel|Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
58092609|NCT05824975|DRUG|bevacizumab|Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
58092610|NCT05824975|DRUG|eribulin|Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
58092611|NCT05824975|DRUG|trastuzumab deruxtecan (T-DXd)|T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
58419963|NCT01180517|PROCEDURE|PCI|balloon angioplasty
58419964|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
58419965|NCT02712424|BIOLOGICAL|DAR-901|
58419966|NCT02712424|BIOLOGICAL|Sterile saline placebo|
58092612|NCT05824975|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
58092613|NCT05824975|DRUG|GI-102|Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
58092614|NCT05042453|DEVICE|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
58092615|NCT05775237|DIETARY_SUPPLEMENT|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
58092616|NCT05775237|DIETARY_SUPPLEMENT|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
58092617|NCT05775237|DIETARY_SUPPLEMENT|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
58092618|NCT06687434|BEHAVIORAL|accurate carb counting|Participants will use precise carb counting to manage their meals
58419967|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
58419968|NCT01875718|DRUG|UC1010|
57734892|NCT02732925|PROCEDURE|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy"
58092619|NCT06687434|BEHAVIORAL|Simplified qualitative meal size estimation|participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
58095316|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
58095317|NCT06606106|DRUG|LY3537031|Administered SC
58095318|NCT06606106|DRUG|Placebo|Administered SC
58419969|NCT01875718|DRUG|Placebo|
57734893|NCT06180824|DRUG|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
57734894|NCT01944501|PROCEDURE|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
58092620|NCT06565832|PROCEDURE|One-Minute Sit-to-Stand Test|This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
58419970|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
58419971|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
58419972|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
58419973|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
58419974|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
58419975|NCT02008357|DRUG|Placebo|Administered IV
58419976|NCT02008357|DRUG|Solanezumab|Administered IV
58092621|NCT06565832|PROCEDURE|Chester Step Test|This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
58092622|NCT06358859|OTHER|Food is Medicine|Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
58092623|NCT05658731|RADIATION|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
58092624|NCT05658731|OTHER|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
58092625|NCT05658731|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
58092626|NCT06699771|DRUG|GCC2005|CAR-NK Cell Therapy
57734895|NCT01944501|PROCEDURE|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
57734896|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
58092627|NCT06699771|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
58092628|NCT06699771|DRUG|Fludarabine|Lymphodepleting chemotherapy
58092629|NCT06463886|BEHAVIORAL|STEP-AD|This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
58092630|NCT06463886|BEHAVIORAL|Enhanced treatment as usual (E-TAU)|Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
58419977|NCT05225259|DRUG|LOXO-260|Oral
58092631|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
58419978|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
58419979|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
58419980|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
58419981|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
58419982|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
58419983|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
58092632|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
58092633|NCT06149624|BEHAVIORAL|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
58092634|NCT06149624|BEHAVIORAL|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
58092635|NCT05109416|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
58092636|NCT05109416|DRUG|Saline 0.9%|Isotonic crystaloid
58092637|NCT03370393|BEHAVIORAL|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
58092638|NCT03212443|PROCEDURE|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
58092639|NCT03212443|PROCEDURE|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
58092640|NCT02803138|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
58092641|NCT02803138|DRUG|Dasabuvir|Tablet
58092642|NCT02803138|DRUG|Ribavirin|Tablet
58092643|NCT02803138|BEHAVIORAL|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
58092644|NCT06416527|DEVICE|Photobiomodulation (Experimental)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each).
58092645|NCT06416527|PROCEDURE|Pompage Technique (manual therapy)|To perform cervical Pompage the patient lies comfortably on their back or sits upright. The therapist locates the target area on the cervical spine. Using gentle pressure, the therapist applies traction to the cervical spine, stretching the muscles and fascia. The traction is held for 20 seconds. The therapist then releases the traction, allowing the cervical spine to return to its neutral position. This process will be repeated 3 times, with adjustments made based on the patient's response and comfort level.
58092646|NCT06416527|DEVICE|Photobiomodulation (Placebo)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each) with the device turned off (inactive), simulating the time with a recorded beep sound.
58092647|NCT05659264|DRUG|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
58092648|NCT05659264|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
58092649|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
58092650|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
58092651|NCT06521138|BEHAVIORAL|Motivational interviewing group|The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
58092652|NCT06521138|OTHER|Control group|Participants in the control group will receive routine care at the center.
58092653|NCT05166512|BEHAVIORAL|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
58092654|NCT05166512|BEHAVIORAL|DPP|Standard DPP
58419984|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
58419985|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
58419986|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
58419987|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
58419988|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
58419989|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
58092655|NCT06563492|DEVICE|insole|evaluation of individuals using different insoles
58092656|NCT04877535|DEVICE|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
57734897|NCT01380327|OTHER|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.
57950289|NCT05176119|DRUG|Nalbuphine Injection|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
57950290|NCT05176119|DRUG|Ketamine|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
57950291|NCT05176119|DRUG|Saline|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
57950292|NCT02744443|DIETARY_SUPPLEMENT|Leucine|
57950293|NCT02744443|DIETARY_SUPPLEMENT|Placebo|
57950294|NCT04739085|DIAGNOSTIC_TEST|Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
57950295|NCT04739085|DIAGNOSTIC_TEST|wDDART - Monocular near visual acuity using the best correction for distance|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
58092657|NCT01947257|OTHER|the measure TRVMAX|by transthoracic echocardiography
58092658|NCT01947257|OTHER|the measure of the pulmonary artery|by transesophageal ultrasound
58092659|NCT01947257|OTHER|the direct measure of the pulmonary pressures|by right catheterization
58092660|NCT00983255|DRUG|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
58092661|NCT00983255|DRUG|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
58092662|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
58092663|NCT01480882|PROCEDURE|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
58092664|NCT01480882|DEVICE|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
58419990|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
58419991|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
58092665|NCT02417207|DRUG|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
58095319|NCT04329013|OTHER|Left lateral Position during intervention|Left lateral position during EGD
58419992|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
58419993|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
58419994|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
58419995|NCT02580513|BEHAVIORAL|Circadian Misalignment|
58419996|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
58419997|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
57950296|NCT01734577|PROCEDURE|Dry needling|Sterile monofilament needles
57950297|NCT01734577|PROCEDURE|Sham needling|Applicator tubes from the sterile monofilament needles
57950298|NCT03754075|PROCEDURE|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
57950299|NCT03754075|PROCEDURE|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
57950300|NCT03379272|DEVICE|GOLDSTANDARD|RECORDING WITH EEG GOLDSTANDARD
57950301|NCT03379272|DEVICE|NEURONAUTE|RECORDING WITH NEURONAUTE
57950302|NCT04885725|DEVICE|All group|All the participants performed the isokinetic proprioception and strength tests and the functional tests, on the same visit.
57950303|NCT05722119|DIAGNOSTIC_TEST|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
57950304|NCT04752709|DEVICE|ELITONE UUI|External electrical stimulation
57950305|NCT05261958|OTHER|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
57950306|NCT03471039|DRUG|PACAP27|Infusion of PACAP27 over 20 minutes.
57950307|NCT03471039|DRUG|Saline|Infusion of Saline over 20 minutes.
57950308|NCT03820622|DEVICE|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
57950309|NCT03820622|DEVICE|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
57950310|NCT00897663|GENETIC|gene expression analysis|
57950311|NCT00897663|GENETIC|microarray analysis|
57950312|NCT00897663|GENETIC|protein expression analysis|
57950313|NCT00897663|OTHER|diagnostic laboratory biomarker analysis|
57950314|NCT00897663|OTHER|immunohistochemistry staining method|
57950315|NCT02682628|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
57950316|NCT01570504|DRUG|Ivermectin|oral formulation
57950317|NCT01255527|DRUG|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
57950318|NCT03357679|PROCEDURE|Tracheal intubation|Intubation of the trachea with endotracheal tube
58095320|NCT04329013|OTHER|Prone Position during intervention|Prone position during EGD
58095321|NCT03307902|BIOLOGICAL|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
58419998|NCT00206882|DRUG|corticosteroids|
58419999|NCT00220207|BEHAVIORAL|Internet co-management module|
57950319|NCT03357679|DEVICE|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
57950320|NCT03357679|DEVICE|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
57950321|NCT02634853|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
57950322|NCT02634853|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
57950323|NCT01803321|DRUG|rilonacept (IL-1 Trap)|
57950324|NCT01803321|OTHER|Placebo|
57950325|NCT04551937|OTHER|Lactose Free 1% Milk|8 oz of study beverage daily
57950326|NCT04551937|OTHER|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
57950327|NCT03852251|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
57950328|NCT03852251|DRUG|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
57950329|NCT03852251|DRUG|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
58092666|NCT02417207|DRUG|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
58092667|NCT03542253|PROCEDURE|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
58092668|NCT04160416|DRUG|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
58092669|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
58092670|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
58092671|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
58092672|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
58092673|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
58092674|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
58092675|NCT05992285|DEVICE|transcranial magnetic stimulation|the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
58092676|NCT04526379|BEHAVIORAL|Questionnaires|Evaluation of behavioral disorders of children with PWS by questionnaires
57950330|NCT00658476|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 fatty acid supplements.
57950331|NCT00658476|BEHAVIORAL|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
57950332|NCT00658476|OTHER|Placebo|
57950333|NCT04919642|DRUG|TT-00420|TT-00420 tablet, administered orally once daily
57950334|NCT04161430|DRUG|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
57950335|NCT04161430|DRUG|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
57950336|NCT04161430|DRUG|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
57950337|NCT02581202|DRUG|lopinavir/ritonavir|tablet
57950338|NCT02581202|DRUG|lamivudine|tablet
57950339|NCT03581786|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
57950340|NCT03581786|DRUG|Placebos|placebo combine with chemotherapy
57950341|NCT00872651|DRUG|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
58306053|NCT04044105|OTHER|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
58306054|NCT02271451|DEVICE|Q collar|collar worn around neck
58306055|NCT01292408|DRUG|Hydrochloroquine|800 mg per os once, and then 400 mg per day
57950342|NCT00872651|DRUG|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
57950343|NCT00370279|PROCEDURE|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
57950344|NCT03445871|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
57950345|NCT03445871|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
58092677|NCT04526379|DEVICE|t-VNS|Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
58092678|NCT03542500|BEHAVIORAL|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
58095322|NCT03307902|BIOLOGICAL|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
58095323|NCT03307902|BIOLOGICAL|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
58306056|NCT04527588|OTHER|Questionaire Michigan|Patient-Reported Outcome Measures (PROMs) are important clinical items for evaluating injuries and recovery of the hand. The Michigan Hand Questionnaire is one of the most important.
58306057|NCT04341935|DRUG|Linagliptin|5 mg Linagliptin administered by mouth once daily
58306058|NCT04341935|DRUG|Insulin regimen|Standard of care insulin regimen as per hospital protocol
58092679|NCT03542500|BEHAVIORAL|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
58092680|NCT04682210|DRUG|Sintilimab|Sintilimab 200mg IV Q3W
58092681|NCT04682210|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
58092682|NCT04856917|DRUG|Imsidolimab|Humanized Monoclonal Antibody
58092683|NCT04856917|BIOLOGICAL|Placebo|Placebo
58092684|NCT03949283|DIAGNOSTIC_TEST|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
58092685|NCT03949283|DRUG|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
58092686|NCT00263393|DRUG|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
58092687|NCT00263393|BEHAVIORAL|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
58092688|NCT06689592|DEVICE|Transcranial Magnetic Stimulation|Intermittent theta burst stimulation
58092689|NCT00039572|DRUG|boronophenylalanine-fructose complex|
58092690|NCT06133907|GENETIC|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
58092691|NCT02310815|DEVICE|ReSure Sealant|
58092692|NCT01590537|DRUG|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
58092693|NCT01590537|DEVICE|Copper IUD|Copper device, inserted intrauterine
58092694|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
58092695|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
58092696|NCT04454957|BEHAVIORAL|Mastering Diabetes|Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
58092697|NCT03750916|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
58092698|NCT00295529|BEHAVIORAL|Multifaceted educational intervention|Educational materials available at end of study
58092699|NCT01319747|PROCEDURE|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
58092700|NCT01319747|PROCEDURE|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
58092701|NCT02628418|OTHER|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
58092702|NCT02628418|DEVICE|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
58092703|NCT02628418|OTHER|Specific hand rehabilitation performed by physiotherapist|"The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
58092704|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
58092705|NCT06698614|DIAGNOSTIC_TEST|MRI|MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).
58092706|NCT06698614|DIAGNOSTIC_TEST|Blood tests|full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
58092707|NCT06698614|DIAGNOSTIC_TEST|Urine tests|Urine protein, Urine creatinine
58092708|NCT06698614|DIAGNOSTIC_TEST|Cardiovascular analysis|24 hour blood pressure, arterial stiffness
58092709|NCT05290805|DIAGNOSTIC_TEST|ECMO flow rate reduction|ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
57734898|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
57734899|NCT03600337|BEHAVIORAL|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
58092710|NCT06354439|DRUG|Letrozole tablets|10 mg of letrozole PO for 7 days
58092711|NCT06354439|DRUG|Methotrexate Sodium|100 mg of methotrexate IM, single dose
58092712|NCT01776060|OTHER|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
58092713|NCT04180371|DRUG|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
58092714|NCT04180371|DRUG|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
58092715|NCT04541433|DRUG|AZD9833|AZD9833 taken orally
58092716|NCT03548454|DRUG|Duloxetine|Open label prescription
58092717|NCT03548454|DRUG|Desipramine|Open label prescription
58092718|NCT06568614|DRUG|SYH2039|SYH2039 dosed orally
58092719|NCT02791581|DIAGNOSTIC_TEST|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
58092720|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
58092721|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
58092722|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
58092723|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
58092724|NCT06489028|DRUG|allo-APZ2-CVU|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
57734900|NCT06308939|DRUG|Eribulin|1.4mg/m\^2 day1、8，repeated every 3 week.
57734901|NCT06308939|DRUG|Sintilimab|500mg once every three weeks.
57734902|NCT06030609|DRUG|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
58092725|NCT06489028|DRUG|Placebo|Placebo
58092726|NCT00771654|DRUG|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
58092727|NCT00771654|OTHER|Placebo|daily for one year
58092728|NCT04681807|BEHAVIORAL|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
58092729|NCT04681807|BEHAVIORAL|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
58092730|NCT06701799|PROCEDURE|CAF+ L-PRF 1 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
58306059|NCT02963480|PROCEDURE|Cardiac Surgery|
58092731|NCT06701799|PROCEDURE|CAF+ L-PRF 2 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
58092732|NCT02937285|DRUG|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
58092733|NCT02937285|DRUG|Mitoxantrone|10 mg / m² monthly infusion for 6 months
58092734|NCT01398449|RADIATION|Elective nodal irradiation (ENI)|
58092735|NCT01398449|OTHER|Adjuvant chemotherapy only|
58092736|NCT06123975|OTHER|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
58092737|NCT01248130|DRUG|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
58092738|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers."
58092739|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
58092740|NCT04338646|OTHER|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
58092741|NCT04308382|BEHAVIORAL|Health Risk Assessment|"Heath Risk Assessment consists of:~* Survey to include questions about physical activity, stress, hope, household hunger and demographics.~* Lipid panel and HbA1c~* Height and Weight, blood pressure and resting pulse"
58092742|NCT05854745|BEHAVIORAL|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
58092743|NCT05854745|BEHAVIORAL|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
58092744|NCT04440631|OTHER|no intervention, observational only|no intervention, observational only
58092745|NCT06362252|DRUG|Ifinatamab deruxtecan|Intravenous administration
58092746|NCT06362252|DRUG|Atezolizumab|Intravenous administration
58092747|NCT06362252|DRUG|Carboplatin|Intravenous administration
58092748|NCT05828667|OTHER|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
58092749|NCT06418074|DIETARY_SUPPLEMENT|Ketone Monoester (KE4)|Each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4) 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
58092750|NCT06418074|OTHER|Placebo|Each subject will receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
58092751|NCT05718557|DRUG|PYX-106|Intravenous (IV) infusion
58092752|NCT04011111|PROCEDURE|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
58092753|NCT01721200|OTHER|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
57950346|NCT04290832|BEHAVIORAL|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
57950347|NCT00930761|BEHAVIORAL|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
57950348|NCT03709654|BIOLOGICAL|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
57950349|NCT03709654|OTHER|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
57950350|NCT04158622|PROCEDURE|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
57950351|NCT04158622|PROCEDURE|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
57950352|NCT02122328|PROCEDURE|Sequential laser photocoagulation of communicating vessels.|
57950353|NCT02122328|PROCEDURE|Selective laser photocoagulation of communicating vessels|
57950354|NCT01307215|DRUG|Ropivacaine|20mLs of 0.5%
57950355|NCT01307215|DRUG|Ropivacaine|30mLs of 0.33%
57950356|NCT01307215|DRUG|Ropivacaine|40mLs of 0.25%
57950357|NCT01986413|DEVICE|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
57950358|NCT01986413|DEVICE|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
57950359|NCT01986413|DEVICE|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
57950360|NCT00317109|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
57950361|NCT00317109|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
57950362|NCT00317109|BIOLOGICAL|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
57950363|NCT05114200|PROCEDURE|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
57950364|NCT00925015|BIOLOGICAL|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
57950365|NCT00925015|BIOLOGICAL|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
57950366|NCT00925015|DRUG|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
57950367|NCT00925015|BIOLOGICAL|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
57950368|NCT02770547|DEVICE|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
57950369|NCT02770547|DEVICE|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
57950370|NCT05597085|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
58420000|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
58420001|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
58420002|NCT02619721|DEVICE|PINS SNS|
58420003|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
58092754|NCT01721200|OTHER|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
58420004|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
58420005|NCT00214929|BEHAVIORAL|treatment at home|
58420006|NCT01462890|BIOLOGICAL|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
58420007|NCT01462890|DRUG|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
58420008|NCT01462890|DRUG|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
58420009|NCT01462890|OTHER|specialized pathology review (Germany only)|before randomization
58092755|NCT02049580|DRUG|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
58092756|NCT02049580|DRUG|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
58420010|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
58420011|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
57950371|NCT00706251|DEVICE|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
57950372|NCT01042015|COMBINATION_PRODUCT|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
58420012|NCT01238978|DRUG|Vildagliptin|
58420013|NCT01238978|DRUG|"Usual Care"|
57950373|NCT01042015|OTHER|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
58420014|NCT05686096|DRUG|MYK-224|Specified dose on specified days
58420015|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
58420016|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
58420017|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
57734903|NCT06030609|DRUG|Normal saline|The patient will receive NSS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
58306060|NCT05591521|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
58306061|NCT03608826|DEVICE|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
58306062|NCT03290625|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
58306063|NCT03290625|DRUG|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
58306064|NCT01622556|DRUG|Fludarabine|35 mg/m2 IV/day x 5 days
58306065|NCT01622556|DRUG|Busulfan|.8 mg/kg IV Q6h x 8 doses
58306066|NCT01622556|DRUG|Thymoglobulin|1.5 mg/kg/day x 3 days
58306067|NCT01622556|RADIATION|Total Body Irradiation|150 cGy for 2 days
58306068|NCT01622556|BIOLOGICAL|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
58420018|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
58420019|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
58420020|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
58092757|NCT02049580|DRUG|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
58092758|NCT06543095|OTHER|Pain level|Post-operative pain levels of the patients with detected using VAS score.
57950374|NCT01732497|DEVICE|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
58092759|NCT04668131|DRUG|Sodium hyaluronate eye drops|eye drops, three times a day
58092760|NCT04668131|OTHER|acupuncture|three times a week
57734904|NCT06482372|DEVICE|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation at both cerebral hemisphere
57734905|NCT04482647|OTHER|Media Intervention|View instructional video
57734906|NCT04482647|PROCEDURE|Meditation Therapy|Perform meditation
57950375|NCT04749823|OTHER|Blended treatment program|A combined treatment program with specific active neck exercises and general aerobic training in counteractive amount will be executed during 12 weeks. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
57950376|NCT04749823|OTHER|Specific strength exercise program|This program includes an individual, patient-tailored exercise program with the aim of retraining the neck musculature. A detailed exercise programme will be constructed in which all exercises are listed with the amount of repetitions and series of each exercise. Strength exercises will be performed by means of dumbbells with different weights and elastic bands with different degrees of resistance. The amount of weight or resistance, and the amount of series and repetitions will be evaluated during the first session. This exercise programme will be re-evaluated repeatedly during the course of the program. Specific strength neck exercises will be performed for 30 minutes. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
57950377|NCT04749823|OTHER|General aerobic exercise program|This control group will receive a general aerobic exercise program. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
57950378|NCT03096964|OTHER|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
57950379|NCT03096964|OTHER|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
57950380|NCT01179464|DRUG|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
57950381|NCT01179464|DRUG|Simvastatin|40 mg once daily
57950382|NCT04038788|DEVICE|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
57950383|NCT04368728|BIOLOGICAL|BNT162b1|Intramuscular injection
57950384|NCT04368728|BIOLOGICAL|BNT162b2|Intramuscular injection
57734907|NCT04482647|OTHER|Quality-of-Life Assessment|Ancillary studies
57950385|NCT04368728|OTHER|Placebo|Intramuscular injection
57950386|NCT04368728|BIOLOGICAL|BNT162b2SA|Intramuscular injection
57950387|NCT01012791|OTHER|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
57950388|NCT01102647|DIETARY_SUPPLEMENT|phytosterol ester|1.6 g phytosterols/day for 29 days
57950389|NCT03478111|DRUG|CMAB008|the study drug
57950390|NCT03478111|DRUG|MTX|basic therapy drug
57950391|NCT03478111|DRUG|Remicade|active comparator
58092761|NCT02660775|BEHAVIORAL|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)"
58092762|NCT02660775|BEHAVIORAL|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
58092763|NCT02660775|BEHAVIORAL|Healthy controls|only social cognitive measures
58306069|NCT02631395|OTHER|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
57734908|NCT04482647|OTHER|Questionnaire Administration|Ancillary studies
57950392|NCT01485627|BEHAVIORAL|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
57950393|NCT05909956|OTHER|KinesioTape|The kinesio tape technique, one of the physiotherapy techniques, is an elastic thin band, water-resistant, air-permeable framework to stimulate muscle movements, assist weak muscles (fascia and soft tissue), reduce discomfort and muscle cramps, facilitate proprioceptive input, boost lymph and blood flow, and relieve pain. Participants in the KT group will receive therapeutic tape on the sacral and suprapubic regions with the Star shape and ligament technique (From initial 4 h to 72 h of the menstruation cycle)
57950394|NCT05909956|OTHER|Sham Tape|This group will receive KT tapping without stretch on the sacral and suprapubic region.
57950395|NCT05909956|OTHER|General Physio session|General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck \& upper trapezius, arm \& shoulder girdle, triceps brachii, teres major \& minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
57950396|NCT03978195|DEVICE|Non-invasive device for middle ear ventilation|Daily use of the device
57950397|NCT04817644|DRUG|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
57950398|NCT02872740|PROCEDURE|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
57950399|NCT02872740|PROCEDURE|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
57950400|NCT04354714|DRUG|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
57950401|NCT04354714|PROCEDURE|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
57950402|NCT05876052|DEVICE|Hypothermic oxygenated Perfusion - HOPE|HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
57950403|NCT01457209|OTHER|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
57950404|NCT06424938|PROCEDURE|Patients who underwent epidural block|The researchers administered an epidural block to prevent post-operative pain to the epidural block group undergoing midline incision surgery for major gynecologic cancer.
57950405|NCT06424938|PROCEDURE|Patients who underwent erector spina plane block|Researchers applied a erector spina plane block to prevent postoperative pain to the erector spina plane block group undergoing midline incision surgery for major gynecological cancer.
57950406|NCT05569707|DEVICE|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with SPIO particles (Magtrace®).
57950407|NCT02471495|DEVICE|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
57950408|NCT04347707|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
57950409|NCT02055105|PROCEDURE|miRNA in Sepsis|miRNA in Sepsis
57950410|NCT05365503|OTHER|Shamiri Intervention|The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
57950411|NCT03328546|OTHER|Dietary intake|Dietary intake converted into dietary pattern scores.
57950412|NCT06424028|OTHER|Right Ventricular Infarct|Consecutive patients presented with isolated inferior, infero-posterior and inferolateral wall MI with or without acute right ventricular infarction.
57734909|NCT04482647|PROCEDURE|Yoga|Perform breathing techniques
57734910|NCT01821469|BEHAVIORAL|psychoeducation|Bipolar disorders are educated to learn about their pathology
58092764|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
58092765|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
58420021|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
58092766|NCT06568991|DIETARY_SUPPLEMENT|Low Protein Rice MATSUBUMAI|"Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group."
58092767|NCT00993629|DRUG|pregnenolone|"Administered adjunctively to treatment as usual"
57950413|NCT05427552|DEVICE|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 \* (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8\*6=16.8(%) were added to the normal intensity.
57950414|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
57950415|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
57950416|NCT01972867|DEVICE|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
58092768|NCT00993629|DRUG|placebo|adjunctive placebo
58092769|NCT03649607|OTHER|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
58092770|NCT03923907|BEHAVIORAL|EIM intervention group|As in arm description
57950417|NCT02237521|OTHER|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
58306070|NCT02631395|OTHER|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
58092771|NCT06703762|OTHER|He-Ne low level laser (LLL)|Patients in the experimental group will receive treatment with LLLT. The ulcer bed will be irradiated locally with red light (660 nm). The ulcer size and its depth will be used as the basis to calculate the duration of exposure needed to deliver 3-10 J/cm² for 15 to 20 minutes. The application will take place in 3 sessions per week for 4 weeks. Each patient will be asked to lie in a supine position with the ulcer easily exposed to the laser beam, and they will be instructed to wear laser glasses and avoid looking directly at the beam until the end of the session.
58092772|NCT06703762|OTHER|Conventional traditional treatment|All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
58092773|NCT06702514|OTHER|Exercise|After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
58092774|NCT06702514|OTHER|Paraffin|It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
58092775|NCT06702514|OTHER|Balneotherapy|The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
58092776|NCT05004181|BIOLOGICAL|BNT162b2|Intramuscular (IM)
58092777|NCT05004181|BIOLOGICAL|Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
57950418|NCT02237521|OTHER|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
57950419|NCT06264700|BEHAVIORAL|Video Directly Observed Therapy (VDOT)|VDOT is an adherence-promoting intervention that involves partnering with an adolescent with SCD (or caregiver of a young patient with SCD) and observing the patient administer their hydroxyurea. In this study, VDOT will be delivered by a small business partner, Scene Health, via a smart phone app.
57950420|NCT06264700|BEHAVIORAL|Health Reminder Tip Alerts|"Participants randomized to this arm will receive an automated, daily, short health or safety tip alert (e.g. Time to get moving! You should be active for at least 30 minutes each day) to receive during the 180-day intervention period on their smartphone. The daily tip will be unrelated to hydroxyurea adherence. After the 180-day intervention period, participants complete a 180-day ongoing monitoring period where they will no longer receive these messages, but they will be reminded to continue to use their electronic adherence monitoring device. All participants will be offered a smart phone with a data plan at enrollment to ensure equal opportunity for participation."
57950421|NCT02268903|DRUG|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
57950422|NCT02268903|DRUG|Placebo|Placebo in one single direct intra venous injection
57950423|NCT01865409|BEHAVIORAL|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
57950424|NCT01735487|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
57950425|NCT01735487|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
57950426|NCT01735487|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
57950427|NCT01735487|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
57950428|NCT01735487|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
57950429|NCT00960661|DRUG|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
58092778|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.7)|Intramuscular (IM)
58092779|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.617.2)|Intramuscular (IM)
58092780|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
58092781|NCT05004181|OTHER|Observational|No vaccination within 3 months after Visit 1.
58306071|NCT01369381|PROCEDURE|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
58306072|NCT05633511|PROCEDURE|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
58306073|NCT05430906|DRUG|AK104 - Chemotherapy|AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
58420022|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
58420023|NCT02092402|OTHER|Fecal transplantation|
58420024|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
58420025|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
58420026|NCT00563862|PROCEDURE|Conventional RT|
58420027|NCT00563862|PROCEDURE|Accelerated RT|
58420028|NCT00563862|DRUG|Cisplatin|
58420029|NCT00563862|DRUG|5-fluorouracil|
58420030|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
57734911|NCT03911492|PROCEDURE|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
57950430|NCT00960661|DRUG|insulin lispro|titrated based on pre-meal glucose level; three times a day
57950431|NCT00960661|DRUG|Metformin|
58420031|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
57734912|NCT02635841|DRUG|Deferiprone|Ferriprox (deferiprone) 100 mg/mL oral solution
57950432|NCT00960661|DRUG|Insulin/ Glargine|
57950433|NCT05331521|DRUG|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
57950434|NCT05331521|DRUG|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
57950435|NCT05331521|RADIATION|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade II and 59.4 Gy in 1.8 Gy fractions for grade III gliomas
57950436|NCT00971178|DRUG|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
57950437|NCT00971178|DRUG|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
57734913|NCT03620942|DRUG|Phenylephrine|"Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
57950438|NCT00971178|DRUG|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
57950439|NCT01337856|OTHER|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
57950440|NCT04255446|DEVICE|Thora3DiTM|Not international
57950441|NCT06240832|OTHER|Physical therapy exercise|Endurance, strength and stretching training in Chronic liver disease children
58092782|NCT05996523|BIOLOGICAL|PRGN-2009|PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
58420032|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
58420033|NCT00215865|DRUG|PEGIntron plus ribavirin|
58420034|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
58420035|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
58420036|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
58420037|NCT01467388|PROCEDURE|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
58420038|NCT06141837|OTHER|Observation|No intervention: observational study
58420039|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
58420040|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
58420041|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
58420042|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
58420043|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
58420044|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
58420045|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
58420046|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
58420047|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
58420048|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
58420049|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
58420050|NCT00635089|DRUG|reslizumab|
58420051|NCT01013415|DRUG|HAART|
58420052|NCT01013415|BIOLOGICAL|T cells|
58420053|NCT02059954|PROCEDURE|Hysterectomy|
58092783|NCT05996523|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
58092784|NCT04393831|PROCEDURE|Retzius sparing|Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
58092785|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
58092786|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
58092787|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
57734914|NCT03620942|DRUG|Ephedrine|"Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min."
58092788|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
57734915|NCT03620942|DEVICE|ADIVA System|"1. When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate \< 60 beats/min;~2. When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~3. When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~4. When SBP \< 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min."
57734916|NCT03620942|DEVICE|DIVA System|"DIVA system works as below:~1. When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate \< 60 beats/min."
58092789|NCT06702462|OTHER|HFA-152A propellant|HFA-152A propellant is administered via oral inhalation
58092790|NCT06702462|OTHER|HFA-134A propellant|HFA-134A propellant is administered via oral inhalation
58092791|NCT00700037|DRUG|high-dose atorvastatin|20mg/day
58092792|NCT00700037|DRUG|low-dose atorvastatin|5mg/day
57734917|NCT00414700|DRUG|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
58092793|NCT06216080|OTHER|D-FF-OCT analysis of CVC|Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
58092794|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
58092795|NCT03666299|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
58092796|NCT03666299|DRUG|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
58092797|NCT04038255|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
58092798|NCT04038255|BEHAVIORAL|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.
58092799|NCT04038255|BEHAVIORAL|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
58092800|NCT04038255|BEHAVIORAL|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
58420054|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
58420055|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
58420056|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
58420057|NCT03561701|DRUG|Placebo|matching placebo capsule
58420058|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
58420059|NCT02668029|DRUG|medical air|Placebo
58420060|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
58420061|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
58420062|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
58420063|NCT04082780|OTHER|Placebo|Placebo arm
58420064|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
58420065|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
58420066|NCT01806649|DRUG|BKM120|
58420067|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
58420068|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
58420069|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
58420070|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
58420071|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
58420072|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
58420073|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
58420074|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
58420075|NCT00005053|DRUG|glufosfamide|
58420076|NCT00319241|BEHAVIORAL|Parenting Intervention|
58420077|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
58420078|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
57734918|NCT00414700|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
57734919|NCT05767944|OTHER|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal \& distal phalanges
58420079|NCT00037674|DRUG|Topiramate|
58420080|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
58420081|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
58420082|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
57734920|NCT05767944|OTHER|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks \& divisions
57734921|NCT01650259|DRUG|OAD|OAD except Trazenta tablets
57734922|NCT01650259|DRUG|Trazenta|Linagliptin
58420083|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
58420084|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
58420085|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
57950442|NCT03548935|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
57950443|NCT03548935|DRUG|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
57950444|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
58420086|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
57950445|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally(once daily) on Day 1
57950446|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
58420087|NCT01926769|DRUG|Metformin|
58420088|NCT02191839|DRUG|Alpha 1-Antitrypsin|
58420089|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
58420090|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
58420091|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
58420092|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
58420093|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
58420094|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
58420095|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
58420096|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
58420097|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
58092801|NCT04038255|BEHAVIORAL|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
58420098|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
58420099|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
58420100|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
58092802|NCT04038255|BEHAVIORAL|Brief advice on quitting smoking|Standard advice on how to quit smoking.
58420101|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
58420102|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
58420103|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
57950447|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
57950448|NCT05345964|DRUG|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
57950449|NCT05345964|DRUG|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
58092803|NCT04038255|BEHAVIORAL|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
58092804|NCT04798274|DEVICE|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
58092805|NCT06653244|DRUG|Injection|dexmedimidine infusion
58420104|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
58092806|NCT05531799|PROCEDURE|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
58092807|NCT01504789|BEHAVIORAL|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
58092808|NCT01504789|BEHAVIORAL|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
58420105|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
58420106|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
57734923|NCT06668935|DEVICE|To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists|All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
57950450|NCT04276714|OTHER|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
57950451|NCT04276714|OTHER|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
57950452|NCT03399877|BIOLOGICAL|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
57950453|NCT03399877|BIOLOGICAL|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
57950454|NCT03399877|BIOLOGICAL|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
57950455|NCT03569709|BEHAVIORAL|Aerobic Exercise|Progressive sub-threshold aerobic exercise
57950456|NCT03569709|BEHAVIORAL|Rest|No structured exercise.
57950457|NCT03569709|BEHAVIORAL|Stretching|Gentle progressive upper and lower extremity stretching program
57950458|NCT04746352|PROCEDURE|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
57734924|NCT01483001|DRUG|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
57734925|NCT02625623|DRUG|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
57734926|NCT02625623|DRUG|Irinotecan|Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
58420107|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
58420108|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
58420109|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
58092809|NCT01504789|BEHAVIORAL|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
58092810|NCT01504789|BEHAVIORAL|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
58092811|NCT00717158|BEHAVIORAL|Usual medical care|
58092812|NCT00717158|BEHAVIORAL|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
58092813|NCT00230217|DRUG|Rasburicase (SR29142)|
58092814|NCT01825499|OTHER|Registry|
58092815|NCT01261650|DEVICE|transcranial direct current stimulation|
58092816|NCT01261650|DEVICE|sham treatment|
58092817|NCT04188860|DRUG|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
58092818|NCT01062100|DEVICE|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
58092819|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
58092820|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
58420110|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
58420111|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
58420112|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
57734927|NCT02625623|DRUG|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
57734928|NCT02625623|OTHER|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
58092821|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
58092822|NCT06701786|PROCEDURE|Compressive Sutures (CSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1mm, 2 horizontal incisions of approximately 3mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed . The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones. Three compressive sutures will be placed on the repositioned flap.
58095324|NCT03910101|PROCEDURE|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
58092823|NCT06701786|PROCEDURE|Without Compressive Sutures (WCSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; than then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
58092824|NCT06702891|OTHER|Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing|The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
58092825|NCT01365741|OTHER|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
58092826|NCT06544265|BIOLOGICAL|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
58092827|NCT05810961|BIOLOGICAL|efgartigimod IV|infusion of efgartigimod
58092828|NCT05810961|OTHER|placebo|infusion of placebo
58092829|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
58092830|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
58092831|NCT00413465|DRUG|Escherichia Coli Endotoxin|
58306074|NCT01190917|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
58306075|NCT01190917|BEHAVIORAL|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
58306076|NCT05837195|DEVICE|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
58306077|NCT02536872|OTHER|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
58306078|NCT05493826|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical record
57950459|NCT04746352|PROCEDURE|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
57950460|NCT05941975|DEVICE|Visual Evoked Potential (VEP)|To assess the integrity of visual pathways through the optic nerves to the visual cortex, latencies and amplitudes of P100 will be measured after pattern-reversal stimuli.
57950461|NCT05941975|DEVICE|Somatosensory evoked potential (SSEP)|To assess the integrity of sensitive pathways through the peripheral nerves and dorsal spinal cord to the somatosensory cortex. For the upper limbs, latencies and amplitudes of N9, N13, P14, N20 and P25 will be measured after median nerve stimulation. For the lower limbs, latency and amplitude of P40 will be measured after tibial nerve stimulation.
57950462|NCT05941975|DEVICE|Transcranial magnetic motor evoked potentials (TCmMEP)|To measure the integrity of motor pathways, the central conduction times will be measured for upper and lower limbs through magnetic stimulations of the primary motor cortex and the spinal cord, at cervical and lumbar levels.
57950463|NCT05941975|DEVICE|Tesla Brain MRI|All patients will undergo a single brain MRI on a 3T scanner. The acquisition protocol will include high-resolution three-dimensional (3D) T2\*-weighted echo-planar imaging and 3D T2-FLAIR images acquired, respectively, during or after intravenous injection of a single dose (0.1mmol/kg) of gadolinium-based contrast material.
57950464|NCT05941975|DIAGNOSTIC_TEST|Blood test - Neurofilament light chain (NfL)|- Neurofilament light chain (NfL) will be tested (Quanterix's Simoa® Technology) in the serum of patients. To evaluate their variation over time, 3 time-point tests will be obtained at 6 months apart (at baseline, at 6- and 12-month follow-up).
57950465|NCT05941975|DIAGNOSTIC_TEST|Blood test - EBV serology|EBV serology will be assessed (VCA IgG) in the serum of patients to evaluate the variation of antibody titers over time (at baseline, at 6- and 12-month follow-up), and compare to titers at the time of diagnosis (when available in their medical record).
57950466|NCT03401515|DRUG|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
57950467|NCT03401515|OTHER|Normal saline|Normal Saline 1 ml every 6 hrs
58092832|NCT03425331|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
58092833|NCT03425331|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
58092834|NCT04083274|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
58092835|NCT04083274|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
58092836|NCT01987843|DRUG|MT-1303-Low|
58092837|NCT01987843|DRUG|MT-1303-Middle|
58092838|NCT01987843|DRUG|MT-1303-High|
57734929|NCT04028700|BIOLOGICAL|G6PD Deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
58092839|NCT01987843|DRUG|Placebo|
58092840|NCT06703294|PROCEDURE|Crow's feet injection filling|Patients with crow's feet of different degree were randomly divided into two groups, which were injected with bovine collagen and humanized collagen respectively
58092841|NCT06703294|PROCEDURE|Humanized collagen filling crow's feet|Bovine collagen filling crow's feet
58092842|NCT04064931|DIAGNOSTIC_TEST|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
58306079|NCT02633722|BEHAVIORAL|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
58306080|NCT02633722|BEHAVIORAL|Lifestyle Intervention D|Time limiting feeding (12-9pm)
58306081|NCT02502370|DRUG|observation alone|
58306082|NCT02502370|DRUG|LV5FU2|
58306083|NCT02502370|DRUG|FOLFOX|
58306084|NCT00560963|DRUG|everolimus|
58092843|NCT04926467|DRUG|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
58092844|NCT01935557|DRUG|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
58092845|NCT01935557|DRUG|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
58092846|NCT01345058|DRUG|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day."
58092847|NCT01345058|DRUG|levetiracetam|Low dose ≤1500 mg/day, High dose \>1500 mg/day
58092848|NCT06566183|PROCEDURE|Guideline-directed medical therapy (GDMT)|Participants receive guideline-directed medical therapy (GDMT).
58306085|NCT02302274|DRUG|flecainide iv|infusion over 10 min
58306086|NCT01003106|DRUG|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
58306087|NCT01003106|DRUG|Ranibizumab 2.0mg (monthly)|
58306088|NCT01003106|DRUG|Pro re nata (prn) ranibizumab|
58092849|NCT06566183|PROCEDURE|Coronary artery bypass grafting (CABG)|Participants receive coronary artery bypass grafting (CABG).
58306089|NCT01003106|PROCEDURE|Pro re nata (prn) Laser photocoagulation|
58306090|NCT03163446|BIOLOGICAL|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
58306091|NCT03163446|DRUG|Placebo|Placebo, given as a single 2 hour iv infusion
58306092|NCT06213987|DRUG|0.025% Tretinoin|Total duration of 8 weeks.
58306093|NCT00805259|BEHAVIORAL|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
58306094|NCT03908411|PROCEDURE|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
58306095|NCT03908411|PROCEDURE|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
58306096|NCT01701245|DEVICE|GammaCore|vagal stimulation
58306097|NCT04137198|DRUG|Sufentanil|intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
58306098|NCT00914368|DRUG|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
58306099|NCT01548404|DRUG|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
58306100|NCT01548404|DRUG|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
58092850|NCT06566183|PROCEDURE|Percutaneous coronary intervention (PCI).|Participants receive percutaneous coronary intervention (PCI).
57734930|NCT04028700|BIOLOGICAL|Non-G6PD deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
58092851|NCT04227769|DRUG|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
57950468|NCT04200261|DRUG|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
58092852|NCT05405478|DRUG|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
58092853|NCT05405478|DIAGNOSTIC_TEST|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
58092854|NCT01700335|DRUG|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
58092855|NCT05778227|DRUG|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
58092856|NCT05778227|DRUG|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
58092857|NCT05778227|DRUG|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
58092858|NCT05778227|DRUG|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
58092859|NCT05021120|DRUG|AK127|Subjects will receive AK127 by intravenous administration
58092860|NCT05021120|DRUG|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
58092861|NCT03123120|DRUG|Spesolimab|12 weeks treatment
58092862|NCT03123120|DRUG|Placebo|12 weeks treatment
58092863|NCT03253601|BEHAVIORAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
58092864|NCT02804191|DRUG|LO2A|eye drop solution.
58092865|NCT02804191|DRUG|Saline|Placebo
58092866|NCT04699721|DRUG|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
57950469|NCT04200261|DRUG|sodium chloride|sodium chloride
57950470|NCT02828553|OTHER|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
57950471|NCT02912572|DRUG|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
57950472|NCT02912572|DRUG|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
57950473|NCT02912572|DRUG|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
57950474|NCT02194751|BIOLOGICAL|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
58092867|NCT05264818|PROCEDURE|Glycocheck|Assessment of the sublingual microvascularization
58092868|NCT05264818|PROCEDURE|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
58092869|NCT05851612|PROCEDURE|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
58092870|NCT05851612|PROCEDURE|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
58092871|NCT05851612|PROCEDURE|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
57734931|NCT04440735|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
57950475|NCT04971291|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks
57950476|NCT04971291|DRUG|Bupropion SR|Bupropion taken twice daily for 6 weeks
57950477|NCT06003114|DRUG|Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment.
57950478|NCT01611974|DRUG|Maribavir|Tablet for oral administration
57734932|NCT04440735|BIOLOGICAL|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
58420113|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
57734933|NCT01195012|BEHAVIORAL|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
57734934|NCT01858168|DRUG|Olaparib|Tablets to be taken on an empty stomach twice a day.
57734935|NCT01858168|DRUG|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
58092872|NCT06700837|OTHER|Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea|To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
58092873|NCT05552235|DEVICE|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
58092874|NCT05552235|OTHER|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
58092875|NCT06153667|DEVICE|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
58092876|NCT03911739|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
57734936|NCT01858168|DRUG|Irinotecan|Administered via IV
58420114|NCT00265265|DRUG|Atomoxetine|
58420115|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
57734937|NCT04717804|OTHER|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
57734938|NCT04717804|OTHER|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
57734939|NCT04952324|OTHER|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
57734940|NCT05323526|DIAGNOSTIC_TEST|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
57950479|NCT01483391|BEHAVIORAL|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
57950480|NCT01483391|BEHAVIORAL|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
58420116|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
58420117|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
58420118|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
58420119|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
58420120|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
57950481|NCT04911803|BEHAVIORAL|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
57950482|NCT04911803|BEHAVIORAL|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
57950483|NCT04643912|DIAGNOSTIC_TEST|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
57950484|NCT00006476|DRUG|suramin|
57950485|NCT00006476|PROCEDURE|conventional surgery|
57950486|NCT00798850|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.
58420121|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
58092877|NCT03911739|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
58420122|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
58420123|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
58420124|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
58420125|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
58420126|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
58420127|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
58420128|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
58420129|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
58420130|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
58420131|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
57734941|NCT05323526|DIAGNOSTIC_TEST|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
57734942|NCT00421499|DRUG|dark chocolate|
58092878|NCT06516549|OTHER|Skipping rope and informational pamphlet|The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
58092879|NCT01426828|BIOLOGICAL|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
58092880|NCT04219956|OTHER|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
58092881|NCT00876109|DRUG|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
58092882|NCT03267316|BIOLOGICAL|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
58092883|NCT03267316|DRUG|Cisplatin|Standard of care treatment
58092884|NCT03267316|DRUG|Gemcitabine|Standard of care treatment
58092885|NCT03267316|DRUG|Nab-paclitaxel|Standard of care treatment
58092886|NCT03267316|DRUG|Carboplatin|Standard of care treatment
58092887|NCT03267316|DRUG|Pemetrexed|Standard of care treatment
58092888|NCT06270537|DEVICE|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
58092889|NCT02095210|OTHER|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
58092890|NCT05676164|DEVICE|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
58092891|NCT05676164|DEVICE|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
58092892|NCT02395094|BEHAVIORAL|Child Life|"Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU"
57734943|NCT01416792|PROCEDURE|Centrifugation|
57734944|NCT01416792|PROCEDURE|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
57950487|NCT00798850|PROCEDURE|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
57950488|NCT00798850|PROCEDURE|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
57950489|NCT04133467|OTHER|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
57950490|NCT00426257|PROCEDURE|Secondary debulking|Secondary debulking
57950491|NCT00426257|PROCEDURE|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
57950492|NCT01956903|GENETIC|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
57950493|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
57950494|NCT05007951|BIOLOGICAL|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
57950495|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
57950496|NCT03698435|DRUG|Ganciclovir|Intravenous ganciclovir + TDM
57950497|NCT03698435|DRUG|Valganciclovir|Oral valganciclovir + TDM
57950498|NCT00530114|DRUG|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
57950499|NCT00530114|DRUG|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
57950500|NCT02543463|DEVICE|Trident X3 Insert with Navigation system|
57950501|NCT02543463|DEVICE|Trident X3 Insert with conventional instrumentation|
57950502|NCT02954367|DIETARY_SUPPLEMENT|PROTEIN|Immediately (\<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
57950503|NCT02954367|DIETARY_SUPPLEMENT|CARBOHYDRATE|Immediately (\<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
57950504|NCT00535132|DRUG|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
57950505|NCT00535132|DRUG|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
57950506|NCT01157364|DRUG|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
58092893|NCT06703086|DIETARY_SUPPLEMENT|Berberine Hydrochloride group|The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.
58092894|NCT06703086|BEHAVIORAL|nutritional plan|nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months
58092895|NCT06703086|BEHAVIORAL|controlled moderate aerobic exercise|controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.
58092896|NCT02444741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
57950507|NCT01157364|DRUG|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
57950508|NCT01157364|DRUG|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
57950509|NCT01157364|DRUG|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
57950510|NCT01157364|DRUG|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
58092897|NCT02444741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58092898|NCT02444741|OTHER|Laboratory Biomarker Analysis|Correlative studies
58092899|NCT02444741|BIOLOGICAL|Pembrolizumab|Given IV
58092900|NCT02444741|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
57950511|NCT01157364|DRUG|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
57950512|NCT01157364|DRUG|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
58092901|NCT02444741|RADIATION|Radiation Therapy|Undergo low dose radiation therapy
58092902|NCT02444741|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58092903|NCT06540677|OTHER|Musical training|Musical training with Meludia software, an online self-paced music training application
58092904|NCT00605839|DEVICE|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
58092905|NCT00605839|DEVICE|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
58092906|NCT00605839|OTHER|Usual Care|This intervention was usual care, without either device.
58092907|NCT05500235|BEHAVIORAL|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
58092908|NCT05500235|BEHAVIORAL|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
57734945|NCT02808962|PROCEDURE|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
57734946|NCT00000457|DRUG|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
57734947|NCT00000457|DRUG|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
57734948|NCT06525623|OTHER|Recommendation: No Further Resuscitation|Treatment teams are encouraged not to administer any additional fluids
57950513|NCT01509196|DRUG|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
58092909|NCT04278833|DRUG|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
58092910|NCT04278833|DRUG|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
58420132|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
58420133|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
58420134|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
58092911|NCT04918927|DRUG|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
58092912|NCT04918927|DRUG|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
58092913|NCT04918927|OTHER|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
58092914|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
58092915|NCT06494059|OTHER|Intermittent theta burst stimulation (iTBS)|iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
58092916|NCT06494059|OTHER|Functional electrical stimulation (FES)|FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
58092917|NCT06494059|OTHER|Transcutaneous spinal cord stimulation (TSCS)|TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
58092918|NCT06494059|OTHER|Sham Intermittent theta burst stimulation (iTBS)|Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
58092919|NCT00865306|BEHAVIORAL|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
58092920|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
58092921|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
58092922|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
58092923|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
58092924|NCT06371079|DEVICE|phakic intraocular lens implantation traditional|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of both cohesive and dispersive OVD
58095325|NCT04681495|BEHAVIORAL|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
58306101|NCT04957901|DRUG|modified BFM-95 protocol|Clinical stage system, risk stratification and treatment for pediatric mature B-NHL were according to the modified BFM-95 protocol. The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
58306102|NCT04697797|OTHER|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
58420135|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
58420136|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
58420137|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
58420138|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
58306103|NCT03030521|DIAGNOSTIC_TEST|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
58420139|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
57734949|NCT06525623|OTHER|Recommendation: Resuscitation with Crystalloid|Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
57734950|NCT06525623|OTHER|Recommendation: Resuscitation with Colloid|Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
58420140|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
58420141|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
58420142|NCT01020903|DRUG|Placebo|Orally, pre-op
57734951|NCT06525623|OTHER|Recommendation: Standard of Care IV Albumin|Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
57950514|NCT05339295|DRUG|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
57950515|NCT02180555|OTHER|Oral glucose tolerance test|
57950516|NCT04818684|OTHER|questionnaire|a questionnaire consisting of a list of support practices
57950517|NCT02401828|DRUG|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
57950518|NCT05376865|DIETARY_SUPPLEMENT|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
57950519|NCT01956513|OTHER|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
57950520|NCT00845650|BIOLOGICAL|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
57950521|NCT00845650|BIOLOGICAL|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
57950522|NCT00845650|BIOLOGICAL|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
57950523|NCT00845650|BIOLOGICAL|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
57950524|NCT00845650|BIOLOGICAL|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
57950525|NCT00845650|BIOLOGICAL|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
57950526|NCT02755311|PROCEDURE|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
57950527|NCT02755311|PROCEDURE|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
57950528|NCT02755311|DRUG|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
57950529|NCT02755311|DRUG|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
57950530|NCT02755311|DRUG|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
57950531|NCT02755311|OTHER|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
57950532|NCT04918199|DEVICE|Computer based assessment (iBox)|Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
57950533|NCT04918199|OTHER|Physician assessement|Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
57950534|NCT00067028|DRUG|Clofarabine 40mg/m^2|40 mg/m\^2 by vein over 1 hour daily for 5 days.
58095326|NCT04760574|DIAGNOSTIC_TEST|Testosterone|Serum total testosterone and free testosterone level
58420143|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
58420144|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
57734952|NCT01517802|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
57734953|NCT01517802|DRUG|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
57734954|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
58420145|NCT00905203|OTHER|exercise|exercise training
58420146|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
58420147|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
58420148|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
58420149|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
58420150|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
58420151|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
57734955|NCT04213196|DRUG|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
58092925|NCT06371079|DEVICE|phakic intraocular lens implantation reduced OVD|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of only cohesive OVD without using dispersive OVD.
58092926|NCT04518475|DRUG|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
58092927|NCT04518475|DRUG|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
58092928|NCT03943199|DIAGNOSTIC_TEST|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
58092929|NCT02549885|OTHER|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
58092930|NCT02549885|OTHER|Static stretching|Static stretching of neck muscles.
58092931|NCT00122148|BEHAVIORAL|Feedback on provision of care|
58092932|NCT06476171|DIAGNOSTIC_TEST|Determination of the level of the studied biomarkers|Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
58092933|NCT06113783|DEVICE|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
58092934|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
58420152|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
57734956|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
58420153|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
58420154|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
58420155|NCT05440136|DRUG|Placebo (SC)|Administered SC.
58420156|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
58420157|NCT05440136|DRUG|Placebo (IV)|Administered IV.
58420158|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
58420159|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
57950535|NCT00067028|DRUG|Idarubicin 10mg/m^2|"10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
57950536|NCT00067028|DRUG|Ara-C 0.75 g/m^2|0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
57734957|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
57734958|NCT04213196|DRUG|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
58420160|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
57734959|NCT04213196|DRUG|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
57950537|NCT00067028|DRUG|Clofarabine 22.5mg/m^2|22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
57950538|NCT00067028|DRUG|Ara-C 1 g/m^2|1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
58420161|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
58420162|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
58420163|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
57734960|NCT04213196|DRUG|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
57734961|NCT04213196|DRUG|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
57950539|NCT00067028|DRUG|Idarubicin 6 mg/m^2|6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
57950540|NCT03900403|OTHER|Walnut Intake|40g of daily walnut intake for 12 weeks
57950541|NCT06156956|PROCEDURE|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14"
57950542|NCT00409084|PROCEDURE|endoscopic variceal band ligation|endoscopic variceal band ligation
57950543|NCT06082986|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
57950544|NCT05429827|OTHER|normal saline|Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
57950545|NCT05429827|DRUG|Dextrose 5% in water|Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
57950546|NCT05429827|DRUG|Dextrose 15% in water|Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
57950547|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
57950548|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone|20ml 0.2% Ropivacaine + 4mg Dexamethasone
57950549|NCT05973604|DIAGNOSTIC_TEST|Screening and Confirmatory diagnostic test for primary aldosteronism|Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is \>30, accompanied by elevated aldosterone values (\>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are \>5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are \>8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (\>6ng/dl) are found at the end of the test).
57950550|NCT03906097|OTHER|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
57950551|NCT02595151|DEVICE|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
57950552|NCT03966742|PROCEDURE|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
57950553|NCT02184078|DRUG|Nevirapine|
57950554|NCT02184078|DRUG|Rifabutin|
57950555|NCT00259883|DRUG|paroxetine|1 or 2 tablets once a day
57950556|NCT06537960|PROCEDURE|18FDG PET-CT|"18FDG PET-CT will be performed in 2 phases:~1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer~2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection."
58095327|NCT06459401|DEVICE|Propulsion Neuroprosthesis|A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
58420164|NCT01181024|DRUG|RO5303253|Single dose
58420165|NCT01181024|DRUG|RO5303253|Multiple doses
58420166|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
57734962|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
57734963|NCT04637204|DRUG|Cabozantinib|oral therapy
57734964|NCT04637204|DRUG|Axitinib|oral therapy
57734965|NCT02046980|PROCEDURE|Gufoni|
57734966|NCT02046980|PROCEDURE|Vibration|
57734967|NCT02046980|PROCEDURE|Sham|
57734968|NCT02049073|DRUG|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
57734969|NCT02049073|DRUG|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
57734970|NCT00989651|BIOLOGICAL|Bevacizumab|Given IV
57734971|NCT00989651|DRUG|Carboplatin|Given IV
58095328|NCT02993016|PROCEDURE|patient-specific instruments|
58420167|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
58420168|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
58092935|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
58092936|NCT06439511|DEVICE|Darwin smartphone app|The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
58092937|NCT06439511|DEVICE|Pulse oxymetry|Heart rate will be measured with pulsoe oximetry (gold standard)
58095329|NCT02993016|DEVICE|The Signature™ Vanguard|
57734972|NCT00989651|DRUG|Cisplatin|Given IP
57734973|NCT00989651|OTHER|Laboratory Biomarker Analysis|Correlative studies
57734974|NCT00989651|DRUG|Paclitaxel|Given IV or IP
57734975|NCT00989651|DRUG|Veliparib|Given PO
57734976|NCT06668064|DRUG|EYP-1901|Intravitreal Injection
57734977|NCT06668064|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
57734978|NCT05804565|PROCEDURE|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
57734979|NCT05804565|PROCEDURE|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
57950557|NCT04553120|BEHAVIORAL|Alternating single stimulus and multiple stimuli|"P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation)."
57950558|NCT05778058|DEVICE|Unilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
57950559|NCT05778058|DEVICE|Bilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
57950560|NCT05778058|DEVICE|Bilateral Sham Stimulation|Participants were shown that the device was working, but no current was given.
57950561|NCT05778058|DIAGNOSTIC_TEST|Bicycle Ergometer Test|Participants in this group were asked to perform bicycle exercise with maximum performance under 30 watts for 30 minutes.
57950562|NCT05778058|DIAGNOSTIC_TEST|Lactat Scout|For lactic acid analysis measurement, the middle fingertip of the athlete is disinfected with an alcohol swab and a blood sample is taken by puncturing the finger.The measuring range is 0.5 - 0.25 mmol/L.
57950563|NCT05778058|DIAGNOSTIC_TEST|Polar H10|RR times transferred to computer with Polar H10 are used in heart rate variability analysis. Heart rate data will be transferred to the Kubios program and heart rate variability parameters will be calculated and data on the autonomic nervous system (RMSSD, PNS index, Stress index, SNS index, pNN50, Power LF, Power HF and LF/HF ratio) will be obtained.
57950564|NCT05778058|DEVICE|Vagustim Device|Vagustim Health Technologies Vagus stimulator device is used for this experiment.
57950565|NCT02376270|DIETARY_SUPPLEMENT|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
57950566|NCT02376270|DIETARY_SUPPLEMENT|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
57950567|NCT04891094|DIAGNOSTIC_TEST|Ultrasound|daily ultrasound of the lung and the diaphragm
57950568|NCT04070742|DRUG|FMX101|
57950569|NCT01536600|DRUG|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
57950570|NCT06402708|DRUG|Chemotherapy|paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
57950571|NCT06402708|RADIATION|Radiotherapy|IMRT, 50Gy/25f
57950572|NCT02960828|PROCEDURE|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
57950573|NCT02960828|DRUG|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
57950574|NCT02960828|DEVICE|Subthreshold Laser|
57950575|NCT02526342|DEVICE|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
57950576|NCT03580252|OTHER|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
57950577|NCT01747642|DIETARY_SUPPLEMENT|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
57950578|NCT01747642|DRUG|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
57950579|NCT00868777|PROCEDURE|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
57950580|NCT04523311|BEHAVIORAL|Hypnosis.|Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
58095330|NCT02993016|PROCEDURE|conventional instruments|
58095331|NCT02993016|DEVICE|Vanguard PS(posterior stabilized)|
57734980|NCT05481879|DRUG|DYNE-101|Administered by IV infusion
57734981|NCT05481879|DRUG|Placebo|Administered by IV infusion
57734982|NCT03682718|DEVICE|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
58092938|NCT01861730|BIOLOGICAL|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
58092939|NCT01861730|BIOLOGICAL|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
58092940|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
58092941|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
58092942|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
58092943|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
58092944|NCT00159367|DEVICE|Repetitive magnetic stimulation to the quadriceps|
58092945|NCT01870752|PROCEDURE|Transplantation of previously cryopreserved ovarian tissu|
58092946|NCT05932407|DRUG|Vortioxetine Tablet|Vortioxetine Tablet
58092947|NCT05932407|DRUG|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
58092948|NCT05027425|DRUG|Durvalumab|1500 mg IV, Q4W
58092949|NCT05027425|DRUG|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
58092950|NCT05027425|PROCEDURE|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
58092951|NCT06291857|BIOLOGICAL|CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant|CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain
58092952|NCT06291857|BIOLOGICAL|Novavax COVID-19 Vaccine|Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant
58092953|NCT06291857|BIOLOGICAL|tNIV Vaccine|2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)
58092954|NCT06291857|BIOLOGICAL|Fluzone High Dose|Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
58092955|NCT06702436|OTHER|Observational Study|This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
58420169|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
57734983|NCT03682718|DRUG|Misoprostol|Misoprstol inserted vaginally for induction of labor
57734984|NCT05663515|DRUG|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
57734985|NCT05663515|DRUG|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
57734986|NCT04551170|DRUG|Theophylline|oral theophylline
57950581|NCT04523311|OTHER|Usual care|Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
57950582|NCT05294055|DRUG|Etoposide|Etoposide 1.5-1.8g/m2, single dose
57950583|NCT05294055|DRUG|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
57950584|NCT05294055|DRUG|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
57950585|NCT05294055|DRUG|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
57950586|NCT01438580|DRUG|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
57950587|NCT01438580|DRUG|aspirin|100mg aspirin was administrated every day
57950588|NCT04945070|DRUG|IGlarLixi|Switching T2DM subjects from MDI to iGlarLixi
57950589|NCT04945070|DRUG|MDI - Multiple dose insulin injection|Continuing with established MDI regimen
57950590|NCT04081350|DRUG|LY3471851|Administered SC
57950591|NCT04081350|DRUG|Placebo|Administered SC
57950592|NCT06282042|PROCEDURE|Early transcatheter edge-to-edge mitral valve repair (TEER).|TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.
57950593|NCT06282042|DEVICE|MitraClip|MitraClip
57950594|NCT06282042|OTHER|Optimal medical treatment|Optimal medical treatment
57950595|NCT06262958|BEHAVIORAL|ASSIST|Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.
57950596|NCT06262958|OTHER|Treatment as usual|Psychotherapy and/or psychotropic drug treatment
57950597|NCT02111161|DRUG|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
57950598|NCT02111161|DRUG|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
57950599|NCT04071821|DRUG|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
58092956|NCT03350880|OTHER|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
58092957|NCT03347929|DRUG|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
58092958|NCT03347929|DRUG|Placebo|10 days treatment with Placebo1 tablet twice daily
58420170|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
57950600|NCT04071821|DRUG|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
57950601|NCT02821507|DRUG|sirolimus and cyclophosphamide|
57950602|NCT04254068|BEHAVIORAL|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
57950603|NCT02260115|DEVICE|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
57950604|NCT02260115|PROCEDURE|Surgical Control|Surgery only
58092959|NCT03451227|DRUG|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
58092960|NCT03451227|DRUG|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
58092961|NCT04954625|PROCEDURE|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
58092962|NCT04954625|PROCEDURE|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
58092963|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
58092964|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
58092965|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
58092966|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
58092967|NCT05619809|DIETARY_SUPPLEMENT|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
58092968|NCT05619809|DIETARY_SUPPLEMENT|Protein supplement|Daily ingestion of protein supplement.
58092969|NCT05619809|DIETARY_SUPPLEMENT|Placebo supplement|Daily ingestion of a placebo dietary supplement.
58092970|NCT02257411|DEVICE|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
58092971|NCT05804240|DIAGNOSTIC_TEST|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
58092972|NCT06076538|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging|PET/MR scan utilizing FDG Radiopharmaceutical
58092973|NCT06195072|DRUG|Amlitelimab|"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"
57734987|NCT04551170|DRUG|Placebo|Placebo capsule or elixir
57734988|NCT03801239|DIAGNOSTIC_TEST|Urodynamic Study|during visit Week 0 patients had urodynamic study
57950605|NCT00338039|DRUG|Cetuximab|500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
57950606|NCT00338039|DRUG|Gemcitabine|"Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off."
57950607|NCT00338039|DRUG|Oxaliplatin|Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
57950608|NCT00338039|DRUG|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
57950609|NCT00338039|RADIATION|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
57950610|NCT02005809|PROCEDURE|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
57950611|NCT04451980|PROCEDURE|Subcutaneous adipose tissue biopsy|Percutaneous adipose tissue biopsy
57950612|NCT04451980|RADIATION|CT scan|CT scan of chest and abdomen without contrast
57950613|NCT04451980|DIAGNOSTIC_TEST|Oral glucose tolerance test|Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
57950614|NCT04451980|DIAGNOSTIC_TEST|Blood collection|Fasting blood collection for plasma cytokines and T cell phenotypes.
57950615|NCT03767023|OTHER|cross sectional|
57950616|NCT05378256|OTHER|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
57950617|NCT01358864|DRUG|BI 201335|BI 201335 once a day (QD) for 24 weeks
58092974|NCT06195072|DRUG|BI 1015550|Study participants will take the active investigational product BI 1015550 or matching placebo provided as film-coated tablets, administered orally BID.
57950618|NCT01358864|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
57950619|NCT01358864|DRUG|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
57950620|NCT01358864|DRUG|Placebo|Placebo to BI201335 for 24 weeks
57950621|NCT01620242|DRUG|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
57950622|NCT00000421|DRUG|Prednisone|
57950623|NCT00000421|DRUG|Placebo|
57950624|NCT02191254|DRUG|Antistax®|
57950625|NCT02191254|DRUG|Placebo|
58092975|NCT06195072|DRUG|Placebo|see Experimental Arm intervention description
57734989|NCT03801239|DIAGNOSTIC_TEST|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
57734990|NCT03801239|DIAGNOSTIC_TEST|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
57734991|NCT03801239|DIAGNOSTIC_TEST|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
57734992|NCT02820779|DEVICE|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
58092976|NCT03907540|DRUG|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
58092977|NCT03907540|DRUG|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
58092978|NCT03907540|DRUG|[14C]-KD025 200 mg capsule|test investigational medicinal product
58092979|NCT00736138|PROCEDURE|training and pellots|training and pellots
58420171|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
58420172|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
58420173|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
58420174|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
58420175|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
58420176|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
58420177|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
58420178|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
58420179|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
58420180|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
58420181|NCT01576185|DRUG|quizartinib|Via gavage
58420182|NCT01576185|DRUG|sorafenib tosylate|Via gavage
57950626|NCT02383732|BEHAVIORAL|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
57950627|NCT02383732|BEHAVIORAL|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
57950628|NCT02383732|BEHAVIORAL|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
57950629|NCT01880931|DRUG|Remifentanil|The effect site concentration of remifentanil
57950630|NCT00004873|DRUG|cisplatin|
57950631|NCT00004873|DRUG|docetaxel|
57950632|NCT00004873|DRUG|epirubicin hydrochloride|
57950633|NCT00004873|DRUG|fluorouracil|
57950634|NCT04195152|OTHER|Observational|No intervention
57950635|NCT02069405|OTHER|Relaxation Music|
57950636|NCT00116350|DRUG|Misoprostol|800 mcg sublingual misoprostol
57950637|NCT00116350|DRUG|Oxytocin|40 IU Oxytocin IV
57950638|NCT05908682|OTHER|Non-interventional study|This is not an interventional study
57950639|NCT03617991|OTHER|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
57950640|NCT02463409|DRUG|Theophylline|24 hour infusion of IV theophylline
57950641|NCT02216032|OTHER|TMW Curriculum|
57950642|NCT02216032|OTHER|Nutrition Curriculum|
57950643|NCT01870102|DRUG|Pelubiprofen IR (Pelubiprofen 30mg) TID|
57950644|NCT01870102|DRUG|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
57950645|NCT03603860|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
58092980|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
58420183|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
58420184|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
58420185|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
58420186|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
58420187|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
58420188|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
58420189|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
58420190|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
58420191|NCT02776592|OTHER|Cow's milk-based formula|
58420192|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
58420193|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
58420194|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
58420195|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
58420196|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
58420197|NCT00143377|DRUG|tolterodine SR, overactive bladder|
58420198|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
58420199|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
58420200|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
58420201|NCT04464824|OTHER|no intervention|no intervention
58420202|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
58420203|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
58420204|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
58420205|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
58420206|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
58420207|NCT02699372|DRUG|Placebo|
58420208|NCT02699372|DRUG|RO6889450|
58420209|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
58420210|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
58420211|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
58420212|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
58420213|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
58092981|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
58092982|NCT03256526|DRUG|Placebo|0 mg
58420214|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
57734993|NCT01925079|BEHAVIORAL|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
58092983|NCT03256526|DRUG|PF-06835919 Low Dose|75 mg once daily
58092984|NCT03256526|DRUG|PF-06835919 High Dose|300 mg once daily
58092985|NCT06315413|PROCEDURE|Socket preservation using xenograft and composite plug|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
58092986|NCT06315413|PROCEDURE|Socket preservation using xenograft and intentionally exposed d-PTFE|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
58306104|NCT03879031|DIAGNOSTIC_TEST|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT)."
58306105|NCT00044291|DRUG|atamestane|
58306106|NCT00044291|DRUG|toremifene|
58306107|NCT00044291|DRUG|letrozole|
58306108|NCT00044291|DRUG|aromatase inhibition|
58306109|NCT00044291|PROCEDURE|hormone therapy|
58306110|NCT00044291|PROCEDURE|endocrine therapy|
57734994|NCT01925079|OTHER|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
58092987|NCT04661124|DEVICE|SPECTRALIS|ophthalmic imaging device with head and chinrest
58092988|NCT04661124|DEVICE|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
58092989|NCT01129518|BIOLOGICAL|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
58092990|NCT01129518|BIOLOGICAL|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
58306111|NCT00044291|PROCEDURE|antiestrogen therapy|
58306112|NCT02755753|DRUG|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
58306113|NCT02755753|DRUG|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
58306114|NCT02755753|DRUG|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
58420215|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
58420216|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
57950646|NCT01535170|DIETARY_SUPPLEMENT|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
57950647|NCT03914794|DRUG|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
57950648|NCT01709149|DRUG|CK-2017357|CK-2017357 125 mg tablets twice daily
57950649|NCT01709149|OTHER|Placebo tablets|Tablets
57950650|NCT01709149|DRUG|Riluzole|Tablets
57950651|NCT05479942|OTHER|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~1. Left/right discrimination (Implicit motor imagery):~2. Explicit motor imagery~3. Mirror Therapy"
58306115|NCT03054428|DRUG|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
58306116|NCT03054428|DRUG|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
58306117|NCT03794895|DEVICE|Doppler|Doing doppler for women having IUCD associated menorrhagia
58306118|NCT00513929|DIETARY_SUPPLEMENT|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
58306119|NCT00381628|PROCEDURE|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
58306120|NCT06166563|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
58420217|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
58092991|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
58092992|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
58092993|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
58092994|NCT05084937|OTHER|CeliCAT form|Systematic summary to support transition
58092995|NCT01610284|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
58092996|NCT01610284|DRUG|BKM120|BKM120 100 mg once daily
58092997|NCT01610284|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
58092998|NCT00233376|PROCEDURE|Access to an antibiotic decision support system|
58420218|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
58420219|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
58420220|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
58420221|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
58420222|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
57950652|NCT05479942|OTHER|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
57950653|NCT00472433|DRUG|Alemtuzumab|
57950654|NCT00081159|DRUG|Doxorubicin hydrochloride|Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
57950655|NCT00081159|DRUG|Goserelin acetate|
57950656|NCT00081159|DRUG|Leuprolide acetate|
57950657|NCT00081159|DRUG|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
58092999|NCT00233376|BEHAVIORAL|Distribution of local antibiotic guidelines|
58420223|NCT02201836|OTHER|One time music therapy|
58420224|NCT02201836|OTHER|Group music therapy|
58420225|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
58420226|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
58420227|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
58093000|NCT01353794|DRUG|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
58093001|NCT02118818|GENETIC|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
58093002|NCT05851976|DRUG|Naproxen|Naproxen 500mg twice daily for 16 days
58093003|NCT05851976|DRUG|Duloxetine|Duloxetine 60mg daily for 14 days
58093004|NCT01462188|PROCEDURE|Immediate stenting|Primary coronary stenting
58093005|NCT01462188|PROCEDURE|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
58093006|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
58093007|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
58093008|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
57734995|NCT05725538|DEVICE|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
57734996|NCT05725538|OTHER|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
57734997|NCT04554875|DIAGNOSTIC_TEST|A scoring system|The scoring system was used to rate score patients.
57734998|NCT03961165|DRUG|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
57734999|NCT03961165|DRUG|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
57950658|NCT00081159|PROCEDURE|orchiectomy|
57950659|NCT00081159|RADIATION|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
57735000|NCT00159211|DRUG|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
57735001|NCT00159211|DRUG|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
57950660|NCT00000761|DRUG|Interferon gamma-1b|
57950661|NCT06182982|DEVICE|auricolotherapy|Magnetic bal plasters are applied on the ear surface
57950662|NCT02250820|DRUG|Dexmedetomidine|Nasal administration
57950663|NCT02250820|DRUG|Pentobarbital|Oral administration
57950664|NCT02250820|OTHER|Oral Placebo|Oral placebo will be cherry syrup
57950665|NCT02250820|OTHER|Nasal Placebo|Nasal placebo will be nasally atomized saline
57950666|NCT05744089|DEVICE|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
57950667|NCT04967937|OTHER|Strengthening, resistance exercise, plyometric and dynamic movement training|(1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
57950668|NCT01505842|PROCEDURE|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
57950669|NCT01505842|PROCEDURE|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
57950670|NCT04584528|OTHER|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
57950671|NCT01859728|DRUG|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
58093009|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
57950672|NCT01859728|DRUG|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
58093010|NCT02181842|DRUG|Pioglitazone|Pioglitazone tablets
58093011|NCT02653469|OTHER|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
58093012|NCT02653469|OTHER|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
58093013|NCT06700486|PROCEDURE|SOCKET SHIELD|in implant dentistry
58093014|NCT06700486|PROCEDURE|Immediate implant and sticky bone|in implant dentistry
58093015|NCT05601193|OTHER|autologous platelet-rich plasma|autologous PRP preparation was done by segregation of PRP following the centrifugation
58093016|NCT02642991|DEVICE|Phenacite|contact lens
58093017|NCT02642991|DEVICE|comfilcon A|contact lens
58093018|NCT03856879|BEHAVIORAL|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
58093019|NCT05145660|RADIATION|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
58420228|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
58420229|NCT01150643|GENETIC|gene expression analysis|
57735002|NCT05917405|DRUG|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
58093020|NCT05145660|DRUG|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
58093021|NCT04166526|DEVICE|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
58420230|NCT01150643|GENETIC|microarray analysis|
58420231|NCT01150643|GENETIC|polymerase chain reaction|
58420232|NCT01150643|GENETIC|polymorphism analysis|
58420233|NCT01150643|OTHER|immunohistochemistry staining method|
57735003|NCT05917405|DRUG|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
57735004|NCT05917405|DRUG|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
57735005|NCT05917405|DRUG|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
57735006|NCT00095264|DRUG|Darbepoetin Alfa|
57735007|NCT05699759|DRUG|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
57950673|NCT01859728|DRUG|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
57950674|NCT01859728|DRUG|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
58093022|NCT04166526|DEVICE|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
58093023|NCT03985800|OTHER|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
58093024|NCT03985800|OTHER|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
58093025|NCT05005000|BIOLOGICAL|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
58093026|NCT05005000|DRUG|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
58420234|NCT01150643|OTHER|laboratory biomarker analysis|
58420235|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
58420236|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
58420237|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
58420238|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
58420239|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
58420240|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
58420241|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
58420242|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
57735008|NCT06636279|PROCEDURE|Gas bubble technique|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
58093027|NCT00650637|DRUG|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
57735009|NCT00450086|DRUG|Budesonide|9 mg per day
58093028|NCT00650637|DRUG|nelfinavir|1250 mg twice a day
58093029|NCT00650637|DRUG|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
58093030|NCT00650637|DRUG|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
58093031|NCT00650637|OTHER|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
58093032|NCT00650637|DRUG|nelfinavir|nelfinavir 1250 mg twice a day
58093033|NCT00650637|DRUG|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
58093034|NCT02292732|DRUG|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
58093035|NCT02292732|DRUG|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
58093036|NCT02292732|DRUG|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
58093037|NCT02292732|DRUG|Placebo|Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
58093038|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
58093039|NCT00591526|DRUG|Arac|Ommit ARAC in the chemotherapy
58093040|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
58093041|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
57735010|NCT00450086|DRUG|Mesalazine|3 g per day
57735011|NCT00450086|DRUG|Placebo|0 g per day
57735012|NCT03861598|DRUG|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
57735013|NCT03755505|DIAGNOSTIC_TEST|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
57735014|NCT02283866|DRUG|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
57735015|NCT02283866|DRUG|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
58093042|NCT04059900|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
58093043|NCT04059900|DRUG|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
58093044|NCT05392712|DEVICE|Magnetometer|inspection equipment for magnetocardiography
58093045|NCT04560920|OTHER|Availability of contextual PGHD at the visit|Contextual PGD will be available in a display at the visit.
58093046|NCT02572427|OTHER|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
58093047|NCT02572427|OTHER|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
58093048|NCT04556773|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
58093049|NCT04556773|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
58093050|NCT04556773|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
58420243|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
58420244|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
57735016|NCT06257758|DRUG|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
57735017|NCT00022256|DRUG|motexafin gadolinium|
57735018|NCT00022256|RADIATION|radiation therapy|
58093051|NCT04556773|DRUG|Capivasertib|Capivasertib: administered orally
58306121|NCT05295381|DEVICE|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
58306122|NCT05295381|DEVICE|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
58420245|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
57950675|NCT04527302|COMBINATION_PRODUCT|ERP combined with high-definition active tDCS|"The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4)."
57950676|NCT04527302|COMBINATION_PRODUCT|ERP combined with sham tDCS|Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
57950677|NCT05260619|DRUG|lenalidomide|Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
57950678|NCT05029635|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
57950679|NCT05029635|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
57950680|NCT01692964|DEVICE|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
57950681|NCT04534478|DRUG|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
57950682|NCT03446950|PROCEDURE|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
57950683|NCT01053871|DRUG|propofol|conscious sedation using propofol
57950684|NCT01053871|DRUG|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
57950685|NCT01791348|OTHER|d2 test of attention|
57735019|NCT03336619|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
57950686|NCT02136030|DRUG|Liposomal amphotericin B|4mg/kg/day, IV infusion
57950687|NCT02136030|DRUG|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
57950688|NCT01794572|DRUG|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
57950689|NCT01794572|BIOLOGICAL|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
58093052|NCT04556773|DRUG|Anastrozole|Anastrozole: administered orally
58093053|NCT04556773|DRUG|Fulvestrant|Fulvestrant: administered as an IM injection
58093054|NCT04556773|DRUG|Capecitabine|Capecitabine: administered orally
58093055|NCT00973531|DEVICE|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
57735020|NCT03336619|DRUG|Placebo|Placebo administered orally twice daily for five days
57735021|NCT00383448|DRUG|Clofarabine|days -7 through -3: 40 mg/m\^2 intravenously over 2 hours
57735022|NCT00383448|PROCEDURE|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
57735023|NCT00383448|DRUG|Melphalan|day -2: 140 mg/m\^2 intravenously over 30 minutes
58093056|NCT00973531|DEVICE|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
58093057|NCT06698263|DRUG|Isotretinoin|ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
58093058|NCT06698263|DRUG|Control group (placebo)|placebo administration
58093059|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
58093060|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
58093061|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
58093062|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
58093063|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
58093064|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
58093065|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
58093066|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
58093067|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
58093068|NCT04729634|OTHER|Mobilization|Mobilization and breathing exercises according to clinical care
58093069|NCT00181974|DRUG|Tisseel Fibrin Sealant|
58093070|NCT04718272|PROCEDURE|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
57735024|NCT00383448|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
57735025|NCT00383448|DRUG|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
58093071|NCT03022318|DRUG|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
58093072|NCT06702917|DEVICE|GSI Cardiac Scan|"The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan."
58093073|NCT06702917|OTHER|Standard of Care CCTA|The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
58306123|NCT00572689|DRUG|Exenatide|10 microgram injected sub-cutaneously once
58093074|NCT06702917|OTHER|Research CCTA|The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
58093075|NCT01741259|DRUG|Meperidine|
58093076|NCT05260658|DRUG|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
58093077|NCT05260658|DRUG|Placebo|CFTX-1554 matching placebo
58093078|NCT06703593|DRUG|Alpha lipoic acid|ALA effectively inhibits nuclear factor-kappa B with subsequent decreasing proinflammatory cytokines production (TNF-α, IL-6) and increasing the release of anti- inflammatory cytokines such as interleukin-10 (Haghighatdoost and Hariri, 2019). Relying on the antioxidant and anti-inflammatory effect of Alpha lipoic acid confirmed by a variety of studies in vitro and in vivo, ALA is selected to be studied in Egyptian breast cancer patients who will be treated with doxorubicin including regimens.
58093079|NCT00956709|DRUG|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
58093080|NCT00956709|DRUG|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
58093081|NCT03290976|OTHER|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
58093082|NCT03290976|OTHER|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
58093083|NCT06700434|OTHER|Bleaching treatment|"After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session."
58093084|NCT05569421|DRUG|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
58093085|NCT05569421|DRUG|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
58093086|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
58093087|NCT06660407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58093088|NCT06660407|PROCEDURE|Computed Tomography|Undergo CT
58420246|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
58420247|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
57735026|NCT00383448|DRUG|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR\<25 mL/minute corrected)
58093089|NCT06660407|OTHER|Immunotherapy|Given immunotherapy
58093090|NCT06660407|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
58093091|NCT06660407|RADIATION|Spatially-fractionated Radiation Therapy|Undergo grid radiation therapy
58093092|NCT05987527|DIAGNOSTIC_TEST|Urine sample|Routine procedures
58093093|NCT05987527|DIAGNOSTIC_TEST|Blood sample|Routine procedures
58093094|NCT05987527|OTHER|Lifestyle questionnaire|Lifestyle questionnaire
58093095|NCT02525146|OTHER|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
58420248|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
58420249|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
58095332|NCT06568887|COMBINATION_PRODUCT|Dextrose Water|Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
58420250|NCT03684694|DRUG|Ibrutinib|Oral capsule.
58420251|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
58093096|NCT05845671|DRUG|Amivantamab 1050mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
58093097|NCT05845671|DRUG|Amivantamab 1400mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
58095333|NCT06568887|COMBINATION_PRODUCT|Corticosteroid Injection|Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
58095334|NCT00402779|DRUG|Erlotinib|150 mg by mouth daily
58095335|NCT00402779|DRUG|Placebo|Tablet by mouth daily
57735027|NCT00383448|DEVICE|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
58095336|NCT05924555|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
58306124|NCT00572689|GENETIC|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
58420252|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
58420253|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
58420254|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
58420255|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
58420256|NCT00049595|BIOLOGICAL|bleomycin sulfate|
58420257|NCT00049595|BIOLOGICAL|filgrastim|
58420258|NCT00049595|BIOLOGICAL|pegfilgrastim|
58420259|NCT00049595|DRUG|ABVD regimen|
58420260|NCT00049595|DRUG|BEACOPP regimen|
58420261|NCT00049595|DRUG|cyclophosphamide|
58420262|NCT00049595|DRUG|dacarbazine|
58420263|NCT00049595|DRUG|doxorubicin hydrochloride|
58420264|NCT00049595|DRUG|etoposide|
58420265|NCT00049595|DRUG|prednisone|
58420266|NCT00049595|DRUG|procarbazine hydrochloride|
57735028|NCT00383448|DRUG|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
58420267|NCT00049595|DRUG|vinblastine sulfate|
58420268|NCT00049595|DRUG|vincristine sulfate|
58420269|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
58420270|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
58420271|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
58420272|NCT05998135|DRUG|Atovaquone|Given PO
58420273|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
58420274|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
58420275|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
58420276|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
58420277|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
58420278|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
58420279|NCT00002039|DRUG|Foscarnet sodium|
58420280|NCT00024375|DRUG|DHA-paclitaxel|
58420281|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
58420282|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
58420283|NCT01713556|DRUG|Propranolol|
58093098|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
58093099|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
58420284|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
58420285|NCT01713556|DRUG|placebo|
57735029|NCT04969081|BEHAVIORAL|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
57735030|NCT04969081|OTHER|treatment as usual|usual treatment
58093100|NCT01447628|DRUG|Saline|intravenous, no active drug
58093101|NCT01447628|DRUG|Ferinject or CosmoFer|Intravenous, 1000 mg iron
58093102|NCT06700941|BIOLOGICAL|HPV vaccine|"The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated."
58093103|NCT03213769|DRUG|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
58093104|NCT03213769|DRUG|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
58095337|NCT05924555|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
58306125|NCT02667652|PROCEDURE|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
58306126|NCT02667652|PROCEDURE|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
58306127|NCT03055871|BEHAVIORAL|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
58306128|NCT03055871|BEHAVIORAL|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
58306129|NCT02524119|DRUG|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
58306130|NCT02524119|PROCEDURE|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
58306131|NCT04665908|OTHER|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
58420286|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
58420287|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
58420288|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
58420289|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
58420290|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
57735031|NCT01408368|PROCEDURE|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
57735032|NCT01408368|PROCEDURE|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
57735033|NCT00847262|DRUG|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
57735034|NCT00847262|DRUG|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
58093105|NCT03544606|DRUG|isosorbide mononitrate|40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
58093106|NCT03544606|DRUG|Placebos|In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
58306132|NCT00514085|BIOLOGICAL|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
58306133|NCT00514085|OTHER|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
57735035|NCT04052672|OTHER|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
57735036|NCT01587664|DEVICE|NewBreez ILP|NewBreez ILP implantation
57735037|NCT06255223|RADIATION|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
57735038|NCT06255223|RADIATION|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
57735039|NCT06255223|DRUG|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
57735040|NCT01556438|BIOLOGICAL|Tabalumab|Administered IV
57735041|NCT01556438|DRUG|Bortezomib IV|Administered IV
57735042|NCT01556438|DRUG|Bortezomib SC|Administered SC
57735043|NCT01556438|DRUG|Dexamethasone|Administered orally
57735044|NCT00017381|BIOLOGICAL|rituximab|Given IV
57950690|NCT03844165|BEHAVIORAL|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
57950691|NCT03844165|BEHAVIORAL|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
57950692|NCT00424424|DRUG|MK0719|
57950693|NCT06186960|DEVICE|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
57950694|NCT03243383|OTHER|DiaTOHC Program|"1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support"
57950695|NCT04257825|DEVICE|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
57950696|NCT05939024|OTHER|Muscle Energy Technique plus Conventional Physical Therapy|Post-Isometric Relaxation of the Muscle Energy Techniques will be applied to Spinal Stabilizers and Mechanoreceptors. Hold time will be 7 seconds with 5 seconds rest between two performance x 3 times /session. Whereas, Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
57950697|NCT05939024|OTHER|Conventional Physical Therapy|Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
57950698|NCT00256737|DRUG|Omeprazole|
57950699|NCT00639483|DRUG|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
57950700|NCT00639483|DRUG|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
57950701|NCT01964014|DRUG|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
57950702|NCT04052451|BIOLOGICAL|MET-2|Subjects will take study medication once daily for the duration of the study
57950703|NCT02898259|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
57950704|NCT02898259|DRUG|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~* Starting lenalidomide Dose (20mg)~* Calculated Creatinine Clearance: \>=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~* Calculated Creatinine Clearance: \>= 30 and \< 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
57950705|NCT02898259|DRUG|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
57950706|NCT01411436|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
57950707|NCT00547846|DRUG|PDC-748|
57735045|NCT00017381|DRUG|cyclophosphamide|Given IV
57735046|NCT00017381|BIOLOGICAL|filgrastim|Given SC
57735047|NCT00017381|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
57735048|NCT00017381|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
57950708|NCT04185688|OTHER|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
57950709|NCT00300664|DRUG|Human Growth hormone|
58093107|NCT02441959|PROCEDURE|Lumbar discectomy Open|Open Discectomy
58093108|NCT02441959|PROCEDURE|Lumbar discectomy Endoscopic|Endoscopic Discectomy
58093109|NCT05981365|DRUG|Voxelotor|Drug drug interaction
58093110|NCT05981365|DRUG|Bupropion|Drug drug interaction
58093111|NCT05981365|DRUG|Repaglinide|Drug drug interaction
58093112|NCT05981365|DRUG|Flurbiprofen|Drug drug interaction
58306134|NCT00514085|OTHER|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
58420291|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
57735049|NCT06668246|DEVICE|Vision-S™ 700, an immersive and compact phoropter with a tunable-focus lens, and Vision-R™ 800, a phoropter with a tunable-focus lens without immersion, with cycloplegic refraction serving as the gold|As of today, no published clinical studies have been conducted with the Vision-S™ 700 neither Vision R 800
57735050|NCT04333667|BEHAVIORAL|Intervention group|The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
57735051|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
57950710|NCT03775954|DIAGNOSTIC_TEST|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
57950711|NCT00047060|OTHER|A matched peripheral donor stem cells|A matched peripheral donor stem cells
57950712|NCT00047060|DRUG|cyclosporine|cyclosporine
57950713|NCT00047060|DRUG|fludarabine|fludarabine
57950714|NCT00047060|DRUG|Campath|Campath
57950715|NCT03205462|DRUG|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
57950716|NCT03205462|DRUG|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
57950717|NCT03205462|DRUG|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
57950718|NCT01437852|BIOLOGICAL|StrataGraft Skin Tissue|
57950719|NCT02316535|DRUG|Capecitabine|adjuvant chemotherapy;
57950720|NCT04671277|OTHER|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
57950721|NCT04608227|DEVICE|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
57950722|NCT04064502|DIAGNOSTIC_TEST|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
58093113|NCT05981365|DRUG|Omeprazole|Drug drug interaction
58093114|NCT05981365|DRUG|Midazolam|Drug drug interaction
58093115|NCT05981365|DRUG|Metformin|Drug drug interaction
58093116|NCT05981365|DRUG|Furosemide|Drug drug interaction
58093117|NCT05981365|DRUG|Rosuvastatin|Drug drug interaction
58093118|NCT00976859|BEHAVIORAL|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
58093119|NCT00976859|BEHAVIORAL|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
58093120|NCT06554665|OTHER|High-intensity interval training group|HIIT sessions will include a 3-minute warm-up, a 20-minute main exercise on a recumbent stepper, and a 2-minute cool-down. The HIIT main exercise will include ten 1-minute high-intensity exercises interspersed with ten 1-minute low-intensity exercises. The high-intensity level will start at 75% of the Heart Rate Reserve (HRR) and will be increased by 5% every 4 weeks to reach 90% at 12 weeks as tolerated.
58095338|NCT05924555|OTHER|Echography of upper leg|Determine upper leg muscle size
58095339|NCT05924555|OTHER|Hand grip strength with hand dynamometer|Determine muscle strength
58306135|NCT00514085|OTHER|pharmacological study|Starting dose of 50μg/kg/day as an IV push
58420292|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
58420293|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
58420294|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
58420295|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
57950723|NCT01761084|BEHAVIORAL|Exercise and behaviour change strategies|"1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
58093121|NCT06554665|OTHER|Moderate-intensity continuous training group|MICT sessions will include a 3-minute warm-up, a 20-minute main exercise on a recumbent stepper, and a 2-minute cool-down. The intensity of the MICT will start at 45% of the Heart Rate Reserve (HRR) and will be increased by 5% every 4 weeks to reach 60% at 12 weeks as tolerated.
58093122|NCT06554665|OTHER|Stretching group|Participants in the stretching group will receive 25 minutes of full-body stretching. The intensity of stretching will reach the point of feeling tightness or slight discomfort. Static stretching at each site will hold for 10-30 s and repeat 2-4 times.
58093123|NCT06638619|BEHAVIORAL|Biofeedback Fixation Training|This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.
58093124|NCT06638619|BEHAVIORAL|Saccadic Reading Training|Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
58093125|NCT02813785|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
58093126|NCT02813785|DRUG|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
58093127|NCT04233788|DEVICE|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
58093128|NCT03367949|OTHER|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
58093129|NCT06701890|OTHER|Blood sample collection|16 mL at inclusion 16 mL at 1 month after return from travel
58093130|NCT06701890|OTHER|Fecal sample collection|"1 sample at inclusion~1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel"
58093131|NCT00270179|DRUG|epoetin alfa|
58093132|NCT06540222|PROCEDURE|Sustained cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
58093133|NCT06540222|PROCEDURE|Routine (< 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
58093134|NCT05789303|DRUG|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
58093135|NCT05789303|DRUG|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
58093136|NCT05789303|DRUG|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
58093137|NCT05789303|DRUG|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
58420296|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
58420297|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
58420298|NCT00262847|DRUG|Carboplatin|Given IV
58420299|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
58420300|NCT00262847|DRUG|Paclitaxel|Given IV
58420301|NCT00262847|OTHER|Placebo|Given IV
58420302|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
58420303|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
58420304|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
58420305|NCT02204852|DRUG|Iloprost+eptifibatide|
58420306|NCT02204852|DRUG|Placebo|
58420307|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
58420308|NCT00803972|DRUG|Insulin Human Injection|injection
58420309|NCT00803972|DRUG|Insulin Lispro Injection|injection
58420310|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
58420311|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
58420312|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
58420313|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
58420314|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
58420315|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
58420316|NCT02539511|DRUG|CI-581a|
58420317|NCT02539511|DRUG|CI-581b|
58420318|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
58420319|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
57735052|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
57735053|NCT00781625|DIETARY_SUPPLEMENT|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
58420320|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
58420321|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
57735054|NCT00781300|DRUG|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
57735055|NCT00781300|DRUG|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
58093138|NCT05830123|DRUG|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
58093139|NCT00191256|DRUG|Gemcitabine|
58093140|NCT00191256|DRUG|Carboplatin|
58093141|NCT00191256|DRUG|Paclitaxel|
58306136|NCT05500586|DRUG|Glucagon response study|Please see information in group descriptions
58306137|NCT02217956|DRUG|Cisplatin|
58306138|NCT02217956|DRUG|Bevacizumab|
58306139|NCT05925192|OTHER|Observational study|N/A - observational study
58093142|NCT05489068|BEHAVIORAL|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
58306140|NCT00469131|DRUG|tacrolimus + steroid|
58306141|NCT00469131|DRUG|tacrolimus + mycophenolate mofetil|
58306142|NCT00427934|DRUG|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
58306143|NCT00427934|DRUG|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
58306144|NCT00178737|BEHAVIORAL|Electronic reminder message|
58306145|NCT00217490|BEHAVIORAL|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
58306146|NCT00217490|BEHAVIORAL|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
58306147|NCT00217490|BEHAVIORAL|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
58306148|NCT00217490|OTHER|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
58306149|NCT05004090|DIAGNOSTIC_TEST|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
58420322|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
58420323|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
58420324|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
58420325|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
58420326|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
58420327|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
58420328|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
58420329|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
58420330|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
58420331|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
58420332|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
58093143|NCT05489068|BEHAVIORAL|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
58093144|NCT06458023|DEVICE|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
58093145|NCT04904978|OTHER|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
58093146|NCT04904978|OTHER|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
58093147|NCT03906565|DRUG|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
58093148|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
58093149|NCT03841903|DIAGNOSTIC_TEST|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
58093150|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
58420333|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
57950724|NCT05373654|OTHER|F-SUS Questionnaire|"This F-SUS questionnaire uses a Likert scale including 5 possible responses ranging from  I do not agree at all to  I completely agree  (Celenza A 2011, Croasmun JT 2011). The F-SUS is a short questionnaire with 10 questions (Brooke J 2013). In its original version half of the questions express strong agreement and the other half disagreement. Thus, all the even-numbered items (2, 4, 6, 8, 10) allow the participant to express a very negative opinion (disagreement). On the other hand, the odd-numbered items allow the participant to express a very positive opinion (strong agreement)."
58093151|NCT02801838|DRUG|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
58093152|NCT06702566|DRUG|PD-1 and PD-L1 inhibitor|"PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab."
58093153|NCT06702566|DRUG|Targeted drugs|Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
57735056|NCT02156713|BEHAVIORAL|CIMT Camp|
58093154|NCT06702566|DRUG|chemotherapy drugs|Chemotherapy drugs are determined based on the investigator's decision.
58093155|NCT03533608|BEHAVIORAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
58093156|NCT04324112|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
58093157|NCT04324112|DRUG|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
58093158|NCT00339066|DRUG|Sertraline|
58093159|NCT04434235|OTHER|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
58093160|NCT00228332|DRUG|Administration of zinkgluconaat or placebo|
58093161|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.
58095340|NCT05924555|OTHER|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
58420334|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
58420335|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
58420336|NCT00351182|DRUG|Telithromycin|
58093162|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP
58093163|NCT00686231|DRUG|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
58093164|NCT00686231|DRUG|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
58093165|NCT00686231|DRUG|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
58093166|NCT00686231|DRUG|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
58093167|NCT00686231|DRUG|Placebo|Topical skin moisturizing cream with same appearance as active agent
58093168|NCT06703840|DRUG|LIB-01|LIB-01 oral suspension
58093169|NCT06703840|DRUG|LIB-01 Placebo|LIB-01 Placebo oral suspension
58093170|NCT00334477|DRUG|tadalafil|
58093171|NCT04806958|OTHER|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
58093172|NCT06703125|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
58093173|NCT05476276|DRUG|ISA specific|ISA specific interventions will be listed in their protocols.
58093174|NCT05052879|DRUG|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
58093175|NCT05052879|DRUG|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
58093176|NCT05052879|OTHER|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
58093177|NCT05052879|OTHER|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
58093178|NCT06694974|BEHAVIORAL|APP calculation for FIB-4|the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
58093179|NCT06694974|BEHAVIORAL|Standard Care (in control arm)|The standard group proceeds as regular practice
58093180|NCT06234930|DEVICE|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
58093181|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
58093182|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
58093183|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
58093184|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
58093185|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
58093186|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
58093187|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
58093188|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
58420337|NCT00351182|DRUG|Doxycycline|
58093189|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
58093190|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
58093191|NCT06080503|RADIATION|LT-SABR|42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
58093192|NCT06080503|RADIATION|IMRT|63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
58093193|NCT06264271|BEHAVIORAL|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
58093194|NCT00267579|BEHAVIORAL|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
58093195|NCT06697756|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
58093196|NCT06697756|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
58093197|NCT05482893|DRUG|PT886|PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
58093198|NCT05482893|DRUG|Paclitaxel|Chemotherapy as a combination partner to PT886 in Part C: Cohort 1
58093199|NCT05482893|DRUG|Gemcitabine|Chemotherapy as a combination partner to Abraxane and PT886 in Part C: Cohort 2
58093200|NCT05482893|DRUG|Abraxane|Chemotherapy as a combination partner to Gemcitabine and PT886 in Part C: Cohort 2
58093201|NCT05482893|DRUG|KEYTRUDA® (pembrolizumab)|Immune checkpoint inhibitor as a combination partner to PT886 in Part D: Cohort 3, 4, and 5.
58420338|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
58420339|NCT01479582|DRUG|Access to unlicensed cord blood units|
58093202|NCT05482893|DRUG|Oxaliplatin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
58093203|NCT05482893|DRUG|Leucovorin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
58093204|NCT05482893|DRUG|Fluorouracil|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
58093205|NCT05482893|DRUG|Capecitabine|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
58093206|NCT05482893|DRUG|FOLFIRINOX|Chemotherapy as a combination partner to PT886 in Part C: Cohort 2b
58093207|NCT04136626|DEVICE|Perspectives OCD|The app-delivered cognitive behavioral therapy (CBT) in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
58093208|NCT04136626|DEVICE|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
58093209|NCT02817269|OTHER|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
58420340|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
58420341|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
58093210|NCT02817269|OTHER|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
58420342|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
58420343|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
58420344|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
58420345|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
58420346|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
58420347|NCT01399008|DRUG|Placebo|Placebo
58420348|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
58420349|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
58420350|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
58420351|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
58420352|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
58420353|NCT04753021|OTHER|Exercise|Progressively increasing training load
58420354|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
58420355|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
58420356|NCT05330858|DRUG|Rabeprazole|Oral Tablet
58420357|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
58420358|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
58306150|NCT05004090|DIAGNOSTIC_TEST|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
58420359|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
58420360|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
58420361|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
58420362|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
58420363|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
58420364|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
58420365|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
58420366|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
58420367|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
58420368|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
58420369|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
58420370|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
58420371|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
58420372|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
58420373|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
58420374|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
58420375|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
58420376|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
58420377|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
58420378|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
58420379|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
57735057|NCT04978493|DRUG|BI 706321|BI 706321
57735058|NCT04978493|DRUG|ustekinumab|ustekinumab
57735059|NCT04978493|DRUG|Placebo|Placebo
58420380|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
58420381|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
58420382|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
58420383|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
58420384|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
58093211|NCT02122744|DEVICE|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
58093212|NCT02122744|DEVICE|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
58093213|NCT06704074|DEVICE|virtual reality (VR) head mounted display|The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.
58093214|NCT01149083|PROCEDURE|Biopsy|Undergo biopsy
58093215|NCT01149083|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58093216|NCT01149083|DRUG|Carboplatin|Given IV
58093217|NCT01149083|PROCEDURE|Computed Tomography|Undergo CT
58093218|NCT01149083|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58093219|NCT01149083|DRUG|Veliparib|Given PO
58093220|NCT03311828|BIOLOGICAL|Daratumumab|Given IV
58306151|NCT05004090|DIAGNOSTIC_TEST|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
58306152|NCT05496023|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES"
58093221|NCT03311828|DRUG|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
58093222|NCT03311828|PROCEDURE|Positron Emission Tomography|Undergo PET
58093223|NCT03311828|OTHER|Pharmacological Study|Correlative studies
58093224|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
58093225|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
58093226|NCT05995964|DRUG|PF-07275315|subcutaneous injection
58093227|NCT05995964|DRUG|PF-07264660|subcutaneous injection
58093228|NCT05995964|OTHER|Placebo|subcutaneous injection
58093229|NCT03963739|OTHER|Interview|Undergo interview
58093230|NCT03963739|OTHER|Questionnaire Administration|Ancillary studies
58093231|NCT05489380|DEVICE|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
58093232|NCT05043324|DRUG|AntiCov-220 (1)|The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
58093233|NCT05043324|DRUG|AntiCov-220 (2)|The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
58093234|NCT06702709|OTHER|Instrument Assisted Soft Tissue Mobilization|The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds
58420385|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
58420386|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
58420387|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
58420388|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
58093235|NCT06702709|OTHER|Neurodevelopmental Therapy|The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
58093236|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
58093237|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
58093238|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
58093239|NCT01474148|DEVICE|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
58093240|NCT05650658|DEVICE|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
58093241|NCT05650658|DEVICE|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
58093242|NCT05394831|DRUG|JIN-A02|PO, QD
58093243|NCT06694168|PROCEDURE|Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery|The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
58093244|NCT06694168|PROCEDURE|REGEND001 Autologous Therapy Product|L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.
58306153|NCT06478641|DRUG|Tafenoquine|Tafenoquine will be self-administered orally as 2 x 100 mg dark pink coated tablets once daily (total daily dose 200 mg) with food on Days 1, 2, 3 \& 4 then weekly thereafter (starting on day 11) until the patient has two consecutive negative PCR tests for Babesia parasites and symptoms of babesiosis have resolved.
58420389|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
58093245|NCT04024280|OTHER|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
58093246|NCT06084481|DRUG|ABBV-400|Intravenous (IV) Infusion
58093247|NCT05480956|BEHAVIORAL|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
58093248|NCT05480956|BEHAVIORAL|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
58420390|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
58420391|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
58420392|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
57735060|NCT06476405|OTHER|Study Product A: Ploom® Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
57735061|NCT06476405|OTHER|Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
57735062|NCT06476405|OTHER|Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
58093249|NCT05480956|BEHAVIORAL|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
58093250|NCT03296215|OTHER|Observational|To determine different patterns of admission and their Outcome
58093251|NCT06038916|DRUG|STSA-1002 Injection Placebo|Intravenous infusion
58306154|NCT05470452|OTHER|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
58306155|NCT05470452|OTHER|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
58306156|NCT01236924|OTHER|Global postural reeducation|
58420393|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
58420394|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
58093252|NCT06038916|DRUG|STSA-1002 Injection|Intravenous infusion
58093253|NCT04794582|DEVICE|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
58093254|NCT04637282|DRUG|PLX-200|15 mg/mL oral solution of experimental drug
58093255|NCT04637282|DRUG|Placebo|Taste and color-matched drug-free solution
58306157|NCT01311219|OTHER|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
58306158|NCT01311219|PROCEDURE|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
58306159|NCT01311219|PROCEDURE|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
58420395|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
58420396|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
58420397|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
58420398|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
58420399|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
58420400|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
58093256|NCT02362646|BIOLOGICAL|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
58093257|NCT02362646|DRUG|Control Solution|
58420401|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
58420402|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
58093258|NCT01072318|DRUG|Letrozole|Letrozole 2.5mg
58306160|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
58420403|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
58420404|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
57735063|NCT06476405|OTHER|Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
57735064|NCT04514848|DEVICE|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
57735065|NCT04514848|DEVICE|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
57735066|NCT00921492|DEVICE|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
58093259|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
58306161|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
58420405|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
57735067|NCT00921492|OTHER|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
58093260|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
58093261|NCT01216319|DEVICE|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
58093262|NCT06700694|OTHER|Technology-assisted, family-engaged in-bed activities|Technology-assisted, family-engaged in-bed activities include handgrip interactive games, virtual reality butterfly catching, virtual reality magic cube games, and immersive in-bed cycling, performed 20 minutes per session, twice daily, five days a week, primarily assisted by family members.
58093263|NCT06700694|OTHER|Protocol-oriented early mobilization program|The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
58093264|NCT04762316|DRUG|SB-UF|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
58093265|NCT04762316|DEVICE|SB-UF Placebo|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
58093266|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
58420406|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
58420407|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
58420408|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
57735068|NCT00263666|BIOLOGICAL|Rotarix|Oral vaccination
57735069|NCT00263666|BIOLOGICAL|Placebo|Oral administration
57735070|NCT00263666|BIOLOGICAL|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
57950725|NCT05373654|OTHER|Interview (only for dissatisfied patients)|"Patients that are dissatisfied with the recharge procedure (Score F-SUS \< 70/100) will be invited to a so-called complementary information interview (an interview after the questionnaire has been completed).~The corpus (the study group that will be interviewed) will naturally be diverse men/women, patients who were improved or not by stimulation, implanted with a rechargeable stimulator directly/replacing a stimulator, different brands of stimulator... The patient must agree to the interview and the way it will be performed (signature of consent form). The interview may be face-to -face at the site or by remote videoconference depending on the wishes and availability of the patient. There is no payment for these interviews but travelling or videoconference expenses are reimbursed All interviews will be audio- taped for further qualitative analysis."
57950726|NCT05030870|DEVICE|Capnography monitoring|Standard monitoring and capnographic monitoring.
57950727|NCT05030870|DEVICE|Standard monitoring|Standard monitoring but no capnographic monitoring
57950728|NCT05032612|DEVICE|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
57950729|NCT05032612|DEVICE|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
57950730|NCT01819051|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
57950731|NCT01379274|DRUG|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
57950732|NCT04963556|DIETARY_SUPPLEMENT|Red Bull|Drinking of Red Bull before exercise
57950733|NCT04687787|OTHER|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
57950734|NCT04687787|OTHER|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
57950735|NCT01187953|DRUG|Prograf (tacrolimus)|Administered per current product labeling
57950736|NCT01187953|DRUG|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
58093267|NCT03368872|OTHER|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
58093268|NCT03368872|OTHER|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
58306162|NCT04236843|DIETARY_SUPPLEMENT|Feces|Feces from healthy donor
57950737|NCT02534701|DEVICE|ERIC® and SOFIA™|a self-expanding clot retrieval system
57950738|NCT00003625|DRUG|cyclosporine|
57950739|NCT00003625|DRUG|etoposide|
57950740|NCT00003625|DRUG|vincristine sulfate|
57950741|NCT00003625|RADIATION|radiation therapy|
57950742|NCT01761292|DRUG|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
57950743|NCT00391573|PROCEDURE|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
57950744|NCT00391573|PROCEDURE|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
57950745|NCT02396134|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Given SC
57950746|NCT02396134|OTHER|Placebo|Given SC
57735071|NCT00263666|BIOLOGICAL|Polio Sabin|Oral administration, concomitant routine vaccination
58420409|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
58420410|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
57735072|NCT00460889|PROCEDURE|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
58093269|NCT03368872|OTHER|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
58093270|NCT01861600|OTHER|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
58093271|NCT01861600|OTHER|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
58093272|NCT01861600|OTHER|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
58093273|NCT01861600|OTHER|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
58093274|NCT01861600|OTHER|Human Milk|Human Milk
58093275|NCT03509688|DRUG|entecavir+resveratrol|entecavir+resveratrol
58420411|NCT00106574|DRUG|Placebo|iv every 4 weeks
58420412|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
58420413|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
58420414|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
57735073|NCT05427669|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
57735074|NCT05427669|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
57735075|NCT01293448|DEVICE|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
57735076|NCT02289300|DRUG|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
57735077|NCT02289300|DRUG|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
57950747|NCT02396134|OTHER|Laboratory Biomarker Analysis|Correlative studies
57950748|NCT03100045|DRUG|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
57950749|NCT00575627|DRUG|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
57950750|NCT00004471|GENETIC|pGT-1 gene lipid complex|
57950751|NCT00114049|DRUG|GW406381|
58093276|NCT03509688|DRUG|Entecavir|Entecavir
58093277|NCT03509688|DRUG|entecavir+thymosin α1|entecavir+thymosin α1
58093278|NCT01542879|PROCEDURE|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
58093279|NCT01542879|PROCEDURE|18-F-FDG PET scan|
58093280|NCT01542879|DRUG|Ferumoxytol|
58093281|NCT01542879|PROCEDURE|18-F-FDG PET/MR scan|
58093282|NCT06702982|BEHAVIORAL|tele-nursing educational program|The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
58093283|NCT00331604|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
58093284|NCT00331604|DRUG|insulin detemir|Injection s.c., 50% of daily dose.
58093285|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
58093286|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
58093287|NCT01802762|DEVICE|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
58093288|NCT04165317|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
58093289|NCT04165317|DRUG|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
58420415|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
57735078|NCT02289300|DRUG|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
57735079|NCT02571569|DRUG|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
57735080|NCT02571569|DRUG|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
58093290|NCT03473145|BEHAVIORAL|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.
58306163|NCT06542367|PROCEDURE|"Tympanoplasty performed under local anesthesia using fat graft and Tachosil."|"Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation"
58306164|NCT04224246|DRUG|Gamma Hydroxybutyrate|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
58420416|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
58306165|NCT01350635|BIOLOGICAL|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
58420417|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
58420418|NCT01915823|DRUG|Dymista vehicle|
58420419|NCT00164957|DEVICE|continuous pump feeding|
58420420|NCT00164957|OTHER|intermittent bolus feeding|
58420421|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
57735081|NCT01212367|BIOLOGICAL|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
57735082|NCT01212367|BIOLOGICAL|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
57735083|NCT05607693|DRUG|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
57735084|NCT05924152|DRUG|Adagrasib|Adagrasib
58420422|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
58093291|NCT03473145|DEVICE|activPAL inclinometer|Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
58093292|NCT03473145|OTHER|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
58093293|NCT06420323|DEVICE|Treatment with NovoX® Cup|NovoX® Cup treatment
58093294|NCT06420323|DEVICE|Treatment with Omnistrip®|Omnistrip® treatment
58093295|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
58093296|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
57735085|NCT05924152|DRUG|Eltrombopag + adagrasib|Eltrombopag + adagrasib
58093297|NCT04332835|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
58093298|NCT04332835|DRUG|Standard Therapy|Standard therapy defined by institutional protocol.
58093299|NCT06009159|DEVICE|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
58093300|NCT01317069|DRUG|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
58093301|NCT03366155|DEVICE|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
58093302|NCT03366155|DRUG|Panitumumab|6 mg/kg, IV
58093303|NCT03366155|DRUG|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
58306166|NCT05465395|PROCEDURE|Upper Cervical Adjustemnt|Upper cervical adjustement
58306167|NCT05465395|PROCEDURE|Thoracic Adjustemnt|Thoracic adjustment
58420423|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
57735086|NCT02979262|BEHAVIORAL|Fathers for Change|
57735087|NCT02979262|BEHAVIORAL|Parent Education|
57735088|NCT00605800|OTHER|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
57735089|NCT00605800|OTHER|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
57735090|NCT04328844|DRUG|IOA-244|IOA-244 will be administered orally once daily (QD)
57735091|NCT04328844|DRUG|Avelumab Injection|Avelumab will be administered IV every 2 weeks
57735092|NCT04328844|DRUG|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
57950752|NCT06171321|DRUG|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
57950753|NCT05654389|OTHER|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
57950754|NCT00466466|DRUG|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
58093304|NCT03366155|DRUG|Oxaliplatin|85 mg/m2, IV
58093305|NCT03366155|DRUG|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
58093306|NCT03366155|DRUG|Irinotecan|150 mg/m2, IV
58093307|NCT03366155|PROCEDURE|HAIP installation|HAI pump installation
58093308|NCT03366155|DRUG|cetuximab|500 mg/m2, IV
58420424|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
58420425|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
58093309|NCT03366155|DEVICE|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
58093310|NCT05269615|DRUG|Valsartan 80 mg|The well-established angiotensin II receptor blocker (ARB) valsartan will be used in the present study to selectively block AT1 receptors. Valsartan is a generic medication widely used in hypertensive patients since 1996 as well as safely applied in physiological studies comprising healthy individuals.1-3 A minimal valsartan dose of 80 mg known to acutely reduce circulating EPO levels in healthy individuals will be provided 4 hours before starting Study 1 to optimize AT1 blockade according to valsartan's half-life.1-3 The same dose of valsartan (80 mg) will be provided 4 hours before each ET session in Study 2. The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
58093311|NCT05269615|DRUG|Placebo|The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
58093312|NCT05179486|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, and blood
58420426|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
58420427|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
58420428|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
58420429|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
58420430|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
58420431|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
58420432|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
57735093|NCT04328844|DRUG|Cisplatin|Cisplatin will be administered IV every 3 weeks
57735094|NCT04328844|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
57735095|NCT06373094|DRUG|Donepezil Dihydroxynaphthalate for Injection|HHT201 will be injected into the muscle of gluteus.
57735096|NCT04251000|DEVICE|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
58093313|NCT05179486|OTHER|Questionnaire Administration|Complete questionnaire
58420433|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
58420434|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
58420435|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
58420436|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
58420437|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
58420438|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
58420439|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
58420440|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
58420441|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
57735097|NCT05222191|DRUG|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
57735098|NCT05222191|DRUG|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
57735099|NCT05222191|DRUG|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
57735100|NCT06185660|DRUG|sodium zirconium cyclosilicate (SZC)|sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
57735101|NCT00275795|PROCEDURE|NAET Procedures|
58093314|NCT05540535|OTHER|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
58093315|NCT05540535|OTHER|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
58093316|NCT05550675|OTHER|Questionnaires|Disease specific questionnaires
58420442|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
58420443|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
58420444|NCT03623178|OTHER|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
58420445|NCT00002742|DRUG|amphotericin B deoxycholate|
58420446|NCT00002742|DRUG|nystatin|
57735102|NCT03443960|DRUG|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
57735103|NCT03443960|DRUG|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
57950755|NCT05168800|BEHAVIORAL|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
57950756|NCT05168800|BEHAVIORAL|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
57950757|NCT05168800|OTHER|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
57950758|NCT04899700|DEVICE|Linked Color Imaging|Inspection of the postpolypectomy scar will be made with Linked Color Imaging
57950759|NCT04899700|OTHER|White light endoscopy|Inspection of the postpolypectomy scar will be made with White light Endoscopy
57950760|NCT06490835|BEHAVIORAL|High-quality palliative care through consultation-based palliative care services in the ICU|"Family Counseling: Social workers implement a supportive process for families, assessing the individualized psychosocial and decisional support needs of patients and families to provide foundational data for palliative care consultations.~Family Meeting Support: In cases of high medical complexity, uncertainty, value conflicts, or communication issues, the palliative care consultation team supports the facilitation of family meetings.~Consultation: The palliative care team provides consultations to the attending physician based on the palliative care needs assessed during family counseling. Topics include symptom management, understanding treatment options, decisional conflict, emotional and practical support, goal of care setting, resources, and bereavement support.~Palliative Care by attending Physician: The attending physician incorporates the consultations received from the palliative care consultation team to provide high-quality palliative care to patients and their families."
57735104|NCT05170373|PROCEDURE|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
57735105|NCT05006781|DRUG|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
57735106|NCT02786082|DRUG|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
57735107|NCT02786082|DRUG|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
58420447|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
58420448|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
58420449|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
58420450|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
58420451|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
58420452|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
58420453|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
58420454|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
58420455|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
58420456|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
58420457|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
58420458|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
58420459|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
58420460|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
58420461|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
58420462|NCT01771614|BEHAVIORAL|Exercise|
58420463|NCT01771614|PROCEDURE|Hyperglycemia|
58420464|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
58420465|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
58420466|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
58420467|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
58420468|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
58420469|NCT01862835|DRUG|Degarelix|
58420470|NCT01862835|DRUG|Testosterone|
58420471|NCT01862835|DRUG|Anastrozole|
58420472|NCT01862835|DRUG|Estrogen patch|
58420473|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
58420474|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
58420475|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
58420476|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
58420477|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
58420478|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
58420479|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
58420480|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
58420481|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
58420482|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
58093317|NCT05181709|DRUG|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
58420483|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
57735108|NCT00093054|DRUG|Cranberry juice|TID dosage for UTI treatment
58093318|NCT05181709|BIOLOGICAL|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
58093319|NCT05181709|BIOLOGICAL|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
58093320|NCT05181709|BIOLOGICAL|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
58093321|NCT05181709|BIOLOGICAL|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
58093322|NCT00345826|DRUG|dasatinib|
58093323|NCT05361798|DRUG|M9241|In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
58093324|NCT05361798|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
58093325|NCT06701097|BEHAVIORAL|Emotion regulation training|Man is a social being and therefore interacts with his environment. In the process of interaction, they can transfer their feelings, thoughts, and information. However, the interaction process may not always continue smoothly. People's inability to express their emotions appropriately today negatively affects communication. The reason why people cannot express their emotions may be the high level of alexithymia. The concept of alexithymia means having difficulty in recognizing, expressing, and naming emotions. High levels of alexithymia in students, who are future healthcare professionals, can negatively affect themselves, other healthcare professionals and the patients they care for; it can cause burnout in healthcare professionals, decrease the quality of care they provide and cause them to experience interpersonal communication conflicts.
58420484|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
58420485|NCT02845531|DRUG|Optimal Medical Therapy|
58420486|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
57735109|NCT00093054|DIETARY_SUPPLEMENT|Placebo cranberry juice|TID placebo dosage to match active comparator
58093326|NCT03681275|DRUG|Tofacitinib 10 MG [Xeljanz]|administered twice daily for two days
58093327|NCT03681275|DRUG|Placebo to match Tofacitinib|administered twice daily for two days
58093328|NCT04035694|OTHER|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
58420487|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
58420488|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
58420489|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
58093329|NCT01299272|DRUG|LY2216684|
58093330|NCT01299272|DRUG|Placebo|
58093331|NCT01299272|DRUG|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
58420490|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
58420491|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
58420492|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
58420493|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
58420494|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
58420495|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
58420496|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
58420497|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
58420498|NCT00083486|DRUG|epoetin alfa|
58420499|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
58420500|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
58420501|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
58420502|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
57735110|NCT04947800|DEVICE|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
58093332|NCT06567951|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
58093333|NCT06681896|OTHER|MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice|"MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3."
58093334|NCT06697821|PROCEDURE|D2＋CME|Whether to perform the whole mesogastric excision
58420503|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
57735111|NCT04947800|DEVICE|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
57735112|NCT01076569|OTHER|laboratory biomarker analysis|Correlative studies
57735113|NCT02302079|DRUG|ASP8232|oral capsule
57735114|NCT02302079|DRUG|ranibizumab|intravitreal (IVT) injection
57735115|NCT02302079|DRUG|Placebo|oral capsule
58093335|NCT03926728|BIOLOGICAL|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
58093336|NCT03926728|BIOLOGICAL|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
58093337|NCT03926728|BIOLOGICAL|CTH522 ID|24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
57950761|NCT01227187|DRUG|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
57950762|NCT00553709|DRUG|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
57950763|NCT04539340|BIOLOGICAL|GNR-055|Single intravenous administration
57950764|NCT03476499|DEVICE|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
57950765|NCT00978211|DRUG|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment."
57950766|NCT03746704|DRUG|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
57950767|NCT04486092|DRUG|Valproic Acid|
57950768|NCT03370783|DRUG|Ethanol|Moderate alcohol consumption
57950769|NCT02544711|DEVICE|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
57950770|NCT02544711|PROCEDURE|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
57950771|NCT05998421|PROCEDURE|acupuncture|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle. Seirin 0.2-×30-mm acupuncture needles were used. First, needles were inserted into Shenting (GV 24) and bilateral Benshen (G 13) to relieve uneasiness of mind. Then, they were inserted into Chung wan (cv 12), Qihai (CV6), Guan yuan, chung chi (cv 3), bilateral Guiai (S 29) and Zigong (Extra 16) to recuperate energy. Finally, bilateral Tsusanli (st 36), Yinlingch'uan (sp 9) and San yin chiao (sp 6) were used to soothe the liver and tonify the spleen and kidney. Each acupuncture treatment session lasted 30 minutes, with mostly bilateral needle retention over 20-30 minutes for evens techniques.
57950772|NCT05998421|DRUG|routine aspirin and heparin treatment|The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
57950773|NCT04989283|BIOLOGICAL|Atezolizumab|Given IV
57950774|NCT04989283|PROCEDURE|Biopsy|Undergo tumor biopsy
57950775|NCT04989283|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57950776|NCT04989283|DRUG|Carboplatin|Given IV
57950777|NCT04989283|DRUG|Cisplatin|Given IV
57950778|NCT04989283|PROCEDURE|Computed Tomography|Undergo PET/CT scan
57950779|NCT04989283|DRUG|Etoposide|Given IV
57950780|NCT04989283|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
57950781|NCT04989283|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57950782|NCT04989283|DRUG|Paclitaxel|Given IV
58093338|NCT03926728|BIOLOGICAL|CTH522 TO|24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
58093339|NCT03926728|BIOLOGICAL|Placebo (Saline)|Placebo only given as IM, ID and TO.
57950783|NCT04989283|DRUG|Pemetrexed|Given IV
57950784|NCT04989283|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
57950785|NCT04989283|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57950786|NCT05956951|DEVICE|Closed-loop auditory stimulation|Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.
57950787|NCT05956951|DEVICE|Sham auditory stimulation|Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
57950788|NCT03490643|OTHER|Postural Analysis|posture and plantar pressure analysis
57950789|NCT03490643|OTHER|plantar pressure analysis|posture and plantar pressure analysis
57950790|NCT01399788|DRUG|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
57950791|NCT01399788|DRUG|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
57950792|NCT00091806|DRUG|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
57950793|NCT00091806|DRUG|Panitumumab|9 mg/kg once every 3 weeks
58093340|NCT03751124|DRUG|Relugolix|Relugolix 40 mg tablet administered orally once daily
58420504|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
57735116|NCT02302079|OTHER|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
58093341|NCT03751124|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
58093342|NCT03751124|DRUG|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
58093343|NCT03751124|DRUG|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
57735117|NCT04997174|DRUG|Celecoxib|Patients in ERAS group received celecoxib
58093344|NCT06498817|BEHAVIORAL|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
58093345|NCT06498817|BEHAVIORAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
58093346|NCT06528938|DEVICE|Theta Burst Stimulation|Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
58093347|NCT06430385|DRUG|ION440|ION440 will be administered by intrathecal bolus (ITB) injection.
58093348|NCT06430385|PROCEDURE|Sham procedure|An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
58093349|NCT06702384|DIAGNOSTIC_TEST|biopsy|Baseline biopsy and biological specimens
58093350|NCT05709054|OTHER|Experimental: Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Breathing Retraining Exercises group:~Diaphragm manual therapy will be carried out and consists of a technique intended to stretch and mobilise the diaphragmatic muscle fibers indirectly. The maneuver will be performed in two sets of 10 repetitions, within a 1-minute interval for 10 minutes.~Breathing retraining exercises will be implemented for 30 minutes, consisting of:~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
58306168|NCT04390165|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
58306169|NCT03054142|OTHER|no intervention|
57735118|NCT03441425|OTHER|Unexpected death|
57950794|NCT02170402|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|"* Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen"
57950795|NCT01166737|PROCEDURE|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
57735119|NCT02384954|BIOLOGICAL|Rituximab|Intravenous infusion 375 mg/m\^2.
57735120|NCT02384954|BIOLOGICAL|N-803|Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
57735121|NCT00629187|DRUG|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
57735122|NCT05562440|OTHER|Focus Group Discussion|Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
57735123|NCT03826667|DEVICE|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~* HEALICOIL™ PK Preloaded Suture Anchors~* BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~* BIORAPTOR™ Knotless Suture Anchors~* MULTIFIX™ S Ultra Knotless Fixation System~* FOOTPRINT™ Ultra PK Suture Anchors~* TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~* SPEEDSCREW™ Knotless Fixation System~* SpeedLock Knotless Fixation Device"
57950796|NCT04800289|OTHER|questionnaires|questionnaires about disease and satisfaction of patient
58306170|NCT03175796|BEHAVIORAL|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
57735124|NCT06670703|DIAGNOSTIC_TEST|Obesity|diagnosis as obese patients
58093351|NCT05709054|OTHER|Sham Breathing Retraining Exercises Group B|"Sham Breathing Retraining Exercises Group B:~Breathing retraining exercises will be implemented for 30 minutes, consisting of :~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
58306171|NCT06307353|OTHER|trends of contraception methods|family planning practice will include number of women current use of family planning methods and its type planning fot ffuture pregnancy suggested duration before next pregnancy.women'ssatisfaction with family planning services atElBalyana urban Medical Center accessibility of the site suitability of waiting time
58306172|NCT06332222|DIETARY_SUPPLEMENT|Tart Cherry|7 day supplementation
58306173|NCT06332222|OTHER|Placebo|7 day supplementation
58306174|NCT00746369|BEHAVIORAL|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
58306175|NCT05553405|DRUG|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
58306176|NCT05671081|DRUG|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
58306177|NCT05671081|DRUG|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
58306178|NCT05671081|DRUG|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
58306179|NCT03642990|DRUG|Nicotinamide Riboside|Capsule
58306180|NCT01670370|DRUG|R-GemOx|Rituximab Gemcitabine Oxaliplatin
58306181|NCT05810402|BIOLOGICAL|Liquid Biopsy|"30mL blood sample:~* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
58306182|NCT05571111|DRUG|FE 999302|Subcutaneous injection as a single dose. 3 different doses
58306183|NCT05571111|DRUG|Ovitrelle|Subcutaneous injection as a single dose. 250 µg (0.5 mL)
58306184|NCT05571111|DRUG|Novarel|Subcutaneous injection as a single dose. 10,000 IU (1 mL)
58306185|NCT05717998|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58306186|NCT05717998|PROCEDURE|Computed Tomography|Undergo cardiac PET/CT
58306187|NCT05717998|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
58306188|NCT05717998|PROCEDURE|Positron Emission Tomography|Undergo cardiac PET/CT
58306189|NCT00621790|DRUG|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
58306190|NCT00621790|DRUG|placebo|placebo
58306191|NCT05247762|DEVICE|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
58306192|NCT02552927|DEVICE|Chest shield with aluminum foil (CALF)|
58306193|NCT02552927|DEVICE|SHIELD|
57735125|NCT02114242|OTHER|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
58093352|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
58093353|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
58306194|NCT05890079|OTHER|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
58093354|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
57735126|NCT02114242|OTHER|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
58093355|NCT06625047|DRUG|Temozolomide|Given PO
58306195|NCT05890079|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
58420505|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
58420506|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
58093356|NCT06567080|BIOLOGICAL|JWCAR201|JWCAR201 is a autologous CAR-T targeting CD19/CD20
58306196|NCT04510272|OTHER|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
58306197|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
57735127|NCT05878639|DRUG|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
57735128|NCT05878639|DRUG|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
58093357|NCT02703779|DRUG|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
58093358|NCT02703779|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
58093359|NCT02703779|DRUG|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
58093360|NCT06448910|DRUG|Cadonilimab (AK104)|Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.
58093361|NCT00209430|DRUG|Iodixanol 320 mgI/mL|
58093362|NCT01818219|PROCEDURE|Records of EADI derived parameters|
58306198|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
58306199|NCT02392780|DRUG|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
58306200|NCT02392780|DRUG|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
58306201|NCT02392780|DRUG|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
57735129|NCT05934344|OTHER|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
57735130|NCT06258174|DRUG|Pirtobrutinib|Administered orally.
57950797|NCT03380260|BEHAVIORAL|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
57950798|NCT05873998|DIAGNOSTIC_TEST|Slow pressure-volume curve|Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
58306202|NCT04579809|PROCEDURE|4 strand technique|4 strand technique reapir of tendin flexor injury
58306203|NCT01403662|DRUG|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
58093363|NCT01186744|DRUG|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
58306204|NCT00623532|BEHAVIORAL|Mind-body exercises|
58306205|NCT00623532|BEHAVIORAL|Adapted Tai-chi|
58093364|NCT01186744|DRUG|CP-690,550|10 mg oral BID
58093365|NCT01186744|DRUG|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
58093366|NCT01186744|DRUG|CP-690,550|5 mg oral BID
58093367|NCT04309760|OTHER|MRI|Subjects will receive structural and functional (resting state) MRI
58093368|NCT05717166|RADIATION|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
58093369|NCT05717166|DRUG|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
58306206|NCT04997304|COMBINATION_PRODUCT|AirDuo Digihaler|"Patients will receive the AirDuo® Digihaler™ at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis."
57950799|NCT05415995|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
57950800|NCT04100889|OTHER|No Intervention|There is no intervention for this study.
58093370|NCT05717166|DRUG|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
58093371|NCT05717166|DRUG|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
58093372|NCT05717166|DRUG|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
58093373|NCT05717166|OTHER|Observation|Pre-specified based on the standard of care approach for that patient.
58093374|NCT05717166|RADIATION|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
58093375|NCT05717166|PROCEDURE|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
58093376|NCT05717166|OTHER|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
58420507|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
58420508|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
58093377|NCT05717166|RADIATION|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
58093378|NCT01126359|DRUG|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
58306207|NCT04997304|COMBINATION_PRODUCT|ProAir Digihaler|Patients will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the patients current inhaled therapy dose. Most patients will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
57735131|NCT05680025|BEHAVIORAL|Physical exercise intervention|"The intervention group will have access to training videos through social networks (WhatsApp and YouTube) and infographics. The mobile phone of each of the participants will allow send dates of workshops, link for videos, messages reminding to perform exercise routines.~The training plan will be designed so the participants will achieve being physically active at the end of 6 months of intervention. Training will be planned to gradually, through 3 levels, increase the duration and intensity of exercises; they will have an important component of aerobic exercises and others for muscular strength. Each level of training will last two months; at each level the participants will be given 4 specific trainings and will be asked to perform two per week at level 1 and 2; and at the 3 level, 3 trainings per week.~The strategy for promoting physical exercise is based on the social cognitive theory, in which the bases of the transtheoretical model are found."
57950801|NCT03537027|DIETARY_SUPPLEMENT|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
58093379|NCT01126359|DRUG|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
58306208|NCT05926609|DIETARY_SUPPLEMENT|EB-PA|1 capsule to be taken after breakfast once a day
58306209|NCT05926609|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken after breakfast once a day
58306210|NCT02948816|BEHAVIORAL|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
58420509|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
58420510|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
58420511|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
58420512|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
58093380|NCT06696261|DRUG|Lianxiaxiaopi Granules|The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
58306211|NCT02948816|BEHAVIORAL|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
58306212|NCT02948816|BEHAVIORAL|Colouring|Participants will spend 30 minutes colouring quietly.
58420513|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
58306213|NCT03120611|OTHER|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
57950802|NCT03116074|BEHAVIORAL|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
57950803|NCT02528903|DRUG|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
57950804|NCT02528903|DRUG|Matching placebo|Single intravenous dose
58306214|NCT03120611|OTHER|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
57950805|NCT03458208|DRUG|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
58093381|NCT06696261|DRUG|a simulated agent of Lianxiaxiaopi Granules|The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
58093382|NCT02174549|DRUG|Tirapazamine|Intra-arterial injection into the tumor feeding artery
58306215|NCT04975425|DIAGNOSTIC_TEST|Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement
58306216|NCT03620799|PROCEDURE|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
58093383|NCT02174549|PROCEDURE|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
58093384|NCT04049448|DRUG|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
58093385|NCT06172127|DRUG|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
58093386|NCT06172127|DRUG|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
58093387|NCT06172127|DRUG|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
58093388|NCT04808960|DIAGNOSTIC_TEST|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine \& Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
58306217|NCT05785962|OTHER|Vojta Therapy|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
58420514|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
58420515|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
58420516|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
58420517|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
58420518|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
58306218|NCT04713072|BIOLOGICAL|ABY-035|ABY-035 solution for injection
58306219|NCT04713072|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
58306220|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
58306221|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
58306222|NCT01294423|DRUG|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
58306223|NCT06054386|OTHER|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
58420519|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
57950806|NCT03458208|DRUG|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
58093389|NCT06602037|DIAGNOSTIC_TEST|[89Zr]Zr-DFO-SHR1920|Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
58093390|NCT06602037|DIAGNOSTIC_TEST|[18F]F-RESCA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.
58093391|NCT06602037|DIAGNOSTIC_TEST|[68Ga]Ga-NOTA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.
58093392|NCT04352907|DEVICE|Continuous Glucose Sensor|Continuous glucose sensor results will be compared with arterial glucose samples
58093393|NCT03594175|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
58093394|NCT03594175|DRUG|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
58093395|NCT03594175|DRUG|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
58093396|NCT06210516|DEVICE|PowerBreathe|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
58093397|NCT06210516|OTHER|Conventional Physiotherapy|"Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
58093398|NCT04359186|OTHER|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
58093399|NCT03834961|DRUG|Larotrectinib Sulfate|Given PO or via NG or G tube
58093400|NCT06541925|DEVICE|Injection with the needle-free (NF) system|Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
58093401|NCT06541925|DEVICE|Injection with the traditional method (TM)|The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
58420520|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
58420521|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
58420522|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
58420523|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
58420524|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
58420525|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
58093402|NCT02787785|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
58093403|NCT04074798|BEHAVIORAL|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
58093404|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
58093405|NCT05620706|BIOLOGICAL|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
58093406|NCT06283745|OTHER|Platelet-rich Plasma (PRP)|Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.
58093407|NCT06283745|OTHER|Saline|Saline intranasal injection (sham injection)
58093408|NCT06041269|DRUG|Rosnilimab|PD-1 agonist antibody
58093409|NCT06041269|DRUG|Placebo|Placebo
58093410|NCT06585202|DRUG|ATI-2138|ATI-2138 Oral Tablets BID
57950807|NCT03458208|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
58420526|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
58420527|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
58420528|NCT01156168|GENETIC|DNA analysis|
58420529|NCT01156168|GENETIC|gene expression analysis|
58420530|NCT01156168|GENETIC|polymorphism analysis|
58420531|NCT01156168|GENETIC|protein expression analysis|
58420532|NCT01156168|OTHER|immunohistochemistry staining method|
58420533|NCT01156168|OTHER|laboratory biomarker analysis|
58420534|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
58420535|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
58420536|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
58420537|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
58306224|NCT06054386|OTHER|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
58420538|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
58420539|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
58420540|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
58420541|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
58420542|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
58420543|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
58420544|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
58420545|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
58420546|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
58420547|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
58420548|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
58420549|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
58306225|NCT03194477|BEHAVIORAL|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
58306226|NCT00049244|DRUG|capecitabine|
58306227|NCT00049244|DRUG|ixabepilone|
58420550|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
58420551|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74_R84-086)
58420552|NCT00499746|DRUG|tramadol|oral dose, once per day
58420553|NCT00499746|DRUG|placebo|oral dose, once per day
57735132|NCT05680025|BEHAVIORAL|Workshops|Six workshops to promote the performance of physical activity. The workshops will be held with groups of 15 participants. During them, the work will be to promote motivation to perform physical exercise, sharing information about the health benefits, benefits for control of the disease, together creating planning of measurable, realistic goals; reinforcing behavior when the desired advances are made, monitoring progress (using a monthly self-report of exercise performed). The participants will be motivated and congratulated each time for goals reached, self-sufficiency will be reinforced as well as greater evaluation of the advantages of performing exercise against the barriers or negative aspects perceived by the participants. These activities will be performed according to the level of exercise performed by the individuals (stage of change).
58093411|NCT06348823|DIAGNOSTIC_TEST|volume survey|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
58093412|NCT05631769|DRUG|Dual antiplatelet agent duration|"Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria)."
58093413|NCT01339468|DRUG|Advagraf|oral
58093414|NCT01339468|DRUG|Prograf|oral
58093415|NCT01339468|DRUG|Prograf|intravenous
58093416|NCT06646991|DEVICE|Nasal canula - up to 6 liters per minute|"Oxygen will be administered via nasal cannula up to 6 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
58093417|NCT06646991|DEVICE|Nasal canula - up to 15 liters per minute|"Oxygen will be administered via nasal cannula up to 15 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
58093418|NCT06646991|DEVICE|Open oxygen mask|"Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
58093419|NCT06646991|DEVICE|Simple oxygen face mask|"Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
58093420|NCT06703879|DRUG|Anesthesia induction with propofol|Establishment of a database of clinical characteristics of propofol-induced loss of consciousness in patients with complete clinical information Acquisition of basic perioperative monitoring data and extended monitoring data: 1,000 patients aged ≥18 years who needed to undergo surgical treatment were included (according to the machine learning diagnosis results, if the poor model fit was due to the small sample size, the necessary number of samples could be continued to be collected), and perioperative monitoring and management of the patients was performed, and a video recorder was used to videotape the whole anesthesia induction process in real time, so as to facilitate the postoperative integration of various data. The basic characteristics of the patients and the perioperative monitoring characteristics were extracted from the surgical anesthesia recording system, including gender, age, height, weight, blood pressure, ASA classification, electroencephalographic parameters, the a
58093421|NCT05297734|OTHER|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
58093422|NCT05297734|BEHAVIORAL|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
58093423|NCT04117958|DRUG|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
58093424|NCT04959175|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
58420554|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
58420555|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
58420556|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
58093425|NCT04959175|PROCEDURE|Allogeneic HSCT|Stem cell transplant
58093426|NCT04959175|DRUG|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
58093427|NCT04959175|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
58093428|NCT04959175|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
58093429|NCT04959175|DRUG|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
58093430|NCT04959175|DRUG|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
58093431|NCT04959175|PROCEDURE|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
58093432|NCT05886413|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application, the investigators will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery. The investigators will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
58093433|NCT06537609|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol)."
58093434|NCT06537609|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole."
58093435|NCT06537609|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed."
58093436|NCT06537609|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses"
58093437|NCT06537609|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
58420557|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
58420558|NCT04118790|PROCEDURE|MRI scan|1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
58420559|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
58420560|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
57735133|NCT02043210|BEHAVIORAL|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
57950808|NCT03458208|DRUG|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
57950809|NCT01553630|PROCEDURE|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
57950810|NCT01553630|PROCEDURE|Surgery without bone graft|Plating of fracture without bone graft
57950811|NCT01685463|DEVICE|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
57950812|NCT01685463|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
57950813|NCT00710476|PROCEDURE|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
58420561|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
58420562|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
58420563|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
58093438|NCT04601831|RADIATION|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
58093439|NCT00334269|BEHAVIORAL|Health messaging at weekly home visits by health counsellor|
58093440|NCT00334269|BEHAVIORAL|Weekly home delivery of bottled spring water|
58093441|NCT00334269|BEHAVIORAL|Weekly afterschool physical activity program for 5-18y.o.|
58420564|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
58420565|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
58420566|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
58420567|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
58420568|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
58420569|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
58420570|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
58420571|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
58420572|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
58420573|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
58420574|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
58420575|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
58420576|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
58420577|NCT04808193|OTHER|Survey|Participants will fill in the survey
58420578|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
58420579|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
58093442|NCT00334269|BEHAVIORAL|Cooking classes and grocery store tours with dietician|
58093443|NCT00334269|BEHAVIORAL|Pedometers to track/increase weekly physical activity|
58420580|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
58093444|NCT06700681|DRUG|Propofol|TIVA induction and maintain with Propofol.
58093445|NCT06700681|DRUG|Remimazolam|TIVA induction and maintain with Remimazolam.
58093446|NCT06700681|DEVICE|With intubation and controlled ventilation to maintain airway|Patient receives intubation and controlled ventilation to maintain airway.
58420581|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
58420582|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
58420583|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
58420584|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
58420585|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
58420586|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
58420587|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
58420588|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
58420589|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
58420590|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
58420591|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
58420592|NCT04064346|DRUG|Placebo|Matching placebo
58093447|NCT06700681|DEVICE|Maintain spontaneous ventilation without intubation|Patient maintains spontaneous ventilation without intubation.
58093448|NCT05505851|OTHER|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
58093449|NCT05505851|OTHER|Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
58093450|NCT02854189|DEVICE|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
58093451|NCT06584708|OTHER|Low-volume high intensity interval training|"Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes"
58093452|NCT06584708|OTHER|Moderate intensity continuous exercise|"Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes"
58093453|NCT03891732|DIAGNOSTIC_TEST|MRI prostate|plain biparametric MRI prostate
58420593|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
58093454|NCT01080911|DRUG|Morphine|spinal morphine 0.05 mg
58093455|NCT01080911|DRUG|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
58093456|NCT05722340|PROCEDURE|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
58093457|NCT05722340|PROCEDURE|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
58093458|NCT01493609|BEHAVIORAL|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
58093459|NCT06133348|BEHAVIORAL|Promoting Resilience in Stress Management Intervention|"PRISM is a manualized, brief, skills-based intervention targeting four resilience resources; PRISM is delivered by trained intervention staff (called coaches within the PRISM program). Session 1, Stress-Management. Session 2, Goal setting. Session 3, Cognitive Restructuring. Session 4, Meaning-Making. Session 5 (optional), Coming Together. Session 6 (optional) involved advance care planning to discuss."
58093460|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
58093461|NCT04101721|DRUG|aflibercept|Administered IVT
58420594|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
57735134|NCT02043210|BEHAVIORAL|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
57735135|NCT03487250|DEVICE|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
57950814|NCT03655808|BIOLOGICAL|Bronchial basal cells (BBCs)|Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
57950815|NCT03655808|PROCEDURE|Bronchoscopic airway clearance treatment （B-ACT）|The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
57950816|NCT03529266|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
57950817|NCT03529266|PROCEDURE|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
57950818|NCT01513421|PROCEDURE|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
57950819|NCT04265183|OTHER|Placing preformed metal crowns using Hall technique.|Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
57950820|NCT04459182|DIAGNOSTIC_TEST|ENDOPAT|digital plethysmography
57950821|NCT04572477|DRUG|[18F]THK-5351|F-18 THK PET Imaging
57950822|NCT04572477|DRUG|[18F]AV-45|F-18 AV45 PET Imaging
58093462|NCT04101721|PROCEDURE|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
58093463|NCT05611710|DRUG|Placebo|"Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
58093464|NCT05611710|DRUG|Anakinra|"Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
58093465|NCT06560463|DEVICE|Access to Dexcom G7 CGM Data|Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
58093466|NCT05828095|BIOLOGICAL|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
58093467|NCT05828095|BIOLOGICAL|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
58093468|NCT06700850|DEVICE|Prototype dressing rectangle|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 30x10cm. Topical application. Single use.
58093469|NCT06700850|DEVICE|Marketed dressing rectangle|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 30x10cm. Topical application. Single use
58093470|NCT06700850|DEVICE|Prototype dressing square|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 7.5x7.5cm. Topical application. Single use.
58420595|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
58420596|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
57950823|NCT03854864|OTHER|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
57950824|NCT02043535|DEVICE|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
57950825|NCT02043535|DEVICE|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
57950826|NCT03241953|PROCEDURE|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
57950827|NCT02854644|OTHER|additional blood sample|
58420597|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
58420598|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
58420599|NCT01840254|DRUG|dexmedetomidine|
58420600|NCT01840254|DRUG|normal saline|
58420601|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
58420602|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
58420603|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
58420604|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
58420605|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
58420606|NCT03924921|OTHER|autogenic training|autogenic training
58420607|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
58420608|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
58420609|NCT00500760|DRUG|Panitumumab|Administered intravenously
58420610|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
58420611|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
58420612|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
58420613|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
58420614|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
58420615|NCT00514345|GENETIC|gene expression analysis|
58420616|NCT00514345|GENETIC|polymorphism analysis|
58093471|NCT06700850|DEVICE|Marketed dressing square|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 7.5x7.5cm. Topical application. Single use.
58420617|NCT00514345|PROCEDURE|management of therapy complications|
57950828|NCT02324075|BEHAVIORAL|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
58093472|NCT02390973|PROCEDURE|Sleeve Gastrectomy|
58093473|NCT02390973|PROCEDURE|Roux-en-Y Gastric Bypass|
58093474|NCT02390973|PROCEDURE|Biliopancreatic Diversion with Duodenal Switch|
58093475|NCT02390973|OTHER|Medical management|
58093476|NCT05524207|PROCEDURE|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
58420618|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
58420619|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
58420620|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
58420621|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
58420622|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
58420623|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
58420624|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
58420625|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
58420626|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
58420627|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
58420628|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
58093477|NCT05183230|BEHAVIORAL|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
58420629|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
58420630|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
58420631|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
58420632|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
58420633|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
58420634|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
58420635|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
58420636|NCT00980304|DRUG|Rituximab|
58420637|NCT00554762|DRUG|GW842166X|Administer
58420638|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
58420639|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
58420640|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
58420641|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
58420642|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
58420643|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
57950829|NCT01881464|DEVICE|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
57950830|NCT01881464|DRUG|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
58420644|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
58420645|NCT01940393|DRUG|Cetirizine|Drug administration
58420646|NCT01940393|DRUG|Desloratadine|Drug Administration
58420647|NCT01940393|DRUG|Fexofenadine|Drug administration
58420648|NCT01940393|DRUG|Ebastine|Drug administration
58420649|NCT01940393|DRUG|Bilastine|Drug administration
58420650|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
57950831|NCT05965349|BEHAVIORAL|Healthy Mind, Healthy Living|A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
57950832|NCT02599701|DRUG|Gabapentin|A single dose Gabapentin 300mg at bedtime.
57950833|NCT02599701|DRUG|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
58420651|NCT00242333|DRUG|AD 237|
58420652|NCT00214084|DRUG|Allopurinol|
58420653|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
57950834|NCT04153864|BEHAVIORAL|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
57950835|NCT03027986|BEHAVIORAL|postural rehabilitation program|This program is based on sensory-motor control
57950836|NCT00343889|BIOLOGICAL|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
58420654|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
58420655|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
57735136|NCT01818323|OTHER|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
57735137|NCT06373757|OTHER|Nano-HAP/Chitosan hydrogel|The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
58420656|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
58420657|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
58420658|NCT00190047|DRUG|DP-b99|
58420659|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
58420660|NCT00386555|DRUG|docetaxel|
58420661|NCT00386555|DRUG|CP-868,596 + docetaxel|
58420662|NCT00386555|DRUG|AG-013736 + docetaxel|
58420663|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
57735138|NCT02468024|PROCEDURE|Lung Surgery|Sublobar Lung Resection
57950837|NCT00343889|BIOLOGICAL|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
57950838|NCT00343889|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine
57950839|NCT00003715|BIOLOGICAL|BCG vaccine|
58420664|NCT00139217|DRUG|iNO|
58420665|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
58420666|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
58420667|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
58420668|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
58420669|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
58420670|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
57735139|NCT02468024|RADIATION|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
57735140|NCT04537962|OTHER|Colgate Periogard® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
57735141|NCT04537962|OTHER|Colgate Peroxyl® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
58420671|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
58420672|NCT04052776|DRUG|Buspirone|40mg
58420673|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
58420674|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
58420675|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
58420676|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
58420677|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
58420678|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
58420679|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
58420680|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
58420681|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
58420682|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
58420683|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
58420684|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
58420685|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
58420686|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
58420687|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
58420688|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
58420689|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
58420690|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
58420691|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
58420692|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
58420693|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
58420694|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
58420695|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
58420696|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
58420697|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
57735142|NCT04537962|OTHER|Colgate Total® Mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
57735143|NCT04537962|OTHER|Toothpaste with sodium monofluorophosphate|Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
58306228|NCT01603680|PROCEDURE|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
58420698|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
58420699|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
58420700|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
58420701|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
58420702|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
58420703|NCT01027260|DRUG|Placebo|Variable dosing
58420704|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
58420705|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
58420706|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
58420707|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
58420708|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
58420709|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
58420710|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
58420711|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
58420712|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
57950840|NCT00003715|BIOLOGICAL|autologous tumor cell vaccine|
58420713|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
58420714|NCT00096018|DRUG|fludarabine phosphate|Given IV
58420715|NCT00096018|DRUG|thalidomide|Orally
58420716|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
58420717|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
58420718|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
57950841|NCT00003715|BIOLOGICAL|recombinant interferon alfa|
57950842|NCT00003715|DRUG|chemotherapy|
57950843|NCT00003715|DRUG|cyclophosphamide|
58306229|NCT01603680|PROCEDURE|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
58306230|NCT00176735|DRUG|Capecitabine|
58306231|NCT05509361|BIOLOGICAL|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
58306232|NCT04761003|DEVICE|Thoracoscopy forceps|take pleural biopsy
58420719|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
58420720|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
58420721|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
58420722|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
58420723|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
58420724|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
58420725|NCT00514020|GENETIC|gene expression analysis|Blood collection
58420726|NCT00514020|GENETIC|polymorphism analysis|Blood collection
58420727|NCT00514020|GENETIC|protein expression analysis|Blood collection
58420728|NCT00514020|OTHER|pharmacological study|Blood collection
58420729|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
58420730|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
58420731|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
58420732|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
58420733|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
58420734|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
58420735|NCT04248894|OTHER|Untraining|Sedentary
58420736|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
58420737|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
58420738|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
58420739|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
58420740|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
58420741|NCT02554214|DEVICE|Glafkos drainage device|
58420742|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
58420743|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
58420744|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
58420745|NCT00317408|DRUG|busulfan|
58420746|NCT00317408|DRUG|carboplatin|
58420747|NCT00317408|DRUG|carmustine|
58420748|NCT00317408|DRUG|cyclosporine|
58420749|NCT00317408|DRUG|cytarabine|
58420750|NCT00317408|DRUG|dexamethasone|
58306233|NCT04361058|DRUG|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
57735144|NCT04537962|OTHER|Toothpaste with sodium fluoride and zinc|Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
57735145|NCT04537962|OTHER|Toothpaste with tin fluoride|Patients will be submitted to brushing with toothpaste with tin fluoride
58306234|NCT03526042|DRUG|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
58306235|NCT03526042|DRUG|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
58306236|NCT06041204|DRUG|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
58420751|NCT00317408|DRUG|etoposide phosphate|
58420752|NCT00317408|DRUG|idarubicin|
58420753|NCT00317408|DRUG|ifosfamide|
58420754|NCT00317408|DRUG|leucovorin calcium|
58420755|NCT00317408|DRUG|lomustine|
58420756|NCT00317408|DRUG|melphalan|
58420757|NCT00317408|DRUG|methotrexate|
58420758|NCT00317408|DRUG|mitoxantrone hydrochloride|
58420759|NCT00317408|DRUG|prednisolone|
58420760|NCT00317408|DRUG|thiotepa|
58420761|NCT00317408|DRUG|vinblastine sulfate|
58420762|NCT00317408|DRUG|vindesine|
58420763|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58093478|NCT05183230|BEHAVIORAL|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
58420764|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
57735146|NCT01785329|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
58420765|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
58420766|NCT00317408|RADIATION|total-body irradiation|
58420767|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
58420768|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
58420769|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
58420770|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
58420771|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
58420772|NCT00054691|DRUG|Iressa|250 mg by mouth daily
58306237|NCT06041204|DRUG|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
58093479|NCT01684306|DRUG|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
58420773|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420774|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420775|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420776|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420777|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420778|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
58420779|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
58420780|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
58306238|NCT04480528|OTHER|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
58420781|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
58420782|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
58420783|NCT00388284|DEVICE|Arterial Sealing|
58420784|NCT04496375|OTHER|Survey|Self-completed questionnaires
58420785|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
58420786|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
58420787|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
58420788|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
58420789|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
58420790|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
58420791|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
58420792|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
58420793|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
58093480|NCT01684306|DRUG|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
58306239|NCT04480528|OTHER|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
58306240|NCT05951634|DEVICE|PerQseal ELITE|"Percutaneous ELITE Arterial Closure Device~The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
58306241|NCT02271321|OTHER|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
58093481|NCT03382457|DEVICE|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
58306242|NCT01494207|BEHAVIORAL|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
58306243|NCT02536911|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
58306244|NCT01873014|DRUG|chinese herbs-I|two agent per day, twice a day
58306245|NCT01873014|DRUG|chinese herbs-II|two agent per day, twice a day
58306246|NCT03451370|DRUG|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
58306247|NCT03451370|DRUG|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
58306248|NCT03451370|DRUG|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
58306249|NCT01700491|DRUG|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
58306250|NCT01700491|DRUG|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
58093482|NCT05138900|RADIATION|SBRT|SBRT for central non small cell lung cancer
58306251|NCT02595658|DIETARY_SUPPLEMENT|Meal composition|
58306252|NCT02595658|DRUG|Rapid-Acting Insulin Dose|
58306253|NCT03217292|PROCEDURE|Serratus Anterior Plane Block|
58306254|NCT03217292|DRUG|IV patient-controlled analgesia (PCA) tramadol|
58420794|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
58420795|NCT01348555|DRUG|Bronchodilatator|
58420796|NCT01348555|DRUG|Bronchodilatator|
58420797|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
58420798|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
58420799|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
58420800|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
58420801|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
58420802|NCT04764344|DRUG|Ondansetron|Ondansetron
58420803|NCT00062608|BEHAVIORAL|Written self-disclosure|
58420804|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
58420805|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
58420806|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
58420807|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
58420808|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
58420809|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
58420810|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
58420811|NCT00710385|DRUG|Heroin|Heroin (25 mg)
58420812|NCT00710385|DRUG|Naloxone|.4 mg
58420813|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
58420814|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
58420815|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
58420816|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
58420817|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
58420818|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
58420819|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
58420820|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
58420821|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
58420822|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
58420823|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
58420824|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
58420825|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
58420826|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
58420827|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
58420828|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
58420829|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
58420830|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
58420831|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
58420832|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
58420833|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
58420834|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
58420835|NCT04132635|OTHER|growth factor|growth factor
58420836|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
58420837|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
58420838|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
58420839|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
58420840|NCT02054793|DRUG|Orteronel|300 mg
57735147|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
58306255|NCT05398107|BEHAVIORAL|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
58306256|NCT05398107|BEHAVIORAL|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
57735148|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
57735149|NCT06151197|BIOLOGICAL|EN3835|Biologic: EN3835 injection
57735150|NCT06151197|OTHER|Placebo|Placebo injection
57735151|NCT01935817|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
57735152|NCT01935817|DRUG|Placebo|
57735153|NCT00802568|BIOLOGICAL|anti-thymocyte globulin|
57735154|NCT00802568|DRUG|busulfan|
57735155|NCT00802568|DRUG|fludarabine phosphate|
57735156|NCT00802568|PROCEDURE|allogeneic bone marrow transplantation|
58093483|NCT06562972|OTHER|Occlusal equilibration of complete denture using articulating paper|Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.
58093484|NCT06562972|OTHER|Occlusal equilibration of complete denture using occulosense|Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
58093485|NCT06686602|OTHER|No drug|This is a non-interventional study and no study drug will be administered.
58093486|NCT00061646|DRUG|ABT-510/Thrombospondin-1 mimetic|
58093487|NCT00061646|DRUG|Carboplatin/Taxol|
58093488|NCT06087198|DIAGNOSTIC_TEST|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
58093489|NCT00134472|PROCEDURE|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
58093490|NCT04557982|PROCEDURE|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
58093491|NCT05967624|OTHER|Teleconsultation|Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
58420841|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
58420842|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
58420843|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
58420844|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
58420845|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
58420846|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
58420847|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
58420848|NCT00154362|DRUG|Oxcarbazepine|
58420849|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
58420850|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
58420851|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
57735157|NCT00802568|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
57735158|NCT06462326|DRUG|Moxifloxacin Oral Tablet|400mg per tablet
57735159|NCT06462326|DRUG|Omadacycline Oral Tablet|150 mg per tablet
57735160|NCT06507267|OTHER|Pain and Clinical Reflections in Pelvic Congestion Syndrome|Pain and Clinical Reflections in Pelvic Congestion Syndrome
57735161|NCT04160819|OTHER|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
58093492|NCT01843439|DIETARY_SUPPLEMENT|Magnesium|
58093493|NCT01843439|BEHAVIORAL|Education for asthma action plan|
58093494|NCT01843439|BEHAVIORAL|hot-lines for acute exacerbation of asthma|
58093495|NCT01843439|BEHAVIORAL|Inhaler technique training|
58093496|NCT06642610|DEVICE|CGM Dynamic Index (CDI)|participants will undergo IV placement for a one-time OGTT and a one-time insertion of a CGM. The CGM will be worn for up to 10 days. The data collected will be used to develop the CDI. A person with CFRD and already using CGM, we will just collect their personal CGM data and they are not required to have OGTT or HbA1c visit.
58093497|NCT06700863|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
58093498|NCT04720573|DRUG|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
58093499|NCT04720573|DRUG|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
58420852|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
58420853|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
58420854|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
58420855|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
58420856|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
58420857|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
58420858|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
58420859|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
58420860|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
58420861|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
58420862|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
58420863|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
58420864|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
58420865|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
58420866|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
58420867|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
58420868|NCT00001307|DRUG|Oxygen-15 Water|
58420869|NCT00001307|DRUG|Capsaicin|
58420870|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
58420871|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
58420872|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
58420873|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
58420874|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
57735162|NCT06669026|DIETARY_SUPPLEMENT|vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel|Scaling and root debridement then inject gel in the pocket
58420875|NCT03505736|BIOLOGICAL|Adenosine|Given IV
57735163|NCT06669026|DIETARY_SUPPLEMENT|vitamin D3 gel (regular non-nanoparticle form)|Scaling and root debridement then inject gel in the pocket
57735164|NCT06669026|OTHER|Poly lactic-co-glycolic acid nanoparticles placebo gel|Scaling and root debridement then inject gel in the pocket
58420876|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
58420877|NCT03505736|DRUG|Regadenoson|Given IV
58420878|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
58420879|NCT00085332|DRUG|docetaxel|
58420880|NCT00031564|BIOLOGICAL|Interleukin-2|
58420881|NCT00031564|BIOLOGICAL|B7-1|
58420882|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
58420883|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
58420884|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
58420885|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
57735165|NCT06669026|PROCEDURE|only mechanical debridement|Scaling and root debridement
57735166|NCT03335033|COMBINATION_PRODUCT|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
57735167|NCT03335033|DEVICE|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
58420886|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
58420887|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
58420888|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
58420889|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
58420890|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
58420891|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
58420892|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
58420893|NCT01968057|DRUG|Baricitinib|Administered orally
58420894|NCT01968057|DRUG|Ciclosporin|Administered orally
58420895|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
58420896|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
58420897|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
58420898|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
58420899|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
57950844|NCT04084574|BEHAVIORAL|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
58093500|NCT00109278|BIOLOGICAL|V205C, measles, mumps, and rubella virus vaccine live|
58306257|NCT04523012|OTHER|Seroprevalence of SARS-CoV-2 infection in patients with HIV infection|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
58420900|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
58420901|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
58420902|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
58420903|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
58093501|NCT00109278|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
58093502|NCT02795780|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
58093503|NCT02795780|PROCEDURE|PET Scan|positron emission tomography (PET) scan
58093504|NCT06084572|OTHER|Questionnaires|FSSG \& BEDQ
58093505|NCT03889405|DEVICE|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
58093506|NCT03889405|DEVICE|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
58093507|NCT03889405|DEVICE|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
58420904|NCT04246814|DEVICE|CC|Application of placebo LASER.
58306258|NCT04486664|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
58306259|NCT06201312|OTHER|COP exercise|crossover point intensity exercise
58420905|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
58420906|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
58420907|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
58420908|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
58420909|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
58420910|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
58420911|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
58420912|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
58093508|NCT06080191|DRUG|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR_Lenti_ALLO~A single infusion of CD19-CAR_Lenti_ALLO on Day 0"
58420913|NCT01290900|DRUG|NXL104|IV Solution
58093509|NCT06700785|DIETARY_SUPPLEMENT|Lysine butyrate|Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.
58420914|NCT01290900|DRUG|Ceftaroline|IV Solution
58420915|NCT01290900|DRUG|Placebo Infusion|IV Saline
58420916|NCT01290900|DRUG|Ceftazidime|IV Solution
58420917|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
58420918|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
58420919|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
58420920|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
58420921|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
57735168|NCT03335033|DEVICE|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
57735169|NCT02289131|PROCEDURE|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
58093510|NCT06700785|DIETARY_SUPPLEMENT|Sodium Butyrate|Oral sodium butyrate supplement.
58306260|NCT03955172|DRUG|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
57735170|NCT02777151|DRUG|REGN3470-3471-3479|
57950845|NCT03551223|BIOLOGICAL|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
57950846|NCT01302951|DRUG|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
58093511|NCT06700785|DIETARY_SUPPLEMENT|Tributyrin|Oral tributyrin supplement.
58093512|NCT04137770|OTHER|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
58093513|NCT06272318|OTHER|Blood Pressure Cuff, EKG, PPG|A blood pressure cuff, an EKG, and a PPG will be utilized to collect subject vitals.
58306261|NCT04078620|DIAGNOSTIC_TEST|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
58420922|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
58420923|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
58420924|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
58420925|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
58420926|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
58420927|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
58420928|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
58420929|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
58420930|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
58420931|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
58420932|NCT04847557|DRUG|Tirzepatide|Administered SC
58420933|NCT04847557|OTHER|Placebo|Administered SC
57735171|NCT02777151|DRUG|Placebo|
58093514|NCT06243016|BEHAVIORAL|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
58420934|NCT01806064|DRUG|TRC105 and Axitinib|
58420935|NCT01806064|DRUG|Axitinib|
58420936|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
58420937|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
58420938|NCT04334564|DRUG|Placebos|Placebos were controls.
58093515|NCT06243016|BEHAVIORAL|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
58093516|NCT05224141|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
58093517|NCT05224141|DRUG|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
58093518|NCT05224141|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
58093519|NCT05224141|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
58093520|NCT05224141|BIOLOGICAL|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
58093521|NCT05224141|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
58093522|NCT00996918|DRUG|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
58093523|NCT00996918|DRUG|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
58093524|NCT05043220|DEVICE|PPG and PROM|description will follow
58093525|NCT06523309|OTHER|Electroacupuncture treatment|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
58093526|NCT00308100|DRUG|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
58093527|NCT00308100|DRUG|5% Albumin|5% albumin, administered intra- and perioperatively
58093528|NCT06702215|DEVICE|Cross-modal paired associative stimulation (cm-PAS) protocol|The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
58093529|NCT06567522|DRUG|Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%|Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
58093530|NCT04067856|DRUG|Bevacizumab Injection|Intravitreal injection
58093531|NCT06214793|DRUG|Taletrectinib|Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
58420939|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
58420940|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
58420941|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
58420942|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
58093532|NCT04816877|DRUG|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
58093533|NCT06701383|DEVICE|Cryoablation|Pulmonary vein isolation using cryoablation
58093534|NCT03126682|DRUG|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
58093535|NCT05581004|DRUG|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
58093536|NCT05581004|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
58093537|NCT05581004|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedules specified in the respective arms.
58093538|NCT02953418|DEVICE|Radiofrequency ablation|RFA
58095341|NCT05759182|DEVICE|Powered Exoskeleton Gait Training|A trained medical professional will adjust the exoskeleton to fit each participant and tailor the program(sit to stand, stand to sit, standing balance and weight shift, walk in place, walk forward) according to their physical condition and specific needs. Based on each participant's walking ability, appropriate safety devices (such as crutches, canes, or a harness) will be used during the intervention.
58095342|NCT03467919|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
58420943|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
57785351|NCT01084928|BEHAVIORAL|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
58093539|NCT05425277|BEHAVIORAL|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
58093540|NCT05425277|BEHAVIORAL|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
58093541|NCT00764244|PROCEDURE|Vitrectomy|Vitrectomy
58093542|NCT00764244|DRUG|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
58093543|NCT00764244|PROCEDURE|Laser photocoagulation|Laser photocoagulation
58093544|NCT05838508|BEHAVIORAL|Exercise intervention|Research participants will be assigned to two exercise conditions.
58093545|NCT05042687|DRUG|Tc99m sestamibi|Given by IV
58093546|NCT03506646|DIETARY_SUPPLEMENT|Placebo|Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
58093547|NCT03506646|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
58093548|NCT03983850|DRUG|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
58093549|NCT03983850|DRUG|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
58093550|NCT03983850|DRUG|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
58093551|NCT03983850|DRUG|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
58093552|NCT03983850|DRUG|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
58093553|NCT06701266|DEVICE|Point of Care Test|PoCT as a chairside test, ELISA as a gold standard
58093554|NCT05259696|BIOLOGICAL|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
58093555|NCT05259696|BIOLOGICAL|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
58093556|NCT03443180|OTHER|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
58093557|NCT05910320|DEVICE|Wearable Vital Signs Monitoring Device|The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
58093558|NCT06036173|OTHER|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
58093559|NCT06036173|OTHER|breast cancer surgery|be diagnosed and undergo surgery
58420944|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
58420945|NCT01978626|BEHAVIORAL|App modules|
58420946|NCT01978626|BEHAVIORAL|Traditional CBT-I|
58420947|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
58093560|NCT04758611|DEVICE|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
58093561|NCT06590987|DEVICE|Strolll AR|Strolll AR is an augmented-reality (AR) neurorehabilitation platform for delivering gait and balance exercises (assisted with cues when deemed beneficial) for Parkinson's disease onto state-of-the-art AR glasses.
58093562|NCT01582828|PROCEDURE|Epicardial (surgical) ablation|"* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure"
58093563|NCT01582828|PROCEDURE|Hybrid|"Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
58420948|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
58420949|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
58420950|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
58420951|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
58420952|NCT02223481|DRUG|Terbogrel low dose|
58420953|NCT02223481|DRUG|Terbogrel high dose|
57785352|NCT02419755|DRUG|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
58093564|NCT04977830|DEVICE|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
58093565|NCT04793815|PROCEDURE|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
58093566|NCT04793815|DRUG|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
58093567|NCT05218083|BEHAVIORAL|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation \& personalized instruction \& coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities \& general resistance exercises for major muscle groups.~Balance incorporates static \& dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward \& backward starting within base of support \& progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
58093568|NCT05558605|DIAGNOSTIC_TEST|AI-guided echo|AI-guided echocardiography
58093569|NCT05558605|DIAGNOSTIC_TEST|Standard echo|Standard echocardiography
58093570|NCT04338581|BIOLOGICAL|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
58093571|NCT04338581|BIOLOGICAL|Placebo|Placebo for AMG 714
58093572|NCT04338581|PROCEDURE|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
58093573|NCT00181831|DEVICE|Proton Magnetic Resonance Spectroscopy|
58093574|NCT05533112|OTHER|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
58093575|NCT06623526|DRUG|YHR2402|Test Drug: YHR2402
58093576|NCT06623526|DRUG|YHR2402+YHR2403|Test Drug: YHR2402+YHR2403
58093577|NCT01508923|DRUG|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
58093578|NCT01508923|DRUG|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
58093579|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58093580|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58420954|NCT02223481|DRUG|Placebo|
58420955|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
57785353|NCT02419755|DRUG|Vorinostat|Vorinostat should be taken orally (PO) with food.
57785354|NCT02419755|DRUG|Mitoxantrone|Given by intravenous (IV) injection.
57785355|NCT02419755|DRUG|Cytarabine|Given by intravenous (IV) injection.
58093581|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58093582|NCT03813394|DRUG|pembrolizumab|-Pembrolizumab in Solution for Injection
58093583|NCT03813394|DRUG|bevacizumab|"* Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution"
58093584|NCT03330847|DRUG|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
58420956|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
58420957|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
58420958|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
58420959|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
58420960|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
58420961|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
58420962|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
58420963|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
58420964|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
58420965|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
58420966|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
58093585|NCT03330847|DRUG|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
58093586|NCT03330847|DRUG|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
58093587|NCT02412696|DEVICE|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
58093588|NCT02412696|OTHER|Nasal Dilator Strips|Nasal dilator strips
58093589|NCT03688503|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
58093590|NCT03688503|DIETARY_SUPPLEMENT|placebo|placebo
58093591|NCT03724292|DRUG|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
58093592|NCT03724292|DRUG|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
58093593|NCT06366204|OTHER|Dietary Lysine Intakes|Participants consume 8 hourly meals that contain the assigned test lysine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 x Resting Energy Expenditure (REE) and adequate protein at 1.5 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and nitrogenous free cookies.
58093594|NCT02763007|DRUG|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
58093595|NCT02763007|DRUG|alogliptin|nesina add on metformin
58093596|NCT02763007|DRUG|pioglitazone|actos add on metformin
58093597|NCT04328311|OTHER|Watermelon Juice|500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
58093598|NCT04328311|OTHER|Water|500 mL low nitrate water
58093599|NCT05282810|OTHER|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
58093600|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention employing Neurofeedback|Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
58093601|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention|Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
58093602|NCT00062036|BIOLOGICAL|aldesleukin|
58093603|NCT00062036|BIOLOGICAL|filgrastim|
58093604|NCT00062036|BIOLOGICAL|incomplete Freund's adjuvant|
58093605|NCT00062036|BIOLOGICAL|interleukin-2 gene|
58093606|NCT00062036|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58093607|NCT00062036|DRUG|cyclophosphamide|
58093608|NCT00062036|DRUG|fludarabine phosphate|
58093609|NCT04112667|OTHER|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
58093610|NCT04112667|OTHER|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
58093611|NCT04112667|OTHER|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
57785356|NCT02419755|DRUG|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
58093612|NCT02548117|DRUG|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
58093613|NCT06102824|DRUG|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
58093614|NCT06102824|DRUG|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
58093615|NCT06102824|DRUG|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
58093616|NCT06102824|DRUG|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
58093617|NCT06102824|DRUG|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
58093618|NCT06102824|DRUG|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
58093619|NCT06102824|DRUG|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
58093620|NCT06102824|DRUG|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
57785357|NCT02419755|DRUG|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
58093621|NCT06102824|DRUG|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
58093622|NCT06102824|DRUG|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
58093623|NCT06102824|DRUG|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
58093624|NCT06617858|DRUG|AMB-05X|Given by IV
58093625|NCT03927989|BEHAVIORAL|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
58093626|NCT03927989|OTHER|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
58093627|NCT00774722|DRUG|Metronidazole|10% ointment, three times daily for 14 days
58093628|NCT03603405|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
58095343|NCT03467919|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
58095344|NCT00583128|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
58093629|NCT04382560|OTHER|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
58093630|NCT04382560|OTHER|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
58093631|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
58093632|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
58093633|NCT03526679|DRUG|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
58093634|NCT03526679|DRUG|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
58093635|NCT05317000|DRUG|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
58093636|NCT05317000|DRUG|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
58093637|NCT05317000|DRUG|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
58093638|NCT06045195|DRUG|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and an eBEACOPP variant without bleomycin (P-EACOPP). Response to induction therapy will be measured after P-mono (PET-1; only for scientific purposes) and after completion of 1x P and 2x P-EACOPP (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two cycles of P-EACOPP while participants with a positive PET-3 will receive four cycles of P-EACOPP. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
58093639|NCT06537440|OTHER|electro-acupuncture|Electroacupuncture ST25 Tianshu (double), TE6 Zhigou (double), LI4 Hegu (double), ST36 Ashisanli (double), ST37 Shangjuhu (double)
58093640|NCT00016835|PROCEDURE|Supra-gingival scaling and placebo|Included in arm/group description.
58093641|NCT00016835|PROCEDURE|Subgingival scaling and metronidazole|Included in arm/group description.
58093642|NCT00016835|PROCEDURE|Subgingival scaling and doxycycline|Included in arm/group description.
58093643|NCT05979688|BEHAVIORAL|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
58093644|NCT02265640|DRUG|BIIL 284 BS boli|
58093645|NCT02265640|DRUG|BIIL 284 BS tablet C|
58093646|NCT02265640|OTHER|standard breakfast|
58093647|NCT03501407|DIAGNOSTIC_TEST|Blood samples|1 or 2 blood samples will be collected from the patient.
58093648|NCT03501407|DIAGNOSTIC_TEST|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
58093649|NCT01842516|DRUG|LCB01-0371 800mg|LCB0-0371 800mg
58093650|NCT01842516|DRUG|LCB01-0371 1200mg|LCB01-0371 1200mg
57785358|NCT02419755|DRUG|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
57785359|NCT02419755|DRUG|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
58093651|NCT01842516|DRUG|Placebo|Placebo
58093652|NCT06451679|OTHER|Observational|Observational prospective study
58093653|NCT03955718|BEHAVIORAL|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
58093654|NCT03955718|BEHAVIORAL|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
58095345|NCT00583128|DRUG|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
58095346|NCT02622607|DRUG|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
58095347|NCT03286400|DEVICE|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
57785360|NCT02419755|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
58093655|NCT03494816|DRUG|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
58093656|NCT06354764|OTHER|no intervention|no intervention
58093657|NCT05640908|DEVICE|iFuse Bedrock Granite Implant System|Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
58093658|NCT05278949|OTHER|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
58420967|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
58093659|NCT06588660|BIOLOGICAL|Vevoctadekin|Given SC
58093660|NCT06588660|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58093661|NCT06588660|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58093662|NCT06588660|OTHER|Medical Chart Review|Ancillary studies
58093663|NCT06588660|DRUG|Teclistamab|Given SC
58093664|NCT06588660|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58093665|NCT06048081|DRUG|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
58093666|NCT02404272|OTHER|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
58093667|NCT05923541|DRUG|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
58093668|NCT02437981|DRUG|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
58093669|NCT00757198|DRUG|remifentanil|remifentanil infusion
58093670|NCT00757198|DRUG|remifentanil|remifentanil infusion
58420968|NCT02355951|OTHER|blood draw|
58420969|NCT00025155|DRUG|ixabepilone|Given IV
58420970|NCT02314364|RADIATION|SBRT with protons or photons|
57785361|NCT02419755|DRUG|Mercaptopurine|Given orally (PO).
57950847|NCT01155804|BEHAVIORAL|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
58420971|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
57785362|NCT02419755|DRUG|Doxorubicin|Given intravenously (IV).
57785363|NCT03494374|DEVICE|UCBL orthosis|toe walking exercise
57950848|NCT01838109|DIETARY_SUPPLEMENT|oral nutritional supplement|
57950849|NCT04296370|DRUG|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
57950850|NCT04296370|DRUG|Fluzoparib|Fluzoparib Orally twice daily
57950851|NCT04296370|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
58093671|NCT06550362|DRUG|iron sulfate|Oral iron administration
58093672|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
58093673|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
57785364|NCT00885495|DRUG|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
58093674|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
58093675|NCT06229262|DIETARY_SUPPLEMENT|Mango group|Participants will consume 1.5 cups of mangos per day for 12 weeks.
58093676|NCT06345183|COMBINATION_PRODUCT|Nivolumab + Ipilimumab combination therapy|As per product label
58093677|NCT06345183|COMBINATION_PRODUCT|Pembrolizumab + Lenvatinib combination therapy|As per product label
58093678|NCT00568100|PROCEDURE|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
58420972|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
58093679|NCT06060314|PROCEDURE|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
58093680|NCT06060314|PROCEDURE|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
58093681|NCT05447559|DRUG|Cefazolin|Intravenous administration of 2 g cefazolin
58093682|NCT05447559|DRUG|Water for injection|Intravenous administration of 10mL sterile water for injection
58093683|NCT04638829|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
58420973|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
58093684|NCT06215313|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|In the EMDR condition, the Dutch version of the treatment protocol based on Shapiro's original work (2001) is followed. In the first session, the rationale of EMDR is explained. The patient describes the memory, and identifies the most aversive still image, the associated negative cognition, desired positive cognition, feelings, somatic sensations, and perceived tension, as measured by Subjective Unit of Distress (SUDs). Desensitization then begins by asking patients to focus on the still image while following the movement of a light bar or the therapist's fingers with their eyes (i.e., eye tracking task). Then, in the installation phase, the patient focuses on the positive cognition during the eye tracking task. When the validity of the positive cognition is 6 to 7 on a 7-point Likert scale, a body scan is performed to ensure that no unresolved traumatic material remains. Each session ends with a reflection and debriefing.
58093685|NCT06215313|BEHAVIORAL|Imagery Rescripting|The IR condition, following Arntz and Weertman's (1999) protocol, addresses traumatic or aversive memories by creating alternative scenarios. In the first session, the method is explained. The patient describes their memory in the present tense, from the first-person perspective, and describes associated feelings, thoughts, and emotional needs. The therapist then seeks permission to 'enter' the scene, guiding the patient to visualise an alternative, emotionally satisfying course of events. This may involve the therapist or patient intervening in the situation, ensuring the patient's emotional needs are met. The patient then relives the memory from the point of view of their younger self, with the adult-self intervening in the scene. The process continues until all emotional needs are fulfilled. Generally, one trauma memory is rescripted per session. The initial IR session involves therapist-led rescripting, with subsequent sessions encouraging patient-led rescripting whenever possible.
58093686|NCT02041000|OTHER|Adipose Derived Stem Cells|
58093687|NCT06702501|DEVICE|PeriCut Catheter System performs minimally invasive pericardiotomy|The PeriCut Catheter System will incise the pericardium to reduce filling pressures of the heart.
58093688|NCT06542445|DRUG|Oral CBD oil enriched with terpenes|"Stage I dosing, increasing titration:~days 1-2: 2.5 mg/kg BW/day; days 3-4: 5 mg/kg BW/day; day 5-7: 7.5 mg/kg BW/day; days 8-35: 10 mg/kg BW/day.~Stage II dosing, increasing titration:~days 36-37: 2.5 mg/kg BW/day; days 38-39: 5 mg/kg BW/day; day 40-42: 7.5 mg/kg BW/day; days 43-70:10 mg/kg BW/day."
58093689|NCT06542445|DRUG|Oral Placebo|Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
58093690|NCT03993288|DRUG|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
58093691|NCT03993288|DRUG|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
58093692|NCT04668300|BIOLOGICAL|Durvalumab|Given IV
58093693|NCT04668300|BIOLOGICAL|Oleclumab|Given IV
58093694|NCT05690464|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
58420974|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
58420975|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
58420976|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
57735172|NCT05695365|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
57735173|NCT04396067|DRUG|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
58093695|NCT05690464|DIETARY_SUPPLEMENT|placebo|placebo
58093696|NCT04443673|DIETARY_SUPPLEMENT|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
58420977|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
58420978|NCT00820404|DRUG|BLI-489|
58420979|NCT00820404|DRUG|Placebo|
58420980|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
58420981|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
58093697|NCT03992456|BIOLOGICAL|Panitumumab|Given IV
58093698|NCT03992456|OTHER|Quality-of-Life Assessment|Ancillary studies
58093699|NCT03992456|OTHER|Questionnaire Administration|Ancillary studies
58093700|NCT03992456|DRUG|Regorafenib|Given PO
58093701|NCT03992456|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
58093702|NCT04960254|BEHAVIORAL|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy \& Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
58093703|NCT06087991|BEHAVIORAL|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
58093704|NCT03684473|BEHAVIORAL|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
58093705|NCT06704152|DRUG|SOC + BSB-1001 Dose Escalation Cohort|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).
58093706|NCT06704152|DRUG|SOC+BSB-1001 Expansion Dose|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
58093707|NCT00929201|DRUG|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
58093708|NCT00929201|DRUG|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
58093709|NCT00929201|DRUG|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
58093710|NCT04400253|BEHAVIORAL|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
58093711|NCT06156631|BEHAVIORAL|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
58093712|NCT03665246|BEHAVIORAL|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
58093713|NCT06704022|DIETARY_SUPPLEMENT|Oral nutritional supplement|Consumption of the oral nutritional supplement
58093714|NCT00398632|DRUG|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
58093715|NCT05442489|DEVICE|GORE Excluder Thoracoabdominal Branch Endoprosthesis|TEVAR
58093716|NCT00424515|DRUG|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
58095348|NCT01811121|DRUG|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
58420982|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
57735174|NCT04396067|DRUG|Aerosolized All trans retinoic acid|The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
57735175|NCT04396067|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
57735176|NCT02853968|PROCEDURE|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
57735177|NCT01559298|DRUG|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
58306262|NCT05301439|PROCEDURE|Restoration with Resin|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months."
58420983|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
57735178|NCT01559298|DRUG|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
57950852|NCT05209503|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
57950853|NCT05209503|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
57950854|NCT05437120|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
57950855|NCT04897464|OTHER|BGaze therapy Alzheimer|BGaze Therapy is an interactive eye tracking game
58420984|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
58420985|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
58420986|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
57950856|NCT03782376|DRUG|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
57950857|NCT03782376|DRUG|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
58420987|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
58420988|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
58420989|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
58420990|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
58420991|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
57950858|NCT03782376|DRUG|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
57950859|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
57950860|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
57950861|NCT04966546|DRUG|Memantine Hydrochloride|Active drug arm
57950862|NCT04966546|DRUG|Placebo|Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
58420992|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
58420993|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
58420994|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
58420995|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
58420996|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
58420997|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
58420998|NCT00148447|DRUG|escitalopram|
58420999|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
58421000|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
57735179|NCT06670209|DRUG|GZR18 and metformin|GZR18: 3 mg-18 mg Metformin: 500 mg
57785365|NCT00885495|DRUG|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
57950863|NCT04342871|BEHAVIORAL|FACT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
57950864|NCT03889314|DRUG|Rosuvastatin 20mg|Statin Therapy
57950865|NCT03889314|OTHER|Placebo|Placebo
57950866|NCT02589444|DIETARY_SUPPLEMENT|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
57950867|NCT02589444|OTHER|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
58095349|NCT01811121|DRUG|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
58421001|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
58421002|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
58093717|NCT06701695|PROCEDURE|Periarticular Injection (PAI)|Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
58093718|NCT06701695|PROCEDURE|Control (Standard treatment)|The control group received the conventional treatment protocol.
58093719|NCT06700811|DRUG|Ketogenic diet|The ketogenic diet formula will be supplied by KetoVie®. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 0.3mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1 (goal 4:1, minimum 1:1 if required for tolerance or high BHB) and will not exceed this ratio. Higher ratios are often required to obtain ketosis of ideally 2-5mmol/L in infants.
58093720|NCT04729504|BEHAVIORAL|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
58093721|NCT04690660|OTHER|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
58093722|NCT04690660|OTHER|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
57950868|NCT02589444|OTHER|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
58093723|NCT04690660|OTHER|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
58421003|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
58421004|NCT03394690|OTHER|control|2 capsuls
58421005|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
58421006|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
58421007|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
58421008|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
58093724|NCT04690660|OTHER|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
58421009|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
58421010|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
58421011|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
58421012|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
58093725|NCT04690660|OTHER|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
58093726|NCT03970278|OTHER|No intervention|No intervention
58093727|NCT06567457|BIOLOGICAL|SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
58093728|NCT06567457|BIOLOGICAL|SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
58093729|NCT02287142|PROCEDURE|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
58421013|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
58421014|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
57950869|NCT02589444|OTHER|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
58093730|NCT06542068|BEHAVIORAL|Line Bot Assistance|"The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.)."
58093731|NCT05630235|DRUG|CBD/CBD-A|Participants will be administered a one-time dose of 217.7 mg of CBD/CBD-A orally.
58093732|NCT05630235|OTHER|Placebo|The placebo equivalent of the CBD/CBD-A dose administered orally.
58421015|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
58421016|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
58421017|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
58421018|NCT00226135|DRUG|lithium or lamotrigine|
58421019|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
58421020|NCT01051401|DRUG|rosuvastatin|Given PO
58421021|NCT01051401|OTHER|placebo|Given PO
58421022|NCT01051401|OTHER|survey administration|Correlative study
58421023|NCT01051401|PROCEDURE|management of therapy complications|
58421024|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
58421025|NCT00109356|DRUG|AQ4N (Chemotherapy)|
58421026|NCT00346645|DRUG|Bortezomid (VELCADE®)|
58421027|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
58421028|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
58421029|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
58421030|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
58421031|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
58421032|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
58421033|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
58421034|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
58421035|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
58421036|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
58421037|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
58421038|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
58421039|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
58421040|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
58421041|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
58421042|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
58421043|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
58421044|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
58093733|NCT02050373|RADIATION|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
58421045|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
57735180|NCT06276192|OTHER|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
58093734|NCT05358392|OTHER|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
58421046|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
58093735|NCT05919069|DRUG|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
58093736|NCT05461248|PROCEDURE|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
58093737|NCT05461248|PROCEDURE|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
58093738|NCT02709759|BEHAVIORAL|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
58093739|NCT02709759|BEHAVIORAL|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
58093740|NCT02709759|BEHAVIORAL|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
58093741|NCT06662435|BEHAVIORAL|GYNCOG|"Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours."
58093742|NCT06702735|BEHAVIORAL|Rainbow tool|The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
58093743|NCT06702735|BEHAVIORAL|Feedback|Feedback sessions with health care professional based on the Rainbow tool.
58095350|NCT06697977|DIETARY_SUPPLEMENT|phytosterols|2 grams of phytosterols given as 7 pills per day
58095351|NCT06697977|DIETARY_SUPPLEMENT|placebo|placebo 7 pills per day
58421047|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
58421048|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
58093744|NCT06581848|DRUG|Elranatamab|According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
58093745|NCT00514709|BIOLOGICAL|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
58093746|NCT00514709|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, IM
58093747|NCT00514709|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine.
58093748|NCT05357261|BEHAVIORAL|Wellness Check and Socialization|In-home delivery with opportunity for driver observation and interaction
58093749|NCT05357261|OTHER|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
58093750|NCT03650179|OTHER|Observational study : No intervention|Observational study : No intervention. Only exporting data
58093751|NCT05705544|DEVICE|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
58093752|NCT05705544|DEVICE|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
58093753|NCT04491942|DRUG|Cisplatin|Given IV
58421049|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
58093754|NCT04491942|DRUG|Elimusertib|Given PO
58093755|NCT04491942|DRUG|Gemcitabine Hydrochloride|Given IV
58093756|NCT03493945|BIOLOGICAL|M7824|1,200 mg IV once every 2 weeks
58093757|NCT03493945|DRUG|N-803|8-15 mcg/kg subcutaneous every 2 weeks
58093758|NCT03493945|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
58093759|NCT03493945|BIOLOGICAL|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA-BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
58093760|NCT03493945|DRUG|Epacadostat|600 mg orally twice daily (1200 MG total)
58093761|NCT04519203|DEVICE|SPI|Either standard monitoring alone or added with SPI
58093762|NCT04519203|DEVICE|Standard|Standard monitoring alone
58093763|NCT05862714|DRUG|Fluconazole|400 mg stat. Follow up at 4 weeks
58093764|NCT05862714|DRUG|Itraconazole|1000 mg stat. Follow up at 4 weeks
58093765|NCT06374147|DEVICE|SVS mattress|The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
58093766|NCT06337968|PROCEDURE|Circum-psoas Block|Ultrasound-guided circum-psoas block with 40 mL of treatment drug (Ropivacaine 0.2% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
58093767|NCT06337968|PROCEDURE|Sham block|Perform ultrasound scanning without puncture.
58093768|NCT03178474|OTHER|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
58093769|NCT03178474|OTHER|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
57735181|NCT06276192|OTHER|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
58093770|NCT03178474|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
58093771|NCT03848000|OTHER|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
58093772|NCT03848000|BEHAVIORAL|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
58093773|NCT05991778|DEVICE|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
58095352|NCT05255783|DEVICE|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
58095353|NCT04247646|DIETARY_SUPPLEMENT|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
58093774|NCT05991778|DIAGNOSTIC_TEST|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
58093775|NCT05991778|DIAGNOSTIC_TEST|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
58093776|NCT06290609|DEVICE|Vibrotactile Coordinated Reset|The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
58093777|NCT05556031|OTHER|Standard care|Standard clinical care
57735182|NCT05450965|DRUG|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
58093778|NCT01251874|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58093779|NCT01251874|DRUG|Carboplatin|Given IV
58421050|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
58421051|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
58421052|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
58421053|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
58421054|NCT05511350|DRUG|TJ210001|
58421055|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
58421056|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
58421057|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
58421058|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
57735183|NCT04616157|BEHAVIORAL|ICBT-I|Cognitive-behavioral therapy for insomnia
57785366|NCT02746536|OTHER|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
58093780|NCT01251874|PROCEDURE|Computed Tomography|Undergo PET/CT
58093781|NCT01251874|OTHER|Fluorothymidine F-18|Given FLT
58093782|NCT01251874|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58093783|NCT01251874|DRUG|Veliparib|Given PO
58093784|NCT05302700|BEHAVIORAL|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
58093785|NCT06702488|DRUG|dexmedetomidine|20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
58421059|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
58421060|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
58421061|NCT00043927|DRUG|topotecan/cisplatin|
58093786|NCT04241185|DRUG|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
58093787|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
58093788|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
58421062|NCT00043927|DRUG|etoposide/cisplatin|
58421063|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
58421064|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
58421065|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
58093789|NCT04241185|RADIATION|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
58093790|NCT04241185|DRUG|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
58093791|NCT04241185|DRUG|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
58421066|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
58421067|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
58421068|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
58093792|NCT04241185|DRUG|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
58093793|NCT04241185|DRUG|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
58093794|NCT04241185|DRUG|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
58093795|NCT03735238|OTHER|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
58093796|NCT06702293|BEHAVIORAL|Digital psychotherapeutic intervention|Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.
58093797|NCT06702293|BEHAVIORAL|Healthy365|Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
58093798|NCT06700512|DEVICE|Hearing Aid Signia Pure C&G 7IX|Receiver in Canal (RIC) hearing aid, M Receiver
58093799|NCT06700512|DEVICE|Own Hearing Aid|subjects' own hearing aids, any brand, any model
58093800|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
58093801|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
58093802|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
58093803|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
58093804|NCT04631406|BIOLOGICAL|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
58093805|NCT06656390|DRUG|ALK201|Administered intravenously, once every 3 weeks
58421069|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
58421070|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
58421071|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
58421072|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
58093806|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
58093807|NCT00719758|DRUG|TRK-100STP (BERASUS LA)|oral
58093808|NCT00719758|DRUG|AST-120 (Kremezin®)|oral
58093809|NCT01342367|DRUG|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
58093810|NCT01342367|DRUG|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
58093811|NCT01342367|DRUG|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
58093812|NCT01342367|RADIATION|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
58421073|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
58093813|NCT06567626|OTHER|Decision Support Tool (DECIDE-CAD)|DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
58093814|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e4|
58093815|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e5|
58093816|NCT02076139|OTHER|Distilled water|
58093817|NCT05470140|BIOLOGICAL|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
58093818|NCT06427954|BEHAVIORAL|Digital Health App|access to a digital health app
58093819|NCT01150409|DRUG|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
58421074|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
58421075|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
58093820|NCT01150409|DRUG|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
58093821|NCT05103410|DRUG|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
58093822|NCT05103410|DRUG|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
58093823|NCT01731431|OTHER|Insulin|
58093824|NCT01731431|DRUG|Glyburide|
58093825|NCT06442384|OTHER|Tobacco and non-tobacco e-cigarettes|Participants with no e-cigarette restrictions.
58093826|NCT06442384|OTHER|Tobacco only e-cigarettes|Participants restricted to tobacco flavored e-cigarettes only.
58093827|NCT01470352|DRUG|Doluxetine|30 mg/d
57735184|NCT05985187|DRUG|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
58093828|NCT01470352|DRUG|Placebo|suger pill 30mg/d
58093829|NCT04365842|BEHAVIORAL|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
58093830|NCT04365842|OTHER|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
58093831|NCT01205542|BEHAVIORAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
58093832|NCT01205542|BEHAVIORAL|Reference|Health check and advice to continue ordinary physical activity
58093833|NCT01612780|DEVICE|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
58093834|NCT05005130|OTHER|TASKPEN|"TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)"
58093835|NCT00001972|DRUG|15 O Water|
58093836|NCT02856620|OTHER|Observational only|Observational only
58093837|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
58093838|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
58093839|NCT06266975|DEVICE|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
58093840|NCT06229379|DEVICE|"Digital twin patient"|"Digital twin patient can serve as patients with specific diseases for medical students to acquire disease history and thus practice clinical questioning skills."
57785367|NCT02746536|OTHER|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
58093841|NCT06229379|BEHAVIORAL|Interaction with real patients|As in traditional medical education, medical students need to interact with real patients to practice history collection skills.
58093842|NCT06195358|DEVICE|Mobile Health (Smartphone) Application|The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
58093843|NCT06195358|OTHER|Printed Caregiving Materials|The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
58095354|NCT04247646|DIETARY_SUPPLEMENT|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
58095355|NCT03192566|DRUG|Tylenol|Dosing of Tylenol for post operative pain control
58095356|NCT05633901|OTHER|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
58093844|NCT06280794|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
58093845|NCT06280794|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
58093846|NCT05150340|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
58093847|NCT03745326|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
58093848|NCT03745326|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.
58093849|NCT03745326|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
58093850|NCT03745326|BIOLOGICAL|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
58093851|NCT04730544|DRUG|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
58421076|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
58421077|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
57735185|NCT05985187|DRUG|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
57735186|NCT03589898|DRUG|Gabapentin|Single dose of gabapentin 900 mg
57735187|NCT01510847|DRUG|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
57735188|NCT05041673|DRUG|Metformin|Antidiabetic drugs
58093852|NCT04730544|DRUG|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
58093853|NCT01556165|DRUG|rasagiline|1 mg/day, tablets, once daily, orally
58093854|NCT01556165|DRUG|placebo|tablets, once daily, orally
58093855|NCT06666426|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
58093856|NCT06666426|DEVICE|Hollister Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.
58093857|NCT03768388|DRUG|levoketoconazole|food effect
58093858|NCT00289939|BEHAVIORAL|Motivational interviewing to reduce risk for HIV and DV|
58093859|NCT06154772|OTHER|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
58093860|NCT01243645|BEHAVIORAL|biofeedback training|
57950870|NCT02589444|PROCEDURE|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
58093861|NCT05418387|BEHAVIORAL|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
58093862|NCT05418387|BEHAVIORAL|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
58421078|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
58421079|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
58421080|NCT02482402|DRUG|Placebo|inhalation solution placebo
58421081|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
57735189|NCT01914796|DRUG|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
58093863|NCT06700525|BEHAVIORAL|Non-Sedentary Behavior Habit Formation|"Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time."
58093864|NCT06700525|BEHAVIORAL|Sedentary Screen Time Reduction Smartphone App|The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
58093865|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
58093866|NCT03911466|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
58421082|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
58421083|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
58421084|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
58421085|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
58421086|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
58421087|NCT02925169|DEVICE|CT Scan|CT imaging
58421088|NCT00199667|DRUG|Mycophenolate Mofetil|
57735190|NCT01914796|DRUG|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
57735191|NCT06529952|PROCEDURE|hysteroscopic surgery by resection and endocoagulation|resection of lower edge, resection of upper edge and endocoagulation
58093867|NCT03911466|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
58093868|NCT06271941|PROCEDURE|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
58093869|NCT06271941|PROCEDURE|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
57950871|NCT01428284|DRUG|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
58093870|NCT01005407|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
57735192|NCT06529952|PROCEDURE|hysteroscopic surgery by endocoagulation only|hysteroscopic endocoagulation to the base of the niche by roller ball
58093871|NCT01005407|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
58093872|NCT02102529|PROCEDURE|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
58093873|NCT03347474|PROCEDURE|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
58093874|NCT04183660|DEVICE|MOBYBOX System|extracorporeal cardiopulmonary support
58093875|NCT06704126|OTHER|Passive movement|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes.
58093876|NCT06704126|OTHER|Passive movement with blood flow restriction|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes. During the 60 seconds on of passive movement training, blood flow restriction cuffs which will be applied to the legs, will be inflated to cause 80% arterial blood flow occlusion.
58093877|NCT01102972|DRUG|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
58093878|NCT01102972|DRUG|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
58093879|NCT05548543|DRUG|HCP2202|Take it once per period.
58093880|NCT05548543|DRUG|RLD2202|Take it once per period.
58093881|NCT05548543|DRUG|RLD2203|Take it once per period.
58093882|NCT02617446|DRUG|Placebo|IV of matching saline solution
58093883|NCT02617446|DRUG|Istaroxime|IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
58093884|NCT01262274|DRUG|Anastrozole|ANA is given 1mg daily for 24 weeks.
57735193|NCT06529952|DRUG|hormonal treatment|using 3rd generation contraceptive pills
57735194|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
57950872|NCT00750737|DRUG|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
57950873|NCT00750737|DRUG|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
58093885|NCT01262274|DRUG|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
58093886|NCT04793828|BEHAVIORAL|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
58093887|NCT06396091|DRUG|zolbetuximab|Zolbetuximab will be administered intravenously on day 1 then every two weeks.
58093888|NCT06396091|DRUG|mFOLFIRINOX|Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
58093889|NCT06019286|DIAGNOSTIC_TEST|SCINEXA score|- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
58093890|NCT06234124|DEVICE|Variable Friction Shoe Training|The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
58095357|NCT05633901|OTHER|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
58095358|NCT06538246|BEHAVIORAL|Blueprint|This is a mobile app-based adaptive coping skills intervention that lasts 1 month
57735195|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
57735196|NCT02370212|DIETARY_SUPPLEMENT|Creatine|
57735197|NCT02370212|DIETARY_SUPPLEMENT|Placebo|
57735198|NCT02370212|OTHER|High intensity interval training|
58421089|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
58421090|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
58421091|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
58421092|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
58421093|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
58421094|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
58093891|NCT06234124|DEVICE|Ankle Foot Orthosis (AFO) Training|The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
58093892|NCT06700746|PROCEDURE|Prolotherapy|Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions
58421095|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
58421096|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
58421097|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
58421098|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
58421099|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
58421100|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
58421101|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
58093893|NCT06700746|DEVICE|Extracorporeal shock wave therapy (ESWT)|Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
58093894|NCT06275893|BIOLOGICAL|IC14|recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
58093895|NCT00923013|DRUG|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
58421102|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
58421103|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
58093896|NCT00923013|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
58421104|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
58421105|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
58421106|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
58421107|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
58421108|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
58421109|NCT02450968|DRUG|Dexamethasone|
58421110|NCT02450968|DRUG|Placebo|
58421111|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
58421112|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
57735199|NCT04830449|DRUG|HCP1904-2|Take it once daily for 8 weeks orally.
57735200|NCT04830449|DRUG|RLD2001-2|Take it once daily for 8 weeks orally.
57950874|NCT03141736|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
58093897|NCT04950413|OTHER|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
58421113|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
58421114|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
58421115|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
58421116|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
58421117|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
58421118|NCT00875940|OTHER|Diagnostic imaging procedures.|
58421119|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
58421120|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
58421121|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
58421122|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
58421123|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
58421124|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
58421125|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
58421126|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
57950875|NCT03141736|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
58093898|NCT04950413|OTHER|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
58095359|NCT06538246|BEHAVIORAL|Education program|This is a mobile app-based education program that lasts 1 month
58421127|NCT06171074|BIOLOGICAL|CM310|CM310 injection
58421128|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
57735201|NCT06666400|BEHAVIORAL|LHMoms Intervention|The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 12-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
57735202|NCT06666400|OTHER|No intervention|Standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
57735203|NCT02868060|DRUG|Romiplostim|
58093899|NCT04950413|DEVICE|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
58093900|NCT04049695|BEHAVIORAL|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
58093901|NCT04049695|BEHAVIORAL|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
58093902|NCT05960773|DRUG|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
58093903|NCT02454413|OTHER|denture brushing with water and soap|denture brushing with water and soap
58093904|NCT02454413|OTHER|ultrasonic denture cleaning|ultrasonic denture cleaning
58093905|NCT02454413|OTHER|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
58093906|NCT06495268|OTHER|Individualised data-driven hearing rehabilitation|"HA fittings will be conducted with the Real-Ear Measurements (REM) method that is recommended by the latest ISO-standard (21388:2020) and by the preliminary results of the BREM study at KUH. After the fitting of the HAs, participants' auditory-related outcomes will be immediately assessed using DigiKuulo and re-fitting is performed if needed based on the following criteria:~1. The absolute improvement in the DIN test is less than 1,5dB (SNR), OR~2. The absolute result of the DIN test is more than -8,5 dB (SNR) OR~3. The participant is unsatisfied with the HA fitting~Participants are invited to intervention-related monitoring appointments at 3, 6 and 12 months after the primary HA fitting. At these visits, auditory outcomes of the rehabilitation are assessed via DigiKuulo and re-fittings are performed as needed."
58095360|NCT05012098|DRUG|Bintrafusp alfa / M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
58421129|NCT01496105|DRUG|Lidocaine|
58421130|NCT01496105|DRUG|saline|
58421131|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
58421132|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
58421133|NCT00024011|DRUG|bortezomib|Given IV
57735204|NCT06369298|DRUG|JK07|JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
58421134|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
57735205|NCT06369298|DRUG|Placebo|0.9% sodium chloride
57735206|NCT05880992|BEHAVIORAL|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
58421135|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
58421136|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
58421137|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
58421138|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
58421139|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
58421140|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
58421141|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
58421142|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
58421143|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
58421144|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
58421145|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
58421146|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
58421147|NCT01123473|DRUG|capecitabine|
58421148|NCT01123473|DRUG|cisplatin|
58421149|NCT01123473|DRUG|epirubicin hydrochloride|
58421150|NCT01123473|DRUG|fluorouracil|
58421151|NCT01123473|DRUG|lapatinib ditosylate|
57735207|NCT05880992|DIETARY_SUPPLEMENT|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
57735208|NCT05880992|BEHAVIORAL|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
57735209|NCT00450827|BIOLOGICAL|bevacizumab|
57735210|NCT00450827|BIOLOGICAL|filgrastim|
58421152|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
58421153|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
58421154|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
58421155|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
58421156|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
58421157|NCT01977690|DEVICE|Clavicle Brace|
58421158|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
58421159|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
58421160|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
58421161|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
57735211|NCT00450827|PROCEDURE|autologous hematopoietic stem cell transplantation|
57735212|NCT00450827|RADIATION|iodine I 131 monoclonal antibody 3F8|
57735213|NCT04347681|OTHER|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
57735214|NCT02136277|DRUG|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
58421162|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
58421163|NCT05883618|OTHER|Exposure|Human Development Index of Country
58421164|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
58421165|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
58421166|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
58421167|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
58421168|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
58421169|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
58421170|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
58421171|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
58421172|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
58421173|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
58421174|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
58421175|NCT00201123|OTHER|Placebo|
58421176|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
58421177|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
58421178|NCT00523497|DEVICE|Non invasive mechanical ventilation|
58421179|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
58421180|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
58421181|NCT01410708|DRUG|Dasatinib|
58421182|NCT00016965|DRUG|ixabepilone|
58421183|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
58421184|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
58421185|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
58421186|NCT04969315|DRUG|TT-10|TT-10 orally administered BID starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate based on emerging safety, PK or PD data).
58421187|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
57735215|NCT04740515|OTHER|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
58093907|NCT06495268|OTHER|Standard care hearing rehabilitation|HA will be fitted with automatic algorithms by HA manufacturers and REM-fitting is only applied in complex cases based on the hearing rehabilitator's clinical judgement. Three months after the HA fitting, participants will be contacted via phone call to inquire about the status of the rehabilitation. Additional monitoring visits may be offered based on the participant's feedback. After the 3-month monitoring phone call participants will be advised to further contact the study team if they are dissatisfied with the amplification or for any other problem with their device.
58093908|NCT02099331|DRUG|Melatonin|
58093909|NCT02099331|DRUG|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
58093910|NCT06462469|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
58093911|NCT06702592|BEHAVIORAL|Virtual support|Subjects will use a virtual support platform that was built for their needs.
58093912|NCT06702592|BEHAVIORAL|Patient educational material|Participants will have access to patient educational material.
58093913|NCT03818867|PROCEDURE|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
58093914|NCT00639158|DRUG|ABT-335|135 mg capsule, daily, 12 weeks
58093915|NCT00639158|DRUG|placebo|placebo capsule, daily, 12 weeks
58421188|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
58421189|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
58421190|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
57735216|NCT03713593|DRUG|lenvatinib|Administered orally once a day
57735217|NCT03713593|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
57735218|NCT03713593|DRUG|saline placebo|Administered as an IV infusion on Day 1 Q3W
57735219|NCT02959437|DRUG|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
58093916|NCT00639158|DRUG|atorvastatin|40 mg, tablet, daily, 12 weeks
58093917|NCT00639158|DRUG|ezetimibe|10 mg capsule, daily, 12 weeks
58093918|NCT06538844|DRUG|Intravenous infusion of human albumin|Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
58093919|NCT06538844|DRUG|Saline|Equivalent volume of isotonic saline control
58093920|NCT06568367|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
58093921|NCT06568367|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
58093922|NCT06568367|DRUG|Placebo|Placebo tablets, taken once daily
58093923|NCT06703554|OTHER|Sage Oil Mouthwash|Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
58093924|NCT06703554|BIOLOGICAL|Chlorohexidine Mouthwash|0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
58093925|NCT03398161|OTHER|Quality-of-Life Assessment|Ancillary studies
58093926|NCT03398161|OTHER|Questionnaire Administration|Ancillary studies
58093927|NCT03398161|RADIATION|Radiation Therapy|Undergo ultra low dose radiation therapy
58421191|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
58421192|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
58421193|NCT00758589|DRUG|Placebo|
58421194|NCT03699137|OTHER|No interventions|No interventions
58421195|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
57735220|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
57735221|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily.
57735222|NCT02959437|DRUG|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
57735223|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
57735224|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
57735225|NCT02959437|DRUG|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
57735226|NCT01240174|BEHAVIORAL|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
57735227|NCT03405987|DIAGNOSTIC_TEST|Strain analysis by CMR|Strain analysis by CMR will be performed
58093928|NCT06703996|OTHER|Discussion|Participate in check-in/goal-setting discussions
58093929|NCT06703996|OTHER|Medical Device Usage and Evaluation|Wear the InBody Band 3 fitness tracker
58421196|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
58093930|NCT06703996|OTHER|Questionnaire Administration|Ancillary studies
58421197|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
58421198|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
58421199|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
58421200|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
58421201|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
58421202|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
58421203|NCT02337725|DRUG|Placebo|Placebo tablets
58421204|NCT00002299|DRUG|Interferon beta-1b|
58421205|NCT00002299|DRUG|Ganciclovir|
58421206|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
58421207|NCT02108665|RADIATION|Radiographic hysterosalpingography|
57735228|NCT06669845|PROCEDURE|Ultrasonography, Pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
57785368|NCT03385057|DRUG|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
58093931|NCT06667076|DRUG|Amivantamab|Amivantamab will be administered subcutaneously.
58093932|NCT06667076|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
58093933|NCT06667076|DRUG|Chemotherapy: Pemetrexed|Pemetrexed will be administered through IV infusion.
58093934|NCT06667076|DRUG|Chemotherapy: Carboplatin|Carboplatin will be administered through IV infusion.
58093935|NCT02339428|DRUG|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
58421208|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
58421209|NCT01731093|DRUG|AT-001|
58421210|NCT01731093|DRUG|Placebo|
58421211|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
58421212|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
58421213|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
58421214|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
58421215|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
58421216|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
58421217|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
58421218|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
58421219|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
58421220|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
57785369|NCT03385057|DRUG|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
58421221|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
58421222|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
58093936|NCT02339428|DRUG|Placebo|Inactive pill manufactured to mimic diclofenac tablet
58093937|NCT05529992|DRUG|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
58093938|NCT06701175|PROCEDURE|Nerve Block|anterolateral geniculate nerve block
58093939|NCT06701175|PROCEDURE|Portal Anesthesia|portal anesthesia
58093940|NCT04930536|DRUG|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
58093941|NCT06312761|DRUG|Relugolix 120Mg Tab|Relugolix 120 mg single dose - All subjects
58093942|NCT06312761|DIETARY_SUPPLEMENT|Curcumin|Curcumin 630 mg single dose
58093943|NCT06312761|DRUG|Testosterone Undecanoate 237 MG Oral Capsule|Testosterone Undecanoate 237 MG Oral Capsule
58421223|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
58421224|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
58421225|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421226|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421227|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421228|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421229|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421230|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
58421231|NCT02411370|BEHAVIORAL|phonetic tests|
58421232|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
57785370|NCT01625338|DRUG|SOF|SOF 400 mg tablet administered orally once daily
57785371|NCT01625338|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
57785372|NCT01625338|DRUG|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
57785373|NCT06097104|OTHER|electrolytes - serum blood samples|"CBC - Kidney function tests - liver function tests - ABG - levels of serum sodium, potassium, magnesium, phosphorus, ionized calcium and chloride, with maximum 5 mm blood sampling per day"
57785374|NCT06096636|OTHER|Study participants|Participants will complete study survey and dietary assessment.
57785375|NCT03670147|DEVICE|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
58093944|NCT06701240|BEHAVIORAL|ParentChild+|92-session early literacy focused intervention
58093945|NCT06701240|BEHAVIORAL|FamilyNutrition+|92-session active control focused on child nutrition
58093946|NCT03939728|RADIATION|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
58093947|NCT04986605|DEVICE|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
58093948|NCT04986605|DRUG|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
58093949|NCT05147350|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
58093950|NCT03495700|PROCEDURE|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
58093951|NCT03495700|PROCEDURE|DBBM|The use of bovine xenograft will be analysed
58421233|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
58421234|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
58421235|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
58421236|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
58421237|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
58421238|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
58421239|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
58421240|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
58421241|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
58421242|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
58421243|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
58093952|NCT06473961|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
58093953|NCT00068003|DRUG|Anti-CD19 CAR PBL|
58421244|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
58421245|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
58421246|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
58421247|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
58421248|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
58421249|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
58421250|NCT00957333|OTHER|ketamine|
58421251|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
58421252|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
58421253|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
58421254|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
57735229|NCT01452269|BEHAVIORAL|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
58093954|NCT06330545|RADIATION|Radiation therapy|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
58421255|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
58421256|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
58421257|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
58421258|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
58421259|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
58421260|NCT04901091|OTHER|Not Provided|Not Provided
58421261|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
58421262|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
58421263|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
58421264|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
58093955|NCT06635577|BEHAVIORAL|Verbal Interference Task|"During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace."
57735230|NCT03601832|PROCEDURE|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
58093956|NCT05940467|OTHER|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
58093957|NCT05232565|PROCEDURE|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
58093958|NCT03220893|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
58093959|NCT03220893|RADIATION|Scintimammography|Undergo MBI
58093960|NCT05778591|DRUG|Placebo|Placebo.
58093961|NCT05778591|DRUG|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
57735231|NCT04237662|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
58093962|NCT04925453|COMBINATION_PRODUCT|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
58095361|NCT02083770|BEHAVIORAL|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
58095362|NCT04335994|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
57735232|NCT04237662|DEVICE|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
57735233|NCT05721859|DEVICE|revision hip arthroplasty|revision hip arthroplasty
57735234|NCT00688636|DRUG|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
58093963|NCT04925453|COMBINATION_PRODUCT|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
58093964|NCT05981573|DEVICE|ISF extraction device 1|FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid
58093965|NCT05981573|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay
58093966|NCT05981573|DEVICE|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and DPV
58093967|NCT05981573|DRUG|Measurement of Methadone in ISF before and after taking prescribed dose|Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )
58093968|NCT05981573|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
58093969|NCT05785299|DIAGNOSTIC_TEST|Cow's milk|clinical introduction of cow's milk
58093970|NCT05785299|DIAGNOSTIC_TEST|Placebo|clinical introduction of placebo
58093971|NCT05785299|DIAGNOSTIC_TEST|Home introduction|home introduction of cow's milk
58093972|NCT06272448|OTHER|Telerehabilitation|The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation...), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
58421265|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
58421266|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
58421267|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
58421268|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
58421269|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
58421270|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
58421271|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
57735235|NCT00688636|DRUG|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
57735236|NCT04479813|DRUG|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
57735237|NCT04479813|OTHER|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
57950876|NCT03141736|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
58421272|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
58421273|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
58421274|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
58421275|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
58421276|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
58421277|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
58421278|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
58421279|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
58421280|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
58421281|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
58421282|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
58421283|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
58421284|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
58421285|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
58421286|NCT02784600|DEVICE|Bioinductive implant|
58421287|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
58421288|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
58421289|NCT00663845|DRUG|Placebo|Matching placebo
58421290|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
58421291|NCT06103994|OTHER|Placebo|Placebo
58421292|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
58421293|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
58421294|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
58421295|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
58421296|NCT02102152|DRUG|Tobramycin|
58421297|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
58421298|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
58421299|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
58421300|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
58421301|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
58421302|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
58421303|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
58421304|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
58093973|NCT02364414|DEVICE|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
58093974|NCT02285452|DRUG|Zingiberis Rhizoma plv.|
58421305|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
58421306|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
58421307|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
58421308|NCT02187315|DEVICE|Routine intravenous drip|
58421309|NCT02187315|DRUG|induction chemotherapy|
58421310|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
58421311|NCT02187315|RADIATION|intensity-modulated radiation therapy|
58421312|NCT02187315|DRUG|cisplatin routine-chemotherapy|
58421313|NCT00112177|DRUG|Itopride Hydrochloride|
58421314|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
58421315|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
58421316|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
58421317|NCT01930890|BIOLOGICAL|BIIB023|
58421318|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
58421319|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
58421320|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
58421321|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
58421322|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
58421323|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
58421324|NCT02584920|DRUG|HLX01|
58421325|NCT02584920|DRUG|Rituximab|
58421326|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
58421327|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
57950877|NCT03141736|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
58421328|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
58421329|NCT00114920|DRUG|Resiquimod|
58421330|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
58421331|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
58421332|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
57785376|NCT00581256|RADIATION|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
58421333|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
58093975|NCT02285452|DRUG|Sinapis nigrea semen|
58093976|NCT02285452|DRUG|Placebo|
58093977|NCT06607692|DRUG|Olaparib; 177Lu-DOTATATE|7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
58093978|NCT00458016|DRUG|MB07803|Daily oral administration
58093979|NCT00458016|DRUG|Placebo|Daily oral administration
58421334|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
58421335|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
58421336|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
58421337|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
58421338|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
58421339|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
58421340|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
58421341|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
58421342|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
58421343|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
58421344|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
58421345|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
58421346|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
58093980|NCT02765542|OTHER|Automated disease assessment & self-care support phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
58093981|NCT06009432|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
58093982|NCT05769322|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
58093983|NCT02118896|DRUG|FK506E|oral
58095363|NCT04335994|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
58421347|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
58421348|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
58093984|NCT06236711|DEVICE|tDCS|tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
58093985|NCT05604521|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
58093986|NCT05604521|BIOLOGICAL|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
58093987|NCT05604521|OTHER|Normal Saline|0.9% sodium chloride
58093988|NCT03080272|OTHER|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
58093989|NCT05981118|DRUG|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
58093990|NCT05981118|DRUG|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
58093991|NCT06446973|OTHER|35 patients with meniscus tear|Have meniscus pathologies in one or both knees confirmed by MRI.
58093992|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.
58093993|NCT03626857|OTHER|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
58093994|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
58093995|NCT03626857|OTHER|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
58093996|NCT04590417|DRUG|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
58093997|NCT05268341|BEHAVIORAL|My Sentence Builder|computer-assisted treatment program for expressive grammar
58093998|NCT06652113|DRUG|hydroxychloroquine and levothyroxine|Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
58093999|NCT06652113|DRUG|Levothyroxine|Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
58094000|NCT05013827|BEHAVIORAL|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
58094001|NCT06222879|DRUG|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
58094002|NCT06222879|DRUG|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
57950878|NCT06232070|DEVICE|Lunit INSIGHT MMG|In the Lunit Assisted arm, the radiographers will also be seeing the Lunit INSIGHT MMG reports while reading the mammograms. The standard of care will be followed in all the cases
57950879|NCT04010214|OTHER|No intervention|No intervention
57950880|NCT04696432|BIOLOGICAL|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
58094003|NCT06222879|DRUG|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
58421349|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
57950881|NCT04294875|DRUG|MPT0B640|PO, every 3 days. dose escalation per MTD
57950882|NCT00751595|BIOLOGICAL|Tat protein|Biologically active recombinant Tat protein
58094004|NCT05136664|DRUG|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
58094005|NCT05136664|DRUG|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
58421350|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
58094006|NCT05136664|DRUG|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
58094007|NCT06274853|DRUG|GS-441524|Oral GS-441524 capsules
58094008|NCT06274853|DRUG|Placebo|Placebo capsules
58094009|NCT06702670|DRUG|Treatment with Diphenhydramine|Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
58094010|NCT06702670|COMBINATION_PRODUCT|Usual Care|Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.
58094011|NCT05811260|OTHER|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
58094012|NCT05811260|OTHER|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
58094013|NCT04824560|BEHAVIORAL|Blood pressure education|One page teaching protocol performed by pharmacy students; phone follow-up
58094014|NCT06703632|DIAGNOSTIC_TEST|blood sampling|PreveCol test based on blood sampling
58094015|NCT06703632|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
58094016|NCT06703632|OTHER|Survey using a questionnaire.|PREMs for colorectal cancer screening programme
58094017|NCT06061302|OTHER|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
58421351|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
57785377|NCT00581256|RADIATION|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
58094018|NCT06061302|OTHER|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
58094019|NCT06700772|PROCEDURE|mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone|open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .
58421352|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
58421353|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
58094020|NCT06700772|PROCEDURE|mixing autogenous bone with bovine bone|open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
58094021|NCT06703021|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
58094022|NCT06703021|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
58094023|NCT06703021|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
58094024|NCT06703021|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
58094025|NCT06562439|BEHAVIORAL|Sickle Cell Collaboration for Child Development|The Sickle Cell Collaboration for Child Development (SCCCD) combines the Parents as Teachers curriculum with experienced occupational therapy to help families and children meet their learning and developmental goals.
58094026|NCT04057898|DRUG|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
58094027|NCT04057898|DRUG|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
58094028|NCT05726318|DRUG|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
58094029|NCT02316743|DRUG|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
58094030|NCT04923906|DRUG|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
58095364|NCT05038410|DRUG|Wobenzym®|Wobenzym®
58421354|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
58421355|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
58421356|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
58421357|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
58421358|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
58421359|NCT01008462|DRUG|Carmustine|Given IV
58421360|NCT01008462|DRUG|Cyclophosphamide|Given IV
58421361|NCT01008462|DRUG|Cytarabine|Given IV
58421362|NCT01008462|DRUG|Etoposide|Given IV
58421363|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
58421364|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
58421365|NCT01008462|DRUG|Melphalan|Given IV
58421366|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
58421367|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
58421368|NCT01008462|DRUG|Tacrolimus|Given IV or PO
58421369|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
58421370|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
58421371|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
58094031|NCT04923906|DRUG|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
57735238|NCT02491008|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
57735239|NCT02491008|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
57735240|NCT00182754|DRUG|octreotide acetate|Given subcutaneously
57735241|NCT00182754|OTHER|placebo|Given subcutaneously
57735242|NCT02486328|DRUG|Midazolam|Dosage adjustment
57735243|NCT02486328|DRUG|Meperidine|Dosage adjustment
57735244|NCT02486328|DRUG|Remifentanil|Dosage adjustment
57735245|NCT02486328|DRUG|Propofol|Dosage adjustment
58094032|NCT06180577|DEVICE|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
58094033|NCT06481995|DRUG|Fibrogammin|Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
58095365|NCT05038410|OTHER|Placebo|Microcrystalline cellulose
58095366|NCT01364246|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
58421372|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
57735246|NCT02882568|BIOLOGICAL|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
58421373|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
58421374|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
58421375|NCT00733057|DRUG|Placebo (200 mg/day)|
58421376|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
58421377|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
58421378|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
58421379|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
58421380|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
58421381|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
58421382|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
58421383|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
58421384|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
57735247|NCT04525391|DRUG|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
58421385|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
58421386|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
57735248|NCT01990469|DRUG|Gemigliptin|DPP-4 inhibitor
58094034|NCT01772394|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
58094035|NCT01772394|BEHAVIORAL|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
58094036|NCT00390507|PROCEDURE|Post-tetanic count frequency|
58094037|NCT03528967|DRUG|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
58094038|NCT03528967|DRUG|Aspirin 100 mg Oral Tablet, Enteric Coated|
58094039|NCT03576547|DRUG|Dexamethasone|Given PO or IV
58094040|NCT03576547|DRUG|Ponatinib Hydrochloride|Given PO
58094041|NCT03576547|BIOLOGICAL|Rituximab|Given IV
58094042|NCT03576547|DRUG|Venetoclax|Given PO
58094043|NCT03612713|DRUG|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
58094044|NCT03612713|DRUG|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
58094045|NCT04331392|BEHAVIORAL|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
58421387|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
58421388|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
58421389|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
57735249|NCT01990469|DRUG|Gemigliptin placebo|Placebo of Gemigliptin
57735250|NCT03771482|BEHAVIORAL|Quiztime modules|Text Messaging or Email system
58095367|NCT03416153|DRUG|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
58095368|NCT03416153|RADIATION|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
58095369|NCT03416153|DRUG|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
58421390|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
58421391|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
58421392|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
58421393|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
57735251|NCT06634485|DEVICE|ultrasound, spirometry|"Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible."
58094046|NCT04331392|BEHAVIORAL|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
58094047|NCT00266461|DRUG|Daikenchuto Extract Granules (TU-100)|
58094048|NCT00093067|DRUG|daptomycin|
58094049|NCT04372563|OTHER|aortic prosthetics|aortic prosthetics
58094050|NCT06704061|BEHAVIORAL|Yoga|A 12-week online yoga course designed to treat pain.
58421394|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
58421395|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
58421396|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
58421397|NCT03474198|DRUG|Rifampicin|10mg/kg
57735252|NCT01049425|DRUG|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
57950883|NCT03069430|BEHAVIORAL|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
57950884|NCT01217671|BIOLOGICAL|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
57950885|NCT01217671|OTHER|Placebo|Placebo
57950886|NCT02816307|OTHER|blood samples|
57950887|NCT04600245|PROCEDURE|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
57950888|NCT04649476|DRUG|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
57950889|NCT04649476|DRUG|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
57950890|NCT02053168|DEVICE|Resorbable Mesh|Phasix Mesh
57950891|NCT04499443|DRUG|GST-HG131 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
57950892|NCT04499443|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
57950893|NCT05922462|DIETARY_SUPPLEMENT|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
57950894|NCT05922462|DIETARY_SUPPLEMENT|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
57950895|NCT04086823|DRUG|RZL-012|Subcutaneous injection to the submental fat area
57950896|NCT04086823|DRUG|Placebo|Placebo
57950897|NCT04884321|OTHER|Complementary And Alternative Medicine|No intervention was done in the cross-sectional study
57950898|NCT01624662|DRUG|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
58094051|NCT06704061|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A 12-week behavioral therapy course designed to treat pain.
58094052|NCT05092802|DRUG|HLX208|450mg bid po
58094053|NCT04218344|OTHER|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
58094054|NCT05900531|DRUG|K-757|administered orally
58094055|NCT05900531|DRUG|K-757 and open-label sitagliptin|both administered orally
58094056|NCT05900531|DRUG|Matching placebo to K-757|administered orally
58094057|NCT05900531|DRUG|Matching placebo to K-757 and matching placebo to K-833|both administered orally
58094058|NCT05900531|DRUG|K-757 and K-833|both administered orally
58094059|NCT05900531|DRUG|Matching placebo to K-757, open-label sitagliptin|both administered orally
58094060|NCT06201598|DEVICE|Group 1 - Intervention 1|Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
58094061|NCT01171131|OTHER|Blood/saliva sampling|one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
58421398|NCT03474198|DRUG|Isoniazid|5mg/kg
58421399|NCT03474198|DRUG|Pyrazinamide|25mg/kg
58421400|NCT03474198|DRUG|Ethambutol|15mg/kg
58421401|NCT03474198|DRUG|Linezolid|600mg
58421402|NCT03474198|DRUG|Clofazimine|200mg
58421403|NCT03474198|DRUG|Rifapentine|1200mg
58421404|NCT03474198|DRUG|Levofloxacin|1000mg
58094062|NCT03130855|DRUG|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
58094063|NCT03130855|DRUG|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
58421405|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
58421406|NCT03474198|DRUG|Rifampicin|35mg/kg
58421407|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
58421408|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
58421409|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
58421410|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
58421411|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
58421412|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
58421413|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
58421414|NCT00427882|DRUG|ALFUZOSIN|
58421415|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
58421416|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
58421417|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
58421418|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
58421419|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
58421420|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
58421421|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
58421422|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
58421423|NCT06436586|OTHER|No intervention|No intervention
58421424|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
58421425|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
58421426|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
58421427|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
57735253|NCT01049425|DRUG|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
57735254|NCT01049425|DRUG|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
58094064|NCT00002560|BIOLOGICAL|monoclonal antibody 3F8|
58094065|NCT00002560|BIOLOGICAL|sargramostim|
58094066|NCT06466187|DRUG|PF-08052666|Given into the vein (IV; intravenously)
58094067|NCT00414011|DRUG|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
58094068|NCT00414011|DRUG|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
58094069|NCT00874042|DRUG|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
58094070|NCT06452316|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
58094071|NCT05636501|OTHER|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
58421428|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
58421429|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
58421430|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
58421431|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
58421432|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
58421433|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
58421434|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
58421435|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
58421436|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
58421437|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
58421438|NCT02048410|OTHER|low satured diet|
58421439|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
58421440|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
58421441|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
58421442|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
58421443|NCT02642965|DRUG|Cytarabine|Given IT or IV
58421444|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
58421445|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
58421446|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
58421447|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
58421448|NCT02642965|OTHER|Pharmacological Study|Correlative studies
58421449|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
58421450|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
58421451|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
58421452|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
58421453|NCT01407796|DRUG|[18F](+/-)NOS|
58421454|NCT05118802|OTHER|Interview|Attends Interviews
58421455|NCT05118802|OTHER|Survey Administration|Complete Survey
58421456|NCT00547040|OTHER|no intervention|no intervention
58421457|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
58421458|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
58421459|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
58421460|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
58421461|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
58421462|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
58421463|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
58421464|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
58421465|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
58421466|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
58421467|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
57735255|NCT01049425|DRUG|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
58094072|NCT05636501|OTHER|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
58094073|NCT06458712|DRUG|DSB2455|PARP1 inhibitor
58421468|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
58421469|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
58421470|NCT03869333|OTHER|Placebo|Saline
58421471|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
58421472|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
58421473|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
58421474|NCT00478309|OTHER|counseling intervention|
58421475|NCT00478309|OTHER|educational intervention|
58421476|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
58421477|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
58421478|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
58094074|NCT06702878|COMBINATION_PRODUCT|nasal antimicrobial photodisinfection therapy|Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
58421479|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
58421480|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
58421481|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
57735256|NCT01049425|DRUG|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
57735257|NCT06585969|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtexan every three weeks
58094075|NCT03030482|PROCEDURE|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
58094076|NCT06297616|DRUG|LY3841136|Administered SC
58094077|NCT06297616|DRUG|LY3841136-Placebo|Administered SC
57735258|NCT06585969|DRUG|Ribociclib with ET|Ribociclib with endocrine therapy
57735259|NCT06585969|DRUG|Abemaciclib with ET|Abemaciclib with endocrine therapy
57735260|NCT05884060|OTHER|No intervention|No interventions
57735261|NCT01697293|DRUG|Cyclophosphamide|Given IV
57735262|NCT01697293|DRUG|Doxorubicin Hydrochloride|Given IV
58094078|NCT06297616|DRUG|Tirzepatide|Administered SC
58094079|NCT06297616|DRUG|Tirzepatide-Placebo|Administered SC
58094080|NCT00996008|DRUG|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
57735263|NCT01697293|OTHER|Laboratory Biomarker Analysis|Correlative studies
57735264|NCT01697293|DRUG|Paclitaxel|Given IV
57735265|NCT01697293|PROCEDURE|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
57735266|NCT01697293|DRUG|Triciribine Phosphate|Given IV
57735267|NCT06038123|DEVICE|China market released 3.0T Magnetic resonance (MR) conditional CIED systems|To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)
57735268|NCT00519181|DRUG|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
57735269|NCT00777725|DEVICE|FibroScan|Liver scan, similar to an ultrasound.
58421482|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
58421483|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
58421484|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
58421485|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
58421486|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
58094081|NCT00996008|DRUG|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
58421487|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
58421488|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
57735270|NCT02958969|DRUG|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
57735271|NCT05903144|OTHER|manual therapy|manual diaphragmatic release technique combined with breathing exercise
57735272|NCT05903144|OTHER|breathing exercise and prone position alone|deep breathing exercise and prone position
58094082|NCT04950803|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
58094083|NCT04950803|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
58421489|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
58421490|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
58094084|NCT06079801|DEVICE|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
58094085|NCT06079801|DRUG|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
58421491|NCT00771121|DRUG|urea/lactic acid|new emulsion type
58421492|NCT00771121|DRUG|Placebo|only emulsion base
58421493|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
58421494|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
58421495|NCT00238459|DRUG|multiple licensed drugs not randomized|
58421496|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
58094086|NCT02530320|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
58421497|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
58421498|NCT00921310|DRUG|Pemetrexed|
58421499|NCT00921310|DRUG|Temsirolimus|
58421500|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
58421501|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
58421502|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
57785378|NCT02647047|PROCEDURE|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
58421503|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
58421504|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
58421505|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
58421506|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
58421507|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
58421508|NCT02282904|RADIATION|Total body 200cGy|Day -1
58421509|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
58421510|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
58421511|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
58094087|NCT00088023|DRUG|PT-523 for Injection|
58094088|NCT03287102|PROCEDURE|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
58094089|NCT05350969|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
57735273|NCT04051229|BEHAVIORAL|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
57735274|NCT04051229|BEHAVIORAL|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
58094090|NCT05350969|DRUG|Placebo to CDR132L|Placebo to CDR132L
58094091|NCT05702827|DRUG|Bupivacaine-Meloxicam|All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
58094092|NCT04920162|OTHER|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
58094093|NCT01417208|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
58094094|NCT05728918|DIETARY_SUPPLEMENT|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
58094095|NCT05728918|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
58094096|NCT05664841|BEHAVIORAL|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
58094097|NCT03262519|DIAGNOSTIC_TEST|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
58094098|NCT06701071|DRUG|Clomiphene Citrate|Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.
58094099|NCT06213389|DEVICE|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
58094100|NCT06213389|DEVICE|Macintosh Blade|Patient will be intubated with Macintosh Blade
58094101|NCT05924672|DRUG|Radium-223|Given IV
58094102|NCT05924672|PROCEDURE|PSMA Positron Emission Tomography (PET) Scan|Undergo PSMA PET/CT
58094103|NCT05924672|DRUG|Technetium Tc 99M Medronate|Undergo MDP
58094104|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
58094105|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
57785379|NCT02647047|PROCEDURE|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
58094106|NCT06568107|BEHAVIORAL|Environmental And Sensory Experience (EASE) intervention|The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
58094107|NCT06264362|BEHAVIORAL|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
58094108|NCT02264509|PROCEDURE|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
58094109|NCT04943913|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
58094110|NCT01213004|PROCEDURE|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
58094111|NCT01213004|PROCEDURE|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
58421512|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
58094112|NCT05754749|DRUG|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
58094113|NCT00713713|PROCEDURE|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
58094114|NCT01823237|DEVICE|Transcranial Magnetic Stimulation|
58094115|NCT03356431|OTHER|Supervised group exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
58094116|NCT03356431|OTHER|Home-based exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
58306263|NCT05301439|PROCEDURE|Hall Technique|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
58306264|NCT05301439|PROCEDURE|Conventional Steel Crown|"* Prophylaxis;~* Relative isolation;~* The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~* Cleaning the cavity with water;~* Slight drying;~* Trial of steel crown;~* Relative isolation;~* Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~* Clinical and radiographic control at 1, 3, 6 and 12 months."
58306265|NCT00373503|DRUG|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
58306266|NCT00373503|DRUG|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
58421513|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
58421514|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
57785380|NCT02647047|PROCEDURE|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
58306267|NCT00373503|DRUG|Marijuana|marijuana intoxication, withdrawal and relapse assessed
58306268|NCT03843996|DEVICE|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
58306269|NCT03017859|DEVICE|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
58306270|NCT01604785|DRUG|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
58306271|NCT01604785|DRUG|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
58306272|NCT00058253|DRUG|tanespimycin|Given IV
58306273|NCT00058253|DRUG|docetaxel|Given IV
58306274|NCT02617537|DRUG|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
58094117|NCT03891979|DRUG|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
58094118|NCT03891979|DRUG|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
58094119|NCT03891979|DRUG|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
58094120|NCT05019638|DRUG|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
58094121|NCT05019638|DRUG|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
58094122|NCT06518993|DEVICE|Total hip arthroplasty with a Trinity cup and a Meije Duo cementless stem|Subjects clinically suitable for a primary THR surgery with Trinity cup and Meije Duo cementless femoral stem.
58094123|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
58094124|NCT04682639|DRUG|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
58094125|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
58094126|NCT05874479|DEVICE|Active PAC|The active PAC will contain HEPA filters inside the device.
58094127|NCT05874479|DEVICE|Sham PAC|The sham PAC will contain no HEPA filters inside the device.
58421515|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
58421516|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
58421517|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
57785381|NCT02647047|PROCEDURE|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
57785382|NCT02647047|DRUG|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
57785383|NCT02647047|DRUG|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
58094128|NCT03837340|OTHER|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
58094129|NCT03837340|OTHER|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
58094130|NCT05681026|BEHAVIORAL|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
58094131|NCT05681026|BEHAVIORAL|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
58094132|NCT05681026|BEHAVIORAL|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
58094133|NCT04427956|PROCEDURE|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
58094134|NCT04427956|DRUG|Isotonic riboflavin|CXL protocol with isotonic riboflavin
58094135|NCT04427956|DRUG|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
58094136|NCT04427956|PROCEDURE|Iontophoresis|CXL protocol with iontophoresis and ricrolin
58421518|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
58421519|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
58421520|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
58094137|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
58094138|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
58094139|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
58094140|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
58094141|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
58095370|NCT04547478|DIAGNOSTIC_TEST|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
58095371|NCT01966107|DRUG|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
58306275|NCT02617537|DRUG|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
58421521|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
57785384|NCT02647047|DRUG|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
57785385|NCT02647047|DRUG|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
58094142|NCT06502730|BEHAVIORAL|Creating Opportunities for Parent Empowerment (COPE) Program|It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
58094143|NCT05531591|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
58094144|NCT05531591|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
58094145|NCT05531591|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
58094146|NCT05531591|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
58094147|NCT05531591|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
58094148|NCT04967989|PROCEDURE|Low Energy SLT|SLT performed at low energy
58421522|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
58421523|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
58421524|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
58094149|NCT04967989|PROCEDURE|Standard Energy SLT|SLT performed at standard energy
58094150|NCT06334354|OTHER|Assessments|Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
58094151|NCT06334354|OTHER|Assessment (Survivors Only)|\*Tumor/Treatment Variables (Survivors Only)
58094152|NCT06334354|OTHER|APOE and DNA Isolation|Biospecimens procurement and processing
58094153|NCT00852072|PROCEDURE|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
58094154|NCT00852072|PROCEDURE|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
58094155|NCT06701201|DRUG|SynKIR-110|Autologous T cells Transduced with Mesothelin KIR-CAR
58094156|NCT06701201|DRUG|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
58094157|NCT06702904|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
58095372|NCT01966107|DRUG|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
58095373|NCT03297801|DIETARY_SUPPLEMENT|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
58095374|NCT05836571|PROCEDURE|Biopsy|Undergo biopsy
58421525|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
58421526|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
57785386|NCT02647047|DRUG|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
58094158|NCT06702904|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
58094159|NCT06702904|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
58094160|NCT06702904|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
58094161|NCT01827072|DRUG|NPB-01|
58094162|NCT06384989|OTHER|Child restraint system with load leg feature|The primary objective is to assess the usability of the load leg design for caregivers who must install the child safety seat into a vehicle. The specific aims are to quantify any errors committed by the participants while installing the car seat (especially related to the use of the load leg) and to assess participants' opinions on the car seat's load leg design.
58094163|NCT05572658|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
58094164|NCT05572658|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58094165|NCT00256217|DRUG|Anastrozole|1 mg. oral every day for 2 - 4 weeks
58094166|NCT05596227|DRUG|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
58421527|NCT00343382|OTHER|placebo|Given orally
58421528|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
58421529|NCT00002447|DRUG|Ritonavir|
58421530|NCT00002447|DRUG|Efavirenz|
58421531|NCT00002447|DRUG|Saquinavir|
58421532|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
57785387|NCT02647047|DRUG|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
57785388|NCT03404869|DRUG|ORL-1M - D-mannose|Oral ORL-1M
57785389|NCT00004767|DRUG|Sodium Benzoate|
57785390|NCT00004767|DRUG|Sodium Phenylacetate|
57785391|NCT00004767|DRUG|Sodium Phenylbutyrate|
57785392|NCT00004767|BEHAVIORAL|Dietary Intervention|
57950899|NCT02097914|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
58094167|NCT05596227|DRUG|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
58094168|NCT05596227|DRUG|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
58094169|NCT05596227|DRUG|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
58095375|NCT05836571|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58095376|NCT05836571|DRUG|Cabozantinib|Given PO
58095377|NCT05836571|PROCEDURE|Computed Tomography|Undergo CT
58095378|NCT05836571|BIOLOGICAL|Ipilimumab|Given IV
58095379|NCT05836571|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58095380|NCT05836571|BIOLOGICAL|Nivolumab|Given IV
58095381|NCT05182008|OTHER|Decision aid|Online interactive decision aid on method of early abortion
58421533|NCT01744314|DRUG|Indomethacin and Pantoprazole|
58421534|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
58421535|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
58421536|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
58421537|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
58421538|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
58421539|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
58421540|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
58421541|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
58421542|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
58421543|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
58421544|NCT04033874|OTHER|kangaroo care|kangaroo care
58421545|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
58421546|NCT04033874|OTHER|white noise listening|white noise listening
58421547|NCT04033874|OTHER|ambient sound listening|ambient sound listening
58421548|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
58421549|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
58421550|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
58421551|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
58421552|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
58094170|NCT05596227|OTHER|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
58095382|NCT05182008|OTHER|Usual care|Patients will be directed to the abortion clinic website
58421553|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
58095383|NCT06188689|DIAGNOSTIC_TEST|Pacing|"1. Ventricular 10 beat burst at 500ms (120bpm)~2. Ventricular 10 beat burst at 400ms (150bpm)~3. Atrial 10 beat burst at 500ms (120bpm)~4. Atrial 10 beat burst at 400ms (150bpm)."
57735275|NCT06669507|BEHAVIORAL|Chronotherapy|"1. The effect of light exposure follows a phase-response curve where circadian phase advancement is strongest in the biological morning, whereas light in the biological evening/night may lead to a phase delay. Light therapy is provided by 30 min light exposure using 10 000 lux light boxes.~2. Melatonin 3 milligram is prescribed in tablet forms (not depot), usually 12 hours before the planned rise time.~3. Additionally, blue-light-blocking glasses are used to block light exposure at night, which has been found to advance circadian rhythms. Patients are advised to wear their blue-blocking glasses 12 hours before rise time.~Which chronotherapeutic interventions that are used, is considered individually by the clinicians in the Sleep Clinic, but often all three treatment components are used at the same time. Duration of chronotherapy given in the Sleep Clinic vary from 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment."
58095384|NCT05078632|OTHER|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
57735276|NCT06669507|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|All participants will receive treatment as usual. CBT-I has several components and consists of the following interventions including psychoeducation about sleep: sleep hygiene, sleep restriction therapy, stimulus control, and challenging beliefs and perceptions of sleep. Special emphasis is placed on providing a rationale for behavior change as a primary means of improving sleep as well as addressing dysfunctional beliefs the patients may hold about sleep. During treatment, tapering sleep medication is not necessary. However, if the patients are motivated to do so, this is discussed and a plan for tapering is provided. Treatment duration is typically between 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment.
58095385|NCT04175691|GENETIC|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
58094171|NCT05596227|OTHER|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
58094172|NCT05408533|DEVICE|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
58421554|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
58094173|NCT06526390|PROCEDURE|f-URS|f-URS with S-UAS
58421555|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
57735277|NCT02468765|OTHER|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
57735278|NCT03317977|BEHAVIORAL|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
58094174|NCT06526390|PROCEDURE|mini-PCNL|mini-PCNL
58094175|NCT01713478|OTHER|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
58094176|NCT06587100|DEVICE|Fitbit|Participants will wear Fitbit device
58306276|NCT04159467|OTHER|Pelvic Floor Muscle Training|4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
58094177|NCT06587100|DEVICE|Apple HealthKit-based devices|Participants will wear personal device and share data with study team.
58094178|NCT04011904|OTHER|Cross-over study|Traditional Inuit Diet vs Westernized Diet
58306277|NCT01531400|OTHER|self-selected music|Investigators played self-selected background music in the music group
58306278|NCT05036681|DRUG|Futibatinib|tablets by mouth 1 time every day
58306279|NCT05036681|DRUG|Pembrolizumab|Given by vein over about 30-60 minutes on Day 1 of all cycles
58306280|NCT00320060|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
58306281|NCT03091153|OTHER|Medication Review|In depth medication review with a focus on deprescribing
58306282|NCT02587208|DEVICE|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
57735279|NCT03317977|BEHAVIORAL|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
58094179|NCT01898117|DRUG|Carbo/cyclo|
58094180|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
58094181|NCT01898117|DRUG|Paclitaxel|
58094182|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
58094183|NCT05354206|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
58094184|NCT05354206|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
58094185|NCT05354206|OTHER|Training with some stimulation|Motor task combined with real or sham stimulation
58421556|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
58421557|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
58421558|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
58421559|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
58421560|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
58421561|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
58421562|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
58421563|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
58421564|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
58421565|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
58421566|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
57735280|NCT03690505|BEHAVIORAL|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
57735281|NCT00288158|DRUG|Allopurinol|
58421567|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
58421568|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
58421569|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
58421570|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
58421571|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
58421572|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
58421573|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
58421574|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
57735282|NCT00288158|DRUG|Probenecid|
57735283|NCT00288158|DRUG|Placebo|
58094186|NCT02426294|DRUG|Pioglitazone|
58094187|NCT02426294|DRUG|Glimepiride|
58094188|NCT06694571|BEHAVIORAL|Skin cancer prevention educational presentation and activities|"An intervention visit, lasting up to 90 minutes, will take place during fall, immediately following completion of a baseline survey. This intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. During the intervention visit, participants will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity.~One month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text."
58094189|NCT05880485|RADIATION|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
58094190|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
58094191|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
58094192|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
58421575|NCT02880813|OTHER|Infusion|infusion of nutrients
58094193|NCT06509815|DEVICE|MIRA|The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
58094194|NCT03216798|OTHER|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
58094195|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 2.5-minute intervals|Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
58094196|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 5-minute intervals|Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
58421576|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
57735284|NCT01994330|DRUG|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
58094197|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
58094198|NCT05887674|BEHAVIORAL|Diet intervention|Low inflammatory-index diet
58094199|NCT05887674|BEHAVIORAL|Exercise|Guided muscle strength training and stretching exercises
58094200|NCT05887674|BEHAVIORAL|Cognitive training|Cognitive training will be implemented in person
58421577|NCT03689712|DRUG|Placebo|60 minute IV infusion
58421578|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
58421579|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
58421580|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
58421581|NCT01824706|PROCEDURE|craniectomy|craniectomy
58421582|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
58421583|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
58421584|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
58421585|NCT04221191|OTHER|PSP|PSPs is to support patient care.
58421586|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
58421587|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
58421588|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
58421589|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
58421590|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
58421591|NCT00324441|DEVICE|Iratherm® 1000|
58094201|NCT03463824|BEHAVIORAL|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
58094202|NCT03463824|BEHAVIORAL|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
58094203|NCT02407405|DRUG|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
58421592|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
58421593|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
58421594|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
58421595|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
58421596|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
58421597|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
58421598|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
58421599|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
58421600|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
58421601|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
57950900|NCT03002584|OTHER|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
58094204|NCT05270512|DEVICE|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
58094205|NCT00630994|DRUG|Dacogen|
58094206|NCT01556646|DRUG|Tolvaptan|15 to 30mg qd titrated to sodium concentration
58421602|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
57950901|NCT05288400|COMBINATION_PRODUCT|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
58094207|NCT04629300|BEHAVIORAL|Supportive Care Mobile Application|Tablet computer with application providing modules on skills for managing symptoms and coping.
57950902|NCT05288400|DRUG|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
57950903|NCT05288400|DRUG|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
57950904|NCT05288400|DRUG|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
58094208|NCT04629300|OTHER|Usual Care|Standard oncology care with monitoring of supportive care services usage
58094209|NCT06704035|DIAGNOSTIC_TEST|Early OGTT Results Revealed|Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
58094210|NCT04377516|OTHER|pelvic floor muscle training|pelvic floor muscle training
58421603|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
58421604|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
58421605|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
58421606|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
58421607|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
58421608|NCT01731067|DRUG|Cocktail probe drugs|
58421609|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
58421610|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
58421611|NCT02334488|DRUG|Everolimus|Active Comparator
58421612|NCT02334488|DRUG|Tacrolimus|Active Comparator
57950905|NCT00004340|DRUG|calcitriol|
58421613|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
58421614|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
58421615|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
57950906|NCT00004340|DRUG|growth hormone|
58094211|NCT04377516|OTHER|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
58094212|NCT04377516|OTHER|education of pelvic girdle|education of pelvic girdle
58094213|NCT04974593|OTHER|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
58094214|NCT06501989|DRUG|Biweekly 5-FLUOROURACIL (5-FU)|5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
58094215|NCT06501989|DRUG|Biweekly Modified FOLFOX6|Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
58094216|NCT06501989|DRUG|Biweekly FOLFIRI|"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."
58094217|NCT06501989|DRUG|mFOLFOXIRI|Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
58306283|NCT02587208|PROCEDURE|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
58421616|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
58421617|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
58421618|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
58421619|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
58421620|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
58421621|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
58421622|NCT02107157|DEVICE|755nm Laser with Cap Array|
58421623|NCT02488642|DRUG|Isosorbide Dinitrate|
58421624|NCT02488642|DRUG|Misoprostol|
58421625|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
58421626|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
58094218|NCT02552394|DRUG|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
58094219|NCT02981667|OTHER|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
58094220|NCT01176578|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
58094221|NCT06192264|DRUG|ASC40|ASC 40 tablets orally once daily
58094222|NCT04652635|PROCEDURE|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
58094223|NCT05188807|DIAGNOSTIC_TEST|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
58306284|NCT00563290|DRUG|dasatinib|Given PO
58306285|NCT00563290|OTHER|laboratory biomarker analysis|Correlative studies
58306286|NCT02578017|BEHAVIORAL|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
58306287|NCT00624988|PROCEDURE|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
58306288|NCT04960215|DRUG|Coenzyme Q10|Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
58306289|NCT04960215|DRUG|Placebo|A soft gelatin capsule containing soy oil, 5 capsules a day.
58421627|NCT06454149|OTHER|MALT lymphoma|New diagnosis with gastric MALT lymphoma
58421628|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
58421629|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
58421630|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
58421631|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
58421632|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
58094224|NCT06680089|DRUG|[18F]RCCB6|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
58094225|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
58094226|NCT04921189|DRUG|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
58094227|NCT04921189|DRUG|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
58094228|NCT05697835|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
58094229|NCT05697835|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
58094230|NCT05697835|OTHER|Care as usual|Care as usual, with written resources provided
58094231|NCT06703658|DRUG|AZD5004(Part A)|Single dose of AZD5004 oral on Day1
58094232|NCT06703658|DRUG|Placebo(Part A)|Single dose of placebo oral on Day1
58094233|NCT06703658|DRUG|AZD5004(Part B)|AZD5004 will be administered as an oral tablet once daily.
58094234|NCT06703658|DRUG|Placebo(Part B)|Placebo will be administered as an oral tablet once daily.
58094235|NCT04650984|DRUG|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
58094236|NCT04650984|DRUG|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
58094237|NCT06220513|PROCEDURE|erector spinae plane block (ESP)|patients will receive Ultrasound-guided erector spinae plane block (ESP) block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
58094238|NCT06220513|PROCEDURE|transversus abdominis plane block(TAP)|patients will receive Ultrasound-guided transversus abdominis plane block(TAP) Block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
58094239|NCT04537052|PROCEDURE|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
58421633|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
58421634|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
58421635|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
58421636|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
58421637|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
58421638|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
58421639|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
58421640|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
58421641|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
58421642|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
58421643|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
58421644|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
58421645|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
58094240|NCT00029042|DRUG|Infliximab|
58094241|NCT00410839|PROCEDURE|ALA rich diet|
58421646|NCT00262990|DRUG|EPO906 (Patupilone)|
58421647|NCT00262990|DRUG|doxorubicin|
58094242|NCT05395702|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
58094243|NCT02143401|OTHER|Laboratory Biomarker Analysis|Correlative studies
58094244|NCT02143401|BIOLOGICAL|Navitoclax|Given PO
58094245|NCT02143401|OTHER|Pharmacological Study|Correlative studies
58094246|NCT02143401|DRUG|Sorafenib|Given PO
58094247|NCT02143401|DRUG|Sorafenib Tosylate|Given PO
58094248|NCT06701136|DRUG|Sudapyridine|In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.
58094249|NCT06701136|DRUG|Itraconazole|In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.
58306290|NCT06391424|DIAGNOSTIC_TEST|Spontaneous Breathing Trial|Patients will undergo an SBT to determine whether they are ready for extubation.
58421648|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
58421649|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
58421650|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
58421651|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
58421652|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
58421653|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
58421654|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
58421655|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
58421656|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
58421657|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
58421658|NCT00506194|DRUG|Insulin|
58421659|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
58421660|NCT02717130|DRUG|Aripiprazole|
58094250|NCT06701136|DRUG|Rifampin|In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
58094251|NCT06103864|DRUG|Dato-DXd|Provided in 100mg vials. IV infusion. Experimental drug.
58094252|NCT06103864|DRUG|Durvalumab|Provided in 500mg vials. IV infusion. Experimental drug.
58094253|NCT06103864|DRUG|Paclitaxel|IV infusion. Active comparator.
58094254|NCT06103864|DRUG|Nab-paclitaxel|IV infusion. Active comparator.
58094255|NCT06103864|DRUG|Gemcitabine|IV infusion. Active comparator.
58421661|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
58421662|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
58421663|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
58421664|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
58421665|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
58421666|NCT00006455|DRUG|cyclophosphamide|
58421667|NCT00006455|DRUG|cytarabine|
58421668|NCT00006455|DRUG|dexamethasone|
58421669|NCT00006455|DRUG|doxorubicin hydrochloride|
58421670|NCT00006455|DRUG|etoposide|
58421671|NCT00006455|DRUG|ifosfamide|
58421672|NCT00006455|DRUG|leucovorin calcium|
58421673|NCT00006455|DRUG|methotrexate|
58094256|NCT06103864|DRUG|Carboplatin|IV infusion. Active comparator.
58094257|NCT06103864|DRUG|Pembrolizumab|IV infusion. Active comparator.
58094258|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
58094259|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.
58094260|NCT03694483|DIAGNOSTIC_TEST|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
58306291|NCT05983263|DRUG|Capsaicin|Capsaicin 8% patch (QUTENZA) apposed in coccygeal area
58306292|NCT02634255|DRUG|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
58421674|NCT00006455|DRUG|therapeutic hydrocortisone|
58421675|NCT00006455|DRUG|vinblastine sulfate|
58421676|NCT03006224|OTHER|One Lung Ventilation|
58421677|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
58094261|NCT03425786|BEHAVIORAL|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
58094262|NCT03425786|BEHAVIORAL|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
58094263|NCT06650800|DRUG|Psilocybin|Single-dose psilocybin administration: oral ingestion of one 25 mg capsule
58094264|NCT06650800|OTHER|MRI|1.5 hour brain MRI before and after psilocybin administration
58421678|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
58421679|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
58421680|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
58421681|NCT01878994|BEHAVIORAL|Counselling group|
58421682|NCT01878994|BEHAVIORAL|Nereu group|
58421683|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
58421684|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
58421685|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
58421686|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
58421687|NCT01793259|DRUG|methotrexate prefilled pen|
58421688|NCT01793259|DRUG|methotrexate prefilled syringe|
58421689|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
58421690|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
57735285|NCT01064739|DIETARY_SUPPLEMENT|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
58421691|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
58421692|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
58421693|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
58421694|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
58094265|NCT05388136|PROCEDURE|Conventional follow up schedule with imaging|Frequent of follow up visit and imaging
58094266|NCT05388136|PROCEDURE|Deintensified follow up schedule without imaging|Less intense follow up visit without imaging
58306293|NCT02634255|DRUG|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
58421695|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
58421696|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
57735286|NCT01064739|OTHER|Fixed Sodium Diet|Fixed sodium low monoamine diet
57735287|NCT05872633|BEHAVIORAL|Online self-management intervention|
57735288|NCT05872633|OTHER|Care-as-usual|
57735289|NCT01371344|DRUG|Tacrolimus granules|oral
57735290|NCT01371344|DRUG|Tacrolimus capsules|oral
58094267|NCT01766141|OTHER|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
58094268|NCT04532489|DRUG|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
58094269|NCT05982158|BEHAVIORAL|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
58094270|NCT05982158|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
58094271|NCT06320080|DRUG|TQB2223 injection|TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
58094272|NCT06320080|DRUG|Penpulimab Injection|Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
58306294|NCT02634255|DRUG|Propofol|
58306295|NCT02634255|DRUG|Fentanyl|
58306296|NCT02634255|OTHER|Ringer Lactate|
58306297|NCT02634255|DEVICE|Acceleromyography device|
58306298|NCT00192114|DRUG|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
58306299|NCT01524315|DRUG|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
58306300|NCT01524315|DRUG|Placebo|100 ml normal saline, intravenous, preoperative
58421697|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
58421698|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
58094273|NCT03080402|DEVICE|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
58094274|NCT03430037|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
58094275|NCT03430037|DRUG|Placebo oral capsule|Placebo
58094276|NCT02416167|DRUG|FYU-981|
58094277|NCT02416167|DRUG|Placebo|
58094278|NCT06696066|BEHAVIORAL|PRS Program|The PRS program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
58094279|NCT03325062|BEHAVIORAL|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
58094280|NCT03325062|BEHAVIORAL|Experimental: MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
58094281|NCT04983823|OTHER|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
58094282|NCT04983823|OTHER|Usual care|This will be provided by participants' usual healthcare professional(s).
58094283|NCT06700603|DRUG|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
58094284|NCT06283069|BEHAVIORAL|compilation of a questionnaire about LifeStyle|compilation of a questionnaire about LifeStyle
58094285|NCT04651582|BEHAVIORAL|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
58094286|NCT04651582|BEHAVIORAL|Cognitive Stimulating Activities|20 hours of traditional computer games
58094287|NCT01588678|DRUG|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
58094288|NCT03784612|BEHAVIORAL|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
58094289|NCT03797339|OTHER|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
58094290|NCT03797339|OTHER|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
58094291|NCT03797339|OTHER|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
58094292|NCT03797339|OTHER|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
58094293|NCT05965401|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
58094294|NCT05965401|OTHER|GLAD-PC guided dosing|SSRI dosing based on GLAD-PC clinical practice guidelines
58094295|NCT06702085|BEHAVIORAL|Lifestyle Management|patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
58421699|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
58421700|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
58421701|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
58421702|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
57735291|NCT02603653|DEVICE|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
58421703|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
58421704|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
58421705|NCT01583816|DRUG|Resiquimod 0.03%|topical application
58421706|NCT01583816|DRUG|Resiquimod 0.01%|topical application
58421707|NCT01583816|DRUG|placebo|topical application
58421708|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
58421709|NCT05538390|OTHER||
58421710|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
58421711|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
58421712|NCT02060032|DRUG|Placebo local drug delivery|
58421713|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
58421714|NCT01472211|DEVICE|placebo filter|filter purifies water
58421715|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
58421716|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
58421717|NCT02913768|DRUG|Ondansetron|
58421718|NCT02913768|DRUG|Normal saline|
58421719|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
58421720|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
58421721|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
58421722|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
57735292|NCT05984953|DRUG|statin|40 mg of rosuvastatin daily for 8-12 weeks
57735293|NCT05984953|DRUG|evolocumab|140 mg evolocumab every 2 weeks (26 weeks)
58421723|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
58421724|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
58421725|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
58421726|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
58421727|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
58421728|NCT00566254|DRUG|Placebo|
58421729|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
58421730|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
58421731|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
58421732|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
57735294|NCT03798860|DIAGNOSTIC_TEST|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
57735295|NCT00274053|DRUG|tiotropium|
57735296|NCT04130646|DEVICE|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
58094296|NCT03259867|DRUG|Nivolumab Injectable Product|a PD-1 immune check inhibitor
58094297|NCT03259867|COMBINATION_PRODUCT|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
58094298|NCT05808894|PROCEDURE|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
58094299|NCT05758246|DRUG|Fisetin-dose 1|20mg/kg once a day for one day.
58094300|NCT05758246|DRUG|Fisetin-dose 2|20mg/kg once a day for two days
58094301|NCT05758246|DRUG|Placebo|Placebo treatment
58094302|NCT03287141|DIAGNOSTIC_TEST|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
58094303|NCT03287141|DEVICE|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
58094304|NCT03287141|DEVICE|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
58094305|NCT06274385|DIETARY_SUPPLEMENT|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
58094306|NCT06274385|OTHER|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
58094307|NCT04843332|BEHAVIORAL|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
58094308|NCT06057233|DIAGNOSTIC_TEST|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
57735297|NCT04130646|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
58094309|NCT06298318|OTHER|vodka|1g/kg body weight
58094310|NCT06298318|OTHER|water|equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
58094311|NCT02864953|DRUG|BIIB093|Administered as specified in the treatment arm.
58094312|NCT02864953|DRUG|Placebo|Administered as specified in the treatment arm.
58094313|NCT05148455|OTHER|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
58094314|NCT05148455|DIAGNOSTIC_TEST|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
58094315|NCT05148455|OTHER|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
58094316|NCT06700564|OTHER|PET scan of FDG|The enrolled patients will undergo PET examination, and the radiation dose generated during the examination will not cause physiological damage to the patients
58094317|NCT06543511|OTHER|Genetic Blood Test|Germline genetic testing using skin fibroblasts
58094318|NCT02517346|OTHER|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
58094319|NCT02517346|OTHER|Telemonitoring|Follow up by telemonitoring system during 3 months
58094320|NCT06262347|BEHAVIORAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
58094321|NCT06262347|BEHAVIORAL|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
58094322|NCT05902767|OTHER|Nuts|"* A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines"
58094323|NCT05902767|OTHER|Control|- Dietary counselling on how to follow the Australian Dietary Guidelines
58421733|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
58421734|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
58421735|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
58421736|NCT00064402|DRUG|Placebo|Placebo BID
58421737|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
58094324|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
58094325|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
58421738|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
58421739|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
58421740|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
58421741|NCT00513955|DRUG|bortezomib|
58421742|NCT00513955|DRUG|cyclophosphamide|
58421743|NCT00513955|DRUG|doxorubicin hydrochloride|
58421744|NCT00513955|DRUG|prednisolone|
58421745|NCT00513955|DRUG|vincristine sulfate|
58421746|NCT00513955|OTHER|questionnaire administration|
58421747|NCT00513955|PROCEDURE|quality-of-life assessment|
58421748|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
58421749|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
58421750|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
58094326|NCT02368119|BIOLOGICAL|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
58094327|NCT02368119|OTHER|Placebo|IM injection injection of Phosphate Buffered Saline
58094328|NCT05840497|OTHER|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
58094329|NCT00455923|DRUG|Seretide|Seretide
58094330|NCT00455923|DRUG|Flixotide|Flixotide
58421751|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
58421752|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
58421753|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
58094331|NCT04318041|DRUG|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
58094332|NCT04318041|DRUG|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
58094333|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
58094334|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
57735298|NCT06291272|DIETARY_SUPPLEMENT|Psyllium|15 g psyllium + 15 g inulin
58094335|NCT05519267|BEHAVIORAL|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
58094336|NCT05519267|BEHAVIORAL|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
58094337|NCT05798923|DRUG|LAM-001|LAM-001 administered via dry powder inhalation
58094338|NCT00561093|DRUG|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094339|NCT00561093|DIETARY_SUPPLEMENT|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094340|NCT00561093|DIETARY_SUPPLEMENT|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094341|NCT00561093|DRUG|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094342|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094343|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
58094344|NCT01778452|PROCEDURE|endometrial biopsy|endometrial biopsy
58094345|NCT05349890|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
58094346|NCT05349890|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
58094347|NCT05349890|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
58094348|NCT03976076|DRUG|JBPOS0101|JBPOS0101 (investigational product)
58094349|NCT03981614|DRUG|Binimetinib|Given PO
58094350|NCT03981614|DRUG|Palbociclib|Given PO
58094351|NCT03981614|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
58094352|NCT06702345|OTHER|encapsulated 10^4 CFU toxigenic. C. difficile spores|12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.
58094353|NCT06702345|DRUG|Vancomycin|oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
58094354|NCT06702345|DRUG|Clindamycin|oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
57735299|NCT06291272|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose + 15 g inulin
57735300|NCT06291272|DIETARY_SUPPLEMENT|Inulin|15 inulin
57735301|NCT06291272|DIETARY_SUPPLEMENT|Maltodextrin|15 maltodextrin
58094355|NCT03146507|RADIATION|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
58094356|NCT03146507|RADIATION|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
58094357|NCT03146507|RADIATION|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
58094358|NCT03394274|OTHER|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
58094359|NCT04676607|DRUG|SHR7390|SHR7390
58094360|NCT00097084|DRUG|insulin detemir|
58094361|NCT00097084|DRUG|insulin glargine|
58094362|NCT00097084|DRUG|insulin aspart|
58094363|NCT03047031|DRUG|Nintedanib|Nintedanib
58094364|NCT03047031|DRUG|Pirfenidone|Pirfenidone
58094365|NCT05968703|DEVICE|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
58094366|NCT03466788|OTHER|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
58094367|NCT00447291|DRUG|Supplement: Omega-3 Fish Oil|
58094368|NCT00447291|BEHAVIORAL|Multi-Disciplinary Nutrition & Exercise program|
58094369|NCT06703905|PROCEDURE|Expanded pancreaticoduodenectomy surgery|Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
58094370|NCT06703905|PROCEDURE|Pancreaticoduodenectomy|Traditional minimally invasive pancreaticoduodenectomy
58094371|NCT05268523|BEHAVIORAL|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
58094372|NCT05268523|BEHAVIORAL|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
58094373|NCT00001729|DRUG|Ribavirin|
58421754|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
58421755|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
57950907|NCT04875546|BEHAVIORAL|Standard treatment|Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
57950908|NCT04875546|BEHAVIORAL|Integrated Intervention|In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
58094374|NCT05839119|DRUG|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
58094375|NCT05839119|COMBINATION_PRODUCT|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
58094376|NCT04489888|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
58094377|NCT04489888|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
58094378|NCT04489888|DRUG|Paclitaxel|At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
57950909|NCT04875546|OTHER|Control|The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
57950910|NCT02620696|DRUG|netazepide|
57950911|NCT06383273|DRUG|MELT-300 sublingual tablet|Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
57950912|NCT06383273|DRUG|Midalozam sublingual tablet|Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
57950913|NCT06383273|DRUG|Placebo sublingual tablet|Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
57950914|NCT06548919|DRUG|Endocrine therapy|All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
58094379|NCT02341976|OTHER|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
58094380|NCT02507115|BEHAVIORAL|TMAP|Text messages for Alcohol Risk Reduction
58094381|NCT02507115|BEHAVIORAL|Mojo Texts|Motivational texts not alcohol related
58094382|NCT02936479|DRUG|C1-INH (Berinert)|
58094383|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
58306301|NCT03720886|BIOLOGICAL|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
58421756|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
58421757|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
57735302|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation|All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.
58094384|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
58094385|NCT03574194|DIETARY_SUPPLEMENT|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
58094386|NCT05340023|BIOLOGICAL|blood sample|to realize proteomic analysis.
58094387|NCT02515981|BEHAVIORAL|NH Medicaid Incentives Program|
58094388|NCT05445778|DRUG|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
58094389|NCT05445778|DRUG|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
58094390|NCT00953927|BIOLOGICAL|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
58094391|NCT00953927|BIOLOGICAL|Candida Skin Test Antigen|1 test, administered once as a placebo control.
58094392|NCT03273712|RADIATION|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
58094393|NCT03273712|DIAGNOSTIC_TEST|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
58094394|NCT03273712|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
58094395|NCT06567990|DIAGNOSTIC_TEST|Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.|"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"
58421758|NCT02973568|OTHER|Observational Study|
58421759|NCT04619277|DEVICE|drug-coated balloon|drug-coated balloon
57950915|NCT06548919|DRUG|Chemotherapy Prednisone|All chemotherapy treatment regimens approved for advanced breast cancer
57950916|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
57950917|NCT01418183|PROCEDURE|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
57950918|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
57950919|NCT04639583|DEVICE|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
57950920|NCT00953368|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
57950921|NCT05133011|PROCEDURE|Tongue base reduction surgery|Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
57950922|NCT02995486|OTHER|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
57950923|NCT00669058|DRUG|Lactic acid (Dermacid)|
57950924|NCT02302508|DRUG|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
57950925|NCT05141760|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
58094396|NCT03891875|COMBINATION_PRODUCT|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
58094397|NCT03891875|COMBINATION_PRODUCT|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
58094398|NCT03953768|DEVICE|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
58094399|NCT05197881|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
58094400|NCT06224673|DRUG|ARX788|Given IV
58094401|NCT06224673|PROCEDURE|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
58094402|NCT06224673|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58094403|NCT02842086|DRUG|F/TAF|200/25 mg tablet administered orally once daily
58094404|NCT02842086|DRUG|F/TDF|200/300 mg tablet administered orally once daily
58094405|NCT02842086|DRUG|F/TAF Placebo|Tablet administered orally once daily
58094406|NCT02842086|DRUG|F/TDF Placebo|Tablet administered orally once daily
58094407|NCT06483711|OTHER|Lifestyle Kit|The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
58094408|NCT00219752|DRUG|Imatinib mesylate 400 mg|
58094409|NCT02574507|BEHAVIORAL|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
58094410|NCT06703372|OTHER|Diode Laser 980 nm, 0.2W|diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone
58094411|NCT06703372|OTHER|Placebo Diode laser|the tip of the instrument will be sealed with blue rubber to prevent the passage of light
58094412|NCT05654623|DRUG|ARV-471|orally, once daily on a 28-day continuous dosing schedule
58094413|NCT05654623|DRUG|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
58094414|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
58094415|NCT04008121|COMBINATION_PRODUCT|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
58094416|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
58094417|NCT04008121|COMBINATION_PRODUCT|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
58094418|NCT04840901|DRUG|Lebrikizumab|Administered SC.
58094419|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
57785393|NCT01316146|DRUG|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
57785394|NCT00000484|DRUG|chlorothiazide|
57785395|NCT00000484|DRUG|Rauwolfia alkaloids|
58094420|NCT05229562|DRUG|BIIB122|Administered as specified in the treatment arm.
58094421|NCT05152004|DRUG|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
58094422|NCT05152004|DRUG|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
58094423|NCT05152004|DRUG|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
58094424|NCT05152004|DRUG|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
58094425|NCT05020730|DRUG|PTM-001|PTM-001 (400 mg) every day for 12 weeks
57785396|NCT00911924|DEVICE|iStent|Glaukos iStent, medication
57785397|NCT03007589|DRUG|otc sunscreens|Sunscreens of various SPF levels and ingredients
57785398|NCT03007589|OTHER|sun protection fabrics|fabrics
58094426|NCT05020730|DRUG|Placebo|Matching placebo every day for 12 weeks
58094427|NCT06472050|DRUG|Romosozumab|osteoporosis treatment
58094428|NCT06472050|DRUG|Denosumab|osteoporosis treatment
58094429|NCT06700499|DRUG|AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)|AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
58094430|NCT05255354|DEVICE|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
58094431|NCT00732784|DRUG|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
58094432|NCT00732784|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
58094433|NCT05088525|PROCEDURE|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
58094434|NCT03455114|DEVICE|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
58094435|NCT02752451|OTHER|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
58094436|NCT02752451|OTHER|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
58094437|NCT02752451|OTHER|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
58094438|NCT04950322|DRUG|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
57950926|NCT01784770|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
58094439|NCT04950322|DRUG|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
58094440|NCT06568666|OTHER|Lumbar spinal manipulation|Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
58094441|NCT06568666|OTHER|Sacroiliac joint manipulation|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
58094442|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
58094443|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
58094444|NCT06160674|OTHER|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
58094445|NCT03172390|DEVICE|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
58306302|NCT03720886|BIOLOGICAL|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
57950927|NCT01739985|DRUG|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
57950928|NCT01739985|DRUG|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
57950929|NCT03005795|DEVICE|Headphones|Music can be heard through headphones
57950930|NCT03005795|OTHER|No Headphones|No Headphones will be used.
57950931|NCT01003275|DRUG|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
57950932|NCT01003275|DRUG|Placebo|Two soft gels by mouth daily for 8 weeks
57950933|NCT02366611|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
57950934|NCT01609946|DEVICE|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
57950935|NCT01609946|PROCEDURE|Cytology (FNAB) or Surgery|
57950936|NCT05462015|BEHAVIORAL|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
57950937|NCT05462015|BEHAVIORAL|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
57950938|NCT05807360|DEVICE|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
57950939|NCT01195727|DRUG|Apixaban|
58094446|NCT02740660|DRUG|Caffeine 100mg / Albuterol 4mg|
58094447|NCT02740660|DRUG|Placebo|
58094448|NCT02740660|BEHAVIORAL|Family weight management counseling|
58306303|NCT03720886|BIOLOGICAL|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
58094449|NCT05365594|DEVICE|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
58094450|NCT05365594|DEVICE|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
58094451|NCT04608656|OTHER|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
58094452|NCT04608656|OTHER|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
58094453|NCT06074159|BEHAVIORAL|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
58094454|NCT01179256|DIETARY_SUPPLEMENT|CURCUMIN|oral supplementation of curcumin 2000mg
58094455|NCT01179256|OTHER|no intervention other than stopping study|no intervention other than stopping study
58094456|NCT06417723|PROCEDURE|Maxillary nerve block|It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
58094457|NCT06704009|DRUG|NT-101 0.05 mM|Low concentration of NT-101 (0.05 mM)
58094458|NCT06704009|DRUG|NT-101 0.2 mM|High concentration of NT-101 (0.2 mM)
58094459|NCT03016988|DRUG|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
58094460|NCT03016988|DRUG|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
58094461|NCT03016988|DRUG|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
58094462|NCT02432521|OTHER|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
58094463|NCT04318002|BIOLOGICAL|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
58094464|NCT06583538|OTHER|Giraffe Healthcare|"An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks"
58094465|NCT00729703|DEVICE|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
58094466|NCT00729703|DEVICE|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
58094467|NCT06701253|DIAGNOSTIC_TEST|point of care ultrasound|Point of care ultrasound for upper airway evaluation.
58094468|NCT04022759|BEHAVIORAL|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
58094469|NCT04022759|BEHAVIORAL|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
58094470|NCT05623449|OTHER|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
58094471|NCT05623449|OTHER|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
58094472|NCT05623449|PROCEDURE|pain scale|Measurement of pain intensity
58094473|NCT05623449|PROCEDURE|hypnosis consultation|5 hypnosis consultation
58094474|NCT05623449|PROCEDURE|Maintenance|Qualitative assessment
58094475|NCT05623449|OTHER|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
58094476|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab Prefilled Syringe|Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
58094477|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab AI|AI for SC injection self-administration of rocatinlimab.
58094478|NCT06254963|OTHER|sand jump training|A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
58094479|NCT06254963|OTHER|land jump training|A series of progressive jumping activities on land increasing in difficulty over the 6 week period
58094480|NCT05996549|DRUG|Quadrivalent Influenza Vaccine|All high-risk groups have been getting one dose of seasonal influenza vaccination (Inactivated Influenza Vaccine ), except children aged six months to 8 years, who will receive two doses four weeks apart. All vaccines are in the southern hemisphere, as Bangladesh's influenza season matches the southern hemisphere areas.
58094481|NCT03390452|BEHAVIORAL|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
58095386|NCT04376918|DEVICE|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
58094482|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT active|Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
57735303|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation Sham|We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
57735304|NCT00089726|BIOLOGICAL|CG8123|
57735305|NCT00089726|DRUG|Cyclophosphamide|
58094483|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
58094484|NCT04415177|DEVICE|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
57735306|NCT02142049|DRUG|Ibrutinib|Ibrutinib
57735307|NCT02142049|DRUG|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
58094485|NCT04415177|DEVICE|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
58094486|NCT03125915|BEHAVIORAL|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
58094487|NCT03125915|BEHAVIORAL|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
58094488|NCT03125915|BEHAVIORAL|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
58094489|NCT02445222|GENETIC|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
58094490|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
58094491|NCT04464200|DRUG|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
58094492|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
58421760|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
57735308|NCT02142049|DRUG|Lenalidomide|Lenalidomide
57735309|NCT06477900|OTHER|SMS reception|reception of 72 SMS encouraging physical activity and nutritional advice
57735310|NCT03369600|DEVICE|Supersonic Imagine Aixplorer SWE Ultrasound Imaging|Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
57735311|NCT04199091|PROCEDURE|Craniosacral Therapy (CST) self-help techniques|Manual self-help techniques based on Craniosacral Therapy (group setting).
57735312|NCT04199091|PROCEDURE|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation according to Jacobsen (group setting).
57735313|NCT03058679|OTHER|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
58094493|NCT04632563|OTHER|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
58094494|NCT04297254|DRUG|Lenvatinib|Lenvatinib capsules.
58094495|NCT06303622|PROCEDURE|MRI-USG fusion approach|MRI-USG fusion approach prostate biopsy
58094496|NCT06303622|PROCEDURE|Cognitive-guided approach|Cognitive-guided approach prostate biopsy
58094497|NCT02587325|DRUG|nab-sirolimus|nab-sirolimus is an mTOR inhibitor
58094498|NCT04454619|DRUG|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
58094499|NCT06696001|BEHAVIORAL|Psychoeducation|For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
58094500|NCT06696001|BEHAVIORAL|Behavioral Activation|Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.
58094501|NCT01275521|DRUG|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
58094502|NCT01275521|DRUG|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
58094503|NCT06340087|OTHER|10% Sucrose|10% sucrose corresponding to a regular soft drink
58421761|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
58421762|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
58421763|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
58421764|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
58421765|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
58421766|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
58421767|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
58421768|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
58421769|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
58421770|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
58421771|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
58094504|NCT06340087|DRUG|Sucrose+ Hesperetin|Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
58421772|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
58421773|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
58421774|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
58421775|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
58421776|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
58094505|NCT06340087|OTHER|7% Sucrose|7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
58094506|NCT05003739|PROCEDURE|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
57785399|NCT03007589|OTHER|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
58094507|NCT06523465|DRUG|Simvastatin combined with Amlodipine besylate|6-month treatment of Simvastatin combined with Amlodipine besylate
58094508|NCT06523465|DRUG|Simvastatin combined with Spironolactone and Amlodipine besylate.|6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
58094509|NCT06523465|DRUG|Amlodipine besylate combined Spironolactone|6-month treatment of Amlodipine besylate combined with Spironolactone
58421777|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
58421778|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
58421779|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
58421780|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
58421781|NCT01781351|OTHER|Taping the ankle|
58421782|NCT02068560|DRUG|dDAVP infusion|
58421783|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
58421784|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
58094510|NCT01284231|DRUG|MEDI-565|MEDI-565 will be administered by IV infusion
58094511|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
58094512|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
58094513|NCT01284231|DRUG|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
58094514|NCT06543134|PROCEDURE|surgery|ENT surgery lasting more than half an hour
58094515|NCT06543134|PROCEDURE|sedation scale|Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
58094516|NCT00826176|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
58421785|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
58421786|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
58421787|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
58421788|NCT00005048|DRUG|estramustine phosphate sodium|
58421789|NCT00005048|DRUG|paclitaxel|
58421790|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
58421791|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
58421792|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
58421793|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
58421794|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
58421795|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
58421796|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
57735314|NCT06481917|OTHER|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
57735315|NCT06481917|OTHER|Ergonomic analysis|Ergonomic analysis throughout the intervention
57735316|NCT06481917|OTHER|Evaluation of intervention acceptability|Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
57735317|NCT03977220|DRUG|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
58306304|NCT02227641|BIOLOGICAL|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
58306305|NCT01682096|RADIATION|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
58306306|NCT01682096|PROCEDURE|Exercise stress echocardiography|Limited by symptoms
58306307|NCT06077539|DRUG|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
58306308|NCT06077539|DRUG|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
58306309|NCT06077539|DRUG|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
58306310|NCT06077539|OTHER|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
58306311|NCT03613493|DIAGNOSTIC_TEST|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
58306312|NCT03613493|BEHAVIORAL|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
58306313|NCT03613493|BEHAVIORAL|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
58306314|NCT03613493|BEHAVIORAL|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
58306315|NCT02352857|OTHER|Sugar|100g of sponge cakes made with 24g of dextrose.
58306316|NCT02352857|OTHER|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
58306317|NCT01228006|DIETARY_SUPPLEMENT|NatusGerin|1 capsule, 2 times a day.
58306318|NCT01228006|OTHER|Placebo capsules|1 capsule, 2 times a day
58306319|NCT04249479|OTHER|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
58306320|NCT04249479|OTHER|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
58306321|NCT04249479|OTHER|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
58306322|NCT03277131|DEVICE|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
58306323|NCT06230263|DIAGNOSTIC_TEST|Visual acuity test|"Assess near high-contrast visual acuity (40cm) using EyeChart PRO on an iPad.~Use the MNREAD app to measure:~Reading Acuity: Smallest font size read without errors. Critical Print Size: Smallest font size for peak reading speed. Maximum Reading Speed: Time to read comfortable font size, in words per minute. Reading Accessibility Index: Single metric summarizing visual access to print. Assess near visual function with the Near Activity Visual Questionnaire.~Evaluate distance visual acuity, both high and low contrast, using logMAR and the E-ETDRS (NIDEK SC-2000)."
58306324|NCT02656030|OTHER|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
58306325|NCT02656030|OTHER|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
58306326|NCT02656030|OTHER|usual care|usual care, 2 time per week, 6 weeks duration
58306327|NCT01192165|DRUG|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
58306328|NCT01192165|DRUG|Docetaxel|Chemotherapy
58306329|NCT01192165|DRUG|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
58306330|NCT01192165|DRUG|Pemetrexed|Chemotherapy
58306331|NCT01192165|DRUG|Carboplatin|Chemotherapy
58306332|NCT01192165|DRUG|nab-Paclitaxel|Chemotherapy
58306333|NCT01192165|DRUG|Cisplatin|Chemotherapy
58306334|NCT02666976|DRUG|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
58306335|NCT04384900|PROCEDURE|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
58094517|NCT01111084|DRUG|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
58094518|NCT06580782|DRUG|Calcium Carbonate 500 MG|Calcium Carbonate 500mg, orally, every 4 hours.
58094519|NCT06580782|DRUG|Standard Dose Synthetic Pitocin|The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
58094520|NCT04450979|DIETARY_SUPPLEMENT|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
58094521|NCT06564467|DRUG|JMT202|subcutaneous injection
58094522|NCT06564467|DRUG|Placrbo|subcutaneous injection
58094523|NCT06537947|PROCEDURE|Endovascular intervention using the SENTANTE endovascular robotic system|"1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.~2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.~3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel."
58094524|NCT04911127|DRUG|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
58094525|NCT04911127|DRUG|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
58094526|NCT04911127|DRUG|Placebo capsules|MCT oil capsules as placebo for CBD
57735318|NCT05229692|DEVICE|NEUBIE|"Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques"
58094527|NCT03923816|DRUG|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
58094528|NCT03978897|DEVICE|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
57735319|NCT03046212|DEVICE|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
58094529|NCT03978897|OTHER|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
58094530|NCT00006385|BIOLOGICAL|MART-1 antigen|
58094531|NCT00006385|BIOLOGICAL|gp100 antigen|
58421797|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
58421798|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
58421799|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
58421800|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
58094532|NCT00006385|BIOLOGICAL|incomplete Freund's adjuvant|
58094533|NCT00006385|BIOLOGICAL|recombinant interferon alfa|
58094534|NCT00006385|BIOLOGICAL|sargramostim|
58094535|NCT00006385|BIOLOGICAL|tyrosinase peptide|
58094536|NCT05077774|DEVICE|Harmony TPV System|Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
58094537|NCT00718978|PROCEDURE|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
58094538|NCT05446376|DRUG|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
58094539|NCT05947799|OTHER|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
58094540|NCT05947799|OTHER|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
58094541|NCT04528992|OTHER|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
58094542|NCT04528992|OTHER|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
58094543|NCT01902524|DRUG|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
58094544|NCT03974217|DRUG|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
58306336|NCT03413592|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
58306337|NCT03413592|OTHER|Car-following test|Driving with simulator program for DCV measurement
58306338|NCT03413592|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
58306339|NCT02461693|DRUG|Caffeine|200mg delivered as pill; one-time dose
58306340|NCT02461693|DRUG|Placebo|Lactose-based pill; one-time dose
58306341|NCT04000113|DEVICE|laser acupuncture|low level laser emission on specific acupuncture points
58306342|NCT04000113|DEVICE|Sham laser|Sham laser
58094545|NCT03974217|DRUG|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
58094546|NCT06384365|BEHAVIORAL|Physical activity|The control and the athletic group differ in the degree of physical acitvity
58094547|NCT06658275|OTHER|Constraint-induced movement therapy|During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
58094548|NCT06658275|OTHER|Hand Arm Bimanual Intensive Training -HABIT|For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
58094549|NCT03930056|DEVICE|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
58094550|NCT03930056|DEVICE|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
58094551|NCT04504097|BEHAVIORAL|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
58094552|NCT04504097|DIAGNOSTIC_TEST|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
58421801|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
58421802|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
58421803|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
58421804|NCT03323190|BEHAVIORAL|Inpatient COPD education|
57735320|NCT03046212|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
57735321|NCT00282620|DRUG|Magnesium L-lactate|
58094553|NCT04493099|DRUG|Alvocidib Hydrochloride|Given IV
58094554|NCT04493099|DRUG|Decitabine|Given IV
58094555|NCT04493099|DRUG|Venetoclax|Given PO
58421805|NCT06061107|BEHAVIORAL|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
58421806|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
58421807|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
58421808|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
58421809|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
58421810|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
58421811|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
58421812|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
58421813|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
58094556|NCT06672458|DEVICE|MyndMove Short Term Therapy|FES therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. FES therapy uses surface electrical stimulation to produce muscle contractions in different combinations to achieve a wide range of reaching and grasping functions. To achieve these movements the single use electrodes will be placed in various combinations on the surface of the different upper arm muscles. Participants will perform hand and finger dexterity tests as well as arm functional mobility tasks while receiving FES.
58094557|NCT06672458|OTHER|Conventional Short Term Therapy|Therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. Conventional therapy will consist of performance hand and finger dexterity tests as well as arm functional mobility tasks
58094558|NCT06672458|DEVICE|MyndMove Long Term Therapy|FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.
58421814|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
57735322|NCT06356064|DEVICE|Extracorporeal shock wave therapy|Radİal ESWT and focus ESWT
57735323|NCT01900990|DEVICE|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
57735324|NCT04019938|RADIATION|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
57735325|NCT03150056|DRUG|GSK525762|GSK525762 will be administered.
57735326|NCT03150056|DRUG|Abiraterone|Abiraterone will be administered.
57735327|NCT03150056|DRUG|Enzalutamide|Enzalutamide will be administered.
57735328|NCT03150056|DRUG|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
57735329|NCT00868439|DRUG|patiromer|Active investigational drug
58094559|NCT02087826|OTHER|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
58094560|NCT02087826|DRUG|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
58094561|NCT06700421|DRUG|Adebrelimab + Apatinib|Adebrelimab combined with apatinib
58094562|NCT00797316|DRUG|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
58094563|NCT00797316|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
58421815|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
58421816|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
58421817|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
58421818|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
58421819|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
58421820|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
58421821|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
58421822|NCT02718014|OTHER|scaling and root planing (srp)|
58421823|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
58421824|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
58421825|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
58421826|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
58421827|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
58421828|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
58421829|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
58421830|NCT00003719|DRUG|irinotecan hydrochloride|
58421831|NCT00238368|BIOLOGICAL|filgrastim|
58421832|NCT00238368|BIOLOGICAL|rituximab|
58421833|NCT00238368|DRUG|busulfan|
58421834|NCT00238368|DRUG|cisplatin|
58421835|NCT00238368|DRUG|cyclophosphamide|
58421836|NCT00238368|DRUG|cytarabine|
57735330|NCT00868439|DRUG|placebo|placebo
58421837|NCT00238368|DRUG|doxorubicin hydrochloride|
58421838|NCT00238368|DRUG|etoposide|
58421839|NCT00238368|DRUG|methylprednisolone|
58421840|NCT00238368|DRUG|prednisone|
58421841|NCT00238368|DRUG|vincristine sulfate|
58421842|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
58421843|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
58421844|NCT00238368|PROCEDURE|positron emission tomography|
58421845|NCT00238368|RADIATION|fludeoxyglucose F 18|
57735331|NCT06027229|BIOLOGICAL|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
57735332|NCT05155826|DEVICE|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
57735333|NCT04525404|DIAGNOSTIC_TEST|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
58094564|NCT05512286|RADIATION|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
58421846|NCT00238368|RADIATION|radiation therapy|
57735334|NCT04525404|DIAGNOSTIC_TEST|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
58421847|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
58421848|NCT02713867|BIOLOGICAL|Nivolumab|
58421849|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
57735335|NCT04525404|OTHER|Cognitive testing|NIH toolbox Cognitive Measures
57735336|NCT04525404|OTHER|Olfaction testing|Brief Smell Identification Test (BSIT)
58094565|NCT05512286|RADIATION|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
58094566|NCT06542692|DEVICE|Whole Body Vibration|treatment duration, frequency
58094567|NCT06542692|DEVICE|physical therapy modalities|ultrasound, hot pack, tens
58306343|NCT01953029|PROCEDURE|cardiac imajing|Cardiac MRI
58306344|NCT02991001|PROCEDURE|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
58306345|NCT02991001|PROCEDURE|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
58306346|NCT02991001|DEVICE|Ultrasound|
58421850|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
58421851|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
58421852|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
58421853|NCT04518163|DRUG|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
58421854|NCT04518163|DRUG|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
58421855|NCT04518163|DEVICE|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
58094568|NCT06055959|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
58094569|NCT04434209|DEVICE|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
58094570|NCT04434209|OTHER|Standard of Care|Standard of Care patient management
58094571|NCT04500054|OTHER|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
58094572|NCT04207892|PROCEDURE|Conservative (non-surgical) treatment|Cast Sling Splint Collar
58094573|NCT04207892|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
58094574|NCT00013273|PROCEDURE|Physical Conditioning|
58094575|NCT06354972|PROCEDURE|Minimally invasive surgical procedure|All the experimental sites underwent a minimally-invasive surgical technique (MIST) procedure under magnification (Cortellini and Tonetti 2007). The full-thickness flap was minimally raised both on the buccal and oral side, avoiding vertical releasing incisions. Granulation tissue was scraped from the bony surfaces of the defect, and the root was debrided using minicurettes/ultrasonic device and chemically treated by EDTA. Regenerative procedure was carried out using a combination of enamel matrix derivatives and bone xenograft. The flaps were then repositioned and sutured in order to obtain passive primary closure.
58095387|NCT04376918|DEVICE|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
58306347|NCT02991001|DRUG|Normal Saline|
58306348|NCT00687908|DRUG|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
58306349|NCT00687908|DRUG|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
58306350|NCT00618293|DRUG|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
58421856|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
58421857|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
58421858|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
58421859|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
58421860|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
58421861|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
58421862|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
58421863|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
58421864|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
58421865|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
58421866|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
57735337|NCT04525404|DIAGNOSTIC_TEST|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
58306351|NCT00618293|OTHER|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
58306352|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
58306353|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
58306354|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
58306355|NCT00848497|DRUG|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
58306356|NCT00848497|OTHER|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
58306357|NCT00848497|DRUG|Viagra®|Viagra 25mg was the dose given to the patient which he started.
58306358|NCT01347463|PROCEDURE|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
58306359|NCT02063672|DEVICE|Lutonix DCB|
58421867|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
58421868|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
58421869|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
58306360|NCT02063672|DEVICE|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
58421870|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
58421871|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
58421872|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
58421873|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
58421874|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
58421875|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
58421876|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
58421877|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
58421878|NCT06398925|DRUG|Placebo|Placebo capsule
58421879|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
58421880|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
58421881|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
58421882|NCT03470363|DRUG|Bupivacaine / SUFentanil|
58421883|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
58421884|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
58421885|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
58421886|NCT00073281|PROCEDURE|Islet transplantation|
58421887|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
58421888|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
58421889|NCT01972685|PROCEDURE|Transbronchial Biopsy|
58421890|NCT01972685|PROCEDURE|VATS biopsy|
58421891|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
58421892|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
58421893|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
58421894|NCT01360177|DRUG|Na134I|25 to 150 mCi
58421895|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
58421896|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
58421897|NCT00073463|GENETIC|tgAAVCF|
58421898|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
58306361|NCT03717571|DIAGNOSTIC_TEST|Glenohumeral translation assessment|amount of glenohumeral translation under load
58421899|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
58421900|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
58421901|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
58421902|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
58421903|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
58421904|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
58421905|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
58421906|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
58421907|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
58421908|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
58421909|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
58421910|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
58421911|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
58421912|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
58421913|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
58421914|NCT01107782|DRUG|placebo|50mg tid
58421915|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
58421916|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
58421917|NCT02322190|PROCEDURE|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
58421918|NCT02322190|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
58421919|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
58421920|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
58421921|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
58421922|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
58421923|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
58421924|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
58421925|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
57735338|NCT04525404|OTHER|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
57735339|NCT05788549|BEHAVIORAL|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
58306362|NCT02936973|DEVICE|Real catgut implantation at acupoints|"1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
58306363|NCT02936973|DEVICE|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
58306364|NCT05634655|OTHER|no interventions between two groups|no interventions between two groups
58306365|NCT00511381|GENETIC|No intervention|No intervention
58306366|NCT01302899|DRUG|Aliskiren|Aliskiren 150 mg (Tablet)
58306367|NCT01302899|DRUG|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
58306368|NCT01302899|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
58306369|NCT01302899|DRUG|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
58306370|NCT01302899|DRUG|Ramipril|Ramipril 10mg (Tablet)
58306371|NCT05449899|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
58306372|NCT05449899|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
58306373|NCT05449899|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
58306374|NCT05449899|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
58306375|NCT05449899|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
58421926|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
58421927|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
58421928|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
58421929|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
58421930|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
58421931|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
58094576|NCT04978194|OTHER|University-based intervention to promote better management of emotions and learning|It included 9 video capsules (that take place over 9 weeks), with the following themes: stress information, learning information, emotion and stress regulation strategies, cognitive and metacognitive learning strategies, motivation for learning, physical activity, diet, sleep, and managing worry and uncertainty. It is based on previous online student mental health intervention studies. It presents two innovative aspects: elements and examples specific to the COVID-19 pandemic and the addition of modules focused on learning strategies. The different modules were designed by 5 associate professors, 2 Master students in clinical psychology and 2 undergraduate students in psychology. For the control group, the videos will be posted every week on a You Tube channel and broadcast on a private discord group. For the hybrid group, student will have to attend 10 lessons of 2 hours. These courses include the viewing of videos and a time for discussion between students and the teacher.
58094577|NCT04580511|DEVICE|CELLIS (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in abdominal reconstruction
58094578|NCT04301089|DEVICE|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
58094579|NCT06515080|DIAGNOSTIC_TEST|Near Red Infrascopy|Monitor of regional cerebral oxygen saturation
58094580|NCT06153979|BIOLOGICAL|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
58094581|NCT05176301|RADIATION|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
57785400|NCT01013480|DRUG|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
58094582|NCT00712907|DIETARY_SUPPLEMENT|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
58094583|NCT00712907|DIETARY_SUPPLEMENT|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
58094584|NCT00712907|OTHER|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
58094585|NCT04149288|DIETARY_SUPPLEMENT|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
58094586|NCT04149288|DIETARY_SUPPLEMENT|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
58094587|NCT06222398|DEVICE|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
58094588|NCT01059942|OTHER|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
58421932|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
58421933|NCT01908439|OTHER|whole-body vibration|High amplitude whole-body vibration
58094589|NCT01059942|OTHER|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
58421934|NCT01387724|GENETIC|RNA analysis|
58421935|NCT01387724|GENETIC|polymerase chain reaction|
58421936|NCT01387724|GENETIC|protein expression analysis|
58421937|NCT01387724|GENETIC|proteomic profiling|
58421938|NCT01387724|GENETIC|western blotting|
57735340|NCT05788549|BEHAVIORAL|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
58094590|NCT00003607|RADIATION|radiation therapy|
58094591|NCT06390111|DRUG|nadofaragene firadenovec|The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
58094592|NCT06700954|OTHER|legume-rich Planetary Health Diet|legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein
58094593|NCT06700954|OTHER|control diet based on Western Diet low in legumes|diet based on the Western dietary pattern including animal protein sources (= control diet)
57785401|NCT03615482|BIOLOGICAL|V114|Single 0.5 mL injection
57785402|NCT03615482|BIOLOGICAL|QIV|Single 0.5 mL injection
58306376|NCT00787826|BIOLOGICAL|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
58306377|NCT06422039|DRUG|HRS-7535（D）Tablets|One HRS-7535（D）Tablet is administered to healthy subjects.
58306378|NCT06422039|DRUG|HRS-7535（C）Tablets|Two HRS-7535（C）Tablets is administered to healthy subjects.
58421939|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
58421940|NCT01387724|OTHER|immunohistochemistry staining method|
58421941|NCT01387724|OTHER|laboratory biomarker analysis|
58421942|NCT01387724|OTHER|liquid chromatography|
58421943|NCT01387724|OTHER|mass spectrometry|
58421944|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
58421945|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
58421946|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
58421947|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
58421948|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
58421949|NCT04627935|BEHAVIORAL|The COPD Assessment Test|Used to assess symptoms in COPD patients.
58421950|NCT04627935|DIAGNOSTIC_TEST|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
58421951|NCT04627935|BEHAVIORAL|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
57735341|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
58094594|NCT06703671|DEVICE|electroacupuncture group|"According to the acupuncture prescription, the acupuncture doctor carried out acupuncture and lifting and twisting, and qi appeared under the needle. Select waist Jiaji point and Shenshu point on the same side to connect a set of electronic needle therapy instrument, the positive pole (red clip) connected to Shenshu point, the negative pole (white clip) connected to waist Jiaji point, after confirming that the electric current intensity of the electric needle instrument returns to zero, open the electronic needle therapy instrument, select continuous wave, 2Hz, current intensity 2mA. During the process of needle retention, the other points were injected every 15 minutes and retained for 30 minutes.The investigators have developed detailed acupoint positioning and operation rules."
58094595|NCT06703671|DEVICE|sham-acupuncture group|The investigators fixed the foam pad with one hand and inserted a comfort needle with the other, making sure the needle only touched the surface of the skin and did not penetrate the point. After the completion of all acupoint operations, the operator selected the simulated needle insertion points of Jiaji point on the waist and Shenshu point on the same side. An electroacupuncture treatment device designed to connect a circuit interrupt treatment is operated with the electroacupuncture group, a process that ensures that the participant does not experience any perceptible stimulation
58094596|NCT03303807|DEVICE|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
58094597|NCT05689034|DRUG|Azvudine|Azvudine po. 5mg daily for 7 days
58094598|NCT05689034|DRUG|Placebo|Placebo po. 5 tablets daily for 7 days
58094599|NCT06700798|DRUG|Orelabrutinib|150mg po
58094600|NCT06700798|DRUG|rituximab|375mg/m\^2, intravenous
58094601|NCT06700798|DRUG|Cyclophosphamide|750mg/m\^2
58094602|NCT06700798|DRUG|Vincristine|1.4mg/m\^2
58094603|NCT06700798|DRUG|Prednisone tablet|60mg/m\^2
58094604|NCT03113175|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
58094605|NCT03113175|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
58421952|NCT04627935|BEHAVIORAL|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
58421953|NCT04627935|BEHAVIORAL|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
58421954|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
58421955|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
58421956|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
58421957|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
58421958|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
58421959|NCT00002077|DRUG|Fluconazole|
58421960|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
57735342|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
58094606|NCT05133843|PROCEDURE|Assession of complete coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
58094607|NCT00130663|DEVICE|PDA blood pressure screening program and chart reminder|
58094608|NCT02280915|OTHER|Savoury food product|
58094609|NCT05647733|PROCEDURE|Low splanchnic blood volume restrictive fluid management strategy|Hemodynamic goal-directed restrictive fluid management strategy.
58094610|NCT05647733|PROCEDURE|Optimized cardiac output liberal fluid management strategy|Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
58094611|NCT05647733|PROCEDURE|Phlebotomy|Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
57735343|NCT00481429|DRUG|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
57785403|NCT03615482|BIOLOGICAL|Matching Placebo for V114|Single 0.5 mL injection
58094612|NCT03739996|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
58094613|NCT03739996|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
58094614|NCT03739996|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
58094615|NCT03739996|BIOLOGICAL|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
58094616|NCT03739996|DRUG|Standard of Care (SOC) Oral ART|SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.
58094617|NCT06155149|OTHER|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
58421961|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
58094618|NCT06155149|OTHER|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
58094619|NCT06073041|OTHER|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then receive an in-depth standardized onboard training.
58094620|NCT05037812|DRUG|Saline injection|Saline
58094621|NCT05037812|DRUG|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
58421962|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
58421963|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
58421964|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
58421965|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
58421966|NCT02401204|OTHER|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
58421967|NCT00006268|BIOLOGICAL|cintredekin besudotox|
58421968|NCT00006268|DRUG|isolated perfusion|
58421969|NCT00006268|PROCEDURE|conventional surgery|
58421970|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
58421971|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
58421972|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
58421973|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
58421974|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
58421975|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
58421976|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
58421977|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
58421978|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
58421979|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
58421980|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
58421981|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
58421982|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
58306379|NCT01348841|OTHER|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
58306380|NCT03271138|DIETARY_SUPPLEMENT|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10\^9 CFU Bifidobacterium infantis NLS super strain
58421983|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
58421984|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
58421985|NCT01722292|DRUG|LY2940680|Administered orally
58421986|NCT01722292|DRUG|Carboplatin|Administered IV
58421987|NCT01722292|DRUG|Etoposide|Administered IV
58421988|NCT01722292|DRUG|Placebo|Administered orally
58421989|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
58421990|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
57735344|NCT06370767|BEHAVIORAL|Bike-Share Travel Training|Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.
57735345|NCT06370767|BEHAVIORAL|Public Transportation Travel Training|Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
58421991|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
57735346|NCT06043050|DRUG|Platelets|Observational data: all platelet transfusions recorded in routine care medical file data.
57735347|NCT05099848|DRUG|Camrelizumab|"Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
57735348|NCT01552213|OTHER|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
57735349|NCT01552213|OTHER|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
58094622|NCT02737072|DRUG|LY2510924|Administered SQ
58094623|NCT02737072|DRUG|Durvalumab|Administered IV
58306381|NCT03271138|OTHER|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
58306382|NCT02069795|OTHER|Voice recording|
58306383|NCT01449253|DRUG|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
58306384|NCT01449253|DRUG|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
58306385|NCT02281708|DRUG|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
58306386|NCT01916200|DRUG|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
58306387|NCT03964207|DRUG|Tiotropium Respimat® (T1)|inhalation solution
58306388|NCT03964207|DRUG|Tiotropium Handihaler® (T2)|Inhalation Powder
58421992|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
58421993|NCT00897624|GENETIC|gene expression analysis|
58421994|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
58421995|NCT00897624|OTHER|laboratory biomarker analysis|
58421996|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
58421997|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
58421998|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
58421999|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
58422000|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
58422001|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
58422002|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
58422003|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
58422004|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
58422005|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
58422006|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
58422007|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
58422008|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
58422009|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
58422010|NCT00131651|DRUG|ATN-161|
58422011|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
58422012|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
58422013|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
58422014|NCT00869401|DRUG|dasatinib|Given orally
58422015|NCT00869401|DRUG|temozolomide|Given orally
58422016|NCT00869401|OTHER|placebo|Given orally
58422017|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
58422018|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
58422019|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
57785404|NCT03073005|OTHER|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
58422020|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
58094624|NCT03500887|DEVICE|intragastric bag|
58422021|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
58422022|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
58422023|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
58422024|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
58422025|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
58422026|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
58422027|NCT00036101|DRUG|aripiprazole|
58422028|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
58422029|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
58422030|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
58422031|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
58422032|NCT02198235|DRUG|Dexamethasone|
58422033|NCT02198235|DRUG|Buprenorphine|
58422034|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58422035|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
58422036|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
58422037|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
58306389|NCT01378208|BEHAVIORAL|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~* 28 days of dietary monitoring~* 28 days measurement by pedometer DAY 1, DAY 28 \& DAY 56: Test 1~* Oral glucose tolerance test with stable isotopes~* Fat and muscle biopsies DAY 2, DAY 29 \& DAY 57: Test 2~* DXA scanning~* Resting Metabolic Rate Measurement~* VO2max test on bicycle~* Cognitive testing~* MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 \& DAY 48: Test 3~* Actiheart for 3 days~* 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~* Fasting from 7am - 9pm~* 28 days of dietary monitoring~* 28 days measurement by pedometer"
58306390|NCT03971331|DEVICE|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
58306391|NCT01868659|BEHAVIORAL|Diagnostic checklist|Diagnostic checklist used before patient discharged
58306392|NCT01868659|BEHAVIORAL|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
58306393|NCT00578903|DRUG|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
58306394|NCT00578903|DRUG|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
58306395|NCT00578903|RADIATION|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
58306396|NCT00578903|DRUG|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
58306397|NCT00578903|DRUG|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
58306398|NCT00578903|PROCEDURE|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
58306399|NCT03673891|DEVICE|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
58306400|NCT05120076|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
58306401|NCT05120076|DRUG|NaCl 0.9%|s. arm/group description
58306402|NCT00313235|BIOLOGICAL|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
58306403|NCT03008044|DEVICE|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
58306404|NCT01895985|DRUG|Latanoprostene bunod|
58306405|NCT00000867|DRUG|Memantine|
58306406|NCT01715831|DRUG|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
58306407|NCT01715831|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
58306408|NCT05652127|OTHER|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
58306409|NCT02309021|OTHER|Sport|
58306410|NCT02309021|OTHER|Non-sport activities|
58306411|NCT02385786|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
58306412|NCT00495053|DRUG|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
58306413|NCT00495053|OTHER|Placebo|Matching placebo (PBS-20% sucrose)
58306414|NCT01140971|DRUG|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
58306415|NCT01140971|DEVICE|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
58422038|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
58422039|NCT04248335|DRUG|Pantoprazole|single-dose administration
58422040|NCT04248335|DRUG|Midazolam injection|single-dose administration
58422041|NCT02198690|OTHER|Mammography decision aid|
58422042|NCT02198690|OTHER|Home safety pamphlet|
57950940|NCT04219345|DEVICE|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
58422043|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
58422044|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
57785405|NCT04357002|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
57785406|NCT04357002|DRUG|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
57785407|NCT04357002|DRUG|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
57950941|NCT01630473|PROCEDURE|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
57950942|NCT01630473|PROCEDURE|Conventional orthodontics|Conventional orthodontic treatment
57950943|NCT06077604|OTHER|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
57950944|NCT00643266|BEHAVIORAL|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
58422045|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
58422046|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
58422047|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
58422048|NCT01943552|DRUG|placebo|normal saline
58422049|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
58422050|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
58422051|NCT00211952|DRUG|celecoxib|
58422052|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
58422053|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
58422054|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
58422055|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
58422056|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
58422057|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
57785408|NCT05666102|BEHAVIORAL|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
57785409|NCT02278796|DRUG|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
57785410|NCT02278796|DRUG|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
57785411|NCT04192812|DRUG|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
57785412|NCT04192812|DRUG|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
57785413|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
57785414|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
57785415|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
57785416|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
57785417|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
57950945|NCT00643266|BEHAVIORAL|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
58094625|NCT06144931|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
58094626|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
58094627|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
58422058|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
58422059|NCT00226070|PROCEDURE|interview and advising|
58422060|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
58422061|NCT00226070|PROCEDURE|interview SF-36 self rated health|
58422062|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
58422063|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
58422064|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
58422065|NCT06181370|OTHER|placebo|placebo inhaled drug
58422066|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
58422067|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
58422068|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
58422069|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
58422070|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
58422071|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
58422072|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
58422073|NCT01836081|OTHER|Volume expansion|
58422074|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
58422075|NCT00549770|DRUG|LCZ696|
58422076|NCT00549770|DRUG|Valsartan|
58422077|NCT00549770|DRUG|AHU377|
58422078|NCT00549770|DRUG|Placebo|
58422079|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
58422080|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
58422081|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
58422082|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
58422083|NCT02901652|DEVICE|noninvasive respiratory support devices|
58422084|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
58422085|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
58422086|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
58422087|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
58422088|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
58422089|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
58422090|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
58422091|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
58422092|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
58422093|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
58422094|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
57950946|NCT00877812|DIETARY_SUPPLEMENT|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
58094628|NCT05353491|BEHAVIORAL|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
58094629|NCT05353491|BEHAVIORAL|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
58306416|NCT06519331|DEVICE|Research FibroScan (FS)|"Patients #1 to #25:~Exam 1: Examination with Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #26 to #75:~Exam 1: Examination with the Research or Reference FibroScan. Exam 2: Examination with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #76 to #114:~Exams 1 \& 2: 2 consecutive examinations with the Research or Reference FibroScan.~Exams 3 \& 4: 2 consecutive examinations with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exams 1 \& 2."
58306417|NCT01105052|BEHAVIORAL|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
58306418|NCT00060970|PROCEDURE|Physical Therapy|
58306419|NCT02937597|BEHAVIORAL|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
58306420|NCT02937597|BEHAVIORAL|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
58306421|NCT02937597|BEHAVIORAL|HSE|National HSE e-learning programme only
58306422|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
58306423|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
58306424|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
58306425|NCT04763720|BEHAVIORAL|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
58306426|NCT03074500|DEVICE|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
58306427|NCT03074500|OTHER|Sham taping|Sham taping will be performed without using any technique
58306428|NCT03074500|OTHER|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
58422095|NCT02001337|OTHER|survey administration|baseline
58422096|NCT02001337|OTHER|Specimen collection|baseline
58422097|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
58422098|NCT02506686|DRUG|Meropenem|Meropenem i.v.
58422099|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
58422100|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
58422101|NCT05025722|OTHER|Non Interventional|This is an observational study.
58422102|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
58422103|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
57950947|NCT00877812|DIETARY_SUPPLEMENT|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
58094630|NCT05368714|BEHAVIORAL|Economic Empowerment (EE)|EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.
58422104|NCT03066167|OTHER|Validation of different dysphagia scores|
58422105|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
58422106|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
58422107|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
58422108|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
58422109|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
58306429|NCT01863771|DRUG|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
58306430|NCT01863771|OTHER|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
58306431|NCT05573243|OTHER|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
58306432|NCT02173782|DRUG|Berodual® Respimat ® high dose|
58306433|NCT02173782|DRUG|Berodual® Respimat ® low dose|
58306434|NCT02173782|DRUG|Berodual® MDI|
58306435|NCT02173782|DRUG|Placebo|
58306436|NCT01213238|DRUG|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
58306437|NCT01213238|DRUG|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
57950948|NCT05554848|DRUG|Dexmedetomidine|dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
57950949|NCT05554848|DRUG|Magnesium sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
58306438|NCT01213238|DRUG|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
58422110|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
58306439|NCT00039403|DRUG|7-hydroxystaurosporine|Given IV
58306440|NCT00039403|DRUG|gemcitabine hydrochloride|Given IV
58306441|NCT00039403|OTHER|pharmacological study|Correlative studies
58306442|NCT00039403|OTHER|laboratory biomarker analysis|Correlative studies
58306443|NCT03778671|DRUG|Levobupivacaine|Patients will receive Levobupivacaine 5%
58422111|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
58422112|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
58422113|NCT03055390|DRUG|placebo|2ml of saline intravenous
58422114|NCT02514005|OTHER|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
58422115|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
58422116|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
58306444|NCT03778671|DRUG|Dexmedetomidine Injection [Precedex]|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
58306445|NCT03778671|DRUG|fentanyl|Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
58306446|NCT00289211|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
58306447|NCT00289211|DRUG|Placebo (saline)|
58306448|NCT03303222|DIAGNOSTIC_TEST|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
58422117|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
58422118|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
58422119|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
57950950|NCT05313451|OTHER|Soluble fiber|15g/day during 2 months
57950951|NCT05313451|OTHER|Placebo|Maltodextrin 15g/day during 2 months
58306449|NCT00919880|DRUG|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
58306450|NCT00919880|DRUG|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
58306451|NCT04942262|DRUG|denture adhesive (Polident®, GlaxoSmithKline, Ireland)|cream-type denture adhesive available as an over-the-counter product in Thailand
58306452|NCT04041622|DIAGNOSTIC_TEST|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
58306453|NCT06207474|OTHER|Video + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
58422120|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
58422121|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
58094631|NCT05368714|BEHAVIORAL|Multiple Family Group based Family Strengthening (MFG-based FS)|MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.
58094632|NCT05368714|BEHAVIORAL|EE plus MFG-based FS|EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
58094633|NCT00294931|DRUG|irinotecan|
58094634|NCT00294931|DRUG|carboplatin|
58094635|NCT00294931|DRUG|bevacizumab|
58094636|NCT03716804|DRUG|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
58094637|NCT03716804|DRUG|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
58094638|NCT06536946|BIOLOGICAL|Immunohistochemical staining|Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
58422122|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
58422123|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
58422124|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
58422125|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
58422126|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
58422127|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
58422128|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
58422129|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
58422130|NCT02644382|OTHER|qualitative data collection|qualitative data collection
58422131|NCT02644382|OTHER|survey|survey pre and post-surgical consult
58422132|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
58422133|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
58094639|NCT06703112|DIAGNOSTIC_TEST|An auxiliary diagnostic model for ovarian tumors|Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).
58306454|NCT06207474|OTHER|Video + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
58306455|NCT06207474|OTHER|Paper + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
58094640|NCT05204628|DRUG|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
58306456|NCT06207474|OTHER|Paper + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
58306457|NCT00480844|DRUG|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
58306458|NCT00480844|DRUG|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
58306459|NCT05555498|DEVICE|Virtual Reality glasses|The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
58422134|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
58422135|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
58422136|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
58422137|NCT03510325|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
58422138|NCT03510325|DRUG|Risperidone|Commonly used oral antipsychotics intervention therapy.
58422139|NCT03510325|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
58422140|NCT03510325|DRUG|Amisulpride|Commonly used oral antipsychotics intervention therapy.
58422141|NCT03510325|DRUG|Paliperidone long-acting injection|long-acting injection
58422142|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
58422143|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
58422144|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
58422145|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
58422146|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
58422147|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
58422148|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
58422149|NCT01848847|PROCEDURE|Hysteroscopy|
58422150|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
58422151|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
58422152|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58306460|NCT00666237|PROCEDURE|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
58306461|NCT00666237|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
58422153|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
58422154|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
58422155|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
57950952|NCT02691442|DRUG|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
57950953|NCT02691442|DRUG|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
58306462|NCT00666237|DRUG|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
58422156|NCT00560495|OTHER|immunoenzyme technique|
57950954|NCT02691442|DRUG|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
58422157|NCT00560495|OTHER|laboratory biomarker analysis|
58422158|NCT00560495|RADIATION|Tc 99m sestamibi|
58422159|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
58422160|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
58422161|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
58422162|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
58422163|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
58422164|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
58422165|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
58422166|NCT00076518|DRUG|Fenofibrate|
58422167|NCT00076518|DRUG|Fish Oil|
58422168|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
58422169|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
58094641|NCT05204628|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
58094642|NCT06445738|RADIATION|Arm A: Radiotherapy Omission|Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.
58094643|NCT06445738|OTHER|Arm B: Standard Treatment|Ineligible for RT omission on study; includes management of MRI-detected lesions.
58094644|NCT03022019|DEVICE|ReNovaCell|
58094645|NCT05534191|OTHER|Experimental, comparator and control|To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.
58422170|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
58422171|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
58094646|NCT06703528|DEVICE|cryoablation|The therapeutic cryoablation agent used in this trial was liquid nitrogen with an evaporation temperature of -196°C, which was transported to the ablation pen through a vacuum line to exchange energy at the heart site to perform cryoablation.
58094647|NCT05900739|BEHAVIORAL|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
58422172|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
58422173|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
57785418|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
58306463|NCT04405336|DRUG|tab block|injection of tab block to women who are doing cs
58306464|NCT04405336|DRUG|PCA|giving women PCA
58306465|NCT04405336|DRUG|women who will not receive tab block or PCA|no tab block or PCA will be given
58306466|NCT06090838|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
58306467|NCT03248037|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
58306468|NCT03248037|DRUG|Placebo|Placebo eye drops
58306469|NCT05480059|OTHER|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
58306470|NCT03074695|PROCEDURE|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
58306471|NCT03074695|PROCEDURE|Standard Epidural (EPL)|Standard epidural placement
58306472|NCT03074695|DRUG|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
58306473|NCT03074695|DRUG|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
58306474|NCT02394769|DRUG|Aspirin|
57785419|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
57950955|NCT02364089|PROCEDURE|Laparoscopic surgical removal of the adrenal tumor|
58094648|NCT03430557|PROCEDURE|PRP|platelet rich plasma
58094649|NCT03430557|PROCEDURE|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
58306475|NCT02394769|DRUG|Placebo for Aspirin|
58306476|NCT06472752|RADIATION|Neoadjuvant radiotherapy|Patients with a clear pathological diagnosis of high-risk UTUC were treated with a short course of 5 days of naSBRT: radiotherapy irradiation was directed to the primary lesion on the affected side and to the lymphatic drainage area, with a dose of 25 Gy (5 Gy\*5 days).The safety of the neoadjuvant radiotherapy dose and regimen can be evaluated by metrological ramping in the initial 5 patients, with subsequent patients following the optimal dose from ramping.
58306477|NCT06472752|COMBINATION_PRODUCT|Neoadjuvant drug therapy|Patients will concurrently complete at least 2-4 cycles of preoperative neoadjuvant chemotherapy/immunotherapy/ADCs as well.
58306478|NCT04907266|OTHER|Structured Questionnaire|A structured proforma to assess outcome
58306479|NCT01968421|DRUG|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
58094650|NCT06701188|BEHAVIORAL|Virtual Coaching|The intervention group will receive Virtual coaching: a) tailored weekly coaching through text messages with a weekly summary of progress and tailored messages on goals based on self-reported exercise through the app, barriers, and self-management of PA. b) Individual, tailored monthly coaching will be delivered by the exercise physiologist via video or phone meetings with a focus on self-efficacy building, problem-solving skills, and relapse.
58094651|NCT04216537|DIAGNOSTIC_TEST|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
58422174|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
58422175|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
58422176|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
58422177|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
58422178|NCT02451891|BIOLOGICAL|MVA-EBO Z|
58422179|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
58422180|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
58422181|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
58422182|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
58422183|NCT05150210|DEVICE|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
58422184|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
58422185|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
58422186|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
58422187|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
58422188|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
58422189|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
58422190|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
58422191|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
58422192|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
58422193|NCT02419170|PROCEDURE|Standard of care surgery|
58422194|NCT02419170|PROCEDURE|Apheresis|
58422195|NCT02419170|DRUG|Cyclophosphamide|
58422196|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
58422197|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
58422198|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
58094652|NCT05867173|OTHER|Experimental Speech Processing Strategy|Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.
58422199|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
58422200|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
58422201|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
58422202|NCT00304005|DRUG|laromustine|
58422203|NCT04547361|DRUG|E2511|E2511 tablets.
58422204|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
57785420|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
58094653|NCT05713916|OTHER|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
58094654|NCT01576731|DRUG|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
58094655|NCT01576731|DRUG|Tenofovir, Emtricitabine, Raltegravir|Combination drug
58094656|NCT00002634|BIOLOGICAL|filgrastim|
58422205|NCT00068094|DRUG|Probiotic-containing powder|
58422206|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
58422207|NCT02603445|DRUG|BCL201|
58422208|NCT02603445|DRUG|Idelalisib|
58422209|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
58422210|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
58422211|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
58422212|NCT00434356|DRUG|sunitinib|Oral repeating dose
58422213|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
58422214|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
58422215|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
58422216|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
58422217|NCT03888118|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
58422218|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
58422219|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
58422220|NCT00230152|DEVICE|Imaging|
58422221|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
58422222|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
58422223|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
58422224|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
58422225|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
58422226|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
58422227|NCT02247180|BEHAVIORAL|standardized cognitive training|
58422228|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
57785421|NCT02661854|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
58422229|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
58422230|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
57785422|NCT02661854|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
57785423|NCT02716597|DRUG|25% Albumin|
58094657|NCT00002634|BIOLOGICAL|monoclonal antibody 3F8|
58094658|NCT00002634|DRUG|cisplatin|
58094659|NCT00002634|DRUG|cyclophosphamide|
58422231|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
58422232|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
58422233|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
58422234|NCT01716104|DRUG|Afalaza|Safety and Efficacy
58422235|NCT01716104|DRUG|Placebo|Safety and Efficacy
58422236|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
58422237|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
58422238|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
58422239|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
58306480|NCT03188575|BEHAVIORAL|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
58422240|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
58422241|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
58422242|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
58422243|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
58422244|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
58422245|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
58422246|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
58422247|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
58422248|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
58422249|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
58306481|NCT03188575|OTHER|Waiting List|8 week waiting list period.
58306482|NCT04151394|PROCEDURE|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
58306483|NCT04246463|DEVICE|Thoracic|Implant of a Relay stent graft system
58306484|NCT04246463|DEVICE|Abdominal|Implant with an Anaconda or Treo Stent graft system
58306485|NCT04246463|DEVICE|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
58306486|NCT04246463|DEVICE|Illiac Artery|Implant with an Anaconda Iliac leg only
58306487|NCT05413798|OTHER|Urine HPV testing|Human papillomavirus (HPV) testing in urine sample.
58306488|NCT05413798|OTHER|Self-collected cervicovaginal specimen|Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
58306489|NCT05413798|OTHER|Provider-collected cervical samples|Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
58306490|NCT02715908|DRUG|LBEC0101|Etanercept 50mg
58306491|NCT00586560|DRUG|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
58422250|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
58422251|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
58422252|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
58422253|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
58422254|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
58422255|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
58422256|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
58422257|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
58422258|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
58306492|NCT05197439|DRUG|Dexmedetomidine|The 4.8ug/kg dexmedetomidine will be diluted into 100ml and pump 2ml/h at the beginning of the second of DBS and last for 48 hours.
58422259|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
58422260|NCT06508242|OTHER|Placebo|placebo
58422261|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
58422262|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
58422263|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
58422264|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
58422265|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
58422266|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
58422267|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
57785424|NCT02716597|DRUG|Placebo|
58306493|NCT05197439|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
58306494|NCT03850626|BIOLOGICAL|Immunotherapy|subcutaneous injection
58422268|NCT00048113|DRUG|Alicaforsen|
58422269|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
58422270|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
57785425|NCT00366262|DRUG|PLA-695|
57785426|NCT00366262|DRUG|Naproxen|
58422271|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
57785427|NCT00366262|DRUG|Placebo|
58094660|NCT00002634|DRUG|doxorubicin hydrochloride|
58094661|NCT00002634|DRUG|etoposide|
58094662|NCT00002634|DRUG|mesna|
58306495|NCT01339065|DRUG|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
58306496|NCT00279084|DRUG|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
58306497|NCT00279084|DRUG|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
58306498|NCT00809796|DRUG|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
58422272|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
58422273|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
58422274|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
58422275|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
58422276|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
58422277|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
58422278|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
58422279|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
58422280|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
58422281|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
58422282|NCT03472690|OTHER|Placebo|Subcutaneous injection
58306499|NCT04886414|OTHER|Phone-based monitoring|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
58422283|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
58422284|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
58422285|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
58422286|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
58422287|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
58422288|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
58422289|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
58422290|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
58422291|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
58306500|NCT04886414|OTHER|Oxygen saturation monitoring|Oxygen saturation will be monitored and recorded at regular intervals.
58306501|NCT04886414|OTHER|Alcohol-based hand sanitizer|Alcohol-based hand sanitizer will be distributed to subjects.
58306502|NCT03504917|DRUG|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
58306503|NCT03504917|DRUG|Placebo|Participants will receive matching placebo.
58306504|NCT05030116|DRUG|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
58422292|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
58422293|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
58422294|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
58422295|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
58422296|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
58422297|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
58422298|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
58422299|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
58422300|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
58422301|NCT01969721|DRUG|fluticasone propionate|low dose
58422302|NCT01969721|DRUG|salmeterol|
58422303|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
58422304|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
58422305|NCT01969721|DRUG|tiotropium|tiotropium high dose
58422306|NCT01969721|DRUG|olodaterol|
58422307|NCT01969721|DRUG|olodaterol|
58422308|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
58422309|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
58422310|NCT01969721|DRUG|tiotropium|tiotropium low dose
58422311|NCT01969721|DRUG|fluticasone propionate|low dose
58422312|NCT01969721|DRUG|salmeterol|
58422313|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
58422314|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
58422315|NCT00053547|DRUG|paricalcitol injection|
58422316|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
58094663|NCT00002634|DRUG|perfosfamide|
58306505|NCT05030116|DRUG|Domperidone suspension|Domperidone suspension
58306506|NCT05983536|DIAGNOSTIC_TEST|HIV Ag +Ab Assay Kit (Sysmex)|Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.
58306507|NCT05925439|DEVICE|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
58306508|NCT05925439|DEVICE|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
58306509|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
58306510|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
58306511|NCT02814526|BEHAVIORAL|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
58306512|NCT02814526|BEHAVIORAL|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
58306513|NCT03994380|DRUG|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
58306514|NCT05878236|DIAGNOSTIC_TEST|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
58306515|NCT05590338|DRUG|GSK1070806|Participants will receive GSK1070806
58306516|NCT05590338|DRUG|Placebo|Participants will receive placebo
58306517|NCT00997334|DRUG|Erlotinib|
58306518|NCT01542827|OTHER|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
58306519|NCT01542827|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
58306520|NCT00776880|OTHER|ASA scale|ASA scale evaluation before operation
58306521|NCT00776880|OTHER|PPS scale|PPS scale evaluation before operation
58306522|NCT03780582|BEHAVIORAL|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
58306523|NCT03836586|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
58306524|NCT03836586|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
58306525|NCT04159714|DEVICE|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
58306526|NCT04668677|OTHER|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
58306527|NCT04929015|PROCEDURE|Biospecimen Collection - blood and tissue sample collection|The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
58306528|NCT04929015|OTHER|Electronic Health Record Review|Medical record reviewed
58306529|NCT03534024|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
58306530|NCT03534024|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
58306531|NCT04104971|DIAGNOSTIC_TEST|blood tests , abdominal US and doppler|
58306532|NCT04477135|OTHER|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
58306533|NCT04477135|PROCEDURE|ultrasonography|ultrasonography
58306534|NCT00000948|DRUG|Aldesleukin|Il-2
58306535|NCT00000948|DRUG|ART|antiretroviral therapy for the treatment of HIV
58094664|NCT00002634|DRUG|vincristine sulfate|
58094665|NCT00002634|PROCEDURE|autologous bone marrow transplantation|
58094666|NCT00002634|PROCEDURE|in vitro-treated bone marrow transplantation|
58094667|NCT00002634|RADIATION|low-LET cobalt-60 gamma ray therapy|
58094668|NCT00002634|RADIATION|low-LET photon therapy|
58094669|NCT00002634|RADIATION|radioisotope therapy|
58094670|NCT01845090|DRUG|Lanthanum carbonate|the effect on serum FGF23
58094671|NCT01845090|DRUG|Calcium Carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
58306536|NCT00648180|DRUG|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
58094672|NCT06598540|BEHAVIORAL|Kindness-focused|This mindset intervention frames food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 4. Examples of such activities include sharing their experiences about considering food choices as an act of self-kindness with other study participants or writing an encouraging letter to a study participant and physician colleague through the private and secure message board of a web-based educational platform.
58094673|NCT06598540|BEHAVIORAL|Health-focused|Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. The recording of the session will be available on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 4. Examples of such activities include writing a brief statement about their perspective on the usefulness of healthy eating and sharing it with physician colleagues in their group through the private and secure message board of a web-based educational platform.
58094674|NCT00182273|PROCEDURE|Canalith repositioning maneuver (CRM)|
58094675|NCT02656875|DRUG|TRV130|
58306537|NCT00648180|DRUG|Adoxa Tablets 100 mg|100mg, single dose fed
58306538|NCT00785083|DRUG|FTY720|
58306539|NCT00785083|DRUG|Placebo|
58306540|NCT06303817|OTHER|Double knots facia closure method during cesarean section|In Group I (double knots group), the edge of the fascia was identified with a Kocher clamp. A synthetic absorbable multifilament suture was used to close the fascia in a continuous fashion, starting from the opposite side up to the Kocher clamp. The knots were tied with the same single suture. I
58094676|NCT03660514|BEHAVIORAL|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
58094677|NCT01467401|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
58094678|NCT01467401|DRUG|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
58094679|NCT00257088|BEHAVIORAL|whole day first grade program|
58094680|NCT04427930|BIOLOGICAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
58094681|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 1|Single inhaled dose of SP-101 and doxorubicin Dose 1
58094682|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 2|Single inhaled dose of SP-101 and doxorubicin Dose 2
58094683|NCT06499896|BIOLOGICAL|MTP-101-C|MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
57950956|NCT02364089|DRUG|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day."
58094684|NCT05907902|DRUG|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
58094685|NCT05558189|DEVICE|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
58306541|NCT06303817|OTHER|Triple knots facia closure method during cesarean section|n Group II (triple knots group), the edge of the fascia was fixed with the same suture material instead of the Kocher clamp. The fascia was closed similarly, starting from the opposite corner via the second loop. The loops from the first suture were tied to the second suture.
58306542|NCT00889304|DEVICE|Position HTO system|open wedge high tibial osteotomy
58306543|NCT01959100|DRUG|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
58306544|NCT01959100|DRUG|Placebo|250 mg x 3/week during a meal for a period of 2 years
58306545|NCT06095908|DRUG|Bupivacain|Bupivacain administered with two different ways to the patients, postoperative pain recorded
58306546|NCT02068937|DRUG|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
58306547|NCT02068937|DRUG|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
58422317|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
58094686|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
58094687|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
58094688|NCT06567288|PROCEDURE|spencer mscle energy technique|The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
58094689|NCT06103838|DRUG|18F-fluciclovine injection|370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
58094690|NCT06103838|PROCEDURE|18F-FDG PET/CT|All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
58094691|NCT06235125|DRUG|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
58094692|NCT00567996|DRUG|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
58094693|NCT00567996|DRUG|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
58306548|NCT02879318|DRUG|Gemcitabine|
58306549|NCT02879318|DRUG|Nab-paclitaxel|
58306550|NCT02879318|DRUG|Durvalumab|
58422318|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
58422319|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
57950957|NCT01826279|DIETARY_SUPPLEMENT|Resveratrol|500mg 3 times daily for 1 month
58306551|NCT02879318|DRUG|Tremelimumab|
58306552|NCT01578772|DRUG|Telmisartan|80mg tablets po daily for 6 weeks
58094694|NCT00567996|DRUG|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
58094695|NCT00567996|DRUG|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
58094696|NCT03934437|BEHAVIORAL|mLTCR|mHealth-enhanced Linkage to Care and Retention
58094697|NCT03934437|BEHAVIORAL|LTCR|Linkage and Retention Services (Standard-of-Care)
58094698|NCT03654807|BEHAVIORAL|High Intensity Walking|70-80% HRmax
58422320|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
58094699|NCT03654807|BEHAVIORAL|Casual Speed Walking|Self selected pace
58094700|NCT00403923|DIETARY_SUPPLEMENT|Lactose in water|
58094701|NCT06675695|DRUG|New use of osimertinib|New use of osimertinib described in electronic health records is used as the exposure.
57950958|NCT01826279|OTHER|Placebo|1 placebo tablet 3 times daily for 1 month
58094702|NCT06675695|DRUG|New use of erlotinib or gefitinib|"New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference."
58094703|NCT03441958|BIOLOGICAL|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
58306553|NCT03651141|OTHER|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
58306554|NCT03651141|OTHER|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
58422321|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
58422322|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
58422323|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
58422324|NCT00805064|DRUG|triamcinolone and bevacizumab|
58422325|NCT04889482|OTHER|No intervention|No intervention
57950959|NCT03050242|DRUG|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
57950960|NCT04338035|BEHAVIORAL|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
58094704|NCT00418756|DRUG|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
58094705|NCT04834297|OTHER|Prapela SVS mattress|The intervention will be using the Prapela SVS crib mattress to complement non-pharmacological management of NOWS for the purposes of prevention of pharmacological treatment of NOWS
58094706|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
58094707|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
58094708|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
58094709|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
58422326|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
58422327|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
58422328|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
58422329|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
58422330|NCT02882386|OTHER|Strength Training|
58422331|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
58422332|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
58422333|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
58422334|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
58422335|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
58422336|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
58094710|NCT06701305|DRUG|Efinopegdutide|Subcutaneous injectable solution
58094711|NCT06701305|DRUG|Placebo|Subcutaneous injectable solution
58422337|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
58422338|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
58422339|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
58422340|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
58422341|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
58422342|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
58422343|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
58422344|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
57785428|NCT05674942|OTHER|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
57785429|NCT05935280|OTHER|Room temperature|Room temperature injection
57785430|NCT05935280|OTHER|Cold temperature|Cold temperature injection
58094712|NCT06701305|DRUG|Acetaminophen|Oral solution
58094713|NCT06263543|DRUG|Sacituzumab govitecan|IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
58094714|NCT02362243|OTHER|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
58306555|NCT03651141|OTHER|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
58422345|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
58422346|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
58422347|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
58422348|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
58422349|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
58094715|NCT02362243|OTHER|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
58094716|NCT03962218|PROCEDURE|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
58094717|NCT03111407|PROCEDURE|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
58094718|NCT00928785|BIOLOGICAL|REPEVAX|1 dose of 0.5 mL at Day 0
58094719|NCT00928785|BIOLOGICAL|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
58094720|NCT06702956|PROCEDURE|laser corticotomy|stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy
58094721|NCT06702956|PROCEDURE|Conventional tooth movement|tooth movement us done using wires and brackets
58094722|NCT01955473|DRUG|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
58094723|NCT00000394|PROCEDURE|Acupuncture therapy|
58094724|NCT00435240|BEHAVIORAL|Paleolithic diet|
58094725|NCT02704299|BIOLOGICAL|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
58094726|NCT02246231|DEVICE|MR imaging|
58094727|NCT03935451|DRUG|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
58094728|NCT03935451|DRUG|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
58094729|NCT01413685|OTHER|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
58306556|NCT03904654|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
58306557|NCT00851487|DRUG|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
58306558|NCT00851487|DRUG|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
57950961|NCT04135430|OTHER|Survey|practice of an updated questionnaire at D0, D2 and D7
58094730|NCT06604299|BEHAVIORAL|Meditation-enhanced Cognitive Behavioral Therapy|Self-guided online intervention
58094731|NCT06538207|DRUG|ONO-4578|Specified dose on specified days
58306559|NCT04539990|BEHAVIORAL|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
58094732|NCT06538207|DRUG|ONO-4538|Specified dose on specified days
58306560|NCT01411852|DRUG|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
58422350|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
58422351|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
58094733|NCT06538207|DRUG|Oxaliplatin|Specified dose on specified days
58094734|NCT06538207|DRUG|Levofolinate|Specified dose on specified days
58094735|NCT06538207|DRUG|Irinotecan|Specified dose on specified days
58094736|NCT06538207|DRUG|Fluorouracil|Specified dose on specified days
58094737|NCT06538207|DRUG|Gemcitabine|Specified dose on specified days
58094738|NCT06538207|DRUG|Nab-Paclitaxel|Specified dose on specified days
58094739|NCT05292079|DEVICE|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
58094740|NCT04127994|OTHER|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
57735350|NCT03913585|BEHAVIORAL|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
58094741|NCT01038531|OTHER|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
58094742|NCT01038531|OTHER|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
58094743|NCT05167227|OTHER|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
58094744|NCT02630004|DRUG|Melatonin oral gel 3%|
58094745|NCT02630004|DRUG|Placebo oral gel|
58094746|NCT01136044|OTHER|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
58094747|NCT00695604|DRUG|Placebo|Placebo via MDI.
58094748|NCT00695604|DRUG|Fluticasone|Fluticasone MDI.
58094749|NCT05652686|DRUG|PT217|A bispecific antibody (bsAb) against DLL3 and CD47.
58422352|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
58422353|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
58422354|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
58422355|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
58422356|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
58422357|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
58422358|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
58094750|NCT05652686|DRUG|Carboplatin + Etoposide|Administered per Standard of Care.
58422359|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
57785431|NCT05935280|DRUG|Lidocain|Unspecific sodium channel blocker
57785432|NCT05935280|DRUG|PF-05105679|Specific antagonist of the TRPM8 ion channel
58094751|NCT05652686|DRUG|Paclitaxel.|Administered per Standard of Care.
58094752|NCT05652686|DRUG|Atezolizumab|Administered per Standard of Care.
58094753|NCT04070469|DRUG|Amoxicillin|dosage of plasma concentration of amoxicillin
58094754|NCT05607719|DRUG|Bevespi|Two puffs twice a day
58094755|NCT05607719|DRUG|Bretzri|Two puffs twice a day
58094756|NCT02758951|OTHER|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
58094757|NCT02758951|COMBINATION_PRODUCT|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
58094758|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
58094759|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
58422360|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
58422361|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
58422362|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
58422363|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
58422364|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
58422365|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
58422366|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
58422367|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
58422368|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
58422369|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
58422370|NCT01110798|OTHER|intraoperative complication management/prevention|
58422371|NCT01110798|PROCEDURE|assessment of therapy complications|
58094760|NCT02758951|PROCEDURE|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy in case of sufficient clinical condition, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
58422372|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
58422373|NCT01110798|PROCEDURE|quality-of-life assessment|
58422374|NCT01110798|PROCEDURE|therapeutic conventional surgery|
58422375|NCT00002254|DRUG|Alovudine|
58422376|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
58422377|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
58422378|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
58422379|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
58422380|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
58422381|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
58422382|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
58422383|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
58422384|NCT06234215|OTHER|functional task training|functional exercise
58422385|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
58422386|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
58422387|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
58422388|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
58422389|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
58422390|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
58422391|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
58422392|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
58422393|NCT02337166|PROCEDURE|Periodontal flap surgery|
58094761|NCT02758951|PROCEDURE|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after randomisation.
58094762|NCT05226013|DRUG|Polyglycol lated urate oxidase for injection|Single dose escalation
58094763|NCT05226013|DRUG|Placebo|Placebo
58094764|NCT06701708|OTHER|Participants are not assigned to interventions based on a protocol.|Participants are not assigned to interventions based on a protocol.
58094765|NCT00928135|DRUG|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
57950962|NCT05455853|OTHER|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
57950963|NCT02501265|BEHAVIORAL|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
58094766|NCT00928135|DRUG|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
58094767|NCT00045396|DRUG|tipifarnib|Given orally
58094768|NCT04760847|OTHER|Intermittent Fasting|These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
57950964|NCT02501265|BEHAVIORAL|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
57950965|NCT02501265|DRUG|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
57950966|NCT02501265|DRUG|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
57950967|NCT04272684|OTHER|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
57950968|NCT00254748|DRUG|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
57950969|NCT00254748|DRUG|Placebo|placebo
57950970|NCT01628588|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
58094769|NCT04760847|OTHER|No intermittent fasting|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
58094770|NCT06576375|DRUG|Dapagliflozin|oral Dapagliflozin
58094771|NCT06576375|DRUG|Metformin|oral metformin
58094772|NCT03199898|DIAGNOSTIC_TEST|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
58094773|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
58422394|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
58094774|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
58094775|NCT04196439|PROCEDURE|continuous epidural analgesia|injection of local anaesthetic into epidural space
58422395|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
57735351|NCT02630264|DRUG|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
57735352|NCT02630264|DRUG|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
57950971|NCT05904977|PROCEDURE|Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)|The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
57950972|NCT05087290|OTHER|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
57950973|NCT05087290|OTHER|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
57950974|NCT03452592|DRUG|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
57950975|NCT03719274|DIETARY_SUPPLEMENT|vitamin c depigementation|locally injected vitamin c depigementation
57950976|NCT06051682|DEVICE|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
57950977|NCT06051682|PROCEDURE|Emergency physician|the emergency physician analyzes the x-rays
57950978|NCT05216042|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
57950979|NCT05216042|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
57950980|NCT05216042|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
57950981|NCT05216042|OTHER|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
57950982|NCT05196126|PROCEDURE|Permament pacemaker implantation|PM implantation
57950983|NCT05196126|PROCEDURE|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
57950984|NCT02241759|DRUG|TA-8995|
57950985|NCT02241759|DRUG|Moxifloxacin|
57950986|NCT02241759|DRUG|Placebo|
57950987|NCT02199938|OTHER|Identification and characterization of molecular markers in musculoskeletal tumors|
57950988|NCT06095661|OTHER|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
57950989|NCT03275194|PROCEDURE|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
58094776|NCT04196439|PROCEDURE|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
58094777|NCT05430009|RADIATION|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
58422396|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
58422397|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
57735353|NCT02630264|DRUG|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
57735354|NCT00444782|BIOLOGICAL|GV1001|
58422398|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
58422399|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
57735355|NCT02931734|DRUG|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
57735356|NCT02931734|DRUG|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
57735357|NCT02931734|PROCEDURE|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
57735358|NCT00734227|PROCEDURE|Emergency portacaval shunt|
58094778|NCT05430009|DRUG|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
58094779|NCT03100786|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
58094780|NCT03100786|OTHER|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
57735359|NCT00734227|OTHER|Emergency TIPS|
58094781|NCT05748483|DRUG|Atogepant|Oral Tablet
58094782|NCT05748483|DRUG|Placebo for Atogepant|Oral Tablet
58094783|NCT05748483|DRUG|Topiramate|Oral Capsule
58094784|NCT05748483|DRUG|Placebo for Topiramate|Oral Capsule
58094785|NCT06201962|OTHER|Massage|Massage applications will be performed for 15 minutes every morning and evening for two days.
58094786|NCT06201962|OTHER|Foot Reflexology|In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
58094787|NCT06201962|OTHER|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
58094788|NCT06394830|DRUG|VNX001|Intravesical administration of VNX001
57735360|NCT04935502|OTHER|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
57735361|NCT04935502|OTHER|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
57785433|NCT05935280|DRUG|A967079|Specific antagonist of the TRPA1 ion channel
58094789|NCT01961635|DEVICE|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
58094790|NCT01961635|DEVICE|Zirconia abutments|place zirconia abutment on the day of implant placement
58094791|NCT01961635|DEVICE|Titanium Abutments|place titanium abutment on the day of implant placement
58094792|NCT01961635|DEVICE|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
58094793|NCT01961635|PROCEDURE|Subcrestal|place implant 2mm below crestal bone
58094794|NCT01961635|DEVICE|platform-switch|abutment platform is narrow than implant diameter
58306561|NCT01411852|DRUG|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
58306562|NCT00454298|DRUG|AGG-523 (Aggrecanase Inhibitor)|
58422400|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
58422401|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
58422402|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
58422403|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
58422404|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
58422405|NCT02207257|DRUG|Edoxaban|
58422406|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
58422407|NCT01651091|OTHER|Treatment as usual|
58422408|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
57735362|NCT01704417|DRUG|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
57950990|NCT04876170|OTHER|Brain-computer-interface: EEG-based musical Neurofeedback task|Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.
57950991|NCT03383445|PROCEDURE|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
57950992|NCT03383445|PROCEDURE|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
58094795|NCT01961635|PROCEDURE|one-time one-abutment|place the final abutment on the day of surgery and not remove it
58094796|NCT01961635|PROCEDURE|Torque 20 n/cm2|the amount of torque applied to the abutment
58094797|NCT06700720|DRUG|Dose 1 YN001|Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
58422409|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
58422410|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
58422411|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
58422412|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
58422413|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
58422414|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
58422415|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
58422416|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
58422417|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
58094798|NCT06700720|DRUG|Dose 2 YN001|Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
58094799|NCT06700720|DRUG|Evolocumab|Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
58094800|NCT04539236|DRUG|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
58094801|NCT04539236|DRUG|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
58094802|NCT03845855|OTHER|virtual reality|Virtual reality with a game
58094803|NCT03845855|OTHER|robotic gait|robotic gait therapy
58094804|NCT02428959|DRUG|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
58094805|NCT02606864|DRUG|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
58094806|NCT05025241|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
58094807|NCT00902278|BIOLOGICAL|Flulaval|one 0.5-mL dose via intramuscular injection
58094808|NCT00902278|BIOLOGICAL|Fluvirin|one 0.5-mL dose via intramuscular injection
58094809|NCT00902278|BIOLOGICAL|Fluzone|one 0.5-mL dose via intramuscular injection
58094810|NCT00902278|BIOLOGICAL|Fluarix|one 0.5-mL dose via intramuscular injection
58094811|NCT00902278|BIOLOGICAL|Afluria|one 0.5-mL dose via intramuscular injection
58094812|NCT02875431|PROCEDURE|Patients undergo ACDF or cervical vertebral body replacement|
58094813|NCT06538909|DEVICE|VR|Virtual reality that simulates obstacles on the road during walking
58094814|NCT06604949|DRUG|LP-003 200mg|Subcutaneous injection of 200 mg LP-003
58094815|NCT06604949|DRUG|Placebo|Subcutaneous injection of placebo
58094816|NCT06408454|DIAGNOSTIC_TEST|Gingival crevicular fluid collection|Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
58422418|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
58422419|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
57735363|NCT01704417|DRUG|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
57735364|NCT01558622|DRUG|dexketoprofen trometamol|50mg intravenous infusion
57735365|NCT01558622|DRUG|tramadol hydrochloride|100mg intravenous infusion
58094817|NCT06408454|DIAGNOSTIC_TEST|periodontal test|A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
58094818|NCT01262729|PROCEDURE|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
58094819|NCT01262729|DRUG|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
57735366|NCT01558622|DRUG|pethidine hydrochloride|50mg intravenous infusion
57735367|NCT01558622|DRUG|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
58422420|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
58422421|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
58422422|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
58422423|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
57735368|NCT01558622|DRUG|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
57735369|NCT01558622|DRUG|vitamin c|500mg intravenous infusion
57735370|NCT06170827|DRUG|AIO-001|AIO-001 Solution for SC injection.
57785434|NCT05935280|DRUG|PF-05089771|Specific antagonist of the Nav1.7 sodium channel
57785435|NCT05935280|DRUG|PF-06305591|Specific antagonist of the Nav1.8 sodium channel
58094820|NCT06172933|BEHAVIORAL|Move with Meaning|Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
58094821|NCT06702124|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
58094822|NCT06702124|DRUG|Placebo|Placebo administration for 24 weeks
58094823|NCT05674864|DRUG|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
58094824|NCT05179980|OTHER|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
58094825|NCT01366365|DRUG|methylnaltrexone|
58094826|NCT01366365|DRUG|placebo|
58094827|NCT05145647|RADIATION|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.
58094828|NCT05145647|DEVICE|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
58094829|NCT05899218|BEHAVIORAL|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
58094830|NCT06213974|OTHER|No Intervention|This is non-interventional study.
58094831|NCT05155956|OTHER|transcranial Doppler ultrasonography (TCD)|"Transcranial Doppler (TCD) is a non-invasive ultrasound-based technique that facilitates insonation of the cerebral arteries. TCD probe design enables continuous monitoring of cerebral blood flow velocity (CBFv). TCD has a variety of clinical applications, including intraoperative monitoring for detection of microemboli. The TCD probe can be comfortably secured to the patient's head by a headframe in order to maintain continuous vessel insonation. Microembolic signals (MES) can be reliably detected based on standard criteria:~1. Brief in duration (\<300msec)~2. High intensity (amplitude \>3 dB above background)~3. Unidirectional~4. Audible chirp or snap~Further, CBFv monitoring during may inform flow perturbations that occur during cardiac or vascular manipulations."
58094832|NCT06090500|PROCEDURE|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
58094833|NCT06090500|PROCEDURE|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
58094834|NCT06090500|PROCEDURE|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
58422424|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
58422425|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
58422426|NCT01409369|DRUG|RO4995819|single oral dose
58422427|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
58422428|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
58422429|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
58422430|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
58094835|NCT06520371|DEVICE|Percutaneous radiofrequency|For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
58094836|NCT06520371|DEVICE|Conventional radiofrequency|For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
58306563|NCT05975489|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
58306564|NCT05164978|DRUG|DEP combine with PD-1 antibody|Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
58306565|NCT05095519|DRUG|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
58306566|NCT03311555|DRUG|Apalutamide|240mg tablet daily for 36 weeks
58306567|NCT03311555|DRUG|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
58306568|NCT03311555|RADIATION|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
58422431|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
58422432|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
58422433|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
58094837|NCT03004417|DRUG|CHF 6001 Dose1|CHF 6001 plus placebo
58094838|NCT03004417|DRUG|CHF 6001 Dose2|CHF 6001 only (high dose)
58094839|NCT03004417|OTHER|Placebo|Placebo only
58422434|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
58422435|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
58422436|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
58422437|NCT00359723|DRUG|methylphenidate|
58422438|NCT00468988|DRUG|Travatan® Z|
58422439|NCT00468988|DRUG|Xalatan®|
58422440|NCT00081133|DRUG|arsenic trioxide|
58422441|NCT00081133|DRUG|imatinib mesylate|
58422442|NCT02259985|DRUG|Itasetron tablet|
58422443|NCT02259985|DRUG|Itasetron infusion|
58422444|NCT02259985|OTHER|high fat breakfast|
58094840|NCT05388032|BEHAVIORAL|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to \<2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
58094841|NCT05105035|DRUG|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
58094842|NCT05105035|DRUG|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
58094843|NCT05105035|DRUG|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
58094844|NCT06470841|DRUG|CHG Combined With Venetoclax and Azacytidine|"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."
58094845|NCT02437929|PROCEDURE|Mobilization|
58094846|NCT02437929|PROCEDURE|Positioning|
58094847|NCT02437929|PROCEDURE|Personal Hygiene Care|
58094848|NCT02437929|PROCEDURE|Bladder catheterization|
58422445|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
58422446|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
58422447|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
58422448|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
58422449|NCT01447160|DRUG|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
57735371|NCT04938895|BEHAVIORAL|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
57735372|NCT00102895|DRUG|CP-724,714|
57735373|NCT01262066|BEHAVIORAL|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
57735374|NCT00421252|DRUG|clopidogrel 600 mg|Clopidogrel load \> 2hrs pre-angiography
57735375|NCT00421252|DEVICE|arterial access sheath|randomize to 5Fr vs 6Fr
57950993|NCT03383445|PROCEDURE|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
58094849|NCT02437929|PROCEDURE|Wound care|
58094850|NCT02437929|PROCEDURE|Subcutaneous drugs administration|
58094851|NCT06543238|OTHER|Breastfeeding card game group|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
58094852|NCT00969267|OTHER|ear-acupuncture A|with needle stimulation
58094853|NCT00969267|OTHER|stimulation B|with bread stimulation on ear acupuncture point
58094854|NCT00969267|OTHER|stimulation C|without needle stimulation
58094855|NCT05044832|BEHAVIORAL|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
58094856|NCT06096181|DRUG|Remifentanil TIVA|Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.
58094857|NCT06096181|DRUG|Dexmedetomidine TIVA|Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.
58094858|NCT06096181|DRUG|Propofol TIVA|Propofol is an anesthetic drug that causes sleep during surgery.
58094859|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
58094860|NCT06099327|DEVICE|Image-based vital sign monitoring|Unobtrusive, vital signs measurements with remote photoplethysmography
58094861|NCT05074602|DRUG|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
58422450|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
58422451|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
58422452|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
58422453|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
58306569|NCT03311555|DRUG|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
57735376|NCT06150027|OTHER|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
57735377|NCT03708198|DRUG|Liposomal Bupivacaine|intercostal block
57735378|NCT06413108|DRUG|TB31F|transmission-blocking monoclonal antibody TB31F
58306570|NCT03599570|BEHAVIORAL|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
58306571|NCT01787552|DRUG|LDE225|
58306572|NCT01787552|DRUG|INC424|
58306573|NCT04499703|DEVICE|RHMS-RTM|Assessment of retinal thickness
58306574|NCT04499703|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure
58306575|NCT03908346|OTHER|Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest|a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
58306576|NCT03805334|OTHER|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
58306577|NCT00337883|DRUG|Erlotinib HCl (OSI-774)|
58306578|NCT03830021|BEHAVIORAL|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
58306579|NCT03830021|BEHAVIORAL|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
58306580|NCT00338117|DRUG|Galantamine hydrobromide|
58306581|NCT02785939|DRUG|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
58306582|NCT02785939|OTHER|Laboratory Biomarker Analysis|Correlative studies
58306583|NCT02785939|DRUG|Palbociclib|Given PO
58306584|NCT05281406|DRUG|Osimertinib|80 mg daily or reduced dose 40 mg daily
58306585|NCT05281406|DRUG|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
58306586|NCT05281406|DRUG|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
58306587|NCT05281406|DRUG|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
58306588|NCT06551038|BEHAVIORAL|Primary suicide prevention intervention|Psychoeducation workshop
58306589|NCT06551038|BEHAVIORAL|Art-based control intervention|Slam poetry workshop
58306590|NCT01420159|DRUG|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
58306591|NCT05374096|OTHER|Patient-Chosen Music|Music played into headphones.
58306592|NCT05374096|OTHER|Placebo|Silence into headphones.
58306593|NCT01132508|DEVICE|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
58306594|NCT02391337|DRUG|Bisoprolol|Drug intervention
58306595|NCT02391337|DRUG|Digoxin|Drug intervention
58306596|NCT00060411|DRUG|erlotinib hydrochloride|Given IV
58306597|NCT00060411|DRUG|fluorouracil|Given IV
58306598|NCT00060411|DRUG|leucovorin calcium|Given IV
58306599|NCT00060411|DRUG|oxaliplatin|Given IV
58306600|NCT00060411|BIOLOGICAL|bevacizumab|Given IV
58306601|NCT03292302|DRUG|Placebo|Placebo comparator
58306602|NCT03292302|DRUG|ELX-02|Synthetic aminoglycoside
58306603|NCT03768193|PROCEDURE|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
58306604|NCT03768193|PROCEDURE|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
58306605|NCT00744939|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
58306606|NCT04145063|OTHER|no stent|following uretroscopy, no stent will be placed
58306607|NCT01990326|DRUG|XAF5 Gel|
58306608|NCT01990326|DRUG|Placebo Gel|
58306609|NCT05067478|DRUG|Vibegron|Vibegron to be administered.
58422454|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
58422455|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
58094862|NCT05074602|DRUG|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
58094863|NCT03392415|PROCEDURE|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
58094864|NCT02214004|DRUG|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
58094865|NCT02214004|DRUG|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
58094866|NCT06533891|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
58094867|NCT06533891|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
58094868|NCT06533891|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
58094869|NCT01080209|DRUG|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
58094870|NCT01080209|OTHER|Sham|Patients who recieved sham in a previous study.
58094871|NCT05073276|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
58094872|NCT04688814|PROCEDURE|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
58094873|NCT04688814|DRUG|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
58422456|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
58422457|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
58422458|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
58422459|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
58422460|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
58422461|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
58094874|NCT04007744|BIOLOGICAL|Pembrolizumab|Given IV
58094875|NCT04007744|DRUG|Sonidegib|Given PO
58094876|NCT06017856|OTHER|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
57735379|NCT06413108|OTHER|Normal saline|normal saline as control (placebo)
57735380|NCT04681638|DRUG|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
58094877|NCT03554473|DRUG|M7824|Arm A \&amp; B: 2400mg IV over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
58094878|NCT03554473|DRUG|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
58094879|NCT03554473|DRUG|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
58094880|NCT04296071|OTHER|Research study|Blood and tracheal aspirates will be collected
58094881|NCT03203746|DRUG|Lycopene + SRP|
58094882|NCT03203746|PROCEDURE|SRP only|
58094883|NCT04968743|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
58094884|NCT05128487|DRUG|NDI-101150|NDI-101150 capsules
58094885|NCT05128487|DRUG|Pembrolizumab|Pembrolizumab IV infusion
58094886|NCT02748616|DRUG|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
58094887|NCT06343142|OTHER|Nuts|Isocaloric meal with nuts
58422462|NCT00189501|DRUG|Sensipar®|
58094888|NCT06343142|OTHER|Nut-free meal|Isocaloric meal without nuts
58422463|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
58422464|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
58422465|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
57735381|NCT04681638|DRUG|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
58094889|NCT06516510|DRUG|lutetium (177Lu) rhPSMA 10.1 and Pluvicto®|Radiopharmaceutical
58094890|NCT02076113|PROCEDURE|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
58094891|NCT02076113|PROCEDURE|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
58094892|NCT02076113|PROCEDURE|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
58094893|NCT06553131|DEVICE|Neuromuscular Transmission Monitoring|A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
58094894|NCT03821142|DEVICE|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
58094895|NCT06096870|DRUG|Enzalutamide|Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
58094896|NCT06096870|DRUG|M9241|M9241 at 12.0 microgram/kg by subcutaneous injection (every 28 days)
58306610|NCT01965327|DRUG|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
58306611|NCT00156260|PROCEDURE|Ductal lavage|
58306612|NCT02485665|DEVICE|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
58306613|NCT06120725|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
58422466|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
58422467|NCT00530920|DRUG|tipranavir|
58422468|NCT00530920|DRUG|ritonavir|
58422469|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
57735382|NCT01682460|DRUG|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
57735383|NCT00003135|DRUG|fluorouracil|
57735384|NCT00003135|DRUG|pegylated liposomal doxorubicin hydrochloride|
57735385|NCT00003135|PROCEDURE|hyperthermia treatment|
57735386|NCT02950246|PROCEDURE|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
57735387|NCT02950246|DRUG|2% alcoholic chlorhexidine|
57735388|NCT02950246|DRUG|povidon iodine|
57735389|NCT01940042|BEHAVIORAL|CO2 was removed by means of trandelenburg positions|
57735390|NCT06430450|DIAGNOSTIC_TEST|Clinical measurements and saliva samples collection|Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
58094897|NCT03599843|BEHAVIORAL|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
58094898|NCT02670980|DEVICE|Intelligent Retinal Implant System|
58094899|NCT04542902|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
58094900|NCT04542902|PROCEDURE|Blood sampling|An amount of a person's blood taken from their body for use in medical.
58094901|NCT04542902|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
58094902|NCT05736432|DIETARY_SUPPLEMENT|Blueberries|Experimental condition
58094903|NCT05736432|DIETARY_SUPPLEMENT|Placebo|Placebo condition
58094904|NCT03644459|BIOLOGICAL|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
58094905|NCT03910010|DRUG|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
58094906|NCT05975216|OTHER|Contact the patient|Phone call, email or letter to contact the patient to relink them.
58094907|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
58094908|NCT06565559|DEVICE|Wearable Wireless Sensor|Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
58094909|NCT05630703|BEHAVIORAL|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
58094910|NCT05630703|OTHER|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
58094911|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
58094912|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
58094913|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
58094914|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
58094915|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
58094916|NCT05001763|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
58094917|NCT05001763|DRUG|Placebo|Glucose, 2mg, tablet.
58094918|NCT02996461|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
58094919|NCT06117566|DRUG|WX390|WX390 tablet, once a day
58094920|NCT06117566|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
58094921|NCT06473558|DEVICE|Biometrics (or AI Biomaker)|Patients will be asked to read a story and their facial expressions and audio cues will be recorded.
58306614|NCT06120725|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
58306615|NCT04584632|DEVICE|Efemoral Vascular Scaffold System (EVSS)|Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
58306616|NCT00069264|DRUG|E7389|E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
58306617|NCT02091232|BIOLOGICAL|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
57735391|NCT03624504|DEVICE|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
58306618|NCT05453136|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
57735392|NCT03404128|OTHER|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
58306619|NCT05453136|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
58094922|NCT06362616|RADIATION|Preoperative accelerated partial breast irradiation|Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
58094923|NCT06362616|PROCEDURE|Breast conserving surgery|Patients will be treated with breast conserving surgery.
58094924|NCT06362616|PROCEDURE|Sentinel node procedure|Patients will undergo a (repeat) sentinel node procedure.
58094925|NCT06362616|PROCEDURE|Biopsy track removal|The biopsy track will be surgically removed.
58094926|NCT06228053|DRUG|SX-682|Specified dose twice daily
58094927|NCT06228053|DRUG|Enzalutamide|Specified dose once daily
58094928|NCT00016406|BIOLOGICAL|filgrastim|
58094929|NCT00016406|DRUG|cyclophosphamide|
58094930|NCT00016406|DRUG|doxorubicin|
58094931|NCT00016406|DRUG|paclitaxel|
58094932|NCT00016406|PROCEDURE|surgery|
58094933|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
58094934|NCT06355583|DRUG|EBX-102|EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
58094935|NCT06355583|DRUG|Placebo|The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
58422470|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
58094936|NCT05789420|OTHER|P1R stick|Regular flavor tobacco stick
58094937|NCT05789420|OTHER|P1M stick|Mentholated flavor tobacco stick
58094938|NCT05789420|OTHER|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
58094939|NCT04446117|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
58094940|NCT04446117|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
58094941|NCT04446117|DRUG|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
58094942|NCT04446117|DRUG|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
58094943|NCT04446117|DRUG|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
57735393|NCT03786679|DEVICE|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
58094944|NCT05588128|DRUG|18F-DCFpyL|Administered to Cohort.
58094945|NCT05945147|DRUG|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
58094946|NCT05945147|DRUG|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
58094947|NCT05945147|DRUG|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
58094948|NCT04282733|BEHAVIORAL|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
58094949|NCT04440163|BIOLOGICAL|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
58422471|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
57735394|NCT05613660|DIETARY_SUPPLEMENT|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
57735395|NCT05613660|DIETARY_SUPPLEMENT|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
57735396|NCT05613660|DIETARY_SUPPLEMENT|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
57735397|NCT05613660|DIETARY_SUPPLEMENT|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
57735398|NCT03887468|DEVICE|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
58094950|NCT04440163|BIOLOGICAL|Saline|Placebo
58094951|NCT04440163|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
58094952|NCT04440163|BIOLOGICAL|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
58094953|NCT05165277|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
58094954|NCT00146003|DRUG|Efalizumab treatment|
58094955|NCT05220904|DEVICE|spectacles|Spectacle is the the most common treatment for refractive errors.
58094956|NCT05220904|DEVICE|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
58094957|NCT05088980|DEVICE|VOLBELLA with Lidocaine|Facial Injection
58094958|NCT05420818|PROCEDURE|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
58306620|NCT05453136|DRUG|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
58422472|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
58094959|NCT04215952|BEHAVIORAL|Semantic Feature Analysis Treatment|On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
58094960|NCT06702358|OTHER|Potential Therapeutic Implications of laser Acupoints on Visceral Fat and Hormonal Changes in Post-menopausal Women|Application of laser acupuncture ( E M E ) on 10 acupuncture procedure for each woman which will be detected by therapist according to Acupuncture points Will stimulate St 25 (Tianshu), St 36 (Zusanli), Liv 3 (Taichong); P 6 (Neiguan), H 7 (Shenmen) for the psychical aspect of the therapy and Auriculothera- py: 55 (Shenmen) and 87 (Stomach) Each point stimulating will be Stimulation time, 30 s/point
58094961|NCT04289584|OTHER|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
58094962|NCT01933932|DRUG|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
58094963|NCT01933932|DRUG|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
58094964|NCT01933932|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
58094965|NCT01933932|DRUG|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
58094966|NCT06132100|DEVICE|digitalized incentive spirometry|digitalized incentive spirometry
58306621|NCT00962286|DRUG|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
57735399|NCT03887468|DEVICE|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
57735400|NCT00317772|DRUG|Topotecan|"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
57735401|NCT00317772|DRUG|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
57735402|NCT01535716|BEHAVIORAL|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia"
58094967|NCT06132100|DEVICE|traditional incentive spirometry|traditional incentive spirometry
58094968|NCT04583384|DIAGNOSTIC_TEST|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
58306622|NCT04606758|PROCEDURE|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
58306623|NCT04606758|PROCEDURE|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
58306624|NCT02453464|DRUG|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
58306625|NCT02453464|DRUG|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
57735403|NCT01535716|BEHAVIORAL|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia"
57735404|NCT02198027|DRUG|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
57735405|NCT02198027|OTHER|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
58094969|NCT05370781|BEHAVIORAL|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
58306626|NCT02453464|DRUG|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
58094970|NCT05370781|BEHAVIORAL|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
58094971|NCT06700629|PROCEDURE|Distal Penile Hypospadias (Disorder)|"Three operations which are Tubularized incised plate urethroplasty (TIP), Mathieu and meatal advancement and glanuplasty (MAGPI).~A three experienced operators with number of operations done by each one more than one hundred operation in the last year.~The operators will be fixed for each surgical technique as follows:~1. Doctor (A) for Matheiu. ( 35 operations)~2. Doctor (M) for MAGPI. ( 35 operations)~3. Doctor (S) for TIP ( 35 operations). Tubularized incised plate urethroplasty:(3,6) Indication: for distal penile hypospadias with or without penile curvature with any width of the uretheral plate and also for any type of distal hypospadias associated with curvature.~Key steps for this operation are as follows:~Glans retraction using stay suture 4-0 or 5-0 silk. Uretheral catheter pass through hypospadic meatus to bladder. Parallel longitudenal incision is done 1-2mm proximal to hypospadic meatus. A circumferential incision is made 2-3 mm below coronal sulcus dorsally"
58094972|NCT02837263|RADIATION|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
58094973|NCT02837263|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
58094974|NCT03760926|DEVICE|May Health Kit|The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
58094975|NCT00792818|DRUG|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
58094976|NCT00792818|DRUG|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
58094977|NCT01066039|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
58094978|NCT03148327|DRUG|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
58094979|NCT03148327|RADIATION|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
58094980|NCT03541668|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
58094981|NCT03541668|DRUG|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
58094982|NCT00358670|BIOLOGICAL|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
58094983|NCT00358670|BIOLOGICAL|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
58094984|NCT03443973|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
58094985|NCT03443973|DRUG|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
58094986|NCT00317967|DRUG|Atorvastatin|80 mg pills daily
58094987|NCT00317967|DRUG|Placebo|80 mg pills daily
58094988|NCT03852407|DRUG|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
58094989|NCT03852407|DRUG|Melphalan|100mg/m² on day -2
58094990|NCT03852407|DRUG|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
58094991|NCT03852407|DRUG|Cyclophosphamid|50 mg/kg on days +3 and +4.
58094992|NCT06430307|DRUG|Saussurea Involucrata Liquid Tonic|This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
58306627|NCT02453464|DRUG|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
58306628|NCT00464022|DEVICE|Carbon dioxide|
58094993|NCT06568120|DEVICE|dragon themed nebulizer masks|This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
58422473|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
58094994|NCT04717869|DIAGNOSTIC_TEST|Ultrasound|2D ultrasound image collection
58094995|NCT04717869|DIAGNOSTIC_TEST|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
58094996|NCT04717869|OTHER|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
58094997|NCT04141761|DIETARY_SUPPLEMENT|Visbiome|This group will receive Visbiome probiotic in powder form.
58094998|NCT04141761|OTHER|Placebo|This group will receive a placebo in powder form.
58094999|NCT03811366|DRUG|Corticosteroid monotherapy|Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
58095000|NCT02587000|DRUG|Ulipristal acetate|
58095001|NCT02587000|DRUG|Placebo|
58095002|NCT02757261|DEVICE|Laser|Low-level laser therapy administrated to acupoints
58095003|NCT02757261|DEVICE|Occlusal splint|Occlusal splint with expander
58095004|NCT02757261|DEVICE|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
58422474|NCT02145871|OTHER|standard fluid management|
58422475|NCT02145871|OTHER|fluid management guided by the EV1000|
58422476|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
58422477|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
58422478|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
58422479|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
58095005|NCT00002879|DRUG|cladribine|
58095006|NCT04057352|DEVICE|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
58095007|NCT01585064|OTHER|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
58095008|NCT01585064|OTHER|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
58095009|NCT01585064|OTHER|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
58095010|NCT03821688|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass
58095011|NCT03821688|PROCEDURE|OAGB|one anastomosis gastric bypass
58095012|NCT03821688|PROCEDURE|LSG|laproscopic sleeve gastrectomy
58095013|NCT01097850|DRUG|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
58095014|NCT05660837|BEHAVIORAL|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session"
58095015|NCT05660837|BEHAVIORAL|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp"
58095016|NCT05724576|BIOLOGICAL|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
58422480|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
58422481|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
58422482|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
58422483|NCT05632783|OTHER|Placebo|Placebo tablets
58422484|NCT05618418|OTHER|No intervention|No intervention
58422485|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
58422486|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
58095017|NCT06551948|DIETARY_SUPPLEMENT|psyllium|15 g psyllium
58095018|NCT06551948|DIETARY_SUPPLEMENT|methylcellulose|15 gm methylcellulose
58095019|NCT06551948|DIETARY_SUPPLEMENT|maltodextrin|15 g maltodextrin
58095020|NCT06551948|DIETARY_SUPPLEMENT|inulin|15g inulin
58095021|NCT05873959|BIOLOGICAL|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
58095022|NCT04442763|DEVICE|Densah Burs|osseodensification method
58095023|NCT04442763|DEVICE|Standard drills|conventional drilling
58095024|NCT04700215|DEVICE|BiPAP|To give bilevel positive airway pressure to the lungs
58095025|NCT04700215|DEVICE|Incentive spirometry|IS for 15 minutes after every 4 hours
58095026|NCT06702033|RADIATION|Radiation therapy|IMRT or IMPT
58095027|NCT06702033|DRUG|Cisplatin|Dose of 100 mg/m\^2 IVPB over 60 minutes
58422487|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
58095028|NCT06702033|PROCEDURE|Surgery|Standard of care
58095029|NCT03461029|DEVICE|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
58095030|NCT01754480|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
58422488|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
58422489|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
58422490|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
58422491|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
58422492|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
58422493|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
58422494|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
58422495|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
58422496|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
58095031|NCT01754480|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
58095032|NCT06565572|DRUG|nL-FLVC-001|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
58095033|NCT00739622|DRUG|TMC278|
58095034|NCT03003728|DRUG|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
58306629|NCT02903446|DRUG|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
58306630|NCT03995563|DRUG|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
58306631|NCT03995563|DRUG|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
58422497|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
58422498|NCT00046553|DRUG|RU-486 (Mifepristone)|
58422499|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
58422500|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
58095035|NCT03003728|DRUG|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
58095036|NCT03003728|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
58095037|NCT03003728|BIOLOGICAL|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
58095038|NCT03003728|DRUG|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
58095039|NCT03640442|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
58095040|NCT03640442|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
58095041|NCT04085263|PROCEDURE|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
58095042|NCT04085263|PROCEDURE|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
58095043|NCT03850262|RADIATION|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
58422501|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
58422502|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
58422503|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
58422504|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
58422505|NCT03000036|DRUG|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
58422506|NCT03000036|DEVICE|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
58422507|NCT03000036|DRUG|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
58422508|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
58422509|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
58422510|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
58422511|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
58422512|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
58422513|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
58306632|NCT05402059|DRUG|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
58422514|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
58422515|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
58422516|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
58422517|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
58422518|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
58422519|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
58422520|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
58422521|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
58422522|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
58422523|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
58422524|NCT00003709|DRUG|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
58422525|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
58422526|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
58095044|NCT06323343|OTHER|Video Intervention|Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.
58095045|NCT06323343|OTHER|Webpage links|Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
58095046|NCT03638102|BEHAVIORAL|Sleep extension|Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching
58422527|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
58422528|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
58422529|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
58422530|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
58422531|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
58422532|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
58422533|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
58422534|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
58422535|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
58422536|NCT05823272|OTHER|ONS|oral nutritional supplement
58422537|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
58422538|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
58422539|NCT02182765|DRUG|Nevirapine|
58422540|NCT02182765|DRUG|Amprenavir|
58422541|NCT02182765|DRUG|Abacavir|
58422542|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
58422543|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
58422544|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
58422545|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
58422546|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
58422547|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
58095047|NCT03638102|BEHAVIORAL|Healthy living|Participants will receive weekly health education
58095048|NCT03328468|OTHER|Breathing Exercise|Breathing exercise for stroke patients
58422548|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
58422549|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
58422550|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
58422551|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
58422552|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
58422553|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
58422554|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
58422555|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
58422556|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
58422557|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
58422558|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
58422559|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
58422560|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
58422561|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
58422562|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
58422563|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
58422564|NCT03095820|BEHAVIORAL|Supportive therapy|
58422565|NCT03095820|BEHAVIORAL|Multidomain intervention|
58422566|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
58422567|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
58422568|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
58422569|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
58422570|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
58422571|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
58422572|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
58422573|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
58422574|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
58422575|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
58422576|NCT02565810|DRUG|Adalimumab PFS and Pen|
58422577|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
58422578|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
58422579|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
58422580|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
58422581|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
58422582|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
58422583|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
58422584|NCT04722757|PROCEDURE|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
58306633|NCT05902065|DEVICE|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
58422585|NCT04722757|PROCEDURE|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
58422586|NCT03495791|OTHER|YouTube Video|Educational Video
58422587|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
58422588|NCT05314933|OTHER|Placebo|Intranasal administration
58422589|NCT00028886|BIOLOGICAL|filgrastim|
58422590|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
58422591|NCT00028886|DRUG|cyclophosphamide|
58422592|NCT00028886|DRUG|dexamethasone|
58422593|NCT00028886|DRUG|doxorubicin hydrochloride|
58422594|NCT00028886|DRUG|melphalan|
58422595|NCT00028886|DRUG|thalidomide|
58422596|NCT00028886|DRUG|vincristine sulfate|
58422597|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
58422598|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
58422599|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
58422600|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
58422601|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
58422602|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
58422603|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
58422604|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
58095049|NCT06247254|BEHAVIORAL|Intensive Clinic Management|The ICM arm includes BP management at in-person follow-up visits occurring every 2 months when BPs are at target and if not in target, monthly visits. Medications will be adjusted to lower BP to the target using evidence-based guidelines and in the context of whether the participant can effectively manage their medications and BP. ICM participants will receive a COMPASS Care plan, which will evaluate social and functional factors for managing stroke recovery.
58095050|NCT06247254|BEHAVIORAL|Intensive Tailored Telehealth Management|The ITTM intervention involves a comprehensive, multi-dimensional approach to using real-time BP data to manage BP after stroke. ITTM includes an in-person visit during which participants will complete a series of questionnaires within the COMPASS-CP® web application and will receive a COMPASS-BP Action Plan home safety checklist, BP Matters documents, and referrals to local resources, as needed.
58422605|NCT02107872|DRUG|REGN1500|
58095051|NCT04976335|DEVICE|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
58422606|NCT02107872|DRUG|placebo|
58422607|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
58422608|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
58422609|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
58422610|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
58422611|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
58422612|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
58422613|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
58422614|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
58422615|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
58095052|NCT06498557|OTHER|Peripheral nerve block methods|We apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.
58095053|NCT04804293|DEVICE|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
58095054|NCT06138626|BEHAVIORAL|Alert|An alert that appears when anesthetic fresh gas flow is excessive
58422616|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
58422617|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
58422618|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
58422619|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
58422620|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
58422621|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
58422622|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
58422623|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
58422624|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
58422625|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
58306634|NCT05902065|DEVICE|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
58422626|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
58422627|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
58422628|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
58422629|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
58422630|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
58422631|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
58422632|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
58422633|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
58422634|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
58422635|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
58422636|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
58422637|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
58422638|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
58422639|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
58422640|NCT02383771|DRUG|Control|No Anti-platelet Therapy
58422641|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
58422642|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
57735406|NCT05966441|DIETARY_SUPPLEMENT|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
58422643|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
58422644|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
58422645|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
57950994|NCT03383445|PROCEDURE|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
58422646|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
58422647|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
58422648|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
58422649|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
58422650|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
58422651|NCT00261508|DRUG|risperidone|
58422652|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
58306635|NCT03567681|DRUG|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
58306636|NCT01529606|OTHER|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
58422653|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
58422654|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
58422655|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
58422656|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
58422657|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
58422658|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
58422659|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
58422660|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
58422661|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
58422662|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
58422663|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
58422664|NCT01055483|DRUG|panobinostat/LBH589B|
58422665|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
57950995|NCT03263962|DRUG|Canrenone|Evaluation of canrenone therapy in patients with CHF
57950996|NCT04506008|RADIATION|Ultra-Hypo-fractionation Radiotherapy|Five fractions of pre-operative radiation
58306637|NCT01529606|PROCEDURE|Plasma treatment|plasma treatment after preparation and for caries prevention
58306638|NCT00004233|DRUG|fluorouracil|
58306639|NCT00004233|DRUG|leucovorin calcium|
58422666|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
58422667|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
58422668|NCT02560298|DRUG|Capecitabine|
58422669|NCT02560298|DRUG|Carboplatin|Given IV
58422670|NCT02560298|DRUG|Cisplatin|Given IV
58422671|NCT02560298|DRUG|Fluorouracil|Given IV
58422672|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
58422673|NCT02560298|DRUG|Paclitaxel|Given IV
58422674|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
58422675|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
58422676|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
58422677|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
58422678|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
58422679|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
57950997|NCT04506008|PROCEDURE|Resection|Surgery
58306640|NCT00004233|DRUG|triacetyluridine|
58306641|NCT03089476|OTHER|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
58306642|NCT03089476|OTHER|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
58306643|NCT01724827|DEVICE|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
58306644|NCT01724827|DEVICE|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
57735407|NCT05966441|DRUG|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
57735408|NCT01426191|DRUG|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
57735409|NCT01672801|DRUG|Placebo|oral administration
58306645|NCT03435055|DRUG|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
58306646|NCT05027854|OTHER|TMS or tES|Transcranial magnetic or electric stimulation
58306647|NCT05027854|OTHER|sham TMS or tES|Sham transcranial magnetic or electric stimulation
58306648|NCT02745470|DRUG|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
58306649|NCT02745470|OTHER|Placebo|Normal saline injection before performing fMRI
58306650|NCT05251597|OTHER|green exercise with aerobic exercise|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
58306651|NCT04905043|DRUG|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
58306652|NCT04905043|DRUG|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
57735410|NCT01672801|DRUG|Nimodipine|oral administration
57735411|NCT05133596|OTHER|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
57735412|NCT05133596|OTHER|Blood collection|12ml-blood sample
57735413|NCT05133596|OTHER|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
57735414|NCT05133596|OTHER|Brushing of olfactory slits|collection of olfactory slits cells.
58306653|NCT02847325|DRUG|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
58306654|NCT02847325|DRUG|Placebo capsules|Placebo capsules
58306655|NCT06114212|DEVICE|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
58306656|NCT03630848|OTHER|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
57950998|NCT04506008|OTHER|Questionnaire Administration|Ancillary studies
58422830|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
57735442|NCT04247620|BEHAVIORAL|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
58422831|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
58422832|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
58422833|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
58422834|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
58422835|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
57735443|NCT04247620|BEHAVIORAL|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
58422836|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
58422837|NCT00349830|PROCEDURE|blood draw|
58422838|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
58422839|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
58422840|NCT04958746|DRUG|Ciprofol|intravenous bolus
58422841|NCT04958746|DRUG|Propofol|intravenous bolus
58422842|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
58422843|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
58422844|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
58422845|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
58422846|NCT02190890|PROCEDURE|Dry needling|
58422847|NCT02190890|PROCEDURE|Control|
58422848|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
58422849|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
58422850|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
58422851|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
58422852|NCT00740623|DRUG|placebo|placebo for 14 weeks
58422853|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
58422854|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
58422855|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
58422856|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
57735444|NCT05247151|OTHER|Oxytocin|Oxytocin nasal spray in a positive social setting.
57735445|NCT05247151|OTHER|Placebo|Placebo nasal spray in a positive social setting.
58422857|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
58422858|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
58422859|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
58422860|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
58422861|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
58422862|NCT00861718|DRUG|Placebo|Capsule, Oral BID
58422863|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
58422864|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
58422865|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
58422866|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
58422867|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
58422868|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
58422869|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
58422870|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
58422871|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
58422872|NCT03400813|BEHAVIORAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
58422873|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
58422874|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
58422875|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
58422876|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
58422877|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
58422878|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
58422879|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
58422880|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
58422881|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
58422882|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
58422883|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
58422884|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
57735446|NCT04916470|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
57735447|NCT04916470|DRUG|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
58422885|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
58422886|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
58422887|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
58422888|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
57735448|NCT05499923|DEVICE|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
58095515|NCT05421715|OTHER|TELEDUC-DIAB|"* Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
58422889|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
58422890|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
58422891|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
58422892|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
58422893|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
58422894|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
58422895|NCT02266875|DRUG|hypertonic saline|
58422896|NCT02266875|DRUG|standard saline|
58422897|NCT05571774|OTHER|collection data|collection data
58422898|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
58422899|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
58422900|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
58422901|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
58422902|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
58422903|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
58422904|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
58422905|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
58422906|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
58422907|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
58422908|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
58422909|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
58422910|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
58422911|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
57735449|NCT03070613|DRUG|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
57735450|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
58422912|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
58422913|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
57735451|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
58422914|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
58095516|NCT04886232|DEVICE|VP1 Lido US|Hyaluronic acid dermal filler containing lidocaine
58306888|NCT05444816|DEVICE|Personalised Neurofeedback training at home|"The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed."
57735452|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
58095517|NCT04886232|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid dermal filler containing lidocaine
58095518|NCT06702995|DRUG|XNW5004|Oral continuous
58095519|NCT06702995|DRUG|enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
58422915|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
58422916|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
58422917|NCT01017445|OTHER|Boonme stick exercise|individual exercise daily
58422918|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
58422919|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
58422920|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
57735453|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
57951318|NCT05029206|PROCEDURE|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~1. In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~2. A minimum of 2 × 10\^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~3. Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~4. After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
57951319|NCT03358719|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
57951320|NCT03358719|DRUG|Decitabine|Given IV
57951321|NCT03358719|OTHER|Laboratory Biomarker Analysis|Correlative studies
57951322|NCT03358719|BIOLOGICAL|Nivolumab|Given IV
57735454|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
57735455|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
57735456|NCT06495736|DIAGNOSTIC_TEST|Experimental: ROSE technique stain|The ROSE technical group uses Diff-Quick stain for diagnosis
57951323|NCT03358719|DRUG|Poly ICLC|Given SC
57951324|NCT03227263|DRUG|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
57951325|NCT03227263|DRUG|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
57735457|NCT02509533|DEVICE|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
58422921|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
58422922|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
58422923|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
58422924|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
58422925|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
58422926|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
58422927|NCT00343707|DRUG|vestipitant|
58422928|NCT00343707|DRUG|paroxetine|
58095520|NCT03112096|DRUG|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
58422929|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
58422930|NCT02925728|OTHER|Without Finger-Food|Without finger-food
58095521|NCT05526924|RADIATION|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
58422931|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
58422932|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
58422933|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
57735458|NCT02509533|DEVICE|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
58095522|NCT05526924|DRUG|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
58306889|NCT03622567|BEHAVIORAL|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
58306890|NCT04412421|PROCEDURE|Gastric Bypass, Sleeve Gastrectomy|Lifelong vitamin and Mineral supplementation
58422934|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
58422935|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
57735459|NCT03975283|DRUG|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
58095523|NCT05526924|DRUG|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
58095524|NCT05526924|DRUG|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
58095525|NCT05526924|DRUG|Tislelizumab|An anti-cancer drug.
58095526|NCT01968837|OTHER|Cervical cancer screening|
58095527|NCT06568211|DEVICE|Virtual Reality|Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.
58095528|NCT06568211|DEVICE|Tablet-Only|PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).
58306891|NCT04951141|BIOLOGICAL|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
58306892|NCT00383799|DRUG|iv Amiodarone|
58306893|NCT00383799|DRUG|iv Procainamide|
58306894|NCT04174066|OTHER|blood sample|blood sample during planned in the follow-up of patients.
58306895|NCT04174066|OTHER|tissue sample|tissue sample during planned in the follow-up of patients.
58306896|NCT04174066|OTHER|excreta|urine sample during planned in the follow-up of patients.
58306897|NCT01313754|PROCEDURE|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
58422936|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
58422937|NCT05037084|OTHER|no intervention|no intervention
58422938|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
58422939|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
58422940|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
58422941|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
58422942|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
58422943|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
58422944|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
58422945|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
58422946|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
58422947|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
58422948|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
58422949|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
58422950|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
58422951|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
58422952|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
58306898|NCT01313754|PROCEDURE|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
58306899|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
58306900|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
58306901|NCT05854641|BIOLOGICAL|Stempeucel®|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
58306902|NCT04768140|PROCEDURE|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
58422953|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
58422954|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
58422955|NCT06481085|DRUG|Placebo|Matching placebo will be provided
58422956|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
58422957|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
58422958|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
58422959|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
58422960|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
58422961|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
58422962|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
58422963|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
58422964|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
58422965|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
58422966|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
58422967|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
58422968|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
58422969|NCT02851823|DEVICE|Periodontal curettes|
58422970|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
58422971|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
58422972|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
57735460|NCT03975283|DRUG|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
58422973|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
58422974|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
57735461|NCT01592643|DEVICE|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
57769526|NCT02069769|BEHAVIORAL|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
58422975|NCT04621487|DRUG|according to antibiogram|according to antibiogram
58422976|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
58422977|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
58422978|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
57951326|NCT04105374|DRUG|Extended Release Flucytosine|Given PO
58422979|NCT01095120|DRUG|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
58422980|NCT03848767|DEVICE|AID System|AID System
58095529|NCT00143546|DRUG|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
58095530|NCT06613412|DIAGNOSTIC_TEST|Remote Robotic Bronchoscopy system|Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
57735462|NCT00395876|DRUG|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
58095531|NCT00418509|DRUG|Mometasone furoate|
58095532|NCT00418509|DRUG|Formoterol fumarate|
58095533|NCT02418559|DRUG|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
58095534|NCT02418559|DRUG|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
58095535|NCT02418559|DRUG|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
58095536|NCT02418559|DRUG|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
58095537|NCT05619484|DEVICE|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
58095538|NCT05912153|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT of the foot and ankle
58095539|NCT05912153|DIAGNOSTIC_TEST|MRI|MRI of the foot and ankle
58095540|NCT05165368|OTHER|Intraneural Facilitation® Therapy (INF® Therapy)|INF® Therapy plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.
58095541|NCT05165368|OTHER|INF® Therapy|"INF® Therapy only (INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)"
58095542|NCT02720094|DRUG|Cabotegravir Oral Tablet|30 mg tablet
58422981|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
58095543|NCT02720094|DRUG|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
57735463|NCT00395876|DRUG|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
58095544|NCT02720094|DRUG|Placebo for TDF/FTC tablets|
58095545|NCT02720094|DRUG|Placebo for cabotegravir oral tablet|
58306903|NCT04768140|PROCEDURE|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
58422982|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
58422983|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
58422984|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
57735464|NCT04423068|BEHAVIORAL|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
58095546|NCT02720094|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
58095547|NCT02720094|DRUG|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
58095548|NCT06703788|DRUG|A fiixed combination of Chinese herbal medicine|a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
58095549|NCT06703788|DEVICE|Laser acupuncture|Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
58095550|NCT05174559|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
58095551|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
58422985|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
58422986|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
58306904|NCT05891548|DRUG|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
58422987|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
58422988|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
57769527|NCT04567693|OTHER|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
58422989|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
58422990|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
58422991|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
58422992|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
57769782|NCT04380337|DRUG|FOLFOX regimen|Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
58306905|NCT05891548|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
58306906|NCT02940301|DRUG|Ibrutinib|Given PO
58306907|NCT02940301|OTHER|Laboratory Biomarker Analysis|Correlative studies
58306908|NCT02940301|BIOLOGICAL|Nivolumab|Given IV
58422993|NCT04250597|DRUG|GNX102|Dose Escalation
58422994|NCT04250597|DRUG|GNX102|Expansion Phase
58422995|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
58422996|NCT05340803|DRUG|midazolam|midazolam
58422997|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
58422998|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
58422999|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
58423000|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
58095552|NCT02532023|DIETARY_SUPPLEMENT|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
58095553|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
58095554|NCT02532023|DIETARY_SUPPLEMENT|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
58423001|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
58423002|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
58095555|NCT05587686|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
58095556|NCT05016310|DIETARY_SUPPLEMENT|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
58095557|NCT05016310|DIETARY_SUPPLEMENT|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
58095558|NCT05500456|DEVICE|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
58095559|NCT05500456|DEVICE|Fixed appliances|Conventional wires and brackets will be used.
58095560|NCT04018937|DRUG|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
58095561|NCT04018937|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
58095562|NCT04018937|DRUG|Melphalan|Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
58095563|NCT06096116|DRUG|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
58095564|NCT06096116|DRUG|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
58095565|NCT03072329|PROCEDURE|Pudendal nerve block|
58095566|NCT03072329|DRUG|Bupivacaine|
58095567|NCT03722849|DRUG|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
58423003|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
58423004|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
57769528|NCT00005881|OTHER|Quality of Life Forms|Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
57769529|NCT02308332|DRUG|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
58095568|NCT03722849|DRUG|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
58095569|NCT03722849|OTHER|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
58095570|NCT06102707|DRUG|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
58095571|NCT01413152|BIOLOGICAL|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
58095572|NCT03354962|COMBINATION_PRODUCT|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
58095573|NCT03354962|COMBINATION_PRODUCT|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
58095574|NCT01691261|BIOLOGICAL|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
58095575|NCT06043219|OTHER|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
58129432|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
58423005|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
58095576|NCT06043219|OTHER|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
58095577|NCT06043219|OTHER|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
58095578|NCT05224297|RADIATION|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
58095579|NCT03614065|DRUG|endostar|endostatin
58095580|NCT03614065|DRUG|Placebos|saline solution
58095581|NCT03614065|RADIATION|radiotherapy|radiotherapy
58095582|NCT04934332|PROCEDURE|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
58095583|NCT04934332|PROCEDURE|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
57735465|NCT04423068|DRUG|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
58095584|NCT04934332|PROCEDURE|Clinical examination|Weekly clinical examination from week-2 to week-5.
58095585|NCT00122031|DEVICE|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
58095586|NCT06684613|DEVICE|PrEP Decision Aid|Patient-facing decision-aid on PrEP that is already gender- and trauma- responsive and will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of contraceptive counseling.
58095587|NCT06684613|OTHER|Generic Information|"Participants will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid."
58095588|NCT04444362|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
58095589|NCT05837130|OTHER|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
58095590|NCT05837130|OTHER|Blood sample collection|No study drug will be administered to study participants.
58095591|NCT02487368|DEVICE|Needle stimulation pad|
57735466|NCT00010491|PROCEDURE|Acupuncture|
58095592|NCT06639854|OTHER|Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study."
58095593|NCT03901027|BEHAVIORAL|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
57735467|NCT00010491|PROCEDURE|Moxibustion|
57735468|NCT06219239|GENETIC|KL003 cell injection Drug Product|No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
57735469|NCT02395120|BEHAVIORAL|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
58095594|NCT03081195|BEHAVIORAL|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
58095595|NCT05404568|PROCEDURE|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
58095596|NCT06703216|DRUG|Anakinra (Kineret®)|Pre-emptive Anakinra at the initial onset of CRS.
58095597|NCT05414019|OTHER|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
58095598|NCT05414019|OTHER|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
58129433|NCT00483496|DRUG|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
57735470|NCT02395120|BEHAVIORAL|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
57735471|NCT02395120|BEHAVIORAL|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
57769530|NCT06017388|BEHAVIORAL|Hypnosis|We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).
57769783|NCT04380337|DRUG|XELOX|Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
58423006|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
58423007|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
58423008|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
58423009|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
57735472|NCT02395120|BEHAVIORAL|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
58095599|NCT05414019|OTHER|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
58423010|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
57951327|NCT04105374|DEVICE|NovoTTF-100A Device|Receive Optune device
58129434|NCT00483496|DRUG|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
58423011|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
58423012|NCT02635997|DRUG|antiresorptive therapy|
58423013|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
58095600|NCT06702540|DEVICE|Biosensor chip|An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
58095601|NCT05262023|DRUG|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
58095602|NCT05262023|DRUG|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
58095603|NCT02344914|DEVICE|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
58095604|NCT06146504|DIETARY_SUPPLEMENT|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
58095605|NCT06146504|OTHER|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
58095606|NCT04418115|OTHER|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
58095607|NCT06703476|PROCEDURE|Stent placement|Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.
58095608|NCT06703476|DRUG|Alvimopan|Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
58129435|NCT00483496|DRUG|bisoctrizole 10% alone (formula RV3131A-MV1237)|
58306909|NCT02809365|DEVICE|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
58306910|NCT02809365|DEVICE|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
58306911|NCT00226252|PROCEDURE|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
57735473|NCT02395120|BEHAVIORAL|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
57735474|NCT03910153|DIETARY_SUPPLEMENT|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
57951328|NCT04105374|OTHER|Quality-of-Life Assessment|Ancillary studies
57951329|NCT04105374|OTHER|Questionnaire Administration|Ancillary studies
57951330|NCT04105374|RADIATION|Radiation Therapy|Undergo radiation
57951331|NCT04105374|DRUG|Temozolomide|Given PO
57951332|NCT04105374|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
57951333|NCT04105374|BIOLOGICAL|Vocimagene Amiretrorepvec|Given via intracranial injection
57951334|NCT03276000|PROCEDURE|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
57951335|NCT04990089|DEVICE|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
57951336|NCT06475859|OTHER|Montreal Imaging Stress Test|A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.
57951337|NCT06475859|OTHER|Relaxation breathing|3 short sessions (4 minutes) of relaxation breathing
57951338|NCT01316861|DRUG|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
57951339|NCT01316861|DRUG|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
57951340|NCT01179009|DRUG|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
57951341|NCT01179009|DRUG|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
57951342|NCT01179009|DRUG|placebo|IV saline (i.e. placebo ketamine)
57951343|NCT03222791|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
57951344|NCT03222791|OTHER|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
57951345|NCT01020864|DRUG|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
57951346|NCT01020864|DRUG|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
57951347|NCT01020864|DRUG|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
57951348|NCT05080023|DEVICE|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
57951349|NCT06493968|DRUG|oxytocin|Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
57951350|NCT06493968|OTHER|placebo|IV bolus of normal saline immediately with the uterine incision
57951351|NCT03177421|OTHER|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
57951352|NCT03177421|OTHER|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
58095609|NCT06419803|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
58095610|NCT03327142|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
58423014|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
58423015|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
58423016|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
58423017|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
58423018|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
58423019|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
58423020|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
58423021|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
58423022|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
58423023|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
57735475|NCT03910153|OTHER|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
57735476|NCT04288570|PROCEDURE|suture anchor socket creation with punch|suture anchor socket creation with punch
57735477|NCT04288570|PROCEDURE|suture anchor socket creation with drill|suture anchor socket creation with drill
57951353|NCT00578305|BIOLOGICAL|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
58095611|NCT03408236|DRUG|Botulinum toxin type A|Experimental
58095612|NCT03408236|DRUG|Botulinum toxin type A|Active Comparator
57951354|NCT00578305|DRUG|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
57951355|NCT00578305|DRUG|Methylprednisolone|
58095613|NCT06401603|DRUG|Decitabine|Given by IV
58423024|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
58423025|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
58423026|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
58423027|NCT02177838|BIOLOGICAL|cetuximab|Given IV
58423028|NCT02177838|DRUG|cisplatin|Given IV
58423029|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
58423030|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
58423031|NCT02796885|OTHER|no intervention - observational study|
57951356|NCT00578305|DRUG|Methotrexate|
58095614|NCT06401603|DRUG|Listaftoclax|Given by PO
58095615|NCT06401603|DRUG|Olverembatinib|Given by PO
58095616|NCT02406365|DEVICE|Diagnostic imaging aid for one-visit management of cervical lesions|
58129436|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
58129437|NCT00483496|DRUG|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
58129438|NCT00483496|DRUG|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
58129439|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
58129440|NCT00483496|DRUG|V0096 CR vehicle (formula RV3131A-MV1197)|
58423032|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
58423033|NCT00007267|BEHAVIORAL|Disease/health education|
58423034|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
58423035|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
58423036|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
58423037|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
58423038|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
58423039|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
58423040|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
58423041|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
58423042|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
58423043|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
58423044|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
58423045|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
58423046|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
58423047|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
57735478|NCT03174223|DRUG|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
57735479|NCT05854472|OTHER|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
57735480|NCT04723875|DRUG|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
57735481|NCT05660746|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
58423048|NCT01916850|DRUG|LX4211 400 mg|
58423049|NCT01916850|DRUG|LX4211 800 mg|
58423050|NCT01916850|DRUG|LX4211 Placebo|
58423051|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
58423052|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
58423053|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
58423054|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
58423055|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
58423056|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
58423057|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
58423058|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
58423059|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
58423060|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
58423061|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
58423062|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
58423063|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
58095617|NCT06424704|DIAGNOSTIC_TEST|Microbiological culture|Samples taken from chronic suppurative otitis media patients in the Medical Microbiology Laboratory of Selçuk University Faculty of Medicine will be planted in 5% sheep blood Columbia agar, eosin methylene blue agar and saboraud dextrose agar, and the media will be incubated at 37oC for 24-48 hours. Growing bacteria and fungi were examined using traditional methods \[Gram staining, catalase test, coagulase test, bacitracin disk, PYR test (L-pyrrolidonyl-β-naphthylamide), oxidase test, IMViC test, lactophenol cotton blue, etc.\] and VITEK 2 (bioMerieux, France).
58095618|NCT05092451|DRUG|Cyclophosphamide|Given by IV
58095619|NCT05092451|DRUG|CAR.70/IL15-transduced CB-NK cells|Given by IV
58095620|NCT05092451|DRUG|Fludarabine phosphate|Given by IV
58095621|NCT06203340|OTHER|Core stabilizasyon and lumbal back school|Lumbal back schooL
58095622|NCT03035981|OTHER|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095623|NCT03035981|OTHER|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095624|NCT03035981|OTHER|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095625|NCT03035981|OTHER|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095626|NCT03035981|OTHER|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095627|NCT03035981|OTHER|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095628|NCT03035981|OTHER|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
58095629|NCT05211037|DIAGNOSTIC_TEST|Kidney function assessment|kidney clearance measured by scintigraphy
58095630|NCT02499406|BEHAVIORAL|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
58423064|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
58423065|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
58458313|NCT04809831|OTHER|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
57735482|NCT05660746|DRUG|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
57735483|NCT06670820|DEVICE|Active rTMS|iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions
57735484|NCT06670820|DEVICE|Sham rTMS|sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
58095631|NCT04741945|DRUG|Metformin|2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
58095632|NCT06704113|DRUG|meloxicam 7,5mg|Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
58095633|NCT00424931|DRUG|JNJ-17216498|50mg one time
58095634|NCT00424931|DRUG|JNJ-17216498|10mg one time
58095635|NCT00424931|DRUG|Modafinil|200 mg X 2
58095636|NCT05218317|DIAGNOSTIC_TEST|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
58095637|NCT05077904|DRUG|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
58095638|NCT05077904|OTHER|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
57735485|NCT03034148|DIAGNOSTIC_TEST|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
57735486|NCT01579708|BEHAVIORAL|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
57735487|NCT04295564|OTHER|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
57735488|NCT02827877|RADIATION|Copper Cu 64-DOTA-Trastuzumab|Given IV
58095639|NCT03567330|BEHAVIORAL|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
58095640|NCT03567330|BEHAVIORAL|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
58095641|NCT05121779|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
58095642|NCT05121779|DRUG|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
58095643|NCT00046020|DRUG|Venlafaxine ER|
58095644|NCT06580184|BEHAVIORAL|LEARN 2 Platform|The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.
58129441|NCT00257153|DEVICE|Coronary thrombus aspiration catheter|
58458314|NCT04809831|OTHER|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
58458315|NCT05720650|OTHER|No intervention|No intervention
58095645|NCT04380701|BIOLOGICAL|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
58095646|NCT04380701|BIOLOGICAL|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
58095647|NCT04380701|BIOLOGICAL|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
58095648|NCT04380701|BIOLOGICAL|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
58095649|NCT05151822|OTHER|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
58306912|NCT00226252|PROCEDURE|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
58306913|NCT00794664|DRUG|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
58306914|NCT00794664|DRUG|Placebo|1 mL weekly subcutaneous injections for 26 weeks
58306915|NCT05075278|BEHAVIORAL|Survey|A survey will be completed by the participants at the conclusion of each day.
58423066|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
58423067|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
57735489|NCT02827877|OTHER|Laboratory Biomarker Analysis|Correlative studies
57735490|NCT02827877|BIOLOGICAL|Pertuzumab|Given IV
57735491|NCT02827877|PROCEDURE|Positron Emission Tomography|Undergo PET
58306916|NCT01284868|DRUG|mirabegron|oral
57735492|NCT02827877|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57951357|NCT00578305|DRUG|Folic acid or folate|
58306917|NCT01284868|DRUG|Bisoprolol|oral
58306918|NCT01284868|DRUG|propranolol|oral
58306919|NCT01284868|DRUG|placebo|oral
57735493|NCT02827877|BIOLOGICAL|Trastuzumab|Given IV
57735494|NCT05290558|DRUG|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
57735495|NCT05290558|DRUG|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
57735496|NCT03704376|DRUG|30 ml of 0.2% ropivacaine|
57735497|NCT03704376|DRUG|15 ml of 0.2% ropivacaine|
57735498|NCT03704376|DRUG|100 mcg clonidine|
57735499|NCT03704376|DEVICE|High-frequency linear ultrasound transducer|
57951358|NCT03051555|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
57735500|NCT05484674|PROCEDURE|Deroofing and laser|Deroofing and laser to axilla
57951359|NCT03586128|DRUG|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
57951360|NCT03586128|DRUG|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
57951361|NCT05656677|BEHAVIORAL|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
57951362|NCT05656677|RADIATION|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
57951363|NCT00066703|DRUG|exemestane|
57951364|NCT00066703|DRUG|tamoxifen|
57951365|NCT00066703|DRUG|triptorelin|
57951366|NCT05632887|OTHER|no intervention|no intervention
57951367|NCT01433237|GENETIC|RNA analysis|
57951368|NCT01433237|GENETIC|gene expression analysis|
57951369|NCT01433237|OTHER|laboratory biomarker analysis|
57951370|NCT04132362|BEHAVIORAL|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
58095650|NCT05151822|OTHER|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
58095651|NCT05151822|OTHER|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
58095652|NCT05151822|OTHER|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
58095653|NCT03740828|DEVICE|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
58095654|NCT06585943|BEHAVIORAL|Forced Rate Exercise + Rehab|The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
58095655|NCT06585943|BEHAVIORAL|Rehabilitation|The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
58095656|NCT06311565|BEHAVIORAL|Education|Individuals in this group will be trained on acquiring healthy lifestyle behaviors to protect against colorectal cancer. Training will be individual, face-to-face and in the form of question and answer. At the end of the training, training brochures prepared by the researchers after taking expert opinions will be distributed to the participants. The training will take approximately 25-30 minutes. The training will take place in the training hall at the family health center.
58095657|NCT03275168|BEHAVIORAL|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
58095658|NCT03275168|BEHAVIORAL|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
58095659|NCT06206421|DRUG|Fezolinetant|oral
58095660|NCT06206421|DRUG|Placebo|oral
58095661|NCT01785472|DRUG|LCZ696|LCZ696 200 mg tablet
58423068|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
58423069|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
57735501|NCT06191913|DEVICE|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
57735502|NCT05294068|OTHER|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
57735503|NCT05294068|OTHER|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
58095662|NCT01785472|DRUG|Olmesartan|Olmesartan 20 mg capsule
58095663|NCT01785472|DRUG|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
58095664|NCT01785472|DRUG|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
58095665|NCT01822964|DEVICE|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
58095666|NCT01822964|DEVICE|Placebo - current clinical practice, no cooling|
58095667|NCT00099320|DRUG|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
58095668|NCT00099320|DRUG|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
58095669|NCT05048342|DRUG|LOU064|Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
58095670|NCT00479739|DRUG|Salmeterol/fluticasone propionate or formoterol/budesonide|
58129442|NCT01932840|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
58458316|NCT04406298|PROCEDURE|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
57735504|NCT05294068|OTHER|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
57735505|NCT03497325|DRUG|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
58458317|NCT04406298|PROCEDURE|Large Volume Paracentesis|Large Volume Paracentesis \> 5litres
57735506|NCT03497325|DRUG|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
57769531|NCT06017388|BEHAVIORAL|Control|We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
58095671|NCT04404530|DRUG|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
57735507|NCT03463902|DEVICE|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
57735508|NCT03463902|DEVICE|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
58095672|NCT00364273|DRUG|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
58095673|NCT00364273|DRUG|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
58095674|NCT00364273|DRUG|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
58095675|NCT06383143|OTHER|no intervention|no intervention
58095676|NCT04805658|DIAGNOSTIC_TEST|Clinical examinations|Clinical examinations
58095677|NCT05359003|BEHAVIORAL|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
58095678|NCT06290739|PROCEDURE|lymph nodes dissection|Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
58095679|NCT01031134|BEHAVIORAL|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
58095680|NCT01031134|OTHER|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
58095681|NCT03402945|DEVICE|Prevena|Negative-Pressure Wound Management System
58095682|NCT03402945|DRUG|Cefazolin|antibiotic
58095683|NCT03402945|DRUG|Vancomycin|antibiotic
58095684|NCT03402945|OTHER|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
58095685|NCT01596049|DEVICE|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
58095686|NCT05218031|BEHAVIORAL|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
58095687|NCT02802007|DEVICE|Elipse Intragastric Balloon|
58095688|NCT02377687|OTHER|observational study|
58095689|NCT06386185|DIAGNOSTIC_TEST|Electrocardiogram|Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart
58423070|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
58423071|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
58423072|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
58458318|NCT01386164|BIOLOGICAL|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
57735509|NCT03463902|DEVICE|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
57769784|NCT04380337|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
58095690|NCT06386185|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound
58095691|NCT06386185|DIAGNOSTIC_TEST|Right heart catheter|Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
58095692|NCT06220838|DRUG|SC-101|All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
58095693|NCT03470896|PROCEDURE|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
58095694|NCT03470896|PROCEDURE|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
58095695|NCT05988411|DEVICE|Renal Denervation|Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
58095696|NCT05988411|DEVICE|Catheter Ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
58095697|NCT01258452|DRUG|CHF 5074|Drug is administered to subject in a fasting state
58095698|NCT01258452|DRUG|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
58095699|NCT06540482|DIAGNOSTIC_TEST|Reliability test|The test was administered two days apart to evaluate the reliability of the retest test.
58095700|NCT00438295|PROCEDURE|temperature control|
58095701|NCT03596086|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
58095702|NCT02786186|DRUG|Secikinumab|
58095703|NCT06245369|BEHAVIORAL|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes"
58423073|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
58423074|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
58423075|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
57735510|NCT03463902|DEVICE|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
58095704|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
58095705|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
58095706|NCT06540898|BEHAVIORAL|Mindfulness-Based Eating and Movement Program|"This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states."
58095707|NCT01938742|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
58095708|NCT01938742|DRUG|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
58095709|NCT04586569|OTHER|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
58095710|NCT05037292|OTHER|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
58129443|NCT02154308|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
58423076|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
58423077|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
58423078|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
58423079|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
58423080|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
58423081|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
57735511|NCT03463902|DEVICE|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
57735512|NCT04728295|DEVICE|Exablate 4000|Exablate Pallidothalamic Tractotomy
58129444|NCT00784849|DRUG|Methylene blue|1 mC1
57735513|NCT00509847|DRUG|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
57735514|NCT02637297|PROCEDURE|Hypnotherapy|Undergo hypnotherapy
57735515|NCT02637297|OTHER|Questionnaire Administration|Ancillary studies
57735516|NCT03310151|PROCEDURE|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
58095711|NCT06700447|BEHAVIORAL|Enhanced inoculation message|Participants enrolled in the enhanced inoculation message arm will receive a similar inoculation message that is enhanced with insights from behavioural economics. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).
58095712|NCT06700447|BEHAVIORAL|Standard inoculation message|Participants enrolled in the standard inoculation message arm will receive a message that warns them about impending HIV vaccine misinformation and explains why that claim is false or misleading. Following this message delivery, all participants will view/watch claims about the HIV vaccine some of which will be false or misleading. The vaccine misinformation claims will be presented using language (and in some cases, visual imagery) consistent with how misinformation exposure will occur in the information ecology (i.e., through social networks and in traditional and social media in real-world settings).
58095713|NCT06700447|BEHAVIORAL|Nutrition information|Participants enrolled in the control group will receive unrelated information on nutrition topics of the same length as the inoculation messages. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
58095714|NCT03739684|DRUG|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
58095715|NCT03739684|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
58095716|NCT06533904|PROCEDURE|Percutaneous Cryoablation of Intercostal Nerves|Percutaneous Cryoablation of Intercostal Nerves
58095717|NCT06533904|OTHER|Multi-modal pain regimen|Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
58095718|NCT03568929|DRUG|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
58095719|NCT05077683|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
58095720|NCT05077683|DRUG|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
58423082|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
58423083|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
58423084|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
57735517|NCT04989348|PROCEDURE|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
57735518|NCT04989348|PROCEDURE|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
57735519|NCT00690703|DEVICE|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
57735520|NCT00991354|BIOLOGICAL|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
57735521|NCT00991354|BIOLOGICAL|IL-12 DNA plasmids|Adjuvant for HIV vaccines
57735522|NCT04866316|OTHER|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
58095721|NCT03782688|DIAGNOSTIC_TEST|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
58095722|NCT05337514|BEHAVIORAL|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
58095723|NCT05337514|BEHAVIORAL|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
58095724|NCT05070169|PROCEDURE|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
58423085|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
57735523|NCT01507870|PROCEDURE|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
57735524|NCT04390438|PROCEDURE|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
57735525|NCT04390438|PROCEDURE|Dry needling|Needle emplacement without electrical current nor substance
57735526|NCT06038565|DEVICE|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
57735527|NCT06038565|DEVICE|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
58095725|NCT06213311|DRUG|Glofitamab|Given by IV
58095726|NCT06213311|DRUG|Obinutuzumab|Given by IV
58423086|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
58423087|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
58423088|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
58423089|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
58423090|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
58423091|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
58423092|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
58423093|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
58423094|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
58423095|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
58423096|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
58095727|NCT06213311|DRUG|Axi-cel|Given by IV
58423097|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
58095728|NCT06299631|PROCEDURE|Ileocolic resection|Ileocolic resection by open or laparoscopic approach
58095729|NCT06678191|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
58095730|NCT05308576|BIOLOGICAL|SCTV01E|D0; intramuscular injection
58095731|NCT05308576|BIOLOGICAL|Placebo|D0; intramuscular injection
58095732|NCT03974516|DRUG|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
58095733|NCT05166421|BIOLOGICAL|AZD7442|AZD7442 will be administered via IM route.
58423098|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
58423099|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
58423100|NCT00002020|DRUG|Zidovudine|
58423101|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
58423102|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
58423103|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
58423104|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
58423105|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
58423106|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
57735528|NCT06647095|DIETARY_SUPPLEMENT|D-Limonene Gelcaps|Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
58095734|NCT05166421|BIOLOGICAL|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
58095735|NCT05166421|BIOLOGICAL|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
58095736|NCT05166421|BIOLOGICAL|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
58095737|NCT05166421|BIOLOGICAL|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
58095738|NCT06033703|DRUG|Netarsudil Ophthalmic|Topical administration of Netarsudil
58095739|NCT01308073|DEVICE|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
58095740|NCT03029000|DRUG|Tbo-filgrastim|solution for subcutaneous injection
58095741|NCT00000510|DRUG|aspirin|
58095742|NCT00000510|DRUG|dipyridamole|
58095743|NCT00000510|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
58423107|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
58423108|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
58423109|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
58423110|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
58423111|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
58423112|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
58423113|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
58423114|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
58423115|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
58423116|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
58423117|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
58423118|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
58423119|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
58423120|NCT03631420|BIOLOGICAL|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
58423121|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
58423122|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
58423123|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
58423124|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
57735529|NCT06647095|DIETARY_SUPPLEMENT|Fish Oil Concentrate, 1000 Mg Oral Capsule|Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
58423125|NCT00233012|DRUG|Topiramate|
58423126|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
58423127|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
58458319|NCT01386164|BIOLOGICAL|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
57735530|NCT05149274|DRUG|DWP14012 Tablet A|DWP14012 10mg
57735531|NCT05149274|DRUG|DWP14012 Tablet B|DWP14012 40mg
57735532|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single ascending dose
57735533|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
57735534|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
58423128|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
58423129|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
58423130|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
58423131|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
58423132|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
58423133|NCT06429189|BEHAVIORAL|Home-based combined exercise program with self-selected intensity|Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
58423134|NCT02955459|DRUG|VNRX-5133|
58423135|NCT02955459|DRUG|Placebo|
58423136|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
58423137|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
57735535|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
57735536|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
57735537|NCT06669429|DRUG|Placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
57961352|NCT00857870|DRUG|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
57961353|NCT00857870|DRUG|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
57961354|NCT03115151|DRUG|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
57735538|NCT04363801|DRUG|DKN-01 300mg|Administered by IV infusion
57735539|NCT04363801|DRUG|DKN-01 600mg|Administered by IV infusion
57735540|NCT04363801|DRUG|DKN-01 400mg|Administered by IV infusion
57735541|NCT04363801|DRUG|Tislelizumab 200mg|Administered by IV infusion
57735542|NCT04363801|DRUG|Tislelizumab 400mg|Administered by IV infusion
57735543|NCT04363801|DRUG|Oxaliplatin|Administered by IV infusion
57735544|NCT04363801|DRUG|Capecitabine 1000mg/ m2 BID|Administered orally
57735545|NCT04363801|DRUG|Leucovorin Calcium|Administered by IV infusion
57961355|NCT03115151|DRUG|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
57961356|NCT03115151|DRUG|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
57961357|NCT04111029|DIAGNOSTIC_TEST|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
57961358|NCT02555423|DRUG|Local anaesthetic - chirocaine|
57961359|NCT01903837|DRUG|Samidorphan (Low Dose)|Tablets taken once daily
57961360|NCT01903837|DRUG|Samidorphan (Medium Dose)|Tablets taken once daily
57961361|NCT01903837|DRUG|Samidorphan (High Dose)|Tablets taken once daily
57961362|NCT01903837|DRUG|Placebo|Tablets taken once daily
57961363|NCT01903837|DRUG|Olanzapine|Tablets taken once daily
57961364|NCT04951687|DIETARY_SUPPLEMENT|Ecologic Barrier©|5x10\^9 CFU/ 2g per day of Ecologic Barrier©
57961365|NCT04951687|DIETARY_SUPPLEMENT|Placebo powder|matched placebo
58306920|NCT04003909|PROCEDURE|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
58306921|NCT04003909|PROCEDURE|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
58423138|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
58423139|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
57735546|NCT04363801|DRUG|Fluorouracil|Administered by IV infusion
57735547|NCT02041195|DRUG|Setmelanotide|
57735548|NCT02041195|DRUG|Placebo|
57735549|NCT03455972|BIOLOGICAL|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
57735550|NCT03455972|DRUG|Immunomodulatory drugs|Maintenance therapy
57961366|NCT02096341|DRUG|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
57961367|NCT00128869|PROCEDURE|spine mobilizations|
57961368|NCT00128869|PROCEDURE|spine manipulations|
57961369|NCT03891901|DRUG|Imatinib|Tablets, administered orally
57961370|NCT03891901|DRUG|Isoniazid|300 mg tablets, administered orally
57961371|NCT03891901|DRUG|Rifabutin|300 mg capsules, administered orally
57961372|NCT00695565|DRUG|Placebo Gel|TID x 12 weeks
57961373|NCT00695565|DRUG|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
57961374|NCT01678144|DEVICE|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
57961375|NCT02177760|DRUG|Sirolimus|
57961376|NCT00875355|DRUG|temozolomide|Given orally
57961377|NCT00875355|RADIATION|radiation therapy|Patients undergo radiotherapy
57961378|NCT02482454|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
57961379|NCT02482454|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
57961380|NCT03842826|DIAGNOSTIC_TEST|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
57961381|NCT00540878|DRUG|SB-751689 oral tablets (400 mg)|
57961382|NCT00006465|DRUG|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
57961383|NCT00006465|DRUG|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
57961384|NCT00006465|DRUG|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
57961385|NCT02758158|DEVICE|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
57961386|NCT05821283|PROCEDURE|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
57961387|NCT05821283|PROCEDURE|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
57961388|NCT01490619|BEHAVIORAL|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
57961389|NCT01490619|OTHER|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
57961390|NCT06170398|DIAGNOSTIC_TEST|Wideband tympanometry|Wideband tympanometry
57961391|NCT06170398|DIAGNOSTIC_TEST|Electrocochleography|Electrocochleography
57961392|NCT06170398|DIAGNOSTIC_TEST|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
57961393|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording."
58095744|NCT05286983|BEHAVIORAL|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
58095745|NCT04774809|DRUG|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
58423140|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
58423141|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
58423142|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
58423143|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
57735551|NCT03936686|OTHER|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
57735552|NCT01349569|DRUG|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
58095746|NCT04774809|DRUG|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
58095747|NCT04774809|OTHER|Placebo Comparator: Vehicle|Placebo
58095748|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
58129445|NCT05184049|DRUG|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
57735553|NCT01349569|BIOLOGICAL|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
58306922|NCT03792646|DIETARY_SUPPLEMENT|Whey protein|Exercise training + 20g whey protein
58423144|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
58423145|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
57735554|NCT01349569|BIOLOGICAL|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
58306923|NCT03792646|OTHER|Exercise training|Strength exercise
58306924|NCT02119299|DEVICE|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
58423146|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
58423147|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
58423148|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
58423149|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
58423150|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
58423151|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
58423152|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
58423153|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58423154|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
58423155|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
58423156|NCT02365571|DRUG|LY3154207|Administered orally
58423157|NCT02365571|DRUG|Placebo|Administered orally
58423158|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
58423159|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
58423160|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
58423161|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
58423162|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
57961394|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
58423163|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
57735555|NCT03131518|BEHAVIORAL|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
57735556|NCT03131518|BEHAVIORAL|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
57735557|NCT03131518|BEHAVIORAL|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
57735558|NCT03137511|OTHER|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
58423164|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
58423165|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
58423166|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
58423167|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
58423168|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
58423169|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
58423170|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
58423171|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
58423172|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
58423173|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
58423174|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
57735559|NCT03565445|DRUG|ASP1948|Intravenously (IV)
57735560|NCT03565445|DRUG|nivolumab|Intravenously (IV)
58423175|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
58423176|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
57735561|NCT03565445|DRUG|pembrolizumab|Intravenously (IV)
57735562|NCT03796988|DEVICE|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
57735563|NCT01478568|DRUG|mirabegron|oral
57735564|NCT01478568|DRUG|desipramine|oral
57735565|NCT00273117|PROCEDURE|transnasal gastroscopy|
57735566|NCT03108924|DRUG|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
57735567|NCT06465849|PROCEDURE|Dentin Etching time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
57735568|NCT06465849|DEVICE|Scotchbond Universal Plus; 3M|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
57735569|NCT06465849|DEVICE|Gluma Universal Bond; Kulzer|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
57961395|NCT03949270|BEHAVIORAL|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
57961396|NCT01610765|DRUG|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
57735570|NCT06465849|PROCEDURE|Dentin Etching time for 15 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
57951371|NCT04132362|BEHAVIORAL|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
58095749|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume."
58095750|NCT05587517|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
58095751|NCT05587517|OTHER|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
58423177|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
58423178|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
58423179|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
58423180|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
58423181|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
58423182|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
58423183|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
57735571|NCT05094323|DRUG|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
57735572|NCT05094323|DRUG|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
57735573|NCT05094323|DRUG|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
57735574|NCT04100746|PROCEDURE|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
57735575|NCT00375687|DRUG|Triptorelin|
57735576|NCT05134454|DIAGNOSTIC_TEST|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
57735577|NCT03578874|DRUG|Sorafenib|PO
58423184|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
58423185|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
58423186|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
58095752|NCT04424407|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
57951372|NCT04132362|BEHAVIORAL|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
57951373|NCT04577235|OTHER|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
57951374|NCT02690155|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
57951375|NCT02690155|DRUG|VKA (Vitamin K antagonist)|As prescribed by treating physicians
57951376|NCT02237300|BEHAVIORAL|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
57951377|NCT02237300|BEHAVIORAL|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
57951378|NCT06223282|OTHER|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
57951379|NCT06223282|OTHER|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
57951380|NCT06223282|OTHER|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
57951381|NCT06223282|OTHER|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
57951382|NCT02079103|DEVICE|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
57951383|NCT02079103|BEHAVIORAL|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
57951384|NCT05021107|OTHER|FDM with isometrics|FDM with isometrics will be done
57951385|NCT05021107|OTHER|FDM without isometrics|FDM without isometrics will be done
57951386|NCT03448237|OTHER|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
57951387|NCT03448237|OTHER|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~* Proprioceptive stimulation of oculomotor muscles (active prisms).~* Oral somatosensory stimulation (ALPH).~* Proprioceptive antigravity stimulation (proprioceptive sole).~* Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
57951388|NCT04304716|DRUG|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
57951389|NCT06402266|DEVICE|tDCS|"The STM task will be combined with respectively two times active tDCS and one sham tDCS. The 3 conditions will be randomised, and both scientific staff and participants will be blinded.~Participants will perform the STM task on a tablet for 45 min. Headsets will deliver the tDCS. Two different placements will be used for the active stimulations: 1) F3 and PZ, and 2) F4 and PZ. The current output range will be 1.6mA and the stimulation will last for 30 min. The sham stimulation will function as a control condition. During the sham stimulation, the current density will be ramped up for 15 sec until the current reaches a density of 1.6mA for 60 sec and then again ramped down for 15 sec.~After the session, participants will fill out a brief questionnaire regarding their experience.~The time interval between sessions will be 1-3 weeks."
57951390|NCT01375842|DRUG|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
57951391|NCT02835183|DEVICE|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
57951392|NCT02835183|DEVICE|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
57951393|NCT01248351|OTHER|autologous stored platelets|Administration of autologous stored platelets
57735578|NCT03578874|DRUG|Capecitabine|PO
57735579|NCT03578874|DRUG|Oxaliplatin|IV
57735580|NCT01097967|OTHER|CPAP|
57735581|NCT00373594|DRUG|Rituximab|
57735582|NCT00373594|DRUG|Fludarabine|
57735583|NCT05827068|BIOLOGICAL|mRNA-1011.1|Sterile liquid for injection
57735584|NCT05827068|BIOLOGICAL|mRNA-1011.2|Sterile liquid for injection
57735585|NCT05827068|BIOLOGICAL|mRNA-1012.1|Sterile liquid for injection
58095753|NCT00000135|DRUG|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
58095754|NCT00000135|OTHER|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
58095755|NCT06636721|BEHAVIORAL|LuCA Behavioral Intervention|The intervention will integrate aspects of Cognitive Behavioral Therapy (identifying and challenging automatic thoughts, engaging in behavioral activation) and Acceptance and Commitment Therapy (integrating one's values, distancing skills). The intervention will include skills such as problem-solving, communicating with close others and the medical team, and breathing techniques to improve shortness of breath related to lung cancer.
58095756|NCT03634007|BIOLOGICAL|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
58095757|NCT05047237|BEHAVIORAL|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
58423187|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
58423188|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
58423189|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
58423190|NCT02062203|DRUG|Placebo|Single oral dose of placebo
58423191|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
58423192|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
57735586|NCT05827068|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
58095758|NCT06307678|DRUG|Calcium Hydroxide|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
58095759|NCT06307678|DRUG|Calcium Silicate|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
58095760|NCT04275388|DRUG|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
58095761|NCT04275388|DRUG|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
58095762|NCT00264082|DRUG|Zometa(drug)|
58095763|NCT05903924|DRUG|Tradipitant|Oral Capsule
58423193|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
58423194|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
57951394|NCT01248351|OTHER|administration of autologous stored platelets|administration of autologous stored platelets
58095764|NCT05903924|DRUG|Placebo|Oral Capsule
58095765|NCT03647280|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
58129446|NCT05184049|DRUG|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
58423195|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
58423196|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
58423197|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
58423198|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
58423199|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
58423200|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
58423201|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
58423202|NCT00165542|OTHER|A PROTEIN level|
57735587|NCT05827068|BIOLOGICAL|mRNA-1010.2|Sterile liquid for injection
57735588|NCT05827068|BIOLOGICAL|mRNA-1010.3|Sterile liquid for injection
57735589|NCT01047839|BIOLOGICAL|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
57735590|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
57735591|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
57735592|NCT01808157|DRUG|CT327 ointment|
57951395|NCT01248351|BIOLOGICAL|autologous stored platelets|transfusion of autologous stored platelets
57951396|NCT03138538|DRUG|Part 1: M8891|Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
57951397|NCT02006342|DRUG|Insulin Glargine|
57951398|NCT02006342|DRUG|Regular Insulin|
58423203|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
58095766|NCT03647280|DRUG|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
58095767|NCT03777839|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
58423204|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
58423205|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
58423206|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
57735593|NCT01808157|DRUG|placebo|
57951399|NCT03114514|BIOLOGICAL|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
57951400|NCT03896516|OTHER|Placebo|Participants will take GL WL-01 450 mg b.i.d or matched placebo for 16 days.
58095768|NCT01053078|DRUG|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
57951401|NCT03896516|DRUG|GLWL-01|A within-subject, counterbalanced, double-blind, placebo-controlled study. Participants will take GLWL-01 450 mg b.i.d. or matched placebo for a minimum of 4 days (Stage I). After a wash-out window, Stage II will take place during which the counterbalanced study drug will be administered for a minimum of 4 days.
58095769|NCT01053078|OTHER|Placebo|1 month treatment; placebo tablet once daily for 28 days
58095770|NCT06033183|BIOLOGICAL|Blood sample|Blood sample collection : 2 X 5 ml
58095771|NCT05343793|OTHER|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
58095772|NCT05343793|OTHER|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
58306925|NCT00103558|DRUG|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
58306926|NCT00010140|DRUG|docetaxel|
57735594|NCT04429490|OTHER|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
57735595|NCT05330962|OTHER|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
58095773|NCT05343793|OTHER|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
58129447|NCT02833038|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
58306927|NCT00010140|DRUG|epirubicin hydrochloride|
58306928|NCT00010140|DRUG|tamoxifen citrate|
58306929|NCT00010140|PROCEDURE|adjuvant therapy|
58306930|NCT06019871|PROCEDURE|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
58306931|NCT04398836|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
58306932|NCT04398836|OTHER|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
58306933|NCT04398836|OTHER|Standard nutrition|Well nurished patients will receive a standard nutrition
58306934|NCT06379243|PROCEDURE|PVP/PKP|PVP or PKP surgery in patients with osteoporotic vertebral compression fractures
58306935|NCT02659501|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
58306936|NCT02659501|DRUG|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
58306937|NCT02659501|DRUG|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
58423207|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
58423208|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
58423209|NCT01755650|RADIATION|18F FPM|
58423210|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
58423211|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
58423212|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
57951402|NCT02132481|OTHER|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
58095774|NCT05343793|OTHER|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
58095775|NCT00585039|DRUG|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
58095776|NCT05919329|DRUG|Piflufolastat|Given IV
58423213|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
58423214|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
57735596|NCT06670196|DRUG|SKB264|4mg/kg, intravenous (IV) infusion
57735597|NCT06670196|DRUG|Osimertinib|80mg, QD
57735598|NCT00197977|BEHAVIORAL|Educational program to address patients' expectations|
57769785|NCT00423293|DRUG|fluorouracil|1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
58095777|NCT05919329|PROCEDURE|PSMA PET/CT Scan|Undergo PSMA PET/CT
58095778|NCT05919329|PROCEDURE|PSMA PET/MRI scan|Undergo PET/MRI
58095779|NCT05919329|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58423215|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
58095780|NCT05919329|OTHER|Electronic Health Record Review|Ancillary studies
58423216|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
58095781|NCT01984619|DEVICE|Cryotherapy for the utilization of wrinkle reduction (iovera)|
58095782|NCT04917029|DRUG|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
58095783|NCT04917029|DRUG|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
58095784|NCT04917029|DRUG|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
58423217|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
58423218|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
58423219|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
58423220|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
58095785|NCT03438474|PROCEDURE|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
58095786|NCT03438474|PROCEDURE|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
58095787|NCT03797573|DEVICE|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
58095788|NCT03797573|DEVICE|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
58423221|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
58423222|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
58423223|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
58423224|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
58423225|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
58423226|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
58423227|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
58095789|NCT05495425|DRUG|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
58095790|NCT05495425|DRUG|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
58095791|NCT05847569|BIOLOGICAL|Belantamab Mafodotin|Given IV
58095792|NCT05847569|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58095793|NCT05847569|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
58095794|NCT05847569|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
58095795|NCT05847569|PROCEDURE|Computed Tomography|Undergo CT scan
58095796|NCT05847569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
58095797|NCT05847569|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
58095798|NCT05619627|DRUG|Dexmedetomidine|Patients will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
58095799|NCT05619627|DRUG|General anesthetic|Patients will receive inhalational anesthetic to provide general anesthesia for undergoing MRI
58095800|NCT04929522|PROCEDURE|local anesthesia|technique for local anesthesia
58095801|NCT06072131|DRUG|Belinostat Injection|Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
58095802|NCT06072131|DRUG|Pralatrexate Injection|Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
58095803|NCT06072131|DRUG|CHOP|CHOP is the comparator arm
58095804|NCT06072131|DRUG|COP|COP is given in combination with Pralatrexate
58095805|NCT00547209|DRUG|air|60% air combined with 40% oxygen for ventilation
58095806|NCT00547209|DRUG|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
58423228|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
58423229|NCT02488993|OTHER|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
58423230|NCT02488993|OTHER|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
58423231|NCT02488993|OTHER|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
58423232|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
58423233|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
58423234|NCT03042130|OTHER|Standard of care|standard of care
58423235|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
58423236|NCT00001410|DRUG|Lysodase|
58423237|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
58423238|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
58423239|NCT02728531|DRUG|Bendamustine|
58423240|NCT02728531|DRUG|Rituximab|
58423241|NCT02728531|DRUG|Cytarabine|
58423242|NCT02728531|DRUG|Pegfilgrastim|
58423243|NCT02728531|PROCEDURE|Leukapheresis|
58423244|NCT02728531|DRUG|Filgrastim|
58423245|NCT02728531|PROCEDURE|Autologous stem cell transplant|
58423246|NCT04958226|DRUG|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
58423247|NCT04958226|DRUG|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
58423248|NCT03417934|PROCEDURE|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
58423249|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
58423250|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
57769786|NCT00423293|DRUG|mitomycin C|10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.
57951403|NCT02132481|OTHER|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
58423251|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
58423252|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
57951404|NCT02132481|OTHER|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
58129448|NCT02833038|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
58423253|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
58423254|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
58423255|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
58423256|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
58458320|NCT04138303|OTHER|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
58095807|NCT04230785|GENETIC|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
58423257|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
58423258|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
58458321|NCT04138303|OTHER|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
57735599|NCT06349369|DEVICE|transcranial direct current stimulation|tDCS is a non-invasive neuromodulation technique that has gained attention for its potential to influence neural activity and address cognitive and functional deficits in individuals with schizophrenia. It involves applying a weak direct electrical current to the scalp, which can increase or decrease the excitability of underlying brain regions.
58095808|NCT06568809|OTHER|Time interval between recovery of body temperature and operation|The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
58095809|NCT00756652|DEVICE|Mentor Silicone Gel-Filled Breast Implants|
58095810|NCT00756652|DEVICE|Saline Breast Implants|
58095811|NCT03933982|DRUG|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
58095812|NCT04288323|DRUG|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
58095813|NCT06419855|DEVICE|Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
58095814|NCT06419855|DEVICE|Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
58095815|NCT04272255|DRUG|scopolamine HBr|Nasal Gel
58095816|NCT04272255|DRUG|Transdermal Scopolamine|Patch
58095817|NCT02629380|BIOLOGICAL|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
58095818|NCT02629380|PROCEDURE|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
58095819|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (Moderate Risk)|Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.
58095820|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (High Risk)|Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
57735600|NCT05967520|DRUG|JMKX000189|JMKX000189 will be administered orally once a day
57735601|NCT05967520|DRUG|Placebo|Placebo will be administered orally once a day
57735602|NCT06667921|DEVICE|Ultrasound|Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
58095821|NCT05706311|OTHER|Standard of Care|Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
58095822|NCT06132412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
58095823|NCT06132412|OTHER|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
58095824|NCT04640909|OTHER|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
58095825|NCT06566040|DEVICE|Wheelchair|Wheelchairs provided to hospital inpatients
58095826|NCT01910597|DRUG|SBG|
58095827|NCT06438159|OTHER|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations."
58095828|NCT06438159|OTHER|Conventional cardiac rehabilitation|The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
58458322|NCT04138303|OTHER|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
58423259|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
58423260|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
58423261|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
58423262|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
58423263|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
58423264|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
58423265|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
58423266|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
58423267|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
58423268|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
58423269|NCT03731260|DRUG|Placebo|Placebo tablet
58423270|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
58423271|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
58423272|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
58423273|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
58423274|NCT02442258|DRUG|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
58423275|NCT02442258|DRUG|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
58423276|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
57769532|NCT06625697|BEHAVIORAL|Mindfulness Meditation|Participants will be instructed on how to wear the physiological monitoring equipment during the 14-unit mindfulness meditation curriculum. Participants will then complete 2-10 minute guided seated Equa training lessons on a laboratory smartphone device while physiological measures are tracked. After training lessons, a respiration biosignal feedback chart will appear on the smartphone screen. Participants will also complete a brief mindfulness survey before and after training lessons.
57769533|NCT04498247|BIOLOGICAL|V591|1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
58095829|NCT00808015|DRUG|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
58095830|NCT05120752|OTHER|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
57769534|NCT04498247|OTHER|Placebo|Placebo (0.9% sodium chloride) administered via IM injection.
58095831|NCT06111417|OTHER|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire"
58095832|NCT06111417|OTHER|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
58095833|NCT03394794|DEVICE|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
58095834|NCT04832984|BEHAVIORAL|Mobile health|Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
58095835|NCT04832984|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
58095836|NCT05777369|DRUG|Rituximab|375 mg/m2, d0
58095837|NCT05777369|DRUG|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
58095838|NCT05777369|DRUG|Cyclophosphamide|750 mg/m2, d1
58095839|NCT05777369|DRUG|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
58095840|NCT05777369|DRUG|Prednisone|60 mg/m2, d1\~d5
58095841|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) as usual|Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
58095842|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) + Smart Parents|"Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session."
58095843|NCT06514118|RADIATION|residual tumor irradiation|lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
58129449|NCT03852706|OTHER|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
57769535|NCT01541618|OTHER|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
57769536|NCT06523738|DIAGNOSTIC_TEST|1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation|1. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
58129450|NCT03852706|OTHER|Treatment as usual|Treatment-as-usual
57769537|NCT05967676|DIAGNOSTIC_TEST|Turkish adaptation, validity and reliability|"This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes"
57735603|NCT06133894|BEHAVIORAL|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
58095844|NCT05231161|DIAGNOSTIC_TEST|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
58095845|NCT04706520|DIETARY_SUPPLEMENT|Study Beverage Consumption|All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
58095846|NCT06525155|DRUG|Triptorelin Embonate|Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
58095847|NCT06525155|DRUG|Triptorelin Embonate|Treatment 2: 3.75 mg once after surgery at week-12
58095848|NCT02913651|DEVICE|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
58095849|NCT05551000|OTHER|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
58095850|NCT06567535|PROCEDURE|Navigation and endoscopy|The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
58095851|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
58095852|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
58095853|NCT04992169|BEHAVIORAL|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
58095854|NCT05394428|OTHER|No intervention|No intervention
58095855|NCT04289467|DRUG|Fenfluramine|Open-label
58095856|NCT05800743|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
58095857|NCT05800743|DEVICE|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
58095858|NCT05800743|PROCEDURE|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
58095859|NCT05653349|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
58095860|NCT05653349|DRUG|Placebo|Intravenous infusion, prepared from matching placebo
58095861|NCT05653349|DRUG|Corticosteroids|Oral or parental (if clinically justified)
58095862|NCT00081835|DRUG|NP-016 Vaccine Immune Globulin (IV-VIG)|
58458323|NCT04499755|DRUG|Nucleo CMP Forte|Nucleo CMP Forte twice daily for 6 weeks
58458324|NCT00000801|DRUG|Filgrastim|
57735604|NCT02485210|PROCEDURE|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
58095863|NCT05348018|DEVICE|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
58095864|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.
58095865|NCT06702241|OTHER|Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
58095866|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
58423277|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58095867|NCT06702241|OTHER|Cycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
58423278|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58423279|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
58423280|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
58423281|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
58423282|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
57735605|NCT03033823|DRUG|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
57735606|NCT03033823|DRUG|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
57735607|NCT02669823|OTHER|None, treatment as actual best practice|
57735608|NCT01752504|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
57735609|NCT01478867|OTHER|Detection of gluten in feces|Detection of Gluten in Feces
58095868|NCT04738552|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
58095869|NCT05329129|DEVICE|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
58095870|NCT05459545|DEVICE|Use of Eko CORE and Eko CORE 500 electronic stethoscope|Auscultation of heart sounds using electronic stethoscopes
58095871|NCT00086931|DRUG|capecitabine|oral dose escalating, twice daily.
58095872|NCT00086931|DRUG|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
58095873|NCT00086931|PROCEDURE|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
58095874|NCT00086931|PROCEDURE|neoadjuvant therapy|chemotherapy and radiation prior to surgery
58095875|NCT00086931|RADIATION|radiation therapy|once daily 5 days a week for 5.5 weeks
58423283|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
58423284|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
58423285|NCT05364762|DRUG|Cyclophosphamide|Given IV
58423286|NCT05364762|DRUG|Itacitinib|Given PO
58423287|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
58423288|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
58423289|NCT05364762|DRUG|Tacrolimus|Given IV or PO
58423290|NCT03688568|DRUG|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
58458325|NCT00000801|DRUG|Vincristine sulfate|
58423291|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
58423292|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
58423293|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
58423294|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
58423295|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
58423296|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
58423297|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
58423298|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
58423299|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
58423300|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
58423301|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
58423302|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
58423303|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
58423304|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
58423305|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
58423306|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
58423307|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
57735610|NCT00808808|BIOLOGICAL|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
58095876|NCT06560996|OTHER|Very low calorie diet with low protein content (VLCD-LP group)|Very low calorie diet (850 kcals per day) with low protein content (10%)
58095877|NCT06560996|OTHER|Very low calorie diet with high protein content (VLCD-HP group)|Very low calorie diet (850 kcals per day) with high protein content (30%)
57735611|NCT00808808|OTHER|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
58095878|NCT02480855|OTHER|Questionnaire and feedback|
58095879|NCT01408407|OTHER|Aveeno cream|Apply cream on irradiated area twice a day
58095880|NCT01408407|OTHER|Alkagin paste|Apply Alkagin paste three times a day.
58095881|NCT05580588|DRUG|SPH4336|400 mg SPH4336 PO QD
58129451|NCT06033482|PROCEDURE|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
58423308|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
58423309|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
58423310|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
58423311|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
58423312|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
58423313|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
58423314|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
58423315|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
58423316|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
58423317|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
58423318|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
58423319|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
58423320|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
58423321|NCT02759224|DRUG|BRI-1501|
58423322|NCT02759224|DRUG|Lafutidine|
58423323|NCT02759224|DRUG|Irsogladine maleate|
58423324|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
58423325|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
58423326|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
58423327|NCT02992535|DEVICE|Intense Pulse Light Energy delivery (IPL)|
58423328|NCT00209898|PROCEDURE|Fast initiation procedure|
58423329|NCT00000713|DRUG|Ampligen|
58423330|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
58129452|NCT00727571|OTHER|Observations|This is a non-interventional, observational study; no investigational product is being used
58423331|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
58423332|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
58423333|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
58306938|NCT02659501|DRUG|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
58423334|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
58306939|NCT02659501|DRUG|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
58423335|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
58458326|NCT00000801|DRUG|Doxorubicin hydrochloride|
58458327|NCT00000801|DRUG|Cyclophosphamide|
58306940|NCT01255163|DRUG|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
58306941|NCT01255163|DRUG|Placebo SC|Placebo SC twice daily
58306942|NCT05201092|DRUG|[14C]-Lu AG06466|\[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
58306943|NCT04644172|BEHAVIORAL|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
58458328|NCT00000801|DRUG|Cytarabine|
58458329|NCT00000801|DRUG|Dexamethasone|
58458330|NCT00321789|BEHAVIORAL|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
58423336|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
58458331|NCT02245477|DEVICE|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
57735612|NCT00808808|BIOLOGICAL|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
57735613|NCT03518177|OTHER|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
57735614|NCT03518177|OTHER|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
58095882|NCT06513988|DEVICE|MI-BCI combined with tDCS treatment|The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
58095883|NCT01614808|OTHER|laboratory biomarker analysis|Correlative studies
58095884|NCT03025659|OTHER|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
58095885|NCT01466959|OTHER|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
58095886|NCT01466959|OTHER|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
58095887|NCT00619671|DRUG|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
58095888|NCT06568978|OTHER|Assessments of respiratory parameters|respiratory muscle strength, respiratory function test
58095889|NCT06579196|DRUG|Trabedersen|Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).
58095890|NCT06579196|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
58095891|NCT04241068|DRUG|Aducanumab|Administered as specified in the treatment arm.
58095892|NCT05875623|OTHER|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
58095893|NCT03771768|RADIATION|Diode laser 980nm&100 mWatt|Diode laser 980 nm \&100 milli Watt.
58095894|NCT03771768|DRUG|Triamcinolone Acetonide|0.1 \&5gm paste 4 times/day
57735615|NCT06059716|BEHAVIORAL|Gluten detection technology|Portable technology to sense gluten after ingestion
57735616|NCT06059716|BEHAVIORAL|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
57735617|NCT03360253|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
57735618|NCT03360253|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
57735619|NCT00574080|DRUG|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
57735620|NCT00574080|DRUG|Induction/Consolidation Dexamethasone|40 mg Days 1-4
57735621|NCT00574080|DRUG|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
57735622|NCT00574080|DRUG|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
57735623|NCT00574080|DRUG|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
57735624|NCT00574080|DRUG|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
57735625|NCT00574080|DRUG|Induction Pegfilgrastim|6 mg Days 6 and 13
57735626|NCT00574080|DRUG|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
57735627|NCT00574080|DRUG|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
58423337|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
58423338|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
58423339|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
58423340|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
58423341|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
58423342|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
58095895|NCT01643928|BIOLOGICAL|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
57735628|NCT00574080|DRUG|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
58095896|NCT01643928|BIOLOGICAL|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
58095897|NCT01643928|BIOLOGICAL|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
57735629|NCT00574080|DRUG|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
57735630|NCT00574080|DRUG|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
57735631|NCT00574080|DRUG|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
57735632|NCT00574080|DRUG|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
57735633|NCT00574080|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
57735634|NCT00574080|DRUG|Transplant 2 Carmustine|300 mg/m2 Day -5
57735635|NCT00574080|DRUG|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
57735636|NCT00574080|DRUG|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
57951405|NCT02132481|OTHER|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
57951406|NCT03861559|DRUG|mometasone furoate nasal spray|intranasal administration
58423343|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
58423344|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
58423345|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
58423346|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
58423347|NCT04229836|DRUG|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
58423348|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
58423349|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
58423350|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
58423351|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
58423352|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
58423353|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
58423354|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
58423355|NCT04971941|DEVICE|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
58423356|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
58423357|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
58423358|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
58423359|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
58423360|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
58423361|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
58423362|NCT00154128|DEVICE|occlusal appliance|
58423363|NCT00495378|DRUG|epoetin alfa|
58423364|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
57735637|NCT00574080|DRUG|Transplant 2 Melphalan|140 mg/m2 Day -1
57735638|NCT00574080|DRUG|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
57735639|NCT00574080|DRUG|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
58423365|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
58423366|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
58423367|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
57735640|NCT00574080|DRUG|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
57735641|NCT01367873|DRUG|Placebo|Oral, matching number of placebo capsule(s) with active arm
57735642|NCT01367873|DRUG|VIA-3196|Oral, capsule(s)
57735643|NCT06143618|BEHAVIORAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
57951407|NCT03861559|DRUG|placebo nasal spray|intranasal administration
57951408|NCT02579070|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
57951409|NCT05075070|BIOLOGICAL|Inactivated COVID-19 vaccine|two doses inactivated COVID-19 vaccine
57951410|NCT00881400|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
57951411|NCT00881400|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
58095898|NCT06568068|BEHAVIORAL|training|"The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days"
58095899|NCT00566969|DRUG|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
58423368|NCT00896441|DRUG|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
58423369|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
58423370|NCT00000480|PROCEDURE|electrophysiology|
58423371|NCT00000480|DRUG|anti-arrhythmia agents|
58423372|NCT00000480|DEVICE|defibrillators, implantable|
58423373|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
57735644|NCT06143618|BEHAVIORAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
57735645|NCT05013450|DRUG|Dupilumab|three q3w cycles
57735646|NCT05013450|DRUG|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
58095900|NCT00566969|DRUG|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
58095901|NCT00566969|DRUG|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
58095902|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
58095903|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
58095904|NCT01563029|DRUG|Fluticasone Furoate|current asthma medicine
58095905|NCT01563029|DRUG|Fluticasone Propionate|Fluticasone propionate
58423374|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
58095906|NCT01563029|DRUG|Placebo|placebo
58095907|NCT03006822|OTHER|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
57951412|NCT03920189|DIAGNOSTIC_TEST|echocariographic ultrasound|left ventricular diastolic function description
57951413|NCT04807907|BEHAVIORAL|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
57951414|NCT00129766|BIOLOGICAL|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
57951415|NCT00129766|BIOLOGICAL|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
57951416|NCT04027400|BEHAVIORAL|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
58095908|NCT03006822|OTHER|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
58095909|NCT03006822|OTHER|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
58095910|NCT02077660|DIETARY_SUPPLEMENT|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
58423375|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
58423376|NCT03668834|PROCEDURE|Dermabrasion with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
58423377|NCT03668834|PROCEDURE|Dermaroller with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
58423378|NCT03668834|PROCEDURE|Liquid nitrogen induced blister with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
58423379|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
58423380|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
57735647|NCT05013450|DRUG|Anakinra|100 mg daily injection for Three q3w cycles
57735648|NCT01615731|DRUG|Mifepristone|200mg Mifepristone orally
58095911|NCT02077660|OTHER|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
58095912|NCT05171127|PROCEDURE|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
58095913|NCT06573697|OTHER|low-frequency continuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
57735649|NCT01615731|OTHER|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
57735650|NCT01615731|DRUG|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
57735651|NCT01615731|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op
58095914|NCT06573697|OTHER|discontinuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
57735652|NCT03364205|BEHAVIORAL|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
57735653|NCT02988973|DRUG|roxadustat|Oral administration
57735654|NCT02988973|DRUG|DA|Subcutaneous administration
57735655|NCT04531046|DRUG|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
57735656|NCT06387901|DRUG|Paclitaxel Chemotherapy|Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
57735657|NCT02698072|OTHER|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
57735658|NCT02698072|DEVICE|Dry needling|Dry needling needle AGUPUNT®
57951417|NCT01231100|OTHER|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
57951418|NCT02372474|BIOLOGICAL|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
57951419|NCT01886365|DEVICE|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
57951420|NCT01886365|OTHER|Conventional therapy with a fixed insulin dosing scheme|Routine care
58423381|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
58423382|NCT02710942|BEHAVIORAL|SPHERE|
58423383|NCT02710942|BEHAVIORAL|PRISM|
58095915|NCT06573697|OTHER|dilatational wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
58423384|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
58423385|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
58423386|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
57735659|NCT02698072|DEVICE|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
57735660|NCT00843167|DIETARY_SUPPLEMENT|broccoli sprout extract|Given orally
58095916|NCT06701955|OTHER|Questionnaire and Physical Exam|self administered questionnaires
58095917|NCT05153590|DRUG|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
58095918|NCT02812368|DRUG|Clonidine|
58095919|NCT02812368|DRUG|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
58095920|NCT06025500|DIAGNOSTIC_TEST|31P-Magnetic Resonance Spectroscopy (31P-MRS)|31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
58095921|NCT04331418|DRUG|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
58095922|NCT04331418|PROCEDURE|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
58306944|NCT04644172|BEHAVIORAL|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
58423387|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
57735661|NCT00843167|OTHER|placebo|Given orally
57735662|NCT02414893|PROCEDURE|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
57735663|NCT01349075|RADIATION|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
57735664|NCT02814318|BIOLOGICAL|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
58095923|NCT03890861|BEHAVIORAL|Physical activity|Promotion of physical activity to the current federal physical activity guidelines.
58095924|NCT03890861|BEHAVIORAL|Successful Aging|Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
57735665|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
57735666|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
57735667|NCT03780764|OTHER|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
58095925|NCT03735095|DRUG|Porfimer Sodium|Given IV
58095926|NCT03735095|PROCEDURE|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
58423388|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
58423389|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
58423390|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
57951421|NCT05639907|DEVICE|K21 Cavity cleanser|K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
57951422|NCT05639907|DEVICE|Ethanol control|Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
58095927|NCT06144827|DEVICE|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
58095928|NCT06144827|DEVICE|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
58095929|NCT03944538|BEHAVIORAL|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
58095930|NCT03944538|BEHAVIORAL|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
58095931|NCT05809986|OTHER|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
58095932|NCT05385744|BIOLOGICAL|BCD-132|anti-CD20 monoclonal antibody
58095933|NCT05385744|DRUG|Teriflunomide|Teriflunomide 14 mg
58095934|NCT01933139|OTHER|Audio-visual presentation|
58095935|NCT00423228|DRUG|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
58423391|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
58423392|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
58423393|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
58423394|NCT03031119|DRUG|Placebo|Tablets administered once or twice daily, with food, in Part A.
58423395|NCT03031119|DRUG|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
58423396|NCT03031119|DRUG|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
58423397|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
58423398|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
58423399|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
58423400|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
58423401|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
58423402|NCT02231268|DRUG|Gladem|
58095936|NCT00423228|DRUG|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
58095937|NCT02717624|DRUG|Acalabrutinib in combination with BR|
58095938|NCT02717624|DRUG|Acalabrutinib in combination with VR|
58095939|NCT03338673|DEVICE|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
58095940|NCT03338673|OTHER|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
58095941|NCT01850108|DRUG|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT"
58095942|NCT01850108|DRUG|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
58095943|NCT01850108|DRUG|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
58095944|NCT01850108|DRUG|Mesna|Days 3 \& 4 after BMT: 40 mg/kg IV
58095945|NCT01850108|DRUG|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
57735668|NCT03780764|OTHER|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
57735669|NCT06628921|DRUG|Eptinezumab 100 or 300 mg ev|Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
58095946|NCT01850108|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
58095947|NCT01850108|PROCEDURE|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
58095948|NCT01850108|RADIATION|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
58095949|NCT05431348|DEVICE|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
58095950|NCT05431348|DIAGNOSTIC_TEST|Serum Cortisol|Level of cortisol in serum will be determined
58095951|NCT05431348|OTHER|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
58095952|NCT05526443|DRUG|all approved chemotherapeutic agents from second line|all approved chemotherapeutic agents from second line
58095953|NCT06644755|DRUG|DS-2243a|"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
58095954|NCT05109273|PROCEDURE|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
58095955|NCT02625961|BIOLOGICAL|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
58423403|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
58423404|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
58095956|NCT02625961|BIOLOGICAL|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
58095957|NCT02625961|BIOLOGICAL|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
58095958|NCT02446197|OTHER|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
58095959|NCT00394992|DRUG|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
58095960|NCT00394992|DRUG|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
58095961|NCT02543229|DRUG|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
58095962|NCT02543229|DRUG|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
58095963|NCT02643810|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
58095964|NCT02411110|COMBINATION_PRODUCT|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
58095965|NCT02411110|COMBINATION_PRODUCT|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
58095966|NCT06702254|BEHAVIORAL|Experimental: Psychological manualized treatment with CBT and ACT|The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.
58095967|NCT06702254|OTHER|Treatment as usual|This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
58095968|NCT04289571|DIAGNOSTIC_TEST|VR Mobility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
58095969|NCT02223598|DRUG|CB-5083|
58095970|NCT02223598|DRUG|Dexamethasone|
58095971|NCT05020197|DIAGNOSTIC_TEST|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
58095972|NCT06127979|PROCEDURE|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
58095973|NCT06127979|OTHER|blood draw|blood draw
58095974|NCT06118086|DRUG|REM-422|"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"
58095975|NCT01506817|PROCEDURE|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
58095976|NCT03285412|DRUG|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
58095977|NCT03285412|OTHER|Endocrine therapy|Hormone therapy
58095978|NCT02228369|DRUG|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
58095979|NCT02228369|DRUG|AZD9291|AZD9291 160mg once daily
58095980|NCT02233465|PROCEDURE|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
58095981|NCT02258399|BEHAVIORAL|Exercise|Moderate intensity exercise
58095982|NCT02258399|DIETARY_SUPPLEMENT|Breakfast|Breakfast consumption
58095983|NCT04556500|OTHER|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
58095984|NCT00296582|BEHAVIORAL|Gastric Motor Function Measurement|
57735670|NCT06153173|DRUG|Mirdametinib|Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule. Consecutive doses should be separated by minimum 6 hours and maximum 14 hours.
58095985|NCT05705531|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
58095986|NCT05705531|OTHER|Electronic Health Record Review|Undergo medical record abstraction
58095987|NCT05705531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58095988|NCT05705531|OTHER|Survey Administration|Complete surveys
58095989|NCT06702969|DEVICE|Intra oral scanner|Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner
58095990|NCT06702969|DEVICE|impression analog|Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
58423405|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
58423406|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
58423407|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
58423408|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
58423409|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
58423410|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
58095991|NCT04982718|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
58095992|NCT04982718|DIAGNOSTIC_TEST|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
58423411|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
58423412|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
58423413|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
58423414|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
58423415|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
58423416|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
58423417|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
58095993|NCT02314949|PROCEDURE|intestinal transplantation|
58095994|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
58095995|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
58095996|NCT06257966|DRUG|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
58095997|NCT06257966|DRUG|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
58423418|NCT03598751|DRUG|Placebo|2 mL
58423419|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
58423420|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
58423421|NCT03591172|DRUG|Propolis|Using propolis as a final irrigation in revascularization
58423422|NCT03591172|DRUG|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
58423423|NCT03591172|DRUG|saline|Using saline as a final irrigation in revasculariztion
58423424|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
58423425|NCT04394715|OTHER|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
58423426|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
58423427|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
58423428|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
58423429|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
58423430|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
58423431|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
57735671|NCT03796624|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
58095998|NCT06356038|PROCEDURE|intra-operative phrenic nerve infiltration|patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
58095999|NCT06673550|PROCEDURE|Intragastric balloon|Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.
57735672|NCT03796624|DEVICE|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
58096000|NCT06701981|OTHER|Filter comparison|Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device
58423432|NCT02170909|DRUG|BIBR 1048 MS low dose|
58423433|NCT02170909|DRUG|BIBR 1048 MS medium dose|
58423434|NCT02170909|DRUG|BIBR 1048 MS high dose|
58423435|NCT02702687|BEHAVIORAL|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
58423436|NCT02702687|BEHAVIORAL|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
58423437|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
58423438|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
58423439|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
58423440|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
58423441|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
58423442|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
58423443|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
58423444|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
58423445|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
58423446|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
58423447|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
58423448|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
58423449|NCT03201159|DRUG|VLX103|150mg tablets
58423450|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
58423451|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
58423452|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
58096001|NCT05413850|DRUG|177Lu-rhPSMA-10.1 injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
58096002|NCT05413850|DIAGNOSTIC_TEST|18F-rhPSMA-7.3 injection|18F-rhPSMA-7.3 at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
58096003|NCT06236165|DRUG|N-acetylcysteine|Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
58096004|NCT06236165|DRUG|Pentoxifylline|Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
58096005|NCT05312255|BEHAVIORAL|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
58096006|NCT05312255|DRUG|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
58096007|NCT05312255|DRUG|Propranolol|Given PO
58096008|NCT05312255|OTHER|Quality-of-Life Assessment|Ancillary studies
58096009|NCT05312255|OTHER|Questionnaire Administration|Ancillary studies
58096010|NCT05312255|OTHER|Resistance Training|Undergo strength training for 6 months
58096011|NCT05312255|OTHER|Short-Term Fasting|Participate in intermittent fasting
58096012|NCT03713294|DRUG|Dexamethasone|Given IV and PO
58423453|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
58423454|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
58423455|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
58423456|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
58423457|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
58096013|NCT03713294|BIOLOGICAL|Elotuzumab|Given IV
58096014|NCT03713294|DRUG|Pomalidomide|Given PO
58096015|NCT03403712|DRUG|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
58096016|NCT03403712|DRUG|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
58096017|NCT03403712|DRUG|dexamethasone|Oral dexamethasone (12 mg)
58096018|NCT05904769|DEVICE|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
58096019|NCT06410118|BEHAVIORAL|DreamChanger+IRT|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
58096020|NCT02564952|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
58096021|NCT02564952|DRUG|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
58096022|NCT06119373|OTHER|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
58096023|NCT06119373|OTHER|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
58096024|NCT01022177|PROCEDURE|acupuncture|acupuncture of the eye in traditional chinese schematics
58096025|NCT01465074|DRUG|Nicotine polacrilex|4 mg
58096026|NCT01465074|DRUG|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
58096027|NCT00685048|BEHAVIORAL|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
58096028|NCT00685048|BEHAVIORAL|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
58096029|NCT00685048|BEHAVIORAL|four 50-minute individual therapy sessions of MET & CBT|MET \& CBT
58423458|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
58423459|NCT02418104|DRUG|CHS-1701|
58423460|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
58423461|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
58096030|NCT02543515|PROCEDURE|office hysteroscopy|diagnostic procedure
58096031|NCT01770639|PROCEDURE|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
58096032|NCT01879709|BEHAVIORAL|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
58096033|NCT01879709|BEHAVIORAL|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
58423462|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
58423463|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
58423464|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
58423465|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
57735673|NCT02975167|OTHER|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
58096034|NCT01879709|OTHER|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
58096035|NCT05166655|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
58096036|NCT06393738|DRUG|ARV-393|Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
58096037|NCT00833976|DRUG|Lovaza|4 grams per day
58096038|NCT03127943|DRUG|Lidocaine|Efficacy for mandibular molar and canine anesthesia
58096039|NCT04250896|OTHER|Control group|Standard child care in health unit plus exposure to EsIAN
58096040|NCT04250896|BEHAVIORAL|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
58423466|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
58423467|NCT05340166|PROCEDURE|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
58423468|NCT05340166|PROCEDURE|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
58423469|NCT00002140|DRUG|Ethambutol hydrochloride|
58423470|NCT00002140|DRUG|Clarithromycin|
58423471|NCT00002140|DRUG|Azithromycin|
58096041|NCT06083220|BEHAVIORAL|Smart Start - School Readiness Program|Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
58423472|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
58423473|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
58423474|NCT04519060|DEVICE|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
58423475|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
58423476|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
58423477|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
58423478|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
58096042|NCT05617625|DRUG|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
58096043|NCT05617625|DRUG|Melphalan|70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
58096044|NCT05617625|DRUG|Fludarabine|25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
58096045|NCT05617625|DEVICE|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
58096046|NCT06204536|OTHER|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
58096047|NCT05221476|OTHER|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
58096048|NCT00378482|DRUG|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
58096049|NCT06283771|OTHER|Heated socks to be developed with wearable technology|The study group will wear heated socks to be developed with wearable technology
58096050|NCT03967418|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
58096051|NCT05137262|OTHER|Abiraterone acetate|Given by IV
58096052|NCT05137262|DRUG|Durvalumab|Given by IV
58096053|NCT05137262|DRUG|Methotrexate|Given by IV
58096054|NCT05137262|DRUG|Vinblastine|Given by IV
58423479|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
58423480|NCT01761812|OTHER|MRI with gadofosveset and MR elastography|
58423481|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
58423482|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
58423483|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
58423484|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
58423485|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
58423486|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
58423487|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
58423488|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
58423489|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
58423490|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
58423491|NCT05579769|DRUG|Bone marrow infusion|Day 0
58423492|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
58423493|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
58423494|NCT05463991|DEVICE|Bioengineered collagen implant|Urethral stricture repair
58423495|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
58423496|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
58423497|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
58423498|NCT02708420|DEVICE|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
58423499|NCT02708420|DEVICE|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
58423500|NCT06312241|BEHAVIORAL|Metacognitive Training-Silver BeWell|Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
58423501|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
58096055|NCT05137262|DRUG|Doxorubicin Hydrochloride|Given by IV
58096056|NCT05137262|DRUG|Cisplatin|Given by IV
58096057|NCT04920565|DEVICE|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
58423502|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
58423503|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
58423504|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
58423505|NCT02461888|DRUG|Ixazomib|Chemotherapy
58423506|NCT02461888|DRUG|Cyclophosphamide|Chemotherapy
58423507|NCT02461888|DRUG|Dexamethasone|Chemotherapy
58096058|NCT06233175|OTHER|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
58096059|NCT06233175|OTHER|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
58423508|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
58423509|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
58423510|NCT01536808|OTHER|Analysis telomere|Analysis telomere
58423511|NCT01536808|OTHER|Stress test|Stress test
58423512|NCT01536808|OTHER|echocardiography|echocardiography
58423513|NCT00933894|DRUG|Telaprevir; Escitalopram|
58423514|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
58423515|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
58096060|NCT01635127|DRUG|Canakinumab|150mg s.c.
58096061|NCT01635127|DRUG|Placebo|Constituent of canakinumab
58096062|NCT04864847|DIAGNOSTIC_TEST|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
58096063|NCT06012175|DIETARY_SUPPLEMENT|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
58423516|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
58423517|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
57735674|NCT02975167|OTHER|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
57735675|NCT02975167|PROCEDURE|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
57735676|NCT02975167|BEHAVIORAL|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
58423518|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
58423519|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
58423520|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
58423521|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
58423522|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
58423523|NCT00306644|DRUG|Rosiglitazone|study drug
58423524|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
58096064|NCT06012175|DIETARY_SUPPLEMENT|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
58096065|NCT05090722|DEVICE|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
58096066|NCT06056531|OTHER|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
58096067|NCT06056531|OTHER|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
58096068|NCT05442515|BIOLOGICAL|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
58096069|NCT05442515|DRUG|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
58096070|NCT05442515|DRUG|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
58096071|NCT05802342|DRUG|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
58096072|NCT01057160|DRUG|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
58423525|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
58423526|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
58423527|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
58096073|NCT03105089|PROCEDURE|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
58096074|NCT00704990|DIETARY_SUPPLEMENT|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
58096075|NCT03105882|DEVICE|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
58096076|NCT06701110|DRUG|[U-14C] WX-081|A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
58096077|NCT04199104|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
58096078|NCT04199104|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
58096079|NCT04199104|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
58096080|NCT00689273|DRUG|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
58423528|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
58423529|NCT00751855|DRUG|placebo|placebo
58423530|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
58096081|NCT00689273|DRUG|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
58423531|NCT00857519|DRUG|Melphalan, Carboplatin|Intra-arterial chemotherapy.
58423532|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
58423533|NCT02983994|DEVICE|TURBUHALER®|
58423534|NCT02983994|DEVICE|SPIROMAX®|
58096082|NCT04060927|DEVICE|SGRT|Surface Guided Radiation Therapy
58096083|NCT03904498|DRUG|Tolcapone|Tolcapone 100 mg tablets
58096084|NCT03904498|DRUG|Placebo|Placebo tablets
58096085|NCT00028938|BIOLOGICAL|epoetin alfa|
58096086|NCT00028938|DRUG|carboplatin|
58096087|NCT00028938|DRUG|paclitaxel|
58096088|NCT00028938|RADIATION|radiation therapy|
58423535|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
58423536|NCT01979939|DRUG|DCV/ASV/BMS-791325|
58423537|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
58423538|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
58423539|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
58423540|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
58423541|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
58423542|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
58423543|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
58423544|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
58096089|NCT02858167|DEVICE|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
58096090|NCT00883259|DRUG|Metformin|850 mg twice daily
58096091|NCT00883259|OTHER|Placebo|Microcristallyne cellulose 1 table twice daily
58096092|NCT03633773|BIOLOGICAL|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
58096093|NCT04808427|DEVICE|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
58096094|NCT01612052|DRUG|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
58096095|NCT06360523|DIAGNOSTIC_TEST|AI modal|The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
58096096|NCT06360523|DIAGNOSTIC_TEST|Standard review|The MRI image will be reviewed by radiologist.
58096097|NCT04586023|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
58096098|NCT04586023|DRUG|Teriflunomide|Participants will receive teriflunomide.
58096099|NCT04586023|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
58096100|NCT00597727|DRUG|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
58096101|NCT00597727|DRUG|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
58096102|NCT06442137|DRUG|Chazhu Xiaozhi decoction|Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
58096103|NCT06442137|DRUG|Control placebo|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
58096104|NCT02987504|DRUG|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
58096105|NCT05485571|DEVICE|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
58096106|NCT06234605|DRUG|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
58096107|NCT06234605|DRUG|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
58096108|NCT02367781|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
58096109|NCT02367781|DRUG|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
58096110|NCT02367781|DRUG|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
58423545|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
58423546|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
58423547|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
58423548|NCT00903331|DRUG|Placebo|matching placebo, once daily
58423549|NCT02174744|OTHER|numeric pain rating scale|
58423550|NCT02745535|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|
58423551|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
58423552|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
58423553|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
58096111|NCT02367781|DRUG|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
58096112|NCT06410573|BEHAVIORAL|Breast Self-Examination and Practice|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
58096113|NCT04323449|DEVICE|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
58096114|NCT05327023|PROCEDURE|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
58096115|NCT05327023|DRUG|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
58096116|NCT05327023|DRUG|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
58096117|NCT05327023|DRUG|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
58423554|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
58423555|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
58423556|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
58423557|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
58096118|NCT05327023|DRUG|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
58096119|NCT05327023|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
58096120|NCT04820335|BEHAVIORAL|Structured External Memory Aid Treatment (SEMAT)|"During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase."
58096121|NCT01365676|DRUG|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
58096122|NCT01365676|DRUG|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
58096123|NCT04000529|DRUG|TNO155|Capsule
58096124|NCT04000529|DRUG|Spartalizumab|Concentrate for solution for infusion
58096125|NCT04000529|DRUG|Ribociclib|Capsule and tablet
58096126|NCT06562335|OTHER|Booster|See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
58096127|NCT06568354|OTHER|Yoga|The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
58096128|NCT06568354|OTHER|Motor control exercises|Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
58096129|NCT03539939|PROCEDURE|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
58096130|NCT03086980|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
58096131|NCT03086980|OTHER|Treatment as Usual|Usual Care will be provided.
58096132|NCT04715737|DRUG|Vasopressin|Administration of vasopressin (20IU) intranasally
58096133|NCT04715737|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
58096134|NCT04715737|DRUG|Placebo|Administration of placebo intranasally
58096135|NCT03622086|OTHER|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
58096136|NCT06588413|DRUG|Olanzapine|Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
58096137|NCT04190966|BEHAVIORAL|Integrated Behavioural therapy|Integrated smoking cessation behavioural therapy
58096138|NCT04190966|DRUG|Integrated Pharmacotherapy|Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
58096139|NCT04190966|DEVICE|Integrated Web-based application|Integrated smoking cessation web-based application
58096140|NCT02360124|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
58096141|NCT02360124|OTHER|Water as placebo|topical application of water as a placebo in the control arm
58096142|NCT02360124|OTHER|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
58096143|NCT01406769|PROCEDURE|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
58096144|NCT01406769|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
58096145|NCT01406769|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
58096146|NCT04723173|DEVICE|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
58096147|NCT04723173|DEVICE|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
58423558|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
58423559|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
58423560|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
58423561|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
58423562|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
58423563|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
57735677|NCT02975167|BEHAVIORAL|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
58423564|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
57951423|NCT05644028|BEHAVIORAL|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
58096148|NCT06520722|DIAGNOSTIC_TEST|Prolapse scoring system|"A FIXED APCD classification system :~A: Associated symptoms:~FIXED:~F: frequency I: infection X: sex problems E: everted mass(external protrusion of mass from the valva as PV lump sensation ,heaviness,itching and ulceration) D: digitation(patient need to digitate to complete the act of micturation or defecation)~APCD:~A: Dependent point on anterior wall. P: Dependent point on posterior wall. C: Cuff point either cervix or vault. Distance to hymen in centimeters (minus above or plus below) after pushing the opposite wall during maximal straining D: Dimensions; base diameter of vestibule/ perineal length.~The staging system will be interpreted as follows:~Normal:~A-3 P-3 C-8 D 2/2~Stages:~0: No prolapse.~A/P-2 OR C-7 to C-2 A,P or C-1 to +1 A,P or C ˃ +1~X component: (alone or with any stage):~Dimension disruption: ˃2 or \<2"
58096149|NCT05340517|PROCEDURE|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
58096150|NCT06544473|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 14 days
58423565|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
58423566|NCT03441503|OTHER|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
58423567|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
58423568|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
58423569|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
58423570|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
58423571|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
58423572|NCT01533922|DEVICE|Respimat|Respimat inhaler
58423573|NCT03258060|PROCEDURE|Temporary pacing study|
58423574|NCT03258060|RADIATION|Body Surface Mapping|
58423575|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
58423576|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
58423577|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
58423578|NCT06292676|OTHER|skills retained for home birth delivery in emergency|skills on mannequin for home birth scenario in emergency
58423579|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
58423580|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
58423581|NCT02846012|OTHER|CSCM2|
58423582|NCT02631265|OTHER|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
58423583|NCT02631265|OTHER|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
58423584|NCT02631265|OTHER|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
58423585|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
58423586|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
58423587|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
58423588|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
58423589|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
58423590|NCT01380704|DRUG|ABT-436|QD Days 1-7
58423591|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
58423592|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
58096151|NCT06544473|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 14 days
58096152|NCT05478499|DRUG|Deucravacitinib|Specified dose on specified days
58096153|NCT05478499|OTHER|Placebo|Specified dose on specified days
58096154|NCT00951899|DRUG|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
58096155|NCT00951899|OTHER|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
58423593|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
58423594|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
58423595|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
58423596|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
58423597|NCT02406729|OTHER|Placebo|Route:subcutaneous
58423598|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
57951424|NCT02024542|OTHER|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
57951425|NCT05504733|DEVICE|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
57951426|NCT05504733|DEVICE|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
57951427|NCT05269485|RADIATION|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
57951428|NCT05269485|RADIATION|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
57951429|NCT00413426|DRUG|Darifenacin (DAR328)|
57951430|NCT01121133|DRUG|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
57951431|NCT01121133|DRUG|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
57951432|NCT02396186|DEVICE|PTCA Balloon Angioplasty|
57951433|NCT02701543|DEVICE|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
57951434|NCT02701543|DEVICE|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
57951435|NCT02386228|GENETIC|collection of CSF and blood|collection of CSF and blood
57951436|NCT02895464|OTHER|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
57951437|NCT03651284|BEHAVIORAL|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
57961397|NCT01610765|DRUG|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
57961398|NCT03296046|BIOLOGICAL|Blood test|30 ml
57961399|NCT05047276|BIOLOGICAL|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
57961400|NCT01888042|DRUG|Everolimus|10 mg (1 tablet of 10 mg)
58423599|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
58096156|NCT00951899|BEHAVIORAL|Diet|Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
58423600|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
58423601|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
58423602|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
58423603|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
58423604|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
58423605|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
58096157|NCT00951899|DRUG|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
58096158|NCT06540183|PROCEDURE|Percutaneous intramyocardial septal radiofrequency ablation|Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) is an innovative minimally invasive ablation treatment. Under the real-time transthoracic echocardiography guidance, a radiofrequency electrode needle is introduced into the hypertrophied interventricular septum via the percutaneous intramyocardial approach. Then the needle tip is pushed to the target region of the interventricular septal (IVS) basal segment 8 to 10 mm from the subaortic valve. The main objective of PIMSRA is to reduce ventricular septal hypertrophy and left ventricular outflow tract obstruction by means of thermal ablation.
58096159|NCT05267184|PROCEDURE|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
58096160|NCT05267184|PROCEDURE|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
58096161|NCT03203265|OTHER|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
58096162|NCT03203265|OTHER|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
58096163|NCT03203265|OTHER|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
58096164|NCT00713622|DRUG|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
58423606|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
58423607|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
58096165|NCT00713622|DRUG|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
58096166|NCT06568900|OTHER|cigarette smoking|continue smoking usual brand of cigarette
58096167|NCT06568900|OTHER|tobacco flavored and unflavored pouch|provide tobacco flavored and unflavored options of nicotine pouch
58096168|NCT06568900|OTHER|unrestricted flavor options pouch|provide unrestricted flavor options of nicotine pouch
58423608|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
58423609|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
58423610|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
58096169|NCT03610646|DRUG|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
58096170|NCT03610646|DRUG|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
58096171|NCT03582059|PROCEDURE|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
58423611|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
58423612|NCT00114088|PROCEDURE|hysterectomy|
58423613|NCT00114088|PROCEDURE|endometrial ablation|
58423614|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
58096172|NCT03582059|PROCEDURE|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
58423615|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
58096173|NCT04012008|OTHER|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
58096174|NCT04012008|OTHER|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
58096175|NCT00696631|DRUG|Dronedarone (SR33589)|oral administration
58096176|NCT00696631|DRUG|Placebo|oral administration
58096177|NCT01732666|DRUG|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
58096178|NCT01732666|DRUG|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
58096179|NCT01732666|DRUG|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
58096180|NCT02816749|PROCEDURE|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
58096181|NCT02816749|PROCEDURE|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
58096182|NCT03216681|DRUG|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
57951438|NCT03651284|BEHAVIORAL|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
58096183|NCT03216681|DRUG|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
58096184|NCT02594137|PROCEDURE|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
58096185|NCT02719015|DRUG|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
58096186|NCT02719015|DRUG|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
58423616|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
57951439|NCT05171257|DRUG|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
57951440|NCT05171257|DRUG|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
58096187|NCT04253379|DIAGNOSTIC_TEST|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
58096188|NCT05494580|DRUG|Pamiparib|Oral
58423617|NCT03713541|OTHER|No intervention|Survey during normal supply.
58423618|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
58423619|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
58423620|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
58423621|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
58423622|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
58423623|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
58423624|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
57951441|NCT01803243|OTHER|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
58423625|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
57951442|NCT01803243|OTHER|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
58096189|NCT05494580|DRUG|Surufatinib|Oral
58423626|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
58096190|NCT02275039|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
58096191|NCT02275039|DRUG|gemcitabine hydrochloride|Given IV
58096192|NCT02275039|OTHER|laboratory biomarker analysis|Correlative studies
58423627|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
58423628|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
58423629|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
58423630|NCT02378207|BIOLOGICAL|BCG|
58423631|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
58423632|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
58423633|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
58423634|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
58423635|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58423636|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
58423637|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
58423638|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58423639|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
58423640|NCT06464419|DEVICE|ultrasound|Measurement of optic nerve sheath diameter by ultrasound
58423641|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
58423642|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
58423643|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
57951443|NCT01803243|OTHER|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
57951444|NCT00390754|BEHAVIORAL|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
58096193|NCT06536582|BIOLOGICAL|Platelet rich growth factor injection (autologous product)|All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
58423644|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
58423645|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
58423646|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
58423647|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
58423648|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
58423649|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
58423650|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
58423651|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
58423652|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
58423653|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
58423654|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
58423655|NCT00290667|BIOLOGICAL|pegfilgrastim|
57735678|NCT02975167|PROCEDURE|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
57951445|NCT02199080|OTHER|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
58423656|NCT00290667|BIOLOGICAL|rituximab|
58423657|NCT00290667|DRUG|cyclophosphamide|
58423658|NCT00290667|DRUG|doxorubicin hydrochloride|
58423659|NCT00290667|DRUG|prednisone|
58423660|NCT00290667|DRUG|vincristine sulfate|
58423661|NCT00290667|OTHER|pharmacological study|
58423662|NCT00290667|RADIATION|radiation therapy|
58423663|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
58423664|NCT05071430|DRUG|Placebo|HB-1 matched placebo
58423665|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
58423666|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
58423667|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
58423668|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
58423669|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
58423670|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
58423671|NCT00439881|DRUG|SB-681323|
58423672|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
58423673|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
58423674|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
58423675|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
58423676|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
58423677|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
58423678|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
58423679|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
58423680|NCT04429399|OTHER|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
58423681|NCT04429399|OTHER|mechanical features assessment|evaluation of the mechanical features of respiratory system
57735679|NCT05461625|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction
57951446|NCT04938583|BIOLOGICAL|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
57951447|NCT04938583|DRUG|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
58423682|NCT04429399|OTHER|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
58423683|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
57735680|NCT05461625|OTHER|ALL anatomic|anatomic anterolateral ligament reconstruction
57735681|NCT05461625|OTHER|ALL tenodesis|anterolateral ligament teondesis
58423684|NCT06194500|DRUG|LY3549492|Administered orally.
58423685|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
58423686|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
58423687|NCT02412059|DRUG|Prednisolone acetate|
58096194|NCT05302414|BEHAVIORAL|Board game-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a board game-based teaching approach.
58096195|NCT05302414|BEHAVIORAL|Simulation-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a simulation-based teaching approach.
58096196|NCT05302414|BEHAVIORAL|Lecture-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through an interactive lecture-based approach.
58096197|NCT04895696|DRUG|Afimetoran|Specified dose on specified days
58096198|NCT04895696|OTHER|Placebo|Specified dose on specified days
58096199|NCT05810974|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
58096200|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
58096201|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
58096202|NCT05207176|DRUG|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
58096203|NCT01336218|DRUG|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
58096204|NCT01336218|DRUG|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
58096205|NCT06399263|DRUG|Psilocybin|The psilocybin will include two dose administration sessions, first a 20mg administration, and second a 30mg administration.
58096206|NCT06399263|BEHAVIORAL|Preparation and Integration Sessions|The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.
58423688|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
58423689|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
58423690|NCT03755661|BEHAVIORAL|MI&TXT4MSM|brief in-person intervention followed by text messaging
57951448|NCT04938583|DRUG|Paclitaxel|175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
57951449|NCT04938583|DRUG|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
57951450|NCT04319133|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
57951451|NCT01353027|DRUG|Placebo|Normal saline
57951452|NCT01353027|DRUG|AVI-6002|Single intravenous administration
57951453|NCT00003462|DRUG|busulfan|
57951454|NCT03709173|BEHAVIORAL|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
57951455|NCT05382637|DRUG|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
57951456|NCT04686721|DIAGNOSTIC_TEST|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
57951457|NCT03512600|DIETARY_SUPPLEMENT|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
57951458|NCT03512600|DIETARY_SUPPLEMENT|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
57951459|NCT03512600|DIETARY_SUPPLEMENT|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
57951460|NCT03512600|DIETARY_SUPPLEMENT|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
57951461|NCT01530984|DRUG|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
57951462|NCT01530984|DRUG|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
58423691|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
58423692|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
58423693|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
58423694|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
58423695|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
58423696|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
58096207|NCT06393816|DRUG|Durvalumab with etoposide and Carboplatin/Cisplatin|"Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months"
58096208|NCT01528046|DRUG|Vincristine|Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
58096209|NCT01528046|DRUG|Irinotecan|Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
58423697|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
58423698|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
58423699|NCT02126007|BEHAVIORAL|Sleep and Rhythm Intervention|
58423700|NCT02126007|BEHAVIORAL|Dietary Modifications|
58423701|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
58423702|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
57735682|NCT05745077|BEHAVIORAL|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
58423703|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
57735683|NCT05745077|BEHAVIORAL|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
58096210|NCT01528046|DRUG|Temozolomide|Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
58096211|NCT01528046|DRUG|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
58096212|NCT02484404|DRUG|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
58096213|NCT02484404|DRUG|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
58096214|NCT02484404|DRUG|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
58096215|NCT05864235|BEHAVIORAL|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
58096216|NCT05864235|BEHAVIORAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
58096217|NCT05864235|BEHAVIORAL|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
58096218|NCT00547807|OTHER|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
58423704|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
58423705|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
58423706|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
58423707|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
58423708|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
58423709|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
58423710|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
58423711|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
58423712|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
58423713|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
58423714|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
58096219|NCT00547807|OTHER|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
58423715|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
58423716|NCT01975610|DRUG|Placebo|Twice daily for 28 days
58423717|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
58423718|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
58423719|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
58423720|NCT02343705|DEVICE|Latella Knee Implant System|
58423721|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
58423722|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
58423723|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
58096220|NCT06515496|DIETARY_SUPPLEMENT|Scale HLV Clinical Formula Hair Vitamins|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
58096221|NCT06515496|OTHER|Placebo|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
58096222|NCT01432782|DRUG|Placebo|Saline 4 ml
58096223|NCT01432782|DRUG|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
58096224|NCT06492018|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
58096225|NCT03291847|DEVICE|fetal monitoring|Maternal fetal monitoring
58096226|NCT03291847|DRUG|Buprenorphine Naloxone|Treatment for opioid use disorder
58096227|NCT05884333|DRUG|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
58096228|NCT05884333|BIOLOGICAL|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
58096229|NCT04201834|DRUG|Risperidone|capsule or tablet, 0.5 mg
58096230|NCT04201834|DEVICE|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
58096231|NCT00357565|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
58096232|NCT00357565|DRUG|busulfan|Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
58096233|NCT00357565|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
58096234|NCT00357565|DRUG|fludarabine phosphate|Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
58096235|NCT00357565|DRUG|melphalan|Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
58423724|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
58096236|NCT00357565|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
58096237|NCT00357565|PROCEDURE|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
58096238|NCT05951959|DRUG|Acalabrutinib|Investigational Product
58096239|NCT05951959|DRUG|Venetoclax|Investigator Product
58096240|NCT05951959|DRUG|Rituximab|Investigator Product
58423725|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
58423726|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
58423727|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
58423728|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
58423729|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
58423730|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
58096241|NCT06352840|BEHAVIORAL|My Pelvic Plan Website|This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.
58423731|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
58423732|NCT00538993|BEHAVIORAL|Stage based counseling|
58423733|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
58423734|NCT02667756|OTHER|Non-interventional|
58423735|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
58423736|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
58423737|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
58423738|NCT03639142|OTHER|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
58423739|NCT03639142|DRUG|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
58423740|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
58423741|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
58423742|NCT02032654|DRUG|Flucloxacillin|
58423743|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
58423744|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
58423745|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
58423746|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
58096242|NCT06352840|BEHAVIORAL|Control Group website|Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
58096243|NCT02557568|OTHER|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
58096244|NCT00279149|PROCEDURE|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
58423747|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
58423748|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
58423749|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
58423750|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
58423751|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
57735684|NCT01357967|DRUG|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
58423752|NCT04397458|DRUG|Saline|0.9% saline on each side
58423753|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
58423754|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
58423755|NCT02920723|OTHER|Training|
58423756|NCT02920723|OTHER|Control|
58423757|NCT02138357|DRUG|buprenorphine transdermal delivery system (BTDS)|
58423758|NCT02138357|DRUG|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
58423759|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
58423760|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
58423761|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
58423762|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
58423763|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
58423764|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
58423765|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
58423766|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
58423767|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
57735685|NCT01357967|DRUG|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime"
57735686|NCT02483169|DRUG|cilostazol|Cilostazol 100mg bid
57735687|NCT02483169|DRUG|Probucol|Probucol 250mg bid
58096245|NCT06235645|DIAGNOSTIC_TEST|Lung ultrasound (LUS)|"If included, an LUS will be performed by an experienced operator, blinded to the results of the chest CT and PFT.~A linear probe (4 to 12 MHz) will be used. The patient will be installed́ in a semi-seated position with the homolateral arm above the head for the anterior and axillary evaluation then, depending on his comfort, in a seated position or in right then left lateral decubitus, arms alongside the body, for the posterior evaluation. It will be practiced by experienced operators (pneumologist) and according to a validated protocol allowing the exploration of 14 intercostal spaces. LUT will be timed, recorded and anonymized.~The operator will note the 3 ultrasound signs (total number of B lines, pleural line thickening and percentage of pleural line irregularity), their location and severity.~The radiologist, on his part, will evaluate the patient's chest CT (gold standard), blinded to the results of the LUS, to make or not the diagnosis of RA-ILD."
57735688|NCT02483169|DRUG|Aspirin|Aspirin 100mg qd
58096246|NCT06703099|DIETARY_SUPPLEMENT|Magnesium Supplementation|Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning over 8 weeks.
58096247|NCT06438354|BIOLOGICAL|subgingival instrumentation plus Perisolv / hyaDent BG|Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.
58096248|NCT06438354|PROCEDURE|subgingival instrumentation|Group B: sites requiring re-treatment are subjected to subgingival scaling
58096249|NCT00590785|DRUG|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
58096250|NCT00590785|DRUG|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
58096251|NCT00590785|DRUG|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
58096252|NCT00590785|DRUG|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
58096253|NCT00590785|DRUG|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
58096254|NCT00981409|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
58096255|NCT00981409|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
58096256|NCT04933903|DRUG|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
58096257|NCT04933903|DRUG|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
58096258|NCT04933903|RADIATION|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
58096259|NCT00759174|DRUG|No intervention|No intervention occurs in this observational study.
58096260|NCT05875064|COMBINATION_PRODUCT|Restoration with resin composite and polyvinyl crown|Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
58096261|NCT05875064|PROCEDURE|Restoration with conventional resin composite|Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
58096262|NCT00593099|DRUG|Bupropion|BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
58096263|NCT00593099|DRUG|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
58096264|NCT03785600|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
58096265|NCT03785600|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
58096266|NCT00174473|DRUG|Voriconazole|
58096267|NCT03405389|PROCEDURE|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
58096268|NCT01468974|DEVICE|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
57735689|NCT02483169|DRUG|placebo of cilostazol|same shape and size of active cilostazol
57735690|NCT02483169|DRUG|Placebo of aspirin|same size and shape of active aspirin 100mg
57735691|NCT02483169|DEVICE|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
58096269|NCT03128047|DEVICE|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.
58096270|NCT02793375|DRUG|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
58096271|NCT02793375|DRUG|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
58423768|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
57951463|NCT01226550|PROCEDURE|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
57951464|NCT05802719|OTHER|Blood sampling|"The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy"
57951465|NCT01040455|DRUG|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
57951466|NCT01040455|DRUG|placebo|placebo once daily for eight weeks
57951467|NCT00153114|DRUG|polyethyleneglycol3350|
57951468|NCT03443908|DEVICE|CPAP|CPAP therapy 3-4 weeks
57951469|NCT04431570|DEVICE|rTMS|The device is made in London, United Kingdom
57951470|NCT04431570|DEVICE|sham stimulation|the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
57951471|NCT03171207|DEVICE|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
57951472|NCT03171207|DEVICE|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
57951473|NCT04481542|DIAGNOSTIC_TEST|MRI|check MRI quality in aorta
57951474|NCT06387407|DRUG|Dabigatran Etexilate 150mg|Oral dabigatran etexilate capsules, 150 mg twice a day.
57951475|NCT02202876|OTHER|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
57951476|NCT02202876|OTHER|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
57951477|NCT02202876|OTHER|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
57951478|NCT02202876|OTHER|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
57951479|NCT02202876|OTHER|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
57951480|NCT05572047|DEVICE|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
57951481|NCT03238859|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
57951482|NCT03238859|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
57951483|NCT02915523|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACi).
58096272|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
58423769|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
58423770|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
57951484|NCT02915523|DRUG|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
57951485|NCT02915523|DRUG|Placebo|A pill containing no active drug ingredient.
57951486|NCT01118351|DRUG|sunitinib malate|Given orally
57951487|NCT01118351|OTHER|immunohistochemistry staining method|Correlative studies
57951488|NCT01118351|OTHER|TdT-mediated dUTP nick end labeling assay|Correlative studies
57951489|NCT01118351|OTHER|light microscopy|Correlative studies
57951490|NCT01118351|OTHER|laboratory biomarker analysis|Correlative studies
57951491|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
57951492|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
57951493|NCT00644787|DRUG|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
57951494|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
57951495|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
57951496|NCT06355765|DIETARY_SUPPLEMENT|Citicoline blackcurrant supplement|Citicoline, Vitamins A, B, C and E, and Blackcurrant
57951497|NCT01279577|DRUG|Low dose TSO|Low dose TSO suspension
57951498|NCT01279577|DRUG|Medium dose TSO|Medium dose TSO suspension
57951499|NCT01279577|DRUG|High dose TSO|High dose TSO suspension
58423771|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
57951500|NCT01279577|DRUG|Placebo|Placebo solution
57735692|NCT06556927|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
57735693|NCT01643694|BEHAVIORAL|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
57735694|NCT05707637|OTHER|Ablation|Unipolar and bipolar ablation
58423772|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
58423773|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
58423774|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
58423775|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
58423776|NCT00358839|DRUG|CGRP|
58423777|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
58423778|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
58423779|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
58423780|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
58423781|NCT06546072|OTHER|MRI|
58423782|NCT05362474|DRUG|Montelukast|10mg orally once a day
58423783|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
58423784|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
58423785|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
58423786|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
58423787|NCT01992562|DRUG|Ziconotide|
58423788|NCT01992562|DRUG|placebo|
58423789|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
58423790|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
57735695|NCT00249236|DRUG|Risperidone, oral tablets|
58423791|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
58423792|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
58423793|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
58423794|NCT01170078|DRUG|Epogen|IV dose 3 times a week
58423795|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
58423796|NCT01132586|DRUG|Lenalidomide|Given PO
58423797|NCT01132586|DRUG|Cytarabine|Given IV
58423798|NCT01132586|DRUG|Idarubicin|Given IV
58423799|NCT01132586|OTHER|Pharmacological Study|Correlative studies
58423800|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
58423801|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
58423802|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
57735696|NCT06485310|OTHER|Teleconsultation for psychological support|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
58096273|NCT05756413|BEHAVIORAL|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
58423803|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
58423804|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
58423805|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
58423806|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
58423807|NCT03802903|DEVICE|Remo-Wax|topical treatment
58423808|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
58423809|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
58423810|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
58423811|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
58423812|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
58423813|NCT05548062|OTHER|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
58423814|NCT05548062|OTHER|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
58423815|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
57735697|NCT02496013|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
57735698|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
57735699|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
57735700|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
57735701|NCT01064037|DRUG|Placebo|Infusion during 48h
57735702|NCT02302729|DIETARY_SUPPLEMENT|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
58096274|NCT05847504|BEHAVIORAL|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
58423816|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
58423817|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
58423818|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
58423819|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
58423820|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
58423821|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
58423822|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
58423823|NCT05848765|DRUG|Rituximab|Monoclonal antibody
58423824|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
58423825|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
58423826|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
58423827|NCT05848765|DRUG|Doxorubicin|Anthracycline
58423828|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
57735703|NCT02302729|BEHAVIORAL|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
57735704|NCT02302729|DIETARY_SUPPLEMENT|Placebo|Riboflavin Vitamin B2
57951501|NCT01862042|OTHER|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
57951502|NCT05289635|PROCEDURE|different suture types|For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
57951503|NCT06244758|DRUG|Finerenone 20 MG Oral Tablet|The intervention is administered orally.
57951504|NCT06244758|DRUG|Placebo|The intervention is administered orally.
57951505|NCT04071184|DRUG|Alofanib|Five dose cohorts and expanded cohort will be included
58423829|NCT05848765|DRUG|Prednisone|Corticosteroid
58423830|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
58423831|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
58423832|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
58423833|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
58423834|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
58423835|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
58423836|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
58423837|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
58423838|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
58423839|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
58423840|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
58423841|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
58423842|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
58423843|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
58423844|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
58423845|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
58423846|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
58423847|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
58423848|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
58423849|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
58423850|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
58423851|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
58423852|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
57951506|NCT04737655|DRUG|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
58096275|NCT04961112|DEVICE|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
58096276|NCT04961112|DEVICE|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
58096277|NCT01931501|DRUG|Torrent's Montelukast Sodium Chewable Tablets 5mg|
58096278|NCT01931501|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
58096279|NCT06267118|DRUG|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
58096280|NCT06267118|DRUG|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
58423853|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
58423854|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
58423855|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
58423856|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
58423857|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
58423858|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
58423859|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
58423860|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
58423861|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
58423862|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
58423863|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
58423864|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
58423865|NCT02310997|DRUG|Cyclophosphamide|
58423866|NCT02310997|RADIATION|Total body irradiation|
58423867|NCT02310997|DRUG|Busulfan|
58423868|NCT02310997|DRUG|Melphalan|
58423869|NCT02310997|DRUG|Fludarabine|
58423870|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
58423871|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
58423872|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
58423873|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
58423874|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
58423875|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
58423876|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
58423877|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
58423878|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
58423879|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
58423880|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
58423881|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
58423882|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
58423883|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
58423884|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
58423885|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
58423886|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
57735705|NCT03627481|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
58423887|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
58423888|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
58423889|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
58423890|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
58423891|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
58423892|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
58423893|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
58423894|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
58423895|NCT02495454|DRUG|Ga101|
57735706|NCT05093231|DRUG|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
57735707|NCT05093231|DRUG|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
57735708|NCT01155544|BEHAVIORAL|Behavioral Intervention|Preventing recurrence of substance use.
57735709|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
57735710|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (90 mg) by single SC injection every other week
58423896|NCT02643589|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
58423897|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
58423898|NCT00127309|DRUG|Glutathione|
58423899|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
58423900|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
58423901|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
58423902|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
58423903|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
58423904|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
58423905|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
58423906|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
58423907|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
58423908|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
58423909|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
58423910|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
58423911|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
58423912|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
57735711|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week
58423913|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
58423914|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
58423915|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
57735712|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
57735713|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
57951507|NCT00360594|DRUG|Acamprosate|3 pills (666 mg) for 1998mg/day
58096281|NCT06547814|BEHAVIORAL|Standard implementation webinar and online training|The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, vaccine eligibility, mechanisms of action, and outcomes. The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.
58423916|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
58423917|NCT02297555|DEVICE|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
58423918|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
58423919|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
57951508|NCT00360594|DRUG|Placebo|3 pills (666mg) for 1998mg/day
57951509|NCT04061421|DRUG|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
58423920|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
58423921|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
58423922|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
58423923|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
58423924|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
58423925|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
58423926|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
58423927|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
58423928|NCT01932255|PROCEDURE|prophylactic spinal tap|
57735714|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
58423929|NCT01932255|PROCEDURE|no prophylactic spinal tap|
58423930|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
57735715|NCT06015854|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
57951510|NCT04061421|DRUG|Itacitinib|Taken by mouth daily during each 28-day cycle
57951511|NCT02980224|DRUG|OmegaD|OmegaD Softgels
57951512|NCT02980224|DRUG|Placebo|Placebo Softgels
57951513|NCT05595824|DRUG|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
58423931|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
58423932|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
58423933|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
58423934|NCT02048371|DRUG|Placebo|21 days on and 7 days off
58423935|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
58423936|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
58423937|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline"
58096282|NCT06547814|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and at least 8, 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
58423938|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline"
58423939|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution"
58423940|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution"
58423941|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
58423942|NCT00544284|DRUG|bortezomib|
58423943|NCT00544284|DRUG|temozolomide|
58423944|NCT00544284|OTHER|pharmacological study|
58423945|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
58423946|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
58423947|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
58423948|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
58423949|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
58423950|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
58423951|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
58423952|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
58423953|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
58423954|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
58423955|NCT00208520|DRUG|Carbamazepine|
58423956|NCT00208520|DRUG|Lamotrigine|
58423957|NCT00208520|DRUG|Levetiracetam|
57951514|NCT05595824|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
58096283|NCT01986400|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
58096284|NCT00060489|DRUG|SEROQUEL (quetiapine fumarate) Tablets|
58096285|NCT04862650|DRUG|Carboplatin|Given IV
58423958|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
58423959|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
57951515|NCT00258674|OTHER|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
58423960|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
58423961|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
58423962|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
58423963|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
58423964|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
58423965|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
58423966|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
58423967|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
58096286|NCT04862650|BIOLOGICAL|Cemiplimab|Given IV
58096287|NCT04862650|DRUG|Paclitaxel|Given IV
58096288|NCT06350331|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
58096289|NCT01579292|BEHAVIORAL|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
58423968|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
58096290|NCT01579292|BEHAVIORAL|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
58096291|NCT05290272|DEVICE|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
58096292|NCT06251154|DEVICE|Lens 1|Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
58423969|NCT03395002|DRUG|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
58423970|NCT03395002|DRUG|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
58423971|NCT03395002|DRUG|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
58423972|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
58423973|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
58423974|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
58096293|NCT06251154|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
58423975|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
58096294|NCT01687400|DRUG|decitabine|
58096295|NCT05076617|DRUG|Staccato alprazolam|"* Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
58096296|NCT00445458|DRUG|HKI-272|
58096297|NCT00445458|DRUG|Paclitaxel|
58423976|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
58423977|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
58096298|NCT03742245|DRUG|Olaparib|PARP inhibitor
58096299|NCT03742245|DRUG|Vorinostat|HDAC inhibitor
58096300|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with novel Dynamic Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.
58096301|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with Standard Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
58096302|NCT04425369|PROCEDURE|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
58423978|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
58423979|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
58423980|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
58096303|NCT05399186|OTHER|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
58423981|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
58423982|NCT01009177|DRUG|Placebo|Placebo
58423983|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
58423984|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
58423985|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
58423986|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
58423987|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
58423988|NCT01694979|OTHER|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
58423989|NCT01694979|OTHER|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
58423990|NCT01694979|OTHER|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
58423991|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
58423992|NCT00638976|DRUG|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
58423993|NCT00638976|DRUG|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
58423994|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
58423995|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
58423996|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
58423997|NCT01264770|DRUG|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
58423998|NCT01264770|DRUG|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
58096304|NCT05083091|BEHAVIORAL|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
58096305|NCT05083091|BEHAVIORAL|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
58423999|NCT02671565|DRUG|Hyaluronic Acid injections|
58424000|NCT03238924|DRUG|Oxytocin|40 IU oxytocin nasal spray, self-administered
58424001|NCT03238924|DRUG|Placebos|Saline nasal spray, self-administered
58096306|NCT05083091|BEHAVIORAL|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
58096307|NCT05350358|DEVICE|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
58096308|NCT06612255|DRUG|Delafloxacin|Delafloxacin tablet
58096309|NCT06612255|DRUG|Delafloxacin Powder|Delafloxacin powder for oral suspension formulation
58424002|NCT05073198|OTHER|Education brochure|In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
57951516|NCT00258674|OTHER|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
58424003|NCT06094400|OTHER|Meditation|Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.
58424004|NCT06094400|OTHER|Control|Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
58424005|NCT03718858|PROCEDURE|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
58424006|NCT03718858|PROCEDURE|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
58424007|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
58424008|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
58424009|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
58424010|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
58424011|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
58424012|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
58424013|NCT00491881|BEHAVIORAL|no added salt diet|
58424014|NCT01872013|DRUG|ASP7991|oral
58424015|NCT01872013|DRUG|Placebo|oral
57735716|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
57735717|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
58096310|NCT06703073|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
58096311|NCT06703073|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
58096312|NCT06703073|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
58096313|NCT06703073|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
58096314|NCT06703073|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
58096315|NCT06703073|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
58424016|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
58096316|NCT06297941|DRUG|REM-422|"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"
58096317|NCT06123494|DRUG|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
58096318|NCT06123494|DRUG|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
58096319|NCT06701396|DRUG|Tasimelteon|Oral capsule
58424017|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
58096320|NCT06701396|DRUG|Placebo|Oral capsule
58096321|NCT06038149|DIAGNOSTIC_TEST|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
58424018|NCT01281228|DRUG|placebo|saline infusion
58424019|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
58424020|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
58424021|NCT00069355|DRUG|Propranolol|
58424022|NCT02116998|BIOLOGICAL|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
58424023|NCT02116998|BIOLOGICAL|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
58424024|NCT02116998|BIOLOGICAL|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
57951517|NCT00258674|OTHER|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
58424025|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
58424026|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
58424027|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
57951518|NCT00137111|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
58096322|NCT00005879|DRUG|arzoxifene|one tablet daily
58096323|NCT00005879|DRUG|Placebo|matched tablet dialy
58096324|NCT05292313|PROCEDURE|Single distal femur implant|Single implant fixation
58096325|NCT05292313|PROCEDURE|Dual distal femur implants|Dual implant fixation
58096326|NCT00128518|DRUG|Indapamide (T2)|1.5 mg/day during 4 weeks
58096327|NCT00128518|DRUG|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
58096328|NCT00128518|DRUG|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
58096329|NCT00128518|DRUG|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
58096330|NCT06463756|OTHER|AI|"Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis."
58096331|NCT06610279|DRUG|TAK-951|TAK-951 SC injection
58096332|NCT06610279|DRUG|Placebo|TAK-951 matching placebo SC injection
58424028|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
58424029|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
58424030|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
58424031|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
58096333|NCT04451109|DEVICE|Dilapan-S|Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
58096334|NCT04057118|DRUG|SKI-O-703|Oral administration, twice per day
58096335|NCT04057118|DRUG|Placebo|Oral administration, twice per day
58096336|NCT06693336|DRUG|SMS001|One time administration
58096337|NCT01838863|BIOLOGICAL|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
58096338|NCT01838863|DRUG|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
58096339|NCT02470962|OTHER|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
58096340|NCT06143683|PROCEDURE|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
58096341|NCT06143683|PROCEDURE|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
58096342|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
58096343|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
58096344|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
58096345|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
58424032|NCT04608734|DRUG|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
58424033|NCT04608734|DRUG|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
58096346|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
58096347|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
58424034|NCT06071481|DRUG|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
58424035|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
58424036|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
58424037|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
58424038|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
58424039|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
58096348|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
58096349|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
58096350|NCT00664417|BIOLOGICAL|Physiological saline|0.5 mL, IM, 2 injections
58096351|NCT03932838|OTHER|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
58096352|NCT05769153|DRUG|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
58096353|NCT05769153|DRUG|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
58096354|NCT05769153|DRUG|Sham procedure|Needleless syringe used to simulate an intravitreal injection
58096355|NCT05769153|DRUG|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
58096356|NCT05503797|DRUG|Plixorafenib|Oral tablets
58096357|NCT05503797|DRUG|Cobicistat|Oral tablets
58096358|NCT01929148|PROCEDURE|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
57735718|NCT04036175|DEVICE|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%
58096359|NCT01929148|PROCEDURE|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
58096360|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
57951519|NCT00137111|DRUG|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
58096361|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
58096362|NCT03973086|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
58096363|NCT06461234|BEHAVIORAL|Pelvic floor muscle training|A therapist will instruct the patient to contract the anus, perineum as well as the urethra, until the patient masters the correct method.
58096364|NCT06461234|OTHER|Biofeedback electrical stimulation|The therapist will place the electrodes of the instrument into the vagina, adjust the current value until the woman feels obvious contraction of the pelvic floor muscles but no pain, and instructs the patient to refer to the biofeedback mode for vaginal and anal contraction and relaxation.
58096365|NCT06461234|OTHER|Magnetic Stimulation|The therapist will use the magnetic stimulator to intermittently stimulate the and adjust the stimulation intensity at any time according to the patient\&amp;amp;amp;#39;s condition, adjusting it until there is a clear sense of contraction and feel comfortable.
58096366|NCT06461234|OTHER|Magnetic stimulation combined with biofeedback electrical stimulation|Pelvic floor magnetic stimulation for 30 minutes followed by biofeedback electrical stimulation.
58096367|NCT05557487|DIAGNOSTIC_TEST|Low dose computed tomography|"1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test."
58096368|NCT00221052|DRUG|Diclofenac|
58424040|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
58424041|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
57951520|NCT00137111|DRUG|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
57951521|NCT00137111|DRUG|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
57951522|NCT00137111|PROCEDURE|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
57951523|NCT00137111|PROCEDURE|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
57951524|NCT00549172|PROCEDURE|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
57951525|NCT00549172|PROCEDURE|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
57951526|NCT02544685|DIETARY_SUPPLEMENT|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
57951527|NCT02544685|DIETARY_SUPPLEMENT|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
57951528|NCT02544685|OTHER|Placebo|Same dosage regimen as active drugs
57951529|NCT05297942|OTHER|Expansion of Abbreviations and Acronyms|Expansion of Abbreviations and Acronyms
57951530|NCT00083031|DRUG|bevacizumab|
57951531|NCT00083031|DRUG|cyclophosphamide|
57951532|NCT00083031|DRUG|methotrexate|
57951533|NCT03061981|DRUG|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
57951534|NCT03061981|DRUG|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
57951535|NCT03061981|DRUG|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
57951536|NCT00096707|DRUG|2-deoxy-D-glucose (2DG)|
57951537|NCT00309634|BIOLOGICAL|4 adjuvanted pandemic influenza candidate vaccines|
57951538|NCT00309634|BIOLOGICAL|4 non-adjuvanted pandemic influenza candidate vaccines|
57951539|NCT00323232|DEVICE|2 Versus 4 Hole DHS|See Detailed Description.
57951540|NCT00619073|DRUG|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
57951541|NCT00619073|DRUG|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
57951542|NCT00619073|DRUG|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
57951543|NCT02284126|DRUG|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
57951544|NCT05860075|DRUG|IMM01|IMM01 will be administered once a week for 4 weeks.
57951545|NCT00000742|DRUG|Atevirdine mesylate|
57951546|NCT00000742|DRUG|Zidovudine|
57951547|NCT00000742|DRUG|Didanosine|
58424042|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
58424043|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
58424044|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
58424045|NCT02868658|BIOLOGICAL|Blood sampling|
57735719|NCT04286373|DEVICE|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
58424046|NCT02868658|OTHER|Nasal swab|
58424047|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
58424048|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
58424049|NCT00109577|DRUG|MCN36 (nutritional supplement)|nutritional supplement
58424050|NCT00109577|DRUG|Placebo|nutritional supplement
58424051|NCT00034736|DRUG|Levofloxacin|
57961401|NCT06500247|DRUG|Dalpicilib|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
57961402|NCT06500247|DRUG|Abiraterone Acetate (II)|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
57961403|NCT06500247|DRUG|Androgen Deprivation Therapy|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
57961404|NCT06500247|DRUG|Prednisone|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
57961405|NCT03729388|OTHER|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
57961406|NCT04467580|DIAGNOSTIC_TEST|abdominal [18F]FDG PET/CT|Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
57961407|NCT05229146|BEHAVIORAL|Episodic Future Thinking|Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
57961408|NCT03777644|PROCEDURE|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
57961409|NCT03777644|PROCEDURE|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
57961410|NCT03777644|DRUG|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
57961411|NCT01496885|OTHER|Observational study|This was an observational study and no study drug was administered.
57961412|NCT04369898|OTHER|Image analysis/ Central vein detection|Image analysis/ Central vein detection will be performed using a fully automated approach based on an ensemble of 3D convolutional neural Networks. The method is applied to T1w, T2w and T2\*w data . Results will be manually reviewed by 2 experts in CVs detection. MRI data must have been collected at 3 Tesla (3T) between 1990 and 2020 and must include T1 w, T2 w, T2-star based sequence (CVs detection).
58096369|NCT01261429|DRUG|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
58096370|NCT03574571|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
58096371|NCT03574571|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
58096372|NCT03574571|DRUG|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
58096373|NCT05274568|DRUG|[18F]UCB-2897|"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."
58096374|NCT03692078|OTHER|OTDN product 1|Oral tobacco-derived nicotine product
58096375|NCT03692078|OTHER|OTDN product 2|Oral tobacco-derived nicotine product
58096376|NCT03692078|OTHER|Tobacco Cessation|Tobacco Cessation
58096377|NCT03257137|OTHER|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
58096378|NCT03875131|OTHER|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~  * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
58096379|NCT01921725|DEVICE|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
58096380|NCT03543046|DEVICE|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
58096381|NCT00945971|OTHER|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
58096382|NCT03190018|DEVICE|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
58096383|NCT03300232|BEHAVIORAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
58096384|NCT05606159|DIETARY_SUPPLEMENT|Bacillus velezensis DSM 33864|1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
58096385|NCT05606159|DIETARY_SUPPLEMENT|Placebo|1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
57951548|NCT01824277|OTHER|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
57951549|NCT03073980|DRUG|IV Acetaminophen|IV Acetaminophen for pain control during procedure
58096386|NCT05801991|DEVICE|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
58096387|NCT05801991|DEVICE|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
58096388|NCT00710086|DRUG|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
58096389|NCT00710086|DRUG|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
58096390|NCT06222411|OTHER|evaluate the impact of organizational interventions for physician development on wellbeing|There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
58096391|NCT01552005|DRUG|Saxagliptin|No Intervention
58096392|NCT05633095|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
58096393|NCT03456973|BEHAVIORAL|Nurse AMIE|Supportive care software platform
58096394|NCT03377387|DRUG|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
58096395|NCT03377387|DRUG|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
57951550|NCT03073980|DRUG|PO Acetaminophen|PO Acetaminophen for pain control during procedure
58096396|NCT03377387|BEHAVIORAL|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
58096397|NCT01614158|DEVICE|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
58096398|NCT01614158|OTHER|D-BCVA|D-BCVA using EDTRS chart
58096399|NCT01614158|OTHER|RAPD|RAPD using swinging flashlight test
58096400|NCT01614158|DEVICE|IOP|IOP using applanation tonometer
58096401|NCT01614158|DEVICE|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
58096402|NCT01614158|OTHER|Fundus photography|Optic disk morphology will be documented by fundus photography
58096403|NCT01785043|DRUG|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
58096404|NCT01785043|DRUG|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
58096405|NCT04169425|PROCEDURE|elective diverting ileostomy|
58096406|NCT04156282|PROCEDURE|knot burial technique|surgical suturing intervention
58096407|NCT04156282|PROCEDURE|classical closure|surgical suturing intervention
58096408|NCT05698524|DRUG|PCI 24781|Patients will take the PCI-24781/Abexinostat on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.
58096409|NCT05698524|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
57951551|NCT03073980|OTHER|Placebo IV Acetaminophen|Placebo IV Acetaminophen
57951552|NCT03073980|OTHER|Placebo PO Acetaminophen|Placebo PO Acetaminophen
58096410|NCT03909971|DRUG|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
58096411|NCT03976843|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
58096412|NCT04318249|BEHAVIORAL|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
58096413|NCT04318249|BEHAVIORAL|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
57951553|NCT05288283|DRUG|GWP42003-P|oral solution
57951554|NCT05288283|DRUG|Placebo|oral solution
57951555|NCT02882633|DRUG|30ml bolus of bupivacaine|Local anesthetic
57951556|NCT03362424|BIOLOGICAL|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
57951557|NCT03362424|PROCEDURE|Rotator cuff repair|Rotator cuff repair
58096414|NCT03235973|DRUG|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
58096415|NCT06102499|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
58096416|NCT05155046|DRUG|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
58096417|NCT05189860|DEVICE|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
58096418|NCT05489523|DRUG|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
58096419|NCT04106947|OTHER|Questionnaires|Questionnaires
58096420|NCT00295308|DRUG|Clonidine|clonidine up to 0.3 mg/day oral
58096421|NCT00295308|DRUG|Placebo|oral capsules daily
58096422|NCT00609063|DRUG|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
58096423|NCT00609063|DRUG|Placebo|Placebo capsules taken daily for 6 months
58096424|NCT06368778|OTHER|Verbal Advice|The participant will receive verbal instructions following the standard physical therapy.
58096425|NCT06368778|OTHER|Bathroom Scale|The participant is given a sense of what a 20 kg load feels like using a scale.
58096426|NCT06368778|DEVICE|Loadsol Biofeedback|Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
58096427|NCT05330143|DRUG|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
58096428|NCT05330143|DRUG|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
58096429|NCT05330143|DRUG|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
58096430|NCT05330143|DRUG|Placebo|0.9% saline vials administered subcutaneously once 4 week.
58096431|NCT03939403|DRUG|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
58096432|NCT06563050|PROCEDURE|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
58096433|NCT06563050|PROCEDURE|Lidocaine spray|Subjects in group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
58096434|NCT06563050|PROCEDURE|Combination of nebulized lidocaine and lidocaine spray|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
57951558|NCT04185090|COMBINATION_PRODUCT|ID1803|Amlodipine 10mg/Valsartan 160mg
57951559|NCT04185090|COMBINATION_PRODUCT|ID1801|Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
57951560|NCT04185090|COMBINATION_PRODUCT|ID1803+ID1801|Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
57951561|NCT01841944|DRUG|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
57951562|NCT01841944|OTHER|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
57951563|NCT01539590|DRUG|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
57951564|NCT01539590|DRUG|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
57951565|NCT02106052|OTHER|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
57951566|NCT02106052|OTHER|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
57951567|NCT06145555|BEHAVIORAL|Acute psychological sleep stabilization|See above (arm description)
57951568|NCT06145555|BEHAVIORAL|Sleep hygiene education|See above (arm description)
57951569|NCT01201161|DRUG|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
57951570|NCT01201161|OTHER|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
57951571|NCT00867373|BEHAVIORAL|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
57951572|NCT03506035|DIAGNOSTIC_TEST|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
57951573|NCT01323426|PROCEDURE|Periurethral injection|Periurethral injection of autologous muscle fibers
57951574|NCT04772937|PROCEDURE|LLETZ|LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
57951575|NCT04772937|PROCEDURE|LEEP|LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
57951576|NCT05183607|OTHER|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
57951577|NCT01365260|DEVICE|MM-II|Single intraarticular (knee) injection of MM-II
57951578|NCT01365260|DEVICE|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
57951579|NCT00949546|DRUG|etanercept|etanercept 50 mg sc twice weekly
57951580|NCT00641589|DRUG|epoetin alfa|
57951581|NCT03036137|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
57951582|NCT03036137|DEVICE|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
57951583|NCT01208350|BEHAVIORAL|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
57951584|NCT01208350|BEHAVIORAL|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
57951585|NCT01208350|BEHAVIORAL|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
57951586|NCT01501305|DIETARY_SUPPLEMENT|Mineral solution|Rehydration mineral solution
57951587|NCT01501305|DIETARY_SUPPLEMENT|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
57951588|NCT00859378|DEVICE|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)
57951589|NCT00859378|DEVICE|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
58096435|NCT02105597|OTHER|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
58096436|NCT03794999|DRUG|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
58096437|NCT03794999|DRUG|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
58096438|NCT06701227|OTHER|In Situ Simulation|"The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker."
58096439|NCT05098444|BEHAVIORAL|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
58096440|NCT05098444|OTHER|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
58096441|NCT02650609|DRUG|Methylprednisolone|
58096442|NCT02650609|DRUG|Placebo|
58096443|NCT06568640|PROCEDURE|Superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
58096444|NCT03380182|OTHER|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
58096445|NCT03380182|OTHER|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
58096446|NCT05673018|DEVICE|Multi-Cancer Early Detection Test (Galleri®)|Blood collection and multi-cancer early detection testing with return of results.
58096447|NCT05777174|DRUG|MB-102|130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.
58096448|NCT05777174|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
58096449|NCT04616079|DRUG|REGN6490|Single dose of REGN6490
58096450|NCT04616079|DRUG|Placebo|Placebo matching single dose of REGN6490
58096451|NCT03756207|PROCEDURE|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
58096452|NCT06328543|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
58096453|NCT06328543|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
58096454|NCT02270840|DEVICE|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
58096455|NCT06692166|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
58096456|NCT06692166|DRUG|Chemotherapy|1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
58096457|NCT05785754|DRUG|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
58096458|NCT05785754|DRUG|Pembrolizumab|Pembrolizumab injection
58096459|NCT02865642|DRUG|Serotonin Uptake Inhibitors|
58096460|NCT02865642|DRUG|Placebo|
58096461|NCT06555562|DEVICE|Ultrasound Stimulation|Ultrasound therapy will be administered to the appropriate target.
58096462|NCT06555562|DEVICE|Non-active ultrasound stimulation|Non-active ultrasound therapy will be administered to the appropriate target
58096463|NCT05957913|DRUG|Truvada (tenofovir/emtricitabine)|Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
58096464|NCT01992770|BEHAVIORAL|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
58096465|NCT01992770|BEHAVIORAL|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
58096466|NCT01992770|BEHAVIORAL|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
58096467|NCT06541977|BEHAVIORAL|Behavioral to reduce sedentary behvaior|This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
58096468|NCT06541977|BEHAVIORAL|Physical activity|This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
58424052|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
58424053|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
58424054|NCT05403229|DRUG|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
58424055|NCT05403229|DRUG|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
58424056|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
58424057|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
58424058|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
58424059|NCT02905006|DRUG|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
58424060|NCT02905006|OTHER|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
58424061|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
58424062|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
58424063|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
58424064|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
58424065|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
58424066|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
58424067|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
58424068|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
58424069|NCT05821725|DEVICE|Control|Hemostatic sponge
58424070|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
58424071|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
58424072|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
58424073|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
58424074|NCT02532985|OTHER|Negative Control|No added fiber beverage
57735720|NCT04286373|DEVICE|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
58424075|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
58424076|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
58424077|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
58424078|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
58424079|NCT00506168|DRUG|Irinotecan, Capecitabine|
58424080|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
58096469|NCT06541977|PROCEDURE|Bariatric Surgery|In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
58096470|NCT06315725|OTHER|Sweet taste perception with/without sweet taste blockade|In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.
58096471|NCT06375837|DEVICE|an alkasite-based restorative material|Cention N
58096472|NCT06375837|DEVICE|hybrid resin composite|Gradia Direct Anterior
58096473|NCT06375837|DEVICE|a highly filled flowable resin composite|G-aenial Universal Flo
58096474|NCT03569566|OTHER|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
58096475|NCT04844931|PROCEDURE|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
58096476|NCT04844931|PROCEDURE|Standard PCI|Standard PCI
58096477|NCT06122649|DRUG|apremilast|Oral tablet
58096478|NCT06122649|DRUG|Placebo|Oral tablet
58096479|NCT04138602|DEVICE|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
58096480|NCT04138602|DEVICE|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
58096481|NCT06606899|DRUG|Melatonin 3 MG|Oral syrup melatonin 3 mg
58424081|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
58424082|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
58424083|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
58424084|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
58096482|NCT06606899|DRUG|Chloral Hydrate|Oral chloral hydrate (50 mg/kg, maximum 2 g)
58424085|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
58096483|NCT06606899|DRUG|Sevoflurane|Inhalational Sevoflurane
58424086|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
58424087|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
58424088|NCT00383396|DRUG|Topical Cyclosporine|
58096484|NCT06065475|BEHAVIORAL|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, injecting 2.5ml of 2% lidocaine on the surface of the thyroid cartilage each side.
58424089|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
58424090|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
58424091|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
58424092|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
57735721|NCT05018611|BEHAVIORAL|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
57735722|NCT02532660|DRUG|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
58424093|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
58424094|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
57735723|NCT02532660|DRUG|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
58096485|NCT05612178|BIOLOGICAL|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
58096486|NCT05612178|BIOLOGICAL|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
58096487|NCT05612178|OTHER|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
58096488|NCT06083051|DEVICE|6Fr Percuflex ureteral stents|The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
58096489|NCT06083051|DEVICE|6Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
58424095|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
58424096|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
57735724|NCT02532660|DRUG|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
57735725|NCT02532660|DRUG|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
58096490|NCT06083051|DEVICE|4.8Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
58424097|NCT02726945|OTHER|Placebo|Placebo Control
58424098|NCT05257707|DIAGNOSTIC_TEST|Molecular biology|"Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples."
58424099|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
58424100|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
58096491|NCT06083051|DEVICE|4.8Fr Percuflex ureteral stents|The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
58096492|NCT06703411|DRUG|Iron Sucrose IV|IV iron sucrose 200mg per visit
58096493|NCT06703411|DRUG|Standard Medical Therapy|Standard of care (HFrEF 4 pillars treatment)
58096494|NCT02836704|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
58096495|NCT02836704|DRUG|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
58096496|NCT02836704|DRUG|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
58096497|NCT05681520|BEHAVIORAL|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
58096498|NCT01010230|DEVICE|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
58096499|NCT01010230|DEVICE|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
58096500|NCT01283373|DRUG|DSTP3086S|DSTP3086S administered intravenously
58096501|NCT01283373|DRUG|DSTP3086S|Escalating intravenous dose
58096502|NCT01929837|DEVICE|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
58096503|NCT01929837|DEVICE|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
58096504|NCT01929837|DEVICE|sham E-field navigated rTMS|
58096505|NCT01929837|DEVICE|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
58096506|NCT02845973|BIOLOGICAL|gut microbiota|
58096507|NCT06541743|DEVICE|Regular Toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
58096508|NCT06541743|DEVICE|Musical toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
58096509|NCT06541743|DEVICE|Electric toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
58096510|NCT06541093|BIOLOGICAL|UVAX-1107|Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
58424101|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
58424102|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
58424103|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
58424104|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
58424105|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
58096511|NCT06541093|BIOLOGICAL|UVAX-1197|Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
58096512|NCT06541093|OTHER|Placebo|Saline injection
58096513|NCT01019278|RADIATION|proton beam radiation therapy|Undergo external proton beam radiation
58096514|NCT01019278|RADIATION|radiation therapy treatment planning/simulation|
58096515|NCT01019278|DRUG|cisplatin|Given IV
58096516|NCT06173765|OTHER|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
58424106|NCT05203159|OTHER|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
58424107|NCT05203159|OTHER|Routine|No sound will be played before, during and after the ROP examination.
58096517|NCT06173765|OTHER|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
58096518|NCT06173765|OTHER|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
58096519|NCT05917093|BEHAVIORAL|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
58096520|NCT00534521|DEVICE|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
58096521|NCT00534521|DEVICE|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
58096522|NCT04676386|DIAGNOSTIC_TEST|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
58096523|NCT06007209|OTHER|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
58096524|NCT03715660|DIAGNOSTIC_TEST|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
58096525|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
58096526|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
58096527|NCT03932474|COMBINATION_PRODUCT|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
58096528|NCT03932474|OTHER|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
58096529|NCT03519360|OTHER|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
58424108|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
58424109|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
58096530|NCT03519360|OTHER|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
58096531|NCT06536647|DIAGNOSTIC_TEST|Contactless measurement of patient vital signs using the VitalsTM system|Contactless measurement of the patient blood pressure, heart rate, respiratory rate, body temperature and SpO2 will be carried out using the VitalsTM platform based on facial video data.
58096532|NCT04315831|DRUG|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
58096533|NCT06594094|GENETIC|HG302|Once intravenous injection; The duration of the study is about 32 weeks for each subject, including a 6 weeks screening period, enrollment visit, treatment visit, and 26 weeks follow-up period.
58096534|NCT01976637|OTHER|no compression|no compression stockings worn during the study
58096535|NCT01976637|DEVICE|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
58096536|NCT02924337|DRUG|Placebo|
58096537|NCT02924337|DRUG|Imeglimin|
58096538|NCT02924337|DRUG|Moxifloxacin|
58096539|NCT03371680|DRUG|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
58096540|NCT06200259|RADIATION|Spot Delete planning for proton therapy|The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy
58096541|NCT06200259|RADIATION|Traditional proton treatment planning system|In the control arm, the proton spots placed by the treatment planning system are not modified.
58096542|NCT03686137|OTHER|Data collection|Colelction of pre-operative, surgical and post-surgical data
58096543|NCT02805673|PROCEDURE|Osteopathy|
58096544|NCT05027945|PROCEDURE|Allogeneic HSCT|stem cell transplant on day 0
58424110|NCT04907045|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
58424111|NCT04907045|BEHAVIORAL|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
58096545|NCT05027945|DRUG|Busulfan test dose|0.8 mg/kg IV over 2 hours. May be skipped if real-time PKs are done during conditioning.
58096546|NCT05027945|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
58096547|NCT05027945|DRUG|Tacrolimus|Starting on day +5, start at 0.02 mg/kg IV continuous infusion over 24 hours until day +180 and titrated to trough levels of 5-15 mg/ml.
58096548|NCT05027945|DRUG|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
58096549|NCT05027945|RADIATION|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
58096550|NCT05027945|DRUG|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
58096551|NCT05027945|DRUG|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
58096552|NCT05027945|DRUG|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
58096553|NCT06454630|DRUG|REGN7508|Administered by single intravenous (IV) dose
58096554|NCT06454630|DRUG|Enoxaparin|Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
58096555|NCT03464786|DEVICE|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
58096556|NCT03464786|DEVICE|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
58096557|NCT05246111|DRUG|[14C]Berzosertib|Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
58096558|NCT05246111|DRUG|Berzosertib|Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
58424112|NCT04907045|BEHAVIORAL|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
58424113|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
58424114|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
58424115|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
57951590|NCT01677533|OTHER|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
58096559|NCT05246111|DRUG|Topotecan|Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
58096560|NCT04905927|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
58096561|NCT05653518|DEVICE|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
58096562|NCT05653518|DEVICE|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
58424116|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
58424117|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
58424118|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
58424119|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
58424120|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
58424121|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
58424122|NCT00668538|DRUG|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
58096563|NCT04460521|DRUG|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
58096564|NCT04460521|DEVICE|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
58096565|NCT05452642|BEHAVIORAL|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
58096566|NCT05452642|BEHAVIORAL|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
58096567|NCT04941274|DRUG|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
58096568|NCT02964078|DRUG|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
58096569|NCT02964078|DRUG|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
58096570|NCT03284424|BIOLOGICAL|Pembrolizumab|IV infusion
58096571|NCT02163629|BEHAVIORAL|Stress management|
58096572|NCT03906773|OTHER|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
58096573|NCT03987737|PROCEDURE|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
58096574|NCT01226654|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
58096575|NCT02462239|OTHER|Whole-body FDG PET-CT|
58096576|NCT04577456|DEVICE|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
58096577|NCT03648385|DRUG|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
58096578|NCT03648385|OTHER|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
58096579|NCT04671303|DRUG|Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets：The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
58096580|NCT06216301|DEVICE|NovoTTF-200T|"The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.~Drug: Pembrolizumab. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.~Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer."
58096581|NCT06216301|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
58096582|NCT06216301|DRUG|Platinum based chemotherapy|Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
58096583|NCT03173521|BIOLOGICAL|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
58096584|NCT04503707|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
58096585|NCT05725577|OTHER|care via the telemedicine system|Care via the telemedicine system
58096586|NCT05725577|OTHER|Routine care|Routine care
58096587|NCT02591316|OTHER|no intervention|
58096588|NCT00523887|DRUG|Fentanyl transdermal therapeutic system|
58096589|NCT05399407|OTHER|Health e-coaching|Management of overweight / obesity
57951591|NCT01677533|OTHER|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
58096590|NCT05685693|PROCEDURE|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
58096591|NCT05685693|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
58096592|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
58096593|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
58096594|NCT01256398|BIOLOGICAL|Alemtuzumab|Given IV
58096595|NCT01256398|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
57951592|NCT01677533|OTHER|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
58096596|NCT01256398|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
58096597|NCT01256398|DRUG|Cyclophosphamide|Given IV
58096598|NCT01256398|DRUG|Cytarabine|Given IV
58096599|NCT01256398|DRUG|Dasatinib|Given PO
58096600|NCT01256398|DRUG|Daunorubicin Hydrochloride|Given IV
58096601|NCT01256398|DRUG|Dexamethasone|Given PO or IV
58096602|NCT01256398|DRUG|Etoposide Phosphate|Given IV
58096603|NCT01256398|BIOLOGICAL|Filgrastim|Given SC
58096604|NCT01256398|DRUG|Fludarabine Phosphate|Given IV
58096605|NCT01256398|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
58096606|NCT01256398|OTHER|Laboratory Biomarker Analysis|Correlative studies
58096607|NCT01256398|DRUG|Leucovorin Calcium|Given IV or PO
58096608|NCT01256398|DRUG|Melphalan|Given IV
58096609|NCT01256398|DRUG|Mercaptopurine|Given PO
58096610|NCT01256398|DRUG|Methotrexate|Given IT, IV, or PO
58096611|NCT01256398|BIOLOGICAL|Pegfilgrastim|Given SC
58096612|NCT01256398|OTHER|Pharmacological Study|Correlative studies
58096613|NCT01256398|DRUG|Tacrolimus|Given IV or PO
58096614|NCT01256398|DRUG|Vincristine Sulfate|Given IV
58096615|NCT02420665|DRUG|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
58096616|NCT02420665|DEVICE|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
58096617|NCT02420665|BEHAVIORAL|Phone Call|Study staff follow up with participant by phone one month after procedure.
58096618|NCT02420665|PROCEDURE|Colposcopy|Colposcopy performed after visual inspection of cervix.
58096619|NCT02420665|DRUG|Acetic Acid|3 - 5% added to cervix before visual inspection.
58096620|NCT06503523|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL
58096621|NCT06503523|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
58096622|NCT06503523|OTHER|Cowhage|This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
58096623|NCT06503523|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
58096624|NCT01356186|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
58096625|NCT04861415|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
58096626|NCT04861415|RADIATION|Conventionally Fractionated Radiation|External beam radiation therapy treatment
58096627|NCT00817869|OTHER|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
58096628|NCT05480384|DRUG|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
58096629|NCT05480384|DRUG|Trastuzumab deruxtecan|Given in combination with Nivolumab.
58096630|NCT01031225|DRUG|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
58096631|NCT03313154|OTHER|Neuropsychiatric screening|"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
58096632|NCT05113862|BIOLOGICAL|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
58096633|NCT05113862|BIOLOGICAL|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
58096634|NCT05113862|BIOLOGICAL|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
58096635|NCT05113862|BIOLOGICAL|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
58096636|NCT01040546|BEHAVIORAL|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
58096637|NCT01040546|BEHAVIORAL|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
58096638|NCT00115466|PROCEDURE|Non-surgical autologous implant of ASCs|
58096639|NCT02604186|OTHER|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
58096640|NCT02604186|OTHER|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
58096641|NCT06465706|DEVICE|LAmbre investigational device|Randomized 1:1 to either experimental group or control group.
58096642|NCT02680730|BEHAVIORAL|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
58096643|NCT01305265|DEVICE|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
58096644|NCT01491373|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
58096645|NCT01491373|DEVICE|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
58096646|NCT05602974|RADIATION|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
58096647|NCT05602974|OTHER|regular follow-up|regular follow-up
58096648|NCT06376773|PROCEDURE|combination chemotherapy with Apatinib or Camrelizumab|Apatinib, chemotherapy alone, Camrelizumab
58096649|NCT06336174|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
58096650|NCT06336174|PROCEDURE|Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
57735726|NCT05411458|OTHER|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
57735727|NCT05108233|OTHER|Survey Administration|Complete survey
58096651|NCT01115699|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
58096652|NCT00227734|DRUG|capecitabine and oxaliplatin + cetuximab|cetuximab
58096653|NCT00227734|DRUG|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
58096654|NCT01485588|DRUG|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
58096655|NCT01485588|DRUG|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
58096656|NCT01485588|DRUG|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
58096657|NCT06457204|DRUG|Pramipexole (from manufacturing site 1)|Pramipexole (from manufacturing site 1) - test treatment
58096658|NCT06457204|DRUG|Pramipexole (from manufacturing site 2)|Pramipexole (from manufacturing site 2) - reference treatment
58096659|NCT00668109|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
58096660|NCT00668109|DRUG|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
57735728|NCT06034860|DRUG|MT-8421|Experimental treatment with MT-8421
57735729|NCT06034860|DRUG|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
57735730|NCT02462746|DIETARY_SUPPLEMENT|L-Cysteine|The trade name is New Root Herbal Inc.
58096661|NCT02665026|PROCEDURE|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
58096662|NCT04668118|DRUG|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
58096663|NCT01466673|DRUG|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
57735731|NCT06293729|DRUG|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
57735732|NCT01840540|DRUG|Arterial infusion of autologous mesenchymal stem cells|
58096664|NCT01466673|DRUG|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
57735733|NCT06027268|DRUG|Trilaciclib|IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
57735734|NCT06027268|DRUG|Pembrolizumab|IV infusion Day 1 every 21 days, at dose of 200 mg
58096665|NCT04704817|OTHER|obsevation|prospective data collection for colonic or rectal surgery
58096666|NCT01618903|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
57735735|NCT06027268|DRUG|Gemcitabine|IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
57735736|NCT06027268|DRUG|Carboplatin|IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
57735737|NCT06656299|DEVICE|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block
57735738|NCT06656299|DRUG|Bupivacaine injection|5 ml local anesthetic for each trocar sides
57951593|NCT04833088|OTHER|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
57951594|NCT03257007|BEHAVIORAL|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
57951595|NCT02725723|DEVICE|Therm-AppTM TH, thermographic camera|
57951596|NCT02725723|DRUG|epidural injection|
57951597|NCT02413112|BEHAVIORAL|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
57951598|NCT05780307|DRUG|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
57951599|NCT03179332|DRUG|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
57951600|NCT03179332|DRUG|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
57951601|NCT03179332|DRUG|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
57951602|NCT01661907|PROCEDURE|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
57951603|NCT01661907|PROCEDURE|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
57951604|NCT02287623|DRUG|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
57951605|NCT02287623|DRUG|bupivacaine|patients will receive a tap with bupivacaine
57951606|NCT03391271|OTHER|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
57951607|NCT03391271|OTHER|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
57951608|NCT00115609|DRUG|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
57951609|NCT00115609|DRUG|tenofovir DF|300mg once a day
57951610|NCT00115609|DRUG|emtricitabine|one pill of 200mg once a day
57951611|NCT06033742|DRUG|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
57951612|NCT06033742|DRUG|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
57951613|NCT05743452|DEVICE|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
57951614|NCT01308970|BEHAVIORAL|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
57951615|NCT01308970|BEHAVIORAL|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
57951616|NCT01308970|BEHAVIORAL|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
57951617|NCT03641066|DEVICE|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
57951618|NCT03553043|BEHAVIORAL|Intervention|Energy label condition.
57951619|NCT03553043|BEHAVIORAL|Control|No label
57951620|NCT01774578|DRUG|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
58096667|NCT01618903|DRUG|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
58096668|NCT04721327|OTHER|remote CI programming|provision of CI programming provided remotely via Zoom in a 2 hour session
58096669|NCT05323409|BEHAVIORAL|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
58096670|NCT03402126|OTHER|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
58096671|NCT04947059|DRUG|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
58096672|NCT04947059|DRUG|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
58424123|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
58424124|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
58424125|NCT00037154|DRUG|Saw Palmetto|
58424126|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
58424127|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
58424128|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
58424129|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
58424130|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
58424131|NCT02648672|DRUG|Placebo|
57951621|NCT01774578|BIOLOGICAL|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
57951622|NCT01774578|DRUG|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
58096673|NCT06564337|DEVICE|Surveyed zirconia crown|Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
58096674|NCT06398080|DRUG|aflibercept 8 mg|No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
58096675|NCT04691739|OTHER|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
58096676|NCT06248073|BEHAVIORAL|on-line self-management training|To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
58096677|NCT06248073|BEHAVIORAL|onsite task-related training|Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
58096678|NCT03412994|DRUG|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
58096679|NCT03412994|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
58096680|NCT03155061|DRUG|ONO-4578|ONO-4578 specified dose on specified days
58096681|NCT03155061|DRUG|ONO-4538|ONO-4538 specified dose on specified days
58096682|NCT02398500|BIOLOGICAL|LMG324|IVT injection
58096683|NCT02398500|BIOLOGICAL|Ranibizumab 0.5 mg|IVT injection
58096684|NCT02398500|BIOLOGICAL|Sham|Fake injection used for masking purposes
58424132|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
58424133|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
58424134|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
58424135|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
58424136|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
58424137|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
58424138|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
58424139|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
58424140|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
58424141|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
58424142|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
58424143|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
58424144|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
58424145|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
58424146|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
58424147|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
58424148|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
57735739|NCT06656299|DRUG|paracetamol, tramadol, and ondansetron|"As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic"
57735740|NCT03987308|DRUG|Beinaglutide|Five-week Beinaglutide pump treatment group
57735741|NCT03987308|DRUG|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
58424149|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
58424150|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
58424151|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
58424152|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
58424153|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
58424154|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
58424155|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
58424156|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
57735742|NCT02605954|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
57735743|NCT02605954|DRUG|ABC/3TC|600/300 mg tablets administered orally once daily
58424157|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
58424158|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
57951623|NCT01774578|DRUG|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
57951624|NCT05394064|GENETIC|SBT101|SBT101 Treatment
57951625|NCT05394064|PROCEDURE|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
57951626|NCT00445419|BIOLOGICAL|PEV2A PEV2B|
57951627|NCT04065555|DRUG|TAK-981|Intratumoral microdose injection by the CIVO device.
57951628|NCT04065555|BIOLOGICAL|Cetuximab|Intratumoral microdose injection by the CIVO device.
57951629|NCT04065555|BIOLOGICAL|Avelumab|Intratumoral microdose injection by the CIVO device.
57951630|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
57951631|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
57961413|NCT04369898|OTHER|Image analysis/ Automatic cortical lesion detection|Image analysis/ Automatic cortical lesion detection will be performed by using a convolutional neural network-based method. MRI data must have been collected at 3T between 1990 and 2020 and must include Double inversion recovery (DIR)/Phase-Sensitive Inversion Recovery (PSIR)/Magnetization Prepared - 2- RApid Gradient Echo Gradient Echo (MP2RAGE) (eventually also high spatial resolution Magnetization Prepared - RApid Gradient Echo (MPRAGE)) for cortical lesion detection.
57961414|NCT03790254|OTHER|systematic review|
57961415|NCT05321836|OTHER|Glucosamine Chondroitin|control group
57961416|NCT05321836|COMBINATION_PRODUCT|glucosamine chondritin & Physiotherapy|experimental group
57961417|NCT05272033|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
57961418|NCT03130088|OTHER|no intervention planed|no intervention planed
57961419|NCT05788939|OTHER|Planned Visual Education Based on Health Belief Model|"The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~."
57961420|NCT01526512|DRUG|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
57961421|NCT06128447|DRUG|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
57961422|NCT06128447|DRUG|Placebo|Matching placebo
57961423|NCT03434977|DRUG|TAK-536|TAK-536 granule formulation
58306945|NCT04644172|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
58424159|NCT02456857|DRUG|Everolimus|Given PO
58424160|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
58424161|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
58424162|NCT02557984|DRUG|Placebo|Placebo Pill
58424163|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
58424164|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
58424165|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
58424166|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
58424167|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
58424168|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
58424169|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
58424170|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
58424171|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
58424172|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
57961424|NCT01047657|BEHAVIORAL|Low caloric diet plus orlistat and sibutramine|All subjetcs
57961425|NCT05594173|OTHER|Food texture modification|Food prepared in three different consistencies: minced and moist, soft and bite-sized and regular, as defined by the International Dysphagia Diet Standardisation Initiative
57961426|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.
57961427|NCT01510678|BEHAVIORAL|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
57961428|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
57961429|NCT00423163|DRUG|micafungin|
57961430|NCT00423163|DRUG|voriconazole|
57961431|NCT05118256|DRUG|Pirfenidone Oral Tablet|Patients will be treated with pirfenidone (oral tablets) during 6 months
57961432|NCT00036179|DRUG|FK463|
57961433|NCT02989519|DRUG|dydrogesterone|
57961434|NCT02989519|DRUG|Micronized progesterone|
57961435|NCT01785212|DEVICE|Stapler|stapler hepatectomy
57961436|NCT01785212|DEVICE|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
57961437|NCT00874120|DRUG|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
57961438|NCT00874120|DRUG|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
57961439|NCT04421495|DRUG|Delamanid|the eligible patients will be give damanid-containing regimen
57961440|NCT02326779|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
57961441|NCT00002356|DRUG|Fomivirsen sodium|
57961442|NCT02355782|BIOLOGICAL|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
57961443|NCT01972074|DRUG|Memantine|Capsule
57961444|NCT01972074|OTHER|Placebo|Capsule
57961445|NCT03379662|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
57961446|NCT03379662|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
57961447|NCT01175291|DRUG|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).
57735744|NCT02605954|DRUG|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
58424173|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
58424174|NCT00005056|DRUG|bryostatin 1|
58424175|NCT05224037|DIAGNOSTIC_TEST|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
58424176|NCT00129961|DRUG|sirolimus|
58424177|NCT00129961|DRUG|cyclosporine or tacrolimus|
58424178|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
58424179|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
58424180|NCT03878303|DRUG|AC0058TA|25 mg capsules
58424181|NCT03878303|DRUG|Placebo AC0058TA|equivalent dose of investigational product
58424182|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
57735745|NCT02765529|PROCEDURE|Blood sampling|
57735746|NCT06101693|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
57735747|NCT00001651|OTHER|[6,6-2H2]-glucose|\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
57735748|NCT05579860|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
58424183|NCT02663141|DRUG|Losartan|
58424184|NCT02663141|DRUG|Intravitreal bevacizumab|
58424185|NCT02663141|DRUG|Placebo|
57735749|NCT04863066|BIOLOGICAL|CAR-T cells|The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
57961448|NCT01175291|DRUG|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
58424186|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
58424187|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
58424188|NCT00428844|DRUG|daptomycin|6 mg/kg
58424189|NCT00428844|DRUG|daptomycin|8 mg/kg
58424190|NCT00428844|DRUG|vancomycin|1 gram
58424191|NCT00428844|DRUG|teicoplanin|6 mg/kg; used only at UK sites
58424192|NCT00428844|DRUG|nafcillin|1-2 gram
57961449|NCT04612998|OTHER|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
57961450|NCT04612998|OTHER|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
58424193|NCT00428844|DRUG|oxacillin|1-2 gram
58424194|NCT00428844|DRUG|flucloxacillin|1-2 mg
58424195|NCT00734721|BEHAVIORAL|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
58424196|NCT00002506|BIOLOGICAL|recombinant interferon alfa|
58424197|NCT00002506|DRUG|isotretinoin|
58424198|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
58424199|NCT04726059|DEVICE|Transcutaneous Spinal Cord Stimulation|Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
58424200|NCT04726059|DEVICE|SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation|Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
58096685|NCT00812227|BEHAVIORAL|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
58424201|NCT04726059|DEVICE|Activity-Based Therapy|"Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics."
58424202|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
58424203|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
58424204|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
58424205|NCT02645617|DRUG|Varnish|Topical application to the teeth
58424206|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
58424207|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
57735750|NCT06189417|BEHAVIORAL|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
58096686|NCT05775536|DRUG|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
58096687|NCT05775536|DIETARY_SUPPLEMENT|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
58096688|NCT05407675|DRUG|BMS-986408|Specified dose on specified days
58096689|NCT05407675|BIOLOGICAL|Nivolumab|Specified dose on specified days
58096690|NCT05407675|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58096691|NCT05407675|BIOLOGICAL|Platinum-doublet chemotherapy|Specified dose on specified days
58096692|NCT05407675|DRUG|Rabeprazole|Specified dose on specified days
58096693|NCT01093040|DRUG|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
58096694|NCT01093040|DRUG|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
58424208|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
58424209|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
58424210|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
58424211|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
58424212|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
58424213|NCT00820872|BIOLOGICAL|trastuzumab|
58424214|NCT00820872|DRUG|carboplatin|
58424215|NCT00820872|DRUG|docetaxel|
58424216|NCT00820872|DRUG|lapatinib ditosylate|
58424217|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
58424218|NCT02139904|OTHER|Active Symptom Control|
58424219|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
58424220|NCT04571996|DRUG|ODM-104|Capsule
58424221|NCT04571996|DRUG|Paracetamol|Rapidly dissolving tablet
58424222|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
58096695|NCT01093040|DRUG|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
58096696|NCT01068795|DRUG|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
58424223|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
58424224|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
58424225|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
58424226|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
58424227|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
57735751|NCT03736434|BEHAVIORAL|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
58096697|NCT05933499|DRUG|IV bimagrumab|IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
58096698|NCT05933499|DRUG|IV placebo|IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
58096699|NCT05933499|DRUG|Semaglutide|Semaglutide 2.4mg SQ qweek
58096700|NCT05933499|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Elemental calcium 1200 mg + vitamin D3 800 IU PO daily
58096701|NCT05933499|BEHAVIORAL|Lifestyle and nutrition counseling|Lifestyle and nutrition counseling consistent with current guidelines for weight management
58096702|NCT05869019|OTHER|education|Premature baby care training will be provided.
58306946|NCT04644172|OTHER|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
58306947|NCT00137553|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
58306948|NCT02295644|DEVICE|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
58306949|NCT02501408|DEVICE|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
58306950|NCT00546403|DRUG|Modafinil|Adjunctive treatment with titrated dose of modafinil
58306951|NCT00546403|DRUG|Placebo|Adjunctive treatment with placebo
58306952|NCT00450957|DIETARY_SUPPLEMENT|lycopene|Given orally
58306953|NCT00450957|OTHER|pharmacological study|Correlative studies
58306954|NCT04051541|OTHER|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
58306955|NCT00915590|DRUG|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
58306956|NCT00915590|DRUG|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
58306957|NCT02965651|BEHAVIORAL|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
58306958|NCT00639119|DRUG|Ropinirole|8 + 8 weeks cross-over placebo controlled
58306959|NCT03985683|OTHER|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
58306960|NCT03985683|DIETARY_SUPPLEMENT|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
58306961|NCT04525521|OTHER|Hand sanitizer and hand washing|All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
58306962|NCT03356652|PROCEDURE|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
58306963|NCT01298830|DRUG|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
58306964|NCT02507791|OTHER|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
58306965|NCT00061581|DEVICE|Isolex 300i Stem Cell Selection|
58306966|NCT03052894|DEVICE|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
58424228|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian...) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
58424229|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
58424230|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
58424231|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
58424232|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
58424233|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
58424234|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
58424235|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
58424236|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
58424237|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
58424238|NCT00444067|OTHER|Standard of Care|Standard of Care
58096703|NCT06696469|DIAGNOSTIC_TEST|Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients|The applicability and reliability of virtual reality systems are important factors to consider. Based on this, this study aimed to investigate the feasibility of using BeCureTM virtual reality in the evaluation of upper extremity functions after stroke.The feasibility of using BeCureTM virtual reality in stroke patients will be determined according to the System Usability Scale (SUS) score.The safety of the use of BeCureTM virtual reality in stroke patients will be assessed with a patient feedback questionnaire. The relationship between the use of BeCureTM virtual reality and cognitive functions in stroke patients will be determined by the Montreal Cognitive Assessment Scale and Mini Mental State Examination.It was aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications.
58424239|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
58424240|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
58424241|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
58424242|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
58424243|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
58424244|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
58424245|NCT03046225|DEVICE|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
58424246|NCT03046225|DEVICE|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
58424247|NCT03046225|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
58424248|NCT02619643|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
57735752|NCT03736434|BEHAVIORAL|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
57735753|NCT06426641|DEVICE|Polyethylene|There is no intervention
57735754|NCT05601973|DRUG|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
57735755|NCT05601973|DRUG|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
58424249|NCT02078388|DRUG|Doxorubicin|
58424250|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
58424251|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
58424252|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
58424253|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
58424254|NCT01313962|OTHER|Placebo|Nasal spray
58424255|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
58424256|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
58424257|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
58424258|NCT06030284|DEVICE|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
58424259|NCT06030284|DEVICE|BurstDR-SCS|BurstDR-SCS system turned off.
58424260|NCT04397328|DRUG|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
58424261|NCT04397328|DRUG|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
58424262|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
57735756|NCT05601973|DRUG|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
57735757|NCT02393794|DRUG|Romidepsin|Histone deacetylase inhibitor
57735758|NCT02393794|DRUG|Cisplatin|Platinum compound
57735759|NCT02393794|DRUG|Nivolumab|Monoclonal antibody, checkpoint inhibitor
57961451|NCT04612998|DRUG|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
57735760|NCT02322957|DRUG|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
57735761|NCT01754831|DEVICE|Fluoride varnish|Topical application of fluoride varnish on present teeth
57961452|NCT04612998|DRUG|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.
57961453|NCT04612998|DRUG|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
57961454|NCT01294800|DRUG|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
58424263|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
58424264|NCT00756951|DRUG|Placebo|Placebo
57961455|NCT01294800|DRUG|Placebo tablet to match Preladenant|tablets taken orally BID
58424265|NCT00756951|DRUG|SCV-07|0.02 mg/kg
58424266|NCT00756951|DRUG|SCV-07|0.10 mg/kg
58424267|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
58424268|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
58424269|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
58424270|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
57735762|NCT06100042|DRUG|BDP/FF/G|"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."
57961456|NCT02237430|DEVICE|MynxGrip|Closure device for femoral artery access closure
58424271|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
58424272|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
58424273|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
58424274|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
58424275|NCT02505360|OTHER|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
58424276|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
58424277|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
58424278|NCT02254395|DEVICE|Deep Brain Stimulation|
58424279|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
58424280|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
58424281|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
57735763|NCT05312775|PROCEDURE|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
57735764|NCT05312775|PROCEDURE|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
57961457|NCT02237430|OTHER|Manual compression|Conventional manual compression
57961458|NCT00300638|PROCEDURE|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
57961459|NCT00300638|BEHAVIORAL|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
57961460|NCT02216838|DRUG|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
57961461|NCT02216838|OTHER|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
57961462|NCT01665963|DEVICE|TopClosure(c) System|
57961463|NCT01665963|DEVICE|Pressure Bandage|
57961464|NCT00305656|DRUG|cediranib maleate|Given orally
57961465|NCT05559827|DRUG|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
57961466|NCT04763070|DRUG|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
57961467|NCT04411550|DRUG|HLX11|healthy volunteers receive HLX11 (420mg) once
57961468|NCT04411550|DRUG|CN-Perjeta(Pertuzumab)|healthy volunteers receive CN-Perjeta (420mg) once
57961469|NCT04411550|DRUG|EU-Perjeta(Pertuzumab)|healthy volunteers receive EU-Perjeta (420mg) once
57961470|NCT04411550|DRUG|US-Perjeta(Pertuzumab)|healthy volunteers receive US-Perjeta (420mg) once
57961471|NCT02933697|DRUG|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
57961472|NCT02933697|DRUG|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
57961473|NCT02432235|DRUG|Camidanlumab tesirine|Intravenous (IV) infusion.
57961474|NCT01082315|DRUG|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
57961475|NCT01913483|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
58424282|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
58424283|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
58424284|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
58424285|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
58424286|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
58424287|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
58424288|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
58424289|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
58424290|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
58424291|NCT02661672|DEVICE|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
58424292|NCT02661672|DEVICE|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
57735765|NCT03069482|DEVICE|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
57961476|NCT01913483|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
57961477|NCT06252272|DIAGNOSTIC_TEST|Biopsy from patients undergoing surgery abdominal.|A small portion (about 10 mm in diameter) of liver tissue was collected macroscopically free from alterations of the parenchyma obtained in the open at the site surgery for primary or secondary liver tumors, for the preparation of cultures of organotypic liver slices.
58096704|NCT01925378|DRUG|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
58424293|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
58424294|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
58424295|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
58424296|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
58424297|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
58424298|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
58424299|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
58424300|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
58424301|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
58424302|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
58424303|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
58424304|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
58424305|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
58424306|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
58424307|NCT03652467|DRUG|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
58424308|NCT03652467|DRUG|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
58424309|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
58424310|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
58424311|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
58424312|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
58424313|NCT00295932|BIOLOGICAL|rituximab|Given IV
58424314|NCT00295932|DRUG|bortezomib|Given IV
58424315|NCT00295932|DRUG|cyclophosphamide|Given IV
58424316|NCT00295932|DRUG|prednisone|Given orally
58424317|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
58424318|NCT00795288|DRUG|placebo|Control group
58424319|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
58424320|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
58424321|NCT00075556|DRUG|capecitabine|
58424322|NCT00075556|PROCEDURE|conventional surgery|
58424323|NCT00075556|PROCEDURE|neoadjuvant therapy|
58424324|NCT00075556|RADIATION|radiation therapy|
58424325|NCT00243984|DRUG|topiramate|
57735766|NCT03069482|DRUG|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
57961478|NCT04600908|OTHER|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
58424326|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
58424327|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
58424328|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
58424329|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
58424330|NCT01024192|DRUG|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
58424331|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
58424332|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
58424333|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
57961479|NCT02838849|DIETARY_SUPPLEMENT|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
58424334|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
58424335|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
58424336|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
58424337|NCT00252772|DRUG|Tesaglitazar|
58424338|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
58424339|NCT01791101|DRUG|Eltrombopag|
58424340|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
58424341|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
58424342|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
58424343|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
58424344|NCT02184832|OTHER|Low tryptophan diet|
58424345|NCT02184832|OTHER|High tryptophan diet|
57735767|NCT03069482|DRUG|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
58424346|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
58424347|NCT01063088|BIOLOGICAL|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
58424348|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
58424349|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
58424350|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
58424351|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
58424352|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
58424353|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
58424354|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
58424355|NCT00790478|DRUG|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
58424356|NCT00790478|OTHER|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
58424357|NCT02264080|DRUG|WAL2014|
58424358|NCT02264080|DRUG|Placebo|
58424359|NCT06206811|DRUG|OD-07656|innate immune modulator
58424360|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
58424361|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
58424362|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
58424363|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
58424364|NCT05570409|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 1g bid for 6 months
57735768|NCT03069482|BEHAVIORAL|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
57961480|NCT02838849|DIETARY_SUPPLEMENT|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
58424365|NCT05570409|DRUG|Prednisolone|initially 1mg/kg in a step-down regime for 6 months
58424366|NCT05570409|DRUG|Mycophenolate Mofetil Placebo|MMF matching Placebo
58424367|NCT05570409|DRUG|Prednisolone Placebo|Prednisolone matching placebo
58424368|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
58424369|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
58424370|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
58424371|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
58424372|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
58424373|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
58424374|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
58424375|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
58424376|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
58424377|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
58096705|NCT05756985|PROCEDURE|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
58096706|NCT04639739|BIOLOGICAL|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
58096707|NCT06702202|DRUG|Mixture of local anesthetics|Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
58424378|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
58424379|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
58424380|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
58424381|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
58424382|NCT01331928|DRUG|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
58424383|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
58424384|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
58424385|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
58424386|NCT04216355|DRUG|Azacitidine|Low-dose AZA
58424387|NCT04216355|DRUG|CAG Protocol|Short term CAG derived regimen
58096708|NCT06702202|DRUG|0.5% hyperbaric bupivacaine|Given in Subarachnoid block group (Group S)
58096709|NCT06703866|OTHER|Non Small Cell Lung Cancer (NSCLC)|"Application of value based medicine predictive model"
58424388|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
58424389|NCT04764110|OTHER|Placebo|Maltodextrin
58424390|NCT03772054|DRUG|Sevoflurane|Inhalation anesthetic agent
58424391|NCT03772054|DRUG|Propofol|Intravenous anesthetic agent
58424392|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
58096710|NCT03869684|DRUG|MT-0814|Randomly assigned dose
58096711|NCT03869684|DRUG|Placebo|Placebo manufactured to mimic MT-0814
58096712|NCT01141049|DRUG|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
58424393|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
58424394|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
58424395|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
58424396|NCT02486250|OTHER|Validation Study|
58424397|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
58096713|NCT01141049|OTHER|Placebo|Placebo, TID
58096714|NCT01379365|DEVICE|Cryo-Touch III|Percutaneous treatment with the device
58096715|NCT02305329|DRUG|BIA 9-1067|
58096716|NCT00871104|DRUG|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
58096717|NCT00871104|DRUG|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
58306967|NCT03052894|DEVICE|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
58096718|NCT03699319|DRUG|CPI 613|"Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months"
58096719|NCT03699319|DRUG|Oxaliplatin|"Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
58096720|NCT03699319|DRUG|Irinotecan|"Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
58096721|NCT03699319|DRUG|5-flurouracil|"Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
58096722|NCT03699319|DRUG|Folinic acid|"Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
58096723|NCT05268588|BEHAVIORAL|MESSSSAGE intervention|group mHealth education and social support intervention
58096724|NCT05462756|DRUG|Insulin Efsitora Alfa|Administered SC
58096725|NCT05462756|DRUG|Insulin Lispro (U100)|Administered SC
58096726|NCT05462756|DRUG|Insulin Glargine (U100)|Administered SC
58096727|NCT03487614|BEHAVIORAL|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
58096728|NCT05720793|COMBINATION_PRODUCT|FMT Capsule + SIMBA Capsule|Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
58424398|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
58424399|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
58424400|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
58096729|NCT03746080|DRUG|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
58096730|NCT03746080|DRUG|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
58096731|NCT03746080|RADIATION|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
58096732|NCT03746080|RADIATION|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
58424401|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
58424402|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
58424403|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
58424404|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
58424405|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
58424406|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
58424407|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
58096733|NCT06568926|DIAGNOSTIC_TEST|Serum Ferritin level|follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
58096734|NCT04188405|DRUG|Decitabine|Given IV
58096735|NCT04188405|DRUG|Ponatinib|Given PO
58096736|NCT04188405|DRUG|Venetoclax|Given PO
58096737|NCT04896918|BEHAVIORAL|Tobacco use|
58096738|NCT00951717|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
58096739|NCT04245397|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
58096740|NCT04245397|DRUG|Decitabine|Decitabine is a hypomethylating agent.
58306968|NCT05247164|PROCEDURE|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
58096741|NCT04709029|DRUG|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
58096742|NCT04709029|DRUG|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
58096743|NCT00486577|PROCEDURE|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
58096744|NCT00486577|PROCEDURE|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
58096745|NCT05848687|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
58096746|NCT05848687|DRUG|Mitoxantrone|Given IV
58096747|NCT05848687|DRUG|PEG asparaginase|Given IV
58096748|NCT05848687|DRUG|Bortezomib|Given IV
57735769|NCT03069482|DEVICE|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
58096749|NCT05848687|DRUG|Vorinostat|Taken PO or NG
58096750|NCT05848687|DRUG|Mercaptopurine|Given PO or NG.
58424408|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
57735770|NCT05583591|DEVICE|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
57735771|NCT05583591|DEVICE|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
58096751|NCT05848687|DRUG|Methotrexate|Given IV, IM or PO
58096752|NCT05848687|DRUG|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
58096753|NCT05848687|DRUG|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
58096754|NCT00391040|BEHAVIORAL|SGS education|
58096755|NCT06453005|PROCEDURE|SMART Hall Technique or procedure|"The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure."
58096756|NCT00572156|DRUG|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
58096757|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
58096758|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
58096759|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
58096760|NCT04946071|BEHAVIORAL|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
58096761|NCT05035407|DRUG|IL-2 (Aldesleukin)|dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
58096762|NCT05035407|DRUG|Cyclophosphamide|30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)
58096763|NCT05035407|BIOLOGICAL|KK-LC-1 TCR|1 x 108 transduced KK-LC-1 TCR T cells
58096764|NCT05035407|DRUG|Fludarabine|25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
58096765|NCT06567964|PROCEDURE|Erector Spinae Plane Block(ESPB)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
57735772|NCT03495050|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
58096766|NCT06567964|PROCEDURE|Wound infiltration|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
58424409|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
58096767|NCT04829422|DRUG|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
58096768|NCT06541171|OTHER|Magnetic resonance imaging as fpr clinical practice|An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.
58096769|NCT06702852|DEVICE|NIRS imaging in addition to SOC|The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
58096770|NCT00174486|DRUG|UK0369,003|
58096771|NCT00174486|DRUG|Cialis (Tadalafil)|
58096772|NCT04192786|OTHER|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
58096773|NCT04192786|OTHER|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
58096774|NCT04192786|OTHER|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
58096775|NCT00411762|DRUG|Capecitabine|
58096776|NCT00411762|DRUG|PHY906|
58096777|NCT06611475|OTHER|MMSE ≤26|A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
58096778|NCT00921765|DRUG|Saline|Saline single bolus dose followed by saline single bolus dose iv
58096779|NCT00921765|DRUG|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
58096780|NCT00921765|DRUG|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
58096781|NCT00921765|DRUG|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
58096782|NCT05892965|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
58096783|NCT02233881|DRUG|Atrovent® - inhalets|
58096784|NCT01892605|BEHAVIORAL|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
58096785|NCT04252326|OTHER|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
58096786|NCT06017011|OTHER|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
58096787|NCT04918810|DRUG|Docetaxel intermittent|After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
58096788|NCT01635686|DRUG|DWP422 25mg|
58096789|NCT01635686|DRUG|ENBREL 25MG PFS INJ.|
58096790|NCT06392321|DRUG|Fentanyl|comparison between bupivacaine, bupivacaine and fentanyl.
58096791|NCT06392321|DRUG|Dexmedetomidine|comparison between bupivacaine, bupivacaine and dexmedetomidine..
58096792|NCT01059552|DRUG|vorinostat|vorinostat once daily for 12 weeks of therapy
58096793|NCT03906786|BEHAVIORAL|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
58096794|NCT06359418|DEVICE|Acupuncture|The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
58096795|NCT06359418|DEVICE|Sham acupuncture|The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
58096796|NCT02606370|OTHER|Unstable shoe|Wearing Unstable shoes during 1 month
58096797|NCT03555500|OTHER|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
58096798|NCT05194280|PROCEDURE|Robotic surgery|Robotic-assisted donornephrectomy
58096799|NCT06565819|DIAGNOSTIC_TEST|The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)|DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
58096800|NCT01988493|DRUG|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
58096801|NCT01988493|DRUG|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
58096802|NCT01988493|DRUG|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
58096803|NCT01988493|DRUG|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
58096804|NCT01988493|DRUG|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
58096805|NCT04900415|DRUG|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
58096806|NCT04900415|DEVICE|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
58096807|NCT05880420|DEVICE|Caregiver operations with medication accessories|After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
58096808|NCT05880420|DEVICE|Nurse operations with medication accessories|Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
58096809|NCT05377866|OTHER|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
58096810|NCT00446771|DRUG|Mannitol|
58096811|NCT00085826|DRUG|Exisulind|
58096812|NCT06479746|BEHAVIORAL|Emotional support|Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
58424410|NCT06335953|BEHAVIORAL|Pharmacist-led deprescribing intervention|The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
58096813|NCT00071708|DRUG|Duloxetine Hydrochloride|
58096814|NCT04389619|DEVICE|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
58096815|NCT04389619|PROCEDURE|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
58096816|NCT06703931|DEVICE|Measures performed on all subjects|In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
58096817|NCT05953883|PROCEDURE|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
58424411|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
58424412|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
58096818|NCT06684405|DIETARY_SUPPLEMENT|sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)|
58096819|NCT06684405|DIETARY_SUPPLEMENT|Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.|
58096820|NCT06539988|BEHAVIORAL|Clinician Coaching Sessions|PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.
58096821|NCT06539988|OTHER|Personalized text messages to patients|Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
58129453|NCT05742529|PROCEDURE|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
58096822|NCT02256319|DRUG|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
58096823|NCT02256319|DRUG|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
58096824|NCT05445830|PROCEDURE|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
58096825|NCT05445830|PROCEDURE|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
58306969|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58306970|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
58424413|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
57951632|NCT05214729|DIAGNOSTIC_TEST|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
57951633|NCT05214729|DIAGNOSTIC_TEST|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
58424414|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
58424415|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
57951634|NCT06444139|DIETARY_SUPPLEMENT|Probiotics|Probiotics
57951635|NCT06444139|DIETARY_SUPPLEMENT|Placebo|Placebo
57951636|NCT03175666|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
57951637|NCT03175666|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
57951638|NCT03175666|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
57951639|NCT03175666|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
57951640|NCT03175666|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
57951641|NCT03175666|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
58306971|NCT03588273|DRUG|Amoxil 500 MG Oral Capsule|
58306972|NCT04752930|DIAGNOSTIC_TEST|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
58096826|NCT05445830|PROCEDURE|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
58096827|NCT05445830|PROCEDURE|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
58096828|NCT05445830|PROCEDURE|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
58096829|NCT00731601|DRUG|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
58096830|NCT00731601|DRUG|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
58424416|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
58424417|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
58424418|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
58424419|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
58424420|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
58096831|NCT02703454|PROCEDURE|FIRM-guided RF ablation|
57735773|NCT02742168|RADIATION|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
58096832|NCT02703454|PROCEDURE|Conventional RF ablation|
58096833|NCT02554344|DRUG|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
58096834|NCT01781689|PROCEDURE|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
58096835|NCT01781689|OTHER|Rehabilitation programs|include occupational therapy and physical therapy
58096836|NCT01973270|BEHAVIORAL|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
58096837|NCT06640023|BEHAVIORAL|Default Intervention|For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
58096838|NCT06640023|BEHAVIORAL|Accountable Justification|"For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the After Visit Summary.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display."
58096839|NCT01508325|DRUG|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
58424421|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
57951642|NCT03175666|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
58424422|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
58424423|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
58424424|NCT01792518|DRUG|Placebo|
58424425|NCT01792518|DRUG|Linagliptin 5mg|
58424426|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
58424427|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
57735774|NCT04158947|DRUG|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
58096840|NCT01508325|DRUG|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
58096841|NCT05309031|OTHER|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
58424428|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
58424429|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
58424430|NCT02887547|PROCEDURE|micro-osteoperforation|
58424431|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
58424432|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
58424433|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
58424434|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
58424435|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
58424436|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
58424437|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
58096842|NCT04772469|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
58424438|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
58424439|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
58424440|NCT01848366|DEVICE|Biowave Treatment|Twelve weekly treatments
58424441|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
58424442|NCT05381285|OTHER|No intervention|Non-interventional study
58424443|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
58424444|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
58424445|NCT03204422|OTHER|No intervention|no any other intervention
58424446|NCT00003711|DRUG|irinotecan hydrochloride|
58424447|NCT00003711|DRUG|pemetrexed disodium|
58424448|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
58424449|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
58424450|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
58424451|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
58424452|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
58424453|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
58424454|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
58424455|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
58424456|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
58424457|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
57735775|NCT04158947|DRUG|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
57735776|NCT03291574|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
57735777|NCT03291574|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
57951643|NCT03175666|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
58096843|NCT04772469|OTHER|Small monetary incentives|Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
57735778|NCT05250596|DRUG|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
57735779|NCT05250596|DRUG|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
57735780|NCT06181162|OTHER|Social and/or physical environmental interventions|To be determined in the co-creation groups on the four sites (Denmark, the Netherlands, Nigeria, South Africa)
57951644|NCT03175666|DRUG|Lovaza|omega-3-acid ethyl esters)
57951645|NCT03175666|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
57951646|NCT03175666|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
57951647|NCT03175666|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
57951648|NCT03175666|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
57951649|NCT03175666|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)
58424458|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
57951650|NCT03175666|BIOLOGICAL|GI-4000|RAS yeast vaccine
58424459|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
58424460|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
58424461|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
58424462|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
58424463|NCT04383938|DRUG|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
58424464|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
58424465|NCT06071156|DRUG|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
58424466|NCT03989323|OTHER|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
58424467|NCT06464965|BIOLOGICAL|CB CAR-NK182|To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer
57735781|NCT01842139|BIOLOGICAL|basiliximab|Given IV
57735782|NCT01842139|BIOLOGICAL|WT1 126-134 peptide vaccine|Given SC
57735783|NCT01842139|DRUG|Montanide ISA 51 VG|Given SC
57735784|NCT01842139|DRUG|poly ICLC|Given SC
57951651|NCT03175666|BIOLOGICAL|GI-6207|CEA yeast vaccine
58424468|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
58424469|NCT06502834|DIETARY_SUPPLEMENT|D piger|Probiotic d piger
58424470|NCT06502834|DIETARY_SUPPLEMENT|Placebo|Placebo
58424471|NCT01818492|BIOLOGICAL|NI-0501|
58424472|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
58424473|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
58424474|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
58424475|NCT00003842|DRUG|isolated perfusion|
58424476|NCT00003842|PROCEDURE|surgical procedure|
58424477|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
58424478|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
58424479|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
58424480|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
58424481|NCT06368908|DEVICE|Transcutaneous Functional Magnetic Muscle Stimulation|Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, SLO). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
58096844|NCT04772469|BEHAVIORAL|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
58096845|NCT04363931|PROCEDURE|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
58424482|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
58424483|NCT02790021|PROCEDURE|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
58424484|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
58424485|NCT03668405|DRUG|Lu AF20513|Injection
57735785|NCT01842139|OTHER|laboratory biomarker analysis|Correlative studies
57735786|NCT05989308|BEHAVIORAL|Email|Email message sent to guardian with proxy information.
57735787|NCT05989308|BEHAVIORAL|Text|Text message sent to guardian with proxy information.
57735788|NCT05989308|BEHAVIORAL|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
57735789|NCT06532214|DIAGNOSTIC_TEST|International Study Group for Liver Surgery (ISGLS)|According to the ISGLS criteria, the patient was judged to have liver failure and further analysis
57951652|NCT03175666|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
57951653|NCT03175666|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
57951654|NCT02517164|OTHER|Measurement of serum 25-hydroxyvitamin D|
57951655|NCT02517164|OTHER|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
57951656|NCT02656485|DRUG|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
57951657|NCT02656485|DRUG|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
57951658|NCT03746912|DRUG|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
58424486|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
58424487|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
58424488|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
58424489|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
58424490|NCT01427634|BEHAVIORAL|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
58424491|NCT01427634|OTHER|Usual Care|Receive usual care as provided by the VAD clinical team.
58424492|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
58424493|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
58424494|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
58424495|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
58424496|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
58424497|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
58424498|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
58424499|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
58424500|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
58424501|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
58424502|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
58424503|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
58424504|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
58424505|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
57951659|NCT02011321|DRUG|clevidipine|clevidipine infusion x4 hours
58424506|NCT01896583|DRUG|Placebo|
58424507|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
58424508|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
57951660|NCT04778046|DRUG|Hyperpolarized 129Xe|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
58424509|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
58096846|NCT04363931|PROCEDURE|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
58096847|NCT02397174|OTHER|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
58096848|NCT02397174|OTHER|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
58096849|NCT03764592|OTHER|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
58096850|NCT03199846|OTHER|Non-Interventional|Non-Interventional
58096851|NCT00753909|DRUG|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
58096852|NCT00753909|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
58096853|NCT00753909|DRUG|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
58096854|NCT05789511|DEVICE|High Resolution Electrogastography|a new generation 64- channel high-resolution electrogastrography recording technology by Alimetry Limited that is able to record and analyze body surface gastric mapping/ HR-EGG
58096855|NCT03576131|BIOLOGICAL|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
58096856|NCT05697107|DRUG|Ripretinib Oral Tablet|Oral kinase inhibitor
58096857|NCT01883518|BIOLOGICAL|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
58096858|NCT01854515|DRUG|Budesonide|
58096859|NCT01854515|DRUG|Dexamethasone acetate|
58096860|NCT02229487|OTHER|Oral glucose tolerance|
58096861|NCT04861831|OTHER|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
58424510|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
58424511|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
58096862|NCT05366153|DIAGNOSTIC_TEST|Coronary CT|Screening/Management Plan
58424512|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
58424513|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
58096863|NCT00212810|DRUG|Topiramate|
58096864|NCT02574260|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection.
58424514|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
58424515|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
58424516|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
58424517|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
58424518|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
58424519|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
58096865|NCT04179123|DEVICE|Customised PAP interfaces|Customised PAP interfaces
58096866|NCT01734213|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
58096867|NCT01734213|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
58096868|NCT01805258|DRUG|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
58096869|NCT01805258|DRUG|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
58096870|NCT05270109|PROCEDURE|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
58424520|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
58424521|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
58096871|NCT05270109|PROCEDURE|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
58096872|NCT00022126|DRUG|asparaginase|
58096873|NCT00022126|DRUG|cyclophosphamide|
58096874|NCT00022126|DRUG|cyclosporine|
58096875|NCT00022126|DRUG|cytarabine|
58096876|NCT00022126|DRUG|daunorubicin hydrochloride|
58096877|NCT00022126|DRUG|dexamethasone|
58096878|NCT00022126|DRUG|doxorubicin hydrochloride|
57951661|NCT05284123|OTHER|Self-compassion workshop|The self-compassion workshop instructs participants to reflect on a source of shame, connect with their suffering related to it, and then direct feelings of support and understanding towards their suffering via a few brief writing tasks. This workshop also provides participants with basic information about mental health resources.
57951662|NCT05284123|OTHER|Mental health literacy workshop|The mental health literacy workshop provides participants with information about the symptoms and treatment of common mental disorders, and asks participants to reflect on what they learned through a couple brief writing tasks. This workshop also provides participants with basic information about mental health resources.
57951663|NCT05284123|OTHER|Control workshop|The control workshop provides participants with basic information about mental health resources.
57951664|NCT03472157|OTHER|Lifestyle therapy|Lifestyle habits (caloric intake and exercise) + pedometer
57951665|NCT03472157|PROCEDURE|Bariatric surgery|Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
57951666|NCT00138788|PROCEDURE|Radiotherapy, dose fractionation|
57951667|NCT04585464|DRUG|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
57951668|NCT04585464|DRUG|Placebo|Placebo is administered orally as a single dose or once daily
57951669|NCT01042860|DIETARY_SUPPLEMENT|Lutein|Lutein supplement, 10 mg daily
57951670|NCT01042860|DIETARY_SUPPLEMENT|Placebo|Placebo
57951671|NCT00584155|DRUG|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
57951672|NCT00584155|DRUG|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
57951673|NCT03646851|DIAGNOSTIC_TEST|Questionnaries|patients will have to do a sputum and to complete some questionnaries
57951674|NCT01950871|DEVICE|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
57951675|NCT06346678|OTHER|Accuhaler tester|Patients will perform testing with Accuhaler tester, Ellipta tester and Turbutester.
57951676|NCT03101228|BEHAVIORAL|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
57951677|NCT00150254|DRUG|CP-526,555 (varenicline)|
57951678|NCT06388655|DEVICE|mobile neurofeedback|The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.
58096879|NCT00022126|DRUG|mercaptopurine|
58096880|NCT00022126|DRUG|methotrexate|
58096881|NCT00022126|DRUG|methylprednisolone|
58096882|NCT00022126|DRUG|pegaspargase|
58096883|NCT00022126|DRUG|thioguanine|
58096884|NCT00022126|DRUG|vincristine sulfate|
58096885|NCT00022126|PROCEDURE|allogeneic bone marrow transplantation|
58096886|NCT00022126|RADIATION|radiation therapy|
58096887|NCT02343497|DIETARY_SUPPLEMENT|Astaxanthin|
58096888|NCT02343497|DIETARY_SUPPLEMENT|Placebo|
58096889|NCT05357742|BEHAVIORAL|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
58096890|NCT05357742|BEHAVIORAL|Enhanced usual care|During each session participants will receive DKD education only.
58096891|NCT06543186|OTHER|Oral health education lecture|Conventional oral health education will be given by trained and calibrated dentists.
58096892|NCT06543186|OTHER|Oral health education via mHealth on WhatsaApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material
58096893|NCT06543186|OTHER|Oral health education via Metaverse platform on Meta-OHE|For oral health education intervention via Meta-OHE, it will be done via computer.
58096894|NCT02838329|OTHER|warming of ropivacaine for BT|
58096895|NCT02838329|DRUG|Ropivicaine|
58096896|NCT03541798|PROCEDURE|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
57951679|NCT06388655|DEVICE|sham mobile neurofeedback|The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
58096897|NCT03541798|PROCEDURE|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
58096898|NCT04793165|DEVICE|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
58096899|NCT02989610|DEVICE|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
58096900|NCT02989610|DEVICE|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
58096901|NCT01015456|DRUG|mycophenolate sodium|per oral, twice daily, for 12 months
58096902|NCT01015456|DRUG|cyclophosphamide|intravenous, monthly, for 6 months
58096903|NCT03725722|DRUG|Delgocitinib cream|Cream for topical application
58096904|NCT03725722|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
58096905|NCT05473247|BEHAVIORAL|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
58096906|NCT06211803|DIAGNOSTIC_TEST|Positron-Emission Tomography Imaging|Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
58096907|NCT06529276|OTHER|Augmented reality clinical learning|Clinical learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation, using augmented reality immersive learning technology.
58096908|NCT06529276|OTHER|Control arm regular clinical learning|Regular bedside learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation,
58096909|NCT05265624|BEHAVIORAL|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
58096910|NCT05265624|BEHAVIORAL|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
58096911|NCT06301737|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
58096912|NCT06301737|PROCEDURE|Injection|the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58424522|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
58424523|NCT01554995|DRUG|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
58424524|NCT01554995|DRUG|Linezolid|Linezolid 600 mg (Cohort 9) none
58424525|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
57951680|NCT05627063|DRUG|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
57951681|NCT00956670|OTHER|Quality-of-Life Assessment|Ancillary studies
57951682|NCT00956670|OTHER|Questionnaire Administration|Ancillary studies
57951683|NCT00956670|PROCEDURE|Study of High Risk Factors|Undergo lymphedema assessment
57951684|NCT00956670|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57951685|NCT00956670|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo surgery
57951686|NCT00956670|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
57951687|NCT04155749|DRUG|anitocabtagene-autoleucel|Chimeric Antigen Receptor T cells
57951688|NCT04891315|DIAGNOSTIC_TEST|Blood test for soluble VAP-1 (sVAP-1).|\~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
57951689|NCT03958162|DIAGNOSTIC_TEST|lung biopsy|transbronchial lung cryobiopsy
57951690|NCT03917173|PROCEDURE|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
58096913|NCT06301737|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58096914|NCT04161118|DRUG|CTL019|IV Infusion
58096915|NCT04095819|PROCEDURE|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
58096916|NCT04095819|PROCEDURE|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
58096917|NCT02792088|DRUG|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
58096918|NCT02792088|DRUG|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
58096919|NCT03567200|BEHAVIORAL|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
58096920|NCT01715259|DRUG|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
58096921|NCT01715259|DRUG|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
58096922|NCT05572424|OTHER|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
58096923|NCT04201418|DRUG|Patisiran|Patisiran-lipid complex injection, for intravenous use
58096924|NCT04989231|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
58096925|NCT04989231|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
58096926|NCT01184378|DIETARY_SUPPLEMENT|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
58096927|NCT04580173|DIAGNOSTIC_TEST|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
58424526|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
58424527|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
57951691|NCT03917173|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
57951692|NCT06423573|DRUG|Filsuvez|Topical gel
57951693|NCT00732511|DRUG|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
57951694|NCT00732511|DRUG|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
57951695|NCT04096274|BEHAVIORAL|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
57951696|NCT04096274|BEHAVIORAL|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
57951697|NCT00457015|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
57951698|NCT00457015|DRUG|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
57951699|NCT01553981|DRUG|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
57951700|NCT01553981|DRUG|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
58096928|NCT06701422|PROCEDURE|Intraoperative stimulation of the cervical spinal cord|The surgeon will place spinal cord electrodes on the epidural surface, with stimulation sites identified using preoperative MRI. Recruitment curves will be generated by systematically increasing the stimulation intensity across various parameter combinations, including frequency, pulse count, pulse shape, and electrode-specific properties such as size, separation, and arrangement.
58096929|NCT02125617|DRUG|Abiraterone|1000 mg/day
57951701|NCT05303545|OTHER|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
57951702|NCT03991130|DRUG|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
57951703|NCT05491928|DRUG|Tempol|Tempol will be given as an adjunct to chemotherapy.
57951704|NCT00678873|PROCEDURE|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
57951705|NCT05917574|OTHER|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
57951706|NCT02125227|DRUG|Rosuvastatin, Metformin, YH14755|single dose
57951707|NCT02125227|DRUG|YH14755|single dose
57951708|NCT03099187|DRUG|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
57951709|NCT03099187|DRUG|Placebo|Matching placebo capsules three times in a day.
57951710|NCT01468584|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
57951711|NCT01468584|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
57951712|NCT01468584|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
57951713|NCT04536688|DRUG|RGLS4326|Solution for subcutaneous injection
57951714|NCT02385630|OTHER|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
57951715|NCT00655031|DIETARY_SUPPLEMENT|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
57951716|NCT00655031|DIETARY_SUPPLEMENT|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
57951717|NCT03080246|BEHAVIORAL|Strength Training Exercise|
58096930|NCT02125617|DRUG|Prednisolone|10 mg/day
57951718|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
57951719|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
57951720|NCT02757560|OTHER|SFA diet|SFA versus control diet
57951721|NCT02757560|OTHER|MUFA diet|MUFA versus control diet
57951722|NCT02757560|OTHER|CARB diet|CARB versus control diet
57951723|NCT02601339|PROCEDURE|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
57951724|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
57951725|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
57951726|NCT00670319|DRUG|Placebo|Placebo one tab orally per day
57951727|NCT00371865|BEHAVIORAL|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
57951728|NCT00371865|BEHAVIORAL|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
57951729|NCT03553342|DRUG|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
57951730|NCT03553342|OTHER|Placebo|Patients will receive placebo for seven days.
57951731|NCT02466152|DRUG|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
57951732|NCT03043248|DRUG|TRK-700|repeated oral administration
57951733|NCT03043248|DRUG|Digoxin|single oral administration with/without TRK-700
57951734|NCT03043248|DRUG|Midazolam|single oral administration with/without TRK-700
57951735|NCT04452981|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
58096931|NCT02399059|PROCEDURE|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
58096932|NCT02399059|PROCEDURE|Normal saline lavage|Peritoneal irrigation with normal saline
58096933|NCT03795064|PROCEDURE|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
58096934|NCT03795064|PROCEDURE|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
58096935|NCT04171089|BEHAVIORAL|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
58424528|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
57951736|NCT04914208|DEVICE|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
58096936|NCT01033201|OTHER|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
58096937|NCT03345953|DRUG|BP 1.4979|Double blind versus placebo
58096938|NCT03345953|DRUG|Placebo|Double blind versus placebo
58096939|NCT03015909|DRUG|Somatropin|
58096940|NCT01855321|DRUG|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
58096941|NCT01855321|DRUG|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
58096942|NCT00004009|DRUG|tipifarnib|
58424529|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
58424530|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
58424531|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
58424532|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
58424533|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
57951737|NCT04914208|DEVICE|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
57951738|NCT04914208|DEVICE|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
57951739|NCT04914208|OTHER|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
57951740|NCT04914208|OTHER|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
57951741|NCT04952298|PROCEDURE|Mesial temporal lobe epilepsy surgery|"Medial temporal lobe epilepsy surgery including~* selective Amygdalohippocempectomy (SAH) including anterior parahippocampal gyrus / entorhinal cortex~* anteromedial temporal lobe resection including amygdalohippocampectomy~* anterior temporal lobe resection"
57951742|NCT03853785|BIOLOGICAL|MMR vaccine|Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
57951743|NCT03853785|BIOLOGICAL|Candida antigen|Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
57951744|NCT03853785|DRUG|Topical Podophyllin|It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
57951745|NCT02757183|DEVICE|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
57951746|NCT01006265|DRUG|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
57951747|NCT01006265|DRUG|Placebo|Matching placebo administered orally once daily
57951748|NCT01006265|DRUG|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
57951749|NCT01006265|DRUG|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
57951750|NCT00004887|DRUG|carboplatin|
57951751|NCT00004887|DRUG|cisplatin|
58096943|NCT02413879|DEVICE|CleanCision|Wound protection during colorectal surgery.
58096944|NCT03914937|OTHER|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
58096945|NCT03914937|OTHER|Music|Music of the patient's choice will be played
58424534|NCT02134288|DRUG|Belatacept|
58424535|NCT02134288|DRUG|Everolimus|
58096946|NCT04979078|DEVICE|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
58096947|NCT04814888|OTHER|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
58096948|NCT05128331|DIETARY_SUPPLEMENT|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
58096949|NCT05128331|DIETARY_SUPPLEMENT|Placebo|dietary supplement that is made of cellulose.
58096950|NCT05598463|DEVICE|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
58096951|NCT06567717|DRUG|Zinc|Zinc has not previously been investigated in the treatment of IPF.
58424536|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
58096952|NCT06567717|OTHER|Placebos for zinc and nicotinamide riboside|These will be identical in appearance to the active substances
58096953|NCT06567717|DRUG|Nicotinamide riboside|Nicotinamide riboside has not previously been investigated in the treatment of IPF.
58096954|NCT01984931|DRUG|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
58096955|NCT01984931|DRUG|Metoclopramide hydrochloride monohydrate|
58096956|NCT05381883|OTHER|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
58096957|NCT06096259|DRUG|Metformin|Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
58096958|NCT06096259|DRUG|Placebo|The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments weekly as tolerated, up to a maximum dose of 1500 mg daily.
58096959|NCT03701490|DRUG|Progesterone subcutaneous|25 mg/twice a day.
58096960|NCT03701490|DRUG|Progesterone Vaginal Product|200 mg three times a day.
58096961|NCT05675930|DEVICE|Photobiomodulation Therapy|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
58096962|NCT05675930|OTHER|Placebo sham device|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
58424537|NCT02087722|DRUG|KI1001|
58424538|NCT02087722|DRUG|Placebo|
58424539|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
58424540|NCT00389675|DRUG|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
58424541|NCT00389675|DRUG|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
58424542|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
58424543|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
57951752|NCT00004887|DRUG|ifosfamide|
57951753|NCT00004887|DRUG|mitomycin C|
57951754|NCT00004887|DRUG|paclitaxel|
57951755|NCT00004887|DRUG|vinblastine sulfate|
57951756|NCT03410173|DRUG|Taurine|
57951757|NCT03410173|DRUG|Placebo|
58424544|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
58424545|NCT00442325|DRUG|Atorvastatin (Lipitor)|
58424546|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
58424547|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
58424548|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
58096963|NCT05875974|DRUG|JZP258 (XYWAV)|Initiate dosage per study protocol and titrate to variable dosage.
58096964|NCT01018342|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
58096965|NCT01018342|DRUG|Macrobid® Capsules 100 mg|
58096966|NCT05796531|BEHAVIORAL|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
58096967|NCT05796531|BEHAVIORAL|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
58096968|NCT05553600|DEVICE|Tampon BR|Modified Regular Absorbency Tampons
58096969|NCT05553600|DEVICE|Tampon CR|Reference Regular Absorbency Tampons
58096970|NCT05553600|DEVICE|Tampon BS|Modified Super Absorbency Tampons
58096971|NCT05553600|DEVICE|Tampon CS|Reference Super Absorbency Tampons
58096972|NCT06241794|PROCEDURE|Group M-TAPA|Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.
58096973|NCT06241794|PROCEDURE|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
58424549|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
58424550|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
58424551|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
58424552|NCT05004129|DRUG|Tideglusib|All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
58424553|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
58096974|NCT06422156|RADIATION|Stereotactic body radiation|Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
58096975|NCT06422156|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
58096976|NCT06422156|DRUG|mono-chemotherapy|Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
58096977|NCT02056431|BEHAVIORAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
58096978|NCT03210142|PROCEDURE|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
58096979|NCT00854386|DRUG|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
58096980|NCT00854386|DRUG|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
58096981|NCT06453720|PROCEDURE|Colonoscopy|A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
58096982|NCT04567160|DRUG|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
58424554|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
58424555|NCT03908970|DRUG|1% OPA-15406|Twice daily
58424556|NCT03908970|DRUG|Placebos|Twice daily
57735790|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
57735791|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
57735792|NCT05440110|DEVICE|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
57951758|NCT03489382|OTHER|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
58096983|NCT04567160|DRUG|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
58096984|NCT04245930|PROCEDURE|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
58096985|NCT04245930|PROCEDURE|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
58096986|NCT02854722|DRUG|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
58096987|NCT02854722|DRUG|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
58096988|NCT06543004|COMBINATION_PRODUCT|AH plus sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
58096989|NCT06543004|COMBINATION_PRODUCT|Bioceramic sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
58424557|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
58424558|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
58424559|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
58424560|NCT00718341|DRUG|AF056|
58424561|NCT00718341|DRUG|Placebo|
58424562|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
57951759|NCT03203239|DEVICE|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
57951760|NCT03203239|DRUG|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
57951761|NCT04288154|DEVICE|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
57951762|NCT04288154|OTHER|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
57951763|NCT03147937|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
58424563|NCT04773236|DRUG|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
58424564|NCT04773236|DRUG|2%lidocaine with 1:80.000 epinphrine|injection
58424565|NCT04773236|DEVICE|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
58096990|NCT04196582|DEVICE|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
58096991|NCT02006355|DRUG|Ropivacaine|
58424566|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
58424567|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
58424568|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
58424569|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
58096992|NCT02069886|DRUG|deferasirox|125, 250, 500 mg dispersable tablets
58424570|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
58424571|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
58424572|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
58424573|NCT04778800|DRUG|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
58424574|NCT04778800|DRUG|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
58096993|NCT04740801|DEVICE|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
58424575|NCT04778800|DRUG|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
58096994|NCT00817778|DRUG|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
58096995|NCT00817778|DRUG|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
58096996|NCT04832178|DIETARY_SUPPLEMENT|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~* S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~* Betaine hydrochloride 250 mg~* Vitamin C 80 mg~* Vitamin B1 1.1 mg~* Vitamin B2 1.4 mg~* Vitamin B6 1.4 mg~* Vitamin B12 2,5 µg~* Folic Acid 200 µg~* Selenium 37 µg"
58424576|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
58424577|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
58424578|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
58424579|NCT05017662|OTHER|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
58424580|NCT00785343|DEVICE|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
58096997|NCT04832178|OTHER|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
58096998|NCT04778176|COMBINATION_PRODUCT|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
58096999|NCT04135456|DRUG|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
58097000|NCT06703970|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
58097001|NCT06703970|DEVICE|Platelet Rich Plasma Joint Injection|\~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
58424581|NCT00785343|PROCEDURE|Conventional Therapy|Occupational therapy that is the current standard of care
58424582|NCT00418054|DRUG|Nitazoxanide plus peginterferon alfa-2b|
58424583|NCT00418054|DRUG|Peginterferon alfa-2b|
58424584|NCT00120601|DRUG|Naltrexone|
58424585|NCT00120601|DRUG|Acamprosate|
58424586|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
58424587|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
58424588|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
58424589|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
58424590|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
58424591|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
57735793|NCT05440110|DEVICE|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
57735794|NCT04250649|PROCEDURE|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
57735795|NCT04323852|DRUG|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
58424592|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
57735796|NCT04323852|DRUG|Placebo|Placebo
57735797|NCT06138977|DEVICE|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
57735798|NCT06401148|BEHAVIORAL|Cardiac rehab intervention group|Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
57951764|NCT01277549|DEVICE|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
57951765|NCT00711984|DEVICE|Herkulink renal artery Stent|renal artery stent
57951766|NCT00711984|OTHER|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
57951767|NCT01627899|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
57951768|NCT05386355|BEHAVIORAL|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
57951769|NCT05386355|OTHER|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
58424593|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
58424594|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
58424595|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
58424596|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
58424597|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
58424598|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
58424599|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
58424600|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
58424601|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
58424602|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
58424603|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
58424604|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
58424605|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
58424606|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
58424607|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
58424608|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
57735799|NCT04899349|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
57735800|NCT04899349|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
58097002|NCT04711512|BEHAVIORAL|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
58097003|NCT04711512|BEHAVIORAL|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
58097004|NCT05243966|DEVICE|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
58097005|NCT03309631|DIAGNOSTIC_TEST|In vitro Diagnostic|
58097006|NCT06003673|COMBINATION_PRODUCT|neoadjuvant therapy|The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.
58097007|NCT02780999|DEVICE|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
58306973|NCT04752930|DIAGNOSTIC_TEST|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
58306974|NCT03365180|DEVICE|Starter Kit Algorithm|Long acting insulin titration to target
58306975|NCT02266823|BEHAVIORAL|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
58306976|NCT01107145|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
58306977|NCT01107145|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
58306978|NCT01107145|DRUG|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
58306979|NCT04101292|OTHER|Characterization of tumor tissue by fluorescence|"* HSI Imaging of the resected specimen, from the serum and the mucous side~* FF-OCT imaging of the tumor and the healthy tissue biopsies~* Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~* Standard anti-VEGF Immunohistochemistry and pathology"
58306980|NCT01973881|PROCEDURE|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
58306981|NCT02965924|DRUG|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
58306982|NCT04509271|DIAGNOSTIC_TEST|MicRNAs battery kits|Novel peripheral blood diagnostic biomarker for MCI due to AD.
58424609|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
57951770|NCT00315744|DRUG|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
58424610|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
58097008|NCT02780999|DEVICE|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
58097009|NCT01878500|DEVICE|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
58097010|NCT02542722|BEHAVIORAL|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
58097011|NCT02542722|BEHAVIORAL|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
58097012|NCT05875116|BEHAVIORAL|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
58097013|NCT05875116|BEHAVIORAL|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
58097014|NCT05875116|BEHAVIORAL|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
58097015|NCT01453101|DRUG|Fludarabine monophosphate, melphalan, Bortezomib|"* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
58306983|NCT02130869|BIOLOGICAL|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
57735801|NCT04899349|DRUG|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
57951771|NCT00315744|DRUG|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
58306984|NCT02130869|BIOLOGICAL|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
58306985|NCT02130869|BIOLOGICAL|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
58306986|NCT02130869|DRUG|Busulfan|Given IV - Group A only.
58306987|NCT02130869|DRUG|Melphalan|Given IV - All groups.
58306988|NCT02130869|BIOLOGICAL|GM-CSF|Given SQ - All groups.
58306989|NCT02130869|DRUG|Bendamustine|Given IV - Group B only.
58306990|NCT02130869|DRUG|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
58306991|NCT02130869|DRUG|Cytarabine|Given IV - Group B only.
58306992|NCT02130869|DRUG|Carboplatin|Given IV - Group C only.
58306993|NCT02130869|DEVICE|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
58306994|NCT02130869|BIOLOGICAL|G-CSF|Given SQ - All Groups.
58306995|NCT02130869|DRUG|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
58424611|NCT04023682|DRUG|Provodine Hand Sanitizer|Intervention with Provodine
58424612|NCT00004274|DRUG|Estrogen|
58424613|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
58424614|NCT04997525|DRUG|Progesterone|Combined with estradiol
57951772|NCT00315744|DRUG|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
57951773|NCT05639127|DRUG|Prednisolone|Nebulization of prednisolone
57951774|NCT01211600|OTHER|Staples|Interrupted Ethicon Staples
57951775|NCT01211600|OTHER|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
57951776|NCT02989064|GENETIC|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
58424615|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
57951777|NCT04342221|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
58097016|NCT04824300|PROCEDURE|erector spinae block|Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
58097017|NCT02321215|OTHER|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
58424616|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
57735802|NCT04899349|DRUG|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
58097018|NCT05654103|DEVICE|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
58097019|NCT05654103|PROCEDURE|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
57735803|NCT04899349|DRUG|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
57735804|NCT00167544|DRUG|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
57735805|NCT00167544|DRUG|Placebo|Saline
58097020|NCT00741117|PROCEDURE|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
58097021|NCT00741117|PROCEDURE|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
58097022|NCT00741117|PROCEDURE|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
58097023|NCT05538286|DEVICE|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
58097024|NCT05538286|PROCEDURE|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
58097025|NCT05606913|DRUG|dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
58097026|NCT05606913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
58097027|NCT02199665|DRUG|selinexor|Given PO
58097028|NCT02199665|DRUG|carfilzomib|Given IV
58097029|NCT02199665|DRUG|dexamethasone|Given PO or IV
58097030|NCT05937750|DRUG|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
58097031|NCT05937750|OTHER|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study|Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
58097032|NCT06468280|PROCEDURE|Local treatment (Surgical)|Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
58097033|NCT06468280|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
57951778|NCT04342221|DRUG|Placebo|Placebo capsules
58306996|NCT02130869|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
58306997|NCT01725672|DRUG|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58306998|NCT01725672|DRUG|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58424617|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
58424618|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
58097034|NCT06468280|DRUG|XELOX Chemotherapy Regimen|"Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle."
58097035|NCT06468280|PROCEDURE|Local Treatment (Non-surgical)|"Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team."
58424619|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
58424620|NCT02237482|DEVICE|Trilogy cup|
58424621|NCT02237482|DEVICE|Trabecular metal cup (TM)|
58424622|NCT02237482|DEVICE|ZCA cup|
58306999|NCT01725672|DRUG|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58424623|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
58424624|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
58424625|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
58424626|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
58424627|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
57735806|NCT06368245|PROCEDURE|long-segment posterior TL instrumented fusion|long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.
58307000|NCT01725672|DRUG|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58307001|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58424628|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
57735807|NCT06635317|DRUG|Aspirin|100 mg/day orally for 25 days
57735808|NCT06635317|DRUG|enoxaparin|40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
57735809|NCT06372730|OTHER|Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)|All patients will undergo a V/Q SPECT/CT scan at inclusion.
57951779|NCT02194127|DRUG|Anthocyan capsules|
58424629|NCT06149377|PROCEDURE|Test cohort|
58424630|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
58424631|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
58424632|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
58424633|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
58424634|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
58424635|NCT02475616|DRUG|PCO371|
58424636|NCT02475616|DRUG|Placebo|
58097036|NCT06568029|OTHER|Questionnaire|In the study, the validity and responsiveness of EQ-5D-3L will be assessed. The EQ-5D-3L measures HRQoL and consists of two parts. The first part contains five questions about mobility, daily activities, self-care, pain/discomfort, and anxiety/depression (EuroQoL 1990, Brooks 1996). Each question can be answered with no problem (1), some/moderate problem (2) unable to perform certain activities/having extreme problems (3). The answers can be summarized in an index value based on an existing preference-based value set. In this study, the EQ-5D-3L value set by Dolan (Dolan 1997) will be used for the main analyses and a Swedish experience-based value set in a sensitivity analysis (Burström, Sun et al. 2014). For the EQ-5D-3L index, 1 represents full health and 0 represents a value equal to being dead. EQ VAS measures the persons health today on a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health) (EuroQoL 1990, Brooks 1996).
58097037|NCT05840601|DEVICE|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
58097038|NCT05840601|DEVICE|Comparator|Unmodified commercially available prosthetic hand.
58097039|NCT03659617|DEVICE|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
58097040|NCT00950001|RADIATION|Stereotactic Radiosurgery|Undergo SRS
58097041|NCT03151226|DEVICE|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
58307002|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58307003|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58307004|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
58307005|NCT03118050|BEHAVIORAL|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
58424637|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
58424638|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
58424639|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
58424640|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
58424641|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
58424642|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
58424643|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
57735810|NCT05205265|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
57735811|NCT01560390|DRUG|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
57735812|NCT01560390|DRUG|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
57735813|NCT04111445|DRUG|ADG116|IV infusion at Day 1 of each cycle
57735814|NCT06119633|PROCEDURE|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
57951780|NCT02194127|DRUG|Placebo|
58424644|NCT04576689|DRUG|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
58424645|NCT04576689|DRUG|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
58424646|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
57951781|NCT00535561|DRUG|Ferrous sulfate tablets 325 mg, po, TID|
57951782|NCT00535561|DRUG|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
58424647|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
58424648|NCT01873690|DRUG|Placebo|5% Dextrose in water
58097042|NCT06440486|DIETARY_SUPPLEMENT|Probiotics|Serum and fecal samples were collected at the beginning and end of the study to evaluate the effects of probiotic consumption on immune markers, metabolites, and gut microbiota before and after administration.
58097043|NCT00822679|DRUG|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
58097044|NCT00822679|OTHER|Placebo|Subjects are given placebo for 3 consecutive nights
58097045|NCT06611033|BIOLOGICAL|V118C|Intramuscular Administration
58097046|NCT06611033|BIOLOGICAL|V118|Intramuscular Administration
58097047|NCT06611033|BIOLOGICAL|PREVNAR 20™|Intramuscular Administration
58097048|NCT06611033|BIOLOGICAL|Saline|Intramuscular Administration
58424649|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
58097049|NCT03546699|DIAGNOSTIC_TEST|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~* To describe clinical characteristics and outcomes for these patients.~* To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
57735815|NCT04110808|DRUG|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
57735816|NCT02352311|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
57735817|NCT02352311|DRUG|AVODART|Dutasteride 0.5 mg
58307006|NCT03118050|BEHAVIORAL|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
58307007|NCT03118050|BEHAVIORAL|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
58307008|NCT02273167|DRUG|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
57735818|NCT02352311|DRUG|CIALIS|Tadalafil 5 mg
57735819|NCT00281541|DRUG|YM155|
57735820|NCT01763931|DRUG|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
58307009|NCT02273167|DRUG|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
58307010|NCT02273167|DRUG|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
58307011|NCT06481787|DRUG|Vonorasan Fumarate|Vonorasan fumarate is taken 30min before breakfast and dinner.
58424650|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
58097050|NCT04083066|DRUG|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
58097051|NCT06542731|DRUG|ONO-4578|Specified dose on specified days
58424651|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
57735821|NCT05345015|DEVICE|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
57951783|NCT01262690|DRUG|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
57951784|NCT01262690|DRUG|PF-05230901|Single dose SC
58097052|NCT06542731|DRUG|ONO-4538|Specified dose on specified days
58097053|NCT06542731|DRUG|Docetaxel|Specified dose on specified days
58097054|NCT06542731|DRUG|Ramucirumab|Specified dose on specified days
58097055|NCT04466956|DEVICE|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
58424652|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
58424653|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
57951785|NCT00841594|DRUG|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
57951786|NCT00841594|DRUG|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
57951787|NCT05778500|DEVICE|COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines
57951788|NCT06169475|DRUG|Dexmedetomidine Hydrochloride|The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
57951789|NCT06169475|DRUG|Esmolol Hydrochloride|The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
57951790|NCT00283075|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
57951791|NCT04186741|DRUG|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
57951792|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
57951793|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
57951794|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
57951795|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
57951796|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
57951797|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
57951798|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
57951799|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
57951800|NCT02326454|DRUG|talaporfin sodium|1 mg/kg
57951801|NCT02326454|DRUG|Saline|
57951802|NCT02326454|DEVICE|Drug Activator 100 J/cm|Light Dose: 100 J/cm
57951803|NCT02326454|DEVICE|Drug Activator 200 J/cm|Light Dose: 200 J/cm
57951804|NCT04923659|DRUG|Carbamazepine|600 mg reconstituted as one table. Administered once
57951805|NCT04923659|DRUG|Lorazepam|2.5 mg mg reconstituted as one table. Administered once
57951806|NCT04923659|DRUG|Dextromethorphan|150 mgmg reconstituted as one table. Administered once
57951807|NCT04923659|DRUG|Nimodipine|30 mg reconstituted as one table. Administered once
57951808|NCT04923659|DRUG|Placebo|Administered once
57951809|NCT02874807|DRUG|Empagliflozin|
57951810|NCT02874807|OTHER|Placebo|
57951811|NCT03116698|DRUG|Low dose DFD07 once daily|Low dose DFD07 once daily
57951812|NCT03116698|DRUG|High dose DFD07 once daily|High dose DFD07 once daily
57951813|NCT03116698|DRUG|High dose DFD07 twice daily|High dose DFD07 twice daily
57951814|NCT03116698|DRUG|Placebo twice daily|Placebo twice daily
57735822|NCT05345015|DEVICE|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
57735823|NCT06193876|OTHER|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
58097056|NCT05776732|OTHER|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
58097057|NCT01249690|DRUG|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
58097058|NCT01249690|DRUG|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
58097059|NCT03159611|DRUG|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
58097060|NCT03159611|DRUG|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
58097061|NCT04065386|DEVICE|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
58097062|NCT04065386|DEVICE|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
58097063|NCT04747678|DRUG|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
58097064|NCT02367807|DRUG|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
58097065|NCT01728363|DRUG|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
57735824|NCT04706832|DEVICE|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
58097066|NCT04078659|DRUG|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
58097067|NCT04078659|DRUG|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
58097068|NCT04078659|DRUG|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
58097069|NCT04078659|DRUG|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
58097070|NCT04078659|DRUG|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
58097071|NCT04078659|DRUG|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
58424654|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
58424655|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
58424656|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
58097072|NCT04078659|PROCEDURE|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
58097073|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
58307012|NCT06481787|DRUG|Zuojin Pills|Zuojin Pills should be taken 30min after breakfast and dinner.
58424657|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
57735825|NCT02576067|DRUG|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
57735826|NCT02576067|DRUG|Placebo|
57735827|NCT06434038|DRUG|Low Dose Regular insulin|Administered intranasally at 40 IU
57735828|NCT06434038|DRUG|High Dose Regular insulin|Administered Intranasally at 80 IU
57735829|NCT06434038|OTHER|0.9% Saline|Placebo control
57735830|NCT00303524|DRUG|Goserelin acetate|Injection 3.6 mg monthly
57735831|NCT00303524|DRUG|Goserelin acetate|injection 10.8 mg every 3 months
57735832|NCT04704063|DRUG|Tocotrienols / Vitamin E|Palm Tocotrienols complex
58424658|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
57735833|NCT04704063|DRUG|Placebo control|Placebo matching Tocovid Suprabio
57735834|NCT02816580|OTHER|Blood collection|
57735835|NCT04327414|BEHAVIORAL|Intervention group|Standing desks
57735836|NCT02734212|BEHAVIORAL|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
58307013|NCT04236037|PROCEDURE|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
58307014|NCT04236037|PROCEDURE|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
58307015|NCT03686592|OTHER|Measurement of body awareness|Questionnaires+ interviews
57735837|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
58307016|NCT01433159|DRUG|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
58307017|NCT01433159|DRUG|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
58307018|NCT01694693|DRUG|Orencia|No Intervention
57735838|NCT01134900|OTHER|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
57735839|NCT02587351|DRUG|Metoprolol succinate|Extended release Metoprolol succinate
57735840|NCT02587351|OTHER|Placebo|Matching placebo
57735841|NCT03853629|OTHER|None. Not applicable|None. Not applicable
57735842|NCT02477618|DRUG|SAGE-547|
57951815|NCT03740971|DEVICE|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
57951816|NCT03740971|DRUG|Guideline-based therapy|Guideline-based therapy
57951817|NCT03801850|DEVICE|3D surface scan|measurement of inter fractional deformations by surface scanning
57735843|NCT02477618|DRUG|Placebo|Placebo
57735844|NCT00458328|DRUG|Z-338|
57735845|NCT02742844|BIOLOGICAL|APZ2 application|Application of IMP on patients wound.
57735846|NCT03881735|DRUG|Enasidenib|Given PO
57735847|NCT03881735|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
57951818|NCT02448030|OTHER|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
57951819|NCT02448030|OTHER|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
57951820|NCT01997411|DRUG|Nasal Glucagon|
57951821|NCT01997411|DRUG|Intramuscular Glucagon|
57951822|NCT04182373|DRUG|Antithrombin gamma|Intravenous infusion, once a day, 7 days
57951823|NCT04182373|DRUG|physiological saline|Intravenous infusion, once a day, 7 days
57951824|NCT04697680|BEHAVIORAL|Algorithm 1|A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
57951825|NCT04697680|BEHAVIORAL|Algorithm 2|A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
58097074|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
58097075|NCT01111994|DRUG|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
58097076|NCT01519895|BEHAVIORAL|Telephone intervention|counseling and education support
58097077|NCT04641273|DRUG|BAY1817080|Tablet, intake orally.
58097078|NCT04641273|DRUG|Placebo for BAY1817080|Tablet, intake orally.
58097079|NCT04641273|DRUG|Placebo for Pregabalin|Capsule, intake orally.
58097080|NCT04641273|DRUG|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
58097081|NCT02645266|DRUG|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
58097082|NCT03534830|DIAGNOSTIC_TEST|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
58097083|NCT03271541|DRUG|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
58097084|NCT00063700|PROCEDURE|reducing exposure to marketing pressures|
57735848|NCT05278273|DEVICE|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
57735849|NCT03664076|DIAGNOSTIC_TEST|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
57951826|NCT04697680|BEHAVIORAL|Algorithm 3|A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
57951827|NCT03169985|DRUG|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
57951828|NCT03169985|DRUG|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
57951829|NCT00794677|DRUG|ezetimibe|Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
57951830|NCT00794677|DRUG|placebo|Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
57951831|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
57951832|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
57951833|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
57951834|NCT00664833|OTHER|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
57951835|NCT04414800|DRUG|Placebo|Distilled water
57951836|NCT04414800|DRUG|Ketamine|1 mg/kg intranasal ketamine
57951837|NCT04414800|DRUG|Fentanyl|1μg/kg intranasal fentanyl
57951838|NCT01834092|OTHER|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
57951839|NCT02210065|BIOLOGICAL|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
58097085|NCT00530088|DRUG|porfimer sodium|IV
58097086|NCT00530088|DRUG|Photdynamic Therapy (PDT)|
58097087|NCT05779488|DIETARY_SUPPLEMENT|maca|2.25 g of Maca extract, twice per day for 12 weeks
58097088|NCT05779488|DIETARY_SUPPLEMENT|placebo|2.25 g of starch, twice per day for 12 weeks
58097089|NCT02591017|DRUG|Morphine|
58097090|NCT02591017|DRUG|Ketamine|
58097091|NCT02591017|DRUG|Placebo|
58097092|NCT02591017|DRUG|Chitosan|
58097093|NCT02378467|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
58097094|NCT02378467|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
58097095|NCT06412991|BEHAVIORAL|Cycle Therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
58307019|NCT05225662|DIAGNOSTIC_TEST|radiofrequency ablation|Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation
57735850|NCT00470951|PROCEDURE|open rectal resection|open rectal resection
57735851|NCT00470951|PROCEDURE|laparoscopic rectal resection|laparoscopic assisted rectal resection
57735852|NCT04901429|PROCEDURE|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
57735853|NCT03386370|DEVICE|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
57735854|NCT04272281|PROCEDURE|medical shared decision|The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
57735855|NCT04272281|PROCEDURE|Standard medical care|control group will act as usual in their practice.
58307020|NCT01892332|DRUG|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
58307021|NCT05143684|PROCEDURE|Left Lateral Uterine Displacement|a wooden wedge wrapped with cotton, to make it comfortable, and medical sheets with a measured angle of 15° under the right flank of the laying down patient
58307022|NCT05463965|BIOLOGICAL|QM1114-DP|Intramuscular injection
58307023|NCT05463965|BIOLOGICAL|OnabotulinumtoxinA|Intramuscular injection
58307024|NCT05463965|BIOLOGICAL|Placebo|Intramuscular injection
58307025|NCT03059667|DRUG|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
58307026|NCT03059667|DRUG|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
58307027|NCT03059667|DRUG|Carboplatin|In accordance with the summary of product characteristics.
57735856|NCT06273072|DRUG|Metformin hydrochloride extended-release tablets|titrated to 2000 mg once daily
57735857|NCT06273072|DRUG|Visually identical placebo Metformin hydrochloride extended-release tablets|placebo
57735858|NCT06669299|PROCEDURE|Re-Do ventricular tachycardia ablation|1. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.
57951840|NCT04077996|DEVICE|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
57951841|NCT04077996|DEVICE|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
57951842|NCT06091215|DEVICE|Sciton Joule System|Sciton Joule System
57951843|NCT03593252|DRUG|Senna|Laxative,used for bowel preparation
57951844|NCT03593252|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
57951845|NCT03593252|DRUG|Metronidazole Oral|Oral antibiotic
57951846|NCT03593252|DRUG|Neomycin|Oral non-absorbable antibiotic
57951847|NCT03593252|DRUG|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
57951848|NCT03593252|DRUG|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
57951849|NCT03593252|OTHER|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for \>=8 hours, no formula milk/full liquids \>= 4hours; no breast milk or clear fluids \>=2hours.
57951850|NCT03593252|OTHER|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
57951851|NCT05341960|BEHAVIORAL|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
57951852|NCT05341960|OTHER|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
57951853|NCT05558280|DRUG|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
57951854|NCT02474433|DRUG|Misoprostol (Cytotec)|
57951855|NCT02732769|DEVICE|GammaKnifePerfexion®|neurosurgery
57951856|NCT02732769|DEVICE|GammaKnifeIcon®|neurosurgery
57951857|NCT02732769|DEVICE|Efficast®|Thermoformed mask
57951858|NCT02732769|DEVICE|MRI|
58307028|NCT03059667|DRUG|Etoposide|In accordance with the summary of product characteristics.
58307029|NCT04042831|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
57951859|NCT01366547|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
58097096|NCT00788723|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
58097097|NCT06176989|DRUG|Enasidenib|100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
58097098|NCT01831596|DEVICE|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
58307030|NCT04042831|PROCEDURE|Computed Tomography|Undergo CT
58307031|NCT04042831|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58307032|NCT04042831|DRUG|Olaparib|Given PO
58307033|NCT06376968|DEVICE|BioLogic Fusion|Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
57951860|NCT01366547|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
57951861|NCT01366547|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
57951862|NCT04284202|DRUG|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
57951863|NCT00309231|PROCEDURE|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
57951864|NCT03699176|DRUG|Vilaprisan (BAY1002670)|2 mg, once daily, oral
57951865|NCT03699176|DRUG|Placebo|Once daily, oral
57951866|NCT06464250|OTHER|Bundla care group|A care package consisting of foot examination, correct foot care behaviours, and regular blood glucose monitoring was used.
57951867|NCT00822965|OTHER|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
57951868|NCT00822965|OTHER|Phone Interviews|2 follow-up phone interviews.
57951869|NCT00822965|BEHAVIORAL|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
57951870|NCT01230307|DRUG|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
57951871|NCT01230307|DRUG|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
57951872|NCT05800548|OTHER|survey application|In data collection; Socio-demographic and obstetric characteristics of puerperant women, descriptive information form including questions about current birth, Postpartum Family Planning Attitude Scale The Health Literacy Scale was used.
57951873|NCT04776382|OTHER|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
57951874|NCT01480336|DRUG|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
57951875|NCT01480336|DRUG|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
57951876|NCT04271436|DEVICE|FDG PET/CT|A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.
58097099|NCT05435872|DEVICE|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
58097100|NCT05581199|DRUG|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
58097101|NCT05581199|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
58097102|NCT05581199|DRUG|Placebo|Matching placebo SC
58307034|NCT00466817|OTHER|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
58307035|NCT00466817|DRUG|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
58097103|NCT01220128|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
58307036|NCT00473655|DRUG|rosuvastatin|10mg or 20mg
58424659|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
58424660|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
58424661|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
58424662|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
57735859|NCT06669299|DRUG|Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)|The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
57735860|NCT04675138|OTHER|No intervention will be provided to the subject|No intervention will be provided to the subject
57735861|NCT05189730|DRUG|Tirelizumab|Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
57735862|NCT05189730|DRUG|Paclitaxel|Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
57735863|NCT05189730|DRUG|Carboplatin|Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
58424663|NCT00006026|DRUG|rubitecan|
58424664|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
58424665|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
58424666|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
58424667|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
57735864|NCT05189730|RADIATION|Neoadiuvant radiotherapy|Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
57735865|NCT05860699|DRUG|Placebo|Placebo made by the same manufacturer to look like the active pills
57735866|NCT05860699|DRUG|Half dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
57735867|NCT05860699|DRUG|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
58424668|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
58424669|NCT05074420|DRUG|Baricitinib|Given Orally
57735868|NCT03372226|BEHAVIORAL|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
57735869|NCT00854451|DRUG|omeprazole plus amoxicillin|
58424670|NCT05498116|DRUG|Montelukast|10mg daily
58424671|NCT05498116|OTHER|Placebo|1 capsule daily
58424672|NCT04394936|DRUG|Guselkumab|100 mg guselkumab administered subcutaneously
58424673|NCT04394936|DRUG|Placebos|Sodiumchloride 0,9% solution for injection
58424674|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
58424675|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
57735870|NCT00854451|DRUG|omeprazole plus amoxicillin|
58424676|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
58097104|NCT01220128|DRUG|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
58424677|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
58424678|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
58424679|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
58097105|NCT01220128|DRUG|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
58097106|NCT01220128|DRUG|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
57735871|NCT00854451|DRUG|omeprazole plus amoxicillin|
57735872|NCT00854451|DRUG|omeprazole plus amoxicillin|
57735873|NCT02362490|DRUG|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
57951877|NCT04271436|DEVICE|FLT PET/CT|. A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
57951878|NCT04271436|DEVICE|PET/MR|MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
57951879|NCT04271436|DRUG|[F-18] flurothymidine|-Radiopharmaceutical
57951880|NCT01152021|DRUG|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
57951881|NCT01152021|DRUG|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
58097107|NCT01220128|DRUG|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
58307037|NCT02080416|DRUG|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
58307038|NCT02126280|OTHER|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
58307039|NCT00236691|DRUG|topiramate|
58307040|NCT03538041|DRUG|Parsaclisib|Parsaclisib administered orally.
58307041|NCT02420639|DEVICE|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
58424680|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
58424681|NCT02337985|DRUG|Prednisone|Given PO
58424682|NCT02337985|BIOLOGICAL|Rituximab|Given IV
58424683|NCT02337985|DRUG|Etoposide|Given IV
58424684|NCT02337985|DRUG|Doxorubicin Hydrochloride|Given IV
58424685|NCT02337985|DRUG|Vincristine Sulfate|Given IV
58424686|NCT02337985|DRUG|Cyclophosphamide|Given IV
58424687|NCT02337985|BIOLOGICAL|Filgrastim|Given SC
58424688|NCT02337985|BIOLOGICAL|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
57951882|NCT03688932|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
58424689|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
58424690|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
58424691|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
58424692|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
58424693|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
58424694|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
58424695|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
58424696|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
58424697|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
58424698|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
58424699|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
58424700|NCT01833234|OTHER|Interviews and questionnaires|
58424701|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
58424702|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
58424703|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
57951883|NCT03688932|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
58424704|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
58424705|NCT00116363|GENETIC|investigational drug INGN 241|
58424706|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
58424707|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
58424708|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
58424709|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
58424710|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
57951884|NCT03688932|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
57951885|NCT04013035|PROCEDURE|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
57951886|NCT04401176|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
58424711|NCT06107660|DRUG|Liposomal bupivacaine|Patients will receive either liposomal bupivacaine as part of the ESPB .
57735874|NCT06025526|OTHER|aktivplan|"The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app."
58424712|NCT06107660|DRUG|Bupivacaine|This is the control group comparator as this is standard of care at the investigator's institution.
58424713|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
58424714|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
58424715|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
58424716|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
58424717|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
58424718|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
58424719|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
58424720|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
58424721|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
58424722|NCT02325297|OTHER|Letter of condolence|
58424723|NCT03212456|DRUG|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
58424724|NCT03212456|DRUG|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
57735875|NCT06025526|OTHER|Usual care|Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
57735876|NCT06669481|OTHER|Semiquantitative 131I-MIBG Scintigraphy Assessment|Patients received thyroid blockade using solution of potassium iodide before the examination. After intravenous administration of 111 MBq of 131I-MIBG, whole body planar images were acquired at 24 hours (Day 1) and 48 hours (Day 2), respectively.
58424725|NCT03212456|PROCEDURE|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
58424726|NCT03212456|PROCEDURE|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
58424727|NCT00273156|BEHAVIORAL|Telephone quitline|
58424728|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
58424729|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
58424730|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
58424731|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
58424732|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
57735877|NCT05084196|DRUG|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
57735878|NCT05084196|OTHER|Placebo Capsule|Placebo capsule by mouth at bedtime
58097108|NCT01220128|DRUG|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
57735879|NCT04519918|BEHAVIORAL|AOA|AOA represents an invasive non-physiological technique.
57735880|NCT01235468|BIOLOGICAL|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
57735881|NCT06111716|OTHER|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
57735882|NCT06111716|OTHER|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
57735883|NCT02676869|DRUG|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
57735884|NCT02676869|DRUG|Pembrolizumab|Administered according to the approved label.
57735885|NCT00563199|BEHAVIORAL|nurse-delivered stage-matched smoking cessation counseling|
57735886|NCT06669650|OTHER|PGx guided personalized post-operative pain management|Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.
57735887|NCT06669650|DRUG|Oxycodone|oxycodone
58097109|NCT01220128|DRUG|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
58097110|NCT01220128|DRUG|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
58097111|NCT01220128|DRUG|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
58097112|NCT01220128|DRUG|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
58097113|NCT01220128|DRUG|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
58424733|NCT05141461|PROCEDURE|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
58424734|NCT05141461|PROCEDURE|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
57735888|NCT06669650|DRUG|Hydromorphone|hydromorphone
57735889|NCT02239783|DEVICE|total hip arthroplasty implant|
57735890|NCT04663152|BEHAVIORAL|INSTACARE|CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
58097114|NCT04807634|DRUG|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
57735891|NCT04628689|OTHER|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
57735892|NCT04016597|DEVICE|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
58424735|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
58424736|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
58424737|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
58424738|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
58424739|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
58424740|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
58097115|NCT03911960|BEHAVIORAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
58097116|NCT03911960|BEHAVIORAL|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
58424741|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
58424742|NCT03737877|OTHER|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners."
58424743|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
58424744|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
57735893|NCT04016597|DEVICE|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
57735894|NCT04082949|BIOLOGICAL|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
58424745|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
57951887|NCT04401176|DRUG|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
57951888|NCT05710471|DRUG|Brolucizumab|Intravitreal injection
57951889|NCT05710471|DRUG|Aflibercept|Intravitreal injection
58097117|NCT04215120|DRUG|Desidustat Oral Tablet|Desidustat tablet
58097118|NCT04215120|DRUG|Epoetin Alfa|Epoetin Injection
58424746|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
58424747|NCT01075984|DRUG|Posaconazole|
58424748|NCT01075984|DRUG|Dextrose 5% in water|
58097119|NCT06648317|OTHER|FDG-PET|All study participants will undergo 18F-FDG PET/CT scan within 1 week
57951890|NCT02833974|DRUG|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
57951891|NCT02833974|DRUG|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
57951892|NCT03870542|PROCEDURE|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
57951893|NCT02422212|OTHER|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
57951894|NCT05885100|DRUG|Eleveld Model|Target plasma propofol
57951895|NCT02503228|PROCEDURE|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
58097120|NCT00545441|DEVICE|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
58097121|NCT00545441|DEVICE|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
58097122|NCT00883740|DRUG|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
58097123|NCT00883740|DRUG|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
58097124|NCT05614479|OTHER|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
58097125|NCT04662086|DRUG|Acebilustat|100 mg capsule administered orally once daily
58097126|NCT04662086|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
58097127|NCT06385145|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
58097128|NCT06385145|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
58424749|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
58424750|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
58424751|NCT00185874|BIOLOGICAL|autologous dendritic cells|
58424752|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
58424753|NCT02747511|DRUG|Haloperidol|
57735895|NCT04082949|OTHER|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
57735896|NCT01235208|OTHER|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
57735897|NCT00457262|PROCEDURE|soy consumption|
57735898|NCT05084872|DRUG|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
57769538|NCT02081456|OTHER|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
58097129|NCT05472623|DRUG|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
58097130|NCT05472623|COMBINATION_PRODUCT|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
58097131|NCT06389968|DEVICE|Light stimulation|see arm description
58097132|NCT06389968|DEVICE|Sham light stimulation|see arm description
58097133|NCT01892020|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
58097134|NCT01892020|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
58097135|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
58097136|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
58097137|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
58097138|NCT01304563|BIOLOGICAL|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
58097139|NCT04179773|OTHER|Current care study|"Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
58097140|NCT00149773|BEHAVIORAL|Cognitive Therapy|
58424754|NCT02747511|DRUG|Placebo|
58424755|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
58424756|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
58424757|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
58424758|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
58424759|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
58424760|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
58424761|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
58424762|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
58424763|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
58424764|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
58424765|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
58424766|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
58424767|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
58424768|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
58424769|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
58424770|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
58424771|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
57735899|NCT06281548|BEHAVIORAL|RESTART|Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
58307042|NCT03404245|BEHAVIORAL|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
58307043|NCT03404245|BEHAVIORAL|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
58307044|NCT03473405|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
58307045|NCT03473405|OTHER|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
58307046|NCT02552485|OTHER|No intervention was applied, because it is an observational study|
58424772|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
58424773|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
58424774|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
58424775|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
58424776|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
58424777|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
58424778|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
58424779|NCT00086411|DRUG|placebo bupropion|placebo pills
58424780|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
58424781|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
58424782|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
58424783|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
58424784|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
58424785|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
58424786|NCT02949388|DRUG|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
58424787|NCT02949388|DRUG|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
58424788|NCT02949388|DRUG|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
58424789|NCT00326248|DRUG|GW679769 (casopitant)|
58424790|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
58424791|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
58424792|NCT00351273|DRUG|Placebo|Methylcellulose
58424793|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
58424794|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
58424795|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
58424796|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
58424797|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
58424798|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
58424799|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
58424800|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
58424801|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
58424802|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
58424803|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
58424804|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
58424805|NCT00354666|DRUG|GSK159797|
58424806|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
57951896|NCT03008850|DRUG|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
58424807|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
58424808|NCT02025439|DEVICE|rTMS|
58424809|NCT02025439|DRUG|Amantadine|
58424810|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
58424811|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
58424812|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
58097141|NCT05277831|OTHER|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
58097142|NCT05277831|OTHER|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
58097143|NCT03669640|DRUG|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
58097144|NCT03669640|DRUG|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
58097145|NCT00835068|OTHER|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
58097146|NCT03469440|OTHER|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
58097147|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
58097148|NCT04561934|DRUG|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
58097149|NCT04561934|OTHER|resin modified glassionomer cement|resin modified glassionomer cement
58097150|NCT06270459|DEVICE|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
58097151|NCT01399073|BEHAVIORAL|virtual reality setup|testing for neglect in a virtual reality setup
58097152|NCT01399073|BEHAVIORAL|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
58097153|NCT01399073|OTHER|c-mri|structural and functional (resting state) imaging
58307047|NCT05074966|DRUG|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
58424813|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
57951897|NCT03008850|DRUG|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
58424814|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
58424815|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
58424816|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
57951898|NCT03729674|DRUG|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
57951899|NCT03729674|DRUG|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
57735900|NCT00996996|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
57735901|NCT02804854|DRUG|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
57735902|NCT04556708|OTHER|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
57735903|NCT04556708|OTHER|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
57735904|NCT04556708|OTHER|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
57735905|NCT06343766|GENETIC|DNA collation and genotyping|"DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression."
57951900|NCT01586351|DEVICE|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
58424817|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
57735906|NCT03762395|DRUG|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
57951901|NCT01486927|BIOLOGICAL|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
58097154|NCT06524401|DEVICE|Limpet|Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
58097155|NCT06524401|DEVICE|Control|Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
58424818|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
58424819|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
58424820|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
58424821|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
58424822|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
58424823|NCT00071448|DRUG|insulin human|
58424824|NCT00071448|DRUG|insulin lispro|
58424825|NCT00071448|DRUG|insulin aspart|
58424826|NCT00445276|DRUG|Diacerein|
58424827|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
58424828|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
58424829|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
58424830|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
57735907|NCT03762395|DRUG|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
57735908|NCT02199236|RADIATION|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
58424831|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
58424832|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
58424833|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
58424834|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
58424835|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
58424836|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
58424837|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
58424838|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
58424839|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
58424840|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
58424841|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
58424842|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
58424843|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
57951902|NCT01486927|BIOLOGICAL|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
57951903|NCT00870051|DEVICE|Endurant Stent Graft|Endurant Stent Graft implantation
57951904|NCT05417724|OTHER|Battlefield Acupuncture|Battlefield Acupuncture
57951905|NCT04560595|BEHAVIORAL|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
57951906|NCT03916211|BIOLOGICAL|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
57951907|NCT03487575|BEHAVIORAL|Open trial|Integrated electronic support and care support manager contact
57951908|NCT04071743|DEVICE|gammaCore Sapphire|non-invasive vagus nerve stimulator
57951909|NCT04071743|DEVICE|sham gammaCore Sapphire|sham gammaCore Sapphire
57951910|NCT00772954|BIOLOGICAL|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
57951911|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
58424844|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
58424845|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
58424846|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
58424847|NCT04881747|DRUG|Lasmiditan|Administered orally.
58424848|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
58424849|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
58424850|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
58424851|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
58424852|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
58424853|NCT06104956|DRUG|Standard of care|Weaning methods will be left to the free choice of the practitioner.
58424854|NCT02526251|OTHER|observational|No intervention
57735909|NCT02199236|DRUG|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
58424855|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
58424856|NCT00002112|DRUG|Nystatin|
57735910|NCT02199236|BEHAVIORAL|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
57735911|NCT02440958|DRUG|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
58424857|NCT00002112|DRUG|Fluconazole|
58424858|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
58424859|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
57735912|NCT02409173|DEVICE|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
58097156|NCT03976349|DRUG|BIIB094|Administered as specified in the treatment arm.
58424860|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
58097157|NCT03976349|DRUG|Placebo|Administered as specified in the treatment arm.
58424861|NCT05597618|OTHER|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~1. Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~2. Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
58424862|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
58424863|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
58424864|NCT02259855|DRUG|Tipranavir|
58424865|NCT02259855|DRUG|Ritonavir|
58424866|NCT02259855|DRUG|Pegylated interferon|
58424867|NCT02259855|DRUG|Ribavirin|
58424868|NCT01536483|DRUG|Butyrate enemas|"Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
57735913|NCT02409173|PROCEDURE|Bariatric Surgery|Standard Roux-en-Y gastric bypass
57735914|NCT01507220|DRUG|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
57951912|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
57951913|NCT04404387|DRUG|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
57951914|NCT04404387|DRUG|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
57951915|NCT03511963|DRUG|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
57951916|NCT03511963|DRUG|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
57951917|NCT05093400|OTHER|no intervention|saliva collection
58424869|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
58424870|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
58424871|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
58424872|NCT05549557|DRUG|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
58424873|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
58424874|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
58424875|NCT01840098|DIETARY_SUPPLEMENT|low leucine content drink|
58424876|NCT01840098|DIETARY_SUPPLEMENT|high leucine content drink|
58424877|NCT01840098|DIETARY_SUPPLEMENT|low leucine + HMB drink|
58424878|NCT01840098|DIETARY_SUPPLEMENT|Control/carbohydrate|
58424879|NCT01840098|BEHAVIORAL|36 hour fasting|
58424880|NCT01746173|DRUG|Cyclophosphamide|
58424881|NCT01746173|DRUG|Doxorubicin|
58424882|NCT01746173|DRUG|Vincristine|
58424883|NCT01746173|DRUG|Etoposide|
58424884|NCT01746173|DRUG|Prednisone|
58424885|NCT01746173|DRUG|Filgrastim|
58424886|NCT01746173|DRUG|Plerixafor|
58424887|NCT01746173|PROCEDURE|Stem Cell Collection|
58424888|NCT01746173|DRUG|Palifermin|
58424889|NCT01746173|DRUG|Gemcitabine|
58424890|NCT01746173|DRUG|Busulfan|
58424891|NCT01746173|DRUG|Melphalan|
58424892|NCT01746173|PROCEDURE|Stem Cell Transplant|
58424893|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
58424894|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
57951918|NCT03134352|DRUG|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
58424895|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
58424896|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
58424897|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
58424898|NCT01391988|PROCEDURE|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
58424899|NCT01391988|PROCEDURE|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
58424900|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
57951919|NCT03134352|DRUG|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
58424901|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
58424902|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
58424903|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
58424904|NCT00208351|DEVICE|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
57735915|NCT01507220|DRUG|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
58097158|NCT06537258|BEHAVIORAL|Biofeedback Enhanced Treatment|"At all 4 assessment points (T1-T4), HRV will be measured using the ECG module of the mobile MindWare system at a sampling rate of 500 Hz, and a Skin Conductance Response (SCR) will be collected at a sampling rate of 10 Hz using eSense for iPad. Electrodes to assess SCR and HRV will be attached to patients during an \~10-minute period.~A 5-minute initial baseline assessment will occur first followed by three 5-minute stress trials.~Stress tasks will be audio recorded to measure study fidelity, and participants will be asked to rate their subjective level of stress with each trial. At all assessment points (T1-T4), participants will be provided with stool collection kits to collect a stool sample within 3 days of the laboratory psychophysiological assessment.~At all assessment points (T1-T4), a blood draw of approximately 3 ml of blood will be collected."
58097159|NCT02958774|RADIATION|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
58097160|NCT04624750|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
58097161|NCT00915473|DRUG|bupivicaine|2.5 mL 0.5% bupivicaine
58097162|NCT00915473|DRUG|normal saline|2.75 mL normal saline
58424905|NCT00208351|DEVICE|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
58424906|NCT00208351|DEVICE|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
58424907|NCT00208351|DEVICE|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
58424908|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
58097163|NCT00915473|DRUG|methylprednisolone|0.5 mL 20 mg methylprednisolone
58097164|NCT00915473|DRUG|lidocaine|0.25 mL 1% lidocaine
58424909|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
58097165|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min|when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
58097166|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min|the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
58424910|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
58424911|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
58097167|NCT05818332|OTHER|Observational study|No intervention, observational only
58424912|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
57735916|NCT04484467|DIETARY_SUPPLEMENT|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
58097168|NCT05742061|DRUG|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
58424913|NCT05104671|OTHER|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:"
58424914|NCT05104671|OTHER|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
57735917|NCT04484467|OTHER|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
57735918|NCT00793468|DRUG|GSK598809|GSK598809 once daily for 12 weeks
57735919|NCT00793468|DRUG|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
57735920|NCT00793468|DRUG|Placebo|Placebo once daily for 12 weeks
57735921|NCT01715987|DRUG|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
57735922|NCT01715987|DRUG|Entecavir|0.5mg oral daily for two years.
57735923|NCT05706805|DEVICE|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
57951920|NCT01701570|BEHAVIORAL|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
57951921|NCT01701570|OTHER|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
57951922|NCT02328430|DEVICE|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
57951923|NCT02250352|OTHER|cytology specimen collection procedure|Correlative studies
57951924|NCT06367257|PROCEDURE|App Usage|Conducting patient surveys with app
57951925|NCT06367257|OTHER|Standard of Care|supportive care during and after radio(chemo)therapy according to hospial standards
57951926|NCT01908985|PROCEDURE|high intensity focused ultrasound for cyclodestruction in the eye|
57951927|NCT02567149|DRUG|Cidofovir|Cidofovir
57951928|NCT02140814|DIETARY_SUPPLEMENT|Niacinamide|
57951929|NCT00484653|PROCEDURE|cervical smear|biological analysis
57951930|NCT02756728|BIOLOGICAL|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
57951931|NCT02756728|OTHER|High dose melphalan|High dose melphalan (HDM)
57951932|NCT02756728|OTHER|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
57951933|NCT01647451|DRUG|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
57951934|NCT01647451|DRUG|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
57951935|NCT02700490|BEHAVIORAL|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
57951936|NCT05200078|DEVICE|Deep inspiration breath-hold technique|Selective application of deep inspiration breath-hold technique
57951937|NCT02261194|BEHAVIORAL|Self-Care Tools|
58097169|NCT05742061|OTHER|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
58097170|NCT02261974|DEVICE|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
58097171|NCT02261974|DEVICE|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
58097172|NCT05657873|RADIATION|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
58097173|NCT05657873|BIOLOGICAL|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
58097174|NCT05657873|DRUG|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
58097175|NCT06540157|OTHER|Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)|Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
58097176|NCT06540157|OTHER|Sham group|Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
58097177|NCT05946382|BEHAVIORAL|RNT-ACT Protocol|Swedish Translation of the 2\*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.
58097178|NCT05946382|BEHAVIORAL|iCBT Treatment|Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
58097179|NCT05920707|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
58097180|NCT05920707|DRUG|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
58097181|NCT05920707|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
57735924|NCT06634810|BEHAVIORAL|Self-Management Support|The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
58097182|NCT06462222|DRUG|Toripalimab, pemetrexed|Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
58097183|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
58097184|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
58424915|NCT05104671|OTHER|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
58424916|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
58424917|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
57735925|NCT06634810|BEHAVIORAL|COPD Education|The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
57735926|NCT02445612|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
58424918|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
58424919|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
57735927|NCT02773615|PROCEDURE|Cardiac computed tomography|Non-invasive CT scan of the heart
58424920|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
58424921|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
58424922|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
58424923|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
58424924|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
58424925|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
58424926|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
57735928|NCT04522401|DIAGNOSTIC_TEST|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
57735929|NCT05519254|DIETARY_SUPPLEMENT|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
57735930|NCT05519254|DIETARY_SUPPLEMENT|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
58424927|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
58424928|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
58424929|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
58424930|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
58424931|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
58424932|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
58424933|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
58424934|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
58424935|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
58424936|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
58097185|NCT05307250|OTHER|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
58097186|NCT06567795|DEVICE|Hemotag|Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
58097187|NCT06152341|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
58097188|NCT04237779|BIOLOGICAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
58097189|NCT04275232|BIOLOGICAL|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
58424937|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
58424938|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
58424939|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
58424940|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
58424941|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
58424942|NCT06194344|BEHAVIORAL|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
58424943|NCT06194344|BEHAVIORAL|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
58424944|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
58424945|NCT06352255|PROCEDURE|Digital block|Frost's H technique
58424946|NCT05399004|OTHER|Survey Administration|Complete surveys
58424947|NCT00001696|DRUG|Genistein|
58424948|NCT05091515|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
58424949|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
58424950|NCT00683969|DRUG|placebo|po bid for 36 weeks
57735931|NCT05519254|COMBINATION_PRODUCT|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
58097190|NCT00079963|DIETARY_SUPPLEMENT|Vitamin C|1000 mg/day
58097191|NCT00079963|DIETARY_SUPPLEMENT|Vitamin E|800 IU/day
58097192|NCT00079963|DIETARY_SUPPLEMENT|Placebo|
58097193|NCT06566508|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide Intracanal medication
58097194|NCT06566508|DRUG|Leddermix Intracanal medication|Leddermix Intracanal medication
57735932|NCT05519254|OTHER|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
58097195|NCT06566508|DRUG|Asiaticoside Intracanal medication|Asiaticoside Intracanal medication
57735933|NCT05033288|OTHER|Electronic Health Record Review|Medical records are reviewed
58097196|NCT05078398|BEHAVIORAL|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
58424951|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
58424952|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
57735934|NCT05033288|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
58424953|NCT02591368|PROCEDURE|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
58424954|NCT02591368|PROCEDURE|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
58424955|NCT02591368|PROCEDURE|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
58424956|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
58424957|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
58424958|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
58424959|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
58424960|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
58424961|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
58424962|NCT05228561|OTHER|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
58424963|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
58424964|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
58424965|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
58424966|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
58424967|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
58424968|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
58424969|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
58424970|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
58424971|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
58424972|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
58424973|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
58424974|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58424975|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
57735935|NCT00400010|BEHAVIORAL|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
57735936|NCT05595304|PROCEDURE|prosthetic refunctioning|Active treatment followed by regular interventions
57735937|NCT05595304|PROCEDURE|conventional prosthetic treatment|new prosthesis
57769539|NCT02081456|DEVICE|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
57735938|NCT01509573|BEHAVIORAL|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
58097197|NCT05078398|BEHAVIORAL|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
58097198|NCT06359756|PROCEDURE|Ischemic postconditioning in carotid surgery|After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.
58097199|NCT06359756|PROCEDURE|Eversion Carotid Endarterectomy|Standard Eversion Carotid Endarterectomy
58097200|NCT04750928|DRUG|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
58097201|NCT05474573|DEVICE|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
58097202|NCT05474573|DEVICE|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
58424976|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
58424977|NCT02012049|DRUG|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
58424978|NCT02012049|DRUG|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
58424979|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
58424980|NCT01238965|DRUG|panobinostat|Given orally
58424981|NCT01238965|DRUG|fluorouracil|Given IV
57735939|NCT02235493|BIOLOGICAL|Retrospective Case Only|
57735940|NCT00179465|DRUG|Tiagabine|Up to 36 mg daily
57735941|NCT00179465|DRUG|Placebo|Placebo
57735942|NCT02223234|BEHAVIORAL|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
58097203|NCT05111626|DRUG|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
58097204|NCT05111626|DRUG|Nivolumab|Nivolumab will be administered as IV infusion.
58097205|NCT05111626|DRUG|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
58097206|NCT05111626|OTHER|Placebo|Placebo will be administered as IV infusion.
58097207|NCT02808663|BIOLOGICAL|fecal calprotectin concentration|
57735943|NCT02223234|BEHAVIORAL|Control|Monthly emails on child health
57735944|NCT02223234|BEHAVIORAL|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
57735945|NCT05668754|DRUG|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
57769540|NCT03375580|DIETARY_SUPPLEMENT|TLC|transform life custom (TLC)
57769541|NCT03375580|DRUG|metformin|0.5g metformin group，PO tid
58097208|NCT02808663|BIOLOGICAL|blood collection|
58097209|NCT06482437|DRUG|NMD670|Tablets taken twice daily for 21 days
58097210|NCT06482437|DRUG|Placebo|Tablets taken twice daily for 21 days
58097211|NCT01494649|DRUG|Test Toothpaste|0.454% stannous fluoride toothpaste
58097212|NCT01494649|DRUG|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
58097213|NCT01771419|DEVICE|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
58097214|NCT01771419|DEVICE|Cannulotome CT-25mm Cook Medical|
58097215|NCT00002902|DRUG|irinotecan hydrochloride|
58097216|NCT00002902|DRUG|raltitrexed|
58424982|NCT01238965|DRUG|leucovorin calcium|Given IV
58424983|NCT01238965|PROCEDURE|biopsy|Correlative studies
58424984|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
58424985|NCT01238965|GENETIC|western blotting|Correlative studies
58424986|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
58424987|NCT01238965|GENETIC|gene expression analysis|Correlative studies
58424988|NCT01238965|GENETIC|RNA analysis|Correlative studies
58424989|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
58424990|NCT01369186|DRUG|Morphine|i.v. bolus injection
58424991|NCT01369186|DRUG|Placebo|i.v. bolus injection
58424992|NCT06124456|OTHER|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
58424993|NCT06124456|OTHER|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
58424994|NCT06124456|OTHER|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
58424995|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
58424996|NCT00676910|DRUG|JNJ-26854165|
58424997|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
58424998|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
58424999|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
57735946|NCT05668754|OTHER|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
58097217|NCT02822807|BIOLOGICAL|Blood sampling|
58097218|NCT00816517|BIOLOGICAL|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
58097219|NCT01561586|DRUG|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
58097220|NCT01561586|DRUG|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
58097221|NCT04955873|DEVICE|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
58097222|NCT04955873|DEVICE|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
58425000|NCT02708355|DRUG|Placebo|Placebo capsules
58425001|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
57735947|NCT03006523|PROCEDURE|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
57735948|NCT00885404|DRUG|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
57735949|NCT03732209|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
57735950|NCT03732209|BEHAVIORAL|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
57735951|NCT01280487|DRUG|ZSTK474|Daily oral dosing for 21 days each cycle
57735952|NCT00319215|DRUG|Ramelteon 8 mg|
57735953|NCT00319215|DRUG|Zopiclone 7.5 mg|
58425002|NCT02474251|OTHER|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
57735954|NCT02672111|DRUG|CAM2038 q1w or q4w exposure to SL BPN/NX|
57735955|NCT02672111|DRUG|CAM2038 q1w or q4w new to BPN treatment|
57735956|NCT06667115|OTHER|PNF exercise|Foundational PNF D2 shoulder flexion exercise incorporating shoulder flexion, abduction, and external rotation. This exercise was performed at a metronome-guided pace of 14 beats per minute to establish a consistent baseline.
58097223|NCT02043093|BEHAVIORAL|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
58097224|NCT00460252|PROCEDURE|insulin titration applying a computer algorithm|
58097225|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
58097226|NCT00343642|DRUG|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
58097227|NCT00343642|DRUG|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
58097228|NCT00343642|DIETARY_SUPPLEMENT|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
58097229|NCT06079853|BEHAVIORAL|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
58097230|NCT03233373|DEVICE|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
57735957|NCT06667115|OTHER|PNF exercise with virtual reality gaming|Combined the PNF D2 shoulder flexion exercise with a virtual reality motion capture game (the U-Ball game).
58097231|NCT06541483|PROCEDURE|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
58097232|NCT06541483|PROCEDURE|conventional general anesthesia (CGA)|(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
58097233|NCT01749618|BEHAVIORAL|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
58097234|NCT03053193|DIAGNOSTIC_TEST|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
58307048|NCT05074966|DRUG|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
58307049|NCT05246254|DIAGNOSTIC_TEST|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
58307050|NCT03207399|DRUG|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
58307051|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
58307052|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
58307053|NCT00927199|DIETARY_SUPPLEMENT|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
58307054|NCT02669849|DRUG|VX-210|
58307055|NCT02669849|DRUG|Placebo|
58307056|NCT00113607|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
58307057|NCT00113607|DRUG|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
58307058|NCT00113607|DRUG|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
57735958|NCT06667115|OTHER|PNF with concurrent feedback|"PNF exercise with the addition of auditory concurrent feedback (Sword) which referenced the action of unsheathing a sword in a diagonal upward direction."
57735959|NCT00712842|OTHER|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
57769542|NCT03375580|DRUG|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
58307059|NCT01477801|DRUG|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
58307060|NCT01477801|DRUG|PLACEBO|Standard guideline based therapy plus placebo
58307061|NCT05393596|BEHAVIORAL|Virtual Reality Software Intervention|Virtual Reality Software Intervention
58425003|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
58425004|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
58425005|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
58425006|NCT01742689|DRUG|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
58425007|NCT01742689|DRUG|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
57735960|NCT03588208|OTHER|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
57735961|NCT03588208|OTHER|Educational Program|Structured education program were performed during one hour class once a week for five weeks
58425008|NCT01742689|DRUG|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
58425009|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
58425010|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
58425011|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
58425012|NCT00779207|BEHAVIORAL|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
58425013|NCT00779207|BEHAVIORAL|weight loss|10 percent weight loss through diet and behavioral modification
58425014|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
58425015|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
58425016|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
58425017|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
58425018|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
58425019|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
58425020|NCT03470753|OTHER|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
57735962|NCT03910127|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
58425021|NCT03470753|OTHER|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
58425022|NCT03470753|OTHER|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
58425023|NCT03470753|OTHER|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
57735963|NCT03910127|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
57735964|NCT03910127|DRUG|Anlotinib|matching placebo
57735965|NCT06012760|DRUG|Iron sucrose, Human Erythropoietin Injection, Vitamin C|The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
57735966|NCT06012760|DRUG|Standard Medical Care|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
57769543|NCT03375580|DRUG|Simvastatin|20mg simvastatin, PO qn
57769544|NCT06229704|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
58307062|NCT01937988|OTHER|Doula Arm|
58097235|NCT04701476|DRUG|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
58097236|NCT04701476|DRUG|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
58097237|NCT04701476|DRUG|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
58097238|NCT02238886|DIETARY_SUPPLEMENT|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
58097239|NCT04569123|DEVICE|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
58097240|NCT04569123|DEVICE|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
58097241|NCT05683496|DRUG|lonigutamab|subcutaneous injection
58097242|NCT05683496|DRUG|Placebo|subcutaneous injection
58097243|NCT00881452|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
58097244|NCT00881452|DRUG|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
58097245|NCT01158976|DIETARY_SUPPLEMENT|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
58097246|NCT01158976|OTHER|Placebo|soybean oils with strawberry flavoring
58097247|NCT01325701|DRUG|ibrutinib|ibrutinib is an inhibitor of BTK
58097248|NCT02588742|DIETARY_SUPPLEMENT|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
58097249|NCT02588742|DIETARY_SUPPLEMENT|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
58097250|NCT03413969|BEHAVIORAL|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
58097251|NCT01286207|DRUG|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
58097252|NCT01286207|DRUG|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
58097253|NCT01286207|DRUG|Standard Care|Active standard care
58097254|NCT05605184|OTHER|Survey|Survey
58097255|NCT01818414|DRUG|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
58097256|NCT01818414|DRUG|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D\&E
58425024|NCT01587092|BEHAVIORAL|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
58425025|NCT01587092|BEHAVIORAL|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
58097257|NCT06621251|DRUG|TRL1068 (calpurbatug), a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
58097258|NCT06621251|PROCEDURE|DAIR|DAIR procedure will be performed between days 15-22
58097259|NCT05563584|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
58425026|NCT01033318|DRUG|MK1809|single oral doses of MK1809
58097260|NCT04583631|PROCEDURE|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
58097261|NCT03456843|DRUG|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
58097262|NCT03456843|DRUG|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
58097263|NCT03456843|OTHER|Laboratory Biomarker Analysis|Correlative studies
58097264|NCT03456843|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
58307063|NCT04533178|DEVICE|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
58097265|NCT03456843|OTHER|Questionnaire Administration|Ancillary studies
58097266|NCT03456843|PROCEDURE|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
58307064|NCT04533178|OTHER|Resting from all sports activities|Resting from all sports activities
58307065|NCT05550168|DEVICE|Low Level Laser therapy|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
58097267|NCT00752401|DRUG|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
58097268|NCT00752401|DRUG|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
58097269|NCT00535301|DEVICE|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
58097270|NCT00535301|PROCEDURE|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
58097271|NCT00874757|DRUG|Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
58097272|NCT06568133|DRUG|UIC201603 and co-administration of UIC201603 and UIC201604|"* UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days"
58097273|NCT06568133|DRUG|UIC201604 and co-administration of UIC201603 and UIC201604|"* UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604"
58097274|NCT01980082|DRUG|Cefazolin|Antibiotic
58097275|NCT01980082|DRUG|Placebo|Placebo
58097276|NCT02343822|OTHER|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
58097277|NCT02343822|OTHER|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
58097278|NCT05895214|PROCEDURE|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
58097279|NCT05451134|OTHER|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
58097280|NCT04862052|PROCEDURE|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
58097281|NCT02885974|DRUG|Celecoxib|Celecoxib (100 mg daily)
58097282|NCT02885974|DRUG|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
58097283|NCT02885974|DRUG|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
58097284|NCT04621097|DEVICE|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
58425027|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
58097285|NCT04621097|OTHER|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
58097286|NCT04621097|DRUG|Medication|regular medications
58097287|NCT00646256|BEHAVIORAL|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
58097288|NCT05764200|DIETARY_SUPPLEMENT|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
58097289|NCT05764200|DIETARY_SUPPLEMENT|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
58097290|NCT05212272|PROCEDURE|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
58097291|NCT05212272|DIAGNOSTIC_TEST|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
58097292|NCT05212272|BEHAVIORAL|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
58097293|NCT05212272|PROCEDURE|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
58097294|NCT05408728|PROCEDURE|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
58307066|NCT01007799|DIETARY_SUPPLEMENT|vitamin D placebo|12 weeks of placebo
58307067|NCT01007799|DIETARY_SUPPLEMENT|Vitamin D|12 weeks supplementation based on serum vitamin D levels
58307068|NCT00707837|OTHER|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
58307069|NCT00707837|OTHER|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
58425028|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
58097295|NCT00820183|OTHER|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
58097296|NCT05575128|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
58097297|NCT05575128|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
58097298|NCT05575128|OTHER|Care as usual|Care as usual, with written resources provided
58097299|NCT05210998|OTHER|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
58097300|NCT05210998|OTHER|Gradual Aerobic exercise training|Aerobic exercise Group
58097301|NCT04828629|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
58097302|NCT01222559|DRUG|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
58097303|NCT01222559|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
58425029|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
58425030|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
58425031|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
58425032|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
58425033|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
58097304|NCT06672198|PROCEDURE|ERAC protocol|our study aimed to evaluate pre-peri-post operative practices in women who underwent elective cesarean section (CS) according to the ERAC protocol. In this context, this study aimed to describe the implementation status of the recommendations regarding the ERAC protocol in CS operations, to identify the missing aspects of the ERAC protocol and to raise awareness about its benefits.
58097305|NCT02224300|BEHAVIORAL|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
58097306|NCT03909373|OTHER|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
58097307|NCT03999229|DRUG|SNO|S-nitrosylating agent (SNO) Inhalation
58097308|NCT03999229|DRUG|Normal Saline|Normal Saline transfusion
58097309|NCT03999229|DRUG|Red Blood Cell|Blood transfusion (RBCs)
58097310|NCT06541730|DRUG|DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
58097311|NCT06541730|DRUG|Placebo of DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
58097312|NCT03853213|BEHAVIORAL|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
58097313|NCT03853213|BEHAVIORAL|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
58097314|NCT00710060|BEHAVIORAL|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
58097315|NCT00710060|BEHAVIORAL|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
58097316|NCT04118855|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
58097317|NCT04118855|DRUG|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
58097318|NCT02177864|DIETARY_SUPPLEMENT|Fiber|
58097319|NCT02177864|OTHER|Placebo (low fiber bar)|
58097320|NCT01281631|DRUG|NP001|Low dose of NP001
58097321|NCT01281631|DRUG|NP001|High dose of NP001
58097322|NCT01281631|DRUG|Placebo|normal saline
58097323|NCT04348292|DRUG|Durvalumab|Given IV
58425034|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
58097324|NCT04348292|DRUG|Sirolimus|Given PO
58097325|NCT05780944|BEHAVIORAL|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
58097326|NCT05694156|OTHER|Music-based cognitive training|8-week music-based cognitive training
58097327|NCT02515461|DEVICE|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
58425035|NCT02497690|BEHAVIORAL|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
58425036|NCT02497690|BEHAVIORAL|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
58425037|NCT02872532|PROCEDURE|Testicular tissue cryopreservation|Testicular tissue will be removed
58425038|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
58425039|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
58425040|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
58425041|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
57769545|NCT06229704|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
58097328|NCT06539039|PROCEDURE|non surgical periodontal therapy|participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
58097329|NCT05980858|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate|Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
58097330|NCT05980858|OTHER|Placebo|Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
58097331|NCT03141931|DIETARY_SUPPLEMENT|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
58097332|NCT03141931|DIETARY_SUPPLEMENT|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
58097333|NCT00774202|DRUG|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
58097334|NCT00774202|DRUG|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
58097335|NCT03008252|OTHER|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
58097336|NCT03008252|OTHER|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
58425042|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
58425043|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
58425044|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
58425045|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
58425046|NCT00337584|PROCEDURE|Pre-surgical screening|
58425047|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
58425048|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
58097337|NCT05614765|DRUG|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
58097338|NCT01491282|OTHER|Enabling and disabling VNS|No intervention
58425049|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
58425050|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
58425051|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
58097339|NCT01368757|DRUG|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
58097340|NCT04594200|BEHAVIORAL|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
58097341|NCT05254093|OTHER|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
58425052|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
58425053|NCT02618668|DRUG|Propofol|2 mg/kg I.V
58097342|NCT05254093|OTHER|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
58425054|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
58097343|NCT03434808|OTHER|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
58425055|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
58097344|NCT03690986|BIOLOGICAL|VX15/2503|Given IV
58097345|NCT03690986|BIOLOGICAL|Ipilimumab|Given IV
58097346|NCT03690986|BIOLOGICAL|Nivolumab|Given IV
58097347|NCT05920018|DIETARY_SUPPLEMENT|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
58097348|NCT05920018|DIETARY_SUPPLEMENT|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
58097349|NCT05920018|OTHER|Maltose placebo|Daily application of four sachets for 48 weeks
58097350|NCT05920018|OTHER|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
58097351|NCT01770197|DRUG|IV rt-PA|IV rt-PA treatment
58425056|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
58425057|NCT01628003|DEVICE|Brain MRI|Brain MRI
58097352|NCT04648774|PROCEDURE|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
58097353|NCT04648774|PROCEDURE|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
58425058|NCT01628003|DEVICE|MRI|Physical examination Neuropsychological testing Questionnaires
58425059|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
58425060|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
58425061|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
58425062|NCT03392623|DRUG|Retinoic acid|topical administration in melasma lesions
58425063|NCT03392623|DEVICE|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
58425064|NCT03392623|DRUG|sunscreen|topical administration in melasma lesions
58425065|NCT03392623|DRUG|Niacinamide|topical administration in melasma lesions
58425066|NCT03465553|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
58097354|NCT01307631|DRUG|Akt Inhibitor MK2206|Given PO
58097355|NCT01307631|OTHER|Laboratory Biomarker Analysis|Correlative studies
58425067|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
58425068|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
58097356|NCT05084209|BEHAVIORAL|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
58097357|NCT06374121|DEVICE|PerSorb cartridge (CytoSorbents Europe GmbH, Germany)|This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.
58097358|NCT06374121|DEVICE|PerLife PerKidney|The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
58097359|NCT05003895|DRUG|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
58097360|NCT05003895|BIOLOGICAL|CAR-T cell|Single infusion on Day 0
58097361|NCT05003895|DRUG|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
58097362|NCT00396981|DEVICE|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
58097363|NCT00396981|DEVICE|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
58097364|NCT03674827|BIOLOGICAL|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
58425069|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
58425070|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
58425071|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
58425072|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
58425073|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
58425074|NCT06019806|OTHER|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
58425075|NCT06019806|OTHER|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
58425076|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
58097365|NCT02236390|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
58097366|NCT02236390|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
58097367|NCT06578559|DRUG|Cetuximab|500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
58097368|NCT06578559|DRUG|Encorafenib|300 mg once daily (four 75 mg oral capsules).
58097369|NCT03095963|OTHER|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
58097370|NCT03095963|DRUG|levothyroxin|replacement therapy for hypothyroidism
58097371|NCT03169660|DRUG|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
57769546|NCT06229704|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
58097372|NCT03496935|DEVICE|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
58097373|NCT03751319|OTHER|CGA|Comprehensive Geriatric Assessment
58097374|NCT01535391|DRUG|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
58097375|NCT03884907|PROCEDURE|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
58097376|NCT04070599|BIOLOGICAL|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
58097377|NCT00057018|PROCEDURE|Constraint-induced movement therapy|
58097378|NCT01385670|DEVICE|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
58097379|NCT03940027|PROCEDURE|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
58097380|NCT01545752|OTHER|teaching by non-interactive CD|teaching book with non-interactive CD
58097381|NCT01545752|OTHER|Interactive CD|Teaching book with interactive CD
58097382|NCT06542861|OTHER|High-frequency simulation-based team training|"The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments."
58097383|NCT03496207|DRUG|Placebo|Placebo
58425077|NCT04231916|DEVICE|Thermal imaging device|
58097384|NCT03496207|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
58097385|NCT03496207|OTHER|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
58097386|NCT06164431|DRUG|ZSP1273 tablet|Participants receive ZSP1273 tablet orally.
58097387|NCT06164431|DRUG|zsp1273 granules|Participants receive ZSP1273 granules orally.
58097388|NCT05137301|DEVICE|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
58097389|NCT05515627|DRUG|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
58097390|NCT01506063|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
58097391|NCT04465916|DRUG|EYP001a|Oral tablets
58097392|NCT04465916|DRUG|Placebo|Oral tablets
58097393|NCT04465916|DRUG|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
58097394|NCT06138678|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
58097395|NCT04707066|BEHAVIORAL|Treatment As Usual (TAU)|Treatment As Usual
58425078|NCT01954563|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
57769547|NCT06229704|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
58097396|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
58097397|NCT04707066|BEHAVIORAL|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
58097398|NCT04707066|BEHAVIORAL|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
58097399|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
58097400|NCT06514209|DRUG|cisatracurium|The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
58097401|NCT01106118|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
58097402|NCT03706274|DRUG|CX-188|CX-188
58097403|NCT02368769|DEVICE|During Tele-expertise|
58097404|NCT03367273|OTHER|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
58425079|NCT00558272|DRUG|AZD0530|Daily oral dose
58425080|NCT00558272|DRUG|Zoledronic Acid|
58097405|NCT03567239|DEVICE|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
58097406|NCT05810181|OTHER|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
58097407|NCT04045600|BEHAVIORAL|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
58097408|NCT04045600|BEHAVIORAL|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
58097409|NCT04045600|BEHAVIORAL|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
58425081|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
58425082|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
57735967|NCT01618838|RADIATION|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
58425083|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
58097410|NCT00105352|PROCEDURE|Mixed Meal Tolerance Test|
58097411|NCT00105352|PROCEDURE|Glucagon Stimulation Test|
58097412|NCT01457729|BEHAVIORAL|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
58425084|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
58425085|NCT03704610|DRUG|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
58097413|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
57735968|NCT03214497|DEVICE|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
57735969|NCT03214497|DEVICE|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
57735970|NCT06060457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58097414|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
58097415|NCT05031962|DEVICE|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
58097416|NCT01738009|OTHER|Induction of flow limitation|
58097417|NCT05643131|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
58097418|NCT06232369|DEVICE|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
58097419|NCT06232369|DEVICE|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
58097420|NCT03575611|PROCEDURE|Biopsy|Undergo tumor biopsy
58097421|NCT03575611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58097422|NCT03575611|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
58097423|NCT03575611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58097424|NCT03575611|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58097425|NCT03575611|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58425086|NCT03704610|DRUG|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
58425087|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
58425088|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
58097426|NCT05854173|DIAGNOSTIC_TEST|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
58425089|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
58425090|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
58425091|NCT00199823|GENETIC|Intracoronary aotologous stem cell transplantation|
58425092|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
58425093|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
58425094|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
58097427|NCT05854173|DIAGNOSTIC_TEST|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
58307070|NCT00843466|OTHER|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
58307071|NCT02523352|PROCEDURE|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
58307072|NCT02523352|PROCEDURE|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
58307073|NCT01830517|DRUG|Amlodipine, Losartan|
58307074|NCT00157339|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
58307075|NCT00157339|DRUG|injected insulin|patient specific dose, injected, before meals, 12 months.
58307076|NCT01087060|PROCEDURE|partial or radical nephrectomy|
58307077|NCT03439137|DRUG|MT-6548|Oral tablet
58307078|NCT03439137|DRUG|Darbepoetin alfa|Intravenous administration
57735971|NCT06060457|BIOLOGICAL|mRNA-1345|Suspension for injection
57735972|NCT06060457|BIOLOGICAL|Fluzone HD|Suspension for injection
57735973|NCT02101892|DRUG|Amitriptyline|per os, daily, evening
58307079|NCT03439137|DRUG|MT-6548-matching placebo|Oral tablet
58307080|NCT03439137|DRUG|Darbepoetin alfa-matching placebo|Intravenous administration
58307081|NCT03347643|DEVICE|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
57735974|NCT02101892|DRUG|placebo|per os, daily, evening
58307082|NCT03347643|DEVICE|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
58307083|NCT01112319|DEVICE|Elf care|elfcare device
58307084|NCT01112319|OTHER|control group|regular physiotherapy treatment
58097428|NCT05037175|BEHAVIORAL|CPT-Text|CPT is a 12-session, trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets \[5,6\]. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one.
58097429|NCT05037175|BEHAVIORAL|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy \[5\].
58097430|NCT05037175|BEHAVIORAL|Retention Incentive|Participants will be told at baseline that they can earn discounts for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
58097431|NCT05037175|BEHAVIORAL|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
58097432|NCT04208529|BIOLOGICAL|CTX001|CTX001 infusion.
58097433|NCT06541821|OTHER|survey evaluation|assessment of physical activity, fear of movement, and ostomy compliance
58097434|NCT06512389|DRUG|Oral solution|300 mg taken morning and evening
58097435|NCT05048745|PROCEDURE|interval appendectomy|interval appendectomy
58097436|NCT01339000|DRUG|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
58097437|NCT01339000|BIOLOGICAL|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
58097438|NCT01339000|BIOLOGICAL|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
58097439|NCT01339000|BIOLOGICAL|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
58097440|NCT01339000|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
58097441|NCT01339000|BIOLOGICAL|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
58097442|NCT06472375|DIAGNOSTIC_TEST|holter|ambulant heart rate monitor (holter) for 24 hour.
58097443|NCT03596879|BEHAVIORAL|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
58097444|NCT03596879|BEHAVIORAL|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
58097445|NCT06340971|OTHER|Policy|"We will work with stakeholders' policy groups e.g. RCOG, RCM, RCP and policy makers e.g. Department for Health and Social Care, Transport Emissions at the Greater London Authority or Mayor of London's office to disseminate our findings and develop public health messages.~We aim to develop guidance on how pregnant women and their families can reduce their exposure to air pollution by highlighting for example travel routes with less pollution and wear face masks."
58097446|NCT01836003|OTHER|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women"
58425095|NCT00257660|DRUG|Placebo|500 units
58425096|NCT00327990|DRUG|Ibandronate|
58425097|NCT00327990|DRUG|Alendronate|
58425098|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
58425099|NCT01623388|PROCEDURE|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
57735975|NCT06041724|DRUG|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
58097447|NCT02151162|BEHAVIORAL|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
58097448|NCT02151162|DIETARY_SUPPLEMENT|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
57735976|NCT00232804|DEVICE|Bx Cypher stent|
57735977|NCT06670079|BEHAVIORAL|Prolonged exposure therapy + incentives for therapy session attendance|Prolonged exposure therapy plus incentives for therapy session attendance
57735978|NCT04282135|DIAGNOSTIC_TEST|MCC IMS|Diagnosis by MCC IMS
57735979|NCT04706468|DRUG|TG-1000|Capsules taken orally
58097449|NCT02151162|BEHAVIORAL|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
58097450|NCT02151162|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
58097451|NCT05686317|DEVICE|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
58097452|NCT05686317|DIAGNOSTIC_TEST|Sham procedure|CS angiography
58097453|NCT00457418|DRUG|PEG-Intron|
57735980|NCT01292603|DRUG|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
58097454|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
58097455|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
58425100|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
58425101|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
58425102|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
58425103|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
58425104|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
58425105|NCT00590577|DRUG|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
58425106|NCT00590577|DRUG|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
57735981|NCT01292603|DRUG|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
57735982|NCT01292603|DRUG|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
57735983|NCT01292603|DRUG|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
57735984|NCT01292603|DRUG|rituximab [MabThera]|6 cycles of intravenous MabThera
57735985|NCT01349634|OTHER|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
57735986|NCT06139874|BEHAVIORAL|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
57735987|NCT06139874|BEHAVIORAL|Parenting Wisely|Online asynchronous parenting program.
57735988|NCT06669910|OTHER|only assesment|only assesment
58097456|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
58097457|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
58097458|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
58097459|NCT04152252|OTHER|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
57735989|NCT02127164|DEVICE|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
57735990|NCT02768896|BEHAVIORAL|Baseline|Patients will walk naturally with EEG measuring brain waves
57735991|NCT02768896|BEHAVIORAL|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
57735992|NCT02768896|BEHAVIORAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
57735993|NCT02768896|BEHAVIORAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
58097460|NCT04152252|BEHAVIORAL|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
58425107|NCT00590577|DRUG|Placebo|Placebo i.m. Days 1, 8, 36, 64
58425108|NCT00590577|DRUG|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
58425109|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
58425110|NCT02880150|OTHER|Stress test|
58425111|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
58425112|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
58425113|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
58425114|NCT01496911|DRUG|Levocetirizine|a single oral dose of 5 mg
58425115|NCT01496911|DRUG|Hydroxyzine|a single oral dose of 50 mg
58425116|NCT01496911|DRUG|Placebo|a single oral dose
58097461|NCT04178018|DEVICE|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
58097462|NCT04178018|DEVICE|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
58097463|NCT05383976|OTHER|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
58097464|NCT01976663|DEVICE|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
58097465|NCT01976663|DEVICE|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
58097466|NCT00392717|DRUG|Atorvastatin|
58097467|NCT00392717|DRUG|Fish oils|
58097468|NCT02494947|BEHAVIORAL|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
58097469|NCT02494947|OTHER|Usual care|
58097470|NCT02525562|DEVICE|Triathlon Total Knee System with X3 insert|Total knee replacement
58097471|NCT02525562|DEVICE|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
58097472|NCT02525562|DEVICE|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
58097473|NCT02525562|PROCEDURE|Total Knee Replacement|Total Knee Replacement
58097474|NCT02525562|PROCEDURE|Partial Knee Resurfacing|Partial Knee Resurfacing
58097475|NCT02426827|DEVICE|Spinal Cord Stimulation|
58097476|NCT06063499|BEHAVIORAL|Healthy Minds Program for Addictions|The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has \>100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
58097477|NCT04483427|COMBINATION_PRODUCT|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
58097478|NCT05727592|DIETARY_SUPPLEMENT|Althernanthera Sissoo|15g of Althernanthera Sissoo consumed with lunch or dinner per day.
58425117|NCT00175448|PROCEDURE|physiotherapy|See Detailed Description.
58425118|NCT00118430|BEHAVIORAL|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
57735994|NCT03500874|DRUG|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
58097479|NCT05727592|BEHAVIORAL|Dietary Consultation|Dietary consultation to improve the intakes of vegetables daily
58097480|NCT02741752|PROCEDURE|Decortication|cortical bone perforation
58097481|NCT00887107|DRUG|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
58097482|NCT06539494|DRUG|Omeprazole 40 MG|Proton pump inhibitor twice a day for 4 weeks
58097483|NCT00155259|DRUG|Docetaxel , Cisplatin , Capecitabine|
58425119|NCT00118430|DRUG|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
57735995|NCT03500874|DRUG|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
58425120|NCT00118430|DRUG|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
58097484|NCT05931952|OTHER|Buteyko breathing technique|"Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
58097485|NCT05931952|OTHER|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
58097486|NCT06617013|OTHER|Discontinuation of GERD therapy|GERD therapy will be discontinued at time of enrollment.
58097487|NCT00005609|BIOLOGICAL|rituximab|
58097488|NCT04075045|BEHAVIORAL|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
58097489|NCT04075045|BEHAVIORAL|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
58097490|NCT04075045|BEHAVIORAL|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
58097491|NCT02040207|DRUG|AM-101|AM-101 gel for intratympanic injection
58097492|NCT06417203|PROCEDURE|spinal anesthesia with hyberbaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
58097493|NCT06417203|PROCEDURE|spinal anesthesia with hypobaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
58097494|NCT04212741|DIETARY_SUPPLEMENT|A+ HA(tm)|oral solution of hyaluronic acid mixture
58097495|NCT04212741|DIETARY_SUPPLEMENT|Placebo|oral solution with no-active ingredients
58097496|NCT05284474|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
58097497|NCT05730088|OTHER|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
58097498|NCT05730088|OTHER|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
58097499|NCT05730088|OTHER|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
58097500|NCT03283007|DRUG|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
58097501|NCT03283007|DRUG|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
58425121|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
58425122|NCT01506661|DRUG|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
58425123|NCT01029041|OTHER|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
58425124|NCT01029041|OTHER|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
58425125|NCT06198686|DRUG|Nalmefene|Opioid antagonist
58425126|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
57735996|NCT03500874|DRUG|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
57735997|NCT03500874|DRUG|5FU|5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
57735998|NCT03500874|DRUG|Irinotecan|Irinotecan 180mg/m2
57735999|NCT03580265|DEVICE|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
58097502|NCT03375996|DRUG|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
57736000|NCT01288482|DEVICE|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
58097503|NCT00168740|DRUG|rituximab|
58097504|NCT05188027|OTHER|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
58097505|NCT05188027|OTHER|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
58097506|NCT05188027|OTHER|No exercise|Participants will rest in a supine position for 30 minutes.
58097507|NCT05479760|OTHER|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
57736001|NCT01288482|DEVICE|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
58097508|NCT00629629|BEHAVIORAL|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
58097509|NCT02677402|OTHER|immersion|
58097510|NCT03628001|PROCEDURE|ERCP|Pts will be randomized with or without sphinterectomy.
58097511|NCT04506346|DIAGNOSTIC_TEST|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
58097512|NCT00296829|BIOLOGICAL|Inactivated, split-virion influenza vaccine|
58097513|NCT00254488|DRUG|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
58097514|NCT00254488|DRUG|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
58425127|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
57736002|NCT02097472|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
58097515|NCT03001869|DRUG|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
58425128|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
58097516|NCT02238470|DRUG|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
58097517|NCT02908607|DEVICE|Thermal imaging|Examination of the cervix by thermal imaging camera
58097518|NCT00141479|DRUG|Bifeprunox|
58097519|NCT00171756|DRUG|valsartan/atenolol|
58097520|NCT06569680|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"
58097521|NCT04654286|PROCEDURE|Nerve transfer procedure|"1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
58097522|NCT04654286|PROCEDURE|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
58425129|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
58097523|NCT02670993|BEHAVIORAL|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
58097524|NCT02670993|BEHAVIORAL|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
58097525|NCT00287235|DEVICE|MARS|
58097526|NCT00287235|DRUG|Standard Medical Therapy|
58425130|NCT02945644|DRUG|Trazodone|take at bedtime for 14 days
57736003|NCT02097472|BIOLOGICAL|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
58097527|NCT06265584|DRUG|ATG dosing platform when combined with standard tacrolimus and mini methotrexate|On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
58097528|NCT02163694|DRUG|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
58097529|NCT02163694|DRUG|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
58097530|NCT02163694|DRUG|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
58097531|NCT02163694|DRUG|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
58097532|NCT05860608|DEVICE|Us2.ai (AI-enabled report) handheld echocardiogram|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
58097533|NCT04142866|DEVICE|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
58097534|NCT04142866|DEVICE|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
58097535|NCT04142866|BEHAVIORAL|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
58425131|NCT02945644|DRUG|Placebo|take at bedtime for 14 days
58425132|NCT04424693|DRUG|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
58425133|NCT03999086|PROCEDURE|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
57736004|NCT02097472|BIOLOGICAL|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
58425134|NCT03999086|OTHER|Control Group|Laboratory analysis to guide transfusion
58425135|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
58425136|NCT02319135|DRUG|Azacitadine|
58425137|NCT02319135|DRUG|Fludarabine|
58425138|NCT02319135|DRUG|Cytarabine|
58425139|NCT02319135|DRUG|Lenograstim|
58425140|NCT02319135|DRUG|Filgastrim|
58425141|NCT03002272|DEVICE|TAVR|subjects that underwent TAVR more than 3 years ago
58425142|NCT03002272|DEVICE|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
58425143|NCT04797962|BEHAVIORAL|Case management|dedicated case management to address social support needs
58425144|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
58097536|NCT06459076|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)|Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1.
58097537|NCT05974865|BEHAVIORAL|Healthy Babies and Healthy Moms|
58097538|NCT05974865|BEHAVIORAL|Baby Basics Prenatal Guide|
58097539|NCT04954209|OTHER|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
58097540|NCT04954209|OTHER|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
58097541|NCT00209495|DRUG|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
58097542|NCT06372379|OTHER|no intervention|no intervention
58425145|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
58425146|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
57736005|NCT02097472|OTHER|Saline|0.9% Sodium Chloride Injection, USP
57736006|NCT06669286|PROCEDURE|implant placement using navigated surgery near alveolar nerve|Dental implant placement in proximity of alveolar nerve (within 2 mm) using navigated surgery.
57736007|NCT01680328|OTHER|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
57736008|NCT01680328|DRUG|sodium chloride 0.9% solution|Solution for injection.
57736009|NCT03151434|DRUG|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
58097543|NCT01227954|RADIATION|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
58097544|NCT04650516|DEVICE|Virtual reality|20 minutes treatment in virtual reality
58425147|NCT00849862|DRUG|Keppra®|750 mg Tablet
58425148|NCT03834220|DRUG|Debio 1347|Debio 1347 oral tablets.
58097545|NCT04650516|DEVICE|Digital control|20 minutes digital control movie on tablet without virtual reality
58097546|NCT05877235|DIETARY_SUPPLEMENT|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
58425149|NCT02894450|OTHER|blood test|bioassay xaban
58425150|NCT03460912|DEVICE|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
58425151|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
58425152|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
58425153|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
58425154|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
58425155|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
58097547|NCT05877235|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 60 days
58425156|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
58425157|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
58425158|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
58425159|NCT01257035|OTHER|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
58425160|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
58425161|NCT02910102|DRUG|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
58425162|NCT02910102|DRUG|Placebo|Placebo once daily, oral
58425163|NCT04374058|OTHER|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
58425164|NCT00389350|DRUG|Extract of Green and Black Tea|
58425165|NCT03898128|DRUG|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
58425166|NCT04761848|DRUG|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
58425167|NCT04761848|DRUG|Placebo|Placebo tablet twice daily
57736010|NCT03151434|DRUG|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
57736011|NCT03151434|DRUG|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
58097548|NCT06576089|OTHER|Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)|"Participants randomized into ORDER will be approached by the Site Coordinator for interest in the host trial. The Coordinator will introduce the trial and share a brief, women-centred, aphasia-friendly, close-captioned video that further describes the trial procedures and an accompanying leaflet.~ORDER recruitment materials will be saved to a mobile tablet. The Coordinator will watch the video together with the potential participant, engage in discussion about the host trial and answer any questions they may have. The Coordinator will offer to leave the tablet with the potential participant, along with printed copies of the leaflet and participant information letter. The Coordinator will encourage them to share these materials with their family members, friends or member of their healthcare team who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial."
58097549|NCT06576089|OTHER|Traditional recruitment and enrollment processes (TRAD)|Participants randomized into the traditional recruitment process (TRAD) will be approached by the Site Coordinator for interest in the CAMAROS trial and presented with the standard participant information letter and full informed consent form. The information letter and consent form will be left with the potential participant to view again; the Coordinator will encourage them to share these materials with their family members or friends who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.
58097550|NCT05969782|DEVICE|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
58097551|NCT03159988|DRUG|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
58097552|NCT03159988|BEHAVIORAL|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
58097553|NCT04440007|DRUG|Abivertinib|Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
58097554|NCT04440007|OTHER|Standard of Care|Standard of Care as determined by the Investigator
58097555|NCT04903717|BEHAVIORAL|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
58097556|NCT03904667|OTHER|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
58097557|NCT03343054|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
58097558|NCT04457531|DRUG|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
58097559|NCT04457531|OTHER|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
58097560|NCT00061945|DRUG|allopurinol|Given PO
58097561|NCT00061945|DRUG|cyclophosphamide|Given IV
58097562|NCT00061945|DRUG|daunorubicin hydrochloride|Given IV
58097563|NCT00061945|DRUG|vincristine sulfate|Given IV
58097564|NCT00061945|DRUG|dexamethasone|Given PO and as eye drops
58097565|NCT00061945|DRUG|asparaginase|Given SC
58097566|NCT00061945|BIOLOGICAL|filgrastim|Given SC
58097567|NCT00061945|DRUG|imatinib mesylate|Given PO
58097568|NCT00061945|DRUG|methotrexate|Given IT, IV, and PO
58097569|NCT00061945|DRUG|cytarabine|Given IV
57736012|NCT02285816|BIOLOGICAL|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
57736013|NCT02285816|BIOLOGICAL|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
58097570|NCT00061945|DRUG|trimethoprim-sulfamethoxazole|Given PO
58097571|NCT00061945|DRUG|mercaptopurine|Given PO
58097572|NCT00061945|DRUG|leucovorin calcium|Given IV and PO
58097573|NCT00061945|BIOLOGICAL|alemtuzumab|Given SC
58097574|NCT00061945|DRUG|acyclovir|Given PO
58097575|NCT00061945|OTHER|laboratory biomarker analysis|Correlative studies
58097576|NCT00061945|OTHER|pharmacological study|Correlative studies
58097577|NCT06045832|DEVICE|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
58097578|NCT06045832|DEVICE|Water|Water
58097579|NCT01319305|DEVICE|FinESS Sinus Treatment|balloon sinuplasty
58425168|NCT06431230|BEHAVIORAL|standard high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.
57736014|NCT06053567|BEHAVIORAL|Aerobic Exercise|Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
57736015|NCT06053567|BEHAVIORAL|Counseling|Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
58097580|NCT04653701|COMBINATION_PRODUCT|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
58097581|NCT01058876|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
58097582|NCT06703463|DRUG|MK-1167|Administered via oral capsule per dosing regimen.
58097583|NCT06703463|DRUG|Diltiazem|Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
58097584|NCT01932801|DRUG|XR-NTX|
58097585|NCT01932801|OTHER|Placebo|
58097586|NCT01932801|BEHAVIORAL|HRC|
58097587|NCT00828516|OTHER|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
58097588|NCT02773446|BIOLOGICAL|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
58097589|NCT03757793|DEVICE|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
58097590|NCT06701760|DRUG|Sodium Lactate|sodium lactate
58097591|NCT06701760|DRUG|placebo|infusion of sodium chloride
58097592|NCT03859570|DRUG|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
58097593|NCT03859570|DRUG|Placebos|Placebo
58097594|NCT01860690|DRUG|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
58097595|NCT02341209|DRUG|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
58097596|NCT01456494|OTHER|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
58097597|NCT01456494|OTHER|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
57736016|NCT06053567|DRUG|Nicotine patch|On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
58097598|NCT04145349|DRUG|Ramucirumab|Administered IV
58097599|NCT04145349|DRUG|Cyclophosphamide|Administered orally
58097600|NCT04145349|DRUG|Vinorelbine|Administered IV
58097601|NCT02060240|BEHAVIORAL|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
58097602|NCT01031342|PROCEDURE|Early colonoscopy|Colonoscopy within 12 hours of presentation
58097603|NCT01031342|PROCEDURE|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
58097604|NCT01803035|DRUG|LTX-109 1 %|
58097605|NCT01803035|DRUG|LTX-109 2 %|
58097606|NCT01803035|DRUG|Placebo gel|
58097607|NCT04876807|DRUG|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
58097608|NCT04876807|DRUG|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
58097609|NCT00500695|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
58097610|NCT00500695|BEHAVIORAL|Psychoeducation|Psychoeducation
58097611|NCT05787860|DRUG|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
58097612|NCT00571220|PROCEDURE|gastric bypass surgery|weight loss bariatric surgery
58097613|NCT00571220|OTHER|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
58425169|NCT06431230|BEHAVIORAL|plyometric high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
58425170|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
57736017|NCT00530361|DRUG|Nesiritide|
57736018|NCT02676479|DEVICE|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
57736019|NCT04241861|OTHER|Respiratory support (High-flow oxygen therapy)|Noninvasive respiratory support respiratory support
58097614|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
58097615|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: intravenous
58097616|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
58097617|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
58097618|NCT02282826|DRUG|acyclovir|Pharmaceutical form:tablet Route of administration: oral
58097619|NCT05189145|DRUG|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
58097620|NCT05189145|OTHER|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
58425171|NCT02628548|BEHAVIORAL|Cognitive training program|8 week cognitive training program
57736020|NCT04241861|OTHER|Respiratory support (Helmet PSV)|Noninvasive respiratory support respiratory support
57736021|NCT04241861|OTHER|Respiratory support (Helmet CPAP)|Noninvasive respiratory support respiratory support
57736022|NCT01369862|BIOLOGICAL|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
57736023|NCT01369862|BIOLOGICAL|Placebo|SPGNH buffer
57736024|NCT03019211|OTHER|Exercise|
57736025|NCT02680054|DRUG|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
57736026|NCT01815268|BIOLOGICAL|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
57736027|NCT01815268|BIOLOGICAL|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
57736028|NCT01815268|BIOLOGICAL|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
57736029|NCT01815268|BIOLOGICAL|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
57736030|NCT05997238|DRUG|without triamcinolone|The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
57736031|NCT05997238|DRUG|20mg triamcinolone|20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
58097621|NCT05189145|DIAGNOSTIC_TEST|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
58097622|NCT05189145|DRUG|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
58097623|NCT05189145|OTHER|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily
57736032|NCT05997238|DRUG|40mg triamcinolone|40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
58097624|NCT05189145|DRUG|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
58425172|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
58425173|NCT00242307|DRUG|Roflumilast|
58097625|NCT02996448|DRUG|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
58097626|NCT02624817|DRUG|Sulfonylurea|See Arm description.
58425174|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
58425175|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
58425176|NCT01893736|OTHER|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
58425177|NCT01893736|OTHER|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
58425178|NCT01895309|DRUG|Enbrel (etanercept)|
58425179|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
58425180|NCT01508260|PROCEDURE|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
58425181|NCT01508260|DRUG|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
58425182|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
58425183|NCT02869698|DEVICE|Hybride electrode|
58425184|NCT02869698|DEVICE|Macro electrode|
58425185|NCT03959917|PROCEDURE|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
57736033|NCT05997238|DRUG|80mg triamcinolone|80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
57736034|NCT00490191|DRUG|Somatropin|
57736035|NCT04897958|DRUG|Degarelix|Degarelix dispensing claim is used as the reference group.
57736036|NCT04897958|DRUG|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
58097627|NCT04554927|OTHER|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
58097628|NCT04554927|OTHER|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
58307085|NCT04526002|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%\* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
58307086|NCT02222662|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
58307087|NCT02222662|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
58307088|NCT04688632|DRUG|Ampreloxetine <Dose A>|Ampreloxetine \<Dose A\> will be administered as 1 tablet of \<Dose A\> and 3 tablets of Ampreloxetine Placebo.
58307089|NCT04688632|DRUG|Ampreloxetine <Dose B>|Ampreloxetine \<Dose B\> will be administered as 4 tablets of \<Dose A\>
58425186|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
57736037|NCT05737810|OTHER|No treatment given|No treatment given
58097629|NCT00431236|DRUG|Oral Casopitant (GW679769)|
58097630|NCT00431236|DRUG|IV Casopitant (GW679769)|
58097631|NCT00431236|DRUG|IV ondansetron hydrochloride|
58097632|NCT00431236|DRUG|Oral dexamethasone|
58097633|NCT03875300|BEHAVIORAL|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
58097634|NCT02015299|DRUG|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
58097635|NCT02015299|DRUG|placebo|one tablet matching placebo/day for 26 weeks
58097636|NCT06348173|DRUG|Mepolizumab|Compare the response to mepolizumab and benralizumab before and after treatment
58097637|NCT06263179|BEHAVIORAL|Target Heartrate Aerobic Exercise|Exercise program
58097638|NCT04310735|BEHAVIORAL|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
58097639|NCT05065242|BEHAVIORAL|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
58097640|NCT01979302|OTHER|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
58097641|NCT01979302|OTHER|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
58307090|NCT04688632|DRUG|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A\> tablet.
58097642|NCT04164394|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
58097643|NCT04164394|DIETARY_SUPPLEMENT|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
58097644|NCT03121989|DRUG|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
58097645|NCT03121989|OTHER|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
57736038|NCT03640260|BEHAVIORAL|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
58097646|NCT03121989|DRUG|NAC|Participants will be receiving NAC as part of their clinical treatment.
58097647|NCT04908956|DRUG|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
58097648|NCT04908956|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
58097649|NCT04479488|OTHER|Hospital admission|Usual care.
58097650|NCT04479488|OTHER|Non-hospitalization procedures|Usual care.
58097651|NCT02682173|OTHER|MR Abdomen|
58097652|NCT04359420|OTHER|BC-Predict|BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
58097653|NCT04359420|OTHER|NHS Breast Screening Programme|usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
58097654|NCT05684497|BEHAVIORAL|LBPSP in Pregnancy|LBPSP is a 50-minute interactive presentation as face to face program according to Pender's Health Promotion Model Parameters.
58097655|NCT05171920|DRUG|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
58097656|NCT05171920|DRUG|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
58307091|NCT04688632|DRUG|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
58307092|NCT04688632|DRUG|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
58307093|NCT03055884|DEVICE|tDCS|active tDCS versus sham tDCS
58307094|NCT03055884|BEHAVIORAL|Verbal paired-associate learning task|with or without repeated retrieval practice
58307095|NCT02262780|DRUG|Low dose of telmisartan|
58307096|NCT02262780|DRUG|High dose of telmisartan|
58307097|NCT02262780|DRUG|HCTZ|
58307098|NCT00259103|DRUG|Serelaxin|
58307099|NCT00259103|DRUG|Placebo|
58307100|NCT00208364|DEVICE|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
58097657|NCT05359380|OTHER|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
58097658|NCT05567588|COMBINATION_PRODUCT|Drug: Pembrolizumab|200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
58097659|NCT03874585|BEHAVIORAL|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
58097660|NCT03874585|BEHAVIORAL|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
58097661|NCT02751255|DRUG|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
58097662|NCT05940870|DEVICE|Nerivio|Patients with migraine who received the Nerivio device for migraine prevention therapy
58097663|NCT04317053|BEHAVIORAL|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
58097664|NCT04270552|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
58097665|NCT04270552|DRUG|Placebo|Matched tablets without any active substance.
58097666|NCT06701604|DIETARY_SUPPLEMENT|Single Strain Probiotic + Milk Protein|• Both conditions matched flavor, color, and serving size
58097667|NCT06701604|DIETARY_SUPPLEMENT|Placebo + Milk Protein|• Both conditions matched flavor, color, and serving size
58097668|NCT05613920|BEHAVIORAL|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
58097669|NCT01956123|DRUG|Follitropin Delta (FE 999049)|
58425187|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
58425188|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
58425189|NCT04943120|PROCEDURE|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
58425190|NCT04943120|PROCEDURE|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
57736039|NCT05427279|DIETARY_SUPPLEMENT|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
58097670|NCT01956123|DRUG|Follitropin Alfa (GONAL-F)|
58097671|NCT00301639|DRUG|OROS methylphenidate hydrochloride|
58097672|NCT00301639|DRUG|methylphenidate hydrochloride|
58097673|NCT06619834|BEHAVIORAL|Financial Navigation and Peer Support|A combined intervention of technology-supported financial navigation and peer support: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks. Participants will also be matched with a Peer Supporter to help improve the participants\&#39; diabetes self-management.
58097674|NCT06619834|BEHAVIORAL|Financial Navigation Only|A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks.
58425191|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
58425192|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
58425193|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
58425194|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
58425195|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
58425196|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
58425197|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
57951938|NCT03077347|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
57951939|NCT00003398|BIOLOGICAL|anti-thymocyte globulin|
57951940|NCT00003398|BIOLOGICAL|filgrastim|
58097675|NCT05226468|DRUG|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
57951941|NCT00003398|DRUG|cyclophosphamide|
57951942|NCT00003398|DRUG|thiotepa|
57951943|NCT00003398|PROCEDURE|allogeneic bone marrow transplantation|
57951944|NCT00003398|PROCEDURE|bone marrow ablation with stem cell support|
57951945|NCT00003398|RADIATION|radiation therapy|
57951946|NCT01743755|DRUG|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
58097676|NCT05728216|OTHER|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
58425198|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
58425199|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
57736040|NCT05427279|DIETARY_SUPPLEMENT|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
57736041|NCT05427279|DIETARY_SUPPLEMENT|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
57736042|NCT05427279|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
57736043|NCT05404542|DRUG|Tavapadon|Oral tablets
57951947|NCT01743755|DRUG|Placebo|Placebo tablet, once daily for four consecutive days
57951948|NCT02829138|GENETIC|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
57951949|NCT02829138|BEHAVIORAL|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
57951950|NCT05411159|PROCEDURE|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
57951951|NCT05411159|PROCEDURE|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
57951952|NCT04029974|DEVICE|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
58425200|NCT06542991|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
58425201|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
58425202|NCT02460341|DRUG|placebo|placebo pill
58425203|NCT06212830|DRUG|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
58425204|NCT06212830|DRUG|Targin|Targin 5 mg twice a day after the procedure for 48 hours
58425205|NCT06212830|DRUG|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
58425206|NCT06212830|DRUG|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
58425207|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
58425208|NCT04088526|COMBINATION_PRODUCT|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
58425209|NCT04193774|DIAGNOSTIC_TEST|Conjunctival swab|Swab of the conjunctival fornices of both eyes
58425210|NCT04193774|DRUG|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
58425211|NCT04193774|DRUG|artificial tears|One drop of artificial tears in the other eye
58425212|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
58425213|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
58425214|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
58097677|NCT06520995|OTHER|Educational video program|Diabetes education video contents are as follows; Type 2 diabetes definition, symptoms and the effect of diabetes on cognitive functions, Medical nutrition therapy and healthy nutrition recommendations in Type 2 diabetes, The importance of diabetes and exercise, Oral antidiabetic treatments, Insulin treatment, Hypoglycemia symptoms, findings and treatment, Macrovascular complications in diabetes, Microvascular complications in diabetes, Foot Protection and care recommendations, Diabetes self-care skills and problem-solving strategies, Diabetes and stress management.
58097678|NCT06520995|OTHER|A mobile application|This mobile application is a science-based application that patients can access via their smartphone or tablet. It consists of verbal, numerical, visual, logical, memory and attention categories and contains 24 different gamified mind exercises
58097679|NCT05658107|DRUG|BI 765423|BI 765423
58425215|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
58097680|NCT05658107|DRUG|Placebo|Placebo
58425216|NCT00221494|DRUG|citalopram + tiodothyronine, or + pindolol, or + placebo|
58425217|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
58425218|NCT01441466|OTHER|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
58425219|NCT01501994|OTHER|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
58425220|NCT01501994|OTHER|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
58425221|NCT01501994|PROCEDURE|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
58425222|NCT04054804|DIAGNOSTIC_TEST|D-Foot|A digital foot check i assessed by using the software D-Foot.
58425223|NCT02133976|BEHAVIORAL|cognitive therapy|
58097681|NCT01888978|DRUG|Gem-OX|
58425224|NCT02133976|BEHAVIORAL|mindfulness training|
58425225|NCT02133976|BEHAVIORAL|behavioral therapy|
58425226|NCT02133976|OTHER|treatment as usual|
57736044|NCT06636409|OTHER|Collection of medical data|A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
57736045|NCT03787394|OTHER|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
57951953|NCT01526161|DRUG|inhaled fluticasone propionate|100 micrograms
58097682|NCT01888978|DRUG|Gem-5FU|
58097683|NCT01888978|DRUG|Gem-Tax|
58097684|NCT01888978|DRUG|Modified FOLFOX-6|
58097685|NCT01888978|DRUG|Ox-Tax|
58097686|NCT01888978|DRUG|FOLFIRI|
58097687|NCT01888978|DRUG|Tax-Iri|
58425227|NCT04487457|OTHER|Blood samples|Blood samples
58425228|NCT00490776|DRUG|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
57951954|NCT01526161|DRUG|salmeterol|50 m
57951955|NCT01526161|DRUG|Montelukast|Double blind double dummy
58425229|NCT03327168|DRUG|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
58425230|NCT03327168|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
58425231|NCT01976143|DRUG|NKTR-102|
58425232|NCT02693379|DEVICE|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
58425233|NCT05477914|OTHER|questionnaire|questionnare about nutritional knowledge of pregnant women
58425234|NCT03737331|BEHAVIORAL|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
58425235|NCT03737331|BEHAVIORAL|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
57736046|NCT06530914|DRUG|MRG003 combined with Pucotenlimab|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
58097688|NCT02515552|BEHAVIORAL|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
58425236|NCT03737331|BEHAVIORAL|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
58425237|NCT04259684|DRUG|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
58425238|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
58425239|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
58425240|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
58425241|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
58425242|NCT00261573|DRUG|galantamine hydrobromide|
58425243|NCT03214731|DRUG|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
58425244|NCT03214731|OTHER|placebo|placebo was produced by pharmaceutical factory for research specifically
58425245|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
58425246|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
58425247|NCT01416623|DRUG|henatinib|Henatinib Maleate Tablets
58425248|NCT00794066|PROCEDURE|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
58425249|NCT05333380|DEVICE|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
58425250|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
58425251|NCT03664765|OTHER|Sham exercise|Daily sham exercises
58425252|NCT01862367|DRUG|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
58425253|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
58425254|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
58425255|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
58425256|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
58425257|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
58425258|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
58425259|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
58425260|NCT01577342|DRUG|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
57736047|NCT06530914|DRUG|MRG003 combined with Pucotenlimab+Cisplatin|All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
57736048|NCT01820728|DRUG|DA-3801 Injection|
57736049|NCT01820728|DRUG|Gonal-F®|
57736050|NCT00755989|DRUG|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
57736051|NCT00755989|DRUG|placebo|topical gel without morphine
57736052|NCT05796570|DRUG|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
57736053|NCT05796570|DRUG|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
58425261|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
58425262|NCT03975569|OTHER|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
58425263|NCT03327467|BIOLOGICAL|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling, autologous, or unrelated donor)
58425264|NCT04097977|OTHER|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
58425265|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
58425266|NCT04891185|DRUG|Indocyanine green|Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
58425267|NCT00649831|DRUG|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
58425268|NCT00649831|DRUG|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
58425269|NCT01269502|DEVICE|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
57736054|NCT06635928|DEVICE|Bright light therapy|30min daily of 10.000 lux bright light therapy
57736055|NCT02175433|DRUG|AGS67E|intravenous (IV) infusion
57736056|NCT04493398|PROCEDURE|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
58307101|NCT04927637|PROCEDURE|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
58307102|NCT00892021|DRUG|NSA-789|
58307103|NCT00892021|DRUG|Placebo|
58307104|NCT05009355|DRUG|Vitamin C|antioxidant
58307105|NCT03735290|BIOLOGICAL|ilixadencel|Intra-tumoral injection
58307106|NCT03735290|DRUG|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
58425270|NCT01269502|OTHER|Inspection|Inspection of feet daily for one year
58425271|NCT00224341|DEVICE|Pacemaker Vitatron Selection 9000|
58425272|NCT00224341|DEVICE|Pacemaker Vitatron T70|
57736057|NCT04493398|PROCEDURE|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
57736058|NCT04493398|PROCEDURE|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
57736059|NCT03131076|DIAGNOSTIC_TEST|IPMN follow up|Follow up with MRI and laboratory blood tests
57951956|NCT03957564|DRUG|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
58307107|NCT02374983|OTHER|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
58307108|NCT01033838|PROCEDURE|rectosigmoid resection|
58307109|NCT02541344|DEVICE|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
58425273|NCT05508893|RADIATION|CT Angiography|A CTA will be performed on asymptomatic individuals
58425274|NCT05508893|DIAGNOSTIC_TEST|Exercise stress test|A routine exercise stress test will be performed on a bicycle
58425275|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
58425276|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
58425277|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
58425278|NCT05318820|DRUG|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
57736060|NCT05234164|DEVICE|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
57736061|NCT05234164|DEVICE|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
58307110|NCT02541344|DEVICE|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
58425279|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
58425280|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
58425281|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
58425282|NCT05845463|DEVICE|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
58425283|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
58425284|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
58425285|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
58425286|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
58425287|NCT00940784|DRUG|Aspirin|81-100 mg qd
58425288|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
58425289|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
58425290|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
58425291|NCT04738630|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
57736062|NCT04310826|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary magnesium intervention
57736063|NCT04310826|OTHER|Media Intervention|Undergo video interviews
57736064|NCT04310826|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
57736065|NCT03761602|OTHER|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
57736066|NCT02466022|DRUG|Dexmedetomidine|Bolus dose prior to spinal anesthetic
58307111|NCT02541344|DEVICE|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
57736067|NCT02466022|DRUG|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
57736068|NCT02466022|DRUG|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
57736069|NCT02466022|DRUG|Fentanyl|Intrathecal Fentanyl 10ug
57736070|NCT02466022|DRUG|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
58307112|NCT03966625|DIAGNOSTIC_TEST|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
58307113|NCT04352348|OTHER|blood samples|"All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
58307114|NCT04352348|OTHER|feces samples (COVI-BIOME ancillary study)|"All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital"
58307115|NCT04352348|OTHER|sweat samples (COVIDOG ancillary study)|"All arms:~2 sweat samples at inclusion (T0)"
58307116|NCT04352348|OTHER|saliva samples|"All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
58307117|NCT04352348|OTHER|6 minutes walk test|"COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization."
58307118|NCT04352348|OTHER|Phone call|"All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection."
58097689|NCT06320093|OTHER|SOUND Intervention|The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
58097690|NCT04064359|DRUG|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
58097691|NCT05204940|BEHAVIORAL|Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Analyzing mechanisms of the LLD-dementia relationship through fMRI acquisitions and analyses, to capture the specific brain networks implicated in executive function and episodic memory decline.
58425292|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
57736071|NCT00622167|DEVICE|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
57736072|NCT00622167|DEVICE|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
57736073|NCT03079752|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
57951957|NCT03957564|OTHER|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
57951958|NCT03957564|OTHER|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
57951959|NCT03957564|OTHER|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
57951960|NCT00518154|DRUG|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
57951961|NCT04795232|OTHER|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
57951962|NCT04795232|OTHER|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
57951963|NCT02318667|BIOLOGICAL|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
57951964|NCT00000299|DRUG|Buprenorphine|
57951965|NCT03798964|OTHER|Placental analysis|Analysis of placenta to determine expression of heparanase
57951966|NCT02350556|OTHER|Dynamic Avoidance Task|
57951967|NCT02350556|PROCEDURE|physical therapy|
57951968|NCT02350556|DEVICE|3D motion on optoelectronic device|
58097692|NCT05204940|BEHAVIORAL|Neuropsychological Data|Neuropsychological Data, including Montreal Cognitive Assessment (MoCA), Wide Range Achievement Test-4 (WRAT-4) Reading subtest, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Delis-Kaplan Executive Function System (D-KEFS) (Color Word Interference, Trail Making and Verbal Fluency).
58097693|NCT05204940|BEHAVIORAL|Clinical Scales|Clinical scales, including the Everyday Cognition Scale (E-Cog), Global Clinical Dementia Rating (CDR), Performance Assessment of Selfcare Skills (PASS)--CIADL (Cognitive Instrumental Activities of Daily Living) Short version, Patient Health Questionnaire (PHQ-9), and Suicide Risk Assessments (Suicide Questions, Baseline Suicidal Ideation, Suicide Intent Scale, Beck Lethality Scale, Decision Outcome Inventory, Columbia-Suicide Severity Rating Scale, and High Suicide Risk Protocol).
58425293|NCT04861428|OTHER|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
58425294|NCT04861428|OTHER|Smoking as Usual|Cigarette smoking
58425295|NCT02027753|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
58425296|NCT02027753|DRUG|Metformin|Pharmaceutical form: tablet Route of administration: oral
58425297|NCT02027753|DRUG|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
58425298|NCT02027753|DRUG|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
58425299|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
58425300|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
58097694|NCT05478486|DRUG|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
58097695|NCT06541106|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma."
58097696|NCT06104592|RADIATION|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
58097697|NCT06104592|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
58097698|NCT00639587|DRUG|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
58097699|NCT00639587|DRUG|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
58307119|NCT04352348|OTHER|Urine samples|"All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
57736074|NCT03079752|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
57736075|NCT03079752|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
57951969|NCT03028571|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
57951970|NCT03028571|OTHER|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
57951971|NCT04267874|PROCEDURE|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
57951972|NCT04267874|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given black raspberry nectar PO
57951973|NCT04267874|DRUG|Placebo Administration|Given PO
57951974|NCT04267874|OTHER|Questionnaire Administration|Ancillary studies
57951975|NCT05386992|DIAGNOSTIC_TEST|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
57951976|NCT01825707|DRUG|[14C]-YH4808 200 mg|\[14C\]-YH4808 200 mg (oral) on day1
58307120|NCT02933853|DRUG|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
58307121|NCT02933853|DRUG|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
58425301|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
58425302|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
58425303|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
58425304|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
58425305|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
58425306|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
58425307|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
58425308|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
58425309|NCT00455208|DRUG|Cura-100|
58097700|NCT02803190|BEHAVIORAL|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
58425310|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
58425311|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
58425312|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
58425313|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
58425314|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
57951977|NCT03620227|OTHER|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
58097701|NCT02803190|BEHAVIORAL|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
58425315|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
58425316|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
58425317|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
58425318|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
58425319|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
58097702|NCT00665704|BEHAVIORAL|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
58097703|NCT05269316|DRUG|IMP9064|IMP9064 Monotherapy administered for 21 days
58097704|NCT05829473|OTHER|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
58425320|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
58425321|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
58425322|NCT01942070|DEVICE|Bioresorbable vascular scaffold|
57951978|NCT03620227|DIETARY_SUPPLEMENT|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
57951979|NCT03620227|DIETARY_SUPPLEMENT|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
58425323|NCT01942070|DEVICE|Durable polymer everolimus-eluting metallic stent|
58425324|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
58425325|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
58425326|NCT02737150|DEVICE|CoreValve Evolut R|
58425327|NCT02737150|DEVICE|Edwards Sapien 3|
58097705|NCT05829473|OTHER|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
58097706|NCT00334828|DRUG|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
57736076|NCT03079752|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
57951980|NCT05870267|DEVICE|Power Knee with bone anchored suspension|Motor powered microprocessor controlled prosthetic knee joint
58097707|NCT00334828|DRUG|Placebo|Matching placebo; intravenous infusion.
58097708|NCT04539158|DEVICE|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
58097709|NCT03620760|DRUG|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
58097710|NCT03620760|DRUG|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
58097711|NCT03620760|DRUG|Aspirin|Aspirin 100 mg once daily dose
58097712|NCT04341207|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
58097713|NCT04341207|DRUG|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
58097714|NCT06239467|DRUG|OKI-219|Oral twice daily
58097715|NCT06239467|DRUG|Fulvestrant|Intramuscular injection
58097716|NCT06239467|DRUG|Trastuzumab|Intravenous (IV)
58425328|NCT02737150|PROCEDURE|Local anesthesia with conscious sedation|
58425329|NCT02737150|PROCEDURE|General anesthesia|
58425330|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
58425331|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
58425332|NCT05503056|OTHER|art therapy|six sessions of art therapy with licensed therapists
58425333|NCT05503056|OTHER|nothing|no intervention to this group
57951981|NCT05870267|DEVICE|C-Leg|Passive hydraulic microprocessor controlled prosthetic knee joint
57951982|NCT05870267|DEVICE|Rheo Knee XC|Passive magneto-rheologic microprocessor controlled knee joint
57736077|NCT01197222|DEVICE|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
57736078|NCT02566031|DRUG|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
58097717|NCT06540365|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
58097718|NCT04529096|DRUG|LY3016859|Administered IV
58097719|NCT04529096|DRUG|Placebo|Administered IV
58097720|NCT00004232|BIOLOGICAL|filgrastim|
58097721|NCT00004232|DRUG|cyclosporine|
58097722|NCT00004232|DRUG|methylprednisolone|
58097723|NCT00004232|DRUG|prednisone|
58097724|NCT00004232|PROCEDURE|allogeneic bone marrow transplantation|
58097725|NCT00004232|PROCEDURE|peripheral blood stem cell transplantation|
58097726|NCT03733184|PROCEDURE|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
58097727|NCT06360679|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted and retrieved once treatment is completed
58425334|NCT06147583|OTHER|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
58425335|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
58425336|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
58425337|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
58097728|NCT04373057|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
58097729|NCT04373057|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
58425338|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
58425339|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
58425340|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
58425341|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
57736079|NCT02566031|DRUG|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
58425342|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
58425343|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
58425344|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
58458332|NCT02245477|OTHER|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
57736080|NCT04458610|BIOLOGICAL|Rituximab|Given IV
57736081|NCT04458610|DRUG|Zanubrutinib|Given PO
57736082|NCT03455426|DRUG|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
57736083|NCT02911948|DRUG|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
57736084|NCT02911948|DRUG|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
57736085|NCT00007189|DRUG|Naproxen Sodium (Aleve)|
58097730|NCT05719129|BEHAVIORAL|Date With Destiny (DWD) Seminar|6 days of immersive seminar
58097731|NCT04776291|RADIATION|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
58097732|NCT03772184|PROCEDURE|Cervical inversion|inverting the cervical lip after delivery
58097733|NCT03535506|DRUG|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
58097734|NCT05942131|OTHER|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
58097735|NCT03720522|PROCEDURE|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
58307122|NCT04268355|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
58425345|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
58425346|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
58425347|NCT02478255|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
58425348|NCT02478255|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
58425349|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
58425350|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
58425351|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
58425352|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
58425353|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
58425354|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
58425355|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
58425356|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
58425357|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
58425358|NCT00006094|DRUG|oxaliplatin|Given IV
58425359|NCT00006094|DRUG|fluorouracil|Given IV
58425360|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
58425361|NCT05819619|DRUG|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
58425362|NCT05819619|DRUG|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
58425363|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
58425364|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
57736086|NCT00007189|DRUG|Celecoxib (Celebrex)|
57736087|NCT02176135|DRUG|Auranofin|3 mg tablets
57951983|NCT05139186|DEVICE|Artificial Intelligence|Artificial intelligence
57736088|NCT02345148|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
57736089|NCT01116570|OTHER|Physical training|Physical training during 24 weeks
57736090|NCT01116570|OTHER|Control|No intervention
58097736|NCT03720522|PROCEDURE|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
58425365|NCT05521438|DRUG|Vehicle|Vehicle Lotion
58097737|NCT03720522|PROCEDURE|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
58097738|NCT03720522|PROCEDURE|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
58097739|NCT01875991|DRUG|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
58097740|NCT01875991|DRUG|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
58097741|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
58307123|NCT03371914|BEHAVIORAL|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
58097742|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
58097743|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
58307124|NCT02660255|DRUG|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
58307125|NCT01009593|DRUG|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
58307126|NCT01009593|DRUG|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
58307127|NCT04610775|OTHER|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
58307128|NCT00664586|DRUG|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
58307129|NCT05064254|OTHER|Treatment as usual (TAU)|TAU may include self-help methods, physician visit, provision of resources etc.
58307130|NCT05064254|OTHER|Mindful Adaptive Practice in Pregnancy Therapy|MAP teaches: a) recognition of personal maladaptive/ distressing patterns driving anxiety; b) how to relate differently; and c) cultivation of more adaptive ways of dealing with anxiety and learning how to effectively control it rapidly which allows re-engagement with life in more flexible ways.
58307131|NCT03174444|BEHAVIORAL|Small Media|Bilingual brochures and access to bilingual website
58307132|NCT04919707|BEHAVIORAL|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
58307133|NCT04919707|PROCEDURE|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
58307134|NCT05079971|DIAGNOSTIC_TEST|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
58307135|NCT00933595|OTHER|Smoking Cessation|"A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
58425366|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
58425367|NCT02641717|OTHER|vaginal swab|
58425368|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
58425369|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
58458333|NCT05472935|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
58458334|NCT06086509|OTHER|Music|Children were played music during computerized tomography.
58425370|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
58425371|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
58097744|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
58097745|NCT04261322|RADIATION|x ray exposure|exposure of whole body to x ray
58097746|NCT03023007|PROCEDURE|Loco-regional anaesthesia|Loco-regional anaesthesia
58097747|NCT06255730|PROCEDURE|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58307136|NCT01776086|BEHAVIORAL|Neurological testing|
58097748|NCT06255730|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58307137|NCT04909060|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
58307138|NCT05523726|BEHAVIORAL|pCBT-I|Telehealth coaching
58307139|NCT03758729|DRUG|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
58307140|NCT03758729|RADIATION|Radiation Therapy|Radiation Therapy
58307141|NCT01931384|DRUG|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
58307142|NCT01931384|DRUG|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
58307143|NCT04700969|OTHER|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
58307144|NCT04071041|DRUG|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
58307145|NCT03702660|OTHER|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
58307146|NCT03702660|OTHER|Peripheral venous cannulation|Intravenous access for infusions
58307147|NCT03702660|OTHER|GLP-1|Peptide infusion
58307148|NCT01166256|DEVICE|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 \>92% or PaO2 \>65 mmHg.
58307149|NCT01166256|DEVICE|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 \>92% or PaO2 \>65 mmHg.
58307150|NCT01123330|BEHAVIORAL|Motivational Interviewing|
58307151|NCT00856180|DRUG|Bevacizumab|
58307152|NCT00856180|DRUG|Cyclophosphamide|
58097749|NCT04522310|OTHER|MR-Pro-ADM|Dosage of MR-pro-ADM
58097750|NCT03759418|DEVICE|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
58307153|NCT03040232|OTHER|biomechanical assessment|biomechanical and strength assessment of both groups
58307154|NCT03468088|BEHAVIORAL|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
58458335|NCT00517764|DRUG|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
58458336|NCT01838317|DRUG|Pioglitazone|
58097751|NCT02659826|DEVICE|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
58097752|NCT02659826|DEVICE|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
58097753|NCT02659826|DEVICE|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
58097754|NCT02659826|DEVICE|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
58097755|NCT02659826|DEVICE|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
58097756|NCT02659826|DEVICE|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
58425372|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
58097757|NCT02659826|DEVICE|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
58097758|NCT06541834|DEVICE|Retinal imaging|Data of retinal imaging were acquired using Spectralis (Heidelberg, Germany) and California (Optos, UK).
58097759|NCT03027973|DRUG|UPA|Experimental drug
58097760|NCT03027973|DRUG|TEA|Active comparator
58097761|NCT03027973|DRUG|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
58097762|NCT03027973|DRUG|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
58097763|NCT04503031|DEVICE|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
58425373|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
58425374|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58425375|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
58425376|NCT05701566|DEVICE|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
58425377|NCT05701566|OTHER|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
58425378|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
58425379|NCT00004874|RADIATION|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
58425380|NCT00313859|DRUG|simvastatin|
58425381|NCT00083928|DRUG|Å6 subcutaneous injection|
58425382|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
58425383|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
58425384|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
58425385|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
58425386|NCT00110461|DRUG|placebo|Placebo tablet
58425387|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
58425388|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
58425389|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
58425390|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
58425391|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
58425392|NCT02407782|DRUG|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
58425393|NCT02407782|DRUG|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
58425394|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
58425395|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
58425396|NCT01657708|OTHER|Shared Decision Making|
57951984|NCT03237104|OTHER|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
58097764|NCT04503031|DEVICE|cylindrical endotracheal tube|endotracheal tube is intubated
58425397|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
58425398|NCT02182271|DRUG|Placebo|
58425399|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
58425400|NCT01705912|OTHER|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
58097765|NCT04068155|DEVICE|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
58097766|NCT05214599|DRUG|Budesonide Gel|Twice daily regimen
58097767|NCT05103488|OTHER|Comprehensive palliative care|CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
58425401|NCT01705912|OTHER|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
57736091|NCT01694862|PROCEDURE|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
57736092|NCT04029922|DRUG|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
58425402|NCT03583736|BEHAVIORAL|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
58425403|NCT03583736|BEHAVIORAL|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
58425404|NCT00436592|DEVICE|NeuroFlo™ Catheter|45 minute Treatment
58425405|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
58425406|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
58425407|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
58425408|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
58425409|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
58425410|NCT02626390|OTHER|Frequent instructions/feedback and an Internal Focus of Attention|
58425411|NCT02626390|OTHER|Minimal instructions/feedback and an External Focus of Attention|
58425412|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
58425413|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
58425414|NCT00694304|DRUG|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
58425415|NCT01067365|DRUG|Androxal|12.5 mg once daily
58425416|NCT01067365|DRUG|Androxal|25 mg once daily
58425417|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
58425418|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
57951985|NCT02229500|DIETARY_SUPPLEMENT|Inulin|
57951986|NCT02229500|DIETARY_SUPPLEMENT|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
57951987|NCT02229500|DIETARY_SUPPLEMENT|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
57951988|NCT02598843|OTHER|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
57951989|NCT02598843|OTHER|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
58425419|NCT03890367|BIOLOGICAL|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58425420|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
58425421|NCT05840588|DRUG|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
58425422|NCT05840588|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
58425423|NCT06303895|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
58425424|NCT06303895|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
58458337|NCT05710055|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
58425425|NCT06303895|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
58425426|NCT02092766|DRUG|artesunate|
58425427|NCT02092766|DRUG|quinine|
58425428|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
58425429|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
58425430|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
58425431|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
58425432|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
58425433|NCT03918707|DIAGNOSTIC_TEST|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
58425434|NCT03335254|DRUG|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
58425435|NCT03339973|BIOLOGICAL|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
58425436|NCT03339973|DRUG|Placebo|Solution for injection in pre-filled syringe
58425437|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
58425438|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
58425439|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
58425440|NCT04329494|DRUG|Cisplatin|Given via PIPAC
58425441|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
58425442|NCT04329494|DRUG|Fluorouracil|Given IV
58425443|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
58425444|NCT04329494|DRUG|Irinotecan|Given IV
58097768|NCT05103488|OTHER|Standard of care|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
58307155|NCT03468088|BEHAVIORAL|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
58307156|NCT02493959|BIOLOGICAL|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
58425445|NCT04329494|DRUG|Leucovorin|Given IV
58425446|NCT04329494|DRUG|Mitomycin|Given via PIPAC
58425447|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
58425448|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
58425449|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
58425450|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
58425451|NCT04617015|DRUG|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
58425452|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
58425453|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
58425454|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
58425455|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
58425456|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
58425457|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
58425458|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
58097769|NCT02035683|PROCEDURE|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
58425459|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
58425460|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
58425461|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
57951990|NCT04338750|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers|Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.
57951991|NCT04338750|BEHAVIORAL|minimally-Enhanced Usual Care|Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
57951992|NCT00663988|PROCEDURE|human transplantation|Allograft composite tissue transplantation. procedure. medication
57951993|NCT00501787|DRUG|Metformin|
58425462|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
58097770|NCT05362409|DRUG|5 Aminolevulinic Acid|5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
58097771|NCT05362409|DEVICE|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
58425463|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
58425464|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
58425465|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
58425466|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
58097772|NCT06016413|DRUG|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
58307157|NCT02493959|BIOLOGICAL|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
58425467|NCT05412628|DIAGNOSTIC_TEST|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
58425468|NCT06186115|COMBINATION_PRODUCT|Gold|Intra articular
58425469|NCT03821194|OTHER|Gua sha|Scrape the skin around the knee joint
58425470|NCT03821194|OTHER|hot pack|hot pack
57736093|NCT06237972|PROCEDURE|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
57736094|NCT06237972|DEVICE|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
57736095|NCT05585723|BEHAVIORAL|Questionnaires completion|Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
57951994|NCT00750958|PROCEDURE|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
57951995|NCT01083303|BEHAVIORAL|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
57951996|NCT01620931|DRUG|RO5469754|Single ascending doses, iv or sc
57951997|NCT01620931|DRUG|Placebo|Single doses, iv or sc
57951998|NCT01326546|BIOLOGICAL|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
57951999|NCT01326546|DRUG|entecavir|0.5mg,per day,oral intake.
57952000|NCT01326546|OTHER|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
57952001|NCT00773812|DRUG|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
57952002|NCT00773812|DRUG|placebo|One pill is taken once daily.
58425471|NCT05518708|DRUG|BI 3032950|BI 3032950
57952003|NCT05952245|BEHAVIORAL|iCBTI-based EMI|Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).
57952004|NCT05952245|BEHAVIORAL|Education-based EMI|Stroke and brief sleep hygiene education with chat-based support on the topics.
58097773|NCT06016413|DRUG|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
58097774|NCT06016413|DRUG|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
58307158|NCT02493959|BIOLOGICAL|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
58307159|NCT02493959|BIOLOGICAL|placebo|Infusion of saline for 2 hrs.
58425472|NCT05518708|DRUG|Placebo|Placebo
58425473|NCT03824093|BEHAVIORAL|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
58425474|NCT03824093|BEHAVIORAL|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
57952005|NCT06087744|BEHAVIORAL|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
57952006|NCT06087744|BEHAVIORAL|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
57952007|NCT03121404|PROCEDURE|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
58425475|NCT03416075|DEVICE|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
58458338|NCT05710055|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
58458339|NCT05710055|DIETARY_SUPPLEMENT|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
58097775|NCT06701019|OTHER|Semi-structured interview/focus group discussion|"All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option."
57736096|NCT02910648|BEHAVIORAL|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
57952008|NCT01796327|DRUG|dacomitinib oral|Dacomitinib 45 mg oral tablet
58425476|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
58425477|NCT00687102|DRUG|tamoxifen|oral tamoxifen plus placebo daily for 5 years
57952009|NCT01796327|DRUG|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
57952010|NCT05884931|DEVICE|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
57952011|NCT05884931|PROCEDURE|Conventional Treatment|Standard hemostatic procedure
57952012|NCT02185404|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
57952013|NCT05229302|BEHAVIORAL|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
58097776|NCT04514809|OTHER|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
58097777|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
58097778|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
58097779|NCT02832739|DEVICE|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
58097780|NCT06338800|BEHAVIORAL|One session exposure with Virtual Reality|Participants will receive one session exposure with virtual reality from their therapists.
58097781|NCT06185556|PROCEDURE|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
57736097|NCT05290350|OTHER|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
58425478|NCT00687102|DRUG|raloxifene|oral raloxifene plus placebo daily for 5 years
57736098|NCT02191982|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
58097782|NCT06185556|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
58097783|NCT06081283|DRUG|Phenobarbital Sodium Injection|"\*This drug can only be selected as part of the intervention for the subgroup of patients with a Glasgow Coma Score of 8 or less.~Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day."
57736099|NCT01972841|DRUG|Solifenacin succinate|Oral tablet
57736100|NCT01972841|DRUG|Mirabegron|Oral tablet
57736101|NCT01972841|DRUG|Placebo to match solifenacin succinate|Oral tablet
58425479|NCT05658380|DRUG|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
58425480|NCT05658380|DRUG|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
58458340|NCT05710055|DIETARY_SUPPLEMENT|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
58458341|NCT00419393|DRUG|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
58458342|NCT01338441|DRUG|Erythromycin|4mg/Kg, IV during 20 min once
57736102|NCT01972841|DRUG|Placebo to match mirabegron|Oral tablet
57736103|NCT06242626|OTHER|observation|analysis of clinical, laboratory and haemodynamics parameters
58097784|NCT06081283|DRUG|Levetiracetam|Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
58307160|NCT03346239|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
58458343|NCT01338441|DRUG|Placebo|4mg/Kg, IV during 20 min once
57736104|NCT02201927|DEVICE|galvanic vestibular stimulation|
57736105|NCT05467553|DRUG|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
57736106|NCT05467553|DRUG|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
57736107|NCT05467553|DRUG|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
57736108|NCT02806180|PROCEDURE|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
57736109|NCT02806180|PROCEDURE|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
57736110|NCT02980159|OTHER|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
58425481|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
58097785|NCT06081283|DRUG|Lacosamide Injectable Product|Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.
58097786|NCT06081283|DRUG|Valproate Sodium|Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day
58097787|NCT06081283|DRUG|Phosphenytoin|Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
58307161|NCT03346239|DRUG|Escitalopram|10-20 mg of Escitalopram
58307162|NCT03346239|BEHAVIORAL|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
58307163|NCT05388799|OTHER|Educational intervention|In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
58307164|NCT04405258|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
58307165|NCT04405258|PROCEDURE|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
58307166|NCT03337516|BIOLOGICAL|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
58307167|NCT03337516|GENETIC|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
58307168|NCT01004939|DRUG|fondaparinux|fondaparinux
58307169|NCT01288300|BEHAVIORAL|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
58307170|NCT01288300|BEHAVIORAL|Diabetes lecture|Diabetes self-management lecture
58307171|NCT03912389|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
58307172|NCT03912389|DRUG|Pemetrexed|IV infusion
58307173|NCT03912389|DRUG|Cisplatin (or carboplatin)|IV infusion
58307174|NCT03912389|OTHER|Placebo|IV infusion
58307175|NCT00228163|DRUG|teriflunomide (HMR1726)|tablet, oral administration once daily.
58307176|NCT02477930|OTHER|No interventions are done|No intervention is done. This is a registry study.
58307177|NCT04143659|BIOLOGICAL|levonorgestrel butanoate (LB) injection|"The initial formulation of the investigational product (IP) is LB Injectable Suspension at a concentration of 40 mg/2 mL (20 mg/mL). Each vial contains 2 mL at 20mg/mL for a total of 40 mg. This formulation will only be used for dosing groups A and B with the injections completed as 40 mg IM (2 mL) or 40 mg SQ (2 mL).~The second formulation of the investigational product (IP) is LB Injectable Suspension is a concentration of 140 mg/2 mL (70 mg/mL). Each vial contains 2 mL at 70 mg/mL for a total of 140 mg. This formulation will only be used for dosing groups B2, C, and D with the injections completed as 40 mg SQ (0.57 mL), 50 mg SQ (0.71 mL), and 60 mg SQ (0.86 mL)."
58307178|NCT06374303|OTHER|NE + Meal Delivery (NE+MD) intervention|NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
58307179|NCT05767983|OTHER|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
57736111|NCT05944419|DEVICE|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
58097788|NCT02296788|BEHAVIORAL|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
58307180|NCT05767983|OTHER|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
58307181|NCT05767983|OTHER|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
58307182|NCT05767983|OTHER|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
58307183|NCT05767983|OTHER|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
58307184|NCT04072861|DRUG|RBT-9|intravenous administration
58307185|NCT00000575|DRUG|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
58307186|NCT00000575|DRUG|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
58307187|NCT00000575|DRUG|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
58307188|NCT05029661|DIAGNOSTIC_TEST|Carotid ultrasound|"* Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~* Intima-media thickness~* Pulse wave velocity"
58307189|NCT03222908|BEHAVIORAL|Intervention1: Contract Agreement|Smoking Cessation Contract
58307190|NCT03222908|BEHAVIORAL|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
58425482|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
58425483|NCT05481047|DEVICE|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
58425484|NCT00671437|PROCEDURE|FDG-PET/CT|
58425485|NCT00671437|DRUG|Cetuximab|
58425486|NCT02231385|DRUG|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
58425487|NCT00141115|DRUG|levetiracetam|Levetiracetam 1500 mg BID
58425488|NCT06547515|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
58425489|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
58425490|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
57736112|NCT04139395|DRUG|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
57736113|NCT04139395|DRUG|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
58097789|NCT00538707|BEHAVIORAL|2-minute Bondet test|2-minute Bondet test
58097790|NCT05924568|OTHER|Educational session with Keep Your Move in the Tube and PrimusRS|
58425491|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
58425492|NCT03716752|PROCEDURE|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
58425493|NCT06256471|OTHER|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
57736114|NCT04139395|DEVICE|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
57736115|NCT04139395|DEVICE|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
58425494|NCT03247725|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
58425495|NCT03247725|OTHER|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
58425496|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
58425497|NCT02561221|BEHAVIORAL|Lifestyle Counseling|"Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
57736116|NCT04139395|DEVICE|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
57736117|NCT03716713|DEVICE|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
57736118|NCT04250272|PROCEDURE|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
57736119|NCT02732366|BEHAVIORAL|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
57736120|NCT02732366|OTHER|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
58097791|NCT01916759|DRUG|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
58097792|NCT04108884|DEVICE|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
58097793|NCT04108884|DEVICE|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
58425498|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
58425499|NCT04594928|DRUG|Placebo|Matching placebo capsules
58425500|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
58425501|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
58097794|NCT04916288|DEVICE|central venous cathterization|central venous catheterization through the right internal jugular vein
58097795|NCT06173986|DRUG|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
58097796|NCT06173986|DRUG|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
58097797|NCT06173986|RADIATION|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
58097798|NCT05135143|COMBINATION_PRODUCT|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
58097799|NCT05377359|DEVICE|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
58425502|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
58097800|NCT05377359|DEVICE|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
58097801|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
58097802|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
58097803|NCT01266473|OTHER|Physiotherapy|Physiotherapy for Airway Clearance
58097804|NCT05220046|DRUG|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
58097805|NCT04183218|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
58097806|NCT04183218|DEVICE|Cardiac Event Monitor|Receive cardiac monitor
58097807|NCT04183218|OTHER|Chemoradiotherapy|Undergo CRT
58097808|NCT04183218|RADIATION|Radiation Therapy|Undergo RT
58425503|NCT03907033|DRUG|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
58425504|NCT03907033|DRUG|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
58425505|NCT03409341|OTHER|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
58425506|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
58425507|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
58425508|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
58097809|NCT06147609|DEVICE|lower lingual holding arch space maintainer|lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar
58307191|NCT00532051|DEVICE|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
57736121|NCT04576169|PROCEDURE|Arthroscopic Debridement|Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
57736122|NCT04576169|PROCEDURE|Placebo surgery|Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
58307192|NCT01092013|BEHAVIORAL|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
57736123|NCT04576169|PROCEDURE|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
57952014|NCT05229302|BEHAVIORAL|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
57952015|NCT06493474|OTHER|Education|PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM
57952016|NCT06493474|OTHER|Routine Care|Non education program only routine care
57952017|NCT03449095|DRUG|Alcohol|Alcohol Target BAC .08%
57952018|NCT04055792|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
57952019|NCT01714687|DEVICE|balloon sinus dilation|
57952020|NCT01714687|OTHER|medical therapy|
57952021|NCT06004843|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
57952022|NCT06004843|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
57952023|NCT00794157|DRUG|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
57952024|NCT00794157|DRUG|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
57952025|NCT00794157|DRUG|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
57952026|NCT04180293|BEHAVIORAL|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot virtual psychoeducation program and its evaluation. Two six-week sessions will be implemented over a virtual care platform (Zoom for healthcare) based out of OSI Clinic in Atlantic Canada - the first in January/February of 2021 and the second in the spring of 2021. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place virtually and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
57952027|NCT04180293|OTHER|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
57952028|NCT01788254|DRUG|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
57952029|NCT01788254|DRUG|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
58097810|NCT06147609|DEVICE|Removable partial denture space maintainer|Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
58097811|NCT01637259|DRUG|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
58097812|NCT01637259|DRUG|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
58097813|NCT01637259|DRUG|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
58097814|NCT05288842|BIOLOGICAL|Lumbar puncture|5 mL of CSF
58097815|NCT05288842|BIOLOGICAL|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
58097816|NCT06317363|OTHER|Base Line + ACEPELLA|Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
58425509|NCT02189278|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
58097817|NCT06317363|OTHER|Base Line + Manual Chest Physiotherapy|The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
58097818|NCT06480565|DRUG|ADI-270|Anti-CD70 CAR-T
58097819|NCT06480565|DRUG|Fludarabine|Chemotherapy for Lymphodepeletion
58097820|NCT06480565|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
58425510|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
58425511|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
58425512|NCT03649204|BEHAVIORAL|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
58425513|NCT03936751|DEVICE|CPAP|This is the standard treatment for OSA.
58425514|NCT03936751|DEVICE|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
58425515|NCT00058682|DRUG|Anidulafungin|
58097821|NCT05775146|RADIATION|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
58097822|NCT01856686|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
58097823|NCT01856686|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
58097824|NCT00485368|DRUG|Coversyl (perindopril)|
58097825|NCT05104736|DRUG|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
58097826|NCT06113263|PROCEDURE|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
58097827|NCT06113263|PROCEDURE|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
58097828|NCT05822024|BEHAVIORAL|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
57952030|NCT01788254|DRUG|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
57952031|NCT01788254|DRUG|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
58097829|NCT00965263|BIOLOGICAL|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
58097830|NCT05115955|DRUG|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
58097831|NCT05115955|DRUG|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
58307193|NCT01092013|BEHAVIORAL|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
58425516|NCT00003658|BIOLOGICAL|filgrastim|
58097832|NCT05674266|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
58425517|NCT00003658|BIOLOGICAL|rituximab|
58425518|NCT00003658|DRUG|cyclophosphamide|
58425519|NCT00003658|DRUG|pentostatin|
58425520|NCT06034353|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
58425521|NCT00135109|DRUG|SPM 927|
58425522|NCT00899158|OTHER|immunologic technique|
58425523|NCT00899158|OTHER|laboratory biomarker analysis|
58425524|NCT00899158|PROCEDURE|biopsy|
58425525|NCT01560455|DEVICE|single stent|single stent
58425526|NCT01560455|DEVICE|two stent|culotte
58425527|NCT01570049|DRUG|Bendamustine|for injection
58097833|NCT05674266|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
58097834|NCT00486642|DRUG|Bicalutamide|Given PO
58097835|NCT00486642|OTHER|Laboratory Biomarker Analysis|Correlative studies
58097836|NCT00486642|DRUG|Pazopanib Hydrochloride|Given PO
58097837|NCT00486642|OTHER|Pharmacological Study|Correlative studies
58097838|NCT01581073|DRUG|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
58097839|NCT05688670|PROCEDURE|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
58097840|NCT05688670|PROCEDURE|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
58097841|NCT05688670|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
58097842|NCT05224206|DEVICE|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
58097843|NCT05224206|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
58097844|NCT06058507|DIAGNOSTIC_TEST|CT angiography|No intervention was made
58425528|NCT03497364|DRUG|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
58097845|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
58097846|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
58097847|NCT00337129|DRUG|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
58097848|NCT01173588|OTHER|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
58307194|NCT01092013|BEHAVIORAL|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
58307195|NCT01851993|DRUG|Ondansetron|
57736124|NCT04576169|PROCEDURE|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
58097849|NCT00288119|DEVICE|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
58097850|NCT00288119|PROCEDURE|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
58307196|NCT01851993|DRUG|Placebo|0.9% saline
58307197|NCT01430377|PROCEDURE|SB predilatation|Initial SB \[predilatation.
58307198|NCT01430377|PROCEDURE|No SB predilatation|Without SB predilatation
58307199|NCT00113477|DRUG|Q10|
58307200|NCT00113477|DRUG|Selen|
58307201|NCT04352673|DIAGNOSTIC_TEST|Elbow flexion and extension strength measurements using a hand-held dynamometer|Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
58307202|NCT03710512|PROCEDURE|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
58307203|NCT04294277|DRUG|Pemigatinib|At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
58307204|NCT04753866|DEVICE|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
58307205|NCT00972270|DEVICE|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
58307206|NCT00972270|DEVICE|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
58097851|NCT06408428|DEVICE|PANAXIUM MicroECoG|The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
58097852|NCT06563973|OTHER|Milk odor|One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
58097853|NCT06563973|OTHER|Pacifier|To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
58097854|NCT02507258|DEVICE|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
58097855|NCT05503264|DRUG|Satralizumab|"In Part 1, study drug will be administered after all other study related procedures have been performed at a site visit at Weeks 0, 2, 4, and Q4W thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.~In Part 2, participants will be asked to choose from one of the following options:~Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments"
58097856|NCT05503264|OTHER|Placebo|Satralizumab placebo PFS is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an NSD and extended finger flange) filled with 0.5 mL of solution, corresponding to 60 mg satralizumab, may be used in Part 2 once it becomes available at the study site.
58097857|NCT04426019|BEHAVIORAL|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
58097858|NCT04426019|BEHAVIORAL|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
58425529|NCT03497364|DRUG|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
58425530|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
57736125|NCT02372409|DEVICE|MRI-guided laser ablation|
58307207|NCT05267665|BEHAVIORAL|Brief Family Intervention (BFI)|A 2-session psychoeducational and skills-based family intervention.
58307208|NCT00153426|BEHAVIORAL|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
58307209|NCT05143424|DRUG|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
57736126|NCT02372409|DRUG|Doxorubicin|
57736127|NCT02372409|DRUG|Etoposide|
58307210|NCT02970084|OTHER|Nutraceutical product based on vitamin K2 (PLAK2)|
58425531|NCT03605316|PROCEDURE|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
58425532|NCT05670132|OTHER|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
58425533|NCT05670132|OTHER|Standard of care|No intervention during the neurocardiac rehabilitation program
58425534|NCT00510978|BIOLOGICAL|Bifidobacterium infantis 35624|1 sachet/day for one year
58425535|NCT00510978|BIOLOGICAL|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
58425536|NCT00510978|BIOLOGICAL|Placebo|1 sachet per day for 1 year
57736128|NCT02372409|DEVICE|Dynamic contrast-enhanced (DCE) MRI|
57736129|NCT02372409|DEVICE|Dynamic susceptibility contrast (DSC) MRI|
57736130|NCT03375944|OTHER|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
57736131|NCT03580876|DRUG|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
57736132|NCT03580876|DRUG|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
57736133|NCT06119100|DIAGNOSTIC_TEST|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
58097859|NCT06285643|DRUG|AAV2-GDNF Gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
58097860|NCT06285643|PROCEDURE|Control Surgery|Bilateral partial burr/twist holes without dural penetration
58097861|NCT01642693|RADIATION|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
58097862|NCT01642693|OTHER|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
58097863|NCT03512067|DEVICE|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
58097864|NCT00896701|OTHER|flow cytometry|
58097865|NCT00896701|OTHER|immunologic technique|
58425537|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
58425538|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
58425539|NCT06267066|DRUG|Vaseline Topical Product|Emollient
58425540|NCT01799434|OTHER|treadmill run|
57736134|NCT00446316|DRUG|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
57736135|NCT00446316|DRUG|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
57736136|NCT01601574|BEHAVIORAL|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
57736137|NCT01601574|OTHER|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
57736138|NCT03330665|BEHAVIORAL|Meditation|Meditate 3 times a week using headspace app
57736139|NCT00108095|DRUG|intravenous ondansetron|
57736140|NCT03160027|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
57736141|NCT00202163|DRUG|DHEA|
57736142|NCT00202163|DRUG|Testosterone|
57736143|NCT01782989|DRUG|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
57736144|NCT01782989|DRUG|Placebo|Placebo capsule daily for 24 months
58425541|NCT04198675|BEHAVIORAL|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
57736145|NCT06624969|OTHER|virtual reality|Virtual reality program to reduce pain in orthopedic fractures
57736146|NCT01019876|DRUG|Fludarabine|
57736147|NCT01019876|DRUG|Cyclophosphamide|
57736148|NCT01019876|DRUG|Busulfan|
57736149|NCT01019876|DRUG|Alemtuzumab|
57736150|NCT01019876|DRUG|Rabbit Anti-thymocyte Globulin|
57736151|NCT01019876|DRUG|Horse Anti-thymocyte Globulin|
57952032|NCT01788254|DRUG|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
58097866|NCT00896701|OTHER|laboratory biomarker analysis|
58097867|NCT05614466|OTHER|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
58097868|NCT00146133|BEHAVIORAL|diet, exercise|
58097869|NCT02163031|DEVICE|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
58097870|NCT00791154|DRUG|AMG 479|AMG 479 is administered to subjects
58097871|NCT00791154|DRUG|Etoposide|Etoposide is administered to subjects
58425542|NCT04198675|BEHAVIORAL|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
58425543|NCT04198675|BEHAVIORAL|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
58425544|NCT02636712|DEVICE|ImageReady™ MR Conditional Pacing System|
58425545|NCT02472236|DRUG|PEX168|200µg,injected subcutaneously,once a week.
58097872|NCT00791154|DRUG|Placebo|Placebo is administered with Carboplatin and Etoposide
58097873|NCT00791154|DRUG|AMG 102|AMG 102 is administered to subjects
58097874|NCT00791154|DRUG|Carboplatin|Carboplatin is administered to some subjects in combination
58097875|NCT00791154|DRUG|Cisplatin|Cisplatin is administered to some subjects in combination
58425546|NCT02472236|DRUG|Digoxin|0.5mg,oral,two times.
58097876|NCT01441401|DRUG|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
58097877|NCT06527846|DRUG|JARDIANCE®|JARDIANCE®
58097878|NCT06425146|PROCEDURE|Cytobrush sample|Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients
58097879|NCT06425146|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam
58097880|NCT02041182|BEHAVIORAL|Pre-Visit Questionnaire|
58097881|NCT01396473|BEHAVIORAL|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
58097882|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery without mesh|retrospective study
58097883|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery with mesh|
58097884|NCT01154673|DRUG|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
58097885|NCT01154673|DRUG|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
58097886|NCT01154673|DRUG|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
58097887|NCT01154673|DRUG|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
58097888|NCT02696018|DEVICE|Ultrasonography|Ultrasonographic assessment of the diaphragm function
58097889|NCT01502917|DRUG|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
57736152|NCT01176539|DEVICE|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
57736153|NCT04372771|OTHER|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
57952033|NCT03143140|OTHER|PAFA|percutaneous ablation of tumor feeding artery
57952034|NCT03143140|OTHER|tumor ablation|ablation of tumor area directly
57952035|NCT03303742|OTHER|deep chamfer|finish line marginal design of a full coverage crown preparation
57952036|NCT03303742|OTHER|feather edge|finish line marginal design of a full coverage crown preparation
57952037|NCT03926663|DRUG|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
57952038|NCT03926663|DRUG|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
57952039|NCT04351984|DEVICE|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
58097890|NCT01502917|RADIATION|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
58097891|NCT00310700|BIOLOGICAL|Meningococcal C conjugate vaccine|
58097892|NCT01293318|OTHER|No intervention|No intervention
57736154|NCT04372771|OTHER|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
57952040|NCT02952157|DRUG|Lidocaine jelly application|
57952041|NCT02952157|DRUG|Normal saline application|
57952042|NCT02967874|PROCEDURE|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
57952043|NCT02967874|DRUG|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
57952044|NCT01930136|BEHAVIORAL|Calorie restriction (25%)|
57952045|NCT01930136|BEHAVIORAL|Ad libitum health diet|
58097893|NCT03801278|DRUG|FPA144|Bemarituzumab administration every two weeks
58097894|NCT04929951|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
58097895|NCT04929951|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
58307211|NCT02064036|RADIATION|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
58458344|NCT05118646|DEVICE|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
58425547|NCT06416254|OTHER|Fibre-enriched diet|The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.
58097896|NCT02218931|BEHAVIORAL|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
58097897|NCT02218931|OTHER|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
58097898|NCT00116207|DRUG|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
58425548|NCT06416254|OTHER|Control diet|The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
58425549|NCT04113551|DRUG|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
58425550|NCT04113551|DRUG|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
58097899|NCT06445608|DEVICE|Percutaneous Mechanical Circulatory Support|Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
58097900|NCT00293475|DRUG|Carboplatin|Given IA
58097901|NCT00293475|DRUG|Mannitol|Given IA
58097902|NCT00293475|DRUG|Methotrexate|Given IA
58097903|NCT00293475|OTHER|Quality-of-Life Assessment|Ancillary studies
58307212|NCT02064036|DRUG|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
58097904|NCT00293475|BIOLOGICAL|Rituximab|Given IV
58097905|NCT00293475|DRUG|Sodium Thiosulfate|Given IV
58097906|NCT06538545|BEHAVIORAL|Sitting position is used in Experimental Arms 1-2|sitting position Comparison of sitting position and lithotomy position in labor
58097907|NCT05862116|OTHER|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
58097908|NCT02231307|DRUG|SUBLIVAC FIX Birch|
58097909|NCT03663205|DRUG|Tislelizumab|Administered intravenously
58097910|NCT03663205|DRUG|Cisplatin|Administered intravenously
58097911|NCT03663205|DRUG|Carboplatin|Administered intravenously
58097912|NCT03663205|DRUG|Pemetrexed|Administered intravenously
58097913|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
58097914|NCT03447054|BEHAVIORAL|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
58097915|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
58307213|NCT02064036|DRUG|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
58307214|NCT01652690|BIOLOGICAL|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
58307215|NCT00427908|BIOLOGICAL|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
58307216|NCT00427908|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
58307217|NCT00427908|BIOLOGICAL|Meningitec™|One intramuscular dose.
58307218|NCT06249581|DRUG|AUX-001 40mg once-daily|AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
58307219|NCT06107452|OTHER|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
58307220|NCT06107452|OTHER|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
58307221|NCT02461212|PROCEDURE|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
58307222|NCT00000687|DRUG|Interferon alfa-2a|
58307223|NCT00000687|DRUG|Zidovudine|
58307224|NCT02073786|DEVICE|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
58307225|NCT02073786|DEVICE|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
58307226|NCT02431013|DRUG|Simvastatin|Simvastatin 40 mg on Day 1 \& Day 8.
58307227|NCT02431013|DRUG|Pravastatin|Pravastatin 20 mg on Day 1 \& Day 8.
58307228|NCT02431013|DRUG|Cilostazol|Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
58097916|NCT03447054|BEHAVIORAL|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
58097917|NCT06537024|PROCEDURE|RTSA|
58425551|NCT04113551|DRUG|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
58097918|NCT01578252|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
58097919|NCT01578252|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
58425552|NCT04113551|DRUG|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
58425553|NCT00710463|DEVICE|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
58097920|NCT05117931|DRUG|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (\<80kg) or 1400mg (\>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh \<80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
58097921|NCT06004401|DRUG|Vonopazan +Amoxicillin|Vonopazan 20mg 2//day+Amoxicillin
58097922|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
58097923|NCT06004401|DRUG|Vonopazan +Minocycline|Vonopazan 20mg 2/day+Minocycline 100mg 2/day
58097924|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
58097925|NCT02282007|BEHAVIORAL|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
58097926|NCT04057573|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
58097927|NCT04057573|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
58097928|NCT00003276|DRUG|irinotecan hydrochloride|
58097929|NCT00684216|DRUG|capecitabine|200 mg, BID, PO, QD until progression of disease
58097930|NCT00684216|DRUG|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
58097931|NCT05764837|OTHER|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
58097932|NCT05974293|DRUG|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
58097933|NCT05974293|DRUG|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
58425554|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
57736155|NCT04367675|DRUG|INO-5401|INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
57736156|NCT04367675|DRUG|INO-9012|INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
58097934|NCT01419873|DRUG|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
58097935|NCT03994419|PROCEDURE|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
58097936|NCT02554825|BEHAVIORAL|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
58097937|NCT02554825|BEHAVIORAL|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
58097938|NCT04871724|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 1 and 14
58097939|NCT04871724|DRUG|Fluconazole|Subjects will receive fluconazole once daily on Days 5 to 18
58425555|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
58425556|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
58425557|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
58097940|NCT03966196|OTHER|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
58097941|NCT00265863|DRUG|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
58097942|NCT04221217|DRUG|Icosapent|Icosapent (MND-2119) capsules.
58097943|NCT02742818|DEVICE|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
58097944|NCT02742818|DEVICE|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
58097945|NCT03870737|DEVICE|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
58097946|NCT06542705|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
58097947|NCT06542705|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace. ACLR technique will be standardized to standard anteromedial (AM) portal femoral drilling to ensure consistency between surgeons.
58097948|NCT02866123|OTHER|ultrasonography|
58097949|NCT02866123|RADIATION|pulmonary radiography|
58097950|NCT05855525|BEHAVIORAL|Experience sampling|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
57736157|NCT04367675|DEVICE|Cellectra 2000|The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
58097951|NCT02256059|PROCEDURE|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
58097952|NCT01887860|OTHER|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
58097953|NCT02367729|DEVICE|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
58097954|NCT02367729|DEVICE|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
58097955|NCT05926544|BEHAVIORAL|Standard implementation webinar and online training|"The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients."
57736158|NCT00476476|DRUG|Erlotinib|Orally every day for about 4-6 weeks
58097956|NCT05926544|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
58097957|NCT03165331|OTHER|Ung Face IT|Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
58097958|NCT02476500|PROCEDURE|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
58097959|NCT06433986|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
58097960|NCT06433986|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
58097961|NCT00348218|DEVICE|NeuroVision|
57736159|NCT00477191|DRUG|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
57736160|NCT06595108|RADIATION|Stereotactic body radiotherapy|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
58097962|NCT03649256|DIAGNOSTIC_TEST|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
58097963|NCT06583148|OTHER|Best Practice|Receive usual care
58097964|NCT06583148|BEHAVIORAL|Smoking Cessation Intervention|Receive the smoke-free home program
58097965|NCT06583148|OTHER|Survey Administration|Ancillary studies
58097966|NCT05486663|OTHER|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
58097967|NCT05070689|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
58097968|NCT05110144|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
58097969|NCT05110144|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
58097970|NCT05110144|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
57736161|NCT01343407|DRUG|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
58097971|NCT05110144|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
58097972|NCT05110144|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
58097973|NCT05110144|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
58425558|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
58425559|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
58097974|NCT05140863|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
58097975|NCT05140863|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
58097976|NCT05140863|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
58097977|NCT05632809|DRUG|NKTR-255|Given by IV (vein)
58097978|NCT05632809|DRUG|Durvalumab|Given by IV (vein)
58425560|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
57736162|NCT01343407|DRUG|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
57736163|NCT01343407|DRUG|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
57736164|NCT01343407|DRUG|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
57736165|NCT06273917|OTHER|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
58097979|NCT02795949|DRUG|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
58097980|NCT02795949|DRUG|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
58097981|NCT03220152|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
58097982|NCT01333475|DRUG|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
58097983|NCT06426992|PROCEDURE|Microwave ablation|Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.
58097984|NCT03120520|DRUG|Plecanatide|
58097985|NCT03120520|DRUG|Matching placebo|
58097986|NCT00922337|DEVICE|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
58097987|NCT03839784|COMBINATION_PRODUCT|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
58097988|NCT04696627|OTHER|Questionnaire|Participants from all 3 groups will be interviewed
58097989|NCT06577090|BIOLOGICAL|Nimacimab injection|Nimacimab injection 200 mg
58097990|NCT06577090|BIOLOGICAL|Nimacimab placebo injection|matching nimacimab placebo injection
58097991|NCT06577090|COMBINATION_PRODUCT|semaglutide injection|semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
58097992|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
58097993|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
58097994|NCT01468168|DRUG|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
58097995|NCT01998035|DRUG|RomiDEPsin 10 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"
58425561|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
58425562|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
58425563|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
58425564|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
58425565|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
58425566|NCT03083145|DIETARY_SUPPLEMENT|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
58425567|NCT03083145|DIETARY_SUPPLEMENT|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
58425568|NCT03083145|BEHAVIORAL|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
58425569|NCT04309058|DRUG|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
58425570|NCT01912690|OTHER|aerobic training|
58425571|NCT01912690|OTHER|aerobic and strength training|
58425572|NCT04345172|DEVICE|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
58097996|NCT01998035|DRUG|Oral 5-Azacitidine 100 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"
58097997|NCT01998035|DRUG|Romidepsin 14 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"
58097998|NCT01998035|DRUG|Oral 5-Azacitidine 200 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"
58097999|NCT01998035|DRUG|Oral 5-Azacitidine 300 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"
58307229|NCT05637502|OTHER|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
58307230|NCT00038766|DRUG|semapimod|semapipmod 60 mg IV x 5 days
58307231|NCT00038766|DRUG|semapimod|IV 30 mg x 5 days
58307232|NCT00038766|DRUG|placebo|placebo IV
58425573|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a neurological examination is taken~* a saliva sample is taken"
58425574|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a saliva sample is taken"
58425575|NCT04046250|DRUG|TK-112690|TK112690 treatment pre-methotrexate treatment
58098000|NCT06647420|BEHAVIORAL|Sedative Music|The participants will come twice in person and listen to 9 minutes of sedative music.
58098001|NCT06647420|BEHAVIORAL|Stimulative Music|The participants will come twice in person and listen to 9 minutes of stimulative music.
58098002|NCT04200781|DRUG|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
58098003|NCT04200781|DRUG|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
58098004|NCT06271837|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
58098005|NCT06271837|DRUG|Bevacizumab|Bevacizumab by intravenous infusion
58098006|NCT06157502|DRUG|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
58425576|NCT04046250|DRUG|Placebo TK-112690|Placebo
58425577|NCT04147546|DIAGNOSTIC_TEST|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
58425578|NCT04147546|DRUG|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
58425579|NCT04147546|OTHER|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
58425580|NCT01326832|DEVICE|Primoris|Total hip arthroplasty with the new Primoris femoral component
58425581|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
58425582|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
58098007|NCT06157502|OTHER|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
58098008|NCT05764434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
58098009|NCT03986645|DEVICE|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
58425583|NCT01549873|DRUG|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
58098010|NCT06435598|OTHER|video-based health education|The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
58098011|NCT06025487|BIOLOGICAL|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
58425584|NCT01549873|DRUG|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
58425585|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
58425586|NCT04460846|DIETARY_SUPPLEMENT|Alkaline water|1.5 liters per day
58425587|NCT04460846|DIETARY_SUPPLEMENT|Reverse osmosis water|1.5 liters per day
58425588|NCT02774655|DEVICE|Pai APP|prescribed 100 PAI weekly
58425589|NCT02774655|DEVICE|FitBit APP|prescribed 10000 steps daily
58425590|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
58425591|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
58425592|NCT05288140|OTHER|use of diary|a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
58425593|NCT05611502|DEVICE|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
58098012|NCT05452616|OTHER|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
58098013|NCT05452616|OTHER|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
58425594|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
58425595|NCT05176756|BEHAVIORAL|Gamification and Social Support|Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
58425596|NCT05176756|BEHAVIORAL|Attention control|Participants will receive a daily text message with their step count from the day prior.
58425597|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
58098014|NCT01999322|DRUG|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
58098015|NCT01999322|DRUG|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
58098016|NCT03295968|OTHER|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
58098017|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
58098018|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
58098019|NCT01506570|BIOLOGICAL|Placebo|One SC injection at Day 0 and Day 180 of placebo
58098020|NCT01067989|DRUG|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
58425598|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
58425599|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
58425600|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
58425601|NCT02886871|BEHAVIORAL|Step Goal Delivery by Smartphone|
58425602|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
58425603|NCT03909451|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
58425604|NCT03909451|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
58425605|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
58425606|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
58098021|NCT03996980|DEVICE|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
58098022|NCT06138756|DEVICE|Nerivio|Neriio is a remote electrical neuromodulation (REN) device for the treatment of migraine
58098023|NCT06551454|DEVICE|Smart Textile Solution Biofeedback Method|The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.
58098024|NCT05385796|OTHER|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
58425607|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
58425608|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
58425609|NCT02593656|BEHAVIORAL|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
58425610|NCT02593656|BEHAVIORAL|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
58425611|NCT01308229|DEVICE|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
58425612|NCT05251038|DRUG|Sotorasib|Intervention instruction outlined in protocol
58425613|NCT05251038|DRUG|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
58425614|NCT05251038|DRUG|5 Fluorouracil (5FU)|Per standard of care
58425615|NCT05251038|DRUG|Leucovorin (LV)|Per standard of care
58425616|NCT05251038|DRUG|Gemcitabine (GEM)|Per standard of care
58425617|NCT05251038|DRUG|Nab paclitaxel|Per standard of care
58425618|NCT05230485|OTHER|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
58425619|NCT05943197|DIAGNOSTIC_TEST|dental prosthetics, biofilm response and oral microbiota|microbiota, biofilm, oral mucosa
58098025|NCT05385796|OTHER|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
58098026|NCT05649852|OTHER|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
58098027|NCT05649852|OTHER|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
58098028|NCT03928613|BEHAVIORAL|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
58098029|NCT06289335|DRUG|saline solution|20 mL of saline
58098030|NCT05019716|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
58425620|NCT00076349|DRUG|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
58425621|NCT01278407|DRUG|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
58425622|NCT01278407|DRUG|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
58425623|NCT01278407|DRUG|Donepezil matched placebo|
58425624|NCT04107441|DRUG|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
58425625|NCT04107441|DRUG|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
58425626|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
58425627|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
58098031|NCT05019716|PROCEDURE|Biopsy|Undergo biopsy
58098032|NCT05019716|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
58425628|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
58425629|NCT00821912|DRUG|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
58425630|NCT00821912|DRUG|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
58425631|NCT05017818|OTHER|Observational retrospective data|Non-intervention
58098033|NCT05019716|PROCEDURE|Chest Radiography|Undergo chest x-ray
58098034|NCT05019716|DRUG|Cisplatin|Given IV
58098035|NCT05019716|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
58098036|NCT05019716|DRUG|Etoposide|Given IV
58098037|NCT05019716|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
58098038|NCT05019716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58098039|NCT05019716|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
58098040|NCT05147792|DEVICE|CLAAS|CLAAS
58425632|NCT00052156|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
58425633|NCT03392870|OTHER|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
57736166|NCT04090424|DEVICE|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
58098041|NCT05147792|DEVICE|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
58098042|NCT01791127|DEVICE|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
58098043|NCT03658356|OTHER|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
58098044|NCT03490331|OTHER|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
58098045|NCT03801213|DEVICE|urinary catheterization|Urinary catheterization with pain controlled
58098046|NCT03801213|PROCEDURE|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
58098047|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
58098048|NCT04537936|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
58098049|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
58098050|NCT04537936|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
58098051|NCT00602979|DEVICE|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
58098052|NCT00602979|DEVICE|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
58098053|NCT00602979|DEVICE|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
58098054|NCT00602979|DEVICE|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
58098055|NCT00602979|DEVICE|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
58098056|NCT00937053|OTHER|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
58098057|NCT00937053|OTHER|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
58098058|NCT00937053|OTHER|Platelet transfusion|Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
57736167|NCT04090424|PROCEDURE|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
58307233|NCT06069804|DRUG|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
58425634|NCT03392870|OTHER|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
58425635|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
58425636|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
58098059|NCT00872365|BEHAVIORAL|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
58098060|NCT00872365|DIETARY_SUPPLEMENT|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
58098061|NCT00872365|OTHER|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
58098062|NCT04061057|DRUG|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
58425637|NCT05808010|BIOLOGICAL|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
58425638|NCT05808010|DRUG|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
58425639|NCT02965885|DRUG|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
58425640|NCT00311909|DEVICE|Thalamic deep brain stimulation|
58425641|NCT06097546|DIAGNOSTIC_TEST|laboratory test (RAI14 and MACC-1 )|Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
58425642|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
58425643|NCT04372459|BEHAVIORAL|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
58098063|NCT04061057|DRUG|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
58098064|NCT00354731|DRUG|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
58098065|NCT00354731|DRUG|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
58098066|NCT06540326|DRUG|irinotecan liposome (II)|irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
58425644|NCT04372459|BEHAVIORAL|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
58425645|NCT00685737|DRUG|1-MNA|Capsule
58425646|NCT00685737|DRUG|Placebo|Capsule
57736168|NCT00002026|DRUG|Acyclovir|
57736169|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
57736170|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
58098067|NCT06540326|DRUG|fluorouracil|fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
58098068|NCT06540326|DRUG|cetuximab|cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
58098069|NCT06540326|DRUG|bevacizumab|bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
58098070|NCT01779349|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
57736171|NCT04957966|BEHAVIORAL|self-selected relaxing music|20 minutes music listening
58098071|NCT00701558|DRUG|Erlotinib|150 mg po daily
58098072|NCT00701558|DRUG|Gemcitabine|1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
58307234|NCT06069804|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
58307235|NCT05552196|DRUG|Ponesimod|Ponesimod tablet will be administered orally.
58307236|NCT05552196|DRUG|Carbamazepine|Carbamazepine tablet will be administered orally.
57736172|NCT03370887|DRUG|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
57736173|NCT03370887|DRUG|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
58098073|NCT00195585|DRUG|Isovorin|
58098074|NCT00195585|DRUG|UFT|
58098075|NCT06217835|OTHER|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
58098076|NCT06217835|OTHER|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
58098077|NCT05426473|OTHER|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
58307237|NCT03456245|DEVICE|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
58425647|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
58425648|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
58425649|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
58425650|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
58425651|NCT03508232|DRUG|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
58098078|NCT06542419|DEVICE|Brain Cooling|Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
58098079|NCT05406622|DEVICE|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
58098080|NCT05406622|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
58098081|NCT00390949|BEHAVIORAL|Peer education among commercial sex workers and clients|
58098082|NCT00390949|BEHAVIORAL|Condom distribution and promotion|
58098083|NCT00390949|PROCEDURE|Syndromic treatment of sexually transmitted infections|
58098084|NCT00390949|PROCEDURE|Systemic counselling for STI patients|
58098085|NCT05432245|DEVICE|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
58098086|NCT02056574|DRUG|NA-1|
58098087|NCT02056574|DRUG|Placebo|
58098088|NCT06702332|DRUG|MSD-001|MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications
58098089|NCT06702332|DRUG|Placebo Comparator|Matching Placebo
58098090|NCT00435825|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
58098091|NCT01832545|OTHER|Aquatic Exercise|
58098092|NCT01832545|BEHAVIORAL|Educational Program|Control Group
58098093|NCT05860712|OTHER|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
58425652|NCT03508232|DRUG|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
58098094|NCT06246513|BIOLOGICAL|SRP-9003|Solution for single IV infusion
58098095|NCT06246513|DRUG|Glucocorticoid|Oral tablet (prophylactic)
58098096|NCT02308865|OTHER|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
58098097|NCT06396221|DRUG|Estetrol 15 mg/Drospirenone 3 mg (24/4)|Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
58098098|NCT06396221|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
58098099|NCT02388607|OTHER|measurements|performance measurements
58098100|NCT05504369|OTHER|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
58098101|NCT05504369|OTHER|Placebo tape|Tape without nano particles applied to the skin
58098102|NCT00190684|DRUG|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
58098103|NCT02534207|DRUG|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
58098104|NCT00430638|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
58098105|NCT00430638|DRUG|Placebo|Oral tablets administered for once daily for 12 weeks
58098106|NCT00478634|DRUG|RAD001, Cetuximab, Irinotecan|
58098107|NCT03411122|DRUG|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
58098108|NCT03411122|DRUG|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
58098109|NCT03282617|BIOLOGICAL|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
58098110|NCT00812305|DRUG|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
58098111|NCT00812305|DRUG|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
58425653|NCT01149902|BIOLOGICAL|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
58098112|NCT04991311|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
58098113|NCT04739852|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
58098114|NCT00854607|OTHER|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
58098115|NCT02582359|DRUG|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
58098116|NCT02582359|DRUG|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
58098117|NCT02582359|DRUG|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
58098118|NCT06044740|DRUG|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
58098119|NCT06044740|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
58098120|NCT04437082|DEVICE|optical coherence tomography|imaging structural and vascular features of the eye
58307238|NCT04809116|DRUG|Pimavanserin|open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
58425654|NCT02784769|OTHER|measurement of skin autofluorescence|
58098121|NCT06151158|BEHAVIORAL|Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)|Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge
58098122|NCT06151158|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)|Five session crisis focused version of IPT for adolescents.
58098123|NCT05652101|OTHER|collection of medical data|"The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available"
58098124|NCT05652101|OTHER|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
58307239|NCT01774981|DRUG|Placebo|Administered IV
58307240|NCT01774981|DRUG|LY3016859|Administered IV
58307241|NCT03236597|OTHER|Treadmill desk|A standing height desk with a treadmill attached.
58307242|NCT00141817|DRUG|pantoprazole for approximately 9 weeks.|
58307243|NCT06001879|OTHER|Simulation in basic life support training (SBLST)|The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation, and clinical simulation training.
58307244|NCT06001879|OTHER|standard treatment by using an AHA-BLS 2020 brochure|The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test
58307245|NCT02834975|DRUG|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
58307246|NCT02834975|DRUG|Paclitaxel|"* NACT: Paclitaxel on Day 1 of each cycle;~* ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
58307247|NCT02834975|DRUG|Carboplatin|Carboplatin IV on Day 1 of each cycle.
58307248|NCT00496418|DEVICE|Mesh in permanent colostomy|
58307249|NCT04265677|OTHER|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
58307250|NCT04265677|OTHER|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
58307251|NCT01518101|DRUG|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
58307252|NCT01518101|DRUG|Liraglutide|1.2 mg once daily by commercially available injection pens
58307253|NCT01518101|DRUG|Metformin|1000 mg tablets twice daily
58307254|NCT00447083|DEVICE|UVB|UVB exposure by a tanning bed
58307255|NCT00447083|PROCEDURE|Non-UVB|Non-UVB exposure by a tanning bed
58425655|NCT02784769|OTHER|skin biopsy collection|
58458345|NCT05118646|DEVICE|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
58458346|NCT01506271|DRUG|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
58307256|NCT03710330|DRUG|normal saline|110 ml normal saline IV just before skin incision
58307257|NCT03710330|DRUG|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
58307258|NCT03710330|DRUG|0.5 gm tranexamic acid|0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
58307259|NCT00262119|DEVICE|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
58307260|NCT01924533|DRUG|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
57952046|NCT05754502|DRUG|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
57952047|NCT01601028|DRUG|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
57952048|NCT01601028|DRUG|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
58307261|NCT01924533|DRUG|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
58307262|NCT01924533|DRUG|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
58307263|NCT03241693|OTHER|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
58307264|NCT03241693|OTHER|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
58307265|NCT04999241|COMBINATION_PRODUCT|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
58307266|NCT04999241|COMBINATION_PRODUCT|regular food|Administration of regular food in the induction phase and the later time.
58307267|NCT05316558|BEHAVIORAL|Body Confident Coaching|The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
58307268|NCT01436734|OTHER|Fasting glycemia|no intervention
58307269|NCT01436734|OTHER|Hypoglycemia|Insulin induced hypoglycemia
58307270|NCT06247150|BIOLOGICAL|Additional blood sample|The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)
58307271|NCT06247150|BIOLOGICAL|cGVHD target tissue biopsy|For chronic GVH patients only, cGVHD target tissue biopsy
58458347|NCT01506271|DRUG|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
58458348|NCT01506271|DRUG|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
57952049|NCT03842423|PROCEDURE|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
57952050|NCT00000580|DRUG|immunoglobulins, intravenous|
57952051|NCT05252364|DRUG|HP518 - Dose Escalation|"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."
57952052|NCT05252364|DRUG|HP518 - Dose expansion|"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."
58425656|NCT02797496|OTHER|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
58425657|NCT02797496|OTHER|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
58425658|NCT05318196|BIOLOGICAL|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
58425659|NCT06584084|DEVICE|WPM-SEMG prototype|Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
58425660|NCT04724395|OTHER|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
58425661|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
58425662|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
57952053|NCT03269435|PROCEDURE|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
57952054|NCT03269435|DRUG|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
57952055|NCT02228590|DRUG|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
57952056|NCT01963312|PROCEDURE|Transarterial Supraselective Embolization of the prostate|
58307272|NCT03844841|DRUG|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
58425663|NCT02023047|DRUG|Nifedipine 12 mg coated suppositories|
58458349|NCT01506271|DRUG|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
58458350|NCT02084485|DRUG|PH-797804|30 MG Single dose
58458351|NCT02084485|DRUG|Placebo|matching placebo
58458352|NCT00214045|DEVICE|Flexible Cystoscopy|
58458353|NCT00214045|DEVICE|Rigid Cystoscopy|
57952057|NCT01963312|PROCEDURE|Transurethral Resection of the prostate|
57952058|NCT02394873|BIOLOGICAL|ALLO-ASC-DFU|Dressing for second-degree burn wound.
57952059|NCT02982343|BEHAVIORAL|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
57952060|NCT02982343|BEHAVIORAL|Falls management only|Participants will undergo a session of falls management and education.
57952061|NCT00610987|DRUG|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
57952062|NCT00610987|DRUG|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
57952063|NCT01951820|DRUG|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
57952064|NCT01951820|DRUG|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
58307273|NCT03844841|DRUG|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
58098125|NCT05073302|PROCEDURE|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
58098126|NCT03760965|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
58098127|NCT03760965|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
58098128|NCT00540007|DRUG|Lenalidomide|
58098129|NCT06569693|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
58098130|NCT06569693|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
58098131|NCT00628745|OTHER|None. Observational Study.|
58098132|NCT01179191|DRUG|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
58098133|NCT06015217|DRUG|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
58098134|NCT04631185|DRUG|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
58098135|NCT04631185|DRUG|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
58098136|NCT05736952|DRUG|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
58098137|NCT04815356|BIOLOGICAL|CD22CART cell infusion|The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 post-CD22CART infusion.
58098138|NCT04537130|BIOLOGICAL|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
58098139|NCT05844644|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
58098140|NCT04196270|DRUG|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
57952065|NCT01951820|DRUG|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
58307274|NCT05697913|OTHER|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
58307275|NCT03337126|DRUG|Metronidazole Tablet|Comparator Drug
57952066|NCT04661709|DRUG|Wen Xin granule|one dose daily, two times per day.
57952067|NCT04661709|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
57952068|NCT04661709|DRUG|Atorvastatin Calcium|20 mg tablet, one tablet each night.
57952069|NCT04661709|DRUG|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
57952070|NCT04661709|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
57952071|NCT04661709|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
58307276|NCT04991714|DRUG|Lactisole|sweet taste inhibitor (decreases sweetness)
58307277|NCT04991714|DRUG|Rebaudioside M|Sweetener (increases sweetness)
58307278|NCT04991714|OTHER|Sucrose|10% Sucrose corresponding to a regular soft drink
58425664|NCT05901103|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
58425665|NCT04524624|DEVICE|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
58425666|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
58425667|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
58425668|NCT02264548|RADIATION|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
58425669|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
58425670|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
58425671|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
57952072|NCT04661709|DRUG|WXG placebo|one dose daily, two times per day.
57952073|NCT04661709|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
57952074|NCT04661709|DRUG|glyceryl trinitrate|be taken when angina pectoris attacks.
57952075|NCT05970900|DRUG|Imatinib Mesylate|"1. For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~2. For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd."
57952076|NCT05970900|PROCEDURE|Local resection|"According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach"
57952077|NCT00913900|BIOLOGICAL|autologous CD133+ cells|Intramuscular injection
57952078|NCT00004231|BIOLOGICAL|aldesleukin|
57952079|NCT00004231|BIOLOGICAL|filgrastim|
57952080|NCT00004231|BIOLOGICAL|recombinant interferon alfa|
57952081|NCT00004231|DRUG|busulfan|
57952082|NCT00004231|DRUG|cyclophosphamide|
57952083|NCT00004231|DRUG|cytarabine|
57952084|NCT00004231|DRUG|doxorubicin hydrochloride|
57952085|NCT00004231|DRUG|leucovorin calcium|
57952086|NCT00004231|DRUG|methotrexate|
57952087|NCT00004231|DRUG|prednisone|
57952088|NCT00004231|DRUG|teniposide|
57952089|NCT00004231|DRUG|vincristine sulfate|
57952090|NCT00004231|PROCEDURE|allogeneic bone marrow transplantation|
57952091|NCT00004231|PROCEDURE|autologous bone marrow transplantation|
57952092|NCT00004231|PROCEDURE|peripheral blood stem cell transplantation|
57952093|NCT04315181|DRUG|Opioid Agonist|Abuse liability evaluation.
57952094|NCT04315181|DRUG|Sedatives|Abuse liability evaluation.
57952095|NCT00529997|DEVICE|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
57952096|NCT00886600|DRUG|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
57952097|NCT00886600|DRUG|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
57952098|NCT00886600|DRUG|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
57952099|NCT04882592|DEVICE|SCiP|Noninvasive spinal cord neuromodulator
57952100|NCT02487420|BEHAVIORAL|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
57952101|NCT01528514|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
57952102|NCT01528514|OTHER|Placebo|Placebo in capsule form, 4 capsules 4 times/day
57952103|NCT03857490|BEHAVIORAL|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
57952104|NCT02713958|OTHER|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
57952105|NCT02713958|OTHER|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
57952106|NCT04526561|PROCEDURE|Latissimus dorsi flap|Breast reconstruction
57952107|NCT04526561|PROCEDURE|Thoracodorsal artery perforator flap to breast|Breast reconstruction
57952108|NCT04526561|PROCEDURE|Deep inferior epigastric perforator flap|Breast reconstruction
58307279|NCT01450488|DRUG|masitinib|masitinib 3 mg/kg/day
58307280|NCT01450488|DRUG|masitinib|masitinib 6 mg/kg/day
58307281|NCT01060462|DRUG|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
58307282|NCT02266485|DRUG|BIBB 515 BS|
58307283|NCT02266485|DRUG|Pravastatin|
58307284|NCT02266485|DRUG|Placebo|
58098141|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
58098142|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
58098143|NCT06421623|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
58098144|NCT06141954|DEVICE|Ultrasound waves therapy|Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
58098145|NCT06141954|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
58098146|NCT00425516|DRUG|Taxotere|
58098147|NCT00425516|DRUG|5-Fluorouracil|
58098148|NCT00425516|DRUG|Epirubicin|
58098149|NCT00425516|DRUG|Cyclophosphamide|
58098150|NCT05369299|DEVICE|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
58098151|NCT05369299|DEVICE|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
58098152|NCT06341192|PROCEDURE|Single-bundle ACL combined anterolateral ligament reconstruction|"Single-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~The single ACL bundle is typically positioned to replicate the anatomic footprint of the native ACL.~For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a gracilis tendon graft.~This combines an intra-articular ACL reconstruction with an extra-articular lateral tenodesis to improve rotational instability."
58098153|NCT06341192|PROCEDURE|Double-bundle ACL combined anterolateral ligament reconstruction|"Double-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL\&#39;s anteromedial and posterolateral bundles.~Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~The double-bundle ACL reconstruction aims to better restore the ACL\&#39;s complex anatomic footprint and bundles\&#39; tension patterns."
58307285|NCT04010279|PROCEDURE|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
58425672|NCT03883087|DRUG|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
58425673|NCT02396394|BEHAVIORAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
58425674|NCT06581172|DIAGNOSTIC_TEST|D_dimer|DIC score including FDPs,D_dimer
58425675|NCT01862549|BEHAVIORAL|Dialectical Behavior Therapy for children|
58425676|NCT01862549|BEHAVIORAL|Treatment as Usual|
58425677|NCT03974295|BEHAVIORAL|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
58425678|NCT00877370|DRUG|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
58425679|NCT00209794|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
58425680|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
58425681|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
58425682|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
58307286|NCT05181150|OTHER|Meal test|Ingestion of an oral liquid meal (nutridrink), 200 mL.
58307287|NCT05181150|OTHER|GIP|Subcutaneous GIP injection.
58307288|NCT05181150|OTHER|GLP-2|Subcutaneous GLP-2 injection.
58307289|NCT05181150|OTHER|GIP + GLP-2|Subcutaneous GIP + GLP-2 injection.
58098154|NCT02857296|OTHER|interview and observation|
58307290|NCT05181150|OTHER|Placebo|Subcutaneous saline injection.
58307291|NCT06073288|OTHER|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
58098155|NCT06700590|BEHAVIORAL|Intensive Treatment|"Participants engage in two preparatory sessions once weekly, lasting 50 minutes each, which focus on psychoeducation and case conceptualization. The core treatment consists of five days of twice-daily sessions delivered over one or two weeks. The first session of the day consists of prolonged exposure (PE). The second session consists of eye movement desensitization and reprocessing (EMDR). Both treatments are performed in strict adherence to their respective manualized protocol. Two closing sessions focus on lessons learned, integration and a prevention plan. The treatment in total lasts 6 weeks and contains 800 minutes of treatment.~To enhance practicality, treatment rotation is allowed and encouraged. Rigorous checks on treatment adhenrence will be implemented."
58098156|NCT06700590|BEHAVIORAL|Treatment as usual|Spaced/weekly treatment consists of a treatment-as-usual condition, increasing the representativeness of the control condition. Treatment duration is 800 minutes, either 13 weeks of 60 minutes (with the last sessions being 80 minutes), or 16 weeks of 50 minutes. All evidence-based treatment modalities of the Dutch guidelines are allowed: PE, EMDR, brief eclectic psychotherapy for PTSD (BEPP), narrative exposure therapy (NET), and imaginary rescripting (ImRs). All have common elements of psychoeducation, imaginal exposure, emotional processing, cognitive restructuring and/or meaning making. Treatment adherence will be monitored throughout the intervention. Therapist rotation is not performed
58425683|NCT01443507|OTHER|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
58425684|NCT00301288|PROCEDURE|Autologous stem cell transplant|
58425685|NCT00056446|DRUG|Vatalanib|
58425686|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
58425687|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
58425688|NCT03693781|DRUG|Placebo Oral Tablet|Corresponding tablets for 30 weeks
58425689|NCT02622646|DRUG|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
58425690|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
58425691|NCT04357977|DIAGNOSTIC_TEST|RBA-2|Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
58425692|NCT05578378|DRUG|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
58425693|NCT05578378|DRUG|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
57952109|NCT00545064|DRUG|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
57952110|NCT00163332|DRUG|Ciclesonide|
57952111|NCT02249650|DRUG|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
57952112|NCT01181011|DRUG|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
57952113|NCT00270517|DRUG|EDP-420 / Duration of Treatment - 3 days|
57952114|NCT00270517|DRUG|Telithromycin / Duration of Treatment - 7 days|
57952115|NCT06496815|DRUG|Donafenib|Donafenib will be taken orally twice a day, 0.2g each time.
57952116|NCT06496815|PROCEDURE|transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy|Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).
57952117|NCT06496815|DRUG|PD-1,PD-L1|PD-1/PD-L1 will be used as previous (if have).
57952118|NCT03002415|OTHER|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
57952119|NCT03002415|OTHER|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
57952120|NCT04919980|DEVICE|Innovalve MR system|Innovalve MR system
57952121|NCT04203524|DIAGNOSTIC_TEST|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
58098157|NCT05112679|DEVICE|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
58425694|NCT02147769|DEVICE|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
58425695|NCT00126984|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
58425696|NCT00126984|BIOLOGICAL|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
58425697|NCT00126984|BIOLOGICAL|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
58425698|NCT00126984|BIOLOGICAL|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
58425699|NCT05066308|DRUG|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
58425700|NCT05066308|OTHER|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
58425701|NCT02263911|DRUG|Baricitinib|Administered orally
58425702|NCT01055678|DRUG|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
58425703|NCT01055678|PROCEDURE|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
58425704|NCT03134131|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
58425705|NCT03853564|BEHAVIORAL|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
58425706|NCT03853564|OTHER|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
58425707|NCT02048033|DEVICE|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
58425708|NCT02048033|DIAGNOSTIC_TEST|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
58425709|NCT01424566|DRUG|Nabiximols|
58425710|NCT01424566|DRUG|Placebo (GA-0034)|
58425711|NCT02575703|DRUG|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
58425712|NCT00867555|DIETARY_SUPPLEMENT|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
58425713|NCT02166827|DEVICE|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
58425714|NCT02166827|DEVICE|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
58425715|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
57952122|NCT04203524|OTHER|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
57952123|NCT05843734|PROCEDURE|Equia forte HT|Restoration of anterior class III caries lesions
58425716|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
57952124|NCT03923543|DIAGNOSTIC_TEST|Neutrophil to lymphosit ratio|
57952125|NCT00573573|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
57952126|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
58098158|NCT05112679|DEVICE|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
57736174|NCT06397469|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
58098159|NCT04659837|BEHAVIORAL|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
58098160|NCT03525327|OTHER|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
58098161|NCT05960708|DRUG|YH35324|Subcutaneous injection of YH35324
58098162|NCT05960708|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
58098163|NCT05960708|DRUG|Placebo|Subcutaneous injection of None of active ingredient
58425717|NCT02127177|DEVICE|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
58425718|NCT02967601|BEHAVIORAL|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
58425719|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
58425720|NCT05732883|DRUG|Normal saline|Placebo
58425721|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
58425722|NCT03948919|OTHER|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
58425723|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
58425724|NCT00175266|DRUG|alemtuzumab|
57952127|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
57952128|NCT03290235|DRUG|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
58425725|NCT00175266|PROCEDURE|islet transplant|
58425726|NCT00175266|DRUG|infliximab|
58425727|NCT01338584|BEHAVIORAL|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
58425728|NCT01338584|BEHAVIORAL|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
57952129|NCT02223260|DRUG|dabigatran|Experimental dose chosen based on age and weight
57952130|NCT05939310|PROCEDURE|Fluorescence guided detection of tumor positive margins.|Intraoperative fluorescence imaging detection of tumor positive margins using the targeted tracer bevacizumab-IRDye800CW.
57952131|NCT04438473|DIETARY_SUPPLEMENT|pectin-supplemented enteral nutrition feeding|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
57952132|NCT04438473|OTHER|enteral nutrition feeding|standard formula enteral nutrition feeding without pectin for 7 days
57952133|NCT04543643|DRUG|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
57952134|NCT04543643|DRUG|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
57952135|NCT06220331|DEVICE|Intra Ocular Lens|Intensity SL Intra Ocular Lens
57952136|NCT02891655|OTHER|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
58098164|NCT01314222|DRUG|BMS-954561|
58098165|NCT01314222|DRUG|Pregabalin|
58098166|NCT01314222|DRUG|Placebo matching BMS-954561|
58425729|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
57952137|NCT06254729|OTHER|Observational study|Our study does not have any exposure factors.
57952138|NCT04423809|OTHER|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
57952139|NCT05697601|DIAGNOSTIC_TEST|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
57952140|NCT05697601|DIAGNOSTIC_TEST|Pathology analysis|Pathology assessment of cells and tissues from respective organs
58098167|NCT01314222|DRUG|Placebo matching Pregabalin|
58098168|NCT01935882|DRUG|Artemether-lumefantrine combination|
58098169|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
58098170|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
58098171|NCT01529749|DRUG|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
58098172|NCT01529749|DRUG|EFV/FTC/TDF|600/200/245 mg, od, oral
58098173|NCT01529749|DRUG|FTC/TDF + MK-0518|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
58098174|NCT01529749|DRUG|FTC/TDF+MK-0518+Losartan|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
58098175|NCT00116129|DRUG|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
58098176|NCT04534387|OTHER|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
58098177|NCT04534387|OTHER|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
58098178|NCT05410509|PROCEDURE|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
58098179|NCT01359072|OTHER|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
58098180|NCT00303134|DRUG|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
58098181|NCT06539286|DEVICE|Laser Irradiation|three different laser wavelengths will be used
58098182|NCT05174078|OTHER|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
58098183|NCT05174078|OTHER|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
58098184|NCT02488473|DRUG|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
58098185|NCT02488473|DRUG|Ropivacaine|20 ml Ropivacaine 5mg/ml
58098186|NCT02488473|DRUG|Isotonic Saline|Placebo
58098187|NCT06613542|DIETARY_SUPPLEMENT|4g of taurine daily|Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
58098188|NCT06613542|DIETARY_SUPPLEMENT|Placebo|Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
58098189|NCT02252497|DRUG|Active comparator : Tranexamic Acid (Exacyl)|"* 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours ."
57736175|NCT06397469|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
57736176|NCT04553757|OTHER|Survey Administration|Complete survey
58098190|NCT02252497|DRUG|Placebo comparator : physiologic serum|"* 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours"
58098191|NCT00438035|PROCEDURE|ECG spectral|
58425730|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
58098192|NCT04476017|DRUG|SAGE-718|Oral tablets.
58098193|NCT01288417|DRUG|boceprevir|10 days of boceprevir 800mg TID
58098194|NCT01288417|DRUG|raltegravir|raltegravir 400mg single dose
58098195|NCT02404779|DRUG|cisatracurium besilate|
57736177|NCT01828242|BEHAVIORAL|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
57736178|NCT01828242|OTHER|Control group following conventional approach|Control group following conventional approach
58098196|NCT02404779|OTHER|Placebo|
58098197|NCT05321121|DRUG|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
58098198|NCT05321121|OTHER|Placebo|The control arm will receive an infusion of normal saline
58098199|NCT00669136|DRUG|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
58425731|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
58425732|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
58425733|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
58425734|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
58425735|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
58425736|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
58425737|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
58425738|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
57736179|NCT06467006|OTHER|Use of IA for proximal humeral fracture prognosis|None (prognosis study)
57736180|NCT02580097|OTHER|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
57736181|NCT01048528|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
58098200|NCT01400373|DEVICE|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
58098201|NCT02706041|PROCEDURE|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
58098202|NCT02706041|PROCEDURE|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
58098203|NCT02825472|BEHAVIORAL|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
58098204|NCT02470442|DRUG|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
58098205|NCT02470442|DRUG|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
58098206|NCT01544816|OTHER|Snack Product|control food product
58098207|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 1
58098208|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 2
58098209|NCT02490527|DIETARY_SUPPLEMENT|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
58098210|NCT02490527|DRUG|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
58098211|NCT02490527|OTHER|Placebo|A substance that has no therapeutic effect and will act as a control.
58425739|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
58425740|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
58098212|NCT04127682|OTHER|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
58425741|NCT04648514|PROCEDURE|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
58425742|NCT04648514|BEHAVIORAL|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
57736182|NCT06505200|OTHER|No intervention|No intervention
58098213|NCT00000318|DRUG|Buprenorphine|"1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication"
58098214|NCT01738490|DEVICE|Bone anchored hearing implant|
58098215|NCT04008082|DRUG|Lenvatinib|Lenvatinib capsule.
58098216|NCT06309615|OTHER|Standard of Care|To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,
58098217|NCT00381446|DEVICE|Marketed contact lens care products|
58098218|NCT01550068|DIAGNOSTIC_TEST|Echocardiography|
58098219|NCT01393626|DRUG|Placebo|oral tablets twice daily
58098220|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
58425743|NCT00386321|DRUG|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
58425744|NCT03484390|BEHAVIORAL|Mindfulness-based stress reduction|
58425745|NCT03484390|BEHAVIORAL|Wellness Group|
58425746|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
58425747|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
58425748|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
58425749|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
58425750|NCT01073007|DRUG|Simvastatin|Simvastatin 40 mgrs daily for three months.
57736183|NCT00733317|DRUG|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
57736184|NCT00733317|DRUG|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
57736185|NCT05472428|COMBINATION_PRODUCT|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
57736186|NCT03118960|DEVICE|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
57736187|NCT03118960|DEVICE|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
58098221|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
58098222|NCT05288374|DRUG|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
58307292|NCT05883514|BEHAVIORAL|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
57736188|NCT06344312|DRUG|Yangxue Qingnao Granules|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
57736189|NCT04499794|DRUG|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
57736190|NCT01519713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
57736191|NCT05319431|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
57736192|NCT05319431|DRUG|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
57736193|NCT05319431|PROCEDURE|TACE|On demand TACE
58307293|NCT04273815|DRUG|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
58307294|NCT04273815|DRUG|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
58307295|NCT04670601|DRUG|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
58307296|NCT04670601|DRUG|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
58307297|NCT00129337|DRUG|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
58307298|NCT00358358|DRUG|Fluticasone Propionate/Salmeterol 500/50mcg combination|
58307299|NCT00358358|DRUG|Fluticasone Propionate 500mcg|
58307300|NCT00358358|DRUG|Salmeterol 50mcg|
58307301|NCT05944939|PROCEDURE|Surgical extraction of impacted third molar|After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
58307302|NCT06253377|DEVICE|Adsorption membrane filter Oxiris™|Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
58307303|NCT02346734|DEVICE|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
58425751|NCT02438813|DRUG|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
58425752|NCT02438813|PROCEDURE|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
58425753|NCT02438813|PROCEDURE|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
58425754|NCT02438813|DEVICE|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
57769548|NCT06229704|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
58098223|NCT05288374|DRUG|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
58098224|NCT00831038|PROCEDURE|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
58425755|NCT02438813|OTHER|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
58425756|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
58425757|NCT02816619|BEHAVIORAL|Free practice of physical activity|
58425758|NCT03683888|BEHAVIORAL|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
58425759|NCT03683888|BEHAVIORAL|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
58425760|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
58425761|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
58425762|NCT01984450|PROCEDURE|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
58425763|NCT01984450|PROCEDURE|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
58425764|NCT01984450|DEVICE|implant with a collagen + fibrin gel mixture|
58425765|NCT06484361|DRUG|68Ga-PSMA|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
58425766|NCT06484361|DRUG|68Ga-RM2|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
58425767|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
58425768|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
58425769|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
58425770|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
58425771|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
58425772|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
58425773|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
58098225|NCT04308109|BEHAVIORAL|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
57769549|NCT05545241|BEHAVIORAL|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
57769550|NCT05545241|BEHAVIORAL|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
58098226|NCT01103401|DRUG|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
58425774|NCT05474222|OTHER|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
58425775|NCT00244634|DRUG|candsartan cilexetil|
58425776|NCT02145598|DRUG|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
58425777|NCT02145598|DRUG|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
58425778|NCT01822613|DRUG|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
58425779|NCT01822613|DRUG|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
57736194|NCT06634446|DEVICE|a mobile application for cognitive training|"Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.~HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.~Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.~User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians."
57736195|NCT06634446|DEVICE|video games|Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement
58307304|NCT03046849|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation.
58425780|NCT01822613|DRUG|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
58425781|NCT01822613|DRUG|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
58425782|NCT01822613|DRUG|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
58425783|NCT04006392|DEVICE|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
58425784|NCT04006392|DEVICE|Placebo Laser|Non-therapeutic output.
58425785|NCT02160145|DRUG|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
58425786|NCT02160145|DRUG|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
58425787|NCT05350189|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|At discretion of attending physician
58425788|NCT02372422|OTHER|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
58425789|NCT02372422|OTHER|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
57736196|NCT01358968|DRUG|LY2603618|Administered intravenously as a 1-hour infusion.
57736197|NCT01358968|DRUG|Desipramine|Administered orally
57736198|NCT01358968|DRUG|Pemetrexed|Administered intravenously as a 10-minute infusion.
58307305|NCT06506123|DEVICE|Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies|Machine learning algorithm to detect and classify patient-ventilator dyssynchronies, which is integrated in the mechanical ventilator (Fleximag Max, Magnamed, Brazil).
58307306|NCT06550778|BEHAVIORAL|Mindfulness-based emotional regulation intervention|"The intervention was conducted once a week for 6 weeks, with each session lasting 90-120 minutes, including a 30-minute parenting course each week. The intervention program was divided into 6 themes, including Entering mindfulness, feeling the connection between emotions and the body, Dealing with negative emotions, Moderate emotional expression, Mindfulness to relieve anxiety, Learning to be grateful and Embrace future life. The intervention content integrates mindfulness training, parental mindful parenting exercises and emotion regulation skills. For details, refer to Greenland's Mindfulness Games, Bögels' Mindful Parenting Manual, mindful breathing and meditation in MBSR and MBCT, as well as emotion regulation skills. The intervention location was the activity room of the child and adolescent psychology unit of the hospital."
58307307|NCT00306176|DRUG|Rosiglitazone|
58307308|NCT03098316|DIAGNOSTIC_TEST|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
58307309|NCT04365335|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
58307310|NCT04365335|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
58307311|NCT04365335|OTHER|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
58307312|NCT04365335|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
58307313|NCT06445933|COMBINATION_PRODUCT|Vitamin B6|The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
58307314|NCT06445933|COMBINATION_PRODUCT|Placebo|Placebo
58307315|NCT01653275|OTHER|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
58307316|NCT04824001|OTHER|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
58307317|NCT04289909|OTHER|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
58307318|NCT04782284|OTHER|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
58307319|NCT04782284|OTHER|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
58307320|NCT03377439|OTHER|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
58307321|NCT02208908|OTHER|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
58307322|NCT01566110|DIETARY_SUPPLEMENT|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
58307323|NCT00171275|DRUG|Fluvastatin|
58307324|NCT00074893|DEVICE|piezoelectric wrist brace|
58307325|NCT02873975|DRUG|LY2606368|
58307326|NCT02841124|OTHER|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
58425790|NCT04770844|OTHER|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
58425791|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
58425792|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
57736199|NCT01358968|DRUG|Gemcitabine|Administered intravenously as a 30-minute infusion.
57736200|NCT01302119|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
57736201|NCT01302119|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
57736202|NCT05239039|DRUG|spesolimab|spesolimab
58098227|NCT01103401|DRUG|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
58425793|NCT03691363|BEHAVIORAL|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
58425794|NCT00123045|BEHAVIORAL|health education|
58425795|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
58425796|NCT03565237|BIOLOGICAL|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
58307327|NCT04626323|PROCEDURE|Roux-en-Y gastric bypass|"1. Pneumoperitoneum closed with Veress needle~2. Identification of Treitz angle~3. Measurement of biliary loop (50 cm)~4. Bowel transection with linear stapler (white load)~5. Measurement of the alimentary limb (100 cm)~6. Laterolateral Entero-anastomoses (white load)~7. Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~8. Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~9. Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
58307328|NCT04626323|DRUG|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
58307329|NCT00079976|DRUG|Tigecycline|
58307330|NCT04753034|DRUG|TER-101|Active Comparator
58307331|NCT04753034|DRUG|Vehicle|Placebo Comparator
58425797|NCT03565237|BIOLOGICAL|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
58307332|NCT01135342|BEHAVIORAL|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
58307333|NCT01135342|BEHAVIORAL|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
58307334|NCT01135342|BEHAVIORAL|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
58307335|NCT01186770|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
58307336|NCT01186770|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
58425798|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
58425799|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
58098228|NCT00549120|DRUG|Propranolol|40 mg tablets
58098229|NCT00549120|DRUG|Salbutamol|Metered dose inhaler (600 μg)
58098230|NCT00549120|DRUG|Ipratropium|Metered dose inhaler (40 μg)
58098231|NCT00549120|DRUG|Placebo|Placebo for propranolol tablets
58098232|NCT03151967|DRUG|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
58098233|NCT03151967|DRUG|Placebo|vaginal applicator with medium containing no drug
58098234|NCT01162135|DRUG|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
58098235|NCT05135286|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
58098236|NCT05135286|DRUG|Carbachol PF|A single drop in each eye at a visit.
58307337|NCT03233074|OTHER|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
58307338|NCT04316117|PROCEDURE|Computed Tomography|Undergo PET/CT
58307339|NCT04316117|OTHER|Fludeoxyglucose F-18|Given IV
58307340|NCT04316117|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58307341|NCT03515746|DEVICE|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
58098237|NCT05135286|DRUG|Vehicle|A single drop in each eye at a visit.
58098238|NCT05527834|DRUG|VNRX-7145|Single oral dose
58098239|NCT05527834|DRUG|Ceftibuten|Single oral dose
58098240|NCT06298500|DEVICE|hernia repair surgery|In recent years, atraumatic mesh fixation with tissue adhesive has increasingly become the method of choice. It is the recommended mesh fixation method by the International Hernia Society Guidelines. In this study patients with inguinal hernia are treated by placing a prosthetic mesh in one of the layers of the abdominal wall to cover the weakness, the mesh is fixed by Histoacryl LapFix,
58098241|NCT03069131|DRUG|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
58098242|NCT03069131|OTHER|Placebo|twice daily administration of 1 rifaximin placebo tablet
58098243|NCT05402865|DRUG|Denosumab|Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
58098244|NCT03539848|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
58098245|NCT04265456|DRUG|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
58098246|NCT04265456|DRUG|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
58098247|NCT04675528|DRUG|DHP107(Oral paclitaxel)|DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
58098248|NCT02328404|DRUG|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
58098249|NCT02328404|DRUG|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
58098250|NCT05760482|DIAGNOSTIC_TEST|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
58098251|NCT05760482|BEHAVIORAL|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
58098252|NCT01305135|DRUG|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
58098253|NCT02406742|DRUG|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
58098254|NCT02406742|DRUG|Ibrutinib|
58098255|NCT02406742|DRUG|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
58425800|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
58425801|NCT05095415|OTHER|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
58425802|NCT05095415|OTHER|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
58425803|NCT04816318|OTHER|Social and public health measures against COVID-19|"1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
58425804|NCT04816318|OTHER|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
58425805|NCT00135252|PROCEDURE|nasal cannula oxygen delivery|
58425806|NCT00135252|PROCEDURE|supplemental oxygen delivery by hood|
58098256|NCT04511884|DIAGNOSTIC_TEST|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
58098257|NCT05988593|DIETARY_SUPPLEMENT|placebo|consume one bottle (30 mL) per day
58098258|NCT05988593|DIETARY_SUPPLEMENT|MelaGene+|consume one bottle (30 mL) per day
58098259|NCT03147521|OTHER|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
58098260|NCT03888092|DRUG|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
58098261|NCT03986918|DEVICE|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
58098262|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 14 days|
58098263|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 28 days|
58098264|NCT03432026|DEVICE|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
58425807|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
58425808|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
58425809|NCT04204356|BEHAVIORAL|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
58425810|NCT04204356|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
58425811|NCT03979599|PROCEDURE|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
58425812|NCT03979599|DRUG|magnesium sulphate& levobupivacaine|magnesium sulphate\& levobupivacaine
58425813|NCT03979599|DRUG|Levobupivacaine|levobupivacaine
58425814|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
58425815|NCT04135846|DRUG|Placebo|Matching placebo
58425816|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
58098265|NCT06232759|DRUG|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
58098266|NCT05380882|DRUG|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
58098267|NCT00414986|BEHAVIORAL|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
58098268|NCT00414986|BEHAVIORAL|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
58098269|NCT00414986|BEHAVIORAL|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
58098270|NCT00554177|DRUG|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
58098271|NCT00554177|DRUG|Placebo|2 doses of 1200mg, administered 2-3 days apart
58098272|NCT05090085|OTHER|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
58098273|NCT05090085|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
58098274|NCT05090085|OTHER|3m ESPE etch|32% phosphoric acid
58098275|NCT05090085|OTHER|OT Primer|Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
58098276|NCT02428231|DRUG|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
58098277|NCT06406231|DEVICE|comparing efficacy of TENS and PEMF in knee osteoarthritis|"Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups."
58098278|NCT00057785|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
58098279|NCT00057785|DRUG|fluorouracil|1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
57736203|NCT02507895|DEVICE|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
57769551|NCT02279147|DRUG|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
58307342|NCT01420536|PROCEDURE|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
58425817|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
58425818|NCT00302757|DRUG|Radioimmunotherapy|
58425819|NCT00302757|PROCEDURE|allogeneic hematopoietic cell transplantation|
58425820|NCT05979168|BEHAVIORAL|Phone call and text Messages|The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
58425821|NCT04293302|OTHER|No intervention|No intervention
58098280|NCT00057785|RADIATION|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
58098281|NCT03654365|OTHER|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
58098282|NCT03654365|OTHER|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
58098283|NCT01270607|PROCEDURE|Acupuncture|Treatment given twice per week for 4 weeks
58098284|NCT04931134|DEVICE|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
58098285|NCT04931134|DEVICE|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
58307343|NCT02696889|PROCEDURE|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
58307344|NCT01477281|DRUG|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
58425822|NCT02789592|DRUG|Melatonin PR|For experimental treatment of RBD
58425823|NCT02789592|DRUG|Clonazepam|For experimental treatment of RBD
58098286|NCT02543164|OTHER|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
58098287|NCT02543164|OTHER|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
58098288|NCT00705796|DRUG|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
58098289|NCT00705796|DRUG|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
58098290|NCT05073263|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
58098291|NCT02729545|OTHER|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
58098292|NCT02729545|DRUG|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
58425824|NCT02789592|DRUG|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
58425825|NCT02789592|DRUG|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
57769552|NCT02323347|OTHER|Progesterone|Progesterone level
58098293|NCT00140101|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
58425826|NCT04855383|DRUG|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
58307345|NCT01477281|DRUG|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
58307346|NCT02024061|BEHAVIORAL|Peer support|
58307347|NCT02024061|BEHAVIORAL|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
57736204|NCT05974527|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
57736205|NCT03680599|BEHAVIORAL|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
58307348|NCT02574585|BIOLOGICAL|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
58307349|NCT05126316|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
58307350|NCT05126316|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
58307351|NCT05621161|DRUG|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
58307352|NCT00045266|BIOLOGICAL|ziv-aflibercept|
58098294|NCT00140101|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
58098295|NCT02102022|DRUG|ADI-PEG 20 plus modified FOLFOX6|
58098296|NCT00791284|DRUG|Intermediate release (IR) Paliperidone|
58098297|NCT00279578|DRUG|ReFacto (Recombinant factor VIII) and Tranexamic acid|
57736206|NCT03680599|BEHAVIORAL|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
57736207|NCT01504594|PROCEDURE|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
58098298|NCT04536467|DRUG|Goserelin|chemotherapy+goserelin
57736208|NCT05338788|OTHER|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
57736209|NCT03586648|DEVICE|senofilcon A Multifocal|TEST Lens
57736210|NCT03586648|DEVICE|senofilcon A Sphere|TEST Lens Sphere
58307353|NCT06458114|OTHER|Assessment of caregiver feeling|The study group includes any caregiver who supported an extremely preterm newborn in a palliative care approach in the delivery room with as intervention type a questionnaire and individual semi-structured interview.
57736211|NCT03586648|DEVICE|etafilcon A Multifocal|CONTROL Lens
57736212|NCT03586648|DEVICE|etafilcon A Sphere|CONTROL Lens Sphere
58098299|NCT04536467|DRUG|Chemotherapy|standard chemotherapy
58098300|NCT05124990|DIAGNOSTIC_TEST|thermal imaging|no risk infrared thermal image would be used to capture pictures of the patients joints that are reported to be painful during a rheumatoid arthritis flare along iwth labs such as esr and crp. these will then be fed to a machine learning algorithm that will learn to predict the DAS 28 score for the RA patient and their flare.
58307354|NCT05137236|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
58098301|NCT06518720|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
58098302|NCT03895307|OTHER|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
58307355|NCT05137236|BIOLOGICAL|mRNA-1283.211|Sterile liquid for injection
58098303|NCT03895307|OTHER|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
58098304|NCT03895307|OTHER|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
58307356|NCT05137236|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
58307357|NCT05137236|BIOLOGICAL|mRNA-1283.529|Sterile liquid for injection
58425827|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
58425828|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
58425829|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
58425830|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
58425831|NCT01825941|DRUG|metoclopramide|10 milligrams, administered intravenously over 15 minutes
58425832|NCT01825941|DRUG|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
58098305|NCT05675072|DRUG|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
58098306|NCT05675072|DRUG|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
58425833|NCT01825941|DRUG|placebo|
58425834|NCT00867906|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
58425835|NCT00867906|BIOLOGICAL|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
58425836|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
58425837|NCT03139617|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
58425838|NCT03139617|PROCEDURE|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
58098307|NCT05386238|BEHAVIORAL|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
58098308|NCT05386238|BEHAVIORAL|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
58098309|NCT04501263|BEHAVIORAL|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
58098310|NCT00765999|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
58425839|NCT00256516|OTHER|Eco-Atkins diet (high vegetable protein and vegetable fat)|
58425840|NCT00256516|OTHER|NCEP diet|
57736213|NCT01566045|PROCEDURE|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
58098311|NCT05315986|DIETARY_SUPPLEMENT|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
58098312|NCT05315986|BEHAVIORAL|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
57736214|NCT01566045|PROCEDURE|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
57736215|NCT01772433|DIETARY_SUPPLEMENT|Olive oil|Phonophoresis with Olive oil for 10 day, daily
58098313|NCT05315986|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
58098314|NCT06462235|DRUG|Part A: ATM-AVI Single Dose, Cohorts 1-4|Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
58098315|NCT06462235|DRUG|Part B: Multiple-dose ATM-AVI, Cohorts 1-4|Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
58098316|NCT00300573|DRUG|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
58425841|NCT03323866|DRUG|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
58425842|NCT03323866|DRUG|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
58425843|NCT06338202|DRUG|Mavacamten|As detailed in the product label
58425844|NCT05633966|DRUG|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
58425845|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
57736216|NCT01772433|DRUG|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
58098317|NCT03150134|DRUG|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
58098318|NCT03150134|DRUG|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
58098319|NCT01888159|PROCEDURE|Bilateral Salpingectomy|
58425846|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
58425847|NCT01897090|OTHER|Elimination Diet|
58098320|NCT01888159|PROCEDURE|Tubal sterilization with bipolar energy|
58098321|NCT00837031|DRUG|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
58098322|NCT00837031|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
58425848|NCT01897090|OTHER|Dietary Guidelines for Americans|
58425849|NCT05950620|OTHER|Medical obesity management.|Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
58098323|NCT05094986|BEHAVIORAL|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
58307358|NCT05691101|OTHER|CISB with IV PCA group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine 4 ml/hour was injected through the continuous brachial plexus block catheter. IV-PCA with fentanyl (basal flow 0 ml with patient selected bolus 14 mcg, lockout 10 minutes) was started."
58307359|NCT05691101|OTHER|CISB group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine (4 ml/hour with patient selected bolus 5 ml, lockout 60 minutes) was injected through the continuous brachial plexus block catheter."
58307360|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
58425850|NCT04365933|DRUG|EYP001a|Oral tablets
58425851|NCT04365933|DRUG|Entecavir|Oral tablets
58307361|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
58425852|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
58425853|NCT01295424|OTHER|No intervention|Observational study, no interventions
58425854|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
58425855|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
58425856|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
58425857|NCT04476875|OTHER|Open Outpatient Clinic Programme|
58425858|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
58425859|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
58425860|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
58098324|NCT05094986|OTHER|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
58098325|NCT00111774|DRUG|ABX-EGF|
58098326|NCT06037031|DRUG|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
58098327|NCT06377969|DEVICE|ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation|The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
58098328|NCT02687763|BIOLOGICAL|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."
58098329|NCT01445431|OTHER|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
58098330|NCT01445431|OTHER|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
58098331|NCT06125873|DRUG|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
58098332|NCT04673266|DRUG|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
58098333|NCT00323635|DRUG|tolterodine|tablet, 4 mg, daily, 1 month
58098334|NCT00839007|DRUG|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
58098335|NCT05037552|PROCEDURE|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
58098336|NCT05037552|PROCEDURE|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
58098337|NCT02386722|DEVICE|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
58098338|NCT02206724|RADIATION|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
58098339|NCT00566618|DRUG|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
58098340|NCT00566618|DRUG|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
58098341|NCT02483260|DRUG|Ribavirin|"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
58098342|NCT01222182|DRUG|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
58098343|NCT02933827|DRUG|ELIXCYTE|Adipose-derived stem cells (ADSCs)
57736217|NCT00187018|BIOLOGICAL|Bone marrow transplant|
58098344|NCT05635773|DEVICE|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
58098345|NCT01336309|BEHAVIORAL|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
58098346|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
58098347|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
58098348|NCT01284816|PROCEDURE|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
58098349|NCT01291069|DRUG|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
58098350|NCT01291069|DRUG|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
58307362|NCT05724758|PROCEDURE|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~* Oncoplastic reconstruction with round-block technique~* Oncoplastic reconstruction using J-Plastic~* Oncoplastic reconstruction using V-Plastic~* Oncoplastic reconstruction using Grisotti~* Oncoplastic reconstruction using Batwing~* Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~* Oncoplastic perforator flap surgery"
57736218|NCT02474927|DRUG|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
57736219|NCT05574127|BEHAVIORAL|Behavioral Activation|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
57736220|NCT05574127|BEHAVIORAL|Supportive Psychotherapy|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
57736221|NCT03913611|OTHER|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
57736222|NCT03913611|OTHER|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
58307363|NCT01407016|DRUG|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
58307364|NCT00325910|DRUG|Metformin|
58307365|NCT06202859|DEVICE|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
58307366|NCT02039934|OTHER|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
58307367|NCT00855218|DRUG|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
58307368|NCT00855218|DRUG|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
58307369|NCT00000352|DRUG|Dextromethorphan|
58307370|NCT02076100|DRUG|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
58307371|NCT04421417|PROCEDURE|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
58307372|NCT04421417|PROCEDURE|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
58307373|NCT06238414|OTHER|Early psychotherapeutic intervention|The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
58307374|NCT03258255|PROCEDURE|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
58307375|NCT02351921|DEVICE|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
58307376|NCT03665337|BEHAVIORAL|mTranS-C|MOBILE HEALTH
58307377|NCT03665337|BEHAVIORAL|Control|MOBILE HEALTH
58307378|NCT02102555|DRUG|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
58307379|NCT02102555|DRUG|placebo|placebo (IV normal saline)
58307380|NCT02711462|DRUG|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
58307381|NCT02711462|DRUG|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
58098351|NCT02754505|OTHER|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
58307382|NCT00587093|OTHER|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
57736223|NCT05046795|DRUG|Revefenacin 175 mcg in 3 ML Inhalation Solution|Revefenacin
57736224|NCT05046795|DRUG|Placebo inhalation solution QD|Placebo
58307383|NCT02087098|DRUG|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
58307384|NCT02936947|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
58307385|NCT02936947|OTHER|Free breathing|Free breathing
58425861|NCT03881904|DRUG|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
58425862|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
57736225|NCT02336334|DEVICE|Positioning measurement|Logging of posturing informations
58307386|NCT02936947|OTHER|Active Breathing Control|Active Breathing Control
58307387|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
58307388|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
58307389|NCT00004658|DRUG|ribose|
58307390|NCT00004658|DRUG|thymidine|
58307391|NCT00004658|DRUG|uridine|
58307392|NCT06253936|OTHER|Magnetic Resonance Venography|Detect the anatomical variants of dural sinuses by Magnetic Resonance Venography
58307393|NCT00605020|DRUG|insulin detemir|
58307394|NCT00605020|DRUG|insulin aspart|
58307395|NCT00605020|DEVICE|biphasic insulin aspart|
58425863|NCT01858753|BIOLOGICAL|placebo sterile saline|
58425864|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
58425865|NCT03316950|DEVICE|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
58307396|NCT02121977|DEVICE|Elevate Anterior and Apical|
58307397|NCT02121977|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
58307398|NCT06047405|DEVICE|Average Volume-Assured Pressure Support (AVAPS)|A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
58425866|NCT03316950|DEVICE|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
57736226|NCT02336334|DEVICE|Patient feedback|Evaluation of patients questionary
57736227|NCT02336334|PROCEDURE|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
57736228|NCT02336334|DEVICE|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
57736229|NCT04339231|PROCEDURE|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
58098352|NCT02754505|OTHER|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
58098353|NCT04155957|OTHER|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
58098354|NCT04155957|DEVICE|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
58425867|NCT03316950|DEVICE|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
58425868|NCT01922843|DRUG|DP001 softgel capsules|
58425869|NCT01922843|DRUG|Placebo|
58425870|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
58425871|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
58425872|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
58425873|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
58425874|NCT01009086|DRUG|Placebo|SC injections
58425875|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
58425876|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
58425877|NCT05890482|BEHAVIORAL|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
58425878|NCT04635813|PROCEDURE|Thyroidectomy|Thyroidectomy
58425879|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
58098355|NCT04144231|BEHAVIORAL|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
58307399|NCT06047405|DEVICE|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
57736230|NCT02730494|DEVICE|Lcr Regenerans® vaginal capsules|
58098356|NCT04144231|BEHAVIORAL|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
58098357|NCT01971229|OTHER|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
58098358|NCT01971229|OTHER|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
58425880|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
58425881|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
58425882|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
58425883|NCT00468975|DRUG|PF-610,355|
58425884|NCT00468975|DRUG|Salmeterol|
58425885|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
58425886|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
58425887|NCT05271331|DRUG|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
58425888|NCT05271331|DRUG|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
58425889|NCT05271331|DRUG|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
58425890|NCT05271331|DRUG|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
58425891|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
57736231|NCT02730494|DEVICE|Lcr Regenerans® vaginal tablet|
57736232|NCT02775526|PROCEDURE|TOT|70 patients
58425892|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
58425893|NCT00212706|DRUG|ONO-8025 (KRP-197)|
58307400|NCT04386447|DRUG|Oxytocin|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
57736233|NCT02775526|PROCEDURE|TVT|70 patients
57736234|NCT02775526|PROCEDURE|Burch Colposuspension|70 patients
57736235|NCT02571504|BEHAVIORAL|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
58425894|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
58425895|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
58425896|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
58425897|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
58425898|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
57736236|NCT02265900|OTHER|Exercise|One type of exercise
57736237|NCT02265900|OTHER|Exercise|A different type of exercise
58425899|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
58425900|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
58425901|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
57736238|NCT02207920|BIOLOGICAL|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
57736239|NCT02207920|BIOLOGICAL|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
58098359|NCT03585868|OTHER|Placebo|Beverage with no flavonoids
58425902|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
58425903|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
58425904|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
58425905|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
58425906|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
58425907|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
58425908|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
58425909|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
58425910|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
58425911|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
58425912|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
58425913|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
58425914|NCT05423912|BEHAVIORAL|Couple in Control (CiC) Program|MCI dyads engaging in the pilot testing aim of the CiC Program meet in virtual intervention group meetings lasting 90 to 120 minutes over the course of 8-9 consecutive weeks. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be interviewed virtually via videoconference for a 30 to 60 minute discussion on their experiences in and perceptions of the intervention.
58425915|NCT05604963|PROCEDURE|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
58425916|NCT05604963|PROCEDURE|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
58425917|NCT00328471|BEHAVIORAL|care management|
58425918|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
58425919|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
58425920|NCT03020017|OTHER|Pharmacological Study|Correlative studies
58425921|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
58425922|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
58425923|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
58425924|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
58425925|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
58425926|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
58425927|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
58425928|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
58425929|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
58098360|NCT03585868|OTHER|Flavonoids|Flavonoids-enriched cacao beverage
57736240|NCT02207920|BIOLOGICAL|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
57736241|NCT02207920|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
57736242|NCT06066060|DRUG|JMKX000623|JMKX000623, administered orally ;
57736243|NCT06066060|DRUG|Metformin|Metformin,administered orally
57736244|NCT04522518|DEVICE|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
57736245|NCT06669559|OTHER|DROM-Test|DROM test: a tool for assessing the ability to decide on returning home
57736246|NCT02856464|OTHER|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
57736247|NCT02856464|OTHER|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
57736248|NCT00325611|BEHAVIORAL|Multidisciplinary palliative care team met with patient|
57736249|NCT04417959|PROCEDURE|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
57736250|NCT04417959|PROCEDURE|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
58425930|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
58425931|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
57736251|NCT05475054|PROCEDURE|Minimally invasive liver resection|A liver resection performed by minimally invasive (keyhole) surgery
58425932|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
58425933|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
58425934|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
57736252|NCT00670774|DRUG|Eculizumab|"* Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
57736253|NCT02034747|DRUG|Advagraf|oral
58425935|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
58307401|NCT04386447|DRUG|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients."
58425936|NCT02841241|DRUG|Esmolol|Esmolol infusion
58425937|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
58098361|NCT03585868|DIETARY_SUPPLEMENT|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
58098362|NCT03054935|OTHER|Indirect Calorimetry|Measurement of resting energy expenditure
58098363|NCT05446480|DRUG|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
58098364|NCT05446480|DRUG|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
58425938|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
58425939|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
58098365|NCT05446480|OTHER|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
58098366|NCT05163431|DEVICE|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
57736254|NCT02034747|DRUG|Corticosteroid|oral
58098367|NCT04886869|DIETARY_SUPPLEMENT|caffeine|oral consumption
58098368|NCT02149862|OTHER|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
58098369|NCT04604288|BIOLOGICAL|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
58098370|NCT06442059|OTHER|Kinesiophobia Level Due to Dyspnea|Kinesiophobia Level Due to Dyspnea
58098371|NCT00197509|BEHAVIORAL|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
58098372|NCT00326300|DRUG|methylphenidate hydrochloride extended-release tablets|
58098373|NCT02706600|BEHAVIORAL|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
58307402|NCT05379920|BEHAVIORAL|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
57736255|NCT01446458|DRUG|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
58098374|NCT02706600|BEHAVIORAL|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
57736256|NCT01446458|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
57736257|NCT03818139|OTHER|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
58098375|NCT06349434|DEVICE|MyoMo|To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).
58098376|NCT06349434|OTHER|conventional therapy|To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
58307403|NCT05379920|BEHAVIORAL|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
58307404|NCT04960267|DEVICE|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
58307405|NCT02117258|DRUG|Z-360|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
58307406|NCT02117258|DRUG|Placebo|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
58307407|NCT01020123|DRUG|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
58307408|NCT01020123|DRUG|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
58307409|NCT01020123|DRUG|Glipizide|Glipizide administered to 1 group of patients
58307410|NCT00138528|DRUG|Fluvastatin|
58307411|NCT01612663|DEVICE|Pain relief by Acupuncture needle at non-specific site|
58307412|NCT01612663|DEVICE|Acupuncture needle|
58307413|NCT01612663|DEVICE|Acupuncture needle|
58307414|NCT01612663|DEVICE|Acupuncture needle|
58307415|NCT03087058|DRUG|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
58307416|NCT03087058|DRUG|Patiromer|2 g/day, 4 g/day and 8 g/day
58307417|NCT03087058|DRUG|Patiromer|1 g/day, 2 g/day and 4 g/day
58307418|NCT03359434|DEVICE|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
58307419|NCT03359434|DEVICE|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
58307420|NCT04818944|DRUG|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
58307421|NCT04818944|DRUG|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
58307422|NCT01717222|DRUG|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
58307423|NCT01717222|DRUG|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
58307424|NCT02737267|BEHAVIORAL|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
58307425|NCT02737267|BEHAVIORAL|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
58307426|NCT01665742|DIETARY_SUPPLEMENT|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
58307427|NCT01665742|DIETARY_SUPPLEMENT|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
58307428|NCT03084237|BIOLOGICAL|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
58307429|NCT03084237|BIOLOGICAL|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
58425940|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
58425941|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
57736258|NCT03512665|DIETARY_SUPPLEMENT|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
58307430|NCT03084237|DRUG|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
57736259|NCT03512665|DIETARY_SUPPLEMENT|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
57736260|NCT03512665|OTHER|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
57736261|NCT05879887|BEHAVIORAL|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
57736262|NCT04484285|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
57736263|NCT01693120|DEVICE|Medtronic Phased RF Ablation System|Phased RF ablation
58307431|NCT02443623|BIOLOGICAL|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
57736264|NCT04564183|OTHER|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
57736265|NCT04564183|OTHER|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
57736266|NCT04564183|RADIATION|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
58425942|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
58425943|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
57736267|NCT04564183|DIAGNOSTIC_TEST|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
57736268|NCT04094311|BIOLOGICAL|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
58307432|NCT02160938|OTHER|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)"
58307433|NCT05514366|PROCEDURE|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
58425944|NCT05095168|DRUG|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
58425945|NCT05095168|DRUG|Placebo|placebo
58425946|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
58425947|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
58425948|NCT03468322|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
58098377|NCT01318200|PROCEDURE|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
58098378|NCT01318200|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
58098379|NCT06495125|DRUG|Avutometinib|Given PO
58098380|NCT06495125|PROCEDURE|Biopsy|Undergo biopsy
58098381|NCT06495125|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58098382|NCT06495125|PROCEDURE|Computed Tomography|Undergo CT
58425949|NCT03468322|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
58098383|NCT06495125|DRUG|Defactinib|Given PO
58098384|NCT06495125|BIOLOGICAL|Nivolumab|Given IV
58098385|NCT06495125|PROCEDURE|Positron Emission Tomography|Undergo PET
58425950|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
58098386|NCT04143997|DIAGNOSTIC_TEST|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
58425951|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
58425952|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
58425953|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
58425954|NCT03403309|DRUG|1) Inosine 5'-monophosphate|1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
58425955|NCT03403309|DRUG|Placebo|2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
58425956|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
58425957|NCT05533710|PROCEDURE|erector spinae plane block|Patients will receive ESB. In the lateral decubitus, after skin sterilization, ESP block will be performed at the level of T9
58425958|NCT05533710|PROCEDURE|transversus abdominis plane block|patients will receive TAP block in supine position after skin sterilization, TAP block will be performed between internal oblique and transversus abdominis muscles
57736269|NCT00511576|DRUG|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
58098387|NCT04690322|DRUG|Eloctate|Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
58098388|NCT04690322|DRUG|Adynovate|Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
58098389|NCT04690322|DRUG|Emicizumab|Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
58098390|NCT06521788|DEVICE|AI-assisted breast ultrasound|AI-assisted breast ultrasound in community-based breast cancer screening
58098391|NCT06521788|DEVICE|Routine breast ultrasound|Routine breast ultrasound conducted by primary care physicians
58098392|NCT01372254|BEHAVIORAL|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
58098393|NCT01372254|BEHAVIORAL|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
58098394|NCT01372254|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
58425959|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
58425960|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
58425961|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
57736270|NCT01168492|DRUG|ketamine|0.5mg/kg ketamine iv
58425962|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
58425963|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
58425964|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
58425965|NCT00300365|OTHER|Placebo|Pioglitazone placebo
58425966|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
58425967|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
58425968|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
58425969|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
58425970|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
58425971|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
58425972|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
58425973|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
58425974|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
58425975|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
58425976|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
58425977|NCT01423916|DRUG|Placebo|OPC-34712 placebo
58425978|NCT00701805|DRUG|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
58425979|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
58425980|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
58425981|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
58425982|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
58425983|NCT00931801|DRUG|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
58425984|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
58425985|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
58425986|NCT00556270|DRUG|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
58425987|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
58425988|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
58425989|NCT01919216|DRUG|Citalopram|
58425990|NCT02964585|DRUG|Canagliflozin|100 mg
58425991|NCT02964585|DRUG|Placebo|1 tablet daily for 16 weeks
58425992|NCT01543776|DRUG|abiraterone acetate|Given PO
58425993|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
58425994|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
58425995|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
58425996|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
58425997|NCT00991406|DEVICE|FES|Surface stimulation to contract the muscles in the lower extremity
58425998|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
57736271|NCT06568705|RADIATION|Moderate hypofractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.
58425999|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
58098395|NCT02476760|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
57736272|NCT06568705|RADIATION|Ultrafractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
58098396|NCT02476760|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
58098397|NCT02476760|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
58426000|NCT06356688|DRUG|paclitaxel polymer micelles and cisplatin combined with Cadonilimab|Paclitaxel polymer micelles:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 375mg, IV drip, d3, q3w;
58426001|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
58426002|NCT00278811|PROCEDURE|mobile crisis team|
58426003|NCT06546137|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing of genomic DNA extracted from buccal swab
58426004|NCT03602859|DRUG|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
58426005|NCT03602859|DRUG|Dostarlimab (TSR-042)|Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
58098398|NCT02476760|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
58098399|NCT02476760|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
58098400|NCT02476760|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
58426006|NCT03602859|DRUG|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
58426007|NCT03602859|DRUG|Dostarlimab-Placebo|Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
58426008|NCT03602859|DRUG|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
58426009|NCT04552288|DRUG|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
58426010|NCT00119665|DRUG|MF101|
58426011|NCT01344720|DRUG|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
58426012|NCT01344720|DRUG|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
58426013|NCT02666612|PROCEDURE|Blood samples|
58426014|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
58098401|NCT02476760|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
58098402|NCT02476760|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
58098403|NCT02433535|DRUG|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
58098404|NCT02433535|OTHER|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
58098405|NCT00881595|DRUG|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
58098406|NCT00881595|RADIATION|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
58098407|NCT00881595|PROCEDURE|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
58098408|NCT00549107|DRUG|Levosimendan|
58098409|NCT00549107|DRUG|Milrinone|
58098410|NCT00388115|PROCEDURE|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
58098411|NCT00388115|PROCEDURE|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
58098412|NCT00388115|PROCEDURE|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
58098413|NCT02100241|PROCEDURE|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
58098414|NCT02106793|DRUG|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
58098415|NCT02106793|DRUG|Identical placebo solution|Identical placebo solution
58426015|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
58426016|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
58426017|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
58426018|NCT02180477|DRUG|UHAC 62 XX - capsules|
58426019|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
58098416|NCT06240572|OTHER|no intervention|no intervention
58098417|NCT04523831|DRUG|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
58426020|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
58426021|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
58098418|NCT04523831|DRUG|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
58098419|NCT04383080|PROCEDURE|Acupuncture|acupuncture at specific acupuncture points
58098420|NCT04383080|DEVICE|Low-level laser therapy|low level laser emission on specific acupuncture points
58098421|NCT03786809|DRUG|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
58098422|NCT03786809|DRUG|Placebo|patients of the placebo group will use placebo once a day for 28 days
58098423|NCT00365469|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
58098424|NCT00365469|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
58098425|NCT06169020|DEVICE|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
58098426|NCT06169020|DEVICE|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
58098427|NCT00656019|DRUG|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
58098428|NCT04227652|DRUG|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
58098429|NCT05220865|PROCEDURE|Hall Technique|"* Only food scraps or debris will be removed from the caries cavity.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
58426022|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
57952141|NCT04546477|DEVICE|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
57952142|NCT05882448|PROCEDURE|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
57952143|NCT05882448|PROCEDURE|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
57952144|NCT03284684|OTHER|Blood test|plasma concentration of circulating DNA of specific genes
57952145|NCT00232102|DRUG|Tegaserod|
58426023|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
57952146|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
57952147|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
57952148|NCT01934556|DRUG|Ranibizumab 0.3 mg intravitreal injection|
57952149|NCT01934556|DEVICE|Guided Laser Photocoagulation|
58426024|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
58426025|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
58426026|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
58426027|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
58426028|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
58426029|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
58426030|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
58098430|NCT05220865|PROCEDURE|Modified Hall Technique|"* Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
58098431|NCT00858234|DRUG|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
58426031|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
58426032|NCT04650425|BEHAVIORAL|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
58426033|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
58426034|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
58426035|NCT00154882|DRUG|Paclitaxel (Phyxol) , Cisplatin|
58426036|NCT02160691|DEVICE|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
58426037|NCT03708666|OTHER|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
58426038|NCT03038854|OTHER|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
58426039|NCT03038854|OTHER|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
57952150|NCT05926700|DRUG|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
57952151|NCT03420690|OTHER|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (\>1) and the death of patients (\> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
57952152|NCT02021045|DEVICE|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
57952153|NCT03298581|DRUG|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
57952154|NCT02554123|DRUG|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
57952155|NCT02554123|DRUG|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
57952156|NCT00779649|OTHER|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
57952157|NCT00779649|OTHER|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
57952158|NCT03924609|DIAGNOSTIC_TEST|Intensive screening / routine screening|Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
57952159|NCT04324359|DRUG|SURF-201|One drop twice daily (BID) in the study eye for 16 days.
58098432|NCT00858234|DRUG|Bortezomib|Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
58098433|NCT01980316|DRUG|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
58098434|NCT01980316|DRUG|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
58098435|NCT04117217|DIAGNOSTIC_TEST|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
58098436|NCT01649245|DRUG|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
58098437|NCT02241200|DRUG|DA3880|
58098438|NCT02241200|DRUG|Aranesp|
58426040|NCT03038854|OTHER|Cows' milk|Homogenized store-bought full fat cow's milk.
58426041|NCT03834935|DRUG|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
58426042|NCT03834935|DRUG|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
58426043|NCT01501552|OTHER|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
57736273|NCT05809037|DEVICE|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
58426044|NCT01501552|OTHER|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
58426045|NCT01501552|OTHER|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
58426046|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
58426047|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
58426048|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
58426049|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
58426050|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
58426051|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
58426052|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
57736274|NCT05809037|DEVICE|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
58426053|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
58426054|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
58426055|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
58426056|NCT04903366|DRUG|Timolol Maleate|timolol maleate 0.5% gel-forming solution
58426057|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
57952160|NCT04324359|DRUG|Placebo|One drop twice daily (BID) in the study eye for 16 days.
57952161|NCT00853671|OTHER|Adenosine Stress Dual-source CTP|"Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure."
57952162|NCT00860210|DEVICE|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
57952163|NCT01725555|DRUG|Fasted treatment: AXL1717|
58098439|NCT06120452|OTHER|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
58426058|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
58426059|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
57952164|NCT01725555|DRUG|Fed treatment: AXL1717|
57952165|NCT03563378|DRUG|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
58426060|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
58426061|NCT00002580|DRUG|cyclophosphamide|
58426062|NCT00002580|DRUG|fluorouracil|
58426063|NCT00002580|DRUG|goserelin acetate|
58426064|NCT00002580|DRUG|leuprolide acetate|
58426065|NCT00002580|DRUG|methotrexate|
58426066|NCT00002580|DRUG|tamoxifen citrate|
58426067|NCT00002580|PROCEDURE|conventional surgery|
58426068|NCT00002580|PROCEDURE|laparoscopic surgery|
58426069|NCT00002580|PROCEDURE|oophorectomy|
58426070|NCT00002580|RADIATION|radiation therapy|
58426071|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
58426072|NCT00688272|DRUG|Ciprofloxacin|Given 500mg BID x 6 days
58426073|NCT00688272|DRUG|Eltrombopag|Given QD x 6 days
58426074|NCT00688272|DRUG|Placebo|Given QD x 6 days
58426075|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
58426076|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
58426077|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
58426078|NCT04842305|DIAGNOSTIC_TEST|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
57952166|NCT03563378|DRUG|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
58098440|NCT03679312|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
57952167|NCT05177120|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
58426079|NCT03342092|OTHER|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
58426080|NCT06347939|DIAGNOSTIC_TEST|Mediastinal lymph nodes cryobiopsies|EBUS Mediastinal lymph nodes cryobiopsies
58426081|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
57952168|NCT05177120|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients
57952169|NCT05177120|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
57952170|NCT05177120|OTHER|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
57952171|NCT05177120|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
58098441|NCT03679312|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
58426082|NCT02580786|BEHAVIORAL|Breastfeeding peer support|
58426083|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
58426084|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
58426085|NCT05556577|DRUG|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
58426086|NCT05556577|OTHER|placebo|Placebo received at SURMOUNT-CN trial
58426087|NCT06110000|OTHER|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization.~5. Pectoralis minor stretch~6. Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
58426088|NCT06110000|OTHER|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
58426089|NCT00819117|DEVICE|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
58426090|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
58426091|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
58426092|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
58426093|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
58426094|NCT05760404|PROCEDURE|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
58426095|NCT05760404|OTHER|in vitro study|on tissues from colorectal resections
58426096|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
58426097|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
58426098|NCT02419820|DRUG|APD791|Temanogrel
58426099|NCT02419820|DRUG|Clopidogrel|Clopidogrel
58426100|NCT02419820|DRUG|Aspirin|Aspirin
58426101|NCT02419820|DRUG|Placebo for APD791|Placebo for APD791
58426102|NCT01949519|DRUG|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
58426103|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
58426104|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
57736275|NCT02358603|DIAGNOSTIC_TEST|Chronotropic Incompetence Diagnostic Algorithm|
57736276|NCT05659602|BIOLOGICAL|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
57736277|NCT00781976|DRUG|AZD7295|700mg per day maximum
57736278|NCT00781976|DRUG|Placebo|matched placebo
57952172|NCT05177120|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
57736279|NCT02992262|DEVICE|Point of care ocular ultrasound|
57736280|NCT01029223|DRUG|ivabradine|
57736281|NCT01029223|DRUG|metoprolol|
57736282|NCT01029223|DRUG|placebo|
57769553|NCT01028079|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
58098442|NCT04767217|DRUG|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
58098443|NCT04767217|DRUG|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
58426105|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
58426106|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
58426107|NCT04365452|DEVICE|Invia Motion|Invia Motion NPWT system at cesarean delivery
58426108|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
58426109|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
58098444|NCT00995930|DRUG|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
58098445|NCT00995930|DRUG|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
58426110|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
58098446|NCT04235764|DEVICE|modified resectoscope|The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
58098447|NCT04235764|PROCEDURE|TURBT|All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
57769554|NCT01028079|DRUG|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
58098448|NCT04281654|OTHER|Active Social Conversation|Active Social Conversation
58098449|NCT04694339|OTHER|Survey|Survey
58098450|NCT02253407|BIOLOGICAL|MMR vaccine|
58098451|NCT03174925|DEVICE|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
58098452|NCT04953208|DEVICE|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
58098453|NCT04953208|DEVICE|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
58426111|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
58426112|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
58426113|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
58426114|NCT05463263|DRUG|STP938|Small molecule
58426115|NCT03044808|DRUG|Lidocaine|
57769555|NCT01028079|DRUG|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
58098454|NCT04953208|BEHAVIORAL|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
58098455|NCT04953208|BEHAVIORAL|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
58098456|NCT06344988|OTHER|The exercise program|The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.
58426116|NCT03044808|DRUG|Saline|
58426117|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
58426118|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
58426119|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
58426120|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
58426121|NCT02477553|BEHAVIORAL|DA - Quantitative|
58426122|NCT02477553|BEHAVIORAL|DA - Verbal|
58426123|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
58426124|NCT05611814|OTHER|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
58426125|NCT05611814|OTHER|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
58426126|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
58426127|NCT02068872|PROCEDURE|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
57769556|NCT06087562|DRUG|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
58098457|NCT06344988|OTHER|Online education presentation|This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
58098458|NCT06344988|DEVICE|Smart band|Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
58426128|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
58426129|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
58426130|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
58426131|NCT02029794|DRUG|3-5% acetic acid|
58426132|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
58426133|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
58426134|NCT03350555|DEVICE|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
58426135|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
58426136|NCT04892108|PROCEDURE|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
58426137|NCT04892108|PROCEDURE|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
57769557|NCT06087562|DRUG|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
57952173|NCT05177120|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
58098459|NCT03980860|OTHER|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
58426138|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
58426139|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
58426140|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
58426141|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
58098460|NCT02885259|DRUG|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
58098461|NCT03682627|PROCEDURE|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
58098462|NCT03682627|PROCEDURE|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
58098463|NCT03705403|DRUG|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
58098464|NCT03705403|RADIATION|Radiation|Radiotherapy
58098465|NCT04831931|OTHER|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
58098466|NCT00963599|DRUG|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
58098467|NCT00963599|DRUG|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
58098468|NCT00963599|DRUG|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
58098469|NCT00963599|DRUG|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
58098470|NCT00716586|DRUG|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
58098471|NCT05663216|OTHER|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
58098472|NCT04859647|OTHER|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
58098473|NCT05799365|OTHER|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
58098474|NCT00755937|OTHER|Data collection post infusion|
58098475|NCT06190873|BEHAVIORAL|post-discharge rehabilitation training|Telephone training will be provided for post-discharge rehabilitation
58426142|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
58098476|NCT01881217|DRUG|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
58098477|NCT05241626|DIAGNOSTIC_TEST|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
58098478|NCT03224741|BEHAVIORAL|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
58098479|NCT03224741|BEHAVIORAL|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
58098480|NCT03224741|BEHAVIORAL|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
58098481|NCT00768105|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
58098482|NCT00768105|DRUG|Placebo|Dosing to match AZD1656
58098483|NCT03601806|OTHER|Laboratory Biomarker Analysis|Correlative studies
58098484|NCT03601806|DRUG|Pomalidomide|Given PO
58098485|NCT00892424|DRUG|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
58098486|NCT01297569|DRUG|Ranibizumab|
58098487|NCT01166997|DEVICE|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
57769558|NCT05126459|COMBINATION_PRODUCT|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
58098488|NCT01166997|DRUG|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
57952174|NCT03129321|DRUG|Econazole Nitrate Cream, 1%|
57952175|NCT03129321|DRUG|Placebo|
58098489|NCT03912350|DRUG|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
58098490|NCT03649906|PROCEDURE|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
58098491|NCT06562296|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
58098492|NCT06562296|OTHER|Amnion-Chorion-Amnion|Dehydrated human placental trilayer allograft derived from donated human tissue.
58098493|NCT06562296|PROCEDURE|Standard of Care|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
58098494|NCT01042002|BEHAVIORAL|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
58098495|NCT02590978|PROCEDURE|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
58098496|NCT02590978|PROCEDURE|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
58098497|NCT00350194|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
58098498|NCT05225116|DRUG|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
58098499|NCT05225116|DRUG|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
58426143|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
58098500|NCT05225116|RADIATION|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
58098501|NCT04089163|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
58098502|NCT04089163|DRUG|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
58426144|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
58426145|NCT00598325|BIOLOGICAL|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
58426146|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
58098503|NCT01835808|DEVICE|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
58098504|NCT00850382|DRUG|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
58098505|NCT00850382|DRUG|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
58098506|NCT00850382|DRUG|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
58426147|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
58426148|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
58426149|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
58426150|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
58098507|NCT06078995|DRUG|Tenecteplase|Thrombolysis wtih rhTNK-tPA
58098508|NCT06078995|DRUG|Alteplase|Thrombolysis wtih rt-PA
58098509|NCT00802776|PROCEDURE|Femtosecond laser assisted keratoplasty|
58098510|NCT00802776|PROCEDURE|PKP|
58098511|NCT02732886|DEVICE|Medifoam®|Foam Dressing
58098512|NCT02732886|DEVICE|Betafoam®|Foam dressing including Betadine iodine
58098513|NCT06552572|DRUG|Glofitamab|Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
58098514|NCT04196088|DEVICE|Ultivision Artificial Intelligence Software|Screening Colonoscopy
58098515|NCT04196088|DEVICE|No Artificial Intelligence Software enhancement|Screening Colonoscopy
58098516|NCT00247130|DRUG|Omeprazole|
58098517|NCT00247130|DRUG|Ranitidine|
58098518|NCT04501341|BIOLOGICAL|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
58098519|NCT04501341|BIOLOGICAL|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
58098520|NCT00533585|DRUG|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
58098521|NCT00533585|DRUG|Paclitaxel|200 mg/m\^2 By Vein Over 3 Hours on Day 1.
58098522|NCT00533585|DRUG|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
58098523|NCT00533585|DRUG|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
58098524|NCT02034227|DRUG|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
58098525|NCT02284152|BEHAVIORAL|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
58426151|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
58426152|NCT00381030|DRUG|carvedilol plus nurse management|
58098526|NCT05469503|DIETARY_SUPPLEMENT|TOTUM-854|12 weeks of TOTUM-854 supplementation
58098527|NCT05469503|DIETARY_SUPPLEMENT|Placebo|12 weeks of placebo supplementation
58098528|NCT01188642|BEHAVIORAL|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
58426153|NCT05830877|OTHER|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
58426154|NCT05830877|OTHER|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
58426155|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58098529|NCT02275182|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
58098530|NCT02275182|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
58098531|NCT01854801|OTHER|Individual medical Care|Individual medical care in occupational and environmental diseases centers
58098532|NCT01854801|OTHER|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
58098533|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
58098534|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
58098535|NCT04274088|PROCEDURE|Cataract surgery|Phacoemulsification surgery
58098536|NCT01610167|DEVICE|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58098537|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58098538|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
58098539|NCT05947149|OTHER|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43."
58098540|NCT04237259|OTHER|Parent-administered TCM pediatric massage training|"Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects)."
58098541|NCT04237259|OTHER|Progressive Muscle Relaxation Exercise|The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
58098542|NCT01725737|DRUG|GlyTI-M|
58098543|NCT01725737|DRUG|Placebo|Placebo Comparator: starch
58098544|NCT00425282|DRUG|RWJ-333369|
58098545|NCT06116448|OTHER|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
58098546|NCT06116448|OTHER|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
58098547|NCT06116448|OTHER|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
58098548|NCT05049460|DEVICE|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
58098549|NCT05049460|DEVICE|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
58426156|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58426157|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58426158|NCT00254891|DRUG|PF-3512676 + Paclitaxel + Carboplatin|"* PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
58426159|NCT00254891|DRUG|Paclitaxel + Carboplatin|"* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
57769559|NCT05126459|COMBINATION_PRODUCT|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
58098550|NCT00159081|DRUG|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
58098551|NCT05052827|DIETARY_SUPPLEMENT|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
58307434|NCT05514366|PROCEDURE|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) \< 97% is detected."
58426160|NCT04721548|DRUG|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
58426161|NCT04721548|DRUG|Placebo|1 mL of solution twice a day.
58098552|NCT05052827|DIETARY_SUPPLEMENT|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
58098553|NCT05052827|DIETARY_SUPPLEMENT|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
58098554|NCT01832688|OTHER|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
58426162|NCT03897595|DEVICE|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
57769560|NCT05126459|COMBINATION_PRODUCT|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
57952176|NCT02882659|BIOLOGICAL|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
58098555|NCT01933412|BIOLOGICAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
58098556|NCT01933412|BIOLOGICAL|Engerix B Hepatitis B Vaccine|
58098557|NCT00934778|PROCEDURE|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
58098558|NCT01563393|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
58098559|NCT01563393|OTHER|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
58098560|NCT00309127|BEHAVIORAL|Multidisciplinary team care|
58098561|NCT00976313|PROCEDURE|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
58098562|NCT00976313|OTHER|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
58098563|NCT02546037|DEVICE|FX100 dialyzer|comparison of dialyzers
58098564|NCT02546037|DEVICE|SOLACEA 21H|comparison of dialyzers
58098565|NCT00897429|PROCEDURE|laboratory biomarker analysis|Correlative studies
58307435|NCT05514366|PROCEDURE|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs \> 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is \>10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
58307436|NCT02111200|DRUG|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
58426163|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
57952177|NCT02279680|DEVICE|Electroencephalography|
57952178|NCT02279680|BEHAVIORAL|Neuropsychological assesments|
57952179|NCT02941627|DEVICE|Neuro Zti|Cochlear implant
57952180|NCT02941627|DEVICE|Neuro One|Sound processor
57952181|NCT04457804|BEHAVIORAL|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
57952182|NCT02215356|DRUG|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
57952183|NCT02215356|DRUG|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
57952184|NCT00203853|DEVICE|pillbox, wristwatch|
57952185|NCT02829840|DRUG|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
57952186|NCT02829840|DRUG|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
58098566|NCT04390074|OTHER|COVID-19 and Intensive Care|No intervention, observational.
58098567|NCT06542796|PROCEDURE|Immunotherapy combined with targeted therapy|Immunotherapy combined with targeted therapy
58098568|NCT06542796|OTHER|Standard treatment plan|Standard treatment plan
57952187|NCT02829840|BEHAVIORAL|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
58098569|NCT03864367|DEVICE|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
58098570|NCT00828581|DRUG|lorcaserin|
58098571|NCT02231671|DRUG|ALS-008176|
58098572|NCT02231671|DRUG|ALS-008112|
58098573|NCT05640375|DRUG|Methylprednisolone|Single dose, 1 mg/kg
58098574|NCT04215653|DRUG|Anaprazole Sodium|administered orally once every 30-60 minutes before breakfast for 4 weeks
58098575|NCT04215653|DRUG|Rabeprazole|administered orally once every 30-60 minutes before breakfast for 4 weeks
58098576|NCT04215653|DRUG|Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
57952188|NCT00000270|DRUG|Cocaine|
57952189|NCT05533983|OTHER|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
57952190|NCT06180200|DIAGNOSTIC_TEST|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
57952191|NCT01916837|OTHER|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
57952192|NCT01916837|OTHER|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
57952193|NCT01916837|PROCEDURE|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
57952194|NCT01308008|BEHAVIORAL|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
57952195|NCT01308008|BEHAVIORAL|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
57952196|NCT05779475|OTHER|No treatment given|Participants will not receive any investigational treatment in this study.
57952197|NCT03426085|DRUG|Liraglutide 6 mg Solution for Injection|
57952198|NCT03426085|OTHER|Placebo|
57952199|NCT02270242|DRUG|Aspirin|
57952200|NCT02270242|DRUG|Placebo|
57952201|NCT02270242|DRUG|ticagrelor|
57952202|NCT03024489|DRUG|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
57952203|NCT03024489|DRUG|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
57952204|NCT03024489|DRUG|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
57952205|NCT03024489|DRUG|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
57952206|NCT03024489|DRUG|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
57952207|NCT03024489|RADIATION|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
57952208|NCT02616289|OTHER|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
57952209|NCT04165707|DEVICE|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
57952210|NCT04165707|OTHER|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
58098577|NCT04215653|DRUG|Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
58098578|NCT00792675|OTHER|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
58098579|NCT04960774|OTHER|Observational study, no intervention|Observational study, no intervention
58098580|NCT00607906|DRUG|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
58098581|NCT00607906|DRUG|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
58426164|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
57952211|NCT06279767|DRUG|6-mercaptopurine|6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
57952212|NCT05388461|OTHER|electroconvulsive therapy|electroconvulsive therapy
58098582|NCT00607906|DRUG|Placebo|Subjects will also receive placebo capsules.
58098583|NCT04698278|DEVICE|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
58426165|NCT01032824|OTHER|Book Arm|Book only.
58098584|NCT01741428|BEHAVIORAL|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
58098585|NCT04863326|BEHAVIORAL|Making Proud Choices|
58098586|NCT04863326|BEHAVIORAL|Business as usual|
58098587|NCT06476743|OTHER|Sensory Integration Therapy|This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
58098588|NCT06476743|OTHER|Balance Board Training|This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
58098589|NCT02260752|PROCEDURE|hysterectomy|surgical removal of the uterus
58098590|NCT02260752|PROCEDURE|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
58098591|NCT02260752|PROCEDURE|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
58098592|NCT02260752|DRUG|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
58098593|NCT02260752|PROCEDURE|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
58098594|NCT02260752|PROCEDURE|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
58098595|NCT02260752|PROCEDURE|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
58098596|NCT02985567|OTHER|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
58098597|NCT02034994|BEHAVIORAL|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
58098598|NCT06301477|OTHER|Resistant Starch|7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption
58098599|NCT06301477|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
58098600|NCT05959707|BIOLOGICAL|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
58098601|NCT05959707|BIOLOGICAL|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
58098602|NCT05959707|BIOLOGICAL|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
58098603|NCT04252690|DEVICE|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
58098604|NCT00999245|OTHER|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
58098605|NCT00999245|OTHER|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
58098606|NCT06156579|DRUG|Decitabine|Decitabine 20 mg/m\^2, i.v., once daily, 10 days
58098607|NCT06156579|DRUG|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
58098608|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
58098609|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
58098610|NCT02524665|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
58098611|NCT02524665|OTHER|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
58098612|NCT02524665|OTHER|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
58098613|NCT02524665|OTHER|Skin Perfecting Lotion|Available over the counter.
58098614|NCT03620773|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
58098615|NCT03620773|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
58098616|NCT03620773|PROCEDURE|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
58098617|NCT03620773|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
58307437|NCT02111200|DRUG|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
58307438|NCT06472739|DRUG|GM-CSF|GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase
58307439|NCT03916588|BEHAVIORAL|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
58098618|NCT04835415|PROCEDURE|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
58098619|NCT04835415|PROCEDURE|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
58426166|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
58307440|NCT04668690|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
58307441|NCT04668690|DRUG|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
58426167|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
58426168|NCT01265303|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
58426169|NCT02870088|BEHAVIORAL|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
58426170|NCT02870088|BEHAVIORAL|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
58426171|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
57952213|NCT04247633|DRUG|Palbociclib|Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
57952214|NCT04563494|DRUG|dexamethasone|Prevention of post op nausea and vomiting
57952215|NCT00658554|DRUG|ARQ 197|Treatment with ARQ 197
57952216|NCT06402864|RADIATION|contact X-ray brachytherapy (CXB)|3 fractions of contact X-ray brachytherapy (CXB) every two weeks before neoadjuvant chemo radiotherapy (nCRT).
57952217|NCT05184608|OTHER|Cycling exercise|20 minutes of cycling (90 rpm).
57952218|NCT05184608|OTHER|Cognitive tasks|20 minutes of cognitive tasks based on the different domains of the UPDRS scale.
57952219|NCT00054067|DRUG|cisplatin|
58307442|NCT03362944|BEHAVIORAL|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
58307443|NCT03362944|BEHAVIORAL|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
58426172|NCT06100874|DRUG|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
58426173|NCT06100874|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
58426174|NCT06100874|DRUG|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
58426175|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
57952220|NCT00054067|PROCEDURE|adjuvant therapy|
58098620|NCT05298215|BIOLOGICAL|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
58098621|NCT05298215|OTHER|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
58307444|NCT03082508|DEVICE|Algisyl|Algisyl device (implants) administered during a surgical procedure
57769561|NCT03327402|DRUG|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
57769562|NCT04942860|DRUG|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
57952221|NCT00054067|PROCEDURE|conventional surgery|
57952222|NCT00054067|RADIATION|brachytherapy|
57952223|NCT00054067|RADIATION|radiation therapy|
57952224|NCT00484497|DRUG|cyclamax|
57952225|NCT05193110|OTHER|Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis|Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
57952226|NCT01541475|DRUG|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
57952227|NCT01541475|DRUG|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
57952228|NCT01356407|DRUG|PICOPREP|
57952229|NCT01356407|DRUG|PEG-ELS|
57952230|NCT00770614|DRUG|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
57952231|NCT00770614|DRUG|Isotonic saline|0.9% sodium chloride
57952232|NCT00770614|DRUG|Placebo|Placebo
57952233|NCT03343496|PROCEDURE|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I\~II, aged 18\~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
57952234|NCT04326335|OTHER|Felt-tip marking|Marking the location of the future stoma with a felt pen
57952235|NCT04326335|OTHER|Felt-tip marking + 3D printed ostomy button|Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
57952236|NCT05593250|DRUG|SHR-1905|subcutaneous
57952237|NCT05593250|DRUG|placebo|subcutaneous ,placebo
57952238|NCT06220539|OTHER|Casting and supervised rehabilitation|casting (8 weeks) followed by supervised rehabilitation
57952239|NCT03134872|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
57952240|NCT03134872|DRUG|Carboplatin|Carboplatin
57952241|NCT03134872|DRUG|Pemetrexed|Pemetrexed
57952242|NCT01131377|DRUG|acetazolamide|"If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
57952243|NCT01131377|DRUG|Saline|They will receive saline 50ml via IV q 24h.
57952244|NCT02588976|DEVICE|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
57952245|NCT01050270|DRUG|Ondansetron|4mgs iv bolus
57952246|NCT01050270|DRUG|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
57952247|NCT01050270|DRUG|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
57952248|NCT00750633|DRUG|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
57952249|NCT00750633|DRUG|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
57952250|NCT00750633|DRUG|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
57952251|NCT00750633|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
57952252|NCT04225923|DRUG|NPC-21 Low dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
57952253|NCT04225923|DRUG|NPC-21 High dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
57952254|NCT04225923|DRUG|NPC-21 Placebo|Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
57952255|NCT04502485|PROCEDURE|Gastric water exchange|Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
57952256|NCT04502485|PROCEDURE|traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
57952257|NCT00312988|DRUG|Hycamtin|
57952258|NCT00312988|DRUG|Gemcitabine|
57952259|NCT02051543|BEHAVIORAL|Brief Behavioral Treatment of Insomnia -Military Version|
57952260|NCT02291120|PROCEDURE|Pulpotomy|
57952261|NCT00404014|DRUG|AL-208|1 dose of 300 mg
57952262|NCT00404014|DRUG|Placebo|1 dose of placebo
57952263|NCT02681237|DRUG|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
57952264|NCT02681237|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
58098622|NCT02797626|PROCEDURE|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
58098623|NCT05216328|DRUG|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
58098624|NCT05216328|DRUG|Magnesium hydroxide 724mg|Information already included in arm/group description.
58098625|NCT02656615|DRUG|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
58098626|NCT01695837|BEHAVIORAL|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
58098627|NCT02357173|OTHER|electronic cigarette|
58098628|NCT02357173|OTHER|cigarette group|
58426176|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
58426177|NCT04421209|DRUG|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
57952265|NCT00790907|DRUG|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
57952266|NCT00790907|DRUG|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
57952267|NCT00790907|DRUG|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
58098629|NCT03343145|BIOLOGICAL|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
58098630|NCT03343145|BIOLOGICAL|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
58098631|NCT06539780|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
58307445|NCT03082508|DRUG|Standard Medical Therapy|as per protocol
58307446|NCT05333497|DEVICE|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
58426178|NCT04421209|DRUG|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
58098632|NCT01325896|DRUG|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
58098633|NCT04752085|DIAGNOSTIC_TEST|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
58098634|NCT00103415|BEHAVIORAL|Endurance training|
58098635|NCT00103415|BEHAVIORAL|Weight-lifting training|
58098636|NCT05130086|DRUG|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
58426179|NCT00012168|DRUG|isosulfan blue|
58426180|NCT00012168|GENETIC|polymerase chain reaction|
58426181|NCT00012168|OTHER|immunohistochemistry staining method|
58426182|NCT00012168|PROCEDURE|lymphangiography|
58426183|NCT00012168|PROCEDURE|radionuclide imaging|
58426184|NCT00012168|PROCEDURE|sentinel lymph node biopsy|
58426185|NCT00012168|RADIATION|technetium Tc 99m sulfur colloid|
58426186|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
58426187|NCT00205816|DRUG|Tigecycline|
58426188|NCT05808517|BEHAVIORAL|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
58426189|NCT05808517|OTHER|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
58426190|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
58426191|NCT03053869|DRUG|Benzodiazepine - limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
57769563|NCT04942860|DRUG|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
57952268|NCT06118684|DRUG|EP395 (Part A and B)|"EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg."
57952269|NCT06118684|DRUG|Verapamil (Part A)|Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
57952270|NCT06118684|DRUG|Midazolam (Part B)|Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
57952271|NCT06118684|DRUG|Digoxin (Part B)|Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
57952272|NCT01081249|DRUG|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
57952273|NCT01081249|DRUG|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
57952274|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
57952275|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
57952276|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
57952277|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
57952278|NCT03488875|BEHAVIORAL|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
57952279|NCT03953066|OTHER|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
57952280|NCT02488369|DEVICE|PET / CT|
57952281|NCT00689468|PROCEDURE|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
58426192|NCT03053869|DRUG|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
58098637|NCT01493063|OTHER|Physiopathology|Samples of breastmilk and infant serum and questionnaires.
58098638|NCT03564509|DRUG|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
58098639|NCT03564509|DRUG|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
58098640|NCT03564509|DRUG|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
58098641|NCT03564509|DRUG|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
58098642|NCT03564509|DRUG|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
58098643|NCT03564509|OTHER|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
58098644|NCT01153022|OTHER|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
58098645|NCT00629668|GENETIC|TNF-alpha and HBV genotype|
57736283|NCT04302350|PROCEDURE|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
57952282|NCT00689468|DIETARY_SUPPLEMENT|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
57952283|NCT00689468|PROCEDURE|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
57952284|NCT00689468|DIETARY_SUPPLEMENT|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
58098646|NCT00629668|OTHER|TNF-alpha and HBV genotypes|
58098647|NCT01817335|PROCEDURE|psychosocial assessment and care|Participate in psycho-educational program
58098648|NCT01817335|OTHER|educational intervention|Participate in psycho-educational program
58098649|NCT01817335|OTHER|communication skills training|Participate in psycho-educational program
58307447|NCT05333497|DEVICE|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
58307448|NCT00869414|DRUG|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
58307449|NCT00869414|DRUG|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
58307450|NCT00869414|DRUG|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
58307451|NCT00634517|DRUG|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
57736284|NCT01673932|BIOLOGICAL|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
57736285|NCT01673932|PROCEDURE|surgery|
58098650|NCT01817335|OTHER|questionnaire administration|Ancillary studies
58307452|NCT00634517|DRUG|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
58307453|NCT02528474|DEVICE|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
58307454|NCT02528474|DEVICE|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
58307455|NCT03194334|BEHAVIORAL|Vegetarian diet|
58307456|NCT03194334|DIETARY_SUPPLEMENT|creatine|1g creatine/day
58307457|NCT03194334|DIETARY_SUPPLEMENT|Placebo|pills
58307458|NCT03194334|DIETARY_SUPPLEMENT|Beta-alanine|0.8g beta-alanine per day
58307459|NCT00569985|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
58098651|NCT05106998|DEVICE|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
58098652|NCT04959279|OTHER|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
58098653|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
58098654|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
58098655|NCT05503914|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
58098656|NCT01052038|DRUG|Placebo administration|Placebo administration
58098657|NCT01052038|DRUG|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
58098658|NCT01052038|DRUG|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
58098659|NCT04815408|DRUG|BGB-A317|PD-1 antibody，Tislelizumab (BGB-A317)
58098660|NCT04815408|DRUG|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
58426193|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
57736286|NCT05780203|BEHAVIORAL|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
58098661|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
57736287|NCT05780203|BEHAVIORAL|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
57736288|NCT05780203|BEHAVIORAL|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
58098662|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
58098663|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
58098664|NCT01257529|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
58098665|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
58426194|NCT00258466|RADIATION|radiation therapy|
57952285|NCT04876014|OTHER|Guided Mobile-Based Perinatal Mindfulness Intervention|GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.
57952286|NCT01660360|BIOLOGICAL|Tanibirumab|
57952287|NCT00893724|DRUG|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
57952288|NCT00893724|DIETARY_SUPPLEMENT|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
58098666|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo MR DENSE imaging
58098667|NCT00875537|OTHER|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
58098668|NCT00875537|OTHER|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
58098669|NCT03901222|DEVICE|tDCS|20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
58098670|NCT02298595|DRUG|cisplatin|75 mg/m2 IV day 1 of each cycle
58098671|NCT02298595|DRUG|Cetuximab|XXXX day 1, 8, and 15 of each cycle
58098672|NCT02298595|DRUG|BYL719|200, 250, 300, or 350 mg/day by mouth every day
58307460|NCT00569985|DRUG|carmustine|Given IV
58426195|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
57736289|NCT00071669|PROCEDURE|Acupuncture|
57736290|NCT05186623|DRUG|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
57736291|NCT00492284|DRUG|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
58307461|NCT00569985|DRUG|cyclophosphamide|Given IV
58307462|NCT00569985|DRUG|etoposide|Given IV
57736292|NCT00492284|DRUG|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
57736293|NCT00492284|DRUG|ranibizumab|0.5 mg intravitreal injection
58426196|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
58426197|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
58426198|NCT05714137|BEHAVIORAL|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
57736294|NCT00492284|DRUG|dexamethasone|0.5 mg intravitreal injection
57736295|NCT05638867|DRUG|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
57736296|NCT05638867|DRUG|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
57736297|NCT01275625|DRUG|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
57736298|NCT03346876|PROCEDURE|Nuss surgery|surgical correction for pectus excacatum
57736299|NCT02062632|DRUG|Doxepin Hydrochloride|Given orally
57736300|NCT02062632|OTHER|Placebo|Given orally
57736301|NCT02062632|OTHER|Quality-of-Life Assessment|Ancillary studies
57736302|NCT02062632|OTHER|Questionnaire Administration|Ancillary studies
57952289|NCT00893724|DRUG|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
58307463|NCT00569985|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
58307464|NCT00049231|DRUG|EF5|
58307465|NCT00049231|OTHER|immunohistochemistry staining method|
58307466|NCT00049231|PROCEDURE|biopsy|
58307467|NCT04844463|DRUG|JNJ-68179280|JNJ-68179280 will be administered as an oral capsule.
58426199|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
58426200|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
58426201|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
58426202|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
58426203|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
57736303|NCT00639717|PROCEDURE|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
57736304|NCT00639717|DRUG|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
57736305|NCT00639717|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
57736306|NCT00639717|DRUG|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
57736307|NCT00639717|DRUG|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
57736308|NCT05880095|OTHER|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
58307468|NCT04844463|OTHER|Placebo|Matching placebo will be administered as an oral capsule.
58307469|NCT00345085|DEVICE|Wavefront and Contrast Sensitivity|
58307470|NCT05802888|DRUG|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
58307471|NCT05802888|DRUG|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
58307472|NCT04041817|OTHER|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
58307473|NCT03326440|OTHER|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
58307474|NCT00207168|BEHAVIORAL|Compliance|
58307475|NCT02911454|OTHER|Infant formula|
58307476|NCT02022358|DRUG|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
58307477|NCT02022358|DRUG|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
58307478|NCT02022358|DRUG|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
58426204|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
57736309|NCT05880095|OTHER|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
57736310|NCT05880095|OTHER|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
57736311|NCT02943603|DRUG|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
57736312|NCT04542343|BEHAVIORAL|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
57736313|NCT03212105|BEHAVIORAL|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
57736314|NCT03212105|OTHER|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
57769564|NCT00742820|DRUG|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
57952290|NCT04784182|DIETARY_SUPPLEMENT|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
57952291|NCT04784182|DIETARY_SUPPLEMENT|placebo|Daily consumption of visually similar placebo pills
57952292|NCT01674101|OTHER|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
57952293|NCT01674101|OTHER|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
57952294|NCT01674101|OTHER|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
57952295|NCT01674101|OTHER|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
57952296|NCT03374189|DEVICE|EZ close|EZ close used.
57952297|NCT03374189|DEVICE|Carter Thomason|Carter Thomason used.
57952298|NCT02343159|DRUG|dimethyl fumarate|120 mg and 240 mg delayed release capsules
57952299|NCT02343159|DEVICE|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
57952300|NCT02343159|BEHAVIORAL|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
57952301|NCT02258451|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
57952302|NCT02258451|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
57952303|NCT02258451|DRUG|Exemestane|One 25 mg tablet once daily after a meal.
57952304|NCT02258451|DRUG|Everolimus|"The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice."
57952305|NCT05580133|PROCEDURE|anterior cruciate ligament reconstruction|Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
57952306|NCT00864643|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
57952307|NCT00864643|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
58307479|NCT04147156|PROCEDURE|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
58426205|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
58426206|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
58426207|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
58426208|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
58426209|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility...) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
58426210|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
57736315|NCT00857324|DRUG|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
57736316|NCT06120764|OTHER|guided imagery|The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts. The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing. Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop. Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients. Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery. If there is an object, person, event, situation, or food that will make them feel good,
58098673|NCT06537206|OTHER|Application Footbath|The foot bath application for the experimental group will be applied with water at 38-40 degrees Celsius for an average of 10 minutes under thermometer control. Immediately afterward, the second physiological parameters will be measured.
58098674|NCT00164086|DRUG|atorvastatin|
57952308|NCT02989558|DRUG|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
57952309|NCT02989558|DRUG|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
57952310|NCT02639000|PROCEDURE|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
58307480|NCT04147156|PROCEDURE|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
58307481|NCT04147156|PROCEDURE|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
58307482|NCT02081989|PROCEDURE|Renal denervation|Renal denervation
57952311|NCT01441830|DEVICE|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
58098675|NCT06522607|DEVICE|rapid palatal expander|Clinical evaluation of the patients who will be treated with rapid palatal expander for about 6 month.
58098676|NCT00306852|PROCEDURE|Baerveldt implant|Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
58098677|NCT00306852|PROCEDURE|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
58307483|NCT03779269|OTHER|meditation|meditation effect assessment using assessment tools.
58307484|NCT05931263|DRUG|C-BEAM Regimen|Chidemide，carmustine, etoposide, cytarabine, and melphalan
58307485|NCT05931263|DRUG|BEAM Regimen|carmustine, etoposide, cytarabine, and melphalan
58307486|NCT05579639|OTHER|Xylitol|Xylitol wipes
58307487|NCT05579639|OTHER|Placebo|Placebo wipes
57952312|NCT01892358|BEHAVIORAL|SKIN Intervention|
58307488|NCT00463736|DRUG|Magnesium sulfate|
58307489|NCT04074811|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.
58307490|NCT02804217|OTHER|Genetic: mutation profile|
58307491|NCT02774317|BIOLOGICAL|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
58098678|NCT01669278|DEVICE|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
58426211|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
58426212|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
58426213|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
58426214|NCT03370562|DRUG|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
58426215|NCT03370562|DRUG|Placebo|Administration of normal saline
58426216|NCT05098509|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
58426217|NCT05098509|DRUG|Placebo|Matching Placebo for RAD011
58426218|NCT04394650|BIOLOGICAL|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
58426219|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
58426220|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
58426221|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
58426222|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
58426223|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
58098679|NCT00944008|DRUG|DepoCyte|
58098680|NCT05812924|BIOLOGICAL|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
58426224|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
58426225|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
58426226|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
58426227|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
58098681|NCT03454672|DEVICE|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
58098682|NCT03454672|DEVICE|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
58098683|NCT00379925|BEHAVIORAL|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
58098684|NCT04745325|BEHAVIORAL|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
58098685|NCT03726086|DIAGNOSTIC_TEST|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
58426228|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
58426229|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
58426230|NCT06285123|BEHAVIORAL|Facillitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
58426231|NCT05653817|DRUG|Carrilizumab|Carrilizumab 200mg Q3W d1
58426232|NCT05653817|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
58426233|NCT05653817|DRUG|Apatinib|Apatinib mesylate tablets for treatment: 250mg
58426234|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
57952313|NCT01892358|OTHER|Treatment as Usual|
58098686|NCT04253756|DEVICE|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
58098687|NCT05831267|OTHER|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
58426235|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
58426236|NCT01477112|DIETARY_SUPPLEMENT|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
58426237|NCT01477112|DIETARY_SUPPLEMENT|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
58098688|NCT05831267|OTHER|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
58307492|NCT01503554|BEHAVIORAL|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
58307493|NCT01503554|BEHAVIORAL|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
58307494|NCT02776293|BEHAVIORAL|Relaxation|
58098689|NCT05831267|OTHER|Negative control|this group will not receive any material.
58098690|NCT06036537|DIAGNOSTIC_TEST|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
58098691|NCT06039878|BEHAVIORAL|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
58098692|NCT06039878|BEHAVIORAL|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
58426238|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
58426239|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
58426240|NCT00054028|DRUG|suramin|Given IV
58426241|NCT00054028|DRUG|paclitaxel|Given IV
58426242|NCT00054028|OTHER|pharmacological study|Correlative studies
58426243|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
58098693|NCT06039878|BEHAVIORAL|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
58307495|NCT02776293|BEHAVIORAL|Music|
58307496|NCT01714115|DRUG|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
58307497|NCT02787980|BIOLOGICAL|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
58307498|NCT02360046|DRUG|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
58307499|NCT02360046|DRUG|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
58307500|NCT00167700|BEHAVIORAL|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
57736317|NCT02065531|OTHER|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
57736318|NCT02065531|OTHER|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
57736319|NCT04169737|DRUG|Acalabrutinib|Given PO
58307501|NCT00167700|BEHAVIORAL|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
58307502|NCT00167700|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
58307503|NCT00167700|DIETARY_SUPPLEMENT|Probiotics|
58307504|NCT00167700|DIETARY_SUPPLEMENT|Prebiotics|
58307505|NCT01898403|DRUG|Indocyanine green solution|Administered peri-tumoral and intradermally
58307506|NCT01898403|DRUG|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
58307507|NCT01898403|DIAGNOSTIC_TEST|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
58307508|NCT04584814|DEVICE|No intervention|Basal analysis
58307509|NCT04584814|DEVICE|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
58307510|NCT04584814|DEVICE|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
58307511|NCT01911247|DRUG|Metformin|Metformin 850 mg once daily
58307512|NCT02959801|PROCEDURE|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
58307513|NCT01819675|DEVICE|Low frequency rTMS|
58307514|NCT01819675|DEVICE|High frequency rTMS|
57736320|NCT04169737|BIOLOGICAL|Obinutuzumab|Given IV
57736321|NCT04169737|DRUG|Venetoclax|Given PO
57736322|NCT03710915|DRUG|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
58307515|NCT01819675|DEVICE|Sham rTMS|
58307516|NCT00093483|BIOLOGICAL|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
58307517|NCT00093483|DRUG|arsenic trioxide|IV over 1 hour on day 1
58307518|NCT00093483|DRUG|cytarabine|IV over 1 hour every 12 hours on days 1-6
58307519|NCT00093483|DRUG|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
58307520|NCT06200532|OTHER|FOOTSAK (FOOTwear self-assessment kit)|FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
58307521|NCT02861313|DEVICE|CM LOC attachment|CM LOC attachment
58307522|NCT02861313|DEVICE|ball attachment|Ball attachment
58307523|NCT05498389|DRUG|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
58307524|NCT05498389|DRUG|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
58307525|NCT06101238|DIETARY_SUPPLEMENT|supplementation with low dose elemental iron|65mg daily
58307526|NCT03795506|DEVICE|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
58307527|NCT03795506|DEVICE|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
57736323|NCT05281380|DIETARY_SUPPLEMENT|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
57736324|NCT03397264|BIOLOGICAL|Aflibercept|Intravitreal injection
57736325|NCT03397264|BIOLOGICAL|OPT-302|Intravitreal Injection
57736326|NCT03397264|OTHER|Sham intravitreal injection|Sham (mock) intravitreal injection
58307528|NCT03766035|DEVICE|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
58307529|NCT03384199|RADIATION|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
58307530|NCT01896063|PROCEDURE|Electroacupuncture|
58307531|NCT03670992|PROCEDURE|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
58307532|NCT03711890|PROCEDURE|Optical Coherence Tomography|Undergo OCT
58307533|NCT03711890|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection will be undertaken
58307534|NCT03711890|DIAGNOSTIC_TEST|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
58307535|NCT05233735|OTHER|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
58426244|NCT03590951|OTHER|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
58426245|NCT03271905|DRUG|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
58426246|NCT03271905|DEVICE|Mesh nebulization|Nebulization with Mesh device.
58426247|NCT01909765|OTHER|Dorsal slit|Skin and mucosa incision made together
58426248|NCT01909765|OTHER|Double incision|Skin and mucosa incision made separately
58426249|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
58426250|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
58426251|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
57736327|NCT02125526|DEVICE|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
58307536|NCT05233735|OTHER|Topical treatment|betamethasone ointment treatment once per day
57736328|NCT03122418|BEHAVIORAL|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
57736329|NCT03453398|OTHER|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
58307537|NCT02687802|OTHER|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
58307538|NCT03962400|PROCEDURE|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
58307539|NCT03962400|PROCEDURE|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
58307540|NCT04539275|DRUG|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
58307541|NCT04539275|OTHER|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
58307542|NCT03445026|DIAGNOSTIC_TEST|dental panorama|radiographic examination
58307543|NCT04182919|DRUG|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
58307544|NCT04182919|DRUG|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
58307545|NCT05239572|COMBINATION_PRODUCT|screening, prevention and counselling|Screening in Intergenerational solidarity clubs in Myanmar and Vietnam and in Posbindu programme in Indonesia
58307546|NCT06026436|BIOLOGICAL|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
58426252|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
58426253|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
58426254|NCT04382417|OTHER|Observational study|Not required
58426255|NCT00002517|DRUG|cytarabine|
58426256|NCT00002517|DRUG|daunorubicin hydrochloride|
57736330|NCT04383496|BEHAVIORAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
57736331|NCT05557942|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
57736332|NCT01815164|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
58307547|NCT06026436|BIOLOGICAL|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
58307548|NCT00051701|DRUG|alemtuzumab|
58307549|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
58307550|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
58307551|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
58307552|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
58307553|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
58426257|NCT00002517|DRUG|dexamethasone|
58426258|NCT00002517|DRUG|etoposide|
57736333|NCT01815164|BEHAVIORAL|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
57736334|NCT02148250|DRUG|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
57736335|NCT02148250|DRUG|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
57769565|NCT00742820|DRUG|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
58426259|NCT00002517|DRUG|idarubicin|
58426260|NCT00002517|DRUG|mitoxantrone hydrochloride|
58426261|NCT00002517|DRUG|thioguanine|
58426262|NCT00002517|PROCEDURE|allogeneic bone marrow transplantation|
58426263|NCT00002517|RADIATION|radiation therapy|
58426264|NCT00172042|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
58426265|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
58426266|NCT04919837|OTHER|Low vision aids|the assisting devices fitting for low-vision patients
58426267|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
58426268|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
58426269|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
58426270|NCT01612208|DEVICE|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
58098694|NCT06039878|BEHAVIORAL|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
57736336|NCT05440526|PROCEDURE|Herbst Group|"Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
58098695|NCT06039878|BEHAVIORAL|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
58098696|NCT06039878|BEHAVIORAL|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
58098697|NCT04926740|OTHER|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
57736337|NCT05440526|DEVICE|TFBC Group|"TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
57736338|NCT01327326|DRUG|Naltrexone|Oral, 50 mg, 1 Time Dose
58426271|NCT01612208|DEVICE|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
58426272|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
58426273|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
58426274|NCT00440830|DRUG|placebo|placebo patch applied to smokers
58426275|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
58426276|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
58426277|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
58426278|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
58426279|NCT03239015|DRUG|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
58426280|NCT03239015|DRUG|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
57736339|NCT01327326|DRUG|Placebo|Oral, 1 Time Dose
57736340|NCT00887497|PROCEDURE|Angioembolization|Angioembolization
57736341|NCT06670937|OTHER|Induced sputum|Patients will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution
57736342|NCT06670937|OTHER|Blood sample|Patients will provide 2) a blood sample.
57736343|NCT05136573|BEHAVIORAL|Combined Exercises|Combined Exercises
58098698|NCT00002628|BIOLOGICAL|filgrastim|
58098699|NCT00002628|DRUG|carboplatin|
58098700|NCT00002628|DRUG|cyclophosphamide|
58098701|NCT00002628|DRUG|mesna|
58098702|NCT00002628|DRUG|paclitaxel|
58098703|NCT00002628|PROCEDURE|peripheral blood stem cell transplantation|
58426281|NCT03239015|DRUG|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
58426282|NCT03239015|DRUG|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
58426283|NCT03239015|DRUG|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
58426284|NCT03239015|DRUG|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
58426285|NCT03239015|DRUG|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
58426286|NCT03239015|DRUG|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
57736344|NCT03353935|OTHER|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
57736345|NCT01334801|PROCEDURE|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~1. BNP (Brain Natriuretic Peptide)~2. (PFA) Platelet Function Analyzer 100~3. von Willebrand Factor (vWF) antigen~4. (vWF) multimers~5. (vWF) \*activity by latex aggregation~6. Plasma stored for development of new testing approaches"
57736346|NCT04024618|PROCEDURE|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
57736347|NCT00228020|DRUG|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
57736348|NCT00228020|DRUG|MMF, cyclosporine, steroids|
57736349|NCT06196268|OTHER|core strengthening exercise|CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge
58098704|NCT04264988|PROCEDURE|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
58098705|NCT01479556|DRUG|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
58426287|NCT03239015|DRUG|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
58426288|NCT03239015|DRUG|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
58426289|NCT03239015|DRUG|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
58426290|NCT03239015|DRUG|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
58426291|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
58098706|NCT01479556|DRUG|Placebo|150mg BID p.o.
58426292|NCT00072774|DRUG|DVS-233 SR|
58426293|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
58426294|NCT00659503|DRUG|Placebo|placebo
58098707|NCT06114017|BEHAVIORAL|Social Media Abstention|People will stop or reduce their social media use for one week.
58098708|NCT00904189|RADIATION|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
58098709|NCT02955394|DRUG|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
58098710|NCT02955394|DRUG|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
58098711|NCT06155825|BEHAVIORAL|no intervention|Group 4 will receive no intervention
58426295|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
58426296|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
58426297|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
58426298|NCT04212689|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
58426299|NCT04212689|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
58426300|NCT01943006|DRUG|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
58098712|NCT06155825|DRUG|nonnutritive suckling|Group 1 will receive nonnutritive suckling
58098713|NCT06155825|DRUG|oral glucose 25%|Group 2 will receive oral glucose 25%
58098714|NCT06155825|BEHAVIORAL|facilitated tuckling|Group 3 will undergo facilitated tuckling
58426301|NCT01943006|DRUG|Placebo cream without active substance|
58426302|NCT02939768|OTHER|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
58426303|NCT02939768|OTHER|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
58426304|NCT02939768|OTHER|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
58426305|NCT00447122|DRUG|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
58426306|NCT00447122|DRUG|Lapatinib 1000mg/d|1000mg/d
58426307|NCT00447122|DRUG|Lapatinib 1500mg/d|1500mg/d
58098715|NCT03717974|OTHER|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
58098716|NCT03717974|OTHER|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
58307554|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
58307555|NCT02951312|DRUG|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
58307556|NCT02917746|DRUG|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
58307557|NCT02917746|PROCEDURE|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
58307558|NCT00921323|BEHAVIORAL|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
58307559|NCT00921323|BEHAVIORAL|Control|The control group will be advised to continue to be physically active and record daily steps
58307560|NCT02554396|DRUG|PRX-100|ophthalmic solution
58307561|NCT02554396|DRUG|Placebo|saline ophthalmic solution
58307562|NCT01075048|DRUG|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
58307563|NCT01075048|DRUG|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
58307564|NCT01075048|DRUG|Cetuximab|Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
58307565|NCT01075048|DRUG|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
58307566|NCT00394641|BEHAVIORAL|listening to music / stories via stereophonic headphones|
58307567|NCT04919317|DRUG|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
58307568|NCT04919317|DRUG|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
58307569|NCT01531426|DEVICE|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
58098717|NCT05886283|PROCEDURE|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
58098718|NCT05886283|PROCEDURE|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
58098719|NCT05886283|PROCEDURE|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
58098720|NCT04219800|BEHAVIORAL|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
58098721|NCT04219800|BEHAVIORAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
58098722|NCT00530439|OTHER|Lifestyle intervention|Dietician counselling and physical training
58098723|NCT00530439|OTHER|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
58098724|NCT00530439|BEHAVIORAL|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
57736350|NCT06196268|OTHER|Pilates exercise|Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
58098725|NCT00869141|DRUG|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
58098726|NCT06296459|OTHER|3D R100 scanner|A cone beam computed tomography used for planning of implant surgery
58098727|NCT06296459|OTHER|Conventional Radiograph|Imaging used as standard of care to plan for implant surgery
58307570|NCT06174285|OTHER|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
58307571|NCT06174285|OTHER|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
58307572|NCT02953730|DRUG|PEG-rhG-CSF|
58307573|NCT03531749|DIETARY_SUPPLEMENT|HIV+ MRPJ|supplemented with (1g/d) MRPJ
58307574|NCT03531749|DIETARY_SUPPLEMENT|HIV+ ascorbic acid|Supplemented with (1g/d) AA
58307575|NCT04006145|DRUG|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
58307576|NCT04006145|DRUG|Placebo oral tablet|Placebo identical in appearance to active drug
58307577|NCT00580320|DRUG|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
58307578|NCT05544097|OTHER|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
58307579|NCT00132626|DRUG|[123I]ß-CIT and SPECT imaging|
58426308|NCT00447122|DRUG|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
58426309|NCT00447122|DRUG|Oxaliplatin 100mg/m2|100mg/m2
57736351|NCT06378346|DRUG|Glycyrrhizin|75mg orally daily
57736352|NCT06378346|OTHER|Glycyrrhizin|150mg orally daily
57736353|NCT06378346|OTHER|Observation|Participants will not receive any Glycyrrhizin
57952314|NCT02175732|BEHAVIORAL|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
57952315|NCT02175732|BEHAVIORAL|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
57952316|NCT04496401|DRUG|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
58098728|NCT02681627|OTHER|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
58307580|NCT06120608|BEHAVIORAL|Novel dietary approach focused on restricting the intake of highly bioavailable potassium|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
58307581|NCT06120608|BEHAVIORAL|Traditional approach|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
57952317|NCT01973777|DEVICE|IUB|intrauterine contraceptive device
57952318|NCT00543426|DRUG|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
57952319|NCT00543426|DRUG|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
57952320|NCT01588795|PROCEDURE|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
57952321|NCT01588795|DRUG|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
57952322|NCT02070029|PROCEDURE|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
57952323|NCT05180942|DRUG|Atorvastatin Calcium 40Mg Tab|One tablet daily
57952324|NCT05938192|PROCEDURE|LASER surgery|Patients will have laser surgery for managing HPV-related lesions
58098729|NCT02681627|OTHER|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
58098730|NCT06200688|OTHER|PEANUT BALL|"Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring."
58307582|NCT04215367|DIETARY_SUPPLEMENT|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
58307583|NCT04215367|DIETARY_SUPPLEMENT|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
58307584|NCT03879070|DEVICE|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
58307585|NCT04237363|BEHAVIORAL|Exercise|Underwater treadmill training and supplemental overground walk training
58426310|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
58426311|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
58426312|NCT04303299|DRUG|Oral|Anti virus treatment
58426313|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
58426314|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
58426315|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
58426316|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
58426317|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
58426318|NCT03067376|DRUG|[14C]-CORT125134|
58426319|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
58426320|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
58426321|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
58426322|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
58426323|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
58307586|NCT03650153|PROCEDURE|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
58426324|NCT02073669|PROCEDURE|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
58426325|NCT03496766|DRUG|Tipifarnib|Tipifarnib 600 mg will be administered until progression
58426326|NCT03712488|DEVICE|flowcytometry|four colour flowcytometry
58426327|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
58307587|NCT03650153|PROCEDURE|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
58307588|NCT04415801|DIAGNOSTIC_TEST|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
58426328|NCT00958737|DRUG|CAPOX|4 or 8 cycles
57736354|NCT03282448|BEHAVIORAL|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
58307589|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) System|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors."
58307590|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch"
58307591|NCT00001566|BIOLOGICAL|therapeutic autologous dendritic cells|3 syringes containing 1 x 10\^6peptide pulsed dendritic cells
58426329|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
58098731|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
58098732|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
58098733|NCT00893230|DIETARY_SUPPLEMENT|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
58098734|NCT00893230|DIETARY_SUPPLEMENT|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
58098735|NCT04819282|DIAGNOSTIC_TEST|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
58098736|NCT02977494|DRUG|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
58098737|NCT02977494|DRUG|Bortezomib|
58098738|NCT02977494|DRUG|Dexamethasone|
57952325|NCT06424184|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|"The rTMS protocol implemented in this study will include approximately 10-minute long sessions of intermittent theta burst stimulation (iTBS) with at least 50 minutes in between iTBS sessions.~Study participants will receive the rTMS intervention for up to 50 sessions across a three-week period. The total of 50 sessions will be administered as up to 4 sessions each day, up to 5 days per week over an up to 3-week-long period."
57952326|NCT02060578|OTHER|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
58098739|NCT04048720|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
58098740|NCT02177773|PROCEDURE|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
58098741|NCT02177773|DRUG|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
58098742|NCT02177773|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
58098743|NCT02177773|PROCEDURE|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
58098744|NCT05351073|DRUG|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
58098745|NCT00386100|DRUG|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
58098746|NCT00386100|DRUG|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
58098747|NCT00386100|DRUG|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
58307592|NCT00001566|DRUG|indinavir sulfate|Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
58098748|NCT00386100|DRUG|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
58098749|NCT00386100|DRUG|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
57736355|NCT01427868|DRUG|LB80380 maleate salt|183 mg (150 mg as a free base)
57736356|NCT01427868|DRUG|LB80380 free base|150 mg
57736357|NCT03727633|DRUG|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
57736358|NCT06415656|DEVICE|TempTraq|TempTraq (Blue Spark Technologies, Westlake, OH) is an FDA 510K cleared wearable, wireless temperature monitoring patch designed to continuously monitor and track body temperature.
57736359|NCT06415656|DEVICE|VitalTraq|VitalTraq (Blue Spark Technologies, Westlake, OH) is an experimental and novel multi-vital sign monitoring platform that allows for interval measurements of heart rate, heart rate variability, and blood pressure.
57736360|NCT02995772|DRUG|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
58098750|NCT00386100|DRUG|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
58098751|NCT00386100|DRUG|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
58098752|NCT00386100|DRUG|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
58098753|NCT05227807|BEHAVIORAL|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
58098754|NCT05227807|BEHAVIORAL|Usual care|routine care including written mouth exercise instructions
58098755|NCT02959554|DRUG|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
57736361|NCT02995772|DRUG|Tamoxifen|Comparison of efficacy with chemotherapy
57736362|NCT02995772|PROCEDURE|SOB|Comparison of efficacy with chemotherapy
57736363|NCT02995772|DRUG|FAC|Comparison of efficacy with hormonal therapy
57736364|NCT02995772|DRUG|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
57736365|NCT02995772|DRUG|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
57736366|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
57736367|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
57736368|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
57736369|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
58307593|NCT00001566|PROCEDURE|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
58307594|NCT03598426|DRUG|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
58307595|NCT02905162|OTHER|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
57736370|NCT02232893|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
57736371|NCT02232893|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
58098756|NCT02959554|DRUG|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
58307596|NCT04460053|PROCEDURE|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
58307597|NCT01925443|OTHER|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
58307598|NCT00190268|DRUG|3,4-diaminopyridine|3,4-diaminopyridine
58307599|NCT05370170|BEHAVIORAL|Acupressure and nutritional advices|Teaching using booklets and application of acupressure
58426330|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
58426331|NCT02517372|DRUG|CRD007|
57736372|NCT04537923|DRUG|Tirzepatide|Administered SC
57952327|NCT05913661|DRUG|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
57952328|NCT05913661|DRUG|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
57952329|NCT00890032|BIOLOGICAL|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
57952330|NCT03150771|DRUG|Aripiprazole|Injection
58426332|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
58426333|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
58426334|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
58426335|NCT01471210|DRUG|Urelumab (BMS-663513)|
58426336|NCT00485966|DRUG|CX-3543|360 mg/m2 daily x 5 q 21 days
58426337|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
58426338|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
58426339|NCT02830620|OTHER|Dosage of chimiokines|
57952331|NCT05075811|DRUG|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
57952332|NCT05075811|OTHER|Placebo|Normal Saline
57736373|NCT04537923|DRUG|Insulin Lispro (U100)|Administered SC
57736374|NCT05921968|DRUG|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
57952333|NCT06090734|OTHER|My Voice|The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
57736375|NCT05921968|DRUG|Lactoferrin|100 mg twice daily orally before breakfast and dinner
57736376|NCT06158750|DEVICE|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
57736377|NCT01865370|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
58426340|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
57736378|NCT01865370|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
57736379|NCT03989947|DRUG|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
57736380|NCT04323618|DEVICE|Breathe Well|
57736381|NCT00428350|DRUG|Quetiapine Fumarate (Seroquel)|
57736382|NCT05772546|DRUG|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
57736383|NCT05772546|DRUG|Matching Placebo|Lactose monohydrate, tablet taken orally.
58098757|NCT02959554|DRUG|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
58098758|NCT06528067|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
58426341|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
58426342|NCT00016549|BIOLOGICAL|Bevacizumab|
58098759|NCT06528067|BEHAVIORAL|Mindful Motivation|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
58426343|NCT04787991|DRUG|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
58426344|NCT04787991|DRUG|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
58098760|NCT05052320|DEVICE|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
58426345|NCT04787991|DRUG|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
57952334|NCT03253588|PROCEDURE|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
58098761|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
58098762|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
58426346|NCT04787991|DRUG|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
58426347|NCT04787991|DRUG|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
58426348|NCT04787991|DRUG|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
58426349|NCT00438594|BEHAVIORAL|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
58426350|NCT03189836|BIOLOGICAL|ACTR707|autologous T cell product
58426351|NCT03189836|BIOLOGICAL|rituximab|CD20-directed cytolytic antibody
58426352|NCT05755659|DRUG|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
58426353|NCT02492282|DEVICE|Closed-Loop propofol and remifentanil system by Bispectral Index|
58426354|NCT02492282|DEVICE|Open-Loop propofol and remifentanil by Target Controlled Infusion|
58426355|NCT02492282|DRUG|propofol|
58426356|NCT02895945|BIOLOGICAL|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
58426357|NCT01147848|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
58426358|NCT01147848|DRUG|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
58426359|NCT01147848|DRUG|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
58426360|NCT01147848|DRUG|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
58426361|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
58426362|NCT06254924|BEHAVIORAL|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
58426363|NCT06254924|BEHAVIORAL|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
58426364|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
58426365|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
58426366|NCT04036929|DRUG|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
58426367|NCT04036929|DRUG|Placebo oral tablet|Placebo oral tablet
58426368|NCT00826670|DRUG|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
58426369|NCT00826670|DRUG|Placebo (Decolonization)|Placebo
58426370|NCT02024126|OTHER|Exercise therapy|Exercise therapy
58426371|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
57952335|NCT05234606|DRUG|SBT6290|Escalating doses by subcutaneous (SC) injection in 21-day cycles
58098763|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
58098764|NCT05155020|BIOLOGICAL|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
58098765|NCT06401642|DRUG|Zavegepant|10 mg intranasal
58426372|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
58426373|NCT02533895|BIOLOGICAL|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
58458354|NCT04706949|DRUG|Pyrotinib combined with pemetrexed plus carboplatin|"1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min."
57952336|NCT05234606|DRUG|SBT6290|Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
58426374|NCT02533895|OTHER|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
57952337|NCT05234606|DRUG|pembrolizumab|200 mg via intravenous (IV) injection in 21-day cycles
57952338|NCT03744351|OTHER|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
57952339|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
57952340|NCT03744351|OTHER|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
57952341|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
58426375|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
58426376|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
58426377|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
58426378|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
58426379|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
58426380|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
58426381|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
58426382|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
57952342|NCT04322773|DRUG|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
57952343|NCT04322773|DRUG|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
57952344|NCT04322773|DRUG|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
58426383|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
58426384|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
58426385|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
58426386|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
58426387|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
58426388|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
58426389|NCT03946085|DIETARY_SUPPLEMENT|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
58098766|NCT04759716|OTHER|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
58426390|NCT03946085|DIETARY_SUPPLEMENT|AREDS2|A commercially-available multivitamin soft gel formula.
58426391|NCT00075738|DRUG|cisplatin|
58426392|NCT00075738|DRUG|fluorouracil|
58426393|NCT00075738|DRUG|irinotecan hydrochloride|
58426394|NCT00075738|DRUG|leucovorin calcium|
58426395|NCT06056856|PROCEDURE|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
58426396|NCT06056856|PROCEDURE|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
58426397|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
58426398|NCT00812565|DRUG|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
58426399|NCT00812565|BIOLOGICAL|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
57736384|NCT01541228|DEVICE|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
58098767|NCT03349437|DEVICE|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
58426400|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
58426401|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
58426402|NCT04364620|DRUG|AB-16B5|AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
58426403|NCT04364620|DRUG|Docetaxel|Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
58426404|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
58426405|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
58426406|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
58098768|NCT03349437|OTHER|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
58098769|NCT03160365|PROCEDURE|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
58426407|NCT03623009|BEHAVIORAL|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
58426408|NCT03623009|BEHAVIORAL|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
58426409|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
58426410|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
58098770|NCT03203005|DRUG|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
58426411|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
57952345|NCT04322773|OTHER|Standard medical care|management as usual
58426412|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
58426413|NCT00000643|DRUG|Pyrimethamine|
58426414|NCT00000643|DRUG|Leucovorin calcium|
58426415|NCT05476523|OTHER|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
58426416|NCT00514462|DEVICE|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
58426417|NCT00028574|DRUG|gabapentin|
58426418|NCT00028574|OTHER|placebo|
58426419|NCT00667667|DEVICE|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
58426420|NCT00667667|DEVICE|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
58426421|NCT00667667|BEHAVIORAL|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
58426422|NCT00300352|DRUG|Folic Acid|
58426423|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
58426424|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
58426425|NCT03589222|DRUG|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
58426426|NCT03589222|DRUG|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
58426427|NCT03589222|DRUG|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
58426428|NCT03589222|DRUG|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
58426429|NCT03255746|BEHAVIORAL|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
58426430|NCT03255746|BEHAVIORAL|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
58426431|NCT02402283|DRUG|Metronidazole benzoate oral granules|Single oral dose of 400 mg
58426432|NCT02402283|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
58426433|NCT03793491|OTHER|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
58426434|NCT03793491|OTHER|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
58426435|NCT00908102|OTHER|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
58426436|NCT00908102|OTHER|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
58426437|NCT00908102|OTHER|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
58426438|NCT00908102|OTHER|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
58426439|NCT06334874|DRUG|Astaxanthin Oral Capsule|12 mg of astaxanthin oral capsule
58098771|NCT06449209|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
58426440|NCT06334874|DRUG|Placebo|starch placebo capsule
58426441|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
58426442|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
58426443|NCT00910169|OTHER|inpatient treatment|Hospitalisation modalities are described but are naturalistic
58426444|NCT01722656|DRUG|Aflibercept|
58426445|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
58426446|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
58426447|NCT03740568|DRUG|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
58426448|NCT03740568|DRUG|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
58426449|NCT00067782|DRUG|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
58426450|NCT00067782|DRUG|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
57736385|NCT01541228|PROCEDURE|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
58098772|NCT06449209|DRUG|BNT327 Dose Level 2 (DL2)|IV infusion
58098773|NCT06449209|DRUG|Etoposide|IV infusion
58098774|NCT06449209|DRUG|Carboplatin|IV infusion
58098775|NCT06449209|DRUG|Paclitaxel|IV infusion
58098776|NCT06449209|DRUG|Topotecan|IV infusion or oral capsules
58098777|NCT01906034|BEHAVIORAL|Exercise with supervision|
58098778|NCT01906034|BEHAVIORAL|Home-based without supervision|
58426451|NCT02348307|DRUG|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
58426452|NCT02348307|DRUG|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
58426453|NCT03887858|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
58426454|NCT03887858|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
58426455|NCT06113536|DIAGNOSTIC_TEST|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
58426456|NCT05715515|DIAGNOSTIC_TEST|Panbio™|"The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
58426457|NCT04964596|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
58426458|NCT04964596|DIAGNOSTIC_TEST|FIT test|faecal immunochemical test
58426459|NCT04964596|DIAGNOSTIC_TEST|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
58426460|NCT06145958|DRUG|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
58426461|NCT04311463|DRUG|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
58426462|NCT04311463|DRUG|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
58426463|NCT04882787|DEVICE|BTE hearing aid|Amplification
58426464|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
58426465|NCT02517320|DRUG|MT-3995 Low|
58426466|NCT02517320|DRUG|MT-3995 Middle|
58426467|NCT02517320|DRUG|MT-3995 High|
58426468|NCT02517320|DRUG|Placebo|
58426469|NCT04043078|OTHER|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
58426470|NCT02209623|BIOLOGICAL|TDAP|
58426471|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
58426472|NCT02387008|DEVICE|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
58426473|NCT02387008|DEVICE|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
57952346|NCT06162299|BIOLOGICAL|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
57952347|NCT05949905|BEHAVIORAL|Stage-matched interventions|The intervention would be using the Processes of Change that match each Stage of Change.
58426474|NCT02387008|DEVICE|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
58426475|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
58426476|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
58426477|NCT06025409|DRUG|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
58426478|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
58426479|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
57952348|NCT06494046|OTHER|Non-Interventional Study|Non-Interventional Study
57952349|NCT01970995|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
58426480|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
58426481|NCT06124794|BIOLOGICAL|PROTOXIN|Clostridium botulinum toxin type A
58426482|NCT04692142|OTHER|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
58426483|NCT00236756|DRUG|topiramate|
58426484|NCT06412913|DEVICE|MJ-Flex The New Metaizeau Nail|Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
58426485|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
58426486|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
58426487|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
58426488|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
57952350|NCT01970995|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
58426489|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
58426490|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
58426491|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
58426492|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
58426493|NCT03806608|PROCEDURE|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
58426494|NCT03806608|PROCEDURE|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
58426495|NCT02316886|DEVICE|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
58426496|NCT02316886|DRUG|Optimal Medical treatment|
58426497|NCT03034902|DEVICE|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
58426498|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
58426499|NCT02772627|DRUG|Nebicapone|Nebicapone 100 mg tablets; oral route.
58426500|NCT02772627|DRUG|Placebo|Placebo tablets; oral route.
58426501|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
58426502|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
58426503|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
58426504|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
58426505|NCT01789606|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
58458355|NCT03308344|BEHAVIORAL|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
58458356|NCT03390465|DRUG|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
58458357|NCT00657046|DRUG|Droxidopa|Capsules containing 200 mg droxidopa
58458358|NCT00657046|DRUG|Placebo|Capsules with mannitol substituted for droxidopa
58458359|NCT03442816|DEVICE|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
58458360|NCT01869738|DEVICE|MGuard Prime|
58098779|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
58098780|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
58098781|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
58426506|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
58458361|NCT01869738|DEVICE|(BMS/DES)|
58458362|NCT03025425|DEVICE|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
58458363|NCT02507765|OTHER|Laboratory Biomarker Analysis|Correlative studies
57952351|NCT01970995|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
57952352|NCT01351935|DRUG|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
57952353|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
57952354|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
57952355|NCT06474754|DIAGNOSTIC_TEST|High-sensitivity troponin, serum|A serum derived measure of myocardial injury. Threshold value of 14ng/L.
58098782|NCT00246441|DRUG|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
58098783|NCT00246441|DRUG|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
58098784|NCT02818179|RADIATION|THERMOGRAPHY IMAGING|
58426507|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
58426508|NCT06175156|PROCEDURE|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
58426509|NCT06175156|PROCEDURE|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
58426510|NCT00391612|DEVICE|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
58426511|NCT00391612|DEVICE|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
58426512|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
58426513|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
58426514|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
58426515|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
58426516|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
58426517|NCT05042102|COMBINATION_PRODUCT|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
58426518|NCT05042102|COMBINATION_PRODUCT|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
58426519|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
58426520|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
58426521|NCT05153213|PROCEDURE|Finger lengths|Vernier caliper was used to measure finger length
58426522|NCT05153213|PROCEDURE|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
58426523|NCT04877236|DEVICE|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
58426524|NCT01802307|RADIATION|Brachytherapy|
58426525|NCT04503824|DIAGNOSTIC_TEST|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
58098785|NCT00637052|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
58307600|NCT03022409|DRUG|Ceralasertib|"Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members."
58426526|NCT01059383|DRUG|VECAM 40/300|1 capsule, orally, once daily at bedtime.
58426527|NCT01059383|DRUG|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
58426528|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
58426529|NCT05875493|DRUG|JAB-21822|2 discrete single doses
58426530|NCT05875493|DRUG|JAB-21822|2 discrete single doses
58426531|NCT01843270|DEVICE|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
58426532|NCT01843270|DEVICE|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
58426533|NCT01694836|BIOLOGICAL|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
58426534|NCT05017532|BEHAVIORAL|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
58426535|NCT00547521|DRUG|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
58426536|NCT00547521|DRUG|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
58426537|NCT02219503|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
58426538|NCT02219503|DRUG|Dasabuvir|Tablet
58426539|NCT00979225|OTHER|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
58426540|NCT00979225|OTHER|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
58426541|NCT05079477|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
57952356|NCT06474754|DIAGNOSTIC_TEST|Submaximal Cardiopulmonary Exercise Testing|FDA-approved device uses breath by breath sampling during calibration and exercise challenge. Analysis is performed using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO2 and a paramagnetic sensor for O2 measurements. Automated calibration using a calibration gas mixture (15.6% O2/5% CO2) is performed at regular intervals. The Shape II calculations used to differentiate causes of exertional dyspnea are Artificial Intelligence (AI) based algorithms and measurements have been previously validated to conventional cardiopulmonary exercise testing methods. Brief smCPET is comprised of a 2-minute calibration phase, 3 minutes of graded exercise using a stair-step and a 1 minute recovery phase for a total of 6 minutes. An instant report is then generated.
58426542|NCT05079477|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
58426543|NCT02001584|DRUG|Baclofen|
58426544|NCT02001584|DRUG|Memantine|
58426545|NCT02001584|DRUG|Placebo|
58426546|NCT00961194|DRUG|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
57736386|NCT04898101|DRUG|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
58426547|NCT00048100|PROCEDURE|Apheresis|Apheresis for T-Cell collection
58426548|NCT00048100|BIOLOGICAL|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
58426549|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
58426550|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
58426551|NCT02966470|DEVICE|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
58426552|NCT03794674|OTHER|No intervention.|No intervention, since this is a validation study
58426553|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
58426554|NCT00015951|BIOLOGICAL|bevacizumab|
58426555|NCT00015951|DRUG|cytarabine|
58426556|NCT00015951|DRUG|mitoxantrone hydrochloride|
58426557|NCT02997982|DRUG|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
58426558|NCT01854268|DRUG|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
58426559|NCT00320463|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
58426560|NCT01438177|DRUG|Velcade|
58426561|NCT01438177|DRUG|Cyclophosphamide|
58426562|NCT01438177|DRUG|Chloroquine|
58458364|NCT02507765|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58458365|NCT02507765|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
58426563|NCT06583577|DEVICE|3D Ostomy simulator|The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
58426564|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
58426565|NCT05529329|PROCEDURE|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
58426566|NCT02607228|DRUG|Alobresib|Tablet administered orally once daily.
58426567|NCT02607228|DRUG|Enzalutamide|Capsules administered orally once daily.
58426568|NCT04518488|OTHER|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
58426569|NCT04518488|OTHER|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
58426570|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
58426571|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
58426572|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
58426573|NCT02189681|PROCEDURE|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
58426574|NCT02189681|PROCEDURE|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
58426575|NCT02189681|DEVICE|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
58426576|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
58426577|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
58426578|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
58426579|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
58426580|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
58426581|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
58426582|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
58426583|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
58426584|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
58426585|NCT05774847|OTHER|No intervention|No intervention
58426586|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
58426587|NCT03238118|OTHER|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
58426588|NCT03238118|OTHER|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
58458366|NCT00610402|OTHER|blood sample tear drop sample|blood sample tear drop sample
58426589|NCT03238118|OTHER|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
58098786|NCT05517863|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
58098787|NCT04526249|DEVICE|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
58098788|NCT06257186|OTHER|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
58307601|NCT03022409|DRUG|Olaparib|"Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents."
58307602|NCT06349876|PROCEDURE|laparoscopic cholecystectomy|slandered laparoscopic cholecystectomy
58307603|NCT06360861|BIOLOGICAL|Allogenic placenta derived mesenchymal stem cells|Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
58307604|NCT04400266|DRUG|Buspirone|Buspirone 15mg once daily
58426590|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
58426591|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
58426592|NCT02478528|DEVICE|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
58426593|NCT02478528|DEVICE|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
58426594|NCT02478528|OTHER|control condition|No exposure of the subject to any light sources (control condition)
58426595|NCT06524232|OTHER|Practice Facilitation (PF)|Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.
57736387|NCT04898101|DRUG|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
57736388|NCT04974164|BIOLOGICAL|Inactivated COVID-19 Vaccine|Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
58098789|NCT01831518|DEVICE|CRT Implant|
58098790|NCT01831518|DEVICE|Body Surface ECG Mapping|
58098791|NCT04604496|DRUG|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
58098792|NCT04210700|PROCEDURE|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
58098793|NCT04210700|PROCEDURE|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
58307605|NCT04400266|DRUG|Mealatonin|Melatonin 3mg once nightly
58098794|NCT01370434|DRUG|PAD combination|"* Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11"
58098795|NCT01206946|DRUG|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
58426596|NCT06524232|OTHER|Learning Collaborative (LC)|Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.
57736389|NCT00342316|PROCEDURE|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"
57736390|NCT01586143|DRUG|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
58098796|NCT01206946|OTHER|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
57736391|NCT01586143|DRUG|Placebo|
57736392|NCT06580574|DRUG|PD1/PDL1 antibody monotherapy, up to 24 weeks|non-specific, according to Drug Instructions
57952357|NCT06474754|DIAGNOSTIC_TEST|Duke Activity Status Index|a validated measure of preoperative functional capacity and will be utilized to cross-validate smCPET peak VO2. Low DASI score has been found to estimate peak oxygen uptak (VO2), predict MINS, myocardial infarction, and inducible myocardial ischemia on myocardial perfusion scintigraphy.
57952358|NCT04486950|DRUG|TAK-951|TAK-951 intravenous infusion.
57952359|NCT04486950|DRUG|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
57952360|NCT03456921|OTHER|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
58098797|NCT05335473|DRUG|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
58098798|NCT04294641|DRUG|Ibrutinib|140 mg capsules for a dose of 420 mg daily for up to 12 months.
58098799|NCT06249217|BEHAVIORAL|Good Nights Sleep Program|The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
58426597|NCT06524232|OTHER|Performance Incentives (PI)|We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
58426598|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
58307606|NCT06403657|OTHER|An enhanced model of hepatitis B testing and linkage to care|Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
58426599|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
58426600|NCT00444340|DRUG|Enbrel (Etanercept)|
58426601|NCT02516319|DRUG|ICG Dye|
58426602|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
58426603|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
58426604|NCT02654938|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
58426605|NCT02654938|DRUG|Placebo|5% infusion solution of dextrose
58426606|NCT02237261|DRUG|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
58426607|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
58426608|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
58426609|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
58426610|NCT03462381|DIETARY_SUPPLEMENT|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
58426611|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
58426612|NCT01633177|DRUG|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
58426613|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
58426614|NCT01633177|DRUG|Fish oil placebo|Fish oil placebo
58458367|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
58098800|NCT06030479|DRUG|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
58307607|NCT02605330|PROCEDURE|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
58307608|NCT02444026|BEHAVIORAL|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
58307609|NCT05869799|DIETARY_SUPPLEMENT|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
58307610|NCT05869799|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
58307611|NCT00773617|BEHAVIORAL|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
58307612|NCT00773617|BEHAVIORAL|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
58307613|NCT02857868|DRUG|ABL001|
58307614|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
58307615|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
58307616|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
58307617|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
58307618|NCT05519865|DRUG|Tucidinostat|30mg orally BIW
58307619|NCT05519865|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
58307620|NCT05508958|PROCEDURE|Anterior approach|Anterior approach
58307621|NCT05508958|PROCEDURE|Posterolateral approach|Posterolateral approach
58307622|NCT02378662|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
57736393|NCT06580574|COMBINATION_PRODUCT|Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd
58098801|NCT06030479|DRUG|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
58307623|NCT03757416|OTHER|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
57952361|NCT04027114|BEHAVIORAL|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
57952362|NCT05363475|DEVICE|ForeSite Intelligent Surface|The ForeSite IS is a continuous bedside pressure mapping system with machine learning and artificial intelligence (ML/AI). It consists of an overlay with over 1500 undetectable integrated sensors and a medical-grade bedside touchscreen monitor. The monitor displays a real-time coloured body pressure image, a turn timer, and a history of previous turns. The ML/AI software tracks 17 body locations and the patient's body position. The system has a centralized dashboard that shows the pressure injury risk and turn history, which can be transmitted to the nursing station. In addition, data is stored in an Amazon Web Services (AWS) secured cloud database, enabling access to individual reports on turn history and compliance and pressure exposure. Data is stored as both, raw pressure data files and real time event information on pressure exposure and turn data.
57952363|NCT00829907|DRUG|ORM-12741|Single dose as a capsule, oral administration
57952364|NCT01647971|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
57952365|NCT00242827|DRUG|Oral CEP-701|
57952366|NCT05413382|DIETARY_SUPPLEMENT|Biofresh® 4plus|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
57952367|NCT05413382|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
57952368|NCT04510233|DRUG|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
57952369|NCT04510233|DRUG|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
57952370|NCT04510233|OTHER|standard care|oxygen via masks or ventilators
58098802|NCT04514146|OTHER|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
58307624|NCT03720925|PROCEDURE|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
58307625|NCT05997277|DRUG|Deucravacitinib|Deucravacitinib is a stable deuterium-containing compound (where deuterium is a stable, nonradioactive isotope of hydrogen) and a potent, highly selective small molecule inhibitor of TYK2. Deucravacitinib has a unique mode of binding that provides the high selectivity over the other members of the JAK family of nonreceptor tyrosine kinases. 1 active oral tablet (6mg) in the morning and evening for 16weeks.
58307626|NCT05997277|DRUG|Placebo|Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
58307627|NCT02499588|DEVICE|Esteem Plus with ConvaTec Moldable Technology|
58307628|NCT02499588|DEVICE|Natura with ConvaTec Moldable Technology|
58307629|NCT02499588|DEVICE|Natura Accordion with ConvaTec Moldable Technology|
58307630|NCT02499588|DEVICE|Esteem synergy Plus with ConvaTec Moldable Technology|
58307631|NCT01589315|DEVICE|focal ECT|FEAST, ECT, unidirectional stimulation
57952371|NCT04677959|DRUG|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
57952372|NCT04677959|DRUG|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
57952373|NCT04677959|DRUG|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
57952374|NCT04677959|DRUG|Standard of Care Rescue Medication|Current rescue medication
57952375|NCT00214370|DRUG|Propofol-Fentanyl|
57952376|NCT00214370|DRUG|Propofol alone|
57952377|NCT00464334|BIOLOGICAL|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
57952378|NCT00464334|BIOLOGICAL|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
57952379|NCT00464334|BIOLOGICAL|Placebo to V950|
57952380|NCT03631732|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
57952381|NCT03631732|DRUG|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
57952382|NCT03631732|DRUG|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
57952383|NCT05428787|PROCEDURE|Left Bundle Branch Area Pacing|The patients will be allocated by randomization to receive the intervention of Left Bundle Branch Area Pacing
57952384|NCT05428787|PROCEDURE|CRT|The patients will be allocated by randomization to receive the intervention of CRT.
57952385|NCT05428787|PROCEDURE|AV node ablation|AV node ablation after 4 weeks of CRT implant or LBBAP implant.
57952386|NCT04479579|DRUG|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
57952387|NCT01701739|DRUG|aleglitazar|Multiple doses of aleglitazar
58307632|NCT03744832|DIAGNOSTIC_TEST|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
57952388|NCT01701739|DRUG|digoxin|Single dose of digoxin
57952389|NCT00075023|DRUG|Thalidomide Gel|
57952390|NCT00075023|DRUG|Placebo Gel|
57952391|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
58307633|NCT03744832|DIAGNOSTIC_TEST|Throat culture|Standard bacterial throat culture.
58307634|NCT00573664|DRUG|Gabapentin|single oral dose of 600mg gabapentin
58307635|NCT00573664|OTHER|lactose|Single dose
58307636|NCT01865357|OTHER|Brain MRI - Clinical and cognitive evaluation|"* Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
58307637|NCT01865357|OTHER|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
58307638|NCT02758782|BIOLOGICAL|Golimumab|
58307639|NCT02758782|DRUG|Celecoxib|
58307640|NCT04212429|DRUG|Levofloxacin Ophthalmic Product|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
58307641|NCT04212429|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
58307642|NCT03885947|BIOLOGICAL|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
58307643|NCT03885947|DRUG|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
58307644|NCT03885947|DRUG|Fludarabine|Fludarabine 150 mg/m2
58307645|NCT03885947|DRUG|cytoxan|Cytoxan 50 mg/m2
58307646|NCT03885947|DRUG|Thiotepa|Thiotepa 10 mg/m2
58307647|NCT03885947|BIOLOGICAL|TBI|TBI 400cGy
58307648|NCT02932657|OTHER|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
58307649|NCT04813523|DRUG|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
58426615|NCT05517694|OTHER|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
58426616|NCT05517694|OTHER|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
58426617|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
58426618|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
58426619|NCT00119964|BEHAVIORAL|internet based weight management tools|
58426620|NCT04228094|OTHER|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
58426621|NCT06065891|PROCEDURE|PALN resection|Resection of paraaortic lymph nodes in pancreatic cancer
58426622|NCT00003569|DRUG|cisplatin|
58426623|NCT00003569|DRUG|dimesna|
58426624|NCT00003569|DRUG|paclitaxel|
58426625|NCT03779074|DRUG|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
57952392|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
57952393|NCT02611388|DEVICE|fake stimulation|Patients were only attached electrodes without electric current
58098803|NCT03564535|DEVICE|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
57952394|NCT02966509|BEHAVIORAL|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
57952395|NCT02330159|PROCEDURE|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
57952396|NCT00935480|DRUG|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
57952397|NCT00935480|DRUG|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
57952398|NCT03814070|PROCEDURE|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
57952399|NCT03814070|PROCEDURE|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
58426626|NCT03779074|DRUG|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
57952400|NCT01744600|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
57952401|NCT03641664|BEHAVIORAL|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
58098804|NCT03564535|DEVICE|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
58098805|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
58098806|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
58098807|NCT00118222|DRUG|porfimer sodium|All patients receive porfimer sodium IV.
58426627|NCT03779074|DRUG|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
58098808|NCT00118222|PROCEDURE|adjuvant therapy|All patients receive porfimer sodium IV.
58098809|NCT00118222|PROCEDURE|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
58098810|NCT00294632|DRUG|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
58098811|NCT00294632|DRUG|Rituximab|375 mg/m\^2 By Vein Weekly for 4 Weeks
58098812|NCT02454322|DRUG|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
58098813|NCT04493554|DRUG|Vasopressin|Administration of vasopressin (20 IU) intranasally
58098814|NCT04493554|DRUG|Placebo|Administration of placebo intranasally
58098815|NCT04084028|BEHAVIORAL|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
58098816|NCT04084028|BEHAVIORAL|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
58098817|NCT04084028|BEHAVIORAL|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
58098818|NCT06260319|GENETIC|Whole genome sequencing and Genome-Epigenome-Phenome Associations|"* Whole genome sequencing (WGS) and bioinformatics analysis~* Functional validation~* Genome-Epigenome-Phenome Associations"
58098819|NCT00779844|PROCEDURE|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
58098820|NCT00779844|PROCEDURE|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
58098821|NCT00003673|DRUG|chemotherapy|
58098822|NCT00003673|DRUG|gemtuzumab ozogamicin|
58098823|NCT05628766|OTHER|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
58098824|NCT00157729|DRUG|pyridoxal-5'-phosphate with and without ACE inhibitor|
58098825|NCT02312531|DRUG|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
58098826|NCT05072093|BEHAVIORAL|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
58098827|NCT05072093|DRUG|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
58098828|NCT05072093|DRUG|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
58098829|NCT05072093|DRUG|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
58098830|NCT02517099|DRUG|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
58098831|NCT02517099|DRUG|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
58098832|NCT02517099|DRUG|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
58098833|NCT01087801|DRUG|ChiRhoStim|Human Secretin for Injection
58098834|NCT01087801|DRUG|Placebo|Saline for Injection
58098835|NCT00666718|DRUG|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
58098836|NCT00666718|DRUG|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
58098837|NCT00666718|DRUG|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
58098838|NCT05199207|BEHAVIORAL|Physical activity programm|adapted physical activity during 3 month
58098839|NCT06516393|DEVICE|The radial shock wave device|The r-ESWT+Kinesio Tape Application
58098840|NCT06346600|GENETIC|SKG0106|Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
58098841|NCT01051973|BEHAVIORAL|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
58098842|NCT01051973|BEHAVIORAL|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
58098843|NCT01856231|BEHAVIORAL|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
58098844|NCT03405909|DIAGNOSTIC_TEST|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
58098845|NCT03405909|DIAGNOSTIC_TEST|MRI|CE-MRI following standardized protocol
58098846|NCT03405909|DIAGNOSTIC_TEST|Histology|diagnostic liver biopsy
58098847|NCT06191185|BEHAVIORAL|BPB, No PIN|"Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
58098848|NCT06191185|BEHAVIORAL|BPB, PIN|"Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
58426628|NCT04367090|DRUG|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
58426629|NCT04367090|DRUG|Pyrotinib|Pyrotinib 400/320 mg orally daily
58426630|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
58426631|NCT01141478|DRUG|Sorafenib|400 mg po bid
58098849|NCT06191185|BEHAVIORAL|No BPB, PIN|Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.
58098850|NCT06191185|BEHAVIORAL|No BPB, No PIN|Patient-level: standard communication from their care team.
58098851|NCT02139085|DEVICE|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
58098852|NCT02139085|DEVICE|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
58098853|NCT05558852|PROCEDURE|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
58098854|NCT05672173|PROCEDURE|Biopsy|Undergo tumor biopsy
58098855|NCT05672173|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
58098856|NCT05672173|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
58098857|NCT05672173|PROCEDURE|Computed Tomography|Undergo PET/CT
58098858|NCT05672173|DRUG|Cyclophosphamide|Given IV
58098859|NCT05672173|DRUG|Fludarabine|Given IV
58098860|NCT05672173|DRUG|Ibrutinib|Given PO
58098861|NCT05672173|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
58098862|NCT05672173|BIOLOGICAL|Nivolumab|Given IV
58098863|NCT05672173|PROCEDURE|Pheresis|Undergo apheresis
58098864|NCT05672173|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58098865|NCT02360059|DRUG|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
58098866|NCT02360059|OTHER|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
58098867|NCT02360059|BEHAVIORAL|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
58098868|NCT02360059|OTHER|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
58098869|NCT05348707|OTHER|epidemiology|To review medical records to describe diagnosis and severity of the disease.
58098870|NCT05348707|OTHER|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
58098871|NCT00919802|DRUG|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
58098872|NCT00919802|OTHER|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
58098873|NCT02689726|DRUG|GTL001+|
58098874|NCT02689726|DRUG|Aldara|5% imiquimod cream
58098875|NCT06325176|OTHER|Cryotherapy|During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
58426632|NCT01467830|PROCEDURE|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
58426633|NCT03824587|DRUG|Tenapanor|Active Drug
58426634|NCT03824587|DRUG|Placebo|Inactive Drug
58426635|NCT03824587|DRUG|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
58426636|NCT03395951|DRUG|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
58426637|NCT00731471|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
58426638|NCT06337708|BEHAVIORAL|Smart Walk|Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
58426639|NCT06337708|BEHAVIORAL|Fitbit|This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.
58098876|NCT06325176|DEVICE|Infrared light therapy|Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
58426640|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
58426641|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
58426642|NCT00955513|DRUG|Placebo|Placebo
58426643|NCT05407350|DIAGNOSTIC_TEST|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
58426644|NCT00123604|DRUG|Carvedilol|25 mg twice daily for five months.
58098877|NCT02908698|DRUG|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
58098878|NCT02908698|DRUG|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
58098879|NCT01280565|DRUG|Masitinib|Masitinib 7.5 mg/kg/day
58098880|NCT01280565|DRUG|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
58098881|NCT00379366|DEVICE|External ionizing radiations|14 Gy in one time
58098882|NCT04565015|BIOLOGICAL|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
58098883|NCT05219773|DEVICE|NuvoAir Air Next spirometer|"* The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey."
58098884|NCT02239601|OTHER|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
58098885|NCT02414074|BEHAVIORAL|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
58098886|NCT02414074|BEHAVIORAL|Parent Education|Everyday Parenting is a parent training curriculum.
58098887|NCT01408056|DRUG|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
58426645|NCT00123604|DRUG|Metoprolol|200 mg twice daily for five months.
58426646|NCT00619307|DRUG|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
58426647|NCT00619307|DRUG|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
58426648|NCT00426543|DRUG|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
58426649|NCT00426543|DRUG|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
58426650|NCT02212769|DRUG|Losartan 50mg|Losartan 50mg once daily for 7 days
58426651|NCT02212769|DRUG|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
58426652|NCT01649024|DRUG|Tremelimumab|Given IV
58426653|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
58098888|NCT01408056|DRUG|Mupirocin 2% Ointment|Topical application twice per day for 60 days
58098889|NCT06072755|DEVICE|Finger pulse oximetry probe|This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
58098890|NCT06072755|DEVICE|Transreflectance oximetry probe|This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
58098891|NCT06165510|DEVICE|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
58098892|NCT06165510|PROCEDURE|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
58098893|NCT04299737|OTHER|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
58426654|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
58098894|NCT01005680|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
58426655|NCT01332747|DRUG|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
57952402|NCT03641664|BEHAVIORAL|Level II or Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
57952403|NCT04467424|DRUG|ketamine, propofol|anesthesia with ketofol in pediatric surgery
58098895|NCT01005680|DRUG|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
57952404|NCT04467424|DRUG|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
57952405|NCT02662036|DRUG|Bupivicaine HCL|
57952406|NCT02662036|DRUG|Liposomal bupivacaine|
57952407|NCT03682523|BEHAVIORAL|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
57952408|NCT00238251|DRUG|gefitinib|Once daily during days 1-28
57952409|NCT00238251|DRUG|temozolomide|Once daily on days 1-21
57952410|NCT00238251|RADIATION|radiation therapy|Whole brain radiotherapy
57952411|NCT00491699|DRUG|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
58098896|NCT01005680|DRUG|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
58098897|NCT04938063|OTHER|Assessing the correlation between Functional Impairment and Parenting Stress|Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
58098898|NCT04924946|OTHER|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"* Time to monitor blood pressure values in target targets~* Need for administration of another antihypertensive drug~* Disappearance of organ failure attributable to hypertension~* Weaning from an extra-renal purification~* Weaning from mechanical ventilation~* Improved kidney function~* Iatrogenic hypotension~* Need for suspension of treatment~* Other side effect"
58098899|NCT06566794|DRUG|Caffeine Tablet|0,5 x 100 mg tablet (50 mg caffeine).
58098900|NCT06566794|DRUG|Bupropion Hydrochloride Capsels|1 x 20 mg tablet.
58098901|NCT06566794|DRUG|Repaglinide Capsels|1 x 0,05 mg tablet.
58098902|NCT06566794|DRUG|Flurbiprofen Capsels|1 x 10 mg tablet.
58098903|NCT06566794|DRUG|Omeprazole 10 MG|1 x 10 mg tablet.
58098904|NCT06566794|DRUG|Dextromethorphan Oral Solution|5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
58098905|NCT06566794|DRUG|Midazolam oral solution|0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
58098906|NCT06566794|DRUG|Simvastatin tablets|1 x 10 mg tablet.
58098907|NCT06566794|DRUG|Placebo|2 x placebo tablets in the Placebo Phase/Arm
58098908|NCT06566794|DRUG|Carvedilol|2 x 25 mg tablets
58098909|NCT06566794|DRUG|Diclofenac|1 x 50 mg tablet (three times daily for three days)
58098910|NCT04638725|OTHER|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
58098911|NCT04150588|DRUG|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
58098912|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098913|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58307650|NCT05966298|OTHER|Core stabilization training|First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.
58307651|NCT05966298|OTHER|Standart Rehabilitation|This treatment includes shoulder exercises and conventional therapy (Infrared, ultrasound, TENS).
58307652|NCT05620524|DRUG|Extra blood samples for determining exposure to 5-FU|Extra blood samples for determining exposure to 5-FU
58426656|NCT01332747|DRUG|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
58426657|NCT01332747|DRUG|Atorvastatin|atorvastatin 10 mgs once daily
58098914|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098915|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
58098916|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098917|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098918|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58307653|NCT02479841|OTHER|Self management program|
58307654|NCT03886272|DRUG|BI 730357 (Test)|tablet
58098919|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098920|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098921|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098922|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098923|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098924|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
58098925|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
57952412|NCT04294719|OTHER|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
57952413|NCT02477059|DRUG|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
57952414|NCT02477059|DRUG|saline solution|La saline solution is administered by intravenous infusion.
57952415|NCT05129059|OTHER|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
57952416|NCT00455234|DRUG|Intramuscular Olanzepine 10 mg|
57952417|NCT00455234|DRUG|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
57952418|NCT04169373|DRUG|Upadacitinib|Upadacitinib tablet administered orally
57952419|NCT04169373|DRUG|Placebo|Placebo for upadacitinib tablet administered orally
57952420|NCT00106275|BEHAVIORAL|Mindfulness Based Stress Reduction|
57952421|NCT03332563|BEHAVIORAL|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
57952422|NCT02813551|DRUG|Torsemide|
57952423|NCT02813551|DRUG|Placebo|
57952424|NCT05726500|DIAGNOSTIC_TEST|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
57952425|NCT05726500|DIAGNOSTIC_TEST|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
57952426|NCT05726500|DIAGNOSTIC_TEST|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
58098926|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098927|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098928|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098929|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098930|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098931|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098932|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
58098933|NCT01289990|DRUG|Sitagliptin 100mg|Sitagliptin once daily
57952427|NCT05726500|DIAGNOSTIC_TEST|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
57952428|NCT05726500|DIAGNOSTIC_TEST|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
57952429|NCT01441037|DRUG|Danazol|Danazol, 800 mg daily by mouth for 2 years
57952430|NCT00073489|DRUG|OSI-461|
57952431|NCT01988064|OTHER|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
57952432|NCT01988064|OTHER|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
57952433|NCT03009266|DRUG|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
58098934|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
58098935|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098936|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098937|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098938|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098939|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
58098940|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
58098941|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
57952434|NCT05298891|OTHER|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~* energy equal to daily energy expenditure (estimated by indirect calorimetry \* physical activity factor)~* fats 28-35%~* carbohydrates 50-60%~* proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
58098942|NCT05835999|DRUG|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
58098943|NCT05835999|DRUG|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
58098944|NCT05835999|DRUG|Placebo once per day|No therapeutic effect
58098945|NCT05835999|DRUG|Placebo once per week|No therapeutic effect
58098946|NCT03668925|RADIATION|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
58307655|NCT03886272|DRUG|BI 730357 (Reference)|tablet
58426658|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
58426659|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
58098947|NCT05232838|DEVICE|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
58098948|NCT00471185|DRUG|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
58098949|NCT04991896|DRUG|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
58098950|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
58098951|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
58098952|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
58098953|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
58098954|NCT03409497|OTHER|Concord Grape Juice|Concord Grape Juice
58098955|NCT03409497|OTHER|Low flavonoid low essence beverage|Low flavonoid low essence beverage
58098956|NCT03409497|OTHER|Low flavonoid beverage|Low flavonoid beverage
58098957|NCT06536699|RADIATION|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
58098958|NCT06536699|RADIATION|Radiotherapy - Conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
58098959|NCT01035593|PROCEDURE|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
58098960|NCT01035593|DRUG|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
58098961|NCT00203632|DRUG|rosiglitazone/placebo|
58098962|NCT00529802|DRUG|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
58098963|NCT01029080|OTHER|no interventions|No interventions
58098964|NCT02375646|DRUG|Warfarin|
58098965|NCT02375646|DRUG|LMW Heparin|
58098966|NCT03179956|DRUG|Ribociclib|Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
58098967|NCT02674074|DEVICE|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
58098968|NCT00034359|DRUG|ACH-126,443|
58098969|NCT00034359|DRUG|Lamivudine|
58098970|NCT00034359|DRUG|Placebo|
58098971|NCT00891501|PROCEDURE|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
58098972|NCT00891501|PROCEDURE|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
58098973|NCT04074473|DRUG|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
58098974|NCT04074473|PROCEDURE|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
58098975|NCT04074473|OTHER|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
58098976|NCT05273398|DRUG|nasal diazepam|Nasal administration of diazepam
58098977|NCT01839227|OTHER|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
58307656|NCT06523127|OTHER|Recording data from the ICU stay and the post-ICU follow-up.|Record analysis of the post-ICU follow-up with the Interpretative Phenomenological Analysis
57736394|NCT06580574|PROCEDURE|Radical surgery|Radical surgery will be recommended per local treatment standards.
57736395|NCT01986257|BEHAVIORAL|Emotion Regulation Group Therapy (ERGT).|
58098978|NCT02146235|BEHAVIORAL|Psycho-Music Therapy|
58307657|NCT03286764|OTHER|Peppermint Oil|
58307658|NCT03286764|OTHER|Distilled water|Distilled water spray as a placebo during Colonoscopy
58307659|NCT02824107|BIOLOGICAL|blood sample|
58307660|NCT02824107|BEHAVIORAL|questionnaires for psychosocial factors|
58307661|NCT05686577|OTHER|no intervention|no intervention
58307662|NCT06104917|DRUG|High Dose Maolactin|Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
58098979|NCT03067506|OTHER|No intervention|No intervention
58098980|NCT01483612|BEHAVIORAL|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
58098981|NCT04789811|OTHER|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
58098982|NCT04789811|OTHER|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
58426660|NCT01363115|DIETARY_SUPPLEMENT|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
58426661|NCT01363115|DIETARY_SUPPLEMENT|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
58426662|NCT01363115|BEHAVIORAL|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
58426663|NCT00528996|DRUG|BEA 2180 BR|Solution
58426664|NCT00528996|DRUG|Tiotropium Bromide|Solution
58426665|NCT00528996|DRUG|Placebo|Solution
57952435|NCT02942745|BEHAVIORAL|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
57952436|NCT02942745|BEHAVIORAL|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
57952437|NCT01106170|DRUG|Provex CV|dietary supplement, 2 capsules per day by mouth
57952438|NCT01106170|OTHER|placebo|corn starch, 2 capsules per day by mouth
57952439|NCT01070472|DRUG|Misoprostol|titrated oral misoprostol solution
57952440|NCT02457637|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
57952441|NCT01910259|DRUG|Amiloride|Comparison with placebo
57952442|NCT01910259|DRUG|Riluzole|Comparison with placebo
57952443|NCT01910259|DRUG|Fluoxetine|Comparison with placebo
57952444|NCT01910259|DRUG|Placebo|Placebo comparator
57952445|NCT02721680|OTHER|Internal Awareness Training Program|
57952446|NCT02721680|OTHER|External Awareness Training Program|
57952447|NCT04640467|DIAGNOSTIC_TEST|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
57952448|NCT04640467|DIAGNOSTIC_TEST|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
57952449|NCT01111851|DRUG|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
57952450|NCT01111851|DRUG|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
58307663|NCT06104917|DRUG|Low Dose Maolactin|Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
58307664|NCT06104917|DRUG|Maltodextrin|Once daily dose of 2 capsules
58307665|NCT02278653|OTHER|Questionnaires for the evaluation of Quality of Life|"1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~2. Short Form (36) health survey~3. EORTC CR38~4. Vaizey score~5. Low Anterior Resection Syndrome (LARS) score~6. International Index of Erectile Function for men~7. International Prostate Symptom Score for men~8. Female Sexual Function Index for women"
58098983|NCT01826968|PROCEDURE|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
58098984|NCT04508621|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
58098985|NCT04508621|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
58098986|NCT05309707|DEVICE|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
58098987|NCT02120859|DEVICE|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
58098988|NCT02120859|DEVICE|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
58098989|NCT05986214|OTHER|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
58098990|NCT01926301|PROCEDURE|continuous veno-venous hemodialysis|
58098991|NCT03833856|PROCEDURE|colonoscopy perforation|The development of perforation after colonoscopy
58098992|NCT03740178|DRUG|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
58098993|NCT03740178|DRUG|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
58098994|NCT03740178|DRUG|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
58307666|NCT02278653|OTHER|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
58307667|NCT04421755|OTHER|Produce delivery|weekly home delivery of fresh fruits and vegetables
58307668|NCT04421755|OTHER|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is \~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (\~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
58098995|NCT04231994|DEVICE|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
58098996|NCT02203188|PROCEDURE|Lid debridgement scaling|
58098997|NCT06023303|DEVICE|Potenza|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
58098998|NCT06023303|DEVICE|Morpheus|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
58098999|NCT00431574|PROCEDURE|dosing|
58099000|NCT04596462|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
58099001|NCT01866995|DRUG|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
58099002|NCT01866995|OTHER|standard prostatostasis therapy|
58099003|NCT04870931|PROCEDURE|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
58099004|NCT03598673|DRUG|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
58099005|NCT03757741|DIAGNOSTIC_TEST|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
58099006|NCT03757741|DIAGNOSTIC_TEST|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
58099007|NCT04663711|BEHAVIORAL|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
58099008|NCT02059031|DRUG|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
58099009|NCT02059031|DRUG|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
58307669|NCT02644044|DRUG|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
58307670|NCT00296244|DRUG|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
58307671|NCT00296244|DRUG|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
58307672|NCT00296244|DRUG|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
58307673|NCT00296244|DRUG|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
58307674|NCT05944640|PROCEDURE|Intraocular surgery|Pars plana vitrectomy or cataract surgery.
58307675|NCT00075231|DRUG|Kaletra® (lopinavir/ritonavir)|
58307676|NCT00075231|DRUG|Combivir® (lamivudine, zidovudine)|
58307677|NCT00075231|DRUG|Sustiva® (efavirenz)|
57736396|NCT00596440|DRUG|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
58099010|NCT02059031|DRUG|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
58099011|NCT01508572|DRUG|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
58099012|NCT04324307|DRUG|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
58099013|NCT04324307|COMBINATION_PRODUCT|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
58099014|NCT04324307|COMBINATION_PRODUCT|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
58099015|NCT00323271|BEHAVIORAL|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
58099016|NCT00323271|OTHER|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
58099017|NCT03128073|DEVICE|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
58099018|NCT00244660|PROCEDURE|Frequent blood pressure measurements|
58099019|NCT00244660|BEHAVIORAL|Education|
58099020|NCT02026882|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
58099021|NCT02065882|BIOLOGICAL|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
58099022|NCT00282425|BIOLOGICAL|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
58099023|NCT04033627|PROCEDURE|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
58099024|NCT06202807|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58099025|NCT06202807|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58307678|NCT04217759|BEHAVIORAL|Healthy lifestyle intervention|"The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention."
58307679|NCT03366246|DRUG|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
58307680|NCT03366246|DRUG|placebo|according randomized this side received placebo or active product
58307681|NCT04559113|DRUG|Methylprednisolone Injectable Product|"1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
58307682|NCT01005667|DEVICE|BirthTrack|Measurement of cervical dilation and head station
58307683|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
58307684|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
58426666|NCT02733965|OTHER|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
58426667|NCT02733965|OTHER|No Pharmaceutical Consultations|
58426668|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
58426669|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
58426670|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
58426671|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
57952451|NCT01111851|DRUG|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
57952452|NCT01111851|DRUG|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
58426672|NCT01507480|DRUG|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
58426673|NCT03134781|BEHAVIORAL|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
58426674|NCT03134781|BEHAVIORAL|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
58426675|NCT03134781|BEHAVIORAL|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
58426676|NCT03277365|OTHER|Receive genetic risk information|Risk scores are provided by ResearchKit app.
58426677|NCT04519853|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
58426678|NCT05889078|BEHAVIORAL|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
58426679|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
57952453|NCT01111851|DRUG|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
58426680|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
58426681|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
57952454|NCT01111851|DRUG|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
57952455|NCT01111851|DRUG|MK0999|I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
58099026|NCT06202807|BEHAVIORAL|comprehensive rehabilitation therapy|"Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58099027|NCT06272812|BIOLOGICAL|MTBVAC|Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
58099028|NCT06272812|BIOLOGICAL|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
58426682|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
58426683|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
57736397|NCT00725296|BIOLOGICAL|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
57736398|NCT00047879|BIOLOGICAL|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
58099029|NCT02855788|DRUG|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
58099030|NCT00734617|DRUG|Nicotine Patch|"Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
58099031|NCT02639195|OTHER|Treatment|Retrospective chart review of patients treated with manual therapy.
58099032|NCT05886673|OTHER|experimental cream|experimental cream
58099033|NCT05886673|OTHER|standard of care|standard of care
58099034|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
58099035|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
58099036|NCT04592198|DRUG|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
58099037|NCT03428009|OTHER|Magnetic Resonance Imaging|Study interventions are minimal risk.
58307685|NCT04821063|DRUG|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
58307686|NCT04821063|DRUG|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
58307687|NCT04821063|DRUG|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
58307688|NCT05512117|DEVICE|Midline insertion|Midline catheter insertion
57736399|NCT00047879|DRUG|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
57736400|NCT02216123|DRUG|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
58099038|NCT02493985|OTHER|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
58099039|NCT02493985|OTHER|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
58099040|NCT00975884|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
58099041|NCT02604238|DRUG|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
58099042|NCT06537245|OTHER|Massage|Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
58307689|NCT05074329|DEVICE|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
58307690|NCT03027947|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
58426684|NCT02666105|DRUG|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
58426685|NCT00188006|DEVICE|heparin-coated cardiopulmonary bypass|
58426686|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
58099043|NCT04651218|BEHAVIORAL|exericse|participants perform aerobic exercise until they expend 500 kcal
58307691|NCT02744716|DRUG|Aspirin|low dose of Aspirin after operation
58307692|NCT02744716|DEVICE|intrauterine balloon|insert intrauterine balloon after operation
58307693|NCT00113165|DRUG|LAMICTAL extended-release|
58307694|NCT02433769|DEVICE|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
58307695|NCT02433769|DEVICE|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
58307696|NCT04023201|OTHER|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
58307697|NCT00879658|DRUG|BAF312|
58307698|NCT00879658|DRUG|Placebo|
58307699|NCT05461040|PROCEDURE|optic capture|optic capture of Intraocular lens without anterior vitrectomy
58099044|NCT03625752|DEVICE|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
58307700|NCT05461040|PROCEDURE|In-the-bag implantation of Intraocular lens|in-the-bag implantation of Intraocular lens with anterior vitrectomy
58307701|NCT03618901|OTHER|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
58307702|NCT03618901|OTHER|PD SAFEx|Progressive proprioception training.
58307703|NCT01005238|DRUG|Lamivudine|
58307704|NCT01005238|DRUG|Telbivudine|
58426687|NCT01306383|OTHER|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
57736401|NCT02216123|DRUG|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
57736402|NCT02216123|DRUG|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
57736403|NCT02216123|DRUG|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
57736404|NCT02216123|DRUG|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
58307705|NCT05158621|PROCEDURE|blood collection for research (next generation sequencing [NGS])|participants will have whole blood collected for NGS
58307706|NCT05158621|PROCEDURE|blood collection for research (HLA typing)|participants will have whole blood collected for HLA typing
58307707|NCT05158621|PROCEDURE|blood collection for research (circulating tumor DNA [ctDNA])|participants will have whole blood collected for ctDNA detection
58307708|NCT04896216|BEHAVIORAL|Stigma Reduction Intervention|Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
58307709|NCT01316614|DEVICE|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
58307710|NCT02845674|DRUG|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
58307711|NCT01156519|OTHER|Salivary Cortisol|"* Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am \> 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy"
58307712|NCT04517682|DIAGNOSTIC_TEST|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
58307713|NCT06466343|PROCEDURE|hysteroscopic resection of lower edge of cesarean scar niche|"Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.~The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)"
58307714|NCT06077175|OTHER|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
58307715|NCT02100124|BEHAVIORAL|Reproductive Life Planning (RLP)|
58307716|NCT02100124|BEHAVIORAL|Contraceptive Action Planning|
58426688|NCT05480709|BEHAVIORAL|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
58307717|NCT02100124|BEHAVIORAL|Contraception information|
58426689|NCT03217214|DIAGNOSTIC_TEST|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
58426690|NCT03968263|DEVICE|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
58099045|NCT03625752|DEVICE|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
58099046|NCT05393882|RADIATION|Computed tomography coronary angiogram|"Preparation~* Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~* Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~* 18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~* Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~* Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~* Scanning coverage: From the thoracic inlet to diaphragm"
58099047|NCT01855100|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
58099048|NCT00102388|DRUG|vildagliptin|
58099049|NCT00102388|DRUG|Gliclazide|
58099050|NCT05932927|BIOLOGICAL|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
58099051|NCT00393978|DRUG|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
58099052|NCT00393978|DRUG|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
58099053|NCT00478673|DEVICE|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
58099054|NCT00478673|DEVICE|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
58099055|NCT00003119|BIOLOGICAL|filgrastim|
58426691|NCT03968263|DEVICE|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
58099056|NCT00003119|BIOLOGICAL|sargramostim|
58099057|NCT00003119|DRUG|carboplatin|
58099058|NCT00003119|DRUG|cyclophosphamide|
58426692|NCT03968263|DEVICE|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
58426693|NCT03968263|DEVICE|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
58426694|NCT05500326|DRUG|Ivermectin Tablets|"ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
58426695|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
57736405|NCT03584698|DRUG|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
58099059|NCT00003119|DRUG|doxorubicin hydrochloride|
58099060|NCT00003119|DRUG|etoposide|
58099061|NCT00003119|PROCEDURE|adjuvant therapy|
58099062|NCT00003119|PROCEDURE|conventional surgery|
58099063|NCT00003119|RADIATION|radiation therapy|
58099064|NCT01204073|DRUG|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
58099065|NCT05828745|DRUG|CB06-036|CB06-036 capsule
58099066|NCT05828745|DRUG|Placebo|Placebo capsule
58426696|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
57736406|NCT03584698|DRUG|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
57736407|NCT00465413|DEVICE|Small volume spacer and/or Rinsing the mouth with water|
57736408|NCT04854291|OTHER|Administration of donor FMT|Intracaecal infusion of FMT
58099067|NCT00893867|DRUG|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
58099068|NCT00893867|DRUG|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
57736409|NCT04854291|OTHER|Administration of placebo|Intracaecal infusion of carrier solution
58099069|NCT02440074|OTHER|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
58307718|NCT01710462|DRUG|Pantoprazole + Domperidone|
58307719|NCT01710462|DRUG|Pantozol®|
58099070|NCT05138328|DEVICE|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
58099071|NCT04106401|OTHER|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
58099072|NCT04106401|OTHER|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
57736410|NCT04757623|PROCEDURE|Purse string closure of Ileostomy|conventional proceedure
58099073|NCT04106401|OTHER|physical activity monitoring|recording of physical activity by actimetry
58099074|NCT04106401|OTHER|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
58099075|NCT04106401|OTHER|24-hour blood pressure|recorded by ambulatory device
58099076|NCT01746849|BIOLOGICAL|Palifermin|
58099077|NCT01746849|BIOLOGICAL|Lupron|
58099078|NCT01746849|PROCEDURE|peripheral blood stem cell transplantation|
58099079|NCT01746849|RADIATION|Total-Body Irradiation (TBI)|
58099080|NCT01746849|DRUG|Thiotepa|
58099081|NCT01746849|DRUG|Cyclophosphamide|
57952456|NCT02756507|BEHAVIORAL|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
58099082|NCT01746849|DRUG|Degarelix|
58099083|NCT06542185|OTHER|online education|online education
58426697|NCT02554981|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
57736411|NCT05131295|DRUG|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
57736412|NCT05131295|DRUG|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
57736413|NCT00297752|DRUG|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
57952457|NCT02756507|BEHAVIORAL|Wait list|Delayed intervention
57952458|NCT02922374|DRUG|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
57952459|NCT03424707|DRUG|DW340(pelubiprofen/eperisone)|DW340
57952460|NCT03424707|DRUG|Pelubi(pelubiprofen)|pelubiprofen
57952461|NCT03424707|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
57952462|NCT02466711|DRUG|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
57952463|NCT02466711|DRUG|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
57952464|NCT01537562|OTHER|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
57952465|NCT06183723|OTHER|Combination of social-behavior model and eHealth|"The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects."
57952466|NCT01202656|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
57952467|NCT01202656|DRUG|Saline|intrauterine saline infusion 1 cc
58426698|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
58426699|NCT00562562|OTHER|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
58426700|NCT01174394|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
58426701|NCT01174394|PROCEDURE|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
58426702|NCT01174394|PROCEDURE|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
58099084|NCT02860273|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
58099085|NCT02860273|DEVICE|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
58099086|NCT03250507|DRUG|Bupivacaine|0.25% bupivacaine for TAP block
58099087|NCT03250507|DRUG|Liposomal bupivacaine|Exparel for TAP block
58099088|NCT03250507|DRUG|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
58099089|NCT04093973|DIAGNOSTIC_TEST|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
58099090|NCT01547273|PROCEDURE|bone graft inside socket only|bone graft inside socket only
58099091|NCT01547273|PROCEDURE|bone graft inside and outside socket|bone graft inside and outside socket
58426703|NCT01174394|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
58099092|NCT01547273|PROCEDURE|no bone graft|no bone graft
58099093|NCT00393770|DRUG|L-acetylcarnitine|250-500 mg/kg/die.
58099094|NCT05841706|BIOLOGICAL|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb \< 7 g/dL)
58099095|NCT05841706|BIOLOGICAL|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb \< 9 g/dL)
58099096|NCT05841706|PROCEDURE|Computed Tomography|Undergo CT scan
58426704|NCT03320330|OTHER|Laboratory Biomarker Analysis|Correlative studies
58426705|NCT03320330|BIOLOGICAL|Pepinemab|Given IV
57736414|NCT00297752|DRUG|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
57736415|NCT01964170|DRUG|degarelix|subcutaneous
58099097|NCT05841706|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
57736416|NCT01964170|DRUG|Goserelin|subcutaneous
57736417|NCT02935335|DRUG|Menotrophin|
57736418|NCT03846700|DEVICE|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
58099098|NCT05841706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58099099|NCT05841706|OTHER|Survey Administration|Ancillary studies
58099100|NCT05841706|PROCEDURE|Pancreatectomy|surgical removal of all or part of pancreas
58099101|NCT00720473|DRUG|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
58099102|NCT04822428|OTHER|Osteopathic manipulation|Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
58099103|NCT02139579|DRUG|Bevacizumab|7.5 mg/kg every 3 weeks
58099104|NCT02173301|DRUG|XP23829 400 mg QD|active dose 1
58099105|NCT02173301|DRUG|XP 23829 800 mg QD|active dose 2
58099106|NCT02173301|DRUG|XP23829 400 mg BID|active dose 3
58099107|NCT02173301|DRUG|Placebo|control
58099108|NCT00758706|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
58099109|NCT00758706|DRUG|Placebo|Dosing to match AZD1236
58099110|NCT06418360|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
58099111|NCT06418360|DEVICE|conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack|10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
58307720|NCT00017641|DRUG|anti-thymocyte globulin|
58307721|NCT00017641|DRUG|cyclophosphamide|
58307722|NCT00017641|DRUG|filgrastim|
58307723|NCT00017641|PROCEDURE|CD34+ Peripheral Blood Stem Cell Reinfusion|
58307724|NCT06083129|DRUG|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
58307725|NCT06083129|DRUG|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
58426706|NCT03320330|OTHER|Pharmacological Study|Correlative studies
58426707|NCT06528912|OTHER|Radiotherapy|Follow-up
58099112|NCT05723861|DEVICE|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
58099113|NCT03284866|OTHER|Laboratory Biomarker Analysis|Correlative studies
58099114|NCT03284866|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
58099115|NCT03284866|OTHER|Saline|Given IM
58099116|NCT05751928|BIOLOGICAL|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
58099117|NCT05751928|BIOLOGICAL|anti-PD1|anti-PD1 agent in the adjuvant setting
58099118|NCT05751928|PROCEDURE|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
58099119|NCT05751928|PROCEDURE|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
58099120|NCT06134765|DRUG|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
58099121|NCT02179931|DRUG|Flupentixol/melitracen film-coated tablet|
58426708|NCT01403116|DRUG|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
58426709|NCT01403116|DRUG|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
58426710|NCT01567995|DRUG|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
58426711|NCT01567995|DRUG|Vehicle (base cream)|Vehicle (base cream)
58426712|NCT01631097|DRUG|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
57736419|NCT03846700|DEVICE|holep|holmium laser enucleation of prostate
57736420|NCT03846700|DEVICE|pvp|photoselectivevaporization of prostate
57736421|NCT06245083|DRUG|Pyrroloquinoline quinone (PQQ)|Oral supplement taken daily
57736422|NCT06245083|DRUG|Placebo with soybean oil|Oral supplement taken daily
57736423|NCT04425564|DRUG|metronomic XELOX|
57736424|NCT04425564|DRUG|Classic XELOX|
58099122|NCT02179931|DRUG|Flupentixol/melitracen coated tablet (Deanxit®)|
58099123|NCT01955031|OTHER|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
58307726|NCT04036604|OTHER|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
58307727|NCT02472899|OTHER|Blood sample|Non-interventional study based on blood samples taken at a single study visit
58307728|NCT06105606|DEVICE|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
58307729|NCT05335616|OTHER|Guideline|Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
58307730|NCT05335616|OTHER|Treatment fee item|Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
58426713|NCT03968848|DRUG|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
58426714|NCT04254120|BEHAVIORAL|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
58426715|NCT04254120|BEHAVIORAL|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
58307731|NCT02930694|DRUG|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
58307732|NCT02930694|DRUG|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
58307733|NCT05889975|DEVICE|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
58307734|NCT05889975|DEVICE|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
57736425|NCT04425564|OTHER|Blood samples for pharmacological studies|
57736426|NCT06415955|OTHER|None, pure observationnal study|None, pure observationnal study
57736427|NCT05918926|BEHAVIORAL|Exercise|Individualised remote exercise intervention
57736428|NCT04636255|PROCEDURE|Physical Characteristics|Body Weight, Height
57736429|NCT04636255|DIAGNOSTIC_TEST|Assessment of Heart rate variability|Holter 24h
57736430|NCT04636255|DIAGNOSTIC_TEST|Blood Pressure and Cardiac Autonomic Control|Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
58307735|NCT05889975|DEVICE|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
58426716|NCT02794545|PROCEDURE|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
58426717|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
58099124|NCT01955031|OTHER|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
58099125|NCT04172779|DRUG|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
58099126|NCT06112184|OTHER|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
58099127|NCT05117073|DIAGNOSTIC_TEST|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
58099128|NCT06567249|PROCEDURE|Intracoronary hypothermia|This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
58099129|NCT06567249|OTHER|Standard percutaneous coronary intervention|Percutaneous coronary intervention is performed in a standard manner.
58099130|NCT02106611|OTHER|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
58426718|NCT05327361|DRUG|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
58426719|NCT05327361|OTHER|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
58426720|NCT02728297|PROCEDURE|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
58426721|NCT02792023|OTHER|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
58426722|NCT02792023|DEVICE|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
58099131|NCT02106611|PROCEDURE|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
58099132|NCT02106611|PROCEDURE|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
58099133|NCT04428060|OTHER|PERSEUS CPR|Resuscitation based on patient physiology
58426723|NCT02792023|DEVICE|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
58426724|NCT00371982|DRUG|Fish oil (Maxepa)|
57736431|NCT04636255|DIAGNOSTIC_TEST|Evaluation of Baroreflex Control|The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
58099134|NCT04428060|OTHER|Standard CPR|Resuscitation based on current guidelines
57736432|NCT04636255|DIAGNOSTIC_TEST|Cardiac Function and Structure|Echocardiogram
58099135|NCT06312501|DEVICE|Satelia®Cardio|Use of a remote patient monitoring system by NP Medical.
58099136|NCT06312501|OTHER|Conventional care|No use of RPM solutions for follow-up
58099137|NCT04962711|OTHER|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
58099138|NCT04962711|OTHER|Usual care|provided by participants' usual healthcare professional(s)
58099139|NCT06111560|OTHER|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
58426725|NCT03464149|DIAGNOSTIC_TEST|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
58426726|NCT06526910|BEHAVIORAL|Swallowing exercises|Standard-of-care swallowing exercises include tongue exercise. The experimental part added in Phase 3 includes some participants completed standard-of-care exercises again and others completing standard-of-care exercises and motor imagery practice of those exercises.
58426727|NCT06463054|BEHAVIORAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
58426728|NCT06463054|BEHAVIORAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
58426729|NCT03792568|OTHER|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
57736433|NCT04636255|DIAGNOSTIC_TEST|Assessment of Coronary Anatomy and Calcium Score|Angiotomography
57736434|NCT04636255|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
57736435|NCT04636255|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary Exercise Test.
57736436|NCT04636255|PROCEDURE|Physical Training|Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
58426730|NCT06342596|DRUG|[14C]-LY3473329|Administered orally
58426731|NCT06342596|DRUG|[14C]-LY3473329|Administered IV
58099140|NCT02703974|BEHAVIORAL|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
58099141|NCT02703974|BEHAVIORAL|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
58099142|NCT02703974|BEHAVIORAL|Nudge|"A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
58099143|NCT02703974|BEHAVIORAL|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
58099144|NCT01788137|DRUG|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
58099145|NCT01788137|DRUG|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
58099146|NCT03225066|DEVICE|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
58426732|NCT06342596|DRUG|LY3473329|Administered orally
58099147|NCT02421770|OTHER|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
58099148|NCT02421770|OTHER|placebo|
58099149|NCT03503474|OTHER|No intervention|There is no intervention, this is observational only
58099150|NCT02672774|PROCEDURE|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
58307736|NCT03597802|OTHER|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
58307737|NCT03597802|OTHER|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
58307738|NCT06321523|DRUG|Tafamidis 61 milligrams|Tafamidis 61mg as provided in real-world practice
58307739|NCT04312100|OTHER|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
58426733|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
58307740|NCT05452265|PROCEDURE|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was \>2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
58307741|NCT03689517|OTHER|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
58307742|NCT03689517|DEVICE|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
58307743|NCT00092196|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
58307744|NCT02669875|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
58307745|NCT02669875|DRUG|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
58099151|NCT02672774|DEVICE|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
58099152|NCT05093192|OTHER|Exercise trial|Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
58426734|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
58426735|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
58426736|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
58426737|NCT03876665|OTHER|No intervention|No intervention
57952468|NCT00574275|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
58426738|NCT05367128|OTHER|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
57952469|NCT00574275|DRUG|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
57952470|NCT00574275|DRUG|Gemcitabine|1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
57952471|NCT01885611|OTHER|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
57952472|NCT01885611|DIETARY_SUPPLEMENT|Virgin Coconut Oil|cold-processed VCO
57952473|NCT03656861|OTHER|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
57952474|NCT03971201|PROCEDURE|hepatic resection|removal of portion of liver containing cancer
58426739|NCT03731078|OTHER|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
57736437|NCT06511232|DRUG|Intraosseous Morphine|More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the early postoperative period compared to the spine and adductor block alone.3 No study to date in the available literature has evaluated the efficacy of intraosseous morphine infusion in managing acute postoperative pain in patients undergoing ACL reconstruction with bone-patellar tendon-bone autograft, so that is the intended evaluation point with this project.
57952475|NCT03971201|DRUG|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
58099153|NCT03196739|DEVICE|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
58099154|NCT02428634|BEHAVIORAL|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
58426740|NCT02305238|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
58426741|NCT04232436|OTHER|Survival at discharge|Survival at discharge
58426742|NCT04232436|OTHER|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
58426743|NCT03555682|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
58426744|NCT03555682|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
58426745|NCT04672421|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
57736438|NCT04014660|DIETARY_SUPPLEMENT|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
57952476|NCT02610595|DRUG|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
57952477|NCT00142467|DRUG|Gemcitabine|
57952478|NCT00142467|DRUG|Oxaliplatin|
57952479|NCT00142467|DRUG|Bevacizumab|
57952480|NCT03366298|COMBINATION_PRODUCT|Epipen 0.3mg|Epipen 0.3mg auto-injector
57952481|NCT03366298|COMBINATION_PRODUCT|Emerade 300mcg|Emerade 300mcg auto-injector
57952482|NCT03366298|COMBINATION_PRODUCT|Emerade 500mcg|Emerade 500mcg auto-injector
57952483|NCT02458755|DRUG|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
57952484|NCT06062186|DIETARY_SUPPLEMENT|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
57952485|NCT06062186|DIETARY_SUPPLEMENT|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
57952486|NCT06062186|DIETARY_SUPPLEMENT|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
57952487|NCT01899833|DIAGNOSTIC_TEST|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
58099155|NCT02428634|BEHAVIORAL|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
58426746|NCT04672421|DEVICE|Placebo|No device after laparoscopic surgery
58426747|NCT03514433|OTHER|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
58426748|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
57952488|NCT04002635|DRUG|Letrozole|Letrozole ovulation induction
57952489|NCT04002635|DRUG|estradiol valerate|hormonal replacement therapy
57952490|NCT00326209|DRUG|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
57952491|NCT04209751|DIAGNOSTIC_TEST|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
57952492|NCT03452696|DIETARY_SUPPLEMENT|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
57952493|NCT01535456|PROCEDURE|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
57952494|NCT02335827|PROCEDURE|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
58099156|NCT01093716|DEVICE|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
58099157|NCT03577119|DIETARY_SUPPLEMENT|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
58426749|NCT06190080|OTHER|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
58099158|NCT03577119|DIETARY_SUPPLEMENT|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
58099159|NCT01379079|DRUG|Acetylsalicylic acid|aspirin intake at bedtime
58099160|NCT01379079|DRUG|Acetylsalicylic acid lysinate|aspirin intake on awakening
58099161|NCT06537271|COMBINATION_PRODUCT|experimental group|Autism awareness, breastfeeding cessation and toilet training knowledge and attitude training guide and weekly training content animation videos will be prepared for the experimental group and uploaded via WhatsApp and training will be provided. All participants will be interviewed face to face before the training and the necessary information about our study will be provided. Feedback will be received from the researcher regarding the videos, and participants in the study will be able to ask their questions via WhatsApp and share digital content in a digital environment. Evaluation will be made by conducting group work with individuals. Reminders such as mobile phone messages will be used. Training will be carried out within an 8-week program. Each week, training videos on the topics prepared in line with the training guide will be prepared and shared via WhatsApp. Feedback will be received by creating interactive communication environments.
58099162|NCT06537271|COMBINATION_PRODUCT|Control Group|After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of the training, survey forms will be filled out by the researcher for the control group and post-test data will be collected.
58099163|NCT03944018|BEHAVIORAL|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
58099164|NCT04266119|BEHAVIORAL|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
58099165|NCT05033028|OTHER|Smartphone app|SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
58099166|NCT02300818|DEVICE|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
58099167|NCT02300818|DRUG|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
58099168|NCT00004086|BIOLOGICAL|filgrastim|
58099169|NCT00004086|DRUG|cisplatin|
58099170|NCT00004086|DRUG|cytarabine|
58099171|NCT00004086|DRUG|etoposide|
58426750|NCT00771056|DRUG|Hydroxychloroquine|400mg by mouth daily x 1 year
57736439|NCT04014660|DIETARY_SUPPLEMENT|Placebo|The placebo supplement consists of corn starch only.
58099172|NCT00004086|DRUG|ifosfamide|
58426751|NCT02379468|DRUG|Pedyphar Ointment|
58426752|NCT02379468|DRUG|Panthenol|Ointment
57952495|NCT04455880|OTHER|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
57952496|NCT03500900|DRUG|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
57952497|NCT03500900|DRUG|Placebo Oral Tablet|Acute administration of placebo tablet
57952498|NCT00331474|BIOLOGICAL|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
57952499|NCT03256500|DEVICE|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
57952500|NCT05158374|DRUG|Aspirin tablet|75mg Aspirin once per day
57952501|NCT05158374|DRUG|Metformin|500mg Metformin once per day
57952502|NCT05158374|DRUG|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
57952503|NCT03539393|DRUG|Fremanezumab|For patients who enter this program, the monthly dose of fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the patient's weight every 3 months.
57952504|NCT00905736|PROCEDURE|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
57952505|NCT00905736|PROCEDURE|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
57952506|NCT04778254|OTHER|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
57952507|NCT04778254|OTHER|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
57952508|NCT04778254|OTHER|conventional obturator|clasp retained obturator for management of hemi maxillectomy
57952509|NCT00975156|OTHER|Physical Therapy|Conventional physical therapy
57952510|NCT00975156|DEVICE|Lokomat|Robotic-assisted walking device
57952511|NCT03294785|PROCEDURE|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
57952512|NCT03294785|DRUG|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
57952513|NCT03294785|PROCEDURE|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
57952514|NCT03171220|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
57952515|NCT03171220|BIOLOGICAL|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
57952516|NCT03171220|DRUG|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
57952517|NCT03171220|DRUG|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
57952518|NCT03171220|BIOLOGICAL|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
58099173|NCT00004086|PROCEDURE|autologous bone marrow transplantation|
58099174|NCT00004086|PROCEDURE|peripheral blood stem cell transplantation|
58099175|NCT00004086|RADIATION|indium In 111 LL2 IgG|
58099176|NCT00004086|RADIATION|yttrium Y 90 epratuzumab|
58099177|NCT06221683|DRUG|Homoharringtonine|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
58099178|NCT06221683|DRUG|Cytarabine|100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
58426753|NCT01042652|DRUG|Raltegravir|Raltegarvir 400mg bid
58426754|NCT04904848|OTHER|Survey evaluation|examine the convergent validity and reliability of a Turkish version
58426755|NCT06137599|OTHER|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
58426756|NCT05240521|OTHER|ARM A|30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
58426757|NCT05240521|OTHER|ARM B|30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days
58426758|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
58426759|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
58426760|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
58099179|NCT06221683|DRUG|Etoposide|100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
58426761|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
58099180|NCT06221683|DRUG|Venetoclax|100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
58099181|NCT06221683|DRUG|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
58099182|NCT06221683|DRUG|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
58426762|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
58426763|NCT01781780|BEHAVIORAL|General Nutrition Recommendations|
58426764|NCT01781780|BEHAVIORAL|Breakfast Recommendation|
58426765|NCT01781780|BEHAVIORAL|No Breakfast Recommendation|
57736440|NCT03684629|BEHAVIORAL|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
57736441|NCT05321420|DRUG|Placebo|placebo
58099183|NCT06221683|DRUG|Idarubicin Hydrochloride|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
58099184|NCT06221683|DRUG|Sorafenib|100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
58099185|NCT06221683|DRUG|Gilteritinib|20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
58099186|NCT06221683|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
58099187|NCT02998515|DEVICE|Companion (Liquid oxygen device)|
58099188|NCT02998515|DEVICE|Activox (concentrator)|
58099189|NCT00423488|DRUG|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
58426766|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
58099190|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
58099191|NCT00423488|DRUG|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
58426767|NCT04005079|DRUG|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
58426768|NCT04005079|DRUG|Ofloxacin|Standard of care
58426769|NCT04005079|DRUG|Prednisolone|Standard of Care
58426770|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58426771|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
58426772|NCT00302913|DRUG|Adjustment of clopidogrel dose|
58426773|NCT01919736|BEHAVIORAL|Gait Retraining|
58426774|NCT03344627|DRUG|Meropenem standard dose|"* Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
58426775|NCT03344627|DRUG|Meropenem high dose|"* Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
57736442|NCT05321420|DRUG|Pirfenidone|pirfenidone 801 mg TID
57736443|NCT05321420|DRUG|Deupirfenidone|Deupirfenidone
57736444|NCT05388253|BEHAVIORAL|Static Stretching|Using Static Stretching exercises
58426776|NCT05351775|DEVICE|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
58426777|NCT05351775|DEVICE|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
58426778|NCT05351775|DEVICE|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
57736445|NCT05388253|BEHAVIORAL|Deep Kneading Massage|Using Deep Kneading Massage technique
57736446|NCT01220011|PROCEDURE|Fetoscopic laser surgery|Fetoscopic laser surgery
57736447|NCT06670248|PROCEDURE|Debridement Surgery|Surgical debridement of burn wounds involving ≥ 20% of the TBSA, including debrided and donor sites.
57736448|NCT06670248|DIAGNOSTIC_TEST|Sdc-1 Level Measurement|"Measurement of plasma sdc-1 levels in different situations to assess endothelial glycocalyx damage using an enzyme-linked immunosorbent assay (ELISA):~Preoperatively:~* Upon admission to the Burn Unit.~* 24 hours after admission to the Burn Unit.~* Prior to the start of surgery, after anesthetic induction.~* If surgery is performed after the fifth day following the burn, an additional sdc-1 measurement will be taken on the fifth day of hospital admission.~Postoperatively:~* 6 hours after surgery.~* 24 hours after surgery.~* 48 hours after surgery."
58099192|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
58099193|NCT00423488|DRUG|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
58426779|NCT05351775|DEVICE|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
58426780|NCT06156501|PROCEDURE|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
58426781|NCT00094848|DRUG|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
57736449|NCT03969654|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
58099194|NCT05718882|DRUG|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
58099195|NCT06236152|DRUG|Ferrous sulfate|Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.
58426782|NCT05283590|DIAGNOSTIC_TEST|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
58426783|NCT03624127|DRUG|BMS-986165|Specified dose on specified days
58426784|NCT03624127|OTHER|Placebo|Specified dose on specified days
57736450|NCT03969654|DEVICE|Vanguard Total Knee|Primary Total Knee Arthroplasty
57736451|NCT03969654|DEVICE|NexGen Total Knee|Primary Total Knee Arthroplasty
57736452|NCT02130193|DRUG|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
57736453|NCT02130193|DRUG|Placebo|Subjects will receive danirixin matching placebo
57769566|NCT00742820|DIETARY_SUPPLEMENT|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
57769567|NCT04953013|DRUG|sodium bicarbonate|Drug exposure
58099196|NCT06236152|DRUG|Deltacortril|Deltacortil 10mg was given orally once daily for 4 to 6 weeks
58099197|NCT04713228|DEVICE|ARTSENS Pen|ARTerial Stiffness Evaluation for Noninvasive Screening
58099198|NCT04101084|OTHER|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
58426785|NCT03624127|DRUG|Apremilast|Specified dose on specified days
58426786|NCT00261703|DRUG|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
58099199|NCT04030884|DIETARY_SUPPLEMENT|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
58099200|NCT05301452|RADIATION|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
58099201|NCT05301452|RADIATION|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
58426787|NCT00261703|DRUG|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
58426788|NCT00261703|OTHER|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
58426789|NCT04759469|BEHAVIORAL|High-intensity interval training|High-intensity interval training is a form of intermittent training using relatively high exercise intensity
58426790|NCT04759469|BEHAVIORAL|Moderate intensity interval training|Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
57769568|NCT02841267|DRUG|PF 06252616|
58426791|NCT01426776|PROCEDURE|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
57952519|NCT01119170|OTHER|Starter formula|standard starter formula given from birth to 6 months of age
57952520|NCT01119170|OTHER|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
57952521|NCT02365714|RADIATION|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
58099202|NCT05301452|PROCEDURE|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
58099203|NCT04388527|BIOLOGICAL|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
58307746|NCT05948085|DRUG|Zavegepant 10 mg IN|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
58307747|NCT02830711|OTHER|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
58307748|NCT03826251|PROCEDURE|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
58307749|NCT00830219|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
58307750|NCT00830219|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
58307751|NCT00417196|DRUG|QAX576|
58307752|NCT04507152|OTHER|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
58307753|NCT04507152|OTHER|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
58307754|NCT04722406|OTHER|This item is not applicable to our observational study.|This item is not applicable to our observational study.
58307755|NCT04578665|BEHAVIORAL|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
57736454|NCT06139523|DEVICE|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
58426792|NCT01935414|DEVICE|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
58099204|NCT05365347|BEHAVIORAL|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
58099205|NCT01304017|OTHER|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
58426793|NCT01935414|DEVICE|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
58426794|NCT04547582|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
58426795|NCT01789216|DRUG|NSAID|
58426796|NCT01789216|DRUG|Gabapentinoids|
58426797|NCT01789216|DRUG|placebo|
58426798|NCT04405245|DRUG|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
58426799|NCT04405245|DRUG|AKB-9778 4%|Razuprotafib opthalmic solution
58426800|NCT04405245|DRUG|Placebo|placebo for razuprotafib opthalmic solution
58426801|NCT00120328|DRUG|SPP301|
58426802|NCT04046731|DIAGNOSTIC_TEST|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
58426803|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
58099206|NCT01304017|OTHER|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
58426804|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
58426805|NCT00902174|DRUG|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
58426806|NCT00902174|DRUG|Placebo|Placebo to imatinib 100 mg film coated tablets
58426807|NCT03461081|DRUG|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
58426808|NCT03368235|DRUG|AZD9567|oral OD SGRM administered as suspension
58426809|NCT03368235|DRUG|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
58426810|NCT00480870|DRUG|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
58426811|NCT00480870|DRUG|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
57952522|NCT05146921|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
57952523|NCT05146921|OTHER|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
58426812|NCT01026220|BIOLOGICAL|bleomycin sulfate|Given IV or SC
58426813|NCT01026220|DRUG|doxorubicin hydrochloride|Given IV
58426814|NCT01026220|DRUG|liposomal vincristine sulfate|Given IV
58426815|NCT01026220|DRUG|vinorelbine tartrate|Given IV
58426816|NCT01026220|DRUG|cyclophosphamide|Given IV
57952524|NCT03422315|DRUG|Propofol|injection;2mg/kg;single-dose
58426817|NCT01026220|DRUG|etoposide phosphate|Given IV
58426818|NCT01026220|DRUG|prednisone|Given IV
58426819|NCT01026220|BIOLOGICAL|filgrastim|Given IV or SC
58426820|NCT01026220|DRUG|ifosfamide|Given IV
58426821|NCT02858557|BEHAVIORAL|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
58426822|NCT02858557|BEHAVIORAL|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
58426823|NCT02157077|DRUG|Aflibercept|Intravitreal Injection
58426824|NCT03617055|DIAGNOSTIC_TEST|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
58426825|NCT03842072|DEVICE|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
58426826|NCT00424697|DRUG|placebo|
58426827|NCT00424697|DRUG|lorazepam|
58426828|NCT00424697|DRUG|GW876008|
58426829|NCT03665584|DEVICE|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
58426830|NCT03665584|DEVICE|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
58426831|NCT04377152|DRUG|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
58426832|NCT04377152|PROCEDURE|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
58426833|NCT02940483|DRUG|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
58426834|NCT02744651|DEVICE|EUS-FNA|"Please note the text in section Arm description"
58099207|NCT05921331|DEVICE|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
58099208|NCT05921331|OTHER|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
58099209|NCT01308658|DRUG|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
58099210|NCT01308658|DRUG|ritonavir|on Day 3
58099211|NCT02103634|DEVICE|NaF PET/MRI|
57952525|NCT03729063|OTHER|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
57952526|NCT03729063|OTHER|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
57952527|NCT01505569|DRUG|Ifosfamide|"* Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
57952528|NCT01505569|DRUG|Etoposide|"* Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age \>36 mos.) approx. hour 75 on days -5, -4, and -3"
57952529|NCT01505569|DRUG|Mesna|"* Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
58099212|NCT02103634|DEVICE|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
58099213|NCT02103634|DEVICE|FDG PET/CT|
58099214|NCT03529318|PROCEDURE|Biopsies from endoscopy|"1) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
58099215|NCT05526274|DIAGNOSTIC_TEST|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
58099216|NCT06004076|OTHER|Release of upper track of deep front fascial line|I will work on upper track of deep front fascial line, I will make release to diaphragm,mediastinum,scalene muscles, scalene fascia,Fascia endothoracic, transversus thoracis,Infrahyoid muscles, fascia pretracheal and Suprahyoid muscles.
58099217|NCT06004076|OTHER|Corrective exercises for upper crossed syndrome|strength for scapular muscles and deep neck flexor
58099218|NCT00871065|DRUG|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
58099219|NCT05676879|OTHER|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
58099220|NCT03791918|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58099221|NCT03791918|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
58426835|NCT02744651|DEVICE|EUS-Endodrill biopsy|"Please note the text in section Arm description"
58426836|NCT05338879|OTHER|Non-Interventional|No study treatment will be administered on this study.
58426837|NCT05188703|BEHAVIORAL|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
58426838|NCT05856565|OTHER|Photo|Photography intake
58426839|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
58426840|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
58426841|NCT01983774|DRUG|Esomeprazole|
58426842|NCT01983774|DRUG|Placebo|Sugar pill
58426843|NCT04181177|OTHER|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
58426844|NCT02953886|DEVICE|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
58426845|NCT05233345|BEHAVIORAL|Occupational Therapy|online occupational therapy sessions are based on the activity training
58426846|NCT00417430|DRUG|ICI 182,780 (Faslodex)|
58426847|NCT01078168|DRUG|Acitretin|30mg per day from Day 1 to Day 28
58426848|NCT01078168|DRUG|Placebo|Placebo
58426849|NCT01341028|PROCEDURE|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
58426850|NCT01341028|PROCEDURE|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
58426851|NCT05281055|PROCEDURE|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
58426852|NCT00695552|BEHAVIORAL|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
58426853|NCT00695552|BEHAVIORAL|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
58426854|NCT06206655|DIAGNOSTIC_TEST|rapid ACTH stimulation test|Take 2ml blood/saliva sample at baseline. Then, we will inject synacthen 250mcg IV to patients and collect 2ml blood/saliva after 30minutes and 60 minutes.
58426855|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
58426856|NCT01142427|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58426857|NCT01142427|OTHER|Laboratory Biomarker Analysis|Correlative studies
58426858|NCT00911339|DRUG|Atorvastatin|Atorvastatin 10 mg associated with stent genous
58426859|NCT00911339|DRUG|Atorvastatin|Atorvastatin 80 mg associated with stent genous
57952530|NCT01505569|BIOLOGICAL|G-CSF|"* Arms A\&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (\>) 1,000/mm\^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3~* Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~* Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~* Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference"
58099222|NCT03791918|PROCEDURE|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
58426860|NCT03543943|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
58426861|NCT03543943|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
58426862|NCT03543943|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
58426863|NCT00653081|PROCEDURE|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
58426864|NCT00653081|PROCEDURE|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
58426865|NCT00651365|DRUG|JNJ-38877605|
58426866|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
58426867|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
58099223|NCT03791918|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
58099224|NCT01284725|DRUG|mycophenolate mofetil or azathioprine|
58099225|NCT01284725|OTHER|immunosuppressive treatment discontinuation|
58099226|NCT03964090|DRUG|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
58099227|NCT03964090|DRUG|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
58426868|NCT04708860|BEHAVIORAL|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
57952531|NCT01505569|DRUG|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
57952532|NCT01505569|DRUG|Melphalan|Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
57952533|NCT01505569|DRUG|Thiotepa|Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age \>36 mos.) approx. hour 72 on days -5, -4, and -3
57952534|NCT01505569|BIOLOGICAL|Autologous stem cell infusion|"Arms A, B \& C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard."
57952535|NCT01505569|RADIATION|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
57952536|NCT01505569|DRUG|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
57952537|NCT01505569|DRUG|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
57952538|NCT01505569|PROCEDURE|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
57952539|NCT01505569|DRUG|Anti-seizure prophylaxis|"Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg."
57952540|NCT01505569|DRUG|Ursodiol|Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
57952541|NCT01183559|DRUG|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
57952542|NCT01183559|DRUG|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
57952543|NCT01183559|DRUG|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
57952544|NCT01183559|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
58099228|NCT03964090|DRUG|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
58099229|NCT03964090|DRUG|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
58099230|NCT03964090|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
58099231|NCT03964090|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
57952545|NCT01183559|RADIATION|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
57952546|NCT05914168|DEVICE|Breast Tomosynthesis|Three dimensional mammography
57952547|NCT00851539|BEHAVIORAL|Video|Behavioral Intervention Video
58099232|NCT02773888|DEVICE|HS-1000|
58099233|NCT04495192|GENETIC|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
58099234|NCT02198755|DEVICE|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
58426869|NCT04708860|BEHAVIORAL|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
58426870|NCT03180307|DRUG|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
58426871|NCT03180307|DEVICE|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
58426872|NCT03180307|PROCEDURE|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
58426873|NCT01702506|DRUG|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
58426874|NCT01702506|DRUG|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
58426875|NCT01702506|DRUG|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
58426876|NCT00169507|BIOLOGICAL|Pneumococcal (vaccine)|
58099235|NCT02198755|DEVICE|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
58099236|NCT05021588|PROCEDURE|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
58099237|NCT02719782|BIOLOGICAL|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
58099238|NCT04141137|DEVICE|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
58099239|NCT01123980|DRUG|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
58099240|NCT01123980|DRUG|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
58099241|NCT01123980|DRUG|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
58099242|NCT01123980|DRUG|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
58099243|NCT01551394|DRUG|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
58099244|NCT01551394|DRUG|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
58426877|NCT03330470|BEHAVIORAL|exercise|participants will be subjected to 3 months supervised exercise intervention
58426878|NCT03330470|DIETARY_SUPPLEMENT|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
58426879|NCT03330470|BEHAVIORAL|stretching|participants will be subjected to 3 months supervised stretching program
58426880|NCT03330470|DIETARY_SUPPLEMENT|supplementation with placebo|participants will be instructed to take placebo 2 times daily
58426881|NCT05817032|BEHAVIORAL|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
58426882|NCT05817032|BEHAVIORAL|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
58426883|NCT01399710|PROCEDURE|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
58099245|NCT03998215|BIOLOGICAL|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
58099246|NCT02095626|DRUG|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
58426884|NCT01399710|PROCEDURE|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
58099247|NCT02095626|DRUG|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
58099248|NCT03090919|BIOLOGICAL|Platelet transfusion|
58099249|NCT03090919|OTHER|Saline|
58099250|NCT01833221|DRUG|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
58099251|NCT04427514|DEVICE|Telemedicine software for data transmission and analysis in CAPD.|Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
58099252|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
58099253|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
58426885|NCT01399710|DEVICE|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
58426886|NCT00483795|DRUG|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
58426887|NCT01431963|DRUG|Lamictal|No comparison.
58426888|NCT01108198|DRUG|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
58426889|NCT01108198|DRUG|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
58426890|NCT01735370|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
58426891|NCT01735370|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
58426892|NCT04631965|BEHAVIORAL|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
58426893|NCT00988364|DRUG|Simvastatin|Simvastatin 20mg daily for 3 months.
58426894|NCT00988364|DRUG|Vytorin|Vytorin 20/10mg daily for 3 months.
58426895|NCT00988364|DRUG|Placebo|Placebo one tablet daily times 3 months.
58426896|NCT00988364|DRUG|Ezetimibe|Ezetimibe 10mg daily for 3 months.
58426897|NCT04194814|DRUG|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
58099254|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
58426898|NCT04194814|DRUG|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
58426899|NCT00057369|DRUG|dalbavancin|
58426900|NCT01970059|DRUG|Extended-Release Carvedilol Sulfate|
58426901|NCT01970059|DRUG|Sustained-release Metoprolol Succinate|
58426902|NCT03125460|DEVICE|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
58426903|NCT01179165|OTHER|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
58426904|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
58426905|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
58426906|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
58426907|NCT01675362|DRUG|Placebo|They will receive placebo
58426908|NCT01086176|DEVICE|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
58426909|NCT02660892|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
58426910|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
58426911|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
58426912|NCT01311440|OTHER|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
58426913|NCT05060965|DRUG|Nicotine lozenge|Nicotine replacement therapy
58426914|NCT05060965|DRUG|Nicotine gum|Nicotine replacement therapy
58426915|NCT05060965|DRUG|Nicotine patch|Nicotine replacement therapy
58426916|NCT05060965|OTHER|Maryland Quitline|Telephone-based tobacco cessation service
58426917|NCT05060965|OTHER|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
58426918|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
58426919|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
57736455|NCT06139523|DEVICE|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
58099255|NCT01098383|DRUG|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
58426920|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
58426921|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
58426922|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
58426923|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
58426924|NCT05974813|DIETARY_SUPPLEMENT|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
58426925|NCT05974813|DIETARY_SUPPLEMENT|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
58426926|NCT03010020|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
58426927|NCT03010020|BEHAVIORAL|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
58426928|NCT00486382|BIOLOGICAL|Leish-111f + MPL-SE Adjuvant|
58426929|NCT03925051|DRUG|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
58426930|NCT03925051|DRUG|CMAB807|human monoclonal antibody targeting RANKL.
57736456|NCT01681589|DEVICE|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
58099256|NCT01098383|DRUG|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
58099257|NCT03932435|DRUG|Fisrt period TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
58426931|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
57736457|NCT01681589|DEVICE|Control Group|This group will receive Sham TDCS
57736458|NCT01681589|OTHER|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
57736459|NCT05354050|DRUG|DARE-BV1|2% Clindamycin 100 MG
57736460|NCT00207272|BEHAVIORAL|1170-1870 kcal/day liquid diet|
57736461|NCT00207272|PROCEDURE|Gastric bypass surgery|
58099258|NCT03932435|DRUG|Fisrt period TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
58099259|NCT03932435|OTHER|Washout period|7 days
58099260|NCT03932435|DRUG|Second period TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
58426932|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
57736462|NCT00207272|PROCEDURE|Biopsy.visceral adipose tissue|
58099261|NCT03932435|DRUG|Second period TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
58099262|NCT01340703|PROCEDURE|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
58099263|NCT02345863|DRUG|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
58099264|NCT02345863|DRUG|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
58099265|NCT02345863|DRUG|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
58099266|NCT04313686|BEHAVIORAL|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
58099267|NCT04313686|BEHAVIORAL|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
58099268|NCT03663959|PROCEDURE|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
58099269|NCT03663959|PROCEDURE|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
58099270|NCT01874730|OTHER|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
58099271|NCT01874730|DRUG|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
58099272|NCT01874730|OTHER|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
58099273|NCT05282823|DEVICE|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
58426933|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
58426934|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
58426935|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
57736463|NCT00207272|PROCEDURE|Biopsy.omental adipose tissue|
57736464|NCT00207272|PROCEDURE|Biopsy. subcutaneous abdominal adipose tissue|
58426936|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
57736465|NCT00207272|PROCEDURE|Blood sample|
57736466|NCT06283550|DRUG|Abrocitinib 200 mg|Abrocitinib will be available in 100 mg strength tablet
57736467|NCT06283550|DRUG|Abrocitinib 100 mg|Abrocitinib will be available in 100 mg strength tablet
57736468|NCT06283550|DRUG|Placebo|Placebo tablet
57736469|NCT06507293|PROCEDURE|Paravertebral block|Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
58426937|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
58426938|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58426939|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
57736470|NCT06507293|PROCEDURE|Erector spiane plane block|Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
57736471|NCT06068413|DEVICE|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
57736472|NCT01892072|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
57736473|NCT03119454|DRUG|Diprospan|Intramuscular
57736474|NCT04184063|DRUG|NBMI|NBMI active treatment
57736475|NCT04184063|OTHER|Placebo|Placebo for comparison
57736476|NCT03234426|OTHER|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
57736477|NCT03234426|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
58426940|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
57736478|NCT03814889|DEVICE|Vibration pattern|Vibration patterns applied to the affected limb based on pilot study results.
57736479|NCT03814889|DEVICE|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
57736480|NCT03882476|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for sepsis detection
57736481|NCT05432193|DRUG|[Ga-68]-PNT6555|\[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
58099274|NCT00005588|RADIATION|radiation therapy|
58099275|NCT03205007|BEHAVIORAL|Health promotion nutrition program|Health promotion nutrition program
58099276|NCT04499690|BEHAVIORAL|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
58099277|NCT02148731|OTHER|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
58099278|NCT00089310|RADIATION|technetium-99|0.25 mCi in 4 equal doses
58099279|NCT02572973|OTHER|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
58099280|NCT05521087|DRUG|JNJ-75276617|JNJ-75276617 will be administered orally.
58099281|NCT05521087|DRUG|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
58099282|NCT05521087|DRUG|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
57736482|NCT05432193|DRUG|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
58099283|NCT05521087|DRUG|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
58099284|NCT05521087|DRUG|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
58099285|NCT05521087|DRUG|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
58099286|NCT05521087|DRUG|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
57736483|NCT06118372|DRUG|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
57736484|NCT03930472|BEHAVIORAL|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
58099287|NCT03121469|DEVICE|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
58099288|NCT00996632|PROCEDURE|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
58099289|NCT00996632|PROCEDURE|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
58099290|NCT05983029|DIAGNOSTIC_TEST|Intergluteal Cleft|Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line
58099291|NCT05983029|DIAGNOSTIC_TEST|Neuraxial Midline|Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line
58099292|NCT05983029|DIAGNOSTIC_TEST|Horizontal Distance between Vertical Markings|The horizontal distance between these two vertical marks will be measured at the level of the intercristal line
58099293|NCT02582801|DRUG|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
58099294|NCT03945760|DRUG|Baricitinib|Baricitinib 2 mg
58099295|NCT03945760|DRUG|Placebo|Placebo
58426941|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58426942|NCT00783081|DRUG|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
58426943|NCT00783081|DRUG|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
58426944|NCT00783081|DRUG|Placebo|Placebo BID for 26 weeks.
58099296|NCT03333382|DEVICE|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
58099297|NCT03333382|DEVICE|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
58426945|NCT02161419|DRUG|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
57736485|NCT03876652|DEVICE|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
57736486|NCT03259633|DRUG|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
57736487|NCT05188846|OTHER|SDF|"1. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
58099298|NCT01900392|BEHAVIORAL|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
58099299|NCT03816956|DRUG|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
58099300|NCT03816956|OTHER|Placebo|Placebo comparator
58099301|NCT02937662|DRUG|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
58099302|NCT02937662|DRUG|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
58099303|NCT02937662|DRUG|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
58426946|NCT02161419|DRUG|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
57736488|NCT05188846|OTHER|SDF + ART (SMART technique )|2. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
57736489|NCT06110923|DRUG|CKD-846|once administration of Investigational Product
57736490|NCT06110923|DRUG|D091|once administration of Investigational Product per day
57736491|NCT05997043|DRUG|oral anti-Parkinson drugs and injection of botulinum toxin|The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
58099304|NCT02937662|DRUG|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
58099305|NCT03775382|OTHER|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
58099306|NCT03775382|OTHER|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
58099307|NCT02711579|DRUG|Celecoxib|
58099308|NCT02711579|DRUG|Placebo|
58099309|NCT02641171|OTHER|Specimen sampling|exhaled air samples blood samples fecal samples
58099310|NCT01398982|DRUG|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
58099311|NCT01398982|DRUG|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
58099312|NCT03467828|GENETIC|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
58099313|NCT01652573|DRUG|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
58099314|NCT01652573|DRUG|Saline Nasal Spray Placebo|
58099315|NCT04769908|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
58099316|NCT04769908|DRUG|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
58426947|NCT03409250|DRUG|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
58426948|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
58426949|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
58099317|NCT04769908|DRUG|Sintilimab|Sintilimab, IV, 200mg, q3w
58426950|NCT02088567|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
58426951|NCT02088567|OTHER|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
58426952|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
58426953|NCT02443818|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
58426954|NCT05047146|OTHER|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
58426955|NCT00559988|DRUG|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
58426956|NCT00559988|DRUG|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
58426957|NCT02251210|DRUG|BIIL 284 BS low dose|
58426958|NCT02251210|DRUG|BIIL 284 BS medium dose|
58426959|NCT02251210|DRUG|BIIL 284 BS high dose|
58426960|NCT02251210|DRUG|Placebo|
58426961|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
57736492|NCT05997043|DRUG|oral anti-Parkinson's drugs|The control group only took oral anti-Parkinson's drugs.
57736493|NCT01093729|DRUG|HM11260C|HM11260C 0.5mcg/kg or Placebo
57736494|NCT01093729|DRUG|HM11260C|HM11260C 2mcg/kg or Placebo
57736495|NCT01093729|DRUG|HM11260C|HM11260C 4mcg/kg or Placebo
57736496|NCT01093729|DRUG|HM11260C|HM11260C 8mcg/kg or Placebo
57736497|NCT01093729|DRUG|HM11260C|HM11260C 14mcg/kg or Placebo
58426962|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
58426963|NCT02350738|OTHER|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
58426964|NCT02350738|OTHER|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
57736498|NCT06377241|DEVICE|ScentAware|ScentAware is a smell test
57736499|NCT06377241|DEVICE|UPSIT|UPSIT is a smell test
57736500|NCT02363946|DRUG|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
57736501|NCT02363946|OTHER|Placebo|0.9 % normal saline
57736502|NCT02363946|DRUG|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
57736503|NCT04582630|DIETARY_SUPPLEMENT|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
57736504|NCT03104634|DRUG|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
57736505|NCT03104634|DRUG|Placebo|Placebo and delivery device matched to active intervention
57736506|NCT06204627|DEVICE|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
57736507|NCT06204627|DEVICE|Recognize (hand) - Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
57736508|NCT06204627|OTHER|Sham TDCS|TDCS sham: The device remains inactive for 20 minutes.
58099318|NCT04509752|OTHER|Survey|An online survey will be sent to each clinic to answer the survey questions.
58426965|NCT02350738|OTHER|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
58426966|NCT05036291|DRUG|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
58426967|NCT05464264|DRUG|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
58426968|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
58426969|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
58426970|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
58426971|NCT00934674|DRUG|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
58426972|NCT06453317|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
58426973|NCT06453317|BIOLOGICAL|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
58099319|NCT04333199|BEHAVIORAL|Timely|Email
58426974|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
58426975|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
58426976|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
58426977|NCT01310478|DRUG|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
58099320|NCT04333199|BEHAVIORAL|Transparency|Email
58099321|NCT04333199|BEHAVIORAL|Foot-in-the-door|Email
58426978|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
58426979|NCT01691976|DRUG|Oestrogen Patches|
58426980|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
57736509|NCT06204627|OTHER|Landscape recognition|Image recognition training that does not refer to right/left discrimination.
58426981|NCT03006887|DRUG|lenvatinib|lenvatinib capsules
58426982|NCT03006887|DRUG|pembrolizumab|pembrolizumab intravenous infusion
58099322|NCT00006225|BIOLOGICAL|filgrastim|
58099323|NCT00006225|BIOLOGICAL|recombinant flt3 ligand|
58099324|NCT00006225|BIOLOGICAL|recombinant human thrombopoietin|
58426983|NCT00119171|DRUG|Ispinesib|
58426984|NCT00119171|DRUG|Capecitabine|
58426985|NCT02215005|DRUG|Telmisartan|
58099325|NCT00006225|BIOLOGICAL|recombinant interleukin-3|
58099326|NCT00006225|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58099327|NCT00437437|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
58099328|NCT06266507|BEHAVIORAL|Ergotherapy Based Parent Coaching|Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.
58099329|NCT06266507|OTHER|Informative Brochure Distribution|No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
58099330|NCT00943384|DEVICE|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
57736510|NCT01015391|DRUG|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
58426986|NCT02215005|DRUG|Ramipril|
58426987|NCT00932165|DRUG|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
58426988|NCT05041348|DIAGNOSTIC_TEST|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
58426989|NCT00006056|DRUG|anti-thymocyte globulin|
58426990|NCT00006056|DRUG|busulfan|
58426991|NCT00006056|DRUG|cyclophosphamide|
58426992|NCT00006056|DRUG|cyclosporine|
58426993|NCT00006056|DRUG|etoposide|
58426994|NCT00006056|DRUG|filgrastim|
57736511|NCT01015391|DRUG|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
57736512|NCT02437591|DRUG|fidaxomicin|oral
57736513|NCT01983293|DEVICE|QLV based implant strategy|
57736514|NCT01983293|DEVICE|Standard of care implant strategy|
57736515|NCT02836418|DRUG|ATYR1940|Concentrate for solution for infusion
57736516|NCT06190301|DRUG|Rituximab|Intralesional Rituximab Injection
57736517|NCT06190301|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
58426995|NCT00006056|DRUG|methotrexate|
58426996|NCT00006056|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58426997|NCT00592332|DRUG|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
58099331|NCT03593772|BEHAVIORAL|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
58099332|NCT04278365|BEHAVIORAL|Positive affect training|Behavioral training involving position emotion enhancement
58426998|NCT00592332|OTHER|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
58426999|NCT03100110|DEVICE|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
58427000|NCT06267664|DRUG|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
58427001|NCT00756210|OTHER|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
58427002|NCT00762541|DEVICE|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
58427003|NCT03254550|OTHER|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
57736518|NCT00364429|DRUG|[123]I-CNS 1261|Study Drug
57736519|NCT00364429|DRUG|Lorazepam|Study Drug
57736520|NCT00364429|DRUG|Risperidone|Study Drug
57736521|NCT04207099|DEVICE|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
57736522|NCT03585244|OTHER|weekly weight|weekly weight data collection for six months
58427004|NCT05505409|DRUG|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
58427005|NCT05505409|DRUG|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
58427006|NCT02412332|PROCEDURE|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
58427007|NCT02412332|PROCEDURE|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
57736523|NCT02412137|OTHER|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
57736524|NCT06670300|DRUG|cardonilimab|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
57736525|NCT06670781|DEVICE|Experimental: Intervention arm: Goal-Directed Valsalva maneuver|For the Goal directed Valsalva maneuver, the same method patients are instructed to blow into a plastic pipe connected to the manometer device, in order to reach a pressure of 40 mmHg for at least 5 seconds. Then patients are instructed to exhale quickly.
57736526|NCT06670781|DEVICE|Control - standard of care: Self-Directed Valsalva maneuver|The Valsalva maneuver is performed by the patient taking a normal (or deep) inspiration, followed by forceful expiration against a closed airway for up to 15 to 20 sec and then release of the expiratory effort on entry of saline into the right atrium.
58427008|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
58427009|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
58427010|NCT03330184|DRUG|Berberine Hydrochloride group|
58427011|NCT03330184|DRUG|Bifidobacterium group|
58427012|NCT03330184|DRUG|Berberine Hydrochloride and Bifidobacterium group|
57736527|NCT06309693|PROCEDURE|Quadratus Lumborum (QL) Block|The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
58099333|NCT03849170|BEHAVIORAL|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
58099334|NCT03849170|OTHER|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
58427013|NCT03330184|DRUG|placebo|
57736528|NCT06309693|PROCEDURE|Enhanced Recovery After Surgical (ERAS) Protocol|Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
57736529|NCT00411567|DRUG|inhaled corticosteroid therapy|
57736530|NCT02931279|DEVICE|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
57736531|NCT02208180|BEHAVIORAL|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
57736532|NCT04396613|PROCEDURE|Closure technique|Randomized assignment to one of three known, effective closure techniques
58099335|NCT03843268|DEVICE|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
58427014|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
58427015|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
58427016|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
58427017|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
58427018|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
58427019|NCT03992092|DEVICE|C-MAC VS|C-MAC Video Stylet
57736533|NCT00687037|DRUG|Cetylpyridinium chloride|
57736534|NCT05598333|DRUG|AB-1002|Intracoronary Infusion of AB-1002 or placebo
57736535|NCT02123654|DRUG|Daclatasvir|
57736536|NCT02123654|DRUG|Asunaprevir|
57736537|NCT02123654|DRUG|DCV 3DAA|
58099336|NCT03843268|DEVICE|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
58099337|NCT04238780|PROCEDURE|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
58427020|NCT03992092|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
58427021|NCT04492761|BEHAVIORAL|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
58427022|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
58099338|NCT04238780|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
58099339|NCT02134769|DEVICE|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
58099340|NCT01255579|DRUG|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
58099341|NCT01255579|DRUG|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
57736538|NCT02123654|OTHER|Placebo for DCV 3DAA|
58099342|NCT02702271|DEVICE|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
57736539|NCT02123654|OTHER|Placebo for Daclatasvir|
57736540|NCT02123654|OTHER|Placebo for Asunaprevir|
57736541|NCT01326364|PROCEDURE|Stereotactic body radiotherapy|Standard of Care
58099343|NCT05165017|BIOLOGICAL|AlloRx Stem Cells®|Umbilical cord-derived allogeneic mesenchymal stem cells
58099344|NCT05165017|OTHER|Placebo control|Placebo infusion without mesenchymal stem cells
58099345|NCT04106856|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58099346|NCT04106856|DRUG|Losartan|Given PO
58099347|NCT04106856|DRUG|Losartan Potassium|Given PO
58099348|NCT04106856|OTHER|Quality-of-Life Assessment|Ancillary studies
58099349|NCT04106856|OTHER|Questionnaire Administration|Ancillary studies
58099350|NCT02567266|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
58099351|NCT02567266|BEHAVIORAL|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
57736542|NCT01326364|DRUG|Iodixanol|IV, calculated per patient
57736543|NCT01326364|DRUG|Iohexol|IV, Calculated per patient
57736544|NCT03569280|COMBINATION_PRODUCT|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
58099352|NCT02567266|BEHAVIORAL|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
58427023|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
58427024|NCT01841255|DEVICE|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
58427025|NCT01841255|DEVICE|facemask|
58427026|NCT02700594|OTHER|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
58427027|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
58427028|NCT04752332|DRUG|Abemaciclib|Administered orally.
58427029|NCT04752332|DRUG|Standard Adjuvant ET|Administered according to label instructions.
58427030|NCT04752332|DRUG|Placebo|Administered orally.
58099353|NCT00145652|DRUG|Neo-Recormon and Venofer|
58099354|NCT02190383|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
58099355|NCT02396069|DRUG|JPI-289|PARP-1 inhibitor
58099356|NCT02396069|DRUG|Placebo|Placebo
58099357|NCT01819701|DIETARY_SUPPLEMENT|LC-1000|L-carnitine 1000 mg /d
58099358|NCT01819701|DIETARY_SUPPLEMENT|LC-2000|L-carnitine: 2000 mg/d
58099359|NCT01819701|DIETARY_SUPPLEMENT|Q10-150|Coenzyme Q10: 150 mg/d
58099360|NCT01819701|DIETARY_SUPPLEMENT|Q10-300|Coenzyme Q10: 300 mg/d
58099361|NCT01819701|OTHER|Placebo|
58099362|NCT04779411|OTHER|Weekly Food Frequency Questionnaire|A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.
58099363|NCT04779411|OTHER|Monthly Food Frequency Questionnaire|A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
58099364|NCT04779411|OTHER|24-Hour Diet Recall|the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.
58099365|NCT04779411|OTHER|Electronic Device Use Questionnaire|1. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.
58099366|NCT04779411|OTHER|24-Hour Electronic Device Use Diary|Participants asked to record their electronic device use in hours and minutes over 24 hours.
58099367|NCT00002126|DRUG|Filgrastim|
58427031|NCT04383275|DRUG|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
58427032|NCT04383275|DRUG|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
58427033|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
58427034|NCT01865383|BEHAVIORAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
58427035|NCT05476029|DIAGNOSTIC_TEST|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
58427036|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
58427037|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
57952548|NCT03841071|OTHER|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
57952549|NCT03670212|DRUG|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
58099368|NCT06319521|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
58099369|NCT06319521|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58427038|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
58427039|NCT04518033|DEVICE|Various commercially available face coverings|Various commercially available face coverings
57952550|NCT03670212|DRUG|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
57952551|NCT03670212|DRUG|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
57952552|NCT02131558|PROCEDURE|ICG Dye|ICG Dye injections
58099370|NCT06319521|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
57736545|NCT00489970|PROCEDURE|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
58099371|NCT06319521|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58099372|NCT01837485|DRUG|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
58427040|NCT01879046|PROCEDURE|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
58099373|NCT01837485|DRUG|Placebo|Placebo pill was applied 3 times a day for 3 months
58099374|NCT02470078|DEVICE|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
58427041|NCT00196768|DRUG|Arsenic trioxide|
58427042|NCT00196768|DRUG|Trisenox|
58427043|NCT02690441|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
58427044|NCT02690441|BEHAVIORAL|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
58427045|NCT02690441|BEHAVIORAL|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
58099375|NCT02470078|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
58099376|NCT01880541|OTHER|hypnosedation|hypnosedation
58427046|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
58427047|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
58427048|NCT03922087|OTHER|No intervention|No intervention
58427049|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
58099377|NCT01880541|OTHER|general anesthésia|general anesthesia
58099378|NCT03865992|DIETARY_SUPPLEMENT|Curcumin|Given capsules for oral administration
58099379|NCT03865992|OTHER|Placebo|Given capsules for oral administration
58099380|NCT03865992|OTHER|Nanoemulsion|Given nanoemulsion curcumin PO
58099381|NCT03865992|OTHER|Quality-of-Life Assessment|Ancillary studies
58099382|NCT03865992|BEHAVIORAL|Questionnaire|Ancillary studies
58099383|NCT04217031|OTHER|No intervention|No intervention
58427050|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
58427051|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
58427052|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
58427053|NCT05261009|DRUG|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
58427054|NCT05261009|OTHER|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
58427055|NCT05157581|DEVICE|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
58427056|NCT05157581|DRUG|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
57736546|NCT00489970|BIOLOGICAL|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
57736547|NCT00489970|BIOLOGICAL|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
58427057|NCT01133119|DRUG|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
58427058|NCT01133119|DRUG|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
58427059|NCT02248402|BIOLOGICAL|Vax-DC/MM|
58427060|NCT00332553|DRUG|Raloxifene|
58427061|NCT00332553|DRUG|medroxyprogesterone acetate|
58427062|NCT00332553|DRUG|estrogen|
58427063|NCT00332553|DRUG|17 beta estradiol|
58427064|NCT04516772|DEVICE|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
58427065|NCT04928118|OTHER|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
58427066|NCT04042727|DRUG|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
58427067|NCT04042727|OTHER|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
58427068|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
58427069|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
58427070|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
58427071|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
57736548|NCT05427799|DIETARY_SUPPLEMENT|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
58427072|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
58427073|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
58427074|NCT05515939|DEVICE|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
58427075|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
58427076|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
58427077|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
58427078|NCT06191107|DEVICE|Removable Partial Denture|Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
58427079|NCT02175914|DRUG|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
58427080|NCT04088110|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
58427081|NCT04088110|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
58427082|NCT04088110|DRUG|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
58427083|NCT04464096|OTHER|non|non
57736549|NCT05427799|DIETARY_SUPPLEMENT|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
58427084|NCT05141604|OTHER|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
58427085|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
58427086|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
58427087|NCT00556413|BIOLOGICAL|cetuximab|
58427088|NCT00556413|DRUG|fluorouracil|
58427089|NCT00556413|DRUG|irinotecan hydrochloride|
58427090|NCT00556413|DRUG|leucovorin calcium|
58427091|NCT00556413|DRUG|oxaliplatin|
58427092|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
58427093|NCT02421679|DRUG|TNX-102 SL|TNX-102 Sublingual tablets
58427094|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
58427095|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
58427096|NCT02045693|DRUG|Methadone|
58427097|NCT02045693|DRUG|DCV 3DAA FDC|
58427098|NCT02045693|DRUG|BMS-791325|
58427099|NCT02045693|DRUG|Buprenorphine|
58427100|NCT02045693|DRUG|Naloxone|
57736550|NCT05602376|BEHAVIORAL|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
57736551|NCT05602376|BEHAVIORAL|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
57736552|NCT04609254|DRUG|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
57736553|NCT04609254|DRUG|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
57736554|NCT04609254|DRUG|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
57736555|NCT06127667|BEHAVIORAL|aerobic exercise|use of single bout of aerobic exercise
57736556|NCT06216457|DEVICE|AI software for Stroke|AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
58307756|NCT04578665|DEVICE|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0\~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0\~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0\~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
58427101|NCT02882100|BIOLOGICAL|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
58427102|NCT02882100|BIOLOGICAL|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
58427103|NCT00005859|DRUG|tipifarnib|
58427104|NCT04680949|DRUG|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
58427105|NCT04680949|DRUG|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
58427106|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
58427107|NCT03807284|BEHAVIORAL|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
58427108|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58427109|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58427110|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
58427111|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
57736557|NCT02173977|OTHER|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
57736558|NCT02173977|OTHER|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
57736559|NCT05403580|DRUG|Olanzapine|Given PO
57736560|NCT05403580|DRUG|Placebo Administration|Given PO
58427112|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
57736561|NCT05403580|OTHER|Questionnaire Administration|Ancillary studies
57736562|NCT03252587|DRUG|BMS-986165|Specified dose on specified days
57736563|NCT03252587|OTHER|Placebo|Specified dose on specified days
57736564|NCT02048943|DRUG|dovitinib lactate|Given PO
57736565|NCT02048943|DRUG|gemcitabine hydrochloride|Given IV
57736566|NCT02048943|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
57736567|NCT02048943|OTHER|pharmacological study|Correlative studies
57736568|NCT02048943|OTHER|laboratory biomarker analysis|Correlative studies
57736569|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
57736570|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
57736571|NCT05194774|PROCEDURE|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
57736572|NCT01837381|PROCEDURE|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
58427113|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
58427114|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
57736573|NCT05987683|PROCEDURE|Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture|Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
57736574|NCT02671435|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
57736575|NCT02671435|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
57736576|NCT02671435|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
58427115|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
58427116|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
57736577|NCT02671435|DRUG|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
57736578|NCT02671435|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
57736579|NCT02526264|OTHER|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
57736580|NCT01909310|PROCEDURE|head extension|the lungs are ventilated with the patient´s head extended
57736581|NCT01909310|PROCEDURE|neutral position|the lungs are ventilated with the patient´s head in neutral position
57736582|NCT01909310|PROCEDURE|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
57736583|NCT06447857|OTHER|Cardiac MRI|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
57769569|NCT05724264|DIAGNOSTIC_TEST|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
58427117|NCT04514211|DRUG|Propofol|General anesthesia using propofol infusion
58427118|NCT04514211|DRUG|Sevoflurane|General anesthesia using sevoflurane
58427119|NCT00156169|DRUG|Dunaliella|
57769570|NCT04879758|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
57952553|NCT04729036|PROCEDURE|open reduction and internal fixation|The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
57952554|NCT00223028|DRUG|sirolimus, mycophenolat mofetil, fluvastatin|
58427120|NCT02924740|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
58427121|NCT02924740|BEHAVIORAL|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
58427122|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
58427123|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
58427124|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
58427125|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
58427126|NCT04306653|DRUG|ACTH|patients with acute gout will receive 100 IU ACTH IM
58427127|NCT04306653|DRUG|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
58427128|NCT04463667|OTHER|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
58427129|NCT06171646|BEHAVIORAL|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
58427130|NCT04878913|DRUG|C21|C21 was administered in the VP-C21-006 trial
58427131|NCT04878913|DRUG|Placebo|Placebo was administered in the VP-C21-006 trial
58427132|NCT05061498|DIAGNOSTIC_TEST|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
58427133|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
58427134|NCT00837759|DRUG|Insulin|
58427135|NCT00837759|DRUG|Lansoprazole|
58427136|NCT00837759|DRUG|Sitagliptin|
58427137|NCT00837759|BIOLOGICAL|Diamyd|
58427138|NCT00837759|DRUG|GAD65 (Diamyd)|
58099384|NCT03962660|OTHER|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
58427139|NCT03728179|COMBINATION_PRODUCT|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
58427140|NCT00245648|DRUG|fibrinolytic therapy or combination reduced fibrinolytic therapy|
58427141|NCT02762331|DRUG|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
58427142|NCT02762331|DRUG|Placebo|Placebo intervention
57736584|NCT06352710|OTHER|OP-Tracker App|"There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery."
57736585|NCT00576069|DRUG|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
57736586|NCT00576069|DRUG|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
57736587|NCT00576069|DRUG|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
57736588|NCT00576069|DRUG|Prednisone|0-15 mg daily as needed
57952555|NCT03710109|OTHER|EEG|non-invasive, non-interventional sensor
58099385|NCT03962660|OTHER|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
58099386|NCT03384420|BIOLOGICAL|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
58099387|NCT04352036|OTHER|no interventional study|no interventional study
58099388|NCT02185235|DEVICE|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
58099389|NCT02185235|DEVICE|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
58099390|NCT02185235|OTHER|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
58427143|NCT03905902|BIOLOGICAL|DCVAC/OvCa|activated autologous dendritic cells
58427144|NCT03905902|BIOLOGICAL|DCVAC/OvCa placebo|placebo for activated autologous cells
58427145|NCT06264258|BEHAVIORAL|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
58427146|NCT02687698|OTHER|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
58427147|NCT00959556|OTHER|laboratory biomarker analysis|
58427148|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
58427149|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
58427150|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
58427151|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
58427152|NCT05683002|DIETARY_SUPPLEMENT|Aronia supplementation|As described in experimental arm
57952556|NCT00542269|DRUG|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
58099391|NCT03743675|BEHAVIORAL|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
58427153|NCT05683002|DIETARY_SUPPLEMENT|Cellulose supplementation|As described in placebo comparator arm
58427154|NCT01254825|PROCEDURE|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
58099392|NCT03743675|BEHAVIORAL|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
58099393|NCT02426125|DRUG|Ramucirumab|Administered IV
58099394|NCT02426125|DRUG|Docetaxel|Administered IV
58099395|NCT02426125|DRUG|Placebo|Administered IV
58099396|NCT05699577|DIAGNOSTIC_TEST|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
58099397|NCT04339361|DRUG|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
58099398|NCT04339361|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
58099399|NCT04339361|DRUG|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
58099400|NCT05406596|DEVICE|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
58099401|NCT04618315|DEVICE|Hearing Aids|Receiver-in-the-ear hearing aids.
58099402|NCT03386071|DRUG|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
57952557|NCT00542269|DRUG|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
57952558|NCT00542269|DRUG|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
57952559|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.
58099403|NCT06060639|DIAGNOSTIC_TEST|transthoracic echocardiography|E wave, A wave, e' and vdi measurement
58099404|NCT05598645|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
58099405|NCT05598645|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
58099406|NCT02606682|DRUG|NPT200-11|Single doses of NPT200-11capsules, orally administered
58099407|NCT02606682|DRUG|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
58307757|NCT04578665|BEHAVIORAL|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error \[difference of the desired trajectory and actual trajectory\] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
58307758|NCT04578665|DEVICE|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
58307759|NCT03228901|DRUG|Oxytocin|Administration of the hormone oxytocin
58307760|NCT03228901|DRUG|Placebos|
58307761|NCT01737606|DEVICE|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
58307762|NCT02532036|BIOLOGICAL|Aerosol inhaled MVA85A|
58307763|NCT02532036|BIOLOGICAL|Intramuscular MVA85A|
58307764|NCT02532036|BIOLOGICAL|Intramuscular Saline placebo|
58307765|NCT02532036|BIOLOGICAL|Aerosol inhaled Saline placebo|
58307766|NCT00163592|DRUG|Tissucol®|
58307767|NCT00163592|PROCEDURE|Control: Conventional treatment, i.e. compression with swabs|
58307768|NCT01470716|DRUG|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
58307769|NCT04346316|DRUG|SHR0302|Oral tablets taken once daily (QD)
58427155|NCT01254825|PROCEDURE|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
58427156|NCT03903887|BIOLOGICAL|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
58427157|NCT05113992|OTHER|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
58427158|NCT05113992|OTHER|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
58427159|NCT01081743|OTHER|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
58427160|NCT01531751|DEVICE|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
58427161|NCT01531751|DRUG|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
58427162|NCT03826199|DRUG|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
57952560|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
57952561|NCT01740375|PROCEDURE|esophagectomy|esophagectomy
58099408|NCT03676673|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
58427163|NCT03826199|BEHAVIORAL|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
57952562|NCT01002235|BIOLOGICAL|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
58099409|NCT02149199|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
58099410|NCT02149199|DRUG|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
58099411|NCT02149199|DRUG|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
58099412|NCT05576285|DIAGNOSTIC_TEST|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
58099413|NCT01946087|PROCEDURE|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
58099414|NCT01946087|PROCEDURE|Control group|keeping the cuff deflated
58099415|NCT04876859|PROCEDURE|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
58427164|NCT00967096|DRUG|Rifaximin|Rifaximin for Bone marrow transplant patients
58427165|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
58427166|NCT01736618|DEVICE|S-ICD System|
58427167|NCT02861599|OTHER|proprioceptive therapy|
57952563|NCT01394627|DRUG|Eplerenone|100mg x 2
57952564|NCT01394627|DRUG|Placebo|
58099416|NCT04876859|PROCEDURE|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
58099417|NCT02946619|BEHAVIORAL|Self-Regulation Condition|
57952565|NCT06090942|OTHER|Smartphone-based cognitive training|Smartphone-based cognitive training
58099418|NCT02946619|BEHAVIORAL|Enhanced self-Regulation Condition|
58099419|NCT03593239|OTHER|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
57952566|NCT04193007|DRUG|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
57952567|NCT04193007|RADIATION|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
57952568|NCT00642915|DRUG|Lantus, Amaryl|
57952569|NCT01202929|PROCEDURE|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
58099420|NCT03593239|OTHER|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
58099421|NCT03593239|OTHER|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
58099422|NCT03593239|OTHER|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
57952570|NCT05537597|PROCEDURE|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
58099423|NCT03593239|OTHER|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
58099424|NCT03593239|OTHER|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
58427168|NCT02861599|OTHER|speech therapy|
58427169|NCT01202058|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
57952571|NCT05537597|PROCEDURE|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
58099425|NCT03593239|OTHER|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
58099426|NCT03593239|OTHER|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
58099427|NCT03593239|OTHER|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
58099428|NCT03593239|OTHER|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
58099429|NCT00047554|DRUG|Travoprost, 0.004% ophthalmic solution|
58099430|NCT00005893|DRUG|anti-thymocyte globulin|
58099431|NCT00005893|DRUG|busulfan|
58099432|NCT00005893|DRUG|cyclophosphamide|
58099433|NCT00005893|PROCEDURE|Bone marrow transplantation|
58099434|NCT02858076|DRUG|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
58099435|NCT02858076|PROCEDURE|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
58099436|NCT01787188|DRUG|Meloxicam Test Capsules|
58099437|NCT01787188|DRUG|Meloxicam Test Capsules|
58099438|NCT01787188|DRUG|Placebo Capsules|
58099439|NCT03812601|PROCEDURE|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
58099440|NCT06191380|BEHAVIORAL|PACE-MS|A single bout of cycling.
58427170|NCT01202058|DEVICE|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
58427171|NCT06002568|PROCEDURE|Silent|Apply wave file created in silence.
58099441|NCT05273606|DEVICE|MiSight mutifocal soft contact lens|Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.
58099442|NCT05273606|DEVICE|Proclear 1 Day soft contact lens|Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.
58099443|NCT04239638|DIAGNOSTIC_TEST|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
58099444|NCT00207974|DRUG|Marine active|
58427172|NCT06002568|PROCEDURE|Binaural beats|Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
58427173|NCT02039856|OTHER|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
58427174|NCT02039856|OTHER|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
57736589|NCT01716312|DRUG|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
57736590|NCT01463748|OTHER|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
58099445|NCT06556745|DRUG|BKR-017|BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
58099446|NCT03804931|PROCEDURE|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
58307770|NCT02135952|PROCEDURE|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
58427175|NCT02039856|OTHER|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
58427176|NCT02039856|OTHER|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
58427177|NCT02039856|OTHER|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
58427178|NCT02039856|OTHER|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
58307771|NCT02135952|OTHER|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
58307772|NCT02135952|DRUG|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
58307773|NCT00236743|DRUG|topiramate|
58307774|NCT05100563|DRUG|50 mg naltrexone|Medication combined with twice a week psychotherapy
58307775|NCT06464627|BEHAVIORAL|Physical activity|16 weeks
58307776|NCT04559984|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
58307777|NCT05143463|DRUG|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
58307778|NCT03052205|DRUG|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
58307779|NCT03523286|OTHER|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
58307780|NCT01217593|PROCEDURE|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
57736591|NCT01463748|OTHER|Placebo|starch
57736592|NCT02201069|BEHAVIORAL|health coaching|
57736593|NCT03809481|DRUG|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
57736594|NCT03809481|DRUG|Argatroban|Synthetic direct thrombin inhibitor
57736595|NCT05013333|DEVICE|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
57736596|NCT03588533|DRUG|Trastuzumab|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"
57736597|NCT03588533|DRUG|Capecitabine|- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
57736598|NCT03588533|DRUG|Cisplatin|- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
57736599|NCT00278434|DRUG|Zoledronate|
57736600|NCT00278434|OTHER|Placebo (Saline)|
57736601|NCT04443023|DEVICE|chosen TAVI valve|chosen TAVI valve
57736602|NCT03139487|DRUG|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
57736603|NCT03139487|DRUG|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
57736604|NCT03139487|DRUG|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
58099447|NCT03804931|PROCEDURE|Infusion of Saline|Infusion of Saline
58099448|NCT03804931|DRUG|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
58099449|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
58099450|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
58099451|NCT03060148|DEVICE|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
58427179|NCT01940081|OTHER|Transthoracic echocardiography|
58427180|NCT01940081|OTHER|Exercise test|
58099452|NCT06536725|OTHER|Building Organoid-on-chips models|This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
58099453|NCT06462209|OTHER|ladder training|"Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step."
58099454|NCT06462209|OTHER|plyometric training|In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
58099455|NCT05187663|PROCEDURE|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH \& Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
58099456|NCT05187663|PROCEDURE|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
58099457|NCT01364259|DRUG|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
58099458|NCT01364259|PROCEDURE|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
58099459|NCT05117866|DRUG|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
58099460|NCT01909817|PROCEDURE|Routine coronary angiogram|
58099461|NCT05672160|DIAGNOSTIC_TEST|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
58307781|NCT01217593|PROCEDURE|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
58307782|NCT00235807|PROCEDURE|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
58427181|NCT01940081|OTHER|24-hour Holter electrocardiogram|
57736605|NCT04242199|DRUG|INCB099280|INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
58307783|NCT00235807|PROCEDURE|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
57736606|NCT05394870|OTHER|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
57736607|NCT05394870|OTHER|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
57736608|NCT01936064|DIETARY_SUPPLEMENT|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
58427182|NCT01940081|OTHER|Contrast-enhanced magnetic resonance imaging|
58427183|NCT01940081|OTHER|123-iodine metaiodobenzylguanidine imaging|
58427184|NCT01940081|OTHER|Blood samples|
58427185|NCT01940081|GENETIC|Genetic analysis|
58427186|NCT01940081|PROCEDURE|Invasive electrophysiological study|
58427187|NCT01940081|PROCEDURE|Endomyocardial biopsy|
58427188|NCT01940081|PROCEDURE|Intraoperative biopsy|
58427189|NCT01940081|PROCEDURE|Intraoperative mapping and/or ablation|
58427190|NCT05551052|DIAGNOSTIC_TEST|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
58427191|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
57736609|NCT01936064|DRUG|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
58099462|NCT05437510|BIOLOGICAL|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
58099463|NCT02049554|OTHER|Preconception Care Screener|
58099464|NCT05361811|BEHAVIORAL|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
58427192|NCT02204488|PROCEDURE|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
58427193|NCT02204488|PROCEDURE|Trapeziectomy|Trapeziectomy
58427194|NCT02757612|RADIATION|laser diode|laser diode
58427195|NCT03652675|BEHAVIORAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
58427196|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
58427197|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
58427198|NCT05132777|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
58427199|NCT05132777|DRUG|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
58427200|NCT02356679|DRUG|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
58427201|NCT02356679|DRUG|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
58427202|NCT00001088|BIOLOGICAL|APL 400-047|
58427203|NCT00001088|DRUG|Bupivacaine hydrochloride|
58427204|NCT04708002|OTHER|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
58427205|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
58427206|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
58427207|NCT05487183|BEHAVIORAL|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
58427208|NCT05487183|BEHAVIORAL|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
58427209|NCT05487183|BEHAVIORAL|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
57736610|NCT01274091|OTHER|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
58099465|NCT05361811|BEHAVIORAL|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
58099466|NCT02756078|DEVICE|TEST Contact Lens|
58099467|NCT02756078|DEVICE|CONTROL Contact Lens|
58099468|NCT05319977|BEHAVIORAL|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
58099469|NCT03422081|DIAGNOSTIC_TEST|arterial doppler ultrasound|doppler ultrasound
58099470|NCT03806478|DRUG|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
58427210|NCT03649009|OTHER|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
58427211|NCT03649009|DRUG|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
58427212|NCT03649009|DRUG|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
58427213|NCT03649009|OTHER|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
58427214|NCT06502938|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
58427215|NCT06502938|PROCEDURE|Traditional artificial percutaneous coronary intervention|Doctors perform traditional percutaneous coronary intervention
58427216|NCT00479479|DRUG|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
58427217|NCT05770024|OTHER|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
58427218|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
58427219|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
58427220|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
58427221|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
57952572|NCT03961815|DRUG|Brazikumab Induction Dose|Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
57952573|NCT03961815|DRUG|Brazikumab Maintenance Dose|Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
58099471|NCT03806478|OTHER|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
58307784|NCT00235807|PROCEDURE|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
58307785|NCT03273855|OTHER|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
58427222|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
58307786|NCT03273855|OTHER|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
58427223|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
58427224|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
58427225|NCT05626127|OTHER|No interventions|As this is a observational study, there are no interventions.
58427226|NCT06037408|DRUG|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
57736611|NCT01274091|OTHER|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
57736612|NCT00384553|DRUG|Rituximab|
58307787|NCT00270023|DRUG|epoetin alfa|
57736613|NCT00384553|DRUG|DHAP|
57736614|NCT00384553|DRUG|TEC|
57736615|NCT00384553|DRUG|autologous stem cell transplantation|
57736616|NCT00272168|BEHAVIORAL|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
58307788|NCT01173172|RADIATION|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
58307789|NCT03225963|RADIATION|Chemoradiation with temozolomide|
58307790|NCT03568201|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
58307791|NCT04031716|BEHAVIORAL|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
58307792|NCT05181267|DIETARY_SUPPLEMENT|Intermittent fasting|Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
58307793|NCT05190614|DIAGNOSTIC_TEST|The biotype of gingiva|The biotype of gingival was determined by periodontal probe.
58307794|NCT02473497|DRUG|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
58307795|NCT02075125|DRUG|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
58307796|NCT02075125|DRUG|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
58307797|NCT03071601|DRUG|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
58307798|NCT03071601|DRUG|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
58307799|NCT02059707|DEVICE|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
58427227|NCT06037408|OTHER|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
58427228|NCT03281083|DRUG|Levothyroxine Sodium|
58099472|NCT03857139|DRUG|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
58427229|NCT03251950|BEHAVIORAL|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
58099473|NCT03102788|BEHAVIORAL|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
58099474|NCT03102788|BEHAVIORAL|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
57952574|NCT02763202|OTHER|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
58099475|NCT00116376|DRUG|AEE788|
58099476|NCT05630001|DRUG|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
58099477|NCT03538522|DRUG|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
58099478|NCT03538522|DRUG|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
58099479|NCT03538522|DRUG|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
58099480|NCT03538522|DRUG|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
58427230|NCT05278832|DRUG|QLS31905|QLS31905 injection
58427231|NCT00799539|DRUG|bortezomib|From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
58427232|NCT00799539|DRUG|bortezomib|From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
58427233|NCT00799539|DRUG|melphalan|9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
58427234|NCT00799539|DRUG|prednisone|60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
58427235|NCT02986815|OTHER|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
58427236|NCT05606055|DRUG|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
58427237|NCT01900288|BEHAVIORAL|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
58427238|NCT01900288|BEHAVIORAL|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
58427239|NCT04672850|DIETARY_SUPPLEMENT|Probiotic|The participants will consume 2 capsules daily for three months
58427240|NCT04672850|DIETARY_SUPPLEMENT|Placebo|The participants will consume 2 capsules daily for three months
58099481|NCT04717232|OTHER|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
58099482|NCT04717232|OTHER|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
58099483|NCT06460246|DEVICE|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
58099484|NCT01027026|OTHER|Early discharge|The patients are discharged the same day as coronary angiography.
58099485|NCT01027026|OTHER|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
58099486|NCT00542958|DRUG|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
58099487|NCT00417859|DEVICE|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
58099488|NCT01294605|BIOLOGICAL|Boostrix™ (dTpa)|Intramuscular, 3 doses
58427241|NCT05897697|OTHER|Interview|Structured interview
58427242|NCT06547073|OTHER|Virtual reality exercise training|Beat saber
58427243|NCT06547073|OTHER|Traditional exercise training|Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
58427244|NCT05894811|DIAGNOSTIC_TEST|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
58427245|NCT05894811|DIAGNOSTIC_TEST|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
58427246|NCT00005014|DRUG|Risperidone|
58427247|NCT03537313|PROCEDURE|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
58427248|NCT03537313|PROCEDURE|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
58427249|NCT00938522|DRUG|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
58427250|NCT00938522|DRUG|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
58427251|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
58427252|NCT04699461|DRUG|Idelalisib|Oral tablet
57952575|NCT06281184|DRUG|Methotrexate|Methotrexate 10-20 mg x 1 per week, combined with folic acid 1mg daily.
57952576|NCT06281184|OTHER|No treatment|No specific treatment after MERINO-trial
57952577|NCT04360070|DRUG|Ketamine Hydrochloride|Parenteral General Anesthetic
57952578|NCT01360554|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
57952579|NCT01360554|DRUG|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
57952580|NCT01360554|DRUG|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
57952581|NCT01360554|DRUG|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
57952582|NCT05084911|DRUG|Pyramax|Pyronaridine-Artesunate(180/60mg) tablet for 3days.
57952583|NCT05084911|DRUG|Placebo|Placebo tablet for 3days.
57952584|NCT00764595|DRUG|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
57952585|NCT04253795|OTHER|Laryngeal mask|After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
57952586|NCT04253795|OTHER|double lumen tube|After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
57952587|NCT04059770|DRUG|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
57952588|NCT04059770|DRUG|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
57952589|NCT04059770|DRUG|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
57952590|NCT02268721|DEVICE|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
57952591|NCT02285621|OTHER|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
58427253|NCT01681524|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
58427254|NCT04538313|DRUG|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
57952592|NCT05627284|PROCEDURE|Stoma reversal with bio-mesh placement|Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.
57952593|NCT04052685|PROCEDURE|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
57952594|NCT04052685|PROCEDURE|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
57952595|NCT04811456|OTHER|multisystem inflammatory syndrome in children (MIS-C)|as in group description
57952596|NCT04265846|DEVICE|bifocal IOL|The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
57952597|NCT04265846|DEVICE|mix bifocal IOL|The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
57952598|NCT04265846|DEVICE|trifocal IOL|The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
58427255|NCT02461082|DEVICE|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
57736617|NCT00272168|OTHER|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
58427256|NCT02461082|OTHER|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
58427257|NCT00303888|DRUG|docetaxel|Given IV
58427258|NCT00303888|DRUG|idronoxil|Given orally
58427259|NCT00303888|OTHER|placebo|Given orally
57736618|NCT00000602|DRUG|hydroxyurea|
57736619|NCT01919008|DRUG|FK949E|Oral
57736620|NCT02271126|DEVICE|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
58099489|NCT01294605|BIOLOGICAL|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
58099490|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
58427260|NCT01306656|DRUG|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
58427261|NCT01306656|OTHER|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
58427262|NCT01306656|DIETARY_SUPPLEMENT|Vitamin D|Daily multivitamin with 400 IU vitamin D.
58427263|NCT03189901|DRUG|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
58427264|NCT02055300|DRUG|LY03005|
58427265|NCT02055300|DRUG|Placebo|
58427266|NCT02055300|OTHER|Meal|
58427267|NCT02055300|DRUG|Pristiq|
57736621|NCT02271126|DEVICE|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
57736622|NCT02271126|DRUG|Heparin|Anticoagulation provided to patients in ECMO
57736623|NCT05525494|BEHAVIORAL|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
57736624|NCT05525494|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
57736625|NCT05525494|BEHAVIORAL|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
57952599|NCT04265846|DEVICE|EDOF IOL|The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
58427268|NCT04353700|BEHAVIORAL|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
58427269|NCT05390658|OTHER|Not application|Not application
58427270|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
58427271|NCT01075503|PROCEDURE|brachial plexus block|0.5% Ropivacaine 40ml
58427272|NCT03172156|GENETIC|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
58427273|NCT02508324|BIOLOGICAL|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
58427274|NCT02508324|BIOLOGICAL|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
58427275|NCT01364311|DIETARY_SUPPLEMENT|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
58099491|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
58099492|NCT04800367|DRUG|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
58099493|NCT04800367|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
57736626|NCT05525494|BEHAVIORAL|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
58099494|NCT06102967|BEHAVIORAL|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
58099495|NCT06122571|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
58099496|NCT01566474|DRUG|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
58099497|NCT01566474|DRUG|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
58427276|NCT05019768|OTHER|accelerated custom-fast CXL|The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
58099498|NCT00468312|DRUG|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
58099499|NCT00468312|DRUG|Placebo|Two sprays in each nostril in the morning
58099500|NCT00129532|DRUG|1.0% C31G SAVVY vaginal gel|
58099501|NCT06382220|DRUG|Bupivacain|drug injection
58099502|NCT02431715|DRUG|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
58099503|NCT02941822|DRUG|Ambroxol|Details outlines in the intervention description.
58099504|NCT00677586|PROCEDURE|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
58099505|NCT00677586|PROCEDURE|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
58099506|NCT00208000|DRUG|Marine active|
58427277|NCT05019768|OTHER|Standard CXL|The standard CXL procedure has been carried on following the Dresden protocol
58427278|NCT03657095|DRUG|Esuberaprost|Sodium tablets
58427279|NCT03657095|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
57736627|NCT05525494|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
57736628|NCT04233268|DIAGNOSTIC_TEST|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
57736629|NCT02167074|DEVICE|25G FNA needle|
57736630|NCT02167074|DEVICE|20G ProCore FNB needle|
57952600|NCT04265846|DEVICE|different IOLs|The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
57952601|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
57952602|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
57952603|NCT04122014|OTHER|Progressive balance training|Progressive balance training program
57952604|NCT04122014|OTHER|Normal daily activities|Usual daily activities
57952605|NCT05461612|DEVICE|Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device|Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
57952606|NCT04914689|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
58427280|NCT03424122|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
58427281|NCT03424122|DRUG|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
58427282|NCT03424122|DRUG|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
58427283|NCT03424122|DRUG|Ibrutinib|Ibrutinib administered orally once daily.
58427284|NCT03337464|OTHER|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
58427285|NCT01533662|DRUG|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
58427286|NCT01533662|DRUG|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
57952607|NCT04914689|OTHER|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
57952608|NCT04914689|OTHER|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
57952609|NCT02821871|DRUG|SP2086|
57952610|NCT02821871|DIETARY_SUPPLEMENT|high fat diet|
57952611|NCT04117464|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
57952612|NCT04117464|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
57952613|NCT04117464|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
57952614|NCT04117464|OTHER|Wait List Group|No psychological intervention
57952615|NCT05288790|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement
57952616|NCT05288790|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
57952617|NCT05789030|DRUG|Diprospan plus iguratimod|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
57952618|NCT05789030|DRUG|Diprospan plus leflunomide|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
57952619|NCT05789030|DRUG|Prednisone plus leflunomide|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
57952620|NCT05932940|PROCEDURE|Gonioscopy-Assisted Transluminal Trabeculotomy|Ab interno angle surgery one of MIGS to lower IOP
57952621|NCT00910793|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
57952622|NCT04176263|BEHAVIORAL|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
57952623|NCT04176263|BEHAVIORAL|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
57952624|NCT02295527|OTHER|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
57952625|NCT02295527|OTHER|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
58427287|NCT03050320|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
58427288|NCT03050320|OTHER|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
58427289|NCT00711789|DRUG|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
58427290|NCT00711789|DRUG|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
58427291|NCT00733941|BEHAVIORAL|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
58427292|NCT00733941|BEHAVIORAL|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
58427293|NCT05345028|DIETARY_SUPPLEMENT|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
58427294|NCT05345028|COMBINATION_PRODUCT|Placebo|250 mg for 5 days
58427295|NCT05784519|DRUG|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
58427296|NCT00079677|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
58427297|NCT00079677|DRUG|Placebo|Matching placebo tablets once daily
58427298|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
58427299|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
58427300|NCT04557046|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
58427301|NCT04557046|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
58427302|NCT04557046|DIAGNOSTIC_TEST|Throat swab|Collection of one more throat swabs
58427303|NCT04557046|DIAGNOSTIC_TEST|Fingerstick|Collection of capillary blood from one or more fingersticks
58427304|NCT04557046|DIAGNOSTIC_TEST|Saliva specimen|Collection of free drool
58427305|NCT01767623|DRUG|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
58427306|NCT00922805|DIETARY_SUPPLEMENT|guar gum|guar gum (20 g/l of formula) for one week
58427307|NCT00679874|OTHER|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
58427308|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
58427309|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
58427310|NCT05082727|DIETARY_SUPPLEMENT|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
58427311|NCT05082727|DIETARY_SUPPLEMENT|Placebo oral softgel|Placebo
58427312|NCT06583915|PROCEDURE|TENS|Non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain using electric pulse generator, lead wires and electrodes.
58427313|NCT06583915|PROCEDURE|Dry Needle|Invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.
58427314|NCT05408026|DRUG|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
58427315|NCT05408026|DRUG|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
58427316|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care and education|Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.
58427317|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care, education and support resources|Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
58427318|NCT00331188|DRUG|Sanvar® (vapreotide)|
58427319|NCT04839120|DRUG|MDPK67b|Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
58427320|NCT04839120|DRUG|Placebo|Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
57952626|NCT01169155|OTHER|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
57952627|NCT02984527|DEVICE|wet wipes|intimate hygiene with disposable wet wipes
57952628|NCT02984527|DEVICE|water and soap|Intimate hygiene with water and soap
57952629|NCT02526459|BEHAVIORAL|Birth plan|Patient will receive a birth plan
57952630|NCT01820364|DRUG|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
57952631|NCT05590260|DRUG|IV iron infusion|single-dose IV iron infusion
57952632|NCT05590260|DRUG|Oral iron tablets|60 mg of elemental iron
57952633|NCT01696526|OTHER|vitamin D fortified fish|fish containing vitamin D3
58427321|NCT04767152|DIAGNOSTIC_TEST|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
58427322|NCT06075966|OTHER|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
57736631|NCT06653439|PROCEDURE|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block (total of 40 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
58099507|NCT00877214|DRUG|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
58099508|NCT00877214|DRUG|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
58099509|NCT06542783|BEHAVIORAL|referring to the results of AI model output|determining the ANA pattern type with or without referring to the results of AI model output.
58099510|NCT06107959|OTHER|Pre-surgical nutrition, hydration, RMR, and body composition assessments|Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.
58099511|NCT06107959|OTHER|Post-surgical nutrition, hydration, RMR and body composition assessments|Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.
58427323|NCT06075966|OTHER|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
58427324|NCT04004013|DIETARY_SUPPLEMENT|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
57736632|NCT06653439|PROCEDURE|Control|Patients in this group will not be performed plane blocks. Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock- in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients. Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
58099512|NCT03414307|PROCEDURE|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
58099513|NCT03414307|DEVICE|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
58307800|NCT06389617|DRUG|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone|Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
58307801|NCT01545336|DRUG|Anastrozole|1 mg tablet to be taken 1 time daily
58307802|NCT01545336|DRUG|Placebo|1 mg tablet to be taken 1 time daily
58307803|NCT00709189|DRUG|Norgestimate/Ehinyl Estradiol; Folic acid.|
58307804|NCT01544036|DRUG|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
58307805|NCT05265117|PROCEDURE|HIPEC|HIPEC is given after primary or interval debulking surgery.
58307806|NCT00419185|PROCEDURE|Delamination of the Internal limiting membrane|
58307807|NCT02123641|OTHER|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
58307808|NCT02123641|OTHER|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
58307809|NCT02123641|OTHER|Control|No training
58307810|NCT06178692|DIAGNOSTIC_TEST|Validation of miRNA-serum signatures associated with IDH1 status|Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
58307811|NCT02709746|DRUG|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
58307812|NCT02709746|DRUG|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
58307813|NCT02709746|DRUG|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
58307814|NCT02709746|OTHER|Placebo|Encapsulated tablet
58427325|NCT04004013|DIETARY_SUPPLEMENT|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
58427326|NCT00370838|DRUG|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
58427327|NCT00370838|DRUG|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
58427328|NCT03610776|DEVICE|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
58427329|NCT03610776|DEVICE|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
58427330|NCT03090555|PROCEDURE|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
58427331|NCT03090555|PROCEDURE|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
58427332|NCT03262467|PROCEDURE|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
57952634|NCT01696526|OTHER|conventional fish|fish containing low concentrations of vitamin D3
58307815|NCT04333004|DRUG|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
58307816|NCT04956211|PROCEDURE|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
58307817|NCT00997945|DRUG|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
58307818|NCT01535885|BIOLOGICAL|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
58307819|NCT01923519|PROCEDURE|bronchofiberscopy|
58307820|NCT06312917|BEHAVIORAL|Physical activity|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
58307821|NCT01932489|PROCEDURE|Biopsy of a metastatic lesion.|
58307822|NCT05024279|DEVICE|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
58307823|NCT05024279|DEVICE|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
58307824|NCT01108939|DRUG|Antimalarial treatment|
58307825|NCT01108939|OTHER|Observation|
58307826|NCT01565863|BEHAVIORAL|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
58427333|NCT02768753|PROCEDURE|The Axillary Bilateral-breast Approach|
57736633|NCT06653439|DRUG|IV morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
58427334|NCT02768753|PROCEDURE|The bilateral Axillo-breast Approach|
57736634|NCT06635213|OTHER|Desensitisation|This technique is utilized to decrease, or normalize, the body's response to particular sensations.
57736635|NCT06635213|OTHER|Pain neuroscience education|PNE is an educational intervention aiming to alter a patient's beliefs and cognitions regarding their pain experience.
57952635|NCT01539681|DRUG|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
57736636|NCT06490484|DRUG|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
57736637|NCT06490484|DRUG|Pregabalin 150mg BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
58427335|NCT03869307|OTHER|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
58427336|NCT02350504|BEHAVIORAL|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
58427337|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
57736638|NCT00700401|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
57736639|NCT00700401|DRUG|ribavirin [Copegus]|800mg po daily for 24 weeks
57952636|NCT01770132|DRUG|porfimer sodium|Given IV
58307827|NCT02592824|DRUG|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
57736640|NCT00113568|DRUG|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
58307828|NCT02592824|DRUG|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
58427338|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
58427339|NCT04675996|DRUG|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
58427340|NCT01431391|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
58427341|NCT01431391|DRUG|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
58427342|NCT03389178|DIAGNOSTIC_TEST|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
57952637|NCT01770132|PROCEDURE|endoscopic ultrasonography|Undergo EUS-PDT
57952638|NCT01770132|PROCEDURE|photodynamic therapy|Undergo EUS-PDT
58427343|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
58427344|NCT06007053|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
58427345|NCT06007053|BEHAVIORAL|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
58427346|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
58427347|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
58427348|NCT01685021|DRUG|MOR00208 (formerly Xmab5574)|
58427349|NCT01415492|BEHAVIORAL|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
58427350|NCT01415492|BEHAVIORAL|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
58427351|NCT05673525|DEVICE|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
57952639|NCT01770132|DRUG|gemcitabine hydrochloride|Given IV
57952640|NCT01744665|DRUG|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
57952641|NCT02563847|DIETARY_SUPPLEMENT|0.52 g L-Tryptophan|
57952642|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
57952643|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
57952644|NCT02563847|DIETARY_SUPPLEMENT|50 g Xylitol|
57952645|NCT02563847|DIETARY_SUPPLEMENT|75 g Erythritol|
57952646|NCT02563847|DIETARY_SUPPLEMENT|75 g Glucose|
57952647|NCT02563847|DIETARY_SUPPLEMENT|300 mL tap water|
57952648|NCT02563847|OTHER|50 mg 13C-sodium acetate|
57952649|NCT05479214|DRUG|Metformin|1gm tablet with the 2 main meals
57952650|NCT05479214|DRUG|Insulin|subcutaneous insulin daily administration
57952651|NCT02282943|DEVICE|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
57952652|NCT02282943|DEVICE|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
58307829|NCT03558516|DRUG|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
58099514|NCT02781688|BEHAVIORAL|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
58427352|NCT04833595|BEHAVIORAL|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
58099515|NCT06148337|DIETARY_SUPPLEMENT|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
58099516|NCT06148337|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
58099517|NCT00675701|DRUG|placebo|capsules
58099518|NCT00675701|DRUG|lixivaptan|capsules
58099519|NCT00675701|DRUG|moxifloxacin|tablets
58427353|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
58427354|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
58427355|NCT02169856|BEHAVIORAL|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
58099520|NCT03943121|PROCEDURE|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
58099521|NCT03943121|PROCEDURE|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
58099522|NCT00287352|DRUG|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
58427356|NCT02169856|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
58099523|NCT00287352|DRUG|Olanzapine and placebo|Olanzapine continuing as clinically indicated
58099524|NCT00419900|PROCEDURE|diagnosis of breast cancer by x-ray diffraction of hair|
58427357|NCT02169856|DRUG|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
58427358|NCT02169856|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
58427359|NCT02169856|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
58427360|NCT02169856|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
58427361|NCT02169856|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
58427362|NCT02169856|DRUG|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
57952653|NCT05209633|DRUG|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
57952654|NCT05209633|DRUG|Placebo|placebo
57952655|NCT00355433|PROCEDURE|Urodymanics|
58427363|NCT02169856|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
57952656|NCT01616407|DRUG|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
57952657|NCT01616407|DRUG|Methylphenidate|40 mg per os, single dose
57952658|NCT01616407|DRUG|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
57952659|NCT00337870|BEHAVIORAL|PAT|Cognitive-Behavioral/Relaxation Intervention
57952660|NCT03997955|OTHER|Myofascial induction|Myofascial induction in plantar fascia
57952661|NCT03997955|OTHER|Sham myofascial induction|Sham myofascial induction in plantar fascia
57952662|NCT06150235|OTHER|Data collection|Data collection
57952663|NCT01970501|DRUG|bucindolol hydrochloride|
57952664|NCT01970501|DRUG|metoprolol succinate|
57952665|NCT01970501|OTHER|Placebo oral capsule|
57952666|NCT03198052|BIOLOGICAL|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
58427364|NCT04476199|COMBINATION_PRODUCT|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
58427365|NCT03590249|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
58427366|NCT00373945|DRUG|Observational Study|
57952667|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
58427367|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
58099525|NCT06541912|PROCEDURE|conventional implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
58427368|NCT05954767|DRUG|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
57952668|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
57952669|NCT04289844|OTHER|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
58099526|NCT06541912|PROCEDURE|UV implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
58099527|NCT03716999|OTHER|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
58099528|NCT00764816|OTHER|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
58099529|NCT00764816|OTHER|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
58099530|NCT00451594|DRUG|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~1. Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~2. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~3. If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~4. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~5. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
58427369|NCT02935413|DEVICE|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
58427370|NCT02935413|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
58427371|NCT05230849|DEVICE|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
58427372|NCT05230849|OTHER|convencional treatment|is a physiotherapy treatment for neurological patients
58427373|NCT03045341|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
58427374|NCT03045341|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|BWL counseling
58427375|NCT03045341|OTHER|Placebo|Placebo
58427376|NCT01089790|DRUG|Dutogliptin|400 mg tablet, once daily
58427377|NCT01089790|DRUG|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
58427378|NCT04067661|BEHAVIORAL|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
58427379|NCT04067661|BEHAVIORAL|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
58427380|NCT02085330|DEVICE|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
58427381|NCT05018858|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58427382|NCT02758327|DRUG|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
58427383|NCT03135977|DRUG|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
58427384|NCT04467125|DRUG|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
58427385|NCT04467125|DRUG|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
58099531|NCT00451594|DRUG|Prednisolone|"Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
58099532|NCT04801030|BEHAVIORAL|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
58099533|NCT02556931|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
58427386|NCT00493961|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
58427387|NCT04194125|DRUG|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
58427388|NCT05382897|OTHER|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
58427389|NCT04868149|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
58427390|NCT05486585|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
58427391|NCT05416307|DRUG|ELA026|Single or multiple daily doses of ELA026
57952670|NCT04289844|OTHER|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
58099534|NCT02556931|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
58427392|NCT04677127|BEHAVIORAL|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
58099535|NCT02556931|RADIATION|Total body irradiation|Day -1: 200 cGy in a single fraction
58099536|NCT02556931|DRUG|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
58099537|NCT02556931|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
58427393|NCT04832763|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58427394|NCT04832763|OTHER|Medical Chart Review|Review of medical charts
58427395|NCT04832763|OTHER|Physical Performance Testing|Undergo physical function testing
58427396|NCT04832763|OTHER|Quality-of-Life Assessment|Ancillary studies
58427397|NCT04832763|OTHER|Questionnaire Administration|Complete questionnaire
58099538|NCT05481554|BIOLOGICAL|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
58099539|NCT05785416|OTHER|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
58099540|NCT05785416|OTHER|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
58099541|NCT01397656|PROCEDURE|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
58099542|NCT01397656|PROCEDURE|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
58099543|NCT02170142|DEVICE|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
58427398|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
58427399|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
58427400|NCT05001139|DEVICE|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
58427401|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
58427402|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
58427403|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
58427404|NCT04499859|DRUG|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
58427405|NCT04499859|DRUG|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
58427406|NCT02385435|DRUG|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
58427407|NCT02385435|DRUG|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
58427408|NCT02385435|DRUG|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
58427409|NCT04439318|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
58427410|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
58427411|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
58427412|NCT05492916|BEHAVIORAL|Diabetes Prevention Program (DPP)|Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.
58427413|NCT05492916|BEHAVIORAL|Community-Supported Agriculture (CSA)|Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
57736641|NCT02774057|DRUG|Captafer®|"2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
58099544|NCT05785221|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
58427414|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
58427415|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
58427416|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
58427417|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
58427418|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
58427419|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
58427420|NCT05501795|DEVICE|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
57736642|NCT02774057|DRUG|Iron Sulfate|195 mg Iron supplement
57736643|NCT05426551|OTHER|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
58427421|NCT05380167|DIETARY_SUPPLEMENT|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
58427422|NCT05380167|DIETARY_SUPPLEMENT|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
58427423|NCT01012323|BIOLOGICAL|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
58427424|NCT05372549|OTHER|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
58427425|NCT05372549|OTHER|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
58427426|NCT05372549|OTHER|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
58427427|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
58427428|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
58307830|NCT03558516|DRUG|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
58307831|NCT05786859|DRUG|Rifaximin 200 mg|Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
58427429|NCT03951558|OTHER|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
58427430|NCT03951558|DRUG|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
58427431|NCT05848362|OTHER|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
58427432|NCT06439303|DRUG|Cytisine 1,5 mg|Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
58427433|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
58427434|NCT02453555|DRUG|Linagliptin|
58427435|NCT02453555|DRUG|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
58427436|NCT02453555|DRUG|Empagliflozin + linagliptin low dose|tablet
58427437|NCT02453555|DRUG|Linagliptin placebo|Matching placebo linagliptin
58427438|NCT02453555|DRUG|Empagliflozin + linagliptin high dose|tablet
58427439|NCT02453555|DRUG|Empa + lina highdose placebo|
58427440|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
57952671|NCT05438823|OTHER|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
58307832|NCT05786859|OTHER|Standard Treatment without Rifaximin|The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
58307833|NCT04351620|DRUG|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
58427441|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
58427442|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
58427443|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
58427444|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
58427445|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
58427446|NCT04114110|OTHER|RTLS data|data extraction from RTLS
58427447|NCT04015674|OTHER|Exercise group|Aerobic exercise on a stationary bicycle
58427448|NCT04015674|OTHER|Control group|In a rest
58427449|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
58427450|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
58427451|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
58427452|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
58427453|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
58427454|NCT06004570|DIETARY_SUPPLEMENT|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
58427455|NCT06004570|DIETARY_SUPPLEMENT|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
58427456|NCT06004570|OTHER|Placebo|Single oral dose - 2 capsules
58427457|NCT04199143|DRUG|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
58427458|NCT04199143|DEVICE|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
58427459|NCT04199143|DEVICE|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
58427460|NCT04687371|OTHER|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
58427461|NCT04687371|OTHER|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
58427462|NCT04687371|OTHER|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
58427463|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
58427464|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
58427465|NCT05435118|OTHER|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
58427466|NCT05836467|PROCEDURE|Valvular interventions|Any kind of intervention on heart valves
58427467|NCT02872272|DRUG|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
58427468|NCT02386501|DRUG|ADXS31-164|
58427469|NCT04311931|OTHER|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
58427470|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
58427471|NCT00240383|DRUG|Muraglitazar|
58427472|NCT03504748|DEVICE|deep rTMS|
58427473|NCT03504748|DEVICE|placebo deep rTMS|
58427474|NCT05840536|DRUG|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
58427475|NCT05840536|DRUG|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
58427476|NCT05077007|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
58427477|NCT05077007|PROCEDURE|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
58427478|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
58099545|NCT05785221|BEHAVIORAL|Personalized nutritional and lifestyle weight reduction intervention|Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
58427479|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
58427480|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
58427481|NCT00490620|DRUG|Placebo|placebo BID for 6 months
57952672|NCT03507920|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
58099546|NCT00203931|DRUG|Cetuximab|
58099547|NCT00203931|DRUG|Pemetrexed|
58099548|NCT03989037|DRUG|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
58099549|NCT03989037|DRUG|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
58099550|NCT03989037|DRUG|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
58099551|NCT03989037|DRUG|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
58099552|NCT06309121|DIETARY_SUPPLEMENT|Postbiotic ABB C3|A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
58099553|NCT06309121|DIETARY_SUPPLEMENT|Placebo|A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
58099554|NCT06309121|DIETARY_SUPPLEMENT|Follow-up Postbiotic ABB C3 (Optional)|Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
58307834|NCT06054841|BEHAVIORAL|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
58307835|NCT06054841|OTHER|Control|No deviation from standard discharge education
58307836|NCT06284499|OTHER|measuring tooth stability after orthodontic treatment using a Periotest® device.|The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
58307837|NCT03318185|PROCEDURE|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
58307838|NCT03318185|PROCEDURE|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
58307839|NCT02700399|DEVICE|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
58307840|NCT02700399|DEVICE|Traditional tilt table from Rehab-Care|Traditional tilt table
58307841|NCT03385733|OTHER|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
58307842|NCT04590118|DRUG|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
58307843|NCT04590118|DRUG|Placebo|Single intravenous infusion of 1 ml/kg placebo
58307844|NCT05122611|OTHER|no intervention, imaging study only|Imaging study only
58307845|NCT05348304|DIETARY_SUPPLEMENT|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
58307846|NCT05159934|DRUG|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
58307847|NCT05159934|DRUG|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
57952673|NCT03507920|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
58099555|NCT01578343|DRUG|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation"
58099556|NCT02632227|PROCEDURE|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
58099557|NCT01692431|DIETARY_SUPPLEMENT|EPA|High fat meal containing EPA
58099558|NCT01692431|DIETARY_SUPPLEMENT|DHA|High fat meal containing DHA
58307848|NCT02860988|BEHAVIORAL|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
58307849|NCT01980953|DRUG|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
57952674|NCT05326542|PROCEDURE|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
57952675|NCT05326542|PROCEDURE|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
57952676|NCT00841789|DRUG|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
58099559|NCT01692431|DIETARY_SUPPLEMENT|Placebo|High fat meal containing negligible EPA/DHA content
58307850|NCT01980953|DRUG|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
58307851|NCT01980953|DRUG|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
58307852|NCT00193908|DRUG|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
58099560|NCT01374906|DRUG|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).
58099561|NCT01374906|DRUG|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
58099562|NCT01374906|DRUG|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
58099563|NCT02997969|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
58099564|NCT02997969|BIOLOGICAL|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
58099565|NCT02997969|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
58307853|NCT00193908|DRUG|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
58307854|NCT00193908|RADIATION|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
57952677|NCT00841789|DRUG|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
57952678|NCT00002300|DRUG|Megestrol acetate|
57952679|NCT01183143|DRUG|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
57952680|NCT04395339|DRUG|Monosialotetrahexosyl ganglioside (GM1)|Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
57952681|NCT04395339|DRUG|Control|250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
57952682|NCT02955615|DRUG|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
57952683|NCT02955615|DRUG|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
57952684|NCT04503954|OTHER|Chronic disease self-management program|The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
57952685|NCT04503954|OTHER|General psychiatric intervention|General psychiatric intervention contains the activities in psychiatric center.
57952686|NCT06407037|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the prone position. 30 ml of 0.25% bupivacaine will be used in applications.
57952687|NCT06407037|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Serratus Posterior Superior Intercostal Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the prone position. 30 ml of 0.25% bupivacaine will be used in applications.
57952688|NCT03296085|PROCEDURE|Exam for quantity of edema|There is no intervention
57952689|NCT02337400|BEHAVIORAL|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
57952690|NCT02337400|BEHAVIORAL|15 minute counseling interview|
57952691|NCT01263171|DRUG|Leucovorin|
57952692|NCT01263171|DRUG|fluorouracil|
57952693|NCT01263171|DRUG|leucovorin calcium|
57952694|NCT01263171|DRUG|oxaliplatin|
57952695|NCT01263171|PROCEDURE|adjuvant therapy|
57952696|NCT01263171|PROCEDURE|neoadjuvant therapy|
57952697|NCT01263171|PROCEDURE|therapeutic conventional surgery|
57952698|NCT01263171|RADIATION|radiation therapy|
57952699|NCT00861952|OTHER|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
57952700|NCT00861952|OTHER|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
57952701|NCT03001050|DEVICE|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
57952702|NCT04472585|DRUG|Ivermectin Injectable Solution|Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
57952703|NCT04472585|OTHER|Injectable Placebo|0.9% normal saline
58099566|NCT00589693|DRUG|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
58099567|NCT00589693|DRUG|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
58099568|NCT00589693|DRUG|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
58099569|NCT04872127|DEVICE|proximal embolism protection device|a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
58099570|NCT04872127|DEVICE|distal embolism protection device|a distal SpiderFX will be used as the embolism protection device during CAS
58099571|NCT03690726|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
58099572|NCT03690726|OTHER|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
58099573|NCT06542497|DRUG|0.75% phentolamine ophthalmic solution|Once daily dosing
58099574|NCT06542497|DRUG|Placebo|Once daily dosing
58099575|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
58099576|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
58099577|NCT00434148|DRUG|Pasireotide|
58099578|NCT00817258|DRUG|cisplatin|Cisplatin 40mg/m2,weekly
58099579|NCT00817258|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
58427482|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
58427483|NCT02516228|DEVICE|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
58427484|NCT01821482|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|
57952704|NCT04472585|DRUG|Zinc|Zinc Sulphate 20mg 3 times a day
58099580|NCT00800722|DRUG|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
58427485|NCT06128746|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
57952705|NCT04472585|DRUG|Placebo empty capsule|Placebo empty capsule
57952706|NCT04472585|DRUG|Oral Ivermectin|0.2mg/kg/day
57952707|NCT03388411|DIAGNOSTIC_TEST|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
57952708|NCT04983914|DEVICE|Transcorneal Electrostimulation via OkuStim System|Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).
57952709|NCT00985335|OTHER|Neem Based External Application Cream|Apply externally 3-4 times per day
57952710|NCT00343668|DRUG|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
57952711|NCT00163774|DEVICE|Brain oxygenation and microdialysis catheters|
57952712|NCT01251107|DRUG|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
57952713|NCT01251107|DRUG|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
57952714|NCT01251107|DRUG|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
57952715|NCT01251107|DRUG|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
58099581|NCT04432818|BEHAVIORAL|Pack Health's digital life coaching (DLC)|Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
58099582|NCT03076528|OTHER|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
58099583|NCT03076528|OTHER|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
57736644|NCT01275573|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
58099584|NCT00148473|DRUG|Misoprostol|
58099585|NCT06199973|DRUG|SHR-A1811|SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
58099586|NCT06199973|DRUG|TAS-102, Regorafenib , Fruquintinib|physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
58099587|NCT05786521|DRUG|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
58099588|NCT05786521|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
58099589|NCT04184479|BEHAVIORAL|LEVAmethod by Bertz et al|Ordinary treatment
58099590|NCT03820999|OTHER|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
58099591|NCT02043561|OTHER|induction of urge by rectal distension|
58099592|NCT01211496|BEHAVIORAL|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
58099593|NCT01211496|BEHAVIORAL|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
58099594|NCT01350531|BEHAVIORAL|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
58099595|NCT01350531|BEHAVIORAL|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
58099596|NCT04542330|BIOLOGICAL|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
58427486|NCT06128746|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
58427487|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
58427488|NCT00888485|BEHAVIORAL|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
58099597|NCT04542330|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
58099598|NCT00351156|PROCEDURE|Blood sample|
58427489|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
58427490|NCT01230138|DRUG|Placebo|Placebo tablets
57736645|NCT00101855|PROCEDURE|An evidence based tailored web site|
57952716|NCT01251107|DRUG|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
57952717|NCT01251107|DRUG|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
57952718|NCT01251107|DRUG|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
57952719|NCT01251107|DRUG|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
57952720|NCT01251107|DRUG|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
57952721|NCT01251107|DRUG|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
57952722|NCT01251107|DRUG|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
57952723|NCT00072735|PROCEDURE|Electrocardiogram|
57952724|NCT00698243|DRUG|OSI-027|Administered orally
57952725|NCT03577730|DRUG|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
57952726|NCT03577730|DRUG|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
58099599|NCT00666731|OTHER|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
58099600|NCT00666731|OTHER|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
58427491|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
58427492|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
58427493|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
58427494|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
58427495|NCT03650790|DIAGNOSTIC_TEST|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
58427496|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
58099601|NCT00666731|OTHER|study of socioeconomic and demographic variables|Repository
58099602|NCT00666731|PROCEDURE|Excess human biological tissue|Tissue procurement.
58099603|NCT00666731|PROCEDURE|quality-of-life assessment|Cancer care.
58099604|NCT01489696|DRUG|mirabegron|oral
58099605|NCT01489696|DRUG|tamsulosin|oral
58307855|NCT05310877|BEHAVIORAL|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
58427497|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
58427498|NCT02156336|DRUG|Ranolazine|Oral administration, BID; for a maximum of 51 days.
58427499|NCT02156336|DRUG|Placebo|Oral administration, BID; for a maximum of 51 days.
58427500|NCT01349764|DRUG|Vitamin D3|
58427501|NCT00242593|DRUG|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
58427502|NCT06259890|OTHER|measurement of salt intake|measurement of salt intake without intervention
57952727|NCT00639249|DRUG|placebo|Oral administration
57952728|NCT00639249|DRUG|SA4503 Low|Oral administration
57952729|NCT00639249|DRUG|SA4503 High|Oral administration
57952730|NCT02531581|DRUG|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc
57952731|NCT02531581|DRUG|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
57952732|NCT00053417|DRUG|Placebo|Placebo for 15 weeks
58307856|NCT01922934|BEHAVIORAL|Commercial weight loss program|vouchers for Weight Watchers
58307857|NCT01922934|BEHAVIORAL|Colorado Weigh|Group behavioral weight loss program
58307858|NCT01922934|DIETARY_SUPPLEMENT|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
58307859|NCT01922934|DRUG|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
58307860|NCT01922934|BEHAVIORAL|Recreation center passes|1 year pass to a Denver recreation center
58307861|NCT06003361|DEVICE|Digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for depression.
58307862|NCT06003361|OTHER|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
58307863|NCT05252637|PROCEDURE|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
58307864|NCT02125240|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
58307865|NCT02125240|DRUG|Placebo|1 tablet three times daily by mouth
58307866|NCT03659344|DRUG|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
58307867|NCT06441409|BEHAVIORAL|Lifestyle intervention|"Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day."
58307868|NCT03203785|DIETARY_SUPPLEMENT|Carbohydrate (maltodextrin)|maltodextrin flavored
58307869|NCT03203785|OTHER|Placebo|non-caloric drink
58307870|NCT05831800|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
58307871|NCT06032637|PROCEDURE|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
58427503|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
58427504|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
58427505|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
57736646|NCT06669390|DRUG|NG11-2|"NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution."
57952733|NCT00053417|DRUG|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
57952734|NCT00053417|DRUG|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
58099606|NCT06537908|DRUG|Anti-PD-1/PD-L1 antibodies|Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
58099607|NCT06537908|DRUG|Anti-VEGF|Anti-VEGF Intravenous injection for at least 6 months
58099608|NCT01825616|DIETARY_SUPPLEMENT|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
58099609|NCT01825616|OTHER|Placebo|Mushroom powder without vitamin D2
58099610|NCT05384327|OTHER|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
58099611|NCT05384327|OTHER|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
58099612|NCT02034500|BIOLOGICAL|S. sonnei 1790GAHB|
58099613|NCT02034500|BIOLOGICAL|Placebo|
58099614|NCT00471588|DRUG|Pramipexole, Amisulpride|Study Drug
58099615|NCT00441207|DRUG|Ascorbic Acid|Delivered via IV Infusion.
58099616|NCT03478345|BEHAVIORAL|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
58099617|NCT03446716|BEHAVIORAL|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
58099618|NCT00467038|BEHAVIORAL|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
58099619|NCT06562530|DEVICE|high tone power therapy|sessions are applied for 30 minutes, 3 times per week, for 3 months
58427506|NCT03822000|OTHER|Survival|Elderly patients with fall-induced femoral fracture who were survived.
58427507|NCT03822000|OTHER|Death|Elderly patients with fall-induced femoral fracture who were dead.
58099620|NCT06562530|DEVICE|transcutaneous electrical nerve stimulation (TENS)|sessions are applied for 30 minutes, 3 times per week, for 3 months
58099621|NCT06562530|OTHER|selected physical therapy program|sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
58099622|NCT01682512|DRUG|BI 695500|
58099623|NCT01682512|DRUG|BI 695500|
57736647|NCT05637606|DRUG|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
57952735|NCT00053417|DRUG|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
57952736|NCT04203615|DEVICE|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
58099624|NCT01682512|DRUG|Rituxan®|
58099625|NCT01682512|DRUG|Rituxan®|
58099626|NCT01682512|DRUG|MabThera®|
58099627|NCT03354923|BEHAVIORAL|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
58099628|NCT00150475|PROCEDURE|Powered Air purifying respirator|
58099629|NCT04058600|BEHAVIORAL|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
58099630|NCT00243282|BEHAVIORAL|Relaxation Response (instruction, pocket practice card prov)|
58099631|NCT00243282|BEHAVIORAL|Mindfulness training using model developed from UMass|
58099632|NCT02913261|DRUG|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
58427508|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
58427509|NCT04706000|GENETIC|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
58427510|NCT01014039|PROCEDURE|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
58427511|NCT06000605|OTHER|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
58427512|NCT06000605|OTHER|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
58427513|NCT03610009|DEVICE|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
58099633|NCT02913261|DRUG|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
58099634|NCT05309174|PROCEDURE|USG-guided iSLN block|Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
58099635|NCT02791711|OTHER|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
58099636|NCT06541899|DEVICE|Polarys Cryolipolysis|The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.
58099637|NCT02460133|DRUG|Paritaprevir|
58099638|NCT02460133|DRUG|Ritonavir|
58099639|NCT02460133|DRUG|Dasabuvir|
58099640|NCT02460133|DRUG|Ombitasvir|
58099641|NCT02460133|DRUG|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
58099642|NCT05318807|OTHER|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~1. Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~2. Patient Activation Measure - to measure patient activation~3. Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~4. Patient Generated Subjective Global Assessment - to identify malnutrition risk~5. Emotions thermometer - to detect emotional disorders and identify risk"
58427514|NCT03610009|DEVICE|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
58427515|NCT05485324|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
58427516|NCT02916251|DRUG|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
58427517|NCT02916251|DRUG|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
57736648|NCT05637606|DRUG|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
58099643|NCT05318807|OTHER|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~* Review the initial questionnaires to inform the personalised plan and goal setting~* Complete a further four questionnaires related to quality of life, diet and exercise~* Measure handgrip strength~* Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
58427518|NCT02454062|DRUG|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
58427519|NCT02454062|DRUG|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
58427520|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
58427521|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
58427522|NCT05413148|OTHER|Placebo|Single Subtenon injection of saline for a single eye
58427523|NCT03678168|OTHER|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
58427524|NCT03678168|OTHER|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
58427525|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
57736649|NCT05637606|DRUG|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
57736650|NCT05637606|DIAGNOSTIC_TEST|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
58099644|NCT05318807|OTHER|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
58099645|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
58099646|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
58099647|NCT01883531|DRUG|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
58099648|NCT01883531|DRUG|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
58099649|NCT06539637|COMBINATION_PRODUCT|OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}|10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery
58099650|NCT06539637|OTHER|Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop|Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
58427526|NCT02032407|DRUG|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
58427527|NCT06371976|OTHER|Blood sampling|Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.
58427528|NCT06371976|OTHER|Vital status|Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.
58099651|NCT06030271|DEVICE|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
58099652|NCT05706454|DRUG|Ramatroban|"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."
58099653|NCT05706454|DRUG|Placebo|Matching placebo will be administered orally twice a day
58099654|NCT01139892|PROCEDURE|Surgical management|
58427529|NCT04322825|DEVICE|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
58427530|NCT00752726|DRUG|Orlistat|Weight loss treatment
58427531|NCT00752726|DRUG|Placebo|Inactive
58099655|NCT01139892|PROCEDURE|Endovascular management|
58099656|NCT01376180|DRUG|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
58099657|NCT04430101|PROCEDURE|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
58099658|NCT04430101|PROCEDURE|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
58099659|NCT05496101|PROCEDURE|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
58099660|NCT03643406|OTHER|Mental Fatigue|modified stroop task
58099661|NCT03643406|OTHER|Control|documentary
58427532|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
58427533|NCT01205477|DRUG|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
58427534|NCT01205477|DRUG|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
58427535|NCT00418977|BEHAVIORAL|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
57952737|NCT04203615|DEVICE|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
57952738|NCT04670185|BEHAVIORAL|BIP SAMBA|Behavioral parent management training
57952739|NCT05094700|OTHER|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
57952740|NCT03285737|DIETARY_SUPPLEMENT|Whey|Supplement provided twice daily in 30g doses
58099662|NCT00788684|DRUG|rituximab|IV infusion once weekly for four doses
58099663|NCT00788684|DRUG|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
58099664|NCT02365818|BIOLOGICAL|CG0070|
58099665|NCT03851731|DRUG|Naltrexone|Intranasal spray
57952741|NCT03285737|DIETARY_SUPPLEMENT|Collagen|Supplement provided twice daily in 30g doses
58099666|NCT03851731|DRUG|Naloxone|Intranasal spray
58099667|NCT03851731|DRUG|Naltrexol|Intranasal spray
58099668|NCT04619069|RADIATION|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
58099669|NCT04619069|DRUG|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
58099670|NCT00377715|DRUG|Dimebon|
58099671|NCT00377715|DRUG|Placebo|
58099672|NCT06390423|DIAGNOSTIC_TEST|Passive leg raise, SVI via bioreactance, Echo based VTI|No interventions other than fluid challenge
58099673|NCT01254994|DRUG|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
58307872|NCT06032637|PROCEDURE|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
58427536|NCT00418977|BEHAVIORAL|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
58427537|NCT05204433|OTHER|no intervention|no intervention
58427538|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
58427539|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
58427540|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
58427541|NCT05781321|RADIATION|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
58427542|NCT05781321|PROCEDURE|Computed Tomography|Undergo CT simulation
58427543|NCT05781321|DRUG|Fluorodopa F 18|Given IV
58427544|NCT05781321|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58427545|NCT05781321|PROCEDURE|Positron Emission Tomography|Undergo PET
58099674|NCT01254994|DRUG|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
58099675|NCT03526185|DRUG|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
58099676|NCT03526185|DRUG|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
58099677|NCT02827422|OTHER|not provided|
58099678|NCT03023098|DEVICE|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
58099679|NCT03023098|DEVICE|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
58099680|NCT03180346|DEVICE|PICO|Single Use Negative Pressure Dressing
58307873|NCT05658939|OTHER|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
58307874|NCT03933488|DRUG|TAK-994|TAK-994 tablets.
58307875|NCT03933488|DRUG|TAK-994 Placebo|TAK-994 placebo-matching tablets.
58427546|NCT05781321|OTHER|Quality-of-Life Assessment|Ancillary studies
58427547|NCT05781321|OTHER|Questionnaire Administration|Complete questionnaires
58427548|NCT05781321|RADIATION|Radiation Therapy|Undergo standard course RT
58427549|NCT05781321|DRUG|Temozolomide|Given PO
58427550|NCT05781321|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58099681|NCT03180346|DEVICE|Aquacel|Occlusive surgical dressing infused with ionized silver
58307876|NCT03320356|OTHER|the French version of the Oxford Shoulder Score|
58427551|NCT04457492|OTHER|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
58427552|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
58427553|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
58427554|NCT05282420|DRUG|Ranibizumab|Ranibizumab
58427555|NCT05282420|DRUG|Aflibercept|Aflipercept
58427556|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
58427557|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
58427558|NCT05406609|OTHER|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
58427559|NCT05406609|OTHER|Time|Time of using operating room
58427560|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
58427561|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
58427562|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
58427563|NCT00973245|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
58427564|NCT00265031|DRUG|Cyclophosphamide|
58427565|NCT00265031|DRUG|Adriamycin|
58427566|NCT00265031|DRUG|Etoposide|
58099682|NCT06537856|OTHER|Health Belief Model Based Cardiovascular Disease Risk Factor Prevention Education|"In line with the literature review, Health Belief Model-Based Cardiovascular Disease Risk Factor Prevention Training was created in order to increase the level of knowledge of firefighters regarding cardiovascular disease risk factors, improve their awareness and positively affect their quality of life. This training was given in 3 different sessions by meeting face-to-face with firefighters in the training hall of the fire stations. Each session lasted 40 minutes. Answers were given to the questions asked at the end of the session. The training was organized under the following main headings:~Perceived Sensitivity, Perceived Seriousness, Perceived Barriers, Perceived Self-Efficacy, Health Motivation/Activators"
58099683|NCT06537856|BEHAVIORAL|Reminder Short Messages|After the Health Belief Model-Based health education, 39 text messages were sent via WhatsApp application 3-4 times a week for 3 months to increase the effectiveness of the education and the motivation of firefighters in CVD prevention.
58099684|NCT00188279|PROCEDURE|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
58099685|NCT02905318|DRUG|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
58099686|NCT05805956|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
58099687|NCT02320838|DEVICE|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58099688|NCT02320838|DEVICE|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58099689|NCT02320838|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58099690|NCT03510013|PROCEDURE|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
58427567|NCT00265031|DRUG|Procarbazine|
57952742|NCT01142102|RADIATION|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
57952743|NCT00805480|DRUG|AIN457|AIN457 was administered intravenously.
57952744|NCT00805480|DRUG|Placebo|Matching placebo to AIN457 was administered intravenously.
58099691|NCT03510013|DRUG|Sevoflurane|Drug used for wash-in protocol
58427568|NCT00265031|DRUG|Prednisone|
58427569|NCT00265031|DRUG|Vincristine|
58427570|NCT00265031|DRUG|Bleomycin|
58427571|NCT00265031|PROCEDURE|radiation therapy|
58427572|NCT01229449|DRUG|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
58427573|NCT01229449|DRUG|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
58427574|NCT01229449|DRUG|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
58427575|NCT01229449|DRUG|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
58427576|NCT01229449|DRUG|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
58427577|NCT04040621|DRUG|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
58427578|NCT01620528|DRUG|elagolix|oral tablet
58427579|NCT01620528|OTHER|placebo|oral tablet
58427580|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
58427581|NCT03291392|GENETIC|Gene expression or biomarkers exploration|
58427582|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
58427583|NCT01093066|DRUG|optimal TURB|The TURB will always try to be optically complete.
58427584|NCT02667470|DRUG|Solifenacin|Oral
57952745|NCT04921735|DRUG|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
58427585|NCT01072253|PROCEDURE|eye amputation|
58427586|NCT03301467|DRUG|Avacopan|Orally administered
58427587|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
58427588|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
58427589|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
58427590|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
58427591|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
57736651|NCT01398488|BEHAVIORAL|Patient education|Patient education by health care professional compared to education via tablet PC
57736652|NCT01882322|DRUG|Prograf|oral
57736653|NCT01882322|DRUG|Advagraf|oral
57736654|NCT02057146|PROCEDURE|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
57736655|NCT02239679|DRUG|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
57736656|NCT02239679|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
57736657|NCT02239679|DEVICE|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
58427592|NCT05117177|DRUG|Inupadenant|Oral administration
58427593|NCT05117177|DRUG|Inupadenant|Oral administration
58427594|NCT05117177|DRUG|Inupadenant|Oral administration
57736658|NCT02239679|PROCEDURE|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
57736659|NCT06633263|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
57736660|NCT06633263|BEHAVIORAL|Behavioral Activation Treatment for Depression|Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
57736661|NCT03057795|DRUG|Brentuximab Vedotin|Given IV
57736662|NCT03057795|OTHER|Laboratory Biomarker Analysis|Correlative studies
57736663|NCT03057795|BIOLOGICAL|Nivolumab|Given IV
57736664|NCT06284876|DRUG|Ilaprazole|Ilaprazole 10 mg
57736665|NCT06284876|DRUG|Lansoprazole|Lansoprazole 15 mg
57736666|NCT06284876|DRUG|Ilaprazole Placebo|Placebo of Ilaprazole 10 mg
57736667|NCT06284876|DRUG|Lansoprazole Placebo|Placebo of Lansoprazole 15 mg
57952746|NCT00763815|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
57952747|NCT00763815|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
57952748|NCT00763815|DEVICE|Pen auto-injector|
58427595|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
58427596|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
58427597|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
58427598|NCT05307809|OTHER|Blood sample collection|Blood sample collection
58427599|NCT05307809|OTHER|Skin sample collection|Skin sample collection
58427600|NCT06041633|DIAGNOSTIC_TEST|Clinical|Questionnaire
57952749|NCT00763815|DRUG|Pioglitazone|Dose to be kept stable.
58427601|NCT01500304|PROCEDURE|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
58427602|NCT00332891|DRUG|SR58611A|
58427603|NCT05675228|OTHER|data collection|Knowledge about genital herpes
58427604|NCT05216471|RADIATION|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
58427605|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
58427606|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
58427607|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
58427608|NCT04940884|BEHAVIORAL|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
58427609|NCT04940884|BEHAVIORAL|Aerobic exercise training|All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
58427610|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
58427611|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
57952750|NCT00763815|DRUG|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
57952751|NCT03971279|DRUG|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
57952752|NCT03963011|DIAGNOSTIC_TEST|Bowel Ultrasound|Ultrasound imaging of the bowel
58427612|NCT02942654|DRUG|Insulin Lispro|Administered SC
58427613|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
58427614|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
58427615|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
58427616|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
57736668|NCT04520984|OTHER|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
57736669|NCT04520984|OTHER|Standard nephrology care|Standard nephrology care
58099692|NCT06365931|DEVICE|Percutaneous neuromodulation|Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
58427617|NCT02427503|PROCEDURE|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
58427618|NCT03595488|DRUG|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
58427619|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
58427620|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
58427621|NCT03584243|PROCEDURE|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
58427622|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
58427623|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
58427624|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
58427625|NCT03040115|OTHER|Non-Interventional Study|
58427626|NCT04588181|BEHAVIORAL|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
58427627|NCT00463554|DEVICE|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
58427628|NCT00791596|OTHER|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
58427629|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
58427630|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
58427631|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
58427632|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
58427633|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
58427634|NCT04803955|DRUG|16mg，KB|16mg,Q8h±3min,Day1-Day7
58427635|NCT04803955|DRUG|Placebos|16mg,Q8h±3min,Day1-Day7
58427636|NCT05293925|BEHAVIORAL|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
58427637|NCT01654809|BIOLOGICAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
58427638|NCT01654809|BIOLOGICAL|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
58427639|NCT01654809|BIOLOGICAL|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
58427640|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
58427641|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
58427642|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
58427643|NCT05896813|DRUG|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
58427644|NCT02248636|DRUG|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
57736670|NCT01898338|DRUG|Fosfomycin 2gr/6h iv|
57736671|NCT01898338|DRUG|Daptomycin 10mg/kg/24h iv|
57736672|NCT02959073|OTHER|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
58427645|NCT02248636|DRUG|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
58427646|NCT05730972|DEVICE|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
57736673|NCT01043666|DRUG|YM178|oral
57736674|NCT01043666|DRUG|Placebo|oral
57961702|NCT05568342|BEHAVIORAL|The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study|Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
58427647|NCT05730972|DEVICE|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
58427648|NCT05730972|DRUG|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
57736675|NCT01043666|DRUG|tolterodine ER|oral
57736676|NCT03986853|PROCEDURE|Blood sampling|Blood sampling under general anesthesia
58427649|NCT00439036|BEHAVIORAL|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
58427650|NCT00439036|BEHAVIORAL|Drug Counseling|
58427651|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
58427652|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
58427653|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
58099693|NCT06365931|DEVICE|Transcutaneous neuromodulation|Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
58099694|NCT06365931|DEVICE|Placebo-percutaneous|Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.
58099695|NCT06365931|DEVICE|Placebo-transcutaneous|patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.
58099696|NCT06365931|DEVICE|Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)|Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.
58099697|NCT05762120|OTHER|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase"
58099698|NCT06114810|BIOLOGICAL|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
58099699|NCT00319020|DRUG|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
58099700|NCT03800186|OTHER|Proximal type A|Patients with fracture of proximal type A
58099701|NCT03800186|OTHER|Proximal type B|Patients with fracture of proximal type B
58099702|NCT03800186|OTHER|Proximal type C|Patients with fracture of proximal type C
58099703|NCT03800186|OTHER|femoral shaft|Patients with fracture of femoral shaft
58099704|NCT03800186|OTHER|distal femur|Patients with fracture of distal femur
58427654|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
58427655|NCT01727414|DRUG|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
58427656|NCT01727414|DRUG|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
58427657|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
58427658|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
58099705|NCT04986566|OTHER|Best Practice|Use standard reporting procedures
58099706|NCT04986566|BEHAVIORAL|Health Education|Use Aetonixx app
58099707|NCT04986566|OTHER|Medical Device Usage and Evaluation|Wear Vivofit 4
58099708|NCT04986566|OTHER|Quality-of-Life Assessment|Complete questionnaires
58099709|NCT03791515|DRUG|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
58099710|NCT03791515|DRUG|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
58099711|NCT04112615|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
58099712|NCT04103411|OTHER|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
58099713|NCT04977817|DIETARY_SUPPLEMENT|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
58427659|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
58427660|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
58427661|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
58427662|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
58427663|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
58099714|NCT02821117|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
58099715|NCT00927979|DRUG|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
58099716|NCT00927979|DRUG|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
58099717|NCT00927979|DRUG|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
58099718|NCT05467865|OTHER|ZELIAKIDE|"The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process."
58099719|NCT04753918|DRUG|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
58099720|NCT04753918|DRUG|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
58099721|NCT04753918|PROCEDURE|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
58099722|NCT04753918|DEVICE|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
58099723|NCT04160676|DRUG|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
58099724|NCT04160676|DRUG|Normal saline|Normal saline
58099725|NCT04147052|BEHAVIORAL|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
57736677|NCT01128413|DEVICE|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
58099726|NCT04957914|DRUG|Insulin Glargine|Administered SC
58307877|NCT05286892|OTHER|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
58307878|NCT05286892|OTHER|Enhanced Education|See control group description above
58307879|NCT05026554|GENETIC|Tape stripping|Optional genetic analysis for chronic hand eczema
57736678|NCT01128413|DEVICE|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
57736679|NCT01128413|DEVICE|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
58307880|NCT02142842|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
58307881|NCT00787878|DRUG|somatropin|SGA previously treated with Norditropin®
58307882|NCT00787878|DRUG|No treatment given|Untreated SGA
58427664|NCT00480389|DRUG|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
57736680|NCT01128413|BEHAVIORAL|CURVES Questionnaire|The CURVES (CardiovascUlar Response \& Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
57736681|NCT01128413|BIOLOGICAL|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, \& 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
57736682|NCT01128413|BIOLOGICAL|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
58307883|NCT00787878|DRUG|No treatment given|AGA (Average gestational age)
58307884|NCT05730426|PROCEDURE|Deep dry needling|Method to decrease pain and improve function in musculoskeletal disorders.
57736683|NCT01128413|BIOLOGICAL|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
57736684|NCT03437005|DRUG|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
57736685|NCT03437005|DRUG|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
57736686|NCT00534196|RADIATION|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
57736687|NCT05308173|PROCEDURE|Surgical Aortic Valve Replacement|Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
57736688|NCT05308173|PROCEDURE|Transcutenous Aortic Valve Implantation|Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
58099727|NCT04957914|DRUG|LY3209590|Administered SC
58307885|NCT05730426|PROCEDURE|Muscle energy technique|Method to decrease pain and improve function in musculoskeletal disorders.
58307886|NCT05730426|PROCEDURE|Neck stability exercise|Method to decrease pain and improve function in musculoskeletal disorders.
58307887|NCT02074514|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
58307888|NCT02074514|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58427665|NCT03459365|DEVICE|Euflexxa|Aspirations performed before each injection and at six weeks.
58427666|NCT02591459|OTHER|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
57952753|NCT04499261|PROCEDURE|laparoscopic surgery|Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
57736689|NCT03797768|BEHAVIORAL|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
57736690|NCT05845229|DIETARY_SUPPLEMENT|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
57952754|NCT04499261|PROCEDURE|Open surgery|Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
57952755|NCT05099861|OTHER|No intervention|this is an observational study
58427667|NCT01286571|DRUG|BI 135585|one oral single dose per subject
58427668|NCT01286571|DRUG|BI 135585|one oral single dose per subject
58427669|NCT04495725|OTHER|Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products|We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (\>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
58427670|NCT01867138|DRUG|Cefazolin|
58427671|NCT01867138|DRUG|Vancomycin|
58427672|NCT01867138|DRUG|Amikacin|
58427673|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
58427674|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
58427675|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
58427676|NCT01262664|DRUG|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
58427677|NCT00013169|BEHAVIORAL|Strong Patient Focus|
58427678|NCT00036257|DRUG|CP-461|
58427679|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
58427680|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
58427681|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
58427682|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
58427683|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
58427684|NCT04622813|DRUG|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
58427685|NCT04622813|DRUG|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
58427686|NCT02788058|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
58427687|NCT02788058|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
58427688|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
58427689|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
58427690|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
58307889|NCT04577872|OTHER|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
58307890|NCT05344469|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
58427691|NCT02423980|DRUG|Glucagon|
58427692|NCT01345682|DRUG|Afatinib|Once daily
58427693|NCT01345682|DRUG|Methotrexate|Weekly
58427694|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
58427695|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
58427696|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
58427697|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
58427698|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
58427699|NCT05387057|BEHAVIORAL|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
58427700|NCT05387057|BEHAVIORAL|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
58427701|NCT05899582|PROCEDURE|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
57952756|NCT00427609|DRUG|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
58099728|NCT06381375|OTHER|Anti Tuberculosis Drug|"1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)."
58427702|NCT05899582|OTHER|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
58307891|NCT05344469|OTHER|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
58427703|NCT01959243|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
58427704|NCT01959243|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
58427705|NCT01959243|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
58427706|NCT01959243|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
58427707|NCT01392612|DRUG|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
58427708|NCT03441698|DEVICE|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
57952757|NCT02302482|OTHER|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
58307892|NCT05344469|OTHER|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
58307893|NCT00914121|DRUG|SKI-606|
58099729|NCT04766593|OTHER|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living."
58307894|NCT00914121|DRUG|Placebo|
58307895|NCT00914121|DRUG|Moxifloxacin|
58307896|NCT01670292|OTHER|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
58307897|NCT01047449|PROCEDURE|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
58307898|NCT01047449|DIETARY_SUPPLEMENT|Fish oil supplementation vs placebo|Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op
58307899|NCT06550479|PROCEDURE|AVF|Distal forearm AVF for hemodialysis.
58427709|NCT03441698|DEVICE|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
58427710|NCT03441698|OTHER|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
58427711|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
58427712|NCT05136261|DEVICE|Basic cream|Basic cream
58427713|NCT01656694|DEVICE|DePuy Sigma HP Partial Knee|
58427714|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
58427715|NCT02315482|PROCEDURE|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
58099730|NCT04390035|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
58427716|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
58427717|NCT04927572|DRUG|FMX114|Active Comparator
58427718|NCT04927572|OTHER|Vehicle|Placebo Comparator
58099731|NCT02966574|DEVICE|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
58099732|NCT01959230|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
58099733|NCT01959230|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
58427719|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
58427720|NCT00875342|DRUG|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
58427721|NCT00875342|OTHER|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
58427722|NCT02934737|OTHER|Progression of diabetes|
58427723|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
58427724|NCT00759525|DRUG|Glycyrrhetic Acid|130 mg daily for fourteen days
58427725|NCT00759525|DRUG|Placebo|Placebo daily for fourteen days
58427726|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
58427727|NCT01107223|OTHER|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
58427728|NCT01107223|OTHER|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
58427729|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
58427730|NCT02578329|BEHAVIORAL|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
58427731|NCT02578329|BEHAVIORAL|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
58427732|NCT01098526|DRUG|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
58427733|NCT01098526|DRUG|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
57736691|NCT05845229|DIETARY_SUPPLEMENT|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
57736692|NCT01702753|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
57736693|NCT02235948|DRUG|folic acid supplementation|0.8mg folic acid/day
58099734|NCT01959230|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
58099735|NCT01959230|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
58099736|NCT03506425|DRUG|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
58099737|NCT00315328|DRUG|Atropine|Atropine 1% each weekend day in the sound eye
58099738|NCT00315328|DEVICE|Patching|Patching 2 hours per day
58099739|NCT00315328|PROCEDURE|Near activities|near visual activities for at least one hour per day
58099740|NCT00035399|PROCEDURE|Acupuncture|
58427734|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
58427735|NCT00003691|BIOLOGICAL|filgrastim|
58427736|NCT00003691|DRUG|cisplatin|
58427737|NCT00003691|DRUG|doxorubicin hydrochloride|
58427738|NCT00003691|DRUG|paclitaxel|
58427739|NCT02567994|DRUG|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
58427740|NCT00001009|DRUG|Dextran sulfate|
58427741|NCT01976260|DEVICE|Fractional Radiofrequency|
58427742|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
58427743|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
58427744|NCT03930407|PROCEDURE|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
58427745|NCT03249103|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
58427746|NCT03249103|DRUG|Placebo oral capsule|Matching placebo capsules.
58427747|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
58427748|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
58427749|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
57952758|NCT04599777|DRUG|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
58099741|NCT06640244|OTHER|Sunscreen|To be used by all participants throughout the study
58099742|NCT06640244|OTHER|Cosmetic product G18|Cosmetic face care product
58427750|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
58099743|NCT06640244|OTHER|Cosmetic product N70|Cosmetic face care product
58427751|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
58427752|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
58427753|NCT05934331|DRUG|LM302+Toripalimab|LM-302 in combination with Toripalimab.
58427754|NCT05314959|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
58427755|NCT05314959|OTHER|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
58427756|NCT02929212|OTHER|Solid Meal|Subjects will receive solid meals during meal study
58427757|NCT02929212|OTHER|Liquid Meal|Subjects will receive liquid meals, during meal study
58427758|NCT02929212|DRUG|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
58427759|NCT02929212|OTHER|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
58099744|NCT06640244|OTHER|Cosmetic product D79|Cosmetic face care product
58099745|NCT06640244|OTHER|Cosmetic product E84|Cosmetic face care product
58099746|NCT06640244|OTHER|Cosmetic product C68|Cosmetic face care product
58427760|NCT02929212|OTHER|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
58427761|NCT02134678|BEHAVIORAL|self-system therapy|
58427762|NCT02134678|BEHAVIORAL|cognitive therapy|
58427763|NCT03902119|DEVICE|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
58427764|NCT03902119|OTHER|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
58427765|NCT03337009|BEHAVIORAL|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
58427766|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
58099747|NCT00450177|DRUG|Ferrous Sulfate|Iron group
58099748|NCT00450177|DRUG|Placebo Oral Tablet|Placebo group
58099749|NCT05442359|DRUG|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
58099750|NCT05442359|DEVICE|stent|Applied as a palatal stent for palatal wound
58099751|NCT02770053|PROCEDURE|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
57952759|NCT04840043|OTHER|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
57952760|NCT04840043|OTHER|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
57952761|NCT01923597|DRUG|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
57952762|NCT03319485|DEVICE|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
57952763|NCT03319485|DEVICE|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
57952764|NCT02256540|DRUG|Climara|
58099752|NCT02192541|DRUG|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
58099753|NCT02192541|DRUG|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
58307900|NCT05136599|BIOLOGICAL|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
58427767|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
58427768|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
58427769|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
58427770|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
58427771|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
58427772|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
58427773|NCT05834348|DRUG|lorlatinib|As provided in real world practice
58427774|NCT05834348|DRUG|crizotinib|As provided in real world practice
58427775|NCT05834348|DRUG|brigatinib|As provided in real world practice
58427776|NCT05834348|DRUG|ceritinib|As provided in real world practice
58427777|NCT05834348|DRUG|alectinib|As provided in real world practice
58427778|NCT05834348|DRUG|atezolizumab|As provided in real world practice
58427779|NCT05834348|DRUG|bevacizumab|As provided in real world practice
58427780|NCT05834348|DRUG|paclitaxel|As provided in real world practice
58427781|NCT05834348|DRUG|carboplatin|As provided in real world practice
58427782|NCT05834348|DRUG|docetaxel|As provided in real world practice
58427783|NCT05834348|DRUG|erlotinib|As provided in real world practice
58427784|NCT05834348|DRUG|gefitinib|As provided in real world practice
58427785|NCT05834348|DRUG|afatinib|As provided in real world practice
58427786|NCT05834348|DRUG|dacomitinib|As provided in real world practice
58427787|NCT05834348|DRUG|osimertinib|As provided in real world practice
58427788|NCT05834348|DRUG|pembrolizumab|As provided in real world practice
58427789|NCT05834348|DRUG|nivolumab|As provided in real world practice
58427790|NCT05834348|DRUG|entrectinib|As provided in real world practice
58427791|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
58427792|NCT03299283|DIAGNOSTIC_TEST|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
58427793|NCT05453045|DRUG|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
58427794|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
58427795|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
58427796|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
58427797|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
58427798|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
58427799|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
58427800|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
58427801|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
58427802|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
58427803|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
58427804|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
58099754|NCT01950338|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
58099755|NCT01094509|BEHAVIORAL|Tai Chi|Tai Chi classes and exercises
58099756|NCT01094509|BEHAVIORAL|Guided autobiography|Autobiographical writing in class and at home
58099757|NCT01094509|BEHAVIORAL|Qigong|Qigong classes and exercises (exploratory)
58099758|NCT01094509|BEHAVIORAL|Successful aging|Seminar series on the theme of successful aging
58099759|NCT01094509|BEHAVIORAL|Combination|Combination of Tai Chi exercises and autobiographical writing
58099760|NCT01094509|BEHAVIORAL|Comparison|No assigned behavioral activity (exploratory)
58099761|NCT01095029|DEVICE|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
58099762|NCT00979238|GENETIC|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
58427805|NCT02424045|DRUG|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
58427806|NCT01181258|DRUG|Rituximab|375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
58427807|NCT01181258|BIOLOGICAL|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
58427808|NCT01181258|BIOLOGICAL|Natural killer cells|administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
58427809|NCT01181258|DRUG|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
58427810|NCT01181258|DRUG|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
58427811|NCT01181258|DRUG|Fludarabine|25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
58427812|NCT04028466|DRUG|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
58427813|NCT04028466|DRUG|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
58427814|NCT01124955|OTHER|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
58427815|NCT01124955|OTHER|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
57952765|NCT02256540|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
58099763|NCT00979238|DRUG|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
58099764|NCT05538169|DEVICE|low-level laser diode (Pioon Laser)|"Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session."
58099765|NCT02322242|DRUG|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
58427816|NCT02136147|DRUG|methylphenidate medication|
58427817|NCT02136147|DRUG|atomoxetine medication|
58427818|NCT02136147|DRUG|lisdexamphetamine medication|
58427819|NCT02136147|DRUG|guanfacine medication|
58427820|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
58427821|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
58427822|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
58427823|NCT02277119|DEVICE|Maestro|OCT machines used for diagnostic purposes
58427824|NCT02277119|DEVICE|iVue|OCT machines used for diagnostic purposes
58427825|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
58427826|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
58427827|NCT00017290|BIOLOGICAL|sargramostim|
58427828|NCT00017290|DRUG|cyclophosphamide|
58427829|NCT00017290|DRUG|prednisone|
58427830|NCT00017290|DRUG|vincristine sulfate|
58427831|NCT00958932|BEHAVIORAL|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
58427832|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
58427833|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
58099766|NCT02322242|DRUG|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
58099767|NCT01189071|DRUG|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
58099768|NCT05430568|PROCEDURE|robot-assisted surgery|"1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement"
58099769|NCT03229239|PROCEDURE|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
58099770|NCT00782275|DRUG|bevacizumab|
58099771|NCT00782275|DRUG|temsirolimus|
58099772|NCT00149552|DIETARY_SUPPLEMENT|zinc|supplementation with zinc gluconate
58099773|NCT05375682|OTHER|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
58099774|NCT04593680|DRUG|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
58099775|NCT00161330|DRUG|oral amoxicilline/clavulanic acid|
58099776|NCT00161330|DRUG|iv ceftriaxone|
58427834|NCT05102253|PROCEDURE|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
58427835|NCT05102253|PROCEDURE|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
58427836|NCT05102253|OTHER|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
58427837|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
58427838|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
57736694|NCT03193164|DEVICE|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
57736695|NCT03193164|OTHER|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
58099777|NCT02802137|DRUG|tafluprost|
58099778|NCT02802137|DRUG|tafluprost and dorzolamide/timolol|
58099779|NCT04179474|DRUG|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
58099780|NCT04179474|DRUG|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
57952766|NCT02256540|DIETARY_SUPPLEMENT|Resveratrol|
58099781|NCT04179474|DRUG|Galcanezumab|2 SC injections of galcanezumab 120 mg \[Intervention C\].
58099782|NCT01674959|RADIATION|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
58099783|NCT03256708|DIETARY_SUPPLEMENT|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
58099784|NCT03256708|DIETARY_SUPPLEMENT|Placebo|Inactive ingredients
58427839|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
58099785|NCT01586117|DRUG|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
58099786|NCT02421107|OTHER|Glysure CGM|
58099787|NCT02421107|OTHER|iStat intermittent testing|
58099788|NCT01040676|BEHAVIORAL|Automated Telephone Nutrition Support|See Intervention Group description.
58427840|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
58427841|NCT01174173|DRUG|Ranolazine|ranolazine 1000 mg PO BID for 3 months
57736696|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
57952767|NCT02256540|DIETARY_SUPPLEMENT|Placebo|Placebo tablets designed to match active resveratrol tablets.
58099789|NCT05949931|DRUG|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
58099790|NCT05949931|DRUG|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
58099791|NCT05445037|DEVICE|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
58099792|NCT05445037|DEVICE|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
58099793|NCT06084273|OTHER|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
58099794|NCT06084273|OTHER|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
58099795|NCT03175445|OTHER|CBCT scan by planmeca promax|software measurement tool of CBCT
58099796|NCT05968755|DEVICE|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
58099797|NCT05968755|OTHER|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
58099798|NCT03667170|BIOLOGICAL|KN035|subcutaneous injection
58099799|NCT03445247|OTHER|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
58099800|NCT03499249|DRUG|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
58099801|NCT05212831|DEVICE|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
58099802|NCT02344459|DEVICE|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
58099803|NCT04006691|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
57736697|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
58099804|NCT02067585|DIETARY_SUPPLEMENT|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
58099805|NCT01921036|PROCEDURE|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
58099806|NCT01921036|PROCEDURE|combined exercise|Moderate endurance and resistance exercise once a week over six months
58099807|NCT00995488|DRUG|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
58099808|NCT00200590|DRUG|acetaminophen and nalbuphine|
58099809|NCT00200590|DRUG|acetaminophen and morphine|
58099810|NCT00200590|DRUG|acetaminophen and reduced dosage of prostaglandin|
58099811|NCT06540612|OTHER|Aerobic exercise|Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
58099812|NCT06540612|BEHAVIORAL|Physical activity counseling|Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
58099813|NCT03537222|DIAGNOSTIC_TEST|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
58099814|NCT02595541|DRUG|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
57736698|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
57952768|NCT05476159|DRUG|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
57952769|NCT05476159|DEVICE|Gastric bypass|Roux and Y Gastric bypass
57952770|NCT02812277|OTHER||This is a Non-Interventional Study, so there are no drug or devices included.
58099815|NCT02595541|DRUG|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
58427842|NCT06229054|DRUG|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
57736699|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
57736700|NCT02246517|DRUG|N2O|
57736701|NCT02246517|DRUG|Oxygen|
58099816|NCT06125964|BEHAVIORAL|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
58427843|NCT06229054|DRUG|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
58427844|NCT03539991|OTHER|Internet-Based Intervention|Complete online courses
58099817|NCT06125964|BEHAVIORAL|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
58099818|NCT06125964|BEHAVIORAL|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
58099819|NCT06125964|BEHAVIORAL|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
58099820|NCT04972760|DRUG|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
57952771|NCT01545856|DRUG|levodopa|levodopa use
58427845|NCT03539991|OTHER|Meeting|Participate in virtual meetings
58427846|NCT03539991|OTHER|Survey Administration|Ancillary studies
58427847|NCT01587235|DRUG|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
57952772|NCT06205888|OTHER|18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT|Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
57952773|NCT01381432|DRUG|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
57952774|NCT01239342|DRUG|Akt Inhibitor MK2206|Given PO
57952775|NCT01239342|DRUG|Everolimus|Given PO
57952776|NCT01239342|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
57952777|NCT05482685|BEHAVIORAL|Questionnaire|Conduct a 10-minute survey
58099821|NCT04972760|DRUG|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
58427848|NCT01587235|DRUG|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
58427849|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
57736702|NCT03491644|DRUG|Titrated Oxygen|Restrictive treatment with oxygen.
57952778|NCT04865328|OTHER|Overactive Bladder-Validated 8-question Screener (OAB-V8)|OAB-V8 is an eight-item, self-reported questionnaire that assesses the burden of OAB and the degree of bother caused by the symptoms. Since its development as a subscale of the overactive bladder questionnaire (OAB-q), the OAB-V8 questionnaire has been used to screen for OAB and to assess OAB symptom burden and severity.
57952779|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4|Testmeal with free FeSO4
57952780|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
57952781|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
57952782|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
57952783|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
57952784|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
57952785|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
57952786|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
57952787|NCT03332602|DIETARY_SUPPLEMENT|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
57952788|NCT03681119|BEHAVIORAL|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
57952789|NCT03681119|BEHAVIORAL|Education and Training|Education and training
58427850|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
58427851|NCT02238834|DRUG|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
58427852|NCT02238834|DRUG|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
57952790|NCT04292509|DEVICE|SAP with stop before low|cross-over comparison from stop on low to stop before low
57952791|NCT04292509|DEVICE|SAP with stop on low|cross-over comparison from stop before low to stop on low
57952792|NCT05062863|DEVICE|T3 dental implant system|This clinical study will evaluate patients being treated with the T3 dental implant to confirm its safety and performance (effect of treatment of edentulism). The patients treated will experience a benefit from treatment of edentulism with the T3 dental implant system. The patients will be followed prospectively from the time of exposure (dental implant placement surgery) to outcome (implant survival at 2 years).
57952793|NCT05622526|DRUG|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
58099822|NCT02528318|COMBINATION_PRODUCT|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
58099823|NCT02528318|DEVICE|nCPAP alone|nCPAP therapy
58099824|NCT03515837|BIOLOGICAL|pembrolizumab|IV infusion
58099825|NCT03515837|DRUG|pemetrexed|IV infusion
58099826|NCT03515837|DRUG|carboplatin|IV infusion
57952794|NCT05622526|OTHER|Group 2 or Control group|capsules of placebo
57952795|NCT00330902|DRUG|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
57952796|NCT00330902|DRUG|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
57952797|NCT00250835|OTHER|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
57952798|NCT04317495|OTHER|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
57952799|NCT00002788|BIOLOGICAL|filgrastim|
57952800|NCT00002788|DRUG|cyclophosphamide|
57952801|NCT00002788|DRUG|dexamethasone|
57952802|NCT00002788|DRUG|etoposide|
57952803|NCT00002788|PROCEDURE|peripheral blood stem cell transplantation|
57952804|NCT00002788|RADIATION|radiation therapy|
57952805|NCT06364111|DEVICE|Vibrabot capsule|Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.
57736703|NCT03491644|DRUG|Liberal Oxygen|Liberal treatment with oxygen.
57952806|NCT06364111|DRUG|polyethylene glycol|Subjects in the control group received polyethylene glycol for 6 weeks
57952807|NCT00718783|OTHER|Tissue samples taken from retinoblastoma|Tissue banking
57952808|NCT00718783|OTHER|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
57952809|NCT02162524|BEHAVIORAL|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
57952810|NCT00088374|DRUG|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
57952811|NCT00088374|DRUG|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
57952812|NCT00088374|DRUG|[15-O] H2O|\[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
58099827|NCT03515837|DRUG|cisplatin|IV infusion
58099828|NCT03515837|DRUG|saline solution|IV infusion
58099829|NCT00488839|DRUG|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
58099830|NCT00488839|DRUG|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
58099831|NCT00488839|DRUG|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
58099832|NCT00488839|DRUG|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
58099833|NCT00488839|DRUG|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
58099834|NCT00488839|DRUG|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
58099835|NCT00488839|DRUG|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
58099836|NCT00488839|DRUG|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
58099837|NCT00488839|DRUG|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
58099838|NCT03319693|GENETIC|Somatic Genetic|NGS analysis
58099839|NCT03858660|OTHER|No intervention|No intervention
58099840|NCT06309472|DRUG|Mirtazapine|30mg mirtazapine at night, escalated to 45mg after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
58099841|NCT06309472|DRUG|Placebo|1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
58099842|NCT00158795|BIOLOGICAL|Haemophilus Influenza type b vaccine|
58427853|NCT02238834|DRUG|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
58427854|NCT02238834|DRUG|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
58427855|NCT02068417|DEVICE|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
57952813|NCT00088374|DRUG|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
57736704|NCT03378167|BIOLOGICAL|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
57952814|NCT03456752|DRUG|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
57952815|NCT03456752|DRUG|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
57952816|NCT03673774|DEVICE|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
57952817|NCT02443883|DRUG|Ramucirumab|Administered IV
57952818|NCT00556452|DRUG|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
57952819|NCT00556452|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
57952820|NCT00556452|RADIATION|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
57952821|NCT05940779|OTHER|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
57952822|NCT05217745|DIETARY_SUPPLEMENT|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
57952823|NCT05217745|DIETARY_SUPPLEMENT|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
57952824|NCT05491356|DRUG|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
58427856|NCT06303245|OTHER|ABDOMINAL BINDERS|will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided
58427857|NCT06303245|OTHER|TENS|will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
58427858|NCT03147989|DRUG|MultiHance|gadolinium contrast agent
58427859|NCT01577472|DRUG|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
58427860|NCT01577472|DRUG|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
58427861|NCT01577472|DRUG|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
58427862|NCT01577472|DRUG|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
58427863|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
57952825|NCT05491356|DRUG|Placebo|0.9% saline solution, intra-catheter administration, sterile
57952826|NCT03473288|BEHAVIORAL|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
57952827|NCT03473288|BEHAVIORAL|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
57952828|NCT01826253|DRUG|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
58099843|NCT03558789|BIOLOGICAL|bovine lactoferrin|mouthwash
58099844|NCT02588352|DIETARY_SUPPLEMENT|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
58427864|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
58427865|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
58427866|NCT03926988|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
57952829|NCT04715061|OTHER|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
57952830|NCT04715061|OTHER|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
58099845|NCT01488071|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
58099846|NCT01488071|DRUG|Agomelatine|encapsulated tablets, daily, orally
58099847|NCT00550420|DRUG|Rosiglitazone XR|experimental drug
58099848|NCT01447316|OTHER|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
58099849|NCT03711942|PROCEDURE|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
57952831|NCT04715061|OTHER|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
57952832|NCT01982929|PROCEDURE|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
57952833|NCT01982929|PROCEDURE|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
58099850|NCT03711942|PROCEDURE|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
58099851|NCT03711942|PROCEDURE|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
58099852|NCT05412069|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
58099853|NCT01755780|OTHER|Left interscalene block|
58099854|NCT01755780|OTHER|Right interscalene block|
58099855|NCT01000142|PROCEDURE|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
58099856|NCT01000142|PROCEDURE|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
58427867|NCT04678791|DRUG|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
58099857|NCT03312725|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
58427868|NCT04678791|DRUG|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
58099858|NCT02952794|PROCEDURE|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
58099859|NCT00657917|DRUG|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
58099860|NCT06315608|DRUG|MRG-001|MRG-001 is a clear liquid solution for subcutaneous injection
58099861|NCT05154994|DRUG|Belinostat|Given IV
58427869|NCT04678791|RADIATION|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
58099862|NCT05154994|BIOLOGICAL|Durvalumab|Given IV
58099863|NCT00484120|DRUG|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
58099864|NCT00484120|DRUG|Placebo cream|Placebo cream
58427870|NCT04678791|RADIATION|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
58427871|NCT02343718|DRUG|Vinblastine|
58427872|NCT02343718|DRUG|Temsirolimus|
58099865|NCT04382690|BEHAVIORAL|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
58099866|NCT06537284|BEHAVIORAL|ImRs-DSR|Imagery Rescripting with Memory Reconsolidation Disruption
58099867|NCT06537284|BEHAVIORAL|ImRs|Imagery Rescripting regular
58427873|NCT00235911|DRUG|budesonide/formoterol Turbuhaler|
58427874|NCT00644111|DRUG|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
58427875|NCT00644111|DRUG|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
58427876|NCT00660985|DRUG|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
58427877|NCT00660985|DRUG|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
58427878|NCT03196531|DRUG|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
58427879|NCT03196531|DRUG|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
58427880|NCT03322670|OTHER|Signs of CAP and a positive chest X-Ray|"* collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28"
58427881|NCT03322670|OTHER|Patients directly hospitalized|"* collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90"
58427882|NCT03322670|DIAGNOSTIC_TEST|Control patients|- bacteriological examinations (urine)
58427883|NCT03322670|OTHER|Patients with partial participation|- collection of clinical examination data
58427884|NCT03322670|OTHER|Signs of CAP and a negative chest X-Ray|"* collection of clinical examination data~* telephone contact on day 28"
58427885|NCT03613363|DEVICE|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
58427886|NCT03207802|DEVICE|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
58427887|NCT00002921|DRUG|suramin|
58427888|NCT00002921|DRUG|therapeutic hydrocortisone|
58427889|NCT02668913|OTHER|Diagnostic analysis|Molecular profiling
57736705|NCT03378167|BIOLOGICAL|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
58427890|NCT03052023|PROCEDURE|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
58427891|NCT03052023|PROCEDURE|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
57736706|NCT05088928|DRUG|Apixaban|Direct Acting Oral Anti coagulant
57736707|NCT05088928|DRUG|Rivaroxaban|Direct Acting Oral Anti coagulant
57736708|NCT04694274|DEVICE|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
58427892|NCT03052023|PROCEDURE|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
58427893|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
58099868|NCT04742816|DIAGNOSTIC_TEST|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
58427894|NCT06455748|DRUG|Daratumumab/daratumumab and hyaluronidase-fihj|Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.
57736709|NCT04694274|PROCEDURE|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
57736710|NCT04694274|DEVICE|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
58427895|NCT06455748|DRUG|Pomalidomide|Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).
58427896|NCT06455748|DRUG|Dexamethasone|Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
57736711|NCT01063400|OTHER|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
57736712|NCT05551949|DRUG|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
57736713|NCT05157191|OTHER|Observational|Observational
57736714|NCT05973526|PROCEDURE|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
57736715|NCT05973526|PROCEDURE|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
58099869|NCT04742816|DRUG|Iohexol|Iohexol clearance measurement
58099870|NCT00355680|DEVICE|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
58427897|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
58427898|NCT04412447|DEVICE|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
58427899|NCT00973492|OTHER|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
58427900|NCT01340599|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given PO
58427901|NCT01340599|OTHER|placebo|Given PO
57736716|NCT02930239|OTHER|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
58099871|NCT00355680|DEVICE|Green Laser (Iridex)|Already available green laser
58099872|NCT04622618|DRUG|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
58099873|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
58099874|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
58099875|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
58307901|NCT03641027|OTHER|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week)~* decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~* decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
58307902|NCT03641027|OTHER|Standard care|
58427902|NCT01340599|OTHER|immunohistochemistry staining method|Correlative studies
58427903|NCT01340599|OTHER|immunoenzyme technique|Correlative studies
58427904|NCT01340599|OTHER|questionnaire administration|Ancillary studies
58427905|NCT01340599|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
58427906|NCT01340599|OTHER|high performance liquid chromatography|Correlative studies
58427907|NCT01340599|OTHER|mass spectrometry|Correlative studies
58427908|NCT00084149|DRUG|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
58427909|NCT00084149|DRUG|Lopinavir/Ritonavir|antiretroviral therapy
58427910|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
58427911|NCT00383162|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
58099876|NCT03654092|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
58427912|NCT00383162|DRUG|Placebo|Matching placebo tablet.
58427913|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
58427914|NCT06083818|OTHER|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
58427915|NCT06083818|OTHER|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
58427916|NCT01417364|DRUG|Testosterone enanthate|100 mg. IM weekly throughout study
58427917|NCT01417364|DRUG|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
58427918|NCT01417364|DRUG|Placebo|Injected IM weekly throughout study
58427919|NCT03867942|DRUG|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
58427920|NCT03867942|DRUG|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
57736717|NCT02930239|OTHER|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
57736718|NCT00236548|DRUG|risperidone|
57736719|NCT01087853|DRUG|Crystalloid|2 litres intravenous infusion in 60 minutes
57736720|NCT01087853|DRUG|Colloid|1 litre intravenous infusion over 30 minutes
58427921|NCT00552604|DRUG|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
57736721|NCT05538624|DRUG|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
57736722|NCT05538624|DRUG|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
57736723|NCT04099810|DIAGNOSTIC_TEST|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
58427922|NCT00552604|DRUG|Placebo|Matching placebo capsules, twice daily
58427923|NCT02707796|PROCEDURE|Hemicolectomy|
58427924|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
58427925|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
58427926|NCT01154751|DEVICE|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
58427927|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
58427928|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
58427929|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
58427930|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
58427931|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
58427932|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
58427933|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
58427934|NCT00756782|DRUG|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
57736724|NCT05003089|DRUG|BAY1834845|Tablet, oral.
57736725|NCT05003089|DRUG|BAY1830839|Tablet, oral.
57736726|NCT05003089|DRUG|Prednisolone|Tablet, oral.
58427935|NCT00756782|DRUG|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
58427936|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
58307903|NCT05916222|BEHAVIORAL|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
57736727|NCT05003089|DRUG|Placebo|Tablet, oral.
57736728|NCT03776981|OTHER|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
58307904|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule and Oral Supplement of Yuyikang|
58307905|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
58427937|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
58427938|NCT04454944|BEHAVIORAL|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
58427939|NCT04454944|BEHAVIORAL|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
58427940|NCT00376766|DRUG|levetiracetam|
58307906|NCT02771756|RADIATION|chemotherapy|
58427941|NCT05600582|BIOLOGICAL|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
58427942|NCT01520025|RADIATION|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
58427943|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
58427944|NCT05014568|DRUG|Vehicle cream|applied topically once daily
58427945|NCT01896245|DRUG|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
57736729|NCT03776981|OTHER|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
58427946|NCT01896245|DRUG|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
58427947|NCT01896245|DRUG|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
57961703|NCT02883751|RADIATION|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
58427948|NCT05158790|OTHER|Questionnaire|Administration of a questionnaire
58427949|NCT02597088|OTHER|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
58427950|NCT00550901|DRUG|cisplatin|
58307907|NCT02771756|OTHER|nutrition education|
58307908|NCT03727165|OTHER|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
57736730|NCT04290026|DRUG|metoclopramide versus granisetron|ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
57961704|NCT02883751|PROCEDURE|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
57961705|NCT01826682|OTHER|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
57961706|NCT01826682|OTHER|Medical treatment|Standard medical treatment without physiotherapy.
57961707|NCT03359876|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
57961708|NCT03359876|DRUG|Warfarin sodium|Individually adjusted dose
57961709|NCT03556930|DEVICE|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
57961710|NCT00941460|DRUG|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
57961711|NCT00941460|DRUG|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
58307909|NCT03727165|OTHER|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
58307910|NCT01603277|BIOLOGICAL|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
58307911|NCT01603277|OTHER|Placebo|Normal Saline
58307912|NCT01276977|DRUG|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
58307913|NCT01276977|DRUG|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
58307914|NCT01350219|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
58307915|NCT00392106|DRUG|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
58307916|NCT00392106|DRUG|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
58307917|NCT00392106|DRUG|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
58307918|NCT00392106|DRUG|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
58307919|NCT00392106|DEVICE|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
58307920|NCT00392106|DRUG|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
58307921|NCT02000921|OTHER|VLNC cigarettes|Modified risk tobacco product
58307922|NCT02000921|OTHER|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
58307923|NCT02000921|OTHER|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
58427951|NCT00550901|DRUG|dexrazoxane hydrochloride|
58427952|NCT00550901|OTHER|high performance liquid chromatography|
58427953|NCT00550901|OTHER|laboratory biomarker analysis|
58427954|NCT00550901|OTHER|mass spectrometry|
58427955|NCT00550901|OTHER|pharmacological study|
58427956|NCT05460156|BEHAVIORAL|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
57952834|NCT04082871|OTHER|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
57952835|NCT02343172|DRUG|HDM201|
58427957|NCT01882868|DRUG|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
57952836|NCT02343172|DRUG|LEE011|
57952837|NCT04852107|OTHER|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
57952838|NCT01083004|PROCEDURE|Indocyanine green|Using indocyanine green as intraoperative dye
57952839|NCT01083004|PROCEDURE|Brilliant blue arm|Using brilliant blue as intraoperative dye
57952840|NCT00428142|BIOLOGICAL|rituximab|375mg/m2 day 1
57952841|NCT00428142|DRUG|bortezomib|1.3mg/m2 days 1 \& 8
57952842|NCT00428142|DRUG|cyclophosphamide|750mg/m2 day 1
57952843|NCT00428142|DRUG|prednisone|40mg/m2 days 1-5
57952844|NCT00428142|DRUG|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
57952845|NCT05309187|BIOLOGICAL|IO-202|IO-202 given as monotherapy
57952846|NCT05309187|BIOLOGICAL|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
58307924|NCT02000921|OTHER|CN cigarettes|Experimental cigarettes with conventional nicotine content.
58307925|NCT02726347|BIOLOGICAL|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
58307926|NCT04907123|OTHER|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
58307927|NCT04907123|OTHER|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
58307928|NCT01297686|OTHER|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
58307929|NCT01297686|OTHER|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
57952847|NCT05309187|BIOLOGICAL|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
57952848|NCT05523037|DRUG|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
57952849|NCT05523037|DRUG|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
57952850|NCT04594590|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
57961712|NCT00666458|DRUG|saxagliptin|tablet, per oral, once daily
57961713|NCT00666458|DRUG|sitagliptin|capsule, per oral, once daily
57961714|NCT04479566|DRUG|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
57961715|NCT04479566|DRUG|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
57961716|NCT03447626|DEVICE|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
57961717|NCT00503165|BIOLOGICAL|Menitorix (MenC and Hib conjugate)|
57961718|NCT01985672|PROCEDURE|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
57961719|NCT00361595|DRUG|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
58307930|NCT01297686|OTHER|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
58307931|NCT01297686|OTHER|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
58307932|NCT01297686|OTHER|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
58307933|NCT01297686|OTHER|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
58427958|NCT01882868|DRUG|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
58427959|NCT01882868|DRUG|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
58099877|NCT01841398|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
58099878|NCT01841398|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
58099879|NCT02022410|OTHER|CAS after primary and revision TKA|CAS and RAPT
58427960|NCT01882868|DRUG|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
58427961|NCT01653236|DRUG|Boceprevir|
58099880|NCT01380860|PROCEDURE|Colostomy with mesh implantation|Colostomy with mesh implantation
58099881|NCT01380860|PROCEDURE|Simple colostomy|Colostomy with no mesh implantation.
58099882|NCT06567470|DRUG|CIT-013 low dose|Subcutaneous injection
58099883|NCT06567470|DRUG|CIT-013 high dose|Subcutaneous injection
58427962|NCT01653236|DRUG|Peginterferon alfa-2b|
58427963|NCT01653236|DRUG|ribavirin|
58427964|NCT02929940|OTHER|No intervention|No Intervention, observational
58427965|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
58427966|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
57736731|NCT01632605|DRUG|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
58099884|NCT06567470|DRUG|Placebo|Subcutaneous injection
58099885|NCT00118573|PROCEDURE|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
58099886|NCT00118573|PROCEDURE|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
58099887|NCT06567158|OTHER|Moderate carbohydrate diet|During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.
58099888|NCT06567158|OTHER|Traditional diet|During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
58427967|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
58427968|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
58427969|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
58427970|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
58099889|NCT00002774|DRUG|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
58099890|NCT00002774|DRUG|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
58099891|NCT00002774|DRUG|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
58427971|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
58427972|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
58427973|NCT01150968|BEHAVIORAL|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
58427974|NCT01073917|OTHER|Spontaneous Breathing|
58427975|NCT01073917|OTHER|Pressure Controlled Ventilation|
58427976|NCT01073917|OTHER|Pressure Support Ventilation|
58427977|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
58427978|NCT06061029|BEHAVIORAL|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
58427979|NCT01304589|DRUG|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
58427980|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
58427981|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
58427982|NCT03536026|PROCEDURE|Biopsy|-Standard of care
58427983|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
57952851|NCT05923632|BEHAVIORAL|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
57952852|NCT04610021|BIOLOGICAL|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
57952853|NCT04668859|DRUG|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
57952854|NCT04668859|DRUG|Methylcellulose|Placebo will consist of inert methylcellulose
57736732|NCT03819660|DRUG|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
57952855|NCT04106700|DRUG|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
57952856|NCT06029621|PROCEDURE|RATS for Thymectomy|a minimally invasive surgical type for Thymoma: RATS
57952857|NCT06029621|PROCEDURE|VATS for Thymectomy|a minimally invasive surgical type for Thymoma: VATS
57952858|NCT05000385|OTHER|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
57952859|NCT05000385|DIAGNOSTIC_TEST|body mass index|as an indication of nutritional status
57952860|NCT00500526|OTHER|Singing practice|
57952861|NCT00500526|OTHER|Singing classes|
58099892|NCT00002774|RADIATION|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
58099893|NCT01844869|DRUG|omacetaxine mepesuccinate|
58099894|NCT00436397|RADIATION|radiation therapy|
58099895|NCT04295044|DIETARY_SUPPLEMENT|high protein diet|receive 1.8g protein/kg
58099896|NCT04295044|DIETARY_SUPPLEMENT|normal protein diet|receive 1g protein/kg
58427984|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
57952862|NCT00500526|OTHER|Hand craft classes|
58099897|NCT05622552|DEVICE|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
58099898|NCT05622552|DEVICE|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
58099899|NCT04700735|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
58099900|NCT03779113|DRUG|HMPL-523|Oral HMPL-523
58099901|NCT01624155|BEHAVIORAL|Education|EMR referral to teratogen and contraception counseling
58307934|NCT01297686|OTHER|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
58427985|NCT03775564|OTHER|TAU|Treatment as usual
58427986|NCT03240159|DRUG|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
58427987|NCT00122655|DRUG|non-nucleoside reverse transcriptase inhibitors|
58427988|NCT00122655|DRUG|nucleoside reverse transcriptase inhibitors|
58427989|NCT00122655|DRUG|protease inhibitors|
58427990|NCT05729984|BEHAVIORAL|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
57952863|NCT04870528|DEVICE|pulsed electromagnetic field device|the pulsed electromagnetic field device treatment parameters will be set as 15 Hz frequency, 20 gauss amplitude, and 20 minutes as total treatment duration.
57952864|NCT04870528|OTHER|Free weights for Strengthening Exercise|"• Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks"
57952865|NCT01154374|DRUG|MEBO Wound Ointment|Topical application twice daily
57952866|NCT01154374|PROCEDURE|Standard of Care (sterile saline moistened gauze)|
58099902|NCT01431235|BEHAVIORAL|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
58099903|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
58427991|NCT05729984|BEHAVIORAL|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
58099904|NCT03399435|COMBINATION_PRODUCT|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
58099905|NCT03399435|COMBINATION_PRODUCT|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
58427992|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
58427993|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
58099906|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
58099907|NCT03399435|DRUG|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
58099908|NCT03399435|DRUG|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
58099909|NCT03399435|DRUG|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
58099910|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
58099911|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
58427994|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
58427995|NCT00898391|GENETIC|DNA analysis|Correlative studies
58427996|NCT00488904|DIETARY_SUPPLEMENT|supportan|2 sip feed pr. day
58427997|NCT00488904|DIETARY_SUPPLEMENT|supportan placebo|2 sip feed pr. day
58427998|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
58427999|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
58428000|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
58099912|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
58099913|NCT03951181|BEHAVIORAL|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
58099914|NCT04816500|DEVICE|Automatic ischemic conditioning treatment instrument|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
58099915|NCT04816500|DRUG|Regular treatment|Antiplatelet agents and statins administration, vascular risk factors control.
58099916|NCT06260384|OTHER|electrocardiogram|it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
58099917|NCT04254731|DRUG|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
58099918|NCT03789058|DRUG|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
58428001|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
58428002|NCT05850923|OTHER|the soothing music|the soothing music
58428003|NCT06583421|BEHAVIORAL|4-week MVPA intervention|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
58099919|NCT04456985|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
57952867|NCT05578729|BEHAVIORAL|Single surgical mask group, Double surgical mask group, N95 mask group|Masks were given to the resting pregnant women 30 minutes before the NST, and they were provided to wear masks. After 30 minutes, the vital signs of the pregnant women were measured just before and after the NST, and the images of the NST traces were taken.
57952868|NCT02271828|PROCEDURE|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
58099920|NCT04456985|DIETARY_SUPPLEMENT|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
58099921|NCT00338494|DRUG|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
58099922|NCT05748522|OTHER|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
58307935|NCT01297686|DRUG|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
58307936|NCT01285518|DRUG|PF-05231023|0.5 mg QD IV x 1 day
58307937|NCT01285518|DRUG|PF-05231023|1.5 mg QD IV x 1 day
58428004|NCT03110575|DRUG|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
58428005|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
58428006|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
58428007|NCT05709639|OTHER|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
57952869|NCT06494189|BIOLOGICAL|Tislelizumab|200mg IV Q3W
57952870|NCT06494189|DRUG|Afatinib|30mg PO QD
57952871|NCT06494189|RADIATION|Low dose radiotherapy|The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.
58099923|NCT05748522|PROCEDURE|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
58099924|NCT05365022|DEVICE|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
58428008|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
58099925|NCT05645055|OTHER|treat these patients with biologics|treat these patients with biologics
58099926|NCT04930198|BEHAVIORAL|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
58099927|NCT01461369|DRUG|Diclofenac|35 mg bid Capsules
58099928|NCT01461369|DRUG|Diclofenac|35 mg tid Capsules
58099929|NCT01461369|DRUG|Placebo|Capsules
58099930|NCT03894917|OTHER|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
58099931|NCT02505165|BEHAVIORAL|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
58099932|NCT02505165|OTHER|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
58099933|NCT02264301|DRUG|Puerarin injection 400 mg|
58099934|NCT02264301|DRUG|Qingkailing injection 40 ml|
58099935|NCT06108674|OTHER|Pharmaceutical care via telepharmacy and usual care|Pharmacotherapeutic monitoring via telephone consultation
58099936|NCT06108674|OTHER|Pharmaceutical care in-person and usual care|Face-to-face pharmacotherapeutic monitoring
58099937|NCT05043727|COMBINATION_PRODUCT|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
58099938|NCT05043727|COMBINATION_PRODUCT|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
58099939|NCT04793932|DRUG|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
58099940|NCT04793932|DRUG|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
58099941|NCT04793932|DRUG|short-course chemotherapy|other two months of chemotherapy after surgery
58099942|NCT04793932|DRUG|long-course chemotherapy|other two months of chemotherapy before surgery
58428009|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
58428010|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
58428011|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
58099943|NCT03863652|PROCEDURE|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
58099944|NCT01238211|DRUG|Cytarabine|Given IV
58099945|NCT01238211|DRUG|Dasatinib|Given PO
58099946|NCT01238211|DRUG|Daunorubicin Hydrochloride|Given IV
58099947|NCT01238211|OTHER|Laboratory Biomarker Analysis|Correlative studies
58099948|NCT00078312|DRUG|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
58307938|NCT01285518|DRUG|PF-05231023|5 mg QD IV x 1 day
58307939|NCT01285518|DRUG|PF-05231023|15 mg QD IV x 1 day
58307940|NCT01285518|DRUG|PF-05231023|50 mg QD IV x 1 day
58307941|NCT01285518|DRUG|PF-05231023|100 mg QD IV x 1 day
58307942|NCT01285518|DRUG|PF-05231023|200 mg QD IV x 1 day
58307943|NCT01285518|OTHER|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
58307944|NCT03167918|DRUG|Calcium Dobesilate|gave each patient 0.5 g bid，
58307945|NCT03167918|DRUG|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
58307946|NCT03167918|DRUG|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
58428012|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
58428013|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
58428014|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
58428015|NCT01501123|DRUG|Haloperidol|5mg IM
58428016|NCT01501123|DRUG|Midazolam|IM midazolam
58428017|NCT04485884|DRUG|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
57952872|NCT04342975|DRUG|Nicotinamide Riboside + Pterostilbene|It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
57952873|NCT04342975|DRUG|Placebo|The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
57952874|NCT00396175|DRUG|MK0906, finasteride / Duration of Treatment : 48 Weeks|
58307947|NCT03167918|DRUG|metformin|gave each patient 1000 mg, bid, PO
58307948|NCT03167918|DRUG|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
58307949|NCT05937880|DRUG|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
58307950|NCT04212117|OTHER|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
58307951|NCT04212117|OTHER|WebMD|Randomization into WebMD arm.
58428018|NCT04485884|DRUG|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
58428019|NCT04485884|DRUG|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
58428020|NCT04485884|DRUG|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
58428021|NCT04485884|DRUG|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
58428022|NCT04485884|DRUG|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
58428023|NCT01092663|DRUG|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
58428024|NCT01092663|DRUG|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
58428025|NCT05606341|DRUG|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
58428026|NCT05606341|DRUG|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
58428027|NCT05606341|DRUG|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
58428028|NCT05606341|DRUG|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
58428029|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
58099949|NCT06418880|DEVICE|AID system with Remote Real-Time CGM|"The Omnipod 5 AID System is comprised of two components:~* Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology)~* Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses."
58099950|NCT06418880|COMBINATION_PRODUCT|Standard of Care Insulin Therapy + CGM|"This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days).~Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns."
58307952|NCT02887703|BEHAVIORAL|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
58307953|NCT04345003|DEVICE|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
58428030|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
58428031|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
58428032|NCT04401878|DRUG|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
58428033|NCT05382611|DIAGNOSTIC_TEST|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
58428034|NCT01331291|DRUG|bosutinib|Taken orally
58428035|NCT06195189|DRUG|Sunvozertinib|Sunvozertinib 200mg Quaquedie (QD)
58428036|NCT06195189|DRUG|Chemotherapy|Pemetrexed +platinum
58428037|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
58428038|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
58428039|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
58428040|NCT05047848|DRUG|Chidamide|chidamide 30mg orally，Biw
58099951|NCT01777607|DEVICE|IMPELLA® RP|
58307954|NCT00526617|DRUG|ABT-888|Oral capsules
58307955|NCT00526617|DRUG|Temozolomide|Oral capsules
58307956|NCT01558934|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
58307957|NCT04173091|DIAGNOSTIC_TEST|No Intervention|No Intervention planed
58307958|NCT00553774|DIETARY_SUPPLEMENT|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
57952875|NCT00396175|DRUG|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
58307959|NCT00553774|OTHER|Placebo|Placebo (BD 21 - 28 Days)
58307960|NCT03613298|DEVICE|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
58307961|NCT05314309|DIAGNOSTIC_TEST|Comparison of two tests (FIT and mtFIT) in the same bowel movement|Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
58307962|NCT04331106|DIAGNOSTIC_TEST|Online Questionnaire|Online Questionnaire via SoSci Survey
58307963|NCT06328140|DRUG|Lurasidone|Daily medication treatment
58307964|NCT06328140|DRUG|FDA Approved antidepressant treatment|Daily treatment with an FDA approved antidepressant
58428041|NCT05047848|DRUG|Fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
58428042|NCT00005875|DRUG|rubitecan|
58428043|NCT01093872|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
58428044|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
58428045|NCT01761695|OTHER|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
58428046|NCT02326233|BIOLOGICAL|Pen of SB5|
58428047|NCT02326233|BIOLOGICAL|PFS of SB5|
58428048|NCT01599741|RADIATION|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
58428049|NCT01599741|RADIATION|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
58428050|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
58099952|NCT03749525|DRUG|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
58099953|NCT03672396|BEHAVIORAL|Home-based exercise|The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
58099954|NCT01083758|DRUG|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
58428051|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
58428052|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
58428053|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
58428054|NCT04408911|DRUG|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
57952876|NCT05243264|BEHAVIORAL|Empower@Home|The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
58099955|NCT06539325|DIAGNOSTIC_TEST|Diagnosis algorithm according to the delay between travel and consultation|Tests : RT-PCR for the most common arboviruses (Dengue, Zika, Chikungunya, and West Nile virus) and serology for dengue infection (NS1 antigen, and IgM and IgG), serologies for chronic viral infections (HIV, HBV and HCV) and schistosomiasis, Blood cultures and Innovativ Diagnostics : panel Dragonfly and two metagenomic analyses
57952877|NCT02830100|OTHER|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
57952878|NCT02830100|DEVICE|MRI|
57952879|NCT04503239|DEVICE|G6|Wear 9 wear periods of the 10-day CGM
58099956|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
58099957|NCT05062031|DEVICE|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
58099958|NCT05062031|DRUG|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
58099959|NCT05062031|DEVICE|Monofocal lenses|Daily wear for 24 months
58307965|NCT05963646|DIAGNOSTIC_TEST|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
58307966|NCT02695069|PROCEDURE|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
58307967|NCT01100385|DIETARY_SUPPLEMENT|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
58307968|NCT01100385|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule, taken once daily for 56 days
58307969|NCT01249131|DRUG|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
58307970|NCT00873158|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
58307971|NCT03903172|DEVICE|Abdominal binder|Abdominal binder
58307972|NCT03444207|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
58307973|NCT03444207|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
58307974|NCT00909467|OTHER|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
58307975|NCT02071537|DRUG|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
58307976|NCT02071537|DRUG|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
58428055|NCT05943782|PROCEDURE|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
58428056|NCT05943782|PROCEDURE|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
58428057|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
58428058|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
58428059|NCT06351722|DIAGNOSTIC_TEST|Before non-surgical periodontal treatment|"Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR."
58428060|NCT06351722|PROCEDURE|non-surgical periodontal treatment|Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
58428061|NCT06351722|DIAGNOSTIC_TEST|3rd month after non-surgical periodontal treatment|"All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT."
58428062|NCT05262283|OTHER|No intervention|No intervention was made.
58428063|NCT01377870|BIOLOGICAL|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
58428064|NCT01377870|BIOLOGICAL|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
58428065|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
58428066|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
58099960|NCT03596060|DRUG|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
58099961|NCT03596060|DRUG|Propofol|Propofol will be used for introduction in general anesthesia.
58099962|NCT03596060|DRUG|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
58099963|NCT03596060|DRUG|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
58428067|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
58428068|NCT04117698|DRUG|Ethambutol|Ethambutol
58428069|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
58428070|NCT03068208|PROCEDURE|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
58428071|NCT00184756|DRUG|somatropin|
58428072|NCT02504307|DEVICE|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
58428073|NCT02504307|DEVICE|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
58428074|NCT02161107|BIOLOGICAL|Grass-SPIRE|Intradermal injection
58099964|NCT03596060|DRUG|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
58099965|NCT01462552|DRUG|Lapatanib|Prescription of lapatinib (Tykerb)
58099966|NCT00351078|DRUG|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
58099967|NCT02881970|DRUG|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
58099968|NCT01577966|DRUG|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
58428075|NCT02161107|BIOLOGICAL|Placebo|Intradermal injection
58099969|NCT00388674|DRUG|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
58099970|NCT00388674|DRUG|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
58099971|NCT00275236|DRUG|Rotigotine|
58099972|NCT04922788|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
58099973|NCT04922788|BIOLOGICAL|Placebo|0,5 mg Aluminum adjuvant
58099974|NCT00810615|OTHER|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
58099975|NCT00810615|OTHER|Sham treatment|
58099976|NCT05495360|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|twice daily serving of the study product
58099977|NCT01063439|DRUG|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
58428076|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
57952880|NCT01527214|RADIATION|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
58099978|NCT02149537|DRUG|hydroxyurea|
58099979|NCT03922815|DRUG|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
58099980|NCT03922815|DRUG|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
58099981|NCT06516302|DRUG|GR1802|GR1802 will be administered SC.
58099982|NCT06516302|DRUG|Placebo|The placebo will be administered SC.
58099983|NCT03745573|BEHAVIORAL|Empateach|Empateach is a behavioural intervention for teachers.
58099984|NCT01954082|DRUG|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
58099985|NCT01954082|DRUG|Placebo|% glucose(dextrose)
58099986|NCT01242332|DRUG|Pregabalin|75 mg po 2 hrs before surgery
58428077|NCT04716920|DEVICE|FitBit|Wear FitBit
58428078|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
58428079|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
58428080|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
58428081|NCT00934908|DIETARY_SUPPLEMENT|Green Tea|Green tea capsules taken twice a day.
58428082|NCT00934908|OTHER|Placebo|"Non-active sugar pill."
58428083|NCT04345094|OTHER|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
58428084|NCT04345094|OTHER|Hydroquinone|Emulsions containing hydroquinone as an active
58428085|NCT05697796|PROCEDURE|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
58428086|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
58099987|NCT06537635|DEVICE|Cubii seated compact elliptical trainer|The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
58099988|NCT04442178|DRUG|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
58428087|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
58428088|NCT03033199|DRUG|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
58428089|NCT03033199|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
58428090|NCT00257972|DRUG|aripiprazole|
58428091|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
58428092|NCT01420822|DRUG|Fluticasone|Collection of safety data
58428093|NCT01181674|DRUG|insulin glargine|sc injection
58428094|NCT01181674|DRUG|metformin|oral administration
58428095|NCT01181674|DRUG|acarbose|oral administration
58428096|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
58428097|NCT01181674|DRUG|insulin glargine|sc injection
58428098|NCT01181674|DRUG|metformin|oral administration
58428099|NCT01181674|DRUG|acarbose|oral administration
58428100|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
58428101|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
58428102|NCT05702086|OTHER|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
58428103|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
58428104|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
58428105|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
58428106|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
57736733|NCT06618326|DEVICE|Acupuncture|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received acupuncture regardless of the number of acupuncture points, frequency, and courses of treatment in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g
58099989|NCT04442178|DRUG|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
58307977|NCT02071537|DRUG|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
58307978|NCT03786107|DIAGNOSTIC_TEST|Almac HER-Seq Assay|whole blood sample analysis
58307979|NCT03175211|DRUG|BI 456906|single dose
58307980|NCT03175211|DRUG|Placebo|single dose
58307981|NCT01268267|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
58307982|NCT01591148|DRUG|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
58307983|NCT03053739|DRUG|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
58428107|NCT01816802|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
58428108|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
58428109|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
58428110|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
58428111|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
58428112|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
58428113|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
58428114|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
58428115|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
58428116|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
58099990|NCT03248778|BEHAVIORAL|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
58099991|NCT01227096|DEVICE|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
58099992|NCT04307225|DEVICE|Zenicor|Handheld Thumb ECG monitoring device
58099993|NCT06290258|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
58099994|NCT02235337|DRUG|Riboflavin 400mg daily|
58099995|NCT05719844|DIAGNOSTIC_TEST|Neuropsychological tests|"List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)"
58428117|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
58428118|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
58428119|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
57736734|NCT06618326|DEVICE|biofeedback|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary
58099996|NCT00064935|PROCEDURE|Endometrial biopsy|
58099997|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
58099998|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
58099999|NCT05498831|OTHER|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
58428120|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
58428121|NCT02349750|PROCEDURE|endometrial scratch injury|ESI using No.8 neonatal feeding tube
58428122|NCT02795091|OTHER|manual cleaning|manual clean the rag and floor towel
58428123|NCT02795091|DEVICE|machine clean|machine clean the rag and floor towel
58428124|NCT04424927|BIOLOGICAL|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
58428125|NCT04424927|OTHER|Placebo|Placebo
58428126|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
58428127|NCT05686642|DRUG|LT3001 Drug:high dose|Administered by intravenous infusion.
58428128|NCT05686642|DRUG|Placebo|Administered by intravenous infusion.
57736735|NCT05568992|DEVICE|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
57736736|NCT01848873|DRUG|Amlodipine|amlodipine 5mg daily
57736737|NCT01848873|DRUG|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
58428129|NCT05686642|DRUG|LT3001 Drug:low dose|Administered by intravenous infusion.
58428130|NCT06220019|DRUG|TCM|We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
58428131|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
58428132|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
58100000|NCT03056001|DRUG|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
58428133|NCT04409093|PROCEDURE|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
58428134|NCT04409093|PROCEDURE|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
58100001|NCT03056001|DRUG|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
58100002|NCT02806635|BEHAVIORAL|OurRelationship|
58100003|NCT02806635|BEHAVIORAL|PREP Online|
58100004|NCT00995540|DRUG|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
58100005|NCT00995540|DRUG|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
58100006|NCT00995540|DRUG|Placebo|Placebo tid subcutaneous injection for 12 weeks
58100007|NCT06329076|DRUG|Losartan|Administration of losartan tablets (50 mg)
58100008|NCT06329076|DRUG|Placebo|Administration of placebo tablets
58100009|NCT00701168|DEVICE|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
58100010|NCT02513693|DRUG|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
58100011|NCT02513693|DRUG|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
58100012|NCT01169844|BIOLOGICAL|AIN457A|
58428135|NCT03341455|BEHAVIORAL|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
58428136|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
58428137|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
58428138|NCT06508229|DRUG|Adebrelimab|adebrelimab, IV
58428139|NCT06508229|DRUG|albumin paclitaxel|albumin paclitaxel, iv
57736738|NCT01848873|DRUG|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
58428140|NCT06508229|DRUG|Nedaplatin|Nedaplatin，IV
58428141|NCT02825212|DRUG|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
57736739|NCT04509947|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
57736740|NCT04509947|BIOLOGICAL|Placebo|Placebo will be administered as IM injection.
58100013|NCT01169844|OTHER|Other|
58100014|NCT01680289|PROCEDURE|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
58100015|NCT01680289|PROCEDURE|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
58100016|NCT04475068|PROCEDURE|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
58100017|NCT04189406|OTHER|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
58100018|NCT02533505|DRUG|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
58428142|NCT02825212|DRUG|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
58428143|NCT02562807|DRUG|TAS-303 18mg single-dose|
58428144|NCT02562807|DRUG|Placebo 18mg single-dose|
58307984|NCT03053739|DRUG|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
58307985|NCT01081197|OTHER|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
58428145|NCT02562807|DRUG|TAS-303 9mg single-dose|
58428146|NCT02562807|DRUG|Placebo 9mg single-dose|
58428147|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
58428148|NCT00737633|DRUG|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
58428149|NCT05652153|OTHER|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
58428150|NCT00209300|DRUG|Pentasa|
58428151|NCT00357825|DRUG|[S,S]-Reboxetine|
58428152|NCT05648565|DEVICE|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
58428153|NCT02193412|PROCEDURE|noxious stimulus|standardized noxious stimulus with tetanic stimulation
58428154|NCT02193412|PROCEDURE|change in operating table slope: head-down tilt position|-30°
58428155|NCT02193412|PROCEDURE|change in operating table slope: head-up tilt position|+30°
58428156|NCT02816229|DEVICE|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
58428157|NCT04456374|OTHER|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
58428158|NCT04708509|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
58428159|NCT04836247|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
58428160|NCT04836247|BEHAVIORAL|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
58428161|NCT01854424|OTHER|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
58428162|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
58307986|NCT00977197|DRUG|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
58307987|NCT00977197|DRUG|Placebo|A matching placebo will be administered twice a day
58307988|NCT04079504|PROCEDURE|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
58307989|NCT04079504|PROCEDURE|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
58307990|NCT06411652|OTHER|Reflexology|"1. First, the patient's foot will be cleaned with cotton dipped in warm water,~2. In order not to disturb the patient, the hands will be warmed and one or two ccs of baby oil will be used to facilitate the massage.~3. Before applying the main technique, the first two minutes of each session will be spent using the relaxation technique, which involves back and forth movements with the palm of the palm on the outer edge of the foot, from the outer part of the ankle to the little toe, to relieve muscle tension and spasm.~4. Then, alternate pressure will be applied to the reflex points of the right thumb by taking the heel of one foot in the left hand."
58458368|NCT04854343|DIAGNOSTIC_TEST|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
58307991|NCT06411652|OTHER|Therapeutic Touch|"1. The procedure will be explained to the woman,~2. The procedure will be performed in the patient's bed.~3. The practitioner will center by making his body, mind and emotions quiet and focused, prepare himself for the practice and remain centered throughout the intervention,~4. There will be good intentions to help the woman get treatment,~5. In order to scan the energy field, the patient's entire body will be held with the palms of the practitioner's hands facing the patient, it will be moved with a soft movement from"
57736741|NCT04928950|DRUG|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
57736742|NCT05974969|DRUG|BCD-264|a single intravenous infusion of BCD-264
57736743|NCT05974969|DRUG|Darzalex|a single intravenous infusion of Darzalex
57736744|NCT04169139|DEVICE|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
57736745|NCT02444455|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
58307992|NCT04630743|BEHAVIORAL|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
58307993|NCT00120471|DRUG|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
58307994|NCT00120471|DRUG|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
58307995|NCT00120471|DRUG|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
58307996|NCT06284161|DIAGNOSTIC_TEST|Quadriceps Combined Test|The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
58307997|NCT00943436|OTHER|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
58307998|NCT00943436|OTHER|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
58307999|NCT02756910|DEVICE|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
58308000|NCT04699539|RADIATION|SBRT|SBRT: in 5-6fractions with Cyberknife.
58308001|NCT04699539|DRUG|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
58308002|NCT00555854|BEHAVIORAL|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
58308003|NCT04366245|BIOLOGICAL|Hyperimmune plasma|PLASMA OF CONVALESCENT COVID-19
58308004|NCT04366245|DRUG|Standard of care for SARS-CoV-2 infection|Standard of care for SARS-CoV-2 infection
58308005|NCT05485753|DRUG|GNC-038|Administration by intravenous infusion
58308006|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
58308007|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
58308008|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
58308009|NCT00021788|PROCEDURE|islet cell transplantation|
58308010|NCT05635903|PROCEDURE|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
58308011|NCT05635903|PROCEDURE|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
58308012|NCT05635903|PROCEDURE|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
58308013|NCT01417169|DRUG|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
58428163|NCT04680819|DIETARY_SUPPLEMENT|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
58428164|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
58428165|NCT05047432|OTHER|Non-interventional trial|Non-interventional trial
58428166|NCT05265897|OTHER|CAQ|Informational document
58428167|NCT01868334|BEHAVIORAL|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
58100019|NCT02533505|DRUG|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
58100020|NCT03991065|DIAGNOSTIC_TEST|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
58428168|NCT01868334|BEHAVIORAL|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
58428169|NCT01868334|BEHAVIORAL|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
58428170|NCT01868334|BEHAVIORAL|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
58428171|NCT01099436|DRUG|cyclophosphamide|
58428172|NCT01099436|DRUG|docetaxel|
58428173|NCT01099436|DRUG|doxorubicin hydrochloride|
58428174|NCT01099436|DRUG|zoledronic acid|
58428175|NCT01099436|PROCEDURE|neoadjuvant therapy|
58428176|NCT05207683|OTHER|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
58428177|NCT03076723|OTHER|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
58428178|NCT03076723|OTHER|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
58428179|NCT00025246|DRUG|imatinib mesylate|Given orally
58428180|NCT00025246|OTHER|laboratory biomarker analysis|Correlative studies
58428181|NCT04253587|DEVICE|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
58100021|NCT04462133|DIAGNOSTIC_TEST|Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)|Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
58428182|NCT04253587|DEVICE|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
58428183|NCT04253587|DEVICE|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
58428184|NCT04253587|DEVICE|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
57736746|NCT06269926|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Treatment for chronic pain that addresses the relationship between thoughts, feelings and behaviors.
58100022|NCT01066273|DEVICE|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
58428185|NCT03951116|DRUG|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
58428186|NCT04896593|BEHAVIORAL|Smartphone App|Smartphone app teaching suicide prevention skills.
58428187|NCT02579681|DRUG|dimethyl fumarate|dimethyl fumarate administered as per the arm description
58428188|NCT05504005|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
58428189|NCT03872791|BIOLOGICAL|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
58428190|NCT03872791|DRUG|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
58428191|NCT04693351|DRUG|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
58428192|NCT04693351|DRUG|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
58428193|NCT02913495|DRUG|Vaginal Progesterone|
58100023|NCT00101894|DRUG|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
58428194|NCT02913495|DRUG|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
58428195|NCT02975726|DEVICE|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
58428196|NCT02975726|PROCEDURE|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
58428197|NCT02975726|BIOLOGICAL|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
58428198|NCT02975726|PROCEDURE|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
58428199|NCT02836431|DRUG|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
58428200|NCT02836431|DRUG|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
58428201|NCT02836431|DRUG|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
58428202|NCT04794023|DEVICE|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
58428203|NCT03865836|BIOLOGICAL|ATB200|
57736747|NCT06269926|OTHER|Pain education|A booklet on chronic pain (in this study, an educational pamphlet from the Oregon state health department) that provides pain education in addition to usual medical care.
58100024|NCT00101894|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
58308014|NCT01125098|OTHER|PRO-CT values|"* continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
58428204|NCT03865836|DRUG|AT2221|
58428205|NCT05831605|PROCEDURE|venipuncture with near-infrared light|with near-infrared light to locate the veins
58428206|NCT06086483|DRUG|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
58428207|NCT06086483|DRUG|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
58428208|NCT05754593|BIOLOGICAL|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
58428209|NCT05754593|OTHER|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
58428210|NCT05754593|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
58428211|NCT00230503|DRUG|pradefovir mesylate|
58428212|NCT00230503|DRUG|adefovir dipivoxyl|
58428213|NCT05417191|BEHAVIORAL|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
58428214|NCT05417191|BEHAVIORAL|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
58100025|NCT00101894|BIOLOGICAL|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
58100026|NCT00101894|DRUG|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
58428215|NCT02092311|PROCEDURE|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
58100027|NCT05754437|DEVICE|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
58100028|NCT00006044|DRUG|therapeutic testosterone|
58100029|NCT06500052|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
58100030|NCT05139901|DRUG|Dornase Alfa|inhalations twice daily
58100031|NCT05139901|DRUG|Saline|inhalations twice daily
58428216|NCT02092311|PROCEDURE|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
57736748|NCT05371184|DRUG|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
57736749|NCT05371184|OTHER|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
58100032|NCT05709626|DRUG|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
58100033|NCT05709626|DRUG|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
58100034|NCT00104117|DRUG|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
58428217|NCT02163421|DRUG|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
57736750|NCT01298128|DRUG|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
57736751|NCT01298128|DRUG|marvelon|marvelon 21 daily
57736752|NCT05790733|OTHER|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
57736753|NCT05790733|OTHER|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
57952881|NCT00579852|PROCEDURE|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
58100035|NCT00323687|DRUG|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
58428218|NCT02163421|DRUG|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
58100036|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58100037|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58100038|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58100039|NCT03709407|OTHER|cervical stimuli|Manouvres Godoy
58100040|NCT03709407|OTHER|terminus|Manouvres Vodder
58100041|NCT03709407|OTHER|Placebo|placebo manouvre
58100042|NCT03709407|OTHER|Control group|lie down
58100043|NCT03137758|DRUG|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
58100044|NCT03455647|BEHAVIORAL|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
58100045|NCT05539599|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
58100046|NCT04808765|PROCEDURE|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
58100047|NCT01177319|DRUG|Glutathione|
58100048|NCT00843063|DRUG|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
58100049|NCT05409807|DEVICE|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
58428219|NCT05021575|OTHER|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
58428220|NCT05021575|OTHER|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
58428221|NCT05021575|OTHER|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
58428222|NCT05021575|OTHER|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
58428223|NCT06392269|DIAGNOSTIC_TEST|Tasso+SST|Clinical evaluation of capillary blood samples collected using the Tasso+SST device for downstream analyte testing.
58428224|NCT04859374|BEHAVIORAL|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
58428225|NCT04859374|DRUG|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
58100050|NCT05409807|DEVICE|Ultrasound guided|Ultrasound guided interscalene nerve block
58100051|NCT03576469|BIOLOGICAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
58100052|NCT05055778|BEHAVIORAL|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
58100053|NCT05596552|DRUG|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
58100054|NCT05596552|DRUG|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
58100055|NCT04015479|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
58100056|NCT04015479|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
58100057|NCT03540407|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
58308015|NCT01948245|DEVICE|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
57961720|NCT06541873|OTHER|Clinical and gait evaluation|The dual-task conditions to be assessed during gait performance will include: counting backwards by 3 (executive simple task); counting backwards by 7 (executive complex task); mnemonic recall of the Rey's Auditory Verbal Learning Test (RAVLT). Performance scores will be correlated with cognitive status and clinical features. Data will be collected at the baseline (i.e., only) visit within the enrollment timeframe of 3 years from study initiation.
57961721|NCT00959816|DRUG|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
57961722|NCT00923117|DRUG|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
58308016|NCT01948245|DEVICE|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
58308017|NCT00855348|OTHER|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
58308018|NCT03057886|DEVICE|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
58308019|NCT03381872|PROCEDURE|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~1. Intravascular imaging arm~2. Angiography arm~   * Definition of Complex Lesions~     1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~    2. Chronic total occlusion (≥3 months) as target lesion~    3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~    4. Implanted stent length ≥38mm~    5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~    6. Multiple stent needed (≥3 more stent per patient)~    7. In-stent restenosis lesion as target lesion~    8. Severely calcified lesion (encircling calcium in angiography)~    9. Ostial coronary lesion (LAD, LCX, RCA)"
58308020|NCT03381872|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
57736754|NCT03939468|DEVICE|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
57736755|NCT01696422|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
57961723|NCT04848922|OTHER|Hot shower intervention|Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
57961724|NCT04405050|DEVICE|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
57961725|NCT04405050|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
57961726|NCT03912129|GENETIC|blood sample|"A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants."
58100058|NCT03540407|DIETARY_SUPPLEMENT|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
58100059|NCT04949984|DEVICE|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
58100060|NCT01079078|DRUG|Acetaminophen|
58100061|NCT04167280|DRUG|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
58428226|NCT03950310|DEVICE|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
58428227|NCT02272166|DRUG|propofol|
58428228|NCT02272166|DRUG|Sevoflurane|
58100062|NCT04167280|DRUG|placebo metered dose inhaler|matched MDI to deliver inactive drug
58428229|NCT06486415|DIAGNOSTIC_TEST|serum BHCG testing|Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
58428230|NCT03530501|OTHER|Diet|Very low calorie ketogenic diet followed by low calorie diet
58100063|NCT04356092|DIAGNOSTIC_TEST|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
58100064|NCT03336645|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
58100065|NCT04261517|DRUG|Hydroxychloroquine|Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
58100066|NCT04193033|OTHER|FLOW intervention|The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
58100067|NCT02688101|DRUG|DpC|iron chelator
58428231|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
58428232|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
58428233|NCT01353911|DRUG|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
58100068|NCT04477317|DRUG|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
58100069|NCT04477317|DRUG|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
58100070|NCT03087773|DRUG|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
58100071|NCT03087773|DRUG|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
58428234|NCT01353911|DRUG|Boceprevir|Four 200 mg capsules orally three times daily.
58428235|NCT01353911|DRUG|Placebo for Grazoprevir|Orally once daily in AM.
58428236|NCT01353911|DRUG|Placebo for Boceprevir|Four capsules orally three times daily.
58428237|NCT01353911|DRUG|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
58100072|NCT01393548|DRUG|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
58100073|NCT01393548|DRUG|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
58428238|NCT01353911|DRUG|Ribavirin|300 mg to 700 mg orally twice daily.
58428239|NCT04100941|DIAGNOSTIC_TEST|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
58428240|NCT04100941|DIAGNOSTIC_TEST|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
58428241|NCT04100941|DIAGNOSTIC_TEST|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
58428242|NCT06070909|DEVICE|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
58458369|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
58100074|NCT06099041|DEVICE|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
58100075|NCT05371418|PROCEDURE|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
58100076|NCT05371418|DEVICE|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
58100077|NCT03154931|OTHER|CBT-SG|To support the group.
58100078|NCT03154931|OTHER|CFT-G|Teach compassionate skills.
58428243|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
58428244|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
58428245|NCT06502847|OTHER|Exosome profile study|Neonatal serum and maternal exosome profiles will be studied in all groups.
58428246|NCT02727491|DRUG|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
58428247|NCT02727491|DRUG|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
58428248|NCT05234203|DIETARY_SUPPLEMENT|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
58428249|NCT02175368|DEVICE|Adhese One F Upgrade|
58428250|NCT02501525|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
58428251|NCT02501525|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
58428252|NCT01065831|BEHAVIORAL|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
58100079|NCT02350322|OTHER|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
58100080|NCT02350322|OTHER|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
58100081|NCT02350322|DIETARY_SUPPLEMENT|Supplement|Omega-3 capsules three times a week for 12 weeks
58428253|NCT04919096|DRUG|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
58428254|NCT04919096|DRUG|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
58428255|NCT01362387|OTHER|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
58428256|NCT03161574|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
58428257|NCT05832749|DEVICE|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
58100082|NCT02380066|DRUG|Anyu Peibo|Placebo
58100083|NCT03448601|OTHER|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
58100084|NCT03448601|OTHER|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
58100085|NCT04754919|OTHER|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
58100086|NCT04754919|OTHER|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
58100087|NCT02561000|DRUG|PZ-128|
58100088|NCT02561000|DRUG|Placebo|
58100089|NCT06170840|DRUG|QY101Placebo/QY101 ointment|External use for BID
58100090|NCT00949052|GENETIC|DNA analysis|
58428258|NCT05832749|DEVICE|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
58428259|NCT06010134|OTHER|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
58428260|NCT00375167|BEHAVIORAL|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
58428261|NCT00375167|BEHAVIORAL|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
58428262|NCT03973762|DEVICE|DR Grading with CAD|A CAD system is used to make DR grading.
58428263|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
58428264|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
58428265|NCT03111953|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
58428266|NCT03111953|PROCEDURE|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
58428267|NCT03422536|BIOLOGICAL|Cetuximab|Given IV
58428268|NCT03422536|DRUG|Ficlatuzumab|Given IV
58428269|NCT06136611|DEVICE|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
58428270|NCT00093821|DRUG|tanespimycin|Given IV
58428271|NCT00093821|OTHER|pharmacological study|Correlative studies
58428272|NCT00093821|OTHER|laboratory biomarker analysis|Correlative studies
57736756|NCT01696422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
57736757|NCT01696422|OTHER|Placebo|Route:subcutaneous
58428273|NCT00372541|DRUG|ceftriaxone|
58428274|NCT00610389|BIOLOGICAL|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
58428275|NCT00310622|DEVICE|HyperQ Signal recording|
58428276|NCT01303198|DEVICE|APAP - Therapy|automatic positive pressure therapy
58428277|NCT04797871|BEHAVIORAL|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
58428278|NCT04797871|BEHAVIORAL|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
58428279|NCT04241263|DEVICE|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
57736758|NCT03315000|DRUG|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
57736759|NCT03315000|DRUG|Fluticasone Furoate|Same as fluticasone arm description
57736760|NCT03315000|DRUG|Placebos|Same as placebo arm description
57736761|NCT03555396|BEHAVIORAL|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
58100091|NCT00949052|GENETIC|polymorphism analysis|
58100092|NCT00949052|OTHER|laboratory biomarker analysis|
58100093|NCT00949052|OTHER|medical chart review|
58100094|NCT00949052|OTHER|questionnaire administration|
58100095|NCT00949052|PROCEDURE|assessment of therapy complications|
58100096|NCT00949052|PROCEDURE|evaluation of cancer risk factors|
58100097|NCT00727896|BEHAVIORAL|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
58100098|NCT00727896|DRUG|Diabetes Treatment|Life style modification and drug therapy
58100099|NCT00654446|DRUG|Rosuvastatin|
58100100|NCT00654446|DRUG|Simvastatin|
58100101|NCT04902261|DRUG|Tislelizumab|Tislelizumab 200 mg every three weeks
58428280|NCT04241263|DEVICE|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
58428281|NCT03117179|OTHER|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
58308021|NCT03381872|DEVICE|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden \<50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: \[1\] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~\[2\] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
57961727|NCT06213909|OTHER|This is a retrospective analysis of health data from inpatient record, no intervention was designed|This is a retrospective analysis of health data from inpatient record, no intervention was designed
58308022|NCT03381872|DEVICE|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
58308023|NCT06399042|DEVICE|SP5M002 inj|pre-filled syringe
58308024|NCT06399042|DEVICE|Synovian inj|pre-filled syringe
58308025|NCT02873234|DRUG|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
58308026|NCT02873234|DRUG|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
58308027|NCT02811770|OTHER|kidney biopsy|
58308028|NCT05232227|DRUG|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
58308029|NCT05232227|DRUG|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
58308030|NCT05423977|DRUG|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
58308031|NCT06467695|DEVICE|BIOPAC Stimsola|Transcranial Electrical Stimulator
58308032|NCT06467695|DEVICE|BIOPAC Stimsola Sham (zero amps)|Transcranial Electrical Stimulator set to 0 amps
58308033|NCT03019484|BEHAVIORAL|Breastfeeding support|Self-efficacy
58308034|NCT04534309|BEHAVIORAL|Written Weight Loss Material|Participants will receive written weight loss material by email.
58308035|NCT04534309|BEHAVIORAL|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
58308036|NCT04534309|BEHAVIORAL|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
58308037|NCT06326736|PROCEDURE|Surgery|Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.
58308038|NCT06326736|DRUG|Camrelizumab|Camrelizumab will be administered 6 weeks post-tumor resection.
58308039|NCT06326736|BIOLOGICAL|SJ-Neo006|SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).
58308040|NCT06326736|DRUG|Gemcitabine+Abraxane|Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
58308041|NCT00526474|DRUG|Vorapaxar|2.5-mg tablet daily for at least 1 year
57961728|NCT00356278|DRUG|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
57961729|NCT00356278|DRUG|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
57961730|NCT00356278|BEHAVIORAL|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
57961731|NCT00356278|DRUG|Placebo|Placebo will be administered in the same manner as the active drugs.
57961732|NCT04509466|DRUG|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
57961733|NCT04509466|DRUG|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
57736762|NCT03555396|BEHAVIORAL|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
57736763|NCT04811027|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
57736764|NCT04811027|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
58458370|NCT02190136|OTHER|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
57736765|NCT00240318|DRUG|Rosuvastatin calcium|
57736766|NCT00345241|DRUG|Systane Ocular Drops (OTC)|
57736767|NCT00345241|DRUG|Placebo - Saline Drops|
58100102|NCT04902261|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
58100103|NCT04902261|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
58428282|NCT06342973|DEVICE|Xenograft and allograft|For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
58428283|NCT04841772|DIETARY_SUPPLEMENT|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
58428284|NCT04841772|DIETARY_SUPPLEMENT|Placebo|Post exercise placebo supplement (32g maltodextrin)
58428285|NCT00100594|DRUG|Efavirenz|
58428286|NCT00100594|DRUG|Lamivudine/zidovudine|
58428287|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
58428288|NCT01920737|DRUG|Vincristine|
58428289|NCT01920737|DRUG|Prednisone|
58428290|NCT01920737|DRUG|PEG-Asparaginase|
58428291|NCT01920737|DRUG|Methotrexate|
58428292|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
58428293|NCT01920737|DRUG|Cyclophosphamide|
58428294|NCT01920737|DRUG|Cytarabine|
58428295|NCT01920737|DRUG|Leucovorin|
58428296|NCT01920737|DRUG|Dexamethasone|
58428297|NCT01920737|OTHER|Blood draw|
58428298|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
58428299|NCT00439374|DRUG|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
58428300|NCT00439374|OTHER|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
58428301|NCT04022655|OTHER|ICU Care|No intervention
58428302|NCT01812512|BEHAVIORAL|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
58428303|NCT02404428|DIETARY_SUPPLEMENT|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
58428304|NCT02404428|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
58428305|NCT05420649|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
58428306|NCT00005834|BIOLOGICAL|filgrastim|Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5
58428307|NCT00005834|DRUG|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
58428308|NCT00005834|DRUG|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
57961734|NCT04509466|DRUG|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
57961735|NCT00522587|DRUG|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
58428309|NCT00005834|DRUG|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
58428310|NCT00005834|DRUG|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
58428311|NCT00005834|DRUG|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
58428312|NCT03931694|DEVICE|e-DOL|e-health program (smartphone and web platform)
58428313|NCT05399290|DRUG|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
58428314|NCT02807688|BEHAVIORAL|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
58428315|NCT00000382|BEHAVIORAL|Infant-Parent Psychotherapy|
57961736|NCT00522587|DRUG|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
57961737|NCT00522587|DRUG|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
57961738|NCT00522587|DRUG|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
57961739|NCT00522587|DRUG|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
57961740|NCT00522587|DRUG|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
57961741|NCT00522587|DRUG|Fixed remifentanil dose 1|Dose 1 of remifentanil
57961742|NCT00522587|DRUG|Fixed remifentanil dose 2|Dose 2 of remifentanil
57961743|NCT00522587|DRUG|Fixed remifentanil dose 3|Dose 3 of remifentanil
57961744|NCT00522587|DRUG|Fixed remifentanil dose 4|Dose 4 of remifentanil
57961745|NCT00522587|DRUG|Fixed remifentanil dose 5|Dose 5 of remifentanil
57961746|NCT00522587|DRUG|Fixed remifentanil dose 6|Dose 6 of remifentanil
57961747|NCT00318760|DRUG|Clonidine|0.1 or 0.2 mg oral, one dose
58428316|NCT00000382|BEHAVIORAL|Child Protective Services|
58428317|NCT00000382|BEHAVIORAL|Psychoeducational Home Visitation|
58428318|NCT00000382|BEHAVIORAL|Parent Education|
58428319|NCT03080636|OTHER|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
58428320|NCT03080636|OTHER|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
58428321|NCT03080636|OTHER|Control session|30 minutes seated resting
57961748|NCT00318760|DRUG|Placebo|oral capsule 1 dose
57961749|NCT04600895|DRUG|Favipiravir|Favipiravir
57961750|NCT04600895|DRUG|Placebo|Placebo
57961751|NCT05336071|DRUG|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
57961752|NCT05336071|DRUG|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
57961753|NCT00813397|DEVICE|Sepraspray|Max. 10g of Sepraspray
57961754|NCT03630731|DRUG|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
57961755|NCT05275062|DRUG|IM92 CAR-T cells|2.5×10\^8 CAR-T cells
57961756|NCT01347736|OTHER|scrambler therapy|Undergo scrambler therapy
57961757|NCT01347736|OTHER|questionnaire administration|Ancillary studies
57961758|NCT01347736|PROCEDURE|dermatologic complications management/prevention|Undergo scrambler therapy
57961759|NCT04874987|OTHER|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
57961760|NCT02448511|OTHER|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
57961761|NCT02448511|DEVICE|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
57961762|NCT02448511|OTHER|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
57961763|NCT01831960|DRUG|cortexolone 17α-propionate|
57961764|NCT04675541|BIOLOGICAL|Afstyla®|Solution for injection
57961765|NCT04456439|BIOLOGICAL|Remestemcel-L|Participants may receive up to 2 infusions of 2 x 10\^6 remestemcel-L within a 5-day period.
58428322|NCT01517386|PROCEDURE|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
58428323|NCT04223414|DEVICE|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
58428324|NCT03753139|DEVICE|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
58428325|NCT05095857|DRUG|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
57961766|NCT04456439|DRUG|Hydrocortisone|Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
58308042|NCT00526474|DRUG|Placebo|matching tablet daily for at least 1 year
58308043|NCT03876925|DRUG|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
58308044|NCT04597567|PROCEDURE|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
58308045|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
58308046|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
58308047|NCT02868515|OTHER|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
58428326|NCT05095857|OTHER|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
58428327|NCT05944627|BIOLOGICAL|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
57961767|NCT04456439|DRUG|Diphenhydramine|Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
57961768|NCT03680495|DRUG|Methylprednisolone|1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
58308048|NCT06312709|BEHAVIORAL|teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)|teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.
58308049|NCT06312709|OTHER|Health Education|Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
58308050|NCT00492492|PROCEDURE|trans-styloid and intrafocal pinning on the one side|
58308051|NCT00492492|PROCEDURE|volar fixed-angle plating on the other side|
58308052|NCT03386526|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
58308053|NCT03964948|DIAGNOSTIC_TEST|Kidney MRI|An MRI examination will be completed per research MRI protocol.
58308054|NCT03951519|OTHER|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
58308055|NCT03951519|OTHER|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
58308056|NCT05639517|OTHER|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
58100104|NCT04498299|DIAGNOSTIC_TEST|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
58100105|NCT05766761|BEHAVIORAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
58100106|NCT06138431|BEHAVIORAL|CBT|Virtual CBT groups
58100107|NCT01372527|OTHER|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
58100108|NCT06183645|DEVICE|Actimyo|Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
58100109|NCT05397288|BEHAVIORAL|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
58100110|NCT05397288|BEHAVIORAL|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
58100111|NCT05397288|BEHAVIORAL|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~* 1st month: group talk (1 time/week), individual consultation (2 times/week)~* 2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~* 3rd month: group talk (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
58428328|NCT05944627|BIOLOGICAL|Placebo|placebo administration in Phase 2a clinical trial
58428329|NCT04071678|BEHAVIORAL|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
58428330|NCT02823379|BEHAVIORAL|Physical Activity|A Smartphone delivered physical activity program
58308057|NCT05639517|OTHER|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
58308058|NCT02819713|OTHER|ultrasound gel|
58308059|NCT02819713|OTHER|Instillagel|
58308060|NCT00676117|DRUG|Esomeprazole (D961H)|20mg
58308061|NCT00676117|DRUG|Loxoprofen|60mg tablet
58308062|NCT04273321|DRUG|Methylprednisolone|Methylprednisolone 1mg/kg/day ivgtt for 7 days.
58308063|NCT00001078|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
58308064|NCT04124133|DEVICE|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
58308065|NCT02090296|DRUG|Hydroxyurea|
58308066|NCT02090296|OTHER|Placebo|
58308067|NCT03720119|DRUG|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
58308068|NCT01164761|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
58308069|NCT01164761|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
58308070|NCT06293833|RADIATION|Low-dose CT scan|Participants get an annual low-dose CT scan in UZA
58308071|NCT06293833|BEHAVIORAL|Smoking Cessation|Smoking cessation campagnes
58308072|NCT03149536|DIAGNOSTIC_TEST|Pharmacogenetic test|To develop a pharmacogenetic prediction test
58308073|NCT04151264|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
58308074|NCT04326257|DRUG|Nivolumab+Relatlimab|IV administration of both Nivolumab and Relatlimab
58308075|NCT04326257|DRUG|Nivolumab+Ipilimumab|IV administration of both Nivolumab and Ipilimumab
58308076|NCT03821038|BIOLOGICAL|CYT107|IV twice a week at 10µg/kg for 3 weeks
58308077|NCT03821038|DRUG|Placebos|IV twice a week at the same volume for 3 weeks
58308078|NCT02060357|DEVICE|Optical coherence tomography|
58308079|NCT00609817|DRUG|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
58308080|NCT00609817|DRUG|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
58308081|NCT03279042|PROCEDURE|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
58308082|NCT03279042|PROCEDURE|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
57736768|NCT03181880|DRUG|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
58100112|NCT04064333|DEVICE|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
58100113|NCT05417126|BIOLOGICAL|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
58100114|NCT05353426|PROCEDURE|Paragastric autonomic neural blockade|Paragastric autonomic neural blockade with Bupivacaine
58428331|NCT02823379|BEHAVIORAL|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
58428332|NCT00995995|DRUG|Rosiglitazone|Rosiglitazone
58428333|NCT04645589|DRUG|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
58428334|NCT04771676|DRUG|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
58428335|NCT05874622|DRUG|VC005 tablets|VC005 groups repeat administration for 4 weeks
58428336|NCT05874622|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
58428337|NCT03599479|DEVICE|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
58428338|NCT01371045|OTHER|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
58428339|NCT00595816|OTHER|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
58428340|NCT04397419|DIETARY_SUPPLEMENT|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
57736769|NCT03181880|DRUG|Standard of Care|Brochodilators
58100115|NCT02585973|DRUG|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
58100116|NCT02585973|DRUG|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
58428341|NCT04397419|OTHER|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
58428342|NCT05417308|DRUG|Minoxidil|Applied topically
58428343|NCT05417308|DRUG|Minoxidil|Given PO
58428344|NCT05417308|OTHER|Quality-of-Life Assessment|Ancillary studies
58428345|NCT05417308|OTHER|Questionnaire Administration|Ancillary studies
58428346|NCT03286283|DEVICE|J-Plasma|Dermal resurfacing procedure with J-Plasma.
58428347|NCT05490004|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
57736770|NCT05876065|DRUG|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
58100117|NCT02585973|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
58428348|NCT01041287|DRUG|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks
58428349|NCT01041287|DRUG|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
58428350|NCT02726022|DRUG|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
58428351|NCT02726022|DRUG|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
57736771|NCT05876065|DRUG|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
57736772|NCT01817179|OTHER|FES neuroprosthesis to dorsiflexors on affected leg|
57736773|NCT03288662|OTHER|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
57736774|NCT01097538|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
58428352|NCT00806143|DEVICE|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
58428353|NCT00806143|DEVICE|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
58428354|NCT00146380|DRUG|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
58428355|NCT00146380|BEHAVIORAL|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
58428356|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
58428357|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
58428358|NCT05722223|COMBINATION_PRODUCT|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
58428359|NCT03865784|OTHER|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
58428360|NCT03865784|OTHER|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
58428361|NCT00172341|DRUG|Staloral TM|
58428362|NCT01735942|DRUG|Ingenol mebutate|
58428363|NCT01735942|PROCEDURE|cryotherapy|
58428364|NCT00877396|BIOLOGICAL|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
58428365|NCT00877396|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
58428366|NCT06583785|OTHER|Black rice (Intervention)|210 g of cooked black rice
57736775|NCT01097538|OTHER|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
57736776|NCT00656591|DRUG|Methotrexate|Methotrexate
57736777|NCT05020639|DRUG|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
57736778|NCT00479011|PROCEDURE|fluid management based on arterial pulse pressure variation|
57736779|NCT02969889|DEVICE|Airtraq|video laryngoscope with a channel
57736780|NCT02969889|DEVICE|ILMA|
58428367|NCT06583785|OTHER|Brown rice (Control)|210 g of cooked brown rice
58428368|NCT02242383|DRUG|Telmisartan|
58428369|NCT02242383|DRUG|Telmisartan in combination with hydrochlorothiazide|
58428370|NCT04576897|DIAGNOSTIC_TEST|Velacur|Ultrasound elasticity imaging
58458371|NCT02190136|OTHER|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
57736781|NCT02300220|DRUG|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
57736782|NCT02300220|DRUG|Placebo|One capsule, twice daily for 1 week
57736783|NCT06104410|RADIATION|Standard fractioned dose|Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
57736784|NCT06104410|RADIATION|Experimental single dose|Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
57736785|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
58428371|NCT06012110|DEVICE|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
58428372|NCT06503380|OTHER|No intervenrion.|This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
58428373|NCT04979494|OTHER|ultrasound examination|We conduct abdominal ultrasound examinations for each patient.
58428374|NCT04169074|DRUG|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
58428375|NCT01010152|DRUG|Codeine Sulfate|30 mg Tablet
58428376|NCT03117413|OTHER|Positron emission tomography scan|"* Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
58428377|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
58428378|NCT05320393|DRUG|OnabotulinumtoxinA|One treatment of 20 units
58428379|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
58428380|NCT06165263|BEHAVIORAL|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students\&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
58428381|NCT03865485|BEHAVIORAL|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
58428382|NCT02670668|OTHER|Mutation analysis|
58428383|NCT01032031|DIETARY_SUPPLEMENT|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
58428384|NCT01032031|DIETARY_SUPPLEMENT|Placebo capsule|One capsule daily for 3 months
58428385|NCT04528056|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
58428386|NCT04528056|DRUG|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
58428387|NCT04528056|DRUG|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
58428388|NCT04528056|DRUG|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
58428389|NCT02300181|DIETARY_SUPPLEMENT|Placebo|
58428390|NCT02300181|DIETARY_SUPPLEMENT|Bacillus subtilis var natto DC-15|
58428391|NCT04797546|PROCEDURE|Adductor Canal Block|Continous peripheral nerve block
58428392|NCT04797546|DEVICE|Morphine Patient Controlled Analgesia|Morphine Patient Controlled Analgesia Delivery System
58428393|NCT06130111|PROCEDURE|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
58428394|NCT02072369|OTHER|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
58428395|NCT02072369|OTHER|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
58428396|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
58428397|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
58428398|NCT00609739|DRUG|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
58428399|NCT00609739|DRUG|cytarabine|3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
58458372|NCT02190136|OTHER|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
57736786|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
57736787|NCT00179023|DRUG|Pseudoephedrine|30mg tablet,VO. Single dose.
57736788|NCT03282227|DRUG|M207 Microneedle System|M207 Microneedle System 3.8 mg
58428400|NCT00609739|DRUG|filgrastim|Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
58428401|NCT00609739|DRUG|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
58428402|NCT00609739|DRUG|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
58428403|NCT00609739|DRUG|mitoxantrone hydrochloride|10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
58428404|NCT00609739|PROCEDURE|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.
58428405|NCT00609739|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
58428406|NCT00609739|DRUG|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
58428407|NCT00784537|DRUG|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
58428408|NCT00784537|DRUG|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
58428409|NCT00473408|DEVICE|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
58428410|NCT00473408|PROCEDURE|Blood sample|See protocol.
58428411|NCT00473408|PROCEDURE|Tumor sample|See protocol.
58428412|NCT00774683|DRUG|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
58428413|NCT03029507|BEHAVIORAL|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
58428414|NCT03029507|BEHAVIORAL|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
58428415|NCT00953940|DRUG|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
58428416|NCT02588209|BEHAVIORAL|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
58428417|NCT02588209|BEHAVIORAL|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
58428418|NCT03782441|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
58428419|NCT05387668|DRUG|BGB-23339|Administered orally as a tablet.
58428420|NCT05387668|DRUG|Placebo|Administered orally as a tablet.
58428421|NCT04268173|OTHER|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
58428422|NCT03730415|PROCEDURE|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
58428423|NCT01997671|OTHER|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
57736789|NCT01870141|BEHAVIORAL|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources"
57736790|NCT03823118|DRUG|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
57736791|NCT05239234|OTHER|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
58428424|NCT03052816|DRUG|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
58428425|NCT03052816|DRUG|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
58428426|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
57736792|NCT06291168|OTHER|Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)|"Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions."
58100118|NCT06538454|BEHAVIORAL|Resistance training|"The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions."
58428427|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
58100119|NCT04149769|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
58100120|NCT06224478|OTHER|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
58100121|NCT04767542|DRUG|Intravenous Infusion|analgesic
58100122|NCT04767542|PROCEDURE|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
58100123|NCT05980351|OTHER|exercise|The children will receive exercise program(stretching exercise,range of motion exercise and isometric exercise)
58428428|NCT05870683|DRUG|Tegoprazan|Included in dual eradication medication.
58428429|NCT05870683|DRUG|Amoxicillin|Included in dual eradication medication.
58428430|NCT05870683|DRUG|Esomeprazole|Included in dual eradication medication.
58428431|NCT02861482|DEVICE|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
58428432|NCT02861482|DRUG|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
58428433|NCT02861482|DRUG|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
58428434|NCT02861482|DRUG|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
58428435|NCT02861482|PROCEDURE|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
58428436|NCT02861482|PROCEDURE|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
58428437|NCT02861482|PROCEDURE|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
58428438|NCT02861482|PROCEDURE|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
58428439|NCT02861482|PROCEDURE|Hysterectomy|Hysterectomy with all the above measures not working
58428440|NCT02861482|DRUG|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
58428441|NCT00225784|DRUG|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
58428442|NCT00225784|PROCEDURE|Radiotherapy|Daily radiotherapy for 28 days
58428443|NCT00865319|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
58428444|NCT00865319|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
58428445|NCT01771445|DRUG|IL-1Ra|100mg, s.c, once only
58428446|NCT01771445|DRUG|Placebo|100mg, s.c., once only
58428447|NCT00844558|OTHER|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
58428448|NCT00844558|OTHER|Control|There is no intervention associated with this arm of the study
58428449|NCT05318911|DIETARY_SUPPLEMENT|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
58428450|NCT05318911|OTHER|Placebo Drink|Placebo drink (skimmed milk)
58428451|NCT00683839|BEHAVIORAL|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
58428452|NCT05557305|DEVICE|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
58428453|NCT05557305|OTHER|Conventional therapy|Occupational therapy with different play materials
58428454|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
58428455|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
58428456|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
58428457|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
58428458|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
58428459|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
58308083|NCT03779646|DRUG|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
58308084|NCT02950701|DEVICE|Observational data collection.|
58308085|NCT05885217|OTHER|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
58308086|NCT04617821|DRUG|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
58308087|NCT04617821|DRUG|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
58308088|NCT06270108|DRUG|Riluzole|50mg twice daily (100mg total daily) for 56 days.
58458373|NCT01152658|BIOLOGICAL|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
58458374|NCT01152658|OTHER|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
58428460|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
58428461|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
58428462|NCT00057408|DRUG|Placebo|Matching Placebo
58428463|NCT00454181|DRUG|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
58428464|NCT00454181|OTHER|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
58428465|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
58428466|NCT00678834|DIETARY_SUPPLEMENT|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
58428467|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
58428468|NCT03133923|BIOLOGICAL|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
58428469|NCT03133923|BIOLOGICAL|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
58428470|NCT03133923|BIOLOGICAL|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
58428471|NCT00788710|DRUG|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
57736793|NCT06291168|OTHER|Yoga-Based Exercise Program|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas."
57736794|NCT06291168|OTHER|Conventional Exercises|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
57736795|NCT05040451|DEVICE|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~* An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~* A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
58428472|NCT00788710|DRUG|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
58428473|NCT00788710|DRUG|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
58428474|NCT01476631|BEHAVIORAL|Walking|"* 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
58428475|NCT06108830|DRUG|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
58428476|NCT06108830|DRUG|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
58428477|NCT06108830|DRUG|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
58428478|NCT06108830|DRUG|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
58428479|NCT01020253|DRUG|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
58428480|NCT01005927|DIETARY_SUPPLEMENT|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
58428481|NCT02248363|OTHER|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
58428482|NCT01961648|DEVICE|Rebreathing bag|
58428483|NCT01961648|DEVICE|Sham rebreathing|
58428484|NCT01961648|DEVICE|Mask|
58428485|NCT00379054|BEHAVIORAL|telephone based skills training intervention|
58428486|NCT03673020|BIOLOGICAL|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
58308089|NCT01621009|DRUG|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
58308090|NCT01621009|DRUG|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
58308091|NCT01621009|DRUG|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
58308092|NCT01621009|DRUG|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
57961769|NCT04779203|DEVICE|Osseodensification Densah Bur|Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
57961770|NCT01456676|DRUG|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
57961771|NCT00269529|PROCEDURE|femoral nerve block|
57961772|NCT00269529|PROCEDURE|knee infiltration and injection via catheter|
57961773|NCT00464178|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
57961774|NCT01964352|DRUG|tiotropium|fixed dose combination
57961775|NCT01964352|DRUG|placebo|
57961776|NCT01964352|DRUG|olodaterol|fixed dose combination
57961777|NCT01964352|DRUG|tiotropium|fixed dose combination
57961778|NCT01964352|DRUG|tiotropium|
57961779|NCT01964352|DRUG|olodaterol|fixed dose combination
57961780|NCT02841969|OTHER|Electrolysed water|Irrigation of wound using electrolysed water
57961781|NCT02841969|OTHER|Prontosan|Irrigation of wound using Prontosan
57961782|NCT05387811|COMBINATION_PRODUCT|Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy|Adherence to International Club of Ascites recommendations for the management of AKI
57961783|NCT04995393|PROCEDURE|Heating with a disposable glove containing water|Heating of the infants heel with a glove before blood sampling.
57961784|NCT04995393|PROCEDURE|Heating with a blanket|Heating of the infants heel with a blanket before blood sampling.
57961785|NCT04995393|PROCEDURE|Heating with a gel pack|Heating of the infants heel with a gel pack before blood sampling.
57961786|NCT05429138|OTHER|biological sampling|Biological sampling: blood and semen
57961787|NCT01545700|DRUG|Control-saline|Patients are randomized to receive saline 2 cc
57961788|NCT01545700|DRUG|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
57961789|NCT01545700|DRUG|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
57961790|NCT01545700|DRUG|Control saline|Patients are randomized to receive saline 2 cc
57961791|NCT01545700|DRUG|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
57961792|NCT01545700|DRUG|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
57961793|NCT03068156|RADIATION|308-nm excimer laser|monochromator UVB laser (308nm)
57961794|NCT05942287|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
57961795|NCT03363633|DRUG|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
57961796|NCT03363633|DEVICE|Compression|20-30 mmHg compression stockings
57961797|NCT01282229|DEVICE|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
57961798|NCT01337076|DEVICE|cochlear implant|Cochlear implant surgery
57961799|NCT02570269|PROCEDURE|AuraGain|Fiberoptic Intubation
57961800|NCT02570269|PROCEDURE|Slotted Guedeltubus|Fiberoptic Intubation
57961801|NCT03747146|DEVICE|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
57961802|NCT03747146|DEVICE|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
57961803|NCT03090126|OTHER|Therapeutic education|Questionnaires
57961804|NCT03287258|OTHER|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
57961805|NCT03287258|OTHER|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
57961806|NCT03804684|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
58100124|NCT03936777|DRUG|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
58428487|NCT05987436|OTHER|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
58428488|NCT00708695|BEHAVIORAL|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
58428489|NCT05602077|DEVICE|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
58428490|NCT03527524|OTHER|exercise with ball|exercise with ball
58100125|NCT04525859|BIOLOGICAL|Safety|See previous Safety group description
58428491|NCT03527524|OTHER|exercise without ball|exercise without ball
57736796|NCT02100982|OTHER|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
58100126|NCT04525859|BIOLOGICAL|Expansion Cohort|See previous Expansion Cohort
58100127|NCT00757263|GENETIC|polymorphism analysis|
58100128|NCT00757263|OTHER|laboratory biomarker analysis|
58100129|NCT00757263|OTHER|questionnaire administration|
58100130|NCT00386854|BEHAVIORAL|physical training|
58100131|NCT06135519|PROCEDURE|Autologous Mesenchymal stem cells injection|Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
58100132|NCT06135519|PROCEDURE|Homogenized fat injection|Autologous fat will be harvested, homogenized and injected.
58100133|NCT05955235|OTHER|Not Applicable(Observation Study)|Not Applicable(Observation Study)
58308093|NCT00003686|DRUG|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
58308094|NCT00003686|DRUG|Placebo|Placebo 5 mg po qid x 4 weeks
58308095|NCT05218694|DIAGNOSTIC_TEST|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
58308096|NCT00005925|DRUG|Muscimol|
58308097|NCT00313872|DRUG|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
57736797|NCT02100982|OTHER|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
58308098|NCT00313872|DRUG|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
58308099|NCT03312816|OTHER|cookies enriched with POP|Cookies
58428492|NCT05201950|OTHER|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
58428493|NCT05201950|OTHER|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
58428494|NCT03570320|OTHER|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
58428495|NCT01276223|DRUG|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
58428496|NCT01276223|OTHER|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
58428497|NCT05900973|DRUG|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
58428498|NCT05792527|DRUG|L-carnitine|One 500 mg tablet twice daily after meals
58428499|NCT03532139|DRUG|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
58428500|NCT03532139|DRUG|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
58428501|NCT03532139|OTHER|Thromboprophylaxis|standard of care therapy
58428502|NCT05013788|OTHER|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
58458375|NCT00963963|BEHAVIORAL|Healthy Futures parent education|Multi-year audio CD parent education
57961807|NCT03804684|DIAGNOSTIC_TEST|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
57961808|NCT02708953|PROCEDURE|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
57961809|NCT02708953|PROCEDURE|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
57961810|NCT03618108|DRUG|Doxycycline Capsule|doxycycline capsule
57961811|NCT03618108|DRUG|Azithromycin Capsule|azithromycin capsule
57961812|NCT03618108|DRUG|Rifabutin Oral Capsule|rifabutin capsule
57961813|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
57961814|NCT03618108|DRUG|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
57961815|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
57961816|NCT05029154|BEHAVIORAL|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
58428503|NCT05013788|OTHER|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
58100134|NCT03983746|DEVICE|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
58100135|NCT01175161|DEVICE|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
58100136|NCT05691699|DRUG|ABBV-903|Capsule; oral
58100137|NCT05691699|DRUG|Placebo for ABBV-903|Capsule; oral
58100138|NCT05691699|DRUG|Itraconazole|Capsule; oral
58100139|NCT02964884|DRUG|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
58100140|NCT02964884|BEHAVIORAL|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
58100141|NCT02964884|DRUG|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
58100142|NCT02964884|BEHAVIORAL|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
58428504|NCT05500430|DEVICE|Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)|Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
58100143|NCT01329705|DEVICE|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
58100144|NCT01329705|OTHER|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized"
58100145|NCT05100849|PROCEDURE|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
58100146|NCT05100849|PROCEDURE|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
58428505|NCT05393024|DRUG|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
58428506|NCT01671631|OTHER|Measurement of intracoronary pressure|
58100147|NCT04403191|DRUG|Ondansetron|ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
58100148|NCT04403191|DRUG|isopropyl alcohol 70% inhalation|inhalation every 15 min for 4 times then repeated after 6 hours
58308100|NCT04175717|OTHER|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
58428507|NCT04654455|OTHER|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
58428508|NCT05301309|BEHAVIORAL|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
58428509|NCT02999633|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
58428510|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:pills Route of administration: oral
58428511|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
58428512|NCT02999633|DRUG|acetaminophen|Pharmaceutical form:pills Route of administration: oral
58428513|NCT02999633|DRUG|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
58428514|NCT02999633|DRUG|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
58428515|NCT01683578|OTHER|Variable Ventilation|
58428516|NCT00700505|DEVICE|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
58428517|NCT03033264|DRUG|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
58428518|NCT03033264|DEVICE|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
58428519|NCT01195493|OTHER|Essential Oils solution|(Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
58428520|NCT01195493|OTHER|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
58428521|NCT03802773|PROCEDURE|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
58428522|NCT04784624|BEHAVIORAL|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
58428523|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
58428524|NCT00671606|PROCEDURE|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
58428525|NCT01686282|DIETARY_SUPPLEMENT|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
58428526|NCT01686282|DIETARY_SUPPLEMENT|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
58428527|NCT06543342|BEHAVIORAL|Bystander Brief Motivational Intervention|Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
58428528|NCT06245538|BEHAVIORAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
58100149|NCT04403191|PROCEDURE|laparoscopic appendectomy|all patients received post operatively after laparoscopic appenectomy
58428529|NCT06245538|BEHAVIORAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
58428530|NCT06245538|BEHAVIORAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
58428531|NCT02837042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
58428532|NCT05040360|DRUG|Capecitabine|Given PO
58428533|NCT05040360|DRUG|Temozolomide|Given PO
58428534|NCT06358144|BEHAVIORAL|Packaging imagery|Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
58428535|NCT06358144|BEHAVIORAL|No Imagery (Control)|Participants in the control condition will see the same four product packages, but without any added imagery.
58428536|NCT00852241|DRUG|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
58428537|NCT00852241|DRUG|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
58100150|NCT04738188|PROCEDURE|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
58428538|NCT05367323|DEVICE|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
58428539|NCT00517569|GENETIC|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
58428540|NCT00517569|DRUG|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
58428541|NCT05522595|DEVICE|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
58428542|NCT02524418|PROCEDURE|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
58428543|NCT04266756|DRUG|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
58308101|NCT04625036|DIAGNOSTIC_TEST|Single passive leg movement|"The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds."
58428544|NCT04266756|DRUG|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
58428545|NCT04266756|DRUG|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
57736798|NCT05715294|OTHER|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
57736799|NCT01027000|BIOLOGICAL|rituximab|
57736800|NCT01027000|DRUG|busulfan|
58428546|NCT01204762|DRUG|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
57736801|NCT01027000|DRUG|cyclophosphamide|
57736802|NCT01027000|DRUG|fludarabine phosphate|
58308102|NCT00550199|DRUG|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
58428547|NCT01204762|DRUG|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
58428548|NCT01204762|DRUG|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
57736803|NCT01027000|DRUG|methotrexate|
57736804|NCT01027000|DRUG|sirolimus|
58308103|NCT03713463|OTHER|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
58428549|NCT01204762|DRUG|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
58428550|NCT01915979|BIOLOGICAL|Plasma rich in growth factors (PRGF)|
58428551|NCT01915979|DRUG|Celestone cronodose (Bethametasone)|
58428552|NCT05496556|OTHER|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
57736805|NCT01027000|DRUG|tacrolimus|
57736806|NCT01027000|PROCEDURE|allogeneic stem cell transplant|
57736807|NCT00003951|DRUG|exatecan mesylate|
57736808|NCT06085170|DIAGNOSTIC_TEST|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
57736809|NCT00607555|DEVICE|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
57736810|NCT00008853|BIOLOGICAL|GBS III-TT-SSI|
57736811|NCT00008853|BIOLOGICAL|GBS III-TT-MPHL|
58100151|NCT04738188|PROCEDURE|cTACE|Transcatheter arterial chemoembolization
58100152|NCT04738188|DEVICE|Drug-eluting Beads|Drug-eluting beads
58428553|NCT01263145|DRUG|Akt Inhibitor MK2206|Given PO
58428554|NCT01263145|OTHER|Laboratory Biomarker Analysis|Correlative studies
58428555|NCT01263145|DRUG|Paclitaxel|Given IV
58428556|NCT01263145|OTHER|Pharmacological Study|Correlative studies
58100153|NCT04738188|DRUG|Epirubicin|Chemotherapy drug for intra-arterial infusion
58100154|NCT02583607|DEVICE|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
58428557|NCT00908037|DRUG|eltrombopag|thrombopoietin receptor agonist
58428558|NCT00908037|DRUG|Placebo|placebo for comparison
58428559|NCT04766554|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
58100155|NCT01938521|DIETARY_SUPPLEMENT|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
58100156|NCT01938521|DIETARY_SUPPLEMENT|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
58100157|NCT02999919|PROCEDURE|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
58308104|NCT05115799|OTHER|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
58308105|NCT05115799|OTHER|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
58308106|NCT05376501|DIETARY_SUPPLEMENT|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
58308107|NCT05376501|OTHER|Placebo|Modified food starch
58308108|NCT01068236|BEHAVIORAL|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
58308109|NCT03501251|DRUG|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
58100158|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
58100159|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
58100160|NCT04064437|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
58308110|NCT03501251|DRUG|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
58308111|NCT03501251|DRUG|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
58308112|NCT03501251|DRUG|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
58308113|NCT03501251|DRUG|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
58308114|NCT03501251|DRUG|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
58308115|NCT03501251|OTHER|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
58308116|NCT04328987|PROCEDURE|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
58308117|NCT01614652|DEVICE|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
58308118|NCT02431598|DRUG|gadoxetate disodium|
58308119|NCT02431598|DRUG|gadoterate dimeglumine|
58308120|NCT02431598|DRUG|Saline|
58308121|NCT02327234|DRUG|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
58428560|NCT00465140|DRUG|creatine supplementation|
58100161|NCT04064437|DIAGNOSTIC_TEST|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
58100162|NCT04064437|DIAGNOSTIC_TEST|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
58428561|NCT00465140|BEHAVIORAL|aerobic exercise training|
58428562|NCT06216548|OTHER|Usual Care and Enhanced Primary Care|"Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice."
58428563|NCT06216548|OTHER|Enhanced Primary Care|The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
58428564|NCT03866564|DIAGNOSTIC_TEST|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
58428565|NCT03866564|DIAGNOSTIC_TEST|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
58428566|NCT03866564|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
57952882|NCT05941078|BEHAVIORAL|ICF-based post-stroke rehabilitation program|Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
57952883|NCT04793256|DEVICE|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).|5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces
57952884|NCT04793256|DEVICE|Resin based fissure sealant (3M Clinpro Sealant)|teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
57952885|NCT03998046|BEHAVIORAL|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
58100163|NCT01488799|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
58100164|NCT01518621|RADIATION|Radiation|Whole brain radiation
58428567|NCT03866564|DIAGNOSTIC_TEST|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
58428568|NCT06415773|DRUG|HTD1801|HTD1801 1000 mg BID administered orally BID as four capsules
58428569|NCT06415773|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablet administered orally QD
57952886|NCT03998046|BEHAVIORAL|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
58100165|NCT01518621|DRUG|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
58100166|NCT04345887|DRUG|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
58100167|NCT04345887|DRUG|Placebo oral tablet|2 x1 placebo tablet
58100168|NCT03944707|DRUG|LOU064 100 mg|LOU064 100 mg once daily orally administered as two 50 mg capsules
58100169|NCT03944707|DRUG|Placebo|Placebo once daily administered orally as capsules
58100170|NCT05202600|PROCEDURE|Appendectomy|Surgical removal of the vermiform appendix.
58100171|NCT05161559|PROCEDURE|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
58100172|NCT05161559|PROCEDURE|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
58100173|NCT05161559|PROCEDURE|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
58100174|NCT01629134|DEVICE|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
58100175|NCT04040907|DRUG|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
58100176|NCT04040907|DRUG|Placebo|Placebo and active drug will have the same appearance
58100177|NCT05940519|OTHER|Dynamic taping technique|The dynamic taping method as specified in the literature will be applied to the right and left lumbar paravertebral muscles in the dynamic taping group. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
58100178|NCT05940519|OTHER|Sham taping|Sham taping will be applied with a surgical patch while the patient is in a comfortable position without any technique or stretching.Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
58100179|NCT02046369|DRUG|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
58100180|NCT02046369|DRUG|Placebo|Placebo Comparator once daily
58100181|NCT05243654|DRUG|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
58100182|NCT05243654|DRUG|Placebo|Placebo + standard-of-care MDT
58100183|NCT00997672|DRUG|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
58100184|NCT00997672|DRUG|Placebo|
58100185|NCT05564273|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
58308122|NCT02327234|DRUG|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
58308123|NCT02284100|BEHAVIORAL|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
58308124|NCT02118623|BEHAVIORAL|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
58308125|NCT02118623|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies."
58308126|NCT02118623|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
58308127|NCT05898516|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
58308128|NCT04625283|DRUG|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
58308129|NCT04625283|DRUG|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
58308130|NCT02465450|DRUG|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
58308131|NCT02465450|OTHER|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
58308132|NCT04198935|DEVICE|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
58308133|NCT01178788|DRUG|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
58308134|NCT01178788|DRUG|micronized Progesterone|daily administration of vaginal progesterone
58308135|NCT01178788|PROCEDURE|Control|
58308136|NCT05327452|BEHAVIORAL|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
58308137|NCT05327452|BEHAVIORAL|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
58308138|NCT05327452|BEHAVIORAL|Attention Control|Stretching Program
58308139|NCT05553834|COMBINATION_PRODUCT|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
58308140|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
58308141|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
58308142|NCT03261206|OTHER|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
58308143|NCT00641563|DRUG|Dexmedetomidine|Infusion of dexmedetomidine
58308144|NCT00641563|DRUG|Midazolam|Midazolam infusion
58308145|NCT00641563|DRUG|Remifentanil|Infusion of remifentanil
58308146|NCT06492629|DRUG|Toripalimab|Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
58308147|NCT06492629|DRUG|chidamide|Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
58308148|NCT00745888|OTHER|Chemiluminescence Analyzer|measure reactive oxygen species
58308149|NCT02049216|OTHER|Flexible tape|Flexible, elasticised, adhesive athletic tape
58308150|NCT02049216|OTHER|Fixomull|
58308151|NCT02049216|OTHER|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
58308152|NCT05739916|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
58308153|NCT05739916|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
58308154|NCT06386406|DEVICE|TAP insole|"The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender."
58308155|NCT06375382|OTHER|acupuncture|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
58308156|NCT06375382|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
58308157|NCT05049005|BEHAVIORAL|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
58308158|NCT00183339|DRUG|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
58308159|NCT00183339|DRUG|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
58308160|NCT00282217|DRUG|Sirolimus|
58308161|NCT04891172|BIOLOGICAL|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
58308162|NCT02597608|BEHAVIORAL|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
58428570|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
58428571|NCT01936415|DEVICE|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
57736812|NCT01412008|DRUG|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
57736813|NCT02368249|DRUG|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
58100186|NCT05564273|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
58100187|NCT06241651|DEVICE|Conduction system pacing|Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
58100188|NCT06241651|DEVICE|Biventricular pacing|Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
58308163|NCT02597608|DIETARY_SUPPLEMENT|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
58308164|NCT02597608|BEHAVIORAL|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
58308165|NCT02597608|DIETARY_SUPPLEMENT|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
58308166|NCT02597608|BEHAVIORAL|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
58308167|NCT02597608|DIETARY_SUPPLEMENT|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
58308168|NCT02597608|OTHER|UPPR: Control|No interventions provided.
58428572|NCT01936415|DEVICE|Regenerex|
58428573|NCT00555737|DEVICE|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
57952887|NCT03998046|BEHAVIORAL|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
57952888|NCT00920673|PROCEDURE|MRI|MRI during 35 to 65 minutes
57952889|NCT00283114|DRUG|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
57952890|NCT06098768|BEHAVIORAL|VR Social Skills|The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
57952891|NCT04460976|BEHAVIORAL|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
57952892|NCT04460976|BEHAVIORAL|Treatment as usual/standard care|Standard care at disability/habilitation services.
58100189|NCT05449158|PROCEDURE|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
58100190|NCT00197470|PROCEDURE|IL-1, TNF-alpha, Il-10|
58100191|NCT00397072|DRUG|ZK 219477|
58100192|NCT03638752|OTHER|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
58100193|NCT01251692|PROCEDURE|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
58100194|NCT05815186|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
58100195|NCT05815186|DRUG|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
58100196|NCT00862888|DRUG|PF-00446687|Single 200mg dose as an oral solution
58100197|NCT00862888|DRUG|Placebo|Placebo for oral solution
58100198|NCT00862888|DRUG|Placebo|Placebo for tablet
58100199|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
58100200|NCT00862888|DRUG|PF-00446687|Single 125 mg dose as an oral solution
58100201|NCT00862888|DRUG|PF-00446687|Single 175 mg dose as an oral solution
58100202|NCT00862888|DRUG|PF-00446687|Single 20 mg dose as an oral solution
58100203|NCT00862888|DRUG|Placebo|Placebo for oral solution
58100204|NCT00862888|DRUG|Placebo|Placebo for tablet
57736814|NCT02368249|DRUG|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
58100205|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
58100206|NCT05000918|DIETARY_SUPPLEMENT|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
58100207|NCT00504842|DRUG|MRX-801|
58100208|NCT00504842|DRUG|Placebo|
58100209|NCT00350337|BIOLOGICAL|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
58100210|NCT00350337|BIOLOGICAL|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
58100211|NCT00350337|BIOLOGICAL|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
57736815|NCT05224050|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
58428574|NCT02973516|DRUG|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
57736816|NCT05224050|BIOLOGICAL|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
57736817|NCT05224050|DRUG|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
58100212|NCT00350337|OTHER|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
58100213|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
58100214|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
58100215|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
58100216|NCT06566495|DEVICE|collection of microbiological material from reusable tourniquets|"Microbiological analysis~The material was collected in each group in the same way."
58100217|NCT00861731|DRUG|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
58428575|NCT02973516|DRUG|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
57736818|NCT06446843|COMBINATION_PRODUCT|(Arthrocentesis following i-PRF +HA)|Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
58100218|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
58100219|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
58100220|NCT01106352|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
58100221|NCT01106352|DRUG|Docetaxel|Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
58100222|NCT05658289|PROCEDURE|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
58428576|NCT06525233|OTHER|Physiotherapy and rehabilitation|The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
58428577|NCT02328027|DRUG|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
58100223|NCT05658289|PROCEDURE|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
58100224|NCT02962869|DRUG|BAY987517|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
58100225|NCT02962869|OTHER|Untreated skin|One site is patched without treatment as control
58428578|NCT01392209|OTHER|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
58428579|NCT00875290|DEVICE|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
58428580|NCT02722707|DEVICE|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
58428581|NCT05698953|OTHER|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
58428582|NCT05698953|OTHER|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
58428583|NCT03292276|DEVICE|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
58428584|NCT02086422|DRUG|ivabradine|
58428585|NCT02086422|DRUG|Placebo|
58428586|NCT02086422|OTHER|Exercise|
58428587|NCT05375214|DEVICE|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
58428588|NCT01659099|DRUG|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
58428589|NCT01659099|DRUG|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
57736819|NCT00265369|DRUG|Spores of Bacillus Clausii Probiotic Strain|
58100226|NCT00647426|DRUG|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
58100227|NCT04976088|DRUG|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
58100228|NCT04976088|DRUG|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
58428590|NCT01659099|DRUG|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
58428591|NCT01659099|DRUG|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
58428592|NCT01659099|DRUG|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
58428593|NCT01659099|DRUG|Bleomycin|in ACBVP 10 mg from D1 to D5
58428594|NCT01659099|DRUG|Vindesin|in ACBVP 2 mg/m² from D1 to D5
58428595|NCT01659099|DRUG|Vincristine|in CHOP 1,4 mg/m² on D1
58428596|NCT03326622|OTHER|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
58428597|NCT03326622|OTHER|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
58428598|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
58428599|NCT02113358|DRUG|Intravenous colloid bolus with Voluven|
58428600|NCT01656070|DRUG|oral cholecalciferol 1000000 UI (vitamin D3)|
58428601|NCT01656070|DRUG|Placebo|
58428602|NCT03675984|BEHAVIORAL|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
58428603|NCT03222024|OTHER|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
58428604|NCT04338737|OTHER|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
58428605|NCT01553643|DRUG|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
58428606|NCT01553643|DRUG|placebo|at a rate of 3g two times per day
58428607|NCT05551507|DRUG|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
58428608|NCT00001644|DRUG|Indinavir|
58428609|NCT00001644|DRUG|Zidovudine|
58428610|NCT00001644|DRUG|Lamivudine|
58428611|NCT00001644|DRUG|Nevirapine|
58428612|NCT00001644|PROCEDURE|Blood testing|
58428613|NCT00001644|PROCEDURE|Lymph node biospy|
58428614|NCT00001644|PROCEDURE|Leukapheresis|
58428615|NCT05137977|PROCEDURE|Intensive Care|Invasive ventilation more than 24hs.
58428616|NCT04166539|BEHAVIORAL|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
58428617|NCT04166539|BEHAVIORAL|Interviews|Behavioral and Memory interviews will take place with the patient.
58428618|NCT04166539|OTHER|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
58428619|NCT04166539|RADIATION|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
58428620|NCT04166539|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
57952893|NCT06267196|OTHER|The use of a stress ball|The effect of the stress ball used during spinal anesthesia on pain and anxiety
58428621|NCT05750550|OTHER|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
58428622|NCT01656668|DRUG|BC1036|
58428623|NCT02854254|DEVICE|peripherally inserted central catheter|peripherally inserted central catheter
58428624|NCT02854254|DEVICE|peripherally venous access|standard over-the-needle intravenous catheter
58428625|NCT05691010|RADIATION|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
58428626|NCT05691010|DRUG|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
58428627|NCT05691010|DRUG|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
58428628|NCT03335280|DRUG|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
58428629|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
58428630|NCT01243827|DRUG|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
58428631|NCT01243827|DRUG|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
58428632|NCT00809653|DEVICE|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
58428633|NCT00809653|DEVICE|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
58428634|NCT03485170|DIAGNOSTIC_TEST|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
58428635|NCT06527534|DRUG|Filgotinib|Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
58428636|NCT06527534|DRUG|Adalimumab|Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
58428637|NCT04758923|PROCEDURE|Cholecystectomy|Under General anaesthesia cholecystectomy and CBD exploration
58428638|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
58428639|NCT03720002|DIETARY_SUPPLEMENT|HF2|placebo
58428640|NCT03180970|DRUG|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
58428641|NCT03180970|DRUG|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
58428642|NCT03180970|DRUG|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
57952894|NCT00729456|OTHER|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
58100229|NCT04976088|DRUG|Placebo|Placebo: Placebo plaster, topical application once a day.
58100230|NCT03923114|RADIATION|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
58100231|NCT01459679|DEVICE|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
58100232|NCT01459679|DEVICE|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
58100233|NCT01459679|DEVICE|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
58428643|NCT03180970|DRUG|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
58100234|NCT01459679|DRUG|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
58100235|NCT01977859|DRUG|Nesiritide|
58100236|NCT01977859|DRUG|Saline|
58100237|NCT00359840|DRUG|darbepoetin alfa|
58100238|NCT05605457|DEVICE|PRG barrier coat + nanohybrid composite|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
58100239|NCT05605457|DEVICE|resin modified glass ionomer|RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction
58100240|NCT04599673|DRUG|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
58100241|NCT04599673|OTHER|normal saline|10 ml normal saline
58100242|NCT04931758|OTHER|Pain Questionnaire|Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
58100243|NCT02540473|BEHAVIORAL|Manualized Therapy|Relational psychotherapy mothers
57952895|NCT02180360|OTHER|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
57952896|NCT01073332|DIETARY_SUPPLEMENT|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
57952897|NCT01073332|DIETARY_SUPPLEMENT|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
57952898|NCT04986397|DEVICE|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
57952899|NCT04986397|OTHER|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
58100244|NCT02540473|BEHAVIORAL|Control Group|one hour of free time to do with as they wish
58100245|NCT02970175|DRUG|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
58428644|NCT03180970|DRUG|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
58100246|NCT02970175|PROCEDURE|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
58100247|NCT02970175|PROCEDURE|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
58100248|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
58100249|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
58100250|NCT05349188|OTHER|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
58100251|NCT00709735|DRUG|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
58100252|NCT00709735|DRUG|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
58100253|NCT05812222|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
58100254|NCT00814619|BIOLOGICAL|panitumumab|Given IV
58100255|NCT00814619|DRUG|capecitabine|Given orally
58100256|NCT00814619|PROCEDURE|therapeutic conventional surgery|Patients undergo surgical resection
58100257|NCT00814619|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
58100258|NCT01387360|DEVICE|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
57736820|NCT05001100|OTHER|rehabilitation|rehabilitation
58100259|NCT01188070|BEHAVIORAL|Usual Care|Educational materials
58100260|NCT01188070|BEHAVIORAL|Psycho-education|Educational group sessions
58100261|NCT01188070|BEHAVIORAL|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
58100262|NCT00140322|BEHAVIORAL|Exercise, fall risk reduction|
58100263|NCT04811911|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
58428645|NCT05954429|DRUG|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
58100264|NCT04811911|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
58308169|NCT05261906|BEHAVIORAL|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
58308170|NCT03581214|OTHER|No oxygen|No facemask, room air only
58308171|NCT03581214|OTHER|Oxygen|10Liters/minute oxygen by facemask
58308172|NCT02089477|OTHER|Support group|"The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
58428646|NCT05954429|DRUG|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
58428647|NCT03746041|DRUG|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
57952900|NCT02181829|RADIATION|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
57952901|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
58308173|NCT01940822|OTHER|Energy Drink|
58308174|NCT01940822|OTHER|Placebo Drink|
58308175|NCT05278468|OTHER|PCR test for covid-19|real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
58308176|NCT01699750|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
58308177|NCT01699750|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
58428648|NCT03746041|DRUG|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
58428649|NCT01640262|OTHER|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
58428650|NCT04473664|DRUG|Quizartinib|Single oral dose, 30 mg tablet
58428651|NCT02335424|BIOLOGICAL|pembrolizumab|IV infusion
57952902|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
57952903|NCT05344521|DEVICE|Integra®|A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
57952904|NCT05344521|DEVICE|Integra®-SC|A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
57952905|NCT05666427|BEHAVIORAL|Pelvic floor muscle training combined with stabilization exercises|While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
57736821|NCT04622579|DRUG|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
57952906|NCT05666427|BEHAVIORAL|Pelvic floor muscle training|Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
57952907|NCT01520935|OTHER|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
57952908|NCT00330382|DRUG|Bowman-Birk inhibitor concentrate|Given orally
57952909|NCT00330382|OTHER|placebo|Given orally
57952910|NCT00330382|OTHER|laboratory biomarker analysis|Correlative studies
57952911|NCT06377787|OTHER|ELDOA and conventional therapy|hot pack and TENS for10 min, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4rep with 6 sec hold once a day) and ELDOA method C0-C1-C2, C2 \& C3 positions for cervical spine (2 sets of five repetitions with 45 sec hold and 15sec rest between each set once a day).
57952912|NCT06377787|OTHER|conventional therapy|include hot pack and TENS for 10 minutes, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4 reps with 6 seconds hold once a day).
57952913|NCT04707157|DRUG|LY3556050|given orally
57952914|NCT04707157|DRUG|Placebo|given orally
57952915|NCT02706821|DIETARY_SUPPLEMENT|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
57952916|NCT02706821|DIETARY_SUPPLEMENT|Placebo|Placebo, crossover design
58428652|NCT04051502|DRUG|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
57736822|NCT00949351|DRUG|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
57736823|NCT05229289|OTHER|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
58100265|NCT00958685|DIETARY_SUPPLEMENT|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
58100266|NCT00958685|DIETARY_SUPPLEMENT|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
58100267|NCT00142844|DRUG|Naltrexone|
58100268|NCT00142844|DRUG|Disulfiram|
58100269|NCT00142844|DRUG|Placebo|
58100270|NCT03957317|OTHER|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
58100271|NCT04791865|BEHAVIORAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
58100272|NCT04791865|BEHAVIORAL|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
58129454|NCT05742529|PROCEDURE|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
58428653|NCT04051502|DRUG|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"
57736824|NCT05229289|OTHER|Fecal Microbiota Transplant|Fecal Microbiota Transplant
57736825|NCT05579327|DRUG|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
57952917|NCT03875898|OTHER|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
57952918|NCT03875898|OTHER|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
57952919|NCT02774837|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
57952920|NCT02774837|DRUG|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
57952921|NCT03046875|OTHER|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
57952922|NCT03046875|OTHER|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
57952923|NCT06494722|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
57952924|NCT06494722|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
57952925|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
57952926|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
57952927|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
57952928|NCT04233190|DRUG|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg|one inhalation, twice daily
57952929|NCT02177968|OTHER|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
57952930|NCT02592239|DEVICE|Functional brain MRI|Functional brain MRI before and after test meal ingestion
57952931|NCT02592239|DIETARY_SUPPLEMENT|A warm ham and cheese sandwich and a 200 ml fruit juice|
58428654|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
58428655|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
58428656|NCT04217213|PROCEDURE|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
58428657|NCT02476292|OTHER|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
57736826|NCT05579327|DRUG|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
57736827|NCT01518868|DEVICE|Investigational contact lens|Worn on a daily wear basis for one week.
57736828|NCT01518868|DEVICE|PureVision contact lens|Worn on a daily wear basis for one week
58100273|NCT06177509|OTHER|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
58100274|NCT00732342|BEHAVIORAL|Contingency Management|Prizes given for targeted behavior of abstinence
58100275|NCT02858518|OTHER|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
58100276|NCT02995265|DEVICE|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
58100277|NCT02995265|OTHER|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
58100278|NCT01651494|DRUG|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
57736829|NCT06143748|DRUG|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
57736830|NCT06143748|DRUG|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
58308178|NCT01699750|DEVICE|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
58308179|NCT01699750|DEVICE|BIOTRUE®|Contact lens care system, Phase 2
58308180|NCT01699750|DEVICE|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
58308181|NCT01699750|DEVICE|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
58308182|NCT00611806|DIETARY_SUPPLEMENT|Folic Acid|Folic acid 2mg po daily
58308183|NCT00611806|DIETARY_SUPPLEMENT|B12|B12 400 micrograms po daily
58308184|NCT00611806|OTHER|Placebo|1 capsule po daily
58308185|NCT05637983|PROCEDURE|US-guided femoral puncture vs Fluoroscopy-guided puncture|US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
58308186|NCT03991871|DEVICE|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
58458376|NCT04061122|DIAGNOSTIC_TEST|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
58458377|NCT01292941|DEVICE|Intermittent catheterisation|Speedicath, Intermittent catheterisation
58458378|NCT01292941|DEVICE|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
58428658|NCT06236490|DIAGNOSTIC_TEST|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
58428659|NCT06236490|DIAGNOSTIC_TEST|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
58428660|NCT06236490|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
58428661|NCT01839136|PROCEDURE|Intrauterine transfer of gametes|
58428662|NCT01839136|PROCEDURE|Intrauterine transfer of embryos|
58428663|NCT00435084|DRUG|APO866|
58428664|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
58100279|NCT01651494|OTHER|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
58428665|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
58428666|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
58428667|NCT00545103|DRUG|Placebo|Placebo administered Once Daily (QD)
58100280|NCT05180630|DEVICE|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
58428668|NCT01574885|DEVICE|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
58100281|NCT05180630|DEVICE|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
58100282|NCT05180630|DEVICE|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
58100283|NCT00864409|DRUG|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
58100284|NCT00864409|DRUG|saline.9%|Wound infiltration with 170 mL sterile saline
57736831|NCT06143748|RADIATION|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
58100285|NCT02717936|PROCEDURE|Immunohistochemistry using Pancytokeratin Staining|
58100286|NCT04976387|DRUG|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
58100287|NCT04976387|DRUG|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
58100288|NCT04976387|DRUG|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
58100289|NCT01839565|DEVICE|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
58100290|NCT00187057|DRUG|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
58100291|NCT00187057|DRUG|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
58100292|NCT00187057|DRUG|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
58100293|NCT00187057|DRUG|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
58100294|NCT00187057|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
58100295|NCT02754180|DRUG|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
58100296|NCT02754180|RADIATION|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
58100297|NCT05371483|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
58100298|NCT05371483|DIAGNOSTIC_TEST|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
58100299|NCT02962739|DRUG|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
57736832|NCT03295188|DIETARY_SUPPLEMENT|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
57736833|NCT03295188|DIETARY_SUPPLEMENT|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
57736834|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57736835|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57736836|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57736837|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57952932|NCT01007578|DEVICE|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
58100300|NCT01629693|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
58100301|NCT01629693|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
57736838|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57736839|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
57736840|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
58100302|NCT02540720|DRUG|Dexamethasone|
58100303|NCT02540720|DRUG|Gamma globulin|
58100304|NCT02540720|PROCEDURE|Hemoperfusion|
58100305|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
58100306|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
58100307|NCT05459168|DEVICE|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
58100308|NCT06520241|OTHER|Pregnant|Data were collected using the Personal Information Form, Depression-Anxiety-Stress Scale (DASS-21), and Oral Health Impact Scale (OHIP-14-TR).
57736841|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
58100309|NCT01416298|OTHER|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and \> 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching \>10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after \>10% is achieved is acceptable and now will be put into standard clinical practice.
58100310|NCT04572399|DEVICE|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
58100311|NCT05958459|OTHER|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
58100312|NCT05958459|OTHER|no intervention|no intervention
58100313|NCT03368547|PROCEDURE|Computed Tomography|Undergo PET/CT scan
58100314|NCT03368547|RADIATION|Gallium Ga 68 Gozetotide|Given IV
58100315|NCT03368547|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
57736842|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
58308187|NCT05615077|OTHER|Combined exercise-education intervention|"Combined exercise and education intervention by fall risk state for 12 months during intervention period.~Exercise intervention includes balance exercise and strength exercise according to protocol.~Education intervention includes medication review, nutrition intervention, and home hazard modification.~The key to medication review is paying special attention to medications known to increase the risk of falls. Reduction of these medications is recommended, and redundant psychotropic medications are withdrawn. Nutrition intervention includes investigating dietary habits and calculate insufficient protein intake to provide customized diet and high protein drink. If vitamin D necessary, supplements are prescribed. Home hazard modification includes providing instructions to reduce and modify the home hazards that increase the risk of falls."
58308188|NCT01235988|DRUG|Eltrombopag|Eltrombopag 50mg \& standard of care
58308189|NCT01235988|DRUG|Placebo|Placebo + standard of care
58308190|NCT00196599|DRUG|emtricitabine, FTC (drug)|
58308191|NCT00196599|DRUG|didanosine, ddI (drug)|
58308192|NCT00196599|DRUG|efavirenz (drug)|
58308193|NCT00453908|DRUG|Alfuzosin|
58308194|NCT02484677|DRUG|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
58100316|NCT00938418|RADIATION|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
58308195|NCT02484677|DRUG|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
58308196|NCT02484677|DRUG|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
58308197|NCT04584788|DEVICE|Masimo O3 Regional Oximeter|Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
58308198|NCT04208893|BEHAVIORAL|Exercise training|See description of Arms
57736843|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
58100317|NCT02083588|DEVICE|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
58100318|NCT01333631|DRUG|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
58308199|NCT04583982|OTHER|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
58308200|NCT03085303|DEVICE|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
58308201|NCT06545305|PROCEDURE|Lensectomy and vitrectomy|Corrections
58308202|NCT06071416|PROCEDURE|Lateral sinus floor augmentation|maxillary sinus floor augmentation by lateral approach
58308203|NCT06071416|DRUG|Biphasic Calcium Phosphate|appliaction of BCP bone substitute
57736844|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
58428669|NCT01574885|DEVICE|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
58428670|NCT04161170|DEVICE|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
58428671|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
58428672|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
58428673|NCT04651829|OTHER|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
58428674|NCT04651829|OTHER|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
58428675|NCT06092775|DEVICE|DEXA scan,X_ray|"DEXA scan detect osteoporosis~,X_ray show subclinical vertebral fractures"
58428676|NCT00441805|DEVICE|Radio Frequency|
58428677|NCT02619032|DRUG|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
58428678|NCT02619032|DRUG|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
58428679|NCT00861471|DRUG|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."
57736845|NCT01217073|DRUG|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
57736846|NCT01217073|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
58100319|NCT03091400|DRUG|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
58428680|NCT00861471|DRUG|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
58428681|NCT00498355|DRUG|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
58428682|NCT05138887|DRUG|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
58428683|NCT05067751|DEVICE|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
58428684|NCT01452919|DRUG|LY2140023|Administered orally
57736847|NCT01217073|DRUG|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
58100320|NCT03091400|DRUG|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
58100321|NCT05048771|OTHER|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
58428685|NCT01452919|DRUG|Placebo|Administered orally
58428686|NCT00020878|DRUG|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
58428687|NCT00828750|DRUG|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
58428688|NCT06085313|BEHAVIORAL|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
58100322|NCT00929864|DRUG|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
58428689|NCT06085313|BEHAVIORAL|CAPA|Web App-based information and coaching/support program for cancer pain management
57736848|NCT01217073|DRUG|Metformin|Metformin 500 mg oral tablet administered once or twice daily
57736849|NCT01217073|DRUG|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
57736850|NCT01183676|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
57736851|NCT01183676|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
58100323|NCT00929864|DRUG|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
58100324|NCT01099280|DRUG|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
58129455|NCT06298019|BIOLOGICAL|KYV-101|The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.
58129456|NCT06121037|PROCEDURE|proximal ultrasound-guided GON radiofrequency ablation|proximal GON radiofrequency
58428690|NCT04110080|PROCEDURE|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
58428691|NCT04110080|OTHER|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
58428692|NCT04110080|OTHER|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
58428693|NCT04110080|PROCEDURE|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
58428694|NCT04110080|PROCEDURE|regional anesthesia|transabdominal plane and rectus sheath nerve block
58100325|NCT01099280|DRUG|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
58100326|NCT05554874|OTHER|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
58428695|NCT06505486|DRUG|Gemcitabine-Oxaliplatin Regimen|Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
58428696|NCT02891382|BEHAVIORAL|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
58428697|NCT02891382|BEHAVIORAL|Goal setting|Goals for weight loss and change in levels of HbA1c
58428698|NCT02891382|BEHAVIORAL|Companion Support|Patient has a companion/team support partner to support achieving goals.
58100327|NCT05554874|OTHER|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
58428699|NCT02891382|BEHAVIORAL|Individual Reward|The cash reward is given to the patient with diabetes.
58428700|NCT02891382|BEHAVIORAL|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
58428701|NCT06564896|DEVICE|CPAP Airsense 10 vs Air-Mini|Patients' satisfaction and CPAP efficacy
58428702|NCT05726747|DIAGNOSTIC_TEST|Quality of Life surveys|QoL and sarcopenia assessments
58428703|NCT04519580|DIAGNOSTIC_TEST|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
57952933|NCT04432883|DEVICE|Active Comparator: Experimental: Active cathodal tDCS + language training|"Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment."
58100328|NCT06280027|OTHER|survey|An online survey was generated to quantitatively evaluate the level of esthetic perception.
58100329|NCT00634192|DRUG|tobramycin|1x300mg/d inhaled
58100330|NCT00634192|DRUG|tobramycin|2x300mg/d inhaled
58100331|NCT04742725|DRUG|Placebo|Placebo
58100332|NCT04742725|DRUG|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
58308204|NCT06071416|PROCEDURE|Injectable platlets rich fibrin|centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
58100333|NCT05724316|DIETARY_SUPPLEMENT|Vitamin D supplement|N/A (says not to repeat information here)
58308205|NCT00792181|DRUG|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
58100334|NCT05588375|BEHAVIORAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
58100335|NCT01716507|PROCEDURE|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
58100336|NCT04296799|DRUG|SMP-100|SAD/MAD
58100337|NCT04296799|DRUG|Placebo|Placebo
58308206|NCT00792181|OTHER|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
58308207|NCT05782517|DEVICE|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
58308208|NCT05782517|DEVICE|Endotracheal Tube|Placement of an Endotracheal Tube.
58308209|NCT00183079|BEHAVIORAL|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
58308210|NCT02215902|DEVICE|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
58308211|NCT00096213|PROCEDURE|conventional surgery|surgery
58308212|NCT02452047|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
58308213|NCT02452047|DRUG|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
58308214|NCT02452047|DRUG|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
58308215|NCT02452047|DRUG|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
58308216|NCT04960787|OTHER|Educational Intervention|Watch online educational videos
58428704|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
58428705|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
58428706|NCT05713435|DEVICE|intravaginal laser|application of intravaginal laser
58428707|NCT00666965|DRUG|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
58428708|NCT03589755|BEHAVIORAL|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
58428709|NCT00620113|DRUG|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
58428710|NCT00620113|DIETARY_SUPPLEMENT|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
58428711|NCT00620113|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
58428712|NCT00620113|DRUG|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
58428713|NCT00000802|DRUG|Atovaquone|
58428714|NCT00000802|DRUG|Dapsone|
58458379|NCT01292941|DEVICE|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
58428715|NCT02636686|DRUG|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
58428716|NCT04411745|OTHER|No intervention, observational study|
58428717|NCT01211340|BEHAVIORAL|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
57736852|NCT05558033|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
57736853|NCT05558033|OTHER|Football Training|Routine football trainings
57736854|NCT00241254|DRUG|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
58129457|NCT06121037|PROCEDURE|distal ultrasound-guided GON radiofrequency ablation|distal GON radiofrequency
58308217|NCT04960787|BEHAVIORAL|Patient Navigation|Meet with CENTS counselor and PAF case manager
58428718|NCT04443166|COMBINATION_PRODUCT|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
58428719|NCT01571453|DRUG|Vortioxetine (Lu AA21004)|10 mg/day
58428720|NCT01571453|DRUG|Venlafaxine extended release|150 mg/day
58428721|NCT04224506|OTHER|No intervention|There is no intervention for this study.
58428722|NCT02678455|BIOLOGICAL|TV005 vaccine|Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
58428723|NCT02678455|BIOLOGICAL|Placebo|Delivered by subcutaneous injection
58428724|NCT00808548|OTHER|counseling, emotional support|
58308218|NCT04960787|OTHER|Quality-of-Life Assessment|Ancillary studies
58428725|NCT00808548|OTHER|emotional support|emotional support during the interview
58428726|NCT00808548|OTHER|emotional support|emotional supporting during the interview
58428727|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
58308219|NCT04960787|OTHER|Questionnaire Administration|Complete questionnaires
58428728|NCT04161001|DRUG|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
58428729|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
58428730|NCT00334711|DRUG|Sulfonylurea|
58428731|NCT05401318|PROCEDURE|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
58428732|NCT01090063|DRUG|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
58428733|NCT01772576|DEVICE|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
58428734|NCT02217917|DRUG|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
58428735|NCT02217917|DRUG|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
58428736|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
58458380|NCT01292941|DEVICE|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
58428737|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
58428738|NCT02217917|DRUG|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
58428739|NCT00395850|DRUG|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
58428740|NCT03310385|DRUG|GHX02|Herbal medicine originating from gualouhengryunhwan
58428741|NCT03310385|DRUG|Placebo|Placebo tablets
58428742|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
57736855|NCT00241254|DRUG|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
57736856|NCT01253434|DRUG|E2022|E2022 Type A patch
58100338|NCT05827965|BEHAVIORAL|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
58308220|NCT04758455|DIAGNOSTIC_TEST|P53, Ki67 and Cyclin A IHC.|P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.
58308221|NCT02896348|DEVICE|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
58308222|NCT02896348|OTHER|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
58308223|NCT03555552|DEVICE|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
58308224|NCT03555552|DEVICE|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
58308225|NCT00150696|DRUG|Risedronate|
58308226|NCT06390098|DRUG|ASN51|ASN51 formulation for oral capsule
58308227|NCT06502548|PROCEDURE|Endometriosis|"Anatomopathology waste will be recovered, i.e. the remainder of the endometriosis lesions and the remainder of the endometrial biopsy.~A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up."
58308228|NCT06502548|PROCEDURE|Tubal ligation or Hysterectomy|During surgery, an endometrial biopsy will be taken for research purposes. A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.
58308229|NCT01244867|BIOLOGICAL|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
58308230|NCT01244867|BIOLOGICAL|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
58308231|NCT01244867|BIOLOGICAL|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
58308232|NCT01244867|BIOLOGICAL|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
58308233|NCT01244867|BIOLOGICAL|Placebo|2 doses given 21 days apart of the placebo
58308234|NCT01880606|PROCEDURE|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
58308235|NCT05673395|DEVICE|Electrolyzed alkaline reduced water generator|Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
58308236|NCT04163874|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
58308237|NCT04163874|DRUG|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
58100339|NCT06566066|OTHER|no intervention|register study without intervention
58308238|NCT04163874|DRUG|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
58308239|NCT04163874|DEVICE|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
58428743|NCT00661947|OTHER|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
58428744|NCT05842681|DRUG|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
58428745|NCT05842681|DRUG|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
58428746|NCT05583019|DEVICE|GENEActiv Accelerometry Device|a watch like wearable sensor
58428747|NCT05583019|DEVICE|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
58428748|NCT05583019|DEVICE|Apple Watch Accelerometry Device|a watch like wearable sensor
58428749|NCT05583019|DEVICE|Polysomnography|Sleep monitor
58428750|NCT05583019|DEVICE|Videography|Thermal Camera
58428751|NCT03891758|BIOLOGICAL|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
57736857|NCT01253434|DRUG|E2022|E2022 Type B patch
58100340|NCT06568653|PROCEDURE|exosome|human placenta mesenchymal stem cell-derived exosome
58100341|NCT06568653|PROCEDURE|routine conventional fistulotomy|routine conventional fistulotomy
58428752|NCT03891758|BIOLOGICAL|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
58428753|NCT03891758|BIOLOGICAL|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
58428754|NCT02653547|OTHER|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
58428755|NCT02653547|OTHER|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
58428756|NCT02653547|OTHER|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
58428757|NCT02653547|OTHER|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
57736858|NCT01253434|DRUG|E2022|E2022 Type C patch
57736859|NCT01253434|DRUG|E2022|E2022 Type D patch
58428758|NCT03355677|PROCEDURE|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
58428759|NCT03355677|PROCEDURE|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
58428760|NCT03355677|OTHER|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
58428761|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
58428762|NCT00871962|OTHER|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
58100342|NCT00002973|DRUG|melphalan|
58100343|NCT00002973|PROCEDURE|hyperthermia treatment|
58100344|NCT05166473|OTHER|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
57736860|NCT01253434|DRUG|E2022|E2022 Type E patch
57736861|NCT06173401|RADIATION|Single-fraction spine SRS|Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)
58100345|NCT05166473|OTHER|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
57736862|NCT06173401|RADIATION|Multi-fraction spine SRS|Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
57736863|NCT01143948|DRUG|Glargine & Glulisine|Basal Glargine \& bolus Glulisine
57736864|NCT01143948|DRUG|Regular insulin|Sliding scale regular insulin
57736865|NCT01143948|DRUG|NPH & regular insulin|Basal NPH \& bolus regular insulin
57736866|NCT00695903|DRUG|daptomycin|daptomycin 10 mg/kg IV every 24 hours
57736867|NCT00695903|DRUG|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
57736868|NCT03206346|DRUG|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
58100346|NCT01906580|DRUG|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
58100347|NCT01906580|DRUG|Entecavir|0.5mg,oral administration every day
58100348|NCT01592227|DRUG|Marketed paracetamol|Marketed paracetamol
58100349|NCT01592227|DRUG|Experimental paracetamol formulation|Experimental paracetamol formulation
58100350|NCT06190899|DRUG|Gedatolisib|Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
58428763|NCT02339792|OTHER|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
58428764|NCT00000466|DRUG|estrogens, conjugated|
58428765|NCT00000466|DRUG|medroxyprogesterone|
58428766|NCT00000466|DRUG|progesterone|
58428767|NCT00000466|DRUG|estrogen replacement therapy|
58428768|NCT02692378|DRUG|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
58100351|NCT06190899|DRUG|Darolutamide|Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
58100352|NCT01702766|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
58428769|NCT01402648|DIETARY_SUPPLEMENT|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
58100353|NCT01383954|DRUG|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
58100354|NCT05654857|DIAGNOSTIC_TEST|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
58100355|NCT02845102|OTHER|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
58100356|NCT05863182|BEHAVIORAL|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
58100357|NCT06265961|OTHER|Education|"In line with the Papadopoulos Tilki Taylor cultural competence development model used in the research, a training presentation titled overview and basic concepts of intercultural nursing will be held at the beginning of the intervention in order to increase the cultural knowledge levels of nurses. In order to test the effectiveness of the bibliotherapy method, training will be given online via Google Meet to both groups (both study and control) at the beginning of the research."
58428770|NCT01402648|DIETARY_SUPPLEMENT|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
58428771|NCT01608841|DRUG|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
58428772|NCT01623739|PROCEDURE|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
58428773|NCT01734759|DRUG|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
58428774|NCT00258934|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
58428775|NCT00258934|BIOLOGICAL|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
58428776|NCT05997706|PROCEDURE|Testicular biopsy|Testicular biopsy is a clinical procedure for extraction of testicular tissue
58428777|NCT00317382|DEVICE|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
58129458|NCT00688064|DRUG|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
58129459|NCT00688064|DRUG|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
58129460|NCT06196242|DIAGNOSTIC_TEST|MRI and CT scan|"An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes."
58428778|NCT00378261|PROCEDURE|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
58428779|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
58428780|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
58428781|NCT02259894|DRUG|BIRT 2584 XX|
58428782|NCT02259894|DRUG|Placebo|
58428783|NCT02286557|DRUG|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
58428784|NCT02286557|DRUG|Placebo|
58428785|NCT06497296|DRUG|Lidocaine|Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
58100358|NCT06265961|OTHER|Bibliotherapy|"The intervention consists of 1 online intercultural nursing training, 2 book and 2 short story reading activities and 1 film evaluation to be carried out over a 3-month period.~After the training, the nurses in the study group will be asked to read the introductions of the books on the reading list and choose 2 books that they feel close to and that they have not read before. Participants will complete readings and assignments (evaluation form, reflective thought essay) asynchronously in time periods convenient to them.~In addition to books, a supporting film will be used to raise awareness. At the end of the movie, they will be asked to write on their notes how they can relate to intercultural nursing, how they can behave when faced with similar situations, and what differences there are between their ideas about intercultural nursing before and after the movie."
58100359|NCT04000373|DEVICE|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
58428786|NCT01780753|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
58428787|NCT02677857|BEHAVIORAL|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
58428788|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
58428789|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
58428790|NCT01555125|DRUG|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
58428791|NCT01555125|DRUG|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
58428792|NCT01555125|DRUG|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
58428793|NCT04809259|DEVICE|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
58100360|NCT00763269|DRUG|Triclosan, Silicon dioxide, fluoride|Brush twice daily
58100361|NCT00763269|DRUG|Triclosan, fluoride|Brush twice daily
58100362|NCT01274273|DRUG|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
58100363|NCT01274273|DRUG|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
58100364|NCT01274273|DRUG|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
58100365|NCT05084807|OTHER|Endoscopy|"* A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
58100366|NCT00866528|DRUG|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
58100367|NCT00866528|DRUG|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
58428794|NCT06398717|PROCEDURE|adductor canal block|"group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound"
58428795|NCT00230542|DRUG|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
58428796|NCT00230542|DRUG|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
58428797|NCT04969692|PROCEDURE|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
58100368|NCT02034617|BEHAVIORAL|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
58428798|NCT03666221|DRUG|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
58428799|NCT00599638|DRUG|pregabalin|75mg bid titrating to 150mg bid on day 4
58428800|NCT00599638|DRUG|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
58428801|NCT00599638|DRUG|Placebo|Placebo
58428802|NCT04684953|PROCEDURE|Throid autotransplantation|Operative
58428803|NCT04684953|DRUG|Hormone|thyroid hormone replacement therapy
58428804|NCT03468894|BEHAVIORAL|Treadmill desk walking|See intervention arm description
58428805|NCT04203420|OTHER|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
58428806|NCT03157037|BIOLOGICAL|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
57736869|NCT03206346|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
58100369|NCT02255734|DRUG|Acyclovir|
58100370|NCT06500039|OTHER|Positive Psychological Intervention Program|An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
58428807|NCT06515262|BIOLOGICAL|Anti-BCMA-GPRC5D CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.
58428808|NCT02678299|DRUG|PREBEN|
58428809|NCT03879304|OTHER|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
58428810|NCT03879304|OTHER|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
58428811|NCT03715946|DRUG|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
58428812|NCT03715946|RADIATION|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
58428813|NCT01587365|BIOLOGICAL|BMS-962476|
58428814|NCT01587365|BIOLOGICAL|Placebo matching with BMS-962476|
58428815|NCT03757377|DEVICE|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
58428816|NCT03757377|DEVICE|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
58428817|NCT02346513|DEVICE|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
58428818|NCT02346513|DEVICE|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
58100371|NCT06500039|OTHER|Writing Daily Routines|An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
58100372|NCT01128153|DRUG|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
58100373|NCT01128153|DRUG|Placebo|tablet once daily for 24 weeks to be taken orally
58100374|NCT03213080|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
58100375|NCT06301256|DRUG|TIRZEPATIDE|Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
58100376|NCT06416761|GENETIC|genetic polymorphisms|
58100377|NCT00074009|DRUG|bortezomib|
58100378|NCT02634567|BEHAVIORAL|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
58100379|NCT05305378|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
58100380|NCT03975088|PROCEDURE|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
58100381|NCT05761015|DRUG|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
58100382|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
58428819|NCT03219411|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
58100383|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
58100384|NCT05912179|DIAGNOSTIC_TEST|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
58428820|NCT03219411|OTHER|placebo|Placebo administered orally as capsules three times a day over 12 weeks
58428821|NCT00738218|OTHER|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
58428822|NCT02258087|RADIATION|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
58428823|NCT02258087|RADIATION|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
58428824|NCT02678923|DRUG|MDCO-216|
58100385|NCT03405701|PROCEDURE|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
58428825|NCT02678923|DRUG|Placebo|
58428826|NCT02178696|OTHER|Placebo, identified as placebo to participants|White tablets
58100386|NCT03405701|PROCEDURE|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
58428827|NCT02178696|DRUG|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
58428828|NCT02178696|OTHER|"Placebo, identifed to participants as Active medication"|Blue Capsule
58428829|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
58428830|NCT02343198|DEVICE|Custom-built research muscle stimulator|Muscle stimulator
58100387|NCT05190640|DIETARY_SUPPLEMENT|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
58100388|NCT04309955|PROCEDURE|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
58100389|NCT06232707|DRUG|Alnuctamab|Specified dose on specified days
58100390|NCT06232707|DRUG|Pomalidomide|Specified dose on specified days
58100391|NCT06232707|DRUG|Daratumumab|Specified dose on specified days
58100392|NCT06232707|DRUG|Elotuzumab|Specified dose on specified days
58100393|NCT06232707|DRUG|Carfilzomib|Specified dose on specified days
58100394|NCT06232707|DRUG|Dexamethasone|Specified dose on specified days
58100395|NCT02738489|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
58100396|NCT00842894|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
58100397|NCT00842894|DRUG|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
58100398|NCT00913861|BEHAVIORAL|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
58100399|NCT00913861|DRUG|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
58100400|NCT00913861|BEHAVIORAL|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
58100401|NCT00646178|DRUG|adalimumab|40 mg adalimumab eow Week 0 - Week 12
58428831|NCT01828411|DEVICE|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
58428832|NCT01828411|DEVICE|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
58428833|NCT01008904|DRUG|magnesium oxide|Given PO
58428834|NCT01008904|OTHER|questionnaire administration|Ancillary studies
58428835|NCT01008904|PROCEDURE|quality-of-life assessment|Ancillary studies
58428836|NCT05120141|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
58428837|NCT05120141|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
58428838|NCT05120141|OTHER|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
58428839|NCT05120141|OTHER|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
58100402|NCT00646178|DRUG|placebo for adalimumab|placebo eow Week 0 - Week 12
58100403|NCT01272739|DIETARY_SUPPLEMENT|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
58100404|NCT01272739|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
58100405|NCT00096200|DRUG|Carboplatin|Given IV
58100406|NCT00096200|DRUG|Paclitaxel|Given IV
58100407|NCT00096200|DRUG|Sorafenib Tosylate|Given orally
58100408|NCT03799094|DRUG|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
58100409|NCT03799094|DRUG|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
58100410|NCT00741520|DEVICE|CPAP|Control - no treatment
58100411|NCT00741520|DEVICE|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
58100412|NCT04098159|DEVICE|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
58100413|NCT02200614|DRUG|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
58100414|NCT02200614|DRUG|Placebo|Matching placebo 2 tablets twice daily with food.
58100415|NCT03526796|PROCEDURE|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
58100416|NCT04682561|BEHAVIORAL|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
58100417|NCT00826722|DRUG|Levetiracetam|1000 mg tablet
58100418|NCT02747251|OTHER|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
58100419|NCT02747251|OTHER|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
58428840|NCT05120141|OTHER|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
58428841|NCT05120141|OTHER|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
58428842|NCT05120141|OTHER|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
58428843|NCT00116116|DRUG|efavirenz, stavudine extended release, lamivudine|
58428844|NCT00225095|DRUG|Mesenchymal Stem Cells|
58428845|NCT00225095|DRUG|Hyaluronan|
58428846|NCT00559676|DRUG|capecitabine|
58428847|NCT00559676|DRUG|fluorouracil|
58428848|NCT00559676|DRUG|irinotecan hydrochloride|
58428849|NCT00559676|DRUG|leucovorin calcium|
58100420|NCT04580524|PROCEDURE|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
58100421|NCT04580524|PROCEDURE|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
58100422|NCT02016755|BIOLOGICAL|HGF Plasmid|Intramuscular injection in the affected limb.
58100423|NCT06564649|DIAGNOSTIC_TEST|CXCL10 Monitoring at clinical frequency|The intervention is the implementation of real-time, serial urinary CXCL10 monitoring, with protocolized further clinical responses in the setting of elevated urinary CXCL10 levels.
58428850|NCT00559676|DRUG|oxaliplatin|
58428851|NCT00559676|OTHER|laboratory biomarker analysis|
58428852|NCT00559676|OTHER|pharmacological study|
58100424|NCT02108366|DRUG|Celecoxib|Celecoxib 200mg daily
58100425|NCT02108366|DRUG|Oseltamivir|Oseltamivir 75mg bid
58100426|NCT02108366|DRUG|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
58100427|NCT05003167|DEVICE|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
58100428|NCT00898742|GENETIC|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
58428853|NCT01504204|DRUG|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
58428854|NCT01504204|DRUG|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
58428855|NCT05903261|RADIATION|SBRT|stereotactic body radiation therapy (SBRT)
58428856|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
58428857|NCT04629027|DRUG|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
58428858|NCT03846557|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
58428859|NCT00705887|BEHAVIORAL|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
57736870|NCT04301336|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
58100429|NCT00898742|GENETIC|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
58428860|NCT04518683|DEVICE|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
58458381|NCT04847843|BEHAVIORAL|Mindfulness Orientated Recovery Enhancement|The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.
58100430|NCT00898742|OTHER|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
58100431|NCT02639507|PROCEDURE|Vitrectomy|
58100432|NCT04794400|OTHER|oxygen mask|All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
58100433|NCT05478603|DRUG|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
58100434|NCT03607656|DRUG|Oxaliplatin|Oxaliplatin powder injection
58100435|NCT03607656|DRUG|Capecitabine|Capecitabine tablet
58100436|NCT03607656|OTHER|TCM|TCM decoction orally taken twice a day for at least 3 months
58100437|NCT03607656|DRUG|S-1|S-1 capsule
58100438|NCT03607656|DRUG|Docetaxel|Docetaxel injection
58100439|NCT03607656|DRUG|5-FU|5-FU injection
58100440|NCT02593084|BEHAVIORAL|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
58100441|NCT02593084|BEHAVIORAL|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
58100442|NCT05110430|OTHER|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
58100443|NCT06310473|DRUG|Cadonilimab|10mg/kg intravenous (IV) every 3 weeks ;
58100444|NCT06310473|DRUG|Oxaliplatin|130mg/m², iv drip for 2h, d1, q3w;
58100445|NCT06310473|DRUG|Capecitabine|1000mg/m² po, Bid, d1-14, q3w ;
58100446|NCT04330482|BEHAVIORAL|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
58100447|NCT04330482|BEHAVIORAL|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
58428861|NCT04518683|DEVICE|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
58428862|NCT00488826|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
57736871|NCT04301336|DRUG|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
57736872|NCT04301336|DRUG|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
58100448|NCT00332345|DRUG|brimonidine/timolol fixed combination|
58100449|NCT00085722|PROCEDURE|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
58100450|NCT00085722|PROCEDURE|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
58100451|NCT00085722|OTHER|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
58308240|NCT05406323|BEHAVIORAL|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
58308241|NCT05670444|DRUG|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
58308242|NCT04344717|DRUG|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
58308243|NCT04344717|DRUG|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
58428863|NCT00488826|BIOLOGICAL|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
57952934|NCT04432883|BEHAVIORAL|Sham Comparator: Placebo cathodal tDCS + Speech and language|Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
58100452|NCT00984828|DRUG|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
58100453|NCT04256057|DRUG|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
58100454|NCT01385501|OTHER|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
58100455|NCT01573494|OTHER|Sampling of blood|7,5 ml of blood
58100456|NCT02963909|BIOLOGICAL|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
58100457|NCT02963909|OTHER|Placebo|0.9% Sodium Chloride 5 mcg
58129461|NCT01632709|DRUG|Bupivacaine|one injection of 10ml of .25%
58129462|NCT01632709|DRUG|Placebo|Dry needling
58428864|NCT05747534|DRUG|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
57736873|NCT04301336|DRUG|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
58100458|NCT02963909|BIOLOGICAL|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
58308244|NCT06227169|BEHAVIORAL|JJ-COPES Training|• The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
58428865|NCT05747534|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
58428866|NCT02640495|DRUG|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
58428867|NCT01257607|DRUG|MIM-D3 Ophthalmic Solution|28 Days, BID
58428868|NCT01257607|DRUG|Placebo Ophthalmic Solution|28 Days, BID
58428869|NCT06141759|OTHER|Exercise|Cheneau brace and Schroth Best Practice exercise
58428870|NCT02037217|DEVICE|ExAblate Transcranial MRgFUS System|
58428871|NCT00997360|DRUG|PKI-179|
58100459|NCT02963909|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
58308245|NCT02404571|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
58308246|NCT05771467|OTHER|Optical Coherence Tomography Angiography (OCTA) • Biometry • Auto refractometry • Non contact tonometry|Ophthalmologic Examination Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
58308247|NCT01207843|BEHAVIORAL|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
58308248|NCT03980067|OTHER|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
58308249|NCT04873726|DEVICE|Magnetic Tape® aplication|Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
58308250|NCT04873726|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
58428872|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
58428873|NCT03204669|OTHER|Trace elements replacement|
58100460|NCT01117714|PROCEDURE|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
58428874|NCT04058886|BEHAVIORAL|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
58428875|NCT02553408|DEVICE|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
58428876|NCT01177566|DRUG|pimecrolimus|pimecrolimus 1% cream twice daily
58428877|NCT01177566|DEVICE|topical medical device|Eletone cream three times daily
58428878|NCT03750643|DRUG|LY3454738|Administered IV
58100461|NCT05027373|DRUG|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
58100462|NCT05027373|DRUG|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
58100463|NCT04222556|BEHAVIORAL|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
58100464|NCT04222556|BEHAVIORAL|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
58100465|NCT03078530|DRUG|Placebo|This is a pill with inactive ingredients
58100466|NCT03078530|DRUG|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
58100467|NCT03078530|DRUG|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
58100468|NCT00552617|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
58428879|NCT03750643|DRUG|LY3454738|Administered SC
58428880|NCT03750643|DRUG|Placebo|Administered IV
58100469|NCT00552617|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
58100470|NCT00552617|DRUG|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
58100471|NCT00552617|DRUG|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
58100472|NCT05593783|PROCEDURE|lithotripsy|lithotripsy
58100473|NCT00429091|DRUG|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
58100474|NCT00429091|DRUG|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
58100475|NCT00429091|DRUG|placebo|Subjects will take BID for up to four weeks
58100476|NCT01864525|DRUG|Octanoic acid|
58100477|NCT01864525|DRUG|Inactive capsule|
58100478|NCT03563235|DRUG|Xulin Jiangu granules|Xulin Jiangu granules tablets
58100479|NCT03563235|DRUG|Calcitriol capsules|Calcitriol capsules tablets
58428881|NCT00682318|DRUG|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
58428882|NCT00682318|DIETARY_SUPPLEMENT|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
58428883|NCT00682318|DIETARY_SUPPLEMENT|Ethanol|"Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
58100480|NCT00934622|DEVICE|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
58100481|NCT01456871|PROCEDURE|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
58100482|NCT01456871|PROCEDURE|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
58100483|NCT00000754|DRUG|Interferon alfa-2a|
58100484|NCT00000754|DRUG|Zidovudine|
58100485|NCT00000754|DRUG|Zalcitabine|
58428884|NCT00682318|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
58428885|NCT00682318|DIETARY_SUPPLEMENT|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)"
58428886|NCT04274556|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
58428887|NCT05094141|OTHER|Virtual reality|Virtual reality game
58100486|NCT01812291|BEHAVIORAL|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement"
58100487|NCT01812291|BEHAVIORAL|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
58100488|NCT01812291|BEHAVIORAL|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
58100489|NCT01812291|BEHAVIORAL|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes"
58100490|NCT01954784|DRUG|fludarabine phosphate|
58100491|NCT01954784|RADIATION|total-body irradiation|Undergo TBI
58100492|NCT01954784|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
58100493|NCT01954784|DRUG|cyclosporine|Given PO
58100494|NCT01954784|DRUG|mycophenolate mofetil|Given PO
58100495|NCT01954784|DRUG|bortezomib|Given SC
58100496|NCT01954784|DRUG|lenalidomide|Given PO
58100497|NCT01954784|OTHER|laboratory biomarker analysis|Correlative studies
58100498|NCT01424618|DRUG|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
58100499|NCT01424618|DRUG|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
58308251|NCT00834041|DRUG|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
58308252|NCT04306523|OTHER|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
58428888|NCT02738424|OTHER|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
58428889|NCT04928560|DIAGNOSTIC_TEST|SMI|ULTRASOUND
58428890|NCT02828332|OTHER|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
58428891|NCT02828332|OTHER|Quality of life|Evaluation of the quality of life and comorbidities
58428892|NCT01371305|DRUG|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
58428893|NCT01371305|DRUG|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
58428894|NCT00952900|BEHAVIORAL|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
58428895|NCT00952900|BEHAVIORAL|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
57736874|NCT04301336|DRUG|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
57736875|NCT04301336|DRUG|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
57736876|NCT04301336|DRUG|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
57736877|NCT04301336|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
58100500|NCT04254263|DRUG|pyrotinib|pyrotinib 400 mg, orally once daily for one year
58100501|NCT04300907|DEVICE|Provant Infinity Therapy System|Treatment with the Provant Infinity Therapy System, PEMF device
58100502|NCT04474288|DIAGNOSTIC_TEST|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
58100503|NCT04647279|DIAGNOSTIC_TEST|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
58100504|NCT04175678|OTHER|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
58100505|NCT04175678|OTHER|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
58100506|NCT04175678|OTHER|Standard care|Observational
58308253|NCT04032132|DRUG|curcumin paste|curcumin is a herb used for medical purpose
58308254|NCT04032132|PROCEDURE|curettage|open flab debridement surgery
57736878|NCT03298126|PROCEDURE|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
57952935|NCT01389752|DRUG|LY2216684|Administered orally
57952936|NCT01389752|DRUG|Activated Charcoal|Administered orally
57952937|NCT01227733|OTHER|Breast Tumor Blocks|
57952938|NCT00583362|BIOLOGICAL|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
58100507|NCT00712491|DRUG|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
58100508|NCT00712491|DRUG|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
58428896|NCT06262243|OTHER|electric blankets|"While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5."
58428897|NCT03194438|BEHAVIORAL|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
58428898|NCT04147806|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
58428899|NCT04147806|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
58428900|NCT04147806|DRUG|Dexamethasone|4 mg by mouth on treatment days only
58428901|NCT04147806|DRUG|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
58428902|NCT05967949|DRUG|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
58428903|NCT03012867|OTHER|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
58100509|NCT02700074|OTHER|No Intervention|Intervention is not a part of this study.
58428904|NCT03012867|OTHER|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
58428905|NCT05328752|DRUG|XXB750|XXB750
58428906|NCT05328752|DRUG|Placebo|Placebo
58428907|NCT02540993|DRUG|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
58428908|NCT02540993|DRUG|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
57736879|NCT05999955|DRUG|Neomycin/ Dexameythasone/Xylometazoline|The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
58100510|NCT01119352|DRUG|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
58308255|NCT00288912|BEHAVIORAL|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
57952939|NCT01682135|BIOLOGICAL|Ramucirumab|Administered IV.
58308256|NCT00288912|BEHAVIORAL|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
58100511|NCT01119352|DRUG|Placebo|Oral suspension, once daily. Totally 8 doses
58100512|NCT04369079|OTHER|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
58100513|NCT04369079|OTHER|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
58428909|NCT00922714|DRUG|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
58428910|NCT00922714|DRUG|saline (placebo)|NaCl 0.9 g/L
58428911|NCT06536556|OTHER|First Assessment|pre-treatment assessment
58428912|NCT06536556|OTHER|Second Assessment|4 days post-treatment assessment
58428913|NCT00890682|DRUG|SKY0402|Local infiltration of 8cc SKY0402
58428914|NCT00890682|DRUG|Placebo|Local infiltration of 8cc Placebo
58428915|NCT02641067|DRUG|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
58428916|NCT04420403|OTHER|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
58428917|NCT04420403|OTHER|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
58428918|NCT00695864|DRUG|Ondansetron and Placebo crossover|
58428919|NCT05945303|PROCEDURE|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
58428920|NCT04556019|PROCEDURE|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
58428921|NCT00003775|DRUG|leflunomide|
58428922|NCT02408263|PROCEDURE|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
57736880|NCT05999955|COMBINATION_PRODUCT|Bacillus subtilis DSM32444|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/ PCBALA In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatmen.
58428923|NCT06035848|PROCEDURE|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
58428924|NCT06035848|PROCEDURE|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
58428925|NCT03981068|RADIATION|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
58428926|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
58428927|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
58428928|NCT03637517|DRUG|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
58428929|NCT06379282|BEHAVIORAL|HIT|Exercise training only
58428930|NCT06379282|BEHAVIORAL|EXE+ Nutritional Guidance|Exercise Training + Nutritional Guidance
58428931|NCT04183608|DRUG|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
58428932|NCT04183608|DIAGNOSTIC_TEST|Calprotectin|Fecal calprotectin dosing at home with IBDoc
58428933|NCT04183608|OTHER|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections"
57736881|NCT02102308|OTHER|Exercise|Multicomponent exercise
58428934|NCT04183608|OTHER|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
58428935|NCT03154749|DRUG|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
58428936|NCT02218944|BEHAVIORAL|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
58428937|NCT00133224|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
58428938|NCT00133224|DRUG|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
58428939|NCT00266682|DEVICE|Pacing Lead|
58428940|NCT01141491|BIOLOGICAL|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
58428941|NCT01141491|BIOLOGICAL|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
58428942|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
58428943|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
58428944|NCT01555489|DRUG|Ascorbic Acid|3x per week
58428945|NCT06068465|DRUG|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
58428946|NCT06068465|DRUG|placebo|placebo, capsule, once daily by mouth for 6 weeks
58428947|NCT04379076|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
58428948|NCT04379076|DRUG|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
58428949|NCT02462993|DRUG|Aloe Vera|Local drug delivery of aloe vera gel
57736882|NCT02102308|OTHER|Education classes|
58100514|NCT03904043|RADIATION|Radiation therapy|-Monday-Friday treatment is strongly recommended
58100515|NCT03904043|DRUG|FOLFOX regimen|-CAPOX can be given as alternative
58428950|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
57736883|NCT05960500|PROCEDURE|implant|All on six versus parallel implant distribution
58100516|NCT03904043|OTHER|Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire|-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
58100517|NCT03904043|PROCEDURE|Rectal biopsy samples|-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction. For patients at affiliate sites who do not have enough tissue from the diagnostic biopsy, a repeat pre-treatment biopsy is optional.
58100518|NCT03904043|PROCEDURE|Blood for ctDNA|-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after RT (if this visit aligns with a follow-up time point, one draw can be used to satisfy both time points), months 3, 6, 9, 12, 16, 20, 24 until salvage surgery or 2 years from completion of chemotherapy (whichever is first)
58428951|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
58428952|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
58428953|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
58428954|NCT03309930|BEHAVIORAL|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
58428955|NCT00269633|DEVICE|Blue Light Box 467 nm|467 nm Blue LED Light
58428956|NCT00269633|DEVICE|Red Light Box 657 nm|657 nm Red LED Light
58428957|NCT04135014|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
58428958|NCT04135014|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
58428959|NCT04135014|DRUG|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
57736884|NCT02324439|DRUG|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
57736885|NCT04764058|DRUG|Tienam 500|Imipenem and cilastatin sodium
57736886|NCT04764058|DEVICE|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
58100519|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
58308257|NCT04574518|BEHAVIORAL|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
58308258|NCT04574518|BEHAVIORAL|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
58428960|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
58428961|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
58428962|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
58428963|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
58428964|NCT03442660|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
57736887|NCT00215267|DRUG|praziquantel|
57736888|NCT02512575|DRUG|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
58428965|NCT06389110|DRUG|Alleance®|Atropine sulfate 0.01%, ophthalmic solution.
58428966|NCT06389110|DRUG|Placebo|Ophthalmic solution.
58428967|NCT02337634|DRUG|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
58428968|NCT02337634|DRUG|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
58428969|NCT06377709|OTHER|ProACTive™|ProACTive™ intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
57736889|NCT02512575|DRUG|Placebo oral suspension/ Placebo capsule|Matching placebo
57736890|NCT02512575|DRUG|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
57736891|NCT01558154|DRUG|Chinese herbs|Chinese herbs special for depression
57736892|NCT01558154|PROCEDURE|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
57736893|NCT01558154|OTHER|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
57736894|NCT01558154|DEVICE|Transcranial magnetic stimulation|Give magnetic stimulation at head
57736895|NCT00784810|DRUG|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
57736896|NCT00784810|DRUG|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
58428970|NCT05769049|BIOLOGICAL|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
58428971|NCT05769049|BIOLOGICAL|Shingrix|Shingrix
58428972|NCT02919514|OTHER|Physical training on hard surface.|Physical training on hard surface.
58428973|NCT02919514|OTHER|Physical training on sand surface.|Physical training on sand surface.
58428974|NCT02919514|OTHER|Physical training on soft surface.|Physical training on soft surface.
58428975|NCT02048488|DRUG|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
58428976|NCT03320590|DIAGNOSTIC_TEST|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
57736897|NCT06458322|OTHER|Home dialysis or In-Center dialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
57736898|NCT02523313|DRUG|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
57736899|NCT02523313|DRUG|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
57952940|NCT03994939|BEHAVIORAL|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
58428977|NCT05379101|DIAGNOSTIC_TEST|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
58428978|NCT05379101|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
58428979|NCT05379101|DIAGNOSTIC_TEST|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
58428980|NCT04507971|BIOLOGICAL|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
58428981|NCT03565835|DRUG|Abiraterone Acetate|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
58428982|NCT03565835|DRUG|Prednisone|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
58100520|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
58100521|NCT01010321|DEVICE|confocal microscopy|non-invasive imaging
58100522|NCT06461676|DRUG|Ventrix Bio Extracellular Matrix|VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
58100523|NCT05785026|OTHER|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
58428983|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
58428984|NCT02215304|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
58428985|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
58428986|NCT02215304|DIETARY_SUPPLEMENT|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
58428987|NCT03076294|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
58428988|NCT03076294|OTHER|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
58428989|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
58428990|NCT03158181|OTHER|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
58428991|NCT05215730|DEVICE|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
58428992|NCT01106235|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
58428993|NCT01106235|BIOLOGICAL|aldesleukin|Given SC
58428994|NCT01106235|DRUG|cyclophosphamide|Given IV
58428995|NCT01106235|PROCEDURE|biopsy|Optional correlative studies
58100524|NCT05785026|OTHER|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
58100525|NCT01552629|DRUG|QGE031|
58100526|NCT01552629|DRUG|Placebo|
58100527|NCT01552629|DRUG|Cyclosporine A|
58100528|NCT01050673|DEVICE|VERSAJET|Hydro-surgery debridement
58100529|NCT01050673|PROCEDURE|Scalpel or blade|Conventional Surgical Debridement
58100530|NCT02777931|DRUG|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
58100531|NCT02777931|DRUG|Placebo|Matching placebo capsules
58100532|NCT00047294|DRUG|celecoxib|
58100533|NCT00047294|DRUG|temozolomide|
58100534|NCT00047294|DRUG|thalidomide|
58428996|NCT03450265|DEVICE|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
58428997|NCT03450265|DEVICE|Tachosil|Applied according to the current instruction for use (IFU).
58100535|NCT00047294|PROCEDURE|adjuvant therapy|
58428998|NCT04725487|OTHER|Standard integration program with social and health promoting intervention|"* Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops"
58100536|NCT00189267|DRUG|Imiquimod 5 % Cream|
58100537|NCT01608776|DEVICE|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
58100538|NCT01608776|OTHER|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
58100539|NCT06066866|OTHER|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
58428999|NCT04725487|OTHER|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
58429000|NCT05908201|BEHAVIORAL|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
58429001|NCT04913740|OTHER|Ointment and dressing for external use|"1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
58429002|NCT04122131|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
57736900|NCT02523313|DRUG|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
57736901|NCT01161316|DRUG|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
57736902|NCT01161316|DRUG|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
57736903|NCT00137033|DRUG|Celecoxib|
58429003|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
58429004|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
57736904|NCT00137033|DRUG|Naproxen|
57736905|NCT00137033|DRUG|ASA|
57952941|NCT05618821|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
58429005|NCT05354193|OTHER|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
58429006|NCT00162812|DRUG|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
58429007|NCT06019377|BEHAVIORAL|Stronger Youth Networks and Coping (SYNC)|SYNC is a 10-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
58429008|NCT03450733|DEVICE|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
58429009|NCT03913494|DEVICE|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
58429010|NCT05368168|DEVICE|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
58429011|NCT00968877|DRUG|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
58429012|NCT05458323|DEVICE|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
58429013|NCT00730548|BEHAVIORAL|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
58429014|NCT02607111|DRUG|Dalteparin|
58429015|NCT03679026|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
58429016|NCT02849015|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
58429017|NCT02849015|BIOLOGICAL|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
58429018|NCT02927938|PROCEDURE|Allogeneic HCT|Allogeneic HCT
58429019|NCT02927938|DRUG|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
58429020|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
57736906|NCT02962713|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
57736907|NCT02962713|PROCEDURE|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
58429021|NCT03729245|DRUG|sunitinib|Specified dose on specified days
58429022|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
58100540|NCT00420888|DRUG|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
58100541|NCT00420888|DRUG|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
58100542|NCT04654156|DIAGNOSTIC_TEST|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
58100543|NCT02407756|DRUG|Dupilumab|
58429023|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
58429024|NCT05733078|DRUG|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
58429025|NCT05733078|DRUG|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
58429026|NCT00164515|BEHAVIORAL|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
58429027|NCT01720238|DRUG|Entecavir|0.5mg qd
58429028|NCT01720238|DRUG|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
58429029|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
58129463|NCT04204577|DRUG|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
58429030|NCT00567411|DRUG|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
58429031|NCT00567411|DRUG|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
58429032|NCT02832024|DEVICE|plaque excision system|
58308259|NCT03587233|BEHAVIORAL|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
58308260|NCT03587233|DEVICE|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
58308261|NCT03587233|BEHAVIORAL|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
58308262|NCT03946423|PROCEDURE|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
58308263|NCT03946423|BEHAVIORAL|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
58308264|NCT03496389|DRUG|Gabapentin|Gabapentin 300mg daily
58308265|NCT03496389|DRUG|Tramadol|Tramadol 50mg QID
58308266|NCT03496389|DRUG|Panadol|Panadol 500mg QID
58308267|NCT02865161|DRUG|NISELAT|NISELAT 600MG BD
58308268|NCT04692987|OTHER|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
58308269|NCT00549393|DRUG|2% Chlorhexidine gluconate cloth|Daily bathing
58308270|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
58308271|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
58308272|NCT05185804|DRUG|Dimolegin|60 mg orally, 1 time per day
58308273|NCT05185804|DRUG|Clexane|40 mg subcutaneously, 1 time per day
58308274|NCT00656526|DRUG|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
58308275|NCT00656526|DRUG|Lidocaine|0.5 cc %2 lidocaine,single injection
58429033|NCT02832024|DEVICE|stent|
58429034|NCT02832024|DEVICE|Balloon|
57736908|NCT03377491|DEVICE|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
57736909|NCT03377491|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
58129464|NCT01715038|DIETARY_SUPPLEMENT|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
58100544|NCT00707122|OTHER|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
58308276|NCT00597818|DRUG|Cobiprostone|18 mcg cobiprostone capsules for oral administration
58429035|NCT03689855|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
58429036|NCT03689855|DRUG|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
58429037|NCT03689855|PROCEDURE|Peripheral blood draw|-Baseline and Cycle 2 Day 1
58429038|NCT03689855|PROCEDURE|Biopsy|"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
58429039|NCT01700712|DIETARY_SUPPLEMENT|Probiotic Lactobacilli reuteri|
58429040|NCT01700712|DIETARY_SUPPLEMENT|Placebo|
58429041|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
58429042|NCT06421922|DIETARY_SUPPLEMENT|Group 1 received a regular constipation diet|Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
58429043|NCT06421922|DIETARY_SUPPLEMENT|Group 2 received a constipation diet rich in soluble fiber|Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
58429044|NCT06421922|DIETARY_SUPPLEMENT|Group 3 received a constipation diet supplemented with probiotic yogurt.|"Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks."
58429045|NCT06014099|BEHAVIORAL|Long peripheral venous catheters for blood collection|used LPC for blood collection
58429046|NCT06014099|BEHAVIORAL|Midline catheter for blood collection|used MCs for blood collection
58429047|NCT06014099|BEHAVIORAL|SPCs for blood collection|used SPCs for blood collection
58429048|NCT05169060|DRUG|Fish Oil Concentrate, 1000 Mg Oral Capsule|Oral capsules, 2 grams or 4 grams per day.
58429049|NCT05169060|DRUG|Salsalate Oral Tablet|Oral tablets, 1.5 gram or 3.0 gram per day.
58429050|NCT03275038|BEHAVIORAL|Tai-Chi exercise|Behavioral: Tai-Chi exercise
57736910|NCT03377491|DRUG|nab paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
58308277|NCT00597818|DRUG|Placebo|Matching placebo capsules for oral administration
58308278|NCT00597818|DRUG|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
58308279|NCT00853294|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
58308280|NCT00853294|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
58429051|NCT03275038|BEHAVIORAL|Aerobic exercise|Behavioral: Aerobic exercise
58429052|NCT04086992|OTHER|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
58429053|NCT01496755|DRUG|Placebo|Single/multiple doses
57736911|NCT06167668|OTHER|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
58308281|NCT03265795|DEVICE|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
58429054|NCT01496755|DRUG|RG7667|Single/multiple ascending doses
58429055|NCT06530771|DIAGNOSTIC_TEST|ultrasound|Conventional US, SWE, and AP of thyroid nodules were conducted successively with a Supersonic Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) using a 5-14 MHz linear transducer.
58429056|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
58429057|NCT01439373|DRUG|GSK2336805|Active Investigational Drug
58429058|NCT01439373|DRUG|Pegylated interferon alfa-2a|Standard of Care drug
58429059|NCT01439373|DRUG|Ribavirin|Standard of Care drug
58429060|NCT01439373|DRUG|GSK2336805 Matching Placebo|Placebo of Investigational Drug
58429061|NCT05964543|DRUG|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
58429062|NCT05628909|PROCEDURE|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
58100545|NCT00707122|OTHER|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
58100546|NCT04816162|DRUG|ketofol|prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
58100547|NCT04816162|DRUG|dexmedetomidine|2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
58429063|NCT05628909|PROCEDURE|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
58429064|NCT05628909|PROCEDURE|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
57736912|NCT06167668|OTHER|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
58100548|NCT04816162|OTHER|normal saline|normal saline 0.9% in a syringe pump
58100549|NCT02076230|DRUG|[14C] TH-302 (Label 1)|\[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
58100550|NCT02076230|DRUG|[14C] TH-302 (Label 2)|\[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
58100551|NCT02076230|DRUG|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
58308282|NCT03738930|BEHAVIORAL|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
58308283|NCT00595361|DRUG|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
58308284|NCT02507076|DRUG|isolated limb perfusion|Undergo ILP with melphalan
58308285|NCT02507076|DRUG|melphalan|Undergo ILP with melphalan
58308286|NCT02507076|PROCEDURE|quality-of-life assessment|Ancillary studies
58308287|NCT00571675|DRUG|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
58100552|NCT04075188|DRUG|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
58100553|NCT05105360|PROCEDURE|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
58129465|NCT01715038|DIETARY_SUPPLEMENT|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
58308288|NCT00571675|DRUG|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
58429065|NCT01784718|DRUG|Buphenyl|
58429066|NCT01701934|DRUG|Roflumilast|500 mcg, oral, once daily for 6 months
58429067|NCT01701934|DRUG|Placebo|One placebo pill daily, for 6 months
58429068|NCT05755984|DIAGNOSTIC_TEST|3D printed model|scan
58429069|NCT00448305|DRUG|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
58429070|NCT00448305|DRUG|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
58429071|NCT00448305|DRUG|Paclitaxel|Paclitaxel 90 mg/m² weekly
58429072|NCT01894438|BEHAVIORAL|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
58429073|NCT01894438|BEHAVIORAL|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
58429074|NCT02195167|DRUG|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
58429075|NCT05347303|OTHER|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
58429076|NCT05347303|OTHER|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
58429077|NCT00197925|BIOLOGICAL|Onco-peptide loaded autologous dendritic cells|
58429078|NCT01940627|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
58429079|NCT01940627|DIETARY_SUPPLEMENT|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
58429080|NCT00881465|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
58429081|NCT00881465|BEHAVIORAL|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
58429082|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
58429083|NCT04858282|OTHER|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
58429084|NCT02725866|DRUG|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
58429085|NCT02725866|DRUG|Dasabuvir|Tablet
58429086|NCT02725866|DRUG|Ribavirin|Tablet
58429087|NCT06197763|DRUG|Colesevelam|625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
58429088|NCT06197763|OTHER|Control Arm|No Treatment: baseline assessment only
58429089|NCT06175013|DEVICE|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
57736913|NCT01306773|DRUG|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
57736914|NCT01306773|DRUG|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
58129466|NCT01715038|DIETARY_SUPPLEMENT|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
58429090|NCT06175013|DEVICE|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
57736915|NCT06669728|DIAGNOSTIC_TEST|AI diagnostic algorithm|The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
58429091|NCT03134690|PROCEDURE|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
58429092|NCT03134690|PROCEDURE|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
58429093|NCT06526065|OTHER|no intervention|no intervention
58429094|NCT03083678|DRUG|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
58100554|NCT05105360|PROCEDURE|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
58100555|NCT05924451|BEHAVIORAL|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
58429095|NCT05188131|DRUG|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
58429096|NCT05188131|DRUG|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
58308289|NCT06432387|OTHER|Patients undergoing complex thoraco-abdominal aortic aneurysm repair|Patients undergoing complex thoraco-abdominal aortic aneurysm repair
58308290|NCT03139500|DRUG|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
58308291|NCT03139500|DRUG|Placebo|Participants will receive matching placebo.
58308292|NCT03139500|DRUG|Midazolam|Participants will receive single oral dose of midazolam.
58308293|NCT01958905|DRUG|Artemether-lumefantrine fixed combination|
58308294|NCT01627548|BEHAVIORAL|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
58308295|NCT06023693|BEHAVIORAL|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
58308296|NCT06023693|BEHAVIORAL|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
58429097|NCT03244826|OTHER|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
58429098|NCT03244826|OTHER|Standard Care|The usual care provided by the transplant center at DFCI.
58429099|NCT06143033|OTHER|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
58429100|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
58429101|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
58429102|NCT02706587|DEVICE|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
58429103|NCT02706587|DEVICE|Sham control|No electrostimulation
58429104|NCT02790424|DEVICE|Imaging devices|technological adjustment tests
58429105|NCT05544149|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
58429106|NCT03342625|DEVICE|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
58429107|NCT01769820|DRUG|Dexamethasone|studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
58429108|NCT01769820|DRUG|placebo|
57736916|NCT03722368|BEHAVIORAL|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
58429109|NCT02126839|DRUG|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
58429110|NCT02126839|DRUG|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
58429111|NCT02126839|DRUG|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
58429112|NCT02936284|BEHAVIORAL|Music Enhancement|
58429113|NCT02936284|BEHAVIORAL|Play Date|
58429114|NCT02243891|PROCEDURE|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
58429115|NCT02243891|PROCEDURE|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
58100556|NCT02609178|PROCEDURE|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
58100557|NCT02609178|PROCEDURE|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
58100558|NCT02503566|DEVICE|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
58100559|NCT06232538|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
58100560|NCT03239795|OTHER|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
58100561|NCT02709122|DEVICE|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
58100562|NCT03512626|DEVICE|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
58100563|NCT03512626|DEVICE|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
58100564|NCT00769158|DRUG|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
58429116|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy plus CME|
58429117|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy|
58429118|NCT05122429|BEHAVIORAL|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
58429119|NCT04544683|DRUG|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
58429120|NCT01818063|DRUG|Paclitaxel|Given IV
58429121|NCT01818063|DRUG|Carboplatin|Given IV
58429122|NCT01818063|DRUG|Doxorubicin|Given IV
58429123|NCT01818063|DRUG|Cyclophosphamide|Given IV
58429124|NCT01818063|DRUG|Veliparib|Given PO
58429125|NCT02152774|DRUG|Rho-Kinase Inhibitor|
58429126|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
58429127|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
58429128|NCT05266391|OTHER|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
58429129|NCT05367843|DRUG|PRIME-2-CoV_Beta|Intramuscular (IM) injection
58429130|NCT05050656|DRUG|Duloxetine 60mg|Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
58429131|NCT05050656|DRUG|Placebo|placebo tablets identical to duloxetine tablets
58100565|NCT00769158|OTHER|Placebo|Placebo Comparator
57952942|NCT04091529|DEVICE|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
58429132|NCT01140061|DRUG|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
58429133|NCT01140061|DRUG|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
58429134|NCT01140061|DRUG|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
58429135|NCT01140061|DRUG|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
58429136|NCT01140061|DRUG|Plain patch|Plain patch containing no MK-0873 or placebo
58429137|NCT06334068|OTHER|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
58429138|NCT06334068|OTHER|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
58429139|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
58429140|NCT01066962|DRUG|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
58429141|NCT01066962|DRUG|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
57952943|NCT02821702|DEVICE|Vaginal ultrasound|
57952944|NCT02821702|BIOLOGICAL|Blood sample|
57952945|NCT01040559|DRUG|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
58429142|NCT01846650|DRUG|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
58429143|NCT01846650|DRUG|XELODA|Single oral XELODA 2000mg qd
58429144|NCT04890015|PROCEDURE|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
58429145|NCT05932368|OTHER|evaluation|examining files and taking records
58429146|NCT03907462|BEHAVIORAL|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
58429147|NCT03778385|OTHER|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
58429148|NCT06228690|OTHER|Gold Fish exercises|Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
58429149|NCT06228690|OTHER|Cervico-thoracic postural correction training|"Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening."
58429150|NCT06228690|OTHER|Conventional PT treatment|"Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO."
58429151|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
58429152|NCT05994079|DEVICE|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
58429153|NCT05994079|OTHER|topical firming creams|medical topical firming creams
58429154|NCT06583564|PROCEDURE|ICG lymphangiography procedure|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
58429155|NCT05032339|DIAGNOSTIC_TEST|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
58429156|NCT04872517|DEVICE|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
58429157|NCT00084487|DRUG|becatecarin|Given IV
58429158|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
58429159|NCT01950312|DRUG|gevokizumab|
58429160|NCT02795325|DRUG|DCR-PH1|IV infusion of DCR-PH1
58429161|NCT02795325|OTHER|Placebo|
58429162|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
58429163|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
58429164|NCT03851432|DEVICE|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
58429165|NCT03852095|OTHER|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
58429166|NCT00248716|DRUG|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
58429167|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
57736917|NCT03722368|BEHAVIORAL|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
58100566|NCT03665480|DRUG|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
58100567|NCT03801759|DRUG|Vadadustat|Oral dose 600 mg
58100568|NCT03801759|DRUG|Furosemide|Oral Furosemide
58429168|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
58429169|NCT02351284|OTHER|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
58429170|NCT05011526|BIOLOGICAL|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
58429171|NCT05011526|BIOLOGICAL|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
58429172|NCT05755568|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
58429173|NCT04683120|DIAGNOSTIC_TEST|Zenith FLIM Diagnostics|In-vitro
58429174|NCT00400569|DRUG|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
57736918|NCT03722368|OTHER|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
57736919|NCT04647526|DRUG|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
57736920|NCT04647526|DRUG|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
57736921|NCT04647526|DRUG|Enzalutamide|Enzalutamide (160 mg orally qd)
57736922|NCT00229125|DRUG|Gabapentin|
57736923|NCT00229125|DRUG|Lorazepam|
58100569|NCT03801759|DRUG|Adefovir|Oral Adefovir
58100570|NCT03801759|DRUG|Digoxin|Oral Digoxin
58100571|NCT01672307|DRUG|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
58100572|NCT01672307|DRUG|Placebo|Placebo is applied twice daily to the other eyebrow.
58100573|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
58100574|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
58100575|NCT00053027|BIOLOGICAL|rituximab|
58100576|NCT00053027|DRUG|cladribine|
58429175|NCT01548196|PROCEDURE|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
58429176|NCT00804934|DRUG|Lucentis|0.5mg Lucentis every four months
58429177|NCT01494597|DRUG|isavuconazole|oral
58429178|NCT01494597|DRUG|cyclosporine|oral
58429179|NCT00699335|DRUG|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
58429180|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
58429181|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
58429182|NCT05553184|DRUG|Formoterol Fumarate 12 micrograms Inhalation Powder|At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
58429183|NCT05553184|DRUG|Nicotinic Acid 50 MG Oral Tablet|a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
58100577|NCT05066607|DRUG|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
58100578|NCT05347082|DRUG|Cholecalciferol|Tablets of 4000 IU
58100579|NCT02475967|OTHER|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
58100580|NCT02475967|OTHER|Control group|The control group patients receive conventional cardiac care alone.
57736924|NCT06355986|BEHAVIORAL|Alert-based computerized decision support|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
58100581|NCT00819858|DIETARY_SUPPLEMENT|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
58100582|NCT02307188|DEVICE|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
58429184|NCT05553184|OTHER|Acute Cold Exposure|Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
58429185|NCT05553184|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
58429186|NCT05553184|DIAGNOSTIC_TEST|Indirect calorimetry|will be repeated every hour, for 20 minutes, using Vmax29n.
58429187|NCT05553184|DIAGNOSTIC_TEST|dual-energy x-ray absorptiometry (DEXA scan)|Whole body scan
57736925|NCT01118208|OTHER|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
58100583|NCT04404816|DRUG|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
58308297|NCT05619133|DEVICE|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~1. A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~2. a presence sensor~3. ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
58308298|NCT06160271|DRUG|PET scan of 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
58429188|NCT05553184|PROCEDURE|Biopsy|After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
58429189|NCT05553184|PROCEDURE|iv lines|for stable tracer perfusion and blood sampling
58429190|NCT05553184|PROCEDURE|Electromyogram (EMG)|Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
58429191|NCT02044861|DRUG|PFK-158|IV dose escalation
58429192|NCT05532605|OTHER|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
58429193|NCT05532605|OTHER|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
58429194|NCT05490927|BEHAVIORAL|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
57736926|NCT01118208|OTHER|Dispense as usual|Dispensing prescription medications in standard pill bottles.
58100584|NCT02828228|DRUG|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
58100585|NCT02828228|DRUG|Placebo|placebo once a day for 26 weeks
58100586|NCT00116259|DRUG|Aripiprazole|
58308299|NCT03183908|BIOLOGICAL|FLUAD®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
58308300|NCT03183908|BIOLOGICAL|Fluzone® High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
58308301|NCT01663623|BIOLOGICAL|Placebo|Placebo
58308302|NCT01663623|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
58429195|NCT00783458|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
58429196|NCT00783458|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
58429197|NCT04241302|DIAGNOSTIC_TEST|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
58429198|NCT05963971|BEHAVIORAL|PEDALL|twenty-six hour nutrition education intervention delivered virtually over a six month period
58429199|NCT05963971|OTHER|Standard of care|Nutrition education per institutional standard of care
57736927|NCT02097108|DRUG|Raltegravir|
57952946|NCT01793155|OTHER|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
58100587|NCT02080065|PROCEDURE|living donor liver transplantation|
58100588|NCT05743686|DEVICE|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
58100589|NCT05415826|PROCEDURE|slow-release dexamethasone implant|The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
58100590|NCT05078801|PROCEDURE|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
58100591|NCT05078801|PROCEDURE|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
58308303|NCT01663623|DRUG|Azathioprine|Azathioprine
58308304|NCT00002551|DRUG|fluorouracil|See arm assignments.
58429200|NCT05994833|BEHAVIORAL|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
57736928|NCT05309265|OTHER|Multidisciplinary vocational rehabilitation intervention|"* Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
57736929|NCT03370653|DRUG|Odiparcil|Investigational product: odiparcil 250 mg tablets
57736930|NCT03370653|OTHER|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
58100592|NCT04833452|PROCEDURE|Endoscopic dacryocystorhinostomy|Endoscopic DCR
58100593|NCT00937599|DIETARY_SUPPLEMENT|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
58100594|NCT01403428|OTHER|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
58100595|NCT01517568|DRUG|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
58100596|NCT00289731|BIOLOGICAL|TWINRIX™|Intramuscular injection, 3 doses
58100597|NCT00289731|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
58100598|NCT00289731|BIOLOGICAL|HAVRIX™|Intramuscular injection, 2 doses
58100599|NCT00289731|BIOLOGICAL|HB VAX PRO™|Intramuscular injection, 3 doses
58100600|NCT00289731|BIOLOGICAL|Vaqta™|Intramuscular injection, 2 doses
58100601|NCT05303480|DRUG|Chlormethine|Chlormethine gel 0.016%
58100602|NCT04307030|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
58308305|NCT00002551|DRUG|leucovorin calcium|See arm assignments.
58308306|NCT00002551|DRUG|levamisole hydrochloride|See arm assignments.
58308307|NCT00002551|RADIATION|radiation therapy|See arm assignments.
58308308|NCT04889040|DRUG|RO7496998|275 mg tablets
58308309|NCT04889040|DRUG|Placebo|Matching tablets
58308310|NCT00948545|OTHER|Observational study - there is no intervention|Observational study - there is no intervention
58308311|NCT03056521|OTHER|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
58308312|NCT05063253|DRUG|TG103|TG103 injection, SC, once weekly
58308313|NCT05063253|DRUG|Placebo|Placebo, SC, once weekly
58308314|NCT01227369|OTHER|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
58100603|NCT05241899|DRUG|Fruquintinib + RC48|Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
58100604|NCT05405530|DEVICE|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
58308315|NCT04112732|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
58308316|NCT04112732|OTHER|Placebo|Placebo
58308317|NCT01912976|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
58429201|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
58429202|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
58100605|NCT05405530|DEVICE|regular nasal cannula|Using nasal cannula for oxygenation.
58100606|NCT06515093|OTHER|SanoGraft|single layer amnion amnion-derived allograft
58429203|NCT01242852|PROCEDURE|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
58100607|NCT06515093|OTHER|PelloGraft|dual layer amnion/chorion-derived allograft
58308318|NCT01912976|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
57736931|NCT00314197|BEHAVIORAL|Telephone Linked Care - Behavior Change Counseling System|
57736932|NCT00314197|BEHAVIORAL|Telephone-linked behavioral counseling|
58100608|NCT02026102|BEHAVIORAL|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
58100609|NCT02377284|OTHER|Photograph|Add a photograph to a chef card.
58100610|NCT06336226|PROCEDURE|Brachio basilic arterio venous fistula one stage versus two stage|Comparative study between one stage brachio basilic arterio venous fistula versus two stage
58429204|NCT03931798|DIAGNOSTIC_TEST|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
58429205|NCT02540265|DRUG|N1539|
58429206|NCT02540265|DRUG|Intravenous Placebo|
58458382|NCT04847843|BEHAVIORAL|Control Intervention|The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
58458383|NCT02639494|DEVICE|Self-Centering Guide Catheter|
58308319|NCT05325359|BEHAVIORAL|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
58308320|NCT04134039|DEVICE|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
58308321|NCT04134039|DEVICE|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
58308322|NCT06281561|DRUG|Normal Saline|Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
58308323|NCT06281561|DRUG|Dexmedetomidine|Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
58100611|NCT04416295|DEVICE|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
58100612|NCT04406883|DRUG|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
58100613|NCT02913469|DRUG|Morphine|The patients in group A would be administrated intravenous morphine 5mg
58429207|NCT05623358|OTHER|Pharmacist-led HFrEF medication optimization|In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a clinical pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy (OMT) for HFrEF as outlined by the 2021 Canadian Cardiovascular Society (CCS) HF guidelines. This will consist of, where possible, the combination of an angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) at target doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines, unless the patient is unable to tolerate these agents/doses.
58100614|NCT02913469|DRUG|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
58429208|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. The standard pathway in the HF clinic consists of an initial consultation with the multidisciplinary team (cardiologist, physician trainees, registered nurse and clinical pharmacist), follow-up visits approximately every 3 months with the nurse and cardiologist until discharge, along with telehealth nurse calls for medication titrations.
58100615|NCT02913469|DRUG|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
58308324|NCT05731115|BIOLOGICAL|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
58308325|NCT04744298|OTHER|TheraPPP|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
58308326|NCT05618223|DRUG|Dapagliflozin|Dapagliflozin 10 mg once daily in addition to standard therapy
58308327|NCT02292576|OTHER|Cocoa Pure|Cocoa Pure.
58308328|NCT02292576|OTHER|Placebo|Placebo.
58429209|NCT05199961|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
58429210|NCT01014468|DRUG|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
58429211|NCT01014468|DRUG|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
58429212|NCT00732108|DRUG|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
58429213|NCT00732108|DRUG|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
57952947|NCT01793155|OTHER|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
57952948|NCT05447494|DRUG|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
57952949|NCT05447494|DRUG|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
57952950|NCT02054026|BEHAVIORAL|Reducing the Risk|
58308329|NCT01607164|BEHAVIORAL|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
58308330|NCT04275336|DRUG|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
58429214|NCT05237947|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
58429215|NCT05237947|OTHER|Questionnaire Administration|Ancillary studies
58429216|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
58100616|NCT01653223|DRUG|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
58429217|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
58429218|NCT03230682|DRUG|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
58429219|NCT06104098|DEVICE|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
58429220|NCT04823624|DRUG|MBG453|intravenous infusion
58429221|NCT05104970|DRUG|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
58100617|NCT05137418|BIOLOGICAL|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
58429222|NCT05104970|DIETARY_SUPPLEMENT|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
58429223|NCT05104970|DRUG|Placebo SunnyD insta ampoule|Olive oil
58429224|NCT05104970|DIETARY_SUPPLEMENT|Placebo SunnyD STAT softgel capsule|Olive oil
58429225|NCT03932630|OTHER|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
58429226|NCT03932630|OTHER|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
58100618|NCT00842088|DRUG|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
58100619|NCT00842088|DRUG|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
58100620|NCT04007588|DRUG|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
58100621|NCT04007588|DRUG|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
58100622|NCT04007588|DRUG|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
58100623|NCT02208388|DEVICE|computed tomography perfusion guided treatment|
58100624|NCT02208388|DEVICE|Fractional flow reserve guided treatment|
58100625|NCT02026037|BEHAVIORAL|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
58429227|NCT02514148|BEHAVIORAL|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
58429228|NCT02514148|OTHER|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
58429229|NCT02514148|OTHER|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
58429230|NCT02514148|OTHER|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
58429231|NCT02134730|BEHAVIORAL|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
58129467|NCT01715038|DIETARY_SUPPLEMENT|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
58429232|NCT05551611|OTHER|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
58429233|NCT05551611|OTHER|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
58429234|NCT00741403|DRUG|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
58429235|NCT05989854|BEHAVIORAL|Exercise|8 week exercise intervention, 3x/wk
58429236|NCT04911972|PROCEDURE|Functional muscle transfer|Muscle transfer to restore lower limb function
58429237|NCT01573156|DRUG|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
58429238|NCT06545695|DRUG|Erlotinib|Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
58429239|NCT04351724|DRUG|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
58429240|NCT04351724|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
58429241|NCT04351724|OTHER|Best standard of care|best standard of care
58429242|NCT04351724|DRUG|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
58429243|NCT04351724|DRUG|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
58429244|NCT04351724|DRUG|Candesartan|starting dose 4mg once daily, titrated to normotension
58429245|NCT04351724|DRUG|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
58429246|NCT04351724|DRUG|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
58429247|NCT04351724|DRUG|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
58429248|NCT04351724|DRUG|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
58429249|NCT04351724|DRUG|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
58429250|NCT04351724|DRUG|Pentaglobin|7ml/kg/day for 12h for 5 days
58429251|NCT00151502|DRUG|Atorvastatin|
57736933|NCT05130658|DEVICE|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
58429252|NCT05949489|DIAGNOSTIC_TEST|WOMAC pain subscale|"The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale is a self-reported questionnaire that is used to measure pain in people with osteoarthritis (OA). The subscale consists of five items that ask about the intensity, frequency, and duration of pain in the hip and knee joints.~The WOMAC Pain Subscale has been shown to be a reliable and valid measure of pain in people with OA. It has been used in a number of clinical trials and is considered to be a standard measure of pain in OA.~The WOMAC Pain Subscale is scored on a scale of 0 to 4, with 0 indicating no pain and 4 indicating severe pain. The total score for the subscale is the sum of the scores for the five items. A higher score indicates more pain."
58429253|NCT05862090|DRUG|RLD2301|Take it once a day per period.
58429254|NCT05862090|DRUG|RLD2007|Take it once a day per period.
58129468|NCT00405678|BEHAVIORAL|Exercise Training|Subjects receiving chemo with exercise training
58429255|NCT01369732|DRUG|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
58429256|NCT01369732|DRUG|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
57736934|NCT05130658|OTHER|Treadmill Training|Conventional gait and balance training using treadmill.
58129469|NCT00405678|BEHAVIORAL|Chemo only|Subjects receiving chemo only
58429257|NCT03974373|PROCEDURE|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
58429258|NCT03645512|BEHAVIORAL|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
58429259|NCT00148941|BIOLOGICAL|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
58429260|NCT00148941|BIOLOGICAL|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
58429261|NCT00148941|BIOLOGICAL|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
58429262|NCT00148941|BIOLOGICAL|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
57736935|NCT04647149|BEHAVIORAL|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
58429263|NCT00148941|BIOLOGICAL|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
58429264|NCT00148941|BIOLOGICAL|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
57736936|NCT05477602|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
57736937|NCT05710601|PROCEDURE|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
58429265|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
58429266|NCT04235712|OTHER|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
58429267|NCT04855019|PROCEDURE|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
58129470|NCT00048048|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
58429268|NCT04291768|OTHER|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
58429269|NCT04291768|OTHER|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
58429270|NCT00376896|DRUG|GW876008 200mcg|GW876008
58429271|NCT00376896|DRUG|GW876008 20mcg|GW876008 20mcg
58429272|NCT00376896|OTHER|Placebo|placebo
57736938|NCT01736813|DRUG|Maraviroc|Twelve patients with 300 mg/bid
58308331|NCT04275336|BEHAVIORAL|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
58429273|NCT02177474|BEHAVIORAL|Telephone based peer support|
57736939|NCT05142267|DRUG|Placebo|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
58100626|NCT05436301|OTHER|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
58100627|NCT04252040|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
58308332|NCT04275336|OTHER|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
58308333|NCT00559260|DEVICE|Passive monitoring with pulse-oximetry, NIBP and ECG|
58308334|NCT02417025|BEHAVIORAL|PE|Prolonged Exposure
58429274|NCT03539575|OTHER|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
58429275|NCT05339230|DIETARY_SUPPLEMENT|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
58429276|NCT01990859|BIOLOGICAL|Ipilimumab|
58429277|NCT00003552|DRUG|allogeneic lymphocytes|
58429278|NCT00003552|DRUG|anti-thymocyte globulin|
58429279|NCT00003552|DRUG|cyclophosphamide|
58429280|NCT00003552|DRUG|fludarabine|
58429281|NCT03667690|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
58429282|NCT03667690|DRUG|Caspofungin|Intravenous antifungal therapy
58429283|NCT03667690|DRUG|Fluconazole|Oral antifungal therapy
58429284|NCT03667690|DRUG|intravenous placebo|Normal saline
58429285|NCT03667690|DRUG|oral placebo|Microcrystalline cellulose
58429286|NCT00387036|DRUG|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
58429287|NCT00387036|DRUG|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
58429288|NCT05595772|DRUG|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
58429289|NCT05595772|DRUG|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
58429290|NCT05595772|PROCEDURE|Surgery: Dental Implant surgery|Immediate implant following extraction
58429291|NCT05595772|PROCEDURE|Tooth extraction|A Traumatic tooth extraction
58429292|NCT05595772|PROCEDURE|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
58308335|NCT03541993|DIETARY_SUPPLEMENT|Resveratrol|
58429293|NCT03665116|DIETARY_SUPPLEMENT|L-arginine|L-arginine capsule
58429294|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
58429295|NCT00386165|DRUG|larazotide acetate|larazotide acetate 4 mg capsules
58429296|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
58429297|NCT03147534|DEVICE|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
58429298|NCT03147534|DEVICE|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
58308336|NCT03541993|OTHER|Placebo|
58308337|NCT05827848|DEVICE|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
58308338|NCT02719977|DRUG|CX5461|
58308339|NCT00003837|DRUG|nelarabine|
58308340|NCT04435496|DEVICE|GYN-CS|placement of the GYN-CS device
58308341|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
58308342|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
58308343|NCT00251758|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
58308344|NCT02944175|DRUG|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
58429299|NCT03147534|DEVICE|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
58429300|NCT03147534|DEVICE|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
58429301|NCT03574402|DRUG|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
58100628|NCT06539091|DRUG|Fluzoparib|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
58100629|NCT06539091|DRUG|Apatinib Mesylate|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
58100630|NCT06540599|DRUG|Analgesic|comparing the effectiveness of analgesics in endometrial biopsy
58100631|NCT00584896|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
58100632|NCT00255476|DRUG|gefitinib|
57952951|NCT00549458|BEHAVIORAL|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
58100633|NCT00255476|DRUG|cisplatin|
58100634|NCT00255476|DRUG|5-flourouracil|
58100635|NCT00921804|DRUG|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
58100636|NCT00921804|DRUG|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
58100637|NCT00921804|DRUG|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
58100638|NCT00921804|DRUG|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
58100639|NCT03079674|OTHER|observational only- no intervention|observational only- no intervention
58100640|NCT01598415|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
58100641|NCT01598415|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
58100642|NCT06358807|PROCEDURE|Arthroscopic microfracture with intraoperative local PRP gel injection|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
58100643|NCT06358807|PROCEDURE|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
58100644|NCT04992481|PROCEDURE|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
58100645|NCT04992481|PROCEDURE|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
58100646|NCT04992481|PROCEDURE|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
58100647|NCT04992481|PROCEDURE|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
58100648|NCT05151796|DRUG|Aspirin|Daily aspirin intake for cardiovascular prevention
58100649|NCT05384197|DRUG|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
58308345|NCT02944175|DRUG|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
57952952|NCT00549458|PROCEDURE|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
58100650|NCT05384197|DRUG|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
58100651|NCT01041937|PROCEDURE|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
58429302|NCT03574402|DRUG|Afatinib|40mg orally once a day, 28 days as one cycle.
58100652|NCT01041937|PROCEDURE|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
58100653|NCT01898858|DEVICE|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
58429303|NCT03574402|DRUG|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
58429304|NCT03574402|DRUG|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
58429305|NCT03574402|DRUG|Chidamide|30mg orally twice weekly, 28 days as one cycle.
58429306|NCT03574402|DRUG|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
58429307|NCT03574402|DRUG|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
58429308|NCT03574402|DRUG|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
57736940|NCT05142267|DRUG|Oxycodone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
57952953|NCT01854619|DEVICE|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
57952954|NCT01854619|DEVICE|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
57952955|NCT05461911|DIETARY_SUPPLEMENT|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
57952956|NCT02872766|DEVICE|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
57952957|NCT00482430|DRUG|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
57952958|NCT00482430|DRUG|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
57952959|NCT02613390|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
57952960|NCT02613390|BEHAVIORAL|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
57952961|NCT01358409|DRUG|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
58429309|NCT03574402|DRUG|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
58429310|NCT03574402|DRUG|Pemetrexed|500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
58429311|NCT03574402|DRUG|Cisplatin|75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
58429312|NCT03574402|DRUG|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
58429313|NCT03574402|DRUG|Gemcitabine|1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
58429314|NCT03574402|DRUG|Gemcitabine|1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
58429315|NCT03574402|DRUG|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
58429316|NCT03461094|DEVICE|Preload assessment and volume expansion|Fluid therapy perform
58100654|NCT01898858|DEVICE|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
58100655|NCT01898858|DEVICE|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
58100656|NCT05349032|DIETARY_SUPPLEMENT|Curcumin|Oral supplement
58100657|NCT00695981|PROCEDURE|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
58100658|NCT00695981|PROCEDURE|Conservative treatment|Physiotherapy according to a standardized protocol
58100659|NCT00837577|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
58100660|NCT00837577|DRUG|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
58100661|NCT00837577|DRUG|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
58100662|NCT02516878|PROCEDURE|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
58100663|NCT04149054|BEHAVIORAL|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
58100664|NCT05069428|DRUG|Ramelteon 8mg|administered crushed, orally at 20:30
58100665|NCT05037942|OTHER|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
58100666|NCT05037942|OTHER|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
58100667|NCT03971669|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
58100668|NCT01891786|BEHAVIORAL|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
58100669|NCT01891786|BEHAVIORAL|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
58100670|NCT00368914|DRUG|sirolimus|
58429317|NCT04407234|DRUG|Tirzepatide|Tirzepatide administered SC.
58429318|NCT04407234|DRUG|Acetaminophen|Acetaminophen administered orally.
58429319|NCT00470418|DRUG|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
58429320|NCT00470418|DRUG|Placebo|placebo comparator
58100671|NCT00368914|OTHER|laboratory biomarker analysis|
58100672|NCT00368914|OTHER|pharmacological study|
58429321|NCT01810315|DRUG|TFV 1% gel|
58429322|NCT01810315|DRUG|Estradiol vaginal cream|
58100673|NCT00368914|PROCEDURE|biopsy|
58100674|NCT03202186|DRUG|Progesterone oral capsule|Oral capsule treatment
58100675|NCT03202186|DRUG|Placebo oral capsule|Oral capsule treatment
58429323|NCT00136669|PROCEDURE|Acupuncture|
58429324|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
58429325|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
58429326|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
58429327|NCT00652080|DRUG|API 31510|Topical Cream; 3% active; AM \& PM application
58429328|NCT05271448|OTHER|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
58429329|NCT05271448|OTHER|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
58429330|NCT02722265|DRUG|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
58429331|NCT00330681|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
58100676|NCT05440084|PROCEDURE|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
58100677|NCT01739088|OTHER|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
58100678|NCT01739088|OTHER|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
58100679|NCT05292430|OTHER|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
58100680|NCT00297206|DRUG|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
58100681|NCT00123058|BEHAVIORAL|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
58100682|NCT00123058|DEVICE|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
58100683|NCT05355987|OTHER|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
58429332|NCT00330681|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
58429333|NCT00941122|DEVICE|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
58429334|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
58308346|NCT01670864|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
58308347|NCT01670864|BEHAVIORAL|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
58429335|NCT00915291|OTHER|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
58429336|NCT00196508|DEVICE|High Viscosity DERMABOND|
58308348|NCT06188117|OTHER|'Digital Game Addiction Awareness Training'|"Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'."
58429337|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
58429338|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
58308349|NCT00853762|DRUG|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
58308350|NCT00853762|DRUG|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
58308351|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
58308352|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
58308353|NCT00117390|PROCEDURE|Measurement of inulin clearance|
58308354|NCT04801095|DRUG|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
58100684|NCT05355987|OTHER|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
58100685|NCT05264766|DEVICE|Cooling helmet on|Cooling helmet with circulating cold water
58100686|NCT05264766|DEVICE|Cooling helmet off|Cooling helmet without circulating cold water
58100687|NCT02623309|BIOLOGICAL|Allogeneic (Allo) hematopoietic stem cell transplantation|
58100688|NCT04734431|BIOLOGICAL|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
58100689|NCT00743119|DRUG|Placebo capsules|Placebo capsules
58100690|NCT00743119|DRUG|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
58100691|NCT00743119|DRUG|Low dose Dronabinol|Dronabinol 10mg
58100692|NCT00743119|DRUG|High dose Dronabinol|Dronabinol 20mg
58100693|NCT00743119|DRUG|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
58100694|NCT00743119|DRUG|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
58100695|NCT01743768|DRUG|SB010|Treatment group (n=19), receiving the active drug substance.
58100696|NCT01743768|DRUG|Placebo|Treatment group (n=19), receiving placebo.
58100697|NCT00276965|DRUG|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
58100698|NCT00276965|DRUG|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
58100699|NCT02336698|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
58100700|NCT02336698|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
58100701|NCT02336698|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
58100702|NCT00291330|DRUG|dabigatran etexilate 150 mg|twice daily
58100703|NCT00291330|DRUG|warfarin (INR 2-3)|prn to maintain INR (2-3)
58100704|NCT01200316|PROCEDURE|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
58100705|NCT01200316|PROCEDURE|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
58308355|NCT06330415|OTHER|The SME tool|The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
58308356|NCT03532737|DRUG|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
58429339|NCT05501743|DRUG|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
57952962|NCT00473707|PROCEDURE|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
58100706|NCT01200316|BEHAVIORAL|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
58308357|NCT01149941|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
58100707|NCT00172094|DRUG|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
58100708|NCT00172094|DRUG|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
58100709|NCT00172094|DRUG|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
58100710|NCT01594580|OTHER|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
58100711|NCT01594580|OTHER|Non-impregnated scrubs|
58100712|NCT04144387|PROCEDURE|Myelogram|Two additional myelograms will be performed comparing to standard of care.
58100713|NCT03185299|OTHER|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
58100714|NCT03185299|OTHER|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
58100715|NCT01382901|DRUG|Ferric Carboxymaltose (FCM)|
58100716|NCT01382901|DRUG|Placebo|
58100717|NCT01339884|DRUG|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
58308358|NCT02955875|BEHAVIORAL|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
58308359|NCT02924935|DIETARY_SUPPLEMENT|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
58308360|NCT01505920|PROCEDURE|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
58308361|NCT01505920|PROCEDURE|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
58308362|NCT06551896|DRUG|Pemigatinib|Pemigatinib and immune checkpoint inhibitors
58308363|NCT01244464|BIOLOGICAL|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
58308364|NCT00623610|PROCEDURE|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
58100718|NCT02632383|DEVICE|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder"
58100719|NCT04620863|OTHER|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
58100720|NCT04620863|OTHER|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
58100721|NCT03896919|DIAGNOSTIC_TEST|HLA-DQ by luminex technology in kidney transplantation|HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
58100722|NCT03412461|OTHER|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
58429340|NCT05501743|PROCEDURE|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
58429341|NCT06315738|BIOLOGICAL|ST266|Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
58429342|NCT03665688|DEVICE|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.
57736941|NCT05142267|DRUG|Naloxone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
57952963|NCT00473707|PROCEDURE|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
58100723|NCT03412461|OTHER|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
58100724|NCT01890694|DRUG|Tolvaptan|15 mg once daily
58100725|NCT01890694|DRUG|Placebo|15 mg once daily
58100726|NCT01890694|BEHAVIORAL|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
58100727|NCT01890694|BEHAVIORAL|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
58100728|NCT01890694|BIOLOGICAL|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
58100729|NCT01890694|BIOLOGICAL|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
57736942|NCT05815524|OTHER|Physical activity training|training on treadmill
57736943|NCT05328401|DEVICE|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
58100730|NCT01890694|PROCEDURE|Ascites Evaluation|Ascites will be assessed at every visit.
57952964|NCT00473707|DRUG|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
57952965|NCT00473707|DRUG|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
58308365|NCT02989974|BEHAVIORAL|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
58308366|NCT01078038|DEVICE|Cypher|Sirolimus-eluting stent implantation
58308367|NCT01078038|DEVICE|Xience V|Everolimus-eluting Stent implantation
58308368|NCT02430558|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
58429343|NCT03665688|DEVICE|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
58429344|NCT02081599|DRUG|Teneli (Teneligliptin)|
58429345|NCT02081599|DRUG|Placebo|
58429346|NCT02081599|DRUG|Insulin|
57736944|NCT05328401|DEVICE|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
57952966|NCT05782621|OTHER|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
58100731|NCT01890694|PROCEDURE|Edema|Edema will be assessed at every visit.
58308369|NCT05482802|BEHAVIORAL|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
58308370|NCT05482802|BEHAVIORAL|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
58308371|NCT01718483|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
58308372|NCT01718483|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
58308373|NCT03261999|DRUG|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
58308374|NCT04818099|DRUG|Vortioxetine 10 mg|Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
58308375|NCT04818099|OTHER|Placebo|Placebo will be used with a dosage of one tablet once a day for 2 months.
58308376|NCT06200012|BEHAVIORAL|Multi-level stigma reduction intervention: educational training plus controlled substance agreement policy change|Pairing a professional training targeting known attitudinal and knowledge drivers of substance use stigma with a policy altering potentially stigmatizing features of controlled substance agreements.
58308377|NCT06200012|BEHAVIORAL|Single-level stigma reduction intervention: educational training|A professional training targeting known attitudinal and knowledge drivers of substance use stigma
58308378|NCT06515288|BEHAVIORAL|Nutrition Goes To School (NGTS) Program Intervention Package|"The NGTS Program intervention package in this project consists of four components:~1. A comprehensive Nutrition Education to improve healthy eating, physical activity, and hygiene-sanitation practices.~   This is a weekly interactive and fun nutrition and health promotion with different kinds of activities.~2. Healthy School Canteen to improve the availability of healthy food in school. This is an effort to strengthen the school canteen referring to the 4 Pillars of a Healthy School Canteen, including School Commitment and Management, Human Resources, Facilities and Infrastructure, and Food Quality.~3. School Garden. This is a gardening activity as a form of school garden as a media for nutrition education, character building, and contribute to supply vegetables during cooking class sessions in school.~4. Entrepreneurship nutrition. Entrepreneurship nutrition aims to foster entrepreneurial potential and skills among school members in providing healthy food at school."
58429347|NCT00082381|DRUG|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
58429348|NCT00082381|DRUG|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
58429349|NCT01257022|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
58100732|NCT02284373|OTHER|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
58100733|NCT02284373|OTHER|Routine wound care for venous ulcers and lymphedema|wound care /dressings
58100734|NCT02284373|DEVICE|Flexitouch pneumonic compression|pneumonic compression only
58308379|NCT06515288|BEHAVIORAL|Nutrition Education Capacity Building for Teachers and Management|The intervention schools will receive Nutrition Education Capacity Building for Teachers and School Management, before the above four NGTS components is implemented in the respective school. Three representatives from each school will be invited to attend a 5-day training that include knowledge on adolescent nutrition and health issues, as well as skills in implementing the NGTS Program.
58429350|NCT05564806|DRUG|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
58308380|NCT00047762|DRUG|Erlotinib (aka Tarceva or OSI-774)|
58308381|NCT00047762|DRUG|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
58429351|NCT03665311|BIOLOGICAL|25% Albumin fluid|25% Albumin fluid (100 mL)
58429352|NCT03665311|OTHER|Normal Saline|0.9% Normal Saline (100 mL)
58429353|NCT03884647|DEVICE|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
58429354|NCT01497782|OTHER|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
58429355|NCT04741672|BEHAVIORAL|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
58429356|NCT04741672|BEHAVIORAL|Discharge routine procedure.|Discharge routine procedure.
58429357|NCT00980759|RADIATION|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
58429358|NCT00980759|RADIATION|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
58429359|NCT04739878|PROCEDURE|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
58429360|NCT00223704|DRUG|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
58429361|NCT00223704|DRUG|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
58429362|NCT00223704|DRUG|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
58429363|NCT04792684|DIAGNOSTIC_TEST|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
58429364|NCT06583772|DIAGNOSTIC_TEST|VR-based 9-hole peg test|The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
58429365|NCT02597140|DRUG|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
58429366|NCT02597140|DRUG|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
58429367|NCT02597140|DRUG|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
58429368|NCT01898013|DRUG|Pregnenolone|
58429369|NCT01898013|DRUG|Placebo|
58429370|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
58429371|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
58429372|NCT00237263|DRUG|Entacapone|
58100735|NCT02379676|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
58100736|NCT02379676|DRUG|Clopidogrel|Clopidogrel 75mg once daily for 30 days
58100737|NCT00572247|BEHAVIORAL|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
58100738|NCT06390358|OTHER|Tefillin|Wrapping of arm
58100739|NCT03386669|DRUG|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
58100740|NCT01399424|DRUG|CP|Immunization
58100741|NCT06538233|DRUG|Buffered articaine|Injecting buffered articaine in maxillary anterior region and evaluate pain response.
58100742|NCT06538233|DRUG|Non buffered articaine|Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
58308382|NCT00622765|DRUG|placebo|Placebo capsule twice daily
58308383|NCT00622765|DRUG|R256918|5 mg capsule twice daily
58308384|NCT00622765|DRUG|R256918|10 mg capsule twice daily
58308385|NCT00622765|DRUG|R256918|15 mg capsule twice daily
58308386|NCT06000644|DEVICE|Combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.
58308387|NCT06000644|DEVICE|Cognitive group|The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .
58100743|NCT05268965|BEHAVIORAL|Experimental: group comparison|"* Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality"
58429373|NCT03517566|DRUG|Placebo|once daily from baseline until week 16
58429374|NCT03517566|DRUG|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
58429375|NCT03517566|DRUG|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
58429376|NCT03517566|DRUG|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
58100744|NCT00660049|DEVICE|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
58100745|NCT00660049|OTHER|SNaP|Daily use
58100746|NCT00660049|OTHER|SNaP|Daily application per protocol
58100747|NCT02329496|DEVICE|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
58100748|NCT05763277|DIAGNOSTIC_TEST|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
58100749|NCT02735226|OTHER|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
58100750|NCT05951231|PROCEDURE|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
58100751|NCT00789568|DRUG|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
58429377|NCT03517566|DRUG|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
58100752|NCT00789568|DRUG|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
58100753|NCT00789568|DRUG|Moxifloxacin placebo|Moxifloxacin placebo tablet
58429378|NCT04809350|DIETARY_SUPPLEMENT|Adjustable Human Milk Fortification|"BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.~Liquid protein will be added based on serum urea."
58429379|NCT04809350|DIETARY_SUPPLEMENT|Targeted Human Milk Fortification|"Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.~Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes."
58429380|NCT04283591|PROCEDURE|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
57952967|NCT05782621|OTHER|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
57952968|NCT05782621|OTHER|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
58100754|NCT03840642|BEHAVIORAL|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
58308388|NCT06000644|DEVICE|Rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
58308389|NCT06000644|DEVICE|Treadmill group|The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
57952969|NCT03045562|DRUG|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
58429381|NCT04283591|OTHER|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
58429382|NCT05930236|DIAGNOSTIC_TEST|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
58429383|NCT05930236|DRUG|Lidocain|Linisol infiltration with depomedrol and omnipaque
58429384|NCT05930236|DRUG|Methylprednisolone|infiltration with linisol and omnipaque
58429385|NCT05930236|DRUG|Omnipaque|infiltration with linisol and methylprednisolone
58429386|NCT03815565|PROCEDURE|continuous femoral block|infusion of anesthetic by PCA pump
58100755|NCT03840642|BEHAVIORAL|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
58429387|NCT05443711|OTHER|No intervention, observational study|No intervention, observational study
58429388|NCT00218972|BEHAVIORAL|Aerobic interval training|
58100756|NCT03560115|DIAGNOSTIC_TEST|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
58429389|NCT00218972|BEHAVIORAL|moderate intensity training|
58429390|NCT00218972|BEHAVIORAL|Recommendation of regular exercise|
58429391|NCT00945932|DRUG|GW870086X|Investigational product
58100757|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy with a radiologist's guidance with map|All patients will undergo prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after mapping extracted by a single genitourinary radiologist in the Department of Radiology of our hospital.
58100758|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy without a radiologist's guidance with map|All patients will undergo cognitive prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after reported by a single genitourinary radiologist in the Department of Radiology of our hospital.
58100759|NCT01124526|DRUG|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
58100760|NCT02236364|DEVICE|Contour, Bayer Healthcare, LLC|Blood glucose measurement
57952970|NCT03045562|DRUG|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
57952971|NCT03775421|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
58100761|NCT06564610|PROCEDURE|Transversus abdominis block|The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
58100762|NCT06564610|PROCEDURE|Erector spinae block|The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
58100763|NCT06564610|PROCEDURE|Bariatric surgery|Laparoscopic bariatric procedure will be performed
58429392|NCT00945932|DRUG|Placebo|Placebo control
57952972|NCT02390011|PROCEDURE|MRI|
57952973|NCT00665457|BIOLOGICAL|filgrastim|
57952974|NCT00665457|DRUG|capecitabine|
57952975|NCT00665457|DRUG|celecoxib|
57952976|NCT00665457|DRUG|cyclophosphamide|
57952977|NCT00665457|DRUG|docetaxel|
57952978|NCT00665457|DRUG|doxorubicin hydrochloride|
57952979|NCT00665457|GENETIC|gene expression analysis|
57952980|NCT00665457|GENETIC|polymorphism analysis|
57952981|NCT00665457|GENETIC|protein expression analysis|
58100764|NCT06564610|DEVICE|Endotracheal intubation|An endotracheal tube will be inserted as a part of general anesthesia to all patients
58429393|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
57952982|NCT00665457|GENETIC|reverse transcriptase-polymerase chain reaction|
57952983|NCT00665457|OTHER|imaging biomarker analysis|
57952984|NCT00665457|OTHER|immunohistochemistry staining method|
57952985|NCT00665457|OTHER|laboratory biomarker analysis|
57952986|NCT00665457|OTHER|pharmacogenomic studies|
58100765|NCT06564610|DRUG|Propofol|The patients will receive propofol for induction of anesthesia
58100766|NCT02923115|DRUG|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
58100767|NCT02923115|DRUG|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
58100768|NCT02923115|DRUG|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
57952987|NCT00665457|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
57952988|NCT00665457|PROCEDURE|needle biopsy|
57952989|NCT00665457|PROCEDURE|neoadjuvant therapy|
57952990|NCT00665457|PROCEDURE|radiomammography|
57952991|NCT00665457|PROCEDURE|ultrasound imaging|
57952992|NCT04220957|OTHER|Digital Impression Technique|Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
57952993|NCT04220957|OTHER|Conventional Impression Technique|Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
57952994|NCT00562588|DRUG|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
57952995|NCT00562588|DRUG|ASA 100 mg qd|
57952996|NCT04036968|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
57952997|NCT06155370|OTHER|construction of organoids from gynecological tumor|organoids construction
57952998|NCT03976011|DEVICE|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
57952999|NCT04716790|PROCEDURE|Ultrasound Debridement|Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
58100769|NCT02637609|OTHER|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
58429394|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
57736945|NCT04939129|DIAGNOSTIC_TEST|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
57736946|NCT05994235|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
57736947|NCT05994235|DRUG|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
57953000|NCT04716790|PROCEDURE|Conventional Treatment|Conventional Treatment based on international guidelines for diabetic foot
57953001|NCT05517642|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
58100770|NCT02637609|OTHER|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
58100771|NCT06303882|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
58308390|NCT04291040|BEHAVIORAL|Decision Aid|Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
58429395|NCT03459456|BEHAVIORAL|Provocation OC task (Provoc)|used to evoke OC-related distress
58429396|NCT03459456|BEHAVIORAL|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
58429397|NCT03459456|BEHAVIORAL|Exposure provocation task|used to elicit overt OCD rituals
58429398|NCT01320592|DRUG|PD0332991|
58429399|NCT01320592|DRUG|Paclitaxel|
57736948|NCT06669949|OTHER|no intervention|No interventions are involved in this observational study.
57736949|NCT03228511|DEVICE|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
57736950|NCT02999165|OTHER|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
57736951|NCT02999165|OTHER|Nasogastric feeding|The control intervention is feeding via nasogastric tube
57736952|NCT02125175|RADIATION|Hypofractionated IMRT boost Radiotherapy|
57953002|NCT05517642|BIOLOGICAL|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
57953003|NCT00301951|BIOLOGICAL|anti-thymocyte globulin|
57953004|NCT00301951|BIOLOGICAL|sargramostim|
57953005|NCT00301951|DRUG|busulfan|
57953006|NCT00301951|DRUG|fludarabine phosphate|
57953007|NCT00301951|DRUG|mycophenolate mofetil|
57953008|NCT00301951|DRUG|tacrolimus|
57953009|NCT00301951|PROCEDURE|umbilical cord blood transplantation|
58100772|NCT06303882|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
58429400|NCT06284733|DEVICE|Whole-body vibration plus conservative care|Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.
58429401|NCT06284733|OTHER|conservative care|"1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care."
58429402|NCT05325385|OTHER|There are no interventions - this is a database study only|There are no interventions - this is a database study only
58429403|NCT03317119|OTHER|Laboratory Biomarker Analysis|Correlative studies
58429404|NCT03317119|DRUG|Trametinib|Given PO
57736953|NCT04083248|BEHAVIORAL|Feasibility group|Same as arm description
57736954|NCT05949762|PROCEDURE|Venetoclax in Combination With Azacitidine and HA Regimen|"Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
58100773|NCT06303882|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
58429405|NCT03317119|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
58429406|NCT05371548|DEVICE|SAM mobile application|See description of intervention group
58429407|NCT01726985|OTHER|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge"
58429408|NCT01219062|DRUG|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
58429409|NCT01219062|OTHER|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
58429410|NCT01219062|DRUG|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
58429411|NCT01626417|DEVICE|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
58429412|NCT00606983|DRUG|Tamsulosin|oral administration of Tamsulosin
58429413|NCT03837132|BEHAVIORAL|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
57736955|NCT04827511|OTHER|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
57736956|NCT00679939|DRUG|Rosiglitazone|up to 8mg/day
57736957|NCT00679939|DRUG|Metformin|up to 2000mg/day
58429414|NCT02578173|DEVICE|AVERT PLUS|
58429415|NCT04545463|DIETARY_SUPPLEMENT|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
58100774|NCT04591600|DRUG|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
58308391|NCT04291040|BEHAVIORAL|Routine Care|The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
58429416|NCT04545463|DIETARY_SUPPLEMENT|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
58429417|NCT04545463|DIETARY_SUPPLEMENT|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
57736958|NCT01158131|BEHAVIORAL|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
57736959|NCT04195009|PROCEDURE|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
57736960|NCT02754648|PROCEDURE|laparoscopic ovarian endometriotic cyst|
57736961|NCT03947918|BEHAVIORAL|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
57736962|NCT03947918|BEHAVIORAL|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
57736963|NCT01381692|DRUG|Bortezomib|Given IV or SC
57736964|NCT01381692|DRUG|Dexamethasone|Given PO
58100775|NCT04591600|DRUG|Standard of care|"Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
58100776|NCT02394431|OTHER|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
58100777|NCT02394431|OTHER|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
58100778|NCT02394431|OTHER|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
58100779|NCT00179374|BEHAVIORAL|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
58100780|NCT00179374|BEHAVIORAL|Print educational intervention|diabetes educational materials by mail
58429418|NCT02708485|OTHER|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
57736965|NCT01381692|OTHER|Laboratory Biomarker Analysis|Correlative studies
57736966|NCT01381692|OTHER|Quality-of-Life Assessment|Ancillary studies
57736967|NCT01381692|BIOLOGICAL|Rituximab|Given IV
58100781|NCT02953132|DRUG|MT-4129|
58100782|NCT02953132|DRUG|Placebo|
57736968|NCT01381692|DRUG|Temsirolimus|Given IV
57736969|NCT05626400|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
57736970|NCT06651515|BIOLOGICAL|Allogeneic Pancreatic Endocrine Cell Clusters|Allogeneic Pancreatic Endocrine Cell Clusters
57736971|NCT05991752|DIAGNOSTIC_TEST|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
57736972|NCT00791024|DRUG|CRC-Pharma 001|50 mg
57736973|NCT00791024|DRUG|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
57736974|NCT02564523|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
57736975|NCT02564523|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units)
57736976|NCT02564523|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline
58100783|NCT00552227|DRUG|ruboxistaurin|oral 32 mg daily
58100784|NCT00552227|OTHER|placebo|placebo
57736977|NCT03886103|DRUG|14C labeled PXL770|Single administration
57736978|NCT06213766|DIAGNOSTIC_TEST|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
57736979|NCT06213766|OTHER|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities."
58100785|NCT00291512|BEHAVIORAL|Theory-based counseling program|
58100786|NCT04349826|DRUG|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
58100787|NCT04349826|DRUG|Cefixime|cefixime 20-30 mg/kg/day for 7 days
58100788|NCT04349826|DRUG|Placebo|cefixime-matched placebo for 7 days
58100789|NCT03967106|OTHER|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
58100790|NCT03967106|OTHER|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
58100791|NCT04529499|DRUG|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
58100792|NCT04529499|DRUG|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
58100793|NCT00221572|PROCEDURE|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
58100794|NCT02374931|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
58100795|NCT02374931|PROCEDURE|Positron Emission Tomography|Undergo 18F-FES PET/CT
58100796|NCT02374931|PROCEDURE|Computed Tomography|Undergo 18F-FES PET/CT
58100797|NCT02374931|OTHER|Laboratory Biomarker Analysis|Correlative studies
58100798|NCT01225237|DRUG|Ramosetron|oral
58429419|NCT03437824|DRUG|Cyanocobalamin|1,000 mg, Once
58429420|NCT03437824|DRUG|Placebo|0.9% Sodium Chloride, Once
58429421|NCT04878952|OTHER|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
58100799|NCT01225237|DRUG|Placebo|oral
58429422|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
58429423|NCT02950376|OTHER|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
58429424|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
57953010|NCT05430035|DRUG|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
57953011|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
57953012|NCT00631371|DRUG|Temsirolimus|Temsirolimus 25 mg IV weekly
57953013|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
57953014|NCT00631371|DRUG|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
57953015|NCT03894930|BEHAVIORAL|Metta meditation|Administered 5 days per week for 8 weeks.
57953016|NCT00205855|DEVICE|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
57953017|NCT03283189|OTHER|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
57953018|NCT02312635|DRUG|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
57953019|NCT02312635|BEHAVIORAL|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
57953020|NCT02806297|PROCEDURE|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
57953021|NCT02806297|PROCEDURE|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
57953022|NCT00599040|BEHAVIORAL|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
57953023|NCT00599040|BEHAVIORAL|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
57953024|NCT00599040|BEHAVIORAL|Dairy diet|participants are given a high dairy, reduced calorie diet
57953025|NCT02586675|DRUG|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
57953026|NCT02586675|DRUG|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
57953027|NCT02586675|DRUG|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
57953028|NCT05468268|DEVICE|20 Hz rTMS|rTMS stimulation
57953029|NCT05468268|DEVICE|Sham rTMS|Sham stimulation
57953030|NCT04791774|DIETARY_SUPPLEMENT|Milk protein (food grade protein)|Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
58100800|NCT04981405|BIOLOGICAL|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
58100801|NCT03355807|DRUG|Magnesium|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4
58100802|NCT00712660|DRUG|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
58100803|NCT00712660|OTHER|no intervention|Treatment as usual
58100804|NCT06016101|OTHER|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~* Pill counting~* Morisky questionnaire"
58100805|NCT06016101|OTHER|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~* Evaluation of user experience~* Evaluation of the report produced by the application"
58100806|NCT04385264|DRUG|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
58429425|NCT05359601|PROCEDURE|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
58429426|NCT03221361|DEVICE|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
58429427|NCT03221361|DEVICE|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
58429428|NCT02643342|DEVICE|Orthokeratology|
58429429|NCT03228212|DEVICE|CONTROL|ACUVUE OASYS
58429430|NCT03228212|DEVICE|TEST|senofilcon A with new UV blocker
58429431|NCT01008085|DEVICE|Stentys coronary stent|Self-expanding Nitinol stent
58429432|NCT01008085|DEVICE|Balloon-expandable stent|VISION/Driver
57953031|NCT04791774|DIETARY_SUPPLEMENT|Fee amino acids (food grade amino acids)|Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
57953032|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
57953033|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
57953034|NCT01314677|PROCEDURE|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
57953035|NCT01314677|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
57953036|NCT05744999|PROCEDURE|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
57953037|NCT04217187|DEVICE|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
57953038|NCT04217187|DEVICE|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
57953039|NCT05296187|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
57953040|NCT03233555|OTHER|Informational Intervention|Receive brochure
57953041|NCT03233555|OTHER|Internet-Based Intervention|Have access to EXCELS
57953042|NCT03233555|OTHER|Quality-of-Life Assessment|Ancillary studies
58100807|NCT04385264|DRUG|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
58100808|NCT05627349|DEVICE|wrist splinting|standard wrist splinting at night for 2 weeks
58100809|NCT05627349|DEVICE|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
58100810|NCT06521281|BEHAVIORAL|Chan-Chuang qigong|Twice daily, every 15 minutes Chan-Chuang qigong
58100811|NCT04807231|BIOLOGICAL|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
58429433|NCT05238805|RADIATION|Observational heart and kidney on siemens TEP scan|Same as arm description
58429434|NCT04629846|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
58429435|NCT04629846|DRUG|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
58429436|NCT04629846|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
58429437|NCT04629846|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
57953043|NCT03233555|OTHER|Questionnaire Administration|Ancillary studies
57953044|NCT03233555|BEHAVIORAL|Telephone-Based Intervention|Receive quarterly calls
58308392|NCT01499485|DRUG|Acetazolamide|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
58308393|NCT01499485|DRUG|Placebo|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
57953045|NCT05030012|DEVICE|Automated Control|The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
57953046|NCT05030012|DEVICE|Manual Control|The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
57953047|NCT04096196|BEHAVIORAL|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
57953048|NCT04096196|OTHER|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
57953049|NCT00015977|BIOLOGICAL|PSA prostate cancer vaccine|
57953050|NCT00015977|BIOLOGICAL|recombinant interleukin-12|
57953051|NCT06096597|DRUG|Clarix Flo|100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
57953052|NCT06096597|DRUG|Placebo|10 mL of 0.9% preservative-free sodium chloride
57953053|NCT01696240|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
57953054|NCT01696240|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
57953055|NCT03162770|BEHAVIORAL|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
57953056|NCT03334890|DIAGNOSTIC_TEST|plasma mSEPT9 level|the plasma level of methylated SEPT9
57953057|NCT03239366|OTHER|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
57953058|NCT03239366|OTHER|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
57953059|NCT05817877|OTHER|phone use|There is no intervention.
57953060|NCT02520232|BEHAVIORAL|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
57953061|NCT02520232|BEHAVIORAL|Stretching and balance exercise program|Stretching and balance exercise program
57953062|NCT00814775|DEVICE|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
57953063|NCT00814775|DEVICE|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
57953064|NCT03067883|DRUG|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
57953065|NCT05972811|OTHER|Cold application|In the experimental group, cold application will be made until the skin temperature of the drain exit area reaches 13.6 °C. And before drain removal, immediately after drain removal and 15 minutes later, pain levels will be measured with VAS and analgesic needs will be questioned
57953066|NCT00435838|DRUG|No Intervention -- Observational study|
58308394|NCT05573152|PROCEDURE|Control|All previously selected patients will be under passive warming by means of blankets
58308395|NCT05573152|PROCEDURE|Nursing|All previously selected patients will be under active air flow warming device at 43 Celsius
58308396|NCT05945095|OTHER|Gum chewing group|The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
58308397|NCT03109483|OTHER|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
58308398|NCT03492203|BEHAVIORAL|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
58100812|NCT03953911|BIOLOGICAL|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
58100813|NCT03953911|BEHAVIORAL|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
58100814|NCT04207554|DEVICE|Test Device-Strip Format|Sponsor's investigational device
58100815|NCT04207554|DEVICE|Test Device-Cassette Format|Sponsor's investigational device
58100816|NCT04207554|DEVICE|Predicate Device|Commercially available device
58100817|NCT01885507|OTHER|Pass recommendations on ventilation factors and extubation|"* the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
58429438|NCT04629846|PROCEDURE|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
57953067|NCT04739514|OTHER|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
58308399|NCT03492203|BEHAVIORAL|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
58429439|NCT04084847|DIETARY_SUPPLEMENT|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
58429440|NCT04084847|DIETARY_SUPPLEMENT|Placebo|Placebo powder
58429441|NCT02562859|DRUG|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
58429442|NCT02562859|DRUG|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
58429443|NCT01474070|DEVICE|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
58429444|NCT02551029|OTHER|Capsaicin|
58429445|NCT02551029|OTHER|Placebo|
58429446|NCT03354624|DRUG|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
58429447|NCT00642317|BEHAVIORAL|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
58429448|NCT05946005|DRUG|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
58429449|NCT05946005|DRUG|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
58429450|NCT05946005|DRUG|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
57953068|NCT02193074|DRUG|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
57953069|NCT02193074|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
57953070|NCT01014689|DRUG|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
58100818|NCT00902252|DEVICE|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
58100819|NCT00902252|DEVICE|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
58100820|NCT00902252|DEVICE|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
58429451|NCT05946005|OTHER|control groups|no intervention is given
57953071|NCT01014689|DRUG|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
58100821|NCT03276962|BIOLOGICAL|RTS,S/AS01E (Full dose)|Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
58100822|NCT03276962|BIOLOGICAL|RTS,S/AS01E (1/5th dose)|Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
58100823|NCT03276962|BIOLOGICAL|Rabies vaccine|Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
58100824|NCT05114018|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Daily oral dose
58100825|NCT05114018|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
58100826|NCT02225028|BEHAVIORAL|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
58100827|NCT03828201|DRUG|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
58429452|NCT05688488|DRUG|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
58429453|NCT05688488|DRUG|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
58429454|NCT00428870|PROCEDURE|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
58429455|NCT03051919|OTHER|observation|
58429456|NCT06418451|PROCEDURE|sacrospinous ligament fixation (SLFF)|SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.
58100828|NCT03828201|DRUG|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
58308400|NCT03492203|BEHAVIORAL|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
58308401|NCT03492203|BEHAVIORAL|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
58308402|NCT03492203|BEHAVIORAL|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
58429457|NCT06418451|PROCEDURE|modified ischial spinous fascia fixation (modified ISFF)|The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
58429458|NCT02146625|DRUG|CJ-40002|
58429459|NCT05989958|COMBINATION_PRODUCT|HepaCure|HepaCure will be administered in extracorporal dialysis for single dose or multiple doses with different treatment duration on top of DPMAS.
58429460|NCT00171847|DRUG|Letrozole|
58429461|NCT00171847|DRUG|Trastuzumab plus Letrozole|
58429462|NCT00171847|DRUG|Letrozole|
58429463|NCT04033783|OTHER|6MWT - accompanied|Assessor walks behind the patient
58308403|NCT03665870|BEHAVIORAL|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
58100829|NCT03828201|DRUG|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
58100830|NCT03828201|DRUG|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
58100831|NCT03828201|DRUG|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
58308404|NCT04194164|OTHER|Fluid intake app|Monitor fluid intake and interdialytic weight gain in patients using the fluid app
58308405|NCT01244477|BEHAVIORAL|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
58308406|NCT00105430|PROCEDURE|Deep Brain Stimulation|
58308407|NCT05677399|OTHER|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
58308408|NCT00906243|BIOLOGICAL|CV9103|CV9103 encodes for 4 prostate specific antigens.
58429464|NCT04033783|OTHER|6MWT - not accompanied|Assessor does not walk behind the patient
58429465|NCT02396368|DRUG|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
58429466|NCT02396368|RADIATION|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
58429467|NCT04266236|PROCEDURE|L3 LPB|ultrasound-guided L3 lumbar plexus block
58429468|NCT04266236|PROCEDURE|L4 LPB|ultrasound-guided L4 lumbar plexus block
58429469|NCT04266236|PROCEDURE|T12 block|ultrasound-guided thoracic 12th segment nerve block
58429470|NCT04266236|PROCEDURE|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
58429471|NCT04266236|DRUG|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
58429472|NCT04266236|DRUG|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
58100832|NCT06120179|DEVICE|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
58100833|NCT02151396|BEHAVIORAL|Working memory training|
58100834|NCT02151396|DEVICE|Functional magnetic resonance imaging (fMRI)|
58100835|NCT01462474|DRUG|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
58100836|NCT01462474|DRUG|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
58100837|NCT01462474|RADIATION|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
58100838|NCT05418257|OTHER|(exposure) telemedicine|medical counseling or treatment only using phone
58100839|NCT02484235|OTHER|HIIT|Group training with HIIT 3 times per week during 10 sessions
58100840|NCT02484235|OTHER|Strength|Group training with strength exercises 3 times per week during 10 sessions
58429473|NCT04266236|PROCEDURE|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
58429474|NCT05082415|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
58429475|NCT02469519|DRUG|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
58429476|NCT02469519|OTHER|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
58429477|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
57736980|NCT06213766|DEVICE|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
57953072|NCT05071950|OTHER|Control period|"* first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal"
58100841|NCT04924114|DRUG|MK-6194|Subcutaneous injection
58429478|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
58429479|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
58429480|NCT02161757|BIOLOGICAL|Tralokinumab|Subcutaneous injection
58100842|NCT04924114|DRUG|MK-6194-matching placebo|Subcutaneous injection
58100843|NCT06008639|DEVICE|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
58100844|NCT06008639|DEVICE|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
58429481|NCT02161757|OTHER|Placebo|Subcutaneous injection
58429482|NCT03696901|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
58429483|NCT04029298|BEHAVIORAL|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
58429484|NCT01174212|PROCEDURE|Prophylactic Antibiotics|Preoperative Antibiotics
58429485|NCT01174212|PROCEDURE|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
58429486|NCT03994198|DIETARY_SUPPLEMENT|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
58429487|NCT03994198|DIETARY_SUPPLEMENT|Collagen peptides|Collagen peptides from bovine sources
57953073|NCT05071950|DIETARY_SUPPLEMENT|D-allulose period|"* \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose"
57953074|NCT00576043|PROCEDURE|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
57953075|NCT01197404|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
57953076|NCT01197404|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
57953077|NCT01659008|DRUG|Estradiol|
57953078|NCT01659008|DRUG|Lysteda|
58100845|NCT02740673|DEVICE|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
58100846|NCT00068445|DRUG|lamotrigine|
58100847|NCT00068445|OTHER|Placebo|
58100848|NCT01681979|DRUG|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
58100849|NCT01257828|DRUG|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
58308409|NCT05068843|PROCEDURE|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
58429488|NCT01321957|DRUG|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
58429489|NCT01321957|DRUG|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
58429490|NCT02736981|BEHAVIORAL|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
58429491|NCT02736981|BEHAVIORAL|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
57953079|NCT05807061|BEHAVIORAL|EmBARK|The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
57953080|NCT05807061|BEHAVIORAL|Popular guidance|The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
57953081|NCT05807061|BEHAVIORAL|Practice first|Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
57953082|NCT00003642|DRUG|cisplatin|
57953083|NCT00003642|DRUG|fluorouracil|
57953084|NCT00003642|RADIATION|radiation therapy|
57953085|NCT03724864|DIETARY_SUPPLEMENT|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
57953086|NCT04823104|OTHER|Home visitation|Home visitation for pregnancy follow-up
58100850|NCT01257828|DRUG|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
58100851|NCT00918697|PROCEDURE|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
58100852|NCT00918697|PROCEDURE|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
58308410|NCT05068843|OTHER|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
58308411|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
58100853|NCT04737811|OTHER|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
58100854|NCT06073184|DRUG|Mounjaro|Tirzepatide injection, starting dose is 2.5mg injected subcutaneously once weekly. After 4 weeks, dose should be increased to 5mg once weekly. The dose then can be increased in 2.5mg increments after no less than 4 weeks on current dose to maximum dose of 15mg once weekly.
58100855|NCT06073184|DRUG|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
58100856|NCT04182984|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
58100857|NCT03422796|DRUG|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58100858|NCT03422796|DRUG|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58100859|NCT03422796|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
58429492|NCT02736981|BEHAVIORAL|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
58429493|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
58429494|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
58429495|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
58429496|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
58429497|NCT05243303|DEVICE|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
58429498|NCT05243303|DEVICE|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
58100860|NCT00470119|BEHAVIORAL|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
58100861|NCT00470119|BEHAVIORAL|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
58100862|NCT05884138|OTHER|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
58308412|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
58308413|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
58308414|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg\*2 single dose
58308415|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
58308416|NCT02144909|BEHAVIORAL|Partners in Care with Semi-Structured Support Group|
58308417|NCT06401291|DEVICE|Transcutaneous Electrical Nerve Stimulation|Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
58308418|NCT05691543|PROCEDURE|sacrospinous fixation Using Posterior Vaginal wall flap|"* Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
58308419|NCT04893161|DRUG|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
58429499|NCT03921177|DIETARY_SUPPLEMENT|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
58429500|NCT03921177|DRUG|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
58429501|NCT00527319|DRUG|VT-122 low dose|VT-122 low dose, dose escalated
58429502|NCT00527319|DRUG|VT-122 high dose|VT-122 high dose, dose escalated
58100863|NCT02237118|DEVICE|Mepitel One|
58100864|NCT02237118|DEVICE|UrgoTul|
58100865|NCT00140738|BIOLOGICAL|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
58100866|NCT04626765|DRUG|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
58100867|NCT04626765|DRUG|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
58100868|NCT04626765|DRUG|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
58100869|NCT04626765|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
58100870|NCT04626765|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
58100871|NCT03047473|BIOLOGICAL|avelumab|add on of avelumab 10mg/kg IV to standard therapy
58100872|NCT04441801|OTHER|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
58429503|NCT02262962|OTHER|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
58429504|NCT02448290|DRUG|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
58429505|NCT02658773|DRUG|lidocaine-Prilocaine cream|
58429506|NCT02658773|DRUG|placebo cream|
58429507|NCT04246632|DEVICE|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
58429508|NCT06303232|OTHER|MANUAL LYMPHATIC DRAINAGE|"MLD was performed after the moist heating of 10 minutes in supine position with both knees bent. It will start from the abdominal lymph drainage followed by the central lymph drainage.~Then, by stimulating the bilateral axillary lymph nodes, the flow of the fluid was directed to the axillary lymph node. Each session lasted for approximately 45 minutes, for 7 days"
58429509|NCT06303232|OTHER|THERAPEUTIC ULTRASOUND|The participants of group B will receive a treatment of manual lymphatic drainage and ultrasound after the moist heat of 10 minutes. After MLD of 45 minutes, ultrasound will be performed in small circular pattern from periphery to the center towards the areola with following parameters: Mode: pulsed, Frequency: 1MHz, Intensity: 1W/cm2, Time: 8 minutes. Treatment was given for 7 consecutive days
58429510|NCT01862653|DEVICE|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
58429511|NCT05360745|DIETARY_SUPPLEMENT|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
58429512|NCT05360745|DIETARY_SUPPLEMENT|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
58429513|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 1|Caffeine content: 200 mg
58429514|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 2|Caffeine content: 400 mg
58429515|NCT02255201|DIETARY_SUPPLEMENT|Performance Energy Blend|Caffeine content: 175 mg
58429516|NCT02255201|DIETARY_SUPPLEMENT|Energy Blend|Caffeine content: 200 mg
58429517|NCT02255201|DIETARY_SUPPLEMENT|Placebo|Caffeine content: 0 mg
58429518|NCT01207349|BEHAVIORAL|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
58429519|NCT01207349|BEHAVIORAL|standard follow up|
58429520|NCT03123328|DEVICE|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
58429521|NCT01224080|DEVICE|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
58429522|NCT01201226|OTHER|Removal of half an ovary|Removal of half an ovary
58429523|NCT02207959|DRUG|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
58429524|NCT02207959|PROCEDURE|White-light examination|standard white light examination
58429525|NCT02207959|PROCEDURE|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
58429526|NCT02215824|DRUG|BIWH 3|
58429527|NCT02215824|DRUG|Placebo|
58429528|NCT06328309|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58429529|NCT06328309|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
58429530|NCT05407155|COMBINATION_PRODUCT|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
58429531|NCT05504551|PROCEDURE|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
58429532|NCT00696969|DRUG|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
58429533|NCT00696969|DRUG|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
58429534|NCT00696969|DRUG|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
58308420|NCT05457699|RADIATION|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
58308421|NCT05457699|OTHER|no RT|no SABR, continued systemic therapy per SOC
58429535|NCT00696969|DRUG|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
58429536|NCT00095173|DRUG|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
58429537|NCT00095173|DRUG|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
58429538|NCT00095173|DRUG|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
58429539|NCT06432166|DRUG|2-hydroxybenzylamine acetate|2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
58429540|NCT06432166|OTHER|Placebo|Placebo taken three times per day for 16 weeks.
58429541|NCT02484222|DRUG|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
58429542|NCT05687513|DRUG|Yisui granule|Yisui granule
58429543|NCT05687513|DRUG|Placebo|placebo
58429544|NCT02301624|BIOLOGICAL|Eculizumab|Intravenous administration of eculizumab.
58308422|NCT03405311|DEVICE|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
58308423|NCT03405311|OTHER|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
58308424|NCT00323063|DRUG|gemcitabine hydrochloride|Given IV
58308425|NCT00323063|DRUG|imatinib mesylate|Given orally
58308426|NCT02397746|DEVICE|total hip arthroplasty implant|
58308427|NCT00000347|DRUG|Risperidone|
58308428|NCT02580656|BEHAVIORAL|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
58429545|NCT02301624|DRUG|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
58429546|NCT04770792|OTHER|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
58429547|NCT04770792|OTHER|Mineral trioxide aggregate.|Mineral trioxide aggregate.
58429548|NCT02022436|DRUG|Contrast Ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
58429549|NCT03085186|DRUG|Crizotinib|
58429550|NCT05409937|OTHER|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
58429551|NCT05409937|OTHER|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
58429552|NCT05409937|OTHER|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
58429553|NCT05254873|OTHER|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
58429554|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
58429555|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
58429556|NCT06410456|OTHER|Exercise therapy|Schroth exercises
57736981|NCT06213766|BIOLOGICAL|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
58429557|NCT04359979|DRUG|Tamsulosin|selective alpha1 receptor antagonist
58429558|NCT01183468|BIOLOGICAL|Aralast NP 45 mg dose|- 45 mg/kg/week
58429559|NCT01183468|BIOLOGICAL|Aralast NP 90 mg dose|- 90 mg/kg/week
58429560|NCT01183468|BIOLOGICAL|Aralast NP 180 mg dose|- 180 mg/kg/week
58429561|NCT03369002|DRUG|seladelpar|Oral single dose 10 mg
58429562|NCT02689167|DRUG|Sunitinib|
58429563|NCT04706156|BIOLOGICAL|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
58429564|NCT02196480|BIOLOGICAL|anti-TNF|Anti-tumor necrosis factor therapy
58429565|NCT02186145|DRUG|Association of metronidazole; nystatin and dexamethasone|
58429566|NCT02186145|DRUG|Flagyl|Vaginal cream of metronidazole and nystatin
58429567|NCT04165629|DRUG|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
58429568|NCT05993962|DIETARY_SUPPLEMENT|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
58429569|NCT05993962|OTHER|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
58429570|NCT04071418|RADIATION|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
58429571|NCT03633812|OTHER|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
58429572|NCT00345618|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
58429573|NCT00345618|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
58429574|NCT00345618|DRUG|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
58429575|NCT00345618|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
58429576|NCT00345618|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
58429577|NCT00345618|DRUG|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
58429578|NCT03688620|OTHER|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
58100873|NCT04391400|DIAGNOSTIC_TEST|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
57736982|NCT06449833|DRUG|Henagliflozein and Metformin|The experimental group will be treated with 10mg Henagliflozein and Metformin.
58308429|NCT05507138|DEVICE|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
58429579|NCT04328272|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
58429580|NCT04328272|DRUG|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
58429581|NCT04328272|DIETARY_SUPPLEMENT|Glucose tablets|administered orally with water
57736983|NCT06449833|DRUG|Linagliptin and Metformin|The control group will be treated with 5mg Linagliptin and Metformin.
57736984|NCT02172508|DRUG|Tiotropium Inhalation Capsule|
57736985|NCT02172508|DRUG|Placebo Lactose Capsule|
58100874|NCT04391400|DIAGNOSTIC_TEST|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~* At least 2mL to 5mL of peripheral blood.~* Collected in EDTA tubes.~* Shipped to ambient LabPMM, LLC within 2 days.~* Specimen Collections:~* Collected at the same time as the NP specimen sent for COVID-19 testing.~* Collected two to three weeks post the original patient's COVID-19 testing."
58100875|NCT03434626|BEHAVIORAL|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
58100876|NCT03434626|OTHER|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
58429582|NCT06023615|OTHER|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
58429583|NCT03006692|OTHER|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
58429584|NCT04939792|DRUG|Vitamin D|Capsules ingested orally
58429585|NCT04939792|DRUG|Placebo|Capsule ingested orally
58429586|NCT04939792|DRUG|Vitamin D + L-cysteine|Capsule ingested orally
58429587|NCT04939792|DRUG|L-cysteine|Capsule ingested orally
58429588|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
58429589|NCT06409364|DRUG|Fludrocortisone|small white tablet containing 100mcg of fludrocortsone
58429590|NCT06409364|DRUG|Placebo|Matched placebo tablet,
58429591|NCT02780544|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
58429592|NCT02780544|DEVICE|incubator|staying in incubator during eye examination.
58429593|NCT02780544|DRUG|Sucrose|oral sucrose before eye examination
58429594|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
57961817|NCT05029154|BEHAVIORAL|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
57961818|NCT03678597|OTHER|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
58308430|NCT05507138|BEHAVIORAL|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
58308431|NCT04211584|DEVICE|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
58308432|NCT01317641|DRUG|ODM-201|ODM-201 administered orally daily
58308433|NCT00325637|DRUG|cilnidipine|Cilnidipine 10\~20mg, qd, po for 4 weeks.
58308434|NCT01586195|DRUG|Vemurafenib|Vemurafenib 960 mg BID
58308435|NCT04325880|DRUG|Mirabegron 50 MG|Patients in this arm will receive Mirabegrone 50 MG once daily
58308436|NCT04325880|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin o.4 MG once daily
58308437|NCT04325880|DRUG|Solifenacin Succinate 10 MG|Patients in this arm will receive Solifenacin Succinate 10 MG once daily
58308438|NCT04325880|DRUG|Placebo oral tablet|Patients in this arm will receive placebo oral tablet once daily
58308439|NCT03042546|DRUG|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
58308440|NCT03042546|DRUG|PMMA|PMMA with abx will be used in the defect
58308441|NCT03042546|OTHER|No treatment|The defect will not be treated
58308442|NCT02391831|OTHER|Strength, function and activity measurements|
58308443|NCT02391831|OTHER|Muscle MRI|
58429595|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
58429596|NCT03969186|BEHAVIORAL|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
58429597|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
58429598|NCT01879969|PROCEDURE|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
58429599|NCT01879969|PROCEDURE|computer assisted orthognathic planning and surgery of asymmetric patients|
58429600|NCT03313336|DRUG|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
58429601|NCT03313336|DRUG|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
58429602|NCT03313336|DRUG|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
58429603|NCT00687531|DRUG|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
58308444|NCT02391831|OTHER|Electrophysiology measurements|
58308445|NCT02391831|OTHER|Blood sampling for biomarker analysis|
58308446|NCT04245774|DRUG|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
58429604|NCT05295355|DRUG|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
58429605|NCT01605721|DEVICE|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
58429606|NCT04845178|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
58429607|NCT04845178|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
58429608|NCT03221309|OTHER|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
58429609|NCT04354883|PROCEDURE|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
58429610|NCT04118595|BEHAVIORAL|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
58429611|NCT04118595|BEHAVIORAL|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
58429612|NCT04118595|BEHAVIORAL|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
58429613|NCT02113332|DRUG|Liraglutide|
58429614|NCT02113332|DRUG|Placebo|
58429615|NCT05169411|DIAGNOSTIC_TEST|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
57961819|NCT03183362|DEVICE|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
58308447|NCT04245774|DRUG|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
58308448|NCT05363228|BEHAVIORAL|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
58308449|NCT05363228|BEHAVIORAL|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
58308450|NCT03713918|OTHER|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
58308451|NCT03713918|OTHER|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
58308452|NCT00748202|DRUG|C1-Esterase Inhibitor|1000 I.E.
58308453|NCT02147301|DEVICE|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
58308454|NCT02462265|DRUG|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
58308455|NCT02462265|DRUG|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
58308456|NCT00947544|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
58308457|NCT00947544|DRUG|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
58308458|NCT06238739|OTHER|Control - Standard Strategies for hypothermia prevention|Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
58308459|NCT06238739|OTHER|Fluid warming before infusion and infiltration|Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
58308460|NCT06238739|DEVICE|Thermal convection blanket by water flow (Blanketrol)|Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
58100877|NCT04033900|DEVICE|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
58100878|NCT04701658|DRUG|Bamlanivimab|Administered intravenously.
58100879|NCT00196573|PROCEDURE|Shoulder bursectomy alone|
58429616|NCT05169411|DIAGNOSTIC_TEST|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
57953087|NCT01202331|DRUG|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
57953088|NCT01033734|DRUG|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
57953089|NCT00903175|DRUG|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
57953090|NCT00903175|DRUG|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
57953091|NCT04017481|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
58100880|NCT00858559|DEVICE|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
58100881|NCT00858559|DEVICE|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
58100882|NCT00990093|DEVICE|test intermittent catheter|CH 12 hydrophilic coated catheter
58100883|NCT00990093|DEVICE|Intermittent catheterization|CH 12 hydrophilic catheter
58100884|NCT05301101|RADIATION|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
58100885|NCT04071275|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
58100886|NCT04071275|OTHER|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
58100887|NCT00200473|DRUG|Nebivolol|
58100888|NCT02726672|DEVICE|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
58100889|NCT00694031|PROCEDURE|Hemodialysis|3 times per week
58100890|NCT00694031|PROCEDURE|On-line hemodiafiltration|3 times per week
58100891|NCT02353299|DRUG|Silenor 6 mg|Silenor 6 mg single nighttime dose.
58100892|NCT02353299|DRUG|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
58308461|NCT06238739|DEVICE|Conductive fabric electric warming device (HotDog)|HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
57953092|NCT04017481|OTHER|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
58100893|NCT02353299|DRUG|Placebo|placebo single nighttime dose-1.5 hours
58100894|NCT02353299|DRUG|Placebo|placebo single nighttime dose-4 hours
58429617|NCT06448039|DRUG|Fibroblast Growth Factor 2|Randomized double-blinded placebo-controlled treatment of 20 patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with FGF2 or saline in a 3:1 ratio, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
58429618|NCT06448039|DRUG|Saline control|Randomized double-blinded placebo-controlled treatment of patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with saline, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
58429619|NCT01799551|BEHAVIORAL|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
58429620|NCT06169488|PROCEDURE|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
58429621|NCT06169488|BEHAVIORAL|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training.
58429622|NCT03401060|DRUG|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
58429623|NCT03401060|DRUG|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
58429624|NCT00673283|DEVICE|bi-plane chest radiography|Bi-plane radiography of the thorax
58429625|NCT06260553|DRUG|tislelizumab and metronomic oral vinorelbine|tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
58429626|NCT01183065|DRUG|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
58429627|NCT04564677|DEVICE|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
58429628|NCT05659472|BEHAVIORAL|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
58429629|NCT05659472|BEHAVIORAL|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
58429630|NCT00965419|DRUG|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
58429631|NCT02387554|DRUG|HGP0904|
57953093|NCT03669302|OTHER|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
57953094|NCT03669302|DEVICE|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
58429632|NCT02387554|DRUG|HGP0608|
58429633|NCT02387554|DRUG|HGP1405|
57953095|NCT03669302|DEVICE|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
57953096|NCT02568813|BEHAVIORAL|Multiscore Depression Inventory for Children scale|
57953097|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
58308462|NCT03297632|BEHAVIORAL|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
57953098|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
57953099|NCT06330389|PROCEDURE|Burn Injuries Graft Surgery|Burn Injuries Graft Surgery
57953100|NCT02414386|OTHER|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
57953101|NCT00001003|DRUG|Pentamidine isethionate|
57953102|NCT00001003|DRUG|Zidovudine|
57953103|NCT00610831|DEVICE|DIRECTVIEW CR Mammography|4 views screening mammogram
57953104|NCT02788942|PROCEDURE|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
57953105|NCT04588779|OTHER|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
57953106|NCT04588779|OTHER|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
57953107|NCT01554137|OTHER|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
57953108|NCT01554137|OTHER|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
57953109|NCT02358642|DRUG|Angiotensin converting enzyme inhibitor (Lisinopril)|
57953110|NCT02358642|DRUG|Placebo|
57953111|NCT06392646|BEHAVIORAL|self-management education program|Intervention through a self-management education program constructed through evidence summarization and expert correspondence.
57953112|NCT03587454|DIAGNOSTIC_TEST|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
57953113|NCT01797575|DRUG|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
58308463|NCT03097601|DIAGNOSTIC_TEST|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
58308464|NCT02265965|DRUG|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
58308465|NCT03277040|OTHER|CSA membership|Bi-weekly fresh food delivery
58429634|NCT00642863|DIETARY_SUPPLEMENT|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
58429635|NCT00642863|DIETARY_SUPPLEMENT|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
58429636|NCT00642863|DIETARY_SUPPLEMENT|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
58429637|NCT04830488|BEHAVIORAL|e-learning didactic module|Participants utilize e-learning
58429638|NCT04830488|BEHAVIORAL|Personal reflection activities|Participants complete questionnaires
58429639|NCT02229526|DIETARY_SUPPLEMENT|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
58429640|NCT02229526|DIETARY_SUPPLEMENT|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
58429641|NCT02229526|DIETARY_SUPPLEMENT|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
58429642|NCT02229526|DIETARY_SUPPLEMENT|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
58429643|NCT00007891|BIOLOGICAL|filgrastim|
58429644|NCT00007891|PROCEDURE|autologous bone marrow transplantation|
58429645|NCT00007891|PROCEDURE|peripheral blood stem cell transplantation|
58429646|NCT00007891|RADIATION|indium In 111 monoclonal antibody BrE-3|
58429647|NCT00007891|RADIATION|yttrium Y 90 monoclonal antibody BrE-3|
58429648|NCT05071014|DRUG|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
58429649|NCT05071014|PROCEDURE|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
58429650|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
58429651|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
58429652|NCT01232855|GENETIC|protein expression analysis|
57953114|NCT01797575|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
57953115|NCT01797575|DRUG|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
57953116|NCT00429403|DRUG|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
57953117|NCT04634500|DRUG|Dapagliflozin|Dapagliflozin Tablet
58429653|NCT01232855|GENETIC|western blotting|
58429654|NCT01232855|OTHER|flow cytometry|
58429655|NCT01232855|OTHER|laboratory biomarker analysis|
58429656|NCT03299712|DEVICE|ArteFill|soft tissue filler
58429657|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
58429658|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
58429659|NCT06354387|DRUG|Alectinib (Alecensa), Nivolumab (Opdivo)|Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
58429660|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
58429661|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
58429662|NCT01143584|DRUG|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
58429663|NCT01143584|DRUG|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
58429664|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
57961820|NCT03183362|DEVICE|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
58429665|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
58429666|NCT01918332|DRUG|Valsartan 160mg|
58429667|NCT01918332|DRUG|Rosuvastatin 20mg|
58429668|NCT01918332|DRUG|Valsartan 160mg placebo|
58429669|NCT01918332|DRUG|Rosuvastatin 20mg placebo|
58429670|NCT03334812|BIOLOGICAL|LNA043|LNA043 Single dose
58429671|NCT03334812|BIOLOGICAL|placebo to LNA043|placebo to LNA043 single dose
58429672|NCT02831933|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
58429673|NCT02831933|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
58429674|NCT02831933|RADIATION|SBRT|Low-dose SBRT
58429675|NCT02831933|DRUG|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
58100895|NCT03711669|BEHAVIORAL|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
58429676|NCT01892891|DRUG|VBY-036|Cathepsin S inhibitor
58429677|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
58429678|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
58429679|NCT01374178|DRUG|LY2963016|Administered subcutaneously
58429680|NCT01374178|DRUG|Lantus|Administered subcutaneously
58429681|NCT01272765|OTHER|Placebo|Placebo
58429682|NCT01272765|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
58429683|NCT02468349|OTHER|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
58429684|NCT04213378|DEVICE|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
58429685|NCT04213378|DEVICE|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
58429686|NCT00742755|BEHAVIORAL|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
58429687|NCT02974842|DEVICE|MAKO 7|Hysteroscopic cell sampling
58429688|NCT04233619|DIAGNOSTIC_TEST|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
58429689|NCT04937283|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
58429690|NCT04937283|PROCEDURE|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
58429691|NCT03776461|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
58100896|NCT01185730|PROCEDURE|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
58308466|NCT01640977|PROCEDURE|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
58458384|NCT06306833|OTHER|Surface Electromyography (sEMG) Biofeedback|Biofeedback sEMG therapy through the use of virtual aids like digital therapeutics would help reduce chronic low back pain in patients by overcoming their psychophysiological manifestations. All participants in the intervention group will receive sEMG biofeedback as an alternative therapy.
57953118|NCT04840108|BEHAVIORAL|Support Person Coaching Intervention|The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.
57953119|NCT04840108|BEHAVIORAL|Support Person Written Materials|Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
57953120|NCT00408694|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
57953121|NCT00408694|BIOLOGICAL|Bevacizumab|Given IV
57953122|NCT00408694|DRUG|Cisplatin|Given IV
57953123|NCT00408694|DRUG|Fluorouracil|Given IV
57953124|NCT00408694|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57953125|NCT00912249|BEHAVIORAL|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
57953126|NCT01743911|OTHER|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
57953127|NCT01743911|DRUG|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
57953128|NCT03428971|PROCEDURE|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
57953129|NCT05013762|BEHAVIORAL|Fast intervention|This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.
57953130|NCT05013762|BEHAVIORAL|Active Monitoring|This is an observation-only group. The training received in this group will be dose equivalent to the active group.
57953131|NCT03237377|DRUG|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
58100897|NCT06265285|OTHER|Home Health Encounter|Receive in-home visits by a home health nurse
58100898|NCT06265285|BIOLOGICAL|Nivolumab|Given SC
58308467|NCT01640977|PROCEDURE|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
57953132|NCT03237377|DRUG|Tremelimumab|75mg via IV infusion every 4 weeks
57953133|NCT03237377|RADIATION|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
58100899|NCT06265285|PROCEDURE|Patient Monitoring|Undergo remote patient monitoring
58100900|NCT06265285|OTHER|Questionnaire Administration|Ancillary studies
57953134|NCT03237377|PROCEDURE|lobectomy|patients may proceed to surgery post drug and radiation intervention for lung lobectomy
57953135|NCT03237377|DRUG|Standard of care adjuvant chemotherapy|patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
57953136|NCT05290025|DRUG|Nicotine patch|\> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
57953137|NCT05290025|DRUG|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
58100901|NCT00420355|DRUG|atazanavir|Atazanavir 300 mg daily on Days 6-12.
58100902|NCT00420355|DRUG|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
58100903|NCT01560182|GENETIC|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
58308468|NCT02158897|OTHER|Prolon diet|3 cycles of a 5-day Prolon diet very month
58308469|NCT04805333|DRUG|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
58308470|NCT04805333|DRUG|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
58308471|NCT04805333|DRUG|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
58308472|NCT04805333|DRUG|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
58429692|NCT04585607|DEVICE|A medium cut-off dialyzer (Theranova) will be used for HDx.|"A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)"
58429693|NCT04585607|DEVICE|A synthetic high-flux dialyzer (Polyflux)|A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
58429694|NCT03286816|DRUG|SodiumChloride|
58429695|NCT03286816|DRUG|Sodium Lactate|
58429696|NCT05643534|DRUG|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
58429697|NCT05643534|DRUG|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
58429698|NCT05643534|DRUG|Placebo|Participants will be randomized to receive matching placebo
58429699|NCT06199453|DRUG|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
58429700|NCT03698656|BEHAVIORAL|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
58429701|NCT01232985|DEVICE|RD047-26|RD047-26 emollient gel
58100904|NCT04573361|OTHER|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
58429702|NCT00288262|DRUG|melatonin 0.5 mg|
58429703|NCT06003088|DRUG|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
58429704|NCT06003088|DRUG|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
58429705|NCT05170178|BEHAVIORAL|inclusion and familiarization|"* presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
57953138|NCT05290025|DRUG|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
57953139|NCT05290025|BEHAVIORAL|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
58100905|NCT04573361|OTHER|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
58100906|NCT04040959|DRUG|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
58100907|NCT04326569|OTHER|Blood sample|Blood sample to quantify copeptin
58308473|NCT04805333|DRUG|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
58308474|NCT03953742|DRUG|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
58458385|NCT04497649|DRUG|Sofosbuvir|Sofosbuvir once daily
58458386|NCT04497649|DRUG|Daclatasvir|daclatasuvir once daily
58458387|NCT04001712|DRUG|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
58458388|NCT00006275|DRUG|calcitriol|
58458389|NCT05754034|DEVICE|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
58308475|NCT03310840|OTHER|others|others
58308476|NCT03618875|OTHER|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
58308477|NCT03618875|OTHER|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
58429706|NCT05170178|BEHAVIORAL|fMRI acquisition and closure|"* Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending"
58429707|NCT00450645|DRUG|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
58429708|NCT02702414|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
58429709|NCT03472144|DRUG|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
57736986|NCT06670859|OTHER|Intervention-Control:|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the mobilization coverall they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the coverall-mobilization-sitting in the wheelchair and moving-taking off the coverall) with the overall.Than,will be asked to evaluate the indicator level that they think the coverall they wear protects physical privacy and the levels of comfort and satisfaction they feel about the coverall with the VAS.During the next mobilization,patients will be asked to perform the same application protocol with a traditional hospital gown.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.Than interview,participants will have completed the study by filling out the QUEST 2.0.
58308478|NCT02017002|PROCEDURE|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
57953140|NCT05290025|OTHER|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
57953141|NCT05290025|OTHER|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
57953142|NCT00416962|DRUG|amantadine hydrochloride|
58308479|NCT02017002|PROCEDURE|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
58308480|NCT04135547|DEVICE|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
58308481|NCT00296517|DRUG|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
58308482|NCT00296517|DRUG|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
58308483|NCT05220423|OTHER|sms and emails reminders|6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
58429710|NCT03472144|DRUG|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
57953143|NCT00416962|DRUG|oseltamivir phosphate|
57953144|NCT05660720|DRUG|Orelabrutinib and placebo (orelabrutinib tablet simulator)|Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
58308484|NCT05220423|OTHER|No reminders|no reminders on top of the National annual communication campaign organized by the French Health System authorities
58308485|NCT03096535|PROCEDURE|Cooling|Individualized cooling protocol.
58308486|NCT03096535|PROCEDURE|Thermoneutral|Thermoneutral control day.
58308487|NCT03164057|DRUG|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
58308488|NCT03164057|DRUG|Decitabine|Administered intravenously (IV) over approximately one hour.
58308489|NCT03164057|DRUG|Cytarabine|Given IV or intrathecally (IT).
58308490|NCT03164057|DRUG|Daunorubicin|Given IV.
58308491|NCT03164057|DRUG|Etoposide|Given IV.
58308492|NCT03164057|COMBINATION_PRODUCT|ITMHA|Given IT.
58308493|NCT03164057|DRUG|Idarubicin|Given IV.
58308494|NCT03164057|DRUG|Fludarabine|Given IV over approximately 30 minutes.
58308495|NCT03164057|DRUG|Mitoxantrone|Given IV.
58308496|NCT03164057|DRUG|Erwinia asparaginase|Given IV or intramuscularly (IM).
58308497|NCT03164057|DRUG|Sorafenib|Given PO.
58429711|NCT03472144|DRUG|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
58100908|NCT01130701|OTHER|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
58100909|NCT02691312|DEVICE|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
58100910|NCT05620459|PROCEDURE|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
57953145|NCT05660720|DRUG|Orelabrutinib|Orelabrutinib will be administered as 8 tablets (400mg)
57953146|NCT05660720|DRUG|Placebo (orelabrutinib tablet simulator)|Placebo will be administered as 8 tablets (400mg).
57953147|NCT05660720|DRUG|Moxifloxacin hydrochloride|Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
57953148|NCT00573430|DRUG|Candesartan Cilexetil|8 mg oral once daily dose
57953149|NCT00573430|DRUG|Candesartan Cilexetil|16 mg oral once daily dose
57953150|NCT00573430|DRUG|Candesartan Cilexetil 32mg|32 mg oral once daily dose
57953151|NCT00872807|BEHAVIORAL|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
57953152|NCT00872807|BEHAVIORAL|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
57953153|NCT02500680|BIOLOGICAL|MER4101|
57953154|NCT02500680|BIOLOGICAL|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
57953155|NCT05492929|OTHER|The deep breathing group|The deep breathing group
57953156|NCT05492929|OTHER|4-7-8 breathing technique|4-7-8 breathing technique Group
57953157|NCT04456309|OTHER|No intervention,|pure observational study
57953158|NCT04570553|PROCEDURE|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
58100911|NCT02558660|BEHAVIORAL|Education|Educational intervention about an existing SNAP healthy food incentive program
58100912|NCT02558660|BEHAVIORAL|voucher|$10 voucher to spend on produce at farmers markets
58308498|NCT03164057|DRUG|G-CSF|Given IV.
58429712|NCT00473538|BEHAVIORAL|Structured exercise training|
58429713|NCT00473538|BEHAVIORAL|Hypocaloric hyperproteic diet|
57961821|NCT03589378|PROCEDURE|PEAF|PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
57961822|NCT00529971|BEHAVIORAL|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
57961823|NCT00529971|OTHER|Control|Treatment as usual, which could include medications or psychotherapy
58429714|NCT04560153|OTHER|karate kata|sessions of karate kata every week during 4 months
58429715|NCT06547489|DRUG|zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
58429716|NCT03993041|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
58429717|NCT00366912|DEVICE|non-invasive ventilation|
57961824|NCT03041558|BEHAVIORAL|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
58429718|NCT04515108|OTHER|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
58429719|NCT05418595|OTHER||
57953159|NCT05504954|BEHAVIORAL|IMARA-SA (intervention group)|The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
58429720|NCT03247959|BEHAVIORAL|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
58429721|NCT03489928|DRUG|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
57953160|NCT05504954|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
57953161|NCT06260254|RADIATION|Railway noise|Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.
57953162|NCT06260254|RADIATION|Low level railway vibration|36 single railway noise events at 0.5 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
58100913|NCT01241812|BEHAVIORAL|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
58100914|NCT05294770|OTHER|Optisource® Plus: Very Low Calorie Diet treatment|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
58100915|NCT05294770|OTHER|Hypocaloric Mediterranean Diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
58100916|NCT00106379|DRUG|Truvada (tenofovir DF + emtricitabine)|
58100917|NCT00106379|DRUG|Emtriva (emtricitabine)|
58100918|NCT00106379|DRUG|Viread (tenofovir DF)|
58100919|NCT00406107|DRUG|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
58429722|NCT03489928|DRUG|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
58429723|NCT03489928|DRUG|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
58429724|NCT02929238|OTHER|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
58429725|NCT02929238|OTHER|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
58429726|NCT06469606|DEVICE|AI tool|"Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes."
58429727|NCT02652078|DEVICE|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
58429728|NCT02114255|OTHER|Placebo|Administration of 0.9% NaCl.
58429729|NCT02114255|BIOLOGICAL|BCG|Vaccination with the live attenuated BCG vaccine.
58429730|NCT01532869|DRUG|Placebo|Subcutaneously weekly, Weeks 0-48
58429731|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
57953163|NCT06260254|RADIATION|Intermediate level railway vibration|36 single railway noise events at 0.7 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
57953164|NCT06260254|RADIATION|High level railway vibration|36 single railway noise events at 0.9 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
57953165|NCT05514626|DEVICE|3D Holographic Display|3D holographic visualization of the anatomy during the planned interventional procedure. The HOLOSCOPE-i will be used in addition to and will not replace conventional displays that are currently being used during the procedure.
58429732|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
58429733|NCT00044902|DRUG|epratuzumab|
57953166|NCT02671136|DEVICE|Hyperbaric Oxygen therapy|
58100920|NCT05933226|BEHAVIORAL|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
58100921|NCT00068406|RADIATION|3-Dimensional Conformal Radiation Therapy|
58429734|NCT05439538|DIAGNOSTIC_TEST|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
58429735|NCT04883034|PROCEDURE|adductor canal block in outpatient clinic|perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
58429736|NCT04883034|DRUG|Analgesics, etoricoxibe|anaelgetic oral intake
58429737|NCT03405519|PROCEDURE|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
58429738|NCT01870648|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
58429739|NCT01870648|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
58429740|NCT06036316|BEHAVIORAL|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
58429741|NCT06036316|BEHAVIORAL|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
58429742|NCT06036316|BEHAVIORAL|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
58429743|NCT06036316|COMBINATION_PRODUCT|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
58429744|NCT02741206|BEHAVIORAL|Bellevue ROSE Intervention|
58429745|NCT02741206|BEHAVIORAL|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
58429746|NCT02741206|BEHAVIORAL|One Psycho-education session and usual, standard of care Control|
58429747|NCT00761202|DRUG|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
58100922|NCT00068406|DRUG|Cisplatin|Given IV
58100923|NCT00068406|PROCEDURE|Conventional Surgery|
58429748|NCT00761202|DRUG|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
58429749|NCT04839445|PROCEDURE|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
58429750|NCT04839445|PROCEDURE|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
58429751|NCT06262217|DEVICE|Mobile MRI scanner|Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
58100924|NCT03954964|BEHAVIORAL|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
58429752|NCT01667874|DRUG|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
58458390|NCT05754034|OTHER|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
58458391|NCT01081691|BIOLOGICAL|CNTO 5825|10 mg/kg single dose IV or matching placebo
58100925|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
58100926|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
58100927|NCT02962531|DRUG|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
58100928|NCT00736931|DRUG|Brivaracetam|Brivaracetam 10 mg tablets
58429753|NCT05113914|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
58429754|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
58429755|NCT05540782|BEHAVIORAL|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
58429756|NCT03809819|PROCEDURE|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
58429757|NCT03809819|DIAGNOSTIC_TEST|FSFI questionnaire|Completion of FSFI questionnaire
58429758|NCT03809819|DIAGNOSTIC_TEST|UDI-6 questionnaire|Completion of UDI-6 questionnaire
58429759|NCT03809819|DIAGNOSTIC_TEST|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
58429760|NCT03769987|OTHER|observation|observe patients every 6 months
57953167|NCT02671136|OTHER|Conventional Wound Therapies|
57953168|NCT04676997|BIOLOGICAL|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
57953169|NCT04676997|DRUG|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
58100929|NCT00736931|DRUG|levetiracetam|500mg tablets
58100930|NCT00736931|DRUG|lorazepam|lorazepam 2 mg over encapsulated tablets
58100931|NCT00736931|OTHER|placebo|placebo capsules
58100932|NCT02762968|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar to the experimental treatments.
58429761|NCT02913716|DRUG|defactinib|Single oral dose of 400 mg \[14C\]-defactinib
58429762|NCT05257902|DRUG|choline alphoscerate|400mg bid/day
58429763|NCT05257902|DRUG|Placebo|Placebo 1T bid/day
58429764|NCT04484207|OTHER|A short video intervention|Three minutes video of a veteran that shares his personal story
58429765|NCT04484207|OTHER|A vignette intervention|A written description of the content of the video
57953170|NCT04676997|DRUG|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
57953171|NCT04676997|DRUG|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
57953172|NCT02017327|DRUG|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
57953173|NCT02017327|DRUG|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
57953174|NCT02017327|DRUG|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
58100933|NCT02762968|DIETARY_SUPPLEMENT|HMB|Capsules containing calcium HMB.
58100934|NCT02762968|DIETARY_SUPPLEMENT|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
58100935|NCT02400827|OTHER|malignant cells|
58100936|NCT03013517|DRUG|Viaskin Peanut 250µg|DBV712 250 µg, once daily
58100937|NCT02258607|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
58100938|NCT02258607|DRUG|Trametinib|Trametinib tablet administered orally once daily
58100939|NCT01863095|BEHAVIORAL|Personalized Feedback and Exercise|
58100940|NCT01514409|DIETARY_SUPPLEMENT|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
58100941|NCT01514409|DIETARY_SUPPLEMENT|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
58429766|NCT02169765|OTHER|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
58429767|NCT02169765|OTHER|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
58429768|NCT00284362|PROCEDURE|Arthroscopic or open surgery for hallux rigidus|
58429769|NCT00913926|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
58429770|NCT01705106|DRUG|capecitabine|Given PO
58429771|NCT01705106|DRUG|celecoxib|Given PO
58429772|NCT01705106|OTHER|pharmacological study|Correlative studies
58429773|NCT01705106|OTHER|laboratory biomarker analysis|Correlative studies
58429774|NCT01705106|OTHER|pharmacogenomic studies|Correlative studies
58429775|NCT04369157|PROCEDURE|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
58458392|NCT01081691|BIOLOGICAL|CNTO 5825|3 mg/kg single dose IV or matching placebo
58429776|NCT03143764|BEHAVIORAL|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
58429777|NCT06024018|DEVICE|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
58100942|NCT02951884|PROCEDURE|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
58100943|NCT02951884|DRUG|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
58100944|NCT03183973|BIOLOGICAL|PRF|patients who will receive PRF suspension
58100945|NCT03183973|BIOLOGICAL|placebo group|patients who will receive Placebo
58100946|NCT02111382|OTHER|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
58100947|NCT02111382|OTHER|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
58429778|NCT06024018|BEHAVIORAL|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
58429779|NCT00395421|DRUG|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
58429780|NCT03311347|OTHER|+Gz accelerations and positive pressure breathing|
58429781|NCT01985568|BEHAVIORAL|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
58429782|NCT01985568|BEHAVIORAL|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
58429783|NCT05899972|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.
58429784|NCT05899972|OTHER|Suboccipital inhibition technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.
58458393|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
58458394|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
57953175|NCT00978315|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
57953176|NCT00978315|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
57953177|NCT00446511|DRUG|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
58429785|NCT05899972|OTHER|Frontal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.
58429786|NCT05899972|OTHER|Parietal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.
58429787|NCT05899972|OTHER|IV ventricle technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
58429788|NCT05111028|BIOLOGICAL|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
58429789|NCT05111028|BIOLOGICAL|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
58458395|NCT01081691|BIOLOGICAL|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
58458396|NCT01081691|BIOLOGICAL|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
58458397|NCT01081691|BIOLOGICAL|CNTO 5825|1 mg/kg single dose IV or matching placebo
58458398|NCT05087771|DRUG|injectable naltrexone|360 mg dose to be given prior to hospital discharge
58458399|NCT05087771|DRUG|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
57736987|NCT06670859|OTHER|Control-Intervention|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the traditional hospital gown they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the gown-mobilization-sitting in the wheelchair and moving-taking off the gown) with the gown.Than,will be asked to evaluate the indicator level that they think the gown they wear protects physical privacy, and the levels of comfort and satisfaction they feel about the gown with the VAS.During the next mobilization, patients will be asked to perform the same application protocol with the mobilization coverall.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.At the end of the interview, participants will have completed the study by filling out the QUEST 2.0.
58458400|NCT04404426|DIETARY_SUPPLEMENT|L-citrulline|Administration of citrulline enterally for 7 days.
57736988|NCT03568318|DRUG|Placebo|Tablets taken orally once a day
57736989|NCT03568318|DRUG|Upadacitinib|Tablets taken orally once a day
57953178|NCT00446511|DRUG|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
57961825|NCT03041558|BEHAVIORAL|SafeCare (SC)|SafeCare intervention as usual
58458401|NCT04404426|OTHER|Placebo|Administration of placebo (water) enterally for 7 days
58458402|NCT00942903|DEVICE|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
57736990|NCT03568318|DRUG|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
58100948|NCT01979588|OTHER|What's Going Around tool|Provider has access to the What's Going Around tool
58429790|NCT06365983|PROCEDURE|Connective Tissue with Free Gingival Graft|The de-epithelialized free gingival grafting will begin with two horizontal incisions, 1.0 to 1.5 mm apical to the margin of the soft tissue of the adjacent teeth and two vertical incisions to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone surface, and once an adequate thickness of soft tissue is obtained, it will be rotated to become almost parallel to the external surface of the palate. The graft thickness will be maintained uniform and the wound will be protected with absorbable collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) and maintained with compressive sutures with non-absorbable 5-0 monofilament thread (Microsuture, São Paulo), anchored to the soft tissue apical to the area of the palatal wound. Immediately after suture completion, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
58429791|NCT06365983|PROCEDURE|Connective Tissue with Linear Incision|The linear technique (Lorenzana ER, Allen EP 2000) will begin with a horizontal incision 2 mm apical to the gingival margin, perpendicular to the palate, which is deepened to the bone crest. Next, a second incision is made to divide the flap and expose the connective tissue bed. The thickness of the outer portion of the flap should be at least 1 mm, with uniformity throughout its extension to reduce the risk of epithelial tissue necrosis. Subsequently, internal lateral incisions (mesial and distal) and the base incision will be made, connecting the vertical incisions to delineate horizontal and vertical boundaries. Immediately after graft removal, an absorbable hemostatic collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) will be placed and sutured using non-absorbable 5-0 monofilament thread (Microsuture, São Paulo).Immediately after suturing is completed, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
58429792|NCT00595010|BEHAVIORAL|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
58429793|NCT01046214|DRUG|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
58429794|NCT01046214|DRUG|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
57953179|NCT00446511|DRUG|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
58100949|NCT01979588|OTHER|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
58100950|NCT00303433|DRUG|Namenda|
58308499|NCT03164057|DRUG|Dexrazoxane|Given IV immediately before idarubicin administration.
58308500|NCT03164057|BIOLOGICAL|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
58308501|NCT03164057|DRUG|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
58429795|NCT06117124|RADIATION|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
58429796|NCT06117124|DIAGNOSTIC_TEST|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
58429797|NCT03394352|OTHER|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
58429798|NCT03394352|OTHER|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
58429799|NCT00879528|OTHER|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
58429800|NCT00879528|OTHER|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~* phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~* phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
58429801|NCT02340910|PROCEDURE|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
57953180|NCT00446511|DRUG|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
58308502|NCT04206865|DRUG|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
57953181|NCT00805831|DEVICE|HDH|sutureless vascular anastomosis
58429802|NCT02340910|PROCEDURE|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
58429803|NCT04499222|DEVICE|Portex|nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.
58429804|NCT04499222|DEVICE|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
58429805|NCT06582134|BEHAVIORAL|Sham BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
58100951|NCT05965622|BEHAVIORAL|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
58100952|NCT05965622|BEHAVIORAL|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
58100953|NCT05762263|BEHAVIORAL|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
58429806|NCT06582134|BEHAVIORAL|BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g. A-B-C and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
58429807|NCT00830492|DRUG|clomiphene citrate|100 mg from cycle day 3 through 7
58100954|NCT00003692|PROCEDURE|therapeutic thoracoscopy|
58100955|NCT00003692|PROCEDURE|video-assisted surgery|
58100956|NCT00646087|DRUG|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
58100957|NCT00646087|DRUG|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
58100958|NCT03628222|DEVICE|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
58100959|NCT03628222|DEVICE|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
58100960|NCT03584204|DIAGNOSTIC_TEST|imaging|computed tomography, magnetic resosnance imaging, ultrasound
58100961|NCT03485131|DEVICE|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
58100962|NCT03485131|DEVICE|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
58100963|NCT00665509|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
58308503|NCT04206865|DRUG|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
58429808|NCT00830492|PROCEDURE|Ultrasound|cycle day 8
57953182|NCT05361772|DRUG|colchicine|colchicine 0.5mg per day for 24 months
57953183|NCT05361772|DRUG|Placebo|placebo 0.5mg per day for 24 months
57736991|NCT01848080|BEHAVIORAL|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
57736992|NCT03850769|DRUG|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
58100964|NCT02018042|DRUG|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
58100965|NCT05582200|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
58100966|NCT03232554|DRUG|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
58100967|NCT03232554|DRUG|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
58100968|NCT03232554|DRUG|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
58100969|NCT01393717|DRUG|brentuximab vedotin|Given IV
58100970|NCT06036901|DIAGNOSTIC_TEST|Coronary CT|Coronary CT evaluation
58308504|NCT06377423|PROCEDURE|Direct technique|The composite was placed directly using free-hand technique
58308505|NCT06377423|PROCEDURE|Indirect technique|The ceramic was placed using indirect method via laboratory casts
58308506|NCT06039163|DRUG|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
58429809|NCT00830492|DRUG|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
58429810|NCT00830492|DRUG|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
58308507|NCT06039163|DRUG|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
58308508|NCT04833374|DRUG|Methylprednisolone|Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
58308509|NCT02139397|DRUG|DFMO|
58308510|NCT02139397|DRUG|Bortezomib|
58308511|NCT04390347|DIETARY_SUPPLEMENT|Yakult|A fermented milk product with live microorganisms.
58308512|NCT04390347|DIETARY_SUPPLEMENT|Placebo|A milk product with no live microorganisms.
58308513|NCT01482559|DRUG|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
58308514|NCT01482559|DRUG|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
58308515|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
58429811|NCT00830492|DRUG|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
58429812|NCT00830492|DRUG|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
58429813|NCT05663957|DRUG|Evusheld|EVUSHELD users
58429814|NCT02457949|OTHER|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
58429815|NCT02457949|OTHER|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
58429816|NCT02825199|DIETARY_SUPPLEMENT|Caffeine|capsule: 300mg caffeine
58429817|NCT02825199|DIETARY_SUPPLEMENT|Non caffeine|capsule: placebo (maize starch)
58429818|NCT04628988|DRUG|CC-90011|Capsule
58429819|NCT04628988|DRUG|Abiraterone|Tablet
58308516|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)|A suitable size precontoured sectional matrix band (Saddle matrix, TORVM, Moscow, Russia) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges, TORVM, Moscow, Russia) and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
58429820|NCT04628988|DRUG|Prednisone|Tablet
58429821|NCT06425432|DEVICE|OVITZ xwave aberrometer|wavefront aberrometer
58429822|NCT00195156|DRUG|ATRA-IV|
58429823|NCT00195156|DRUG|Depakote|
58429824|NCT04780464|DRUG|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
58429825|NCT04780464|DRUG|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
58308517|NCT05625243|OTHER|Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
58308518|NCT05418829|DRUG|AT-007|AT-007 20 mg/kg once daily
58308519|NCT00287430|DRUG|Growth Hormone|
58308520|NCT00287430|PROCEDURE|Whole body Protein Turnover Study|
58308521|NCT00287430|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
58308522|NCT01441869|DRUG|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
58308523|NCT01441869|DRUG|Diabex|Extended release oral tablets, 1000 mg, single dose
58308524|NCT01441869|DRUG|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
58308525|NCT01441869|DRUG|Diabex|Extended release oral tablets, 500 mg, single dose
58308526|NCT01441869|DRUG|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
58308527|NCT00437463|DRUG|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
58308528|NCT04119687|BIOLOGICAL|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
57736993|NCT03877042|DEVICE|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
58308529|NCT01953991|DEVICE|Dentures|Removable prosthesis to replace missing teeth
58308530|NCT05110664|DRUG|PYY (3-36) Peptide|oral PYY3-36 solution
58308531|NCT05110664|DRUG|Placibo|oral placebo solution
58308532|NCT01104961|DEVICE|Contact lens packaging solution|These test solutions are the intervention being tested.
58429826|NCT04780464|DRUG|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
57736994|NCT03877042|DEVICE|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
57736995|NCT01002326|BEHAVIORAL|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
58429827|NCT04780464|DRUG|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
58429828|NCT04780464|DRUG|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
58429829|NCT01533142|PROCEDURE|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
58429830|NCT01533142|PROCEDURE|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
58100971|NCT06134973|DIAGNOSTIC_TEST|ultrasonic testing|ultrasonic testing
57736996|NCT01864564|OTHER|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
57736997|NCT00933569|DRUG|LACTIC ACID(ND)|treatment period: 21 consecutive days
57736998|NCT06241404|PROCEDURE|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
57736999|NCT06241404|PROCEDURE|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
58100972|NCT01246986|DRUG|LY2157299|Administered orally
58100973|NCT01246986|DRUG|Sorafenib|Administered orally
58308533|NCT01104961|DEVICE|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
58308534|NCT04659005|OTHER|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
58308535|NCT04659005|OTHER|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
58429831|NCT00241904|BEHAVIORAL|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
58429832|NCT00241904|DRUG|Antiplatelet Agents|Aspirin 81 mg q day
58429833|NCT00241904|DRUG|Beta Blocker|Oral medication
58429834|NCT00241904|DRUG|ACE Inhibitors|Oral medications, received 1-2 times per day
58429835|NCT06136130|DEVICE|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
58429836|NCT06192680|DRUG|Liposomal irinotecan|70 mg/m² IV
58429837|NCT06192680|DRUG|Capecitabine|1000 mg/m² PO BID
58429838|NCT06192680|DRUG|Bevacizumab|5mg/kg IV
58429839|NCT04575207|DIAGNOSTIC_TEST|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
58429840|NCT04575207|DIAGNOSTIC_TEST|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
58429841|NCT01105377|DRUG|entinostat|Given orally
58429842|NCT01105377|DRUG|azacitidine|Given SC
58429843|NCT01105377|OTHER|laboratory biomarker analysis|Correlative studies
58429844|NCT05861141|OTHER|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights."
57737000|NCT06446804|OTHER|None, pure observationnal study|Pure observatonnal study
58100974|NCT01246986|DRUG|Ramucirumab|Administered IV
57737001|NCT03356925|DIAGNOSTIC_TEST|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
57737002|NCT06296368|BEHAVIORAL|Preference Reporting to Improve Management and Experience (PRIME)|PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities
57737003|NCT05646953|OTHER|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
58100975|NCT02028156|OTHER|Partially Hydrolyzed Infant Formula|Commercially available infant formula
58100976|NCT01664000|DRUG|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
58429845|NCT05861141|DEVICE|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
58429846|NCT06051006|OTHER|ESR and ECAP measurements|"Measurement of electrically evoked stapedial reflexes (ESRT) by stimulation via the cochlear implant. Measurement of the Electric compound action potentials (ECAPs) on the electrodes where the ESRT were performed.~The measurements and tests will be performed during a routine visit to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
58100977|NCT05280873|DRUG|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
58429847|NCT06051006|OTHER|Device setting|"The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
58429848|NCT06051006|OTHER|Speech audiometry|"This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
58429849|NCT06051006|OTHER|Intelligibility in noise test|"The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
58429850|NCT06051006|OTHER|Cochlear implant datalogging, speech audiometry test, FraSimat test|"The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR."
58429851|NCT02933502|DRUG|DSXS topical product|treatment daily for 28 days
58429852|NCT03184285|PROCEDURE|baseline alert 1|measurement in supine position
58429853|NCT03184285|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
58429854|NCT03184285|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
58429855|NCT03184285|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
58429856|NCT03184285|PROCEDURE|passive leg raising|measurement under passive leg raising
58429857|NCT03184285|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
58429858|NCT03184285|PROCEDURE|baseline in narcosis 2|measurement in supine position
58429859|NCT03184285|PROCEDURE|start capnoperitoneum|measurement in supine position
58429860|NCT03184285|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
58429861|NCT03184285|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
58429862|NCT03184285|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
58429863|NCT03184285|PROCEDURE|baseline|measurement in supine position
58429864|NCT03184285|PROCEDURE|baseline alert 2|measurement in supine position
58429865|NCT03184285|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
58429866|NCT03184285|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
58429867|NCT02321761|DRUG|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
58429868|NCT05215158|DRUG|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
58429869|NCT05901402|BEHAVIORAL|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
58429870|NCT00930007|OTHER|Blood sampling|Blood sampling for later hormone measurements
58429871|NCT00597493|DRUG|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
58429872|NCT00486668|DRUG|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
58429873|NCT00486668|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
58429874|NCT00486668|DRUG|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
58429875|NCT00486668|DRUG|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
58429876|NCT00486668|DRUG|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
58429877|NCT01171391|DRUG|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
58429878|NCT01171391|OTHER|Placebo|Placebo on Day 1
58429879|NCT04346849|PROCEDURE|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
58429880|NCT02389439|DRUG|Pyronaridine-artesunate|
58429881|NCT01108380|PROCEDURE|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
58429882|NCT05583084|OTHER|Investigation|
58429883|NCT04378231|DRUG|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
58429884|NCT04254094|OTHER|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
58429885|NCT04942782|OTHER|lumbopelvic stabilization exercises|the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
58429886|NCT04942782|OTHER|pilates exercise|the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
58429887|NCT04942782|OTHER|conventional therapy|Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
58429888|NCT05464615|DRUG|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
58429889|NCT01324869|BIOLOGICAL|KH902|Intravitreal injection of 0.5mg/eye/time KH902
58429890|NCT02670967|DIETARY_SUPPLEMENT|Soluble Fibre|
58429891|NCT03576573|DEVICE|PROCOTYL® C|Hip Arthroplasty
58429892|NCT01961063|DRUG|busulfan|Given IV
58429893|NCT01961063|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
58429894|NCT01961063|OTHER|pharmacological study|Correlative studies
58429895|NCT01961063|OTHER|laboratory biomarker analysis|Correlative studies
58100978|NCT05280873|DRUG|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
58429896|NCT02110797|OTHER|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
58429897|NCT06217588|OTHER|Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.|The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.
58429898|NCT00005107|DRUG|N-monomethyl-L-arginine|
58429899|NCT03761810|DRUG|S6G5T-3|Once a day topical cream
58100979|NCT03577652|DRUG|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
58100980|NCT05744531|OTHER|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
58100981|NCT02065973|BIOLOGICAL|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
58429900|NCT03761810|DRUG|S6G5T-8|Once a day topical cream
58429901|NCT04945109|OTHER|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
58429902|NCT04945109|OTHER|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
58429903|NCT04977219|BEHAVIORAL|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
58429904|NCT05648019|BIOLOGICAL|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
58429905|NCT05510674|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
58429906|NCT06099834|OTHER|Patients selection|Patient selection were selected according to selected criteria.
58429907|NCT06099834|OTHER|Implnat placement|dental implants were applied as recommended by the manufacturer.
58429908|NCT06099834|OTHER|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
58429909|NCT04672915|DIAGNOSTIC_TEST|test of HBV DNA|Real time PCR or nested PCR to check
58429910|NCT02036866|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
58429911|NCT02036866|OTHER|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
58429912|NCT02036866|OTHER|No Intervention|Patients will be instructed to maintain their usual activity level.
58429913|NCT00900367|OTHER|high performance liquid chromatography|
58429914|NCT00900367|OTHER|laboratory biomarker analysis|
58429915|NCT00900367|PROCEDURE|spectroscopy|
58429916|NCT05735249|DRUG|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
58429917|NCT05735249|DRUG|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
58429918|NCT02253784|DRUG|Dexamethasone|
58429919|NCT02253784|DRUG|Bupivacaine|
58429920|NCT03002714|OTHER|Exercise|
58429921|NCT03137498|DRUG|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
58429922|NCT03137498|DRUG|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
58429923|NCT01289366|DEVICE|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
58429924|NCT03541902|DRUG|Cabozantinib|Given PO
58429925|NCT03541902|DRUG|Sunitinib Malate|Given PO
57737004|NCT04144842|BIOLOGICAL|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
57737005|NCT03053050|DRUG|SEL|Tablets administered orally once daily
58429926|NCT02961946|DRUG|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
58429927|NCT04382378|DEVICE|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
58429928|NCT01729208|DEVICE|Dual Focus Soft Contact Lens|
58429929|NCT01729208|DEVICE|Single Vision Soft Contact Lens|
57737006|NCT03053050|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
57737007|NCT03053050|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
57953184|NCT05626270|DEVICE|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
57953185|NCT00001287|DRUG|intravenous immunoglobulin (IVIg)|
57961826|NCT03698006|DRUG|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
58429930|NCT04480216|DEVICE|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
58429931|NCT02252965|DRUG|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
58429932|NCT02252965|DRUG|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
58429933|NCT03695822|DRUG|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
58308536|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
58429934|NCT03037983|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
58429935|NCT03037983|DEVICE|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
58429936|NCT05607862|OTHER|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
58429937|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
58429938|NCT00854841|DRUG|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
58429939|NCT01706783|DRUG|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
58429940|NCT01706783|DRUG|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
58429941|NCT05462418|PROCEDURE|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
58429942|NCT05462418|PROCEDURE|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
58429943|NCT01979133|DRUG|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
57737008|NCT06670222|DRUG|Arsenic Trioxide (ATO)|"Study treatment: oral Arsenic 5d/7 for 21 days over a 28-day cycle, three doses tested (0.10 mg/kg, 0.15 mg/kg and 0.20 mg/kg).~Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme, 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients.~Tolerability will be assessed after one treatment cycle. Response will be assessed after 3 cycles of treatment. Responders may continue study treatment until progression or limiting toxicity. Limiting toxicity is defined as any grade III/IV extra-hematological toxicity or grade IV hematological toxicity lasting more than 25 days."
58458403|NCT01884077|DEVICE|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
57737009|NCT03414138|BEHAVIORAL|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
57737010|NCT03414138|BEHAVIORAL|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
57737011|NCT05942313|DRUG|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
57737012|NCT01771198|DRUG|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
57737013|NCT05774964|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
57737014|NCT05774964|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
57737015|NCT05774964|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
57737016|NCT05774964|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
57737017|NCT05774964|DRUG|Vitamin A|Vitamin A 5,000 units/time, qd
22443559|NCT06416423|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
22443560|NCT06416423|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
58429944|NCT04548518|BIOLOGICAL|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
58429945|NCT04548518|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
58429946|NCT06300268|DEVICE|AdvaPro Sirolimus Eluting Coronary Stent System|Cardiac Stent
58429947|NCT05708339|OTHER|virtually fabricated ear prosthesis|virtually designed ear prosthesis
58429948|NCT05708339|OTHER|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
58429949|NCT04739579|DIAGNOSTIC_TEST|C-Reactive Protein|C-Reactive Protein trend in post-operative course
58429950|NCT02650102|DRUG|Risperidone|a kind of antipsychotics
58429951|NCT02650102|DRUG|Olanzapine|a kind of antipsychotics
58429952|NCT02650102|DRUG|Quetiapine|a kind of antipsychotics
58429953|NCT02650102|DRUG|Aripiprazole|a kind of antipsychotics
58429954|NCT02650102|DRUG|Ziprasidone|a kind of antipsychotics
58429955|NCT03121703|OTHER|lumbar stabilization exercise|lumbar stabilization exercise
57737018|NCT05774964|DRUG|Folic acid|Folic acid 5 mg/time, qd
57737019|NCT01880424|DRUG|Placebo|matching Placebo Capsules, Oral, once daily
57737020|NCT01880424|DRUG|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
57737021|NCT00325468|DRUG|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
58429956|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
57961827|NCT03698006|DRUG|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
57961828|NCT03067909|OTHER|CIED surgery|
57961829|NCT06099587|DIAGNOSTIC_TEST|high-resolution diffusion MRI|The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
57961830|NCT03391947|PROCEDURE|semilunar coronally positioned flap|The description of this intervention has been already given before
57961831|NCT03391947|PROCEDURE|coronally advanced flap|The description of this intervention has been already given before
57961832|NCT02566304|DRUG|Fludarabine|Given IV
57961833|NCT02566304|RADIATION|Total-Body Irradiation|Undergo TBI
57961834|NCT02566304|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
57961835|NCT02566304|DRUG|Cyclophosphamide|Given IV
57961836|NCT02566304|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
57961837|NCT02566304|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
57961838|NCT02566304|DRUG|Tacrolimus|Given PO
57961839|NCT02566304|DRUG|Mycophenolate mofetil|Given IV
57961840|NCT02566304|OTHER|Laboratory Biomarker Analysis|Correlative studies
57961841|NCT04240977|BEHAVIORAL|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
57961842|NCT02062658|DRUG|Ketamine|0.5mg/kg IV
57961843|NCT02062658|BEHAVIORAL|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
57961844|NCT00924937|BEHAVIORAL|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).
57961845|NCT00924937|BEHAVIORAL|Low Fat Diet|Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
57961846|NCT02681016|DEVICE|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
57953186|NCT03682679|DIAGNOSTIC_TEST|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
57953187|NCT00333359|DRUG|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
58308537|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
58308538|NCT03580018|DRUG|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
58308539|NCT03580018|PROCEDURE|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
58308540|NCT05171907|BEHAVIORAL|Teleobesity|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
58308541|NCT04451018|OTHER|evaluation of arterial anomalies in upper limbs|evaluation of arterial anomalies in upper limbs with doppler ultrasound
58308542|NCT03150459|DRUG|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
58308543|NCT03150459|DRUG|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
58308544|NCT03150459|DRUG|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
58308545|NCT03150459|OTHER|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
57953188|NCT03505021|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
57953189|NCT03505021|DRUG|Placebo for levosimendan|Placebo capsule for oral administration
57953190|NCT03742414|COMBINATION_PRODUCT|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
58308546|NCT03150459|OTHER|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
58308547|NCT03159143|DRUG|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
58308548|NCT03159143|DRUG|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
58429957|NCT00306709|BEHAVIORAL|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
58429958|NCT00524615|DRUG|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
58458404|NCT01884077|DEVICE|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
58458405|NCT00871767|DRUG|AZD5672|40 mg tablet (Test formulation)
58100982|NCT06454903|BEHAVIORAL|ACT to RECOVER|During Phase 3 (Stage 1b RCT), the treatment condition will employ ACT to RECOVER. ACT to RECOVER will be a smartphone app designed to act as a flexible, semi-structured, user-friendly adjunct to standard medication treatment for opioid use disorder. Content will include components appropriate for either self-management and/or use with providers. ACT to RECOVER will be designed to have major ACT-focused modules completable within 1 month.
58100983|NCT06454903|BEHAVIORAL|Smartphone-based Symptom-Monitoring|During Phase 3 (Stage 1b RCT), the control condition will employ a smartphone-based symptom monitoring program in an effort to provide a balanced alternative to the treatment condition with respect to attention, time using a mobile application, and nonspecific intervention effects. This condition will not, however, include any content or components from the Prototype Digital Intervention hypothesized to produce active clinical effects.
58100984|NCT04514328|DEVICE|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
58100985|NCT05797857|OTHER|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
58429959|NCT04078984|OTHER|Experimental|"* Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
58100986|NCT02029313|DRUG|Montelukast|
58308549|NCT04937790|BEHAVIORAL|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
58308550|NCT04937790|BEHAVIORAL|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
58308551|NCT00947206|BEHAVIORAL|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
58308552|NCT00947206|BEHAVIORAL|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
58308553|NCT06094816|DRUG|Furosemide (Diuretic)|The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
58308554|NCT06094816|OTHER|Hypertonic Saline Infusion|3% Hypertonic saline infusion to acutely increase sodium and osmolality
58308555|NCT04779177|DRUG|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
58308556|NCT04779177|DRUG|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
58308557|NCT02240667|DRUG|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
58308558|NCT02240667|DRUG|Vitamin K antagonists|International Normalized Ratio (INR) 2-3
58308559|NCT00774085|OTHER|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
58308560|NCT02151721|DRUG|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
58308561|NCT01224379|DEVICE|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
58429960|NCT02921087|DEVICE|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
58100987|NCT02029313|DRUG|Montelukast sodium|
58100988|NCT06456398|OTHER|Virtual reality|"Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans."
58308562|NCT01224379|DEVICE|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
58308563|NCT03736967|DRUG|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
58308564|NCT03736967|DRUG|Dupilumab|Administered SC q2w
58308565|NCT03736967|DRUG|REGN3500 + Dupilumab Combo|Administered SC q2w
58308566|NCT03736967|DRUG|Placebo|Administered SC q2w
58308567|NCT01367197|BEHAVIORAL|exercise training|group based exercise training
58308568|NCT05939687|PROCEDURE|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
58308569|NCT05939687|PROCEDURE|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
58429961|NCT02921087|DEVICE|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
58458406|NCT00871767|DRUG|AZD5672|40 mg tablet (Reference formulation)
58458407|NCT00871767|DRUG|AZD5672|100 mg tablet (Test formulation)
58429962|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
57953191|NCT03742414|COMBINATION_PRODUCT|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
58100989|NCT03304990|OTHER|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
58100990|NCT00000282|DRUG|Pemoline|
58100991|NCT05151172|DEVICE|endovascular thrombectomy (EVT)|minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
58100992|NCT05151172|OTHER|Standarad medical care|Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
58100993|NCT06416007|RADIATION|Lattice therapy (LRT)|5 Fractions LRT
58100994|NCT01953627|PROCEDURE|Surgical procedure with the system Kymerax|
58100995|NCT01953627|DEVICE|The system Kymerax|
58100996|NCT03903952|DIETARY_SUPPLEMENT|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
58100997|NCT06541613|DRUG|local anesthetic injection (bupivacaine)|The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
58100998|NCT06541613|OTHER|normal saline injection|the control group will receive 30ml of normal saline bilaterally into the external oblique intercostal plane on both sides
58100999|NCT01094873|BIOLOGICAL|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
58101000|NCT01094873|BIOLOGICAL|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
58101001|NCT03417531|DIETARY_SUPPLEMENT|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
58101002|NCT03417531|DIETARY_SUPPLEMENT|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
58101003|NCT03417531|PROCEDURE|Active Exercise|Program includes five strength exercises that can be easily performed at home
58101004|NCT03417531|PROCEDURE|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
58101005|NCT03582501|OTHER|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
58101006|NCT04209244|DIETARY_SUPPLEMENT|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
58101007|NCT04209244|DIETARY_SUPPLEMENT|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
58429963|NCT03369236|DRUG|Danicopan|Danicopan was administered as an oral tablet.
58429964|NCT03369236|DRUG|Placebo|Matching placebo was administered as an oral tablet.
58101008|NCT06073717|BEHAVIORAL|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
58101009|NCT06073717|BEHAVIORAL|Motor-cognitive Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
58101010|NCT06073717|BEHAVIORAL|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
58101011|NCT00422773|DRUG|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
58101012|NCT03406039|BEHAVIORAL|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
58101013|NCT03016104|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
58429965|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
58429966|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
58429967|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
58308570|NCT01878799|DRUG|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
58308571|NCT06400901|OTHER|No interventions|No interventions were given to patients except for the deep brain stimulation surgery they originally planned to take
57953192|NCT03742414|OTHER|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
57953193|NCT00848861|DRUG|propofol (sedation for outpatient colonoscopy)|
57953194|NCT00848861|DRUG|midazolam plus meperidine (sedation for outpatient colonoscopy)|
58308572|NCT00012116|DRUG|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
57953195|NCT05022329|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|This arm receives Pfizer-BioNTech COVID-19 Vaccine
58308573|NCT05461066|BEHAVIORAL|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
58429968|NCT01545440|DRUG|placebo|subcutaneous dose every 4 weeks
58458408|NCT00871767|DRUG|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
57953196|NCT05022329|BIOLOGICAL|MODERNA SARS-CoV-2 Vaccine|This arm receives MODERNA SARS-CoV-2 Vaccine
58308574|NCT04700865|DIAGNOSTIC_TEST|AF screening|Continous ECG monitoring for minimum 3 days
58308575|NCT00236626|DRUG|topiramate|
58458409|NCT06005935|OTHER|Survey|Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
58101014|NCT03016104|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
58429969|NCT05768815|BEHAVIORAL|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
58101015|NCT03016104|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
58101016|NCT04009057|OTHER|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
58101017|NCT04295109|DRUG|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
58429970|NCT05768815|BEHAVIORAL|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
58429971|NCT01408342|DRUG|Alemtuzumab and Rituximab|"* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21"
58429972|NCT03267914|OTHER|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
58429973|NCT03267914|OTHER|Brush|Patients will brush with the fluoride for 2 minutes each day.
58429974|NCT00562146|PROCEDURE|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
58308576|NCT03460041|DRUG|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
57737022|NCT01920230|BEHAVIORAL|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
57737023|NCT01920230|BEHAVIORAL|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
58101018|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
58101019|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
58101020|NCT00390169|BEHAVIORAL|Mindfulness Meditation-Based Stress Reduction|
58308577|NCT03460041|DRUG|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
58308578|NCT03460041|DRUG|Bupivacaine|Caudal bupivacaine for pain management
58308579|NCT03328988|PROCEDURE|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
58308580|NCT03113734|OTHER|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
58308581|NCT05707221|OTHER|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
58308582|NCT05707221|OTHER|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
58308583|NCT05707221|OTHER|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
58308584|NCT03363906|DRUG|Dulaglutide (Reference)|Administered SC
58308585|NCT03363906|DRUG|Dulaglutide (Test)|Administered SC
58308586|NCT06414863|DEVICE|IPE|"Invisalign palatal expander system:~The Invisalign® Palatal Expander System (AlignTechnology, inc.) is 3D-printed orthodontic device for maxillary expansion."
58429975|NCT01091818|DRUG|dexmedetomidine|Dexemedethomidine is given as major sedative drug
58101021|NCT00390169|BEHAVIORAL|Supportive-Expressive Group Therapy|
58308587|NCT06414863|DEVICE|HE|"Hyrax expander:~The Hyrax-type maxillary expander will include a midline self-locking screw. The expansion screw is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician"
58101022|NCT04034199|DRUG|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
58101023|NCT04034199|DRUG|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
58101024|NCT02104401|DEVICE|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
58101025|NCT05854277|OTHER|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
58101026|NCT05245617|DEVICE|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
58429976|NCT01091818|DRUG|Midazolam|Midazolam is given as major sedative drug
58429977|NCT03048877|DRUG|Apatinib Oral Tablet|Apatinib Mesylate Tablets
58429978|NCT03048877|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
58429979|NCT00216489|DRUG|rabeprazole sodium|
58429980|NCT04374955|DIETARY_SUPPLEMENT|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
58101027|NCT05467449|DEVICE|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
58101028|NCT03753373|OTHER|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
58308588|NCT05403645|DIAGNOSTIC_TEST|Movement With Mobilization|with the help of Movement With Mobilization technique
58308589|NCT05403645|DIAGNOSTIC_TEST|Exercise Therapy|with the help of Exercise Therapy technique
58308590|NCT04933318|OTHER|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
58429981|NCT04374955|OTHER|Routine care|Routine care of the hospital will be provided.
58429982|NCT06577415|DRUG|RAY1225|Administered SC
58429983|NCT01835834|PROCEDURE|zirconia bridge restoration|
58429984|NCT06525064|OTHER|Health-E You app|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
58429985|NCT01086943|DEVICE|LT2420|
58429986|NCT02572622|OTHER|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
58429987|NCT02572622|OTHER|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
58101029|NCT03753373|OTHER|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
58101030|NCT02094430|DRUG|biological: human fibrinogen concentrate|
58101031|NCT02917356|OTHER|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
58101032|NCT02917356|OTHER|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
58101033|NCT02917356|OTHER|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
58308591|NCT04933318|OTHER|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
58308592|NCT04933318|OTHER|IFC|Interferential current therapy (IFC)- analgesic current therapy
58308593|NCT04933318|OTHER|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
57737024|NCT06086730|DEVICE|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.
57953197|NCT06046144|DIAGNOSTIC_TEST|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
57953198|NCT06046144|DIAGNOSTIC_TEST|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
58308594|NCT06005649|BIOLOGICAL|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells"
58308595|NCT05775380|DRUG|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
58308596|NCT01628536|DIETARY_SUPPLEMENT|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
58308597|NCT04447859|DRUG|Semaglutide|Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
58308598|NCT04447859|OTHER|label recommended titration|label recommended titration
58308599|NCT03424148|DEVICE|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
58308600|NCT05598567|OTHER|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
58308601|NCT05598567|OTHER|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
58308602|NCT03805841|DRUG|tarloxotinib bromide|weekly intravenous infusion
58308603|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
58308604|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
58308605|NCT05285111|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
58308606|NCT05285111|BEHAVIORAL|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
58308607|NCT01788761|DIETARY_SUPPLEMENT|Probiotic Supplemented Group|
58308608|NCT01788761|DIETARY_SUPPLEMENT|Control Group|
58308609|NCT05571410|BEHAVIORAL|HTN Chat bot|Remote monitoring via automated messaging program
58308610|NCT00906321|BEHAVIORAL|Web-Based Decision Support|
58308611|NCT02581592|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
57953199|NCT06046144|DIAGNOSTIC_TEST|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
57953200|NCT05711004|BEHAVIORAL|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
57953201|NCT06373809|BIOLOGICAL|Transplantation of Placenta Derived Stem Cells|Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
57953202|NCT03223428|DRUG|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
58308612|NCT04039724|DRUG|HCP0605 + HGP0816|
58308613|NCT04039724|DRUG|HCP1305|
58101034|NCT04078087|DRUG|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
58101035|NCT04078087|DRUG|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
58101036|NCT05005676|DIAGNOSTIC_TEST|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
58308614|NCT03181308|DRUG|Carotuximab (TRC105)|Anti Endoglin Antibody
58308615|NCT03181308|DRUG|OPDIVO|Programmed Death Receptor-1
58308616|NCT02009943|DRUG|Ferric carboxymaltose|One time dosing
58429988|NCT02572622|OTHER|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
58429989|NCT02572622|OTHER|exercise|special lumbar stabilization exercises were applied in advanced protocol.
58429990|NCT04768803|BIOLOGICAL|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
58429991|NCT06331689|OTHER|Mortality ratio|Mortality rates at 30-day, 90-day and 1-year intervals
58308617|NCT02009943|DRUG|Iron sucrose|Goal-directed dosing
58308618|NCT05912556|DEVICE|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
58429992|NCT06168617|DIAGNOSTIC_TEST|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
58429993|NCT03761069|DRUG|PTC299|PTC299 will be administered per the treatment arm description
57953203|NCT02114437|DEVICE|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
58101037|NCT00205465|DRUG|VX-765|
58101038|NCT03550794|DRUG|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
58308619|NCT05912556|DEVICE|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
58308620|NCT05144763|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
58308621|NCT01987856|PROCEDURE|Blastocyst morphology|microscopic examination only
58308622|NCT00386334|DRUG|Eszopiclone|2 mg tablet once per day in the evening
58308623|NCT00386334|DRUG|Placebo|Tablet one per day in the evening.
58429994|NCT00255528|DRUG|metoprolol succinate|
58429995|NCT05026203|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
58101039|NCT03550794|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
58101040|NCT03545529|OTHER|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
58101041|NCT03874533|DEVICE|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
58101042|NCT06538636|OTHER|PCP-Facing Tools|PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
58308624|NCT02590458|PROCEDURE|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
58308625|NCT02590458|BEHAVIORAL|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
58308626|NCT00477009|DEVICE|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
58308627|NCT02354768|DRUG|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
58308628|NCT02354768|DRUG|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
58308629|NCT03684746|OTHER|No Intervention|It is an observational Study with staff
58429996|NCT05026203|DRUG|Midazolam|Midazolam
58429997|NCT02756494|BIOLOGICAL|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
58308630|NCT03922880|DRUG|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
58308631|NCT03922880|DRUG|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
58429998|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
58429999|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
58430000|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
58430001|NCT02645630|OTHER|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
58458410|NCT04303455|DIAGNOSTIC_TEST|blood sampling|sampling serum renin
58430002|NCT02645630|OTHER|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
58430003|NCT02645630|OTHER|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
58101043|NCT06538636|OTHER|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
58101044|NCT03745027|DIAGNOSTIC_TEST|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
58101045|NCT05155072|DRUG|DW1903|DW1903
58101046|NCT05155072|DRUG|DW1903-R1|DW1903-R1
58101047|NCT05155072|DRUG|DW1903-R2|DW1903-R2
58430004|NCT00102427|BEHAVIORAL|Telephone-based collaborative care management|
58430005|NCT02706197|DEVICE|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
58430006|NCT00988572|OTHER|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
57953204|NCT02114437|DEVICE|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
57953205|NCT06300658|DRUG|Stellate ganglion block|Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
57953206|NCT02102321|DRUG|albendazole|
57953207|NCT02102321|DRUG|placebo|
58101048|NCT01741909|BEHAVIORAL|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
58101049|NCT03149965|OTHER|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
58101050|NCT04635904|BEHAVIORAL|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
58101051|NCT04635904|BEHAVIORAL|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
58101052|NCT04089137|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
58101053|NCT03871569|OTHER|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
58101054|NCT06528327|OTHER|Pre coated impants|Pre coated impants with microstructured bioactive antimicrobial coating with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
58101055|NCT06528327|OTHER|Non coated implant surface|Non-coated implant with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
58101056|NCT00769431|OTHER|educational intervention|
58101057|NCT00769431|OTHER|study of socioeconomic and demographic variables|
58308632|NCT03922880|DRUG|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
58308633|NCT03847571|DRUG|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
58308634|NCT04585919|BEHAVIORAL|Paired Screening Intervention|The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
58308635|NCT02858401|DRUG|Vesatolimod|Tablet(s) administered orally once every 2 weeks
58430007|NCT03634254|OTHER|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
58430008|NCT01652131|OTHER|Tetrastarch (130/0.4)|
58430009|NCT05254249|DRUG|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
58430010|NCT05254249|OTHER|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
58458411|NCT00648336|DRUG|Mercaptopurine 50 mg|50mg, single dose fasting
58458412|NCT00648336|DRUG|Purinethol® Tablets 50 mg|50mg, single dose fasting
57953208|NCT01705600|BEHAVIORAL|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
58101058|NCT03876873|PROCEDURE|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
58101059|NCT03876873|DEVICE|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
58101060|NCT06428526|DEVICE|Continuous stimulation strategy|Participants will be administered stimulation with a constant frequency stimulation.
58308636|NCT02858401|DRUG|Placebo|Tablet(s) administered orally once every 2 weeks
58308637|NCT02858401|DRUG|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
58308638|NCT06157450|DRUG|ZSP1273|Participants receive ZSP1273 orally.
58308639|NCT05348252|OTHER|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
58308640|NCT05348252|OTHER|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
58101061|NCT06428526|DEVICE|Closed-loop stimulation strategy|Participants will be administered with an activity-dependent stimulation.
58101062|NCT05784727|DEVICE|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
58308641|NCT04213443|OTHER|Analysis of a patient registry|Analysis of a patient registry.
58458413|NCT06274463|BEHAVIORAL|Exercise therapy including a trunk stabilization exercise program|All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
58101063|NCT05200507|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
58430011|NCT05697068|BEHAVIORAL|COVID Prevention Program (CPP)|This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
58430012|NCT02037906|RADIATION|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
58101064|NCT00640614|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
58101065|NCT05100394|RADIATION|Laser Therapy|Therapeutic laser therapy was applied.
58101066|NCT05100394|OTHER|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
58101067|NCT01835470|DRUG|Abatacept|
58101068|NCT04307537|PROCEDURE|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
58430013|NCT02037906|RADIATION|Constant Energy SWL|Constant dose at 20 kv
58430014|NCT02037906|RADIATION|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
58430015|NCT04297605|DRUG|Pembrolizumab|Pembrolizumab 200 mg
58430016|NCT04297605|OTHER|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
58430017|NCT04297605|OTHER|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
58430018|NCT00219778|DRUG|mifepristone|
58430019|NCT02170181|RADIATION|SBRT|SBRT to Oligometastases
58430020|NCT05767827|DRUG|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
58101069|NCT02317094|OTHER|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
58101070|NCT02317094|DRUG|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
58101071|NCT01412710|DRUG|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
58101072|NCT02215239|BEHAVIORAL|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
58101073|NCT01558869|DRUG|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
58101074|NCT01558869|DRUG|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
58101075|NCT01558869|DRUG|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
57953209|NCT03797586|OTHER|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
58101076|NCT06568965|OTHER|De-stress & happy gut powder-U001|Take one sachet daily, 30 minutes before breakfast, for 60 days
58101077|NCT06568965|OTHER|De-Stress & Happy Gut powder-I001|Take one sachet daily, 30 minutes before breakfast, for 60 days
58101078|NCT06568965|OTHER|Placebo Powder 001|Take one sachet daily, 30 minutes before breakfast, for 60 days
58101079|NCT04959006|DIETARY_SUPPLEMENT|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
58101080|NCT04959006|DIETARY_SUPPLEMENT|Placebo|Placebo
58101081|NCT05257174|DIETARY_SUPPLEMENT|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
58101082|NCT05257174|DIETARY_SUPPLEMENT|Placebo|intake Placebo twice daily for three months
58101083|NCT01638754|PROCEDURE|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
58101084|NCT01638754|PROCEDURE|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
58101085|NCT04580472|DRUG|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
58308642|NCT02084524|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
58308643|NCT00533338|BEHAVIORAL|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
58308644|NCT00533338|BEHAVIORAL|Questionnaire|Packet of questionnaires will be completed.
58308645|NCT01472055|DRUG|Fludarabine|"1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
58101086|NCT04580472|OTHER|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
58101087|NCT00127569|DRUG|Rituximab|
58101088|NCT02603159|DRUG|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
58101089|NCT02603159|RADIATION|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
58101090|NCT05398731|OTHER|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
58308646|NCT05294952|GENETIC|real time PCR|diagnostic test
58101091|NCT02881463|OTHER|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
58101092|NCT01538589|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
58101093|NCT06566105|GENETIC|precision medicine approach|precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
58101094|NCT03821831|DEVICE|Continuous Positive Airway Pressure|CPAP machine
58101095|NCT03821831|DEVICE|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
58101096|NCT02693652|BIOLOGICAL|CVI-HBV-002|"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"
58101097|NCT00437710|PROCEDURE|cell therapy, bone marrow derived stem cell|
58101098|NCT06254521|DRUG|Tislelizumab combined with chemotherapy|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic"
58101099|NCT02268019|PROCEDURE|tourniquet application|
58101100|NCT02268019|DRUG|epinephrine injection|
58101101|NCT04744077|BEHAVIORAL|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
58101102|NCT04744077|BEHAVIORAL|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
58101103|NCT00566631|DRUG|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
58101104|NCT00517257|DRUG|Atorvastatin|80 mg orally once daily for 24 weeks
58101105|NCT00517257|DRUG|Placebo|Placebo tablet orally once daily for 24 weeks
58101106|NCT01770678|OTHER|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
58101107|NCT01284569|BIOLOGICAL|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
58430021|NCT05767827|DRUG|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
58101108|NCT01284569|BIOLOGICAL|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
58101109|NCT01048268|DRUG|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
58101110|NCT01048268|DRUG|Placebo|copy GIP infusion rates
58101111|NCT00546832|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
58101112|NCT00546832|DRUG|celecoxib|
58101113|NCT00546832|OTHER|placebo|
58101114|NCT05341115|DRUG|Leuprorelin Acetate Depot 3M|Leuprorelin Acetate Depot 3M SC injections.
58101115|NCT01445873|DRUG|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
58101116|NCT00802269|PROCEDURE|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
58308647|NCT03510065|DEVICE|Prevision®|One time Evaluation with documentation of one follow-up visit
58308648|NCT05402709|OTHER|Posterior mobilisation technique|Posterior mobilisation technique were applied
58308649|NCT05402709|OTHER|Posterior capsule stretching|Posterior capsule stretching were applied
58308650|NCT04539418|DRUG|Vitamin K 2|Patients will be monitored during the whole protocol.
58430022|NCT04978818|DRUG|Vaxelis|Eligible infants will be block randomized to one of two study arms.
58430023|NCT04978818|DRUG|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
58430024|NCT02625714|DRUG|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
58430025|NCT02625714|DRUG|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
58458414|NCT04886323|DEVICE|Cold atmospheric plasma treatment device|Treat with cold atmospheric plasma treatment device.
58458415|NCT04886323|DRUG|Itraconazole Capsules|Treat with Itraconazole capsules
58101117|NCT02441179|OTHER|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
57737025|NCT06086730|DEVICE|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes"
57737026|NCT06670729|OTHER|Quran listening|listening to quran recitation via head phone
57737027|NCT06670729|OTHER|silent headphones group|headphones were silent, patient do not listen to any thing
57953210|NCT03797586|OTHER|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
58101118|NCT02441179|OTHER|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
58101119|NCT02441179|OTHER|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
58101120|NCT01925742|OTHER|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
58101121|NCT01925742|OTHER|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
58101122|NCT01925742|OTHER|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
58101123|NCT01925742|OTHER|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
58101124|NCT01925742|OTHER|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
58101125|NCT04363294|DIAGNOSTIC_TEST|PYP scan|99mTc-labeled pyrophosphate
58101126|NCT04559217|BIOLOGICAL|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
58101127|NCT02306434|BEHAVIORAL|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
58101128|NCT02306434|OTHER|Standard care-counselling|Standard care (Counselling by midwives)
58101129|NCT05050357|DEVICE|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
58101130|NCT05050357|DRUG|Progestins Norethindrone|oral ethisteron twice daily for three months
58101131|NCT03940586|DRUG|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
58101132|NCT03940586|DRUG|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
57953211|NCT03270735|DRUG|Snake venom thrombin (Treatment)|Snake venom thrombin
58101133|NCT03940586|DRUG|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
58101134|NCT04304846|OTHER|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
58101135|NCT03719261|DRUG|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
58308651|NCT04616443|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
58308652|NCT04616443|BIOLOGICAL|HX008 injection|Recombinant humanized anti-PD-1 monoclonal antibody of injection
58308653|NCT01537172|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
57737028|NCT02955511|DEVICE|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
57737029|NCT02955511|DEVICE|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
57737030|NCT02955511|DEVICE|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
57737031|NCT02904304|DRUG|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
57737032|NCT02904304|DRUG|Placebo|01 tablet, orally, every 12 hours.
57953212|NCT03270735|DRUG|Placebo|No snake venom thrombin
57737033|NCT03943732|DIAGNOSTIC_TEST|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
57953213|NCT05511272|BIOLOGICAL|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
58101136|NCT03719261|DRUG|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
58101137|NCT00731510|DIETARY_SUPPLEMENT|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
58101138|NCT00731510|DIETARY_SUPPLEMENT|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
58101139|NCT05764902|BEHAVIORAL|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
58101140|NCT02585531|DRUG|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
58101141|NCT02585531|DRUG|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
58101142|NCT03341715|DRUG|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
58308654|NCT01537172|DRUG|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
58308655|NCT05332223|DIAGNOSTIC_TEST|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
58308656|NCT00626639|DRUG|Placebo|Administered by intravenous (IV) bolus injection
58308657|NCT00626639|DRUG|palifermin|Administered by intravenous (IV) bolus injection
58308658|NCT00626639|RADIATION|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
57737034|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
57953214|NCT05875259|DRUG|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
57953215|NCT05875259|DRUG|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
57953216|NCT05875259|DRUG|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
57953217|NCT02858414|OTHER|additional blood sample|
57953218|NCT06076512|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
57953219|NCT05314608|COMBINATION_PRODUCT|IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee|Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
57953220|NCT03186170|OTHER|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
57953221|NCT03443674|DRUG|SCB-313|Lyophilized powder in a single-use vial
57953222|NCT03278470|DRUG|HL237|Experimental
57953223|NCT03278470|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
57953224|NCT02656095|DRUG|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
57953225|NCT05735431|DRUG|Administration of investigation drug|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
57953226|NCT05735431|DRUG|Administration of comparator|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
57953227|NCT03287219|DRUG|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
57953228|NCT00150657|DRUG|bevacizumab|
57953229|NCT00150657|DRUG|carboplatin|
57953230|NCT00150657|DRUG|gemcitabine|
58101143|NCT03341715|OTHER|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
58101144|NCT04242368|DRUG|Isotonic saline|Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
58101145|NCT04242368|DRUG|Hypertonic Nasal Wash|Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
58101146|NCT04242368|DRUG|Fluticasone Propionate|Fluticasone nasal spray administered two sprays to each nare twice a day
58101147|NCT04276285|PROCEDURE|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
58101148|NCT04276285|PROCEDURE|US TAP|Subcostal TAP block will be performed after surgery under US guidance
58101149|NCT04325061|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
58101150|NCT00732394|OTHER|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
58101151|NCT02460315|PROCEDURE|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
58101152|NCT02460315|PROCEDURE|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
58101153|NCT03964220|DRUG|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
58101154|NCT03964220|DRUG|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
58101155|NCT03604601|PROCEDURE|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
58101156|NCT04442373|DIAGNOSTIC_TEST|Rotational thromboelastometry|1.8 ml blood sample
58101157|NCT01020773|BEHAVIORAL|spontaneous breathing trial|
58101158|NCT02129530|BEHAVIORAL|Community Social Mobilization program|
58101159|NCT02295280|DRUG|Metoclopramide|IV
58101160|NCT02295280|DRUG|Diphenhydramine|iv
58101161|NCT02295280|DRUG|Codeine|PO
57737035|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
58101162|NCT01456000|DEVICE|EAS-AC (HeartLight)|Pulmonary vien isolation
58101163|NCT01456000|PROCEDURE|Control Arm Ablation|Treatment with standard ablation.
58101164|NCT00959387|DRUG|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
58101165|NCT00959387|RADIATION|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
58308659|NCT00626639|DRUG|Cisplatin|100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
57737036|NCT00373334|DRUG|placebo|placebo
57737037|NCT05883813|PROCEDURE|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction \& maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
57737038|NCT05883813|PROCEDURE|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
58308660|NCT06208501|DIAGNOSTIC_TEST|Urine sample for proteomic analysis|Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
58308661|NCT06208501|DIAGNOSTIC_TEST|ABPM|ABPM in screen visit and 3 months after renal denervation procedure.
58308662|NCT06208501|DIAGNOSTIC_TEST|OBPM|OBPM in screen visit and 3 months after renal denervation procedure.
57737039|NCT05883813|PROCEDURE|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
58101166|NCT04857684|DRUG|Atezolizumab|Intravenous Infusion
58101167|NCT04857684|DRUG|Bevacizumab|Intravenous Infusion
58101168|NCT04857684|RADIATION|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
58101169|NCT05614999|OTHER|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
58101170|NCT02362594|BIOLOGICAL|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
58101171|NCT02362594|DRUG|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
58101172|NCT01234428|PROCEDURE|Laparoscopic surgery|Gastric banding
58308663|NCT04552197|DRUG|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
58101173|NCT01234428|PROCEDURE|gastric banding|laparoscopic gastric banding
58101174|NCT00665626|DRUG|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
58101175|NCT00665626|DRUG|Placebo|Placebo, orally, twice-a-day
58101176|NCT05178043|DRUG|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
58101177|NCT05178043|DRUG|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
58101178|NCT06538168|BEHAVIORAL|Diabetes Self-Management Education (DSME)|The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
58101179|NCT02875067|BIOLOGICAL|Pembrolizumab|
58101180|NCT02875067|DRUG|Lenalidomide|
58101181|NCT00530452|DRUG|CG100649|Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
58101182|NCT00530452|DRUG|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
58101183|NCT02453100|BEHAVIORAL|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
58101184|NCT02453100|BEHAVIORAL|Education|Education on simple ways to manage incontinence
58101185|NCT00410215|DRUG|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
58101186|NCT00410215|DRUG|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
58101187|NCT00410215|DRUG|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
58101188|NCT05652816|PROCEDURE|Split-thickness skin graft|Transplantation of autologous skin to burn area
58101189|NCT05652816|BIOLOGICAL|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
58101190|NCT05652816|BIOLOGICAL|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
58101191|NCT03087929|OTHER|Follow up|
58101192|NCT05303831|OTHER|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
58101193|NCT01311856|BEHAVIORAL|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
57737040|NCT06610617|DEVICE|transcranial direct current stimulation (tDCS)|tDCS designed to facilitate the excitability of the left dlPFC or sham stimulation on separate visits separated by at least one week in random order, using a double-blinded, within-subject crossover design. Electrode placement and current parameters will be optimized to each participant with the goal of generating an average electric field of 0.25 V/m within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA using the Stimweaver algorithm. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort
57737041|NCT06610617|DEVICE|Sham tDCS|Active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention delivers currents and mimics the sensations induced by tDCS, but does not significantly influence cortical tissue.
58101194|NCT01311856|BEHAVIORAL|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
58101195|NCT01311856|BEHAVIORAL|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
58101196|NCT01311856|BEHAVIORAL|Exercise and Diet|15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
58101197|NCT06212232|PROCEDURE|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
58101198|NCT02023320|DIETARY_SUPPLEMENT|Low dose of blueberry dry powder|
58101199|NCT02023320|DIETARY_SUPPLEMENT|High dose of blueberry dry powder|
58101200|NCT02194231|DRUG|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
58101201|NCT04395131|DEVICE|Clearum HF Hemodialyzer|the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
58430026|NCT02430987|DIAGNOSTIC_TEST|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of \>23 and \> 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria \> 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
58308664|NCT04552197|DRUG|Tofacitinib|Tofacitinib tablets will be administered orally.
58101202|NCT04492007|BEHAVIORAL|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
58101203|NCT02243059|DRUG|Gadofosveset trisodium (Ablavar™ )|
58101204|NCT02243059|DEVICE|MRI|
58101205|NCT05715788|DRUG|Nitric oxide|Nitric oxide inhalation at 20 ppm
58101206|NCT05715788|BEHAVIORAL|prone positioning|vatilation in prone position
58101207|NCT03554642|DEVICE|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
58101208|NCT03554642|BEHAVIORAL|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
58430027|NCT02430987|DIAGNOSTIC_TEST|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
58101209|NCT06279936|OTHER|Neuropsychological battery|COVID-19 patients with persistent complaints of cognitive disabilities (more than 4 weeks post-infection) in daily life are examined with an extensive neuropsychological test battery (see below) at the outpatient clinic of the University Psychiatric Centre in Duffel and at the University Hospital Antwerp. This battery covers a broad range of reliable and valid tests divided into six cognitive domains: attention, memory, visuospatial functions, language, executive functions and psychomotor speed/coordination. The neuropsychological examination lasts an average of 2 hours per participant. The tests are carried out by the same experienced neuropsychologist and also follow a standardized sequence. In addition to the neuropsychological assessment, two self-report scales are filled out by each patient. These scales are used to detect possible complaints of fatigue and possible cognitive problems which are experienced by the patient during daily life activities.
58101210|NCT06279936|OTHER|Surveys and symptom severity questionnaires|Both self-rated surveys and clinician administered questionnaires
58101211|NCT06279936|OTHER|Blood withdrawal|"Blood samples will be collected in a standardized manner by venipuncture. Two blood vials will be collected and processed to perform the following analyses:~* serum collection tube(s) allowing for HERV-W ENV and serological assays~* plasma collection tubes for the assessment of other immune-related biomarkers (including but not limited to CRP, IL-6, IL-1b, TNF-a, IFN-g, tryptophan, kynurenine, 3-OH-kynurenine, quinolinic acid, kynurenic acid, enzymes of the kynurenine pathway)."
58430028|NCT02430987|DIAGNOSTIC_TEST|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
58430029|NCT05819320|OTHER|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
58430030|NCT00518193|DRUG|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
58430031|NCT00935441|BEHAVIORAL|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
58430032|NCT00935441|BEHAVIORAL|usual case management|telephone contact with a case manager
58430033|NCT02709876|BIOLOGICAL|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
58430034|NCT04530500|GENETIC|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
58430035|NCT01537822|PROCEDURE|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
58430036|NCT01537822|PROCEDURE|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
58430037|NCT02879578|DRUG|Valbenazine|
58101212|NCT06279936|OTHER|Saliva swabs|Salivary cortisol measures will be used as functional measure of the HPA axis activity, as the unbound cortisol fraction in saliva is highly correlated to plasma cortisol. Baseline diurnal cortisol and CAR levels will be measured using saliva, collected at home with Salivette® (Sarstedt) synthetic swabs. The rationale behind the choice of home sampling, is to maximize normal circumstances and to minimize stress related to the measuring procedure.
58101213|NCT05147285|OTHER|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
58101214|NCT05147285|OTHER|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
58101215|NCT05147285|OTHER|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
58101216|NCT03673475|PROCEDURE|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
58101217|NCT04069104|BEHAVIORAL|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
58101218|NCT04069104|BEHAVIORAL|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
58101219|NCT04069104|BEHAVIORAL|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
58101220|NCT04069104|BEHAVIORAL|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
58430038|NCT02634827|DRUG|Decitabine|Given IV
57737042|NCT02081846|OTHER|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
57737043|NCT02081846|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
57737044|NCT03959865|DRUG|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
57737045|NCT03959865|DRUG|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
58101221|NCT04368182|BIOLOGICAL|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
58430039|NCT02634827|OTHER|Laboratory Biomarker Analysis|Correlative studies
57737046|NCT03959865|DRUG|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
57737047|NCT03959865|DRUG|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
58430040|NCT02634827|DRUG|Midostaurin|Given PO
58430041|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
58458416|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
58458417|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
58101222|NCT01783899|DEVICE|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
58101223|NCT05602935|DRUG|Camrelizumab|200mg, intravenously, d1
58101224|NCT05602935|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
58101225|NCT05602935|PROCEDURE|Surgery|Surgery
58101226|NCT00776269|PROCEDURE|argon laser and radiofrequency|
58101227|NCT00324090|BEHAVIORAL|High and low glycemic index|
58101228|NCT00047437|BEHAVIORAL|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
58101229|NCT02135094|DEVICE|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
58101230|NCT02135094|DEVICE|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
58101231|NCT04368663|DRUG|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
58101232|NCT04741139|DRUG|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
57737048|NCT03959865|DRUG|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
58101233|NCT06338189|OTHER|The 5Ad Diet|Participants are to follow the 5Ad diet.
58101234|NCT06338189|OTHER|The Low FODMAP Diet|Participants are to follow the active phase of the Low FODMAP diet.
58101235|NCT04229277|DIAGNOSTIC_TEST|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
58101236|NCT06540755|GENETIC|genetic polymorphism analysis|Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
58430042|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
58430043|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
58430044|NCT00002148|DRUG|OPC 14117|
57737049|NCT03959865|DRUG|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
57737050|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
57737051|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
58101237|NCT02306473|DRUG|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
58101238|NCT00803673|DRUG|100mcg|100mcg '719
58101239|NCT00803673|DRUG|500mcg|500mcg '719
58101240|NCT00803673|DRUG|1000mcg|1000mcg '719
58101241|NCT00803673|DRUG|Placebo|Placebo '719
58430045|NCT02240602|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
58430046|NCT02240602|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
58430047|NCT02240602|DRUG|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
58101242|NCT05458622|BIOLOGICAL|Blood sample|"- Total volume of blood (on each sampling occasion): 54,5mL.~* Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~* Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
58101243|NCT05458622|BIOLOGICAL|Urine sample|- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
58101244|NCT05458622|BIOLOGICAL|Saliva sample|- Saliva: will be collect in special container for saliva microbiome and methylation;
58101245|NCT05458622|BIOLOGICAL|Stood sample|- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
58101246|NCT05458622|PROCEDURE|Tissue sample|"- Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
58101247|NCT06515717|DIETARY_SUPPLEMENT|ketone ester|oral supplement
58101248|NCT06515717|DIETARY_SUPPLEMENT|dextrose (placebo)|oral supplement calorie and taste matched to ketone supplement
58101249|NCT01416207|DRUG|Avonex|4 weekly injections of Avonex (IM)
58430048|NCT05727514|OTHER|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
58430049|NCT04508491|OTHER|Rhythm control|Rhythm control with medications or any procedure
58430050|NCT04508491|OTHER|Rate control|Rate control
58430051|NCT01643824|RADIATION|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
58430052|NCT02437370|DRUG|Pembrolizumab|Given IV
58430053|NCT02437370|DRUG|Docetaxel|Given IV
58430054|NCT02437370|DRUG|Gemcitabine Hydrochloride|Given IV
57737052|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
57737053|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
58430055|NCT03995706|DRUG|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
57737054|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
58101250|NCT00886782|DRUG|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
58101251|NCT05433688|DEVICE|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
58430056|NCT00289081|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
58430057|NCT00289081|DEVICE|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
58430058|NCT04286516|DEVICE|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
58430059|NCT02477189|PROCEDURE|Silicone Block|
58430060|NCT00445770|DRUG|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
58430061|NCT00445770|DRUG|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
58430062|NCT00445770|DRUG|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
57737055|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
58430063|NCT05374330|OTHER|Electroacupuncture|Acupuncture needles are inserted into the body at standardized acupuncture points. An electrical current is then applied to 4 needles through 2 channels of electrical current. The sham group receives the same protocol with sham needles and sham electrical current.
58430064|NCT04511065|OTHER|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
58308665|NCT06317974|BEHAVIORAL|Breastfeeding education based on the Health Belief model|Training was given face to face with the participant, lasting approximately 40 minutes. One week after the training presentation, three short messages about the training were sent to the couples (both the pregnant woman and her partner) every other day. Two weeks after the training was given, a phone call was made for feedback. Post-test data were taken four weeks later.
58430065|NCT02145065|DRUG|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
58430066|NCT02145065|DEVICE|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
57737056|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
57953231|NCT03958227|OTHER|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
57953232|NCT03958227|OTHER|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
57953233|NCT00094055|DRUG|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
57953234|NCT00934570|DRUG|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
57953235|NCT00934570|DRUG|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
57953236|NCT00934570|BEHAVIORAL|Placebo Standard exercise|Standard exercise
57953237|NCT00934570|BEHAVIORAL|Intensive exercise|Placebo Intensive exercise
57953238|NCT03245073|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
57953239|NCT03245073|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
57953240|NCT01595152|DRUG|solifenacin succinate|8 mg once daily for 60 days
57953241|NCT01595152|DRUG|fesoterodine|8 mg, once daily for 60 dyas
57953242|NCT05810064|OTHER|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
57961847|NCT02681016|DEVICE|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
57961848|NCT02681016|PROCEDURE|Coronary angioplasty|
58308666|NCT04005768|DRUG|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
58308667|NCT04005768|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
58101252|NCT03990246|OTHER|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
58101253|NCT03990246|OTHER|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
58308668|NCT05812248|DIAGNOSTIC_TEST|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
58308669|NCT02459626|OTHER|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
58308670|NCT01225549|DRUG|AZD5423|Suspension for nebulisation once daily 7 days
58308671|NCT01225549|DRUG|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
58308672|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
58308673|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
58308674|NCT05624853|DRUG|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
58308675|NCT05624853|DRUG|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
58308676|NCT03807635|DEVICE|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
58308677|NCT03807635|DEVICE|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
58308678|NCT01963871|OTHER|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
58308679|NCT06473584|DIAGNOSTIC_TEST|Diabetes detection|Fasting glycemia on blood sample
58308680|NCT01041170|DRUG|THC|
58308681|NCT01041170|DRUG|Rimonobant|
58308682|NCT01041170|DRUG|Rimonabant|
58308683|NCT01533532|DRUG|KLH-2109|
58308684|NCT01533532|DRUG|KLH-2109|
58308685|NCT01533532|DRUG|KLH-2109|
58308686|NCT01533532|DRUG|placebo|
58308687|NCT05164211|OTHER|Didgeridoo|the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
58308688|NCT01716273|OTHER|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
58308689|NCT01716273|OTHER|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
58308690|NCT06140290|DRUG|Etrasimod Immediate Release (IR)|An immediate release tablet
58308691|NCT00667264|PROCEDURE|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
58458418|NCT02040623|OTHER|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
57737057|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
57737058|NCT04294368|OTHER|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
57961849|NCT05697510|DRUG|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
57961850|NCT04201483|OTHER|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
57737059|NCT04641143|DRUG|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
57737060|NCT04641143|DRUG|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
57737061|NCT05854511|DRUG|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
57961851|NCT04201483|OTHER|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
57961852|NCT03396965|OTHER|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
57961853|NCT04352439|DRUG|Aspirin|81 mg aspirin daily
57961854|NCT05495555|DEVICE|INTREPID® Hybrid tip|INTREPID® Hybrid tip for cataract removal
57961855|NCT02475642|OTHER|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
57961856|NCT02475642|OTHER|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
57961857|NCT03386175|DEVICE|therapy with negative pression and instillation|therapy with negative pression and instillation
57961858|NCT00132067|DRUG|vorinostat|Given orally
57961859|NCT01608412|DRUG|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
57961860|NCT01608412|DRUG|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
57961861|NCT03939507|OTHER|AEP score available to the treating physician|the treating physician knew the AEP score results
57961862|NCT02988583|DEVICE|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
57961863|NCT02988583|DEVICE|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
57961864|NCT01659645|DRUG|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
57961865|NCT01777152|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
57961866|NCT01777152|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
57961867|NCT01777152|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
57961868|NCT01777152|DRUG|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
57961869|NCT01777152|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
57961870|NCT05279846|DRUG|MOB015B|Applied topically for 48 weeks
57961871|NCT05279846|DRUG|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
57961872|NCT01290965|DRUG|Placebo|Oral tablet given once or three times daily for 15 consecutive days
57961873|NCT01290965|DRUG|SCY-635|oral capsule
57961874|NCT03509350|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
57961875|NCT03509350|DRUG|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
57961876|NCT03509350|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
57961877|NCT03509350|DRUG|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
57961878|NCT03509350|DRUG|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
57961879|NCT03509350|DRUG|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
57961880|NCT02302963|DEVICE|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
57961881|NCT02302963|DEVICE|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
57961882|NCT03370497|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
57961883|NCT03370497|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
57961884|NCT01731678|PROCEDURE|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
58101254|NCT03990246|OTHER|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
58101255|NCT03990246|OTHER|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
58101256|NCT00387868|DRUG|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33
58101257|NCT00387868|PROCEDURE|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
58101258|NCT00387868|RADIATION|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
58430067|NCT02748928|DEVICE|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
58430068|NCT00615173|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
58430069|NCT00615173|DRUG|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
58430070|NCT03317782|DEVICE|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.
58430071|NCT06216210|DRUG|opioid-FREE anesthesia.|"They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,"
58430072|NCT06216210|DRUG|opioid-CONTAINING anesthesia.|The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
58430073|NCT00321633|DRUG|carboplatin|
58430074|NCT00321633|DRUG|docetaxel|
58430075|NCT02128412|DEVICE|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
58101259|NCT05743478|BEHAVIORAL|Forging Hopeful Futures|Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
58430076|NCT02128412|DEVICE|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
58430077|NCT04607369|DEVICE|EyeCTester|Smartphone app that allows vision testing
58101260|NCT05743478|BEHAVIORAL|Wellness Check-ins|Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
58101261|NCT01890109|BIOLOGICAL|Erenumab|Administered via subcutaneous injection.
58101262|NCT01890109|DRUG|Placebo|Administered via subcutaneous injection
58101263|NCT03478774|DRUG|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher\&Paykel.
58101264|NCT03478774|DRUG|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
58101265|NCT03478774|DRUG|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
58430078|NCT00724204|DIETARY_SUPPLEMENT|follow on formula without probiotics|A follow on formula without probiotics
58101266|NCT03478774|PROCEDURE|Jaw thrust|Continuous
58101267|NCT03478774|PROCEDURE|Videolaryngoscopy|Continuous
58101268|NCT03478774|DRUG|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
58430079|NCT00724204|DIETARY_SUPPLEMENT|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
58430080|NCT04933461|DEVICE|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
58458419|NCT02368665|DRUG|Amlodipine 5mg|- Daily oral administration for 8 weeks
58430081|NCT02798471|DRUG|Edoxaban|15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
58430082|NCT02798471|DRUG|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
58430083|NCT04316676|DIAGNOSTIC_TEST|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
58101269|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
58101270|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
58101271|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
58430084|NCT04316676|DIAGNOSTIC_TEST|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s."
58430085|NCT04316676|DIAGNOSTIC_TEST|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml.
58430086|NCT04316676|DRUG|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
58430087|NCT04316364|DRUG|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
58430088|NCT04316364|DRUG|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
58430089|NCT04316364|DRUG|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
58430090|NCT05790720|DRUG|Propofol|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
58458420|NCT02368665|DRUG|Amlodipine 5mg, Candesartan cilexetil 16mg|- Daily oral administration Amlodipine 5mg for 8 weeks
57737062|NCT02741960|DRUG|metformin|500 mg metformin three times daily
58101272|NCT03677635|BEHAVIORAL|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
58101273|NCT05107154|BEHAVIORAL|Dialectical Behavioural Therapy|DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
58101274|NCT00857493|BIOLOGICAL|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
58101275|NCT00857493|BIOLOGICAL|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
58101276|NCT06569108|DRUG|KN057|KN057 will be administered subcutaneously once a week.
58101277|NCT02523729|DIETARY_SUPPLEMENT|Anke Malz|non-alcoholic malt drink
58101278|NCT05296369|DRUG|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
58101279|NCT00577954|PROCEDURE|Multimodal MRI|Multimodal MRI
58101280|NCT05813665|DRUG|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
58458421|NCT02368665|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
57737063|NCT02741960|DRUG|placebo|500 mg placebo three times daily
57737064|NCT03898206|OTHER|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
57737065|NCT03898206|OTHER|Prolonged sitting|See Prolonged sitting arm description
58430091|NCT05767190|BEHAVIORAL|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
58430092|NCT04654078|DRUG|IN-C004 with water|One time dose of IN-C004 taken with water
58430093|NCT04654078|DRUG|IN-C004 without water|One time dose of IN-C004 taken without water
58430094|NCT04654078|DRUG|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
58430095|NCT02476006|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
58430096|NCT02476006|DRUG|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
58430097|NCT02476006|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
58430098|NCT02476006|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
58430099|NCT02476006|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
58430100|NCT02476006|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
58430101|NCT00001967|DRUG|HAART|
57961885|NCT03322059|BEHAVIORAL|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
58430102|NCT06186986|DRUG|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
58430103|NCT01650272|DRUG|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
58430104|NCT01650272|DRUG|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
58430105|NCT06350305|OTHER|questionnaire survey|subjects fill out questionnaires
58430106|NCT05861661|OTHER|The study do not include an intervention|The study do not include an intervention
58430107|NCT06416410|DRUG|JAB-21822|JAB-21822 administered orally as a tablet
58430108|NCT06416410|DRUG|Tislelizumab|Tislelizumab administered as an intravenous (IV) infusion
58430109|NCT06416410|DRUG|JAB-3312|JAB-3312 administered orally as a tablet or capsule
58430110|NCT06416410|DRUG|Pemetrexed|Pemetrexed administered as an intravenous (IV) infusion
58430111|NCT06416410|DRUG|Carboplatin|Carboplatin administered as an intravenous (IV) infusion
58430112|NCT05941013|DEVICE|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
58430113|NCT00392990|DRUG|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
58430114|NCT00392990|DRUG|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
58430115|NCT00520260|DRUG|bromfenac|0.09%, BID, 6 weeks
58430116|NCT00520260|DRUG|ketorolac|0.4%, BID, 6 weeks
57961886|NCT03322059|BEHAVIORAL|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
57961887|NCT04975061|DRUG|YY-20394|YY-20394 is a small molecule inhibitor.
57961888|NCT01318044|DRUG|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
58430117|NCT06453291|DRUG|NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):|"Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence."
58430118|NCT06453291|PROCEDURE|Standard Physical Therapy|"Objective: To improve mobility, strength, and reduce pain.~Techniques:~Stretching exercises. Strengthening exercises for core and back muscles. Manual therapy techniques. Postural training. Frequency: Twice a week sessions. Duration: 45-60 minutes per session. Monitoring: Progress will be assessed during each session and adjusted as necessary"
58430119|NCT06453291|PROCEDURE|Neuromodulation via Dorsal Root Ganglion (DRG):|"Objective: To modulate excitatory pathways and reduce pain through targeted stimulation.~Procedure:~Placement of electrodes near the DRG. Application of pulsed radiofrequency (RF) at 42°C for 3-20 minutes.~Frequency:~Initial treatment: Once a week for the first month. Maintenance: Monthly sessions if needed. Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels and functional improvement will be assessed before and after each session."
58458422|NCT05143840|DRUG|Asciminib|Potent tyrosine kinase inhibitor that displays anti-tumor activity by specifically targeting the ABL myristate-binding pocket (STAMP).
58458423|NCT05143840|DRUG|Ascimininb + Nilotinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of nilotinib 300mg, once daily, with the goal of attaining MR4.5.
58430120|NCT06453291|PROCEDURE|Platelet-Rich-Plasma Therapy|"Objective: To promote healing and reduce inflammation through the application of concentrated platelets.~Procedure:~Blood draw from the patient. Centrifugation to separate platelets. Injection of PRP into the affected area of the lower back.~Frequency:~Initial treatment: Once a week for the first three weeks. Follow-up: Additional injections may be given based on patient response and clinical judgment.~Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels, inflammation markers, and functional improvement will be assessed before and after each injection."
58430121|NCT06584253|OTHER|Musculoskeletal System Health Questionnaire Scale|It is a 14-item scale that evaluates pain intensity, physical function, sleep, fatigue, emotional state, physical activity level, impact on work and social life, independence, self-management ability and general impact.
58430122|NCT06584253|OTHER|International Physical Activity Questionnaire (short form)|"International Physical Activity Questionnaire (short form) -~The IPAQ assesses a range of physical activities, including leisure-time physical activities, indoor and outdoor activities, work-related physical activities, and transportation-related physical activities."
58430123|NCT06584253|OTHER|Pittsburgh Sleep Quality Index|It is a questionnaire that evaluates sleep quality with questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, use of sleep aids and daytime functions.
58430124|NCT06584253|OTHER|Cognitive Failures Questionnaire|The questionnaire aims to measure daily cognitive errors. It assesses simple errors made over the last 6 weeks, as well as perception (e.g., are there times when you can't see something you need at the supermarket even though it's there?), memory (e.g., have you ever forgotten people's names?) and motor functioning (e.g., have you ever bumped into anyone?).
58430125|NCT06584253|OTHER|Jamar hand dynamometer|Jamar hand dynamometer - students will perform grip strength assessments with their dominant hand while seated. As recommended by the American Association of Hand Therapists protocol, students will sit in a comfortable chair with their shoulders neutrally rotated and adducted, elbow flexed to 90°, and wrist and forearm in neutral positions.
58430126|NCT06584253|OTHER|Depression Anxiety Stress Scale - 21 Short Form|DASÖ-21 consists of 3 subcategories (depression, anxiety and stress). Each category consists of 7 separate questions and a total of 21 questions.
58430127|NCT06584253|OTHER|Body Awareness Questionnaire|The questionnaire aims to determine the level of body composition sensitivity.
57737066|NCT06459609|DIETARY_SUPPLEMENT|protein supplementation|Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
58101281|NCT05813665|DRUG|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
58101282|NCT01542684|DRUG|Azacytidine|Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
58101283|NCT01542684|DRUG|GM-CSF|250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
58101284|NCT02085005|DRUG|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
58101285|NCT02085005|DRUG|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
58101286|NCT02085005|DRUG|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
58101287|NCT00448630|OTHER|No intervention|Non-interventional study
58430128|NCT06584253|OTHER|SF-12|This questionnaire consists of two general components related to physical and mental function, consisting of 12 questions and 8 scales measuring physical function (2 questions), bodily pain (1 question), role limitations due to physical problems (2 questions), general health (1 question) vitality (40).
57737067|NCT02428868|DRUG|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
58101288|NCT06562712|PROCEDURE|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
58101289|NCT06562712|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
58101290|NCT06361316|DRUG|Irinotecan liposome injection|Postoperative adjuvant therapy
58101291|NCT02432456|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
58101292|NCT02432456|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
58101293|NCT02432456|PROCEDURE|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
58430129|NCT01595555|BEHAVIORAL|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
57737068|NCT02428868|DRUG|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
57737069|NCT02428868|OTHER|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
57737070|NCT06125392|DIAGNOSTIC_TEST|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
57737071|NCT06100627|DRUG|AP301|Orally administered
58430130|NCT06256926|DRUG|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
58430131|NCT06256926|DRUG|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
58430132|NCT05647785|DEVICE|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
58430133|NCT05647785|DEVICE|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
58430134|NCT01786252|DRUG|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
58430135|NCT01786252|DRUG|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
58430136|NCT03647267|DEVICE|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
58430137|NCT03647267|OTHER|Observation|No intervention; sham injection only
58430138|NCT00115661|DRUG|Rosiglitazone|
58430139|NCT00049712|BIOLOGICAL|etaracizumab|
58430140|NCT03813992|DRUG|MED2005|Topical Product
58430141|NCT02969460|BEHAVIORAL|Neurotrack Virtual Cognitive Health Program|
57737072|NCT04460742|BEHAVIORAL|CAPABLE Transitions|The CAPABLE Transitions intervention group will receive an occupational therapy-led multidisciplinary in-home intervention in which the study occupational therapist (\<6 visits), registered nurse (\<5 visits), and handyman (\<2 visits) work with participants over 3-4 months. This intervention group also will receive home health agency care as usual services. CAPABLE Transitions in embedded within a home health agency and includes a care transitions emphasis.
58430142|NCT03811301|DEVICE|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
58430143|NCT00049660|DRUG|capecitabine|
58430144|NCT00049660|DRUG|vinorelbine tartrate|
58430145|NCT02239315|OTHER|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
58430146|NCT01778101|DRUG|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
58430147|NCT03954262|BEHAVIORAL|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
58430148|NCT01785823|OTHER|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
58458424|NCT05143840|DRUG|Asciminib + Imatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of imatinib 300mg, once daily, with the goal of attaining MR4.5.
58430149|NCT01785823|OTHER|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
58430150|NCT01785823|OTHER|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
58101294|NCT02432456|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
58308692|NCT00823654|OTHER|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
58430151|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
58430152|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
58430153|NCT00771290|PROCEDURE|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
58430154|NCT03236987|DRUG|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
58430155|NCT03236987|DRUG|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
58430156|NCT03236987|DRUG|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
58430157|NCT03236987|DRUG|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
58430158|NCT04361305|DRUG|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
58430159|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
58101295|NCT02432456|DRUG|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
58308693|NCT00823654|OTHER|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
58430160|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
58430161|NCT03098745|DEVICE|Omafilcon A|contact lens
58308694|NCT03448848|DRUG|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
58308695|NCT03448848|DRUG|sterile normal saline|sterile normal saline in a volume equal to the study drug
58308696|NCT00898755|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58308697|NCT00898755|OTHER|Laboratory Biomarker Analysis|Correlative studies
58308698|NCT01571843|OTHER|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
58308699|NCT01571843|OTHER|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
58308700|NCT03413514|DRUG|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)
58430162|NCT03098745|DEVICE|Somofilcon A|contact lens
58430163|NCT03098745|DEVICE|Omafilcon A - Proclear (PC)|contact lens
58430164|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
58430165|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
58430166|NCT05030480|DIAGNOSTIC_TEST|renal functions|urea, creatinine, GFR
58430167|NCT04883814|DIAGNOSTIC_TEST|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
58430168|NCT04591847|DRUG|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
58430169|NCT04591847|DRUG|Placebo drug|Placebo drugs 1 tab oral weekly
58430170|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
58430171|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
58430172|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
58430173|NCT02050087|DEVICE|Simple sling.|
58430174|NCT02050087|DEVICE|Neutral brace|
58430175|NCT03291990|DRUG|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
58430176|NCT01288547|DIETARY_SUPPLEMENT|theobromine|700 mg theobromine in gelatin capsules given one time only
58430177|NCT01288547|DIETARY_SUPPLEMENT|Caffeine|120 mg caffeine in capsules given one time only
58430178|NCT01288547|DIETARY_SUPPLEMENT|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
58430179|NCT01288547|DIETARY_SUPPLEMENT|placebo|cellulose in capsules given one time only
58430180|NCT05400993|COMBINATION_PRODUCT|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
58430181|NCT01818284|DRUG|Filgrastim|5 µg/kg in the morning daily for 4 days.
58430182|NCT01818284|DRUG|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
58430183|NCT01818284|PROCEDURE|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
58430184|NCT00004245|DRUG|sodium salicylate|
58430185|NCT03287427|DRUG|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
58430186|NCT03287427|DRUG|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
58430187|NCT00679172|BIOLOGICAL|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
58430188|NCT00679172|BIOLOGICAL|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
57737073|NCT04460742|BEHAVIORAL|Home Health Agency Care|Both the CAPABLE Transitions intervention and care as usual treatment arms will receive home health agency care as usual services, which can include nursing, health aide, medical social work, and occupational, physical, and speech therapy services. Home health agency clinicians will determine the types and duration of CHHA services that the study participants receive; these services will be completely independent from the research study.
57737074|NCT02283060|DRUG|Stribild|To be administered orally, once daily with food.
57737075|NCT02283060|DRUG|Atripla|To be administered orally, once daily at bedtime on an empty stomach
58101296|NCT02432456|DRUG|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
58430189|NCT00679172|BIOLOGICAL|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
58430190|NCT00679172|BIOLOGICAL|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
58430191|NCT00679172|OTHER|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
58430192|NCT04318600|DRUG|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
58430193|NCT00016991|DRUG|gefitinib|
58430194|NCT01309685|DRUG|Varenicline|
58430195|NCT05825391|DRUG|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
58430196|NCT02400021|DRUG|Prometrium|
58430197|NCT05273463|BEHAVIORAL|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
58430198|NCT05273463|BEHAVIORAL|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
57737076|NCT05224791|PROCEDURE|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
58308701|NCT03413514|PROCEDURE|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
58308702|NCT03413514|PROCEDURE|Surgery|Radical surgery with D2 lymph node dissection
58308703|NCT03413514|DRUG|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)
58308704|NCT03413514|OTHER|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
58308705|NCT03556306|PROCEDURE|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively \[17\] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
58308706|NCT00565864|DRUG|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
58308707|NCT05387642|DRUG|10 mg PRAX-114, 20 mg PRAX-114, and Placebo|Single dose with a washout period between doses
58308708|NCT05387642|DRUG|10 mg PRAX-114 or 20 mg PRAX-114|Once daily oral treatment for 28 days
58308709|NCT05090254|OTHER|Treatment algorithms targeting cardiac output|Treatment algorithms targeting maximization or personalization of cardiac output
58308710|NCT01737736|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
58308711|NCT01930539|DEVICE|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
58308712|NCT01688713|DRUG|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
58308713|NCT01466361|DRUG|Nicotine lower dose|lower dose nicotine lozenge
58308714|NCT01466361|DRUG|Nicotine higher dose|higher dose nicotine lozenge
58308715|NCT01466361|DRUG|Placebo|placebo
58308716|NCT05241301|OTHER|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
58308717|NCT01061372|DRUG|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
58308718|NCT01061372|DRUG|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
58308719|NCT01061372|DRUG|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
58308720|NCT01613924|DEVICE|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
58308721|NCT01613924|DEVICE|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
58308722|NCT03316846|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|
58430199|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
58308723|NCT02783898|DEVICE|AliveCor Heart Monitor|Smart phone based ECG event recorder
58308724|NCT00284856|DRUG|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
58430200|NCT01021904|BIOLOGICAL|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
58430201|NCT03580226|OTHER|No intervention|No intervention
58430202|NCT03887221|DRUG|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
58430203|NCT03887221|DRUG|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
58458425|NCT05143840|DRUG|Asciminib + Dasatinib|For subjects that do not achieve MR4.5 (molecular response) after 24 months of single-agent asciminib will be offered the addition of dasatinib 50mg, once daily, with the goal of attaining MR4.5.
58430204|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
58430205|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
57737077|NCT05224791|PROCEDURE|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
58101297|NCT02432456|DRUG|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
58101298|NCT02432456|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
58308725|NCT00284856|DRUG|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
58308726|NCT00284856|DRUG|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
58308727|NCT00284856|DRUG|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
58308728|NCT01235377|OTHER|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
58308729|NCT02632617|OTHER|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
58308730|NCT01514916|DEVICE|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
58308731|NCT06288568|OTHER|No intervention|No intervention
58308732|NCT03037632|BEHAVIORAL|Family Heart Talk Booklet|
58308733|NCT05761600|OTHER|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
58308734|NCT05761600|OTHER|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
58308735|NCT05761600|OTHER|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
58308736|NCT06300502|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
58308737|NCT06300502|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
58308738|NCT06300502|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion.
58308739|NCT06300502|DEVICE|1064nm Nd:YAG Laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
58308740|NCT04678284|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
58308741|NCT01254370|DRUG|Latanoprost|0.005%
58308742|NCT01254370|DRUG|Travatan Z|0.004%
58308743|NCT00889239|OTHER|lithia-disilicate-based crown|all-ceramic crown
58308744|NCT01181167|DRUG|edoxaban|
58308745|NCT01181167|DRUG|enoxaparin sodium|
58308746|NCT03332537|BEHAVIORAL|Personalized IBS Pain SM|
58430206|NCT01008449|DEVICE|Surgical staples|Surgical staples will be used once for wound closure.
58430207|NCT01008449|DEVICE|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
57737078|NCT01744028|DEVICE|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
58430208|NCT05131230|DEVICE|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
58430209|NCT04965662|DRUG|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
58430210|NCT04965662|DRUG|Truvada|Truvada one tablet once daily
58430211|NCT02760316|DRUG|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
58430212|NCT02760316|DRUG|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
58430213|NCT02760316|DRUG|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
58430214|NCT02760316|DRUG|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
58430215|NCT02760316|DRUG|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
58430216|NCT02760316|DRUG|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
58430217|NCT02760316|DRUG|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
58430218|NCT02760316|DRUG|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
58430219|NCT02760316|DRUG|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
58101299|NCT06536686|GENETIC|Silent myocardial ischemia, STEMI|Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs
58430220|NCT02447978|BIOLOGICAL|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
58430221|NCT02447978|BIOLOGICAL|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
58430222|NCT02447978|BIOLOGICAL|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
58430223|NCT04741763|DIETARY_SUPPLEMENT|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
58430224|NCT05961137|OTHER|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
58430225|NCT05961137|OTHER|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
58430226|NCT02555384|OTHER|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
58430227|NCT02555384|OTHER|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
58430228|NCT04313478|BEHAVIORAL|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
58430229|NCT03659877|BEHAVIORAL|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
58430230|NCT05095948|PROCEDURE|Discussion|Undergo audio recording of clinic conversations
58430231|NCT05095948|OTHER|Electronic Health Record Review|Review of medical records
58430232|NCT05095948|OTHER|Questionnaire Administration|Complete questionnaires
58430233|NCT03954613|COMBINATION_PRODUCT|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
58430234|NCT01910467|DEVICE|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
58101300|NCT03823339|DRUG|Insulin degludec/liraglutide|Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
58101301|NCT03347227|PROCEDURE|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
58101302|NCT03547531|OTHER|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
58308747|NCT04630548|DEVICE|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
58308748|NCT02600117|DRUG|Tenofovir disoproxil fumarate|300 mg, oral, once a day
58430235|NCT01910467|DEVICE|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
58430236|NCT01647334|RADIATION|Adaptive radiotherapy|
58430237|NCT05122299|PROCEDURE|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
58430238|NCT05122299|PROCEDURE|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
58101303|NCT03547531|OTHER|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
58430239|NCT05122299|PROCEDURE|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
58101304|NCT06082531|DRUG|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
58101305|NCT06290427|DEVICE|DaVinci RAPN|Robot-assisted Partial Nephrectomy with DaVinci® Surgical System
58101306|NCT06290427|DEVICE|Hugo RAS RAPN|Robot-assisted Partial Nephrectomy with Hugo™ RAS System
58101307|NCT06290427|DEVICE|Versius® RAPN|Robot-assisted Partial Nephrectomy with Versius® System
58101308|NCT02190344|DEVICE|8-channel paddle coil|MRI Coil
58101309|NCT03406832|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
58101310|NCT03406832|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
58101311|NCT03406832|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
58308749|NCT01356095|OTHER|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
58308750|NCT01356095|OTHER|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
58308751|NCT05312996|OTHER|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
58308752|NCT05312996|OTHER|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
58308753|NCT02709317|BEHAVIORAL|Prevention Intervention|
58308754|NCT02709317|BEHAVIORAL|Brief Intervention|
58308755|NCT05138146|DRUG|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
58308756|NCT05138146|DRUG|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
58308757|NCT04656990|BEHAVIORAL|Integrated Intervention|Gross motor and social-emotional integrated intervention
58308758|NCT06088641|DIAGNOSTIC_TEST|preoperative BNP value|preoperative BNP value
58308759|NCT00694772|PROCEDURE|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
58308760|NCT00694772|PROCEDURE|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
58308761|NCT00244439|DRUG|MALG|30 minute application
58308762|NCT00244439|DRUG|Ovide (malathion) lotion 0.05%|8-12 hour application
58308763|NCT00244439|DRUG|Permethrin 1%|10 minute application
58308764|NCT05029492|OTHER|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
58308765|NCT05029492|OTHER|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
58101312|NCT02733458|DRUG|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
58101313|NCT02733458|RADIATION|Radiotherapy|Radiotherapy: 50-56Gy
58101314|NCT01444274|DEVICE|Obalon Gastric Balloon(s)|One or two balloons administered per patient
58101315|NCT06127004|OTHER|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
58101316|NCT06127004|OTHER|Supportive Counselling|Se arm/group descriptions
58308766|NCT00492011|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
58308767|NCT00492011|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
58308768|NCT00492011|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
58308769|NCT00492011|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
58308770|NCT03613831|DEVICE|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
58308771|NCT02938663|BEHAVIORAL|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
58308772|NCT02014272|DRUG|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
58308773|NCT02014272|DRUG|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
58430240|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
58101317|NCT05531838|DEVICE|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
58101318|NCT00438932|DRUG|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
58101319|NCT00438932|DIETARY_SUPPLEMENT|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
58101320|NCT00438932|DIETARY_SUPPLEMENT|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
58101321|NCT00438932|DRUG|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
58101322|NCT03118765|DRUG|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
58101323|NCT03118765|DRUG|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
58101324|NCT03118765|DRUG|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
58101325|NCT05324709|BEHAVIORAL|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
58101326|NCT01046721|DRUG|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
58101327|NCT01046721|DRUG|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
58101328|NCT05049304|OTHER|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
58101329|NCT05049304|OTHER|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
58101330|NCT06087302|BEHAVIORAL|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
58101331|NCT01838278|BEHAVIORAL|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
58101332|NCT06070493|OTHER|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
58101333|NCT06070493|OTHER|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
58458426|NCT05129748|DRUG|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
58458427|NCT03936114|BEHAVIORAL|SMART|SMART program mindfulness training program
58101334|NCT01392170|DRUG|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
58101335|NCT03959137|OTHER|None - Common practice|None - Common practice
58101336|NCT00735033|OTHER|Physiotherapy with Swiss Ball|
58101337|NCT05597163|DRUG|low concentration atropine (0.01%)|0.01% atropine eye drop
58101338|NCT05597163|DRUG|low concentration atropine (0.025%)|0.025% atropine eye drop
58101339|NCT05597163|DRUG|low concentration atropine (0.05%)|0.05% atropine eye drop
58101340|NCT05597163|DRUG|Placebo|Placebo eye drop
58101341|NCT05354427|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
58101342|NCT03424694|RADIATION|HDR brachytherapy as monotherapy|
58430241|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
58430242|NCT01440881|DRUG|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
58430243|NCT01440881|DRUG|Placebo|infuses at 0.01MCG/KG/min for 48 hours
58430244|NCT06180707|DRUG|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
58430245|NCT06180707|DRUG|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
58430246|NCT06180707|OTHER|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
58430247|NCT02847104|OTHER|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
58101343|NCT04581031|DEVICE|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
58430248|NCT02847104|OTHER|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
58101344|NCT04581031|OTHER|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
58101345|NCT01412073|DRUG|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
58101346|NCT01412073|DRUG|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
58101347|NCT04228289|DRUG|Oxytocin|40 IU intranasal spray
58101348|NCT04228289|OTHER|Placebo|matching intranasal spray
58101349|NCT05467709|DRUG|Midazolam|2 mg Day 1 and Day 16
58430249|NCT05687019|COMBINATION_PRODUCT|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
58430250|NCT04230824|DIETARY_SUPPLEMENT|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
58430251|NCT04230824|OTHER|Placebo|placebo product consumed prior and after exercise
58430252|NCT04230824|OTHER|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
58430253|NCT03742453|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
58430254|NCT03742453|DIAGNOSTIC_TEST|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
58430255|NCT03178669|DRUG|cobitolimod|Rectal administration
58430256|NCT03178669|DRUG|Placebo|Solution manufactured to mimic cobitolimod
58430257|NCT02846649|BEHAVIORAL|PIER|Daily text message queries with tailored support
58430258|NCT05995899|DRUG|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
58430259|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
58430260|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
58430261|NCT00820417|DRUG|Cetuximab/Gefitinib combination and/or monotherapy|
58430262|NCT04225793|DRUG|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
58430263|NCT04225793|DRUG|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
58430264|NCT01620944|DRUG|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
58430265|NCT01620944|DRUG|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
58430266|NCT01620944|DRUG|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
58430267|NCT01620944|DRUG|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
58430268|NCT00852501|OTHER|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
57737079|NCT01744028|OTHER|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
57737080|NCT05855044|OTHER|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
57737081|NCT05463328|PROCEDURE|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
58101350|NCT05467709|DRUG|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
58101351|NCT00452998|PROCEDURE|Q-switched fd Nd:yag in Laser Iridotomy|
58101352|NCT00154830|BEHAVIORAL|cerebral palsy|
58101353|NCT00154830|BEHAVIORAL|crouch gait|
58101354|NCT03635619|OTHER|No intervention|No intervention
58101355|NCT02399488|DEVICE|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
58430269|NCT02500446|DRUG|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
58430270|NCT02500446|OTHER|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
58430271|NCT03748459|OTHER|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
58430272|NCT03748459|OTHER|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
58430273|NCT00288327|BEHAVIORAL|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
58430274|NCT00288327|BEHAVIORAL|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
58430275|NCT02501200|DRUG|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
58430276|NCT02501200|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
58430277|NCT03256318|OTHER|No intervention|No intervention; surveys/questionnaires only
58430278|NCT00938691|PROCEDURE|Intradermal Suture|
58430279|NCT00938691|PROCEDURE|Intradermal Suture|
58430280|NCT04353778|DRUG|Pyridostigmine|Eight weeks of low-dose pyridostigmine
58430281|NCT04353778|DRUG|Placebos|matching placebo x 8 weeks
58430282|NCT04353778|PROCEDURE|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
58430283|NCT04541628|COMBINATION_PRODUCT|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
58430284|NCT00119496|DRUG|rosiglitazone|oral tablet, 4mg bd for 4 weeks
58430285|NCT00119496|DRUG|theophylline|Oral theophylline, 200mg bd
58430286|NCT00119496|DRUG|beclomethasone|inhaled beclomethasone, 200mcg bd
58430287|NCT00119496|DRUG|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
58430288|NCT01651663|DRUG|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
58430289|NCT01651663|OTHER|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
58101356|NCT06018246|DIETARY_SUPPLEMENT|Malnutrition five-step treatment model + conventional nutritional intervention|"1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
58101357|NCT06018246|OTHER|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
58308774|NCT02644746|DEVICE|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
58430290|NCT01651663|DRUG|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
58430291|NCT01651663|OTHER|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
58430292|NCT03697681|DRUG|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
58430293|NCT03697681|DRUG|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
58430294|NCT02861638|DEVICE|Experimental group|Video of the exercises
58430295|NCT02861638|DEVICE|Control group|video of nature scenes
58430296|NCT02861638|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
58430297|NCT06084221|BEHAVIORAL|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
58430298|NCT06084221|BEHAVIORAL|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
58430299|NCT03088813|DRUG|Irinotecan liposome injection|IV
58430300|NCT03088813|DRUG|Topotecan|IV
58430301|NCT00260416|PROCEDURE|Primary angioplasty with stent and abciximab|
58430302|NCT02123576|DRUG|Pentoxyfylline|
58430303|NCT02123576|DRUG|Placebo|
58430304|NCT02123576|DRUG|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
58430305|NCT01781559|DIETARY_SUPPLEMENT|phenolic acid|phenolic acid
58430306|NCT01631396|DRUG|Sugammadex vs. Neostigmine|"* Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
58430307|NCT00333918|DRUG|bromfenac ophthalmic solution|
58430308|NCT00333918|DRUG|placebo comparator|
58430309|NCT03905850|DRUG|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
58430310|NCT05032885|OTHER|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
58430311|NCT04967339|DEVICE|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
58430312|NCT04967339|DEVICE|Lateral wedge insoles|Lateral wedge insoles
58430313|NCT05974319|OTHER|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
57737082|NCT05463328|PROCEDURE|Open pancreaticduodenctomy|Open pancreaticduodenctomy
57737083|NCT02854774|BEHAVIORAL|Muscle activation exercises|Activation of either muscles activating the knee or hip.
58101358|NCT02899442|OTHER|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
58430314|NCT05974319|OTHER|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
58430315|NCT06183333|BEHAVIORAL|Heidelberg Emotion Regulation Training|The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
58430316|NCT02402413|PROCEDURE|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
58430317|NCT02402413|PROCEDURE|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
58430318|NCT02402413|DEVICE|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
58430319|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
58101359|NCT03849079|OTHER|Hyponut|Prick tests with hyponut
58101360|NCT03077594|DEVICE|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
58101361|NCT03077594|OTHER|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
58101362|NCT03077594|DEVICE|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
58101363|NCT00189696|DRUG|YM060|
58101364|NCT02686710|DRUG|Sevoflurane|
58101365|NCT02686710|DRUG|Propofol|
58101366|NCT04568642|DEVICE|Activate FiO2 controller|Closed-loop FiO2 controller will be activated in the experimental arm
58101367|NCT04568642|DEVICE|Deactivate FiO2 controller|Closed-loop FiO2 controller will be deactivated in the experimental arm
58101368|NCT00888030|OTHER|there are no interventions currently listed for this study|
58430320|NCT01315444|DRUG|Stop PPI gradually|
57737084|NCT00466518|DRUG|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
58101369|NCT02898064|DEVICE|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
58101370|NCT02898064|OTHER|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
58101371|NCT02476851|DEVICE|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
58101372|NCT02476851|DEVICE|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
58430321|NCT01315444|DRUG|Stop PPI gradually|
58430322|NCT00848224|BEHAVIORAL|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
58430323|NCT04119596|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
58430324|NCT04119596|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
58430325|NCT02122224|OTHER|High fiber breakfast|Breakfast will contain 10-11g fiber.
58430326|NCT02122224|OTHER|High Protein Breakfast|Breakfast will contain 19-20g of protein.
58430327|NCT02122224|OTHER|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
58430328|NCT05969340|DIAGNOSTIC_TEST|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
58430329|NCT04602247|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
58430330|NCT04602247|DIETARY_SUPPLEMENT|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
58430331|NCT04602247|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
58430332|NCT04602247|DIETARY_SUPPLEMENT|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
58430333|NCT04602247|OTHER|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
58430334|NCT04602247|OTHER|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
58430335|NCT05562609|DRUG|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
58430336|NCT05562609|OTHER|Placebo|Ampoules and packaging for all arms will be identical in appearance.
58430337|NCT00147004|DRUG|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
58430338|NCT00147004|DRUG|Placebo|
58430339|NCT04796350|DEVICE|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
58430340|NCT02551419|DIETARY_SUPPLEMENT|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
58430341|NCT02551419|DIETARY_SUPPLEMENT|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
58430342|NCT02027948|OTHER|nutritional and functional assessments|"Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention."
58430343|NCT05727800|DRUG|VX-668|Suspension for oral administration.
58430344|NCT05727800|DRUG|Placebo|Suspension for oral administration.
58430345|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
58101373|NCT04234373|OTHER|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
58101374|NCT02234258|BEHAVIORAL|Cognitive behavioral social skills|
58430346|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
58430347|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
58430348|NCT01218399|DRUG|Symbicort|
58430349|NCT04908865|DRUG|Belimumab|Belimumab will be administered.
58430350|NCT04908865|DRUG|Standard therapy|Standard therapy will be continued.
58430351|NCT04434014|DIETARY_SUPPLEMENT|proper diet|diet containing all essential vitamins
58430352|NCT00652886|DRUG|Oxandrolone|Tablets, 10mg, single-dose
58430353|NCT00652886|DRUG|Oxandrin|tablets, 10mg, single-dose
58430354|NCT03057782|DEVICE|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
58430355|NCT03057782|DEVICE|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
58101375|NCT02234258|BEHAVIORAL|Psychoeducation|
58308775|NCT02644746|DEVICE|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
58430356|NCT03057782|DEVICE|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
58430357|NCT03057782|DEVICE|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
58430358|NCT03057782|DEVICE|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
58308776|NCT03528421|BIOLOGICAL|IM19|CAR-T cells
58101376|NCT03224117|DRUG|DWJ211|inject the Drug into submental fat via subcutaneous
58101377|NCT03224117|DRUG|Normal saline|inject the Drug into submental fat via subcutaneous
58101378|NCT04974645|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
58308777|NCT03528421|DRUG|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
58308778|NCT03528421|DRUG|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
58101379|NCT04974645|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
58101380|NCT02670512|DEVICE|Telehome Monitoring|
58101381|NCT04824144|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
58101382|NCT04552080|DRUG|Amoxicillin|Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
58101383|NCT04552080|OTHER|Placebo|Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
58101384|NCT05021328|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
58101385|NCT05021328|DRUG|Anlotinib|Anlotinib 12 mg/d, d1-14, q3w.
58430359|NCT04697732|OTHER|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
58430360|NCT05238883|DRUG|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
58430361|NCT05238883|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
58430362|NCT04218591|OTHER|PRP|Platelet rich plasma
58430363|NCT04218591|OTHER|Placebo|Saline
57737085|NCT01759589|DRUG|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
58101386|NCT05021328|DRUG|SBRT 7Gy✖️5 QD|SBRT 7Gy✖️5 QD
58101387|NCT05285917|DRUG|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
58101388|NCT01101581|DRUG|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).
58101389|NCT01101581|DRUG|90Y-epratuzumab tetraxetan|
58101390|NCT01101581|DRUG|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
58101391|NCT05854316|DIAGNOSTIC_TEST|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
58101392|NCT02287506|OTHER|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
58101393|NCT02044965|OTHER|Antibiotic|2 mg/kg per day via oral ingestion.
58101394|NCT02044965|DRUG|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
58101395|NCT00829439|DRUG|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
58430364|NCT06584227|DRUG|Adebrelimab and Chidamide Combined with Gemcitabine and S1|Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
58430365|NCT01716455|DRUG|SSP-004184|
58101396|NCT02862535|DRUG|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
58101397|NCT02862535|DRUG|S-1|Administered orally
58430366|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
58101398|NCT02862535|DRUG|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
57737086|NCT01759589|DRUG|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
57737087|NCT01759589|DRUG|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
57737088|NCT04288908|OTHER|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
57737089|NCT06395064|DRUG|Dimenhydrinate|Dimenhydrinate 50mg intravenously
57737090|NCT06578923|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
57737091|NCT06578923|BEHAVIORAL|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
58101399|NCT02862535|DRUG|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
58101400|NCT02862535|DRUG|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
58101401|NCT03791619|DEVICE|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
58101402|NCT03791619|DEVICE|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
57737092|NCT01808690|DRUG|Metformin|
57737093|NCT01808690|DRUG|Placebo|
57737094|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
57737095|NCT00727272|DRUG|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
57737096|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
57737097|NCT02015117|OTHER|Laboratory Biomarker Analysis|Correlative studies
57737098|NCT02015117|OTHER|Pharmacological Study|Correlative studies
57737099|NCT02015117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
58101403|NCT01148680|BIOLOGICAL|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
58101404|NCT02011516|DRUG|Baclofen|
58101405|NCT02011516|BEHAVIORAL|Psychosocial|
58101406|NCT02011516|DRUG|Placebo|
57737100|NCT02015117|DRUG|Trametinib|Given PO
57737101|NCT02015117|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
57737102|NCT01736228|DEVICE|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
57737103|NCT04700293|DIETARY_SUPPLEMENT|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
57737104|NCT03760237|OTHER|observation only|No intervention, observational study only
57737105|NCT06320860|DEVICE|Kidney Stone Retrieval|Using FlexStone Basket aimability to retrieve kidney stones
58101407|NCT01188005|DEVICE|n-CPAP|administration of continuous positive airway pressure through a nasal device
58101408|NCT01188005|DEVICE|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
58101409|NCT01188005|DRUG|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
58101410|NCT01872858|DRUG|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
58101411|NCT01872858|DRUG|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
58101412|NCT02613416|DRUG|Denosumab|monthly subcutaneous injections
58101413|NCT05091879|GENETIC|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
58101414|NCT05899478|DEVICE|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
58101415|NCT05899478|DEVICE|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
58101416|NCT05626231|BEHAVIORAL|Gender-Affirming Psychotherapy (GAP) Training|"The GAP training is a modular online asynchronous training intervention designed to increase mental health providers' use of gender-affirming practices with GMY (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (GMY, their caregivers, mental health providers). In this open trial, GAP training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
58308779|NCT01988207|BEHAVIORAL|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
58430367|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
58430368|NCT00245843|BEHAVIORAL|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
58430369|NCT03908918|OTHER|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
58430370|NCT02974049|DRUG|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
58101417|NCT03840135|DRUG|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
58430371|NCT02974049|DRUG|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
58430372|NCT02974049|DRUG|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
58430373|NCT06155539|OTHER|No intervention|No intervention
58430374|NCT01088594|DRUG|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
58430375|NCT01088594|DRUG|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
58430376|NCT01088594|DRUG|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
58430377|NCT01088594|DRUG|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
58430378|NCT01088594|DRUG|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
58308780|NCT01988207|BEHAVIORAL|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
58430379|NCT01088594|DRUG|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
58430380|NCT05521321|BEHAVIORAL|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
58430381|NCT05385588|OTHER|cognitive functional assessment|"* Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)"
58430382|NCT05830825|PROCEDURE|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
58430383|NCT04492163|DEVICE|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
58430384|NCT01679886|RADIATION|Rubidium PET|Rubidium PET
58430385|NCT03057860|OTHER|No study intervention|
58430386|NCT02542787|DRUG|VSN16R|Small molecule
58430387|NCT02542787|OTHER|Placebo|dummy tablet
58430388|NCT03473899|DEVICE|rESWT|"rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
58430389|NCT03473899|DEVICE|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
58430390|NCT00006656|DRUG|carmustine in ethanol|
58430391|NCT00006656|PROCEDURE|conventional surgery|
58101418|NCT03840135|OTHER|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
58101419|NCT05677984|PROCEDURE|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
58430392|NCT00857974|OTHER|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
58430393|NCT00292539|DEVICE|Any pacemaker with right ventricular pacing option|
58430394|NCT06222528|BEHAVIORAL|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
58101420|NCT01696227|DRUG|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
58101421|NCT04775368|OTHER|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
58101422|NCT00004288|DRUG|olsalazine|
58308781|NCT03804281|PROCEDURE|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
58308782|NCT03804281|PROCEDURE|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
58430395|NCT06222528|BEHAVIORAL|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
58430396|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
57737106|NCT03925376|PROCEDURE|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
57737107|NCT06581549|OTHER|Translation analysis|Bulk GEP analysis, Spatial whole transcriptome analysis, mIF analysis of tumors
57737108|NCT04695223|DRUG|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
57737109|NCT00526123|DEVICE|Symmetric Tip Catheter|Dialysis catheter
57737110|NCT00526123|DEVICE|Conventional Split-tip Catheter|Dialysis Catheter
57737111|NCT03155607|BEHAVIORAL|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
57737112|NCT06103136|DEVICE|Laparoscopic surgery using the Maestro Platform|"Patients scheduled for laparoscopic surgery will be operated on as per standard of care, using standard port, surgical table and instrument placements (following local applicable guidelines), and off-the-shelf surgical equipment. Standard of care surgical technique following local applicable guidelines will be used.~The Maestro Platform may be used to position and hold the scope as well as the retractor in the locations determined by the surgeon during the procedure, with the ability to revert at any time to standard of care (manual minimally invasive surgery) without the usage of the Maestro Platform, or to convert to open surgery."
57737113|NCT00385931|DRUG|Valsartan and simvastatin|
57737114|NCT04873570|DRUG|Moxifloxacin 400mg|Moxifloxacin 400mg IR tablet
57737115|NCT03626948|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
57737116|NCT06497478|DIAGNOSTIC_TEST|Ultrasonographic examination|"Ultrasonographic examination will be performed using a high-resolution (Epiq Elite Philips Medical Systems, Monza, Italia) and a linear 12-9 MHz transducer.~The patients will be placed in a supine position. Starting with the probe at the base of the neck, the common carotid artery will be explored on the transverse plane and then on the sagittal one, continuing in a cranial sense up to the carotid bifurcation. The medium-intimal thickness will be measured, defined as distance from the first hyperechoic line to the second hyperechoic line.~The femoropopliteal and run-off segments will be continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments will be examined for the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements will be obtained using spectral Doppler imaging and color Doppler imaging."
57737117|NCT03214913|OTHER|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
57737118|NCT03214913|OTHER|Ruijin Strategy|"Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%."
57737119|NCT00749138|DRUG|tamoxifen|giving drug tamoxifen
57737120|NCT06223620|OTHER|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
57737121|NCT01904448|DEVICE|Auditory Brainstem Implantation in Children|
58308783|NCT00676949|BIOLOGICAL|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
57737122|NCT03341910|DRUG|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
57737123|NCT03341910|DRUG|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
58101423|NCT05610982|BEHAVIORAL|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
58430397|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
58430398|NCT06222528|BEHAVIORAL|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
58430399|NCT06222528|BEHAVIORAL|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
58430400|NCT06222528|BEHAVIORAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
58430401|NCT06222528|BEHAVIORAL|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
58430402|NCT00004113|DRUG|temozolomide|
58430403|NCT03576716|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
58430404|NCT04533867|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
58430405|NCT04533867|DRUG|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
58430406|NCT04533867|DRUG|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
57737124|NCT03341910|DRUG|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
57953243|NCT04291950|PROCEDURE|Needle core biopsy|"Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab."
57953244|NCT02823691|DRUG|Lanreotide and Metformin|Lanreotide and Metformin
57953245|NCT00325026|DRUG|Misoprostol|
57953246|NCT00325026|DEVICE|Foley bulb|
57953247|NCT04389021|DEVICE|Virtual Reality|"The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol."
57953248|NCT00035282|DRUG|aprepitant|
57953249|NCT00035282|DRUG|Comparator: placebo (unspecified)|
57953250|NCT05988060|OTHER|Experimental Intervention|"Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week."
57953251|NCT00011921|BIOLOGICAL|filgrastim|
57953252|NCT00011921|DRUG|carboplatin|
57953253|NCT00011921|DRUG|epirubicin hydrochloride|
57953254|NCT00011921|DRUG|etoposide|
57953255|NCT00011921|DRUG|etoposide phosphate|
57953256|NCT00011921|DRUG|ifosfamide|
57953257|NCT00011921|DRUG|paclitaxel|
57953258|NCT00011921|PROCEDURE|autologous bone marrow transplantation|
57953259|NCT00011921|PROCEDURE|bone marrow ablation with stem cell support|
57953260|NCT00011921|PROCEDURE|peripheral blood stem cell transplantation|
57953261|NCT00011921|RADIATION|radiation therapy|
57953262|NCT03430921|DEVICE|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
57953263|NCT04608812|DRUG|OS2966|OS2966 is a humanized monoclonal antibody antagonizing CD29 (Beta 1 integrin)
57953264|NCT04608812|DRUG|Gadoteridol|Gadoteridol is a contrast agent which will be added to OS2966 to allow investigators to observe how OS2966 distributes within the brain tumor. Gadoteridol is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
57737125|NCT03341910|DRUG|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
58430407|NCT05966948|DRUG|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
57737126|NCT06409026|DRUG|Sotatercept|As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
57737127|NCT03754296|DEVICE|CATCHVIEW|Revascularization device
57737128|NCT05475951|DIAGNOSTIC_TEST|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
57737129|NCT00622128|BEHAVIORAL|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
58308784|NCT02153918|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
58308785|NCT02153918|BIOLOGICAL|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
58308786|NCT04150315|DIAGNOSTIC_TEST|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
58308787|NCT04976725|OTHER|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
58308788|NCT04454424|DRUG|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
58308789|NCT04454424|DRUG|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
58308790|NCT02688790|DRUG|Dalbavancin|
58308791|NCT01563939|DRUG|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
58308792|NCT06516432|PROCEDURE|Parasternal block|In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified.
58308793|NCT06516432|PROCEDURE|Requirement of total dose regarding fentanyl|In case-control groups, obtain measurement of total postoperative fentanyl requirement.
58308794|NCT01901185|DRUG|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
58308795|NCT00857506|DRUG|florbetapir F 18|370 Mega Becquerel (10 mCi)
58308796|NCT05777655|OTHER|Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)|Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
58308797|NCT02758418|OTHER|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
58430408|NCT05966948|DRUG|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
58430409|NCT00830180|BIOLOGICAL|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
58430410|NCT01115374|PROCEDURE|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
58430411|NCT01115374|DEVICE|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
58101424|NCT01692418|DRUG|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
58101425|NCT01692418|DRUG|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
58308798|NCT05906368|DIAGNOSTIC_TEST|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
58308799|NCT05906368|DIAGNOSTIC_TEST|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
58308800|NCT00562406|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
58308801|NCT00562406|PROCEDURE|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
58308802|NCT05722691|DRUG|Double-Stranded RNA sodium salt|Once intramuscular injection 5 mg (1 vial)
58308803|NCT05722691|DRUG|Placebo|Once intramuscular injection (1 vial)
58308804|NCT02191826|DRUG|SOM0226|Oral
58458428|NCT01295359|OTHER|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
58458429|NCT03309878|BIOLOGICAL|Mogamulizumab|Given IV
57737130|NCT02436148|OTHER|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
57737131|NCT06266767|DRUG|Levobupivacaine and Fentanyl|Programmed Intermittent Epidural Bolus
57961889|NCT03730805|BEHAVIORAL|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller \& Rollnick, 1991).
57961890|NCT03730805|BEHAVIORAL|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
57961891|NCT03730805|BEHAVIORAL|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
57961892|NCT05152797|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
57961893|NCT05941598|DEVICE|Electroacupuncture|Participants in the electroacupuncture group will receive electroacupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
57961894|NCT05941598|DEVICE|Sham acupuncture|Participants in the sham acupuncture group will receive minimal acupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
57961895|NCT05401305|BIOLOGICAL|Vaccine for the prevention of infections caused by Haemophilus influenza type b|The vaccine is administered into the region of the deltoid muscle
57961896|NCT05401305|BIOLOGICAL|Placebo|The placebo is administered into the region of the deltoid muscle
57961897|NCT01673321|OTHER|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
57961898|NCT04976894|OTHER|open|open
57961899|NCT01617941|DRUG|BGG492|
57961900|NCT01617941|DRUG|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
57961901|NCT04009044|DRUG|Afimoxifene|Apply topically
57961902|NCT04009044|PROCEDURE|Core Biopsy|Undergo core needle biopsy
57961903|NCT04009044|OTHER|Questionnaire Administration|Ancillary studies
57961904|NCT05111587|OTHER|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
57961905|NCT00803179|DRUG|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
57961906|NCT01625754|BEHAVIORAL|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
57961907|NCT03313245|OTHER|No Intervention/Observational Study|No Intervention/Observational Study
57961908|NCT05037110|BEHAVIORAL|Physical activity|For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
58101426|NCT04379973|DRUG|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
58430412|NCT02536222|OTHER|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
58430413|NCT00903305|OTHER|medical chart review|
58430414|NCT00903305|OTHER|questionnaire administration|
58430415|NCT00903305|PROCEDURE|fatigue assessment and management|
58101427|NCT02176642|DRUG|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
58101428|NCT02176642|DEVICE|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
58101429|NCT02176642|DRUG|Placebo|Tablet taken by mouth daily for 6 weeks
58101430|NCT02949778|PROCEDURE|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
58101431|NCT02949778|DRUG|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
58430416|NCT00903305|PROCEDURE|psychosocial assessment and care|
57953265|NCT02562456|PROCEDURE|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
57737132|NCT03152253|BEHAVIORAL|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
58101432|NCT02949778|DRUG|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
58101433|NCT06218888|DRUG|Tislelizumab|Tislelizumab 200mg，D1, Q3W
58101434|NCT06218888|DRUG|Fruquintinib|Fruquintinib 3mg ,D1-D14, Q3W
57737133|NCT03152253|BEHAVIORAL|Peer Support|A group chat room for peer support
57737134|NCT03152253|OTHER|Motivational Messages|Generic motivational messages not related to smoking cessation
58101435|NCT06218888|DRUG|Chidamide|Chidamide 30mg
58101436|NCT01174368|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
58101437|NCT02917928|DIETARY_SUPPLEMENT|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
58101438|NCT02917928|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
58101439|NCT02955810|DRUG|Daratumumab|
58101440|NCT02955810|DRUG|Cyclophosphamide|
58101441|NCT02955810|DRUG|Bortezomib|
58101442|NCT02955810|DRUG|Dexamethasone|
58101443|NCT04088734|DRUG|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
58101444|NCT02440100|DRUG|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
58101445|NCT02440100|DRUG|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
58101446|NCT02440100|DRUG|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
58101447|NCT01678924|DRUG|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
58101448|NCT01678924|DRUG|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
58101449|NCT04449588|DRUG|BDB-001 Injection|BDB-001 Injection+Conventional treatment
58101450|NCT04449588|OTHER|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
58430417|NCT00903305|PROCEDURE|quality-of-life assessment|
58430418|NCT00803062|BIOLOGICAL|Bevacizumab|Given IV
58430419|NCT00803062|DRUG|Cisplatin|Given IV
58430420|NCT00803062|OTHER|Laboratory Biomarker Analysis|Correlative studies
58430421|NCT00803062|DRUG|Paclitaxel|Given IV
58308805|NCT00945737|DIETARY_SUPPLEMENT|Soy protein; 25 grams/day|Soy protein
58308806|NCT00945737|DIETARY_SUPPLEMENT|Control protein|Milk protein
58430422|NCT00803062|OTHER|Quality-of-Life Assessment|Ancillary studies
58430423|NCT00803062|OTHER|Questionnaire Administration|Ancillary studies
57953266|NCT02562456|PROCEDURE|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
58101451|NCT02624349|DRUG|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
58101452|NCT01818037|PROCEDURE|Cataract surgery|
58101453|NCT01547637|PROCEDURE|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
58101454|NCT01547637|PROCEDURE|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
58308807|NCT00002844|DRUG|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
58308808|NCT00002844|PROCEDURE|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
58430424|NCT00803062|DRUG|Topotecan Hydrochloride|Given IV
58430425|NCT05797597|DRUG|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
58430426|NCT05797597|DRUG|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
58430427|NCT03561818|OTHER|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
58430428|NCT03561818|OTHER|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
58430429|NCT05880173|DIAGNOSTIC_TEST|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
58430430|NCT04534270|DRUG|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
58430431|NCT00455143|DRUG|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
58430432|NCT00455143|DRUG|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
58430433|NCT01799824|BIOLOGICAL|ANT-1403|
58430434|NCT01799824|BIOLOGICAL|placebo|
58430435|NCT03633266|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
58430436|NCT03633266|PROCEDURE|PRP|vitreoretinal surgery combined with intraoperative PRP
58430437|NCT06583967|OTHER|Physical Training|Group 1 - Elliptical Trainer Group 2 - Treadmill
58430438|NCT04159792|OTHER|no intervention|No intervention
58430439|NCT02549131|PROCEDURE|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
58430440|NCT02357589|PROCEDURE|2D laparoscopic cholecystectomy|
58430441|NCT02357589|PROCEDURE|3D laparoscopic cholecystectomy|
57737135|NCT02159833|OTHER|Intranasal challenge with active substance (food protein)|
57737136|NCT02159833|OTHER|Intranasal challenge with placebo|
57737137|NCT06191848|DRUG|Tirzepatide|Participants will receive tirzepatide subcutaneously
57953267|NCT06022952|OTHER|Stone MD stent radar|Mobile app
58308809|NCT00002844|PROCEDURE|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
58308810|NCT00002844|RADIATION|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
58308811|NCT02691715|PROCEDURE|Endometrial saline plus curettage|
58308812|NCT02691715|PROCEDURE|Endometrial curettage|
58308813|NCT06294561|DRUG|Itraconazole+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11
58308814|NCT06294561|DRUG|Efavirenz+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20
58430442|NCT01399320|PROCEDURE|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
58458430|NCT03309878|BIOLOGICAL|Pembrolizumab|Given IV
58458431|NCT02319941|DRUG|ticagrelor|
58458432|NCT02319941|DRUG|clopidogrel|
58458433|NCT06298084|DRUG|Patritumab deruxtecan|5.6 mg/kg every 21 days
58458434|NCT06298084|DRUG|Olaparib|100 mg b.i.d PO days 8-14 every 21 days
58458435|NCT02203877|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
58101455|NCT03801018|OTHER|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
58101456|NCT03430089|BIOLOGICAL|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
58430443|NCT04422704|BEHAVIORAL|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
58430444|NCT01750905|DRUG|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
58430445|NCT01750905|DRUG|Placebo|Vehicle (D5W) SQ
58430446|NCT06480149|OTHER|SMALC|Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
58101457|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
58430447|NCT06480149|OTHER|no application|In the control group, there was no massage application and only pain and sleep quality were evaluated.
58101458|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
58101459|NCT06375954|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
58101460|NCT06375954|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
58101461|NCT06375954|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
58101462|NCT03457337|DRUG|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
58101463|NCT03457337|DRUG|Gefitinib|Gefitinib: 250mg, 1 day, orally
58308815|NCT02601755|BEHAVIORAL|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
58308816|NCT02601755|BEHAVIORAL|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
58308817|NCT04675892|PROCEDURE|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
58308818|NCT04675892|PROCEDURE|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
58308819|NCT00003819|BIOLOGICAL|QS21|
58308820|NCT00003819|BIOLOGICAL|TF(c)-KLH conjugate vaccine|
58308821|NCT00003819|BIOLOGICAL|Thomsen-Friedenreich antigen|
58308822|NCT00003819|BIOLOGICAL|keyhole limpet hemocyanin|
58308823|NCT02991079|OTHER|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
58308824|NCT02991079|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
58430448|NCT03291652|DIAGNOSTIC_TEST|DSA/3DRA|DSA/3DRA
58430449|NCT05124171|BIOLOGICAL|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older"
58430450|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older"
58430451|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older"
58430452|NCT06319859|DRUG|Morphine|The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
58430453|NCT06319859|DRUG|Placebo|The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
58430454|NCT04150952|OTHER|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
58430455|NCT04150952|OTHER|TRAD training|Traditional endurance training
58430456|NCT00534833|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
58430457|NCT00534833|BIOLOGICAL|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
58430458|NCT00534833|BIOLOGICAL|Oral Polio Vaccine|0.5 mL, Oral
58430459|NCT00187525|DRUG|Memantine|
58101464|NCT04334330|DRUG|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
58101465|NCT02559531|DEVICE|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
58101466|NCT01030276|OTHER|Bright light therapy|Bright light therapy
58101467|NCT01030276|OTHER|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
58101468|NCT05413902|DRUG|Toradol|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101469|NCT05413902|DRUG|Morphine|Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
58101470|NCT05413902|DRUG|Orphenadrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101471|NCT05413902|DRUG|Gabapentin|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101472|NCT05413902|DRUG|Acetaminophen|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101473|NCT05413902|DRUG|Bupivacaine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101474|NCT05413902|DRUG|Epinephrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101475|NCT05413902|DRUG|Xylocaine Injectable Solution|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101476|NCT05413902|DRUG|Methylprednisolone|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
58101477|NCT06568250|BEHAVIORAL|RAMP program|The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
57737138|NCT06191848|DRUG|Placebo|Participants will receive placebo subcutaneously
57953268|NCT04450121|DEVICE|Patients will be intubated using Air-Q airway|"Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)"
57953269|NCT05044208|DIAGNOSTIC_TEST|ECG monitoring|After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
57953270|NCT01664728|DRUG|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
57953271|NCT01664728|DRUG|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
57953272|NCT00931359|DEVICE|DTS-G2 System|Treatment with microwave energy
57953273|NCT00931359|DEVICE|DTS System (Sham treatment)|Sham treatment - no energy is delivered
57737139|NCT05655312|DRUG|[203Pb]VMT01|\[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
57953274|NCT05266378|PROCEDURE|PECs block|The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
57953275|NCT05266378|OTHER|Not receiving PECs Block|In this group, the PECs block was not implemented.
58101478|NCT02528422|DRUG|Acyl-Ghrelin|
58101479|NCT02036827|DRUG|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
58101480|NCT01382134|DRUG|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
58101481|NCT01382134|DRUG|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
57737140|NCT05655312|DRUG|[212Pb]VMT01|Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
57737141|NCT05655312|DRUG|Nivolumab|For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
57737142|NCT02105116|DRUG|fludarabine phosphate|Given IV
58101482|NCT06057909|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Test that looks at the structure of the brain.
58101483|NCT06057909|DIAGNOSTIC_TEST|Electroencephalography|Non-invasive technique to measure brain waves
58101484|NCT06057909|DIAGNOSTIC_TEST|Electromyography|Technique to evaluate muscle activity
58308825|NCT00472420|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
57737143|NCT02105116|DRUG|cytarabine|Given IV
57737144|NCT02105116|BIOLOGICAL|donor lymphocytes|Undergo infusion of donor lymphocytes
57737145|NCT02105116|OTHER|laboratory biomarker analysis|Correlative studies
57737146|NCT02105116|DRUG|G-CSF|Given IV
57737147|NCT05271617|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
57737148|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 60 mg dextrose
57737149|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 80 mg dextrose
57737150|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 100 mg dextrose
57953276|NCT05999188|OTHER|Observational|No interventions will be given to patients.
57953277|NCT02820428|OTHER|Healthy participants|Semi-structured interview
57953278|NCT02562924|DEVICE|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
57737151|NCT04304144|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
57737152|NCT04304144|DRUG|SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|According to institutional standard of care.
57953279|NCT02562924|DRUG|Budesonide|Topical steroid
57737153|NCT04304144|DRUG|Daratumumab|Treatment for AL amyloidosis
57737154|NCT00722761|DRUG|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
57737155|NCT00722761|DRUG|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
57737156|NCT01314651|BEHAVIORAL|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
57953280|NCT02562924|DRUG|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
57953281|NCT02562924|DRUG|Prednisone|Post-operatively, 40 mg daily for 7 days
57953282|NCT02562924|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
57953283|NCT02562924|DRUG|nasal saline spray|saline nasal mist every hour while awake
57953284|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
57953285|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
57953286|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
57953287|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
57953288|NCT04350853|PROCEDURE|Surgical extrusion|Surgically coronal reposition of the tooth
57953289|NCT06539910|PROCEDURE|General Anesthesia|All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
57953290|NCT06539910|PROCEDURE|TIPS block|Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection. Distal adductor canal block via another needle puncture.Ten mL of a mixture of 0.25 % bupivacaine and 8 mg dexamethasone will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane lateral to medial approach just lateral to the superficial femoral artery
57953291|NCT06539910|PROCEDURE|Modified TIPS block|Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane.Both groups will receive a mixture of 0.25 % bupivacaine and 8 mg dexamethasone. Ten mL will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA anaesthetic mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane medial to lateral approach just lateral to the superficial femoral artery. Then, the needle will be redirected just underneath the ALM and 10 mL of the LA mixture will be injected in the plane between the ALM and the adductor magnus muscle (AMM).Total volume of LA will be 50 mL.
58101485|NCT01966341|BEHAVIORAL|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
58101486|NCT01966341|DRUG|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
58101487|NCT03633019|DRUG|rhTPO|high dose rhTPO ih
58101488|NCT03460119|DEVICE|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
58101489|NCT02364219|OTHER|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
58101490|NCT02364219|DEVICE|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
58101491|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
58101492|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
57737157|NCT01314651|BEHAVIORAL|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
58101493|NCT01315054|BEHAVIORAL|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
58101494|NCT01315054|BEHAVIORAL|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
58101495|NCT01315054|OTHER|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
58101496|NCT01963221|RADIATION|fludeoxyglucose(18f)|
58101497|NCT01963221|OTHER|blood sample|
58101498|NCT01963221|OTHER|cardiac and aortic magnetic resonance imaging|
58101499|NCT01963221|OTHER|carotid femoral pulse wave velocity|
58101500|NCT01963221|RADIATION|positron emission tomography|
58101501|NCT01963221|RADIATION|computed tomography|
57737158|NCT04560257|DEVICE|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
57737159|NCT03131388|DIAGNOSTIC_TEST|Access AMH Assay|
57737160|NCT03435133|DRUG|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
57737161|NCT03435133|DRUG|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
58101502|NCT01732198|BIOLOGICAL|NU300|
58101503|NCT01732198|BIOLOGICAL|ActHIB|
58101504|NCT01732198|BIOLOGICAL|Prevnar 13|
58430460|NCT01773304|OTHER|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
57737162|NCT03899883|DRUG|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
57737163|NCT02605980|BEHAVIORAL|Sedentary time|
57737164|NCT04545541|DRUG|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
57737165|NCT00081367|BEHAVIORAL|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
58101505|NCT02532140|DRUG|WCK 5107 250 mg to 2000 mg|
58101506|NCT02532140|DRUG|Cefepime 2000 mg|
58101507|NCT02532140|DRUG|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
58101508|NCT02532140|DRUG|Placebo|
58101509|NCT05678218|PROCEDURE|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
58101510|NCT02313519|DIETARY_SUPPLEMENT|Probiotics|Probiotics are prepared in capsule form
58101511|NCT02313519|DIETARY_SUPPLEMENT|Placebo|Glucose powder
58101512|NCT05595174|BIOLOGICAL|self ligating bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed
58101513|NCT05595174|BIOLOGICAL|conventional bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
58101514|NCT05595174|BIOLOGICAL|conventional bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment
58101515|NCT05595174|BIOLOGICAL|self ligating bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
58101516|NCT02337426|DRUG|Dimethyl Fumarate|Given PO
58101517|NCT02337426|DRUG|Temozolomide|Given PO
58101518|NCT02337426|RADIATION|Radiation Therapy|Undergo radiation therapy
58101519|NCT06251323|OTHER|iPATH implementation approach|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.
58101520|NCT00053599|DRUG|Simvastatin|
58308826|NCT00472420|DRUG|First line chemotherapy|As prescribed
58430461|NCT04846465|OTHER|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
58430462|NCT06256419|DRUG|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
58101521|NCT02221583|DRUG|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
58101522|NCT02221583|DRUG|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
58101523|NCT02221583|DRUG|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
58101524|NCT02268188|OTHER|education|Attend classes as part of Harvesting Health program
58101525|NCT02268188|OTHER|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
58430463|NCT06256419|DRUG|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
57737166|NCT00081367|BEHAVIORAL|Standard care alone|Participants will receive standard care for suicide prevention.
58101526|NCT02268188|BEHAVIORAL|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
58101527|NCT02268188|OTHER|questionnaire administration|Ancillary studies
58101528|NCT02268188|OTHER|laboratory biomarker analysis|Correlative studies
58101529|NCT02268188|OTHER|quality-of-life assessment|Ancillary studies
58101530|NCT04641754|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
58101531|NCT01096407|OTHER|laboratory biomarker analysis|Collection of urine samples
58101532|NCT01096407|OTHER|questionnaire administration|Completion of questionnaires
58101533|NCT01096407|PROCEDURE|assessment of therapy complications|An assessment will be completed.
58101534|NCT03996382|DIAGNOSTIC_TEST|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
58101535|NCT03001856|PROCEDURE|Oblique Intradermal Suture|
58101536|NCT03001856|PROCEDURE|Intradermal Suture|
58101537|NCT03608696|DRUG|Buprenorphine|buprenorphine 0.075 mg/ml solution
58101538|NCT03918395|DIETARY_SUPPLEMENT|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
58101539|NCT03918395|DIETARY_SUPPLEMENT|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
58101540|NCT06520878|DIETARY_SUPPLEMENT|NANO-PSO (pomegranate seed oil)|NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
58101541|NCT06520878|DIETARY_SUPPLEMENT|Placebo|Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
58101542|NCT04288115|DRUG|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
58101543|NCT04288115|OTHER|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
58101544|NCT00479401|DRUG|Pramipexol Extended Release|
58101545|NCT00479401|DRUG|Pramipexol Immediate Release|
58101546|NCT00479401|DRUG|Placebo|
58101547|NCT06541236|PROCEDURE|Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix|Incorporation of various bone grafting materials for alveolar ridge preservation
58430464|NCT02787915|BIOLOGICAL|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
57737167|NCT00396903|DEVICE|catheter|
57737168|NCT04858269|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
57737169|NCT04858269|DRUG|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
57737170|NCT04858269|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
58430465|NCT00898456|GENETIC|gene expression analysis|
58430466|NCT00898456|GENETIC|molecular genetic technique|
58430467|NCT00898456|GENETIC|polymorphism analysis|
58430468|NCT00898456|GENETIC|protein expression analysis|
58430469|NCT00898456|OTHER|diagnostic laboratory biomarker analysis|
58430470|NCT02249182|DRUG|LDV/SOF|LDV/SOF FDC administered orally once daily
58430471|NCT02249182|DRUG|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
58308827|NCT05676554|OTHER|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
58308828|NCT02901223|PROCEDURE|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
58308829|NCT02901223|PROCEDURE|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
58308830|NCT02838745|DRUG|Pemetrexed|
58308831|NCT02838745|DRUG|Cisplatin|
58308832|NCT05053581|OTHER|Survey|Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
58308833|NCT04836377|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
58308834|NCT06395467|BEHAVIORAL|InTEGRA|"Session topics are as follows: Parent Info Session - Informational and Q\&A format; Motivation Building- Addressing AA/NA Expectancies and Experiences; AA/NA Expectancies and Treatment Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management (AA/NA and Hungry, Angry, Lonely, Tired HALT; Effective Communication (Sharing at AA/NA meetings; getting a sponsor); Depression Management; Using AA/NA for enhancing Social Support and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse"
58308835|NCT06395467|BEHAVIORAL|MET/CBT|Session topics are as follows: Motivation Building Session; Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management; Effective Communication; Depression Management; Enhancing the Social Support Network and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse
58308836|NCT03173274|BEHAVIORAL|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
58308837|NCT03173274|BEHAVIORAL|Contingency Management|Contingent Reinforcement for negative breath CO samples
58308838|NCT03173274|BEHAVIORAL|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
58308839|NCT02183363|DRUG|BI 1356 - Tablet TFII|
58308840|NCT02183363|DRUG|BI 1356 - Tablet iFF|
58308841|NCT02183363|DRUG|BI 1356 - Tablet TFIIb|
58308842|NCT00926523|OTHER|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
58430472|NCT04294147|DRUG|Galcanezumab|Administered SC
58430473|NCT04294147|DRUG|Erenumab|Administered SC
58430474|NCT02870530|PROCEDURE|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
58430475|NCT00494507|DRUG|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
58430476|NCT00494507|DRUG|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
58430477|NCT00494507|DRUG|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
58308843|NCT00926523|OTHER|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
58308844|NCT00926523|OTHER|Spirometry|To assess subjects lung function
58308845|NCT00926523|OTHER|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
58308846|NCT04952259|DRUG|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
58430478|NCT03253328|DRUG|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
58430479|NCT03253328|DRUG|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
58430480|NCT03841370|PROCEDURE|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
58430481|NCT06393881|DRUG|UI059|take UI059 once a day for 7 days
58430482|NCT06393881|DRUG|UIC202201|take UIC202201 once a day for 7 days
58430483|NCT03113695|DRUG|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
58430484|NCT03113695|DRUG|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
58430485|NCT03113695|DRUG|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
58430486|NCT01248637|DRUG|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
58430487|NCT02295605|OTHER|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
58430488|NCT02295605|OTHER|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
58430489|NCT03218930|BEHAVIORAL|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
58430490|NCT03218930|BEHAVIORAL|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
58430491|NCT03218930|BEHAVIORAL|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
58430492|NCT03218930|BEHAVIORAL|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
58430493|NCT02394717|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
58430494|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
58430495|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
58430496|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
58430497|NCT02528682|BIOLOGICAL|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
58101548|NCT04114526|OTHER|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
58101549|NCT04473729|OTHER|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
58101550|NCT04722081|OTHER|physical therapy|physical therapy-specific exercises
58430498|NCT04118894|DEVICE|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
58430499|NCT05286216|BEHAVIORAL|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
58430500|NCT03125772|DEVICE|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
58430501|NCT03125772|DEVICE|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
58430502|NCT03194113|BEHAVIORAL|Trauma-focused treatment|Weekly sessions
58430503|NCT03194113|BEHAVIORAL|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
58430504|NCT03194113|BEHAVIORAL|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
58101551|NCT06541418|BEHAVIORAL|Transtheoretic Model Based Behavior Change Program|The Behavior Change Program was implemented in 7 sessions of 50 minutes, once a week. Each session in the Behavior Change Program; The warm-up exercise consisted of giving general information about the purpose and the main theme of the session, discussion and feedback on the subject, and the planning of the next week, and a closing process. The Transtheoretic Model Based Behavior Change Program was prepared by the researcher with reference to the behavior change programs in the literature and the elements of the Transtheoretic model.
58101552|NCT02815930|OTHER|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
58101553|NCT05652894|DRUG|HX008|Drug: HX008 200 mg ,Q3W
58101554|NCT05652894|DRUG|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI."
58101555|NCT06262633|DEVICE|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation|Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.
58101556|NCT04656574|BEHAVIORAL|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
58101557|NCT03339531|RADIATION|2D radiotherapy|
58101558|NCT04690387|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
58308847|NCT04952259|PROCEDURE|routine treatment|percutaneous coronary intervention
58308848|NCT01248416|DRUG|Aromatase Inhibitor|
58308849|NCT01248416|DRUG|Growth Hormone|
58308850|NCT01248416|DRUG|Aromatase Inhibitor and Growth Hormone|
58101559|NCT04690387|OTHER|GM-CSF|GM-CSF as an adjuvant
58101560|NCT05473858|DRUG|OraVerse Injectable Product|injection of oraverse,
58101561|NCT05473858|DEVICE|diode laser|patient exposed to diode laser
58101562|NCT02953262|BEHAVIORAL|My HealtheVet Brochure|Participants will receive a mailed brochure with basic My HealtheVet content.
58101563|NCT02953262|BEHAVIORAL|My HealtheVet Training Guide for Veterans Living with Diabetes|Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
58101564|NCT02953262|BEHAVIORAL|My HealtheVet Group Training|Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
58308851|NCT00689065|DRUG|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
58308852|NCT01982864|DRUG|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance...).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
58308853|NCT04031495|DEVICE|central vein cannulation|central vein cannulation
58308854|NCT05302011|DRUG|Pembrolizumab|Pembrolizumab 200mg i.v. day 1-22-43-64
58308855|NCT05302011|DRUG|Carboplatin or Cisplatin|Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
58308856|NCT05302011|DRUG|Docetaxel|75mg/m2 i.v. day 1-22-43-64
58308857|NCT03335046|BEHAVIORAL|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
58308858|NCT03335046|BEHAVIORAL|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
58308859|NCT03477162|DRUG|Metformin|Metformin will be given to patients prior to surgery.
58430505|NCT02173587|DIETARY_SUPPLEMENT|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
58430506|NCT02173587|DIETARY_SUPPLEMENT|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
58430507|NCT05586841|DRUG|Dalpiciclib|Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
58430508|NCT05586841|DRUG|Chidamide|Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
58101565|NCT02953262|BEHAVIORAL|My HealtheVet Individual Training|Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
58101566|NCT04585906|BEHAVIORAL|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
58101567|NCT05739227|OTHER|allogenic CD19-CAR-NK cells|The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10\^6/kg, 5x10\^6/kg, 2x10\^7/kg) after FCE chemotherapy
58101568|NCT00725725|BEHAVIORAL|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
58101569|NCT00725725|DRUG|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
58101570|NCT00725725|DRUG|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
58101571|NCT00725725|DRUG|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
58430509|NCT04216576|OTHER|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
58430510|NCT04216576|OTHER|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
58101572|NCT02523274|DRUG|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
58101573|NCT02523274|DRUG|Placebo|Vegetable-based cellulose
58101574|NCT02523274|BEHAVIORAL|Exercise|Multi-modal exercise regimen, 3 days/week
58308860|NCT05283746|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
58430511|NCT00634062|DRUG|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
58101575|NCT04656171|RADIATION|MRI of the hand and forearm,|MRI of the hand and forearm,
58308861|NCT00388245|PROCEDURE|Percutaneous Coronary Intervention|
58308862|NCT00388245|PROCEDURE|Coronary Artery Bypass Grafting|
58430512|NCT00634062|DRUG|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
57737171|NCT04357574|OTHER|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
57737172|NCT00152776|DRUG|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
57737173|NCT06395597|DIAGNOSTIC_TEST|Nine Hole Peg Test|3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
58101576|NCT02491307|OTHER|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
58101577|NCT03046147|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
58101578|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
58101579|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
58101580|NCT01987258|BEHAVIORAL|Interval Walking|
58101581|NCT01987258|BEHAVIORAL|Continuous walking|
58101582|NCT01426321|OTHER|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
58430513|NCT02687581|DEVICE|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
58101583|NCT05380622|DIAGNOSTIC_TEST|Coronary CT angiography|"Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab."
58101584|NCT00709020|DRUG|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
58101585|NCT00709020|OTHER|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
58101586|NCT00709020|OTHER|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
58101587|NCT00709020|OTHER|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
58101588|NCT00709020|OTHER|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
58101589|NCT00709020|OTHER|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
58101590|NCT00709020|OTHER|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
58101591|NCT00109629|DRUG|VRC-HIVDNA016-00-VP|
58101592|NCT00109629|DRUG|VRC-HIVADV014-00|
58101593|NCT05224518|BEHAVIORAL|elastic band training|elastic band training include stretching exercises
57737174|NCT02580604|DRUG|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
58101594|NCT02030834|BIOLOGICAL|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
58101595|NCT03178422|DRUG|CQSS2|Nicotine Replacement Therapy
58101596|NCT03178422|DRUG|NicoDerm CQ Patch|Nicotine Replacement Therapy
58101597|NCT05221879|OTHER|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
58101598|NCT06282666|PROCEDURE|Spinal anesthesia|Before the beginning of surgery, all patients will be anesthetized with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 1.5 - 2.5 mL solution. A pencil point spinal needle will be used.
58430514|NCT02687581|DEVICE|patch|6-hour of eye patch on the fellow eye
58101599|NCT06282666|PROCEDURE|lumbar erector spinae plane block|Investigators will perform the lumbar ESPB under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, we will leave a catheter in the ESP. Then, we used 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL.
58101600|NCT06282666|PROCEDURE|Epidural analgesia|After identifying the epidural space and spinal anesthesia (combined technique), a catheter will be placed in the epidural space. Investigators will give an epidural catheter a test dose of 2% lidocaine (2 mL). At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL).
58101601|NCT06282666|PROCEDURE|patient-controlled analgesia|Each participant will receive a pump with oxycodone (1mg/ml) using a patient-controlled analgesia (PCA) technique, a bolus of 1 mL, and a lockout of 5 minutes for the first postoperative day.
58101602|NCT06282666|DIAGNOSTIC_TEST|Timed Up and Go test|Investigators will measure the time the patient took to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while rotating 180 degrees. We will assess the patient before the surgery and 24 and 48 hours after hip replacement.
58430515|NCT02104947|DRUG|idarucizumab|idarucizumab
58430516|NCT04256252|DRUG|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
58458436|NCT02203877|DIETARY_SUPPLEMENT|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
58458437|NCT00468299|DRUG|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
58101603|NCT06282666|DIAGNOSTIC_TEST|neuropathic pain symptom inventory|The Neuropathic Pain Symptom Inventory (0-100; 0 denotes no pain, 100 the most severe pain) will be evaluated before the surgery and three and six months following the procedure.
58101604|NCT06282666|DIAGNOSTIC_TEST|Lovett test|A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
58101605|NCT06282666|DIAGNOSTIC_TEST|Visual analog scale|Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.
58101606|NCT06282666|DIAGNOSTIC_TEST|Quality of Recovery 40|Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.
58101607|NCT06282666|DIAGNOSTIC_TEST|Ability to sit, stand upright, and walk|A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
58101608|NCT02063386|DRUG|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
58101609|NCT06413589|OTHER|SMOF lipid 20%|Drug: SMOF lipid 20% SMOF 20%, a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
58101610|NCT06413589|OTHER|standard treatment for clozapine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg) \[29\].~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
58101611|NCT00781131|DRUG|Pregabalin|pregabalin 75 or 150 mg
58101612|NCT00781131|DRUG|Placebo|lactulose placebo
58101613|NCT04398888|OTHER|Banxie Xiexin Decoction (BXD)|A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
58101614|NCT01116765|OTHER|no stimulation of the oral structure|
58101615|NCT01116765|OTHER|stimulation of the oral structure|
58101616|NCT04626882|PROCEDURE|Staged in-hospital or Immediate complete revascularization|Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
58101617|NCT02294552|DRUG|Cyclophosphamide|
58430517|NCT05192434|BEHAVIORAL|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
58430518|NCT05192434|BEHAVIORAL|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
58430519|NCT04842981|DRUG|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
57953292|NCT06539910|PROCEDURE|Mutimodal analgesia|Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes
58101618|NCT02294552|DRUG|Busulfan|
58101619|NCT02294552|DRUG|Fludarabine monophosphate|
58101620|NCT02294552|DRUG|Tacrolimus|
58101621|NCT02294552|DRUG|Mycophenolate mofetil|
58101622|NCT02294552|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
58101623|NCT02843347|PROCEDURE|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
58101624|NCT05817084|PROCEDURE|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
58101625|NCT05817084|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
58101626|NCT04297553|PROCEDURE|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
58101627|NCT04297553|PROCEDURE|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
58101628|NCT02394353|DEVICE|Transient hepatic elastography|
57737175|NCT02580604|DRUG|Placebo|Saline Infusion
58101629|NCT00305071|DRUG|compound cranberry extract tablet|
58101630|NCT00091507|DRUG|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
58430520|NCT04842981|DRUG|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
58430521|NCT03074682|DEVICE|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
57953293|NCT03269071|DRUG|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
58101631|NCT00091507|DRUG|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
58101632|NCT05001373|BIOLOGICAL|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
58101633|NCT05001373|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
58101634|NCT06038266|PROCEDURE|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
58101635|NCT05182983|OTHER|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
58101636|NCT00103259|DRUG|bortezomib|Given IV
58101637|NCT00103259|DRUG|irinotecan hydrochloride|Given IV
58101638|NCT00103259|OTHER|laboratory biomarker analysis|Optional correlative studies
58430522|NCT03074682|DEVICE|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
58101639|NCT04098068|DRUG|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
58101640|NCT03948737|DRUG|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
58101641|NCT03948737|DRUG|Placebo oral tablet|
58101642|NCT04337515|DEVICE|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
58101643|NCT03651895|DRUG|Metformin|Drug
58101644|NCT03651895|DRUG|Placebo|Placebo
58101645|NCT05802979|DRUG|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
58101646|NCT01904552|DEVICE|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
58430523|NCT03074682|DEVICE|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
58430524|NCT00153192|DRUG|Marinol (dronabinol)|
58430525|NCT02188849|OTHER|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
58430526|NCT02188849|DRUG|Creatine|Creatine powder 5 g day
58430527|NCT00375518|DRUG|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
58430528|NCT00375518|DRUG|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
58430529|NCT03390309|OTHER|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
58430530|NCT03390309|OTHER|Normal Formula|Normal Formula
58430531|NCT03821116|OTHER|Milk|Swedish milk from cow.
58101647|NCT03305783|PROCEDURE|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
58101648|NCT06520267|DRUG|Antibiotic therapy|Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
58101649|NCT04098471|PROCEDURE|transanal local excision following radiotherapy|transanal local excision following radiotherapy
58308863|NCT06523179|OTHER|quantify the impact of genetic risk factors|the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
58101650|NCT06540313|OTHER|Stellate Ganglion Block|Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
57737176|NCT05509413|DEVICE|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
58101651|NCT01261416|DRUG|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
58101652|NCT04075383|PROCEDURE|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
58101653|NCT04075383|PROCEDURE|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
58101654|NCT01136005|OTHER|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
58101655|NCT01136005|OTHER|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
58101656|NCT06528990|BEHAVIORAL|Telehealth Intervention|This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.
58101657|NCT06528990|OTHER|Standard of care|standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
58101658|NCT03078192|DRUG|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
58101659|NCT03078192|DEVICE|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
58101660|NCT02623426|DRUG|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
58101661|NCT02623426|DRUG|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
58101662|NCT02623426|DRUG|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
58101663|NCT00000160|PROCEDURE|Xenon Photocoagulation|
58101664|NCT00000160|PROCEDURE|Argon Photocoagulation|
58101665|NCT00000160|PROCEDURE|Photocoagulation|
58101666|NCT06112405|OTHER|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
58101667|NCT06112405|OTHER|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
58101668|NCT01585831|DRUG|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
58101669|NCT01585831|DRUG|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
58101670|NCT02276911|DRUG|Ibuprofen|
58101671|NCT02276911|OTHER|normal saline|
58101672|NCT03435822|OTHER|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
58101673|NCT03435822|OTHER|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
58430532|NCT03821116|OTHER|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
58101674|NCT04060472|DRUG|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
58101675|NCT02840214|DEVICE|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
58101676|NCT02840214|DEVICE|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
58101677|NCT03304210|DRUG|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
58430533|NCT01868386|RADIATION|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
58101678|NCT00730470|DRUG|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
58101679|NCT06567236|OTHER|3D software|Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
58101680|NCT06373419|DEVICE|TFL|Participant undergoing bladder tumour resection that has been randomized to this arm.
58101681|NCT06373419|DEVICE|MOSES holmium laser|Participant undergoing bladder tumour resection that has been randomized to this arm.
58101682|NCT06282068|DIAGNOSTIC_TEST|AI computer-aided detection software|non-invasive
58101683|NCT06070168|OTHER|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
58101684|NCT02228031|DRUG|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
58101685|NCT02228031|OTHER|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
58101686|NCT01436669|DEVICE|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
58101687|NCT03092089|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
58101688|NCT03092089|DEVICE|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
58101689|NCT03092089|PROCEDURE|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
58101690|NCT03746886|OTHER|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
58430534|NCT04029103|OTHER|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
58430535|NCT05977829|DIAGNOSTIC_TEST|Ultrasound|Transvaginal ultrasound to carry out uterine surveillance
58430536|NCT05977829|DIAGNOSTIC_TEST|Hysteroscopy|Outpatient hysteroscopy to carry out uterine surveillance
58430537|NCT02073019|DRUG|BL-8040|
58430538|NCT02073019|DRUG|Placebo|
58101691|NCT03961945|DEVICE|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
58101692|NCT02764073|DEVICE|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
58101693|NCT02764073|DEVICE|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
58308864|NCT03738735|DRUG|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
58430539|NCT05656482|OTHER|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
58430540|NCT04777292|DEVICE|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
58430541|NCT02128074|DRUG|KRX-0502|1g tablets of KRX-0502
58430542|NCT02793791|PROCEDURE|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
58430543|NCT00337090|DRUG|YM178|
58458438|NCT00468299|DRUG|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
58101694|NCT02764073|DEVICE|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
58101695|NCT06537804|RADIATION|Screening by low-dose CT scan|Screening for lung cancer by low-dose CT scan
58101696|NCT04170049|BEHAVIORAL|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
58101697|NCT00004861|DRUG|gemcitabine hydrochloride|
58101698|NCT00004861|DRUG|tacedinaline|
58101699|NCT00004161|DRUG|fenretinide|
58101700|NCT00004161|DRUG|Placebo|
58101701|NCT02232269|OTHER|Black Coffee|
58101702|NCT02232269|OTHER|Grapefruit Juice|
58101703|NCT02232269|OTHER|Water|
58101704|NCT02232269|DRUG|Felodipine|
58101705|NCT03448809|BEHAVIORAL|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
58430544|NCT03473795|BEHAVIORAL|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
57737177|NCT06188065|DIAGNOSTIC_TEST|Blood eosinophil count|To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
57737178|NCT02500992|PROCEDURE|Transrectal sigmoidectomy|
57737179|NCT03191318|OTHER|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
57737180|NCT03191318|OTHER|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
58101706|NCT03448809|BEHAVIORAL|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
58101707|NCT01083901|BEHAVIORAL|Resistance training|high intensity progressive resistance exercise training
58430545|NCT03473795|OTHER|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
58430546|NCT00311259|DRUG|Melatonin (drug)|
58430547|NCT00311259|DRUG|Laktose|
57737181|NCT03319277|OTHER|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
57737182|NCT03319277|OTHER|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
57737183|NCT01673802|DRUG|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
57737184|NCT05019339|BEHAVIORAL|Healthy HomeStyles|Comparison of 2 educational interventions
57737185|NCT05019339|BEHAVIORAL|Eat Healthy Be Active|Comparison of 2 educational interventions
57737186|NCT02263404|DEVICE|Deep Brain Stimulation|DBS Implant Stimulation
57737187|NCT04305925|DEVICE|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
57737188|NCT06147102|PROCEDURE|Surgery|Surgical treatment for the unruptured intracranial aneurysm
57737189|NCT06147102|PROCEDURE|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
58101708|NCT02354352|DRUG|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
58101709|NCT02354352|DRUG|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
58101710|NCT00612794|DRUG|exenatide once weekly|subcutaneous injection, once weekly
58101711|NCT00612794|DRUG|placebo|subcutaneous injection, once weekly
58101712|NCT02726373|OTHER|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
58101713|NCT02535247|DRUG|MK-3475|
58101714|NCT02535247|DRUG|Copanlisib|
58101715|NCT05700110|OTHER|Non-Interventional|Non-interventional
58101716|NCT06536816|OTHER|Game Profile-based training Group|Game profile-based training is a methodology in sports, including football, where training sessions are designed to simulate the specific conditions and challenges that players face during actual games. Coaches analyze individual and team performance data to identify patterns, positions, and scenarios commonly encountered in matches. The training is then structured to replicate these situations, helping players develop the skills, tactics, and decision-making abilities required in real-game scenarios. This approach aims to make training more targeted and relevant to the dynamics of competitive play.
58101717|NCT06536816|OTHER|Small-sided games Group|"small-sided game in football, often referred to as a SSG, is a practice or training activity where players compete in a reduced playing area with fewer players than a full team."
58101718|NCT06536816|OTHER|Combined training Group with both Game Profile-based training and Small-sided Games|Combined training Group with both Game Profile-based training and Small-sided Games
58430548|NCT04849715|DRUG|parsaclisib|parsaclisib will be administered orally once daily.
58430549|NCT04849715|DRUG|rituximab|rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
58430550|NCT04849715|DRUG|bendamustine|bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
58101719|NCT06542471|DEVICE|Dual intramedullary nailing|- Elastic nailing for radius under image guidance through distal entry point and physeal sparing technique.
57737190|NCT01194960|DRUG|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
58101720|NCT06542471|DEVICE|Dual plating|- ORIF for radius done first through volar approach.
58101721|NCT01758315|OTHER|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
58101722|NCT04184154|OTHER|Questionnaires|The self-questionnaire of 104 questions collected personal and socio-demographics data, global and sexual quality of life characteristics (European Organisation for Research and Treatment of Cancer \[EORTC\] quality of life questionnaires: QLQ-C30 and gynecologic and cervical cancer specific-questionnaire QLQ-CX24), vaginal dilatators and moisturizers use, and barriers and facilitators of their use. Clinical data were extracted from the patients' medical files. Vaginal stenosis was evaluated at 6 weeks after the end of brachytherapy and after 1-year follow-up by in-town gynecologists or in our Institute, and censored in case of complete vaginal obliteration
58101723|NCT03216954|DRUG|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
58101724|NCT03216954|DRUG|Placebos|Subjects will receive placebo capsules
58308865|NCT05912868|DEVICE|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
58308866|NCT06039202|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
58308867|NCT06039202|DRUG|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
58430551|NCT04849715|DRUG|Placebo|placebo will be administered orally once daily
57737191|NCT01194960|DRUG|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
57737192|NCT00440050|DRUG|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
57737193|NCT00440050|DRUG|Placebo|2 placebo capsules twice a day for 18 months
57737194|NCT05080400|DIETARY_SUPPLEMENT|White rice|Jasmine rice 179g of cooked weight
57737195|NCT05080400|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
57737196|NCT04195464|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
57737197|NCT04195464|OTHER|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
57953294|NCT04961788|DRUG|Gemox combimed PD1 antibody|"1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
57953295|NCT02474732|DEVICE|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
57953296|NCT06465797|DIAGNOSTIC_TEST|Bronchoscopy|No intervention will take place in this study, only image material will be captured from the standard-of-care bronchoscopy
57953297|NCT03718286|DRUG|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
57953298|NCT03718286|OTHER|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
57953299|NCT00500084|DRUG|Liprotamase|Administered orally
57953300|NCT06073496|OTHER|Electroacupuncture|Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator
57953301|NCT03006510|OTHER|Hypoglycemia prediction alert|"In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is \>35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
57953302|NCT06333509|BIOLOGICAL|CT071|a single CAR-T infusion of CT071
58101725|NCT03216954|DRUG|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
58308868|NCT06039202|BIOLOGICAL|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
58308869|NCT03638323|OTHER|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
58430552|NCT05329870|OTHER|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
58430553|NCT05322369|OTHER|periodontal charting only|Periodontal charting only
57737198|NCT04517266|RADIATION|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
57737199|NCT04517266|RADIATION|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
58430554|NCT01660620|DRUG|Betaxolol|
58430555|NCT01660620|DRUG|topical betaxolol|given topically
58430556|NCT05244733|BEHAVIORAL|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
58430557|NCT05244733|BEHAVIORAL|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
58430558|NCT04113525|DEVICE|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
58430559|NCT05244551|DRUG|ABSK061|In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
58430560|NCT02547168|DEVICE|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
58430561|NCT04384523|DRUG|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
58430562|NCT04384523|DRUG|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
58430563|NCT04384523|DRUG|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
57737200|NCT02766751|BEHAVIORAL|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
57737201|NCT02766751|BEHAVIORAL|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
57737202|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
57953303|NCT03551444|DRUG|Administration of DAA-based treatment|"* Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered."
57953304|NCT06129266|OTHER|oral care with breastmilk|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
57953305|NCT03801655|DIETARY_SUPPLEMENT|Bio-Kult|4 capsules/day
58308870|NCT00465179|DRUG|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
58308871|NCT05695703|OTHER|Core Strength Training Group|"The participants of experimental group will perform core strength training regime for 6 weeks (3 days per week). Each exercise session will last for a period of 45 mins, the exercises would be performed in 3 sets of 5 repetitions with 5 seconds hold time and 10 seconds rest between each repetition and a minutes rest in between each set.~Following exercises would be performed :~Bridge, Crunch, Plank, Side Plank, Mountain Climb."
58101726|NCT04628221|DEVICE|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
58308872|NCT05695703|OTHER|Conventional Training Group|"The participants of conventional group will perform following exercises :~Running (10 repetitions X 3 sets), Jogging (10 repetitions X 3 sets), Stretching (10 repetitions X 3 sets)~Rest between Exercises : 10-15 Seconds Rest between Set of Exercises : 30-60 Seconds Cricketers will receive exercises for 8 weeks. There will be 3 sessions per week."
58308873|NCT00624091|PROCEDURE|Cardiac surgery|Cardiac surgery within 48 hours of randomization
58308874|NCT00624091|PROCEDURE|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
58308875|NCT01836237|DEVICE|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
58308876|NCT03513952|DRUG|Atezolizumab|Given IV
58308877|NCT03513952|PROCEDURE|Biopsy|Undergo biopsy of tumor
58308878|NCT03513952|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
58308879|NCT03513952|PROCEDURE|Computed Tomography|Undergo CT
58308880|NCT03513952|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given IM
58430564|NCT04384523|DRUG|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
58430565|NCT04384523|DRUG|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
58430566|NCT04384523|OTHER|Placebo|Normal Saline (0.9% Sodium Chloride)
58430567|NCT06166108|DRUG|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
58430568|NCT03044184|DRUG|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
58430569|NCT00246246|DRUG|risperidone|
58458439|NCT04351217|BEHAVIORAL|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
58458440|NCT04351217|BEHAVIORAL|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
58458441|NCT00333775|DRUG|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
58458442|NCT00333775|DRUG|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
58458443|NCT00333775|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
57737203|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
57737204|NCT06435234|BEHAVIORAL|risky sexual behavior intervention|Intervening in risky sexual behaviors among college students
58101727|NCT00233350|DEVICE|use of navigated 3D ultrasound during surgery|
58101728|NCT01825915|PROCEDURE|Laparoscopic Hysterectomy|
58101729|NCT01825915|PROCEDURE|Laparoscopic Supracervical Hysterectomy|
58101730|NCT00583245|OTHER|Gait Training|Gait training with physical therapist 2/week for 3 months
58101731|NCT01277406|DRUG|4SC-201(Resminostat)|oral administration
58101732|NCT01277406|DRUG|FOLFIRI|i.v. administration
58101733|NCT04783844|DIAGNOSTIC_TEST|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
58101734|NCT04664283|DEVICE|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
58101735|NCT03137485|PROCEDURE|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
58101736|NCT03137485|PROCEDURE|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
58101737|NCT03137485|DEVICE|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
58458444|NCT05425056|DRUG|Sirolimus|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
58458445|NCT00763113|DEVICE|Vanguard PS Knee|Vanguard PS Knee
58458446|NCT00763113|DEVICE|Vanguard CR Knee|Vanguard CR Knee
58458447|NCT02530021|OTHER|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
57737205|NCT04179487|DIAGNOSTIC_TEST|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
58101738|NCT04911660|DRUG|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
58101739|NCT04911660|OTHER|Placebo|1 placebo capsule per day for 14 days
58101740|NCT02851953|DEVICE|Aqueduct-100|
58101741|NCT04629131|BIOLOGICAL|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
58101742|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 1, given once
57953306|NCT03801655|OTHER|Placebo|4 capsules/day
58101743|NCT04629131|BIOLOGICAL|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
58101744|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 2, given once
58101745|NCT04629131|BIOLOGICAL|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
58101746|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 3, given once
58101747|NCT04629131|BIOLOGICAL|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
58101748|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 4, given once
57953307|NCT02868697|DRUG|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
57953308|NCT02868697|DRUG|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
58101749|NCT05675384|DEVICE|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
58101750|NCT05675384|DEVICE|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
58101751|NCT01777802|RADIATION|SBRT|
58101752|NCT01777802|RADIATION|IMRT|
58101753|NCT01777802|RADIATION|Brachytherapy|
58101754|NCT05786781|DEVICE|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
58101755|NCT00601276|DRUG|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
58101756|NCT00601276|DRUG|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
58101757|NCT02319954|PROCEDURE|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
58101758|NCT01896700|DRUG|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
58101759|NCT01896700|DRUG|Placebo|Escalating matched dose of placebo
58101760|NCT02715466|DRUG|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
58101761|NCT02715466|DRUG|Balanced electrolyte solution|Sterofundin ISO
58101762|NCT04471558|OTHER|Music|A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
58101763|NCT04727619|BEHAVIORAL|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
58308881|NCT03513952|OTHER|Laboratory Biomarker Analysis|Correlative studies
58308882|NCT03513952|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58308883|NCT03513952|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
57953309|NCT02788747|DRUG|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
57953310|NCT02788747|DRUG|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
58101764|NCT00921219|DRUG|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
58101765|NCT03232905|DRUG|PF-06651600|PF-06651600 will be administered as tablet
58101766|NCT03232905|DRUG|Placebo|Matching placebo will be administered as tablet
58430570|NCT06289309|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
58430571|NCT01705678|DIETARY_SUPPLEMENT|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
58430572|NCT01705678|DIETARY_SUPPLEMENT|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
58430573|NCT03585049|OTHER|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
58430574|NCT06482450|OTHER|LetsTalkShots (patient-facing CDS)|LetsTalkShots is a website which provides patients/parents with tailored videos addressing vaccine concerns.
58430575|NCT06482450|OTHER|LetsTalkShots (provider-facing CDS)|The provider-facing CDS component will propagate patient concerns obtained from LetsTalkShots (and the appropriate talking points to address the talking points) into the electronic health record (EHR) for the provider at the point of care.
58101767|NCT06271135|BEHAVIORAL|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
57953311|NCT02788747|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
58101768|NCT04348344|BEHAVIORAL|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
58101769|NCT00504127|DRUG|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
58101770|NCT00504127|DRUG|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
58308884|NCT06201104|OTHER|Patient empowerment education|"After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients."
58308885|NCT00309517|DRUG|Fluourouracil|
58308886|NCT00309517|DRUG|Leucovorin|
58308887|NCT00309517|DRUG|MAb 17-1A|
58430576|NCT06482450|OTHER|Appointment Reminder Message|"The regular text message and e-mail appointment reminder includes a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
58430577|NCT01849419|DRUG|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
58101771|NCT00504127|DRUG|Naproxen 500 mg bid|Naproxen 500 mg bid
58430578|NCT01849419|DRUG|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
58430579|NCT01849419|DRUG|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
58101772|NCT00504127|DRUG|placebo|placebo
58101773|NCT05322421|OTHER|Topical Olive Oil|Olive oil will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
58101774|NCT05322421|OTHER|Sodium bicarbonate 5% solution|Sodium bicarbonate 5% solution will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
58101775|NCT00400426|PROCEDURE|Radiotherapy|20 Gy in 4 fx
58101776|NCT04419077|BEHAVIORAL|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
58101777|NCT01003548|DEVICE|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
58101778|NCT01003548|DEVICE|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
58101779|NCT00689208|DRUG|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
58101780|NCT00689208|DRUG|Physostigmine|0,12ug/kg/min
58308888|NCT01933594|DRUG|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
58308889|NCT01933594|DRUG|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
58308890|NCT04801212|OTHER|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
58308891|NCT04801212|OTHER|core stability exercises|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
58308892|NCT05148728|PROCEDURE|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
58308893|NCT04739228|BEHAVIORAL|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
58430580|NCT03080363|DRUG|Bupivacaine|10 ml %0.5 bupivacaine
58430581|NCT03080363|DRUG|Lidocaine|10 ml %2 lidocaine
58430582|NCT01153698|DRUG|dabigatran|anticoagulation
58430583|NCT01748825|DRUG|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
58430584|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
58430585|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
58430586|NCT01657734|OTHER|MR imaging|MR imaging
58430587|NCT03358134|DRUG|Secukinumab|anti IL17 therapy (subcutaneous)
58430588|NCT04720300|OTHER|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
58101781|NCT00689208|DRUG|Placebo Sodium|
58101782|NCT03679845|DRUG|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
58101783|NCT03907475|PROCEDURE|Biopsy|Undergo tissue biopsy
58101784|NCT03907475|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58101785|NCT03907475|DRUG|Capecitabine|Given PO
58101786|NCT03907475|DRUG|Carboplatin|Given IV
58101787|NCT03907475|PROCEDURE|Computed Tomography|Undergo CT
58101788|NCT03907475|BIOLOGICAL|Durvalumab|Given IV
58101789|NCT03907475|PROCEDURE|Echocardiography|Undergo ECHO
58101790|NCT03907475|DRUG|Gemcitabine Hydrochloride|Given IV
58430589|NCT04720300|OTHER|No app|students receive no app or housing information
58101791|NCT03907475|DRUG|Nab-paclitaxel|Given IV
58101792|NCT03907475|DRUG|Paclitaxel|Given IV
58101793|NCT03907475|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
58101794|NCT01677169|DIETARY_SUPPLEMENT|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
58101795|NCT01677169|DIETARY_SUPPLEMENT|Placebo|
58101796|NCT04839315|BIOLOGICAL|mRNA COVD19 vaccine|Subjects will receive two doses of mRNA based COVID19 vaccines.
58308894|NCT04739228|BEHAVIORAL|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
58308895|NCT05046600|DEVICE|Products listed in cohort description|Depending on approved indication per product
58101797|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
58101798|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
58430590|NCT04651608|BEHAVIORAL|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
58430591|NCT04651608|BEHAVIORAL|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
58430592|NCT04651608|BEHAVIORAL|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
58430593|NCT04651608|BEHAVIORAL|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
58101799|NCT04973839|BEHAVIORAL|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
58430594|NCT03846284|DRUG|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
58430595|NCT03846284|DRUG|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
58101800|NCT04973839|BEHAVIORAL|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
58430596|NCT03846284|DRUG|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
58430597|NCT02690714|BIOLOGICAL|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
58430598|NCT04716101|OTHER|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
58101801|NCT03402165|DRUG|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir|Response to DAAD's and developing HCC
58101802|NCT04948385|DRUG|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
58101803|NCT04948385|PROCEDURE|No sedation|No sedation
58308896|NCT06221709|PROCEDURE|Conventional Radiofrequency (CRF group)|Radiofrequency will be performed with a 22-gauge CRF cannula, 10/15 cm long, 10mm curved active tip, at 90º for 90 seconds, introduced in the anteroposterior and lateromedial directions, to reach the teardrop landmark. Denervation of the articular branches of the Obturator Nerve will be performed in 2 cycles, starting lateral to the lateral edge of the obturator foramen, followed by a point approximately 1cm lateral to the first point. Next, the cannula will be repositioned in a more cranial location, parallel to the superolateral edge of the acetabular dome, to reach the sensory branches of the Femoral Nerve, performing 3 cycles at the 01, 12, and 11 o'clock positions. All lesions will be preceded by motor stimulation at 2,5V and cycles will be followed by the infusion of 2ml of 1% ropivacaine. After concluding the procedure, hip intraarticular infiltration will be performed as described for the control group.
58430599|NCT04716101|OTHER|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
58430600|NCT02300519|OTHER|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
58430601|NCT02237638|BIOLOGICAL|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
58430602|NCT00158951|DEVICE|CONTAK RENEWAL 2/4/4HE CRT-D|
58430603|NCT00158951|DEVICE|EASYTRAK 2 Lead|
58430604|NCT01900743|DRUG|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
58101804|NCT02996617|DRUG|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
58430605|NCT01900743|DRUG|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
58430606|NCT06000410|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
58430607|NCT06000410|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
58430608|NCT01640899|DEVICE|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
58430609|NCT05321251|DRUG|Insulin|see arm description
58430610|NCT05321251|PROCEDURE|Tarsorrhaphy|see arm description
58430611|NCT01217372|DIETARY_SUPPLEMENT|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
58430612|NCT02253485|DRUG|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
58430613|NCT04390841|DEVICE|Cardiac Stimulator|The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
58430614|NCT00868036|PROCEDURE|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
58430615|NCT01083589|DRUG|Imatinib Mesylate|Oral 400 mg daily
58430616|NCT01083589|DRUG|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
58430617|NCT02191813|DRUG|Seresis®|
58430618|NCT02191813|DRUG|Placebo|
58430619|NCT04499989|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
58430620|NCT04499989|DRUG|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
58430621|NCT03270891|DIAGNOSTIC_TEST|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
58430622|NCT04477655|PROCEDURE|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
58430623|NCT04477655|PROCEDURE|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
58430624|NCT01779635|DEVICE|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
58430625|NCT01779635|DEVICE|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
58430626|NCT03977493|DRUG|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
58430627|NCT03977493|DRUG|Placebo - Concentrate|One injection in each muscle.
58430628|NCT02883101|BEHAVIORAL|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
58430629|NCT04326049|DEVICE|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
58430630|NCT04326049|DEVICE|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
58430631|NCT01123707|DRUG|Aripiprazole|Aripiprazole oral capsules
58430632|NCT01123707|DRUG|Escitalopram|Escitalopram oral capsules
57737206|NCT05102890|OTHER|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
57737207|NCT06579573|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
58101805|NCT02996617|DRUG|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
58101806|NCT03361917|DEVICE|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
58101807|NCT06506097|BEHAVIORAL|Family-school Partnership Intervention (FSPI)|"FSPI includes implementation activities across multiple levels.~FSPI Planning Team Meetings will be held monthly to plan project activities, practice staff and parent coaching strategies, and troubleshoot implementation challenges.~FSPI Staff Training (3 hours) will be provided during a single professional development day (3 hours), and attended by members of the FSPI Planning Team and teachers.~FSPI Playgroups. Over the course of the school year, each parent-child dyad will be invited to participate in three FSPI Playgroup events. Typically, teachers from two classrooms will collaborate in hosting playgroup events, and each playgroup will be attended by four parent-child dyads (i.e., two per classroom). Teachers will be provided with a curriculum and learning outcomes to target.~FSPI Debrief Meetings are held after each FSPI Playgroup to debrief, reflect, and improve FSPI implementation."
58101808|NCT01185639|RADIATION|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
58101809|NCT03516838|DRUG|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
58430633|NCT06583746|OTHER|Group1|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
58430634|NCT05397639|DRUG|Masupirdine 50 mg|Tablet, Once Daily
58430635|NCT05397639|DRUG|Masupirdine 100 mg|Tablet, Once Daily
58430636|NCT05397639|DRUG|Placebo|Matching Placebo Tablet, Once Daily
57737208|NCT03913741|DRUG|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
57737209|NCT04104867|DRUG|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
57737210|NCT04104867|DRUG|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
58101810|NCT03516838|DRUG|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
58101811|NCT04243499|BIOLOGICAL|IV ICT01|humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
58101812|NCT04662684|DRUG|Rivaroxaban 10 MG|No intervention
58101813|NCT04860726|OTHER|Joint mobilization|Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
58430637|NCT02202538|DEVICE|Indego|Indego
58430638|NCT01351155|DEVICE|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
58430639|NCT04787055|DEVICE|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
58430640|NCT03312426|DRUG|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
58430641|NCT02268994|DRUG|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
58430642|NCT02268994|DRUG|Placebo|Matching placebo
58430643|NCT03669237|PROCEDURE|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
58430644|NCT06549660|DEVICE|Active PBMT|Active with a dose of 165 J per site, resulting in a total dose of 495J.
58430645|NCT06549660|DEVICE|Placebo PBMT|Placebo, without therapeutic dose.
58430646|NCT03752749|OTHER|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
58430647|NCT03752749|OTHER|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
58430648|NCT00169091|DRUG|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
57737211|NCT04104867|OTHER|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
57737212|NCT01604330|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
58101814|NCT04860726|OTHER|Myofascial Release|"Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes"
58101815|NCT04860726|OTHER|Joint mobilization & Myofascial Release|"Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min"
58101816|NCT02055183|DRUG|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
58101817|NCT06529458|OTHER|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
58101818|NCT06529458|OTHER|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
58101819|NCT06529458|OTHER|Control Group|No interference will be made
58101820|NCT00614458|DRUG|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
58101821|NCT01472315|DRUG|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
58430649|NCT00169091|DRUG|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
58430650|NCT03920930|PROCEDURE|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
58430651|NCT03920930|PROCEDURE|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
58430652|NCT04805710|DRUG|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
57737213|NCT01604330|DRUG|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
57737214|NCT01587651|DRUG|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
57737215|NCT01587651|DRUG|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
57737216|NCT01587651|DRUG|Ticagrelor Maintenance Dose|one 90mg film coated tablet
57737217|NCT03358225|PROCEDURE|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
57737218|NCT03358225|PROCEDURE|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
57737219|NCT03358225|PROCEDURE|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
58101822|NCT01472315|DRUG|Placebo|Placebo pills were taken in same way as active comparator
58101823|NCT03958071|DRUG|Nintedanib|Nintedanib initiators
58101824|NCT03958071|DRUG|Pirfenidone|Pirfenidone initiators
58308897|NCT06221709|PROCEDURE|Intraarticular Infiltration ( Control group)|For the control group (IA), an epidural anesthesia needle (22G spinal needle) will be used, positioned anteroposteriorly towards the central portion of the femoral neck, which will be introduced until transfixion of the anterior hip capsule through tactile sensitivity. After checking the correct positioning with the use of fluoroscopy and infusion of 3 ml of 50% diluted iodinated contrast, an infusion of 4 ml of 1% Ropivacaine and 80mg of methylprednisolone 40mg/ml will be done.
57737220|NCT01396967|DEVICE|surgery|cataract surgery
58308898|NCT04066374|DEVICE|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
58308899|NCT03895801|DRUG|IFX-1|intravenously administered
58308900|NCT03895801|DRUG|Placebo-IFX-1|intravenously administered
58308901|NCT03895801|DRUG|Glucocorticoid (GC)|orally administered
58308902|NCT03895801|DRUG|Placebo-Glucocorticoid (Placebo-GC)|orally administered
58308903|NCT01330082|OTHER|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
58308904|NCT01330082|OTHER|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
58101825|NCT03958071|OTHER|Untreated Cohort|Untreated
57737221|NCT06670612|OTHER|nature based music concert|It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
58101826|NCT06346054|DIAGNOSTIC_TEST|Breath analysis|Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
58101827|NCT06346054|DIAGNOSTIC_TEST|Blood analysis|Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
58101828|NCT02284295|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
58430653|NCT00924508|DEVICE|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
58430654|NCT00924508|DRUG|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
57737222|NCT00126516|DRUG|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
57737223|NCT00126516|DRUG|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
58101829|NCT02284295|OTHER|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
58101830|NCT00878137|DEVICE|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
58101831|NCT02494310|DEVICE|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
57737224|NCT04753840|OTHER|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
57737225|NCT04753840|OTHER|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
58101832|NCT05160727|DRUG|Tislelizumab|200mg ivgtt d1 q3w
58101833|NCT05160727|DRUG|Irinotecan|"Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w."
58101834|NCT05160727|RADIATION|radiotherapy|radiotherapy
58430655|NCT01545427|DRUG|Imatinib mesylate|200 mg bid for 6 months
58430656|NCT01545427|OTHER|Placebo|Placebo coated to match appearance of Gleevec identically.
58430657|NCT05859243|BEHAVIORAL|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
58101835|NCT01395693|DEVICE|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
58101836|NCT03969784|OTHER|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
58101837|NCT00003290|BIOLOGICAL|gonadotrophin releasing hormone|
58101838|NCT00003290|RADIATION|radiation therapy|
58101839|NCT02551302|DEVICE|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
58101840|NCT02551302|DEVICE|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
58101841|NCT02038959|OTHER|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
58308905|NCT01330082|OTHER|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
58308906|NCT00927407|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
58430658|NCT05859243|BEHAVIORAL|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
58430659|NCT00829959|BEHAVIORAL|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
58430660|NCT02593825|BEHAVIORAL|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
58430661|NCT02593825|BEHAVIORAL|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
58430662|NCT02219074|DEVICE|Sebacia microparticle and laser treatment|
58430663|NCT02219074|DEVICE|Vehicle and laser treatment|
58430664|NCT03860363|DEVICE|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
58430665|NCT01960153|DRUG|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
58430666|NCT01960153|DRUG|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
58430667|NCT01399866|DRUG|D-cycloserine|2 single weekly doses, 50 mg capsule
58430668|NCT01399866|DRUG|Placebo|
58430669|NCT05580068|DEVICE|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
58430670|NCT02051634|DRUG|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
58430671|NCT02051634|DRUG|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
58430672|NCT05036967|DRUG|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
58430673|NCT00604890|DRUG|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
58430674|NCT00604890|DRUG|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
58430675|NCT00604890|OTHER|Placebo|Topical treatment placebo applied to the lesion
58430676|NCT05178485|DRUG|Bupivacain|FDA approved drug
58430677|NCT05178485|OTHER|Normal Saline|FDA approved
58430678|NCT04267081|DRUG|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
58430679|NCT03459638|OTHER|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
58430680|NCT01699568|DEVICE|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
58430681|NCT01227863|DRUG|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
58430682|NCT01227863|DRUG|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
58430683|NCT05552066|OTHER|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
57737226|NCT04753840|BEHAVIORAL|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
57737227|NCT04092218|OTHER|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
57737228|NCT01348451|DEVICE|surgical implantation|human spinal cord stem cell implantation in ALS patients
57737229|NCT02089672|DEVICE|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
57737230|NCT00070590|DRUG|Bosentan|
58308907|NCT00927407|DRUG|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
58308908|NCT05143697|BEHAVIORAL|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
58308909|NCT05003674|DEVICE|Focused stimulation strategy|Investigational focused stimulation strategy
58308910|NCT05003674|DEVICE|ACE stimulation strategy|Standard of care stimulation strategy
58308911|NCT05122481|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
58308912|NCT01470534|DIETARY_SUPPLEMENT|carbohydrate drink|carbohydrate drink
58308913|NCT01470534|PROCEDURE|Muscle biopsy|Open muscle biopsy
58308914|NCT01470534|PROCEDURE|Blood sampling|Venopuncture
58308915|NCT01470534|DIETARY_SUPPLEMENT|Placebo|
58308916|NCT00611052|BEHAVIORAL|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
58308917|NCT00611052|BEHAVIORAL|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
58308918|NCT00611052|OTHER|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
58308919|NCT05297357|DIETARY_SUPPLEMENT|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
58308920|NCT04084496|DRUG|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
58308921|NCT06124508|BEHAVIORAL|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
58308922|NCT06124508|BEHAVIORAL|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
57737231|NCT03577600|PROCEDURE|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
57737232|NCT00105326|DRUG|paliperidone ER|
57737233|NCT00333463|BEHAVIORAL|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
57737234|NCT05153980|DEVICE|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
58308923|NCT06124508|BEHAVIORAL|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
58308924|NCT04611880|DRUG|Crizanlizumab|Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
58308925|NCT03176771|DRUG|MT-5199|MT-5199 40 mg capsules
58308926|NCT03176771|DRUG|Placebo|MT-5199 placebo capsules
58308927|NCT02029417|DRUG|cytarabine|Given SC
58308928|NCT02029417|DRUG|omacetaxine mepesuccinate|Given SC
58308929|NCT02029417|DRUG|decitabine|Given IV
58308930|NCT02029417|OTHER|laboratory biomarker analysis|Correlative studies
58308931|NCT02330341|DIETARY_SUPPLEMENT|Artemisia dracunculus|
58308932|NCT02330341|OTHER|Placebo|
58308933|NCT00523211|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
58308934|NCT00523211|DRUG|Placebo|One tablet of placebo once daily.
58308935|NCT02650375|DRUG|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
58308936|NCT01893606|DRUG|N-acetyl-D-glucosamine|
58308937|NCT01893606|DRUG|placebo|
58308938|NCT03351803|OTHER|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
58308939|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
58101842|NCT04234152|OTHER|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
58101843|NCT04234152|OTHER|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
58430684|NCT05552066|OTHER|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
58430685|NCT03028779|PROCEDURE|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
58430686|NCT04545710|DRUG|Abemaciclib|Abemaciclib 150mg BID
58430687|NCT04545710|DRUG|Osimertinib|Osimertinib 80mg daily
58430688|NCT00723359|DRUG|BT062|biologic
57737235|NCT05153980|OTHER|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
57737236|NCT06665945|DIAGNOSTIC_TEST|Platelet RNA expression|The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.
58101844|NCT04064528|DIETARY_SUPPLEMENT|Amino Acids|10 g bolus of essential amino acids
58101845|NCT01409018|DRUG|Itraconazole|pharmacokinetics
58101846|NCT01077531|DRUG|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
58101847|NCT01077531|DRUG|Matching placebo|Matching placebo for intravenous infusion
58101848|NCT03174509|PROCEDURE|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
58101849|NCT03174509|PROCEDURE|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
58101850|NCT00063596|DRUG|Vitamin A supplementation|
58101851|NCT02464085|OTHER|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
58101852|NCT01523769|PROCEDURE|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
58308940|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
58308941|NCT05158569|OTHER|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
58308942|NCT05158569|OTHER|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
58308943|NCT05017844|DRUG|KSR-001-04|One drop to both eyes four times a day for 12 weeks
58308944|NCT05017844|DRUG|KSR-001-02|One drop to both eyes four times a day for 12 weeks
58308945|NCT05017844|DRUG|KSR-001-03|One drop to both eyes four times a day for 12 weeks
58308946|NCT03928366|DRUG|Propofol|sedation
58308947|NCT03928366|DRUG|Remifentanil|remifentanil
58308948|NCT04236284|DEVICE|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 _ 7 cm saline-soaked surface sponge electrodes.
58308949|NCT04236284|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
58308950|NCT03881683|DIAGNOSTIC_TEST|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
58308951|NCT05647187|DIAGNOSTIC_TEST|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
58308952|NCT05647187|RADIATION|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
58101853|NCT05402319|COMBINATION_PRODUCT|Antibiotic combination therapy|Anti-infective treatment with at least two different types of sensitive antibiotics.
58101854|NCT02006407|RADIATION|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
58101855|NCT02006407|DEVICE|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
58101856|NCT02006407|BEHAVIORAL|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
58101857|NCT03989180|DEVICE|C-Scan System|"* Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~* The recorder will be secured to their lower back to test its functionality"
58101858|NCT05721716|BEHAVIORAL|Mindfulness Booster Course|The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
58430689|NCT06077032|DRUG|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
58430690|NCT06077032|DRUG|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
57737237|NCT06627920|DEVICE|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
58101859|NCT05721716|BEHAVIORAL|Usual care|Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
58101860|NCT05013255|DRUG|Pioglitazone 15mg|PIO 15mg orally once daily for 2 weeks
58101861|NCT05013255|DRUG|Pioglitazone 30 mg|PIO 30mg orally once daily for 2 weeks
58101862|NCT04716673|OTHER|Down-phase targeted auditory stimulation|The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
58101863|NCT00569335|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
58430691|NCT06077032|DRUG|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
58101864|NCT06536933|DIAGNOSTIC_TEST|Abdominal Ultrasound|Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis
58101865|NCT02311543|DRUG|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
58101866|NCT00176501|BIOLOGICAL|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
58101867|NCT03467971|DRUG|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
58101868|NCT05291156|DRUG|Cetuximab|"Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week."
58101869|NCT05291156|DRUG|Avelumab|Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
58101870|NCT00153868|BIOLOGICAL|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
58101871|NCT04123483|DRUG|EnBrace HR Softgel|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
58430692|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
58430693|NCT04277039|OTHER|osteopathic treatment + cognitive training|This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
58430694|NCT04277039|OTHER|osteopathic treatment|manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
57737238|NCT02367261|DEVICE|SPI implant|SPI implant - the original spiral implant
58101872|NCT00827073|DRUG|tetracaine 0.5%|betadine 5%
58101873|NCT00827073|DRUG|Lidocaine 2% Jelly|Betadine 5%
58101874|NCT05673369|DRUG|CKD-387|1 Tablet
58101875|NCT05673369|DRUG|D484|1 Tablet
58101876|NCT03251209|OTHER|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
58430695|NCT04277039|OTHER|usual care|administration of non-steroid inflammatory drug according to international guidelines
58430696|NCT03507738|BIOLOGICAL|MT-5625 low dose|Intramuscular injection
58430697|NCT03507738|BIOLOGICAL|MT-5625 middle dose|Intramuscular injection
58430698|NCT03507738|BIOLOGICAL|MT-5625 high dose|Intramuscular injection
57737239|NCT02277106|DRUG|SAGE-547|
57737240|NCT02277106|DRUG|Placebo|
58308953|NCT06419491|OTHER|Partner notification by a trained counsellor|"One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them.~During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient"
57737241|NCT01345006|BIOLOGICAL|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
57737242|NCT05534581|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
58308954|NCT03456661|DRUG|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
58308955|NCT03456661|DRUG|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
58430699|NCT03507738|BIOLOGICAL|Rotarix|Oral administration
58430700|NCT03507738|BIOLOGICAL|Placebo|Intramuscular injection
58430701|NCT00524017|BIOLOGICAL|cetuximab|given IV
58101877|NCT03251209|OTHER|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
58101878|NCT03251209|OTHER|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
58101879|NCT05567601|DRUG|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
58101880|NCT04943055|PROCEDURE|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
58101881|NCT04943055|PROCEDURE|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
58101882|NCT06568861|DRUG|ALG-097558|Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
58430702|NCT04984382|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
58430703|NCT06514833|BEHAVIORAL|lifestyle recommendations to nap regularly|Participants will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00
58430704|NCT06514833|OTHER|No recommendations to nap regularly|No lifestyle recommendations to nap regularly
58101883|NCT01752322|DRUG|Lidocaine 5% medicated plaster|
58101884|NCT01752322|DRUG|Placebo plaster|
58101885|NCT05341076|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
58101886|NCT05341076|DRUG|Oxytocin|oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
58101887|NCT05341076|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
58101888|NCT00299273|BEHAVIORAL|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
58101889|NCT02046499|DRUG|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
58101890|NCT02046499|DRUG|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
58101891|NCT01733186|BIOLOGICAL|CARTISTEM®|
58430705|NCT06583291|DRUG|Allogeneic dopaminergic neural precursor cell(iDAP)|Bilateral implantation
58430706|NCT00997594|PROCEDURE|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
58430707|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
58430708|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
58101892|NCT00177099|DRUG|FK506, GP11046, GP11511|
58101893|NCT03547596|OTHER|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
58101894|NCT01225315|DRUG|Placebo|Matching placebo administered orally twice daily
58101895|NCT01225315|DRUG|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
58101896|NCT01718301|DRUG|boceprevir|
58101897|NCT01718301|DRUG|Ribavirin|
58101898|NCT01718301|DRUG|Peginterferon alfa-2a|
58430709|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube|
58430710|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes|
58430711|NCT02299284|OTHER|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
58430712|NCT05785936|PROCEDURE|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
58430713|NCT04794127|DRUG|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
58430714|NCT04794127|DRUG|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
58430715|NCT05464368|DRUG|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
58430716|NCT05464368|DRUG|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
58430717|NCT05464368|DRUG|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
58430718|NCT04917913|DIETARY_SUPPLEMENT|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
58430719|NCT04917913|DIETARY_SUPPLEMENT|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
58430720|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
58430721|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
58430722|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
58430723|NCT00500396|PROCEDURE|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
58430724|NCT01019850|DRUG|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
58430725|NCT01019850|RADIATION|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
58430726|NCT01019850|PROCEDURE|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
58101899|NCT01718301|DRUG|Peginterferon alfa-2b|
58430727|NCT01019850|DRUG|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
58430728|NCT02979223|DRUG|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
58430729|NCT04994678|OTHER|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
58430730|NCT04994678|OTHER|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
58430731|NCT06284512|DIAGNOSTIC_TEST|Sonography, color fundus photography|Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
58430732|NCT05563831|OTHER|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
58430733|NCT03802591|DRUG|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
58430734|NCT03802591|DRUG|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
58430735|NCT03802591|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
58430736|NCT03802591|DRUG|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
58430737|NCT01969032|DRUG|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
58430738|NCT00767767|DRUG|Placebos|IV Saline infusion for 2 hours.
57737243|NCT05534581|DEVICE|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
57737244|NCT02771951|BEHAVIORAL|"Lights of Change"|
57737245|NCT02771951|BEHAVIORAL|Usual Care|
58101900|NCT02488707|PROCEDURE|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
58101901|NCT02488707|PROCEDURE|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
58430739|NCT00767767|DRUG|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
58430740|NCT00767767|DRUG|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
58430741|NCT00767767|DRUG|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
58430742|NCT00767767|DRUG|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
58430743|NCT01835730|DRUG|PE0139 Injection|
58430744|NCT01835730|DRUG|Placebo|
58430745|NCT01160432|DRUG|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
58430746|NCT00435851|DRUG|Thyrogen, thyroid hormone withdrawal, iode 131|
58430747|NCT00467233|PROCEDURE|Laser Treatment|Laser treatment to half of the face at each study visit
58430748|NCT00467233|PROCEDURE|Acid Peel|Acid peel to half of the face at each study visit
58430749|NCT05024903|OTHER|Serious illness medical planning plus the novel e-health platform (PWG 2.0)|"PWG 2.0 consists of the following components:~1. A diagnostic questionnaire, Preparedness for the Future Questionnaire and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement.~2. A comprehensive e-workbook that helps users understand the science behind personal behavior change.~3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A).~4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content.~5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general.~6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator."
58430750|NCT05024903|OTHER|Standard of care|Participants are not planning for their future (PWG 2.0) or using the e-health platform
58430751|NCT04167137|DRUG|SYNB1891|SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
58430752|NCT04167137|DRUG|Atezolizumab|Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
58101902|NCT02602561|DIETARY_SUPPLEMENT|HMB|
58101903|NCT02602561|DIETARY_SUPPLEMENT|Placebo|
58101904|NCT00004375|PROCEDURE|ultraviolet A-1 light treatment|
58101905|NCT01210742|DEVICE|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
58101906|NCT01210742|OTHER|Routine management|Routine non-operative management for knee OA (NICE guidelines)
58101907|NCT00387231|PROCEDURE|Percutaneous coronary angioplasty/intervention (PCI)|
58101908|NCT00387231|DRUG|Anti-ischemic drug therapy|
58430753|NCT03087292|OTHER|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
58430754|NCT02696239|DEVICE|V-lock suture|
58430755|NCT02696239|DEVICE|Vicryl Suture|
58101909|NCT02759627|OTHER|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training."
58101910|NCT03433326|DRUG|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
58101911|NCT02172183|DRUG|Psychopharmacological treatment|methylphenidate or atomoxetine
58101912|NCT02172183|BEHAVIORAL|CBT group|
58101913|NCT04405674|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
58101914|NCT04405674|DRUG|Carboplatin|Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
58430756|NCT02696239|DEVICE|Lapra-Ty II|
57953312|NCT00754832|DRUG|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
57953313|NCT00754832|DRUG|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
57953314|NCT04517747|DRUG|Ramucirumab|chemotherapy i.v.
57953315|NCT04517747|DRUG|TAS 102|p.o. twice daily
57953316|NCT01741649|PROCEDURE|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
57953317|NCT01741649|PROCEDURE|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
58101915|NCT04405674|DRUG|Pemetrexed|Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
58430757|NCT01300572|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
58430758|NCT01300572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
57953318|NCT06145295|BEHAVIORAL|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
58101916|NCT04405674|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
58101917|NCT04405674|DRUG|Nab paclitaxel|Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
58101918|NCT02865473|DRUG|Pilocarpine|topical instillation into the study eye
58101919|NCT02952937|DRUG|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
58101920|NCT02952937|DRUG|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
57953319|NCT06145295|BEHAVIORAL|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
57953320|NCT05880446|OTHER|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
58101921|NCT05152407|OTHER|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
58430759|NCT01300572|DRUG|Cyclosporine|Given PO or IV
57953321|NCT03362021|PROCEDURE|transvaginal oocyte retrieval|sedation for oocyte retrieval
57953322|NCT01533376|DRUG|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
58101922|NCT00000891|DRUG|Ritonavir|
58430760|NCT01300572|DRUG|Fludarabine Phosphate|Given IV
58430761|NCT01300572|BIOLOGICAL|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
58430762|NCT01300572|OTHER|Laboratory Biomarker Analysis|Correlative studies
58430763|NCT01300572|DRUG|Mycophenolate Mofetil|Given PO or IV
57953323|NCT01533376|DRUG|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
57953324|NCT00429208|DRUG|Nicotine|
57953325|NCT01745250|DEVICE|Emervel Lips|Lip treatment of both upper and lower lip
57953326|NCT01745250|DEVICE|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
58101923|NCT00000891|DRUG|Saquinavir|
58101924|NCT00000891|DRUG|Delavirdine mesylate|
58101925|NCT00000891|DRUG|Lamivudine|
58101926|NCT00000891|DRUG|Stavudine|
58101927|NCT00000891|DRUG|Zidovudine|
58101928|NCT00000891|DRUG|Didanosine|
58101929|NCT05876208|OTHER|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
58101930|NCT05876208|OTHER|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
58430764|NCT01300572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
58430765|NCT01300572|OTHER|Pharmacological Study|Correlative studies
58430766|NCT01300572|RADIATION|Total-Body Irradiation|Undergo TBI
58430767|NCT01300572|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
58430768|NCT06264856|PROCEDURE|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
58430769|NCT06264856|PROCEDURE|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
58430770|NCT03245983|BEHAVIORAL|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
58430771|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
58430772|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
58430773|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
58430774|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
57737246|NCT02322671|DRUG|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
58430775|NCT01707082|DRUG|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
58430776|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
58430777|NCT01707082|DRUG|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
57737247|NCT02322671|DRUG|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
57737248|NCT02322671|DRUG|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
57737249|NCT04443738|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for recieved treatment will be conducted over the phone for patients.
58101931|NCT03039205|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
58430778|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
58430779|NCT01707082|DRUG|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
58430780|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
58430781|NCT01707082|DRUG|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
58430782|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
58430783|NCT01707082|DRUG|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
57737250|NCT01817413|PROCEDURE|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
58101932|NCT03039205|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
58101933|NCT03797222|DIETARY_SUPPLEMENT|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if \>17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive \<600 IU daily, or for any subjects who prefer liquid medication to capsules.
58101934|NCT06117982|DRUG|Neupogen|Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
58101935|NCT04506125|OTHER|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
58430784|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
58430785|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
58430786|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
58430787|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
58430788|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
58430789|NCT02195141|RADIATION|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
58430790|NCT02195141|RADIATION|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
58430791|NCT00360568|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
58430792|NCT00360568|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
58430793|NCT00360568|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
58430794|NCT00360568|DEVICE|J-tube|jejunal tube
58430795|NCT05945160|DRUG|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
58430796|NCT05945160|DRUG|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
58430797|NCT00002218|DRUG|CI-1012|
58430798|NCT03672526|DEVICE|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
58430799|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
58430800|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
58430801|NCT04186871|DRUG|branebrutinib|Specified dose on specified days
58430802|NCT04186871|DRUG|abatacept|Specified dose on specified days
58430803|NCT04186871|DRUG|branebrutinib placebo|Specified dose on specified days
58430804|NCT04899453|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
58101936|NCT04506125|OTHER|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
57737251|NCT01817413|PROCEDURE|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
57953327|NCT04818593|DEVICE|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
58430805|NCT04899453|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
58101937|NCT00677677|BIOLOGICAL|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
58101938|NCT04283838|BEHAVIORAL|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
58129471|NCT04669236|BEHAVIORAL|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
58430806|NCT04899453|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
58430807|NCT02277912|DEVICE|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
58430808|NCT02277912|DEVICE|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
58430809|NCT02277912|DEVICE|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
58430810|NCT01836926|PROCEDURE|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
57737252|NCT05947877|PROCEDURE|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
57737253|NCT03298139|OTHER|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
57737254|NCT01854827|DRUG|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
57953328|NCT04818593|OTHER|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
57953329|NCT02878954|OTHER|No intervention (Observational study)|"160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed."
58430811|NCT01836926|DEVICE|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
58430812|NCT03294850|PROCEDURE|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
58430813|NCT03294850|DEVICE|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
58430814|NCT05691647|BEHAVIORAL|Chronotherapy|Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, they will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
58430815|NCT05691647|BEHAVIORAL|Treatment as usual|Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
58430816|NCT05385250|OTHER|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
58430817|NCT03246659|DRUG|111In-CP04|Radiopharmaceutical preparation
58430818|NCT03246659|DRUG|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
58430819|NCT00675220|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58430820|NCT00961714|DEVICE|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
58430821|NCT03300921|DRUG|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
58430822|NCT04538079|DEVICE|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
58430823|NCT00051922|BIOLOGICAL|PolyEnv1|Recombinant vaccinia virus vaccine
58430824|NCT03040986|OTHER|Laboratory Biomarker Analysis|Correlative studies
58430825|NCT03040986|DRUG|Selumetinib Sulfate|Given by mouth (PO)
58430826|NCT03759106|OTHER|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
58430827|NCT03759106|OTHER|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
58430828|NCT02714283|DRUG|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
58430829|NCT02714283|DRUG|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
58430830|NCT01471925|DRUG|Nexium®|
58430831|NCT01471925|DRUG|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
58430832|NCT03779087|DRUG|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
58430833|NCT03779087|DRUG|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
58430834|NCT00294255|DRUG|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
58430835|NCT03649724|DRUG|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
58430836|NCT03649724|DRUG|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
58430837|NCT04326088|OTHER|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
58430838|NCT04326088|OTHER|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
58430839|NCT02759081|DEVICE|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
58430840|NCT02759081|PROCEDURE|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
58430841|NCT02860572|OTHER|follow-up without intervention|
58430842|NCT02860572|OTHER|fluid bolus|
58430843|NCT04450095|DRUG|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
58430844|NCT05876338|OTHER|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
58430845|NCT01032499|DRUG|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
58430846|NCT01032499|DRUG|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
58430847|NCT06584305|PROCEDURE|AI-Powered Body Dysmorphic Disorder Screening Procedure|The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
58430848|NCT06005519|OTHER|low AGE diet education|Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
58430849|NCT04348006|DRUG|Bortezomib 3.5 MG|"VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)"
57953330|NCT02878954|OTHER|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
57953331|NCT02878954|OTHER|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
57953332|NCT02742285|DRUG|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
57953333|NCT02788097|PROCEDURE|Progesterone supplementation|artificial frozen embryo transfers
57953334|NCT02409654|OTHER|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
57953335|NCT02409654|OTHER|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
57953336|NCT01808300|DRUG|Pregabalin 300mg, Thioctic acid 600mg|"* A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
57953337|NCT00513500|DRUG|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
57953338|NCT00513500|DRUG|Coartem|Give Coartem without RDT and refer fast breathing
57953339|NCT03609021|PROCEDURE|Screening Mammography|Provide bilateral mammogram
57953340|NCT03609021|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
57953341|NCT01107678|OTHER|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
57953342|NCT00996944|DRUG|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
58101939|NCT06136494|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
58101940|NCT06136494|BEHAVIORAL|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
58101941|NCT02619734|BIOLOGICAL|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
58101942|NCT02643394|DRUG|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
58430850|NCT03123991|BEHAVIORAL|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
58430851|NCT03123991|BEHAVIORAL|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
58101943|NCT02643394|DRUG|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
58430852|NCT04814056|DRUG|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
58430853|NCT04070612|OTHER|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
58430854|NCT04095091|DEVICE|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
58430855|NCT01975597|PROCEDURE|Bone marrow aspirates and biopsy|
58430856|NCT03327558|DRUG|Apriso 0.375G ER CAP|ER capsule
58101944|NCT05292469|BEHAVIORAL|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
58101945|NCT03455335|DRUG|20 million hMSCs|
58430857|NCT03327558|DRUG|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
58101946|NCT03455335|DRUG|40 million hMSCs|
58430858|NCT01432990|DEVICE|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
58101947|NCT03455335|DRUG|80 million hMSCs|
58101948|NCT01092390|DIETARY_SUPPLEMENT|Lovaza (fish oil)|4 grams per day
58430859|NCT01432990|OTHER|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
58101949|NCT02813707|OTHER|QoL questionnaire regarding the long term complication|Micronutrients evaluation
58101950|NCT02010970|DRUG|Group 1 AZD3293|AZD3293 oral solution
58430860|NCT04090463|RADIATION|Intraoperative radiotherapy|"IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ"
58430861|NCT02859441|DRUG|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
58430862|NCT02859441|DRUG|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
58430863|NCT02089126|DRUG|Gemigliptin/Glimepiride combination|
58430864|NCT01179152|DRUG|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
58430865|NCT03878901|COMBINATION_PRODUCT|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
58430866|NCT03878901|COMBINATION_PRODUCT|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
58430867|NCT03878901|COMBINATION_PRODUCT|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
58430868|NCT03878901|OTHER|passive warming|cotton blanket warming through operation
58430869|NCT00992823|DRUG|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
58430870|NCT00992823|BIOLOGICAL|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
58430871|NCT03763136|BIOLOGICAL|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
58430872|NCT02380040|DEVICE|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
58101951|NCT02010970|DRUG|Group 2 AZD3293|AZD3293 oral solution
58101952|NCT02010970|DRUG|Group 3 AZD3293|AZD3293 oral solution
58101953|NCT02010970|DRUG|Group 1 Itraconazole|itraconazole capsule
58101954|NCT02010970|DRUG|Group 2 Diltiazem|Diltiazem ER tablet
58101955|NCT02010970|DRUG|Group 3 Midazolam|midazolam syrup
58101956|NCT04099082|OTHER|samples|blood sample nasal swab
58101957|NCT00567346|DRUG|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
58101958|NCT00567346|DRUG|grass pollen extract|Patients will receive matching placebo sublingually
58101959|NCT04215107|OTHER|Standard breakfast meal|"The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting."
58101960|NCT00906685|DRUG|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
58430873|NCT05655013|DRUG|Zoledronate|zoledronate 5 mg
58430874|NCT05655013|DRUG|Placebo|isotonic saline 100 mL
58430875|NCT01113580|BIOLOGICAL|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
58430876|NCT05825885|DRUG|E2|micronized E2 at a daily dose of 4-6mg,
58430877|NCT03393949|DRUG|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
58430878|NCT03393949|DRUG|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
58430879|NCT04887987|OTHER|Pilates training + active PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
58430880|NCT04887987|OTHER|Pilates training + sham PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
58430881|NCT04887987|OTHER|Multicomponent training + active PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
58101961|NCT00906685|DRUG|Sham bevacizumab injection|Sham intravitreal injection
58430882|NCT04887987|OTHER|Multicomponent training + sham PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
58430883|NCT01596036|BEHAVIORAL|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
58430884|NCT01596036|OTHER|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
58430885|NCT04232111|DEVICE|Heat|Heat applied to hand
58430886|NCT04232111|DEVICE|Vacuum|vacuum applied to hand
57953343|NCT00996944|DRUG|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
57953344|NCT03778619|DRUG|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
58101962|NCT04220034|BIOLOGICAL|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
58430887|NCT04232111|DEVICE|sham|neither heat nor vacuum
58430888|NCT02474953|DIETARY_SUPPLEMENT|Proprietary Curcumin Formulation|
58430889|NCT02474953|DIETARY_SUPPLEMENT|Unformulated Comparator Curcumin Product|
58430890|NCT04292223|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
58430891|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
58430892|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with tumor lysate|
58430893|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with MUC-1/WT-1 peptides|
58430894|NCT06023043|DRUG|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
58430895|NCT05354687|OTHER|Small-group Teaching|The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
58430896|NCT05354687|OTHER|Self-directed Learning|The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
58101963|NCT00563524|DRUG|ILV-094|SC and IV administration on days 1, 14, 28, and 42
58101964|NCT01120522|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
58101965|NCT03137095|OTHER|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.
58101966|NCT03137095|OTHER|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
58101967|NCT05627388|OTHER|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
58101968|NCT04624841|DRUG|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
57953345|NCT03778619|DRUG|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
58430897|NCT04517643|OTHER|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
58430898|NCT02808468|BEHAVIORAL|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
58430899|NCT00665964|DEVICE|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
58430900|NCT00665964|DEVICE|N2Vac polethylene|conventional polyethylene
58430901|NCT03937492|OTHER|GMI protocol|"This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
58430902|NCT03937492|OTHER|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
57953346|NCT03778619|DRUG|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
58101969|NCT00627458|BIOLOGICAL|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
58101970|NCT05640583|DEVICE|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
58101971|NCT03880929|OTHER|no intervention|no intervention
58101972|NCT02876705|OTHER|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
58101973|NCT04162730|OTHER|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
58101974|NCT01766310|DRUG|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
57953347|NCT03778619|BIOLOGICAL|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
57953348|NCT03778619|DRUG|Interleukin-2|1 x 10\^6 IU/m2, together with MG4101
57953349|NCT00183274|DRUG|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
57953350|NCT00183274|DRUG|Placebo|six month intervention with placebo drug
57953351|NCT04229745|DEVICE|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
58101975|NCT01766310|DRUG|placebo|sugar tablet manufactured to mimic folic acid tablet
58101976|NCT00176852|DRUG|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
58101977|NCT00176852|DRUG|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
58101978|NCT00176852|DRUG|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
58101979|NCT00176852|RADIATION|Total Body Irradiation|300 cGY Day -1
58101980|NCT00176852|PROCEDURE|Stem cell infusion|Given Day 0
58430903|NCT04772508|PROCEDURE|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
58430904|NCT04772508|BIOLOGICAL|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
58430905|NCT04772508|DRUG|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
58430906|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
58430907|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
58430908|NCT04378114|DRUG|Acetominophen|One time administration of acetaminophen.
58430909|NCT01707381|DRUG|BOL-303259-X|Topical ophthalmic solution
58430910|NCT01707381|DRUG|Timolol maleate|Topical ophthalmic solution
58430911|NCT04044976|DRUG|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
58430912|NCT03370666|OTHER|HFNT|High flow nasal therapy
58430913|NCT03370666|OTHER|NIV|Noninvasive ventilation
58430914|NCT02409342|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
57953352|NCT02595723|DRUG|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
58430915|NCT02409342|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
58430916|NCT02409342|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
58101981|NCT02023788|BIOLOGICAL|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
58101982|NCT01002131|DEVICE|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
58430917|NCT02409342|DRUG|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
58430918|NCT02409342|DRUG|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
58430919|NCT00554372|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
58430920|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
58430921|NCT05019534|DRUG|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
58430922|NCT05019534|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
58430923|NCT05019534|DRUG|Camrelizumab|Camrelizumab 200mg Q2W
58430924|NCT06200883|DRUG|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
58430925|NCT06200883|DRUG|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
57737255|NCT06347172|BEHAVIORAL|Nudge Intervention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
57737256|NCT02107118|BIOLOGICAL|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
57737257|NCT02107118|OTHER|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
57737258|NCT00127244|PROCEDURE|Periodontal Treatment|
57953353|NCT02595723|DRUG|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
57953354|NCT02595723|DRUG|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
57953355|NCT02595723|DRUG|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
58430926|NCT01918059|PROCEDURE|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
58430927|NCT01918059|PROCEDURE|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
57953356|NCT04631146|DRUG|Camrelizumab|PD-1 inhibitors
57953357|NCT00322283|DRUG|Oglemilast|Oglemilast, 15mg once per day, oral administration
58430928|NCT01918059|PROCEDURE|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
58430929|NCT04217044|DIAGNOSTIC_TEST|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
58430930|NCT04956653|OTHER|Without additional intervention|Only patients' information was collected
57953358|NCT00322283|DRUG|Placebo|Dose-marched placebo, once per day, oral administration
57953359|NCT03792815|DRUG|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
57953360|NCT03792815|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
57953361|NCT03792815|DRUG|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
58101983|NCT00656396|DEVICE|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
58101984|NCT00656396|PROCEDURE|Control Intervention|Standard care
57953362|NCT04743102|PROCEDURE|multi-points and full-thickness Biopsy|Four points around the tumor site and center of the tumor site full-thickness Biopsy
57953363|NCT04743102|DIAGNOSTIC_TEST|traditional cCR|diginal examination, endoscopy test, rectal MRI, and serum CEA level
57953364|NCT04245007|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
58430931|NCT00500825|PROCEDURE|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
58101985|NCT01485705|OTHER|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
58101986|NCT06102837|BIOLOGICAL|tumor vaccine|tumor vaccine produced by our team
58430932|NCT04255303|OTHER|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
58430933|NCT02381275|DRUG|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
58430934|NCT01960517|DEVICE|ACS Catheter|
58430935|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
58430936|NCT00789672|DEVICE|patching|2 hours daily patching
58430937|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
58430938|NCT03760679|DEVICE|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
58430939|NCT03760679|DEVICE|i-gel evaluation|Device: i-gel evaluation
58430940|NCT04219644|DEVICE|Breatheasy device|
58430941|NCT04956458|PROCEDURE|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
58430942|NCT04956458|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
58430943|NCT03526510|RADIATION|Conventionally Fractionated versus Hypofractionated Boost|
57737259|NCT04390737|DRUG|HH2853 Tablets|Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
57737260|NCT05198765|BEHAVIORAL|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
57737261|NCT00001430|PROCEDURE|PBSC|
58430944|NCT03615066|DRUG|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
58430945|NCT03615066|DRUG|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
58430946|NCT03615066|DRUG|TAF|Tablet(s) administered orally once daily with food
58430947|NCT00005116|BEHAVIORAL|psychotherapy|
58430948|NCT05532280|DRUG|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
57737262|NCT00001430|DRUG|IL-2|
58101987|NCT06102837|RADIATION|Radiotherapy|conventional treatment in clincial
58101988|NCT06102837|DRUG|Chemotherapy|conventional treatment in clinical
58101989|NCT06102837|PROCEDURE|Surgery|conventional treatment in clinical
58101990|NCT03250013|DRUG|ADHD medications|
58101991|NCT01353105|PROCEDURE|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
58430949|NCT05532280|DRUG|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
58430950|NCT02848391|OTHER|Environmental|hypobaric flight simulation
58430951|NCT05392036|OTHER|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
57737263|NCT00001430|DRUG|EPOCH II|
57737264|NCT00518115|DRUG|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
57737265|NCT00185185|DRUG|Olmesartan medoxomil|
57737266|NCT00185185|DRUG|Atenolol|
57737267|NCT00185185|DRUG|Hydrochlorothiazide|tablets
57737268|NCT00185185|DRUG|olmesartan medoxomil|tablets
57737269|NCT00185185|DRUG|atenolol|tablets
58101992|NCT06332365|COMBINATION_PRODUCT|Acetonide triamcinolone 0.2% +hyaluronicacid 1%|topical application cream form twice a day for 4 weeks
58101993|NCT06332365|DRUG|Corticoid Acetonide triamcinolone 0.2%|topical application cream form twice a day for 4 weeks
58101994|NCT06332365|DRUG|Hyaluronic acid 1%|topical application cream form twice a day for 4 weeks
58101995|NCT00127192|DRUG|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
58101996|NCT00127192|DRUG|Comparator: placebo (unspecified)|placebo QD 12-weeks
58101997|NCT03242993|DRUG|[18F]-AzaFol|\[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
58101998|NCT03242993|DRUG|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
58101999|NCT02248285|DEVICE|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
58102000|NCT04985942|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
58102001|NCT04985942|DRUG|Placebo|Matching capsules administered orally, once daily.
58102002|NCT02846467|OTHER|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
58102003|NCT02846467|OTHER|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
58102004|NCT01447979|DEVICE|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
58102005|NCT04312399|PROCEDURE|blood take|Blood is taken to analyse degratdation products of the metabolism of amyloid
58102006|NCT02156466|DRUG|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
58102007|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
58102008|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
58102009|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
58102010|NCT02156466|DRUG|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
58102011|NCT04724928|RADIATION|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
58102012|NCT04724928|DRUG|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
58102013|NCT04724928|PROCEDURE|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
58102014|NCT05285631|DEVICE|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
58102015|NCT04071392|PROCEDURE|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
58102016|NCT04394910|DIETARY_SUPPLEMENT|Pomegranate Juice|
58102017|NCT04394910|DIETARY_SUPPLEMENT|Placebo Juice|
58102018|NCT06515444|BEHAVIORAL|10 minutes program|The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
57737270|NCT02697253|DRUG|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
58102019|NCT06515444|BEHAVIORAL|1 hour PD program|The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
58102020|NCT06365151|OTHER|Osteopathic manual therapy|osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.
58102021|NCT06365151|OTHER|Sham osteopathic manual therapy|a sham osteopathic manual treatment without therapeutic effect
58102022|NCT04643054|DIETARY_SUPPLEMENT|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
58102023|NCT02410031|DRUG|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
58102024|NCT00226902|PROCEDURE|Changing hemoglobin concentration|
58430952|NCT05392036|OTHER|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
58430953|NCT03936972|PROCEDURE|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
58430954|NCT03216746|BEHAVIORAL|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
58430955|NCT03216746|BEHAVIORAL|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
58430956|NCT03216746|BEHAVIORAL|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
58430957|NCT03216746|BEHAVIORAL|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
58430958|NCT06089512|PROCEDURE|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
58430959|NCT06089512|PROCEDURE|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
58430960|NCT06089512|PROCEDURE|Control group|Only general anesthesia was applied to the patients.
58430961|NCT00663403|DRUG|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
57737271|NCT02697253|DRUG|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
58430962|NCT03704714|DRUG|Cyclophosphamide|Given IV
58430963|NCT03704714|DRUG|Doxorubicin Hydrochloride|Given IV
58430964|NCT03704714|BIOLOGICAL|Nivolumab|Given IV
58430965|NCT03704714|DRUG|Prednisone|Given PO
58430966|NCT03704714|OTHER|Quality-of-Life Assessment|Ancillary studies
58430967|NCT03704714|BIOLOGICAL|Rituximab|Given IV
58430968|NCT03704714|DRUG|Vincristine Sulfate|Given IV
58430969|NCT00125021|DRUG|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
58430970|NCT00125021|DRUG|OSI-774|Given once daily
58430971|NCT05118334|DRUG|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
58430972|NCT05118334|DRUG|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
58430973|NCT05259839|DRUG|ABBV-383|Intravenous (IV) Infusion
58430974|NCT05259839|DRUG|Dexamethasone|Oral; Tablet or IV Infusion
58430975|NCT05259839|DRUG|Lenalidomide|Oral; Capsule
58430976|NCT05259839|DRUG|Pomalidomide|Oral; Capsule
58430977|NCT05259839|DRUG|Nirogacestat|Oral; Tablet
58430978|NCT05259839|DRUG|Daratumumab|Subcutaneous Injection (SC)
58102025|NCT02789124|OTHER|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
58102026|NCT01032330|DEVICE|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
58102027|NCT00479765|DRUG|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
58102028|NCT02221622|DRUG|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
57953365|NCT01109875|OTHER|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
57953366|NCT05821803|OTHER|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
57953367|NCT05821803|OTHER|Foot Core Exercises|4 weeks including
57953368|NCT04622007|DRUG|Tomivosertib|Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
58102029|NCT02221622|DRUG|Placebo injection (intravenous solution)|Placebo intravenous infusion
58102030|NCT01917188|BEHAVIORAL|Full simulation and education|
58102031|NCT01917188|BEHAVIORAL|See simulation room, usual education|
58430979|NCT03485196|OTHER|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
58430980|NCT02593318|DRUG|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
58430981|NCT02593318|DRUG|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
58430982|NCT02481609|DRUG|N-acetyl cysteine (NAC)|
57737272|NCT06670183|OTHER|Dietary patterns|Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.
57953369|NCT04622007|BIOLOGICAL|Pembrolizumab|Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
57953370|NCT04622007|DRUG|Pemetrexed|Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
57953371|NCT02821715|DRUG|Active comparator: Modafinil + placebo|
57953372|NCT02821715|DRUG|THN102 300/3|
57953373|NCT02821715|DRUG|THN102 300/27|
57953374|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
57953375|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
57953376|NCT00977951|DRUG|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
57953377|NCT00977951|DRUG|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
58102032|NCT04765189|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
58102033|NCT04765189|DIETARY_SUPPLEMENT|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
58102034|NCT04765189|DIETARY_SUPPLEMENT|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
58102035|NCT04765189|DIETARY_SUPPLEMENT|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
58102036|NCT05224479|OTHER|Traditional workflow triage|Workflow triage is based on order location, STAT designation, and first-in-first-out status.
58102037|NCT05224479|OTHER|Machine learning workflow triage|Workflow triage is based on the machine learning model's confidence of abnormality.
58102038|NCT05224479|OTHER|Random workflow triage|Workflow triage is based on random order.
58129472|NCT00795665|DRUG|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
58129473|NCT00795665|DRUG|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
57737273|NCT06670183|OTHER|Food groups and Nutrients|Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.
57737274|NCT06670183|OTHER|Alcohol intake|Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.
58430983|NCT04292613|OTHER|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
58430984|NCT01052077|DRUG|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
58430985|NCT01052077|DRUG|Placebo|Placebo
58430986|NCT01052077|DRUG|ADT|
58430987|NCT05172804|BEHAVIORAL|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
58430988|NCT05172804|BEHAVIORAL|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
58430989|NCT05172804|BEHAVIORAL|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting) \[11\]."
58430990|NCT05172804|OTHER|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
58430991|NCT05308771|DEVICE|VPC syringe|Use of the visual pressure control syringe for epidural space detection
58430992|NCT02448589|DRUG|TAS-119|
58430993|NCT06485466|COMBINATION_PRODUCT|TACE plus camrelizumab and apatinib|"TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
58430994|NCT06485466|COMBINATION_PRODUCT|Camrelizumab and apatinib|"Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
57953378|NCT03655756|BIOLOGICAL|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
57953379|NCT00153686|PROCEDURE|capsule endoscopy|capsule endoscopy of small intestine
57953380|NCT00153686|PROCEDURE|Mesenteric Angiogram|Mesenteric Angiogram
58430995|NCT06429774|OTHER|Neurological function|Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
58430996|NCT06429774|OTHER|Mental State, cognitive function, and life quality assessment|Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).
57953381|NCT02127437|DRUG|Lanreotide|120 mg, subcutaneously, once every 4 weeks
57953382|NCT02127437|DRUG|saline|0,5 ml, subcutaneously, once every 4 weeks
57737275|NCT06670183|OTHER|Vitamin D status|Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
57737276|NCT00245895|DRUG|Aranesp|Aranesp
58129474|NCT05223556|DEVICE|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
58430997|NCT06429774|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
58430998|NCT06429774|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
58430999|NCT04924153|OTHER|No Intervention|Administered as specified in the treatment arm.
58431000|NCT05126628|DRUG|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
58431001|NCT05126628|DRUG|Placebo|Placebo 3 tablets q.d. for 14 days
58431002|NCT00771524|DRUG|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
58431003|NCT03465995|DEVICE|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
58431004|NCT06238206|OTHER|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
58431005|NCT00580762|PROCEDURE|Roux-en-y gastric bypass (RYGB)|
58431006|NCT00880594|DRUG|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
58431007|NCT05009667|DEVICE|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
58102039|NCT04675073|PROCEDURE|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
58102040|NCT01437137|DEVICE|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
58102041|NCT01437137|DEVICE|i-gel™|Insertion of I-gel
58102042|NCT01122043|DEVICE|Endoglide|Device
58102043|NCT05537142|DRUG|BV100|Rifabutin for Infusion
58102044|NCT00295620|DRUG|Anastrozole|1mg tablet daily
58102045|NCT00972153|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
58102046|NCT00972153|DEVICE|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
58102047|NCT04318535|DRUG|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
58102048|NCT04318535|DRUG|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
58102049|NCT04318535|DRUG|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
58102050|NCT01900379|PROCEDURE|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
58102051|NCT01900379|OTHER|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
58102052|NCT06061718|DRUG|iDose TR|anchored intracameral implant containing travoprost
58102053|NCT04347031|DRUG|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
58102054|NCT04347031|DRUG|Hydroxychloroquine|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
58102055|NCT04347031|COMBINATION_PRODUCT|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
58102056|NCT04347031|COMBINATION_PRODUCT|Hydroxychloroquine + azithromycin + / - tocilizumab|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
58102057|NCT05357209|DEVICE|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
58102058|NCT04556838|DRUG|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
58102059|NCT04556838|DRUG|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
58102060|NCT04556838|DRUG|Vehicle|VVN001 Ophthalmic Solution Vehicle
58102061|NCT04818151|DRUG|Warfarin|Warfarin treatment for VTE
58102062|NCT04818151|DRUG|Apixaban|Apixaban treatment for VTE
58102063|NCT06565728|DRUG|Vitamin D3 2000 UNT Oral Tablet|To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
58102064|NCT03084978|PROCEDURE|General Anesthesia|General anesthesia by standard endotracheal intubation.
57737277|NCT05802810|DRUG|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
58102065|NCT03084978|PROCEDURE|Conscious Sedation|Conscious sedation
58129475|NCT05223556|DEVICE|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
58129476|NCT00928083|DRUG|OZ439 50mg API capsules|
58129477|NCT00928083|DRUG|OZ439 200mg API capsules|
58129478|NCT00928083|DRUG|OZ439 400mg aqueous dispersion|
58431008|NCT05009667|DEVICE|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
58431009|NCT02333019|BEHAVIORAL|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
58431010|NCT02333019|BEHAVIORAL|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
58431011|NCT06344156|DRUG|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
58431012|NCT03504631|OTHER|No intervention|no intervention
58431013|NCT00952887|BIOLOGICAL|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
58431014|NCT00952887|BIOLOGICAL|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
58431015|NCT04611451|OTHER|classic lumbar home exercise|classic lumbar home exercise
58129479|NCT00928083|DRUG|OZ439 800mg aqueous dispersion|
58431016|NCT04611451|DEVICE|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
58129480|NCT00928083|DRUG|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
58129481|NCT00928083|DRUG|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
58129482|NCT00928083|DRUG|OZ439 1600mg aqueous dispersion|
58129483|NCT00928083|DRUG|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
58129484|NCT00928083|DRUG|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
58129485|NCT00928083|DRUG|Placebo|
58431017|NCT04611451|OTHER|Whole body vibration exercise|Whole body vibration exercise
58431018|NCT04793334|PROCEDURE|sleeve gastectomy|routine sleeve gastrectomy
58431019|NCT06142006|OTHER|Diabetes Staging System (DSS) use among Primary Care Teams|Evaluate the feasibility of using the DSS in PACT clinics to increase SGLT2i and/or GLP-1 agonist use in Veteran DM2 patients with cardiovascular disease
58431020|NCT00328861|DRUG|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
58431021|NCT00328861|BIOLOGICAL|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
58431022|NCT00328861|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
58431023|NCT00328861|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
58431024|NCT05141084|OTHER|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
58431025|NCT04060966|BEHAVIORAL|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
58431026|NCT04060966|BEHAVIORAL|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.
58102066|NCT03986164|DEVICE|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
58102067|NCT03986164|DEVICE|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
58102068|NCT00649155|DRUG|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
58102069|NCT00649155|DRUG|Cipro® XR Tablets (500 mg|500mg, single dose fasting
58102070|NCT03744065|PROCEDURE|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
58102071|NCT03744065|PROCEDURE|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
58102072|NCT06309290|OTHER|Prehabilitation with resistance-exercise training|The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
58102073|NCT06309290|OTHER|Usual care program|The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
58102074|NCT02711189|DRUG|Oxytocin|Oxytocin nasal spray given in dose 80
58102075|NCT02711189|OTHER|Placebo|
58102076|NCT03117777|BEHAVIORAL|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
58102077|NCT02212561|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
58102078|NCT02212561|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
58431027|NCT04060966|DEVICE|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
58431028|NCT01996124|DRUG|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
58431029|NCT01996124|DRUG|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
58431030|NCT01882504|DRUG|gevokizumab|
58431031|NCT04957056|PROCEDURE|Hospitalization|Hospitalization
58431032|NCT03846609|DEVICE|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
58431033|NCT03846609|DEVICE|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
58431034|NCT02214745|OTHER|Questionnaire|Questionnaire developed for this purpose by the investigators
57737278|NCT05415735|BEHAVIORAL|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
57737279|NCT05606120|DEVICE|CL TRAUMA femoral stem|Hip arthroplasty according to the instruction for use.
58102079|NCT02212561|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
58102080|NCT02212561|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
58102081|NCT05587101|DIAGNOSTIC_TEST|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
58102082|NCT05587101|DIAGNOSTIC_TEST|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
58102083|NCT05587101|DIAGNOSTIC_TEST|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
58102084|NCT01570218|BEHAVIORAL|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
58102085|NCT01638637|DEVICE|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
58102086|NCT05833373|DEVICE|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
58102087|NCT05833373|DEVICE|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
58102088|NCT03740685|DIAGNOSTIC_TEST|High sesitive C reactive protien|High sesitive C reactive protien will be evaluated at admission time and after 36 hours
58102089|NCT02007187|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
58102090|NCT02007187|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
58102091|NCT02007187|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
58129486|NCT00928083|DRUG|OZ439 200mg aqueous dispersion|
58431035|NCT03247127|RADIATION|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
58431036|NCT02816463|DEVICE|Ambu AuraGain|
58431037|NCT02816463|DEVICE|LMA Supreme|
58431038|NCT01364025|PROCEDURE|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
58431039|NCT04479124|DIAGNOSTIC_TEST|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
58431040|NCT06217003|DRUG|Trilaciclib|Preoperative application of trilaciclib during perioperative chemotherapy
58431041|NCT06137651|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57737280|NCT00149253|DRUG|a single-dose of Etoricoxib before induction of anesthesia|
58431042|NCT06137651|PROCEDURE|Computed Tomography|Undergo CT scan
58431043|NCT06137651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58431044|NCT06137651|RADIATION|Radiation Therapy|Undergo radiation therapy
58431045|NCT06137651|PROCEDURE|Resection|Undergo surgery
58431046|NCT06137651|DRUG|Trotabresib|Given PO
58431047|NCT06137651|DRUG|Vinorelbine|Given IV
58102092|NCT03970382|BIOLOGICAL|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
58102093|NCT03970382|BIOLOGICAL|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
58102094|NCT03970382|BIOLOGICAL|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
58102095|NCT01895088|DEVICE|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
58102096|NCT06419673|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
58102097|NCT06419673|DRUG|Cisplatin|IV infusion
58102098|NCT06419673|DRUG|Carboplatin|IV infusion
58102099|NCT06419673|RADIATION|Brachytherapy and External Beam Radiotherapy|Brachytherapy and External Beam Radiotherapy
58102100|NCT05211752|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
58102101|NCT03428048|PROCEDURE|Hybrid procedure|Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
58102102|NCT03428048|PROCEDURE|Endocardial ablations|ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
58102103|NCT03428048|PROCEDURE|left atrial appendage occlusion|A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
58102104|NCT03613077|PROCEDURE|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
58102105|NCT05355831|DEVICE|Active Transcranial Direct Current Stimulation|See arm/group description
58102106|NCT05355831|DEVICE|Sham stimulation|See arm/group description
58102107|NCT03820778|DIAGNOSTIC_TEST|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
58102108|NCT02328001|BEHAVIORAL|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
58102109|NCT05190900|OTHER|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
58102110|NCT01440023|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
58102111|NCT01440023|BEHAVIORAL|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
58102112|NCT01440023|BEHAVIORAL|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
58102113|NCT00297492|BEHAVIORAL|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
58102114|NCT00297492|BEHAVIORAL|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
58129487|NCT03482882|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
58129488|NCT04640103|OTHER|No interventions|No interventions
58102115|NCT00297492|BEHAVIORAL|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
57737281|NCT04981587|PROCEDURE|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
58102116|NCT00297492|DRUG|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
58102117|NCT00297492|DRUG|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
58102118|NCT02458898|BEHAVIORAL|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
58102119|NCT03362242|DRUG|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
58102120|NCT03362242|OTHER|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
58431048|NCT03296150|BEHAVIORAL|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
58431049|NCT05910008|PROCEDURE|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
58431050|NCT05910008|PROCEDURE|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
58431051|NCT00527982|DRUG|Celecoxib|600 mg by mouth daily for a total of 12 months.
58431052|NCT03671915|DEVICE|Continuous Glucose Monitoring|collection of glucose data
58431053|NCT03671915|DEVICE|External Insulin Pump|Insulin delivery
58431054|NCT03671915|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
58431055|NCT03671915|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
58431056|NCT01406015|DRUG|Spironolactone|50 mg once daily for 6 weeks.
58431057|NCT01406015|DRUG|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
57737282|NCT04981587|OTHER|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
57737283|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
57737284|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
57737285|NCT04050826|DRUG|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
57737286|NCT04050826|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
57953383|NCT01208714|DRUG|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%)."
57953384|NCT01208714|PROCEDURE|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
57953385|NCT04540042|DRUG|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
57953386|NCT04540042|DRUG|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
57953387|NCT04540042|DRUG|SelK2 (Part 2)|I.V., single-dose (Day 1)
57953388|NCT04540042|DRUG|Placebo (Part 2)|I.V., single-dose (Day 1)
58102121|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
58102122|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
58102123|NCT03134417|DIETARY_SUPPLEMENT|Placebo|Daily placebo are given to participants daily for 12 weeks.
58102124|NCT05535595|DRUG|genotyping and selection of renin-angiotensin system blocker|"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping"
58102125|NCT05535595|DRUG|Perindopril|perindopril 4 mg/d without genotyping
58102126|NCT04031066|DRUG|Velmanase Alfa|infusion i.v. treatment
58102127|NCT04031066|DRUG|Placebo|infusion i.v. treatment
58102128|NCT06146686|DEVICE|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
58102129|NCT06146686|DEVICE|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
58102130|NCT00570726|DRUG|Ranibizumab (Lucentis)|
58102131|NCT03352219|BEHAVIORAL|Reality Check|
58431058|NCT05995236|DRUG|PSMA radionuclide therapy|Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
58431059|NCT03870412|DRUG|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
58431060|NCT00810784|BEHAVIORAL|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
57953389|NCT02211027|BIOLOGICAL|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
57953390|NCT05458076|DRUG|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
57953391|NCT05458076|DRUG|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
57953392|NCT05458076|DRUG|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
57953393|NCT02115464|DRUG|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
57953394|NCT02115464|RADIATION|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
57953395|NCT01732809|DRUG|AbobotulinumtoxinA (ABO)|Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
57953396|NCT01732809|DRUG|OnabotulinumtoxinA (ONA)|Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
58102132|NCT03352219|BEHAVIORAL|Physical Activity Attention Control|
58102133|NCT00717873|DEVICE|Airway clearance Device|Provided by the Vest Airway clearance system
58102134|NCT00001144|DRUG|Modified bone marrow stem cell transplantation|
58102135|NCT05807347|DRUG|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
58102136|NCT05590325|DRUG|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
58102137|NCT04472065|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
58102138|NCT04472065|OTHER|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
58129489|NCT00726960|DRUG|aprepitant|Oral, 125 mg once daily for one week
58129490|NCT00726960|DRUG|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
58431061|NCT00715858|DRUG|doxycycline|capsule, 100 mg, b.i.d., 12 months
58431062|NCT00715858|DRUG|rifampin|capsule, 300 mg, od, 12 months
58431063|NCT00715858|DRUG|placebo|placebo matched to rifampin; placebo matched to doxycycline
58431064|NCT04421248|DRUG|Methylphenidate|In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
58431065|NCT04421248|DRUG|Placebo|In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
58431066|NCT03521479|DRUG|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
58431067|NCT01737853|DRUG|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
58431068|NCT01737853|DRUG|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
58431069|NCT03440489|DIAGNOSTIC_TEST|Six-minute walking test|physical performance of the muscle measured by these tests
58431070|NCT03440489|DIAGNOSTIC_TEST|30 seconds chair stand test|physical performance of the muscle measured by these tests
58431071|NCT06583603|BEHAVIORAL|Barriers to Implementing Sensory Strategies Survey|Survey, see arm description
58431072|NCT04623840|OTHER|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
58431073|NCT04623840|DRUG|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
58431074|NCT03995355|DEVICE|9618X investigational lipid eye drops|Test Eye Drops
58431075|NCT03995355|DEVICE|Blink® Tears|Control Eye Drops
58129491|NCT02805322|DEVICE|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
58431076|NCT00299117|BEHAVIORAL|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
58431077|NCT03419065|BEHAVIORAL|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
58431078|NCT00122044|DRUG|trihexyphenidyl|
58431079|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
58431080|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
58431081|NCT02459678|BEHAVIORAL|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
58431082|NCT02459678|OTHER|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
58431083|NCT05378061|DRUG|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
58431084|NCT05378061|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
57737287|NCT04050826|PROCEDURE|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
57737288|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
58431085|NCT01289054|DRUG|Tasigna|
58431086|NCT01289054|DRUG|Gleevec|
58431087|NCT03150628|DRUG|Perioperative chemotherapy|Perioperative chemotherapy
58431088|NCT03150628|PROCEDURE|Cytoreduction|Cytoreductive surgery
58431089|NCT03150628|DRUG|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
58431090|NCT05331794|BEHAVIORAL|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
58431091|NCT05331794|BEHAVIORAL|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
58431092|NCT01338857|DRUG|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
58102139|NCT06045429|DRUG|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
58102140|NCT06045429|DRUG|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
58102141|NCT02107963|BIOLOGICAL|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
58102142|NCT02107963|DRUG|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
58308956|NCT06082479|PROCEDURE|intraoral cryotherapy,ice gel|A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
58308957|NCT03281044|DRUG|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
58308958|NCT03281044|DRUG|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
58308959|NCT02969785|OTHER|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
58308960|NCT02969785|OTHER|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
58431093|NCT06584214|DIAGNOSTIC_TEST|Diagnostic test: Determine™ Syphilis Advanced test|The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.
58431094|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
58431095|NCT05108558|DRUG|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
57737289|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
58431096|NCT05108558|DRUG|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
58431097|NCT05108558|DEVICE|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
58102143|NCT02107963|DRUG|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
58102144|NCT00179153|DIETARY_SUPPLEMENT|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
58102145|NCT06500299|DRUG|HDM1002 100 mg QD|HDM1002 tablets 100mg daily, 12weeks
58102146|NCT06500299|DRUG|HDM1002 200 mg QD 12weeks|HDM1002 tablets 200mg daily, 12weeks
58102147|NCT06500299|DRUG|HDM1002 400 mg QD 12weeks|HDM1002 tablets 400mg daily, 12weeks
58102148|NCT06500299|DRUG|Placebo|Matching placebo will be provided
58102149|NCT02872337|BEHAVIORAL|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
58102150|NCT02872337|BEHAVIORAL|Group Preoperative Education Session (per the standard of care)|
58102151|NCT05786053|PROCEDURE|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
58102152|NCT00000737|DRUG|Dronabinol|
58102153|NCT00000737|DRUG|Megestrol acetate|
58102154|NCT03910582|PROCEDURE|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
58102155|NCT03910582|PROCEDURE|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
58102156|NCT01259700|BEHAVIORAL|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
58431098|NCT03897842|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
58431099|NCT01298271|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
58431100|NCT01124591|BEHAVIORAL|Brief motivational intervention|two session delivered two weeks apart
57737290|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
57737291|NCT05556863|DRUG|ELA026|Single dose of ELA026
58102157|NCT01259700|BEHAVIORAL|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
58102158|NCT01143272|DRUG|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
58102159|NCT01143272|DRUG|Placebo|Placebo
58102160|NCT06225778|OTHER|Exercise|6-week online exercise group
57737292|NCT05556863|DRUG|ELA026|Multiple doses of ELA026
58102161|NCT02455583|BEHAVIORAL|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
58102162|NCT01692080|BEHAVIORAL|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
58102163|NCT02076932|BEHAVIORAL|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
58102164|NCT00552526|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet is a very strict high fat diet
58129492|NCT02805322|DEVICE|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
58129493|NCT02805322|DEVICE|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
58129494|NCT00789984|DEVICE|noncontact specular microscopy|
58129495|NCT01739283|OTHER|GIP|
58129496|NCT01739283|OTHER|GLP-1|
58129497|NCT01739283|OTHER|Saline|
58431101|NCT06143982|BEHAVIORAL|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
58431102|NCT00856804|DRUG|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
58431103|NCT03245398|DRUG|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
58431104|NCT06069635|OTHER|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
58102165|NCT00552526|DRUG|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
58102166|NCT02968641|DRUG|Lonafarnib|antiviral farnesyltransferase inhibitor
58431105|NCT06069635|OTHER|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
58431106|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail|
58431107|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
58431108|NCT02209974|DRUG|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
58431109|NCT02209974|DRUG|Inhaled Placebo|
57953397|NCT05266937|COMBINATION_PRODUCT|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
57953398|NCT01489839|OTHER|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
57953399|NCT06378814|PROCEDURE|Selective Caries Removal (No Pulp Exposure)|Caries excavation technique where clinician leaves carious tissue so close to pulp
58102167|NCT02968641|DRUG|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
58102168|NCT00021229|DRUG|imatinib mesylate|"* Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
58308961|NCT02169882|DRUG|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
58308962|NCT02169882|DRUG|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
58431110|NCT06010407|OTHER|Survey|"* Working Alliance Inventory~* Attitude Towards Psychiatry-30 Scale"
57737293|NCT00235976|DRUG|Gantacurium Chloride for Injection (AV430A)|
57737294|NCT05894876|OTHER|No treatment is given|No treatment is provided to the participants as part of this study.
57953400|NCT06378814|PROCEDURE|Non-Selective Caries Removal (No Pulp exposure)|Complete caries removal even in areas so close to pulp
57953401|NCT06378814|PROCEDURE|Partial Pulpotomy (Pulp Exposed)|In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
58102169|NCT00021229|RADIATION|local irradiation therapy|"* Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
58308963|NCT02169882|DRUG|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
58308964|NCT02169882|DRUG|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
58431111|NCT04230213|DRUG|PF-06410293|SC injection
58431112|NCT04230213|DRUG|adalimumab|SC injection
58431113|NCT00525096|DRUG|placebo|2 tablets twice a day per os
58431114|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
58431115|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
58431116|NCT00924339|DIETARY_SUPPLEMENT|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
58431117|NCT00924339|DIETARY_SUPPLEMENT|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
58431118|NCT04891484|DRUG|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
58431119|NCT04891484|DRUG|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
58102170|NCT05294614|BEHAVIORAL|"Sonreír es diveritdo - Smiling is fun"|Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on... what?; a relapse prevention module.
58102171|NCT00773552|DRUG|solifenacin succinate|5mg PO Qday x 90 days
58431120|NCT00742729|BEHAVIORAL|Arm 1|Educational small group session with free FOBT kit
58431121|NCT00742729|BEHAVIORAL|Arm 2|Educational small group session with no FOBT kit
58431122|NCT00742729|BEHAVIORAL|Arm 3|Educational small group session, exercise
57953402|NCT02486198|DRUG|placebo|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
57953403|NCT02486198|DRUG|GM|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
57953404|NCT02486198|DRUG|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
57953405|NCT04075721|DRUG|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
57953406|NCT04075721|DRUG|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
57953407|NCT03999762|DEVICE|sample prep|Effectiveness of a sample preparation protocol
57953408|NCT01319409|PROCEDURE|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
57953409|NCT01319409|PROCEDURE|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
57953410|NCT05690529|PROCEDURE|Ablation|Radiofrequency AF ablatoon
57953411|NCT05555537|DIAGNOSTIC_TEST|MiRNA223 and High mobility group box1(HMGB1)|Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
57953412|NCT04309240|DRUG|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
57953413|NCT00114582|PROCEDURE|family style dinner|
57953414|NCT01387243|DRUG|Orlistat|60 mg
58431123|NCT02277808|DRUG|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
58431124|NCT02277808|DEVICE|Respirgard II|
57737295|NCT03422874|DRUG|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
57737296|NCT03422874|DRUG|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
57953415|NCT05899244|OTHER|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
58102172|NCT00773552|DRUG|placebo|1 tab PO Qday x 90 days
58431125|NCT02277808|DEVICE|Isoneb®|
58431126|NCT00345722|PROCEDURE|strawberry dietary intervention|
58431127|NCT00565136|DEVICE|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
58431128|NCT05694299|DEVICE|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
58431129|NCT05694299|OTHER|Nasal patch|Regular adhesive tape for medical use.
58431130|NCT02800980|PROCEDURE|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
58102173|NCT03008031|PROCEDURE|CESM with a reduced dose of contrast agent|
58102174|NCT00127257|BEHAVIORAL|Biofeedback|
58102175|NCT00127257|DRUG|Diazepam|
58102176|NCT00127257|BEHAVIORAL|Pelvic floor retraining|
58102177|NCT06003491|DEVICE|Intra-articular Cages|Using reduction using posterior intra-articular distraction and fusion technique with cages.
58431131|NCT02800980|PROCEDURE|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
58431132|NCT06397235|DRUG|DEB-TACE+HAIC|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."
58431133|NCT06397235|DRUG|DEB-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
58431134|NCT01453907|DRUG|"ETI-204, Anthim"|intravenously, single dose
58102178|NCT03937973|BEHAVIORAL|Social rejection|Social rejection paradigm
58102179|NCT01862120|DRUG|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
58102180|NCT01862120|DRUG|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
58102181|NCT01862120|DRUG|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
58102182|NCT01862120|DRUG|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
58102183|NCT05012085|OTHER|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
58308965|NCT03444558|DIETARY_SUPPLEMENT|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
58308966|NCT03444558|OTHER|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
58431135|NCT01453907|DRUG|placebo|intravenously, single dose
58431136|NCT05313737|OTHER|Automated message|Automated message via phone call (audiocare)
58431137|NCT05313737|OTHER|Opt-out scheduling|Scheduling via non-automated phone call
58431138|NCT02600091|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
58431139|NCT01521377|DRUG|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
58431140|NCT01521377|DRUG|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
58431141|NCT01521377|DRUG|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
58102184|NCT00738920|BEHAVIORAL|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
58102185|NCT00738920|BEHAVIORAL|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
58129498|NCT02802371|BEHAVIORAL|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
58431142|NCT01521377|DRUG|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
58431143|NCT01521377|DRUG|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
58431144|NCT01521377|DRUG|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
58102186|NCT00738920|BEHAVIORAL|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
58102187|NCT01345890|PROCEDURE|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
58431145|NCT01894022|DRUG|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
58431146|NCT04582955|DRUG|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
58431147|NCT04599036|DEVICE|MARK|EMG controlled arm orthosis
58431148|NCT06583434|BEHAVIORAL|core-lower extremity Pilates Training Group|Participants in this group will engage in a stabilization-based Pilates exercise program focusing on core and lower extremity stabilization. The program consists of twice-weekly sessions, each lasting 50 minutes, over a period of 8 weeks. The primary goal of the intervention is to improve gait patterns and balance in women with flexible pes planus
58431149|NCT06583434|OTHER|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study.
58431150|NCT06583499|BEHAVIORAL|Sustainable nutrition education based on the transtheoretical model|"Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set.."
58431151|NCT00156871|BEHAVIORAL|exercise|
58431152|NCT06474403|PROCEDURE|standard Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
58431153|NCT06474403|PROCEDURE|modified Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
58431154|NCT04788056|PROCEDURE|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
58431155|NCT03858530|DIAGNOSTIC_TEST|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
58431156|NCT02596945|DRUG|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
58431157|NCT06021509|DEVICE|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
58431158|NCT00223249|DRUG|Quetiapine|
58431159|NCT03972878|OTHER|control snack|dry fruit snack (200 kcal) + 250 ml water
58431160|NCT03972878|OTHER|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
58431161|NCT03972878|OTHER|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
57953416|NCT05899244|OTHER|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
58102188|NCT01908998|OTHER|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
58102189|NCT00727298|BIOLOGICAL|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
58102190|NCT03673839|OTHER|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
58431162|NCT03972878|OTHER|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
57737297|NCT01290835|RADIATION|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
58102191|NCT03673839|OTHER|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
58102192|NCT03673839|OTHER|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
58102193|NCT03673839|OTHER|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
58102194|NCT02096029|OTHER|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
58308967|NCT06104397|OTHER|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
58308968|NCT06104397|OTHER|Physical therapy|A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
58308969|NCT02147626|BEHAVIORAL|Web-based educational and motivational modules|
58308970|NCT02147626|BEHAVIORAL|Information and Screening Group|
58308971|NCT04506736|OTHER|ARM|"The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step."
58308972|NCT04506736|OTHER|spontanous ventilation|volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
58308973|NCT02111083|BIOLOGICAL|Insulin Lispro|LY275585 administered SC.
58308974|NCT03795415|BEHAVIORAL|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
58308975|NCT02333253|DRUG|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach \>12 mm
58308976|NCT01719653|DRUG|MiraLAX|MiraLAX consumed as described in each arm.
58308977|NCT01719653|OTHER|Gatorade|Gatorade consumed as described in each arm.
58308978|NCT01719653|DRUG|MoviPrep|MoviPrep consumed as described in each arm.
58308979|NCT01719653|DRUG|SUPREP|SUPREP consumed as described in each arm.
58308980|NCT00076570|DRUG|Sirolimus|
58308981|NCT00076570|DRUG|Tacrolimus|
58308982|NCT00485355|PROCEDURE|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
58308983|NCT00485355|PROCEDURE|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
58308984|NCT04222491|DRUG|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
58308985|NCT03370952|PROCEDURE|laproscopy|laparoscopic ovarian cystectomy
58308986|NCT03370952|PROCEDURE|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
58308987|NCT03945630|PROCEDURE|anterior Quadratus Lumborum Block|Interfascial plane block
58308988|NCT03945630|PROCEDURE|Standard of Care|No QLB
58308989|NCT05516303|GENETIC|Genetic polymorphism|One blood tube will be taken for genetic testing
58308990|NCT05516303|DIAGNOSTIC_TEST|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
58308991|NCT02519725|OTHER|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
58308992|NCT00321763|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
57737298|NCT01290835|RADIATION|stereotactic radiotherapy|
57737299|NCT05411887|DRUG|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
58102195|NCT02096029|BEHAVIORAL|Ask, Advise, Refer (physician brief advice)|
57737300|NCT00144703|DRUG|Sirolimus|
58102196|NCT03358342|OTHER|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
58102197|NCT01461148|BIOLOGICAL|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
58102198|NCT00653887|OTHER|Biofeedback|4 sessions of biofeedback one session each week
58431163|NCT03972878|OTHER|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
58431164|NCT03972878|OTHER|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
58431165|NCT03972878|OTHER|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
58431166|NCT06039358|DIETARY_SUPPLEMENT|Caffeine.|Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
58431167|NCT06039358|DRUG|Cellulose.|Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
58431168|NCT05800275|DRUG|Tucatinib Oral Tablet|300 mg, twice daily
58431169|NCT05800275|DRUG|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
58431170|NCT05800275|DRUG|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
58431171|NCT02861859|DRUG|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
58431172|NCT02861859|DRUG|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
58431173|NCT01893775|BIOLOGICAL|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
58431174|NCT03869879|OTHER|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
58431175|NCT03869879|OTHER|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
58431176|NCT04951700|OTHER|Other|This is not an intervention study
57737301|NCT00144703|DRUG|Tacrolimus|
58102199|NCT00653887|OTHER|Placebo|4 sessions, one each week, of discussion about anorectal disease
58102200|NCT05969028|DEVICE|igel|First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
58308993|NCT00321763|BIOLOGICAL|Fluarix TM|Single dose, Intramuscular injection
58308994|NCT04547400|OTHER|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
58308995|NCT05485311|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
58308996|NCT00599560|GENETIC|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
58308997|NCT00880217|DRUG|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
58308998|NCT00880217|DRUG|Placebo|Placebo capsule once daily for 42 days
57737302|NCT00729833|DRUG|CP-751,871|CP-751,871 IV, every 3 weeks
57737303|NCT00729833|DRUG|Sunitinib|Sunitinib - daily dosing
57737304|NCT05579353|OTHER|nothing|nothing
58308999|NCT00880217|DRUG|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
58309000|NCT00880217|DRUG|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
58309001|NCT00880217|DRUG|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
58309002|NCT00880217|DRUG|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
58309003|NCT04998708|OTHER|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
58309004|NCT00005793|DRUG|Cytarabine|
58309005|NCT00005793|DRUG|Daunorubicin|
58309006|NCT00005793|DRUG|Etoposide|
58309007|NCT00005793|DRUG|Topotecan|
58309008|NCT01782339|DRUG|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
58309009|NCT03561194|DIETARY_SUPPLEMENT|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
58431177|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
58431178|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
58431179|NCT05491434|DIETARY_SUPPLEMENT|Protein supplement|One líquid brick every day during 3 weeks
58431180|NCT00336635|BIOLOGICAL|cell-culture derived smallpox vaccine|
58431181|NCT01199562|PROCEDURE|infection prophylaxis and management|Undergo infection prophylaxis and management
58431182|NCT01199562|OTHER|laboratory biomarker analysis|Correlative studies
58431183|NCT01199562|OTHER|flow cytometry|Correlative studies
58431184|NCT01199562|GENETIC|DNA analysis|Correlative studies
58431185|NCT01199562|GENETIC|RNA analysis|Correlative studies
58431186|NCT01199562|PROCEDURE|management of therapy complications|undergo infection prophylaxis and management
58431187|NCT01199562|DRUG|ganciclovir|Given IV
58431188|NCT01199562|DRUG|valganciclovir|Given orally
58309010|NCT01217996|BEHAVIORAL|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
58309011|NCT01217996|BEHAVIORAL|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
58431189|NCT01199562|DRUG|foscarnet sodium|Given orally
58431190|NCT01199562|PROCEDURE|antiviral therapy|undergo infection prophylaxis and management
58431191|NCT01199562|GENETIC|polymerase chain reaction|Correlative studies
58431192|NCT01199562|GENETIC|protein expression analysis|Correlative studies
58431193|NCT04932642|BEHAVIORAL|HIIT+RT experimental group|Each experimental group will be compared with their another contrast order session group
58431194|NCT04932642|BEHAVIORAL|RT+HIIT experimental group|Each experimental group will be compared with their another contrast order session group
58431195|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
58431196|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
58431197|NCT01506011|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
58431198|NCT03594812|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
58431199|NCT03594812|DEVICE|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
58431200|NCT03594812|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
58431201|NCT06330610|OTHER|Intermittent enteral nutrition|Patients will receive intermittent enteral nutrition, defined as 3 60-minute administrations every 8 hours.
58431202|NCT02698150|DEVICE|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
57737305|NCT00606372|PROCEDURE|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
58431203|NCT04685525|BEHAVIORAL|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
58431204|NCT05105217|OTHER|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
58431205|NCT01984996|DEVICE|Freedom ProFlor Inguinal Hernia Implant|
58431206|NCT02307162|DRUG|RPL554|Phosphodiesterase 3 and 4 Inhibitor
58431207|NCT02307162|DRUG|Placebo|Dummy solution
58431208|NCT03262441|DRUG|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
58431209|NCT02068287|DRUG|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
58431210|NCT00248456|DRUG|Calcipotriol plus betamethasone dipropionate ointment|
58431211|NCT03054324|DIAGNOSTIC_TEST|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
58431212|NCT00923845|DRUG|Pentostatin|Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
58431213|NCT00923845|DRUG|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
58431214|NCT00923845|DRUG|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
58431215|NCT00923845|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
58431216|NCT00923845|PROCEDURE|Th2 rapa cells|Th2 rapa cell Transplantation
58431217|NCT00923845|PROCEDURE|Donor Lymphocyte Harvest|Apheresis
58431218|NCT00923845|PROCEDURE|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
58431219|NCT00923845|PROCEDURE|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
58431220|NCT00923845|PROCEDURE|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
58431221|NCT02291588|DRUG|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
58431222|NCT02291588|DRUG|Placebo|contains no active drug
58431223|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
58431224|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
58431225|NCT03537196|DRUG|Ribavirin|"In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
58431226|NCT03537196|DRUG|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
58431227|NCT03302637|OTHER|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
58431228|NCT00017407|BIOLOGICAL|ISIS 3521|
57737306|NCT01353014|OTHER|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
57737307|NCT01353014|OTHER|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
58431229|NCT00017407|DRUG|carboplatin|
58431230|NCT00017407|DRUG|paclitaxel|
58431231|NCT00306540|DRUG|Quetiapine Fumarate|oral flexible dose
58431232|NCT00306540|DRUG|quetiapine fumarate placebo|oral 0 mg
58431233|NCT04666194|PROCEDURE|Cold forceps|
58431234|NCT04666194|PROCEDURE|Cold snare|
58431235|NCT04666194|PROCEDURE|Hot snare|
58431236|NCT02853435|DRUG|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
57737308|NCT04477252|DEVICE|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
57737309|NCT04477252|OTHER|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
57737310|NCT02515136|BEHAVIORAL|Stimulus-response|See summary
58102201|NCT05969028|PROCEDURE|Compression Rate|Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
58431237|NCT02853435|DRUG|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
58431238|NCT02853435|DRUG|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
58102202|NCT04622488|DRUG|Diclofenac Potassium|- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
58431239|NCT02424682|OTHER|No intervention|No intervention administered in this study
58431240|NCT04137250|PROCEDURE|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
58431241|NCT04137250|PROCEDURE|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
58431242|NCT05077293|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
57737311|NCT02438618|PROCEDURE|Surgery for Ponto bone anchored hearing aids|
57737312|NCT03541759|DRUG|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.
57953417|NCT05899244|OTHER|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
58431243|NCT05077293|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
58431244|NCT02374567|DRUG|Phenobarbital|
58431245|NCT02374567|DRUG|Phenytoin|
57737313|NCT03541759|DRUG|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
58102203|NCT00343122|PROCEDURE|echocardiography for intrapulmonary vasodilatation|
58102204|NCT05005650|PROCEDURE|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
58102205|NCT04895319|DEVICE|Computer-assisted surgery|The reconstruction was performed with the help of virtual surgical plan and 3D printed models.
58431246|NCT02374567|DRUG|Carbamazepine|
58431247|NCT02374567|DRUG|Oxcarbazepine|
58431248|NCT02374567|DRUG|Valproic Acid|
58431249|NCT02374567|DRUG|Lamotrigine|
58431250|NCT02374567|DRUG|Topiramate|
58431251|NCT02374567|DRUG|Gabapentin|
58431252|NCT02374567|DRUG|Levetiracetam|
58431253|NCT02374567|DRUG|Pregabalin|
58431254|NCT02374567|DRUG|Lacosamide|
58431255|NCT02374567|DRUG|Clonazepam|
58431256|NCT02374567|DRUG|Biperiden|
58431257|NCT02374567|DRUG|Levomepromazine|
58431258|NCT02374567|DRUG|Fluphenazine|
58431259|NCT02374567|DRUG|Perphenazine|
58431260|NCT02374567|DRUG|Perazine|
58431261|NCT02374567|DRUG|Thioridazine|
58431262|NCT02374567|DRUG|Haloperidol|
58431263|NCT02374567|DRUG|Melperone|
58431264|NCT02374567|DRUG|Pipamperone|
58431265|NCT02374567|DRUG|Bromperidol|
58431266|NCT02374567|DRUG|Benperidol|
58431267|NCT02374567|DRUG|Sertindole|
58431268|NCT02374567|DRUG|Ziprasidone|
58431269|NCT02374567|DRUG|Flupentixol|
58431270|NCT02374567|DRUG|Chlorprothixene|
58431271|NCT02374567|DRUG|Zuclopenthixol|
58431272|NCT02374567|DRUG|Fluspirilene|
57737314|NCT01672775|DRUG|AGS-16C3F|intravenous (IV) infusion
58431273|NCT02374567|DRUG|Pimozide|
58431274|NCT02374567|DRUG|Clozapine|
58431275|NCT02374567|DRUG|Olanzapine|
58431276|NCT02374567|DRUG|Quetiapine|
58431277|NCT02374567|DRUG|Sulpiride|
58431278|NCT02374567|DRUG|Tiapride|
58431279|NCT02374567|DRUG|Amisulpride|
58431280|NCT02374567|DRUG|Prothipendyl|
58431281|NCT02374567|DRUG|Risperidone|
58431282|NCT02374567|DRUG|Aripiprazole|
58431283|NCT02374567|DRUG|Paliperidone|
58431284|NCT02374567|DRUG|Diazepam|
58431285|NCT02374567|DRUG|Oxazepam|
58431286|NCT02374567|DRUG|Lorazepam|
58431287|NCT02374567|DRUG|Bromazepam|
58431288|NCT02374567|DRUG|Clobazam|
58431289|NCT02374567|DRUG|Alprazolam|
58431290|NCT02374567|DRUG|Hydroxyzine|
58431291|NCT02374567|DRUG|Buspirone|
58431292|NCT02374567|DRUG|Chloral Hydrate|
58431293|NCT02374567|DRUG|Flurazepam|
58431294|NCT02374567|DRUG|Nitrazepam|
58431295|NCT02374567|DRUG|Triazolam|
58431296|NCT02374567|DRUG|Lormetazepam|
58431297|NCT02374567|DRUG|Temazepam|
58431298|NCT02374567|DRUG|Midazolam|
58431299|NCT02374567|DRUG|Brotizolam|
58431300|NCT02374567|DRUG|Zopiclone|
58431301|NCT02374567|DRUG|Zolpidem|
58431302|NCT02374567|DRUG|Zaleplon|
58431303|NCT02374567|DRUG|Melatonin|
58431304|NCT02374567|DRUG|Clomethiazole|
58431305|NCT02374567|DRUG|Diphenhydramine|
58431306|NCT02374567|DRUG|Promethazine|
58431307|NCT02374567|DRUG|Imipramine|
58431308|NCT02374567|DRUG|Clomipramine|
58431309|NCT02374567|DRUG|Opipramol|
58431310|NCT02374567|DRUG|Trimipramine|
58431311|NCT02374567|DRUG|Amitriptyline|
58431312|NCT02374567|DRUG|Nortriptyline|
58431313|NCT02374567|DRUG|Doxepin|
58431314|NCT02374567|DRUG|Maprotiline|
58431315|NCT02374567|DRUG|Amitriptyline oxide|
58431316|NCT02374567|DRUG|Fluoxetine|
58431317|NCT02374567|DRUG|Citalopram|
58431318|NCT02374567|DRUG|Paroxetine|
58431319|NCT02374567|DRUG|Sertraline|
58431320|NCT02374567|DRUG|Fluvoxamine|
58431321|NCT02374567|DRUG|Escitalopram|
58431322|NCT02374567|DRUG|Tranylcypromine|
58431323|NCT02374567|DRUG|Moclobemide|
58431324|NCT02374567|DRUG|Mianserin|
58431325|NCT02374567|DRUG|Trazodone|
58431326|NCT02374567|DRUG|Mirtazapine|
58431327|NCT02374567|DRUG|Bupropion|
58431328|NCT02374567|DRUG|Venlafaxine|
58431329|NCT02374567|DRUG|Reboxetine|
58431330|NCT02374567|DRUG|Duloxetine|
58431331|NCT02374567|DRUG|Agomelatine|
58431332|NCT02374567|DRUG|Pyritinol|
58431333|NCT02374567|DRUG|Piracetam|
58431334|NCT02374567|DRUG|Donepezil|
58431335|NCT02374567|DRUG|Rivastigmine|
58431336|NCT02374567|DRUG|Galantamine|
58431337|NCT02374567|DRUG|Memantine|
58431338|NCT02374567|DRUG|Nicergoline|
58431339|NCT02374567|DRUG|Acamprosate|
58431340|NCT02374567|DRUG|Lithium|
58431341|NCT00147316|DRUG|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
58431342|NCT01925248|DIETARY_SUPPLEMENT|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
58431343|NCT01925248|DIETARY_SUPPLEMENT|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
58431344|NCT02809378|DRUG|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
58431345|NCT02809378|DRUG|sevoflurane|Inhalational anesthetics Halogenated.
58431346|NCT02809378|DRUG|remifentanil|ultra-short acting opioid anesthetics
58431347|NCT02809378|DRUG|pentothal sodium|intra-venous anesthetics for anesthesia induction
58431348|NCT02809378|DRUG|propofol|intra-venous anesthetics for anesthesia induction and maintenance
58431349|NCT06386679|BIOLOGICAL|allogenic amniotic fluid mesenchymal stem cell|Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
58431350|NCT02943421|PROCEDURE|Transverse B-Lynch suture|
58431351|NCT01300260|BIOLOGICAL|LY2189265|Administered subcutaneously
58431352|NCT01300260|DRUG|Placebo|Administered subcutaneously
58431353|NCT01300260|DRUG|Insulin|Administered intravenously
57737315|NCT03878810|BEHAVIORAL|Exergaming|A video game-based physical activity training applied using a commercial game console.
57737316|NCT03106818|DRUG|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
57737317|NCT03106818|DRUG|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
57737318|NCT03106818|DRUG|conventional|only conventional post operative analgesics will be used
57953418|NCT01066364|DRUG|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
58102206|NCT04793438|BEHAVIORAL|Motive-specific intervention|Three appointments are made with the patients of the intervention group within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. The time frame of 45 minutes for each intervention must be strictly adhered to. Patients are additionally asked to complete tasks between the sessions. All appointments take place in the Psychiatric University Hospital directly on the ward.
58431354|NCT01300260|DRUG|Glucose|Administered intravenously
58431355|NCT01300260|DRUG|Glucagon|Administered intravenously
58431356|NCT04872790|DRUG|Dasatinib|Given PO
58431357|NCT04872790|DRUG|Methotrexate|Given IT
58431358|NCT04872790|DRUG|Prednisone|Given PO
58431359|NCT04872790|BIOLOGICAL|Rituximab|Given IV
58431360|NCT04872790|DRUG|Venetoclax|Given PO
58431361|NCT04872790|BIOLOGICAL|Blinatumomab|Given IV
58431362|NCT04872790|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
58431363|NCT04872790|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
58431364|NCT04872790|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58431365|NCT04713501|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
58431366|NCT02923076|OTHER|CCR5 delta32/delta32 cord blood transplantation|
58431367|NCT00446173|DRUG|Busulfan|130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
58431368|NCT00446173|DRUG|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
57737319|NCT05991154|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
57737320|NCT03705091|DIAGNOSTIC_TEST|Magnetic resonance imaging|ASL and DWI MRI
57737321|NCT01867151|DIETARY_SUPPLEMENT|Gluten Free Diet|
57737322|NCT01867151|DIETARY_SUPPLEMENT|Normal Diet|
57737323|NCT00778674|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
57737324|NCT02390284|DRUG|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
57737325|NCT02390284|DRUG|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
58431369|NCT00446173|DRUG|G-CSF|10 mcg/kg Subcutaneously Once Daily
58431370|NCT00446173|DRUG|GM-CSF|250 mcg/kg Subcutaneously Once Daily
58431371|NCT01483911|BIOLOGICAL|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
58431372|NCT01483911|BIOLOGICAL|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
58431373|NCT03597594|DRUG|Anti-thymocyte globulin (rabbit)|given intravenously
58431374|NCT03597594|DRUG|Busulfan|given intravenously
58431375|NCT03597594|DRUG|Fludarabine|given intravenously
58431376|NCT03597594|DRUG|Thiotepa|given intravenous infusion
58431377|NCT03597594|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
58431378|NCT03597594|OTHER|Donor Lymphocyte Infusion|given intravenous infusion
58431379|NCT03203291|DEVICE|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
58431380|NCT04202133|BEHAVIORAL|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
58431381|NCT04202133|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
58431382|NCT05084898|OTHER|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
58431383|NCT05084898|OTHER|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
58431384|NCT03441230|DEVICE|Balloon characteristics|Different size balloon
58431385|NCT02832336|DRUG|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
58431386|NCT02832336|DRUG|Fiber|Fiber will be used as placebo.
58431387|NCT05018104|OTHER|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
58431388|NCT02568592|DIETARY_SUPPLEMENT|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
58431389|NCT02568592|DIETARY_SUPPLEMENT|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
58431390|NCT02568592|DIETARY_SUPPLEMENT|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
58431391|NCT04462965|COMBINATION_PRODUCT|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
58431392|NCT04462965|COMBINATION_PRODUCT|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
58431393|NCT05533970|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
58431394|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
58431395|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
58431396|NCT00971295|DRUG|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
58431397|NCT00971295|DRUG|Eslicarbazepine acetate|
58431398|NCT02629003|DRUG|[11C]Cimbi-36|
58431399|NCT02629003|DRUG|[11C]Cimbi-36-5|
58431400|NCT03092635|DRUG|OPC|OPC is a derivative of grape seed extract
58431401|NCT05167591|DIAGNOSTIC_TEST|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
58431402|NCT00005120|DRUG|Calanolide A|
58431403|NCT04558359|OTHER|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
58102207|NCT04793438|BEHAVIORAL|Supportive conversations|Since we want to check whether the patients benefit from the specific intervention and not only from getting more speaking time, patients without the motive-specific intervention should also be given three sessions, in which no intervention takes place. They will be carried out in the sense of supportive conversations (i.e. conversations that do not follow a specific psychotherapy concept). All appointments take place in the Psychiatric University Hospital directly on the ward.
58431404|NCT04558359|DRUG|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
58431405|NCT02973308|OTHER|Observer|Observer A and observer B
58431406|NCT00267852|OTHER|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
58431407|NCT03582995|PROCEDURE|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
58431408|NCT03582995|PROCEDURE|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
58431409|NCT05788497|DRUG|Hemorrane plus|Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
58431410|NCT05788497|DRUG|Hemorrane|Hemorrane 10 mg/g rectal ointment
58431411|NCT05788497|DRUG|Placebo|Rectal ointment
58431412|NCT03046030|OTHER|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
58431413|NCT03046030|OTHER|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
58431414|NCT03046030|OTHER|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
58102208|NCT01418352|DRUG|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
58102209|NCT01418352|DRUG|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
58102210|NCT05826769|DIETARY_SUPPLEMENT|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
57737326|NCT02390284|DRUG|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
57737327|NCT02390284|DRUG|Timolol|Lower intraocular pressure by decreasing production of fluid
58431415|NCT03046030|OTHER|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
58431416|NCT03432559|DIAGNOSTIC_TEST|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
58431417|NCT01354366|OTHER|Infant formula|
58431418|NCT04255641|OTHER|time lapse analysis|grading of the embryos before freezing using time lapse/
58431419|NCT04674488|BIOLOGICAL|TILs|a single center, single-arm, open label, interventional study
58431420|NCT00099866|DRUG|vildagliptin|
58431421|NCT00099866|DRUG|Metformin Comparator|
58431422|NCT03079219|DRUG|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
58431423|NCT03079219|DRUG|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
58431424|NCT03079219|DRUG|Experimental drug: Dexamethasone|Day 1: 12mg QD
58431425|NCT03079219|DRUG|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
58431426|NCT03079219|DRUG|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
58431427|NCT03079219|DRUG|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
58431428|NCT03079219|DRUG|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
58431429|NCT03854383|DRUG|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
58431430|NCT03854383|DRUG|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
58431431|NCT03940118|DEVICE|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
58431432|NCT03940118|COMBINATION_PRODUCT|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
58102211|NCT06568185|DRUG|Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA|BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
58102212|NCT00136734|DRUG|Methylphenidate|
58431433|NCT03940118|DEVICE|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
58431434|NCT03940118|COMBINATION_PRODUCT|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
58431435|NCT06172725|OTHER|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
58431436|NCT01717326|DRUG|Grazoprevir|100 mg tablet orally QD
58431437|NCT01717326|DRUG|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
58431438|NCT01717326|DRUG|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
57737328|NCT02390284|DRUG|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
58431439|NCT01717326|DRUG|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
58431440|NCT00950742|DRUG|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
58431441|NCT00950742|DRUG|BIBW 2992|Increased dose cohorts from low dose to MTD
58431442|NCT01255995|DEVICE|Capsular Tension Ring|Capsular Tension Ring
58431443|NCT02604914|DRUG|ND0612|Subcutaneous solution
58431444|NCT02604914|DRUG|LCIG|Intrajejunal Gel
58431445|NCT05850338|DEVICE|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
58102213|NCT00136734|OTHER|placebo|placebo
58102214|NCT05244174|DEVICE|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
58102215|NCT05645224|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
58431446|NCT05850338|BEHAVIORAL|autogenic training|Autogenic relaxation for three times a day for eight weeks
58431447|NCT06320314|OTHER|tested product (2039125 03)|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
57737329|NCT02390284|DRUG|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
57737330|NCT02390284|DRUG|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
58431448|NCT00810992|BEHAVIORAL|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
58431449|NCT00810992|BEHAVIORAL|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
57737331|NCT02390284|DRUG|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
58431450|NCT04132674|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
58431451|NCT02353728|DRUG|Nilotinib|
58431452|NCT04985669|DRUG|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
58431453|NCT01943240|DRUG|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
58431454|NCT01943240|DRUG|10 cc of 0.375% ropivacaine pectoral nerve block|
58431455|NCT04844528|DRUG|Nicotinamide|oral nicotinamide 500 mg twice daily (BID)
58431456|NCT04844528|DRUG|Placebo|oral placebo twice daily for first year. Cross over to oral nicotinamide 500 mg twice daily (BID) for year two.
58102216|NCT02488902|DRUG|Placebo|Placebo
58431457|NCT00324376|DRUG|Sevelamer hydrochloride|
58431458|NCT05699564|OTHER|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
58431459|NCT03615339|DIETARY_SUPPLEMENT|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
58431460|NCT06583694|BEHAVIORAL|Health promotion campaigns to correct the health problems|
58431461|NCT06372496|DRUG|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate|Participants will receive FF/UMEC/VI
58431462|NCT06372496|DRUG|Inhaled corticosteroids/long-acting beta-2 agonists|Participants will receive ICS/LABA
58431463|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
58431464|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
58431465|NCT06050785|DRUG|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
57737332|NCT01970826|PROCEDURE|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
57737333|NCT01970826|PROCEDURE|Sterilized Aseptic|Operatory room will be prepared totally aseptic
57737334|NCT01970826|PROCEDURE|Sterilized Clean|Operatory room will be prepared clean but not aseptic
57737335|NCT01970826|PROCEDURE|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
57737336|NCT01970826|PROCEDURE|Partial Rehabilitation|two or more implants to support partial rehabilitation
57737337|NCT01970826|PROCEDURE|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
57737338|NCT04224155|DEVICE|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
57737339|NCT04224155|DEVICE|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
57737340|NCT00522275|DRUG|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
57737341|NCT04862793|DEVICE|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
57737342|NCT04862793|DEVICE|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
58102217|NCT02488902|DRUG|Tafenoquine 25mg|Tafenoquine 25mg
58102218|NCT02488902|DRUG|Tafenoquine 50mg|Tafenoquine 50mg
58102219|NCT02488902|DRUG|Tafenoquine 100 mg|Tafenoquine 100 mg
58102220|NCT02488902|DRUG|Tafenoquine 200 mg|Tafenoquine 200 mg
58102221|NCT02488902|DRUG|Mefloquine 250 mg|Mefloquine 250 mg
58102222|NCT04264663|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
58102223|NCT04264663|DRUG|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
58431466|NCT05346653|DRUG|SGLT2i|dapagliflozin (10 mg daily)
58431467|NCT05346653|OTHER|No SGLT2i|No SGLT2i
58431468|NCT01440205|BEHAVIORAL|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
58431469|NCT01440205|BEHAVIORAL|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
58431470|NCT01440205|BEHAVIORAL|Control|No check box element
58431471|NCT01953913|DRUG|Afatinib|Patient will receive afatinib once daily
58431472|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
58102224|NCT04671160|DIAGNOSTIC_TEST|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
58102225|NCT02245360|DRUG|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
58102226|NCT02245360|DRUG|placebo|placebo tablet given once daily over 60 days
58431473|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
58431474|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
58431475|NCT06197620|OTHER|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
58431476|NCT04001283|DRUG|Sodium Nitrite|Intravenous drug infusion
58102227|NCT02995694|DRUG|Estradiol|Estradiol Vaginal Cream
58102228|NCT02995694|DRUG|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
58102229|NCT02995694|DRUG|Reference|Estrace Vaginal Cream
58102230|NCT06352398|PROCEDURE|erector spina plan block|erector spina plan block
58102231|NCT06352398|PROCEDURE|Serratus posterior superior intercostal plan block (SPSIPB)|Serratus posterior superior intercostal plan block (SPSIPB)
58102232|NCT06352398|DRUG|0.25% bupivacaine|Before the operation, 0.25% bupivacaine 30 ml was administered to both groups.
58102233|NCT01858129|DRUG|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
58102234|NCT01858129|DRUG|placebo|
58102235|NCT02983227|DRUG|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
58102236|NCT00488046|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
58102237|NCT04658446|DEVICE|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
58431477|NCT04001283|DRUG|0.9% Sodium-chloride|Matched placebo
58431478|NCT03010280|DIETARY_SUPPLEMENT|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
58431479|NCT03010280|DIETARY_SUPPLEMENT|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
58431480|NCT01088022|DRUG|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
58431481|NCT01088022|DRUG|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
58431482|NCT05155774|DEVICE|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
58431483|NCT00733681|DEVICE|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
58431484|NCT00128115|DRUG|MK0677|
58431485|NCT01500668|DRUG|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
58431486|NCT01500668|DRUG|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
58431487|NCT03727906|OTHER|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
58431488|NCT03727906|OTHER|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
58431489|NCT03727906|OTHER|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
58431490|NCT05082311|OTHER|Observational study|This is an observational study
58431491|NCT05160129|DEVICE|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
58431492|NCT05096312|DIETARY_SUPPLEMENT|Zinc gluconate|oral zinc gluconate 200mg
58431493|NCT05096312|DRUG|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
58431494|NCT05096312|OTHER|Placebo|contains cornstarch
58431495|NCT03797456|DRUG|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
58431496|NCT00234169|DRUG|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
58431497|NCT05151757|OTHER|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
58431498|NCT02294734|DRUG|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
58431499|NCT02294734|DRUG|Placebo|Dry powder for inhalation via DISKUS 'device'
57737343|NCT05785780|BEHAVIORAL|Targeted CRC Screening Toolkit|Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
58102238|NCT04658446|DEVICE|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
58102239|NCT06128031|OTHER|questionaire|"Psychiatric interview: this will be assessed by (SCID-5)semi structural clinical interview based on Diagnostic and Statistical manual of Mental disorders-5 criteria~-Psychometric assessment include; Hamilton depression rating scale(7) and Hamilton anxiety rating scale(8) , used to score the symptoms of anxiety or depression Quality of life assessment: will be assessed by the Patient assessment of constipation-quality of life questionnaire"
58102240|NCT00831922|DRUG|masitinib (AB1010)|3 mg/kg/day
58431500|NCT01618149|RADIATION|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
58431501|NCT00201942|PROCEDURE|PET scan|
58431502|NCT02406404|BEHAVIORAL|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
58431503|NCT06508840|OTHER|Verbal Health Literacy training session|"Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff."
58431504|NCT00039663|DRUG|Pravastatin|
58431505|NCT00039663|DRUG|Gemfibrozil|
58431506|NCT00039663|DRUG|Rosiglitazone|
58431507|NCT00545896|PROCEDURE|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
58102241|NCT00831922|DRUG|masitinib (AB1010)|6 mg/kg/day
58431508|NCT06242015|OTHER|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
58431509|NCT06242015|OTHER|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
58102242|NCT04898400|PROCEDURE|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
58309012|NCT02904746|BEHAVIORAL|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
58431510|NCT05885802|OTHER|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
58431511|NCT04465292|DRUG|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
58431512|NCT00488696|DEVICE|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
58431513|NCT02220712|DRUG|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
58431514|NCT00128986|PROCEDURE|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
58431515|NCT06502808|OTHER|Hyperbaric oxygen therapy|Series of 30 HBOT sessions of 60 minutes at 2 ATA in the hyperbaric chamber for five consecutive days per week.
58431516|NCT06312319|DEVICE|Respiratory training|Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.
58431517|NCT06312319|OTHER|Orofacial exercises|The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
58431518|NCT05651815|DEVICE|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
58431519|NCT01940536|DRUG|Tranexamic Acid|antifibrinolytic
58431520|NCT01940536|DRUG|Placebo|Placebo
58431521|NCT04405076|BIOLOGICAL|Biological: mRNA-1273|Sterile liquid for injection
58102243|NCT02073305|OTHER|No Sleep Apnea|No intervention
58102244|NCT02073305|OTHER|Sleep Apnea - untreated|No intervention
58102245|NCT02073305|DEVICE|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
58102246|NCT00646100|PROCEDURE|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
58102247|NCT01989195|DRUG|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
58102248|NCT04185701|OTHER|SiVIEW software|Eye examination by a technician with the SiVIEW software
58309013|NCT00339417|DRUG|Albendazole|
58309014|NCT00339417|DRUG|Ivermectin|
58309015|NCT05808985|DRUG|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
58309016|NCT06367543|DIAGNOSTIC_TEST|Time in therapeutic range of vital parameters|"Treatment adherence on NICU to the following vital parameters:~1. Temperature (T\<37,5°C) (every 4 hours during the first 96 h after admission to neurocritical care unit)~2. systolic blood pressure ICD-10 (International Statistical Classification of Diseases 10th Revision) (I60, 161 \& 162): 100-140 mmHg ICD-10 (I63): 120-180 mmHg (every 4 hours during the first 96 h after admission to neurocritical care unit)~3. Mean arterial blood pressure (MAP: 60-90 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~4. Arterial oxygen partial pressure (paO2: 75 - 100 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~5. Arterial carbon dioxide partial pressure (paCO2: 35 - 45 mmHg). (every 4 hours during the first 96 h after admission to neurocritical care unit)~6. Blood glucose (BG: 80-180 mg/dL). (every 4 hours during the first 96 h after admission to neurocritical care unit)"
58431522|NCT04405076|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58431523|NCT04405076|BIOLOGICAL|mRNA-1273.351|Sterile liquid for injection
58431524|NCT05330091|DIETARY_SUPPLEMENT|Once Daily Women's Probiotic|Active product
58431525|NCT05330091|OTHER|Placebo|Placebo product
58431526|NCT05998174|OTHER|Faecal Microbiota Transplantation|treatment with capsules
58431527|NCT01297725|PROCEDURE|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
58431528|NCT01297725|PROCEDURE|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
58431529|NCT00986362|DRUG|Ocriplasmin|175µg ocriplasmin intravitreal injection
58431530|NCT00986362|DRUG|Placebo|Placebo intravitreal injection
58431531|NCT02371031|DRUG|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
58431532|NCT02371031|DEVICE|PET/MRI|
58431533|NCT02371031|PROCEDURE|Surgical resection (standard of care)|
58431534|NCT04735146|OTHER|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
58431535|NCT02922179|DRUG|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
58431536|NCT00180011|DRUG|Omalizumab|injectable medication
58431537|NCT03383380|DRUG|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
58431538|NCT01900808|DEVICE|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
58431539|NCT01900808|DEVICE|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
58431540|NCT01900808|DEVICE|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
58431541|NCT02335593|DIETARY_SUPPLEMENT|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
58431542|NCT02335593|OTHER|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
58431543|NCT02335593|DRUG|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
58431544|NCT02335593|DRUG|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
58431545|NCT03410121|DEVICE|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
58431546|NCT03410121|DEVICE|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
58431547|NCT01844778|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
58431548|NCT01844778|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
58431549|NCT01844778|DRUG|Colistimethate|Colistimethate was administered via nebuliser.
58431550|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
58431551|NCT03265782|DRUG|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
58102249|NCT04185701|OTHER|Expert|Eye examination by an expert including optimal correction in distance and near vision
58102250|NCT02561013|DEVICE|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
58431552|NCT03265782|DRUG|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
58431553|NCT03478735|PROCEDURE|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
58431554|NCT03478735|PROCEDURE|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
58431555|NCT01996085|DRUG|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"
58431556|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
58431557|NCT01996085|DRUG|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"
58431558|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
58431559|NCT01996085|DRUG|Amlodipine|1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
58431560|NCT01996085|DRUG|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
58431561|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
58431562|NCT01996085|DRUG|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
58431563|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
58431564|NCT01996085|DRUG|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
58431565|NCT03025243|DEVICE|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
58431566|NCT03160885|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
58431567|NCT03160885|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
58431568|NCT01575925|DRUG|4 mg Oral POM + 40 mg Oral DEX|
58431569|NCT01575925|DRUG|2 mg Oral POM + 40 mg Oral DEX|
58431570|NCT01881568|DRUG|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
58431571|NCT01881568|DRUG|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
58431572|NCT03853070|DEVICE|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
58431573|NCT00761826|DEVICE|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
58431574|NCT00002458|BIOLOGICAL|monoclonal antibody 3F8|
58431575|NCT04496011|OTHER|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
58102251|NCT02561013|DEVICE|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
58102252|NCT06542757|RADIATION|1.5 T Elekta Unity MR-Linac system|Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.
58309017|NCT03236454|DEVICE|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
58309018|NCT06007976|DEVICE|Erchonia® Trident|Low-level laser therapy
58431576|NCT03295773|DIAGNOSTIC_TEST|3DRA|
58431577|NCT04194073|DEVICE|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
58431578|NCT03508609|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34 cells
58431579|NCT03918525|OTHER|Sindhi families|It is an observational study and no intervention is involved
58431580|NCT03433352|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
58431581|NCT03433352|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
58431582|NCT02731443|PROCEDURE|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
58431583|NCT02731443|PROCEDURE|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
58431584|NCT00346229|BIOLOGICAL|filgrastim|
58431585|NCT00346229|BIOLOGICAL|pegfilgrastim|
58431586|NCT00346229|DRUG|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
58431587|NCT00346229|PROCEDURE|hyperthermia treatment|
58431588|NCT02777827|DRUG|Abediterol 0.156 μg|Dry powder for inhalation
58431589|NCT02777827|DRUG|Abediterol 2.5 μg|Dry powder for inhalation
58431590|NCT02777827|DRUG|Abediterol 0.05 μg|Pressurised metered-dose inhaler
58431591|NCT02777827|DRUG|Abediterol 0.156 μg|Pressurised metered-dose inhaler
58309019|NCT04376281|DRUG|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
58309020|NCT00971113|DIETARY_SUPPLEMENT|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
58309021|NCT05285839|DRUG|Dupixent|dupilumab 300mg
58309022|NCT00000732|DRUG|Sulfamethoxazole-Trimethoprim|
58309023|NCT00000732|DRUG|Zidovudine|
58309024|NCT01905696|DRUG|Oral N-acetylcysteine|
58309025|NCT03415516|DEVICE|Gluma Universal|Adhesive systems
58309026|NCT03415516|DEVICE|All Bond Universal|Adhesive systems
58309027|NCT03415516|DRUG|Single Bond2|Adhesive systems
58309028|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2"
58309029|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
58309030|NCT04710732|DRUG|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
58309031|NCT04710732|DEVICE|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
58431592|NCT02777827|DRUG|Abediterol 2.5 μg|Pressurised metered-dose inhaler
58431593|NCT02777827|OTHER|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
58431594|NCT03796351|DRUG|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
58431595|NCT03796351|DRUG|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
58102253|NCT06542757|DEVICE|Hydrogel rectal spacer (SpaceOAR)|A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.
58102254|NCT05027009|PROCEDURE|Physical Examination|Undergo total body exam
58431596|NCT01277484|DRUG|Decitabine|"1. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
58431597|NCT02505113|DRUG|Montelukast|Montelukast (10mg, q.d., p.o.)
58431598|NCT00642447|DRUG|helium:oxygen mixture|
58431599|NCT02676934|DEVICE|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
58431600|NCT03001687|DIETARY_SUPPLEMENT|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
58431601|NCT03001687|OTHER|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
58431602|NCT02359227|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
58431603|NCT05211817|BEHAVIORAL|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
58431604|NCT05211817|DIETARY_SUPPLEMENT|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
58102255|NCT05027009|OTHER|Solar Simulated Light|Undergo exposures to simulated sunlight
58309032|NCT04710732|DIAGNOSTIC_TEST|Thrombodynamic test (TD)|"Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
58309033|NCT01218308|BIOLOGICAL|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
58309034|NCT01218308|BIOLOGICAL|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
58431605|NCT04260945|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
58431606|NCT00847197|DRUG|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
58431607|NCT00847197|DRUG|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
58431608|NCT05448391|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
58431609|NCT02990676|BEHAVIORAL|Computerised cognitive training|Computerised cognitive training regime
58431610|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
58431611|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
58431612|NCT04286815|DEVICE|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
58431613|NCT02687087|DEVICE|Visco-ease|19.6 mg/mL of LMS-611
58431614|NCT02687087|DEVICE|Placebo|Physiological Saline
58431615|NCT06583993|DRUG|HNF4α srRNA|HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
58431616|NCT06017869|BIOLOGICAL|MNV-201|Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.
58309035|NCT00381212|BIOLOGICAL|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
58309036|NCT03288038|DRUG|Rosuvastatin|
58309037|NCT03288038|DRUG|Ezetimibe|
58309038|NCT04538508|DEVICE|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
58309039|NCT04538508|OTHER|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
58309040|NCT03273062|DRUG|Tolcapone 200 MG|Tolcapone 200 MG TID
58102256|NCT06520228|BEHAVIORAL|Active video games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
58309041|NCT03273062|OTHER|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
58309042|NCT00388921|DRUG|Vitamin A|
58309043|NCT02701634|DRUG|ENTO|Tablets administered orally
58309044|NCT02701634|DRUG|Placebo|Tablets administered orally
58309045|NCT03543163|PROCEDURE|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
58309046|NCT03543163|PROCEDURE|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
58309047|NCT06359899|DRUG|AK0901 capsule|Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
58309048|NCT06359899|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
58431617|NCT05175742|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
58431618|NCT05175742|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
58431619|NCT05175742|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58431620|NCT05409898|DEVICE|smart wearable device|screening masked hypertension with smart wearable devices
58431621|NCT03327194|DEVICE|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
58431622|NCT02464514|OTHER|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
58431623|NCT02464514|OTHER|High fat meal|58% fat, 17% protein, and 25% carbohydrate
58431624|NCT03993522|OTHER|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
58309049|NCT04377295|DRUG|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
58309050|NCT04228224|DEVICE|Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)|The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
58309051|NCT04228224|BEHAVIORAL|Conventional gait rehabilitation|Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
58309052|NCT02415972|OTHER|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
58309053|NCT04341090|DRUG|Apatinib Mesylate|Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
58309054|NCT00320047|DRUG|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
58309055|NCT01491516|DEVICE|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
58309056|NCT03348449|OTHER|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
58309057|NCT02399332|OTHER|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
58309058|NCT00706316|BIOLOGICAL|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
58309059|NCT06281509|PROCEDURE|Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.|Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)
58309060|NCT06281509|PROCEDURE|Ultrasound|A small mobile ultrasound device will be used to further asses the presence of the tendon.
58309061|NCT04120935|OTHER|Observation|Prospective Observation of standard clinical practice.
58309062|NCT03306199|DEVICE|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
58309063|NCT01559441|DIETARY_SUPPLEMENT|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
58309064|NCT01559441|DIETARY_SUPPLEMENT|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
58309065|NCT00748241|DEVICE|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
58309066|NCT01033136|BEHAVIORAL|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
58309067|NCT01033136|BEHAVIORAL|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
58431625|NCT03238833|OTHER|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
58102257|NCT06520228|BEHAVIORAL|Traditional sports games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
58102258|NCT01089985|DRUG|Autologous serum eyedrops|3 times a day for the duration of the study
58309068|NCT05955482|OTHER|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
58431626|NCT03238833|OTHER|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
58431627|NCT06440551|BEHAVIORAL|TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)|Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
57737344|NCT02362698|OTHER|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
57737345|NCT02362698|OTHER|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
57737346|NCT00833638|DRUG|Placebo|One tablet orally daily
58102259|NCT03497988|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
58309069|NCT00835718|DRUG|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
58309070|NCT00835718|DRUG|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
58309071|NCT00835718|DRUG|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
58309072|NCT00835718|DRUG|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
58309073|NCT06258252|OTHER|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
58309074|NCT02844478|BEHAVIORAL|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
58309075|NCT02844478|BEHAVIORAL|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
57737347|NCT00833638|DRUG|Tadalafil|Orally once daily
57737348|NCT05079620|DRUG|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
58102260|NCT03497988|DRUG|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
58102261|NCT04748809|OTHER|Diet 1|Dietary intervention
58102262|NCT04748809|OTHER|Diet 2|Dietary intervention
58102263|NCT01825876|DRUG|Evacetrapib|Oral administration
58102264|NCT01825876|DRUG|Warfarin|Oral administration
58102265|NCT02846740|DEVICE|Alpha-Stim®.|cranial electrical stimulation
58431628|NCT06440551|BEHAVIORAL|TeleSalud General Health Intervention|Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
58431629|NCT02314832|PROCEDURE|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
58431630|NCT02314832|PROCEDURE|femoral nerve block|ultrasound guided femoral nerve block
58431631|NCT01669083|DRUG|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
58431632|NCT01669083|DRUG|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
58431633|NCT01669083|DRUG|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
58431634|NCT01669083|DRUG|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
58431635|NCT02428205|DRUG|Propranolol|Participant will receive Propranolol prior to each EIBI session
58431636|NCT02428205|DRUG|Placebo|Participant will receive placebo prior to each EIBI session
58431637|NCT01184417|DRUG|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
58431638|NCT01184417|DRUG|placebo|100 m l saline
58431639|NCT04166617|OTHER|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
57737349|NCT05079620|DRUG|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
57737350|NCT05079620|DRUG|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
58309076|NCT05151185|OTHER|Case Management Service Program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
58309077|NCT04764045|DRUG|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
58309078|NCT05504057|DRUG|Antihistamine|Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with
58309079|NCT05504057|DRUG|Amantadine|Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine
58309080|NCT02891512|OTHER|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
58309081|NCT02891512|OTHER|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
58309082|NCT02891512|OTHER|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
58431640|NCT04166617|OTHER|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
58431641|NCT06258408|DRUG|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
58431642|NCT00004275|DRUG|growth hormone|
58431643|NCT00004275|DRUG|oxandrolone|
58431644|NCT05526898|DEVICE|SyntrFuge System|Microsized Adipose Tissue
58431645|NCT05526898|DRUG|Triamcinolone Injection|Corticosteroid
58431646|NCT00064792|DRUG|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
58431647|NCT00064792|DRUG|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
58431648|NCT01505816|DEVICE|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
58431649|NCT06303219|OTHER|RADITIONAL MODERATE INTENSITY TRAINING|"It consists of patients who will receive High-intensity interval training, including running as well as walking at 80% to 95% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes"
57737351|NCT05079620|DRUG|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
57737352|NCT05079620|DRUG|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
57737353|NCT00233558|DRUG|adalimumab (up to 9 months exposure)|
57737354|NCT00233558|DRUG|methotrexate|
58431650|NCT06303219|OTHER|HIGH INTENSITY INTERVAL TRAINING|"It consists of patients who will receive Moderate-intensity interval training, including running as well as walking at 60% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes ("
58431651|NCT05556694|DIAGNOSTIC_TEST|calculation of cumulative fluid balance|- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
58431652|NCT05684029|DEVICE|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
58431653|NCT05684029|DIAGNOSTIC_TEST|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
57737355|NCT04878562|BEHAVIORAL|I-COPE|The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
57737356|NCT04829370|OTHER|PLT|The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled will be applied 2 mL PLT solution on the right face. Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
57737357|NCT04829370|OTHER|Saline|"The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled left face be applied 2 mL normal saline.~Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed."
57737358|NCT05909631|OTHER|Beetroot juice|250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
57737359|NCT05909631|OTHER|placebo|250 ml of a placebo
57737360|NCT05909631|OTHER|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
57737361|NCT05909631|COMBINATION_PRODUCT|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD).
57737362|NCT04797338|DRUG|Synarel, 0.2 Mg/Inh Nasal Spray|Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
57737363|NCT04797338|DRUG|Estrofem|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
58102266|NCT02846740|BEHAVIORAL|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
58102267|NCT06528860|DEVICE|MiSight® 1 day soft contact lenses|Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.
58102268|NCT06528860|DEVICE|Proclear® 1 day soft contact lenses|Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
58102269|NCT01963676|DEVICE|tDCS|
58102270|NCT01963676|DEVICE|Sham stimulation|
58431654|NCT04454242|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
58431655|NCT01860950|DEVICE|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
57737364|NCT04797338|DRUG|Utrogestan|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
57737365|NCT04797338|DRUG|Hydroxyprogesterone Caproate|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
57737366|NCT05256173|OTHER|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
57737367|NCT05256173|OTHER|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
57737368|NCT05256173|DEVICE|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
58102271|NCT00624975|BIOLOGICAL|Peru-15 Vaccine|up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
58102272|NCT00624975|BIOLOGICAL|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
58309083|NCT05681988|PROCEDURE|Early minimally invasive image guided endoscopic hematoma evacuation|The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
58309084|NCT05681988|PROCEDURE|Best medical treatment (BMT)|The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
58309085|NCT02936999|DRUG|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
58309086|NCT02410759|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
58309087|NCT02410759|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
58309088|NCT02347618|RADIATION|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
58309089|NCT04576000|DRUG|Janus Kinase Inhibitor|Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
58309090|NCT01776957|DEVICE|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
58309091|NCT00505921|DRUG|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
58309092|NCT00505921|DRUG|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
58309093|NCT00505921|DRUG|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
58309094|NCT00505921|DRUG|BCNU|300 mg/m2 IV over 1 hour on day -6
58102273|NCT06527573|DEVICE|active repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
58102274|NCT06527573|DEVICE|sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
57737369|NCT05256173|DEVICE|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
57737370|NCT05222919|DIETARY_SUPPLEMENT|Bare performance supplement|dietary supplement
58431656|NCT01860950|DEVICE|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
58102275|NCT06209424|BEHAVIORAL|Habitual Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).
58102276|NCT06209424|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
58102277|NCT06209424|BEHAVIORAL|Resistance Exercise|Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups
58102278|NCT02239692|DRUG|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
58102279|NCT02277639|DEVICE|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
58102280|NCT06540274|PROCEDURE|lumbar surgery|Discectomy, lumbar fusion or laminectomy
58102281|NCT03186963|PROCEDURE|No immobilization|Conventional wrist dressing
58102282|NCT03186963|PROCEDURE|Volar splint|Volar plaster splint
58431657|NCT01860950|DEVICE|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
58431658|NCT00705146|DEVICE|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
58431659|NCT00705146|DEVICE|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
58431660|NCT00085891|DRUG|Quetiapine Fumarate|
58102283|NCT06567041|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
58431661|NCT04783077|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
57737371|NCT05222919|DIETARY_SUPPLEMENT|Placebo|Placebo
57737372|NCT03362905|DRUG|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
57737373|NCT00487162|PROCEDURE|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
57737374|NCT00487162|DRUG|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
57737375|NCT01031810|DRUG|tranylcypromine|MAO-Inhibitor 60mg-120mg
57737376|NCT03581305|DRUG|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
57737377|NCT03581305|DRUG|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
58102284|NCT06567041|DRUG|Placebo|Placebo will be administered subcutaneously.
58102285|NCT05396443|BEHAVIORAL|Black Girls for Wellness Telehealth|Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
58102286|NCT01467570|DIETARY_SUPPLEMENT|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
58102287|NCT01467570|DIETARY_SUPPLEMENT|ESPGHAN ORS|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
58431662|NCT04783077|BEHAVIORAL|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
58431663|NCT04783077|BEHAVIORAL|Docudrama|Participants will be exposed to a document-drama related to blood donation.
58102288|NCT03208283|DIAGNOSTIC_TEST|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
58102289|NCT03208283|DIAGNOSTIC_TEST|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
58102290|NCT01846832|DRUG|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
58102291|NCT01846832|DRUG|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
58102292|NCT01846832|DRUG|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is \< 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is \> or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
58102293|NCT01576627|DIETARY_SUPPLEMENT|zinc citrate|10 mg of zinc as either zinc citrate
58102294|NCT01576627|DIETARY_SUPPLEMENT|Zinc Gluconate|10 mg of zinc as either zinc gluconate
58102295|NCT01576627|DIETARY_SUPPLEMENT|Zinc oxide|10 mg of zinc as either zinc oxide
58102296|NCT04150926|OTHER|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
58431664|NCT03116256|DIETARY_SUPPLEMENT|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
57737378|NCT03796455|DIETARY_SUPPLEMENT|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
58102297|NCT04150926|OTHER|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
58102298|NCT04150926|OTHER|Quinoa base|The effect of black currant puree will be compared with quinoa base
58102299|NCT01247974|DEVICE|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
58309095|NCT00505921|DRUG|Stem Cell Transplant|Stem cell infusion on Day 0.
58431665|NCT03116256|OTHER|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
58431666|NCT03116256|OTHER|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
58431667|NCT05029739|DEVICE|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
58102300|NCT05099783|DIAGNOSTIC_TEST|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
58102301|NCT05803538|DEVICE|SMS, telephone interview or diary card|SMS, telephone interview or diary card
58102302|NCT03715673|DIAGNOSTIC_TEST|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
58102303|NCT04280393|DEVICE|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
58102304|NCT06155669|DEVICE|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
58102305|NCT06334250|DEVICE|Catheter ablation of atrial fibrillation using Pulsed Field Ablation|Pulsed Field Ablation of atrial fibrillation at the time of left atrial appendage occlusion
58102306|NCT06334250|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion using the Watchman device
58102307|NCT06476873|BEHAVIORAL|Online self-questionnaire.|"Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French.~An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available.~The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press."
58102308|NCT03138239|RADIATION|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
58431668|NCT06195410|OTHER|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
58431669|NCT02741427|OTHER|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
58431670|NCT02741427|OTHER|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
58431671|NCT02741427|OTHER|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
58431672|NCT00391625|DRUG|GA-GCB|15-60 U/kg every other week via intravenous infusion
58102309|NCT00899288|PROCEDURE|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
58102310|NCT02956005|DRUG|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
58102311|NCT04622865|DRUG|Masitinib|Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.
58431673|NCT02479139|BIOLOGICAL|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
58431674|NCT02479139|BIOLOGICAL|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
58102312|NCT04622865|DRUG|Isoquercetin|Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.
58102313|NCT04622865|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
58431675|NCT02193308|DRUG|Telmisartan/Amlodipine FDC|
58431676|NCT02193308|DRUG|Telmisartan|
58431677|NCT02193308|DRUG|Amlodipine|
58431678|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
58431679|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
58431680|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
58431681|NCT01745042|OTHER|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
58431682|NCT03492801|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58431683|NCT03492801|OTHER|Laboratory Biomarker Analysis|Correlative studies
58431684|NCT05621174|DRUG|Dexamfetamine|Magisterial Dexamfetamine
58102314|NCT00670267|DRUG|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
58102315|NCT02446665|DEVICE|MR Elastography (MRE) and FibroScan|
58102316|NCT05492019|DRUG|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
58102317|NCT05492019|DRUG|Placebo|Oral placebo identical to Doxycycline
58102318|NCT05265169|DEVICE|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
58102319|NCT01399125|DRUG|Rivastigmine Patch|Once-daily target patch size 10 cm²
58102320|NCT01399125|DRUG|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
58431685|NCT05621174|DRUG|Dexamfetamine|Tentin
58431686|NCT05506527|OTHER|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~- Children of the study group B will receive sensorimotor program alone."
58431687|NCT00753363|OTHER|Weight Loss|6 months of weight loss
58431688|NCT00753363|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training
58431689|NCT06429800|DRUG|ATA3219|ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
58431690|NCT05284344|DRUG|Anti-Diabetics|The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
58431691|NCT06501612|OTHER|Continuous Glucose Monitor and Undermyfork App|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
58431692|NCT06501612|OTHER|Continuous Glucose Monitor|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
58431693|NCT00293020|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
58431694|NCT00562991|DEVICE|measurement of exhaled NO is used to guide treatment|exhaled NO
58102321|NCT01399125|DRUG|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
58102322|NCT01399125|DRUG|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
58102323|NCT02331069|DRUG|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
58102324|NCT02331069|OTHER|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
58102325|NCT02056405|DRUG|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
58102326|NCT02056405|DRUG|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
58102327|NCT06539806|DRUG|Losartan 50mg Tab|The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
58102328|NCT06371261|OTHER|Biological analyses|"A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion.~The micro-organisms will be quantified.~The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021)."
58102329|NCT05801640|OTHER|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
58431695|NCT02992509|DEVICE|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
58431696|NCT04534322|DRUG|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
58431697|NCT04534322|DRUG|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
58431698|NCT05672550|DRUG|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
58431699|NCT05672550|DRUG|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
58431700|NCT04391803|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
58309096|NCT00505921|DRUG|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
58431701|NCT04584242|DRUG|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
57737379|NCT03796455|OTHER|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
57737380|NCT05301751|DRUG|AG-73305|AG-73305 Ophthalmic Solution
57737381|NCT01260350|DRUG|SOF|Sofosbuvir (SOF) tablets administered orally once daily
57737382|NCT01260350|DRUG|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
57737383|NCT01260350|DRUG|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
57737384|NCT01260350|DRUG|LDV|Ledipasvir (LDV) tablets administered orally once daily
58102330|NCT05801640|OTHER|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
58102331|NCT02349009|DRUG|C-82 Topical Gel, 1%|active
58309097|NCT00505921|DRUG|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
58431702|NCT04584242|DRUG|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
58431703|NCT05825560|DRUG|OFA multimodal analgesia|Multimodal opioid free analgesia
58431704|NCT05825560|DRUG|Standard multimodal analgesia|Standard remifentanil analgesia
58431705|NCT02337881|DRUG|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
58431706|NCT02337881|DRUG|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
58431707|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
58309098|NCT00505921|DRUG|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
58309099|NCT00505921|DRUG|Melphalan|140 mg/m2 IV on day -1.
58431708|NCT02513472|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
58431709|NCT02513472|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
58309100|NCT00505921|DRUG|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
58431710|NCT01356199|DIETARY_SUPPLEMENT|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
57737385|NCT01260350|DRUG|GS-9669|GS-9669 tablets administered orally once daily
57737386|NCT01260350|DRUG|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
57737387|NCT05969093|DIAGNOSTIC_TEST|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
57737388|NCT06580132|DIETARY_SUPPLEMENT|Pectin|Pectin fibre (20g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
57737389|NCT06580132|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with pectin.
58309101|NCT00505921|DRUG|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
58309102|NCT00505921|DRUG|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
58102332|NCT02349009|DRUG|C-82 Topical Gel, Placebo|placebo
58102333|NCT00971685|DRUG|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
58102334|NCT05697146|OTHER|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
58102335|NCT00109135|DRUG|taranabant|
58309103|NCT00505921|RADIATION|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
58309104|NCT03500978|BEHAVIORAL|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
58102336|NCT03171610|DRUG|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
58102337|NCT03171610|DRUG|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
58102338|NCT01425931|PROCEDURE|Heart Lung machine|measurement of microcirculation with O2C device
58102339|NCT03888716|DRUG|KL1333|25 and 100 mg KL1333 encapsulated tablets
58102340|NCT03888716|DRUG|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
58102341|NCT02580201|BIOLOGICAL|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
58102342|NCT00981864|RADIATION|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
58309105|NCT05313308|DRUG|Midazolam|Midazolam oromucosal solution
58309106|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
58309107|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
58431711|NCT01356199|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO. 6 per day for 8 months.
58431712|NCT02747368|DEVICE|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
58431713|NCT02834247|DRUG|TAK-659|TAK-659 Tablets.
58431714|NCT02834247|DRUG|Nivolumab|Nivolumab intravenous infusion.
58431715|NCT04125277|OTHER|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
58431716|NCT05293626|DRUG|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
58431717|NCT05293626|DEVICE|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
58431718|NCT01796821|DRUG|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
57737390|NCT05403541|DRUG|Batoclimab 680 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
57737391|NCT05403541|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
57737392|NCT05403541|DRUG|Matching Placebo SC|Placebo
57737393|NCT05403541|DRUG|Batoclimab 340 mg SC bi-weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
57737394|NCT01089972|DEVICE|22 gauge catheter|radial artery cannulation using 22 gauge catheter
57737395|NCT01089972|DEVICE|20 gauge catheter|radial artery cannulation using 20 gauge catheter
57737396|NCT02068573|DEVICE|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
57737397|NCT02068573|DEVICE|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
57737398|NCT03813654|BEHAVIORAL|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
57737399|NCT03813654|BEHAVIORAL|8-h Free Sleep|8 consecutive hours time in bed at any time.
57737400|NCT02558010|DRUG|Methadone|Perioperative IV methadone to be given
57737401|NCT02558010|OTHER|Normal Saline|control arm
58102343|NCT03001011|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
58102344|NCT03001011|DRUG|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
58102345|NCT04821570|BIOLOGICAL|COVID-19 Vaccine|Per recommended dosing schedule
58309108|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
58431719|NCT01796821|DRUG|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
58431720|NCT01796821|DRUG|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
58431721|NCT03515642|BEHAVIORAL|HIIT group|Physical Training
58102346|NCT02861352|OTHER|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
58431722|NCT00951652|BEHAVIORAL|CBT|
58431723|NCT00951652|OTHER|Interpersonal and emotional processing therapy|
58431724|NCT00951652|BEHAVIORAL|supportive listening|
58431725|NCT00876434|DRUG|Sirolimus|
58431726|NCT04079114|DEVICE|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
58431727|NCT05455502|DRUG|VX-548|Tablet for oral administration.
57737402|NCT02558010|DRUG|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
57737403|NCT00248729|DRUG|Etomidate (20mg) or Midazolam (7mg)|
57961909|NCT05037110|OTHER|Smell training|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
57961910|NCT00918151|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study
57961911|NCT00785330|DRUG|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
57961912|NCT00785330|DRUG|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
57961913|NCT05298137|PROCEDURE|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
57961914|NCT02059200|BEHAVIORAL|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
57961915|NCT01355705|DRUG|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
57961916|NCT01355705|DRUG|Lenalidomide|15 mg daily by mouth
57961917|NCT01355705|DRUG|Dexamethasone|40 mg weekly by mouth
57961918|NCT01355705|DRUG|Aspirin|81 or 325 mg daily by mouth
57961919|NCT01355705|DRUG|Pegfilgrastim|6 mg subcutaneous on Day 2
57961920|NCT00782366|GENETIC|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
57961921|NCT01162330|OTHER|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
57961922|NCT04930575|OTHER|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
57961923|NCT04930575|OTHER|Mulligan Technique|"* The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~* Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
57961924|NCT00268242|DRUG|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
57961925|NCT00268242|DRUG|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
57961926|NCT05020600|DRUG|Duloxetine|First-line fibromyalgia treatment
57961927|NCT05020600|DRUG|Pregabalin|First-line fibromyalgia treatment
57961928|NCT05020600|DRUG|Amitriptyline|First-line fibromyalgia treatment
57961929|NCT01318330|DRUG|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
57961930|NCT03310970|DRUG|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
57961931|NCT03310970|DRUG|Lidocaine hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
57961932|NCT03310970|DRUG|Lidoderm 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
57961933|NCT06076577|BEHAVIORAL|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
57961934|NCT06501651|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
57961935|NCT06501651|DRUG|Valsartan|Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
57961936|NCT02560610|DRUG|OC000459|
57961937|NCT02560610|DRUG|Placebo|
57961938|NCT03714529|BIOLOGICAL|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
58431728|NCT05018663|OTHER|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
58431729|NCT01868477|DRUG|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
58431730|NCT01868477|DRUG|Erythropoietin alpha|
58431731|NCT01868477|DRUG|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
58431732|NCT05373342|DEVICE|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
58431733|NCT05254327|DRUG|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
58431734|NCT05501951|OTHER|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
57961939|NCT04663958|DIAGNOSTIC_TEST|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
57961940|NCT03400800|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
57961941|NCT03400800|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
57961942|NCT03849339|DRUG|CKD-387|Test drug
57961943|NCT03849339|DRUG|D635|Reference drug
57961944|NCT04850209|OTHER|oral and written education|oral and written education
57961945|NCT04850209|OTHER|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
57961946|NCT06454331|DEVICE|Transcranial direct current stimulation|The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.
57961947|NCT06454331|DEVICE|Sham transcranial direct current stimulation|it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days
57961948|NCT05416294|DEVICE|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
57961949|NCT05416294|DEVICE|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
57961950|NCT02175680|DRUG|PRO 140|CCR5 Antagonist
57961951|NCT02175680|OTHER|Historical data|Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
57961952|NCT01908647|BEHAVIORAL|RT fMRI|Real-time fMRI with neurofeedback.
57961953|NCT01908647|BEHAVIORAL|Cognitive Training|Computer based attention training.
57961954|NCT01908647|BEHAVIORAL|Control RT fMRI|Control condition for real-time fMRI.
57961955|NCT01908647|BEHAVIORAL|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
57961956|NCT03350217|DRUG|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
57961957|NCT03350217|DRUG|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
57961958|NCT00968851|DRUG|EVP-6124|Arms: 1
57961959|NCT00968851|DRUG|Placebo|Arm: 3
57961960|NCT00968851|DRUG|EVP-6124|Arms: 2
57961961|NCT03008395|BEHAVIORAL|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
57961962|NCT03008395|OTHER|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
57961963|NCT06030843|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG
57961964|NCT06030843|DRUG|Placebo|Matching placebo containing Lactose content (0.26 gram)
57961965|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
57961966|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
57961967|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
58431735|NCT05501951|OTHER|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
58431736|NCT06168266|DEVICE|Eccentric bike|Received eccentric cycling exercise
58431737|NCT06168266|OTHER|conventional group|Received conventional treatment
58431738|NCT05391256|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|"Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided."
58431739|NCT06510010|DRUG|Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)|"Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid."
58431740|NCT06510010|DRUG|Oxaliplatin With S-1 （SOX）|"Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle."
58431741|NCT05938127|DEVICE|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
58431742|NCT05938127|DEVICE|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
58431743|NCT06304779|DRUG|Lidocaine|"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."
58431744|NCT06304779|DRUG|Placebo|atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
58431745|NCT02868229|DRUG|COR-001|
58431746|NCT02868229|OTHER|Placebo|
57737404|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
58309109|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
58431747|NCT01298765|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
58431748|NCT05028270|PROCEDURE|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
58309110|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
58431749|NCT03036618|DIETARY_SUPPLEMENT|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
58431750|NCT03036618|DIETARY_SUPPLEMENT|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
58431751|NCT00187447|DRUG|indomethacin (two different dosing regimens)|
58431752|NCT02540668|DRUG|Lanabecestat|Administered orally
58431753|NCT02540668|DRUG|Warfarin|Administered orally
57961968|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
57961969|NCT02025426|DRUG|Phenylephrine|
57961970|NCT02025426|DRUG|Ephedrine|
58309111|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
58309112|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
58309113|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
58309114|NCT05941806|DRUG|pr Sandoz Tamsulosin|Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
58309115|NCT05941806|DRUG|Glucose|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
58102347|NCT01776996|DRUG|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
58431754|NCT03071289|RADIATION|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
58431755|NCT03071289|DRUG|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
58102348|NCT05011019|DRUG|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
58102349|NCT00631800|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
58102350|NCT05555186|DEVICE|BWL classrooms (Experimental)|Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.
58102351|NCT05555186|DEVICE|DWL classrooms (Comparison)|Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
58102352|NCT04408300|PROCEDURE|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
58102353|NCT02600273|OTHER|Usual brand cigarettes|Usual brand cigarettes
58102354|NCT02600273|OTHER|Lower nicotine content cigarettes|SPECTRUM research cigarettes
58102355|NCT02600273|OTHER|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
58102356|NCT02600273|OTHER|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
58102357|NCT06418087|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]|"Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit."
58102358|NCT01000857|DRUG|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
58431756|NCT03071289|RADIATION|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
58431757|NCT00003336|BIOLOGICAL|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58431758|NCT00003336|DRUG|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58431759|NCT00003336|DRUG|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58431760|NCT00003336|DRUG|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58431761|NCT00003336|DRUG|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58431762|NCT00003336|PROCEDURE|bone marrow ablation with stem cell support|
58431763|NCT00003336|PROCEDURE|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
58431764|NCT00003336|RADIATION|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
58102359|NCT03031405|DRUG|Oxytocin nasal spray|
58102360|NCT03031405|DRUG|Placebos|Placebo nasal spray
58102361|NCT05885529|OTHER|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
58102362|NCT03845322|DRUG|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
58102363|NCT03845322|DRUG|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
58102364|NCT00201734|DRUG|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
58102365|NCT00201734|DRUG|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
58102366|NCT00201734|DRUG|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
58102367|NCT00509340|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
58102368|NCT04385082|DRUG|Active Cannabis|Smoked cannabis with THC
58431765|NCT01238328|DRUG|Conditioning regimen|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
58431766|NCT01238328|DRUG|Graft-versus-host disease (GVHD) prophylaxis|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
58431767|NCT01238328|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
58431768|NCT02508909|PROCEDURE|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
58431769|NCT02610452|OTHER|Clown therapy|"The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
58102369|NCT04385082|DRUG|Placebo Cannabis|Placebo smoked cannabis (no THC)
58102370|NCT01298154|OTHER|Dietary intervention|Dietary treatments with beverages
58102371|NCT01528631|OTHER|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
58102372|NCT01528631|OTHER|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
58102373|NCT01858558|BIOLOGICAL|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
58102374|NCT01858558|DRUG|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
58102375|NCT02670200|BEHAVIORAL|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
58102376|NCT06154915|OTHER|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
58309116|NCT04172740|DEVICE|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
58309117|NCT01328015|DRUG|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
58102377|NCT05862519|DIETARY_SUPPLEMENT|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
58102378|NCT05862519|DIETARY_SUPPLEMENT|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds \& Flaxseed. Taken from Day 7 through Day 21.
58102379|NCT05862519|DIETARY_SUPPLEMENT|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
58102380|NCT05862519|DIETARY_SUPPLEMENT|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
58102381|NCT04834999|OTHER|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
58102382|NCT01339858|DRUG|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
58102383|NCT01339858|OTHER|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
58102384|NCT01178112|DRUG|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
58102385|NCT01178112|DRUG|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
58102386|NCT01178112|DRUG|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
58102387|NCT01178112|DRUG|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
58102388|NCT01178112|OTHER|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
58102389|NCT06538103|PROCEDURE|Eye soft surgery|Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
58102390|NCT06538103|OTHER|Physical Rehabilitation|Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
58102391|NCT02119182|BEHAVIORAL|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
58102392|NCT02119182|BEHAVIORAL|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
58102393|NCT02119182|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
58102394|NCT02119182|PROCEDURE|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
58102395|NCT05012735|DRUG|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
58309118|NCT03678077|OTHER|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
58309119|NCT02198196|BEHAVIORAL|Weight Talk-Mindfulness|
58309120|NCT04151511|PROCEDURE|Continuous Erector Spinae Plane Block|"1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block"
58309121|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
58309122|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
58309123|NCT01627665|DRUG|D->R->C+R|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
58309124|NCT01627665|DRUG|D->R->C+D|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
58309125|NCT01627665|DRUG|R->D->C+D|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
58309126|NCT01627665|DRUG|R->D->C+R|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
58309127|NCT02329717|DRUG|PBI 05204|PBI 05204 daily dosing
58309128|NCT01900444|BIOLOGICAL|IMOJEV|0.5 mL, Subcutaneous
58309129|NCT03851575|OTHER|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
58309130|NCT03851575|OTHER|Usual guideline therapy|Usual guideline therapy
58102396|NCT05012735|DEVICE|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
58431770|NCT04840134|BEHAVIORAL|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in two consecutive phases:~1. Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~2. Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~1. Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~2. One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~3. Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief)."
58431771|NCT05972837|DEVICE|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
58431772|NCT05972837|OTHER|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
58431773|NCT05905731|BIOLOGICAL|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
58431774|NCT03772665|DRUG|Emixustat|Once daily oral tablet taken for 24 months
58431775|NCT03772665|DRUG|Placebo|Once daily oral tablet taken for 24 months
58431776|NCT04580095|OTHER|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
58431777|NCT01162811|BEHAVIORAL|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
58431778|NCT00158691|DRUG|Ethyol|
58431779|NCT02486965|DEVICE|thermode (TSA-II model)|thermal stimulation with test thermode
58431780|NCT02486965|OTHER|Adapted Physical Activity|
58431781|NCT02486965|OTHER|Physical activity|
58102397|NCT04829279|OTHER|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
58102398|NCT01252836|DEVICE|AWBAT-D|Application of AWBAT-D bioengineered device
58431782|NCT05270798|DRUG|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
58458448|NCT04383509|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
58102399|NCT02615873|DRUG|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
58102400|NCT06428006|BEHAVIORAL|Cognitive behavioral therapy for insomnia|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
58102401|NCT06428006|BEHAVIORAL|Sleep and lifestyle education|"The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises"
58102402|NCT01335399|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102403|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
58309131|NCT01622322|DRUG|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
58431783|NCT02999412|PROCEDURE|Comprehensive medication review|"* A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
58102404|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102405|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102406|NCT01335399|DRUG|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102407|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102408|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
58102409|NCT01213719|DIETARY_SUPPLEMENT|creatine|20g/d throughout 10 days
58102410|NCT01213719|DIETARY_SUPPLEMENT|betaine|2g/d throughout 10 days
58102411|NCT01213719|DIETARY_SUPPLEMENT|dextrose|dextrose (placebo), 20 g/d throughout 10 days
58102412|NCT01213719|DIETARY_SUPPLEMENT|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
58102413|NCT06568198|DEVICE|Real tACS|α-tACS at a frequency of alpha band at S1
58102414|NCT06568198|DEVICE|Sham tACS|Sham tACS with no stimulation applied
58102415|NCT01602198|DRUG|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
58102416|NCT01602198|DRUG|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
58102417|NCT01784419|DRUG|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
58102418|NCT01784419|DRUG|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
58102419|NCT01463566|DEVICE|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
58102420|NCT03012620|DRUG|Pembrolizumab|Treatment
58102421|NCT00039507|PROCEDURE|conventional surgery|
58102422|NCT00039507|PROCEDURE|radiofrequency ablation|
58102423|NCT03886428|OTHER|100% portion size|Entree portion size 100% of baseline
58102424|NCT03886428|OTHER|125% portion size|Entree portion size 125% of baseline
58102425|NCT03886428|OTHER|150% portion size|Entree portion size 150% of baseline
58102426|NCT03886428|OTHER|175% portion size|Entree portion size 175% of baseline
58102427|NCT01337609|DRUG|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
58102428|NCT01337609|OTHER|Placebo (sugar pill)|1 pill daily for 60 days
58309132|NCT01622322|OTHER|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
57737405|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
58431784|NCT02999412|PROCEDURE|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
57961971|NCT03872804|PROCEDURE|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
57961972|NCT03872804|PROCEDURE|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
57961973|NCT03872804|PROCEDURE|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
57961974|NCT03872804|OTHER|Oral pulse steroid with narrow band|"* A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~* All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
57961975|NCT05980520|DIETARY_SUPPLEMENT|Taurine+corn starch+white sugar|Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.
57961976|NCT05980520|DIETARY_SUPPLEMENT|Corn starch+white sugar|0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.
57961977|NCT05980520|BEHAVIORAL|Behavioral rehabilitation therapy|Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
57961978|NCT03273166|DEVICE|INVSENSOR00001|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
57961979|NCT03273166|DEVICE|Control SpHb sensor|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
57961980|NCT03273166|PROCEDURE|Hemodilution|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
57961981|NCT01182831|PROCEDURE|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
58431785|NCT02999412|PROCEDURE|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
58431786|NCT05629468|DRUG|Azithromycin|antibiotic
58431787|NCT05629468|DRUG|Probiotic Formula|probiotics
58431788|NCT05629468|DRUG|Benzoyl Peroxide 4 % Topical Cream|topical cream
58431789|NCT00746434|DRUG|Roflumilast cream|Roflumilast cream 0.5%
58431790|NCT00746434|DRUG|Placebo cream|Placebo cream
58431791|NCT06471075|BEHAVIORAL|Mindful Pain Management|The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
58431792|NCT06471075|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
57961982|NCT01182831|PROCEDURE|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
58431793|NCT06261359|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
58431794|NCT06261359|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
58431795|NCT06261359|DRUG|Nab paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
58431796|NCT04995549|DEVICE|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
58431797|NCT03651609|PROCEDURE|Simple decompression of the ulnar nerve|Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
58431798|NCT03651609|BEHAVIORAL|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
58431799|NCT01227005|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
58431800|NCT04598412|OTHER|No intervention|Cross-sectional
57961983|NCT02041377|DEVICE|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
57961984|NCT04814693|DEVICE|EndoRotor® System (Interscope, Inc., Northbridge, MA USA),|The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
57961985|NCT04814693|PROCEDURE|Conventional endoscopic devices (according to standards of care)|Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
57961986|NCT01478854|RADIATION|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
57961987|NCT01478854|DRUG|Chemotherapy|Temozolomide
57961988|NCT03841357|DRUG|Abatacept Injection|Supplied as a weekly injection via a pre-filled syringe
57961989|NCT03841357|OTHER|Usual Care|Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
57961990|NCT01420146|DRUG|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
57961991|NCT00575809|OTHER|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
57961992|NCT05069584|PROCEDURE|Biopsy|patient must have a biopsy for his prostate cancer
57961993|NCT00280007|DRUG|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
57961994|NCT00398463|DRUG|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
57961995|NCT00398463|DRUG|Placebo|Saline infusion will be administered for 14-24 hours
57961996|NCT02282592|OTHER|Observation about the presence of metabolic syndrome|
58102429|NCT01337609|OTHER|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
58431801|NCT03298763|GENETIC|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
58431802|NCT03298763|DRUG|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
58431803|NCT05917171|BEHAVIORAL|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
58102430|NCT04250519|DRUG|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
58102431|NCT04282044|BIOLOGICAL|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
58102432|NCT04282044|COMBINATION_PRODUCT|Fludarabine|25mg/m IV (five doses given from Day -7 until Day -3)
58102433|NCT04282044|COMBINATION_PRODUCT|Cyclophosphamide|60mg/kg intravenous (IV) (two doses given on Day -7 and -6)
58102434|NCT05096026|BEHAVIORAL|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
58102435|NCT05096026|BEHAVIORAL|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
58102436|NCT01831531|DRUG|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28
58102437|NCT01831531|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
58102438|NCT00467337|PROCEDURE|Medial-Wedge Insole intervention|
58102439|NCT01180842|OTHER|Yoga treatment program|yoga program designed specifically for the patient with CF
58102440|NCT02523079|BEHAVIORAL|Cognitive Behavioral Group Therapy for Insomnia|
58102441|NCT02523079|BEHAVIORAL|Cognitive Behavioral Self-help Therapy for Insomnia|
58102442|NCT02523079|BEHAVIORAL|Sleep Hygiene Guidance|
58102443|NCT03355222|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
58102444|NCT05948436|PROCEDURE|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
58102445|NCT02162511|DEVICE|CliniMACS CD34+ cell enrichment and T-cell depletion|
58102446|NCT03849794|OTHER|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
58102447|NCT03849794|OTHER|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
58102448|NCT00276731|DRUG|carboplatin|
58431804|NCT06153472|DEVICE|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
58431805|NCT00912457|DRUG|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
58431806|NCT00912457|DRUG|placebo|placebo 1 p/day for 28 days
58431807|NCT01949610|DRUG|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
58431808|NCT02119390|BEHAVIORAL|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
58431809|NCT02119390|OTHER|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
58431810|NCT02119390|OTHER|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
58431811|NCT01364389|DRUG|AIN457|3 mg/kg
58102449|NCT00276731|DRUG|cisplatin|
58102450|NCT00276731|DRUG|cyclophosphamide|
58102451|NCT00276731|DRUG|etoposide|
58431812|NCT01364389|DRUG|ACZ885|3 mg/kg
58431813|NCT01364389|DRUG|Prednisone|20 mg
58431814|NCT01364389|DRUG|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
58431815|NCT00697710|DRUG|50 mg S-777469|S-777469, 50 mg BID
58431816|NCT00697710|DRUG|200 mg S-777469|S-777469, 200 mg BID
58431817|NCT00697710|DRUG|800 mg S-777469|S-777469, 800 mg BID
58431818|NCT00697710|DRUG|Placebo|Matching Placebo
58431819|NCT03496805|DRUG|MGE|The patients will take 4 capsules by mouth BID (twice daily).
58431820|NCT03496805|OTHER|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
58431821|NCT03496805|OTHER|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
57737406|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
57961997|NCT06196086|DIAGNOSTIC_TEST|Echocardiography examination|Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
58431822|NCT01336023|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
58431823|NCT01336023|DRUG|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
58102452|NCT00276731|DRUG|vincristine sulfate|
58431824|NCT01336023|DRUG|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
58431825|NCT01722435|DRUG|Opiate Substitution Treatment|
58431826|NCT05664802|BEHAVIORAL|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
58431827|NCT01335269|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
58431828|NCT04088591|DRUG|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
58431829|NCT04088591|DRUG|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
58431830|NCT00527904|DRUG|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
58431831|NCT00527904|DRUG|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
58431832|NCT04478604|OTHER|applied forms to pregnant women|
58431833|NCT01073930|DRUG|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
57961998|NCT04593654|DRUG|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
57961999|NCT05196854|OTHER|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
57962000|NCT05196854|OTHER|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
57962001|NCT01141595|DRUG|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
57962002|NCT03206697|OTHER|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
57962003|NCT06339879|OTHER|High Whole Grain, Low Sugar|6 servings of whole grain and \<13% energy from added sugars.
57962004|NCT06339879|OTHER|Low Whole Grain, Low Sugar|3 servings of whole grain and \<13% energy from added sugars.
57962005|NCT06339879|OTHER|High Whole Grain, High Sugar|6 servings of whole grain and \>13% energy from added sugars.
57962006|NCT06339879|OTHER|Low Whole Grain, High Sugar|3 servings of whole grain and \>13% energy from added sugars.
57962007|NCT00961883|BIOLOGICAL|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU
57962008|NCT00961883|BIOLOGICAL|Placebo|Sodium Chloride for injection, delivered intramuscularly
57962009|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU
57962010|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU
57962011|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
57962012|NCT00380328|DRUG|neratinib|HKI-272
57962013|NCT02440815|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
58102453|NCT00276731|PROCEDURE|conventional surgery|
58102454|NCT00276731|PROCEDURE|neoadjuvant therapy|
58102455|NCT00276731|RADIATION|radiation therapy|
58102456|NCT02014649|DRUG|20 mg laninamivir octanoate|
58102457|NCT02014649|DRUG|Placebo|
58102458|NCT02014649|DRUG|40 mg laninamivir octanoate|
58102459|NCT00623909|DEVICE|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
58309133|NCT03563222|DRUG|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
58102460|NCT01804530|DRUG|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
58102461|NCT02509520|DIETARY_SUPPLEMENT|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
58129499|NCT02802371|OTHER|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
58431834|NCT01073930|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
58431835|NCT01073930|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
58431836|NCT01135095|RADIATION|low-dose imaging|"The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
58102462|NCT05700929|BEHAVIORAL|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
58102463|NCT00267007|DRUG|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
58102464|NCT00267007|DRUG|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
58431837|NCT01320202|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
58431838|NCT01320202|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
58431839|NCT01646242|PROCEDURE|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
58431840|NCT01646242|PROCEDURE|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
58431841|NCT05336149|PROCEDURE|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
58102465|NCT00407043|DRUG|Lotemax|
58102466|NCT00407043|DRUG|Restasis|
58129500|NCT02538445|OTHER|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
58129501|NCT02538445|OTHER|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
58431842|NCT05336149|PROCEDURE|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
58431843|NCT01853605|DEVICE|Anatomically shaped silicone gel-filled breast implants|Surgical implant
58431844|NCT05772013|DRUG|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
58431845|NCT05772013|DRUG|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
58431846|NCT00543335|DRUG|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
58431847|NCT00543335|PROCEDURE|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
58431848|NCT03892239|BEHAVIORAL|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
58102467|NCT04175652|BEHAVIORAL|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
58102468|NCT01498900|DRUG|repaglinide|Prescription according to the product labelling at the physicians' discretion
58431849|NCT03892239|BEHAVIORAL|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
58431850|NCT01012544|DRUG|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
58431851|NCT05320003|DIAGNOSTIC_TEST|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
58431852|NCT05320003|DIAGNOSTIC_TEST|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
58431853|NCT05320003|DIAGNOSTIC_TEST|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
58431854|NCT03466736|DIAGNOSTIC_TEST|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
58431855|NCT00782483|DEVICE|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
58431856|NCT00782483|DEVICE|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
58431857|NCT00782483|DEVICE|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
58431858|NCT04673539|DIAGNOSTIC_TEST|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
58431859|NCT06366230|DRUG|Urea in the dialysate|Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
58431860|NCT04660396|DEVICE|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
58431861|NCT03720288|DRUG|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
58431862|NCT03720288|DRUG|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
58431863|NCT03408184|DRUG|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
58431864|NCT03408184|DRUG|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
58431865|NCT05825976|DIETARY_SUPPLEMENT|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
58431866|NCT05825976|OTHER|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
58431867|NCT06358092|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
58431868|NCT06358092|DIAGNOSTIC_TEST|Two-Dimensional Shear Wave Elastography|2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
58431869|NCT03094715|DEVICE|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
58431870|NCT03094715|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
58431871|NCT01999725|DRUG|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
58431872|NCT01999725|DRUG|Placebo|Matching placebo capsules or matching suspension
58431873|NCT01301170|PROCEDURE|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
58431874|NCT03420885|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
58431875|NCT03420885|BEHAVIORAL|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
58431876|NCT03945149|DIETARY_SUPPLEMENT|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
58102469|NCT04843800|PROCEDURE|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
58102470|NCT03701620|DIAGNOSTIC_TEST|HRV monitoring|HRV monitoring derived from electrocardiogram
58102471|NCT06497361|BIOLOGICAL|PRG-2311|PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
58431877|NCT03945149|DIETARY_SUPPLEMENT|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
58431878|NCT05185414|DIAGNOSTIC_TEST|Venipuncture and skin biopsy for RNA extraction|"* Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)"
58431879|NCT05475236|BEHAVIORAL|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
58431880|NCT06228859|PROCEDURE|overdentures with different attachments|different types of overdenture attachments in relation to retention, bite force, and periimplant tissue health.
58431881|NCT03387358|DEVICE|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
58431882|NCT03104257|DRUG|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
58431883|NCT02332291|DRUG|Escitalopram|Escitalopram 10-20mg daily
58431884|NCT02332291|DRUG|Bupropion XL|Bupropion XL 150-450mg daily
58102472|NCT03241407|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
58102473|NCT03241407|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
58102474|NCT01676311|DRUG|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
58102475|NCT01676311|DRUG|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
58102476|NCT05636774|DRUG|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
58102477|NCT05636774|DRUG|Placebo|Placebo tables / infusion
58102478|NCT06087185|BEHAVIORAL|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
58102479|NCT06087185|BEHAVIORAL|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
58102480|NCT00612079|DRUG|Sertindole|oral 3 x 4mg
58102481|NCT00612079|DRUG|Placebo|3 x 4mg Placebo
58431885|NCT00156390|DEVICE|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
58431886|NCT00156390|OTHER|LV lead placement as per standard of care (without echo guidance)|
58431887|NCT00186901|DRUG|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
58431888|NCT00186901|OTHER|Placebo|Placebo
58431889|NCT01068769|DRUG|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
58431890|NCT06016868|PROCEDURE|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
58431891|NCT06016868|PROCEDURE|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
58431892|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
58431893|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
58431894|NCT04929080|BIOLOGICAL|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
58431895|NCT05126849|OTHER|Allogenic transplantation|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
58431896|NCT05463250|DEVICE|Smartwatch|Wearing a smartwatch and having access to its data
58431897|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
58431898|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
58431899|NCT06259175|DRUG|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
58431900|NCT01161537|DRUG|VX-770|Tablet.
58431901|NCT01161537|DRUG|Placebo|Tablet.
58431902|NCT01301859|BEHAVIORAL|TIP|Treatment visits as usual with MD
58431903|NCT00741442|DRUG|RDEA806|Uricosuric agent for the treatment of gout
57962014|NCT03875261|DRUG|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
57962015|NCT00003385|DRUG|carboplatin|
58431904|NCT00741442|DRUG|Placebo|Matching Placebo.
58431905|NCT02681315|DEVICE|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
58431906|NCT02681315|DEVICE|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
58431907|NCT04649177|DEVICE|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
57962016|NCT00003385|DRUG|paclitaxel|
57962017|NCT00003385|DRUG|pegylated liposomal doxorubicin hydrochloride|
57962018|NCT01079481|DRUG|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
57962019|NCT00939198|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
58431908|NCT06002516|OTHER|RELIEF-pathway|"The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory."
58431909|NCT04412707|DRUG|Melphalan|Peripheral versus central administration
58431910|NCT04412707|DRUG|Dexamethasone|Oral tablets
58431911|NCT06423131|PROCEDURE|TCRαβ Depleted haploidentical HCT|Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
58431912|NCT02327988|OTHER|Cryotherapy|
58431913|NCT02327988|DEVICE|Laser therapy|
58431914|NCT01959438|DRUG|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
58431915|NCT01959438|DRUG|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
57962020|NCT01407094|DRUG|Sertraline|50-200mg/day
57962021|NCT01407094|DRUG|Placebo|1-4 pills per day
57962022|NCT01407094|DRUG|BupropionXL|150-450 mg/day
57962023|NCT03146572|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
57962024|NCT03146572|OTHER|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
57962025|NCT00185393|BIOLOGICAL|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
57962026|NCT00185393|OTHER|no treatment|no treatment
57962027|NCT00796315|DRUG|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
57962028|NCT02491814|OTHER|1% M.F. Milk|
57962029|NCT02491814|OTHER|Yogurt Beverage|
57962030|NCT02491814|OTHER|Soy Beverage|
57962031|NCT02491814|OTHER|Almond Beverage|
57962032|NCT02491814|OTHER|Water|
57962033|NCT02491814|OTHER|Breakfast cereal|
57962034|NCT05449678|BEHAVIORAL|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
57962035|NCT02164656|BEHAVIORAL|mindfulness for smokers|
57962036|NCT05744739|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57962037|NCT05744739|DRUG|Tomivosertib|Given PO
57962038|NCT01517477|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
57962039|NCT01517477|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
57962040|NCT01517477|DEVICE|iStent|Implantation of Three iStents through a small temporal clear corneal incision
57962041|NCT00778037|DRUG|Cyclobenzaprine hydrochloride 10 mg tablet|
57962042|NCT05019131|BEHAVIORAL|Training|trainings to reduce conscious bias and stress
57962043|NCT05019131|BEHAVIORAL|Peer support and mentorship|facilitated peer and mentorship opportunities
57962044|NCT05019131|BEHAVIORAL|Leadership engagement|Engaged leadership at the county and facility levels
57962045|NCT05019131|BEHAVIORAL|Embedded champions|Facilitate local champions to promote intervention
58102482|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
58102483|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
58102484|NCT01618773|DRUG|0.1% adapalene / 2.5% benzoyl peroxide|topical application
58431916|NCT01776723|DRUG|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
58431917|NCT04976361|OTHER|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
58431918|NCT04138290|DEVICE|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
58431919|NCT02211066|DRUG|Clopidogrel|
58431920|NCT02211066|DRUG|Ticagrelor|
58102485|NCT06420401|DIETARY_SUPPLEMENT|araboxylan|During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
58102486|NCT06420401|DIETARY_SUPPLEMENT|inulin|During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
58102487|NCT06420401|DIETARY_SUPPLEMENT|inulin and araboxylan|During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
58102488|NCT06420401|DIETARY_SUPPLEMENT|placebo control|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
58102489|NCT03082820|DIAGNOSTIC_TEST|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
58431921|NCT06526091|OTHER|Cerebral NIRS monitoring at delivery|Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
58431922|NCT06077942|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
58431923|NCT04790071|OTHER|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
58431924|NCT04790071|OTHER|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
58431925|NCT00983385|DRUG|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
58431926|NCT00983385|OTHER|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
58431927|NCT00983385|DRUG|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
58431928|NCT02221388|DRUG|BI 671800 HEA, 200 mg tablets|
58431929|NCT02221388|DRUG|BI 671800 HEA EC, 200 mg tablets|
58431930|NCT02221388|DRUG|BI 671800 HEA, 50 mg tablets|
58431931|NCT02221388|DRUG|BI 671800 ED, 100 mg capsules|
58431932|NCT02221388|OTHER|Standard meal|
58431933|NCT04152798|PROCEDURE|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
58431934|NCT04152798|PROCEDURE|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
58431935|NCT00028327|DRUG|Lamivudine/Zidovudine|
58431936|NCT00028327|DRUG|Nelfinavir mesylate|
58431937|NCT00028327|DRUG|Efavirenz|
58431938|NCT00028327|DRUG|Lamivudine|
58431939|NCT00028327|DRUG|Zidovudine|
58431940|NCT06584019|OTHER|Range Of Motion applied group|Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
58431941|NCT03296943|COMBINATION_PRODUCT|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
58431942|NCT03296943|COMBINATION_PRODUCT|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
58431943|NCT03296943|BEHAVIORAL|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
58431944|NCT01114438|DEVICE|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
58431945|NCT06584032|DRUG|fruquintinib|Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
58431946|NCT06584032|BIOLOGICAL|sintilimab|Sintilimab will be intravenously administrated on Day 1 every three weeks.
58431947|NCT06584032|DRUG|paclitaxel|175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
58431948|NCT06584032|DRUG|doxorubicin|60mg/m\^2 via IV infusion, on Day 1 every three weeks.
58431949|NCT06203769|DRUG|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
58431950|NCT06203769|DRUG|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
58431951|NCT03603106|DRUG|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
58431952|NCT03603106|DRUG|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
58431953|NCT01150565|DRUG|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
57953419|NCT06336252|BEHAVIORAL|Digital nudging intervention target to change behavior|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
57962046|NCT02229344|OTHER|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
58431954|NCT01879943|DEVICE|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
57962047|NCT02889432|DRUG|Oral Melatonin 10mg|
57962048|NCT02889432|DRUG|Placebo|
57962049|NCT04423250|OTHER|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|- Failure to trace, Lack of product information, absence of product in the operating room
57962050|NCT03639090|DIAGNOSTIC_TEST|mass spectrometry|mass spectrometry for bladder cancer cells
57962051|NCT06501443|DRUG|Usual care|Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
57962052|NCT06501443|DRUG|KJX839|Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
57962053|NCT04851600|DEVICE|prosthesis|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
57962054|NCT04632498|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
58431955|NCT01879943|PROCEDURE|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
58431956|NCT04014569|DEVICE|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
58431957|NCT06426914|OTHER|Clinical Pilates|"Warmup: 5-10 minutes Pilates Clinical (Introductory program) The Hundred modified The Roll-up modified The roll-over modified Spine twist modified Single-leg circle modified Rolling like a ball Shoulder Bridge modified~For every Step emphasizing:~FOCUS: On muscle involved REPETITIONS: 3-5 VISUALIZATION: Imagination process (Different for each step) Cool down: 5 minutes Total Time: 30 minutes"
58102490|NCT03082820|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
58102491|NCT03082820|DIAGNOSTIC_TEST|Nerve conduction studies (NCS)|NCS were performed with patients only.
58431958|NCT06426914|OTHER|Cardiac Rehabilitation|"Chest Physical therapy (Chest percussions and active huffs as per need) Breathing strategies (Diaphragmatic and purse lip 1-3 sets \* 5 Reps/Day)~Functional mobility (walk /cycling as per patient tolerance)~Patient education and Wound care Sternal Precaution guidance"
58431959|NCT03273309|OTHER|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
57953420|NCT05223946|DIAGNOSTIC_TEST|Microwave Radiometry|The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
57953421|NCT05223946|DEVICE|SCENAR-CHENS-01|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
57953422|NCT05223946|COMBINATION_PRODUCT|Traditional Combination Therapy|ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
57953423|NCT03001674|DEVICE|Conductance catheterization|CD Leycom Conductance Catheter
57953424|NCT06503172|BIOLOGICAL|Taiwanese whole grain job's tear (red job's tear)|300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
57953425|NCT06503172|BIOLOGICAL|White job's tear|300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
57953426|NCT03579784|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
57953427|NCT03579784|DRUG|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
57953428|NCT03579784|DRUG|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
57953429|NCT01271283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
57953430|NCT01271283|DRUG|Lenalidomide|Given orally
57953431|NCT05815108|OTHER|NO INTERVENTION|NO INTERVENTION
57953432|NCT00940589|DRUG|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
58102492|NCT05925569|OTHER|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
58431960|NCT03273309|OTHER|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
58431961|NCT03524638|OTHER|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
58431962|NCT03524638|PROCEDURE|Colorectal Surgery|Colorectal surgery alone
58431963|NCT02056327|DEVICE|A novel monitoring suite of sensors will be inserted into the standard oral device.|
57953433|NCT00940589|DRUG|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
57953434|NCT06375109|DRUG|Tislelizumab|administered via Intravenous (IV) injection
58309134|NCT03563222|DRUG|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
58309135|NCT03886909|BEHAVIORAL|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
58309136|NCT03886909|BEHAVIORAL|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
58309137|NCT03750721|OTHER|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
58309138|NCT05966103|OTHER|Exercises|For control group; Cervical conventional exercises. For treatment group; scapulothoracic exercises including strengthening, proprioceptive and stabilization exercises in addition to cervical conventional exercises
58309139|NCT00459017|DEVICE|Portable blood pressure wrist manometer|
58309140|NCT03432832|BEHAVIORAL|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
58309141|NCT03432832|BEHAVIORAL|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
58309142|NCT00129831|DRUG|QAB149|
58309143|NCT05963399|DEVICE|CAREUP platform|The Experimental Group will test the CAREUP platform at home for 12 months.
58309144|NCT00002557|DRUG|CHOP regimen|
58309145|NCT00002557|DRUG|doxorubicin hydrochloride|
58309146|NCT00002557|DRUG|etoposide|
58309147|NCT00002557|DRUG|leucovorin calcium|
58309148|NCT00002557|DRUG|methotrexate|
58309149|NCT02765035|DEVICE|C-Leg 4|Microprocessor Controlled Knee
58309150|NCT02765035|DEVICE|C-Leg 3|Microprocessor Controlled Knee
58309151|NCT02303665|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
58309152|NCT02303665|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
58309153|NCT00827567|DRUG|RAD 001|RAD 001-10 mg by mouth once everyday
58309154|NCT03758469|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
58431964|NCT00446082|DRUG|Pasireotide|
58309155|NCT03758469|DRUG|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
58309156|NCT03274817|DRUG|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
58431965|NCT05477797|DRUG|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
58431966|NCT02655575|BEHAVIORAL|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
58431967|NCT02655575|BEHAVIORAL|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
58431968|NCT06481566|RADIATION|stereotactic ablative body radiotherapy|The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
57953435|NCT06375109|DRUG|Carboplatin injection|administered via IV injection
57953436|NCT06375109|DRUG|Cisplatin injection|administered via IV injection
57953437|NCT06375109|DRUG|Etoposide injection|administered via IV injection
57953438|NCT03302845|DRUG|Omeprazole 40 MG|Omeprazole 40 mg capsule
57953439|NCT03302845|DRUG|Famotidine 40 mg|Famotidine 40 mg tablet
58309157|NCT03274817|DRUG|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
58309158|NCT03274817|DRUG|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
58431969|NCT03067623|DRUG|PRP|PRP intrauterine infusion
58431970|NCT03067623|DEVICE|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
58431971|NCT01069705|DRUG|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
58431972|NCT01948063|DRUG|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
58431973|NCT01948063|DIETARY_SUPPLEMENT|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
58431974|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
58431975|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
58431976|NCT00064051|DRUG|gemcitabine hydrochloride|
58431977|NCT00064051|DRUG|triapine|
58431978|NCT01512992|PROCEDURE|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management."
58431979|NCT06583486|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.
58431980|NCT04038567|BEHAVIORAL|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
58431981|NCT06130462|DIAGNOSTIC_TEST|Aluminum|Different concentrations of aluminium added to the blood test in vitro
58431982|NCT06130462|DIAGNOSTIC_TEST|Tetanus toxoid|Used as control substance
58431983|NCT05845853|OTHER|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
58431984|NCT05533320|DEVICE|Cold Cap Therapy|Undergo scalp cooling
58431985|NCT05533320|OTHER|Quality-of-Life Assessment|Ancillary studies
58431986|NCT05533320|OTHER|Questionnaire Administration|Ancillary studies
58431987|NCT03665272|PROCEDURE|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
58431988|NCT05360719|BEHAVIORAL|Group tele-exercise|This tele-exercise class will be tailored to the physical and emotional needs of individuals with SCI based on results of our feasibility study, the initial emergent themes from qualitative data collection in this study, and input from our co-leader with lived experience (examples: seated exercise to accommodate wheelchair users, active co-leader with SCI).The research clinician will lead the instruction of each class while our co-leader will model movements alongside her and offer tailored modifications as needed. Each 45-minute class provides a comprehensive fitness experience to maximize functional independence and improve global physical activity engagement. Elements incorporated into each class session include a collective check-in and breathing meditation, postural control, trunk and shoulder strength, cardiovascular fitness, and body awareness.
58431989|NCT01605110|DRUG|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
58431990|NCT01605110|DRUG|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
58431991|NCT01978223|PROCEDURE|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
58431992|NCT03612765|BEHAVIORAL|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
58431993|NCT00432770|DRUG|ARC1779|
58431994|NCT01623869|OTHER|Laboratory Biomarker Analysis|Correlative studies
58431995|NCT01623869|BIOLOGICAL|Trebananib|Given IV
58431996|NCT01642108|DRUG|Sitagliptin|50 mg once per day
58431997|NCT02446080|DIETARY_SUPPLEMENT|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
58431998|NCT02446080|DIETARY_SUPPLEMENT|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
57953440|NCT03302845|DRUG|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
57953441|NCT02479009|DEVICE|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
58431999|NCT02202369|OTHER|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
58432000|NCT02202369|OTHER|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
58432001|NCT00547027|BEHAVIORAL|print-based physical activity intervention|individually-based, print-based physical activity intervention
58432002|NCT00547027|BEHAVIORAL|usual care|print-based materials of nutritional information
58432003|NCT01357460|DEVICE|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
58432004|NCT03669289|OTHER|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
58432005|NCT06187077|BEHAVIORAL|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
58432006|NCT06187077|BEHAVIORAL|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
58432007|NCT01041521|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
58432008|NCT06526559|DEVICE|Barbed suture|Use of two absorbable barbed sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
58432009|NCT06526559|DEVICE|PGA suture|Use of two absorbable polyglactin sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
58432010|NCT05042284|DRUG|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
58432011|NCT00006196|DRUG|Vitamin D|
58432012|NCT00411814|DRUG|GSK679586|Active Drug
58432013|NCT00411814|DRUG|Placebo|Saline
58432014|NCT00695422|GENETIC|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
58432015|NCT00695422|OTHER|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
58432016|NCT00695422|OTHER|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
58432017|NCT00695422|PROCEDURE|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
58432018|NCT03916081|DRUG|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
58432019|NCT03916081|DRUG|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
57953442|NCT02765568|BEHAVIORAL|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
58129502|NCT02538445|OTHER|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
58432020|NCT03916081|DRUG|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
58432021|NCT02012712|BEHAVIORAL|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
58432022|NCT00557453|DRUG|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
57953443|NCT02765568|BEHAVIORAL|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
58102493|NCT03606239|RADIATION|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
58102494|NCT03014531|OTHER|almond|
58102495|NCT03014531|OTHER|high-carbohydrate control food|
58432023|NCT00557453|DRUG|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
57769571|NCT04879758|OTHER|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
57953444|NCT02765568|BEHAVIORAL|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
57953445|NCT05988671|DRUG|normal Saline|Intraperitoneal route
57953446|NCT05988671|DRUG|Dexamethasone|Intraperitoneal route
57953447|NCT05988671|DRUG|Dexmedetomidine|Intraperitoneal route
57953448|NCT05988671|DRUG|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
57953449|NCT04435509|DIETARY_SUPPLEMENT|1000+ Greek Mountain Tea|Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month
57953450|NCT04435509|OTHER|Mediterranean Diet|a Mediterranean dietary protocol
57953451|NCT03263507|DRUG|Placebo|Saline .9%
57953452|NCT03263507|DRUG|Donidalorsen|Donidalorsen administered subcutaneously
57953453|NCT02956551|BIOLOGICAL|DC vaccine|subcutaneous administration
57953454|NCT00964327|DRUG|TMC114|
57953455|NCT00015288|DRUG|Buprenorphine/naloxone|
57953456|NCT06206759|DRUG|administration of vitamin C|administration of vitamin C to ICU patients
57953457|NCT00985062|PROCEDURE|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
57953458|NCT00985062|PROCEDURE|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
57953459|NCT02248727|DEVICE|somofilcon A|somofilcon A lens
57953460|NCT04155671|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
57953461|NCT04155671|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
57953462|NCT03711500|DRUG|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
57953463|NCT03711500|DRUG|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
57953464|NCT06183658|DIAGNOSTIC_TEST|Fluids biomarker and neuroimaging of AD diagnosis|Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.
57953465|NCT00414102|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
57953466|NCT00414102|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
58102496|NCT01155284|DRUG|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
58432024|NCT06356389|DRUG|JX11502MA|Oral capsule
58432025|NCT06356389|DRUG|Placebo|Oral capsule
58432026|NCT03364738|BIOLOGICAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
58102497|NCT01155284|DRUG|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
58102498|NCT03031431|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
58102499|NCT02736526|PROCEDURE|recession or resection of the horizontal extraocular muscles|
58102500|NCT01672814|DRUG|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
58102501|NCT01672814|DEVICE|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
58102502|NCT03115060|DRUG|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
58102503|NCT02438865|DRUG|Immediate instillation of intravesical chemotherapy-Epirubicin-|
58102504|NCT02438865|DRUG|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
58102505|NCT03661294|DIAGNOSTIC_TEST|GE Healthcare Metabolic Oxygenator|
58102506|NCT01655433|DEVICE|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
58102507|NCT01655433|OTHER|No Hypothermia Treatment|
58102508|NCT00975273|BEHAVIORAL|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
58102509|NCT00975273|BEHAVIORAL|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
58102510|NCT04120714|DEVICE|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
58102511|NCT04120714|DEVICE|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
57953467|NCT02530528|DRUG|CHG|Varied application times
57953468|NCT01849471|OTHER|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
57953469|NCT01714271|BEHAVIORAL|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
57953470|NCT01714271|BEHAVIORAL|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
57953471|NCT01319695|DRUG|corifollitropin alfa|100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg
57953472|NCT01319695|DRUG|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
57953473|NCT03723382|OTHER|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
57953474|NCT03557892|DEVICE|CGM+CSII|Animas Vibe Platinum insulin pump and Dexcom G4 CGM
57953475|NCT03557892|DEVICE|MDI with degludec|Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
57953476|NCT04392518|OTHER|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
57953477|NCT04684446|BIOLOGICAL|AZD1222|Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
57953478|NCT04684446|BIOLOGICAL|rAd26-S|Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
58102512|NCT04120714|OTHER|Questionnaires|"* visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale"
58102513|NCT04664569|OTHER|observational study|observational study
58102514|NCT06545448|PROCEDURE|Percutaneous Coronary Intervention (PCI)|A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
58129503|NCT02538445|OTHER|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
58129504|NCT03056248|DRUG|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
58102515|NCT01176474|BIOLOGICAL|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
58102516|NCT01176474|DRUG|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
58102517|NCT01176474|BIOLOGICAL|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
58102518|NCT01176474|DRUG|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
58102519|NCT01176474|DRUG|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
58102520|NCT01176474|PROCEDURE|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
58102521|NCT03881579|BEHAVIORAL|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
58102522|NCT06394921|PROCEDURE|2 day cardiopulmonary exercise test|Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
58102523|NCT01286688|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
58102524|NCT05181761|OTHER|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
58102525|NCT02038101|BEHAVIORAL|Education and Feedback|"1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email"
58102526|NCT02830490|OTHER|functional tests|Test-retest reliability of physical function in hemodialysis patients
58102527|NCT04171986|DRUG|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
58129505|NCT03056248|DRUG|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
58432027|NCT05094908|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
58432028|NCT00627055|DRUG|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
58432029|NCT00627055|DRUG|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
57769572|NCT01861834|DRUG|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
57769573|NCT00004438|DRUG|leuprolide|
58129506|NCT00252356|DRUG|SR58611A|
58432030|NCT05080374|OTHER|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
58432031|NCT05080374|OTHER|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
58432032|NCT05080374|OTHER|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
58102528|NCT05525299|BEHAVIORAL|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, _____ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
58432033|NCT03366467|OTHER|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
58432034|NCT03366467|OTHER|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
58432035|NCT03696589|BEHAVIORAL|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
58432036|NCT06526052|BEHAVIORAL|Mindfulness Program|Online, coached mindfulness training program
58102529|NCT05787210|OTHER|Conventiional Physiotherapy|The Control group will be administered with Conventional Physiotherapy that Includes 5 minutes of trunk control training, 5 minutes walking in the hall with And without the therapist assistance, walker or crutches, and finally 5 minutes of Breathing exercises for Relaxation
58102530|NCT05787210|OTHER|Quadriceps Strength Training|The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
58102531|NCT06567938|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
58102532|NCT02757131|OTHER|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
58309159|NCT02879058|PROCEDURE|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
58309160|NCT02727712|PROCEDURE|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4)program
58309161|NCT02727712|DEVICE|Transesophageal Echocardiography（TEE）|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management"
58309162|NCT02727712|DEVICE|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
58432037|NCT06526052|BEHAVIORAL|Active Comparator|Remote meetings with a supportive coach
58432038|NCT00005824|BIOLOGICAL|filgrastim|
58432039|NCT00005824|DRUG|busulfan|
58432040|NCT00005824|DRUG|cyclophosphamide|
58432041|NCT00005824|PROCEDURE|peripheral blood stem cell transplantation|
58432042|NCT02776254|OTHER|START|Point of care testing for rapid ART initiation
58432043|NCT02776254|OTHER|CAG|Community Adherence Group
58432044|NCT02776254|OTHER|UAG|Urban Adherence Group
58432045|NCT02776254|OTHER|FAST-TRACK|Prescription refill only
58432046|NCT03182907|BIOLOGICAL|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
58432047|NCT03182907|DRUG|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
58432048|NCT03182907|DRUG|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
58432049|NCT03534622|DRUG|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
58432050|NCT05791240|BEHAVIORAL|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
58432051|NCT04635514|PROCEDURE|Lateral colporrhaphy|
58432052|NCT00085449|BIOLOGICAL|alemtuzumab|
58432053|NCT00085449|DRUG|cyclosporine|
58432054|NCT00085449|DRUG|fludarabine phosphate|
58432055|NCT00085449|DRUG|melphalan|
58432056|NCT00085449|DRUG|mycophenolate mofetil|
58432057|NCT00085449|PROCEDURE|peripheral blood stem cell transplantation|
58432058|NCT00085449|RADIATION|radiation therapy|
58432059|NCT02518373|BIOLOGICAL|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
58432060|NCT02518373|DRUG|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
58432061|NCT04623229|PROCEDURE|MCS|Manual Cataract Surgery
58432062|NCT04623229|PROCEDURE|ReLACS Early|ReLACS with early administration of anesthesia
58432063|NCT04623229|PROCEDURE|ReLACS Standard|ReLACS with standard time administration of anesthesia
58432064|NCT03964688|DRUG|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
58432065|NCT03964688|DRUG|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
58432066|NCT05977088|DEVICE|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group."
58432067|NCT05061628|DRUG|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
58432068|NCT05061628|DRUG|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
58432069|NCT00456651|DEVICE|CPAP (Continuous Positive Airway Pressure)|
58432070|NCT00459654|DRUG|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
58432071|NCT00459654|DRUG|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
58432072|NCT01323140|DRUG|testosterone matrix transdermal system|
58432073|NCT02731612|DRUG|lurasidone|Atypical Antipsychotic
58432074|NCT02731612|OTHER|Placebo|Inactive substance
58432075|NCT05890469|COMBINATION_PRODUCT|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
58432076|NCT05890469|COMBINATION_PRODUCT|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
58432077|NCT06584162|DRUG|Vedolizumab Injection|"Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week"
58432078|NCT03936647|PROCEDURE|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
58432079|NCT03936647|DEVICE|WEB embolization device|WEB embolization device
58432080|NCT04651127|DRUG|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
58432081|NCT01770015|PROCEDURE|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
58432082|NCT01770015|PROCEDURE|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
58432083|NCT01770015|PROCEDURE|endotracheal aspiration|fungi and bacteria endotracheal aspiration
58432084|NCT03723109|PROCEDURE|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
58432085|NCT06118957|DRUG|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
58432086|NCT01366729|DEVICE|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
58432087|NCT01366729|DEVICE|Cane walking|All walking activities must take place with cane from waking until sleeping
58432088|NCT02518191|DRUG|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
58432089|NCT03170193|DRUG|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
58432090|NCT03170193|DRUG|Placebo|Single doses of matching placebo by SC or IV injection
58432091|NCT03784807|DIAGNOSTIC_TEST|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
58432092|NCT04941846|DRUG|nimodipine and euvolemia|administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration
58432093|NCT05145244|OTHER|NO intervention|No intervention
58432094|NCT03964402|DRUG|intervention treatment|intervention treatment (any)
58432095|NCT00393614|DRUG|levetiracetam|20 mg pr. kg a day
58432096|NCT01616368|BEHAVIORAL|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
58432097|NCT05700227|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
58432098|NCT00377364|DRUG|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
58432099|NCT05392803|DEVICE|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
58432100|NCT05392803|DEVICE|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
58432101|NCT03739515|OTHER|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
58432102|NCT03739515|OTHER|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
58432103|NCT01710098|DRUG|Degarelix|subcutaneous injection
58432104|NCT02458443|OTHER|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
58432105|NCT06523244|PROCEDURE|PHOTODYNAMIC THERAPY|Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
58432106|NCT04077931|OTHER|exercises|Walking on treadmill with fixed 0% grade inclination
58432107|NCT03172130|DEVICE|Straight CPAP|
58432108|NCT03172130|DEVICE|Sham CPAP|
58102533|NCT04816422|OTHER|Proprioceptive neuromuscular facilitation|"rocedure~1. Bilateral upper extremity pattern for trunk by Chopping, Lifting~2. Bilateral lower extremity pattern for trunk.~3. Trunk lateral flexion.~4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion."
58309163|NCT02727712|DRUG|Anesthesia drugs during the surgery|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
58309164|NCT02727712|PROCEDURE|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml\*2)program
58309165|NCT01530542|DRUG|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
58309166|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
58309167|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
58309168|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
58309169|NCT01530542|DRUG|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
58309170|NCT00199173|DEVICE|SIR Spheres intra-arterial hepatic|
58309171|NCT05919628|OTHER|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
58309172|NCT03304236|DEVICE|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
58309173|NCT04755010|DEVICE|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
58309174|NCT06440928|BEHAVIORAL|mobilization|mobilization and exercise to be applied to patients with chronic lateral epicondylitis
58309175|NCT06440928|OTHER|standard treatment|standard treatment
58309176|NCT06440928|OTHER|deep friction|deep friction
58309177|NCT03549026|DRUG|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
58309178|NCT03549026|DRUG|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
58309179|NCT00921024|DRUG|CXA-101|intravenous
58309180|NCT00921024|DRUG|Ceftazidime|intravenous
58309181|NCT04653311|DEVICE|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
58309182|NCT03826615|DRUG|Gabapentin|Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
58432109|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
58432110|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
58432111|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
58432112|NCT01407445|DRUG|Placebo|1 tablet/ oral/ 3 times a day for 90 days
58309183|NCT01576848|DIETARY_SUPPLEMENT|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
58309184|NCT01576848|DIETARY_SUPPLEMENT|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
58309185|NCT01579214|OTHER|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
58432113|NCT01407445|DRUG|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
58432114|NCT03546088|DEVICE|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
58432115|NCT03546088|DRUG|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
58432116|NCT03546088|DRUG|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
58432117|NCT01209221|DRUG|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
58432118|NCT01209221|DRUG|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
58432119|NCT01209221|DRUG|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
58432120|NCT01209221|DRUG|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
57769574|NCT00715663|DRUG|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
57953479|NCT04006964|DEVICE|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
57953480|NCT01201239|DRUG|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
58309186|NCT04791176|RADIATION|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
58309187|NCT06018012|DEVICE|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
57953481|NCT01914380|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
57953482|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
57953483|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
57953484|NCT00368511|PROCEDURE|Music Listening|Listen to music and posture measurements
57953485|NCT02201407|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
57953486|NCT05839873|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
58309188|NCT04292236|DIETARY_SUPPLEMENT|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
58309189|NCT05058963|BEHAVIORAL|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
58309190|NCT06429241|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
58309191|NCT00535470|DRUG|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
58432121|NCT05243589|OTHER|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
57769575|NCT02454036|BEHAVIORAL|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
57769576|NCT04432532|OTHER|No intervention|There are no interventions
57953487|NCT00599495|PROCEDURE|allogeneic HSCT|dose-reduced conditioning regimen
57953488|NCT04730843|DRUG|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
57953489|NCT01798589|DRUG|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
57953490|NCT01905280|PROCEDURE|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
57953491|NCT01905280|PROCEDURE|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
57953492|NCT02400788|DRUG|Resminostat|
57953493|NCT02400788|DRUG|Sorafenib|
57953494|NCT05967637|OTHER|Whole body vibration|The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.
58309192|NCT01727921|DEVICE|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
58309193|NCT01727921|DEVICE|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
58309194|NCT06285500|OTHER|Patient-specific treatments|Treatment will be decided specifically for the patient based on biomarker test results.
58309195|NCT01857752|DRUG|Temozolomide|
58309196|NCT00002438|DRUG|Itraconazole|
58432122|NCT05243589|OTHER|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
58432123|NCT01727336|DRUG|Dalantercept and axitinib|
58432124|NCT01727336|DRUG|Placebo and axitinib|
58432125|NCT03502174|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
58432126|NCT03642730|DEVICE|TransThoracic Echocardiography imaging|ultrasound scanning
58432127|NCT02013245|BIOLOGICAL|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
58432128|NCT02013245|BIOLOGICAL|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
58432129|NCT05433597|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
58432130|NCT05433597|DRUG|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
58432131|NCT05433597|RADIATION|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
58432132|NCT05433597|DRUG|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
58432133|NCT05433597|DRUG|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
58432134|NCT05800912|OTHER|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
57953495|NCT05967637|OTHER|Sham-Whole body vibration|The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
58458449|NCT04383509|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
58432135|NCT05800912|OTHER|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
58432136|NCT01534195|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
58432137|NCT01534195|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
58432138|NCT02101489|OTHER|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
58432139|NCT05763771|BEHAVIORAL|Smart Phone App|Collection of data
58432140|NCT05763771|OTHER|NIcotine Patches|Place on the skin
58432141|NCT05852860|OTHER|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
58432142|NCT05852860|OTHER|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
58432143|NCT00873184|BEHAVIORAL|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
58432144|NCT02918357|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
58432145|NCT01659684|BIOLOGICAL|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
58432146|NCT02403401|DRUG|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
58432147|NCT04445337|PROCEDURE|Stellate Ganglion Block|An injection of local anesthetic into the front of the neck. Medication used for the block include- clonidine 100 mcg, Decadron PF 5mg, and 0.25% bupivacaine 5 ml is delivered.
58102534|NCT04816422|OTHER|Conventional treatment|"Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
58432148|NCT04130698|BEHAVIORAL|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
58432149|NCT04130698|DRUG|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
58432150|NCT04130698|BEHAVIORAL|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
58432151|NCT03668093|OTHER|ICCM|comprehensive system for caries management
58432152|NCT03668093|OTHER|CAMBRA|Caries risk assessment model
58432153|NCT02331017|BEHAVIORAL|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
58432154|NCT03249987|OTHER|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
58432155|NCT05377944|DRUG|BAT2306|150 mg/1 ml/injection (2 injections/visit)
58432156|NCT05377944|DRUG|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
58102535|NCT06246526|DEVICE|Evoke|The Saluda Medical Evoke® CL-SCS System (Evoke System). The Evoke System measures and records spinal cord (SC) activation resulting from stimulation via evoked compound action potentials (ECAPs). The Evoke System can be programmed to provide ECAP-controlled, closed-loop SCS or open-loop, fixed-output (traditional) SCS; ECAPs may be measured and recorded in either stimulation mode.
58432157|NCT05873491|OTHER|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
58432158|NCT05406869|DEVICE|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
58432159|NCT05329064|BIOLOGICAL|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
58432160|NCT03235089|DEVICE|Test Lens|Daily disposable contact lens
58432161|NCT03235089|DEVICE|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
58432162|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
58432163|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
58432164|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
58432165|NCT01563172|OTHER|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
58432166|NCT05788913|BIOLOGICAL|Heparin|subcutaneous Heparin
58432167|NCT06276166|OTHER|No intervention|No intervention
58432168|NCT02470884|DEVICE|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
58432169|NCT02077400|DRUG|Cephazolin|Cephazolin
58432170|NCT03513627|PROCEDURE|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
58432171|NCT06175624|OTHER|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
58432172|NCT06175624|OTHER|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
58432173|NCT06175624|OTHER|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
58432174|NCT02854748|DRUG|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
58432175|NCT02854748|DRUG|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
58102536|NCT03586037|DRUG|AD-2011 10/20 mg|AD-2011 10/20 mg tablet
58432176|NCT02854748|DRUG|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
58432177|NCT01979458|DEVICE|PSE|
58432178|NCT03483545|COMBINATION_PRODUCT|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
58432179|NCT03360058|BEHAVIORAL|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
58432180|NCT03360058|BEHAVIORAL|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
58432181|NCT00837850|DEVICE|Bone cement 1|Bone cement SmartSet® HV
58432182|NCT00837850|DEVICE|Bone cement 2|Bone cement Palacos R
58432183|NCT05134480|PROCEDURE|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
58432184|NCT00901121|DEVICE|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
58432185|NCT00901121|DEVICE|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
58432186|NCT00391924|DRUG|Dehydroepiandrosterone|
58432187|NCT01453608|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
58102537|NCT03586037|DRUG|AD-2012 80mg|AD-2012 80mg tablet
58102538|NCT03586037|DRUG|AD-2011 10/20 mg + AD-2012 80mg|AD-2011 10/20 mg + AD-2012 80mg tablet
58432188|NCT01453608|DRUG|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
58432189|NCT01189591|DEVICE|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
58432190|NCT00418327|DRUG|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
57953496|NCT03757533|BEHAVIORAL|Health Coaching|10 phone calls with a trained health coach
58102539|NCT01745484|OTHER|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
58102540|NCT02369627|DEVICE|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
58102541|NCT02369627|DEVICE|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
58309197|NCT04627636|OTHER|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
58432191|NCT04341948|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
58432192|NCT04369950|DRUG|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
58432193|NCT04369950|DRUG|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
58432194|NCT03219684|DIAGNOSTIC_TEST|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
57953497|NCT03757533|OTHER|Surveys|Surveys to assess Behavioural and Psychosocial measures
57953498|NCT04601948|BEHAVIORAL|mHealth Activity Intervention|Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
57953499|NCT06539013|DRUG|Remifentanil|remifentanil infusion
57953500|NCT06539013|DRUG|N2O|Use of N2O for analgesia
57953501|NCT06539013|DRUG|Fentanyl|Use of Fentanylfor analgesia
57953502|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
58102542|NCT02369627|OTHER|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
58102543|NCT05250947|DEVICE|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
58102544|NCT05250947|DRUG|Platelet Rich Plasma|6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
58102545|NCT01202994|DRUG|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
58102546|NCT00002084|DRUG|Valacyclovir hydrochloride|
58102547|NCT00002084|DRUG|Acyclovir|
58102548|NCT04061889|OTHER|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
58102549|NCT00411801|BIOLOGICAL|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
58102550|NCT00411801|BIOLOGICAL|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
58102551|NCT05400200|DIAGNOSTIC_TEST|questionnary administration|questionary
58102552|NCT02850445|DRUG|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
58102553|NCT02850445|OTHER|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
58102554|NCT02850445|OTHER|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
58102555|NCT02850445|OTHER|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
58102556|NCT05033379|BEHAVIORAL|Control|Importance of sleep
58102557|NCT05033379|BEHAVIORAL|Resilience coaching|Arena Strive
58102558|NCT04769128|OTHER|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
58102559|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
58102560|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
58102561|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
58102562|NCT01856374|DEVICE|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
58102563|NCT01856374|DEVICE|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
58102564|NCT01856374|DRUG|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
58102565|NCT01856374|DRUG|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
58102566|NCT02228746|DIETARY_SUPPLEMENT|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
58102567|NCT00297986|DEVICE|Helmet|Evaluation of different interfaces for NPPV
58102568|NCT03963856|OTHER|parbolic flight|weightlessness during parabolic flight
58102569|NCT02844179|DRUG|HTBZ|
58102570|NCT03862937|DIETARY_SUPPLEMENT|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
58102571|NCT03862937|OTHER|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
58102572|NCT01746563|DRUG|Ranibizumab|Intravitreal injection
58102573|NCT01746563|PROCEDURE|Laser therapy|Laser therapy
58102574|NCT05661656|PROCEDURE|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
58432195|NCT04369976|DEVICE|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
58432196|NCT05194527|OTHER|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
58432197|NCT01912339|DEVICE|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
58432198|NCT01912339|PROCEDURE|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
58432199|NCT04794075|OTHER|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
58432200|NCT05551884|PROCEDURE|Metabolites and HVPG|"HVPG measurement are performed by well-trained interventional radiologists in accordance with standard operating procedures.~All enrolled patients were analyzed for potential differential metabolites using metabolomics."
58432201|NCT01496820|DIETARY_SUPPLEMENT|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
58432202|NCT01496820|DIETARY_SUPPLEMENT|Placebo|placebo 1500mg/day for 12weeks
58309198|NCT04627636|OTHER|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
58309199|NCT04627636|OTHER|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
58309200|NCT02178514|OTHER|Formula fed with BabyNes Nutrition System|
58309201|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
58309202|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
58309203|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
58309204|NCT00607217|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
57953503|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
58309205|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
57953504|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
57953505|NCT01967537|DRUG|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
57953506|NCT01967537|PROCEDURE|Radio-guided surgery|Using 68Gallium DOTATATE
58432203|NCT01423734|OTHER|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
58432204|NCT01704404|DRUG|TD-4208|
58432205|NCT01704404|DRUG|Placebo|
58432206|NCT06339931|OTHER|SMWLM combined Spinal traction with belt|Group A, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Wrap the traction belt around both your hips and the proximal aspect of the patient's thighs.Apply traction by leaning backward and shifting your body weight onto your posterior leg.
58432207|NCT06339931|OTHER|SMWLM combined spinal traction without belt|Group B, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Manual traction is applied by placing the patient over a rolled pillow while lying sideways. The roll should be 6-8 inches in diameter and should be placed at the level of the spine where the traction or separation is to occur. Pull the patient's legs toward you as you lean your body backward to apply a traction force.
58432208|NCT04505579|DEVICE|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
58432209|NCT03750331|OTHER|Ap'Telecare|an internet application on a computer, tablet or smartphone
58432210|NCT03750331|OTHER|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
58432211|NCT06299462|DRUG|ATG 5.0|ATG 2.5 mg/kg on days -2 and -1
58432212|NCT06299462|DRUG|Cyclophosphamide injection|Cyclophosphamide 50 mg/kg on days +3 and +4
58432213|NCT06299462|DRUG|ATG 2.5±1.5|ATG 2.5 mg/kg on day -1 ± 1.5 mg/kg on day -2
58432214|NCT01710631|DRUG|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
57953507|NCT04733690|DIETARY_SUPPLEMENT|Common bean product|"Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected"
58432215|NCT01710631|DRUG|placebo|placebo
58432216|NCT04888013|OTHER|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
57953508|NCT00707070|DRUG|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
57737407|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
57737408|NCT03671096|OTHER|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
57737409|NCT06373822|DIAGNOSTIC_TEST|Circulating-mirna|A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
58432217|NCT03420833|DEVICE|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
58309206|NCT00881166|DRUG|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
58432218|NCT02906267|OTHER|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
58432219|NCT00534976|DRUG|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
57737410|NCT01921569|BEHAVIORAL|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
57737411|NCT01921569|OTHER|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
57737412|NCT01921569|OTHER|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
57953509|NCT00707070|DRUG|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
57953510|NCT03413280|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
57953511|NCT03413280|DRUG|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
57953512|NCT00390546|DRUG|Digoxin|
57953513|NCT00390546|DRUG|Propranolol|
58309207|NCT00881166|DRUG|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
58309208|NCT00881166|DRUG|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
58432220|NCT00534976|DRUG|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
58432221|NCT03797300|DEVICE|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
58432222|NCT01158391|DEVICE|NTrainer® Intervention|
58432223|NCT01158391|DEVICE|Control Intervention|
57737413|NCT05928598|BEHAVIORAL|Survey questionnaires|Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
57769577|NCT02179372|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
58309209|NCT00881166|DRUG|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
58309210|NCT00881166|DRUG|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
58309211|NCT05426785|DEVICE|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
58309212|NCT03880513|DIAGNOSTIC_TEST|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
58309213|NCT00243243|DRUG|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
58309214|NCT00243243|DRUG|Placebo|intravenous infusion of placebo (sterile water)
58309215|NCT01679743|DRUG|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
58432224|NCT00364143|DRUG|IHL-305 (irinotecan liposome injection)|
58432225|NCT05864937|OTHER|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
58432226|NCT06405477|DIETARY_SUPPLEMENT|L-arginine|Capsules of 3 grams of L-arginine per Dose
58432227|NCT06405477|DIETARY_SUPPLEMENT|Placebo|Capsules of 3 grams of maize Starch per Dose
58432228|NCT05532904|BEHAVIORAL|Personalized multidisciplinary day-hospital intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
58432229|NCT04059120|OTHER|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
58432230|NCT04059120|OTHER|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
58432231|NCT01805557|DRUG|R-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
58432232|NCT01805557|DRUG|BR-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
58432233|NCT02349685|PROCEDURE|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
58432234|NCT02349685|DRUG|14 day PBMT group|Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
58432235|NCT02349685|DRUG|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
58432236|NCT02292706|DRUG|Sofosbuvir|Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.
58432237|NCT02292706|DRUG|Ribavirin|
58432238|NCT02292706|DRUG|LDV/SOF|Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
58432239|NCT02292706|DRUG|SOF/VEL|Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
57953514|NCT04654494|PROCEDURE|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
58432240|NCT02292706|DRUG|SOF/VEL/VOX|Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
58432241|NCT02292706|DRUG|Other SOF-Based Regimen|"The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF"
58432242|NCT02292706|OTHER|Ineligible parent treatment|Participants were enrolled from ineligible parent treatment group.
58432243|NCT06253169|DIAGNOSTIC_TEST|HPV DNA self-test|HPV DNA swab from the cervix performed by the patient herself.
58432244|NCT05253781|DRUG|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
57953515|NCT04654494|PROCEDURE|Total colectomy|excision of the colon with preservation of the rectum
58432245|NCT05253781|OTHER|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
58432246|NCT01204216|BIOLOGICAL|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
58432247|NCT01204216|BIOLOGICAL|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
58432248|NCT01204216|BEHAVIORAL|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
58432249|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
58432250|NCT03147443|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
58102575|NCT04693182|OTHER|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
58432251|NCT03147443|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
58432252|NCT03147443|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
58432253|NCT01058629|DEVICE|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
58432254|NCT05688020|DRUG|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
58432255|NCT05688020|DRUG|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
57737414|NCT05928598|BEHAVIORAL|Epilepsy Visit Planner|"Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record."
58432256|NCT06437470|OTHER|blood flow restriction technique|"All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff."
58432257|NCT04132596|DEVICE|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
58432258|NCT04132596|OTHER|Activity Based Therapy|Physical therapy
58432259|NCT03004755|OTHER|Tissue Harvest|
57737415|NCT05928598|BEHAVIORAL|Questionnaires for Providers|Providers will be asked to complete a survey after the clinic visit for the intervention group.
58102576|NCT01514656|OTHER|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
58102577|NCT01514656|OTHER|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
58102578|NCT01514656|OTHER|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
58432260|NCT00496288|RADIATION|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
58432261|NCT03581838|BEHAVIORAL|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
58432262|NCT04078581|OTHER|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
58432263|NCT01100775|DRUG|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
58432264|NCT01100775|DRUG|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
58432265|NCT04223908|OTHER|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
58432266|NCT02300740|DIETARY_SUPPLEMENT|Nicotinamide riboside|NIAGEN, ChromaDex
58432267|NCT02445066|DIETARY_SUPPLEMENT|Vitamin D3|
58432268|NCT00442221|DRUG|Sumatriptan and Naproxen sodium|
58432269|NCT03700437|OTHER|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
58432270|NCT05930691|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
58432271|NCT06260306|OTHER|Hip activation home exercise program|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
58432272|NCT06260306|OTHER|Hip activation plus core stabilization home exercise program|The hip activation plus core stabilization HEP group will receive the same hip exercises, plus core stabilization exercises used by previous researchers. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
58432273|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
58432274|NCT03761342|BEHAVIORAL|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
58432275|NCT03761342|BEHAVIORAL|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
58432276|NCT05184816|DRUG|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
58432277|NCT01433094|BEHAVIORAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
58102579|NCT03208257|DRUG|Esmolol|Esmolol hydrochloride infusion
58102580|NCT02299674|OTHER|Level overground ambulation|
58432278|NCT01433094|BEHAVIORAL|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
58432279|NCT01303926|DRUG|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
58432280|NCT01303926|DRUG|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
58432281|NCT02685904|BIOLOGICAL|ENIA11|
58432282|NCT02685904|BIOLOGICAL|Placebo|
58432283|NCT01794676|GENETIC|Blood draw|Blood draw
58432284|NCT01620762|DRUG|Cat-PAD|1 dose every 4 weeks
58432285|NCT01620762|DRUG|Placebo|1 dose every 4 weeks
58432286|NCT00118950|DRUG|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
58432287|NCT00118950|DRUG|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
58432288|NCT00118950|DRUG|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
58432289|NCT00118950|DRUG|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
57953516|NCT04654494|PROCEDURE|Segmental colectomy|excision of a segment of colon
57953517|NCT04015453|PROCEDURE|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
58432290|NCT00118950|OTHER|Diet-only.|Diet-only treatment. Duration: One month.
58432291|NCT05196555|PROCEDURE|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
58432292|NCT05941832|DEVICE|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
58432293|NCT03588936|DRUG|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
58432294|NCT03588936|DRUG|Tocilizumab|Participants will receive 2 doses of tocilizumab
58432295|NCT03588936|DRUG|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
58432296|NCT05282433|DRUG|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
58432297|NCT04995861|PROCEDURE|Adductor canal block and IPACK block|Peripheral nerve blocks
58432298|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
58432299|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
58432300|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
58432301|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
58432302|NCT00532506|DRUG|SK-0403|
58432303|NCT03488277|OTHER|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
58432304|NCT02006849|DRUG|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
58432305|NCT00855972|DRUG|Low Dose Naltrexone|
58432306|NCT02036008|OTHER|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
58432307|NCT02036008|OTHER|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
58432308|NCT03992443|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
58102581|NCT05602233|OTHER|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
58102582|NCT05602233|OTHER|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
58102583|NCT05205668|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
58102584|NCT05205668|BIOLOGICAL|Placebo|Placebo administered intravenously
58102585|NCT00333073|DEVICE|Bulkamid|initial injection with option for second (if required)
58102586|NCT00627627|DRUG|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
58102587|NCT00991042|OTHER|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
58102588|NCT03506854|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
58102589|NCT00003061|DRUG|cytarabine|
58102590|NCT00003061|DRUG|methotrexate|
58102591|NCT00003061|RADIATION|radiation therapy|
58432309|NCT04090619|OTHER|Questionnaire Administration|Complete questionnaires
58432310|NCT04942405|BIOLOGICAL|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
58102592|NCT05741983|PROCEDURE|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
58102593|NCT05741983|DEVICE|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
58102594|NCT04048174|OTHER|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
58102595|NCT04048174|OTHER|Saline irrigation|Nasal and sinus irrigation with saline solution
58432311|NCT04942405|BIOLOGICAL|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
57737416|NCT04386096|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
58102596|NCT01808014|DRUG|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
58102597|NCT01485224|DRUG|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
58102598|NCT04252508|OTHER|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
58102599|NCT04113538|DRUG|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
58102600|NCT01392586|PROCEDURE|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
58102601|NCT01392586|OTHER|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
58432312|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
58432313|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
57953518|NCT02678481|DEVICE|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
57953519|NCT02678481|DEVICE|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
57953520|NCT01028664|DEVICE|SENSIMED Triggerfish|2-hour continuous IOP monitoring
57953521|NCT05648279|OTHER|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
57953522|NCT06044480|DRUG|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
57953523|NCT06044480|OTHER|Placebo|Administration of the same amount of saline solution instead of dexamethasone
57953524|NCT01755715|PROCEDURE|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
57953525|NCT03216473|DRUG|Neuronox|Clostridium Botulinum Toxin A 100 U
57953526|NCT03216473|DRUG|Botox|Clostridium Botulinum Toxin A 100 U
57953527|NCT03766048|PROCEDURE|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
57953528|NCT03766048|PROCEDURE|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
57953529|NCT01612260|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
57953530|NCT01612260|DRUG|placebo Capsule|4 granules t.i.d. po for 12 weeks
57953531|NCT00002000|DRUG|Valacyclovir hydrochloride|
57953532|NCT00002000|DRUG|Acyclovir|
57953533|NCT00893321|PROCEDURE|Inferior Oblique Muscle Recession and Myectomy|
57953534|NCT04391699|DEVICE|heated humidification|heated humidification system
57953535|NCT03569527|DIETARY_SUPPLEMENT|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
57953536|NCT03569527|DIETARY_SUPPLEMENT|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
57953537|NCT03569527|DIETARY_SUPPLEMENT|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
58102602|NCT03887819|DIAGNOSTIC_TEST|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
58102603|NCT01293409|OTHER|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
58432314|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
58432315|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
58432316|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
58102604|NCT06389565|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.
58102605|NCT06389565|OTHER|Change My Story|Change My Story is a narrative game with a choose-your-own-adventure format in which players navigate emotionally difficult experiences along with the character(s) and interact with the virtual environment to choose a narrative path toward the story's conclusion. It will used to address important obstacles in the mental health treatment gap for Y-PLWH.
58102606|NCT01600014|DRUG|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
58102607|NCT01600014|DRUG|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
58102608|NCT04373161|DEVICE|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen \<92% or for worsening symptoms.
58102609|NCT01626131|BEHAVIORAL|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
58102610|NCT01626131|BEHAVIORAL|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
58102611|NCT00593931|OTHER|fMRI|Functional Magnetic Resonance Imaging without contrast
58102612|NCT00884663|DRUG|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
58102613|NCT00884663|DRUG|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
58102614|NCT00884663|DRUG|placebo|placebo tablets and capsules
58102615|NCT00642031|DRUG|Triciribine|15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
58102616|NCT02197221|DRUG|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
58102617|NCT02197221|DRUG|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
58432317|NCT03997110|RADIATION|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
58432318|NCT03997110|RADIATION|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
58432319|NCT03800511|DIAGNOSTIC_TEST|sliding test|ultrasound detected sliding test before doing repeated caesarean section
58432320|NCT04957368|DRUG|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
58432321|NCT04957368|DRUG|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
58432322|NCT04085913|DRUG|Lidocaine Epinephrine|Preincision injection, as is current practice
58432323|NCT04085913|DRUG|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
57769578|NCT02179372|DIETARY_SUPPLEMENT|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
57769579|NCT00518128|PROCEDURE|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
57769580|NCT00518128|PROCEDURE|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
57953538|NCT00157976|DRUG|Photrex (rostaporfin)|
57953539|NCT03080909|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
58102618|NCT03797365|OTHER|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
58432324|NCT04085913|DRUG|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
58432325|NCT02683863|DRUG|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
58432326|NCT00119821|BEHAVIORAL|Weight Reducing Diet|Behavioral intervention
58432327|NCT00119821|BEHAVIORAL|Exercise|Moderate exercise implemented plus behavioral intervention.
58432328|NCT00119821|BEHAVIORAL|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
58432329|NCT03706183|DIAGNOSTIC_TEST|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
57953540|NCT03080909|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
58432330|NCT03706183|DIAGNOSTIC_TEST|Hearing thresholds|The hearing levels will be determined for each group.
58432331|NCT03640221|DRUG|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
58432332|NCT03640221|DRUG|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
57769581|NCT03792321|DRUG|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
57769582|NCT03792321|DRUG|Placebo|
57769583|NCT02851966|PROCEDURE|mTESE|mTESE time may be postponed or advanced.
57953541|NCT03760575|DRUG|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
57953542|NCT03760575|PROCEDURE|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
57953543|NCT03760575|DRUG|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
57953544|NCT03760575|DRUG|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
58102619|NCT03797365|BEHAVIORAL|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on...
58102620|NCT00908531|DRUG|letrozole (Femara)|tablet 2.5 mg daily
58102621|NCT03061773|OTHER|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
58102622|NCT03061773|BEHAVIORAL|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
58102623|NCT04685941|DRUG|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
58102624|NCT04685941|OTHER|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
58102625|NCT02761265|PROCEDURE|Surgical intervention|Surgery to correct spinal deformity
58102626|NCT02761265|OTHER|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
58102627|NCT04979065|DIETARY_SUPPLEMENT|Probiotics, Vitamin D|Combination of two supplement that given separately
58432333|NCT03640221|DEVICE|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively."
58432334|NCT03640221|OTHER|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
58102628|NCT04979065|OTHER|Placebo|Placebo with inactive ingredient
58102629|NCT04543305|DRUG|PRT1419|PRT1419 will be administered orally
58102630|NCT04754321|RADIATION|External Beam Radiation Therapy|Undergo EBRT
58102631|NCT04754321|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
58102632|NCT04754321|BIOLOGICAL|Pembrolizumab|Given IV
58102633|NCT04754321|OTHER|Quality-of-Life Assessment|Ancillary studies
58102634|NCT04754321|PROCEDURE|Salvage Surgery|Undergo salvage surgery
58102635|NCT02387307|DRUG|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
58102636|NCT05940688|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
58102637|NCT05940688|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
58102638|NCT05940688|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
58102639|NCT02622503|DRUG|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
58102640|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
58102641|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid|Ascorbic acid
58102642|NCT00045604|DRUG|cisplatin|
58102643|NCT00045604|DRUG|imatinib mesylate|
58102644|NCT00045604|DRUG|irinotecan hydrochloride|
58102645|NCT03822936|DRUG|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
58102646|NCT03822936|RADIATION|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
58102647|NCT05294198|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract capsule
57769584|NCT00127972|DRUG|stavudine|
58432335|NCT03640221|OTHER|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
58432336|NCT03640221|OTHER|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
58432337|NCT03640221|OTHER|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
58432338|NCT01183455|DRUG|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
58432339|NCT01183455|DRUG|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
58432340|NCT05768035|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
58432341|NCT05755802|PROCEDURE|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
58432342|NCT05755802|PROCEDURE|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
58432343|NCT03845959|DRUG|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
58432344|NCT03845959|DRUG|Placebo oral capsule|Placebo
58432345|NCT02317978|PROCEDURE|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
58432346|NCT02898298|BEHAVIORAL|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
58432347|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
58432348|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
58432349|NCT04380805|BIOLOGICAL|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
58432350|NCT00461461|PROCEDURE|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.~3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
58432351|NCT02807870|DRUG|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
58432352|NCT02807870|BEHAVIORAL|Parental training|Weekly parental training conducted by behavioral psychologists.
58432353|NCT02807870|OTHER|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
58432354|NCT02807870|DRUG|Placebo pill|Placebo pill during 8 weeks.
58432355|NCT05315089|OTHER|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
58432356|NCT05315089|OTHER|Conventional exercises|Conventional exercises
58432357|NCT05150938|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
57769585|NCT00127972|DRUG|lamivudine|
57769586|NCT00127972|DRUG|nevirapine|
57769587|NCT00127972|DRUG|efavirenz|
57769588|NCT00127972|DRUG|trizivir|
57769589|NCT01914809|OTHER|samples blood|
58102648|NCT00303381|DRUG|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
58102649|NCT00303381|DRUG|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
58432358|NCT05150938|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
58432359|NCT05150938|DRUG|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
58432360|NCT05150938|DRUG|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
57737417|NCT04386096|OTHER|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
58102650|NCT00303381|DRUG|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
58102651|NCT00667719|DRUG|Aliskiren|300 mg tablet
58102652|NCT00667719|DRUG|Amlodipine|5 mg tablet
58432361|NCT00659230|DRUG|Nepicastat|100-800mg
58432362|NCT00659230|DRUG|Placebo|100-800mg placebo
57769590|NCT01914809|OTHER|biopsy placentaire|
58432363|NCT04313114|BEHAVIORAL|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
58432364|NCT04313114|BEHAVIORAL|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
58458663|NCT01029496|PROCEDURE|different time of umbilical cord clamping|"1. for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~   control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~2. for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
58102653|NCT00667719|DRUG|Hydrochlorothiazide|12.5 mg and 25 mg capsule
58102654|NCT03503227|DRUG|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
58102655|NCT03503227|DRUG|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
58102656|NCT05350098|OTHER|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
58102657|NCT05350098|OTHER|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
58102658|NCT00952185|OTHER|cytology specimen collection procedure|
58102659|NCT00952185|OTHER|fluorescent antibody technique|
58102660|NCT00952185|PROCEDURE|assessment of therapy complications|
58102661|NCT02583178|DEVICE|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
58102662|NCT00316576|PROCEDURE|Blood sampling for PCR|
58102663|NCT03782584|OTHER|modified pilates exercise|modified exercises from original pilates exercises.
58102664|NCT03782584|OTHER|daily life advises|they will be given daily life advises to prevent neck pain
58432365|NCT04313114|BEHAVIORAL|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 \& 3 - follow-up will follow same procedure as year 1."
58432366|NCT00061633|DRUG|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
58102665|NCT01316588|OTHER|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
58432367|NCT00061633|DRUG|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
58102666|NCT01316588|OTHER|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
58432368|NCT03274518|DEVICE|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
58432369|NCT03274518|DEVICE|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
58432370|NCT04083157|BIOLOGICAL|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
58432371|NCT04083157|BIOLOGICAL|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
58432372|NCT03287362|BEHAVIORAL|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
58432373|NCT03287362|BEHAVIORAL|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
58432374|NCT03287362|BEHAVIORAL|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
58432375|NCT01873651|DEVICE|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
58432376|NCT03939936|OTHER|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
58432377|NCT03939936|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
58102667|NCT01070277|DRUG|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
58102668|NCT01070277|DRUG|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
58102669|NCT00116285|BIOLOGICAL|Ragweed MATA MPL|
58102670|NCT02118207|OTHER|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
58102671|NCT03666546|DRUG|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
58102672|NCT03666546|DRUG|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
58102673|NCT03666546|DRUG|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
58102674|NCT03666546|DRUG|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
58102675|NCT03666546|DRUG|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
58102676|NCT03666546|DRUG|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
58102677|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
58102678|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
57737418|NCT03960190|DEVICE|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
58432378|NCT03939936|OTHER|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
58432379|NCT01209078|DRUG|GSK1322322|GSK1322322 1500mg BID
58432380|NCT01209078|DRUG|Linezolid|Linezolid 600mg
58432381|NCT01209078|DRUG|GSK1322322 placebo|Placebo
58432382|NCT01209078|DRUG|Linezolid placebo|placebo
58432383|NCT00680797|DRUG|Testosterone|Testosterone gel
58432384|NCT00680797|DRUG|Estrogen|Estrogen patch
58432385|NCT06134843|COMBINATION_PRODUCT|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
58432386|NCT04417231|DEVICE|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
58432387|NCT00646399|DRUG|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
57737419|NCT04295226|OTHER|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
57737420|NCT00786929|PROCEDURE|Catheter drainage|
57953545|NCT05736900|DIAGNOSTIC_TEST|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
57953546|NCT03368170|DRUG|Mesdopetam (IRL790)|Mesdopetam (IRL790) capsule
57953547|NCT03791788|DIAGNOSTIC_TEST|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
57953548|NCT02305355|DRUG|Omega-3-acids ethylesters 90 4g|
57953549|NCT02305355|DRUG|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
57953550|NCT06188156|PROCEDURE|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
58432388|NCT00646399|DRUG|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
58432389|NCT03570801|OTHER|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
58432390|NCT02868047|PROCEDURE|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
57737421|NCT00786929|DRUG|Conservative treatment|
58432391|NCT01876693|PROCEDURE|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
58432392|NCT02130505|DIETARY_SUPPLEMENT|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
58432393|NCT05419726|DRUG|Semaglutide Injectable Product (not provided by the study)|"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
58432394|NCT01590654|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
58432395|NCT01590654|DRUG|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
58432396|NCT02353390|OTHER|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
58432397|NCT02624531|DRUG|Taxane|NACT and Fertility-sparing Treatment Strategy
58432398|NCT02624531|PROCEDURE|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
58432399|NCT00715767|BEHAVIORAL|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
58432400|NCT03479710|BIOLOGICAL|FMT infusion|Fecal microbiota transplantation via OGD
58432401|NCT01087216|DEVICE|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
58432402|NCT01087216|DRUG|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
58432403|NCT06388317|BEHAVIORAL|Adaptive Step Goal (Intervention)|Receiving automated personalized daily step goals,
58432404|NCT06388317|BEHAVIORAL|Static Step Goal (Control)|Receiving fixed daily step goals of 10,000 steps per day
58432405|NCT04569357|DRUG|Prospekta|Oral administration.
58432406|NCT04569357|DRUG|Placebo|Oral administration.
57737422|NCT03185611|DRUG|Rifaximin|Antibiotics
57737423|NCT03185611|DRUG|Azathioprine|immunomodulator
57953551|NCT05107856|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
58432407|NCT02372981|DEVICE|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
58432408|NCT03229941|PROCEDURE|Blood Transfusion|Blood Transfusion
57737424|NCT02504073|OTHER|No intervention|No intervention
57737425|NCT04981665|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
57737426|NCT04981665|DRUG|TACE|TACE will be performed after curative resection (4±1w)
57953552|NCT05107856|DRUG|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
58432409|NCT02606058|PROCEDURE|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
58432410|NCT04832880|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.
58432411|NCT04832880|DRUG|Remdesivir|Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
58432412|NCT04832880|DRUG|Dexamethasone|Intravenous dexamethasone 6 mg for 10 days
58432413|NCT02235545|DEVICE|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
58432414|NCT04248088|BEHAVIORAL|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
58432415|NCT01299116|DRUG|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
58432416|NCT01299116|DRUG|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
58432417|NCT01299116|DRUG|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
58432418|NCT01299116|DRUG|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
58432419|NCT01299116|DRUG|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
58432420|NCT00411632|DRUG|Bexarotene|400 mg/m\^2 by mouth daily x 28 Days
58432421|NCT00411632|DRUG|Erlotinib|150 mg by mouth daily x 28 Days
58432422|NCT01509911|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
58309216|NCT01679743|DRUG|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
58309217|NCT03721354|OTHER|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
57953553|NCT05107856|DRUG|Venetoclax|Venetoclax will be administered orally
57953554|NCT06297668|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.
57953555|NCT06297668|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
57953556|NCT06297668|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
57953557|NCT06297668|DEVICE|AeroChamber Plus Flow-Vu spacer|Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.
57953558|NCT04842201|DRUG|CM326|subcutaneous injection
57953559|NCT04842201|DRUG|Placebo|subcutaneous injection
57953560|NCT04893772|DIETARY_SUPPLEMENT|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
57953561|NCT00650910|DRUG|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
57953562|NCT00650910|DRUG|Digoxin|0.5mg on Days 1 and 9
57953563|NCT03031275|RADIATION|High-resolution computed tomography|HRCT of the thorax
57953564|NCT03031275|RADIATION|Magnetic resonance imaging|MRI of the brain
57953565|NCT03031275|BEHAVIORAL|Cognitive testing|Neuropsychological testing
57953566|NCT02463175|DRUG|Plasmalyte|Boluses of 5ml/kg of plasmalyte
57953567|NCT02463175|PROCEDURE|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
57953568|NCT04091633|BEHAVIORAL|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
57953569|NCT04091633|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
57953570|NCT06519786|DRUG|Metformin|Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
57953571|NCT01003496|BEHAVIORAL|Treatment as Usual (TAU)|Outpatient substance abuse treatment
57953572|NCT01003496|BEHAVIORAL|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
57953573|NCT00119535|BEHAVIORAL|Implementation of Proactive Diabetes Eye Care Program|
57953574|NCT04509778|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
57953575|NCT04636619|PROCEDURE|Colonic polypectomy|Cold snare resection of colorectal polyps
57953576|NCT04636619|BEHAVIORAL|Online training course|Polypectomy technique online course
58102679|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
58102680|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
58432423|NCT01509911|DRUG|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
58102681|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
58432424|NCT01211821|DRUG|metoprolol|Tablets, Oral, 200 mg, once, 1 day
58432425|NCT01211821|DRUG|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
58432426|NCT06457698|PROCEDURE|Double-puncture TMJ arthrocentesis under local anaesthesia|The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
58432427|NCT06329206|DRUG|GH2616 Tablets|GH2616 tablets will be given orally
58432428|NCT05037617|DRUG|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
58432429|NCT01454765|OTHER|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
58432430|NCT03468647|OTHER|soles|Volunteer must walk this this connected seamless to measure different walking parameters
58432431|NCT03468647|OTHER|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
58432432|NCT03468647|OTHER|gripping force|this machine measure the gripping force of volunteer
58432433|NCT02464722|DRUG|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
58432434|NCT02464722|DRUG|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
58432435|NCT02464722|DRUG|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
58432436|NCT02464722|DRUG|Propofol|Anesthesia was induced with propofol 2 mg kg-1
58432437|NCT02464722|DRUG|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
58432438|NCT02574689|BEHAVIORAL|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
57953577|NCT03031301|DEVICE|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
57953578|NCT03031301|DEVICE|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
57953579|NCT00005070|DRUG|irofulven|
57953580|NCT04839380|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
57953581|NCT05054972|PROCEDURE|Exclusion of the aortic aneurysm.|Surgical procedure in which an aortic aneurysm is excluded.
57953582|NCT05965284|DRUG|Azathioprine|All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
57953583|NCT05965284|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
57953584|NCT04840160|DIETARY_SUPPLEMENT|Cherry juice|A tart cherry juice intervention
58432439|NCT02574689|BEHAVIORAL|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
58432440|NCT00960479|DRUG|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
58432441|NCT00960479|DRUG|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
58432442|NCT00773747|DRUG|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
57737427|NCT03989466|BIOLOGICAL|Alemtuzumab|Given IV
57953585|NCT04840160|DIETARY_SUPPLEMENT|Placebo|A tart cherry juice placebo
57737428|NCT03989466|DRUG|Itacitinib|Given PO
57953586|NCT03629457|BEHAVIORAL|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
57953587|NCT01860924|BEHAVIORAL|exercise|vigorous intensity exercise
57953588|NCT01860924|BEHAVIORAL|health education|education
57953589|NCT04814251|OTHER|Observationnal cohort|data collection
57953590|NCT02550886|OTHER|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
58432443|NCT00773747|DRUG|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
58432444|NCT00773747|DRUG|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
58432445|NCT00367835|DRUG|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
58432446|NCT00367835|DRUG|Placebo|Placebo
58432447|NCT06246578|DEVICE|Continuos glucose monitoring and blood glucose measurement|The individuals who use Dexcom G 7 sensors for continous glucose monitoring is in addition applied a Libre 2 sensor and asked to wear both sensors for 14 days. In case of a Dexcom glucose value \< 5 mmol/l, the participants is aked to measure a blood glucose as well uising fingerprick and Contour Next One
58432448|NCT00005994|DRUG|ondansetron|
58432449|NCT01057563|DEVICE|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
58432450|NCT01057563|DEVICE|bare-metal stent (BMS)|BMS implantation
58432451|NCT01057563|DEVICE|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
58432452|NCT03803436|PROCEDURE|Liver transplant|Liver transplant from cadaveric donors
58432453|NCT03803436|DRUG|Chemotherapy|mFOLFOX
58432454|NCT03803436|DRUG|Chemotherapy|Panitumumab
58432455|NCT02728388|DRUG|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
58432456|NCT01281033|PROCEDURE|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
58432457|NCT01281033|PROCEDURE|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
57953591|NCT04925609|DRUG|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
57953592|NCT06430281|OTHER|Manual therapy|A manual force will be applied to a manikin positioned on a chiropractic treatment table. The force exerted during the manual therapy must align with the trial label indicated on the Manual Therapy Force Perception \[MTFP\] scale.
58432458|NCT00802893|DRUG|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
58432459|NCT00802893|OTHER|Placebo|placebo given BID for entire length of study
58432460|NCT02516592|DRUG|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
58432461|NCT02516592|DRUG|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
58432462|NCT03458689|PROCEDURE|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
58432463|NCT03875664|DRUG|Liposomal bupivacaine|Extended-release local anesthetic
58432464|NCT03875664|DRUG|Placebo - injection|Injectable normal saline solution
58432465|NCT05492357|OTHER|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
58432466|NCT05492357|OTHER|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
58432467|NCT02172404|DEVICE|Placebo capsule administered via the HandiHaler®|
58432468|NCT02172404|DEVICE|Ipratropium metered dose inhaler (MDI)|
58432469|NCT05612425|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
58432470|NCT05612425|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
58432471|NCT02376803|DRUG|Warfarin|Morning vs Evening administration
58432472|NCT00383942|DRUG|Misoprostol|Misoprostol,25 micrograms every 4 hours.
58432473|NCT00383942|DEVICE|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
58432474|NCT01636128|DRUG|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
58432475|NCT01636128|DRUG|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
58432476|NCT01853878|BIOLOGICAL|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
58432477|NCT01853878|BIOLOGICAL|Placebo|Intramuscular administration
57737429|NCT06636357|DRUG|50% N2O plus 50% O2|Inhalation of 50% N2O plus 50% O2 for 45 min
57953593|NCT04248439|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
58309218|NCT02026349|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
57737430|NCT06636357|DRUG|Oxygen (O2)|50% O2 plus 50% air for 45 min
57737431|NCT00389558|PROCEDURE|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
57737432|NCT00389558|PROCEDURE|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
57769591|NCT05619510|BEHAVIORAL|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
57953594|NCT04295161|DRUG|Abiraterone Acetate|Abiraterone acetate immediate release formulations
57953595|NCT00811135|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
58309219|NCT02026349|DRUG|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
58309220|NCT01712178|BIOLOGICAL|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
58309221|NCT01712178|BIOLOGICAL|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
58102682|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
58102683|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
58102684|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
58102685|NCT00913471|OTHER|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
58102686|NCT04446819|DEVICE|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
58102687|NCT05448768|DEVICE|TBS for Amyloid-positive MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
58102688|NCT05448768|DEVICE|TBS for Amyloid-negative MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
58102689|NCT00918229|DEVICE|balloon implant|Absorbable perirectal spacer implantation
58102690|NCT00918229|PROCEDURE|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
58102691|NCT05115331|RADIATION|Experimental Radiation Dose|16 Gy in 2 fractions
58102692|NCT05115331|RADIATION|Conventional Radiation Dose|8 Gy in a single fraction
58102693|NCT04901871|DRUG|0.02 mg/kg, age<65|Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
58102694|NCT04901871|DRUG|0.07 mg/kg, age<65|Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
58102695|NCT04901871|DRUG|0.12 mg/kg, age<65|Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
58102696|NCT04901871|DRUG|0.17 mg/kg, age<65|Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
58102697|NCT04901871|DRUG|0.22 mg/kg, age<65|Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
58102698|NCT04901871|DRUG|0.27 mg/kg, age<65|Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
58102699|NCT04901871|DRUG|0.02 mg/kg, age≥65|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
58102700|NCT04901871|DRUG|0.07 mg/kg, age≥65|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
58102701|NCT04901871|DRUG|0.12 mg/kg, age≥65|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
58102702|NCT04901871|DRUG|0.17 mg/kg, age≥65|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
58102703|NCT04901871|DRUG|0.22 mg/kg, age≥65|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
58102704|NCT04901871|DRUG|0.27 mg/kg, age≥65|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
58102705|NCT04496882|DRUG|Vemlidy|25mg Tenofovir Alafenamide
58102706|NCT01834573|BEHAVIORAL|physical exercise|10 weeks physical exercise; three times a week
58102707|NCT06567093|OTHER|Baby Foot and Leg Massage|"Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down."
58102708|NCT00973037|DRUG|Tamoxifen|Tamoxifen 20mg qd
58102709|NCT03527537|DRUG|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
58102710|NCT04810507|DRUG|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
58102711|NCT03168269|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
58102712|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM)|
58102713|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).|
57769592|NCT00005788|BIOLOGICAL|aldesleukin|
58102714|NCT01589029|DRUG|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
58102715|NCT00618631|DRUG|Nicotine|
58102716|NCT00618631|DRUG|Carfentanil|
58102717|NCT04603079|BEHAVIORAL|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q\&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
58102718|NCT06007573|DRUG|The control group received oral nimodipine tablets|The control group received oral nimodipine tablets
58102719|NCT04951973|DIAGNOSTIC_TEST|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
58102720|NCT02915588|OTHER|early isometric loading after rotator cuff surgery|
58102721|NCT02915588|OTHER|passive motion after rotator cuff surgery|
58102722|NCT04175873|OTHER|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
58432478|NCT00372697|DRUG|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
58102723|NCT05970809|DEVICE|SAGA-001 (A)|Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
58102724|NCT05970809|DEVICE|SAGA-001 (B)|Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
58102725|NCT05154188|DEVICE|Neuro Cochlear Implant system|Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose
58102726|NCT02253654|DRUG|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
58102727|NCT04765852|OTHER|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
58102728|NCT04765852|OTHER|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
58432479|NCT03413709|OTHER|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
58432480|NCT05808413|BEHAVIORAL|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
58458664|NCT00936234|DRUG|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
58102729|NCT04765852|OTHER|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
58102730|NCT02595528|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
58102731|NCT02595528|DRUG|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
58102732|NCT02595528|DRUG|AGN-190584 vehicle|Vehicle to AGN-190584
58102733|NCT02595528|DRUG|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
58102734|NCT02595528|DRUG|AGN-199201 vehicle|Vehicle to AGN-199201
58102735|NCT05663931|OTHER|DM Discharge Toolkit|"The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content."
58102736|NCT03933839|BEHAVIORAL|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
58102737|NCT01268319|DEVICE|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
58102738|NCT01268319|DEVICE|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
57953596|NCT00811135|DRUG|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
58309222|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
57737433|NCT02967185|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
57953597|NCT00811135|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
57953598|NCT02188875|BEHAVIORAL|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
57953599|NCT02188875|BEHAVIORAL|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
58309223|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
58309224|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
58432481|NCT05808413|BEHAVIORAL|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
58432482|NCT05808413|BEHAVIORAL|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
58432483|NCT02364934|DRUG|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
58432484|NCT02364934|DRUG|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
58432485|NCT06136065|DIAGNOSTIC_TEST|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
58432486|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
58432487|NCT05124132|BEHAVIORAL|Exercise|Exercise
58432488|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
57953600|NCT02079571|DIETARY_SUPPLEMENT|Coconut water|250 ml Coconut water for each subject
57953601|NCT02079571|DIETARY_SUPPLEMENT|ginger tea|250 ml for each subject
57962055|NCT01408147|BEHAVIORAL|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
57962056|NCT01442883|DEVICE|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
57962057|NCT02077088|OTHER|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
57962058|NCT04239625|DRUG|ALK-001|Oral administration of a pill for up to 24 months
57962059|NCT02270203|RADIATION|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
57962060|NCT02956161|DEVICE|Stimulation of up-phase of sleep slow oscillation|
57962061|NCT02956161|DEVICE|Random stimulation of up phase of sleep slow oscillation|
57962062|NCT02956161|DEVICE|No stimulation|
57962063|NCT04206449|OTHER|Therapeutic decision PSG|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
57962064|NCT04206449|OTHER|Therapeutic decision Infrared thermgraphy system|Also randomizing for Infrared thermography system
57962065|NCT00009971|DRUG|fenretinide|
57962066|NCT03978559|DRUG|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
57962067|NCT03978559|DRUG|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
57962068|NCT03978559|DRUG|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
57962069|NCT00704964|BIOLOGICAL|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
57962070|NCT00704964|DRUG|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
57962071|NCT01864278|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
57962072|NCT01555203|BEHAVIORAL|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
58102739|NCT01268319|DEVICE|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
58102740|NCT02522754|BIOLOGICAL|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
58102741|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
58102742|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
58309225|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
57953602|NCT01671852|DRUG|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
57953603|NCT01671852|DRUG|Placebo|
57953604|NCT05213377|PROCEDURE|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
57953605|NCT01632514|DRUG|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
57953606|NCT01677806|PROCEDURE|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
57953607|NCT01677806|OTHER|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
57953608|NCT03739632|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
57953609|NCT03739632|OTHER|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
57953610|NCT04643951|BEHAVIORAL|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
57953611|NCT03398577|DRUG|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
57953612|NCT03398577|DRUG|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
57953613|NCT03361397|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
57953614|NCT03361397|DRUG|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
57953615|NCT04990466|DRUG|IIBR-100|Administration of IIBR-100 vaccine
57953616|NCT04990466|DRUG|Active Comparator|Administration of a currently-approved vaccine for COVID-19
57953617|NCT03002155|OTHER|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
57953618|NCT06078969|DRUG|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
57953619|NCT00481650|DRUG|Leios/Alesse|
57953620|NCT02007174|DRUG|Bevacizumab|
57953621|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
57953622|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
57953623|NCT02007174|PROCEDURE|Argon laser treatment|
57953624|NCT00719927|BEHAVIORAL|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
57953625|NCT06264895|BEHAVIORAL|Exercise|three times weekly exercise intervention with protein supplementation
57953626|NCT01816009|OTHER|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
57953627|NCT06017596|DEVICE|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
57953628|NCT04778098|OTHER|Received SMS reminder|telenursing
57953629|NCT03576937|DIAGNOSTIC_TEST|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
57953630|NCT01676714|DRUG|Dovitinib|
58102743|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
58102744|NCT05177237|DRUG|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
58102745|NCT04895228|PROCEDURE|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
58102746|NCT00000773|DRUG|Atovaquone|
58102747|NCT02123069|DEVICE|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
58102748|NCT02123069|DRUG|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
58309226|NCT02860052|DRUG|SB208 2%|Apply once daily to one or both feet for 14 days
58432489|NCT05124132|BEHAVIORAL|Health Education|Health Education
58102749|NCT02123069|DRUG|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
58102750|NCT02123069|DRUG|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
57737434|NCT04672551|BEHAVIORAL|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
58102751|NCT02123069|DRUG|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
58102752|NCT00783562|OTHER|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
58102753|NCT00783562|OTHER|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
58102754|NCT00089115|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
58102755|NCT00089115|BIOLOGICAL|rituximab|
58102756|NCT00089115|BIOLOGICAL|sargramostim|
58102757|NCT06284707|OTHER|swimming training|2 sessions per week of swimming training
58102758|NCT06284707|OTHER|rhythmic gymnastics training|2 training sessions of rhythmic gymnastics
58102759|NCT02897453|DEVICE|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
58102760|NCT05165433|BIOLOGICAL|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion
58102761|NCT04445129|DEVICE|Portable EEG Device|Portable EEG device is lightweight and designed for nighttime wear.
58102762|NCT04445129|DEVICE|Portable ECG Device|Portable ECG device is waterproof and will be adhered to the chest of the participant.
58102763|NCT04445129|DEVICE|Accelerometry|Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
58102764|NCT00787670|OTHER|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
58309227|NCT02860052|DRUG|SB208 4%|Apply once daily to one or both feet for 14 days
57737435|NCT00788996|BEHAVIORAL|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
57737436|NCT04567537|DEVICE|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
57737437|NCT04916223|OTHER|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
57737438|NCT06267053|DIAGNOSTIC_TEST|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
58102765|NCT00787670|PROCEDURE|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
58102766|NCT00787670|OTHER|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
58102767|NCT05001399|BEHAVIORAL|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
58102768|NCT02688309|DRUG|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
58309228|NCT02860052|DRUG|SB208 16%|Apply once daily to one or both feet for 14 days
58309229|NCT02860052|DRUG|Vehicle Gel|Apply once daily to one or both feet for 14 days
58432490|NCT05417087|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
58432491|NCT05417087|DRUG|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
58432492|NCT02370797|RADIATION|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
58432493|NCT02651220|DRUG|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
58432494|NCT02651220|DRUG|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
58432495|NCT02651220|DRUG|placebo gel|vehicle used as placebo
58432496|NCT02831517|DRUG|BIIB074|Administered as specified in the treatment arm
57737439|NCT06267053|DIAGNOSTIC_TEST|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
58432497|NCT02831517|DRUG|Placebo|Matched Placebo
58432498|NCT05933343|PROCEDURE|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
58432499|NCT05933343|PROCEDURE|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
58432500|NCT04897763|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
58432501|NCT04438291|OTHER|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
58432502|NCT04438291|OTHER|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
58432503|NCT02358226|BEHAVIORAL|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
58432504|NCT02358226|BEHAVIORAL|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
58432505|NCT04292743|BIOLOGICAL|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
58432506|NCT04292743|DRUG|FOLFIRINOX|intravenous administration of FOLFIRINOX
57737440|NCT06267053|DIAGNOSTIC_TEST|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
57737441|NCT06267053|DIAGNOSTIC_TEST|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
57953631|NCT03851900|OTHER|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
58432507|NCT03028935|BEHAVIORAL|Exercise Intervention|Undergo instructor-led exercise program
58432508|NCT03028935|BEHAVIORAL|Nutritional Intervention|Undergo instructor-led nutritional education program
57953632|NCT03851900|OTHER|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
57953633|NCT03851900|OTHER|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
57962073|NCT01157039|DIETARY_SUPPLEMENT|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
57962074|NCT03433170|PROCEDURE|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
58432509|NCT01447186|BEHAVIORAL|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
58432510|NCT01447186|BEHAVIORAL|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
58432511|NCT01447186|BEHAVIORAL|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
57962075|NCT03433170|PROCEDURE|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
58432512|NCT04840329|BEHAVIORAL|Education|One-time educational session about menstrual health and endometriosis
58432513|NCT06393023|DEVICE|Continuous Positive Airway Pressure|Although this study is designed as an observational cohort study, where patients were not assigned to intervention or non-intervention groups, there is still an intervention project indicator present in the observational cohort. The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
58432514|NCT04091295|DRUG|DeltaRex-G|Intravenous infusions of DeltaRex-G for treatment of advanced pancreatic cancer and sarcoma that have failed standard therapies
58432515|NCT04751877|DRUG|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
58432516|NCT04751877|DRUG|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
58432517|NCT04751877|DRUG|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
58432518|NCT04751877|DRUG|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
58432519|NCT03064919|BEHAVIORAL|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
58432520|NCT03156374|DEVICE|Test use|Use of home ovulation test to predict ovulation
58432521|NCT03153995|PROCEDURE|soft tissue expansion|"Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months"
58432522|NCT03190460|OTHER|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
57953634|NCT01974544|DRUG|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
58432523|NCT03190460|OTHER|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
58432524|NCT04887896|DEVICE|GS500|Device: GS500
58432525|NCT04887896|DEVICE|Placebo|Device: Placebo
58432526|NCT02697435|OTHER|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
58432527|NCT02697435|OTHER|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
58432528|NCT05435417|RADIATION|CBCT radiation|CBCT scanning
58432529|NCT04036500|DRUG|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
58432530|NCT00615030|DRUG|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
58432531|NCT00615030|DRUG|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
58432532|NCT00615030|DRUG|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
58432533|NCT00615030|DRUG|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
58432534|NCT01891474|DEVICE|U-health care|voice inception technique based U-healthcare service
58432535|NCT03043651|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
58432536|NCT05963997|DRUG|Samuraciclib|Samuraciclib capsules by mouth once a day
58432537|NCT05963997|DRUG|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
58432538|NCT00820716|OTHER|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
58432539|NCT06128603|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
58432540|NCT02106494|DRUG|APF530|
58432541|NCT02106494|DRUG|Ondansetron|
58432542|NCT02106494|DRUG|Ondansetron placebo|
58432543|NCT02106494|DRUG|APF530 placebo|
58432544|NCT02106494|DRUG|Fosaprepitant|
58432545|NCT02106494|DRUG|Dexamethasone|
58432546|NCT06321770|DIETARY_SUPPLEMENT|Bioactive collagen peptides|2,5 g collagen peptides
58432547|NCT06321770|DIETARY_SUPPLEMENT|Placebo|Placebo sachet daily
58432548|NCT02541734|DRUG|Gelofusine|Infusion of gelofusine
58432549|NCT02541734|RADIATION|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
58432550|NCT02541734|DRUG|Placebo|
58432551|NCT04522349|DEVICE|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
57737442|NCT04223180|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
58432552|NCT04522349|DEVICE|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
58432553|NCT01906528|DRUG|Mivacurium|Effect of Mivacurium in males vs females
58432554|NCT05541445|DRUG|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
58432555|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
58432556|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
58432557|NCT02620488|BEHAVIORAL|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
58432558|NCT03779581|OTHER|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
58432559|NCT03779581|DEVICE|orthotic devices|the orthotic devices designed to correct the scoliosis curve
58432560|NCT00003354|PROCEDURE|conventional surgery|
57737443|NCT02293629|DRUG|BMS-986147|
57737444|NCT02293629|DRUG|Placebo matching BMS-986147|
57737445|NCT04396834|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
57737446|NCT04396834|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
57737447|NCT05629351|OTHER|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
57953635|NCT01974544|PROCEDURE|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
57953636|NCT01974544|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
57962076|NCT05599490|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
57962077|NCT01781494|PROCEDURE|Immobilization followed by protected range of motion|
57962078|NCT01781494|PROCEDURE|Immediate range of motion|
57962079|NCT01526668|BEHAVIORAL|Follow-up strategy|Comparison of different follow-up strategies
58432561|NCT00003354|PROCEDURE|laparoscopic surgery|
58432562|NCT02755896|RADIATION|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
58432563|NCT02755896|RADIATION|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
58432564|NCT05100446|DRUG|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
58432565|NCT05100446|DRUG|Pylera|Eradication with Pylera, for 10 days.
57962080|NCT01526668|BEHAVIORAL|No contact after discharge|
57962081|NCT02911428|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
58432566|NCT05100446|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
58432567|NCT04897178|DIAGNOSTIC_TEST|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
58432568|NCT04129892|BEHAVIORAL|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
58432569|NCT04305561|PROCEDURE|Contrast-enhanced ultrasound|"Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma)."
58432570|NCT03052049|DEVICE|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
58432571|NCT04918732|DIAGNOSTIC_TEST|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
58432572|NCT05393973|OTHER|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
58432573|NCT05393973|OTHER|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
58432574|NCT03970291|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
58432575|NCT01513122|DRUG|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
58432576|NCT01513122|DRUG|2-3N(t)RTI|
58432577|NCT01513122|DRUG|raltegravir|raltegravir 400mg 1 tablet twice daily.
58432578|NCT06572852|OTHER|No intervention|No intervention
57962082|NCT00717600|DIETARY_SUPPLEMENT|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
57962083|NCT04025827|OTHER|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
57962084|NCT04583371|OTHER|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
57962085|NCT06287034|PROCEDURE|Primary suture|The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
57962086|NCT03742037|DRUG|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
57962087|NCT03742037|DRUG|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
57962088|NCT03742037|DRUG|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
57962089|NCT03742037|DRUG|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
57962090|NCT03742037|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
57962091|NCT03742037|DRUG|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
57962092|NCT05154695|DEVICE|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
57962093|NCT05154695|DEVICE|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
57962094|NCT05154695|DRUG|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
57962095|NCT01887977|OTHER|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
57962096|NCT02297802|DRUG|PD-0325901|
58432579|NCT00082199|DRUG|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
58432580|NCT00082199|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks.
58432581|NCT00320424|DRUG|Fondaparinux|
58432582|NCT05768984|OTHER|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
58432583|NCT00724633|OTHER|Lowering the dialysate sodium|Please see above
58432584|NCT06551259|DRUG|Dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
58432585|NCT06551259|DRUG|physiological saline|physiological saline
58432586|NCT03549715|DRUG|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
58432587|NCT03549715|DRUG|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
58432588|NCT03549715|DRUG|MVAC Protocol|"1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1"
58432589|NCT01962870|DRUG|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
58432590|NCT01962870|DRUG|Placebo|
58432591|NCT01805037|DRUG|brentuximab vedotin|Given IV
58432592|NCT01805037|BIOLOGICAL|rituximab|Given IV
58432593|NCT01805037|OTHER|laboratory biomarker analysis|Correlative studies
58432594|NCT00999518|BIOLOGICAL|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
58432595|NCT00999518|BIOLOGICAL|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
58432596|NCT00999518|BIOLOGICAL|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
58432597|NCT00999518|BIOLOGICAL|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
58432598|NCT00999518|OTHER|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
58432599|NCT00001317|DRUG|interferon-gamma|
57737448|NCT06052449|BEHAVIORAL|Social determinants of health screening assessment and referral process|Unite Us is an electronic SDoH screening and referral tool assessing: (1) financial resource strain; (2) housing stability; (3) transportation needs; and (4) food insecurity. Upon completion, the Unite Us platform identifies a list of geographically-tailored resources to connect the individual in need. A staff member will administer the SDoH screening and referral tool, review the results with the participant, and use the geographically-tailored resources to make SDoH-related referrals.
57962097|NCT00563342|DRUG|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
58432600|NCT05887531|OTHER|Prehabilitation|Patients will be included in a prehabilitation program
58432601|NCT05133661|DIAGNOSTIC_TEST|HPV testing|Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.
58432602|NCT06101277|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
58432603|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
58432604|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
58432605|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
58432606|NCT03771274|DEVICE|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
58432607|NCT02283788|DRUG|BIA 2-093|
58432608|NCT02283788|DRUG|Moxifloxacin|
58432609|NCT02283788|DRUG|Placebo|
57962098|NCT00417586|DEVICE|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
57962099|NCT04421274|BIOLOGICAL|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
57962100|NCT04421274|DRUG|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
57962101|NCT04421274|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
57962102|NCT01091701|BIOLOGICAL|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
57962103|NCT01091701|OTHER|Plasmalyte-A|Single IV dose of Plasmalyte-A
57962104|NCT03609307|DRUG|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
57962105|NCT03609307|DRUG|Intravitreal bevacizumab|these patients receive only Bevacizumab
57962106|NCT05877976|BEHAVIORAL|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
57962107|NCT04762628|DIETARY_SUPPLEMENT|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
57962108|NCT04762628|DIETARY_SUPPLEMENT|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
57962109|NCT04762628|OTHER|Standard of care|Standard of care
57962110|NCT02962050|PROCEDURE|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
58432610|NCT02971553|DEVICE|Upright Resuscitator with PEEP|
58102769|NCT02688309|PROCEDURE|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
58432611|NCT02971553|DEVICE|Upright Resuscitator|
58432612|NCT02764684|DRUG|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
57737449|NCT06052449|BEHAVIORAL|Current practice - Community-based lunch cancer screening (LungTalk)|The current practice during community events is to offer LungTalk. LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled LCS knowledge and health beliefs (p \< 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% Confidence Interval (CI), 1.03, 3.85, p = 0.03.
58432613|NCT04119011|BIOLOGICAL|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
58432614|NCT04119011|OTHER|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
58432615|NCT00924443|DRUG|clofarabine|
57737450|NCT00342862|DRUG|Amevive exposure|Observational
58432616|NCT02690649|OTHER|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
58432617|NCT03934853|DEVICE|Dynamic Dental Navigation|Aid in dental implant placement in humans
58432618|NCT04856904|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
57737451|NCT03182868|DEVICE|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
57737452|NCT01475136|DRUG|LY2140023|
58432619|NCT04856904|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
58432620|NCT02409719|OTHER|Schedule|Illustrative daily planner to point the day that the exercise was performed
58432621|NCT02409719|OTHER|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
57737453|NCT05634395|DEVICE|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
57737454|NCT05244473|DRUG|brentuximab vedotin|Given into the vein (IV; intravenously)
57737455|NCT05244473|DRUG|Placebo|Given by IV
58432622|NCT02021630|OTHER|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
58432623|NCT00719888|DRUG|Cyclophosphamide|Given IV
58432624|NCT00719888|DRUG|Cyclosporine|Given IV and PO
58432625|NCT00719888|PROCEDURE|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
58432626|NCT00719888|DRUG|Fludarabine|Given IV
58432627|NCT00719888|OTHER|Laboratory Biomarker Analysis|Correlative studies
58432628|NCT00719888|DRUG|Mycophenolate Mofetil|Given IV and PO
58432629|NCT00719888|RADIATION|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
58432630|NCT00719888|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
58432631|NCT00719888|DRUG|Thiotepa|Given IV
57953637|NCT01974544|DRUG|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
58432632|NCT06303063|DEVICE|SINOMED IAS Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
58432633|NCT06303063|DEVICE|Neuroform Atlas Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
58432634|NCT00166530|DRUG|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
58432635|NCT00166530|DRUG|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
58432636|NCT00166530|DRUG|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
58432637|NCT02583555|BEHAVIORAL|Interview followed by frequent telephone support|Interview followed by telephone support
58432638|NCT00644436|DEVICE|Tetrix|single topical application
58432639|NCT00644436|DEVICE|Tetrix|Single topical application
58432640|NCT03869606|DEVICE|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
58432641|NCT04870372|DRUG|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
58432642|NCT02261766|DEVICE|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
58432643|NCT06414577|DRUG|Irinotecan Liposomal combined With Nituzumab|Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
58432644|NCT02346617|BIOLOGICAL|IFN-γ positive selected T-cells|No intervention
58432645|NCT00966550|OTHER|Tomato|Tomato with high carb/fat meal
58432646|NCT00966550|OTHER|Non-tomato|Non-tomato with high carb/fat meal
58432647|NCT03229733|DEVICE|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
58432648|NCT03229733|BEHAVIORAL|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
58432649|NCT03068767|DIETARY_SUPPLEMENT|Vitamin D|
58432650|NCT03138161|DRUG|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
58432651|NCT03138161|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
58432652|NCT03138161|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
58432653|NCT01647776|OTHER|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
58432654|NCT01647776|PROCEDURE|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
58432655|NCT01647776|OTHER|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
57737456|NCT05244473|DRUG|ART|Daily use of a combination of HIV medicines
57953638|NCT01974544|DRUG|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
58432656|NCT02333786|OTHER|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
58432657|NCT02333786|OTHER|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
58432658|NCT05870878|OTHER|Standard care|Individual lifestyle consultation
58432659|NCT05870878|OTHER|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
58432660|NCT06351254|PROCEDURE|Sine sound waves|Group A 8 participants will be given sine sound waves treatment with the frequency of 80 pulses on C1 vertebrae. Treatment session will be 6 session 3 times a week followed by 6 sessions 2 times a week.
58432661|NCT06351254|PROCEDURE|Kinesthetic exercises|Kinesthetic exercises was conducted for GROUP 2 8 patients for 6 weeks. Before and after assessment was taken to track patient progress. Cervicocephalic kinesthetic sensibility tests were performed. The first test was Head-to-Neutral Head Position(NHP) repositioning test. In the second repositioning test is Head-toTarget repositioning tests.
58432662|NCT06351254|PROCEDURE|Sine sound waves plus kinesthetic exercises|Group C 8 was given combine treatment of sine sound waves and kinesthetic exercises before and after measurement was taken.
58432663|NCT06315127|DIETARY_SUPPLEMENT|Human donor milk|The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.
58432664|NCT06315127|DIETARY_SUPPLEMENT|Formula|The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
58432665|NCT01091012|DRUG|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
58432666|NCT01024842|BIOLOGICAL|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.
58432667|NCT01024842|OTHER|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
58432668|NCT01024842|BIOLOGICAL|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.
58432669|NCT01024842|OTHER|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
58432670|NCT01829022|PROCEDURE|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
58432671|NCT04185389|OTHER|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
58432672|NCT01630889|DRUG|Roxadustat|Oral capsule
58432673|NCT04433065|DEVICE|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
58432674|NCT01401608|DEVICE|RF Ablation|Ablation of arrhythmogenic ventricular tissue
58432675|NCT04988009|OTHER|Electronic Health Record Review|Review of medical chart
58432676|NCT04988009|OTHER|Survey Administration|Complete survey
58432677|NCT02122367|OTHER|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
58102770|NCT02688309|PROCEDURE|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
58102771|NCT00844727|DRUG|Rofecoxib|
58102772|NCT00844727|DRUG|placebo|placebo pills
58102773|NCT05532046|DRUG|BAY2413555 Dose 1|BAY2413555 Dose 1
58102774|NCT05532046|DRUG|BAY2413555 Dose 2|BAY2413555 Dose 2
58102775|NCT05532046|DRUG|Placebo to BAY2413555|Placebo to BAY2413555
58102776|NCT01631370|PROCEDURE|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
58102777|NCT03433807|DRUG|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
58432678|NCT01054625|BIOLOGICAL|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
58432679|NCT01622777|DRUG|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
58432680|NCT01622777|DRUG|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
58102778|NCT00508235|BEHAVIORAL|Questionnaire|Questionnaire about the patient's relationship with their best friend.
58432681|NCT04356716|DRUG|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
58432682|NCT04356716|OTHER|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
58432683|NCT04356716|DIAGNOSTIC_TEST|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
58432684|NCT04356716|OTHER|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
58432685|NCT05880498|BEHAVIORAL|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
58432686|NCT00004689|DRUG|amithiozone|
58432687|NCT00004689|DRUG|clarithromycin|
58432688|NCT00004689|DRUG|ethambutol|
58432689|NCT00004689|DRUG|rifampin|
58102779|NCT03362528|DEVICE|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
58102780|NCT05269017|DRUG|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
58102781|NCT05269017|DRUG|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
58432690|NCT00004689|DRUG|streptomycin|
58432691|NCT06232785|DRUG|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
58432692|NCT06232785|DRUG|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
58432693|NCT02220426|DRUG|Xenon|Inhalation of hyperpolarized xenon gas
58432694|NCT05236244|OTHER|İntervention group|Diaphragmatic Breathing Exercises
58432695|NCT04112394|OTHER|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
58432696|NCT04112394|OTHER|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
58432697|NCT00692419|BEHAVIORAL|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
58432698|NCT00692419|BEHAVIORAL|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
58432699|NCT05526339|DEVICE|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
58432700|NCT05526339|DEVICE|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
58432701|NCT02978950|OTHER|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
58432702|NCT02978950|OTHER|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
58432703|NCT02919527|OTHER|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
58432704|NCT02919527|OTHER|Stretching|Static Stretching performed at the anterior thigh
58102782|NCT04667273|PROCEDURE|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
58102783|NCT04667273|PROCEDURE|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
58432705|NCT02673684|DEVICE|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
58432706|NCT02673684|DEVICE|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
58432707|NCT03997825|DEVICE|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
58432708|NCT05795153|DRUG|LOU064|LOU064 (Open-Label) taken orally for 12 weeks
58432709|NCT06121024|PROCEDURE|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
58432710|NCT04816058|BEHAVIORAL|Determining the level of ankle instability|Ankle instability
58432711|NCT04870918|BEHAVIORAL|self-care intervention|Health education will be carried out by the nurse.
58432712|NCT00839761|DIETARY_SUPPLEMENT|iron fortified rice|
58432713|NCT00839761|DIETARY_SUPPLEMENT|iron drops|
57737457|NCT01022437|OTHER|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
57737458|NCT02271958|DRUG|Mifepristone|
57737459|NCT02271958|DRUG|PLACEBO|
57737460|NCT03398005|DRUG|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
57737461|NCT03398005|DRUG|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
58309230|NCT03980119|OTHER|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
57737462|NCT04051372|DIAGNOSTIC_TEST|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS"
57737463|NCT00000392|DRUG|Peptide T|
57737464|NCT00000392|DRUG|Placebo|
57737465|NCT06219759|OTHER|Observational study|Observational study.
57962111|NCT02962050|DEVICE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
57962112|NCT02962050|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
57962113|NCT02962050|DRUG|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
57962114|NCT02962050|DEVICE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
57962115|NCT02962050|OTHER|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
57962116|NCT02962050|OTHER|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
57962117|NCT04789486|DRUG|AGuIX|Injected gadolinium-based nanoparticles
57962118|NCT04789486|RADIATION|Radiotherapy|Stereotactic magnetic resonance-guided adaptive radiation therapy
57962119|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
57962120|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
57962121|NCT02798796|DEVICE|MRI|All patients will be submitted to MRI
57962122|NCT05532410|DEVICE|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
57962123|NCT01042600|DEVICE|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
57962124|NCT01042600|DEVICE|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
57962125|NCT02113735|DRUG|H.P. Acthar® Gel (repository corticotropin injection)|
57962126|NCT02113735|DRUG|Placebo|
57962127|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
57962128|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
57962129|NCT01699555|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
57962130|NCT01699555|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
57962131|NCT01400451|DRUG|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
57962132|NCT01400451|DRUG|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
57962133|NCT01512264|DEVICE|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
57962134|NCT03132181|DRUG|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
57962135|NCT03132181|OTHER|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
57962136|NCT05410288|DEVICE|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
58432714|NCT03090204|PROCEDURE|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
58102784|NCT06439264|OTHER|bentonite clay gel with hydroxyapatite|bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
58102785|NCT02072174|DRUG|Anaferon for Children|Anaferon for children: For oral use.
58102786|NCT01355523|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
58102787|NCT01355523|DRUG|Placebo|6 mg oral placebo daily 1 hour before bedtime
58102788|NCT06481423|BEHAVIORAL|dCBT-I|A digital cognitive behavioral intervention course that addresses multiple aspects such as basic sleep knowledge, sleep hygiene, sleep behaviors, improving negative cognition, and improving emotions. The intervention is delivered through video, audio, and text formats.
58432715|NCT00193921|DRUG|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
58432716|NCT00193921|RADIATION|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
58432717|NCT00193921|DRUG|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
58102789|NCT06481423|BEHAVIORAL|Relaxing music|Participants can freely listen relaxing music
58432718|NCT00193921|DRUG|Cisplatin|20mg/m2, IV, weekly
58432719|NCT00193921|RADIATION|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
58432720|NCT06009328|OTHER|fundamental movement skills|measured by test of gross motor development
58102790|NCT00831467|BIOLOGICAL|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
58102791|NCT04093167|DRUG|Pembrolizumab|Per current Product Monograph/U.S. Drug Label and/or local guidelines.
58102792|NCT05976217|DRUG|Venetoclax|100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
58102793|NCT05474937|DRUG|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
58102794|NCT05474937|DRUG|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
58102795|NCT04403373|BEHAVIORAL|Waitlist control|waitlist control
58102796|NCT04403373|BEHAVIORAL|Moderate-intensity walking exercise|walking exercise
58432721|NCT00773773|OTHER|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
58432722|NCT04751188|DRUG|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
58102797|NCT04403373|BEHAVIORAL|Vigorous-intensity walking exercise|walking exercise
58432723|NCT04751188|DRUG|Placebo|Placebo one tablet every 12 hours for six months.
58102798|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
58432724|NCT04751188|DRUG|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
58102799|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
58102800|NCT01067859|DRUG|Placebo|Infusion of placebo during 48 hours
58102801|NCT00084617|DRUG|oxaliplatin|Given IV
58102802|NCT00084617|DRUG|irinotecan hydrochloride|Given IV
58432725|NCT01078844|DRUG|memantine|memantine 5-20 mg daily
58102803|NCT00084617|DRUG|capecitabine|Given orally
58309231|NCT03675217|OTHER|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
58432726|NCT01078844|DRUG|Placebo|Look-alike placebo
58432727|NCT01340573|DRUG|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
58432728|NCT01340573|DRUG|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
58102804|NCT05200806|OTHER|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
58102805|NCT05761132|DRUG|Pembrolizumab|neoadjuvant immunotherapy
58432729|NCT02537184|PROCEDURE|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
58432730|NCT06478303|OTHER|Motor imagery|Participants were asked to imagine arm or foot movements.
58432731|NCT06478303|OTHER|Action reading|Participants were asked to read sentences involving arm or foot movements
58432732|NCT06478303|OTHER|Motor localizer|Participants were asked to perform arm or foot movements
57737466|NCT01766557|OTHER|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
57953639|NCT01974544|BEHAVIORAL|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
58102806|NCT05660473|DRUG|Vincristine|Anti-tumor alkaloids
58102807|NCT05660473|DRUG|Daunorubicin|Anthracycline
58102808|NCT05660473|DRUG|Cyclophosphamide|Alkylating agent
58102809|NCT05660473|DRUG|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
58309232|NCT03675217|OTHER|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
58309233|NCT03311906|DRUG|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
58309234|NCT03311906|PROCEDURE|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
58309235|NCT00336544|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
57953640|NCT03063710|DRUG|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
57953641|NCT04856553|OTHER|Acute effects of handgrip exercise|The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
57953642|NCT04194099|DEVICE|20 Hz rTMS (Brain)|Higher frequency (\>5 Hz) trains increase cortical excitability.
57953643|NCT04194099|DEVICE|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
58102810|NCT05660473|DRUG|Prednisone|Glucocorticoids
58102811|NCT05660473|DRUG|Cytarabine|Pyrimidine antimetabolites
58102812|NCT05660473|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
58309236|NCT00336544|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
58309237|NCT01240746|BIOLOGICAL|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
58309238|NCT01240746|BIOLOGICAL|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
58309239|NCT01240746|BIOLOGICAL|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
58102813|NCT05660473|DRUG|Dexamethasone|Glucocorticoids
58102814|NCT05660473|DRUG|Methotrexate|Antifolate antineoplastic drug
58102815|NCT05660473|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
58102816|NCT04778007|OTHER|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
58102817|NCT00525564|DRUG|Placebo|Placebo diskus inhalation powder
58102818|NCT00525564|DRUG|Salmeterol diskus inhalation powder|50 micrograms twice a day
58102819|NCT03634488|DRUG|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
58309240|NCT06456385|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The intervention applied is called transcutaneous auricular vagus nerve stimulation (taVNS) which administers electrical stimulation at the ear which targets the auricular branch of the vagus nerve.
58309241|NCT06456385|DEVICE|Sham Auricular Stimulation|The sham auricular stimulation administers electrical stimulation at the ear lobe which has less auricular branch of the vagus nerve.
58432733|NCT03725761|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
58432734|NCT05532891|OTHER|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
58432735|NCT02818049|PROCEDURE|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
58432736|NCT04790292|DRUG|group M|10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
58102820|NCT03634488|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
58432737|NCT04790292|DRUG|group MD|10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
58432738|NCT04767984|DRUG|Atorvastatin Calcium|Given PO
57737467|NCT01766557|OTHER|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
57953644|NCT04194099|DEVICE|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
57953645|NCT04194099|DEVICE|20 Hz current square-wave pulses (Spinal)|Higher frequency (\>5 Hz) of current increase cortical excitability.
58309242|NCT04058496|OTHER|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
58309243|NCT01938326|PROCEDURE|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
58309244|NCT01064544|PROCEDURE|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
58309245|NCT01072591|DRUG|MEDI-578|intravenous infusion, once
58309246|NCT01072591|DRUG|Placebo for MEDI-578|Intravenous infusion, once
58309247|NCT00848016|DRUG|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
58309248|NCT02033798|DRUG|Tamsulosin|Once Daily 0.2mg per oral for 6 months
58309249|NCT02378272|OTHER|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
58309250|NCT03434288|OTHER|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
58309251|NCT02318199|PROCEDURE|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
58309252|NCT03225430|BEHAVIORAL|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
58309253|NCT03225430|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
58309254|NCT00641056|DRUG|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
58309255|NCT00641056|DRUG|Insulin Glargine|subcutaneous injection, variable dose, QD
58309256|NCT02460510|DRUG|Mannitol|
58309257|NCT02460510|DRUG|3% hypertonic saline|
58309258|NCT01939912|DRUG|Adenosine|Antiarrhythmic agent.
58309259|NCT02980016|DRUG|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
58309260|NCT02980016|DRUG|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
58309261|NCT01849614|OTHER|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
58309262|NCT05141032|PROCEDURE|Endoscopic Submucosal Dissection with Pathfinder/Overtube device|Removal of gastrointestinal polyps via ESD
58309263|NCT01935115|DRUG|Propofol|Propofol anesthesia for ECT
58309264|NCT01935115|DRUG|Ketamine|Ketamine anesthesia for ECT
58432739|NCT04767984|PROCEDURE|Biopsy of Colon|Undergo colonoscopy with biopsy
58432740|NCT04767984|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58432741|NCT04767984|DRUG|Placebo Administration|Given PO
58309265|NCT02016846|DRUG|Liraglutide|
58309266|NCT02016846|DRUG|Placebo|
58309267|NCT04327778|PROCEDURE|Music Therapy|Automate music therapy every two weeks
58309268|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
58309269|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
58309270|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
58309271|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
58432742|NCT04767984|OTHER|Questionnaire Administration|Ancillary studies
58432743|NCT04003987|DRUG|Liposomal bupivacaine|20ml
58432744|NCT04003987|DRUG|bupivacaine, 0.125%|60ml
58432745|NCT05801614|OTHER|Low carb diet|Low calori diet
58432746|NCT04715698|OTHER|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
58432747|NCT04715698|OTHER|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
58102821|NCT04434638|OTHER|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
58432748|NCT05987956|DRUG|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
58102822|NCT04434638|OTHER|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
58102823|NCT00002227|DRUG|Efavirenz|
58102824|NCT00002227|DRUG|Lamivudine|
58102825|NCT00002227|DRUG|Stavudine|
58102826|NCT04521439|DIAGNOSTIC_TEST|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
58309272|NCT01994200|OTHER|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
58432749|NCT05987956|DRUG|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
57953646|NCT04194099|DEVICE|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
57953647|NCT04194099|DEVICE|sham|with sham stimulation on brain and spinal.
58309273|NCT01994200|OTHER|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
58309274|NCT05262374|PROCEDURE|Procedure/Surgery: Laparoscopic|Surgeon
58309275|NCT05262374|PROCEDURE|Robotic|Versius system.
58309276|NCT02055586|OTHER|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
58309277|NCT02055586|DEVICE|positron emission tomography|Undergo FLT-PET/MRI
58309278|NCT02055586|DEVICE|magnetic resonance imaging|Undergo FLT-PET/MRI
58309279|NCT05737511|DRUG|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
58309280|NCT05737511|DRUG|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
58309281|NCT01777841|OTHER|Electronic Care plan delivery|
58432750|NCT02903732|OTHER|observational|registry
58432751|NCT04180566|OTHER|Ultrasound Examination|Includes a regular growth ultrasound examination.
58432752|NCT04180566|OTHER|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
58432753|NCT04730531|PROCEDURE|Local infiltration with 0.25% bupivacaine and epinephrine|The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
58432754|NCT04730531|PROCEDURE|Placebo of equal volume injectable saline|An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
58432755|NCT01378468|OTHER|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
58432756|NCT03124082|DRUG|Remifentanil|continuous infusion intraop
57953648|NCT01996800|PROCEDURE|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
58309282|NCT01777841|OTHER|Standard care|
58309283|NCT02865863|DIETARY_SUPPLEMENT|Eurycomalongifoliawater extract (Physta®)|
58309284|NCT02865863|DIETARY_SUPPLEMENT|Placebo|
58432757|NCT03124082|DRUG|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
58432758|NCT03124082|DRUG|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
58432759|NCT03124082|DRUG|Clonidine|clonidine 4 mcg/kg
58432760|NCT03295617|PROCEDURE|Thoracoscopy|Thoracoscopy surgery
58432761|NCT02083497|OTHER|rigid bandage|
58432762|NCT02083497|OTHER|elastic bands|
58432763|NCT02083497|OTHER|without the use of banding|
58102827|NCT00367679|DRUG|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
58309285|NCT02865863|DIETARY_SUPPLEMENT|Multivitamin|
58432764|NCT06167707|DRUG|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
58432765|NCT06167707|DRUG|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
58432766|NCT00002822|DRUG|carboplatin|
58432767|NCT00002822|DRUG|cisplatin|
58432768|NCT00002822|DRUG|cyclophosphamide|
58432769|NCT00002822|DRUG|doxorubicin hydrochloride|
58432770|NCT00002822|DRUG|etoposide|
58432771|NCT00002822|DRUG|ifosfamide|
57737468|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
57737469|NCT01512225|DRUG|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
57737470|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
58432772|NCT00002822|DRUG|mesna|
57737471|NCT06185803|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
57737472|NCT03886818|DEVICE|Standard dressings|Standard dressings will be used from surgery to wound healing
57737473|NCT03886818|DEVICE|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
57953649|NCT01996800|PROCEDURE|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
57953650|NCT01384227|DRUG|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
57953651|NCT06247709|OTHER|Immunohistochemical expression in pitNET cells of KLHL14|Lab essay evaluating the expression of KLHL 14
57953652|NCT02705638|DRUG|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
57953653|NCT02705638|DRUG|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
57953654|NCT00285727|DRUG|Ropinirole CR|
57953655|NCT04160702|BEHAVIORAL|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
57953656|NCT03048669|OTHER|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
57953657|NCT02803021|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
58102828|NCT04874220|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
58102829|NCT03325452|BIOLOGICAL|venous lactate|value of venous lactate
58102830|NCT00850005|BIOLOGICAL|Intravenous immunoglobulin|2 g/kg divided over five days
58102831|NCT00850005|BIOLOGICAL|Normal Saline|Same volume as experimental arm
58102832|NCT01711671|DRUG|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
58309286|NCT00636727|PROCEDURE|arthrocentesis|Irrigate the TMJ with lactated ringers
58309287|NCT00636727|PROCEDURE|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
58309288|NCT00636727|PROCEDURE|arthroplasty|The disc will be surgically repositioned with open surgery
58309289|NCT03189082|PROCEDURE|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
58309290|NCT04069117|DRUG|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
58432773|NCT00002822|DRUG|vincristine sulfate|
58432774|NCT00002822|RADIATION|radiation therapy|
58432775|NCT00005818|DRUG|irinotecan hydrochloride|Given IV
58432776|NCT00005818|DRUG|semaxanib|Given IV
58432777|NCT00005818|OTHER|laboratory biomarker analysis|Correlative studies
58432778|NCT00051896|DRUG|GBR 12909|
58432779|NCT00662545|DRUG|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
58432780|NCT00662545|DRUG|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
58432781|NCT03154437|BIOLOGICAL|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
58432782|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
58102833|NCT01711671|DRUG|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
57953658|NCT06033079|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
58102834|NCT01711671|DRUG|Standard of Care|Current approved standard of care
58102835|NCT03763617|DEVICE|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
58102836|NCT03612401|DRUG|Mirabegron|Beta-3 adenoreceptor agonist
58102837|NCT01155635|DRUG|Carvedilol|Use of Carvedilol with any dose
58102838|NCT01155635|DRUG|No Carvedilol|No use of Carvedilol
58102839|NCT04413669|PROCEDURE|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
58102840|NCT00348569|DEVICE|64 Channel VCT|
58102841|NCT04895631|DRUG|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
58102842|NCT04895631|PROCEDURE|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
58102843|NCT01058044|OTHER|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
58432783|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
57953659|NCT03849378|DIETARY_SUPPLEMENT|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
57953660|NCT03849378|DIETARY_SUPPLEMENT|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
57953661|NCT04089007|DEVICE|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
57953662|NCT04089007|OTHER|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
57953663|NCT04091087|DRUG|crisaborole ointment|crisaborole ointment
57953664|NCT04091087|OTHER|vehicle ointment|vehicle ointment
57953665|NCT00345176|DIETARY_SUPPLEMENT|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
57953666|NCT00345176|DIETARY_SUPPLEMENT|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
58102844|NCT03569020|OTHER|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
58102845|NCT02556099|DRUG|Hydroxyurea|drug to be administered
58102846|NCT05066100|OTHER|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
58102847|NCT03952663|PROCEDURE|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
58102848|NCT03952663|PROCEDURE|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
58102849|NCT01946971|DRUG|Lansoprazole|
58102850|NCT01946971|DRUG|Placebo|
58102851|NCT05331846|BEHAVIORAL|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
58102852|NCT02453867|OTHER|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels \> 5ng/ml) Stop mycophenolate at month 6
58102853|NCT02453867|DRUG|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
58102854|NCT02453867|DRUG|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
58102855|NCT02453867|DRUG|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
58309291|NCT03913234|DRUG|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
58309292|NCT04780321|BIOLOGICAL|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
58432784|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
58309293|NCT04780321|DRUG|Placebo|30 patients receipt placebo intravenous infusion on day 1
58432785|NCT01025830|DRUG|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
58432786|NCT01025830|DRUG|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
58432787|NCT06579846|DRUG|Cytisinicline and exercise|"Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes."
58432788|NCT06579846|DRUG|Cytisinicline|Same intervention as the experimental group without directed exercise prescription
58432789|NCT03424603|DRUG|STRO-001|intravenous antibody drug conjugate
58432790|NCT02828020|DRUG|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
57737474|NCT05046353|DRUG|D-serine|Auditory remediation +/-D-serine
57953667|NCT00345176|DRUG|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
57737475|NCT05046353|OTHER|Placebo|Auditory remediation +/-D-serine
57737476|NCT04475913|OTHER|DIG Axial|patients received 4 axial implants and digital impression
57953668|NCT02970292|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
57953669|NCT02970292|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
57953670|NCT01348997|BEHAVIORAL|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
57953671|NCT01348997|BEHAVIORAL|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
57953672|NCT03747250|DEVICE|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
57953673|NCT03747250|DEVICE|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
57953674|NCT00622648|DRUG|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
57953675|NCT00622648|DRUG|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
57953676|NCT03787498|DRUG|PLX2853|Tablets
57953677|NCT04358835|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio enteral ketogenic formula within 48 hours of intubation
57953678|NCT04358835|OTHER|standard of care|standard of care/supportive therapy
57953679|NCT03057925|DEVICE|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
57953680|NCT05630079|DEVICE|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
58309294|NCT02084823|BIOLOGICAL|cancer stem cell vaccine|
58309295|NCT04503044|OTHER|Retrospective observational study|No intervention to occur
57737477|NCT04475913|OTHER|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
57737478|NCT04475913|OTHER|CIG Axial|patients received 4 axial implants and conventional impression
57737479|NCT04475913|OTHER|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
57737480|NCT00990158|DRUG|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
57737481|NCT00990158|DRUG|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
57737482|NCT02270450|PROCEDURE|therapeutic conventional surgery|Undergo abdominal surgery
57737483|NCT02270450|PROCEDURE|gastrointestinal complications management/prevention|Undergo non-surgical management
57737484|NCT02270450|OTHER|quality-of-life assessment|Ancillary studies
57953681|NCT05630079|DEVICE|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% \[-\] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
58432791|NCT02828020|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
58432792|NCT01674777|DRUG|ASP1941|oral
58432793|NCT03579641|DEVICE|HeartLogic Sensors|HeartLogic Sensors
58432794|NCT02168608|OTHER|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
57953682|NCT04454190|DIAGNOSTIC_TEST|Collection of genetic material|Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
57953683|NCT02195388|OTHER|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
57737485|NCT05714189|OTHER|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
58432795|NCT02168608|OTHER|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
58432796|NCT02572765|OTHER|PET/CT scan|PET/CT scan
57953684|NCT05376228|DRUG|Oral Vancomycin|As part of standard of care
57953685|NCT02500121|OTHER|Placebo|Normal saline
57953686|NCT02500121|DRUG|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
57953687|NCT02195752|OTHER|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
57953688|NCT03561571|OTHER|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
58432797|NCT01824433|DRUG|venlafaxine|venlafaxine 75-225mg qd
58432798|NCT01824433|DRUG|fluoxetine|fluoxetine 20-60mg qd
58432799|NCT01511081|RADIATION|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
57953689|NCT03561571|OTHER|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
57953690|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
57953691|NCT06087055|DRUG|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
57953692|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
57953693|NCT01452152|DRUG|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
57953694|NCT01452152|DRUG|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
57953695|NCT05121974|DRUG|Tebipenem Pivoxil|Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.
57953696|NCT05121974|DRUG|Azithromycin|Oral Azithromycin antibiotic (Macrolides)
57953697|NCT05121974|DRUG|Ceftriaxon|IV Ceftriaxone (Cephalosporin)
58432800|NCT01511081|RADIATION|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
58432801|NCT02343809|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
58432802|NCT02343809|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
58432803|NCT02343809|OTHER|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
57953698|NCT05381818|BEHAVIORAL|Daily Inspiratory Muscle Training (dIMT)|Daily IMT training sessions for 2-4 weeks prior to surgery
57953699|NCT05381818|BEHAVIORAL|Acute Inspiratory Muscle Training (aIMT)|A single session of IMT provided within 30 minutes prior to anesthesia induction.
57953700|NCT05381818|OTHER|Standard of Care (SOC)|Standard of care only pre and post-operatively.
57953701|NCT03937180|BEHAVIORAL|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
57953702|NCT03937180|BEHAVIORAL|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
58309296|NCT04716244|OTHER|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
58432804|NCT01992211|DRUG|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
58432805|NCT01992211|DRUG|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
58432806|NCT01992211|DRUG|BCWP_C003|Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
58432807|NCT03786471|OTHER|Health System-based Dementia Care|Active comparator
58432808|NCT03786471|OTHER|Community-based Dementia Care|Active comparator
58432809|NCT03786471|OTHER|Usual Care|Control
58432810|NCT02643732|DRUG|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
58432811|NCT02643732|DRUG|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
58432812|NCT01111279|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
58432813|NCT01111279|BIOLOGICAL|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
58432814|NCT01111279|BIOLOGICAL|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
58432815|NCT06156241|BIOLOGICAL|Stem Cell|Stem cells derived from human cord tissue.
58432816|NCT00002230|DRUG|Hydroxyurea|
58432817|NCT00002230|DRUG|Efavirenz|
58432818|NCT00002230|DRUG|Stavudine|
58432819|NCT00002230|DRUG|Didanosine|
58432820|NCT04381650|DRUG|TAK-981|TAK-981 IV infusion.
58432821|NCT04381650|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
58309297|NCT03807024|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
58309298|NCT01192178|DRUG|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
58432822|NCT01029847|DRUG|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
58432823|NCT01029847|DRUG|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
58432824|NCT01226576|DEVICE|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
58432825|NCT03625999|BEHAVIORAL|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
58432826|NCT06347263|OTHER|Entire papilla preservation technique|Minimally invasive periodontal surgery
58432827|NCT03659136|DRUG|Xentuzumab|Intravenous infusion
58102856|NCT06542770|DEVICE|Early implant of cardiac monitor|ICM implant 3-4 days after the stroke and prior to discharge. All devices (Abbott Confirm or Jot) were implanted subcutaneously under local anaesthesia in the left chest region and programmed with an specific algorithm for AF detection set at 30 seconds for detection. All patients were included in remote monitoring system (Merlin), which was programmed to send alerts in case of registering episodes qualifying for AF detection, and a monthly routine registration. All ICM recordings were reviewed by a specialized cardiologist.
58102857|NCT05101356|BIOLOGICAL|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
58102858|NCT05101356|BIOLOGICAL|Sargramostim|Given SC
58102859|NCT05101356|BIOLOGICAL|Pembrolizumab|Given IV per standard of care
58102860|NCT01893151|DRUG|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
58102861|NCT01893151|DRUG|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
58432828|NCT03659136|DRUG|Placebo|Intravenous infusion
58432829|NCT03659136|DRUG|Everolimus|Tablet
58432830|NCT03659136|DRUG|Exemestane|Tablet
58432831|NCT01278797|DRUG|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
58432832|NCT01278797|DRUG|Amlodipine Monocomponent|Active Comparator
58309299|NCT01192178|DRUG|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
58309300|NCT01578265|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
58309301|NCT01578265|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
58432833|NCT05040074|DEVICE|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
58432834|NCT00622388|DRUG|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
58432835|NCT03304873|DRUG|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
58432836|NCT03304873|DRUG|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
58432837|NCT06536192|OTHER|Model group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam."
58432838|NCT00168454|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
58432839|NCT00168454|DRUG|Placebo|Placebo (normal saline) injected into detrusor on Day 1
58432840|NCT04600583|DEVICE|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
58432841|NCT01816867|DEVICE|Intramesh T1 implantation|
58432842|NCT02980133|DRUG|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
58432843|NCT02980133|DRUG|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
58432844|NCT02980133|DRUG|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
58432845|NCT03578328|PROCEDURE|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
58432846|NCT03342118|DRUG|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
58432847|NCT03342118|DRUG|Normal saline|The control group was treated with normal saline before endoscopy
58432848|NCT03219346|OTHER|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
58432849|NCT03618316|DRUG|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
58432850|NCT03618316|DRUG|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
57737486|NCT05714189|OTHER|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
57953703|NCT06470269|BEHAVIORAL|Eye tracking|Recording the eye movement of participants while they read medical cases.
57953704|NCT03902509|DRUG|Pirfenidone|pirfenidone capsule made in China
57953705|NCT03902509|DRUG|basic treatment|glucocorticoid and expectant treatment etc.
57953706|NCT01805622|BEHAVIORAL|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
58309302|NCT03767712|DIAGNOSTIC_TEST|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
58309303|NCT02810782|DRUG|Phenobarbital|Phenobarbital per os
58309304|NCT02810782|DRUG|Chlorpromazine|Chlorpromazine per os
58432851|NCT02021955|BEHAVIORAL|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
58432852|NCT04415411|OTHER|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
58432853|NCT02223806|BEHAVIORAL|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
58432854|NCT02223806|BEHAVIORAL|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
58432855|NCT02767661|DRUG|Capecitabine|Capecitabine, 500mg, orally three times daily (continuously)
58432856|NCT02767661|DRUG|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
58432857|NCT05024708|OTHER|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
58309305|NCT02810782|DRUG|Morphine|Morphine per os
58309306|NCT01182025|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
58102862|NCT01749033|OTHER|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
58102863|NCT01749033|OTHER|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
58102864|NCT01749033|OTHER|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
58102865|NCT02269007|BIOLOGICAL|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
58102866|NCT04632628|BEHAVIORAL|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
58432858|NCT00837343|DRUG|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
58432859|NCT02703480|BIOLOGICAL|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
58432860|NCT02703480|BIOLOGICAL|Ti-mesh|Titanium mesh
58432861|NCT02019875|DRUG|Rifampin|P450 inducer
58432862|NCT02019875|DRUG|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
58432863|NCT02019875|OTHER|Grapefruit Juice|CYP3A4 inhibitor in intestine
58432864|NCT02019875|OTHER|Placebo|
58432865|NCT00994643|BIOLOGICAL|Rituximab|Given IV
58432866|NCT00994643|BIOLOGICAL|Interleukin-2|Given SC
58432867|NCT04534881|DRUG|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
58432868|NCT04534881|DRUG|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
58432869|NCT00500955|DRUG|Rosiglitazone|
58102867|NCT00736060|OTHER|Observational|Summary of clinical and laboratory data
58102868|NCT01124682|PROCEDURE|diagnostic cystoscopy|
58102869|NCT01124682|PROCEDURE|diffusion-weighted magnetic resonance imaging|
58102870|NCT01124682|PROCEDURE|implanted fiducial-based imaging|
58102871|NCT01124682|PROCEDURE|quality-of-life assessment|
58102872|NCT01124682|RADIATION|3-dimensional conformal radiation therapy|
58102873|NCT01124682|RADIATION|image-guided radiation therapy|
58102874|NCT01124682|RADIATION|selective external radiation therapy|
58102875|NCT00000478|DRUG|atenolol|
58102876|NCT00000478|DRUG|nifedipine|
58102877|NCT00000478|DRUG|diltiazem|
58102878|NCT00000478|DRUG|isosorbide dinitrate|
58102879|NCT00000478|PROCEDURE|coronary artery bypass coronary artery bypass|
58102880|NCT00000478|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
58102881|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
58102882|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
58102883|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
58102884|NCT04247594|DRUG|Voxelotor|synthetic small molecule supplied as 500 mg tablets
58102885|NCT04399720|PROCEDURE|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
58102886|NCT05567094|DRUG|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
58102887|NCT05567094|DRUG|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
58102888|NCT03485508|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
58102889|NCT02820935|DRUG|CC-220|
58102890|NCT02820935|DRUG|Rifampin|
58102891|NCT02820935|DRUG|Itraconazole|
58102892|NCT04518319|DRUG|Omega-3 polyunsaturated fatty acids|Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
58432870|NCT01085292|DRUG|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
58432871|NCT01085292|DRUG|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
58432872|NCT00769457|DEVICE|Access Arm|Active OptiVol-System with CareAlert via CareLink
58432873|NCT05945251|OTHER|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
58432874|NCT02205528|DRUG|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
58432875|NCT02205528|DRUG|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
58432876|NCT02205528|DRUG|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
58432877|NCT02205528|DRUG|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
58432878|NCT03214042|DEVICE|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
58432879|NCT03752658|DRUG|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
58432880|NCT04439981|DIETARY_SUPPLEMENT|Ice cream|Curcumin extract was added into ice cream
58432881|NCT03719989|DRUG|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
58102893|NCT04518319|BEHAVIORAL|Xbox aerobic exercise|Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
58432882|NCT05582174|DRUG|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
58432883|NCT05582174|DRUG|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
58102894|NCT04518319|DEVICE|transcranial direct current stimulation,tDCS|Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
58102895|NCT04518319|DRUG|Olanzapine|Patients will take only olanzapine pills.
58102896|NCT02611245|DRUG|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
58102897|NCT03218631|DRUG|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
58432884|NCT00477152|DRUG|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
58432885|NCT00232856|DEVICE|drug-eluting stent|PCI
58432886|NCT02363296|DEVICE|TMS|Paired associative stimulation and single pulse TMS
58432887|NCT01670773|DRUG|CAT-1004|
58432888|NCT01670773|DRUG|Salsalate + DHA|
57737487|NCT06004310|BEHAVIORAL|Pulmonary Rehabilitation|Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
57769593|NCT00545350|OTHER|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
58102898|NCT05233371|OTHER|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
58309307|NCT01182025|DRUG|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
58432889|NCT01670773|DRUG|Placebo|
58432890|NCT04859816|OTHER|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
58432891|NCT04859816|OTHER|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
58432892|NCT04859816|OTHER|MRS|Magnetic resonance spectroscopy of liver fat content
58432893|NCT04859816|OTHER|Feces collection|4-day feces collection
58432894|NCT04930094|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg
58432895|NCT04930094|OTHER|Placebo|Placebo
58432896|NCT04930094|BIOLOGICAL|Secukinumab 150 mg|Secukinumab
58432897|NCT00604045|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
58432898|NCT00604045|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
58432899|NCT04050813|BEHAVIORAL|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
58432900|NCT03034824|PROCEDURE|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
58432901|NCT03034824|PROCEDURE|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
58102899|NCT05233371|OTHER|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~* Frequency and duration of rehabilitation sessions by type of health professionals,~* Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
58102900|NCT05233371|OTHER|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
58432902|NCT03034824|PROCEDURE|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
58102901|NCT00481962|DRUG|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
58102902|NCT06539065|DEVICE|VR interactive games|The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
58102903|NCT03783845|COMBINATION_PRODUCT|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
58102904|NCT06542744|DEVICE|Training with the Emagina device at home until birth|The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
58102905|NCT06542744|OTHER|No intervention|The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
58102906|NCT04726514|DEVICE|SleepFlex|SleepFlex Program
58102907|NCT01997099|DEVICE|CADD®-Solis VIP Pump|
58102908|NCT01997099|DEVICE|CADD™ Solis Medication Safety Software Administrator|
58102909|NCT00955760|DRUG|Neramexane|Drug-Drug Interaction Study
58102910|NCT04181216|DEVICE|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
58102911|NCT04058431|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
58102912|NCT04058431|OTHER|Control- No Intervention|This group will refrain from getting OMT while in the study.
58432903|NCT03291860|PROCEDURE|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
58432904|NCT03963427|PROCEDURE|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
58432905|NCT02409771|DEVICE|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
58432906|NCT02556060|DRUG|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
58432907|NCT02556060|DRUG|Placebo|Same dosing schedule as study drug
58432908|NCT00465777|BEHAVIORAL|Guideline adherence and financial incentive|
58102913|NCT01782950|DRUG|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
58102914|NCT05244382|OTHER|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
58102915|NCT02542228|OTHER|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
58102916|NCT03329586|OTHER|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
58102917|NCT02918825|DRUG|Olanzapine|Olanzapine
58102918|NCT02918825|DRUG|Paliperidone|Paliperidone
58102919|NCT02073188|DEVICE|iBGStar|
57953707|NCT01689298|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
58102920|NCT02073188|DEVICE|Traditional Glucometer|
58102921|NCT05182931|DRUG|Dabrafenib 75 MG|Refer arm description
58102922|NCT05182931|DRUG|Trametinib 2 MG|Refer arm description
58102923|NCT02059369|PROCEDURE|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
58102924|NCT02059369|PROCEDURE|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
58102925|NCT06538363|BEHAVIORAL|Education|Personalized training advice
58102926|NCT06538363|BEHAVIORAL|Generic Education|Generic training advice
58102927|NCT04676919|DEVICE|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
58102928|NCT04676919|DEVICE|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
58102929|NCT04676919|DEVICE|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
58102930|NCT01697397|DEVICE|Recording of Myoelectric Signals|Obtain recordings of the electrical signals of the gut.
58102931|NCT00890227|PROCEDURE|Traditional technique|All level open instrumented posterior spinal fusions
58102932|NCT00890227|PROCEDURE|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
58432909|NCT00351507|DRUG|Vildagliptin|
58102933|NCT02873468|DRUG|Florence 30 μg/mL|10 mL, oral, twice a day.
58102934|NCT02873468|DRUG|Florence 60 μg/mL|10 mL, oral, twice a day.
58102935|NCT02873468|DRUG|Florence 90 μg/mL|10 mL, oral, twice a day.
58102936|NCT02873468|OTHER|Placebo|10 mL, oral, twice a day.
58102937|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58102938|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58102939|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58102940|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58432910|NCT05693506|OTHER|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
58432911|NCT04886791|PROCEDURE|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
58432912|NCT04886791|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy
58432913|NCT00428389|DRUG|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
58432914|NCT00428389|DRUG|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
58432915|NCT03900273|OTHER|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
58432916|NCT03900273|OTHER|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
58432917|NCT04510103|DRUG|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
58432918|NCT04510103|OTHER|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
58432919|NCT04510103|PROCEDURE|Regression|2 week regression period after 6 weeks of moisturizer use.
58432920|NCT04510103|PROCEDURE|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
58432921|NCT01246336|OTHER|collection of exhaled breath|no intervention
58432922|NCT01700153|OTHER|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
58432923|NCT01700153|OTHER|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
58432924|NCT05096949|OTHER|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
58432925|NCT06583356|BEHAVIORAL|Motivational interviewing|Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
58432926|NCT01506284|PROCEDURE|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
58432927|NCT05485623|DEVICE|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
58432928|NCT03777319|DRUG|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
58432929|NCT03777319|DRUG|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
58432930|NCT05198843|DRUG|Dasatinib|Given PO
58432931|NCT05198843|DIETARY_SUPPLEMENT|Icosapent Ethyl|Given PO
58432932|NCT05804032|DRUG|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
58432933|NCT05804032|DRUG|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
58432934|NCT05804032|DRUG|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
58432935|NCT05804032|DRUG|Bortezomib|Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
58432936|NCT05804032|DRUG|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
58432937|NCT02812927|DEVICE|Edelvaiss Multiline-8|Optimised infusion line
58432938|NCT02812927|DEVICE|Standard infusion line|
58432939|NCT04046978|OTHER|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
58432940|NCT04046978|OTHER|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
58432941|NCT04046978|OTHER|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
58432942|NCT04046978|OTHER|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
58432943|NCT04046978|OTHER|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
58432944|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
58432945|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
58432946|NCT01870310|PROCEDURE|Catheterised renal denervation|
58102941|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58102942|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58432947|NCT02211456|PROCEDURE|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
58432948|NCT05407779|BIOLOGICAL|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
58432949|NCT05407779|BIOLOGICAL|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
58432950|NCT05407779|BIOLOGICAL|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
58432951|NCT05407779|BIOLOGICAL|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
58432952|NCT05407779|BIOLOGICAL|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
58432953|NCT05407779|BIOLOGICAL|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
58432954|NCT05407779|BIOLOGICAL|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
58432955|NCT06548932|DRUG|GZR33 Injection|A single dose
58432956|NCT06548932|DRUG|GZR101 Injection|A single dose
58432957|NCT06548932|DRUG|Placebo|A single dose
58432958|NCT02797782|OTHER|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
58432959|NCT03505528|DRUG|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
58432960|NCT03505528|DRUG|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
58432961|NCT00208533|DRUG|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
58432962|NCT04200144|DEVICE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
58432963|NCT00250276|BIOLOGICAL|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
58432964|NCT05050864|PROCEDURE|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
57953708|NCT01689298|DRUG|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
58102943|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58102944|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
58309308|NCT01182025|DRUG|Xiyanping Injection with western medicine|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
58309309|NCT01064011|PROCEDURE|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
58432965|NCT05050864|PROCEDURE|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
58432966|NCT04557709|OTHER|Medical Chart Review|Review of medical charts
58432967|NCT06426849|OTHER|Liuzijue Exercise|"LiuzijueExercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. It is performed by delivering 6 distinct sounds, (xū,hē, hū sī, chuī, and xī) through termination along with comparing body activities.~The following are 6-8 vital parts of body movements:~1. Swaying and twisting~2. Hip rotations~3. Arm movements~4. Knee bends~5. Foot pivots~6. Spine elongation~7. Hand gestures~8. Breath synchronization Frequency: 1 session per day for a week Intensity:In first week 1 set of Luizijue exercise will be performed then progressively increase to 4 sets till 6th week .~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Luizijue Exercise."
58432968|NCT06426849|OTHER|Tai Chi Chuan Exercise|"Tai Chi Chuan Exercise combines deep diaphragmatic breathing and relaxation with many fundamental postures.~Names of the 10 Movements in Sequence~1. Commencing Form~2. Repulsing the Monkey~3. Brush Knee~4. Parting the Horse's Mane~5. Cloud Hands~6. Golden Cockerel Standing on the Left, then the Right~7. Kick Out Right, Kick Out Left~8. Grasping the Bird's Tail~9. Cross Hands or Embrace the Tiger~10. Closing Form Frequency: 3 sessions / week Intensity: Initially each posture will be performed 3 times then progressively leads to 6 or 10 reps according to patient tolorance.~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Tai Chi Chuan Exercise."
58432969|NCT04488016|DRUG|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
58432970|NCT04488016|DRUG|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
58309310|NCT01064011|PROCEDURE|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
58102945|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
58309311|NCT00720499|DRUG|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
58309312|NCT00720499|DEVICE|Respimat® Inhaler|
58432971|NCT04488016|DRUG|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
58432972|NCT04488016|DRUG|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
58432973|NCT04488016|DRUG|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
58432974|NCT04488016|DRUG|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
58432975|NCT04488016|DRUG|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
58432976|NCT04488016|DRUG|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
58432977|NCT03825016|DRUG|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
58309313|NCT03984357|DRUG|PD-1 blocking antibody|"1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
58432978|NCT03825016|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium
58432979|NCT06543329|PROCEDURE|polyglactin 910|75 PARTICIPANT, Vicryl suture was used in subcuticular suture
58432980|NCT06543329|PROCEDURE|poliglecaprone 25|75 PARTICIPANT, monocryl suture was used in subcuticular suture
58309314|NCT03984357|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
58432981|NCT06543329|PROCEDURE|polypropylene|75 PARTICIPANT, Prolene suture was used in subcuticular suture
58432982|NCT06543329|PROCEDURE|polyester|75 PARTICIPANT, Polyester suture was used in subcuticular suture
58432983|NCT00260624|DRUG|Escitalopram (Lexapro)|
58432984|NCT04443309|DRUG|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
58432985|NCT04443309|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
58432986|NCT00002122|DRUG|Azithromycin|
58432987|NCT00002122|DRUG|Rifabutin|
58432988|NCT00002122|DRUG|Fluconazole|
58432989|NCT05673070|DIETARY_SUPPLEMENT|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
58432990|NCT05673070|DIETARY_SUPPLEMENT|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
58432991|NCT02275442|OTHER|EPICES scale|
58432992|NCT00136552|DRUG|rituximab|
58432993|NCT05437432|PROCEDURE|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
58432994|NCT05437432|PROCEDURE|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
58432995|NCT02904148|PROCEDURE|Shoulder mobilisation|early shoulder mobilisation
58432996|NCT03009084|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
58102946|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
58102947|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
58102948|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
58102949|NCT04901130|DEVICE|Computer-aided Real-time Automatic Quality Control System (AQCS)|Automatic quality-control system(AQCS), developed based on deep convolutional neural network (DCNN) models, could improve the colonoscopists' performance during withdrawal phase and significantly increase polyp and adenoma detection.
58102950|NCT02872155|OTHER|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
58102951|NCT02872155|DRUG|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
58102952|NCT02872155|DRUG|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
58102953|NCT04553692|DRUG|Aplitabart (IGM-8444)|DR5 Agonist Investigational Drug
58102954|NCT04553692|DRUG|FOLFIRI|Chemotherapy Regimen
58102955|NCT04553692|DRUG|Bevacizumab (and approved biosimilars)|Targeted Therapy
58102956|NCT04553692|DRUG|Birinapant|SMAC-mimetic Investigational Drug
58102957|NCT04553692|DRUG|Venetoclax|Targeted Therapy
58102958|NCT04553692|DRUG|Gemcitabine|Chemotherapy
58102959|NCT04553692|DRUG|Docetaxel|Chemotherapy
58102960|NCT04553692|DRUG|Azacitidine|Chemotherapy
58102961|NCT04911673|BEHAVIORAL|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
58102962|NCT04911673|DIETARY_SUPPLEMENT|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
58102963|NCT00405210|DRUG|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
58102964|NCT00569231|DRUG|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
58102965|NCT03494205|DRUG|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
58102966|NCT03494205|DRUG|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
58102967|NCT02487173|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
58102968|NCT02487173|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
58102969|NCT02487173|DEVICE|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
57953709|NCT06302907|PROCEDURE|Buffered Local anaesthesia|A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
58102970|NCT06039098|DEVICE|DCS|DCS monitoring of brain
57737488|NCT05477745|PROCEDURE|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
58102971|NCT02577900|DEVICE|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
58102972|NCT02577900|DEVICE|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
58309315|NCT03984357|DRUG|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
58309316|NCT03984357|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
57737489|NCT02137369|DRUG|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
57737490|NCT02137369|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
57737491|NCT02137369|OTHER|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
57953710|NCT06302907|PROCEDURE|Unbuffered Local anaesthesia|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
57953711|NCT05364242|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
57953712|NCT03302715|GENETIC|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
58102973|NCT02577900|DEVICE|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
58102974|NCT02522949|DEVICE|ColdZyme® mouth spray|
58102975|NCT02522949|DEVICE|Placebo|
58102976|NCT00349882|DEVICE|soft contact lens|
58102977|NCT00349882|DRUG|Marketed multipurpose disinfection regimen|
58102978|NCT01208168|DRUG|NAB001|nail lacquer, once daily, 52 weeks
57737492|NCT04871490|DIAGNOSTIC_TEST|Blood test for HPV DNA|All participants will have blood tested for HPV DNA.
58309317|NCT01565577|BIOLOGICAL|MenbVac|Blood test
58432997|NCT05248477|OTHER|Premex Protocol|"This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents."
58432998|NCT02524873|DEVICE|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
58432999|NCT06441149|OTHER|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
58433000|NCT06441149|OTHER|Standard informed consent|Standard informed consent
58433001|NCT02508428|DEVICE|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
58433002|NCT02508428|DEVICE|Hip Replacement with noncrosslinked Enduron polyethylene|
58433003|NCT01189643|DRUG|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
58433004|NCT04072263|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
58433005|NCT04072263|DRUG|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
58433006|NCT04072263|DRUG|Carboplatin|chemotherapy i.v.
58433007|NCT04072263|DRUG|Paclitaxel|Chemotherapy i.v.
58433008|NCT00417963|DEVICE|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
58433009|NCT05503225|DRUG|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
58433010|NCT01627028|PROCEDURE|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
58433011|NCT01153360|DRUG|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
57737493|NCT05373251|DIAGNOSTIC_TEST|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
57737494|NCT00146835|BIOLOGICAL|Pediarix|1 or more injections
57737495|NCT00146835|BIOLOGICAL|Licensed DTPa containing vaccine|1 or more injections
58309318|NCT00737178|DEVICE|CuT380A|Comparison of different timing of IUD insertion
58433012|NCT01153360|DRUG|placebo|vitamin B12
58433013|NCT03502902|DRUG|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
58433014|NCT03502902|DRUG|Placebo|Placebo
58433015|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
58433016|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
58433017|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
58433018|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
58433019|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
58433020|NCT06409494|BIOLOGICAL|EuHZV|Drug(injection)
58433021|NCT06409494|BIOLOGICAL|Shingrix|Drug(injection)
58433022|NCT02199561|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
58433023|NCT06468670|DRUG|sintilimab，programmed death 1 monoclonal antibody|"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"
58433024|NCT01076413|BEHAVIORAL|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
58433025|NCT01076413|BEHAVIORAL|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
58102979|NCT01208168|DRUG|Vehicle alone|nail lacquer, once daily, 52 weeks
58102980|NCT04133090|PROCEDURE|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
57737496|NCT00146835|BIOLOGICAL|Prevnar®: (Wyeth)|Concomitant vaccination
58102981|NCT04133090|PROCEDURE|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
58309319|NCT03615963|DIAGNOSTIC_TEST|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
58309320|NCT04429958|OTHER|GDM|different degrees of hyperglycaemia during pregnancy
58433026|NCT02696759|OTHER|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
58433027|NCT02724527|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
58433028|NCT02724527|DRUG|Placebo|Matched Placebo capsule
58309321|NCT02053103|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
58309322|NCT02053103|DRUG|Placebo|Tablet, 0 mg, twice daily, 6 weeks
58309323|NCT04909944|DEVICE|i-gel Supraglottic insertion|i-gel Supraglottic insertion for oxygenation
58309324|NCT04909944|DEVICE|Laryngeal Tube Suction Disposable Supraglottic insertion|Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
57737497|NCT01303666|PROCEDURE|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
58309325|NCT03168373|PROCEDURE|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
58309326|NCT02244632|DRUG|Modufolin (arfolitixorin)|IV injection every second week for 8 weeks.
58309327|NCT02244632|DRUG|Fluorouracil|IV injection every second week for 8 weeks.
58309328|NCT02244632|DRUG|Oxaliplatin|IV infusion every second week for 8 weeks.
58309329|NCT02244632|DRUG|Irinotecan|IV infusion every second week for 8 weeks.
58309330|NCT02244632|DRUG|Bevacizumab|IV infusion every second week for 8 weeks.
58309331|NCT01281696|DRUG|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
58433029|NCT03162081|DIAGNOSTIC_TEST|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
58433030|NCT03162081|DIAGNOSTIC_TEST|EQ-5D|Health related Quality of life
58433031|NCT03162081|DIAGNOSTIC_TEST|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
58433032|NCT03162081|DIAGNOSTIC_TEST|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
58433033|NCT03162081|DIAGNOSTIC_TEST|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
58433034|NCT03162081|DIAGNOSTIC_TEST|Cognistat|Assessment of cognitive domains
58433035|NCT03162081|DIAGNOSTIC_TEST|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
58433036|NCT03162081|OTHER|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
58433037|NCT03162081|OTHER|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
57953713|NCT05468632|DRUG|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
57953714|NCT04502251|DRUG|Low-Dose Naltrexone|4.5mg daily dose, orally, during 26 days
57953715|NCT04502251|DEVICE|Transcranial Direct Current Stimulation|An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
57953716|NCT04502251|DRUG|Placebo|The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
57953717|NCT04502251|DEVICE|Sham Transcranial Direct Current Stimulation|Sham-tDCS stimulation consists of an active current during 30 seconds
57953718|NCT04370080|DEVICE|Silver Diamine Fluoride 38%|Dental caries arrest medication
57953719|NCT03837470|DRUG|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
57953720|NCT03837470|DRUG|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
57953721|NCT02984046|DRUG|Protein CC16|
57953722|NCT05110053|DEVICE|Spinal Cord Stimulator|"Spinal Cord stimulation is a recognized treatment of chronic neuropathic pain. The procedure of implantation is the same in this study. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
57953723|NCT04453046|DEVICE|Hemopurifier|Two Hemopurifier treatments on Day 1 and Day 21
57953724|NCT04453046|DRUG|Pembrolizumab 200mg IV|Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
58102982|NCT04785833|DRUG|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
58102983|NCT01317420|DRUG|BI 836845|Intravenous infusion once every three weeks
58102984|NCT05474560|DRUG|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
58433038|NCT03162081|OTHER|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
58433039|NCT01068158|DRUG|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
57953725|NCT04155138|DEVICE|Naida Hearing Aid|hearing aid
57953726|NCT04155138|DEVICE|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
58102985|NCT05474560|DRUG|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
58102986|NCT05474560|BEHAVIORAL|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
58102987|NCT00970931|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
58309332|NCT01281696|DRUG|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
58309333|NCT01649219|BEHAVIORAL|Exercise|
58309334|NCT04059718|BEHAVIORAL|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
58309335|NCT02442609|OTHER|questionaire|questionaire before surgery
58433040|NCT01068158|DRUG|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
58433041|NCT03207594|OTHER|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
58433042|NCT03207594|OTHER|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
58433043|NCT03207594|OTHER|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
58309336|NCT03885557|OTHER|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
58433044|NCT00038558|DRUG|Filgrastim SD/01|
58433045|NCT00038558|DRUG|Adriamycin|
58433046|NCT00038558|DRUG|Bleomycin|
58433047|NCT00038558|DRUG|Vinblastine|
58433048|NCT00038558|DRUG|DTIC|
58433049|NCT06385054|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
58433050|NCT06385054|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
58433051|NCT05809492|OTHER|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
58433052|NCT03012204|DEVICE|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
58433053|NCT03012204|DEVICE|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
58433054|NCT03012204|DEVICE|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
58433055|NCT03012204|DEVICE|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
58309337|NCT03885557|OTHER|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
58309338|NCT02251353|PROCEDURE|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
58309339|NCT02251353|DRUG|systemic treatment|Systemic therapy
58309340|NCT01926158|DRUG|Denosumb|Prefilled syringe of 1 mL denosumab solution
58433056|NCT06120439|COMBINATION_PRODUCT|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
58433057|NCT06120439|COMBINATION_PRODUCT|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
58433058|NCT03263338|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
58433059|NCT00614484|RADIATION|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
58433060|NCT00614484|DRUG|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
58433061|NCT00614484|DRUG|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
58433062|NCT00106353|DRUG|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
58433063|NCT04316026|DEVICE|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
58433064|NCT06229327|BEHAVIORAL|THERAPEUTICGAMES|THERAPEUTICGAMES
58102988|NCT00970931|DRUG|placebo|Oral placebo once a day, for 18 months
58102989|NCT01973842|DRUG|0.1 mg triptorelin|
58102990|NCT01973842|DRUG|0.2 mg triptorelin|
58102991|NCT01973842|DRUG|0.4 mg triptorelin|
58102992|NCT04608578|BEHAVIORAL|Silver|A serious game to improve mental health in youth
58433065|NCT06469528|DRUG|Colchicine 0.5 MG|Low dose daily colchicine
58102993|NCT01852773|PROCEDURE|Open repair of thoracic aorta injury|open surgical management of aortic injury
58102994|NCT01852773|PROCEDURE|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
58433066|NCT05322226|BEHAVIORAL|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
57953727|NCT03464994|DIAGNOSTIC_TEST|ophthalmological examination|"* Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis"
58102995|NCT05177705|BEHAVIORAL|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
58102996|NCT00931385|DRUG|BI 1744|BI1744 Respimat Med Dose Once Daily
58102997|NCT00931385|DRUG|bi1744|1744 low dose
58102998|NCT00931385|DRUG|Placebo|Placebo Respimat and Foradil Placebo
58102999|NCT00931385|DRUG|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
58103000|NCT03124173|OTHER|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
58103001|NCT03124173|OTHER|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
58103002|NCT03124173|OTHER|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
58103003|NCT03124173|OTHER|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
58103004|NCT00644098|DIETARY_SUPPLEMENT|soluble fibre complex and medium chain triglycerides|
58103005|NCT00644098|DIETARY_SUPPLEMENT|cellulose and soybean oil|
58103006|NCT04794452|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
58103007|NCT04794452|DEVICE|Manual toothbrush|Device on plaque removal efficacy
58103008|NCT02579369|OTHER|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
58309341|NCT01926158|DRUG|Placebo (for denosumab)|
58309342|NCT03353220|DRUG|Belviq|Belviq is an oral drug
58309343|NCT03353220|DRUG|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
58103009|NCT02579369|DEVICE|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
58103010|NCT01086735|BIOLOGICAL|donor lymphocyte infusion|Donor T-cell transduction
58103011|NCT06304545|DRUG|Camrelizumab|Camrelizumab IV 200mg
58103012|NCT06304545|DRUG|Chemotherapy|Capecitabine PO oxaliplatin IV
58103013|NCT06304545|RADIATION|Radiotherapy|Radiotherapy 50Gy /45Gy /25 fractions
58103014|NCT06129565|DEVICE|Q-collar|Q-collar is placed for all patients that are admitted with low-pressure hydrocephalus
58103015|NCT06330077|DRUG|Ifenprodil|Treatment administration
58103016|NCT06330077|DRUG|Placebo|Treatment administration
58103017|NCT04056299|BIOLOGICAL|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
58103018|NCT04056299|BIOLOGICAL|Placebo powder|Placebo powder provided in capsules
58103019|NCT03751527|DEVICE|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
58103020|NCT04385199|BIOLOGICAL|Convalescent plasma|One 200mL transfusion of ABO compatible convalescent plasma over 3 hours
58103021|NCT04896723|DIAGNOSTIC_TEST|Sexual function questionnaire|Sexual function questionnaire and cognitive screening assessments
58103022|NCT06008977|OTHER|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
57737498|NCT01303666|PROCEDURE|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
58103023|NCT05930509|DEVICE|Non-invasive transcranial direct current stimulation (tDCS)|Electrical stimulation
58103024|NCT00654888|PROCEDURE|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
58103025|NCT00654888|DRUG|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
58103026|NCT06385665|BEHAVIORAL|Graded companionship|Accompanying levels are divided into beginner, intermediate and advanced
58103027|NCT01358708|DRUG|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
58103028|NCT01358708|DRUG|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
58103029|NCT00822263|DRUG|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
58103030|NCT00822263|DRUG|Placebo|Control for study
58103031|NCT02549274|OTHER|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
58103032|NCT02549274|OTHER|physiotherapy|14 physiotherapy sessions (2 by week)
58103033|NCT02331030|PROCEDURE|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
58103034|NCT02331030|PROCEDURE|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
58103035|NCT02331030|PROCEDURE|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
58103036|NCT02331030|DRUG|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
58103037|NCT02331030|DRUG|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
58103038|NCT02366065|DRUG|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
58103039|NCT02112422|DRUG|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
58103040|NCT02112422|DRUG|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
58103041|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
58103042|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
58433067|NCT01423266|PROCEDURE|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
58433068|NCT06294847|DRUG|Ursolvan|single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
58309344|NCT01737801|PROCEDURE|Lung function test|Lung function test.
58309345|NCT00880126|BEHAVIORAL|Community Development Teams|CDTs bring together counties who are implementing a new practice
58309346|NCT04052828|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
58309347|NCT03111290|DEVICE|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
58309348|NCT03111290|DEVICE|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
58309349|NCT04938791|OTHER|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
58309350|NCT03556033|DRUG|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
58309351|NCT03556033|DRUG|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
58309352|NCT00643175|BEHAVIORAL|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
58309353|NCT00501631|DRUG|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
58309354|NCT00501631|DRUG|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
58309355|NCT04751617|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
58309356|NCT00374634|DRUG|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
58309357|NCT00374634|DRUG|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
58309358|NCT05246449|OTHER|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
58309359|NCT03468621|PROCEDURE|Wound closure|Method of wound closure
58309360|NCT04496232|DEVICE|PICSI|Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate
58309361|NCT04496232|OTHER|Second ejaculate|Semen processing by density gradient centrifugation for the second ejaculate
58309362|NCT02177500|DRUG|Telmisartan + hydrochlorothiazide|
58309363|NCT02177500|DRUG|Telmisartan|
58309364|NCT02177500|DRUG|Placebo|
58309365|NCT02108301|DRUG|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
58309366|NCT00888654|DRUG|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
58433069|NCT06294847|DRUG|Placebo|Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
58433070|NCT05547308|DEVICE|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
58433071|NCT00167310|DRUG|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
58103043|NCT00755508|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
58103044|NCT00755508|DRUG|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
58103045|NCT00755508|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
58433072|NCT00167310|DRUG|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
58433073|NCT01705093|DIETARY_SUPPLEMENT|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
58433074|NCT01705093|DIETARY_SUPPLEMENT|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
58103046|NCT03519022|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
58103047|NCT03519022|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
58103048|NCT03519022|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
57737499|NCT06093113|BEHAVIORAL|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
57737500|NCT06093113|BEHAVIORAL|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
58309367|NCT00888654|PROCEDURE|Radical Prosatectomy|
58309368|NCT01741415|BEHAVIORAL|SIDI|
58309369|NCT01741415|BEHAVIORAL|SC|
58433075|NCT03094065|OTHER|News items with spin|Interpretation of news items with spin
58433076|NCT03094065|OTHER|News items without spin|Interpretation of news items without spin
58433077|NCT06434467|DRUG|Nelarabine injection|Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
58433078|NCT02522130|DRUG|Lidocaine|intracervical injection
58433079|NCT02522130|DRUG|oral misoprostol|oral treatment
58433080|NCT02522130|DRUG|naproxen|oral treatment
58433081|NCT02522130|OTHER|placebo|oral treatment
58433082|NCT04107207|DIETARY_SUPPLEMENT|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
58433083|NCT04107207|DIETARY_SUPPLEMENT|Ginger Water|Placebo
58433084|NCT03447847|OTHER|Water|1 liter of water in meals; 1 liter out of meals
58433085|NCT02750839|PROCEDURE|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
58433086|NCT01138501|DRUG|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
58433087|NCT01138501|DRUG|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
58433088|NCT00811174|DRUG|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
58129507|NCT03176550|DEVICE|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
58433089|NCT03036189|BEHAVIORAL|baa nnilah|7 meetings in the community led by a trained community facilitator
58433090|NCT04986930|RADIATION|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
58433091|NCT04986930|DRUG|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
58433092|NCT06444802|DRUG|Linezolid|Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
58433093|NCT03350906|DRUG|n3-PUFA|The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
58433094|NCT03350906|DRUG|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
58433095|NCT03350906|PROCEDURE|Biopsy|Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
58433096|NCT03350906|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
58433097|NCT06343909|OTHER|Hip abductor strengthening exercise|in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
58433098|NCT06343909|OTHER|Intrinsic foot muscle strengthening along with conventional exercises|in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
58433099|NCT02592460|OTHER|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
58433100|NCT02592460|OTHER|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
58433101|NCT03137628|OTHER|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
58433102|NCT01786395|DRUG|UF-021|
58433103|NCT01786395|DRUG|Placebo|
58433104|NCT04667546|OTHER|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
58433105|NCT00211887|DRUG|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
58433106|NCT00211887|DRUG|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
58433107|NCT00211887|OTHER|placebo|an inactive substance
58433108|NCT05984888|BEHAVIORAL|MIND Diet Intervention Group|Participants will receive individually tailored nutrition counseling on adopting the MIND diet pattern from a registered dietitian nutritionist (RDN) for a total of 8 sessions spanning 12 weeks. After completing the counseling sessions participants will be followed up 6 months later to collect additional questionnaires and assessments.
57737501|NCT05230238|DEVICE|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
58433109|NCT05984888|BEHAVIORAL|General Health Curriculum (GHC) Group|Participants will meet with trained study staff for 8 sessions spanning 12 weeks covering content on non-diet related health topics. After these sessions, participants will be followed up 6 months later to collect additional questionnaires and assessments. Once 6-month follow-up has been completed, participants will be offered to receive the MIND diet intervention offered in the MIND Diet Intervention Group.
58433110|NCT03133351|DEVICE|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
58433111|NCT04566432|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
58433112|NCT02141139|DRUG|NSAIDS (ketorolac and ibuprofen)|
57737502|NCT01297062|DRUG|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
58433113|NCT06279507|DRUG|Sodium Hyaluronate|Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
58103049|NCT06468735|DIAGNOSTIC_TEST|sarcopenia assessment|"Quadriceps muscle thickness measurement at the midpoint between the anterior superior iliac spine and the upper pole of the patella.~Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia"
58103050|NCT06468735|DIAGNOSTIC_TEST|visceral fat thickness measurement|Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.
58103051|NCT04438629|DRUG|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
58103052|NCT05041244|DEVICE|Negative pressure wound therapy delivered through VAC|Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
58103053|NCT05041244|DEVICE|Standard of care|"Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated."
58103054|NCT00266552|DRUG|risperidone|
58129508|NCT05274711|OTHER|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
58433114|NCT06279507|DRUG|Normal Saline|0.9% sodium chloride 2 mL prepared in plastic syringe
58433115|NCT06279507|DRUG|Triamcinolone Acetonide 10mg/mL|10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
58433116|NCT01730586|DRUG|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
58433117|NCT00376857|DRUG|Surgery with and without the aid of Indocyanine Green (ICG)|
58433118|NCT02406105|RADIATION|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
58433119|NCT02406105|DRUG|CyberKnife|
58433120|NCT05826847|PROCEDURE|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
57737503|NCT01297062|DRUG|Moxifloxacin|Oral Moxifloxacin (400 mg)
57737504|NCT01297062|DRUG|Placebo comparator|IV Placebo (matching volume of placebo)
57737505|NCT04764396|COMBINATION_PRODUCT|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
58103055|NCT05819931|DEVICE|Mechanical In-Exsufflator treatment|"The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit."
58103056|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
58103057|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
58103058|NCT05336682|PROCEDURE|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
58103059|NCT01987024|DEVICE|Actim Partus® test|
58103060|NCT01987024|OTHER|usual procedure|
58103061|NCT04649801|PROCEDURE|Atrial fibrillation ablation|Catheter ablation
58433121|NCT05826847|PROCEDURE|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
58103062|NCT02445989|DRUG|NuvaRing|Provide NuvaRing to women seeking contraception
58103063|NCT01958593|DRUG|Placebo|Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
58103064|NCT01958593|DRUG|Midomafetamine|Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
58103065|NCT01958593|BEHAVIORAL|Psychotherapy|Psychotherapy before and after experimental sessions.
58103066|NCT05171699|OTHER|electroacupuncture|The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
58103067|NCT05171699|OTHER|shame electroacupuncture|The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
58103068|NCT04535271|DRUG|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
58103069|NCT01637675|DRUG|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
58103070|NCT01637675|DRUG|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
58103071|NCT05589428|DIETARY_SUPPLEMENT|Low sodium bread|Bread low in sodium
58103072|NCT05589428|OTHER|Placebo|Normal bread from bakery
58103073|NCT03471182|BEHAVIORAL|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
58103074|NCT03471182|DRUG|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
58433122|NCT05826847|PROCEDURE|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
58433123|NCT03376685|BEHAVIORAL|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
58433124|NCT03376685|BEHAVIORAL|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
58433125|NCT05735535|DRUG|Antiviral Agents|two-drug one-pill once day
57737506|NCT04764396|DRUG|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
57737507|NCT01454583|DRUG|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
58103075|NCT03471182|RADIATION|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.
58103076|NCT03471182|OTHER|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
58103077|NCT00802529|DRUG|Methylprednisolone|2 transtympanic injections at interval of two weeks.
58433126|NCT06584266|DIAGNOSTIC_TEST|Transoesophageal echocardiography|Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
58433127|NCT06584266|PROCEDURE|Catheter ablation|Cathether ablation of atrial fibrillation substrate using one of available methods.
58433128|NCT06066008|DRUG|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
58433129|NCT06066008|DRUG|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
58433130|NCT04913662|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
58433131|NCT00006433|DRUG|Doxil|
58103078|NCT00802529|DRUG|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
58103079|NCT03860571|DRUG|Placebo|Oral tablet
58103080|NCT03860571|DRUG|BT-11|Oral tablet
58103081|NCT06237699|OTHER|Digital ICU diary|A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
58103082|NCT05792865|DRUG|paxlovid|Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
58103083|NCT05792865|DRUG|No paxlovid|Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
58103084|NCT05792865|DRUG|Paxlovid|Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.
58433132|NCT00006433|PROCEDURE|heat treatment|
58433133|NCT03491111|OTHER|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
58433134|NCT03491111|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
58433135|NCT03491111|OTHER|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
58433136|NCT00895310|DRUG|Ketoconazole|Ketoconazole is taken three times a day by mouth.
58433137|NCT00895310|DRUG|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
58103085|NCT00750009|OTHER|educational intervention|Patients receive a tailored intervention or generic information
58103086|NCT02910453|PROCEDURE|Pulmonary lobectomy|
58103087|NCT01884116|DRUG|NSAID patch|
58103088|NCT01884116|DRUG|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
58433138|NCT01616251|OTHER|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
58433139|NCT01905449|BEHAVIORAL|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
58433140|NCT02280317|DRUG|VAL201|VAL201-001 Sub-cutaneous injection.
58433141|NCT01971008|DEVICE|Elastic abdominal binder|
57737508|NCT01454583|DRUG|ACE-I/ARB|
57737509|NCT01454583|DRUG|No RAS-inhibition|
58433142|NCT01971008|DEVICE|Placebo binder|
58433143|NCT00242099|PROCEDURE|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
58433144|NCT00065845|PROCEDURE|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
58433145|NCT03878758|DEVICE|BD Nano™ PRO|Insulin Pen needle
58433146|NCT03878758|DEVICE|33G Artsana Insupen Extr3me|Insulin Pen Needle
58433147|NCT03878758|DEVICE|34G Artsana Insupen Extr3me|Insulin Pen Needle
58433148|NCT03878758|DEVICE|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
58433149|NCT02752373|DEVICE|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
58433150|NCT01587430|DRUG|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
58433151|NCT01587430|DRUG|standard dose ARA-C|
58433152|NCT06205082|DRUG|LIT-00814|LIT-00814 is an oral tablet.
58433153|NCT05564585|OTHER|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
58433154|NCT05564585|OTHER|Sham Taping|The sham tape was applied over the calf muscle of either leg.
58433155|NCT00151372|BEHAVIORAL|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
58433156|NCT00151372|BEHAVIORAL|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
58433157|NCT03422666|DRUG|Teduglutide|Teduglutide
58433158|NCT03422666|DRUG|Placebo|Placebo
58433159|NCT03248089|DIAGNOSTIC_TEST|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
58433160|NCT00147303|DRUG|MCI-9042|
58103089|NCT01884116|DRUG|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
58103090|NCT01884116|DRUG|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
58433161|NCT02386826|DRUG|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
58433162|NCT02386826|BIOLOGICAL|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
58433163|NCT04689789|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
58433164|NCT00855049|DRUG|Acetaminophen|Intranasal acetaminophen administration
58433165|NCT00855049|DRUG|Acetaminophen|Oral acetaminophen administration
58433166|NCT00639626|DRUG|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
58433167|NCT00305487|DRUG|Ciclesonide nasal spray|
58433168|NCT06579690|DRUG|8.4% sodium bicarbonate solution|Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
58433169|NCT06579690|OTHER|0.9% Normal Saline|The comparision group will receive 50 mls of 0.9% Normal Saline
58433170|NCT00794885|DRUG|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
57737510|NCT06300008|DRUG|cetylated fatty acid|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
58433171|NCT00794885|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
58433172|NCT06547255|DRUG|Bupivacaine liposome injectable suspension|At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
58433173|NCT05107765|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
58433174|NCT05107765|DRUG|Placebo|Pill capsules will look same as that of active drug.
58433175|NCT06454877|DEVICE|active heating|"Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°."
58433176|NCT06454877|BEHAVIORAL|pasive heating|"In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets."
58433177|NCT00748319|OTHER|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
58433178|NCT03897855|OTHER|Post Traumatic Stress Disorder|"The test Think / No-Think"
58433179|NCT02020408|DRUG|[11C]raclopride|1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
58433180|NCT02020408|DRUG|[11C]DASB|BPND of \[11C\]DASB.
58433181|NCT02020408|DRUG|amphetamine|The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
58433182|NCT06379269|DEVICE|App healthcare|Self-developed app: includes home stretching and strengthening exercises, muscle release technique instruction.
58433183|NCT06379269|OTHER|Control|general education and home rehab program
58433184|NCT05740332|DRUG|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
58433185|NCT05454124|BEHAVIORAL|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
58433186|NCT05454124|BEHAVIORAL|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
58433187|NCT03515564|BEHAVIORAL|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
58433188|NCT05378737|DRUG|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
58433189|NCT02171741|DRUG|BIBW 2992|continuous daily dosing for 20 or 13 days
57737511|NCT06300008|DRUG|Placebo|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
58433190|NCT02171741|DRUG|Docetaxel|single infusion on day 1
58433191|NCT02421588|DRUG|Lurbinectedin (PM01183)|
58433192|NCT02421588|DRUG|Pegylated liposomal doxorubicin (PLD)|
58433193|NCT02421588|DRUG|Topotecan|
58433194|NCT03244163|DEVICE|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
57737512|NCT05989633|OTHER|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
57737513|NCT06670716|OTHER|Examination by a speech therapist|MASTcz test
57737514|NCT06670716|DIAGNOSTIC_TEST|Cognitive examination|ALBA test, PICNIR test
57737515|NCT06670716|OTHER|Examination of delirium|CAM-ICU and ICDSC questionnaire
57953728|NCT04703075|DRUG|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
58433195|NCT03244163|DEVICE|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
58433196|NCT01368081|DRUG|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
58433197|NCT01368081|DRUG|BI 10773|BI 10773 low dose tablet once daily
58433198|NCT01368081|DRUG|Placebo (low dose)|Placebo tablets once daily
58433199|NCT01368081|DRUG|BI 10773|BI 10773 high dose tablet once daily
58433200|NCT01368081|DRUG|Placebo (high dose)|Placebo tablets once daily
58433201|NCT01817959|DRUG|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
58433202|NCT01817959|DRUG|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
57737516|NCT06670716|OTHER|History taking|The first page includes several sections: personal information, pre-stroke history, time-related data, neurological deficit data, radiological evaluation, pre-admission and admission treatment, and a medical examination focused on motor and speech impairments. The third page will document the physician's delirium examination and the speech therapy assessment. A questionnaire will be given to the relatives or close persons of the patients to fill out in order to collect systematic personal and pre-stroke anamnestic data and to assess the presence of dementia signs before the stroke using the Blessed Dementia Scale (BDS) questionnaire. All pages of the record form and the Questionnaire for Relatives are included in the appendices.
58103091|NCT06330428|BEHAVIORAL|Sexuality-Based Family Planning Education via Podcast|The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
58433203|NCT00888342|DRUG|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
58433204|NCT00888342|DRUG|zopiclone|5 mg sedative given approximately 1 hour before sleep
58433205|NCT00888342|OTHER|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
58433206|NCT02624427|DEVICE|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
58433207|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
58433208|NCT03791775|DRUG|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
58433209|NCT05247281|DIAGNOSTIC_TEST|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
58433210|NCT05247281|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
58433211|NCT05487417|DRUG|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
58433212|NCT05758428|DRUG|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
58433213|NCT05758428|DRUG|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
58433214|NCT04522479|OTHER|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
58433215|NCT02804035|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
58433216|NCT00478686|PROCEDURE|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
58433217|NCT02915978|DRUG|Fentanyl|Fentanyl delivered via sublingual spray
58433218|NCT02915978|DRUG|Placebo|Matching placebo delivered via sublingual spray
58433219|NCT00501865|DRUG|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
58433220|NCT00278616|BIOLOGICAL|Stem Cell Transplantation|Autologous Stem Cell Transplantation
58433221|NCT01307462|DRUG|fluticasone propionate|Given inhaled PO
58433222|NCT01307462|DRUG|montelukast sodium|Given PO
58433223|NCT01307462|DRUG|azithromycin|Given PO
58433224|NCT02116088|BEHAVIORAL|Teacher Coaching|
58103092|NCT05741775|OTHER|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
57737517|NCT00735046|BEHAVIORAL|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
57737518|NCT00735046|OTHER|Control|Patients and proxies who are assigned to treatment as usual
58433225|NCT04682535|OTHER|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
58433226|NCT00667849|DEVICE|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
57737519|NCT04669496|DRUG|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
57737520|NCT01780922|OTHER|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
58103093|NCT05741775|OTHER|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
58433227|NCT00667849|DEVICE|Sham|sham device identical to active device with the exception of administration of ultrasound
58433228|NCT06384755|BEHAVIORAL|Honest Open Proud program|The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
57737521|NCT01780922|OTHER|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
58433229|NCT03167528|BEHAVIORAL|Relaxation|Relaxation
58433230|NCT03167528|BEHAVIORAL|Hypnosis|Hypnosis
58433231|NCT03167528|BEHAVIORAL|Holistic gymnastics|holistic gymnastics
58433232|NCT03167528|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS
58433233|NCT03167528|BEHAVIORAL|Sophrology|Sophrology
57737522|NCT01780922|OTHER|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
57737523|NCT04486352|DRUG|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
57737524|NCT04486352|DRUG|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
58433234|NCT00407017|DRUG|Gatifloxacin|
58433235|NCT00407017|DRUG|Ketorolac LS|
58433236|NCT00407017|DRUG|Pred Forte|
58433237|NCT00407017|DRUG|Moxifloxacin|
58433238|NCT00407017|DRUG|Nepafenac|
58433239|NCT00407017|DRUG|EconoPred Plus|
58433240|NCT05150522|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cells infusion
58433241|NCT02642380|DRUG|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
58433242|NCT02642380|DRUG|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
58433243|NCT03114384|OTHER|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
58433244|NCT02391519|PROCEDURE|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
58433245|NCT03857542|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
58433246|NCT03857542|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
58433247|NCT04718493|PROCEDURE|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
58433248|NCT04718493|PROCEDURE|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
58433249|NCT03300063|OTHER|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
58433250|NCT00902707|DRUG|Mucinex 1200mg|Compared to Placebo
58433251|NCT00902707|DRUG|Placebo|Compare to active Mucinex
58433252|NCT04302545|PROCEDURE|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
58433253|NCT00365274|DRUG|Cyclophosphamide|Given IV 750 mg/m\^2 day 1
58433254|NCT00365274|DRUG|Doxorubicin hydrochloride|Given 50 mg/m\^2 IV day 1
58433255|NCT00365274|DRUG|vincristine sulfate|Given 1.4 mg/m\^2 IV
58433256|NCT00365274|DRUG|prednisone|100 mg orally daily days 1 - 5
58433257|NCT00365274|DRUG|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
58433258|NCT05176834|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
58433259|NCT04494126|DRUG|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
58433260|NCT04494126|DRUG|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
58433261|NCT00815594|DRUG|bevacizumab|0.05ml, 1.25mg
58433262|NCT03614299|OTHER|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
58433263|NCT03614299|DIAGNOSTIC_TEST|Interferometry|Evaluation of the mebomian function using the LipiView methodology
58433264|NCT04369625|BEHAVIORAL|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
58433265|NCT04369625|BEHAVIORAL|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
57953729|NCT04703075|DRUG|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
58433266|NCT04369625|BEHAVIORAL|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
58433267|NCT04369625|BEHAVIORAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
58433268|NCT01223183|DRUG|hypertonic saline (7%)|single treatment by inhalation
58433269|NCT01223183|DRUG|isotonic saline|single treatment by inhalation
57737525|NCT04486352|DRUG|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
57737526|NCT04486352|DRUG|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
57737527|NCT04486352|DRUG|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
57953730|NCT00077792|DRUG|Enoxaparin sodium (XRP4563)|
57953731|NCT00522431|DRUG|Testosterone|2% gel
58103094|NCT00849524|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
58433270|NCT05236504|DIETARY_SUPPLEMENT|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
58433271|NCT05236504|OTHER|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
58433272|NCT06141291|DIETARY_SUPPLEMENT|High protein diet|Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
58433273|NCT06141291|DIAGNOSTIC_TEST|OGTT|Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
58433274|NCT05340790|DRUG|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
58433275|NCT05340790|DRUG|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
58433276|NCT00429533|DRUG|Dapsone|
58433277|NCT03534375|OTHER|The study is an observational cross sectional study|An intervention will not be performed
58433278|NCT02646813|PROCEDURE|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
58433279|NCT02646813|PROCEDURE|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
58433280|NCT06317168|DIAGNOSTIC_TEST|Mean awake ambulatory BP measurements|Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
58433281|NCT02413047|DRUG|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
58433282|NCT02413047|DRUG|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
58433283|NCT02413047|DRUG|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
57737528|NCT04486352|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
57737529|NCT04486352|DRUG|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
57737530|NCT04486352|DRUG|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
58309370|NCT02332265|OTHER|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
58309371|NCT01549158|DRUG|torasemide-PR|Single oral dose of torasemide PR 10 mg
58309372|NCT01549158|DRUG|Furosemide-IR|Single oral dose of furosemide IR 40 mg
58309373|NCT01549158|DRUG|torasemide-IR|Single oral dose of torasemide IR 10 mg
58309374|NCT01426581|BEHAVIORAL|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
58309375|NCT01426581|BEHAVIORAL|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
58309376|NCT04740307|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
58309377|NCT04740307|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
58309378|NCT04740307|BIOLOGICAL|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
58309379|NCT02526238|DEVICE|TMS and trunk rotation|TMS and trunk rotation
58309380|NCT02526238|DEVICE|Sham TMS and trunk rotation|Sham TMS and trunk rotation
58433284|NCT04787354|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
58433285|NCT04787354|DRUG|Capecitabine|Capecitabine: 2,000 mg/m2/day
58433286|NCT05158725|DEVICE|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
58433287|NCT05158725|DEVICE|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
58309381|NCT06140186|DRUG|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
58433288|NCT05158725|DEVICE|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
58433289|NCT04599595|DEVICE|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
58433290|NCT04691908|BIOLOGICAL|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
58433291|NCT04691908|OTHER|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
58433292|NCT01267526|DEVICE|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
58433293|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
58433294|NCT05695144|DEVICE|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
58433295|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
58433296|NCT05695144|DEVICE|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
58433297|NCT05494034|DEVICE|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
58433298|NCT03465930|PROCEDURE|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
58433299|NCT00122369|BEHAVIORAL|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
58433300|NCT00122369|BEHAVIORAL|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
58433301|NCT00863291|DRUG|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
58433302|NCT00863291|DRUG|placebo|Placebo in a manner similar to the active comparator
58433303|NCT03595527|DIAGNOSTIC_TEST|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
58433304|NCT01108523|DEVICE|HP828-101|
58433305|NCT04934657|OTHER|no intervention|no intervention
58433306|NCT01345669|DRUG|Placebo|Once daily
58309382|NCT06140186|DRUG|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
58309383|NCT04149080|PROCEDURE|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
58309384|NCT04149080|PROCEDURE|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
58309385|NCT03773874|OTHER|Assessment|Evaluation
58309386|NCT02495389|DRUG|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
58433307|NCT01345669|DRUG|Afatinib|Once daily
58433308|NCT03663335|BIOLOGICAL|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
58433309|NCT03663335|DRUG|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
58433310|NCT05700032|DIAGNOSTIC_TEST|high MI impulses|patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
58433311|NCT05700032|DIAGNOSTIC_TEST|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
57953732|NCT01830504|DRUG|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
57953733|NCT03767075|DRUG|Atezolizumab|1200 mg, administered IV, once every 3 weeks
58103095|NCT05447429|PROCEDURE|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
58103096|NCT05447429|DRUG|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
58103097|NCT06352931|DEVICE|transcranial and transcranial dopp;er|"All patients will be subjected to Transcranial ultrasound examination and compared with other neuroimaging modalities: CT brain or MRI brain and/or MRA \& MRV.~Patients suspected to have ischemic or hemorrhagic disorder, CNS infection or increase intracranial pressure will be evaluated with transcranial Doppler ultrasound and compared with other neuroimaging modalities."
58103098|NCT03109860|BEHAVIORAL|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
58103099|NCT00561405|BEHAVIORAL|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
58129509|NCT05274711|OTHER|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
58309387|NCT01427140|OTHER|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
58309388|NCT01427140|OTHER|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
58433312|NCT05818267|DRUG|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
58309389|NCT06233708|DRUG|Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use|Non-selective blocker including Propranolol, Carvedilol PO was prescribed
58309390|NCT04020536|DRUG|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
58433313|NCT00745433|DRUG|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
58433314|NCT00745433|DRUG|metformin|Start dose and frequency at the discretion of the physician following clinical practice
58433315|NCT01005758|DRUG|cyclophosphamide|
58433316|NCT01005758|DRUG|cytarabine|
58433317|NCT01005758|DRUG|dexamethasone|
57737531|NCT04486352|DRUG|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
57737532|NCT04486352|DRUG|Giredestrant|Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
57737533|NCT04486352|DRUG|Abemaciclib|Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
57953734|NCT03767075|DRUG|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
58103100|NCT00561405|BEHAVIORAL|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
58103101|NCT00165711|DRUG|Mecobalamin|
58103102|NCT02746029|OTHER|Clinical examination|
58103103|NCT06134739|OTHER|No intervention.|Observational study, no intervention.
58433318|NCT01005758|DRUG|doxorubicin hydrochloride|
57737534|NCT00357864|DRUG|carbachol|
58103104|NCT00867126|DRUG|pioglitazone hydrochloride|
57737535|NCT04152018|DRUG|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
58433319|NCT01005758|DRUG|etoposide phosphate|
58433320|NCT01005758|DRUG|hydrocortisone sodium succinate|
58433321|NCT01005758|DRUG|imatinib mesylate|
57737536|NCT04152018|DRUG|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
57737537|NCT02266069|OTHER|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
57737538|NCT06147895|BIOLOGICAL|CVI-HBV-002|Investigational Product
58433322|NCT01005758|DRUG|mercaptopurine|
57737539|NCT05789433|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
57737540|NCT05789433|BEHAVIORAL|Progressive stretching|Statistic stretching of eight major muscle groups
57737541|NCT01956526|DEVICE|CORolla™ TAA device|
58103105|NCT00867126|OTHER|laboratory biomarker analysis|
58103106|NCT00867126|OTHER|questionnaire administration|
58103107|NCT00867126|PROCEDURE|quality-of-life assessment|
58433323|NCT01005758|DRUG|methotrexate|
58433324|NCT01005758|DRUG|methylprednisolone|
58433325|NCT01005758|DRUG|pegaspargase|
58433326|NCT01005758|DRUG|prednisolone|
58433327|NCT01005758|DRUG|prednisone|
58433328|NCT01005758|DRUG|vincristine sulfate|
58433329|NCT01005758|OTHER|laboratory biomarker analysis|
58433330|NCT01005758|RADIATION|radiation therapy|
58433331|NCT03399474|DRUG|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
58433332|NCT03399474|DRUG|Dexmedetomidine 0.5 ug/kg|pecedex
58433333|NCT03399474|DRUG|Dexmedetomidine Injection 0.25 ug/kg|pecedex
58433334|NCT00408434|DRUG|CS-7017|CS-7017 0.05mg and 1.0mg tablets
58433335|NCT01180010|PROCEDURE|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
57737542|NCT03775850|BIOLOGICAL|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
57737543|NCT03775850|BIOLOGICAL|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
57737544|NCT01297933|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
57737545|NCT03007927|DRUG|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
57737546|NCT03007927|DRUG|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
57737547|NCT00680212|DIETARY_SUPPLEMENT|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
58103108|NCT04072744|DEVICE|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
58129510|NCT03274310|BEHAVIORAL|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
58129511|NCT02175797|DEVICE|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
58129512|NCT01695070|DRUG|Melatonin|4mg prolonged release melatonin oral tablets twice daily
58129513|NCT00345410|DRUG|AVE1625 B|
58433336|NCT05426941|BEHAVIORAL|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
58433337|NCT05426941|BEHAVIORAL|Music Listening|Up to 15 participants will be randomized to independent music listening.
58433338|NCT00336414|DRUG|cyclophosphamide-prednisone-azathioprine|
58433339|NCT03332446|OTHER|cold water immersion|10 min at 12-15°C
58433340|NCT02948738|BEHAVIORAL|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
58433341|NCT02948738|BEHAVIORAL|Standard Asthma Education|Basic review of asthma action plan and inhaler use
58433342|NCT01089205|DRUG|Metformin|
58103109|NCT04072744|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
58103110|NCT05277922|DRUG|C21|C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
58433343|NCT01793883|DRUG|40 mg Laninamivir Octanoate|
58433344|NCT01793883|DRUG|80 mg Laninamivir Octanoate|
58103111|NCT05277922|DRUG|Sodium Nitroprusside|Ascending doses of 4, 8 and 16 µg
58103112|NCT00709475|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58433345|NCT01793883|DRUG|Placebo|
58433346|NCT06584435|DRUG|Tremelimumab|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
58103113|NCT06540300|OTHER|rTMS stimulation of right IPL|The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
58103114|NCT04507789|OTHER|exercise intervention|Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
58433347|NCT04025229|BEHAVIORAL|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
58433348|NCT04364152|BEHAVIORAL|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
58433349|NCT06470646|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body.By employing specialized catheters and devices,endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the targetsite,without the need for conventional open surgery.
58309391|NCT04221529|DRUG|Atezolizumab|1200 mg i.v. on day 1 of each cycle
58433350|NCT00668668|DRUG|Lactic acid (Dermacid)|
58433351|NCT05226312|OTHER|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
58433352|NCT04591444|DRUG|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
58433353|NCT04591444|DRUG|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
58433354|NCT04591444|OTHER|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
58433355|NCT01628965|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
57737548|NCT00680212|DIETARY_SUPPLEMENT|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
58129514|NCT01179880|DRUG|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
58433356|NCT00003066|DRUG|docetaxel|
58433357|NCT00003066|DRUG|estramustine phosphate sodium|
58433358|NCT06553872|DRUG|Pirtobrutinib|Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
58433359|NCT06553872|DRUG|Brexucabtagene Autoleucel|Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
58433360|NCT02238860|DRUG|Entacavir|Entacavir-0.5 mg ,OD,for
57737549|NCT06187467|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
58433361|NCT02238860|DRUG|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
57737550|NCT06009341|OTHER|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
57737551|NCT01703364|DRUG|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
57737552|NCT02232113|DRUG|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
57737553|NCT05932134|DIETARY_SUPPLEMENT|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
57737554|NCT05932134|BEHAVIORAL|UC + HP + core muscle rehabilitation|Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks
58103115|NCT04507789|OTHER|routine radiotherapy protokol|This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
58103116|NCT01854073|DRUG|Hyoscine butyl bromide|
58103117|NCT01854073|DRUG|Normal saline|
58103118|NCT05136456|DRUG|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
58103119|NCT05136456|DRUG|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
58103120|NCT05136456|DRUG|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
58433362|NCT00421135|DRUG|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
57737555|NCT05932134|DEVICE|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
57737556|NCT02147548|DRUG|etifoxine|
57737557|NCT02147548|DRUG|lorazepam|
57737558|NCT02147548|DRUG|Placebo|
57737559|NCT06669195|DEVICE|Intravascular lithotripsy group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Intravascular lithotripsy group.
58103121|NCT04768023|DRUG|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
58103122|NCT04768023|DRUG|Placebo|Matching amount of vegetable oil to the vitamin D3.
58103123|NCT04189289|PROCEDURE|ESP block group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
58433363|NCT01835002|DEVICE|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
58103124|NCT04189289|PROCEDURE|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
58433364|NCT04271033|DEVICE|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
58433365|NCT06006403|BIOLOGICAL|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
58433366|NCT05179759|BEHAVIORAL|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
58433367|NCT05179759|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
58433368|NCT01990612|PROCEDURE|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
58433369|NCT02864160|BEHAVIORAL|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
58433370|NCT02864160|BEHAVIORAL|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
58433371|NCT05620264|DIAGNOSTIC_TEST|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
58433372|NCT04757545|OTHER|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
58433373|NCT02878837|DRUG|Dexmedetomidine|
58103125|NCT02390466|BIOLOGICAL|VAC-3S|Administered via intra-muscular injection in the arm
57737560|NCT06669195|DEVICE|high-pressure balloon group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of high-pressure balloon group.
58433374|NCT02878837|DRUG|Midazolam|
58433375|NCT02870634|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
58433376|NCT01939639|DRUG|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
58433377|NCT01939639|DRUG|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
58433378|NCT04623814|OTHER|Food|HEC113995 20mg will be taken orally fasted or with food
57737561|NCT02747134|BEHAVIORAL|Emotion Regulation and Mindfulness skills|
58103126|NCT05355337|DRUG|Pramipexole|9 weeks of treatment with Pramipexole
58103127|NCT05355337|DRUG|Placebo|9 weeks of treatment with Placebo
58103128|NCT06005337|BEHAVIORAL|Blogshots 1-3|"1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection"
58129515|NCT01179880|DRUG|Placebo|Matching placebo for each step
58433379|NCT04623814|DRUG|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
58433380|NCT04623814|DRUG|placebo|The placebo will be administered fasted or with food for 10 days.
58433381|NCT06301932|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
58433382|NCT01196416|DRUG|Cisplatin|Given IV
58103129|NCT06005337|BEHAVIORAL|Blogshots 4-6|"1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media"
58433383|NCT01196416|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
58433384|NCT01196416|OTHER|Laboratory Biomarker Analysis|Correlative studies
57737562|NCT03326687|BEHAVIORAL|Treatment ABAB|Participants will perform the phases in the ABAB order.
58433385|NCT01196416|OTHER|Pharmacological Study|Correlative studies
58433386|NCT01196416|DRUG|Temozolomide|Given PO
58433387|NCT01196416|DRUG|Vinblastine Sulfate|Given IV
58433388|NCT00745043|DRUG|bronchodilator response|
58433389|NCT04356235|PROCEDURE|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
58433390|NCT04356235|PROCEDURE|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
58433391|NCT04356235|PROCEDURE|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
58433392|NCT04356235|PROCEDURE|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
58433393|NCT04356235|PROCEDURE|E: unilateral simple mastectomy|unilateral simple mastectomy
58433394|NCT04356235|PROCEDURE|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
58433395|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
58433396|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
58433397|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
58433398|NCT01540669|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
58433399|NCT04536207|OTHER|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
58433400|NCT06464016|DEVICE|Ventricular Assist Device with Berlin Heart EXCOR|"The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body."
58433401|NCT02841462|DEVICE|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
58433402|NCT05820984|OTHER|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
58433403|NCT05820984|OTHER|Usual practice|Peer review as it is usual practice at the journal
58433404|NCT00490048|PROCEDURE|Induced sputum (inhalation of 3.5% saline)|
58433405|NCT00006400|DRUG|Hydroxyurea|Participants will receive hydroxyurea.
58103130|NCT05201820|DEVICE|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
58129516|NCT02886078|PROCEDURE|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
58433406|NCT00006400|DRUG|Placebo|Participants will receive placebo.
58433407|NCT01554800|DRUG|ACP-501|A single dose infusion
58433408|NCT06224803|DIETARY_SUPPLEMENT|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
58433409|NCT06224803|DIETARY_SUPPLEMENT|Indigestible dextrin|Indigestible dextrin as placebo intervention
58433410|NCT00206713|DRUG|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
58433411|NCT00206713|DRUG|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
58433412|NCT02724709|PROCEDURE|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
58433413|NCT02724709|PROCEDURE|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
58433414|NCT04137458|BIOLOGICAL|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
58433415|NCT06348628|BEHAVIORAL|Motivational Interview|4 Motivational interviews within first 6 months
58433416|NCT06348628|BEHAVIORAL|Placebo|Advices on standard of care treatment of NAFLD within first 6 months
58433417|NCT01575314|DEVICE|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
58433418|NCT03989362|DRUG|Vopratelimab|Specified dose on specified days
58433419|NCT03989362|DRUG|Ipilimumab|Specified dose on specified days
57737563|NCT03326687|BEHAVIORAL|Treatment BABA|Participants will perform the phases in the BABA order.
57737564|NCT03526250|OTHER|Laboratory Biomarker Analysis|Correlative studies
58433420|NCT03401268|DRUG|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
58433421|NCT02227199|DRUG|Brentuximab Vedotin|Given IV
58433422|NCT02227199|DRUG|Carboplatin|Given IV
57737565|NCT03526250|DRUG|Palbociclib|Given PO
57737566|NCT03526250|OTHER|Pharmacological Study|Correlative studies
57737567|NCT01913600|DEVICE|Resolute Integrity Stent|Drug eluting stent (DES)
57737568|NCT03942250|BIOLOGICAL|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
58433423|NCT02227199|DRUG|Etoposide|Given IV
58433424|NCT02227199|DRUG|Ifosfamide|Given IV
58433425|NCT02227199|OTHER|Laboratory Biomarker Analysis|Correlative studies
58433426|NCT01549977|DRUG|Febuxostat|Febuxostat tablets
58433427|NCT01549977|DRUG|Placebo|Febuxostat placebo-matching tablets
58433428|NCT02564224|PROCEDURE|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
58433429|NCT02564224|PROCEDURE|Conventional Wound Closure|Procedure: Conventional Wound Closure
58433430|NCT02564224|DEVICE|prolene|
58433431|NCT00621140|DRUG|linagliptin|active
58433432|NCT00621140|DRUG|placebo|placebo
57737569|NCT05677087|BEHAVIORAL|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
57737570|NCT00242112|PROCEDURE|MRI Prostate|
57737571|NCT06104475|OTHER|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
57737572|NCT01460329|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
57737573|NCT05674422|DRUG|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
57737574|NCT05719454|DEVICE|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
57737575|NCT04514159|DRUG|ZN-c5|ZN-c5 is the study drug.
57737576|NCT04514159|DRUG|Abemaciclib|Abemaciclib (VERZENIO®) is an approved drug.
57737577|NCT00738777|DRUG|Anastrozole|1 mg,QD,PO
57737578|NCT00738777|DRUG|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
57737579|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
57737580|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
57737581|NCT06390241|DRUG|Avidin-biotin-Dota-90Y|Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
57737582|NCT01603576|DEVICE|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
57737583|NCT06451172|DRUG|ASO|Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
57953735|NCT03767075|DRUG|Amivantamab|1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
57953736|NCT05374538|DRUG|VIC-1911|VIC-1911 tablets for oral administration
58433433|NCT04565951|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
58433434|NCT04565951|BEHAVIORAL|Sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
58433435|NCT00344422|DRUG|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
58433436|NCT01584362|DRUG|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
58433437|NCT01584362|DRUG|placebo|single oral dose of placebo
58433438|NCT01584362|DRUG|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
58433439|NCT01584362|DRUG|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
58433440|NCT01584362|DRUG|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
58433441|NCT01584362|DRUG|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
58433442|NCT01584362|DRUG|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
58433443|NCT03458156|BIOLOGICAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
58433444|NCT03458156|BIOLOGICAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
58433445|NCT03458156|OTHER|the control group|The patients will be assigned to the control group.
58309392|NCT03447834|OTHER|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
58309393|NCT03447834|OTHER|Standard PPCI|PPCI per routine
58309394|NCT03703895|DRUG|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
58309395|NCT03703895|DRUG|Topical Placebo|Placebo Comparator, Topical Placebo.
58309396|NCT03713099|DEVICE|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
58309397|NCT03468504|DEVICE|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
58309398|NCT03468504|DEVICE|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
58309399|NCT03468504|DEVICE|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
58309400|NCT02903979|OTHER|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
58309401|NCT02903979|OTHER|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
58309402|NCT05840445|DRUG|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
58309403|NCT05840445|DRUG|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
58309404|NCT02388451|DEVICE|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
58309405|NCT04620499|DEVICE|EEG|PEER EEG
58309406|NCT03812419|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
58309407|NCT03812419|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
58309408|NCT06211023|DRUG|SHR-1921|SHR-1921
58309409|NCT06211023|DRUG|carboplatin|carboplatin AUC 4
58309410|NCT06211023|DRUG|carboplatin|carboplatin AUC 5
58309411|NCT06211023|DRUG|platinum-based doublet chemotherapy|platinum-based doublet chemotherapy
58309412|NCT03736252|DEVICE|Orthosis provision|Hely and Weber CMC controller
58309413|NCT01879293|DRUG|Metformin|
58309414|NCT01879293|DRUG|placebo|
58309415|NCT04971603|OTHER|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) \*, Sanyinjia (SP 6) \*, Weizhong (BL 40) \*, Baihui (GV 20), Shuigou (GV 26) \*, Zusanli (ST 36) \*, Quchi (LI 11) \*, Waiguan (TE 5) \*, Hegu (LI 4) \*, Huantiao (GB 30) \*, Yanglingquan (GB 34)\* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
58309416|NCT05399797|OTHER|Educational training|Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
58309417|NCT04850989|DEVICE|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
58309418|NCT05409365|OTHER|Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)|Immunohistochemical staining
57953737|NCT05374538|DRUG|sotorasib|Sotorasib tablets for oral administration
58309419|NCT04035616|DIETARY_SUPPLEMENT|microbial cell preparation [MCP]|active microbial cell preparation
58309420|NCT04035616|OTHER|placebo|inactive ingredient
57737584|NCT04805723|PROCEDURE|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
57737585|NCT04805723|PROCEDURE|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
58103131|NCT00515385|DRUG|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
58103132|NCT00515385|DRUG|MGAWN1|Single IV dose
58433446|NCT05290116|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
58433447|NCT01831674|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
58433448|NCT01831674|DRUG|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
57737586|NCT01055769|DRUG|Linezolid|"1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG"
58103133|NCT00515385|OTHER|Placebo|Single IV dose
58129517|NCT02886078|PROCEDURE|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
58129518|NCT03266237|DRUG|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
57737587|NCT01055769|DRUG|Linezolid|"1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG"
58103134|NCT05958810|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
58103135|NCT05958810|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
58103136|NCT00206219|DRUG|Gefitinib|
58103137|NCT00206219|DRUG|methotrexate|
58433449|NCT01468350|DRUG|dalfampridine-ER 10mg|
58103138|NCT02669628|PROCEDURE|Surgical technique|Laparoscopic surgery
58103139|NCT02669628|PROCEDURE|Alcohol sclerotherapy|US-guided sclerotherapy
58433450|NCT01468350|OTHER|Placebo|
58103140|NCT05036239|OTHER|Eccentric biceps curls|10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
58103141|NCT01665573|DRUG|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
58103142|NCT01665573|DRUG|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
58103143|NCT04591769|DEVICE|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
58103144|NCT05614388|DIAGNOSTIC_TEST|COVID-19 Self testing and related messaging|Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
58103145|NCT01219088|DRUG|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
58103146|NCT04909125|RADIATION|Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy|The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes
58103147|NCT02768220|DRUG|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
58103148|NCT02768220|DRUG|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
58309421|NCT03918317|DEVICE|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
57737588|NCT04020770|OTHER|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
58103149|NCT01799213|DRUG|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
58103150|NCT01799213|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
58103151|NCT01675869|BEHAVIORAL|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
58103152|NCT01675869|BEHAVIORAL|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
58433451|NCT01458015|DRUG|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
58433452|NCT00900029|BIOLOGICAL|No HP802 Treatment|
58433453|NCT00900029|OTHER|No HP802 Vehicle Treatment|
58433454|NCT02371408|DRUG|ravidasvir hydrochloride|200 mg
58433455|NCT02371408|DRUG|sofosbuvir|400 mg
58433456|NCT02371408|DRUG|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
58433457|NCT05571020|OTHER|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
57737589|NCT06669234|DRUG|ALN-F1202|Administered per the protocol
58103153|NCT05422235|OTHER|Routine Medical Treatment|Subjects will continue their routine medical treatment.
58129519|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
57737590|NCT06669234|DRUG|Matching Placebo|Administered per the protocol
57737591|NCT05073016|OTHER|neuromodulation|neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.
57737592|NCT05073016|OTHER|motor learning training|motor learning training requires performing a sequential training called finger taping task
58129520|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
58129521|NCT04183231|DRUG|Anti-caries varnish|topical tooth varnish
58103154|NCT05422235|OTHER|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
58103155|NCT05422235|OTHER|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
58103156|NCT00481871|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
58103157|NCT00481871|DRUG|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
58103158|NCT00481871|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
58103159|NCT00481871|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
58103160|NCT03941223|PROCEDURE|PECSII and paravertebral blocks|Regional anesthesia for mastectomy outcomes
58103161|NCT01964898|BEHAVIORAL|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
58103162|NCT01964898|BEHAVIORAL|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
58103163|NCT01964898|DRUG|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
58103164|NCT01964898|OTHER|Printed Self-help materials for Smoking Cessation|
58103165|NCT00003981|DRUG|indisulam|
58103166|NCT01897558|DEVICE|Pacemaker implantation|
58103167|NCT05695079|OTHER|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
58103168|NCT05695079|OTHER|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
57953738|NCT02246062|BEHAVIORAL|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
57953739|NCT02246062|BEHAVIORAL|smartphone|the child received smartphone application immediately before entering the operating room
58103169|NCT05695079|OTHER|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
58103170|NCT06293573|DEVICE|Whole-body vibration|GROUP A : will receive whole body vibration exercises combined with resistance exercises
58103171|NCT06293573|OTHER|aerobic exercises|Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.
58103172|NCT06293573|OTHER|resistance exercises|Group c: will receive progressive resistance exercises with diet modification life style.
57737593|NCT06204731|OTHER|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
58103173|NCT04965402|DRUG|BMS-986166|Specified dose on specified days
58103174|NCT04965402|OTHER|Placebo|Specified dose on specified days
58103175|NCT01682278|DEVICE|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
58103176|NCT00005578|BIOLOGICAL|bleomycin sulfate|
58103177|NCT00005578|BIOLOGICAL|filgrastim|
58103178|NCT00005578|DRUG|cyclophosphamide|
58103179|NCT00005578|DRUG|dexrazoxane hydrochloride|
58103180|NCT00005578|DRUG|doxorubicin hydrochloride|
58103181|NCT00005578|DRUG|etoposide|
58103182|NCT00005578|DRUG|prednisone|
58103183|NCT00005578|DRUG|vincristine sulfate|
58103184|NCT00005578|RADIATION|radiation therapy|
58103185|NCT05882968|DIAGNOSTIC_TEST|kidney function tests|using GFR test according to kdigo guide lines
58103186|NCT02257827|RADIATION|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
58103187|NCT00795782|PROCEDURE|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
58433458|NCT01093391|DEVICE|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
58103188|NCT00237328|DRUG|Heparin|Heparin will be used as the intra-operative anticoagulant
58309422|NCT05782153|DEVICE|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
57953740|NCT04829851|DEVICE|PROTEIN Mobile App|All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
58103189|NCT04157361|DIAGNOSTIC_TEST|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
58103190|NCT01755611|DRUG|Minocycline 100mg|Test product
58103191|NCT01755611|DRUG|Minocycline 100mg|Reference product
58103192|NCT00268151|DRUG|Oxaliplatin|
58103193|NCT00268151|DRUG|Capecitabine|
58103194|NCT01188161|DEVICE|Rotating Chair|Subjects will be spun in rotating chair
58103195|NCT00256100|DRUG|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
58103196|NCT02533323|DRUG|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
58103197|NCT02533323|DRUG|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
58103198|NCT02533323|DRUG|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
58103199|NCT03779685|PROCEDURE|General anesthesia|Sevoflurane and morphine
58103200|NCT03779685|PROCEDURE|Regional anesthesia|Paravertebral block
58103201|NCT00085852|BIOLOGICAL|BLVR|10 mL Hydrogel
58103202|NCT03611751|DRUG|BMS-986165|Specified dose on specified days
58103203|NCT03611751|OTHER|Placebo|Specified dose on specified days
58103204|NCT03611751|DRUG|Apremilast|Specified dose on specified days
58103205|NCT05991570|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
58103206|NCT03334526|OTHER|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
58103207|NCT03334526|OTHER|mental training|The task to imagine for the training group will be an abduction of the thumb
58103208|NCT03334526|OTHER|electrical stimulation|electrical stimulation of the muscles
58103209|NCT01000545|DRUG|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
58103210|NCT01000545|DRUG|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
58103211|NCT05088824|PROCEDURE|hernia repair by desarda technique|It involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. This is a physiological repair and is tension free, can be used in strangulated hernia
58103212|NCT06539273|DRUG|Exosome Complex, RNA|A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
58103213|NCT02020655|OTHER|Shear- force model|Shear- force model
58103214|NCT04268784|DRUG|DNL343|Single and repeating oral dose(s)
58103215|NCT04268784|DRUG|Placebo|Single and repeating oral dose(s)
57953741|NCT04829851|DEVICE|Expert Dashboard|Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
57953742|NCT05536765|PROCEDURE|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
57953743|NCT03846752|PROCEDURE|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
57953744|NCT03846752|PROCEDURE|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
57953745|NCT02892474|PROCEDURE|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
57953746|NCT02892474|PROCEDURE|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
57953747|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
57953748|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
58103216|NCT06485492|PROCEDURE|Implant an aneurysm embolization system|The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
58103217|NCT02105831|OTHER|Contrast ultrasound skeletal muscle perfusion imaging|1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
58309423|NCT05782153|DEVICE|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
57953749|NCT01437397|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
57953750|NCT01437397|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
57953751|NCT01437397|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
58103218|NCT04437537|DEVICE|PHOENIX Wound Matrix|PHOENIX Wound Matrix will be applied to each subject's DFU following debridement.
58103219|NCT02665611|BEHAVIORAL|intervention for improvement of adherence|intervention for improvement of adherence
58103220|NCT02665611|BEHAVIORAL|treatment as usual|The control group will be treated according to the usual stadard of care.
58103221|NCT01715415|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
58103222|NCT01715415|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
58103223|NCT01715415|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
58103224|NCT01715415|DRUG|Placebo for ABT-333|Tablet
58103225|NCT01715415|DRUG|Placebo for ribavirin|Capsule
58103226|NCT02911779|PROCEDURE|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
58103227|NCT00566215|PROCEDURE|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
58433459|NCT01093391|DEVICE|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
58433460|NCT04811482|BEHAVIORAL|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
58433461|NCT03687606|DRUG|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
58433462|NCT03687606|DRUG|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
58433463|NCT02144025|DRUG|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
58433464|NCT06560905|DRUG|68Ga-PSMA|This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
58433465|NCT00761722|DRUG|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
57953752|NCT05057169|BIOLOGICAL|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
57953753|NCT05057169|BIOLOGICAL|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
57953754|NCT04707898|DEVICE|Single Bond Universal|Adhesive system
57953755|NCT04707898|DEVICE|G-Premio Bond|Adhesive system
57953756|NCT05862181|PROCEDURE|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
58433466|NCT00558181|DRUG|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
57953757|NCT03987503|DRUG|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
57953758|NCT03987503|DRUG|Standard of care|Standard of HCV care provided by medical care provider
58103228|NCT00566215|PROCEDURE|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
58103229|NCT04244994|DEVICE|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
58103230|NCT05647200|DRUG|Treatment: additional albumin during cardiopulmonary bypass|Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
58103231|NCT05647200|DRUG|control: additional ringers during cardiopulmonary bypass|Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
58103232|NCT05777070|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
58103233|NCT01543607|DEVICE|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
58103234|NCT04127968|DRUG|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
58103235|NCT04127968|DRUG|Oil|Children in control group will receive equal volume of oil.
58103236|NCT03853356|DEVICE|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
58103237|NCT04717999|BIOLOGICAL|NKG2D CAR-T|The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.
58103238|NCT05756868|BEHAVIORAL|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
58103239|NCT00667498|DRUG|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
58103240|NCT00667498|DRUG|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
58129522|NCT05478148|DEVICE|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
58129523|NCT00631033|DRUG|Placebo|
58129524|NCT00631033|DRUG|Diazoxide|
57769594|NCT04116944|BEHAVIORAL|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
57953759|NCT03987503|DEVICE|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
57953760|NCT03373305|DRUG|Brentuximab Vedotin|Given IV
57953761|NCT03373305|DRUG|Lenalidomide|Given PO
57953762|NCT03373305|OTHER|Laboratory Biomarker Analysis|Correlative studies
57953763|NCT03569800|OTHER|self completed questionnaire|self completed questionnaire
57953764|NCT01614314|OTHER|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
57953765|NCT01614314|OTHER|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
57953766|NCT04286061|OTHER|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
57953767|NCT05931146|OTHER|MyNetDiary app group|MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
57953768|NCT05931146|OTHER|Paper diary group|Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
58129525|NCT00631033|DRUG|Metformin + Diazoxide|
58129526|NCT01860976|DRUG|Abatacept|
58129527|NCT01860976|DRUG|Placebo|
58103241|NCT05417490|OTHER|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~* for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~* for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
58433467|NCT05553392|DEVICE|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
58433468|NCT05553392|DRUG|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
58433469|NCT04356352|DRUG|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
58309424|NCT02818504|OTHER|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
58309425|NCT03117504|OTHER|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
58433470|NCT04356352|DRUG|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
57737594|NCT04091139|BEHAVIORAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
57737595|NCT04091139|BEHAVIORAL|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
57737596|NCT02959996|DRUG|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
57737597|NCT02959996|DRUG|Placebo|placebo injection in the Pfannenstiel incision
57737598|NCT05361031|BIOLOGICAL|Engensis (VM202)|Intramuscular injections
57737599|NCT02341417|DRUG|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
57953769|NCT04226820|OTHER|examination: blood pressure assessment|blood pressure measurement for 30 minutes, dominant side
57953770|NCT04226820|OTHER|examination: Flow Mediated Dilatation (FMD)-test|Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality
57953771|NCT04226820|OTHER|examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring|participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation
57953772|NCT04226820|OTHER|examination: measurement of glucose by a finger prick|follow-up of blood sugar (glucose) during examinations by a finger prick
57953773|NCT01401725|BEHAVIORAL|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
57953774|NCT01401725|BEHAVIORAL|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
57953775|NCT01401725|OTHER|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
57953776|NCT02027142|OTHER|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality."
57953777|NCT02027142|OTHER|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
58433471|NCT04356352|OTHER|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
58433472|NCT05229029|DRUG|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
58103242|NCT05417490|DEVICE|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~* characterization of alerts~* structured follow-up of remote patients.~This non-medical human assistance is provided by:~* nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~* to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~* remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
58103243|NCT04372888|BEHAVIORAL|choice decision frame|active choice for genetic testing
58103244|NCT04372888|BEHAVIORAL|opt-in decision frame|"gain frame for genetic testing"
58103245|NCT04372888|BEHAVIORAL|opt-out decision frame|"loss frame for genetic testing"
58103246|NCT04372888|BEHAVIORAL|enhanced choice (context) decision frame|consequences of genetic testing
58103247|NCT04372888|BEHAVIORAL|enhanced choice (norms) decision frame|social norms for genetic testing
58433473|NCT05229029|DRUG|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
58103248|NCT04372888|BEHAVIORAL|enhanced choice (affect) decision frame|commitments for genetic testing
58103249|NCT00118196|DRUG|arsenic trioxide|
58103250|NCT00118196|DRUG|azacitidine|
58103251|NCT01731574|DRUG|dapivirine|
58103252|NCT01731574|DRUG|miconazole|
58103253|NCT02020785|OTHER|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
58103254|NCT02020785|OTHER|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
58103255|NCT02222285|OTHER|Medical Food : Vayarin_005|
58103256|NCT02222285|OTHER|Placebo|
58103257|NCT04972071|OTHER|Knowledge translation (KT) of the CSRS based practice recommendations|The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
58103258|NCT05475678|DRUG|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
58103259|NCT05475678|DRUG|TCb regimen|docetaxel + carboplatin regimen
58103260|NCT04921150|OTHER|standardization management|Apply standardization management to improve the outcomes of pregnancy
58103261|NCT01246973|DRUG|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
58103262|NCT01246973|DRUG|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
58103263|NCT03263871|DIETARY_SUPPLEMENT|PTM202|PTM202 given twice daily for 30 days.
58103264|NCT03263871|DIETARY_SUPPLEMENT|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
58103265|NCT05189483|DRUG|Albumin-Bound Paclitaxel|Enrolled patients will receive 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
58433474|NCT06388603|DEVICE|Bioactive Glass|Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
57737600|NCT06609005|DRUG|INV-9956|INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
57737601|NCT04880564|DRUG|CN1, 0.5mg/kg and CN401, 400mg|CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
57737602|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 600mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
57737603|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 800mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
58103266|NCT05189483|DRUG|Camrelizumab|Enrolled patients will receive the following treatment: 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
58103267|NCT02009982|PROCEDURE|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
58103268|NCT02009982|DEVICE|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
58103269|NCT00067288|BEHAVIORAL|Meaning-Centered Group Psychotherapy|
58103270|NCT00067288|BEHAVIORAL|Standard Supportive Group Psychotherapy|
58433475|NCT06388603|OTHER|Standard of Care|The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
58433476|NCT05457088|OTHER|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
58103271|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
58103272|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
58103273|NCT03358732|DEVICE|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
58103274|NCT03765944|DRUG|sirolimus|SIngle administration under fasted condition
58103275|NCT00751998|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
58103276|NCT00003682|DRUG|doxorubicin hydrochloride|
58433477|NCT05457088|OTHER|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
58433478|NCT02982941|DRUG|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
58433479|NCT04729335|DIAGNOSTIC_TEST|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
58433480|NCT00083135|BIOLOGICAL|filgrastim|
58433481|NCT00083135|PROCEDURE|autologous bone marrow transplantation|
58433482|NCT00083135|PROCEDURE|peripheral blood stem cell transplantation|
58433483|NCT00083135|RADIATION|iobenguane I 131|
58433484|NCT00524472|OTHER|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
57737604|NCT04880564|DRUG|CN1, 3mg/kg and CN401, 800mg|CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
57737605|NCT04880564|DRUG|CN1, 10mg/kg and CN401, 800mg|CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
57737606|NCT02073084|DRUG|K-877 Low Dose|K-877 Low Dose
57737607|NCT02073084|DRUG|Moxifloxacin|
58433485|NCT00524472|OTHER|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
58433486|NCT01580202|DRUG|Entecavir|Entecavir 0.5mg daily per os
58103277|NCT00003682|DRUG|methylprednisolone|
58103278|NCT03539731|DRUG|Fluorine F 18 DASA-23|Given IV
58103279|NCT03539731|PROCEDURE|Positron Emission Tomography|Undergo PET scan
58103280|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
58103281|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
58103282|NCT02039817|DRUG|IDN-6556|
58103283|NCT04366778|DIAGNOSTIC_TEST|TEM-tPA|325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
58103284|NCT00639665|OTHER|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
58103285|NCT01186952|BEHAVIORAL|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
58129528|NCT05965609|BEHAVIORAL|CBTI|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
58129529|NCT05965609|BEHAVIORAL|MRTI|Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
58433487|NCT01580202|DRUG|Lamivudine|lamivudine 100mg daily per os
58433488|NCT03973294|DEVICE|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
58103286|NCT01186952|BEHAVIORAL|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
58103287|NCT03836365|OTHER|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
58103288|NCT03836365|OTHER|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
58103289|NCT02586545|OTHER|Shared care|
58103290|NCT01038882|DRUG|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation
58103291|NCT01038882|OTHER|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
58103292|NCT03458026|OTHER|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
58103293|NCT03458026|OTHER|Without connected object|Any intervention except follow-up visit
58103294|NCT01477957|PROCEDURE|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
58103295|NCT05529628|DIAGNOSTIC_TEST|Cytokine levels|Preoperative cytokine levels of the patients
58103296|NCT02855632|DRUG|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
58103297|NCT02855632|DRUG|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
58103298|NCT02855632|DRUG|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
58103299|NCT02855632|OTHER|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
58103300|NCT04529161|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
58103301|NCT04529161|DIETARY_SUPPLEMENT|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
58103302|NCT00520494|DRUG|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
58103303|NCT03156582|OTHER|Data collecting|
58103304|NCT02869295|DRUG|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
58103305|NCT01470586|PROCEDURE|Surgery for colorectal cancer|Surgical resection of colorectal cancer
58103306|NCT01179139|OTHER|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
58103307|NCT01498107|BEHAVIORAL|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
58129530|NCT01118936|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
57737608|NCT02073084|OTHER|Placebo|
58129531|NCT01118936|DIETARY_SUPPLEMENT|Placebo|3 tablets of placebo daily for 12 weeks
58129532|NCT05587088|DRUG|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
58309426|NCT00864110|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
58309427|NCT00864110|RADIATION|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
57737609|NCT02073084|DRUG|K-877 High Dose|K-877 High Dose
57737610|NCT02936557|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)"
57737611|NCT05465226|DRUG|Oliceridine|see arm description
57737612|NCT05465226|DRUG|Historical opioid use|Historical matched, control group in 2:1 ratio
57737613|NCT00058123|DRUG|poly ICLC|
57737614|NCT03592212|DRUG|Salbutamol|Measurement of bronchodilator response (BDR)
57737615|NCT03695172|DRUG|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
58309428|NCT00864110|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
58433489|NCT00358969|DRUG|guanfacine (Tenex)|
58103308|NCT05437484|BEHAVIORAL|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
57737616|NCT03695172|PROCEDURE|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
58103309|NCT03252574|OTHER|A|AIR+ Smart Mask Only
58103310|NCT03252574|OTHER|B|AIR+ Smart Mask with micro-ventilator
58103311|NCT02143089|DEVICE|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
58103312|NCT04637685|DEVICE|Centurion Phacoemulsification System|Infusion Pressure
58103313|NCT05827783|PROCEDURE|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
58103314|NCT05827783|PROCEDURE|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
58103315|NCT04395885|OTHER|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
58103316|NCT03966573|RADIATION|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
58103317|NCT03966573|OTHER|Evaluating function|Test function and physical capasity
58433490|NCT05567926|DIETARY_SUPPLEMENT|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
58433491|NCT05567926|DIETARY_SUPPLEMENT|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
58433492|NCT01776866|PROCEDURE|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
58433493|NCT02267538|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
57737617|NCT03695172|BIOLOGICAL|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
58103318|NCT03966573|OTHER|Forms|Forms for evaluating quality of life, pain, function
58103319|NCT04497090|DEVICE|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
58103320|NCT04497090|DEVICE|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
58103321|NCT02080533|OTHER|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
58129533|NCT05587088|DRUG|Placebo|Placebo in pill
58103322|NCT06522230|OTHER|Fascial Stretch Therapy|Fascial Stretch Protocol uses a combination of circumduction, traction, proprioceptive neuromuscular facilitation (PNF) and specific FST maneuvers. Stretch is applied in both active \& passive methods taking into consideration: (1) Oscillatory - slow passive joint oscillations (back and forth movement in a regular rhythm). Small controlled oscillations help with proprioceptors around the joints, acilitates blood flow, gently stretches the ligaments, tendons, nerves, \& muscles and slows the nervous system down; (2) Traction - allows for assessment of the joint capsule movement and to decompress the joint. (3) Movement - designed to enhance the reflexes and are intentionally gentle to maximize benefits; (4) PNF - helps improve flexibility by alternating muscle contractions and relaxations. This stimulates the neuromuscular system, allowing muscles to relax deeper and increase range of motion. (5) Breath - allows the body to increase oxygen consumption to facilitate recovery.
58103323|NCT03372083|DRUG|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
58103324|NCT01039584|DRUG|Butoconazole Nitrate Vaginal Cream|vaginal cream
58103325|NCT01039584|DRUG|Placebo|vaginal cream
58103326|NCT01039584|DRUG|Gynazole 1 vaginal cream|vaginal cream
58103327|NCT00611741|DRUG|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
58103328|NCT02458365|BEHAVIORAL|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
58103329|NCT02458365|BEHAVIORAL|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
58103330|NCT05678699|BEHAVIORAL|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries"
58103331|NCT05678699|BEHAVIORAL|Doula|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1. health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~2. care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania."
58103332|NCT05678699|BEHAVIORAL|Standard Care|Participants receive standard care without quality interventions or doula care
58103333|NCT01656967|DEVICE|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
58103334|NCT01656967|DEVICE|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
58103335|NCT01453374|DRUG|VIVITROL 380mg|380 mg IM injection given once monthly
58103336|NCT01384864|DRUG|proflavine|2-6 ml of 0.01% proflavine
58103337|NCT04564040|DRUG|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
58103338|NCT04564040|DRUG|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
58103339|NCT04564040|DRUG|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
58103340|NCT04564040|DRUG|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
58103341|NCT06541210|OTHER|Non-Interventional Study|Non-interventional study
58103342|NCT05829382|DIETARY_SUPPLEMENT|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
58103343|NCT05829382|DIETARY_SUPPLEMENT|Placebo|Capsule containing placebo administered daily by the participant during the trial period
58103344|NCT00574379|DRUG|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
58103345|NCT00574379|DRUG|Placebo|Placebo tablets twice daily for 14 days
58103346|NCT02633761|DRUG|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
58103347|NCT02633761|DRUG|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
58103348|NCT02633761|DRUG|Misoprostol 200mcg|Buccal misoprostol 200mcg
58103349|NCT02121405|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
58103350|NCT02121405|RADIATION|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
58129534|NCT05223582|DRUG|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
58129535|NCT05223582|DRUG|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
58129536|NCT05223582|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
58129537|NCT05223582|DRUG|Androgen deprivation therapy|Patients would get medical castration.
58103351|NCT02121405|DRUG|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
58103352|NCT02121405|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
58103353|NCT04892342|DRUG|ESG401|Administered via intravenous (IV) infusion
58103354|NCT05870826|OTHER|Multiwave locked system laser therapy|High intensity laser therapy
58103355|NCT05870826|OTHER|Sham laser therapy|Sham laser therapy
58103356|NCT06403566|OTHER|hand massage|three group randomized controlled trials
58103357|NCT00344526|DRUG|Melphalan|
58103358|NCT00344526|DRUG|Dexamethasone|
58103359|NCT00344526|PROCEDURE|Autologous stem cell transplantation|
58103360|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
58103361|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
58103362|NCT00913588|DRUG|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
58103363|NCT03007537|DRUG|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
58103364|NCT03007537|DRUG|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
58103365|NCT03007537|PROCEDURE|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
58103366|NCT04626557|PROCEDURE|biopsy|biopsy of the endometrium
58103367|NCT03676894|DEVICE|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
58103368|NCT03676894|DEVICE|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
58103369|NCT03676894|DEVICE|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
58103370|NCT06469476|BEHAVIORAL|depression post partum|visit post partum
58103371|NCT02491619|PROCEDURE|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
58103372|NCT04024085|OTHER|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
58103373|NCT03491319|PROCEDURE|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
58103374|NCT03491319|PROCEDURE|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
58433494|NCT02267538|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery."
58433495|NCT01496846|DRUG|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
58103375|NCT03491319|PROCEDURE|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
58103376|NCT00415142|DRUG|saredutant (SR48968)|oral administration (capsules)
58103377|NCT00415142|DRUG|placebo|oral administration (capsules)
58103378|NCT00415142|DRUG|escitalopram|oral administration (capsules)
58103379|NCT05258435|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
58103380|NCT04538768|PROCEDURE|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
58103381|NCT04538768|PROCEDURE|Direct suture|direct fascia suture
58103382|NCT05402631|PROCEDURE|Epidural Injection|patient receives an epidural injection due to lower back pain
58103383|NCT05402631|PROCEDURE|Periradicular Injection|patient receives a periradicular injection due to lower back pain
58103384|NCT00267020|DRUG|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
58103385|NCT00267020|DRUG|gemcitabine|1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
58103386|NCT02067988|DEVICE|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
58129538|NCT05223582|PROCEDURE|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
58103387|NCT01704235|OTHER|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
58103388|NCT01925807|BEHAVIORAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
58103389|NCT03235765|DIAGNOSTIC_TEST|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
58103390|NCT05734170|DIETARY_SUPPLEMENT|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
58103391|NCT05734170|DIETARY_SUPPLEMENT|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
58103392|NCT05734170|DIETARY_SUPPLEMENT|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
58103393|NCT01244607|DRUG|Placebo|single i.v. administration
58103394|NCT01244607|DRUG|NI-0801|single i.v. administration
58103395|NCT03296774|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
58103396|NCT03296774|BEHAVIORAL|Usual Care|
58433496|NCT01496846|DRUG|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
58433497|NCT01496846|DRUG|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
58433498|NCT00293436|DRUG|celecoxib|
58433499|NCT00293436|DRUG|erlotinib hydrochloride|
58433500|NCT00293436|PROCEDURE|adjuvant therapy|
58103397|NCT04527003|DRUG|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
58103398|NCT04527003|DRUG|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
58309429|NCT03863353|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
58309430|NCT01464762|DRUG|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
58433501|NCT01103063|DRUG|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
58433502|NCT01103063|DRUG|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
58433503|NCT05090033|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
58433504|NCT03721497|DRUG|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
58433505|NCT04897880|DRUG|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
58433506|NCT04087135|OTHER|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
57737618|NCT03695172|PROCEDURE|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
58433507|NCT04087135|OTHER|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
58433508|NCT04087135|OTHER|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
58103399|NCT04527003|OTHER|Placebo|a substance or treatment which is designed to have no therapeutic value
58129539|NCT05680350|PROCEDURE|Laparoscopic Exploration|Laparoscopic Exploration to diagnose \& grade endometriosis
58129540|NCT05680350|DIAGNOSTIC_TEST|Estimation of Plasma Expression level of MICRO RNA 203 & 210|"estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR"
58129541|NCT00059371|PROCEDURE|male circumcision|
58309431|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
58103400|NCT04023318|BEHAVIORAL|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
58103401|NCT05186350|PROCEDURE|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
58103402|NCT05186350|PROCEDURE|ESWL+ ERCP|ESWL + Stone removal through ERCP
58103403|NCT04416672|OTHER|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~* the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~* the Hospital Anxiety and Depression Scale (HADS)~* The Patients' Global Impression of Change (PGIC) Scale."
58103404|NCT00183469|DRUG|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
58103405|NCT00183469|DRUG|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
58103406|NCT00183469|DRUG|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
58103407|NCT02475980|BEHAVIORAL|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
58103408|NCT04399850|OTHER|Hypnosis group|Patients who receive hypnosis
58103409|NCT03096717|DIAGNOSTIC_TEST|colonoscopy and histology|colonic biopsies for detection of dysplasia
58103410|NCT04466696|BEHAVIORAL|ERAS protocol|items of ERAS protocol applied
57737619|NCT05233228|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
58103411|NCT06149195|DIAGNOSTIC_TEST|Standard medical care for heart failure|Standard treatment and care for heart failure patients from the heart failure center of Sichuan Provincial People's Hospital.
58103412|NCT00115258|OTHER|parenteral nutrition titrated to measured REE|
58103413|NCT02169531|DRUG|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
58103414|NCT02690584|BEHAVIORAL|Metacognitive therapy|
58103415|NCT06312774|OTHER|This is observational study|This is observational study
58103416|NCT03732729|DEVICE|massage chair|Patient should use massage chair, twice per day, for 30minutes
58103417|NCT04209218|DRUG|Dexamethasone|Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
58103418|NCT04209218|OTHER|Targeted blood pressure management|Blood pressure is maintained within ±10% from baseline.
58103419|NCT04209218|DRUG|Placebo|Placebo (2 ml normal saline) is administered before anesthesia induction.
58103420|NCT04209218|OTHER|Routine blood presure management|Blood pressure is maintained according to routine practice.
58309432|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
58103421|NCT01532011|DRUG|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
58103422|NCT01532011|DRUG|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
58129542|NCT05116930|DRUG|Neostigmine|IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
58129543|NCT05116930|DRUG|Glycopyrrolate|IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
58129544|NCT03976713|DRUG|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
58309433|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
58433509|NCT04954157|DIAGNOSTIC_TEST|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
58433510|NCT04954157|DIAGNOSTIC_TEST|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
58309434|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
58309435|NCT01324102|BEHAVIORAL|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
58309436|NCT00742950|PROCEDURE|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
58309437|NCT00742950|PROCEDURE|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
58309438|NCT00742950|PROCEDURE|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
58309439|NCT00493675|PROCEDURE|endoscopic bile duct stenting|
58309440|NCT01548365|OTHER|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
58309441|NCT00560729|DIETARY_SUPPLEMENT|Renutryl 500|
58309442|NCT00560729|DIETARY_SUPPLEMENT|Generique|
58309443|NCT00560729|DIETARY_SUPPLEMENT|Generique + Renutryl 500|
58309444|NCT02359240|PROCEDURE|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
58309445|NCT02359240|PROCEDURE|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
58309446|NCT05553327|BEHAVIORAL|Multimodal prehabilitation|"* Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~* Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~* Mental health: mindfulness group sessions led by psychologists will be held."
58309447|NCT00385840|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
58309448|NCT00385840|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
58309449|NCT01170585|DRUG|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
58309450|NCT01170585|DRUG|Placebo|Placebo
58309451|NCT03952819|DIAGNOSTIC_TEST|serum sclerostin|blood samples obtained
58309452|NCT02247388|BEHAVIORAL|Computerized Alcohol Screening|iPad based automated alcohol screening
58309453|NCT02247388|BEHAVIORAL|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
58309454|NCT06051513|DRUG|treatment with or without colistin|For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
58433511|NCT00799591|OTHER|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
58433512|NCT06583811|DRUG|Remifentanil|to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
58433513|NCT01589393|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
57737620|NCT05233228|BEHAVIORAL|Self-help materials (to support smoking cessation)|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
58103423|NCT04657237|PROCEDURE|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
58103424|NCT04084054|DIAGNOSTIC_TEST|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
58433514|NCT01589393|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
58103425|NCT06519734|OTHER|Questionnaire|"Questionnaire intended for patients on contraceptive modalities and use of menstrual hygiene products.~Consultation of the medical records of patients who have reported infectious complications linked to the use of intrauterine devices, tampons or menstrual cups."
58433515|NCT05830071|DRUG|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
58433516|NCT05830071|DRUG|CHF5259|GB 12.5 μg pMDI
58433517|NCT05830071|DRUG|Moxifloxacin 400mg|400 mg Oral Tablets
58103426|NCT01520766|DEVICE|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
58433518|NCT05830071|DRUG|CHF5993 Placebo|placebo pMDI
57769595|NCT04116944|OTHER|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
57953778|NCT02027142|OTHER|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
58103427|NCT01520766|DEVICE|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
58103428|NCT06006351|OTHER|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
58103429|NCT06006351|OTHER|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
58103430|NCT04528277|DRUG|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
58103431|NCT00108758|DRUG|activated recombinant human factor VII|
58103432|NCT06160479|DRUG|Calcium supplement|Different amount of calcium supplement in pregnancy
58103433|NCT02845635|OTHER|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
58103434|NCT04011839|DRUG|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
58309455|NCT00822848|DRUG|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
58433519|NCT03322150|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
58433520|NCT03322150|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
58433521|NCT02697188|DRUG|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
58433522|NCT02697188|DRUG|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
58433523|NCT06341933|OTHER|Duration of Surgery|Total surgery time in minutes
58433524|NCT06341933|OTHER|Volume of Fluid in Surgery|Fluid volume given during surgery in ml
58433525|NCT06341933|OTHER|Blood Loss|Blood loss during surgery in ml
58433526|NCT00597415|DRUG|celecoxib|celecoxib 200mg
58433527|NCT00597415|DRUG|placebo|placebo
58103435|NCT02162901|BEHAVIORAL|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
58103436|NCT02162901|BEHAVIORAL|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
58103437|NCT02162901|BEHAVIORAL|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
58103438|NCT02162901|BEHAVIORAL|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
58103439|NCT02162901|BEHAVIORAL|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
58103440|NCT00533884|OTHER|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
58103441|NCT00533884|OTHER|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
58103442|NCT00533884|OTHER|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
58103443|NCT02253758|DRUG|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
58433528|NCT03311789|DRUG|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
58433529|NCT06245213|DRUG|ANAVEX3-71 oral capsules|ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
58433530|NCT06245213|DRUG|Placebo oral capsules|The placebo comparator for the study.
58433531|NCT01963156|BEHAVIORAL|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
58433532|NCT03937960|OTHER|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
58433533|NCT03937960|OTHER|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
58433534|NCT02800083|DRUG|Pitolisant (BF2.649)|
58433535|NCT02800083|DRUG|Placebo|
58103444|NCT04790409|DRUG|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
58103445|NCT04084912|DRUG|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
58433536|NCT06584175|BEHAVIORAL|Internet Delivered Cognitive Behavioural Therapy|The tinnitus ICBT program consists of 1) an overview of tinnitus, depression, and anxiety; 2) managing unhelpful thoughts and learning problem solving strategies association with pain, anxiety, depression, and disability; 3) management of common symptoms associated with tinnitus, anxiety, and depression; 4) developing strategies to maintain activities while minimizing fatigue; and 5) strategies to improve quality of life through effective goal setting. Supplementary lessons can be accessed at any time (e.g., sleep, communication, problem solving, assertiveness training). Materials are presented in a didactic (i.e., text-based and audio with visual images) and case-enhanced learning format (i.e., stories demonstrate the application of skills). Case vignettes that specifically reflect the experiences of those with tinnitus are included.
58433537|NCT01497249|DIETARY_SUPPLEMENT|A dietary fiber (FCHO)|15 g twice per day in beverage
58433538|NCT01497249|DIETARY_SUPPLEMENT|Placebo|Placebo drink
58433539|NCT06524622|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) measurements will be performed for all participants
58433540|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
57769596|NCT01598402|DRUG|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
58103446|NCT04084912|DRUG|Saline Solution|intravenous injection of one ampoule saline
58103447|NCT05286099|OTHER|Imaging examination and/or blood test|Imaging examination and/or blood test will be performed at a certain time
58309456|NCT00822848|DRUG|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
58309457|NCT00822848|DRUG|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
58103448|NCT01875133|OTHER|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
58103449|NCT01253889|DRUG|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
58103450|NCT01253889|OTHER|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
58433541|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
58103451|NCT05883020|OTHER|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
58103452|NCT05883020|OTHER|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
58103453|NCT00133094|DRUG|Simvastin|
58103454|NCT00133094|PROCEDURE|Computer-based decision support technology|
58103455|NCT05351281|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
58103456|NCT03045029|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
58309458|NCT00822848|OTHER|immunoenzyme technique|
58309459|NCT00822848|OTHER|immunohistochemistry staining method|
58309460|NCT00822848|OTHER|laboratory biomarker analysis|
58309461|NCT00822848|PROCEDURE|adjuvant therapy|Preoperative administration has been the preference at our institution.
58309462|NCT00822848|PROCEDURE|neoadjuvant therapy|
58309463|NCT00822848|PROCEDURE|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
58309464|NCT00822848|RADIATION|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
58309465|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
58309466|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
58309467|NCT01500980|BIOLOGICAL|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
58309468|NCT01500980|DRUG|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
58309469|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
58309470|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
58309471|NCT06516770|DEVICE|Transcranial direct current stimulation|The subject will receive the tDCS using 5X7 cm electrodes. The anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes
58433542|NCT00284310|PROCEDURE|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
58433543|NCT06339970|OTHER|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
58309472|NCT06516770|DEVICE|Neuromuscular electrical stimulation|The participants will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes.
58309473|NCT06516770|OTHER|Motor control exercise|The participant will be instructed to perform co-contraction of transverse abdominis and lumbar multifidus muscle, while performing self-selected pace forward bend. Emphasis will be given to move in control manner (smooth and symmetrical movement). The participant will perform 4 minutes of continuous movement for 4 sets with 1 minute rest between sets.
58309474|NCT06516770|OTHER|Isometric exercise|The participant will be instructed to perform isometric back extension exercise in modified Sorensen position. The participant will hold 60 seconds in neutral position for 5 repetitions with 3 minutes rest between repetitions.
58309475|NCT05076734|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
58309476|NCT03933059|OTHER|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
58309477|NCT03628443|DIAGNOSTIC_TEST|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
58309478|NCT00089219|BIOLOGICAL|IFA|vaccine adjuvant
58309479|NCT00089219|BIOLOGICAL|6MHP|melanoma helper peptides
58309480|NCT00089219|BIOLOGICAL|GM-CSF|vaccine adjuvant
57737621|NCT05233228|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
58433544|NCT06339970|OTHER|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
58433545|NCT03893162|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
58433546|NCT03893162|OTHER|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
58433547|NCT01418742|DRUG|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
58433548|NCT01418742|DRUG|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
58433549|NCT00901199|DRUG|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
58433550|NCT04478448|DRUG|Flupirava|1 tablet contains 200 mg Favipiravir
58433551|NCT04478448|DRUG|Avigan|1 tablet contains 200 mg Favipiravir
57737622|NCT03946943|DRUG|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
58433552|NCT05642299|DEVICE|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
58433553|NCT00138775|DRUG|D-serine|
58433554|NCT06038734|DIAGNOSTIC_TEST|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
57737623|NCT03946943|DRUG|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
57737624|NCT03946943|PROCEDURE|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
57737625|NCT03946943|PROCEDURE|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
57953779|NCT02027142|OTHER|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
58433555|NCT06086834|OTHER|McKenzie Retraction Exercises|McKenzie Retraction exercises 5 days a week and 10-15 times for active exercises and 5-6 repetitions of clinician assisted exercise for a period of 4 weeks and a rest interval of 2 minutes between exercises.
57737626|NCT03137303|DEVICE|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
57737627|NCT03137303|DRUG|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
57737628|NCT03137303|DEVICE|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
57953780|NCT06079450|OTHER|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
57953781|NCT00768521|DRUG|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
57953782|NCT00768521|DRUG|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
58433556|NCT06086834|OTHER|Bruegger's Exercise|Bruegger's Exercise will be started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time will be 30 seconds, 4 sets 12 times repetition, for duration of 30 mins per session, 5 days a week for a period of 4 weeks.
58129545|NCT03976713|DRUG|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
57737629|NCT01564550|DRUG|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
57737630|NCT01564550|DRUG|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
57737631|NCT01564550|OTHER|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
57737632|NCT01564550|OTHER|no diet|The subjects will ingest a non-restricted diet prior to the study day.
57737633|NCT06669806|DEVICE|TIPS Stent Graft|a covered TIPS stent graft
57737634|NCT04790318|PROCEDURE|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
58433557|NCT03940391|DRUG|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
58433558|NCT03940391|DRUG|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
58433559|NCT02092025|DRUG|Azilsartan|Azilsartan tablets
57737635|NCT04790318|PROCEDURE|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
57737636|NCT00297154|BEHAVIORAL|Lifestyle Modification (diet, exercise, and behavior)|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
57737637|NCT02298192|DRUG|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
57737638|NCT06667960|DRUG|JK06|Biparatopic anti-5T4 antibody
57737639|NCT02679690|BEHAVIORAL|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
58309481|NCT03211065|DRUG|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
58433560|NCT00551603|DRUG|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
58433561|NCT00551603|DRUG|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
58103457|NCT02638961|OTHER|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
58129546|NCT03976713|DRUG|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
58129547|NCT01941030|DEVICE|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
57737640|NCT02679690|BEHAVIORAL|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
57737641|NCT05111236|OTHER|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
58129548|NCT01941030|DEVICE|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
58433562|NCT01811186|DRUG|Oxycodone/naloxone|Oxycodone/naloxone titration
58433563|NCT01221493|PROCEDURE|Cryo biopsy|Cryoprobe, Erbe Company
58433564|NCT05275036|DEVICE|early detection test|Blood collection and early detection testing
58433565|NCT04320901|DEVICE|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
58433566|NCT04320901|DEVICE|Harmonic|Harmonic ACE 7+
58433567|NCT01169935|DRUG|Administration of intra-dermal Endorem|single dose, intradermal
58433568|NCT01169935|BIOLOGICAL|Mantoux test|single dose, intradermal
58433569|NCT01169935|BIOLOGICAL|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
58433570|NCT01169935|DRUG|Administration of Endorem|single dose, intravenous
57737642|NCT05111236|OTHER|Traditional massage|Rehabilitation strategies in management of children with spastic CP
57737643|NCT01390454|PROCEDURE|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
58433571|NCT02577016|DRUG|Sitagliptin|50 mg tablet administered orally
58433572|NCT02577016|DRUG|Placebo|Placebo to sitagliptin administered orally
58433573|NCT02577016|DRUG|Ipragliflozin|50 mg tablet administered orally as background medication
58433574|NCT05949632|DRUG|INCB099280|Administered as specified in the treatment arm description
58433575|NCT05949632|DRUG|axitinib|Administered as specified in the treatment arm description
57737644|NCT01390454|PROCEDURE|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
57737645|NCT01390454|PROCEDURE|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
57737646|NCT01046305|BEHAVIORAL|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
57953783|NCT04174781|DRUG|Sintilimab|Sintilimab: 200mg iv Q3W D1
57953784|NCT04174781|DRUG|DEB-TACE|DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
57953785|NCT02157675|DIETARY_SUPPLEMENT|Polyherbal capsule|
57953786|NCT02157675|DIETARY_SUPPLEMENT|Placebo capsule|
57953787|NCT02972255|DRUG|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
57953788|NCT02972255|DRUG|Meropenem|Meropenem will be administered as per schedule described in individual arm.
57953789|NCT02972255|OTHER|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
57953790|NCT02972255|OTHER|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
57953791|NCT05664087|DRUG|Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
57953792|NCT00001386|DRUG|PCLUS 3-18 MN|
57953793|NCT00001386|DRUG|PCLUS 6.1 MN|
57953794|NCT02298829|DRUG|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
57953795|NCT03725878|PROCEDURE|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
58433576|NCT03653988|PROCEDURE|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
58433577|NCT03653988|PROCEDURE|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
58433578|NCT03764683|DRUG|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
58433579|NCT03764683|DRUG|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
58433580|NCT02207491|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
58433581|NCT02207491|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
58433582|NCT02207491|OTHER|Placebo|1 drop QD, AM, OU
58433583|NCT00718705|DRUG|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
58433584|NCT00718705|DRUG|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
58433585|NCT01887353|DRUG|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
58433586|NCT01887353|DRUG|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
58433587|NCT00053144|DRUG|cytarabine|
58433588|NCT00053144|DRUG|irinotecan hydrochloride|
58433589|NCT01266590|DRUG|LY2216684|Administered orally
58433590|NCT01266590|DRUG|Digoxin|Administered orally
58433591|NCT04715971|DIAGNOSTIC_TEST|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
58433592|NCT05926830|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
58433593|NCT02082730|DEVICE|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
57737647|NCT01046305|BEHAVIORAL|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
57737648|NCT01046305|BEHAVIORAL|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
58129549|NCT06306742|OTHER|Open-label placebo|Light pressure manual therapy
58433594|NCT05164614|COMBINATION_PRODUCT|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
58433595|NCT05164614|DRUG|Forteo|A commercial formulation of PTH for SC control (20 µg)
57737649|NCT01741623|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
57737650|NCT01741623|DRUG|Bisoprolol|10 mg tablet once a day
57737651|NCT02640768|OTHER|educational training|implementation of a structured educational program for physicians and nurses
57737652|NCT05110859|OTHER|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
57737653|NCT04543110|DRUG|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
58129550|NCT06306742|OTHER|Osteopathic manipulative treatment|Manual therapy
58433596|NCT05164614|COMBINATION_PRODUCT|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
58433597|NCT04487925|DRUG|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
58433598|NCT04487925|DRUG|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
58433599|NCT05781464|PROCEDURE|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
58433600|NCT05781464|PROCEDURE|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
58433601|NCT00420121|PROCEDURE|laboratory analysis|blood withdrawal for laboratory analysis
58433602|NCT01846741|DEVICE|M106 VNS Therapy System|
58433603|NCT06431269|OTHER|Screening for neurodevelopmental disorders by an advanced practice nurse|Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
58433604|NCT06024668|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
58433605|NCT04043468|OTHER|Audit and feedback|Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
58433606|NCT06303323|OTHER|Qigong Exercise|"Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin.~In the first 2 weeks, two sets of Baduanjin will be performed. Total Duration: 6 weeks Frequency: for 3 days/week. (alternative days) Intensity: low-intensity exercise Total Time: 50 Minutes Type: aerobic training"
58433607|NCT06303323|OTHER|Wu Dang Tai Chi|"Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.~Total Duration: 6 weeks Frequency: 3 times/ week (alternative day ) Intensity: Low to Moderate Intensity Time: 50 Minutes Type: aerobic training"
58433608|NCT01673620|DRUG|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
58433609|NCT01673620|DRUG|Placebo|Matching placebo tablet administered once daily
58433610|NCT01954108|DEVICE|hyaluronic acid sodium salt|
58433611|NCT01954108|DEVICE|ESWT|
58433612|NCT01742806|DEVICE|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
58433613|NCT03845738|DEVICE|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
58433614|NCT05471089|DEVICE|Diathermy by emission of Radiofrequency|Applied only to experimental group
58433615|NCT05471089|OTHER|Therapeutic exercise|Applied to both arms/groups
58433616|NCT00360724|DRUG|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
58433617|NCT04016077|DRUG|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
58433618|NCT04300036|DIETARY_SUPPLEMENT|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
58433619|NCT04300036|DIETARY_SUPPLEMENT|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
58433620|NCT02713828|DRUG|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
58433621|NCT02713828|DRUG|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
58433622|NCT06420180|PROCEDURE|hip arthroscopy|"CT rotational profile Will be used for measurement of LL rotational abnormality.~MRI will be evaluated for the presence of labral tears, chondral lesions, ligamentum teres pathology, and other soft-tissue disorders."
58103458|NCT02638961|OTHER|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
58433623|NCT04294836|DRUG|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
58433624|NCT04294836|DRUG|Placebo oral tablet|PLACEBO Capsules 500mg
58433625|NCT01290744|DRUG|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
58433626|NCT01290744|DRUG|Placebo|Daily for 12 months
58433627|NCT00410007|BEHAVIORAL|High Sodium Diet|250-350 mmol
58433628|NCT00410007|BEHAVIORAL|Low Sodium Diet|25-35 mmol
58433629|NCT00410007|BEHAVIORAL|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
58433630|NCT03709394|PROCEDURE|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
58433631|NCT03709394|PROCEDURE|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
58433632|NCT03709394|PROCEDURE|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
58433633|NCT03851055|DRUG|Zinc|One arm will receive Zinc Second arm will receive placebo
58433634|NCT00088894|DRUG|gemcitabine hydrochloride|Given IV
58433635|NCT00088894|BIOLOGICAL|bevacizumab|Given IV
58433636|NCT00088894|OTHER|placebo|Given IV
58433637|NCT00088894|OTHER|laboratory biomarker analysis|Correlative studies
58433638|NCT00088894|OTHER|pharmacogenomic studies|Correlative studies
58433639|NCT00088894|OTHER|pharmacological study|Correlative studies
58433640|NCT05446571|DRUG|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
58103459|NCT02638961|OTHER|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
58103460|NCT03181178|DIETARY_SUPPLEMENT|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
58103461|NCT03181178|DIETARY_SUPPLEMENT|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
58433641|NCT05446571|DRUG|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
58433642|NCT03018977|OTHER|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
58433643|NCT03018977|OTHER|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
58433644|NCT03323801|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
58433645|NCT04672122|DEVICE|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
58433646|NCT06291064|DRUG|Cyclophosphamide|Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
58433647|NCT06291064|DRUG|Epirubicin|Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
58433648|NCT06291064|DRUG|Docetaxel|Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
58433649|NCT06291064|DRUG|Carboplatin|Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
58433650|NCT06291064|PROCEDURE|Breast Surgery|Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
58433651|NCT06291064|DRUG|Capecitabine|Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
58433652|NCT06432504|OTHER|Caffeine content|Participants will drink the same volume of coffee with different amounts of caffeine.
58433653|NCT00317096|PROCEDURE|FCM|Active comparator: Chemotherapy
58433654|NCT00317096|PROCEDURE|R-FCM|experimental: Chemotherapy with additional rituximab
58433655|NCT00317096|DRUG|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
58433656|NCT00317096|OTHER|observation only|no Intervention after completion of FCM or R-FCM
58433657|NCT00274677|DRUG|Placebo|Experimental treatment arm
58433658|NCT00274677|DRUG|lamotrigine|Experimental treatment
58433659|NCT05216341|DRUG|OLP-1002|"Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection."
58433660|NCT05325840|OTHER|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
58103462|NCT03181178|BEHAVIORAL|Nutrition education|This intervention provided nutrition education sessions
58103463|NCT02832882|PROCEDURE|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
58433661|NCT03817268|DRUG|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
58103464|NCT02832882|PROCEDURE|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
58129551|NCT02659852|PROCEDURE|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
57737654|NCT04543110|RADIATION|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
57737655|NCT03842657|COMBINATION_PRODUCT|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
58129552|NCT02659852|PROCEDURE|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
58433662|NCT05222386|OTHER|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
58103465|NCT05161663|BEHAVIORAL|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
58103466|NCT06526767|DEVICE|Vibrabot capsules twice a week|Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
58103467|NCT06526767|DEVICE|Vibrabot capsules three times a week|Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
58103468|NCT06526767|DEVICE|Vibrabot capsules five times a week|Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
58103469|NCT06526767|DEVICE|Vibrabot capsules loading dose|Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
58103470|NCT05891873|DIAGNOSTIC_TEST|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
58103471|NCT05891873|DIAGNOSTIC_TEST|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
58103472|NCT05891873|DIAGNOSTIC_TEST|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
58103473|NCT05891873|DIAGNOSTIC_TEST|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
58103474|NCT05891873|DIAGNOSTIC_TEST|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
58103475|NCT05891873|DIAGNOSTIC_TEST|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
58103476|NCT05891873|DIAGNOSTIC_TEST|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
58103477|NCT00818831|DRUG|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
58103478|NCT03750825|DEVICE|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
58103479|NCT04765254|OTHER|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
58103480|NCT05880628|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)"
58103481|NCT04829409|PROCEDURE|Paravertebral block|Patients receive ultrasound-guided paravertebral block
58103482|NCT04829409|PROCEDURE|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
58103483|NCT04829409|PROCEDURE|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
58103484|NCT00439751|DRUG|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
58103485|NCT01949207|PROCEDURE|EVLA|Endovenous laser ablation of great saphenous vein
58103486|NCT01949207|PROCEDURE|phlebectomies|removal of incompetent veins
58103487|NCT01949207|PROCEDURE|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
58309482|NCT01831843|DEVICE|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
58309483|NCT01831843|DEVICE|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
58309484|NCT01831843|DEVICE|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
58309485|NCT06076785|DEVICE|OdySight|At home measurements of visual acuity through a mobile app.
58103488|NCT06469138|DRUG|Bemcentinib|Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
58433663|NCT05222386|OTHER|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
58433664|NCT03937414|DEVICE|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
58433665|NCT02369419|OTHER|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
58433666|NCT04371666|DRUG|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
58433667|NCT04371666|DRUG|Placebo|Matching placebo per schedule specified in the arm description
58433668|NCT04371666|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
58433669|NCT03145948|DRUG|ABBV-553|It is administered orally.
58433670|NCT03145948|DRUG|Placebo|It is administered orally.
58433671|NCT02241343|DEVICE|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
58433672|NCT00410605|BIOLOGICAL|bevacizumab|Given IV
58433673|NCT00410605|DRUG|lenalidomide|Given orally
58103489|NCT06537167|DEVICE|Transcutaneous electrical acupoint stimulation|Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
58433674|NCT00410605|DRUG|dexamethasone|Given orally
58433675|NCT03691571|DEVICE|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
58433676|NCT03691571|DEVICE|Control|Standard of care involves standard temperature probe monitoring.
58309486|NCT04664218|DEVICE|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
58433677|NCT06394245|OTHER|Progressive muscle exercises|The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
58433678|NCT03122782|DRUG|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
58433679|NCT03122782|DRUG|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
58309487|NCT04409613|OTHER|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
58309488|NCT05116553|BEHAVIORAL|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
58309489|NCT05116553|DEVICE|APP + CA|An APP with a CA (Conversational Agent).
58433680|NCT02481817|PROCEDURE|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
58433681|NCT02481817|PROCEDURE|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
58433682|NCT02481817|PROCEDURE|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
58433683|NCT02472704|DIETARY_SUPPLEMENT|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
58433684|NCT02472704|DIETARY_SUPPLEMENT|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
58433685|NCT04530864|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
58433686|NCT00049608|DIETARY_SUPPLEMENT|mistletoe extract|
58103490|NCT06537167|DEVICE|Sham stimulation|Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
58103491|NCT00033631|RADIATION|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
58103492|NCT00033631|RADIATION|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
58103493|NCT06204276|DEVICE|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
58103494|NCT06204276|DEVICE|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
57737656|NCT04290754|BEHAVIORAL|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
58103495|NCT02059187|DRUG|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
58103496|NCT02059187|DRUG|Lantus™|Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
58103497|NCT02059187|DRUG|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
58103498|NCT00534209|BIOLOGICAL|Allogeneic B7.1/HLA-A1|Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
58103499|NCT00534209|OTHER|Placebo|Given intradermally
58103500|NCT00760188|DEVICE|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
58103501|NCT03151785|OTHER|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
58103502|NCT03151785|OTHER|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
58103503|NCT03151785|OTHER|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
58103504|NCT02625207|DRUG|Maraviroc (Part 1)|300 mg twice daily x 5 days
58309490|NCT05512663|DEVICE|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
58309491|NCT05720403|OTHER|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
58433687|NCT00049608|DRUG|gemcitabine hydrochloride|
58433688|NCT03021772|DRUG|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
58433689|NCT03021772|DRUG|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
58103505|NCT02625207|DRUG|Maraviroc (Part 2)|150 mg once daily x 10 days
58103506|NCT02625207|DRUG|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
58103507|NCT01887379|DRUG|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
58433690|NCT03908814|DRUG|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
58433691|NCT04408040|BIOLOGICAL|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
58103508|NCT04421066|PROCEDURE|Gingival and bone sample collection|Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
58309492|NCT00591877|PROCEDURE|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus."
58433692|NCT04416906|DRUG|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
58433693|NCT00151476|DRUG|Celecoxib|800 mg total daily dosing
58433694|NCT00151476|OTHER|Routine Medical Care|
58433695|NCT04243733|OTHER|CEM and MTA|Pulpotomy agent
58433696|NCT04243733|OTHER|MTA and CEM|Pulpotomy agent
57737657|NCT04290754|BEHAVIORAL|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
57737658|NCT02300753|DRUG|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
57737659|NCT03413436|DRUG|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
57737660|NCT03413436|DRUG|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
57737661|NCT03815721|DEVICE|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
57737662|NCT00958269|DRUG|dutogliptin|100 mg QD
58433697|NCT05521789|DRUG|ESB Thoracic|Erector spinae thoracic block with bupivacaine
58433698|NCT04279665|DEVICE|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
57737663|NCT00958269|DRUG|dutogliptin|200 mg QD
57737664|NCT00958269|DRUG|placebo|
58103509|NCT04421066|PROCEDURE|Healthy individuals|Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
58103510|NCT02270905|DEVICE|dCELL® Meniscus|decellularised porcine xenograft
58433699|NCT06208111|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
57737665|NCT00958269|DRUG|sitagliptin|25 mg QD
57737666|NCT00958269|DRUG|sitagliptin|50 mg QD
57737667|NCT02647112|OTHER|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
57737668|NCT02007850|DRUG|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
57737669|NCT04219033|OTHER|EEG(Electroencephalogram) change|patients are found to have characteristic EEG change
57737670|NCT01178086|DRUG|Rituximab|Rituximab IV
58433700|NCT03801603|BEHAVIORAL|HPV vaccination training and education|1) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
58433701|NCT03956524|BIOLOGICAL|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
58433702|NCT03956524|BIOLOGICAL|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
58433703|NCT03956524|BIOLOGICAL|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
58433704|NCT06172478|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
58433705|NCT05305963|RADIATION|Mammogram|mammogram
58433706|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
58433707|NCT02180841|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
58103511|NCT04259801|DRUG|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
58103512|NCT04259801|DRUG|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
58103513|NCT04259801|DRUG|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
58103514|NCT04259801|DRUG|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
58103515|NCT04768764|PROCEDURE|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
57737671|NCT05005832|OTHER|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
57737672|NCT00373776|DRUG|miltefosine 2.5 mg/kg/day for 28 days|
58103516|NCT04768764|PROCEDURE|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
58433708|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
58433709|NCT01359189|DEVICE|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
58433710|NCT01359228|DRUG|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
58433711|NCT01359228|DRUG|Placebo|Placebo 1 tablet three times a day for 14 days.
58433712|NCT02785068|DRUG|MM-151|Oligoclonal antibody
58103517|NCT04768764|DRUG|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
58103518|NCT04768764|PROCEDURE|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
58103519|NCT05571657|BEHAVIORAL|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
58103520|NCT05003128|DEVICE|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
58103521|NCT03883971|OTHER|3D printed model|Same as previously reported in arm descriptions
58103522|NCT03883971|OTHER|Placebo|nothing other than the ultrasound
58103523|NCT05423301|PROCEDURE|Experimental|Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
58433713|NCT02785068|DRUG|nal-IRI|Nanoliposomal irinotecan
58103524|NCT05423301|PROCEDURE|Control|The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
58433714|NCT02785068|DRUG|Leucovorin|folinic acid
58103525|NCT01909388|RADIATION|MRI-TRUS fusion guided real time HDR|
58103526|NCT04067024|PROCEDURE|Local anesthesia made by surgeon|infiltration with local anesthetics
58433715|NCT02785068|DRUG|5-FU|Chemotherapy
58433716|NCT04903795|DRUG|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
58433717|NCT05501470|DRUG|Probiotic|Probiotic
58433718|NCT05501470|DRUG|Placebo|Placebo
58433719|NCT05501470|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
58103527|NCT04067024|PROCEDURE|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
58433720|NCT05981183|DEVICE|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
57737673|NCT01181050|DRUG|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
58103528|NCT02833558|DEVICE|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
58103529|NCT02833558|PROCEDURE|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
58103530|NCT01780688|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
58103531|NCT01780688|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
58103532|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58309493|NCT00591877|PROCEDURE|Sham Acupuncture|"The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
58309494|NCT00591877|OTHER|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
58309495|NCT00002419|DRUG|Abacavir sulfate|
58309496|NCT00002419|DRUG|Amprenavir|
58309497|NCT00002419|DRUG|Efavirenz|
58309498|NCT00002419|DRUG|Adefovir dipivoxil|
58309499|NCT01556217|DRUG|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
58309500|NCT01556217|DRUG|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
58309501|NCT01655875|DRUG|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
58309502|NCT03694704|DEVICE|FineHearing strategy|Cochlear implant with FineHearing strategy
58309503|NCT00488397|OTHER|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
58309504|NCT04434508|PROCEDURE|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
58309505|NCT04434508|PROCEDURE|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
58309506|NCT04369417|BEHAVIORAL|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
58309507|NCT02239211|DRUG|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
58309508|NCT05773742|DEVICE|Low-volume irrigation|Qufora IrriSedo MiniGo
58309509|NCT00004921|BIOLOGICAL|filgrastim|
58309510|NCT00004921|DRUG|carboplatin|
58309511|NCT00004921|DRUG|cyclophosphamide|
58309512|NCT00004921|DRUG|melphalan|
58309513|NCT00004921|DRUG|paclitaxel|
58309514|NCT00004921|PROCEDURE|adjuvant therapy|
58309515|NCT00004921|PROCEDURE|bone marrow ablation with stem cell support|
58309516|NCT00004921|PROCEDURE|peripheral blood stem cell transplantation|
58309517|NCT01459926|DRUG|TD-1211|once daily
58309518|NCT01459926|DRUG|TD-1211|Once daily
58309519|NCT01459926|DRUG|TD-1211|Once daily
58309520|NCT01459926|DRUG|Placebo|Once daily
58309521|NCT06032728|DRUG|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
58309522|NCT03865823|PROCEDURE|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
58309523|NCT01231217|OTHER|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
58309524|NCT01231217|OTHER|Coffee|Patients are recommended to drink as much coffee as they tolerate.
58309525|NCT02631941|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
58309526|NCT02631941|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
58433721|NCT05067738|OTHER|same day discharge|same day discharge
58433722|NCT03242356|OTHER|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~* oral intake of clear fluid during the labor~* oral intake of solid meal during the labor~* fasting duration for solid and liquids~* instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, ...)~* discomfort related to thirst during labor~* discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
58433723|NCT06583369|DRUG|Liangxue ointment（Traditional Chinese Ointment）|"The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses."
58433724|NCT06583369|DRUG|Urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
58433725|NCT00158041|DRUG|Amifostine administered subcutaneously|
58433726|NCT02211430|BEHAVIORAL|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
58433727|NCT02211430|BEHAVIORAL|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
58433728|NCT05482841|DIAGNOSTIC_TEST|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
58433729|NCT01931163|DRUG|Everolimus|
58103533|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103534|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103535|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103536|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103537|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103538|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
57737674|NCT01181050|DRUG|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
57737675|NCT01300130|DIETARY_SUPPLEMENT|low docosahexaenoic acid formula|
57737676|NCT01300130|DIETARY_SUPPLEMENT|medium docosahexaenoic acid formula|
57737677|NCT01300130|DIETARY_SUPPLEMENT|high docosahexaenoic acid formula|
58433730|NCT03223376|COMBINATION_PRODUCT|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
58433731|NCT03223376|COMBINATION_PRODUCT|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
58433732|NCT05652387|BEHAVIORAL|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
58433733|NCT04833296|DRUG|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
58433734|NCT03565614|BEHAVIORAL|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
58433735|NCT03565614|BEHAVIORAL|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
58433736|NCT02491606|DRUG|Tafenoquine|Tafenoquine 200mg and 400 mg
58433737|NCT02491606|OTHER|Placebo|Placebo
58433738|NCT01481077|DRUG|Latanoprost-PPDS|Sustained release for 12 weeks
58433739|NCT01271374|DRUG|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
58433740|NCT01271374|DRUG|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
58433741|NCT01670435|DRUG|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
58433742|NCT01677858|DRUG|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
58433743|NCT01677858|DRUG|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
58433744|NCT02337192|DRUG|Curcumin|
58433745|NCT02337192|DEVICE|LED|
58433746|NCT02337192|DRUG|Surfactant|
58433747|NCT02337192|DRUG|DMSO + water|
58433748|NCT02337192|DRUG|Chlorhexidine gluconate|
58433749|NCT03269058|DRUG|Dapagliflozin|Dapagliflozin 10 mg daily per os
58433750|NCT03269058|DRUG|Placebos|Placebo of Dapagliflozin per day per os
58433751|NCT01250041|PROCEDURE|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
58433752|NCT01250041|PROCEDURE|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
58433753|NCT06525142|BEHAVIORAL|Audiovisual Intervention|"【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person."
58129553|NCT04141033|DIAGNOSTIC_TEST|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
58129554|NCT04506242|DRUG|SHR-1210|PD-1
58433754|NCT00068302|DRUG|sirolimus|3-6 subjects will be enrolled into each dose level
58433755|NCT06349668|DRUG|spinal analgesia with morphine and bupivacaine|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
58433756|NCT06349668|DRUG|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
58433757|NCT06430723|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
58433758|NCT02721095|OTHER|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
58433759|NCT02721095|OTHER|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
58433760|NCT01510743|PROCEDURE|Catheterization of subclavian vein|Catheterization of subclavian vein
58433761|NCT01510743|PROCEDURE|Catheterization of internal jugular vein|Catheterization of internal jugular vein
58433762|NCT05239767|DRUG|NSAID|We will administer oral NSAIDs
58433763|NCT03989401|OTHER|Multimedia video health education|The experimental group conducted multimedia video education while admission.
58433764|NCT04236739|DRUG|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
58433765|NCT04360876|DRUG|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
58129555|NCT04506242|DRUG|Apatinib|VEGFR2
58433766|NCT04360876|DRUG|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
58433767|NCT05693792|OTHER|Observational|No treatment regimen will be deployed in this follow-up study.
58433768|NCT06210230|DIETARY_SUPPLEMENT|MLCT supplementation|MLCT 25g/d for 6 months
58433769|NCT06210230|DIETARY_SUPPLEMENT|Olive oil|Matching placebo (olive oil) 25g/d for 6 months
58433770|NCT00285168|BEHAVIORAL|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
58433771|NCT02339194|PROCEDURE|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
58433772|NCT02401984|OTHER|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
58103539|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
58103540|NCT02232139|DRUG|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
57737678|NCT01300130|DIETARY_SUPPLEMENT|breast milk|a non randomized group of breast milk fed infants was included
57737679|NCT03273946|DRUG|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
58103541|NCT03774173|DRUG|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
58129556|NCT00525590|DRUG|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
58309527|NCT02631941|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
57737680|NCT02048228|DRUG|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
57737681|NCT02048228|DRUG|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
57737682|NCT05498376|DEVICE|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
58309528|NCT02631941|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
58309529|NCT02789371|PROCEDURE|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
58309530|NCT02789371|PROCEDURE|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
58309531|NCT06228404|DRUG|Enhanced autologous PSMA-CAR T|"3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T:~cohort A： CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort B： CART-PSMA cells 0.75×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort C： CART-PSMA cells 2×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;"
58309532|NCT02808988|PROCEDURE|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
57737683|NCT05498376|DEVICE|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
57737684|NCT02510495|PROCEDURE|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
58433773|NCT04188145|DRUG|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
58433774|NCT04188145|DRUG|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
58433775|NCT06341023|BEHAVIORAL|Functional Balance Intervention|Participants in the intervention group will undergo a multi-component FBI exercise program, both in a lab setting (Study 1) and at home (Study 2), for 2 days/week over 4 months. This evidence-based protocol, previously piloted with chronic stroke patients, older adults with mild cognitive impairment, and pre-frail older adults, focuses on improving physical (endurance, strength, balance, and gait) and cognitive function (processing speed, attention, and memory). The program consists of functional agility, functional strength, dual-task, and vestibular exercises, with each 1-hour session including 10 minutes dedicated to each component. The exercise order will be randomized for each session, preceded by a warm-up with gentle self-stretching exercises.
57737685|NCT02510495|PROCEDURE|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
57737686|NCT02510495|PROCEDURE|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
58129557|NCT03843203|DEVICE|Transcranial Direct Current Stimulation - tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
58129558|NCT02853500|DEVICE|TriNav|TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
58309533|NCT02808988|PROCEDURE|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
58433776|NCT06341023|BEHAVIORAL|Stretching|Participants in the control group will undergo a 4-month lab-based stretching program, with the same frequency and session length as the intervention group (1 hour/session for 2 days/week). The stretching regimen will include progressive stretches targeting upper and lower-limb muscles, core, and back muscles, followed by a 10-minute cool-down comprising relaxation and breathing exercises. These stretches are designed to improve performance in daily living activities. In Study 2, stretching participants will receive a detailed printed exercise manual for home-based training, ensuring consistency with the lab-based program. No additional equipment, such as computers or tablets, is required for the home stretching program.
58433777|NCT01160913|PROCEDURE|Continuous wound infusion|
58433778|NCT01160913|PROCEDURE|Continuous wound|
58433779|NCT03424460|BIOLOGICAL|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
58433780|NCT03424460|BIOLOGICAL|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
58433781|NCT03424460|GENETIC|RNA extraction|RNA extraction from liver tissue
58309534|NCT02808988|OTHER|zoledronic acid|5 mg/year zoledronic acid (i.v.)
58309535|NCT01872962|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
58433782|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
58433783|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
58433784|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
58433785|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
58433786|NCT04776863|DEVICE|optical biometry measurement|The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
58433787|NCT04807257|COMBINATION_PRODUCT|Auger Molecular Therapy (AMT)|The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
58433788|NCT00853138|BEHAVIORAL|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
58433789|NCT02381340|DEVICE|ACE stapling procedure|Endoscopic trans-oral gastroplication
58433790|NCT04667104|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
58433791|NCT04667104|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
58433792|NCT04667104|DRUG|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
58433793|NCT04667104|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
58433794|NCT04667104|DRUG|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
58433795|NCT00917488|OTHER|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
58433796|NCT04165499|COMBINATION_PRODUCT|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
58433797|NCT04165499|COMBINATION_PRODUCT|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
58433798|NCT01982461|DRUG|Rosuvastatin|10mg,once daily
58433799|NCT01982461|DRUG|Crestor®|10mg,once daily
58433800|NCT00761527|DRUG|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
58433801|NCT00379067|DRUG|Tamsulosin OCAS|Adrenoceptor antagonist
58433802|NCT00379067|DRUG|Placebo|placebo
58433803|NCT06293313|PROCEDURE|Mindfulness training|Before starting the study, an appointment will be made to meet with the students participating in the mindfulness group with randomization on the specified day and time. The students and the researcher will meet in a quiet, calm room of the school. Students will be informed about the practice of mindfulness and their written and verbal consents will be obtained before participating in the study. Then, a pre-test will be applied to the students who agree to participate in the study.
58433804|NCT06293313|OTHER|Will not be given any application|Before starting the research, the students in the control group determined by the randomization method will be informed about the research. Written and verbal consent will be obtained from the students that the students agree to participate in the research. Afterwards, students will meet in a quiet and calm room of the school on the specified day and time. Before starting the research, students will be given a pre-test. A mid-term test will be performed 8 weeks after the pre-test.
58433805|NCT02484482|DRUG|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
58129559|NCT02853500|DEVICE|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
58433806|NCT01674205|BIOLOGICAL|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
58433807|NCT01674205|BIOLOGICAL|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
58433808|NCT01674205|BIOLOGICAL|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
58433809|NCT01674205|BIOLOGICAL|Vaccine placebo (Leibovitz-15 [L-15])|
58433810|NCT01674205|BIOLOGICAL|Vaccine placebo (FluMist®)|
58433811|NCT00533624|DRUG|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
58433812|NCT00533624|DRUG|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
58433813|NCT04703491|BEHAVIORAL|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
58433814|NCT04703491|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
58433815|NCT04703491|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
58433816|NCT05688332|DRUG|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
58433817|NCT05688332|DRUG|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
58433818|NCT06576219|BEHAVIORAL|Group Music Therapy|My Life Is Music group therapy model
58433819|NCT04358965|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
58433820|NCT04358965|DRUG|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
58433821|NCT04358965|DRUG|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
58433822|NCT02403232|PROCEDURE|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
58433823|NCT02403232|DEVICE|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
58433824|NCT02403232|DEVICE|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
58433825|NCT02783599|DRUG|Olaratumab|Administered IV
58433826|NCT02783599|DRUG|Doxorubicin|Administered IV
58433827|NCT02783599|RADIATION|External Beam Radiotherapy|
58433828|NCT03287037|DEVICE|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
58433829|NCT01707901|DRUG|ONO-8539|Treatment
58433830|NCT01707901|OTHER|Placebo|Placebo
58433831|NCT00744107|DEVICE|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
58433832|NCT00888953|OTHER|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
58433833|NCT00888953|OTHER|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
58433834|NCT03449472|DRUG|Quetiapine|Patients are tested for their normal prescription quetiapine medication
58433835|NCT04240158|DRUG|IW-6463|IW-6463 Tablet
58433836|NCT04240158|DRUG|Matching Placebo|Matching Placebo Tablet
58433837|NCT05799794|BEHAVIORAL|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
57737687|NCT02510495|PROCEDURE|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
58129560|NCT02853500|DRUG|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
58103542|NCT04478370|BIOLOGICAL|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
58433838|NCT05669651|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
58433839|NCT05921799|PROCEDURE|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
58433840|NCT04949074|OTHER|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
58433841|NCT06039618|OTHER|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
58433842|NCT04038450|OTHER|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
58433843|NCT00546949|PROCEDURE|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
58433844|NCT00546949|PROCEDURE|Interspinous Process Decompression (IPD)|Interspinous device
58433845|NCT04597073|PROCEDURE|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
58433846|NCT03305978|DEVICE|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
58433847|NCT03305978|DEVICE|Low dose chest CT|standard diagnostic low dose chest CT
58103543|NCT01984229|DRUG|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
57737688|NCT02768961|DRUG|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
57737689|NCT02768961|DRUG|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
58129561|NCT02924480|PROCEDURE|Cystectomy|
58433848|NCT03876899|DIETARY_SUPPLEMENT|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
58433849|NCT03876899|DIETARY_SUPPLEMENT|Placebo|Pill
58433850|NCT01167660|DEVICE|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
58433851|NCT02396589|BEHAVIORAL|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
58433852|NCT02396589|BEHAVIORAL|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
58433853|NCT05041140|DEVICE|29-XeMRI imaging|129-XeMRI scan
58433854|NCT01609998|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
58433855|NCT01609998|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
58433856|NCT04316637|DRUG|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
58433857|NCT06485388|DRUG|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
58433858|NCT06485388|DRUG|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
58433859|NCT00218699|BEHAVIORAL|Cognitive-Behavioral Intervention|
57737690|NCT06413524|DEVICE|Whole-body Vibration Therapy|Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of vibration training, and 10 minutes of stretching exercises at the end. Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles. After vibration starts, the patient squat and stand at a steady pace until the two minutes are over.
57953796|NCT03725878|PROCEDURE|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration \>400 ng/ml before pregnancy is recommended.
58103544|NCT01984229|DRUG|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
58103545|NCT06339008|DRUG|LY3650150|Administered SC
58103546|NCT06339008|DRUG|Placebo|Administered SC
58103547|NCT06339008|DRUG|Standard therapy for INCS|Administered as intranasal spray
58103548|NCT03987022|DRUG|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
58433860|NCT04916379|DIETARY_SUPPLEMENT|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
58433861|NCT04916379|OTHER|Placebo|Placebo: 2000 mg per day for 12 weeks
58433862|NCT01337544|OTHER|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
58433863|NCT01258283|OTHER|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
58433864|NCT04678947|BEHAVIORAL|Baxter Retching Faces (BARF) scale|"* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
58433865|NCT04073485|PROCEDURE|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
58433866|NCT05389033|DIETARY_SUPPLEMENT|Probiotic bacteria|28 days daily supplementation with active probiotic
58433867|NCT05389033|OTHER|Placebo Capsule|28 days daily supplementation with placebo
58433868|NCT05597553|OTHER|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
58433869|NCT05597553|OTHER|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
58433870|NCT05006027|PROCEDURE|Percutaneous coronary intervention via the distal radial approach|Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
58103549|NCT03987022|DRUG|Opioids|Use of narcotic for pain control post operatively
58103550|NCT03987022|OTHER|Ice Packs|Placement of Ice packs on surgical sites post operatively
58103551|NCT03987022|DRUG|Tylenol|Use of pain medication post operatively
57953797|NCT03725878|PROCEDURE|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
58103552|NCT03987022|DRUG|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
58103553|NCT03987022|DRUG|dilaudid|Use of narcotic for pain control post operatively
58103554|NCT04537585|COMBINATION_PRODUCT|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
58103555|NCT04537585|DRUG|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
58103556|NCT04749810|DRUG|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
58103557|NCT02543736|DEVICE|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
58103558|NCT02116413|PROCEDURE|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
58103559|NCT02116413|PROCEDURE|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
58103560|NCT01364298|DRUG|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram \[mg\] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
58103561|NCT01364298|DRUG|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
58103562|NCT00112515|DRUG|modafinil|
58103563|NCT00112515|PROCEDURE|cognitive assessment|
58103564|NCT00112515|PROCEDURE|psychosocial assessment and care|
58103565|NCT00112515|PROCEDURE|quality-of-life assessment|
58103566|NCT03301428|OTHER|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
58103567|NCT03301428|OTHER|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
58433871|NCT06506825|DIAGNOSTIC_TEST|Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker|Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
58103568|NCT03050528|BEHAVIORAL|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
58103569|NCT03050528|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
58103570|NCT04394052|DIAGNOSTIC_TEST|MR imaging|Medical imaging
58103571|NCT02733601|OTHER|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
58103572|NCT05710315|DRUG|Relizorb|Relizorb cartridges will be used with routine enteral feedings for 5 days
58433872|NCT04313270|DRUG|Evolocumab|12 weeks of treatment with Evolocumab
58103573|NCT05710315|OTHER|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days
58103574|NCT03086083|BEHAVIORAL|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
58103575|NCT03086083|BEHAVIORAL|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
58129562|NCT02924480|DRUG|Lidocaine|Patients will receive lidocaine infusion during surgery
58129563|NCT02924480|DRUG|Saline|Patients will receive saline infusion during surgery
58103576|NCT04694131|DEVICE|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
58103577|NCT02454309|DIETARY_SUPPLEMENT|Cranberry concentrate|
58103578|NCT02454309|DIETARY_SUPPLEMENT|Placebo|
58103579|NCT05980988|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
58103580|NCT05980988|DIETARY_SUPPLEMENT|Placebo|Placebo
58103581|NCT04660409|DIAGNOSTIC_TEST|Blood test for serum Adropin|Blood test for serum Adropin
58103582|NCT03695406|BEHAVIORAL|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
58103583|NCT05807048|DRUG|Daratumumab and Hyaluronidase-fihj|DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
58103584|NCT05807048|DRUG|Pre-Intervention Medication|"The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously"
58433873|NCT02286635|DRUG|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
58433874|NCT02286635|DRUG|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
58433875|NCT03063905|DRUG|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
58433876|NCT02353195|OTHER|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
58433877|NCT02449590|DIETARY_SUPPLEMENT|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
58433878|NCT02449590|DIETARY_SUPPLEMENT|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
58433879|NCT04508153|DEVICE|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
58433880|NCT04508153|OTHER|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
58433881|NCT01558050|DIETARY_SUPPLEMENT|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
58433882|NCT02566590|DEVICE|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
58433883|NCT02566590|DIETARY_SUPPLEMENT|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
58433884|NCT02566590|DIETARY_SUPPLEMENT|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
58433885|NCT00759408|DRUG|BQ-123|6-120 µg/min
58433886|NCT01791478|DRUG|PI3K inhibitor BYL719|Given PO
58433887|NCT01791478|DRUG|letrozole|Given PO
58433888|NCT01791478|OTHER|laboratory biomarker analysis|Correlative studies
58433889|NCT01791478|OTHER|pharmacological studies|Correlative studies
58433890|NCT03075709|OTHER|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
57953798|NCT01708109|OTHER|no measures taken to clear bile ductus|biliary calculus remain
58103585|NCT05807048|DRUG|Post-Intervention Medication|"The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment."
58103586|NCT06540573|DIAGNOSTIC_TEST|Laboratory tests (examination)|Laboratory tests (examination) to be performed include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function tests and kidney function tests; rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and C-C Motif Chemokine Ligand 21 (CCL21).
58103587|NCT06540573|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) This questionnaire is used to assess the health status of osteoarthritis patients introduced in 1988 (13). It is consisted of 33 items which evaluates the health and function of the patient from various aspects including: clinical symptoms (5 questions), severity of joint stiffness (2 questions), degree of pain (9 questions), and activity of daily living (17 questions).The test questions are scored on a scale of 0-4, which correspond to: None(0),Mild (1),Moderate (2),Severe(3),and Extreme (4).The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores.Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
58103588|NCT06540573|DIAGNOSTIC_TEST|The Disease Activity Score28 (DAS28)|The Disease Activity Score (DAS) was created as a numerical tool for quantifying and assessing disease activity in rheumatoid arthritis (RA).The DAS28 (Disease Activity Score using 28 joint counts) was developed from the original DAS (Disease Activity Score).The DAS28 evaluates the disease activity by assessing the number of tender and swollen joints in a patient. Specifically, it considers 28 joints. The DAS28 also takes into account a blood marker of inflammation, typically the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level.A patient with a DAS28 score of less than 2.6 is in remission; a score greater than or equal to 2.6 and less than 3.1 indicates low activity; a score greater than or equal to 3.1 and \<5.1 indicates moderate activity and a score 5.1 or more indicates high activity
58103589|NCT06540573|DIAGNOSTIC_TEST|Patient global assessment (PGA)|Patient global assessment (PGA) of disease activity will be reported by patients. PGA was developed in the late 1970s and was initially designed for the measurement of self-assessed pain in RA \[8\], although it has since been used to evaluate RA more globally. It is interesting to note that the way PGA is used in clinical practice covers, in fact, two very different concepts, one related to global health and the other to overall disease activity. They are both usually used under the heading of PGA without further specification for which is being assessed.
58309536|NCT01872962|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
58309537|NCT00681200|BEHAVIORAL|Enhanced health education|health education and social support
58309538|NCT00681200|BEHAVIORAL|Transcendental Meditation program|The TM program plus didactic-based health education classes
58309539|NCT06378177|BIOLOGICAL|LVGN6051 Monoclonal Antibody Injection|LVGN6051 Monoclonal Antibody Injection:1 mg/kg or 2 mg/kg, every 3 weeks(Q3W) , on the first day of the treatment cycle for up to 2 years.
58309540|NCT06378177|BIOLOGICAL|toripalimab Injection|toripalimab Injection: 240mg fixed dose,Q3W, on the first day of the treatment cycle for up to 2 years.
58309541|NCT06378177|DRUG|Paclitaxel injection|paclitaxel Injection:5ml:100 mg/m2(80 mg/m2 or 60 mg/m2 can be used if necessary),Q3W,on the first and eighth day of the treatment cycle for up to 2 years
58309542|NCT02825823|DIETARY_SUPPLEMENT|Ketone Salt|
57953799|NCT01708109|PROCEDURE|clearance of bile ductus|biliary calculus removed at surgery
57953800|NCT03182270|DIAGNOSTIC_TEST|nCLE|Procedure: EUS-FNA Device: nCLE
57953801|NCT00385255|BIOLOGICAL|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
57953802|NCT00385255|BIOLOGICAL|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
57953803|NCT04505241|BEHAVIORAL|Remotely-delivered physical activity promotion|Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
57953804|NCT05015088|OTHER|No interventions will be performed in this study|This study will not include any intervention
57953805|NCT04010396|OTHER|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
57953806|NCT05785143|PROCEDURE|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
57953807|NCT02185950|DEVICE|ultrasound|
57953808|NCT02185950|DEVICE|paraffin|
57953809|NCT02185950|DEVICE|endermotherapy|
57953810|NCT04156880|OTHER|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
57953811|NCT03042507|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
57953812|NCT03951623|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
58309543|NCT02825823|DIETARY_SUPPLEMENT|Placebo|
58103590|NCT06540573|DIAGNOSTIC_TEST|Physician global assessment (PhGA)|Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
58103591|NCT06540573|DIAGNOSTIC_TEST|Health Assessment Questionnaire (HAQ)|Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
58103592|NCT06540573|DIAGNOSTIC_TEST|Clinical disease activity index (CDAI)|Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76
58103593|NCT06540573|DIAGNOSTIC_TEST|The Simplified Disease Activity Index (SDAI)|The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as \>26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17
58103594|NCT06540573|DIAGNOSTIC_TEST|Knee Radiography|Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity
58103595|NCT01210885|BIOLOGICAL|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
58103596|NCT02514031|DRUG|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
58309544|NCT01592214|OTHER|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
57953813|NCT03951623|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
57953814|NCT01757678|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
57953815|NCT01757678|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
58309545|NCT01592214|DRUG|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
58309546|NCT01592214|DRUG|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
58309547|NCT00356018|BEHAVIORAL|Compliance|
58433891|NCT04492111|PROCEDURE|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
58433892|NCT00517361|DRUG|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
58433893|NCT00517361|DRUG|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
57953816|NCT01757678|PROCEDURE|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
57953817|NCT01757678|OTHER|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
58433894|NCT03268291|OTHER|Standard outpatient observation|Outpatient management according to Ministry of health standards
58103597|NCT02514031|DRUG|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
58433895|NCT03268291|BEHAVIORAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
58433896|NCT04858295|DEVICE|Texting|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
58103598|NCT02514031|DRUG|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
58103599|NCT04887974|PROCEDURE|canine retraction|Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
58103600|NCT04444752|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
58433897|NCT04858295|DEVICE|mHealth app|Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
57737691|NCT06413524|DEVICE|Local Vibration Therapy|Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of vibration training, and a final 10-minute stretching exercise. Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. After the vibration begins, the patient squat and stand at a steady pace until the two minutes are over.
57953818|NCT03825770|BEHAVIORAL|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
57953819|NCT03825770|BEHAVIORAL|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
57953820|NCT06229795|DRUG|Green Tea Leaf Extract Decaffeinated|300 mg film coated tablet
57953821|NCT06229795|DRUG|Metformin Hydrochloride 500 MG|500 mg tablet
57953822|NCT00849732|BIOLOGICAL|V520|Intentionally Blank
57953823|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26
57953824|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26
57953825|NCT00849732|BIOLOGICAL|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
57953826|NCT01157221|OTHER|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
57953827|NCT01157221|OTHER|EMSMTA|end-range mobilization/scapular mobilization treatment approach
57953828|NCT03445455|DEVICE|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
57953829|NCT03652662|DEVICE|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
57953830|NCT03652662|BEHAVIORAL|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
57953831|NCT05858905|DEVICE|Intravascular Lithotripsy|The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
57953832|NCT01836432|DRUG|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
57953833|NCT01836432|BIOLOGICAL|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
58103601|NCT04444752|DRUG|placebo|subcutaneous(SC) injection
58103602|NCT03917563|DEVICE|WATCHMAN LAA occluder|WATCHMAN LAA occluder
58433898|NCT04596748|DIETARY_SUPPLEMENT|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
58103603|NCT01945554|PROCEDURE|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
58103604|NCT01945554|PROCEDURE|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
58433899|NCT04596748|DIETARY_SUPPLEMENT|Placebo|Placebo caps
58433900|NCT05937789|DIETARY_SUPPLEMENT|Vitamin D3|Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
58103605|NCT01945554|DRUG|Mephamesone|
58433901|NCT05937789|DIETARY_SUPPLEMENT|Medium Chain Triglycerides (MCT)|Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
58433902|NCT01754571|BEHAVIORAL|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
58103606|NCT01945554|DRUG|0.5% bupivacaine (Bupivacain®)|
58103607|NCT01945554|DRUG|Kenacort®|
58103608|NCT00575328|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
58103609|NCT00575328|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
58103610|NCT04322227|DRUG|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
58103611|NCT04322227|DRUG|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
58103612|NCT04322227|DRUG|Placebo (treatment C)|Placebo, BID capsules, orally
58103613|NCT03179501|DRUG|NP001|NP001
58433903|NCT04775264|PROCEDURE|Pulsed Electric Field Ablation|Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
58433904|NCT03054779|OTHER|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
58433905|NCT03054779|OTHER|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
58433906|NCT03054779|OTHER|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
58433907|NCT02843828|DEVICE|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
58433908|NCT02843828|OTHER|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
57953834|NCT01836432|RADIATION|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
57953835|NCT01836432|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
58103614|NCT03179501|DRUG|Placebo|Normal saline
58433909|NCT03725813|OTHER|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
58433910|NCT02636023|DEVICE|SPhENo-Cardiograph|SPhENo-Cardiograph
58433911|NCT02589106|DEVICE|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
58433912|NCT01601262|DEVICE|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
57953836|NCT01836432|DRUG|Capecitabine|Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
57953837|NCT01836432|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
57953838|NCT00432614|DRUG|SR58611A|oral administration
57953839|NCT00432614|DRUG|escitalopram|oral administration
57953840|NCT00432614|DRUG|placebo|oral administration
57953841|NCT03464656|DRUG|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)"
57953842|NCT03464656|DIAGNOSTIC_TEST|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
57953843|NCT03464656|DIAGNOSTIC_TEST|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
57953844|NCT03464656|DIAGNOSTIC_TEST|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
57953845|NCT05916365|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
58103615|NCT05918575|DEVICE|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
58103616|NCT05918575|DEVICE|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
58103617|NCT05282355|DIETARY_SUPPLEMENT|Astaxanthin|Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.
58433913|NCT03452709|BEHAVIORAL|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
58433914|NCT03452709|DEVICE|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
58103618|NCT05282355|DIETARY_SUPPLEMENT|Placebo|To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
58103619|NCT03276533|DRUG|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
58433915|NCT03151187|OTHER|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
58433916|NCT02427776|BIOLOGICAL|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
58433917|NCT06584461|DRUG|Lidocaine (drug)|IV lidocaine, administered once during the induction of anesthesia.
58433918|NCT06584461|DRUG|Saline (NaCl 0,9 %) (placebo)|IV placebo (normal saline), administered once during the induction of anesthesia.
57737692|NCT06413524|DEVICE|Sham Comparator|Patients are instructed to perform squatting and standing exercises at home without vibration equipment. Health education is provided at the time of enrollment, and patients are instructed to perform the exercises twice a week at home, with follow-up via telephone to check compliance. Each session consists of 10 minutes of warm-up exercises for the upper limbs, lower limbs, and spine, six sets of squatting and standing exercises, and a final 10-minute stretching exercise. Each session includes six series, each lasting 2 minutes, with a 60-second rest interval between series. After the warm-up exercises, participants should hold onto large household furniture or walls and squat and stand at a steady pace until the two minutes are up.
58103620|NCT03276533|DRUG|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
58103621|NCT03276533|DRUG|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
58103622|NCT03276533|DRUG|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
58103623|NCT06122272|OTHER|Test Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
58433919|NCT06578065|DEVICE|Echelon Circular™ Powered Stapler|Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.
58433920|NCT06578065|DEVICE|2-row circular staplers manual|2-row circular staplers manual will be used in colorectal anastomosis.
58433921|NCT00963794|OTHER|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
58433922|NCT02020317|BEHAVIORAL|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
57737693|NCT04885023|OTHER|Hippotherapy|The hippotherapy program for 10 weeks
58433923|NCT06201286|OTHER|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
58433924|NCT06201286|OTHER|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
58103624|NCT06122272|OTHER|Control Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.
58433925|NCT00286871|DRUG|Neoral|
57737694|NCT05893758|DEVICE|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
57953846|NCT04170361|OTHER|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
58103625|NCT05491278|DRUG|Fospropofol disodium for injection|Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
58103626|NCT05491278|DRUG|Propofol|Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
58103627|NCT00612482|OTHER|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
58103628|NCT00449930|DRUG|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
58103629|NCT00449930|DRUG|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
58103630|NCT04628143|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
58433926|NCT00286871|DRUG|Tacrolimus|
58433927|NCT00757822|DRUG|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
58433928|NCT00757822|DRUG|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
58433929|NCT04008251|GENETIC|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
58433930|NCT05406102|DRUG|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
58433931|NCT05406102|DRUG|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
58433932|NCT02528786|OTHER|No Intervention|No study drug will be administered in this study.
58103631|NCT01581762|PROCEDURE|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
58103632|NCT01804192|OTHER|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
58103633|NCT02406703|DRUG|Chloroprocaine|
58103634|NCT02406703|DRUG|Mepivacaine|
58103635|NCT00002269|DRUG|Ampligen|
58103636|NCT00002269|DRUG|Zidovudine|
58433933|NCT05348239|DRUG|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
58433934|NCT02487030|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
58433935|NCT02487030|DRUG|RBV|Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58433936|NCT00385749|DEVICE|RV apical vs RV septal defibrillation threshold testing|
58433937|NCT04471324|DEVICE|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
58433938|NCT04792411|BEHAVIORAL|Prehabilitation|Multimodal, tailored prehabilitation programme
58433939|NCT01894243|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
58433940|NCT01548508|OTHER|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
58433941|NCT01548508|OTHER|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
57737695|NCT06292455|OTHER|Elastic resistance training|six-weeks elastic resistance training of upper limb. Three days per week. volume per session would be 10 repetitions and three sets. 2 minute rest interval between each set.
57737696|NCT06292455|OTHER|Conventional Resistance Training|players follow their routine exercise protocol
58103637|NCT00280774|DRUG|Memantine|
58103638|NCT00213031|DRUG|Carraguard (PC-515)|
58103639|NCT00141531|DRUG|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
58433942|NCT03875352|PROCEDURE|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
58433943|NCT03875352|PROCEDURE|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
58433944|NCT03077204|BIOLOGICAL|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
57737697|NCT00093301|DRUG|Levosimendan|
57953847|NCT04170361|OTHER|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
58103640|NCT02956824|OTHER|Standard care|Current care
57953848|NCT00599482|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
58103641|NCT04297488|DIETARY_SUPPLEMENT|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
58103642|NCT04283487|DIETARY_SUPPLEMENT|Fructans|500ml 0.9% normal saline containing 40g fructans
57737698|NCT00093301|DRUG|Dobutamine|
57737699|NCT04136951|OTHER|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
58103643|NCT04283487|DIETARY_SUPPLEMENT|Glucose|500ml 0.9% normal saline containing 40g glucose
58103644|NCT04283487|DIETARY_SUPPLEMENT|Saline|500ml 0.9% normal saline
58103645|NCT00245427|DRUG|all macrolide antibiotics|Varies based on antibiotic
58103646|NCT00245427|DRUG|all beta-lactam antibiotics|Varies based on antibiotic
58103647|NCT02272881|PROCEDURE|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
58103648|NCT02272881|PROCEDURE|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
58103649|NCT04972006|BEHAVIORAL|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
58103650|NCT03707522|BEHAVIORAL|Growth mindset|10 minute interactive article describing neuroplasticity
58103651|NCT03707522|BEHAVIORAL|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
58103652|NCT03707522|BEHAVIORAL|Control|10 minute interactive article describing activity scheduling
58433945|NCT03077204|DEVICE|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
58433946|NCT05933668|BIOLOGICAL|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
58433947|NCT05411939|OTHER|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
58103653|NCT02576054|BIOLOGICAL|V501|Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
58103654|NCT01532037|OTHER|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
58103655|NCT01532037|OTHER|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
58309548|NCT02643277|BEHAVIORAL|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
58433948|NCT05411939|OTHER|Video|Short video that describes knee osteoarthritis and possible treatment options.
58433949|NCT05411939|OTHER|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
57953849|NCT05957289|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
58103656|NCT06292806|DRUG|FSH-R|controlled ovarian stimulation for IVF
58129564|NCT01924858|DRUG|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
58433950|NCT05704790|OTHER|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
58433951|NCT04398550|OTHER|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
58433952|NCT04398550|OTHER|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
58433953|NCT03100773|OTHER|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
58433954|NCT03100773|PROCEDURE|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
58433955|NCT00605345|DRUG|Darbepoetin alfa|As prescribed
58129565|NCT01924858|DRUG|[18F]GSK2647544 IV bolus|\[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
58309549|NCT02643277|OTHER|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
58309550|NCT05928923|DEVICE|CPAP|CPAP usage 3 months
58309551|NCT04693403|PROCEDURE|HFNC|40-60l/min humidified oxygen by nasal cannula
58309552|NCT04693403|PROCEDURE|CPAP|Oxygen therapy by boussignac Continuous positive airway pressure face mask
58309553|NCT04693403|PROCEDURE|Standard Oxygen|Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
58309554|NCT01868646|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
58309555|NCT01868646|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
58309556|NCT05429840|DRUG|MT1980|single dose
58309557|NCT05429840|DRUG|Placebo|single dose
58309558|NCT05748899|BEHAVIORAL|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
58309559|NCT04555603|DRUG|Inlyta|axitinib
58309560|NCT04555603|DRUG|Bavencio|avelumab
58309561|NCT04555603|DRUG|Keytruda|Pembrolizumab
58309562|NCT05084391|DEVICE|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
58309563|NCT05084391|OTHER|Standard of Treatment|Standard of care
58309564|NCT02899520|OTHER|Reference method|Electrostimulation associated to perineal training
58309565|NCT02899520|OTHER|CMP ® method|Method based on Knowledge and Control of Perineum
58309566|NCT06517381|OTHER|Digital Online Warning Signs of Mental Illness Literacy Program|Digital Online Warning Signs of Mental Illness Literacy Program is comprised of 30-minute pre-recorded video and question-and-answer sessions. The videos were followed by case studies, success stories, and interactive question-and-answer sessions
58309567|NCT06551402|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
58309568|NCT06551402|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
58309569|NCT04422067|OTHER|Fetal cephalometry|Fetal cephalometry
58433956|NCT00605345|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
58433957|NCT04186338|DEVICE|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
58433958|NCT05485285|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
58103657|NCT06089850|OTHER|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
58433959|NCT02359513|DRUG|Antidepressants|bulimic patients are treated during 3 months
58433960|NCT02359513|DRUG|Positron Emission Tomography (PET)|PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
58103658|NCT04618952|DRUG|Calcium D|calcium D supplementation given to postmenopausal females
58433961|NCT03799276|OTHER|Opticare study|"Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
58103659|NCT04618952|DRUG|Placebo|Placebo
57953850|NCT03320759|BEHAVIORAL|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
58103660|NCT04992338|DEVICE|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
58309570|NCT03553147|OTHER|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
58309571|NCT03210740|DRUG|AM001 Cream, 7.5%|Active Cream
58309572|NCT03210740|DRUG|Vehicle Cream|Placeo
58309573|NCT05263193|DRUG|Caplacizumab|as in real world practice
58309574|NCT04881643|BEHAVIORAL|Trauma-focused cognitive behavioural therapy via a digital support|A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
58309575|NCT02411643|DRUG|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
58309576|NCT00587067|DRUG|FLOXURIDINE|"\[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is \>25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
58309577|NCT01860859|PROCEDURE|Closure of the hysterotomy at the time of primary cesarean|
58433962|NCT02021903|OTHER|V1: HGPO + meal and V2: placebo + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
58103661|NCT04726839|OTHER|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
58103662|NCT05949216|BEHAVIORAL|Musical engagement sessions|Musical engagement sessions will be 2 hours long and involve improvisation and sight-reading of sheet music. Participants will supply their own instrument of choice to play. There will be four sessions total.
58103663|NCT00243815|DRUG|ibuprofen|
58103664|NCT02482571|DEVICE|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
58309578|NCT05802433|DIETARY_SUPPLEMENT|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
58309579|NCT06249230|DIAGNOSTIC_TEST|Hematologic features|Hematologic features include coagulation indicators, autoimmune indicators, and endocrine indicators.
58309580|NCT06249230|DIAGNOSTIC_TEST|Ultrasound indices of uterine artery blood flow|Ultrasound indices of uterine artery blood flow include endometrial thickness, endometrial artery blood flow parameters , and bilateral uterine artery blood flow parameters.
58309581|NCT06249230|OTHER|Demographic characteristics|Demographic characteristics include age, the number of previous spontaneous abortions (including biochemical pregnancies), BMI, fertility history, past disease history, chromosomal status, family and genetic history, etc.
58309582|NCT03748329|DEVICE|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
58309583|NCT05675163|DIETARY_SUPPLEMENT|Vitamin K2|(K2VITAL® 1% MCT Oil)
58309584|NCT05675163|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
58309585|NCT02256098|DEVICE|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
57953851|NCT06308042|OTHER|30 second sit and stand test|The individual sits in the middle of the chair with his back upright, his feet on the ground, and his arms crossed in front of his chest. The individual starts the test with the start command while in this position and takes off as fully as he can for 30 seconds.
57953852|NCT01490437|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
57953853|NCT01490437|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
57953854|NCT01490437|DRUG|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
57953855|NCT01490437|DRUG|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
57953856|NCT01653548|BEHAVIORAL|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
57953857|NCT01653548|BEHAVIORAL|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
57953858|NCT01653548|BEHAVIORAL|Habituation|Participants will habituate to personally-relevant stressor.
57953859|NCT05686200|BEHAVIORAL|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
58309586|NCT02256098|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
58309587|NCT05362201|PROCEDURE|therapeutic position of the anterior repositioning splints|the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
58309588|NCT02657330|DRUG|SBP-101|Subcutaneous drug, escalating dose cohorts
58433963|NCT02021903|OTHER|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
58433964|NCT00033553|DRUG|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
58433965|NCT00033553|DRUG|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
58103665|NCT05279326|BEHAVIORAL|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
58433966|NCT00033553|DRUG|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
58103666|NCT01721967|DRUG|Ranolazine|
58103667|NCT02357407|DRUG|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
58103668|NCT02357407|DRUG|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
58103669|NCT00747422|DEVICE|Ulthera™ System|ultrasound treatment
58103670|NCT02493088|OTHER|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
58103671|NCT01797952|DRUG|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
58103672|NCT01797952|OTHER|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
58433967|NCT00033553|RADIATION|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
58433968|NCT00399399|DRUG|azathioprine|
58433969|NCT00399399|DRUG|cyclophosphamide|
58433970|NCT00371904|DRUG|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
58433971|NCT00371904|DRUG|Standard Care|Standard care
58433972|NCT04377555|DRUG|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
57953860|NCT05317520|PROCEDURE|Cold vapor|"The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated."
57953861|NCT04863300|BEHAVIORAL|Collaborative stepped care and peer support|"Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked."
57953862|NCT02586935|DRUG|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
57953863|NCT02586935|OTHER|Placebo|Administered orally after dispersion in approximately 100 ml of water
57953864|NCT05373927|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
58433973|NCT01279681|BIOLOGICAL|bevacizumab|Given IV
58433974|NCT01279681|DRUG|capecitabine|Given PO
58433975|NCT01279681|DRUG|fluorouracil|Given IV
58433976|NCT01279681|DRUG|leucovorin calcium|Given IV
58433977|NCT01279681|DRUG|oxaliplatin|Given IV
58433978|NCT02889445|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
58433979|NCT03319212|DEVICE|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
58433980|NCT04791631|PROCEDURE|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
58433981|NCT02921711|DEVICE|LVIS®|Low-profile Visualized Intraluminal Support device
58433982|NCT01394913|DRUG|Reumatocept (etanercept)|50mg each week for 30 weeks
58433983|NCT01394913|DRUG|Enbrel (etanercept)|50mg each week for 30 weeks
58103673|NCT04567173|DRUG|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
58103674|NCT05672134|DIAGNOSTIC_TEST|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
58103675|NCT05672134|DRUG|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
58103676|NCT05672134|DIAGNOSTIC_TEST|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
58103677|NCT05672134|DIAGNOSTIC_TEST|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
58103678|NCT05672134|DIAGNOSTIC_TEST|EndoPAT|Use of EndoPAT to measure endothelial function.
58103679|NCT05672134|DIAGNOSTIC_TEST|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
58103680|NCT05672134|DIAGNOSTIC_TEST|Electrocardiogram|12-lead Electrocardiogram
58103681|NCT03492580|DRUG|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
58103682|NCT03492580|DRUG|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
58103683|NCT03492580|DRUG|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
58103684|NCT03492580|DRUG|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
58103685|NCT03492580|DRUG|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
58103686|NCT03492580|DRUG|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
58103687|NCT03492580|DRUG|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
58103688|NCT03492580|DRUG|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
58309589|NCT06209918|DEVICE|bioptron light therapy|patient will be sitting on comfortable chair with the hand placed on an armrest in an extended and supinated position. Firstly, the skin over the wrist area will be exposed and cleaned by alcohol to achieve maximal penetration of light. Then, the bioptron device will be held perpendicular to the surface of the treated area, at a distance of 10 cm.
58309590|NCT06209918|DEVICE|wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
58433984|NCT05416736|PROCEDURE|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
58433985|NCT05416736|PROCEDURE|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
58433986|NCT04581551|PROCEDURE|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
58103689|NCT03492580|DRUG|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
58309591|NCT06474533|DRUG|Fluorethyltyrosine (18-F)|Given intravenously (IV)
58433987|NCT04581551|PROCEDURE|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
58433988|NCT04581551|PROCEDURE|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
58433989|NCT04581551|PROCEDURE|No stretch intervention|Passive mobilisation of the hemiplegic hand.
58433990|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
58433991|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
58433992|NCT03631017|DRUG|[18F]- PARPi|injection of a microdose (\< 100 ug) of \[18F\]- PARPi
58433993|NCT03631017|DIAGNOSTIC_TEST|PET/CT Scans|"Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
58103690|NCT02824991|PROCEDURE|detection of local twitch response intensities during dry needling|
58433994|NCT00964561|DRUG|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
57953865|NCT00993928|BEHAVIORAL|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
58309592|NCT06474533|PROCEDURE|Positron Emission Tomography (PET)|Undergo Imaging Procedure
58309593|NCT04726553|DRUG|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
57953866|NCT01959711|PROCEDURE|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
57953867|NCT01959711|PROCEDURE|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
57953868|NCT00710528|DRUG|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
57953869|NCT05725616|PROCEDURE|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
57953870|NCT01273051|DRUG|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
58103691|NCT06311539|OTHER|Theraband Strengthening Exercise Program|"Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00)."
58309594|NCT04726553|DRUG|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
58309595|NCT03804658|DEVICE|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
58309596|NCT06190340|DRUG|TNP-2092 capsules|Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg, 300 mg, and 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
58309597|NCT06190340|DRUG|Placebo|Subjects received Placebo orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
58309598|NCT04270188|OTHER|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
58309599|NCT05016596|DIETARY_SUPPLEMENT|turmeric|Turmeric supplement
58309600|NCT05016596|DIETARY_SUPPLEMENT|placebo|Placebo
58309601|NCT02070510|DRUG|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
58309602|NCT02070510|DRUG|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
58309603|NCT02070510|DRUG|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
58309604|NCT02070510|DRUG|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
58309605|NCT02579629|DRUG|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
58309606|NCT02579629|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
58309607|NCT02579629|DRUG|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
58309608|NCT02579629|DEVICE|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
58433995|NCT00964561|DRUG|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
58433996|NCT00964561|OTHER|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
58433997|NCT02819401|OTHER|pediatric formula|high-fiber enteral formula
58433998|NCT03325036|DIAGNOSTIC_TEST|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
58433999|NCT06006624|DRUG|Exparel 30 mL|30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
58434000|NCT06006624|DRUG|0.5% bupivacaine|5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
58434001|NCT06006624|DRUG|Dexamethasone|10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
58434002|NCT06006624|DRUG|iPACK block|iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
58434003|NCT04164420|BEHAVIORAL|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
58434004|NCT04164420|BEHAVIORAL|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
58434005|NCT02161055|DRUG|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
58434006|NCT05014997|OTHER|no intervention|this study was designed as retrospective observational study
58434007|NCT00793130|DIETARY_SUPPLEMENT|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
58434008|NCT01743040|DIAGNOSTIC_TEST|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
58434009|NCT03245775|BEHAVIORAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
58434010|NCT03245775|BEHAVIORAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
58434011|NCT04481360|DEVICE|CT of the chest|Degree of affection on the lung infected by COVID19
58434012|NCT05414552|DRUG|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
58434013|NCT06238804|PROCEDURE|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
58434014|NCT00637962|BIOLOGICAL|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
58434015|NCT00637962|BIOLOGICAL|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
58434016|NCT03416452|DEVICE|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
58434017|NCT03416452|DEVICE|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
57953871|NCT01273051|RADIATION|radiotherapy|radiation 25x2 Gy
57953872|NCT01273051|PROCEDURE|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
58434018|NCT01797913|DRUG|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
58434019|NCT02587819|DRUG|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
58434020|NCT04773834|OTHER|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
58434021|NCT04773834|OTHER|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
58434022|NCT03596684|DIETARY_SUPPLEMENT|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
58434023|NCT03596684|DIETARY_SUPPLEMENT|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
58434024|NCT03596684|PROCEDURE|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
58434025|NCT00568126|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
58434026|NCT00568126|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
58434027|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
58434028|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
58434029|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
58434030|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
58434031|NCT05860465|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
58434032|NCT05860465|DRUG|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
58434033|NCT06141876|DRUG|APEX-002-A02|Active
58434034|NCT06141876|OTHER|Placebo|placebo
58434035|NCT02483117|OTHER|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
58434036|NCT00141128|DRUG|SS-RBX|
57737700|NCT03955432|DEVICE|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
58434037|NCT03404297|OTHER|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
58434038|NCT03817112|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
58434039|NCT03817112|DRUG|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
58434040|NCT01088399|DRUG|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
58434041|NCT04201613|DEVICE|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
58434042|NCT04201613|BEHAVIORAL|Usual Care|This group will receive standard care with no additional therapy.
58434043|NCT06583408|OTHER|Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
58434044|NCT06583408|OTHER|REVEAL Questionnaire|Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
58434045|NCT06027450|OTHER|NHIg prescription|Analysis of NHIg prescription
58434046|NCT02653937|DRUG|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
58434047|NCT03408964|OTHER|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
58434048|NCT04016844|DEVICE|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
58434049|NCT02166268|DRUG|AVANZ Phleum pratense 15,000 SQ+|
58434050|NCT02166268|DRUG|Placebo|
58434051|NCT03960892|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
58434052|NCT00856297|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
58434053|NCT00856297|BIOLOGICAL|Licensed comparator|
58103692|NCT05818163|DEVICE|electroencephalography spectral analysis|"Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device.~The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis."
58434054|NCT03680300|OTHER|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
57737701|NCT02596815|PROCEDURE|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
57737702|NCT02596815|DEVICE|Goniometer|
57737703|NCT04539574|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
57737704|NCT04539574|OTHER|Questionnaire Administration|Ancillary studies
57737705|NCT06013644|DEVICE|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
57737706|NCT06013644|DEVICE|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
58103693|NCT06542211|BEHAVIORAL|Intervention plan for improving ankle dorsiflexion limitation group (experimental group)|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
58434055|NCT03680300|OTHER|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
58103694|NCT06542211|BEHAVIORAL|Plantar fasciitis routine rehabilitation group|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
58434056|NCT03680300|OTHER|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
58434057|NCT04807049|OTHER|Observational|Observational
58434058|NCT05665907|OTHER|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
58434059|NCT00364741|DRUG|Oxygen|During and 2 hours after surgery
58434060|NCT04486872|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
58434061|NCT05792917|DRUG|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
58434062|NCT05792917|DRUG|tafolecimab (a original manufacturing process)|450mg，SC，single dose
58434063|NCT00087854|DRUG|Amonafide L-malate (drug)|
58434064|NCT00774982|DRUG|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
57737707|NCT06013644|DRUG|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
58103695|NCT00309413|DRUG|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
58103696|NCT00309413|DRUG|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
58103697|NCT03548324|DEVICE|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
58103698|NCT03548324|DEVICE|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
58434065|NCT00774982|DRUG|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
58434066|NCT02899702|DRUG|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
58434067|NCT02899702|DRUG|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
58434068|NCT05455931|DRUG|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
58434069|NCT00145132|PROCEDURE|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
58434070|NCT03764306|PROCEDURE|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
58434071|NCT03764306|PROCEDURE|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
58434072|NCT04975100|DRUG|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
58103699|NCT00770354|DRUG|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
58103700|NCT00770354|DRUG|Letrozole|Daily 2.5 mg oral letrozole tablet
58103701|NCT00724074|DEVICE|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
58103702|NCT00724074|DEVICE|Usual Care|Usual Care
58434073|NCT04975100|DRUG|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
57737708|NCT03505632|DEVICE|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
57953873|NCT01273051|PROCEDURE|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (\<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
58103703|NCT05723341|DRUG|Bupivacain|%0,25
58103704|NCT05723341|DRUG|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
58103705|NCT00163436|DRUG|Ciclesonide|
58103706|NCT04975282|DEVICE|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
58103707|NCT04975282|DEVICE|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
58103708|NCT00568152|DIETARY_SUPPLEMENT|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
58103709|NCT00568152|DIETARY_SUPPLEMENT|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
58103710|NCT00568152|DRUG|Aspirin|75mg dispersable aspirin taken daily for 14 days
58103711|NCT06256731|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
58103712|NCT04416828|DEVICE|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
58103713|NCT04416828|DEVICE|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
58103714|NCT05385471|BIOLOGICAL|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
58103715|NCT05124431|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
58103716|NCT05124431|DRUG|everolimus|5mg po，qd
58103717|NCT03162354|OTHER|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
58103718|NCT02127229|PROCEDURE|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
58103719|NCT04185831|DRUG|Atezolizumab|PD-L1 inhibitor
58103720|NCT04185831|DRUG|Everolimus|MTOR inhibitor
58103721|NCT04185831|DRUG|Cobimetinib|MEK inhibitor
58309609|NCT02555592|PROCEDURE|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2\~4 weeks after adjuvant chemotherapy.
58309610|NCT05540119|PROCEDURE|Surgery|Patients who undergo surgery are separately assessed
57953874|NCT03284736|PROCEDURE|Resorbable membrane|
57953875|NCT03284736|PROCEDURE|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
58103722|NCT04185831|DRUG|Niraparib|PARP inhibitor
58103723|NCT01296152|DRUG|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
58309611|NCT01256515|BEHAVIORAL|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
58309612|NCT01256515|BEHAVIORAL|Health Education Training|8 weeks of group training regarding health education techniques.
58309613|NCT00627692|DRUG|Prucalopride|0.5 mg o.d.
58309614|NCT00627692|OTHER|Placebo|o.d.
58309615|NCT00627692|DRUG|Prucalopride|1 mg o.d.
58309616|NCT00627692|DRUG|Prucalopride|2 mg o.d.
58309617|NCT00627692|DRUG|Prucalopride|4 mg o.d.
57953876|NCT05011929|BEHAVIORAL|Cognitive behavioral therapy|refer to the arm description
57953877|NCT02010164|DIETARY_SUPPLEMENT|Co-enzyme Q10|600mg for 3 months
58309618|NCT03546465|DRUG|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
58434074|NCT05574088|PROCEDURE|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
58434075|NCT02071069|DRUG|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
58434076|NCT02071069|DRUG|irinotecan|180 mg/m2 IV every 2 weeks
58434077|NCT02071069|DRUG|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
58103724|NCT02199834|BEHAVIORAL|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
57953878|NCT04589273|DIETARY_SUPPLEMENT|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
58103725|NCT02199834|BEHAVIORAL|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
58103726|NCT05928273|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
58103727|NCT05053919|DEVICE|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
58434078|NCT02240264|DIETARY_SUPPLEMENT|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
58103728|NCT05053919|DEVICE|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
58103729|NCT04367922|BEHAVIORAL|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
58103730|NCT06044259|PROCEDURE|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
58103731|NCT06044259|PROCEDURE|Conventional hemiarch replacement|Coventional open hemiarch replacement
58103732|NCT03423589|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
58434079|NCT02240264|DIETARY_SUPPLEMENT|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
57737709|NCT03505632|DEVICE|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
58434080|NCT01359501|DRUG|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
58434081|NCT01359501|DRUG|Placebo|Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
58434082|NCT05405101|PROCEDURE|Thermal ablation of aldosterone producing adenoma.|"On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance."
58434083|NCT05405101|PROCEDURE|Unilateral adrenalectomy|Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
58434084|NCT03406897|DRUG|Cholecalciferol|Oral Administration
58434085|NCT03406897|DRUG|Omega 3 fatty acid|Oral Administration
57953879|NCT04589273|OTHER|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
58434086|NCT02815644|DRUG|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
57737710|NCT00536003|DRUG|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
57737711|NCT00536003|DRUG|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
57737712|NCT02090101|DRUG|ANAKINRA|
57953880|NCT05950087|OTHER|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy
57953881|NCT05326984|DRUG|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
57953882|NCT02752516|DRUG|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
57953883|NCT05069246|OTHER|Nigella Sativa oil|5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
57953884|NCT05069246|DRUG|Chlorhexidine mouthwash|10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
58434087|NCT00528801|BEHAVIORAL|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
58103733|NCT05016765|DEVICE|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
58434088|NCT00528801|PROCEDURE|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
58434089|NCT05095350|BIOLOGICAL|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
58103734|NCT03229382|DRUG|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
57953885|NCT05194540|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
57953886|NCT03919526|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
57953887|NCT03919526|DRUG|Fludarabine|30mg/m2/d
58103735|NCT02464527|BEHAVIORAL|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
58309619|NCT01548599|OTHER|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
58434090|NCT05095350|BIOLOGICAL|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
58434091|NCT06529861|DIAGNOSTIC_TEST|[15O]H2O-PET Imaging|This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
57953888|NCT03919526|DRUG|Cyclophosphamide|300mg/m2/d
58434092|NCT01569048|DRUG|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
58434093|NCT01569048|DRUG|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
57953889|NCT05082103|OTHER|Enzyme lozenge 1|Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
57953890|NCT05082103|OTHER|Enzyme lozenge 2|Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
57953891|NCT05082103|OTHER|Placebo lozenge|Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
57953892|NCT01251809|DRUG|Oncaspar|2000 U/m2 BSA, single infusion
57953893|NCT01251809|DRUG|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
57953894|NCT00004259|DRUG|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
57953895|NCT00004259|DRUG|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
57953896|NCT00004259|RADIATION|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
57953897|NCT00004259|DRUG|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
58434094|NCT03100175|BEHAVIORAL|physiotherapy|strength training for upper and lower limbs fitness and balance work out
57737713|NCT02859857|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
57737714|NCT04236791|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
57737715|NCT04236791|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
57737716|NCT03923413|OTHER|Blood samples|Blood samples for MP evaluation
57737717|NCT01247129|PROCEDURE|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
57737718|NCT00726752|DRUG|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
57953898|NCT00004259|DRUG|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
57953899|NCT00004259|DRUG|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
57953900|NCT00004259|DRUG|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
57953901|NCT00004259|DRUG|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
57953902|NCT05070221|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
57953903|NCT05070221|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
57953904|NCT05070221|DRUG|Axitinib|5mg，bid，p.o.；
57953905|NCT01258504|DRUG|St. Johns Wort|"* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
57953906|NCT02918383|DIAGNOSTIC_TEST|Indocyanin Green Dye (ICG)|
57953907|NCT04252430|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
57953908|NCT05618665|OTHER|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
57953909|NCT05618665|OTHER|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
57953910|NCT05488587|DIAGNOSTIC_TEST|magnesium and zinc levels|measuring magnesium and zinc levels
57953911|NCT02388438|DEVICE|Bongener|
57953912|NCT04314856|DRUG|18F-FTC-146|18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
57953913|NCT06279156|DEVICE|Bioelectrical Impedance Analysis (BIA)|"Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition."
57953914|NCT05068336|DIAGNOSTIC_TEST|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
57953915|NCT05068336|DIAGNOSTIC_TEST|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
57953916|NCT01050309|DRUG|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
58309620|NCT00494663|DRUG|DIO-902|150mg tablet once per day for 16 weeks
58309621|NCT00494663|DRUG|DIO-902|300mg tablet once per day for 16 weeks
58434095|NCT01850407|BEHAVIORAL|Education Counseling|
58434096|NCT03372174|DEVICE|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
58434097|NCT03372174|DEVICE|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
58434098|NCT03739346|BEHAVIORAL|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
58434099|NCT03739346|BEHAVIORAL|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
58434100|NCT05014685|DRUG|Rabeprazole|20mg bid
58434101|NCT05014685|DRUG|Bismuth potassium citrate|0.6g bid
58434102|NCT05014685|DRUG|Metronidazole|0.4g tid
57953917|NCT05382975|BEHAVIORAL|CSPAP-T|"Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning"
57953918|NCT05777200|BEHAVIORAL|Supportive psychotherapy|Counselling patients, providing supportive psychotherapy to help them detox their illicit drug usage, and help them rehabilitate again into society.
57953919|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
57953920|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
57953921|NCT05609890|DIETARY_SUPPLEMENT|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
57953922|NCT05609890|OTHER|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
57953923|NCT00082888|OTHER|Laboratory Biomarker Analysis|Correlative studies
57953924|NCT00082888|DRUG|Tipifarnib|Given PO
58434103|NCT05014685|DRUG|Amoxicillin|1g tid
58434104|NCT03438136|BEHAVIORAL|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
58434105|NCT04204044|DRUG|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
58434106|NCT04204044|DRUG|Myo-inositol|Myo inositol used in PCO
58434107|NCT04161261|PROCEDURE|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
58434108|NCT01354119|PROCEDURE|Aortic stent-graft|Early intervention with aortic stent-graft
57953925|NCT05220826|PROCEDURE|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
57953926|NCT04599556|BIOLOGICAL|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
58103736|NCT02464527|OTHER|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
57737719|NCT03963726|RADIATION|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
57737720|NCT03963726|OTHER|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
57737721|NCT04656847|DRUG|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
57737722|NCT05641168|OTHER|Adhesive material|Newly developed adhesive material
57737723|NCT05641168|OTHER|Standard adhesive material|Standard adhesive material
57737724|NCT06192888|DRUG|Glofitamab|IV Glofitamab
57737725|NCT06192888|DRUG|Obinutuzumab|IV Obinutuzumab
57737726|NCT06192888|DRUG|Lenalidomide|Oral Lenalidomide
57953927|NCT00510926|DRUG|Imatinib Mesilate (Glivec)|
57953928|NCT03785990|OTHER|adipose tissue|taking a sample of the adipose tissue during operation
57769597|NCT03270813|BEHAVIORAL|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
57953929|NCT03785990|OTHER|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
57953930|NCT03785990|DIAGNOSTIC_TEST|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
57953931|NCT05883891|DIAGNOSTIC_TEST|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
57953932|NCT02559440|DRUG|mometasone furoate|50μg, 1 puff in each nostril every evening
57953933|NCT02559440|DRUG|Placebo|1 puff in each nostril every evening
57953934|NCT02559440|DRUG|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
57953935|NCT02559440|DRUG|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
57953936|NCT02559440|DRUG|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
57953937|NCT02559440|DRUG|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
57953938|NCT03949920|DRUG|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
57953939|NCT01632462|DRUG|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
57953940|NCT02350270|OTHER|gait and cognitive testing|
57953941|NCT02715037|OTHER|Throat swabbing|
58103737|NCT05954338|DRUG|DWC202307|DWC202307
58103738|NCT05954338|DRUG|DWJ1543|DWJ1543
58103739|NCT05954338|DRUG|DWC202216|DWC202216
58434109|NCT02356848|BEHAVIORAL|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
58434110|NCT02356848|BEHAVIORAL|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
58434111|NCT00238238|BIOLOGICAL|rituximab|Given IV
58434112|NCT00238238|DRUG|lenalidomide|Given orally
58434113|NCT00249678|BEHAVIORAL|Behavior Therapy|
58434114|NCT01504841|DRUG|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
58434115|NCT01753089|BIOLOGICAL|WDVAX|
58434116|NCT04560387|BEHAVIORAL|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
58434117|NCT04560387|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
58434118|NCT04338971|DEVICE|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
58434119|NCT04423081|OTHER|EXIT scale|completion of EXIT scale translated in french
58434120|NCT02237755|DRUG|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
58434121|NCT02237755|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
58434122|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 1|
58434123|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 2|
58434124|NCT02929459|OTHER|Placebo|
58434125|NCT05400304|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
58434126|NCT05862311|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
58434127|NCT00520156|DEVICE|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
58434128|NCT05182268|PROCEDURE|endoscopic ear surgery|a ear surgery via endoscopic
58434129|NCT05182268|PROCEDURE|microscopic ear surgery|a ear surgery via microscopic
58434130|NCT02227394|DRUG|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
58434131|NCT02227394|DRUG|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
57769598|NCT03270813|BEHAVIORAL|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
58103740|NCT02805582|DRUG|10ml ropivacain 0.5%|Ultrasound guided nerve block
58103741|NCT06558201|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
58434132|NCT00917839|DRUG|lamotrigine|100 mg, once daily, 12 months
58434133|NCT01714999|PROCEDURE|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
58434134|NCT01714999|PROCEDURE|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
58434135|NCT01099397|OTHER|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
58434136|NCT05262296|PROCEDURE|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
58434137|NCT05262296|PROCEDURE|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
58434138|NCT02103777|DRUG|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
58434139|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
58434140|NCT04611802|OTHER|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
58434141|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
58103742|NCT05430282|OTHER|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
58434142|NCT04611802|OTHER|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
58434143|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
58434144|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
58434145|NCT01938040|DRUG|ibuprofen|single preoperative dose prior to surgery
58434146|NCT01938040|OTHER|sugar water/placebo|single preoperative dose prior to surgery
58434147|NCT00769509|OTHER|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
57769599|NCT03607513|DRUG|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
58103743|NCT05430282|OTHER|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
58103744|NCT01866982|PROCEDURE|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
58434148|NCT00769509|OTHER|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
57953942|NCT05517941|OTHER|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
57953943|NCT05517941|OTHER|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
57953944|NCT00645957|PROCEDURE|penrose drain|incision and drainage of the infection with placement of a penrose drain
57953945|NCT00645957|PROCEDURE|red rubber drain|incision and drainage of infection and placement of a red rubber drain
57953946|NCT04503278|BIOLOGICAL|CLDN6 CAR-T|administered as an intravenous (i.v.) infusion.
58103745|NCT01866982|PROCEDURE|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
58103746|NCT06181682|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine
58103747|NCT06181682|DRUG|Midazolam|Intranasal midazolam
58103748|NCT06543160|OTHER|Immediate SSC and early breastfeeding during CS|Upon birth, the neonate is promptly placed prone on the mother's chest, with their head turned to one side for optimal skin contact. The drying process begins within 5 seconds and is completed within 20 to 30 seconds while the neonate remains on the mother's chest. Delayed cord clamping is practiced, with the cord clamped approximately 1-3 minutes after birth. Breastfeeding cues such as tongue movements or head turning are monitored, and the obstetric nurse assists the mother in initiating breastfeeding as soon as possible. SSC continues throughout the cesarean procedure, and upon completion, the newborn is temporarily separated from the mother for safety during transfer to the surgical cart. SSC is resumed immediately post-transfer and continues for a cumulative duration of at least 90 minutes. The neonate's skin color, breathing, and feeding responses are continuously observed.
58434149|NCT04198077|DRUG|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
58434150|NCT04560075|BEHAVIORAL|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
58434151|NCT04560075|BEHAVIORAL|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
58434152|NCT05118399|DRUG|Bupivacaine Injection [Marcaine]|Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
58434153|NCT05118399|DRUG|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
58434154|NCT06226584|DIETARY_SUPPLEMENT|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
58434155|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
58434156|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
58434157|NCT01398748|DRUG|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
58434158|NCT01192412|PROCEDURE|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
58434159|NCT01192412|PROCEDURE|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
58434160|NCT03460561|PROCEDURE|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
58434161|NCT03460561|PROCEDURE|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
58434162|NCT05623657|OTHER|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
58434163|NCT05623657|OTHER|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
58434164|NCT00296140|BEHAVIORAL|self management of PSD symptoms|
58434165|NCT00296140|PROCEDURE|screening and treatment of PSD|
58434166|NCT03162237|OTHER|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
58434167|NCT03162237|OTHER|Autologous Treg|Autologous Treg: 2x10\^6/Kg
58434168|NCT01771159|DEVICE|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
58434169|NCT04165603|PROCEDURE|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
57953947|NCT04503278|BIOLOGICAL|CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|administered as an i.v. injection at protocol-specified intervals.
58103749|NCT06543160|OTHER|Delayed SSC and breastfeeding after CS|The neonate is dried within 20-30 seconds after birth, the cord is clamped after 1-3 minutes, and then the neonate is sent to the ward to wait for the mother to complete the surgery. Immediate SSC is initiated within one hour after birth and maintained with the mother for at least 90 minutes post-surgery, during which the neonate's skin color and breathing are continuously monitored. The obstetric nurse supports the mother in initiating breastfeeding at the earliest opportunity.
57769600|NCT03607513|DRUG|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
57953948|NCT00446602|DRUG|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
58103750|NCT06543160|OTHER|Routine newborn care|Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
57953949|NCT00273104|PROCEDURE|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
58434170|NCT06075121|OTHER|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
58434171|NCT01964638|PROCEDURE|Targeted Biopsy|
58434172|NCT01874444|DEVICE|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
58434173|NCT01874444|DEVICE|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
58434174|NCT01874444|DEVICE|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
58434175|NCT01874444|DEVICE|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
58434176|NCT05363111|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
58434177|NCT05363111|BIOLOGICAL|Daratumumab|Given IV
58434178|NCT05363111|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
58434179|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
58434180|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
58434181|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
58434182|NCT02726724|OTHER|5 observers|
58434183|NCT02726724|OTHER|1 observer|
58434184|NCT02425514|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
57737727|NCT01565707|DRUG|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
58434185|NCT02425514|DEVICE|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
58434186|NCT01622387|PROCEDURE|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
58434187|NCT01622387|PROCEDURE|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
58434188|NCT02913950|OTHER|validation of pediatric stool scale|validation of pediatric stool scale
57769601|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
58434189|NCT00027911|BIOLOGICAL|NY-ESO-1 peptide vaccine|
58434190|NCT00027911|BIOLOGICAL|sargramostim|
58434191|NCT04723680|OTHER|Qualitative interview|Qualitative semi structured interview
58434192|NCT03762018|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
58434193|NCT03762018|DRUG|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
58434194|NCT03762018|DRUG|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
58309622|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
58434195|NCT03762018|DRUG|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
58434196|NCT04861376|DRUG|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
58434197|NCT04861376|DRUG|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
58434198|NCT04861376|OTHER|Placebo|The placebo group will take the same dose as the other two groups.
58434199|NCT01600937|BEHAVIORAL|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
58434200|NCT01488201|DRUG|Placebo|
58434201|NCT01488201|DRUG|KHK4827|
58434202|NCT06223126|OTHER|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
58434203|NCT06223126|OTHER|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
58103751|NCT03262545|DRUG|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
58103752|NCT03262545|DRUG|Placebos|Physical properties of placebos are consistent with apatinib
57769602|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
57769603|NCT05970380|OTHER|Erector spinae plane block|Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.
58103753|NCT02527616|DEVICE|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
58103754|NCT00181116|DRUG|Levetiracetam|
58103755|NCT00681824|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
58103756|NCT00681824|PROCEDURE|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
58103757|NCT00823459|DRUG|Everolimus|Given PO
58103758|NCT00823459|OTHER|Archival Tissue Analysis|Correlative studies
58103759|NCT03875560|BIOLOGICAL|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
58103760|NCT03875560|DRUG|Placebo|Inactive
58103761|NCT00681577|BIOLOGICAL|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
58103762|NCT00442715|PROCEDURE|Exercise chalenge test|
58103763|NCT04828902|PROCEDURE|cardiac surgery|Any heart surgery on or without cardiopulmonary bypass performed under general anesthesia in the Cardiac Surgical Department, Medical University of Gdańsk.
58103764|NCT02419469|DRUG|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
58103765|NCT02419469|DRUG|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
58103766|NCT02419469|DRUG|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
58103767|NCT02419469|DRUG|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
58103768|NCT02419469|DRUG|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
58103769|NCT02419469|DRUG|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
58103770|NCT02419469|DRUG|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
58103771|NCT02419469|DRUG|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
58103772|NCT02419469|DRUG|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
58309623|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
58434204|NCT00348309|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
58434205|NCT00348309|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
58434206|NCT00348309|OTHER|Placebo|Placebo
58434207|NCT00348309|OTHER|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
57769604|NCT05970380|OTHER|Local anesthesia|Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
58103773|NCT02419469|DRUG|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
58103774|NCT02419469|DRUG|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
58103775|NCT02419469|DRUG|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
58434208|NCT01712425|BIOLOGICAL|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
58434209|NCT01712425|BIOLOGICAL|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
58434210|NCT03767751|BIOLOGICAL|Dual Specificity CD38 and bcma CAR-T Cells|1) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
58434211|NCT04724967|DRUG|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
58434212|NCT04724967|DRUG|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
58434213|NCT03006874|DRUG|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
58434214|NCT03006874|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
58434215|NCT03006874|DRUG|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
58434216|NCT04638114|PROCEDURE|Mini-open DAA|Direct anterior approach hip
58434217|NCT04638114|PROCEDURE|Hip arthroscopy|arthroscopic treatment of hip pathology
57953950|NCT00273104|BEHAVIORAL|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
58103776|NCT02419469|DRUG|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
58103777|NCT03627182|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
58103778|NCT03627182|DRUG|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
58434218|NCT03274856|DRUG|GLWL-01|Oral administration of 3 capsules, twice a day
58434219|NCT03274856|DRUG|Placebo|Oral administration of 3 capsules, twice a day
58434220|NCT02415270|OTHER|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
57953951|NCT03655613|BIOLOGICAL|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
58103779|NCT01472809|DRUG|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
58103780|NCT01472809|DRUG|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
58434221|NCT02415270|OTHER|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
57953952|NCT03655613|DRUG|APL-101|Oral specific c-Met inhibitor
57953953|NCT03655613|BIOLOGICAL|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
58103781|NCT00064779|DRUG|IL13-PE38QQR|
58103782|NCT00064779|PROCEDURE|targeted fusion protein therapy|
58103783|NCT00064779|PROCEDURE|surgery|
58103784|NCT06276894|DEVICE|Motek C-Mill™ treadmill|We will enroll 10 to 15 participants to participate in a VR treadmill training session while wearing an fNIRS cap.
58309624|NCT00494663|DRUG|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
58309625|NCT00494663|DRUG|DIO-902|300mg DIO-902 tablet daily for 16 weeks
58309626|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet for 16 weeks
58309627|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
58434222|NCT02415270|OTHER|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
58434223|NCT04934644|PROCEDURE|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
58434224|NCT03129360|DRUG|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
57769605|NCT06445387|OTHER|Virtual Reality Glasses|"Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam."
58309628|NCT05297682|DEVICE|anesthesia with propofol|General anesthesia with propofol
58309629|NCT04802200|OTHER|Data collect|Data collect following a vascular closure by MANTA
58434225|NCT03129360|DRUG|Placebo|Prepared in capsules to appear identical to levetiracetam.
58434226|NCT06407531|OTHER|VR-G|Patients watched videos with virtual glasses before undergoing colonoscopy
58434227|NCT00544791|DRUG|melatonin|5 mg, oral, daily dose for 6 months
58434228|NCT00544791|DRUG|placebo like melatonin tablets|
58434229|NCT02147288|DEVICE|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
57737728|NCT01565707|DRUG|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
58309630|NCT01683461|BEHAVIORAL|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
58309631|NCT01683461|BEHAVIORAL|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
58434230|NCT00102284|DRUG|levodopa|
58434231|NCT00102284|DRUG|rivastigmine|
58434232|NCT00102284|DRUG|pergolid|
58434233|NCT00102284|DRUG|modafinil|
58434234|NCT05914207|BEHAVIORAL|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
58434235|NCT05914207|OTHER|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
58434236|NCT02038075|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|
58434237|NCT02038075|BEHAVIORAL|Treatment As Usual (TAU)|
58434238|NCT03515096|DRUG|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
57737729|NCT01565707|BEHAVIORAL|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
58103785|NCT06276894|OTHER|training session with and without VR wearing the fNIRS cap|training session with and without VR wearing the fNIRS cap
58103786|NCT00934037|PROCEDURE|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
58309632|NCT05012267|OTHER|16-hour PP|PP according to previous study
58309633|NCT00151944|DRUG|SPD476 (mesalazine)|
58434239|NCT03515096|DRUG|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
58309634|NCT00216255|DRUG|Pagoclone|
58309635|NCT00216255|DRUG|Placebo|
58434240|NCT03779815|DRUG|[18F]Florbetaben|"* Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously"
58434241|NCT02772185|DEVICE|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
58434242|NCT02772185|DEVICE|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
58434243|NCT02772185|BEHAVIORAL|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
58434244|NCT02772185|BEHAVIORAL|placebo CT|Videos (short films) will be presented during the neurostimulation
58434245|NCT03392649|DEVICE|Parasym|Tragus stimulation was done using the Parasym device.
58434246|NCT05191875|DRUG|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"
58434247|NCT05191875|DRUG|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
58434248|NCT06584500|OTHER|Dry needling|"Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop."
58434249|NCT06584500|OTHER|Sham Dry Needling|The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
58434250|NCT03098225|RADIATION|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
58103787|NCT00934037|OTHER|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
58309636|NCT05131763|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
58434251|NCT03098225|DRUG|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
58434252|NCT05262647|DIAGNOSTIC_TEST|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
58309637|NCT06381245|DIAGNOSTIC_TEST|PPG-based remote heart rhythm/rate monitoring|PPG-based remote heart rhythm/rate monitoring
58309638|NCT06381245|DIAGNOSTIC_TEST|ECG-based remote heart rhythm/rate monitoring|ECG-based remote heart rhythm/rate monitoring
58309639|NCT06381245|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography examination|Transthoracic and transesophageal echocardiography examination
58309640|NCT06381245|DIAGNOSTIC_TEST|Liver ultrasound examination|Liver ultrasound examination
58309641|NCT06381245|DIAGNOSTIC_TEST|Rotational angiography with three-dimensional reconstruction|Rotational angiography with three-dimensional reconstruction
58309642|NCT06381245|DIAGNOSTIC_TEST|Blood-derived biomarker analysis|Blood-derived biomarker analysis
58309643|NCT06381245|DIAGNOSTIC_TEST|Mobile health-based spirometry|Mobile health-based spirometry
58309644|NCT05052580|OTHER|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
58309645|NCT01349595|DRUG|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
58309646|NCT05550324|PROCEDURE|Blood draw|One time intravenous blood draw
58309647|NCT03307421|OTHER|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
58309648|NCT03307421|OTHER|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
58309649|NCT05366855|BIOLOGICAL|Imsidolimab|Solution for infusion; Solution for injection
58309650|NCT05366855|OTHER|Placebo|Solution for injection
58434253|NCT06204081|DEVICE|CSO_without cueing|The sole is worn without using the cueing application
58434254|NCT06204081|DEVICE|CSO_cueing|The sole is worn with using the cueing application
58103788|NCT02536131|OTHER|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
58103789|NCT03147001|OTHER|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
58309651|NCT05543304|DIAGNOSTIC_TEST|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
58309652|NCT03540862|DEVICE|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
58309653|NCT01448733|DRUG|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
58309654|NCT00505635|DRUG|Temozolomide|250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
58309655|NCT00505635|DRUG|Velban|1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
58309656|NCT00505635|DRUG|Cisplatin|20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
58309657|NCT00505635|DRUG|Interleukin-2|9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
58434255|NCT00356343|DEVICE|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
58309658|NCT00505635|DRUG|Intron-A|5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
57737730|NCT06550791|BEHAVIORAL|Anticancer Learning Circle|All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
57737731|NCT02491671|DEVICE|Hemopatch|
58103790|NCT03147001|OTHER|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
58434256|NCT00356343|OTHER|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
58309659|NCT00505635|DRUG|Thalidomide|400 mg By Mouth Daily
58434257|NCT06169111|BIOLOGICAL|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
58434258|NCT03188510|BIOLOGICAL|LY3074828|Administered SC
58434259|NCT04138680|BEHAVIORAL|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
58434260|NCT04138680|BEHAVIORAL|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
58434261|NCT00089466|DRUG|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
58434262|NCT06206915|DRUG|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
58434263|NCT00152308|DEVICE|2% rapamycin-eluting YUKONdes PEARL-stent|
58434264|NCT00152308|DEVICE|1% rapamycin-eluting YUKONdes PEARL-stent|
58434265|NCT00152308|DEVICE|YUKONdes PEARL-stent coated with placebo (ethanol)|
58434266|NCT04179253|DIAGNOSTIC_TEST|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
58103791|NCT05202522|BEHAVIORAL|Virtual GERAS DANCE|Dance is a form of aerobic exercise that involves multicomponent training with physical, cognitive, and social dimensions and may have synergetic benefits when delivered in combination. GERAS DANcing for Cognition and Exercise (DANCE), a community-based rehabilitation program for older adults with cognitive decline and/or mobility impairments, has been adapted for virtual delivery through videoconferencing systems. Participants will receive twice-weekly (one hour per session) virtual dance sessions for a total of 6 weeks.
58309660|NCT03974464|DIAGNOSTIC_TEST|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
58434267|NCT05573126|DRUG|EP0062|EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
58434268|NCT04209595|DRUG|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
57737732|NCT02491671|PROCEDURE|standard preventive measures|
57737733|NCT06294301|BIOLOGICAL|LP-005 Dose 1 (Single)|A single dose of LP-005 (Dose 1) was administered intravenously.
58103792|NCT06208852|OTHER|Virtual Navigator Program|For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
57737734|NCT06294301|BIOLOGICAL|LP-005 Dose 2 (Single)|A single dose of LP-005 (Dose 2) was administered intravenously.
58103793|NCT04522011|OTHER|intraoperative or postoperative hyperthermic intraperitoneal chemotherapy|Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
58434269|NCT04209595|DRUG|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
58434270|NCT04209595|DRUG|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
58434271|NCT05186506|DRUG|Ensatinib|225 mg administered once daily orally for two years.
57953954|NCT06067737|DRUG|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
57953955|NCT06067737|DRUG|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
57953956|NCT02868008|PROCEDURE|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
57953957|NCT05106309|DRUG|10 mg CVL-231 as IR formulation|Tablets
57953958|NCT05106309|DRUG|30 mg CVL-231 as slow-release MR formulation|Capsules
57953959|NCT05106309|DRUG|30 mg CVL-231 as medium release MR formulation|Capsules
57953960|NCT05106309|DRUG|30 mg CVL-231 as fast release MR formulation|Capsules
57953961|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fasted|Capsules
57953962|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fed|Capsules
57953963|NCT06166186|OTHER|music|A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.
57953964|NCT06166186|OTHER|no music|Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
57953965|NCT05595083|DRUG|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
57953966|NCT05595083|DRUG|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
57953967|NCT01981590|DEVICE|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
58103794|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of placebo
57737735|NCT06294301|BIOLOGICAL|LP-005 Dose 3 (Single)|A single dose of LP-005 (Dose 3) was administered intravenously.
57737736|NCT06294301|BIOLOGICAL|LP-005 Dose 4 (Single)|A single dose of LP-005 (Dose 4) was administered intravenously.
57737737|NCT06294301|BIOLOGICAL|LP-005 Dose 5 (Single)|A single dose of LP-005 (Dose 5) was administered intravenously.
57737738|NCT06294301|BIOLOGICAL|LP-005 Dose 6 (Single)|A single dose of LP-005 (Dose 6) was administered intravenously.
57737739|NCT06294301|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
57737740|NCT06294301|BIOLOGICAL|LP-005 Dose 7 (Multiple)|LP-005 (Dose 7) was administered multiple times intravenously.
57737741|NCT06294301|BIOLOGICAL|LP-005 Dose 8 (Multiple)|LP-005 (Dose 8) was administered multiple times intravenously.
57953968|NCT05261022|BEHAVIORAL|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
57953969|NCT02126709|DRUG|Repigel|Repigel will be used as the intervention in the treatment group
57953970|NCT02370615|DRUG|TAK-272|TAK-272 tablet.
57953971|NCT02370615|DRUG|Digoxin|Digoxin tablet.
58103795|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
58309661|NCT03423069|DIETARY_SUPPLEMENT|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
57737742|NCT06294301|BIOLOGICAL|LP-005 Dose 9 (Multiple)|LP-005 (Dose 9) was administered multiple times intravenously.
57737743|NCT06294301|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times intravenously.
57737744|NCT03047668|DIETARY_SUPPLEMENT|diet with/without supplementation|diet with/without supplementation with PUFAs
57737745|NCT02559674|BIOLOGICAL|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
57737746|NCT02559674|BIOLOGICAL|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
58103796|NCT05134259|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
58103797|NCT06140615|DEVICE|Ultrasound|Ultrasound of lungs
57737747|NCT02559674|BIOLOGICAL|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
57737748|NCT02099838|DRUG|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
57737749|NCT02099838|DRUG|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
57737750|NCT02157038|DEVICE|Pedometer|
58103798|NCT01212731|RADIATION|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
58309662|NCT03423069|DIETARY_SUPPLEMENT|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
57737751|NCT02157038|DEVICE|MRI|
57737752|NCT02766530|OTHER|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
57737753|NCT06385938|DIAGNOSTIC_TEST|Ultrasound with quantitative vibro-acoustic assessment|Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
57737754|NCT04571398|OTHER|ApricityRx mobile application|AE detection and monitoring software
57737755|NCT06134544|DIETARY_SUPPLEMENT|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
57737756|NCT00303966|DRUG|sorafenib tosylate|Given orally
57737757|NCT01839929|DRUG|Prograf|oral
57737758|NCT01839929|DRUG|Advagraf|oral
57737759|NCT05496881|OTHER|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
57737760|NCT05496881|OTHER|Exercise Group 2|Prescribed exercises will focus on physical fitness.
57737761|NCT05496881|OTHER|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
57737762|NCT04748744|COMBINATION_PRODUCT|Butyrylcholinesterase|Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
57737763|NCT05674695|DRUG|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
57769606|NCT06445387|OTHER|Ice Application Group|Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.
57769607|NCT06445387|OTHER|Control Group|They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
57953972|NCT02370615|DRUG|Itraconazole|Itraconazole oral solution
58103799|NCT01212731|RADIATION|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
58103800|NCT01212731|BEHAVIORAL|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
58103801|NCT01212731|DEVICE|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
58103802|NCT01542736|DRUG|Carboplatin|Administered concurrently with craniospinal radiation.
58103803|NCT01542736|DRUG|Vincristine|Administered concurrently with craniospinal radiation.
58103804|NCT01542736|RADIATION|24 Gy|Craniospinal radiation.
57953973|NCT02370615|DRUG|Midazolam|Midazolam syrup.
57953974|NCT03603821|DIAGNOSTIC_TEST|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
58103805|NCT03533920|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
58103806|NCT00039416|DRUG|imatinib mesylate|Given orally
58103807|NCT00039416|OTHER|laboratory biomarker analysis|Correlative studies
58103808|NCT02729493|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
58103809|NCT01027884|DRUG|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
57769608|NCT04032379|OTHER|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
57953975|NCT01883635|BEHAVIORAL|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
57953976|NCT01883635|BEHAVIORAL|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
57953977|NCT05687071|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
57953978|NCT05006469|DRUG|Bendamustine|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
57953979|NCT02037932|DEVICE|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
57953980|NCT00713427|DEVICE|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
57953981|NCT04133532|DRUG|Metoprolol|metoprolol 50 mg daily for three months
57953982|NCT06542055|OTHER|Preoperative and postoperative pulmonary rehabilitation exercise|Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.
57953983|NCT06542055|OTHER|Preoperative education and postoperative exercise|Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises
57953984|NCT01253655|DRUG|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
57953985|NCT04753827|OTHER|Drug eluting stent|Put a Drug eluting stent in the blood vessel
57953986|NCT04753827|OTHER|Durg coated balloon|Put a Durg coated balloon in the blood vessel
58103810|NCT01027884|DRUG|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
58103811|NCT05775263|PROCEDURE|CT angiogram|CT angiography of the brain 30 minutes from establishment of NRP
58103812|NCT03483844|DIAGNOSTIC_TEST|GE CT 750 HD|Low-dose dual-energy CT imaging
58103813|NCT01995006|DRUG|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
58103814|NCT01995006|DRUG|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
57769609|NCT02779023|BEHAVIORAL|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
57953987|NCT04459780|BIOLOGICAL|Skin biopsies|3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
57953988|NCT04459780|BIOLOGICAL|Blood sample|One blood sample for the group 1 only.
57953989|NCT01697735|DRUG|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
58103815|NCT02643966|DEVICE|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
58103816|NCT05851482|DIAGNOSTIC_TEST|High resolution manometry|Standard chicago classification 4.0 HRM protocol
58103817|NCT02898766|OTHER|Enteral Nutrition Formula|
58103818|NCT06412068|DRUG|Combined anti-PD-1 and R-CHOP|Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
58103819|NCT00273247|DRUG|Interferon alpha-2b|
57737764|NCT02635633|DEVICE|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
57953990|NCT01697735|DRUG|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
58103820|NCT05762510|GENETIC|GMCN-508B (LentiRed)|LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
58103821|NCT02913508|DRUG|Vedolizumab intravenous injection|Vedolizumab intravenous injection
58103822|NCT02913508|DRUG|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
57953991|NCT02937818|DRUG|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
57953992|NCT02937818|DRUG|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
57953993|NCT02937818|DRUG|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
57953994|NCT05056532|DIAGNOSTIC_TEST|patient assessment|subjective and objective measurement will be performed in patients with PAH
57953995|NCT01221064|PROCEDURE|Early drainage removal|Drainage will be removed in postoperative day 1
57953996|NCT01221064|PROCEDURE|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
57953997|NCT01310894|DRUG|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
57953998|NCT05444595|BEHAVIORAL|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
57953999|NCT05444595|BEHAVIORAL|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
57954000|NCT03685539|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
57954001|NCT03940859|DEVICE|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
57954002|NCT03424252|DRUG|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
57954003|NCT05651295|BEHAVIORAL|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
57954004|NCT05651295|BEHAVIORAL|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
57954005|NCT05651295|BEHAVIORAL|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
57954006|NCT04519385|DRUG|Tocilizumab|Tocilizumab therapy
57954007|NCT04519385|DRUG|Dexamethasone|dexamethsone pulse therapy
57954008|NCT01713023|DIETARY_SUPPLEMENT|Glucose|The same described in Arm description
57954009|NCT01713023|DIETARY_SUPPLEMENT|Fructose|The same described in Arm description
57954010|NCT04131335|DRUG|AEONTM Repair|Lubricating eye drops
57954011|NCT04131335|OTHER|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
57954012|NCT02972073|OTHER|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
57954013|NCT02646982|DRUG|Placebo|A matched placebo will be given once daily for 12 months.
58103823|NCT02007746|OTHER|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
58103824|NCT02007746|OTHER|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
58309663|NCT05047744|DEVICE|Touch Dual Mobility CMC I Prosthesis|Surgery
58434272|NCT05186506|DRUG|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
58434273|NCT01748721|BIOLOGICAL|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
58434274|NCT01748721|OTHER|pharmacological study|Correlative studies
58434275|NCT01748721|OTHER|laboratory biomarker analysis|Optional correlative studies
58434276|NCT02687100|DRUG|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
58434277|NCT02687100|DRUG|Placebo|patients will receive 8 mL of saline without any drug
58434278|NCT03759691|BEHAVIORAL|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
58434279|NCT03410303|DIAGNOSTIC_TEST|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
58434280|NCT05009290|DRUG|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
58434281|NCT05009290|DRUG|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
58434282|NCT05633173|PROCEDURE|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
58434283|NCT05633173|PROCEDURE|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
58434284|NCT00862056|PROCEDURE|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
58434285|NCT03057275|DEVICE|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
58434286|NCT04901273|PROCEDURE|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
58434287|NCT04901273|PROCEDURE|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
58434288|NCT01105156|BEHAVIORAL|VEW Questionnaire|Patient Self reported questionnaire filled in.
58434289|NCT02578056|DEVICE|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
57954014|NCT02646982|DRUG|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
57954015|NCT06460090|BEHAVIORAL|Happy Talk|A targeted selective speech language and communication programme embedded in the community, designed for people livling in social disadvantage.
58434290|NCT02578056|PROCEDURE|Genital prolapse surgery|Surgical correction of genital prolapse
58434291|NCT01653990|DRUG|moxifloxacin|oral dose of 400mg moxifloxacin
57954016|NCT01605526|DRUG|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
57954017|NCT01605526|DRUG|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
58103825|NCT02007746|PROCEDURE|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
58434292|NCT01653990|DRUG|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
57954018|NCT01058096|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
57954019|NCT01058096|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
58434293|NCT02728466|DIETARY_SUPPLEMENT|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
57737765|NCT03061253|OTHER|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
57737766|NCT03061253|OTHER|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
57737767|NCT03061253|OTHER|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
57737768|NCT06570863|OTHER|Antibiotics(doxycycline)|doxycycline 100 mg 2 stat the first day followed by od for 14 days
57737769|NCT06570863|OTHER|Probiotics|Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
57737770|NCT06570863|OTHER|Metronidazole gel 25%|After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
57737771|NCT04827212|BEHAVIORAL|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
57737772|NCT01814371|DRUG|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
58434294|NCT02728466|DIETARY_SUPPLEMENT|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
58434295|NCT02728466|DIETARY_SUPPLEMENT|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
58434296|NCT01023724|DRUG|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
57737773|NCT01814371|OTHER|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
57769610|NCT03813628|OTHER|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
57769611|NCT03813628|OTHER|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
58434297|NCT01023724|DRUG|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
58434298|NCT06372691|OTHER|Subparaneural Injection (Grup S), Block|Comparison of two different methods in terms of various features
58434299|NCT06372691|OTHER|Interneural Injection (Grup I), Block|Comparison of two different methods in terms of various features
58434300|NCT03382808|BEHAVIORAL|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
58434301|NCT03382808|BEHAVIORAL|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
58434302|NCT02819687|DRUG|RDX5791|
58434303|NCT02819687|DRUG|Placebo|
58434304|NCT01523509|DEVICE|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
58434305|NCT06083298|PROCEDURE|control group|patients will be operated under general anesthesia
58434306|NCT06083298|PROCEDURE|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
58434307|NCT06083298|PROCEDURE|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
58434308|NCT06526533|OTHER|Liberal Transfusion|Liberal transfusion trigger group (patient receives RBC transfusion if Hb ≤ 90g/L).
58434309|NCT06526533|OTHER|Restrictive Transfusion|Restrictive transfusion trigger group (patient receives RBC transfusion if Hb≤70g/L).
58103826|NCT05727280|BEHAVIORAL|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
58103827|NCT00156286|DRUG|Gleevec|
58434310|NCT03605914|DRUG|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
58434311|NCT03605914|DRUG|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
58434312|NCT00665548|RADIATION|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
58434313|NCT02566694|PROCEDURE|Implant|orthopaedic implant
58434314|NCT04510896|OTHER|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
58434315|NCT04510896|OTHER|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
58434316|NCT04510896|OTHER|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
58434317|NCT05964036|DEVICE|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
58103828|NCT03398460|DIAGNOSTIC_TEST|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
57769612|NCT03813628|OTHER|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
58434318|NCT05964036|DEVICE|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
58434319|NCT04519697|DRUG|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
58434320|NCT04519697|OTHER|Placebo|Normal Saline
58434321|NCT01054001|DRUG|sildenafil 100mg|sildenafil 100mg per oral twice a week
58434322|NCT04979611|DRUG|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
58434323|NCT01500902|OTHER|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
58434324|NCT01500902|OTHER|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
58434325|NCT04115098|DRUG|Celecoxib|Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
58434326|NCT04115098|DRUG|Naproxen|Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
58434327|NCT04115098|DRUG|Meloxicam|Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
58434328|NCT01235234|DRUG|CF101|orally q12h
58434329|NCT06034249|BEHAVIORAL|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
58434330|NCT06034249|BEHAVIORAL|Audio|The mindfulness-based audio files for six weeks.
58434331|NCT01743820|DRUG|dihydroartemisinin-piperaquine|
58434332|NCT01743820|DRUG|0.125 mg/kg Primaquine|
58434333|NCT01743820|DRUG|0.5 mg/kg Primaquine|
57737774|NCT01814371|BEHAVIORAL|Hygiene Protocol|"Follow key hygiene tips:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors, brushes, or deodorant.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
57737775|NCT02499874|DRUG|Efavirenz|oral Efavirenz 400mg
57737776|NCT02499874|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
57737777|NCT02499874|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
58103829|NCT04202354|DRUG|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
58103830|NCT04202354|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
57737778|NCT02499874|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
58103831|NCT01154127|DRUG|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
58103832|NCT01154127|DRUG|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
58103833|NCT01256346|DEVICE|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
58103834|NCT02878811|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
58103835|NCT04934891|DRUG|ION547|ION547 will be administered by SC injection.
58103836|NCT04934891|DRUG|Placebo|ION547-matching placebo will be administered by SC injection.
58103837|NCT00251771|PROCEDURE|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
58103838|NCT00501696|DRUG|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
57954020|NCT00801879|DRUG|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
58103839|NCT00501696|DRUG|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
58103840|NCT00383019|DRUG|Xalatan|latanoprost 0.005%, one rop once daily in evening
58103841|NCT00383019|DRUG|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
58103842|NCT04121299|DRUG|Carvedilol|Carvedilol 40mg Extended Release Once Daily
58103843|NCT04121299|DRUG|Amlodipine|Amlodipine 10mg Once Daily
58103844|NCT05143086|OTHER|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
58434334|NCT01743820|DRUG|0.25 mg/kg Primaquine|
58434335|NCT01743820|DRUG|0.0625 mg/kg Primaquine|
58434336|NCT05777512|PROCEDURE|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
58434337|NCT05777512|PROCEDURE|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
58434338|NCT03841435|RADIATION|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
58434339|NCT05293236|DRUG|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
58434340|NCT05293236|OTHER|Saline|Saline for intravenous infusion
58434341|NCT02870608|OTHER|lung and liver elastography measurement of fetus|
58434342|NCT01832532|DRUG|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
58434343|NCT02397148|RADIATION|Computed Tomography|imagery with ionizing radiation
58434344|NCT02397148|RADIATION|Cone Beam Computed Tomography|imagery with ionizing radiation
58103845|NCT05143086|OTHER|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
57737779|NCT01930370|DRUG|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
58103846|NCT05143086|OTHER|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
58103847|NCT05143086|OTHER|Placebo|Use 10 ml of mouthwash without fluoride
58103848|NCT00438958|BIOLOGICAL|filgrastim|Given on day 0.
58103849|NCT00438958|PROCEDURE|allogeneic bone marrow transplantation|Given on day 0
58103850|NCT00438958|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
58103851|NCT02156518|PROCEDURE|Vocal Function Exercises|Vocal Function Exercises
58103852|NCT02156518|PROCEDURE|Vocal Hygiene|Vocal Hygiene
57737780|NCT01930370|DRUG|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
57737781|NCT00105638|BEHAVIORAL|educational program, by telephone|
57737782|NCT06105073|PROCEDURE|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
58103853|NCT03365219|DEVICE|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
58103854|NCT03365219|OTHER|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
58103855|NCT03880331|PROCEDURE|Debridement|Aggressive vs Minimal Debridement
58103856|NCT06267677|DIETARY_SUPPLEMENT|High protein liquid formula|liquid and high amount of protein
58434345|NCT05663671|DIAGNOSTIC_TEST|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC\&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
57737783|NCT01331473|PROCEDURE|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
58103857|NCT03470909|PROCEDURE|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
58103858|NCT03470909|PROCEDURE|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
58103859|NCT04923269|DRUG|LY3532226|Administered SC.
58103860|NCT04923269|DRUG|Placebo|Administered SC.
57737784|NCT01331473|PROCEDURE|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
58103861|NCT05540977|DRUG|Donepezil|Donepezil 5mg QN
58103862|NCT05540977|OTHER|Usual care|Usual care
58103863|NCT01406275|DRUG|Amoxicillin and clavulanate|
58103864|NCT00047242|DRUG|7-hydroxystaurosporine|
58103865|NCT00047242|DRUG|irinotecan hydrochloride|
57737785|NCT01053208|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
58103866|NCT00211666|BEHAVIORAL|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
58103867|NCT03576430|DEVICE|active stress handling|biofeed back stress handling
58103868|NCT01977352|DRUG|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
58103869|NCT01977352|DRUG|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
58103870|NCT05103397|DRUG|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
58103871|NCT05103397|DRUG|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
58103872|NCT05103397|DRUG|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
58103873|NCT05861440|DRUG|Prednisolone|adjunct steroid per study protocol
58434346|NCT00869518|DRUG|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
58434347|NCT00869518|DRUG|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
58434348|NCT00240500|BIOLOGICAL|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
58434349|NCT05400772|OTHER|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
58434350|NCT00321815|DRUG|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
58434351|NCT00321815|DRUG|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
58434352|NCT05485337|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
58434353|NCT05608551|BEHAVIORAL|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
58434354|NCT05608551|BEHAVIORAL|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
58434355|NCT02769169|DRUG|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
57737786|NCT05167864|DRUG|Onabotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
57737787|NCT05167864|DRUG|Abobotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
57737788|NCT05167864|DRUG|IncobotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
57737789|NCT05167864|DRUG|PrabotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
57737790|NCT02087163|DEVICE|Movement Enhancement Technique|Conventional Orthodontic treatment
57737791|NCT02087163|DEVICE|Clear Aligner|Orthodontic treatment with Clear Aligner
57737792|NCT06670794|BEHAVIORAL|Web-based intervention for concerned partners|The web-based intervention will comprise sessions focusing on community reinforcement and family therapy principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to their partner (PPR; i.e., actively listening, showing understanding, expressing interest in what their partner is thinking and feeling, and trying to see where their partner is coming from), (3) understanding their partner's drinking reinforcers, and (4) supporting their partner if they want help and engaging in positive, healthy activities with their partner.
57737793|NCT06670794|BEHAVIORAL|Psychoeducation control|This is a psychoeducation control condition.
57737794|NCT03755453|DEVICE|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
57737795|NCT03156049|PROCEDURE|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
57954021|NCT00801879|DRUG|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
57954022|NCT04689529|DIAGNOSTIC_TEST|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
57954023|NCT02787863|BIOLOGICAL|Prevenar-13|Conjugate 13 serotype pneumococcal vaccine
57954024|NCT02787863|BIOLOGICAL|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
57954025|NCT02362958|DRUG|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
57954026|NCT04793178|DEVICE|Oxygen Reserve Index, Masimo Corporation, USA.|The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
57954027|NCT01748539|DRUG|KHK4827|
57954028|NCT01748539|DRUG|Placebo|
57954029|NCT03608176|OTHER|PASO diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
57954030|NCT03608176|OTHER|Low-fat diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
57954031|NCT03608176|OTHER|Waiting list group|This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
57954032|NCT00393107|DRUG|rituximab|
58103874|NCT05861440|DRUG|standard anti-tuberculosis agents|standard anti-tuberculosis agents
58434356|NCT02769169|DRUG|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
58434357|NCT03193736|DEVICE|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
57954033|NCT00393107|DRUG|rituximab,fludarabine, cyclophosphamide|
57954034|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with muscle stretching
57954035|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
58103875|NCT02648399|PROCEDURE|surgery：BCND（bilateral central lymph node dissection）|
58103876|NCT02648399|PROCEDURE|surgery：UCND（unilateral central lymph node dissection）|
58434358|NCT05091125|DIAGNOSTIC_TEST|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
58434359|NCT00039858|DRUG|Argatroban|
58434360|NCT00087659|DRUG|zoledronic acid|
58434361|NCT03078855|DIETARY_SUPPLEMENT|Vitamin D|vitamin D3 2,000 IU daily
58434362|NCT03078855|BIOLOGICAL|Rituximab|Administered weekly x 4
58434363|NCT03078855|OTHER|Placebo|methylcellulose
58434364|NCT00713895|BEHAVIORAL|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
58434365|NCT00713895|BEHAVIORAL|Standard Self-Help|standard smoking cessation self-help manual
58434366|NCT06583889|DRUG|Heparin|The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
58434367|NCT06583889|PROCEDURE|Endovascular treatment|Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
58434368|NCT01192568|DRUG|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
58434369|NCT01192568|DRUG|Placebo|Topical gel
58434370|NCT06524817|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
58434371|NCT02464410|BEHAVIORAL|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
58434372|NCT02464410|BEHAVIORAL|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
58434373|NCT02464410|OTHER|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
58434374|NCT01050244|DIETARY_SUPPLEMENT|Whole soybean soymilk powder|
58434375|NCT01050244|DIETARY_SUPPLEMENT|Whole milk powder|
58434376|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
58434377|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
58434378|NCT02873338|DRUG|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
58434379|NCT02873338|DRUG|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
58434380|NCT02873338|DRUG|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
58434381|NCT02429791|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
58434382|NCT02429791|DRUG|RPV 25 mg|Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
58434383|NCT02429791|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
58434384|NCT01709656|BIOLOGICAL|MSC|"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
57954036|NCT03223064|DIAGNOSTIC_TEST|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
57954037|NCT03223064|DIAGNOSTIC_TEST|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
58434385|NCT01709656|DRUG|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
57954038|NCT00586495|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
58434386|NCT05691205|OTHER|PEEP|After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
58434387|NCT01819350|OTHER|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
58434388|NCT01819350|OTHER|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
58434389|NCT00487071|DEVICE|Anal fistula plug|
57954039|NCT01489566|DRUG|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
57954040|NCT01489566|DRUG|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
58434390|NCT03144986|DEVICE|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
58434391|NCT03041896|DEVICE|coflex® Interlaminar Technology|Interlaminer Technology
57737796|NCT03156049|PROCEDURE|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
57737797|NCT04210453|DRUG|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
57954041|NCT04191382|DRUG|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
57737798|NCT04210453|DRUG|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
58103877|NCT06539455|DRUG|standard anti-TB treatment|standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
58103878|NCT01972542|DIETARY_SUPPLEMENT|Oral fat tolerance test|
58434392|NCT04314011|BIOLOGICAL|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
58434393|NCT04314011|BIOLOGICAL|Placebo|Placebo
58434394|NCT01325805|BEHAVIORAL|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
58434395|NCT01325805|BEHAVIORAL|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
58434396|NCT01764828|DRUG|Refametinib (BAY86-9766)|
58434397|NCT01764828|DRUG|Gemcitabine|
58434398|NCT04371601|DRUG|Oseltamivir|Oseltamivir capsules
58434399|NCT04371601|DRUG|hormones|a moderate amount of hormone
57737799|NCT06414434|DRUG|BTX-A51|Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
57737800|NCT04250194|DEVICE|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
57737801|NCT04250194|DEVICE|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
57737802|NCT04654338|RADIATION|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
58434400|NCT04371601|DEVICE|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
58434401|NCT04371601|PROCEDURE|mesenchymal stem cells|mesenchymal stem cells
58434402|NCT04115137|DEVICE|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
58434403|NCT04383054|BEHAVIORAL|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
58103879|NCT04517981|BEHAVIORAL|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
57737803|NCT03955653|PROCEDURE|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
57954042|NCT04191382|DRUG|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
57954043|NCT06275360|DRUG|Nivolumab|Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
58103880|NCT04517981|OTHER|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
58103881|NCT00193570|DRUG|Topotecan|
58434404|NCT04383054|BEHAVIORAL|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
58434405|NCT00979771|DRUG|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
58434406|NCT00979771|DRUG|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
58434407|NCT03163901|OTHER|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
58434408|NCT00477646|BEHAVIORAL|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
58434409|NCT01678612|OTHER|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
58103882|NCT00193570|DRUG|Docetaxel|
58103883|NCT04630366|DRUG|NST-1024|NST-1024
58103884|NCT04630366|DRUG|Placebo|Matching placebo to NST-1024
58103885|NCT00127348|DEVICE|CPAP (Continuous Positive Airway Pressure)|
58434410|NCT05889637|DIAGNOSTIC_TEST|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
58103886|NCT05741268|BEHAVIORAL|Dialectical behavior therapy|14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
58103887|NCT00051636|DRUG|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
58434411|NCT05068219|PROCEDURE|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)"
57737804|NCT02042235|BEHAVIORAL|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
58103888|NCT00051636|DRUG|Risedronate|Oral risedronate 30 mg capsules.
58103889|NCT00051636|DRUG|Placebo to Risedronate|Oral placebo of risedronate capsules.
57737805|NCT02347761|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
58103890|NCT00051636|DRUG|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
58103891|NCT00051636|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
58103892|NCT05576909|DRUG|Donafenib|"0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy"
58103893|NCT05576909|PROCEDURE|TACE|For downstaging treatment
58103894|NCT02266966|DRUG|F2695|
58103895|NCT02266966|DRUG|Placebo|
58434412|NCT05068219|PROCEDURE|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
58434413|NCT06584370|PROCEDURE|Pericardial insufflation with carbon dioxide through a transatrial microcatheter|Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
58434414|NCT04725500|DEVICE|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
58434415|NCT01474720|DRUG|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
57954044|NCT02567890|BEHAVIORAL|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
57954045|NCT02567890|BEHAVIORAL|Expressive writing|Participants will be asked to reflect upon issues related to body image.
57954046|NCT04936295|DRUG|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
57954047|NCT06476067|PROCEDURE|Surgery|Esophagectomy
57954048|NCT05769335|OTHER|eCR|Eating time window from 8:00 to 16:00
57954049|NCT05769335|OTHER|dCR|Eating time window from 12:00 to 20:00
57954050|NCT05769335|OTHER|CR|Eating time window from 8:00 to 20:00
57954051|NCT01425008|DRUG|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
58434416|NCT05502510|BEHAVIORAL|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
58434417|NCT04474821|OTHER|Educational Intervention|Receive educational materials on HPV
58434418|NCT04474821|OTHER|Survey Administration|Ancillary studies
58434419|NCT00764673|DEVICE|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
58434420|NCT00781859|DRUG|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
58434421|NCT00781859|DRUG|Placebo|Placebo intravitreal injection
58103896|NCT02983526|DEVICE|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
58103897|NCT01334736|BEHAVIORAL|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
57737806|NCT02347761|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
57737807|NCT02347761|DRUG|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
57737808|NCT04074642|PROCEDURE|Neurosurgery|adenoma removal
57737809|NCT04365660|DRUG|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
58434422|NCT04054375|DRUG|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
58434423|NCT01711450|PROCEDURE|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
57737810|NCT04177758|DRUG|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
57737811|NCT04177758|DRUG|Control|Patients randomized to the control will receive a placebo
58434424|NCT01711450|PROCEDURE|Control sham procedure|Injection of Normal saline into the paravertebral space
58434425|NCT00966212|BEHAVIORAL|parent education|Especially for Daughters audio-cd parent education
57737812|NCT04987515|PROCEDURE|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
58434426|NCT00077649|DRUG|ribavirin [Copegus]|600mg po bid for 48 weeks
58434427|NCT00077649|DRUG|ribavirin [Copegus]|800mg po bid for 48 weeks
58434428|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
58434429|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
58434430|NCT03157765|PROCEDURE|endometrial biopsy|endometrial biopsy
58434431|NCT01022424|DRUG|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
58434432|NCT00268970|DRUG|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
58434433|NCT05749328|DIETARY_SUPPLEMENT|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
58434434|NCT03167021|OTHER|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
58434435|NCT06085924|DRUG|SoC|COVID-19 treatment as per government guidance
58434436|NCT06085924|OTHER|Disease description|No intervention
58434437|NCT04310566|DEVICE|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
58434438|NCT04310566|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL
58434439|NCT00053872|DRUG|cisplatin|
58434440|NCT00053872|DRUG|lomustine|
58434441|NCT00053872|DRUG|vincristine sulfate|
58434442|NCT00053872|PROCEDURE|adjuvant therapy|
58434443|NCT00053872|RADIATION|radiation therapy|
58434444|NCT06191172|BEHAVIORAL|Reminiscence Therapy|Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.
58434445|NCT06191172|BEHAVIORAL|Montessori application|Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop
58434446|NCT06191172|BEHAVIORAL|Environmental Layout|Dining place Music Lighting Heat
57737813|NCT03776513|BEHAVIORAL|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
58434447|NCT06191172|BEHAVIORAL|Application of contrast ergonomic special equipment|White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
58434448|NCT02564809|BEHAVIORAL|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
58434449|NCT02564809|BEHAVIORAL|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
58434450|NCT02564809|BEHAVIORAL|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
58103898|NCT01334736|BEHAVIORAL|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
58434451|NCT06131138|OTHER|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
58434452|NCT06131138|OTHER|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
58434453|NCT05574842|BEHAVIORAL|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
58434454|NCT00148876|DRUG|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
58434455|NCT00148876|DRUG|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
58434456|NCT06031363|DRUG|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
58434457|NCT01318148|DRUG|caspofungin|Intermittent intravenous application of caspofungin
58434458|NCT01985425|DRUG|Colchicine 0.6 mg|
58434459|NCT01985425|DRUG|Placebo Colchicine|
58434460|NCT06043973|DRUG|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
58434461|NCT01445197|BIOLOGICAL|Biostate|200 IU/kg administered daily
58434462|NCT05189028|DRUG|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
58434463|NCT02302391|OTHER|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
58434464|NCT00687674|DRUG|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
58434465|NCT00687674|DRUG|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
58434466|NCT00687674|DRUG|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
58434467|NCT01012778|BEHAVIORAL|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
58434468|NCT05228483|DEVICE|CO2 fractional laser|CO2 fraction laser
58434469|NCT05228483|COMBINATION_PRODUCT|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
57737814|NCT00454558|DRUG|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
57737815|NCT03681028|DRUG|Individualized therapy|"1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
57737816|NCT04675788|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
57737817|NCT04675788|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
57737818|NCT04675788|DRUG|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
57737819|NCT04675788|DRUG|Placebo|Lactose capsules
57737820|NCT00620841|OTHER|genotyping|Restriction fragment lenght polymorphisms
58434470|NCT05228483|DRUG|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
58434471|NCT02922426|DRUG|ALKS 3831|Daily dosing for 21 consecutive days
58434472|NCT02922426|DRUG|Olanzapine|Daily dosing for 21 consecutive days
58434473|NCT02922426|DRUG|Placebo|Daily dosing for 21 consecutive days
58434474|NCT01462396|DEVICE|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
57737821|NCT05034705|DEVICE|Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
57737822|NCT05034705|DEVICE|Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
57737823|NCT02230072|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
57737824|NCT01084876|DRUG|CT-P6|Administered every 3 weeks
57737825|NCT01084876|DRUG|Herceptin|Administered every 3 weeks
57737826|NCT01084876|DRUG|Paclitaxel|Administered every 3 weeks
58434475|NCT03029091|DRUG|Losartan Potassium|Losartan potassium
58434476|NCT02554578|OTHER|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
58434477|NCT01973725|DRUG|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
58434478|NCT04079075|OTHER|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
58434479|NCT04079075|BEHAVIORAL|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
58434480|NCT04079075|BEHAVIORAL|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
57737827|NCT01988246|DRUG|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
58309664|NCT01019993|PROCEDURE|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.
57737828|NCT01988246|DRUG|Sham|Sham injection. No actual injection. No medication is used.
57737829|NCT02388633|PROCEDURE|Plasmapharesis|Clinically-indicated LDL apheresis
57737830|NCT06575218|DEVICE|Virtual reality training|Virtual reality training
57737831|NCT06575218|OTHER|Conventional exercise and cognitive exercise|Conventional exercise and cognitive exercise
58309665|NCT03776279|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
58434481|NCT04079075|BEHAVIORAL|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
58309666|NCT04901624|BEHAVIORAL|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
57737832|NCT06575218|OTHER|control|no intervention
58309667|NCT04901624|BEHAVIORAL|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
58103899|NCT01334736|BEHAVIORAL|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
58103900|NCT01334736|BEHAVIORAL|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
58434482|NCT04079075|DIAGNOSTIC_TEST|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
58309668|NCT04901624|BEHAVIORAL|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
58434483|NCT04766008|DRUG|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
58434484|NCT03405428|OTHER|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
58434485|NCT03405428|OTHER|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
57737833|NCT01816594|DRUG|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
57737834|NCT01816594|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
57769613|NCT03340558|BIOLOGICAL|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
58309669|NCT04901624|BEHAVIORAL|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
58309670|NCT04808583|PROCEDURE|TLH with uterine artery ligation at its origin at the beginning of the operation|After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
58434486|NCT03405428|OTHER|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
58103901|NCT03182686|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
57737835|NCT01816594|DRUG|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
58434487|NCT05784298|DEVICE|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
58434488|NCT03684382|OTHER|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
58434489|NCT01833572|DRUG|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
57737836|NCT01816594|DRUG|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
58434490|NCT03108417|DEVICE|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
58434491|NCT02732431|OTHER|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
58434492|NCT06584474|DRUG|Azithromycin neubilization|"nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro"
58434493|NCT06584474|DEVICE|Lung ultrasound|Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
58434494|NCT05816434|BEHAVIORAL|Sleep extension|\>1 hour additional time in bed per night for 1 week.
58434495|NCT02493231|DRUG|Nefopam|
58434496|NCT02493231|DRUG|Ketamine|
58434497|NCT02493231|DRUG|Saline|
58434498|NCT05809063|OTHER|observational|document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
57737837|NCT05129826|BEHAVIORAL|the association between periodontitis and malnutrition status|be determine the association between periodontitis and malnutrition status in older adult.
57737838|NCT05123508|DEVICE|2940nm and BBL treatment|2940nm and BBL treatment
57737839|NCT05123508|OTHER|Non-treatment side (Control)|No treatment
57737840|NCT01356017|DRUG|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
57737841|NCT01356017|DRUG|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
57737842|NCT04226430|DEVICE|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
57769614|NCT03340558|DRUG|Cobimetinib|MEK inhibitor
57769615|NCT00790920|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
57769616|NCT00790920|DRUG|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
57769617|NCT06026319|DRUG|CD79b-19 CAR T cells|Intravenous infusion
58434499|NCT06123143|OTHER|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
58434500|NCT04840225|OTHER|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
58434501|NCT06085014|OTHER|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
58434502|NCT06085014|OTHER|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
58434503|NCT03295019|DEVICE|Test Oral Spray|HA formulation of FDA listed ingredients
58434504|NCT03295019|DEVICE|Placebo Oral Spray|Placebo formulation without the active ingredients
57769618|NCT06026319|DRUG|Cyclophosphamide|Intravenous infusion
57769619|NCT06026319|DRUG|Fludarabine|Intravenous infusion
58103902|NCT03182686|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
58103903|NCT04499235|DRUG|Mometasone furoate|Topical mometasone furoate
58103904|NCT04499235|DRUG|AKST4290|Oral AKST4290
58103905|NCT04499235|DRUG|Placebo|Oral placebo
57737843|NCT02791724|BEHAVIORAL|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
57737844|NCT02791724|OTHER|CAU|Care as Usual
57737845|NCT01540851|BEHAVIORAL|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
57737846|NCT01540851|OTHER|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
57737847|NCT04663048|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
57769620|NCT06205641|DRUG|Xuanfei Baidu Granule Placebo|Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
57769621|NCT06205641|DRUG|Xuanfei Baidu Granule|Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
58434505|NCT01571011|BEHAVIORAL|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
58434506|NCT03155438|DIAGNOSTIC_TEST|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
58434507|NCT03155438|DIAGNOSTIC_TEST|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
58434508|NCT03718897|DIAGNOSTIC_TEST|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
58434509|NCT03135938|PROCEDURE|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
58434510|NCT03135938|PROCEDURE|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
57737848|NCT03311438|OTHER|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
57737849|NCT05378399|DRUG|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
58309671|NCT04808583|PROCEDURE|conventional TLH with uterine artery ligation after the cornual pedicles|"Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides."
57737850|NCT05378399|DEVICE|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
57737851|NCT05378399|DEVICE|Beiwe|Digital phenotyping app
58434511|NCT00880191|DRUG|dexamethasone|Given orally
58434512|NCT00880191|DRUG|gabapentin|Given orally
58434513|NCT00880191|OTHER|placebo|Given orally
58309672|NCT01850316|RADIATION|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
58309673|NCT01496456|DEVICE|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
58309674|NCT01496456|BEHAVIORAL|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
58434514|NCT03063268|BEHAVIORAL|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
58434515|NCT03063268|BEHAVIORAL|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
58434516|NCT03063268|BEHAVIORAL|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
58434517|NCT06354478|DRUG|Dexmedetomidine Hydrochloride 0.5 MG/ML|Will be used either alone or in combination of gabapentin
57737852|NCT03491865|BEHAVIORAL|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
57737853|NCT02999555|PROCEDURE|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
58309675|NCT02897349|DRUG|placebo|
58309676|NCT02897349|DRUG|linagliptin|
58309677|NCT02897349|DRUG|background therapy|insulin with or without metformin
58309678|NCT04941872|DIAGNOSTIC_TEST|68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
58309679|NCT04513509|DRUG|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
57737854|NCT05010148|DRUG|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
58434518|NCT06354478|DRUG|Gabapentin|Will be used either alone or in combination of Dexmedetomidine
58434519|NCT04218539|DRUG|Psilocybin|10mg Psilocybin
58434520|NCT04218539|DRUG|Placebo|25mg Diphenhydramine
58434521|NCT04551950|DRUG|M7824|Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
58434522|NCT04551950|DRUG|Carboplatin|Carboplatin was administered intravenously as per standard of care.
58434523|NCT04551950|DRUG|Paclitaxel|Paclitaxel was administered intravenously as per standard of care.
58434524|NCT04551950|DRUG|Bevacizumab|Bevacizumab was administrated as indicated for standard of care.
58434525|NCT04551950|DRUG|Cisplatin|Cisplatin was administered intravenously as per standard of care.
58434526|NCT04551950|RADIATION|Radiotherapy|Participants received radiotherapy as per standard of care.
57737855|NCT05010148|DRUG|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
57737856|NCT03962387|OTHER|Not applicable(observational study)|Not applicable(observational study)
58103906|NCT05966636|PROCEDURE|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
58434527|NCT01564732|DEVICE|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
58434528|NCT01564732|DEVICE|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
58103907|NCT06118671|BEHAVIORAL|personalized lifestyle intervention by AI|The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
58103908|NCT02260141|DIETARY_SUPPLEMENT|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
58103909|NCT00833547|DRUG|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
58103910|NCT00833547|DRUG|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
58309680|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
58309681|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
58309682|NCT00328705|DEVICE|Implantable Cardioverter Defibrillator|
58434529|NCT04999345|OTHER|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
58434530|NCT04999345|OTHER|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
58434531|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks."
58434532|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed facing away from the skull to avoid an effect."
57737857|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
57737858|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
57954052|NCT05256407|OTHER|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
57737859|NCT00251745|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
57737860|NCT02647398|BEHAVIORAL|Vigorous aerobic training|Supervised vigorous aerobic training
57737861|NCT06386523|DIAGNOSTIC_TEST|Passage of olfactory tests|test TODA2 and Sniffin Stick Test
57737862|NCT00331981|DRUG|Amisulpride|
57737863|NCT04543123|DEVICE|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
57737864|NCT04543123|DRUG|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
57954053|NCT03053479|PROCEDURE|Laparoscopic sacrocolpopexy|see arm/group descriptions
57954054|NCT03053479|PROCEDURE|Transvaginal mesh procedure|see arm/group descriptions
57954055|NCT03053479|PROCEDURE|Amreich-Richter procedure|see arm/group descriptions
57954056|NCT04578795|DEVICE|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
57954057|NCT04509921|OTHER|asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness|Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
58434533|NCT02123368|DRUG|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
58103911|NCT01168700|DRUG|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
58103912|NCT01168700|DRUG|Placebo|Placebo 1.2 g per day for 12 weeks.
58434534|NCT02123368|BIOLOGICAL|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
58434535|NCT02123368|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
58103913|NCT04947020|DRUG|Metformin|Metformin use before operation due to previously diagnosed diabetes.
58103914|NCT02067715|DRUG|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
58103915|NCT05465707|BIOLOGICAL|CM313 2 mg/kg|Once 1 week, intravenous infusion.
58103916|NCT05465707|BIOLOGICAL|CM313 4 mg/kg|Once 1 week, intravenous infusion.
58103917|NCT05465707|BIOLOGICAL|CM313 8 mg/kg|Once 1 week, intravenous infusion.
58103918|NCT05465707|BIOLOGICAL|CM313 16 mg/kg|Once 1 week, intravenous infusion.
58103919|NCT05465707|BIOLOGICAL|Placebo|Once 1 week, intravenous infusion.
58103920|NCT00344305|BIOLOGICAL|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
58103921|NCT00827359|DRUG|Everolimus|Tablet form taken orally once a day
58103922|NCT01779908|DIETARY_SUPPLEMENT|Vitamin D|
57737865|NCT03461068|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
57737866|NCT03461068|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
58103923|NCT01779908|OTHER|Placebo|
58103924|NCT00238056|DRUG|domperidone Drug|
58103925|NCT05320614|OTHER|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
58103926|NCT05320614|OTHER|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
58103927|NCT03061279|DEVICE|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
58103928|NCT03061279|DEVICE|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
58103929|NCT00690768|DRUG|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
58103930|NCT00690768|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
58103931|NCT00240305|DRUG|Rosuvastatin|
58103932|NCT01159119|DRUG|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
58103933|NCT01159119|DRUG|Zenpep|Capsules taken for daily for 28 days during treatment period 2
58103934|NCT01159119|DRUG|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
58103935|NCT02766088|PROCEDURE|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
57737867|NCT03094026|BEHAVIORAL|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
57737868|NCT03094026|BEHAVIORAL|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
57737869|NCT05430490|PROCEDURE|MRI|Multimodal neuroimaging on 3T Prisma Fit MRI
58434536|NCT06525701|OTHER|Execise Group|SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.
58434537|NCT06525701|OTHER|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
58103936|NCT01548183|BEHAVIORAL|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
58103937|NCT00095095|DEVICE|Lumbar Interbody Fusion|
58434538|NCT05034250|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
58434539|NCT03981627|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
57737870|NCT05430490|OTHER|NeuroPsychological Testing|A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
57737871|NCT05430490|PROCEDURE|Blood Draw|Laboratory reports (CMP, CBC, Lipids)
57737872|NCT05430490|OTHER|Questionnaires|Life history, current behaviors, and substance use surveys
57737873|NCT05430490|PROCEDURE|Lumbar Puncture|Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
57737874|NCT05278000|OTHER|Presence of scarcity mindset|"This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
58103938|NCT00935896|PROCEDURE|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
58103939|NCT00935896|PROCEDURE|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
58103940|NCT00935896|OTHER|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
58103941|NCT01952639|DIETARY_SUPPLEMENT|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
58103942|NCT02214498|DRUG|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
58103943|NCT02214498|DRUG|Placebo|
58103944|NCT05508074|DRUG|IFB-088 50mg/day|Tested product
58103945|NCT05508074|DRUG|Placebo|Placebo
58103946|NCT05508074|DRUG|Riluzole 100mg/day|Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
58309683|NCT03751813|DIETARY_SUPPLEMENT|Supplement|Supplement will be given to this group to take daily for 8 weeks
57737875|NCT00000985|DRUG|Vidarabine|
58103947|NCT03250065|DEVICE|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
58103948|NCT01120600|DRUG|Odanacatib|One 50 mg tablet once weekly
58309684|NCT06369064|OTHER|CVVHD Dialysis parameters|In the CVVHD group, patients will receive a dialysis dose of 25ml/kg/h dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate
58434540|NCT03981627|DRUG|NovoRapid®|Subcutaneous injection of insulin aspart
58434541|NCT02188654|DRUG|Metformin|500mg/day retarded formulation of metformin
58434542|NCT02188654|DRUG|Placebo|500 mg/day of placebo tablets
58434543|NCT05483517|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
58434544|NCT05483517|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
58434545|NCT05483517|BEHAVIORAL|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
58434546|NCT01076387|PROCEDURE|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
57954058|NCT03064737|OTHER|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
58103949|NCT01120600|DRUG|Placebo for Odanacatib|One 50 mg tablet once weekly
58103950|NCT01120600|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
58103951|NCT01120600|DIETARY_SUPPLEMENT|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
58309685|NCT06369064|OTHER|CVVHDF Dialysis parameters|In the CVVHD group, patients will receive a dialysis dose of 25ml/kg/h dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine
57954059|NCT00290485|DRUG|Imatinib mesylate|
57954060|NCT00870961|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
57954061|NCT00870961|OTHER|placebo|Given orally
57954062|NCT03344315|DEVICE|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
57954063|NCT03344315|OTHER|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
58434547|NCT01076387|PROCEDURE|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
58434548|NCT00418574|BIOLOGICAL|Abagovomab|2 mg/ml SC (subcutaneously)
58434549|NCT00418574|BIOLOGICAL|Placebo|2 mg/ml SC (subcutaneously)
58434550|NCT02108314|BEHAVIORAL|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
58103952|NCT04681222|PROCEDURE|LFCN|LFCN block was performed in combination with PENG block
58103953|NCT04681222|PROCEDURE|Wound infiltration|Wound infiltration was performed in combination with PENG block
58103954|NCT02495870|OTHER|Pork|
58103955|NCT05698420|DEVICE|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
58103956|NCT05698420|DEVICE|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
58434551|NCT03600532|BEHAVIORAL|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
58434552|NCT02110264|DRUG|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
58434553|NCT02110264|BEHAVIORAL|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
58434554|NCT02110264|BEHAVIORAL|ETAU|Participants assigned to the ETAU group will receive drug education.
58434555|NCT02249039|DRUG|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
58434556|NCT02361008|DEVICE|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
58434557|NCT02361008|PROCEDURE|Surgery repair with CBP|Traditional surgery repair under the CBP.
58103957|NCT05416359|DRUG|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
58103958|NCT05040815|RADIATION|chemo-radiation treatment|Radiotherapy (RT) with concurrent 5-fluorouracil and mitomycin-C (5FU/MMC) combination is the treatment of choice for non-metastatic locally advanced anal squam
58103959|NCT05186922|BIOLOGICAL|CM326|CM326 injection
58103960|NCT05186922|OTHER|Placebo|Placebo
58103961|NCT02341963|DRUG|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
57737876|NCT00000985|DRUG|Acyclovir|
58103962|NCT03568526|OTHER|Educational Intervention|Attend a therapy session
58434558|NCT00682955|DRUG|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
58434559|NCT00682955|DRUG|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
57737877|NCT00000985|DRUG|Foscarnet sodium|
58103963|NCT03568526|BEHAVIORAL|Exercise Intervention|Complete exercise
58103964|NCT03568526|OTHER|Quality-of-Life Assessment|Ancillary studies
58103965|NCT03568526|OTHER|Questionnaire Administration|Ancillary studies
58103966|NCT03568526|OTHER|Survey Administration|Ancillary studies
58103967|NCT00553748|DRUG|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
58434560|NCT01549119|BIOLOGICAL|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
58434561|NCT01549119|BIOLOGICAL|Placebo|Comparison with experimental vaccine
58434562|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
58103968|NCT04073693|DIETARY_SUPPLEMENT|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
58103969|NCT03523013|DEVICE|CPAP|CPAP treatment with different pressure for OSA patients
58103970|NCT05906498|DRUG|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
58103971|NCT05906498|DRUG|Vitamin E|vitamin E possessing an anti-inflammatory action
58103972|NCT06543212|OTHER|physiotherapy exercises|physiotherapy exercises to improve eye alignment and eye control post strabismus surgery
58103973|NCT01147016|BIOLOGICAL|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
58103974|NCT01147016|DRUG|cyclophosphamide|As prescribed by physician, standard of care.
58103975|NCT01147016|DRUG|doxorubicin hydrochloride|As prescribed by physician, standard of care.
58309686|NCT06522425|OTHER|mindfulness-based serious games|The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.
58309687|NCT04372368|BIOLOGICAL|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
58309688|NCT03105011|BEHAVIORAL|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
58309689|NCT01918228|BEHAVIORAL|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
58309690|NCT00033280|DRUG|temozolomide|
57737878|NCT03701568|DRUG|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
58309691|NCT00033280|PROCEDURE|neoadjuvant therapy|
57737879|NCT03884751|BIOLOGICAL|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
57737880|NCT01741753|DRUG|BKM120|Orally, every morning
57737881|NCT01741753|DRUG|Abiraterone|Orally, 1000 mg, every morning
57737882|NCT01741753|DRUG|Prednisone|Orally, 5 mg, every morning
58309692|NCT00033280|RADIATION|radiation therapy|
58309693|NCT06307262|DEVICE|T-TEER|T-TEER using the PACAL or TriClip device
58309694|NCT01252368|BIOLOGICAL|hypertension|patients taking daily ACE inhibitors or sartanes
58309695|NCT05811481|PROCEDURE|TACE|Transcatheter Arterial Chemoembolization
58309696|NCT05811481|DRUG|Regorafenib|Regorafenib alone
58309697|NCT04382534|COMBINATION_PRODUCT|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
58309698|NCT01641042|BIOLOGICAL|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
58309699|NCT05981924|OTHER|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
58309700|NCT03564990|OTHER|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
58309701|NCT03564990|OTHER|conventional approach|conventional follow-up
58309702|NCT02523209|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
58309703|NCT02523209|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
58309704|NCT01055990|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
58309705|NCT01055990|OTHER|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
57737883|NCT03772067|DEVICE|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
57737884|NCT03772067|DIAGNOSTIC_TEST|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
57737885|NCT03772067|DIAGNOSTIC_TEST|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
57737886|NCT03772067|DIAGNOSTIC_TEST|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
58103976|NCT01147016|DRUG|paclitaxel|As prescribed by physician, standard of care.
58103977|NCT01147016|OTHER|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
58103978|NCT01147016|PROCEDURE|neoadjuvant therapy|As prescribed by physician, standard of care.
58103979|NCT01147016|PROCEDURE|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
58434563|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
58103980|NCT01824108|PROCEDURE|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
58103981|NCT01824108|PROCEDURE|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
58103982|NCT01845701|DRUG|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
58103983|NCT01845701|DRUG|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
58103984|NCT01845701|DRUG|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
58103985|NCT05799378|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
58103986|NCT05799378|DRUG|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
58103987|NCT03744988|DIAGNOSTIC_TEST|serum androgen levels|measurement of serum free and total testosterone
58103988|NCT02780921|PROCEDURE|prehabilitation|
58103989|NCT02780921|OTHER|nutritional support|
58103990|NCT06545526|DRUG|celecoxib monotherapy|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
58309706|NCT01534793|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
58309707|NCT00978952|DEVICE|Large Diameter Advanta™ V12 Covered Stent|Stent placement
58309708|NCT00158353|BEHAVIORAL|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
58309709|NCT00158353|BEHAVIORAL|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
58309710|NCT00499122|DRUG|Cyclophosphamide|
58309711|NCT00499122|DRUG|Docetaxel|
58309712|NCT00499122|DRUG|Doxorubicin|
58309713|NCT00499122|DRUG|NOV 002|
58309714|NCT03361046|DEVICE|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
58309715|NCT03506477|DRUG|Enstilar® foam|for 4 weeks
58309716|NCT03506477|DRUG|Vehicle foam|for 4 weeks
58434564|NCT05316506|OTHER|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
58434565|NCT05316506|OTHER|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
58434566|NCT02545244|DIETARY_SUPPLEMENT|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
58434567|NCT02545244|DIETARY_SUPPLEMENT|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
58309717|NCT06454786|OTHER|Simulation Method|Management of cardiogenic shock scenario on an advanced simulation mannequin
57769622|NCT06205641|DRUG|Baloxavir Marboxil Tablet|Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
58309718|NCT05252858|DEVICE|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
58103991|NCT06545526|DRUG|celecoxib and metformin combination|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
58103992|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
58103993|NCT00640822|DRUG|Tacalcitol Ointment|Once daily application for up to 8 weeks
58103994|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
58103995|NCT05407337|BEHAVIORAL|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
58103996|NCT02033577|PROCEDURE|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
58103997|NCT02033577|PROCEDURE|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
58103998|NCT05350982|DEVICE|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
57737887|NCT03772067|DIAGNOSTIC_TEST|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
57954064|NCT01982292|DRUG|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
57954065|NCT01982292|DRUG|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
57954066|NCT03129490|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
57954067|NCT03129490|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
57954068|NCT03129490|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
57954069|NCT03129490|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
57954070|NCT05773001|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
57954071|NCT03465189|DEVICE|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
57954072|NCT04720482|DIAGNOSTIC_TEST|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
57954073|NCT04720482|DIAGNOSTIC_TEST|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
57954074|NCT06320769|DEVICE|Plate Technique|Using Plates, non-absorbable sutures or cerclage wires to guide the distal femoral physis towards rotational growth to correct deformity
57954075|NCT06256510|DRUG|Midazolam|Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
57954076|NCT06256510|DRUG|Vepdegestrant|Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
57954077|NCT00991523|DIETARY_SUPPLEMENT|protein|protein
57954078|NCT00991523|DIETARY_SUPPLEMENT|placebo|placebo control
57737888|NCT03772067|DIAGNOSTIC_TEST|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
57737889|NCT03772067|DIAGNOSTIC_TEST|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
57954079|NCT04268121|DRUG|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
57954080|NCT04268121|DRUG|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
57954081|NCT01072214|DRUG|pazopanib|gw786034
57954082|NCT01072214|DRUG|pazopanib|gw786034
57954083|NCT01072214|DRUG|pazopanib|gw786034
58103999|NCT01731860|DEVICE|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
57954084|NCT01072214|DRUG|Placebo|placebo
57954085|NCT05723705|OTHER|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
57954086|NCT06320561|OTHER|Longitudinal prospective cohort study|Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
58104000|NCT02766400|BEHAVIORAL|Guided Training|
58434568|NCT02545244|DRUG|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
58434569|NCT03405818|DRUG|Tavaborole 5% Topical Solution|topical solution for application to toenails
58434570|NCT00011622|DEVICE|Continuous ambulatory subcutaneous glucose monitor|
58434571|NCT00483938|DRUG|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
57737890|NCT03772067|DIAGNOSTIC_TEST|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
57737891|NCT03772067|DIAGNOSTIC_TEST|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
57737892|NCT03772067|OTHER|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
57737893|NCT03772067|DIAGNOSTIC_TEST|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
58104001|NCT02766400|BEHAVIORAL|Directed Training|
58104002|NCT01001715|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
58434572|NCT00483938|DRUG|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
58434573|NCT02422849|OTHER|hospital specialist|
57737894|NCT04192994|DRUG|Intravitreal Antibiotic Injection|Intravitreal Antibiotic Injection
58104003|NCT01001715|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
58434574|NCT02422849|OTHER|General Practitioner|
57737895|NCT04192994|PROCEDURE|Pars Plana Vitrectomy|Pars Plana Vitrectomy
57737896|NCT04969523|PROCEDURE|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
57737897|NCT02457572|PROCEDURE|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
57737898|NCT02457572|OTHER|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
57737899|NCT04850300|PROCEDURE|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
57737900|NCT04850300|PROCEDURE|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
58434575|NCT01397942|OTHER|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
58434576|NCT02567565|OTHER|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
58434577|NCT04866901|BEHAVIORAL|Slow-Paced Breathing (SPB)|see arm description
58434578|NCT04866901|BEHAVIORAL|Mindfulness (M)|see arm description
58434579|NCT04866901|BEHAVIORAL|Yogic Breathing (SPB+M)|see arm description
58434580|NCT05640895|PROCEDURE|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
58434581|NCT02725229|PROCEDURE|parasternal block|parasternal block and PCA for sternotomy pain
58434582|NCT02725229|DEVICE|TENS group|TENS and PCA for sternotomy pain
58434583|NCT02725229|DEVICE|control group|PCA for sternotomy pain
58434584|NCT02547584|PROCEDURE|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
58434585|NCT02597387|DRUG|Mitoxantrone HCL Liposome Injection|
58434586|NCT04382742|BEHAVIORAL|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
58434587|NCT02822261|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66_R84-088)
58434588|NCT04481217|OTHER|Self-questionnaires battery|"* Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
58434589|NCT04481217|OTHER|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
58434590|NCT02376023|OTHER|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
58434591|NCT04611828|DEVICE|Philips SmartSleep|closed-loop auditory stimulation
58434592|NCT03899987|DRUG|Aspirin|Given PO
58434593|NCT03899987|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
58434594|NCT03899987|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
58434595|NCT03899987|DRUG|Rintatolimod|Given IV
58434596|NCT04241406|DEVICE|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
58104004|NCT03429374|DEVICE|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
58104005|NCT03429374|DEVICE|Absorbable tack|Absorbable tack
58309719|NCT05252858|OTHER|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
58309720|NCT05224830|OTHER|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
58309721|NCT01943617|DRUG|Entecavir|anti-viral therapy
58309722|NCT01943617|DRUG|Thymosin-α|anti-viral and antitherapy
58309723|NCT00861081|BEHAVIORAL|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
58434597|NCT05052567|DRUG|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
58434598|NCT02982057|DEVICE|the ABSORB:bioresorbable vascular scaffold|
58434599|NCT02982057|DRUG|O.M.T|
58434600|NCT05084092|RADIATION|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
58104006|NCT03799874|DRUG|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
58104007|NCT03799874|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
58309724|NCT00861081|BEHAVIORAL|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
58309725|NCT05129696|BEHAVIORAL|Treatment (T)|Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
58309726|NCT05129696|BEHAVIORAL|Treatment + (T+)|Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
58434601|NCT05084092|PROCEDURE|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
58434602|NCT00006208|DRUG|Efavirenz|
58434603|NCT00006208|DRUG|Emtricitabine|
58434604|NCT00006208|DRUG|Stavudine|
58434605|NCT00006208|DRUG|Didanosine|
58104008|NCT06160882|OTHER|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
58104009|NCT06160882|PROCEDURE|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
58104010|NCT05680311|BIOLOGICAL|measurement of serum autotaxin serum level|autotaxin expression
58104011|NCT03552679|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
58104012|NCT02280356|RADIATION|external beam radiation therapy|
58104013|NCT02280356|RADIATION|brachytherapy|
58104014|NCT02280356|BEHAVIORAL|questionnaires|
58104015|NCT05725564|BEHAVIORAL|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
58104016|NCT05725564|BEHAVIORAL|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
58104017|NCT05725564|BEHAVIORAL|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
58104018|NCT04904601|DIETARY_SUPPLEMENT|Kale supplement|Kale (blanched freeze-dried Kale) group1
58434606|NCT03863808|BEHAVIORAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
58104019|NCT04904601|DIETARY_SUPPLEMENT|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
58104020|NCT06119074|OTHER|Gifted Savings|Gifted Savings assets will be in the form of cash, Bitcoin, and/or stock. Participants will receive identical asset portfolios. The asset mix will be determined by Gifted Savings. Participants will not have any control over the assets they receive, nor the proportion of each in their account. After registration on the Gifted Savings website, participants can immediately withdraw $100 USD if they choose. Then, for each of the first two years, participants may withdraw up to $500 USD for an emergency (self-attested) if the value of the account is 50% or more of its value 30 days prior and the account has sufficient funds to fulfill the request. Two years post-enrollment, participants may withdraw the entire value of their GS account or continue holding the assets in their GS account (in perpetuity or until the GS non-profit ceases to exist). GS funds are unconditional; there are no restrictions or limitations on how the money can be spent.
58104021|NCT00990028|DRUG|Rosuvastatin|20 mg oral, for 10 days
58104022|NCT00990028|DRUG|Placebo|20 mg vehicle
58104023|NCT03724968|DRUG|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
58104024|NCT03724968|DRUG|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
58309727|NCT02530775|PROCEDURE|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
58104025|NCT03724968|DRUG|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
58104026|NCT01162018|PROCEDURE|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
58104027|NCT01162018|OTHER|placebo|
58104028|NCT00366678|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
58104029|NCT00366678|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
58434607|NCT03863808|OTHER|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
58104030|NCT00366678|DRUG|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
58104031|NCT03687437|DIAGNOSTIC_TEST|Blood sample|Complete blood count
58104032|NCT02071758|BIOLOGICAL|LEISH-F3 + SLA-SE|
58104033|NCT02071758|BIOLOGICAL|LEISH-F3 + GLA-SE|
58104034|NCT01931137|DRUG|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
58104035|NCT05357781|DIAGNOSTIC_TEST|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
58104036|NCT04974359|DRUG|Lu AG06466|Lu AG06466 - capsules
58104037|NCT04974359|DRUG|Placebo|Placebo - capsules
58104038|NCT01140620|DRUG|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
58104039|NCT01140620|DRUG|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
58104040|NCT01140620|DRUG|saline|saline infusion. Duration approximately 3 hours
58104041|NCT01140620|DRUG|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
58104042|NCT06567587|DRUG|Dexmedetomidine|Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
58104043|NCT06567587|DEVICE|BIPAP|Put exaggerated COPD patients on non invasive ventillation
58104044|NCT02830230|DRUG|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
58104045|NCT02594345|OTHER|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
58104046|NCT00524576|BIOLOGICAL|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
58104047|NCT03764553|DRUG|Liposomal Irinotecan|Iv liposomal irinotecan
58309728|NCT02530775|PROCEDURE|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
58309729|NCT04741048|DEVICE|CI624 Slim 20 Electrode|Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
58104048|NCT03764553|DRUG|Carboplatin|IV Carboplatin
58104049|NCT03764553|DRUG|Capecitabine|PO Capecitabine
58104050|NCT03764553|DRUG|Oxaliplatin|IV Oxaliplatin
58104051|NCT03764553|DRUG|5-fluorouracil|IV 5-fluorouracil
58104052|NCT03764553|DRUG|Leucovorin|IV Leucovorin
58104053|NCT05180344|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
58104054|NCT02424656|PROCEDURE|MRI|EEG-functional MRI, structural MRI, diffusion MRI
58104055|NCT02424656|PROCEDURE|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
58104056|NCT02424656|PROCEDURE|FDG-PET|
58104057|NCT02424656|OTHER|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
58104058|NCT04931147|DRUG|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
58104059|NCT04931147|DRUG|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
58104060|NCT03125629|DRUG|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
58309730|NCT00453687|DRUG|GSK233705|investigational drug
58309731|NCT04725669|DIAGNOSTIC_TEST|ELISA IgG Testkit|All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
58309732|NCT04865809|OTHER|Peribioma Toothpaste and Mousse|Use of Peribioma Toothpaste and Mousse for home oral care.
58104061|NCT03125629|DRUG|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
58104062|NCT03125629|DEVICE|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
58104063|NCT03125629|DEVICE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
58104064|NCT04397250|BEHAVIORAL|High-intensity interval training|Arm-cranking exercise
58104065|NCT04821492|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD expressed in absolute values as g/cm2 and T-scores
58104066|NCT00120068|BEHAVIORAL|Nursing inservices|
58104067|NCT00120068|PROCEDURE|Academic detailing to MDs; concurrent review and feedback|
58104068|NCT02068404|DRUG|Nifedipine|
58104069|NCT06272370|OTHER|Asthma Symptom Monitoring online tools|All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above
58104070|NCT06272370|DRUG|Inhaled Steroids|participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
58434608|NCT00588354|DRUG|Clonidine|200 or 400 micrograms clonidine
58434609|NCT00588354|DRUG|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
58434610|NCT00588354|DRUG|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
58434611|NCT00989963|DRUG|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
58434612|NCT03042884|BEHAVIORAL|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
58434613|NCT03042884|DEVICE|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
58309733|NCT04865809|OTHER|Standard toothpaste|Use of Biorepair Plus Parodontgel for home oral care
58434614|NCT00196456|PROCEDURE|photosensitisation|
58434615|NCT02399657|DRUG|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
57769623|NCT00366301|DRUG|Insulin glargine injection|Once daily for 14 weeks
58104071|NCT06272370|DRUG|Azithromycin Pill|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
58104072|NCT02107937|BIOLOGICAL|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
58104073|NCT02107937|BIOLOGICAL|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
58104074|NCT02107937|DRUG|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
58104075|NCT01255696|BIOLOGICAL|ALV003|
58309734|NCT06032806|OTHER|moderate intensity|"* Arm circles~* Leg swings~* Lunges"
58434616|NCT00258323|DRUG|cisplatin|20mg/m2d/IV continuous infusion x days
58434617|NCT00258323|DRUG|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
58434618|NCT00258323|DRUG|Iressa|250mg po qd days 1-28 then x 2 years
58434619|NCT00258323|PROCEDURE|conventional surgery|conventional surgery
58434620|NCT00258323|RADIATION|radiation therapy|150 cGy bid
58434621|NCT00514371|DRUG|tanespimycin|High dose
58434622|NCT00514371|DRUG|Bortezomib|Mid dose, and low dose
58434623|NCT05304897|PROCEDURE|PRP treatment|PRP treatment for bronchopleural fistula
58434624|NCT04213716|COMBINATION_PRODUCT|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
58434625|NCT04213716|COMBINATION_PRODUCT|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
58434626|NCT05901883|DRUG|CEL383|Subjects will receive CEL383
58434627|NCT05901883|DRUG|Placebo|Subjects will receive placebo
58434628|NCT05131191|DIAGNOSTIC_TEST|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
58434629|NCT05131191|PROCEDURE|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
58434630|NCT05025878|DIETARY_SUPPLEMENT|[U-13C]Glucose|Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
58434631|NCT06148506|OTHER|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
58434632|NCT06148506|OTHER|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
58434633|NCT03465267|DEVICE|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
58434634|NCT03465267|DEVICE|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
58434635|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
58434636|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
58434637|NCT02585921|BEHAVIORAL|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
58434638|NCT02585921|BEHAVIORAL|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
58104076|NCT01255696|BIOLOGICAL|ALV003 placebo|
58434639|NCT01239823|OTHER|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
58434640|NCT01239823|OTHER|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
58434641|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt and Suspenders|Endoscopic sleeve gastroplasty using belt and suspender plications.
58434642|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt|Endoscopic sleeve gastroplasty using belt only plications.
58104077|NCT02280642|BIOLOGICAL|Both 2nd and 3rd doses on time|
58104078|NCT02280642|BIOLOGICAL|2nd dose late and 3rd dose on time|
58104079|NCT02280642|BIOLOGICAL|2nd dose on time and 3rd dose late|
58104080|NCT02280642|BIOLOGICAL|Both doses late|
58104081|NCT00393835|DRUG|Azithromycin SR|
58104082|NCT04267016|DIAGNOSTIC_TEST|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
58104083|NCT03522090|DIAGNOSTIC_TEST|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
58309735|NCT06032806|OTHER|High intensity|"* Arm circles~* Leg swings~* Lunges~* Butt kicks"
58309736|NCT03147326|DIAGNOSTIC_TEST|FDG-PET-CT|scanning method
57769624|NCT00366301|DRUG|metformin|Up to 4 pils per day (2g per day) maximum
57769625|NCT00366301|DRUG|Placebo pill|Up to 4 pills per day
57769626|NCT01024959|OTHER|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
58309737|NCT03147326|DIAGNOSTIC_TEST|NaF-PET-CT|scanning method
58434643|NCT05466357|PROCEDURE|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
58434644|NCT03322917|BIOLOGICAL|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
58434645|NCT05252663|PROCEDURE|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
58434646|NCT05252663|PROCEDURE|Traditional chest physiotherapy|postural drainage - percussion
58434647|NCT01023672|DRUG|Armodafinil|150-250 mg armodafinil by mouth daily
58434648|NCT02736565|BIOLOGICAL|pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex|"Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks."
58434649|NCT02307578|DRUG|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
58434650|NCT00815893|DRUG|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
58434651|NCT00815893|DRUG|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
58434652|NCT00815893|DRUG|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
58434653|NCT03107494|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
58434654|NCT02008773|DRUG|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
58434655|NCT02008773|DRUG|placebo|placebo capsules 6/day oral for 16 weeks
58434656|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
58434657|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
58434658|NCT01371734|DRUG|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
58434659|NCT02451462|DRUG|Zoledronic acid|
58434660|NCT00996983|DRUG|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
58434661|NCT00139555|DRUG|amlodipine/benazepril|
58434662|NCT05691114|BIOLOGICAL|hAESCs|human Amniotic Epithelial Stem Cells
58434663|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
58434664|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
58309738|NCT03147326|DIAGNOSTIC_TEST|Whole-body MRI|scanning method
58434665|NCT05938673|OTHER|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
58434666|NCT05938673|OTHER|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
58434667|NCT05049109|BEHAVIORAL|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
57737901|NCT06393049|OTHER|Hyperglycaemic clamp|"Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L."
57954087|NCT06077266|OTHER|Change of weight class to normal weight|The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
57954088|NCT01445951|DRUG|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
58434668|NCT05049109|BEHAVIORAL|Usual post-stroke follow-up care|"* 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
58434669|NCT02075892|DIETARY_SUPPLEMENT|Mushroom Blend|Scivation
58434670|NCT02075892|DIETARY_SUPPLEMENT|Placebo|
58434671|NCT03137329|BEHAVIORAL|Exercise program|Physical therapy for aerobic and resistance training exercises
58434672|NCT03137329|DIETARY_SUPPLEMENT|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
58434673|NCT03137329|PROCEDURE|WLS|Weight loss surgery as planned
58104084|NCT00769782|PROCEDURE|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
58434674|NCT02489669|DEVICE|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
58434675|NCT00006158|DRUG|Testosterone|
58434676|NCT04836884|PROCEDURE|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
58104085|NCT00646152|DRUG|Poly-ICLC|
58104086|NCT00878449|DRUG|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
58104087|NCT00878449|DRUG|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
58104088|NCT00197184|BIOLOGICAL|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
58104089|NCT00197184|BIOLOGICAL|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
58104090|NCT01183845|PROCEDURE|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
58104091|NCT00765466|DRUG|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
58104092|NCT00879424|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
58104093|NCT00879424|DIETARY_SUPPLEMENT|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
58104094|NCT00191620|DRUG|Gemcitabine|
58104095|NCT00191620|DRUG|cisplatin|
58434677|NCT00801398|DRUG|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
58434678|NCT05268172|DRUG|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
58434679|NCT02401451|DEVICE|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
58434680|NCT05670418|DEVICE|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
58434681|NCT04031989|DEVICE|CorVista Capture|The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
58434682|NCT01743742|DRUG|Vitamin E, Vitamin C|
57954089|NCT01445951|DRUG|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
57954090|NCT01445951|DRUG|Insulin Aspart in combination with a basal insulin|Injectable insulin
58104096|NCT02914496|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
58104097|NCT06242873|OTHER|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
58434683|NCT02366156|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
58434684|NCT02366156|DIETARY_SUPPLEMENT|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
58434685|NCT02366156|DIETARY_SUPPLEMENT|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
58434686|NCT05927363|OTHER|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
58434687|NCT05927363|OTHER|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
58434688|NCT05927363|OTHER|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
58434689|NCT05927363|OTHER|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
58434690|NCT05927363|OTHER|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
58434691|NCT05927363|DIAGNOSTIC_TEST|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
58434692|NCT05927363|DIAGNOSTIC_TEST|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
58434693|NCT05927363|DEVICE|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
58434694|NCT05927363|OTHER|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
58434695|NCT05318872|DEVICE|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
58434696|NCT06477185|DRUG|Doxycycline|Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
58434697|NCT06477185|DRUG|Placebo|This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
58434698|NCT04481061|GENETIC|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
58434699|NCT00933465|DRUG|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
57737902|NCT05374421|DEVICE|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
58104098|NCT05852587|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
58104099|NCT05852587|DRUG|Placebo|The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
57737903|NCT05374421|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
58104100|NCT04737915|BEHAVIORAL|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
58104101|NCT04737915|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
58104102|NCT02686489|OTHER|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
58104103|NCT02686489|OTHER|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
58104104|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
58104105|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
58104106|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
58104107|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
58104108|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
58434700|NCT00933465|DRUG|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
57737904|NCT05735873|OTHER|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
57737905|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
57737906|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
57737907|NCT04810598|DRUG|Venetoclax|Oral Tablet
58434701|NCT06507488|DRUG|Daphnetin Capsule|Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
58434702|NCT06507488|DRUG|Placebo|The placebo is a Daphnetin Capsule simulants
57737908|NCT03595904|BEHAVIORAL|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
58104109|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
58104110|NCT05496595|DRUG|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
58104111|NCT01283711|DEVICE|apollo device|RF treatments for wrinkles and rhytides reduction
58434703|NCT00357617|DRUG|celecoxib|
58104112|NCT05805774|PROCEDURE|Distal Femur Replacement|Knee surgery to remove the lower part of the femur and knee joint (where the broken bones are) and will replace them with an artificial knee joint (prosthesis).
58434704|NCT00357617|GENETIC|microarray analysis|
58434705|NCT00357617|GENETIC|protein expression analysis|
58104113|NCT05805774|PROCEDURE|Surgical fixation|Knee surgery to fix the fracture, that can use wires, nails, screws, pins or plates to health and fix the bones together.
58434706|NCT00357617|OTHER|immunoenzyme technique|
58104114|NCT02972970|DEVICE|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
58104115|NCT00012194|DRUG|7-hydroxystaurosporine|Given IV
58104116|NCT00012194|DRUG|cisplatin|Given IV
58104117|NCT00012194|OTHER|laboratory biomarker analysis|Correlative studies
58434707|NCT00357617|OTHER|immunohistochemistry staining method|
58434708|NCT00357617|OTHER|laboratory biomarker analysis|
58434709|NCT00357617|PROCEDURE|biopsy|
58434710|NCT00357617|PROCEDURE|conventional surgery|
58434711|NCT00357617|PROCEDURE|neoadjuvant therapy|
58434712|NCT00429169|DRUG|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
58434713|NCT00429169|DRUG|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
58434714|NCT03193710|DRUG|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
58434715|NCT03193710|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
58434716|NCT03193710|DRUG|Remifentanil|Remifentanil will be used for analgesia in both groups.
58434717|NCT03888729|DRUG|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
58104118|NCT03124797|DEVICE|RD DCI Sensor|Noninvasive pulse oximeter sensor
58104119|NCT03264066|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
58434718|NCT03888729|DRUG|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
58434719|NCT02522325|DRUG|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
58434720|NCT02522325|DRUG|Cocaine|Intranasal cocaine will be administered during experimental sessions.
58434721|NCT02522325|DRUG|Placebo|Placebo capsules will contain only cornstarch.
58104120|NCT03264066|DRUG|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
58104121|NCT03264066|DRUG|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
58434722|NCT04720742|DRUG|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
58434723|NCT03680443|OTHER|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
58434724|NCT04036812|PROCEDURE|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
58434725|NCT04036812|OTHER|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
58434726|NCT01505439|DRUG|solifenacin|oral
58434727|NCT05297513|DRUG|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
58434728|NCT05884775|OTHER|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
58434729|NCT06176638|BEHAVIORAL|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
58434730|NCT05191108|BEHAVIORAL|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
58434731|NCT01867086|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
58434732|NCT01867086|DRUG|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
58434733|NCT01867086|DRUG|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
58434734|NCT04267055|DEVICE|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
58434735|NCT04501796|DRUG|Double-Blind NT-I7|Administered by intramuscular (IM) injection
58434736|NCT04501796|DRUG|Double-Blind Placebo|Placebo
58434737|NCT05160376|OTHER|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
58309739|NCT05968105|PROCEDURE|Lateral Sagittal Infraclavicular Block|Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
58309740|NCT05968105|PROCEDURE|Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
58309741|NCT05968105|DIAGNOSTIC_TEST|Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
58104122|NCT03956511|OTHER|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
58104123|NCT02889536|OTHER|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
58104124|NCT01074307|DRUG|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
58434738|NCT05160376|OTHER|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
58434739|NCT00214058|DRUG|Carboplatin|
58434740|NCT00214058|DRUG|Docetaxel|
58434741|NCT05107622|OTHER|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
58434742|NCT05107622|OTHER|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
58434743|NCT04625764|PROCEDURE|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
58434744|NCT03691662|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
58434745|NCT03691662|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
58434746|NCT02085278|DEVICE|Apollo Micro Catheter device|Detachable Tip Micro catheter
58434747|NCT02794519|DRUG|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
58434748|NCT02794519|DRUG|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
58434749|NCT02794519|DRUG|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
58434750|NCT03262636|DRUG|Indocyanine Green|Indocyanine Green
58434751|NCT04414566|DRUG|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
58434752|NCT04414566|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
58104125|NCT01074307|DRUG|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
58104126|NCT05525637|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
58104127|NCT05525637|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
58104128|NCT05525637|DRUG|Placebo|Match placebo tablets, once daily in the evening
58434753|NCT04414566|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
58434754|NCT02930304|OTHER|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
58434755|NCT02930304|OTHER|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
58104129|NCT04156867|DEVICE|Dynesys|discectomy with Dynesys
58104130|NCT01794156|BEHAVIORAL|Cognitive behavior therapy|
58104131|NCT01794156|BEHAVIORAL|Mindfulness-based stress reduction|
57737909|NCT03595904|BEHAVIORAL|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
58104132|NCT01794156|BEHAVIORAL|Inference-based therapy|
58104133|NCT00493181|DRUG|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
58104134|NCT05103085|DIAGNOSTIC_TEST|Rapid diagnostic orientation test (TROD) for Hepatitis C|Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
58104135|NCT02917837|OTHER|Usual QCNL DI utilization report|See arm descriptions.
58104136|NCT02917837|OTHER|New DI utilization report|See arm descriptions.
58104137|NCT02917837|OTHER|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
58104138|NCT02932384|BEHAVIORAL|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
57737910|NCT00489606|DRUG|SK3530|
58309742|NCT02432599|RADIATION|F18-choline PET examination|F18-choline PET examination will be performed before surgery
58309743|NCT02105324|DEVICE|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
58434756|NCT02930304|OTHER|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
58434757|NCT03415438|DIAGNOSTIC_TEST|Visual Analogue Scale|intensity of pain perception patients feel
58434758|NCT03415438|DIAGNOSTIC_TEST|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
58434759|NCT03415438|DIAGNOSTIC_TEST|shortness tests for lumbar movements|tape measurement for lumbar movements
58434760|NCT03415438|DIAGNOSTIC_TEST|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
58434761|NCT03415438|DIAGNOSTIC_TEST|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
58434762|NCT03415438|DIAGNOSTIC_TEST|Modify Schober test|tape measurement of spinal flexion between designated regions
58434763|NCT03123016|DRUG|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
58434764|NCT03123016|PROCEDURE|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
57737911|NCT05261178|OTHER|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
58309744|NCT02105324|OTHER|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
58309745|NCT06115655|DIAGNOSTIC_TEST|cfDNA methylation detection|Extract cfDNA from bile and plasma, and perform methylation detection.
57737912|NCT04959370|DEVICE|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
57737913|NCT04959370|DEVICE|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
58309746|NCT03884010|OTHER|No intervention|Cross-sectional
58309747|NCT05063994|DRUG|Chronocort|Over-encapsulated hydrocortisone modified-release capsules for oral administration - 5mg and 10mg
58309748|NCT05063994|DRUG|Cortef|Over-encapsulated immediate-release hydrocortisone capsules for oral administration - 5mg and 20mg
58309749|NCT02979704|DRUG|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
58309750|NCT02979704|DRUG|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
58309751|NCT05307393|BEHAVIORAL|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
58309752|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
58309753|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
58104139|NCT02932384|BEHAVIORAL|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
58104140|NCT01422720|DRUG|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
58104141|NCT00123331|DRUG|Cyclosporine discontinuation|
58104142|NCT00123331|DRUG|Rapamycin medication|
58104143|NCT06542094|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
58104144|NCT00148928|BIOLOGICAL|P501-AS15 vaccine|
58104145|NCT00503932|PROCEDURE|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
58104146|NCT00503932|DRUG|Capecitabine|825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
58104147|NCT05262933|OTHER|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
58104148|NCT05262933|OTHER|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
58104149|NCT04739956|OTHER|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
58104150|NCT04739956|OTHER|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
58104151|NCT00457665|DRUG|Nelfinavir|
58104152|NCT00457665|DRUG|Efavirenz|
58104153|NCT04147611|DEVICE|BAHA|Participant's pediatric bone conduction hearing device.
58104154|NCT04147611|DEVICE|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
58104155|NCT04147611|DEVICE|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
58104156|NCT04147611|DEVICE|Hearing Aid|Participant's unilateral hearing aid with contralateral plug.
58104157|NCT00123487|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
58104158|NCT00123487|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
58104159|NCT01132235|BIOLOGICAL|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
58104160|NCT02543086|DRUG|KAE609|Study drug
58104161|NCT02543086|DRUG|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
58104162|NCT01386619|BIOLOGICAL|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
58104163|NCT02869828|DEVICE|Monitoring by arterial catheter and Spot-on|
58104164|NCT02869828|DEVICE|Monitoring by oesophagal probe and Spot-on|
58104165|NCT05506475|PROCEDURE|Blood samples|venous blood collected in a 5 mL EDTA tube
58104166|NCT03174041|DRUG|Midazolam|Single dose midazolam
58104167|NCT03174041|DRUG|GDC-0853|Multiple doses GDC-0853 for 6 days
58104168|NCT03174041|DRUG|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
58104169|NCT03174041|DRUG|Rosuvastatin|Single dose rosuvastatin
58104170|NCT03174041|DRUG|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
58104171|NCT03174041|DRUG|Simvastatin|Single dose simvastatin
58104172|NCT03174041|DRUG|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
58104173|NCT03174041|DRUG|GDC-0853|Single dose GDC-0853
58104174|NCT03174041|DRUG|Itraconazole|Multiple doses itraconazole for 6 days
58104175|NCT03174041|DRUG|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
58104176|NCT02120482|DEVICE|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
58104177|NCT02097368|PROCEDURE|tongue strength measurement|tongue strength measurement
58104178|NCT02097368|PROCEDURE|respiratory function measurement|respiratory function measurement
58104179|NCT02097368|PROCEDURE|swallowing tests|swallowing tests
58104180|NCT02097368|OTHER|Magnetic resonance imaging|Magnetic resonance imaging
58104181|NCT01770782|PROCEDURE|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
58104182|NCT01770782|OTHER|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
58104183|NCT02007369|BEHAVIORAL|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
58104184|NCT02007369|BEHAVIORAL|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
58104185|NCT03726437|BEHAVIORAL|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
58104186|NCT03726437|BEHAVIORAL|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
58104187|NCT01800669|OTHER|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
58104188|NCT01800669|OTHER|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
58104189|NCT02902666|DRUG|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
58104190|NCT02902666|DRUG|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
58104191|NCT00881049|DRUG|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
58104192|NCT00196443|DEVICE|urea contained compressing stockings|
58104193|NCT00196443|DEVICE|compressing stockings|
58104194|NCT05617573|PROCEDURE|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
58104195|NCT05474261|PROCEDURE|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
58104196|NCT03648086|OTHER|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
58104197|NCT03912688|DEVICE|acupoint stimulation|
58434765|NCT06576128|DEVICE|ultrasound|In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
57737914|NCT00922454|PROCEDURE|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
58104198|NCT03912688|DEVICE|single acupoint|
58104199|NCT03912688|DEVICE|dual acupoints|
58104200|NCT01774695|BEHAVIORAL|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
58434766|NCT06576128|PROCEDURE|parenteral local anesthesia|As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
58104201|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
58104202|NCT02184507|DIETARY_SUPPLEMENT|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
58104203|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
58104204|NCT02184507|DRUG|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
58104205|NCT06514924|OTHER|height and weight measurement|Height and weight measurements and socioeconomic status survey
58104206|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of extended release capsules
58104207|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
58104208|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
58104209|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
58104210|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
58104211|NCT06254391|DRUG|Low-dose aspirin|Implementation of low-dose aspirin (30 mg)
58104212|NCT05766215|BEHAVIORAL|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
58104213|NCT03843255|OTHER|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
58104214|NCT03843255|OTHER|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
58104215|NCT03285334|DEVICE|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
57737915|NCT00922454|DEVICE|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
57737916|NCT00922454|DEVICE|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
58104216|NCT03285334|DEVICE|iRace files|rotary mechanical preparation
58104217|NCT03151993|DRUG|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
58104218|NCT03151993|DRUG|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
57954091|NCT06463613|DEVICE|STR Skin Tag Removal device with diary and follow-up|The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.
57954092|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
58104219|NCT05472857|BIOLOGICAL|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
58104220|NCT00429468|DRUG|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
58104221|NCT02684669|DRUG|Naloxone|active drug infusion
57954093|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
58104222|NCT02684669|DRUG|Normal saline|placebo comparator
58104223|NCT05620238|DRUG|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
58104224|NCT00148694|DRUG|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
58104225|NCT02614885|DEVICE|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
58104226|NCT01373476|DRUG|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
58309754|NCT05598697|OTHER|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
58434767|NCT05809362|DEVICE|WHOOP 4.0 Strap|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
58104227|NCT01373476|DRUG|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
58104228|NCT04890704|DRUG|Curcuminoid|Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
58104229|NCT04890704|DRUG|Placebo|Identical capsules were used for the placebo from the same manufacturer.
58104230|NCT00701935|DRUG|placebo|subcutaneous injection, twice a day
58104231|NCT00701935|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
58104232|NCT03333460|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
58309755|NCT06134063|DRUG|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
58309756|NCT06134063|DRUG|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
58309757|NCT03938571|PROCEDURE|Duodenal Switch|
58309758|NCT00496561|BIOLOGICAL|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
58309759|NCT00496561|OTHER|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
58309760|NCT06550908|OTHER|Lutetia Training Plattform|Training platform Lutetia offers training the Paris classification using real or artificial images of colon polyps.
58309761|NCT00671268|BIOLOGICAL|AL0704rP|strict subcutaneous
58104233|NCT01004900|PROCEDURE|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
58104234|NCT01004900|DRUG|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
58104235|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
58104236|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 3, single dose
58104237|NCT01387308|DRUG|Fostamatinib|Oral tablets, 100 mg, single dose
58104238|NCT01387308|DRUG|Fostamatinib|Oral tablets, 150 mg, single dose
58104239|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
58104240|NCT01528566|BEHAVIORAL|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
58104241|NCT01528566|BEHAVIORAL|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
58104242|NCT06438237|PROCEDURE|Bowel preparation before colonoscopy|Patients use purgative for bowel cleansing before colonoscopy.
58104243|NCT04515511|OTHER|4% gelatin|Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
58104244|NCT04711278|DEVICE|Mask-wearing hypnosis|"Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient."
58104245|NCT04711278|OTHER|Without hypnosis|No hypnosis during surgery of Hallux valgus.
58104246|NCT01168882|DRUG|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
58104247|NCT05676138|OTHER|Measuring PK and PD indices in patients who receive conventional treatment|Measuring plasma concentration of commonly used antibiotics in NTM-PD
58104248|NCT01168128|OTHER|Tailored Change Strategy|e.g. Education, decision support tools
58104249|NCT05529719|OTHER|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
58104250|NCT05233774|DRUG|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
58104251|NCT05233774|OTHER|Placebo|Placebo
58104252|NCT05139173|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
58104253|NCT04397354|DRUG|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
58104254|NCT04397354|DRUG|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
58104255|NCT04397354|DRUG|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
58104256|NCT02038400|DEVICE|KINETUBE medical Device|
58104257|NCT02038400|DEVICE|insertion of tympanic ventilation tubes (tympanostomy)|
58104258|NCT03479242|OTHER|no interventions|no interventions are planned
58104259|NCT02887482|BIOLOGICAL|GLS-5700|GLS 5700 at 2 mg DNA/dose
57737917|NCT02526693|DIAGNOSTIC_TEST|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
57737918|NCT00989287|BIOLOGICAL|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
58104260|NCT02887482|BIOLOGICAL|Placebo|
58104261|NCT02744625|DRUG|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
58104262|NCT02744625|DRUG|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
58104263|NCT02744625|DRUG|Propofol for light sedation|Propofol for light sedation
58104264|NCT03823677|PROCEDURE|Hypoxia|hypoxia
58104265|NCT00807625|DRUG|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
58104266|NCT00807625|DEVICE|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
58104267|NCT02402933|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
58104268|NCT04211272|DRUG|Macitentan|Macitentan will be administrated as film-coated tablet in Part A and Part B.
58104269|NCT04211272|DRUG|Sildenafil|Sildenafil will be administrated as film-coated tablet in Part A.
58104270|NCT04211272|DRUG|Riociguat|Riociguat will be administrated as film-coated tablet in Part A.
58104271|NCT04211272|DRUG|Rosuvastatin|Rosuvastatin will be administrated as film-coated tablet in Part B.
58104272|NCT02268331|OTHER|Active Surveillance|
58104273|NCT02268331|OTHER|Passive Surveillance|
58104274|NCT00729365|DRUG|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
58104275|NCT00729365|DRUG|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
58434768|NCT05809362|DEVICE|BioTel ePatch|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
58434769|NCT00707954|DRUG|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
58434770|NCT00707954|DRUG|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
58434771|NCT05595733|DEVICE|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
58434772|NCT04707300|DRUG|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
58434773|NCT00959127|DRUG|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
58434774|NCT03485521|PROCEDURE|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
58434775|NCT01895959|DRUG|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
58434776|NCT01895959|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
58434777|NCT04802187|OTHER|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
57954094|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent totally covers the deep femoral artery
57954095|NCT02033564|DEVICE|Macintosh/Miller Laryngoscope|
57954096|NCT02033564|DEVICE|Glidescope Laryngoscope|
57954097|NCT03884738|OTHER|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
57954098|NCT03884738|OTHER|Nordic Eccentric exercise|"1. st week - 1 day - 2 sets of 5 repeats.~2. nd week - 2 days - 2 sets of 6 repeats.~3. rd week - 3 days - 3 sets of 6-8 repeats.~4. th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
57954099|NCT03884738|OTHER|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
57954100|NCT01526902|DEVICE|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
57954101|NCT01526902|DEVICE|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
57954102|NCT02177201|OTHER|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
57954103|NCT02177201|OTHER|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
58104276|NCT00729365|DRUG|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
58104277|NCT01456585|OTHER|Gemcitabine|
58104278|NCT01456585|DRUG|CP-870,893|
58104279|NCT05626010|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
58104280|NCT05626010|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
57737919|NCT00989287|BIOLOGICAL|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
58104281|NCT04744064|DIETARY_SUPPLEMENT|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
57954104|NCT00743951|BEHAVIORAL|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
58434778|NCT04802187|OTHER|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
57737920|NCT05080166|OTHER|Interview with Clinicians|One time, qualitative interview of clinicians for feedback on UPLYFT intervention
57737921|NCT05080166|OTHER|Field Test of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors for feedback
57737922|NCT05080166|BEHAVIORAL|Pilot of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors
57954105|NCT00743951|BEHAVIORAL|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
57954106|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 3 mg/kg
57954107|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 15 mg/kg
57954108|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 30 mg/kg
57954109|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 0.3 mg/kg
57954110|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
57954111|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
57954112|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
58104282|NCT04494282|PROCEDURE|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
58104283|NCT06320899|DEVICE|SpineShape System IV straight rod elastic|Implantation of SpineShape System IV straight rod elastic
58309762|NCT00671268|BIOLOGICAL|Placebo|strict subcutaneous
58309763|NCT00930618|DRUG|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
58309764|NCT00930618|DRUG|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
58309765|NCT02830139|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
58309766|NCT02830139|PROCEDURE|Radical colorectal resection|radical colorectal resection with lymphadenectomy
58434779|NCT00495625|DRUG|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
58434780|NCT03024190|OTHER|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
58434781|NCT03024190|OTHER|stretching exercise|15- min stretching exercise for upper extremity twice daily
58434782|NCT03024190|OTHER|OT rehabilitation program|regular rehabilitation program for 3 weeks
58434783|NCT01499966|PROCEDURE|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
57737923|NCT00983073|DRUG|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
57737924|NCT03464227|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
57737925|NCT03464227|OTHER|Placebo|"* Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use"
57737926|NCT02430194|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
57737927|NCT02430194|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
57737928|NCT02430194|DRUG|Pegylated interferon-alfa-2a|immunomodulator
57737929|NCT05829161|BEHAVIORAL|no intervention|no intervention
57954113|NCT04194255|DIETARY_SUPPLEMENT|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
58309767|NCT02830139|DRUG|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
58309768|NCT02830139|DRUG|Normal saline , Cisplatin , 5-Fu|
58309769|NCT02365883|DEVICE|Photoacoustic Imaging System|manufactured by Endra
58309770|NCT05493631|BIOLOGICAL|MG1113|MG1113 subcutaneous (SC) injection
58434784|NCT01755455|DRUG|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
57954114|NCT02154282|BEHAVIORAL|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
58309771|NCT00366496|DEVICE|Acrysof single piece (SA60AT)|
58309772|NCT00366496|DEVICE|Acrysof IQ (SN60WF)|
58309773|NCT04420988|BIOLOGICAL|COVID-19 Convalescent Plasma|COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
58309774|NCT02328508|DEVICE|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
58309775|NCT01201863|DRUG|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
58309776|NCT01201863|OTHER|Placebo gel|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
58309777|NCT01515124|BEHAVIORAL|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
58434785|NCT01755455|DRUG|Placebo|Matching placebo capsule
58434786|NCT01555333|DRUG|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
58104284|NCT06320899|DEVICE|SpineShape System IV straight rod medium|Implantation of SpineShape System IV straight rod medium (mid-flex)
58104285|NCT06320899|DEVICE|SpineShape System IV straight rod stiff|Implantation of SpineShape System IV straight rod stiff (low-flex)
58104286|NCT05450042|DEVICE|SELUTION SLR DCB|Sirolimus DCB
58434787|NCT02400541|BEHAVIORAL|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
58309778|NCT01515124|BEHAVIORAL|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
58309779|NCT00311051|DRUG|ramatroban|
58309780|NCT00311051|DRUG|montelukast|
58309781|NCT00922636|DRUG|LY2216684|Taken in tablet form QD po.
58434788|NCT02400541|OTHER|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
58434789|NCT01251835|DRUG|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
58434790|NCT01251835|DRUG|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
58434791|NCT01251835|DRUG|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
57954115|NCT04286204|OTHER|Basic Life Support training based on ICTs|This intervention is defined as a self-training course consisting of a 5-minute educational video in basic life support and a Kit with the elements to build the home dummy and the home DEA allowing integrally students to develop the steps as the video. The Kit will be delivered at the beginning of the study and every month the necessary materials will be complemented. The strategy will be carried out by the students every month and supervised by their teachers. Students will have constant access to an educational platform based on ICTs.
57954116|NCT04286204|OTHER|Classic Basic Life Support training|It is defined as a module carried out by trained personnel in basic resuscitation (pre-hospital care program staff of the UdeA medical school), which includes two subcomponents of the conventional BLS course that are basic resuscitation and DEA in adults. The duration of the subcomponents is a theoretical part of 30 minutes and a practical part in a low fidelity simulator with 1.5 hours duration.
57954117|NCT04073771|DEVICE|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
57954118|NCT04213612|DRUG|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
58104287|NCT05450042|DEVICE|Paclitaxel DCB|Paclitaxel DCB
58104288|NCT05114265|DRUG|KUR-101|Single oral dose of KUR-101
58104289|NCT05114265|DRUG|OxyNorm|Single oral dose of OxyNorm
58104290|NCT05114265|DRUG|Placebo|Single oral dose of placebo
58104291|NCT04358731|BIOLOGICAL|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
58309782|NCT00922636|DRUG|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
58309783|NCT00922636|DRUG|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
58309784|NCT00922636|DRUG|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
58309785|NCT05791617|DIAGNOSTIC_TEST|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
58309786|NCT05791617|DIAGNOSTIC_TEST|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
58309787|NCT05791617|DIAGNOSTIC_TEST|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
58309788|NCT03355144|DIETARY_SUPPLEMENT|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
58309789|NCT00000552|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
58309790|NCT00000552|PROCEDURE|coronary artery bypass|
58309791|NCT00000552|DRUG|thrombolytic therapy|
58309792|NCT05414188|BEHAVIORAL|Pulmonary rehabilitation|Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
58309793|NCT01911832|PROCEDURE|esophagojejunostomy after total gastrectomy|
57769627|NCT05883917|PROCEDURE|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
57769628|NCT06320873|OTHER|archery respiratory parameters|Evaluation of respiratory functions, respiratory muscle strength and shooting performance in archers
57954119|NCT03098784|OTHER|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
57954120|NCT03098784|OTHER|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
57769629|NCT04699227|PROCEDURE|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
57769630|NCT04699227|OTHER|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
57954121|NCT00245362|BIOLOGICAL|CG 8020 and CG 2505|
57954122|NCT03363815|DRUG|CC-90001|CC-90001
57954123|NCT03363815|DRUG|Omeprazole|Omeprazole
57954124|NCT03363815|DRUG|Midazolam|Midazolam
57954125|NCT03363815|DRUG|Warfarin|Warfarin
57954126|NCT03363815|DIETARY_SUPPLEMENT|Vitamin K|Vitamin K
57954127|NCT03363815|DRUG|Rosuvastatin|Rosuvastatin
57954128|NCT03363815|DRUG|Metformin|Metformin
57954129|NCT03363815|DRUG|Digoxin|Digoxin
57954130|NCT03363815|DRUG|Nintedanib|Nintedanib
57954131|NCT00623428|DRUG|peginterferon alfa-2a|
57954132|NCT00623428|DRUG|Ribavirin|
57954133|NCT04922476|DIETARY_SUPPLEMENT|Alflorex®|Each probiotic capsule contains 1 x 10\^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
58104292|NCT04358731|BIOLOGICAL|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
58104293|NCT06383208|DIAGNOSTIC_TEST|lipid metabolomics|Extract 4 milliliters of fasting peripheral venous blood from enrolled patients for targeted lipid metabolism metabolomics research. Utilize a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system to conduct metabolomics analysis on patient blood samples.
58104294|NCT01016496|OTHER|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
58104295|NCT01016496|OTHER|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
58309794|NCT01911832|PROCEDURE|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
58309795|NCT01911832|PROCEDURE|wide tube reconstruction after subtotal gastrectomy|
58309796|NCT01911832|PROCEDURE|narrow tube reconstruction after subtotal gastrectomy|
58309797|NCT00338780|DRUG|Lamivudine/ Placebo 100mg daily|
58309798|NCT06195085|RADIATION|CT-guided radioactive iodine-125 seed implantation|The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
58309799|NCT06082440|BIOLOGICAL|Human Umbilical Mesenchymal Stem Cells|Ntra-articular injection inject a corresponding dose of cells suspension into each joint cavity according to the lesion site.
58104296|NCT04952441|BEHAVIORAL|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
58309800|NCT06330714|OTHER|Symptoms of chronic illness.|"The patient is advised to monitor BP and body weight daily in a standardized fashion as described below:~* Body weight should be measured in the morning without clothes or shoes after emptying the urinary bladder but before breakfast.~* BP should be measured in the morning preferably using the right arm, sitting comfortably in a chair after 5 minutes of rest in the seated position."
58309801|NCT03916666|PROCEDURE|Epiduroscopy|Endoscopic intervention
58309802|NCT02111018|DEVICE|CytoSorb Device|
58309803|NCT02111018|PROCEDURE|CVVH|
58309804|NCT03571035|DIAGNOSTIC_TEST|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
58309805|NCT06472479|BIOLOGICAL|LCAR-M61S cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
58309806|NCT06472479|BIOLOGICAL|LCAR-M61D cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
58309807|NCT02770703|DEVICE|DynaMesh visible mesh|Implantation of a MRI visible mesh
58309808|NCT00175227|DRUG|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
58309809|NCT00175227|DRUG|intravenous saline hydration|500 mls half-normal saline
58309810|NCT05267704|DEVICE|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
58309811|NCT03477656|PROCEDURE|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
58309812|NCT03477656|PROCEDURE|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
58309813|NCT06366789|DRUG|ZE46-0134|oral capsules QD
58309814|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
58309815|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
58309816|NCT02104440|BIOLOGICAL|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
58309817|NCT04887363|BEHAVIORAL|Core exercise|Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
58309818|NCT04887363|BEHAVIORAL|Tai Chi exercise|Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
58309819|NCT01120262|GENETIC|gene expression analysis|
58309820|NCT01120262|GENETIC|polymorphism analysis|
58309821|NCT01120262|OTHER|laboratory biomarker analysis|
58309822|NCT03095235|DIETARY_SUPPLEMENT|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
58309823|NCT03498677|BEHAVIORAL|presentation order|section presentation one
58309824|NCT03498677|BEHAVIORAL|alternative presentation order|section presentation two
58309825|NCT01242982|PROCEDURE|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
58309826|NCT01242982|PROCEDURE|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
58309827|NCT00306254|DRUG|PD 0348292|
58309828|NCT00306254|DRUG|Enoxaparin|
58309829|NCT04913831|DRUG|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
58309830|NCT04913831|DRUG|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
58309831|NCT04879368|DRUG|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
58309832|NCT04879368|BIOLOGICAL|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
58309833|NCT04879368|DRUG|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
57954134|NCT01617980|OTHER|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
58104297|NCT03605771|OTHER|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
58104298|NCT03364985|DRUG|DWP16001|DWP16001 tablets
58104299|NCT03364985|DRUG|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
58104300|NCT03364985|DRUG|Dapagliflozin|Forxiga®
58104301|NCT03882216|PROCEDURE|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
58104302|NCT03882216|PROCEDURE|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
58104303|NCT00139490|BEHAVIORAL|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
58104304|NCT00139490|BEHAVIORAL|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
58104305|NCT00139490|BEHAVIORAL|Control Group|Usual Care
58434792|NCT01184924|BEHAVIORAL|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
57954135|NCT00456989|DRUG|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
58104306|NCT03252132|OTHER|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
58309834|NCT04879368|DRUG|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
57954136|NCT00456989|DRUG|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
57954137|NCT00193063|DRUG|Trastuzumab|Trastuzumab
57954138|NCT00193063|DRUG|Gemcitabine|Gemcitabine
57954139|NCT01972048|BEHAVIORAL|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
57954140|NCT01972048|OTHER|Print brochure|Mailed print brochure about breast cancer screening and community resources.
57954141|NCT00879697|BEHAVIORAL|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
58104307|NCT00973856|OTHER|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
58434793|NCT04336033|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
58434794|NCT04336033|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
57954142|NCT00879697|BEHAVIORAL|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
57954143|NCT05852535|PROCEDURE|Exploration|abdominal exploration
57954144|NCT06203561|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
57954145|NCT06203561|BEHAVIORAL|comprehensive rehabilitation therapy|including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.
57954146|NCT06203561|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
57954147|NCT06203561|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
57954148|NCT00800332|DRUG|CYT003-QbG10|subcutaneous injection
57954149|NCT00800332|DRUG|Placebo|subcutaneous injection
57954150|NCT01991782|OTHER|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
58104308|NCT00973856|OTHER|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
58104309|NCT00092651|DRUG|MK0653A, ezetimibe (+) simvastatin|
58104310|NCT00092651|DRUG|Comparators: simvastatin and ezetimibe|
58104311|NCT00786266|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
58104312|NCT00786266|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
58104313|NCT05097378|DRUG|Encorafenib + Binimetinib|"Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity"
58104314|NCT05097378|DRUG|Standard Adjuvant Treatment|Standard Adjuvant Treatment
58104315|NCT02713243|DRUG|LJN452|Capsules containing LJN452
58434795|NCT04336033|OTHER|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
58434796|NCT02757118|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58434797|NCT02757118|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58434798|NCT04992845|DEVICE|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
58434799|NCT00714311|BEHAVIORAL|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
58434800|NCT00714311|BEHAVIORAL|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
58434801|NCT04373746|DEVICE|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
58434802|NCT05008198|OTHER|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
58434803|NCT01380834|DRUG|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
58434804|NCT01380834|DRUG|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
58434805|NCT01622465|BEHAVIORAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
58434806|NCT01622465|BEHAVIORAL|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
58434807|NCT03422965|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
58434808|NCT03422965|DIAGNOSTIC_TEST|Blood test|Blood test, systemic markers
58434809|NCT03422965|DIAGNOSTIC_TEST|Urine test|Urine test, systemic markers
58434810|NCT04224961|DEVICE|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
58434811|NCT03576911|DIETARY_SUPPLEMENT|Coenzyme Q10|
58434812|NCT03576911|OTHER|Placebo|
58434813|NCT04785924|DRUG|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
58434814|NCT01192308|DRUG|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
58434815|NCT02956798|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
58434816|NCT02371603|DRUG|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
58434817|NCT02371603|DRUG|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
58434818|NCT02371603|DRUG|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
58434819|NCT02371603|DRUG|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
58434820|NCT04764318|BEHAVIORAL|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
58434821|NCT04764318|BEHAVIORAL|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
58434822|NCT01834079|BIOLOGICAL|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
58434823|NCT05113381|DEVICE|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
58434824|NCT04736628|DRUG|Avenciguat|Avenciguat
58434825|NCT04736628|DRUG|Placebo|Placebo
58434826|NCT00005085|DRUG|becatecarin|
58434827|NCT04483336|OTHER|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
58434828|NCT04483336|OTHER|TV Screen Distraction|A cartoon video was played on a regular TV screen.
58434829|NCT02718716|DRUG|UCB7665|"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
58434830|NCT05169606|OTHER|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
58104316|NCT02713243|DRUG|Placebo to LJN452|Capsules containing placebo to LJN452
58434831|NCT05169606|OTHER|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
58434832|NCT05169606|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
58434833|NCT06256341|OTHER|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
58434834|NCT03796026|DRUG|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
58434835|NCT03796026|DRUG|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
58434836|NCT00883441|OTHER|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
58434837|NCT06256263|PROCEDURE|total laryngectomy|pharyngeal repair after total laryngectomy
58104317|NCT00765323|DRUG|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
58104318|NCT00765323|DRUG|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
58104319|NCT00283686|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
58104320|NCT00283686|DRUG|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
58434838|NCT03938506|OTHER|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
58434839|NCT03589027|DRUG|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
58434840|NCT03589027|DRUG|Rilpivirine|Oral ripilvirine 25mg once daily
57737930|NCT05916651|BEHAVIORAL|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
58104321|NCT00283686|DRUG|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
58434841|NCT03589027|DRUG|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
58434842|NCT03082092|DRUG|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
58434843|NCT03082092|DRUG|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
58434844|NCT03787797|DIAGNOSTIC_TEST|Echocardiography|Assessment of epicardial adipose tissue thickness
58434845|NCT06493240|RADIATION|radiation|45 Gy radiation dose in 25 fractions to the pelvis
58434846|NCT06493240|DRUG|PD-1 Monoclonal Antibody|200mg Sintilimab after radiation (3 times, 2-week interval)
58434847|NCT06493240|PROCEDURE|TME surgery|TME surgery for 6\~8 weeks after radiation
58434848|NCT06333366|DEVICE|Intra-gastrointestinal monitoring device (PDT)|The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
58434849|NCT04831177|PROCEDURE|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
58434850|NCT02754258|DRUG|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
58434851|NCT02754258|DRUG|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
58434852|NCT05856019|OTHER|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
57954151|NCT02519933|PROCEDURE|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
57954152|NCT02519933|PROCEDURE|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
57954153|NCT03809611|DRUG|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
57954154|NCT03809611|DRUG|Placebo|placebo
57954155|NCT05178238|OTHER|Fecal sample|Fecal sample taken to investigate intestinal microbiota
57954156|NCT01223703|DRUG|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
57954157|NCT01223703|DRUG|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
57954158|NCT02879565|OTHER|Semi structured interviews + EEG exams|
57954159|NCT04765800|BEHAVIORAL|weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy|according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
57954160|NCT01621633|DRUG|LCZ696|
57954161|NCT05985031|DIAGNOSTIC_TEST|Tendon tap|While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
57954162|NCT05985031|DIAGNOSTIC_TEST|Tibial nerve stimulation|H-reflex responses were examined by tibial nerve stimulation
58104322|NCT00283686|OTHER|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
58434853|NCT05856019|OTHER|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
58434854|NCT01092052|DRUG|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
58434855|NCT02251938|DRUG|DE-109 440 μg|Medium Dose
58434856|NCT06114927|BEHAVIORAL|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
58434857|NCT03442218|DRUG|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
58434858|NCT03442218|DRUG|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
58434859|NCT04920383|DRUG|ALPN-202|Various doses
58434860|NCT04920383|DRUG|pembrolizumab KEYTRUDA®|Varies
58434861|NCT06551935|BEHAVIORAL|Habitual sleep habits without intervention|Sleep habits maintenance
58434862|NCT06551935|BEHAVIORAL|Sleep extension and sleep hygiene|Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
58104323|NCT00283686|OTHER|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
58104324|NCT02476734|OTHER|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
58434863|NCT01800136|DEVICE|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
58434864|NCT04629651|DRUG|Captopril|Oral, to be administered per the dose escalation scheme.
58434865|NCT02669992|PROCEDURE|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
58434866|NCT02669992|PROCEDURE|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
58434867|NCT01813448|DRUG|Fidaxomicin|oral
58434868|NCT01813448|DRUG|Placebo|oral
58104325|NCT01389206|DRUG|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
58104326|NCT02015468|OTHER|Early mobilization|Early weightbearing and physiotherapy
58104327|NCT02015468|OTHER|Late mobilization|Late mobilization, none-weightbearing and home exercises
58104328|NCT00990119|DEVICE|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
58104329|NCT00990119|DEVICE|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
58104330|NCT00964223|DRUG|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
58104331|NCT00964223|DRUG|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
58104332|NCT03523507|DEVICE|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
58104333|NCT03523507|DEVICE|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
58434869|NCT02226887|PROCEDURE|MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit."
58434870|NCT02226887|PROCEDURE|NO MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit"
58434871|NCT02226887|RADIATION|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
58434872|NCT02226887|RADIATION|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
58434873|NCT02226887|OTHER|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
58434874|NCT02315560|DEVICE|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
58434875|NCT05299008|DRUG|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
58434876|NCT00859937|DRUG|Dasatinib|Given PO
58434877|NCT00859937|OTHER|Laboratory Biomarker Analysis|Correlative studies
58434878|NCT03748719|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
58434879|NCT05535829|OTHER|Laboratory analysis of samples|Laboratory analysis of samples
58434880|NCT03907150|DIAGNOSTIC_TEST|Strain ultrasound|Post-interpretation of recorded ultrasound loops
58434881|NCT01552356|OTHER|Laboratory Biomarker Analysis|Correlative studies
58434882|NCT01552356|DRUG|Pazopanib Hydrochloride|Given PO
58104334|NCT00673322|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
58104335|NCT03313479|DRUG|Dexmedetomidine|Dexmedetomidine will be given with GS
58434883|NCT01552356|OTHER|Pharmacological Study|Correlative studies
58434884|NCT02634502|PROCEDURE|radiofrequency ablation|
58434885|NCT02634502|DRUG|S-1|
58434886|NCT00927238|DEVICE|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
58434887|NCT00927238|OTHER|Lumbar fusion surgery|Lumbar fusion surgery
58434888|NCT06006117|DRUG|Mosunetuzumab + Lenalidomide|"* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
58434889|NCT06006117|DRUG|- Rituximab + Lenalidomide (28-days cycles|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
58434890|NCT06006117|DRUG|- Rituximab + Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
58309835|NCT04879368|DRUG|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
58434891|NCT06006117|DRUG|- Rituximab + CHOP (21-days cycles)|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
58434892|NCT01714401|DRUG|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
58434893|NCT01714401|DRUG|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
58434894|NCT03698123|OTHER|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
58434895|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
58434896|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
58434897|NCT02097654|OTHER|SENATOR software generated pharmacotherapy advice report.|
58434898|NCT05325346|DRUG|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
58434899|NCT05325346|DRUG|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
58434900|NCT03240770|DEVICE|VPro5 device|Use of the VPro5 device for 5 minutes a day
58104336|NCT04672057|OTHER|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
58309836|NCT04879368|DRUG|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
58309837|NCT04867759|PROCEDURE|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
58309838|NCT05423951|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
58309839|NCT05423951|DRUG|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
58434901|NCT03240770|OTHER|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
58434902|NCT02075788|OTHER|Commercial white bread|
58434903|NCT02075788|OTHER|Corn based products (porridge etc.)|
58434904|NCT02075788|OTHER|Millet based products (porridge etc.)|
58434905|NCT02595294|PROCEDURE|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
58434906|NCT05090852|DEVICE|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
58434907|NCT06017505|DIAGNOSTIC_TEST|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
58434908|NCT06257173|BEHAVIORAL|Education|The experimental group will receive 2 hours of patient safety training with a peer educator.
58434909|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
58104337|NCT05578222|DRUG|Pembrolizumab|Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
58309840|NCT05423951|DRUG|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
58434910|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
57954163|NCT06399887|OTHER|Exercise|All patients in these groups are taught diaphragmatic breathing, which is the basis for DNS, and are asked to maintain it throughout the exercises. The DNS protocol includes a 5-minute warm-up, 40 minutes of DNS exercises (10 minutes for each of the 4 different body parts) and breathing exercises. The DNS exercises included diaphragmatic breathing, Baby Rock, Roll Over, Lying on the Side, Sitting Down, Sitting Upright, Tripod, Kneeling, Squatting, Prone, and Pull Up (CGU). The focus of the first week is to teach and practice basic DNS exercises.
57954164|NCT06399887|OTHER|Biofeedback|Patients in Group II and Group III will be trained in animated CP using the Aymed Medical Locum Wireless System v.2.69.0.12 device. During CP, 10-second contraction and 30-second relaxation cycles are maintained throughout the animated game. Each session will last approximately 20 minutes. The training protocol will consist of a total of 12 sessions of 20 minutes per week for 3 months.
57954165|NCT02152852|BEHAVIORAL|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
57954166|NCT00533442|DRUG|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
57954167|NCT00533442|DRUG|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
57954168|NCT00533442|DRUG|Tacrolimus|Part of standard maintenance.
57954169|NCT00533442|DRUG|Steroids|Part of standard maintenance
57954170|NCT02915081|OTHER|Blue light|"Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
57954171|NCT02739607|BEHAVIORAL|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
57954172|NCT03048929|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
57954173|NCT03048929|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
57954174|NCT05026398|DRUG|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
57954175|NCT05026398|OTHER|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
57954176|NCT05286970|DRUG|AK115|Abdominal subcutaneous injection
57954177|NCT05286970|DRUG|Placebo|Abdominal subcutaneous injection
57954178|NCT02034890|DRUG|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
57954179|NCT00776607|DRUG|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
58104338|NCT00002594|BIOLOGICAL|Sargramostim|Given IV
58104339|NCT00002594|DRUG|cyclophosphamide|Given IV
58104340|NCT00002594|DRUG|melphalan|Given IV
58104341|NCT00002594|PROCEDURE|autologous bone marrow transplantation|
58104342|NCT00002594|PROCEDURE|bone marrow ablation with stem cell support|
58104343|NCT00002594|PROCEDURE|peripheral blood stem cell transplantation|
58309841|NCT05423951|DRUG|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
58434911|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
58434912|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
58434913|NCT02376972|DRUG|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
58434914|NCT02376972|DRUG|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
58434915|NCT04292314|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
58434916|NCT04292314|DRUG|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
58434917|NCT04292314|DRUG|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
58434918|NCT04292314|DRUG|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
58434919|NCT04292314|DRUG|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
58434920|NCT04292314|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
58434921|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
58434922|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
58434923|NCT03736876|BEHAVIORAL|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
58434924|NCT06393179|OTHER|pressure-volume curve with a low-flow insufflation of 5 L/min|The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
58434925|NCT03267888|BIOLOGICAL|Pembrolizumab|Given 200 mg IV.
58434926|NCT03267888|RADIATION|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
58434927|NCT00516256|BEHAVIORAL|CHESS System|Internet-based computer program for 6 months.
58434928|NCT00516256|BEHAVIORAL|Cancer Information Mentor|Phone calls to the patient for 6 months.
58434929|NCT03795727|DEVICE|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
58434930|NCT03795727|DEVICE|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
58434931|NCT06402032|OTHER|Hesperidin|Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.
58434932|NCT06402032|OTHER|Mineral Trioxide Aggregate (MTA)|Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
58434933|NCT03263260|DEVICE|implant|coronary stent implantation
58434934|NCT02846701|DRUG|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
57954180|NCT00776607|DRUG|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
57954181|NCT02702765|PROCEDURE|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
57954182|NCT02702765|PROCEDURE|Ultrasound|Ultrasound is a non-invasive procedure
57954183|NCT02702765|DRUG|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
58104344|NCT06541717|OTHER|Video-Based Fertility Awareness Training|Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
58104345|NCT02052037|DIETARY_SUPPLEMENT|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
58104346|NCT02052037|DIETARY_SUPPLEMENT|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
58104347|NCT02758587|DRUG|Defactinib|cross reference with arm/group descriptions
58434935|NCT05926024|BEHAVIORAL|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
57954184|NCT02702765|PROCEDURE|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
57954185|NCT02702765|PROCEDURE|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
57954186|NCT00069498|DRUG|5-aminosalicylic acid|
58104348|NCT02758587|DRUG|Pembrolizumab|cross reference with arm/group descriptions
58104349|NCT00923728|DRUG|AVN944|
58104350|NCT05818631|DIAGNOSTIC_TEST|fusion cognitive prostate biopsy|A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
58104351|NCT05122962|DIAGNOSTIC_TEST|Remote Heart Rhythm Monitoring|We will be looking to see if remote heart rhythm monitoring for 30 days at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.
58104352|NCT05564702|OTHER|traditional drug treatment|The patients in this arm will be given doctor specified dosage.
58104353|NCT05564702|OTHER|Opt-IVF predicted dosage|The patients in this arm will be given dosage predicted by Opt-IVF.
58104354|NCT06345742|OTHER|No parental participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Diaper care will be performed by the primary nurse.~4. Premature Infant Comfort Scale will be evaluated during and after the diaper care application."
58104355|NCT06345742|OTHER|Mother participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Mothers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Mothers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the mothers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
58434936|NCT05926024|BEHAVIORAL|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
57954187|NCT06103201|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
57954188|NCT01500109|DRUG|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
57954189|NCT01500109|DRUG|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
57954190|NCT01500109|DRUG|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
57954191|NCT04523077|DIAGNOSTIC_TEST|determination of thyroid hormones and antibodies|TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
57954192|NCT00094978|DRUG|Depsipeptide|
57954193|NCT00094978|DRUG|Flavopiridol (alvocidib)|
57954194|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 1|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
57954195|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 2|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
57954196|NCT01836783|OTHER|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
58434937|NCT05926024|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
58434938|NCT05926024|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
58434939|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
58434940|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
58434941|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
58434942|NCT05926024|BEHAVIORAL|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
58434943|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
58434944|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
58434945|NCT05926024|DIAGNOSTIC_TEST|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
58434946|NCT05463523|DEVICE|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
58434947|NCT02275156|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
58434948|NCT04615039|DEVICE|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
58434949|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
57954197|NCT01836783|OTHER|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
57954198|NCT01432691|PROCEDURE|Hemi (hemialloplastik)|THA vs hemi
58434950|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
58434951|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
58434952|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
58434953|NCT00235716|DRUG|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
58434954|NCT02416895|OTHER|In vivo immunity model|A measure of in vivo immune function.
58434955|NCT02051322|DEVICE|Jet Nebulizer|
58434956|NCT02051322|DEVICE|Trunk Mask Nebulizer|
58434957|NCT02051322|DEVICE|Aerobika Nebulizer|
58434958|NCT03672058|OTHER|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
58434959|NCT03672058|OTHER|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
58434960|NCT04752358|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
58434961|NCT01252030|DEVICE|physical activity monitors|physical activity monitors
58434962|NCT01252030|OTHER|No physical activity monitors|No physical activity monitors
58434963|NCT06060587|DRUG|Docetaxel|75 mg/m2 via IV
58434964|NCT06060587|DRUG|ADT|Prior to randomization as part of standard of care.
58434965|NCT06060587|DRUG|Abiraterone|1000 mg by mouth
58434966|NCT05492201|DRUG|LY3873862|Administered orally.
58434967|NCT05492201|DRUG|Placebo|Administered orally.
58434968|NCT05894785|PROCEDURE|External cephalic version|An ECV attempt is made on the study group
58434969|NCT00461279|BEHAVIORAL|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
58434970|NCT00461279|BEHAVIORAL|Interpersonal Psychotherapy|Established psychotherapy for depression
58434971|NCT03771950|BEHAVIORAL|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
58434972|NCT00083005|DRUG|docetaxel|
58434973|NCT00083005|DRUG|estramustine phosphate sodium|
57954199|NCT05372523|DIAGNOSTIC_TEST|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
58309842|NCT02426099|DRUG|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
58434974|NCT00083005|DRUG|thalidomide|
58434975|NCT05793242|DEVICE|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
58309843|NCT02426099|OTHER|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
58309844|NCT04077762|PROCEDURE|Radial Access|Radial Access
58309845|NCT04077762|PROCEDURE|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
58309846|NCT04077762|PROCEDURE|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
58309847|NCT00275652|DRUG|LdT (Telbivudine) and lamivudine|
58309848|NCT05198141|DRUG|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
58309849|NCT05198141|PROCEDURE|laparoscopic salpingectomy|laparoscopic salpingectomy
58309850|NCT00257790|DRUG|Tobramycin once a day|
58309851|NCT02859883|DEVICE|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
58434976|NCT05793242|DEVICE|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
57737931|NCT05916651|BEHAVIORAL|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
57737932|NCT06636526|GENETIC|The i4i PRODICT™ test.|The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
57737933|NCT06636526|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all participants identified as high risk from the i4i PRODICT™ test for three years in order to track development of cancer in the future.
57737934|NCT06636526|PROCEDURE|MRI Scan|MRI scan will be offered to participants identified in the high-risk category of the i4i PRODICT™ test depending on their PSA test results. Where PSA is above age-specific threshold (\&gt;2.5ug/L for people with prostates (PwPs) aged 40-50 years and \&gt;3.5ug/L for PwPs aged 50-55 years), those with raised PSA levels will be referred for multiparametric MRI at The Royal Marsden Hospital.
57954200|NCT05372523|DIAGNOSTIC_TEST|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
58434977|NCT05793242|DEVICE|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
58434978|NCT05793242|OTHER|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
58434979|NCT04649684|DEVICE|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
58434980|NCT04649684|DEVICE|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
58434981|NCT03533244|DRUG|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
58434982|NCT03533244|DRUG|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
58434983|NCT03533244|DRUG|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
58104356|NCT06345742|OTHER|Father participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Fathers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Fathers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the fathers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
58104357|NCT01850303|DRUG|Pemetrexed|
58104358|NCT01850303|DRUG|Gemcitabine|
58104359|NCT01850303|DRUG|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
57737935|NCT06636526|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to to participants identified in the high-risk category of the i4i PRODICT™ test depending on their MRI results. Where a lesion is visible on MRI (defined as a PIRAD score ≥3) onward referral will be made for a transperineal targeted prostate biopsy (or current gold standard NHS practice).
57737936|NCT01695967|PROCEDURE|turbinate cauterization|
57737937|NCT06164626|PROCEDURE|Extraction|extraction: in all groups, extraction will be performed
57737938|NCT06164626|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
57737939|NCT06164626|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
58104360|NCT02958748|OTHER|taking blood sample|
58104361|NCT03191019|BEHAVIORAL|Mobile-phone app for smoking cessation|Android App for smoking cessation
58104362|NCT01135108|DRUG|Placebo|Placebo IV Infusion
58104363|NCT01135108|DRUG|KAI-1678|KAI-1678 IV Infusion
58104364|NCT04590898|DEVICE|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
58104365|NCT04062461|OTHER|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
58104366|NCT04062461|OTHER|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
58104367|NCT02760784|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
58104368|NCT06098222|BEHAVIORAL|Slow breathing exercise training|Slow breathing exercise training will be given by the researcher in a single one-hour session in the meeting room of the unit 24 hours after the PCI and/or the next day. After a 20-minute silent rest in the training, patients will be asked to breathe slowly through the nostrils for 4 seconds and slowly exhale through the mouth for 6 seconds to reach 6-8 breaths/min. The patient will rest for 5 seconds after every 6 slow breaths. During the training period, a stopwatch will be used by observing the patient's chest and abdominal movements in order to determine whether the patients have reached the required respiratory rate.
58104369|NCT03474289|DRUG|SHR-1316|Monotherapy
57737940|NCT02891187|BEHAVIORAL|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
57737941|NCT02891187|BEHAVIORAL|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
58104370|NCT01669668|PROCEDURE|radiofrequency ablation|Undergo RFA
58104371|NCT01669668|PROCEDURE|laparoscopy|Undergo laparoscopic ultrasound
58104372|NCT03291678|PROCEDURE|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
58104373|NCT03291678|PROCEDURE|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
58104374|NCT05079152|BIOLOGICAL|COVAX+PPV23;COVAX+IIV4|1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
58104375|NCT05079152|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
58104376|NCT05079152|BIOLOGICAL|PPV23 for the 1st dose and IIV4 for the 2nd dose|1st dose: PPV23 only; 2nd dose: IIV4 only
58434984|NCT00863005|DRUG|K201|Cream
58434985|NCT00863005|DRUG|K201|
58434986|NCT01211314|DRUG|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
58434987|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
58434988|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
58434989|NCT03688516|BEHAVIORAL|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
58434990|NCT03688516|BEHAVIORAL|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
58434991|NCT03688516|BEHAVIORAL|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
58434992|NCT01625546|DEVICE|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
58434993|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 60 degrees.
58434994|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
58434995|NCT04209933|DRUG|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
57737942|NCT03725644|BEHAVIORAL|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
58434996|NCT04209933|DRUG|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
57954201|NCT04989920|BEHAVIORAL|Experimental group: CIMT group (Constraint-Induced Movement Therapy)|2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
57954202|NCT06123065|BEHAVIORAL|Yoga|8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
57954203|NCT03784976|OTHER|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
58434997|NCT04209933|DRUG|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
58434998|NCT04209933|DRUG|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
57954204|NCT04943991|DIAGNOSTIC_TEST|blood sampling (alpha-Galactosidase & LysoGb3)|"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"
57954205|NCT05754814|OTHER|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
57954206|NCT05186142|OTHER|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
57954207|NCT01243710|DEVICE|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
57954208|NCT04627272|DEVICE|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
58104377|NCT04507529|OTHER|Peer-mentoring|Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
58104378|NCT01523522|OTHER|Myoblast injection|Autologous myoblast injection in the anal sphincter
58434999|NCT06202040|PROCEDURE|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
58104379|NCT01523522|PROCEDURE|saline solution injection|saline solution injection in anal sphincter
57954209|NCT05619198|BEHAVIORAL|High Intensity Interval Exercise|"High Intensity Interval Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~* 5 minutes resting phase @ 0 watts."
57954210|NCT05619198|BEHAVIORAL|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of MICE 65% VO2max.~* 5 minutes resting phase @ 0 watts."
58104380|NCT02720224|DRUG|Estetrol|15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
57954211|NCT00751400|DRUG|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
57954212|NCT02951715|DRUG|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
57954213|NCT04766021|DRUG|Mirabegron|Dose-response effect on thermogenesis
57954214|NCT04766021|DRUG|Placebo|Placebo control condition
57954215|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
57954216|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
57954217|NCT01318109|DRUG|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
57954218|NCT06474559|DEVICE|LMA Protector|LMA Protector will be inserted by a researcher after standard anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale.Mini bronchoalveolar lavage will be collected before the end of the procedure
57954219|NCT06474559|DEVICE|Endotracheal tube|tracheal intubation will be perform after standard anaesthetic induction. Cormack Lehane will be recorded. Mini bronchoalveolar lavage will be collected before the end of the procedure
57954220|NCT02369614|OTHER|Active Comparator: 1 Hz rTMS|1 Hz rTMS
57954221|NCT02369614|OTHER|Active Comparator: 10 Hz rTMS|10 Hz rTMS
57954222|NCT02369614|OTHER|Sham Comparator:|Sham rTMS
58104381|NCT02412956|BEHAVIORAL|SmokefreeMOM Text|
58104382|NCT05956171|OTHER|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
58104383|NCT05956171|OTHER|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
58104384|NCT05573373|DRUG|Parimparib|The dosage and protocol of the drug were carried out according to the description.
58104385|NCT05573373|DRUG|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
58104386|NCT05573373|DRUG|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
58104387|NCT00897273|GENETIC|comparative genomic hybridization|
58104388|NCT00897273|GENETIC|gene expression analysis|
58104389|NCT00897273|OTHER|study of socioeconomic and demographic variables|
58104390|NCT00897273|PROCEDURE|evaluation of cancer risk factors|
58104391|NCT00897273|PROCEDURE|study of high risk factors|
58435000|NCT06202040|PROCEDURE|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
58435001|NCT00583063|DRUG|sunitinib|25 mg daily (oral dosing)
58104392|NCT04844307|OTHER|Shorter duration higher frequency PT|The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.
58104393|NCT04844307|OTHER|Standard PT|The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
58309852|NCT04979871|PROCEDURE|Venous bleeding|Blood samples collected 5 times with approx. 2-4 weeks interval
58309853|NCT04290104|DRUG|1gr oral ampicillin/sulbactam group|Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
57954223|NCT00549367|BEHAVIORAL|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
57954224|NCT05637918|OTHER|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
57954225|NCT05637918|OTHER|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
57954226|NCT05640778|DRUG|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
57954227|NCT04418076|DEVICE|Group A_No feedback|In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
58104394|NCT03597399|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
58104395|NCT05103514|OTHER|Online Survey|There are no interventions planned for this study. This is an observational study only.
58104396|NCT03005379|DRUG|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
58104397|NCT03005379|DRUG|Placebo|Oral capsule-delivered placebo
58104398|NCT04971915|OTHER|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
58309854|NCT04482634|OTHER|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
58309855|NCT04482634|OTHER|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
58104399|NCT05699811|BIOLOGICAL|MSC-IFNα|MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks
58309856|NCT05719168|DEVICE|Body Surface Gastric Mapping|64-channel electrode array placed on the outer abdomen
58309857|NCT01813747|DEVICE|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
58309858|NCT02426684|DRUG|IdeS® (Imlifidase)|0.24mg/kg IdeS
58435002|NCT00583063|DRUG|rapamycin|4 mg daily (oral dosing)
58435003|NCT05100576|DEVICE|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
58104400|NCT05699811|DRUG|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
58104401|NCT05699811|DRUG|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
58104402|NCT05699811|DRUG|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
58104403|NCT00451269|DEVICE|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
58104404|NCT04407468|PROCEDURE|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
58104405|NCT04664829|DRUG|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m\^2
58104406|NCT04664829|DRUG|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m\^2
58104407|NCT02966522|DRUG|Thalidomide|
58104408|NCT02966522|DRUG|Dexamethasone|
58104409|NCT02124746|DRUG|Momelotinib|Momelotinib tablets administered orally once daily
58104410|NCT00124475|DRUG|alitretinoin|
57954228|NCT04418076|DEVICE|Group B_Automated feedback|For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
58104411|NCT01160198|DRUG|ferrous ascorbate|100 mg elemental iron
58104412|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
58104413|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
58104414|NCT04429373|PROCEDURE|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
58104415|NCT04429373|PROCEDURE|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
58104416|NCT06517732|OTHER|Secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
58104417|NCT03811249|DEVICE|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
58104418|NCT05795517|DRUG|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
58104419|NCT05795517|DRUG|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
58104420|NCT05795517|DRUG|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
58104421|NCT05795517|DRUG|Placebo|placebo ，QD，oral，Day1 to week 12
58104422|NCT05795517|DRUG|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
58104423|NCT01829295|DRUG|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.
58104424|NCT01829295|DRUG|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
58104425|NCT01829295|DRUG|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
58104426|NCT01278199|OTHER|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 \> 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
58104427|NCT01278199|OTHER|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
58435004|NCT01957410|DRUG|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
57954229|NCT04418076|DEVICE|Group C_Automated feedback + Clinician feedback|For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
57954230|NCT04418076|DEVICE|Group D_Automated feedback + Social Network feedback|For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
57954231|NCT00264238|DRUG|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
57954232|NCT00865826|OTHER|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
57954233|NCT04334980|BIOLOGICAL|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
57954234|NCT04655443|OTHER|Standard Care|Standard cardiovascular care
57954235|NCT05482230|OTHER|Changes in intubation position|The change of intubation mode is accomplished in lateral position
57954236|NCT01250379|DRUG|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
57954237|NCT01250379|DRUG|Chemotherapy|Standard chemotherapy (doublets not allowed)
57954238|NCT04906174|OTHER|Electronic Health Record Review|Medical records are reviewed
57954239|NCT01246440|DRUG|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
57954240|NCT03561909|OTHER|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
57954241|NCT01508871|OTHER|Observational study, no intervention|No intervention
57954242|NCT05210530|COMBINATION_PRODUCT|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
57954243|NCT05541809|OTHER|Aromatherapy|Peppermint aroma inhalation
57954244|NCT05541809|OTHER|Placebo|Water inhalation
57954245|NCT02940509|DRUG|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)"
57954246|NCT02940509|DRUG|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
57954247|NCT01203384|DRUG|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
57954248|NCT01203384|DRUG|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
57954249|NCT01203384|DRUG|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
57954250|NCT01203384|DRUG|Placebo|oral tablet, placebo, once a day in the morning for 14 days
57954251|NCT04163250|DIAGNOSTIC_TEST|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
57954252|NCT01604265|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
57954253|NCT01604265|DRUG|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
57954254|NCT04338503|DIAGNOSTIC_TEST|Partial IVC occlusion|Partial balloon occlusion of the inferior vena cava.
57954255|NCT04411264|DEVICE|virtual reality|Use of a virtual reality headset while caring for chronic wound dressings
57954256|NCT01337128|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
57954257|NCT01337128|PROCEDURE|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
57954258|NCT01337128|PROCEDURE|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
58104428|NCT00046384|DRUG|aripiprazole|
58104429|NCT00142454|DRUG|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
57737943|NCT03725644|BEHAVIORAL|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
57954259|NCT01337128|PROCEDURE|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
57954260|NCT01337128|PROCEDURE|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
57954261|NCT01337128|PROCEDURE|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
57954262|NCT04246879|OTHER|MRI|Subjects undergo one additional delayed MRI sequence
57954263|NCT01566773|DRUG|PT001 MDI|Administered as two puffs BID for 14 days
57954264|NCT01566773|DRUG|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
57954265|NCT01566773|DRUG|PT001 Placebo MDI|
57954266|NCT04004650|PROCEDURE|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
57954267|NCT04687800|DRUG|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
57954268|NCT04687800|DRUG|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
57954269|NCT04087525|DRUG|HIP1701|Vildagliptin
57954270|NCT04087525|DRUG|HGP1809|Vildagliptin
57954271|NCT00414453|DRUG|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
57954272|NCT00414453|DRUG|Extended-release oxycodone|extended-release oxycodone titrating schedule
57954273|NCT00414453|DRUG|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
57954274|NCT00414453|DRUG|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
57954275|NCT00837109|BEHAVIORAL|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
57954276|NCT00837109|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
57954277|NCT00401375|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
57954278|NCT00401375|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
57954279|NCT01806363|DRUG|Telmisartan 80mg|
57954280|NCT01806363|DRUG|Chlorthalidone 25mg|
57954281|NCT00762892|DRUG|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
57954282|NCT00762892|DRUG|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
57954283|NCT04473378|DEVICE|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
57954284|NCT00945776|BEHAVIORAL|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
57954285|NCT00945776|BEHAVIORAL|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
57954286|NCT00945776|BEHAVIORAL|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
57954287|NCT04066972|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
57954288|NCT03981237|DEVICE|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
57954289|NCT03981237|DEVICE|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).
57954290|NCT03981237|PROCEDURE|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
57954291|NCT02062788|DIETARY_SUPPLEMENT|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
57954292|NCT02877173|DRUG|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
58435005|NCT01957410|DRUG|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
58435006|NCT06584123|DIAGNOSTIC_TEST|18F-Fluoro-ethyl-tyrosine (FET) PET|18F-Fluoro-ethyl-tyrosine PET study of the pituitary
58435007|NCT05258916|PROCEDURE|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
58435008|NCT03088943|OTHER|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
58435009|NCT03088943|OTHER|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
58435010|NCT03088943|OTHER|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
57954293|NCT02877173|DRUG|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
57954294|NCT02510027|OTHER|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
57954295|NCT05407584|DRUG|Orevogomab+PLD|"PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
57954296|NCT05407584|DRUG|Orevogomab+Paclitaxel|"paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
57954297|NCT03294031|OTHER|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
57954298|NCT03294031|OTHER|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
57954299|NCT04719182|OTHER|Adjunctive therapies|Determine and compare practice of adjunctive and supportive treatments for COVID-19
57737944|NCT02267395|OTHER|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
57737945|NCT02267395|OTHER|(2) scapular dyskinesis test|Test to determine scapular control
57954300|NCT01074190|DRUG|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
57954301|NCT01074190|DRUG|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
57954302|NCT01074190|DRUG|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
57954303|NCT03057236|BEHAVIORAL|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
58104430|NCT00142454|BIOLOGICAL|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
58104431|NCT01869712|OTHER|Cupping therapy|
58104432|NCT01869712|OTHER|Acupuncture|
58104433|NCT03556917|COMBINATION_PRODUCT|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
58435011|NCT04908358|OTHER|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
58435012|NCT04908358|OTHER|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
58435013|NCT01601665|DEVICE|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
57737946|NCT02267395|OTHER|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
57737947|NCT02530307|DRUG|HT-3951|
57737948|NCT02530307|DRUG|Placebo|
57737949|NCT05496127|OTHER|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
58435014|NCT01601665|DEVICE|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
58435015|NCT01601665|DEVICE|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
57954304|NCT03716869|OTHER|Universal Screening Arm|"Students with PHQ-9 score \>10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
58309859|NCT04897620|OTHER|Scanning the blood test results|"Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations were recorded. NLR was calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula platelet numberxneutrophil number/lymphocyte number"
58435016|NCT01601665|DEVICE|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
58435017|NCT01601665|DEVICE|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
58435018|NCT05766657|DIETARY_SUPPLEMENT|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
58435019|NCT05766657|DIETARY_SUPPLEMENT|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
58435020|NCT03955991|BEHAVIORAL|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
58435021|NCT03955991|BIOLOGICAL|Influenza vaccine|Standard of care Influenza vaccine for that given year.
57954305|NCT06179771|DEVICE|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
57954306|NCT05791656|DEVICE|Mectascrew-C|reconstruction of ACL or PCL rupture
57954307|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
57954308|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
57954309|NCT03403114|BEHAVIORAL|Questionnaire|a 15min questionnaire
57954310|NCT05567237|OTHER|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
57954311|NCT05567237|OTHER|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
57954312|NCT05567237|OTHER|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
57954313|NCT05567237|OTHER|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
57954314|NCT01783119|DIETARY_SUPPLEMENT|Aloe Barbadensis Miller|
57954315|NCT01783119|DIETARY_SUPPLEMENT|placebo water|
57954316|NCT00385632|DRUG|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
57954317|NCT00240409|DRUG|Pramipexole|
57954318|NCT00240409|DRUG|Bromocriptine|
57954319|NCT03600662|OTHER|TriRec|Trileaflet Reconstruction of the Aortic Valve
57954320|NCT03600662|OTHER|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
57954321|NCT00586261|DRUG|Pioglitazone|Pioglitazone 30 mg daily for 6 months
57954322|NCT00586261|DRUG|Placebo|Placebo 30 mg daily for 6 months
57954323|NCT00586261|DRUG|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
57954324|NCT03969121|DRUG|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
57954325|NCT03969121|DRUG|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
57954326|NCT02018731|DRUG|Metformin and Metformin & L-Citrulline|
57954327|NCT02018731|DRUG|L-Citrulline and Metformin & L-Citrulline|
57954328|NCT02459795|DRUG|Ingenol Mebutate (Perrigo)|
57954329|NCT02459795|DRUG|Ingenol Mebutate (Reference)|
57954330|NCT02459795|DRUG|Placebo gel|
58435022|NCT00306059|PROCEDURE|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
58435023|NCT03296449|PROCEDURE|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
58435024|NCT03296449|PROCEDURE|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
58435025|NCT03472586|BIOLOGICAL|Ipilimumab|Given IV
58435026|NCT03472586|BIOLOGICAL|Nivolumab|Given IV
58435027|NCT03472586|DRUG|Embolization Therapy|Undergo immunoembolization
58435028|NCT00133666|BEHAVIORAL|Asthma Communication Education|
57954331|NCT03927274|DRUG|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
58309860|NCT03495518|OTHER|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
58309861|NCT03495518|OTHER|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
57954332|NCT06403527|OTHER|Ultrasound guided venous access during AF ablation|Ultrasound guided venous access during AF ablation
58309862|NCT03797859|PROCEDURE|Apneic ventilation|Ventilation by THRIVE
58309863|NCT01913301|DRUG|Alagebrium|
58309864|NCT00913601|DEVICE|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
58309865|NCT05920005|DRUG|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
58435029|NCT00133666|BEHAVIORAL|Standard Asthma Education|
58435030|NCT06549426|DRUG|anti-seizure medication + sedative agent(s)|"Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)"
58435031|NCT03301298|DRUG|SXC-2023|Oral capsule
58435032|NCT03301298|DRUG|Placebo oral capsule|Placebo given as oral capsule.
58435033|NCT00996255|DRUG|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
58435034|NCT01754493|DRUG|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
58309866|NCT05920005|DRUG|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
58435035|NCT04266054|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
58435036|NCT02052401|OTHER|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
58435037|NCT03172572|PROCEDURE|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
57954333|NCT03914807|OTHER|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
57954334|NCT03914807|OTHER|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
57954335|NCT00796276|DRUG|IR OROS paliperidone and ER OROS paliperidone|
57954336|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
57954337|NCT04962022|DRUG|Itraconazole|Administered orally once daily for 8 days from Days 1 through 8
57954338|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
57954339|NCT05458388|PROCEDURE|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
58309867|NCT01835106|PROCEDURE|Epidural catheter is used postoperatively|
58309868|NCT01835106|PROCEDURE|Fascia iliaca compartment catheter is used postoperatively|
58309869|NCT05440032|DIAGNOSTIC_TEST|Semi-quantitative electrochemical leukocyte esterse test strip|Electrochemical assay to detect level of leukocyte esterase in sample
58309870|NCT05440032|DIAGNOSTIC_TEST|Roche Chemstrip|Urinalysis chemstrip
58435038|NCT03172572|PROCEDURE|Open pancreatoduodenectomy|Open resection
58435039|NCT03915470|DRUG|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
58435040|NCT03915470|DRUG|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
58435041|NCT05562258|BEHAVIORAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
58435042|NCT05562258|BEHAVIORAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
58435043|NCT06462781|DRUG|Lidocaine hydrochloride|Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
58435044|NCT06462781|DRUG|Methylprednisolone sodium succinate|Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
58309871|NCT02879214|RADIATION|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
58435045|NCT06462781|OTHER|Standard of Care|Acute and/or preventative therapeutic approaches currently used in practice
58435046|NCT03190616|DRUG|apatinib|apatinib 500mg/qd, 28d/cycle
58435047|NCT00398320|DRUG|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
58435048|NCT00398320|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
58435049|NCT00398320|DRUG|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
58435050|NCT04140045|OTHER|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
57954340|NCT05458388|PROCEDURE|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
57954341|NCT04043546|BEHAVIORAL|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
57954342|NCT01417715|DEVICE|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
57954343|NCT04575558|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
57954344|NCT05194085|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
57954345|NCT05194085|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
57954346|NCT00725400|OTHER|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
57954347|NCT00725400|PROCEDURE|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
57954348|NCT04683250|DRUG|TAS0953/HM06|Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
58309872|NCT02686996|DIETARY_SUPPLEMENT|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
58435051|NCT01628055|BIOLOGICAL|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
58435052|NCT01628055|OTHER|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
58435053|NCT03873935|OTHER|Evaluation of periodontal status|Clinical examination
58104434|NCT06257576|DRUG|Tamsulosin|"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."
58435054|NCT05998382|BEHAVIORAL|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
58435055|NCT00280085|PROCEDURE|MR imaging|
58104435|NCT06257576|OTHER|Control Group|A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
58104436|NCT00971399|DRUG|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
58104437|NCT00971399|DRUG|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
58104438|NCT05229315|DRUG|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
58104439|NCT05229315|PROCEDURE|Intensity modulated radiotherapy|Intensity modulated radiotherapy
58104440|NCT01901146|DRUG|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
58104441|NCT01901146|DRUG|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
57954349|NCT04683250|DRUG|TAS0953/HM06|Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
57954350|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
57954351|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
57954352|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
57954353|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
58104442|NCT01901146|DRUG|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
58104443|NCT01901146|PROCEDURE|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
58104444|NCT00568776|DRUG|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
58104445|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
58104446|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
58104447|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
58435056|NCT00280085|PROCEDURE|Glucose clamp|
58435057|NCT00280085|DRUG|Arginine|
57954354|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
58104448|NCT03826771|BEHAVIORAL|Power training|high-intensity lower extremity resistance training
58104449|NCT03826771|BEHAVIORAL|Stretching|upper and lower body range of motion exercises
58104450|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Resistance Exercise Training|Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
58435058|NCT04091243|DRUG|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
58435059|NCT01750723|DRUG|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
58435060|NCT02599233|OTHER|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
58435061|NCT02599233|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
58435062|NCT02599233|OTHER|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
58435063|NCT02503501|DRUG|Insulin glulisine|
58104451|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Endurance Exercise Training|Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
58104452|NCT04313023|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
58104453|NCT04313023|DRUG|Placebo|Sterile saline for inhalation
58104454|NCT03755700|DRUG|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
58104455|NCT03755700|DRUG|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
58104456|NCT03755700|DRUG|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
58435064|NCT02503501|DRUG|Placebo|Bacteriostatic 0.9% Sodium Chloride
58435065|NCT01357252|DRUG|vildagliptin|
58435066|NCT01357252|DRUG|Placebo|
58435067|NCT06245382|DIETARY_SUPPLEMENT|Goode Health Beverage|This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.
58435068|NCT06245382|DIETARY_SUPPLEMENT|Vanilla Base Beverage Blend|This is a commercially available beverage powder.
58435069|NCT01810718|DRUG|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
58435070|NCT00544427|DEVICE|Optical coherence tomography|Optical coherence tomography imaging
58435071|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case Group - Tomato-free diet|Nutritional intervention without tomatoes and sauce
58435072|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case group - Diet enriched with tomatoes|Nutritional intervention enriched with tomatoes and souce
58435073|NCT02956187|BEHAVIORAL|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
58435074|NCT02956187|DIETARY_SUPPLEMENT|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
58104457|NCT03755700|DRUG|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
58104458|NCT03755700|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
58104459|NCT00418080|DRUG|bicalutamide|
58104460|NCT00079144|BIOLOGICAL|NY-ESO-1 peptide vaccine|
58104461|NCT00079144|BIOLOGICAL|aldesleukin|
58435075|NCT01088620|DRUG|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
58435076|NCT01088620|DRUG|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
58435077|NCT01088620|DRUG|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
58435078|NCT05846555|PROCEDURE|urologic surgery|surgery
58435079|NCT02105675|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
58435080|NCT02105675|DRUG|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
58435081|NCT05352425|DEVICE|MobiusHD|The MobiusHD® device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
58104462|NCT00079144|BIOLOGICAL|filgrastim|
58104463|NCT00079144|BIOLOGICAL|incomplete Freund's adjuvant|
58104464|NCT00079144|BIOLOGICAL|therapeutic autologous lymphocytes|
58104465|NCT00079144|DRUG|cyclophosphamide|
58104466|NCT00079144|DRUG|fludarabine phosphate|
58104467|NCT01142466|DRUG|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
58104468|NCT05674071|BEHAVIORAL|Articulation/HVT|Osteopathy 1
58104469|NCT05674071|BEHAVIORAL|Soft-tissue massage|Osteopathy 2
58104470|NCT05674071|BEHAVIORAL|Craniosacral techniques|Osteopathy 3
58104471|NCT05674071|BEHAVIORAL|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
58104472|NCT00581386|DEVICE|LTS-D|supra-glottic airway device
58104473|NCT00581386|DEVICE|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
58104474|NCT00581386|DEVICE|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
58435082|NCT06576206|OTHER|Bin therapy and finger gnosia|Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
58104475|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
58104476|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
58104477|NCT01625286|DRUG|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
58104478|NCT01625286|DRUG|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
58104479|NCT00096486|DRUG|everolimus|
58104480|NCT00096486|DRUG|gefitinib|
58435083|NCT06576206|OTHER|conventional therapy|schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
58435084|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
57954355|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
58104481|NCT02050607|OTHER|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
57954356|NCT05779462|OTHER|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
57954357|NCT03269708|BEHAVIORAL|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
58104482|NCT05585268|OTHER|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
58309873|NCT02686996|OTHER|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
58309874|NCT05216484|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
58309875|NCT03045172|BIOLOGICAL|Platelet Rich Plasma|PRP
58309876|NCT03045172|DRUG|Placebo|Saline
58435085|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
58435086|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
58435087|NCT02140749|DIETARY_SUPPLEMENT|Placebo|Chewing tablets without short-chain Fructooligosaccharides
58435088|NCT01680744|OTHER|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
58435089|NCT00139919|DRUG|Bifeprunox|
58435090|NCT04659525|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
58435091|NCT04659525|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
58435092|NCT04659525|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
58435093|NCT05539313|DEVICE|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
58435094|NCT01456312|DRUG|Peginterferon alfa-2a|Duration and combination
58435095|NCT01456312|DRUG|Entecavir|combination
58435096|NCT02205242|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
57737950|NCT04455672|DEVICE|splints|"* Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
57737951|NCT03347968|BIOLOGICAL|MEDI0382|All participants will receive MEDI0382
57737952|NCT03347968|DRUG|Warfarin|All participants will receive Warfarin
57737953|NCT03347968|DRUG|Esmolol|All participants will receive Esmolol
57737954|NCT03996473|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
57737955|NCT03996473|DRUG|Pembrolizumab|200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
57737956|NCT01453816|PROCEDURE|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
57737957|NCT03973619|PROCEDURE|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
57737958|NCT03973619|PROCEDURE|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
57954358|NCT05715970|DIAGNOSTIC_TEST|PoCT+questionnaire administration|"In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital."
57954359|NCT00736346|BEHAVIORAL|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
57954360|NCT00736346|BEHAVIORAL|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
57954361|NCT00736346|DRUG|paroxetine|40 mg die, for 6 months
57954362|NCT01859442|PROCEDURE|Structured responsive interval exercise training programme|
57954363|NCT01859442|OTHER|Sham group|NO intervention in this group, only standard care (no exercise programme)
57954364|NCT03167996|BEHAVIORAL|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
57954365|NCT01926288|DRUG|Entecavir maleate tablets|
57954366|NCT01926288|DRUG|blank Baraclude tablets|
57954367|NCT01926288|DRUG|Blank maleate entecavir tablets|
57954368|NCT01926288|DRUG|Baraclude tablets|
57954369|NCT05087550|PROCEDURE|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
58435097|NCT02205242|DEVICE|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
58435098|NCT02205242|DRUG|Placebo|
58104483|NCT04912635|OTHER|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
58104484|NCT01653470|DRUG|Paclitaxel|
58104485|NCT01653470|DRUG|5-Fluorouracil (5FU)|
58104486|NCT01653470|DRUG|Carboplatin|
58104487|NCT01653470|DRUG|Leucovorin|
58104488|NCT01653470|DRUG|Irinotecan|
58104489|NCT01653470|DRUG|Paclitaxel|
58104490|NCT01653470|DRUG|BMS-906024|
58104491|NCT00331773|RADIATION|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
58104492|NCT00331773|RADIATION|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
58104493|NCT03841565|BIOLOGICAL|Daratumumab|Given IV
58104494|NCT03841565|DRUG|Dexamethasone|Given PO
58104495|NCT03841565|DRUG|Pomalidomide|Given PO
58104496|NCT02164539|DRUG|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
58104497|NCT02164539|DRUG|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
58104498|NCT02164539|DRUG|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
58104499|NCT02252484|OTHER|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
58104500|NCT02252484|OTHER|Standard of Care|Standard of Care for this patient population.
58104501|NCT05644938|PROCEDURE|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
58104502|NCT05644938|PROCEDURE|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
58104503|NCT06521606|PROCEDURE|Primary open reduction and internal fixation|The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.
58435099|NCT04085757|DRUG|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
58435100|NCT04085757|DRUG|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
58435101|NCT05432986|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
57737959|NCT05258825|DRUG|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
57737960|NCT04769167|OTHER|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
58104504|NCT06521606|PROCEDURE|Temporary external fixator|). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
58104505|NCT00044005|DRUG|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
58104506|NCT00044005|DRUG|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
58104507|NCT00044005|DRUG|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
58104508|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
58104509|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
58104510|NCT03296553|DRUG|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
58435102|NCT01506999|BIOLOGICAL|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
58104511|NCT03296553|DRUG|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
58104512|NCT01358019|DRUG|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
58104513|NCT04399902|DEVICE|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
58104514|NCT00447707|BEHAVIORAL|Positive Choice|
58309877|NCT04474483|DRUG|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
58309878|NCT04474483|OTHER|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
58309879|NCT06088693|OTHER|Electroacupuncture and Standard Therapy|Acupuncture Needle Insertion with Electroacupuncture machine.
58309880|NCT01950962|OTHER|Sampling of blood|
58309881|NCT04958967|DRUG|Furmonertinib 240mg|treated subjects will receive Furmonertinib 240mg/day
58309882|NCT04958967|DRUG|Furmonertinib 160mg|treated subjects will receive Furmonertinib 160mg/day
58309883|NCT04614506|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
58309884|NCT04614506|DEVICE|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
58309885|NCT01218802|DRUG|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
58309886|NCT01218802|DRUG|Placebo|participants will take a sugar pill daily for 96 weeks
58309887|NCT00076388|DRUG|Gefitinib|
58309888|NCT00076388|DRUG|Docetaxel|
58309889|NCT06015100|DRUG|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
58104515|NCT02624921|OTHER|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
58104516|NCT00698425|OTHER|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
58104517|NCT00698425|DRUG|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
58104518|NCT00926653|DRUG|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
58104519|NCT01332513|DRUG|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
58104520|NCT01332513|DRUG|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
58309890|NCT00194376|PROCEDURE|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
58309891|NCT06022913|BEHAVIORAL|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
58309892|NCT00123344|DEVICE|AT501 pacemaker|
58309893|NCT06525467|PROCEDURE|radical nephrectomy|open radical nephrectomy and lymph node dissection.
58435103|NCT05043389|OTHER|myofunctional therapy program|Exercise oral cavity muscle
58435104|NCT00982839|PROCEDURE|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
58435105|NCT00982839|PROCEDURE|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
58435106|NCT05335941|DRUG|Pemetrexed|Given by vein (IV)
58435107|NCT05335941|DRUG|Zimberelimab|Given by vein (IV)
58435108|NCT05335941|DRUG|Etrumadenant|Given by PO
58104521|NCT01332513|DRUG|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
58104522|NCT01332513|DRUG|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
58435109|NCT05431504|DRUG|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
57737961|NCT04769167|OTHER|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
58435110|NCT04120363|DRUG|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
58104523|NCT01332513|DRUG|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
58104524|NCT01332513|DRUG|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
58104525|NCT02529085|OTHER|blood samples|blood samples for the bank
58104526|NCT03140085|BIOLOGICAL|PYO Phage|Intravescial instillation
58104527|NCT03140085|DRUG|Antibiotics|Oral application
58104528|NCT03140085|OTHER|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
58104529|NCT03927781|DRUG|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
58104530|NCT06110221|OTHER|Periodontal clinical measurements, GCF and saliva sampling|"Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
58104531|NCT05221385|DRUG|Gentulizumab|Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
58104532|NCT04495465|OTHER|Radial Shock Wave Therapy|2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
58104533|NCT04495465|OTHER|Manual Therapy|25 minute massage to neck muscles
58104534|NCT04495465|OTHER|placebo shock waves|3 minutes of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
58104535|NCT00619619|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
58104536|NCT04167488|DEVICE|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
58435111|NCT04120363|DRUG|Sesame Oil|single intramuscular injection of 750 mg sesame oil solution
58435112|NCT01815840|DRUG|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
58435113|NCT01815840|DRUG|Placebo|Vismodegib placebo orally once daily
57737962|NCT04575467|DRUG|CBL-514|CBL-514 will be administered via injection into the subcutaneous adipose layer.
57737963|NCT03860857|RADIATION|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
57737964|NCT03860857|DRUG|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
57737965|NCT03860857|BEHAVIORAL|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
57737966|NCT03860857|OTHER|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
57737967|NCT06247839|DRUG|Psilocybin|COMP360 (Brand name of psilocybin to be used)
58435114|NCT03458650|DRUG|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
58435115|NCT03458650|DRUG|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
58435116|NCT03458650|DRUG|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
58435117|NCT03458650|DRUG|Placebo|matching placebo tablets
58435118|NCT03637569|OTHER|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
58104537|NCT01014026|OTHER|Screening test|Two Vaginal self sampling devices and HPV test
58435119|NCT03843983|DEVICE|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
58104538|NCT04001205|DRUG|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
58104539|NCT03056352|DRUG|Metoclopramide|Intravenous medication drip
58435120|NCT04741490|DRUG|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
57737968|NCT03117738|DRUG|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
57737969|NCT03117738|OTHER|Placebo-Control|Saline with 30% auto-serum
57737970|NCT05225493|BEHAVIORAL|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
57737971|NCT05225493|DIAGNOSTIC_TEST|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
58104540|NCT03056352|DRUG|Diphenhydramine|Intravenous medication drip
58104541|NCT01315366|DIETARY_SUPPLEMENT|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
58104542|NCT01315366|DIETARY_SUPPLEMENT|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
58104543|NCT03446079|OTHER|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
58104544|NCT04800900|OTHER|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
58104545|NCT05951517|DRUG|MMF|MMF treat refractory gastrointestinal Henoch-Schönlein purpura
58104546|NCT04553484|DIAGNOSTIC_TEST|No intervention|No intervention
58104547|NCT02801851|BEHAVIORAL|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
58104548|NCT06253754|OTHER|MRI examination|All included subjects will be examined with MRI
58435121|NCT04741490|RADIATION|radiotherapy|45-55Gy/1.8～2.0Gy
58435122|NCT02085109|DIETARY_SUPPLEMENT|Fat milkshake|
58435123|NCT02085109|DIETARY_SUPPLEMENT|Theobromine|
58435124|NCT05002179|DRUG|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
58435125|NCT03308994|OTHER|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
58435126|NCT03308994|OTHER|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
58435127|NCT00492336|DRUG|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
58104549|NCT06424678|OTHER|Only data collection in the Utstein template|The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
58104550|NCT01789008|OTHER|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
58435128|NCT00492336|DRUG|Placebo|Placebo 1 tablet each day
58435129|NCT05389176|DRUG|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
58435130|NCT02624453|DRUG|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
58435131|NCT02624453|DRUG|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
58435132|NCT02736916|RADIATION|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
58435133|NCT02736916|RADIATION|Conventional PCI|LD-SCLC patients with conventional PCI
58435134|NCT03105349|DRUG|elbasvir/grazoprevir|16 weeks treatment
57737972|NCT04020900|OTHER|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
57737973|NCT04879186|PROCEDURE|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
57737974|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
58104551|NCT01493531|DRUG|Lesinurad|Tablets, 200 mg QD
58104552|NCT01493531|DRUG|Lesinurad|Tablets, 400 mg QD
58104553|NCT01493531|DRUG|Placebo|Tablets, Placebo QD
58104554|NCT01493531|DRUG|Allopurinol|Tablets
58104555|NCT02173626|BEHAVIORAL|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
58104556|NCT06552377|DEVICE|Ultrasound Attenuation imaging measurement|Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
58104557|NCT03402620|DRUG|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
58435135|NCT03105349|DRUG|Sofosbuvir|16 weeks treatment
58435136|NCT03105349|DRUG|Ribavirin|16 weeks treatment
58435137|NCT02484352|DRUG|saline|different dosage of IV oxycodone was given before intubation
58435138|NCT02484352|DRUG|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
58435139|NCT02484352|DRUG|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
58435140|NCT02484352|DRUG|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
58435141|NCT02484352|DRUG|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
58435142|NCT01459744|BEHAVIORAL|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
58435143|NCT01459744|OTHER|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
58435144|NCT01646606|PROCEDURE|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
58104558|NCT03865524|DEVICE|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
58104559|NCT03865524|DEVICE|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
58104560|NCT06537895|OTHER|EDCRN questionnaires|Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset.
58104561|NCT06295575|DIETARY_SUPPLEMENT|probiotics containing Bifidobacterium infantis and Lactobacillus|Patients were provided with probiotics containing Bifidobacterium infantis and Lactobacillus. This intervention was started the day after patients' administration and lasted until the day before discharge.
58104562|NCT06295575|DIETARY_SUPPLEMENT|placebos containing lactose|Patients received lactose as placebo.This intervention was started the day after patients' administration and lasted until the day before discharge.
58104563|NCT01957631|DRUG|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
58104564|NCT01957631|BIOLOGICAL|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
58104565|NCT03719729|DRUG|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
58104566|NCT04493060|BIOLOGICAL|Dostarlimab|Given IV
58104567|NCT04493060|DRUG|Niraparib|Given PO
58104568|NCT03680482|OTHER|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
58104569|NCT03680482|OTHER|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
58435145|NCT01646606|PROCEDURE|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
58435146|NCT01629953|OTHER|Group vocational intervention|Group based manualized vocational rehabilitation
58435147|NCT01629953|OTHER|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
58104570|NCT01327638|DRUG|etoricoxib|Patients with SpA/AS who took etoricoxib
58104571|NCT01327638|DRUG|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
58104572|NCT01327638|DRUG|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
58104573|NCT02017535|DRUG|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
58309894|NCT01882452|BEHAVIORAL|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
58435148|NCT01516463|DRUG|Collagenase Santyl|Applied topically (2 mm thickness once daily)
57737975|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
58104574|NCT02017535|BEHAVIORAL|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
58104575|NCT04322968|DRUG|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
58104576|NCT03580759|BEHAVIORAL|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
58104577|NCT05578885|PROCEDURE|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
58104578|NCT02077959|DRUG|lenalidomide|Given PO
58104579|NCT02077959|BIOLOGICAL|pidilizumab|Given IV
58104580|NCT02077959|OTHER|pharmacological study|Correlative studies
58435149|NCT01516463|BIOLOGICAL|Bacitracin|Applied topically (2 mm thickness) once daily
58435150|NCT00795301|DRUG|Capecitabine, Cetuximab, Oxaliplatin|
58435151|NCT03507010|RADIATION|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
58435152|NCT03507010|OTHER|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
57737976|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
57737977|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
57737978|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
58435153|NCT05150717|DRUG|[14C]-Jaktinib|Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
58435154|NCT02186678|OTHER|PET-CT|
58435155|NCT05604742|DRUG|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
58435156|NCT01870726|DRUG|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
58435157|NCT01870726|DRUG|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
58435158|NCT03636646|DEVICE|X.ray|Surgical treatement of posterior acetabular wall fractures
58435159|NCT03388047|DEVICE|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
58435160|NCT02462018|DEVICE|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
58435161|NCT04557501|DIAGNOSTIC_TEST|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
57954370|NCT04261673|PROCEDURE|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
57954371|NCT04261673|PROCEDURE|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
57954372|NCT02844556|PROCEDURE|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
58435162|NCT04557501|OTHER|Control Arm|Control - Treatment without PSMA PET/CT
58435163|NCT04440657|BEHAVIORAL|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
58435164|NCT00006249|BIOLOGICAL|pegylated interferon alfa|
58435165|NCT00006249|PROCEDURE|adjuvant therapy|
58435166|NCT06017791|OTHER|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade. One on each side of the frenum~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
58104581|NCT02077959|OTHER|laboratory biomarker analysis|Correlative studies
58104582|NCT02757300|DEVICE|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
58104583|NCT02757300|DEVICE|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
58309895|NCT01882452|BEHAVIORAL|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
58435167|NCT01092910|DEVICE|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
58435168|NCT01013857|BEHAVIORAL|Health coaching|Calling patients every week to discuss medication adherence
58435169|NCT01013857|BEHAVIORAL|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
58435170|NCT04912817|OTHER|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
58435171|NCT04912817|OTHER|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
58435172|NCT00669383|DRUG|betamethasone|12 mg IM q 24 hours x 2 doses
58435173|NCT00669383|DRUG|placebo|Placebo IM q 24 hours x 2 doses
58435174|NCT05171712|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
57737979|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
58104584|NCT04695639|OTHER|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
58104585|NCT04695639|OTHER|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
58309896|NCT03040726|DRUG|Netupitant|Given PO
58309897|NCT03040726|DRUG|Palonosetron|Given PO
58309898|NCT03040726|DRUG|Palonosetron Hydrochloride|Given PO
58309899|NCT03040726|OTHER|Placebo|Given PO
58309900|NCT03040726|OTHER|Questionnaire Administration|Ancillary studies
57737980|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
58309901|NCT02466399|DRUG|POLAT-001|Subconjunctival injection
57737981|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
57954373|NCT02844556|OTHER|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
57954374|NCT01779973|BEHAVIORAL|Remote Observed Dosing|
58104586|NCT04695639|OTHER|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
58104587|NCT02323139|DRUG|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
58104588|NCT05199311|DRUG|Carfilzomib|20 mg/m2 C1D1; 56 mg/m2 thereafter
58104589|NCT05199311|DRUG|Iberdomide|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
58104590|NCT05199311|DRUG|Oral Dexamethasone|40 mg (\<=75 years old); 20 mg (\>75 years old)
58104591|NCT05234242|PROCEDURE|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
58104592|NCT04636398|BEHAVIORAL|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
58104593|NCT04715386|DRUG|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
58104594|NCT00764049|DEVICE|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
58104595|NCT06248034|DEVICE|Smartphone application with tele-monitoring rehabilitation|This Smartphone application includes an automated criterion-based progression based on participant's regular recorded self-measurement of knee range-of-motion and five-repetition-sit-to-stand. The rehabilitation program is designed to (i) increase knee range-of-motion, (ii) strengthen lower limb strength, (iii) improve postural balance, and (iv) improve physical function.
58104596|NCT06248034|PROCEDURE|Hospital-based rehabilitation program|Participants will be provided with the usual preoperative, inpatient physiotherapy and a physiotherapy house visit within the first 2-weeks postoperation. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion.
58104597|NCT01318785|OTHER|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
58104598|NCT03844568|DEVICE|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
58104599|NCT01981629|DEVICE|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
58104600|NCT02766231|DEVICE|Physica CR|Cruciate tretaining total knee replacement
58104601|NCT02766231|DEVICE|Physica PS|Posterior Stabilized total knee replacement
58104602|NCT03536247|PROCEDURE|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
58104603|NCT03536247|PROCEDURE|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
58104604|NCT03793595|DEVICE|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
58104605|NCT03793595|DEVICE|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
58104606|NCT00789828|DRUG|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
58104607|NCT00789828|DRUG|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
58104608|NCT05717088|OTHER|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively."
58104609|NCT01051999|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine powder
58104610|NCT01051999|DIETARY_SUPPLEMENT|L-alanine|L-alanine oral powder
58104611|NCT02100852|DRUG|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
58104612|NCT03728699|DIAGNOSTIC_TEST|Sample Collection Blood|Collected from each patient twice weekly.
58104613|NCT03728699|DIAGNOSTIC_TEST|Stool Sample|Collected from each patient twice weekly.
58104614|NCT00141596|DRUG|Cardura XL 4 mg bd|
58104615|NCT00141596|DRUG|Amiloride 5 mg bd|
58104616|NCT00141596|DRUG|Furosemide 40 mg bd|
58104617|NCT04676516|DRUG|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
58104618|NCT02755233|OTHER|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
58104619|NCT01098734|DRUG|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
58104620|NCT03373409|DRUG|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
58309902|NCT02466399|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
57737982|NCT05709834|OTHER|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
58104621|NCT03373409|DRUG|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
58104622|NCT03373409|DRUG|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
58104623|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (high dose)|From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
58104624|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (low dose)|From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
58435175|NCT05240625|DEVICE|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
58435176|NCT05240625|PROCEDURE|Standard colonoscopy|Standard colonoscopy procedure.
58435177|NCT04676035|DRUG|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
58435178|NCT06172075|BEHAVIORAL|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
58104625|NCT02580318|DEVICE|breathalyzer|
58104626|NCT01559818|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
58435179|NCT06172075|BEHAVIORAL|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
58435180|NCT06172075|BEHAVIORAL|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
58435181|NCT06172075|BEHAVIORAL|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
58104627|NCT01282827|DEVICE|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
58435182|NCT05268952|OTHER|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
57737983|NCT05709834|OTHER|Conventional treatment|Patients will receive conventional treatment
57737984|NCT06015321|DRUG|Enzalutamide|enzalutamide 160 mg PO daily
58104628|NCT01282827|DEVICE|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
58104629|NCT06274125|PROCEDURE|Robotic-Assisted Laparoscopic Radical Prostatectomy|To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
58104630|NCT01336608|DRUG|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
58104631|NCT01336608|DRUG|Vilanterol|Inhaled long acting beta-agonist
58104632|NCT01336608|DRUG|Placebo|Placebo
58435183|NCT05268952|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
58104633|NCT01999790|PROCEDURE|blepharotomy|upper eyelid surgery by blepharotomy
58104634|NCT01999790|PROCEDURE|posterior approach|upper eyelid surgery by posterior approach
58104635|NCT03880864|RADIATION|Ultrasound|Lung ultrasound
58104636|NCT00171119|DRUG|valsartan|
58435184|NCT03617146|BEHAVIORAL|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
58435185|NCT03617146|OTHER|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
58435186|NCT02774369|BEHAVIORAL|Physical exercise|Individualized aerobic intervention program
58435187|NCT02774369|BEHAVIORAL|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
58435188|NCT03220386|OTHER|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
58435189|NCT03330795|BIOLOGICAL|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
58435190|NCT05582941|OTHER|No intervention will be performed.|No intervention will be performed.
57954375|NCT03770585|PROCEDURE|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
57954376|NCT03770585|PROCEDURE|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
57954377|NCT05512546|DRUG|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
57954378|NCT00261430|BEHAVIORAL|GAIN Acceptance Approach|
57954379|NCT03008356|DIETARY_SUPPLEMENT|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
57954380|NCT03008356|BEHAVIORAL|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
57954381|NCT03008356|DIETARY_SUPPLEMENT|Placebo capsules|
57954382|NCT05231382|PROCEDURE|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
57954383|NCT05231382|PROCEDURE|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
57954384|NCT03964961|OTHER|Functional massage|It's a massage combined with a stretching of the muscles.
57954385|NCT03964961|OTHER|Conventional massage|It's a regular massage made with the therapist's hands.
57954386|NCT04788654|DRUG|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
57954387|NCT04788654|PROCEDURE|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
57954388|NCT00441597|DRUG|atorvastatin|atorvastatine 80mg, during 3 days
57954389|NCT05125237|DRUG|Amiloride|Amiloride claim is used as the exposure group.
57954390|NCT05125237|DRUG|Triamterene|Triamterene claim is used as the reference group.
57954391|NCT05378451|PROCEDURE|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
58104637|NCT02793999|DEVICE|Near-Infrared Spectroscopy (NIRS)|
58104638|NCT02293811|OTHER|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
58104639|NCT02011802|DEVICE|Algosteril TM|
58104640|NCT02011802|DEVICE|Sorbact TM|
58104641|NCT03631459|DRUG|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
58104642|NCT00175383|DRUG|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
58104643|NCT04711863|DRUG|Fluvoxamine|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
58435191|NCT06095609|OTHER|Early mobilization plus chest physiotherapy|"Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay."
58435192|NCT04382222|PROCEDURE|prenatal ultrasound|prenatal cardiac ultrasound
58435193|NCT04523961|DRUG|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
57737985|NCT00443976|DRUG|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
57737986|NCT06532630|GENETIC|Anti-CD19-CAR-T cells|"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."
58104644|NCT04711863|DRUG|Placebo|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
58104645|NCT05975463|PROCEDURE|HAIC|hepatic artery infusion for 3-4 times.
58104646|NCT05975463|DRUG|Adebrelimab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
58104647|NCT05975463|DRUG|Bevacizumab|hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
58104648|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with Er:YAG laser|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.
58104649|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with neutral sodium fluoride gel|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
58104650|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus moderate intensity exercise|
58104651|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus health education|
58104652|NCT02465580|DRUG|hrIL-2 active|active group: placebo group =1:1
58104653|NCT02465580|DRUG|hrIL-2 placebo|active group: placebo group =1:1
58435194|NCT04523961|DRUG|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
58104654|NCT05613335|PROCEDURE|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
58104655|NCT05613335|PROCEDURE|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
58104656|NCT02803645|BIOLOGICAL|blood sample|
57737987|NCT06532630|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
58104657|NCT04811222|DIAGNOSTIC_TEST|Ga-DOTATATE PETMRI scan|Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
57737988|NCT06532630|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
57737989|NCT02804594|DRUG|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
57737990|NCT02804594|DRUG|Placebo|placebo taken three times daily
58104658|NCT01407679|DRUG|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
58435195|NCT03455816|DEVICE|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
58435196|NCT03455816|DEVICE|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
57737991|NCT03133975|DRUG|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
57737992|NCT03133975|OTHER|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
57737993|NCT05798195|OTHER|conventional western medicine treatment|conventional western medicine treatment only
57737994|NCT05798195|DRUG|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
57737995|NCT05798195|OTHER|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
57737996|NCT04112004|OTHER|Collecting sodium reports and outcome measures|
57737997|NCT03189017|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
57737998|NCT03189017|DRUG|Placebos|The placebo is a white, round, uncoated tablet.
58435197|NCT04927403|OTHER|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
58435198|NCT05805891|DRUG|bortezomib|bortezomib 2mg/week subcutaneous injection
58435199|NCT06514313|DRUG|Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
58435200|NCT06514313|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 4 cycles
58435201|NCT01768195|DRUG|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
58435202|NCT02384018|BIOLOGICAL|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
58435203|NCT05872347|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
58435204|NCT04387578|DEVICE|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
58435205|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
58435206|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
58435207|NCT00727155|BEHAVIORAL|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
58435208|NCT01106508|DRUG|LEQ506|
58435209|NCT04797351|BEHAVIORAL|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
58435210|NCT03400163|DRUG|BMS-986036|BMS-986036 20 mg QD
58435211|NCT03400163|DRUG|Placebo|Placebo QD
58435212|NCT00856544|DRUG|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
58435213|NCT00856544|DRUG|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
58435214|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
58435215|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
58435216|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
58435217|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
58435218|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
58435219|NCT04527146|OTHER|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
58435220|NCT04527146|OTHER|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the PennChart/EPIC electronic medical record dashboard.
58435221|NCT04527146|OTHER|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
58435222|NCT03203434|DIAGNOSTIC_TEST|Urinary volatile organic compound analysis|
58435223|NCT02815423|BIOLOGICAL|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
58435224|NCT02815423|BIOLOGICAL|Percutaneous|Percutaneous injection
58435225|NCT02476695|DEVICE|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
58435226|NCT02476695|DEVICE|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
58435227|NCT02476695|DEVICE|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
58435228|NCT04499287|OTHER|15-minute walk at preferred walking speed.|
58435229|NCT04499287|DIETARY_SUPPLEMENT|Fiber|9 grams soluble fiber
58435230|NCT04499287|OTHER|control|control
58435231|NCT02024724|DRUG|Bupivacaine|4 mL of 0.25% bupivacaine
58435232|NCT02024724|DRUG|Triamcinolone|40 mg of Triamcinolone
58104659|NCT03767673|DIAGNOSTIC_TEST|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
58104660|NCT03767673|DIAGNOSTIC_TEST|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
58104661|NCT03767673|DIAGNOSTIC_TEST|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
58104662|NCT03767673|DIAGNOSTIC_TEST|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
58104663|NCT03767673|DIAGNOSTIC_TEST|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
58435233|NCT02024724|DRUG|Dexamethasone|4 mg of Dexamethasone
58104664|NCT03767673|DIAGNOSTIC_TEST|weight|Determined by Kilogram on a medical weight scale
58435234|NCT00601549|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery
58435235|NCT00601549|PROCEDURE|Traditional open surgery|Open surgery
58435236|NCT00894946|PROCEDURE|Lipiodol + IVF|IVF preceded by lipiodol
57737999|NCT06201338|PROCEDURE|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
58104665|NCT03767673|OTHER|age|Determination of age by patient's Report and past medical history
58104666|NCT03371238|BEHAVIORAL|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
58104667|NCT00078819|DRUG|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
58104668|NCT00078819|DRUG|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
58104669|NCT03020836|BEHAVIORAL|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
58104670|NCT03020836|BEHAVIORAL|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
58435237|NCT00894946|PROCEDURE|IVF|IVF alone
58435238|NCT02389400|DRUG|methotrexate|Single Group Assignment
58435239|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
58435240|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
58435241|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
58435242|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
58435243|NCT00615992|DRUG|Tiotropium|
58435244|NCT04600934|DEVICE|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
58435245|NCT04600934|DEVICE|Plain old balloon angioplasty|POBA
58435246|NCT02229409|BEHAVIORAL|Walkadoo|Walkadoo is a MeYou Health, LLC product.
58435247|NCT00240669|DEVICE|Resorbable device PLLA/PGA|
58435248|NCT00240669|DEVICE|Titanium device|
58435249|NCT00696839|BEHAVIORAL|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
58435250|NCT05854342|OTHER|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
58435251|NCT01302197|OTHER|No intervention|longitudinal follow-up after stroke
58435252|NCT04959305|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
57954392|NCT05033470|DEVICE|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
58104671|NCT03156270|DEVICE|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
58104672|NCT01698762|OTHER|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
58104673|NCT01698762|OTHER|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
58104674|NCT01698762|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
58104675|NCT02464059|DRUG|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
57954393|NCT03053297|OTHER|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
57738000|NCT02119351|DEVICE|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
57738001|NCT02119351|DEVICE|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
57738002|NCT04300738|DEVICE|CCS wit CT Scann measurement|Measurement with 2 devices
58104676|NCT02759211|OTHER|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
58104677|NCT02759211|OTHER|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
58104678|NCT03302299|DRUG|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
58104679|NCT03302299|DRUG|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
58104680|NCT02060552|DRUG|Diacerein|oral administration of IL-1βinhibitory
58435253|NCT04959305|DRUG|RLD2003|Take it once daily for 8 weeks orally.
58435254|NCT04959305|DRUG|RLD2004|Take it once daily for 8 weeks orally.
58435255|NCT04959305|DRUG|RLD2005|Take it once daily for 8 weeks orally.
58435256|NCT04959305|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
58435257|NCT04959305|DRUG|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
58435258|NCT05240001|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
58435259|NCT05240001|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
58435260|NCT03778502|DRUG|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
58435261|NCT06366087|DRUG|Atropine Sulfate Ophthalmic Solution USP, 1%|Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
58435262|NCT06366087|DRUG|Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)|Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
58435263|NCT00995423|DEVICE|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
58435264|NCT00995423|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent
58435265|NCT00169208|DRUG|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
58435266|NCT00169208|DRUG|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
58435267|NCT00169208|DRUG|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
58435268|NCT06160492|DRUG|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
58435269|NCT03560167|DEVICE|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
58435270|NCT03223259|BEHAVIORAL|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
58435271|NCT03360799|OTHER|Questionnaire Administration|Complete questionnaires
58435272|NCT03554447|DRUG|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
58435273|NCT03554447|DRUG|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
58435274|NCT03719911|BEHAVIORAL|Live diabetes coaching program|Live diabetes coaching program
58435275|NCT05405140|OTHER|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
58435276|NCT05405140|OTHER|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
58435277|NCT04228601|DRUG|Fluzoparib|PARP
58435278|NCT04228601|DRUG|Fluzoparib placebo|Placebo
58435279|NCT04228601|DRUG|mFOLFIRINOX|mFOLFIRINOX
58435280|NCT03927144|DRUG|AMG334|Subcutaneous Injection
58435281|NCT03927144|DRUG|Oral Prophylactic|SOC Oral Tablet/Capsule
58435282|NCT04894890|DRUG|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
58435283|NCT02657447|DRUG|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
58435284|NCT02657447|DRUG|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
58435285|NCT02829580|PROCEDURE|Echocardiography|Measures by Doppler and study of endothelial function
58435286|NCT02908750|DRUG|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
58435287|NCT02908750|DRUG|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
57954394|NCT01251367|BIOLOGICAL|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
58309903|NCT02287077|PROCEDURE|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
58435288|NCT02820025|DRUG|doxapram|
58435289|NCT02820025|OTHER|saline|
58435290|NCT01480310|DRUG|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
58435291|NCT01480310|DRUG|Placebo|may receive up to 3 subcutaneous doses of placebo
58435292|NCT03043391|BIOLOGICAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
58435293|NCT06130592|DIAGNOSTIC_TEST|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
58435294|NCT00177255|DRUG|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
58435295|NCT00177255|DRUG|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
58435296|NCT03305315|OTHER|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
58435297|NCT03305315|OTHER|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
58435298|NCT06446791|PROCEDURE|Mehri Turki Surgical Technique of the Webbed Neck|The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
58435299|NCT02082704|BEHAVIORAL|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
58435300|NCT02082704|BEHAVIORAL|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
58435301|NCT04554771|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
58435302|NCT04554771|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
57738003|NCT04013815|PROCEDURE|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
58435303|NCT04554771|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
58435304|NCT04554771|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
58435305|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub A)|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
58435306|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
58435307|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub B)|Spatial Automation profile
58435308|NCT05248139|DRUG|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
58435309|NCT05248139|DRUG|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
57738004|NCT04013815|PROCEDURE|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
58104681|NCT02060552|DRUG|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
58104682|NCT02060552|DRUG|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
58435310|NCT04735991|BEHAVIORAL|Kapok Initiative|"The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
58435311|NCT05226299|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
58435312|NCT05226299|BIOLOGICAL|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
57954395|NCT03225053|DEVICE|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
58435313|NCT03969927|DEVICE|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
58435314|NCT03969927|DEVICE|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
58435315|NCT06395532|OTHER|Observetional|After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
58104683|NCT00869089|DRUG|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
58104684|NCT05778708|BEHAVIORAL|Tai-Chi intervention|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
58104685|NCT05778708|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
58435316|NCT04386694|DEVICE|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
58435317|NCT04386694|DEVICE|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
57954396|NCT02146612|OTHER|Amino Acid Supplement Group|Group receiving nutritional supplement
57954397|NCT00000522|BEHAVIORAL|diet, sodium-restricted|
57954398|NCT00000522|BEHAVIORAL|diet, reducing|
57954399|NCT00000522|BEHAVIORAL|exercise|
57954400|NCT00000522|BEHAVIORAL|alcohol restriction|
57954401|NCT00000522|DRUG|chlorthalidone|
57954402|NCT00000522|DRUG|acebutolol|
57954403|NCT00000522|DRUG|doxazosin|
57954404|NCT00000522|DRUG|amlodipine|
57954405|NCT00000522|DRUG|enalapril|
57954406|NCT01499420|BIOLOGICAL|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
57954407|NCT01499420|BIOLOGICAL|Placebo|Single intravenous doses of normal saline (0.9%)
57954408|NCT02481388|OTHER|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
57954409|NCT05979298|DRUG|Gemcitabine|Chemotherapeutics
58309904|NCT01418469|DIETARY_SUPPLEMENT|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
58309905|NCT01418469|DIETARY_SUPPLEMENT|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
58309906|NCT01418469|DIETARY_SUPPLEMENT|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
57954410|NCT05979298|BIOLOGICAL|ELENAGEN|DNA plasmid
57954411|NCT04009863|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
57954412|NCT04009863|RADIATION|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
57954413|NCT01272700|PROCEDURE|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
57954414|NCT01272700|PROCEDURE|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
57954415|NCT00933075|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
57954416|NCT03111446|PROCEDURE|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
57954417|NCT03111446|PROCEDURE|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
57954418|NCT01564355|DEVICE|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
58309907|NCT01418469|DIETARY_SUPPLEMENT|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
58309908|NCT04244136|DEVICE|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
58309909|NCT01396564|DRUG|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
58309910|NCT01396564|DRUG|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
58104686|NCT03207360|BEHAVIORAL|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
58104687|NCT04703530|OTHER|hot footbath|The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
58104688|NCT00891878|DRUG|capecitabine|Given orally
58104689|NCT00891878|DRUG|sunitinib malate|Given orally
58104690|NCT00272961|DRUG|Placebo|placebo tablet once daily for 12 weeks
58104691|NCT00272961|DRUG|TBC3711|10 mg tablets once daily for 10 weeks
58104692|NCT00272961|DRUG|TBC3711|50 mg tablet once daily for 10 weeks
58104693|NCT00272961|DRUG|TBC3711|100 mg tablet once daily for 10 weeks
58104694|NCT00272961|DRUG|TBC3711|200 mg tablet once daily for 10 weeks
58435318|NCT02675530|DRUG|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
58435319|NCT06011369|PROCEDURE|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
57738005|NCT03477435|BEHAVIORAL|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
57738006|NCT05602363|DRUG|Docirbrutinib|oral tablet, twice daily
58104695|NCT05347030|OTHER|Acupuncture|During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
58104696|NCT05347030|OTHER|Sham Acupuncture|During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
58104697|NCT02883387|OTHER|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
58435320|NCT02225834|DRUG|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
58435321|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
58435322|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
58435323|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
58435324|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
58435325|NCT03437577|DRUG|immediate-release tacrolimus|Standard of care for transplant patients
58435326|NCT03437577|DRUG|extended release tacrolimus|Experimental care
57954419|NCT01564355|DRUG|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
57954420|NCT00710073|DEVICE|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
57954421|NCT06421558|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
57954422|NCT06421558|DEVICE|Transcutaneous Electrical Stimulation|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
58104698|NCT02883387|OTHER|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
58104699|NCT01612702|DRUG|Dexamethasone|Dexamethasone 10 mg intravenous administration
58104700|NCT05297071|DEVICE|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
58104701|NCT05297071|DEVICE|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
58104702|NCT01032759|DRUG|Memantine|20 mg, BID
58104703|NCT01032759|DRUG|Placebo|BID
58104704|NCT04773171|OTHER|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
58104705|NCT04773171|OTHER|Conventional training programmes|Existing conventional activities in the settings
58309911|NCT00199953|DRUG|Rabeprazole 20 mg twice a day for 90-day period treatment|
58309912|NCT00454870|DRUG|MEM 3454|
58309913|NCT06328088|DIETARY_SUPPLEMENT|Non vegetarian|Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
58435327|NCT03785964|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
58435328|NCT03785964|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
58435329|NCT00187473|PROCEDURE|liver biopsy|Liver biopsy every 5 years
58435330|NCT01309776|DRUG|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
58435331|NCT01309776|DRUG|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
58104706|NCT05634018|DIAGNOSTIC_TEST|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
58435332|NCT06208774|PROCEDURE|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
58435333|NCT03328351|OTHER|manual therapy|"1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
58435334|NCT03328351|OTHER|Superficial soft tissue massage|"1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
57738007|NCT01738048|PROCEDURE|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
57954423|NCT02639585|DRUG|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
57954424|NCT00513409|BIOLOGICAL|Synflorix|Intramuscular injection, 1 or 2 doses
57954425|NCT00513409|BIOLOGICAL|Infanrix Hexa|1 Intramuscular injection
57954426|NCT00513409|BIOLOGICAL|Havrix|1 Intramuscular injection
57954427|NCT00274027|DRUG|tiotropium bromide|
57954428|NCT03611855|DEVICE|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
57954429|NCT03611855|OTHER|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
57954430|NCT02321436|BIOLOGICAL|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
57954431|NCT02321436|DRUG|Placebo|Placebo administered intramuscularly in the targeted upper limb.
57954432|NCT04925232|DEVICE|Transcranial Magnetic Stimulation device|Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
57954433|NCT03927001|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
57954434|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
57954435|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
57954436|NCT05598099|BEHAVIORAL|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
57954437|NCT00479791|BEHAVIORAL|Test meals rich in different fatty acids|
57954438|NCT00357500|DRUG|celecoxib|
57954439|NCT00357500|DRUG|cyclophosphamide|
57954440|NCT00357500|DRUG|etoposide|
57954441|NCT00357500|DRUG|fenofibrate|
57954442|NCT00357500|DRUG|thalidomide|
57954443|NCT01560000|DIETARY_SUPPLEMENT|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
57954444|NCT02217605|DIETARY_SUPPLEMENT|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
57954445|NCT03389282|DIAGNOSTIC_TEST|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
57954446|NCT00080509|DRUG|KOS-862|
57954447|NCT06035900|DRUG|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
57954448|NCT03539250|RADIATION|IMRT|IMRT with and without chemotherapy
57954449|NCT02976870|RADIATION|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
57954450|NCT05222256|DRUG|Levosimendan|Patients in this group will receive levosimendan
57954451|NCT05222256|DRUG|Adrenaline|Patients in this group will receive Adrenaline
57954452|NCT00641251|OTHER|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
58435335|NCT04000581|OTHER|Best Practice|Receive standard of care
58435336|NCT04000581|OTHER|Physical Activity|Walk for minimum 30 minutes per day
58435337|NCT04000581|OTHER|Questionnaire Administration|Ancillary studies
58435338|NCT04638426|DRUG|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
58435339|NCT04638426|DRUG|Placebo of HL237 tablet|Placebo of HL237, twice a day
58435340|NCT03563196|RADIATION|Chest Radiograph|Chest radiogram will be obtained on day 1
58435341|NCT03563196|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be done on day 1
58435342|NCT01185977|DRUG|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
58435343|NCT01185977|DRUG|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
58104707|NCT05028751|DRUG|Lanraplenib|Orally via tablets
58435344|NCT00573014|OTHER|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
58435345|NCT01428739|DEVICE|MRS|Procedure
58435346|NCT04359485|PROCEDURE|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
58435347|NCT04359485|OTHER|Saline|Sodium chloride
58435348|NCT06173908|PROCEDURE|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
58435349|NCT06173908|PROCEDURE|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
58435350|NCT05686564|DRUG|ALXN1840|bis-choline tetrathiomolybdate
58435351|NCT00293618|DEVICE|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
58435352|NCT00293618|OTHER|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
58435353|NCT00293618|OTHER|Feedback|Feedback about the physician's personal performance on prevention of PONV
58435354|NCT05218525|OTHER|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
58435355|NCT02720406|DRUG|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
58435356|NCT02720406|DRUG|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
57954453|NCT00641251|OTHER|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
57954454|NCT04034862|DRUG|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
58104708|NCT05028751|DRUG|Gilteritinib|Orally via tablets
58104709|NCT05783609|DRUG|Epcoritamab|T-cell bispecific antibody, via subcutaneous injection
58104710|NCT05783609|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, via IV infusion
58104711|NCT03292133|DRUG|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
58104712|NCT03292133|DRUG|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
58435357|NCT02720406|DRUG|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
58435358|NCT02720406|DRUG|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
58435359|NCT06013384|DEVICE|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
58435360|NCT06013384|DEVICE|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
58435361|NCT05603598|DRUG|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
58435362|NCT05775731|DIAGNOSTIC_TEST|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
58435363|NCT03139344|OTHER|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
58435364|NCT03139344|OTHER|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
58435365|NCT03212534|OTHER|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
58435366|NCT00604695|DRUG|Tenecteplase|Intracoronary injection of IV tenecteplase.
58435367|NCT00604695|DRUG|Sterile Saline|Intracoronary injection of IV sterile saline
58435368|NCT02023684|DRUG|control saline|Surgical bed irrigation with saline 40ml
58104713|NCT05726773|PROCEDURE|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
58435369|NCT02023684|DRUG|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
58435370|NCT02023684|DRUG|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
58435371|NCT05356585|GENETIC|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
58104714|NCT05726773|PROCEDURE|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
58435372|NCT01007838|OTHER|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
58435373|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
58435374|NCT01007838|OTHER|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
58435375|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
58435376|NCT06077890|OTHER|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
58435377|NCT06077890|OTHER|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
58435378|NCT02782221|DRUG|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
58435379|NCT02782221|DRUG|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
58104715|NCT00503854|BEHAVIORAL|Questionnaire|Ancillary studies
58104716|NCT05666674|OTHER|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
58104717|NCT02039583|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
58104718|NCT00397839|DRUG|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
58104719|NCT00397839|DRUG|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
58435380|NCT02141360|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
58435381|NCT03854461|BEHAVIORAL|Personalised dietary advice and educational material|As within arm/group description
58435382|NCT03854461|BEHAVIORAL|Educational material|As within arm/group description
58435383|NCT05670613|OTHER|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
58435384|NCT02842749|DRUG|everolimus|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
58435385|NCT00866814|DEVICE|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
58435386|NCT04854382|BEHAVIORAL|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
58435387|NCT01716780|OTHER|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
58435388|NCT00384332|DRUG|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
58435389|NCT00384332|DRUG|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
58435390|NCT04072887|DRUG|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
58435391|NCT04072887|DRUG|Placebo|Placebo oral capsules administered twice a day for 24 weeks
58435392|NCT04072887|DRUG|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
58435393|NCT01678625|DEVICE|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
58435394|NCT04692532|OTHER|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
58435395|NCT04692532|OTHER|Calorie restriction|25% energy restriction every day
58435396|NCT06524323|DRUG|5-fluorouracil Injection|The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
58435397|NCT06524323|DRUG|Triamcinolone Acetonide|The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
58435398|NCT05762406|DEVICE|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
58435399|NCT01847976|DRUG|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
58435400|NCT00304655|DRUG|Aripiprazole|
58435401|NCT06247904|DEVICE|Active rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
58435402|NCT06247904|DEVICE|sham rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
58435403|NCT01452581|OTHER|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
58435404|NCT01452581|DRUG|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
58435405|NCT02513576|OTHER|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
58435406|NCT04651491|DRUG|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
58435407|NCT06399250|OTHER|meal service|We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
58435408|NCT00648557|DRUG|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
58435409|NCT00648557|DRUG|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
58435410|NCT01081899|OTHER|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
58435411|NCT00650403|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
58435412|NCT00650403|DRUG|Paxil® 40 mg Tablet|40mg, single dose fed
58435413|NCT01347996|DRUG|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
58435414|NCT02812719|DRUG|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
58435415|NCT02812719|DRUG|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
58435416|NCT03774030|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
58435417|NCT03521245|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
58435418|NCT03521245|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
58435419|NCT03521245|DRUG|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
58435420|NCT03521245|DRUG|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
58435421|NCT02340416|DEVICE|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
58435422|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
58104720|NCT03722537|PROCEDURE|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
58104721|NCT03722537|PROCEDURE|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
58104722|NCT05731388|DIAGNOSTIC_TEST|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
58104723|NCT00821457|DRUG|Juvista|250ng
57738008|NCT03456193|PROCEDURE|LA transplant|"The proposed study treatment will include three central components:~* Harvest of the left atrium and pulmonary veins from a suitable donor~* Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~* Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
57738009|NCT05322616|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
58104724|NCT00821457|DRUG|Placebo|Powder for solution for injection
58104725|NCT00821457|DRUG|Juvista|500ng
58104726|NCT05584774|PROCEDURE|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
58104727|NCT04500691|OTHER|pain intensity reporting|pain intensity reporting
58104728|NCT02908828|DIETARY_SUPPLEMENT|Calanus oil|
58104729|NCT02908828|DIETARY_SUPPLEMENT|placebo dietary oil|
58104730|NCT05086120|OTHER|eCARIBOU|A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
58104731|NCT00196222|PROCEDURE|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
58104732|NCT00196222|PROCEDURE|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
58104733|NCT04317963|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
58104734|NCT04317963|DRUG|Standard CDI treatment|Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
57738010|NCT05322616|DRUG|Matching Placebo|Vehicle control
57738011|NCT05461872|OTHER|No intervention|No intervention
58104735|NCT05449327|DRUG|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
58104736|NCT01241162|BIOLOGICAL|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
58104737|NCT03911089|OTHER|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
57738012|NCT00307827|DRUG|Visilizumab|Visilizumab administered intravenously once per day for two days
57738013|NCT05285813|DRUG|Vibecotamab|Given by vein (IV)
58104738|NCT04610073|BEHAVIORAL|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
58104739|NCT02718976|PROCEDURE|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
58104740|NCT02718976|PROCEDURE|Ultrasound guided lumbar plexus block (Shamrock)|
58104741|NCT02718976|DRUG|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
58104742|NCT03335943|DRUG|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
57738014|NCT05285813|DRUG|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
57738015|NCT05285813|DRUG|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
57738016|NCT05285813|DRUG|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
57738017|NCT05020223|OTHER|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
57738018|NCT05535816|DIAGNOSTIC_TEST|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
57738019|NCT04988308|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
57738020|NCT04988308|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
57738021|NCT04988308|DRUG|Placebo|Placebo will be administered subcutaneously.
57738022|NCT06544733|DRUG|GS-1720|Tablets administered orally without regard to food
57738023|NCT06544733|DRUG|GS-4182|Tablets administered orally without regard to food
57954455|NCT05632185|BEHAVIORAL|Equine-assisted Therapy|An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
58104743|NCT05103267|DEVICE|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
58104744|NCT03312582|DRUG|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
58104745|NCT03312582|PROCEDURE|Placebo|
58104746|NCT02197169|DRUG|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
58104747|NCT02197169|DRUG|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
58435423|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
58435424|NCT04706728|OTHER|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
58435425|NCT01107847|PROCEDURE|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
58435426|NCT02591485|BEHAVIORAL|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
58435427|NCT05034601|PROCEDURE|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
58435428|NCT05034601|PROCEDURE|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
58435429|NCT00003968|DRUG|bryostatin 1|
58435430|NCT01943591|DEVICE|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
58435431|NCT04680975|DRUG|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
58435432|NCT01372176|OTHER|Early Goal-Directed Nutrition|"1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
58435433|NCT01372176|OTHER|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
58435434|NCT06325865|OTHER|Interview|Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.
58435435|NCT02098278|DRUG|CAT-2003|
58435436|NCT02098278|DRUG|Placebo|
58435437|NCT00307203|DRUG|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
58435438|NCT00307203|BEHAVIORAL|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
58435439|NCT00307203|DRUG|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
58435440|NCT06330337|DRUG|Temozolomide（TMZ） injection or oral administration|Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
58435441|NCT06330337|DRUG|Albumin-Bound Paclitaxel(ABX) intravenous drip|ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
57738024|NCT06544733|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
58104748|NCT00335790|PROCEDURE|Hyperbaric Therapy|
58104749|NCT04091685|DEVICE|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
58104750|NCT05957107|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|The drug was administered once every 4 weeks.
57738025|NCT06544733|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
57738026|NCT06544733|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
58435442|NCT06330337|DEVICE|Specific mode electroacupuncture stimulation(SMES) intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8."
58435443|NCT02146001|OTHER|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
58435444|NCT02146001|OTHER|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
58435445|NCT05906459|DIAGNOSTIC_TEST|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
58435446|NCT01932502|DRUG|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
58435447|NCT01932502|DRUG|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
58435448|NCT01932502|DRUG|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
58435449|NCT01932502|DRUG|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
58435450|NCT01932502|DRUG|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
58435451|NCT05652712|DRUG|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
58435452|NCT00648700|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
58435453|NCT00648700|DRUG|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
58435454|NCT06075407|DEVICE|Assessment of fluid responsiveness by electrical cardiometry|"Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler)."
58435455|NCT01408459|DIETARY_SUPPLEMENT|Tomato Product|Motivational Telephone Counseling weekly
58435456|NCT01408459|DIETARY_SUPPLEMENT|Control|No Motivational telephone Counseling
58435457|NCT01439594|DEVICE|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
58435458|NCT03009617|BEHAVIORAL|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
57738027|NCT06544733|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
57738028|NCT05663294|RADIATION|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
57738029|NCT05663294|RADIATION|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
58104751|NCT06130709|PROCEDURE|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
58435459|NCT02065817|OTHER|stable isotope of cholesterol|
58435460|NCT00474617|DRUG|Sugammadex|
58435461|NCT00474617|DRUG|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
58435462|NCT02263443|PROCEDURE|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
58435463|NCT02263443|PROCEDURE|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
58435464|NCT02263443|PROCEDURE|No enema|Patients NPO groups will NPO and no bowel preparation.
58435465|NCT05641636|DIAGNOSTIC_TEST|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
58435466|NCT05510336|PROCEDURE|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
58435467|NCT05921253|DEVICE|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
58435468|NCT05921253|DEVICE|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
58435469|NCT03702036|DRUG|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
58435470|NCT01139177|DEVICE|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
58435471|NCT00486824|DRUG|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
58435472|NCT00486824|DRUG|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
58435473|NCT04683445|DRUG|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
58435474|NCT04683445|DRUG|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
57738030|NCT04401384|DRUG|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
58104752|NCT01822015|DRUG|Sirolimus|Given PO
58435475|NCT04683445|DRUG|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
58435476|NCT04683445|DRUG|Pyrotinib|Pyrotinib，400mg，oral，every day
58435477|NCT04683445|DRUG|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
58104753|NCT01822015|DRUG|Idarubicin|Given IV
58104754|NCT01822015|DRUG|Cytarabine|Given IV
58435478|NCT04683445|DRUG|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
58435479|NCT01688115|PROCEDURE|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
58435480|NCT01688115|OTHER|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
58435481|NCT01031173|BIOLOGICAL|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
58104755|NCT00965913|DRUG|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
58104756|NCT00965913|DRUG|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
58435482|NCT01958359|BEHAVIORAL|Short IVR|IVR-based alcohol diary with feedback
58435483|NCT01958359|BEHAVIORAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
58435484|NCT02805855|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
58435485|NCT00822536|DRUG|Aspirin and Clopidogrel|Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
58435486|NCT00822536|DRUG|Aspirin|Aspirin : \<= 325 mg/j
58435487|NCT00964821|BIOLOGICAL|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
58435488|NCT00964821|OTHER|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
58435489|NCT00964821|OTHER|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
58435490|NCT04471506|OTHER|interval training|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
58435491|NCT04471506|OTHER|diet recommendations|the control group will follow diet recommendations for 12 weeks
58435492|NCT04471506|OTHER|mindfulness breathing|Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
58435493|NCT06272500|OTHER|oral administration of receives only oral administration of placebo|receives only oral administration of placebo , with one capsule taken three times a day.
58435494|NCT06272500|OTHER|oral administration of compound digestive enzyme capsule|receives only oral administration of compound digestive enzyme capsule, with one capsule taken three times a day.
58435495|NCT06272500|OTHER|oral administration of Betaine hydrochloride|receives oral administration of Betaine hydrochloride(BHCL),with one capsule before each meal.
58435496|NCT04869306|DEVICE|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
58435497|NCT04869306|DEVICE|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
58435498|NCT05654454|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
58435499|NCT05654454|DRUG|Paclitaxel|Paclitaxel 175 mg/m2
58435500|NCT05654454|DRUG|Carboplatin|Carboplatin AUC 6
58435501|NCT06507696|OTHER|Ice Application|Drinking water was placed in a syringe and filled in the refrigerator
58435502|NCT06507696|OTHER|Wetted Gauze Application|Sterile gauze soaked with drinking water
58435503|NCT05293158|DRUG|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
58435504|NCT02888288|BEHAVIORAL|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
58435505|NCT02888288|BEHAVIORAL|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
58435506|NCT05838092|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
58435507|NCT05838092|DRUG|Placebo|Placebo
58435508|NCT03776591|PROCEDURE|Open surgery|
58435509|NCT03776591|PROCEDURE|Right colectomy|
58435510|NCT03776591|PROCEDURE|Laparoscopic surgery|
58435511|NCT03776591|PROCEDURE|Central lymphadenectomy and vascular ligation|
58435512|NCT01998308|DRUG|Crespine gel|50 Knees will have single injection of Crespine gel
58435513|NCT01998308|DRUG|Intragel|50 Knees will have single injection of 2 ampules of Intragel
57738031|NCT04401384|DRUG|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
58435514|NCT01998308|DRUG|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
57738032|NCT04401384|DEVICE|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
58435515|NCT01998308|DRUG|Monovisc|50 Knees will have single injection of Monovisc
58435516|NCT00451516|DRUG|Herbal medicine (St. John's wort and Kava)|
58435517|NCT00851929|DRUG|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
58435518|NCT02518633|DEVICE|Continuous positive airway pressure devices|overnight use of CPAP device
58435519|NCT02762214|DEVICE|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
58435520|NCT02762214|OTHER|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
58435521|NCT01971385|DRUG|Squaric Acid solution|
58435522|NCT01971385|DRUG|Placebo solution|
58104757|NCT00965913|DRUG|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
58435523|NCT00296920|DEVICE|Deep Brain Stimulation|
58435524|NCT03676140|DRUG|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
58435525|NCT03676140|DRUG|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
58435526|NCT03676140|DRUG|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
58435527|NCT03676140|DRUG|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
58435528|NCT03676140|DRUG|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
58435529|NCT00932867|DRUG|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
58435530|NCT06297382|BEHAVIORAL|ChatGPT Based Nursing Process Training|"ChatGPT Based Nursing Process Training topics:~Lesson 1: Use of artificial intelligence and ChatGPT in healthcare Lesson 2: Using ChatGPT in determining nursing diagnoses and goals Lesson 3: Using ChatGPT to determine nursing interventions Lesson 4: Things to consider and ethical principles when using ChatGPT when creating a nursing process."
58435531|NCT02905669|DEVICE|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
58435532|NCT03363880|OTHER|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
58435533|NCT03363880|OTHER|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
58435534|NCT04677504|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
58435535|NCT04677504|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
58435536|NCT04677504|OTHER|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
58435537|NCT04677504|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
58435538|NCT04677504|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
58435539|NCT03102060|OTHER|Dietary Intervention|Undergo gluten free diet
58435540|NCT03102060|OTHER|Laboratory Biomarker Analysis|Correlative studies
58435541|NCT02955342|OTHER|no intervention|no intervention
58309914|NCT05632614|DEVICE|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
58309915|NCT05632614|DEVICE|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
58309916|NCT05613348|BIOLOGICAL|CD19 CAR T-Cell(CAT19T2)|Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
58309917|NCT06017271|DIAGNOSTIC_TEST|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
58435542|NCT00881816|DRUG|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
58435543|NCT00627341|BEHAVIORAL|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
58435544|NCT00627341|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
58435545|NCT05296564|DRUG|CYCLOPHOSPHAMIDE and FLUDARABIN|1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
58435546|NCT05296564|DRUG|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
58435547|NCT05296564|BIOLOGICAL|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
58435548|NCT05296564|DRUG|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
58435549|NCT02904018|OTHER|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
58435550|NCT05246813|OTHER|Blood and bone marrow cell collection|Collection of blood and bone marrow
58435551|NCT02617654|DRUG|Liraglutide|Treatment with liraglutide for 52 weeks
58435552|NCT02617654|DRUG|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
58435553|NCT05814952|GENETIC|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
58104758|NCT03187080|PROCEDURE|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
58104759|NCT03187080|OTHER|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
58435554|NCT03471741|RADIATION|IMRT with concomitant boost|
58435555|NCT03471741|RADIATION|3D-RT with sequential boost|
58309918|NCT02230215|DEVICE|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
58309919|NCT04158765|OTHER|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
58309920|NCT01677286|DRUG|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
58309921|NCT03758508|DEVICE|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
58309922|NCT03758508|DEVICE|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
58309923|NCT05881811|DRUG|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
58309924|NCT03809390|PROCEDURE|Vaginal seeding|The same as that stated in arm descriptions.
58309925|NCT00938938|OTHER|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
58309926|NCT00004558|BEHAVIORAL|dietary n-3 polyunsaturated fatty acids|
58309927|NCT05277207|BEHAVIORAL|Personalized Smoking Cessation Facilitation Meetings|Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
58435556|NCT06583681|OTHER|The measuring of the sagittal curvatures of the spine|Research tool was Baseline Bubble inclinometer.
58435557|NCT00264264|PROCEDURE|Closure Device|
58435558|NCT00264264|PROCEDURE|Direct Compression|
58435559|NCT03191045|DIAGNOSTIC_TEST|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
58435560|NCT00516165|DRUG|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
58435561|NCT03701919|DRUG|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
58435562|NCT03701919|DRUG|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
57738033|NCT04401384|DEVICE|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
58435563|NCT01526395|DRUG|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
57738034|NCT00389714|DEVICE|dental restoration|
58435564|NCT03252002|DRUG|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
58435565|NCT03252002|DRUG|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
57738035|NCT02862106|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
57738036|NCT06319807|BEHAVIORAL|Digital Health Intervention|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
58309928|NCT05277207|DRUG|Personalized Smoking Cessation Pharmacotherapy|Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
58309929|NCT05277207|BEHAVIORAL|Personalized Text Messaging Support|If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
58309930|NCT05277207|BEHAVIORAL|SmokefreeVET|Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
58309931|NCT05277207|BEHAVIORAL|VA Quitline|Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
58309932|NCT05277207|OTHER|Education about pharmacotherapy|Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
58309933|NCT02518334|OTHER|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
58309934|NCT04081688|DRUG|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
58309935|NCT04081688|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
58309936|NCT04081688|DRUG|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
58309937|NCT06122558|DIETARY_SUPPLEMENT|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
58435566|NCT03874884|DRUG|Olaparib|"During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42."
58435567|NCT03874884|COMBINATION_PRODUCT|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
57738037|NCT06319807|BEHAVIORAL|Safety Control|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
57738038|NCT00562887|BIOLOGICAL|Placebo|every 4 weeks, IV
57738039|NCT00562887|BIOLOGICAL|ABT-874|400 mg IV every 4 weeks
57738040|NCT00562887|BIOLOGICAL|ABT-874|700 mg IV every 4 weeks
57954456|NCT02498639|PROCEDURE|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
57954457|NCT03627260|BEHAVIORAL|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
57954458|NCT03353571|DEVICE|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
57954459|NCT05424653|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
57954460|NCT00252343|DRUG|SR58611A|
58309938|NCT06122558|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
58309939|NCT03186755|DRUG|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
58309940|NCT03186755|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
58435568|NCT04362423|DEVICE|fNIRS|Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
57738041|NCT04769076|COMBINATION_PRODUCT|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
57738042|NCT03137134|DRUG|Crizotinib|Crizotinib in a coated microsphere formulation
57738043|NCT03137134|DRUG|Esomeprazole|Proton pump inhibitor, esomeprazole
57738044|NCT06304259|DRUG|Saline|Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine
57738045|NCT06304259|DRUG|Saline|root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
58435569|NCT04028141|DRUG|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
58435570|NCT01549925|OTHER|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
58435571|NCT01549925|DEVICE|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
58435572|NCT06371521|DIETARY_SUPPLEMENT|Sportlegs|Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).
57738046|NCT00249925|BEHAVIORAL|Home-Based Intervention|
57738047|NCT00249925|BEHAVIORAL|Multi-component home-based intervention|
58435573|NCT06371521|DIETARY_SUPPLEMENT|Placebo|Empty Capsules to serve as a placebo control
58435574|NCT05351866|DEVICE|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
58435575|NCT05351866|DEVICE|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
58435576|NCT00653380|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
58435577|NCT00653380|DRUG|Monodox|Capsules, 100 mg, single-dose
58435578|NCT03604796|DRUG|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
57738048|NCT01373528|DRUG|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
57954461|NCT05573074|DEVICE|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
57954462|NCT05573074|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
57738049|NCT03905200|DIAGNOSTIC_TEST|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
57954463|NCT03724565|PROCEDURE|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
57954464|NCT05858619|DRUG|Dupilumab|dupilumab 600 mg injection initially and then 300 mg every other week
57954465|NCT05352152|DIAGNOSTIC_TEST|Next generation sequence|Next generation sequence will be used to detect the pathogens in ascites.
58435579|NCT03604796|DRUG|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
58435580|NCT04284475|DIAGNOSTIC_TEST|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
58435581|NCT04284475|DIAGNOSTIC_TEST|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
58435582|NCT04284475|DIAGNOSTIC_TEST|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
57738050|NCT01614665|DRUG|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
58435583|NCT02673502|DIETARY_SUPPLEMENT|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
57954466|NCT05342675|PROCEDURE|Rapid Rollover|Repositioning of the participant post biopsy
58309941|NCT01547715|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
58309942|NCT01203696|DRUG|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
58309943|NCT01203696|DRUG|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
58435584|NCT02673502|DIETARY_SUPPLEMENT|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
58435585|NCT00439062|DRUG|Roxithromycin|
58435586|NCT00759421|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
58435587|NCT00759421|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
58435588|NCT05705427|DRUG|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
58435589|NCT05705427|BIOLOGICAL|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
57738051|NCT01614665|DRUG|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
57738052|NCT05870800|DRUG|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
57738053|NCT05870800|DRUG|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
58435590|NCT05705427|DRUG|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
58435591|NCT06230939|OTHER|Examination|"Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method."
57738054|NCT05870800|DRUG|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPEOX Q3 weeks x 4 cycles (12 weeks)
57738055|NCT03671668|OTHER|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
58435592|NCT01546688|DRUG|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
58435593|NCT01546688|DRUG|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
57738056|NCT06374485|DRUG|AU409 capsules|Oral administration
57954467|NCT03033875|BEHAVIORAL|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
57962137|NCT05410288|OTHER|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
57962138|NCT05410288|OTHER|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
57962139|NCT05410288|OTHER|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
57962140|NCT02072031|DRUG|Anlotinib|Anlotinib p.o. qd
57962141|NCT02072031|DRUG|Sunitinib maleate|Sunitinib 50 mg p.o. qd
57962142|NCT04409873|DRUG|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
57962143|NCT04409873|DRUG|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
57962144|NCT04409873|DRUG|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
57962145|NCT04409873|DRUG|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
57962146|NCT04409873|DRUG|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
57954468|NCT03033875|BEHAVIORAL|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
57954469|NCT03586414|DIETARY_SUPPLEMENT|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
57954470|NCT03586414|DIETARY_SUPPLEMENT|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
57954471|NCT02090322|PROCEDURE|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
57954472|NCT03108313|DRUG|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
57954473|NCT03108313|DRUG|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
57954474|NCT05459831|DEVICE|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
57954475|NCT06338956|DRUG|LDL reduction therapy|LDL reduction therapy
57954476|NCT04820894|OTHER|Electronic Medical Record|Medical records are reviewed
57954477|NCT04820894|OTHER|Survey Administration|Complete surveys
58104760|NCT03187080|PROCEDURE|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
58104761|NCT03187080|DRUG|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
57954478|NCT02408471|DEVICE|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
57954479|NCT00365521|PROCEDURE|Photodynamic Therapy|
57954480|NCT00439946|DRUG|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
57954481|NCT00439946|DEVICE|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
57954482|NCT02484911|DRUG|Olanzapine|5mg,twice a day orally on day 1 to day 4
57954483|NCT02484911|DRUG|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
57954484|NCT02484911|DRUG|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
58104762|NCT06174519|DEVICE|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
58104763|NCT03213054|BIOLOGICAL|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
58104764|NCT03213054|RADIATION|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
58104765|NCT03044431|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
58104766|NCT03841721|DRUG|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
58104767|NCT02490566|OTHER|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
58104768|NCT03039582|DIAGNOSTIC_TEST|Bidigital palpation|palpation of the anovaginal distance with two fingers
57954485|NCT02484911|DRUG|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
57954486|NCT01014832|DRUG|Intensive insulin therapy|Intensive insulin therapy
58435594|NCT06583707|PROCEDURE|Dry needling with and without ultrasound guidance|The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
58435595|NCT01497301|BEHAVIORAL|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
58435596|NCT04254601|DEVICE|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
58435597|NCT04254601|DRUG|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
58435598|NCT01002274|DRUG|MCS-2|2 soft-gel capsules Qd for 40 weeks
58435599|NCT03902834|OTHER|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
58435600|NCT05952388|OTHER|Behavioral Patient care|chart review
58435601|NCT03775746|DRUG|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
58435602|NCT03775746|DRUG|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
58435603|NCT03775746|DRUG|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
58435604|NCT02808910|BEHAVIORAL|Nudged to eat less added salt and more other seasonings|
57738057|NCT06052410|OTHER|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
57738058|NCT06052410|OTHER|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
58104769|NCT03039582|DIAGNOSTIC_TEST|Perineal ultrasound|ultrasound measurement of the anovaginal distance
58104770|NCT00496106|BEHAVIORAL|Telephone counseling|6 telephone counseling sessions
58435605|NCT02808910|BEHAVIORAL|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
58435606|NCT02808910|BEHAVIORAL|Nudged to eat more vegetables|
58435607|NCT02808910|BEHAVIORAL|Nudged to eat smaller portions|
58104771|NCT00496106|BEHAVIORAL|Telephone interview|telephone interview
58435608|NCT02808910|BEHAVIORAL|Nudged to eat less calorie-dense food|
58435609|NCT00002138|DRUG|Tecogalan sodium|
58435610|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
58435611|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
58435612|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
58435613|NCT01270815|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
58435614|NCT03215199|OTHER|NAPT|Web-based depression and distress monitoring application
58435615|NCT02856204|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood
58435616|NCT02856204|OTHER|Laboratory Biomarker Analysis|Correlative studies
58435617|NCT01719133|DRUG|placebo|saline solution
58435618|NCT01719133|DRUG|Histamine|positive control
58435619|NCT01719133|DRUG|AllerT1|synthetic peptide T1
58435620|NCT01719133|DRUG|AllerT2|synthetic peptide T2
58435621|NCT01719133|DRUG|AllerT3|synthetic peptide T3
58435622|NCT01719133|DRUG|AllerT4|synthetic peptide T4
58435623|NCT01719133|DRUG|AllerT5|synthetic peptide T5
58435624|NCT01719133|DRUG|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
58435625|NCT01719133|DRUG|mix of AllerT4-T5|mix T4-T5
58435626|NCT06442670|DEVICE|Electroencephalography|Phase synchrony during the completion of the semantic memory task
58435627|NCT02819791|OTHER|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
58435628|NCT02819791|BEHAVIORAL|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
58435629|NCT02707328|DRUG|Gemcitabine|
58435630|NCT02707328|DRUG|nab-paclitaxel|
58435631|NCT02707328|RADIATION|CyberKnife|
58435632|NCT03314311|BEHAVIORAL|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
58435633|NCT05213520|OTHER|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
57962147|NCT03965559|PROCEDURE|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]"
57962148|NCT04702165|DEVICE|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
57962149|NCT03899454|DRUG|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
57962150|NCT03899454|DRUG|Placebo Control|Placebo Control
57962151|NCT05256498|DEVICE|Picostim Amber|Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
57962152|NCT01654510|BEHAVIORAL|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
58435634|NCT05213520|OTHER|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
58435635|NCT05942599|BIOLOGICAL|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
58435636|NCT04698993|DIAGNOSTIC_TEST|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
58435637|NCT05856981|DRUG|ADU-1805|anti-SIRPα monoclonal antibody
57962153|NCT01654510|OTHER|Vocational Services as Usual|
57962154|NCT04372927|DRUG|Cisplatin|Given IV
57962155|NCT04372927|BIOLOGICAL|Durvalumab|Given IV
57962156|NCT04372927|DRUG|Etoposide|Given IV
57962157|NCT04372927|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
57962158|NCT04372927|DRUG|Pemetrexed|Given IV
57962159|NCT01418001|DRUG|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
57962160|NCT06549569|PROCEDURE|TFS|burn coverage with TFS
57962161|NCT03981783|BEHAVIORAL|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
57962162|NCT03981783|BEHAVIORAL|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
57962163|NCT01763450|DRUG|bevacizumab plus chemotherapy|"1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
57962164|NCT03602079|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
57962165|NCT02799680|BIOLOGICAL|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
57962166|NCT03770065|DEVICE|VML-0001|Medical device
57962167|NCT04783636|DRUG|leuprorelin acetate 3.75mg|PT105, PT105R
58435638|NCT05856981|DRUG|Pembrolizumab|Keytruda
58435639|NCT05231460|DRUG|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
58435640|NCT05231460|DRUG|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
58435641|NCT05231460|DRUG|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
58435642|NCT05231460|DRUG|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
58435643|NCT02260947|DRUG|PF-06273340|PF-06273340 50 mg
58435644|NCT02260947|DRUG|PF-06273340|PF-06273340 400 mg
58435645|NCT02260947|DRUG|Pregabalin|Pregabalin 300 mg
58435646|NCT02260947|DRUG|Ibuprofen|Ibuprofen 600 mg
58435647|NCT02260947|DRUG|Placebo|Matching Placebo
58435648|NCT03856827|DRUG|IW-6463|IW-6463 Tablet
58435649|NCT03856827|DRUG|Matching Placebo|Matching Placebo Tablet
58435650|NCT02085304|PROCEDURE|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
58435651|NCT02085304|RADIATION|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
58435652|NCT02085304|RADIATION|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
58435653|NCT02085304|DRUG|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
58435654|NCT02741765|BEHAVIORAL|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
58435655|NCT02741765|OTHER|Real rTMS|Subjects will participate in a combination of rTMS
57738059|NCT04313231|DIAGNOSTIC_TEST|Next Generation Sequencing|"Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%."
58104772|NCT03966469|OTHER|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
58435656|NCT02741765|BEHAVIORAL|Supervised aerobic exercise|
58104773|NCT03966469|OTHER|Patient Present Only|Patient presents to their preoperative appointment without a support person.
58309944|NCT05105256|DRUG|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
58309945|NCT05105256|DRUG|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
58435657|NCT03346200|DRUG|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
58435658|NCT03346200|DRUG|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
58435659|NCT04916912|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
58435660|NCT01240200|DRUG|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
58435661|NCT01240200|DEVICE|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
58435662|NCT02356289|DRUG|Placebo|
58435663|NCT02356289|DRUG|MYK-461|
58435664|NCT04839549|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
58435665|NCT04839549|DRUG|Fluoromethalone .01%|Fluoromethalone .01%
58435666|NCT03150420|DRUG|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
58435667|NCT03150420|DRUG|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
58435668|NCT04260347|DRUG|Alteplase|Intravenous injection
58435669|NCT01122849|DEVICE|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
58435670|NCT01122849|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
58435671|NCT01122849|DEVICE|Placebo Nasal Strip|Placebo strip
58435672|NCT02164266|DRUG|Placebo|Matching placebo daily oral administration
58435673|NCT02164266|DRUG|RO6799477|Daily oral administration of RO6799477
58435674|NCT06396624|RADIATION|Intervention Group photobiomodulation|Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.
58435675|NCT06396624|OTHER|Control Group|The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
58435676|NCT02014168|BIOLOGICAL|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
58104774|NCT04347161|DEVICE|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
58435677|NCT02014168|BIOLOGICAL|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
58435678|NCT02523781|OTHER|information pamphlet|The intervention group receives the information pamphlet
57954487|NCT00847912|DRUG|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
58104775|NCT04347161|OTHER|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
58104776|NCT04549909|OTHER|collect retrospectively data|Analyse the incidence of BPL in these populations
58104777|NCT01615302|PROCEDURE|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
58104778|NCT01615302|OTHER|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
58309946|NCT02426697|DRUG|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
58435679|NCT00397436|PROCEDURE|UV Irradiation|UV irradiation
58435680|NCT02215135|DRUG|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
58435681|NCT00771771|OTHER|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
58435682|NCT00771771|OTHER|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
58435683|NCT00305149|PROCEDURE|interim therapy scintigraphy study gallium scan or PET/CT|
58435684|NCT00305149|PROCEDURE|"interim gallium or PET/CT"|
58435685|NCT00067379|PROCEDURE|interceptive orthodontic treatments|orthodontic procedures
58435686|NCT00627133|DRUG|levetiracetam|2 gram iv load, 500mg bid
57954488|NCT00847912|DRUG|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
57954489|NCT02762474|DRUG|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
57954490|NCT02022488|DRUG|midazolam|Group M
57954491|NCT02022488|DRUG|alfentanil|Group MA
57954492|NCT02022488|DRUG|ketamine|Group MK
58104779|NCT03148288|DIETARY_SUPPLEMENT|Vitamin D|VItamin D
58104780|NCT03148288|DIETARY_SUPPLEMENT|placebo|placebo
58104781|NCT01027637|OTHER|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
58104782|NCT02290028|DEVICE|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
58435687|NCT04702425|DRUG|VOB560|Powder for concentrate for solution for infusion
58435688|NCT04702425|DRUG|MIK665|Concentrate for solution for infusion
58435689|NCT06040853|DRUG|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
58435690|NCT06040853|DRUG|Saline|Participant was given intravenous 100 ml saline
58435691|NCT03522220|BEHAVIORAL|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
58435692|NCT03522220|BEHAVIORAL|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
58435693|NCT03522220|BEHAVIORAL|No 3D navigation|Participants read on a kindle device (control group)
58435694|NCT03540199|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
58435695|NCT03540199|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
58435696|NCT05758350|BEHAVIORAL|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
58435697|NCT06436703|BIOLOGICAL|Influenza ModRNA Vaccine|Intramuscular injection
58435698|NCT06436703|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|Intramuscular injection
58104783|NCT00762983|DRUG|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
58104784|NCT00056459|DRUG|Vatalanib|
58104785|NCT02477007|DRUG|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
58104786|NCT02477007|DRUG|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
58104787|NCT02477007|DRUG|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
58104788|NCT02477007|DRUG|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
58104789|NCT01595074|OTHER|medical chart review|Correlative studies
58104790|NCT01595074|OTHER|laboratory biomarker analysis|Correlative studies
57738060|NCT04313231|DIAGNOSTIC_TEST|Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction|"Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit."
58104791|NCT02602964|OTHER|Deep neuromsucular block|Deep or standard neuromuscular block
58104792|NCT03360656|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
58309947|NCT02426697|DRUG|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
58309948|NCT01381497|DRUG|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
58309949|NCT01381497|DRUG|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
58309950|NCT01780623|DEVICE|Bright white light|
58309951|NCT01780623|DEVICE|Dim red light|
58309952|NCT06050681|BEHAVIORAL|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 \& 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
58104793|NCT06542276|DEVICE|Thermal Vectored Pulsation|The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
58104794|NCT01004796|GENETIC|cytogenetic analysis|
57954493|NCT03528512|DRUG|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
58104795|NCT01004796|GENETIC|microarray analysis|
58104796|NCT01004796|GENETIC|mutation analysis|
58104797|NCT01004796|OTHER|immunohistochemistry staining method|
58309953|NCT05339958|DIETARY_SUPPLEMENT|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
58309954|NCT05339958|OTHER|Placebo Supplement|The placebo capsules contain no active ingredients.
57954494|NCT03528512|DRUG|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
58104798|NCT01004796|OTHER|immunologic technique|
58104799|NCT01004796|OTHER|mass spectrometry|
58104800|NCT00704717|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
58104801|NCT00704717|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
58309955|NCT01607658|DRUG|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
58309956|NCT01607658|DRUG|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
58435699|NCT00003512|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58435700|NCT00535119|DRUG|Carboplatin|Given IV
58435701|NCT00535119|OTHER|Laboratory Biomarker Analysis|Correlative studies
58435702|NCT00535119|DRUG|Paclitaxel|Given IV
58435703|NCT00535119|OTHER|Pharmacological Study|Correlative studies
58435704|NCT00535119|DRUG|Veliparib|Given PO
58435705|NCT05502445|OTHER|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
58435706|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
58435707|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
58104802|NCT06247293|PROCEDURE|intraperitoneal hyperthermic perfusion chemotherapy|"（1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding."
58435708|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
58435709|NCT04771637|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
58435710|NCT01122615|DRUG|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
58435711|NCT01122615|DRUG|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
57738061|NCT04313231|DIAGNOSTIC_TEST|flow cytometry|A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
57954495|NCT03246737|OTHER|monitoring|
57954496|NCT05182957|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
58104803|NCT01754090|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
58104804|NCT01754090|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
58435712|NCT05419934|BEHAVIORAL|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization."
58435713|NCT05419934|BEHAVIORAL|Routine Care|Children in the routine care group receive psychological monitoring administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P). The proposed treatment is a psychological follow-up associated with relational support psychotherapy
57954497|NCT05182957|DRUG|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
57954498|NCT05182957|DRUG|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
58435714|NCT05169424|DEVICE|Trelegy Ellipta|Trelegy Ellipta
58435715|NCT05169424|DEVICE|Stiolto Respimat|Stiolto Respimat
58435716|NCT05169424|DRUG|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
58435717|NCT05169424|DRUG|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
58435718|NCT02736435|DEVICE|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
58435719|NCT02736435|DRUG|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
58435720|NCT03186417|BIOLOGICAL|2 million hMSC/kg|2 million hMSCs/kg infusion
58435721|NCT03186417|BIOLOGICAL|4 million hMSC/kg|4 million hMSC/kg infusion
58435722|NCT03186417|BIOLOGICAL|6 million hMSC/kg|6 million hMSC/kg infusion
58435723|NCT03186417|BIOLOGICAL|placebo|placebo infusion
58435724|NCT04808739|BIOLOGICAL|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
58435725|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
58435726|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
58435727|NCT06525584|OTHER|Control|Without ketamine
58435728|NCT05552352|OTHER|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
57954499|NCT04996121|DRUG|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
57954500|NCT02595450|DRUG|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
57954501|NCT00295984|DRUG|nicotine|
57954502|NCT03976037|DRUG|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
57954503|NCT01695473|DRUG|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
57954504|NCT02805777|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
57954505|NCT02325219|DRUG|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
57954506|NCT02325219|DRUG|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
57954507|NCT02325219|DRUG|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
57954508|NCT02325219|DRUG|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
57954509|NCT04145011|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
57954510|NCT04145011|DEVICE|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
58435729|NCT05260762|DIETARY_SUPPLEMENT|Arabinoxylan|Dietary fiber product
58435730|NCT05260762|DIETARY_SUPPLEMENT|Control|Potato starch
58104805|NCT01754090|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
58104806|NCT06543017|OTHER|Experimental group|This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
58104807|NCT04727346|RADIATION|CBCT|Cone Beam Computed Tomography
58104808|NCT04727346|PROCEDURE|DISE|Drug Induced Sleep Endoscopy
58104809|NCT00420849|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
58104810|NCT00420849|DRUG|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
58104811|NCT02688816|DEVICE|Xpert HPV|Point-of-care HPV DNA PCR test
58104812|NCT02688816|DEVICE|OncoE6|Point-of-care E6 oncoprotein test
58104813|NCT06496906|PROCEDURE|Tooth extraction|A regular closed tooth extraction was performed with the different devices from each arm.
58104814|NCT06496906|DEVICE|Benex|Benex was used to perform the intervention.
58309957|NCT01607658|DRUG|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
58309958|NCT01607658|DRUG|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
58309959|NCT05475145|PROCEDURE|Resin based sealing [RBS]|
58309960|NCT04333693|PROCEDURE|Vascular surgery|Open vascular, endovascular or hybrid procedures
58309961|NCT00781950|DIETARY_SUPPLEMENT|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
58309962|NCT00781950|DIETARY_SUPPLEMENT|Placebo|Wheat and Mixed Dietary Oils
58309963|NCT00551369|RADIATION|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
58309964|NCT04989673|OTHER|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
58435731|NCT05386693|PROCEDURE|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
58435732|NCT04813887|OTHER|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
58435733|NCT02395614|DRUG|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
58104815|NCT06496906|DEVICE|Physics Forceps|Physics forceps were used to perform the intervention.
58104816|NCT06496906|DEVICE|Conventional Extraction Forceps|Conventional Extraction Forceps were used to perform the intervention.
58104817|NCT04934111|DRUG|LNP-nCOV saRNA-02 Vaccine|a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
58104818|NCT01433198|OTHER|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
58104819|NCT06527001|OTHER|No intervention|This is an observational study and did not involve interventions.
58309965|NCT04989673|OTHER|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
58309966|NCT04989673|OTHER|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
58309967|NCT04989673|OTHER|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
58309968|NCT00957359|DRUG|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
58309969|NCT00957359|DRUG|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
58435734|NCT02395614|DRUG|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
58435735|NCT05972746|DEVICE|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
58435736|NCT05972746|OTHER|Standard of care|Standard of care
58435737|NCT05755672|DRUG|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
58435738|NCT05755672|PROCEDURE|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
58309970|NCT04918823|DRUG|Restasis|Subject will use one drop of Restasis in the lens before insertion
58104820|NCT03113825|DEVICE|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
58104821|NCT03113825|DRUG|AVB-620|AVB-620 will be administered IV before the surgical procedure.
58104822|NCT05824156|BIOLOGICAL|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
58104823|NCT05824156|OTHER|Placebo|Placebo
57738062|NCT04313231|DIAGNOSTIC_TEST|Metagenomics of stool samples|DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
58104824|NCT02971345|PROCEDURE|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
58104825|NCT02971345|DEVICE|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
58104826|NCT02971345|DEVICE|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
58104827|NCT02971345|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
58104828|NCT02971345|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
58104829|NCT02971345|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
58309971|NCT00102323|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
58435739|NCT05755672|PROCEDURE|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
58435740|NCT05755672|PROCEDURE|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
58435741|NCT05599243|DRUG|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
58435742|NCT05599243|OTHER|Placebo|Vehicle excipient
58309972|NCT00102323|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
58309973|NCT01868568|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin).
58435743|NCT05593627|DRUG|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
58435744|NCT05593627|DRUG|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
58435745|NCT01129661|BIOLOGICAL|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
58435746|NCT01129661|BIOLOGICAL|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
58435747|NCT04228367|DEVICE|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
58435748|NCT01344083|DRUG|T1210|2 drops T1210 once a day
58435749|NCT01344083|DRUG|Olopatadine hydrochloride|2 drops once a day Olopatadine
58435750|NCT03955627|BEHAVIORAL|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
57738063|NCT04313231|DIAGNOSTIC_TEST|Clinical/demographic data|Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
58104830|NCT06161740|PROCEDURE|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
58104831|NCT01096706|DRUG|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
58104832|NCT01096706|DRUG|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
58104833|NCT01096706|DRUG|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
58309974|NCT01868568|DRUG|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
58309975|NCT01868568|DRUG|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
58309976|NCT01868568|DRUG|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
58309977|NCT01868568|DRUG|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
58309978|NCT01868568|DRUG|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
58309979|NCT01868568|DRUG|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
58309980|NCT01868568|DRUG|placebo|A single dose administered subcutaneously (s.c., under the skin).
58309981|NCT05094427|PROCEDURE|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
58309982|NCT00976339|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
58309983|NCT06062992|DIAGNOSTIC_TEST|Contrast Enhanced Stereotactic Biopsy|Stereotactic breast biopsy using CEM as targeting modality
58309984|NCT03002896|BEHAVIORAL|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
58309985|NCT03002896|OTHER|Treatment as Usual|
58309986|NCT01198405|DEVICE|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
58309987|NCT01198405|DRUG|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
58309988|NCT01478659|DIETARY_SUPPLEMENT|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
58435751|NCT01632436|DRUG|Pixantrone|Experimental Drug
57738064|NCT04313231|OTHER|Elicitation of the HRQoL|Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
58435752|NCT02229929|DRUG|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
57954511|NCT00498173|DRUG|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
57954512|NCT00498173|DRUG|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
57954513|NCT00450476|DEVICE|Hi-Lo Evac Endotracheal Tube|
58435753|NCT02229929|DRUG|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
58435754|NCT02229929|DRUG|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
58104834|NCT01096706|DRUG|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
58309989|NCT01478659|DIETARY_SUPPLEMENT|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
58435755|NCT02229929|DRUG|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
58309990|NCT04315402|OTHER|prospective, descriptive study via survey|"* Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review."
58309991|NCT04698811|BEHAVIORAL|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
58309992|NCT02243657|DRUG|ASP3652|oral
58309993|NCT02243657|DRUG|Placebo|oral
58309994|NCT00744341|DRUG|SLV320|1.25mg i.v. bid
58309995|NCT00744341|DRUG|SLV320|3.75mg i.v. bid
58309996|NCT00744341|DRUG|SLV320|7.5mg i.v. bid
58309997|NCT00744341|DRUG|SLV320|15.0mg i.v. bid
58309998|NCT00744341|DRUG|Placebo|
58309999|NCT01052948|OTHER|Retrospective study-|
58310000|NCT01052948|OTHER|Retrospective study-|
58310001|NCT01052948|OTHER|Retrospective study-|
58310002|NCT01052948|OTHER|Retrospective study-|
58310003|NCT03023995|PROCEDURE|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
58310004|NCT03023995|PROCEDURE|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
58310005|NCT00581217|OTHER|Aquacel Ag|Aquacel Ag will be applied to one donor site.
58310006|NCT00581217|OTHER|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
58310007|NCT06044987|PROCEDURE|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
58310008|NCT06044987|PROCEDURE|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
58310009|NCT05093868|DEVICE|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
58310010|NCT00106002|DRUG|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
58310011|NCT03019380|DEVICE|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
58310012|NCT03242785|OTHER|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
58310013|NCT01785381|OTHER|Added value of coordinator|Added value of coordinator
58310014|NCT04018066|DIETARY_SUPPLEMENT|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
58310015|NCT04321889|DEVICE|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
58310016|NCT04321889|OTHER|Placebo|nanotechnological system loaded with placebo cream
58310017|NCT05043740|DRUG|Repatha or Praluent|Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
57738065|NCT06285682|DIETARY_SUPPLEMENT|OliPhenolia®)|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
57738066|NCT04734210|DRUG|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
58310018|NCT00395577|DRUG|VX-702|
58310019|NCT05495178|PROCEDURE|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
58435756|NCT02229929|DRUG|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
58435757|NCT02229929|DRUG|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
58435758|NCT03100058|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
58435759|NCT03100058|DRUG|Placebo|Placebo
57738067|NCT04734210|DRUG|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
58104835|NCT01096706|DRUG|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
58104836|NCT05759169|OTHER|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
58310020|NCT06432348|OTHER|Reformer pilates|Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Reformer Pilates sessions and three team training days.
58310021|NCT06432348|OTHER|Mat Pilates|Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Mat Pilates sessions and three team training days.
58310022|NCT03099525|OTHER|ILD|This is an observational study without any intervention.
58310023|NCT03279458|DEVICE|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
58310024|NCT03635918|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
58310025|NCT03159403|DRUG|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
58310026|NCT03409744|DRUG|evinacumab|Intravenous (IV) administration
58310027|NCT02944292|PROCEDURE|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
58435760|NCT05127239|BEHAVIORAL|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
58435761|NCT02065505|OTHER|Mat Pilates|
58435762|NCT02065505|OTHER|Water Pilates|
58435763|NCT06464263|DRUG|Dexmedetomidine|to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
58435764|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
58435765|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
58435766|NCT05813691|DIAGNOSTIC_TEST|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
58435767|NCT04431492|PROCEDURE|CABG|aminoacids and NO levels
57738068|NCT04734210|DRUG|Placebo|topical vehicle solution
57738069|NCT03857659|DIAGNOSTIC_TEST|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
57954514|NCT05318456|DIETARY_SUPPLEMENT|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
58104837|NCT05990647|DIAGNOSTIC_TEST|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
58104838|NCT05990647|DIAGNOSTIC_TEST|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
58104839|NCT05990647|DIAGNOSTIC_TEST|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
58104840|NCT05990647|DIAGNOSTIC_TEST|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
58104841|NCT00986154|DRUG|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
58435768|NCT02630303|DEVICE|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
58104842|NCT00986154|DRUG|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
58104843|NCT00986154|DRUG|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
57738070|NCT03857659|DIAGNOSTIC_TEST|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
57738071|NCT03857659|DIAGNOSTIC_TEST|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
57738072|NCT01781728|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
58104844|NCT02980562|DRUG|Polyethylene Glycols|(Split dose 2L PEG-Asc)
58104845|NCT02980562|DRUG|Bisacodyl|(1L PEG-Asc plus bisacodyl)
57738073|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
57738074|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
57738075|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
57738076|NCT01846338|DIETARY_SUPPLEMENT|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
57738077|NCT06669962|DIAGNOSTIC_TEST|Study of coronary microcirculation and biomarkers of microvascular dysfunction|Patients with tako-tsubo syndrome will undergo to coronary angiography, ventriculography and assessment of physiological indexes of coronary circulation as per clinical practice
57738078|NCT03747926|DRUG|BI 705564|single-rising oral dose
57738079|NCT03747926|DRUG|Placebo|single-rising oral dose
57738080|NCT05794269|OTHER|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
57738081|NCT01260844|DRUG|briakinumab|single dose briakinumab and 2 doses of CYP substrates
57954515|NCT05318456|DIETARY_SUPPLEMENT|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
58104846|NCT05974345|DRUG|Inclisiran sodium|Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
58104847|NCT05974345|DRUG|Placebo|Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
58104848|NCT05974345|DRUG|Ezetimibe|Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
58104849|NCT05974345|DRUG|Evolocumab|Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
58104850|NCT00029328|DRUG|etanercept|
58104851|NCT01248611|DRUG|fentanyl|nasally, dose titrated to effect
58104852|NCT01339078|PROCEDURE|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
58435769|NCT02630303|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
58435770|NCT03801226|DRUG|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
58435771|NCT03801226|DRUG|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
58435772|NCT02716181|DEVICE|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
58435773|NCT02716181|DEVICE|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
58435774|NCT06239103|DEVICE|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
58104853|NCT01339078|PROCEDURE|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
58104854|NCT03798522|PROCEDURE|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
58104855|NCT03798522|DRUG|Nalbuphine|in nalbuphine for analgesia after GA
58435775|NCT06239103|DEVICE|Sham treatment|Sham treatment, using the same PEMF device
58104856|NCT01796041|DRUG|Indocyanine Green|
58435776|NCT03064971|BEHAVIORAL|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
58435777|NCT03064971|BEHAVIORAL|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
58435778|NCT03064971|BEHAVIORAL|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
58104857|NCT00659581|DRUG|Telmisartan|Oral administration
58104858|NCT05025982|PROCEDURE|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
58435779|NCT00932412|DRUG|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
58435780|NCT00932412|DRUG|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
58435781|NCT00448747|DRUG|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
58435782|NCT00448747|DRUG|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
58104859|NCT01611168|OTHER|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
58435783|NCT04448769|BIOLOGICAL|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
58435784|NCT03700489|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
58104860|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
58104861|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
58104862|NCT00918632|DRUG|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
58435785|NCT05913024|BIOLOGICAL|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
58435786|NCT05888753|PROCEDURE|Adrenalectomy|Scheduled adrenal surgery
58435787|NCT02997059|DRUG|Fluconazole|200 mg/ day
58435788|NCT02997059|OTHER|Placebo|
58435789|NCT01894932|BEHAVIORAL|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
57954516|NCT05318456|OTHER|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
57954517|NCT05561517|OTHER|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
58435790|NCT01894932|BEHAVIORAL|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
58104863|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
58104864|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
58104865|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
58435791|NCT04374045|OTHER|ECG-Holter|Patient will have a ECG-Holter recording during all their hospitalization.
57738082|NCT05751473|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
57954518|NCT03318146|DEVICE|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
58104866|NCT05491213|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
58104867|NCT02165566|DRUG|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
57954519|NCT03318146|DRUG|XALATAN®|one drop in the affected eye(s) once daily in the evening
58435792|NCT00098579|DRUG|alvocidib|Given IV
58435793|NCT00098579|DRUG|doxorubicin hydrochloride|Given IV
58435794|NCT04440813|BEHAVIORAL|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
58435795|NCT04440813|BEHAVIORAL|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
57954520|NCT05910866|DEVICE|Left bundle branch area pacing (LBBAP)|Pacing of the conduction system of the heart to obtain physiological activation
58435796|NCT03834831|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10
57954521|NCT05910866|DEVICE|Right ventricular pacing (RVP)|Conventional ventricular pacing
58104868|NCT02165566|DRUG|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
58435797|NCT03834831|DIETARY_SUPPLEMENT|Selenium|Selenium
58435798|NCT00336297|PROCEDURE|Woman Abuse Screening Tool|
58435799|NCT00336297|PROCEDURE|Partner Violence Screen|
58435800|NCT00336297|PROCEDURE|Computerized screening|
58435801|NCT00336297|PROCEDURE|Face to face screening|
58435802|NCT00336297|PROCEDURE|Written screening on forms|
58435803|NCT02211612|DIETARY_SUPPLEMENT|PUFA-group|
58435804|NCT02211612|DIETARY_SUPPLEMENT|SFA-group|
58435805|NCT01918956|BIOLOGICAL|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
58435806|NCT04202887|DRUG|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
58435807|NCT04202887|DRUG|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
58435808|NCT04202887|DEVICE|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
58435809|NCT01586221|OTHER|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
57954522|NCT02197676|DRUG|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
57954523|NCT01262521|DIETARY_SUPPLEMENT|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
57954524|NCT01262521|DIETARY_SUPPLEMENT|Water|150 ml Chapelle mineral water
58435810|NCT06124391|OTHER|Long-term follow-up|Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
58435811|NCT04991129|DRUG|WJ01024|5mg QD: WJ01024, Q4W, once per day
58435812|NCT04991129|DRUG|WJ01024|5mg BID: WJ01024, Q4W, twice per day
58435813|NCT04991129|DRUG|WJ01024|10mg BID: WJ01024, Q4W, twice per day
58435814|NCT04991129|DRUG|WJ01024|40mg BIW: WJ01024, Q4W, twice per week
58435815|NCT04991129|DRUG|WJ01024|60mg BIW: WJ01024, Q4W, twice per week
58435816|NCT04991129|DRUG|WJ01024|80mg BIW: WJ01024, Q4W, twice per week
58435817|NCT04991129|DRUG|WJ01024|60mg QW: WJ01024, Q4W, once per week
58435818|NCT04991129|DRUG|WJ01024|80mg QW: WJ01024, Q4W, once per week
58435819|NCT04991129|DRUG|WJ01024|50mg QW: WJ01024, Q4W, once per week
58435820|NCT04991129|DRUG|WJ01024|40mg QW: WJ01024, Q4W, once per week
58435821|NCT05545839|BEHAVIORAL|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
58435822|NCT04588116|BEHAVIORAL|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
57954525|NCT06063109|DRUG|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
57954526|NCT06063109|DRUG|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
57954527|NCT02072811|DRUG|DAC|"* DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
57954528|NCT02072811|DRUG|CLAG|"* G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
57954529|NCT02072811|DRUG|Consolidation, I HAM cycle|"* Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
58435823|NCT03985371|DRUG|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
58435824|NCT01618825|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
58435825|NCT01618825|DRUG|Lamotrigine|2 x 25 mg tablet once a day
58435826|NCT02395523|RADIATION|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
58104869|NCT04501549|PROCEDURE|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
58104870|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
58104871|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
58104872|NCT02677675|BEHAVIORAL|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
58104873|NCT00388570|DEVICE|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
58104874|NCT05839860|OTHER|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
58104875|NCT05839860|OTHER|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
58104876|NCT05839860|OTHER|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
57954530|NCT02072811|DRUG|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
57954531|NCT02072811|DRUG|Consolidation, III HiDAraC cycle|"* Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~* 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
58104877|NCT02130895|OTHER|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with \>=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
58104878|NCT02486471|PROCEDURE|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
58104879|NCT02486471|OTHER|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
57954532|NCT01311037|OTHER|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
58104880|NCT00454311|PROCEDURE|Biopsy of Day 3 Embryo|
58104881|NCT00454311|PROCEDURE|· day embryo biopsy|
58104882|NCT02122471|DRUG|Plecanatide|
57954533|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
57954534|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
57954535|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 1 mg/kg IV on Day 1
57954536|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 5 mg/kg IV on Day 1
57954537|NCT00607308|DRUG|Placebo|Single dose of placebo IV on Day 1
57954538|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 10 mg/kg IV on Day 1
57954539|NCT02335996|BIOLOGICAL|Blood samples for measuring adiponectin, leptin and omentin plasma|
57954540|NCT02335996|DEVICE|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
57954541|NCT01220895|BIOLOGICAL|CMV-specific T-cells, single infusion following single positive CMV PCR result|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
57954542|NCT02890810|OTHER|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
57954543|NCT02890810|OTHER|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
57954544|NCT02690311|DEVICE|smartphone display|
58104883|NCT02122471|DRUG|Placebo|
58104884|NCT01890330|OTHER|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
58435827|NCT02329899|OTHER|Second step of investigations|"Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia."
58435828|NCT05463016|DEVICE|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
58435829|NCT05463016|DEVICE|Placebo Group 1: Placebo Lenses|Placebo Lenses
58104885|NCT01890330|OTHER|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
58104886|NCT06542627|DEVICE|Freestyle Libre|Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
57738083|NCT05751473|BEHAVIORAL|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
58104887|NCT04089280|DIETARY_SUPPLEMENT|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
58104888|NCT04089280|OTHER|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
58104889|NCT05130866|DRUG|REC-2282|Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
58104890|NCT05130866|DRUG|Placebo|Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
58435830|NCT05463016|DEVICE|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
58435831|NCT05463016|DEVICE|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
58435832|NCT05463016|DEVICE|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
57738084|NCT01733056|BIOLOGICAL|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
57954545|NCT03829930|DRUG|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
57954546|NCT03829930|DRUG|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
57954547|NCT01962571|DRUG|Erythropoietin alfa|
57954548|NCT01962571|DRUG|Placebo|
57954549|NCT00434564|PROCEDURE|Stress nuclear scan|
57954550|NCT02626507|DRUG|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
57954551|NCT02626507|DRUG|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
57954552|NCT02626507|DRUG|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
57954553|NCT02626507|DRUG|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
58104891|NCT02584205|DEVICE|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
58104892|NCT00149669|BEHAVIORAL|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
58104893|NCT01289938|DRUG|Diphenhydramine|Diphenhydramine 50 mg oral once
58104894|NCT01289938|DRUG|Metoclopramide|10 mg i.v. metoclopramide once
58104895|NCT02965469|BEHAVIORAL|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
58104896|NCT00665717|DRUG|Pravastatin|40 mg tablet; QD; 4 days
58104897|NCT00665717|DRUG|Raltegravir|400mg tablet; BD 4 days
58104898|NCT00665717|DRUG|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
58104899|NCT02195960|DIETARY_SUPPLEMENT|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
58435833|NCT02396355|DEVICE|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
58435834|NCT02396355|DEVICE|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
58435835|NCT02396355|DEVICE|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
58435836|NCT03781778|OTHER|Dietary Intervention (resistant starch)|Eat foods with resistant starch
58435837|NCT03781778|OTHER|Dietary Intervention (regular starch)|Eat foods with regular corn starch
58435838|NCT03781778|OTHER|Questionnaire Administration|Ancillary studies
58435839|NCT03676907|PROCEDURE|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
58435840|NCT06294340|OTHER|Exposure to loud pre-recorded road traffic noise|Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
58435841|NCT02435927|DRUG|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
58435842|NCT02435927|DRUG|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
58435843|NCT06160427|BIOLOGICAL|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
58435844|NCT06160427|BIOLOGICAL|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
58435845|NCT03421912|OTHER|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
58435846|NCT03421912|OTHER|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
58435847|NCT00461084|DRUG|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
58435848|NCT00461084|DRUG|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
58435849|NCT02313974|PROCEDURE|Renal Biopsy|
58435850|NCT00066027|DRUG|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
58435851|NCT00066027|DRUG|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
58435852|NCT06447402|DRUG|Normal saline|5 mL of normal saline will be nebulised in the control arm
58435853|NCT06447402|DRUG|Amphotericin B deoxycholate|2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
58435854|NCT00416455|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
57738085|NCT02234531|DEVICE|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
57738086|NCT02234531|DEVICE|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
57738087|NCT03637946|OTHER|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
57738088|NCT01390467|DRUG|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
58435855|NCT00416455|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
58435856|NCT00416455|PROCEDURE|computed tomography|Undergo FDG PET/CT
58435857|NCT00416455|DRUG|ferumoxtran-10|Undergo femoxtran-10 MRI
58435858|NCT00416455|PROCEDURE|magnetic resonance imaging|Undergo femoxtran-10 MRI
58435859|NCT00416455|PROCEDURE|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
57954554|NCT03712397|DRUG|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
57954555|NCT00248183|DRUG|PRX-00023|
58435860|NCT00416455|PROCEDURE|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
58435861|NCT02699710|DRUG|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
58435862|NCT02699710|DRUG|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
58435863|NCT02699710|DRUG|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
58435864|NCT02699710|DRUG|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
58435865|NCT01412788|PROCEDURE|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
58435866|NCT01412788|PROCEDURE|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
58104900|NCT02195960|DIETARY_SUPPLEMENT|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
57954556|NCT04933929|BEHAVIORAL|Post-hospitalization nutritional monitoring|Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
57954557|NCT04505098|DRUG|Icosapent ethyl|2 g by mouth twice daily for at least 6 months
58104901|NCT01531868|OTHER|Video|Video of physician
58104902|NCT01531868|OTHER|Video|Video of physician
58104903|NCT01531868|OTHER|Video|Video of physician
58104904|NCT01531868|OTHER|Video|Video of physician
58104905|NCT01531868|OTHER|Video|Video of physician
58104906|NCT01531868|OTHER|Video|Video of physician
58310028|NCT02944292|DRUG|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
58310029|NCT05646914|OTHER|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
58310030|NCT05646914|OTHER|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
58310031|NCT01646437|DRUG|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
58310032|NCT01646437|DRUG|Aspirin|75 mg daily
58310033|NCT01646437|DRUG|Vitamin D|60,000 IU monthly
58310034|NCT01646437|DRUG|Matching Placebo|Matching Placebo
58310035|NCT05966233|DRUG|R-DHAP|"* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
58310036|NCT05966233|DRUG|Pola-R-DHAP|"* Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
58310037|NCT03542578|DEVICE|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
58310038|NCT03708146|DRUG|BIA 5-1058|"25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
58435867|NCT05670158|BIOLOGICAL|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
58104907|NCT05771116|PROCEDURE|ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:|catheter will be placed for ERECTOR SPINAE PLANE BLOCK
58104908|NCT05771116|PROCEDURE|PARAVERTEBRAL BLOCK:|catheter will be placed for PARAVERTEBRAL BLOCK
58104909|NCT02219295|DIETARY_SUPPLEMENT|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
58104910|NCT02219295|DIETARY_SUPPLEMENT|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
58104911|NCT02219295|DIETARY_SUPPLEMENT|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
58104912|NCT02219295|OTHER|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
58104913|NCT00868582|OTHER|PET scanning in cancer|Collection of institutional practice PET imaging data
58104914|NCT01862718|PROCEDURE|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
58104915|NCT01862718|PROCEDURE|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
58104916|NCT03985033|OTHER|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
58104917|NCT03403920|OTHER|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
58104918|NCT03513978|OTHER|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
58435868|NCT05670158|PROCEDURE|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
58435869|NCT01890564|OTHER|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
58435870|NCT01890564|OTHER|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
58435871|NCT01890564|OTHER|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
58435872|NCT03401671|DRUG|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
58435873|NCT00681928|DRUG|anastrozole|As determined by the subject's physician
58435874|NCT00681928|DRUG|letrozole|As determined by the subject's physician
58435875|NCT00681928|OTHER|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
58435876|NCT00681928|PROCEDURE|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
58435877|NCT00681928|PROCEDURE|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
58435878|NCT04487652|OTHER|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
58435879|NCT04487652|DRUG|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
58104919|NCT03513978|OTHER|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
58104920|NCT05860790|DIAGNOSTIC_TEST|Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery|This is a clinical prediction model that uses perioperative clinical indicators and laboratory tests to predict the occurrence of VTE after neurosurgery.
58104921|NCT01757236|DRUG|VANCOMYCIN|
58435880|NCT04487652|DRUG|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
58435881|NCT00033891|DRUG|Infliximab|
58435882|NCT02233023|DRUG|Pramipexole|
58435883|NCT02233023|DRUG|Bromocriptine and other dopamine agonists|
58435884|NCT00112125|DEVICE|OPTIMIZER System|
58435885|NCT06584201|PROCEDURE|Erector Spinae Plane Block (ESP)|The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
58435886|NCT06584201|PROCEDURE|Paravertebral Block (PVB)|The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
58435887|NCT02087111|DRUG|Telaprevir|375 mg film coated tablets
58435888|NCT02087111|DRUG|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
58435889|NCT02087111|DRUG|Ribavirin|200 mg tablets
58435890|NCT03314272|DEVICE|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
58435891|NCT00000470|PROCEDURE|cardiac surgical procedures|
58435892|NCT00000470|PROCEDURE|cardiopulmonary bypass|
58435893|NCT02695693|BEHAVIORAL|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
57954558|NCT03113500|DRUG|Brentuximab Vedotin|Given IV
58104922|NCT01757236|DRUG|CEFTRIAXONE|
58104923|NCT01757236|DRUG|CLINDAMYCIN|
58104924|NCT01757236|DRUG|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
58104925|NCT01757236|DRUG|FLUOROQUINOLONE|
58104926|NCT01757236|DRUG|LINEZOLID|
58435894|NCT02695693|BEHAVIORAL|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
58435895|NCT02695693|BEHAVIORAL|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
58435896|NCT02695693|BEHAVIORAL|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
58435897|NCT04374240|GENETIC|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"
58435898|NCT03320135|PROCEDURE|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
58435899|NCT03320135|PROCEDURE|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
58435900|NCT03214406|DRUG|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
58435901|NCT03214406|DRUG|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
58435902|NCT01903629|DEVICE|MCE|MCE first, followed by standard gastroscopy
58435903|NCT01903629|DEVICE|Standard gastroscopy|
58435904|NCT06284668|DRUG|normal Saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
58104927|NCT01757236|DRUG|RIFAMPIN|
58435905|NCT06284668|DRUG|Esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
58435906|NCT06284668|DRUG|Remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
58435907|NCT03548467|BIOLOGICAL|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
58435908|NCT03548467|DRUG|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
58435909|NCT01098305|DRUG|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
58435910|NCT01098305|BEHAVIORAL|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
58435911|NCT03501940|PROCEDURE|Computed Tomography|Undergo 18F-DCFPyL PET/CT
58435912|NCT03501940|RADIATION|Fluorine F 18 DCFPyL|Given IV
58435913|NCT03501940|OTHER|Laboratory Biomarker Analysis|Correlative studies
58435914|NCT03501940|PROCEDURE|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
58435915|NCT00475189|DRUG|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
58104928|NCT04858074|DRUG|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
58435916|NCT00475189|DRUG|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
58435917|NCT00195663|BIOLOGICAL|Adalimumab|
58435918|NCT00195663|DRUG|Methotrexate|
58104929|NCT04953481|OTHER|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
58104930|NCT01249391|DEVICE|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
58104931|NCT00739687|DRUG|ALT-711|200 mg tablet BID for 9 months.
58104932|NCT00739687|DRUG|Placebo|200 mg tablet BID for 9 months.
57738089|NCT05812001|BEHAVIORAL|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
57954559|NCT03113500|DRUG|Cyclophosphamide|Given IV
58104933|NCT00752154|DRUG|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
58435919|NCT00195663|BIOLOGICAL|Adalimumab placebo|
58435920|NCT00195663|DRUG|Methotrexate placebo|
58435921|NCT06383260|BEHAVIORAL|Behavioral diagnostic|Diagnosing the behavioral pattern
58435922|NCT04305847|OTHER|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
58435923|NCT03197376|BIOLOGICAL|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
58435924|NCT03197376|BIOLOGICAL|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
58435925|NCT00682526|DEVICE|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
58435926|NCT02661867|BEHAVIORAL|delivery|delivery either vaginal or by cesarean section
58435927|NCT05675501|DRUG|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
58104934|NCT01017458|DRUG|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
58104935|NCT01017458|DRUG|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
58104936|NCT01017458|DRUG|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
58104937|NCT01017458|DRUG|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
58104938|NCT03687021|DRUG|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
58104939|NCT01340274|BEHAVIORAL|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
58435928|NCT03963648|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
58435929|NCT04467034|BEHAVIORAL|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
58435930|NCT03321422|OTHER|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
58435931|NCT04584957|DEVICE|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
58104940|NCT01340274|BEHAVIORAL|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
58104941|NCT03829033|RADIATION|Radiotherapy|Radiotherapy with either photons or protons.
58104942|NCT00956683|PROCEDURE|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
58104943|NCT00956683|PROCEDURE|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
58104944|NCT00031837|DRUG|dalteparin|
58104945|NCT00031837|DRUG|gemcitabine hydrochloride|
58104946|NCT00031837|PROCEDURE|quality-of-life assessment|
58104947|NCT01591031|DRUG|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
58104948|NCT01591031|DRUG|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
58435932|NCT01822392|BEHAVIORAL|Online Parent Management Training (Interactive)|
58435933|NCT01822392|BEHAVIORAL|Online Parent Management Training (Recorded)|
58435934|NCT04166097|OTHER|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
57954560|NCT03113500|DRUG|Doxorubicin|Given IV
57954561|NCT03113500|DRUG|Doxorubicin Hydrochloride|Given IV
57954562|NCT03113500|DRUG|Etoposide|Given IV
57954563|NCT03113500|DRUG|Etoposide Phosphate|Given IV
57954564|NCT03113500|OTHER|Laboratory Biomarker Analysis|Correlative studies
57954565|NCT03113500|DRUG|Prednisone|Given PO
57954566|NCT01750112|DEVICE|Macrolane VRF20|Injection treatment with Macrolane VRF20
57954567|NCT04671849|DRUG|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
57954568|NCT02586168|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
57954569|NCT02586168|DRUG|Placebo|Placebo
57954570|NCT02597946|DRUG|afatinib|
57954571|NCT02597946|DRUG|paclitaxel|
58104949|NCT06386471|OTHER|Whole grain rye bread|Single consumption of 4.3 oz of whole grain rye bread
58104950|NCT06386471|OTHER|Refined grain rye bread|Single consumption of 4.3 oz of refined grain rye bread
58310039|NCT03708146|DRUG|Placebo|"matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
58310040|NCT02889419|DEVICE|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
58310041|NCT05074901|BEHAVIORAL|digital behavioral intervention|interaction with a conversational agent to implement physical and cognitive programs
58435935|NCT01921764|BEHAVIORAL|Workplace physical exercise|
58435936|NCT01921764|BEHAVIORAL|Home physical exercise|
57954572|NCT04317274|BEHAVIORAL|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
57954573|NCT04317274|BEHAVIORAL|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
57954574|NCT04317274|BEHAVIORAL|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
57954575|NCT04317274|BEHAVIORAL|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
58104951|NCT01873079|DRUG|Esomeprazole|
58104952|NCT01873079|OTHER|Standard care|No PPI or other study medication given
58104953|NCT03459833|DRUG|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
58104954|NCT00811265|DEVICE|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
58104955|NCT00185328|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
58104956|NCT00871728|DRUG|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
58104957|NCT00357474|PROCEDURE|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
58104958|NCT00357474|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
58310042|NCT04793945|COMBINATION_PRODUCT|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
58310043|NCT01036802|DRUG|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
57954576|NCT00939900|DRUG|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
57962168|NCT01975012|DRUG|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
57962169|NCT02490085|OTHER|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
57962170|NCT02490085|OTHER|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
57962171|NCT02490085|DRUG|Insulin|Subject's usual insulin analog will be used.
57962172|NCT02490085|DEVICE|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
57962173|NCT02490085|DEVICE|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
57962174|NCT04682886|DIAGNOSTIC_TEST|diagnosis|there is no intervention diagnosis or treatment for patients
57962175|NCT02163174|DRUG|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
57962176|NCT02163174|DRUG|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
57962177|NCT00393874|BEHAVIORAL|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
57962178|NCT00393874|DRUG|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
57962179|NCT00393874|DRUG|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
57962180|NCT03584867|OTHER|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
57962181|NCT04927728|OTHER|Mental Practice|MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.
57962182|NCT04927728|OTHER|Repetitive-Task Practice|Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.
57962183|NCT04927728|OTHER|Traditional Therapy|Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
57962184|NCT00702078|BEHAVIORAL|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
57962185|NCT00702078|BEHAVIORAL|usual care|follow-up according to todays best practice
57962186|NCT00931398|DRUG|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
57962187|NCT00931398|DRUG|Placebo|Matched placebo for all Concerta doses.
57962188|NCT03870555|DRUG|TAK-954|TAK-954 infusion administered intravenously.
57962189|NCT03870555|DRUG|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
58435937|NCT02151890|BIOLOGICAL|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
58104959|NCT00798785|DRUG|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
58104960|NCT00798785|DRUG|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
58104961|NCT00798785|DRUG|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
58104962|NCT00798785|PROCEDURE|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels \>= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
58104963|NCT02197754|OTHER|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
58104964|NCT01667965|BEHAVIORAL|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
58104965|NCT00597207|DEVICE|AutoPulse|Mechanical device that provides chest compression
58104966|NCT00597207|OTHER|Manual|Manual chest compression
58104967|NCT05329090|DRUG|Rituximab Injection|anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
58104968|NCT05329090|DRUG|placebo|placebo experimental treatment
58104969|NCT05839093|DEVICE|Inferior Alveolar Nerve Block Group|A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
58310044|NCT01036802|DRUG|Placebo|
58310045|NCT04789122|OTHER|Attitude assessment|The study covered a representative group of 1000 people. Own questionnaire and standardized tools sent online via the Statistical Research and Analysis Office, in compliance with the privacy policy and personal data protection of the General Data Protection Regulation.
58310046|NCT06426745|PROCEDURE|Bowel preparation|to compare bowel cleanliness, compliance, tolerability, and patient satisfaction of a single regimen versus a split regimen for colonoscopy.
58310047|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
58310048|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
57738090|NCT05812001|BEHAVIORAL|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
58104970|NCT05839093|DEVICE|Intraligamentary Injection Group|An infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. Then, an intraligamentary injection was performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle. The needle was placed alongside the tooth and inserted at a 30 angle relative to the longitudinal axis of the crown with the needle between the teeth and the bone. Then, in the mesiobuccal, distobuccal, mesiolingual and distolingual portions of teeth, 0.18 mL of the solution was injected. Five minutes later, the teeth were isolated and the endodontic procedure was started.
58435938|NCT00870545|BEHAVIORAL|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
58435939|NCT00502008|DRUG|Coccinia Cordifolia (herbal extract)|
58104971|NCT00812435|DRUG|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
57738091|NCT05356052|COMBINATION_PRODUCT|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
58104972|NCT01495169|DRUG|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
58104973|NCT05742399|DRUG|Hyaluronic acid NanoGel|Hyaluronic acid nanoparticles (2%)
58104974|NCT05742399|DRUG|Placebo gel|conventional gel having the same color, form and packaging
58104975|NCT01255722|DRUG|iobitridol|single IV injection
58104976|NCT01255722|DRUG|iopromide|Single IV injection
58104977|NCT01255722|DRUG|iomeprol|Single IV injection
58104978|NCT00013182|BEHAVIORAL|social activity|
58104979|NCT04449640|PROCEDURE|Hysteroscopic septum resection.|Resection of a uterine septum by hysteroscopic surgery.
58104980|NCT05443217|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
58104981|NCT02131337|OTHER|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
58104982|NCT03153059|OTHER|Stool frequency|This study is just observational study.
58310049|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
58310050|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
58310051|NCT02737358|DRUG|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
58310052|NCT02737358|OTHER|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
58310053|NCT01824667|DIETARY_SUPPLEMENT|B-GOS|
58310054|NCT01824667|DIETARY_SUPPLEMENT|Maltodextrin|
58104983|NCT00481273|DRUG|Azacitidine|Physician's discretion
58310055|NCT04324749|OTHER|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
58310056|NCT04324749|OTHER|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
58310057|NCT04324749|OTHER|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
58310058|NCT01715051|DRUG|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
58310059|NCT01715051|BEHAVIORAL|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
58310060|NCT01715051|DRUG|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
58310061|NCT06394258|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy to the vaginal cuff with the aim to reproduce adjuvant high dose rate (HDR) brachytherapy dose distribution by means of external beam radiotherapy in patients operated for intermediate risk endometrial carcinoma
58435940|NCT04205617|OTHER|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
58435941|NCT01966224|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
58435942|NCT06049030|DRUG|HS-10516|Oral HIF-2α inhibitor
58435943|NCT02082600|OTHER|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
58435944|NCT02082600|OTHER|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
58435945|NCT00898833|OTHER|laboratory biomarker analysis|
58435946|NCT02331667|OTHER|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
58310062|NCT01466868|DRUG|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
58310063|NCT02823119|DEVICE|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
58310064|NCT02823119|DEVICE|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
58310065|NCT02650817|DRUG|RAD1901|RAD1901, a novel selective ER degrader (SERD)
58310066|NCT05412134|DEVICE|Pro2 - 75% of participant's MIP|"Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
58310067|NCT05412134|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
58310068|NCT05349305|DRUG|continuous renal replacement therapy|continuous renal replacement therapy
58310069|NCT06157229|OTHER|MAT|"The protocol consists of four phases: 1) immobilization phase, 2) early protective phase, 3) intermediate phase and 4) late phase. The detailed guideline can be found in the following article:~Gaunt, B. W., Shaffer, M. A., Sauers, E. L., Michener, L. A., McCluskey, G. M., \& Thigpen, C. A. (2010). The American Society of Shoulder and Elbow Therapists' Consensus Rehabilitation Guideline for Arthroscopic Anterior Capsulolabral Repair of the Shoulder. Journal of Orthopaedic \& Sports Physical Therapy, 40(3), 155-168. https://doi.org/10.2519/jospt.2010.3186"
58310070|NCT06157229|OTHER|CABRR|"The protocol consists of four phases: 1) immobilization phase, 2) early phase, 3) intermediate phase and 4) advanced phase.~The protocol comprises education, modified cognitive behavioral therapy, neuromuscular control exercises, kinetic chain exercises, range of motion enhancing exercises, strength and conditioning exercises, and sport-specific exercises. The protocol is currently unpublished."
58310071|NCT04820907|DRUG|HCP1904-1|Take it once daily for 8 weeks orally.
58310072|NCT04820907|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
58310073|NCT04894708|PROCEDURE|colonoscopy|addition of polyp detection algorithm by Fujifilm
58310074|NCT04093271|DIETARY_SUPPLEMENT|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
58310075|NCT04093271|DRUG|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
58310076|NCT04093271|OTHER|Placebo|No active ingredients
58310077|NCT03072186|DEVICE|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
58310078|NCT03817528|DRUG|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
58310079|NCT06094465|OTHER|Different phase of the learning curve of RPD|Different phases of the learning curve of RPD (learning phase or proficiency phase)
58310080|NCT00697320|DRUG|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
58310081|NCT04301973|OTHER|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
58310082|NCT01376219|OTHER|asthma control test|results of asthma control testing collected
58310083|NCT02333643|DRUG|CLS003|
58310084|NCT02333643|DRUG|Furosemide|
58310085|NCT02333643|DRUG|Digoxin|
58310086|NCT02333643|DRUG|Vehicle topical|
57738092|NCT05667246|OTHER|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
58310087|NCT00109096|DRUG|Pemetrexed|
58310088|NCT05087589|DRUG|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
58310089|NCT02020941|DRUG|carfilzomib|Given IV
58310090|NCT02020941|DRUG|dexamethasone|Given IV or PO
58435947|NCT02331667|OTHER|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
58104984|NCT03708861|DRUG|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
58104985|NCT05233800|BEHAVIORAL|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
58104986|NCT05233800|BEHAVIORAL|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
58104987|NCT03787173|DEVICE|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
58104988|NCT03787173|DEVICE|Automated|Inspiratory trigger and Expiratory trigger settings automatized
58104989|NCT00659854|DIETARY_SUPPLEMENT|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
58104990|NCT00659854|DIETARY_SUPPLEMENT|milk based formula|Babies will be given a milk based formula for 12 weeks
58104991|NCT04128696|DRUG|feladilimab|feladilimab is available as an intravenous infusion.
58104992|NCT04128696|DRUG|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
58104993|NCT04128696|DRUG|Placebo|Placebo is available as an intravenous infusion.
58104994|NCT03614871|OTHER|Epidemiological study|
58104995|NCT00280501|DRUG|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
57738093|NCT05667246|OTHER|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
57738094|NCT02716974|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
57738095|NCT02716974|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
57738096|NCT02716974|DRUG|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
57738097|NCT02716974|PROCEDURE|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
57738098|NCT02716974|RADIATION|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
58104996|NCT00280501|DRUG|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
57738099|NCT02385344|DEVICE|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
57738100|NCT06305351|DRUG|K-757 and K-833 QD|Both administered orally once daily
57738101|NCT06305351|DRUG|K-757 and K-833 BID|Both administered orally twice daily
57738102|NCT06305351|DRUG|Matching placebo to K-757 and K-833 QD|Both administered orally once daily
58104997|NCT00280501|DRUG|Placebo|Placebo
58104998|NCT01019005|DEVICE|Catheter|Catheter inserted into either perineural tibial nerve or wound
58104999|NCT04004273|BEHAVIORAL|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
58105000|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
58105001|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
58105002|NCT02505711|BEHAVIORAL|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
58105003|NCT00059514|BEHAVIORAL|Modified Project Toward No Tobacco Use|
58105004|NCT05238311|DRUG|Elranatamab|
58105005|NCT00344630|DEVICE|TAXUS Stent and Cypher Stent|
58105006|NCT00190554|DRUG|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
58105007|NCT00190554|DRUG|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
58310091|NCT02020941|OTHER|laboratory biomarker analysis|Correlative studies
57738103|NCT06305351|DRUG|Matching placebo to K-757 and K-833 BID|Both administered orally twice daily
57738104|NCT00987974|DRUG|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
57738105|NCT00987974|DRUG|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
57738106|NCT00987974|DRUG|placebo|placebo for 3 days.
57738107|NCT00987974|DRUG|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
57738108|NCT00987974|DRUG|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
57738109|NCT00987974|DRUG|placebo 7 days|placebo 7 days
57738110|NCT04901858|DIAGNOSTIC_TEST|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
57738111|NCT02218567|BEHAVIORAL|questionnaire qualilty of life|
57738112|NCT02218567|BEHAVIORAL|psychological interview|
57738113|NCT02218567|BEHAVIORAL|psychological tests|
57738114|NCT02218567|OTHER|Motor evaluation|
57738115|NCT02218567|BEHAVIORAL|Behavioral evaluation|
57738116|NCT02218567|BEHAVIORAL|cognitive tests|
57738117|NCT01856127|DRUG|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
57738118|NCT01856127|DRUG|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
58435948|NCT00842543|DIETARY_SUPPLEMENT|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
58435949|NCT00842543|DIETARY_SUPPLEMENT|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
58435950|NCT06576401|DRUG|[14C] HDM1002|Administered orally
58435951|NCT00241592|DRUG|Cannabis|
58435952|NCT02815592|DRUG|BMS-986012|
58435953|NCT02815592|DRUG|Cisplatin|
58435954|NCT02815592|DRUG|Etoposide|
58435955|NCT02815592|DRUG|Platinum|
57738119|NCT06448091|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
58105008|NCT05793788|BEHAVIORAL|Outreach Text Messages|"The investigators will send randomized participants an SMS message encouraging them to click provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures. Message content will vary based on randomization arm as noted below."
58435956|NCT02815592|DRUG|Carboplatin|
58105009|NCT05793788|BEHAVIORAL|Specific|The message will inform patients that the care team has identified tests/screenings that they are due for.
58105010|NCT05793788|BEHAVIORAL|General|The message will inform patients that the care team has identified a care gap in their record.
58105011|NCT05793788|BEHAVIORAL|Elevating Intentions|The message will point out that even if patients feel healthy, their doctor recommends them to take care of their health gaps.
58105012|NCT05793788|BEHAVIORAL|Prompting Action|The message will prompt patients to take care of their health gaps right away before they forget.
58105013|NCT03390634|OTHER|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
58105014|NCT04804982|OTHER|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
58435957|NCT02669121|BIOLOGICAL|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
57738120|NCT03386903|DEVICE|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
58105015|NCT00579254|DRUG|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
58105016|NCT04718857|BEHAVIORAL|Online education|health education
58105017|NCT00944385|DRUG|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
58105018|NCT05052515|DIETARY_SUPPLEMENT|Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts|Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation
58105019|NCT05052515|OTHER|Placebo|Patients with NAFLD will be randomly allocated to receive placebo
58105020|NCT00003054|DRUG|paclitaxel|
58105021|NCT02409537|DIETARY_SUPPLEMENT|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
58310092|NCT02548871|BEHAVIORAL|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
58435958|NCT02669121|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
57738121|NCT03386903|DEVICE|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
57738122|NCT05853848|BEHAVIORAL|Postcard|Postcard with phone number to call for help scheduling a mammogram.
57738123|NCT05853848|BEHAVIORAL|Letter|Letter with phone number to call for help scheduling a mammogram.
58435959|NCT06480318|DEVICE|TENS|The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
58435960|NCT01059994|DRUG|Placebo sildenafil|Oral, daily, 1 week.
57738124|NCT05853848|BEHAVIORAL|Auto-dialer|Auto-dialer with option to press button for help scheduling a mammogram.
57738125|NCT05853848|BEHAVIORAL|Live call|Live call offering help scheduling a mammogram.
57738126|NCT04541238|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging
57738127|NCT05888597|DRUG|L-menthol|(Sigma-Aldrich, St. Louis, US)
57738128|NCT05888597|OTHER|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
58105022|NCT02409537|DIETARY_SUPPLEMENT|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
58105023|NCT02409537|OTHER|placebo|the individuals were given placebo for 1 month
58435961|NCT01059994|DRUG|Sildenafil|oral, 25mg, daily for 1 week
58435962|NCT06144047|DEVICE|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
58435963|NCT00030862|DRUG|cisplatin|
58435964|NCT00030862|DRUG|irinotecan hydrochloride|
58435965|NCT01611194|DRUG|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
58105024|NCT05674994|DRUG|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
58105025|NCT05674994|OTHER|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
58105026|NCT02964897|BEHAVIORAL|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
58105027|NCT02964897|BEHAVIORAL|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
57738129|NCT01740674|OTHER|Electronic data collection|
58105028|NCT01340365|BEHAVIORAL|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
58105029|NCT01340365|BEHAVIORAL|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
58105030|NCT00685022|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI"
58105031|NCT00685022|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI"
58105032|NCT02270931|DEVICE|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
58105033|NCT02100527|DRUG|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
58105034|NCT02100527|DRUG|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
58105035|NCT01890785|DRUG|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
58105036|NCT03373266|DRUG|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
58105037|NCT03373266|DRUG|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
58105038|NCT00056082|DRUG|celecoxib|Celecoxib daily for 12 months
58105039|NCT03744806|DRUG|Bevacizumab Injection|
58105040|NCT04799470|DEVICE|Novel DBS stimulation patterns|Stimulation patterns
58105041|NCT05798871|PROCEDURE|Subgingival erythritol air polishing|"The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement"
58105042|NCT05798871|PROCEDURE|Conventional root planing|The intervention will start with supragingival debridement followed by root planing by curette.
58310093|NCT00302900|BEHAVIORAL|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
58435966|NCT01611194|DRUG|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
58435967|NCT01737216|DRUG|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
57738130|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
57738131|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
57738132|NCT02906150|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
57738133|NCT02906150|DRUG|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
58105043|NCT00003299|DRUG|cisplatin|
58105044|NCT00003299|DRUG|etoposide|
58105045|NCT00003299|DRUG|paclitaxel|
58310094|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
58310095|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
58105046|NCT00924183|OTHER|Treatment-as-usual|
58105047|NCT05580549|DIAGNOSTIC_TEST|Alcohol biomarker Phosphatidylethanol (PEth)|The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
58105048|NCT02498899|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
58105049|NCT02498899|BEHAVIORAL|Video|Participants watch a video lasting about 4 minutes.
58105050|NCT00296452|BEHAVIORAL|behavior|
58105051|NCT04068571|BEHAVIORAL|I-PUSH|Innovative partnership for universal and sustainable healthcare
58105052|NCT03779100|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58105053|NCT03779100|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
58105054|NCT03412019|OTHER|Music|Selections of Mozart piano sonatas
58105055|NCT00786019|BEHAVIORAL|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
58105056|NCT00786019|DRUG|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
58105057|NCT00802633|DEVICE|Stapling device during radical cystectomy|Hemostasis
58105058|NCT00802633|DEVICE|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
58105059|NCT06515340|OTHER|Allulose Dose 1|5 gram consumed orally
58105060|NCT06515340|OTHER|Allulose Dose 2|10 gram consumed orally
58105061|NCT06515340|OTHER|Allulose Dose 3|20 gram consumed orally
58105062|NCT02359734|OTHER|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
58105063|NCT03608410|OTHER|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
58105064|NCT05459051|DIAGNOSTIC_TEST|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
58105065|NCT05459051|DIAGNOSTIC_TEST|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
58105066|NCT02521831|DRUG|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
58105067|NCT02521831|DRUG|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
58310096|NCT05531877|DIAGNOSTIC_TEST|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
58435968|NCT01737216|DRUG|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
58105068|NCT00192088|DRUG|pemetrexed|
58105069|NCT00192088|DRUG|oxaliplatin|
58105070|NCT02586688|DEVICE|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
58105071|NCT02586688|DEVICE|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
58105072|NCT02586688|DEVICE|Open Label Active NeuroStar® TMS|Open label NeuroStar® coil.
58105073|NCT06432205|PROCEDURE|surgery|any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery
58105074|NCT00736099|DRUG|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
58105075|NCT00736099|DRUG|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
58105076|NCT01788059|OTHER|injection the mesenchymal stem cell in non union site|
58105077|NCT03803085|BEHAVIORAL|Control condition|Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
58105078|NCT03803085|BEHAVIORAL|Treatment condition|Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
58105079|NCT00263796|DRUG|Oxytocin|10 international units = 1 cc, IV over 4 hours
58105080|NCT00263796|DRUG|Placebo|Normal Saline, IV over 4 hours
58105081|NCT05772234|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
58105082|NCT05772234|DRUG|normal saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
58105083|NCT01660490|PROCEDURE|ORIF|Open reduction internal fixation of the proximal femur
58310097|NCT02593500|DRUG|Budesonida Pulmictan® 200 µg|
58310098|NCT02593500|DRUG|Budesonide 200 µg|
58310099|NCT02439164|DRUG|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
58310100|NCT00801944|DRUG|Solifenacin succinate|oral
58105084|NCT00895583|DRUG|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
58105085|NCT00895583|DRUG|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
58105086|NCT00895583|DRUG|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
58105087|NCT06530043|OTHER|Senobi exercises|Senobi exercise began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.
58105088|NCT06530043|OTHER|Jacobsons Muscular relaxation exercises|Jacobsons Muscular relaxation exercises started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.
58105089|NCT06536920|DIAGNOSTIC_TEST|Migraine screening questionnaire|Screening test
58105090|NCT01258816|DRUG|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
58105091|NCT01460121|DEVICE|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
58105092|NCT01460121|DEVICE|Placebo|
58105093|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
58105094|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
58105095|NCT02496221|DRUG|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
58105096|NCT02496221|DRUG|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
58105097|NCT02496221|DRUG|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
58105098|NCT01946282|OTHER|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
58435969|NCT01583842|DRUG|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."
58105099|NCT01946282|OTHER|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
58105100|NCT01946282|OTHER|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
58105101|NCT02856815|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
58105102|NCT00000512|DRUG|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
58310101|NCT00801944|DRUG|Placebo|oral
58310102|NCT03397017|OTHER|Transfusion|
58435970|NCT01583842|DRUG|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."
58435971|NCT01583842|PROCEDURE|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
58435972|NCT04010591|DEVICE|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
58435973|NCT02458781|DRUG|Metronidazole|Metronidazole 500mg given twice daily for 14 days
58435974|NCT02458781|DRUG|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
58435975|NCT02458781|DRUG|Placebo|Placebo given twice daily for 14 days
58435976|NCT04747587|OTHER|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
58435977|NCT00777361|DRUG|AZD3480|Iv single dose, 4-hour infusion of 25 mg
58435978|NCT00777361|DRUG|AZD3480|Oral solution single dose of 50 mg
58435979|NCT04241471|PROCEDURE|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
58435980|NCT04241471|DEVICE|traditional incision and drainage (I&D)|traditional incision and drainage (I\&D)
58105103|NCT00000512|DRUG|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
58105104|NCT00000512|DRUG|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
58105105|NCT00000512|OTHER|Placebo for colestipol|Placebo for colestipol.
58105106|NCT00000512|OTHER|Placebo for lovastatin|Placebo for lovastatin
58105107|NCT02581761|DRUG|CYTOTEC|synthetic prostaglandin E1
58310103|NCT02787499|PROCEDURE|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
58435981|NCT00214916|DRUG|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
58435982|NCT00214916|DRUG|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
58435983|NCT02599779|DRUG|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
58435984|NCT02599779|RADIATION|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
58435985|NCT05613023|RADIATION|SBRT|Stereotactic Body Radiotherapy
58105108|NCT02581761|OTHER|Placebo|no active material
58105109|NCT01614925|DEVICE|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
58310104|NCT01769547|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
58310105|NCT01940848|DRUG|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
58310106|NCT01940848|DRUG|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
58310107|NCT04596319|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
58310108|NCT04596319|OTHER|Placebo|Inactive Placebo administered via inhalation
58310109|NCT01806181|OTHER|Exercise|
58310110|NCT00722020|DEVICE|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
58435986|NCT03517228|DEVICE|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
58435987|NCT05538143|OTHER|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
58435988|NCT02177682|DRUG|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
58435989|NCT04688255|BEHAVIORAL|MSTEP|Aerobic exercise that is advanced weekly
58435990|NCT04688255|BEHAVIORAL|Stretching|Stretching exercises that are advanced weekly
58435991|NCT01725594|DRUG|CAT 2003|
58435992|NCT01725594|DRUG|Placebo|
58435993|NCT03794154|DRUG|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
58435994|NCT03794154|DRUG|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
58435995|NCT05934903|DEVICE|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
58435996|NCT02471222|DRUG|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
58435997|NCT02471222|OTHER|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
58105110|NCT01614925|PROCEDURE|Periodontal surgery|Periodontal surgery alone
58105111|NCT00491673|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
58105112|NCT00491673|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
58435998|NCT02128880|BEHAVIORAL|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
58310111|NCT00606008|DRUG|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
58105113|NCT06201910|OTHER|Observation of Blood loss|Retrospetive observation of bloodloss and RBC transfusions.
58105114|NCT06521671|DEVICE|Dynaloc implant|Internal fixation with Dynaloc implant
58105115|NCT06521671|DEVICE|Cannulated cancellous screws|Internal fixation with two or three cannulated cancellous screws
58105116|NCT03909568|PROCEDURE|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
58105117|NCT00683332|DRUG|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
58105118|NCT00505505|DRUG|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
58105119|NCT03338270|DIAGNOSTIC_TEST|MRI|MRI sequence without intravenous contrast
58105120|NCT05110950|PROCEDURE|No suction EBUS-TBNA|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
57738134|NCT04405596|DRUG|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
57954577|NCT05773196|OTHER|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~* 10 mL EDTA Vial (Box 1; Frozen)~  o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~* 10 mL EDTA Vial (Box 2; Ambient)~  * Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
57954578|NCT03106623|DRUG|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
57954579|NCT03106623|DRUG|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
57954580|NCT03106623|DRUG|Placebo|Oral administration of Placebo once a daily for 4 weeks
57954581|NCT00185003|DRUG|endotoxin|
57954582|NCT00185003|DRUG|Potassium channel blockers: TEA, Quinin, Tolbutamide|
57954583|NCT00185003|DRUG|L-NMMA|
57954584|NCT02317120|GENETIC|NGS BRCA 1 and BRCA 2 full sequencing|
57954585|NCT02317120|GENETIC|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
57954586|NCT01962233|BIOLOGICAL|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
57954587|NCT06020456|DRUG|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
57954588|NCT03685786|BIOLOGICAL|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
58435999|NCT02128880|BEHAVIORAL|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
58105121|NCT05110950|PROCEDURE|Passive suction through dedicated EBUS-TBNA syringe|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
57954589|NCT04697485|DRUG|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
58310112|NCT03387293|OTHER|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
58436000|NCT01240135|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
57954590|NCT03707600|DEVICE|TMS|MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
57954591|NCT03826550|DRUG|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
57954592|NCT03826550|DRUG|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
57954593|NCT03826550|OTHER|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
57954594|NCT05385861|DRUG|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
57954595|NCT06417021|OTHER|Frontal Ultrasound Machine|Ultrasound machine will be placed in a frontal position
57954596|NCT06417021|OTHER|Lateral Ultrasound Machine|Ultrasound machine will be placed in a lateral position
57954597|NCT03313076|DRUG|Omega-3 fatty acids (fish oil)|4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
57954598|NCT03313076|DRUG|Vitamin D3 (cholecalciferol)|1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
57954599|NCT03313076|DRUG|Vitamin D3 (cholecalciferol) placebo|1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
57954600|NCT03313076|DRUG|Omega-3 fatty acid placebo|4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
57954601|NCT01081795|DRUG|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
57954602|NCT01081795|DRUG|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
57954603|NCT03405259|DEVICE|Super Seal® Desensitizer|Single dose professional application.
57954604|NCT03405259|DEVICE|Acclean® Fluoride Varnish|Single dose professional application.
57954605|NCT02261727|DRUG|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
57954606|NCT02261727|DRUG|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
57954607|NCT02261727|DRUG|Placebo (for prednisone)|"* Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
57954608|NCT02261727|DRUG|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
57954609|NCT03420950|OTHER|Rapid sequence intubation: sedative first|Sedative first
57954610|NCT03420950|OTHER|Rapid sequence intubation: paralytic first|Paralytic first
57954611|NCT06144905|OTHER|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
58310113|NCT03387293|OTHER|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
58310114|NCT00460967|DEVICE|Rheopheresis|8 rheopheresis treatments over 10 wks.
58310115|NCT00460967|DEVICE|Rheopheresis|Sham treatment
58310116|NCT02458066|OTHER|IRS: bendiocarb|carbamate insecticide
58310117|NCT02458066|OTHER|IRS: deltamethrin|Pyrethroid insecticide
58310118|NCT01059331|DRUG|Pregabalin|150 mg x 2 daily for 2 days
58436001|NCT01240135|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
58436002|NCT01240135|DEVICE|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
58436003|NCT04358224|BIOLOGICAL|Dupilumab Prefilled Syringe|open-label
58436004|NCT02941224|DEVICE|SELUTION DCB (sirolimus coated balloon)|
57954612|NCT03828591|PROCEDURE|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
58310119|NCT01059331|DRUG|Sugar pill|1 tablet x 2 daily, for 2 days
58105122|NCT05110950|PROCEDURE|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.."
58105123|NCT04609865|DRUG|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
58310120|NCT06467721|DEVICE|Self-adhesive silicone gel waterproof dressing|Self-adhesive silicone gel waterproof dressing is used after artificial joint replacement surgery.
58310121|NCT06467721|DEVICE|Sterile gauze dressing|Sterile gauze dressing is used after artificial joint replacement surgery.
58310122|NCT02675166|OTHER|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
58310123|NCT02254642|PROCEDURE|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
58436005|NCT00520910|DRUG|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
58436006|NCT05295108|OTHER|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
57954613|NCT03828591|PROCEDURE|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
57954614|NCT01133587|OTHER|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
57954615|NCT01133587|BEHAVIORAL|admissions contract|"contract regarding patient-guided admissions starting immediately"
57954616|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
57954617|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
57954618|NCT00838331|BIOLOGICAL|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
57954619|NCT00838331|BIOLOGICAL|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions."
57954620|NCT00835237|BIOLOGICAL|Boostrix®|Intramuscular, single dose.
57954621|NCT00835237|BIOLOGICAL|Decavac™|Intramuscular, single dose.
57954622|NCT00927095|DRUG|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
57954623|NCT00927095|DRUG|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
57954624|NCT00927095|DRUG|placebo|daily placebo
57954625|NCT06475638|DEVICE|brachial artery doppler|brachial artery doppler evaluation before and after supraclavicular block
57954626|NCT01868048|DRUG|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
57954627|NCT01868048|DRUG|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
57954628|NCT03757208|DIETARY_SUPPLEMENT|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
57954629|NCT03178227|BEHAVIORAL|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
57954630|NCT03313427|OTHER|Physical Therapy Early Intervention|"At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
57954631|NCT03313427|OTHER|Usual Care|NICU usual care
57954632|NCT05007275|BIOLOGICAL|1x10^9 vp AZD1222|A single dose of 1x 10\^9 vp AZD1222
58436007|NCT05295108|OTHER|Attention control|informational materials provided to educate on life domains that are important to social health
58436008|NCT05192655|OTHER|Observation|Observation Study
58436009|NCT06477913|DEVICE|Rauha|A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
58105124|NCT04609865|DRUG|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
58105125|NCT02059577|DIETARY_SUPPLEMENT|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
58105126|NCT06306794|OTHER|crochet octopus|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
58105127|NCT00532454|DRUG|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
58105128|NCT04146454|OTHER|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
58105129|NCT02857374|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
58105130|NCT02857374|DRUG|Fluorescein Sodium Injection|Given IV
58105131|NCT02857374|OTHER|Laboratory Biomarker Analysis|Correlative studies
58105132|NCT02857374|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
58105133|NCT01011907|DRUG|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
58105134|NCT01011907|DRUG|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
57954633|NCT05007275|BIOLOGICAL|5x10^9 vp AZD1222|A single dose of 5x 10\^9 vp AZD1222
57954634|NCT05007275|BIOLOGICAL|1x10^10 vp AZD1222|A single dose of 1x10\^10 vp AZD1222
57954635|NCT02288507|DRUG|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
57954636|NCT02288507|RADIATION|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
57954637|NCT01972555|PROCEDURE|Minimally invasive aortic valve replacement|
57954638|NCT01972555|PROCEDURE|Conventional aortic valve replacement|
57954639|NCT05526833|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
57954640|NCT02092194|PROCEDURE|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
57954641|NCT02092194|PROCEDURE|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
57954642|NCT00871312|DEVICE|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
57954643|NCT00871312|DEVICE|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
57954644|NCT05919979|BEHAVIORAL|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
57954645|NCT05919979|BEHAVIORAL|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
57954646|NCT03461757|DRUG|Rimegepant|75 mg ODT QD
57954647|NCT03461757|DRUG|Placebo|Placebo ODT to match rimegepant dose QD
57954648|NCT01600443|DEVICE|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
57954649|NCT01600443|DEVICE|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
57954650|NCT01600443|DEVICE|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
57954651|NCT06448403|DEVICE|MRI Scanning|MRI scanning with volumetric, resting and activity-based sequences.
57954652|NCT06448403|DEVICE|64-channel EEG|EEG to quantifiy electric activity.
57954653|NCT06448403|DEVICE|Polysomnography|A randomized group will undergo polysomnography.
57954654|NCT06448403|BIOLOGICAL|Blood samples|Analysis of specific blood biomarkers.
57954655|NCT06448403|BIOLOGICAL|Fecal samples|Analysis of bacterial composition.
57954656|NCT06448403|BEHAVIORAL|Cognitive tests|Interview-based cognitive tests for assesment of cognitive levels.
57954657|NCT04319978|DRUG|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
57954658|NCT05704478|DRUG|Vericiguat|soluble guanylate cyclase stimulator
57738135|NCT04405596|OTHER|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
57738136|NCT01187758|BEHAVIORAL|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
58105135|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
58105136|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
58105137|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
58436010|NCT03707470|DEVICE|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
58436011|NCT03707470|DEVICE|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
57954659|NCT01512303|BEHAVIORAL|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
58105138|NCT02543268|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
58105139|NCT02543268|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
58105140|NCT01619085|DRUG|Nintedanib|Nintedanib twice a day
58105141|NCT02903316|PROCEDURE|Fluids|
58105142|NCT02343562|DIETARY_SUPPLEMENT|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
58105143|NCT02343562|DIETARY_SUPPLEMENT|Placebo|Multivitamin off-the-counter.
58105144|NCT02197182|DRUG|LUXSOL copper containing cream|Active comparator arm
58105145|NCT02197182|DRUG|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
58105146|NCT06339021|PROCEDURE|OCT-guided PCI|OCT-guided PCI based on MLD MAX algorithm
58105147|NCT06339021|PROCEDURE|Conventional angiography-based PCI|Conventional angiography-based PCI
58105148|NCT06339021|DRUG|DAPT de-escalation|Aspirin and clopidogrel 30 days after DES implantation
58105149|NCT06339021|DRUG|default DAPT regimen|Aspirin and ticagrelor 30 days after DES implantation
58105150|NCT00119132|DRUG|artesunate-amodiaquine|
58105151|NCT00119132|DRUG|sulphadoxine-pyrimethamine|
58105152|NCT02420899|DRUG|rosuvastatin|10mg/d or 20mg/d,po
58105153|NCT05302284|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
58310124|NCT02254642|PROCEDURE|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
58310125|NCT03608605|DEVICE|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
58310126|NCT02366871|DRUG|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
58310127|NCT02366871|DRUG|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
58310128|NCT04845230|BEHAVIORAL|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
58310129|NCT04796701|OTHER|Follow-Home-intervention|x
58310130|NCT04676373|DRUG|ALGLUCOSIDASE ALFA|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
58436012|NCT03707470|PROCEDURE|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
58436013|NCT02560012|DRUG|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
58436014|NCT02560012|DRUG|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
58105154|NCT05302284|DRUG|Toripalimab|3.0 mg/kg IV every 2 weeks
58105155|NCT05302284|DRUG|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
58105156|NCT05302284|DRUG|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
58105157|NCT05302284|DRUG|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
58105158|NCT05138393|OTHER|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
58105159|NCT05138393|OTHER|Observation|Non-specific physical activity 60 minutes per day.
58105160|NCT05105711|BEHAVIORAL|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
58105161|NCT01838161|BEHAVIORAL|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
58105162|NCT01838161|BEHAVIORAL|Part III|•video educational
58105163|NCT01838161|BEHAVIORAL|Part I|Parental Interviews
58310131|NCT00573924|DRUG|Proton pump inhibitor (lansoprazole)|"1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
58310132|NCT05002803|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
58436015|NCT02560012|DRUG|Sorafenib|400 mg (2 tablets) orally twice daily without food
58436016|NCT02560012|DRUG|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
58436017|NCT02560012|DRUG|Everolimus|10 mg orally once daily with or without food
58436018|NCT02560012|DRUG|Axitinib|5 mg orally twice daily
58436019|NCT00002609|BIOLOGICAL|lintuzumab|
57738137|NCT06580886|DEVICE|Ultrasound|All patients having ultrasound with Clarius L15/L20 and GE logic E9/E10 in same visit.
58436020|NCT00002609|DRUG|cytarabine|
58436021|NCT00002609|DRUG|idarubicin|
58436022|NCT00003763|PROCEDURE|radionuclide imaging|
58436023|NCT00003763|RADIATION|indium In 111 folic acid|
58436024|NCT02267161|OTHER|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
58436025|NCT04385134|OTHER|No intervention|No intervention
58436026|NCT04312347|DRUG|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
58436027|NCT04601805|DEVICE|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
58436028|NCT02006979|OTHER|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
58436029|NCT04479202|DRUG|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
58436030|NCT04479202|DRUG|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
57738138|NCT02376218|DRUG|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
57738139|NCT05211765|DIAGNOSTIC_TEST|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
58436031|NCT00778908|RADIATION|Late-course accelerated hyperfractionated IMRT|"1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
58436032|NCT00778908|DRUG|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
58436033|NCT00778908|RADIATION|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
58436034|NCT00544037|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
58436035|NCT05144867|RADIATION|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
58105164|NCT04981626|OTHER|Clinical and experimental session|"Psychologic profile with standardized interview and scales (see below for details: SCID, BDI, STAI, BPQ, EDE Q, Pictorial Body Image Scale (PBIS) and EDI).~Measure the stomach-brain synchrony during EEG/EGG resting state, the distribution of voluntary actions across the respiratory phase, and the distribution of saccadic eye movements across the cardiac-cycle."
58105165|NCT00475111|BEHAVIORAL|Cognitive Behavior Therapy for Pain (CBT-P)|
58105166|NCT00475111|BEHAVIORAL|Mindfulness Meditation for Emotion Regulation (MM-ER)|
58310133|NCT05906849|BEHAVIORAL|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
58310134|NCT01042626|OTHER|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
58310135|NCT05238623|DIAGNOSTIC_TEST|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
58310136|NCT02246933|OTHER|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
58310137|NCT02246933|OTHER|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
58310138|NCT05596799|BEHAVIORAL|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
58310139|NCT03927443|DRUG|SDP-133|one drop
58310140|NCT03927443|DRUG|Lumigan|one drop
58310141|NCT05776667|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
58310142|NCT01664091|RADIATION|post-mastectomy radiation therapy (PMRT)|
58310143|NCT01664091|DEVICE|tissue expander (TE)|
58310144|NCT01664091|DEVICE|acellular dermal matrix (ADM)|
58310145|NCT02812784|DEVICE|Nephrocheck TM|
58105167|NCT00475111|BEHAVIORAL|Rheumatoid arthritis education|
58105168|NCT02528630|OTHER|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
58105169|NCT02528630|OTHER|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
58105170|NCT03906149|COMBINATION_PRODUCT|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
58310146|NCT04533256|PROCEDURE|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
58310147|NCT03108482|DRUG|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
58310148|NCT03108482|DRUG|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
58310149|NCT03108482|DRUG|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
58310150|NCT03108482|DRUG|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
58436036|NCT02136628|PROCEDURE|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
58105171|NCT03906149|COMBINATION_PRODUCT|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
58105172|NCT02834065|DEVICE|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
57738140|NCT05634538|DEVICE|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
58105173|NCT04049890|OTHER|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
58105174|NCT04049890|OTHER|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
58310151|NCT02364557|RADIATION|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~* For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~* For a single liver metastases, patients receive a single fraction of 30 Gy.~* For metastases in the abdominal-pelvic or liver (\>1), patients receive 3 fractions for a total of 45 Gy.~* For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~* For spinal metastases, patients receive 1 fraction of 20 Gy.~* For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~* For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
57738141|NCT05634538|PROCEDURE|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
58105175|NCT04049890|OTHER|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
58105176|NCT01201356|DRUG|Fingolimod|0.5 mg/day
58105177|NCT03433118|DEVICE|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
58310152|NCT02364557|PROCEDURE|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
58310153|NCT00114556|DRUG|zoledronic acid|
58310154|NCT03971760|OTHER|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
58310155|NCT01389739|OTHER|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
57738142|NCT05916768|OTHER|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
57738143|NCT05916768|OTHER|usual care|symptomatic treatments
57738144|NCT02625103|PROCEDURE|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
58105178|NCT06446947|OTHER|blood sampling|Blood sampling (6ml) on admission and a second on discharge from intensive care.
58105179|NCT06541535|DRUG|Fluid resuscitation with isotonic saline only|"Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
58436037|NCT03592563|BEHAVIORAL|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
58436038|NCT04233541|DIAGNOSTIC_TEST|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
58436039|NCT00406536|DIETARY_SUPPLEMENT|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
58436040|NCT00406536|DIETARY_SUPPLEMENT|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
58310156|NCT04235946|OTHER|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
58310157|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
58310158|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
58310159|NCT03265561|DEVICE|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
58310160|NCT03265561|DEVICE|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
58436041|NCT04864951|DIAGNOSTIC_TEST|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
58436042|NCT04864951|OTHER|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
58436043|NCT00586885|DRUG|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
58436044|NCT04314583|BEHAVIORAL|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
58436045|NCT04314583|BEHAVIORAL|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
58436046|NCT06388798|OTHER|Education|Psychoeducational training
58436047|NCT05118373|BEHAVIORAL|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
57738145|NCT02625103|DRUG|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
58436048|NCT03085745|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
58436049|NCT01304004|OTHER|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)"
58436050|NCT01238302|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
58436051|NCT01238302|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
58436052|NCT01228526|DEVICE|PriMatrix|
58436053|NCT05006482|OTHER|Best Practice|Receive usual follow-up survivorship care
57738146|NCT01392560|DRUG|BI 10773|Oral once daily
58105180|NCT06541535|DRUG|Fluid resuscitation with Ringer Lactate|"Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
58436054|NCT05006482|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
57738147|NCT03257826|DEVICE|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
58105181|NCT05394558|DRUG|AsiDNA|Administration of AsiDNA followed by radiotherapy
58105182|NCT03076671|BEHAVIORAL|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
58310161|NCT04609137|PROCEDURE|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
58436055|NCT05006482|OTHER|Educational Intervention|Participate in survivorship health education sessions
58436056|NCT05006482|OTHER|Exercise Intervention|Participate in EXCAP program
58436057|NCT05006482|OTHER|Questionnaire Administration|Ancillary studies
57738148|NCT06345027|BIOLOGICAL|Treatment Arm A|"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."
57738149|NCT03756181|BEHAVIORAL|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
57738150|NCT06668896|DRUG|Progesterone|Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
57738151|NCT04272268|DEVICE|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
57738152|NCT05027165|OTHER|Non-interventional|No intervention
58105183|NCT00002338|DRUG|Raluridine|
58436058|NCT05006482|PROCEDURE|Tailored Intervention|Participate in GEM consultation
58436059|NCT06106191|BEHAVIORAL|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
58436060|NCT06106191|OTHER|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
58436061|NCT06106191|OTHER|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
58436062|NCT01812265|DRUG|PF-06305591|single Dose
58436063|NCT01812265|DRUG|PF-06305591|single Dose
58436064|NCT01812265|DRUG|Placebo|Single Dose
58436065|NCT02290977|RADIATION|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
58436066|NCT00973687|DRUG|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
58436067|NCT00973687|DRUG|Dexamethasone|
58436068|NCT06049303|OTHER|Paraffin wax bath therapy and Maitland joint mobilization techniques|"In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)"
58436069|NCT06049303|OTHER|Maitland knee joint mobilization|"Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above"
58436070|NCT00487292|BEHAVIORAL|naps and pulses of bright light|
58436071|NCT03722394|BEHAVIORAL|Pain Neuroscience Education|15 minute verbal one-on-one education session
58436072|NCT05665803|PROCEDURE|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
58436073|NCT05665803|PROCEDURE|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
58436074|NCT02523573|PROCEDURE|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
58436075|NCT04193592|DRUG|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
58436076|NCT03326206|OTHER|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
58436077|NCT04951505|DRUG|cefepime-taniborbactam|IV infusion
57738153|NCT03435874|BIOLOGICAL|ChAd63 RH5|Vaccine
57738154|NCT03435874|BIOLOGICAL|MVA RH5|Vaccine
58436078|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
58436079|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
58436080|NCT02717052|DRUG|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
58436081|NCT02717052|DRUG|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
58436082|NCT02717052|DRUG|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
58436083|NCT02717052|DRUG|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
58436084|NCT02717052|OTHER|PILOT Study II: PET1|\[11C\]DASB PET
57738155|NCT03435874|BIOLOGICAL|Rabies Vaccine|Vaccine
57738156|NCT05686057|DEVICE|percutanous coronary angiography with stenting|Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
57738157|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
57954660|NCT01512303|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
57954661|NCT06353451|BEHAVIORAL|Digital Detox|In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
58436085|NCT02717052|OTHER|PILOT Study II: PET2|\[11C\]DASB PET
58436086|NCT02717052|OTHER|Main Study: PET1|\[11C\]DASB PET
58436087|NCT02717052|OTHER|Main Study: PET2|\[11C\]DASB PET
58105184|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
58105185|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
58105186|NCT06286410|OTHER|Bespoke glasses prescription worn during amblyopia treatment.|The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
58105187|NCT02832076|PROCEDURE|Subcutaneous negative suction drain for 10 days|
58105188|NCT02832076|PROCEDURE|No subcutaneous drain|
58105189|NCT01375010|DRUG|Vitamin D3|2000 mg QD
58436088|NCT02717052|OTHER|PILOT Study I: PET1|\[11C\]DASB PET
58436089|NCT02717052|OTHER|PILOT Study I: PET2|\[11C\]DASB PET
57738158|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
58105190|NCT01375010|OTHER|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
58105191|NCT01375010|DRUG|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
58105192|NCT01656954|PROCEDURE|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
58105193|NCT01920074|DRUG|Nitroglycerin Ointment 0.4%|
58105194|NCT04514770|DRUG|Misoprostol|rupture of membrane early and late
58105195|NCT03271463|BEHAVIORAL|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
58105196|NCT02387788|DRUG|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
58105197|NCT02236754|DRUG|18 F-FP-DTBZ|The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
58310162|NCT04609137|PROCEDURE|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
58310163|NCT02817139|DEVICE|TDCS|
58436090|NCT02717052|DRUG|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
58310164|NCT00576511|DRUG|prucalopride|4 mg o.d.
58310165|NCT00576511|DRUG|placebo|Placebo o.d.
57738159|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
57738160|NCT05119920|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
57738161|NCT01750138|DRUG|Glutamine|
57738162|NCT01750138|DRUG|Dextrose powder|
57738163|NCT01775904|DRUG|LY2886721 in a Capsule|Administered orally.
57738164|NCT01775904|DRUG|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
57738165|NCT05238935|OTHER|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
57738166|NCT04721054|DRUG|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
57738167|NCT04721054|DRUG|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
58436091|NCT02717052|DRUG|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
58105198|NCT02236754|RADIATION|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
58105199|NCT01343628|DRUG|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
58105200|NCT01343628|DRUG|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
58105201|NCT00678379|DRUG|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
58105202|NCT00678379|DRUG|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
58436092|NCT02717052|OTHER|PILOT Study III: PET1|\[11C\]DASB PET
57738168|NCT03100617|BEHAVIORAL|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
57738169|NCT03342638|DRUG|Cyclophosphamide|Potent immunosuppressive agent; an alkylating agent
57738170|NCT03342638|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
57738171|NCT03342638|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
58105203|NCT00678379|DRUG|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
58105204|NCT06496113|PROCEDURE|Minimally invasive liver resection|Patients underwent liver resection either by robotic or laparoscopic approach
58310166|NCT05630196|DRUG|LY3857210|Administered orally
58310167|NCT05630196|DRUG|Placebo|Administered orally
58310168|NCT00619827|DRUG|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
58310169|NCT00619827|DRUG|Placebo tablet|Placebo tablet once daily during four months
58436093|NCT02717052|OTHER|PILOT Study III: PET2|\[11C\]DASB PET
58105205|NCT05260983|BEHAVIORAL|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
58105206|NCT05260983|BEHAVIORAL|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
58105207|NCT01493726|DRUG|ALKS 9072, Low dose|IM injection, given monthly
58105208|NCT01493726|DRUG|ALKS 9072, Med dose|IM injection, given monthly
58105209|NCT01493726|DRUG|ALKS 9072, High dose|IM injection, given monthly
58105210|NCT01493726|DRUG|Placebo|Dosed matched placebo IM injection, given monthly
58105211|NCT02542150|DRUG|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
58436094|NCT05842018|DRUG|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
58436095|NCT00579072|BEHAVIORAL|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
58436096|NCT00579072|BEHAVIORAL|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
58436097|NCT00579072|DEVICE|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
58436098|NCT06366360|OTHER|Immersive Virtual Reality Intervention|"The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice."
58436099|NCT06366360|OTHER|Conventional rehabilitation|The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
58436100|NCT03471780|DIAGNOSTIC_TEST|ultrasound|Transperineal us are made to pregnant ladies in labour
57738172|NCT03342638|DRUG|Methylprednisolone|Steroid
58105212|NCT02542150|DRUG|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
58105213|NCT04989621|DRUG|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
58105214|NCT04989621|DRUG|Orelabrutinib|Orelabrutinib 150mg po qd
58105215|NCT00018746|DEVICE|repetitive transcranial magnetic stimulation|
58105216|NCT03319901|DRUG|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
58105217|NCT03319901|DRUG|Standard Chemotherapy|Standard treatment of chemotherapy is administered
58105218|NCT03046537|DIAGNOSTIC_TEST|Breath test|Collecting breath test from participants
58105219|NCT00189345|BIOLOGICAL|anti-EpCAM x anti-CD3 (removab)|
58105220|NCT05068206|DRUG|AK105 injection|AK105 is programmed death 1（PD-1） monoclonal antibody
58105221|NCT05068206|DRUG|Anlotinib hydrochloride capsule|Anlotinib is small molecule multi-target tyrosine kinase inhibitor.
58105222|NCT05068206|DRUG|CapeOX|CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
58105223|NCT05068206|DRUG|Bevacizumab|Bevacizumab is a recombinant human monoclonal antibody.
58105224|NCT05616611|RADIATION|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
58105225|NCT05616611|OTHER|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
58105226|NCT05616611|RADIATION|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
58436101|NCT00185224|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
58436102|NCT00185224|DRUG|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
58105227|NCT00054015|DRUG|triapine|
58105228|NCT05149287|DRUG|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
58105229|NCT05149287|OTHER|Placebo|1% lidocaine and saline
58105230|NCT02593890|DEVICE|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
58105231|NCT06536842|OTHER|Postoperative Drain Placement|These drains will be placed with the intention to decrease the incidence of postoperative hematoma
58105232|NCT06536842|OTHER|No Postoperative Drain Placement|Participant will undergo lumbar spine fusion surgery and will not receive a postoperative drain
58436103|NCT03250208|DIETARY_SUPPLEMENT|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
58436104|NCT03250208|OTHER|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
58105233|NCT04582409|DRUG|HSY244|HSY244 concentrate solution for injection via intravenous infusion
58105234|NCT04582409|OTHER|Placebo|Placebo concentrate solution for injection via intravenous infusion
58105235|NCT04198350|PROCEDURE|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
58105236|NCT05183100|PROCEDURE|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
58436105|NCT02210975|DEVICE|LES-Stimulation Device|
58436106|NCT06054139|OTHER|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
58436107|NCT05152576|DRUG|OnabotulinumtoxinA X|Intramuscular Injection
57738173|NCT03342638|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
58105237|NCT05183100|PROCEDURE|Lying in supine|Lying in supine position for about 13 minutes.
58436108|NCT05152576|DRUG|Placebo|Intramuscular Injection
58436109|NCT03821610|DRUG|Fludarabine|IV
58436110|NCT03821610|DRUG|Melphalan|IV
58436111|NCT03821610|DRUG|Alemtuzumab|IV
58436112|NCT03821610|DRUG|Cyclophosphamide|IV
58436113|NCT03821610|DRUG|Mesna|IV
58436114|NCT03821610|RADIATION|Total Body Irradiation (8Gy)|TBI (8Gy)
58436115|NCT00555217|DRUG|losartan|50 or 100mg/day
58436116|NCT00555217|DRUG|lisinopril|10, 20 or 40 mg/day
58436117|NCT02425059|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
58436118|NCT02425059|DEVICE|NanoKnife|
57738174|NCT03342638|BIOLOGICAL|IVIg|Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
57738175|NCT03342638|BIOLOGICAL|Autologous Stem Cells|Infusion of participant's own stem cells
58105238|NCT00389649|DEVICE|heart rate setting|
58105239|NCT06066307|OTHER|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
58105240|NCT05436496|BIOLOGICAL|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10\^6 cells/kg body weight via IV
58105241|NCT04071626|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
58105242|NCT04071626|DRUG|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
58105243|NCT00567528|DRUG|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
58105244|NCT00567528|DRUG|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
58310170|NCT03659630|BEHAVIORAL|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
58310171|NCT03659630|BEHAVIORAL|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
58310172|NCT04796415|BEHAVIORAL|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
58310173|NCT05355155|DRUG|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
58105245|NCT04741685|DEVICE|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
58310174|NCT02835716|DRUG|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
58310175|NCT02835716|BIOLOGICAL|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
58310176|NCT01562899|DRUG|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
58436119|NCT03052595|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
58105246|NCT04741685|DEVICE|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
58436120|NCT03052595|DIAGNOSTIC_TEST|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
58436121|NCT03052595|DIAGNOSTIC_TEST|Stroop test|Stroop test will be used to test cognitive function
58436122|NCT00793325|DRUG|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
57738176|NCT00780208|DRUG|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
58105247|NCT02717286|PROCEDURE|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
58105248|NCT02135367|BIOLOGICAL|PRP|injections of Platelet rich Plasma
58105249|NCT03786874|OTHER|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
58436123|NCT03141632|DRUG|Dulaglutide|Evaluation visit with assessment of fluid intake
58436124|NCT03141632|OTHER|Placebo|Evaluation visit with assessment of fluid intake
58105250|NCT03786874|OTHER|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
58105251|NCT03786874|OTHER|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
58105252|NCT01677442|PROCEDURE|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
58310177|NCT01562899|DRUG|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
58310178|NCT03559816|OTHER|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
58310179|NCT03559816|PROCEDURE|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
58310180|NCT02352194|OTHER|Rehabilitation|Physiotherapy and physical activity
58310181|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
58310182|NCT05604898|OTHER|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
58310183|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
58310184|NCT05604898|OTHER|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
58310185|NCT03862638|OTHER|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
58310186|NCT04562974|DEVICE|MRI-scanner|Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.
58310187|NCT06032663|DIAGNOSTIC_TEST|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
58310188|NCT00017251|BIOLOGICAL|oblimersen sodium|Given IV
58310189|NCT00017251|DRUG|carboplatin|Given IV
58310190|NCT00017251|DRUG|etoposide|Given IV
58310191|NCT00017251|OTHER|pharmacological study|Correlative studies
57738177|NCT04592068|DEVICE|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
57738178|NCT04592068|OTHER|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
58105253|NCT01677442|PROCEDURE|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
58105254|NCT02115737|BEHAVIORAL|Dialectical Behavior Therapy Skills Group|
58105255|NCT02115737|BEHAVIORAL|Psychoeducation group treatment|
58105256|NCT03775148|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
58105257|NCT02980328|DEVICE|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
58310192|NCT00017251|OTHER|laboratory biomarker analysis|Correlative studies
58310193|NCT03927170|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
58310194|NCT03927170|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
58310195|NCT05654038|BIOLOGICAL|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
58310196|NCT04271215|OTHER|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
58105258|NCT02980328|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
58105259|NCT03812679|DEVICE|AMIA APD Solution Generation System|The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
58105260|NCT01375569|DRUG|TRC105|
58105261|NCT03855124|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
58105262|NCT01273922|BIOLOGICAL|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
58105263|NCT01496690|DRUG|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
58105264|NCT01496690|DRUG|Pregabalin Placebo Capsules|Parallel to Active Comparator
58105265|NCT02629237|OTHER|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
58105266|NCT03468374|DEVICE|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
58105267|NCT03468374|DEVICE|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
58105268|NCT01964105|DEVICE|3D Imaging|
58105269|NCT05991245|OTHER|Collecting datas|Blood, Tissue and Urine samples
58436125|NCT06335017|DIETARY_SUPPLEMENT|Induction of labor|In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
58436126|NCT04424342|OTHER|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
58436127|NCT04424342|OTHER|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
58436128|NCT04375059|OTHER|using interactive attention training system|using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
58436129|NCT05230784|OTHER|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
58436130|NCT05230784|OTHER|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
58436131|NCT00008229|BIOLOGICAL|filgrastim|
58436132|NCT00008229|DRUG|melphalan|
58436133|NCT00008229|PROCEDURE|peripheral blood stem cell transplantation|
58436134|NCT00008229|RADIATION|holmium Ho 166 DOTMP|
58436135|NCT00305630|DRUG|Periocular injection of triamcinolone acetonide 40mg|
58436136|NCT01262534|OTHER|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
58436137|NCT01262534|OTHER|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
58436138|NCT01262534|OTHER|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
58436139|NCT02112292|DRUG|tetrahydrocannabinol|
57738179|NCT02348073|DRUG|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
57738180|NCT02348073|DRUG|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
58436140|NCT02112292|DRUG|cannabidiol|
58436141|NCT02112292|DRUG|Placebo|
58436142|NCT02659436|OTHER|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
58436143|NCT02659436|OTHER|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
58436144|NCT00793169|PROCEDURE|Blood Draw|Serum levels were measured
58436145|NCT02610946|BEHAVIORAL|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
58436146|NCT02610946|BEHAVIORAL|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
58436147|NCT03202134|OTHER|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
58436148|NCT06414447|DIAGNOSTIC_TEST|Huxley Medical|diagnostic
58436149|NCT03322410|BIOLOGICAL|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49."
58436150|NCT06584058|DRUG|HPP737|\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
58436151|NCT01188304|DRUG|aleglitazar|repeated daily doses
57738181|NCT00253591|DRUG|cisplatin|
57738182|NCT00253591|DRUG|vinorelbine tartrate|
57738183|NCT00253591|RADIATION|radiation therapy|
58105270|NCT00087399|DRUG|gabapentin|
58105271|NCT00087399|DRUG|antidepressant|
58436152|NCT01188304|DRUG|aspirin|repeated daily doses
58436153|NCT01188304|DRUG|placebo|repeated daily doses
58436154|NCT03722524|DRUG|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
58436155|NCT04397562|DRUG|Levilimab|Levilimab 324 mg
58436156|NCT04397562|DRUG|Placebo|Placebo
58105272|NCT02837367|DIETARY_SUPPLEMENT|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
58105273|NCT02579785|BEHAVIORAL|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
58105274|NCT03970668|DRUG|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
58105275|NCT03970668|DRUG|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
58105276|NCT02462382|PROCEDURE|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
58105277|NCT02462382|DRUG|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
58105278|NCT02462382|DRUG|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
58436157|NCT06096662|BEHAVIORAL|Verb Network Strenghtening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
58436158|NCT03990428|BEHAVIORAL|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
58436159|NCT02735954|OTHER|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
58436160|NCT03330639|OTHER|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
58436161|NCT03330639|OTHER|Placebo|This group will receive the saline placebo solution.
58436162|NCT03829722|DRUG|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
58436163|NCT03829722|DRUG|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
58436164|NCT03829722|DRUG|Paclitaxel|Given IV once per week during radiation therapy (30mg/m\^2)
58436165|NCT03829722|RADIATION|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
58436166|NCT00603122|BEHAVIORAL|ascent protocol|ascent protocol for the two groups has different acclimatization time
58436167|NCT02473367|DRUG|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
57738184|NCT01581281|DRUG|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
57738185|NCT01581281|DRUG|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
58436168|NCT02473367|DRUG|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
58436169|NCT02473367|DRUG|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
58436170|NCT04429724|DIAGNOSTIC_TEST|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
58436171|NCT02609789|DRUG|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
58436172|NCT02609789|DRUG|Placebo|0.9 percent (%) normal saline.
58436173|NCT03222401|DRUG|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
58436174|NCT03222401|DRUG|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
58436175|NCT03222401|DRUG|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
58436176|NCT00370565|DRUG|Inhaled Human Insulin|
58436177|NCT06330207|BEHAVIORAL|Clinical decision support tool|The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
58436178|NCT02022163|BIOLOGICAL|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
58436179|NCT02022163|BIOLOGICAL|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
58436180|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
58436181|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
58436182|NCT02022163|BIOLOGICAL|Placebo|Placebo, 2 doses given 21 days apart
58436183|NCT03991429|DIAGNOSTIC_TEST|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
58436184|NCT03991429|BEHAVIORAL|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
57738186|NCT01581281|DRUG|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
58105279|NCT02971332|PROCEDURE|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
58105280|NCT04575974|OTHER|No intervention|No intervention
58105281|NCT06538272|DRUG|ONO-2910|ONO-2910 Tablet will be orally administered once daily.
58105282|NCT06538272|DRUG|Placebo|Placebo Tablet will be orally administered once daily.
57738187|NCT00249535|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
58105283|NCT05087199|DIAGNOSTIC_TEST|Rt-PCR.|Nasopharyngeal swab for Rt-PCR for COVID-19
58105284|NCT06265688|DRUG|CX-2051|Investigational drug monotherapy
58436185|NCT03991429|OTHER|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
58105285|NCT00982774|BIOLOGICAL|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
58105286|NCT02192216|BEHAVIORAL|Exercise|
58105287|NCT02400073|DEVICE|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
57738188|NCT02789280|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
57738189|NCT02789280|OTHER|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
57738190|NCT00687648|DRUG|anastrozole|Given as previously prescribed
57738191|NCT00687648|DRUG|cyclophosphamide|Given by mouth
57738192|NCT00687648|DRUG|exemestane|Given as previously prescribed
57738193|NCT00687648|DRUG|letrozole|Given as previously prescribed
57738194|NCT00687648|DRUG|methotrexate|Given by mouth
58436186|NCT03991429|DIAGNOSTIC_TEST|Urinalysis|Urine sample
58436187|NCT00979927|DRUG|SPC3649|5 weekly doses
58436188|NCT00979927|DRUG|saline|5 weekly doses
57738195|NCT00687648|DRUG|prednisolone|Given by mouth
57738196|NCT02388724|DRUG|Vonoprazan|Vonoprazan tablets
57738197|NCT02388724|DRUG|Lansoprazole|Lansoprazole capsules
57738198|NCT02388724|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
57738199|NCT02388724|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
58436189|NCT06418659|DRUG|CD-801|CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
58310197|NCT04322136|PROCEDURE|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
58310198|NCT04322136|DEVICE|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
58310199|NCT00490035|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
58310200|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
58310201|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
58310202|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
58310203|NCT02152007|DRUG|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
58310204|NCT00329108|DRUG|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
58310205|NCT00329108|DRUG|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
58310206|NCT02629783|OTHER|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
58310207|NCT02629783|OTHER|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
58436190|NCT00245037|BIOLOGICAL|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
58436191|NCT00245037|DRUG|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
57954662|NCT03345108|DEVICE|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
58436192|NCT00245037|DRUG|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
58436193|NCT00245037|DRUG|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments."
58436194|NCT00245037|DRUG|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
58436195|NCT00245037|PROCEDURE|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
58436196|NCT00245037|RADIATION|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
57954663|NCT03345108|DEVICE|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
57954664|NCT03345108|OTHER|No Adhesive|No adhesive applied.
57954665|NCT05996172|BEHAVIORAL|CAMS Single Session Consultation|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation. CAMS is based around a model of STB which states that youth become suicidal in response to overwhelming pain, and treatment identifies and targets the drivers of suicide as the primary focus of assessment and intervention.
57954666|NCT05996172|BEHAVIORAL|Driver Focused Skills Training|The CAMS approach focuses on therapeutic assessment, collaborative identification and treatment of the patient-defined STB drivers (i.e., the problems that make suicide compelling to the patient) and utilizes problem-focused treatment sessions to address the drivers in order to reduce the wish to die. In the SOARS brief intervention model, specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality.
57954667|NCT05996172|BEHAVIORAL|Caregiver Skills Training|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills adapted from evidence-based treatments for youth suicidality including DBT and CBT.48,49 Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
57954668|NCT05996172|BEHAVIORAL|Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means safety over two, 30-minute modules delivered across 2 sessions.
57954669|NCT02236520|DRUG|Spironolactone|
57954670|NCT02236520|DRUG|Chlorthalidone|
57954671|NCT02236520|DIETARY_SUPPLEMENT|Diet|
57954672|NCT02236520|DRUG|Placebo|
57954673|NCT00470600|DRUG|Caldolor|800 milligrams intravenous
58436197|NCT00245037|DRUG|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
58436198|NCT00245037|DRUG|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
57954674|NCT00470600|OTHER|Normal Saline|Placebo comparator
58310208|NCT02629783|DRUG|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
58310209|NCT00448799|RADIATION|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of \[123I\] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
58310210|NCT01308619|DRUG|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
58310211|NCT01308619|OTHER|Placebo|Placebo, oral, one capsule daily in the morning
58310212|NCT02693067|DRUG|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
58310213|NCT00003261|DRUG|methotrexate|
58310214|NCT00003261|DRUG|zidovudine|
58310215|NCT00003261|PROCEDURE|neoadjuvant therapy|
58310216|NCT00003261|RADIATION|radiation therapy|
58310217|NCT05774314|BEHAVIORAL|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
58310218|NCT01712711|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
58310219|NCT03380286|DEVICE|Firehawk|Firehawk stent
58310220|NCT01309334|PROCEDURE|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
58310221|NCT01309334|PROCEDURE|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
58310222|NCT04773132|OTHER|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
58310223|NCT00963508|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
58310224|NCT00963508|DRUG|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
58310225|NCT05346029|BEHAVIORAL|Lifestyle intervention|Resistance training and nutritional counseling
58310226|NCT03220503|PROCEDURE|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
58310227|NCT05557864|DEVICE|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
58105288|NCT04562298|BIOLOGICAL|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
58105289|NCT02692352|OTHER|Goal Management Training|Goal Management training, 8 sessions of 2 hours
58105290|NCT02692352|OTHER|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
58105291|NCT03235531|DRUG|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
58105292|NCT03235531|DRUG|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
58105293|NCT03996707|OTHER|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery
58105294|NCT03996707|OTHER|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot \& ankle surgery
58105295|NCT05938335|GENETIC|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
58105296|NCT03443219|DEVICE|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
58105297|NCT03443219|DEVICE|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
58105298|NCT00368238|DRUG|Recombinant human erythropoietin alfa (drug)|
58105299|NCT00368238|DRUG|Aspirin (drug)|
58105300|NCT00368238|DRUG|Clopidogrel (drug)|
58105301|NCT04987671|DRUG|AMX0035|Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
58105302|NCT00279799|BEHAVIORAL|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
58105303|NCT00279799|BEHAVIORAL|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
58105304|NCT05889026|DEVICE|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
58105305|NCT05889026|PROCEDURE|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
58105306|NCT03124056|DEVICE|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
58105307|NCT02684383|BIOLOGICAL|rDEN3∆30|10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
58105308|NCT02684383|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
58310228|NCT05563558|DRUG|Pembrolizumab|Included in arm/group description
58310229|NCT05563558|DRUG|Carboplatin|Included in arm/group description
58105309|NCT06157333|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
58310230|NCT05563558|DRUG|Cabazitaxel|Included in arm/group description
58310231|NCT04896671|BEHAVIORAL|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
58310232|NCT04424979|DEVICE|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
58310233|NCT00825240|BEHAVIORAL|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
58310234|NCT02283398|OTHER|without RIPC|the cuff will be placed around the left arm without being inflated
58310235|NCT02283398|PROCEDURE|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
58310236|NCT06237270|PROCEDURE|Nerve transfer surgery for elbow flexion|A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
58310237|NCT00630916|DEVICE|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
58436199|NCT00245037|DRUG|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
58436200|NCT03002883|BEHAVIORAL|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
58436201|NCT03002883|BEHAVIORAL|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
58436202|NCT03002883|BEHAVIORAL|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
58436203|NCT02346253|RADIATION|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
58436204|NCT02346253|DRUG|Bicalutamide|Given PO
58436205|NCT02346253|DRUG|Leuprolide Acetate|Given IM or SC
58436206|NCT02346253|DRUG|Goserelin Acetate|Given SC
58436207|NCT02346253|DRUG|Triptorelin Pamoate|Given IM
58436208|NCT02346253|DRUG|Degarelix|Given SC
58436209|NCT02346253|OTHER|Laboratory Biomarker Analysis|Correlative studies
58436210|NCT02346253|OTHER|Quality-of-Life Assessment|Ancillary studies
57954675|NCT04469296|DIETARY_SUPPLEMENT|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
57954676|NCT04469296|DIETARY_SUPPLEMENT|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
57954677|NCT05772260|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
57954678|NCT00109707|DRUG|Nilotinib|
57954679|NCT01547455|DRUG|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
57954680|NCT01547455|DRUG|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
57954681|NCT02231554|OTHER|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
57954682|NCT02231554|OTHER|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
57954683|NCT04417894|DRUG|dupilumab|Solution for subcutaneous (SC) injection administration
57954684|NCT04417894|DRUG|Placebo|Solution for SC injection administration
57954685|NCT02189135|DEVICE|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
57954686|NCT01297335|DRUG|clonidine|Intrathecal Clonidine
58436211|NCT04253002|BEHAVIORAL|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
58310238|NCT05720819|DEVICE|Combined biofeedback-virtual reality device|The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
58436212|NCT04253002|BEHAVIORAL|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
58436213|NCT02153580|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
58436214|NCT02153580|DRUG|Bendamustine Hydrochloride|Given IV
58436215|NCT02153580|DRUG|Cyclophosphamide|Given IV
58436216|NCT02153580|DRUG|Etoposide|Given IV
58436217|NCT02153580|DRUG|Fludarabine Phosphate|Given IV
58310239|NCT00005649|DRUG|capecitabine|
58310240|NCT00005649|DRUG|paclitaxel|
58310241|NCT01231269|OTHER|MRI|MRI scan without administration of contrast/without radiation
58310242|NCT02650739|PROCEDURE|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
58310243|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 6 weeks.|
58310244|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 5 weeks.|
58310245|NCT00952198|DRUG|ARRY-403, glucokinase activator; oral|multiple dose, escalating
58310246|NCT00952198|DRUG|Placebo; oral|matching placebo
58436218|NCT03218176|DEVICE|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
57954687|NCT01401634|OTHER|Oral water|2 Liters of water given orally
57954688|NCT01401634|OTHER|Intravenous normal saline|2 Liters Intravenous normal saline
57954689|NCT02670135|DRUG|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
57954690|NCT02670135|DRUG|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
57954691|NCT00720109|DRUG|Asparaginase|Given IT
57954692|NCT00720109|DRUG|Cyclophosphamide|Given IV
57954693|NCT00720109|DRUG|Cytarabine|Given IT or IV
57954694|NCT00720109|DRUG|Dasatinib|Given PO
57954695|NCT00720109|DRUG|Daunorubicin Hydrochloride|Given IV
57954696|NCT00720109|DRUG|Dexamethasone|Given IV or PO
57954697|NCT00720109|DRUG|Etoposide|Given IV
57954698|NCT00720109|BIOLOGICAL|Filgrastim|Given IV or SC
57954699|NCT00720109|DRUG|Hydrocortisone Sodium Succinate|Given IT
57954700|NCT00720109|DRUG|Ifosfamide|Given IV
57954701|NCT00720109|OTHER|Laboratory Biomarker Analysis|Correlative studies
57954702|NCT00720109|DRUG|Leucovorin Calcium|Given IV or PO
57954703|NCT00720109|DRUG|Mercaptopurine|Given PO
57954704|NCT00720109|DRUG|Methotrexate|Given IT, PO, or IV
57954705|NCT00720109|DRUG|Methylprednisolone|Given IV
57954706|NCT00720109|DRUG|Pegaspargase|Given IM
57954707|NCT00720109|DRUG|Prednisone|Given PO or IV
57954708|NCT00720109|RADIATION|Radiation Therapy|Some patients undergo cranial RT
57954709|NCT00720109|DRUG|Vincristine Sulfate|Given IV
57954710|NCT00332995|DRUG|dapivirine (TMC120) vaginal ring|
57954711|NCT04298983|DRUG|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
57954712|NCT04298983|DRUG|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
57954713|NCT04298983|RADIATION|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
57954714|NCT00586209|DRUG|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
57954715|NCT00586209|DRUG|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
57954716|NCT01889290|DRUG|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
57954717|NCT06426355|DIETARY_SUPPLEMENT|NMN|NMN capsules (total of 600mg/day) for 2-5 months
57954718|NCT06426355|OTHER|Placebo|NMN-free placebo capsules for 2-5 months
57954719|NCT01240161|DRUG|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
58105310|NCT03757052|DIAGNOSTIC_TEST|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
58436219|NCT03218176|DEVICE|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436220|NCT03218176|DEVICE|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436221|NCT03218176|DEVICE|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436222|NCT03218176|DEVICE|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
57738200|NCT06335433|OTHER|Exercise Training (Isometric Handgrip Exercise)|Participants allocated to the exercise groups will complete 6 weeks of isometric handgrip exercise training (IHGT) using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong) for either 2 or 4 sessions per week. Each exercise session will consist of 4 x 2-minute isometric contractions at 30% MVC with 1 minute rest periods between contractions. The first bout will be performed on the dominant arm and then the arm will be alternated for each subsequent two-minute bout. Participants will be instructed to try keep the contraction tension as close as possible to the set tension of 30% MVC using visual feedback from the dynamometer's electronic display.
57738201|NCT03603665|BIOLOGICAL|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
57738202|NCT03603665|OTHER|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
58105311|NCT03038282|DIETARY_SUPPLEMENT|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
58105312|NCT03038282|OTHER|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
58105313|NCT01671735|OTHER|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
58105314|NCT04230954|DRUG|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
58105315|NCT04230954|DRUG|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
58105316|NCT04264559|DIAGNOSTIC_TEST|Infrared thermal imaging|A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
58105317|NCT04264559|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes."
58105318|NCT04259879|OTHER|Fasting|Food intake restriction
58105319|NCT03095482|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
58105320|NCT03095482|BEHAVIORAL|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
58105321|NCT05547100|DRUG|LYBALVI|5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
58105322|NCT03060031|DRUG|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
58105323|NCT03060031|DRUG|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
58436223|NCT03218176|DEVICE|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436224|NCT03218176|DEVICE|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436225|NCT03218176|DEVICE|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
58436226|NCT02650063|DRUG|DE-117|
58436227|NCT01003652|PROCEDURE|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
58436228|NCT03113981|DEVICE|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
58436229|NCT02103972|DIETARY_SUPPLEMENT|GM080|
58436230|NCT02103972|DIETARY_SUPPLEMENT|Maltodextrin|
58105324|NCT00405483|PROCEDURE|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
58105325|NCT00405483|PROCEDURE|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
58105326|NCT00202657|PROCEDURE|echocardiography|
58105327|NCT00690924|DRUG|calcitriol|Oral
57954720|NCT05098795|BEHAVIORAL|Behavioral Activation (BA)|BA seeks to increase the positive reinforcement patients experience from their natural environment by promoting prosocial and valued experiences. BA has been found to improve substance use treatment retention and adherence, as well as medication adherence in low-income individuals with HIV/AIDS.
58105328|NCT00690924|OTHER|laboratory biomarker analysis|Correlative Study
57954721|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using dehydrated corneas
58105329|NCT00690924|OTHER|pharmacological study|Correlative Study
58105330|NCT01241565|DEVICE|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
57954722|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using standard organ culture stored corneas
57954723|NCT01395394|DRUG|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
57954724|NCT01395394|OTHER|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
57954725|NCT06199388|OTHER|Survival state|We recorded clinically relevant information and survival status of pediatric glioma patients
58310247|NCT06170710|DRUG|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
58436231|NCT04039217|DRUG|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
57954726|NCT02247323|OTHER|Risk of malignancy index|Calculation of RMI before sugery.
57954727|NCT01478035|DRUG|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
57954728|NCT01478035|DRUG|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
57954729|NCT03339921|DRUG|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
57954730|NCT03339921|PROCEDURE|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
57954731|NCT02266992|BIOLOGICAL|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
57954732|NCT05531175|OTHER|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
57954733|NCT01232829|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
57954734|NCT03687151|OTHER|non intervention / observationnal|non intervention / observationnal
57954735|NCT00199563|DRUG|Viagra|Sildenafil 100mg daily for 12 weeks
57954736|NCT01648127|DRUG|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
58105331|NCT01341522|PROCEDURE|MRI exam|MRI exam
58105332|NCT01341522|PROCEDURE|control|waiting room
58105333|NCT00830388|DRUG|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
58105334|NCT04554407|DEVICE|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
58105335|NCT05035485|DRUG|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
58105336|NCT05035485|DRUG|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
58105337|NCT01677403|DRUG|Tobramycin|Nebulised 80mg twice daily
58105338|NCT01677403|DRUG|Saline|Nebulised 5mls 0.9% Saline twice daily
58105339|NCT01457131|DRUG|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
58310248|NCT06170710|OTHER|Postoperative CCRT|Postoperative chemoradiotherapy
58310249|NCT01145482|DRUG|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
58436232|NCT05860153|DRUG|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
58436233|NCT05860153|DRUG|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
58105340|NCT01457131|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
58105341|NCT01457131|OTHER|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
58105342|NCT05974020|OTHER|Control|No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
58105343|NCT05974020|OTHER|Intrinsic Muscle Training|"In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program."
57954737|NCT01437774|DEVICE|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
57954738|NCT05044156|OTHER|salivary sample|salivary sample
58105344|NCT05974020|OTHER|Aerobic Exercise|In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
58105345|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
58105346|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
58105347|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
58105348|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
58105349|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
58436234|NCT02465203|DRUG|Previous treatment in DEB025 study|Follow-up after DEB025 active study
58436235|NCT02544919|DRUG|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
58105350|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
58105351|NCT00947245|DRUG|Placebo|Capsules, Oral, Single Dose, One day
58105352|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours, 14 days
58105353|NCT00947245|DRUG|Placebo|Capsules, Oral, Once Daily, 14 days
58105354|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
58105355|NCT03820973|BEHAVIORAL|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
58105356|NCT01950806|OTHER|Pecan-containing diet|
58105357|NCT01950806|OTHER|Nut-free diet|
58436236|NCT04686383|DRUG|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
58310250|NCT01145482|OTHER|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
58310251|NCT00379106|PROCEDURE|Arm exercises.|Basic active exercise program at home.
57954739|NCT01135498|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
57954740|NCT01135498|DRUG|eloxatin|Intravenous repeating dose
58310252|NCT00379106|PROCEDURE|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
57954741|NCT01135498|DRUG|capecitabine [Xeloda]|Oral repeating dose
57954742|NCT01135498|DRUG|erlotinib [Tarceva]|Oral repeating dose
57954743|NCT05224583|PROCEDURE|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
57954744|NCT01984268|DRUG|ACTHAR|
58105358|NCT00524875|DRUG|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
58105359|NCT05913388|DRUG|GB1211|Administered orally twice daily at 400mg.
58105360|NCT05913388|DRUG|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
58105361|NCT05913388|DRUG|Placebo|Administered orally twice daily at 400mg.
58105362|NCT04953585|PROCEDURE|radical gastrectomy|According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
58105363|NCT01866488|DRUG|Misoprostol|
58105364|NCT01866488|OTHER|Placebo|
58310253|NCT02751229|BEHAVIORAL|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~1. Considering pros and cons of disclosing:~   * hurtful and helpful attitudes about mental illness~  * identify beliefs participants hold about themselves~  * explore five-step process to challenge their personally hurtful beliefs~  * weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~2. Different ways to disclose:~   * different levels of (non-) disclosure and how to weigh the cons and pros~  * disclosure via social media versus disclosing face to face~  * how to find people that are better to disclose to than others and how to 'test them out'~  * participants will discuss how others might respond to their disclosure and how that will affect them~3. Telling your story:~   * how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
58310254|NCT05318664|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
58310255|NCT04127370|PROCEDURE|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
58310256|NCT04194112|DIAGNOSTIC_TEST|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
58310257|NCT00458237|DRUG|Everolimus|Everolimus is being administered orally 7 days per week.
58310258|NCT00458237|DRUG|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
58310259|NCT00461058|DRUG|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
58436237|NCT02682992|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
58436238|NCT04384055|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
58436239|NCT06293768|DEVICE|continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)|Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
58436240|NCT04077515|DRUG|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
58436241|NCT04077515|DRUG|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
57954745|NCT00999531|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
57954746|NCT00999531|DRUG|Placebo|Inhaled Placebo, sterile saline
57954747|NCT06536660|PROCEDURE|Magnesium bone plate and screw fixation in jaw surgery|Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.
57954748|NCT00634829|DRUG|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
57954749|NCT00634829|DRUG|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
57954750|NCT00634829|DRUG|Placebo-HFA|Placebo containing HFA propellant without active drug substance
57954751|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
57954752|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
57954753|NCT02606422|DEVICE|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
57954754|NCT02606422|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
57954755|NCT02111642|OTHER|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
57954756|NCT01335763|DRUG|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
57954757|NCT05392686|DRUG|PD-1 inhibitor|Tirelizumab
57954758|NCT05392686|DRUG|PARP inhibitor|Fluzopari capsule
57954759|NCT02202629|OTHER|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
57954760|NCT04586283|OTHER|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
57954761|NCT05070767|DEVICE|Neurolens spectacle lens|spectacle lens
57954762|NCT05070767|DEVICE|Placebo spectacle lens|spectacle lens for refractive error correction
57954763|NCT00659204|DRUG|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
57954764|NCT00659204|DRUG|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
58105365|NCT04371419|BEHAVIORAL|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later."
58105366|NCT04632693|PROCEDURE|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
58105367|NCT04632693|PROCEDURE|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
58105368|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
58105369|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
58105370|NCT01645228|RADIATION|coronary calcium score measurement|
58105371|NCT01645228|BIOLOGICAL|high sensitivity C reactive protein measurement|
58105372|NCT01645228|PROCEDURE|ankle brachial index measurement|
58105373|NCT00811070|DRUG|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
58105374|NCT06412237|DEVICE|RELab tenoexo|The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.
58105375|NCT04627870|DEVICE|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
58105376|NCT04627870|DEVICE|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
58105377|NCT02832791|PROCEDURE|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
58105378|NCT02832791|PROCEDURE|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
58105379|NCT04428502|DRUG|Enbrel|As provided in real world practice
58105380|NCT06543316|PROCEDURE|Low Thermal Plasma (LTP) Treatment|For patients randomized to the LTP group, the first LTP treatment will be administered during the initial esophagogastroduodenoscopy (EGD) using a single-use 2.3 mm filtered argon plasma coagulation (FiAPC probe). The argon plasma will be applied at low power settings (\~1 W) to the ulcerated areas using pulsed APC effect 0.1.
58436242|NCT02622893|DRUG|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
57954765|NCT06126432|DIETARY_SUPPLEMENT|Yugart|Yugart 2 bottles per day for 1 month
57954766|NCT00674050|DRUG|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
57954767|NCT00674050|DRUG|Albuterol (Salbutamol)|2 puff= 200ug total dose
57954768|NCT00674050|DRUG|Fluticasone|2 puffs= 500ug total dose
57954769|NCT03559855|BEHAVIORAL|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
57954770|NCT04647500|DRUG|Concerta|Evaluation of a treatment of Concerta over a period of 13 days.
57954771|NCT01112540|DRUG|Morphine|0.1 mg/kg Intravenous bolus
57954772|NCT01548339|PROCEDURE|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
57954773|NCT04320238|DRUG|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
58436243|NCT02622893|DRUG|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
58436244|NCT02119663|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
58436245|NCT02119663|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
58436246|NCT02119663|DRUG|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
58436247|NCT04951466|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
58105381|NCT06543316|OTHER|Standard of Care Ulcer Treatment (typically PPI Administration)|Standard of care for treatment of ulcers is administration of a proton pump inhibitor (PPI). For patients in the SOC group whose ulcers have not healed completely by the second follow-up at 8 weeks, crossover to LTP treatment will be offered. This treatment will follow the same procedure as the initial LTP treatment.
58105382|NCT02642107|RADIATION|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
58105383|NCT02642107|RADIATION|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
58105384|NCT04729218|BEHAVIORAL|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
58105385|NCT04945161|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
58105386|NCT04945161|OTHER|Placebo|Placebo
58105387|NCT04448691|DIAGNOSTIC_TEST|CCTA|requested follow up CCTA
58436248|NCT04951466|BEHAVIORAL|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
58436249|NCT04791618|BEHAVIORAL|Health360x plus health coach|Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
58436250|NCT04791618|BEHAVIORAL|Health360x only (High tech)|All participants will have access to Helath360x with reminders generated for goal setting.
58436251|NCT00042991|DRUG|gefitinib|Given orally
58105388|NCT06527391|DRUG|choline bitartrate|Daily supplementation for 9 months with 200 mg choline bitartrate
58105389|NCT06527391|OTHER|placebo drug|Daily supplementation for 9 months with identical placebo
58436252|NCT00042991|RADIATION|radiation therapy|Undergo standard brain irradiation
58436253|NCT00042991|OTHER|pharmacological study|Correlative studies
58105390|NCT00529568|DRUG|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
58105391|NCT00529568|DRUG|placebo|double-blind matched placebo control daily oral administration
58105392|NCT06516497|OTHER|Group using traditional method in long bone deformity correction|Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.
58105393|NCT06516497|DEVICE|Group using computer-aided sensors in long bone deformity correction|After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
58105394|NCT06348654|BEHAVIORAL|introduction of digital listening may improve the quality of life of patients withe breast cancer|Introduction of a digital listening and communication pathway aimed at improving the quality of life of patients with advanced HER2-negative breast cancer
58105395|NCT06536790|OTHER|hang clean training|This include hang clean training thrice a week for twelve weeks
58436254|NCT00042991|OTHER|laboratory biomarker analysis|Correlative studies
58436255|NCT04770948|DEVICE|19 gauge needle|EBUS-TBNA performed using 19G needle
58436256|NCT04770948|DEVICE|22 gauge needle|EBUS-TBNA performed using 22G needle
58436257|NCT05843929|DIAGNOSTIC_TEST|LSCI|"1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
58436258|NCT04542031|OTHER|Questionnaire|Questionnaire to be completed at 6 and 12 months
58436259|NCT05018078|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
58436260|NCT03830346|OTHER|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
58436261|NCT00038233|DRUG|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
58436262|NCT02286232|BEHAVIORAL|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
58436263|NCT02286232|BEHAVIORAL|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
58436264|NCT05878951|DRUG|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
58436265|NCT00516867|RADIATION|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
58436266|NCT00516867|RADIATION|UV radiation|UVB 1.4 % and UVA 98.6
57738203|NCT06579378|DEVICE|VSail 3D|"The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life."
57738204|NCT06579378|OTHER|WEB-Health|The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
58105396|NCT06536790|OTHER|half squat training|This include half squat training thrice a week for twelve weeks
58436267|NCT01078649|DRUG|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
58436268|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
57954774|NCT04320238|DRUG|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
57954775|NCT06494137|OTHER|inulin|inulin from chicory root
57954776|NCT00034658|DRUG|Posaconazole|
57954777|NCT02300298|DRUG|Nintedanib|Nintedanib
58105397|NCT01303874|DRUG|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
58105398|NCT01303874|DRUG|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
58105399|NCT04636801|DRUG|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
58436269|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
58436270|NCT01548066|DRUG|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
58436271|NCT01548066|DRUG|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
57954778|NCT02300298|DRUG|Docetaxel|Docetaxel
58105400|NCT04636801|DRUG|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
58105401|NCT04636801|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid.
58310260|NCT00461058|DRUG|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
58310261|NCT06479902|PROCEDURE|Core stability exercise|Core stability exercises featured moves such as planks and side planks.
58436272|NCT05168020|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
58436273|NCT05168020|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
58436274|NCT01835223|DRUG|Tivozanib (1mg)|Given PO
58436275|NCT01835223|DRUG|Tivozanib (1.5mg)|Given PO
58436276|NCT04965532|DRUG|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
58436277|NCT04965532|DRUG|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
58436278|NCT04375514|DRUG|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
58436279|NCT04375514|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
58436280|NCT05002491|OTHER|High protein diet|Normal vs high protein dietary feeding
58436281|NCT03653728|DEVICE|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
58436282|NCT02439034|DRUG|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
58436283|NCT02439034|DRUG|Ketoprofen|Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
58436284|NCT02736344|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent|
58436285|NCT04569227|DRUG|EC-18|2000 mg PO daily
58436286|NCT04569227|DRUG|Placebo|PO daily
58436287|NCT04274335|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
58436288|NCT04274335|DRUG|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
58436289|NCT04274335|DRUG|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
58436290|NCT05196191|BIOLOGICAL|VIAGENEX Max|Collagenous membrane derived from umbilical cord
58436291|NCT05196191|PROCEDURE|Hibiclens wash|Antiseptic skin cleanser
58436292|NCT00650845|DRUG|Dotarem®-enhanced MRI|Single IV administration before MRI exam
58436293|NCT00650845|OTHER|non-enhanced MRI|non injected MRI
58436294|NCT05490940|DRUG|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
58436295|NCT00277784|PROCEDURE|Ultrasound examination|one ultrasound examination
58436296|NCT04532905|OTHER|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
58436297|NCT06413238|DRUG|curcumin, saffron, Combination of saffron and curcumin and placebo|This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
58436298|NCT00003712|DRUG|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
58105402|NCT03805178|DRUG|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
58105403|NCT03805178|DRUG|Carfilzomib|20mg/m2 Plasmapheresis
58436299|NCT02397057|DRUG|Injectafer|
58436300|NCT02397057|OTHER|Placebo|
58436301|NCT05494437|COMBINATION_PRODUCT|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
58436302|NCT05494437|COMBINATION_PRODUCT|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
58436303|NCT05494437|DRUG|Placebo|Placebo comparator
58436304|NCT05494437|DRUG|Nabilone|CB1 receptor
58436305|NCT05494437|DRUG|Gabapentin|GABAergic modulator
58436306|NCT02709603|DRUG|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
58436307|NCT02709603|DRUG|placebo|oral placebo; 2 tablets 30 minutes before the procedure
58436308|NCT00306527|BIOLOGICAL|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
58436309|NCT00306527|BIOLOGICAL|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
58436310|NCT02964442|OTHER|Capsinoids|12 mg of Gel capsules
58436311|NCT02964442|OTHER|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
58436312|NCT01126944|DEVICE|heart mate II|left ventricular assist device
58436313|NCT02561442|DRUG|ceftriaxone|
58436314|NCT04384939|DEVICE|magnetic-end Double-J ureteral stent|"* Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
58436315|NCT01142622|DRUG|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
58436316|NCT01142622|DRUG|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
58436317|NCT00857857|DRUG|GW870086X|Investigational product
58436318|NCT00857857|DRUG|FP|Positive control
58436319|NCT00857857|DRUG|Placebo|Placebo control
58436320|NCT02679170|DRUG|Crizotinib|Treatment with crizotinib following routine clinical practice
58436321|NCT02942485|DRUG|Metronidazole|P/r suppositories
58436322|NCT02942485|DRUG|Tinidazole|P/o tablets
58436323|NCT02173171|OTHER|Information collection|Q3M Information collection
58436324|NCT00766714|DEVICE|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
58436325|NCT00766714|DEVICE|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
58436326|NCT00180583|DEVICE|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
58436327|NCT05370833|DEVICE|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
58436328|NCT03656991|OTHER|Bicycle intervention|
58436329|NCT02130596|BEHAVIORAL|Acceptance-Based Behavioral Intervention|
58436330|NCT02130596|OTHER|Nutritional Counselling|
58436331|NCT04860141|DRUG|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
58436332|NCT04860141|DRUG|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
58436333|NCT02327494|DRUG|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
58436334|NCT05063682|BIOLOGICAL|EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes|ICV administration
58436335|NCT02715986|DEVICE|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
58436336|NCT01304537|DRUG|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
58436337|NCT01304537|DRUG|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
58436338|NCT01304537|DRUG|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
58436339|NCT05507151|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
58436340|NCT04190732|BEHAVIORAL|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
58436341|NCT05515991|OTHER|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
58436342|NCT05515991|OTHER|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
58436343|NCT05089864|OTHER|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
58436344|NCT05089864|OTHER|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
58436345|NCT04563962|BEHAVIORAL|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
58436346|NCT04563962|BEHAVIORAL|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
58436347|NCT02106403|OTHER|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
58436348|NCT02106403|OTHER|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
58436349|NCT02106403|OTHER|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
58436350|NCT03824600|DIAGNOSTIC_TEST|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
58436351|NCT02183233|DRUG|Eschscholtzia Californica|
58436352|NCT02183233|DRUG|Eschscholtzia Californica Placebo|
58105404|NCT03956667|OTHER|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
58105405|NCT01081483|DRUG|ABT-072|See arm description for more information
58105406|NCT01081483|DRUG|Placebo|See arm description for more information
58105407|NCT01113294|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
58105408|NCT01452113|DRUG|Vildagliptin|one 50 mg tablet per os
58105409|NCT03548207|BIOLOGICAL|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
58105410|NCT01001871|DIETARY_SUPPLEMENT|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
58105411|NCT01001871|DIETARY_SUPPLEMENT|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
58105412|NCT00218621|PROCEDURE|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
58105413|NCT04946422|PROCEDURE|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
58105414|NCT00845754|DRUG|ketorolac|15mg IV every6 hours for 4doses
58105415|NCT00845754|DRUG|saline|15mg IV every 6hrs for 4 doses
58105416|NCT04504929|DEVICE|Sham tape|Use sham type on the pitching shoulder
58105417|NCT04504929|DEVICE|Dynamic tape|Use dynamic type on the pitching shoulder for supporting internal rotation
58105418|NCT00966082|PROCEDURE|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
58105419|NCT00966082|PROCEDURE|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
58105420|NCT04137991|DEVICE|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
58105421|NCT04137991|OTHER|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
58105422|NCT05148130|DIAGNOSTIC_TEST|oral glucose tolerance test|GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
58105423|NCT05927805|OTHER|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
58105424|NCT05927805|OTHER|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
58105425|NCT00213213|DRUG|Sucrose|
58105426|NCT00328042|BEHAVIORAL|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
58105427|NCT00328042|BEHAVIORAL|Information Only|This is an individual self-paced at home study program.
58105428|NCT04188496|OTHER|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
58105429|NCT04188496|OTHER|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
58105430|NCT02657356|DRUG|Placebo capsules|
58105431|NCT02657356|DRUG|Bardoxolone methyl capsules|
58105432|NCT03178019|OTHER|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
58105433|NCT03570580|OTHER|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
58105434|NCT01807962|DRUG|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
58105435|NCT01807962|DRUG|sterile saline|Placebo = 5ml of sterile saline solution
58105436|NCT00002747|DRUG|cisplatin|
58105437|NCT00002747|DRUG|fluorouracil|
58105438|NCT00002747|PROCEDURE|conventional surgery|
58105439|NCT00002747|RADIATION|low-LET cobalt-60 gamma ray therapy|
58105440|NCT00002747|RADIATION|low-LET photon therapy|
58105441|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
58105442|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
58105443|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
58105444|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
58105445|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
58105446|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
58105447|NCT00950599|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
58310262|NCT06479902|PROCEDURE|Diaphragmatic Strengthening Exercise|. Diaphragmatic exercises included diaphragmatic breathing in various positions.
58310263|NCT03248297|DRUG|Azithromycin|Azithromycin tablet
58105448|NCT05485688|OTHER|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
58105449|NCT05934552|DRUG|Lactulose|lactulose and lactobacillus acidophilus on ckd patients
58105450|NCT01448265|PROCEDURE|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
58105451|NCT05424107|OTHER|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
58105452|NCT00137358|PROCEDURE|Radiation Therapy|
58436353|NCT01886703|BEHAVIORAL|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
58436354|NCT00005949|BIOLOGICAL|aldesleukin|Given SC
58436355|NCT00005949|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|Given SC
58436356|NCT00005949|OTHER|laboratory biomarker analysis|Correlative studies
58436357|NCT01916343|PROCEDURE|Study Laparoscopic Curriculum|
58436358|NCT04879173|DEVICE|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
58105453|NCT00137358|DRUG|Cisplatin|
58105454|NCT00137358|DRUG|Amifostine|
58105455|NCT00945152|DRUG|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
58105456|NCT00945152|DRUG|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
58436359|NCT02806453|DIETARY_SUPPLEMENT|thickened formula|
57738205|NCT00270218|BIOLOGICAL|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
58105457|NCT04596930|PROCEDURE|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
58105458|NCT05103059|DIAGNOSTIC_TEST|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
58105459|NCT02301780|DRUG|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
58105460|NCT02301780|DRUG|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
58105461|NCT03473470|DEVICE|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
58105462|NCT03473470|DEVICE|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
58105463|NCT04097119|DIETARY_SUPPLEMENT|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
58436360|NCT02806453|DIETARY_SUPPLEMENT|Mg alginate|
58436361|NCT02806453|BEHAVIORAL|reassurance with lifestyle changes|
58436362|NCT00235144|DEVICE|sirolimus-coated Bx Velocity stent|drug-eluting stent
58436363|NCT00235144|DEVICE|uncoated Bx Velocity stent|bare-metal stent
58436364|NCT03910114|DRUG|Magnevist|GBCA enhancement
58436365|NCT03910114|DRUG|Dotarem|GBCA enhancement
57738206|NCT00270218|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
58436366|NCT03910114|DRUG|Gadovist|GBCA enhancement
58436367|NCT03849222|PROCEDURE|Apexification|
58436368|NCT03849222|DRUG|MTA|
58436369|NCT03849222|DRUG|Ca(OH)2|
58436370|NCT03849222|DRUG|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
58436371|NCT00685789|DEVICE|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
58436372|NCT00685789|DEVICE|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
58436373|NCT02080299|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
58436374|NCT02080299|PROCEDURE|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
58436375|NCT00555672|DRUG|5-fluorouracil|5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
58436376|NCT00555672|DRUG|cisplatin|Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
58105464|NCT02001870|PROCEDURE|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
58105465|NCT02001870|PROCEDURE|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
58436377|NCT00555672|DRUG|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
58436378|NCT05056506|PROCEDURE|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
58436379|NCT05056506|PROCEDURE|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
58436380|NCT05325333|BEHAVIORAL|Retrieval-based word learning|"Learning sessions: Novel nouns and their meanings are practiced on Day 1. In both conditions, retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and its meaning twice. One week after Day 1, this recall test is completed again. At this time, the child will complete a recognition test: viewing sets of 4 pictures, the child will hear each novel noun and point to its referent in the array."
58436381|NCT06583616|DIAGNOSTIC_TEST|Anion Gap|Patient with acute pulmonary embolism who not survive after hospitalization
58436382|NCT00975949|OTHER|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
58436383|NCT00209703|DRUG|Oxaliplatin|
58436384|NCT00209703|DRUG|l-Leucovorin|
58436385|NCT00209703|DRUG|5-Fluorouracil|
58436386|NCT00032357|PROCEDURE|Ferritin reduction to 25 ng/ml by phlebotomy|
58436387|NCT02197650|DRUG|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
58436388|NCT03217994|DRUG|gel HP|gel of hygrogen peroxide for teeth bleaching
58436389|NCT06330259|DIAGNOSTIC_TEST|menstrual cycle monitoring|frequent serum sampling and 3D ultrasound
58436390|NCT04627207|DRUG|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
58436391|NCT04627207|DRUG|CKD-333 1 Tab|Other names: Test
58436392|NCT04278976|OTHER|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
58436393|NCT03160820|BIOLOGICAL|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
58436394|NCT02623621|DRUG|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
58436395|NCT00002847|BIOLOGICAL|aldesleukin|
58436396|NCT00002847|BIOLOGICAL|recombinant interferon alfa|
58436397|NCT00002847|PROCEDURE|conventional surgery|
58105466|NCT00606801|DRUG|Galantamine|Galantamine 8 mg/day
58436398|NCT01802125|OTHER|laboratory biomarker analysis|Correlative studies
58436399|NCT05795985|DIAGNOSTIC_TEST|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
57738207|NCT00270218|BIOLOGICAL|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
58105467|NCT00606801|DRUG|placebo|sugar pill
58105468|NCT01037101|BEHAVIORAL|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
58105469|NCT01037101|BEHAVIORAL|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
58105470|NCT01037101|DRUG|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
58105471|NCT01037101|DRUG|Placebo|50 mg placebo administered 30 minutes before the session
58105472|NCT03598452|DRUG|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
58105473|NCT02593734|DRUG|olanzapine|oral antipsychotic drug therapy
58436400|NCT00892775|BIOLOGICAL|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
58436401|NCT00892775|BIOLOGICAL|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
58436402|NCT03190278|BIOLOGICAL|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
58436403|NCT00988091|DEVICE|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
58436404|NCT00988091|DEVICE|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
58436405|NCT00373178|DRUG|rosiglitazone|
58436406|NCT00373178|DRUG|metformin|
58436407|NCT00373178|DRUG|Anti-diabetic medications|
58436408|NCT03546114|OTHER|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
58436409|NCT00118742|DRUG|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
58436410|NCT00118742|DRUG|Tacrolimus|As prescribed, for 12 months
58436411|NCT00118742|DRUG|Cyclosporine|As prescribed, for 12 months
58436412|NCT00118742|DRUG|Sirolimus|2-4 mg orally once daily for 9-11 months
58436413|NCT00006773|DRUG|bortezomib|Given IV
58436414|NCT03625336|DIAGNOSTIC_TEST|MRI|An MRI will be obtained utilizing 3 different MRI sequences
57738208|NCT00270218|BIOLOGICAL|PBS|phosphate buffered saline
57738209|NCT02611466|DRUG|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
57738210|NCT02611466|DRUG|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
57738211|NCT02611466|DRUG|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
57738212|NCT04385953|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
58105474|NCT02593734|DRUG|risperidone|oral antipsychotic drug therapy
58436415|NCT06455865|OTHER|TPACK-Based Blended Learning Instruction|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
58436416|NCT04227132|DEVICE|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
58436417|NCT04227132|DEVICE|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
58436418|NCT03268941|DRUG|TAK-906 Maleate|TAK-906 Maleate Capsules
57738213|NCT02459873|BEHAVIORAL|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
57738214|NCT06669936|DRUG|Fecal microbiota transplantation ± bezlotoxumab|Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
57738215|NCT05889143|DRUG|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
58436419|NCT03268941|DRUG|Metaclopramide|Metaclopramide Tablets
58436420|NCT03268941|DRUG|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
58436421|NCT00916019|OTHER|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
58105475|NCT02593734|DRUG|amitryptaline|oral antidepressant drug therapy
58436422|NCT04688229|DEVICE|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
58436423|NCT04688229|OTHER|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
58436424|NCT03406117|DRUG|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
58436425|NCT03406117|OTHER|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
58105476|NCT02593734|DRUG|fluoxetine|oral drug therapy for depression
58105477|NCT06327477|PROCEDURE|Biopsy|Undergo biopsy
58105478|NCT06327477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58105479|NCT06327477|PROCEDURE|Computed Tomography|Undergo CT
58105480|NCT06327477|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
57738216|NCT00639873|DRUG|Artesunate|2 or 4 mg/kg/day for 7 days
57738217|NCT00639873|DRUG|quinine-doxycycline|quinine-doxycycline for 7 days
57738218|NCT04182490|BIOLOGICAL|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
58105481|NCT06327477|PROCEDURE|Resection|Undergo surgical resection
58105482|NCT06327477|RADIATION|Spatially-fractionated Radiation Therapy|Undergo P-SFRT
58105483|NCT03089099|OTHER|Blood drawing|Blood drawing
58105484|NCT04682431|DRUG|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
58105485|NCT04682431|DRUG|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
58105486|NCT04682431|DRUG|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
58105487|NCT04682431|DRUG|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
58436426|NCT03825211|PROCEDURE|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
58436427|NCT03825211|PROCEDURE|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
58436428|NCT00321867|PROCEDURE|Graft augmented posterior repair|Posterior repair with graft
58436429|NCT00321867|PROCEDURE|Control|Native tissue repair
58436430|NCT01802710|BEHAVIORAL|Psychological support|
58105488|NCT04682431|DRUG|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
58436431|NCT01802710|OTHER|No intervention|
58105489|NCT04682431|DRUG|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
58105490|NCT04682431|DRUG|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
58105491|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
58105492|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
58105493|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
58105494|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
58105495|NCT04682431|DRUG|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
58105496|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58105497|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58105498|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58105499|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58310264|NCT03248297|DRUG|Azithromycin and amoxicillin|azithromycin and amoxicillin
58310265|NCT03248297|DRUG|Placebo|Placebo tablet
58105500|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58436432|NCT04519281|DRUG|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
58436433|NCT05271760|PROCEDURE|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
58436434|NCT05271760|PROCEDURE|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
58436435|NCT05271760|PROCEDURE|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
58436436|NCT06082856|DRUG|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
58436437|NCT06082856|DRUG|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
58436438|NCT01195480|GENETIC|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10\^8/m2
58436439|NCT01195480|BIOLOGICAL|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
58436440|NCT04010877|BIOLOGICAL|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
58436441|NCT01462617|DRUG|GSK2269557|Study Drug
58436442|NCT01462617|DRUG|GSK2269557 matching placebo|Study Drug
57738219|NCT04182490|DRUG|Placebo|Identical appearing placebo
57954779|NCT05711290|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
57954780|NCT05711290|OTHER|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
57954781|NCT02056483|OTHER|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
57954782|NCT04766307|DRUG|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
57954783|NCT00143455|DRUG|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
58105501|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
58436443|NCT01291407|DRUG|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
58436444|NCT01291407|DRUG|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
58436445|NCT01291407|DRUG|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
58436446|NCT01291407|DRUG|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
58436447|NCT01291407|DRUG|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
58436448|NCT01291407|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
58436449|NCT03536234|DRUG|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
57738220|NCT01747772|DEVICE|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
57738221|NCT04501861|DRUG|Norepinephrine|Hemodynamic effect of norepinephrine on the pulmonary circulation in cardiac surgery patients
57738222|NCT04501861|DRUG|Vasopressin|Hemodynamic effect of vasopressin on the pulmonary circulation in cardiac surgery patients
57738223|NCT06670339|OTHER|No Cooling|Participants will not be pre-cooled prior to completing a 60-minute moderate-intensity exercise bout in the heat.
58105502|NCT00595387|OTHER|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
58436450|NCT04146935|DRUG|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
58436451|NCT06094790|DRUG|CORT125134 150 mg|CORT125134 150 mg (3 X 50 mg current capsule formulation)
58105503|NCT00595387|OTHER|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
58105504|NCT04725565|BEHAVIORAL|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
58105505|NCT04725565|BEHAVIORAL|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
58105506|NCT00046371|DRUG|THERATOPE® vaccine|
58105507|NCT03521544|OTHER|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
58105508|NCT00783978|OTHER|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
57954784|NCT00143455|DRUG|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
58105509|NCT02701816|DEVICE|innova stent (Boston scientific)|
58105510|NCT04336488|DRUG|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
58105511|NCT04336488|DRUG|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
58105512|NCT01861119|DRUG|Silicone gel Kelo-cort™;|
58105513|NCT01861119|DRUG|Onion extract gel Contractubex™|
58105514|NCT01411670|DRUG|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
58105515|NCT01411670|DRUG|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
58105516|NCT01411670|DRUG|Placebo comparator|Standard treatment
58436452|NCT06094790|DRUG|CORT125134 250 mg|CORT125134 250 mg (5 X 50 mg current capsule formulation)
58105517|NCT05785078|BEHAVIORAL|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
57954785|NCT00075504|DRUG|triapine|Given IV
58105518|NCT00390988|PROCEDURE|blood sampling|
58105519|NCT01311310|OTHER|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
58105520|NCT03110393|DEVICE|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
58105521|NCT03110393|DEVICE|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
58105522|NCT06204432|DRUG|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
58105523|NCT06204432|DRUG|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
58105524|NCT06204432|OTHER|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
58105525|NCT04817098|BEHAVIORAL|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
58105526|NCT04242381|OTHER|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
57954786|NCT00075504|DRUG|gemcitabine|Given IV
58105527|NCT04242381|OTHER|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
58310266|NCT00653874|DEVICE|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
58310267|NCT00653874|PROCEDURE|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
57954787|NCT05912842|BEHAVIORAL|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
58310268|NCT00653874|OTHER|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
58436453|NCT06094790|DRUG|CORT125134 dose to be determined|CORT125134 current capsule formulation, dose to be determined
58436454|NCT03536507|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
58436455|NCT03536507|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
58436456|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
58436457|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
58436458|NCT03207633|PROCEDURE|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
58105528|NCT04242381|OTHER|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
58105529|NCT04242381|OTHER|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
58105530|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
58105531|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
58436459|NCT03265457|OTHER|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
58436460|NCT03689816|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
58105532|NCT02868905|PROCEDURE|Blood sample|
58105533|NCT01593150|DRUG|Pradaxa|Pradaxa for 3 weeks prior to DC
58105534|NCT01593150|PROCEDURE|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
58436461|NCT03689816|PROCEDURE|gastric bypass|gastric bypass
58436462|NCT02328534|BEHAVIORAL|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
58436463|NCT02328534|PROCEDURE|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
58105535|NCT01593150|OTHER|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
58105536|NCT06250400|BIOLOGICAL|human histaglobulin|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
58105537|NCT06250400|BIOLOGICAL|placebo|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
58105538|NCT06250400|DRUG|Loratadine 10 Mg|orally, 10mg once a day for 4 weeks
58436464|NCT02328534|PROCEDURE|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
58436465|NCT00465647|DRUG|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
58436466|NCT02258646|BEHAVIORAL|Exercise training at home|
58436467|NCT02258646|BEHAVIORAL|Telemonitoring and education/self-management|
58105539|NCT01071109|PROCEDURE|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
58105540|NCT01701778|DRUG|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
58105541|NCT01701778|DRUG|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
58436468|NCT06066398|PROCEDURE|medical thoracoscope|Medical thoracoscopy will be performed during which pleural brush will be used first followed by forceps biopsy to obtain pleural specimens from suspect areas under visual control and pleural lavage will be performed by injecting 300 mL of normal saline
58436469|NCT06066398|DIAGNOSTIC_TEST|Forceps biopsy and pleural brush histopathology|Forceps biopsy and pleural brush will be obtained for histopathological examination for diagnosis
58436470|NCT06066398|DIAGNOSTIC_TEST|pleural lavage cytology|pleural lavage will be obtained for cytological examination for diagnosis
58436471|NCT04619498|DEVICE|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
58436472|NCT04619498|OTHER|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
57954788|NCT05912842|BEHAVIORAL|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
58105542|NCT01701778|DRUG|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
58105543|NCT01701778|DRUG|sevoflurane|Induction and maintain anaesthesia
58105544|NCT01726478|DRUG|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
58105545|NCT01726478|DRUG|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
58105546|NCT03780569|DEVICE|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
58105547|NCT03780569|RADIATION|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
58436473|NCT03405649|BEHAVIORAL|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
58105548|NCT03780569|DRUG|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m\^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m\^2 in the absence of toxicity."
57738224|NCT06670339|OTHER|Pre-Cooling|Participants will be immersed in cold (\~17°C) water to elicit a decrease in rectal temperature by 0.5°C from baseline values prior to completing a 60-min moderate-intensity exercise bout in the heat.
57738225|NCT02119416|DRUG|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
58105549|NCT06394531|DIETARY_SUPPLEMENT|Jaboticaba Peel Extract|Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
57738226|NCT02119416|DRUG|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
57738227|NCT02119416|DRUG|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
57738228|NCT03037710|DEVICE|HealthPatch|A multi-sensor device to collect continuous vital signs
57738229|NCT03244527|DIETARY_SUPPLEMENT|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
57954789|NCT01471457|DRUG|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
57738230|NCT03244527|OTHER|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
57738231|NCT06042348|DIAGNOSTIC_TEST|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
57738232|NCT06090266|DRUG|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
57738233|NCT06090266|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
57738234|NCT06215274|OTHER|Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.|The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
57738235|NCT01300546|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
57954790|NCT05875675|DRUG|Drug: Pioglitazone Oral Tablet|Dietary Supplement: Pioglitazone 30 mg by mouth daily
57954791|NCT05875675|DIETARY_SUPPLEMENT|Placebo|Dietary: Supplement: Placebo
57954792|NCT02965807|DEVICE|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
57954793|NCT00890565|DRUG|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
57954794|NCT05464225|DEVICE|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
57954795|NCT05464225|DEVICE|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
57954796|NCT03976960|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
57954797|NCT01968135|DRUG|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
57954798|NCT01968135|DRUG|Placebo Sugar Pill|Placebo Sugar Pill
57954799|NCT04003233|DEVICE|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
57954800|NCT04003233|DEVICE|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
57954801|NCT03692728|OTHER|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
57954802|NCT04052659|DRUG|Sintilimab|200 mg IV, every 3 weeks, d1
57954803|NCT04052659|DRUG|Chidamide|30 mg PO, 2 times every week, d1 and d4
57954804|NCT04052659|DRUG|Azacidine|100 mg SC, every 3 weeks, d1 to d7
58436474|NCT03405649|BEHAVIORAL|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
58105550|NCT06394531|OTHER|Placebo|Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
58105551|NCT03508362|DEVICE|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
58105552|NCT04386668|OTHER|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
58105553|NCT04386668|OTHER|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
58105554|NCT04608084|BIOLOGICAL|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
58436475|NCT03666689|PROCEDURE|surgical technique|surgical reconstruction
58436476|NCT01045694|DRUG|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
58436477|NCT01045694|DRUG|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
58436478|NCT01045694|DRUG|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
58436479|NCT01775605|DRUG|Synera|Synera Pain Patch
58436480|NCT02321345|OTHER|Palliative Care Support|Palliative care meetings Quality of Life Assessments
58436481|NCT00147121|DRUG|Rituximab + Standard CHOP|Rituximab + Standard CHOP
58436482|NCT00147121|DRUG|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
58436483|NCT02909374|OTHER|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
57738236|NCT01300546|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
57738237|NCT05069350|DRUG|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
57954805|NCT04034160|OTHER|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
57954806|NCT04034160|OTHER|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
57954807|NCT05315921|DRUG|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954808|NCT05315921|DRUG|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954809|NCT05315921|DRUG|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954810|NCT05315921|DRUG|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954811|NCT05315921|DRUG|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954812|NCT05315921|DRUG|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
57954813|NCT01891487|DRUG|Track A|Bimatoprost 0.03% solution applied to eyebrow
58105555|NCT04032275|OTHER|Chronic hepatitis B infection|Chronic hepatitis B infection patients
58105556|NCT05747833|OTHER|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
58436484|NCT05275101|BEHAVIORAL|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
58436485|NCT05275101|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
58436486|NCT02671097|DRUG|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
58436487|NCT02671097|DRUG|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
58436488|NCT04374006|DRUG|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
58436489|NCT04374006|DRUG|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
58105557|NCT03398928|OTHER|Acupuncture|Acupuncture added to usual care
58105558|NCT02079428|OTHER|No interventions|
58105559|NCT02499185|DEVICE|Nephro Check Test|Urine sample
58105560|NCT02499185|OTHER|serum creatinine measurement|Blood sample
58105561|NCT04965649|GENETIC|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
58105562|NCT00903591|OTHER|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
58105563|NCT02751632|BEHAVIORAL|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
58105564|NCT02751632|BEHAVIORAL|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
58105565|NCT02751632|DRUG|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
58105566|NCT02751632|DRUG|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
58105567|NCT02751632|BEHAVIORAL|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
58105568|NCT02440932|DIETARY_SUPPLEMENT|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
58105569|NCT02440932|OTHER|Normal (control) diet|Breakfast, lunch and open buffet dinner
58105570|NCT01476345|DRUG|LY2963016|Administered subcutaneously
58105571|NCT01476345|DRUG|Lantus|Administered subcutaneously
58105572|NCT01872468|BEHAVIORAL|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
58105573|NCT05872074|DIAGNOSTIC_TEST|Coronary angiography plus percutenous coronary intervention|"1. wire both branches, MV and SB, with two coronary guide wires.~2. Main branch pre-dilation~3. Side branch pre-dilation using (ordinary balloon in group A and Drug coated balloon in group B for the side branch)~4. Main vessel stenting~5. Proximal optimization technique (POT) of the main vessel stent"
58105574|NCT05706428|DEVICE|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
58105575|NCT05706428|DEVICE|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
58436490|NCT04374006|OTHER|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
58436491|NCT02486393|PROCEDURE|Parotid surgery|Surgery of the parotid gland tumours
57738238|NCT06635369|DIAGNOSTIC_TEST|Periodontal Indices|Saliva, serum and periodontal indexes were obtained from patients
57738239|NCT04393441|DRUG|011516X (New Artificial Tear Formulation)|Topical eye drops
57738240|NCT04393441|DRUG|Systane Ultra Multidose|Topical eye drops
58105576|NCT02841605|PROCEDURE|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
58105577|NCT02841605|PROCEDURE|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
58105578|NCT04643782|DEVICE|ANNE Sleep|ANNE sleep system
58105579|NCT03667625|OTHER|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
58105580|NCT03667625|OTHER|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
58105581|NCT03242382|DRUG|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
58105582|NCT01433133|BIOLOGICAL|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
58105583|NCT04597554|DIETARY_SUPPLEMENT|Cranberry|Cranberry beverage and gummies supplement
58105584|NCT04597554|DIETARY_SUPPLEMENT|Placebo|Placebo beverages and gummies supplement
58105585|NCT00410592|DRUG|Esomeprazole 40mg|
58105586|NCT00410592|DRUG|Pantoprazole 40mg|
58105587|NCT00410592|DRUG|Lansoprazole 30mg|
58105588|NCT00961051|DEVICE|Investigational MPS|Multi-purpose solution
58105589|NCT00961051|DEVICE|Opti-Free|Multi-purpose solution
58436492|NCT02504580|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
58105590|NCT01407575|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
58105591|NCT01407575|DRUG|Placebo|matched placebo
57738241|NCT04393441|DRUG|REFRESH PLUS®|Topical eye drops
57954814|NCT01891487|DRUG|Track B|Refresh Tears applied to eyebrows
58105592|NCT05926336|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
58105593|NCT05926336|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
58105594|NCT04300777|DEVICE|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
58105595|NCT02823873|DEVICE|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
58105596|NCT01760694|OTHER|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
58105597|NCT02597283|DEVICE|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
58105598|NCT02597283|DEVICE|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
58436493|NCT02504580|DRUG|Placebo|Saline placebo by injection.
58105599|NCT01134588|OTHER|Paper questionnaire|
58436494|NCT02504580|DRUG|HTX-002|HTX-002, by injection or instillation (pooled).
58105600|NCT01134588|OTHER|Touch screen questionnaire|
58105601|NCT06542510|BEHAVIORAL|working night shift|working night shift
58105602|NCT06083896|PROCEDURE|Photodynamic nails|stab incision is made at the entry site
58105603|NCT05897762|BEHAVIORAL|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
58105604|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
58105605|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
58105606|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
57738242|NCT04139070|DRUG|Bleomycin|Electroporation in combination with systemically administered bleomycin
57954815|NCT01634555|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
57954816|NCT01634555|DRUG|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
57954817|NCT01634555|DRUG|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
57954818|NCT01634555|DRUG|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
58105607|NCT01767545|DRUG|Dexamethasone implant|
58105608|NCT01767545|DRUG|Bevacizumab|
58105609|NCT03091894|DRUG|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
58105610|NCT03091894|DRUG|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
58105611|NCT05504616|OTHER|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
58105612|NCT02465307|BEHAVIORAL|Confusion Assessment Method|Confusion Assessment Method (CAM) score
58105613|NCT02465307|DEVICE|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
58105614|NCT02465307|DEVICE|Commercially available camera|As part of facial recognition video system
57738243|NCT02088268|OTHER|wound healing|wound healing
57738244|NCT02423187|OTHER|No Intervention|
57738245|NCT02014714|DRUG|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
58105615|NCT02465307|DEVICE|Internet Pod (iPod)|Monitors noise levels in the room
58105616|NCT02465307|DIAGNOSTIC_TEST|Cortisol Swab|Cortisol level collected through self administered salivary swab
58105617|NCT04832165|OTHER|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
58105618|NCT04916860|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
58105619|NCT00204932|DRUG|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
58105620|NCT02948478|OTHER|Exposed|Precarious patients
58105621|NCT02948478|OTHER|Non exposed|Non precarious patients
58105622|NCT06379022|BEHAVIORAL|Plaque control|Subjects are motivated for optimal oral hygiene
58436495|NCT02504580|DRUG|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
58436496|NCT02504580|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
58436497|NCT02504580|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
58436498|NCT02504580|DRUG|HTX-009|HTX-009 by injection and instillation (combination).
58436499|NCT02421289|DRUG|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
58436500|NCT02421289|DRUG|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
58436501|NCT02421289|OTHER|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
58105623|NCT04498052|OTHER|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~* An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~* Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~Improvements may also be introduced based on user feedback. All major enhancements will be introduced with the support and approval of the appropriate governance group.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
58105624|NCT02969733|DRUG|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
58105625|NCT02969733|DRUG|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
58105626|NCT02969733|DRUG|isotonic saline serum intravenous administration|
58105627|NCT00065065|DRUG|Rosiglitazone|4mg orally twice daily for 12 weeks
58105628|NCT00065065|DRUG|Placebo|pill that looks identical to rosiglitazone
58105629|NCT01838083|DRUG|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
58105630|NCT03630718|BEHAVIORAL|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
58105631|NCT03630718|BEHAVIORAL|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
57954819|NCT03640923|OTHER|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
57954820|NCT04940910|DIETARY_SUPPLEMENT|Black rice bran extract|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
57954821|NCT04940910|DIETARY_SUPPLEMENT|Placebo|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
57954822|NCT03452371|BEHAVIORAL|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
57954823|NCT03452371|BEHAVIORAL|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
57954824|NCT00732303|DRUG|Pemetrexed|Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
57954825|NCT00732303|RADIATION|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
57954826|NCT00963001|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
57954827|NCT00963001|OTHER|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
57954828|NCT03116932|BEHAVIORAL|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
58105632|NCT03579147|DEVICE|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
58105633|NCT00003669|DRUG|arzoxifene hydrochloride|
57954829|NCT02204150|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
57954830|NCT02551159|BIOLOGICAL|MEDI4736|Anti-PD-L1 antibody
57954831|NCT02551159|BIOLOGICAL|Tremelimumab|Anti-CTLA-4 Antibody
57954832|NCT02551159|BIOLOGICAL|MEDI4736+Tremelimumab|
57954833|NCT02551159|BIOLOGICAL|Cetuximab|Monoclonal Antibody
57954834|NCT02551159|DRUG|5-fluorouracil (5FU)|Chemotherapy Agent
57954835|NCT02551159|DRUG|Cisplatin|Chemotherapy agent
57954836|NCT02551159|DRUG|Carboplatin|Chemotherapy Agent
58105634|NCT03319381|BEHAVIORAL|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
57954837|NCT03743870|DRUG|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
57954838|NCT03743870|DRUG|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
57954839|NCT05914909|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
57954840|NCT05914909|OTHER|Placebo|Placebo
57954841|NCT03241914|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
57954842|NCT03241914|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
57954843|NCT00602108|PROCEDURE|adjuvant therapy|
57954844|NCT00602108|PROCEDURE|conventional surgery|
57954845|NCT00602108|RADIATION|hypofractionated radiation therapy|
57954846|NCT00602108|RADIATION|intraoperative radiation therapy|
57954847|NCT04989855|DRUG|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
57954848|NCT03834428|BEHAVIORAL|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
57954849|NCT03834428|BEHAVIORAL|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
57954850|NCT02789904|OTHER|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
57954851|NCT02069899|DRUG|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
57954852|NCT05093738|OTHER|Cognitive Rehabilitation|In the content of the person-centered intervention program, attention, memory, orientation, praxis (motor planning) training; metacognition (metacognition) training; visual perception; There will be cognitive training for executive functions. The intervention will consist of play activities (games, computer-assisted games) for cognitive skills; The games will be applied in a way that suits the child from simple to complex. Visual perception applications (designing blocks, recognizing and sorting the shapes in the picture, matching opposite shapes etc.); attention practices, memory practices, strategy development, space-time orientation, motor planning, games and metacognitive strategies aimed at developing skills such as planning, organization, working memory, impulse control, time management and awareness, abstract thinking, cognitive flexibility will form our intervention program.
57954853|NCT06495086|DEVICE|NIV|The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.
57954854|NCT06495086|DEVICE|HFNC-30|The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
57954855|NCT06495086|DEVICE|HFNC-50|The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
57738246|NCT02014714|DRUG|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
57738247|NCT06192485|OTHER|proactive balance training|20 participants will receive a proactive balance training program
57738248|NCT06192485|OTHER|Reactive balance training|20 participants will receive a Reactive balance training program
57954856|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954857|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
58436502|NCT05900232|DIAGNOSTIC_TEST|Anti _KU antibodies|aim of the work is to determine the relationship between Anti_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
57954858|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954859|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954860|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954861|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954862|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
57954863|NCT00848055|DRUG|AbGn168 subcutaneous injection|single dose subcutaneous injection
57954864|NCT00637884|DRUG|Fexofenadine HCl|
57954865|NCT05946369|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient
57954866|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
57954867|NCT03239821|DRUG|Codeine Phosphate|58.8 mg codeïne phosphate
58436503|NCT05602701|OTHER|Preoperative assessment|Preoperative assessment of physical fitness
57954868|NCT03239821|DRUG|Placebo|Sirupus Simplex
57954869|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
57954870|NCT00832507|DRUG|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
57954871|NCT00832507|DRUG|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
58105635|NCT00667433|DRUG|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
58105636|NCT05789680|PROCEDURE|Surgical treatment of parathyroid carcinoma|Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
58105637|NCT00420290|DRUG|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
58105638|NCT00420290|DRUG|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
58105639|NCT04317729|DEVICE|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
58436504|NCT02506023|DRUG|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
58436505|NCT03765892|OTHER|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
58436506|NCT03765892|OTHER|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
58436507|NCT04317989|OTHER|Practice Facilitation|"1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
58436508|NCT04474015|DEVICE|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
58436509|NCT05766176|DIAGNOSTIC_TEST|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
58436510|NCT05636761|DIAGNOSTIC_TEST|Heart rate variability|Collection and Analysis of Heart Rate Variability
57954872|NCT04243863|DRUG|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
57954873|NCT04243863|DRUG|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
57954874|NCT05398315|BEHAVIORAL|Empathic Statements/Reflections|Presence of Empathic Statements
58105640|NCT04124978|DEVICE|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
58105641|NCT01497574|DRUG|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
57954875|NCT05398315|BEHAVIORAL|Narrator Backstory|Presence of a narrator backstory
57954876|NCT05398315|BEHAVIORAL|Male Narrator|Presence of a male narrator
57954877|NCT05398315|BEHAVIORAL|Female Narrator|Presence of a female narrator
57954878|NCT05398315|BEHAVIORAL|MI Techniques|Presence of MI techniques
57954879|NCT00005071|PROCEDURE|biopsy|
57954880|NCT00005071|PROCEDURE|bronchoscopy|
57954881|NCT00005071|PROCEDURE|computed tomography|
57954882|NCT00005071|PROCEDURE|quality-of-life assessment|
57954883|NCT03286842|DRUG|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
57954884|NCT04193163|DEVICE|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
57954885|NCT00218491|DRUG|N-Acetylcysteine|1200mg N-Acetylcysteine
57954886|NCT00218491|DRUG|N-Acetylcysteine|2400mg N-Acetylcysteine
58105642|NCT01497574|DRUG|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
58105643|NCT04867967|BEHAVIORAL|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
58105644|NCT04867967|BEHAVIORAL|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
58105645|NCT02063698|DRUG|auranofin|Given PO
58105646|NCT02063698|OTHER|placebo|Given PO
58105647|NCT02063698|OTHER|questionnaire administration|Ancillary studies
58105648|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
58105649|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
58436511|NCT05704660|BEHAVIORAL|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
58436512|NCT05704660|BEHAVIORAL|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
58436513|NCT04629690|OTHER|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
58436514|NCT00268541|BEHAVIORAL|Physical activity|
58436515|NCT00680459|DRUG|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
58436516|NCT00680459|DRUG|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
58436517|NCT03870204|DIAGNOSTIC_TEST|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
58436518|NCT03152591|DRUG|LIK066|LIK066 tablets for oral administration
58436519|NCT03152591|DRUG|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
58436520|NCT02412046|PROCEDURE|Muscle biopsy|
58105650|NCT05332080|PROCEDURE|Telerehabilitation via application on cell phone|Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
58436521|NCT01732016|OTHER|Normobaric hypoxia chamber|
58436522|NCT00656435|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
57954887|NCT00218491|DRUG|Matching Placebo|Matching Placebo
58436523|NCT06282913|BEHAVIORAL|Mindfulness Meditation|Mindfulness Meditation application will be implemented online by the researcher in 20-minute group sessions once a week for 8 weeks. Participants will be asked to provide a quiet, ventilated, dimly lit environment for the practice. The researcher will start the application when the participants take their places as they feel comfortable. In the first stage, the researcher will teach physicians and nurses to take deep diaphragmatic breaths through the nose and out through the mouth.
57954888|NCT02287727|OTHER|Laboratory Biomarker Analysis|Correlative studies
57954889|NCT02287727|DRUG|Regorafenib|Given PO
58105651|NCT01284244|DEVICE|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
58105652|NCT01284244|DEVICE|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
58105653|NCT03262233|COMBINATION_PRODUCT|nicotine|
58105654|NCT03262233|OTHER|placebo|
58105655|NCT03603431|DRUG|MRG-110|Single ascending doses of MRG-110
58105656|NCT03603431|DRUG|Placebo|Single doses of placebo
58105657|NCT03603431|DRUG|MRG-110|Multiple ascending doses of MRG-110
58105658|NCT03603431|DRUG|Placebo|Multiple doses of Placebo
58105659|NCT03374137|BIOLOGICAL|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
58105660|NCT01725074|BEHAVIORAL|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening"
58105661|NCT01725074|BEHAVIORAL|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
58105662|NCT03268031|DIAGNOSTIC_TEST|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
58105663|NCT03064633|DRUG|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
58105664|NCT03064633|DRUG|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
58105665|NCT03064633|DRUG|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
58105666|NCT06305637|DRUG|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
58105667|NCT06305637|DRUG|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
58105668|NCT06305637|DRUG|Placebo|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
58105669|NCT04537702|BEHAVIORAL|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
58436524|NCT04740216|BEHAVIORAL|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
58436525|NCT04740216|BEHAVIORAL|exercise therapy|the control group performed 20-minute stretching exercises each time.
58436526|NCT06366425|DIAGNOSTIC_TEST|Blood sample then fibroscan|"The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 2.67 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan."
58436527|NCT04667741|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
58436528|NCT00015808|DRUG|Idebenone|
58436529|NCT01438450|DRUG|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
58436530|NCT01438450|OTHER|Supportive|No specific therapy will be given
58436531|NCT00931775|DRUG|Pindolol|Pill orally administered. 15 mg/day t.i.d.
58436532|NCT04146662|DIAGNOSTIC_TEST|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
58436533|NCT05374551|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
58436534|NCT00718692|DRUG|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
58436535|NCT03073993|PROCEDURE|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
58436536|NCT01857297|BIOLOGICAL|Enzira® vaccine|
58436537|NCT04331002|DRUG|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
57738249|NCT04966468|DEVICE|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
58436538|NCT04331002|OTHER|Placebo|5 mL normal saline
58436539|NCT05310331|COMBINATION_PRODUCT|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
58436540|NCT04520256|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
58436541|NCT04520256|BEHAVIORAL|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
58436542|NCT04520256|BEHAVIORAL|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
58436543|NCT04520256|BEHAVIORAL|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
58436544|NCT04520256|BEHAVIORAL|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
58436545|NCT04520256|BEHAVIORAL|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
57954890|NCT03378076|DRUG|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
57954891|NCT03378076|DRUG|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
57954892|NCT04947670|PROCEDURE|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
57954893|NCT04947670|PROCEDURE|Sham Renal arteriography|Renal arteriography only
58436546|NCT01590693|DRUG|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
58436547|NCT04836845|DEVICE|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
58436548|NCT04836845|DEVICE|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
58436549|NCT04836845|DEVICE|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
58436550|NCT06332105|DIETARY_SUPPLEMENT|Glytactin|Glycomacropeptide based protein substitute for dietary treatment of PKU
58105670|NCT04537702|BEHAVIORAL|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
58105671|NCT05394142|DRUG|Placebo|Comparator arm with placebo
58436551|NCT06332105|DIETARY_SUPPLEMENT|L-AA|Amino acid based protein substitute for dietary treatment of PKU
58105672|NCT05394142|DRUG|Pioglitazone|Pioglitazone 7.5 mg/day
58105673|NCT05394142|DRUG|Spironolactone|Spironolactone 50 mg/day
58105674|NCT05394142|DRUG|Metformin|Metformin 850 mg/day
58436552|NCT05486611|DEVICE|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
58436553|NCT05486611|DEVICE|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
58436554|NCT04325620|DRUG|HIP1601|HIP1601
58436555|NCT04325620|DRUG|HGP1805|Placebo of HIP1601
58436556|NCT01210586|BEHAVIORAL|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
58436557|NCT06370013|DRUG|Tinengotinib|Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
58436558|NCT06527417|DEVICE|Neuro Trac Myo Plus Pro|Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
58436559|NCT06527417|OTHER|Trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
58436560|NCT06015087|OTHER|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
58105675|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
58105676|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
58105677|NCT02836340|DRUG|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
58105678|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
58105679|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
58105680|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
58105681|NCT02692430|OTHER|No intervention is studied|
58105682|NCT03725787|DEVICE|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
58105683|NCT02177747|OTHER|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
58105684|NCT02177747|DEVICE|Smartphone|
58105685|NCT04311138|OTHER|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
58105686|NCT04311138|OTHER|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
58105687|NCT04844996|PROCEDURE|Surgical induction of endometriotic explants|"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"
58105688|NCT05703555|DRUG|Tusamitamab ravtansine|Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
58105689|NCT02868307|BEHAVIORAL|Answering questionnaire|
58105690|NCT03342326|OTHER|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
58436561|NCT01808235|BEHAVIORAL|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
57738250|NCT04966468|OTHER|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
58436562|NCT05529836|DEVICE|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
58436563|NCT05529836|DEVICE|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
58436564|NCT05529836|DEVICE|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
58436565|NCT06183073|PROCEDURE|caudal block|bupivacaine 0.25% in a dose of (1 ml / kg)
58436566|NCT06183073|DRUG|Dexmedetomidine|dexmedetomidine 1μg/ kg.
58436567|NCT06183073|PROCEDURE|TAP|analgesia
58436568|NCT06183073|DRUG|Bupivacain|bupivacaine 0.25% in a dose of (0.5 ml / kg
58436569|NCT05165758|OTHER|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
58436570|NCT01280695|DRUG|Placebo|Placebo Capsules
58436571|NCT01280695|DRUG|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
58436572|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
58436573|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
58436574|NCT01280695|DRUG|Pioglitazone|Pioglitazone 45 mg Capsules
58436575|NCT02768519|DRUG|OTS167IV|diluted to final concentration with cherry syrup
58436576|NCT02768519|OTHER|Cherry syrup|
58436577|NCT03731247|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
58436578|NCT03731247|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
58436579|NCT03941626|BIOLOGICAL|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
57738251|NCT02052505|PROCEDURE|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
58436580|NCT05998577|DEVICE|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
58105691|NCT03342326|OTHER|Music Experience Questionnaire|questions about the past music training
58436581|NCT04924998|DRUG|current treatment of AL-CM|current treatment of AL-CM
58436582|NCT04352023|PROCEDURE|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
57738252|NCT01571505|BIOLOGICAL|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
58105692|NCT03342326|OTHER|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
58105693|NCT03342326|OTHER|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
58436583|NCT03453580|RADIATION|multislice computed tomography portography|imaging modality
58436584|NCT05760768|BEHAVIORAL|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
58436585|NCT01521663|DRUG|IPX159|
58436586|NCT01521663|DRUG|Placebo|
58436587|NCT01792115|DRUG|Vitamin E 200 IU/d|Supplement-low dose
58436588|NCT01792115|DRUG|Vitamin E 400 IU/d|Supplement-intermediate dose
58436589|NCT01792115|DRUG|Vitamin E 800 IU/d|Supplement High Dose
58436590|NCT01792115|BEHAVIORAL|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
58436591|NCT02718092|DEVICE|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
58436592|NCT02718092|DEVICE|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
58436593|NCT01445080|OTHER|Laboratory Biomarker Analysis|Correlative studies
58105694|NCT05066074|PROCEDURE|Distal Radial Vascular Access|Distal Radial Vascular Access
58105695|NCT05966870|OTHER|Unsweetened flavored sparkling water|Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
58105696|NCT01893983|BEHAVIORAL|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
58105697|NCT03456726|DRUG|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
58105698|NCT04009954|OTHER|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
58105699|NCT01424774|DRUG|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
58105700|NCT01362959|DRUG|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
58105701|NCT01362959|OTHER|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
58105702|NCT03126851|OTHER|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
58105703|NCT02934386|DEVICE|WinMedical WinPack device|
58436594|NCT01445080|OTHER|Pharmacological Study|Correlative studies
58436595|NCT01445080|DRUG|Sorafenib Tosylate|Given orally
58436596|NCT03288922|PROCEDURE|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
58436597|NCT03288922|PROCEDURE|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
58436598|NCT02953574|PROCEDURE|daily sleep enhancement nursing protocol|
58436599|NCT03333629|BEHAVIORAL|Enhanced early detection|standardized screening
58436600|NCT06474312|BEHAVIORAL|Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
58436601|NCT05930184|PROCEDURE|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
58436602|NCT05930184|PROCEDURE|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
58436603|NCT01166204|RADIATION|Radiotherapy|Radiotherapy
58105704|NCT03395574|DRUG|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
58105705|NCT03395574|DRUG|Normal saline|drug will be given after 30 minutes as placebo in control group
58105706|NCT02649608|DRUG|0.04 mg Lu AE04621|0.04 mg dose group
58105707|NCT02649608|DRUG|0.08 mg Lu AE04621|0.08mg dose group
58105708|NCT02649608|DRUG|0.2 mg Lu AE04621|0.2 mg dose group
58105709|NCT02649608|DRUG|0.4 mg Lu AE04621|0.4 mg dose group
58105710|NCT02649608|DRUG|0.6 mg Lu AE04621|0.6 mg dose group
58105711|NCT02649608|DRUG|0.8 mg Lu AE04621|0.8 mg dose group
58105712|NCT02649608|DRUG|1.0 mg Lu AE04621|1.0 mg dose group
58105713|NCT02649608|DRUG|1.2 mg Lu AE04621|1.2 mg dose group
58105714|NCT06119646|OTHER|Warm Pads Applied to the Breast|Applying a warm pad to a breast during episiotomy repair
58105715|NCT02139605|PROCEDURE|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
58105716|NCT04337190|BIOLOGICAL|blood sampling|blood sampling at the day of admission, day 3 and day 7
58105717|NCT03644602|DIETARY_SUPPLEMENT|low FODMAPs diet|Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
58105718|NCT00821041|BEHAVIORAL|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
58105719|NCT01368679|PROCEDURE|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
58105720|NCT03233737|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
58105721|NCT03233737|DEVICE|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
58105722|NCT03233737|DEVICE|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
58105723|NCT02082262|DRUG|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
58436604|NCT00231413|BIOLOGICAL|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
57738253|NCT06137261|DIAGNOSTIC_TEST|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
57738254|NCT00657618|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
57738255|NCT04232423|DRUG|Olanzapine 10 Mg ORAL TABLET|"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
57738256|NCT04232423|DRUG|Olanzapine 5 Mg ORAL TABLET|"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
57738257|NCT04232423|DRUG|Placebo ORAL TABLET|"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
57954894|NCT01617278|DEVICE|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
58105724|NCT01416142|DEVICE|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
58105725|NCT01416142|DEVICE|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
58105726|NCT02501031|DIETARY_SUPPLEMENT|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
58310269|NCT04020562|OTHER|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
58436605|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436606|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436607|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436608|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436609|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436610|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
58436611|NCT02436538|OTHER|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
58436612|NCT05716360|DIAGNOSTIC_TEST|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
58436613|NCT05716360|PROCEDURE|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
58105727|NCT05482087|DRUG|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
58105728|NCT01562431|OTHER|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
58105729|NCT00944437|DEVICE|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
58436614|NCT05716360|PROCEDURE|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
58436615|NCT03180125|DRUG|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
58436616|NCT03180125|DEVICE|ultrasound|ultrasound guided injection
58436617|NCT03180125|DRUG|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
58436618|NCT03180125|DRUG|Corticosteroid and 1%lidocain|injection in the carpal tunnel
58436619|NCT01477489|DRUG|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
58436620|NCT01477489|RADIATION|Standard radiation treatment|Limited to 60 Gy.
58436621|NCT01022099|PROCEDURE|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
58436622|NCT05177367|OTHER|Sequential Variety|3 courses each consisting of a different food
58436623|NCT05177367|OTHER|Simultaneous Variety|3 courses each consisting of 3 foods
58436624|NCT05177367|OTHER|Single Food|3 courses each consisting of the same food
58105730|NCT00944437|DEVICE|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
58105731|NCT02828748|OTHER|no intervention in patients treatment, only biopsy taken|
58105732|NCT04856579|PROCEDURE|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
58105733|NCT04238468|PROCEDURE|Intradermal stromal vascular fraction injection|After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
58105734|NCT01580020|BIOLOGICAL|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
58105735|NCT01580020|DRUG|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
58105736|NCT05439759|BEHAVIORAL|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
58105737|NCT05439759|BEHAVIORAL|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
58310270|NCT04020562|OTHER|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
58436625|NCT05177367|OTHER|Small portion|Small meal portion size
58436626|NCT05177367|OTHER|Large Portion|Large meal portion size
58436627|NCT05787925|DRUG|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning"
58436628|NCT05787925|DRUG|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
58436629|NCT05513053|BIOLOGICAL|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
58436630|NCT01755871|DRUG|Fingolimod|0,5mg Fingolimod once a day
58436631|NCT00874848|BIOLOGICAL|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
58436632|NCT00874848|BIOLOGICAL|Cetuximab|initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
58436633|NCT00874848|DRUG|Paclitaxel|200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
58436634|NCT00874848|DRUG|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
58436635|NCT02604563|OTHER|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
58436636|NCT02604563|OTHER|Activities of Daily Living Questionnaire|"* 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
57954895|NCT01617278|DEVICE|HD Colon|High definition white light
57954896|NCT01617278|DEVICE|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
58105738|NCT05439759|BEHAVIORAL|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
58105739|NCT05439759|BEHAVIORAL|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
58105740|NCT03723928|OTHER|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
58105741|NCT03723928|OTHER|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
58105742|NCT03723928|OTHER|Quality-of-Life Assessment|Ancillary studies
58436637|NCT02604563|OTHER|Instrumental Activities of Daily Living, subscale of the OARS|"* 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
58436638|NCT02604563|OTHER|Karnofsky Self-reported Performance Rating Scale|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
58436639|NCT02604563|OTHER|Number of Falls|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
58436640|NCT02604563|OTHER|Physical Health Section, subscale of the OARS|"* 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death"
58436641|NCT02604563|OTHER|MOS Social Activity Survey|"* 4 items about social activity~* Baseline and no more frequently than every 6 months until death"
58436642|NCT02604563|OTHER|Unintentional Weight Loss|"* 2 items about nutrition~* Baseline and no more frequently than every 6 months until death"
58436643|NCT02604563|GENETIC|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
58436644|NCT02604563|GENETIC|Buccal Swab|"* Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death"
58436645|NCT02604563|OTHER|Heart Health and Smoking History from BRFSS questionnaire|"* 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death"
58436646|NCT02604563|OTHER|Gait Speed|"* Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death"
58436647|NCT02604563|OTHER|Grip Strength|"* Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death"
58436648|NCT02604563|OTHER|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
58436649|NCT02604563|OTHER|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
58436650|NCT02604563|PROCEDURE|Optional bone marrow biopsy|-1 optional bone marrow biopsy
58105743|NCT03723928|OTHER|Anxiety Questionnaire Administration|Ancillary studies
58436651|NCT02604563|PROCEDURE|Blood draw for trauma measurements|-For Arm E only
58436652|NCT01001793|DEVICE|Levacor Ventricular Assist Device|Surgical procedure
58436653|NCT01557907|DEVICE|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
58436654|NCT01557907|DEVICE|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
58436655|NCT03406013|BEHAVIORAL|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
58436656|NCT03406013|BEHAVIORAL|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
58436657|NCT03406013|BEHAVIORAL|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
58436658|NCT03406013|BEHAVIORAL|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
58436659|NCT02087969|PROCEDURE|Dry Needling|
58436660|NCT02087969|PROCEDURE|Stretching|
58436661|NCT00950248|DRUG|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
58436662|NCT00950248|OTHER|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
58436663|NCT02700828|DRUG|Hydrocortisone|4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
58436664|NCT02700828|DRUG|Placebo|4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
58436665|NCT00681733|DRUG|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
58436666|NCT00681733|DRUG|Pioglitazone|30 mg OD
58436667|NCT00681733|DRUG|Pentoxifylline|1200 mg/d
58105744|NCT03876158|DEVICE|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
58105745|NCT06133088|DRUG|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
58436668|NCT05289479|PROCEDURE|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
58436669|NCT05289479|PROCEDURE|no pre-heating of resin composite before application|The control group
58436670|NCT02712528|DRUG|remifentanil-based|
58436671|NCT02712528|DRUG|sevoflurane-sufentanil balanced|
58436672|NCT05917054|OTHER|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
58436673|NCT00003883|DRUG|fluconazole|
58436674|NCT00003883|DRUG|itraconazole|
58436675|NCT02235896|BEHAVIORAL|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
58436676|NCT04844853|DEVICE|electroencephalography|128-channel electroencephalography
58436677|NCT04844853|DEVICE|Tactile stimulation|Vibrotactile sequence on the forearm
58436678|NCT04844853|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
58105746|NCT02955992|BEHAVIORAL|Improving communication during the end-of-life process|
58105747|NCT01776619|DRUG|PF-06305591|14 day repeated 20mg BID doses
58105748|NCT01776619|DRUG|Placebo|14 day repeated BID doses
58105749|NCT01776619|DRUG|PF-06305591|14 day repeated 80mg BID doses
58436679|NCT04844853|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
58436680|NCT04844853|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
58436681|NCT04844853|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
57954897|NCT00505999|BEHAVIORAL|Questionnaire|Questionnaire taking 30-40 minutes to complete.
57954898|NCT06208592|DEVICE|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
57954899|NCT03301493|OTHER|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
58105750|NCT01776619|DRUG|Placebo|14 day repeated BID doses
58105751|NCT01776619|DRUG|PF-06305591|14 day repeated 40mg BID doses
58105752|NCT01776619|DRUG|Placebo|14 day repeated BID doses
58105753|NCT01776619|DRUG|PF-06305591|14 day repeated BID doses
58105754|NCT01776619|DRUG|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
58436682|NCT04844853|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
58436683|NCT02485704|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
58436684|NCT02485704|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
58436685|NCT06443983|OTHER|AI-supported case|In the artificial intelligence-supported case lesson, students will listen to audio and visual content prepared by artificial intelligence.
58436686|NCT00556816|BEHAVIORAL|on demand clinic|Outpatient on demand clinic
58436687|NCT00556816|BEHAVIORAL|Control|conventional outpatient clinic
58436688|NCT02274740|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
58436689|NCT02274740|DRUG|metformin|Pharmaceutical form:tablet Route of administration: oral
58436690|NCT03799939|DEVICE|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
58436691|NCT04896281|DIETARY_SUPPLEMENT|Phenylalanine-free milk|Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
58436692|NCT04771702|DEVICE|Edmon|Exhaled air will be analyzed for propofol
58436693|NCT01178203|DRUG|Placebo|Placebo
58436694|NCT01178203|DRUG|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
58436695|NCT01178203|DRUG|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
58436696|NCT01178203|DRUG|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
58436697|NCT03813914|DIETARY_SUPPLEMENT|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
58105755|NCT05668715|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
58105756|NCT03284073|PROCEDURE|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
58105757|NCT03933319|DRUG|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
58105758|NCT02353429|DRUG|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
58105759|NCT00644605|DRUG|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
58105760|NCT00644605|DRUG|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
58105761|NCT00644605|DRUG|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
58105762|NCT00644605|DRUG|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
58105763|NCT03835975|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
57738258|NCT03030300|DRUG|Novolin 30R;Pioglitazone;Metformin|"* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
57738259|NCT05317234|GENETIC|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
57738260|NCT01262651|DRUG|Nabiximols|
57738261|NCT01262651|DRUG|Placebo (GA-0034)|
57738262|NCT01248338|DRUG|metoprolol succinate|once daily 50 or 100 mg for one year
57738263|NCT01248338|DRUG|Nebivolol|once daily 5 mg capsule for one year
57738264|NCT05166408|PROCEDURE|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
58105764|NCT03835975|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
58105765|NCT03835975|BIOLOGICAL|20vPnC|Pneumococcal conjugate vaccine
58105766|NCT01187160|PROCEDURE|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
58105767|NCT05587478|DRUG|EDP-323|Oral administration
58105768|NCT05587478|DRUG|Placebo|Placebo to match EDP-323, oral administration
58105769|NCT01683552|DRUG|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
58105770|NCT01683552|DRUG|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
58105771|NCT01683552|DRUG|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
58105772|NCT00362856|DRUG|larazotide acetate|capsule
58105773|NCT00362856|DRUG|Placebo|capsule
58105774|NCT00184964|PROCEDURE|CT-scan, PET-scan|
58105775|NCT03571854|DEVICE|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
58105776|NCT03571854|DEVICE|Group VCV|Volume controlled ventilation
58105777|NCT03343977|DRUG|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
58105778|NCT03343977|DRUG|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
58436698|NCT00523081|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
57738265|NCT05166408|PROCEDURE|Bardach two flap palatoplasty|Bardach two flap palatoplasty
57738266|NCT05972629|DRUG|SAR444836|Infusion pump, intravenous infusion (IV)
58436699|NCT00523081|BEHAVIORAL|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
58105779|NCT00465504|PROCEDURE|iontophoresis|See Detailed Description.
58436700|NCT03686475|OTHER|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
58436701|NCT03686475|OTHER|MTA pulpotomy|MTA pulpotomy
58436702|NCT02138968|OTHER|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
58436703|NCT02850380|OTHER|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
57738267|NCT01348867|OTHER|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
57954900|NCT01217021|DRUG|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
57954901|NCT03033537|DRUG|Verapamil|Local treatment of erectile dysfunction
57954902|NCT03279380|OTHER|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
58105780|NCT04272736|DIETARY_SUPPLEMENT|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
58105781|NCT06013761|OTHER|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
57738268|NCT05652517|PROCEDURE|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
57738269|NCT05777642|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
57738270|NCT05777642|DIETARY_SUPPLEMENT|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
58436704|NCT01675193|BEHAVIORAL|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
58436705|NCT02450162|PROCEDURE|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
57954903|NCT03279380|OTHER|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
58436706|NCT03565146|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
58436707|NCT01119092|OTHER|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
58436708|NCT01119092|OTHER|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
57738271|NCT03138148|OTHER|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
57738272|NCT04454866|DRUG|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
57738273|NCT04454866|DRUG|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
57738274|NCT04454866|DRUG|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
57738275|NCT01859481|DRUG|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
58105782|NCT01303588|BEHAVIORAL|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
58105783|NCT01303588|BEHAVIORAL|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
58105784|NCT05717283|DIAGNOSTIC_TEST|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
58105785|NCT01566669|DRUG|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
58105786|NCT01566669|DRUG|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
58105787|NCT00486499|PROCEDURE|I-125 versus Pd-103 radioactive seed insertion|
58105788|NCT04716400|BEHAVIORAL|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
58105789|NCT01215682|DIETARY_SUPPLEMENT|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
58105790|NCT01215682|DIETARY_SUPPLEMENT|placebo|sweetened water
58105791|NCT04921046|DRUG|lignocaine|After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
58105792|NCT04921046|DRUG|Midazolam 1 milligram Prefilled Syringe|after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
58105793|NCT04171388|DRUG|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
58105794|NCT04171388|DIETARY_SUPPLEMENT|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) \>=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC \<23 cm
58105795|NCT04171388|DRUG|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
58105796|NCT04171388|OTHER|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
58105797|NCT02991833|OTHER|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
58105798|NCT02991833|OTHER|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
58105799|NCT05617859|DRUG|Lenvatinib mesylate capsule|Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
58105800|NCT03670407|PROCEDURE|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
58105801|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105802|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105803|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105804|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105805|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105806|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
58105807|NCT02407028|DRUG|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
58105808|NCT02407028|OTHER|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
58436709|NCT03893682|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
58436710|NCT03027349|OTHER|No intervention are provided|
58436711|NCT06555328|DRUG|CSU lower dose treatment|CSU lower dose treatment
58436712|NCT06555328|DRUG|CSU high dose treatment|CSU high dose treatment
58105809|NCT01222715|BIOLOGICAL|Bevacizumab|Given IV
58105810|NCT01222715|DRUG|Cyclophosphamide|Given IV
58105811|NCT01222715|OTHER|Laboratory Biomarker Analysis|Correlative studies
58105812|NCT01222715|DRUG|Temsirolimus|Given IV
58105813|NCT01222715|DRUG|Vinorelbine Tartrate|Given IV
58105814|NCT04293640|DIAGNOSTIC_TEST|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
58105815|NCT03461315|OTHER|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
58105816|NCT04449679|OTHER|Patient Monitoring System|Receive RT-CAMSS
58105817|NCT04449679|OTHER|Questionnaire Administration|Complete questionnaires
58436713|NCT06555328|DRUG|CSU non responders IgE - high dose treatment|CSU non responders IgE - high dose treatment
58436714|NCT06555328|DRUG|HS low dose treatment|HS low dose treatment
58436715|NCT06555328|DRUG|HS medium dose treatment|HS medium dose treatment
58436716|NCT06555328|DRUG|HS high dose treatment|HS high dose treatment
58436717|NCT01249547|DRUG|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
58436718|NCT04904874|DEVICE|intense pulsed light|treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
58436719|NCT05465343|DRUG|Furmonertinib|Furmonertinib 160mg orally QD
58436720|NCT05985967|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
58436721|NCT05985967|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
58436722|NCT05985967|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
58436723|NCT05985967|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
58436724|NCT05546229|PROCEDURE|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
58436725|NCT05729243|DRUG|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
58436726|NCT05729243|OTHER|Placebo|A placebo identical in appearance to cytisine will be used
58105818|NCT04449679|OTHER|Consultation|Receive tailored feedback, including consultation with nurse
58105819|NCT06338683|DRUG|Olanzapine 2.5 MG|Oral olanzapine 2.5 mg once daily at bedtime until disease progression
58105820|NCT06338683|DRUG|Standard anti-tumor treatment|Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
58436727|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
58436728|NCT00310817|BIOLOGICAL|MenACWY polysaccharide vaccine|
58436729|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
58436730|NCT05912972|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
58436731|NCT04396158|RADIATION|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
58436732|NCT03781440|PROCEDURE|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
58436733|NCT03781440|PROCEDURE|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
58436734|NCT06208995|OTHER|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html
58436735|NCT03105336|BIOLOGICAL|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
58436736|NCT03105336|DRUG|Cyclophosphamide|Administered intravenously
58105821|NCT06338683|DIETARY_SUPPLEMENT|Nutritional advice|All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition
58105822|NCT00490737|DRUG|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
58310271|NCT03485625|DRUG|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
58436737|NCT03105336|DRUG|Fludarabine|Administered intravenously
58436738|NCT01691040|DRUG|NOX-H94|intravenous injection
58436739|NCT01691040|DRUG|Placebo solution|intravenous injection
58436740|NCT05745519|OTHER|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
58105823|NCT04871178|BEHAVIORAL|Mindfulness-based intervention|"Eight, 2-hour instructor-led MBI group sessions once a week for 8 weeks, combined with formal meditative training at home for 20 minutes per day, 6 days a week.~Course material consists of facts booklet, weekly training manuals, audio recordings on a CD, with the five formal guided meditative exercises (body scan, breathing anchor, breathing space, mindful movements, sitting meditation).~The weekly home-work also included informal training of being present in daily life activities.~The program is provided according to the standard MBI protocol. Compared to MBSR and MBCT durations of formal meditative practices are shorter and no 'all-day in silence' session is included. Because of participants' physical limitations and safety, the 'mindful movements' sequence, is adapted and performed in a sitting position.~Adherence to the MBI was followed by self-reported weekly training in manuals asked to be submitted at group sessions."
58105824|NCT03905499|DEVICE|Robotic assisted therapy with MJS (multi joint system) Tecnobody|The intervention will include 18 30-minutes trainings evenly distributed over a time period of 6 weeks and will be administered by the same two physiotherapists at the Schulthess clinic based on the standardized protocol
58436741|NCT05745519|DEVICE|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
58436742|NCT05220358|DRUG|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
58436743|NCT03308253|DEVICE|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
58436744|NCT03308253|DRUG|Vancomycin|0.5 g Vancomycin per patient
58436745|NCT03308253|DRUG|Tobramycin|120 mg tobramycin per patient
58436746|NCT03308253|OTHER|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
58436747|NCT02420236|BEHAVIORAL|High-intensity resistance training|
58436748|NCT02420236|BEHAVIORAL|General physical activity|
58436749|NCT02420236|BEHAVIORAL|Multidisciplinary rehabilitation program|
58436750|NCT02074839|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
58105825|NCT03905499|OTHER|Usual Care|Patients randomized in the usual care will receive standard of care treatment without receiving any active intervention
58436751|NCT01153724|DRUG|BI 1744|10 mcg solution for oral inhalation
58436752|NCT01153724|DRUG|Fluconazole|400 mg capsule
58436753|NCT02781168|DEVICE|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
58436754|NCT00999440|DRUG|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
58436755|NCT02725541|DRUG|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
58436756|NCT01865643|DEVICE|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
58436757|NCT03549377|BEHAVIORAL|Deception|Participants will be deceived during delayed gratification task.
58436758|NCT04924270|BIOLOGICAL|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
58436759|NCT04924270|OTHER|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
58436760|NCT05999500|BEHAVIORAL|Temple stay experience|Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
58436761|NCT03515356|BEHAVIORAL|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
58436762|NCT03515356|BEHAVIORAL|Physical Activity Education Pamphlet|Physical activity education pamphlet only
58105826|NCT03932747|OTHER|pre- Hydratión skin|Measurement of hydration of the skin.
58105827|NCT03932747|OTHER|post- Hydratión skin|Measurement of hydration of the skin.
58105828|NCT05765045|DIAGNOSTIC_TEST|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
58105829|NCT02777853|DIETARY_SUPPLEMENT|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
58105830|NCT02777853|DIETARY_SUPPLEMENT|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
58105831|NCT05875766|OTHER|Osteopathy|4 sessions of osteopathy after DIDT surgery
58105832|NCT05875766|OTHER|Physiotherapy|Physiotherapy after DIDT surgery (reference treatment)
58105833|NCT01987661|DEVICE|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
58105834|NCT01987661|DEVICE|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
58105835|NCT01127386|DRUG|Lenalidomide|25mg od, dose reduction according to toxicity
58105836|NCT01127386|DRUG|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
58105837|NCT01127386|OTHER|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
58105838|NCT04329650|DRUG|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
58105839|NCT04329650|DRUG|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
58105840|NCT05879900|OTHER|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
58105841|NCT05879900|OTHER|Physical Education classes|Physical Education classes according their previously planned contents.
58436763|NCT05293184|OTHER|Observational study only|
58105842|NCT00267293|DRUG|Acetaminophen|Given for fever control 15mg/kg
58105843|NCT00267293|DRUG|Ibuprofen|Given for fever control 10 mg/kg
58105844|NCT02479932|OTHER|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
58105845|NCT02479932|OTHER|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
58436764|NCT00003364|DRUG|cisplatin|
58436765|NCT00003364|DRUG|cyclophosphamide|
58436766|NCT00003364|DRUG|doxorubicin hydrochloride|
58105846|NCT01276028|PROCEDURE|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
58105847|NCT03768219|BIOLOGICAL|APVO210|APVO210
58105848|NCT03768219|BIOLOGICAL|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
58105849|NCT02598622|DRUG|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
58105850|NCT02598622|DRUG|Placebo|Placebo is taken 2 times a day for days 1 through 21.
58436767|NCT00003364|DRUG|etoposide|
58436768|NCT00003364|DRUG|vincristine sulfate|
58436769|NCT00003364|RADIATION|radiation therapy|
58436770|NCT05933707|BEHAVIORAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
58436771|NCT06167876|RADIATION|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
58310272|NCT03485625|DRUG|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
58436772|NCT06167876|OTHER|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
58436773|NCT04489472|DIETARY_SUPPLEMENT|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
58436774|NCT03964324|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
58105851|NCT06389474|BIOLOGICAL|INM004|Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
58105852|NCT06389474|OTHER|Placebo|Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
58105853|NCT00265083|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
58105854|NCT00265083|BIOLOGICAL|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
58105855|NCT00265083|BIOLOGICAL|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
58105856|NCT00117585|OTHER|Treatment Phase 1|"* Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma"
58105857|NCT00117585|DRUG|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet"
58105858|NCT00117585|OTHER|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
58105859|NCT01726335|DRUG|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
58105860|NCT02383537|OTHER|Diabetes|the trial is observational with no intervention
58105861|NCT05578755|BEHAVIORAL|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
58105862|NCT05578755|BEHAVIORAL|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
58105863|NCT06133699|PROCEDURE|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
58436775|NCT03492034|DEVICE|IUD during CS|IUD insertion during CS
58436776|NCT03492034|DEVICE|IUD after puerperium|IUD after puerperium
58436777|NCT01444846|DRUG|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
58436778|NCT01444846|DRUG|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
58436779|NCT01444846|DRUG|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
58105864|NCT06133699|DIAGNOSTIC_TEST|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
58436780|NCT01444846|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
57738276|NCT01859481|DRUG|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
58105865|NCT04976049|PROCEDURE|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
58105866|NCT03165643|DIAGNOSTIC_TEST|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
58105867|NCT00438685|BEHAVIORAL|Outpatient MST/OPTION-A|
58105868|NCT00438685|BEHAVIORAL|Usual Services|
58105869|NCT04714684|DEVICE|Fitostimoline proctogel|Medical device for topical use for the treatment of fissures
58105870|NCT04714684|DEVICE|Fitostimoline proctogel + muscle relaxant|medical device for topical use for the treatment of fissures
58105871|NCT01864473|OTHER|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
58105872|NCT06087393|DEVICE|CONVIVO|Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
58105873|NCT02902380|DRUG|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
58105874|NCT02902380|DRUG|control group|0.9% saline infusion
58105875|NCT04784845|BIOLOGICAL|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
58105876|NCT01318265|DRUG|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
58105877|NCT00751569|OTHER|blood donation|obtaining cord blood
58105878|NCT04496778|DEVICE|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
58105879|NCT04496778|OTHER|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
58105880|NCT01205529|DRUG|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
58105881|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
58105882|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
58105883|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
58105884|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
58105885|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
58105886|NCT05089240|DEVICE|Ophthalmic lens with extra power|
58105887|NCT04463277|BEHAVIORAL|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
58105888|NCT04463277|BEHAVIORAL|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
58436781|NCT06583902|DRUG|Intravenous iron|Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
57738277|NCT01859481|DRUG|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
57738278|NCT06529107|BEHAVIORAL|intermittent catheterization protocol based on the best evidence|A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
57738279|NCT00234065|DRUG|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
58105889|NCT04463277|BEHAVIORAL|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
58105890|NCT04192617|DRUG|SM03|SM03: 600 mg intravenous (IV)
58105891|NCT04192617|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
58105892|NCT04192617|DRUG|Methotrexate|methotrexate: 7.5-20 mg/week oral
58436782|NCT06583902|OTHER|Retrospective case-control analysis|the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
57738280|NCT00234065|DRUG|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
57738281|NCT02569580|DEVICE|Topically|"use the No More medical device as anti lice treatment"
57954904|NCT03279380|OTHER|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
57954905|NCT00418353|DRUG|Betamethasone(Celestone soluspan) and Dexamethasone|
57954906|NCT06475014|PROCEDURE|Total knee replacement|Mechanical Alignment Using PSI Pre and post-operative CT Scan
57954907|NCT02317666|PROCEDURE|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
57954908|NCT01849302|DIETARY_SUPPLEMENT|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
57954909|NCT02587533|OTHER|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
57954910|NCT02587533|OTHER|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
57954911|NCT02587533|OTHER|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
57954912|NCT02587533|OTHER|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
57954913|NCT04347200|DRUG|Antiplatelet Drug|single or dual antiplatelets, triple antithrombotic theraphy
57954914|NCT05761028|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
57954915|NCT05761028|OTHER|Placebo|Placebo
57954916|NCT06053515|BEHAVIORAL|Rosie the Chatbot|"Participants in the intervention group will be using the chatbot to ask questions related to the mom and baby's health, provide feedback selecting thumbs up or thumbs down on the questions' response, and use the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus). In addition, participants will be taking a pre-test health survey, mid-test health survey, and post-test health survey."
57954917|NCT02419560|DRUG|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
57954918|NCT00919035|DRUG|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
57954919|NCT01125280|PROCEDURE|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
57954920|NCT04642339|BIOLOGICAL|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
57954921|NCT04642339|BIOLOGICAL|Placebo|Placebo
57954922|NCT01866007|DRUG|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
57954923|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
57954924|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
57954925|NCT01866007|DRUG|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
57954926|NCT00366587|DEVICE|Cataract surgery and IOL implantation|
57954927|NCT05243927|OTHER|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
57954928|NCT05243927|OTHER|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
57954929|NCT02227693|DRUG|avatrombopag|E5501 (avatrombopag) 20-mg tablets
57954930|NCT02227693|DRUG|Placebo|Placebo matching 20-mg tablets
57954931|NCT03382795|DRUG|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
57954932|NCT03469765|OTHER|does not apply|biological sample taking: urine, blood
57954933|NCT05207826|DIAGNOSTIC_TEST|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
57954934|NCT00716755|DRUG|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
57954935|NCT03948828|BIOLOGICAL|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
57954936|NCT03948828|DRUG|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
58105893|NCT02230085|OTHER|Administration of the questionnaire and monitoring of CPAP adherence|
58105894|NCT06337630|DRUG|PLX038 + Tuvusertib|"Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor."
58105895|NCT06381427|OTHER|Interdisciplinary decision-making for perioperative care|Interdisciplinary decision-making for perioperative care involving a cardiologist, anesthesiologist, and surgeon in collaboration with the primary care physician. Decisions include determining whether surgery is feasible or if patient optimization is necessary first. Subsequently, targeted postoperative visits by a heart failure nurse and appropriate postoperative care, also after discharge from the hospital, through the primary care physician.
58105896|NCT03816800|DIETARY_SUPPLEMENT|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
58105897|NCT03816800|DIETARY_SUPPLEMENT|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
58105898|NCT02444156|OTHER|Indoor rowing|
58105899|NCT06176859|OTHER|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
58105900|NCT05691673|OTHER|No intervention|Observational during 16 weeks
58105901|NCT02615379|DEVICE|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
58105902|NCT03150030|OTHER|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
58105903|NCT03150030|DEVICE|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
58105904|NCT03150030|DEVICE|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
58105905|NCT01174641|OTHER|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
58105906|NCT01174641|OTHER|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
58105907|NCT02343016|DEVICE|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
58105908|NCT06537518|DRUG|Dexamethasone injection|Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
58105909|NCT06537518|DRUG|Bupivacaine 0.375% Injectable Solution|Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
58105910|NCT06537518|DRUG|Bupivacaine 0.5% Injectable Solution|20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
58310273|NCT03485625|DRUG|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
58310274|NCT02673749|DRUG|RP-G28|Study drug taken orally
58310275|NCT02673749|OTHER|Placebo|Placebo taken orally
58310276|NCT02870491|BEHAVIORAL|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
58310277|NCT02870491|BEHAVIORAL|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
58310278|NCT01220570|DRUG|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
58310279|NCT01220570|DRUG|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
58436783|NCT05716932|PROCEDURE|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
58310280|NCT01220570|DRUG|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
58310281|NCT05981846|BIOLOGICAL|BIMERVAX|One dose of booster vaccine
58310282|NCT05981846|BIOLOGICAL|SIIV|One dose
58310283|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
58310284|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
58310285|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
58310286|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
58310287|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
58310288|NCT01704365|BIOLOGICAL|Placebo|0.5mL IM Injection
58105911|NCT00989040|DRUG|usual treatment: Versatis|"* To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~* To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
57738282|NCT06129773|PROCEDURE|antibiotic coated vicryl used for fascial closure|in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
58105912|NCT05329415|DIAGNOSTIC_TEST|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
58310289|NCT03342066|DIAGNOSTIC_TEST|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
58310290|NCT04087512|OTHER|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
58310291|NCT04087512|OTHER|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
58310292|NCT04113135|OTHER|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
58310293|NCT04113135|OTHER|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
58310294|NCT04063839|DRUG|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
58436784|NCT04435028|DRUG|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
58436785|NCT01387464|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed QD
58436786|NCT01387464|DRUG|Bromday™|0.09% bromfenac dosed QD
58436787|NCT01389037|BEHAVIORAL|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
58436788|NCT01389037|BEHAVIORAL|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
58436789|NCT01438606|BIOLOGICAL|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
58436790|NCT01438606|BIOLOGICAL|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
57738283|NCT05152433|DEVICE|E-BRAiN therapy|The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
58436791|NCT03392818|OTHER|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
58105913|NCT05003583|BEHAVIORAL|Speaking after viewing pictures with negative and neutral valence|"Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations."
58436792|NCT03392818|OTHER|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
58436793|NCT03392818|DEVICE|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
58105914|NCT04060654|DRUG|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
58105915|NCT02373735|OTHER|crystalloid|Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
58105916|NCT02373735|OTHER|colloid|Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%
58105917|NCT02373735|OTHER|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%
58105918|NCT02373735|OTHER|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
58105919|NCT01540682|DRUG|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
58105920|NCT01540682|DRUG|Cetuximab|\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
58105921|NCT01540682|RADIATION|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.
58105922|NCT00363129|DIETARY_SUPPLEMENT|vitamin E|Given orally
58105923|NCT00363129|OTHER|placebo|Given orally
58105924|NCT02277795|DEVICE|AccuCirc|Circumcision with the use of the AccuCirc device.
58105925|NCT04615676|OTHER|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
58105926|NCT02639819|DRUG|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
58105927|NCT02537067|DRUG|CHONDRON|"1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
58105928|NCT00738010|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
58105929|NCT00738010|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
58105930|NCT00738010|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
58105931|NCT01145703|DIETARY_SUPPLEMENT|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
58105932|NCT01145703|DIETARY_SUPPLEMENT|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
58105933|NCT01145703|OTHER|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
58436794|NCT03559933|DEVICE|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
58105934|NCT01145703|OTHER|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
58105935|NCT02170701|DRUG|BIBR 1048|Ascending doses (in mg) given twice daily
58436795|NCT01679873|OTHER|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
58436796|NCT01590160|DRUG|Ganetespib|IV, Using dose from Phase I
58436797|NCT03345537|OTHER|Non interventional study|Non interventional study - only data collected and one blood sample additional
58105936|NCT00261937|DRUG|Inhaled Furosemide vs Placebo (Normal Saline)|
58436798|NCT01760772|DRUG|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
58436799|NCT01760772|DRUG|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
58436800|NCT01760772|OTHER|saline|Constant infusion
58436801|NCT01839812|DRUG|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
58436802|NCT04578184|DIAGNOSTIC_TEST|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
58436803|NCT04922307|PROCEDURE|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
58436804|NCT04922307|PROCEDURE|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
58436805|NCT02908789|RADIATION|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
58105937|NCT00372827|DRUG|Brinzolamide 1% added to Travoprost 0.004%|
58105938|NCT04168047|PROCEDURE|Barostat procedure|Pressure threshold will be measured during the barostat procedure
58436806|NCT02908789|OTHER|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
58436807|NCT03704909|DRUG|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
58436808|NCT03704909|DRUG|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
58436809|NCT00626171|PROCEDURE|Allergen Challenge|Allergen challenge
58105939|NCT04168047|OTHER|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
58436810|NCT04569981|OTHER|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
58310295|NCT05446103|OTHER|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
58436811|NCT04569981|OTHER|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
58436812|NCT00959205|DEVICE|CARTO 3D|CARTO (3D Electroanatomic imaging)
58436813|NCT00959205|DEVICE|Angiography|Conventional fluoroscopically guided activation mapping
58436814|NCT06359080|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
57738284|NCT05152433|BEHAVIORAL|Conventional therapy|Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
58105940|NCT04168047|OTHER|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
58436815|NCT04681963|OTHER|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
58436816|NCT03577678|PROCEDURE|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
58436817|NCT05099835|DRUG|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
58105941|NCT06536491|DRUG|EC-104 high dose|Intravitreal injection
58105942|NCT06536491|DRUG|EC-104 low dose|Intravitreal injection
58105943|NCT06536491|DRUG|Dexamethasone intravitreal implant|Marketed product intravitreal injection
58105944|NCT00613678|BEHAVIORAL|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
58105945|NCT00613678|BEHAVIORAL|Education|The health education program is based on educational materials from the Arthritis Foundation.
58436818|NCT05099835|DRUG|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
58436819|NCT06348667|OTHER|Specific ankle stability exercises|Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
58436820|NCT06348667|OTHER|Conventional physiotherapy exercises program|Conventional exercise program performed in the center twice a week, of which all participants are part.
58436821|NCT02240355|DRUG|RO6885247|oral solution
58436822|NCT02240355|DRUG|placebo|oral solution
58436823|NCT01918280|PROCEDURE|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
58436824|NCT04701567|DIAGNOSTIC_TEST|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
58436825|NCT02120326|DEVICE|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
58436826|NCT02120326|DEVICE|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
58436827|NCT02596789|DEVICE|"TMS Magpro®, Magventure Inc device"|
58436828|NCT01806909|BIOLOGICAL|Ad4-H5-Vtn|
57738285|NCT04101643|DRUG|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
57738286|NCT03969719|DRUG|Placebo|Placebo
57738287|NCT03969719|DRUG|PF-06835919|150 mg once daily
57738288|NCT03969719|DRUG|PF-06835919|300 mg once daily
57738289|NCT05275894|BEHAVIORAL|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
57738290|NCT05275894|PROCEDURE|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
57738291|NCT05275894|PROCEDURE|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
57954937|NCT00864435|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
57954938|NCT00864435|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
57954939|NCT01739179|PROCEDURE|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
57954940|NCT01739179|PROCEDURE|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
57954941|NCT00092846|DRUG|MK0803, lovastatin|
57954942|NCT00092846|BEHAVIORAL|Self-Management System|
57954943|NCT03499028|OTHER|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
58310296|NCT05446103|OTHER|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
58310297|NCT06551740|DRUG|HUC2-344|per oral
58310298|NCT06551740|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
58310299|NCT05054634|BEHAVIORAL|Psycho-oncological Intervention Based on Counselling (PIBC)|Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
58310300|NCT00720135|BIOLOGICAL|DI-Leu16-IL2 immunocytokine|Given IV
58310301|NCT00720135|BIOLOGICAL|rituximab|Given IV
58310302|NCT00720135|OTHER|flow cytometry|Correlative studies
58310303|NCT00720135|OTHER|immunohistochemistry staining method|Correlative studies
58310304|NCT00720135|OTHER|pharmacological study|Correlative studies
58310305|NCT00720135|OTHER|laboratory biomarker analysis|Correlative studies
58310306|NCT00720135|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58310307|NCT00720135|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
58310308|NCT05445089|DRUG|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
58310309|NCT05445089|OTHER|Control group|Placebo
58310310|NCT00512525|DRUG|Ghrelin and saline (as placebo)|Intravenous infusion
58310311|NCT03006432|DRUG|Oxaliplatin|
58310312|NCT03006432|DRUG|5Fluorouracil bolus|
58310313|NCT03006432|DRUG|5Fluorouracil continu|
58310314|NCT03006432|DRUG|Docetaxel|
58310315|NCT03006432|DRUG|Folinic Acid|
58310316|NCT04412889|BIOLOGICAL|BCMA/CD19 dual-target CAR-T cell immunotherapy|The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
57954944|NCT03232086|OTHER|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
57954945|NCT03232086|OTHER|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
57954946|NCT00369356|DRUG|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
57954947|NCT00369356|DEVICE|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
57954948|NCT00369356|DEVICE|Bare metal coronary stent|Stenting with BMS only
57954949|NCT03174132|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
57954950|NCT03174132|DEVICE|Restylane Perlane|Intradermal injection
57954951|NCT03730155|OTHER|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
57954952|NCT02611986|DEVICE|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
57954953|NCT02611986|DEVICE|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
58310317|NCT04615936|OTHER|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
58310318|NCT00747214|DRUG|CRx-102|
58310319|NCT00747214|DRUG|Placebo|
58310320|NCT00747214|DRUG|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
58310321|NCT02696798|DRUG|Ixekizumab|Administered SC
58310322|NCT02696798|DRUG|Placebo|Administered SC
58310323|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 1）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58310324|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 2）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
57738292|NCT05275894|PROCEDURE|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
57738293|NCT05275894|PROCEDURE|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
57738294|NCT05275894|DRUG|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
57738295|NCT05275894|PROCEDURE|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
58310325|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 3）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58436829|NCT05186168|DEVICE|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
58436830|NCT05186168|DEVICE|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
58436831|NCT02580461|BEHAVIORAL|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
58436832|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (600 IU)|Daily oral dose for 12 months
58436833|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (2000 IU)|Daily oral dose for 12 months
58436834|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (4000 IU)|Daily oral dose for 12 months
58436835|NCT01992263|OTHER|Placebo|Daily oral dose for 12 months
58436836|NCT02069392|BEHAVIORAL|Cognitive remediation training|
58436837|NCT02069392|DRUG|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
58436838|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
58436839|NCT03170960|DRUG|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
58436840|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
58436841|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
58436842|NCT01630291|DEVICE|Electrode device|Lacrimal gland stimulation
58436843|NCT05162313|DEVICE|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
58436844|NCT00509626|BEHAVIORAL|exercise intervention|
57738296|NCT06635525|BIOLOGICAL|Influenza vaccination|Single-dose
57738297|NCT06635525|BIOLOGICAL|SARS-CoV-2 vaccine|Single-dose
58105946|NCT02930109|DRUG|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
58105947|NCT02930109|DRUG|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
58105948|NCT00507182|PROCEDURE|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
58105949|NCT04603937|DRUG|KSI-301|Intravitreal Injection
58436845|NCT00509626|OTHER|questionnaire administration|
58436846|NCT00509626|PROCEDURE|CAM exercise therapy|
58436847|NCT00509626|PROCEDURE|management of therapy complications|
58436848|NCT00509626|PROCEDURE|psychosocial assessment and care|
58436849|NCT00509626|PROCEDURE|quality-of-life assessment|
58436850|NCT01248741|RADIATION|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
58436851|NCT01657292|DRUG|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
57738298|NCT06097312|OTHER|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
58105950|NCT04603937|DRUG|Aflibercept|Intravitreal Injection
58105951|NCT04603937|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
58105952|NCT02467088|OTHER|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
58105953|NCT01430104|DRUG|Teriparatide|Administered subcutaneously during the Treatment Period
58105954|NCT01430104|DRUG|Aspara-CA 600 mg|Administered orally throughout the study
58436852|NCT01657292|DEVICE|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
58436853|NCT00230958|DRUG|Viramidine|
58436854|NCT00230958|DRUG|Ribavirin|
58436855|NCT00230958|DRUG|pegylated interferon alfa-2b|
58436856|NCT01561053|BIOLOGICAL|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
58436857|NCT01561053|BIOLOGICAL|Albumin 20%|Low volume plasma exchange with human albumin 5%
58105955|NCT01430104|DRUG|Alfarol 1.0 µg|Administered orally throughout the study
58105956|NCT00459589|BEHAVIORAL|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
58105957|NCT00459589|BEHAVIORAL|usual nutritional care|usual nutritional care
58105958|NCT03306784|OTHER|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
58436858|NCT01561053|BIOLOGICAL|Immunoglobulin|Intravenous human immunoglobulin 5%
58436859|NCT02431078|PROCEDURE|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
58436860|NCT02487862|BEHAVIORAL|Stress Reduction Protocol|Stress Reduction Protocol
58436861|NCT02865902|DEVICE|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
58436862|NCT04233450|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
58436863|NCT00081055|BIOLOGICAL|autologous expanded mesenchymal stem cells OTI-010|
58436864|NCT00081055|DRUG|busulfan|
58436865|NCT00081055|DRUG|cyclophosphamide|
58436866|NCT00081055|DRUG|cyclosporine|
58436867|NCT00081055|DRUG|methotrexate|
58436868|NCT00081055|PROCEDURE|peripheral blood stem cell transplantation|
58436869|NCT00081055|RADIATION|radiation therapy|
58436870|NCT04407741|DRUG|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
58436871|NCT04407741|DRUG|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
58436872|NCT03226470|BIOLOGICAL|T512|T512 suppository contain 500 µg of T512 and suppocire.
58105959|NCT01693276|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
58436873|NCT05346406|DEVICE|Long Peripheral Catheter|Bard Powerglide 8 cm midline catheter
58105960|NCT01693276|DRUG|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
58105961|NCT01693276|RADIATION|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
58436874|NCT05346406|DEVICE|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
58436875|NCT06435923|DRUG|[14C]-darigabat|Oral capsule
58105962|NCT01488266|DRUG|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
58105963|NCT01488266|DRUG|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
58105964|NCT01990898|DRUG|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
58105965|NCT01039571|PROCEDURE|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
58105966|NCT00125476|BEHAVIORAL|Exercise|
58105967|NCT03575182|OTHER|Gait retraining program|Supervised gait retraining with verbal and real-time visual feedback.
58105968|NCT00293826|DRUG|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
58105969|NCT00293826|DRUG|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
58105970|NCT00293826|DRUG|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
57954954|NCT03334331|OTHER|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
57954955|NCT03334331|OTHER|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
58105971|NCT00293826|DRUG|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
57954956|NCT00102206|DRUG|Abacavir sulfate|
57954957|NCT00102206|DRUG|Emtricitabine|
57954958|NCT00102206|DRUG|Lamivudine|
57954959|NCT00102206|DRUG|Lopinavir/ritonavir|
57954960|NCT00102206|DRUG|Saquinavir|
57954961|NCT00102206|DRUG|Tenofovir disoproxil fumarate|
58105972|NCT02204215|DEVICE|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
58105973|NCT02204215|OTHER|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
58436876|NCT04607811|BEHAVIORAL|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
58436877|NCT00958646|OTHER|Osteopathic Manipulation|Standardized rib raising protocol
58436878|NCT00958646|OTHER|Placebo|Light touch control procedure
58436879|NCT02338700|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
58436880|NCT02338700|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
58436881|NCT03806686|BIOLOGICAL|Placebo|Sterile normal saline
58436882|NCT03806686|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
58436883|NCT05300789|OTHER|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
57738299|NCT04682496|PROCEDURE|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
57954962|NCT00102206|DRUG|Zidovudine|
57954963|NCT00847483|DRUG|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
57954964|NCT00847483|DRUG|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
58310326|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 4）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58436884|NCT05761002|BIOLOGICAL|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
58436885|NCT04456192|BEHAVIORAL|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
58436886|NCT03370224|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
58436887|NCT03370224|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
58436888|NCT06369116|DEVICE|INSTI HCV Self Test|"Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received."
57954965|NCT00847483|DRUG|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
57954966|NCT00037180|DRUG|Celecoxib|
57954967|NCT00037180|DRUG|Irinotecan|
57954968|NCT00037180|DRUG|5-fluorouracil|
57954969|NCT00037180|DRUG|Leucovorin|
57954970|NCT00817531|DRUG|Dasatinib|pill form, 100 mg daily
58436889|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
58436890|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
58436891|NCT01635881|DEVICE|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
58105974|NCT02087228|DEVICE|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
58436892|NCT03872856|DEVICE|BP-ICAN|"One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff"
58436893|NCT06546852|BEHAVIORAL|education|Patient education will be provide
58436894|NCT00437411|BEHAVIORAL|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
58105975|NCT02087228|DEVICE|radiofrequency energy ablation device|
58310327|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 5）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58105976|NCT06526858|DEVICE|HyperQureTM Renal Denervation (RDN) System:|"The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA."
58310328|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 6）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58436895|NCT03828851|OTHER|Domiciliary care - Activities of Daily Living|Home-based ADL training.
58436896|NCT01351961|BIOLOGICAL|blood sampling|take a sample of blood, 46 ml
58436897|NCT01351961|PROCEDURE|brain MRI and TEP cerebral|magnetic resonance imaging
58436898|NCT01351961|OTHER|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
58105977|NCT00184431|BEHAVIORAL|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
58436899|NCT01351961|OTHER|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
58436900|NCT01351961|PROCEDURE|Vascular explorations|Pulse wave velocity, VWF, IMT
58436901|NCT01351961|BIOLOGICAL|Urine sample|
58436902|NCT03007602|OTHER|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
58436903|NCT03144375|OTHER|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
58436904|NCT03144375|PROCEDURE|Standard of Care sinus surgery|
58436905|NCT00303225|DRUG|Vaccine: SIGA-246|
58105978|NCT04629183|OTHER|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
58436906|NCT02384512|DRUG|Azilect®|AZILECT® 1mg Tablets
58436907|NCT02481245|DRUG|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
58436908|NCT05669872|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
58436909|NCT05669872|DRUG|RBC|pack RBC transfusion
58436910|NCT03851198|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
58436911|NCT04410406|DRUG|Ivermectin|Ivermectin (IVM) 200 µg/kg
58436912|NCT04410406|DRUG|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
58105979|NCT02755545|DRUG|Product A|Product A applied topically to the entire face or other affected area of the skin once daily
58105980|NCT02755545|DRUG|Product B|Product B applied topically to affected area of the skin 1 to 3 times daily
58105981|NCT04063384|OTHER|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
58105982|NCT04063384|OTHER|Placebo beverage|placebo beverage conditions.
58105983|NCT05846828|OTHER|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~1. Verbal ability.~2. Abstract/Visual ability.~3. Quantaitive potential.~4. Short-Term Memory Scales"
58310329|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 7）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58310330|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 8）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58310331|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 9）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
58436913|NCT04410406|DRUG|Albendazole|Albendazole (ABZ) 400 mg
58436914|NCT04410406|DRUG|Moxidectin|Moxidectin (Mox) 8 mg
58436915|NCT00625781|DRUG|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
58436916|NCT00635882|DRUG|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
58436917|NCT00635882|DRUG|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
58436918|NCT00635882|DRUG|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
58436919|NCT00635882|DRUG|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
58436920|NCT00635882|DRUG|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
58436921|NCT00635882|DRUG|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
58436922|NCT00077324|GENETIC|proteomic profiling|
58436923|NCT00077324|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
58436924|NCT00077324|PROCEDURE|biopsy|
58436925|NCT00077324|PROCEDURE|surgery|
58436926|NCT03682913|BEHAVIORAL|P-CIT protocol|Personalized inhibitory control training for one week.
58436927|NCT03682913|BEHAVIORAL|Placebo|without personalized inhibitory control training for one week.
58436928|NCT00119366|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
57954971|NCT00000879|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
57954972|NCT00000879|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
58310332|NCT03799861|OTHER|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
58310333|NCT03799861|OTHER|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
58310334|NCT05976945|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
58310335|NCT04155801|DIETARY_SUPPLEMENT|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
58310336|NCT02678117|DRUG|Pregabalin & Placebo|
58310337|NCT02678117|DRUG|Magnesium sulphate & Placebo|
58310338|NCT02678117|DRUG|Pregabalin & Magnesium sulphate|
58310339|NCT02678117|DRUG|Placebo|
58310340|NCT03146390|DRUG|Essential oils|all subjects will perform all interventions of all arms
58310341|NCT03146390|DRUG|Alcohol free essential oils|all subjects will perform all interventions of all arms
58310342|NCT03146390|OTHER|Water|all subjects will perform all interventions of all arms
58310343|NCT06001671|DRUG|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
58310344|NCT04451096|DIETARY_SUPPLEMENT|Probiotics with prebiotic|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
58310345|NCT04451096|DIETARY_SUPPLEMENT|Placebo|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
58310346|NCT03786835|OTHER|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
58310347|NCT05126693|OTHER|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
58310348|NCT04188054|BEHAVIORAL|Change in sleeping position|The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.
58310349|NCT04188054|BEHAVIORAL|No change in sleeping position|No change to your normal sleeping position
58310350|NCT02071498|DEVICE|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
58310351|NCT02071498|OTHER|oral and written information|oral and written information about the most common errors of patients
57954973|NCT00000879|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
57954974|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
57954975|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
58310352|NCT01001741|OTHER|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
58310353|NCT06517992|OTHER|Health education for cadre (communicated project)|The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.
58310354|NCT05786313|PROCEDURE|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
58310355|NCT06208813|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
58436929|NCT00119366|DRUG|fludarabine phosphate|Given IV
58436930|NCT00119366|RADIATION|total-body irradiation|Undergo TBI
58436931|NCT00119366|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
58436932|NCT00119366|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
58436933|NCT00119366|DRUG|cyclosporine|Given IV or PO
58436934|NCT00119366|DRUG|mycophenolate mofetil|Given PO
58436935|NCT00119366|OTHER|laboratory biomarker analysis|Correlative studies
58436936|NCT05519007|OTHER|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
58436937|NCT05519007|OTHER|Saline irrigation|The surgical site will be irrigated with Saline
58436938|NCT03626285|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
58436939|NCT03626285|DEVICE|CliniMACS CD34 Reagent System|CD34 selection ex vivo
58436940|NCT03626285|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
58436941|NCT02792153|DRUG|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
58436942|NCT04453189|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
58436943|NCT04453189|DRUG|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
58436944|NCT04453189|DRUG|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
58436945|NCT03579810|OTHER|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
58436946|NCT03579810|OTHER|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
58436947|NCT06575374|DRUG|Letermovir|Given by mouth or intravenously
58436948|NCT01839149|DRUG|TI-001|TI-001 is intranasal oxytocin
58436949|NCT01839149|DRUG|Placebo|
58436950|NCT02176161|DRUG|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
58436951|NCT04971720|DRUG|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
58436952|NCT04971720|DRUG|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
58436953|NCT04532775|DRUG|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
58436954|NCT04532775|DRUG|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
58105984|NCT04466774|DIAGNOSTIC_TEST|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
58310356|NCT06269835|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
58436955|NCT04532775|DRUG|Bupivacaine Hydrochloride|local anesthetic drug
58436956|NCT04532775|DRUG|saline 0.9%|solution for intravenous and epidural injection
58310357|NCT06269835|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
58310358|NCT06269835|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
58310359|NCT03573297|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily
58310360|NCT03573297|DRUG|Placebo|Matching placebo capsules, oral administration, once daily
58310361|NCT01554124|DRUG|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
58436957|NCT00193180|DRUG|Imatinib|Imatinib
58436958|NCT00193180|DRUG|Docetaxel|Docetaxel
58436959|NCT05419544|BEHAVIORAL|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
58436960|NCT00699660|BEHAVIORAL|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
58436961|NCT00699660|BEHAVIORAL|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
58436962|NCT02109809|RADIATION|total nodal irradiation|Undergo TLI
58436963|NCT02109809|OTHER|laboratory biomarker analysis|Correlative studies
58436964|NCT02109809|OTHER|questionnaire administration|Ancillary studies
58436965|NCT00550381|DRUG|HKI-357|Single-dose capsule
58436966|NCT01128192|DRUG|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
58436967|NCT04020497|BEHAVIORAL|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
58105985|NCT04466774|DEVICE|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
58105986|NCT04154566|OTHER|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
58105987|NCT03108391|DEVICE|Ambu AuraGain|
58436968|NCT04020497|OTHER|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
58436969|NCT02567019|OTHER|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
58436970|NCT04109326|OTHER|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
58436971|NCT05464823|OTHER|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
58436972|NCT06583525|OTHER|Intensive Transition Support|A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
58436973|NCT04116125|PROCEDURE|Radiotherapy|Adjuvant radiotherapy on axillary region
58436974|NCT02615340|DRUG|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
58436975|NCT02615340|DRUG|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
58436976|NCT02649894|DEVICE|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
58436977|NCT02649894|DEVICE|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
58436978|NCT04760405|OTHER|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
58436979|NCT06146829|OTHER|no intervention|no intervention
58436980|NCT06537674|DRUG|Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection|Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
58436981|NCT05232331|DIETARY_SUPPLEMENT|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming \~ 350 mg of nitrate daily from vegetables
58436982|NCT05354271|OTHER|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
58436983|NCT05354271|OTHER|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
58105988|NCT03108391|DEVICE|LMA Supreme|
58105989|NCT05409131|DEVICE|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
58436984|NCT03746717|DEVICE|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
58436985|NCT03746717|DEVICE|conventional wound closure|wound closure with surgical staples
58310362|NCT03136393|BEHAVIORAL|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
58105990|NCT01289431|DRUG|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
58105991|NCT01289431|DRUG|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
58105992|NCT05054166|OTHER|No intervention, it was a retrospective study.|This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.
58436986|NCT04523883|RADIATION|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
58105993|NCT02535052|BIOLOGICAL|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
58310363|NCT03136393|BEHAVIORAL|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
58436987|NCT04523883|DRUG|JS001|JS001 240mg every three week
58436988|NCT01528722|DRUG|Bupivacaine|0.25% 20ml administered intraperitoneal
58436989|NCT01528722|OTHER|Normal saline|sodium chloride 0.9% solution
58436990|NCT02745028|DIETARY_SUPPLEMENT|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
58436991|NCT03316703|PROCEDURE|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
58436992|NCT03316703|PROCEDURE|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
58310364|NCT06313645|OTHER|Several biomarkers|Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
58436993|NCT04680481|DEVICE|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
58436994|NCT01072994|DIETARY_SUPPLEMENT|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
58436995|NCT00947115|PROCEDURE|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
58436996|NCT00947115|PROCEDURE|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
58436997|NCT03775512|DEVICE|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
58436998|NCT00338923|DRUG|HO/03/03|
58436999|NCT00721188|DRUG|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
58437000|NCT04348981|DEVICE|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
58437001|NCT00697372|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
57954976|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
58105994|NCT06538324|DIETARY_SUPPLEMENT|Omega-3|Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.
58310365|NCT03054623|PROCEDURE|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
58310366|NCT04483765|PROCEDURE|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
58437002|NCT00697372|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
58437003|NCT04102072|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
58437004|NCT04102072|DIAGNOSTIC_TEST|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
58437005|NCT04511858|OTHER|maximum effort test on a cycloergometer|5 h test on cycloergometer
58437006|NCT04511858|OTHER|maximum effort test on a treadmill|5 h test on treadmill
58437007|NCT00657579|DRUG|DE-104 ophthalmic solution, low concentration|
58437008|NCT00657579|DRUG|DE-104 ophthalmic solution, medium concentration|
58437009|NCT00657579|DRUG|DE-104 ophthalmic solution, high concentration|
58437010|NCT00657579|DRUG|DE-104 vehicle|
58437011|NCT01465815|DRUG|erlotinib hydrochloride|Given PO
58437012|NCT01465815|DRUG|linsitinib|Given PO
58437013|NCT01465815|DRUG|placebo|Given PO
58437014|NCT01465815|RADIATION|radiation therapy|Undergo radiation therapy
58437015|NCT01465815|PROCEDURE|therapeutic conventional surgery|Undergo planned surgery
58105995|NCT06538324|DIETARY_SUPPLEMENT|HOSO|Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.
58105996|NCT04539509|BEHAVIORAL|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
58437016|NCT01465815|OTHER|laboratory biomarker analysis|Correlative studies
58437017|NCT00003917|DRUG|topotecan hydrochloride|
58437018|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
58105997|NCT04539509|BEHAVIORAL|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
58105998|NCT04539509|DEVICE|Monitoring|Activity monitoring using a Fitbit.
58437019|NCT06104332|DEVICE|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
58437020|NCT06104332|DEVICE|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
58437021|NCT06104332|DEVICE|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
58437022|NCT06104332|DEVICE|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
58437023|NCT06104332|DEVICE|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
58437024|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
58437025|NCT04659473|OTHER|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
58437026|NCT03422497|OTHER|Male sex|Male sex-as listed in the discharge abstract database
58437027|NCT03422497|OTHER|Female sex|Male sex-as listed in the discharge abstract database
58437028|NCT04360837|PROCEDURE|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
58437029|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
58437030|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
58105999|NCT04624061|BEHAVIORAL|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
58106000|NCT04937751|DIAGNOSTIC_TEST|biomarkers|galactomannan, betaDglucan, resistance markers
58310367|NCT04021433|DRUG|Ketamine|Repeated doses of IM/SC ketamine up to 3 times a week
58437031|NCT03239444|DEVICE|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
58437032|NCT01110369|DIETARY_SUPPLEMENT|Protein drink|Protein drink twice a day during 6 months.
58437033|NCT01110369|OTHER|Resistance exercise training|Resistance exercise training twice per week during 6 months.
58437034|NCT01110369|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink twice a day during 6 months.
58437035|NCT06583265|DRUG|Observational|To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
58437036|NCT00766051|OTHER|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
58437037|NCT01000324|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
58437038|NCT01000324|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
58437039|NCT01000324|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
58437040|NCT02345213|DRUG|E2020|E2020 tablets will be orally administered once daily after breakfast
58437041|NCT02345213|DRUG|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
58106001|NCT01150513|DRUG|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
58106002|NCT01150513|DRUG|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
57954977|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
58437042|NCT02534246|DEVICE|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
58437043|NCT02534246|DEVICE|Ultrasound biopsy needle SharkCore|
58106003|NCT04005105|BEHAVIORAL|Intensive management|Management based on premorbid MAP and MPP
58106004|NCT02551003|DRUG|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
58106005|NCT02551003|DEVICE|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
57954978|NCT03506243|BIOLOGICAL|Follitrope PFS|Follitrope PFS
58106006|NCT03156517|DEVICE|Deep Brain Stimulation|
58106007|NCT05358561|DIETARY_SUPPLEMENT|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
58106008|NCT01882231|OTHER|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
58106009|NCT04321733|DRUG|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
58106010|NCT04670029|OTHER|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
58106011|NCT05697484|DEVICE|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
58437044|NCT06428370|PROCEDURE|Damage Control Surgery|Simple resection, drop, and open abdomen in case of Hinchey III-IV
57954979|NCT03506243|BIOLOGICAL|Gonal-f pen|Gonal-f pen
57954980|NCT03869359|OTHER|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
57954981|NCT03869359|OTHER|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
57954982|NCT03358888|DRUG|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
57954983|NCT03358888|DRUG|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
57954984|NCT03358888|DRUG|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
58106012|NCT03501199|OTHER|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
58106013|NCT03501199|OTHER|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
58106014|NCT03501199|OTHER|no extra material|filling the buccal gap with no material after immediate dental implant placement
58106015|NCT03501199|PROCEDURE|tooth extraction|extraction of tooth which is unrestorable
58106016|NCT03501199|PROCEDURE|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
58106017|NCT03501199|OTHER|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
58106018|NCT03501199|PROCEDURE|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
58437045|NCT03192761|PROCEDURE|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
58437046|NCT03192761|PROCEDURE|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
58106019|NCT01230866|RADIATION|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
57954985|NCT03882814|DRUG|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
58106020|NCT01230866|RADIATION|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
58106021|NCT01837420|DRUG|VB-201 80mg|
58106022|NCT01837420|DRUG|VB-201 160mg|
58106023|NCT01837420|DRUG|Placebo|
58106024|NCT05620680|BIOLOGICAL|CD7 CAR-T cells|patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
58310368|NCT06514339|DRUG|shenhuang granule|"Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification."
58310369|NCT06514339|DRUG|placebo|Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
58437047|NCT03192761|PROCEDURE|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
58437048|NCT01376414|OTHER|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
58437049|NCT05712278|DRUG|SAR445419|Cell suspension, by intraveneous (IV) injection
58437050|NCT05712278|DRUG|fludarabine|Solution for injection , by IV injection
58437051|NCT05712278|DRUG|cytarabine|Solution for injection, by IV injection
58437052|NCT01020552|OTHER|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
58437053|NCT01424033|DRUG|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
58437054|NCT02110095|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
58437055|NCT00130611|OTHER|BNP measurement|
58437056|NCT00130611|OTHER|Clinical examination|
58437057|NCT00014833|OTHER|No intervention|No intervention
58437058|NCT02424175|BIOLOGICAL|Fecal Microbiota Transplantation|
58437059|NCT06491784|OTHER|Exercise Therapy|12 week personalised exercise, nutrition and wellbeing programme
58437060|NCT04880369|DIETARY_SUPPLEMENT|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
58437061|NCT04880369|DIETARY_SUPPLEMENT|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
57738300|NCT04656626|BEHAVIORAL|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
57738301|NCT04656626|BEHAVIORAL|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
57738302|NCT02015676|DRUG|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
58106025|NCT05712915|OTHER|RRT operation|"A retrospective observational study was conducted at a 990-bed tertiary care referral teaching hospital from April 2014 to December 2020. The RRT implemented in April 2017 as a part-time RRT operating 8 hours on weekdays. In March 2018, operation time was extended to 15 hours on weekdays and finally, extended to 24 hours a day, 7 days a week in February 2019.~Impact of RRT operation on CPR incidence was retrospective analyzed without any prospective intervention."
58310370|NCT01855022|BEHAVIORAL|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
58310371|NCT00042211|BEHAVIORAL|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
58310372|NCT00042211|BEHAVIORAL|Control|No treatment control
58310373|NCT01997125|DEVICE|Neural Bridge System|Implanted device
58437062|NCT04880369|DIETARY_SUPPLEMENT|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
58437063|NCT02453503|DRUG|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
58437064|NCT02453503|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
58437065|NCT02578186|DRUG|Diphenhydramine Hydrochloride|30 mL at bedtime
58437066|NCT02578186|DRUG|Placebo|30 mL at bedtime
58437067|NCT06386991|OTHER|Using ethylenediaminetetraacetic acid (EDTA), citric acid ((MONO/ANH) and etidronic acid (HEBP) to clean root canals during regenerative endodontic treatments|Regenerative endodontic treatment using different irrigation solutions
58437068|NCT05615740|DIAGNOSTIC_TEST|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
58437069|NCT00642161|DRUG|budesonide|
58437070|NCT04180904|OTHER|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
58437071|NCT04180904|OTHER|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
58437072|NCT00391950|DRUG|Zoledronic acid|
58437073|NCT00940498|DRUG|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
58437074|NCT01257945|BEHAVIORAL|Aerobic Exercise|
58437075|NCT01257945|BEHAVIORAL|Flexibility and Function exercise program|
58437076|NCT01257945|BEHAVIORAL|Home exercise program|
58437077|NCT05030350|DRUG|PH94B|Nasal spray
58437078|NCT00576225|DRUG|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
58437079|NCT00576225|DRUG|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
58310374|NCT05903352|OTHER|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
58310375|NCT05903352|DRUG|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
58310376|NCT03020368|BIOLOGICAL|Leeches|
58437080|NCT04266925|BEHAVIORAL|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
58310377|NCT03020368|DRUG|Diclofenac|
58437081|NCT04266925|OTHER|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
58437082|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
58437083|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
58437084|NCT03469791|PROCEDURE|Surgical treatment of Degenerative Spondylolisthesis|
58437085|NCT04590716|OTHER|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
58437086|NCT03364309|DRUG|Ixekizumab|Administered SC
58437087|NCT03364309|DRUG|Placebo|Administered SC
58437088|NCT03512392|OTHER|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
58437089|NCT03512392|OTHER|Usual care strategy|Usual care at the discretion of the clinical team
58437090|NCT00307788|PROCEDURE|acupuncture|acupuncture
58437091|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
58437092|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
58437093|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
58437094|NCT00973323|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
58437095|NCT03536559|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
58437096|NCT03536559|DRUG|Placebo|Placebo is liquid with identical color and taste
58437097|NCT06445816|DRUG|chemotherapy|"* Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers."
58437098|NCT02990039|BEHAVIORAL|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
58437099|NCT00415922|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
58437100|NCT02222376|DRUG|Pirfenidone|Twice a day topical application
58437101|NCT02222376|PROCEDURE|Debridement|Weekly ulcer debridement
58437102|NCT03631134|DRUG|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
57738303|NCT02015676|DRUG|paclitaxel|60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
57738304|NCT02015676|DRUG|Myocet|40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
57954986|NCT03882814|DRUG|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
57954987|NCT02476721|OTHER|detection of pulmonary embolism|
57954988|NCT00861744|BIOLOGICAL|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
57954989|NCT00861744|BIOLOGICAL|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
57954990|NCT00861744|BIOLOGICAL|Varivax®|Subcutaneous injection, one dose
57954991|NCT00861744|BIOLOGICAL|Havrix®|Intramuscular injection, one dose
57954992|NCT00861744|BIOLOGICAL|Prevnar®|Intramuscular injection, one dose
58437103|NCT01973413|DEVICE|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
58437104|NCT01973413|DEVICE|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
58437105|NCT01973413|DEVICE|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
58437106|NCT00258804|DRUG|Insulin glargine|
58437107|NCT04044742|DRUG|Resiniferatoxin|Receiving Resiniferatoxin injection
58437108|NCT04044742|DRUG|Placebo|Receiving Placebo injection
58437109|NCT00013013|PROCEDURE|Systems Support|
58437110|NCT05041972|DRUG|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
58437111|NCT01922791|DIETARY_SUPPLEMENT|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
58437112|NCT06262464|BEHAVIORAL|Prevention|A cognitive-behavioural prevention programme.
58437113|NCT03657849|DEVICE|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
58437114|NCT03862235|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
58437115|NCT03862235|DIAGNOSTIC_TEST|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
58437116|NCT04346446|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
58437117|NCT04346446|OTHER|Supportive Care|Supportive Care
58437118|NCT04346446|DRUG|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
58437119|NCT04007419|BEHAVIORAL|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
58437120|NCT02783092|DRUG|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
58437121|NCT02783092|DRUG|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
58437122|NCT02430116|PROCEDURE|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
58437123|NCT03781453|BEHAVIORAL|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
58437124|NCT02058563|BIOLOGICAL|Priorix®|1 dose administered as a subcutaneous (SC) injection.
58437125|NCT02058563|BIOLOGICAL|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
57738305|NCT05198960|DRUG|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
57738306|NCT05198960|DRUG|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
57738307|NCT01354158|DRUG|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
57738308|NCT02539342|DRUG|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
57738309|NCT02539342|DRUG|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
57738310|NCT00092131|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
57738311|NCT00092131|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
57738312|NCT00818857|BEHAVIORAL|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
58310378|NCT05723926|DEVICE|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
58310379|NCT04499885|DEVICE|Paraffin oil gastric lavage|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
58437126|NCT06443684|DIAGNOSTIC_TEST|MRD|MRD（LC-10）include 10 lung cancer-related driver gene mutation site
58437127|NCT02692001|OTHER|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
58437128|NCT04309708|DEVICE|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
58437129|NCT06535620|OTHER|red wine with alcohol|200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
58437130|NCT06535620|OTHER|red wine without alcohol|200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
58437131|NCT00236236|DEVICE|Cardiac Resynchronization Therapy|
58437132|NCT00785473|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
58437133|NCT00785473|DIETARY_SUPPLEMENT|calcium carbonate|calcium carbonate 500 mg daily for 2 years
58106026|NCT04862104|BEHAVIORAL|Intervention group|In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
58106027|NCT02946502|PROCEDURE|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
58106028|NCT02444182|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
58106029|NCT02444182|DIETARY_SUPPLEMENT|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
58106030|NCT04290806|OTHER|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
58310380|NCT04499885|DEVICE|Gastric lavage with saline and sodium bicarbonate 8.4%|Gastric lavage with saline and sodium bicarbonate 8.4%
58437134|NCT02209896|DEVICE|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
58437135|NCT02502825|OTHER|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
57738313|NCT00818857|BEHAVIORAL|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
58437136|NCT02502825|DEVICE|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
58437137|NCT02502825|DEVICE|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
58437138|NCT03087903|DIETARY_SUPPLEMENT|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
58437139|NCT02210416|PROCEDURE|inguinal hernia surgery|
58437140|NCT05122091|DRUG|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
58437141|NCT04386954|PROCEDURE|observational study|observation study
58437142|NCT02563938|DRUG|AK001|Given parenterally.
58437143|NCT02563938|DRUG|Placebo|
58437144|NCT06256744|OTHER|exercise|Resistance exercise
58437145|NCT03558490|DEVICE|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
58437146|NCT03558490|DRUG|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
57738314|NCT04822220|OTHER|Fatigue Self-management Programme|Fatigue Self-management Programme
58106031|NCT02282111|DEVICE|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
57738315|NCT03369444|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
57738316|NCT02361320|PROCEDURE|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
58310381|NCT03534674|DIETARY_SUPPLEMENT|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
58310382|NCT04015362|PROCEDURE|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
58106032|NCT02282111|DEVICE|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
58106033|NCT05356351|DRUG|RC48- ADC|RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
58106034|NCT02372682|DEVICE|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
58106035|NCT00253461|PROCEDURE|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
57738317|NCT02361320|BEHAVIORAL|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
57738318|NCT03438123|DEVICE|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
57738319|NCT00315250|DRUG|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
57738320|NCT05589051|DIETARY_SUPPLEMENT|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
58106036|NCT00253461|PROCEDURE|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
57738321|NCT03816904|OTHER|Blood samples|Blood samples before the introduction of chemotherapy
58106037|NCT00253461|RADIATION|11C topotecan|Phase I and II: IV over 10 minutes
58106038|NCT00253461|RADIATION|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
57738322|NCT00901693|DRUG|AL-46383A Ophthalmic Solution|
58106039|NCT00817466|DRUG|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
58106040|NCT00817466|DRUG|Isotonic saline|2ml NaCl 9mg/ml.
58106041|NCT02313116|DEVICE|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
58106042|NCT06381596|DEVICE|OcuMet Beacon|OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
58106043|NCT01873638|PROCEDURE|Cholecystectomy|
57738323|NCT00901693|DRUG|AL-46383A Ophthalmic Solution Vehicle|
57738324|NCT02202226|DRUG|Lu AF35700|
57738325|NCT02202226|DRUG|Placebo|
57738326|NCT04798976|DRUG|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
58310383|NCT04015362|PROCEDURE|Sham|Application of sham magnetic stimulation to spinal cord
58310384|NCT04823234|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound signs in Covid 19 positive pregnant patients
58437147|NCT05700383|BEHAVIORAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
58437148|NCT05700383|BEHAVIORAL|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
58437149|NCT03470402|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
58437150|NCT03470402|OTHER|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
58437151|NCT03470402|OTHER|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
58437152|NCT03470402|OTHER|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
58437153|NCT03470402|OTHER|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
58437154|NCT00742716|DRUG|CTA018 Injection|Comparison of different dosages of drug
58437155|NCT03618862|BIOLOGICAL|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
58437156|NCT03922620|DRUG|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
58437157|NCT03922620|DRUG|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
58437158|NCT01279616|DRUG|Fludarabine monophosphate|180 mg/m2 over 6 days.
58437159|NCT01279616|DRUG|Rituximab|375 mg/m2 on day -13 and day -3
58437160|NCT01279616|DRUG|Busulfan|AUC 1000-1200 microM.mt
58437161|NCT01279616|DRUG|ATG|2.5 mg/kg for 3 days
58437162|NCT01279616|DRUG|Cyclophosphamide|50 mg/kg on day +3
58437163|NCT01279616|DRUG|Mycophenolate mofetil|15 mg/kg q 8 hours
57738327|NCT03008148|RADIATION|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
58310385|NCT04347772|DIETARY_SUPPLEMENT|Oral Nutrition Support|Intensive Nutrition Intervention
58437164|NCT01279616|DRUG|Tacrolimus|0.03 mg/kg /d
58437165|NCT02218593|DEVICE|WREX orthosis|Upper extremity exoskleton used to assist movement
57738328|NCT03008148|DRUG|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
58437166|NCT02396563|PROCEDURE|epidural analgesia|
57738329|NCT03008148|DRUG|Siroquine|"1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
57954993|NCT00774462|DRUG|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
57954994|NCT00286273|DRUG|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
57954995|NCT00286273|DRUG|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
57954996|NCT02699892|DRUG|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
57954997|NCT04799886|OTHER|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
58310386|NCT04025424|GENETIC|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
58437167|NCT02396563|DRUG|Ropivacaine|
57954998|NCT00006456|RADIATION|stereotactic radiosurgery|
57954999|NCT00452751|PROCEDURE|laparoscopy-assisted distal gastrectomy|
57955000|NCT00452751|PROCEDURE|open distal gastrectomy|
57955001|NCT00086203|DRUG|Talabostat mesylate (PT-100) tablets|
57955002|NCT00086203|DRUG|Rituximab|
58106044|NCT03836729|DRUG|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
58310387|NCT05589974|DRUG|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
58437168|NCT05723107|DRUG|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
58437169|NCT05723107|DEVICE|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
57738330|NCT04391023|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
58310388|NCT05608057|OTHER|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
57738331|NCT04391023|BEHAVIORAL|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
58106045|NCT03836729|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
58106046|NCT00657397|DRUG|Methadone|Methadone sirup once daily
58310389|NCT05608057|RADIATION|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
58310390|NCT03077217|DRUG|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
58310391|NCT01026493|DRUG|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
58310392|NCT01026493|DRUG|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
58310393|NCT01026493|DRUG|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
58310394|NCT01026493|DRUG|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
58310395|NCT01026493|DRUG|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
58310396|NCT01026493|DRUG|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
58310397|NCT00001132|DRUG|Abacavir sulfate|
58310398|NCT03448198|PROCEDURE|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
58310399|NCT06369636|PROCEDURE|Thyroid Surgery|EGRI scores and airway ultrasonographic values will be recorded in patients who undergo thyroid surgery.
58310400|NCT05209919|DIAGNOSTIC_TEST|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
58310401|NCT05965414|DRUG|CS6253 Solution for Injection|Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
58310402|NCT05965414|DRUG|Placebo|Physiological saline solution for intra-venous injection
58310403|NCT02703766|BEHAVIORAL|overfeeding induced weight gain|
58437170|NCT04280731|DIETARY_SUPPLEMENT|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
58437171|NCT05641922|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
58437172|NCT03009734|DRUG|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
58437173|NCT05287893|DRUG|Pyronaridine|Single dose
58437174|NCT05287893|BIOLOGICAL|P. falciparum IBSM infection|Induced Blood Stage Malaria
58437175|NCT01371552|DEVICE|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
58437176|NCT01371552|DEVICE|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
58106047|NCT03152227|OTHER|ACGG|50 high-producing chicks to households along with provision of technical input on production
58106048|NCT03152227|BEHAVIORAL|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
58106049|NCT00003583|DRUG|amifostine trihydrate|
58106050|NCT00003583|DRUG|cisplatin|
58106051|NCT00003583|DRUG|etoposide|
58106052|NCT00003583|RADIATION|radiation therapy|
58437177|NCT01371552|DEVICE|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
58437178|NCT05075590|DIAGNOSTIC_TEST|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
58437179|NCT06003153|DRUG|oral semaglutide|Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
58310404|NCT03647592|DRUG|Erlotinib/Gefitinib combined with Bevacizumab|Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
58437180|NCT06003153|OTHER|Mixed Meal Tolerance Test (MMTT)|The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
58437181|NCT01105273|BIOLOGICAL|anti-thymocyte globulin|On days -3 to -1
58437182|NCT01105273|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
58437183|NCT01105273|DRUG|Fludarabine|30mg/M2 once daily IV on days -6 to -2
58437184|NCT01105273|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
58437185|NCT01105273|PROCEDURE|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
58437186|NCT01086371|OTHER|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
58437187|NCT01086371|OTHER|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
58437188|NCT05327972|DRUG|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
58437189|NCT05327972|OTHER|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
58437190|NCT00762047|DEVICE|Durasphere FI|Durasphere Injection
58437191|NCT00762047|DEVICE|Sham|Sham injection with anesthesia
58437192|NCT05159570|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
58437193|NCT05159570|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
58310405|NCT03429413|BEHAVIORAL|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
58437194|NCT04983420|OTHER|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
58437195|NCT04983420|OTHER|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
58437196|NCT04983420|OTHER|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
58437197|NCT04983420|OTHER|lemonade|intake of 1 L lemonade per day for 2 weeks
58437198|NCT03445689|OTHER|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
58437199|NCT03445689|OTHER|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
58437200|NCT03445689|OTHER|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
58437201|NCT03445689|OTHER|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
58437202|NCT03445689|OTHER|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
58106053|NCT03066635|DRUG|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
58310406|NCT03429413|BEHAVIORAL|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
58106054|NCT03066635|DRUG|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
58310407|NCT04487990|DRUG|unfractionated Heparin|Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
58310408|NCT02426801|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
58106055|NCT04218006|GENETIC|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
58106056|NCT03143088|BEHAVIORAL|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
58310409|NCT02426801|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
58310410|NCT01837745|DRUG|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
58310411|NCT01837745|DRUG|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
58437203|NCT03445689|OTHER|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
58106057|NCT06263465|OTHER|Lactobacillus cispatus|10\^9 cfu,5 days
58437204|NCT00458458|DRUG|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
58437205|NCT00458458|DRUG|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
58437206|NCT04984577|DRUG|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
58437207|NCT04984577|DRUG|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
58437208|NCT04984577|DRUG|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
58437209|NCT04984577|DRUG|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
58437210|NCT05895240|DRUG|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
58437211|NCT05492786|BEHAVIORAL|Alert|Non-interruptive best practice alert in the electronic health record
58437212|NCT05492786|BEHAVIORAL|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
58437213|NCT05492786|BEHAVIORAL|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
58437214|NCT05492786|BEHAVIORAL|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
58437215|NCT03749278|BEHAVIORAL|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
58437216|NCT01671917|OTHER|Educational and exercise program|"* 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour"
58106058|NCT06263465|OTHER|placebo|0 cfu,5 days
58106059|NCT02795130|PROCEDURE|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
58106060|NCT05099328|BEHAVIORAL|Recast Therapy|Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
58437217|NCT01671917|OTHER|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
58437218|NCT01645410|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
57955003|NCT02601521|BEHAVIORAL|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
58106061|NCT05099328|BEHAVIORAL|Syntax Stories|Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
58106062|NCT06529081|RADIATION|Palliative Radiotherapy|Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).
58437219|NCT05621993|DRUG|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
58106063|NCT06529081|RADIATION|Radical/Ablative Radiotherapy|Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
58310412|NCT01837745|OTHER|Follow up|"* 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
58310413|NCT04152590|DEVICE|Uincare|Interactive digital healthcare system
58437220|NCT05006950|DEVICE|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
58437221|NCT03416127|DRUG|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
58106064|NCT01004484|OTHER|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
58106065|NCT01004484|OTHER|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
58437222|NCT03416127|DRUG|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
58437223|NCT03416127|DRUG|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
58106066|NCT06406985|BEHAVIORAL|Weight-loss through dietary and lifestyle changes|Weight-loss participants will complete one online, self-paced education session each week for 12 weeks. Education sessions focus on topics such as self-monitoring weight, meal routines, and dietary habits with an emphasis on protein and fiber intake. During these 12 weeks, participants will receive weekly messages from nutrition coaches as well as a monthly nutrition coaching call. After the first 12 weeks, participants will enter a follow-up period where nutrition coaching messaging will occur as needed and with the opportunity to still participate in a monthly nutrition coaching call. Participants are asked to weigh daily on a provided WiFi scale that automatically uploads their weight data to a website for researchers and coaches to monitor. Participants will also submit food records and self-reported weight and hip circumferences.
58106067|NCT03210233|PROCEDURE|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
58106068|NCT00294320|DRUG|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
58106069|NCT00294320|OTHER|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
58106070|NCT02122510|DRUG|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
58106071|NCT02122510|DRUG|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
58106072|NCT04857827|DRUG|QLS-101|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
58106073|NCT04857827|DRUG|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
58106074|NCT02209454|DRUG|Enantyum® oral solution|One dose of 25 mg DKP oral solution
58106075|NCT02209454|DRUG|Keral® tablet|One dose of 25 mg DKP tablet
58106076|NCT06375031|DRUG|HR011408 injection; HR011408 injection Placebo|"Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum"
58106077|NCT06375031|DRUG|NovoRapid®; HR011408 injection Placebo|"Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum"
57955004|NCT02601521|BEHAVIORAL|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
58106078|NCT06375031|DRUG|HR011408 injection Placebo; HR011408 injection|"Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum"
58106079|NCT00962182|DRUG|STAN1|3-4 capsules/day at meals
58106080|NCT00962182|DRUG|Placebo enzyme|3-4 capsules/day at meals
58106081|NCT00962182|DRUG|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
58106082|NCT03333681|BIOLOGICAL|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
58310414|NCT05063240|BEHAVIORAL|Mobile phone text messaging plus prospective motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
57955005|NCT00525395|GENETIC|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
57955006|NCT00525395|PROCEDURE|Continuous phototherapy|Group B: 6 months non-stop treatment.
57955007|NCT01055158|BEHAVIORAL|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
57955008|NCT01055158|BEHAVIORAL|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
57955009|NCT05312034|BEHAVIORAL|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
57955010|NCT02018822|DEVICE|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
57955011|NCT02018822|DEVICE|TPH3|light-cured resin composite for teeth
57955012|NCT02018822|DEVICE|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
57955013|NCT02997761|BIOLOGICAL|Blinatumomab|Given IV
57955014|NCT02997761|DRUG|Ibrutinib|Given PO
57955015|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 10mcg|10 mcg
57955016|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
57955017|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 60mcg|60 mcg
57955018|NCT02109484|OTHER|Placebo|
57955019|NCT03784066|DRUG|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
58437224|NCT04429698|DIAGNOSTIC_TEST|Point of care ultrasonography|Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
58437225|NCT03318016|DRUG|Cyclophosphamide 500 MG|ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
58437226|NCT03318016|DRUG|Cyclophosphamide 1000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
58437227|NCT03318016|DRUG|Cyclophosphamide 2000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
58437228|NCT03318016|DRUG|Cyclophosphamide 3000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
57738332|NCT04391023|DEVICE|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
57738333|NCT04391023|DEVICE|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
57738334|NCT00533377|DRUG|CP-533, 536|Active study drug
57738335|NCT00533377|DRUG|Placebo|Placebo vehicle
58106083|NCT05117086|BEHAVIORAL|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
58310415|NCT05063240|BEHAVIORAL|Standard infant feeding counselling|Standard infant feeding counselling as part of routine practice at primary healthcare facility
58310416|NCT02457975|DEVICE|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
58310417|NCT02457975|DRUG|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
58310418|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
58310419|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
58310420|NCT01712282|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
58310421|NCT03521310|PROCEDURE|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
58310422|NCT03521310|PROCEDURE|Conventional care|Neonates will get Conventional care the first 72 hours after birth
58310423|NCT04662333|PROCEDURE|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
57738336|NCT00533377|PROCEDURE|Standard of Care|Standard surgical procedure
57738337|NCT00533377|DRUG|CP-533,536|Active study drug
58106084|NCT00447187|DRUG|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
58106085|NCT00447187|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
58106086|NCT04266678|BEHAVIORAL|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
57738338|NCT00533377|DRUG|CP-533,536|Active study drug
57738339|NCT00533377|DRUG|CP-533,536|Active study drug
57738340|NCT02158676|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharides
57738341|NCT02158676|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
57738342|NCT02158676|OTHER|Placebo|Maltodextrin
58310424|NCT04662333|PROCEDURE|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
57955020|NCT03784066|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
57955021|NCT00387400|DRUG|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
57955022|NCT00387400|DRUG|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
57955023|NCT00387400|GENETIC|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
58106087|NCT03884595|DIAGNOSTIC_TEST|IG, IPF, NRBC, CRP, PCT, presepsin|Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
58106088|NCT01330615|DRUG|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
58106089|NCT01330615|DRUG|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
58106090|NCT03264079|DRUG|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
58106091|NCT03264079|DRUG|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
58106092|NCT03096574|OTHER|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
58106093|NCT01271933|DRUG|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
58106094|NCT01271933|DRUG|placebo|matching placebo tablet; given once daily
58106095|NCT00108901|BEHAVIORAL|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
58106096|NCT01217528|DEVICE|device settings for group A|VT zone: 350ms VF zone: 280ms
58310425|NCT01553929|OTHER|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
58310426|NCT01553929|OTHER|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
58310427|NCT01553929|OTHER|control group|no physical training and no cognitive activity
58310428|NCT02559167|DRUG|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
58310429|NCT02577029|DRUG|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
58310430|NCT02577029|DRUG|entecavir|0.5 mg once daily; oral
58310431|NCT02577029|BIOLOGICAL|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
58310432|NCT02577029|DRUG|tenofovir disoproxil|300 mg once daily; oral
58310433|NCT02577029|DRUG|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
58310434|NCT01220791|OTHER|In vitro fertilization treatment for infertility|IVF treatment
58106097|NCT01217528|DEVICE|Device settings for group B|VT zone: 320ms VF zone: 250ms
58106098|NCT00443131|BIOLOGICAL|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
58106099|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
58106100|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
58106101|NCT02996253|PROCEDURE|FHL transfer|endoscopic transfer og flexor hallucis longus
58106102|NCT02856451|BIOLOGICAL|Nivolumab|Specified dose on specified days
58106103|NCT01318941|DRUG|Ranibizumab|
58106104|NCT01318941|OTHER|Ranibizumab|
58310435|NCT00826839|DRUG|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
58310436|NCT00826839|DRUG|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
58106105|NCT03374150|BEHAVIORAL|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
58106106|NCT03866837|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
57955024|NCT00387400|OTHER|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
58106107|NCT03866837|DIETARY_SUPPLEMENT|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
58106108|NCT03866837|DIETARY_SUPPLEMENT|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
58106109|NCT01535846|BEHAVIORAL|Conscious food tasting intervention|Six weekly 2-hour workshops
58106110|NCT00054119|DRUG|Cositecan|Given IV
58310437|NCT01399307|PROCEDURE|Liposuction|Elective Liposuction
58310438|NCT00423046|BIOLOGICAL|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
58310439|NCT00423046|BIOLOGICAL|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
58310440|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
58310441|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
58310442|NCT00000965|DRUG|Zidovudine|
58310443|NCT06050213|DEVICE|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
58310444|NCT02596048|OTHER|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
58310445|NCT05584098|OTHER|qSOFA and MEWS|qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
58310446|NCT04079790|DRUG|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
58310447|NCT04079790|DRUG|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
58310448|NCT01217346|OTHER|no intervention is involved in this study|no intervention is involved in this study
58310449|NCT06002100|OTHER|fNIRS measurement|Kernel Flow2 measurements.
58310450|NCT06238180|DEVICE|VIOSync-SPI|The intervention in this study involves an AI-driven clinical decision-support system, VIOSync Sepsis Prediction Index (SPI), designed for the early prediction of sepsis in patients undergoing abdominal surgery. VIOSync integrates data from PPG-based wearable wireless devices that monitor vital signs, electronic health records, and laboratory tests. The AI model analyzes this multimodal data to proactively identify signs of sepsis providing an early warning score, the SPI, to clinicians. The distinguishing feature of this intervention is its use of real-time data and advanced AI analytics to enhance early sepsis detection, aiming to improve patient outcomes in postoperative care.
58310451|NCT04596904|OTHER|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
58437229|NCT03318016|DRUG|Cyclophosphamide 4000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
58437230|NCT04793113|OTHER|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
58437231|NCT04584593|BIOLOGICAL|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
58437232|NCT05686291|BEHAVIORAL|Hybrid volunteer training programme|The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
58106111|NCT00054119|OTHER|Pharmacological Study|Correlative studies
58437233|NCT03057652|DEVICE|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
58437234|NCT03057652|DEVICE|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
58437235|NCT03057652|DEVICE|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
58437236|NCT04379401|DEVICE|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
58106112|NCT03255031|OTHER|Ketogenic Diet (KD)|For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
58106113|NCT03255031|OTHER|Standard American (SA) Meals and Shakes|For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
58106114|NCT03810664|DRUG|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
58106115|NCT01990066|BEHAVIORAL|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
58437237|NCT05736601|DEVICE|focus motion knee brace|knee brace that captures knee motion
58437238|NCT03514875|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
58437239|NCT03514875|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
58437240|NCT02623582|BIOLOGICAL|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
58437241|NCT02623582|DRUG|Cyclophosphamide|Given IV
58437242|NCT03848936|OTHER|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
58437243|NCT02487004|DEVICE|hemodialysis|
58437244|NCT00599755|RADIATION|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
58437245|NCT00599755|DRUG|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
58437246|NCT05113537|DRUG|Abemaciclib|Given Orally
58106116|NCT01673165|OTHER|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
58106117|NCT01673165|OTHER|Specialized Formula|Infants will receive our standard of care - specialized formula
58437247|NCT05113537|DRUG|Lutetium Lu 177-PSMA-617|Given IV
58437248|NCT01128946|DRUG|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
58437249|NCT01128946|DRUG|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
58310452|NCT04596904|OTHER|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
58310453|NCT06150261|DIETARY_SUPPLEMENT|AvailOm|5 capsules taken once daily with main meal
58310454|NCT06150261|DIETARY_SUPPLEMENT|Placebo|5 capsules taken once daily with main meal
58310455|NCT03453294|DEVICE|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
58310456|NCT03453294|DEVICE|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
58437250|NCT01128946|DRUG|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
58437251|NCT02711007|DRUG|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
58437252|NCT01209429|DRUG|GH hormone infusion|Norditropin 30 ng/kg/min
58437253|NCT01209429|BEHAVIORAL|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
58437254|NCT01209429|BEHAVIORAL|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
58437255|NCT03679624|DRUG|Ibrutinib|Ibrutinib, 420mg orally, once daily
58437256|NCT03679624|DRUG|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
58310457|NCT05279872|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
58437257|NCT01718444|DRUG|Progestin|
58437258|NCT01718444|DRUG|Clomiphene Citrate|
58437259|NCT00056953|BEHAVIORAL|Peer mentoring program|
58437260|NCT03282097|BEHAVIORAL|DECAD decision aid|A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.
58437261|NCT03282097|OTHER|Home safety guide|The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
58437262|NCT04239690|OTHER|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
58437263|NCT04994301|DIAGNOSTIC_TEST|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
58437264|NCT02846441|PROCEDURE|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
57738343|NCT04369092|OTHER|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
58310458|NCT02491762|PROCEDURE|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
58310459|NCT03336125|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
58437265|NCT04658043|OTHER|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
58437266|NCT05958680|BEHAVIORAL|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
58310460|NCT03336125|DIETARY_SUPPLEMENT|Placebo|120 mg olive oil
58437267|NCT03482492|DRUG|Tramadol|Tramadol iv
58437268|NCT03482492|DRUG|Paracetamol|Paracetamol iv
58437269|NCT02679287|DEVICE|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
58437270|NCT04338763|DRUG|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
58437271|NCT04338763|DRUG|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
58437272|NCT02644577|DRUG|Metformin|
58437273|NCT02644577|OTHER|Starch|
58437274|NCT03970369|BEHAVIORAL|Usual care|Personalized goals and an activity prescription.
58437275|NCT03970369|BEHAVIORAL|Monitor|Participants wear a step counter to track activity goals.
58437276|NCT01517464|GENETIC|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
58437277|NCT02112864|DRUG|Dexamethasone|10 mg (2.5 ml)
58310461|NCT02164916|BIOLOGICAL|cetuximab|Given IV
58310462|NCT02164916|DRUG|irinotecan hydrochloride|Given IV
58310463|NCT02164916|DRUG|vemurafenib|Given PO
58310464|NCT00635505|DRUG|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
58310465|NCT00635505|DRUG|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
58310466|NCT00635505|DRUG|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
58310467|NCT05790590|DIAGNOSTIC_TEST|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
58437278|NCT02112864|DRUG|Normal Saline|2.5 mL normal saline
58437279|NCT03034330|OTHER|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
58437280|NCT03034330|OTHER|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
58437281|NCT00305539|DRUG|adalimumab|40 mg sc / for 3 months
58437282|NCT00305539|DRUG|placebo|placebo
58437283|NCT06185075|PROCEDURE|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
58437284|NCT01907425|OTHER|Blood samples|
58437285|NCT06307093|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
58437286|NCT06307093|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
58437287|NCT06254287|DRUG|Avatrombopag|Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.
58437288|NCT06254287|DRUG|Avatrombopag +rhTPO|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
58437289|NCT03975686|OTHER|neuromuscual realigning exercise|neuromuscular realigning exercise
58437290|NCT03629353|PROCEDURE|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
58437291|NCT03629353|PROCEDURE|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
58437292|NCT00002812|DRUG|asparaginase|Given IV
58437293|NCT00002812|DRUG|cyclophosphamide|Given IV
58437294|NCT00002812|DRUG|cytarabine|Given IV
58437295|NCT00002812|DRUG|daunorubicin hydrochloride|Given IV
58437296|NCT00002812|DRUG|dexamethasone|Given IV
58437297|NCT00002812|DRUG|doxorubicin hydrochloride|Given IV
58437298|NCT00002812|DRUG|idarubicin|Given IV
58437299|NCT00002812|DRUG|mercaptopurine|Given IV
58437300|NCT00002812|DRUG|methotrexate|Given PO
58437301|NCT00002812|DRUG|pegaspargase|Given IV
58437302|NCT00002812|DRUG|prednisone|Given PO
58437303|NCT00002812|DRUG|thioguanine|Given IV
58437304|NCT00002812|DRUG|vincristine sulfate|Given IV
58437305|NCT00002812|RADIATION|radiation therapy|
58437306|NCT00216216|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
58437307|NCT02479815|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
58437308|NCT05015569|DEVICE|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
58437309|NCT05015569|OTHER|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
58437310|NCT05311787|PROCEDURE|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
58437311|NCT06579911|DEVICE|High-frequency micro-ultrasound target biopsy|"1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate"
58437312|NCT06579911|DEVICE|conventional Multiparametric MRT target biopsy|"1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate"
58437313|NCT06340893|BEHAVIORAL|Exercise|Participants will participate in cardiovascular, agility, balance, strength and coordination training.
58437314|NCT06340893|BEHAVIORAL|Restful Play|This group will engage in restful play activities such as coloring and playing with legos.
58437315|NCT04079998|DEVICE|Procellera®|Application of Procellera® dressing.
58437316|NCT04079998|OTHER|Standard of Care|Application of standard of care dressings as prescribed.
58437317|NCT04027894|DRUG|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
58437318|NCT04027894|DRUG|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
58437319|NCT03258775|OTHER|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
58437320|NCT04009395|OTHER|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
58437321|NCT04009395|OTHER|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
58437322|NCT05154318|PROCEDURE|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
58437323|NCT05154318|PROCEDURE|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
58437324|NCT03998969|DRUG|Pantoprazole|Pantoprazole 40mg tablet
58437325|NCT03998969|DRUG|DA-5204|DA-5204 tablet
58437326|NCT03998969|DRUG|Placebo|Film-coated tablet manufactured to mimic DA-5204
58437327|NCT05020210|DRUG|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
58437328|NCT03654885|DEVICE|XEN-45 Gel Stent|XEN-45 gel stent device implant
58437329|NCT03654885|PROCEDURE|Trabeculectomy|Trabeculectomy surgery
58437330|NCT02863328|DRUG|semaglutide|Oral administration once-daily.
58437331|NCT02863328|DRUG|empagliflozin|Oral administration once-daily.
58437332|NCT05062486|DRUG|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
58437333|NCT05062486|DRUG|Curcumin|1000 mg curcumin BID
58437334|NCT01229722|DEVICE|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
58437335|NCT01229722|DEVICE|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
58437336|NCT03487185|DEVICE|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
58437337|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
58437338|NCT02218008|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58437339|NCT02218008|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58437340|NCT04955327|DRUG|A. Paniculata|Extract from A. Paniculata
58437341|NCT04955327|DRUG|A. Chilensis|Extract from A. Chilensis
58437342|NCT04955327|DRUG|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
58437343|NCT04955327|DRUG|Microcrystalline cellulose|Placebo comparator
58437344|NCT04885413|DRUG|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
58437345|NCT02466009|DRUG|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
58437346|NCT01365858|OTHER|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
58437347|NCT03570359|DRUG|Interferon Beta-1A|Interferon Beta-1A via inhalation
58437348|NCT03570359|OTHER|Placebo|Placebo via inhalation
58437349|NCT03070899|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
58437350|NCT03070899|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
58437351|NCT03070899|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
58437352|NCT03070899|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
58437353|NCT05270239|BEHAVIORAL|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
58437354|NCT05270239|BEHAVIORAL|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
58437355|NCT05219058|PROCEDURE|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
58437356|NCT05219058|PROCEDURE|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
58437357|NCT05219058|PROCEDURE|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
58437358|NCT04480632|BIOLOGICAL|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
58437359|NCT04153045|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
58437360|NCT03261453|DEVICE|Active Elipse Device|Intervention Device
58437361|NCT03261453|DEVICE|Elipse Sham Device|Control Device
58437362|NCT01204021|BEHAVIORAL|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
58437363|NCT01204021|BEHAVIORAL|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
58437364|NCT01189981|BEHAVIORAL|Lifestyle counseling|One health conversation at baseline
58437365|NCT01189981|BEHAVIORAL|eHealth intervention|SMS based encouragements to intensive exercise
58437366|NCT06251583|DEVICE|duramesh suture|Duramesh-suture will be used for trocar closure in the experimental group
58437367|NCT05466331|OTHER|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
58437368|NCT05466331|OTHER|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
58106118|NCT04891367|OTHER|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
58106119|NCT01309828|DRUG|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
58106120|NCT01309828|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
57738344|NCT05137574|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
57955025|NCT03563469|OTHER|Salivary bacterial and pH level|"1. Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~2. The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
57955026|NCT00236834|DRUG|levofloxacin; imipenem/cilastitin|
57955027|NCT01273883|DIETARY_SUPPLEMENT|Magnesium|Magnesium 532 mg a day
57955028|NCT01273883|OTHER|Placebo|matching form/dosage
58106121|NCT05599204|OTHER|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
58437369|NCT06583330|DRUG|Low Molecular Weight Heparin (dalteparin)|All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
58437370|NCT05096000|BEHAVIORAL|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
58437371|NCT05096000|OTHER|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
58437372|NCT00763841|DEVICE|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
58437373|NCT00763841|DEVICE|Sham|
58437374|NCT03042143|BIOLOGICAL|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
58437375|NCT03042143|BIOLOGICAL|Placebo (Plasma-Lyte 148)|Infusion of placebo
58437376|NCT01832155|BEHAVIORAL|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
58437377|NCT01832155|BEHAVIORAL|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
58437378|NCT04342117|DRUG|duvelisib|25 mg BID, 15 mg BID
57738345|NCT05137574|DRUG|propofol|propofol
57738346|NCT05137574|DRUG|ketamine|ketamine
58106122|NCT05599204|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
58437379|NCT04342117|DRUG|PI3K inhibitor|FDA approved PI3K inhibitors
58437380|NCT05357508|BEHAVIORAL|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
58437381|NCT05357508|BEHAVIORAL|Control brochure|Provide participants with general information about options for colorectal cancer screening.
58437382|NCT04933487|DEVICE|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
58106123|NCT02496871|BEHAVIORAL|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
58106124|NCT02496871|BEHAVIORAL|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
58310468|NCT05790590|DIAGNOSTIC_TEST|Standard dose CT|CT with standard radiation dose and contrast media dose
58437383|NCT04673578|DRUG|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
58437384|NCT04673578|OTHER|Placebo|Microcrystalline cellulose
58437385|NCT04039737|DRUG|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
58437386|NCT01840345|DRUG|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
58437387|NCT05776953|DRUG|Ketorolac|IV Ketorolac for pain
58437388|NCT03125551|DIETARY_SUPPLEMENT|Ginger|Ginger dosage at daily recommended allowance
58437389|NCT03125551|DIETARY_SUPPLEMENT|Garlic|Garlic dosage at daily recommended allowance
58437390|NCT03125551|DIETARY_SUPPLEMENT|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
57738347|NCT05061004|DEVICE|Cephea Mitral Valve System|Transcatheter mitral valve replacement
57738348|NCT02243943|DRUG|Sugammadex|
57738349|NCT02243943|DRUG|Neostigmine|
57738350|NCT00736372|DRUG|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
57738351|NCT06131866|OTHER|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
57738352|NCT06385808|DRUG|MTBF regimen|"The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2."
57955029|NCT00631748|DRUG|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
57955030|NCT00631748|DRUG|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
57955031|NCT00631748|BEHAVIORAL|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
57955032|NCT00014456|BIOLOGICAL|filgrastim|
57955033|NCT00014456|DRUG|docetaxel|
58106125|NCT00907036|BIOLOGICAL|alemtuzumab|
58310469|NCT03528941|DRUG|Lamivudine|Patients who received lamivudine to prevent hepatitis B
58310470|NCT03528941|OTHER|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
58310471|NCT05580016|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activation Receptor measurement|In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
58310472|NCT04568655|DEVICE|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
58437391|NCT03125551|DIETARY_SUPPLEMENT|Ginseng|Ginseng dosage at daily recommended allowance
58437392|NCT03125551|OTHER|Placebo|Daily dosage strategy
58437393|NCT04151134|DIAGNOSTIC_TEST|Step serial sectioning histological processing|Step serial sectioning histological processing
58437394|NCT01900652|DRUG|Emibetuzumab|Administered IV
58437395|NCT01900652|DRUG|Erlotinib|Administered Orally
58437396|NCT02975674|DEVICE|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
58437397|NCT02975674|DEVICE|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
58437398|NCT01588600|OTHER|Dietary Fiber|Fiber added to breakfast
58437399|NCT00176462|DRUG|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437400|NCT00176462|DRUG|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437401|NCT00176462|DRUG|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437402|NCT00176462|DRUG|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437403|NCT00176462|DRUG|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58106126|NCT00907036|BIOLOGICAL|donor lymphocytes|
58437404|NCT00176462|DRUG|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437405|NCT00176462|DRUG|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437406|NCT00176462|DRUG|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437407|NCT00176462|DRUG|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437408|NCT00176462|DRUG|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
58437409|NCT00176462|DRUG|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
58437410|NCT00176462|DRUG|Leucovorin|
58437411|NCT06018623|OTHER|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
58106127|NCT00907036|DRUG|cyclosporine|
58106128|NCT00907036|DRUG|fludarabine phosphate|
58106129|NCT00907036|DRUG|melphalan|
58106130|NCT00907036|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58437412|NCT03373838|OTHER|Census|Survey and interview
58437413|NCT00254670|DRUG|Naltrexone|
58437414|NCT01356446|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
58437415|NCT05397249|BEHAVIORAL|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
58437416|NCT01324362|DRUG|Placebo|Twice daily dosing
58106131|NCT02620319|DEVICE|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
58106132|NCT01586767|RADIATION|Proton radiation therapy|Daily proton radiation therapy
58106133|NCT01586767|RADIATION|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
58437417|NCT01324362|DRUG|Placebo|Twice daily dosing
58437418|NCT01324362|DRUG|FP 100mcg|Twice daily dosing
58437419|NCT01324362|DRUG|FP 250mcg|Twice daily dosing
57955034|NCT00014456|DRUG|gemcitabine hydrochloride|
57955035|NCT01234272|DRUG|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
58437420|NCT01324362|DRUG|FP 500mcg|Twice daily dosing
58437421|NCT01324362|DRUG|FSC 100/50mcg|Twice daily dosing
58437422|NCT01324362|DRUG|FSC 250/50mcg|Twice daily dosing
58437423|NCT01324362|DRUG|FSC500/50mcg|Twice daily dosing
58437424|NCT00365040|PROCEDURE|Prk with mitomycin vs Lasik|
58310473|NCT00934375|DRUG|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
58310474|NCT00934375|DRUG|placebo|
57738353|NCT05490615|BEHAVIORAL|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
58106134|NCT05363852|DIAGNOSTIC_TEST|Standard set of visual word and picture stimuli|Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
58106135|NCT00304954|DRUG|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
58106136|NCT00304954|DRUG|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
58106137|NCT00304954|OTHER|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
58106138|NCT00304954|DRUG|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
58310475|NCT05468320|DRUG|Caplacizumab|Lyophilized powder for solution for injection.
58310476|NCT05468320|DRUG|Corticosteroids|Solution for injection or Tablet
58310477|NCT05468320|BIOLOGICAL|anti-CD20 antibody|Solution for injection
58310478|NCT03470922|BIOLOGICAL|Relatlimab|Specified dose on specified day
58437425|NCT01810497|PROCEDURE|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
58106139|NCT04972136|DEVICE|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
58310479|NCT03470922|BIOLOGICAL|Nivolumab|Specified dose on specified days
58310480|NCT03891225|PROCEDURE|Amniotic Membrane implantation|Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
58310481|NCT00481663|DRUG|Sitagliptin|
58310482|NCT00481663|DRUG|Placebo to sitagliptin|
58310483|NCT00481663|DRUG|Metformin|
58437426|NCT05984485|PROCEDURE|neoadjuvant chemotherapy plus total mesorectal excision|Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
58106140|NCT04972136|DEVICE|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
58437427|NCT05984485|PROCEDURE|total mesorectal excision|Standard total mesorectal excision
58437428|NCT05345301|DIAGNOSTIC_TEST|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
58437429|NCT03062111|PROCEDURE|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
58437430|NCT03062111|PROCEDURE|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
58437431|NCT01696890|DEVICE|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
57738354|NCT06266338|DRUG|Pembrolizumab|200 mg IV q 3 weeks
58437432|NCT01696890|DEVICE|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
58437433|NCT04247295|DEVICE|Traditional Cast|Application of a traditional cast
58437434|NCT04247295|DEVICE|Woodcast|Application of a woodcast
58437435|NCT02243735|DRUG|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
58437436|NCT02243735|DRUG|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
58437437|NCT06153368|DRUG|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
58437438|NCT05842148|OTHER|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
58437439|NCT05842148|OTHER|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
58437440|NCT05842148|OTHER|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
57738355|NCT06266338|DRUG|Lenvatinib|20 mg PO daily
57738356|NCT00062127|DRUG|irinotecan hydrochloride|Given IV
57738357|NCT00062127|DRUG|thalidomide|Given orally
57738358|NCT00062127|OTHER|pharmacological study|Correlative studies
57738359|NCT06665763|OTHER|Sodium Lactate Solution|Infusion of sodium-lactate solution
57738360|NCT06665763|OTHER|Saline infusion (placebo)|NaCl solution
58106141|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
58106142|NCT05085197|DRUG|Placebo|Intravenous injection
58106143|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
58106144|NCT05085197|DRUG|Placebo|Intravenous injection
58106145|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
58106146|NCT05085197|DRUG|Placebo|Intravenous injection
58106147|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
58106148|NCT05085197|DRUG|Placebo|Intravenous injection
58106149|NCT02084979|BEHAVIORAL|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
58106150|NCT05085860|BEHAVIORAL|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
58106151|NCT05085860|BEHAVIORAL|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
58437441|NCT04887753|OTHER|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
58106152|NCT02182960|DRUG|Ibuprofen syrup|
58106153|NCT02182960|DRUG|Brufen syrup|
58106154|NCT04583488|DRUG|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
58106155|NCT04296461|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
58106156|NCT03171506|OTHER|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
58106157|NCT03171506|OTHER|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
58106158|NCT01736137|OTHER|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
58106159|NCT06121349|DRUG|ocrelizumab|infusion therapy administered every six months
58106160|NCT06121349|DRUG|ofatumumab|self-injectable every month
58106161|NCT03634631|OTHER|Focused Ultrasound|Test ultrasound in 7T MRI scanner
58106162|NCT03724916|DRUG|TAK-079|TAK-079 subcutaneous injection.
58106163|NCT03724916|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
58437442|NCT01450098|DRUG|LY2484595 Reference Formulation (RF)|Administered orally
58437443|NCT01450098|DRUG|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
58437444|NCT05332652|DEVICE|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
58437445|NCT06043908|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
58437446|NCT06043908|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
58437447|NCT00856726|DRUG|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
58437448|NCT00728091|DRUG|Satavaptan|tablets
58106164|NCT01928654|DEVICE|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
58106165|NCT01928654|DEVICE|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
58106166|NCT02492295|DRUG|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
58106167|NCT03496532|DEVICE|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
58106168|NCT03496532|DEVICE|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
58106169|NCT03496532|DEVICE|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
58106170|NCT03496532|DEVICE|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
58106171|NCT03496532|DEVICE|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
58106172|NCT01491490|DRUG|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
58106173|NCT01491490|DRUG|Placebo|Capsules taken once a day for 6 weeks
58106174|NCT01420835|OTHER|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
58106175|NCT01420835|OTHER|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
58106176|NCT02698631|PROCEDURE|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
58437449|NCT00728091|DRUG|placebo|tablets
58437450|NCT00066963|DEVICE|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
58106177|NCT02698631|PROCEDURE|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~* Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~* In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
58437451|NCT03213834|PROCEDURE|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
58106178|NCT02358954|PROCEDURE|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
58106179|NCT02358954|PROCEDURE|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
58437452|NCT03213834|PROCEDURE|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
58437453|NCT03213834|DRUG|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
58437454|NCT03213834|DRUG|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
58437455|NCT03060278|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials.
58437456|NCT03060278|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
58437457|NCT03060278|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
58437458|NCT03060278|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
58437459|NCT05813002|OTHER|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
58437460|NCT05813002|OTHER|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
58437461|NCT05813002|OTHER|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
58437462|NCT05350852|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
58437463|NCT05844358|DEVICE|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
58437464|NCT05813704|DEVICE|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
58437465|NCT04046224|BIOLOGICAL|ST-920|Single dose of investigational product ST-920
58437466|NCT04767503|DRUG|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
58437467|NCT04767503|DRUG|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
58437468|NCT02105038|OTHER|Spinner knob|
58437469|NCT02105038|OTHER|No Knob|
58106180|NCT02358954|PROCEDURE|3D Turntable|
58437470|NCT06455501|PROCEDURE|Ventral mesh rectopexy|Ventral mesh rectopexy is performed with a superficial peritoneal incision from the right side of the sacral promontory, extended over the right outer border of the mesorectum, towards the deepest part of pouch of Douglas, sparing the right hypogastric nerve. In women, the vagina is retracted anteriorly and a dissection of the rectovaginal septum is performed down to the pelvic floor. A strip of mesh is attached to the ventral part of distal rectum and then fixed upon the sacral promontory.
58437471|NCT01635855|DEVICE|Belotero®|Hyaluronic acid dermal filler
58437472|NCT03929640|DRUG|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
58437473|NCT03929640|DRUG|Placebo|Placebo oral tablet every 6 hours
58437474|NCT03929640|DRUG|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
58437475|NCT06315946|DEVICE|Pixie® skin tag|The skin tag is treated by treatment with the cryogenic device. To protect the surrounding skin, a protective foam plaster is applied before the device is used on the skin tag. The skin tag is treated for 20 seconds after loading the device for 2 seconds.
58437476|NCT06315946|DEVICE|Wortie® Skin Tag Remover|The skin tag is treated by treatment with the cryogenic device. The frozen metal nib is applied on the skin tag for 40 seconds.
58437477|NCT02296255|BIOLOGICAL|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
58437478|NCT02967510|DRUG|Estriol|
58437479|NCT02967510|DRUG|Placebo|
58437480|NCT03402828|DRUG|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
58437481|NCT05824169|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
58437482|NCT02575170|DRUG|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
58106181|NCT02358954|PROCEDURE|Vection stimulation|
58106182|NCT00736333|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles
58106183|NCT02226939|DRUG|BILN 2061 ZW|
58106184|NCT02226939|DRUG|Placebo|
58437483|NCT02575170|DRUG|Ringer's lactate solution|200 ml of Ringer's lactate solution
58437484|NCT01708135|BEHAVIORAL|Use of smartphone app|
58106185|NCT05131490|BEHAVIORAL|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~1. Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~2. Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~3. Module 3: Current developments on gynecological cancers will be included.~4. Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~5. Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
58106186|NCT01920373|DRUG|Group A (corticosteroid injection group)|
58106187|NCT01920373|BIOLOGICAL|Group B (platelet rich plasma injection group)|
58106188|NCT05837598|BEHAVIORAL|Virtual Cancer and Mental Health Tumor Board|The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
58106189|NCT02044276|DRUG|lipegfilgrastim|6 mg
58106190|NCT02044276|DRUG|pegfilgrastim|6 mg
58106191|NCT00004328|DRUG|enalapril|
58437485|NCT01037738|PROCEDURE|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
58106192|NCT00004328|DRUG|polystyrene sulfonate|
58437486|NCT04573608|DRUG|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
58437487|NCT04573608|DRUG|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
57955036|NCT01234272|DRUG|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
58437488|NCT05383456|DIAGNOSTIC_TEST|Diagnostic Test|Standard diagnostic tests.
58437489|NCT05383456|DRUG|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
57955037|NCT04704232|DRUG|ACD440|Double blind, parallel within subject comparison
57955038|NCT04704232|DRUG|PLAC|Double blind, parallel within subject comparison
58106193|NCT03351127|RADIATION|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
58106194|NCT04106466|DEVICE|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
58106195|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
58106196|NCT00124566|DRUG|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
58106197|NCT00124566|DRUG|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m\^2 per day, once every 3 weeks.
58106198|NCT00124566|DRUG|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
58106199|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
58106200|NCT06189352|OTHER|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
58106201|NCT04063618|PROCEDURE|Osteopathic Manipulative Therapy|The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.
58106202|NCT04063618|PROCEDURE|Standard of Care Concussion Treatment|Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
58106203|NCT02530879|DRUG|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
57955039|NCT01156584|BIOLOGICAL|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
58106204|NCT02530879|BEHAVIORAL|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
58106205|NCT02530879|OTHER|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
58106206|NCT05153291|PROCEDURE|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
58106207|NCT05153291|PROCEDURE|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
58106208|NCT01986790|BEHAVIORAL|Plain Language|
58106209|NCT01986790|BEHAVIORAL|Plain Language + Visuals|
58106210|NCT01986790|BEHAVIORAL|Plain Language + Narratives|
58106211|NCT06334978|OTHER|Osteopathic intervention|The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
58106212|NCT06496594|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
58106213|NCT06496594|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
58106214|NCT03833037|OTHER|Soft tissue sarcomas in adults|Adult sinovial sarcoma
57955040|NCT01156584|DRUG|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
57955041|NCT00336973|DRUG|efalizumab|Subcutaneous repeating dose
58106215|NCT05512715|PROCEDURE|radioactive iodine|radioactive iodine 15mci
58106216|NCT05020054|DEVICE|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
58106217|NCT05020054|DEVICE|placebo tecartherapy|tecartherapy with equipment turned off
58106218|NCT00305110|DRUG|2 mg IV hydromorphone|
58106219|NCT01796431|DRUG|Eviplera®|
58106220|NCT01236053|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
58106221|NCT06217952|DRUG|SPL84|SPL84 solution for nebulization
58106222|NCT06217952|OTHER|Placebo|Placebo solution for nebulization
58106223|NCT04349176|DRUG|Dose|Randomized to either 100U or 155U
58106224|NCT02693600|PROCEDURE|Ligamentoplasty with partial trapeziectomy|
58106225|NCT02693600|PROCEDURE|Ligamentoplasty with total trapeziectomy|
58106226|NCT00522327|OTHER|remote simultaneous medical interpreting|remote simultaneous medical interpretation
58106227|NCT00522327|OTHER|usual and customary|usual and customary interpreting
58437490|NCT02461940|BEHAVIORAL|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
58106228|NCT00522327|OTHER|ENglish speaking|English speakers
58106229|NCT00722111|DEVICE|lingual press|lingual press (high-intensity, oral, non-swallowing)
58106230|NCT00722111|BEHAVIORAL|effortful swallowing|effortful swallowing (high-intensity swallowing)
58106231|NCT00722111|BEHAVIORAL|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
58106232|NCT00722111|BEHAVIORAL|non-oral sham (control) exercise|non-oral sham (control) exercise
58106233|NCT03367286|OTHER|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
58106234|NCT01480908|PROCEDURE|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
58437491|NCT04282525|OTHER|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
58437492|NCT04436172|PROCEDURE|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
58437493|NCT03749772|BEHAVIORAL|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
58437494|NCT00465023|PROCEDURE|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
58437495|NCT02057159|BIOLOGICAL|NeuroVax|TCR peptides in IFA
58437496|NCT02057159|BIOLOGICAL|IFA Placebo|IFA Placebo
58106235|NCT01480908|PROCEDURE|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
58437497|NCT05526287|OTHER|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
58437498|NCT05526287|OTHER|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
58437499|NCT01206582|BIOLOGICAL|Hemin|10 iv infusions for 8 weeks
58437500|NCT01206582|BIOLOGICAL|Albumin|10 iv infusions for 8 weeks
58437501|NCT02088021|DEVICE|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
58437502|NCT02474407|DRUG|diazepam nasal spray|
58437503|NCT02474407|DRUG|diazepam rectal gel|
58437504|NCT00269854|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
58437505|NCT00269854|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
58106236|NCT01480908|PROCEDURE|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
58437506|NCT00269854|DRUG|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
58106237|NCT01480908|PROCEDURE|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
58106238|NCT03829449|DRUG|rVA576 (Coversin)|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
58106239|NCT02657083|DEVICE|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
58437507|NCT00269854|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
58106240|NCT02657083|DEVICE|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
58106241|NCT00158327|BEHAVIORAL|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
58106242|NCT00158327|BEHAVIORAL|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
58437508|NCT00902460|DRUG|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
58437509|NCT00902460|DRUG|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
58106243|NCT03352817|OTHER|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
58106244|NCT02881073|OTHER|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
58437510|NCT04957121|OTHER|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
58437511|NCT04957121|OTHER|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
58437512|NCT06010446|OTHER|No intervention, just retrospective analysis of data.|
58437513|NCT00564213|DRUG|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
58437514|NCT04891354|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
58437515|NCT04891354|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
58437516|NCT06584526|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).
58106245|NCT06416137|DIAGNOSTIC_TEST|Neuropsychological tests|Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
58106246|NCT04740112|OTHER|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
58437517|NCT06584526|OTHER|Physical Therapy and Aerobic Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
58437518|NCT06584526|OTHER|Physical Therapy and Strength Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
58437519|NCT04302233|OTHER|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
58437520|NCT05748457|BEHAVIORAL|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
58437521|NCT05748457|BEHAVIORAL|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015)."
58437522|NCT06464562|BEHAVIORAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|An adapted dialectical behavioral therapy skills training intervention
58437523|NCT01658761|PROCEDURE|vitrectomy|Surgery
58437524|NCT01873625|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
58437525|NCT01873625|BIOLOGICAL|placebo|
58437526|NCT01970267|PROCEDURE|Laser Ablation of Floaters|
58437527|NCT01970267|PROCEDURE|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
58437528|NCT03227666|BEHAVIORAL|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
58437529|NCT04045379|PROCEDURE|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
58437530|NCT04045379|PROCEDURE|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
58437531|NCT04045379|DRUG|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
58437532|NCT00887926|BIOLOGICAL|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
58437533|NCT00206336|DRUG|Topiramate (drug)|Topiramate 25 mg to 200 mg
58437534|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
58437535|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
58437536|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
58437537|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
58437538|NCT04357808|DRUG|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
57738361|NCT01260220|PROCEDURE|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
57738362|NCT01260220|PROCEDURE|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
57738363|NCT06097468|DRUG|NisinZ® P|NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
57738364|NCT06097468|PROCEDURE|Surgery (non-interventional, standard of care)|Surgical removal of tumor as part of standard of care treatment
57738365|NCT04010994|PROCEDURE|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
57738366|NCT00456638|DRUG|Depodur|Depodur vs. traditional management
57738367|NCT05428735|PROCEDURE|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
57738368|NCT02978027|BEHAVIORAL|Brief Advice|
57738369|NCT02978027|BEHAVIORAL|NIAAA Clinician's Guide|
57738370|NCT02978027|BEHAVIORAL|Motivational Interviewing (MI)|
57738371|NCT05615792|OTHER|No intervention|No intervention
57738372|NCT04608370|BEHAVIORAL|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
58437539|NCT04357808|OTHER|Standar of care|Usual clinical care
58310484|NCT00481663|DRUG|Rescue|Patients whose FPG \>240 mg/dL from Week 16 or HbA1C \>8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently \>240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C \>8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C \>7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
58437540|NCT00765570|RADIATION|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
58437541|NCT00765570|RADIATION|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
58437542|NCT00765570|RADIATION|Standard radiation|15 Standard radiation treatments
58437543|NCT00765570|RADIATION|Standard radiation|standard radiation treatment
58437544|NCT00179946|PROCEDURE|HLA typing|
58437545|NCT01157026|DIETARY_SUPPLEMENT|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
58437546|NCT01157026|OTHER|placebo plus tamoxifen|20mg tamoxifen daily
58437547|NCT00612196|DRUG|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
58437548|NCT00612196|DRUG|Placebo|
58437549|NCT06030167|BEHAVIORAL|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
58437550|NCT02612922|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
58437551|NCT02612922|DRUG|Placebo|Placebo administered orally twice daily for five days
58106247|NCT03075657|DRUG|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
58106248|NCT03075657|DRUG|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
58106249|NCT03075657|DRUG|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
58106250|NCT03075657|DRUG|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
58106251|NCT06085482|DRUG|LY3502970|Administered orally
58437552|NCT03406338|PROCEDURE|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
58437553|NCT03406338|DRUG|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
58106252|NCT06085482|DRUG|[14C]-LY3502970|Administered IV
58106253|NCT02981602|DRUG|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
58106254|NCT02981602|DRUG|Placebo|Placebo
58106255|NCT01089049|DIETARY_SUPPLEMENT|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
58106256|NCT03621020|DIAGNOSTIC_TEST|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
58106257|NCT03621020|DIAGNOSTIC_TEST|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
58106258|NCT00773981|PROCEDURE|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
58437554|NCT03576859|OTHER|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
58437555|NCT04988750|DEVICE|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
58437556|NCT02638168|DRUG|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
58437557|NCT02638168|DRUG|Placebo|inert placebo ingredient
58437558|NCT03004235|DEVICE|Observational data collection|Observational data collection
58437559|NCT06438055|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
58437560|NCT01561742|DRUG|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
58437561|NCT01561742|DRUG|Placebo|EquivalentPlacebo will be given
58437562|NCT00652951|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
58310485|NCT04866576|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
58437563|NCT00652951|BIOLOGICAL|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
58437564|NCT00652951|BIOLOGICAL|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
58437565|NCT00652951|BIOLOGICAL|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
58437566|NCT06490042|BEHAVIORAL|Questionnaire|A questionnaire about helmet use and attitude towards helmet use.
58437567|NCT00219505|PROCEDURE|acupuncture|
58437568|NCT00117039|DRUG|Aranesp®|
58437569|NCT01629758|BIOLOGICAL|Denenicokin|
58437570|NCT01629758|BIOLOGICAL|Nivolumab|
58437571|NCT00661817|BEHAVIORAL|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
58437572|NCT00661817|BEHAVIORAL|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
58437573|NCT00580385|OTHER|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
58437574|NCT01969435|DRUG|Carmustine|
58310486|NCT04866576|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
58310487|NCT06115460|DRUG|oral sitagliptin supplementation|oral sitagliptin supplementation for three months
58310488|NCT02262117|OTHER|standard care|No specific medical care
58310489|NCT02262117|DRUG|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
58310490|NCT03183817|BEHAVIORAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform
58310491|NCT04694469|PROCEDURE|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
58310492|NCT05291507|DEVICE|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
58310493|NCT05354297|DEVICE|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
58310494|NCT05354297|DEVICE|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
58310495|NCT05354297|DEVICE|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
58310496|NCT05354297|DEVICE|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
58437575|NCT01969435|DRUG|Etoposide phosphate|
58437576|NCT01969435|DRUG|Cytarabine|
58437577|NCT01969435|DRUG|Melphalan HCl (propylene glycol-free)|
58437578|NCT03165916|DEVICE|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
58437579|NCT00258791|DRUG|Ibuprofen|
58437580|NCT04326582|OTHER|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
58437581|NCT03161106|DIETARY_SUPPLEMENT|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
58437582|NCT03161106|DRUG|Lactulose|Lactulose plus diet consumed by patient
58437583|NCT03161106|DIETARY_SUPPLEMENT|Diet|Protein Powder 15 to 20 gm/meal/day
58437584|NCT00851461|DRUG|Goserelin|Goserelin 10.8 mg SC every 3 months
58437585|NCT00851461|PROCEDURE|Electrophysiologic study|Nerve conduction study Electromyogram
58437586|NCT00851461|PROCEDURE|tissue biopsy|skin and muscle biopsy before and after treatment every year
58437587|NCT00006133|DRUG|estradiol|
58437588|NCT00006133|DRUG|ethinyl estradiol|
58437589|NCT00006133|DRUG|medroxyprogesterone|
58437590|NCT00006133|DRUG|norethindrone|
58437591|NCT06058325|OTHER|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
58437592|NCT00416325|DIETARY_SUPPLEMENT|lycopene|
58437593|NCT00416325|OTHER|laboratory biomarker analysis|
58437594|NCT04269876|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
57738373|NCT04608370|BEHAVIORAL|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
57738374|NCT05428566|DIETARY_SUPPLEMENT|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
57738375|NCT05428566|DIETARY_SUPPLEMENT|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
57738376|NCT04003116|DRUG|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
58437595|NCT04269876|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
58106259|NCT01886170|OTHER|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
58437596|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
58437597|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
58437598|NCT02276443|DRUG|Chemotherapy|Receive standard chemotherapy
58106260|NCT04455594|DRUG|Almonertinib|Oral, 110mg QD
58106261|NCT04455594|DRUG|Erlotinib|Oral, 150mg QD
58106262|NCT04455594|DRUG|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
58106263|NCT04455594|DRUG|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
58310497|NCT03261193|DRUG|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
58310498|NCT03261193|DRUG|ITM + Bupivacaine QLB|QL plane block with local anesthesia
58437599|NCT02276443|OTHER|Immunotherapy|Receive standard immunotherapy
58437600|NCT02276443|OTHER|Laboratory Biomarker Analysis|Correlative studies
58437601|NCT02276443|PROCEDURE|Lymph Node Biopsy|Undergo baseline lymph node evaluation
58437602|NCT02276443|PROCEDURE|Ultrasonography|Undergo standard ultrasound
58437603|NCT03587441|DRUG|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
58437604|NCT03587441|DRUG|Dextrose 5% in water|intrathecal
58437605|NCT01359202|BIOLOGICAL|rfVIIa|80ug/kg IV bolus
58437606|NCT01359202|OTHER|Standard saline solution|Saline
58437607|NCT02120391|OTHER|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
58437608|NCT01112748|DRUG|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
58437609|NCT01578122|DEVICE|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
58106264|NCT04455594|DRUG|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
58106265|NCT02411656|OTHER|Laboratory Biomarker Analysis|Correlative studies
58106266|NCT02411656|BIOLOGICAL|Pembrolizumab|Given IV
58106267|NCT02194166|DRUG|Trastuzumab|Trastuzumab IV or SC will be administered as described.
58106268|NCT02194166|DRUG|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
58106269|NCT02194166|DRUG|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
58106270|NCT02740933|DRUG|Demeclocycline|
58310499|NCT04896463|RADIATION|Abdominal ultrasound (US)|abdominal examination with US device
58310500|NCT02410629|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
58310501|NCT02410629|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
58310502|NCT00944554|DRUG|Varenicline|Varenicline given twice a day or five weeks.
58310503|NCT00944554|DRUG|Placebo|Placebo given twice a day or five weeks.
58310504|NCT03966066|DRUG|erythromycin|3-5mg/kg.d orally for 6 months
58310505|NCT00764114|DRUG|antibiotic|6 or 12 weeks
58310506|NCT00266318|DRUG|Interferon Alfacon-1 and Ribavirin|
58310507|NCT01299584|DRUG|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
58310508|NCT00880841|DRUG|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
58310509|NCT03797352|OTHER|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
58310510|NCT03695081|PROCEDURE|Patient Pathway Pharmacist intervention|"1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge"
58310511|NCT02117518|OTHER|blood drawing|
58310512|NCT00112749|BIOLOGICAL|infliximab|A single infusion of 1mg/kg will be administered.
58106271|NCT00580333|DRUG|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
58437610|NCT01578122|DEVICE|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
58437611|NCT00470925|DRUG|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
58437612|NCT04177212|DEVICE|MRZF111|MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
58437613|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
58437614|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
58437615|NCT03238625|DRUG|Lidocaine|Lidocaine injection
58437616|NCT03238625|DRUG|Sodium cloride 0.9%|Placebo
58437617|NCT01574651|DRUG|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
58437618|NCT01574651|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
58437619|NCT01574651|DRUG|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
58437620|NCT01574651|DRUG|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
58106272|NCT00580333|DRUG|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
58106273|NCT00580333|DRUG|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
58437621|NCT01574651|DRUG|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
58437622|NCT01574651|DRUG|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
58437623|NCT00970229|DRUG|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
58106274|NCT00580333|DRUG|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
58106275|NCT00580333|DRUG|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
58106276|NCT01292460|DRUG|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
58106277|NCT00002484|RADIATION|radiation therapy|
58106278|NCT03376984|COMBINATION_PRODUCT|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
58106279|NCT03376984|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
58106280|NCT03997331|OTHER|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
58437624|NCT06479941|OTHER|antibiotic treatment|AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
58437625|NCT04467281|DRUG|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
58437626|NCT04467281|DIAGNOSTIC_TEST|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
58437627|NCT01834352|DRUG|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
58437628|NCT01834352|DRUG|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
58437629|NCT00126360|DRUG|Timing of Anastrozole in respect to radiotherapy|
58437630|NCT02106520|DRUG|Bevacizumab|
58437631|NCT02106520|DRUG|placebo|
58437632|NCT03878680|OTHER|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis."
58437633|NCT00315016|DRUG|eplerenone|active comparator
58106281|NCT03997331|OTHER|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
58106282|NCT03012815|DRUG|Gabapentin|Gabapentin administered as a taper
58106283|NCT03012815|DRUG|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
58437634|NCT00315016|DRUG|fosinopril|doubling of fosinopril dose
58437635|NCT00315016|DRUG|placebo|placebo (double dummy)
58437636|NCT01478308|DRUG|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
58437637|NCT01478308|DRUG|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
58437638|NCT01478308|DRUG|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
58437639|NCT02373774|DEVICE|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
58437640|NCT01053039|DRUG|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
58106284|NCT03012815|DRUG|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
58310513|NCT00112749|OTHER|Clinical Assessment|Medical, psychiatric, and immune evaluation.
58310514|NCT00112749|OTHER|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
58437641|NCT01053039|DRUG|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
58437642|NCT04958174|DEVICE|web-application|web application for monitoring children's development
58437643|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1|packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
58437644|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
58437645|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
58437646|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
58437647|NCT02355210|DIETARY_SUPPLEMENT|galactooligosaccharide|5 g galactooligosaccharide
58437648|NCT02355210|DIETARY_SUPPLEMENT|Placebo|lactose powder, 5 grams
58437649|NCT02639520|DRUG|Canephron® N|2 tablets 3 times a day for 7 days
58437650|NCT02639520|DRUG|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
58437651|NCT02639520|DRUG|Canephron® N-placebo|2 tablets 3 times a day for 7 days
58437652|NCT02639520|DRUG|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
58437653|NCT05013203|DIAGNOSTIC_TEST|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
58437654|NCT05013203|DIAGNOSTIC_TEST|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
58310515|NCT00112749|OTHER|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
58310516|NCT00128128|DRUG|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
58310517|NCT02033512|DRUG|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
58437655|NCT05465291|PROCEDURE|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
58437656|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation group|"* Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
58437657|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
58437658|NCT05660317|OTHER|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
58437659|NCT06245668|DEVICE|SaCoVLM™ video laryngeal mask|The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
58437660|NCT06245668|DEVICE|LMA Supreme|The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
58437661|NCT05677009|DEVICE|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
58437662|NCT05677009|OTHER|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
58437663|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
58437664|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
58437665|NCT02652260|DRUG|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
58437666|NCT02652260|DRUG|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
58437667|NCT02652260|DRUG|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
58437668|NCT03368846|DRUG|Varlitinib|\[14C\]-Varlitinib
58437669|NCT03117478|OTHER|Magneto-encephalography (MEG)|Magneto-encephalography
58437670|NCT03117478|OTHER|Electro-encephalography (EEG)|Electro-encephalography
58437671|NCT03117478|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
58437672|NCT03117478|OTHER|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
58437673|NCT03117478|OTHER|Meditation|Meditation
58437674|NCT00774800|DRUG|Humalog|
58437675|NCT00774800|DRUG|Humulin-R|
58437676|NCT00774800|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
58437677|NCT00774800|OTHER|Liquid meal|
58106285|NCT05084534|DRUG|Midodrine|"Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)"
58106286|NCT05084534|OTHER|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
58106287|NCT00769678|DEVICE|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
58437678|NCT03430232|DRUG|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
58437679|NCT03430232|DRUG|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
58437680|NCT03430232|DRUG|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
58437681|NCT03430232|DRUG|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
58437682|NCT03430232|DRUG|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
58437683|NCT03430232|DRUG|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
58437684|NCT03430232|DRUG|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
58437685|NCT03430232|DRUG|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
58437686|NCT03430232|DRUG|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
58437687|NCT03430232|DRUG|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
58437688|NCT03430232|DRUG|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
58437689|NCT03430232|DRUG|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
58437690|NCT03430232|DRUG|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
58437691|NCT00174369|DRUG|PD-0325901|15 mg BID
58106288|NCT05368233|OTHER|ERAS protocol|ERAS protocol whch helps to optimise the length of hospital stay.
58106289|NCT03639961|BEHAVIORAL|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
58106290|NCT03639961|BEHAVIORAL|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
58106291|NCT01352559|DRUG|responders|Antidepressants administration for 6 weeks under therapeutic dose
58437692|NCT05307042|DIAGNOSTIC_TEST|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
58437693|NCT01447953|OTHER|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
58437694|NCT01447953|OTHER|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
58437695|NCT03151330|OTHER|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
58437696|NCT06525896|DEVICE|NSSD|A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
58437697|NCT06525896|DEVICE|Sham NSSD|A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
58437698|NCT02965430|DEVICE|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
58437699|NCT01603485|DRUG|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
58437700|NCT01603485|DRUG|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
58437701|NCT01603485|DRUG|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
58437702|NCT01603485|DRUG|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
58437703|NCT01603485|DRUG|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
58437704|NCT03494582|PROCEDURE|Sacral Hysteropexy|Abdominal approach for uterine suspension
58437705|NCT03494582|PROCEDURE|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
58437706|NCT05297188|DEVICE|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
58437707|NCT00915707|OTHER|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
58437708|NCT00915707|OTHER|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
58437709|NCT00915707|OTHER|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
58437710|NCT03662594|OTHER|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
58437711|NCT03878784|DRUG|Imigran|All patients will undergo this intervention on one of two study days
58437712|NCT03878784|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
58437713|NCT00612560|DRUG|Anastrozole|1 mg per day
58437714|NCT00612560|DIETARY_SUPPLEMENT|flaxseed|25 g per day ground
58437715|NCT00612560|DRUG|Placebo|Placebo pill 1 per day
58437716|NCT06010511|OTHER|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
58437717|NCT06010511|OTHER|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
58437718|NCT06010511|BEHAVIORAL|Neuropsychological assessment|"* Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly"
58437719|NCT06010511|OTHER|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
58437720|NCT06351059|DIAGNOSTIC_TEST|InModi acoustic emission analysis|All diagnosis tests
58437721|NCT04256681|OTHER|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
58437722|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
58106292|NCT01352559|DRUG|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
58106293|NCT00002777|DRUG|exemestane|
58106294|NCT00002777|DRUG|tamoxifen citrate|
58106295|NCT01235858|PROCEDURE|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
58106296|NCT01235858|PROCEDURE|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
58106297|NCT05014425|PROCEDURE|pancreaticoduodenectomy|
58106298|NCT02272582|DEVICE|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
58437723|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
58437724|NCT03860805|PROCEDURE|Laparoscopic tubal ligation|Laparoscopic tubal ligation
58437725|NCT03860805|PROCEDURE|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
58437726|NCT00328458|DRUG|EPO906 (epothilone B)|
58437727|NCT00896025|DRUG|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
58437728|NCT05942443|PROCEDURE|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
58437729|NCT05942443|PROCEDURE|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
58437730|NCT00467129|GENETIC|microarray analysis|
58437731|NCT00467129|GENETIC|mutation analysis|
58437732|NCT00467129|GENETIC|polymerase chain reaction|
58437733|NCT00467129|GENETIC|polymorphism analysis|
58437734|NCT00467129|OTHER|laboratory biomarker analysis|
58437735|NCT00467129|OTHER|questionnaire administration|
58106299|NCT02272582|OTHER|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
58437736|NCT02813161|BIOLOGICAL|cellular and tissue based therapy|
58437737|NCT02813161|DEVICE|negative pressure wound therapy|
58437738|NCT02813161|PROCEDURE|debridement|
58437739|NCT02813161|PROCEDURE|advanced wound therapy|
58437740|NCT02813161|DIETARY_SUPPLEMENT|Nutritional screening|
58437741|NCT02813161|DEVICE|off-loading|
58437742|NCT02813161|DEVICE|Hyperbaric oxygen Therapy|
58437743|NCT00475904|DRUG|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
58437744|NCT00475904|DRUG|Gabapentin Capsules|1800mg/day capsules for 4 weeks
58437745|NCT00475904|DRUG|placebo|placebo cream and caps
58437746|NCT05015270|DIAGNOSTIC_TEST|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
58437747|NCT03161080|DEVICE|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
58437748|NCT03161080|DEVICE|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
58437749|NCT03161080|DEVICE|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
58437750|NCT01181869|DEVICE|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
58437751|NCT01609881|DRUG|Acuvail|Dosing of drug 3 days prior to surgery
58437752|NCT01609881|OTHER|Placebo|Artificial tears qid for 3 days preoperatively
58437753|NCT04480658|DRUG|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
58106300|NCT01073683|PROCEDURE|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
58106301|NCT01073683|DRUG|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
58106302|NCT04188769|DEVICE|constant deep pressure applied by an air splint|inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
58437754|NCT05678257|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
58437755|NCT05678257|DRUG|Leucovorin|Intravenous infusion
58106303|NCT04188769|DEVICE|intermittent deep pressure applied by an air splint|continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
58106304|NCT04188769|DEVICE|uninflated air splint|no deep pressure applied by the air splint
58106305|NCT04188769|OTHER|contralateral movement|non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
58106306|NCT00311571|DRUG|Ethidronate|
58106307|NCT00311571|BEHAVIORAL|Physical training|
58106308|NCT05787977|OTHER|Visual Feedback and Rhythmic Auditory Cue|Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
58106309|NCT02954120|OTHER|no intervention provided|
58106310|NCT03221439|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
58106311|NCT03221439|OTHER|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
58437756|NCT05678257|DRUG|Irinotecan|Intravenous infusion
58437757|NCT05678257|BIOLOGICAL|Bevacizumab|Intravenous infusion
58106312|NCT02997956|DRUG|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
58106313|NCT02997956|PROCEDURE|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
58106314|NCT00766506|DEVICE|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
58106315|NCT00766506|DEVICE|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
58106316|NCT05578417|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
58437758|NCT05678257|DRUG|5-FU|Intravenous infusion
58106317|NCT05057234|DIAGNOSTIC_TEST|FoundationOne liquid CDx|FoundationOne liquid CDx testing
58106318|NCT05057234|BEHAVIORAL|Quality of life questionnaires|Quality of life questionnaire - EQ5D
58106319|NCT03230968|BEHAVIORAL|Integral Action Program for Respiration|
58106320|NCT04663269|DRUG|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
58437759|NCT02503150|BIOLOGICAL|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
58106321|NCT04663269|DRUG|Control Test|Peritubal block - standard local analgesic administration
58106322|NCT02717338|BEHAVIORAL|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
58437760|NCT02503150|DRUG|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
58106323|NCT02717338|BEHAVIORAL|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
58106324|NCT02717338|BEHAVIORAL|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
58106325|NCT06542549|DRUG|AK104|The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
58106326|NCT00676026|DRUG|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
58106327|NCT00676026|DRUG|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
58106328|NCT00676026|DRUG|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
58106329|NCT01571635|DRUG|SOTATERCEPT (ACE-011)|0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
58106330|NCT02964052|OTHER|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
58310518|NCT02033512|DRUG|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
58310519|NCT02033512|DRUG|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
58310520|NCT02653820|OTHER|Reflexology|
58310521|NCT01781897|DEVICE|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
58310522|NCT01781897|DRUG|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
58310523|NCT00322322|DRUG|L-Carnitine|L-Carnitine
58310524|NCT01277029|OTHER|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
58310525|NCT05971589|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
58310526|NCT05816941|PROCEDURE|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
58310527|NCT05816941|PROCEDURE|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
58310528|NCT01014234|DRUG|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
58310529|NCT01014234|DRUG|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
58310530|NCT01356420|DIETARY_SUPPLEMENT|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
58310531|NCT02308046|DRUG|Terconazole|
58310532|NCT02308046|DRUG|Placebo|
58437761|NCT04543292|DEVICE|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
58437762|NCT04152408|DEVICE|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
58437763|NCT01061502|DEVICE|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
58437764|NCT01061502|DEVICE|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
58310533|NCT03130413|DEVICE|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
58310534|NCT03130413|DEVICE|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
58310535|NCT06283017|DEVICE|Hypoglossal nerve stimulation|Device stimulation of the hypoglossal nerve
58310536|NCT03874611|OTHER|electrophysiological data from DBS|For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
58310537|NCT04186156|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
58310538|NCT01384656|DRUG|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
58310539|NCT00367926|DRUG|American ginseng root / polysaccharides|
58310540|NCT00434486|DRUG|SKI-606|
58310541|NCT03228082|DEVICE|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
58310542|NCT03359746|DRUG|Grazoprevir/Elbasvir|Medication for treatment of patient
58310543|NCT03847402|BEHAVIORAL|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
58310544|NCT03847402|BEHAVIORAL|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
58310545|NCT03847402|BEHAVIORAL|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
58310546|NCT03847402|BEHAVIORAL|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
58437765|NCT03323177|DIETARY_SUPPLEMENT|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
58106331|NCT03630588|COMBINATION_PRODUCT|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
58106332|NCT03630588|COMBINATION_PRODUCT|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
58106333|NCT05774873|DRUG|IBI334 D|Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58106334|NCT05774873|DRUG|IBI334 C|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58437766|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
58437767|NCT00256802|DEVICE|MR-angiography, GTN|
57955042|NCT06017804|OTHER|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
57955043|NCT06017804|OTHER|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
57955044|NCT00290433|DRUG|Cyclophosphamide|Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
57955045|NCT00290433|DRUG|Mesna|Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
57955046|NCT00290433|DRUG|Vincristine|Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
57955047|NCT00290433|DRUG|Methotrexate|Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
57955048|NCT00290433|DRUG|Ara-C|Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
57955049|NCT00290433|DRUG|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
57955050|NCT00290433|DRUG|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
57955051|NCT00290433|DRUG|Doxil|Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
57955052|NCT02702037|DIETARY_SUPPLEMENT|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
58437768|NCT00609570|DIETARY_SUPPLEMENT|NanoGreens|fruits and vegetables
58437769|NCT00609570|DIETARY_SUPPLEMENT|Whey protein|Whey
58437770|NCT00609570|DIETARY_SUPPLEMENT|Calcium pills|CA
58437771|NCT06244680|DEVICE|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
57955053|NCT02702037|OTHER|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
57955054|NCT05173064|DEVICE|Machine learning-based exercise training system|"The video-based exercise training system will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records."
57955055|NCT05173064|DEVICE|Video-based exercise training system|The video-based system will only include the exercise videos as those involved in the machine learning-based system. The features of real-time movement feedback and tracking of exercise progress will not be provided.
57955056|NCT00585507|DRUG|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
57955057|NCT01618942|DEVICE|pressure algometer|
57955058|NCT01109888|DRUG|Cetrotide|
57955059|NCT02731209|DEVICE|urinary catheter|
57955060|NCT02642133|PROCEDURE|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
57955061|NCT02258828|DRUG|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
57955062|NCT02258828|DRUG|Placebo|Matched placebo
58437772|NCT05545683|BIOLOGICAL|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
58437773|NCT00390039|DRUG|Intranasal Morphine|MNS075 7.5mg q1h PRN
58437774|NCT00390039|DRUG|Placebo|IN Placebo q1h PRN
58437775|NCT00390039|DRUG|IV morphine|IV morphine 7.5mg q3h PRN
58437776|NCT00390039|DRUG|Placebo|IV Placebo q3h PRN
58437777|NCT00390039|DRUG|Intranasal morphine|MNS075 15mg q3h PRN
58437778|NCT00390039|DRUG|Placebo|IN Placebo q3h PRN
58106335|NCT05774873|DRUG|IBI334 A|Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58106336|NCT05774873|DRUG|IBI334 B|Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58106337|NCT05774873|DRUG|IBI334 F|Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58106338|NCT05774873|DRUG|IBI334 E|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
58106339|NCT03100253|DRUG|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
58106340|NCT03100253|DRUG|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
58106341|NCT03100253|DRUG|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
58106342|NCT03100253|DRUG|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
58106343|NCT03100253|DRUG|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
58106344|NCT03100253|DRUG|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
58106345|NCT04324398|OTHER|Cryotherapy|cold application
58106346|NCT02783742|BEHAVIORAL|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
58106347|NCT05607810|GENETIC|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
58106348|NCT02572180|BEHAVIORAL|EMG-based biofeedback training|
58106349|NCT02572180|BEHAVIORAL|NIRS-based neurofeedback training|
58106350|NCT03677778|PROCEDURE|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
58106351|NCT03677778|OTHER|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
58106352|NCT00301431|DRUG|DVS-233|
58106353|NCT04368325|DIAGNOSTIC_TEST|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
58106354|NCT06517849|BEHAVIORAL|Monetary Incentive for Take-Up of Cognitive Behavioral Therapy|Both treatment arms will be offered a monetary incentive (in form of a retail gift card) for undergoing a certain number of CBT sessions.
58106355|NCT04331652|PROCEDURE|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
58106356|NCT00067158|DRUG|nicotine transdermal system|
58106357|NCT01406873|DRUG|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
58106358|NCT01406873|DRUG|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
58106359|NCT01050166|OTHER|Transplantation of labeled islets|
58106360|NCT00894465|DRUG|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
58106361|NCT00894465|DRUG|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
58106362|NCT00821522|PROCEDURE|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
58106363|NCT02046473|PROCEDURE|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
58106364|NCT05541601|OTHER|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
58106365|NCT05828433|OTHER|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
58106366|NCT05828433|OTHER|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
58310547|NCT03847402|BEHAVIORAL|Community intervention for GDD|community intervention based on developmental approaches
58310548|NCT03847402|BEHAVIORAL|community intervention for ADHD|School and family education
58310549|NCT03882632|DEVICE|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
58106367|NCT01826318|BEHAVIORAL|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
58106368|NCT05066087|BEHAVIORAL|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
58106369|NCT05066087|OTHER|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
58106370|NCT04737668|OTHER|Intrathecal pump refill with Virtual Reality|VR game
58106371|NCT04737668|OTHER|Intrathecal pump refill with distraction|Video
58106372|NCT04737668|OTHER|Intrathecal pump refill|daily routine care for pump refill
58106373|NCT00838500|DRUG|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
58106374|NCT00838500|DRUG|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
58106375|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|600 IU daily oral supplementation
58106376|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU supplementation bi-monthly
58437779|NCT02133092|OTHER|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
58437780|NCT02992392|DRUG|Liposic|one eye of the participant recieved Lipoic
58437781|NCT02992392|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
58437782|NCT00079573|BEHAVIORAL|Atkins diet (extremely low carbohydrate)|
58437783|NCT00079573|BEHAVIORAL|Zone diet (low carbohydrate, high protein)|
58437784|NCT00079573|BEHAVIORAL|Ornish diet (very low fat)|
58437785|NCT03179397|DEVICE|Model SC9|Experimental
58106377|NCT00358774|PROCEDURE|homeopathic nasal spray|
58106378|NCT06537882|DIETARY_SUPPLEMENT|G-NiiB synbiotics formula (SLP07)|SLP07 consists of a blend of food-grade Bifidobacterium and Lactobacillus as active probiotics, omega 3, and vitamin E.
58106379|NCT06537882|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 2mg of vitamin C with corn starch filler
58106380|NCT04812704|DIETARY_SUPPLEMENT|Whey protein|Patient receive protein supplement in liquid form after each exercice session
58106381|NCT00042042|BEHAVIORAL|Family based educational program|
58106382|NCT00349310|DRUG|Pramipexole|
58437786|NCT03179397|DEVICE|Model LI61SE|Active Comparator
58437787|NCT01110031|BIOLOGICAL|Ofatumumab|Anti-CD20 monoclonal antibody
58437788|NCT03662516|DRUG|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
58106383|NCT03900845|DEVICE|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
58437789|NCT03662516|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
58437790|NCT01732770|BIOLOGICAL|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
58437791|NCT01732770|DRUG|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
58437792|NCT01732770|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
58437793|NCT01732770|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
58437794|NCT05246709|DEVICE|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
58437795|NCT05246709|DEVICE|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
58437796|NCT03928717|BEHAVIORAL|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
58437797|NCT03928717|BEHAVIORAL|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
58437798|NCT05047952|DRUG|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
58437799|NCT05047952|DRUG|Placebo|A placebo pill will be taken once daily.
58437800|NCT05852236|OTHER|Assigned Interventions|Pressure ulcer care package application.
58437801|NCT06464445|DEVICE|Monophasic iTBS|"iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
58437802|NCT06464445|DEVICE|Biphasic iTBS|"iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
58437803|NCT06464445|DEVICE|Monophasic-Long iTBS|"iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
58437804|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
58437805|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
58437806|NCT00364091|DRUG|R89674 0.025% ophthalmic solution|
58437807|NCT00160836|DEVICE|"Tissue sampling (G.I.U.M. catheter)"|
58106384|NCT03900845|DEVICE|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (\~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
58437808|NCT03836911|OTHER|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
58437809|NCT03836911|OTHER|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
58437810|NCT00847886|DRUG|LX3305|Daily oral intake of LX3305 for 14 days.
58437811|NCT00847886|DRUG|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
58437812|NCT00847886|DRUG|Methotrexate|Once weekly stable-dose methotrexate.
58437813|NCT00583037|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
58437814|NCT03190889|OTHER|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
58437815|NCT03190889|OTHER|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
58437816|NCT03276546|BEHAVIORAL|shared decision-making tool (SHARE-D)|questionnaire
58437817|NCT01760343|BIOLOGICAL|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
58437818|NCT01760343|BIOLOGICAL|CSL830|CSL830 is a formulation of Berinert.
58437819|NCT04503720|DEVICE|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
58437820|NCT04503720|DEVICE|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
58437821|NCT01925547|DIETARY_SUPPLEMENT|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
58437822|NCT01925547|DIETARY_SUPPLEMENT|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
58437823|NCT03971448|DEVICE|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
58437824|NCT03971448|DEVICE|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
58106385|NCT03900845|DEVICE|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
58106386|NCT04822961|DRUG|Placebo|Senaparib-matched placebo capsules
58106387|NCT04822961|DRUG|Senaparib|20 mg capsules
58106388|NCT03008629|DEVICE|Podofix nail brace|Podofix nail brace
58106389|NCT03008629|DEVICE|Combiped nail brace|Combiped nail brace
58106390|NCT03008629|DEVICE|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
58106391|NCT01245595|DRUG|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
58106392|NCT01245595|DRUG|Placebo|Normal Saline
58106393|NCT00771901|DRUG|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
58106394|NCT00771901|OTHER|placebo|7 pills daily for 4 weeks
58106395|NCT00771901|DRUG|sodium phenylbutyrate|20g/day for four weeks.
58106396|NCT01198119|DEVICE|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared"
58106397|NCT01198119|PROCEDURE|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
58106398|NCT01198119|PROCEDURE|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
58106399|NCT04537325|DEVICE|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
58106400|NCT04748094|DEVICE|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
58106401|NCT04748094|OTHER|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
58106402|NCT06538974|DEVICE|Hands-free exoskeleton|During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
58106403|NCT05801354|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
58106404|NCT05801354|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
58106405|NCT04571957|OTHER|No Intervention|No Intervention
58106406|NCT02942173|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
58106407|NCT02814669|DRUG|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
58106408|NCT02814669|DRUG|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
58106409|NCT03086668|PROCEDURE|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
58106410|NCT03086668|PROCEDURE|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
58106411|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
58106412|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
57738377|NCT06145542|BEHAVIORAL|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
57738378|NCT06145542|BEHAVIORAL|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
58106413|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
58437825|NCT05587192|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
58437826|NCT00349778|DRUG|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
58310550|NCT04744623|DRUG|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
58310551|NCT03451071|DRUG|Gardasil9|Gardasil 9
58310552|NCT04556747|OTHER|VR - Distraction|Participants will be instructed to use any application.
58310553|NCT04556747|OTHER|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
58437827|NCT00349778|DRUG|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
58437828|NCT00349778|DRUG|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
58437829|NCT00349778|DRUG|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
58437830|NCT00349778|DRUG|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
58437831|NCT05159115|OTHER|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
58437832|NCT05159115|OTHER|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
58437833|NCT05451563|DEVICE|Double-S|Wearable device for intercourse
58437834|NCT03749811|DEVICE|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
58437835|NCT01145339|DRUG|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
58437836|NCT02893696|OTHER|Various sitting time|Various sitting time
58437837|NCT06572124|PROCEDURE|universal adhesive without Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive without acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
58437838|NCT06572124|PROCEDURE|universal adhesive with Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive which contains acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
58437839|NCT03520907|DRUG|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
58437840|NCT03520907|DRUG|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
58437841|NCT03511157|OTHER|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
58437842|NCT03511157|OTHER|Control Group|See Control group description
58437843|NCT03559647|DRUG|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
58437844|NCT00293995|PROCEDURE|Repair of unilateral inguinal hernia|
58437845|NCT06026878|DRUG|gemcitabine,nimotuzumab, toripalimab|same as before
58437846|NCT06026878|DRUG|gemcitabine, cisplatin|same as before
58437847|NCT00651638|DRUG|Treatment with ARQ 197|Treatment with ARQ 197
58437848|NCT02413489|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
58437849|NCT06583278|DEVICE|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
58437850|NCT02663622|DRUG|Efprezimod alfa|Acute GVHD prophylaxis
58437851|NCT02663622|DRUG|Methotrexate|Acute GVHD prophylaxis
58437852|NCT02663622|DRUG|Tacrolimus|Acute GVHD prophylaxis
58437853|NCT02663622|DRUG|Placebo|100 ml saline IV infusion.
58437854|NCT01385241|BEHAVIORAL|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
58437855|NCT06040164|OTHER|Observational study|No intervention will be performed
58437856|NCT00044473|DRUG|levofloxacin|
58106414|NCT06542848|OTHER|Physiotherapy and Rehabilitation Practices|The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
58106415|NCT04612205|DEVICE|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
58106416|NCT04612205|OTHER|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
58106417|NCT04222322|DEVICE|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
58106418|NCT04222322|OTHER|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
58106419|NCT05543070|RADIATION|Low-dose radiotherapy|Electron Beam/3D-CRT/IMRT/VMAT
58106420|NCT02926183|DRUG|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
58106421|NCT06047366|DRUG|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
58106422|NCT06047366|DRUG|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
58106423|NCT06047366|DRUG|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
58106424|NCT06047366|DRUG|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
58106425|NCT00150930|DEVICE|narrowband UVB phototherapy at home|
58106426|NCT05400837|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
58106427|NCT04938401|OTHER||
58106428|NCT03823365|BIOLOGICAL|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109"
58106429|NCT00969059|DRUG|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
57738379|NCT03774628|BIOLOGICAL|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
58106430|NCT00969059|DRUG|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
58106431|NCT00559884|DRUG|GSK189075 (Modified and immediate release formulations)|
58106432|NCT00896883|DEVICE|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
58106433|NCT03068910|DRUG|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
57738380|NCT03774628|BIOLOGICAL|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
58106434|NCT03068910|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
57738381|NCT01436058|BIOLOGICAL|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
58106435|NCT03068910|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
58106436|NCT04056507|PROCEDURE|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
58106437|NCT06020105|BEHAVIORAL|NURLIFE|After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
58106438|NCT01200394|DRUG|PF-00489791|Tablet, 20 mg once daily for 12 weeks
58106439|NCT01200394|DRUG|Placebo|Tablet, placebo once daily for 12 weeks
58106440|NCT04451382|BIOLOGICAL|OnabotulinumtoxinA (BoNTA)|
58106441|NCT04451382|PROCEDURE|Percutaneous tibial nerve stimulation (PTNS)|
58106442|NCT04661566|BEHAVIORAL|"Basic Education (Education)"|All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
58106443|NCT04661566|BEHAVIORAL|"Narrative Videos (Narratives)"|The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
58106444|NCT04661566|BEHAVIORAL|"Skills Building Videos (Skills)"|The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
58106445|NCT04661566|BEHAVIORAL|"Interactive Scenarios (Scenarios)"|The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
58106446|NCT04661566|BEHAVIORAL|"Future Life Planning Tool (Future)"|The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
58106447|NCT04661566|BEHAVIORAL|"Epidemiological Risk Scenario (Risk)"|The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
58106448|NCT02816554|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
58106449|NCT02816554|BIOLOGICAL|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
58106450|NCT02816554|BIOLOGICAL|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
58106451|NCT02816554|BIOLOGICAL|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
58106452|NCT02626182|DRUG|sildenafil|active sildenafil
58106453|NCT02626182|DRUG|placebo|sugar pill that looks like sildenafil tablets
58106454|NCT05478005|PROCEDURE|Femoral nerve block|Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
57738382|NCT05624658|COMBINATION_PRODUCT|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
57738383|NCT00563108|DRUG|Basiliximab|
57738384|NCT00563108|DRUG|Placebo|
57738385|NCT01452750|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
58106455|NCT05478005|PROCEDURE|Intra-articular block|Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
58310554|NCT00776256|DIETARY_SUPPLEMENT|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
57738386|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
57738387|NCT01452750|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
57738388|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
57738389|NCT01452750|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
58106456|NCT03318328|OTHER|survey|
58106457|NCT04126733|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
58106458|NCT04126733|BIOLOGICAL|Nivolumab (Opdivo)|Administered on day 1 of every treatment cycle.
58310555|NCT02645890|DRUG|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
58310556|NCT02645890|DRUG|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
57738390|NCT01452750|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
57738391|NCT04788758|OTHER|Educational Intervention|Receive G8 screening tool administration training
57738392|NCT04788758|OTHER|Screening Questionnaire Administration|Complete G8 screening tool
57738393|NCT04788758|OTHER|Referral|Receive referral
58106459|NCT03360526|DEVICE|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
58106460|NCT03360526|PROCEDURE|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
58106461|NCT02957682|DRUG|Praluent (Alirocumab)|
58106462|NCT02957682|DRUG|Placebo|
58106463|NCT00127764|DRUG|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
58106464|NCT01218737|DRUG|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
58106465|NCT01218737|DRUG|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
58106466|NCT02516631|DRUG|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
58106467|NCT02516631|DRUG|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
58106468|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
58106469|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
58106470|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
58106471|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
58106472|NCT01440595|DRUG|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
58106473|NCT01440595|DRUG|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
58106474|NCT01440595|DRUG|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
58310557|NCT03310567|DRUG|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
58310558|NCT01924598|DEVICE|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
58437857|NCT06361017|PROCEDURE|endovascular thrombectomy|All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
58437858|NCT00407303|DRUG|Obatoclax mesylate|30 mg, 45 mg
58437859|NCT00407303|DRUG|Bortezomib|1.0mg/m2, 1.3 mg/m2
57738394|NCT04788758|OTHER|Questionnaire Administration|Ancillary studies
57738395|NCT05121753|DIETARY_SUPPLEMENT|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
57738396|NCT02265042|DEVICE|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
57738397|NCT00937924|DRUG|Meperidine, Midazolam|
58106475|NCT01440595|DRUG|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
58106476|NCT03451331|DRUG|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
58106477|NCT03451331|DRUG|Gemcitabine|1000 mg/m\^2
58106478|NCT03451331|DRUG|Carboplatin|AUC 4.5 (based on the Calvert formula)
58106479|NCT03451331|DRUG|Oxaliplatin|130 mg/m\^2
58106480|NCT04608149|DEVICE|Carpediem System|Continuous renal replacement therapy
58106481|NCT00166374|PROCEDURE|balloon kyphoplasty|
58106482|NCT00032370|PROCEDURE|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
58106483|NCT00032370|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
58106484|NCT00032370|PROCEDURE|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
58106485|NCT03705884|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
58106486|NCT03705884|DRUG|Prednisolone|Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
58106487|NCT06156228|BEHAVIORAL|Multilevel Intervention|Clinic patients from the randomly assigned intervention clinics will be provided with additional vaccine information and will have the opportunity to ask any questions they might have about any of the 4 study focused vaccines (COVID-19, Shingles, Pneumococcal, Influenza). Health educators will provide them with additional information, address any misinformation and disinformation and will offer to schedule their vaccine appointment(s) for them.
58310559|NCT00114985|DEVICE|Prostate Immobilization Device|Device placed during radiation treatment
58310560|NCT03779555|OTHER|Medication Event Monitoring System|-Microchipped bottle cap
58106488|NCT01559831|BIOLOGICAL|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
57738398|NCT00937924|DRUG|Diphenhydramine|
58106489|NCT05288673|DRUG|ALXN1210|ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
58106490|NCT05288673|DRUG|Placebo|Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
58106491|NCT02601911|DRUG|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
58106492|NCT02601911|DRUG|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
58437860|NCT03203083|OTHER|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
58437861|NCT01773187|DRUG|Pacritinib|
58437862|NCT01773187|DRUG|Best Available Therapy|
58437863|NCT01357551|BEHAVIORAL|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
58437864|NCT04489082|DEVICE|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
58310561|NCT03347591|GENETIC|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
58310562|NCT03347591|DIAGNOSTIC_TEST|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
58310563|NCT03332342|OTHER|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
58310564|NCT03332615|BEHAVIORAL|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
58310565|NCT03332615|BEHAVIORAL|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
57738399|NCT00937924|DRUG|Promethazine|
57738400|NCT01435538|BEHAVIORAL|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
57738401|NCT04067466|DIETARY_SUPPLEMENT|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
58106493|NCT02601911|OTHER|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
58106494|NCT03346031|PROCEDURE|music therapy|patients will listen to music with an MP3 headset
58106495|NCT04938609|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
58106496|NCT04938609|RADIATION|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
58106497|NCT04938609|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
58106498|NCT03687099|OTHER|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
58106499|NCT01208259|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
57738402|NCT04067466|DIETARY_SUPPLEMENT|Control product|Placebo product with maltodextrin and plum powder
57738403|NCT03297788|RADIATION|SRS|"For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
58437865|NCT03475589|DRUG|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
58437866|NCT05235542|DRUG|AK104|IV infusion,Specified dose on specified days
58437867|NCT05235542|DRUG|AK117|IV infusion,Specified dose on specified days
58106500|NCT01208259|BEHAVIORAL|Interpersonal Therapy (IPT)|
58106501|NCT01400672|BIOLOGICAL|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
58106502|NCT01400672|DRUG|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
58106503|NCT01400672|RADIATION|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
58106504|NCT01092299|DRUG|AZD1446|ER Fast, 90mg, p.o. capsule
58106505|NCT01092299|DRUG|AZD1446|ER Moderate, 90mg, p.o. capsule
58437868|NCT05235542|DRUG|Capecitabine tablets|Oral,Specified dose on specified days
58437869|NCT05235542|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
58437870|NCT05235542|DRUG|Cisplatin|IV infusion,Specified dose on specified days
58437871|NCT05235542|DRUG|Paclitaxel|IV infusion,Specified dose on specified days
58437872|NCT05235542|DRUG|Irinotecan|IV infusion,Specified dose on specified days
58437873|NCT05235542|DRUG|Docetaxel|IV infusion,Specified dose on specified days
58437874|NCT05235542|DRUG|5-FU|IV infusion,Specified dose on specified days
58437875|NCT01957813|BEHAVIORAL|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
58437876|NCT01957813|OTHER|Standard Health Services|Peer education and health services
58437877|NCT00958165|DEVICE|CardioFocus EAS-AC|PVI for PAF
58437878|NCT02945813|DRUG|Metformin|850mg PO BID; 48 weeks
58437879|NCT02945813|RADIATION|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
58437880|NCT06584318|OTHER|Intermittent hypoxia intervention|The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
58437881|NCT04343755|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
58437882|NCT02716623|OTHER|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
58437883|NCT02716623|BEHAVIORAL|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
58437884|NCT04441255|DRUG|TAK-788|TAK-788 Capsule.
58106506|NCT01092299|DRUG|AZD1446|ER Slow, 90mg, p.o. capsule
58106507|NCT01092299|DRUG|AZD1446|MR
58106508|NCT01092299|DRUG|AZD1446|IR, 90 mg p.o. capsule
58106509|NCT01092299|DRUG|Placebo|IR
58106510|NCT01092299|DRUG|Placebo|ER/MR
58106511|NCT03559010|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
58106512|NCT06545682|DRUG|Alpelisib + Pembrolizumab|Given by mouth (PO) Given by vein (IV)
58106513|NCT00902291|BIOLOGICAL|AGS-1C4D4|IV infusion
58106514|NCT00902291|BIOLOGICAL|Gemcitabine|IV infusion
58310566|NCT03424278|OTHER|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
58310567|NCT03424278|OTHER|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
58310568|NCT01294813|DEVICE|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
58310569|NCT03276208|OTHER|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
58310570|NCT03276208|OTHER|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
58310571|NCT04367805|DIAGNOSTIC_TEST|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
58310572|NCT02060409|GENETIC|spliceosome|spliceosome mutations
58437885|NCT01379196|DRUG|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
58437886|NCT01154426|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58437887|NCT01154426|DRUG|Gemcitabine Hydrochloride|Given IV
58437888|NCT01154426|OTHER|Pharmacological Study|Correlative studies
58437889|NCT01154426|DRUG|Veliparib|Given orally
58437890|NCT06426836|OTHER|Amoxicillin-clavulanate|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
58437891|NCT06426836|OTHER|Piperacillin-tazobactam|blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
58437892|NCT06426836|OTHER|Meropenem|blood sampling in patients receiving meropenem as part of routine clinical care.
58437893|NCT06426836|OTHER|Cefazolin|blood sampling in patients receiving cefazolin as part of routine clinical care.
58437894|NCT06426836|OTHER|Vancomycin|blood sampling in patients receiving vancomycin as part of routine clinical care.
58437895|NCT06426836|OTHER|Teicoplanin|blood sampling in patients receiving teicoplanin as part of routine clinical care.
58437896|NCT06426836|OTHER|Ciprofloxacin|blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
58437897|NCT06426836|OTHER|Amikacin|blood sampling in patients receiving amikacin as part of routine clinical care.
58437898|NCT05865717|BEHAVIORAL|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) \& desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
58437899|NCT05865717|OTHER|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
57955063|NCT03369964|DRUG|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
58106515|NCT01664273|DRUG|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
58106516|NCT04559165|OTHER|sericin and chitosan cream|sericin and chitosan cream
58437900|NCT05533424|OTHER|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
58437901|NCT05533424|OTHER|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
58437902|NCT00868127|DRUG|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
58437903|NCT00868127|DRUG|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
58437904|NCT03361982|OTHER|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
58437905|NCT03867357|DRUG|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
58106517|NCT02134691|BEHAVIORAL|Prolonged Exposure|
58106518|NCT02134691|BEHAVIORAL|Applied Relaxation|
58106519|NCT02148783|DRUG|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
58437906|NCT03079596|PROCEDURE|ERAS perioperative cares|Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
58106520|NCT02148783|DRUG|Placebo|
58310573|NCT03622450|DRUG|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
58106521|NCT02664766|BEHAVIORAL|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
58106522|NCT01802840|DIETARY_SUPPLEMENT|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
58106523|NCT02683187|DRUG|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
58106524|NCT02683187|DRUG|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
58106525|NCT03970720|DRUG|Metoclopramide|10 mg metoclopramide four times a day
58106526|NCT03970720|DRUG|Placebo|10 mg matching placebo capsules four times a day
58106527|NCT01814995|BEHAVIORAL|Nutrition/Physical Activity Intervention|Please see Arm description.
58106528|NCT00769015|BEHAVIORAL|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
58106529|NCT00769015|BEHAVIORAL|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
58106530|NCT02279576|DRUG|Pazopanib|Pazopanib 800mg/day continuously administered.
58106531|NCT02279576|DRUG|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
58106532|NCT04271683|PROCEDURE|Pressure controlled ventilation with PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
58437907|NCT03079596|PROCEDURE|Conventional perioperative cares|No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
58437908|NCT00544336|OTHER|questionnaire administration|no intervention
58437909|NCT00544336|OTHER|survey administration|no intervention
58106533|NCT04271683|PROCEDURE|Manual ventilation without PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
58437910|NCT00544336|PROCEDURE|quality-of-life assessment|no intervention
58437911|NCT04578067|BEHAVIORAL|Lifestyle intervention|on physical activity and healthier eating
58437912|NCT06451081|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
58437913|NCT06451081|BEHAVIORAL|Opt-out active referral|Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
58437914|NCT06451081|BEHAVIORAL|Behavioral economic mobile messaging|Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
58106534|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II SC|
58106535|NCT01463683|BIOLOGICAL|1XP HEPTAVAX™-II SC|
58106536|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II IM|
58106537|NCT00897533|GENETIC|gene mapping|
58106538|NCT00897533|GENETIC|polymorphism analysis|
58106539|NCT00897533|OTHER|diagnostic laboratory biomarker analysis|
58106540|NCT00897533|OTHER|immunohistochemistry staining method|
58106541|NCT02593188|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
58106542|NCT03774927|DEVICE|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
58106543|NCT03774927|DEVICE|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
58106544|NCT03774927|DEVICE|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
58106545|NCT00968396|PROCEDURE|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
58437915|NCT06451081|BEHAVIORAL|Opt-in active referral|Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
58437916|NCT05460143|OTHER|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
58437917|NCT05460143|OTHER|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
58437918|NCT06259539|BEHAVIORAL|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
58106546|NCT00968396|PROCEDURE|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
58106547|NCT00968396|DRUG|Melphalan|100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
58106548|NCT00406822|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
58437919|NCT05244083|OTHER|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
58437920|NCT05244083|OTHER|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
58437921|NCT00248586|BEHAVIORAL|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
58106549|NCT06439615|DRUG|Baricitinib 4 MG|Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
58106550|NCT06439615|OTHER|Standard treatment|Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
58106551|NCT01497873|DRUG|Topotecan|1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
58106552|NCT01497873|DRUG|Belotecan|0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
58437922|NCT00248586|BEHAVIORAL|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
58437923|NCT03944408|PROCEDURE|stent implantation|stent implantation
58437924|NCT03842449|DIAGNOSTIC_TEST|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
58437925|NCT03842449|OTHER|Biological samples|"The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment"
58437926|NCT06186258|DEVICE|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
58437927|NCT01448499|DRUG|Clozapine|escalating dose of clozapine up to 900 mg/day
58437928|NCT01448499|DRUG|Amisulpride|escalating dose of amisulpride up to 800 mg/day
58437929|NCT01448499|DRUG|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
58437930|NCT00882960|DRUG|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
58437931|NCT00882960|DRUG|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
58437932|NCT01986608|DRUG|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
58437933|NCT01986608|DRUG|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
58437934|NCT03850535|DRUG|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
58437935|NCT03850535|DRUG|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
58437936|NCT03850535|DRUG|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
58437937|NCT03850535|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
58437938|NCT01152034|BEHAVIORAL|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
58437939|NCT04345315|OTHER|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
58437940|NCT04345315|OTHER|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
58437941|NCT04345315|GENETIC|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
58437942|NCT04345315|OTHER|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
58437943|NCT03658824|OTHER|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
58437944|NCT05741112|DEVICE|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
58437945|NCT01041820|BEHAVIORAL|Exercise|Children will be exposed to a 10-week exercise intervention
58437946|NCT05727657|DRUG|Satralizumab|120mg subcutaneous Day 0 and Day 14
58437947|NCT01600989|OTHER|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
58437948|NCT01600989|OTHER|blood sampling|Blood samples will be taken twice at a 7 day interval
58437949|NCT01500486|DEVICE|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
57738404|NCT03297788|RADIATION|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
57955064|NCT03369964|DRUG|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
57738405|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
57955065|NCT03369964|DRUG|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
58310574|NCT03622450|DRUG|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
58437950|NCT06061835|OTHER|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
58437951|NCT06061835|OTHER|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
58437952|NCT01180296|DRUG|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
58437953|NCT01180296|DRUG|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
58437954|NCT04093440|OTHER|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
58437955|NCT00765063|DRUG|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
58437956|NCT00002201|DRUG|Ritonavir|
58437957|NCT00002201|DRUG|Nelfinavir mesylate|
58437958|NCT03809494|DEVICE|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
58437959|NCT03809494|OTHER|Saline|Normal (0.9%) saline
58437960|NCT00153465|BEHAVIORAL|Motivational intervention, parent training|
58437961|NCT04238507|DEVICE|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
58437962|NCT04238507|DEVICE|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
57955066|NCT05758259|DRUG|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
57955067|NCT05758259|DRUG|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
57955068|NCT05758259|DRUG|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
58106553|NCT04516694|BEHAVIORAL|Financial incentive (gain)|Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
58310575|NCT01067391|DRUG|tadalafil|20 mg tablet, administered once per study protocol
58310576|NCT01067391|DRUG|placebo|placebo tablet administered once per study protocol
58310577|NCT04366674|PROCEDURE|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
58310578|NCT00523432|DRUG|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
58310579|NCT00523432|DRUG|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
58437963|NCT05712954|OTHER|music group|music
58437964|NCT05712954|OTHER|video group|video
58437965|NCT02775916|DRUG|CDZ173|
58437966|NCT02775916|DRUG|Placebo|
58437967|NCT05403671|OTHER|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
58437968|NCT06100913|BIOLOGICAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
58437969|NCT06437977|RADIATION|SBRT|SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
58437970|NCT06437977|DRUG|Toripalimab|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
58437971|NCT00285402|DRUG|AST-726 Low dose|
57738406|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
57738407|NCT05265468|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
58310580|NCT05088356|DRUG|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10\^6 cells/ kg to 3x10\^6 cells/kg"
58310581|NCT05088356|DRUG|Fludarabine|Fludarabine (160 mg/m2)
58310582|NCT05088356|DRUG|Melphalan|Melphalan (50 mg/m2)
58310583|NCT05088356|DEVICE|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
58310584|NCT05088356|DRUG|Tacrolimus|4-6ng/mL
58310585|NCT05088356|DRUG|Cyclophosphamide|40mg/kg
58310586|NCT05088356|DRUG|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
58310587|NCT05088356|DRUG|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
58310588|NCT05088356|DRUG|Thiotepa|Thiotepa 10 mg/kg
58310589|NCT05088356|DRUG|Mycophenolate Mofetil (MMF)|MMF 1000 mg BID
58310590|NCT05088356|DRUG|Ruxolitinib|Ruxolitinib 5 mg BID
58437972|NCT00285402|DRUG|AST-726 High dose|
58437973|NCT00285402|DRUG|AST-726 Placebo|
58437974|NCT00117260|DRUG|Seasonale (levonorgestrel and ethinyl estradiol)|
58437975|NCT04427020|DIETARY_SUPPLEMENT|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
58437976|NCT04427020|DIETARY_SUPPLEMENT|Milk protein|Both conditions matched flavor, color, and serving size
58437977|NCT04098861|DRUG|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
58437978|NCT05992350|OTHER|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
58437979|NCT01958983|BEHAVIORAL|Music Therapy Group Session|
58437980|NCT03274063|OTHER|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
57738408|NCT05265468|OTHER|Lewit Group|Isometric muscular exercise acompained with stretching technique
58106554|NCT04516694|BEHAVIORAL|Financial incentive (loss)|Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
58437981|NCT03274063|OTHER|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
57738409|NCT05265468|OTHER|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
57738410|NCT05265468|OTHER|Placebo Group|No pain positioning of participants
57738411|NCT01745432|DEVICE|ADBLOCK|Laparoscopic surgery
58106555|NCT06274216|DRUG|Vitamin D3|5000 IU of vitamin D3 orally every day for 12 weeks
58106556|NCT06274216|DRUG|Vitamin E 400|400mg of vitamin E orally every day for 12 weeks
58310591|NCT06222801|DRUG|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
58310592|NCT06222801|DRUG|Interferon gamma|Immunostimulating agent.
58310593|NCT03979066|DRUG|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
58310594|NCT03979066|DRUG|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
58310595|NCT00667511|DEVICE|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
58310596|NCT03798236|DRUG|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
58310597|NCT03798236|DRUG|Placebo oral capsule|solid microcrystalline cellulose
58310598|NCT00933153|DIETARY_SUPPLEMENT|Ensure Plus|Ensure plus supplement with meals
58310599|NCT00933153|DIETARY_SUPPLEMENT|Meals on Wheels|Two Meals on Wheels twice daily
58310600|NCT04968704|OTHER|3D photography and computer modelling|3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
58310601|NCT02576470|BEHAVIORAL|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
58310602|NCT02576470|DEVICE|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
58310603|NCT02576470|BEHAVIORAL|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
58310604|NCT02576470|BEHAVIORAL|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
58310605|NCT02576470|RADIATION|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
58310606|NCT02576470|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
58310607|NCT02576470|DEVICE|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
57738412|NCT03695497|PROCEDURE|Direct anterior approach|total hip arthroplasty with DAA
57738413|NCT03695497|PROCEDURE|Direct Lateral Approach|total hip arthroplasty with DLA
57738414|NCT00057096|PROCEDURE|On-site vs. referral methods of care|
58106557|NCT04856995|OTHER|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
57955069|NCT02072655|PROCEDURE|socio-aesthetic care|"* care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
58106558|NCT04677582|BEHAVIORAL|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
58106559|NCT04379388|BEHAVIORAL|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
57955070|NCT05279547|OTHER|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
58106560|NCT04130919|DRUG|Tilpisertib|Tablets administered orally once daily
58106561|NCT04130919|DRUG|Placebo|Tablets administered orally once daily
58310608|NCT05994742|DRUG|Rifampicin|Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
58310609|NCT05994742|DRUG|Azithromycin|Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
58310610|NCT05994742|DRUG|Isoniazid|Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
58310611|NCT05994742|DRUG|Pyridoxine Hydrochloride|Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
58310612|NCT05994742|BEHAVIORAL|The Friendship Bench|The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
57738415|NCT05560672|OTHER|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
57955071|NCT05279547|OTHER|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
57955072|NCT02663388|PROCEDURE|gastric bypass, sleeve, gastric banding|
58106562|NCT01880645|PROCEDURE|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
58106563|NCT01880645|PROCEDURE|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
58106564|NCT01880645|PROCEDURE|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
58106565|NCT05834257|PROCEDURE|Normal Saline for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).
58310613|NCT05994742|BEHAVIORAL|Care for Child Development|Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
58310614|NCT05994742|BEHAVIORAL|Educational and behaviour-change modules|Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
58437982|NCT06438666|DEVICE|Anodic Transcranial Direct Current Stimulation|This study will apply the anodic transcranial direct current stimulation over 20 children between 14-18 years old. The protocol that it will follow is the next one: 3 days to value the outcome measures, 4 days (1 sessions per day of 17 minutes and 30 seconds) to apply the protocol of anodic transcranial direct current stimulation (0,6 mA of intensity). It will use the EPTE V07 Bipolar System by IONCLINICS ®; 3 days to value the outcome measures studying the effects produced at the affected upper limb. Another evaluation will be realized 3 weeks after the last sessions of anodic transcranial direct current stimulation to know if the effects obtained last at medium-long term.
58437983|NCT02681289|OTHER|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
58437984|NCT05643339|DIAGNOSTIC_TEST|microvascular flow imaging|microvascular flow imaging
58437985|NCT06154356|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
57738416|NCT02151279|OTHER|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
58106566|NCT05834257|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
58106567|NCT05834257|PROCEDURE|Ringer's Lacatate for fluid resusciation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
58106568|NCT02996370|OTHER|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
58106569|NCT02996370|OTHER|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
58106570|NCT02996370|OTHER|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
58437986|NCT06154356|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
58437987|NCT06574516|DRUG|Ibuprofen 200 mg|Ibuprofen every 8 hours for three days post operatively
58437988|NCT06574516|DRUG|paracetamol|Paracetamol PRN for three days
57955073|NCT04468165|DRUG|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
58106571|NCT02996370|OTHER|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
58106572|NCT02996370|OTHER|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
58106573|NCT03768882|DRUG|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
57738417|NCT02151279|OTHER|Control|
57738418|NCT03438162|BEHAVIORAL|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
57955074|NCT02728193|PROCEDURE|RFA|
57955075|NCT02728193|PROCEDURE|MWV|
57955076|NCT02728193|PROCEDURE|PEI|Percutaneous ethanol injection
58106574|NCT03768882|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
58106575|NCT05472285|DIETARY_SUPPLEMENT|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
58106576|NCT05472285|DIETARY_SUPPLEMENT|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
58106577|NCT06157489|OTHER|Kinesio tape|Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
58106578|NCT01253876|DIETARY_SUPPLEMENT|soy milk, Caw's milk|
58106579|NCT06370195|BEHAVIORAL|Comprehensive rehabilitation|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.
58310615|NCT05994742|DIETARY_SUPPLEMENT|Reformulated Ready to Use Therapeutic Food|A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
58310616|NCT05994742|OTHER|Standard Care|All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
58437989|NCT03680183|DRUG|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
58106580|NCT06370195|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58437990|NCT01939327|DRUG|Lenalidomide/Rituximab|
58437991|NCT06115590|DIETARY_SUPPLEMENT|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
58437992|NCT02621294|OTHER|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
58437993|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
58437994|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
58437995|NCT00787189|DEVICE|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
58437996|NCT00787189|DEVICE|Placebo Laser|inactive low level laser light therapy with no therapeutic output
58437997|NCT02881762|DRUG|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
58437998|NCT05623241|DIAGNOSTIC_TEST|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
58437999|NCT01435629|DRUG|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
57738419|NCT01787617|BEHAVIORAL|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
58310617|NCT03356093|OTHER|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
58310618|NCT01799889|DRUG|Entospletinib MM|Entospletinib MM tablet administered orally
58310619|NCT01799889|DRUG|Entospletinib SDD|Entospletinib SDD tablet administered orally
58310620|NCT01005381|DIETARY_SUPPLEMENT|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
58438000|NCT00850538|RADIATION|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
58438001|NCT00850538|PROCEDURE|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
58438002|NCT02234804|DEVICE|Xience Prime Stent|
58438003|NCT02234804|DEVICE|Medtronic Resolute Integrity stent|
58438004|NCT02234804|PROCEDURE|Angiography|
58438005|NCT02234804|PROCEDURE|OCT|
58438006|NCT04616222|DRUG|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
58438007|NCT04616222|DRUG|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
58438008|NCT00028236|DRUG|Gene-Transduced Autologous CD34+ Stem Cells|
58438009|NCT04996485|DRUG|Secukinumab Injection|Pathogenetic therapy with biologic drugs
58438010|NCT04996485|DRUG|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
58438011|NCT04996485|DRUG|Dupilumab Injection|Pathogenetic therapy with biologic drugs
58438012|NCT04996485|OTHER|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
58438013|NCT05897892|DIETARY_SUPPLEMENT|Clinical study on the mangrove sword bean food bar effect for older people|The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
58438014|NCT00406679|DRUG|Paracetamol (acetaminophen) solution experimental|1 gm IV
58438015|NCT00406679|DRUG|paracetamol (acetaminophen) solution commercial|1 gm IV
58438016|NCT00406679|DRUG|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
58438017|NCT05325021|DIAGNOSTIC_TEST|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
58438018|NCT05325021|DIAGNOSTIC_TEST|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
58438019|NCT06470503|BEHAVIORAL|Exercise Program|8-week program and four-week short maintenance period.
58438020|NCT00543387|DRUG|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
58438021|NCT00543387|DRUG|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
58438022|NCT01406197|DRUG|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
58438023|NCT01406197|DRUG|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
58106581|NCT06370195|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58310621|NCT01005381|DIETARY_SUPPLEMENT|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
58310622|NCT01005381|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
58310623|NCT01005381|DIETARY_SUPPLEMENT|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
58310624|NCT04894058|PROCEDURE|Ureteroscopic lithotripsy|"After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz."
58310625|NCT03139539|DEVICE|Ioban|
58310626|NCT04975139|DEVICE|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
58310627|NCT06522113|DRUG|Cilostazol|patients were given cilostazol 100mg twice a day with aspirin
58310628|NCT06522113|DRUG|Clopidogrel|patients were given clopidogrel 75mg with aspirin
58310629|NCT04103840|OTHER|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
58310630|NCT03039075|DRUG|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
58310631|NCT05227248|DIETARY_SUPPLEMENT|Dark chocolate|Patients were administered 20 grams of dark chocolate
58310632|NCT05227248|DIETARY_SUPPLEMENT|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
58310633|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
58310634|NCT02425553|OTHER|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
58310635|NCT02425553|OTHER|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
58310636|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
58310637|NCT04968496|OTHER|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
58310638|NCT02931461|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
58310639|NCT06389461|OTHER|4th Ventricular Compression Technique|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
58310640|NCT06389461|OTHER|"Sham Therapy"|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
58310641|NCT00941343|DRUG|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
58310642|NCT06436768|DRUG|Sugammadex|"After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight."
58310643|NCT06436768|DRUG|Neostigmine|"After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight."
58310644|NCT04168242|DEVICE|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
58310645|NCT04168242|OTHER|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
58310646|NCT00644059|BIOLOGICAL|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
58310647|NCT00644059|BIOLOGICAL|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
58310648|NCT00644059|BIOLOGICAL|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections"
58438024|NCT01406197|DRUG|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
58438025|NCT02406170|DRUG|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
58438026|NCT02406170|DRUG|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
58106582|NCT06370195|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58438027|NCT01882530|DRUG|Paracetamol|
58438028|NCT01882530|DRUG|Nefopam|
58438029|NCT01882530|DRUG|Ketoprofen|
58438030|NCT01882530|DRUG|Morphine|
58438031|NCT01904045|OTHER|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
58438032|NCT01904045|OTHER|tacrolimus Prograf|intake of Prograf twice daily for 3 months
58438033|NCT03120715|DRUG|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
58438034|NCT03120715|DRUG|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
58438035|NCT03120715|DRUG|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
58438036|NCT03120715|DRUG|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
58438037|NCT01378767|DIETARY_SUPPLEMENT|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
57738420|NCT01787617|BEHAVIORAL|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
57738421|NCT02323971|DRUG|Ticagrelor|
57738422|NCT04593446|DRUG|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
57738423|NCT04593446|DRUG|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
58438038|NCT05591391|OTHER|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
58438039|NCT05591391|OTHER|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
58438040|NCT06449495|DEVICE|NIRVANA|"NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection."
57738424|NCT02982252|BEHAVIORAL|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
57738425|NCT03819491|DIETARY_SUPPLEMENT|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
58106583|NCT01595490|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
58438041|NCT02748070|DRUG|Prednisone|
58438042|NCT02748070|DRUG|Flonase|
58438043|NCT00538070|DIETARY_SUPPLEMENT|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
58106584|NCT01268137|PROCEDURE|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
58310649|NCT06351176|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
58310650|NCT06351176|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
58310651|NCT06351176|DIAGNOSTIC_TEST|DXA scan with TBS and VFA|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.
58310652|NCT06351176|DIAGNOSTIC_TEST|AGEReader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
58310653|NCT01865019|DEVICE|mechanical ventilation|
58310654|NCT02347709|PROCEDURE|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
58310655|NCT02347709|OTHER|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
58310656|NCT02347709|OTHER|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
58310657|NCT02347709|OTHER|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
58310658|NCT00619840|DRUG|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
58310659|NCT00619840|DRUG|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
58310660|NCT01077492|OTHER|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
58310661|NCT01553851|DRUG|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
58310662|NCT05442008|DRUG|Erenumab 70/140 mg s.c.|Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)
58310663|NCT03044418|OTHER|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
58310664|NCT04547816|PROCEDURE|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
58310665|NCT04547816|PROCEDURE|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
58310666|NCT04547816|BEHAVIORAL|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
58310667|NCT04547816|BEHAVIORAL|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
58310668|NCT02997163|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
58438044|NCT02391181|DRUG|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
57738426|NCT00715546|PROCEDURE|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
57738427|NCT04870216|OTHER|Questionnaire regarding intimate protections habit.|Questionnaire regarding intimate protections habit.
57738428|NCT05789043|DRUG|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
58106585|NCT02666365|PROCEDURE|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
58106586|NCT02666365|PROCEDURE|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
58106587|NCT02149550|OTHER|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
58106588|NCT02149550|OTHER|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
58106589|NCT02149550|OTHER|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
58106590|NCT02149550|OTHER|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
58106591|NCT02149550|OTHER|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
58106592|NCT02149550|OTHER|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
58106593|NCT06056700|BEHAVIORAL|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
58106594|NCT03157310|DRUG|Gefitinib|Daily oral administration of 250 mg Gefitinib
58106595|NCT05285332|PROCEDURE|surgical treatment 1|Mastectomy OR Breast conserving surgery
58106596|NCT05285332|PROCEDURE|surgical treatment 2|Resection of metastasis
58106597|NCT05285332|DRUG|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
58106598|NCT05203588|DRUG|Denosumab 60 mg/ml Injectable Solution [Prolia]|Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
58106599|NCT05203588|DRUG|calcium and vitamin D|calcium (≥1·0 g) and vitamin D (≥400 IU).
58106600|NCT02113969|DEVICE|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
58438045|NCT02391181|DRUG|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
58438046|NCT04102995|DRUG|Sepranolone injection low dose|Subcutaneous (SC) administration
57738429|NCT05789043|DRUG|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
57738430|NCT05789043|DRUG|camrelizumab|camrelizumab 200mg，q2w
57738431|NCT03932448|OTHER|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
57738432|NCT04817553|OTHER|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
58106601|NCT05935319|OTHER|Vivifrail|Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
58106602|NCT06159439|DIAGNOSTIC_TEST|Contrast enhanced ultrasound scan|Contrast enhanced ultrasound using Sonovue microbubble contrast
21916381|NCT05996224|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progenitor cells administrated for intra- articular use
21916382|NCT05996224|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
58438047|NCT04102995|DRUG|Sepranolone injection high dose|Subcutaneous (SC) administration
58438048|NCT04102995|DRUG|Placebo injection|Subcutaneous (SC) administration
58438049|NCT01847989|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
58438050|NCT01847989|DRUG|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
58438051|NCT04764227|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
58438052|NCT04764227|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
58438053|NCT04764227|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
58438054|NCT01665391|DRUG|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
58438055|NCT01665391|DRUG|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
58438056|NCT01665391|DRUG|Placebo|Placebo administered to match active treatment group
58438057|NCT00770601|DRUG|Canakinumab|
58438058|NCT03046576|DIAGNOSTIC_TEST|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
58438059|NCT02146391|DRUG|Androxal 25 mg Capsules|
58438060|NCT03731091|DRUG|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
58106603|NCT06159439|DIAGNOSTIC_TEST|MRI scan|Arterial-spin labelling magnetic resonance imaging
58106604|NCT06045975|DRUG|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"* Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by IRE procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions."
58438061|NCT03731091|DRUG|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
58438062|NCT03731091|OTHER|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
58106605|NCT00077402|DRUG|fenretinide|
58438063|NCT03543137|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
58438064|NCT03543137|DRUG|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
58106606|NCT04461652|PROCEDURE|prophylactic air-extraction catheter drainage|This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
57738433|NCT03581721|DEVICE|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
57738434|NCT03325712|DRUG|BI 705564|Film-coated tablet
58106607|NCT05944770|OTHER|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
58106608|NCT05944770|OTHER|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
58106609|NCT05251415|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity.
58310669|NCT05943951|PROCEDURE|Right hemicolectomy|It begins with a thorough laparoscopic inspection of the abdomen for evidence of metastatic disease and to confirm the location of the tumor. Usually is performed dissection using a medial-to-lateral approach. A lateral or inferior approach can also be used depending on the anatomy. The vascular dissection may begin at the ileocolic pedicle or over the superiore mesenteric vein. After completing the medial-to-lateral dissection, the sourgeons return to the ileocolic pedicle to begin vascular dissection. Whether a D2 (until encountering the right branch of the middle colic) or D3 dissection (until the root of ileocolic artery and vein) is performed depends upon the tumor stage. For an intracorporeal anastomosis, the bowel is transected proximally and distally using a linear stapler. The terminal ileum is positioned along the transverse colon in an isoperistaltic fashion. After that a colotomy and an enterotomy are made on the antimesenteric edge of the colon and small bowel respectively
58106610|NCT05756088|DIAGNOSTIC_TEST|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
58106611|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
58310670|NCT04343144|DRUG|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
58310671|NCT00384631|OTHER|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
58310672|NCT00384631|DRUG|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
58310673|NCT05412277|OTHER|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
58310674|NCT00639184|OTHER|Early intervention counseling|Bi-monthly home visits by counselor
58310675|NCT00639184|OTHER|Health education counseling|World Health Education health education counseling program at home visits,twice per month
58310676|NCT05623527|DEVICE|cardiac electronic implants|Cardiac electronic implants(CIED) includes permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), three-chamber pacemaker for cardiac resynchronization therapy defibrillator, lead free pacemaker, etc.
58438065|NCT01472068|DEVICE|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
58438066|NCT03047239|DEVICE|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
58438067|NCT05058924|DRUG|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
58438068|NCT05058924|DRUG|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
58438069|NCT04770402|OTHER|Acupuncture|12 acupuncture sessions over 10 weeks
58438070|NCT04770402|OTHER|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
58438071|NCT00662116|DRUG|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
58438072|NCT00662116|DRUG|placebo|placebo tablets - two tablets taken twice daily
58438073|NCT06508671|DRUG|DL-3-n-butylphthalide|Take butylphthalide soft capsules orally
58438074|NCT06508671|DRUG|Empty Medication Capsules|Take empty medication capsules orally
57738435|NCT03325712|DRUG|Placebo|Film-coated tablet
57738436|NCT03325712|DRUG|Midazolam|Solution for injection
57738437|NCT01650753|DIETARY_SUPPLEMENT|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)
58106612|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a sham face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
58106613|NCT04153201|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg
58438075|NCT04519346|OTHER|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
58438076|NCT03157284|DIETARY_SUPPLEMENT|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
58438077|NCT03157284|DIETARY_SUPPLEMENT|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
58438078|NCT00720343|DRUG|Choline|Oral Choline 20 grams before surgery
58438079|NCT00720343|DRUG|Placebo|Gelatin Capsule
58438080|NCT04520399|OTHER|none intervention|there is no intervention in this study
58438081|NCT02293603|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
58438082|NCT04294602|OTHER|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
57738438|NCT01650753|DIETARY_SUPPLEMENT|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
57738439|NCT01233791|DRUG|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
58438083|NCT04294602|OTHER|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
58438084|NCT04294602|OTHER|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
58438085|NCT04294602|OTHER|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
58438086|NCT03427723|DEVICE|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
57738440|NCT01233791|DRUG|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
57738441|NCT04838743|DRUG|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
57738442|NCT05628324|BEHAVIORAL|practice muscle activation patterns|practice upper limb muscle activation patterns using EMG-controlled games
58106614|NCT03963999|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
58106615|NCT03963999|DRUG|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
58438087|NCT03427723|OTHER|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
58438088|NCT05887050|DIETARY_SUPPLEMENT|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
58438089|NCT05887050|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
58438090|NCT03187444|PROCEDURE|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
57738443|NCT05628324|BEHAVIORAL|task practice|practice functional upper limb tasks
57738444|NCT03382496|OTHER|Non-Interventional|Non-Interventional
57738445|NCT01453595|DRUG|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
57738446|NCT05309304|DRUG|Cefazolin|Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
58106616|NCT01469988|DRUG|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
58438091|NCT00453804|DRUG|injectable naltrexone|
58438092|NCT00453804|DRUG|oral naltrexone|
58438093|NCT03023293|OTHER|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
58438094|NCT06025981|OTHER|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
58438095|NCT06025981|OTHER|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
58438096|NCT06025981|OTHER|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
58438097|NCT03106974|DEVICE|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
57738447|NCT02269670|DRUG|everolimus|Given PO
58438098|NCT03106974|DEVICE|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
58438099|NCT06265506|BEHAVIORAL|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
58438100|NCT06265506|BEHAVIORAL|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
57738448|NCT02269670|DRUG|anastrozole|Given PO
57738449|NCT02269670|DRUG|letrozole|Given PO
58310677|NCT05069467|DEVICE|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
58310678|NCT05069467|DEVICE|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
57738450|NCT02269670|DRUG|tamoxifen citrate|Given PO
57738451|NCT02269670|DRUG|fulvestrant|Given IM or PO
57738452|NCT02269670|DRUG|megestrol acetate|Given PO
57738453|NCT05252767|BEHAVIORAL|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
57738454|NCT05252767|BEHAVIORAL|Educational Guide|Control participants will receive a brief educational guide about pain management.
58106617|NCT05270694|BEHAVIORAL|Public Health Intervention Package|"The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
58106618|NCT06321666|OTHER|WB-MRI|All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
58106619|NCT02626065|BIOLOGICAL|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
58106620|NCT02626065|DRUG|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
58106621|NCT02316678|OTHER|No intervention|There is no intervention
58106622|NCT04384926|PROCEDURE|Elective Cancer Surgery|Planned, curative cancer surgery
58106623|NCT02401893|BIOLOGICAL|Influenza Vaccine|Everyone immunized as recommended by current guidelines
58106624|NCT01354600|OTHER|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
58106625|NCT04683887|DEVICE|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
58106626|NCT03398655|DRUG|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
58438101|NCT03282513|DRUG|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
58438102|NCT06555484|DEVICE|Cross Over Assignment Supplemental Oxygen and Supplemental Air|"Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned)."
58438103|NCT00374933|DRUG|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
58438104|NCT00374933|DRUG|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
58438105|NCT00374933|DRUG|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
58438106|NCT05900791|PROCEDURE|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
58438107|NCT03803384|OTHER|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
58438108|NCT04417608|PROCEDURE|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
58438109|NCT00539305|DRUG|testosterone gel|50-100mg applied topically daily for six months
58438110|NCT00539305|DRUG|placebo gel|applied topically daily for six months
58438111|NCT02091765|BEHAVIORAL|Internet-based cognitive behavioral therapy.|
57738455|NCT01371851|DRUG|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
58106627|NCT03398655|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
58106628|NCT02008331|DIETARY_SUPPLEMENT|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
58106629|NCT06074419|DEVICE|Occulus quest 2 virtual reality glasses|Patients will be shown nature videos via the specified virtual reality connection.
58106630|NCT05183399|DEVICE|GORE® VIABAHN® Endoprosthesis|
58438112|NCT05495165|OTHER|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
58438113|NCT04543695|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
58106631|NCT05972070|DEVICE|ROMTech Portable Connect|The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
58106632|NCT03202511|DRUG|Probenecid Oral Tablet|Included in arm/group descriptions.
58106633|NCT03202511|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
58310679|NCT04903301|PROCEDURE|Contoura Vision LASIK|Topography-Guided LASIK using Phorcides Analytic Software
58438114|NCT04543695|DRUG|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
58438115|NCT04543695|DRUG|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
58438116|NCT04543695|PROCEDURE|TME|Total mesorectal excision
58438117|NCT02168218|OTHER|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
58310680|NCT01903226|OTHER|High intensity training|
58438118|NCT00729963|DRUG|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
58310681|NCT01903226|OTHER|Moderate intensity training|
58438119|NCT00729963|DEVICE|CPAP|
58438120|NCT02167516|DRUG|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
58438121|NCT02167516|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
58438122|NCT05739461|OTHER|Dental implant|Dental implants with triangular cross-section neck design
58438123|NCT00496639|PROCEDURE|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
58310682|NCT00236717|DRUG|Topiramate; Carbamazepine; Valproate|
58310683|NCT03470467|OTHER|No intervention|No intervention planed
58438124|NCT00496639|PROCEDURE|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
58438125|NCT03646474|DRUG|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
58438126|NCT03646474|DRUG|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
57738456|NCT06411457|DRUG|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
57738457|NCT04325750|PROCEDURE|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
58310684|NCT06135038|OTHER|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
57738458|NCT04325750|OTHER|Placebo|simulated TECAR Therapy (machine off)
57738459|NCT05836766|DRUG|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
58106634|NCT00877266|PROCEDURE|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
58310685|NCT06135038|OTHER|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
58310686|NCT03848663|BEHAVIORAL|Traditional Remapping|Shifting text outside of scotoma
58310687|NCT03848663|BEHAVIORAL|Personalized Remapping|Shifting text based on individual letter-based perimetry
58310688|NCT02870868|BEHAVIORAL|Slow breathing|Slow breathing techniques from yoga
58310689|NCT00109343|BIOLOGICAL|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
58310690|NCT00109343|BIOLOGICAL|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
58310691|NCT06399159|PROCEDURE|Thyroidectomy and lymph node dissection|All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
58310692|NCT02935920|BEHAVIORAL|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
58310693|NCT06057064|BIOLOGICAL|Biological: AZD3152|300 mg single dose of AZD3152 IM
58310694|NCT06057064|BIOLOGICAL|Biological: Placebo|Single dose of Placebo IM (0.9% sodium chloride)
58310695|NCT00081003|GENETIC|gene expression analysis|
58310696|NCT00081003|GENETIC|protein expression analysis|
58310697|NCT00081003|OTHER|cytology specimen collection procedure|
58310698|NCT00081003|OTHER|laboratory biomarker analysis|
57738460|NCT05836766|DRUG|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
58310699|NCT00081003|OTHER|physiologic testing|
58310700|NCT00081003|PROCEDURE|breast duct lavage|
58310701|NCT00081003|PROCEDURE|endoscopic biopsy|
58106635|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered SC
58106636|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered IV
58106637|NCT03053622|BIOLOGICAL|Mirikizumab Reference|Administered SC
58106638|NCT04354337|BEHAVIORAL|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
58310702|NCT00081003|PROCEDURE|study of high risk factors|
58438127|NCT04705506|DRUG|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
58438128|NCT00826618|DRUG|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
58438129|NCT02751476|OTHER|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
58438130|NCT02751476|OTHER|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
58438131|NCT02751476|DEVICE|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
58438132|NCT02751476|OTHER|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
58438133|NCT03996031|DEVICE|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
58438134|NCT03071822|DRUG|cisplatin|PIGLETs
58438135|NCT03071822|DRUG|ifosfamide|PIGLETs
58438136|NCT03071822|DRUG|gemcitabine|PIGLETs
58438137|NCT03071822|DRUG|L-asparaginase|PIGLETs
57738461|NCT02568241|OTHER|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
58438138|NCT03071822|DRUG|etoposide|PIGLETs
58438139|NCT03071822|DRUG|dexamethasone|PIGLETs
58438140|NCT00332228|DRUG|depot naltrexone|long-acting depot parenteral formulation of naltrexone
58438141|NCT00332228|BEHAVIORAL|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
58438142|NCT00332228|DRUG|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
58438143|NCT04182672|DRUG|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
58438144|NCT03205176|DRUG|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
57738462|NCT05060328|OTHER|Medical Device Usage and Evaluation|"Use Google Translate Conversation Mode translation application."
57738463|NCT05060328|OTHER|Survey Administration|Complete survey
57738464|NCT00796081|DRUG|ER OROS paliperidone, paliperidone ER|
57738465|NCT05510843|DRUG|THB001|100 mg capsules for oral administration
57738466|NCT02049086|BEHAVIORAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
58106639|NCT02866019|DEVICE|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
58106640|NCT04013022|BEHAVIORAL|Exercise History|The groups will be divided based on their exercise history
58106641|NCT02662608|DRUG|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
58106642|NCT01328054|DRUG|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
58438145|NCT03205176|DRUG|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
58438146|NCT03795220|DRUG|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
58438147|NCT03795220|DRUG|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
58438148|NCT03795220|DRUG|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
58106643|NCT01328054|DRUG|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
58106644|NCT04087083|OTHER|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
57738467|NCT02049086|BEHAVIORAL|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
57955077|NCT00678405|BEHAVIORAL|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
57955078|NCT00678405|BEHAVIORAL|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
57955079|NCT01212302|DRUG|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
57955080|NCT03945708|DEVICE|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
57955081|NCT00706134|DRUG|Placebo|Placebo tablet taken once daily in the morning with a light meal.
57955082|NCT00706134|DRUG|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
57955083|NCT00706134|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
57955084|NCT00706134|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
57955085|NCT03624322|DRUG|Zyprexa IM|5mg
57955086|NCT03624322|DRUG|Zydis|10mg orally disintegrating wafer
57955087|NCT03624322|DRUG|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
57955088|NCT03624322|DEVICE|I231 POD® Device|Precision Olfactory Delivery (POD) device
57955089|NCT04077658|BEHAVIORAL|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
57955090|NCT04077658|BEHAVIORAL|Waitlist Control|Standard of Care Migraine Treatment
57955091|NCT00236977|DRUG|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
57955092|NCT00236977|DRUG|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
57955093|NCT04804254|DRUG|ABBV-623|Oral Tablets
57955094|NCT04804254|DRUG|ABBV-992|Oral Tablets
57955095|NCT02354937|DRUG|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
57955096|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
57955097|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
58106645|NCT04087083|OTHER|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
57738468|NCT03204097|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
57955098|NCT02105402|BEHAVIORAL|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
57955099|NCT03288909|OTHER|MRI|
57955100|NCT06126237|BIOLOGICAL|CM313 injection|CM313, subcutaneous injection
57955101|NCT01116908|DEVICE|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
57955102|NCT01464502|PROCEDURE|Standard CRT Implant|
57955103|NCT01464502|PROCEDURE|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
57955104|NCT02243215|OTHER|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
57955105|NCT03030430|BIOLOGICAL|BAT1706 injection|1mg/kg, IV on day 1
58106646|NCT06327321|DRUG|Deucravacitinib|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
58106647|NCT06327321|OTHER|Volunteer without treatment|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
58106648|NCT02459639|OTHER|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
58106649|NCT02459639|OTHER|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
58106650|NCT01644578|PROCEDURE|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
58106651|NCT01681043|BEHAVIORAL|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks"
58106652|NCT03039374|OTHER|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
58106653|NCT00655005|OTHER|questionnaire administration|Newly diagnosed HNC patients
58106654|NCT00655005|PROCEDURE|quality-of-life assessment|following treatment
58106655|NCT04918537|DIETARY_SUPPLEMENT|Walnuts|30g of plain walnuts in addition to habitual food intakes
58106656|NCT01195389|DEVICE|Resonator|Treatment group vs. Placebo group
58106657|NCT02535676|DEVICE|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
58106658|NCT01131702|DRUG|Ranitidine|Ranitidine Tablets, 300 mg
58106659|NCT05578300|DIAGNOSTIC_TEST|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
58106660|NCT05578300|DIAGNOSTIC_TEST|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
58106661|NCT01883999|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
58106662|NCT05217056|OTHER|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
58106663|NCT00616928|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
58106664|NCT00616928|BIOLOGICAL|Placebo|Two intramuscular injections at Days 0 and 21.
58106665|NCT00135291|PROCEDURE|Leukoreduced blood transfusion|
58106666|NCT03218410|PROCEDURE|surgical pulmonary embolectomy|
58106667|NCT03218410|COMBINATION_PRODUCT|catheter-directed thrombolysis|
58106668|NCT00626587|DEVICE|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
58106669|NCT05016076|DRUG|Dexamethasone 8 mg|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
58438149|NCT03795220|DRUG|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
58438150|NCT06496165|DRUG|Remimazolam|Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
58438151|NCT06496165|DRUG|Propofol|Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
57738469|NCT03204097|DRUG|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
57738470|NCT03204097|DRUG|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
57738471|NCT02263651|PROCEDURE|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
57738472|NCT02263651|PROCEDURE|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
57955106|NCT03030430|BIOLOGICAL|EU-sourced Avastin|1mg/kg, IV on day 1
57955107|NCT03030430|BIOLOGICAL|US-sourced Avastin|1mg/kg, IV on day 1
57955108|NCT05893927|OTHER|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
57955109|NCT04042779|OTHER|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
57955110|NCT04042779|OTHER|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
57955111|NCT04042779|OTHER|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
57955112|NCT04042779|OTHER|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
57955113|NCT05480748|DEVICE|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
57955114|NCT04160130|PROCEDURE|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
57955115|NCT05197192|DRUG|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
57955116|NCT05197192|DRUG|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
57955117|NCT05197192|DRUG|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
57955118|NCT06359509|BIOLOGICAL|BCMA Targeted CAR T-cells|Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.
57955119|NCT01150539|OTHER|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
57955120|NCT01150539|OTHER|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
57955121|NCT00199862|DRUG|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
57955122|NCT00882609|DEVICE|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
57955123|NCT03733223|DRUG|Ateptidase|Treatment of ischemic stroke with Ateptidase
57955124|NCT01710449|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
57955125|NCT02730884|DRUG|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
57955126|NCT02730884|BEHAVIORAL|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
58106670|NCT05016076|DIAGNOSTIC_TEST|Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)|A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
58106671|NCT05016076|DEVICE|Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy|In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
58106672|NCT05016076|DEVICE|Goal-directed hemodynamic therapy targeting cardiac index|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
58106673|NCT05016076|DRUG|Placebo (0.9% sodium chloride)|Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
58106674|NCT06191510|PROCEDURE|Bio-Oss Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
58106675|NCT06191510|PROCEDURE|Mucograft Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
58106676|NCT01664494|DRUG|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
58106677|NCT04470622|DRUG|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
58438152|NCT05311267|OTHER|Action observation training|Subject is asked to observe videos with motor contents
58106678|NCT04470622|DRUG|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
58106679|NCT05086081|DRUG|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
58106680|NCT05086081|DRUG|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
58106681|NCT03099967|DEVICE|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
58106682|NCT04036383|OTHER|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
57738473|NCT04320160|PROCEDURE|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
57955127|NCT01219010|BIOLOGICAL|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
57955128|NCT01661140|DRUG|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
57955129|NCT01661140|DRUG|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
57955130|NCT01661140|DRUG|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
58438153|NCT02377648|DEVICE|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
57955131|NCT05044676|OTHER|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
58310703|NCT00945243|DEVICE|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
58310704|NCT02254746|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
57955132|NCT04369365|DRUG|Azithromycin 500 milligram (mg) oral Tablet|weekly oral use
57955133|NCT04369365|DRUG|Placebo|weekly oral use
58106683|NCT04036383|OTHER|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
58106684|NCT04036383|OTHER|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
58106685|NCT03341598|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
58438154|NCT00572208|DRUG|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
58438155|NCT05797636|DEVICE|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
58438156|NCT00672906|BEHAVIORAL|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
58438157|NCT00672906|BEHAVIORAL|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
58438158|NCT02100969|DRUG|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
58438159|NCT03967054|DRUG|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
57955134|NCT03428893|DEVICE|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
58106686|NCT03341598|PROCEDURE|R|Restorative procedure to treat tooth structure loss.
58106687|NCT03341598|PROCEDURE|MC|Xenogenous graft placed in the surgical site.
58310705|NCT05423418|BIOLOGICAL|A244|Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
58310706|NCT05423418|BIOLOGICAL|B.63521|Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
58310707|NCT05423418|BIOLOGICAL|50μg ALFQ|Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
57738474|NCT04320160|PROCEDURE|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
57955135|NCT04772261|DIAGNOSTIC_TEST|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
57955136|NCT05543564|PROCEDURE|PRP|Single session prophylactic early Pan-retinal Photocoagulation
57955137|NCT05378438|OTHER|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
57955138|NCT02820129|DEVICE|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
57955139|NCT02820129|DEVICE|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
57955140|NCT00657891|DRUG|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
57955141|NCT00657891|DRUG|Placebo|Placebo Injection
58310708|NCT05423418|BIOLOGICAL|100μg ALFQ|Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
58438160|NCT03967054|DRUG|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
58438161|NCT04139356|PROCEDURE|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
58438162|NCT02983864|BEHAVIORAL|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
58438163|NCT02983864|BEHAVIORAL|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
58438164|NCT02983864|BEHAVIORAL|Relaxation|A one session intervention focused on increasing relaxation skills
58438165|NCT02983864|BEHAVIORAL|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
58438166|NCT01755728|DRUG|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
58438167|NCT01755728|DRUG|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
58438168|NCT01755728|PROCEDURE|Closure of PDA|Open surgery for closure of PDA
58438169|NCT02816528|BEHAVIORAL|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
58438170|NCT03168178|DRUG|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
58438171|NCT03168178|OTHER|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
58438172|NCT04370353|DIETARY_SUPPLEMENT|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
58438173|NCT04370353|DIETARY_SUPPLEMENT|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
58438174|NCT03421106|BEHAVIORAL|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
58438175|NCT03421106|OTHER|Control Food Pantries|Normal food pantry use
58438176|NCT02489942|DRUG|Jardiance|Empagliflozin
58438177|NCT04067414|BIOLOGICAL|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells."
58438178|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
58438179|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
58438180|NCT03463785|OTHER|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
58438181|NCT05112003|DEVICE|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
58310709|NCT05423418|BIOLOGICAL|200μg ALFQ|Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
58310710|NCT03869099|OTHER|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
58438182|NCT00549445|DRUG|Azithromycin|250 mg daily
58438183|NCT00549445|DRUG|Placebo|Daily
58310711|NCT05645198|DRUG|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
58310712|NCT05645198|DRUG|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
58438184|NCT02139488|OTHER|Fiducial markers|
58438185|NCT02139488|OTHER|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
58438186|NCT01339897|DRUG|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
58438187|NCT01339897|DRUG|Placebo|Same administration procedures as active
57955142|NCT03454022|BEHAVIORAL|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
58438188|NCT01339897|DRUG|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
58438189|NCT01339897|DRUG|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
58438190|NCT04022252|DEVICE|Cheese dental laser|810 nm GaAlAs diode laser device
58438191|NCT04022252|DEVICE|OrthoPulse|850 nm LED (light emitting diode)
58438192|NCT04022252|OTHER|Placebo|810 nm GaAlAs diode laser device
58438193|NCT05551104|DRUG|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
58438194|NCT05551104|DRUG|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
58438195|NCT06268964|DRUG|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
58438196|NCT06268964|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
58106688|NCT02869932|RADIATION|Lung CT scan|Lung CT scan without injection
58310713|NCT02371616|DEVICE|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
58438197|NCT06268964|OTHER|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
58438198|NCT03727932|DEVICE|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
58438199|NCT04918511|DRUG|OPD5|OPD5 solution for i.v. infusion
58438200|NCT04180332|DIAGNOSTIC_TEST|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
58438201|NCT05310812|DIAGNOSTIC_TEST|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
57955143|NCT03454022|BEHAVIORAL|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
57955144|NCT01455688|DRUG|early HAART|Initiation of HAART within 5 days of ICU admission
57955145|NCT01455688|DRUG|Late HAART|Initiation of HAART after ICU discharge
57955146|NCT03166033|OTHER|the disease|Observation the patients and non-patients
57955147|NCT05195008|DRUG|BIIB113|Administered as specified in the treatment arm.
57955148|NCT05195008|DRUG|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
57955149|NCT05195008|DRUG|11^C]BIO-1819578|Administered as specified in the treatment arm.
57955150|NCT06294457|DEVICE|Non-Invasive Neuromodulation NESA|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
57738475|NCT02245152|DIETARY_SUPPLEMENT|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
57955151|NCT00705211|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets,
57955152|NCT00705211|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
58106689|NCT00700869|PROCEDURE|mechanical ventilation|mechanical ventilation
58310714|NCT02371616|OTHER|Sodium fluoride|1426 ppm fluoride as sodium fluoride
58310715|NCT02371616|OTHER|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
58310716|NCT06027515|BEHAVIORAL|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
58438202|NCT01771250|BIOLOGICAL|Insulin Peglispro|Daily doses administered SC.
58438203|NCT01771250|BIOLOGICAL|Insulin Glargine|Daily doses administered SC.
58438204|NCT04064762|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
58310717|NCT05808179|DEVICE|Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s
57738476|NCT02245152|BEHAVIORAL|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
57955153|NCT04153188|DEVICE|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
57955154|NCT04153188|DRUG|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
57955155|NCT06500143|DIAGNOSTIC_TEST|Gastric ultrasound|"Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create ring-down artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value."
57955156|NCT06458803|DRUG|Eltrombopag|patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
57955157|NCT02464384|PROCEDURE|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
58106690|NCT05725707|BEHAVIORAL|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
58310718|NCT05808179|BEHAVIORAL|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
58310719|NCT05808179|DEVICE|Sham Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
57738477|NCT02245152|BEHAVIORAL|National policy well-baby visits|
57955158|NCT02447588|OTHER|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
57955159|NCT02447588|OTHER|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
57955160|NCT05550311|OTHER|Robot-assisted rehabilitation|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program. Range of motion exercises will display on the monitor as a game form. There are 4 games available on the computer (airplane game, rabbit shooting game, ball game, and shopping game) and these games can provide exercises for three joints (shoulder, elbow wrist). There are also 3 different levels of resistance apparatus for each joint. People with a full range of motion can do these exercises with resistance. Before starting the rehabilitation, which joint and which movement to do is determined. To the person; After explaining the desired movement and how to play the game shown on the monitor, the exercises are started. The exercises last 45 minutes, during which exercises are performed for the shoulder, elbow, and wrist.
57955161|NCT05550311|OTHER|Conventional rehabilitation|The conventional Rehabilitation Program consists of; range of motion exercises, strengthening exercises, stretching exercises, balance, and walking exercises and Bobath based neurophysiological approaches.
57955162|NCT02433652|BIOLOGICAL|Recombinant live attenuated trivalent dengue vaccine|Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.
57955163|NCT02433652|BIOLOGICAL|Placebo|
57955164|NCT02433652|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
57955165|NCT02504021|BEHAVIORAL|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
57955166|NCT04238390|DRUG|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
57955167|NCT04238390|DRUG|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
57955168|NCT05532774|DEVICE|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
57955169|NCT05433506|DRUG|HU6 Tablet|Six subjects will receive a tablet formulation.
57955170|NCT05433506|DRUG|HU6 Capsule|Six subjects will receive the capsule formulation
57955171|NCT01709435|DRUG|Cabozantinib S-malate|Given PO
57955172|NCT01709435|OTHER|Laboratory Biomarker Analysis|Correlative studies
57955173|NCT01709435|OTHER|Pharmacological Study|Correlative studies
57955174|NCT05846685|OTHER|Patient Phone Interviews|Collecting perceptions about automated falls-risk screening and referral tool
57955175|NCT05846685|OTHER|Patient In Person Interviews|Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
57955176|NCT04453982|OTHER|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
58310720|NCT02192788|RADIATION|Stereotactic Body Radiation Therapy for Oligometastases|
58310721|NCT01094288|DRUG|Alisertib|Alisertib ECT
58310722|NCT01094288|DRUG|Docetaxel|Docetaxel IV infusion
58310723|NCT01822444|OTHER|Biomarker analysis|
58310724|NCT01673386|DRUG|Tivozanib|
58310725|NCT01673386|DRUG|Sunitinib|
58310726|NCT02957201|OTHER|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
58438205|NCT05501834|OTHER|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
58438206|NCT05407038|OTHER|Exercise Counseling|Receive call from health coach
58438207|NCT05407038|OTHER|Exercise Intervention|Undergo routine exercise
58438208|NCT05407038|OTHER|Internet-Based Intervention|Receive Android tablet
58438209|NCT05407038|OTHER|Interview|Complete a qualitative interview
58438210|NCT05407038|OTHER|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
58438211|NCT05407038|OTHER|Questionnaire Administration|Ancillary studies
58438212|NCT05719675|BEHAVIORAL|Intervention|"The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
58438213|NCT03394586|DRUG|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
58438214|NCT02170870|DRUG|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
58438215|NCT02170870|DRUG|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
58438216|NCT02170870|DRUG|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
58438217|NCT02189291|PROCEDURE|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
58438218|NCT02189291|PROCEDURE|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
58438219|NCT03118089|DIETARY_SUPPLEMENT|Biscuit style oral nutritional supplement|
58438220|NCT06231979|DRUG|Dexmedetomidine|1 μg/kg Dexmedetomidine per side in erector spinae block
58106691|NCT02095119|DRUG|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
57955177|NCT05148923|PROCEDURE|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
57955178|NCT01639677|PROCEDURE|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
58438221|NCT06231979|DRUG|Bupivacain|18 mL of bupivacaine 0.25 % per side in erector spinae block
58438222|NCT06231979|DRUG|Normal saline|2 ml normal saline 0.9% per side in erector spinae block
58438223|NCT04872660|DRUG|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
57955179|NCT01639677|PROCEDURE|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
58438224|NCT04872660|DRUG|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
57738478|NCT05315193|OTHER|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
57955180|NCT02425826|DRUG|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
58106692|NCT02095119|DRUG|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is \>/= 60. The administration form will be intravenously.
58106693|NCT02095119|DRUG|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation \< 60). The administration form will be intravenously.
58106694|NCT02095119|PROCEDURE|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
58106695|NCT03334916|DRUG|YMC026|YMC026 20mL TID
58106696|NCT03334916|DRUG|Placebo|Placebo 20mL TID
58106697|NCT05530642|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire \& Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
58106698|NCT00371488|DRUG|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
58106699|NCT02556632|DRUG|Curcumin-based Gel|Applied topically
58106700|NCT02556632|PROCEDURE|Dermatologic Complications Management|Apply HPR Plus topically
58106701|NCT02556632|OTHER|Laboratory Biomarker Analysis|Correlative studies
58106702|NCT02556632|OTHER|Placebo|Apply placebo gel topically
58106703|NCT02556632|OTHER|Questionnaire Administration|Ancillary studies
58106704|NCT04412876|DRUG|Duloxetine|Duloxetine 30 mg qd
58106705|NCT04412876|DRUG|Imipramine|Imipramine 25mg qd
58106706|NCT03287479|PROCEDURE|Gavi® Vitrification|A closed, semi-automated vitrification system
58106707|NCT03287479|PROCEDURE|Cryotop® Vitrification|An open, manual vitrification system
58106708|NCT00700310|DRUG|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
58106709|NCT00700310|DRUG|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
58106710|NCT00700310|DRUG|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
57955181|NCT02425826|DRUG|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
57955182|NCT02425826|DRUG|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
57955183|NCT01006421|DIETARY_SUPPLEMENT|GINGKO BILOBA|MEMOREX 60 MG BID
57955184|NCT01515384|DRUG|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
58106711|NCT00700310|DRUG|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
58106712|NCT03235583|DEVICE|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
58106713|NCT04401787|PROCEDURE|Anterior resection for upper rectal cancer in obese|Anterior resection for upper rectal cancer in obese
58106714|NCT02205866|OTHER|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
58310727|NCT02332603|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
57955185|NCT04995081|BIOLOGICAL|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
58310728|NCT02332603|DRUG|Isotonic Sodium Chloride|Placebo
57955186|NCT04995081|OTHER|Placebo|Sterile Saline Solution 0.9%
57955187|NCT01457807|DRUG|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
57955188|NCT01457807|DRUG|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
58438225|NCT01487889|OTHER|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
58438226|NCT01517555|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
58106715|NCT05998733|DIAGNOSTIC_TEST|Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring|"* Correlation analysis of sepsis severity with FDP and D-Dimer~* Discussion on the critical value and area under the curve of FDP and D-Dimer in diagnosis of sepsis~* Differences in age and sex of FDP and D-Dimer in diagnosis of sepsis~* Effect of FDP and D-Dimer diagnosis of sepsis on severe conversion rate and all-cause mortality of patients~* The difference of thromboelastogram in patients with sepsis of different severity~* Thromboelastogram items (R time α Correlation between angle, k time, maximum blood clot strength and comprehensive coagulation index) and sepsis"
58106716|NCT04117152|OTHER|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
58106717|NCT02807324|OTHER|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
58106718|NCT02175654|DRUG|Regorafenib|
58106719|NCT06427330|DRUG|Inotuzumab ozogamicin|"1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2"
58106720|NCT04495387|DRUG|Chemotherapy|standard adjuvat chemotherapy for reast and colo cancer
58438227|NCT01517555|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
58438228|NCT01517555|DRUG|paracetamol|One single dose of 1 g. Tablet
58438229|NCT02470481|OTHER|No Intervention|This is an obervational study
58438230|NCT00466921|DRUG|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
58438231|NCT05423964|DIAGNOSTIC_TEST|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
58438232|NCT05423964|OTHER|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
58438233|NCT03601702|DEVICE|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
58438234|NCT04099784|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
58438235|NCT04099784|OTHER|Physical development and General Health|Physical development and General health examination
58438236|NCT04099784|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
58438237|NCT06272123|OTHER|no intervention|no intervention
58438238|NCT02078128|DIETARY_SUPPLEMENT|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
58438239|NCT02078128|DRUG|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
58438240|NCT06166368|OTHER|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
58438241|NCT04826640|OTHER|Observational|Observational
58438242|NCT02744196|BIOLOGICAL|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
58438243|NCT02744196|DRUG|Placebo|Placebo solution will look identical to the Acellbia solution.
57955189|NCT01457807|DRUG|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
58106721|NCT05719610|OTHER|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
58106722|NCT05719610|OTHER|Swiss Ball Exercises|Swiss Ball Exercises
58106723|NCT00004187|DRUG|capecitabine|
58106724|NCT00004187|DRUG|oxaliplatin|
58106725|NCT04888741|DRUG|Thymoglobulin|GVHD prophylaxis
58106726|NCT04888741|DRUG|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
58106727|NCT04888741|DRUG|Cyclosporine|immunosuppressant
58106728|NCT04888741|DRUG|Sirolimus|immunosuppressant
58106729|NCT04888741|DRUG|Mycophenolate Mofetil|immunosuppressant
58106730|NCT03573115|DRUG|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
58106731|NCT04212182|DEVICE|HFNC|HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
58106732|NCT04212182|DEVICE|NPPV|NPPV is the standard therapy for ventilatory failure in AECOPD.
58438244|NCT02744196|DRUG|Methotrexate|
58438245|NCT06312436|PROCEDURE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
58438246|NCT03443804|DRUG|Test(DW1401)|DW1401+Placebo of Stillen tab.
58438247|NCT03443804|DRUG|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
58438248|NCT03624595|DRUG|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
58438249|NCT03624595|DRUG|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
58438250|NCT00663754|BEHAVIORAL|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
58106733|NCT03223285|BEHAVIORAL|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
58106734|NCT03223285|BEHAVIORAL|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
58106735|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
57738479|NCT05315193|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
58438251|NCT00663754|BEHAVIORAL|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
58438252|NCT01593592|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
58438253|NCT01593592|DIETARY_SUPPLEMENT|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
58438254|NCT01593592|DRUG|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
58438255|NCT01593592|DRUG|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
58438256|NCT01593592|DRUG|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
58438257|NCT01286025|BEHAVIORAL|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
57955190|NCT04640688|PROCEDURE|Bariatric procedures|510(k) summary K081853 dated June 26, 2008, Endoscopic Sleeve Gastroplasty lecture, Methodist Dallas Medical Center Endobariatric Pathway \& Endoscopic Sleeve Gastroplasty Procedure Description
58106736|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
58106737|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
58106738|NCT03533530|DIAGNOSTIC_TEST|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
58106739|NCT03533530|DIAGNOSTIC_TEST|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
58438258|NCT01286025|BEHAVIORAL|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
58438259|NCT04068116|PROCEDURE|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
58438260|NCT00856947|DIETARY_SUPPLEMENT|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
57738480|NCT01388816|DRUG|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
57738481|NCT00717990|DRUG|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
57738482|NCT00717990|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
57738483|NCT00717990|DRUG|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
57738484|NCT05598190|DEVICE|Pro-Yellow laser 577|4 session for cases with digtal photo before and after sessions
57738485|NCT00291785|DRUG|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 \& 29 of each 42-day cycle
57738486|NCT00291785|DRUG|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
58106740|NCT03533530|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
58106741|NCT01347879|DRUG|Visonac PDT|cream application prior to illumination with red light
58438261|NCT00856947|OTHER|Placebo tablet|2 tablets containing no active substance
57738487|NCT00291785|DRUG|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
58106742|NCT01347879|DRUG|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
58106743|NCT04354402|OTHER|No intervention|No intervention
58106744|NCT00069160|DRUG|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
58106745|NCT00069160|DRUG|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
58106746|NCT00069160|OTHER|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
58106747|NCT02309918|DRUG|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
58106748|NCT03438305|OTHER|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
58438262|NCT00988949|DRUG|PF-04455242|Single oral 18 mg dose of PF-04455242.
58438263|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
58106749|NCT03438305|OTHER|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
58106750|NCT01220089|BEHAVIORAL|Standard maintenance|Participants will receive written materials in months 7-18
58106751|NCT01220089|BEHAVIORAL|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
58106752|NCT02289027|BIOLOGICAL|cAd3-EBOZ vaccine|
58106753|NCT02289027|BIOLOGICAL|Placebo (for cAd3-EBOZ vaccine)|Diluent
58106754|NCT01308983|DRUG|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
58106755|NCT05651529|DIETARY_SUPPLEMENT|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
58106756|NCT05651529|DIETARY_SUPPLEMENT|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
58438264|NCT00988949|OTHER|Placebo|Oral placebo.
58438265|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
57738488|NCT05312138|DEVICE|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
57738489|NCT05312138|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
58438266|NCT00988949|DRUG|PF-04455242|Single 30 mg oral dose of PF-04455242.
57738490|NCT04883632|COMBINATION_PRODUCT|Saypha Volume Lidocaine|correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma
57738491|NCT03827954|OTHER|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
57738492|NCT01655030|DIETARY_SUPPLEMENT|creatine monohydrate|
57955191|NCT04153721|BEHAVIORAL|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
58106757|NCT01058382|DRUG|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
58106758|NCT01058382|DRUG|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
58106759|NCT02309554|OTHER|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
58438267|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
58438268|NCT03225703|BEHAVIORAL|Hopping|A unilateral, hopping based exercise programme lasting six months.
58438269|NCT05370443|BEHAVIORAL|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
58438270|NCT05630677|DRUG|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
58438271|NCT05630677|DRUG|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
58438272|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
58438273|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
57738493|NCT01655030|DIETARY_SUPPLEMENT|placebo|
57738494|NCT05795582|DEVICE|POPMETRE® (Axelife , France)|Measurement with 2 devices
57738495|NCT00827450|DIETARY_SUPPLEMENT|Ctl|Control, isocaloric diet; no coffee
57738496|NCT00827450|DIETARY_SUPPLEMENT|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
58438274|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
58438275|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
58438276|NCT02210260|PROCEDURE|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
58438277|NCT02210260|PROCEDURE|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
58438278|NCT02210260|DRUG|Bupivacaine|
58438279|NCT02210260|DRUG|Diamorphine|500mcg
58438280|NCT02210260|DEVICE|A Painbuster® catheter|
58438281|NCT02210260|DEVICE|25G Whitacre needle|
58438282|NCT04714034|DIAGNOSTIC_TEST|"to develop and validate a scale measuring online dating addiction (ODA) in sexual minorities - the ODA Scale"|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of ODA Scale scores with sexual health and mental health outcomes."
58438283|NCT01205971|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
58438284|NCT01205971|BEHAVIORAL|Dental Preventive Services|Written oral health educational materials
58438285|NCT01224366|DRUG|Vildagliptin|
57955192|NCT05841823|BEHAVIORAL|Virtual reality exposure therapy (VRET)|The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
58438286|NCT01224366|DRUG|Placebo|
58438287|NCT00654979|DEVICE|SafeFlo IVC Filter|SafeFlo IVC Filter
58438288|NCT05696756|BEHAVIORAL|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
58106760|NCT02309554|OTHER|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
58438289|NCT05696756|BEHAVIORAL|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
58438290|NCT06351449|OTHER|The patch under study is photographed using the SkinCam®|Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.
58438291|NCT00734968|DRUG|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
58438292|NCT00734968|OTHER|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
58438293|NCT02595255|OTHER|No intervention|No intervention
58438294|NCT00858637|DRUG|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
58438295|NCT00858637|DRUG|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
57738497|NCT00827450|DIETARY_SUPPLEMENT|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
57738498|NCT00827450|DIETARY_SUPPLEMENT|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
58106761|NCT02309554|OTHER|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
58106762|NCT01133444|DRUG|Finasteride|Finasteride tablets 1 mg
58438296|NCT00858637|DRUG|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
58438297|NCT00858637|DRUG|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
58438298|NCT01700543|PROCEDURE|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
58438299|NCT06399237|DEVICE|Foot Orthoses|Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
58438300|NCT03051386|BIOLOGICAL|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
58106763|NCT03978169|DIAGNOSTIC_TEST|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
58438301|NCT03644667|BIOLOGICAL|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
58438302|NCT03644667|BIOLOGICAL|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
57738499|NCT00827450|DIETARY_SUPPLEMENT|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
58106764|NCT06536634|OTHER|SAES|The experimental intervention consists of SAES with a glove or adhesive electrodes at 20Hz, 300µs, intensity between 2-10mA, during 30 minutes per day, 5x/week, for 5 weeks, combined with conventional occupation therapy. The subsequent therapy sessions will take place at home, with in-between telephone checks.
58106765|NCT06536634|OTHER|TAU|Treatment as usual
58106766|NCT03355859|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
58106767|NCT05078710|DRUG|Telitacicept|160mg once a week for 24 weeks
57738500|NCT01027546|DRUG|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
57738501|NCT04013711|DIAGNOSTIC_TEST|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
57955193|NCT05841823|BEHAVIORAL|Acceptance and commitment therapy (ACT)|The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
57955194|NCT06434311|DIAGNOSTIC_TEST|3 meter Backward Test|evaluation
57955195|NCT00820521|DRUG|active|
57955196|NCT00820521|DRUG|placebo|
58106768|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58310729|NCT04117022|DIETARY_SUPPLEMENT|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
58310730|NCT03668106|PROCEDURE|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
58310731|NCT05643235|DEVICE|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
58310732|NCT00346866|DRUG|anecortave acetate|
58310733|NCT05016960|BEHAVIORAL|Sleep-SMART|Sleep-SMART will be a treatment for insomnia that will follow the standard 6 session 50-minute CBT-I format and will deliver CBT-I treatment along with training in select CogSMART strategies to enhance intervention learning and adherence. It will be delivered via video-based telehealth.
58310734|NCT04457856|BIOLOGICAL|TJ003234 injection|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
58310735|NCT05001620|OTHER|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
58310736|NCT00133796|DRUG|Herceptin|IV
58310737|NCT06243302|PROCEDURE|OTSC Closure After VAAFT|Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
58310738|NCT06517199|DRUG|Olanzapine 2.5 MG|olanzapine 2.5 mg/day for 28 days
58310739|NCT06517199|DRUG|Olanzapine 5 MG|olanzapine 5 mg/day for 28 days
58310740|NCT06517199|DRUG|Placebo|placebo 1 tab/day for 28 days
58310741|NCT02294266|DRUG|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
58310742|NCT02294266|DRUG|Mephedrone|Single oral dose mephedrone
58310743|NCT02294266|DRUG|Alcohol|Single oral dose alcohol
58310744|NCT02294266|DRUG|Placebo|Single oral dose placebo
58310745|NCT00235261|DRUG|Pregabalin|
58310746|NCT00235261|DRUG|Dexamethasone|
58310747|NCT00122057|DRUG|antibiotic treatment|
58106769|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58106770|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58106771|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58106772|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58106773|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
58106774|NCT01956682|DIETARY_SUPPLEMENT|HA formula + starch + L. reuteri|
58106775|NCT02122159|BIOLOGICAL|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
58438303|NCT03644667|DRUG|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
58438304|NCT04766775|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
58438305|NCT01716741|OTHER|Enzyme analysis|
58438306|NCT00257361|DRUG|D-Cycloserine|
57955197|NCT06149780|DEVICE|Patients treated with laser|Patients treated with laser with topical steroid Patients treated with laser with vehicle
58438307|NCT01147354|DIETARY_SUPPLEMENT|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
58106776|NCT03712228|BIOLOGICAL|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
58310748|NCT02424825|BEHAVIORAL|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
58310749|NCT05947331|PROCEDURE|Graded Anderson procedure|In graded Anderson proceduren only recession of yoke muscles is done.
58438308|NCT01147354|OTHER|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
58438309|NCT01706588|DRUG|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
58438310|NCT05740943|DRUG|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
58438311|NCT04731272|DRUG|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
57955198|NCT04082754|BIOLOGICAL|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
57955199|NCT04082754|DRUG|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
57955200|NCT05304351|BIOLOGICAL|CRV-101 Vaccine Antigen High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
57955201|NCT05304351|BIOLOGICAL|CRV-101 Vaccine Antigen Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
57955202|NCT05304351|BIOLOGICAL|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
57955203|NCT05304351|BIOLOGICAL|CRV-101 Vaccine Adjuvant High Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
57955204|NCT05304351|BIOLOGICAL|CRV-101 Vaccine Adjuvant Middle Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
58106777|NCT03712228|DRUG|Placebo|Buffer without active ingredient
58106778|NCT02267850|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
58106779|NCT02267850|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
58106780|NCT02267850|DEVICE|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
58106781|NCT03637673|OTHER|No intervention|No intervention
58106782|NCT03066154|DRUG|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
58106783|NCT03066154|DRUG|androgen deprivation therapy|ADT according to the standard of care
58106784|NCT03066154|RADIATION|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
58310750|NCT05947331|PROCEDURE|Kestenbaum procedure|In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
58310751|NCT05662969|DEVICE|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
58310752|NCT01977833|OTHER|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
58106785|NCT03530033|DRUG|Lidocaine|Local injection of lidocaine reduces muscle tremor
58106786|NCT02751086|PROCEDURE|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
58106787|NCT02751086|PROCEDURE|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
58106788|NCT03778359|DRUG|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
58106789|NCT03778359|DEVICE|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
58106790|NCT03778359|DRUG|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
58106791|NCT03778359|DRUG|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
58106792|NCT01684449|DRUG|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
58106793|NCT03101579|DRUG|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
58106794|NCT03101579|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
58438312|NCT06418672|BEHAVIORAL|Go Sun Smart Georgia (GSSG)|"Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups."
58438313|NCT05810350|DRUG|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
58438314|NCT03567746|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
58106795|NCT03101579|DRUG|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
58106796|NCT03101579|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
58106797|NCT00751972|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
58106798|NCT05409599|OTHER|Exercises|Exercises
58438315|NCT03567746|PROCEDURE|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
58438316|NCT00093652|DRUG|gefitinib|
58438317|NCT00093652|DRUG|oxaliplatin|
58106799|NCT04567199|OTHER|Observational, retrospective|retrospective analysis of observed results, for both study groups.
58106800|NCT03777787|DIETARY_SUPPLEMENT|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
58106801|NCT03777787|DIETARY_SUPPLEMENT|Water|A single intragastric administration of water
58310753|NCT01977833|OTHER|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
58438318|NCT00093652|PROCEDURE|conventional surgery|
58310754|NCT03034967|DRUG|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
58438319|NCT00093652|PROCEDURE|neoadjuvant therapy|
58438320|NCT00093652|RADIATION|radiation therapy|
58438321|NCT02463682|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
58106802|NCT04133480|DRUG|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
58106803|NCT04422015|OTHER|No intervention|No intervention
58106804|NCT06058468|PROCEDURE|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration \>30% is achieved or if radiofrequency time exceeds 120 seconds.
58106805|NCT06058468|PROCEDURE|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
58106806|NCT01111630|DRUG|recomon (Epoetin Beta)|administer once weekly
58106807|NCT01111630|DRUG|recomon (Epoetin Beta)|administer three times weekly
58106808|NCT02627365|BEHAVIORAL|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
58106809|NCT06464237|OTHER|Mio-App|The Mio-App aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and motor skills to reduce cognitive and physical long-term sequelae after cancer during adolescence.
58106810|NCT00155441|BEHAVIORAL|cognitive-behavioral therapy|
58310755|NCT03034967|DRUG|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
58310756|NCT03034967|DRUG|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
58310757|NCT03034967|DRUG|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
58310758|NCT02652793|DRUG|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
58310759|NCT02652793|DRUG|Lamivudine|Lamivudine 300 mg once dailly
58310760|NCT01803438|DEVICE|cryoballoon ablation system|
58310761|NCT01803438|DRUG|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
58310762|NCT03927092|OTHER|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
58310763|NCT05295407|GENETIC|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
58310764|NCT01803386|DEVICE|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
58310765|NCT04140448|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
58310766|NCT04140448|DEVICE|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
58310767|NCT02016326|DEVICE|HD Colon|High Definition White Light
58310768|NCT02016326|DEVICE|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
58310769|NCT02016326|DEVICE|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
58310770|NCT04197440|DRUG|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
58310771|NCT04197440|DRUG|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
58310772|NCT04197440|DRUG|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
58310773|NCT04197440|DRUG|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
58310774|NCT04197440|DRUG|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
58310775|NCT04197440|DRUG|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
58438322|NCT02463682|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
58438323|NCT02955537|OTHER|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
58438324|NCT04702022|DIAGNOSTIC_TEST|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
58438325|NCT00832429|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
58438326|NCT00832429|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
58438327|NCT00832429|DRUG|Technetium Tc-99m Sulfur Colloid|Given ID
58438328|NCT01418079|DEVICE|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
58438329|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
58438330|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
58438331|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
58438332|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
58438333|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
58438334|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
58438335|NCT00930878|DEVICE|Cardiac Stenting|Drug Eluting stent
58438336|NCT06438432|OTHER|RAIT|The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
57738502|NCT05668728|OTHER|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
57955205|NCT05304351|BIOLOGICAL|CRV-101 Vaccine Adjuvant Low Dose|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
58438337|NCT03642496|BIOLOGICAL|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
58438338|NCT03642496|BIOLOGICAL|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
58438339|NCT03642496|BIOLOGICAL|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
58438340|NCT02937558|DRUG|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
58438341|NCT02937558|OTHER|Placebo|Isotonic saline
58438342|NCT04086914|PROCEDURE|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
58438343|NCT05799417|OTHER|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
58438344|NCT03512379|DEVICE|TIANJI Robot|A robotic system for spinal surgery
58438345|NCT03512379|DEVICE|Fluoroscopy|For fluoroscopy-based free hand surgery
58438346|NCT03512379|DEVICE|Navigation|For navigation-assisted spinal surgery
58438347|NCT02478164|DRUG|Ponatinib|
58438348|NCT00550693|DEVICE|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
58438349|NCT06433089|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block was performed before surgery
58310776|NCT04197440|DRUG|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
58438350|NCT04279522|DEVICE|Relivion®DP- Active|Relivion®DP- Active stimulation device
58438351|NCT04279522|DEVICE|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
58106811|NCT06206499|PROCEDURE|soft tissue augmentation|"Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants."
58106812|NCT00860574|DRUG|treosulfan|Given IV
58106813|NCT00860574|DRUG|fludarabine phosphate|Given IV
58106814|NCT00860574|RADIATION|total-body irradiation|Low dose starting at 2Gy
58106815|NCT00860574|PROCEDURE|peripheral blood stem cell transplantation|Given IV per institutional standard practice
58106816|NCT00860574|DRUG|tacrolimus|Given IV or PO
58106817|NCT00860574|PROCEDURE|allogeneic bone marrow transplantation|Given IV per institutional standard practice
58106818|NCT00860574|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
58106819|NCT00860574|DRUG|methotrexate|Given IV
58106820|NCT04039165|BEHAVIORAL|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
58438352|NCT01711125|DRUG|Baclofen 30mg/day|30mg/day 10 mg t.i.d
58438353|NCT01711125|DRUG|Baclofen 75mg/day|75mg/day 25 mg t.i.d
58438354|NCT01711125|DRUG|Placebo|Placebo 3 matched tabs/day
58438355|NCT03225378|OTHER|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
58106821|NCT01676259|DRUG|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
58106822|NCT01676259|DRUG|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
58106823|NCT01676259|DRUG|Folfirinox|Folfirinox or modified Folfirinox
58106824|NCT01408576|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
58106825|NCT01408576|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
58106826|NCT00459381|DRUG|pazopanib hydrochloride|Given orally
58438356|NCT03225378|OTHER|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
58106827|NCT00459381|OTHER|laboratory biomarker analysis|Correlative studies
58106828|NCT04540120|DRUG|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
58106829|NCT04540120|DRUG|placebo capsules|Hard opaque capsules containing 0 mg of API.
58106830|NCT02864680|OTHER|Electroretinography|
58106831|NCT02864680|OTHER|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
58106832|NCT02864680|OTHER|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
58106833|NCT02864680|OTHER|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
58438357|NCT04188704|PROCEDURE|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
58106834|NCT02864680|OTHER|CAST (cannabis abuse screening test)|
58106835|NCT02864680|OTHER|PANSS (Positive And Negative Symptoms Scale) test|
58106836|NCT02864680|OTHER|Delayed Matching to Sample (DMS) test|
58106837|NCT02864680|OTHER|Spatial Working Memory (SWM) test|
58438358|NCT00004050|BIOLOGICAL|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
58438359|NCT03226925|DIAGNOSTIC_TEST|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
58438360|NCT03226925|DIAGNOSTIC_TEST|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
58438361|NCT03226925|DIAGNOSTIC_TEST|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
58106838|NCT02864680|OTHER|Rapid Visual Information Processing (RVP) test|
58106839|NCT02864680|OTHER|Test for attentional performance (TAP) / Divided Attention|
58106840|NCT02864680|OTHER|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
58106841|NCT05074563|OTHER|REsOluTioN (Resilience Enhancement Online Training for Nurses)|The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
58106842|NCT05074563|OTHER|Control|Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
58106843|NCT03877237|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
58106844|NCT03877237|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
58106845|NCT02169583|DRUG|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
58106846|NCT02169583|DRUG|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
58106847|NCT02169583|DRUG|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
58106848|NCT02169583|DRUG|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
58106849|NCT05162885|PROCEDURE|Socket Preservation technique|Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama\&salama Class 3 labial wall defect
58106850|NCT02651896|RADIATION|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
58106851|NCT02295683|DEVICE|Renal Denervation|
58106852|NCT01291719|DEVICE|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
58106853|NCT06485037|BEHAVIORAL|Time-restricted eating|Self-selected 10-hour eating window for 2 months
58106854|NCT00380913|DRUG|Cesamet™ (nabilone)|
58106855|NCT00391937|DEVICE|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
58106856|NCT05950633|OTHER|Standard of Care|Participants will receive standard of care postoperative instructions
58106857|NCT05950633|OTHER|Active Recovery|Participants will receive instructions to increase their fitness to walking at least 30 minutes a day for 5 days a week following surgery and abdominal and pelvic floor exercises will focus on abdominal wall strengthening and abdominal pressure management, urinary urgency and retention, bowel and constipation management
58106858|NCT00591487|DRUG|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
58106859|NCT06388668|DIAGNOSTIC_TEST|Lipid panel|Lipid panel measuring levels of LDL, non-HDL and apoB
58106860|NCT00345683|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
58106861|NCT00345683|BIOLOGICAL|PedvaxHIB|Booster dose by intramuscular injection
58106862|NCT00345683|BIOLOGICAL|Prevnar|Booster dose by intramuscular injection
58106863|NCT00345683|BIOLOGICAL|M-M-R II|Single dose by subcutaneous injection
58106864|NCT00345683|BIOLOGICAL|Varivax|Single dose by subcutaneous injection
58106865|NCT02191956|BEHAVIORAL|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
58310777|NCT04197440|DRUG|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
58310778|NCT01627132|DRUG|Dasatinib|100mg QD
58310779|NCT06294470|DIAGNOSTIC_TEST|Ballon expulsion test|Rectal latex balloon probe filled with saline solution. Patients expelled balloon and time recorded (\<1 or \>1 min).
58106866|NCT04009473|COMBINATION_PRODUCT|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
58106867|NCT03893409|OTHER||this is a observation study, no any intervention in patients
58106868|NCT05633537|PROCEDURE|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
58106869|NCT05633537|RADIATION|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
58106870|NCT00240864|DRUG|placebo|
58106871|NCT00240864|DRUG|acetaminophen|
58106872|NCT00240864|DRUG|ibuprofen|
58106873|NCT06529224|OTHER|Online questionnaire|An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
58106874|NCT04583839|BEHAVIORAL|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
58106875|NCT01335464|DRUG|placebo|placebo matching BIBF1120, BID
58106876|NCT01335464|DRUG|BIBF 1120|BIBF1120 BID (twice daily)
57738503|NCT05668728|OTHER|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
58106877|NCT01588587|DRUG|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
58106878|NCT01588587|DRUG|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
58106879|NCT01588587|DRUG|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
58106880|NCT00512356|BIOLOGICAL|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
58106881|NCT01501201|PROCEDURE|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
58106882|NCT01501201|DRUG|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
58106883|NCT03165266|DIAGNOSTIC_TEST|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~1. . Right Ventricle fractional area change.~2. . Tricuspid annular plane systolic excursion .~3. . Tissue Doppler derived tricuspid annular systolic velocity.~4. . Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~* Right ventricular basal, mid ,and longitudinal dimensions.~* Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
58106884|NCT05640882|OTHER|VRET|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
58106885|NCT05640882|OTHER|VRET OLFACTION|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
58106886|NCT05888207|DRUG|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
58106887|NCT05888207|DRUG|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
58106888|NCT05151094|OTHER|Observation|Observation of clinical outcomes and comparison to non-treated patients
58106889|NCT04551807|PROCEDURE|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
58310780|NCT06294470|DIAGNOSTIC_TEST|Colonic transit time|Patients ingested capsules with 24 radiopaque markers and underwent standing abdominal radiographs on Day 3 and Day 5. Over 80% expulsion within five days was considered normal, while retention indicated defecatory obstruction.
58310781|NCT06294470|PROCEDURE|Stapled hemorrhodopexy|Circumferential stapled hemorrhoidopexy with a 34mm circular stapler is a surgical procedure used to treat mucohemorrhoidal prolapse.
58310782|NCT02431429|DRUG|Miltefosine|
58310783|NCT02387086|DRUG|Thalidomide|
58310784|NCT02387086|DRUG|placebo|
58310785|NCT02387086|DRUG|Gefitinib|
58310786|NCT02387086|DRUG|Aspirin|
58310787|NCT02597413|PROCEDURE|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
58310788|NCT02149134|DIETARY_SUPPLEMENT|TeHF2013-01|
58310789|NCT03028441|OTHER|Placebo|Placebo
58310790|NCT03028441|BIOLOGICAL|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
58310791|NCT03164642|BEHAVIORAL|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
58310792|NCT03164642|BEHAVIORAL|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
58310793|NCT06447636|DRUG|Surufatinib|Surufatinib: 250mg qd，d1-21, q3w
58310794|NCT06447636|DRUG|Sintilimab|Sintilimab：200mg ivdrip, d1, q3w
58310795|NCT06447636|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
58310796|NCT06447636|DRUG|S1|S1：40\~60mg Bid，d1\~14, q3w
58310797|NCT02678819|DEVICE|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
58310798|NCT06045117|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
58310799|NCT00068185|DRUG|Black cohosh|
58310800|NCT02005796|OTHER|Dietary intervention|
58310801|NCT03496740|PROCEDURE|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
58310802|NCT03496740|PROCEDURE|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
58310803|NCT03496740|DRUG|Bupivacaine (Block Drug)|Block drug
58310804|NCT06326957|OTHER|SELF-BREATHE|SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
58310805|NCT03953716|DEVICE|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
58310806|NCT03953716|DRUG|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
58310807|NCT03953716|DRUG|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
58310808|NCT03953716|DRUG|Marvelon|Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
58310809|NCT03893786|DEVICE|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
58438362|NCT00738751|DRUG|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
58438363|NCT00738751|DRUG|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
58438364|NCT03003403|BEHAVIORAL|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
58438365|NCT05495867|PROCEDURE|implant placement|implant placement in edentulous area
58438366|NCT05456620|OTHER|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
58438367|NCT05456620|OTHER|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
58438368|NCT03893500|DEVICE|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
58106890|NCT04551807|PROCEDURE|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
58106891|NCT04821440|DEVICE|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
58310810|NCT01795443|OTHER|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
58438369|NCT00369499|DEVICE|PFO Closure|
58438370|NCT00258167|BEHAVIORAL|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
57738504|NCT05668728|OTHER|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
57738505|NCT00653640|PROCEDURE|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
57738506|NCT00653640|PROCEDURE|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
57738507|NCT02276846|DEVICE|Paclitaxel-Eluting Balloon|
58438371|NCT06337812|DIETARY_SUPPLEMENT|Potato Starch|"Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study."
58438372|NCT03683953|OTHER|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
58438373|NCT03683953|DRUG|0.9% sodium chloride|0.9% sodium chloride in control group
58438374|NCT01121432|PROCEDURE|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
58438375|NCT00000422|BEHAVIORAL|Cognitive-behavioral psychotherapy and physical exercise|
58438376|NCT02806960|DRUG|Nasal Glucagon|Administered intranasally.
57955206|NCT05288270|DEVICE|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~* 1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~* 5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
58438377|NCT03818451|DIETARY_SUPPLEMENT|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
58438378|NCT05429398|DRUG|Linperlisib Tablet|"1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
58438379|NCT06104111|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
58438380|NCT03384641|DRUG|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
58438381|NCT05492864|PROCEDURE|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
58438382|NCT04016259|DEVICE|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
58438383|NCT04016259|DEVICE|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
58438384|NCT05487911|DEVICE|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
58438385|NCT01090440|DRUG|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
58438386|NCT00934128|DEVICE|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
58438387|NCT00934128|DEVICE|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
58438388|NCT01247194|DRUG|PPI-461|capsule, oral, once daily for 3 days
58438389|NCT01247194|DRUG|Placebo|capsules, oral, once daily for 3 days
58438390|NCT04355793|DRUG|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
58438391|NCT01504685|PROCEDURE|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
58438392|NCT01504685|PROCEDURE|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
58438393|NCT01769196|DRUG|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
58438394|NCT01769196|DRUG|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
58438395|NCT03306511|OTHER|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
58438396|NCT00385138|DRUG|Cangrelor|cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
58438397|NCT00385138|DRUG|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
58438398|NCT00385138|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
58438399|NCT00385138|DRUG|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
58438400|NCT00385138|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
58438401|NCT05481489|DRUG|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
57955207|NCT05288270|OTHER|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
57738508|NCT04361929|DEVICE|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
57955208|NCT04495309|RADIATION|Metastases-directed Radiotherapy|Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
58438402|NCT02684149|PROCEDURE|relational touch|
58438403|NCT02000297|PROCEDURE|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
58438404|NCT02000297|PROCEDURE|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
58438405|NCT00866073|DRUG|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
58438406|NCT03478033|DRUG|Rifampicin|Rifampicin capsules, 150mg
58438407|NCT03478033|DRUG|Rifabutin|Rifabutin capsules, 150mg
58438408|NCT04683367|PROCEDURE|laparoscopic surgery|laparoscopic repair of hernia
58438409|NCT03209856|DRUG|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
58438410|NCT01699165|DEVICE|Nasal filter|Active nasal filter
58438411|NCT01699165|DEVICE|Placebo nasal filter|Placebo nasal filter
58438412|NCT05355948|DEVICE|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
58438413|NCT05355948|DEVICE|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
58438414|NCT01267942|DRUG|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
58438415|NCT00870987|BIOLOGICAL|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
58438416|NCT00870987|BIOLOGICAL|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
58438417|NCT00313105|DRUG|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
58438418|NCT00313105|BEHAVIORAL|smoking cessation counseling|individual visits
58438419|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd|Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
58438420|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w|The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
58438421|NCT05888987|BIOLOGICAL|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
58438422|NCT00225498|DRUG|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
58438423|NCT02902393|BIOLOGICAL|Thromboelastography|
58438424|NCT02113033|DEVICE|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
58438425|NCT03607955|DRUG|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
58438426|NCT03607955|DRUG|Paclitaxel|Commercially available
58438427|NCT03607955|DRUG|Carboplatin|Commercially available
58438428|NCT03607955|PROCEDURE|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
58438429|NCT03607955|PROCEDURE|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
57955209|NCT00746135|DEVICE|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
57955210|NCT04889300|BEHAVIORAL|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
58438430|NCT03607955|PROCEDURE|Interval Debulking|"* Standard of Care~* Research tissue samples will be collected"
58438431|NCT03607955|PROCEDURE|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
58438432|NCT03607955|PROCEDURE|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
58438433|NCT05618067|BEHAVIORAL|breathing exercise training|Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
58438434|NCT05504993|OTHER|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
58438435|NCT01393639|DRUG|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
58438436|NCT01393639|DRUG|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
58438437|NCT01393639|DRUG|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
58438438|NCT01393639|DRUG|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
58438439|NCT01393639|DRUG|prednisone|5 mg capsule once daily for 8 weeks
58438440|NCT01393639|OTHER|prednisone|10 mg capsule once daily for 8 weeks
58438441|NCT01393639|OTHER|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
58438442|NCT04611087|BEHAVIORAL|Discussion|Attend focus groups
58438443|NCT04611087|OTHER|Interview|Attend interviews
58438444|NCT04611087|OTHER|Survey Administration|Ancillary studies
58438445|NCT04130672|PROCEDURE|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
58438446|NCT04130672|PROCEDURE|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
58438447|NCT05347706|DIETARY_SUPPLEMENT|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
58438448|NCT01640444|DRUG|FOLFIRI + bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
58438449|NCT01640444|DRUG|FOLFIRI + cetuximab|"* Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
58438450|NCT02800525|DEVICE|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
58438451|NCT02800525|DEVICE|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
58438452|NCT04306588|OTHER|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
58438453|NCT01366885|DRUG|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
58438454|NCT05224453|OTHER|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)
58438455|NCT05224453|OTHER|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
58106892|NCT04821440|DEVICE|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
58438456|NCT04909658|BEHAVIORAL|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
58438457|NCT04909658|BEHAVIORAL|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
58438458|NCT00008528|DRUG|Enfuvirtide|
58438459|NCT00369642|BEHAVIORAL|Cognitive-behavioral therapy|
58438460|NCT03256201|BEHAVIORAL|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
58438461|NCT03256201|BEHAVIORAL|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
58438462|NCT03256201|BEHAVIORAL|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
58438463|NCT01835665|DRUG|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
58438464|NCT01196832|PROCEDURE|blood sample|blood sample for fibrocytes analysis
58438465|NCT01196832|PROCEDURE|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
58438466|NCT01913002|DRUG|LX4211 800 mg|
58438467|NCT01913002|DRUG|LX4211 2000 mg|
58438468|NCT01913002|DRUG|moxifloxacin 400 mg|
57738509|NCT00205569|BEHAVIORAL|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
57738510|NCT00512395|DRUG|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
57738511|NCT02552004|DEVICE|pCLE|Histological examination by pCLE technique preceding the frozen section
57738512|NCT02552004|DRUG|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
57955211|NCT04889300|BEHAVIORAL|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
57955212|NCT01681264|DRUG|Morphine|
57955213|NCT01681264|DRUG|Guanfacine 1mg|
57738513|NCT02676167|BEHAVIORAL|PrEP Intervention|
57955214|NCT01681264|DRUG|Guanfacine 2mg|
57955215|NCT01681264|DRUG|Placebo|
57955216|NCT02723500|DEVICE|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
57955217|NCT00337064|PROCEDURE|Radiation Therapy|
58310811|NCT01795443|OTHER|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
58438469|NCT01913002|DRUG|LX4211 Placebo|
58438470|NCT00881647|OTHER|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
58438471|NCT00851786|BIOLOGICAL|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
58438472|NCT00851786|BIOLOGICAL|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
58438473|NCT03204370|DRUG|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
58438474|NCT01740401|DRUG|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
58438475|NCT03111329|OTHER|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
58106893|NCT06243081|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
58106894|NCT01440647|PROCEDURE|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
58106895|NCT01440647|PROCEDURE|Extubation to CPAP|After extubation infants were placed on CPAP
58106896|NCT00201929|PROCEDURE|Standard Decision Board|
58106897|NCT00201929|PROCEDURE|Computer Decision Board|
58106898|NCT00201929|PROCEDURE|Paper Decision Board|
58106899|NCT04052074|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
58106900|NCT04052074|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
58106901|NCT00920335|OTHER|tumoral sample|Ependymoma tumoral sample
58106902|NCT00548288|DRUG|pamidronate|
58106903|NCT06536829|OTHER|Myofacial release technique and sciatic nerve slider technique|Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
58106904|NCT06536829|OTHER|Myofacial release technique|0week,6 week, 12 weeks
58106905|NCT01695798|BIOLOGICAL|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
58106906|NCT03941171|PROCEDURE|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
58106907|NCT03941171|OTHER|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
58106908|NCT03941171|OTHER|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
58106909|NCT05402761|BEHAVIORAL|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
58106910|NCT05402761|BEHAVIORAL|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
57738514|NCT05314439|DRUG|ION904|ION904 will be administered by SC injection.
58106911|NCT02677610|DRUG|MSRD-100|MSRD-100 is a topical gel.
58106912|NCT02677610|DRUG|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
58438476|NCT05367544|BEHAVIORAL|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
58438477|NCT05367544|BEHAVIORAL|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
57738515|NCT05314439|DRUG|Placebo|Placebo will be administered by SC injection.
57738516|NCT02866890|DEVICE|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
57738517|NCT03044301|COMBINATION_PRODUCT|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
57738518|NCT03044301|COMBINATION_PRODUCT|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
57738519|NCT03044301|COMBINATION_PRODUCT|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
58106913|NCT00688610|OTHER|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
58106914|NCT06189183|RADIATION|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
58106915|NCT01331083|DRUG|PX-866|PX-866: 8mg orally taken daily
58106916|NCT00947765|BIOLOGICAL|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
58106917|NCT00947765|DRUG|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
58106918|NCT04768829|DRUG|Moringa oleifera leaf 10mg/100ml|ear drops
58106919|NCT04768829|DRUG|Ear Drop|plain ear drop formulation without moringa
58106920|NCT01190826|DRUG|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
57738520|NCT05978531|DRUG|Monomethyl Fumarate|95 mg oral capsule, 190 mg (2 x 95 mg) twice daily
57738521|NCT05369975|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
57738522|NCT05369975|OTHER|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
58106921|NCT01190826|DRUG|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
58106922|NCT01190826|DRUG|Placebo|Placebo administered once by inhalation
58106923|NCT05755594|PROCEDURE|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
58106924|NCT00172302|DRUG|vitamin C, intravenous injection|
58106925|NCT03565666|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
58106926|NCT03565666|DRUG|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
58106927|NCT03565666|OTHER|Usual care|Usual care
58106928|NCT00492388|DRUG|PMI-150 (intranasal ketamine)|intranasal dosing
58106929|NCT00492388|DRUG|placebo|placebo
58106930|NCT00406432|DRUG|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
58106931|NCT01357785|PROCEDURE|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
57738523|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
57738524|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
57955218|NCT03957837|DIAGNOSTIC_TEST|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
58106932|NCT00821990|DRUG|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
58106933|NCT00821990|OTHER|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
58106934|NCT02323295|RADIATION|Radiation (Surgical Arm)|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
58106935|NCT02323295|RADIATION|Radiation (Non-surgical Arm)|Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
58106936|NCT02323295|PROCEDURE|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
58106937|NCT01560091|DRUG|silodosin|8mg PO Qday
58106938|NCT01560091|PROCEDURE|Extra-corporeal shock wave lithotripsy|ESWL
58106939|NCT01560091|DRUG|Tamsulosin|Tamsulosin 0.4mg PO Qday
58106940|NCT06445556|BEHAVIORAL|NatureUplift|a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.
58106941|NCT06445556|BEHAVIORAL|NatureUplift+Active|NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
58106942|NCT04656093|BEHAVIORAL|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
58106943|NCT04656093|BEHAVIORAL|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
57955219|NCT00515801|DRUG|glibenclamide|glibenclamide 15 mg single dose
57955220|NCT00515801|DRUG|placebo|placebo capsules, single dose
58438478|NCT05367544|BEHAVIORAL|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
58438479|NCT04264364|PROCEDURE|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
58438480|NCT04264364|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
58438481|NCT04042324|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
58438482|NCT04042324|DRUG|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
58438483|NCT03374540|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
58438484|NCT03374540|DRUG|Vitamin K antagonist (VKA)|Individually adjusted dose
57955221|NCT06036862|PROCEDURE|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
57955222|NCT05981833|DEVICE|Repair with DAA (dermal allograft augmentation)|Patients undergo rotator cuff repair with dermal allograft augmentation.
57955223|NCT05656209|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
58106944|NCT04656093|BEHAVIORAL|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
58106945|NCT04656093|BEHAVIORAL|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
58106946|NCT01226875|PROCEDURE|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
58438485|NCT03369912|BIOLOGICAL|CSJ148|Active
58438486|NCT03369912|OTHER|Placebo|No Drug
58438487|NCT00727792|PROCEDURE|MRI -Clinical|MRI done is standard of care
58438488|NCT00727792|PROCEDURE|MRI-Research|MRI includes extra sequences
58438489|NCT02187068|DRUG|Dexmedetomidine|Dexmedetomidine administered intravenously
58438490|NCT05309148|BEHAVIORAL|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
57738525|NCT01786512|DRUG|Placebo|Modified release tablets matching to omecamtiv mecarbil
58438491|NCT05309148|BEHAVIORAL|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
58438492|NCT05309148|BEHAVIORAL|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
58106947|NCT03952936|OTHER|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
58106948|NCT03104088|DIAGNOSTIC_TEST|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
58438493|NCT03348176|OTHER|Vegetable exposure|Repeated exposure to variety of vegetables
58438494|NCT03348176|BEHAVIORAL|VIPP-Feeding Infants|Promoting responsive feeding practices
58438495|NCT03348176|OTHER|Control|Phone calls with mother about development of child, no advice on complementary feeding
58438496|NCT01620814|DRUG|Dinoprostone|
57738526|NCT01786512|DRUG|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
58438497|NCT01620814|DRUG|misoprostol|
58438498|NCT01620814|DRUG|control|
57738527|NCT02732418|DRUG|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
58106949|NCT03104088|DIAGNOSTIC_TEST|MOCA|Montreal cognitive assessment (MOCA) in German
58106950|NCT03049137|PROCEDURE|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
58438499|NCT04649463|DIAGNOSTIC_TEST|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
58106951|NCT03049137|PROCEDURE|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
58106952|NCT03049137|DRUG|Platelet-rich fibrin (PRF)|
58106953|NCT03049137|DEVICE|implant|
58106954|NCT01632683|DEVICE|C-MAC|C-MAC arm
58106955|NCT01632683|DEVICE|Glidescope|Glidescope arm
58438500|NCT00269555|DRUG|Genistein Combined Polysaccharide (GCP)|
57738528|NCT02732418|DRUG|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
57738529|NCT05160051|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
58438501|NCT01966835|BEHAVIORAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
58438502|NCT03408613|PROCEDURE|Positive Airway Pressure|See arm/group description
58438503|NCT03408613|PROCEDURE|Supplemental Oxygen|See arm/group description
57738530|NCT01662310|DRUG|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
57738531|NCT01662310|DRUG|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
57738532|NCT06309953|DRUG|Miebo|Miebo treatment
57738533|NCT04210817|OTHER|No Intervention|There is no intervention for this study
57955224|NCT05307029|PROCEDURE|rehabilitation with fixed full-arch prosthesis|
57955225|NCT04940143|DRUG|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
57955226|NCT04940143|OTHER|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
57955227|NCT01082432|OTHER|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
57955228|NCT03720431|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
57955229|NCT02500524|DRUG|Cocamide diethanolamine|Topical lotion
57955230|NCT02500524|DRUG|Permethrin|Topical creme rinse
57955231|NCT00879229|DRUG|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
57955232|NCT00879229|DRUG|Placebo|Placebo to match ambrisentan administered orally once daily.
57955233|NCT00295334|DRUG|alcohol|
57955234|NCT02645357|OTHER|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
57955235|NCT02645357|OTHER|Control group|control group
57955236|NCT00005613|DRUG|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
57955237|NCT00005613|DRUG|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
57955238|NCT00005613|DRUG|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
58106956|NCT05113901|DRUG|Methylprednisolone|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
58438504|NCT03408613|PROCEDURE|Sham|See arm/group description
58438505|NCT00928694|DRUG|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
58438506|NCT00928694|DRUG|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
58438507|NCT02644785|DRUG|protamine|Protamine infusion exposures
58438508|NCT03015935|PROCEDURE|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
58438509|NCT03015935|PROCEDURE|Veress entry|First trocar entry will be performed with Veress
58106957|NCT05113901|DRUG|Placebo|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
58106958|NCT05033015|PROCEDURE|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
58438510|NCT01079494|OTHER|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
58438511|NCT05696496|DEVICE|night recording|"The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera."
58438512|NCT01920308|DEVICE|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
58438513|NCT03060954|DEVICE|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
58438514|NCT03060954|DEVICE|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
58438515|NCT03568669|OTHER|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
58438516|NCT02389036|DRUG|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
58438517|NCT02389036|DRUG|SDD Gastric Suspension|2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
58438518|NCT02389036|DRUG|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
58438519|NCT01598922|BEHAVIORAL|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
58438520|NCT01162902|DRUG|Diltiazem treated group|Diltiazem 180mg for 9 months
58438521|NCT01162902|DRUG|Bisoprolol treated group|Bisoprolol 5mg for 9 months
58438522|NCT01162902|DRUG|Candesartan treated group|Candesartan 32mg for 9 months
58438523|NCT03259061|DEVICE|Flexible fiberoptic nasopharyngoscopy|"1. Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~2. Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
58438524|NCT05882149|DIETARY_SUPPLEMENT|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
58438525|NCT05882149|DIETARY_SUPPLEMENT|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
57955239|NCT03841929|OTHER|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
58106959|NCT04208191|BEHAVIORAL|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
58106960|NCT04881591|DEVICE|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
58106961|NCT03232749|PROCEDURE|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
58106962|NCT03232749|DRUG|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
58106963|NCT03232749|DEVICE|Ultrasound|ultrasound-guided IACSI
58106964|NCT00170261|DEVICE|Use of an Implantable Loop Recorder|
58106965|NCT02267252|OTHER|Antibody-sperm binding|
58106966|NCT05338710|OTHER|STELLA-FTD|Behavioral intervention for caregivers for those with FTD
58106967|NCT02425865|DRUG|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
58438526|NCT00825903|BEHAVIORAL|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
58438527|NCT00411372|DRUG|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
58438528|NCT06434246|BEHAVIORAL|pulley system exercise regimen|The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.
58438529|NCT06434246|BIOLOGICAL|physical therapy program for CP|Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
58438530|NCT06109207|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
58106968|NCT06190782|COMBINATION_PRODUCT|PD-1 inhibitor+/- chemotherapy combined with local therapy|"1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation"
58438531|NCT06109207|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
58438532|NCT06109207|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
58438533|NCT02602418|OTHER|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
58438534|NCT02602418|OTHER|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
58438535|NCT02440685|DRUG|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
58438536|NCT02440685|DRUG|ASN002 RD|Recommended dose of ASN002 from Part A
58438537|NCT02703324|DRUG|LY900014|Administered subcutaneously (SC)
58438538|NCT02703324|DRUG|Insulin Lispro|Administered SC
58438539|NCT02003092|DRUG|RX-5902|escalating doses (mg)
58438540|NCT06324396|DRUG|Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)|A single oral dose of sildenafil will be administered to all study subjects.
58438541|NCT06324396|DRUG|Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)|A single oral dose of pravastatin will be administered to all study subjects.
58438542|NCT02641301|DRUG|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
58438543|NCT01301833|DRUG|teneligliptin|
58438544|NCT01301833|DRUG|glinide|
58438545|NCT01301833|DRUG|biguanide|
58438546|NCT01301833|DRUG|alpha-glucosidase inhibitor|
58438547|NCT04047979|BIOLOGICAL|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
58438548|NCT03219632|DRUG|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
58438549|NCT00502788|DRUG|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
58438550|NCT00502788|DRUG|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
58438551|NCT00731146|OTHER|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
58438552|NCT00731146|OTHER|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
58438553|NCT01609504|PROCEDURE|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
58438554|NCT01609504|PROCEDURE|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
58438555|NCT03315572|OTHER|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
58438556|NCT03315572|OTHER|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
58438557|NCT03315572|OTHER|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
58438558|NCT03733613|OTHER|no intervention|no intervention
58438559|NCT02682082|PROCEDURE|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
58438560|NCT02682082|DRUG|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
58438561|NCT06078436|DEVICE|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
58438562|NCT06552650|BEHAVIORAL|Exercise|Four supervised exercise interventions after surgery: One exercise education session per week from postoperative day 5 through 1 month Subsequent home-based exercise: Home-based exercise recommendations from 1 month to 3 months post-surgery
58438563|NCT06552650|OTHER|Usual Care|The full spectrum of patient care practices in which clinicians have the opportunity (which is not necessarily seized) to individualize care
58438564|NCT05692102|OTHER|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
58438565|NCT02699320|OTHER|Complications|Not involved
58438566|NCT02239952|DRUG|Sunitinib|50 mg once daily, oral use for 14 days
58438567|NCT02239952|DRUG|vandetanib|300 mg, once daily, oral use for 14 days
57738534|NCT01009268|PROCEDURE|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
58438568|NCT02239952|DRUG|Erlotinib|150 mg, once daily, oral use for 14 days
58438569|NCT00791908|PROCEDURE|Electrodessication|Treatment applied to a third of the torso at each study visit.
58438570|NCT00791908|PROCEDURE|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
58438571|NCT00791908|PROCEDURE|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
58438572|NCT01623375|DRUG|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
57738535|NCT00277667|DRUG|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
57738536|NCT00737126|DRUG|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
58438573|NCT01623375|DRUG|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
58438574|NCT01821703|DRUG|LY3045697|Administered as oral solution
58438575|NCT01821703|DRUG|Placebo|Administered as oral solution
58438576|NCT01821703|DRUG|Spironolactone|Administered as capsule
58438577|NCT01821703|DRUG|Placebo|Administered as capsule
58438578|NCT06367283|DRUG|Metformin|Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
58438579|NCT06367283|DRUG|Placebo|Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
58438580|NCT01111344|DIETARY_SUPPLEMENT|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
58438581|NCT01111344|DIETARY_SUPPLEMENT|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
58438582|NCT01898429|DEVICE|SCC DBS|Deep Brain Stimulator
58438583|NCT05454657|DEVICE|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
58438584|NCT05454657|BEHAVIORAL|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
58438585|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
58438586|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
58438587|NCT04282707|PROCEDURE|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
58438588|NCT04282707|OTHER|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
58438589|NCT02830321|OTHER|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
58438590|NCT02397044|PROCEDURE|Implant surgery|Compare surgical protocols
58438591|NCT03918915|DRUG|SYD-101 Dose 1|Sterile topical ophthalmic solution
58438592|NCT03918915|DRUG|SYD-101 Dose 2|Sterile topical ophthalmic solution
58438593|NCT03918915|DRUG|Vehicle|Sterile topical ophthalmic solution without active ingredient
58438594|NCT04833114|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
58438595|NCT04833114|DRUG|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
58438596|NCT04833114|DRUG|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
57738537|NCT00737126|DRUG|Placebo|Administration of an oral placebo pill
57738538|NCT04528511|DEVICE|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
57738539|NCT00091312|DRUG|FOLFIRI regimen|
57738540|NCT00091312|DRUG|fluorouracil|
57738541|NCT00091312|DRUG|irinotecan hydrochloride|
58438597|NCT04833114|DRUG|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
58438598|NCT04833114|DRUG|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
58438599|NCT05523050|PROCEDURE|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
57738542|NCT00091312|DRUG|leucovorin calcium|
58438600|NCT05525650|DRUG|House Dust Mite Extract, Dermatophagoides Farinae|"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
58438601|NCT01858740|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
58438602|NCT01858740|DRUG|Fludarabine Phosphate|Given IV
58438603|NCT01858740|OTHER|Laboratory Biomarker Analysis|Correlative studies
58438604|NCT01858740|DRUG|Methotrexate|Given IV
58438605|NCT01858740|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
58438606|NCT01858740|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
57738543|NCT00091312|PROCEDURE|adjuvant therapy|
58438607|NCT01858740|DRUG|Tacrolimus|Given IV or PO
58438608|NCT01858740|DRUG|Thiotepa|Given IV
58438609|NCT01858740|RADIATION|Total-Body Irradiation|Undergo TBI
58438610|NCT03580980|DRUG|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
58438611|NCT03580980|PROCEDURE|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
58438612|NCT03580980|DRUG|Morphine|patient controlled analgesia by morphine
58438613|NCT04435275|OTHER|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
58438614|NCT04435275|OTHER|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
58438615|NCT02628353|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
58438616|NCT02628353|DIETARY_SUPPLEMENT|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
58438617|NCT02421718|RADIATION|Radiotherapy|
57738544|NCT01733004|DRUG|MM-141|
57738545|NCT00441610|DRUG|Gimatecan|
57738546|NCT04027556|OTHER|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
57738547|NCT04027556|OTHER|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
57738548|NCT03789266|PROCEDURE|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
57962190|NCT00060346|BIOLOGICAL|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
58438618|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
58438619|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
58438620|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
58438621|NCT03867643|BIOLOGICAL|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
58438622|NCT04857580|DEVICE|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
58438623|NCT01856582|BIOLOGICAL|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
58438624|NCT00711971|DRUG|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
58438625|NCT00711971|DRUG|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
58438626|NCT00711971|DRUG|placebo|control arm
58438627|NCT03658447|DRUG|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
58438628|NCT03658447|DRUG|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
58438629|NCT03306719|BIOLOGICAL|Blood sampling|Serial blood sampling
58438630|NCT00753454|DRUG|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
58438631|NCT04215900|BEHAVIORAL|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
58438632|NCT04842383|DRUG|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
58438633|NCT03932760|BEHAVIORAL|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
58438634|NCT03932760|BEHAVIORAL|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
58438635|NCT00158288|BEHAVIORAL|LAAM|
58438636|NCT01934010|DRUG|AM-101|AM-101 gel for intratympanic injection
58438637|NCT00334984|DRUG|glutamine|
58438638|NCT00334984|PROCEDURE|chemoprotection|
58438639|NCT00334984|PROCEDURE|management of therapy complications|
58310812|NCT01795443|OTHER|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
58310813|NCT01795443|OTHER|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
58310814|NCT01795443|OTHER|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
58310815|NCT01099644|BIOLOGICAL|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
58310816|NCT03012646|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
58310817|NCT01118299|DEVICE|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
58310818|NCT05024448|DRUG|Prednisone|oral administration, 60mg/d for 10d
58310819|NCT05321537|OTHER|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
58310820|NCT03746496|DIAGNOSTIC_TEST|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
58310821|NCT05600959|DIAGNOSTIC_TEST|cytokine|Peripheral blood samples were collected at diagnosis, 2 weeks after the first cycle of chemotherapy and 2 weeks after the second cycle of chemotherapy to monitor cytokine level changes.
58310822|NCT04529694|OTHER|Psychotherapy|
58310823|NCT00390715|DRUG|chemotherapy|
58310824|NCT01481493|BIOLOGICAL|BT061|subcutaneous administration of the monoclonal antibody BT061
58310825|NCT01481493|BIOLOGICAL|Placebo|subcutaneous injection of placebo
58310826|NCT00144313|BIOLOGICAL|hepatitis B vaccine|
58310827|NCT02915835|DRUG|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
58310828|NCT02915835|DRUG|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
58310829|NCT05859698|DRUG|Valbenazine|Valbenazine capsules for oral administration
58310830|NCT05893238|PROCEDURE|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
58438640|NCT00334984|PROCEDURE|therapeutic nutritional supplementation|
58438641|NCT02917395|DEVICE|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
58438642|NCT02206035|DRUG|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
58438643|NCT02206035|DRUG|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
58438644|NCT02206035|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
58438645|NCT03469687|DEVICE|Symax uncemented hip stem|
58438646|NCT02702180|DRUG|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
58438647|NCT02702180|DRUG|Placebo|Placebo nebulizer solution for inhalation
58438648|NCT02702180|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
58438649|NCT06442488|DEVICE|Respiratory Monitoring System|Comparing the SNR and accuracy of measurement (RR, TV, MV, apnea duration) in a noisy external environment when the RMS has adaptive filtering and active noise cancellation turned on versus turned off.
58438650|NCT04845763|OTHER|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
58438651|NCT05703581|PROCEDURE|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
58438652|NCT04599465|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
58438653|NCT04599465|DRUG|IVA|Tablets for oral administration.
58438654|NCT02956941|BEHAVIORAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
58438655|NCT03787355|COMBINATION_PRODUCT|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
58438656|NCT01578577|BEHAVIORAL|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
58438657|NCT01578577|BEHAVIORAL|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
58438658|NCT02181764|DRUG|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
57962191|NCT00060346|DRUG|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
57962192|NCT00060346|DRUG|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
57962193|NCT00060346|DRUG|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
58438659|NCT06089837|DRUG|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
58438660|NCT06089837|DRUG|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
58438661|NCT06507826|BEHAVIORAL|Self-Compassionate Writing for Caregivers of Older Adults|Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
57738549|NCT05627180|BEHAVIORAL|Tailored Health Literacy follow-up in cancer|"1. Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~2. Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~3. Telephone/digital conversations with the project every second month for a period of 9 months."
57738550|NCT05164744|DIAGNOSTIC_TEST|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
58310831|NCT05893238|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in serum
58310832|NCT05893238|DIAGNOSTIC_TEST|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
58310833|NCT05893238|DIAGNOSTIC_TEST|Sperm samples for analysis|Oxidation-reduction potential
58310834|NCT05893238|PROCEDURE|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
58310835|NCT02663700|DRUG|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
58438662|NCT06196606|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
58106969|NCT06190782|DRUG|systemic therapy alone|"1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)"
58106970|NCT00003985|DRUG|KRN7000|
58106971|NCT02941237|DEVICE|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
58106972|NCT04249063|DRUG|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
58106973|NCT04249063|DRUG|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
58106974|NCT02077751|DRUG|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
58106975|NCT02431884|PROCEDURE|collect body fluids/tissues & med history|collect tissues/fluids \& history
58438663|NCT01202630|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
58438664|NCT01202630|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
58438665|NCT05777395|PROCEDURE|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
58438666|NCT05777395|PROCEDURE|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation"
58438667|NCT05777395|PROCEDURE|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
58438668|NCT01456065|BIOLOGICAL|Procure|The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
58438669|NCT01456065|BIOLOGICAL|Procure|The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
58106976|NCT05429853|DIETARY_SUPPLEMENT|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
58106977|NCT04926961|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
58106978|NCT04926961|DEVICE|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
58106979|NCT03032588|BIOLOGICAL|sIPV|Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.
58106980|NCT03032588|BIOLOGICAL|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
58106981|NCT01757366|DRUG|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
58106982|NCT01757366|DRUG|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
58438670|NCT00793507|OTHER|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
58438671|NCT03688464|DRUG|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
58438672|NCT03688464|DRUG|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
58438673|NCT03688464|DRUG|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
58438674|NCT01059318|DRUG|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
58310836|NCT02663700|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
57962194|NCT00060346|DRUG|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
57962195|NCT03719157|PROCEDURE|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
57962196|NCT03719157|PROCEDURE|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
57962197|NCT03719157|PROCEDURE|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
57962198|NCT03719157|DRUG|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
58310837|NCT02663700|OTHER|Placebo|Placebo
58310838|NCT03774108|DRUG|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
58310839|NCT03774108|OTHER|Placebo|8 weeks tratment with oral placebo
58310840|NCT03599960|DRUG|Chemotherapy|"* Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)"
58310841|NCT05788263|OTHER|neuroscience based aproach|exercise for pain
58310842|NCT04270877|DRUG|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
58310843|NCT04270877|DRUG|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
58310844|NCT02996383|DEVICE|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
58310845|NCT02996383|DEVICE|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
58310846|NCT01086488|DRUG|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
58310847|NCT01685437|BIOLOGICAL|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
58310848|NCT03023501|DRUG|Gabapentin|
58310849|NCT03023501|DRUG|Placebo Oral Capsule|
58438675|NCT01065701|DRUG|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
58438676|NCT03979885|BEHAVIORAL|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
58438677|NCT03979885|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
58438678|NCT03979885|BEHAVIORAL|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
58438679|NCT03979885|BEHAVIORAL|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
58438680|NCT02737345|OTHER|Rotem|
58438681|NCT00627367|DRUG|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
58438682|NCT00627367|DRUG|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
58438683|NCT01023360|DRUG|Clopidogrel and proton pump inhibitors|"baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week"
58438684|NCT04619732|DIAGNOSTIC_TEST|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
58438685|NCT03591315|DIAGNOSTIC_TEST|resting state fMRI|Define the visual resting state network.
58438686|NCT03591315|DIAGNOSTIC_TEST|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
58438687|NCT03591315|DIAGNOSTIC_TEST|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
58438688|NCT03591315|DIAGNOSTIC_TEST|automated visual field|Identify the existence and type of visual field defect.
58438689|NCT03591315|DIAGNOSTIC_TEST|visual acuity|Assess the visual acuity by using ETDRS scales.
58438690|NCT04701736|DEVICE|Picture Medication Calendar|
58438691|NCT05830175|OTHER|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
58438692|NCT05830175|OTHER|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
58438693|NCT00890110|BIOLOGICAL|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
58438694|NCT05373264|DRUG|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
58438695|NCT05373264|DRUG|Placebo|A matching oral capsule containing placebo
58438696|NCT01877213|BEHAVIORAL|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
58438697|NCT04903054|BIOLOGICAL|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
58438698|NCT04903054|DRUG|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
58438699|NCT04903054|BIOLOGICAL|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
58438700|NCT04903054|DRUG|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
58438701|NCT04903054|DRUG|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
58438702|NCT04903054|DRUG|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
58438703|NCT02434042|DIETARY_SUPPLEMENT|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
58438704|NCT02434042|OTHER|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
58438705|NCT03232866|OTHER|Pilates exercise|Pilates methods exercises
58438706|NCT04800146|PROCEDURE|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
58438707|NCT03842241|DEVICE|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
58438708|NCT01610336|DRUG|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
58438709|NCT01610336|DRUG|Gefitinib|Gefitinib 250 mg taken once daily
58438710|NCT04602442|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
58438711|NCT04602442|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
58438712|NCT04602442|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
58438713|NCT01047982|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
58438714|NCT01047982|OTHER|folic acid 400 mcg|2 pills a day
58438715|NCT00534547|PROCEDURE|Duodenal Exclusion|duodenal-jejunal bypass
58438716|NCT04767906|DRUG|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
58106983|NCT06129487|BEHAVIORAL|Narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
58438717|NCT03066414|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
58438718|NCT00288236|DRUG|Rimonabant (SR141716)|
58438719|NCT00288236|DRUG|Placebo|
58438720|NCT04371939|DRUG|Romiplostim|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
58438721|NCT04371939|DRUG|Eltrombopag|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
58438722|NCT01162915|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
58438723|NCT05231239|DEVICE|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
58438724|NCT01463306|DRUG|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
58438725|NCT00921843|DRUG|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
58438726|NCT00921843|DRUG|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
58438727|NCT00921843|DRUG|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
58438728|NCT00921843|DRUG|Control|Subjects will not receive methadone as their intraoperative opioid.
58438729|NCT03137225|DEVICE|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
58106984|NCT06129487|BEHAVIORAL|Non-narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
58438730|NCT03137225|DEVICE|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
58438731|NCT02155920|DRUG|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
58438732|NCT02490592|OTHER|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
58438733|NCT02490592|OTHER|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
58438734|NCT01663064|DEVICE|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
58438735|NCT00281346|PROCEDURE|Doppler echocardiography|Echocardiography
58106985|NCT05274399|OTHER|surveys and questionnaires|The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
58438736|NCT00217568|BIOLOGICAL|pegfilgrastim|
58438737|NCT00217568|DRUG|carboplatin|
58438738|NCT00217568|DRUG|docetaxel|
58438739|NCT05276921|OTHER|ultrasound|Quadriceps and abdominal muscle ultrasonography
58438740|NCT04887259|BIOLOGICAL|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
58438741|NCT04887259|BIOLOGICAL|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
58438742|NCT01043991|DRUG|Darbepoetin alfa|
58438743|NCT01043991|DRUG|Placebo|
58438744|NCT05248880|DRUG|AGN-151586|Intramuscular Injection
58438745|NCT05248880|DRUG|Placebo|Intramuscular Injection
58438746|NCT00866255|DEVICE|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
58438747|NCT02315534|DRUG|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
58438748|NCT02315534|DRUG|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
57738551|NCT05164744|DIAGNOSTIC_TEST|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
57738552|NCT05164744|DIAGNOSTIC_TEST|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
58106986|NCT00796211|DRUG|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
58106987|NCT00796211|DRUG|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
58438749|NCT02944786|BEHAVIORAL|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
58438750|NCT05643651|DRUG|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
58438751|NCT05643651|DRUG|Aspirin or Clopidogrel|Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[0.2\~1.0 mg/kg(\<2 years old),1 mg/kg(≥2 years old); once daily\]
58438752|NCT05643651|DRUG|Warfarin|Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
58438753|NCT03024125|OTHER|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
58438754|NCT03024125|OTHER|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
57738553|NCT05164744|DIAGNOSTIC_TEST|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
58106988|NCT00796211|DRUG|Nortriptyline|0.1% nortriptyline HCl topical cream
57738554|NCT06418633|OTHER|60-minute walking test|Treadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up.
58106989|NCT00796211|DRUG|Calcipotriol|0.005% calcipotriol topical cream
57738555|NCT06418633|DIAGNOSTIC_TEST|Static blood test|33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test
57738556|NCT06418633|DIAGNOSTIC_TEST|Post-effort blood test|33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test.
57738557|NCT06418633|OTHER|Electrocardiogram|An electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery.
57738558|NCT06418633|OTHER|Blood pressure monitoring|Blood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery.
57738559|NCT03071692|DRUG|K-877|0.2mg tablet
57738560|NCT03071692|DRUG|Placebo|K-877 matching placebo tablet
57738561|NCT05808387|DIETARY_SUPPLEMENT|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
57738562|NCT05808387|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 90 days
57738563|NCT04303897|DEVICE|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
57738564|NCT06427772|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty for neck femur fracture
58106990|NCT00796211|OTHER|Placebo|Vehicle of CRx-197 topical cream (placebo)
58106991|NCT04407195|OTHER|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
58438755|NCT03024125|OTHER|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
58438756|NCT01802190|GENETIC|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
58438757|NCT00000228|DRUG|Buprenorphine|
58438758|NCT03413306|DRUG|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
57738565|NCT04788550|COMBINATION_PRODUCT|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
58438759|NCT03413306|DRUG|IST (ATG + CsA)|
57738566|NCT04788550|COMBINATION_PRODUCT|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
57738567|NCT04788550|COMBINATION_PRODUCT|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
57738568|NCT03303157|OTHER|no intervention|not relevant
57738569|NCT00074282|BIOLOGICAL|rituximab|
57738570|NCT00074282|DRUG|cyclophosphamide|
58106992|NCT04472182|DRUG|Fluoride varnish with xylitol coated calcium and phosphate|Fluoride varnish with xylitol coated calcium and phosphate
58106993|NCT02796898|DRUG|SM88 (Cohort 1)|"* Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
58106994|NCT02796898|DRUG|SM88 (Cohort 2)|"* Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
58106995|NCT05589610|DRUG|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
58438760|NCT03209466|DRUG|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
58106996|NCT05488652|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
58438761|NCT03209466|DRUG|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
58438762|NCT01224743|DIETARY_SUPPLEMENT|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
58438763|NCT01224743|DIETARY_SUPPLEMENT|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
57738571|NCT00074282|DRUG|pentostatin|
57738572|NCT00074282|DRUG|Alemtuzumab|
57962199|NCT01857869|BIOLOGICAL|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
57962200|NCT01857869|BIOLOGICAL|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
57962201|NCT01857869|PROCEDURE|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
57962202|NCT03984058|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
57962203|NCT00866138|DRUG|masitinib (AB1010)|masitinib 9 mg/kg/day per os
57962204|NCT04072458|DRUG|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
57962205|NCT04340973|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
58438764|NCT01224743|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
58438765|NCT05310981|BEHAVIORAL|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
58438766|NCT04120402|DRUG|EP-104IAR 25 mg|Single 5 mL intra-articular injection
58438767|NCT04120402|DRUG|Vehicle|Single 5 mL intra-articular injection
58106997|NCT02116491|DEVICE|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
57738573|NCT06257069|DEVICE|Tremor Retrainer Smartphone Application|The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
58106998|NCT02178449|DRUG|Dexamethasone acetate|
58106999|NCT02178449|DRUG|Placebo|
58107000|NCT02178449|DRUG|Ropivacaine|
58107001|NCT03636542|DRUG|liposomal bupivacaine|Experimental
58107002|NCT03636542|DRUG|bupivacaine|Active comparator
58107003|NCT05397600|DRUG|Bimatoprost Ophthalmic|Eyedrops
57738574|NCT06535971|OTHER|Manual therapy combined exercise|"1. Manual therapy included fascia release, progressive passive stretch, mobilization, etc.(depend on subject's current condition)~2. Exercise included muscle strengthening, trunk (spine) stabilization exercise. (depend on subject's current condition)"
57738575|NCT02284438|DEVICE|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
57738576|NCT00594269|DRUG|Risperidone|Discontinuation
57738577|NCT00594269|DRUG|Escitalopram|Discontinuation
58107004|NCT02971865|BEHAVIORAL|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
58107005|NCT02971865|OTHER|Control group traditional primary care|No change in care usually given
58107006|NCT06156410|DRUG|Cabozantinib|Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
58107007|NCT06314984|OTHER|Group I A (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].
58438768|NCT05225857|DRUG|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
58438769|NCT05225857|DRUG|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
58438770|NCT06142617|DRUG|Pembrolizumab, pemetrexed, platinum|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
58438771|NCT06142617|DRUG|Osimertinib|Osimertinib will be the sequential treatment strategy at progression until resistance develops.
58438772|NCT01855360|DRUG|Tauroursodeoxycholic Acid and Doxycycline|
58438773|NCT06200792|DEVICE|eSense device|eSense device for monitoring electrodermal activity. Visual analogic scale (VAS) for pain and discomfort; TOL-R tests for investigating working performances.
58438774|NCT04844268|BIOLOGICAL|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
58438775|NCT04844268|BIOLOGICAL|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
58438776|NCT04844268|BIOLOGICAL|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
58438777|NCT04844268|BIOLOGICAL|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
58438778|NCT03853863|BEHAVIORAL|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
58438779|NCT03853863|BEHAVIORAL|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
58438780|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
57962206|NCT06025435|OTHER|SAIA-HIV-SSP|The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
57738578|NCT00594269|DRUG|Citalopram|Discontinuation
57738579|NCT00594269|DRUG|Sertraline|Discontinuation
57738580|NCT00594269|DRUG|Paroxetine|Discontinuation
57738581|NCT02580565|OTHER|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
57738582|NCT05736718|BEHAVIORAL|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
57738583|NCT05736718|BEHAVIORAL|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
57955240|NCT00689715|PROCEDURE|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
57955241|NCT04353180|DRUG|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
57955242|NCT04353180|DRUG|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
57955243|NCT04353180|DRUG|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
57955244|NCT04353180|DRUG|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
57955245|NCT04353180|DRUG|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
57955246|NCT04372277|DRUG|Enstilar|topical Enstilar foam
57955247|NCT02590588|DRUG|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
57738584|NCT01227889|DRUG|GSK2118436|150 mg twice daily
57738585|NCT01227889|DRUG|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
58438781|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
58438782|NCT00779025|DEVICE|PD-F-5254|Female Personal Lubricant (MINE)
58438783|NCT00779025|DEVICE|10855-096|Male Personal Lubricant (YOURS)
58438784|NCT02110862|OTHER|Transittime. Defecography|
58438785|NCT02975258|PROCEDURE|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
58438786|NCT02975258|OTHER|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
58438787|NCT02975258|PROCEDURE|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
58438788|NCT02975258|PROCEDURE|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
58438789|NCT02975258|RADIATION|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
57738586|NCT05197335|DEVICE|Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws|The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
57955248|NCT02234154|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
57955249|NCT00006130|PROCEDURE|Core decompression|
58438790|NCT02975258|PROCEDURE|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
57738587|NCT01756092|PROCEDURE|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
57738588|NCT01024569|BEHAVIORAL|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
57738589|NCT00568529|DRUG|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
57738590|NCT01603069|DRUG|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
57955250|NCT06297746|PROCEDURE|Subvastus approach|Subvastus approach
57955251|NCT06297746|PROCEDURE|Medial Parapatellar approach|Medial Parapatellar approach
57955252|NCT01173991|BEHAVIORAL|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
57955253|NCT05001321|RADIATION|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
57955254|NCT05001321|OTHER|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
57955255|NCT03410888|PROCEDURE|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
58438791|NCT02975258|PROCEDURE|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
58438792|NCT02975258|PROCEDURE|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
57738591|NCT01603069|DRUG|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
57738592|NCT01603069|DRUG|Placebo|Placebo to AZD3241 BID
57738593|NCT01694303|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
57738594|NCT04838899|RADIATION|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
57738595|NCT01087008|DRUG|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
57738596|NCT01087008|OTHER|No treatment control|Patients doesn't receive treatment
57738597|NCT06265103|OTHER|Clinical care and quality improvement|All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
58438793|NCT01771237|BEHAVIORAL|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
58438794|NCT01771237|BEHAVIORAL|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
58438795|NCT02373644|OTHER|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
58107008|NCT06314984|OTHER|Group I B (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the conventional needle syringe \[Infiltration\].
58107009|NCT06314984|DEVICE|Group II A (Comfort-in Jet Injector)|The injection site was isolated using a cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].
58107010|NCT06314984|DEVICE|Group II B (Comfort-in Jet Injector)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
58438796|NCT02373644|OTHER|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
58438797|NCT01487850|BIOLOGICAL|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
58438798|NCT01252706|BEHAVIORAL|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
57738598|NCT05450848|DEVICE|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
58107011|NCT02621827|OTHER|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
58107012|NCT01492712|DRUG|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
58107013|NCT01492712|DRUG|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
58107014|NCT02661282|BIOLOGICAL|Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Given IV
58107015|NCT02661282|OTHER|Laboratory Biomarker Analysis|Correlative studies
58107016|NCT02661282|DRUG|Temozolomide|Given PO
58107017|NCT02661282|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58107018|NCT01319071|OTHER|Blood sample|Extraction of blood sample from top-level athletes
58107019|NCT03931057|DRUG|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
58107020|NCT03931057|DRUG|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
58107021|NCT02916160|DRUG|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
58107022|NCT05840666|OTHER|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
58438799|NCT02775448|DRUG|Carduus marianus 6cH|
58438800|NCT02775448|DRUG|Carduus marianus 12cH|
58438801|NCT02775448|DRUG|Carduus marianus 30cH|
58438802|NCT02775448|DRUG|Placebo|
58438803|NCT02775448|BEHAVIORAL|Exercise|aerobic exercise, 30 minutes, daily
58438804|NCT02775448|OTHER|Diet|1600 calories
58438805|NCT05639530|BIOLOGICAL|IBI333|Intravitreal injection of IBI333
58438806|NCT01191177|DRUG|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
58438807|NCT01191177|DIETARY_SUPPLEMENT|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
58438808|NCT06256393|OTHER|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
58438809|NCT04262076|OTHER|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
58438810|NCT00379912|DRUG|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
58438811|NCT00379912|DRUG|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
58107023|NCT05840666|OTHER|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
57955256|NCT03410888|PROCEDURE|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
57955257|NCT05022797|DRUG|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
57955258|NCT03066102|OTHER|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
57955259|NCT04907760|OTHER|Personalized care program|It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
58107024|NCT05840666|OTHER|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
58107025|NCT01890018|BEHAVIORAL|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
58107026|NCT01890018|BEHAVIORAL|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
58107027|NCT01890018|BEHAVIORAL|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
58107028|NCT02872545|PROCEDURE|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
58438812|NCT00379912|DRUG|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
58438813|NCT02290041|DRUG|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
58438814|NCT02290041|DRUG|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
58438815|NCT05311930|DRUG|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
58438816|NCT02377999|DRUG|Picato|
58438817|NCT03477838|DEVICE|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
58438818|NCT03631758|OTHER|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
57738599|NCT05450848|OTHER|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
57738600|NCT03594448|PROCEDURE|Specimen Collection|Undergo collection of blood samples
57738601|NCT03594448|PROCEDURE|Serial Liquid Biopsy|Undergo serial liquid biopsy
58438819|NCT03631758|BEHAVIORAL|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
58438820|NCT03631758|OTHER|Sham information|Educational information not specific to mammography or cancer screening
58438821|NCT01189695|DRUG|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
58438822|NCT01189695|DRUG|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
57738602|NCT00909012|DIETARY_SUPPLEMENT|high oleic sunflower oil|placebo, which does not provide DHA
57738603|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
58107029|NCT02872545|PROCEDURE|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
57738604|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
57738605|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
57738606|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
58310850|NCT01341704|BIOLOGICAL|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
58310851|NCT01341704|BIOLOGICAL|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
58438823|NCT02481739|OTHER|retrospective study|
58438824|NCT02499705|DIETARY_SUPPLEMENT|Sucralose|2 packets
58438825|NCT02499705|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
58438826|NCT02499705|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
58438827|NCT05498467|DRUG|Anakinra|100 mg Anakinra injections s.c.
57738607|NCT04450108|DIAGNOSTIC_TEST|Vivatmo pro FeNO Test|Breath gas analysis
57738608|NCT06427226|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
57738609|NCT04729257|DEVICE|Philips IntelliSpace Cognition (ISC).|Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
58107030|NCT02872545|PROCEDURE|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
58310852|NCT01341704|OTHER|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
58310853|NCT02759458|DEVICE|Smith & Nephew Healicoil Anchor|
58438828|NCT05498467|DRUG|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
58438829|NCT03976206|BIOLOGICAL|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
58438830|NCT03539601|DRUG|Crisaborole ointment, 2%|Applied twice a day (BID)
58438831|NCT03539601|DRUG|Hydrocortisone butyrate cream, 0.1%|Applied BID
58438832|NCT03539601|DRUG|Pimecrolimus cream, 1%|Applied BID
58438833|NCT03539601|DRUG|Crisaborole Vehicle|Applied BID
58438834|NCT06288074|DIAGNOSTIC_TEST|Multi-omics tests|Biological sample collection for Multi-omics tests
58438835|NCT00079092|DRUG|procarbazine hydrochloride|
58438836|NCT00079092|DRUG|thalidomide|
58107031|NCT06017765|BEHAVIORAL|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~1. Education about stress response~2. Elicitation of the Relaxation Response through Mindfulness Training~3. Creating adaptive perspectives~4. Coping strategiest."
58107032|NCT06017765|BEHAVIORAL|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
58107033|NCT01666925|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu
58107034|NCT01666925|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
58107035|NCT03856671|DRUG|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
58107036|NCT05415982|OTHER|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
58438837|NCT05405335|OTHER|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
58438838|NCT00930228|DRUG|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
57738610|NCT04729257|DIAGNOSTIC_TEST|Paper-Pencil Tests.|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
57738611|NCT05873114|DIAGNOSTIC_TEST|Mobilization|Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
57738612|NCT05873114|DIAGNOSTIC_TEST|Muscle Energy Technique (MET)|Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
58107037|NCT00505128|PROCEDURE|Endoscopic sphincterotomy|procedure
58107038|NCT00130000|DRUG|Eculizumab|
58107039|NCT04221087|DRUG|Placebos|Sugar water based on same ml dosing of intervention arm drug
58107040|NCT04221087|DRUG|Dexamethasone Oral|0.6mg/kg/dose - single oral dose administration to intervention arm
58107041|NCT05155631|BEHAVIORAL|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
58107042|NCT04157634|DIAGNOSTIC_TEST|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
58107043|NCT01637961|DRUG|Alisertib|Given PO
58107044|NCT01637961|OTHER|Laboratory Biomarker Analysis|Correlative studies
58310854|NCT02759458|DEVICE|Smith & Nephew Twinfix Anchor|
58310855|NCT02265523|OTHER|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
58438839|NCT00930228|DRUG|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
57738613|NCT03843229|DRUG|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
57738614|NCT03843229|PROCEDURE|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
57738615|NCT03843229|DRUG|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
57738616|NCT00046358|DRUG|Lovostatin|
57738617|NCT00046358|DRUG|Ibuprofen|
58438840|NCT02489383|OTHER|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
58438841|NCT02489383|OTHER|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
58438842|NCT02489383|BEHAVIORAL|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
58438843|NCT00854815|PROCEDURE|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
57738618|NCT02313428|DEVICE|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
58107045|NCT04825509|DEVICE|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
58438844|NCT00854815|PROCEDURE|No Irrigation|Suction only using suction/irrigator
58438845|NCT00105690|BEHAVIORAL|Telemedicine intervention|
58438846|NCT04321434|OTHER|Hyperoxia|
58438847|NCT04321434|OTHER|Normoxia|
58438848|NCT04321434|DEVICE|laser Doppler|laser Doppler
58107046|NCT01535157|DRUG|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
58438849|NCT02914574|OTHER|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
58438850|NCT06069947|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
57738619|NCT06669143|DRUG|Zanubrutinib|160 mg bid, po, day 1-21, a maximum of 2 years.
58438851|NCT03999840|DRUG|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
58438852|NCT03999840|DRUG|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
58438853|NCT03944291|PROCEDURE|Pudendal Nerve Block|Pudendal Nerve Block
58438854|NCT03547895|DRUG|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
58438855|NCT03547895|DRUG|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
58438856|NCT05844267|BEHAVIORAL|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
58438857|NCT05844267|BEHAVIORAL|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
58438858|NCT05633888|DEVICE|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
58438859|NCT03051308|COMBINATION_PRODUCT|NPT and UW Solution|Tissue preservation solutions for transplantation
58438860|NCT04178720|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
58438861|NCT04178720|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
58438862|NCT04178720|DEVICE|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
58438863|NCT04346836|BEHAVIORAL|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
58438864|NCT04346836|BEHAVIORAL|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
58438865|NCT05496569|DRUG|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
58438866|NCT05496569|DRUG|TQB3616 placebo|Placebo
58438867|NCT00005644|DRUG|gemcitabine hydrochloride|
58438868|NCT00005644|DRUG|paclitaxel|
58438869|NCT04572451|DRUG|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
58438870|NCT04572451|DRUG|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
58438871|NCT04572451|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
58438872|NCT06152107|PROCEDURE|BTVA treatment plus optimal medical therapy (GOLD guidelines)|"Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments. Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will be treated in the ipsilateral lobe in a single procedure with the air+tissue volume of at least≥500 ml and≤1,700 ml in per procedure. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded."
58438873|NCT00365924|DRUG|Forteo|Open label single arm study with Forteo as an intervention
58438874|NCT00554047|OTHER|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
58438875|NCT00554047|OTHER|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
58438876|NCT02781610|DRUG|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
58438877|NCT04573686|DRUG|Erythropoietin|Erythropoietin will be given subcutenous to all patients
58438878|NCT00559247|DRUG|BMS-650032 or Placebo|Oral, Once daily, Single Dose
58438879|NCT02632487|BEHAVIORAL|Exercise|Center-based walking + balance, stretching, and light resistance
58438880|NCT02632487|BEHAVIORAL|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
58438881|NCT02481778|OTHER|Blood sampling|
58438882|NCT04417153|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
58438883|NCT00066404|BIOLOGICAL|recombinant adenovirus-hIFN-beta|
58438884|NCT04259008|OTHER|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
58438885|NCT04259008|OTHER|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
58438886|NCT01969630|DEVICE|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
58438887|NCT01969630|DEVICE|PES|Systematic Paclitaxel eluting stent angioplasty
58438888|NCT04205734|DIAGNOSTIC_TEST|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
58438889|NCT01947751|PROCEDURE|CVC exchange|CVC exchange when related infection is suspected
58438890|NCT01947751|DRUG|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
58438891|NCT03616509|DRUG|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
58438892|NCT03616509|DRUG|Placebo|2 months on placebo, sodium chloride 0,9% injections
58438893|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
58438894|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
58438895|NCT05280600|OTHER|Not applicable - non-interventional study|Not applicable - non-interventional study
58438896|NCT00169156|DRUG|Rituximab|375 mg/m2 D1
58438897|NCT00169156|DRUG|Prednisone|40 mg/m2 D1 to D5
58438898|NCT00169156|DRUG|Doxorubicine|50 mg/m2 D1
58438899|NCT00169156|DRUG|Cyclophosphamide|750 mg/m2 D1
58438900|NCT00169156|DRUG|Vincristine|1,4 mg/m2 D1
58438901|NCT04922138|DRUG|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
58438902|NCT01402739|OTHER|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
58438903|NCT01402739|OTHER|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
58438904|NCT05412368|OTHER|Focus Groups|Focus Groups
58438905|NCT00003154|DRUG|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
58438906|NCT00202956|DRUG|Bugusan|
58438907|NCT05181124|DRUG|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
58438908|NCT05181124|DRUG|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
58438909|NCT05181124|DRUG|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
58438910|NCT05181124|DRUG|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
58438911|NCT05385055|OTHER|THS use|N/A: No intervention was assigned.
58438912|NCT05385055|OTHER|Cigarette smoking|N/A: No intervention was assigned.
58438913|NCT05385055|OTHER|Smoking abstinence|N/A: No intervention was assigned.
58107047|NCT04512027|OTHER|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
58107048|NCT04512027|OTHER|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
58107049|NCT01325857|PROCEDURE|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
58107050|NCT01325857|PROCEDURE|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
58107051|NCT01325857|PROCEDURE|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
58107052|NCT00520247|DRUG|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
58107053|NCT04042974|DRUG|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
58107054|NCT04042974|DRUG|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
58107055|NCT00558519|DRUG|cyclophosphamide|
58438914|NCT02843672|PROCEDURE|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
58438915|NCT02843672|PROCEDURE|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
58438916|NCT05361044|BIOLOGICAL|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
58107056|NCT00558519|DRUG|cytarabine|
58107057|NCT00558519|DRUG|daunorubicin hydrochloride|
58107058|NCT00558519|DRUG|dexamethasone|
58107059|NCT00558519|DRUG|doxorubicin hydrochloride|
58107060|NCT00558519|DRUG|mercaptopurine|
58107061|NCT00558519|DRUG|methotrexate|
58107062|NCT00558519|DRUG|pegaspargase|
58107063|NCT00558519|DRUG|thioguanine|
58438917|NCT04102527|OTHER|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation"
58438918|NCT02091843|PROCEDURE|DBS of the Basolateral Nucleus of the Amygdala|
58438919|NCT02091843|DEVICE|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
58438920|NCT05639192|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
57738620|NCT06669143|DRUG|Lenalidomide|25 mg qd, po, day 1-10, a maximum of 2 years.
58438921|NCT05639192|OTHER|Placebo|Placebo will be administered once per week as an i.v. infusion
57738621|NCT00491049|DRUG|0.5% levofloxacin eye drops|
58107064|NCT00558519|DRUG|vincristine sulfate|
58107065|NCT00558519|RADIATION|radiation therapy|
58107066|NCT05187312|PROCEDURE|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
58107067|NCT05187312|PROCEDURE|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
58107068|NCT04809038|OTHER|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
58107069|NCT04809038|OTHER|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
58107070|NCT04809038|OTHER|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
58107071|NCT05140018|PROCEDURE|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
58107072|NCT05140018|COMBINATION_PRODUCT|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
58107073|NCT05140018|PROCEDURE|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
58107074|NCT02451969|BIOLOGICAL|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
58107075|NCT02451969|BIOLOGICAL|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
58107076|NCT00137085|DRUG|ketamine|
57738622|NCT02351531|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
58438922|NCT02519595|DRUG|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
58310856|NCT02978469|OTHER|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
58438923|NCT02519595|DRUG|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
58438924|NCT02519595|DRUG|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
58438925|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
58438926|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
58438927|NCT04558372|OTHER|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
58438928|NCT04674657|DRUG|blood drug concentration|blood drug concentration
58438929|NCT05665296|OTHER|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
58438930|NCT05665296|OTHER|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
58438931|NCT01237236|DRUG|LEE011|
58438932|NCT01529034|DRUG|USL261|
58310857|NCT06099535|DRUG|LNK01001 Dose A|Capsules taken orally
58310858|NCT06099535|DRUG|LNK01001 Dose B|Capsules taken orally
58310859|NCT06099535|DRUG|placebo|Capsules taken orally
58310860|NCT06181149|BEHAVIORAL|Delaying speech initiation|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
58107077|NCT04698057|DRUG|Placebo|The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
58438933|NCT06289218|DEVICE|interferential current|IFC plus exercise
58438934|NCT06289218|OTHER|kinesio taping|KT plus exercise
58438935|NCT06289218|OTHER|exercise|exercise only
58438936|NCT00000706|DRUG|Quinine sulfate|
57962207|NCT04568226|OTHER|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
58438937|NCT00000706|DRUG|Probenecid|
58438938|NCT00000706|DRUG|Zidovudine|
58438939|NCT03833414|PROCEDURE|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
58438940|NCT04787172|RADIATION|Multi Slice computed tomography|use of MSCT as a diagnostic tool in evaluation of patients with congenital cardiovascular anomalies
58438941|NCT04647097|BEHAVIORAL|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
58438942|NCT04647097|BEHAVIORAL|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
58438943|NCT04119232|BEHAVIORAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
58438944|NCT01712204|DRUG|Placebo|Placebo Capsule BID for 16 Weeks
58438945|NCT01712204|DRUG|AC-201|AC-201 50mg Capsule BID for 16 Weeks
58438946|NCT01712204|DRUG|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
58438947|NCT00590343|DRUG|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
57962208|NCT04568226|OTHER|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
57962209|NCT01558362|DRUG|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
57962210|NCT06539546|OTHER|Yttria stabilized multilayered (YML) zirconia restorations|Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties
57962211|NCT06539546|OTHER|Lithium disilicate restorations|Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
58107078|NCT04698057|DRUG|Amoxicillin Clavulanate|Will be administred to all patients
58107079|NCT04698057|DRUG|Ciprofloxacin|Will be administred to patients in the standard of care arm
58107080|NCT01700751|DRUG|brentuximab vedotin|
58107081|NCT01935531|DRUG|3% diclofenac in 2.5% hyaluronic acid gel|
58107082|NCT04026295|BEHAVIORAL|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
58107083|NCT04026295|BEHAVIORAL|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of \< 6/10.
58107084|NCT01068873|DRUG|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
58107085|NCT04380324|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
58107086|NCT04380324|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
58310861|NCT06181149|BEHAVIORAL|Auditory errors and pre-speech auditory modulation|This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
58310862|NCT06181149|BEHAVIORAL|Contributions of the speech premotor cortex to pre-speech auditory modulation|This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
58310863|NCT06181149|BEHAVIORAL|Delaying auditory feedback|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
58310864|NCT02790177|DRUG|Hyaluronic Acid|
58310865|NCT02790177|DRUG|NORMAL SALINE|
58310866|NCT02530541|DRUG|CHG|Varied application times
58310867|NCT03426345|DRUG|Placebo|Placebo injected subcutaneously twice daily.
58310868|NCT03426345|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
58310869|NCT03532763|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
58310870|NCT03532763|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
58310871|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
58310872|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
58310873|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
58310874|NCT03043053|DRUG|oxytocin nasal spray|oxytocin intranasal spray
58310875|NCT03043053|DRUG|Placebo|Placebo nasal spray
58310876|NCT00729742|DRUG|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
58310877|NCT00729742|DRUG|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
58310878|NCT01183923|OTHER|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
58310879|NCT01183923|OTHER|Alfalfa Sprouts|Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
58310880|NCT02251847|DRUG|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
58310881|NCT03444584|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
58310882|NCT03444584|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382.
58310883|NCT03444584|DRUG|Dapaglifozin|Oral dose of dapaglifozin 10 mg tablet.
58310884|NCT03444584|DRUG|Metformin|Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
58310885|NCT05259631|DRUG|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
58310886|NCT05259631|DRUG|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
58107087|NCT04892940|DEVICE|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
58107088|NCT04892940|DRUG|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
58107089|NCT00407433|DRUG|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
58107090|NCT06203691|DIETARY_SUPPLEMENT|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre \& post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
58107091|NCT06203691|DIETARY_SUPPLEMENT|Non-Supplementation Group|Intervention will measure strength pre \& post operatively. Intervention group will not receive liquid supplements.
58107092|NCT06518941|DRUG|Donepezil|Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
58107093|NCT01016821|DRUG|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
58107094|NCT05105477|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
58107095|NCT05105477|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
58107096|NCT03359928|BEHAVIORAL|Boxing|as already discussed
58107097|NCT03359928|BEHAVIORAL|Stair stepping|as already discussed
58107098|NCT03359928|BEHAVIORAL|Stair climbing|as already discussed
58107099|NCT00069407|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy
58107100|NCT03526952|OTHER|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
57738623|NCT06362681|OTHER|Fluoride|Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
57738624|NCT05180760|BEHAVIORAL|Smartphone app use|Smartphone app use in the active arm
57738625|NCT05180760|BEHAVIORAL|Standard of care|Standard of care
57738626|NCT01886924|BEHAVIORAL|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
57738627|NCT01886924|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
58107101|NCT03526952|OTHER|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
58107102|NCT00248820|PROCEDURE|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
58310887|NCT04116333|DEVICE|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
58310888|NCT04116333|DEVICE|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
58310889|NCT05805449|PROCEDURE|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
58438948|NCT05612334|BEHAVIORAL|exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)|the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
58438949|NCT04342078|DIETARY_SUPPLEMENT|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
58107103|NCT02545010|DRUG|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
58107104|NCT02545010|RADIATION|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
57738628|NCT01217710|BEHAVIORAL|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
57738629|NCT00374322|DRUG|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
57738630|NCT00374322|OTHER|placebo|6 tablets daily for 12 months
57738631|NCT05556525|OTHER|Fluorescein|Given IV
57738632|NCT05556525|DEVICE|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
58107105|NCT02886481|DEVICE|perioperative monitoring|
58107106|NCT06354712|DRUG|N-Acetyl-Cysteine with Institutional standard care|A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
58107107|NCT06354712|DRUG|Institutional standard care|Benzydamine Mouthwash
58310890|NCT05805449|OTHER|Platelet-rich plasma (PRP)|Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
58310891|NCT05805449|DEVICE|Matrix|"Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition."
58310892|NCT03667521|PROCEDURE|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
58310893|NCT01973751|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
58310894|NCT00322036|DRUG|MPC-7869|Oral 800 mg BID
58310895|NCT00322036|DRUG|MPC-7869|Oral BID dosing
58310896|NCT04192149|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
58310897|NCT00930020|DRUG|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
58310898|NCT00930020|DRUG|Matched placebo|matched placebo (cornstarch) once a day for 5 days
58310899|NCT02226770|DEVICE|Implantable Cardioverter Defibrillator (ICD)|
58310900|NCT05884593|DEVICE|Pedicle screw instrumentation using Mazor X robotic system|Pedicle screw instrumentation using Mazor X robotic system
57738633|NCT05556525|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
58310901|NCT00110708|DRUG|Oralgam (human immunoglobulin)|
58310902|NCT03601676|OTHER|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
58310903|NCT01383278|BEHAVIORAL|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
58310904|NCT01383278|BEHAVIORAL|Screening and resource provision|Screening and resource provision
58310905|NCT05187221|BEHAVIORAL|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
58310906|NCT00909870|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
58310907|NCT00909870|DEVICE|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
58310908|NCT02337764|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
58310909|NCT03369782|DRUG|Rocuronium|rocuronium is administered in bolus and continuous infusion
58310910|NCT03369782|DRUG|Sugammadex|Sugammadex is administered just before reduction of the joint
58310911|NCT03369782|DRUG|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
57738634|NCT03459430|OTHER|Core stability training|Effect of different core stability programs using diverse training intensities
57738635|NCT02883114|DRUG|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
57738636|NCT02883114|DRUG|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
57738637|NCT02962908|BIOLOGICAL|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
57738638|NCT02962908|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
58310912|NCT06380569|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 10 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
58310913|NCT04364516|DRUG|Anticoagulation|Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
58310914|NCT01130844|DRUG|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
58310915|NCT01130844|DRUG|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
57738639|NCT02962908|BIOLOGICAL|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
57738640|NCT02962908|BIOLOGICAL|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
58310916|NCT01130844|DRUG|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
57738641|NCT00522158|DRUG|simvastatin|
57738642|NCT00522158|DRUG|atorvastatin|
57962212|NCT01237366|BEHAVIORAL|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
57962213|NCT04031703|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
57962214|NCT04031703|DRUG|Carboplatin|Carboplatin chemotherapy (injection)
57962215|NCT04031703|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
57962216|NCT04031703|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
58310917|NCT00650962|OTHER|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
57738643|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
57738644|NCT00617760|BIOLOGICAL|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
57962217|NCT04031703|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
57962218|NCT04031703|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
58438950|NCT06508515|BEHAVIORAL|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|"The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation."
58438951|NCT06508515|BEHAVIORAL|RUBI in Educational Settings (RUBIES)-Team|RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
58438952|NCT00946543|RADIATION|hypofractionated radiation therapy|
58438953|NCT00946543|RADIATION|intensity-modulated radiation therapy|
57738645|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
57738646|NCT05470868|DRUG|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
57955260|NCT04027933|BEHAVIORAL|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
57955261|NCT01077843|DRUG|Etoricoxib|Cox-2 inhibitor
58310918|NCT00650962|OTHER|Rhythm analysis|Rhythm analysis as soon as AED is ready
58310919|NCT01032928|BEHAVIORAL|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
58310920|NCT02850835|OTHER|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
58310921|NCT02225418|DRUG|Ropivacaine|
58310922|NCT02225418|DRUG|saline|
58310923|NCT05216575|DRUG|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
58310924|NCT05188105|DEVICE|Alpha tACS (12 Hz) over the occipital cortex|Single session of alpha tACS (12 Hz) over the occipital cortex
58310925|NCT02676804|OTHER|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own."
58310926|NCT01096940|DRUG|AZD1656|Oral tablet, BID dose
58310927|NCT01096940|DRUG|simvastatin|Oral tablet, single dose
58438954|NCT00939458|DRUG|Lamotrigine|
57955262|NCT01077843|DRUG|Other Cox-2 inhibitors|Cox-2 inhibitor
57955263|NCT01077843|DRUG|Other Non-selective NSAIDs|Non-selective NSAID
58310928|NCT03257267|DRUG|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
57738647|NCT04183764|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
57955264|NCT01077843|OTHER|No anti-inflammatory treatment|No anti-inflammatory prescription
57955265|NCT00000625|DRUG|Zidovudine|
57955266|NCT00000625|DRUG|Zalcitabine|
57955267|NCT00000625|DRUG|Didanosine|
57955268|NCT00120458|DIETARY_SUPPLEMENT|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
57955269|NCT04667351|DRUG|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
58310929|NCT03257267|DRUG|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
58310930|NCT03592628|OTHER|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
58310931|NCT03592628|OTHER|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
58310932|NCT01631942|DRUG|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
58310933|NCT04793568|DRUG|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
57738648|NCT01777854|DRUG|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
58438955|NCT00632619|BEHAVIORAL|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
58438956|NCT00632619|DRUG|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
58438957|NCT00632619|BEHAVIORAL|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
58438958|NCT04207060|DRUG|Indomethacin|One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
58438959|NCT04207060|DRUG|Placebo|One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
58438960|NCT04207060|PROCEDURE|Endoscopy for Pancreatic Function Testing|All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
58438961|NCT01273324|DEVICE|ADM Cup|ADM Cup
58438962|NCT00794950|DRUG|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
58438963|NCT02760641|OTHER|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
58438964|NCT02760641|OTHER|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
58438965|NCT01659749|BEHAVIORAL|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
58438966|NCT03747640|DEVICE|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
58438967|NCT03747640|BEHAVIORAL|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
58438968|NCT03747640|DEVICE|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
57738649|NCT02308384|BEHAVIORAL|Intervention|CME, Start-package and status mail
57738650|NCT03877445|DEVICE|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
57738651|NCT03556462|OTHER|Sleep Health Education|Parents and children receive sleep health education
57955270|NCT04667351|DRUG|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
58310934|NCT04793568|DRUG|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
58310935|NCT01715246|OTHER|Infant Formula|
58310936|NCT05426174|BIOLOGICAL|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57962219|NCT03423342|DIETARY_SUPPLEMENT|nicotinamide riboside|nicotinamide riboside capsule
58310937|NCT05426174|BIOLOGICAL|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58310938|NCT03881436|DIAGNOSTIC_TEST|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence"
58310939|NCT01597986|DRUG|isavuconazole|oral
58310940|NCT01597986|DRUG|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
58310941|NCT03662412|DRUG|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
58310942|NCT02266524|DRUG|Tamsulosin hydrochloride, very low dose|
58310943|NCT02266524|DRUG|Tamsulosin hydrochloride, low dose|
57738652|NCT01404520|OTHER|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
58438969|NCT03747640|BEHAVIORAL|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
58438970|NCT06116006|OTHER|Upper limb pointing movements in 3 experimental conditions|Recording of cerebral hemodynamic with fNIRS during upper limb pointing movements with a robotic device in three conditions: movements with robot assistance, movements without robot assistance and movements with robot resistance. Each subject are recorded during 6 trials for each condition (18 trials). The order is counterbalanced among the subjects.
58438971|NCT00571805|DRUG|varencline|2.0 mg/day varencline (1.0 mg BID)
58438972|NCT00571805|DRUG|placebo|matching placebo
58438973|NCT02452450|DRUG|Ibuprofen Acid|
58438974|NCT02452450|DRUG|Ibuprofen Lysine|
58438975|NCT02452450|DRUG|Ibuprofen Sodium|
58438976|NCT02452450|DRUG|Ibuprofen Liquid Capsules|
58438977|NCT02452450|DRUG|Paracetamol|
58438978|NCT04043039|PROCEDURE|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
58438979|NCT04043039|PROCEDURE|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
58438980|NCT01836302|OTHER|Observation|
58438981|NCT05879497|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
58438982|NCT02919254|DIETARY_SUPPLEMENT|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
58438983|NCT02919254|OTHER|Placebo|Fruit juice cordial containing negligible nitrate
57738653|NCT01166633|DRUG|pitavastatin|pitavastatin 2mg per daily
57738654|NCT01166633|DRUG|atorvastatin|atorvastatin 10mg per daily
57738655|NCT02244866|DRUG|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
57738656|NCT02244866|DRUG|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
57738657|NCT03813940|BIOLOGICAL|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
57962220|NCT03423342|DRUG|Placebo|matching placebo capsule
57962221|NCT04743557|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
57962222|NCT02173795|DRUG|Berodual® Respimat®|
57962223|NCT02173795|DRUG|Berodual® MA HFA|
57962224|NCT01228123|OTHER|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
57962225|NCT01228123|OTHER|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
57962226|NCT05558540|DEVICE|spinal cord stimulator|By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
57962227|NCT06260280|DIAGNOSTIC_TEST|Cerebral Nuclear Magnetic Resonance|Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
57962228|NCT06405464|DRUG|VOCABRIA 30Mg Tablet|CAB 30 mg Film-coated tablets
57962229|NCT06405464|DRUG|EDURANT 25Mg Tablet|RPV 25 mg film-coated tablets
57962230|NCT06405464|DRUG|Cabotegravir Injectable Suspension|CAB LA 600 mg prolonged release suspension for injection (3 mL)
57962231|NCT06405464|DRUG|Rilpivirine Injectable Suspension|RPV LA 900 mg prolonged release suspension for injection (3 mL)
57962232|NCT06405464|BIOLOGICAL|Intact proviral DNA assay|HIV-1 latent reservoir size
57962233|NCT06405464|BIOLOGICAL|Full-length sequencing|Proviral DNA
57962234|NCT03321097|DEVICE|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
57962235|NCT03321097|DEVICE|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
57962236|NCT04277845|DRUG|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
57962237|NCT02897895|BIOLOGICAL|levels of CNI in whole blood|
58310944|NCT02266524|DRUG|Tamsulosin hydrochloride, medium dose|
58438984|NCT00284219|DEVICE|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
58438985|NCT00284219|DEVICE|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
58438986|NCT05977062|OTHER|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
58438987|NCT05977062|OTHER|Phone call|Phone call at the beginning of the program and at the middle and at the end.
58438988|NCT05977062|OTHER|Online questionnaires|To be completed at week 1, 6, 12 and 24.
58438989|NCT03439930|OTHER|Balance training|6 weeks lasting balance training program
58438990|NCT02238158|DRUG|Atrovent® inhalets|
58438991|NCT06432335|OTHER|E-Socket Monitoring|Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
58438992|NCT02059603|PROCEDURE|Electroacupuncture|
58438993|NCT02059603|PROCEDURE|Fast-track program|
58438994|NCT01336153|DRUG|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
58438995|NCT01336153|DRUG|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
58438996|NCT00704860|OTHER|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
58438997|NCT05727982|DIAGNOSTIC_TEST|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
58438998|NCT06233006|OTHER|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
58438999|NCT05098171|BIOLOGICAL|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
57738658|NCT03813940|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
58439000|NCT05320172|DRUG|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
58439001|NCT02688985|DRUG|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
58439002|NCT02688985|PROCEDURE|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
58439003|NCT02688985|DRUG|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
58439004|NCT02688985|DRUG|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
58439005|NCT05641415|OTHER|Imaging|MRI and x-ray of both shoulders
58439006|NCT00998088|OTHER|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
58439007|NCT00998088|DRUG|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
58439008|NCT00998088|DEVICE|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
57955271|NCT04584580|DRUG|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
58310945|NCT02266524|DRUG|Tamsulosin hydrochloride, high dose|
58439009|NCT00998088|DEVICE|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
58439010|NCT00998088|OTHER|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
58439011|NCT00998088|OTHER|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
58439012|NCT00998088|DEVICE|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
57955272|NCT03659682|DRUG|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
58107108|NCT02104128|DRUG|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
58439013|NCT06524908|BEHAVIORAL|Exercise and dietary calorie restriction|The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
58439014|NCT01989806|DEVICE|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
58439015|NCT01989806|DEVICE|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
58107109|NCT02414425|PROCEDURE|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
58107110|NCT02414425|PROCEDURE|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
58439016|NCT03143504|DIAGNOSTIC_TEST|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
58439017|NCT01479361|DRUG|Atovaquone 750 mg twice daily|
58439018|NCT01479361|DRUG|Atovaquone 1500 mg twice daily|
57955273|NCT01094769|DRUG|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
58107111|NCT02414425|DRUG|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
58107112|NCT00619086|DRUG|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
58107113|NCT00619086|DRUG|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
58107114|NCT02924103|DEVICE|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
58107115|NCT03125824|DEVICE|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
58107116|NCT04343911|DEVICE|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
58107117|NCT02726737|DRUG|sodium bicarbonate|
58107118|NCT02726737|DRUG|Lidocaine|
58107119|NCT02726737|DRUG|sterile distilled water|
58310946|NCT04980404|DRUG|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
58439019|NCT06530732|PROCEDURE|Deep Cervical lymphatlc-Venous Anastomosis Surgery|Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
58439020|NCT06530732|DRUG|Lecanemab|The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
58439021|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
58439022|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
58439023|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
58439024|NCT01481454|BIOLOGICAL|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
58439025|NCT04148742|DRUG|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
58439026|NCT05037019|PROCEDURE|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
57738659|NCT05873855|BEHAVIORAL|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
58439027|NCT05651672|DRUG|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
58439028|NCT01882699|DEVICE|Cereve Sleep System|cerebral hypothermia
58439029|NCT01806675|DRUG|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
57738660|NCT05873855|BEHAVIORAL|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
58439030|NCT01806675|DRUG|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
58439031|NCT00330122|PROCEDURE|fore locked plate|
58439032|NCT00330122|PROCEDURE|external radiocarpal fixer|
58439033|NCT01429181|DRUG|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
58439034|NCT06135935|OTHER|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
58439035|NCT06135935|OTHER|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
58439036|NCT06393647|OTHER|Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
58439037|NCT03715244|PROCEDURE|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery \< 90 minutes
58439038|NCT03715244|PROCEDURE|General anesthesia (current standard)|General anesthesia in patients with duration of surgery \< 90 minutes
58439039|NCT02627989|DRUG|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
58439040|NCT02627989|DRUG|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
58439041|NCT05126836|DRUG|Cilostazol 100Mg Tab|Cilostazol Twice a Day
58439042|NCT05126836|DRUG|Placebo|Placebo
58439043|NCT03745521|OTHER|no intervention|no intervention
58439044|NCT01361178|DRUG|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
58439045|NCT05021146|OTHER|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
58439046|NCT05021146|OTHER|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
58439047|NCT05021146|OTHER|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
57738661|NCT01549613|DRUG|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
57738662|NCT01549613|DRUG|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
58310947|NCT01308515|DEVICE|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
57955274|NCT01094769|DRUG|Placebo|lactose capsule taken once daily
57955275|NCT05386615|DEVICE|Body System - Functional|MR-Guided Focused Ultrasound
57955276|NCT01652885|DRUG|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
57955277|NCT03239574|DEVICE|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
57962238|NCT02897895|BIOLOGICAL|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
57738663|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
58107120|NCT05323500|OTHER|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
58107121|NCT05139654|OTHER|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
58107122|NCT05139654|OTHER|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
58107123|NCT05139654|OTHER|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
58439048|NCT02656953|OTHER|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
58439049|NCT02656953|OTHER|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
58439050|NCT03688074|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
58439051|NCT03688074|OTHER|Placebo|Placebo subcutaneous injection
58439052|NCT04205721|BEHAVIORAL|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
58439053|NCT05769205|DEVICE|MRI|MRI with contrast
58439054|NCT06514404|OTHER|observational study|Observational study of the effects on anxiety and empathy of personality the situation of start academic year in health sciences
58439055|NCT00349869|BEHAVIORAL|yoga|8-week yoga program.
58439056|NCT01478724|DIETARY_SUPPLEMENT|Milk proteins fraction|capsules, one per day, 24 months
58439057|NCT05687162|BEHAVIORAL|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
58107124|NCT05882981|OTHER|Sit and reach test|It will be used to measure the flexibility of the participants.
58439058|NCT05687162|BEHAVIORAL|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
58439059|NCT05687162|BEHAVIORAL|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
58439060|NCT05687162|BEHAVIORAL|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
58439061|NCT05687162|BEHAVIORAL|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
58107125|NCT05882981|OTHER|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
58107126|NCT05882981|OTHER|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
58107127|NCT05882981|OTHER|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
58439062|NCT05687162|BEHAVIORAL|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
58439063|NCT05687162|BEHAVIORAL|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
57738664|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
58107128|NCT05882981|OTHER|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
58107129|NCT05758935|OTHER|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
58107130|NCT04275661|PROCEDURE|Ultrasound (US) bi-level erector spinae block|nerve block
58107131|NCT04275661|DRUG|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
58107132|NCT04275661|DRUG|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
58107133|NCT04275661|DRUG|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
58310948|NCT01308515|DEVICE|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
58310949|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
58439064|NCT05687162|BEHAVIORAL|Overcoming loneliness SSI 8-minute version|A shortened version of an online self-guided intervention based on principles of CBT for loneliness. The research team created this intervention by cutting lengthy didactic material and exercises from the 23-minute version, while maintaining its core concepts.
57738665|NCT03838042|DRUG|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
57738666|NCT03966157|DEVICE|Nasal Bridle|Feeding tube secured with nasal bridle
57738667|NCT01775228|BEHAVIORAL|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
57738668|NCT04690855|DRUG|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
58107134|NCT04490083|PROCEDURE|Extra corporeal shock wave lithotripsy|ESWL will be performed with a third generation electromagnetic lithotripter (Delta Compact, Dornier Med Tech, Germany) This has both fluoroscopy and ultrasound imaging facility. Radio opaque calculi will be targeted directly while a naso pancreatic tube (NPT) was placed for all radiolucent calculi and contrast was passed through this to localize the calculi. Between 5000 and 6000 shocks were delivered per session with frequency of 90 shocks per minute. The aim will be to fragment the calculi to \<3 mm or demonstrate a decrease in heterogeneity or density of the calculi in the main pancreatic duct. Shocks will be delivered on consecutive days till fragmentation is achieved. If there is no fragmentation after four sessions of ESWL the procedure will be labeled as unsuccessful and patient will be advised surgery. Procedures will be performed under epidural anesthesia.
58107135|NCT01335152|BEHAVIORAL|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
58107136|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
58310950|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
58107137|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
58107138|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
58107139|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
58107140|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
58310951|NCT02339688|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
58310952|NCT02078544|OTHER|Integrated Molecular Analysis|
58439065|NCT00474214|BEHAVIORAL|Early hospital discharge facilitated by close nurse practitioner follow-up|
58439066|NCT02397538|DRUG|Fimasartan|
58439067|NCT02397538|DRUG|Amlodipine|
58107141|NCT05185687|BEHAVIORAL|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
58107142|NCT05185687|BEHAVIORAL|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
58439068|NCT02397538|DRUG|Rosuvastatin|
58439069|NCT00289926|DRUG|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
58439070|NCT00289926|DRUG|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
57738669|NCT04690855|DRUG|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
58107143|NCT05185687|BEHAVIORAL|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
58107144|NCT01572831|OTHER|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and \>4,000).
58107145|NCT01604382|DRUG|General Anesthesia|General Anesthesia as described above
58107146|NCT01604382|DRUG|Neuraxial anesthesia|Neuraxial anesthesia as described above
58439071|NCT00668603|DRUG|17-b-estradiol|2mg oral daily for 6 months
57738670|NCT04690855|RADIATION|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
58107147|NCT02133352|DRUG|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
58107148|NCT03236493|DRUG|PF-06700841|PF-06700841 will be administered as tablet
58107149|NCT03236493|DRUG|Placebo|Matching placebo will be administered as tablet
58107150|NCT00382291|DRUG|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
58107151|NCT00382291|DRUG|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
57738671|NCT04988854|BEHAVIORAL|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
58107152|NCT00382291|DRUG|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
58107153|NCT01204060|OTHER|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
58107154|NCT01204060|OTHER|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
58107155|NCT01119976|BEHAVIORAL|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
58107156|NCT01119976|BEHAVIORAL|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
58107157|NCT03654261|BEHAVIORAL|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
58439072|NCT00668603|DRUG|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
58439073|NCT00668603|DRUG|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
58439074|NCT00668603|DRUG|placebo pill + gel|placebo daily for 6 months
58439075|NCT03582891|DEVICE|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
58439076|NCT03582891|DIAGNOSTIC_TEST|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
58439077|NCT03582891|DEVICE|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
58439078|NCT04944849|DIAGNOSTIC_TEST|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
58107158|NCT02232451|DEVICE|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
58107159|NCT02232451|DEVICE|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
58439079|NCT04056897|BIOLOGICAL|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
58439080|NCT04056897|DRUG|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
58439081|NCT04056897|DRUG|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
58439082|NCT04056897|BIOLOGICAL|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
58439083|NCT06242301|OTHER|The collective person-centered dialogue intervention|"* Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
58439084|NCT01772732|DRUG|Simotinib Hydrochloride|
58439085|NCT02268825|DRUG|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
58439086|NCT05055817|OTHER|bloody stool group|bloody stool appear in the hospitalized neonate
58439087|NCT05055817|OTHER|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
58439088|NCT04188093|OTHER|PACU discharge criteria and continuous monitoring on the ward|"* PACU discharge criteria (modified aldrete score).~* Continous monitoring of vital signs 96 postoperative hours"
58439089|NCT05536570|DRUG|IncobotulinumtoxinA 100 UNT|Scalene injection
58439090|NCT06448624|DRUG|Ampicillin sulbactam 3 days|Ampicillin sulbactam 1.5 gram IV TID for 3 days after CIED implantation
57738672|NCT00415987|PROCEDURE|Hematopoietic Stem Cell Transplantation|
58310953|NCT02890017|OTHER|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
57738673|NCT06635161|DEVICE|Trancranial pulse stimulation (without a stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.
58107160|NCT06547463|OTHER|nasal oxygenation device|Use of the nasal oxygenation device on one of the two nights during which polysomnography will be performed.
58107161|NCT02839356|DRUG|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
58107162|NCT02839356|DRUG|normal saline|20-mL irrigation with physiological saline over the entire papilla
58107163|NCT05125679|DRUG|Guselkumab|Guselkumab will be administered by subcutaneous injection.
58310954|NCT02890017|OTHER|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
58439091|NCT06448624|DRUG|Placebo 3 days|Placebo for 3 days after CIED implantation
58439092|NCT06400953|OTHER|Kinetic Brain Exercises and Core Stabilization Exercises|Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.
58107164|NCT01279590|DRUG|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
58107165|NCT01279590|DRUG|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
58439093|NCT06400953|OTHER|Core Stabilization Exercises|Core Stabilization Exercise Program in groups of 8-10 people, for 40 minutes, 2 days a week, for 8 weeks.These exercises included a 5-minute active warm-up, a 30-minute Core Stabilization exercise that included upper and lower extremity movements, and immediately followed by a 5-minute cool-down exercise.The exercises are pilates-based and in the first stage of the program. Movements were performed in standing and sitting positions.Movements were started with 6-8 repetitions, increased by 1-2 repetitions each week, and in the last week, 12-15 repetitions were performed, with contraction times increasing from 5 seconds to 10 seconds. As the exercises progressed from easy to difficult, from simple movements to complex movements, the movements were continued by adding an elastic band and 0.5 kg weight.While advancing the exercise program, the exercises were personalized by taking into account the individual's strain levels.
58439094|NCT01431781|DRUG|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
58439095|NCT01431781|OTHER|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
58439096|NCT03521141|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
58107166|NCT01279590|DRUG|Placebo|2 placebo capsules twice daily for 12 weeks
58439097|NCT03521141|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
58439098|NCT03521141|GENETIC|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
58439099|NCT03521141|GENETIC|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
58107167|NCT05742854|PROCEDURE|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
58107168|NCT05742854|DRUG|Oxytocin|Oxytocin
58107169|NCT05742854|DRUG|Carbetocin|Carbetocin
58107170|NCT00131430|DRUG|taranabant|
58107171|NCT05081076|DEVICE|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain \& Glaze Kit, following the manufacturer's instructions.
58107172|NCT05081076|DEVICE|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
58107173|NCT01537549|DRUG|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
58107174|NCT04551352|DRUG|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
58107175|NCT04551352|DRUG|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
58107176|NCT04551352|DRUG|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
58107177|NCT04551352|DRUG|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
58107178|NCT02682433|DEVICE|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
58310955|NCT05513547|OTHER|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
58310956|NCT05513547|OTHER|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
58439100|NCT03521141|BEHAVIORAL|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
58439101|NCT00848783|DRUG|Irinotecan|
58439102|NCT00848783|DRUG|Cisplatin|
58439103|NCT00848783|PROCEDURE|Surgery|
58439104|NCT00848783|DRUG|Floxuridine|
58439105|NCT00848783|DRUG|Capecitabine|
58439106|NCT02879825|DEVICE|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
58439107|NCT00767819|DRUG|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
58310957|NCT05513547|OTHER|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
58439108|NCT03812315|COMBINATION_PRODUCT|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
58310958|NCT02737137|PROCEDURE|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
58310959|NCT02737137|PROCEDURE|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
58439109|NCT03812315|COMBINATION_PRODUCT|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
58439110|NCT00757055|DRUG|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
58439111|NCT00757055|DRUG|Placebo|No active treatment given
58439112|NCT05344586|OTHER|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
58107179|NCT02682433|DEVICE|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
58107180|NCT06053879|OTHER|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
58107181|NCT02982447|DEVICE|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
58107182|NCT02982447|DEVICE|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
58107183|NCT06527235|DRUG|ultrasound-guided betamethasone infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 megahertz (MHz) linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of lidocaine injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
58107184|NCT06527235|DRUG|ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
58310960|NCT01612195|PROCEDURE|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
58439113|NCT05344586|OTHER|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
58439114|NCT04327726|DRUG|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
58439115|NCT04327726|OTHER|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
58439116|NCT05313087|BIOLOGICAL|COVID-19 vaccine|assess response to vaccine
58439117|NCT01957202|DRUG|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
58439118|NCT01957202|DRUG|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
58439119|NCT01957202|DRUG|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
58439120|NCT01957202|DRUG|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
58439121|NCT01138488|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
57738674|NCT06635161|DEVICE|Transcranial pulse stimulation (with Neurology stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.
58107185|NCT04401319|DEVICE|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
58107186|NCT04401319|DEVICE|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
58107187|NCT04401319|DEVICE|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
58107188|NCT04401319|DEVICE|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
58107189|NCT04401319|DEVICE|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
58107190|NCT04401319|DEVICE|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
58107191|NCT01533272|DRUG|Tenofovir, emtricitabine, maraviroc|experimental drug
58310961|NCT01242436|PROCEDURE|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
58310962|NCT05442658|OTHER|Microbiota|
58107192|NCT01533272|DRUG|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
58107193|NCT04256005|OTHER|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
58107194|NCT05740059|OTHER|Adjusted Transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
58107195|NCT01652261|DRUG|ABVD + FDG-PET/CT Scan treatment adaptation|
58107196|NCT01652261|DRUG|BEACOPPesc|
58107197|NCT01785186|DRUG|SQ109|SQ109 300 mg
58439122|NCT06407245|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
58107198|NCT01785186|DRUG|Rifampicin|Rifampicin 10 to 35 mg/kg
58107199|NCT01785186|DRUG|Moxifloxacin|Moxifloxacin 400mg
58107200|NCT01785186|DRUG|isoniazid|isoniazid 75 mg
58107201|NCT01785186|DRUG|pyrazinamide|pyrazinamide 400 mg
58310963|NCT01060371|GENETIC|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
58439123|NCT06407245|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
58439124|NCT06303596|OTHER|Hippotherapy|Hippotherapy: Hippotherapy in psychiatry is not concerned only about the patient sitting on a horse and the horseback movement influencing the physical condition of the patient and his functional and postural disorders. This therapy is concerned with positive effects on a patient's mental state and use mainly contact with the horse, work with the horse from the ground and riding on horseback. It aims for enjoyment, social communication, and the development of cognitive and executive functions.
58439125|NCT06303596|OTHER|Standard psychiatric treatment|Standard psychiatric treatment: Standard psychiatric treatment includes medication and routine activities provided by the Community Mental Health Center.
58439126|NCT02813239|OTHER|hCG|Oocyte maturation with hCG
58439127|NCT02813239|OTHER|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
58439128|NCT02843841|OTHER|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
58310964|NCT03311191|DEVICE|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
58310965|NCT04166214|OTHER|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
58310966|NCT04009616|DRUG|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
58310967|NCT04009616|DRUG|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
58439129|NCT05992363|DEVICE|ureteral stent\s insertion|ureteral stent\\s insertion in the operating room
58107202|NCT01785186|DRUG|ethambutol|ethambutol 275 mg
58107203|NCT01785186|DIETARY_SUPPLEMENT|pyridoxine|pyridoxine 25 mg
58107204|NCT02022371|PROCEDURE|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
58107205|NCT01532349|DRUG|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
58107206|NCT01363401|BIOLOGICAL|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
58107207|NCT01363401|OTHER|Control group|No treatment of HYNR-CS inj
58107208|NCT06156969|DEVICE|Robot-Assisted Gait Training|"Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes."
58107209|NCT05139407|DIAGNOSTIC_TEST|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
58310968|NCT04009616|DRUG|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
58310969|NCT02730962|DRUG|Vancomycin|Vancomycin 3 times a day for 7 days
58439130|NCT04872543|DRUG|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
58439131|NCT02586727|DRUG|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
57738675|NCT06635161|DEVICE|Transcranial pulse stimulation (with a sham stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
57738676|NCT02205944|OTHER|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
57738677|NCT04011553|OTHER|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
58107210|NCT04592991|DIAGNOSTIC_TEST|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
58310970|NCT02730962|OTHER|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
58310971|NCT02730962|DRUG|Neomycin|Neomycin 3 times a day for 1 day
58310972|NCT02730962|DRUG|Clindamycin|Clindamycin 3 times a day for 5 days
58310973|NCT02730962|PROCEDURE|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
58310974|NCT04939467|DRUG|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
58310975|NCT04939467|DRUG|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
58310976|NCT04939467|DRUG|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
58310977|NCT02160626|DRUG|A-101 Vehicle|Placebo control
58310978|NCT02160626|DRUG|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
58310979|NCT02160626|DRUG|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
58439132|NCT03962075|PROCEDURE|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
58107211|NCT04592991|DIAGNOSTIC_TEST|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
58107212|NCT02712385|OTHER|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
58107213|NCT02712385|DEVICE|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
58107214|NCT02712385|PROCEDURE|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
58107215|NCT02712385|BEHAVIORAL|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
58107216|NCT03605537|DRUG|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
58107217|NCT00990561|DRUG|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
58107218|NCT00990561|DRUG|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
58439133|NCT06148883|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously
58107219|NCT06290869|BEHAVIORAL|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention|In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.
58107220|NCT06290869|BEHAVIORAL|E-Referral to the Tobacco Quitline|In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
58107221|NCT01927081|BEHAVIORAL|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
58107222|NCT01927081|BEHAVIORAL|gentle exercise|Patients learn gentle exercise and breathing techniques
58107223|NCT00458718|DRUG|rimonabant (SR141716)|
58107224|NCT02629965|DRUG|tiotropium|fixed dose combination
57738678|NCT03142048|OTHER|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
58107225|NCT02629965|DRUG|olodaterol|fixed dose combination
58107226|NCT02629965|DRUG|tiotropium|
58107227|NCT06369337|DIAGNOSTIC_TEST|Ultrasound|The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
58107228|NCT05943496|DRUG|Acalabrutinib|Given PO
58107229|NCT05943496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58107230|NCT05943496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
57738679|NCT01546896|DRUG|buspirone+alprazolam|day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
58107231|NCT05943496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
58107232|NCT05943496|PROCEDURE|Computed Tomography|Undergo CT scan
58107233|NCT05943496|PROCEDURE|Echocardiography|Undergo ECHO
58107234|NCT05943496|BIOLOGICAL|Obinutuzumab|Given IV
58107235|NCT05943496|OTHER|Questionnaire Administration|Ancillary studies
58107236|NCT05943496|BIOLOGICAL|Tafasitamab|Given IV
58107237|NCT02617173|DEVICE|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
58439134|NCT04057846|DEVICE|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
57738680|NCT01546896|DRUG|alprazolam|0.5mg/d
57738681|NCT00581230|DEVICE|Laryngoscopy with RAMP|inflatable positioning ramp
57955278|NCT02363686|PROCEDURE|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
58107238|NCT04006847|DRUG|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
58107239|NCT04006847|DRUG|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
58107240|NCT03818919|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
58107241|NCT03818919|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
58107242|NCT03818919|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
57738682|NCT00581230|DEVICE|Laryngoscopy without RAMP|Laryngoscopy without RAMP
57738683|NCT03146520|DEVICE|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
58107243|NCT03818919|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
58107244|NCT03818919|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
57738684|NCT03068338|DEVICE|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
57738685|NCT03068338|DEVICE|Intermittent pneumatic compression|Conventional device used by hospitals
57738686|NCT04933955|PROCEDURE|vital pulp therapy|pulpotomy
58107245|NCT03818919|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
58107246|NCT05659706|OTHER|cognitive evaluations and non cognitive evaluations|Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
58107247|NCT02354365|DEVICE|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
58107248|NCT05178147|DEVICE|Compression bandaging without reference to GraduCheck pressure measurements|To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
58107249|NCT05178147|DEVICE|Compression bandaging using GraduCheck pressure measurements to monitor compression pressure|To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
58107250|NCT00328783|DEVICE|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
58107251|NCT00328783|RADIATION|Radiation Therapy|
58107252|NCT00941252|DRUG|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
58439135|NCT03369249|BEHAVIORAL|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
58439136|NCT05036317|DRUG|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
58439137|NCT05036317|OTHER|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
58439138|NCT01421953|DEVICE|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
58439139|NCT06426329|BEHAVIORAL|Therapeutic Touch|Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
58107253|NCT01377961|DRUG|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
58439140|NCT06078852|DIAGNOSTIC_TEST|Diaphragmatic ultrasound|Each patient will undergo a diaphragmatic ultrasound using a MyLab TM 50 Gold Cardiovascular ultrasound machine (Esaote Spa, Rome, Italy), both in a semi-recumbent position (45° inclined bed) and in sitting position. If the patient is unable to maintain the supine position, the examination will be assessed only in the sitting position. Diaphragmatic thickness (DT) and diaphragmatic contractility will be assessed bilaterally with a 10 MHz linear probe. The amplitude of the diaphragm excursion will also be calculated with a 5 MHz convex probe in order to evaluate the cranio-caudal excursion of the diaphragm.
58439141|NCT03079089|DRUG|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
58107254|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
58107255|NCT01377961|OTHER|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
58107256|NCT01377961|OTHER|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
58107257|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
58107258|NCT01377961|OTHER|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
58107259|NCT01225991|DRUG|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
58439142|NCT03079089|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at DO
58439143|NCT03079089|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
58439144|NCT03079089|DRUG|Care supports|According to the protocols of each center
58439145|NCT03079089|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II."
58107260|NCT03560505|DIAGNOSTIC_TEST|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
58107261|NCT06381570|DRUG|Tovorafenib|"Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)"
58107262|NCT00852956|DRUG|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
58107263|NCT06246851|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
58107264|NCT05824468|DRUG|Zimberelimab|Injectable solution
58439146|NCT02601833|DEVICE|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
57738687|NCT06378450|BEHAVIORAL|Mindfulness meditation guided practice|Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.
58107265|NCT05824468|DRUG|Lenvatinib|Capsule
58107266|NCT04591418|DEVICE|Rotary handpieces|Dental Caries removal
58107267|NCT04591418|DEVICE|Er:YAG laser|Dental Caries removal
58107268|NCT00038519|DRUG|Amprenavir/ritonavir|
58107269|NCT00038519|DRUG|Saquinavir/ritonavir|
58439147|NCT02601833|PROCEDURE|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
58439148|NCT03977103|BIOLOGICAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
58439149|NCT01318837|DRUG|solifenacin|oral
57738688|NCT04027153|OTHER|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
57738689|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
58107270|NCT01776450|DEVICE|Endovascular AAA repair|
58107271|NCT01400854|DRUG|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
58107272|NCT01604954|BEHAVIORAL|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
58107273|NCT01604954|BEHAVIORAL|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
58439150|NCT00252408|DRUG|Hormone replacement therapy|
58439151|NCT05348200|DRUG|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
58439152|NCT05348200|DRUG|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
58107274|NCT01604954|BEHAVIORAL|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
58107275|NCT05537337|BEHAVIORAL|Multicomponent Intervention|"The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution"
58107276|NCT04906473|DRUG|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
58107277|NCT01015911|DRUG|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
58107278|NCT03320473|DEVICE|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
58107279|NCT02227537|DEVICE|Providence Nighttime Bracing System|Providence Nighttime Bracing System
58107280|NCT02227537|DEVICE|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
58107281|NCT05146869|DRUG|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
58107282|NCT00813501|BIOLOGICAL|immunosuppressive therapy|
58107283|NCT00813501|OTHER|immunological diagnostic method|
58107284|NCT00813501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58107285|NCT05848271|OTHER|Patient Registry|Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.
58107286|NCT05848271|OTHER|Dry blood spots sampling|Dry blood splots require 500nl of blood.
58107287|NCT00732771|DRUG|LCI699|
58107288|NCT00894985|BIOLOGICAL|heparin sodium - blausiegel|heparin sodium 5.000UI
58107289|NCT00894985|BIOLOGICAL|heparin sodium - APP|heparin sodium 5.000 USP - APP
58107290|NCT05535517|OTHER|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
58107291|NCT05535517|OTHER|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
58107292|NCT05535517|OTHER|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
58107293|NCT05535517|OTHER|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
58107294|NCT05535517|OTHER|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
58107295|NCT05535517|OTHER|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
58107296|NCT01224756|DRUG|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
58107297|NCT01224756|DRUG|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
58107298|NCT02053571|PROCEDURE|TIPS with 3D Overlay|
58107299|NCT06522516|BEHAVIORAL|Evidence-based caregiving training|This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.
58107300|NCT06522516|BEHAVIORAL|family resilience intervention|The intervention will be developed based on the Maccubbin Family Resilience Theory, and Delphi methods. The content will contain 8 topics and be incorporated into caregiving training manual.
58107301|NCT06522516|BEHAVIORAL|usual service|This means the usual service provided by the local community health center from nurses during bi-weekly home visit.
58310980|NCT03705325|DEVICE|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
58439153|NCT05348200|DRUG|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
58439154|NCT05348200|DRUG|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
58107302|NCT04728737|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
58107303|NCT04728737|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
58107304|NCT04728737|OTHER|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
58107305|NCT04180254|PROCEDURE|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
58107306|NCT04806477|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
58107307|NCT04806477|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
58107308|NCT04182139|OTHER|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
58107309|NCT02924571|DEVICE|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
58439155|NCT05348200|DRUG|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
58439156|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
58107310|NCT02924571|DEVICE|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
58107311|NCT02924571|PROCEDURE|Autograft|Autograft with bone marrow aspirate.
58107312|NCT00634283|DRUG|venlafaxine|venlafaxine IR 150mg
58107313|NCT06042894|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
58107314|NCT06042894|DRUG|SI-B003|SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
58107315|NCT03876288|DEVICE|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
58107316|NCT03876288|DRUG|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
58107317|NCT03876288|PROCEDURE|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
58107318|NCT01318733|DRUG|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
58107319|NCT00217971|DRUG|Dronabinol|Dronabinol
58107320|NCT00217971|DRUG|Placebo|placebo
58107321|NCT03582007|DRUG|Murepavadin|Murepavadin + ertapenem
58107322|NCT03582007|DRUG|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
58107323|NCT01827371|BIOLOGICAL|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
58107324|NCT01484028|DEVICE|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
58107325|NCT01484028|DEVICE|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
58107326|NCT01484028|DEVICE|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
58107327|NCT03220763|OTHER|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
58107328|NCT01558531|DEVICE|DEB|paclitaxel-eluting balloon angioplasty
57738690|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
58107329|NCT01558531|DEVICE|POBA|conventional balloon angioplasty
58439157|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
58439158|NCT01038167|DRUG|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
58439159|NCT01038167|DRUG|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
58439160|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
58107330|NCT00410852|PROCEDURE|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
58107331|NCT00410852|PROCEDURE|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
58107332|NCT00410852|PROCEDURE|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
58107333|NCT00798824|PROCEDURE|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
58107334|NCT00798824|PROCEDURE|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
58107335|NCT00798824|DEVICE|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
58439161|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
58439162|NCT02546492|DRUG|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
58439163|NCT05705557|DEVICE|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
58439164|NCT06237400|DRUG|ZG19018|ZG19018 Given by PO (mouth)
58107336|NCT00798824|DEVICE|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
58107337|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
58107338|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
58107339|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
58310981|NCT06403943|DRUG|BaiDiZiYin Pill, ShenQiYiFei Pill|"Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating."
58439165|NCT02669212|BEHAVIORAL|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
58439166|NCT04413097|PROCEDURE|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
58439167|NCT04413097|PROCEDURE|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
58310982|NCT06403943|DRUG|Anti tuberculosis chemotherapy|2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
58310983|NCT01458626|DRUG|mirtazapine|mirtazapine 30mg QD
58310984|NCT01458626|DRUG|paroxetine 20mg QD|paroxetine 20mg QD
58310985|NCT02144766|DRUG|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
58310986|NCT02144766|DRUG|saline|caudal block with 1 ml/kg of saline
58310987|NCT04111835|DIAGNOSTIC_TEST|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -\> colposcopy~Normal reflex LBC -\> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
58310988|NCT05189002|DRUG|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
58310989|NCT05189002|DRUG|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
58310990|NCT05189002|DRUG|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
58310991|NCT05916547|PROCEDURE|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
58310992|NCT00279929|PROCEDURE|DHEA Replacement|
58310993|NCT04942704|OTHER|Non interventional Imaging - MRI|MRI Scanning using short protocols
58107340|NCT04320459|DIAGNOSTIC_TEST|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
58107341|NCT04320459|DIAGNOSTIC_TEST|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
58310994|NCT06405893|BEHAVIORAL|Mindful breathing exercise|Participants do a 10 minute guided mindful breathing exercise or participants do listen to a 10 minute control recording
58107342|NCT04320459|DIAGNOSTIC_TEST|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
58107343|NCT00014521|DRUG|karenitecin|
58107344|NCT05215041|OTHER|Non intervention|If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
58439168|NCT06294392|BEHAVIORAL|KEEP-CK|The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
58107345|NCT02345928|DRUG|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
58439169|NCT05413720|OTHER|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
58107346|NCT02345928|DRUG|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
58107347|NCT02345928|DRUG|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
58439170|NCT02017925|BEHAVIORAL|exercise intervention|Undergo pulmonary rehabilitation
58107348|NCT02345928|DRUG|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
58107349|NCT03994094|OTHER|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
58107350|NCT06530992|OTHER|tucking break|"All participants will provide a semen sample for sperm analysis after 2-7 days of abstinence from ejaculation, a venous blood sample will be taken at the same time, and quality of life will be assessed using a questionnaire.~Participants in the study group are then asked to refrain from tucking or wearing tight underwear for at least 73 days. At least 73 days (10.5 weeks) after the first spermiogram, another semen collection is scheduled after 2-7 days of abstinence from ejaculation for the preparation of a spermiogram, a venous blood sample is taken at the same time, and quality of life is assessed in all participants. At this point, depending on the participant's wishes, it is possible to perform sperm cryopreservation for fertility preservation before starting gender affirming hormonal treatment."
58310995|NCT00769418|DRUG|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
58310996|NCT00769418|DRUG|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
58310997|NCT02765165|DRUG|USL311|Administered once weekly in a 21-day cycle
58439171|NCT02017925|PROCEDURE|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
58439172|NCT02017925|PROCEDURE|quality-of-life assessment|Ancillary studies
58439173|NCT02017925|OTHER|questionnaire administration|Ancillary studies
58107351|NCT05771311|DEVICE|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
58310998|NCT02765165|DRUG|USL311|Administered once daily in a 21-day cycle
58107352|NCT05771311|DEVICE|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
58107353|NCT04217668|DRUG|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
58107354|NCT06301633|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
58310999|NCT02765165|DRUG|USL311|Administered once daily in a 42-day cycle
58311000|NCT02765165|DRUG|Lomustine|Administered once every 6 weeks in a 42-day cycle
58107355|NCT06301633|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
58107356|NCT06301633|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
58107357|NCT05058144|DIETARY_SUPPLEMENT|Drinkable solution|the volunteer will consume the volume 300 ml of water with
58107358|NCT01783925|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
58107359|NCT03536819|DEVICE|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
58107360|NCT03438799|DEVICE|Cordio System|App, cloud and web device
58107361|NCT06271421|DEVICE|NanoTherm therapy|Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.
57955279|NCT02363686|PROCEDURE|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
58107362|NCT06271421|PROCEDURE|Glioma Resection|Removal of brain tumor - gross total ressection
58107363|NCT06271421|RADIATION|radiotherapy according to Stupp protocol|The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.
58107364|NCT06271421|DRUG|chemotherapy according to Stupp protocol|Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
58107365|NCT02082912|DRUG|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
58439174|NCT06271395|DRUG|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
58439175|NCT00994422|DRUG|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
57955280|NCT03793712|DRUG|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
58107366|NCT02082912|OTHER|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
58107367|NCT02082912|DEVICE|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
58107368|NCT06530160|OTHER|ELISA|Enzyme-linked immunosorbent assay
58311001|NCT03412214|DEVICE|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
58311002|NCT03412214|DEVICE|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
57955281|NCT03793712|DRUG|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
57955282|NCT03793712|DRUG|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
57955283|NCT01811251|DRUG|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
58311003|NCT05583630|DEVICE|A gap plate with the function of knee joint pressure detection|A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
58311004|NCT04578366|DEVICE|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
58311005|NCT04578366|OTHER|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
58311006|NCT02667639|BIOLOGICAL|RPH-104|Anti-IL-1 Mab
58311007|NCT02667639|OTHER|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
58439176|NCT00994422|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
58439177|NCT02430883|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
58439178|NCT01403493|BEHAVIORAL|Patient education|
58439179|NCT01009008|DEVICE|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
58107369|NCT06064981|BEHAVIORAL|Text message nudges|"Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life)."
58107370|NCT06064981|BEHAVIORAL|Commitment contract|"In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone."
58107371|NCT01207401|DRUG|Lidocaine|1% Lidocaine
58107372|NCT02857725|DRUG|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58107373|NCT02857725|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58107374|NCT00447018|DRUG|20% mannitol|
58107375|NCT00447018|DRUG|7.45% hypertonic saline solution|
58107376|NCT02681107|RADIATION|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
58107377|NCT01392859|DRUG|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
58107378|NCT02519972|DEVICE|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
58107379|NCT04881422|BEHAVIORAL|B-HIPE (Brief High Impact Preparatory Experience)|The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
58107380|NCT01208922|DRUG|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
58107381|NCT01208922|DRUG|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
58107382|NCT00707915|DRUG|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
57738691|NCT02967627|DEVICE|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
58107383|NCT05102045|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
58107384|NCT05102045|OTHER|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
58107385|NCT05102045|DRUG|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
58107386|NCT05102045|DRUG|Memantine|Memantine were given for Alzheimer's disease. .
58107387|NCT00838669|DRUG|Extended release OROS paliperidone|
58107388|NCT01917903|BEHAVIORAL|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
58107389|NCT01917903|BEHAVIORAL|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
58107390|NCT04036448|DRUG|REVLIMID®|REVLIMID®
58107391|NCT06520436|PROCEDURE|Arthroscopic-Assisted Reduction|The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
58107392|NCT03473847|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
58107393|NCT03473847|DEVICE|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
58439180|NCT00344500|BEHAVIORAL|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition"
58311008|NCT03000153|OTHER|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
58311009|NCT04871464|DRUG|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
58311010|NCT04871464|OTHER|Placebo|Oral
58311011|NCT05719961|DRUG|INS062 injection|Part I: A single dose of 1.2noml/kg is administered.
58311012|NCT05719961|DRUG|Insulin Aspart|Part I: A single dose of 0.2U/kg is administered.
58311013|NCT05719961|DRUG|HR20014 injection|Part II: Ascending single doses at three dose levels
58311014|NCT05719961|DRUG|Insulin Aspart 30 Injection|Part II: A single dosewas administered
58439181|NCT05542654|OTHER|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
58439182|NCT06085781|OTHER|fMRI|Functional Magnetic Resonance Imaging
58439183|NCT06085781|OTHER|Oral Pimonidazole|200 mg and 300 mg tablets
58439184|NCT00704288|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
58439185|NCT04603118|PROCEDURE|Optic ultrasonography|
58439186|NCT04603118|PROCEDURE|Lumbar puncture|
58439187|NCT04406025|PROCEDURE|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
58439188|NCT04406025|PROCEDURE|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
58439189|NCT04720677|OTHER|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
58439190|NCT04584437|OTHER|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
58439191|NCT02647424|DRUG|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
58439192|NCT02647424|DRUG|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
58439193|NCT03492541|OTHER|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
57955284|NCT00234611|PROCEDURE|Echocardiogram guided left ventricular lead placement|
58439194|NCT05209373|BEHAVIORAL|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
57955285|NCT01688154|DIETARY_SUPPLEMENT|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
57955286|NCT01688154|OTHER|2 empty capsules|
57955287|NCT00123214|DRUG|Controlled Dietary Intervention|
57955288|NCT01032304|DRUG|Erdosteine|One 300 mg capsule twice a day
57955289|NCT01032304|DRUG|Placebo|One capsule twice a day
57955290|NCT05858671|OTHER|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
57955291|NCT05858671|OTHER|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
57955292|NCT00709215|DRUG|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
57955293|NCT02480127|PROCEDURE|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
57955294|NCT01967550|DRUG|diclofenac diethylamine, DDEA 2.32% gel|
57955295|NCT01967550|DRUG|Placebo|
57955296|NCT00003437|DRUG|asparaginase|
57955297|NCT00003437|DRUG|cyclophosphamide|
57955298|NCT00003437|DRUG|cytarabine|
57955299|NCT00003437|DRUG|daunorubicin hydrochloride|
57955300|NCT00003437|DRUG|dexamethasone|
57955301|NCT00003437|DRUG|doxorubicin hydrochloride|
57955302|NCT00003437|DRUG|mercaptopurine|
57955303|NCT00003437|DRUG|methotrexate|
57955304|NCT00003437|DRUG|pegaspargase|
57955305|NCT00003437|DRUG|prednisolone|
57955306|NCT00003437|DRUG|thioguanine|
57955307|NCT00003437|DRUG|vincristine sulfate|
57955308|NCT00003437|RADIATION|radiation therapy|
57955309|NCT05234632|DEVICE|PICO 14 single-use Negative Pressure Wound Therapy System|The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
57955310|NCT02745275|BEHAVIORAL|Peer-led Health Education|Peer-led health education
57955311|NCT05185271|BEHAVIORAL|Dyad-focused strategy training|"Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
57955312|NCT00977821|OTHER|IVF|
57955313|NCT00977821|OTHER|Oocyte Vitrification|
58107394|NCT03473847|DEVICE|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
58311015|NCT02909062|DEVICE|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
58311016|NCT02909062|BEHAVIORAL|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
57738692|NCT02967627|DEVICE|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
57738693|NCT02552524|DEVICE|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
58439195|NCT05209373|BEHAVIORAL|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
58439196|NCT00004932|DRUG|imatinib mesylate|
58439197|NCT04035239|DEVICE|BGS goggles|BGS goggles use for 3-6 weeks
58439198|NCT00411255|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
57738694|NCT02552524|DEVICE|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
57738695|NCT03215095|DRUG|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
57738696|NCT03215095|RADIATION|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
57955314|NCT01403012|OTHER|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
57955315|NCT02982954|DRUG|Nivolumab|Specified dose on specified day
57955316|NCT02982954|DRUG|Ipilimumab|Specified Dose on Specified Day
57955317|NCT05607875|BEHAVIORAL|The Grow to Recovery Train-the-Trainer program|"Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training."
57955318|NCT05607875|OTHER|Control group|Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
57955319|NCT03157427|DEVICE|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
57955320|NCT01391000|PROCEDURE|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
57955321|NCT01391000|PROCEDURE|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
57955322|NCT02766738|OTHER|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
57955323|NCT02766738|OTHER|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
57955324|NCT02263183|DIETARY_SUPPLEMENT|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
57955325|NCT02263183|DIETARY_SUPPLEMENT|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
57955326|NCT05332158|BEHAVIORAL|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
57955327|NCT03460782|BIOLOGICAL|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
57955328|NCT04110457|PROCEDURE|spinal decompression|spinal surgery by decompression or fixation
57955329|NCT00820651|DIETARY_SUPPLEMENT|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
58107395|NCT03473847|DEVICE|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
58107396|NCT01735877|OTHER|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
58311017|NCT00486044|DRUG|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
58311018|NCT00486044|DRUG|Placebo|Matching tablet each night for 9 months
58311019|NCT02382939|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
58311020|NCT02382939|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
58311021|NCT03998735|DRUG|Herbal Snuff (Smokeless Tobacco)|4 levels of \[D4\]nornicotine in herbal snuff
58311022|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer without cycloplegia|Objective refraction without cycloplegia
58439199|NCT00413790|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
58439200|NCT00413790|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
58439201|NCT00413790|DRUG|Placebo|Placebo tablet once daily
58439202|NCT03875742|DEVICE|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
57738697|NCT01840267|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
57955330|NCT00820651|OTHER|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
58311023|NCT06524115|OTHER|Distance visual acuity check using objective refraction without cycloplegia|Distance visual acuity is checked, using objective refraction without cycloplegia
57955331|NCT04313127|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
57955332|NCT02549209|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
57955333|NCT02549209|DRUG|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
58439203|NCT03875742|DEVICE|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
58107397|NCT01735877|OTHER|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
58107398|NCT00268554|DRUG|dipyridamole|
58107399|NCT00268554|DRUG|caffeine|
58107400|NCT02236156|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
58107401|NCT02236156|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
58107402|NCT02236156|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
58107403|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
58107404|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
58107405|NCT00591253|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
58107406|NCT00094315|DRUG|Cocaine (IV)|
58107407|NCT06146621|BEHAVIORAL|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
58107408|NCT06146621|BEHAVIORAL|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
58107409|NCT06146621|BEHAVIORAL|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
58107410|NCT06146621|BEHAVIORAL|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
58107411|NCT05639569|DEVICE|Ankura™ TAA Stent Graft System|All patients will be implanted with Ankura™ TAA Stent Graft System in accordance with the instructions for use (IFU).
57738698|NCT01968239|DRUG|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
57738699|NCT00864032|DRUG|Sorafenib|400mg twice daily
57738700|NCT05061251|DRUG|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
57955334|NCT02549209|DRUG|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
57955335|NCT02589262|DRUG|AUT00206|
57955336|NCT03670953|DRUG|IR CD-LD|Active comparator - IR CD-LD
57955337|NCT03670953|DRUG|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
57955338|NCT03670953|OTHER|Placebo Matching IPX203|Double dummy placebo capsules
57955339|NCT03670953|OTHER|Placebo Matching IR CD-LD|Double dummy placebo tablets
57955340|NCT03808727|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
57955341|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
57955342|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
57955343|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
57955344|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
57738701|NCT05382780|OTHER|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
58107412|NCT05770401|BEHAVIORAL|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
57738702|NCT05382780|OTHER|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
57738703|NCT05382780|OTHER|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
57738704|NCT04659980|DEVICE|hilotherapy|continuous cooling of hands and feet at a constant temperature
58107413|NCT05770401|BEHAVIORAL|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
58107414|NCT02278731|OTHER|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
57738705|NCT04659980|DEVICE|frozen gloves|cooling of hands and feet using frozen gloves
58107415|NCT00871598|DRUG|BTT1023|intravenous, three infusions over three weeks
58107416|NCT00871598|DRUG|Placebo|intravenous, three infusions over three weeks
58107417|NCT00871598|DRUG|BTT1023|Test challenge
58107418|NCT03914144|OTHER|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
58107419|NCT01389024|DRUG|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
58107420|NCT01389024|DRUG|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
58311024|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer with cycloplegia|Objective refraction with cycloplegia
57955345|NCT00661115|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
57955346|NCT00661115|DRUG|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
57955347|NCT00620412|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.
57955348|NCT00620412|DIETARY_SUPPLEMENT|placebo control|2 capsules by mouth twice a day for 28 days
58107421|NCT01361906|BEHAVIORAL|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
58107422|NCT00236782|DRUG|norelgestromin + ethinyl estradiol; mercilon|
58311025|NCT06524115|OTHER|Distance visual acuity check using objective refraction with cycloplegia|Distance visual acuity is checked, using objective refraction with cycloplegia
58311026|NCT05109715|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
58311027|NCT05109715|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
58311028|NCT01464138|DRUG|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
58311029|NCT01147822|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
58311030|NCT01147822|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
58311031|NCT06519058|OTHER|self-myofascial stretching|self-myofascial stretching exercise
58311032|NCT06519058|OTHER|conventional physical therapy|conventional physical therapy treatment, including exercises
58311033|NCT05037630|BEHAVIORAL|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
58311034|NCT00038285|PROCEDURE|Amputation Prevention|
58311035|NCT01482832|BEHAVIORAL|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
58439204|NCT05542758|OTHER|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
58439205|NCT01807299|DIETARY_SUPPLEMENT|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
58439206|NCT01807299|OTHER|Physical Training|
58439207|NCT01427426|DIETARY_SUPPLEMENT|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
58439208|NCT01427426|OTHER|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
58439209|NCT04954924|OTHER|standardized physiotherapy program and Kinesio tape|
58439210|NCT00390663|PROCEDURE|Nasal Cautery|
58439211|NCT02148055|OTHER|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
58439212|NCT06525129|OTHER|Cerebellar stimulation group (CbSG)|Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.
57738706|NCT05164159|DRUG|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
58107423|NCT00407459|DRUG|Bevacizumab, Pemetrexed, Carboplatin|"* Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
58107424|NCT00190320|PROCEDURE|Induction of labor vs waiting|
57738707|NCT05164159|DRUG|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
57738708|NCT03281902|PROCEDURE|Biopsy|Undergo tumor biopsy
57738709|NCT03281902|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
57738710|NCT03281902|OTHER|Laboratory Biomarker Analysis|Correlative studies
58107425|NCT06307600|DRUG|RD06-03 cell injection|The patients in this intervention will use RD06-03 cell injection
58107426|NCT05843838|PROCEDURE|Hypotension during spinal anesthesia for cesarean section|Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value
58107427|NCT05843838|DIAGNOSTIC_TEST|Mini-mental test|"A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated."
58107428|NCT05843838|PROCEDURE|Spinal anesthesia|It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
58107429|NCT05843838|DIAGNOSTIC_TEST|The Bromage scale|"The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet"
58107430|NCT05843838|DRUG|Heavy Bupivacaine for spinal anesthesia|Routine clinical heavy bupivacaine doses
58107431|NCT03335709|BEHAVIORAL|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
58107432|NCT02555618|BIOLOGICAL|TAK-850|TAK-850 subcutaneous injection
58107433|NCT02555618|BIOLOGICAL|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
58439213|NCT06525129|OTHER|Cerebral (M1) Stimulation group (MSG)|In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.
57738711|NCT03424824|DRUG|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
57738712|NCT03424824|DRUG|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
57955349|NCT00620412|BIOLOGICAL|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
57955350|NCT03142802|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~   - Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~   - Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~   * Patient goes off study"
57955351|NCT02192827|DRUG|Dexamethasone Sodium Phosphate Injection|
57955352|NCT06495034|DEVICE|airwave compression therapy|Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb
57955353|NCT06495034|OTHER|standard care: health education and routine functional exercise|standard care: health education and routine functional exercise
57955354|NCT04952064|DRUG|Monosialoganglioside GM1|Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
57955355|NCT03921021|DRUG|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
57955356|NCT05450198|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
57955357|NCT05450198|BIOLOGICAL|Placebo|Placebo comparator to MK-6194 administered SC
57955358|NCT00892307|RADIATION|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
57955359|NCT00858858|DRUG|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
57955360|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
57955361|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） High Dose|
57955362|NCT01411254|DRUG|Sham|
57955363|NCT04042103|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
57955364|NCT05372029|BEHAVIORAL|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
57955365|NCT05372029|BEHAVIORAL|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
57955366|NCT01049841|DRUG|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
57955367|NCT04601987|BEHAVIORAL|Breastfeeding|Counseling about the maternal health benefits of lactation.
58107434|NCT03402178|DRUG|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
58107435|NCT03402178|DRUG|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
58107436|NCT02450760|OTHER|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
58107437|NCT01682941|DIETARY_SUPPLEMENT|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
58107438|NCT01682941|DIETARY_SUPPLEMENT|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
58107439|NCT00962949|DRUG|Angiotensin II|Angiotensin II infusion for 1 hour
58107440|NCT00080288|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
58107441|NCT00080288|DRUG|Placebo|Matching placebo tablets once daily
58107442|NCT04078139|DRUG|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
58107443|NCT04078139|DRUG|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
58107444|NCT00370669|DRUG|bevacizumab|
58107445|NCT00370669|DRUG|triamcinolone acetonide|
58107446|NCT00404586|DRUG|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
58107447|NCT00404586|DRUG|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
58107448|NCT00404586|DRUG|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
58107449|NCT04312919|BEHAVIORAL|Family Based Activity Intervention|Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
58107450|NCT00428194|DRUG|cisplatin|40 mg/m\^2 every 7 days during radiation
58107451|NCT00428194|DRUG|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
58107452|NCT00428194|PROCEDURE|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
58107453|NCT05131997|DRUG|AD-221|PO, Once daily(QD), 8 weeks
58107454|NCT05131997|DRUG|AD-221A|PO, Once daily(QD), 8 weeks
58107455|NCT05131997|DRUG|AD-221B|PO, Once daily(QD), 8 weeks
58107456|NCT05131997|DRUG|AD-221C|PO, Once daily(QD), 8 weeks
58107457|NCT06537986|BEHAVIORAL|Neurocognitive and psychosocial intervention module|"The module comprised of various intervention methods that include- I. Cognitive Retraining: Pen-and-paper-based cognitive rehabilitation program that is divided into five hierarchically graded modules: Attention, Visual Processing, Memory, Information Processing, and Executive Functions.~2.Cognitive-behavioral interventions. Cognitive-behavioral interventions would be carried out for activities scheduling, problem-solving teachings, anger management techniques, modifications of negative cognitions, stigma address measures, and irrational beliefs about epilepsy, etc.~3. Marital/Family counseling: Marital/family counseling would be done to ensure family understanding of the patient's illness, his/her treatment, prognosis, and outcome. Family complications arising due to illness would also be discussed. Individual and personal needs of the husband, a wife will also be discussed."
57738713|NCT03424824|DRUG|Placebo|Tablet, once daily oral administration
58107458|NCT04688983|DRUG|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
58107459|NCT04688983|DRUG|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
58107460|NCT04688983|DRUG|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
58107461|NCT03185247|BEHAVIORAL|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
58311036|NCT05115396|OTHER|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
57738714|NCT03424824|DRUG|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
57738715|NCT01570101|DEVICE|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
57738716|NCT06580626|PROCEDURE|decompression technique|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
58311037|NCT05115396|OTHER|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
58107462|NCT01450579|BIOLOGICAL|ASP7373|Intermuscular administration
58107463|NCT01450579|BIOLOGICAL|Placebo|Intramuscular administration
58107464|NCT00763984|BEHAVIORAL|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
58107465|NCT00763984|BEHAVIORAL|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
58107466|NCT04821050|DEVICE|Sacral nerve stimulation|"A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
58107467|NCT04821050|DEVICE|Sham stimulation|"Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
58107468|NCT04292171|DRUG|Gabapentin|Preoperative treatment with Gabapentin
58107469|NCT04292171|DRUG|Placebos|Preoperative treatment with Placebo
58107470|NCT05570968|PROCEDURE|C-arm device|Percutaneous Transluminal Angioplasty
58107471|NCT03549663|DRUG|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
58107472|NCT03549663|DRUG|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
58311038|NCT00717886|RADIATION|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
57738717|NCT06580626|PROCEDURE|guided bone regenaration using Ethoss|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.
57738718|NCT06580626|PROCEDURE|ridge splitting technqiue|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
57738719|NCT06503211|BIOLOGICAL|UTAA09 injection|The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
58311039|NCT01494558|OTHER|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
58311040|NCT02435134|OTHER|no intervention|
57738720|NCT06497465|DRUG|Dolutegravir 50mg Tab|Participants will receive Dolutegravir 50mg
57955368|NCT04601987|BEHAVIORAL|Smokefree Homes|Counseling about the importance of smoke-free homes.
57955369|NCT06101056|BEHAVIORAL|Junior Enlisted Component|"Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7."
57738721|NCT06497465|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
58107473|NCT06097611|DRUG|Tranexamic Acid administration|Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
58107474|NCT02414854|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
58107475|NCT02414854|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
58439214|NCT06525129|OTHER|Sham Stimulation group (SSG)|In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
58107476|NCT02414854|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
58311041|NCT03334175|DRUG|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
58311042|NCT04812158|OTHER|standard ankle physiotherapy or rehabilitation for chronic ankle instability|6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
58311043|NCT04239924|BEHAVIORAL|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
58311044|NCT00141609|DRUG|Slow Sodium|
58311045|NCT03968809|DIAGNOSTIC_TEST|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
58311046|NCT03702699|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
58311047|NCT00000498|BEHAVIORAL|diet, sodium-restricted|
58311048|NCT00000498|BEHAVIORAL|diet, reducing|
58311049|NCT00000498|BEHAVIORAL|alcohol restriction|
58311050|NCT00000498|DRUG|antihypertensive agents|
58311051|NCT01749371|DRUG|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
57738722|NCT06497465|DRUG|Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)|Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
57738723|NCT02248870|DRUG|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
57738724|NCT02248870|DRUG|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
57738725|NCT03835533|DRUG|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
57738726|NCT03835533|DRUG|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
58107477|NCT02414854|DRUG|Albuterol/Salbutamol|Oral inhalation as needed
58107478|NCT02414854|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed
58107479|NCT05465330|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min
58311052|NCT03614000|OTHER|Screening Questionnaires|"Measurement tools:~* Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~* The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~* The VG\&O The VG\&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
58311053|NCT05724290|GENETIC|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
58311054|NCT02456896|DRUG|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
58311055|NCT01154660|OTHER|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
58311056|NCT02251275|DRUG|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
58439215|NCT03053843|DIETARY_SUPPLEMENT|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
58439216|NCT01158781|BEHAVIORAL|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
58439217|NCT05720299|DRUG|Treatment with Akkermansia muciniphila|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
57738727|NCT03835533|RADIATION|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
57738728|NCT03835533|DRUG|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
57738729|NCT03835533|DRUG|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
58107480|NCT05465330|DRUG|Desflurane, Propofol|After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
58311057|NCT06262984|OTHER|Therapeutic Play|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
58311058|NCT05884216|DEVICE|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
58311059|NCT05884216|DEVICE|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
58311060|NCT02002663|DRUG|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
58311061|NCT02002663|DRUG|Methylprednisolone 1mg/kg|
58311062|NCT02002663|DRUG|saline 0.9%|
58311063|NCT03988660|DIAGNOSTIC_TEST|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
58311064|NCT03699748|BEHAVIORAL|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
58311065|NCT03699748|OTHER|Usual Care|Usual care as provided by Unite Here Health and local oncologists
58311066|NCT00513214|DRUG|XOMA 052|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
57738730|NCT03835533|DRUG|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
57738731|NCT03835533|DEVICE|Cellectra 2000|Electroporation device
57738732|NCT00689650|DEVICE|1540 nm fractional laser|
57738733|NCT01638910|DRUG|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
58311067|NCT00513214|DRUG|Placebo|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
58107481|NCT05528289|DEVICE|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
58439218|NCT05720299|OTHER|Treatment with placebo|120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
58439219|NCT00673777|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
58439220|NCT00001094|DRUG|Lamivudine/Zidovudine|
58439221|NCT00001094|DRUG|Nelfinavir mesylate|
58439222|NCT00001094|DRUG|Saquinavir|
58439223|NCT00001094|DRUG|Delavirdine mesylate|
58439224|NCT05942547|DRUG|Diosmin|diosmin 600mg twice daily
58439225|NCT05942547|DRUG|Placebo|twice daily
58439226|NCT03075358|DRUG|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
58439227|NCT03075358|OTHER|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
58439228|NCT01761019|DRUG|Taclonex Topical Suspension|topical medication for psoriasis
58439229|NCT05839249|OTHER|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
58439230|NCT00099658|BIOLOGICAL|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
58439231|NCT01992835|OTHER|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
58439232|NCT01992835|OTHER|placebo|
58107482|NCT05528289|DEVICE|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
58107483|NCT04431531|OTHER|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
57738734|NCT00327626|DRUG|ISIS 113715|
57738735|NCT05105295|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
57738736|NCT05711654|BEHAVIORAL|Health coaching|Coaching interview will be held with patients at regular intervals.
58311068|NCT05278897|DEVICE|Soft Tissue Adapted Biocompatible Hyaluronic Acid|1% sodium hyaluronate
58311069|NCT00560716|DRUG|CYC116|Dose escalation of CYC116
58311070|NCT03722576|DRUG|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
58311071|NCT06332482|DEVICE|Implant supported screw retained prosthesis|All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
58311072|NCT05107375|BIOLOGICAL|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
58311073|NCT05107375|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
58311074|NCT03409965|DEVICE|Lutronic Infini System|A microneedle radiofrequency device
58311075|NCT03409965|DEVICE|Lutronic LaseMD System|A fractional thulium laser device
58439233|NCT05345717|DRUG|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
58439234|NCT05945446|DIAGNOSTIC_TEST|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
58439235|NCT03331757|OTHER|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439236|NCT03331757|OTHER|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439237|NCT03331757|OTHER|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439238|NCT03331757|OTHER|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
57738737|NCT01347333|RADIATION|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
58107484|NCT04431531|OTHER|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
58311076|NCT02026297|DRUG|Tranexamic Acid|1 gram IV over 10 minutes
58311077|NCT02026297|DRUG|Placebo; Normal Saline|0.9% Normal Saline
58439239|NCT03331757|OTHER|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439240|NCT03331757|OTHER|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439241|NCT03331757|OTHER|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
58439242|NCT03620084|DEVICE|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
57738738|NCT01347333|RADIATION|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
57738739|NCT02813850|DEVICE|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
57738740|NCT00969033|DRUG|CS-1008|CS-1008
57738741|NCT00969033|DRUG|irinotecan|irinotecan
57738742|NCT04534595|OTHER|COVID-19|To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
58311078|NCT01626170|OTHER|laboratory biomarker analysis|Correlative studies
58311079|NCT01620424|DRUG|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
58311080|NCT01620424|DRUG|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
58311081|NCT02282462|OTHER|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
58311082|NCT02282462|OTHER|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
58311083|NCT02282462|OTHER|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
58311084|NCT02282462|OTHER|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
58311085|NCT02282462|OTHER|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
58311086|NCT02282462|OTHER|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
58311087|NCT01118676|DRUG|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
58311088|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
58311089|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
58311090|NCT02517749|DEVICE|Chest Drain Insertion and Talc Pleurodesis|
58311091|NCT02517749|DEVICE|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
58311092|NCT01366391|DRUG|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
58311093|NCT00771108|BEHAVIORAL|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
58311094|NCT00988182|OTHER|dietary intervention|whey protein
58311095|NCT00988182|OTHER|water control|
58311096|NCT02900716|DRUG|DTRMWXHS-12|DTRMWXHS-12
58311097|NCT02900716|DRUG|DTRM-505|DTRMWXHS-12 and everolimus
57738743|NCT04439422|BEHAVIORAL|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
58439243|NCT05777135|DRUG|Ringer Lactate prior to surgery and Propofol|Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
58311098|NCT02900716|DRUG|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
57738744|NCT04439422|OTHER|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
57738745|NCT03195257|OTHER|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
58311099|NCT00980876|DRUG|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
58311100|NCT00980876|DRUG|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
58311101|NCT00029237|BEHAVIORAL|Cognitive-behavioral relaxation (Positively Living)|
58311102|NCT00029237|BEHAVIORAL|Spiritual growth group|
58311103|NCT00029237|BEHAVIORAL|Focused Tai Chi|
58311104|NCT01860196|DRUG|Meditoxin|
58311105|NCT01860196|DRUG|Normal saline|
58311106|NCT01548963|PROCEDURE|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
58107485|NCT04364724|OTHER|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
58107486|NCT00096369|DRUG|tamoxifen citrate|
58311107|NCT01657617|RADIATION|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
58439244|NCT06291831|DRUG|nirmatrelvir, ritonavir|Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
58439245|NCT06291831|OTHER|Controls|Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
58439246|NCT00765804|DRUG|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
58439247|NCT00765804|DRUG|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
58439248|NCT04871958|DEVICE|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
58439249|NCT00788788|DRUG|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
58439250|NCT01711645|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
58439251|NCT01212393|BEHAVIORAL|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
58439252|NCT00197899|DRUG|E. Coli endotoxin|
57738746|NCT03195257|OTHER|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
57738747|NCT03195257|OTHER|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
58107487|NCT05649982|BEHAVIORAL|ALVA|Behavioural digital self-help intervention
58107488|NCT00206622|DRUG|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
58311108|NCT03890575|PROCEDURE|Airway stent implantation|The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
58311109|NCT01922453|OTHER|Music and Sound|
58311110|NCT04936893|BEHAVIORAL|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
58311111|NCT04936893|BEHAVIORAL|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
58439253|NCT01528189|OTHER|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
58439254|NCT01528189|OTHER|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
58439255|NCT05856266|PROCEDURE|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
58439256|NCT05856266|OTHER|Haemophilia Joint Health Score (HJHS)|Functional joint examination
58107489|NCT00206622|DRUG|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
58107490|NCT00206622|DRUG|Placebo transdermal|Placebo
58107491|NCT04998253|DRUG|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
58107492|NCT02413697|DEVICE|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
58439257|NCT02443168|DRUG|AG-221|Part 1: oral solution containing 100 mg \[14C\]-AG-221
57738748|NCT00594854|DRUG|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
58439258|NCT02443168|RADIATION|14C AG-221|5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
58439259|NCT06272110|OTHER|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
58439260|NCT04248023|BEHAVIORAL|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
58439261|NCT01843062|DRUG|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
57738749|NCT00594854|DRUG|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
57738750|NCT03902379|OTHER|Internet-Based Intervention|Receive CCI intervention
57738751|NCT03902379|OTHER|Quality-of-Life Assessment|Ancillary studies
57738752|NCT03902379|OTHER|Questionnaire Administration|Ancillary studies
57738753|NCT03902379|OTHER|Survey Administration|Ancillary studies
58311112|NCT02638792|BEHAVIORAL|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
58311113|NCT02638792|BEHAVIORAL|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
58439262|NCT01843062|DRUG|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
58439263|NCT01843062|DRUG|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
58439264|NCT05132218|DRUG|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
58439265|NCT00133601|BEHAVIORAL|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
58439266|NCT00862693|DRUG|Calcitriol|0.5ug/Biw
57738754|NCT02170987|DRUG|Dabigatran etexilate low|
57738755|NCT02170987|DRUG|Dabigatran etexilate high|
57738756|NCT02170987|DRUG|Moxifloxacin|
57738757|NCT02170987|DRUG|Placebo|
57738758|NCT00463710|DRUG|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
57738759|NCT02703675|DEVICE|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
57738760|NCT03735329|DEVICE|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
57738761|NCT05630274|DRUG|Selpercatinib|Administered orally
57738762|NCT05630274|DRUG|Moxifloxacin|Administered orally
57738763|NCT05630274|DRUG|Placebo|Administered orally.
57738764|NCT05124704|DRUG|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
58439267|NCT04522141|BEHAVIORAL|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
58107493|NCT02413697|DEVICE|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
58107494|NCT06237140|OTHER|PNF+ biofeedback exercise group|Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
58107495|NCT03716505|DEVICE|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
58107496|NCT03716505|DEVICE|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
58107497|NCT03456362|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
58107498|NCT03167814|DIETARY_SUPPLEMENT|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
58107499|NCT05301166|BEHAVIORAL|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
58107500|NCT05301166|OTHER|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
58107501|NCT04458779|DEVICE|CPAP|CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
58107502|NCT05195554|OTHER|Psycho-educational intervention|Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
58107503|NCT03263819|DIAGNOSTIC_TEST|Oral glucose tolerance test|75 grams of glucose
57738765|NCT05124704|OTHER|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
57738766|NCT04878094|DIAGNOSTIC_TEST|Intravenous Indocyanine Green/ICG injection|Intravenous Indocyanine Green/ICG injection will be administered for visualization
57738767|NCT04878094|DIAGNOSTIC_TEST|PINPOINT endoscopic fluorescence imaging system|After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.
57738768|NCT04878094|DIAGNOSTIC_TEST|Endoscopy|Standard technique and assessment of anastomosis without the use of NIR angiography
57738769|NCT01008033|DRUG|IDP-108|Topical application once a day for 48 weeks
58107504|NCT02359084|BEHAVIORAL|Family Navigation|
58439268|NCT04522141|BEHAVIORAL|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
58107505|NCT02359084|BEHAVIORAL|Conventional Care Management|
58107506|NCT05350254|OTHER|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
58107507|NCT05350254|OTHER|Standard chiropractic care|Standard care based on clinician's judgement
58439269|NCT00724984|DRUG|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
57738770|NCT01008033|DRUG|Vehicle|Topical application once a day for 48 weeks
58107508|NCT04303494|BIOLOGICAL|immunisation|combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
58107509|NCT05531045|DIAGNOSTIC_TEST|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
57738771|NCT00003718|DRUG|temozolomide|
57738772|NCT06670989|BEHAVIORAL|Fixation training|Training (adapting) microsaccades during fixation
58439270|NCT05973253|DRUG|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
58439271|NCT00658463|DRUG|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
58107510|NCT03036995|DRUG|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
58439272|NCT00658463|DRUG|Placebo|Placebo
58439273|NCT05858372|DIETARY_SUPPLEMENT|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
58439274|NCT05858372|OTHER|Placebo|Placebo
58439275|NCT05892328|OTHER|Watermelon Flesh Dose 1|1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
58439276|NCT05892328|OTHER|Watermelon Flesh Dose 2|2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
58439277|NCT05892328|OTHER|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
58439278|NCT02675608|BIOLOGICAL|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
58439279|NCT03320720|OTHER|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
57738773|NCT05590819|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
58107511|NCT03036995|OTHER|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
58107512|NCT04262869|DRUG|Carboplatin|Given IV
58439280|NCT03320720|OTHER|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
58439281|NCT06038422|DRUG|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
57738774|NCT05590819|DEVICE|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
58107513|NCT04262869|BIOLOGICAL|Durvalumab|Given IV
58107514|NCT04262869|DRUG|Paclitaxel|Given IV
58107515|NCT04262869|DRUG|Pemetrexed|Given IV
58439282|NCT02632357|OTHER|Spinal Manipulation|
58439283|NCT02860104|DEVICE|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
58439284|NCT02481531|OTHER|Previously marketed infant formula|
58439285|NCT02481531|OTHER|Previously marketed formula using a similar protein|
58439286|NCT04921228|BEHAVIORAL|Heart rate variability biofeedback|"* 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
58107516|NCT00597584|DRUG|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
57738775|NCT05590819|DEVICE|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
57738776|NCT03762473|DRUG|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
57738777|NCT03762473|DRUG|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
58107517|NCT00597584|DRUG|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
58107518|NCT06290700|BEHAVIORAL|Neonatal Care education|Participants who met the study inclusion criteria were provided with information about the purpose and conduct of the study, and their consent to participate was then obtained. The interviews were conducted in the breastfeeding room at the Uşak Dikilitaş Family Health Centre. The data were collected between November 2022 and November 2023. The Family Health Centre has two vaccination rooms, two antenatal care rooms, two observation rooms, and two breastfeeding rooms. Each pregnant woman was individually enrolled in an education session held in the breastfeeding room. The breastfeeding room was approximately 20 m², which was considered standard for accommodating training for an average of three pregnant women. The breastfeeding room was quiet, had a suitable temperature, and was located on the first floor in the middle of the corridor.
58107519|NCT00464256|DRUG|rimonabant|
58107520|NCT06529874|OTHER|Pressure pain tolerance measurement using Digital Pressure Algometer|Pressure pain tolerance will be measured using pressure algometer for all participants in both groups. Pressure pain tolerance will be measured in a relaxed sitting position to evaluate on quadriceps muscle. Initially, a teddy bear will be used for demonstration.
58107521|NCT06529874|OTHER|Balance assessment using HUMAC balance system|"HUMAC balance system will be calibrated, then will conduct~1. center of pressure: will instructed child to stand on platform, and maintain own body stability, and focus on the red dot in the center of screen that will move in response to body sway. after a rest, second trial will be done.~2. Eye open/ closed firm surface tests: First for Eye open firm surface test; the child will be asked to look at a target on the wall that was set at his/ her eye level, and to stare at this target for 30 seconds while standing on firm surface. After 5 seconds rest. Eye closed firm surface test; child will be asked to close his/ her eyes for 30 seconds, and conducting the same procedures for balance testing.~The researcher will documented the values resented on the screen ."
58107522|NCT06529874|OTHER|Lower limb muscular strength using Lafayette hand held dynamometer|Lower limb muscular ' Isometric quadriceps strength' will be measured for all participants in both groups. each participating child will be instructed to sit to assess the strength of knee extension, which minimize positional changes, and enhance feasibility of this clinical test. then The researcher will apply resistance to child's quadriceps to gain maximal voluntary isometric contraction with pressing the activated Lafayette hand held dynamometer padded stirrup against quadriceps belly, then recorded and documented measured value.
58107523|NCT06129331|DRUG|Amyloid-specific treatment|Amyloid-specific treatment
58107524|NCT06129331|OTHER|No amyloid-specific treatment|No amyloid-specific treatment
58439287|NCT06127628|PROCEDURE|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
58439288|NCT00709072|BEHAVIORAL|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
58439289|NCT04119193|DEVICE|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
58439290|NCT04548856|PROCEDURE|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
57738778|NCT04991168|OTHER|Questionnaire|Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
57738779|NCT05163366|DRUG|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
57738780|NCT05163366|DRUG|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
58107525|NCT05926219|BEHAVIORAL|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
58107526|NCT05588830|DRUG|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
58439291|NCT04548856|PROCEDURE|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
58439292|NCT02189512|OTHER|blood sampling|cases - blood sampling controles - blood sampling
58439293|NCT01415401|DRUG|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
58439294|NCT01018485|DRUG|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
58439295|NCT01618006|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
58439296|NCT01618006|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
58439297|NCT01618006|DRUG|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
58439298|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
58439299|NCT04998981|DRUG|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
58439300|NCT04998981|DRUG|Placebo tablet|Placebo tablet x 2 twice daily
58439301|NCT04998981|DRUG|Placebo capsule|Placebo capsule once daily
58439302|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
58439303|NCT04998981|DRUG|Placebo tablet|Placebo tablet twice daily
58439304|NCT03411421|DRUG|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
58439305|NCT03411421|DRUG|Placebo|Matching placebo tablets will be administered.
58439306|NCT05334628|PROCEDURE|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
58439307|NCT05334628|PROCEDURE|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
57738781|NCT00000831|DRUG|Lamivudine|
58439308|NCT00050947|DRUG|oxcarbazepine|
58439309|NCT01358058|RADIATION|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
58439310|NCT01923662|DEVICE|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
58439311|NCT03060200|OTHER|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
58439312|NCT03060200|OTHER|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
58439313|NCT00525005|DRUG|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
58439314|NCT02272712|BEHAVIORAL|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
58439315|NCT06210100|DEVICE|Active iTBS|Mag-TD stimulator
58439316|NCT06210100|DEVICE|Sham iTBS|Mag-TD stimulator
57738782|NCT00000831|DRUG|Stavudine|
57738783|NCT00000831|DRUG|Zidovudine|
57738784|NCT00000831|DRUG|Didanosine|
58107527|NCT05588830|DRUG|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
58107528|NCT04000828|DEVICE|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
58107529|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)|the intervention is conducting electrical posterior box isolation plus rotor modulation ablation
58311114|NCT05844540|PROCEDURE|harvesting bone block|Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.
58439317|NCT00816192|PROCEDURE|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
58439318|NCT04373928|PROCEDURE|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
58439319|NCT00243711|DRUG|Carboxymethylcellulose sodium and Glycerin|
58439320|NCT03933228|PROCEDURE|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
58439321|NCT03933228|PROCEDURE|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
58439322|NCT02861898|DRUG|Intra-arterial Cetuximab|
58439323|NCT02861898|DRUG|Intra-arterial Mannitol|
58439324|NCT00614848|DEVICE|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
58439325|NCT00438165|BEHAVIORAL|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
58439326|NCT00423449|DRUG|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
58439327|NCT00423449|DRUG|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
58439328|NCT00423449|DRUG|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
58439329|NCT03487497|PROCEDURE|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
58439330|NCT01295957|BEHAVIORAL|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
58439331|NCT01295957|BEHAVIORAL|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
58439332|NCT01295957|OTHER|control|advise and informal counseling
57738785|NCT03240848|PROCEDURE|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
57738786|NCT03240848|PROCEDURE|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
57738787|NCT03240848|PROCEDURE|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
58107530|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation group (BO group)|the intervention is conducting electrical posterior box isolation alone
58107531|NCT00141284|DRUG|nelfinavir 1,250 mg twice daily|
58107532|NCT00141284|DRUG|Zidovudine 300 mg twice daily|
58107533|NCT00141284|DRUG|Lamivudine 150 mg twice daily|
58107534|NCT06529393|PROCEDURE|SHAC block|with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .
58439333|NCT00559221|DRUG|FLAG+IDA|Fludarabine, cytarabine, G-CSF
58439334|NCT04768543|DEVICE|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
58439335|NCT05876468|DEVICE|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~* First CACC : the applied pressure is equal to the one observed in the prone position~* Second CACC : The applied pressure is set at 60 - 80 cmH20"
58439336|NCT00020124|DRUG|doxorubicin hydrochloride|
57738788|NCT04339192|PROCEDURE|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
58439337|NCT01890408|DRUG|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
58439338|NCT00303485|DRUG|Placebo|po monthly for 6 months
58439339|NCT00303485|DRUG|Vitamin D and calcium supplementation|As prescribed
58439340|NCT00303485|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
58439341|NCT01436474|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
58439342|NCT01436474|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
58439343|NCT03029923|BEHAVIORAL|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
58439344|NCT03029923|BEHAVIORAL|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
58439345|NCT06098248|DIAGNOSTIC_TEST|cCeLL - Ex vivo|Neoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.
58439346|NCT04070417|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
58439347|NCT06380075|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
58439348|NCT06380075|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
57738789|NCT01474681|BIOLOGICAL|HSC835|
58439349|NCT06380075|DEVICE|Clarus imaging|Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
58439350|NCT02779647|BEHAVIORAL|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
58439351|NCT01683825|DRUG|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
58439352|NCT00002399|DRUG|Posaconazole|
58439353|NCT00002399|DRUG|Fluconazole|
58439354|NCT01863329|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
58439355|NCT00319254|DRUG|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
58439356|NCT04678388|DRUG|Reference drug|1 Cap., single oral administration under fasting condition
58439357|NCT04678388|DRUG|Test drug 1|1 Tab., single oral administration under fasting condition
58439358|NCT04678388|DRUG|Test drug 2|1 Tab., single oral administration under fasting condition
58439359|NCT04472455|DIAGNOSTIC_TEST|HRME|
58439360|NCT04890288|PROCEDURE|Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.|Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 \> 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).
58439361|NCT02982421|BEHAVIORAL|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
58311115|NCT05844540|PROCEDURE|Recipient site preparation|At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.
58311116|NCT05844540|PROCEDURE|implant insertion|"Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion."
58311117|NCT04931615|DRUG|ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|Wound sealant
58311118|NCT04931615|OTHER|no ARTISS|Wound closed without sealant
58311119|NCT02629770|DRUG|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
58311120|NCT04078386|BIOLOGICAL|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
58311121|NCT04078386|BIOLOGICAL|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
58311122|NCT04078386|BIOLOGICAL|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
58311123|NCT00223821|DRUG|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
58311124|NCT00223821|BEHAVIORAL|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
58311125|NCT04059952|DEVICE|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
58311126|NCT00726245|BIOLOGICAL|PRGF|3-6mg IM (to area of muscle tear)
58311127|NCT00726245|BIOLOGICAL|Placebo|3cc IM of physiological saline
58107535|NCT06529393|PROCEDURE|suprascapular nerve block|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
58107536|NCT01918709|DRUG|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107537|NCT01918709|DRUG|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107538|NCT01918709|DRUG|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107539|NCT01918709|DRUG|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107540|NCT01918709|DRUG|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107541|NCT01918709|DRUG|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
58107542|NCT04839237|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
58107543|NCT04839237|DRUG|Liraglutide;metformin|The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
58107544|NCT02442752|DRUG|Dexlansoprazole|Dexlansoprazole capsules
58107545|NCT01462500|DRUG|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
58107546|NCT01796860|OTHER|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
58107547|NCT02085707|PROCEDURE|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
57738790|NCT01283412|DRUG|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
57738791|NCT01283412|DRUG|Dexmedetomidine|Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
57738792|NCT03479372|DRUG|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
57738793|NCT05172765|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
58107548|NCT02085707|PROCEDURE|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
58107549|NCT03227822|PROCEDURE|Short spot stenting|
58107550|NCT03227822|PROCEDURE|Long lesion stenting|
58107551|NCT00897442|OTHER|Laboratory Biomarker Analysis|Correlative studies
58107552|NCT05725278|BEHAVIORAL|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
58107553|NCT05725278|OTHER|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
58439362|NCT02982421|BEHAVIORAL|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
58439363|NCT00889525|DRUG|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
58107554|NCT04155697|DRUG|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
58107555|NCT04155697|DRUG|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
58107556|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
58107557|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
58107558|NCT00926289|DRUG|Hydrochlorothiazide|Hydrochlorothiazide25mg
58439364|NCT05899374|BEHAVIORAL|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
58439365|NCT04979117|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
58439366|NCT04298437|BEHAVIORAL|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
58439367|NCT00705367|DRUG|Placebo|Infusion, Intravenous, single dose, Day 1
58439368|NCT00705367|DRUG|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
58439369|NCT00705367|DRUG|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
58439370|NCT00964652|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
58439371|NCT05097495|PROCEDURE|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~* Materials shall be prepared (napkins, non-sterile gloves, pacifier)~* Hands shall be washed; gloves shall be worn.~* The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
58439372|NCT05097495|PROCEDURE|NNS Combined with Breast Milk|"* Before the procedure, the Premature Infant Comfort Scale shall be filled out.~* Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~* Hands shall be washed; gloves shall be worn.~* The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
58439373|NCT01325688|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
58439374|NCT01325688|DEVICE|Aluminium disk|
58439375|NCT01325688|DEVICE|OpSite(TM) disk|
58439376|NCT05489367|BIOLOGICAL|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
58439377|NCT00335296|DEVICE|PFx catheter|
58107559|NCT02217345|DRUG|Growth hormone|growth hormone, Genotropin (Pfizer)
58107560|NCT02217345|DRUG|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
58107561|NCT01283607|BEHAVIORAL|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
58107562|NCT04098549|OTHER|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
58107563|NCT04098549|OTHER|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
58107564|NCT04825080|DIAGNOSTIC_TEST|duplex ultrasound and computed tomography angiography|Identification of carotid artery stenosis \> 60% NASCET criteria
58107565|NCT00162786|DRUG|Rupatadine|
58107566|NCT00162786|DRUG|Hydroxyzine|
58107567|NCT00162786|DRUG|Placebo|
58107568|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
58107569|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
58107570|NCT03275779|BEHAVIORAL|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
58107571|NCT03275779|BEHAVIORAL|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
58107572|NCT02226809|DEVICE|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
58107573|NCT06155799|DEVICE|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
58439378|NCT00566462|DRUG|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
58439379|NCT00566462|DRUG|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
58439380|NCT00491582|DRUG|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
58439381|NCT01100359|DRUG|carboplatin|
58107574|NCT00228540|DRUG|Modafinil|
58107575|NCT02964065|BIOLOGICAL|Live-Attenuated influenza Vaccine(LAIV)|
58107576|NCT02964065|BIOLOGICAL|Placebo|
58439382|NCT01100359|DRUG|liposome-encapsulated doxorubicin citrate|
58439383|NCT01100359|OTHER|laboratory biomarker analysis|
58439384|NCT01100359|PROCEDURE|quality-of-life assessment|
58439385|NCT04384029|OTHER|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
58439386|NCT03609411|PROCEDURE|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
58439387|NCT05050461|OTHER|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
58439388|NCT04423692|OTHER|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
58439389|NCT04693286|BIOLOGICAL|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
58439390|NCT04693286|OTHER|Placebo|Placebo contains no active ingradients, only sucrose in buffer
58439391|NCT02502045|DEVICE|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
58439392|NCT02502045|DEVICE|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
58311128|NCT05230836|OTHER|High-frequency alternating current stimulation|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group"
58439393|NCT01009606|OTHER|Usual strategy|Usual strategy
58439394|NCT01009606|OTHER|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
58107577|NCT05841966|DIAGNOSTIC_TEST|Transoral Ultrasound|The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
58439395|NCT03723369|DEVICE|accupuncture|accupuncture
58439396|NCT02279095|DRUG|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
58439397|NCT02279095|DRUG|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
58439398|NCT02279095|DRUG|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
58439399|NCT02279095|DRUG|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
58439400|NCT00083525|DRUG|WX-UK1 in combination with Capecitabine|
58439401|NCT05669053|BEHAVIORAL|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
58439402|NCT05669053|BEHAVIORAL|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
58439403|NCT05669053|BEHAVIORAL|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
58439404|NCT02303028|DRUG|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
58439405|NCT04840212|OTHER|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
58107578|NCT02827513|DRUG|CTN SR1|
58107579|NCT02827513|DRUG|CTN XR1|
58107580|NCT02827513|DRUG|CTN XR2|
58107581|NCT02827513|DRUG|CTN XR3|
58107582|NCT05502068|DIETARY_SUPPLEMENT|Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion|This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
58439406|NCT05499468|OTHER|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
58439407|NCT00056004|DRUG|zileuton|
58439408|NCT00709618|DRUG|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
58439409|NCT02978833|BIOLOGICAL|PRP|
58439410|NCT02978833|BIOLOGICAL|Whole Blood|
58439411|NCT02978833|DEVICE|Ultrasound|
58439412|NCT00002695|GENETIC|DNA stability analysis|
58439413|NCT00002695|GENETIC|microsatellite instability analysis|
58439414|NCT00002695|GENETIC|mutation analysis|
58439415|NCT00002695|OTHER|laboratory biomarker analysis|
58439416|NCT04631848|DEVICE|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
58439417|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
57738794|NCT06470321|BEHAVIORAL|Flexiquit Computerized Smoking Cessation Program|Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
57738795|NCT00377234|DRUG|Risedronate|35mg po weekly for 12 weeks
57738796|NCT00377234|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
57738797|NCT00882947|DRUG|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
57738798|NCT01796574|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
57738799|NCT00002933|DRUG|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
58439418|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
57738800|NCT03839251|DRUG|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
58107583|NCT03768609|DRUG|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
58107584|NCT03768609|DRUG|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
58439419|NCT03858374|DEVICE|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
58439420|NCT03858374|DEVICE|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
58439421|NCT03858374|DEVICE|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
58439422|NCT04118049|OTHER|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
58439423|NCT04118049|OTHER|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
58439424|NCT04386642|DRUG|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
58439425|NCT04386642|DRUG|Placebo|normal saline solution in a clear 50-ml syringe
58439426|NCT04993443|DRUG|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
58439427|NCT04993443|OTHER|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
58439428|NCT00309270|DRUG|Campath-1H|
58439429|NCT04814147|PROCEDURE|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
58439430|NCT04091880|BIOLOGICAL|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
58439431|NCT04091880|BIOLOGICAL|EV71 vaccine|administrated with EV71 vaccine only
58439432|NCT04091880|BIOLOGICAL|influenza vaccine|administrated with influenza vaccine only
58439433|NCT02451124|DEVICE|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
58439434|NCT02451124|OTHER|Questionnaire Administration|Ancillary studies
58439435|NCT02451124|OTHER|Laboratory Biomarker Analysis|Correlative studies
58439436|NCT02451124|PROCEDURE|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
58439437|NCT03084601|DRUG|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
58439438|NCT03084601|DRUG|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
58439439|NCT06409247|BEHAVIORAL|iExposure|There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
58439440|NCT06409247|BEHAVIORAL|iExposure plus attention guidance|The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
58439441|NCT06409247|BEHAVIORAL|iExposure plus attention control|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
58439442|NCT06136013|BEHAVIORAL|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
58439443|NCT02322970|DEVICE|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
58439444|NCT06478563|DRUG|NNC0487-0111 (formulation D)|Participants will receive NNC0487-0111 (formulation D) tablet once daily.
58439445|NCT06478563|DRUG|NNC0487-0111 (formulation C)|Participants will receive NNC0487-0111 (formulation C) tablet once daily.
58439446|NCT01378325|DRUG|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
58439447|NCT01378325|DRUG|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
58439448|NCT05144711|PROCEDURE|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
58439449|NCT05144711|PROCEDURE|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
57738801|NCT05316441|BEHAVIORAL|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
58107585|NCT03459781|BEHAVIORAL|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
58107586|NCT03459781|BEHAVIORAL|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
58439450|NCT00897468|OTHER|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
58439451|NCT00897468|OTHER|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
58439452|NCT03424356|DRUG|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
58439453|NCT03424356|DRUG|Saline Solution|1-2 ml saline solution
58107587|NCT04317833|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
58439454|NCT03424356|DRUG|Fentanyl|1mcg/kg for induction
58439455|NCT03424356|DRUG|Propofol|2-3mg/kg for anaesthetic induction
58107588|NCT04317833|DRUG|Placebo|matched placebo
58107589|NCT03634332|DRUG|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
58107590|NCT03634332|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
58107591|NCT03078803|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
58439456|NCT03424356|PROCEDURE|cystoscopy|patients will treated with this surgical procedure
58439457|NCT01441323|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
58439458|NCT01441323|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
58107592|NCT03078803|BIOLOGICAL|Placebo|Transfer of water only
58107593|NCT02926391|DEVICE|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
58107594|NCT01536691|DRUG|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
58107595|NCT01536691|DRUG|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
58107596|NCT03292965|DRUG|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
58107597|NCT03292965|DRUG|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
58107598|NCT05992649|OTHER|physical therapy|Aquatic physiotherapy in warm water
58107599|NCT03787108|OTHER|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
58107600|NCT02515357|BEHAVIORAL|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
58107601|NCT02515357|BEHAVIORAL|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
58107602|NCT02515357|BEHAVIORAL|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
58439459|NCT04526041|OTHER|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
58107603|NCT06043999|PROCEDURE|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
58107604|NCT06043999|OTHER|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
58107605|NCT01809795|OTHER|Blueberry Smoothie|
58107606|NCT01809795|OTHER|Sham Smoothie|
58439460|NCT04526041|OTHER|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
58107607|NCT06035705|OTHER|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
58439461|NCT04526041|OTHER|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
58439462|NCT04526041|OTHER|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
58439463|NCT00192413|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
58439464|NCT00192413|BIOLOGICAL|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
58107608|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
58439465|NCT05218642|DRUG|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
58439466|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
58439467|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
58439468|NCT05218642|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
58439469|NCT02608463|BEHAVIORAL|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
58439470|NCT02608463|BEHAVIORAL|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
57738802|NCT04982900|DRUG|furmonertinib|AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
57738803|NCT04982900|DRUG|Placebo|The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
57738804|NCT04259268|OTHER|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
58439471|NCT02608463|BEHAVIORAL|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
58107609|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
58107610|NCT04779385|PROCEDURE|PIPAC|"under general anaesthesia, a laparoscopy was performed using an open laparoscopic technique to prevent intestinal wounds, which would contraindicate the procedure. A 12 mmHg pneumoperitoneum was created, and to ensure the safety of the procedure the pressure of the pneumoperitoneum was maintained constant throughout the procedure. Two laparoscopic balloon trocars (of 11 and 12 mm) were used. A thorough exploration of the abdomen, Peritoneal Cancer Index assessment, images, peritoneal biopsies, and ascites cytology (in the case of ascites) were performed prior to administration of the chemotherapy aerosol.~For carcinomas of gastric origin, Doxurubicin at a dose of 1.5 mg/m2 was administered in combination with Cisplatin 7.5 mg/m2 diluted in 40 and 150 mL of 0.9% sodium chloride, respectively. In the case of contraindication, Oxaliplatine at a dose of 92 mg/m2 in a 5% dextrose solution was recommended."
58107611|NCT01682473|DRUG|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
58107612|NCT02521454|BEHAVIORAL|MBRT|
58107613|NCT05487872|BEHAVIORAL|Mindfulness skills training to reduce experiential avoidance and anxiety symptoms|The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
58107614|NCT04071366|DRUG|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
58107615|NCT04071366|DRUG|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
58107616|NCT04071366|DRUG|Placebo|Participants will receive placebo twice daily.
58107617|NCT04071366|BIOLOGICAL|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
58107618|NCT05758779|BEHAVIORAL|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
58107619|NCT01073059|DRUG|Valproic acid and Ertapenem|
58439472|NCT02608463|BEHAVIORAL|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
58107620|NCT00320593|DEVICE|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
58107621|NCT00320593|DEVICE|Single Vision Lenses (SVLs)|Single vision lenses
58107622|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
58107623|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
58107624|NCT04235231|DEVICE|Bed tilting|15° lateral tilt, original product brand name LINET Eleganza 5
58107625|NCT04235231|OTHER|Body positioning|Manual positioning of body by nurse: left side, back, right side, using positioning pillows
58107626|NCT04933669|DRUG|Imatinib|Imatinib neoadjuvant therapy
58107627|NCT04568369|DEVICE|rTMS|See treatment arm description.
58439473|NCT02608463|BEHAVIORAL|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
58439474|NCT02608463|BEHAVIORAL|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
58439475|NCT02608463|DEVICE|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
58439476|NCT00358436|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
58439477|NCT00358436|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
57738805|NCT04259268|OTHER|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
58439478|NCT03067389|DIAGNOSTIC_TEST|Diagnostic test|Genetic diagnostic test
58439479|NCT00748423|DRUG|Nitric Oxide|NO in inhalation for 3 days
58439480|NCT00748423|DRUG|Placebo|Placebo in inhalation for 3 days
57738806|NCT02561858|OTHER|acid load test|
58107628|NCT02746705|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
58439481|NCT02150447|DRUG|Proton pump inhibitor|Lansoprazole 30 mg, daily
58107629|NCT02746705|DEVICE|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
58311129|NCT05230836|OTHER|Sham current stimulation|"Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
58439482|NCT02150447|DRUG|Placebo|Placebo, daily
58439483|NCT01193114|BEHAVIORAL|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
58439484|NCT01193114|BEHAVIORAL|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
58439485|NCT04967027|DEVICE|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
58439486|NCT00513435|DRUG|saracatinib|Given PO
58107630|NCT02746705|BEHAVIORAL|Cognitive Training Program|
58439487|NCT00513435|OTHER|laboratory biomarker analysis|Correlative studies
58439488|NCT04888169|DEVICE|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
58439489|NCT04888169|DEVICE|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
58439490|NCT04888169|DEVICE|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
58439491|NCT04888169|DEVICE|SMART Mobile App - Control|Participants will only answer questions.
58107631|NCT04189419|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
58311130|NCT04772443|DRUG|DWJ1506|DWJ1506
58311131|NCT04772443|DRUG|DWJ1507|DWJ1507
58311132|NCT04772443|DRUG|DWC202011|DWC202011
58311133|NCT04772443|DRUG|DWJ1177|DWC202011
58439492|NCT01443702|DRUG|Lapis Judaicus|2 g capsule per day.
58439493|NCT01443702|DRUG|Placebo|2 g capsule per day.
58439494|NCT05984602|DRUG|Canakinumab|250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
58439495|NCT05984602|DRUG|Tislelizumab|300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
58439496|NCT05984602|DRUG|Nab-Paclitaxel|125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
58439497|NCT05984602|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
58439498|NCT02069119|DRUG|OPC-108459|
58439499|NCT02069119|DRUG|Placebo|
58439500|NCT01425125|DRUG|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
58439501|NCT00320515|DRUG|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
58311134|NCT02696616|DRUG|BI 655088|
58311135|NCT02696616|DRUG|Placebo|
58311136|NCT00091078|BIOLOGICAL|oblimersen sodium|Given IV
58311137|NCT00091078|DRUG|imatinib mesylate|Given orally
58311138|NCT00091078|OTHER|laboratory biomarker analysis|Correlative studies
58311139|NCT00587665|DRUG|ketamine|Single IV dose of 0.1 mg/kg of ketamine
58311140|NCT00587665|DRUG|Placebo|Saline given of equal volume to drug
58311141|NCT03934775|DEVICE|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
58311142|NCT05407883|BEHAVIORAL|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
58311143|NCT00519350|PROCEDURE|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
58311144|NCT06524258|DIAGNOSTIC_TEST|testicular elastography|testicular elastography for predicting non obstructive azoospermia
58311145|NCT02767531|DRUG|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
58311146|NCT02057341|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
58439502|NCT00320515|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
58439503|NCT05004220|PROCEDURE|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
58439504|NCT03450382|OTHER|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
58439505|NCT06267534|DEVICE|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
58439506|NCT06415227|DRUG|Vericiguat|The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
58107632|NCT04189419|OTHER|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
58311147|NCT05184855|DIETARY_SUPPLEMENT|Blueberry|Blueberry powder intake
58311148|NCT05184855|DIETARY_SUPPLEMENT|Placebo|Placebo powder intake
58311149|NCT05127460|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
58439507|NCT05109923|DIETARY_SUPPLEMENT|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
58439508|NCT05109923|DIETARY_SUPPLEMENT|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
58439509|NCT02776059|DRUG|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
58107633|NCT02410070|PROCEDURE|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
58107634|NCT03070431|RADIATION|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
58439510|NCT02776059|DRUG|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
58439511|NCT04085497|OTHER|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
58439512|NCT03036020|RADIATION|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
58439513|NCT03833466|DRUG|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
57738807|NCT05208073|BEHAVIORAL|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
57738808|NCT02355808|BEHAVIORAL|Tailored Leaflet|
58107635|NCT03850054|PROCEDURE|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
58311150|NCT05024383|OTHER|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
58311151|NCT05024383|OTHER|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
58311152|NCT00448656|PROCEDURE|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
58311153|NCT05503498|OTHER|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
58439514|NCT02689115|OTHER|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
58439515|NCT02978196|PROCEDURE|Injection of 99mTc-NM-01|Patient is injected with micro-dose of 99mTc-NM-01
58439516|NCT02978196|PROCEDURE|Injection of 68Ga-NM-01|Patient is injected with micro-dose of 68Ga-NM-01
58439517|NCT01067144|DRUG|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
57738809|NCT02355808|BEHAVIORAL|GP visit|
57738810|NCT03434951|DRUG|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
57738811|NCT03434951|DRUG|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
57738812|NCT03434951|DRUG|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
57738813|NCT01114568|DRUG|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
57738814|NCT01114568|DRUG|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
57738815|NCT01114568|DRUG|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
57738816|NCT04575896|DRUG|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
58107636|NCT03836274|DIETARY_SUPPLEMENT|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
58107637|NCT01162395|DRUG|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
58107638|NCT05911347|DIETARY_SUPPLEMENT|Psyllium|15g psyllium added to inulin solution to form a gel
58107639|NCT05911347|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
58107640|NCT05911347|DIETARY_SUPPLEMENT|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
58107641|NCT01572428|PROCEDURE|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
58107642|NCT01572428|PROCEDURE|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
58107643|NCT05765929|OTHER|Non-operative treatment|Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
58439518|NCT01067144|DRUG|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
58107644|NCT04129034|DEVICE|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
58107645|NCT02953197|RADIATION|FDG-PET guided radiation dose escalation|Selective dose escalation
58107646|NCT04681456|BEHAVIORAL|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
58107647|NCT03038178|DRUG|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
58107648|NCT05306080|DRUG|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
58107649|NCT03625817|BEHAVIORAL|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having \>800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
58107650|NCT01190098|DRUG|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
58107651|NCT01190098|DRUG|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
58107652|NCT01951547|PROCEDURE|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
58107653|NCT01951547|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
58107654|NCT05627908|OTHER|Contrast-enhanced ultrasound|Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
58107655|NCT04534192|DEVICE|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
58107656|NCT00330200|DRUG|ISIS 113715|
58107657|NCT03875430|DIETARY_SUPPLEMENT|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
58107658|NCT04948255|OTHER|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
58107659|NCT05398575|BEHAVIORAL|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
58107660|NCT01260571|DRUG|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
58107661|NCT00370396|BIOLOGICAL|Synflorix|1 dose injected IM in the right thigh or deltoid.
58107662|NCT00370396|BIOLOGICAL|Prevenar|1 dose injected IM in the right thigh or deltoid.
58107663|NCT00370396|BIOLOGICAL|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
58107664|NCT01260480|OTHER|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
58439519|NCT01067144|DRUG|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
57738817|NCT01386528|DRUG|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
57738818|NCT00955084|DRUG|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
57738819|NCT02047838|OTHER|Anti-mullerian hormone (AMH) level dosage.|
58107665|NCT00359554|BIOLOGICAL|VAXIGRIPPE|
58107666|NCT01988428|DRUG|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
58107667|NCT01710878|DEVICE|Intergard Synergy Graft|
58107668|NCT02746159|DEVICE|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
58107669|NCT06452433|DRUG|gumarontinib|300 mg , qd ,po, expect 6 months.
57738820|NCT02047838|OTHER|Follicle-stimulating hormone (FSH) level dosage.|
57738821|NCT02047838|OTHER|Antral follicle count (AFC).|
58107670|NCT06452433|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|According to the actual situation of patients. Take as recommended, expect 6 months.
58439520|NCT00192816|BEHAVIORAL|reaction to pain|
57955370|NCT06101056|BEHAVIORAL|Leadership Component|"Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7."
57955371|NCT06101056|BEHAVIORAL|Social Marketing Campaign|"All participating Airmen (including Junior Enlisted Airmen and Leaders) will be exposed to X-CoRe's social marketing campaign, which includes posters, flyers, postcards, and digital content for social media. Messages are designed to increase awareness of consent and foster Wing-wide norms that are supportive of healthy relationships. Resources for Service members to receive support if they have experienced SH or SA will also be provided through the social marketing materials. Social marketing materials, such as posters, will be distributed at hot spots for SA (e.g., dorms)."
58107671|NCT02144493|OTHER|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
58107672|NCT02144493|OTHER|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
58107673|NCT04869488|DRUG|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
58107674|NCT04869488|DRUG|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
58107675|NCT04869488|DRUG|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
58107676|NCT00513565|DRUG|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
57738822|NCT05462665|BEHAVIORAL|theory training|theory training
57738823|NCT05462665|BEHAVIORAL|theory and simulation training|theory and simulation training
57738824|NCT04622696|DIAGNOSTIC_TEST|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
57738825|NCT02073396|DIAGNOSTIC_TEST|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
57738826|NCT03028974|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
57738827|NCT03028974|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
57738828|NCT04227782|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
57738829|NCT04227782|OTHER|Stable Isotope Study|Stable Isotope study
58439521|NCT02428569|BEHAVIORAL|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
58439522|NCT00791752|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
57738830|NCT02675361|BEHAVIORAL|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
57738831|NCT01754662|DIETARY_SUPPLEMENT|Soy protein|2 bars daily for 8 weeks.
58311154|NCT03913247|OTHER|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
57738832|NCT01754662|DIETARY_SUPPLEMENT|Isoflavones|2 bars daily for 8 weeks.
57955372|NCT00472524|PROCEDURE|Mydriasis/cycloplegia via different modes of administration|
57955373|NCT05511168|PROCEDURE|Craniostnostosis surgery|Surgery of craniosynostosis
57955374|NCT04845828|PROCEDURE|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3. Sentinel lymph node is excised"
57955375|NCT04845828|PROCEDURE|Routine lymph node dissection|"1. Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~2. Lymph node detection is performed."
58107677|NCT05057429|DEVICE|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
58107678|NCT05057429|OTHER|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
58107679|NCT06447519|DRUG|Ca(OH)2 as intracanal medicament|Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
58311155|NCT06525792|PROCEDURE|Oxygen|Oxygen and standard therapy were given
58311156|NCT06525792|PROCEDURE|Ozone|Ozone and standard therapy were given
58439523|NCT00791752|DRUG|Placebo|Placebo
58439524|NCT00214981|DRUG|Modafinil|
58439525|NCT02519205|OTHER|Survey|
57738833|NCT01754662|DIETARY_SUPPLEMENT|Cocoa|2 bars daily for 8 weeks.
57738834|NCT01754662|DIETARY_SUPPLEMENT|Placebo|
57955376|NCT02182687|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
58311157|NCT06525792|PROCEDURE|Standard therapy|Best standard of care
58311158|NCT03786640|RADIATION|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
58439526|NCT01984502|RADIATION|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
58439527|NCT05490576|RADIATION|[18F] PI-2620 Tau Ligand|Tau binding ligand
58439528|NCT04153682|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
58107680|NCT00820391|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
58107681|NCT00820391|BEHAVIORAL|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
57738835|NCT01428648|BEHAVIORAL|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
58107682|NCT00566098|BIOLOGICAL|MILs|
58107683|NCT00566098|DRUG|Melphalan|
58107684|NCT00566098|BIOLOGICAL|PCV13|
58107685|NCT03682783|DIAGNOSTIC_TEST|Fundus Image|Fundus image of optic nerve
57738836|NCT01691066|BEHAVIORAL|Infant Toddler Years PRT|
58107686|NCT02038985|OTHER|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
58107687|NCT00037973|BEHAVIORAL|ventilation feedback|
58311159|NCT00407511|DRUG|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
58439529|NCT04153682|DIAGNOSTIC_TEST|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
57738837|NCT05842928|BEHAVIORAL|PARTNER intervention|"The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)"
57955377|NCT02182687|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
57955378|NCT02182687|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
57955379|NCT03961503|DRUG|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
57955380|NCT03961503|DRUG|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
57955381|NCT00841685|DEVICE|Goldlock|Insertion of Goldlock marker
57955382|NCT00841685|DEVICE|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
57955383|NCT00841685|DEVICE|Visicoil larger size|Insertion of Visicoil, larger size, marker
57955384|NCT00841685|DEVICE|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
57955385|NCT00841685|DEVICE|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
57955386|NCT01452334|BIOLOGICAL|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
58107688|NCT00037973|BEHAVIORAL|exercise|
58107689|NCT02533388|DEVICE|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
58107690|NCT02533388|DEVICE|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
58107691|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation|Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
58107692|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation|Healing Progression: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
58439530|NCT02900768|BEHAVIORAL|Exercise|Combination of resistance and aerobic exercises for 100 days.
58439531|NCT02152319|DEVICE|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
58439532|NCT02152319|PROCEDURE|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
58439533|NCT05700994|BEHAVIORAL|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
58439534|NCT05700994|BEHAVIORAL|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
58439535|NCT04202237|OTHER|Speckle Doppler imaging|Speckle Doppler Laser imaging
58439536|NCT04202237|OTHER|Blood sample|Blood sampling
58107693|NCT05522933|OTHER|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health \& work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
58439537|NCT01063647|DRUG|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
58439538|NCT01063647|DRUG|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
58439539|NCT01063647|DRUG|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
58439540|NCT03611673|OTHER|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
58439541|NCT04875091|BEHAVIORAL|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
58439542|NCT02197091|OTHER|questionnaire administration|Ancillary studies
58439543|NCT02197091|OTHER|medical chart review|Ancillary studies
58439544|NCT04428957|OTHER|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
58107694|NCT03908112|BEHAVIORAL|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
58439545|NCT04086199|PROCEDURE|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
58439546|NCT05083312|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
58439547|NCT05083312|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet
58439548|NCT00239889|DRUG|Salmon calcitonin|
58439549|NCT03523572|DRUG|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
58107695|NCT03908112|BEHAVIORAL|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
58107696|NCT03908112|BEHAVIORAL|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
58311160|NCT04394325|BEHAVIORAL|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
58439550|NCT03523572|DRUG|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
58439551|NCT02008227|DRUG|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
58439552|NCT02008227|DRUG|Docetaxel|75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
58439553|NCT04567394|BEHAVIORAL|Peer Network Counseling-txt|4-week text counseling program
58439554|NCT05967650|BIOLOGICAL|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
58439555|NCT05967650|BIOLOGICAL|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
58439556|NCT00108316|DRUG|Fluoxetine (Liquid Prozac)|
58439557|NCT04803227|DRUG|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
58439558|NCT04803227|OTHER|Placebo|Placebo BID \*days 1-14). Oral (capsule) administration.
58439559|NCT03369977|DEVICE|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
58439560|NCT03369977|OTHER|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
58439561|NCT05799768|BEHAVIORAL|Ketogenic diet|Ketogenic diet counseling
58107697|NCT01076166|DRUG|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
58439562|NCT04357483|DRUG|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
58439563|NCT04357483|DRUG|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
58439564|NCT01625000|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
58439565|NCT01625000|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
57738838|NCT05842928|BEHAVIORAL|Control intervention|The control intervention only comprises a pharmacy visit with brown bag review.
57738839|NCT00406835|PROCEDURE|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
58107698|NCT00399490|DRUG|RN624 (PF-04383119)|50 mcg/kg
58107699|NCT04014101|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
57738840|NCT00198562|DRUG|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
57738841|NCT04616768|OTHER|PRO questionnaire|These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
57738842|NCT04616768|OTHER|Step monitoring|A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
57955387|NCT06190171|BEHAVIORAL|Active respiratory muscle strength training|Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
58439566|NCT01625000|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
58439567|NCT01625000|DRUG|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
58439568|NCT01625000|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
58439569|NCT01033916|OTHER|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
58439570|NCT02809339|OTHER|Questionnaires|
57955388|NCT06190171|BEHAVIORAL|Sham respiratory muscle strength training|Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
57955389|NCT03471702|DEVICE|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
57955390|NCT02995109|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)"
57955391|NCT02995109|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
57955392|NCT04956380|OTHER|Self-administered Triage|Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
57955393|NCT01946321|OTHER|Post-amputation functional rehabilitation (normal clinical practice)|
57955394|NCT02820311|DRUG|TD-4208 175 mcg|via nebulizer
57955395|NCT02820311|DRUG|TD-4208 700 mcg|via nebulizer
58439571|NCT05342272|DRUG|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
58439572|NCT05342272|DRUG|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
58439573|NCT03089541|BEHAVIORAL|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
58439574|NCT03804853|OTHER|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
58439575|NCT00034827|DRUG|CI-1040|
58439576|NCT02602119|DRUG|OTL38|Infusion of OTL38 prior to surgery
58439577|NCT04647123|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
57738843|NCT04616768|OTHER|Active nudge text feedback|"Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.)."
57955396|NCT02820311|DRUG|Placebo for TD-4208|via nebulizer
57955397|NCT02820311|DRUG|Moxifloxacin 400 mg|oral
58107700|NCT04014101|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor.
58311161|NCT04443192|DRUG|ZF874|ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
58311162|NCT04443192|DRUG|Placebo|Placebo to ZF874
58311163|NCT04447729|DRUG|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
58439578|NCT05868837|DRUG|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
58439579|NCT05868837|OTHER|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
58439580|NCT05065853|DIAGNOSTIC_TEST|urine self-sampling group|collection of urine and vaginal samples
58439581|NCT05065853|DIAGNOSTIC_TEST|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
58311164|NCT05822466|BEHAVIORAL|Virtual tai ji quan: moving for better balance intervention (V-TJQMBB)|This intervention involves a tai ji quan exercise program, named tai ji quan: moving for better balance
58439582|NCT05018650|DEVICE|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
58439583|NCT01629459|BEHAVIORAL|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
58439584|NCT05426070|BEHAVIORAL|Strength training-based exercise|Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
58439585|NCT03954821|DEVICE|prefabricated insoles|
58439586|NCT03603483|PROCEDURE|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
58439587|NCT06108206|OTHER|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)"
58439588|NCT03634930|BEHAVIORAL|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
58439589|NCT00741013|DRUG|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
58439590|NCT00741013|DRUG|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
58439591|NCT00741013|DRUG|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
58439592|NCT00741013|BIOLOGICAL|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
58439593|NCT05541575|OTHER|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
58439594|NCT03781505|DRUG|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
58439595|NCT03781505|DRUG|Placebo|Caudal ropivacaine
58439596|NCT01825967|OTHER|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
58439597|NCT04301544|BEHAVIORAL|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
58439598|NCT04301544|BEHAVIORAL|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
58439599|NCT04301544|BEHAVIORAL|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
58439600|NCT02470325|DRUG|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
58439601|NCT02470325|DRUG|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
58439602|NCT06583863|DRUG|Echinacea Extract|175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
58439603|NCT06583863|DRUG|MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]|500 mg of metronidazole was provided as an oral tablets twice daily
58439604|NCT03628976|OTHER|tVNS|Intervention
58439605|NCT03628976|OTHER|Motor training|Same finger training for both arms
58439606|NCT02376868|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
58439607|NCT02376868|DEVICE|iVue|OCT machines used for diagnostic purposes
58439608|NCT04123145|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
58439609|NCT04909203|DEVICE|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
58439610|NCT04909203|DEVICE|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
58439611|NCT03162419|DRUG|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
58439612|NCT03162419|BIOLOGICAL|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
58439613|NCT03162419|BIOLOGICAL|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
58439614|NCT05370872|DIAGNOSTIC_TEST|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
58311165|NCT05822466|BEHAVIORAL|Virtual multimodal exercise intervention (V-Multimodal)|This intervention involves a multimodal exercise program that consists of balance, strength, light walking, and stretching exercises
58311166|NCT05090644|GENETIC|DNA analysis|GWAS
58311167|NCT00164359|DRUG|Amodiaquine plus artesunate|
58311168|NCT00164359|DRUG|chlorproguanil-dapsone plus artesunate|
58311169|NCT03133013|DEVICE|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
58311170|NCT01853865|OTHER|Instruction in self-referral|
58311171|NCT06452342|DRUG|Tranexamic acid|Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
58311172|NCT06452342|OTHER|No Tranexamic acid|Routine clinical care without Tranexamic acid
58311173|NCT01414244|DRUG|Glutamine|Drug
58311174|NCT02866643|DRUG|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
58311175|NCT02866643|DRUG|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
58311176|NCT04224467|OTHER|Intravenous ICG and Real-Time Near-infrared Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
58311177|NCT03093181|OTHER|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
58311178|NCT03093181|OTHER|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
58439615|NCT04087577|OTHER|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
58439616|NCT04087577|OTHER|mirror therapy|mirror therapy
58439617|NCT04983355|DIETARY_SUPPLEMENT|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
58439618|NCT04983355|DIETARY_SUPPLEMENT|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
58439619|NCT03579043|OTHER|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
57738844|NCT04616768|OTHER|PROStep Dashboard (clinicians)|"The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~1. Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~2. Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~3. A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~4. Whether the patient has had an outpatient palliative care visit~5. Whether the patient has had a documented Serious Illness Conversation"
57738845|NCT01898819|DRUG|Dexmedetomidine|
58439620|NCT03579043|OTHER|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
57738846|NCT01898819|DRUG|saline|
58439621|NCT03579043|OTHER|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
58439622|NCT05365126|BEHAVIORAL|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
58439623|NCT03302247|BIOLOGICAL|Nivolumab|Monoclonal antibody against non small cell lung cancer
58439624|NCT03302247|DRUG|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
58439625|NCT04820413|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
58439626|NCT01963845|DRUG|Sitagliptin|
58439627|NCT01963845|DRUG|Placebo|
57738847|NCT04910893|DEVICE|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
57738848|NCT04910893|OTHER|Standard of Care|Standard intensive care of patients suffering septic shock
57738849|NCT06213454|DRUG|TAP Anesthesia|ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
58107701|NCT01528878|RADIATION|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
58107702|NCT04365088|DRUG|Deflazacort 30 MG Oral Tablet|After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
58107703|NCT04365088|DRUG|Sugar pill|Sugar pill
58107704|NCT02798237|OTHER|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
58107705|NCT02798237|OTHER|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
58107706|NCT02434796|BEHAVIORAL|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
58107707|NCT02434796|BEHAVIORAL|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
58107708|NCT00361257|DRUG|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
58439628|NCT02865655|PROCEDURE|Hysteroscopic|
58107709|NCT00361257|DRUG|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
58107710|NCT05471219|OTHER|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
58107711|NCT05295251|OTHER|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
58107712|NCT02021266|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
58439629|NCT03593044|DRUG|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
58439630|NCT04063592|PROCEDURE|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
58439631|NCT00748371|DRUG|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
57738850|NCT06213454|DRUG|Surgeon-Initiated Local Anesthetic|266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
58439632|NCT00748371|DRUG|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
58439633|NCT00748371|DRUG|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
58439634|NCT01848119|DRUG|Gabapentin|
58439635|NCT01848119|DRUG|lactose|
58439636|NCT03257683|DRUG|Ranolazine|Study group will receive additional therapeutic dosing of drug.
58439637|NCT00691184|DRUG|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
58439638|NCT00691184|DRUG|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
58439639|NCT00691184|DRUG|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
58439640|NCT00691184|DRUG|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
58439641|NCT03469713|DRUG|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
58439642|NCT05179525|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
58439643|NCT05179525|DRUG|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
58439644|NCT03833219|BEHAVIORAL|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
58439645|NCT03833219|BEHAVIORAL|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
58439646|NCT03833219|BEHAVIORAL|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
58439647|NCT01746225|DRUG|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
58439648|NCT05706441|OTHER|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
58439649|NCT03124836|DEVICE|Pulse Oximeter Sensor|
57738851|NCT01401751|DEVICE|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
58107713|NCT02874638|DIETARY_SUPPLEMENT|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
57738852|NCT00829387|BEHAVIORAL|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
57738853|NCT00829387|BEHAVIORAL|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
57738854|NCT01737580|DRUG|resiquimod|
57738855|NCT01737580|DRUG|placebo gel|
57738856|NCT02283931|DEVICE|TTE / NICOM|
58107714|NCT02874638|DIETARY_SUPPLEMENT|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
58107715|NCT02874638|DIETARY_SUPPLEMENT|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
58107716|NCT02874638|DIETARY_SUPPLEMENT|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
58439650|NCT06530966|DRUG|ICP-332 Tablets|Eligible patients will receive ICP-332 tablets orally as per the protocol
58439651|NCT06530966|DRUG|ICP-332 Placebo Tablets|Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
58439652|NCT01177189|DIETARY_SUPPLEMENT|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
58439653|NCT01558453|DRUG|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
58439654|NCT00760318|DRUG|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
58439655|NCT00227812|DRUG|Bupropion|
57738857|NCT03130400|PROCEDURE|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
58107717|NCT06530420|PROCEDURE|Umbilical hernia repair surgery|collected information about: gender, age, comorbidities, body weight, time of surgery, hernia size and treatment methods and reccurence
58107718|NCT00004158|DRUG|melphalan|
58107719|NCT00004158|PROCEDURE|peripheral blood stem cell transplantation|
58107720|NCT00004158|RADIATION|holmium Ho 166 DOTMP|
58107721|NCT05578833|DIAGNOSTIC_TEST|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
57738858|NCT02622854|PROCEDURE|plasma exchange|see arm description
57738859|NCT02622854|DRUG|conservative treatment|see arm description
57738860|NCT04977882|PROCEDURE|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
57955398|NCT03304015|BEHAVIORAL|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
57955399|NCT03656679|PROCEDURE|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
57955400|NCT03656679|PROCEDURE|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
57955401|NCT00000414|BEHAVIORAL|Arthritis Self-Management Program|
58311179|NCT03093181|OTHER|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
58311180|NCT03093181|OTHER|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
57738861|NCT04977882|DRUG|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
57955402|NCT00000414|BEHAVIORAL|SMART Program|
57955403|NCT00039793|PROCEDURE|Moderate-intensity and low-intensity bodywork therapy|
57955404|NCT05712044|DRUG|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
58439656|NCT01037686|RADIATION|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
58439657|NCT01037686|BEHAVIORAL|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
58439658|NCT01037686|DEVICE|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
58439659|NCT00195286|DRUG|piperacillin/tazobactam|
58439660|NCT05728398|OTHER|Music|Music played within the fluoroscopy suite during an interventional radiology procedure.
58439661|NCT05728398|OTHER|No Music|No music played within the fluoroscopy suite during an interventional radiology procedure.
58439662|NCT00571038|BEHAVIORAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
58439663|NCT00571038|BEHAVIORAL|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
58439664|NCT00125320|DRUG|RSD1235|
58439665|NCT05267951|DEVICE|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
58439666|NCT05267951|DEVICE|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
58439667|NCT05267951|OTHER|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
58439668|NCT01248949|DRUG|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
58439669|NCT01248949|DRUG|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
58439670|NCT01248949|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
58439671|NCT01248949|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
58439672|NCT06040762|OTHER|Best Practice|Receive SOC educational materials
58439673|NCT06040762|OTHER|Exercise Intervention|Receive (P)REHAB exercise program
58439674|NCT06040762|OTHER|App-Based Intervention|Use ExerciseRx app
58439675|NCT06040762|OTHER|App-Based Intervention|Use FitBit app
58439676|NCT06040762|OTHER|Interview|Ancillary studies
58439677|NCT06040762|OTHER|Wearable Activity Tracker|Wear FitBit
58439678|NCT06040762|OTHER|Physical Performance Testing|Ancillary studies
57955405|NCT05951608|DRUG|AK127 in combination with AK112|AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years
58439679|NCT06040762|OTHER|Questionnaire Administration|Ancillary studies
57955406|NCT02429414|DEVICE|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
57955407|NCT02429414|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
58439680|NCT04529343|OTHER|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
58439681|NCT04529343|OTHER|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
58439682|NCT00276809|BIOLOGICAL|alemtuzumab|
58439683|NCT00276809|BIOLOGICAL|filgrastim|
58439684|NCT00276809|DRUG|carmustine|
58439685|NCT00276809|DRUG|cyclophosphamide|
58439686|NCT00276809|DRUG|cytarabine|
58439687|NCT00276809|DRUG|dexamethasone|
58439688|NCT00276809|DRUG|etoposide|
58439689|NCT00276809|DRUG|fludarabine phosphate|
58439690|NCT00276809|DRUG|melphalan|
58439691|NCT00276809|PROCEDURE|autologous bone marrow transplantation|
58439692|NCT00276809|PROCEDURE|peripheral blood stem cell transplantation|
57955408|NCT02429414|DEVICE|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
57955409|NCT01534533|DIETARY_SUPPLEMENT|Placebo|one gelatine capsule containing starch per day, for 12 months
58439693|NCT00276809|RADIATION|radiation therapy|
58439694|NCT03355066|DRUG|SM08502|SM08502 tablets to be administered orally.
58439695|NCT00640497|BIOLOGICAL|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
58439696|NCT04405973|DEVICE|vv-ECMO|vv-ECMO required in severe COVID-19 ARDS
58107722|NCT05578833|DIAGNOSTIC_TEST|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
58107723|NCT05578833|DIAGNOSTIC_TEST|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
58107724|NCT01584726|DRUG|Magnesium Sulfate|single dose of magnesium sulfate nebulization
58439697|NCT05594628|OTHER|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
57955410|NCT01534533|DIETARY_SUPPLEMENT|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
57955411|NCT01534533|DIETARY_SUPPLEMENT|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
57955412|NCT01534533|DIETARY_SUPPLEMENT|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
57955413|NCT02128230|DEVICE|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
57955414|NCT02128230|DRUG|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, \& 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
58439698|NCT02606331|PROCEDURE|Piezosurgery|Corticotomy cuts will be performed by this technique.
58439699|NCT02606331|RADIATION|ER:YAG laser|Corticotomy cuts will be performed by this technique.
58439700|NCT04314674|DRUG|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
58439701|NCT04314674|DRUG|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
58439702|NCT04314674|DRUG|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
58439703|NCT06583759|PROCEDURE|Full coverage Crowns|The crown will be prepared accordingly. Try in of the best fitted crown will be done and cementation.
58439704|NCT01080846|DRUG|Misoprostol|600 mcg of sublingual misoprostol
58439705|NCT01957371|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
58439706|NCT01777776|DRUG|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
58439707|NCT01777776|DRUG|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
58439708|NCT01260597|BEHAVIORAL|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
58107725|NCT04878250|DRUG|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
58107726|NCT01001676|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
58107727|NCT01001676|DEVICE|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
58107728|NCT00303264|DRUG|dexloxiglumide|
58107729|NCT00303264|DRUG|Nexium (esomeprazole)|
58107730|NCT02360410|BEHAVIORAL|Check Yourself App with Feedback|
58439709|NCT01260597|BEHAVIORAL|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
58439710|NCT02564978|DRUG|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
58439711|NCT00907504|DRUG|CP-751,871|CP-751,871 20mg/kg every 3 weeks
58439712|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
58439713|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
58439714|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
58439715|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
58439716|NCT00587704|PROCEDURE|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
58439717|NCT00587704|PROCEDURE|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
58439718|NCT01451385|DRUG|COV795|COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
58439719|NCT05822622|OTHER|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
58439720|NCT01974011|PROCEDURE|Performing dorsal penile nerve block (DPNB)|
58439721|NCT03326700|PROCEDURE|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
58439722|NCT01286077|DRUG|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
58439723|NCT02059304|DEVICE|Measurement of cervical length with embryo transfer catheter|
58439724|NCT01055314|BIOLOGICAL|Cixutumumab|Given IV
58439725|NCT01055314|DRUG|Cyclophosphamide|Given IV
58439726|NCT01055314|BIOLOGICAL|Dactinomycin|Given IV
58439727|NCT01055314|DRUG|Doxorubicin Hydrochloride|Given IV
58439728|NCT01055314|DRUG|Etoposide|Given IV
58439729|NCT01055314|DRUG|Ifosfamide|Given IV
58439730|NCT01055314|DRUG|Irinotecan Hydrochloride|Given IV
58439731|NCT01055314|OTHER|Laboratory Biomarker Analysis|Correlative studies
58439732|NCT01055314|DRUG|Temozolomide|Given PO
58439733|NCT01055314|DRUG|Vincristine Sulfate Liposome|Given IV
57738862|NCT04977882|PROCEDURE|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
57738863|NCT04977882|PROCEDURE|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
58107731|NCT03951597|DRUG|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
58107732|NCT02680977|OTHER|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
58107733|NCT02680977|OTHER|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
58107734|NCT02680977|OTHER|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
58107735|NCT02680977|DRUG|LD+DDCI|Levodopa plus Benserazide
58107736|NCT02680977|DRUG|LD-DDCI|Levodopa without any DDCI
58107737|NCT02680977|OTHER|Placebo|Groundnuts powder
58107738|NCT06025396|DRUG|TMP-301|Multiple ascending dose active
58107739|NCT06025396|DRUG|Placebo|Multiple ascending dose comparator
58439734|NCT06166199|BEHAVIORAL|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
58439735|NCT00531869|BEHAVIORAL|biases towards products|
58439736|NCT03694834|DRUG|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
58439737|NCT03694834|PROCEDURE|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
58439738|NCT01984918|OTHER|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
58439739|NCT01984918|OTHER|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
58439740|NCT05003596|DRUG|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
58439741|NCT05003596|OTHER|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
58439742|NCT05629130|DEVICE|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
58439743|NCT05725980|DIAGNOSTIC_TEST|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
58439744|NCT01331980|DEVICE|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
58439745|NCT01331980|DEVICE|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
58439746|NCT04280796|BEHAVIORAL|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
58439747|NCT04280796|BEHAVIORAL|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
58439748|NCT05330767|DEVICE|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
58439749|NCT05330767|DEVICE|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
58439750|NCT05330767|DEVICE|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
58439751|NCT00853151|DRUG|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
58439752|NCT00853151|DRUG|TT223|subcutaneous injection once a day for 4 weeks
58439753|NCT00853151|DRUG|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
58439754|NCT00853151|DRUG|Placebo for TT223|subcutaneous injection once a day for 4 weeks
58439755|NCT02336672|DEVICE|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
58439756|NCT02393937|DRUG|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
58439757|NCT02393937|DRUG|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
58439758|NCT02393937|DRUG|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
58439759|NCT05205174|DEVICE|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
58439760|NCT05808140|DRUG|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
58439761|NCT05808140|DEVICE|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
58439762|NCT00572013|DRUG|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
58439763|NCT00572013|DRUG|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
57738864|NCT05234827|OTHER|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
58439764|NCT00572013|PROCEDURE|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
58107740|NCT02544945|OTHER|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
58107741|NCT02544945|OTHER|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
58107742|NCT00740467|BIOLOGICAL|anti-thymocyte globulin|
58107743|NCT00740467|DRUG|busulfan|
58107744|NCT00740467|DRUG|cyclophosphamide|
58107745|NCT00740467|DRUG|cyclosporine|
58107746|NCT00740467|DRUG|fludarabine phosphate|
58107747|NCT00740467|DRUG|mycophenolate mofetil|
58107748|NCT00740467|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
58439765|NCT00248807|DRUG|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
58107749|NCT02499549|DRUG|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
58107750|NCT01092702|DRUG|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
58107751|NCT05990205|DRUG|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
58107752|NCT05990205|BEHAVIORAL|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
58107753|NCT00323609|PROCEDURE|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
58107754|NCT00323609|PROCEDURE|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
58107755|NCT03166306|DIAGNOSTIC_TEST|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
58107756|NCT04345731|OTHER|Over the counter drug labels|A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
58107757|NCT06242522|OTHER|Telephone interview|Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
58439766|NCT00248807|OTHER|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
58439767|NCT00104624|DRUG|docetaxel|
58439768|NCT00104624|PROCEDURE|quality-of-life assessment|
58439769|NCT02848807|DIETARY_SUPPLEMENT|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
58439770|NCT05355792|DEVICE|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
57738865|NCT05234827|OTHER|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
58107758|NCT00711867|DEVICE|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
58107759|NCT00711867|DEVICE|Bair Hugger|Arizant Bair Hugger temperature management system.
58107760|NCT05202613|DRUG|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
58107761|NCT02267733|DRUG|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
58311181|NCT05974761|OTHER|massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.
58311182|NCT05974761|OTHER|Traditional Chinese massage|Through the point, massage, bone-setting treatment
58311183|NCT06185296|DEVICE|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
58311184|NCT06185296|DEVICE|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
58311185|NCT01760902|BEHAVIORAL|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
58311186|NCT02968810|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58311187|NCT02968810|PROCEDURE|Computed Tomography|Undergo CT
58311188|NCT02968810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58107762|NCT04455074|OTHER|FN scale auto-questionnaire|Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
58311189|NCT02968810|OTHER|Placebo Administration|Given PO
58311190|NCT02968810|OTHER|Questionnaire Administration|Ancillary studies
58311191|NCT02968810|DRUG|Simvastatin|Given PO
58311192|NCT02923869|DRUG|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
58311193|NCT02923869|DRUG|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
58439771|NCT02055378|DRUG|Atropine|topical 0.125% atropine eye drops
58439772|NCT02055378|DEVICE|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
58439773|NCT03222297|DEVICE|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
58439774|NCT03222297|DEVICE|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
58107763|NCT04273152|DIAGNOSTIC_TEST|advanced glycation endproducts reader|advanced glycation endproducts reader
58439775|NCT02732782|OTHER|Isometric exercise|
58439776|NCT02732782|OTHER|Eccentric exercise|
58439777|NCT00630435|DRUG|Premarin®/MPA formulation A|
58439778|NCT00630435|DRUG|Premarin®/MPA formulation B|
58439779|NCT00630435|DRUG|Premarin®/MPA formulation C|
58439780|NCT00630435|DRUG|Premarin®/MPA currently marketed product|
58107764|NCT06383377|DEVICE|Tooth extraction and bone graft procedure|"The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated."
58107765|NCT02169661|OTHER|Burger and Beetroot Study|50% fat, 10% beetroot extract
58439781|NCT00122174|BEHAVIORAL|Stress Busting Program for family caregivers|
58439782|NCT04473248|DEVICE|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
58439783|NCT02435420|DEVICE|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
58107766|NCT05238285|BEHAVIORAL|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
58311194|NCT03920956|OTHER|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
58311195|NCT00405769|DRUG|red yeast rice|600 mg 3 caps bid
58311196|NCT00405769|DRUG|placebo|3 caps bid
58311197|NCT05711368|BEHAVIORAL|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
58311198|NCT00000220|DRUG|Buprenorphine|
58439784|NCT00966251|DRUG|CT-011|CT-011
58439785|NCT00352430|DRUG|Nitric Oxide/INP Pulse Delivery|
58439786|NCT00352430|DRUG|Nitric Oxide/INO Pulse Delivery|
58439787|NCT04981652|DIETARY_SUPPLEMENT|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
58439788|NCT04981652|DIETARY_SUPPLEMENT|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
58439789|NCT04981652|DIETARY_SUPPLEMENT|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
58439790|NCT03831035|OTHER|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
58439791|NCT03896945|DRUG|Placebo|oral capsules
58439792|NCT03896945|DRUG|AVP-786|oral capsules
58439793|NCT05041270|DRUG|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
58439794|NCT05041270|DRUG|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
58439795|NCT05041270|DRUG|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
58439796|NCT05194800|OTHER|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
58439797|NCT01885624|BIOLOGICAL|TAB08|monoclonal antibody
58439798|NCT02356718|BEHAVIORAL|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
58439799|NCT02356718|BEHAVIORAL|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
58107767|NCT01901211|OTHER|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
58439800|NCT05154526|OTHER|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
58107768|NCT04562584|DEVICE|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
58107769|NCT00066807|DRUG|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
58107770|NCT00066807|DRUG|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
58439801|NCT05154526|OTHER|Exercise Program|Exercise program
58439802|NCT05020080|OTHER|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
58439803|NCT01695356|DRUG|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
58107771|NCT00066807|DRUG|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
58107772|NCT00066807|DRUG|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
58107773|NCT00066807|PROCEDURE|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
58107774|NCT00066807|PROCEDURE|ovarian irradiation|Bilateral ovarian irradiation.
58439804|NCT01695356|DRUG|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
58107775|NCT01259518|DRUG|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
58439805|NCT05905367|DRUG|Fentanyl|Symptom-inhibited IV fentanyl induction
58439806|NCT05905367|DRUG|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
58439807|NCT05905367|DRUG|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
58439808|NCT02904733|OTHER|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
58439809|NCT04870125|DRUG|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
58439810|NCT04870125|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
58439811|NCT03094533|DRUG|TIVA|total intravenous anesthesia with propofol
58439812|NCT03094533|DRUG|VIMA|volatile induction and maintenance anesthesia with sevoflurane
58439813|NCT02742376|OTHER|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
58439814|NCT02742376|OTHER|Floor|A marked path on the floor where the subject is instructed to walk.
58439815|NCT02742376|OTHER|Kyboot shoes|Special shoes will be worn by the subject.
58439816|NCT03016091|DRUG|Pembrolizumab|anti PD-L1
58107776|NCT01259518|DRUG|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
58107777|NCT00493363|DRUG|Artesunate|Artesunate 2 mg/kg/day for 7 days
58439817|NCT05572164|PROCEDURE|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
58439818|NCT05572164|PROCEDURE|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
58439819|NCT03808012|OTHER|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
58107778|NCT00493363|DRUG|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
57955415|NCT02128230|DRUG|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
58107779|NCT00492466|DRUG|Interferon-beta-1a|dosage and frequency as per label
58107780|NCT00492466|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
58107781|NCT04141995|DRUG|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
58439820|NCT01983085|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
58439821|NCT01983085|DEVICE|Standard of Care|Dressing changed as per normal clinical practice
58439822|NCT04177979|BEHAVIORAL|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
58439823|NCT03383510|OTHER|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
58107782|NCT04141995|DRUG|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
58107783|NCT04141995|DRUG|Calcium Leucovorin|IV injection over 90 minutes
58439824|NCT03383510|OTHER|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
58439825|NCT03383510|OTHER|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
58439826|NCT03383510|OTHER|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
58439827|NCT05792189|OTHER|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
58439828|NCT05792189|OTHER|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
58439829|NCT05792189|OTHER|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
58439830|NCT05792189|OTHER|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
58439831|NCT00001954|DRUG|Etanercept|
58439832|NCT03682692|DRUG|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
58439833|NCT03682692|DRUG|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
58439834|NCT00005773|DRUG|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
58439835|NCT00005773|DRUG|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
58439836|NCT02523378|BEHAVIORAL|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
58439837|NCT02523378|BEHAVIORAL|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
58439838|NCT01461707|BEHAVIORAL|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
58439839|NCT01461707|BEHAVIORAL|Activity monitor|Participants will receive an activity monitor
58439840|NCT00391313|DRUG|Chloroquine|
58439841|NCT04590573|BEHAVIORAL|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
58439842|NCT03778996|DRUG|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
58439843|NCT02330692|OTHER|No intervention|
58439844|NCT02606799|DEVICE|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
58439845|NCT01597713|DRUG|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
58439846|NCT01597713|DRUG|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
58439847|NCT01597713|DRUG|placebo|Subjects will receive a single dose of oral placebo within each dose group
58439848|NCT01597713|DRUG|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
58439849|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
58439850|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
58439851|NCT05243082|DEVICE|Radio frequency ablation|Radio frequency ablation of pancreatic neuroendocrine tumors
58439852|NCT00163020|DRUG|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
58439853|NCT00163020|DRUG|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
57738866|NCT06496945|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
58439854|NCT00166439|DRUG|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
58439855|NCT02947737|OTHER|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
58439856|NCT02947737|OTHER|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
58439857|NCT03594136|DEVICE|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
58439858|NCT00484978|PROCEDURE|Stereotactic Radiosurgery|
58107784|NCT04141995|DRUG|Irinotecan|IV administration over 90 minutes
58107785|NCT04141995|DRUG|Oxaliplatin|IV administration
58107786|NCT05550558|DRUG|Anlotinib + Camrelizumab|Anlotinib PO plus Camrelizumab IV
58439859|NCT00294294|BIOLOGICAL|Prevenar|
58439860|NCT00294294|BIOLOGICAL|Infanrix hexa|
58107787|NCT03552354|DRUG|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
58107788|NCT05941468|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
57738867|NCT06496945|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
57738868|NCT00636870|DRUG|Fexofenadine|
58439861|NCT02457676|BEHAVIORAL|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
58439862|NCT00015795|DEVICE|airway interruption test|
58439863|NCT01576497|PROCEDURE|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
58439864|NCT01576497|DEVICE|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
58439865|NCT01576497|DEVICE|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
58439866|NCT02276703|DEVICE|Skin Conductance Monitor|monitors skin conductance values
58439867|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
58439868|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
58439869|NCT06364462|OTHER|lifestyle intervention|Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating components (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable. Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence.
58439870|NCT06499831|DIAGNOSTIC_TEST|0-(2-18F-Fluoroethyl)-L-Tyrosine|0-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (FET) is an amino acid agent derived from tyrosine that is able to cross the blood brain barrier. It has been studied primarily in diagnosis and detection of tumor recurrence in glioblastomas with emerging evidence for its use in brain metastases. Compared to conventional MRI, FET-PET has been shown to delineate geographically distinct tumor volume in newly diagnosed GBM suggesting the complementarity of the two modalities.
57738869|NCT01754467|BEHAVIORAL|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
57738870|NCT00126438|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
57738871|NCT02301143|DRUG|nab-Paclitaxel|
57738872|NCT02301143|DRUG|Gemcitabine|
57738873|NCT02301143|DRUG|Chemoradiation|
57738874|NCT02301143|DRUG|Capecitabine|
57738875|NCT02301143|PROCEDURE|Surgery|Surgical intervention
58107789|NCT03532477|DRUG|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
58107790|NCT06360900|DEVICE|taVNS|Electrical transcutaneous auricular vagus nerve stimulation
58107791|NCT06360900|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
58107792|NCT06360900|BEHAVIORAL|Education Control|Education of FD condition
58107793|NCT06360900|DEVICE|Sham taVNS|Sham (no current) transcutaneous auricular vagus nerve stimulation
58107794|NCT02778763|DRUG|CBLB612|4 μg CBLB612 SQ
58439871|NCT06174610|DIAGNOSTIC_TEST|Measurement of Renal Resistive Index|"The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card)."
57738876|NCT03834779|BEHAVIORAL|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
58311199|NCT05224323|OTHER|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
58311200|NCT00924898|DRUG|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
57738877|NCT02725632|DEVICE|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
57738878|NCT02238262|DRUG|Telmisartan|
58107795|NCT02778763|DRUG|Placebo|
58107796|NCT01906099|OTHER|nutritional intervention|
58311201|NCT01047319|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
58311202|NCT04623710|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
58311203|NCT03845894|DRUG|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
58311204|NCT03845894|DRUG|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
58311205|NCT00490308|DRUG|Treatment with estradiol valerate|
58311206|NCT00010998|PROCEDURE|Yoga|
58311207|NCT06473805|PROCEDURE|VISTA technique and 3D printed PMMA implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the sub nasal area and plan the position, size and thickness of PMMA implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
57738879|NCT03299608|DIAGNOSTIC_TEST|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
58107797|NCT01906099|OTHER|life style modification|
58107798|NCT00010933|DRUG|chamomile tea|
58107799|NCT00010933|PROCEDURE|Relaxation/Guided Imagery|
58439872|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
57738880|NCT04832503|BEHAVIORAL|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
57738881|NCT04832503|BEHAVIORAL|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
57738882|NCT03593655|DEVICE|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
57738883|NCT03593655|DRUG|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
57738884|NCT03194802|BEHAVIORAL|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
57738885|NCT03194802|BEHAVIORAL|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
57738886|NCT01953081|DRUG|TD-8954|
58439873|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
58439874|NCT00532298|BIOLOGICAL|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
57738887|NCT01953081|DRUG|Metoclopramide|
57738888|NCT03521960|DRUG|Buspirone oral capsule|15 milligrams, three times daily
57738889|NCT03521960|DRUG|Placebo oral capsule|0 milligrams (placebo), three times daily
58439875|NCT00532298|BIOLOGICAL|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
58439876|NCT02301026|DRUG|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
57738890|NCT06182995|BEHAVIORAL|Usual Care post-Intensive Care Unit (ICU)|routine clinic visits
58439877|NCT03100591|DRUG|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
58107800|NCT04528303|GENETIC|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
58107801|NCT04528303|GENETIC|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
58107802|NCT03734679|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
58107803|NCT04582097|DRUG|Ramipril|angiotensin-converting enzyme inhibitor
58107804|NCT04582097|DRUG|placebo|same odor, color and size as the drug but without the active ingredient
58107805|NCT06085742|DRUG|Cyclophosphamide|60mg/m2 PO once a day (21 continuous days)
58107806|NCT06085742|DRUG|Methotrexate|10mg/m2 PO BID on days 1, 8, and 15
57738891|NCT06182995|BEHAVIORAL|Anticipating Decline and Providing Therapy (ADAPT)|routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
58107807|NCT06085742|DRUG|Capecitabine|825mg/m2 PO BID on days 1-14
58107808|NCT05906784|OTHER|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
58107809|NCT05906784|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
58107810|NCT04624269|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
58107811|NCT04372212|DEVICE|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
57738892|NCT02327026|PROCEDURE|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
58107812|NCT05836597|DEVICE|Virtual reality|Virtual reality
58107813|NCT00028730|BIOLOGICAL|anti-thymocyte globulin|
58311208|NCT06473805|PROCEDURE|VISTA technique and 3D printed PEEK implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the subnasal area and plan the position, size and thickness of PEEK implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
58439878|NCT02828436|DEVICE|Precision Spectra System|Spinal Cord Stimulation
58107814|NCT00028730|BIOLOGICAL|filgrastim|
58107815|NCT00028730|DRUG|cyclophosphamide|
58439879|NCT02828436|BEHAVIORAL|Exercise Intervention|Standard Exercise
58107816|NCT00028730|DRUG|fludarabine phosphate|
58107817|NCT00028730|DRUG|thiotepa|
58107818|NCT00028730|PROCEDURE|allogeneic bone marrow transplantation|
58107819|NCT00028730|RADIATION|radiation therapy|
58107820|NCT04423653|BEHAVIORAL|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
58107821|NCT02328807|PROCEDURE|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
58107822|NCT06526871|PROCEDURE|Low-Level Laser acceleration|This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .
58311209|NCT00822471|BEHAVIORAL|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
58311210|NCT03567096|DEVICE|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
58107823|NCT06526871|PROCEDURE|clear aligner therapy|Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
58107824|NCT01503242|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
58107825|NCT01503242|DRUG|Cyclosporine|Given PO
58311211|NCT03567096|DEVICE|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
58311212|NCT05576311|OTHER|Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.
58107826|NCT01503242|DRUG|Fludarabine Phosphate|Given IV
58311213|NCT05217030|OTHER|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
58311214|NCT02783066|DEVICE|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
58107827|NCT01503242|DRUG|Mycophenolate Mofetil|Given IV or PO
58311215|NCT02242617|DEVICE|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
58311216|NCT02242617|DEVICE|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
58107828|NCT01503242|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
58107829|NCT01503242|RADIATION|Total-Body Irradiation|Undergo TBI
58311217|NCT00433836|DRUG|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
58439880|NCT05725083|PROCEDURE|Lower thoracic epidural|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
58439881|NCT05725083|PROCEDURE|Erector spinae plane block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
58439882|NCT04168671|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
58439883|NCT04027751|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
58439884|NCT04027751|DRUG|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
58439885|NCT01078363|DRUG|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
58439886|NCT01078363|DRUG|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
58439887|NCT03009799|DRUG|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
58439888|NCT03009799|DRUG|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
58439889|NCT01618695|DRUG|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
58439890|NCT01618695|DRUG|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
58439891|NCT02154256|BEHAVIORAL|Increasing incentives|Offer incentives that increase over time.
58439892|NCT02154256|BEHAVIORAL|Decreasing incentives|offer incentives that decrease over time
58439893|NCT02154256|BEHAVIORAL|stable incentives|offer incentives that are stable over time, but higher than usual care
58439894|NCT00463619|DRUG|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
57738893|NCT02327026|PROCEDURE|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
58107830|NCT01503242|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
58311218|NCT00433836|DRUG|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
58311219|NCT04898881|OTHER|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
58311220|NCT04898881|OTHER|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
58311221|NCT03094156|DRUG|Placebo|1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
58311222|NCT03094156|DRUG|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
58311223|NCT03094156|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
58311224|NCT03094156|DRUG|Comtan®|Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
58107831|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
58439895|NCT05929625|DEVICE|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
58439896|NCT05929625|DEVICE|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
58439897|NCT01939184|DRUG|WC3055|12.5, 25, 50 or 75 mg dose
58439898|NCT01939184|OTHER|Placebo|Placebo
58439899|NCT02401503|DRUG|Bendamustine|Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.
58439900|NCT02401503|DRUG|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
58439901|NCT02401503|DRUG|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
58439902|NCT03878849|DRUG|2X-121|Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.
58439903|NCT03878849|DEVICE|2X-121 DRP®|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
57955416|NCT02128230|DRUG|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
58107832|NCT02174900|DRUG|Artemether-Lumefantrine (AL) combination|
58107833|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
58107834|NCT05694429|OTHER|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
58439904|NCT03461640|OTHER|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
58439905|NCT03461640|BEHAVIORAL|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
58439906|NCT00752479|BIOLOGICAL|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
58439907|NCT00752479|DRUG|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
58439908|NCT00103740|DRUG|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
58439909|NCT00103740|DRUG|placebo to zoledronic acid|5 mL of sterile water for infusion
58439910|NCT00103740|DRUG|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
58439911|NCT00103740|DRUG|Placebo to risedronate|oral capsules
58439912|NCT00103740|DRUG|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
58439913|NCT02445326|DRUG|Dexamethasone|
58439914|NCT02445326|OTHER|Placebo Vehicle|
58107835|NCT03595709|DRUG|3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
58107836|NCT04800107|BIOLOGICAL|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
58107837|NCT04800107|BIOLOGICAL|Placebo capsule|Placebo capsule
58107838|NCT00242775|DRUG|Budesonide/formoterol Turbuhaler|
58107839|NCT00242775|DRUG|Salmeterol/fluticasone Diskus|
58107840|NCT02996435|BEHAVIORAL|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
58107841|NCT02996435|OTHER|No Intervention|Participants will receive physician- or nurse-guided standard of care.
58107842|NCT05898490|BEHAVIORAL|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
58107843|NCT03413865|OTHER|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
58107844|NCT06530394|DIETARY_SUPPLEMENT|Greek yogurt|Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.
58107845|NCT00350519|DRUG|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
58107846|NCT00350519|DRUG|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
58107847|NCT00854620|DRUG|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
58107848|NCT00409188|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
58107849|NCT00409188|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
58107850|NCT00409188|DRUG|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
58107851|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
58107852|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
58107853|NCT01454882|BEHAVIORAL|Effects of Clothing|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
58107854|NCT01454882|BEHAVIORAL|Effects of Temperature|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
58107855|NCT01454882|BEHAVIORAL|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
58107856|NCT01454882|BEHAVIORAL|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
58107857|NCT01454882|BEHAVIORAL|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
58107858|NCT04952532|OTHER|Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)|The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
58107859|NCT00004739|DRUG|Antiretroviral therapy|
58439915|NCT05820854|OTHER|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
58107860|NCT02069834|DRUG|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
58107861|NCT02069834|DRUG|Arm 2 (control)|Continuation of existing HAART at the time of randomization
58107862|NCT03454100|BEHAVIORAL|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
58107863|NCT06413654|DRUG|B001|The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP
58107864|NCT06413654|OTHER|Placebo|The subjects will receive IV dose of placebo matched to B001 on Day 1 and Day 15 of the RCP
58439916|NCT05343377|DIAGNOSTIC_TEST|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
58439917|NCT01272635|DRUG|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
58439918|NCT01272635|DRUG|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
58107865|NCT02836197|BEHAVIORAL|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
58107866|NCT05837065|OTHER|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
58107867|NCT01999231|BIOLOGICAL|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
58107868|NCT01517334|DRUG|Minocycline HCl Microspheres|
58107869|NCT03712137|DEVICE|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
58107870|NCT03712137|OTHER|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
58107871|NCT03604354|DRUG|Tapentadol 100 MG Oral Tablet|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
58107872|NCT03604354|DRUG|Pregabalin 150mg|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
58107873|NCT02118701|OTHER|Shared Decision-Making educational training|
58107874|NCT05350683|PROCEDURE|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
58107875|NCT05695235|DEVICE|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
58107876|NCT05695235|DEVICE|Oura ring|Wearable sleep tracking device
58107877|NCT05695235|BEHAVIORAL|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
58107878|NCT05105087|DRUG|Perflubutane Microbubble|Given subdermally
58107879|NCT05105087|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo ultrasound
58107880|NCT01504867|DRUG|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
58107881|NCT01504867|DRUG|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
58107882|NCT03016663|PROCEDURE|Technique of Breast Lipofilling|"1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
58107883|NCT04304235|DEVICE|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
58107884|NCT04304235|OTHER|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
58107885|NCT03439293|DRUG|Ixazomib|Ixazomib capsule.
58107886|NCT03439293|DRUG|Daratumumab|Daratumumab IV infusion.
58107887|NCT03439293|DRUG|Dexamethasone|Dexamethasone tablets.
58107888|NCT00449579|DEVICE|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
58439919|NCT01272635|OTHER|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
58439920|NCT01272635|DRUG|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
58107889|NCT06466044|BEHAVIORAL|Ear point pressure bean method in ear concha area|The method of pressing beans on auricular points is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, relevant auricular points are selected, and appropriate stimulation such as kneading, pressing, pinching and pressing is given to the seeds of Vaccaria seed attached to the concha auricularis, so that the auricular points can produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
58107890|NCT06466044|BEHAVIORAL|Ear point pressure bean method in earlobe|The auricular point pressing bean method is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, the relevant auricular points are selected, and the seeds attached to the ear lobe, which is the least innervated part of vagus nerve, are given appropriate stimulation such as kneading, pressing, pinching and pressing, so that the auricular points produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
58107891|NCT00403364|DRUG|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
58107892|NCT01039285|DRUG|Curosurf|2.5 ml/kg instilled in the trachea
58107893|NCT01039285|OTHER|Air|2.5ml/kg of Air will be instilled in the trachea
58107894|NCT00543582|DRUG|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
58107895|NCT00159666|DRUG|pregabalin|
58107896|NCT02605083|DRUG|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
58107897|NCT00271999|BEHAVIORAL|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
58107898|NCT01001663|DEVICE|FemoSeal®|Closure device for femoral artery access closure
58107899|NCT01001663|OTHER|Manual compression|Conventional manual compression
58107900|NCT06529523|DRUG|Tislelizumab|Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
58107901|NCT01480271|DRUG|2 ng GSK2445053|2ng GSK2445053 administered intranasally
58439921|NCT01031979|DRUG|Yohimbine|alpha-2 adrenergic receptor antagonist
58439922|NCT01031979|DRUG|Placebo|Placebo
58439923|NCT06413979|BEHAVIORAL|Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)|(1) Family Engagement of caregivers and primary supports in treatment planning and services; (2) Relational Reframing of family constraints, resiliencies, and social capital connected to the youth's ID symptoms; (3) Functional Analysis of the youth's ID symptoms and related behaviors; (4) Cognitive-behavioral therapy (CBT) core techniques to address the youth's ID symptoms and functional needs, featuring three transdiagnostic interventions (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation underlying both depression and anxiety; and (5) Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of youth self-harm. All interventions featured in each module have strong empirical support.
58439924|NCT01612130|DRUG|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
58439925|NCT01612130|DRUG|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
57738894|NCT04021953|BEHAVIORAL|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
58107902|NCT01480271|DRUG|20ng GSK2445053|20ng GSK2445053 administered intranasally
58107903|NCT01480271|DRUG|100ng GSK2445053|100ng GSK2445053 administered intranasally
58107904|NCT01480271|DRUG|200ng GSK2445053|200ng GSK2445053 administered intranasally
58107905|NCT01480271|DRUG|400ng GSK2445053|400ng GSK2445053 administered intranasally
58107906|NCT01480271|DRUG|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
58107907|NCT01480271|DRUG|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
58107908|NCT01480271|DRUG|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
58107909|NCT01480271|DRUG|Placebo|Placebo administered intranasally
58107910|NCT02306603|PROCEDURE|Endoscopic Mucosal Resection|
58107911|NCT03541213|PROCEDURE|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
58107912|NCT03541213|PROCEDURE|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
58107913|NCT03541213|BIOLOGICAL|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
58439926|NCT01736371|DRUG|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
58107914|NCT03899974|OTHER|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
58107915|NCT03545737|OTHER|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
58107916|NCT03545737|OTHER|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
58107917|NCT02450409|PROCEDURE|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
58107918|NCT02450409|PROCEDURE|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
58107919|NCT04364542|PROCEDURE|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
58107920|NCT04364542|PROCEDURE|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
58107921|NCT04364542|PROCEDURE|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
58107922|NCT01047904|DEVICE|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
58107923|NCT02028702|DIETARY_SUPPLEMENT|Placebo|water with color
58107924|NCT02028702|DIETARY_SUPPLEMENT|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
58107925|NCT03386149|DRUG|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~* Rehmannia Root 1.7g~* Achyranthes Root 1.0g~* Cornus Fruit 1.0g~* Dioscorea Rhizome 1.0g~* Psyllium Husk 1.0g~* Alisma Rhizome 1.0g~* Hoelen 1.0g~* Moutan Root Bark 1.0g~* Cinnamon Bark 0.3g~* Pulvis Aconiti Tuberis Purificatum 0.3g"
58107926|NCT03386149|DRUG|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
58107927|NCT03386149|PROCEDURE|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
58439927|NCT01736371|DRUG|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
58439928|NCT01736371|DRUG|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
58439929|NCT06335316|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58107928|NCT03256383|DEVICE|Lead testing|Fingerstick
58107929|NCT05735782|DIAGNOSTIC_TEST|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
58107930|NCT05735782|DIAGNOSTIC_TEST|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
58107931|NCT00317083|PROCEDURE|Cough reflex test|
58107932|NCT03839888|DRUG|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
58107933|NCT05006183|PROCEDURE|PCI|Percutaneous coronary intervention with Drug-Eluting Stents
58107934|NCT04537819|DRUG|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
58107935|NCT04537819|DRUG|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
58107936|NCT00923195|DRUG|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
58439930|NCT06335316|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
57738895|NCT04021953|BEHAVIORAL|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
58439931|NCT06335316|BEHAVIORAL|Comprehensive therapy|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
58439932|NCT06335316|BEHAVIORAL|placebo|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
58107937|NCT00923195|DRUG|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
58439933|NCT04780412|DRUG|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
58107938|NCT00923195|DRUG|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
58107939|NCT00923195|PROCEDURE|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
58439934|NCT04780412|DRUG|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
58107940|NCT00923195|DRUG|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
58107941|NCT00923195|DRUG|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
58439935|NCT00132808|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous
58439936|NCT00132808|DRUG|Placebo|Physiologic 0.9% normal saline
58439937|NCT06262724|PROCEDURE|Breast auto-augmentation|Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
58439938|NCT04099615|PROCEDURE|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
58439939|NCT02324816|DEVICE|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
58107942|NCT00923195|DRUG|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
58107943|NCT00923195|GENETIC|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
58107944|NCT00923195|GENETIC|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
58107945|NCT06529198|DEVICE|NeuroGyn Genital Neuromodulation System|Genital Neuromodulation
58107946|NCT00101205|DRUG|oxaliplatin|Given IV
58107947|NCT00101205|DRUG|etoposide|Given IV
58107948|NCT03689140|BEHAVIORAL|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
58107949|NCT03689140|BEHAVIORAL|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
58107950|NCT03689140|BEHAVIORAL|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
58439940|NCT01166425|DRUG|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
58107951|NCT01634022|PROCEDURE|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
58107952|NCT00595049|DRUG|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
58107953|NCT06221345|DRUG|Systane HYDRATION® Preservative-Free Lubricant Eye Drops|The HPG/HA group will receive Systane HYDRATION® Preservative-Free Lubricant Eye Drops and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
58107954|NCT06221345|DRUG|Optive Fusion® Lubricant Eye Drops (Unit Dose)|The CMC/HA group will receive Optive Fusion® Lubricant Eye Drops (Unit Dose) and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
58107955|NCT01824459|DRUG|S-1|S-1：40\~60mg bid，d1\~14 q3W
58439941|NCT01166425|DRUG|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
58107956|NCT01824459|DRUG|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
58107957|NCT01824459|DRUG|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
58107958|NCT03779594|DRUG|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
58107959|NCT02769000|RADIATION|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
58107960|NCT02769000|RADIATION|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
58107961|NCT01884870|PROCEDURE|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
58107962|NCT04892966|DIAGNOSTIC_TEST|TXI Light Imaging|Standard Colonoscopy using TXI imaging
58439942|NCT00082914|BIOLOGICAL|denileukin diftitox|
58439943|NCT05225363|BIOLOGICAL|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
57955417|NCT02128230|DRUG|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
57955418|NCT02128230|DRUG|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
57955419|NCT02128230|DRUG|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
57955420|NCT04824508|BEHAVIORAL|position|teamleaders are instructed to allocated position
57955421|NCT05667896|DRUG|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
57955422|NCT05209100|PROCEDURE|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
57955423|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
57955424|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
57955425|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
57955426|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
57955427|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
58107963|NCT04892966|DIAGNOSTIC_TEST|WLI Imaging|Standard Colonoscopy using White Light Imaging
58107964|NCT02577042|DRUG|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
58107965|NCT02577042|DRUG|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
58439944|NCT05225363|DRUG|Cyclophosphamide|Given IV
57955428|NCT04382170|DRUG|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
57955429|NCT00673166|PROCEDURE|Staff incentive & supervision|Control \& management of funds for incentive of staff; supervision
57955430|NCT00673166|BEHAVIORAL|Staff motivation|Supervision, control of funds
58107966|NCT02577042|DRUG|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
58107967|NCT04601662|PROCEDURE|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
58439945|NCT05225363|DRUG|Fludarabine|Given IV
58439946|NCT00434642|DRUG|Carboplatin|Carboplatin was provided as commercially available drug.
58439947|NCT00434642|DRUG|Gemcitabine|Gemcitabine was provided as commercially available drug.
58439948|NCT00434642|DRUG|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
58439949|NCT00434642|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
58439950|NCT05039944|DRUG|SI-B001|In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
58439951|NCT05039944|DRUG|Irinotecan|Administration by intravenous infusion, 180 mg/m2 Q2W.
58439952|NCT05039944|DRUG|FOLFIRI Protocol|FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
58439953|NCT05039944|DRUG|FOLFOX Protocol|FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
58439954|NCT00992459|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
58439955|NCT00992459|DRUG|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
58439956|NCT05987163|DEVICE|GP0116|GP0116 is an injectable, sterile, transparent product.
58439957|NCT05987163|DEVICE|Active Comparator: FDA approved dermal filler device|FDA approved dermal filler device
57955431|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
57955432|NCT00949832|DIETARY_SUPPLEMENT|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
57955433|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D2|50,000 IU given orally once
58439958|NCT02583295|BEHAVIORAL|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
58439959|NCT02583295|BEHAVIORAL|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
58439960|NCT01702246|DRUG|Simvastatin|40 mg, orally, once daily for 3 months
58439961|NCT00887510|DRUG|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
58439962|NCT00887510|DRUG|Trandolapril|4 mg tablet once daily for 6 weeks
57738896|NCT06275204|DRUG|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
57955434|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU given orally once
57955435|NCT05530226|DRUG|Traditional Chinese medicine|Traditional Chinese medicine, oral administration, twice daily
57955436|NCT06290050|DRUG|Midazolam|Midazolam syrup.
57955437|NCT06290050|DRUG|Repaglinide|Repaglinide tablets.
58439963|NCT03250182|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
58439964|NCT00881348|DRUG|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
58439965|NCT05512780|DRUG|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
58439966|NCT01317901|DRUG|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
58439967|NCT01317901|DRUG|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
58439968|NCT01317901|DRUG|Rituximab|Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
58439969|NCT02756117|DRUG|L-Lysine|
58107968|NCT04601662|OTHER|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
58107969|NCT05480527|DEVICE|Transcutaneous pulsed radiofrequency current|Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
58107970|NCT01823484|DEVICE|AN 69 ST hemofilter|
58107971|NCT01823484|DEVICE|AN 69 hemofilter|
58107972|NCT02580188|DRUG|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
57738897|NCT06275204|DRUG|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
57738898|NCT06275204|DRUG|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
57738899|NCT06275204|DRUG|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
58107973|NCT04287452|OTHER|Control|Control
58107974|NCT04287452|OTHER|Dog Therapy|Exposure to certified therapy dogs and their handler.
58107975|NCT03739359|OTHER|nasal cannula gas flow|High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
58107976|NCT02938910|OTHER|non interventional study|Non invasive imaging study without interventional procedures
58107977|NCT03054961|DEVICE|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
58107978|NCT02355795|BEHAVIORAL|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
58107979|NCT02355795|BEHAVIORAL|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
58107980|NCT02355795|BEHAVIORAL|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
57738900|NCT03031691|DRUG|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
57738901|NCT03031691|DRUG|trifluridine/tipiracil|
58107981|NCT06527300|DRUG|NHWD-870 HCl|Administered P.O.
58107982|NCT01706770|DEVICE|enfilcon A|
57738902|NCT06241326|OTHER|Immunotherapy-based Combination Therapies|immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
57955438|NCT06290050|DRUG|TAK-279|TAK-279 capsules.
57955439|NCT02215720|DRUG|Cetuximab|
57955440|NCT02215720|DRUG|Temsirolimus|
57955441|NCT06548984|OTHER|diaphragmatic exercises|Perform controlled and supervised diaphragmatic exercises
57955442|NCT06548984|OTHER|Respiratory muscle training|Perform respiratory muscle training with controlled and supervised devices
57955443|NCT01430039|PROCEDURE|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
57955444|NCT01430039|PROCEDURE|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
58107983|NCT01706770|DEVICE|galyfilcon A|
58107984|NCT04346290|DRUG|Dexmedetomidine|Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
58107985|NCT01433952|DIETARY_SUPPLEMENT|Thiamine|Vitamin B1
58107986|NCT01433952|DIETARY_SUPPLEMENT|Placebo|Placebo
58107987|NCT03670537|DIAGNOSTIC_TEST|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
58107988|NCT01613131|DRUG|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
58107989|NCT01613131|DRUG|Estradiol|Topical, .06%, Applied once daily for 50 days.
58107990|NCT01613131|DRUG|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
58107991|NCT01357031|DRUG|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
58439970|NCT02756117|DRUG|Normal (0.9%) Saline|
58439971|NCT01898039|BIOLOGICAL|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
58439972|NCT01898039|PROCEDURE|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
58439973|NCT01898039|DRUG|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
58439974|NCT06233565|DRUG|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
58439975|NCT06233565|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
58439976|NCT06233565|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
58439977|NCT02954393|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
58439978|NCT02954393|DRUG|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
58439979|NCT02954393|DRUG|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
58107992|NCT01357031|DRUG|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
58107993|NCT01357031|DRUG|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
58107994|NCT06013020|DRUG|NOAC+DAPT|Century Clot-guided rivaroxaban plus DAPT.
58439980|NCT02954393|DRUG|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
58439981|NCT02954393|DRUG|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
58439982|NCT02954393|DRUG|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
58439983|NCT02954393|DRUG|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
58107995|NCT06013020|DRUG|DAPT|Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
58439984|NCT04350996|OTHER|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
58439985|NCT02611843|BEHAVIORAL|Peer-Supported Web CBT|
58439986|NCT02611843|BEHAVIORAL|Self-Managed Web CBT|
58439987|NCT01178099|DRUG|Prasugrel|Oral, daily for 12 days
58439988|NCT04063163|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
58439989|NCT04063163|DRUG|carboplatin and etoposide|chemotherapeutics
58439990|NCT04063163|DRUG|placebo|placebo
58439991|NCT00432341|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
58439992|NCT00432341|BIOLOGICAL|botulinum toxin type A|500 Units at Visit 1 (Day 1)
57738903|NCT06367621|DEVICE|iStatis Syphilis Antibody Test|1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
58107996|NCT00078468|DRUG|PELITREXOL/AG-2037|
58439993|NCT01858766|DRUG|SOF|400 mg tablet administered orally once daily
58439994|NCT01858766|DRUG|VEL|Tablet administered orally once daily
58439995|NCT01858766|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58439996|NCT01578655|DRUG|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
58439997|NCT01578655|DRUG|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
58439998|NCT01578655|DRUG|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
58439999|NCT00262899|BEHAVIORAL|counseling intervention|
58440000|NCT00262899|OTHER|educational intervention|
58440001|NCT00262899|PROCEDURE|psychosocial assessment and care|
58440002|NCT03877302|OTHER|reflexology|foot reflexology
58440003|NCT04298957|PROCEDURE|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
58440004|NCT04368780|OTHER|Effect of Progressive Muscle Relaxation Combined With Music|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
58440005|NCT04869969|PROCEDURE|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
58440006|NCT04869969|PROCEDURE|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
58440007|NCT04139850|DRUG|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
58107997|NCT05612737|PROCEDURE|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
58440008|NCT03069157|PROCEDURE|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
58107998|NCT03405337|DRUG|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
58107999|NCT03405337|DRUG|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
58108000|NCT05948293|DEVICE|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
58108001|NCT05948293|PROCEDURE|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
58108002|NCT02108613|BEHAVIORAL|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
58108003|NCT02108613|BEHAVIORAL|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
58108004|NCT02108613|BEHAVIORAL|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
58440009|NCT04967404|DIETARY_SUPPLEMENT|Phosphatidylserine|800 mg per day for 10 days
58440010|NCT01884272|DRUG|lesinurad 400 mg|
58440011|NCT01884272|DRUG|naproxen 250 mg|
58440012|NCT01884272|DRUG|indomethacin 25 mg|
58440013|NCT03623568|DRUG|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
58440014|NCT06125782|DRUG|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
58440015|NCT06125782|DRUG|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
58440016|NCT06468189|DEVICE|transcranial direct stimulation|Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
58440017|NCT06468189|DEVICE|Sham treatment|The same device used for stimulation will be used, but no stimulation will be given.
58440018|NCT05990361|DIAGNOSTIC_TEST|clinical diagnostic test|"The clinical diagnosis tests are Active Straight Leg Rise ASLR, Posterior Pelvic Pain Provocation, Long Dorsal Sacroiliac Ligament Palpation (LDSLP), Pelvic Compression, Pelvic Distraction, Patrick-Faber Test (PF), and Gaenslen Test (GT).~The subjects who had at least one positive result from ASLR and P4 Tests; and at least two positive results from the Pelvic Compression and Distraction, PF, GT and LDSLP tests are classified as with PGP group."
58440019|NCT01494077|OTHER|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
58440020|NCT05731479|OTHER|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
58440021|NCT05731479|OTHER|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
58108005|NCT02328261|DRUG|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
58108006|NCT01213355|DRUG|Placebo|Capsule, single dose, oral, 1 day
57738904|NCT02420002|DRUG|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
58108007|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
58108008|NCT01213355|DRUG|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
58108009|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
58108010|NCT01213355|DRUG|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
58108011|NCT01213355|DRUG|scopolamine|injectable subcutaneous formulation, single dose, 1 day
58108012|NCT01213355|DRUG|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
58108013|NCT01213355|DRUG|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
58108014|NCT01213355|DRUG|Donepezil|Tablet, 10mg, single dose, 1 day
58108015|NCT01213355|DRUG|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
58108016|NCT02741362|OTHER|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
58108017|NCT02741362|OTHER|Lipoaspiration|
58440022|NCT05971537|DRUG|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
58440023|NCT05971537|DRUG|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
58440024|NCT04120272|PROCEDURE|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
57738905|NCT02420002|OTHER|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
57738906|NCT02420002|PROCEDURE|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
57738907|NCT02313467|DRUG|Topical application of 1.5% Butenyl ALA|
57738908|NCT02313467|DRUG|Topical application of sham control|
57738909|NCT00083408|DRUG|Pamidronate|
57738910|NCT00083408|DRUG|Thalidomide|
57955445|NCT05936450|BIOLOGICAL|delivery of placentrex gel after open flap debridement|placentrex gel is placed after open flap debridement only in the test group
58440025|NCT02156778|BEHAVIORAL|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
57955446|NCT05936450|PROCEDURE|Open Flap Debridement|Open Flap Debridement done in both test and control groups
58108018|NCT00933660|OTHER|ERC-training by instructor|Standard way of training with an instructor
58108019|NCT00933660|OTHER|Web-based training only|Experimental way of training with a web based training application
58108020|NCT00933660|OTHER|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
58108021|NCT03151499|DRUG|BI 409306|Reference and Test Treatment
58108022|NCT03151499|DRUG|Rifampicin|Test Treatment
58108023|NCT02841540|DRUG|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
58108024|NCT02734615|DRUG|LSZ102|LSZ102
58108025|NCT02734615|DRUG|LEE011|LEE011
58108026|NCT02734615|DRUG|BYL719|BYL719
58108027|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
58108028|NCT01511900|DRUG|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
58108029|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
58108030|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
58108031|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
58108032|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
58108033|NCT00839020|PROCEDURE|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
58108034|NCT00839020|PROCEDURE|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
58108035|NCT04904432|GENETIC|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
57738911|NCT00716872|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
58108036|NCT05460026|OTHER|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
58108037|NCT05460026|OTHER|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
58108038|NCT02778568|BEHAVIORAL|Resistance training|Resistance training exercises
58108039|NCT02778568|BEHAVIORAL|Control|Stretching exercises
58108040|NCT05388188|DRUG|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
58108041|NCT03062865|OTHER|No intervention|
58108042|NCT06039787|BEHAVIORAL|single bout of moderate intensity continuous training (MICT)|the MICT consists of 60 min continuous cycling
58108043|NCT06039787|BEHAVIORAL|single bout of High Intensity Interval Training (HIIT)|HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
58440026|NCT02156778|BEHAVIORAL|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
58440027|NCT00582777|BEHAVIORAL|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
58440028|NCT00582777|BEHAVIORAL|HS DOSING|Take your usual BP meds at bed time
58440029|NCT00582777|DRUG|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
58440030|NCT02769221|DEVICE|Rigid video stylet|
58440031|NCT02769221|DEVICE|Video laryngoscope|
58108044|NCT06039787|BEHAVIORAL|waiting control|sitting in a waiting room for 60 min
58108045|NCT02087579|DRUG|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
58108046|NCT02087579|DRUG|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
58108047|NCT02087579|DRUG|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
58108048|NCT02087579|DRUG|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
58108049|NCT02087579|DRUG|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
58108050|NCT02087579|DRUG|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
58108051|NCT02087579|DRUG|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
58108052|NCT00367666|DEVICE|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
58440032|NCT02994875|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
58440033|NCT02994875|OTHER|Placebo|Sugar pill
58440034|NCT02524002|DIETARY_SUPPLEMENT|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
58440035|NCT02524002|DIETARY_SUPPLEMENT|Usual clear diet|Usual clear liquids
58440036|NCT01433562|DRUG|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
58440037|NCT01433562|DRUG|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
58440038|NCT06189131|DEVICE|Ventriject|Ventriject is a non-exercise method for estimating V02Max
58440039|NCT03536832|PROCEDURE|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
58440040|NCT03536832|PROCEDURE|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
58440041|NCT02357121|DEVICE|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
57738912|NCT00716872|BEHAVIORAL|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
57738913|NCT06371833|DEVICE|Shoulder Arthroplasy with PRIMA humeral stem|Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
57738914|NCT02470338|PROCEDURE|MBP plus arthroscopy (Group A)|
57738915|NCT02470338|PROCEDURE|MBP alone (Group B)|
58108053|NCT03665571|DIAGNOSTIC_TEST|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
58108054|NCT03808220|BEHAVIORAL|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
58108055|NCT03808220|BEHAVIORAL|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
58440042|NCT04370106|OTHER|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
58108056|NCT03808220|BEHAVIORAL|Side effect|investigate the presence of any side effect
58108057|NCT03627195|DRUG|DSP-1349M|DSP-1349M injectable
58108058|NCT03627195|DRUG|placebo|placebo injection
58108059|NCT00343811|DRUG|Modafinil|
58440043|NCT00607867|OTHER|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
58440044|NCT00607867|OTHER|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
58440045|NCT05472922|DEVICE|Placement of MiniMizer Gastric Ring|Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
58440046|NCT05472922|PROCEDURE|Normal MGB-OAGB|No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
58440047|NCT04499625|PROCEDURE|Sinus floor elevation|
58440048|NCT04499625|DEVICE|Sinus floor elevation using an ultrasonic device|
58440049|NCT05178602|BEHAVIORAL|Tai Chi Intervention Group|Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
58440050|NCT03359252|PROCEDURE|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
58440051|NCT03359252|PROCEDURE|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
58440052|NCT01104727|PROCEDURE|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
57738916|NCT03667950|PROCEDURE|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
57955447|NCT01258764|DRUG|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
57955448|NCT01258764|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
58108060|NCT02768142|OTHER|Natural cesarean delivery|Natural cesarean delivery
58108061|NCT02768142|OTHER|Standard cesarean delivery|Standard cesarean delivery
58108062|NCT00686790|BIOLOGICAL|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
57738917|NCT01913067|DRUG|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
57738918|NCT01913067|PROCEDURE|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
58108063|NCT01583751|PROCEDURE|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
57738919|NCT00386880|OTHER|Sounds|
57738920|NCT00754845|DRUG|letrozole|Given orally
57738921|NCT00754845|OTHER|placebo|Given orally
58108064|NCT04857216|DEVICE|Perfusion Index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
58108065|NCT05309837|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose-enriched food products
58108066|NCT05309837|DIETARY_SUPPLEMENT|placebo-controlled|Control food products
58108067|NCT03908983|DEVICE|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
58108068|NCT02020733|DEVICE|Balloon catheter|
58108069|NCT02020733|DEVICE|metal cannula|
58108070|NCT00720733|BEHAVIORAL|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
58108071|NCT00720733|BEHAVIORAL|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning \& Purpose.
58108072|NCT02328547|DRUG|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
58108073|NCT02328547|DRUG|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
58108074|NCT04310748|DRUG|Total Intravenous Anesthesia(TIVA)|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded"
58108075|NCT04310748|DRUG|Inhalation Anesthesia|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded."
58108076|NCT00984906|OTHER|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
58440053|NCT01104727|PROCEDURE|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
58440054|NCT06346015|PROCEDURE|Gamma Entrainment Stimulation|"Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）"
58440055|NCT06205238|OTHER|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
58440056|NCT03226496|BEHAVIORAL|motivational interviewing|
58440057|NCT04518540|DRUG|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
58440058|NCT04518540|DRUG|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
58440059|NCT06524193|BEHAVIORAL|Telepractice group voice therapy|"* Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
58440060|NCT06524193|BEHAVIORAL|Face-to-face group voice therapy|"* Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
58440061|NCT00897221|DRUG|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
58440062|NCT00897221|DRUG|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
58440063|NCT00003199|DRUG|tamoxifen citrate|Given orally
58440064|NCT00003199|DRUG|busulfan|Given orally
58440065|NCT00003199|DRUG|thiotepa|Given IV
58440066|NCT00003199|DRUG|melphalan|Given IV
58440067|NCT00003199|BIOLOGICAL|aldesleukin|Given SC
58440068|NCT00003199|BIOLOGICAL|sargramostim|Given SC
58440069|NCT00003199|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
58440070|NCT00003199|RADIATION|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
58440071|NCT00002913|DRUG|paclitaxel|Given IV
58440072|NCT00002913|DRUG|cisplatin|Given IV
58440073|NCT00002913|DRUG|topotecan hydrochloride|Given IV
57738922|NCT05218967|OTHER|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
57738923|NCT04313881|DRUG|Magrolimab|Administered intravenously
57738924|NCT04313881|DRUG|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
57738925|NCT04313881|DRUG|Placebo|Placebo to match magrolimab administered intravenously
58440074|NCT00002913|BIOLOGICAL|filgrastim|Given SC
58108077|NCT00047489|DRUG|ABT-751|
58440075|NCT02663830|DRUG|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
58440076|NCT02663830|DRUG|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
58440077|NCT00950898|OTHER|decaff|2 mugs of decaffeinated coffee
58440078|NCT00950898|OTHER|caffcoff|2 mugs of caffeinated coffee
58440079|NCT00950898|OTHER|caffeine|2 mugs of hot water containing caffeine
57955449|NCT04950257|DEVICE|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
57955450|NCT03610061|DRUG|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
57955451|NCT03610061|RADIATION|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
57955452|NCT03610061|RADIATION|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
57955453|NCT03659019|OTHER|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
57955454|NCT04479111|PROCEDURE|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
58108078|NCT01700920|PROCEDURE|bone marrow aspirate|
58108079|NCT04452500|DRUG|CORT108297|CORT108297- 180mg daily for 7 days
58108080|NCT04452500|DRUG|Placebo|Placebo- 180mg daily for 7 days
58108081|NCT00916422|BIOLOGICAL|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
58108082|NCT00916422|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
58108083|NCT01270373|DRUG|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
58108084|NCT01270373|DRUG|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
58440080|NCT00950898|OTHER|placebo|2 mugs of hot water
58440081|NCT02949063|BEHAVIORAL|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
58440082|NCT03261791|DRUG|Apatinib|Apatinib mesylate tablets 500 mg po qd.
58440083|NCT03807414|DEVICE|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
58440084|NCT00976833|OTHER|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
58440085|NCT00976833|OTHER|Usual Care|Usual Physical Therapy care
58440086|NCT01616680|DRUG|brentuximab vedotin|Given IV
58440087|NCT01616680|OTHER|laboratory biomarker analysis|Correlative studies
58440088|NCT01616680|OTHER|pharmacological study|Correlative studies
58440089|NCT05185050|DIAGNOSTIC_TEST|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
57738926|NCT00003334|DRUG|paclitaxel|
57738927|NCT00003334|DRUG|pegylated liposomal doxorubicin hydrochloride|
57738928|NCT05483348|PROCEDURE|Endometrial Ablation|Thermal endometrial ablation
57738929|NCT05483348|PROCEDURE|Repeated gynecological procedure|subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
57738930|NCT04266782|OTHER|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
57738931|NCT04266782|OTHER|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
58311225|NCT03350919|DEVICE|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
58108085|NCT04225273|DEVICE|Sculptra Aesthetic 8 ml and Lidocaine|Treatment of nasolabial folds
58440090|NCT01196351|OTHER|Dietary Supplement: water with noncalorie sweetener|
57738932|NCT01490996|DRUG|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
57738933|NCT01490996|DRUG|Chemotherapy only|Standard care chemotherapy
57738934|NCT00395902|DRUG|Sensipar after Post Transplant|
58440091|NCT01196351|OTHER|Activity: With noncalorie sweetener or glucose|
58440092|NCT02061514|PROCEDURE|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
58440093|NCT02061514|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
58440094|NCT00932581|OTHER|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
58440095|NCT00932581|OTHER|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
58440096|NCT01776034|BEHAVIORAL|SystemCHANGE Group Lifestyle counseling|
58440097|NCT01776034|BEHAVIORAL|Phone Lifestyle Counseling|
58440098|NCT01336413|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
58440099|NCT01336413|DRUG|Placebo|Same as active comparator, except placebo dispensed.
58440100|NCT02547558|PROCEDURE|Arterial blood gases|Measured through radial arterial catheter
58440101|NCT02547558|PROCEDURE|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
58440102|NCT02547558|PROCEDURE|Vital signs|As measured in clinical practice
58440103|NCT02547558|PROCEDURE|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
58440104|NCT02547558|PROCEDURE|Spirometry|In a daily calibrated spirometer.
58440105|NCT02547558|DRUG|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
57738935|NCT03317600|DEVICE|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
57738936|NCT03317600|DRUG|Placebo|"Intervention is a placebo nerve block with isotonic saline"
58440106|NCT04954768|OTHER||This is a observational study, and there is no interventions.
58440107|NCT01112878|DRUG|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
58440108|NCT01112878|DRUG|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
58440109|NCT01112878|DRUG|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
58440110|NCT01685697|PROCEDURE|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
58440111|NCT01685697|PROCEDURE|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
58440112|NCT00117299|DRUG|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
58440113|NCT05240365|DEVICE|SDF modified Hall technique|"* Preparation for Hall technique and selection of the crown.~* Clinical application of SDF.~* Cementation of the selected crown."
58440114|NCT05240365|DEVICE|Conventional pulpotomy and stainless steel crown|"* Teeth will be anesthetized .~* Rubber dam will be used and high suction in pulpotomy procedure.~* Cavity outline will be performed by sterile #330 high speed bur using water spray.~* Caries will be removed by large spoon excavator.~* pulpal exposure will be occurred then the roof of pulp chamber will be removed by low speed round bur. Hemostasis will be obtained by applying pressure with moist cotton pellet with saline.~* Teeth will be treated by using sterile cotton pellet with formcresol for three to five min then, remove it.~* Pulp stumps of will be dressed with reinforced zinc oxide eugenol, IRM®\*~* Tooth Preparation will be done followed by placement of stainless-steel crown"
58440115|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
58108086|NCT00476684|PROCEDURE|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
58108087|NCT00476684|PROCEDURE|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
58440116|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
58108088|NCT06188481|OTHER|whole-body electromyostimulation training|The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.
58108089|NCT06188481|OTHER|activity tracker|Participants wear the activity tracker on their wrist for the entire 16-week study period.
58108090|NCT06188481|OTHER|evidence-based lifestyle education program|Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).
58108091|NCT05737888|OTHER|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
58440117|NCT05658705|PROCEDURE|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
58440118|NCT05658705|PROCEDURE|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
58440119|NCT04239651|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
58440120|NCT04239651|OTHER|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
58108092|NCT05737888|OTHER|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
58440121|NCT02586948|DEVICE|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
58440122|NCT05508919|DEVICE|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
58440123|NCT05508919|OTHER|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
58440124|NCT05767359|DRUG|Ciltacabtagene Autoleucel|Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
58440125|NCT05767359|DRUG|Cyclophosphamide|Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
58440126|NCT05767359|DRUG|Fludarabine Phosphate|Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
58440127|NCT00121186|DRUG|fludarabine phosphate|30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).
58440128|NCT00121186|DRUG|melphalan|70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).
57738937|NCT03421054|DIETARY_SUPPLEMENT|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
57738938|NCT04814329|OTHER|genetic characteristic|the underlying genetic characteristics that prodicting response
57738939|NCT00440648|DRUG|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
57955455|NCT05796635|OTHER|Herpecin L|Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
57955456|NCT01588717|DRUG|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
58108093|NCT05737888|BEHAVIORAL|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
58108094|NCT06336889|PROCEDURE|Pelvic Angioembolization|Embolization is performed by placing a small catheter inside the blood vessels that supply the area that is bleeding. Carefully navigating the catheter, under image guidance, to the safest and farthest point, a variety of different materials can then be used to block the bleeding vessels.
58108095|NCT00528879|DRUG|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
58440129|NCT00121186|DRUG|methotrexate|5 mg/m\^2 on days 1, 3, and 7 post-transplant.
58440130|NCT00121186|DRUG|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
58440131|NCT00121186|PROCEDURE|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
58440132|NCT00121186|PROCEDURE|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
58440133|NCT04548804|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
58440134|NCT02265250|OTHER|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
58440135|NCT02265250|OTHER|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
58440136|NCT02265250|OTHER|Laboratory blood test|Cardiovascular biomarkers
58440137|NCT03240094|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
58440138|NCT04364295|DEVICE|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
58440139|NCT06238284|OTHER|no intervention|Since it is a retrospective study, no intervention is needed.
58440140|NCT05388617|DEVICE|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
58440141|NCT04040829|BEHAVIORAL|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
58440142|NCT04040829|BEHAVIORAL|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
58440143|NCT04040829|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
58440144|NCT01854034|DRUG|AUY922|AUY922 administered intravenously once a week at 70mg/m2
58440145|NCT06141265|DRUG|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
58440146|NCT02817243|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
58440147|NCT02817243|DRUG|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
58440148|NCT00550966|BEHAVIORAL|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
58440149|NCT05373849|DIETARY_SUPPLEMENT|essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
58440150|NCT05373849|DIETARY_SUPPLEMENT|no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
58440151|NCT00544219|BIOLOGICAL|rituximab|375 mg/m2 i.v. per cycle
58440152|NCT00544219|DRUG|cyclophosphamide|750 mg/m2 i.v. per cycle
57738940|NCT00440648|DRUG|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
57738941|NCT01011829|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
57738942|NCT01011829|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
57738943|NCT00811876|OTHER|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
58108096|NCT00528879|DRUG|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
58108097|NCT00528879|DRUG|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
58108098|NCT00168337|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
58440153|NCT00544219|DRUG|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
58440154|NCT00544219|DRUG|prednisone|100 mg/day p.o. per cycle
58440155|NCT00544219|DRUG|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
58440156|NCT00544219|PROCEDURE|positron emission tomography|PET Scan during treatment
58440157|NCT01811134|DEVICE|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
58311226|NCT03350919|DEVICE|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
57738944|NCT00344786|DRUG|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
57738945|NCT03119857|DRUG|Antiandrogen|
57738946|NCT03119857|DRUG|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
58311227|NCT05105685|DRUG|recombinant human growth hormone|RhGH treatment was started at 0.1 IU/kg once daily
57738947|NCT00791765|BIOLOGICAL|Etanercept|Etanercept for subcutaneous injection.
57738948|NCT00791765|BIOLOGICAL|Placebo|Placebo for subcutaneous injection.
57738949|NCT00872352|PROCEDURE|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
57738950|NCT00907153|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
57738951|NCT00907153|DRUG|Placebo|Placebo by mouth once daily for 12 weeks
57738952|NCT00417079|DRUG|cabazitaxel (XRP6258) (RPR116258)|25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
57738953|NCT00417079|DRUG|mitoxantrone|12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
57738954|NCT00417079|DRUG|prednisone|10 mg daily administered by oral route
57738955|NCT01016769|DRUG|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
57738956|NCT00517712|DRUG|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
57738957|NCT02216058|DEVICE|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
57738958|NCT04222348|DRUG|Metformin|850-2550 mg every 24h.
58311228|NCT05105685|DRUG|Saline|Saline was started at 0.1 IU/kg once daily as the placebo
58311229|NCT00982345|DRUG|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
58311230|NCT02855255|BEHAVIORAL|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
58108099|NCT00168337|OTHER|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
58108100|NCT00482287|DRUG|MTR105|Intravenous administration, dose escalating (4 arms), single dose
58108101|NCT02024698|DEVICE|omafilcon A|contact lens
58108102|NCT02024698|DEVICE|etafilcon A|contact lens
58108103|NCT00846196|DRUG|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
58108104|NCT00846196|DRUG|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
58108105|NCT03346928|PROCEDURE|Head and neck reconstruction|Head and neck free flap reconstruction
58108106|NCT06392737|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
58108107|NCT06392737|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
58108108|NCT03957278|DEVICE|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
58108109|NCT06322810|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral ESP: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
58108110|NCT06322810|PROCEDURE|Pecto-intercostal fascial plane blok (PIFB)|Bilateral PIFB: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
58108111|NCT04888260|OTHER|Laboratory parameter levels in blood samples|Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
58108112|NCT06460987|DRUG|Finerenone|Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
58108113|NCT06460987|DRUG|RAS inhibitor|Receive RAS inhibitor treatment as specified in the KDIGO guidelines
58108114|NCT06460987|DRUG|Immune Suppressant|Receive immune suppressant treatment as specified in the KDIGO guidelines
58311231|NCT02855255|BEHAVIORAL|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
57738959|NCT04222348|DRUG|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
57738960|NCT03847324|OTHER|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
57738961|NCT03847324|OTHER|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
57738962|NCT03847324|OTHER|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
58108115|NCT04641572|OTHER|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
58108116|NCT04698564|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
58108117|NCT01630265|OTHER|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
58108118|NCT01630265|OTHER|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
58311232|NCT01502553|DEVICE|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
58440158|NCT01811134|DEVICE|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
57738963|NCT02098200|DEVICE|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
57738964|NCT04377165|BEHAVIORAL|Gamification|This will provide the user with the newsfeed function and the addition of a gamification function
57738965|NCT04377165|BEHAVIORAL|Newsfeed function|This will provide the user with reliable accurate information on the pandemic.
57738966|NCT03774186|DEVICE|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
58440159|NCT03478800|PROCEDURE|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
58440160|NCT04153916|DEVICE|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
58440161|NCT04124705|DRUG|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
58440162|NCT04124705|DRUG|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
58440163|NCT05168228|PROCEDURE|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
58440164|NCT00510744|DRUG|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
58440165|NCT02156414|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
58440166|NCT02156414|PROCEDURE|Extended Lymphadenectomy|Extended Lymphadenectomy
58440167|NCT02048085|DRUG|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
57738967|NCT03774186|DEVICE|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
57738968|NCT02478619|OTHER|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
58440168|NCT02048085|DRUG|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
58440169|NCT02858947|PROCEDURE|Aelite Flo|Microhybrid flowable composite
58440170|NCT02858947|PROCEDURE|x-tra base|Bulk-fill flowable composite
58440171|NCT04036526|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
58440172|NCT04036526|OTHER|Placebo|Placebo
58440173|NCT05138627|OTHER|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
57738969|NCT02478619|OTHER|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
57738970|NCT00003857|DRUG|tamoxifen citrate|
57738971|NCT00003857|PROCEDURE|adjuvant therapy|
57738972|NCT00003857|RADIATION|radiation therapy|
58440174|NCT03481699|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
58440175|NCT03481699|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
58440176|NCT05238545|OTHER|gluten-free diet|Diet excluding foods containing gluten.
58440177|NCT03301610|OTHER|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
58440178|NCT03301610|OTHER|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
58440179|NCT01286740|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
58440180|NCT01207752|DRUG|Systane Balance|Artificial tear emulsion drop
58440181|NCT01207752|DRUG|Optive Lubricant Eye Drops|Artificial tear eye drop
58440182|NCT03451123|DRUG|FET PET/MRI|FET PET/MRI scan before and after surgery
57738973|NCT00942214|DRUG|Natalizumab|300mg, IV, every 4 weeks
57738974|NCT05983822|DEVICE|Technological Group|Specific rehabilitation for the recovery of hand function using the end-effector robot
58108119|NCT02995837|OTHER|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
58108120|NCT02995837|OTHER|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
58108121|NCT02995837|OTHER|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
58108122|NCT02995837|OTHER|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
58440183|NCT05698602|DEVICE|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~* measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~* store the measurements in the embedded memory~* extract from the measurement basic respiratory markers:~* detect if and when a patient is using the respiratory assist device,~* calculate leakage~* calculate respiratory frequency~* transmit the measured values via the NivolisBox component to NivolisPortal"
58440184|NCT05698602|DEVICE|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 \& tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
58440185|NCT03592485|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
58440186|NCT03592485|PROCEDURE|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
58440187|NCT03592485|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
58440188|NCT03592485|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
58440189|NCT03592485|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
58440190|NCT03282929|DEVICE|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
58440191|NCT03282929|DEVICE|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
58440192|NCT03282929|DRUG|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
58440193|NCT03282929|DEVICE|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
58440194|NCT03282929|DEVICE|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
58108123|NCT01894113|PROCEDURE|transbronchial lung biopsy|
58108124|NCT02502409|OTHER|Standard care with blood and urine sample collection|
58108125|NCT05692466|DIAGNOSTIC_TEST|Comprehensive molecular panel test|Lab test
58108126|NCT05692466|OTHER|EORTC QLQ-30|Quality of life questionnaire
58108127|NCT00012155|BIOLOGICAL|NV1020|
57738975|NCT05983822|OTHER|Conventional Treatment|Conventional rehabilitation
58108128|NCT03884933|OTHER|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
58108129|NCT03828656|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
58108130|NCT05815719|DRUG|Corifollitropin Alfa|150 micrograms per dose
58108131|NCT05815719|DRUG|Follitropin Alfa|Variable dose.
58108132|NCT05815719|DRUG|Follitropin Alfa Biosimilar|Variable dose.
58108133|NCT05815719|DRUG|Urinary Human follicle stimulating hormone|Variable dose.
58108134|NCT04477083|DRUG|inhalable hydroxychloroquine (HCQ)|inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
58108135|NCT04477083|DRUG|supportive and symptomatic treatment|supportive and symptomatic treatment
58108136|NCT04393155|OTHER|COVID-19+ observational|This is observational -- there is no intervention
58108137|NCT01940237|BEHAVIORAL|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
58108138|NCT00545181|DRUG|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
58108139|NCT00545181|DRUG|Metronidazole control|oral metronidazole therapy alone
58108140|NCT05379569|DRUG|Fludarabine|The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
58108141|NCT01965535|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
58108142|NCT01965535|DRUG|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
58108143|NCT01965535|DRUG|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
58108144|NCT01965535|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
58108145|NCT02766387|OTHER|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
58108146|NCT03889457|OTHER|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
58108147|NCT02065791|DRUG|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
58108148|NCT02065791|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily
57738976|NCT03543254|DRUG|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
58108149|NCT01005264|DEVICE|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
57738977|NCT03157713|BEHAVIORAL|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
58108150|NCT01005264|DEVICE|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
58108151|NCT04498156|OTHER|No intervention|No intervention, observational study
58108152|NCT02818478|OTHER|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
58108153|NCT00764998|BIOLOGICAL|Fluviral|
58108154|NCT01843907|BEHAVIORAL|Empowerment|To give patients the necessary resources to take care of their own health
58108155|NCT01843907|OTHER|Conversation with nurse|To find out, if the nurse, using her ....
58108156|NCT02431403|DRUG|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
58108157|NCT01638793|DEVICE|Microcap (Oridion, Needham, MA, USA)|
58108158|NCT01638793|DEVICE|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
58108159|NCT01537965|DEVICE|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~* elastography with Fibroscan®~* ultrasound elastography in supersonic mode with Aixplorer®~* ultrasound analysis of the surface liver with QRS software,~* quantification of acoustic structure with Aplio XG,~* elastography ARFI with Acuson S2000."
58108160|NCT04220203|DRUG|Tucatinib|300 mg orally two times per day
58108161|NCT04220203|DRUG|Capecitabine|1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle
58440195|NCT00719355|BEHAVIORAL|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
58108162|NCT04220203|DRUG|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
58108163|NCT00001951|DRUG|TMTDS|
58108164|NCT02999373|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
58440196|NCT00719355|BEHAVIORAL|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
58440197|NCT02720692|DRUG|N1539|
58440198|NCT02720692|DRUG|Intravenous Placebo|
58440199|NCT04071158|BIOLOGICAL|RSV Vaccine|RSV vaccine
58440200|NCT04071158|BIOLOGICAL|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
58108165|NCT03788798|DEVICE|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
58440201|NCT04071158|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
58440202|NCT03854513|DEVICE|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
58440203|NCT03659071|OTHER|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
58440204|NCT05269108|PROCEDURE|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
58440205|NCT05269108|PROCEDURE|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
58440206|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
58440207|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
58440208|NCT03999060|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
58440209|NCT05909839|OTHER|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
57738978|NCT03157713|BEHAVIORAL|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
58108166|NCT00388479|DRUG|Alvimopan|
58108167|NCT03337737|DIETARY_SUPPLEMENT|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
58108168|NCT03337737|OTHER|Placebo|
58108169|NCT00004582|DRUG|Lopinavir/Ritonavir|
58108170|NCT00004582|DRUG|Efavirenz|
58108171|NCT03746301|DRUG|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
58108172|NCT01405885|BIOLOGICAL|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58440210|NCT01600079|BIOLOGICAL|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
58440211|NCT00465088|DRUG|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
58440212|NCT00465088|DRUG|atorvastatin|40 mg at bedtime
58440213|NCT06268938|PROCEDURE|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
58440214|NCT02696213|OTHER|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
58108173|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58440215|NCT02696213|OTHER|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
58440216|NCT03257839|DEVICE|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
58440217|NCT03257839|DEVICE|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
58440218|NCT03257839|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
58440219|NCT04949022|DEVICE|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
57738979|NCT03157713|BEHAVIORAL|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to \<2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to \<5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to \<5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
57738980|NCT02071004|DRUG|DS-1040b|IV of 6 mg given once over 30 minutes
57738981|NCT02071004|DRUG|Aspirin|Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
58440220|NCT00098683|DRUG|amifostine trihydrate|
57738982|NCT04478968|OTHER|presence of AVF|Functioning AVF may have cardiotoxic potential
57738983|NCT03488901|OTHER|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
58440221|NCT05950698|DEVICE|Holter Faros 360° EKG (Bittium Corporation)|Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.
58440222|NCT05950698|DIAGNOSTIC_TEST|Beck Depression Inventory (BDI)|The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
57738984|NCT01733654|BIOLOGICAL|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
57738985|NCT02834780|DRUG|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
57738986|NCT06406569|DEVICE|H-Man Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
58108174|NCT01405885|BIOLOGICAL|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58108175|NCT01405885|BIOLOGICAL|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58440223|NCT05950698|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scales - HADS|The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
58440224|NCT05950698|DIAGNOSTIC_TEST|Three Factor Eating Questionnaire-R21 - TFEQ-R21|The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
58108176|NCT01405885|BIOLOGICAL|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58440225|NCT05950698|DIAGNOSTIC_TEST|hort-Form Health Survey-36 itens - SF-36|he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
58440226|NCT06584045|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
58440227|NCT04189549|DIAGNOSTIC_TEST|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
58108177|NCT01405885|BIOLOGICAL|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58108178|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
58440228|NCT05575193|OTHER|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
57738987|NCT06406569|DEVICE|ReHandyBot|ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.
57738988|NCT06406569|DEVICE|MyoPanda|MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
57738989|NCT01210391|OTHER|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
57738990|NCT01210391|OTHER|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
57738991|NCT06046274|BIOLOGICAL|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
57738992|NCT06046274|BIOLOGICAL|Acasunlimab|Acasunlimab IV infusion
58311233|NCT04472702|PROCEDURE|cRFA|cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
58311234|NCT04553419|DRUG|Cephalexin|Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin
58311235|NCT04553419|DRUG|Placebo|Cellulose capsules or suspension
58311236|NCT05733910|RADIATION|simultaneous integrated boost of carbon ions radiation therapy|"CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB).~The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion)."
57738993|NCT02820623|BEHAVIORAL|Self-report|
57738994|NCT02820623|BEHAVIORAL|Chart-Stimulated Recall|
58440229|NCT02275741|BIOLOGICAL|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
58440230|NCT02462720|DRUG|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
58440231|NCT02462720|DEVICE|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
57738995|NCT02820623|BEHAVIORAL|Behavioral Rehearsal|
57738996|NCT00837863|DRUG|Somatropin|ALTU-238 0.3 mg/kg daily
57738997|NCT00837863|DRUG|Somatropin|ALTU-238 0.6 mg/kg daily
57738998|NCT00837863|DRUG|Somatropin|ALTU-238 0.9 mg/kg daily
57955457|NCT05272800|DEVICE|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
58108179|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
58108180|NCT01405885|BIOLOGICAL|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
58108181|NCT01405885|BIOLOGICAL|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
58311237|NCT03620162|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
58440232|NCT01331109|DRUG|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
58440233|NCT03101501|DRUG|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
58440234|NCT03101501|DEVICE|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
58440235|NCT02745808|BIOLOGICAL|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
58440236|NCT02745808|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
58440237|NCT05789563|OTHER|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
58440238|NCT05383716|DRUG|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
58440239|NCT03062293|DEVICE|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
58440240|NCT00420069|DEVICE|MRTX device|device for ventilation
57738999|NCT00837863|DRUG|Somatropin|Nutropin AQ 0.043 mg/kg daily
57955458|NCT05272800|OTHER|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
57955459|NCT02750540|DRUG|Tenofovir enema|
57955460|NCT02750540|OTHER|Saline enema|
57955461|NCT04156451|PROCEDURE|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
58440241|NCT04203004|PROCEDURE|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
58440242|NCT00325117|DRUG|Vildagliptin|
58311238|NCT03620162|BIOLOGICAL|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
58440243|NCT05695274|BEHAVIORAL|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
58440244|NCT00582998|PROCEDURE|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
58440245|NCT00582998|DEVICE|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
58440246|NCT02278861|DRUG|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
58440247|NCT02278861|DRUG|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
58440248|NCT02278861|DRUG|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
58440249|NCT02903498|DRUG|UFT|UFT 360mg/m2 qd po d1-14, q3w
58440250|NCT01907763|DRUG|SOTB07 200mg|
58311239|NCT03620162|BIOLOGICAL|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
58311240|NCT03620162|BIOLOGICAL|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
57955462|NCT04156451|PROCEDURE|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
58440251|NCT01907763|DRUG|SOTB07 400mg|
58440252|NCT01907763|DRUG|SOTB 200mg placebo|Placebo of SOTB07 200mg
57739000|NCT01667601|OTHER|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
57739001|NCT01667601|BEHAVIORAL|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
57955463|NCT00343174|DRUG|Ancrod|
57955464|NCT02264990|DRUG|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
58440253|NCT01907763|DRUG|SOTB 400mg placebo|Placebo of SOTB07 400mg
57739002|NCT01667601|BEHAVIORAL|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
57739003|NCT00243204|DRUG|talabostat mesylate|
57739004|NCT00243204|DRUG|docetaxel|
57955465|NCT02264990|DRUG|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
57955466|NCT02264990|DRUG|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
57955467|NCT02264990|DRUG|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
57955468|NCT02264990|DRUG|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
58311241|NCT03620162|BIOLOGICAL|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
58440254|NCT00939562|DRUG|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
58440255|NCT00939562|DRUG|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
58440256|NCT00004052|BIOLOGICAL|QS21|
57739005|NCT04459026|PROCEDURE|combination|instillation and infiltration of ropivacaine
57739006|NCT04459026|PROCEDURE|infiltration|local infiltration ropivacaine
57739007|NCT04459026|PROCEDURE|instillation|intraperitoneal ropivacaine instillation
57739008|NCT02549898|DRUG|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
58440257|NCT00004052|BIOLOGICAL|bcr-abl peptide vaccine|
58440258|NCT02134470|DRUG|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
58440259|NCT03492606|PROCEDURE|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
57739009|NCT02549898|DRUG|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
58311242|NCT03620162|BIOLOGICAL|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
58311243|NCT03620162|BIOLOGICAL|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
58440260|NCT02255084|BEHAVIORAL|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
58311244|NCT03620162|BIOLOGICAL|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
58311245|NCT03627676|PROCEDURE|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
58311246|NCT06215742|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
58311247|NCT06215742|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58311248|NCT02779985|DIETARY_SUPPLEMENT|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
58311249|NCT02779985|DIETARY_SUPPLEMENT|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
57739010|NCT02549898|OTHER|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
57739011|NCT02549898|OTHER|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
57955469|NCT04817111|DRUG|MIB-626|Two (2) 500 mg Tablets, By Mouth, Daily
57955470|NCT04854837|DRUG|Remdesivir|Remdesivir treatment
57955471|NCT01409135|DRUG|AGS-22M6E|IV Infusion
58440261|NCT02255084|BEHAVIORAL|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
58440262|NCT02813291|DEVICE|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
57955472|NCT01409135|DRUG|ASG-22CE|IV Infusion
57955473|NCT01290692|BIOLOGICAL|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
57955474|NCT04434391|OTHER|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
58311250|NCT03136198|OTHER|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours"
58311251|NCT03136198|OTHER|Usual Care|Patients will receive usual AHF care
58311252|NCT03136198|DRUG|Intravenous Loop Diuretic|IV loop diuretic
57955475|NCT03887897|PROCEDURE|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
57955476|NCT00092430|BIOLOGICAL|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
57955477|NCT01075555|DRUG|pravastatin sodium|
57955478|NCT01075555|DRUG|sorafenib tosylate|
58311253|NCT03136198|DRUG|Vasodilator|IV, topical, or SL Vasodilator
58311254|NCT03136198|DEVICE|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
58311255|NCT03603613|BEHAVIORAL|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
58311256|NCT03603613|BEHAVIORAL|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
58311257|NCT04053582|BEHAVIORAL|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
58440263|NCT02813291|DEVICE|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
57955479|NCT02213809|BEHAVIORAL|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
57955480|NCT02213809|BEHAVIORAL|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
58440264|NCT00513942|OTHER|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
58440265|NCT01698723|DRUG|Ribavirin|
58440266|NCT01698723|DRUG|Placebo|
58440267|NCT02630914|DEVICE|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
58440268|NCT05505006|DRUG|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
58440269|NCT05505006|DRUG|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
58440270|NCT05505006|DRUG|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
58440271|NCT03288636|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
58440272|NCT03288636|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
58440273|NCT03288636|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
58440274|NCT03288636|DRUG|Placebo|Placebo
58440275|NCT00001146|DRUG|Ethyl Eicosapentaenoic Acid|
58108182|NCT00612833|PROCEDURE|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
58108183|NCT05064488|DRUG|Evobrutinib|Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
58440276|NCT00001146|DRUG|OmegaBrite|
58440277|NCT05796492|DEVICE|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
58440278|NCT05796492|DEVICE|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
58440279|NCT02602158|DIETARY_SUPPLEMENT|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
58440280|NCT02602158|DIETARY_SUPPLEMENT|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
58440281|NCT04347629|BEHAVIORAL|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
58440282|NCT03419988|BEHAVIORAL|Exercise Intervention|24 sessions of aerobic exercise
57739012|NCT03777098|DEVICE|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
57739013|NCT04146714|OTHER|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
57739014|NCT04146714|OTHER|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
58440283|NCT01966913|DRUG|Bevacizumab|
58440284|NCT01966913|DRUG|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
57739015|NCT06230848|PROCEDURE|Multisensory Early Oral Administration of Human Milk (M-MILK)|M-MILK is implemented as droplets, at day 3 of life, after every hands-on care, and during the beginning of a full gavage feeding. The infant may be supportively positioned in bed, held skin-to-skin by caregiver, or held/cradled by nurse or caregiver. The nurse draws up 1 mL of milk into the 1-mL syringe from a prepared bottle or enteral feeding syringe. The nurse then proceeds to implement M-MILK while observing the infant's responses closely. The nurse talks to the infant with a soft calm voice while providing gentle touch throughout the intervention. The nurse begins M-MILK by first placing 1-2 drops of milk onto the infant's upper lip, allowing the infant to feel and smell the milk. The nurse gently strokes the infant's lips with a pacifier/swab or infant's fingers. M-MILK will be provided based on infants' responses and cues. M-MILK is concluded if the infant is no longer engaged or has finished the 1 mL of milk.
57739016|NCT02004782|DRUG|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
58440285|NCT00317304|BEHAVIORAL|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
58440286|NCT03081871|OTHER|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
58440287|NCT03081871|OTHER|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
58440288|NCT03081871|OTHER|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
58440289|NCT03456232|OTHER|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
58440290|NCT03456232|OTHER|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
58440291|NCT03865641|DEVICE|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
58108184|NCT05064488|DRUG|Digoxin|Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
58440292|NCT00656864|DRUG|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
58440293|NCT00656864|DRUG|Placebo|placebo
58440294|NCT00101985|DRUG|talnetant|
58440295|NCT04500886|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
58108185|NCT05064488|DRUG|Metformin|Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
58108186|NCT05064488|DRUG|Rosuvastatin|Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
58440296|NCT04500886|DRUG|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
58440297|NCT04332718|DEVICE|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
58440298|NCT01303601|DRUG|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
58311258|NCT04053582|BEHAVIORAL|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
58108187|NCT05064488|DRUG|Sumatriptan|Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
58311259|NCT02265835|OTHER|no intervention|no intervention
58311260|NCT05453721|PROCEDURE|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
58311261|NCT05453721|PROCEDURE|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
58440299|NCT01303601|DRUG|Starch|
58440300|NCT02272374|PROCEDURE|AVF creation|
58440301|NCT02272374|PROCEDURE|TCC placement|
58440302|NCT02272374|PROCEDURE|AVG creation|
58440303|NCT01838915|DIETARY_SUPPLEMENT|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
58440304|NCT01838915|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, 20 g.
58440305|NCT04003740|DEVICE|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
58440306|NCT06271889|DEVICE|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal \& Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
58440307|NCT01910415|DRUG|Lumacaftor|
58440308|NCT01910415|DRUG|Lumacaftor Placebo|
58440309|NCT01910415|DRUG|Ivacaftor|
58440310|NCT01910415|DRUG|Ivacaftor Placebo|
58440311|NCT01910415|DRUG|moxifloxacin hydrochloride|
58440312|NCT03840954|OTHER|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
58108188|NCT01996176|BEHAVIORAL|Intervention group|"The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
58440313|NCT01822262|PROCEDURE|minimally invasive cholecystolithotomy with gallbladder reservation|
58440314|NCT01822262|PROCEDURE|laparoscopic cholecystectomy|
58440315|NCT01916434|OTHER|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
58440316|NCT01916434|OTHER|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
58440317|NCT01916434|OTHER|No salmon|The placebo group will continue to consume their habitual diet.
58108189|NCT01996176|BEHAVIORAL|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
58108190|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period I)
58108191|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period II)
58108192|NCT04494178|OTHER|Placebo|Intervention period I
58440318|NCT05077332|DRUG|Famotidine|80 mg tablet, QID for 14 days
58440319|NCT05077332|DRUG|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
58440320|NCT05077332|OTHER|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
58440321|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
58440322|NCT01764555|DRUG|acetaminophen 2 g|
58311262|NCT06069388|PROCEDURE|diaphragm technique|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
58311263|NCT06069388|PROCEDURE|conventional therapy|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
58311264|NCT03629288|OTHER|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
58311265|NCT03629288|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
58311266|NCT03783065|DRUG|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
58311267|NCT03783065|PROCEDURE|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
58311268|NCT03783065|PROCEDURE|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
58311269|NCT05250232|OTHER|onlays conservative|Partial coverage of cusps with shoulder finish line
58311270|NCT05250232|OTHER|onlays conventional|all coverage of cusps as overlay with shoulder finish line
58311271|NCT00434434|DRUG|omalizumab|Aged Liquid; subcutaneous repeating dose
58311272|NCT00434434|DRUG|omalizumab|Lyophilized; subcutaneous repeating dose
58311273|NCT00434434|DRUG|placebo|Subcutaneous repeating dose
58311274|NCT05150574|BEHAVIORAL|Core Health Program|8-week structured stress management and health behaviour change program
58311275|NCT05150574|BEHAVIORAL|Daily resting HRV|Take regular HRV readings in the morning
58311276|NCT05150574|BEHAVIORAL|Momentary HRV feedback|Take regular HRV readings throughout the day when stressed and perform mindfulness activity
58311277|NCT05150574|BEHAVIORAL|Behavioural initiation coaching|15-minute health coaching session in first week of program to help participant set goals and create an action plan
58311278|NCT05150574|BEHAVIORAL|Practice with feedback coaching|15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
58311279|NCT05265572|BEHAVIORAL|Domestic Hygiene and household hygiene Intervention|A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
58311280|NCT00815152|BEHAVIORAL|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
57739017|NCT02004782|DRUG|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
58311281|NCT00815152|BEHAVIORAL|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
58311282|NCT04597437|DRUG|Zanamivir|Intravenous zanamivir
58311283|NCT04597437|OTHER|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
58311284|NCT01979432|OTHER|Cardiovascular evaluation|
58311285|NCT06354608|BEHAVIORAL|Audio Book Group|Audiobook will be applied during the entire IM injection procedure and until the end of the procedure. After the procedure is over, the children will be taken to the waiting area. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior, and the same nurse who is independent from the study, will independently rate the child's pain and fear level during the procedure.
58440323|NCT02816489|DEVICE|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
58440324|NCT02816489|DEVICE|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
58440325|NCT02746640|PROCEDURE|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
58440326|NCT00614146|DEVICE|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
58440327|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
58440328|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
58440329|NCT02444325|BEHAVIORAL|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
58440330|NCT05747183|PROCEDURE|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
58440331|NCT05747183|PROCEDURE|ProTaper Gold|Root canal preparation using ProTaper Gold files.
58440332|NCT05795192|DRUG|SB17170|Taking SB17170 orally once a day
58440333|NCT05795192|DRUG|Placebo|Taking Placebo orally once a day
58440334|NCT05848427|OTHER|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
57955481|NCT06177756|BEHAVIORAL|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
57955482|NCT06182332|OTHER|Electronic Health Record Review|Undergo medical record review
58440335|NCT05728268|DRUG|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
58440336|NCT01865448|DIETARY_SUPPLEMENT|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
58440337|NCT01865448|OTHER|Placebo|Patients in control group take daily 2 placebo capsule
58440338|NCT02898896|BIOLOGICAL|blood test|Additional 21 ml of blood will be collected
58440339|NCT02363959|DRUG|Hyperbaric Oxygen Therapy|2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
57955483|NCT06182332|OTHER|Internet-Based Intervention|Use AI algorithm
58108193|NCT04494178|OTHER|Placebo|Intervention period II
58440340|NCT02363959|PROCEDURE|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
57739018|NCT00054353|DRUG|fludarabine phosphate|Given IV
57739019|NCT00054353|DRUG|melphalan|Given IV
57739020|NCT00054353|RADIATION|total-body irradiation|Undergo TBI
58440341|NCT00839644|DEVICE|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
58440342|NCT00839644|DEVICE|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
58440343|NCT00839644|OTHER|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
58440344|NCT06371846|OTHER|Selected signals from Pacing System Analyzers|Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
58440345|NCT00630344|DRUG|RAD001|
58440346|NCT00630344|DRUG|Bicalutamide|
58440347|NCT01122693|DEVICE|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
58440348|NCT01122693|DEVICE|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
58440349|NCT03221842|DRUG|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
58440350|NCT03221842|DRUG|Placebo|Excipients of C1-INH plus albumin
58440351|NCT05962892|OTHER|No Intervention|No Intervention
58440352|NCT05615207|OTHER|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
58440353|NCT02219373|DRUG|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
58440354|NCT02219373|DRUG|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
58440355|NCT02219373|OTHER|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
58440356|NCT04248543|DEVICE|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
58108194|NCT04396483|PROCEDURE|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
58440357|NCT01351116|RADIATION|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
58440358|NCT01351116|RADIATION|EBR|EBR of 20 Gy in 5 daily fractions over one week
58440359|NCT05204030|OTHER|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
58440360|NCT05204030|OTHER|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
58440361|NCT05280353|OTHER|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
58440362|NCT03260296|OTHER|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
58440363|NCT00548145|DRUG|Pitavastatin|2 mg by orally/day Duration: 12 months
58311286|NCT06354608|DEVICE|Local Vibration Group|In the local vibration group, IM injection will be performed with a vibrating massage device. After the procedure is finished, the children will be taken to the waiting section. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior and the same nurse who is independent from the study will independently rate the pain and fear level of the child during the procedure.
58440364|NCT00548145|DRUG|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
58311287|NCT01824017|OTHER|Blood Draw|
58311288|NCT02690727|DRUG|RP6530|Single oral dose
58440365|NCT04057430|DEVICE|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
58440366|NCT04057430|DEVICE|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
58440367|NCT00506688|DRUG|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
58440368|NCT00506688|DRUG|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
58440369|NCT03747679|DRUG|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
57739021|NCT00054353|DRUG|mycophenolate mofetil|Given PO
57955484|NCT05813912|DRUG|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
58440370|NCT03747679|DRUG|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
58440371|NCT03747679|DRUG|Bosutinib Mannitol|Bosutinib mannitol solution
58440372|NCT03747679|DRUG|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
58440373|NCT03747679|DRUG|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
58440374|NCT03747679|DRUG|bosutinib taste low flavour|bosutinib solution low flavour
58440375|NCT03747679|DRUG|bosutinib high flavour|bosutinib solution high flavour
58440376|NCT03747679|DRUG|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
57739022|NCT00054353|DRUG|cyclosporine|Given PO
57739023|NCT00054353|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
58311289|NCT05342571|OTHER|Behavioral, Psychological or Informational Intervention|Participate in ABC session
58311290|NCT05342571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58440377|NCT03747679|DRUG|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
58440378|NCT03747679|DRUG|bosutinib capsules in water|sham comparator, bosutinb in water retest
58440379|NCT03747679|DRUG|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
57739024|NCT00054353|PROCEDURE|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
57739025|NCT00054353|OTHER|laboratory biomarker analysis|Correlative studies
57739026|NCT05136820|DEVICE|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
57739027|NCT05136820|DEVICE|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
57955485|NCT05813912|DRUG|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
57955486|NCT01258907|DRUG|MLDL1278A|Single intravenous dose
57955487|NCT01258907|DRUG|MLDL1278A|Repeating intravenous dose
57955488|NCT01258907|DRUG|placebo|Repeating intravenous dose
58440380|NCT03747679|DRUG|bosutinib capsules high sweet|Bosutinib capsules high sweet
58440381|NCT03747679|DRUG|bosutinib capsules low flavour|Bosutinib capsules low flavour
58440382|NCT03747679|DRUG|bosutinib capsules high flavour|bosutinib capsules in high flavour
58440383|NCT04231604|BEHAVIORAL|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
58440384|NCT04231604|BEHAVIORAL|Waiting list control|Control group placed on a twelve-week waiting list.
58440385|NCT04800237|DRUG|VQW-765|oral capsule
58440386|NCT04800237|DRUG|Placebo|oral capsule
57955489|NCT01258907|DRUG|statin, stable dose|Repeating oral dose
58108195|NCT04396483|PROCEDURE|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
58108196|NCT04711122|DRUG|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
58311291|NCT05342571|OTHER|Electronic Health Record Review|Medical records reviewed
58311292|NCT05342571|OTHER|Informational Intervention|Receive patient guidebook
58108197|NCT03472833|DRUG|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
58108198|NCT03472833|DRUG|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
58108199|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
58108200|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
58108201|NCT00384358|OTHER|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
58108202|NCT05334602|PROCEDURE|Addition of dermal fat graft as protection over bone graft|A barrier membrane
58108203|NCT02784860|DRUG|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
58108204|NCT02784860|DRUG|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
58440387|NCT00386243|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
58440388|NCT00386243|BEHAVIORAL|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
58440389|NCT00386243|DRUG|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
58440390|NCT00386243|DRUG|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
58108205|NCT00297479|BEHAVIORAL|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
57739028|NCT02836808|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
58108206|NCT00297479|DRUG|Nicotine|6 weeks of nicotine patch therapy
58108207|NCT00297479|BEHAVIORAL|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
58108208|NCT00297479|BEHAVIORAL|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
58108209|NCT04168762|OTHER|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
58108210|NCT05522517|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
58108211|NCT05522517|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
58108212|NCT01674842|RADIATION|Radiation Therapy|Once daily, Monday - Friday for six weeks
58108213|NCT01674842|DRUG|Cisplatin|Intravenously, once weekly for six weeks
58108214|NCT01281579|DRUG|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
58108215|NCT01281579|DRUG|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
58108216|NCT01281579|DRUG|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
58108217|NCT02204683|DRUG|Aflibercept|Intravitreal aflibercept
58108218|NCT01017029|DRUG|Everolimus|
58108219|NCT01017029|DRUG|Mycophenolate mofetil + Everolimus|
58108220|NCT04708405|OTHER|Observation|Follow up and observe under standard of care given
58440391|NCT00851279|DEVICE|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
57739029|NCT01205594|DEVICE|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
57739030|NCT00115700|DRUG|Cyclophosphamide|1000 mg/m2 I.V. on day 1
57739031|NCT00115700|RADIATION|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
58108221|NCT00004871|DRUG|azacitidine|
58108222|NCT00004871|DRUG|sodium phenylbutyrate|
58108223|NCT04826185|DRUG|IMB-1018972|Modified release (MR) oral tablet
58108224|NCT04826185|DRUG|Placebo|Matching oral tablet
58108225|NCT05784506|OTHER|Macronutrients|Three successive food tolerance tests (glucose, protein and fat) at one-week intervals.
58108226|NCT05784506|OTHER|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
58440392|NCT06363539|DRUG|Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION|steroid used for umblical granuloma
58440393|NCT06363539|DRUG|Silver Nitrate|silver nitrate used for treatment
58440394|NCT05747703|COMBINATION_PRODUCT|Ria Treatment Platform|combined medication, coaching, education, and monitoring
58440395|NCT03063281|OTHER|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
57739032|NCT00115700|DRUG|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
57739033|NCT00115700|DRUG|Prednisolone|50 mg/m2 orally daily for days 1 - 5
58108227|NCT06208761|OTHER|Triphala capsule supplementation and high-intensity interval training|Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
58108228|NCT06452823|PROCEDURE|Catheter Ablation|catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
58108229|NCT02589769|OTHER|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
58108230|NCT02589769|OTHER|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
58108231|NCT06120010|DEVICE|MRI|To detect prevalence of anatomical variants of dural sinuses by MRV
58108232|NCT05953285|OTHER|Sleep restriction|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
58108233|NCT02483481|DIAGNOSTIC_TEST|shear wave ultrasound elastography|shear wave ultrasound elastography
58108234|NCT05493033|PROCEDURE|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
58108235|NCT05493033|PROCEDURE|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
58108236|NCT00512187|OTHER|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
58311293|NCT05342571|OTHER|Survey Administration|Complete surveys
58108237|NCT05332626|DIETARY_SUPPLEMENT|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10\^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
58108238|NCT05332626|DIETARY_SUPPLEMENT|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
58108239|NCT00455533|DRUG|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
58440396|NCT03647644|DIAGNOSTIC_TEST|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
58440397|NCT04811495|OTHER|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
58440398|NCT06327828|DEVICE|Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)|Semi-automated computer-aided treatment based on a mathematical model
58440399|NCT06327828|PROCEDURE|Usual care|Guiding methimazole therapy based on the treating physician's decision
58440400|NCT05326867|DEVICE|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
58108240|NCT00455533|DRUG|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
57739034|NCT00115700|DRUG|Rituximab|375 mg/m2 IV Infusion day 1
57955490|NCT06087354|OTHER|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
57955491|NCT05008107|OTHER|Virtual reality|Using VR goggles to watch peri-operative instructional video.
57955492|NCT02919436|DRUG|Tamsulosin|Active drug
57955493|NCT02919436|DRUG|Placebo|Lactose-filled capsules identical to active drug
57955494|NCT04814394|DIAGNOSTIC_TEST|flowcytometry|The study of CD4,CD25,FOXP3 and PD-1 on peripheral blood sample
57955495|NCT06106464|OTHER|Aerobic exercise+6.5 h of prolonged sitting|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
57955496|NCT06106464|OTHER|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
57955497|NCT06106464|OTHER|Aerobic exercise+4 minutes of walking breaks every 1-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
57955498|NCT06106464|OTHER|Aerobic exercise+8 minutes of walking breaks every 2-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
57955499|NCT02981680|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
57955500|NCT02981680|PROCEDURE|sham-RIPC|
57955501|NCT03462407|BEHAVIORAL|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
57955502|NCT03462407|BEHAVIORAL|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
57955503|NCT05776862|DRUG|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
57955504|NCT05776862|OTHER|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
57955505|NCT04357821|DRUG|Combination Intervention|"1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34"
57955506|NCT03803098|DEVICE|reference measure|measure of a physiological parameter performed with the gold standard medical device
57955507|NCT03803098|DEVICE|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
57955508|NCT02037737|DRUG|Abatacept|
57955509|NCT04639180|DRUG|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
57955510|NCT04639180|DRUG|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
57955511|NCT05826756|OTHER|There are no interventions in this study. All participants complete online surveys.|There are no interventions in this study. All participants complete online surveys.
57955512|NCT01391507|DRUG|0.9 % sodium chloride|Monthly intravenous injection for 6 months
57955513|NCT01391507|DRUG|COR-1|Monthly intravenous injection for 6 months
58108241|NCT00455533|DRUG|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
58108242|NCT00455533|DRUG|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
58108243|NCT00360867|DRUG|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
58108244|NCT03615079|BEHAVIORAL|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
58311294|NCT05841511|BEHAVIORAL|"Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version"|"The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program."
58440401|NCT05326867|DEVICE|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
58440402|NCT04367246|OTHER|No Intervention|No intervention is assigned.
58311295|NCT00169299|DRUG|Black cohosh|
58311296|NCT00169299|DRUG|Multibotanical preparation|
58311297|NCT00169299|DRUG|Multibotanical preparation + dietary soy counseling|
58440403|NCT01347242|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
58440404|NCT02117180|OTHER|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
57955514|NCT01391507|DRUG|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
58311298|NCT00169299|DRUG|Conjugated equine estrogen +/- medroxyprogesterone acetate|
58311299|NCT05987800|DIAGNOSTIC_TEST|Titration procedure|"The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV."
58311300|NCT05987800|DIAGNOSTIC_TEST|Electrical impedance tomography|This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.
58311301|NCT05987800|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|"Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure."
58311302|NCT04337632|DRUG|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
58311303|NCT04337632|DRUG|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
58311304|NCT05569096|DIAGNOSTIC_TEST|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
58311305|NCT05899361|DEVICE|Electromagnetic Guided Laparoscopy|Standard Care
58311306|NCT05899361|DEVICE|Ultrasound|Standard Care
58311307|NCT02517281|PROCEDURE|Biopsy|
58311308|NCT05462574|OTHER|No Intervention|No Intervention
58440405|NCT02558777|OTHER|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
58440406|NCT05303818|DRUG|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
58440407|NCT03095729|OTHER|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
58440408|NCT02697318|DRUG|Timolol maleate 0.5% ophthalmic solution|
57739035|NCT04637412|OTHER|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
57955515|NCT01281566|DRUG|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
58108245|NCT01047085|PROCEDURE|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
58108246|NCT03003533|GENETIC|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
58108247|NCT04896359|DIETARY_SUPPLEMENT|Vitamin C|12.5 grams of ascorbic acid
58108248|NCT04896359|OTHER|Placebo|vehicle
58108249|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started
58440409|NCT03779048|BEHAVIORAL|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
58108250|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
58108251|NCT02340078|DEVICE|HA IDF II plus|
58108252|NCT02340078|DEVICE|HA IDF II|
58108253|NCT05322265|PROCEDURE|laparoscopic surgery for renal and adrenal diseases|type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
58108254|NCT02330250|OTHER|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
58108255|NCT02330250|OTHER|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
58108256|NCT05798858|DIAGNOSTIC_TEST|NIPT|universal nipt in group a, NIPT for intermediate risk in Group B
58108257|NCT04093726|OTHER|lollipop|chewing lollipop for 20min
58108258|NCT00875368|DRUG|maraviroc|maraviroc dose dependent on co-medication
58108259|NCT00875368|DRUG|Placebo|Placebo drug
58108260|NCT01298596|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
58108261|NCT01298596|PROCEDURE|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
58108262|NCT03974984|PROCEDURE|Colon Resection|All patients undergo laparoscopic colon cancer resection.
58311309|NCT02576899|BEHAVIORAL|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
58311310|NCT02576899|BEHAVIORAL|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
58311311|NCT03693196|OTHER|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
58440410|NCT03779048|DRUG|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
58440411|NCT03779048|DRUG|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
57955516|NCT01281566|DRUG|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
58440412|NCT02799498|DEVICE|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
58440413|NCT02799498|OTHER|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
58440414|NCT02799498|DRUG|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
57739036|NCT00944138|BEHAVIORAL|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
57955517|NCT04753073|PROCEDURE|Non-invasive physical plasma|Treatment with non invasive physical low-temperature plasma
58108263|NCT03974984|PROCEDURE|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
58108264|NCT03974984|DRUG|NSAID|NSAID administered according to standard operating procedure postoperatively
58108265|NCT00469534|PROCEDURE|IMRT|
58108266|NCT00606879|DRUG|SGX523 Capsules|This is a dose escalation study
58108267|NCT01410695|DRUG|masitinib 3 mg|
58108268|NCT01410695|DRUG|masitinib 6.0 mg|
58108269|NCT01410695|DRUG|methotrexate|
58108270|NCT01410695|DRUG|Placebo (methotrexate)|
58108271|NCT01410695|DRUG|Placebo (masitinib)|
58108272|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
58108273|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
58108274|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
58108275|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
58108276|NCT02437890|BIOLOGICAL|ALX-0061|
58108277|NCT02437890|BIOLOGICAL|Placebo|
58108278|NCT01561118|OTHER|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
58108279|NCT06110585|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
57739037|NCT04298138|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
57739038|NCT01383733|DRUG|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
58108280|NCT06110585|PROCEDURE|Sham|A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
58108281|NCT01823315|DRUG|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
58108282|NCT01823315|DRUG|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, \>4h)
58108283|NCT01823315|BIOLOGICAL|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
58108284|NCT03953781|DRUG|Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males|
58108285|NCT03953781|DRUG|Effect of levetiracetam on epileptic males reproductive function|
58108286|NCT00240084|DRUG|nesiritide (Natrecor(TM))|administration of IV nesiritide
58108287|NCT05514028|OTHER|Salivary samples|"For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)"
58108288|NCT03101293|DRUG|TAK-831|TAK-831 film-coated tablet.
57739039|NCT04075123|OTHER|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
57739040|NCT03066336|DEVICE|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
57739041|NCT05110092|BEHAVIORAL|leg resistance combined with breathing exercise training|The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
57739042|NCT01090453|BIOLOGICAL|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
57739043|NCT01090453|BIOLOGICAL|Prevenar 13®|3 co-administered doses
57739044|NCT01090453|BIOLOGICAL|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
57739045|NCT01090453|BIOLOGICAL|Menjugate®|3 co-administered doses
57739046|NCT01090453|BIOLOGICAL|Rotarix™|Oral, two doses
57955518|NCT05479500|OTHER|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
57955519|NCT05479500|OTHER|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
58108289|NCT05928728|DRUG|Colchicine|Colchicine 0.5 mg once daily
58108290|NCT05928728|DRUG|Placebo|Placebo once daily
58108291|NCT01272193|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
58108292|NCT01272193|DRUG|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
58108293|NCT05896332|DEVICE|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
58108294|NCT04681274|DEVICE|Image features extraction and clustering|"The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures."
57955520|NCT05841043|DRUG|SHR8028 eye drops|SHR8028 eye drops
57955521|NCT05841043|DRUG|Vehicle eye drops.|Vehicle eye drops.
57955522|NCT03954535|BEHAVIORAL|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
58108295|NCT04681274|DEVICE|Phenotype signature database building|Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
58108296|NCT00615771|PROCEDURE|Day 3 embryo transfer|Standard of care
58108297|NCT00615771|PROCEDURE|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
58108298|NCT01114542|DRUG|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
58108299|NCT01114542|DRUG|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
58108300|NCT04246190|DRUG|CKD-501 and D759|Reference drug, CKD-501 1T and D759 1T, QD, PO
58108301|NCT04246190|DRUG|CKD-396|Reference drug, CKD-396 1T, QD, PO
58108302|NCT01377233|DRUG|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
58108303|NCT01377233|DRUG|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
58108304|NCT01377233|DRUG|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
58108305|NCT01377233|DRUG|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
58108306|NCT01377233|DRUG|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
58108307|NCT04058678|DRUG|Danazol/Placebo|This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
58108308|NCT04058678|OTHER|Without intervention|Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
58108309|NCT03351218|BEHAVIORAL|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
58108310|NCT02348619|DRUG|JZP-110|
58311312|NCT03693196|OTHER|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
58440415|NCT01258023|BIOLOGICAL|Fluad 1x|"15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
58440416|NCT06422013|DIETARY_SUPPLEMENT|GTB1|oral administration of GTB1 powder packet once daily
58440417|NCT06422013|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo powder packet once daily
58440418|NCT05003258|DEVICE|Intravitreal injection of Dexamethasone implant|Intravitreal injection of Dexamethasone implant
58108311|NCT06547203|DRUG|Cetuximab|Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks
58108312|NCT06547203|DRUG|Toripalimab|Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
58108313|NCT06547203|DRUG|Irinotecan|Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
58108314|NCT01077349|PROCEDURE|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis \>1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).
58108315|NCT01077349|PROCEDURE|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine \> 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea \> 36 mmol/l OR~* Or life threatening hyperkalemia"
58108316|NCT01335178|BEHAVIORAL|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project \[parents.org.il\];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
58108317|NCT05319340|OTHER|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
58108318|NCT03551678|DEVICE|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
58108319|NCT06259929|DRUG|Abemaciclib 150 MG + Giredestrant 30 MG|Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
58108320|NCT01440478|DRUG|LY2140023|Administered orally
58108321|NCT01440478|DRUG|Ammonium chloride|Administered orally
58108322|NCT01440478|DRUG|Sodium bicarbonate|Administered orally
58108323|NCT05751083|OTHER|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises"
58108324|NCT05751083|OTHER|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down."
58108325|NCT02880163|DEVICE|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
58108326|NCT03809013|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
58108327|NCT03426319|DIAGNOSTIC_TEST|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
58108328|NCT02162030|BEHAVIORAL|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
58108329|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
58108330|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
58108331|NCT02023502|OTHER|collection of urine and blood sample|
58108332|NCT05760378|DRUG|Famitinib|TKI
58108333|NCT05760378|DRUG|Camrelizumab|PD1 inhibitor
58311313|NCT03693196|OTHER|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
58108334|NCT05760378|DRUG|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
58108335|NCT01771861|OTHER|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
58108336|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Pre-Workout Supplement|"The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
58440419|NCT02434419|DEVICE|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
58440420|NCT02434419|OTHER|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
58440421|NCT03083301|OTHER|Medical Files data extraction|Medical Files data extraction
58440422|NCT05613829|OTHER|Burn surgery|Patients underwent burn surgery
58440423|NCT02638649|PROCEDURE|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
58440424|NCT02638649|DEVICE|ultrasound|
58440425|NCT02249611|DEVICE|Mobile physical activity promotion tool|"1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel"
58440426|NCT02249611|OTHER|Standard care|Counseling on lifestyles with health education material
58440427|NCT02774148|DRUG|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
58440428|NCT02774148|DRUG|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
58440429|NCT01402713|BIOLOGICAL|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
58440430|NCT01402713|BIOLOGICAL|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
58440431|NCT05512416|DRUG|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
58440432|NCT05854979|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
57739047|NCT02199262|OTHER|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
58440433|NCT00381693|DRUG|azacitidine|
58311314|NCT03693196|OTHER|Demographic|Age, gender and state of smoking were compared between groups.
58311315|NCT01951716|DRUG|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
58440434|NCT04483609|OTHER|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
58440435|NCT04483609|OTHER|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
58440436|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
58440437|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
58440438|NCT05377619|DRUG|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
58440439|NCT05377619|DRUG|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
57739048|NCT02199262|OTHER|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
57739049|NCT02199262|OTHER|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
58311316|NCT01951716|DRUG|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
58440440|NCT05377619|DRUG|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
58440441|NCT02309008|DRUG|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
58440442|NCT02309008|OTHER|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
58108337|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|"The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
58108338|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
58108339|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
58108340|NCT00946465|DRUG|Ramipril 10 Capsule (Sandoz)|
58108341|NCT00946465|DRUG|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
58440443|NCT04742114|DEVICE|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
58440444|NCT04742114|DEVICE|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
58440445|NCT05253885|DEVICE|Smartphone use|"* Smartphone addiction scale (short version) higher than 33~* Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159\*79\*9 mm."
57739050|NCT06670768|DIAGNOSTIC_TEST|Stress Dynamic MPI SPECT|BMI standardized radiopharmaceutical injection in pharmacological stress (dipyridamole or adenosine) is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
57739051|NCT06670768|DIAGNOSTIC_TEST|Stress Static MPI SPECT|30-60 minutes after stress dynamic SPECT imaging is performed, an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
57739052|NCT06670768|DIAGNOSTIC_TEST|Rest Dynamic MPI SPECT|3 hours after the stress phase, the rest phase is also recorded. A radiopharmaceutical injection with a three-fold dose at rest is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
57955523|NCT03954535|BEHAVIORAL|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
57739053|NCT06670768|DIAGNOSTIC_TEST|Rest Static MPI SPECT|30-60 minutes after rest, dynamic SPECT imaging is performed, and an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
57739054|NCT06670768|DIAGNOSTIC_TEST|Cardiac CT|Within 30 days of MPI SPECT imaging, a cardiac CT is performed for every patient, including a native calcium-scoring scan and a coronary CT angiography as a reference standard. A photon-counting detector CT is used.
57739055|NCT00126971|DRUG|chlorproguanil-dapsone|
57739056|NCT01440153|OTHER|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
57739057|NCT01440153|OTHER|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
57739058|NCT03320070|DRUG|Acthar Gel|Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
57739059|NCT03320070|DRUG|Placebo|Placebo gel for SC injection
57955524|NCT03571646|BEHAVIORAL|Capnostream 20 monitoring|Continuous monitoring on a general ward
57955525|NCT03571646|DEVICE|PM1000N-RR monitoring|Continuous monitoring on a general ward
58108342|NCT04655482|DRUG|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
58108343|NCT02625415|DEVICE|Vitamin B6 cream|Topical Vitamin B6 cream
58108344|NCT02625415|DEVICE|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
58440446|NCT04852198|PROCEDURE|OAGB|Simplified gastric bypass procedure
58440447|NCT04852198|PROCEDURE|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
58440448|NCT00242996|BIOLOGICAL|filgrastim|
57739060|NCT02247427|DEVICE|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
57955526|NCT03847675|BEHAVIORAL|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
57955527|NCT02173574|DRUG|DEB025|
57955528|NCT02173574|DRUG|EDP239|
58108345|NCT01559961|DRUG|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
57739061|NCT05080569|DRUG|Progesterone Vaginal Product|3dd200mg
57739062|NCT05080569|DRUG|Placebo|3dd1 vaginal capsule
57739063|NCT00881387|BIOLOGICAL|rituximab|Given IV
57739064|NCT00881387|DRUG|gemcitabine hydrochloride|Given IV
57739065|NCT00881387|DRUG|vinorelbine ditartrate|Given IV
58440449|NCT00242996|BIOLOGICAL|rituximab|
58440450|NCT00242996|BIOLOGICAL|sargramostim|
58440451|NCT00242996|DRUG|carmustine|
58440452|NCT00242996|DRUG|cyclophosphamide|
58108346|NCT00242450|DRUG|Metoclopramide|
58440453|NCT00242996|DRUG|etoposide|
57955529|NCT00716651|DRUG|mepolizumab|750 mg mepolizumab iv q4wk until week 32
57955530|NCT04772729|DRUG|Insulin faster aspart (Fiasp, Novo Nordisk)|"Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent."
57955531|NCT05454215|DEVICE|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
57955532|NCT05454215|DEVICE|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
57955533|NCT04002011|DRUG|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
57955534|NCT04002011|DRUG|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
57955535|NCT04002011|DRUG|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
57955536|NCT04002011|DRUG|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
57955537|NCT04002011|DRUG|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
57955538|NCT03165097|DRUG|ACT-709478|Hard gelatine capsules for oral administration
57955539|NCT03165097|DRUG|Placebo|Placebo capsules matching ACT-709478 capsules
57955540|NCT03165097|DRUG|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
57955541|NCT03165097|DRUG|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
57955542|NCT01556607|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
57955543|NCT01556607|DRUG|Placebo|
57955544|NCT03630328|DIETARY_SUPPLEMENT|Cogni.Q|AGN
57955545|NCT03630328|OTHER|Placebo|Placebo
57955546|NCT00896207|DRUG|Akt inhibitor SR13668|Given orally as a single dose
57955547|NCT02750033|DEVICE|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
57955548|NCT03889977|OTHER|Resistance exercise|2 major muscle groups (lower extremity, chest)
57955549|NCT03223545|BEHAVIORAL|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
57955550|NCT03223545|BEHAVIORAL|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
57955551|NCT04559958|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
57955552|NCT02282644|BIOLOGICAL|Bone marrow sampling|
57955553|NCT03607838|DRUG|SI-6603|SI-6603 will be injected into an intervertebral disc.
57955554|NCT03607838|DRUG|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
57955555|NCT05968573|OTHER|Video Format with Captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
57955556|NCT05968573|OTHER|Video Format without Captions|A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
57955557|NCT05968573|OTHER|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
57955558|NCT03173092|DRUG|Ixazomib|Ixazomib capsules.
58108347|NCT00652379|DRUG|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
58108348|NCT00652379|DRUG|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
58108349|NCT01098240|DRUG|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
58108350|NCT01098240|OTHER|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
58108351|NCT00355069|BEHAVIORAL|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
58440454|NCT00242996|PROCEDURE|adjuvant therapy|
58440455|NCT00242996|PROCEDURE|bone marrow ablation with stem cell support|
58440456|NCT00242996|PROCEDURE|peripheral blood stem cell transplantation|
58108352|NCT04590469|OTHER|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
58108353|NCT03047954|DRUG|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
58311317|NCT01951716|DRUG|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
58311318|NCT01951716|DRUG|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
58311319|NCT01951716|DRUG|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
58440457|NCT04119674|DRUG|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
58440458|NCT04119674|DRUG|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
58440459|NCT04119674|RADIATION|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
58108354|NCT03047954|DRUG|Placebo - Cap|Matching Placebo capsule administered
58108355|NCT05900609|DIETARY_SUPPLEMENT|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (\~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes per day + a snack. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
58440460|NCT04150094|OTHER|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
58440461|NCT04150094|OTHER|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
58440462|NCT02545764|OTHER|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
58440463|NCT05932472|DRUG|Aspirin|Aspirin at currently prescribed dose
58440464|NCT00189605|DEVICE|Perc-DLR/Perc-DLG|Device technique will be used per IFU
58440465|NCT00189605|DRUG|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
58440466|NCT03071393|DEVICE|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
58440467|NCT03071393|DEVICE|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
58440468|NCT01444885|DRUG|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
58440469|NCT01928901|DRUG|administration of Sinupret|
58440470|NCT01928901|DRUG|administration of Bronchipret|
58440471|NCT01928901|DRUG|administration of Sinupret Placebo|
57955559|NCT03173092|DRUG|Lenalidomide|Lenalidomide capsules.
57955560|NCT03173092|DRUG|Dexamethasone|Dexamethasone.
57955561|NCT01312246|DEVICE|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
57955562|NCT04362280|BEHAVIORAL|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
58440472|NCT01928901|DRUG|administration of Bronchipret Placebo|
58440473|NCT04406558|OTHER|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
58440474|NCT04829916|DRUG|RMC-035|Multiple dosing during 48 hours following cardiac surgery
58440475|NCT04829916|DRUG|Placebo|Multiple dosing during 48 hours following cardiac surgery
58440476|NCT05332132|DEVICE|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
58440477|NCT01818102|DEVICE|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
57955563|NCT04362280|BEHAVIORAL|TAU|PE class as usual led by PE teacher.
57955564|NCT00115154|DRUG|Aldara (imiquimod) cream, 5%|
57955565|NCT03339661|DRUG|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
57955566|NCT03339661|DRUG|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
57955567|NCT03339661|DRUG|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
57955568|NCT03754426|DEVICE|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
58440478|NCT01818102|DEVICE|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
58440479|NCT06169813|OTHER|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
58440480|NCT06169813|OTHER|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
57739066|NCT06167187|PROCEDURE|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
57739067|NCT06167187|DRUG|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
58108356|NCT05900609|DIETARY_SUPPLEMENT|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
58108357|NCT05900609|DIETARY_SUPPLEMENT|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
58108358|NCT01689974|DRUG|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
58108359|NCT01689974|RADIATION|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
58108360|NCT05491564|DEVICE|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
58108361|NCT06312085|DEVICE|Endofill|Endofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
57955569|NCT01765101|OTHER|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
57955570|NCT01765101|OTHER|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
58108362|NCT00955188|OTHER|computer-assisted intervention|
58108363|NCT00955188|OTHER|educational intervention|
58108364|NCT00955188|OTHER|medical chart review|
58108365|NCT01281878|DRUG|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
58108366|NCT02357550|DRUG|ketone|3-OHB is infused intravenously.
58108367|NCT02357550|DRUG|placebo|Saline infusion.
58108368|NCT05093179|PROCEDURE|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
58108369|NCT05093179|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
58108370|NCT01315483|OTHER|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
58108371|NCT05509634|DRUG|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
58108372|NCT05509634|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
58108373|NCT00245622|BIOLOGICAL|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
58108374|NCT00245622|BIOLOGICAL|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
58108375|NCT03558997|DRUG|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
58108376|NCT03558997|DRUG|Timothy Grass SCIT|Timothy grass extract was administered SC.
58108377|NCT03558997|DRUG|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
58108378|NCT03558997|DRUG|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
58108379|NCT01313390|DRUG|docetaxel|
58108380|NCT01313390|DRUG|everolimus|
58440481|NCT06169813|BEHAVIORAL|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
58440482|NCT00366691|DRUG|Acular LS|
58440483|NCT00366691|DRUG|Lotemax|
58440484|NCT00325390|DRUG|clopidogrel (SR25990C)|
58440485|NCT06393166|DRUG|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
58440486|NCT03637478|BEHAVIORAL|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
58440487|NCT00629811|DRUG|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
58440488|NCT00629811|DRUG|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
58440489|NCT00032981|BEHAVIORAL|Behavior Therapy|
58440490|NCT01035281|DRUG|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
58440491|NCT05496296|DEVICE|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
58108381|NCT01313390|OTHER|laboratory biomarker analysis|
57955571|NCT04795557|DIETARY_SUPPLEMENT|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
57955572|NCT04795557|OTHER|Placebo oral solution|Excipients
58108382|NCT01313390|OTHER|pharmacological study|
58108383|NCT03244995|PROCEDURE|Mind-Body Intervention Procedure|Undergo CBMB program
58108384|NCT03244995|OTHER|Quality-of-Life Assessment|Ancillary studies
58108385|NCT03244995|OTHER|Questionnaire Administration|Ancillary studies
58108386|NCT03483181|DRUG|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
58440492|NCT04117529|OTHER|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
58440493|NCT05836883|BIOLOGICAL|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
58440494|NCT05836883|OTHER|Local injection of normal saline|Placebo
58440495|NCT05994027|BEHAVIORAL|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
58440496|NCT00637416|DRUG|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
58440497|NCT00637416|OTHER|Placebo|placebo taken by mouth daily for 3 months
57955573|NCT05275907|DRUG|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
57955574|NCT05275907|DRUG|Chlorthalidone|25mg capsule once daily for 6 weeks
58108387|NCT03483181|DRUG|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
58440498|NCT04306263|DIETARY_SUPPLEMENT|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
58440499|NCT04306263|DIETARY_SUPPLEMENT|Standard formula|Infants receiving a standard infant formula.
58108388|NCT04405193|DRUG|N-acetyl cysteine|Eligible patients will be randomised to receive N-acetylcysteine or placebo
58440500|NCT04306263|DIETARY_SUPPLEMENT|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
57955575|NCT01871974|DRUG|FK949E|oral
57955576|NCT02573363|DRUG|Cytarabine|Given per standard of care
57955577|NCT02573363|DRUG|Mitoxantrone Hydrochloride|Given per standard of care
57955578|NCT02573363|DRUG|Selinexor|Given PO
57955579|NCT00916357|DRUG|Humalog|
57955580|NCT00916357|DRUG|Humulin-R|
57955581|NCT00916357|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
57955582|NCT03730337|DRUG|ONO-7475|ONO-7475 specified dose on specified days
57955583|NCT03730337|DRUG|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
57955584|NCT04623983|DEVICE|bonding tray|Orthodontic bonding tray
57955585|NCT02014636|DRUG|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
57955586|NCT02014636|DRUG|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
57955587|NCT00633659|DRUG|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
57955588|NCT00633659|DRUG|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
57955589|NCT06108895|OTHER|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
57955590|NCT06108895|OTHER|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
57955591|NCT02858674|OTHER|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
57955592|NCT02858674|OTHER|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
57955593|NCT04083482|PROCEDURE|continous venovenous hemofiltraion|CVVH
57955594|NCT01815307|DRUG|Gemcitabine|1000mg/m2, day 1 every 2 weeks
57955595|NCT01815307|DRUG|S-1|80mg/m2/day, day 1-28, every 6 weeks
57955596|NCT01295216|BEHAVIORAL|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
57955597|NCT06437808|COMBINATION_PRODUCT|Training with Portable Force Plates Integration|This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.
57955598|NCT06437808|OTHER|Standard Training|This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
58108389|NCT04405193|DRUG|Placebo|Matching Placebo
58108390|NCT03793075|DRUG|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
58108391|NCT03793075|DRUG|Propofol|propofol 17 mcg /kg/min
58108392|NCT01458119|DRUG|migalastat hydrochloride|Oral capsule QOD
58108393|NCT03437460|DRUG|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
58440501|NCT02779790|OTHER|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
58440502|NCT05210387|OTHER|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
58440503|NCT05076890|DIETARY_SUPPLEMENT|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
58440504|NCT05076890|DIETARY_SUPPLEMENT|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
58440505|NCT02034838|DRUG|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
58440506|NCT03614325|OTHER|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
58440507|NCT06583629|BEHAVIORAL|Emotional Freedom Technique|EFT is a self-help technique that incorporates conscious awareness of thoughts and feelings with a gentle touch involving tapping with fingertips on acupuncture/acupressure points on the face, hands, and body. EFT also helps relieve primary physical and emotional symptoms. Gary Craig created EFT, which involved lightly tapping on the body on 12 acupressure sites (also known as acupoints). This acupoints are situated along the body's meridians, or virtual energy channels
58108394|NCT03437460|DIETARY_SUPPLEMENT|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
58440508|NCT04371965|DRUG|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
58440509|NCT01991522|BEHAVIORAL|Curriculum Group|
57955599|NCT04269226|PROCEDURE|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
57955600|NCT04269226|PROCEDURE|No recruitment maneuver|Usual ventilation procedures will be applied.
57955601|NCT05175833|COMBINATION_PRODUCT|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
57955602|NCT05175833|OTHER|Oral placebo|Oral gel containing placebo
58108395|NCT03338049|DEVICE|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
58440510|NCT01991522|BEHAVIORAL|Self-directed learning group|
58440511|NCT06279832|OTHER|trascriptomic profiling|The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
58440512|NCT02945514|OTHER|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
58440513|NCT00196144|DEVICE|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
58440514|NCT00196144|DEVICE|Nominal PVAB|nominal pacemaker settings
58440515|NCT03235947|DRUG|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
58440516|NCT03235947|DRUG|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
58440517|NCT03235947|DRUG|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
58440518|NCT02289794|BIOLOGICAL|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
57739068|NCT05922358|COMBINATION_PRODUCT|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours."
57739069|NCT03734627|DRUG|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
58311320|NCT01951716|DRUG|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
58440519|NCT02289794|BIOLOGICAL|Placebo|Single dose, intramuscular injection (0.5 mL)
58440520|NCT03887234|PROCEDURE|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
58440521|NCT06155461|PROCEDURE|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
58440522|NCT04712708|DEVICE|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
58440523|NCT04712708|OTHER|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
58440524|NCT05950984|OTHER|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
58440525|NCT04383327|BEHAVIORAL|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers and PTAs (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training before the 1st school term. They will also receive 8 sessions (12 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
58440526|NCT04383327|BEHAVIORAL|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including a half-day workshop for common stress management and a half-day for burnout management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group in each school, a total 15 hours of coaching).
58440527|NCT01771796|BEHAVIORAL|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
58440528|NCT02277925|OTHER|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
58440529|NCT02277925|OTHER|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
58440530|NCT01411956|OTHER|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
58440531|NCT01411956|OTHER|Placebo video|The control group watched a 25-minute patient education video on depression.
57955603|NCT06194890|OTHER|Distraction technique with comedy video|Women in the intervention group will watch an average of 6 minutes of comedy videos during the active phase, transition phase and latent phase of labor.
58440532|NCT03325842|DIAGNOSTIC_TEST|ASKp|30 items questionnaire
58440533|NCT05643950|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
58440534|NCT05643950|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
58440535|NCT05137769|BEHAVIORAL|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
58440536|NCT00001894|PROCEDURE|pacemaker implantation|
58440537|NCT00001894|PROCEDURE|percutaneous transluminal septal ablation (PTSA)|
58440538|NCT04680429|DRUG|RP7214|Participants will receive single and multiple ascending doses of RP7214
57739070|NCT03734627|DRUG|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
58440539|NCT04680429|DRUG|Placebo|Participants will receive single and multiple ascending doses of matching placebo
58440540|NCT02569684|DIETARY_SUPPLEMENT|Prebiotic fibers: oligofructose and inulin|
58440541|NCT02569684|DIETARY_SUPPLEMENT|Maltodextrin|
58440542|NCT00244101|DRUG|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
58440543|NCT00244101|DEVICE|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
58440544|NCT00244101|DRUG|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
58440545|NCT01663012|DRUG|Etirinotecan pegol|
58440546|NCT00479856|DRUG|Lapatinib|Small molecule tyrosine kinase inhibitor
58440547|NCT00479856|DRUG|Capecitabine|Chemotherapy
58440548|NCT00479856|DRUG|Docetaxel|Chemotherapy
57739071|NCT03734627|DRUG|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
57739072|NCT03734627|DRUG|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
57739073|NCT03734627|DIAGNOSTIC_TEST|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
58440549|NCT00479856|DRUG|nab-Paclitaxel|Chemotherapy
58440550|NCT02524158|BEHAVIORAL|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
58440551|NCT06356051|DEVICE|Echocardiography|cardiovascular evaluation
58440552|NCT00695526|DIETARY_SUPPLEMENT|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
58440553|NCT04610398|DRUG|Dexamethasone 4mg|s. arm/group description
58440554|NCT04610398|DRUG|NaCl 0.9%|s. arm/group description
58440555|NCT03020706|DRUG|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
57739074|NCT01003899|DRUG|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
57739075|NCT01043770|BEHAVIORAL|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
57739076|NCT02212704|OTHER|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
58440556|NCT01359943|BIOLOGICAL|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
58440557|NCT01359943|DRUG|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
58440558|NCT05345275|OTHER|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
58440559|NCT02287467|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
58440560|NCT02287467|BIOLOGICAL|Placebo for IVIG|Administered IV as 500 mL of normal saline
58440561|NCT05921175|DEVICE|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
58440562|NCT05921175|DEVICE|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
58440563|NCT02898402|PROCEDURE|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
58440564|NCT05921838|OTHER||
58440565|NCT03112655|DIAGNOSTIC_TEST|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
58440566|NCT02465372|BEHAVIORAL|CSPAP|Comprehensive School Physical Activity Program.
58440567|NCT01406977|DRUG|BPS804|
58440568|NCT03019094|DEVICE|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
58440569|NCT02474602|DEVICE|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
58440570|NCT03963843|BEHAVIORAL|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
58440571|NCT03963843|OTHER|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
58440572|NCT00390650|DRUG|Saredutant|
58440573|NCT03255551|DRUG|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
58440574|NCT04717817|DEVICE|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
58440575|NCT04717817|OTHER|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
58440576|NCT00812773|DRUG|GSK2190915|Investigational Product
58440577|NCT05377138|OTHER|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
58440578|NCT01900587|DRUG|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
58440579|NCT01900587|DRUG|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
58440580|NCT02540070|PROCEDURE|Periarticular|
58440581|NCT02540070|PROCEDURE|Motor free|
58440582|NCT02540070|PROCEDURE|Motor free with dex|
58440583|NCT02540070|DRUG|Ropivacaine|
58440584|NCT02540070|DRUG|epinephrine|
58440585|NCT02540070|DRUG|morphine|
58440586|NCT02540070|DRUG|Ketorolac|
58440587|NCT02540070|DRUG|Dexmedetomidine|
58440588|NCT02540070|DRUG|saline|
58440589|NCT04373005|DIAGNOSTIC_TEST|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
58440590|NCT01949090|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
58440591|NCT01949090|BIOLOGICAL|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
58440592|NCT02035917|DEVICE|Locking plate|
58440593|NCT02035917|DEVICE|Non-Locking plate|
58440594|NCT01817439|DRUG|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
58440595|NCT04916236|DRUG|RMC-4630|"* SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week"
58440596|NCT04916236|DRUG|LY3214996|"* ERK inhibitor~* Powder in capsule~* Administered every day"
58440597|NCT00764062|DRUG|Amoxicillin|Amoxicillin :drug
58440598|NCT04269356|DRUG|BMS-986256|Specified dose on specified days
58440599|NCT04269356|DRUG|Milk of magnesia|Specified dose on specified days
58440600|NCT02692755|DRUG|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
58440601|NCT00730080|DRUG|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
58440602|NCT01103570|PROCEDURE|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
58440603|NCT01103570|PROCEDURE|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
58440604|NCT05370053|DIAGNOSTIC_TEST|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
58440605|NCT01431053|DRUG|aspirin|Aspirin 50mg po daily
58440606|NCT01431053|DRUG|Exemestane|Exemestane 25mg po daily
58440607|NCT04270539|BEHAVIORAL|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
58440608|NCT02095080|DIETARY_SUPPLEMENT|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
58440609|NCT04308629|OTHER|Transcranial direct current stimulation|
58440610|NCT02416154|PROCEDURE|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
58440611|NCT04876352|OTHER|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
58440612|NCT04876352|OTHER|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
58440613|NCT04876352|OTHER|No intervention|Only baseline evaluations, without longitudinal assessment
58440614|NCT02779413|DRUG|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
57739077|NCT02212704|OTHER|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
57739078|NCT02212704|OTHER|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
58440615|NCT00772265|BIOLOGICAL|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
58440616|NCT00772265|BIOLOGICAL|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
58440617|NCT00558298|DRUG|risperidone|
58440618|NCT00079716|DRUG|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
58440619|NCT02338050|BIOLOGICAL|Moxetumomab Pasudotox|
58440620|NCT00005084|PROCEDURE|conventional surgery|
58440621|NCT00005084|PROCEDURE|magnetic resonance spectroscopic imaging|
58440622|NCT00005084|RADIATION|radiation therapy|
58108396|NCT03542318|OTHER|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
58108397|NCT00001633|PROCEDURE|Coronary magnetic resonance angiography imaging|
57769631|NCT03875079|DRUG|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
58108398|NCT05466513|OTHER|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
58108399|NCT02431481|DRUG|LEE011|400 mg
58108400|NCT03940326|DRUG|Levetiracetam|Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
58440623|NCT04270084|BEHAVIORAL|Alive-Family|All participants receive lifestyle modification through use of m-health app
58108401|NCT03940326|DRUG|Valproate|Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
58440624|NCT04607746|DEVICE|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
58440625|NCT05746156|DIAGNOSTIC_TEST|lymphatic mapping|"1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
58440626|NCT03371784|DRUG|Hydrocortisone|I.V. administration
58440627|NCT03371784|DRUG|Placebo|I.V. administration
58440628|NCT01824355|DEVICE|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
58440629|NCT01458418|DRUG|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
58440630|NCT01458418|OTHER|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
58440631|NCT01458418|DRUG|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
58440632|NCT05844241|OTHER|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
58440633|NCT05844241|OTHER|Audiobooks|Listening to audiobooks for 30 minutes
58440634|NCT00546000|DRUG|Fluticasone propionate 0.05% lotion|Daily applications
58440635|NCT01651325|DRUG|Isavuconazole|oral
58440636|NCT01651325|DRUG|dextromethorphan|oral
58440637|NCT03325595|DRUG|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
58440638|NCT03325595|DRUG|Placebo|Matching capsule placebo
58440639|NCT03466853|DIAGNOSTIC_TEST|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of \<25 is considered as fetal malnutrition.
58440640|NCT03466853|DIAGNOSTIC_TEST|Anthropometric indices|weight, length and head circumference
58440641|NCT03466853|DIAGNOSTIC_TEST|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI \<2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI \<11.2 kg/m2 is considered as malnutrition)
58440642|NCT06418490|DEVICE|Three-dimensional visualization technology|Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step. The software is called Abdominal Medical Image 3D Visualization Software (MI-3DVS, software copyright registration number: 2008SR18798).The AR-ANS (Software Copyright No.: 2018SR840555) is an intraoperative navigation system that integrates three-dimensional visualization technology.This modification provides visual guidance for surgeons when ligating or protecting critical vascular tissues during surgery.
58440643|NCT04345679|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
58440644|NCT02889211|BEHAVIORAL|Gambling Task|
58440645|NCT01996280|BEHAVIORAL|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
58440646|NCT01996280|BEHAVIORAL|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
58440647|NCT01770236|DRUG|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
58440648|NCT04787978|OTHER|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
58440649|NCT03084835|BEHAVIORAL|Usual Care|Brief cessation counseling
58440650|NCT03084835|BEHAVIORAL|WEB+TXT|Access to Become an Ex website plus text messaging
58440651|NCT03084835|BEHAVIORAL|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
57739079|NCT05247996|PROCEDURE|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
58440652|NCT00048347|DRUG|AVONEX|30µg IM every week for 12 weeks
58440653|NCT00904904|DRUG|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
58440654|NCT00904904|DRUG|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
58440655|NCT00055692|BIOLOGICAL|bevacizumab|Given orally
58440656|NCT02454478|DRUG|Lenvatinib|
58440657|NCT02454478|DRUG|Everolimus|
58440658|NCT04382885|DRUG|Cariprazine|Oral Solution
58440659|NCT01670721|DRUG|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
58440660|NCT01670721|DRUG|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
58440661|NCT01670721|DRUG|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
57955604|NCT03260387|PROCEDURE|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
57955605|NCT00176995|DRUG|15% Eflornithine Hdyrochloride|
58440662|NCT01670721|DRUG|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
57739080|NCT05247996|DRUG|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
57739081|NCT05247996|DRUG|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
58440663|NCT02681471|OTHER|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
58440664|NCT02681471|OTHER|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
57955606|NCT00225472|DEVICE|Modified Viaspan|
58440665|NCT02681471|DEVICE|monopolar resectoscope|
58440666|NCT02681471|DEVICE|bipolar resectoscope TURis|
57955607|NCT06501404|DIETARY_SUPPLEMENT|High dose group|A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
58440667|NCT03529981|OTHER|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
58440668|NCT03529981|OTHER|no active intervention|No intervention will be administered
58440669|NCT05798221|BEHAVIORAL|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
58440670|NCT05798221|OTHER|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
58440671|NCT06122038|DIETARY_SUPPLEMENT|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
57739082|NCT05247996|PROCEDURE|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
58440672|NCT06122038|DIETARY_SUPPLEMENT|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
58108402|NCT03759769|OTHER|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
57739083|NCT04838262|OTHER|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
57739084|NCT00001533|DRUG|cyclosporine|
58108403|NCT03759769|OTHER|Video game|'Kart' driving video game
58108404|NCT06355960|DRUG|GROUP Dexmedetomidine|Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
58108405|NCT06355960|DRUG|GROUP B|Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
58108406|NCT06355960|DRUG|GROUP C|Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
58440673|NCT04322617|DRUG|Anlotinib plus the same Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
58108407|NCT02868281|DRUG|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
58108408|NCT02868281|DRUG|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
58108409|NCT01956227|BEHAVIORAL|Home-based exercise|exercise to look at balance and lower limb strength record in diary
58108410|NCT01956227|BEHAVIORAL|Education|sessions to discuss self-management ideas to modify risk of falling
58108411|NCT01956227|BEHAVIORAL|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
58108412|NCT02264457|DEVICE|T-flex Aspheric Toric IOL|
58108413|NCT02264457|DEVICE|AT TORBI toric IOL|
58440674|NCT04322617|DRUG|Anlotinib plus the new Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
58440675|NCT04322617|DRUG|Anlotinib|Anlotinib, 8mg po qd, D1-D14 every 21days.
58440676|NCT02240511|DIETARY_SUPPLEMENT|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
58440677|NCT02240511|OTHER|Resistance Exercise|
58440678|NCT02770989|PROCEDURE|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
58440679|NCT01361893|OTHER|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
58440680|NCT05156957|OTHER|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
58440681|NCT00253123|DRUG|risperidone|
58440682|NCT04220944|DRUG|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
58440683|NCT04220944|PROCEDURE|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
58440684|NCT04220944|PROCEDURE|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
58440685|NCT02240771|PROCEDURE|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
58440686|NCT02240771|DRUG|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days"
58440687|NCT03917095|DEVICE|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
58440688|NCT03917095|DRUG|Glutamine|The medications were infused into the colon
58440689|NCT03917095|DRUG|Mesalazine|The medications were infused into the colon
58440690|NCT02381015|GENETIC|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
58108414|NCT03853083|DEVICE|Hypoxi Equipment|Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
58440691|NCT02381015|GENETIC|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
58440692|NCT02381015|BEHAVIORAL|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
58440693|NCT02381015|BEHAVIORAL|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
58440694|NCT03030469|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
58440695|NCT04859426|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
58108415|NCT03853083|DEVICE|Recumbent Bicycle|Recumbent bike is a piece of exercise equipment used as the comparison group
57769632|NCT03875079|DRUG|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
58440696|NCT01426022|OTHER|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
58440697|NCT01426022|BEHAVIORAL|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
57769633|NCT06546098|DRUG|Molgramostim nebulizer solution|Solution for inhalation
58108416|NCT03807882|OTHER|Bilateral M-ECT|Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
58108417|NCT03807882|DRUG|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
58440698|NCT02542826|OTHER|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
58440699|NCT04395690|PROCEDURE|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
58440700|NCT04521985|PROCEDURE|thoracolumbar kyphosis surgery|patients receiving surgery or not
58440701|NCT05017467|DRUG|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
58440702|NCT02618161|RADIATION|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
58440703|NCT02618161|RADIATION|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
58440704|NCT04499560|DIETARY_SUPPLEMENT|Supplement Drink|Superfoods based nutritional supplement
58440705|NCT00275067|DRUG|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
58440706|NCT00275067|DRUG|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
58440707|NCT00275067|RADIATION|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
58440708|NCT01096693|DRUG|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
58108418|NCT01722266|DRUG|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
58440709|NCT01096693|DRUG|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
58440710|NCT00089531|DRUG|VRC-HIVDNA016-00-VP|
58440711|NCT03127176|OTHER|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
58440712|NCT01687101|DRUG|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
58440713|NCT00051909|DRUG|LY451395|
58440714|NCT04370613|BEHAVIORAL|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
57739085|NCT01189916|PROCEDURE|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
57739086|NCT02010840|BEHAVIORAL|Psychoeducation program|
58108419|NCT01722266|DRUG|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
58440715|NCT03658733|DRUG|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
58440716|NCT03658733|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
58440717|NCT05081206|DRUG|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
58440718|NCT05081206|DRUG|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
58108420|NCT06363201|DIETARY_SUPPLEMENT|Ocoxin Oral solution|Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
58108421|NCT00472706|PROCEDURE|excision|excision 3 mm margin
58108422|NCT00472706|PROCEDURE|Photodynamic therapy|Photodynamic therapy
58108423|NCT01913873|OTHER|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
58108424|NCT03555890|DRUG|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
58108425|NCT03555890|DRUG|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
58108426|NCT04128878|DRUG|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
58108427|NCT04128878|DRUG|Dofetilide|Same as described above with sotalol.
58108428|NCT03197805|DIAGNOSTIC_TEST|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
58108429|NCT04949867|DRUG|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
58108430|NCT04949867|DEVICE|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
58108431|NCT04150783|PROCEDURE|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
58440719|NCT04137185|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection|rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
58108432|NCT05649631|DIETARY_SUPPLEMENT|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
57739087|NCT06722053|OTHER|virtual reality and digital education|Breastfeeding education through virtual reality and digital education
57739088|NCT06722053|OTHER|virtual reality and digital education and lemon scent|virtual reality and digital education and lemon scent inhalation
57739089|NCT03953092|DRUG|YG1699|YG1699 at Multiple Doses
57739090|NCT03953092|DRUG|Placebos|Placebos
57955608|NCT06501404|DIETARY_SUPPLEMENT|Low dose group|A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
57955609|NCT02369276|OTHER|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
57955610|NCT01359475|PROCEDURE|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
57955611|NCT04742088|DEVICE|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
57955612|NCT02881632|DEVICE|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
57955613|NCT02004080|OTHER|Intensive Care treatment|intensive care treatment
57955614|NCT00252057|BEHAVIORAL|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
57955615|NCT04403581|OTHER|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
57955616|NCT02189850|DRUG|BLI800 - Dose 1|BLI800 oral solution
57955617|NCT02189850|DRUG|BLI800 - Dose 2|BLI800 oral solution
57955618|NCT01857661|DEVICE|sound generator|hearing aid with an integrated sound generator
57955619|NCT01857661|DEVICE|hearing aids with only amplification|
57955620|NCT04411355|DIETARY_SUPPLEMENT|control by dietitian|
57955621|NCT04411355|OTHER|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
57955622|NCT04411355|BEHAVIORAL|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
57955623|NCT01372904|DRUG|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
57955624|NCT04697875|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
57955625|NCT04697875|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
57955626|NCT02666573|DEVICE|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
57955627|NCT02666573|OTHER|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
57955628|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
57955629|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
57955630|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
57955631|NCT04873752|BIOLOGICAL|UDI-001|2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
57955632|NCT04234711|PROCEDURE|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
57955633|NCT01146873|DRUG|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
57955634|NCT01146873|DRUG|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
57955635|NCT01146873|DRUG|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
57955636|NCT01146873|DRUG|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
58108433|NCT05489679|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
58108434|NCT01228396|DRUG|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
58108435|NCT04651283|OTHER|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
58108436|NCT04651283|OTHER|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
58108437|NCT06069765|OTHER|TUPEX|"This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks."
58108438|NCT02667496|DRUG|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
58108439|NCT02667496|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
58108440|NCT02667496|DRUG|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
58108441|NCT05881200|DEVICE|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
58108442|NCT01968681|PROCEDURE|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
58108443|NCT02888925|OTHER|Mooney test|
58108444|NCT02888925|OTHER|Benton Face Recognition test|
58108445|NCT02888925|OTHER|Face inversion effect test|
58108446|NCT02888925|OTHER|Face composite effect test|
58108447|NCT02888925|OTHER|Cambridge Face Memory Test|
57739091|NCT05962853|OTHER|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
57739092|NCT04666168|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
57739093|NCT04666168|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
57739094|NCT04666168|PROCEDURE|Leukapheresis|Leukapheresis
57739095|NCT03229369|PROCEDURE|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
58108448|NCT02888925|OTHER|Matching different view test|
57739096|NCT03229369|PROCEDURE|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
57739097|NCT04351867|DRUG|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
58108449|NCT02888925|OTHER|Memorizing and recognition of new faces test|
58108450|NCT02888925|OTHER|Memorizing and recognition of new objects test|
58108451|NCT02888925|OTHER|Recognition of celebrities and access to semantic information test|
58108452|NCT02888925|PROCEDURE|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
58108453|NCT03289637|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
58108454|NCT02775227|DRUG|Hydrocortisone|
58440720|NCT02773485|RADIATION|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
58440721|NCT02773485|DRUG|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
58440722|NCT00567359|DRUG|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
58440723|NCT04079816|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
57739098|NCT04351867|DRUG|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
57739099|NCT02468427|OTHER|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
57955637|NCT05138081|OTHER|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
58440724|NCT02728089|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
58440725|NCT04417335|BIOLOGICAL|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
58440726|NCT04417335|BIOLOGICAL|Placebo|0.9% NaCl
58440727|NCT05536687|DEVICE|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~* In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~* In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~* Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
58440728|NCT05322720|BIOLOGICAL|EOC202|EOC202 will be SC injection
58440729|NCT05322720|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
57739100|NCT02468427|OTHER|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
57739101|NCT00223860|DRUG|Human chorionic gonadotropin (hCG)|
57739102|NCT00223860|DRUG|Luteinizing hormone releasing hormone (LHRH)|
57739103|NCT05185310|PROCEDURE|Ablation|Ablation strategy during repeat AF ablation
57955638|NCT05138081|OTHER|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
57739104|NCT01667432|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
57739105|NCT01852539|DRUG|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
57739106|NCT01852539|DRUG|propofol|Propofol 2.0 mg/kg was administrated
57739107|NCT01852539|DEVICE|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
57955639|NCT06050044|DRUG|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
57955640|NCT06050044|DRUG|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
57955641|NCT00326807|DRUG|Naltrexone|
57955642|NCT01550562|DEVICE|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
57955643|NCT01069822|DRUG|AZD6765|IV solution
57955644|NCT01069822|DRUG|midazolam|
57955645|NCT01099852|OTHER|biological sample collection|blood sample collection urine sample cerebrospinal fluid sample
57955646|NCT01099852|OTHER|Quality of life Questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
57955647|NCT01099852|OTHER|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
57955648|NCT01099852|OTHER|Neuropathic Pain Questionnaire (DN4)|Questionnaire used during the follow up
57955649|NCT05346705|BEHAVIORAL|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
57955650|NCT03467464|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
57955651|NCT00316680|BIOLOGICAL|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
58311321|NCT04900311|DRUG|pyrotinib + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
58440730|NCT01354925|DRUG|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
58440731|NCT01354925|DRUG|Standard of care|Standard of care during Ramadan according to physicians decision
58440732|NCT04917965|OTHER|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
58311322|NCT04900311|DRUG|pertuzumab + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
58311323|NCT06369480|PROCEDURE|Resection/Ablation of tumor|Curative treatment
58311324|NCT06369480|PROCEDURE|Palliative chemotherapy|Chemotherapeutic medications
58311325|NCT06369480|PROCEDURE|Neoadjuvant chemotherapy|Chemotherapeutic medications after surgery
58311326|NCT06369480|PROCEDURE|Stereotatic radiotherapy|Radiotherapy
58311327|NCT06369480|PROCEDURE|Best supportive care|Symptomatic treatment, non-curative treatment
58311328|NCT03699592|BEHAVIORAL|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
58311329|NCT03587636|DRUG|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
58311330|NCT03587636|DRUG|Bupivacaine|interscalene block with bupivacaine
58311331|NCT02394756|DEVICE|Marketed Soft Contact lens|Replacement schedule every 2 weeks
58311332|NCT02394756|DEVICE|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
58311333|NCT02394756|DEVICE|Biofinity®|Replacement schedule every 4 weeks
58440733|NCT00274963|DRUG|bendamustine hydrochloride|
58440734|NCT00274963|DRUG|mitoxantrone hydrochloride|
58440735|NCT02674347|DRUG|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
58440736|NCT02674347|DRUG|Placebo|IV matching the Investigational drug
58108455|NCT02775227|DRUG|Pasireotide|
58440737|NCT03565016|OTHER|no interventional study|no interventional study
58440738|NCT03671304|DEVICE|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
58440739|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
57739108|NCT01990950|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
58108456|NCT04149899|DRUG|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
58108457|NCT04149899|DRUG|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
58311334|NCT03906864|OTHER|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
57739109|NCT06635681|DRUG|combined chemotherapy|"Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease."
57739110|NCT01834066|BIOLOGICAL|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
58108458|NCT04149899|DRUG|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
58108459|NCT04149899|DRUG|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
58108460|NCT04744896|DEVICE|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
58108461|NCT04744896|DEVICE|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
58311335|NCT04219189|OTHER|Vaping condition|Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
58311336|NCT04219189|OTHER|Control condition|Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
58311337|NCT01706328|DRUG|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
58311338|NCT01706328|DRUG|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
58311339|NCT01706328|DRUG|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
58440740|NCT01149720|DRUG|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
58108462|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
58108463|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.
58108464|NCT00899665|GENETIC|fluorescence in situ hybridization|
58108465|NCT00899665|GENETIC|microarray analysis|
58108466|NCT00899665|GENETIC|molecular diagnostic method|
58108467|NCT00899665|OTHER|immunohistochemistry staining method|
58108468|NCT00899665|OTHER|laboratory biomarker analysis|
57739111|NCT00209417|DRUG|Iodixanol 320-Arm 1|
57739112|NCT00209417|DRUG|Iopamidol 300-Arm 2|
57739113|NCT00794612|DRUG|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
58108469|NCT00899665|PROCEDURE|biopsy|
58108470|NCT00899665|PROCEDURE|immunoscintigraphy|
58311340|NCT01706328|DRUG|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
58311341|NCT01706328|DRUG|Salbutamol as needed|Salbutamol inhalation powder
58311342|NCT04524156|OTHER|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
58440741|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
58440742|NCT05564312|DEVICE|Transabdominal ultrasonographic guidance at embryo transfer.|During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
58440743|NCT00781833|DEVICE|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
57739114|NCT02372396|BEHAVIORAL|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
58311343|NCT00922584|DRUG|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
58108471|NCT02787226|DRUG|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
58108472|NCT02787226|DRUG|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
58108473|NCT00091182|DRUG|oxaliplatin|Given IV
58108474|NCT02739802|DRUG|Coppertone(BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
58108475|NCT02077192|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
58108476|NCT01917578|DEVICE|Ultrasound|"1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards."
58311344|NCT04287348|DRUG|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
58311345|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
58311346|NCT01100788|OTHER|Placebo|Treatment without scFOS fiber
58311347|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
58311348|NCT05627596|BEHAVIORAL|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
58311349|NCT05627596|DRUG|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
58311350|NCT05627596|DRUG|Nicotine lozenge|4mg nicotine lozenge
58311351|NCT04096690|DRUG|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
58311352|NCT04096690|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
58440744|NCT06267222|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
57739115|NCT02372396|BEHAVIORAL|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
57739116|NCT05283317|BIOLOGICAL|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
57739117|NCT06431282|OTHER|CO2 laser + HA|Probands will be treated with a CO2 laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
57739118|NCT06431282|OTHER|Thulium laser + HA|Probands will be treated with a thulium laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
58440745|NCT00273429|DRUG|timolol maleate 0.5%|
58440746|NCT00273429|DRUG|dorzolamide/timolol maleate fixed combination|
58440747|NCT00273429|DRUG|latanoprost 0.005%|
58440748|NCT00273429|DRUG|placebo|
57739119|NCT05216094|OTHER|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
57739120|NCT05216094|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
58440749|NCT06457711|DIETARY_SUPPLEMENT|Free diet Group (FDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
58440750|NCT06457711|DIETARY_SUPPLEMENT|Very low Calorie Ketogenic Diet Group (VLCKDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
58440751|NCT06457711|DIETARY_SUPPLEMENT|Intermittent Fasting Group (IFG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
58440752|NCT02410239|BIOLOGICAL|Mesenchymal Stem Cells|
58440753|NCT02016079|DIETARY_SUPPLEMENT|omega-3|200 ml fruit drink containing omega-3
58108477|NCT01917578|PROCEDURE|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
58108478|NCT01917578|PROCEDURE|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
58108479|NCT01917578|DEVICE|Pathologic Large Tissue Selected Table|"1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~2. Each piece of breast tissues by cutting with the table has 3mm thickness."
58108480|NCT01917578|DEVICE|Leica TP1020|"Procedure:~1. Alcohol 70 % 1h~2. Alcohol 80 % 1h~3. Alcohol 85 % 1h~4. Alcohol 90 % 1h~5. Alcohol 95 % 1h~6. Alcohol Ⅰ 100 % 1h~7. Alcohol Ⅱ 100 % 1h~8. Xylene Ⅰ 2h~9. Xylene Ⅱ 2h~10. Xylene Ⅲ 2h~11. Paraffin 6h~12. Paraffin 6h"
58108481|NCT01917578|DEVICE|Pathologic Large Tissue Embedded Table|"1. The table is made of brass .It is applying for a chinese patent.~2. The table can simultaneously embed 8 piece of breast tissues."
57739121|NCT01229098|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
58440754|NCT00666406|DRUG|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
58440755|NCT00666406|DRUG|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
58440756|NCT02191332|DRUG|Viramune|
57739122|NCT04876248|BIOLOGICAL|Belantamab Mafodotin|Given IV
57739123|NCT04876248|DRUG|Lenalidomide|Given PO
57739124|NCT04551378|OTHER|Quality-of-Life Assessment|Ancillary studies
57739125|NCT04551378|OTHER|Survey Administration|Complete survey
58108482|NCT01917578|DEVICE|Leica SM2000 R|Each of paraffin section has 4 um thickness.
57739126|NCT01250977|DRUG|Donepezil|
58311353|NCT04642222|BEHAVIORAL|APOLO-Teens web-based intervention|The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
57739127|NCT01250977|DRUG|Placebo|
57739128|NCT03664687|DRUG|Zoledronate|Administered intravenously (IV)
57739129|NCT01538550|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
57739130|NCT01538550|PROCEDURE|iFOBT|Biennial screening with iFOBT
58440757|NCT04104776|DRUG|CPI-0209|CPI-0209 alone
58440758|NCT03562312|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
58440759|NCT03562312|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
58440760|NCT03845647|PROCEDURE|contralateral central lymph node dissection|contralateral central lymph node dissection
58440761|NCT04152915|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
58440762|NCT04468841|DIAGNOSTIC_TEST|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
57739131|NCT04068753|DRUG|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
57739132|NCT04068753|DRUG|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
57739133|NCT01221987|PROCEDURE|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
58108483|NCT01917578|PROCEDURE|HE Stain|"Procedure:~1. Xylene Ⅰ 60℃ 15-20 minutes~2. Xylene Ⅱ 60℃ 15-20 minutes~3. Alcohol 100% Ⅰ 3-5 minutes~4. Alcohol 100% Ⅱ 3-5 minutes~5. Alcohol 95% Ⅱ 3-5 minutes~6. Alcohol 90% Ⅱ 3-5 minutes~7. Wash in running tap water for 3 minutes~8. Hematoxylin 5-10 minutes~9. Wash in running tap water for 3 minutes~10. Differentiate in 1% acid alcohol for 30 seconds~11. Wash in running tap water for 1 minute~12. Bluing in 0.2% ammonia water for 30-60 seconds~13. Wash in running tap water for 3 minutes~14. Counterstain in eosin Y solution for 30-60 seconds~15. Wash in running tap water for 1 minute~16. Alcohol 90% Ⅱ 2-3 minutes~17. Alcohol 95% Ⅱ 2-3 minutes~18. Alcohol 100% Ⅱ 3-5 minutes~19. Alcohol 100% Ⅱ 3-5 minutes~20. Xylene Ⅲ 5-10 minutes~21. Xylene Ⅳ 5-10 minutes~22. Mounting with neutral resin"
58108484|NCT01917578|DEVICE|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
57739134|NCT01221987|OTHER|Data collection|Questionnaire completion
58108485|NCT01917578|DEVICE|Epson V600|"1. Each slice that has been microscopically outlined is scanned by Epson V600.~2. Every image by scanning should be saved as JPG."
58108486|NCT01917578|DEVICE|MRI|"1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.~3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
58311354|NCT04642222|OTHER|Treatment as Usual for Pediatric Obesity|Treatment as Usual for pediatric obesity in portuguese public hospitals.
58440763|NCT04468841|OTHER|sample of saliva or fingernail clipping|collected in clinic one time
58440764|NCT04468841|DIAGNOSTIC_TEST|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
58440765|NCT04468841|DIAGNOSTIC_TEST|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
58440766|NCT05045300|PROCEDURE|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
58440767|NCT01740414|DRUG|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
57739135|NCT04778033|OTHER|Sperm collection|Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.
57739136|NCT02114593|BEHAVIORAL|Parent support program|Parent support program
57739137|NCT02570490|DRUG|sodium fusidate|
57739138|NCT02570490|DRUG|linezolid|
57739139|NCT05556681|DEVICE|BD™ Sirolimus Drug Coated Balloon Catheter percutaneous transluminal angioplasty|The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries. Eligible patients will undergo percutaneous transluminal angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
57739140|NCT03624101|DRUG|Trikafta|CFTR modulator
57739141|NCT03624101|DRUG|symdeko/Trikafta|CFTR modulator
57739142|NCT03624101|DRUG|Ivacaftor/Trikafta|CFTR modulator
57739143|NCT00423176|DRUG|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
57739144|NCT00423176|DRUG|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
57739145|NCT05022680|BEHAVIORAL|mhealth|the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
57739146|NCT05278455|BEHAVIORAL|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
57739147|NCT05260801|OTHER|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
58440768|NCT01740414|DRUG|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
58440769|NCT02744638|OTHER|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
58440770|NCT02744638|OTHER|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
58440771|NCT02744638|DRUG|Arilin|2 tablets Arilin 500mg for 7 days
58440772|NCT01427933|BIOLOGICAL|Ramucirumab (IMC-1121B)|Administered intravenously
58440773|NCT01427933|DRUG|Eribulin|Administered intravenously
58440774|NCT04141540|GENETIC|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
58440775|NCT00542607|DRUG|levocetirizine dihydrochloride|
58440776|NCT01651871|DRUG|S-555739 Dose 1|
58440777|NCT01651871|DRUG|S-555739 Dose 2|
58440778|NCT01651871|DRUG|Cetirizine HCl Dose 1|
58440779|NCT01651871|DRUG|S-555739 placebo|
58440780|NCT01651871|DRUG|Cetirizine HCl placebo|
58440781|NCT03420274|BEHAVIORAL|NEST|This is a point-of-care shared decision-making instrument.
57739148|NCT05260801|OTHER|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
57739149|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
57739150|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
57739151|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
57739152|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
57955652|NCT00105651|BEHAVIORAL|Combined nursing invention|
58311355|NCT01955811|DRUG|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
58311356|NCT02750995|BIOLOGICAL|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
58311357|NCT02750995|DRUG|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
58311358|NCT06055374|DRUG|BxC-I17e|Pharmaceutical form : solution for injection
58311359|NCT06055374|DRUG|Placebo|Pharmaceutical form : solution for injection
58311360|NCT03473990|OTHER|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
58311361|NCT03485586|DEVICE|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
58440782|NCT03420274|BEHAVIORAL|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
58440783|NCT04459520|BEHAVIORAL|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
58440784|NCT04459520|BEHAVIORAL|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
58440785|NCT04459520|BEHAVIORAL|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
58440786|NCT06311422|OTHER|resin nanoceramic block|Resin-based CAD/CAM materials
58440787|NCT06311422|OTHER|zirconia-reinforced lithium silicate|zirconia reinforced lithium silicate ceramic
58440788|NCT05645523|DRUG|Indocyanine Green|Given in to the vein (IV)
58440789|NCT00230841|DEVICE|nebulized humidity|
58440790|NCT02391363|BEHAVIORAL|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
58440791|NCT02391363|BEHAVIORAL|Information and referral|Resource counseling and follow-up for mental health and basic needs
58440792|NCT06189924|DIAGNOSTIC_TEST|Proteomic analysis of exhaled breath condensate|Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.
58440793|NCT00917761|DRUG|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
58440794|NCT00917761|DRUG|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
58440795|NCT00917761|DRUG|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
58440796|NCT01884896|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
58440797|NCT01884896|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
58440798|NCT03979859|DRUG|WCK 4873|
58440799|NCT03979859|DRUG|Placebo Oral Tablet|
58440800|NCT00038064|DRUG|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
58440801|NCT00038064|DRUG|rHuEPO|150 IU/kg TIW
58440802|NCT03893032|DRUG|Modafinil 200mg|single 200 mg dose
58440803|NCT03893032|DRUG|mixed amphetamine salts|single 10 mg dose
58440804|NCT03893032|DRUG|Placebo|single oral-administration placebo tablet
58440805|NCT01991236|BEHAVIORAL|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
58440806|NCT01991236|BEHAVIORAL|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
58440807|NCT00214513|BEHAVIORAL|Home-based exercise training|
57769634|NCT05782205|PROCEDURE|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
58440808|NCT04340544|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
58440809|NCT04340544|DRUG|Placebo|Placebo capsules
58440810|NCT05771740|DEVICE|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
58440811|NCT00880295|PROCEDURE|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
58440812|NCT00880295|PROCEDURE|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
58440813|NCT04561908|DEVICE|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
58440814|NCT04561908|DEVICE|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
58440815|NCT01944540|PROCEDURE|Optimized ESD with snaring|
58440816|NCT01944540|PROCEDURE|Conventional ESD|
58440817|NCT02907684|DIETARY_SUPPLEMENT|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
58440818|NCT02907684|DIETARY_SUPPLEMENT|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
58440819|NCT01222780|DRUG|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
58440820|NCT05696886|DRUG|Pethidine|Group A received Pethidine alone in the period between January 2021 and December 2021
58440821|NCT05696886|DRUG|Tramadol with pethidine|Group B got Tramadol with pethidine in the period between January 2022 and December 2022
58311362|NCT03485586|DEVICE|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
58311363|NCT05233813|BEHAVIORAL|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
58311364|NCT02815371|PROCEDURE|Needle Acupuncture|See above
58440822|NCT00412243|DRUG|Clofarabine|40 mg/m\^2 Daily for 3 Days
58440823|NCT00412243|DRUG|Cyclophosphamide|Beginning dose 200 mg/m\^2 every 12 hours for 3 days
58440824|NCT01487265|DRUG|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
58440825|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
58440826|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
58311365|NCT02815371|PROCEDURE|Laser Acupuncture|See above
58311366|NCT02815371|PROCEDURE|Sham Laser Acupuncture|See above
58311367|NCT06101498|DIAGNOSTIC_TEST|Akut kidnet injury(AKI)|postoperative 24 hours
58440827|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
58440828|NCT01504412|DRUG|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
58440829|NCT01504412|DRUG|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
58440830|NCT03742583|OTHER|Square Knot|Standard square knot
58440831|NCT03742583|OTHER|RHAP Knot|Reversing half-hitch alternating post knot
58440832|NCT05819697|OTHER|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
57769635|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 4000IU/100µg.|Vitamin D3 supplementation
57769636|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 600IU/15µg.|Vitamin D3 supplementation
58440833|NCT02977858|OTHER|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
58440834|NCT02977858|OTHER|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
58440835|NCT00334243|DRUG|Microflare protocol for IVF|
58440836|NCT00334243|DRUG|Antagonist protocol for IVF|
58440837|NCT00334243|DRUG|Demi-halt protocol for IVF|
58440838|NCT03890744|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
58440839|NCT06366841|OTHER|Psychological tests administration|Psychological tests administration to evaluate stigma, personality characteristics and quality of life of rectal and anal cancer patients.
58440840|NCT05547568|PROCEDURE|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
58440841|NCT02150915|OTHER|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
58440842|NCT03132701|DRUG|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
58440843|NCT03132701|DRUG|Saline|Same volume of saline is infused until 5 minutes before surgery ends
58440844|NCT06298786|DIAGNOSTIC_TEST|Functional 6-minute mastication test|All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
58440845|NCT01485328|DRUG|AMARGOL®|per oral solution, 40 mL single dose
58440846|NCT02837185|PROCEDURE|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
58440847|NCT02837185|OTHER|Physiological measures|These include TMS and EMG measurements
58440848|NCT05476016|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
58440849|NCT03483493|BEHAVIORAL|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
58440850|NCT03483493|OTHER|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
58440851|NCT04364360|DIETARY_SUPPLEMENT|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
58440852|NCT03106636|BEHAVIORAL|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
58440853|NCT03106636|BEHAVIORAL|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
58440854|NCT01063153|DRUG|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
58458450|NCT02608658|OTHER|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test"
58440855|NCT05954000|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
58440856|NCT05476172|DRUG|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
57955653|NCT06072885|OTHER|Lung Ultrasound Scoring|Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
57955654|NCT01014741|DRUG|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
58440857|NCT05476172|DRUG|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
58440858|NCT06072417|OTHER|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
58440859|NCT06072417|OTHER|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
58440860|NCT01229306|PROCEDURE|Ablation|Ablation of atrial fibrillation
58440861|NCT02211248|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
58440862|NCT02211248|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
58440863|NCT04966949|PROCEDURE|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
58440864|NCT03906539|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg per day
58440865|NCT03906539|DIETARY_SUPPLEMENT|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
58440866|NCT03906539|OTHER|Placebo|Placebo capsule - 1 capsule per day
58440867|NCT02836405|DEVICE|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
58440868|NCT02536924|BEHAVIORAL|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
58440869|NCT02536924|BEHAVIORAL|Treatment as usual.|The patient will receive treatment as usual.
58440870|NCT00350844|DRUG|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
58440871|NCT03081650|DEVICE|Airvo Humidifier|
58440872|NCT00791089|DRUG|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
58440873|NCT00791089|DRUG|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
58440874|NCT00791089|OTHER|placebo|Control group will receive placebo before \& after ablation.
58458451|NCT04910295|DRUG|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
58440875|NCT01242605|DRUG|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
57739153|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
57739154|NCT01835886|OTHER|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
58440876|NCT01242605|DRUG|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
58440877|NCT01242605|DRUG|cisplatin|cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
58440878|NCT04375345|DEVICE|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
57955655|NCT01014741|DRUG|Placebo|Placebo after PV isolation prior to CFE ablation.
57955656|NCT02386150|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
57955657|NCT00822107|DRUG|Hydrochlorothiazide|50 mg one time
57955658|NCT01485757|DRUG|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
57955659|NCT06022263|DRUG|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
57955660|NCT06022263|DRUG|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
57955661|NCT01425151|DEVICE|i-Gel|Oropharyngeal leak pressure Insertion success
57955662|NCT01425151|DEVICE|ProSeal|Oropharyngeal leak pressure Insertion success
57955663|NCT02092571|DRUG|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
57955664|NCT02035995|OTHER|Pregnant volunteers with GDM|
57955665|NCT00601068|OTHER|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
57955666|NCT04697628|DRUG|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
57955667|NCT04697628|DRUG|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
58108487|NCT01917578|PROCEDURE|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~3. Observe the shrinkage modes in three-dimensional space.~4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
58311368|NCT01455519|DRUG|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
58311369|NCT01455519|DRUG|Sugar pill|Sugar pill
58311370|NCT03312738|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
58311371|NCT03312738|DRUG|Exemestane|Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
58440879|NCT05511571|DEVICE|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
58440880|NCT05511571|OTHER|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
58440881|NCT05511571|OTHER|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
58311372|NCT03312738|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
57955668|NCT04697628|DRUG|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
57955669|NCT04697628|DRUG|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
57955670|NCT04697628|DRUG|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
58311373|NCT02258672|OTHER|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
58311374|NCT02471339|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
58311375|NCT03816358|BIOLOGICAL|Anetumab Ravtansine|Given IV
58311376|NCT03816358|PROCEDURE|Biopsy|Undergo biopsy
58311377|NCT03816358|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57955671|NCT04697628|DRUG|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
57955672|NCT02386488|DRUG|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
57955673|NCT02386488|DRUG|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
58440882|NCT02380911|OTHER|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
58440883|NCT00278746|DRUG|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
58440884|NCT00278746|DRUG|ORS only|Promoted routine management of diarrhea in underfive with ORS
58440885|NCT03977766|PROCEDURE|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
58440886|NCT03948841|OTHER|magnetic resonance imaging|
58440887|NCT02564185|OTHER|Usual practice|
58440888|NCT02564185|OTHER|Education program|
58440889|NCT04030793|DEVICE|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
58311378|NCT03816358|DRUG|Gemcitabine Hydrochloride|Given IV
58311379|NCT03816358|BIOLOGICAL|Ipilimumab|Given IV
57739155|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - carbon fibers-based implants|Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
58311380|NCT03816358|BIOLOGICAL|Nivolumab|Given IV
58311381|NCT04707937|OTHER|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
58311382|NCT04707937|OTHER|Regular standard of care education|Access only to regular standard of care education
58311383|NCT06380283|DEVICE|Virtual reality headset|Use of a virtual reality headset during pediatric dental care
58311384|NCT04765787|DRUG|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
58311385|NCT01967199|DEVICE|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
58311386|NCT01967199|DEVICE|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
58311387|NCT05300282|DRUG|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
58311388|NCT05300282|COMBINATION_PRODUCT|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
58311389|NCT00183430|DRUG|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
58311390|NCT00183430|DRUG|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
58311391|NCT00183430|BEHAVIORAL|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
58311392|NCT02181595|OTHER|Group reading and discussion|
58311393|NCT02783911|DEVICE|MTA|Mineral Trioxide Aggregate grey paste
58311394|NCT02783911|DRUG|Ferric Sulfate|Ferric Sulfate paste
58311395|NCT01124253|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
58440890|NCT04030793|DEVICE|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
58440891|NCT02352753|DRUG|Denosumab|Subcutaneous (SC) injection.
58440892|NCT02533492|DEVICE|vicryl|wound closure with vicryl suture
58440893|NCT02533492|DEVICE|Vicryl plus|wound closure with vicryl plus suture
58440894|NCT06284083|DIAGNOSTIC_TEST|taking a blood sample|Blood samples collected from patienst, only 7 mL
58108488|NCT01917578|DEVICE|Mammography|"1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size and calcification extent refers to WHO standards.~3. Calcification extent is not only measured in mammography image but also under microscope."
58311396|NCT05455775|DEVICE|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
58311397|NCT03272152|GENETIC|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
58311398|NCT00247234|BEHAVIORAL|Schema Therapy|group based schema therapy
58311399|NCT00247234|BEHAVIORAL|standard care|standard psychiatric out-patient care
58311400|NCT00670059|GENETIC|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
58440895|NCT03700567|OTHER|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
58440896|NCT02648568|BEHAVIORAL|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
58440897|NCT02648568|BEHAVIORAL|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
58440898|NCT01919801|DRUG|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
58440899|NCT01919801|DRUG|Placebo|
58440900|NCT05385003|DIETARY_SUPPLEMENT|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
58440901|NCT05385003|DIETARY_SUPPLEMENT|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
58440902|NCT05385003|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
58311401|NCT00670059|GENETIC|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
58311402|NCT02011178|PROCEDURE|Optimal medical treatment and surgery|
58311403|NCT02011178|PROCEDURE|Optimal medical treatment|
58311404|NCT04337788|OTHER|telehealth applications|telehealth applications during 30 days/patient
57739156|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - titanium implants|Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
57955674|NCT02386488|DRUG|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
58311405|NCT01080261|DEVICE|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
58311406|NCT02188550|DRUG|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
58311407|NCT05741697|DRUG|bi-level ventillation|non-invasive mechanical ventilation
58311408|NCT03831022|OTHER|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
58311409|NCT00844311|DRUG|rFSH|150 iu/day of rFSH
58311410|NCT00844311|DRUG|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
58311411|NCT00844311|DRUG|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
58311412|NCT00844311|DRUG|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
58311413|NCT03406663|BEHAVIORAL|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
57955675|NCT02386488|DRUG|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
58311414|NCT03406663|BEHAVIORAL|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
58311415|NCT03889392|PROCEDURE|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
58311416|NCT00006362|DRUG|bortezomib|
58311417|NCT01131273|DRUG|methadone|12 weeks of methadone maintenance with counseling
58311418|NCT01131273|DRUG|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
58311419|NCT03794596|DRUG|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
58311420|NCT03794596|DRUG|Aspirin|300mg tablets
58311421|NCT03794596|DRUG|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
58311422|NCT04913922|DRUG|Azacitidine Injection|s.c. 75 mg/m2 BSA for 7 days
58311423|NCT04913922|DRUG|Nivolumab|480 mg i.v.
58311424|NCT04913922|DRUG|Relatlimab|80-160mg i.v.
58311425|NCT01470170|DRUG|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
58311426|NCT01470170|DRUG|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
58311427|NCT01470170|DEVICE|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
58311428|NCT01470170|DRUG|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
58311429|NCT04642989|OTHER|Sham Treatment|All movements of facial effleurage except applying pressure
58311430|NCT04642989|OTHER|Facial Effleurage|Facial massage to remove any lymphatic blockages
58311431|NCT04642989|DRUG|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
58311432|NCT04716985|DIETARY_SUPPLEMENT|MOLECULAR HYDROGEN|Magnesium Tablet
58311433|NCT04716985|DIETARY_SUPPLEMENT|PLACEBO MAGNESIUM|Magnesium carbonate tablet
58311434|NCT06279715|OTHER|Preimplantation Genetic Testing for Aneuploidy|PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
58311435|NCT00772837|DRUG|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
58311436|NCT00772837|DRUG|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
58311437|NCT04452864|DEVICE|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
58311438|NCT04452864|DEVICE|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
58311439|NCT01654276|DRUG|Febuxostat|One 40 mg tablet once a day for 6 months
58311440|NCT05029531|COMBINATION_PRODUCT|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
58311441|NCT06305481|DEVICE|P200TE|SLO and OCT imaging
58311442|NCT00411320|DRUG|oral steroid-dexamethasone|2 week steroid trial
58311443|NCT00000972|BIOLOGICAL|MTP-PE/MF59|
58311444|NCT00000972|BIOLOGICAL|Env 2-3|
58440903|NCT05501717|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
58440904|NCT05501717|DRUG|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
57739157|NCT06293157|RADIATION|Stereotactic body radiotherapy|Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
57739158|NCT02779153|DRUG|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
58440905|NCT01930838|PROCEDURE|Gastric bypass operation|
58440906|NCT05581069|BEHAVIORAL|STEPS|STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
58440907|NCT06127719|OTHER|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
58440908|NCT04255589|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
58440909|NCT04255589|DRUG|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
58440910|NCT04255589|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
58440911|NCT04255589|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
58440912|NCT05505864|BEHAVIORAL|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
58440913|NCT06209827|BEHAVIORAL|Intervention for reducing benzodiazepines long-term use.|"Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor."
58440914|NCT05564039|DRUG|Tirzepatide|Administered SC
57739159|NCT02779153|DRUG|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
58440915|NCT05564039|DRUG|Dulaglutide|Administered SC
58440916|NCT00942825|DRUG|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
58440917|NCT00942825|DRUG|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
58440918|NCT04521244|OTHER|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
58440919|NCT04521244|OTHER|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
58440920|NCT01210898|BIOLOGICAL|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
58440921|NCT03570541|DRUG|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
58440922|NCT03570541|DRUG|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
57739160|NCT04541134|DRUG|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
57739161|NCT04541134|DRUG|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
57739162|NCT03412669|OTHER|Supporting Addiction Affected Families Effectively|Counselling
58440923|NCT03570541|DEVICE|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
58440924|NCT03570541|DRUG|Morphine|intravenously administered morphine via PCA-pump
58440925|NCT03570541|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
58440926|NCT03570541|DIAGNOSTIC_TEST|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
58440927|NCT03570541|BEHAVIORAL|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
58440928|NCT03570541|DIAGNOSTIC_TEST|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
58440929|NCT03056339|DRUG|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
58311445|NCT04092478|OTHER|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
58440930|NCT03056339|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
57739163|NCT03412669|OTHER|Enhanced Usual Care|Information sheet
57955676|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
57955677|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
57955678|NCT03922009|DEVICE|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
57955679|NCT01309659|DRUG|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
57955680|NCT01309659|DRUG|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
57955681|NCT04599283|DEVICE|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
57955682|NCT04515693|OTHER|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
57955683|NCT05517876|DEVICE|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
57955684|NCT02849366|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
57955685|NCT02849366|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
58311446|NCT02764736|DRUG|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
58440931|NCT03056339|DRUG|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
58311447|NCT00912366|PROCEDURE|Lobectomy|Assessment of VATS versus open surgery.
58311448|NCT01502891|OTHER|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
58311449|NCT01885065|OTHER|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
58311450|NCT05793411|OTHER|Questionnaire risk behaviors in adolescents with chronic diseases|Questionnaire risk behaviors in adolescents with chronic diseases
58440932|NCT03056339|BIOLOGICAL|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
57739164|NCT04380454|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
57739165|NCT04380454|OTHER|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
57955686|NCT05670587|DEVICE|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
57955687|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
57955688|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
57955689|NCT00436371|DRUG|Amisulpride|Oral tablets
57955690|NCT06323109|DEVICE|MRI-UDS; US-UDS; MCUD|Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
57955691|NCT02791061|OTHER|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
58440933|NCT03056339|DRUG|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
58108489|NCT01917578|DRUG|TAC,TC,TA,CAF,CEF|"1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
57739166|NCT03543826|COMBINATION_PRODUCT|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
58108490|NCT01917578|DRUG|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
58108491|NCT03980327|DIETARY_SUPPLEMENT|probiotic|Lactobacillus probiotic
58108492|NCT03980327|DIETARY_SUPPLEMENT|medium chain triglyceride oil|
58108493|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
58108494|NCT01575119|BEHAVIORAL|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
58108495|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
58108496|NCT01575119|BEHAVIORAL|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
58108497|NCT05738564|DRUG|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
58108498|NCT00451932|DRUG|FK778|
58108499|NCT02354976|DRUG|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
58108500|NCT02354976|DRUG|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
58108501|NCT02354976|DRUG|Fenofibrate 200mg|200mg capsule administered once daily
58108502|NCT02354976|DRUG|Placebo|Placebo matching to fenofibrate 200mg
58108503|NCT01754181|DRUG|Insulin|the intervention is applied only at the dose of insulin
58108504|NCT06540092|DIAGNOSTIC_TEST|ultrasound|ultrasound measurements during first trimester
58108505|NCT06292910|DIAGNOSTIC_TEST|arterial and central venous blood gas analysis, lactate|blood gas analysis
58108506|NCT05549128|DEVICE|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
58108507|NCT05549128|DEVICE|Photobiomodulation sham|The red laser (DMC) will be applied off. I
58311451|NCT05877989|DRUG|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
58311452|NCT05877989|PROCEDURE|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
57739167|NCT04483050|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
57955692|NCT02791061|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
58440934|NCT04852939|OTHER|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
58440935|NCT04852939|OTHER|Conventional physical therapy|"* Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
58440936|NCT03939975|DRUG|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
58440937|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
58440938|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
58440939|NCT05873972|DRUG|Cetuximab|"AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0"
58440940|NCT01060696|DRUG|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
58440941|NCT02450513|DRUG|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
58440942|NCT04910035|OTHER|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
58440943|NCT05118698|DRUG|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
58440944|NCT05118698|OTHER|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
58440945|NCT00005030|DRUG|SCH 66336|
58440946|NCT00005030|PROCEDURE|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
58311453|NCT01788514|OTHER|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
57955693|NCT02791061|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
57955694|NCT04499872|OTHER|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
58440947|NCT03058900|DRUG|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
58440948|NCT03058900|OTHER|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
58440949|NCT03058900|DRUG|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
58440950|NCT06496880|DIETARY_SUPPLEMENT|Oxyjun TM|One capsule daily to be taken after breakfast for 56 days
58440951|NCT06496880|DIETARY_SUPPLEMENT|Placebo|One capsule daily to be taken after breakfast for 56 days
58440952|NCT02152761|DRUG|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
58440953|NCT02152761|OTHER|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
58440954|NCT01279603|DRUG|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
57955695|NCT03895866|OTHER|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
57955696|NCT01946607|DRUG|Citalopram|
58311454|NCT01814540|DIETARY_SUPPLEMENT|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
58311455|NCT01814540|DIETARY_SUPPLEMENT|Placebo Glucose Polymer|
57955697|NCT01946607|DRUG|Placebo|
57955698|NCT01262365|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
58311456|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
58311457|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
58311458|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
58311459|NCT01399996|DIETARY_SUPPLEMENT|A capsule containing the probiotic|A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
58440955|NCT02152176|DEVICE|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
58440956|NCT01302028|DRUG|ASP1941|Oral
58440957|NCT03694431|OTHER|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
58440958|NCT03694431|OTHER|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
57955699|NCT01262365|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
57955700|NCT01262365|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
57955701|NCT00800501|DRUG|sNN0029|Continuous ICV infusion at one of three dose levels
57955702|NCT00800501|DRUG|Placebo|Continuous ICV infusion
57955703|NCT02922062|OTHER|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
57955704|NCT02922062|OTHER|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
58440959|NCT04921904|DRUG|Abemaciclib|150mg dose administered orally twice daily every day
58440960|NCT04921904|DRUG|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
58440961|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
58440962|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
58440963|NCT00660179|DRUG|placebo|Matching placebo, once daily
58440964|NCT02454777|BEHAVIORAL|Exercise Intervention|Undergo HIT
58440965|NCT02454777|OTHER|Laboratory Biomarker Analysis|Correlative studies
58440966|NCT02454777|OTHER|Quality-of-Life Assessment|Ancillary studies
58440967|NCT02454777|OTHER|Questionnaire Administration|Ancillary studies
58108508|NCT02972151|DRUG|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
58108509|NCT02972151|OTHER|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
58108510|NCT03596918|BIOLOGICAL|Bleomycin Sulfate|Given IV
58440968|NCT02181283|BEHAVIORAL|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
58440969|NCT02181283|BEHAVIORAL|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
58108511|NCT03596918|OTHER|Laboratory Biomarker Analysis|Correlative studies
58108512|NCT03596918|OTHER|Quality-of-Life Assessment|Ancillary studies
58108513|NCT03596918|OTHER|Questionnaire Administration|Ancillary studies
58108514|NCT03596918|DRUG|Vincristine Sulfate|Given IV
58108515|NCT03077828|DRUG|Carboplatin|Given IV
58108516|NCT03077828|DRUG|Etoposide|Given IV
58108517|NCT03077828|DRUG|Ifosfamide|Given IV
58108518|NCT03077828|OTHER|Laboratory Biomarker Analysis|Correlative studies
58108519|NCT03077828|BIOLOGICAL|Pembrolizumab|Given IV
58108520|NCT06528028|DRUG|CAZ/AVI|continuous infusion is used
58440970|NCT03852667|BEHAVIORAL|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
58108521|NCT06528028|DRUG|CAZ/AVI|2h-infusion is used
58108522|NCT02917616|OTHER|Alkaline drinking-water|
58108523|NCT02917616|OTHER|Neutral drinking-water|
58108524|NCT05060952|DIAGNOSTIC_TEST|Calprotectin Lateral Flow Test|Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate
58108525|NCT03109522|PROCEDURE|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
58108526|NCT03109522|PROCEDURE|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
58108527|NCT05386745|BEHAVIORAL|physical activity|A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
58108528|NCT01026688|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
58108529|NCT01026688|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
58440971|NCT03852667|OTHER|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
58440972|NCT00978146|DRUG|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
58440973|NCT01849094|DRUG|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
58440974|NCT01849094|DRUG|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
58440975|NCT01849094|DRUG|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
58440976|NCT04482582|RADIATION|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
58440977|NCT04482582|OTHER|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
57955705|NCT02922062|OTHER|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
57955706|NCT05382351|DRUG|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
57955707|NCT05382351|DRUG|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
57955708|NCT00216411|BIOLOGICAL|Botulinum toxin type A|
57955709|NCT00216411|DRUG|Placebo|
57955710|NCT04081363|DRUG|Centanafadine|Extended-release and immediate-release capsules.
57955711|NCT01222546|DRUG|CH5132799|
57955712|NCT00520364|OTHER|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
57955713|NCT00290615|BIOLOGICAL|bevacizumab|
57955714|NCT00290615|BIOLOGICAL|cetuximab|
57955715|NCT00290615|DRUG|capecitabine|
57955716|NCT00290615|DRUG|oxaliplatin|
57955717|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
57955718|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
57955719|NCT04359303|OTHER|Systemic indirect endovenous ozone therapy|200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
57955720|NCT05383027|BEHAVIORAL|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
57955721|NCT05383027|BEHAVIORAL|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
57955722|NCT00775632|DRUG|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
57955723|NCT00775632|DRUG|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
57955724|NCT05810220|DEVICE|Electrode-Neural Interface|Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
57955725|NCT04017260|PROCEDURE|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
58440978|NCT05274269|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
58440979|NCT05274269|DRUG|IVA|Tablet for oral administration.
58440980|NCT05274269|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
58440981|NCT05274269|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
57739168|NCT00272857|GENETIC|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
57739169|NCT01362738|PROCEDURE|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
57739170|NCT01362738|PROCEDURE|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
58440982|NCT02302872|DEVICE|ARTO System|
58440983|NCT06584240|DRUG|Sequence 1|Single treatment, intramuscularly injected. The total injection 100-150U.
58108530|NCT05485857|PROCEDURE|Arrangement of small intestine order before close the abdomen|After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
58108531|NCT06180811|OTHER|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
58440984|NCT06584240|DRUG|Sequence 2|Single treatment, intramuscularly injected. The total injection 200-250U.
58440985|NCT06584240|DRUG|Sequence 3|Single treatment, intramuscularly injected. The total injection 350-400U.
58440986|NCT06584240|DRUG|Sequence 4|Single treatment, intramuscularly injected. The total injection ≤400U.
58440987|NCT06584240|DRUG|Sequence 5|Single treatment, intramuscularly injected.
58440988|NCT05266677|OTHER|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
57955726|NCT04017260|PROCEDURE|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
58108532|NCT06180811|OTHER|Usual Standard of Care|Participants will receive the usual standard of care.
58108533|NCT03724669|BEHAVIORAL|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
58440989|NCT05266677|OTHER|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
58440990|NCT02159976|DRUG|Pantoprazole|Pantoprazole 40mg bid
58440991|NCT02159976|DRUG|Amoxicillin|Amoxicillin 1000mg bid
58440992|NCT02159976|DRUG|Clarithromycin|Clarithromycin 500mg bid
58440993|NCT02159976|DRUG|Metronidazole|Metronidazole 500mg tid
58440994|NCT02159976|DRUG|Tetracycline|Tetracycline 1000mg bid
58440995|NCT02159976|DRUG|Bismuth|Bismuth 600mg bid
58440996|NCT02501499|OTHER|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
58440997|NCT02024139|OTHER|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
58440998|NCT02024139|OTHER|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
58440999|NCT00654082|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
58441000|NCT00654082|DRUG|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
58441001|NCT02699567|OTHER|No intervention|
58108534|NCT03724669|BEHAVIORAL|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
58311460|NCT03246178|OTHER|MSD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
58441002|NCT03676244|DEVICE|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
58441003|NCT03045718|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
58441004|NCT04402723|DRUG|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
58441005|NCT02694900|OTHER|Manually chest compressions|Chest compressions performed manually without any device
58441006|NCT02694900|DEVICE|Cardiopump|Chest compressions performed with Cardiopump
58441007|NCT02694900|DEVICE|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
57955727|NCT04017260|PROCEDURE|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
58108535|NCT00004699|DRUG|insulin-like growth factor I|
58108536|NCT06205199|DRUG|Hydromorphone was injected into the subarachnoid space|The dose of hydromorphone is 50 micrograms
58108537|NCT01149616|DRUG|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
58441008|NCT04361578|DIAGNOSTIC_TEST|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
58108538|NCT01149616|DRUG|placebo|2 ml normal saline IV x1
58108539|NCT05198115|BEHAVIORAL|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
58108540|NCT02803723|PROCEDURE|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
58441009|NCT00133042|DRUG|omalizumab|
58441010|NCT00003811|BIOLOGICAL|bleomycin sulfate|
58441011|NCT00003811|DRUG|amifostine trihydrate|
58441012|NCT00003811|DRUG|cisplatin|
58441013|NCT00003811|DRUG|etoposide|
58441014|NCT00003811|PROCEDURE|conventional surgery|
58441015|NCT05318404|DIETARY_SUPPLEMENT|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
58441016|NCT01455896|DRUG|ITCA 650|ITCA 650
58441017|NCT01455896|OTHER|ITCA placebo|ITCA placebo
58441018|NCT02930902|DRUG|Gemcitabine Hydrochloride|Given IV
58441019|NCT02930902|OTHER|Laboratory Biomarker Analysis|Correlative studies
58441020|NCT02930902|DRUG|Nab-paclitaxel|Given IV
57739171|NCT05258162|OTHER|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
58108541|NCT02803723|PROCEDURE|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
58108542|NCT04181996|DRUG|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
58108543|NCT04181996|DRUG|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
58108544|NCT04575038|DRUG|Brequinar|Dihydroorotate dehydrogenase inhibitor (DHODHi)
58108545|NCT04575038|DRUG|Placebo|Placebo capsules
58108546|NCT01999387|DIETARY_SUPPLEMENT|Allergenic food|
58108547|NCT00333333|PROCEDURE|Cord blood|Cord blood will be obtained at the time of delivery.
58108548|NCT00285415|DRUG|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
58108549|NCT00553033|PROCEDURE|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
58311461|NCT03246178|OTHER|HFD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
58311462|NCT00997893|DIETARY_SUPPLEMENT|Soy Phytoestrogen|Novasoy® pill (55 mg)
58311463|NCT00997893|DRUG|Estradiol|Estradiol pill (1 mg)
58311464|NCT00997893|DRUG|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
58311465|NCT00997893|DRUG|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
58311466|NCT00997893|DRUG|MPA Placebo|oral placebo pill (0mg MPA)
58311467|NCT02313402|DEVICE|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
58311468|NCT02265510|DRUG|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
58311469|NCT02265510|DRUG|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
58441021|NCT02930902|DRUG|Paricalcitol|Given IV
58108550|NCT03418077|DIETARY_SUPPLEMENT|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
58108551|NCT03418077|DIETARY_SUPPLEMENT|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
58108552|NCT05983237|DRUG|Fluzoparib Camrelizumab Temozolomide|Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
58108553|NCT04487145|DRUG|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
58441022|NCT02930902|BIOLOGICAL|Pembrolizumab|Given IV
58441023|NCT02930902|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
58441024|NCT03312842|DRUG|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
58108554|NCT06424925|OTHER|Artificial intelligence for the prediction of clinical outcomes|Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
58441025|NCT01423292|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
58441026|NCT01423292|DRUG|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
58441027|NCT01423292|DRUG|Placebo|placebo
58441028|NCT03145259|DRUG|Diclofenac Epolamine Patch|patch
58441029|NCT03145259|DRUG|diclofenac sodium solution|solution
58441030|NCT04756648|DRUG|CT0180 Cells|Five dose levels were tentatively determined.
58441031|NCT04090242|DEVICE|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
58441032|NCT05492097|BEHAVIORAL|Exercise Therapy|Traditional exercise therapy and NMES
58441033|NCT05492097|BEHAVIORAL|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
58441034|NCT00104650|GENETIC|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
58441035|NCT00104650|DRUG|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
58441036|NCT00104650|GENETIC|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
58441037|NCT05034419|DEVICE|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
58441038|NCT05034419|DEVICE|Sham stimulation|Sham stimulation
58441039|NCT05733052|OTHER|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
58441040|NCT00481923|DRUG|rimonabant (SR141716)|
58441041|NCT04304872|BEHAVIORAL|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
58441042|NCT04304872|BEHAVIORAL|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
58441043|NCT00123175|DEVICE|Intrauterine Device|Mirena and Provera
58441044|NCT00903435|OTHER|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
58441045|NCT01564147|OTHER|immediate therapeutic education|Access to the course of immediate therapeutic education
58441046|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
58441047|NCT05632302|DEVICE|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
58108555|NCT01915381|OTHER|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
58108556|NCT01462695|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58108557|NCT01462695|OTHER|Pharmacological Study|Correlative studies
58108558|NCT01462695|DRUG|Sunitinib Malate|Given PO
58108559|NCT06542328|DEVICE|ERI CVX-air portable X-ray system|investigational device
58108560|NCT06542328|DEVICE|Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)|The commercially available comparator equipment used for pulmonology.
58108561|NCT06542328|DEVICE|Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)|The commercially available comparator equipment used for Orthopaedic.
58441048|NCT05411289|PROCEDURE|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
58108562|NCT04316897|DEVICE|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
58108563|NCT04087382|DEVICE|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
58108564|NCT04087382|OTHER|non intervention group|medical treatment (Asprin, statin, nootropic drug)
58108565|NCT00415961|DEVICE|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
58108566|NCT00003070|DRUG|enalapril maleate|
58108567|NCT00003070|PROCEDURE|quality-of-life assessment|
58311470|NCT02265510|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
58311471|NCT02265510|DRUG|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
58311472|NCT02265510|DRUG|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
58311473|NCT02265510|DRUG|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
58311474|NCT02265510|DRUG|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
58441049|NCT05411289|PROCEDURE|sham acupressure|Pressures were applied on sham points consecutively
58108568|NCT02691806|OTHER|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
58108569|NCT04863456|PROCEDURE|Total resection|Total resection of HIPA in a single surgery
58108570|NCT04863456|PROCEDURE|Staged resection|HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date
58311475|NCT02265510|DRUG|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
58311476|NCT02265510|DRUG|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
58311477|NCT02265510|DRUG|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
58108571|NCT04863456|PROCEDURE|Subtotal resection followed by stereotactic radiation therapy|HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
58108572|NCT04341818|OTHER|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
58108573|NCT04341818|OTHER|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
58108574|NCT04341818|OTHER|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
58108575|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
58108576|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
58108577|NCT00180869|PROCEDURE|transfusion of allogeneic red blood cell concentrate|
58311478|NCT02265510|DRUG|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
58311479|NCT02265510|DRUG|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
58311480|NCT00129636|PROCEDURE|Additional specific letter written to patient|
58108578|NCT00180869|PROCEDURE|transfusion of leuko-reduced red blood cell concentrate|
58441050|NCT05711823|DRUG|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
58441051|NCT05711823|DRUG|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
58441052|NCT02932748|DIETARY_SUPPLEMENT|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
58441053|NCT02932748|BEHAVIORAL|Group Phone (GP)|Weight management program delivered via group conference call.
58441054|NCT02932748|DIETARY_SUPPLEMENT|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
58441055|NCT02932748|BEHAVIORAL|Individual Phone (IP)|Weight management program delivered via individual phone call.
58441056|NCT02932748|BEHAVIORAL|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
58441057|NCT04168099|DRUG|Cefotaxime|Cefotaxime IV
57955728|NCT04017260|PROCEDURE|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
57955729|NCT01093027|OTHER|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
57955730|NCT01093027|OTHER|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
57955731|NCT01779024|DRUG|Ghrelin|
57955732|NCT01779024|DRUG|Placebo|
57955733|NCT01779024|PROCEDURE|fMRI|
57955734|NCT01779024|DRUG|Alcohol|
57955735|NCT03813537|OTHER|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
57955736|NCT05448911|PROCEDURE|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
57955737|NCT05448911|PROCEDURE|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
57955738|NCT03344302|DRUG|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
57955739|NCT03267121|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
57955740|NCT03267121|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
57955741|NCT00003022|RADIATION|iodine I 131 monoclonal antibody 3F8|
58108579|NCT01418261|DEVICE|Renal denervation (Symplicity Catheter System)|
58108580|NCT01418261|DIAGNOSTIC_TEST|Renal angiogram|
58108581|NCT00188071|DRUG|paracetamol|
58441058|NCT04168099|DRUG|Gemifloxacin|Gemifloxacin oral
57955742|NCT03522870|DEVICE|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
57955743|NCT03522870|DEVICE|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
57955744|NCT04027998|DIAGNOSTIC_TEST|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
57955745|NCT02154386|DEVICE|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
58108582|NCT00188071|DRUG|ketoprofen|
58108583|NCT00188071|DRUG|ketoprofen + paracetamol|
58108584|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
58108585|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
58108586|NCT04051632|DEVICE|Medtronic 670G insulin pump|"* percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range"
58108587|NCT03292783|DRUG|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
58108588|NCT06458686|DRUG|Vit D|Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
58441059|NCT05624073|DEVICE|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
58108589|NCT06458686|OTHER|Placebo|Placebo is a non drug formulation
58108590|NCT01399021|OTHER|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
58441060|NCT05624073|DEVICE|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
57739172|NCT05258162|OTHER|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks."
57739173|NCT01060293|DRUG|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
58108591|NCT01399021|OTHER|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
58108592|NCT05979051|DRUG|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
58108593|NCT05979051|DRUG|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
58108594|NCT02086526|DRUG|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
58108595|NCT05715606|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
58108596|NCT00700284|DRUG|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
58108597|NCT00700284|DRUG|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
58108598|NCT06457464|DRUG|Chemotherapy|combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
58108599|NCT00068237|PROCEDURE|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
58108600|NCT00068237|RADIATION|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
58108601|NCT01438333|DIETARY_SUPPLEMENT|lactobacillus brevis tablets|5 tablets a day for 6 weeks
58108602|NCT01438333|DIETARY_SUPPLEMENT|PLACEBO|5 tablets a day for 6 weeks
58108603|NCT00845026|DRUG|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
58108604|NCT00845026|DRUG|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
58108605|NCT00845026|DRUG|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
58108606|NCT00845026|DRUG|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
58108607|NCT05955170|DRUG|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
58108608|NCT04927819|DEVICE|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
58108609|NCT04261933|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
58441061|NCT03933761|DRUG|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
58441062|NCT03156283|BEHAVIORAL|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
58441063|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
58441064|NCT03454607|DEVICE|FREE robot|FREE robot to hold endoscope
58441065|NCT03749720|OTHER|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
58441066|NCT06236685|DEVICE|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
58441067|NCT04776512|PROCEDURE|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
58441068|NCT04776512|PROCEDURE|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
58441069|NCT00004030|DRUG|VX-853|
58441070|NCT00004030|DRUG|pegylated liposomal doxorubicin hydrochloride|
57739174|NCT01060293|DRUG|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
57739175|NCT01060293|DRUG|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
58108610|NCT04454970|DEVICE|Urethrotech Urethral catheterisation device (UCD)|Urethral indwelling catheter
58108611|NCT04454970|DEVICE|Bardia Aquafil long term catheter|Urethral indwelling catheter
58311481|NCT04671199|OTHER|MP 3000 monitor|Additional monitoring
58441071|NCT03503760|DEVICE|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
57739176|NCT05131048|OTHER|conventional group|this group will perform conventional therapy
57739177|NCT05131048|OTHER|experimental group|this group will perform home based exercises
58441072|NCT05426278|DEVICE|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
58441073|NCT01524146|PROCEDURE|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
57739178|NCT04868266|OTHER|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
58311482|NCT01841372|OTHER|Second Life|Second Life is an online virtual reality environment.
58311483|NCT01841372|BEHAVIORAL|Group Phone Conference Call|
58311484|NCT02980315|OTHER|CAR-T cells|the patients treat with CAR-T cells
58311485|NCT04716543|DIAGNOSTIC_TEST|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
58441074|NCT02500953|DRUG|ASP3325|
58441075|NCT02500953|DRUG|Placebo|
58441076|NCT05791227|DIAGNOSTIC_TEST|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
58441077|NCT05791227|DIAGNOSTIC_TEST|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
58441078|NCT00206440|DRUG|esomeprazole|nexium
58441079|NCT00206440|OTHER|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
57739179|NCT03101735|DRUG|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
57739180|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
57739181|NCT05688995|BIOLOGICAL|Naser Al-Husban|COVID-19 vaccines
57739182|NCT04513990|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
58311486|NCT02937376|DRUG|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
58441080|NCT05678634|BEHAVIORAL|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
58441081|NCT05678634|BEHAVIORAL|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
58441082|NCT05678634|BEHAVIORAL|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
58441083|NCT05678634|BEHAVIORAL|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
57739183|NCT04513990|OTHER|Questionnaire Administration|Demographic information, sample collection type preferences; clinical outcome information
57739184|NCT06497400|OTHER|Brazilian Jiu Jitsu|Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu
57739185|NCT06497400|OTHER|Hatha Yoga|Instruction of two classes each week for ten weeks of Hatha Yoga
57739186|NCT06497400|OTHER|Waitlist|Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
57739187|NCT02792075|OTHER|5-year Follow-up|
57739188|NCT06187753|DIAGNOSTIC_TEST|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
57739189|NCT02866565|DRUG|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
57739190|NCT01726868|DEVICE|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
57739191|NCT02324933|DRUG|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
58311487|NCT02937376|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
58311488|NCT00004261|DRUG|EF5|
58311489|NCT00004261|OTHER|flow cytometry|
58311490|NCT00004261|OTHER|fluorescent antibody technique|
58311491|NCT00004261|OTHER|immunohistochemistry staining method|
58311492|NCT00004261|PROCEDURE|biopsy|
58441084|NCT05678634|BEHAVIORAL|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
58108612|NCT02899052|DRUG|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
58108613|NCT02899052|DRUG|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
58108614|NCT02899052|DRUG|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
58108615|NCT05157607|BEHAVIORAL|Family Connections Protocol for Relatives of Patients with SBD.|Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
58108616|NCT05157607|BEHAVIORAL|Treatment as Usual Optimized Protocol (TAU-O)|Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.
57739192|NCT05446987|OTHER|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
58108617|NCT04699643|DRUG|EVER4010001|Please refer to information in arm/group descriptions.
57739193|NCT05446987|OTHER|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
58108618|NCT03198637|DRUG|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
58108619|NCT03198637|DRUG|clinical assessment|
58108620|NCT00165854|DRUG|E7070|
58108621|NCT03769181|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58108622|NCT03769181|DRUG|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58108623|NCT04582448|DRUG|Insulin icodec|A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
58108624|NCT03061760|PROCEDURE|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
58441085|NCT05678634|BEHAVIORAL|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
58108625|NCT03061760|DIAGNOSTIC_TEST|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
58108626|NCT03061760|DIAGNOSTIC_TEST|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
58108627|NCT04854980|OTHER|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
58108628|NCT00931853|DRUG|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
58108629|NCT04541888|DRUG|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
58108630|NCT04541888|DRUG|Placebo|Placebo
58108631|NCT04541888|DRUG|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
58108632|NCT02182258|DRUG|BIBF 1120 soft gelatine capsule|
58108633|NCT02182258|DRUG|BIBF 1120 intravenous solution|
58108634|NCT02182258|DRUG|Placebo ampoule|
58108635|NCT05919459|BEHAVIORAL|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
58108636|NCT05919459|BEHAVIORAL|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
58108637|NCT03634670|OTHER|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
57739194|NCT03199625|BEHAVIORAL|Cognitive therapy|
57739195|NCT03199625|BEHAVIORAL|Behavior therapy|
57739196|NCT03199625|DRUG|SSRI antidepressants|
57739197|NCT06326515|BEHAVIORAL|psychoeducation|"To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017)."
58108638|NCT02305420|DEVICE|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
58108639|NCT02305420|DEVICE|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
57739198|NCT06326515|BEHAVIORAL|Stigma Reduction and Relapse Management|"To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011)."
58108640|NCT04519489|DEVICE|PAP therapy with telemonitoring|This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
58441086|NCT02989883|OTHER|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
58441087|NCT03566706|BEHAVIORAL|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
58441088|NCT03566706|BEHAVIORAL|Discussion Tool: Marijuana Use|Parent Discussion Tools
58441089|NCT03566706|BEHAVIORAL|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
57739199|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
58108641|NCT04519489|OTHER|AF standard management and OSA general care|Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
58108642|NCT02128867|OTHER|Assisted Autogenic Drainage (AAD)|
58108643|NCT02128867|OTHER|bouncing and AAD|
58108644|NCT02128867|OTHER|bouncing|
58108645|NCT02805374|DRUG|ASP1517|Oral
58108646|NCT03804801|DIETARY_SUPPLEMENT|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
58108647|NCT04819347|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
58108648|NCT04819347|DRUG|3BNC117|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
58108649|NCT04777773|OTHER|dual-task training|dual-task training
58441090|NCT00126776|BEHAVIORAL|case management|case/self management for COPD vs usual care
58441091|NCT00126776|BEHAVIORAL|usual care|usual care for COPD
58441092|NCT05535413|DRUG|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
58441093|NCT00434109|DRUG|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
58441094|NCT00434109|PROCEDURE|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
58441095|NCT02913378|PROCEDURE|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
58441096|NCT02913378|PROCEDURE|Sling|Conservative treatment with sling and rehabilitation
58108650|NCT00540709|DRUG|Insulin Glargine|
58108651|NCT02350530|DRUG|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
58108652|NCT02350530|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
58108653|NCT01848652|DRUG|infusion of MYOCET|
58311493|NCT05441007|OTHER|Hypoxic|Hypoxic gas mixture Gas mixture of 10% O2 and 90% N2 for six minutes.
58311494|NCT05441007|OTHER|Hypercapnic|Hypercapnic gas mixture Gas mixture of 21% O2, 5% CO2 74% N2 for six minutes.
58311495|NCT05441007|OTHER|Hypoxic and Hypercapnic|Hypoxic and Hypercapnic gas mixture Gas mixture of 10% O2, 5% CO2 85% N2 for six minutes.
58441097|NCT01843023|DRUG|Extended Release Naltrexone|naltrexone for extended release injectable suspension
58441098|NCT01843023|BEHAVIORAL|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
58441099|NCT01843023|DRUG|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
58441100|NCT00972530|BEHAVIORAL|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
58108654|NCT01623232|BIOLOGICAL|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~1. Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~2. Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~3. Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
58108655|NCT01623232|BIOLOGICAL|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
58441101|NCT02214290|DRUG|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
58441102|NCT02214290|DRUG|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
58441103|NCT02214290|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
58441104|NCT05835180|DRUG|TVB-2640 - 50 mg|TVB-2640 -50 mg administered orally once daily
57739200|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
57739201|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
57739202|NCT02639130|DRUG|Exendin [9-39]|Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
57739203|NCT02639130|DRUG|Placebo|Placebo infusion as challenge agent
58108656|NCT06169657|DEVICE|Body-weight-supported treadmill training (BWSTT)|Walking on a treadmill in a harness with body weight support as needed
58108657|NCT06169657|DEVICE|EksoNR exoskeleton gait training|Walking in the EksoNR exoskeleton
58441105|NCT00534963|PROCEDURE|cervical vs. uterine placement of balloon catheter|
58441106|NCT03690895|OTHER|Retrospective survival analysis|Kaplan-Meier model
58441107|NCT01428531|DRUG|Fondaparinux Sodium|
58441108|NCT04847765|DEVICE|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
58441109|NCT01626092|DRUG|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
58441110|NCT01626092|DRUG|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
58441111|NCT01626092|DRUG|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
58108658|NCT06169657|DEVICE|Overground gait training|Walking overground in a harness with body weight support as needed
58108659|NCT01321112|DRUG|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
58108660|NCT05354245|DIETARY_SUPPLEMENT|Fibre supplement (potato-pectin)|Fibre supplement
58108661|NCT05354245|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
58108662|NCT05354245|DIETARY_SUPPLEMENT|High-protein diet|High-protein diet
58108663|NCT02883673|DEVICE|Jada System|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
58108664|NCT06543225|OTHER|No intervention|No intervention
58108665|NCT01483222|DEVICE|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
58108666|NCT01483222|DEVICE|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
58108667|NCT04934514|BIOLOGICAL|IAH0968|IAH0968 is an investigational product.
58108668|NCT04934514|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenous infusion
58108669|NCT04934514|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 intravenous infusion
58108670|NCT01545219|DIETARY_SUPPLEMENT|Prebiotic|8g/day xylo-oligosaccharide
58108671|NCT01545219|DIETARY_SUPPLEMENT|Bi-07|10\^9 CFU B. lactis / day
58108672|NCT01545219|DIETARY_SUPPLEMENT|Synbiotic|8g/day xylo-oligosaccharide + 10\^9 CFU Bi-07
58108673|NCT01545219|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
58108674|NCT03872700|DRUG|Intranasal fentanyl|Fentanyl Citrate
58108675|NCT03872700|DRUG|Placebo|Sterile Water Up to 5Cc
58108676|NCT00040625|DRUG|Pemetrexed|
58108677|NCT00040625|DRUG|Cisplatin|
58108678|NCT01878747|BEHAVIORAL|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
58108679|NCT06527976|DRUG|Dexmedetomidine|dexmedetomedine added to bupivacaine for adductor canal block
58108680|NCT06527976|DRUG|Dexamethasone|dexamethasone added to bupivacaine for adductor canal block
58108681|NCT03447483|OTHER|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
58108682|NCT03083054|BIOLOGICAL|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
58441112|NCT01626092|RADIATION|Total Body Irradiation with Marrow Boosting|"1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
58441113|NCT01626092|BIOLOGICAL|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
58108683|NCT04465383|DEVICE|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
58108684|NCT04465383|DRUG|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
58108685|NCT00740064|DRUG|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
58108686|NCT03155828|DEVICE|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
58108687|NCT05049889|OTHER|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
58108688|NCT05049889|OTHER|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
58108689|NCT05049889|DEVICE|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
58108690|NCT05049889|DEVICE|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
58108691|NCT05049889|BIOLOGICAL|Blood collection|Several blood samples will be collected at visit 1 and 2.
58441114|NCT01626092|DRUG|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
58441115|NCT01626092|DRUG|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
58441116|NCT03991455|DEVICE|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
58441117|NCT04926246|DRUG|R1: Reference Product X|under fasted conditions
58108692|NCT00939133|DRUG|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
58108693|NCT00939133|DRUG|vehicle gel|Placebo
58441118|NCT04926246|DRUG|T1: Test Product M|under fasted conditions
58441119|NCT04926246|DRUG|T2: Test Product N|under fasted conditions
58441120|NCT04926246|DRUG|T3: Test Product O|under fasted conditions
58441121|NCT04926246|DRUG|T4: Test Product O|under fed conditions
58441122|NCT04926246|DRUG|R2: Reference Product Y|under fasted conditions
58441123|NCT04926246|DRUG|T5: Test Product P|under fasted conditions
58441124|NCT04926246|DRUG|T6: Test Product P|under fed conditions
57955746|NCT04349527|PROCEDURE|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
57955747|NCT04349527|PROCEDURE|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
57955748|NCT01714427|DRUG|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
57955749|NCT01714427|DRUG|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
58108694|NCT02535000|DRUG|Duloxetine|duloxetine 60 mg
58108695|NCT02535000|DRUG|Placebo|placebo
58108696|NCT06105619|DRUG|PLB1001|PLB1001 is a capsule in the form of 300mg,twice daily.
58441125|NCT04926246|DRUG|T7: Test Product Q|under fasted conditions
58441126|NCT04926246|DRUG|R3: Reference Product Z|under fasted conditions
58441127|NCT04926246|DRUG|T8: Test Product S|under fasted conditions
58441128|NCT04926246|DRUG|T9: Test Product S|under fed conditions
58108697|NCT06105619|DRUG|Temozolomide|100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
58108698|NCT06105619|DRUG|Cisplatin combined with Etoposide|Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
58108699|NCT02883309|OTHER|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
58441129|NCT04926246|DRUG|T10: Test Product U|under fasted conditions
58441130|NCT00943332|PROCEDURE|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
58441131|NCT00291603|DEVICE|FX-class of dialyser|
58441132|NCT01661894|DEVICE|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
58108700|NCT02350010|DEVICE|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
58108701|NCT00293670|DRUG|Goserelin (Zoladex)|
58441133|NCT03464019|DRUG|Etripamil|Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
58108702|NCT00444132|DRUG|clopidogrel|
58108703|NCT05483920|BEHAVIORAL|One-time educational video|One-time educational video
58108704|NCT05483920|BEHAVIORAL|One-time educational video plus automated text messaging|Educational video plus automated text messaging
58108705|NCT06297499|DRUG|Ondansetron 8mg|administration of an IV solution of 8mg ondansetron (4ml)
58311496|NCT02457091|BEHAVIORAL|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
58441134|NCT03464019|DRUG|Placebo|Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
57739204|NCT05176808|BEHAVIORAL|Early Achievements- Parent Coaching Intervention|Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
57739205|NCT03894865|OTHER|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
57955750|NCT00003362|BIOLOGICAL|QS21|
57955751|NCT00003362|BIOLOGICAL|gp100 antigen|
57955752|NCT00003362|BIOLOGICAL|incomplete Freund's adjuvant|
57955753|NCT00003362|BIOLOGICAL|sargramostim|
57955754|NCT00003362|BIOLOGICAL|tyrosinase peptide|
57955755|NCT04204278|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
57955756|NCT02655432|DEVICE|Spot photoscreener|Screening of vision problem through an automated device
57955757|NCT02655432|PROCEDURE|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
57955758|NCT02655432|PROCEDURE|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
57955759|NCT04802993|OTHER|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
57955760|NCT02678390|DIETARY_SUPPLEMENT|MCT|A 5 day consecutive MCT intake of 30 g/day.
57955761|NCT02678390|DIETARY_SUPPLEMENT|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
57955762|NCT02678390|DIETARY_SUPPLEMENT|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
57955763|NCT02678390|DIETARY_SUPPLEMENT|Control day|No MCT or aerobic exercise
57955764|NCT05681507|DRUG|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
57955765|NCT05681507|PROCEDURE|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
58108706|NCT06112457|OTHER|Survey|Anonymous self-administered questionnaire
58108707|NCT02291107|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
57955766|NCT04147104|DEVICE|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
58108708|NCT02291107|OTHER|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
58108709|NCT00162435|DRUG|Warfarin|
58108710|NCT04050800|DRUG|Carbon 11 Butanol|Two sequential administrations of a PET tracer
58108711|NCT02332135|PROCEDURE|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
58311497|NCT02457091|BEHAVIORAL|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
58311498|NCT01118078|GENETIC|DNA methylation analysis|Undergo DNA methylation analysis
58311499|NCT01118078|GENETIC|gene expression analysis|Undergo gene expression analysis
58311500|NCT01118078|GENETIC|microarray analysis|Undergo microarray analysis
58311501|NCT01118078|GENETIC|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
58108712|NCT02332135|DRUG|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
58108713|NCT05401331|DEVICE|Treadmilll|Hemodynamic changes before and after treadmill use
58108714|NCT05401331|OTHER|mask|mask
58108715|NCT06541392|OTHER|breakfast 6.30 am|This group will have breakfast time from 6.30 to 7.30 am
58108716|NCT06541392|OTHER|breakfast 7.31 am|This group will have breakfast time from 7.31 to 8.31 am
58108717|NCT01947556|DRUG|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
58108718|NCT01416649|DRUG|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
58108719|NCT05642611|PROCEDURE|Biospecimen Collection|Undergo collection of blood, plasma, and serum
58108720|NCT05642611|PROCEDURE|Cryocompression Therapy|Undergo cryocompression
58108721|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo continuous compression
58108722|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo low cyclic compression
58108723|NCT05642611|OTHER|Quality-of-Life Assessment|Ancillary studies
57739206|NCT03894865|OTHER|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
57739207|NCT00649194|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
58108724|NCT05642611|OTHER|Questionnaire Administration|Ancillary studies
58311502|NCT01118078|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
58311503|NCT03150043|DEVICE|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
58311504|NCT03174639|PROCEDURE|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
58311505|NCT02500498|DRUG|Nulojix|
58311506|NCT00116181|DRUG|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
58311507|NCT03427411|DRUG|M7824|Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
58311508|NCT04495621|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
58311509|NCT04495621|DRUG|Cetuximab|Cetuximab solution for infusion administered weekly via IV infusion.
58311510|NCT05340699|DEVICE|Defocus Distributed Multi-point lens|Wear DDM lens
58311511|NCT05340699|DEVICE|Single vision lens|Wear single vision lens
57739208|NCT00649194|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
58108725|NCT04331119|DRUG|Duvelisib|SecuraBio will supply duvelisib
58108726|NCT04331119|PROCEDURE|Peripheral blood draw|-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
58108727|NCT06198985|PROCEDURE|Dynamic balance exercise with tecnobody prokin 252 balance device|Dynamic balance exercise with tecnobody prokin 252 balance device
58108728|NCT02076191|DRUG|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
58441135|NCT03464019|DRUG|Etripamil Test Dose|During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
58441136|NCT03703089|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
57739209|NCT01512862|DRUG|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
57955767|NCT04147104|DEVICE|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
58108729|NCT02076191|DRUG|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
58311512|NCT03834350|OTHER|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
58311513|NCT03834350|DEVICE|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
57955768|NCT01780662|DRUG|Brentuximab Vedotin|Given IV
57955769|NCT01780662|DRUG|Gemcitabine Hydrochloride|Given IV
57955770|NCT01380431|DRUG|Lisinopril|Tablets, 40 mg, single oral dose
57955771|NCT01380431|DRUG|lisinopril|Tablets, 40 mg, single, oral dose
57955772|NCT01380431|DRUG|Lisinopril|50% of subjects received the Par formulated product.
57955773|NCT06488131|PROCEDURE|MTA Pulpotomy|Complete coronal MTA pulpotomy.
57955774|NCT06488131|PROCEDURE|Root Canal Treatment|Conventional root canal treatment.
57955775|NCT01681433|DRUG|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
57955776|NCT01681433|DRUG|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
57955777|NCT01681433|DRUG|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
57955778|NCT04993404|DRUG|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
57955779|NCT02469285|DIETARY_SUPPLEMENT|Modified pork|Pork with modified fatty acid composition
57955780|NCT02469285|DIETARY_SUPPLEMENT|Pork|Pork with normal fat composition
57955781|NCT02469285|DIETARY_SUPPLEMENT|Pork and berries|Pork with normal fat composition and Finnish berries
57955782|NCT02683200|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
57955783|NCT02683200|RADIATION|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
57955784|NCT02137564|DRUG|gamma secretase inhibitor PF-03084014|Given PO
57955785|NCT02137564|OTHER|pharmacological study|Correlative studies
58311514|NCT05257070|DIAGNOSTIC_TEST|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
57955786|NCT02137564|OTHER|laboratory biomarker analysis|Correlative studies
57955787|NCT05920876|DRUG|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
57955788|NCT04252846|DRUG|Perampanel|Perampanel oral tablets or oral suspension.
58311515|NCT01858961|DRUG|BI 201335|Once a day
58311516|NCT01858961|DRUG|ribavirin|Twice a day
58311517|NCT01858961|DRUG|BI 207127|Twice a day
58311518|NCT01858961|DRUG|Telaprevir|Three times a day
58311519|NCT01858961|DRUG|ribavirin|Twice a day
58311520|NCT01858961|DRUG|Pegylated Interferon|Once a week
58311521|NCT06094036|BEHAVIORAL|Structured and personalized program of physical exercise|"In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality."
57955789|NCT04623242|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
57955790|NCT04623242|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
57955791|NCT04623242|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
57955792|NCT04623242|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
58108730|NCT03385187|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
58441137|NCT03703089|DRUG|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
58441138|NCT04229628|OTHER|No special intervention|No special intervention
58441139|NCT03239080|DRUG|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
58441140|NCT03239080|OTHER|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
58441141|NCT00535002|DRUG|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
58441142|NCT00535002|DRUG|Placebo|
58441143|NCT06334640|DIAGNOSTIC_TEST|Three questionaires|Berlin, Pittsburgh and Epworth tests administered during study visit
58441144|NCT00870012|DRUG|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
58441145|NCT00870012|OTHER|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
57739210|NCT01512862|DRUG|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
57739211|NCT00006231|PROCEDURE|quality-of-life assessment|
58108731|NCT02996006|PROCEDURE|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
58311522|NCT00964782|DRUG|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
57739212|NCT00006231|PROCEDURE|standard follow-up care|
57739213|NCT00006231|RADIATION|radiation therapy|
58311523|NCT00964782|DRUG|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
58108732|NCT02662322|OTHER|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
58311524|NCT00964782|DRUG|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
58311525|NCT00964782|DRUG|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
58311526|NCT05475639|OTHER|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
58311527|NCT05475639|OTHER|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
58311528|NCT05475639|OTHER|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
58311529|NCT05222867|PROCEDURE|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
58311530|NCT05655871|OTHER|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
58311531|NCT05655871|OTHER|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
58311532|NCT01211171|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
58311533|NCT01726166|PROCEDURE|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
58311534|NCT01726166|PROCEDURE|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
58441146|NCT00414518|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
58441147|NCT00414518|DRUG|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
58441148|NCT01768364|DRUG|Trimetoprim-Sulfa (Bactrim)|
58441149|NCT01768364|OTHER|No antibiotics|
58441150|NCT05846373|DRUG|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
58441151|NCT05846373|DRUG|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
58108733|NCT02662322|OTHER|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
58108734|NCT02662322|OTHER|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
58108735|NCT02662322|OTHER|peripheral intravenous catheterization|peripheral intravenous catheterization
58108736|NCT04714099|DRUG|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
58108737|NCT04714099|DRUG|Placebo|Placebo
58441152|NCT05846373|OTHER|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
58441153|NCT04099121|DEVICE|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
58441154|NCT03325374|OTHER|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
58441155|NCT01821859|DRUG|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
58441156|NCT01821859|DRUG|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
58441157|NCT00005024|DRUG|carboplatin|
58441158|NCT00005024|DRUG|cyclophosphamide|
58441159|NCT00005024|DRUG|doxorubicin hydrochloride|
58441160|NCT00005024|DRUG|granisetron hydrochloride|
58441161|NCT03606187|DEVICE|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
58441162|NCT03606187|DEVICE|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
58441163|NCT00834262|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58441164|NCT00834262|DRUG|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
57739214|NCT06231173|OTHER|Visual Feedback Therapy and Conventional Therapy|In experimental group individuals will receive visual feedback therapy and Conventional rehabilitation therapy. In visual feedback therapy, bilateral method is used to receive the visual feedback from the mirror. This visual feedback therapy consists of the following parts as the patient is asked to follow the involved hand that did the mimicking while the non-involved side will be performing wrist flexion, wrist extension, ulnar deviation, radial deviation, supination, pronation, and closing hand and opening hand.In conventional therapy, Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the noninvolved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
58108738|NCT02269215|DRUG|BIII 890 CL|
58108739|NCT02269215|DRUG|Placebo|
57739215|NCT06231173|OTHER|Conventional Therapy|In control group individuals will receive only conventional therapy. In conventional therapy, Patients are instructed to perform a sandbag and hand grip exercise with a resistive exercise for the non-involved side. At last, patients are instructed to perform a moving small object (ball of wool) and card flip operation to induce wrist and finger movements as functional activities. Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the non involved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. .This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
58441165|NCT00834262|DRUG|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58441166|NCT02369393|BEHAVIORAL|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
58311535|NCT02742207|OTHER|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
58311536|NCT02742207|OTHER|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
58311537|NCT00276302|DRUG|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
58311538|NCT00581191|DRUG|SLV-351|SLV-351 capsules taken once
58311539|NCT05598736|DEVICE|FlowOx 2.0|-40mmHg intermittent negative pressure for 60 minutes per day
58311540|NCT00355927|PROCEDURE|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
58311541|NCT02977351|PROCEDURE|Non-surgical periodontal treatment|
58311542|NCT01131936|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
58311543|NCT04330872|DRUG|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
58311544|NCT04330872|DRUG|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
58311545|NCT02422758|DEVICE|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
58311546|NCT02422758|OTHER|Passive Prewarming|
58311547|NCT03754920|BEHAVIORAL|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
58311548|NCT05347628|DRUG|PLB1004|PLB1004 is a capsule in the form of 10mg and 40mg.
58311549|NCT02598674|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
58311550|NCT02598674|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
58441167|NCT02369393|BEHAVIORAL|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
58441168|NCT01413139|DEVICE|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
58441169|NCT00491933|PROCEDURE|Quantiferon-TB Gold assay|
58441170|NCT00491933|PROCEDURE|Tuberculin skin test|
57739216|NCT01923155|PROCEDURE|Colonoscopy|
57739217|NCT05188573|DEVICE|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
57739218|NCT05188573|DEVICE|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
57739219|NCT06392776|OTHER|Early diagnosis and treatment|Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
58311551|NCT02598674|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
57739220|NCT06382350|DEVICE|MiniMed 780 G|none, observational study
58311552|NCT02598674|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
58311553|NCT02598674|DRUG|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
58311554|NCT05644496|DRUG|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
58311555|NCT00761098|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
58441171|NCT05367297|DIAGNOSTIC_TEST|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
58441172|NCT00096980|DRUG|Raptiva (efalizumab)|
58441173|NCT05254483|BEHAVIORAL|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
58311556|NCT00761098|DRUG|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
58311557|NCT03798314|BIOLOGICAL|Nivolumab|Given IV
58311558|NCT03798314|DRUG|Pomalidomide|Given PO
58311559|NCT00299520|DRUG|intravenous iclaprim or intravenous linezolid|
58311560|NCT04061785|OTHER|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
58311561|NCT06079294|OTHER|FDG PET|Brain FDG PET performed 3 months after treatment initiation
58311562|NCT03353077|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
58311563|NCT04211376|OTHER|No Intervention|There is no intervention for this study
58311564|NCT03502824|DEVICE|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
58311565|NCT03502824|OTHER|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
58311566|NCT00374868|DRUG|pemetrexed|"Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
58311567|NCT00374868|DRUG|cisplatin|"Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
58311568|NCT00610415|PROCEDURE|tumor biopsy|
58311569|NCT00166699|PROCEDURE|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
58311570|NCT04905992|OTHER|Hypertonic saline at 6%|Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
58311571|NCT04905992|OTHER|Airway clearance techniques (oscillating positive expiratory pressure therapy)|Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
57739221|NCT06580808|OTHER|Fontan Training Group|The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
58441174|NCT05254483|BEHAVIORAL|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
58441175|NCT05254483|DEVICE|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
58441176|NCT04583332|OTHER|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
58441177|NCT04583332|OTHER|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
57739222|NCT01200212|DRUG|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
57739223|NCT01200212|DRUG|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
57739224|NCT00517738|OTHER|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
57955793|NCT04057274|OTHER|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
58311572|NCT02375503|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
58311573|NCT02375503|DIETARY_SUPPLEMENT|Placebo|
58311574|NCT03483428|BEHAVIORAL|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
58441178|NCT04583332|OTHER|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
58441179|NCT01598467|PROCEDURE|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
58108740|NCT04109378|PROCEDURE|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
58108741|NCT02931565|DRUG|Olinciguat|oral tablet
58108742|NCT02931565|DRUG|Matching Placebo|oral tablet
58441180|NCT06402006|PROCEDURE|PENG block|pericapsular nerve group block
57739225|NCT00517738|OTHER|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
57739226|NCT05052801|DRUG|Bemarituzumab|Intravenous (IV) infusion
58108743|NCT03629847|DRUG|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
58108744|NCT06079086|DEVICE|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
58108745|NCT02122211|DRUG|Betaine supplement|
58311575|NCT03483428|BEHAVIORAL|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
58311576|NCT05841420|DRUG|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
58311577|NCT05841420|DRUG|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
58311578|NCT00336908|DRUG|a combination of MCT, LCT , and Fish Oil|
58311579|NCT02406820|DEVICE|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
58311580|NCT04546841|BIOLOGICAL|multipeptide cocktail|"Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening"
58311581|NCT06550323|DEVICE|Group using virtual reality glasses|Group using virtual reality glasses: During the procedure, individuals will wear glasses.
58441181|NCT06402006|PROCEDURE|LFCN block|Lateral femoral cutaneous nerve block
58441182|NCT06402006|PROCEDURE|ESP block|Erector spinae plane block
58108746|NCT05123027|BEHAVIORAL|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
58108747|NCT05123027|BEHAVIORAL|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
58108748|NCT00307619|DRUG|topiramate|
58108749|NCT04741503|OTHER|Breast Cancer Screening Decision Support Tool|-Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
58441183|NCT04138446|OTHER|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
58441184|NCT01546662|DIETARY_SUPPLEMENT|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
58441185|NCT01546662|DIETARY_SUPPLEMENT|Placebo|1/ 2 capsules, twice daily for 12 weeks
58441186|NCT00292019|PROCEDURE|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
58441187|NCT05791968|PROCEDURE|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
58441188|NCT02717039|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
57739227|NCT05052801|DRUG|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
57955794|NCT01484626|DRUG|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m\^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m\^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m\^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m\^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
57955795|NCT02554097|PROCEDURE|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
58108750|NCT04741503|OTHER|National Cancer Institute Breast Cancer Screening PDQ|-Provides current information about breast cancer screening and is meant to inform and help patients
58311582|NCT05968378|BEHAVIORAL|Standard healthy eating advice|Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
58311583|NCT05968378|BEHAVIORAL|eTRE plus Mediterranean diet|Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
58441189|NCT00191230|DRUG|gemcitabine|
58441190|NCT00191230|DRUG|carboplatin|
58441191|NCT00191230|DRUG|cisplatin|
58441192|NCT00003515|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58441193|NCT02139865|BEHAVIORAL|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
58441194|NCT02139865|BEHAVIORAL|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
58441195|NCT05396144|DRUG|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
58441196|NCT03360474|BEHAVIORAL|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
57739228|NCT05052801|DRUG|Placebo|IV infusion
58441197|NCT01183949|DRUG|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
58441198|NCT01183949|DRUG|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
58441199|NCT03068754|DRUG|Acthar|Repository corticotropin for subcutaneous injection
58441200|NCT03068754|DRUG|Placebo|Matching placebo for subcutaneous injection
58441201|NCT01542710|DRUG|Ganfort|Bimatoprost/Timolol fixed combination
58441202|NCT01542710|DRUG|Duotrav|Fixed combination of Travoprost and Timolol
58441203|NCT00291486|DRUG|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
58441204|NCT00291486|DRUG|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
57739229|NCT00450762|DRUG|gemcitabine|
57739230|NCT00450762|DRUG|carboplatin|
58441205|NCT01819896|DRUG|Pacemaker and defibrillator|
58441206|NCT02161991|DRUG|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
58441207|NCT02161991|DRUG|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
58441208|NCT02196935|OTHER|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
57739231|NCT02672631|OTHER|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
57739232|NCT02672631|OTHER|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
57739233|NCT02672631|OTHER|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
58441209|NCT03781141|PROCEDURE|Wound closure|Comparison of two wound closures
57955796|NCT02554097|PROCEDURE|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
58441210|NCT02966561|BEHAVIORAL|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
58441211|NCT02966561|BEHAVIORAL|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
58441212|NCT02966561|OTHER|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
58441213|NCT01770171|DRUG|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
58441214|NCT01770171|DRUG|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
58441215|NCT06300073|DEVICE|Experimental: U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
58441216|NCT06300073|DEVICE|Placebo Comparator: Soft Manual Toothbrush|Twice daily brushing for 2 minutes with fluoride toothpaste
58441217|NCT00589771|DRUG|Saccharomyces boulardii|"1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
58441218|NCT00589771|DRUG|Placebo|"1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
58441219|NCT02457468|DEVICE|coflex|
58441220|NCT04548791|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
58441221|NCT00584259|OTHER|Coffee|3 cups of coffee over a 24 hour period
58441222|NCT01363908|DRUG|SPD602|
58441223|NCT03909308|BEHAVIORAL|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
58441224|NCT03223337|DRUG|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
58441225|NCT04239742|DIAGNOSTIC_TEST|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
58441226|NCT04239742|DIAGNOSTIC_TEST|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
58441227|NCT02434562|OTHER|Serum (with or without urine) samples|
58441228|NCT00437814|DRUG|Ketamine, effect on intracranial pressure|
58441229|NCT05688696|DRUG|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
58441230|NCT05688696|DRUG|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
58441231|NCT05688696|DRUG|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
58441232|NCT01926990|DEVICE|perfusion computed tomography|Undergo perfusion CT
58441233|NCT02378545|DRUG|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
57955797|NCT02554097|PROCEDURE|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
58441234|NCT05977764|OTHER|Ultrasound|Contrast enhanced ultrasound
58441235|NCT05138315|DEVICE|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
58441236|NCT01198639|DEVICE|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
58441237|NCT01198639|DEVICE|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
58441238|NCT02951078|PROCEDURE|Thulium Laser en Bloc Resection of bladder tumor|
58441239|NCT02951078|PROCEDURE|Electrical transurethral resection of bladder tumor|
58441240|NCT02657304|BEHAVIORAL|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
58441241|NCT02657304|OTHER|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
58441242|NCT00954499|BEHAVIORAL|Tactile stimulation added to Standard care|"* Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
58441243|NCT00954499|BEHAVIORAL|Standard care|"* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
58441244|NCT04355819|BEHAVIORAL|Disclosure timing|When patients are told that a hernia was present on the CT scan
58441245|NCT03487211|DRUG|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
58441246|NCT03487211|DRUG|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
58441247|NCT05971927|BEHAVIORAL|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
58441248|NCT00852787|DRUG|Digoxin immune fab|Intravenously one time
58108751|NCT04595227|DEVICE|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
57739234|NCT04824404|BEHAVIORAL|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
57739235|NCT06195917|DEVICE|Robotic-assisted Interventional Percutaneous transhepatic puncture|Robotic-assisted Interventional Percutaneous transhepatic puncture
57739236|NCT00674986|DEVICE|Accu-Chek 360° View Blood Glucose Analysis Tool|
57739237|NCT00674986|DEVICE|Accu-Chek Aviva Glucose Meter|
57955798|NCT02554097|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
58441249|NCT00852787|DRUG|Placebo|Intravenously one time
58441250|NCT05371912|DEVICE|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
58441251|NCT01221350|DIETARY_SUPPLEMENT|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
58441252|NCT01221350|DIETARY_SUPPLEMENT|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
58441253|NCT04346992|OTHER|no intervention|no intervention
58441254|NCT00003727|BIOLOGICAL|filgrastim|
58441255|NCT00003727|BIOLOGICAL|recombinant interferon alfa|
58441256|NCT00003727|BIOLOGICAL|sargramostim|
58441257|NCT00003727|BIOLOGICAL|therapeutic autologous lymphocytes|
58441258|NCT00003727|DRUG|carmustine|
58441259|NCT00003727|DRUG|cyclophosphamide|
58441260|NCT00003727|DRUG|etoposide|
58441261|NCT00003727|DRUG|gemcitabine hydrochloride|
58441262|NCT00003727|DRUG|melphalan|
58441263|NCT00003727|PROCEDURE|bone marrow ablation with stem cell support|
58441264|NCT00003727|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58441265|NCT03735992|BEHAVIORAL|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
58441266|NCT01807598|DRUG|Brentuximab vedotin|
58311584|NCT00473083|DRUG|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
57739238|NCT06496529|BEHAVIORAL|DoF intervention|Training of specific uniarticular and single plane movement of the upper limb through an exoskeleton and videogames that will be supervised by a physiotherapist.
58311585|NCT00473083|DRUG|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
58311586|NCT00473083|DRUG|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
58311587|NCT00473083|DRUG|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
58311588|NCT02974504|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
58311589|NCT02974504|DRUG|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
58311590|NCT03028246|DEVICE|ExAblate 4000 System|Focused ultrasound
58311591|NCT01860209|PROCEDURE|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
58441267|NCT04280627|OTHER|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
58441268|NCT01902121|DRUG|Technosphere® Insulin 10U + 20U|Inhaled Insulin
58441269|NCT01902121|DRUG|Technosphere® Insulin 30U|Inhaled Insulin
58441270|NCT01467921|DRUG|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
58441271|NCT03181399|DRUG|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
58441272|NCT03770117|PROCEDURE|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
58441273|NCT03770117|PROCEDURE|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
58441274|NCT01873040|BEHAVIORAL|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
58441275|NCT01873040|BEHAVIORAL|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
58441276|NCT00825812|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
58441277|NCT00825812|DRUG|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
58441278|NCT00145574|DRUG|colesevelam HCl|Tablets
58441279|NCT00145574|DRUG|placebo|Matching Tablets
58441280|NCT03400475|DRUG|Simvastatin|One topical application in peri-implant gingival crevice
58441281|NCT03400475|OTHER|Placebo|One topical application in peri-implant gingival crevice
58441282|NCT03114332|PROCEDURE|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
58441283|NCT03992846|DRUG|75 mg linzagolix tablet|For oral administration once daily
58441284|NCT03992846|DRUG|200 mg linzagolix tablet|For oral administration once daily
58441285|NCT03992846|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
57739239|NCT06496529|BEHAVIORAL|Task intervention|Training of multiarticular upper limb movements (vertical, horizontal and diagonal) through videogames and also training of functional task (raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass). This activities will be supervised by a physiotherapist.
57739240|NCT03655353|DIAGNOSTIC_TEST|ABY-PET|Diagnostic PET for HER2 expression
57955799|NCT05099471|DRUG|Venetoclax; Rituximab|Combination of venetoclax and rituximab
58441286|NCT03992846|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
58441287|NCT03992846|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
58441288|NCT03992846|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
58441289|NCT02794233|OTHER|Impedance measurements|Refer to study description
57955800|NCT05099471|DRUG|DRC|Combination of Dexamethasone / Rituximab / Cyclophosphamide
58441290|NCT01581060|DRUG|WX-554|Capsules of WX-554
58441291|NCT03630757|OTHER|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
58441292|NCT02013297|RADIATION|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
58441293|NCT05223049|OTHER|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
58441294|NCT05223049|OTHER|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
58441295|NCT05223049|OTHER|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
58441296|NCT05223049|OTHER|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
58441297|NCT05223049|OTHER|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
58108752|NCT05909306|OTHER|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
58108753|NCT00001428|DRUG|5-fluorouracil|
58108754|NCT02346981|BEHAVIORAL|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
58311592|NCT01220284|DRUG|Satraplatin in combo with vinorelbine|"* Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
58311593|NCT03789721|OTHER|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
58311594|NCT03789721|OTHER|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
58311595|NCT05232721|DIAGNOSTIC_TEST|The new instrument and colonoscopy with pathological examination|Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
58311596|NCT05161390|DRUG|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
58311597|NCT03314480|DIAGNOSTIC_TEST|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
58311598|NCT03002402|BEHAVIORAL|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
58311599|NCT01512888|GENETIC|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
58311600|NCT01512888|DRUG|Busulfan|Given intravenously (IV).
58311601|NCT01512888|DEVICE|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
58441298|NCT05223049|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
58441299|NCT03941717|OTHER|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
58441300|NCT03941717|OTHER|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
58441301|NCT01314131|BEHAVIORAL|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
58441302|NCT00136045|DRUG|Rotigotine|
57739241|NCT04897776|DEVICE|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
58108755|NCT01914315|BEHAVIORAL|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
58311602|NCT03243396|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
58311603|NCT02943213|DRUG|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
58311604|NCT00264212|DRUG|irbesartan and irbesartan-hydrochlorothiazide|
58311605|NCT05815966|BEHAVIORAL|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
58311606|NCT04056169|DRUG|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
58311607|NCT04056169|DRUG|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
58311608|NCT01569022|DEVICE|CPAP|CPAP Treatment for 12 weeks
58311609|NCT01569022|DEVICE|MAD|MAD Treatment for 12 weeks
58311610|NCT01740232|PROCEDURE|trephination|Artroscopic meniskal repair with trephination.
58311611|NCT01740232|PROCEDURE|Normal meniscal repair|Artroscopic meniskal repair without trephination.
58311612|NCT02667899|DEVICE|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
58311613|NCT02667899|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
58311614|NCT02667899|OTHER|Routine treatment|Means without above additional treatment.
58311615|NCT04664205|OTHER|High Intensity Interval Exercise|One session of high intensity interval exercise
58311616|NCT04664205|OTHER|Moderate Intensity Continuous Exercise|One session of calorically matched moderate intensity exercise
58441303|NCT04289961|DIAGNOSTIC_TEST|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
58311617|NCT04664205|OTHER|Control|No exercise, resting measures
58311618|NCT03415178|DRUG|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
58108756|NCT01914315|OTHER|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
58108757|NCT05910710|GENETIC|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
58108758|NCT03543033|DRUG|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
58108759|NCT03112993|DRUG|sugammadex|once at the end of the surgery
58108760|NCT03112993|DRUG|Neostigmine|once at the end of the surgery
58108761|NCT02012205|PROCEDURE|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
58108762|NCT05436691|OTHER|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
58108763|NCT04911920|OTHER|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
58108764|NCT00543790|DRUG|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
58108765|NCT06214026|DEVICE|META-Arc foot locked|Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.
58108766|NCT06214026|DEVICE|META-Arc foot unlocked|Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
58108767|NCT04452799|DRUG|Hesperidin and Diosmin mixture|Interventional Clinical Trial
57739242|NCT04897776|DEVICE|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
57739243|NCT02748915|OTHER|Electrophysiological and psychoacoustic tests|
57739244|NCT01045629|OTHER|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
57739245|NCT02576678|DRUG|Apremilast|
57739246|NCT04786158|DRUG|Apomorphine|Reporting the effects of subcutaneous apomorphine on pain and on quality of life
57739247|NCT04461977|OTHER|True acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
58311619|NCT03415178|DEVICE|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
58311620|NCT03415178|DEVICE|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
58311621|NCT03415178|DRUG|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
58311622|NCT03415178|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
58311623|NCT05223127|OTHER|Aloe vera|The leaves of Aloe vera (Aloe barbadensis) will be identified and verified by Selçuk University Faculty of Agriculture. Aloe vera leaves will be washed with antiseptic solution and cut crosswise using gloves and sterile knife. The thick epidermis will be removed from the middle of the leaf. The gel will be obtained from the parenchyma of the thick juicy leaves of aloe vera.
58311624|NCT02218463|DRUG|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
58311625|NCT02218463|DRUG|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
58311626|NCT02629302|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
58311627|NCT02629302|OTHER|standard therapy|standard physiotherapy, speech therapy and occupational therapy
58311628|NCT02404142|DRUG|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
58311629|NCT02404142|DRUG|saline isotonic solution|
58441304|NCT01518842|BIOLOGICAL|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
58108768|NCT01015612|DEVICE|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
58108769|NCT05484271|PROCEDURE|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
58108770|NCT06351137|OTHER|Intravenous administration|Analgesia is administered intravenously.
58108771|NCT06351137|OTHER|Intranasal administration|Analgesia is administered intranasally using an atomizer.
58108772|NCT00699634|DRUG|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
58108773|NCT03996265|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
58311630|NCT01130272|DRUG|Eluxadoline|Tablets, orally, twice daily.
58311631|NCT01130272|DRUG|Placebo|Matching placebo oral tablets twice daily.
58311632|NCT04223947|PROCEDURE|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
58311633|NCT04156698|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
58311634|NCT04156698|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
58311635|NCT04156698|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
58311636|NCT04156698|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
58311637|NCT00393315|DEVICE|paclitaxel coated balloon catheter|
58311638|NCT01584934|DRUG|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
58441305|NCT01946737|RADIATION|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
58441306|NCT01946737|RADIATION|Active Comparator: Invasive coronary angiography (ICA)|
58441307|NCT01915043|OTHER|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
58441308|NCT01391936|PROCEDURE|Tension Band Wiring|AO technique of TBW for fixation of fracture.
58441309|NCT01391936|PROCEDURE|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
58441310|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
58108774|NCT03996265|OTHER|Placebo Administration|Given PO
58108775|NCT03996265|OTHER|Quality-of-Life Assessment|Ancillary studies
58311639|NCT01584934|DRUG|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
58311640|NCT03568435|OTHER|Non-Interventional|Non-Interventional
58311641|NCT04260165|PROCEDURE|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
58311642|NCT04260165|PROCEDURE|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
58311643|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
58311644|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
58311645|NCT05507450|BIOLOGICAL|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
58311646|NCT05507450|BIOLOGICAL|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
58311647|NCT05507450|BIOLOGICAL|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
58441311|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
58441312|NCT06413797|BEHAVIORAL|FDA warnings + Image|For six days (days 2-7) participants will be contacted and asked to complete a daily survey. As part of the survey, participants will view FDA-proposed LCC warnings with images at 30% size on a cigarillo package. Participants will be contacted each day to be invited to complete the survey for that day of the study protocol.
58441313|NCT06413797|BEHAVIORAL|FDA Warnings Text-Only|Participants will receive messages including images in 30% size.
58441314|NCT06413797|BEHAVIORAL|Surgeon General Text-Only Warnings|Participants will receive messages including Surgeon General Text-only Warnings.
58441315|NCT05145868|BEHAVIORAL|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
58441316|NCT05145868|OTHER|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
58441317|NCT00456287|DEVICE|CPAP (Continuous Positive Airway Pressure)|
58441318|NCT02160652|PROCEDURE|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
58441319|NCT00563459|DRUG|carisbamate|400-1200 mg/day for 12 months
58441320|NCT00563459|DRUG|topiramate|200-400mg/day for 12 months
58441321|NCT00563459|DRUG|levetiracetam|1000-3000mg/day for 12 months
58441322|NCT02354872|DRUG|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
58441323|NCT02354872|BEHAVIORAL|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
58441324|NCT02354872|BEHAVIORAL|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
57955801|NCT05198271|OTHER|Management of risk factors|"* For all patients:~  * Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~ * Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~ * Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~* Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
57955802|NCT05198271|BEHAVIORAL|Smoking cessation|"- For active smoking patients:~* Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~* Nicotine substitutes +/- varenicline according to tobacco consumption~* Online notebook to record tobacco consumption and triggers"
57955803|NCT05198271|BEHAVIORAL|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
57955804|NCT05198271|OTHER|periodontal disease treatment|- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
57955805|NCT05198271|BEHAVIORAL|increased physical activity|- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
57955806|NCT05198271|BEHAVIORAL|Decreased anxiety|"- For anxious patients:~* Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~* Delivery of connected equipment for the practice of cardiac coherence"
57955807|NCT01972750|DRUG|Dovitinib|daily oral intake of capsule
57955808|NCT02086539|OTHER|Large Envelope|
57955809|NCT02086539|OTHER|Priority Mail|
57955810|NCT02086539|OTHER|Amazon|
58108776|NCT03996265|OTHER|Questionnaire Administration|Ancillary studies
58108777|NCT04427696|BEHAVIORAL|Aerobic walking intervention|Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
58108778|NCT06356376|DEVICE|Heat Stimulation|Heat stimulation at a painful, but to the subject tolerable level.
58108779|NCT03208933|DRUG|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
58108780|NCT00095199|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
58108781|NCT00095199|BIOLOGICAL|Cetuximab|Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
58108782|NCT00095199|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
58108783|NCT06526130|PROCEDURE|General anaesthesia|Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
58108784|NCT06526130|PROCEDURE|Neuraxial anaesthesia|spinal or epidural injections of local anesthetic with or without opioid
58108785|NCT02619071|PROCEDURE|Tumor sampling|Bone marrow aspirate, blood sampling
58108786|NCT02619071|BIOLOGICAL|Constiutional DNA sampling|Buccal swab or Hair follicles
58108787|NCT03273127|DRUG|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
58108788|NCT03273127|DRUG|Placebo|Abediterol matching placebo without any pharmacological activity.
58108789|NCT03066440|DRUG|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
58108790|NCT03066440|DRUG|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
58108791|NCT05009628|PROCEDURE|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
58441325|NCT02354872|BEHAVIORAL|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
58441326|NCT02354872|OTHER|No Treatment|No Treatment
58441327|NCT04287387|DRUG|Glucophage 500Mg Tablet|0.5g three times daily
58441328|NCT04287387|DRUG|Acarbose Tablets|50mg three times daily
58441329|NCT04287387|DRUG|Sitagliptin tablet|100mg once daily
58108792|NCT05009628|PROCEDURE|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
58108793|NCT05009628|PROCEDURE|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
58108794|NCT05165511|BEHAVIORAL|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
58311648|NCT05507450|BIOLOGICAL|Placebo|0.5 mL SC dose of placebo
58311649|NCT03504553|OTHER|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
58311650|NCT04808102|DEVICE|IER AG|The game is a web-based single-player adventure game with 3 levels created with the RPG Maker MV. Playtime is approximately 3 hours.
58311651|NCT04808102|DEVICE|BubbleShooter|A free-to-play arcade browser puzzle game called BubbleShooter.
58441330|NCT04287387|DRUG|Dapagliflozin Tablet|10mg once daily
58441331|NCT04287387|DRUG|Pioglitazone Tablets|30mg once daily
58441332|NCT04287387|DRUG|Glimepiride Tablets|2mg once daily
58441333|NCT04063969|OTHER|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
58311652|NCT02279953|DRUG|Vortioxetine 10-20 mg|
58311653|NCT02279953|DRUG|Placebo|
58311654|NCT02279953|DRUG|SSRI|escitalopram, citalopram or sertraline
58441334|NCT04063969|OTHER|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
58108795|NCT05145296|COMBINATION_PRODUCT|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
58108796|NCT04116294|OTHER|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
58108797|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
58441335|NCT04063969|OTHER|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
58441336|NCT04063969|OTHER|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
58441337|NCT02073682|DRUG|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
58441338|NCT02073682|DRUG|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
58441339|NCT02073682|DRUG|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
58441340|NCT02137096|DRUG|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
58441341|NCT02137096|DRUG|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
57955811|NCT06047691|BEHAVIORAL|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
57955812|NCT06047691|BEHAVIORAL|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
57955813|NCT05298007|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
57955814|NCT05298007|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
57955815|NCT02933034|DRUG|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
57955816|NCT02933034|DRUG|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
57955817|NCT00291408|PROCEDURE|Skin Prick Test|
57955818|NCT00291408|PROCEDURE|Impulse Oscillometry|
57955819|NCT00291408|PROCEDURE|Exhaled Nitric Oxide|
57955820|NCT00291408|PROCEDURE|Spirometry|
58441342|NCT02137096|DRUG|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
58441343|NCT02137096|PROCEDURE|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
58441344|NCT03031366|OTHER|3d roadmap guidance|TIPS was established using 3d roadmap
58441345|NCT03031366|OTHER|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
58441346|NCT03482037|DRUG|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
58441347|NCT03482037|DRUG|placebo|Each vial content will be administered via the catheter used for the self-catheterization
57955821|NCT00291408|PROCEDURE|Reversibility|
57955822|NCT00291408|PROCEDURE|Exhaled Breath Condensate|
57955823|NCT00291408|PROCEDURE|Sputum Induction|
57955824|NCT03336021|OTHER|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
57955825|NCT04617951|DIETARY_SUPPLEMENT|Ishige Okamurae extracts group|Ishige Okamurae extracts 300 mg/day for 12 weeks
57955826|NCT04617951|DIETARY_SUPPLEMENT|Placebo group|Placebo 300 mg/day for 12 weeks
57955827|NCT04595903|DEVICE|Hemopurifier|Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
57955828|NCT01665183|DRUG|ADI-PEG 20|
58108798|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
58108799|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
58311655|NCT03243149|DEVICE|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
58311656|NCT06551545|DIETARY_SUPPLEMENT|Tryptophan intake|There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
57955829|NCT02360020|DEVICE|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
57955830|NCT01225484|PROCEDURE|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
58311657|NCT04786769|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
58311658|NCT04996030|DRUG|SY-2101|SY-2101 will be administered per dose and schedule specified in arm description.
58441348|NCT03936257|OTHER|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
58441349|NCT03936257|OTHER|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
58441350|NCT03936257|OTHER|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
58441351|NCT01237613|DEVICE|Artelon|Artelon Tissue Reinforcement
58311659|NCT04996030|DRUG|Arsenic Trioxide|IV ATO will be administered per dose and schedule specified in arm description.
58311660|NCT05627687|BEHAVIORAL|Heart Rate Variability Biofeedback|Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
58311661|NCT05627687|BEHAVIORAL|Music Listening Control|Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
58311662|NCT02934594|OTHER|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
58441352|NCT02718209|DEVICE|Mid-Infrared Spectroscopy with ATR|
58441353|NCT02092792|DRUG|DLYE5953A|Escalating doses of DLYE5953A
58441354|NCT02092792|DRUG|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
58441355|NCT04789369|BEHAVIORAL|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
57955831|NCT01225484|PROCEDURE|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
57955832|NCT02913937|DEVICE|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
57955833|NCT02913937|DEVICE|Endodontic needle|Endodontic irrigation
57955834|NCT03467646|PROCEDURE|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
58108800|NCT00914797|DRUG|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
58311663|NCT05761847|OTHER|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
58311664|NCT02437292|OTHER|Ischemic compression with stretching|
58311665|NCT05899998|BEHAVIORAL|Bright IDEAS|Bright IDEAS® (Identify, Define, Evaluate, Act, See) is a problem-solving skills training program that was originally developed to alleviate distress in caregivers of children recently diagnosed with cancer. Intervention materials include instructor and user manuals, a brochure, and worksheets to be completed by the parent caregiver, initially with the help of the interventionist and then with increasing independence.
58311666|NCT04092413|DEVICE|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
58441356|NCT01969695|DRUG|ABT-199|ABT-199 continuous once daily dosing
58441357|NCT02987270|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
58441358|NCT02936024|PROCEDURE|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
57955835|NCT03467646|PROCEDURE|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
57955836|NCT03467646|PROCEDURE|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
58108801|NCT06049667|DRUG|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
58108802|NCT05644912|DEVICE|Transanal irrigation (TAI)|Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
58108803|NCT02289924|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
58108804|NCT02436395|PROCEDURE|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
58311667|NCT02582489|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
58311668|NCT02582489|PROCEDURE|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
58311669|NCT00431418|DRUG|Sildenafil|Sildenafil oral solution
58311670|NCT00431418|DRUG|Placebo|Placebo solution
58311671|NCT03829176|GENETIC|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
58311672|NCT03151369|DRUG|Morphine|patients with the visual analog scale over 3 will receive morphine
58311673|NCT00976365|DIETARY_SUPPLEMENT|THL-P|20ml/bottle, TID, 24weeks
58311674|NCT01391611|DRUG|Pazopanib|800 mg; PO
58311675|NCT04518696|PROCEDURE|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
58311676|NCT05244200|OTHER|Pharmaceutical care and insulin staging.|Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
58311677|NCT02636621|DEVICE|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
58311678|NCT02636621|OTHER|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
58311679|NCT02438579|OTHER|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
58311680|NCT01366716|BEHAVIORAL|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
58311681|NCT01366716|BEHAVIORAL|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
58311682|NCT03329885|DRUG|BMS-986251|Escalating oral dose
58311683|NCT03329885|OTHER|Placebo|Escalating oral dose
58311684|NCT05551416|OTHER|Identification of risk factors|Demographics, life habits and risk factors studies
58311685|NCT05551416|OTHER|Characterization of premalignant gastric lesions|Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
58311686|NCT05551416|OTHER|Identification of biomarkers|Multiomic studies
58311687|NCT05551416|OTHER|Identification of gastric cancer hereditary predisposition|Genomic studies for the identification of individuals with hereditary GC predisposition
58441359|NCT02936024|PROCEDURE|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
58441360|NCT00894361|PROCEDURE|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
57955837|NCT01192022|BIOLOGICAL|TachoSil®|Intraoperative application as secondary hemostatic treatment
57955838|NCT01192022|DEVICE|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
57955839|NCT05682027|DIAGNOSTIC_TEST|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
58108805|NCT02436395|PROCEDURE|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
58108806|NCT03578276|DRUG|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
58108807|NCT03578276|DRUG|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
58108808|NCT03578276|DRUG|Gatifloxacin Ophthalmic|Antibiotic
58108809|NCT03578276|DRUG|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
58108810|NCT03349918|BEHAVIORAL|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
58311688|NCT04260633|DEVICE|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
58441361|NCT00894361|PROCEDURE|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
58441362|NCT03202719|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
58441363|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
57955840|NCT03074487|DEVICE|Near-infrared spectroscopy|
58108811|NCT03063489|DRUG|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
58311689|NCT02245711|BIOLOGICAL|Stem Cell|
58441364|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
58108812|NCT00125931|DRUG|Talwin Nx|Talwin NX 50mg po twice
58108813|NCT00515073|DRUG|Paclitaxel|50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
58108814|NCT00515073|RADIATION|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
58108815|NCT00515073|DRUG|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
58441365|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
58441366|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
58108816|NCT00515073|DRUG|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
58441367|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
57955841|NCT03074487|DEVICE|Long loop reflex measurements|
57955842|NCT03124563|BEHAVIORAL|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
58108817|NCT00515073|DRUG|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
58108818|NCT05938452|DRUG|Glyceryl Tribenzoate|Oral Solution
58311690|NCT00504400|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
58311691|NCT02574091|DRUG|1% icotinib hydrochloride cream|Topical administration for twice daily
58311692|NCT02574091|DRUG|2% icotinib hydrochloride cream|Topical administration for twice daily.
58311693|NCT02574091|DRUG|Placebo|Topical administration for twice daily.
58311694|NCT02497469|DRUG|Vedolizumab|Vedolizumab infusion
58311695|NCT02497469|DRUG|Adalimumab placebo|Adalimumab placebo-matching injection
58311696|NCT02497469|DRUG|Adalimumab|Adalimumab injection
58311697|NCT02497469|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching infusion
58311698|NCT01516216|DRUG|FOLFOX + bevacizumab|
58311699|NCT01516216|DIETARY_SUPPLEMENT|Vitamin D|
58311700|NCT00434629|DRUG|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
58441368|NCT01040442|OTHER|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
58441369|NCT00255541|DRUG|Tesaglitazar|
58441370|NCT00255541|DRUG|Glibenclamide|
58441371|NCT03441087|DEVICE|Transvaginal ultrasound|
58441372|NCT03441087|DEVICE|Hysteroscopy|
58311701|NCT02841696|DEVICE|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
58311702|NCT01477567|DRUG|LY3009385|
58311703|NCT01477567|DRUG|Placebo|
58311704|NCT00193635|DRUG|mycophenolate mofetil|oral drug administration
58311705|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
58311706|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
58311707|NCT05227716|DRUG|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
58311708|NCT05152121|OTHER|Carb and fat counting|In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
58311709|NCT00723827|DRUG|Temozolomide|Administration of temozolomide based on the product labeling.
58311710|NCT00723827|RADIATION|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
58311711|NCT01416038|BIOLOGICAL|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
58311712|NCT01416038|DRUG|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
58311713|NCT00400244|PROCEDURE|Wheelchair skills traing program|
58311714|NCT02613130|DRUG|Stannous fluoride toothpaste|
58311715|NCT02613130|DRUG|Potassium nitrate toothpaste|
58311716|NCT00299858|DRUG|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
58441373|NCT00302211|DRUG|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
58441374|NCT00302211|DRUG|Inhaled Placebo|inhaled placebo
58441375|NCT00302211|DRUG|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
58441376|NCT00302211|DRUG|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
58441377|NCT02376179|DEVICE|Cuffed ETT|
58441378|NCT05982496|DRUG|FES|16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
58441379|NCT05982496|PROCEDURE|PET/MRI A|An additional FES PET/MRI will be performed before surgery.
58441380|NCT05982496|PROCEDURE|PET/MRI B|Two additional PET/MRI will be performed before and after induction ET.
58441381|NCT05982496|PROCEDURE|PET/MRI C|Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
58441382|NCT05982496|PROCEDURE|PET/MRI D|Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
58441383|NCT05982496|GENETIC|Translational analysis|Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
58441384|NCT02183766|DIETARY_SUPPLEMENT|Galactooligosaccharide prebiotic|6 mL once a day
58441385|NCT02183766|DRUG|Maltodextrin|6 mL once a day
58441386|NCT05705362|PROCEDURE|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
58441387|NCT05705362|PROCEDURE|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
58441388|NCT00000358|DRUG|Lofexidine|
58441389|NCT04119128|DEVICE|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
58441390|NCT04119128|DEVICE|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
58311717|NCT04732793|DEVICE|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
58311718|NCT04732793|DEVICE|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
58311719|NCT05047900|DIAGNOSTIC_TEST|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
58311720|NCT00112164|DRUG|Xigris|
58311721|NCT00006180|DRUG|Alendronate|
58311722|NCT01038765|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
58311723|NCT05622006|BEHAVIORAL|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
58311724|NCT02130999|DRUG|tasimelteon 20 mg capsule|
58311725|NCT02130999|DRUG|tasimelteon 2 mg I.V.|
58311726|NCT04050033|DEVICE|Evoke Device|Subjects will undergo treatment with Evoke Device
58311727|NCT01576614|BEHAVIORAL|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
58311728|NCT02983123|PROCEDURE|1-hour hs-cTnT|
58311729|NCT02585440|DRUG|CMX157|Oral tablet
58311730|NCT02585440|DRUG|placebo|Oral tablet
58311731|NCT05053906|DEVICE|Endoscope|effect of FESS on eustachian tube function
58311732|NCT01248455|DRUG|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
58311733|NCT06270134|OTHER|Bicarbonate|Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
58441391|NCT00606619|OTHER|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
58441392|NCT00606619|OTHER|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
58441393|NCT01196026|BIOLOGICAL|Fluarix™|One or two intramuscular injections
58441394|NCT01196026|BIOLOGICAL|Havrix™ Junior|Two intramuscular injections
58441395|NCT01440816|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
58441396|NCT01440816|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
58441397|NCT04625439|BEHAVIORAL|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
58441398|NCT03908359|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
58441399|NCT03908359|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
58441400|NCT04709445|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
58441401|NCT00434187|DRUG|ERB-041|
58441402|NCT02750319|DRUG|Amiodarone|
58441403|NCT02750319|DRUG|N-Acetylcysteine|
58441404|NCT02750319|DRUG|Placebo|
58441405|NCT01000259|OTHER|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
58441406|NCT02115763|DRUG|Caffeine|
58441407|NCT02115763|DRUG|Placebo|
58441408|NCT01883544|DRUG|ALXN1007|
58441409|NCT03197922|BEHAVIORAL|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
58441410|NCT03197922|DRUG|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
58441411|NCT03197922|COMBINATION_PRODUCT|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
58441412|NCT05194930|BEHAVIORAL|The ABC of Insomnia (Acceptance and the Behavioral Changes to treat Insomnia)|5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) provided by a trained instructor.
58108819|NCT04384341|RADIATION|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
58108820|NCT04384341|BIOLOGICAL|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
58441413|NCT05194930|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
58441414|NCT03968835|OTHER|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
58441415|NCT03968835|OTHER|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
58441416|NCT02531724|DRUG|Levosimendan|
58441417|NCT02531724|DRUG|Placebo|Sodium chloride
58441418|NCT04878965|DEVICE|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
58441419|NCT00252603|DRUG|Galantamine|
58441420|NCT02771197|DRUG|Fludarabine|
58441421|NCT02771197|DRUG|Melphalan|
58441422|NCT02771197|DRUG|Pembrolizumab|
58441423|NCT00351910|DRUG|Quetiapine|
58441424|NCT00351910|DRUG|Amitriptyline|
58441425|NCT00351910|DRUG|Bupropion|
58441426|NCT00351910|DRUG|Citalopram|
58441427|NCT00351910|DRUG|Duloxetine|
58441428|NCT00351910|DRUG|Escitalopram|
58441429|NCT00351910|DRUG|Fluoxetine|
58441430|NCT00351910|DRUG|Paroxetine|
58441431|NCT00351910|DRUG|Sertraline|
58441432|NCT00351910|DRUG|Venlafaxine|
58441433|NCT05323474|OTHER|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
58441434|NCT05323474|OTHER|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
58441435|NCT03871699|DRUG|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
58441436|NCT04653194|DRUG|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
58441437|NCT04653194|DRUG|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
57739248|NCT04461977|OTHER|Sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
57739249|NCT02475096|BEHAVIORAL|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
58108821|NCT03968900|BEHAVIORAL|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB \[Time in Bed\]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
58108822|NCT03968900|BEHAVIORAL|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
58108823|NCT05415319|BEHAVIORAL|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
58108824|NCT05131503|OTHER|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
58108825|NCT03654911|DIAGNOSTIC_TEST|EEG|EEG
58108826|NCT03654911|GENETIC|ApoE|ApoE
58108827|NCT04272177|OTHER|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
58108828|NCT00174759|DRUG|Clopidogrel|
58108829|NCT00436527|DRUG|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
58108830|NCT03621085|DRUG|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
58108831|NCT03621085|OTHER|Placebo|Subjects will receive placebo
58108832|NCT01260428|DEVICE|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
58108833|NCT03392961|DRUG|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
58441438|NCT04677010|OTHER|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
57739250|NCT03591068|DRUG|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
58108834|NCT03392961|OTHER|Placebo comparator|Placebo tablet for oral use
58108835|NCT02191579|BIOLOGICAL|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
58441439|NCT03277027|OTHER|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
58441440|NCT05433922|DRUG|Avatrombopag|cyclosporine in combination with Avatrombopag to treat
58441441|NCT00959595|DRUG|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
58441442|NCT00959595|DRUG|EMLA cream|50g applied according to description of intervention
58441443|NCT00473200|DIETARY_SUPPLEMENT|S-adenosylmethionine|1200 mg daily
58108836|NCT02191579|DRUG|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
58441444|NCT00004223|DRUG|docetaxel|
58441445|NCT00004223|DRUG|gemcitabine hydrochloride|
58441446|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
58441447|NCT02687139|DRUG|18F-DCFPyL|
58441448|NCT02687139|PROCEDURE|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
58441449|NCT02457156|PROCEDURE|Blumgart Anastomosis|"1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
57739251|NCT01142206|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
58441450|NCT02457156|PROCEDURE|Cattell-Warren Anastomosis|"1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
58441451|NCT02457156|DRUG|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
58441452|NCT04591158|DEVICE|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
58441453|NCT02921490|DEVICE|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
58441454|NCT05811169|GENETIC|Next generation sequencing|Next generation sequencing
58441455|NCT03661333|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
58441456|NCT03258086|DIAGNOSTIC_TEST|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
58441457|NCT02832635|DRUG|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
58441458|NCT02832635|RADIATION|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
57955843|NCT03124563|BEHAVIORAL|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
58108837|NCT02301962|DRUG|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
58441459|NCT02832635|RADIATION|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
58441460|NCT06323382|PROCEDURE|Locoregional therapy|"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."
58441461|NCT06323382|DRUG|Bevacizumab|15mg/kg or 7.5mg/kg intravenously every 3 weeks
58441462|NCT06323382|DRUG|Atezolizumab|1200mg intravenously every 3 weeks
58441463|NCT06323382|DRUG|Tislelizumab|200mg intravenously every 3 weeks
58441464|NCT06323382|DRUG|Toripalimab|220mg intravenously every 3 weeks
58441465|NCT06323382|DRUG|Sintilimab|200mg intravenously every 3 weeks
58441466|NCT06323382|DRUG|Camrelizumab|200mg intravenously every 3 weeks
58441467|NCT03485235|PROCEDURE|D&C|Dilatation and curettage
58441468|NCT03485235|PROCEDURE|ICSI|Intra Cytoplasmic Sperm Injection
58441469|NCT05170763|DRUG|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
58108838|NCT01427803|DRUG|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
58108839|NCT01824069|OTHER|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
57739252|NCT01142206|BEHAVIORAL|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
58108840|NCT05571085|OTHER|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
58441470|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
57739253|NCT01142206|BEHAVIORAL|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
57739254|NCT04338100|PROCEDURE|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
57739255|NCT06011590|OTHER|No intervention.|No intervention.
58108841|NCT05571085|OTHER|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
58108842|NCT03675191|DRUG|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
58441471|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
58108843|NCT03675191|DRUG|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
58108844|NCT05680207|BEHAVIORAL|Diabetes self- management education (DSME) program|We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
58108845|NCT05028686|OTHER|No intervention|Observational cohort
58108846|NCT02757534|DRUG|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
58108847|NCT05693857|OTHER|Cardiovascular prevention guidelines|Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making
58108848|NCT00780715|DRUG|Gliclazide MR|30mg daily increased to 60mg if HbA1c \> 7% at 3 months
58441472|NCT05170763|DRUG|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
58441473|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
57739256|NCT02001857|DRUG|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
57739257|NCT01640808|DRUG|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
57739258|NCT01640808|DRUG|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
57739259|NCT01987648|PROCEDURE|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
57739260|NCT06211400|OTHER|Whole body vibration exercise|6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
57739261|NCT00934466|DRUG|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
57739262|NCT00934466|DRUG|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
57739263|NCT00934466|DRUG|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
57739264|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
57739265|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
57739266|NCT03558048|DIAGNOSTIC_TEST|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
58108849|NCT00780715|DRUG|Sitagliptin|Sitagliptin 100mg daily for 6 months
58311734|NCT03517904|PROCEDURE|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
58311735|NCT03517904|PROCEDURE|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
58441474|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
58441475|NCT05170763|DRUG|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
57739267|NCT05973071|BEHAVIORAL|Tuune Supplemented Contraceptive Visit|Participants complete the Tuune contraceptive decision aid health questionnaire (Tuune for clinics) as part of their standard OBGYN clinic appointment.
57739268|NCT05973071|BEHAVIORAL|Traditional Contraceptive Visit|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire (Tuune for Clinics).
58108850|NCT00780715|DRUG|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c \>7% at 3 months. 6 months duration
58311736|NCT03294915|DIETARY_SUPPLEMENT|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
57739269|NCT03173040|DRUG|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
57739270|NCT03905655|DRUG|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
57739271|NCT03905655|DRUG|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
57739272|NCT03283904|OTHER|Multicomponent physical activity intervention|School-based multicomponent intervention
58311737|NCT03294915|DIETARY_SUPPLEMENT|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
58441476|NCT06241105|DRUG|Lenvatinib+Toripalimab.|Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
58441477|NCT05645965|DEVICE|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
58441478|NCT05711472|OTHER|birth ball exercise|birth ball exercise used in childbirth
58441479|NCT01311609|OTHER|Systane|Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
58441480|NCT04368715|DEVICE|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
58441481|NCT04191317|OTHER|Pain Neuroscience Education and gradual exposure|Education covering the pathophysiology of apin and exercises based on the gradual exposure principle
58441482|NCT04191317|OTHER|Pilates and postural education|Postural education and pilates exercises
58441483|NCT02292563|PROCEDURE|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
58441484|NCT02292563|PROCEDURE|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
58441485|NCT04706481|PROCEDURE|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
58441486|NCT06725290|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI) questionnaire|The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
58441487|NCT01652339|DRUG|Exforge tab. 10/160mg|
58441488|NCT01652339|DRUG|Lodivixx tab. 5/160mg|
58441489|NCT00270062|DRUG|epoetin alfa|
58441490|NCT02212041|OTHER|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
58441491|NCT01342588|PROCEDURE|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
57739273|NCT04680455|OTHER|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
57739274|NCT02968420|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
57739275|NCT00891267|DRUG|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
58311738|NCT00911911|PROCEDURE|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
58311739|NCT00911911|PROCEDURE|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
58311740|NCT00911911|PROCEDURE|SURGERY|Surgery after neoadjuvant chemotherapy
58311741|NCT05005598|OTHER|catheter dysfunction|prevalence of catheter dysfunction
58311742|NCT02517619|DRUG|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
58311743|NCT02517619|DRUG|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
58311744|NCT01897116|DRUG|Hydroxychloroquine (HCQ)|
58311745|NCT01897116|DRUG|Vemurafenib (VEM)|
58311746|NCT00660452|DRUG|Staloral|Sublingual immunotherapy with Staloral dust mites solution
58311747|NCT06068959|DEVICE|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
58311748|NCT06068959|DEVICE|Placebo|Photobiomodulation Placebo
58311749|NCT02008656|DRUG|Oxaliplatin (OXAL)|
58311750|NCT02008656|DRUG|5-Fluorouracil (5-FU)|
58311751|NCT02008656|DRUG|Leucovorin|
58311752|NCT02008656|DRUG|Capecitabine (Xeloda®)|
58311753|NCT02008656|RADIATION|intensity modulated radiotherapy (IMRT)|
58311754|NCT02008656|BEHAVIORAL|Quality of Life Questionnaires|
58311755|NCT02008656|PROCEDURE|DRE-Endoscopy|
58311756|NCT04318197|OTHER|Personalized rehabilitation program with electrostimulation|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.
58441492|NCT00889824|DEVICE|balance prosthesis|vibrotactile stimulation
58441493|NCT00622375|DRUG|mesalamine|encapsulated mesalamine granules
58441494|NCT04007016|PROCEDURE|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
58441495|NCT01574066|PROCEDURE|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
58441496|NCT06352749|BEHAVIORAL|Advice to increase physical activity and reduce sedentary behavior|After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations will be transmitted verbally and through written material.
58441497|NCT06352749|BEHAVIORAL|Online Physical Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised online by trained physiotherapists or sports physiologists."
58441498|NCT06352749|BEHAVIORAL|Face-to-Face Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists."
58441499|NCT02761382|OTHER|Mindfulness-based psychological treatment|
58441500|NCT02761382|OTHER|Non-specific psychological treatment|
58441501|NCT05130749|OTHER|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
58441502|NCT02348996|OTHER|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
58441503|NCT02348996|OTHER|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
58441504|NCT06240949|DEVICE|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
58441505|NCT06240949|DEVICE|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
58441506|NCT03449719|RADIATION|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
58441507|NCT03449719|DRUG|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
58441508|NCT04221646|DEVICE|BTL-899|Treatment with study device.
58311757|NCT04318197|OTHER|Global rehabilitation program|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
58441509|NCT00543777|DIAGNOSTIC_TEST|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
58441510|NCT00543777|DIAGNOSTIC_TEST|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
58441511|NCT06245252|OTHER|passive stretching for group A|A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).
58441512|NCT06245252|OTHER|electrical stimulation for group b|reated by 30 minutes electrical stimulation three times per week for 12 weeks
58441513|NCT05260827|OTHER|Heated tobacco product|Sham heated tobacco product
58441514|NCT00716846|DRUG|simvastatin|10mg, 2 weeks
58441515|NCT00716846|DRUG|atorvastatin|10mg
58441516|NCT00716846|DRUG|pitavastatin|2mg
58441517|NCT00666224|DRUG|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
57739276|NCT00891267|DRUG|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
57739277|NCT00891267|DRUG|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
57739278|NCT04217863|BEHAVIORAL|GDP|Guided Disclosure Protocol
57739279|NCT02750254|DRUG|Fludarabine|
58441518|NCT00666224|DRUG|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
57739280|NCT02750254|RADIATION|Fractionated total body irradiation|
57739281|NCT02750254|DRUG|Busulfan|
57739282|NCT02750254|DRUG|Cyclophosphamide|
57739283|NCT02750254|RADIATION|Single dose total body irradiation|
57739284|NCT02750254|DRUG|Melphalan|
57739285|NCT02750254|DRUG|Granulocyte-colony stimulating factor|
57739286|NCT02750254|PROCEDURE|Stem cell transplant|
57739287|NCT02750254|DRUG|Azacitidine|
57739288|NCT04158531|DEVICE|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
57739289|NCT06082037|DRUG|Belumosudil|Tablet, Oral
57739290|NCT06082037|DRUG|Azithromycin|Depends on pharmaceutical presentation, Oral
57739291|NCT06082037|DRUG|Placebo|Tablet, Oral
57739292|NCT01037920|BEHAVIORAL|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
57739293|NCT01037920|BEHAVIORAL|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
57739294|NCT02211716|DEVICE|BeGraft Peripheral Stent Graft System|
57739295|NCT04160780|PROCEDURE|L-PRF|sinus augmentation using L-PRf as sole graft material
57739296|NCT04160780|PROCEDURE|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
57739297|NCT04160780|PROCEDURE|xenograft|sinus augmentation using xenograft as sole graft material
57739298|NCT06354101|DRUG|Tirzepatide|Once-weekly subcutaneous injectable
57739299|NCT06354101|DRUG|Semaglutide|Once-weekly subcutaneous injectable
57739300|NCT05615298|RADIATION|Mammography|FFDM (Full-Field Digital mammography)
57739301|NCT05234684|DRUG|Orelabrutinib + R-CHOP|The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
58108851|NCT00780715|DRUG|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
58441519|NCT00666224|DRUG|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
58441520|NCT01593553|OTHER|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
58441521|NCT03863756|RADIATION|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
58441522|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
58441523|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
58441524|NCT02231619|BEHAVIORAL|Baseline verbal instruction on LSUPT|
58441525|NCT05917418|DIETARY_SUPPLEMENT|nutritional support|nutritional support
57739302|NCT05234684|DRUG|Placebo + R-CHOP|The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
58108852|NCT02891265|BEHAVIORAL|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
58108853|NCT01773174|DRUG|dabigatran etexilate|age \& weight adjusted equivalent of adult dose
58441526|NCT00596830|DRUG|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
58441527|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
58441528|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
57739303|NCT00682734|DRUG|metoclopramide|metoclopramide 20 mg
57739304|NCT00682734|DRUG|metoclopramide|metoclopramide 40 mg
57739305|NCT00682734|DRUG|metoclopramide|metoclopramide 10 mg
57739306|NCT00682734|DRUG|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
57739307|NCT01212770|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
58441529|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
58108854|NCT04668222|DRUG|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
58108855|NCT04668222|DRUG|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
58108856|NCT04668222|DRUG|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
57739308|NCT01212770|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
57739309|NCT01212770|DRUG|Placebo|
57739310|NCT04559789|BEHAVIORAL|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
57739311|NCT04559789|OTHER|Health Education|Health education materials delivered electronically
58108857|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
58441530|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
58441531|NCT01340053|DRUG|RDX5791|Capsule, QD
58441532|NCT02047214|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
58441533|NCT02047214|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
58441534|NCT02309801|DIETARY_SUPPLEMENT|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
58441535|NCT02309801|DIETARY_SUPPLEMENT|Alcohol|Alcohol single oral dose
58441536|NCT02321553|OTHER|Brown rice|brown rice cake
58441537|NCT02321553|OTHER|White rice|white rice cake
58441538|NCT02135237|BEHAVIORAL|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
58441539|NCT02135237|BEHAVIORAL|Standard Care|
58441540|NCT00558116|DEVICE|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
57739312|NCT04745182|BEHAVIORAL|MASTERY|A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
57739313|NCT04417023|OTHER|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
57739314|NCT01562574|DRUG|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
58108858|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
57739315|NCT01562574|DRUG|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
57739316|NCT05734560|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
57739317|NCT05734560|DRUG|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
57955844|NCT02982135|OTHER|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
57955845|NCT00630266|DEVICE|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
57955846|NCT01327157|PROCEDURE|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
58108859|NCT00948025|DEVICE|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
58108860|NCT00948025|OTHER|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
58108861|NCT02477904|OTHER|Ketogenic Diet|Dietary
58311758|NCT04600349|BEHAVIORAL|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
58311759|NCT04600349|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
58441541|NCT03483415|DRUG|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
58441542|NCT03483415|DRUG|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
58108862|NCT01360632|DRUG|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
58108863|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
58108864|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
58311760|NCT03621956|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
58311761|NCT03621956|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
58441543|NCT01363661|DRUG|Coruno|Molsidomine 16 mg tablet, per os, once a day
58441544|NCT01363661|DRUG|Placebo|Placebo (16 mg tablet, per os; once-daily)
57739318|NCT02287935|PROCEDURE|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
57739319|NCT02287935|PROCEDURE|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
58108865|NCT04242966|OTHER|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
58108866|NCT04242966|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
58441545|NCT06090084|OTHER|Evaluation|Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
57739320|NCT05576987|BEHAVIORAL|Education|Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
57739321|NCT06302166|OTHER|High Intensity Circuit training (HICT)|High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.
57739322|NCT06302166|OTHER|Intermittent Fasting (IF)|Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.
57739323|NCT06302166|OTHER|Combination of HICT and IF|The participants will follow both HICT and IF for 8 weeks.
57739324|NCT00785369|DEVICE|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
57739325|NCT05800132|DEVICE|MammoScreen|Diagnostic reading aid for breast cancer screening
57739326|NCT02489500|DRUG|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
58441546|NCT06174129|OTHER|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
58441547|NCT02630511|DRUG|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
58441548|NCT02630511|DRUG|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
58441549|NCT02630511|DRUG|Placebo|Placebo consists of inhaling humidified air
58441550|NCT02630511|OTHER|Rest|
58441551|NCT02630511|OTHER|Exercise|
58441552|NCT02452424|DRUG|PLX3397|PLX3397 capsules, 200 mg
58441553|NCT02452424|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 200 mg, IV
57955847|NCT01327157|BEHAVIORAL|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
57955848|NCT02590380|DEVICE|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
57955849|NCT02590380|DEVICE|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
57955850|NCT02285725|PROCEDURE|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
58108867|NCT04242966|OTHER|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
58108868|NCT06092645|DRUG|surufatinib plus cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
58311762|NCT04174742|DRUG|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
58311763|NCT02240329|BEHAVIORAL|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
58311764|NCT02240329|BEHAVIORAL|Respiratory measures|We will collect measures of cough airflow and breathing strength.
58311765|NCT02240329|DRUG|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
58311766|NCT00177697|BEHAVIORAL|behavioral weight loss program|
58311767|NCT05572580|OTHER|questionnaire|the patients are asked to fill in a questionnaire
58311768|NCT04283318|BEHAVIORAL|12h fasting|12h fasting (overnight)
58311769|NCT04283318|BEHAVIORAL|36h fasting|36h fasting ( one day and two nights fasting)
58441554|NCT04703764|DRUG|HSG4112|Once-daily, 14-day multiple oral administration
58441555|NCT04703764|DRUG|Placebo|Once-daily, 14-day multiple oral administration
58441556|NCT02116452|DIETARY_SUPPLEMENT|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
58441557|NCT05502354|DEVICE|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
58441558|NCT04425382|DRUG|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
58441559|NCT04425382|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
58441560|NCT00006343|BIOLOGICAL|recombinant interferon alfa|
58441561|NCT00006343|DRUG|cytarabine|
58441562|NCT00006343|DRUG|imatinib mesylate|
58441563|NCT05040568|DRUG|Cetuximab|Given IV
58441564|NCT05040568|DRUG|Expanded CB-NK cells|Given IV
58441565|NCT05040568|DRUG|Fludarabine phosphate|Given IV
57739327|NCT02489500|DRUG|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
58108869|NCT03678961|BEHAVIORAL|external rotation of leg|external rotation of leg by 45 degrees
58108870|NCT03678961|BEHAVIORAL|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
58108871|NCT01344395|DRUG|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
58108872|NCT01344395|DRUG|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
58108873|NCT02565082|OTHER|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
58108874|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
58311770|NCT02066571|DRUG|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
58311771|NCT02066571|DRUG|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
58311772|NCT03588117|BEHAVIORAL|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
58311773|NCT01357772|DRUG|Tamoxifen|
58311774|NCT01357772|DRUG|placebo|
58311775|NCT02542527|PROCEDURE|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
58311776|NCT02837588|DEVICE|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
58311777|NCT05482334|DRUG|Sargramostim for Injection|Recombinant human GM-CSF
58311778|NCT05482334|DRUG|Saline Placebo|Bacteriostatic Saline
58311779|NCT01262586|DRUG|Vildagliptin|
58311780|NCT01262586|DRUG|Glimepiride|
58311781|NCT02606812|DIETARY_SUPPLEMENT|Traditional-food|Intake of ethnic local food
58311782|NCT04210518|OTHER|Neuromuscular training|This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
58311783|NCT04210518|OTHER|Stroboscopic glasses|Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
58311784|NCT03594006|BEHAVIORAL|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
58311785|NCT01279746|DEVICE|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
58311786|NCT06265311|PROCEDURE|IDUS examination|for patients with high risks of bile duct stones recurrence using IDUS during ERCP
58311787|NCT03885973|DRUG|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
58311788|NCT03885973|DRUG|Placebo|Fermented milk containing placebo for three weeks
58311789|NCT02170714|OTHER|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
58311790|NCT01044524|RADIATION|SLV 334|2000 mg via i.v. solution
58311791|NCT02698293|DRUG|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
58311792|NCT02698293|DRUG|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
58311793|NCT02698293|OTHER|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
57739328|NCT02489500|DRUG|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
57739329|NCT02489500|PROCEDURE|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
57739330|NCT02489500|PROCEDURE|Stem cell infusion|infusion of previously collected autologous stem cells
57739331|NCT05200195|PROCEDURE|Liver transplantation|Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
57739332|NCT00709969|DRUG|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
58441566|NCT05040568|DRUG|Cyclophosphamide|Given IV
58441567|NCT01629173|PROCEDURE|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
58441568|NCT01629173|PROCEDURE|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
58441569|NCT01629173|PROCEDURE|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
58441570|NCT01629173|PROCEDURE|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
58441571|NCT04340453|OTHER|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
57739333|NCT00957866|DRUG|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
57739334|NCT00963365|DRUG|AZD6765|Single oral dose and single IV infusion of AZD6765
57739335|NCT00963365|DRUG|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
58311794|NCT05424341|OTHER|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
58311795|NCT05424341|OTHER|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
58311796|NCT00833755|DRUG|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
58311797|NCT00833755|DRUG|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
58311798|NCT00221780|DEVICE|left ventricular pacing|
58311799|NCT02654678|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
58311800|NCT06515990|DRUG|DM005|An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
58311801|NCT01859039|BIOLOGICAL|Administration of Live attenuated influenza vaccine|
58311802|NCT02230163|BIOLOGICAL|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
58311803|NCT03057574|DRUG|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
58311804|NCT04550299|OTHER|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
57739336|NCT03512327|OTHER|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
57739337|NCT00506064|DRUG|Melatonin|0.15 mg/kg by mouth (PO) Daily
57739338|NCT00506064|DRUG|Placebo|Two, three, or four starch tablet or capsules before bed
57739339|NCT00506064|BEHAVIORAL|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
57739340|NCT00778648|DIETARY_SUPPLEMENT|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
57739341|NCT00778648|DIETARY_SUPPLEMENT|Placebo|Four capsules of placebo daily.
57739342|NCT03046459|BIOLOGICAL|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
57739343|NCT00829257|DRUG|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
57739344|NCT00829257|DRUG|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
57739345|NCT00829257|DRUG|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
57739346|NCT04440566|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
58311805|NCT06317012|PROCEDURE|Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate|"Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software."
57739347|NCT03806153|OTHER|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
57739348|NCT04022668|RADIATION|Coronary angiogram|Routine coronary angiogram, if indicated
57739349|NCT04151082|DRUG|Methylprednisolone|Given IV
57739350|NCT04151082|DRUG|Prednisone|Given PO
57739351|NCT04151082|OTHER|Quality-of-Life Assessment|Ancillary studies
57739352|NCT04151082|OTHER|Questionnaire Administration|Ancillary studies
58108875|NCT02565082|OTHER|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
57739353|NCT01343550|OTHER|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
57739354|NCT03465280|PROCEDURE|Microdebrider|Removal of lesions via microdebrider
57739355|NCT03465280|PROCEDURE|Cold-steel surgery (forceps)|Removal of lesions via forceps
57739356|NCT03465280|PROCEDURE|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
57739357|NCT03465280|PROCEDURE|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
57739358|NCT03465280|PROCEDURE|Pulsed dye laser|Removal of lesions via pulsed dye laser
57739359|NCT03465280|PROCEDURE|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
57739360|NCT03465280|PROCEDURE|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
57739361|NCT03465280|PROCEDURE|Plasma coagulation|Removal of lesions via plasma coagulation
57739362|NCT03465280|PROCEDURE|Other|Removal of lesions via other methods
57739363|NCT03465280|OTHER|Adjuvant therapies|All adjuvant therapies
57955851|NCT02285725|PROCEDURE|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
57955852|NCT01988610|DRUG|28 days treatment with Mifepristone.|
58108876|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
58311806|NCT01721798|DEVICE|Mirena levonorgestrel IUD|Intrauterine contraception system
58311807|NCT01721798|DEVICE|Copper T-380a IUD|intrauterine contraception system
58311808|NCT00064311|DRUG|ravuconazole|
58311809|NCT03229499|DRUG|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
58311810|NCT03229499|DRUG|Placebo Oral Tablet|matching placebo tablet
58311811|NCT02832713|DRUG|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
58311812|NCT02832713|DEVICE|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
58311813|NCT06169722|DRUG|TDI01 suspension|200mg or 400mg oral once a day
58311814|NCT04970940|DRUG|Treatment A|AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
58311815|NCT04970940|DRUG|Treatment B|AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
58311816|NCT04970940|DRUG|Treatment C|AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
57739364|NCT04302727|BEHAVIORAL|Med-South Weight Loss Intervention|Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.
58108877|NCT05559216|OTHER|Plyometric Training|Plyometric training exercises are being given to the participants to see the changes after the 8 week period
58108878|NCT03197961|COMBINATION_PRODUCT|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
58108879|NCT03197961|DRUG|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
58441572|NCT04340453|OTHER|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
58441573|NCT04340453|OTHER|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
58441574|NCT03100604|DRUG|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
58441575|NCT03100604|DRUG|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
57739365|NCT04302727|BEHAVIORAL|WW|If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
57739366|NCT06224452|DRUG|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
57739367|NCT03095040|DRUG|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
57739368|NCT03095040|DRUG|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
57739369|NCT03095040|DRUG|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
58108880|NCT00947518|DRUG|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
58108881|NCT00947518|DRUG|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
58311817|NCT01517217|PROCEDURE|No girdle|No girdle is used for the first five postoperative days
57739370|NCT00672074|DRUG|Ipamorelin|IV
57739371|NCT00672074|DRUG|placebo|IV
57739372|NCT05826392|OTHER|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
58311818|NCT01517217|PROCEDURE|Girdle|Girdle the first five postoperative days
58311819|NCT04942067|DRUG|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
58311820|NCT04942067|DRUG|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
58108882|NCT05463458|OTHER|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
57739373|NCT03725683|DEVICE|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
57739374|NCT03725683|DEVICE|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
58108883|NCT00136019|DRUG|SPM 927|
58108884|NCT06545058|PROCEDURE|Penile block|Penile block with local anesthetics
58108885|NCT01234688|OTHER|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
58108886|NCT04130945|OTHER|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
58108887|NCT00634582|DRUG|paricalcitol|
58108888|NCT00634582|OTHER|immunoenzyme technique|
58108889|NCT00634582|OTHER|laboratory biomarker analysis|
58108890|NCT00634582|PROCEDURE|dual x-ray absorptometry|
58108891|NCT00634582|PROCEDURE|quality-of-life assessment|
58108892|NCT00565370|DRUG|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
58108893|NCT03216200|DEVICE|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
58108894|NCT02115685|OTHER|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
58108895|NCT00647166|DRUG|corticosteroid and azathioprine|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
58108896|NCT00647166|DRUG|corticosteroid and placebo|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
58108897|NCT02619331|PROCEDURE|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
58108898|NCT03553277|OTHER|transfluthrin|passive emanator with formulated transfluthrin
58108899|NCT03553277|OTHER|placebo|passive emanator with formulated inert ingredients
58108900|NCT04745780|DIETARY_SUPPLEMENT|Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin|Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months
58108901|NCT04745780|DIETARY_SUPPLEMENT|Placebo|Placebo - Two-times daily on an empty stomach, for 6 months
58108902|NCT02751060|OTHER|No intervention|
58108903|NCT00919139|OTHER|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
58108904|NCT04609527|PROCEDURE|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
58108905|NCT02856997|DRUG|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
58108906|NCT04843176|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
58108907|NCT04843176|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
58311821|NCT00637013|PROCEDURE|Acromioplasty|Arthroscopic or open acromioplasty
58108908|NCT01878656|DRUG|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
58311822|NCT00637013|PROCEDURE|Physiotherapy|Physiotherapy according to a standardized protocol
57739375|NCT05683548|DRUG|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
57739376|NCT05683548|DRUG|Tenofovir Disoproxil Fumarate|
58108909|NCT01878656|DRUG|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
58311823|NCT05863442|DRUG|Soliris 300 MG in 30 ML Injection|Active Comparator
58311824|NCT05863442|DRUG|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
58311825|NCT01637168|DRUG|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
58311826|NCT01637168|DRUG|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
58311827|NCT06532305|BEHAVIORAL|HOPE empowerment classes|A three-month empowerment course.
58311828|NCT00299039|DRUG|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
58311829|NCT00299039|DRUG|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
58311830|NCT05220488|OTHER|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
58441576|NCT05969704|PROCEDURE|MRI fusion targeted prostatic biopsy|combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
58441577|NCT05969704|PROCEDURE|MRI cognitive targeted prostatic biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
58441578|NCT02386449|DRUG|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
58441579|NCT02386449|DRUG|mannitol|
58441580|NCT02386449|DRUG|Bisacodyl|
58441581|NCT00308971|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
58441582|NCT00308971|DRUG|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
58441583|NCT00308971|DRUG|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
58441584|NCT00308971|DRUG|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
58441585|NCT06224179|PROCEDURE|ultrasound guided subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,"
57739377|NCT05683548|DRUG|Pegylated interferon alpha2a|
57739378|NCT05003531|DRUG|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
57955853|NCT02977195|DRUG|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
57955854|NCT01362036|DRUG|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
57955855|NCT01409733|DEVICE|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
57955856|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
58108910|NCT06009900|DEVICE|Low intensity laser treatment|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
58441586|NCT06224179|PROCEDURE|ultrasound guided combined posterior and subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,"
58441587|NCT02919072|DRUG|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
57739379|NCT05003531|DRUG|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
57739380|NCT05003531|DRUG|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
57739381|NCT05003531|DRUG|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
57739382|NCT05003531|DRUG|placebo|Participants will receive placebo SC
57739383|NCT02710799|OTHER|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
58441588|NCT02919072|DRUG|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
58441589|NCT01994265|DRUG|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
58441590|NCT01994265|DRUG|Dabigatran|
58441591|NCT00381147|DRUG|Clarithromycin|
58441592|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
58441593|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
57739384|NCT02710799|OTHER|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
57739385|NCT03966833|BEHAVIORAL|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
58441594|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
58441595|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
57739386|NCT03966833|BEHAVIORAL|Unconditional Cash Transfer|Lump sum cash transfer
57739387|NCT00379613|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
57739388|NCT00379613|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
58108911|NCT06009900|DRUG|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
58311831|NCT02785211|BEHAVIORAL|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
58311832|NCT00806065|DRUG|ENMD-2076|
58311833|NCT00937339|DEVICE|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
58311834|NCT00937339|DEVICE|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
58311835|NCT02072200|DRUG|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
58311836|NCT06353061|DRUG|Metformin|Patients randomized to the metformin group will start taking metformin within 1 day after group allocation. They will take one tablet of metformin (850 mg) once daily for three consecutive days. Subsequently, they will take metformin orally twice daily throughout the entire external and internal irradiation period, with each administration consisting of one tablet.
58311837|NCT06353061|RADIATION|Radiotherapy|The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions \>4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
58311838|NCT06353061|DRUG|Chemotherapy|The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
58311839|NCT06353061|DIAGNOSTIC_TEST|PET/CT|Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
58311840|NCT00314145|BIOLOGICAL|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
58311841|NCT00314145|BIOLOGICAL|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
58311842|NCT03430739|OTHER|No intervention|No intervention
58311843|NCT05545150|PROCEDURE|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
58311844|NCT05545150|DEVICE|Lumpectomy|Per standard of care (SOC)
58311845|NCT04325997|DEVICE|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
58311846|NCT04325997|DEVICE|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
58311847|NCT06232096|DRUG|MBS314 Injection|"Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ."
58441596|NCT02672462|DEVICE|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
58441597|NCT01090193|PROCEDURE|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
58441598|NCT05458804|DEVICE|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
58441599|NCT03870399|DRUG|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
58441600|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
58441601|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
58441602|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
57955857|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
57955858|NCT04543994|OTHER|Placebo|Normal saline
58441603|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
58441604|NCT00310596|DRUG|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
58441605|NCT00310596|DRUG|Placebo|0,9% saline at 0,6mL/kg at bolus rate
58441606|NCT05802862|DRUG|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
58441607|NCT04336072|BEHAVIORAL|RFPP|
58441608|NCT04336072|BEHAVIORAL|TFCBT|
58441609|NCT02677272|OTHER|Appropriateness of NH resident's transfer to ED|
58441610|NCT02595619|DEVICE|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
58441611|NCT06236386|OTHER|VR Experience|VR headset and video experience.
58441612|NCT02518763|DRUG|Vitamin D3, 100 000 IU weekly, 4 times|
58441613|NCT02518763|BIOLOGICAL|25 OH vitamin D serum concentration measurements|
58441614|NCT00200668|DRUG|FDG = fluorodeoxyglucose|
58441615|NCT00761696|DRUG|IPI-926|Oral daily dosing
58441616|NCT00771966|PROCEDURE|Standard therapy|Standard therapy
58441617|NCT00771966|PROCEDURE|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
58441618|NCT05020275|DIAGNOSTIC_TEST|Blood Samples|"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"
58441619|NCT05549791|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
58441620|NCT03833063|DRUG|botulinum toxin A|glabellar injections with botulinum toxin A
58441621|NCT03833063|DRUG|Placebos|glabellar injections with sodium chloride
58441622|NCT01966289|DRUG|CY|CY is administered intravenously at 200 mg/m2
58441623|NCT01966289|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
58441624|NCT01966289|DRUG|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
58441625|NCT01514201|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
58441626|NCT01514201|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58441627|NCT01514201|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58441628|NCT01514201|OTHER|Pharmacological Study|Correlative studies
58441629|NCT01514201|DRUG|Temozolomide|Given PO
58441630|NCT01514201|DRUG|Veliparib|Given PO
58441631|NCT03556709|DEVICE|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
58441632|NCT06404489|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
58441633|NCT03495102|DRUG|Dulaglutide|Administered SC
58441634|NCT04489199|OTHER|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
58441635|NCT02744885|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
58441636|NCT02744885|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
58441637|NCT04991662|DRUG|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
58441638|NCT04991662|DRUG|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
58441639|NCT04991662|DRUG|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
58441640|NCT02781480|BIOLOGICAL|AAV RPE65|Comparison of different dosages of AAV RPE65
58441641|NCT01964625|OTHER|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
58441642|NCT06309589|DRUG|Vitamin D|experimental group received UDCA combined with vitamin D3 (1200 IU per day) treatment
58108912|NCT03551366|BEHAVIORAL|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
58441643|NCT05972005|OTHER|The Intervention (Stronger at Home Intervention)|The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.
57955859|NCT00517829|DRUG|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
58108913|NCT03551366|BEHAVIORAL|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
58108914|NCT05699837|DEVICE|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
58108915|NCT01526915|PROCEDURE|Bone curettage + PRF|Bone curettage and PRF insertion
57739389|NCT01353313|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
57739390|NCT01353313|DRUG|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
57739391|NCT06089811|DIETARY_SUPPLEMENT|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
57739392|NCT06089811|DIETARY_SUPPLEMENT|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
58108916|NCT01526915|PROCEDURE|Bone curettage alone|Bone curettage without PRF insertion
58108917|NCT06078085|OTHER|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
58108918|NCT00409578|DRUG|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
58108919|NCT00409578|DRUG|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
58441644|NCT05972005|OTHER|Usual care (Control)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
57739393|NCT06089811|DIETARY_SUPPLEMENT|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
57739394|NCT06530823|DRUG|Pemigatinib and Durvalumab|Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
57739395|NCT05141669|DRUG|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
57739396|NCT04050189|BIOLOGICAL|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
57739397|NCT04050189|OTHER|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
57739398|NCT04337814|DRUG|EMLA Cream|Topical anaesthetic cream
57739399|NCT04337814|DRUG|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
57739400|NCT04337814|DRUG|Placebo syrup|Placebo syrup similar to Ibuprofen
57739401|NCT04337814|DRUG|Placebo cream|Placebo cream similar to EMLA
57739402|NCT06669468|OTHER|PFME|All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
57739403|NCT06669468|OTHER|PFME + Anal ES|Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
57739404|NCT06669468|OTHER|PFME + Perineal ES|Perineal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
57739405|NCT01509729|PROCEDURE|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
57739406|NCT01509729|PROCEDURE|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
58108920|NCT00409578|DRUG|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
58108921|NCT00409578|DRUG|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
58108922|NCT02037373|BIOLOGICAL|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
58108923|NCT02037373|BIOLOGICAL|Plasma|Plasma as prescribed by the treating physician.
58108924|NCT02878278|DRUG|Chidamide BIW|Chidamide is given 30mg, twice a week
58108925|NCT02878278|DRUG|Chidamide QD|Chidamide is given 10mg,QD
58441645|NCT05433025|DEVICE|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
58441646|NCT02678507|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
58441647|NCT03944512|DRUG|Pravastatin|20 mg Pravastatin taken daily
58441648|NCT03944512|OTHER|Placebo|Identical appearing placebo pill
58441649|NCT01052506|DRUG|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
57739407|NCT03753438|PROCEDURE|Intragstric Ballooning|Intragstric Ballooning will be put.
57739408|NCT04364646|BEHAVIORAL|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
57739409|NCT03036163|DRUG|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
57739410|NCT03036163|DRUG|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
57739411|NCT03036163|DRUG|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
57739412|NCT03036163|DRUG|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
58108926|NCT03083132|DRUG|modafinil 50mg|1 capsule oral daily
58108927|NCT03083132|DRUG|Placebo oral capsule|1 capsule oral daily
58441650|NCT01052506|DRUG|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
58441651|NCT05538676|DIAGNOSTIC_TEST|BPA-PET imaging|PET imaging
58441652|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
58441653|NCT02496299|DRUG|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
58441654|NCT02496299|DRUG|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
58441655|NCT05796895|BEHAVIORAL|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
58441656|NCT05796895|BEHAVIORAL|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
58441657|NCT06170918|DRUG|Remimazolam|remimazolam is given intravenously
57739413|NCT03036163|DRUG|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
58108928|NCT05890326|BEHAVIORAL|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
58108929|NCT05890326|BEHAVIORAL|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
58108930|NCT05890326|BEHAVIORAL|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
58108931|NCT02729194|DRUG|Pazopanib|
58108932|NCT02729194|OTHER|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
58108933|NCT04273672|DIAGNOSTIC_TEST|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
58108934|NCT04273672|BEHAVIORAL|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
58108935|NCT04273672|BEHAVIORAL|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
58108936|NCT04273672|GENETIC|DNA Analysis|Participants will have their blood drawn for DNA analysis.
58108937|NCT00299728|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
58441658|NCT05981027|OTHER|Mulligan bent leg raise technique|In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
57739414|NCT03036163|DRUG|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
57739415|NCT03036163|DRUG|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
58108938|NCT02103647|DRUG|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
58108939|NCT02103647|DRUG|sustained release tablet|sustained release tablet
58108940|NCT02199652|DRUG|Prazosin|
58108941|NCT02199652|DRUG|Placebo|
58108942|NCT00005583|DRUG|cisplatin|
57739416|NCT04352179|BEHAVIORAL|Virtual Education Simulation|"The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~1. Fitness \& Nutrition~2. Smoking Cessation~3. Alcohol Use~4. Distress \& Anxiety"
57739417|NCT04360148|DIETARY_SUPPLEMENT|very-low-calorie-ketogenic-diet|VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
57955860|NCT00517829|DRUG|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
58108943|NCT00005583|DRUG|doxorubicin hydrochloride|
58108944|NCT00005583|DRUG|epirubicin hydrochloride|
58108945|NCT00005583|PROCEDURE|adjuvant therapy|
58108946|NCT00005583|PROCEDURE|conventional surgery|
58108947|NCT00005583|RADIATION|radiation therapy|
58108948|NCT01718054|DIETARY_SUPPLEMENT|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
58108949|NCT01718054|DIETARY_SUPPLEMENT|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
58108950|NCT01718054|DRUG|Chloroquine|
58108951|NCT02893852|BEHAVIORAL|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
58108952|NCT02893852|BEHAVIORAL|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
58108953|NCT00274144|DRUG|telmisartan 40 mg|
58108954|NCT00274144|DRUG|placebo 40 mg|
58108955|NCT04264299|PROCEDURE|T tube drainage|closure of common bile duct over T tube
58108956|NCT04264299|PROCEDURE|Primary closure|Primary closure of common bile duct
58108957|NCT04264299|PROCEDURE|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
58108958|NCT06527729|DRUG|sildenafil-loaded liposomes|Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
58108959|NCT06527729|DRUG|minoxidil gel|Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
58441659|NCT05981027|OTHER|Static stretching exercise|The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
58441660|NCT02200276|BIOLOGICAL|Influenza|
57955861|NCT00517829|DRUG|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
57955862|NCT00087009|BIOLOGICAL|beta-glucan|Given orally
57955863|NCT00087009|BIOLOGICAL|rituximab|Given IV
57955864|NCT05850221|OTHER|weight training|weight training
58108960|NCT01880099|DRUG|placebo|placebo compared to 8mg of Galantamine
58108961|NCT01880099|DRUG|Galantamine 8mg|8mg of galantamine compared to placebo
58108962|NCT01880099|DRUG|Galantamine 16mg|16mg of galantamine compared to placebo
58108963|NCT00176683|PROCEDURE|Capnography|device which measures carbon dioxide at intubation
58108964|NCT04166669|DRUG|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
58108965|NCT04166669|DRUG|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
58108966|NCT04166669|DRUG|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
58108967|NCT01313000|PROCEDURE|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
58108968|NCT01473758|DRUG|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
58108969|NCT01473758|DRUG|Placebo|tablet, od, oral administration in the morning after breakfast
58108970|NCT05339828|PROCEDURE|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
58108971|NCT02015923|PROCEDURE|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
58108972|NCT02015923|DRUG|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
58311848|NCT02360332|BEHAVIORAL|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
58311849|NCT02815761|OTHER|NO intervention, just observation|No intervention.
58311850|NCT01631214|BIOLOGICAL|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
58441661|NCT06087484|BEHAVIORAL|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
57739418|NCT04360148|OTHER|hypocaloric-balanced-diet|HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
57739419|NCT03240692|DEVICE|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
57955865|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
57739420|NCT00517491|DRUG|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
58108973|NCT02746458|OTHER|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
58108974|NCT02746458|DEVICE|Delfi PTSII Tourniquet System|
58108975|NCT05296122|DEVICE|TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.|The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
58108976|NCT01386879|DRUG|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
58108977|NCT00534092|DEVICE|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
58108978|NCT06011473|DEVICE|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
58108979|NCT06110884|BEHAVIORAL|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
58108980|NCT06110884|BEHAVIORAL|speech therapy|receive only traditional language therapy
58311851|NCT01631214|DRUG|Alendronate|Alendronate 70 mg tablet taken once a week
57955866|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
57955867|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
57955868|NCT04853784|PROCEDURE|intracorporeal anastomosis|intracorporeal anastomosis
57955869|NCT03027700|DEVICE|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
57955870|NCT05047809|OTHER|"Jingchuang Ointment(JCO)"|Applied once a day on the wounds
57955871|NCT05047809|OTHER|Regular Treatment|"Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual."
57955872|NCT00097344|DRUG|Atamestane|
57955873|NCT00097344|DRUG|Toremifene|
57955874|NCT00097344|DRUG|Letrozole|
57955875|NCT00097344|DRUG|Aromatase inhibition|
58311852|NCT01631214|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
58311853|NCT01631214|DRUG|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
58441662|NCT03632772|DRUG|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
57955876|NCT00097344|DRUG|Estrogen receptor blocker|
57955877|NCT00097344|PROCEDURE|Hormone therapy|
57955878|NCT00097344|PROCEDURE|Endocrine therapy|
57955879|NCT00097344|PROCEDURE|Antiestrogen therapy|
57955880|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
57955881|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
58311854|NCT00352183|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
58311855|NCT00352183|DRUG|Simvastatin|Simvastatin 40mg
58311856|NCT02721784|DEVICE|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
58108981|NCT04021901|DEVICE|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
57739421|NCT01464203|OTHER|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
58108982|NCT04023994|DRUG|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
58108983|NCT04023994|DRUG|Placebo|Participants will be administered a single intravenous dose of matching placebo.
58311857|NCT02721784|RADIATION|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
58311858|NCT05338463|DRUG|Fespixon Cream|"1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks"
58311859|NCT06516224|OTHER|Liftactiv® B3 Serum|In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
58311860|NCT06516224|OTHER|Liftactiv® B3 retinol night cream|In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
58311861|NCT06516224|OTHER|Sunscreen UVAage® Inter SPF 50+|twice daily (morning and beginning of the afternoon)
57739422|NCT01464203|OTHER|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
57739423|NCT05414682|OTHER|MIND+SOUL Diet|The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
58311862|NCT06516224|OTHER|Mineral 89 cream|2 drops in the morning before sunscreen application for 6 months
57955882|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
57955883|NCT02543567|BIOLOGICAL|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
57955884|NCT02543567|BIOLOGICAL|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
57955885|NCT02543567|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
57955886|NCT02544308|DRUG|Lenalidomide|Experimental Arm
57955887|NCT02544308|DRUG|Dexamethasone|Experimental Arm
57955888|NCT02544308|OTHER|No further treatment|Comparator Arm
57955889|NCT04640337|OTHER|IPE applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
57955890|NCT04640337|OTHER|IPE applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
57955891|NCT04640337|OTHER|IPE not applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
57955892|NCT04640337|OTHER|IPE not applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
57955893|NCT02214238|DEVICE|PAP device|
57955894|NCT00001498|DRUG|methotrexate|
57955895|NCT00001498|DRUG|leucovorin|
57955896|NCT00001498|DRUG|5-fluorouracil|
57955897|NCT00001498|DRUG|cyclophosphamide|
57955898|NCT00001498|PROCEDURE|peripheral blood progenitor cell|
57955899|NCT00001498|DRUG|paclitaxel|
57955900|NCT00001498|DRUG|doxorubicin|
57955901|NCT01998828|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
57955902|NCT02776488|DRUG|Sodium Lactate|Infusion of exogenous sodium lactate
57955903|NCT02776488|DRUG|Placebo|Infusion of normal saline
58311863|NCT01757132|DEVICE|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
58311864|NCT02030600|DRUG|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
57739424|NCT04763850|OTHER|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
57739425|NCT02959632|BEHAVIORAL|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
57739426|NCT04899518|DRUG|ALY688 Ophthalmic Solution|Ophthalmic Solution
57739427|NCT06222450|BEHAVIORAL|Vestibular Rehabilitation Therapy (VRT)|customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
58441663|NCT03632772|DRUG|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
58441664|NCT04160663|DIAGNOSTIC_TEST|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
58441665|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
58441666|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
58441667|NCT00003419|PROCEDURE|antiviral therapy|
58441668|NCT06164834|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
58441669|NCT06164834|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
58441670|NCT06164834|DRUG|Esomeprazole 20mg|Esomeprazole 20 mg tablet
58441671|NCT06521372|OTHER|Magenta AI image analysis tool|MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
58441672|NCT03487744|OTHER|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
58441673|NCT03487744|OTHER|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
58441674|NCT03186729|DRUG|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
58441675|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
58441676|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
57739428|NCT05095753|DEVICE|Earbud|In ear headphone with embedded infrasonic hemodynography technology
58441677|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
58441678|NCT04577430|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
58441679|NCT03876119|DRUG|Intraarterial alteplase|See arm/group descriptions.
57739429|NCT04669158|DRUG|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
57739430|NCT04669158|DRUG|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
58108984|NCT06040957|BIOLOGICAL|Bone marrow aspirate concentrate injection|single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
58311865|NCT02030600|DRUG|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
58441680|NCT03876119|DRUG|Placebo|See arm/group descriptions.
58441681|NCT06240104|DIAGNOSTIC_TEST|cardiac output index monitor|During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
58441682|NCT00566852|DRUG|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
58441683|NCT00566852|OTHER|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
58441684|NCT00566852|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
57739431|NCT06695546|OTHER|VExUS evaluation ultrasound|"VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity."
57739432|NCT06470854|DRUG|Nebulized Dexmedetomidine|Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
58441685|NCT03538366|OTHER|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
58441686|NCT05822180|DRUG|NANOS1 , argent colloïdal ,|orally, during 5 day
58441687|NCT03139123|OTHER|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
58441688|NCT04679194|BIOLOGICAL|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
58441689|NCT04789889|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
58441690|NCT04789889|RADIATION|postoperative radiotherapy|postoperative radiotherapy
58441691|NCT01022138|BIOLOGICAL|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
58441692|NCT01022138|DRUG|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
58441693|NCT01022138|OTHER|Laboratory biomarker analysis|The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
58441694|NCT00756990|DRUG|Depot Naltrexone|228mg of injectable naltrexone
58441695|NCT02041338|DRUG|Paclitaxel and carboplatin|
58441696|NCT02041338|DRUG|Paclitaxel|
57739433|NCT06470854|PROCEDURE|Bilateral greater occipital nerve block|The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
58441697|NCT02041338|DRUG|Epirubicin and Paclitaxel|
58441698|NCT03276897|OTHER|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
58441699|NCT01076036|DEVICE|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
57955904|NCT03147729|RADIATION|Radiofrequency non ablation|Use of radiofrequency
57955905|NCT03070847|DRUG|Tranexamic Acid|Dose: 5mg/kg
58441700|NCT01076036|DEVICE|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
58441701|NCT02450292|PROCEDURE|Bioabsorbable screw fixation|
58441702|NCT06153537|DRUG|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
58441703|NCT02745834|OTHER|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
58441704|NCT03356678|DRUG|Pralatrexate|"* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
58441705|NCT02769910|DRUG|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
58441706|NCT02769910|DRUG|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
58441707|NCT02769910|OTHER|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
58441708|NCT00623870|DRUG|RO5045337|Multiple ascending doses
58441709|NCT03657290|DRUG|vadadustat|Vadadustat Tablets
58441710|NCT04971356|DRUG|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
58441711|NCT04971356|DRUG|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
58441712|NCT04971356|DRUG|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
58441713|NCT04971356|DRUG|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
58441714|NCT04971356|DRUG|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
58441715|NCT05765123|DIAGNOSTIC_TEST|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
57739434|NCT01554072|OTHER|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
58441716|NCT03654508|GENETIC|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
58441717|NCT03654508|OTHER|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
58441718|NCT03423316|BEHAVIORAL|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
58441719|NCT06526819|DRUG|SMP3124LP|Liposomal encapsulation formulation of SMP-3124
58441720|NCT00858208|DRUG|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
58441721|NCT05242172|DIAGNOSTIC_TEST|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
58441722|NCT00891241|DRUG|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
58441723|NCT01147055|DRUG|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
58441724|NCT01147055|DRUG|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
57739435|NCT04783467|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
57739436|NCT03386968|BEHAVIORAL|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
57739437|NCT03386968|BEHAVIORAL|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
58108985|NCT06040957|BIOLOGICAL|intra-articular injection of Minimally manipulated adipose tissue|single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
58441725|NCT01147055|DRUG|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
58441726|NCT06122974|DEVICE|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
58441727|NCT06122974|DEVICE|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
58441728|NCT00735722|DEVICE|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
58441729|NCT05249569|DRUG|Axitinib|Axitinib to be administered orally BID
57955906|NCT03070847|DRUG|Tranexamic Acid|Dose: 10mg/kg
58108986|NCT04271150|DEVICE|Self-etch|Universal adhesive with self-etch mode
58441730|NCT05249569|DRUG|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
58441731|NCT05249569|DRUG|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
58441732|NCT05909384|OTHER|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
58441733|NCT04826939|DEVICE|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
58441734|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
58441735|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
58441736|NCT00286429|DRUG|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
57739438|NCT04180657|GENETIC|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
57739439|NCT06304766|PROCEDURE|Laparoscopic ablation|Heat-based ablation modality performed by laparoscopy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
58441737|NCT05600244|PROCEDURE|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
57739440|NCT06304766|PROCEDURE|Open ablation|Heat-based ablation modality performed by laparotomy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
57739441|NCT02293538|DRUG|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
57739442|NCT02293538|DRUG|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
57739443|NCT02293538|DEVICE|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
57739444|NCT05268133|DIETARY_SUPPLEMENT|Aronia|As described in experimental arm
57739445|NCT05268133|DIETARY_SUPPLEMENT|Control|As described in placebo comparator arm
57739446|NCT06496932|OTHER|Listen to music|Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
57739447|NCT02139033|DRUG|Retaine™|
57739448|NCT02701218|PROCEDURE|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
58441738|NCT05600244|PROCEDURE|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
58441739|NCT05600244|PROCEDURE|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
58441740|NCT03165422|OTHER|Non-Interventional|Non-Interventional
57739449|NCT00361543|DRUG|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
57739450|NCT00361543|OTHER|Lactose Capsules|1 tablet daily for 12 weeks
57739451|NCT00978601|PROCEDURE|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
57739452|NCT00960466|BEHAVIORAL|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
57739453|NCT00960466|BEHAVIORAL|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
58108987|NCT04271150|DEVICE|Total-etch|Universal adhesive with total-etch mode
58441741|NCT02386163|BIOLOGICAL|MSC from synovial membrane and infrapatellar Fat Pad|
58441742|NCT04246658|OTHER|conventional physical therapy program|traditional physical therapy program
58441743|NCT04246658|OTHER|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
58441744|NCT06273397|DRUG|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
57739454|NCT00611013|DEVICE|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
57739455|NCT02403726|PROCEDURE|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
58108988|NCT03509051|BIOLOGICAL|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
58108989|NCT04525157|DRUG|Afamelanotide|
58108990|NCT04525157|DRUG|Placebo|
58311866|NCT01299909|BEHAVIORAL|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
57739456|NCT02403726|PROCEDURE|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
58311867|NCT01299909|BEHAVIORAL|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
58311868|NCT01299909|BEHAVIORAL|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
58441745|NCT06273397|DRUG|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
58441746|NCT06273397|DRUG|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
58311869|NCT03024567|DIETARY_SUPPLEMENT|Salt|10 capsules daily for 14 days
58311870|NCT03024567|DIETARY_SUPPLEMENT|Placebo|10 capsules daily for 14 days
58311871|NCT00770406|DRUG|botulinum toxin type A|100 or 200 units intravesically
58311872|NCT02659735|DRUG|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
57955907|NCT03070847|DRUG|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
58311873|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
58311874|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
58311875|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
58311876|NCT01075776|DRUG|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
58311877|NCT01075776|DRUG|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
58311878|NCT01075776|DRUG|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
58311879|NCT01327768|PROCEDURE|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
58311880|NCT00908934|DRUG|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
58311881|NCT00908934|DRUG|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
58108991|NCT04550715|BEHAVIORAL|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
58108992|NCT04550715|BEHAVIORAL|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
58108993|NCT04550715|BEHAVIORAL|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
58108994|NCT02731833|OTHER|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
58108995|NCT02731833|OTHER|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
58311882|NCT00908934|DRUG|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
58311883|NCT00908934|DRUG|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
58311884|NCT02786303|DEVICE|Whole-body diffusion- weighted MRI|
58311885|NCT06477978|DIAGNOSTIC_TEST|Hand grip function testing|The use of Bio-impedance to measure the skeletal muscle mass
58311886|NCT00722696|OTHER|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
58441747|NCT01486342|RADIATION|PET-CT scan|"PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
58441748|NCT03262168|OTHER|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
58441749|NCT04550494|PROCEDURE|Biopsy|Undergo biopsy
58441750|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58108996|NCT03250650|DEVICE|TTNS|Transcutaneous tibial electric stimulation
58108997|NCT03250650|DEVICE|ES+TTNS|Transvaginal electric stimulation
58108998|NCT02314273|DRUG|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
58108999|NCT03736395|BEHAVIORAL|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
58109000|NCT03736395|BEHAVIORAL|Control|Schools in this condition will receive a four-day training session about SWPBIS.
58109001|NCT00035165|DRUG|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
58109002|NCT06219382|DEVICE|Neurorehabilitation ecosystem|Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
58109003|NCT02896868|DRUG|LY3041658|Administered IV.
58109004|NCT02896868|DRUG|Placebo|Administered IV.
58109005|NCT01363609|DRUG|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
58311887|NCT06034496|DEVICE|Active CES|Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4\~6 weeks), 20 minutes per day.
58311888|NCT06034496|DEVICE|Sham CES|Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
58311889|NCT00902863|BEHAVIORAL|YOGA|Patients with chronic pain will undergo a six week course of YOGA
58311890|NCT05066477|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
58311891|NCT05066477|OTHER|Placebo|Pure maltodextrin
58311892|NCT03340883|BIOLOGICAL|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
58441751|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
58441752|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58441753|NCT04550494|DRUG|Talazoparib|Given PO
58441754|NCT05805046|DEVICE|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
58441755|NCT01582399|DRUG|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
58311893|NCT03143023|DRUG|arginine toothpaste|acid neutralizer toothpaste
58441756|NCT04867733|OTHER|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
58311894|NCT03143023|DRUG|fluoride toothpaste|bactericidal toothpaste
58441757|NCT00745537|OTHER|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
58441758|NCT00897455|GENETIC|DNA analysis|
58311895|NCT03966989|BEHAVIORAL|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
58441759|NCT00897455|GENETIC|mutation analysis|
58441760|NCT00897455|GENETIC|polymorphism analysis|
57739457|NCT03936855|PROCEDURE|Direct composite resin|"For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal"
58109006|NCT01363609|DRUG|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
58109007|NCT01363609|DRUG|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
58109008|NCT03700528|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
58109009|NCT00410566|DRUG|rhASM|Single dose of 0.03mg/kg body weight IV
58109010|NCT00410566|DRUG|rhASM|Single dose of 0.1mg/kg body weight IV
58109011|NCT00410566|DRUG|rhASM|Single dose of 0.3mg/kg body weight IV
58311896|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
58311897|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
58311898|NCT00327158|PROCEDURE|Transesophageal transducer|One time use of reamer during surgery
58109012|NCT00410566|DRUG|rhASM|Single dose of 0.6mg/kg body weight IV
58109013|NCT00410566|DRUG|rhASM|Single dose of 1.0mg/kg body weight IV
58311899|NCT00327158|PROCEDURE|echocardiography|takes photos of right atrium during the reaming processes
58311900|NCT01277861|DRUG|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
57739458|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
57739459|NCT00564122|DEVICE|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
57739460|NCT00564122|OTHER|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
58311901|NCT03537833|OTHER|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
58311902|NCT00181025|DRUG|Tasonermine (TNFa)|
58311903|NCT00181025|DRUG|Melphalan|
58311904|NCT05662813|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
58441761|NCT00897455|OTHER|laboratory biomarker analysis|
58441762|NCT00897455|PROCEDURE|evaluation of cancer risk factors|
58441763|NCT06011837|DEVICE|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
58109014|NCT05944549|BEHAVIORAL|Financial coaching using TrustPlus|Participants will be assigned a financial coach, who will, prepare a budget, conduct a soft pull of their credit report and score to analyze the credit score. Based on the participant's goals and financial limitations as highlighted by the, the participant and financial coach will create a personalized financial action plan comprising of strategies, follow-up actions, and resources, which includes unlimited access to one-on-one sessions with the financial coach. After the intensive financial coaching, participants will maintain access to the TrustPlus Portal and can continue to connect with their financial coach as needed throughout the 6-month intervention period. Participants will also have ongoing access to educational webinars and Trust+Ed, an interactive resource that provides self-guided content on many financial topics of interest, such as credit building and debt management.
58109015|NCT05944549|BEHAVIORAL|Brighter Bites|Families receive a weekly distribution of fresh fruits and vegetables for 24 weeks, there will be Nutrition education in school throughout the school year using the evidence-based CATCH (Coordinated Approach to Child Health) program and weekly healthy recipe tastings and cooking skill demos for families during produce pick-up time.Fruit and vegetable access is complemented by CATCH, an evidence based, Texas Education Agency-approved, coordinated school health program designed to promote healthy nutrition, physical activity, and prevent obesity in schoolchildren. In addition, the Brighter Bites website and mobile app are freely available in English and Spanish.
58441764|NCT03719742|OTHER|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
58311905|NCT04980729|DEVICE|Acetabular reconstruction after tumor resection.|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
58311906|NCT01125930|DRUG|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
58441765|NCT00185575|DRUG|duloxetine|
58441766|NCT02150278|BEHAVIORAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
58441767|NCT06379776|OTHER|Education through a 3D model|Training through a 3D model of the spine fractures
58441768|NCT06379776|OTHER|Education through a traditional pedagogical support|Training through a traditional pedagogical support
58109016|NCT05944549|BEHAVIORAL|Noom|Participants will get access to Noom which is a mobile app for weight loss that shifts the paradigm from dieting to a digitally supported and artificial intelligence (AI)-driven cognitive behavioral therapy approach to support personalized behavior changes towards eating, physical activity and stress management. The Noom Healthy Weight curriculum covers foundations in weight loss, nutrition, physical activity, sleep and stress management.Daily tasks (e.g., weight and food logs, readings) are organized vertically in simple cards on the phone screen, allowing users to easily scroll through what needs to be done. It will pull physical activity data (e.g., steps) directly from the health app on smartphones or apps associated with external devices such as Fitbit. Furthermore, Noom stands out from other app-based programs by assigning a personal coach to each user, helping users navigate the emotional and physiological experiences of the Noom weight loss experience.
58109017|NCT05209061|OTHER|Biopsy|Participants included in the study, will have a full thickness biopsy of the middle of the appendix taken, after the resected bowel has been removed during surgery.
58109018|NCT06540378|DRUG|Stiripentol|
58109019|NCT01633749|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
58109020|NCT05841381|DRUG|Pyrotinib|pyrotinib: 400mg orally daily for 1 year
58109021|NCT05841381|DRUG|Trastuzumab|8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
58109022|NCT05841381|DRUG|Paclitaxel|80mg/m2 per week for a total of 12 weeks
57739461|NCT02724553|DEVICE|Acrylic lens implantation|
57739462|NCT03314415|DEVICE|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
58109023|NCT00689663|PROCEDURE|Laparoscopic cholecystectomy|Randomized to three arm.
58109024|NCT03000868|PROCEDURE|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
58109025|NCT03000868|PROCEDURE|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
58109026|NCT00005960|BIOLOGICAL|filgrastim|
58109027|NCT00005960|DRUG|cyclophosphamide|
58109028|NCT00005960|DRUG|docetaxel|
58109029|NCT00005960|DRUG|doxorubicin hydrochloride|
58109030|NCT00005960|PROCEDURE|pain therapy|
58109031|NCT00124176|DRUG|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
58109032|NCT00124176|DRUG|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
58109033|NCT04446832|OTHER|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
58109034|NCT00235833|BIOLOGICAL|adalimumab|40 mg every other week (eow), subcutaneous (sc)
58109035|NCT01806883|BEHAVIORAL|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
58311907|NCT01125930|DRUG|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
58441769|NCT01817504|PROCEDURE|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
58109036|NCT01806883|BEHAVIORAL|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
58109037|NCT06234800|PROCEDURE|Removal of failed dental implants|Removal (with various techniques) of failed dental implants.
58109038|NCT02378506|BIOLOGICAL|etanercept|50mg subcutaneous, once weekly, 24 weeks
58109039|NCT01077115|PROCEDURE|Laparoscopic cholecystectomy|
58109040|NCT01077115|PROCEDURE|Open Surgery|
58109041|NCT04976140|BIOLOGICAL|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
58109042|NCT00192751|BEHAVIORAL|Psychoeducational group sessions|
58109043|NCT05621200|DEVICE|Transcranial stimulation over the cerebellar hemispheres|Single session of Transcranial stimulation over the cerebellar hemispheres
58109044|NCT06267261|DEVICE|KOLMI® surgical face mask (OP-Air)|12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
58311908|NCT02532400|DRUG|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
58311909|NCT02532400|DRUG|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
58311910|NCT05237141|DRUG|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
58311911|NCT01070680|DRUG|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
58311912|NCT01070680|DRUG|sodium chlorid 0,9%|continuous intravenous infusion
58109045|NCT00786110|DRUG|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
58109046|NCT00786110|DRUG|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
58109047|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
58109048|NCT00219557|DRUG|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
58311913|NCT03711721|DIETARY_SUPPLEMENT|Food basket|
58311914|NCT03711721|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|
58311915|NCT06180057|DRUG|Chenodeoxycholic acid|Two capsules were administered orally
58311916|NCT06180057|DRUG|Chenodeoxycholic acid leadiant|Two capsules were administered orally
58311917|NCT05019677|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
58109049|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
58311918|NCT04705090|DRUG|YY-20394 treatment|Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
58311919|NCT02914327|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
58311920|NCT06002204|OTHER|Observational Study|No Treatment or Intervention Provided
58311921|NCT04468711|DRUG|Vitamin D|Vitamin D plus topical 1% hydrocortisone cream twice daily
58109050|NCT03984136|BEHAVIORAL|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
58109051|NCT03984136|BEHAVIORAL|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
58109052|NCT04964622|DRUG|nurofen|tablet
58109053|NCT05895981|DEVICE|G132 system, Beijing PINS Medical Co., China|Neuromodulation was performed according to the usual protocol
58109054|NCT01348542|DRUG|Trazodone|50 mg once a day, for 3 months
58109055|NCT01348542|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
58441770|NCT01817504|PROCEDURE|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
58441771|NCT01568294|DRUG|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
57739463|NCT05878197|BEHAVIORAL|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
58109056|NCT03782649|DEVICE|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
58441772|NCT00994526|OTHER|Ham|Ham : 180 g per day during 4 days
58441773|NCT00994526|OTHER|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
58441774|NCT00994526|OTHER|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
58441775|NCT00133861|DRUG|Botulinum toxin|
57769637|NCT02757222|RADIATION|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
58109057|NCT05295602|RADIATION|CT scan|CT of lower leg
58109058|NCT05496114|DEVICE|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
58109059|NCT04816188|OTHER|Exercise Therapy and Activity Modification|Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
58109060|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
58109061|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
58109062|NCT01040013|PROCEDURE|Laparoscopy|Laparoscopic Left-Colectomy
58109063|NCT01040013|PROCEDURE|left colectomy by laparotomy|PatientS will be operated by laparotomy
58109064|NCT05837559|OTHER|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
58441776|NCT03005548|DEVICE|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
58441777|NCT03005548|DRUG|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
58109065|NCT04298125|BEHAVIORAL|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
57739464|NCT05878197|BEHAVIORAL|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
58109066|NCT02391883|DRUG|Clopidogrel|
58109067|NCT06306027|BEHAVIORAL|Web-based education|The patient discharged after knee arthroplasty surgery will attend a follow-up appointment 15 days later, and during this visit, they will be granted permission to resume work. The patient will receive detailed information about accessing, entering, and using the web-based training. Scales with pre-test data will be completed by the patient. They will be encouraged to log in at least twice a week, and the patient will be monitored for a total of 1 month (4 weeks). After one month, the patient will be asked to fill out the scales again.
58109068|NCT01993420|DRUG|DRM02|
58109069|NCT01993420|OTHER|Vehicle|
58109070|NCT00442585|DRUG|S(+)-ibuprofen|
58441778|NCT01247168|DRUG|AZD2461|oral capsules, continuous dosing and intermittent dosing
58441779|NCT04637425|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
58109071|NCT06481826|DRUG|Glofitamab|Glofitamab given in standard dosage
58109072|NCT02609737|DEVICE|PET/CT Imaging|
58109073|NCT02609737|RADIATION|68Ga-DOTA-JR11|
58109074|NCT02609737|RADIATION|177Lu-DOTA-JR11|
58109075|NCT04313283|BEHAVIORAL|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
58109076|NCT04692220|OTHER|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
58109077|NCT05373433|DRUG|SSD8432 750mg|Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
58109078|NCT05373433|DRUG|SSD8432 placebo|Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
58311922|NCT04468711|DRUG|Placebo|placebo plus topical 1% hydrocortisone cream twice daily
58441780|NCT04637425|DRUG|Placebo|Matched tablets without any active substance.
58441781|NCT03387020|DRUG|Everolimus|Given PO
58441782|NCT03387020|OTHER|Laboratory Biomarker Analysis|Correlative studies
58441783|NCT03387020|OTHER|Pharmacological Study|Correlative studies
58441784|NCT03387020|DRUG|Ribociclib|Given PO
58441785|NCT04942613|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
58441786|NCT04942613|OTHER|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
58441787|NCT04942613|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
58441788|NCT04942613|OTHER|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
58441789|NCT05627024|DRUG|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
58109079|NCT05792410|DRUG|SHR-A1811 & Dalpiciclib Isethionate Tablets|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral
58109080|NCT05792410|DRUG|SHR-A1811 & Fulvestrant|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
58109081|NCT05792410|DRUG|SHR-A1811 & Bevacizumab injection|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
58441790|NCT05627024|DRUG|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
58441791|NCT01435135|BIOLOGICAL|ALVAC-HIV|1 mL per injection containing 10\^6 CCID50/dose administered
58109082|NCT05585619|OTHER|Pain treatment|Any pain treatment to include medications, procedures, or referrals
58109083|NCT05271201|OTHER|treadmill exercise (mild)|mild intensity treadmill training.
58109084|NCT05271201|OTHER|treadmill exercise (moderate)|moderate-intensity treadmill training
58109085|NCT02360657|DRUG|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
58109086|NCT02360657|DRUG|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
58109087|NCT02360657|DRUG|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
58109088|NCT02170129|DEVICE|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
58441792|NCT01435135|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
58441793|NCT01435135|BIOLOGICAL|ALVAC-HIV Placebo|1 ml per injection
58441794|NCT01435135|BIOLOGICAL|AIDSVAX B/E Placebo|1 ml per injection
58441795|NCT04389723|DIETARY_SUPPLEMENT|Qualia Mind|Multi-ingredient Dietary supplement
58441796|NCT04389723|DIETARY_SUPPLEMENT|Placebo|Multi-ingredient Placebo
58441797|NCT00363623|DEVICE|Silicone hydrogel contact lens|
58441798|NCT01712802|OTHER|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
58441799|NCT01712802|OTHER|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
58441800|NCT01712802|OTHER|Saline|work as control for Denture Adhesives: Cream and Powder
58441801|NCT03475485|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
58441802|NCT03475485|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
58441803|NCT03475485|DEVICE|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
58441804|NCT05701696|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
58441805|NCT05701696|DIAGNOSTIC_TEST|Widespread pain index|Total the number of painful body areas
58441806|NCT05701696|DIAGNOSTIC_TEST|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
58441807|NCT05701696|OTHER|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
58441808|NCT05701696|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
58441809|NCT05701696|DIAGNOSTIC_TEST|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
58109089|NCT02170129|DEVICE|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
58109090|NCT06168305|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
58441810|NCT06324292|PROCEDURE|complete denture, CG|fabrication of conventional complete denture followed by a digital denture
58441811|NCT06324292|PROCEDURE|complete denture, DG|fabrication of digital complete denture followed by a conventional one
58441812|NCT02172378|DRUG|Tiotropium inhalation capsules|
58441813|NCT02172378|DRUG|Placebo inhalation capsules|
58441814|NCT02402140|OTHER|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
58441815|NCT05981469|DEVICE|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
58441816|NCT05981469|OTHER|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
58441817|NCT04887519|OTHER|No Intervention|This is a non-interventional study.
58441818|NCT01732276|DRUG|gefitinib|
58441819|NCT00633529|DRUG|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
58109091|NCT00145756|DRUG|low sodium high potassium salt substitute|
58441820|NCT05555706|DRUG|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
58109092|NCT03640000|DIAGNOSTIC_TEST|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
58441821|NCT00751803|DRUG|BI 44370 TA Low Dose|
58441822|NCT00751803|DRUG|Eletriptan|
58441823|NCT00751803|DRUG|Placebo|
58441824|NCT00751803|DRUG|BI 44370 TA Medium Dose|
58109093|NCT03586830|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
58109094|NCT03586830|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
58109095|NCT03586830|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
58109096|NCT03586830|DRUG|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
58109097|NCT00931567|BIOLOGICAL|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
58109098|NCT00931567|DEVICE|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
58109099|NCT01712230|DRUG|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
58109100|NCT01712230|BEHAVIORAL|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
58109101|NCT01712230|DRUG|Placebo|Placebo
58109102|NCT01222871|DRUG|Triamcinolone|Triamcinolone soaked nasopore dressing
58109103|NCT01222871|DRUG|Saline soaked sponge|saline soaked sponge
58109104|NCT00179452|BEHAVIORAL|Yoga|
58109105|NCT02361190|DRUG|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
58109106|NCT02361190|DRUG|Placebo|Administration of 1ml aqueous saline spray
58109107|NCT01691365|DIETARY_SUPPLEMENT|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
58109108|NCT01691365|DRUG|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
58109109|NCT01110499|DRUG|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
58109110|NCT01110499|DRUG|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
58441825|NCT05582772|OTHER|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
58441826|NCT05582772|OTHER|RSM intervention|Telephone-based, symptom management of patients with cancer
58441827|NCT05582772|OTHER|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
58109111|NCT01110499|DRUG|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
58109112|NCT01110499|DRUG|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
58109113|NCT01110499|DRUG|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
58109114|NCT01110499|DRUG|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
58109115|NCT01110499|DRUG|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
58109116|NCT01110499|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
58109117|NCT00557973|DRUG|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
58109118|NCT00557973|DRUG|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
58109119|NCT00557973|DRUG|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
58109120|NCT00557973|DRUG|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
58109121|NCT06344702|DEVICE|CPAP|70% of nights use CPAP for more than 4 hours
58109122|NCT02726217|BEHAVIORAL|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
58109123|NCT02726217|BEHAVIORAL|Standard of Care Reminders and Self Assessments|
58109124|NCT02784717|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
58109125|NCT02604069|DEVICE|Continuous Glucose Monitor|
58441828|NCT05137899|COMBINATION_PRODUCT|Neoadjuvant|Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
58441829|NCT00650767|DRUG|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
58441830|NCT00650767|DRUG|Placebo; oral|matching placebo
58109126|NCT00229450|DRUG|Estrogen|0.625 mg/day of conjugated Estrogen
58311923|NCT02679976|DEVICE|etafilcon A|Marketed Multifocal Contact Lens
58109127|NCT04356573|DIETARY_SUPPLEMENT|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
58109128|NCT04356573|DIETARY_SUPPLEMENT|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
58109129|NCT00478361|DRUG|Gemcitabine hydrochloride|Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.
58109130|NCT00478361|DRUG|Paclitaxel|135 mg/m\^2 IV over 1 hour
58109131|NCT00478361|DRUG|Doxorubicin hydrochloride|Doxorubicin 40 mg/m\^2 IV over 20 minutes
58109132|NCT00478361|DRUG|Pegfilgrastim|Subcutaneously injection on day 1.
58109133|NCT04978285|OTHER|Anemia|Depends on Day 3 Hb result
58109134|NCT02598193|DRUG|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
58109135|NCT02598193|DRUG|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
58311924|NCT04663516|OTHER|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
58311925|NCT05919134|DIETARY_SUPPLEMENT|Dentoblis|dissolve the tablets in the mouth once a day for 4 weeks
58311926|NCT05919134|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
58311927|NCT00261521|DRUG|epoetin alfa|
58441831|NCT03016065|DIETARY_SUPPLEMENT|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
58441832|NCT03016065|DIETARY_SUPPLEMENT|Control|Baked goods (2 snacks) without added fiber
58441833|NCT00498589|DRUG|methotrexate|25 mg per week IM or SC during 24 weeks
58109136|NCT03175783|DEVICE|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
57739465|NCT05878197|BEHAVIORAL|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
57955908|NCT04760561|PROCEDURE|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
57955909|NCT02735369|DRUG|2% OC-10X|2% OC-10X
57955910|NCT02735369|DRUG|Placebo Comparator|Placebo
58109137|NCT02685761|PROCEDURE|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
58109138|NCT02685761|PROCEDURE|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
57955911|NCT03760900|COMBINATION_PRODUCT|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
57955912|NCT03183193|OTHER|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
58109139|NCT03229993|DIAGNOSTIC_TEST|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
57955913|NCT03183193|OTHER|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
58109140|NCT02457728|DEVICE|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
58109141|NCT04793503|OTHER|conventional complete denture|the complete denture constructed by packing technique
58441834|NCT00498589|DRUG|placebo|one intramuscular injection per week
58109142|NCT04793503|OTHER|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
58109143|NCT04793503|OTHER|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
58109144|NCT05952427|OTHER|ACE Questionnaire|The only intervention consists of completing the validated ACE questionnaire
58109145|NCT05599906|OTHER|questionnaires|Completion of 3 questionnaires (HADS; SF-12; FAS) at the beginning and end of the rehabilitation and after 3 months
58109146|NCT00693784|BIOLOGICAL|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
58109147|NCT00971204|DEVICE|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
58109148|NCT02799316|OTHER|HBV core antibodies testing. • Real time PCR testing.|"* HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies."
58109149|NCT00139386|DRUG|Candesartan|Candesartan Cilexetil (4-12 mg per day)
58109150|NCT04336267|DEVICE|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
58109151|NCT04336267|DEVICE|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
58109152|NCT01866683|BEHAVIORAL|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
58109153|NCT01866683|BEHAVIORAL|1 month waiting period|waiting or detraining period
58109154|NCT05934279|DEVICE|Resistance Training|All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
57955914|NCT01565070|DRUG|Biofreeze|Use of Biofreeze ointment
57955915|NCT01565070|OTHER|Placebo|Use of placebo ointment
57955916|NCT00636766|DRUG|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
58311928|NCT03087240|PROCEDURE|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
58441835|NCT02797392|BEHAVIORAL|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
58441836|NCT04299035|PROCEDURE|Erector spinae plane block|Erector spinae plane block
58441837|NCT03162471|DIAGNOSTIC_TEST|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
58109155|NCT03180983|BEHAVIORAL|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
58441838|NCT02313584|DRUG|dabigatran|
58441839|NCT02313584|DRUG|placebo|
57739466|NCT00955357|DRUG|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
57739467|NCT00941330|DRUG|Exemestane|25 mg daily by mouth for 6 to 12 months.
58109156|NCT03401645|OTHER|Wrist Alarm|Wrist device with alarm timer
58311929|NCT03475238|PROCEDURE|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
58311930|NCT04603755|DEVICE|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
58311931|NCT04272229|DIAGNOSTIC_TEST|Cognition|Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
58441840|NCT00269867|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
58441841|NCT00269867|DRUG|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
58441842|NCT00269867|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
58441843|NCT04962867|DRUG|E7090|140 mg of E7090 is orally administered once daily.
58441844|NCT00391027|DRUG|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
58441845|NCT00391027|DRUG|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
58441846|NCT04108195|DRUG|Daratumumab|Participants will receive daratumumab.
58441847|NCT04108195|DRUG|Talquetamab|Participants will receive talquetamab.
58441848|NCT04108195|DRUG|Teclistamab|Participants will receive teclistamab.
58441849|NCT04108195|DRUG|Pomalidomide|Participants will receive pomalidomide.
58441850|NCT01763606|DRUG|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
58441851|NCT01763606|DRUG|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
58441852|NCT04923568|DEVICE|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
58441853|NCT03814408|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
58441854|NCT01848327|DIETARY_SUPPLEMENT|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
58109157|NCT03401645|BEHAVIORAL|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
58109158|NCT01967888|DRUG|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
58109159|NCT01967888|DRUG|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
58441855|NCT01848327|DIETARY_SUPPLEMENT|Placebo|Placebo (40 gram packet orally once a day for 90 days)
58441856|NCT02661243|DEVICE|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
58441857|NCT04786795|DRUG|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
58441858|NCT04786795|DRUG|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
58441859|NCT04872699|DIAGNOSTIC_TEST|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
58441860|NCT05882461|BEHAVIORAL|90Second Caregiver health letter|Participant receives the weekly health letter via email
58441861|NCT04694027|DRUG|Omega 3 fatty acid|omega 3 1000 mg
57955917|NCT00636766|DRUG|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
57955918|NCT00636766|DRUG|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
58441862|NCT04694027|DRUG|VitaE|vitamin e 400 mg
58441863|NCT05566171|DIETARY_SUPPLEMENT|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
58441864|NCT04863872|OTHER|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
58441865|NCT04863872|BEHAVIORAL|my hypo compass education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
58441866|NCT06361589|DRUG|Lorlatinib|lolatinib 100mg qd po
58441867|NCT02352844|DRUG|Everolimus|
58441868|NCT05550935|DEVICE|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
57739468|NCT00941330|DRUG|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
57739469|NCT00941330|DRUG|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
57739470|NCT06304818|DRUG|SCTB14|SCTB14,IV
58441869|NCT05580939|OTHER|Intervention group|They use Web-based Simulation Application for 4 weeks
58441870|NCT03785379|BEHAVIORAL|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
58441871|NCT03785379|BEHAVIORAL|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
58441872|NCT02629822|DRUG|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
58441873|NCT04753749|DRUG|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
58441874|NCT04753749|DRUG|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
58441875|NCT04906304|DRUG|Everolimus Pill|standard dose versus low dose Sandimun
57739471|NCT03524040|DEVICE|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
57739472|NCT04477642|DRUG|Abatacept|10mg/kg intravenously administered on Day 1
57739473|NCT03460977|DRUG|Mervometostat (PF-06821497)|Oral continuous
57739474|NCT03460977|DRUG|Enzalutamide|Oral continuous
57739475|NCT04323813|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
58441876|NCT04906304|DRUG|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
58441877|NCT06163222|BEHAVIORAL|Additional message with behavioural science-informed content and associated web pages|Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
58441878|NCT06163222|OTHER|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
58441879|NCT03210961|DRUG|PF-06826647 tablet|PF-06826647 tablet for oral administration
57739476|NCT05713617|BEHAVIORAL|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
57739477|NCT02158299|DRUG|Avitene|
57739478|NCT02158299|DRUG|Sapylin|
58441880|NCT03210961|DRUG|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
57739479|NCT02158299|BEHAVIORAL|axillary drainage|
57739480|NCT02158299|OTHER|reexamine|
57739481|NCT04126226|OTHER|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
57739482|NCT04126226|OTHER|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
57739483|NCT04126226|OTHER|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
57739484|NCT01538381|DRUG|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
57739485|NCT01538381|OTHER|Observation|Observation
57739486|NCT05744895|DEVICE|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
57739487|NCT05744895|DEVICE|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
57739488|NCT05744895|DEVICE|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
57739489|NCT05744895|DEVICE|FocusMotion app|Will survey patients with PROMS
57739490|NCT04625712|PROCEDURE|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
57739491|NCT00818753|DRUG|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
57739492|NCT00818753|DRUG|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
57739493|NCT00818753|DRUG|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
58109160|NCT00802750|DEVICE|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
58109161|NCT00802750|DEVICE|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
58441881|NCT03210961|OTHER|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
58441882|NCT03210961|OTHER|Placebo tablet|Matching placebo tablet
58441883|NCT00960492|DRUG|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
58441884|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
58441885|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
58441886|NCT00960492|RADIATION|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
58441887|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
58441888|NCT01002183|DRUG|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
58441889|NCT04807218|BEHAVIORAL|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
58441890|NCT01805479|OTHER|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
58441891|NCT01805479|OTHER|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
58441892|NCT02709811|DRUG|Electrochemotherapy|
58441893|NCT00519272|BEHAVIORAL|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
57739494|NCT00605436|BEHAVIORAL|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
57739495|NCT02085252|DRUG|Leuprorelin|Solution for injection
58441894|NCT02843503|DEVICE|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
58441895|NCT02843503|DEVICE|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
58441896|NCT02843503|DEVICE|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
57739496|NCT02085252|DRUG|Bicalutamide|Bicalutamide tablets
57739497|NCT02844946|BEHAVIORAL|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
58109162|NCT04339088|OTHER|Questionnaires|Questionnaires to assess quality of life
58109163|NCT05664750|DRUG|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
58109164|NCT05664750|DRUG|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
58109165|NCT00038129|PROCEDURE|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
58109166|NCT02464878|DRUG|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
58441897|NCT04385459|OTHER|Coronary artery disease|Exposure
58109167|NCT02464878|PROCEDURE|Islet Transplantation|
58109168|NCT02464878|DRUG|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
57739498|NCT01409538|OTHER|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
58109169|NCT02464878|DRUG|Basiliximab|Basiliximab will be used for subsequent transplants.
58441898|NCT05275595|OTHER|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
58441899|NCT05275595|OTHER|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
58441900|NCT01281540|DRUG|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
58441901|NCT01281540|DRUG|Placebo|one placebo tablet 4 times a day for 8 weeks
58441902|NCT06207526|BEHAVIORAL|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
58441903|NCT05152771|OTHER|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
58441904|NCT05611021|BEHAVIORAL|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
58109170|NCT02464878|DRUG|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
58109171|NCT03057288|DEVICE|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
58109172|NCT05238506|DRUG|Intravenous lidocaine|Intraoperative intravenous lidocaine infusion.
58109173|NCT05238506|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
58109174|NCT03703739|DIETARY_SUPPLEMENT|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
58109175|NCT03703739|DIETARY_SUPPLEMENT|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
58109176|NCT03703739|DIETARY_SUPPLEMENT|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
57739499|NCT01409538|OTHER|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
57739500|NCT03753061|DEVICE|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
58109177|NCT03703739|DIETARY_SUPPLEMENT|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
58109178|NCT03703739|DIETARY_SUPPLEMENT|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
58441905|NCT01740024|BIOLOGICAL|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
58441906|NCT03058055|BEHAVIORAL|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
58441907|NCT03058055|BEHAVIORAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
58441908|NCT03058055|BEHAVIORAL|Reading|Book club that includes weekly one hour meetings and daily reading assignments
58441909|NCT04043650|BEHAVIORAL|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
58441910|NCT02124681|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
58441911|NCT02124681|OTHER|Placebo|Placebo PO for 13±1 weeks
58441912|NCT06060054|DIAGNOSTIC_TEST|Device measurements|Overnight device measurements
58441913|NCT00729625|DEVICE|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
58441914|NCT05579808|PROCEDURE|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
58441915|NCT02360228|DEVICE|tACS (alpha)|
58441916|NCT02360228|DEVICE|tDCS|
58441917|NCT03158441|DIAGNOSTIC_TEST|Breast MRI|comparison of DTI to dynamic MRI
58441918|NCT01073202|DRUG|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
58441919|NCT01073202|DRUG|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
57739501|NCT03753061|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
57955919|NCT00636766|DRUG|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
58441920|NCT02735343|DRUG|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
58441921|NCT02735343|DRUG|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
58441922|NCT00577824|DRUG|exenatide|subcutaneous injection, 5mcg, twice a day
58441923|NCT00577824|DRUG|exenatide|subcutaneous injection, 10mcg, twice a day
58441924|NCT00577824|DRUG|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
58441925|NCT06530368|OTHER|Calisthenic home exercise programs|Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
57739502|NCT04238806|DRUG|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
58441926|NCT02411435|DRUG|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
58441927|NCT02411435|DRUG|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
58441928|NCT00002404|DRUG|Valacyclovir hydrochloride|
58441929|NCT06314607|GENETIC|Prospective Biological Collection|"All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)"
58441930|NCT06314607|GENETIC|Retrospective Biological Collection|Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
58441931|NCT04951583|COMBINATION_PRODUCT|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
58441932|NCT06267391|DEVICE|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
58311932|NCT04272229|DIAGNOSTIC_TEST|Sympathetic Nervous System|The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
58311933|NCT04272229|DIAGNOSTIC_TEST|Concentratio and Attention|Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
58311934|NCT06370793|OTHER|Patient with schizophrenia without intervention|Patients with schizophrenia identified based on exposures of interest to the study
58311935|NCT01253161|DRUG|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
58311936|NCT03630393|OTHER|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
58311937|NCT03630393|OTHER|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
58311938|NCT03651804|PROCEDURE|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
58311939|NCT03651804|DRUG|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
58311940|NCT03651804|DRUG|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
58311941|NCT03651804|DRUG|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
58311942|NCT03651804|BEHAVIORAL|Physical therapy|Physical Therapy.
58311943|NCT03651804|DRUG|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
58311944|NCT06248606|DRUG|Adagrasib|Adagrasib 600mg orally
58311945|NCT06248606|RADIATION|Stereotactic Radiosurgery|Delivered as per standard of care
58311946|NCT01704261|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
58311947|NCT01704261|DRUG|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
58311948|NCT01704261|DRUG|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
58311949|NCT01704261|DRUG|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
58311950|NCT00004817|DRUG|phenytoin|
58311951|NCT00004817|DRUG|valproate sodium|
58311952|NCT01259245|OTHER|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
58311953|NCT01259245|OTHER|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
58441933|NCT06267391|DEVICE|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
58441934|NCT04848272|DRUG|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
58441935|NCT04848272|OTHER|Saline control|Saline control
58441936|NCT03852719|DRUG|Bulevirtide|Administered via SC injections
58311954|NCT05733338|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
58441937|NCT00180765|PROCEDURE|Up to 100ml blood will be taken by venupuncture.|
58441938|NCT03117985|OTHER|no drug|Stopping antiretroviral therapy
58441939|NCT03499834|BIOLOGICAL|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
58311955|NCT05733338|OTHER|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
58311956|NCT04111302|OTHER|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
58311957|NCT04111302|OTHER|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
58311958|NCT04111302|OTHER|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
58441940|NCT03704259|OTHER|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
58441941|NCT04305171|PROCEDURE|non-surgical periodontal treatment|scaling and root planing, home care instruction
58441942|NCT01994044|PROCEDURE|Cervical fusion|
58441943|NCT06403917|OTHER|Evaluation of breast screening|Evaluation of breast screening program at egyptian women health intiaive
58441944|NCT01735981|OTHER|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
57955920|NCT00896922|GENETIC|microarray analysis|
58441945|NCT01735981|OTHER|hand-held video game|hand-held video games
58441946|NCT05411744|DRUG|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
58441947|NCT02209701|DRUG|Porfiromycin|
58441948|NCT01959139|DRUG|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
58441949|NCT01959139|DRUG|Oxaliplatin|85 mg/m\^2, on Day 2, IV over 2 hours
58441950|NCT01959139|DRUG|Leucovorin|400 mg/m\^2, on Day 2, IV over 2 hours
58441951|NCT01959139|DRUG|Irinotecan|180 mg/m\^2, on Day 2, IV over 1.5 hours
58441952|NCT01959139|DRUG|5-fluorouracil|2,400 mg/m\^2, Days 2-4, IV over 46 hours
58441953|NCT00726232|DRUG|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
58441954|NCT03205683|OTHER|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
58441955|NCT03205683|OTHER|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
58441956|NCT03919474|DIAGNOSTIC_TEST|microvascular markers|follow up of microvascular biomarkers during patient follow up
58441957|NCT03190434|DEVICE|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
58441958|NCT00156416|BEHAVIORAL|Mindfulness Meditation|8 weeks of meditation training
58441959|NCT01888224|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
58441960|NCT00282659|DRUG|magnesium L-lactate|
58441961|NCT02338089|DRUG|Oxytocin|Oxytocin, 100 micromolar solution
57739503|NCT02535273|DRUG|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
57955921|NCT00896922|OTHER|immunohistochemistry staining method|
57955922|NCT00896922|OTHER|laboratory biomarker analysis|
57955923|NCT00188643|DRUG|Venlafaxine and Lamotrigine|
57955924|NCT00371293|BEHAVIORAL|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
58441962|NCT02199925|DRUG|Gammaplex 5%|
58441963|NCT05080530|DRUG|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
58441964|NCT01800630|DRUG|Gemcitabine HCl Oral Formulation|
58441965|NCT04617730|DEVICE|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
58441966|NCT04617730|OTHER|Flamigel®|The control arm will be treated according to the standard of care.
58441967|NCT01447732|DRUG|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
58441968|NCT02269930|DRUG|peginterferon beta-1a|Administered as subcutaneous injection
58441969|NCT02269930|DRUG|Rebif|Administered as subcutaneous injection
58441970|NCT00003202|DRUG|cisplatin|
58441971|NCT00003202|DRUG|gemcitabine hydrochloride|
58441972|NCT00003202|RADIATION|radiation therapy|
58441973|NCT01186055|BEHAVIORAL|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
57739504|NCT02535273|DRUG|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
57739505|NCT02535273|DRUG|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
58441974|NCT01554449|PROCEDURE|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
58441975|NCT01554449|PROCEDURE|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
58441976|NCT00823667|OTHER|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
58441977|NCT00823667|OTHER|medical chart review|Occurs at 1 year post study enrollment
58441978|NCT00823667|OTHER|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
58441979|NCT00823667|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
58441980|NCT00823667|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
58441981|NCT00823667|PROCEDURE|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
58441982|NCT04666896|OTHER|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
58441983|NCT04666896|OTHER|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
58441984|NCT04339673|PROCEDURE|masseteric nerve block|regional bloc of masseter
57739506|NCT02535273|DRUG|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
57739507|NCT02535273|DRUG|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
57739508|NCT02535273|DRUG|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
57955925|NCT00371293|DEVICE|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
57955926|NCT06471400|OTHER|interview|patient relatives or legal authorized representatives will be interviewed
57955927|NCT01292642|BEHAVIORAL|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
57955928|NCT01292642|DRUG|Nicotine Replacement Therapy|"1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
58441985|NCT04339673|PROCEDURE|trigger point injection|trigger point injection with local anesthetic
58441986|NCT04339673|PROCEDURE|dry needling|needling with acupuncture needles of trigger points in masseter
58441987|NCT03761238|DEVICE|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
58441988|NCT03761238|OTHER|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
58441989|NCT01776606|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
58441990|NCT01776606|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
58441991|NCT00475709|DEVICE|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
58441992|NCT00342849|DRUG|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
58441993|NCT00342849|DRUG|Placebo|
58441994|NCT05875298|OTHER|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
58441995|NCT05875298|OTHER|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
58441996|NCT05875298|OTHER|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
58441997|NCT00034086|DRUG|Lopinavir/Ritonavir|
58441998|NCT00034086|DRUG|Lamivudine/Zidovudine|
57739509|NCT03371420|DRUG|PU-AD|
57739510|NCT03371420|DEVICE|PET Scan|
58441999|NCT00034086|DRUG|Tenofovir disoproxil fumarate|
58442000|NCT00034086|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
58442001|NCT00034086|DRUG|Lamivudine|
58442002|NCT00034086|DRUG|Stavudine|
58442003|NCT00034086|DRUG|Zidovudine|
58442004|NCT00034086|DRUG|Didanosine|
58442005|NCT00034086|BIOLOGICAL|Lyme Disease Vaccine Recombinant OspA|
58442006|NCT00034086|BIOLOGICAL|Haemophilus B Conjugate Vaccine|
58442007|NCT05342766|DIETARY_SUPPLEMENT|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
58442008|NCT02133885|DRUG|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
58442009|NCT02133885|OTHER|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
58442010|NCT04131075|PROCEDURE|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
58442011|NCT04375111|PROCEDURE|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
58442012|NCT04375111|PROCEDURE|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
58442013|NCT00694018|OTHER|Education and standard care|Educational program for individuals with chronic back pain.
58442014|NCT00694018|BEHAVIORAL|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
58442015|NCT05655949|DRUG|Gemcitabine|Intravenous infusion
58442016|NCT05655949|DRUG|Cisplatin|Intravenous infusion
58442017|NCT05655949|DRUG|Durvalumab|Intravenous infusion
58442018|NCT05655949|RADIATION|Yttrium-90|Injection of radiation microsphere beads
58442019|NCT06281093|OTHER|questionary|Parental questionnaire on pregnancy history and environmental exposure
58442020|NCT06281093|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (1 week) by positioning a dosimeter close to the incubator
57739511|NCT03371420|OTHER|Blood Draws|
57955929|NCT06493955|OTHER|Adapted physical activity for 12 months|6 additional months of adapted physical activity after the 6 first months
57955930|NCT06493955|OTHER|Adapted physical activity for 6 months|standard 6-month prescription for adapted physical activity
58442021|NCT06281093|OTHER|Follow-up of daily infants clinical parameters|Follow-up of daily infants clinical parameters
58442022|NCT06281093|OTHER|recording of cerebral (EEG)|recording of cerebral (EEG)
58442023|NCT06281093|OTHER|autonomic nervous (ECG) activity|autonomic nervous (ECG) activity
58442024|NCT06206018|PROCEDURE|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
58442025|NCT04696679|OTHER|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
58442026|NCT04696679|OTHER|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
57739512|NCT06063135|OTHER|Physical Exercise Intervention|Two strength training session per week and one endurance training session per week
57739513|NCT05238233|DRUG|Tropicamide|One drop will be given to participants
57739514|NCT05238233|DRUG|1% Pilocarpine|One drop will be given to participants
57739515|NCT05238233|DRUG|Proparacaine Hydrochloride|One drop will be given to participants
57739516|NCT05238233|DEVICE|Tono pen AVIA|Participant intraocular pressures measured
57739517|NCT05238233|DEVICE|VG4 Gonio|Participant iridocorneal angle measured
57739518|NCT05238233|DEVICE|Reichert phoropter|Participant screened for hyperopia \>+1 diopter
57739519|NCT01798927|DEVICE|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
57955931|NCT06273332|OTHER|AI-assisted registration|We will use artificial intelligence to register 3d model on intra-oral scan
57739520|NCT06605079|BEHAVIORAL|Complex intervention|"A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed."
57739521|NCT06605079|OTHER|Routine treatment|No complex intervention is established, just routine procedures.
57955932|NCT06273332|OTHER|Point-based registration|We will use five references points or more to perform model registration
57739522|NCT01608074|PROCEDURE|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
58109179|NCT03703739|DIETARY_SUPPLEMENT|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
57739523|NCT01608074|OTHER|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
57739524|NCT00624299|DRUG|Botox|Botox injection (100 ius) per muscle
57739525|NCT00624299|OTHER|Saline|Saline injection
57739526|NCT06496997|DRUG|Methylprednisolone|Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
57739527|NCT06496997|DRUG|Dexamethasone|Dexamethasone at an equivalent dose of 13 mg/day
57739528|NCT06496997|DRUG|Hydrocortisone|Hydrocortisone at an equivalent dose of 350 mg/day
58109180|NCT03703739|DIETARY_SUPPLEMENT|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
58109181|NCT01783769|BEHAVIORAL|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
58109182|NCT06381726|DIAGNOSTIC_TEST|Resting State Functional Magnetic Resonance Imaging (rs-fMRI)|rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop
57739529|NCT03112018|BEHAVIORAL|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
57739530|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
57739531|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
57739532|NCT03112018|BEHAVIORAL|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
57739533|NCT03112018|BEHAVIORAL|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
57739534|NCT05455099|RADIATION|Carotid ultrasound examination 1|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.
57739535|NCT05455099|RADIATION|Carotid ultrasound examination 2|Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
57739536|NCT03089918|DRUG|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
57739537|NCT02389972|DRUG|Dasatinib|
57739538|NCT00988312|BIOLOGICAL|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
58442027|NCT02930915|DEVICE|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
58442028|NCT00261027|DRUG|Exemestane|
58442029|NCT04257526|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
58442030|NCT06071650|BEHAVIORAL|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
58442031|NCT00722956|DRUG|AZD5672|100 mg once daily, 10 days
58442032|NCT00722956|DRUG|atorvastatin|one single dose of 40 mg on day 10
58442033|NCT04289311|BEHAVIORAL|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
58442034|NCT03832751|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
58442035|NCT06051344|DRUG|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
58442036|NCT02652156|DRUG|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
58442037|NCT02652156|DRUG|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
58442038|NCT02652156|DRUG|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
58442039|NCT02738554|OTHER|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
58442040|NCT00064961|BEHAVIORAL|Individualized dietary-control and exercise program|
58442041|NCT00064961|BEHAVIORAL|Weight-management and smoking cessation maintenance|
58442042|NCT00064961|BEHAVIORAL|Smoking Cessation program|
58442043|NCT04124640|OTHER|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
58442044|NCT02814942|DEVICE|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
58442045|NCT03012711|OTHER|Neuromuscular exercise training|
58442046|NCT06064383|DEVICE|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
58442047|NCT06353906|DRUG|Carboplatin/Paclitaxel|Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
58442048|NCT06353906|DRUG|Pembrolizumab|"Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery"
58442049|NCT06353906|PROCEDURE|Partial or total penectomy with inguinal and/or pelvic lymph node dissection|Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
58442050|NCT05532202|BEHAVIORAL|NICU Mom and Baby Net|See arm descriptions.
58442051|NCT05532202|OTHER|NICU Developmental Awareness System|See arm description.
58109183|NCT06381726|BEHAVIORAL|Up-front Motor Rehabilitation|personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop
58109184|NCT06381726|DRUG|Up-front Chemotherapy|Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
58109185|NCT03317145|DEVICE|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
58442052|NCT06020703|BEHAVIORAL|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
58442053|NCT05334407|PROCEDURE|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
57739539|NCT01763944|BEHAVIORAL|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
58109186|NCT03317145|DEVICE|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
58109187|NCT01286337|PROCEDURE|bipolar vessel sealing|
58109188|NCT01286337|PROCEDURE|control|
58109189|NCT06276179|DRUG|Oxycodone|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
57739540|NCT00230828|DRUG|bifeprunox|
58109190|NCT06276179|DRUG|Bupivacaine|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
58109191|NCT01434706|OTHER|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
58442054|NCT05334407|BEHAVIORAL|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
58442055|NCT05334407|PROCEDURE|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
58442056|NCT05334407|BEHAVIORAL|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
58442057|NCT02989753|DIETARY_SUPPLEMENT|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
58442058|NCT02989753|DIETARY_SUPPLEMENT|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
58442059|NCT02989753|DIETARY_SUPPLEMENT|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
58442060|NCT00264537|DRUG|Placebo injections|SC injections
58442061|NCT00264537|DRUG|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
58442062|NCT00264537|DRUG|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
58109192|NCT03671265|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
58109193|NCT03671265|RADIATION|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
58109194|NCT03671265|DRUG|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
58442063|NCT00264537|BIOLOGICAL|Golimumab 50 mg injections|SC injections
58442064|NCT00264537|BIOLOGICAL|Golimumab 100 mg injections|SC injections
58442065|NCT01389869|BIOLOGICAL|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
58442066|NCT01389869|BIOLOGICAL|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
58442067|NCT01389869|BIOLOGICAL|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
58442068|NCT01389869|BIOLOGICAL|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
57739541|NCT06303739|DRUG|psilocybin|25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
57739542|NCT00181948|DRUG|atomoxetine (Strattera)|
57739543|NCT04289818|OTHER|Health Coaching|Health Coaching as face to face with a coach
57739544|NCT01505296|DRUG|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
58109195|NCT01179282|BIOLOGICAL|dust mite extract or placebo|intervention will be to stop study drug or placebo
57739545|NCT01505296|PROCEDURE|Catheter ablation|Complete PVI
57955933|NCT01538654|PROCEDURE|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
57955934|NCT06280482|DRUG|Nicotinamide riboside (NR)|Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
58109196|NCT02530632|DRUG|Propofol|General anesthesia maintained with intravenous propofol infusion
58442069|NCT02701153|PROCEDURE|Conventional Surgery|Undergo surgery
58442070|NCT02701153|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58442071|NCT02701153|OTHER|Laboratory Biomarker Analysis|Correlative studies
58442072|NCT02701153|OTHER|Questionnaire Administration|Ancillary studies
58442073|NCT01771523|PROCEDURE|Thyroidectomy|total thyroidectomy or lobectomy
58442074|NCT01771523|DEVICE|use of drain|drain will be used
58442075|NCT01103427|DEVICE|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
58442076|NCT01103427|DEVICE|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
58442077|NCT01103427|DEVICE|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
58442078|NCT01103427|DEVICE|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
58442079|NCT03840707|BEHAVIORAL|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
57955935|NCT05506189|OTHER|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
57955936|NCT01426139|DEVICE|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
57955937|NCT00896675|OTHER|proteomic profiles|blood samples analysis
57955938|NCT00896675|OTHER|proteomic profiles|blood samples analysis
58109197|NCT02530632|DRUG|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
58311959|NCT04111302|OTHER|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
58311960|NCT02472353|DRUG|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
58311961|NCT02472353|DRUG|Doxorubicin|Standard of care treatment with doxorubicin
58311962|NCT02450643|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
57955939|NCT06006793|DRUG|SY-5933|KRAS p.G12C inhibitor
58311963|NCT02450643|OTHER|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
58311964|NCT00836732|PROCEDURE|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
58109198|NCT02530632|PROCEDURE|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
58109199|NCT05037682|OTHER|Dissemination and Implementation Research|The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
58109200|NCT03163095|DEVICE|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
58109201|NCT03163095|OTHER|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
58109202|NCT04257240|PROCEDURE|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
58109203|NCT04257240|PROCEDURE|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
58109204|NCT04703725|BEHAVIORAL|Psychosocial Care|"1. First Follow-Up: One of the implementation of the module~2. Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~3. Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~4. Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~5. Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~6. Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~7. Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
58109205|NCT00665197|RADIATION|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
58109206|NCT00665197|RADIATION|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
58109207|NCT05244824|OTHER|Adaptation into Turkish, Examining The Reliability and Validity for People with RA|Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
58311965|NCT01687439|DRUG|Endostar|7.5mg/m2, D1-14
57739546|NCT06193252|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
58109208|NCT05926882|DRUG|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
58109209|NCT02351973|DRUG|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
58311966|NCT01687439|DRUG|Vinorelbine|25-30mg/m2, D1,8
57739547|NCT04154956|DRUG|SAR408701|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
57739548|NCT04154956|DRUG|Docetaxel|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
58311967|NCT01687439|DRUG|Cisplatin|25 mg/m2, D1-3
58311968|NCT01687439|RADIATION|Radiotherapy|
58311969|NCT02943122|DEVICE|Ambulatory blood pressure monitor|
58109210|NCT02351973|DRUG|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
58109211|NCT02351973|DRUG|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
58109212|NCT01963819|OTHER|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
58109213|NCT01562470|OTHER|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
58109214|NCT05995145|BEHAVIORAL|Active hamstring flexibility exercises with hip flexion mobilization|8 weeks x 5 times per week for 20 min. In the experimental intervention, the exercise program will be based on participant education, home-based individual exercises, and regular group meetings for check-ups by a physiotherapist according to a precise set schedule.
58109215|NCT01724398|OTHER|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
58109216|NCT01724398|OTHER|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
58442080|NCT02104466|PROCEDURE|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
58442081|NCT00769912|DRUG|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
58442082|NCT00769912|DRUG|Placebo (air)|Placebo administration during the intervention
58442083|NCT02914665|DRUG|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
58109217|NCT01724398|OTHER|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
58109218|NCT01724398|OTHER|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
58109219|NCT03457025|DRUG|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
58109220|NCT03457025|DRUG|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
58109221|NCT03457025|DEVICE|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
58109222|NCT02390219|DRUG|Lumacaftor|
58109223|NCT02390219|DRUG|Ivacaftor|
58109224|NCT00263978|DRUG|Defibrotide|
58109225|NCT03648333|DRUG|Exforge tab. 10/160mg|
58109226|NCT03648333|DRUG|Lodivixx tab. 5/160mg|
58109227|NCT02012179|OTHER|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
58442084|NCT02914665|DRUG|Placebo|Placebo administered intravenously once daily for 7 consecutive days
58442085|NCT00370916|BEHAVIORAL|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
58442086|NCT00370916|BEHAVIORAL|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
57739549|NCT03902587|DEVICE|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
57739550|NCT01857531|DRUG|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
58109228|NCT05354531|PROCEDURE|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
58109229|NCT03306602|DEVICE|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
58442087|NCT00838240|DRUG|clofarabine|Given IV
58442088|NCT00838240|DRUG|cytarabine|Given IV
58442089|NCT00838240|DRUG|idarubicin|Given IV
58442090|NCT03565380|OTHER|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
58442091|NCT03565380|OTHER|Usual post-operative care|No intervention will be provided
57739551|NCT01857531|DRUG|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
57739552|NCT02635880|DEVICE|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
58109230|NCT03306602|DEVICE|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
58109231|NCT01864720|BEHAVIORAL|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
58311970|NCT06472921|BEHAVIORAL|Butylphthalide treatment initiation time|Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).
58311971|NCT02146183|DIETARY_SUPPLEMENT|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
58311972|NCT02146183|DIETARY_SUPPLEMENT|Placebo Corn Starch|500 mg/day
58442092|NCT03565380|OTHER|Untreated asymptomatic controls|No intervention will be provided
58442093|NCT05107570|OTHER|Cold exposure|Cold air exposure (\~ 9°C, maximum 1 hour duration)
58442094|NCT04994548|PROCEDURE|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
58442095|NCT05904795|OTHER|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
58442096|NCT05904795|OTHER|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
58442097|NCT03769038|DEVICE|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
58109232|NCT01864720|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
58109233|NCT02094937|DRUG|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
58109234|NCT02094937|DRUG|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
58109235|NCT02094937|DRUG|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
58109236|NCT02094937|DRUG|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
58109237|NCT02094937|DRUG|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
58109238|NCT02094937|DRUG|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
57739553|NCT05812157|DIETARY_SUPPLEMENT|Daily dietary supplementation with Fibruline|Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
58442098|NCT03710642|DRUG|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
58442099|NCT03710642|DRUG|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
58442100|NCT01510158|DRUG|Lesinurad|Tablets, 200 mg once daily (qd)
58442101|NCT01510158|DRUG|Lesinurad|Tablets, 400 mg qd
58442102|NCT01510158|DRUG|Placebo|Tablets, Placebo qd
57739554|NCT05812157|DRUG|Anti-IL-17 therapy|Patients in both groups will be on anti-IL-17 therapy
58109239|NCT05692752|OTHER|No intervention|Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
58109240|NCT05257603|BEHAVIORAL|RPCW|Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
58109241|NCT05257603|BEHAVIORAL|HEC|Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
58109242|NCT02971514|BEHAVIORAL|Flossing before Brushing|
58109243|NCT02971514|BEHAVIORAL|Brushing before Flossing|
58311973|NCT03764605|DRUG|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
58442103|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
58442104|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
58442105|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
58442106|NCT05499533|PROCEDURE|implant site preparation|a hole were created in the edentulous ridge area before implant placement
58442107|NCT05938998|BEHAVIORAL|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
58442108|NCT05456971|DEVICE|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
58442109|NCT05456971|DEVICE|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
58442110|NCT00043732|DRUG|SCIO-469|
58442111|NCT03265340|DEVICE|dTMS|
58442112|NCT02032498|DRUG|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
58442113|NCT05606276|OTHER|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
58109244|NCT02998333|PROCEDURE|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
58109245|NCT05385029|DRUG|Thyroxine|treatment for hypothyroidism or hyperthyroidism
58109246|NCT05187403|DRUG|Laquinimod|Eye-drops
58109247|NCT05187403|DRUG|Placebo|Eye-drops
58109248|NCT05164848|DRUG|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
58109249|NCT05164848|DRUG|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
58109250|NCT00744887|DRUG|Darunavir|
58109251|NCT05881265|DRUG|Chidamide+venetoclax|Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
58109252|NCT00211783|PROCEDURE|fMRI|there is no intervention
58109253|NCT06141382|OTHER|English Langugae-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
58109254|NCT06141382|OTHER|English Language-Narrative intervention|Narrative intervention with the help of only pictures in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administred thrice a week in 45-minute long session for 6 weeks.
58109255|NCT06141382|OTHER|Urdu Langusge-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
58109256|NCT06141382|OTHER|Urdu Language-Narrative intervention|Narrative intervention with the help of only pictures in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
58109257|NCT06141382|OTHER|Bilingual-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
58109258|NCT06141382|OTHER|Bilingual-Narrative intervention|Narrative intervention with the help of only pictures in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
58109259|NCT05826249|DRUG|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
58109260|NCT03295539|DEVICE|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
58109261|NCT03786510|BEHAVIORAL|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
58109262|NCT03786510|BEHAVIORAL|Intensive + Maintenance program|"Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
58109263|NCT03786510|BEHAVIORAL|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
58311974|NCT03764605|DRUG|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
58442114|NCT05606276|OTHER|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
58109264|NCT06478446|OTHER|observation|HD patients were observed and evaluated with three scales.
58109265|NCT00065897|PROCEDURE|Amniocentesis|
58109266|NCT00065897|PROCEDURE|Transabdominal chorionic villus sampling (TA CVS)|
58311975|NCT04105608|DIETARY_SUPPLEMENT|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
58311976|NCT04105608|DIETARY_SUPPLEMENT|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
58311977|NCT01276834|DRUG|everolimus|comparison of everolimus-based and CNI-based immunosuppression
58311978|NCT01141608|OTHER|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
58442115|NCT03590353|DEVICE|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
58442116|NCT03590353|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
58442117|NCT00894868|DRUG|vildagliptin|
58442118|NCT00894868|DRUG|placebo of vildagliptin|
58442119|NCT01922908|BIOLOGICAL|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
58442120|NCT01922908|BIOLOGICAL|Placebo Comparator|Normal saline
58442121|NCT01672424|OTHER|Ice Chips|11 ounces of ice chips given to the laboring parturient
58442122|NCT01672424|OTHER|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
58442123|NCT04096287|BIOLOGICAL|PNT001|PNT001 diluted in 5% dextrose
58442124|NCT04096287|DRUG|Placebo|5% dextrose
58442125|NCT01714765|DRUG|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
58442126|NCT01714765|DRUG|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
58442127|NCT06027099|DRUG|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
58442128|NCT06027099|BEHAVIORAL|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
58442129|NCT06027099|DRUG|Placebo|1 tablet three times a day for 5 weeks after surgery
58442130|NCT06027099|BEHAVIORAL|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
58442131|NCT03842059|DEVICE|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
58442132|NCT03842059|DEVICE|Standard colonoscopy|Standard colonoscopy
58442133|NCT03019718|OTHER|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
58442134|NCT04295239|PROCEDURE|MRI|Pre and Post operative MRI
58442135|NCT03574636|DEVICE|OCT guidance|OCT guide stent implantation
58442136|NCT03574636|DEVICE|IVUS guidance|IVUS guide stent implantation
58442137|NCT03574636|DEVICE|QCA|QCA guide stent implantation
58442138|NCT00962325|BEHAVIORAL|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
58442139|NCT01989247|BEHAVIORAL|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
58442140|NCT05993910|OTHER|Hyperthermie Register|"* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie"
58442141|NCT06334848|PROCEDURE|transobturator tape|Women with stress urinary incontinence are treated by transobturator tape versus mini sling
58442142|NCT06727292|DIETARY_SUPPLEMENT|Food supplement|Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).
57739555|NCT02998281|DEVICE|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
58311979|NCT01141608|OTHER|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
58311980|NCT00487188|DRUG|Enfuvirtide|90 mg subcutaneous injection twice a day
58311981|NCT00487188|DRUG|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
58311982|NCT05368649|OTHER|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
58311983|NCT06443008|DEVICE|Observation Group|On the basis of myoelectric biofeedback treatment in the control group, the control group was trained alternately in each muscle group (triangle muscle, triceps brachii muscle group and forearm extensor muscle group). For example,After disinfection of the triangular, triceps and extensor muscles of the patient, the feedback electrode was attached to the area. The stimulation frequency was set at 50 Hz and the stimulation pulse width was set at 200 μs.During treatment, the patient is instructed to listen carefully to the device's password, drive the affected limb according to the specific password, and then perform tension and relaxation training.For each muscle group, the training time of each muscle group is about 0.5 h, 1 / d.In the later stage of treatment, the training intensity can be increased appropriately, so that the patient can carry out weight lifting during the feedback treatment, and listen to the password issued by the device to carry out muscle strength exercise.
58442143|NCT06727292|DIETARY_SUPPLEMENT|Placebo|Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
58442144|NCT05258149|DEVICE|JJVC Investigational Multifocal Contact Lenses|TEST
58442145|NCT05258149|DEVICE|Dailies Total 1® Multifocal Contact Lenses|CONTROL
58442146|NCT01295645|DRUG|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
58442147|NCT01295645|OTHER|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
58442148|NCT03770221|BEHAVIORAL|CATCH|Brief, intensive case management service.
58442149|NCT03770221|OTHER|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
58442150|NCT00536471|DRUG|Duloxetine hydrochloride|
57739556|NCT06395662|OTHER|Observational|Search for biomarkers
57739557|NCT04989959|DRUG|[18F]PT2385|\[18F\]PT2385 infusion
58442151|NCT00536471|DRUG|Placebo|
58442152|NCT05192460|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
57739558|NCT04989959|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after \[18F\]PT2385 infusion
57739559|NCT04989959|PROCEDURE|Biopsy|CT-guided tumor biopsy
57739560|NCT00696254|BEHAVIORAL|Nerve excitability measurement|
57739561|NCT06358573|DRUG|INT230-6|"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."
57739562|NCT06358573|OTHER|neoadjuvant immuno-chemotherapy|Standard of care
57739563|NCT06541262|DRUG|Silmitasertib|Capsules
57739564|NCT06541262|DRUG|Irinotecan|IV
57739565|NCT06541262|DRUG|Temozolomide|Oral
57739566|NCT06541262|DRUG|Vincristine|IV
57739567|NCT00098969|DRUG|resveratrol|
57739568|NCT05942001|DRUG|HRS-5041|HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
57739569|NCT05596045|DRUG|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
58442153|NCT04748614|OTHER|Cost|ICU cost
58442154|NCT06244667|PROCEDURE|facet median block with prilocain|facet median block with prilocain
58442155|NCT06244667|PROCEDURE|facet median block with lidocaine|facet median block with lidocaine
58442156|NCT03047421|DIAGNOSTIC_TEST|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
58442157|NCT04182243|OTHER|Evaluation of job satisfaction in emergency health care providers by questionnaire|
58442158|NCT03403439|DRUG|BI 1015550|Reference and Test Treatment
58442159|NCT03403439|DRUG|itraconazole|Test treatment
58442160|NCT05690048|DRUG|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
58442161|NCT05690048|DRUG|Vancomycin Oral Capsule|Vancomycin orally (125 mg 4xd, day -3 to 0).
58442162|NCT05690048|DRUG|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
58442163|NCT05690048|DRUG|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (125 mg 4xd, day -3 to 0).
58442164|NCT05690048|DRUG|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21.
58442165|NCT04775641|OTHER|questionnaire|questionnaire
58442166|NCT06010784|BEHAVIORAL|Family support|"* Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~* Weeks 1-4 (4 weeks):~  i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~* Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~  i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
58442167|NCT06010784|BEHAVIORAL|BGCAA's after-school program with CATCH curriculum|"1. The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~2. In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~3. Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
58442168|NCT05921565|BEHAVIORAL|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
58442169|NCT01103388|DRUG|Rituximab|375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
58442170|NCT00213265|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
58442171|NCT00213265|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
58442172|NCT02223715|OTHER|CDI Pts|
57739570|NCT05596045|DRUG|Placebo|Participants will be randomized to receive placebo
57739571|NCT02363556|PROCEDURE|Misoprostol administered vaginally|
57739572|NCT02363556|PROCEDURE|Misoprostol administered buccally|
58442173|NCT03000855|PROCEDURE|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
58442174|NCT03000855|PROCEDURE|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
58442175|NCT00246701|DRUG|Simvastatin|Simvastatin
58442176|NCT00246701|DRUG|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
58442177|NCT02246426|OTHER|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
58442178|NCT02246426|OTHER|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
58442179|NCT00006116|DRUG|cisplatin|
58442180|NCT00006116|DRUG|gemcitabine hydrochloride|
58442181|NCT00087334|DRUG|capecitabine|
58442182|NCT00087334|DRUG|gefitinib|
58442183|NCT00087334|DRUG|oxaliplatin|
57739573|NCT02363556|PROCEDURE|Misoprostol administered vaginally with Dilapan|
57739574|NCT02363556|PROCEDURE|Misoprostol administered buccally with Dilapan|
57739575|NCT04240366|PROCEDURE|Control intervention|patients treated with balloon-based ablation of AF by PVI
57739576|NCT04240366|PROCEDURE|Experimental intervention|patients treated with balloon-based ablation of AF by PVI
57739577|NCT06351566|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
58109267|NCT04303052|DEVICE|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
58109268|NCT04303052|DEVICE|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
58109269|NCT00936884|DRUG|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
58109270|NCT00936884|DRUG|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
58109271|NCT05827900|BEHAVIORAL|Metacognitive Training|Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
58109272|NCT00856778|DEVICE|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
58109273|NCT01326702|DRUG|Bendamustine Hydrochloride|Given IV
58109274|NCT01326702|OTHER|Pharmacological Study|Correlative studies
58109275|NCT01326702|BIOLOGICAL|Rituximab|Given IV
58109276|NCT01326702|DRUG|Veliparib|Given PO
58109277|NCT02092961|DRUG|Fostamatinib|Fostamatinib 100mg twice daily.
58109278|NCT02092961|DRUG|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
58109279|NCT02092961|DRUG|Placebo of Fostamatinib|Placebo bid for 6 weeks.
58109280|NCT02092961|DRUG|Placebo of Adalimumab|Placebo injection once every two weeks.
58109281|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
58109282|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
58109283|NCT00005091|DRUG|exatecan mesylate|
58109284|NCT01447329|OTHER|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
58109285|NCT01447329|DRUG|Standard Treatment|
58109286|NCT00773526|DRUG|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
58109287|NCT01252238|DRUG|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
58109288|NCT01252238|DRUG|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
58442184|NCT05504044|OTHER|Glucose control|50 g glucose dissolved in 250 mL water
58442185|NCT05504044|OTHER|Bread control|91.4 g white bread
58442186|NCT05504044|OTHER|Almond paste|88.7 g white bread and 15 g almond paste
58442187|NCT05504044|OTHER|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
58442188|NCT05504044|OTHER|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
58109289|NCT01252238|DRUG|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
58109290|NCT01361607|DRUG|Nabiximols|
58109291|NCT01361607|DRUG|Placebo (GA-0034)|
58442189|NCT04054076|DEVICE|Prefabricated insoles|The participants received prefabricated insoles
58442190|NCT04054076|DEVICE|Soft custom-made insoles|The participants received soft custom-made insoles
58442191|NCT04054076|DEVICE|Hard custom-made insoles|The participants received hard custom-made insoles
58442192|NCT00590863|DRUG|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
58442193|NCT00590863|DRUG|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
58442194|NCT00590863|DRUG|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
58442195|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
58442196|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
58109292|NCT02305368|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
58109293|NCT03501342|OTHER|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
58109294|NCT03501342|OTHER|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
58109295|NCT06525441|OTHER|Plant-based Diet|Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
58442197|NCT00311883|DRUG|hydroxychloroquine|
58442198|NCT03018639|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
58442199|NCT03357016|OTHER|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
58442200|NCT05610527|OTHER|Proposed study design and randomization scenarios|Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
58442201|NCT05610527|OTHER|Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments|We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
57739578|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
57739579|NCT06351566|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
58109296|NCT06525441|OTHER|Animal-based Diet|Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
58109297|NCT01325532|DEVICE|Active CES|CES current
58109298|NCT01325532|DEVICE|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
57739580|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo, 10g per day.
57955940|NCT04015895|OTHER|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
58109299|NCT05775458|DIAGNOSTIC_TEST|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
58109300|NCT03210259|DRUG|Humira®|Duration - 58 weeks
58109301|NCT03210259|DRUG|BI 695501|Duration - 58 weeks
58109302|NCT00770315|BIOLOGICAL|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
58109303|NCT00770315|BIOLOGICAL|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
58109304|NCT04846218|DRUG|hCG|
58442202|NCT05610527|OTHER|Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing|In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
58442203|NCT01048658|DRUG|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
58442204|NCT01048658|OTHER|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
58442205|NCT06040944|DRUG|antipsychotic drugs inducing hyperprolactinemia|not exposed
57739581|NCT04339036|DRUG|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
57739582|NCT04339036|DRUG|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
57739583|NCT04339036|COMBINATION_PRODUCT|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
57739584|NCT00889538|DRUG|placebo|50 mL of 1/2 normal saline IV
57739585|NCT00889538|DRUG|glutathione|glutathione 600 mg IV
57739586|NCT00889538|DRUG|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
57955941|NCT05343286|PROCEDURE|blood sample|blood sample before and after 12 weeks of physical activity
57955942|NCT05343286|OTHER|physical assessement|"physical assessement before and after 12 weeks of physical activity~* Standardized geriatric assessment (physician visit)~* ICOPE Monitor Assessment~* Sit-to-stand Test~* Quantified Gait Analysis (QAM)~* Bone densitometer measurement of body composition"
57955943|NCT05343286|BEHAVIORAL|psychometric assessment|"Psychometric questionnaires~* Cognitive tests (MMSE)~* The long questionnaire of personality traits: Big Five Inventory~* Perceived health and subjective age~* Age group identification~* Attitudes towards aging: French version of the Attitudes Toward Own Aging scale~* Physical self-perception: French version of the Physical Self-Perception Profile~* MOTIVATION SCALE FOR PA FOR HEALTH PURPOSES: Motivation Scale for Physical Activity in a Health Context~* Aging Stereotypes and Exercise Scale"
57955944|NCT00015223|DRUG|Methylphenidate|
57955945|NCT02222207|DRUG|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
57955946|NCT02222207|PROCEDURE|Sham IVT|Sham injections
57955947|NCT02222207|DRUG|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
57955948|NCT02222207|DRUG|Placebo|Placebo eye drops
57955949|NCT06247943|PROCEDURE|Lung Protective Ventilation Strategy|After 10 minutes of pneumoperitoneum, VT 7 ml/kg was used, PEEP 6 cmH2O, FiO2 was 40%, and plateau pressure \<30 cmH2O was maintained throughout.
57955950|NCT06247943|PROCEDURE|regular ventilation|VT 9ml /kg without PEEP, FiO2 of 60%
57955951|NCT01806779|DRUG|Chantix|
57955952|NCT01806779|DRUG|Zyban|
58109305|NCT04846218|DRUG|Progesterone|
58109306|NCT04846218|DRUG|Triptorelin|
58109307|NCT03938298|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
58109308|NCT03938298|OTHER|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
57739587|NCT04211038|DEVICE|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
57739588|NCT03756103|DRUG|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
58109309|NCT04316598|DRUG|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
58109310|NCT04316598|DRUG|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
58442206|NCT06458985|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
58442207|NCT01407757|GENETIC|DNA analysis|
58442208|NCT01407757|GENETIC|gene expression analysis|
58442209|NCT01407757|OTHER|laboratory biomarker analysis|
58442210|NCT01407757|OTHER|pharmacogenomic studies|
58442211|NCT01756404|DRUG|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
58442212|NCT01756404|DRUG|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
58442213|NCT00917618|OTHER|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
58442214|NCT00917618|OTHER|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
58442215|NCT03648515|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
57739589|NCT03756103|DRUG|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
57739590|NCT03756103|DRUG|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
57739591|NCT03756103|DRUG|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
57739592|NCT05077787|OTHER|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
57739593|NCT05077787|OTHER|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
57739594|NCT04699266|DEVICE|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
58442216|NCT03648515|DIAGNOSTIC_TEST|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
58442217|NCT03648515|DIAGNOSTIC_TEST|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
58442218|NCT06225687|OTHER|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
58442219|NCT06552637|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
58442220|NCT05916469|DRUG|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
58442221|NCT05916469|DRUG|Norethindrone Acetate|norethindrone acetate 5 mg daily
57739595|NCT05717933|DIAGNOSTIC_TEST|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
57739596|NCT03203369|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
57739597|NCT03929029|DRUG|Nivolumab (480 mg infusion)|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
57739598|NCT03929029|BIOLOGICAL|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
57739599|NCT03929029|DRUG|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
58442222|NCT05751369|BEHAVIORAL|Education plus Support|Brief behavioral support for using TECW Tracker
57739600|NCT00867217|DIETARY_SUPPLEMENT|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
57739601|NCT00867217|DIETARY_SUPPLEMENT|Placebo|Placebo comparator
57739602|NCT00867217|DIETARY_SUPPLEMENT|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
57739603|NCT00867217|DRUG|Letrozole 2.5mg|All subjects received letrozole as standard of care.
57739604|NCT06485817|DRUG|Oxycodone|"3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
57739605|NCT06485817|DRUG|Placebo|"Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
57739606|NCT06485817|BEHAVIORAL|Stress State Induction|"ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting."
58442223|NCT00078247|DRUG|Abacavir|300 mg tablet taken orally twice daily
58442224|NCT00078247|DRUG|Lamivudine|300 mg tablet taken orally daily
58442225|NCT00078247|DRUG|Zidovudine|300 mg tablet taken orally twice daily
58442226|NCT00078247|DRUG|Tuberculosis treatment|Tuberculosis treatment
58442227|NCT05498519|DRUG|SY-4798|FGFR4 selective inhibitor
58442228|NCT05096689|OTHER|MRI|Magnetic Resonance Imaging
58442229|NCT01909089|DRUG|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
58442230|NCT00719680|BIOLOGICAL|IgPro20|
58442231|NCT05527821|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
58442232|NCT05527821|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
58442233|NCT05527821|RADIATION|Short course radiotherapy|5Gy\*5F short course radiotherapy will be delivered
58442234|NCT03470207|PROCEDURE|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
58442235|NCT01429701|DRUG|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
58442236|NCT01429701|DRUG|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
57739607|NCT06485817|BEHAVIORAL|Control State Induction|Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
57739608|NCT03359265|DEVICE|underpants|
57739609|NCT01290432|DIETARY_SUPPLEMENT|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
57739610|NCT03681626|PROCEDURE|no tracheal suction|No tracheal suctioning during extubation
58442237|NCT04886778|DIETARY_SUPPLEMENT|Low-carbohydrate diet|Participants will be instructed to maintain a daily dietary energy intake of less than 1600 kcal.Based on the low-carbohydrate diet model, the proportion of daily intake of carbohydrate was about 30%, and this ratio was up to 30%, 40% of protein and fat respectively.Participants should choose unprocessed whole grains, potatoes, vegetables, meat, fish, eggs, soy products, sugar-free dairy products, designated varieties of low-GI fruits and nuts, etc. as breakfast, and avoid processed meats and high-fat red meat and poultry skins. Standard nutritious meal instead of daily lunch and dinner meals, that is to say, participants should take one nutritional bar for lunch and dinner (310 kcal totally, provided by Guangzhou Nanda Fett Nutrition and Health Consulting Co., Ltd.), and avoid starchy foods. Other food varieties are required to be the same as breakfast. Plant oil is the main cooking oil, and participants will be instructed to drink 2L water every day.
57739611|NCT03681626|PROCEDURE|tracheal suction|tracheal suctioning during extubation
57739612|NCT00194558|BEHAVIORAL|Internet co-management module|
58442238|NCT04886778|DIETARY_SUPPLEMENT|Probiotic compound preparations|The probiotic compound preparation，named Junyi Yili® Probiotics，is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus and Bifidobacterium lactis, and resistant dextrin contained water-soluble dietary fiber. The subjects will take this probiotic compound preparations with purified water after three meals every day, 1 sachet each time.
58442239|NCT04886778|DIETARY_SUPPLEMENT|Placebo|Placebo is made of resistant dextrin which contained water-soluble dietary fiber. The subjects were taken this placebo with purified water after three meals every day, 1 sachet each time.
57739613|NCT03744273|PROCEDURE|breast capsule biopsy|
57739614|NCT04243317|BEHAVIORAL|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
57739615|NCT04243317|BEHAVIORAL|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
57739616|NCT02278094|DEVICE|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
57739617|NCT02278094|DEVICE|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
57739618|NCT02278094|PROCEDURE|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
58109311|NCT03406130|PROCEDURE|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
57739619|NCT02278094|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
58442240|NCT01356459|DEVICE|Mepilex Border Dressing|Soft silicone self adherent dressing
58442241|NCT05741398|DEVICE|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
58442242|NCT01267305|DRUG|Fondaparinux|2.5mg IH qd(8AM) after operation
57739620|NCT04649398|DRUG|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
57739621|NCT00802074|DRUG|Raltegravir|400mg BID
57739622|NCT00802074|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
57739623|NCT00802074|DRUG|Ritonavir|100 mg BID or QD
57739624|NCT01767740|DEVICE|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
57739625|NCT01767740|DEVICE|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
57739626|NCT04538729|BEHAVIORAL|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
58442243|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
58442244|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
58442245|NCT02121249|DEVICE|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
58442246|NCT02121249|PROCEDURE|free hand technique|"No specific device is necessary in the free hand technique"
57739627|NCT06535048|DRUG|Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons|"Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks."
57739628|NCT06580691|PROCEDURE|Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads|"Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision."
57739629|NCT01356875|DRUG|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
58442247|NCT03579277|PROCEDURE|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
57739630|NCT01356875|DRUG|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
58442248|NCT03579277|PROCEDURE|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
58442249|NCT05590507|BEHAVIORAL|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
58442250|NCT05267119|PROCEDURE|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
58442251|NCT02262702|DRUG|Paracetamol 665 mg|Paracetamol 665 mg tablet
58442252|NCT02262702|DRUG|Paracetamol 500 mg|Paracetamol 500 mg tablet
58442253|NCT06473792|OTHER|Probiotic Toothpaste|"Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily."
58442254|NCT02764658|DEVICE|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
58442255|NCT02764658|OTHER|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
58442256|NCT02764658|OTHER|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
58442257|NCT02748395|DRUG|Triamcinolone|
57739631|NCT02811861|DRUG|Lenvatinib|
57739632|NCT02811861|DRUG|Everolimus|
57739633|NCT02811861|DRUG|Pembrolizumab|
57739634|NCT02811861|DRUG|Sunitinib|
57739635|NCT06273423|OTHER|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
58442258|NCT02748395|OTHER|Placebo|
58442259|NCT02748395|DRUG|Lidocaine|
58442260|NCT00317330|DRUG|Isoniazid|
58442261|NCT00317330|DRUG|Pyrazinamide|
58442262|NCT00317330|DRUG|Rifampin|
58442263|NCT03785158|OTHER|Liquid Melatonin|Melatonin is a natural supplement.
58442264|NCT03785158|OTHER|Placebo|Similar looking/tasting placebo syrup
58442265|NCT01294969|DRUG|AL-4943A|Once daily topical ocular allergy medication used for 7 days
58442266|NCT00213499|PROCEDURE|non invasive ventilation|
58442267|NCT02253953|DRUG|BILR 355 BS, D1|
58442268|NCT02253953|DRUG|BILR 355 BS, D2|
58442269|NCT02253953|DRUG|BILR 355 BS, D3|
58442270|NCT02253953|DRUG|BILR 355 BS, D4|
58442271|NCT02253953|DRUG|BILR 355 BS, D5|
58442272|NCT02253953|DRUG|BILR 355 BS, D6|
58442273|NCT02253953|DRUG|BILR 355 BS, D7|
57955953|NCT01806779|DRUG|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
58109312|NCT03406130|PROCEDURE|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
58442274|NCT02253953|DRUG|BILR 355 BS, D8|
58442275|NCT02253953|DRUG|BILR 355 BS, D10|
58442276|NCT02253953|DRUG|Placebo|
58442277|NCT02253953|OTHER|high-fat breakfast|
58442278|NCT02253953|DRUG|Ritonavir|
58442279|NCT00668811|DRUG|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
58442280|NCT01053988|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
58442281|NCT01053988|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
58442282|NCT01053988|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
58442283|NCT01053988|DRUG|Placebo|Placebo
58442284|NCT02056093|DEVICE|PSV mode|Application of PSV in all patients
58442285|NCT02056093|DEVICE|PAV mode|Application of PAV mode in all patients
58442286|NCT02056093|DEVICE|NAVA|
58442287|NCT04750304|BEHAVIORAL|Application ARTHe|Patient will use ARTHe Application for 3 months
58442288|NCT00952081|DRUG|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
58442289|NCT05594407|DRUG|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
58442290|NCT05594407|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
58442291|NCT01794260|DRUG|Cream from Zingiber cassumunar Roxb. extract|
58442292|NCT01794260|DRUG|Placebo cream|
58442293|NCT03332836|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
58442294|NCT01636986|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
58442295|NCT01636986|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
58442296|NCT04561440|DIAGNOSTIC_TEST|molecular karyotyping|performed by NGS or CMA chip
58442297|NCT03776201|OTHER|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
58442298|NCT04289792|DRUG|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
58442299|NCT04289792|RADIATION|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
58442300|NCT01405612|DRUG|Midazolam|Single oral administration on Day 1 or Day 5
58442301|NCT01405612|DRUG|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
58442302|NCT06725160|BEHAVIORAL|Parent Coaching|Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
58442303|NCT06725160|BEHAVIORAL|Active Control|General parent support based on child directed interactions skills from standard PCIT.
58442304|NCT06671106|OTHER|toothbrushing|manual toothbrush (meridol)
58442305|NCT06671106|OTHER|flossing|dental floss (meridol)
58442306|NCT06671106|DEVICE|Toothpaste Product|amine and zinc lactate - containing toothpaste (meridol Gum Protection)
58442307|NCT06671106|DEVICE|Mouthrinse|amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
58442308|NCT05026216|DRUG|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
58109313|NCT05450666|OTHER|mobility exercises|Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
58442309|NCT02128724|DRUG|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
58109314|NCT05569733|DIAGNOSTIC_TEST|simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)|All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).
57739636|NCT05170165|OTHER|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
58442310|NCT06080685|BEHAVIORAL|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
58442311|NCT04633928|BIOLOGICAL|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
58442312|NCT04579159|DEVICE|Preventicus heartbeat app in combination with wearables|CE certified devices
58442313|NCT00721240|DRUG|montelukast|5mg montelukast once daily for 12 weeks
58442314|NCT01999400|DRUG|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
58442315|NCT01999400|DRUG|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
58442316|NCT01999400|DRUG|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
58109315|NCT01805310|OTHER|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
57739637|NCT04079621|DRUG|primaquine|Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
57739638|NCT03112382|DRUG|zinc supplement plus vitamin A and E|
57739639|NCT03112382|DRUG|vitamin A and E|
57739640|NCT06115733|DRUG|Fruquintinib、Capecitabine Tablets|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
57739641|NCT04897074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
57739642|NCT01456026|DIETARY_SUPPLEMENT|Glycated beta-lactoglobulins.|oral, 20 g, single administration
58442317|NCT01999400|DRUG|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
57739643|NCT01456026|DIETARY_SUPPLEMENT|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
57739644|NCT02057900|BIOLOGICAL|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
58442318|NCT03505203|BEHAVIORAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
58442319|NCT03505203|BEHAVIORAL|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
58442320|NCT02960464|DEVICE|Transcranial direct current stimulation|
58442321|NCT02960464|DEVICE|Sham Transcranial direct current stimulation|
58442322|NCT03761901|DRUG|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
58442323|NCT03761901|DRUG|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
58442324|NCT03761901|DRUG|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
58442325|NCT06112691|DEVICE|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
58442326|NCT04247737|OTHER|gluten free diet|Participants keep a gluten free diet for six weeks
58442327|NCT02088489|DEVICE|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
58442328|NCT02088489|DEVICE|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
58442329|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
57739645|NCT05063838|OTHER|Pharmacogenomic optimisation of anaesthetic medications|Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
57739646|NCT05695053|DEVICE|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
57739647|NCT05695053|OTHER|Placebo|Placebo
57739648|NCT05653466|BEHAVIORAL|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
57739649|NCT05653466|BEHAVIORAL|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
57739650|NCT05653466|BEHAVIORAL|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
57739651|NCT05855980|PROCEDURE|Wound closure|Wound is closed or left open to heal secondarily after amputation.
57739652|NCT05726929|OTHER|Osteopathic treatment|Osteopathic Manual Treatment
57739653|NCT05726929|OTHER|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
57739654|NCT03640650|COMBINATION_PRODUCT|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
57739655|NCT03640650|DRUG|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
57739656|NCT02115958|BIOLOGICAL|cancer stem cell vaccine|
57739657|NCT05110885|OTHER|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
57739658|NCT03768167|PROCEDURE|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
58109316|NCT01805310|OTHER|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
58109317|NCT06147219|PROCEDURE|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
58109318|NCT01203319|BIOLOGICAL|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
58442330|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
58442331|NCT03914755|DRUG|Tucatinib|Administered via oral tablet
57955954|NCT02505880|OTHER|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
58442332|NCT00971139|BEHAVIORAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
57955955|NCT02505880|DRUG|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
57739659|NCT05192525|DEVICE|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
58109319|NCT01203319|BIOLOGICAL|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
58109320|NCT01203319|BIOLOGICAL|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
58109321|NCT02125578|DRUG|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
58109322|NCT02125578|DRUG|Placebo|Each participant will receive placebo every other week or every 4 weeks.
58109323|NCT00782236|DEVICE|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
58109324|NCT00874900|OTHER|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
58109325|NCT00874900|OTHER|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
58109326|NCT00874900|OTHER|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
58442333|NCT04195217|BEHAVIORAL|Art therapy|"When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist."
58442334|NCT04327024|DRUG|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
58442335|NCT04327024|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
58442336|NCT04327024|DRUG|Placebo for verinurad|Matching Capsule
58442337|NCT04327024|DRUG|Placebo for allopurinol|Matching tablet
58442338|NCT01939847|OTHER|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
58442339|NCT00377208|BEHAVIORAL|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
58442340|NCT02581215|DRUG|mFOLFIRINOX|"mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
58442341|NCT02581215|DRUG|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
58109327|NCT01710852|DRUG|ISIS CRP Rx|
58109328|NCT01710852|DRUG|Placebo|
58442342|NCT02581215|OTHER|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
58442343|NCT03081026|DIAGNOSTIC_TEST|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
58442344|NCT03683017|DEVICE|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
58109329|NCT02856867|DRUG|Nintedanib|
57739660|NCT03506958|PROCEDURE|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
57955956|NCT04774835|DIAGNOSTIC_TEST|HIVST|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
58109330|NCT02856867|DRUG|Fluorouracil|
58109331|NCT02856867|DRUG|Leucovorin|
58109332|NCT02856867|DRUG|Oxaliplatin|
58109333|NCT02856867|DRUG|Placebo|
58109334|NCT00872391|RADIATION|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
58109335|NCT02588131|DRUG|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
58109336|NCT04242186|OTHER|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
58109337|NCT00601328|DRUG|Calcitriol|
58109338|NCT04340700|DRUG|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
58442345|NCT03683017|DEVICE|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
58442346|NCT03683017|DEVICE|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
58442347|NCT03683017|DEVICE|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
58442348|NCT02931552|BEHAVIORAL|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
58442349|NCT06140966|DRUG|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
58442350|NCT06140966|DRUG|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
58442351|NCT06140966|DRUG|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
58442352|NCT06140966|DRUG|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
58442353|NCT06140966|DRUG|Cisplatin|Given by vein: days 1-4 of each Induction cycle
58442354|NCT06140966|DRUG|epirubicin|Given by vein: days 1-4 of each Induction cycle
58442355|NCT06140966|DRUG|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
58442356|NCT06140966|DRUG|Etoposide|Given by vein: days 1-4 of each Induction cycle
58442357|NCT06140966|DRUG|Melphalan|Given by vein: day -1 of Transplant
58442358|NCT06140966|PROCEDURE|ASCT|day 0 of Transplant
58442359|NCT06140966|DRUG|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
58442360|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
58442361|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
58442362|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
58442363|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
58442364|NCT04853719|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
58442365|NCT04381169|DRUG|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
58442366|NCT00878748|DRUG|Effexor XR|
58442367|NCT00878748|OTHER|Effexor XR discontinue|
58442368|NCT02134925|OTHER|Laboratory Biomarker Analysis|Correlative studies
58109339|NCT00971672|OTHER|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
58442369|NCT02134925|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
58442370|NCT02134925|OTHER|Quality-of-Life Assessment|Ancillary studies
58442371|NCT02134925|OTHER|Saline|Given SC
58442372|NCT05044858|PROCEDURE|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
58442373|NCT05044858|PROCEDURE|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
58442374|NCT00659932|BEHAVIORAL|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
58442375|NCT00659932|BEHAVIORAL|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
58442376|NCT06126341|OTHER|Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM|Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
58442377|NCT06126341|BEHAVIORAL|Hospital Anxiety and Depression Scale|Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
58442378|NCT06126341|BEHAVIORAL|Duke-UNC Functional Social Support Questionnaire|A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
58442379|NCT06126341|BEHAVIORAL|Distress Thermometer|The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
58442380|NCT06126341|BEHAVIORAL|FACT-BMT|The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
58442381|NCT06126341|BEHAVIORAL|Psychosocial Assessments of Candidates for Transplantation|The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
58442382|NCT04926948|OTHER|Immunotherapy|Immunotherapy
58442383|NCT04926948|OTHER|Quality-of-Life Assessment|Ancillary studies
58442384|NCT04926948|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58442385|NCT02698514|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
58442386|NCT02698514|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
58442387|NCT03079895|BEHAVIORAL|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
58442388|NCT02655549|BIOLOGICAL|Px563L, RPA563, or placebo|Two intramuscular injections
58442389|NCT05011513|DRUG|PF-07321332|PF-07321332 (tablet)
58442390|NCT05011513|DRUG|Ritonavir|Ritonavir (capsule)
57739661|NCT04364958|OTHER|A web based-Patient Decision Aid (PtDA) (shown on the computer)|Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
58109340|NCT06325982|DRUG|Triethanolamine cream|"Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months.~Preparation method: Pull out the syringe piston, add 15ml triethanolamine cream, add 30ml normal saline, gently pat, shake well.~Specific methods of retention enema: at night before going to bed, empty urine and feces, prepare enema liquid into the syringe, connect the special catheter, and insert the other end of the special catheter into the anus (the special catheter can be applied with lubricant such as tea oil before insertion). The patient remained prone and semi-seated. Use a special catheter, insert a special catheter about 15cm from the anus, and inject enteral liquid while withdrawing, so that the liquid is retained in the rectum; The above treatment was performed before bed and retained overnight."
58109341|NCT01888328|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
58442391|NCT05011513|DRUG|Placebo|Placebo (tablet)
58442392|NCT05011513|DRUG|Placebo|Placebo (capsule)
58442393|NCT01407666|PROCEDURE|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
58442394|NCT05455528|DIAGNOSTIC_TEST|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
58442395|NCT04057521|OTHER|Care Coordination|Comprehensive care coordination.
58442396|NCT05285540|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
58442397|NCT05285540|DRUG|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
58442398|NCT02451514|BIOLOGICAL|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
58442399|NCT04778826|PROCEDURE|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
58442400|NCT03653143|BEHAVIORAL|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
58442401|NCT03374033|DIETARY_SUPPLEMENT|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
58442402|NCT03374033|BEHAVIORAL|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
58442403|NCT00432406|DRUG|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
58442404|NCT00432406|DRUG|Etanercept|Etanercept 25 mg twice weekly
58442405|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
58109342|NCT01340950|DRUG|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
58109343|NCT01340950|DRUG|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
58311984|NCT00600522|PROCEDURE|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
58311985|NCT02224417|BEHAVIORAL|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
58311986|NCT02224417|BEHAVIORAL|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~* SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~* SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~* SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
58311987|NCT02224417|BEHAVIORAL|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~* SGD 2 weekly if one glucose readings falls within the normal range,~* SGD 7 weekly if two glucose readings fall within the normal range,~* SGD 14 weekly if all three glucose readings fall within the normal range."
58311988|NCT02043977|DRUG|propofol injectable emulsion|
58311989|NCT00350545|DRUG|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
58442406|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
58442407|NCT02001935|DRUG|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
58109344|NCT04451265|OTHER|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
58109345|NCT05959369|DIAGNOSTIC_TEST|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
58109346|NCT03779516|OTHER|Saline|Effect of saline on postoperative sore throat
58311990|NCT00350545|DRUG|Prednisone|1 mg/kg; po per day with taper
58311991|NCT00350545|DRUG|Cyclosporine A|trough 200-300 or lower; po
58442408|NCT05851820|OTHER|comparison of outcomes/exposure|analysing if diabetes mellitus have an impact on the primary outcomes: hospital stay, admission to the ICU, death.
58442409|NCT06263816|DRUG|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
57739662|NCT04364958|OTHER|A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.|Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
57739663|NCT02871648|DRUG|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
57739664|NCT02871648|DRUG|Fludrocortisone|Fludrocortisone 0.1 mg
58311992|NCT00350545|DRUG|tacrolimus|trough 5-10 or lower; po
58442410|NCT06263816|OTHER|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
57739665|NCT02871648|DRUG|Eplerenone|Epleronone 100 mg
57739666|NCT02395939|PROCEDURE|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
57739667|NCT02395939|PROCEDURE|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
57739668|NCT06669689|DEVICE|operating position|In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.
58311993|NCT02005107|DRUG|Venlafaxine IR and Venlafaxine XR|
58311994|NCT01092767|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
58311995|NCT05563324|GENETIC|DNA extraction and genotyping of candidate genetic polymorphisms|
58311996|NCT05563324|OTHER|self-assessment questionnaires|
58442411|NCT03672292|DRUG|SCY-078|Oral tablets of SCY-078
58442412|NCT03672292|DRUG|Voriconazole|Voriconazole IV vials or oral tablets
57739669|NCT06669689|DEVICE|pneumoperitoneum|Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.
58311997|NCT04227834|BEHAVIORAL|Health hygiene education|A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
58311998|NCT05856968|PROCEDURE|continuous subcutaneous tissue closure|The use of continuous subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
58311999|NCT05856968|PROCEDURE|Interrupted subcutaneous tissue closure|The use of interrupted subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
58312000|NCT01300403|OTHER|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
58312001|NCT01300403|OTHER|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
58442413|NCT03672292|OTHER|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
57739670|NCT04758312|BEHAVIORAL|MY-Skills Mobile|Yoga and Self-Management Education
57739671|NCT06202066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57739672|NCT06202066|PROCEDURE|Computed Tomography|Undergo CT scan
57739673|NCT06202066|BIOLOGICAL|Incomplete Freund''s Adjuvant|Given SC
57739674|NCT06202066|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58312002|NCT01300403|OTHER|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
58312003|NCT02323074|PROCEDURE|Brain Computer Interface|
58312004|NCT05689437|OTHER|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
58312005|NCT05689437|OTHER|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
58442414|NCT02451995|DEVICE|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
58442415|NCT02451995|DEVICE|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
58442416|NCT04929470|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
57739675|NCT06202066|BIOLOGICAL|Sargramostim|Given SC
57739676|NCT06202066|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
57739677|NCT06202066|DRUG|Temozolomide|Given PO
57739678|NCT06243146|OTHER|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
57739679|NCT05926401|OTHER|ECG monitoring prior and after cardioversion|Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
57739680|NCT04704375|DEVICE|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
57739681|NCT04704375|PROCEDURE|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
58109347|NCT03779516|OTHER|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
58109348|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
58109349|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
58109350|NCT00071409|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
58109351|NCT06321237|DEVICE|Vagus nerve stimulation for 8 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks
58109352|NCT06321237|DEVICE|Vagus nerve stimulation for the first 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks
58109353|NCT06321237|DEVICE|Vagus nerve stimulation for the last 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks
58109354|NCT06321237|DEVICE|Pseudostimulus|The patient is given some electrical stimulation but not vagus nerve stimulation
58312006|NCT05689437|OTHER|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
58442417|NCT02581735|OTHER|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
58442418|NCT02906397|DRUG|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
58442419|NCT02906397|RADIATION|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
58442420|NCT05484115|DEVICE|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
57739682|NCT04704375|PROCEDURE|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
57739683|NCT06670846|DEVICE|Lollipop|Distraction using a Lollipop 15 minutes before anesthesia
58109355|NCT03859609|PROCEDURE|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
58109356|NCT06447454|RADIATION|radiotherapy|radiotherapy
58109357|NCT06447454|DRUG|gemcitabine + cisplatin|Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.
58109358|NCT06447454|DRUG|slulimumab|Slulimumab, 4.5mg/kg intravenous infusion, Q3W
58109359|NCT00388882|DRUG|tiotropium|
58109360|NCT00388882|DRUG|ipratropium bromide / albuterol|
57739684|NCT06670846|DRUG|distraction using intranasal Midazolam|Distraction using intranasal Midazolam 15 minutes before anesthesia
57739685|NCT04474626|DRUG|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
58109361|NCT02611999|BEHAVIORAL|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
58109362|NCT02611999|BEHAVIORAL|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
58109363|NCT06238492|BEHAVIORAL|game-like computerized activities|Experimental
58109364|NCT06238492|BEHAVIORAL|Placebo|game-like computerized activities
58109365|NCT05997485|DRUG|Nirmatrelvir/Ritonavir|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
58109366|NCT01297192|DRUG|solifenacin succinate|Oral
58109367|NCT01297192|DRUG|mirabegron|Oral
58109368|NCT00826631|PROCEDURE|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
58109369|NCT00253097|BEHAVIORAL|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
58109370|NCT00397319|DRUG|Growth Hormone|
58109371|NCT05093283|DEVICE|Virtual Reality Glasses|Virtual Reality Glasses
58109372|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
58109373|NCT04080882|OTHER|Placebo|Treatment of platysmal bands
58109374|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
58109375|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
58109376|NCT03198988|DEVICE|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
58109377|NCT05705440|BIOLOGICAL|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
58109378|NCT05705440|OTHER|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
58109379|NCT05835206|DRUG|Microbiome Therapeutic|"Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
58109380|NCT05835206|DRUG|Placebo|"Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
58109381|NCT01405170|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
58109382|NCT01405170|DRUG|methylprednisolone|tablets 32 mg single dose
58109383|NCT01792856|OTHER|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
58109384|NCT01792856|OTHER|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
58109385|NCT02118753|DRUG|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
58109386|NCT05970601|DIETARY_SUPPLEMENT|Soup|Intake of a single soup with different sodium chloride and potassium chloride content
58442421|NCT05484115|DEVICE|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
58442422|NCT01800591|BEHAVIORAL|Financial incentive|
58442423|NCT00025558|BIOLOGICAL|filgrastim|
58442424|NCT00025558|DRUG|carboplatin|
58442425|NCT00025558|DRUG|temozolomide|
58109387|NCT03370484|DIETARY_SUPPLEMENT|Control|Water with 80 mg sucralose
58109388|NCT03370484|DIETARY_SUPPLEMENT|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
58109389|NCT04160949|OTHER|No Intervention|There is no intervention for this study.
58109390|NCT06382779|PROCEDURE|reverse shoulder arthroplasty|resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty
58442426|NCT00025558|DRUG|thiotepa|
58442427|NCT00025558|PROCEDURE|autologous bone marrow transplantation|
58442428|NCT00025558|PROCEDURE|peripheral blood stem cell transplantation|
58442429|NCT03701672|OTHER|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
58442430|NCT04872595|OTHER|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
58442431|NCT04872595|RADIATION|Hyper fractionated total body irradiation|"(1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
58442432|NCT04872595|DRUG|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
58442433|NCT04872595|DRUG|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
58442434|NCT04872595|DRUG|GCSF|Day +7
58442435|NCT04872595|DRUG|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
58442436|NCT04872595|DRUG|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
58442437|NCT04872595|DRUG|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
58442438|NCT02814175|DRUG|methotrexate (MTX)|
58442439|NCT02814175|BIOLOGICAL|adalimumab (ADA)|
57739686|NCT03620344|OTHER|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
57739687|NCT03620344|OTHER|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
58442440|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
58442441|NCT01149915|DRUG|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
58442442|NCT02741141|OTHER|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
58442443|NCT02741141|OTHER|Classical partograph|Classical partograph used as standard care
58442444|NCT01010971|DRUG|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
58442445|NCT01010971|DRUG|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
58442446|NCT01010971|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily
58442447|NCT05846815|DEVICE|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
58442448|NCT05846815|OTHER|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
58442449|NCT04158583|DRUG|RO7296682|RO7296682 will be administered by the schedules specified in the respective arms.
58442450|NCT00952393|DRUG|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
58442451|NCT04886713|DIAGNOSTIC_TEST|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
58442452|NCT04886713|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and \> 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume"
58442453|NCT04886713|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
57739688|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with bupivacaine|"drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
57739689|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Ketamine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
58442454|NCT04473027|DIAGNOSTIC_TEST|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
58442455|NCT02255461|DRUG|palbociclib isethionate|Given PO
57739690|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Dexmedetomidine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
57739691|NCT02638038|DRUG|INT131|INT- 131
57739692|NCT03991611|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
58312007|NCT05689437|OTHER|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
58442456|NCT02255461|OTHER|pharmacological study|Correlative studies
58442457|NCT02255461|OTHER|laboratory biomarker analysis|Correlative studies
58442458|NCT03177928|DEVICE|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
58442459|NCT06546046|DEVICE|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
58442460|NCT00526591|DRUG|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
57739693|NCT03991611|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
58442461|NCT00526591|PROCEDURE|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
58442462|NCT03402724|OTHER|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
58442463|NCT02411019|BIOLOGICAL|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
58442464|NCT02197663|PROCEDURE|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
58442465|NCT04922606|DIAGNOSTIC_TEST|US ot the GSV|Ultrasound of the Great Saphenous Vein
58442466|NCT03683342|PROCEDURE|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
58442467|NCT03683342|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
58442468|NCT03255577|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
58442469|NCT00595491|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
58442470|NCT04383782|BEHAVIORAL|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
58442471|NCT04383782|BEHAVIORAL|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
58442472|NCT04383782|BEHAVIORAL|Control|Neutral reading condition (see description in study arms).
58442473|NCT04355546|OTHER|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
58442474|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
58442475|NCT05674019|OTHER|MRI exam|Brain MRI Morphometric exam
58442476|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
58442477|NCT02227667|DRUG|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
58442478|NCT05619367|DRUG|Odronextamab|
58442479|NCT06113055|DRUG|L-serine|Active comparator
58442480|NCT06113055|DRUG|Placebo|Placebo comparator
58442481|NCT05035732|RADIATION|18F-fluciclovine|IV
58442482|NCT00000355|DRUG|Buprenorphine|
58442483|NCT04759105|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
58442484|NCT04759105|OTHER|Sham Procedure|anaesthesia, no disc injection, no placebo injection
58442485|NCT05391633|BEHAVIORAL|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
58442486|NCT05391633|BEHAVIORAL|Placebo Recording|60-minute blank recording played once daily for 14 total days.
58442487|NCT06226038|OTHER|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
58442488|NCT06226038|OTHER|Stainless steel|For control
58442489|NCT00284700|DRUG|Iron|
58442490|NCT02625844|OTHER|No intervention|No intervention administered in this study.
58442491|NCT01332383|DRUG|Naratriptan|
58442492|NCT01318408|DRUG|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
58442493|NCT05158517|DRUG|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
58442494|NCT01302353|DRUG|Emulsified Isoflurane|
58442495|NCT05908903|COMBINATION_PRODUCT|Drinks with active ingredients such as poria and GABA|Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.
58442496|NCT00955539|DEVICE|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
58442497|NCT00955539|DEVICE|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
58109391|NCT06000189|PROCEDURE|Standardized skin surface biopsies (SSSB)|Skin samples will be obtained from four regions of the participants' faces, including the forehead, right cheek, left cheek, and the nose, before phototherapy and after 20 sessions of phototherapy. The SSSB will be performed as follows: a 1 cm² square will be drawn on a glass slide using a ruler. The skin areas to be sampled will be gently swabbed with a dry gauze to induce irritation by this way to obtain more mites. Then, one drop of cyanoacrylate adhesive will be dropped onto the marked area on the glass slide, and the adhesive surface of the slide will be pressed onto the skin surface for approximately one minute. Afterwards, the slide will be gently lifted, and the sampled area will be examined under a light microscope at x10 and x40 magnifications after applying immersion oil. The presence of more than five Demodex mites per square centimeter will be defined as increased Demodex density.
58109392|NCT02371967|DRUG|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
58109393|NCT05045794|DEVICE|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
58109394|NCT05045794|OTHER|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
58109395|NCT03229031|DRUG|ES135|ES135 will be administered via intrathecal
58109396|NCT04719897|BEHAVIORAL|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
58109397|NCT05064865|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
58109398|NCT05064865|DIETARY_SUPPLEMENT|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
58109399|NCT02457624|BEHAVIORAL|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
58109400|NCT03017599|DEVICE|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
58109401|NCT01596816|RADIATION|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
58109402|NCT01596816|PROCEDURE|Fiducials placement|Placement of intra-prostatic markers for the tracking
58109403|NCT01596816|RADIATION|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
58109404|NCT06177379|OTHER|healthy volunteer|Volunteers age between 50 and 75 years
58109405|NCT01270841|DRUG|Placebo|Placebo capsule 1x daily for 3 months
58109406|NCT01270841|DRUG|topical testosterone|testosterone gel applied 1x daily for 3 months
58109407|NCT01270841|DRUG|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
58442498|NCT00939536|DRUG|Zolpidem Tartrate Tablets 10 mg|
58442499|NCT01550809|OTHER|iBolus|Insulin bolus calculated from data obtained through CGM
58109408|NCT00480220|PROCEDURE|Global care and support program|
58109409|NCT03560622|DEVICE|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
58312008|NCT05689437|OTHER|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
58442500|NCT01550809|OTHER|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
58442501|NCT05233592|DEVICE|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
58442502|NCT00270309|BEHAVIORAL|Self-management|
58442503|NCT04847934|BEHAVIORAL|distraction methods|distraction methods
58109410|NCT04158479|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
58109411|NCT00332137|DRUG|Tolterodine|
58109412|NCT02939638|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
58442504|NCT05681494|PROCEDURE|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
58442505|NCT05681494|PROCEDURE|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
58442506|NCT05726006|OTHER|No Intervention in This study|No Intervention in This study
57739694|NCT03991611|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
57739695|NCT03991611|OTHER|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
57739696|NCT03991611|OTHER|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
57739697|NCT05571631|OTHER|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
57739698|NCT04647851|OTHER|Remote exercise intervention Down syndrome|See arm description
58442507|NCT05697562|PROCEDURE|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
58442508|NCT05697562|PROCEDURE|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
58442509|NCT05697562|PROCEDURE|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
57739699|NCT05403801|BEHAVIORAL|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
57739700|NCT02733900|PROCEDURE|femoral head removal|
58109413|NCT02939638|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
58109414|NCT01888471|PROCEDURE|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
58442510|NCT06050694|DRUG|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
57739701|NCT03819153|DRUG|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
58442511|NCT05195658|DEVICE|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
58442512|NCT05708456|OTHER|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
58442513|NCT01499615|DEVICE|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
58442514|NCT02511886|DRUG|Arbaclofen Placarbil|Arbaclofen Placarbil
58442515|NCT02511886|DRUG|Placebo|Placebo matched tablets
58442516|NCT00190723|DRUG|Enzastaurin|
57739702|NCT03819153|DRUG|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
58442517|NCT03778450|DRUG|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
58442518|NCT03778450|DRUG|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
58109415|NCT01888471|OTHER|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
58109416|NCT00124449|DRUG|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g"
58442519|NCT01478334|BEHAVIORAL|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
58442520|NCT01478334|BEHAVIORAL|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
58109417|NCT00124449|DRUG|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
58109418|NCT03568500|DEVICE|Digital Medicine System|DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
58109419|NCT03568500|DRUG|Aripiprazole|Dosage determined by the healthcare professionals.
58109420|NCT03568500|DRUG|Olanzapine|Dosage determined by the healthcare professionals.
58109421|NCT03568500|DRUG|Quetiapine|Dosage determined by the healthcare professionals.
58109422|NCT03568500|DRUG|Risperidone|Dosage determined by the healthcare professionals.
58109423|NCT05977751|DEVICE|FemBloc|Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
58109424|NCT05693181|BIOLOGICAL|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10\*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
58109425|NCT05693181|OTHER|Control vehicle (sterile saline)|Sterile saline infusion in control patients
58109426|NCT00362570|DRUG|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
58109427|NCT02460874|DRUG|Glyburide|1.25mg, twice a day
58109428|NCT02460874|OTHER|Placebo|1.25mg, twice a day
58109429|NCT06047782|OTHER|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
58109430|NCT05351385|PROCEDURE|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
58109431|NCT05351385|PROCEDURE|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
58109432|NCT05351385|PROCEDURE|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
58109433|NCT05351385|PROCEDURE|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
58109434|NCT05351385|PROCEDURE|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
58109435|NCT05351385|PROCEDURE|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
58442521|NCT05300776|DIAGNOSTIC_TEST|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
58442522|NCT01921504|DEVICE|Acupuncture|"Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
58442523|NCT04740775|DEVICE|LiquiBand Exceed|Cyanoacrylate glue for closure of surgical wounds
58442524|NCT04740775|DEVICE|LiquiBand Rapid|Cyanoacrylate glue for closure of surgical wounds
58442525|NCT03218436|PROCEDURE|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
58442526|NCT02901418|BIOLOGICAL|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
58442527|NCT02210858|OTHER|Laboratory Biomarker Analysis|Correlative studies
58442528|NCT02210858|DRUG|Tipifarnib|Given PO
58442529|NCT05524584|DRUG|Fulvestrant|Given intramuscularly
58442530|NCT05524584|DRUG|Anastrozole|Given orally
58442531|NCT05524584|DRUG|Abemaciclib|Given orally
58109436|NCT03479385|BEHAVIORAL|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
58109437|NCT03479385|BEHAVIORAL|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
58109438|NCT00840359|PROCEDURE|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
58109439|NCT00840359|PROCEDURE|Cryotherapy|Cryotherapy for 2 times 20 sec
58109440|NCT02943681|BIOLOGICAL|Measles vaccine|
58109441|NCT00489931|DRUG|VRC-AVIDNA036-00-VP|
58109442|NCT04261296|OTHER|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
58109443|NCT04261296|OTHER|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
58109444|NCT04261296|OTHER|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
58109445|NCT03635684|DRUG|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
58109446|NCT04894994|DRUG|FLX475|Tablet
58109447|NCT04894994|DRUG|Ipilimumab|IV infusion
58109448|NCT04388033|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
58109449|NCT04388033|DRUG|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
58109450|NCT04388033|DRUG|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
58109451|NCT01950754|BEHAVIORAL|standing with both feet|
58109452|NCT01950754|BEHAVIORAL|descent of the platform|
58109453|NCT01950754|BEHAVIORAL|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
58442532|NCT00863499|DRUG|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
58442533|NCT00863499|DRUG|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
58109454|NCT01140269|OTHER|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
57739703|NCT05568433|DIAGNOSTIC_TEST|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
58109455|NCT03168685|DEVICE|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
58109456|NCT00923494|DRUG|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
58109457|NCT00923494|DRUG|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
58442534|NCT06407284|OTHER|Produce Prescription Group|Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
58442535|NCT06407284|OTHER|Control Group|Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
58442536|NCT02717494|BIOLOGICAL|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
58442537|NCT02717494|BIOLOGICAL|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
58442538|NCT02717494|OTHER|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
58109458|NCT00923494|DRUG|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
58109459|NCT04204486|BEHAVIORAL|Exercise|Functional strength training, 1 hour, 3 times a week.
58109460|NCT05717829|PROCEDURE|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
58109461|NCT01403454|BEHAVIORAL|Interactive Health Communication Application|web-based application
57739704|NCT06009081|BEHAVIORAL|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
57739705|NCT06009081|BEHAVIORAL|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
57739706|NCT01339585|DEVICE|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
57739707|NCT06241274|OTHER|Moxibustion|Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
58109462|NCT04295460|DRUG|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
58109463|NCT01448031|DRUG|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
58109464|NCT01448031|DRUG|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
57739708|NCT06241274|OTHER|Symptomatic supportive treatment|Symptomatic supportive treatment.
57739709|NCT04192981|DRUG|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
58109465|NCT06526715|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
57739710|NCT04192981|RADIATION|whole brain radiation therapy radiation|30Gy in 10 fractions
58442539|NCT04082715|DRUG|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
58442540|NCT04082715|DRUG|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
58442541|NCT04082715|DRUG|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
58442542|NCT04639024|DRUG|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
58442543|NCT06453681|OTHER|bilateral PECS|ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
58442544|NCT06453681|DRUG|Dexmedetomidine|Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
58442545|NCT05277558|OTHER|Observational|Investigators are observing brain health over time (21 months) in these groups
58442546|NCT05833997|PROCEDURE|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
58442547|NCT05833997|PROCEDURE|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
57739711|NCT02035800|DRUG|Adalimumab|Patient will received medication as standard of care
57739712|NCT06064227|OTHER|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
57739713|NCT02527798|DRUG|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
57739714|NCT02527798|DRUG|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
57739715|NCT02527798|DRUG|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
57739716|NCT02527798|OTHER|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
57739717|NCT06665607|PROCEDURE|Intrinsic Mucle Training|Conventional physiotherapy treatment and the intrinisc foot muscles strengthening program for 8 weeks.
58442548|NCT01295593|DRUG|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
58442549|NCT04136730|BEHAVIORAL|Home-based|Resistance exercise carried out unsupervised at home
58442550|NCT01895595|BEHAVIORAL|Guided Imagery|
58442551|NCT01895595|BEHAVIORAL|Digital Storytelling|
57739718|NCT06670157|OTHER|Detachable Clip|After the varicose vessels basically disappeared under the endoscope, the removable titanium clamp was removed
57739719|NCT05833750|OTHER|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
58442552|NCT04334993|DRUG|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
58442553|NCT02549001|DRUG|P-3058 10%|
58442554|NCT02549001|DRUG|vehicle of P-3058 10%|
58442555|NCT02549001|DRUG|amorolfine 5%|
58442556|NCT01520376|BEHAVIORAL|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
58442557|NCT00644488|DRUG|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
58442558|NCT06476353|OTHER|Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures|The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
58442559|NCT00002203|DRUG|Lamivudine/Zidovudine|
58442560|NCT00002203|DRUG|Lamivudine|
58442561|NCT00002203|DRUG|Zidovudine|
58442562|NCT01947764|BEHAVIORAL|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
58442563|NCT04276519|PROCEDURE|Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen|Opening of the mechanical interface of the nerve root, neurodynamics
57739720|NCT00905918|DIETARY_SUPPLEMENT|vitamin E|Given orally
57739721|NCT00905918|OTHER|laboratory biomarker analysis|All patients undergo biomarker analyses
57739722|NCT01140880|DRUG|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
58442564|NCT02317848|OTHER|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
58442565|NCT01828229|BEHAVIORAL|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
58442566|NCT01828229|BEHAVIORAL|inactivity|inactivity for 2 weeks
58442567|NCT01828229|BEHAVIORAL|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
58442568|NCT01828229|BEHAVIORAL|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
58442569|NCT01828229|BEHAVIORAL|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
58442570|NCT00387634|BIOLOGICAL|TBE vaccine for adults|Serology blood draw.
58442571|NCT06422689|DRUG|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
58442572|NCT03450954|PROCEDURE|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
57739723|NCT06030674|OTHER|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
57739724|NCT02941302|PROCEDURE|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
57739725|NCT03535935|DRUG|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
57739726|NCT03535935|OTHER|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
57739727|NCT02414191|BEHAVIORAL|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
57739728|NCT02414191|BEHAVIORAL|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
58442573|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
58109466|NCT03786913|DIAGNOSTIC_TEST|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
58109467|NCT04443283|OTHER|No intervention|This is a observation study, with no intervention
58109468|NCT05499494|OTHER|Beautifil Flow Plus X F00 injectable composite|bioactive injectable composite
58442574|NCT00265317|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
58442575|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
58442576|NCT00265317|DRUG|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
58442577|NCT01867502|DRUG|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
58442578|NCT01867502|DRUG|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
58442579|NCT05932225|OTHER|Propylene glycol solution/drops|commercially available eye drops
58109469|NCT05499494|OTHER|Tetric N ceram resin composite|Nano hybrid resin composite
58109470|NCT01944189|DIETARY_SUPPLEMENT|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
58109471|NCT00353938|DRUG|3,4-methylenedioxymethamphetamine (125 mg)|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
58442580|NCT02444052|DEVICE|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
58442581|NCT02444052|DEVICE|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
58109472|NCT00353938|DRUG|3,4-methyelendioxymethamphetamine (25 mg)|Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
58109473|NCT00353938|BEHAVIORAL|Therapy|Non-directive therapy performed by a team of two co-therapists
58109474|NCT05775809|DRUG|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
58109475|NCT05775809|DEVICE|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
58442582|NCT06056557|DEVICE|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
58442583|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
58442584|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
58442585|NCT05154253|OTHER|Standard gait training|Standard gait training without a device.
58442586|NCT05154253|DEVICE|Ankle foot orthosis|Standard ankle foot orthosis
58442587|NCT05154253|OTHER|Standard physical therapy|Physical therapy without a device.
58442588|NCT05154253|OTHER|Standard walking|Walking without a device
58442589|NCT06486896|OTHER|Pelvic floor training|It will be in the form of pelvic floor relaxation with biofeedback, as well as stretching exercises for the pelvic floor and the adjacent muscles. The patient will be asked to lie in a comfortable crock lying position. She will be instructed to do diaphragmatic breathing exercises. The vaginal electrode of the biofeedback will be gently introduced into the vagina to start pelvic floor relaxation training. Then, the patient will be asked to perform pelvic floor relaxation by slightly contracting the pubococcygeus muscle. After 10 minutes of pelvic floor relaxation training, the patient will then be instructed to return to the active state gradually, the treatment procedure will be performed 3 times/ week for 8 weeks. Stretching exercises for the pelvic floor and the adjacent muscles: Levator ani \& perineal muscles stretch, hip adductor muscles stretch, piriform muscle stretch, hip flexor muscles stretch, and obturator internus muscle stretch.
57739729|NCT06614504|OTHER|Varying the nicotine content of cigarettes|Altering the nicotine content of the tobacco research cigarettes
57739730|NCT06614504|OTHER|Varying the nicotine content of e-cigarettes|Altering the nicotine content of the research e-cigarettes
57739731|NCT05314517|DRUG|Namilumab|Namilumab administered subcutaneously
57739732|NCT05314517|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
57739733|NCT04334668|DIETARY_SUPPLEMENT|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
57739734|NCT04334668|OTHER|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
58109476|NCT04942041|OTHER|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
57739735|NCT02311712|DEVICE|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
57739736|NCT05625958|DEVICE|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
58109477|NCT00751153|DRUG|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
58109478|NCT06477315|OTHER|survey|telephone surveys
58109479|NCT02544061|BIOLOGICAL|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
57739737|NCT05422326|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
57739738|NCT05422326|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
57739739|NCT05422326|BIOLOGICAL|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
57739740|NCT00990990|DRUG|PNU-100480|100 mg BID for 14 days
58109480|NCT02544061|DRUG|Placebo|single subcutaneous dose
58109481|NCT06282588|DRUG|Darolutamide|2x300 mg tablets twice daily, for up to 96 weeks
58109482|NCT06282588|DRUG|Darolutamide matched placebo|2x300 mg tablets twice daily, for up to 96 weeks
58109483|NCT06282588|RADIATION|Radiotherapy|Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
57739741|NCT00990990|DRUG|Placebo|to match 100 mg BID for 14 days
58109484|NCT06282588|DRUG|Zoladex 3.6Mg Implant|3.6 mg, subcutaneous use
58109485|NCT06282588|DRUG|Zoladex LA|10.8 mg, subcutaneous use
58109486|NCT06282588|DRUG|Decapeptyl sustained release 22.5 mg|22.5 mg, intramusculair injection
58109487|NCT06282588|DRUG|Decapeptyl sustained release 11.25 mg|11.25 mg, intramusculair injection
58109488|NCT06282588|DRUG|Depo-Eligard 45 mg|45 mg, subcutaneous use
58109489|NCT06282588|DRUG|Depo-Eligard 22.5 mg|22.5 mg, subcutaneous use
58109490|NCT06282588|DRUG|Depo-Eligard 7.5 mg|7.5 mg, subcutaneous use
57739742|NCT00990990|DRUG|PNU-100480|300 mg BID for 14 days
57739743|NCT00990990|DRUG|Placebo|to match 300 mg BID for 14 days
58109491|NCT06282588|DRUG|Firmagon 120 MG Injection|120 mg, subcutaneous use
58442590|NCT06486896|DEVICE|Interferential current|Each female in the experimental group will receive interferential current, 3o minutes per session, 2 sessions per week, for 8 weeks. The applied parameters will be a frequency of 2000Hz, a modulated amplitude of frequency of 80Hz, pulse width of 200μs, and the intensity is modulated according to the sensory level of each participant. While the participant is in a comfortable crock lying position with abducted hips, the position of the electrodes will be maintained in all sessions
58442591|NCT06486896|BEHAVIORAL|General advice|The patients in both groups will follow general advice to help vaginismus for 8 weeks
58442592|NCT02347306|OTHER|Telephone interview|
58442593|NCT00830466|DRUG|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
58442594|NCT05584280|DEVICE|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
57739744|NCT00990990|DRUG|PNU-100480|600 mg BID for 14 days
58109492|NCT06282588|DRUG|Firmagon 80 MG Injection|80 mg, subcutaneous use
58442595|NCT05584280|DEVICE|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
58442596|NCT06304623|BIOLOGICAL|Autologous adipose-derived SVF IV administration|Subjects received an intravenous injection of autologous adipose-derived SVF.
57739745|NCT00990990|DRUG|Placebo|to match 600 mg BID for 14 days
57739746|NCT00990990|DRUG|PNU-100480|1200 mg QD for 14 days
57739747|NCT00990990|DRUG|Placebo|to match 1200 mg QD for 14 days
57739748|NCT00990990|DRUG|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
57739749|NCT00990990|DRUG|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
57739750|NCT00990990|DRUG|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
57739751|NCT00990990|DRUG|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
57739752|NCT00990990|DRUG|Linezolid|300 mg QD for 4 days (open label)
57739753|NCT04794803|DRUG|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
57739754|NCT04794803|DRUG|Standard of care|Standard of care
58109493|NCT06282588|DRUG|Docetaxel|75 mg per square m, IV infusion
58109494|NCT05316103|DEVICE|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
58109495|NCT04579497|OTHER|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
58109496|NCT04579497|OTHER|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
58109497|NCT04579497|OTHER|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
58109498|NCT04579497|OTHER|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
58109499|NCT04962126|DRUG|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
58442597|NCT01060852|BEHAVIORAL|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
58442598|NCT06168682|DEVICE|SuperNO2VA™ Et by Vyaire Medical, Inc.|SuperNO2VA™ Et provides a nCPAP between 3 to 10 cmH20 using a oxygenflowrate of 6l/O2
58442599|NCT06168682|DEVICE|nasal oxygen cannula|Standard Operating Procedure (SOP) for endoscopy: Using a nasal oxygen cannula with oxygenflowrate of 6l/O2
58442600|NCT02369913|OTHER|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
57739755|NCT02638948|DRUG|BMS-986142|BMS986142 specific dose on specific days
58109500|NCT04962126|DRUG|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
57739756|NCT02638948|DRUG|Placebo|Placebo of BMS-986142 specific dose on specific days
58109501|NCT04962126|RADIATION|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
58109502|NCT04783259|OTHER|Structured approach|Structured approach with a narrow learning objective. The structured approach concerns a pre-escape room lecture and post-escape room debriefing
58442601|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
57739757|NCT02638948|DRUG|Methotrexate|Methotrexate specific dose on specific days
57739758|NCT06498661|PROCEDURE|Biospecimen Collection|Undergo collection of cervical samples by clinician
57739759|NCT06498661|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
58442602|NCT00531635|DRUG|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
58442603|NCT05518357|BIOLOGICAL|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
58442604|NCT03987516|OTHER|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
58109503|NCT02311426|OTHER|Observational study|Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
58109504|NCT00446264|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
58109505|NCT00446264|DRUG|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
58109506|NCT04684784|DEVICE|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
58109507|NCT04684784|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
58109508|NCT03922659|COMBINATION_PRODUCT|Transcranial magnetic stimulation and Cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
58109509|NCT04162392|OTHER|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
58442605|NCT00279916|DRUG|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
58442606|NCT00279916|DRUG|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
58442607|NCT00649428|BIOLOGICAL|Autologous Human Fibroblast (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
58442608|NCT00649428|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face."
58442609|NCT03213288|DIETARY_SUPPLEMENT|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
57739760|NCT06498661|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
57739761|NCT06498661|OTHER|Electronic Health Record Review|Ancillary studies
57739762|NCT06498661|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
57739763|NCT06498661|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
57739764|NCT06498661|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal samples
57739765|NCT06498661|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
57739766|NCT06498661|OTHER|Questionnaire Administration|Ancillary studies
57739767|NCT06498661|OTHER|Survey Administration|Ancillary studies
57739768|NCT02017340|DRUG|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
57739769|NCT02017340|DRUG|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
58109510|NCT04162392|OTHER|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
58109511|NCT02009956|DEVICE|Subjects receiving DESyne Novolimus Eluting CSS|
58109512|NCT01669044|DRUG|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
58109513|NCT01669044|DRUG|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
58109514|NCT01132287|OTHER|FID 112903|lubricant eye drop FID 112903
58109515|NCT00606268|DRUG|Micafungin|IV
58442610|NCT03213288|DIETARY_SUPPLEMENT|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
58442611|NCT03213288|DIETARY_SUPPLEMENT|Placebo|No anthocyanins
58442612|NCT02952833|DRUG|Saline|Sodium chloride solution.
58442613|NCT02952833|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
57739770|NCT05208138|DEVICE|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
57739771|NCT00001020|BIOLOGICAL|rgp120/HIV-1IIIB|
57739772|NCT00001020|BIOLOGICAL|rgp120/HIV-1MN|
57739773|NCT04584060|COMBINATION_PRODUCT|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
57739774|NCT04584060|COMBINATION_PRODUCT|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
57739775|NCT04584060|COMBINATION_PRODUCT|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
57739776|NCT02039037|DEVICE|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
58109516|NCT04987177|OTHER|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
58109517|NCT00804349|DEVICE|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
58109518|NCT01484990|DRUG|Levodopa-Carbidopa|Intestinal Gel
58109519|NCT05081752|DEVICE|OTSC Stentfix|Stent placement with fixation of the esophageal stent using OTSC Stentfix.
58109520|NCT05081752|PROCEDURE|Stent Suturing / Endoscopic Clips|Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
58109521|NCT06429761|DRUG|Trastuzumab deruxtecan|IV infusion
58109522|NCT05610605|OTHER|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
58109523|NCT01557491|PROCEDURE|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
58109524|NCT01557491|PROCEDURE|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
58109525|NCT02270983|DRUG|Linaclotide 145 micrograms|
58109526|NCT02270983|DRUG|Linaclotide 290 micrograms|
58109527|NCT02270983|DRUG|Placebo|Matching placebo
58109528|NCT06530563|DRUG|Oliceridine Injection [Olinvyk]|Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.
58109529|NCT06530563|DRUG|Sufentanil Citrate|Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.
58109530|NCT01033864|DRUG|MMF|1 g per day b.i.d. p.o. for at least 1 month
58109531|NCT01033864|DRUG|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
58109532|NCT01033864|DRUG|Prednisone|5 mg per day p.o.
58442614|NCT00696046|PROCEDURE|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical \& steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
58442615|NCT01887184|DRUG|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranasally
58442616|NCT01887184|DRUG|Placebo|Intranasal saline was given
58109533|NCT04905719|DIAGNOSTIC_TEST|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
58109534|NCT04848350|OTHER|Lavender essential oil|Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
58442617|NCT01961622|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
58442618|NCT01961622|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
57739777|NCT02039037|DEVICE|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
57739778|NCT04006327|OTHER|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
58109535|NCT01902134|DRUG|Placebo|Placebo single oral dose (first 8 hours)
58109536|NCT01902134|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
58109537|NCT01902134|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
58109538|NCT01902134|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
58109539|NCT01902134|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
58109540|NCT01902134|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
58109541|NCT01902134|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
58109542|NCT02314520|DEVICE|peripherally inserted central catheter|Any complication associated with central access
58109543|NCT02314520|DEVICE|centrally inserted central catheter|Central access not associated with any complication
58109544|NCT01543815|BEHAVIORAL|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
58109545|NCT01543815|BEHAVIORAL|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
58442619|NCT04355208|OTHER|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
58109546|NCT01543815|OTHER|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
58109547|NCT04852991|PROCEDURE|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
58109548|NCT04852991|PROCEDURE|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
58109549|NCT04602390|DRUG|ANK-700|Intravenous (IV) infusion
58109550|NCT04602390|DRUG|Placebo|Intravenous (IV) infusion
58109551|NCT05842577|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
58109552|NCT05842577|OTHER|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
58109553|NCT06524778|RADIATION|brachytherapy|Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
58109554|NCT02117479|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
58109555|NCT02117479|DRUG|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
58109556|NCT02117479|DRUG|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
57739779|NCT06302751|DEVICE|Care 4 Today ® (Johnson and Johnson) mobile app|Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
58109557|NCT01773278|DRUG|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
58442620|NCT02067936|DRUG|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
58442621|NCT02067936|DRUG|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
58442622|NCT02067936|DRUG|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
58442623|NCT02067936|DRUG|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
58442624|NCT02084550|DIETARY_SUPPLEMENT|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
58442625|NCT02084550|OTHER|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
58442626|NCT00972725|BIOLOGICAL|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
58442627|NCT00972725|DRUG|Chloroquine|One dose of 300 mg
58442628|NCT04392843|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
57739780|NCT01921439|BEHAVIORAL|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
57739781|NCT04597268|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mic/kg
57739782|NCT04597268|DRUG|Ketamine|ketamine 1mg/kg
58442629|NCT04392843|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
57739783|NCT04597268|DRUG|Midazolam|midazolam 0.05 mg/kg
57739784|NCT01009931|DRUG|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
57739785|NCT01009931|DRUG|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
58109558|NCT01773278|DRUG|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
58312009|NCT05689437|OTHER|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
58442630|NCT00959738|PROCEDURE|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
58442631|NCT00959738|PROCEDURE|diverting loop ileostomy without rod|diverting loop ileostomy without rod
57739786|NCT01009931|DRUG|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
58312010|NCT01985178|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|
57739787|NCT01387880|DRUG|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
57739788|NCT01387880|DRUG|Everolimus|1.66 mg per day up to 7½ mg per day
57739789|NCT01944904|DIETARY_SUPPLEMENT|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
57739790|NCT01944904|DIETARY_SUPPLEMENT|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
58312011|NCT04259333|DRUG|Celecoxib 200mg|Celecoxib tablet
58312012|NCT04259333|DRUG|Acetaminophen, Codeine Drug Combination|acetaminophen-codeine-caffeine tablet
58312013|NCT01398241|DRUG|RO5267683|Multiple ascending doses
57739791|NCT06630039|OTHER|Scale validity and reliability|The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
57739792|NCT04464928|OTHER|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
58312014|NCT01398241|DRUG|placebo|Multiple ascending doses
58442632|NCT01190501|DEVICE|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
58442633|NCT06502782|DIAGNOSTIC_TEST|digital assesment|Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
58442634|NCT00203424|DRUG|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
58442635|NCT01641601|DEVICE|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
58442636|NCT04043442|DEVICE|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
58442637|NCT00932321|DRUG|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
58442638|NCT00932321|DRUG|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
58442639|NCT03285269|DIAGNOSTIC_TEST|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
58442640|NCT03285269|DEVICE|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
58109559|NCT00665522|DRUG|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
57739793|NCT04464928|OTHER|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
57739794|NCT02278328|DRUG|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
57739795|NCT02278328|DRUG|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
57739796|NCT02278328|DRUG|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
57739797|NCT04791449|OTHER|Structured exercise program|Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
58109560|NCT00665522|DRUG|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
58109561|NCT04229797|PROCEDURE|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
58109562|NCT03294278|OTHER|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
58109563|NCT00318344|DRUG|Atuna Racemosa|
58109564|NCT04057755|DRUG|botulinum toxin A|
58109565|NCT04057755|DRUG|NaCl|
58109566|NCT05015881|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|Drink a single dose of ketone ester 1.9 kcal/kg
58109567|NCT05015881|DRUG|FDG|Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
58312015|NCT03427892|DRUG|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
58442641|NCT03285269|PROCEDURE|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
58442642|NCT01960582|BEHAVIORAL|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
58442643|NCT02761343|OTHER|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
58109568|NCT05182398|OTHER|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
58109569|NCT01268449|RADIATION|Low dose laser|5mv laser with a wavelength of 650nm
58109570|NCT01268449|RADIATION|Placebo|The act of radiating laser to the ear is done while the set is off.
58109571|NCT02032290|PROCEDURE|Assessment of Coronary Flow Reserve|
58109572|NCT02032290|PROCEDURE|Percutaneous coronary intervention|
58109573|NCT02032290|DRUG|ticagrelor loading|
58109574|NCT02032290|DRUG|Clopidogrel loading|
58109575|NCT00538187|DRUG|obatoclax mesylate|Given IV
58109576|NCT00538187|DRUG|bortezomib|Given IV
58109577|NCT00538187|OTHER|laboratory biomarker analysis|correlative study
58109578|NCT00538187|OTHER|pharmacological study|correlative study
58109579|NCT01484171|DRUG|idarubicin|idarubicin 10-12 mg/m2 for three days
58109580|NCT01484171|BIOLOGICAL|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
58109581|NCT02984683|DRUG|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
58109582|NCT03727464|BEHAVIORAL|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
58109583|NCT03727464|BEHAVIORAL|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
58109584|NCT03727464|BEHAVIORAL|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
58442644|NCT03136289|BEHAVIORAL|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
58442645|NCT04505332|PROCEDURE|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
58109585|NCT03727464|DRUG|Propofol|Propofol general anesthesia
58109586|NCT03727464|DRUG|Sevoflurane|Sevoflurane general anesthesia
58109587|NCT02614937|DRUG|ranibizumab|0.5 mg IVT ranibizumab
58109588|NCT02614937|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
58109589|NCT00058617|BIOLOGICAL|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
58109590|NCT01287780|DEVICE|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
58109591|NCT01063725|DIETARY_SUPPLEMENT|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
58109592|NCT01063725|OTHER|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
58442646|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
58442647|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
58442648|NCT05234047|PROCEDURE|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
58442649|NCT05234047|PROCEDURE|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
58442650|NCT04734067|OTHER|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
58442651|NCT03753555|DRUG|Atorvastatin Calcium|20mg Qd for 12 months
58442652|NCT03753555|DRUG|Atorvastatin Calcium|40-80mg Qd for 6 months
58442653|NCT03753555|DRUG|Probucol|0.5g Bid for 6 months
58442654|NCT03753555|DRUG|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
57739798|NCT00222833|DRUG|Aripiprazole|
57739799|NCT00442143|PROCEDURE|Stem cell implantation|
57739800|NCT03630874|OTHER|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
57739801|NCT01802372|BEHAVIORAL|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
57739802|NCT01802372|BEHAVIORAL|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
57739803|NCT02810054|PROCEDURE|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
57739804|NCT02810054|PROCEDURE|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
57739805|NCT03210805|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
58109593|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
58109594|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
58109595|NCT04128449|DIETARY_SUPPLEMENT|docosahexaenoic acid|5 dragees every 24 hours
58109596|NCT04128449|DIETARY_SUPPLEMENT|Placebo|5 dragees every 24 hours
58109597|NCT00591422|DRUG|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
58109598|NCT00036582|DRUG|Clozapine|
58109599|NCT06362876|BEHAVIORAL|Breastfeeding Counseling Based on Motivational Interviewing|Breastfeeding Counseling Based on Motivational Interviewing Program The breastfeeding counseling based on motivational interviewing program consists of 6 sessions and 4 hours. It includes information about breastfeeding, motivational preparation for the breastfeeding experience.
58109600|NCT06362876|BEHAVIORAL|Standard Breastfeeding Consultancy|Standart Breastfeeding Consultancy The standard breastfeeding consultancy program consists of 6session and 4 hours. It contains only information and applications about breastfeeding
58109601|NCT06036654|DEVICE|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
58109602|NCT02175407|DRUG|ASP1707|oral
58109603|NCT02175407|DRUG|itraconazole|oral
58109604|NCT05017376|PROCEDURE|small incision lenticular extraction|In patients with the same degree of myopia, different optical zones were designed for operation
58109605|NCT01488019|DRUG|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
58109606|NCT01488019|DRUG|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
58109607|NCT02544100|OTHER|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
58109608|NCT04180189|OTHER|Weighted fiber blanket|Using weighted blanket for four weeks
58109609|NCT06531265|PROCEDURE|Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy|Bronchoscopic evaluation of endobronchial lesion with biopsy and cryotherapy for recanalisation
58109610|NCT01208402|DRUG|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
58109611|NCT02678897|DRUG|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
58109612|NCT02678897|DRUG|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
58109613|NCT04302428|BIOLOGICAL|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
58109614|NCT04302428|BIOLOGICAL|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
58109615|NCT06217133|DEVICE|CPAP|"Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage."
58109616|NCT03010085|PROCEDURE|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
58109617|NCT03010085|PROCEDURE|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
58109618|NCT03474705|DEVICE|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
58109619|NCT04887545|DIAGNOSTIC_TEST|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
58109620|NCT02288689|DEVICE|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
58109621|NCT00062556|DRUG|Niacin Extended Release and Lovastatin Tablets|
58109622|NCT00379587|DRUG|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
58109623|NCT00379587|DRUG|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
57739806|NCT03031938|DRUG|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
57739807|NCT02190331|OTHER|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
58109624|NCT05213507|DRUG|aerosol inhaled Amikacin Sulfate Injection|0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
58109625|NCT05213507|OTHER|conventional therapy|According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
58109626|NCT02157233|BEHAVIORAL|Rest|
58109627|NCT02157233|BEHAVIORAL|Exercise|
58109628|NCT05756699|DIAGNOSTIC_TEST|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
58109629|NCT01155063|OTHER|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
58109630|NCT02323659|DRUG|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
58109631|NCT02323659|DRUG|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
58109632|NCT06366672|BIOLOGICAL|JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection|live, nonreplicating vaccine delivered according to the FDA approved package insert
58442655|NCT04637737|DEVICE|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
57739808|NCT02190331|OTHER|Control Group physical education classes|Only performed the physical education classes
57955957|NCT04774835|DIAGNOSTIC_TEST|Standard aPS|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
57955958|NCT02931721|DIAGNOSTIC_TEST|MRI|Pelvis MRI
57955959|NCT01143753|DRUG|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
58109633|NCT06366672|PROCEDURE|Phlebotomy|Research blood draw
58442656|NCT04637737|BEHAVIORAL|Conventional therapy|The control group received the usual gait training.
58442657|NCT03831217|PROCEDURE|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
58442658|NCT03305770|DEVICE|verofilcon A contact lenses|Daily disposable soft contact lenses
57739809|NCT06225765|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
57739810|NCT06225765|PROCEDURE|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
57739811|NCT01891916|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
57739812|NCT02349295|DRUG|Placebo|Administered SC
57955960|NCT04938128|DEVICE|CPAP|Gold standard treatment for obstructive sleep apnea. In this group, patients will be prescribed CPAP treatment according to local policy.
57955961|NCT02342002|DRUG|Mifepristone|Mifepristone for treatment of missed abortion
57955962|NCT02342002|DRUG|Misoprostol|Misoprostol for treatment of missed abortion
58109634|NCT06366672|PROCEDURE|Research bronchoscopy|Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.
57739813|NCT02349295|DRUG|Ixekizumab 80 mg Q4W|Administered SC
57739814|NCT02349295|DRUG|Ixekizumab 80 mg Q2W|Administered SC
58109635|NCT06366672|PROCEDURE|Skin punch biopsy|Skin punch biopsy performed with topical anesthesia.
58109636|NCT06366672|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration performed with local anesthesia.
58442659|NCT03305770|DEVICE|delefilcon A contact lenses|Daily disposable soft contact lenses
57739815|NCT05642481|DIAGNOSTIC_TEST|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
57739816|NCT03561090|DRUG|IW-3718|oral tablet
57739817|NCT03561090|DRUG|placebo|oral tablet
57739818|NCT03561090|DRUG|Standard-dose PPIs QD|background therapy
57955963|NCT03565627|DEVICE|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
57955964|NCT03565627|DEVICE|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
58109637|NCT03279484|DEVICE|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
58312016|NCT03200223|BEHAVIORAL|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
58312017|NCT01653691|PROCEDURE|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
58312018|NCT01653691|PROCEDURE|Sham|No treatment to one side of subject's scar.
58312019|NCT01543165|DRUG|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
58312020|NCT01543165|DRUG|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
58312021|NCT01543165|DRUG|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
58312022|NCT05029284|BEHAVIORAL|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
58312023|NCT00003858|DRUG|mitoxantrone hydrochloride|
58312024|NCT00726453|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
58312025|NCT04541121|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
58312026|NCT04541121|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
58312027|NCT03401957|DRUG|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
58312028|NCT03401957|DIAGNOSTIC_TEST|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
58312029|NCT02164617|OTHER|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
57739819|NCT02023970|DEVICE|Patients receiving animal-derived bioprosthetic heart valves.|
57739820|NCT02023970|OTHER|Echocardiography (1)|
57739821|NCT02023970|OTHER|Echocardiography (2)|
58442660|NCT01292096|OTHER|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
58442661|NCT02885246|OTHER|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
58442662|NCT06303102|OTHER|Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.
58442663|NCT06303102|OTHER|Manual PT/Conventional PT Treatment|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
57739822|NCT02023970|OTHER|Echocardiography (3)|
57739823|NCT02023970|BIOLOGICAL|Blood sample (1)|
57739824|NCT02023970|BIOLOGICAL|Blood sample (2)|
57739825|NCT02023970|BIOLOGICAL|Blood sample (3)|
57955965|NCT02949180|DEVICE|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
57955966|NCT02008682|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
58312030|NCT00489463|DEVICE|intra-uterine device (TCu 380A)|
58442664|NCT05230472|DRUG|Simvastatin|simvastatin 60 mg tab
58442665|NCT03386487|DRUG|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
58442666|NCT03386487|DRUG|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
58442667|NCT03319134|DEVICE|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
58442668|NCT03319134|DEVICE|sham HD-tDCS|2) sham HD-tDCS with memory task
58442669|NCT03319134|DEVICE|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
58442670|NCT03314064|DRUG|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
58442671|NCT04587310|DIAGNOSTIC_TEST|Laparoscopic Sleeve Gastrectomy|bariatric surgery
58442672|NCT02342899|DEVICE|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
58442673|NCT02342899|DEVICE|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
58442674|NCT00982826|DRUG|ABT-072|See Arms information for a detailed description.
58442675|NCT00982826|DRUG|Placebo|See Arms information for a detailed description.
58442676|NCT02593942|DRUG|Remifentanil|0.1-0.5 mcg/kg/min infusion
57739826|NCT01511848|DRUG|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
58442677|NCT02593942|DRUG|Propofol|75-200 mcg/kg/min infusion
58442678|NCT03441386|BEHAVIORAL|Physical Exercise Session|
58442679|NCT06098534|BEHAVIORAL|Hospi'Senior|The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.
58442680|NCT06098534|BEHAVIORAL|Conventional room|"The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair."
58442681|NCT03004352|OTHER|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
58442682|NCT03004352|OTHER|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
58442683|NCT01647893|DRUG|CTB-001|IV bolus or IV infusion
58442684|NCT04354675|GENETIC|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
58442685|NCT04354675|GENETIC|Genetics counselor|Traditional in-person genetic counseling
57739827|NCT01511848|DRUG|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
57739828|NCT00956865|OTHER|Voucher|Vouchers given to reimburse transportation
57739829|NCT00956865|OTHER|Telephone Call|Telephone reminder calls
57739830|NCT00956865|OTHER|Contact|Contact at senior center to encourage follow up
57739831|NCT00036569|PROCEDURE|adjuvant therapy|
57739832|NCT00036569|BIOLOGICAL|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
57739833|NCT00221442|DRUG|Zonegran|zonegran (zonisamide)
57739834|NCT00221442|DRUG|sugar pill|fake pill
57739835|NCT05449834|DRUG|Fibrinogen Concentrate|3g Fibrinogen Concentrate
57955967|NCT02008682|DRUG|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
57955968|NCT00708578|DRUG|Glimepiride|Once a day before breakfast
57955969|NCT00708578|DRUG|Metformin|After breakfast and supper
58442686|NCT04354675|OTHER|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
58442687|NCT04354675|OTHER|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
58442688|NCT04354675|DEVICE|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
58442689|NCT02202343|BEHAVIORAL|school based health and nutrition education|
58442690|NCT00031759|DRUG|imiquimod|
58442691|NCT00031759|PROCEDURE|Ablative or excisional therapy|
58442692|NCT02926638|DRUG|Erlotinib Hydrochloride|Given PO
58442693|NCT02926638|OTHER|Laboratory Biomarker Analysis|Correlative studies
58442694|NCT02926638|BIOLOGICAL|Rilotumumab|Given IV
58442695|NCT06453967|DIAGNOSTIC_TEST|blood glucose levels|measurement of blood glucose level at admission ,during ICU admission and at discharge for patients with acute decompensated heart failure
58442696|NCT03831100|BEHAVIORAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
57955970|NCT00708578|DRUG|Insulin Glargine|Injection in the morning
57955971|NCT00288756|PROCEDURE|lv injection of contrast|
57955972|NCT01029132|DRUG|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
57955973|NCT02751502|DEVICE|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
57955974|NCT02305862|DRUG|Rosuvastatin 5mg|drug intervention
57955975|NCT02305862|DRUG|Rosuvastatin 20mg|drug intervention
57955976|NCT04532060|DRUG|Nystatin|
57955977|NCT04532060|PROCEDURE|Antimicrobial Photodynamic Therapy|
57955978|NCT03166293|BEHAVIORAL|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
57955979|NCT06548061|DEVICE|Visualase Thermal Therapy System|Spine laser interstitial therapy used instead of open decompression followed by SSRS.
57955980|NCT03325673|DEVICE|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
57955981|NCT03325673|DEVICE|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
57955982|NCT05559229|PROCEDURE|laparoscopic whole-layer cholecystectomy|laparoscopic whole-layer cholecystectomy.
57955983|NCT03963635|DIAGNOSTIC_TEST|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
57955984|NCT03170297|OTHER|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
57955985|NCT05572762|DEVICE|Cannula plastic part while applying peribulbar block|Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
57955986|NCT05572762|PROCEDURE|traditional technique|the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
57955987|NCT03311711|BEHAVIORAL|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
57955988|NCT03311711|BEHAVIORAL|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
57955989|NCT03311711|BEHAVIORAL|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
57955990|NCT03428178|DRUG|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
57955991|NCT04888273|BEHAVIORAL|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
57955992|NCT04408690|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
57955993|NCT04408690|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
58109638|NCT01814137|DRUG|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
58109639|NCT01814137|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
58109640|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
58442697|NCT03831100|BEHAVIORAL|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
58442698|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
58442699|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
58442700|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
58442701|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
58442702|NCT01552863|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
58442703|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
58442704|NCT06310421|DIAGNOSTIC_TEST|Screening SMA test|Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
58442705|NCT01978041|OTHER|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
58442706|NCT01978041|OTHER|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
58442707|NCT01978041|OTHER|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
57739836|NCT05449834|OTHER|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
57955994|NCT04408690|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
57955995|NCT04268485|DIAGNOSTIC_TEST|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
57955996|NCT04319107|OTHER|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
57955997|NCT02481921|BEHAVIORAL|Group medical visits|Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
57955998|NCT04799392|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
57955999|NCT00514956|BEHAVIORAL|Emotional Freedom Techniques (EFT)|
57956000|NCT02562560|BEHAVIORAL|Neuropsychological tests|
58109641|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
58109642|NCT06019130|DRUG|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
58442708|NCT01978041|OTHER|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
57739837|NCT01880723|DRUG|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
57739838|NCT01880723|DRUG|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
57956001|NCT02562560|DEVICE|Cerebral imaging (MRI, PET-FDG)|
57956002|NCT06368713|BEHAVIORAL|Exercise|"* Frequency: Exercise sessions will occur no less than three times per week.~* Intensity: The intensity will be based on a rating of perceived exertion score ranging from 12 to 16 on a scale of 6 to 20.~* Exercise duration: Each exercise session will last approximately 30 minutes.~* Exercise Type:The exercise regimen will include aerobic exercise, resistance exercise, and flexibility training."
57956003|NCT03899779|OTHER|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
57956004|NCT03899779|OTHER|Online hypnotherapy|12 weeks treatment with online hypnotherapy
57956005|NCT03899779|OTHER|Online psychoeducation|12 weeks treatment with online psychoeducation
57956006|NCT04675866|OTHER|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
57956007|NCT03011346|DEVICE|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
58442709|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
58442710|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
58442711|NCT01181817|OTHER|fMRI and MRS|fMRI and MRS
58442712|NCT06009055|DRUG|Remimazolam|0.3mg/kg，injection completed in 30 seconds
58442713|NCT06009055|DRUG|Propofol|2mg/kg，injection completed in 30 seconds
58442714|NCT04532034|BEHAVIORAL|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
58442715|NCT02732548|OTHER|Negative Pressure Wound Therapy (NPWT)|
58442716|NCT02732548|OTHER|MIRODERM Application(s)|
58442717|NCT02732548|OTHER|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
58442718|NCT02384733|RADIATION|Loco-regional RT|
57739839|NCT05962242|RADIATION|Radiation Therapy|External Beam Radiation to Head and Neck
57739840|NCT04341116|DRUG|TJ003234|patients receive a single infusion
58442719|NCT00345865|DRUG|carmustine|Day -6, 300 mg/m\^2 over 2 hour
58442720|NCT00345865|DRUG|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
58442721|NCT00345865|DRUG|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
58442722|NCT00345865|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
58442723|NCT00345865|RADIATION|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."
57956008|NCT03011346|DEVICE|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
57956009|NCT03899766|OTHER|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
57956010|NCT03899766|OTHER|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
57956011|NCT03899766|OTHER|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
57956012|NCT03694496|BEHAVIORAL|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
57956013|NCT00803075|DEVICE|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
57956014|NCT03115307|DRUG|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
58109643|NCT06019130|DRUG|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
58109644|NCT06019130|DRUG|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
58442724|NCT00345865|BIOLOGICAL|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."
58442725|NCT00345865|DRUG|Cytarabine|100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
58442726|NCT03301350|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
58442727|NCT03301350|DRUG|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
58442728|NCT03301350|DRUG|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
58442729|NCT03301350|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
58442730|NCT03301350|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
58442731|NCT03301350|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
58442732|NCT02285387|PROCEDURE|Rhythm control|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
58442733|NCT02285387|PROCEDURE|Rate control|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
58442734|NCT06056583|DRUG|Cimetidine 200 MG|Cimetidine will serve as the probe drug
58442735|NCT05023993|OTHER|Exercise Intervention|Complete home exercise
58442736|NCT05023993|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Given PO
58442737|NCT01629277|DEVICE|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
58442738|NCT01629277|DEVICE|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
58442739|NCT00206843|DEVICE|Triage BNP Test|
58442740|NCT03531086|DRUG|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
58442741|NCT02895100|DRUG|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
58442742|NCT02895100|DRUG|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
58442743|NCT00452868|DRUG|Donepezil|Donepezil 5 milligrams a day for 6 weeks
58442744|NCT05356780|DEVICE|Aligner|A method of straightening teeth without fixed braces
58442745|NCT01005498|DIETARY_SUPPLEMENT|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
58442746|NCT01005498|DIETARY_SUPPLEMENT|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
58442747|NCT03315312|DRUG|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
58442748|NCT03315312|DRUG|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
58442749|NCT04086095|DEVICE|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
58109645|NCT06019130|DRUG|Gemcitabine|Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis
58442750|NCT02399774|DEVICE|Leboride|"1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
58442751|NCT00394706|DEVICE|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
58442752|NCT00394706|DEVICE|Sham ITD|Sham ITD
58442753|NCT00394706|OTHER|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
58442754|NCT00394706|OTHER|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
58442755|NCT02312297|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
58442756|NCT04957394|BEHAVIORAL|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
58442757|NCT01079416|DEVICE|Capsule endoscopy, Esophagogastroduodenoscopy|
58442758|NCT03769558|OTHER|Non-Interventional|Non-Interventional
58442759|NCT00394550|PROCEDURE|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
58442760|NCT00394550|PROCEDURE|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
58442761|NCT04031859|DRUG|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
57739841|NCT04341116|DRUG|Placebo|patients receive a single infusion
57739842|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR and PVI|
57739843|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR|
57739844|NCT03276351|DEVICE|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
58109646|NCT06019130|RADIATION|Radiotherapy|After induction therapy in all patients
58109647|NCT06019130|DRUG|Interferon beta-1a|In patients \< 26 years after end of radiochemotherapy for 6 months
58109648|NCT06019130|PROCEDURE|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
58442762|NCT04343456|PROCEDURE|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
58109649|NCT06019130|PROCEDURE|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
58109650|NCT06019130|BEHAVIORAL|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
58312031|NCT00526175|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
58109651|NCT03700710|BEHAVIORAL|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
58442763|NCT03686293|OTHER|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
58442764|NCT04761133|DRUG|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
58442765|NCT02144857|DRUG|etanercept|50 mg
58442766|NCT02144857|DRUG|ustekinumab|45 mg
58442767|NCT02144857|DRUG|cyclosporine|Cyclosporine 2.5-3 mg/kgr
58442768|NCT02144857|DRUG|Secukinumab|300 mg
58442769|NCT02144857|DRUG|Apremilast|30mg
58442770|NCT00921778|DEVICE|Lapcone|Use of Lapcone during LSH
58442771|NCT00921778|PROCEDURE|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
58442772|NCT01502228|DRUG|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
58442773|NCT01502228|DRUG|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
58442774|NCT01502228|PROCEDURE|Positron Emission Tomography|PET Scan
58442775|NCT01502228|DRUG|Sunitinib|
58442776|NCT04632589|DRUG|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
58442777|NCT04632589|DRUG|Placebo|subjects ingest placebo tablet daily for 6 weeks
58442778|NCT04120961|DRUG|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
58442779|NCT04120961|DRUG|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
57739845|NCT03276351|DEVICE|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
57739846|NCT05640349|BIOLOGICAL|Positive blood culture|Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
57739847|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
57739848|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
57739849|NCT01491854|OTHER|Bloodsampling|Bloodsampling
58109652|NCT03700710|BEHAVIORAL|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
58442780|NCT05297591|OTHER|assessment of UL function and prognostic factors|clinical assessments and questionnaires
58442781|NCT00300313|DRUG|Escitalopram|10 to 20 mg / day
58442782|NCT00300313|DRUG|Placebo|1-2 capsules
58442783|NCT01216137|OTHER|Exercise: Vestibular Rehabilitation|Balance and eye movement training
58442784|NCT01216137|OTHER|Exercise|Bicycle ergometry and stretching
58442785|NCT00032734|DRUG|satavaptan (SR121463B)|
58442786|NCT02145117|BEHAVIORAL|MBSR|Behavioral
58442787|NCT02737124|DRUG|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
58442788|NCT02737124|OTHER|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
58442789|NCT03449069|DRUG|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
58442790|NCT04459871|BIOLOGICAL|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
58442791|NCT04459871|BIOLOGICAL|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
58442792|NCT03971409|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
58442793|NCT03971409|DRUG|Avelumab|Given IV
58442794|NCT03971409|DRUG|Binimetinib|Given PO
58442795|NCT03971409|BIOLOGICAL|Utomilumab|Given IV
58442796|NCT03971409|DRUG|Liposomal Doxorubicin|Given IV
58442797|NCT03971409|DRUG|Sacituzumab Govitecan|Given IV
58442798|NCT05357027|BIOLOGICAL|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
58442799|NCT05357027|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
58442800|NCT05357027|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
58442801|NCT05357027|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
58442802|NCT04849169|DEVICE|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
58442803|NCT05599971|DRUG|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
58442804|NCT05599971|DRUG|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
58442805|NCT05599971|OTHER|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
58442806|NCT02458833|BEHAVIORAL|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
58442807|NCT02076282|OTHER|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
57739850|NCT03288116|DIAGNOSTIC_TEST|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
58109653|NCT00748813|BIOLOGICAL|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
58312032|NCT00526175|DRUG|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
58442808|NCT00529425|DRUG|Ropivacaine|
58442809|NCT04451499|OTHER|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
58442810|NCT06213155|DEVICE|Cryoneurolysis|Cryoneurolysis
58442811|NCT06213155|DEVICE|Stimulation|Stimulation
58442812|NCT05414630|DRUG|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
58442813|NCT04576026|BEHAVIORAL|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
58442814|NCT04576026|BEHAVIORAL|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
58442815|NCT04576026|BEHAVIORAL|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
57739851|NCT01414387|PROCEDURE|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
57739852|NCT01414387|PROCEDURE|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
57739853|NCT01734304|BIOLOGICAL|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
58109654|NCT00851266|BIOLOGICAL|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
58442816|NCT00301418|DRUG|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
58442817|NCT05938803|BEHAVIORAL|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
58442818|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
58442819|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
58442820|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
58442821|NCT03619772|OTHER|Bilateral|Participants will control game using EMG from both upper limbs.
58442822|NCT03619772|OTHER|Unilateral|Participants will control game using EMG from the more impaired upper limb.
58442823|NCT05659368|DRUG|Tirzepatide|tirzepatide once weekly
58442824|NCT00933998|OTHER|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
58442825|NCT03077230|BEHAVIORAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
58442826|NCT03196544|BEHAVIORAL|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
58442827|NCT03196544|BEHAVIORAL|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
58442828|NCT01426672|OTHER|Monovision Correction (with the help of glasses or contact lenses)|
58442829|NCT01944124|BEHAVIORAL|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
58312033|NCT00526175|DRUG|Daunorubicin|30 mg/m2, i.v., days 8 and 15
58109655|NCT00851266|BIOLOGICAL|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
58109656|NCT04315012|OTHER|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
58109657|NCT00828490|BEHAVIORAL|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
58109658|NCT00828490|BEHAVIORAL|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
58442830|NCT01944124|BEHAVIORAL|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
58442831|NCT02527785|DRUG|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7"
58442832|NCT01732315|BEHAVIORAL|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
58442833|NCT03243357|PROCEDURE|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
58442834|NCT03243357|PROCEDURE|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
58442835|NCT00933868|DRUG|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
58109659|NCT00828490|BEHAVIORAL|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
58109660|NCT05589935|DIETARY_SUPPLEMENT|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
58109661|NCT01423565|DEVICE|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
58312034|NCT00526175|DRUG|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
58312035|NCT00526175|DRUG|Cyclophosphamide|1000 mg/m2, i.v., day 22.
58442836|NCT00933868|DRUG|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
58442837|NCT02075151|PROCEDURE|Bronchial Thermoplasty|Bronchial thermoplasty
58442838|NCT04267835|PROCEDURE|MIDCAB|Surgery: MIDCAB
58442839|NCT04267835|PROCEDURE|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
58442840|NCT05150015|DEVICE|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
58312036|NCT00526175|DRUG|Methotrexate|Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
58442841|NCT02956317|DRUG|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
58312037|NCT00526175|DRUG|Cytosine Arabinoside|Edad \<1 year 1-2 years 2-3 years \> 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
58109662|NCT01055444|DRUG|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
58312038|NCT00526175|DRUG|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
58312039|NCT00526175|DRUG|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
58312040|NCT05853263|DRUG|paracetamol|paracetamol IV to substitute morphine IV.
58312041|NCT05853263|DRUG|Morphine|standard care
58442842|NCT02956317|DRUG|Placebo|Normal Saline
58442843|NCT04215640|DEVICE|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
58442844|NCT04215640|DEVICE|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
58312042|NCT00730184|DIETARY_SUPPLEMENT|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
58312043|NCT00730184|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
58312044|NCT02141932|PROCEDURE|Bed-side pocket size ultrasound imaging|
58312045|NCT02141932|DEVICE|GE Ultrasound Vscan|
58312046|NCT03170310|DRUG|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
58312047|NCT00075075|DRUG|Infliximab|
58442845|NCT04270968|DEVICE|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
57739854|NCT05748548|OTHER|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
57739855|NCT05748548|OTHER|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
57739856|NCT05748548|OTHER|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
57739857|NCT04994457|DEVICE|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
58442846|NCT04270968|DRUG|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
57739858|NCT04994457|DIAGNOSTIC_TEST|Standard Automated Perimetry|Standard of care perimeter
57739859|NCT05054374|DRUG|Mirdametinib|Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
57739860|NCT05054374|DRUG|Fulvestrant|"The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant"
58312048|NCT02171455|DRUG|Dabigatran etexilate low dose|
58312049|NCT02171455|DRUG|Dabigatran etexilate medium dose|
58312050|NCT02171455|DRUG|Dabigatran etexilate high dose|
58312051|NCT02171455|DRUG|Placebo|
57739861|NCT04885062|DEVICE|Belun Ring|The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.
57739862|NCT04885062|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
57739863|NCT01641250|DRUG|RO5429083|Multiple escalating doses
57739864|NCT01641250|DRUG|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
58312052|NCT00283179|DRUG|Aripiprazole|
58442847|NCT05375721|PROCEDURE|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
58312053|NCT00283179|DRUG|Risperidone|
58109663|NCT03568825|PROCEDURE|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
58109664|NCT03311009|DRUG|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
58109665|NCT03311009|DRUG|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
57739865|NCT06159634|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) will be the technique used to remove target lesions.
57739866|NCT06159634|DEVICE|Traction Device|Use of traction device to aid in removing target lesions
58109666|NCT03311009|DRUG|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
58109667|NCT03311009|DRUG|Placebo|Matching placebo provided as oral tablets q.d.
58312054|NCT06491498|DIAGNOSTIC_TEST|Supraclavicular Brachial Plexus Blockade|Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
58312055|NCT00942643|DEVICE|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
58312056|NCT03229603|OTHER|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
58312057|NCT00012909|BEHAVIORAL|Hormone Replacement Therapy Decision-Aid|
58312058|NCT00424242|DRUG|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
58109668|NCT02879747|DRUG|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
58109669|NCT01324063|BIOLOGICAL|sargramostim|
58109670|NCT01324063|DRUG|amsacrine|
58109671|NCT01324063|DRUG|cytarabine|
58109672|NCT01324063|DRUG|daunorubicin hydrochloride|
58109673|NCT01324063|PROCEDURE|quality-of-life assessment|
58109674|NCT03354156|DRUG|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
58109675|NCT00212771|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
57739867|NCT02636634|OTHER|imaging|
58109676|NCT00212771|DRUG|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
58109677|NCT00973778|OTHER|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
58312059|NCT02349386|DRUG|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
58312060|NCT02349386|DRUG|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
58312061|NCT00339053|DRUG|Immunonutrition ( Impact)|
58312062|NCT03101020|OTHER|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
58312063|NCT03101020|OTHER|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
58312064|NCT03101020|OTHER|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
58312065|NCT05993104|DIAGNOSTIC_TEST|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
58312066|NCT05993104|OTHER|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
57739868|NCT06670872|DRUG|Eravacycline combination therapy group|"Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines."
58109678|NCT02611206|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
58312067|NCT00001891|PROCEDURE|Myocardial contrast echocardiography|
58312068|NCT00001891|PROCEDURE|Dobutamine echocardiography|
58442848|NCT03940300|DIETARY_SUPPLEMENT|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
58312069|NCT02500251|DRUG|belimumab|Belimumab will be administered per study protocol.
58442849|NCT00006195|DRUG|risperidone|
58442850|NCT00006195|DRUG|olanzapine|
58442851|NCT01199419|PROCEDURE|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
58442852|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
57739869|NCT05374980|DIETARY_SUPPLEMENT|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
57739870|NCT05374980|DIETARY_SUPPLEMENT|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
58312070|NCT02500251|DRUG|Bortezomib|Bortezomib will be administered per study protocol.
58312071|NCT02500251|DRUG|Rituximab|Rituximab will be administered per study protocol.
58312072|NCT02500251|DRUG|Plasmapheresis|Plasmapheresis will be administered per study protocol.
58312073|NCT02552940|DRUG|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
58312074|NCT04490408|PROCEDURE|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
58312075|NCT04490408|PROCEDURE|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
58312076|NCT05807282|OTHER|Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho|The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
58312077|NCT05652777|DEVICE|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
58312078|NCT05067855|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
58312079|NCT06144372|DEVICE|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
58312080|NCT01729195|PROCEDURE|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
58312081|NCT05359484|DIAGNOSTIC_TEST|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
58312082|NCT00300729|DRUG|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
58312083|NCT00300729|DRUG|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
58442853|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
58442854|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
58442855|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
58442856|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
58442857|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
58442858|NCT05924594|DRUG|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
58442859|NCT04805437|DEVICE|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
58442860|NCT04805437|DEVICE|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
58442861|NCT04327791|DRUG|Baloxavir|administered PO once
58442862|NCT04327791|DRUG|Placebos|administered PO once
58442863|NCT00313417|DIETARY_SUPPLEMENT|Creatine monohydrate|Up to 10 grams
58442864|NCT00313417|OTHER|Placebo|Placebo will be given in the same way and appearance as the active treatment
58442865|NCT00837070|PROCEDURE|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
58442866|NCT03642509|DEVICE|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
58442867|NCT03642509|DRUG|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
58442868|NCT00685113|DRUG|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
58442869|NCT00685113|DRUG|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
58442870|NCT00685113|DRUG|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
58442871|NCT03956212|DRUG|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
58442872|NCT03956212|DRUG|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
58442873|NCT00828763|DRUG|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
58442874|NCT03903419|DIAGNOSTIC_TEST|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
58442875|NCT03409783|DEVICE|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
58442876|NCT03409783|DEVICE|Sham Device|Sham Device
58442877|NCT02790801|OTHER|observation|observation
58442878|NCT01433172|BIOLOGICAL|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
57739871|NCT00957476|DIETARY_SUPPLEMENT|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
58109679|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
58442879|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
58442880|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
58442881|NCT02012660|OTHER|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
58442882|NCT06408038|OTHER|For each patient included, the samples described below will be collected:|"* A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study."
58442883|NCT05318703|BEHAVIORAL|tai ji quan|cognitively enhanced tai ji quan exercise
58442884|NCT05318703|BEHAVIORAL|Stretching|Stretching exercise
58442885|NCT00927212|DRUG|AS101 ointment|Twice daily topical application
58442886|NCT03236077|BEHAVIORAL|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
58442887|NCT06467461|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
58442888|NCT06467461|DIAGNOSTIC_TEST|Speech testing|Speech Testing to quantify evolving signs of 5-HT RBD
58442889|NCT06467461|DIAGNOSTIC_TEST|Ultra high field 7T MRI|7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
58442890|NCT01756196|DRUG|Spinal Steroid Injection|Steroid Injection
58442891|NCT05743361|DIAGNOSTIC_TEST|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
58442892|NCT04867746|OTHER|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
58442893|NCT04867746|OTHER|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
57739872|NCT00961090|DRUG|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
57739873|NCT03466333|DRUG|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
57739874|NCT03466333|DRUG|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
57739875|NCT02889991|OTHER|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
57739876|NCT02889991|OTHER|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
57739877|NCT02889991|OTHER|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
58109680|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
58312084|NCT03980678|DIETARY_SUPPLEMENT|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
58312085|NCT03980678|DIETARY_SUPPLEMENT|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
58442894|NCT04867746|OTHER|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 \* 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
58442895|NCT04867746|OTHER|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
58312086|NCT06173284|DRUG|611|subcutaneous injection
58312087|NCT06173284|DRUG|Matching placebo|subcutaneous injection
58312088|NCT05545917|OTHER|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
57739878|NCT02889991|OTHER|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling."
57739879|NCT01889953|OTHER|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach"
57739880|NCT04866173|OTHER|Dog|Subjection to standardised stress situations in the presence of a dog and a person
57739881|NCT04866173|OTHER|No Dog|Subjection to standardised stress situations in the presence of a person
57739882|NCT06423846|DRUG|Total intravenous anesthesia group|Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour
57739883|NCT06423846|DRUG|sevoflurane group|For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
57739884|NCT02492100|BEHAVIORAL|Multi-modality sexual dysfunction intervention|
58312089|NCT05545917|OTHER|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
58442896|NCT04867746|OTHER|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
58442897|NCT04527367|PROCEDURE|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
58312090|NCT03980912|DIAGNOSTIC_TEST|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
58312091|NCT03055936|DRUG|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
57739885|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
57739886|NCT00902304|DRUG|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
57739887|NCT00902304|DRUG|Usual care|As directed by investigator
57739888|NCT00902304|DRUG|Valsartan|Valsartan 160mg per day to 320mg per day orally
57739889|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
58109681|NCT03382210|OTHER|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
58109682|NCT01217203|DRUG|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
58109683|NCT03105115|DRUG|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
58109684|NCT03105115|DRUG|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
57739890|NCT01688700|DRUG|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
57739891|NCT00529399|DRUG|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
58109685|NCT06059742|OTHER|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
58109686|NCT06059742|OTHER|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
58109687|NCT06090747|BEHAVIORAL|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
58109688|NCT06090747|BEHAVIORAL|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
58109689|NCT01559974|DRUG|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
58109690|NCT01559974|DRUG|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
58312092|NCT03055936|DRUG|Carbidopa|Carbidopa 12.5 mg or 25 mg or 65 mg
58312093|NCT03055936|DRUG|ODM-104|ODM-104 50 mg or 100 mg
58312094|NCT03607318|BEHAVIORAL|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
58312095|NCT04934358|BEHAVIORAL|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
58312096|NCT04934358|BEHAVIORAL|Usual care|Usual rehabilitation program
58312097|NCT00419705|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
58312098|NCT05817123|OTHER|Questionnaires|"Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)"
58312099|NCT06513299|DEVICE|low tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
58312100|NCT06513299|DEVICE|high tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
58312101|NCT06513299|DEVICE|low driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
58312102|NCT06513299|DEVICE|high driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
58312103|NCT00080262|DRUG|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
58312104|NCT00217451|DRUG|Fosmidomycin-clindamycin|
58312105|NCT01077557|OTHER|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
58312106|NCT01077557|DRUG|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
57739892|NCT00529399|DRUG|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
58109691|NCT05720728|DIAGNOSTIC_TEST|collection of blood samples|For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
58109692|NCT04917900|DRUG|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
58442898|NCT01633164|BEHAVIORAL|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
58442899|NCT01633164|OTHER|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
58442900|NCT02553395|DEVICE|Phenacite (Test) contact lens|
58442901|NCT02553395|DEVICE|comfilcon A contact lens|
58442902|NCT04089761|DEVICE|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
58442903|NCT00694668|BEHAVIORAL|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
57739893|NCT00529399|DRUG|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
57739894|NCT02025881|DRUG|Carboplatin + etoposide|"Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
57739895|NCT02025881|DRUG|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
58109693|NCT02531230|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
58109694|NCT03183271|RADIATION|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
58109695|NCT04797156|DRUG|High Dose Tranexamic acid|50mg/kg IV TXA
58109696|NCT04797156|DRUG|Low Dose Tranexamic acid|20mg/kg IV TXA
58312107|NCT05923996|DRUG|microbotox|Will be treated by single session of microbotox injection
58312108|NCT05923996|RADIATION|fractional carbon dioxide laser|Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
58109697|NCT04797156|DRUG|Tranexamic acid Topical|2g topical TXA
58312109|NCT05500937|DRUG|UDCA|UDCA vs. placebo together with statin in ASCVD patients
58312110|NCT01922999|DRUG|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
58312111|NCT00435344|BEHAVIORAL|Pediatric Practice-Based Smoking Intervention|
58312112|NCT00357942|DRUG|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
58442904|NCT00694668|BEHAVIORAL|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
58442905|NCT00407472|DEVICE|ATS-1 needle free device|
58442906|NCT05220306|DEVICE|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
58442907|NCT05702138|OTHER|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
58109698|NCT04797156|DRUG|Normal saline|Normal saline poured on wound
58109699|NCT02360397|DRUG|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
58109700|NCT01505595|OTHER|Proprioceptive training|12 weeks
58312113|NCT00357942|DRUG|Placebo|Placebo mouthwash
58312114|NCT00357942|DRUG|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
58312115|NCT00357942|DRUG|Placebo|Placebo solution for injection every 3 hour for 24 hours
58312116|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
58312117|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
58312118|NCT01533259|DRUG|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
58442908|NCT05844020|BEHAVIORAL|Educational materials|Trauma-informed intimate partner violence screening, brief interventions, and referrals to treatment by providers
58442909|NCT00256724|DEVICE|Impedance Threshold Device|Active impedance threshold device
58442910|NCT00256724|DEVICE|sham ITD|sham impedance threshold device
58109701|NCT01505595|OTHER|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
58109702|NCT01690520|DRUG|Cyclophosphamide|Given IV
58109703|NCT01690520|DRUG|Cyclosporine|Given IV or PO
58109704|NCT01690520|BIOLOGICAL|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
58109705|NCT01690520|DRUG|Fludarabine Phosphate|Given IV
58109706|NCT01690520|DRUG|Mycophenolate Mofetil|Given IV or PO
58109707|NCT01690520|DRUG|Thiotepa|Given IV
58109708|NCT01690520|RADIATION|Total-Body Irradiation|Undergo high dose or middle intensity TBI
58109709|NCT01690520|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
58109710|NCT00395200|PROCEDURE|MSC Treatment|Intravenous administration of up to 2x10\^6 autologous MSCs per kg
58109711|NCT06223022|BEHAVIORAL|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
58109712|NCT02921347|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
58109713|NCT02235961|DRUG|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
58109714|NCT02235961|DRUG|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
58442911|NCT01559051|PROCEDURE|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
58442912|NCT02598206|DRUG|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
58442913|NCT00936000|DIETARY_SUPPLEMENT|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
58442914|NCT00001870|DRUG|Acetylcholine|
58442915|NCT06128577|COMBINATION_PRODUCT|3-month intensive intervention|"Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week."
58442916|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
58442917|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
58442918|NCT01561521|DRUG|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
58442919|NCT02175979|DIETARY_SUPPLEMENT|enriched enteral nutrition|enriched enteral tube feeding perioperative
58442920|NCT02175979|DIETARY_SUPPLEMENT|standard|standard of care
57739896|NCT02025881|DRUG|Cyclophosphamide + Busilvex|"Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose."
57739897|NCT02025881|DRUG|Temozolimide + Irinotecan|"During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12"
57739898|NCT02025881|COMBINATION_PRODUCT|Etoposide + radiotherapy|"* Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)"
58109715|NCT02235961|DRUG|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
58109716|NCT04410341|DRUG|Vildagliptin 50 MG|Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.
58109717|NCT04410341|DRUG|Escitalopram 20 mg|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
58109718|NCT00618397|DRUG|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
58109719|NCT00654043|DRUG|Torsemide|tablets, 20 Mg, single-dose
58109720|NCT00654043|DRUG|Demadex|Tablets, 20 mg, single-dose
58109721|NCT02309203|DEVICE|FRED|Flow Re-Direction Endoluminal Device
58109722|NCT03827785|DEVICE|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
58109723|NCT03827785|DEVICE|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
58109724|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
58109725|NCT01684722|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
58109726|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D3 placebo
58109727|NCT01684722|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
58312119|NCT05213780|OTHER|No intervention is involved|No intervention is involved
58312120|NCT03658980|BEHAVIORAL|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
57739899|NCT02025881|DRUG|Temozolomide|150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
58442921|NCT04383457|DEVICE|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
58442922|NCT01004926|DEVICE|Echelon foot|One Echelon foot for each subject, for a period of a month.
58442923|NCT01460758|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
58442924|NCT01460758|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
58442925|NCT01460758|DEVICE|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
58442926|NCT01602289|BIOLOGICAL|LY2875358|Administered IV
58442927|NCT01602289|DRUG|Erlotinib|Administered orally
58442928|NCT01602289|DRUG|Gefitinib|Administered orally
58442929|NCT06160947|OTHER|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
58442930|NCT06160947|OTHER|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
58442931|NCT02578199|BEHAVIORAL|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
58442932|NCT03186027|DIETARY_SUPPLEMENT|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
58442933|NCT03186027|DIETARY_SUPPLEMENT|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
58442934|NCT04149561|OTHER|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
58442935|NCT04618744|DRUG|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
58442936|NCT04618744|OTHER|Placebo|Matching Placebo
58442937|NCT06519812|PROCEDURE|Combined Intrarenal Surgery and percutaneous nephrolithotomy|A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
57739900|NCT00951483|DRUG|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
58442938|NCT06423924|OTHER|no intervention|no intervention
58442939|NCT00983320|DRUG|quetiapine|flexible dosage (50 to 300 mg)
58442940|NCT00983320|DRUG|placebo|placebo
58442941|NCT04865419|DRUG|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
57739901|NCT05478655|OTHER|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
58442942|NCT04865419|DRUG|Voriconazole|Voriconazole film-coated tablet will be administered orally.
58442943|NCT03716219|OTHER|Exercise Training|Physical activity in children and adults with asthma.
58442944|NCT06341556|DRUG|Zanubrutinib|Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
58442945|NCT02333799|DRUG|Bedaquiline|100mg tablets
58442946|NCT02333799|DRUG|PA-824|200mg tablets
58442947|NCT02333799|DRUG|Linezolid|Scored 600mg tablets
57739902|NCT01507168|DRUG|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
57739903|NCT01507168|DRUG|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
57739904|NCT01371331|DRUG|Tacrolimus granules|oral
58442948|NCT00714415|DRUG|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
58442949|NCT05858892|OTHER|usual care|usual care(rehabilitation program)
58442950|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
58442951|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
57739905|NCT04534231|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
57739906|NCT03616548|DIAGNOSTIC_TEST|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
57739907|NCT04100005|OTHER|No intervention|There is no intervention for this study.
57739908|NCT00796770|BIOLOGICAL|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
57739909|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
57739910|NCT04014608|OTHER|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
57739911|NCT04351256|DRUG|Durvalumab Injection [Imfinzi]|Durvalumab fixed dose of 1,500 mg
57739912|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) conventionally|Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
58109728|NCT05548218|OTHER|Automated health education using a digital health pathway|MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
58109729|NCT04929171|OTHER|Physical Therapy|Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
58109730|NCT03230032|DEVICE|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
58109731|NCT01082198|BIOLOGICAL|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
57739913|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) hypofractionated|Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
58109732|NCT01082198|BIOLOGICAL|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
58109733|NCT01082198|BIOLOGICAL|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
58109734|NCT01082198|BIOLOGICAL|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
58109735|NCT01082198|BIOLOGICAL|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
57739914|NCT05935787|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
58442952|NCT04649515|OTHER|0.9% saline|Placebo
58442953|NCT05292716|DEVICE|MitraClip|MitraClip
58442954|NCT05211427|PROCEDURE|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
58109736|NCT01082198|OTHER|flow cytometry|
58109737|NCT01082198|PROCEDURE|adjuvant therapy|
58109738|NCT06173895|DRUG|LY3454738|Administered subcutaneously (SC)
58109739|NCT00853931|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
58109740|NCT01625845|DRUG|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
58109741|NCT01625845|OTHER|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
58109742|NCT01625845|BEHAVIORAL|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
58109743|NCT00562692|DRUG|Nesiritide|Nesiritide 4 hour infusion
57739915|NCT05935787|DRUG|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
57739916|NCT03950739|DRUG|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
58109744|NCT00562692|DRUG|Placebo|Placebo infusion
58109745|NCT00325429|DRUG|Vildagliptin|
58109746|NCT06326268|DEVICE|Phototherapy system CareMin650TM|"* As part of preventive treatment: Photobiomodulation sessions will be carried out at a dose of 3 joules for 1 minute 51 seconds, 3 times a week (for a maximum duration of 4 to 6 weeks).~* As part of curative treatment (i.e. for patients developing mucositis, from grade I): photobiomodulation will be carried out at a curative dose of 6 joules daily (for a maximum duration of 4 to 6 weeks ) for 3 minutes 34 seconds."
58109747|NCT04601064|BEHAVIORAL|Collaborative Care Model|Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
58109748|NCT01933828|PROCEDURE|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
58109749|NCT01933828|PROCEDURE|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
58109750|NCT01933828|DEVICE|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
58442955|NCT01669772|DRUG|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
58442956|NCT01669772|DRUG|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
58442957|NCT03084003|DIETARY_SUPPLEMENT|Almonds|
58442958|NCT03084003|DIETARY_SUPPLEMENT|Graham crackers|
58442959|NCT03838081|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
58442960|NCT03838081|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
58109751|NCT01663714|BIOLOGICAL|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
58109752|NCT05547893|OTHER|simulation|participating a simulated clinical ethical situation with simulation patients
57739917|NCT05022030|DRUG|mCapOX plus cetuximab|capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
57739918|NCT05022030|DRUG|mFOLFOX6 plus cetuximab|oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
58109753|NCT05178589|DEVICE|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
58109754|NCT05178589|DEVICE|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
58109755|NCT03330028|DRUG|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
58109756|NCT03330028|DRUG|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
58109757|NCT03330028|DRUG|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
58109758|NCT03330028|DRUG|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
58109759|NCT03330028|DRUG|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
58109760|NCT03330028|DRUG|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
58109761|NCT02713503|OTHER|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
58109762|NCT02713503|OTHER|VisionCoach|Visual field evaluation using VisionCoach
58442961|NCT03838081|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
57739919|NCT06430567|DEVICE|Blood flow restriction (50% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 1) BFR Group with 50% AOP compression~Group 1 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 30-15-15-15 at 40% 1RM (repetition maximum)~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
57739920|NCT06430567|DEVICE|Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
57739921|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
57739922|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
57739923|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
57739924|NCT01163097|DRUG|Palifermin|40 µg/kg IV bolus injections for three consecutive days
57739925|NCT01163097|DRUG|Heparin|Heparin continuous IV infusion
58442962|NCT03838081|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
58442963|NCT00607087|DRUG|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
58442964|NCT00607087|DRUG|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
58442965|NCT00607087|DRUG|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
58442966|NCT05984589|BEHAVIORAL|RISE Personalized Self-Managament Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
57739926|NCT01083251|DRUG|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
57739927|NCT01083251|DRUG|Peginterferon|180 mcg/week
58458452|NCT05574023|DEVICE|Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|"Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
58442967|NCT05984589|BEHAVIORAL|Standardized Self-Managament Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the OT interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
58442968|NCT00048698|PROCEDURE|TMS|
58442969|NCT00048698|PROCEDURE|EEG|
58442970|NCT00037492|PROCEDURE|home-based sessions/family meetings with trained clinician|
58442971|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
58442972|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
58442973|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
58442974|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58442975|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
58442976|NCT03470090|BEHAVIORAL|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
58442977|NCT03470090|BEHAVIORAL|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
58442978|NCT03935243|BEHAVIORAL|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
58442979|NCT03935243|BEHAVIORAL|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
58442980|NCT04030572|DRUG|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
58442981|NCT05242484|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
58442982|NCT05242484|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
58442983|NCT05242484|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
58442984|NCT05242484|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
57739928|NCT01083251|DRUG|Sebivo|Telbivudine 600 mg daily
57739929|NCT01083251|DRUG|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
57739930|NCT02648581|DRUG|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
58442985|NCT06029569|PROCEDURE|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
58442986|NCT06029569|PROCEDURE|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
58442987|NCT05906433|DRUG|Kenalog with bupivacaine Injection|Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
58442988|NCT04563195|DRUG|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
58442989|NCT00122408|DIETARY_SUPPLEMENT|Ergyphilus|5 pills a day of Ergyphilus or placebo
58442990|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
57739931|NCT06246409|BEHAVIORAL|Modernized patient instructions|Patients will be given modernized patient instructions prior to radiotherapy treatment.
58442991|NCT01908478|DRUG|Veliparib|
57739932|NCT06246409|BEHAVIORAL|Existing patient instructions|Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
58442992|NCT01908478|DRUG|Gemcitabine|
57739933|NCT05163574|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of peanut flour (300 mg peanut protein) mixed with well-tolerated fruit mousse.
57739934|NCT05163574|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of peanut flour (150 mg peanut protein) mixed with well-tolerated fruit mousse.
57739935|NCT05959122|DIAGNOSTIC_TEST|CBC serum iron serum ferritin|"1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
57739936|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
57739937|NCT05511363|DRUG|Placebo|Placebo Capsules
58442993|NCT01908478|RADIATION|Intensity modulated radiation therapy|
58442994|NCT01985750|DRUG|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
57739938|NCT00411905|DRUG|Bortezomib|
58442995|NCT01985750|DRUG|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
58442996|NCT06727266|DIAGNOSTIC_TEST|Shoulder ultrasound|The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.
58442997|NCT04728607|DEVICE|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
58442998|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
58442999|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
58443000|NCT05522257|DIAGNOSTIC_TEST|[18F]-JK-PSMA-7 PET/CT scan|A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
58443001|NCT02602522|DRUG|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
58443002|NCT02602522|DRUG|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
58443003|NCT04259125|DIAGNOSTIC_TEST|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
58443004|NCT04259125|OTHER|Survey|Regarding epilepsy and development.
58443005|NCT05586984|PROCEDURE|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
58443006|NCT05586984|PROCEDURE|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
58443007|NCT05654168|DIAGNOSTIC_TEST|Imaging|The thickness of the musculature to be studied will be measured with ultrasonography
58443008|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
58443009|NCT06184750|PROCEDURE|Biopsy|Undergo biopsy
58443010|NCT06184750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58109763|NCT03525665|OTHER|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
58109764|NCT01052805|PROCEDURE|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
58443011|NCT06184750|PROCEDURE|Mammography|Undergo mammography
58443012|NCT06184750|OTHER|Questionnaire Administration|Ancillary studies
58443013|NCT06184750|DRUG|Tamoxifen|Given PO
58443014|NCT06436404|OTHER|Hammock intervention|It is a hammock made of 100% cotton fabric that prevents heat loss and has an internal apparatus to support the position, which can be adapted to the incubator by the researchers.
58443015|NCT06436404|OTHER|Kangaroo care intervention|In the clinic, the baby will receive kangaroo care with his mother in a quiet room with reduced lighting.
58443016|NCT06241053|OTHER|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
58443017|NCT06241053|OTHER|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
58443018|NCT05929287|PROCEDURE|Tablet-based CT|This group will perform digital CT tasks.
58443019|NCT05929287|PROCEDURE|Paper-and-pencil CT group|This group will perform paper-and-pencil CT tasks.
58443020|NCT01049529|DIETARY_SUPPLEMENT|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
58443021|NCT01049529|DIETARY_SUPPLEMENT|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
58443022|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
58443023|NCT05163652|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
58443024|NCT03549104|BEHAVIORAL|Fear Reduction Intervention|FREE
58443025|NCT03549104|BEHAVIORAL|Attention Control|DSMES
58443026|NCT03124576|DEVICE|Implantable loop recorder|Continuous rhythm monitoring Medtronic
58443027|NCT03600740|DEVICE|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
58443028|NCT03468361|OTHER|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
58109765|NCT06526845|OTHER|Video-Conference based rehabilitation|"All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
58109766|NCT06526845|OTHER|Home-Based rehabilitation|"Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
58109767|NCT05509322|OTHER|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
58109768|NCT05509322|OTHER|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
58109769|NCT04102228|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
58109770|NCT04102228|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
58109771|NCT04102228|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
58109772|NCT03295058|DRUG|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
58109773|NCT03295058|DRUG|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
58109774|NCT03295058|PROCEDURE|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
58109775|NCT03295058|DRUG|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
58109776|NCT00651547|DRUG|budesonide/formoterol|
58109777|NCT00651547|DRUG|budesonide|
58109778|NCT00651547|DRUG|formoterol|
58443029|NCT03468361|OTHER|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
58443030|NCT03694717|DRUG|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
58443031|NCT06421584|DEVICE|Surgical telementoring|The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
58443032|NCT01219985|OTHER|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
58443033|NCT03263572|BIOLOGICAL|Blinatumomab|Given IV
58443034|NCT03263572|DRUG|Cytarabine|Given intrathecally via spinal tap
58443035|NCT03263572|DRUG|Methotrexate|Given intrathecally via spinal tap
58443036|NCT03263572|DRUG|Ponatinib|Given PO
58458453|NCT05574023|DEVICE|Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia|"in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
58443037|NCT06726876|DIETARY_SUPPLEMENT|Manuka honey oral rinse.|"Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte"
58443038|NCT06726876|DRUG|Normal saline rinses.|"Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm."
58443039|NCT05938075|BIOLOGICAL|VXCO-100|Sterile suspension for injection
57739939|NCT01556373|OTHER|NA : non interventional study|NA : non interventional study
58109779|NCT04133519|DEVICE|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
57739940|NCT03185533|BEHAVIORAL|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting."
58109780|NCT04133519|DEVICE|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
58312121|NCT05094375|DRUG|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
58312122|NCT05094375|DRUG|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
58312123|NCT02254655|DRUG|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
58312124|NCT02254655|DRUG|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
58312125|NCT00981617|DRUG|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
58312126|NCT00981617|DRUG|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
58312127|NCT00981617|DRUG|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
58312128|NCT00981617|DRUG|Placebo|Matching placebo taken once daily for 12 weeks
58312129|NCT03505346|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
58312130|NCT03408899|DRUG|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
58312131|NCT01587313|DRUG|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
58312132|NCT02542969|DRUG|Simvastatin|
58312133|NCT02542969|DRUG|Rosuvastatin|
58312134|NCT02542969|DRUG|MGL-3196|
58312135|NCT01828658|OTHER|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
58109781|NCT00512174|OTHER|BladderScan BVI 3000|
58109782|NCT04878874|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
58312136|NCT03048786|BEHAVIORAL|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
58312137|NCT03048786|BEHAVIORAL|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
58443040|NCT05938075|BIOLOGICAL|COVID-19 mRNA vaccine|Sterile suspension for injection
58109783|NCT04878874|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
58109784|NCT05521490|OTHER|Usual Care Control|30 minutes of physical activity on each school day.
58443041|NCT04162522|DRUG|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
58443042|NCT04162522|DRUG|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
57739941|NCT01417026|DRUG|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
57739942|NCT05476146|PROCEDURE|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
58109785|NCT05521490|BEHAVIORAL|Physical Activity Enhanced Curriculum|Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
58312138|NCT06261723|PROCEDURE|non-chirurgical periodontal treatment|The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
58443043|NCT03744767|DRUG|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
57739943|NCT00686166|BIOLOGICAL|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78"
57739944|NCT00686166|DRUG|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)"
58312139|NCT02695407|OTHER|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
58312140|NCT02695407|OTHER|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
58312141|NCT03036267|BEHAVIORAL|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
57739945|NCT00686166|DRUG|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78"
58443044|NCT06292780|DRUG|Linvoseltamab|anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
58443045|NCT06727357|DRUG|Chemotherapy|in according to institutional guidelines
58443046|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
58443047|NCT03885024|OTHER|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
58443048|NCT05897229|OTHER|Analysis of costs with patient care during hospitalization|Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
58443049|NCT03127293|DIAGNOSTIC_TEST|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
58443050|NCT04702841|DRUG|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
58443051|NCT01069965|DRUG|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
58443052|NCT01069965|DRUG|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
58443053|NCT01069965|DRUG|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
58443054|NCT01069965|DRUG|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
58443055|NCT01069965|DRUG|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
58443056|NCT01069965|DRUG|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
58443057|NCT00273065|DRUG|Neosaxitoxin|
58443058|NCT06579963|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
58443059|NCT05721521|OTHER|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
58109786|NCT04650607|OTHER|Adverse event after injection of phages|rate and description of adverse event after injection of phages
58312142|NCT03036267|OTHER|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
58443060|NCT05721521|OTHER|Control|30 minute completing seated activities (e.g., wordsearches)
58443061|NCT06726512|DEVICE|XEOS AURA 10|Surgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
58443062|NCT02087449|DEVICE|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
58443063|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
58443064|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
58443065|NCT04880655|DEVICE|WSD|Post debridement and within 24 hours of injury, wound care and WSD applied daily
58443066|NCT04880655|DEVICE|Dressed with bacitracin and petrolatum gauze|Post debridement and within 24 hours of injury, wound care and dressing applied daily
58443067|NCT04827888|PROCEDURE|Orthopaedic surgery|One of the 25 most common orthopedic surgeries reported in the database which are the following as per surgical types: spine surgery (CPT codes 63030, 63047, 22612, 22551 or 22558), trauma (CPT codes 27236, 27125, 27244, 27814, or 27792), sports medicine injuries (CPT codes 29881, 29827, 29880, 29888, 29826, 29877, 29807, or 23412), or joint arthroplasty (CPT codes 27447, 27130, 23472, 27487, 27134, 27446, or 27486).
58443068|NCT01584739|DRUG|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
58443069|NCT01584739|DRUG|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
58443070|NCT01454986|DRUG|ALXN1007|Single dose, IV
58443071|NCT01454986|OTHER|Placebo|Single dose, IV
58443072|NCT02668887|BEHAVIORAL|Quality of Life, status of employment|
58109787|NCT02156349|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
58109788|NCT02156349|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
58109789|NCT06356870|PROCEDURE|BMAC MIXED WITH ALLOGRAFT|Study group
58109790|NCT06356870|PROCEDURE|Cancellous bone from anterior iliac crest|Control group
58109791|NCT06120881|DRUG|Metformin|Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
58312143|NCT00187408|DRUG|Low Molecular Weight Heparin (dalteparin)|
58312144|NCT05989425|DRUG|surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
58312145|NCT06437756|OTHER|Theraband resistance training|Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.
58312146|NCT06437756|OTHER|Conventional Resistance Training|The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
58443073|NCT04240574|DEVICE|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
58443074|NCT06458452|OTHER|Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support|Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
58443075|NCT06543810|OTHER|Hula for Parkinson's|A feasibility study for a Hula program for Parkinson's Disease patients.
58443076|NCT00935311|DRUG|ABT-712 Extended-release|ABT-712 extended-release tablet
58443077|NCT00935311|DRUG|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
58443078|NCT00935311|DRUG|Placebo|Placebo tablet
58443079|NCT05487261|DRUG|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
58443080|NCT05487261|DRUG|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
58443081|NCT05487261|DRUG|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
58443082|NCT05487261|DRUG|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
58443083|NCT02273661|DRUG|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
57739946|NCT00686166|PROCEDURE|therapeutic surgical procedure|Surgical resection
57739947|NCT00686166|RADIATION|radiation therapy|IMRT (intensity-modulated radiation therapy)
57956015|NCT03224429|OTHER|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
58109792|NCT01764854|DRUG|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
58109793|NCT01764854|DRUG|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
58109794|NCT01764854|DRUG|AZD1722 (out-patient)|doses between 5 and 45 mg BID
58443084|NCT02273661|DRUG|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
58443085|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
58443086|NCT06364267|DRUG|Tamoxifen 10 MG|Blinded tamoxifen 10 mg every other day
58443087|NCT06364267|DRUG|Exemestane 25 MG|Blinded exemestane 25 mg every other day
58443088|NCT04829149|OTHER|Observational|Statin therapy group and Rosuzet tablet group
58443089|NCT06106958|BEHAVIORAL|Home Exercise Program|"Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily."
57956016|NCT03224429|OTHER|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
57956017|NCT03891940|PROCEDURE|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
57956018|NCT03623607|OTHER|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
58109795|NCT01764854|DRUG|Placebo|Placebo, size and color matched to experimental drug
58109796|NCT03172260|DEVICE|E Balance Pro Therapy|Micro-current treatment
58109797|NCT00630682|DRUG|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
58109798|NCT00630682|DRUG|Placebo|9 weeks of placebo 60mg capsules QD.
58109799|NCT05056337|DRUG|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
58109800|NCT05056337|DRUG|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
58109801|NCT05056337|PROCEDURE|TACE|Hepatic arterial chemoembolization
58312147|NCT05553717|DRUG|Carvedilol|Carvedilol 12.5mg\\12hr
58443090|NCT06106958|BEHAVIORAL|Minimalist Shoes|"Participants will receive a pair of minimalist shoes. They will wear them for an allotted amount of time per day each week, in order to allow for a slow adjustment into the shoes. The protocol is as follows:~* Week 1: 1 hour per day~* Week 2: 2 hours per day~* Week 3: 4 hours per day~* Week 4: 6 hours per day~* Week 5: 8 hours per day~* Week 6: 8 hours per day~* Week 7: 8 hours per day~* Week 8: 8 hours per day"
58443091|NCT05379595|DRUG|Amivantamab|Amivantamab will be administered as intravenous infusion.
58443092|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
58443093|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
58443094|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
58443095|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
58443096|NCT00002359|BIOLOGICAL|HIV-1 Immunogen|
58443097|NCT04339829|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
58443098|NCT02641470|DIETARY_SUPPLEMENT|DA9301 (Vaccinium uliginosum extract)|
58443099|NCT02641470|DIETARY_SUPPLEMENT|Placebo|
58443100|NCT04185675|DEVICE|The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.|All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
58443101|NCT04327947|OTHER|Hyaluronic acid - Research product 1|Health care product (intimate gel)
58443102|NCT04327947|OTHER|Hyaluronic acid - Research product 2|Health care product (intimate gel)
58443103|NCT04327947|OTHER|Hyaluronic acid - Comparator product|Health care product (intimate gel)
58443104|NCT03484247|OTHER|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
58443105|NCT03484247|OTHER|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
58443106|NCT00392730|DIETARY_SUPPLEMENT|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
58443107|NCT04077853|DRUG|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
58443108|NCT03575728|OTHER|MyChart-MHT|All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
58443109|NCT03223116|PROCEDURE|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
58443110|NCT01354717|DRUG|Brand Carac|treatment of actinic keratosis
58443111|NCT01354717|DRUG|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
58109802|NCT05565183|DIAGNOSTIC_TEST|MRI (with injection of contrast product)|All patients included in the study will undergo two MRI examinations (with injection of contrast product) before and after the ablation procedure.
58109803|NCT03049956|DIAGNOSTIC_TEST|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
58443112|NCT01354717|OTHER|Placebo cream|treatment of actinic keratosis
58443113|NCT01077401|DRUG|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
58443114|NCT01077401|DRUG|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
58443115|NCT05010980|OTHER|CMR|clinical indication
58443116|NCT05010980|OTHER|scintigraphy|clinical indication
58109804|NCT05214157|PROCEDURE|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
58443117|NCT05281198|DIETARY_SUPPLEMENT|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
58443118|NCT05281198|DIETARY_SUPPLEMENT|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
58443119|NCT00519051|OTHER|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
58443120|NCT06149208|BEHAVIORAL|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
58443121|NCT00116220|DRUG|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
58443122|NCT00116220|RADIATION|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
58443123|NCT03639025|DEVICE|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
58443124|NCT05717400|DRUG|Bevacizumab|Given by vein (IV)
58109805|NCT03618082|DRUG|Anesthesic agent guided by ANI (Interventional Group)|Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
58109806|NCT03618082|DRUG|Administration of the lowest effective concentration of desflurane (Interventional Group)|Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
58109807|NCT06385977|BEHAVIORAL|lifestyle|Life habits and personal preferences
58109808|NCT06385977|BEHAVIORAL|sexual habits|Sexual experience and activities
58109809|NCT06385977|DRUG|medication|use of medication
58109810|NCT04959110|DIAGNOSTIC_TEST|Pharmacokinetic study|"* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter"
58443125|NCT05717400|DRUG|Atezolizumab|Given by vein (IV)
58443126|NCT05717400|DRUG|Sofosbuvir|Given by PO
58443127|NCT05717400|DRUG|Velpatasvir|Given by PO
58443128|NCT05717400|DRUG|Voxilaprevir|Given by PO
58443129|NCT05717400|DRUG|Ribavirin|Given by PO
58443130|NCT00726635|BEHAVIORAL|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
58443131|NCT00726635|OTHER|Control group|A one hour conversation with a nurse
58443132|NCT00726635|OTHER|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
58443133|NCT04275973|DEVICE|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
58443134|NCT04275973|DEVICE|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
58443135|NCT04275973|DEVICE|Footwear|Different footwear will be used.
58443136|NCT04931251|BEHAVIORAL|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
58443137|NCT05958797|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
58109811|NCT02707432|BEHAVIORAL|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
58109812|NCT06092606|DRUG|Control group:DH001 placebo|Dosage: DH001 placebo (8 tablets)
58109813|NCT06092606|DRUG|Trial group: DH001 low-dose group|Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)
58109814|NCT06092606|DRUG|Trial group: DH001 high-dose group|Dosage: DH001 400mg (8 tablets).
58109815|NCT01710826|BIOLOGICAL|Genz-682452|Capsules for oral administration.
58109816|NCT01710826|BIOLOGICAL|Placebo|Placebo capsules matching the Genz-682452 capsules.
58109817|NCT01456702|PROCEDURE|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
58109818|NCT05476679|DRUG|RZL-012|50mg/ml drug formulation
58109819|NCT05476679|DRUG|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
58443138|NCT05958797|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
58443139|NCT02184858|DRUG|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
58458454|NCT00786292|OTHER|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
58458455|NCT00121017|DRUG|Kaletra (lopinavir/ritonavir)|
58458456|NCT00121017|DRUG|Sustiva (efavirenz)|
58458457|NCT00121017|DRUG|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
58109820|NCT05476679|DRUG|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
58109821|NCT05476679|DRUG|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
58109822|NCT05476679|DRUG|RZL-012+facial and neck wrap|Universal Facial Band
58109823|NCT05463783|DRUG|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
58109824|NCT05463783|DRUG|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
58443140|NCT03401255|OTHER|Partosure test|To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal swab provided in the PAMG-1 Detection Test Kit.After removing the swab from its packaging, hold the swab in the middle of the stem and carefully insert the end of the swab into the vagina over a length of 5-7cm (using a speculum). Is not necessary for sampling), when the patient is lying down.Remove the swab from the vagina after 30 seconds. Once the swab has been removed, immediately place the end in the solvent vial provided for this purpose, then rinse the swab by repeating several rotations for 30 seconds. The strip is removed as soon as two bands are clearly visible in the test area, or after 5 minutes.Two bands in the test area indicate a positive result, while a line in the test area indicates a negative result. It is not recommended to read or interpret results beyond 10 minutes of immersion.
58443141|NCT06373146|DRUG|Tirzepatide|Administered SC
58443142|NCT06373146|DRUG|Mibavademab|Administered SC
58443143|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
58109825|NCT01720940|DRUG|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
58109826|NCT01720940|DRUG|intermittent vancomycin infusion|
58109827|NCT01248312|DEVICE|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
58109828|NCT01248312|DEVICE|sentec monitor|transcutaneous monitoring
58109829|NCT00049634|DRUG|busulfan|
58109830|NCT00049634|DRUG|cyclophosphamide|
58109831|NCT00049634|DRUG|cyclosporine|
58109832|NCT00049634|DRUG|methotrexate|
58109833|NCT00049634|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58109834|NCT01051622|OTHER|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
58109835|NCT04536233|BIOLOGICAL|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
58109836|NCT04536233|OTHER|physiological saline|The physiological saline was injected on the wound
58443144|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
58443145|NCT01288989|BIOLOGICAL|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
58443146|NCT03377153|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
58443147|NCT03377153|OTHER|control|no supplementation
58443148|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
58109837|NCT03900611|DEVICE|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
58109838|NCT04351191|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
58109839|NCT04351191|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
58109840|NCT04351191|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
58109841|NCT04351191|DRUG|Placebo|Standard of Care plus placebo
58312148|NCT05806970|OTHER|Email Nudge|An email to UCLA Health Cardiology clinic managers with a list of MRA-eligible HFrEF patients and a request to schedule or change cardiology appointments.
58443149|NCT02877303|DRUG|Cyclophosphamide|Given IV
58443150|NCT02877303|DRUG|Cytarabine|Given IT and IV
58443151|NCT02877303|DRUG|Dexamethasone|Given PO
58443152|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
58443153|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
58443154|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
58443155|NCT02877303|DRUG|Mercaptopurine|Given PO
58443156|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
58443157|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
58443158|NCT02877303|DRUG|Prednisone|Given PO
58443159|NCT02877303|BIOLOGICAL|Rituximab|Given IV
58443160|NCT02877303|DRUG|Vincristine Sulfate|Given IV
58109842|NCT00096382|BIOLOGICAL|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
58109843|NCT00096382|BIOLOGICAL|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.
58109844|NCT00096382|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
58109845|NCT00096382|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
58109846|NCT00096382|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
58109847|NCT00096382|RADIATION|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
58109848|NCT04304326|OTHER|Resistence Exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
58109849|NCT04614974|DRUG|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
58109850|NCT04614974|OTHER|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
58109851|NCT05163379|OTHER|MOBILIZATION|EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
58109852|NCT05723627|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
58109853|NCT05723627|DRUG|Propofol|Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
58109854|NCT00628394|DRUG|Atomoxetine|40mg 2po qam
58109855|NCT00628394|DRUG|Placebo|40mg 2po qam
58109856|NCT02277873|BEHAVIORAL|pregnancy|Observational study in order to establish relationship between moon and births
58109857|NCT02961452|OTHER|Cross reaction detection|
58109858|NCT05358873|DEVICE|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
58109859|NCT05358873|DEVICE|Placebo|Normal saline
58109860|NCT05423691|DRUG|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
58109861|NCT01914822|DRUG|methylphenidate hydrochloride|
58109862|NCT01914822|DRUG|Sugar pill (placebo)|
58109863|NCT05992545|DEVICE|Mobile application 'DangDang Care' under usual care|"The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care."
58109864|NCT02963298|PROCEDURE|Continuous renal replacement therapy|
58109865|NCT04624022|DIAGNOSTIC_TEST|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
57739948|NCT05228600|DRUG|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
58109866|NCT04270526|DRUG|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
58109867|NCT04270526|DRUG|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
58443161|NCT04843761|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
57739949|NCT02111590|DRUG|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
58109868|NCT04505514|DRUG|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
58109869|NCT04505514|DRUG|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding"
58109870|NCT04505514|DRUG|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
58109871|NCT01876199|BEHAVIORAL|intense follow up|
58109872|NCT00995332|DRUG|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
58109873|NCT03016078|DEVICE|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
58109874|NCT03960918|BEHAVIORAL|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
58109875|NCT03120702|DEVICE|Investigational Rainbow SpHb sensor|Investigational Rainbow SpHb sensor
58109876|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
58109877|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol/ Triclosan|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
57739950|NCT03955601|DRUG|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
57739951|NCT03594669|OTHER|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
58109878|NCT00285350|DRUG|mycophenolate mofetil|
58109879|NCT04347590|DEVICE|Unblinded - CGM (Medtronic Guardian)|Data from device will be readable and alarms on
57739952|NCT02557152|DEVICE|GentleWave System Treatment|
58109880|NCT04347590|DEVICE|Blinded - CGM (Medtronic Guardian)|Data from device will be blinded and alarms off
58109881|NCT00446654|DRUG|CGC-11047|16.5 mg (3.3%) subconjunctival injection
58443162|NCT04843761|DRUG|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
58443163|NCT04843761|BIOLOGICAL|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
58443164|NCT04843761|DRUG|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
58443165|NCT04843761|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
57739953|NCT05557045|DRUG|JZP815|JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
58109882|NCT05341557|DRUG|BPI-371153|Subjects will receive BPI-371153 until disease progression
58109883|NCT02112812|DRUG|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
58109884|NCT02112812|DRUG|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
58109885|NCT02112812|DRUG|Eradication therapy for Helicobacter pylori|
58109886|NCT06521034|DRUG|FHND-9041|"In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled."
58109887|NCT05880563|DRUG|[18F]-RoSMA-18-d6|\[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
58109888|NCT03875391|DRUG|Oxytocin|Drug: Oxytocin nasal spray
58443166|NCT04700540|DEVICE|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
58443167|NCT02489292|BIOLOGICAL|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
58109889|NCT03875391|DRUG|Placebo|Drug: Placebo nasal spray
57739954|NCT03769142|PROCEDURE|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
57739955|NCT02925455|DEVICE|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
58109890|NCT00448682|DRUG|Docetaxel|
58109891|NCT00448682|DRUG|Floxuridine|
58443168|NCT02923570|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
58443169|NCT02923570|RADIATION|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
58443170|NCT02905630|OTHER|Exercise training|high intensity aerobic interval training
58443171|NCT04208438|DIAGNOSTIC_TEST|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
58443172|NCT04208438|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
58443173|NCT06069414|OTHER|Type of anesthesia induction|Patients will receive inhalatory or intravenous anesthesia at their choice; both groups will be evaluated with lung ultrasound after induction to detect ultrasonografic signs of atelectasis
58109892|NCT00448682|DRUG|Leucovorin|
58109893|NCT00448682|DRUG|Oxaliplatin|
57739956|NCT02925455|DEVICE|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
57739957|NCT05338333|DEVICE|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
58109894|NCT01489956|BIOLOGICAL|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
58109895|NCT01489956|BIOLOGICAL|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
58109896|NCT01489956|BIOLOGICAL|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
58109897|NCT03372369|OTHER|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
58109898|NCT03372369|OTHER|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
58109899|NCT01960933|PROCEDURE|Percutaneous coronary intervention|
58109900|NCT01960933|PROCEDURE|FFR|
58109901|NCT04726917|BEHAVIORAL|Pulmonary rehabilitation|Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
58109902|NCT01551550|PROCEDURE|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
58109903|NCT01551550|PROCEDURE|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
58109904|NCT01551550|PROCEDURE|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
57739958|NCT05338333|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
57739959|NCT05338333|DEVICE|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
57739960|NCT01788748|DEVICE|bipolar radiofrequency and infrared|
58109905|NCT00654303|DRUG|Rosuvastatin|
58443174|NCT02950909|PROCEDURE|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
57739961|NCT01788748|DEVICE|fractional bipolar radiofrequency|
57739962|NCT01952626|DRUG|Ondansetron|intravenous injection
57739963|NCT01952626|DRUG|Palonosetron|intravenous injection
57739964|NCT06063226|OTHER|Experimental|Orally administred probiotics with L. plantarum and L. rhamnosus
57739965|NCT06063226|OTHER|Negative control|Only routinary oral hygiene procedures
57739966|NCT06063226|OTHER|Positive control|Orally administred placebo without probiotics
57739967|NCT05019430|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
58109906|NCT04898023|DRUG|zinc-green tea extract-ascorbic acid|Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
58109907|NCT04898023|DRUG|Placebo|Compounded capsules containing microcrystalline cellulose.
58109908|NCT06407895|OTHER|Lower Limb Fitness Program|the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity
58109909|NCT06407895|OTHER|Routine Therapy|In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
58109910|NCT01347398|PROCEDURE|PSG|Sleep study made by PSG (polysomnography)
58109911|NCT01347398|PROCEDURE|MicroMESAM system|Sleep study made by MicroMESAM system
58443175|NCT02950909|PROCEDURE|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
57739968|NCT05019430|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
57739969|NCT05019430|DRUG|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
57739970|NCT00615043|PROCEDURE|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
57739971|NCT06703060|BEHAVIORAL|Peer Navigation Group|Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
58109912|NCT05750225|OTHER|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
58109913|NCT05750225|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
58109914|NCT04942379|OTHER|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
58109915|NCT04942379|OTHER|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
58109916|NCT00879970|DRUG|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
58109917|NCT00879970|DRUG|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
57739972|NCT01270126|DEVICE|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
57739973|NCT03896035|BEHAVIORAL|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
57739974|NCT00045110|DRUG|erlotinib hydrochloride|given orally
57739975|NCT00045110|OTHER|laboratory biomarker analysis|correlative studies
58443176|NCT02950909|PROCEDURE|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
57739976|NCT00045110|OTHER|pharmacological study|correlative studies
58109918|NCT00879970|DRUG|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
58109919|NCT00879970|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D factor intervention
58109920|NCT00879970|DIETARY_SUPPLEMENT|Placebo|Vitamin D factor intervention
58109921|NCT00790075|DRUG|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was \>30 minutes.
58109922|NCT01537575|BIOLOGICAL|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
58109923|NCT01537575|BIOLOGICAL|Saline solution|Placebo
58443177|NCT02950909|PROCEDURE|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
58443178|NCT06216821|DRUG|standard DAPT|standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
58443179|NCT06216821|DRUG|OPT-CAD score guided DAPT de-escalation|De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
57739977|NCT00874861|BIOLOGICAL|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
57739978|NCT04447326|DRUG|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
57739979|NCT04447326|DRUG|IC＋CCRT|IC＋CCRT
57769638|NCT02757222|RADIATION|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
58109924|NCT03757585|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
58109925|NCT03757585|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
58109926|NCT01188954|DRUG|doxycycline|50 ml/mg
58109927|NCT01188954|OTHER|No intervention|Normal Saline/Water
58109928|NCT00778271|DRUG|Gabapentin 400mg capsules|
58109929|NCT01557270|DRUG|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
58109930|NCT01557270|DRUG|saline|ropivacaine + saline placebo, single shot perineural application
58109931|NCT04447833|DRUG|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
58109932|NCT02525029|DRUG|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
58443180|NCT04131062|BEHAVIORAL|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
58443181|NCT00706420|PROCEDURE|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
58443182|NCT00706420|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
58443183|NCT00223483|GENETIC|Isolation of genomic DNA|One time blood draw
58443184|NCT02312050|DRUG|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
58443185|NCT02312050|DRUG|Placebo|
58443186|NCT00291018|DEVICE|Total Disc Replacement|Total Disc Replacement using ProDisc-C
58109933|NCT04808245|DRUG|Tecentriq 1200 MG in 20 ML Injection|One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
58109934|NCT04808245|BIOLOGICAL|H3K27M peptide vaccine|The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
58109935|NCT04808245|OTHER|Imiquimod (5%)|One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
58109936|NCT05683314|PROCEDURE|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
58109937|NCT00381056|BEHAVIORAL|Labor and Delivery Team Coordination Course|
58109938|NCT00003533|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58109939|NCT03723590|DEVICE|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
57739980|NCT04567472|BEHAVIORAL|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
58109940|NCT00677924|DRUG|Zalutumumab|Solution for infusion
57739981|NCT04461301|PROCEDURE|Multimodal Prehabilitation|A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
57739982|NCT00496041|PROCEDURE|Registry|A Registry will be used.
57739983|NCT00001587|PROCEDURE|Isolated hepatic portal and arterial perfusion|
58109941|NCT05207319|OTHER|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
57739984|NCT00001587|DRUG|Melphalan|
58109942|NCT02557594|DRUG|Viread 300mg|single dose administration after 10hr fasting
58109943|NCT02557594|DRUG|DA-2802 319mg|single dose administration after 10hr fasting
58109944|NCT00772252|OTHER|liver support treatment|plasma exchange for liver support treatment
58443187|NCT00291018|DEVICE|ACDF|Anterior Cervical Discectomy and Fusion
57739985|NCT04653103|PROCEDURE|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
57769639|NCT03145467|DRUG|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
58443188|NCT06362317|DRUG|Toripalimab|Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.
57769640|NCT03145467|DRUG|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
58443189|NCT06362317|DRUG|Lenvatinib|When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
57739986|NCT03330379|DEVICE|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
57769641|NCT05266105|DRUG|Palazestrant|Complete Estrogen Receptor Antagonist
58109945|NCT05681377|DRUG|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
58109946|NCT06528223|DIAGNOSTIC_TEST|biopsy or operation|To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
58443190|NCT06362317|DRUG|Gemox Chemotherapy（Gemox or GC）|"Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1."
58443191|NCT00674414|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
58443192|NCT00674414|DRUG|everolimus|Oral everolimus once daily
58443193|NCT00674414|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
58443194|NCT00255788|DRUG|everolimus|
58443195|NCT04556279|PROCEDURE|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
58443196|NCT04556279|DRUG|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
58443197|NCT02005588|DRUG|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
58443198|NCT02005588|DRUG|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
58443199|NCT05750576|DEVICE|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
58443200|NCT05750576|DEVICE|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
58443201|NCT03434158|DRUG|Olaparib|300 mg twice a day
58443202|NCT01624116|DRUG|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
58443203|NCT01624116|OTHER|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
58443204|NCT01624116|DRUG|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
58443205|NCT01624116|DRUG|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
58443206|NCT01624116|DRUG|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
58443207|NCT03432169|OTHER|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
58443208|NCT03432169|OTHER|Stretching|Stretching alone
58443209|NCT05668286|DRUG|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
58443210|NCT02669251|DRUG|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
58443211|NCT06507930|OTHER|Telehealth Hospice Visits|Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
58443212|NCT02899091|BIOLOGICAL|CB-AC-02|"Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)"
58443213|NCT02899091|BIOLOGICAL|Placebo|"Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)"
58443214|NCT03648957|BEHAVIORAL|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
57739987|NCT02346383|DEVICE|preset program|Change to different present program using epidural and peripheral lead to cover pain
57739988|NCT00541515|DEVICE|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
58443215|NCT03648957|BEHAVIORAL|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
58443216|NCT03648957|DEVICE|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
58109947|NCT03994588|PROCEDURE|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
58109948|NCT03845478|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
58109949|NCT03845478|BEHAVIORAL|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
58109950|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect \& cigarettes are available.
58109951|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
58109952|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
58109953|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
58109954|NCT04376489|BEHAVIORAL|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
58109955|NCT04376489|BEHAVIORAL|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
58109956|NCT04376489|BEHAVIORAL|Joy|Smart phone app that teaches participants to practice breathing exercise.
58109957|NCT04376489|BEHAVIORAL|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
58109958|NCT04376489|BEHAVIORAL|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
58109959|NCT01122472|DRUG|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
58109960|NCT01122472|DRUG|Placebo|Daily for 3 weeks every 4 weeks for 24 months
57739989|NCT01445938|DRUG|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
57739990|NCT01445938|DRUG|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
57739991|NCT05187676|DEVICE|Oxygen saturation measurement using the IPAM device|Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
57739992|NCT05187676|DEVICE|Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device|Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
58109961|NCT03503656|DEVICE|epidural catheter placement|insertion of an epidural catheter using Compuflo System
58109962|NCT01127191|OTHER|military equipment|Military exercise of 24 hours
57739993|NCT00160433|DRUG|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
57739994|NCT00160433|DRUG|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
58109963|NCT04104711|OTHER|Home visits, health education|
58109964|NCT02958878|DRUG|Tamsulosin|
58109965|NCT02958878|DRUG|Placebo Oral Capsule|
58109966|NCT01565382|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
58109967|NCT06267547|OTHER|HAIL Online Platform|The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F\&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F\&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F\&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F\&S! program, which yielded positive results.
58109968|NCT06267547|BEHAVIORAL|Fit and Strong! Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
57739995|NCT00160433|DRUG|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
57739996|NCT00160433|DRUG|Placebo|Tablet, oral Daily for 12 weeks
57739997|NCT06500481|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
58443217|NCT05877755|DEVICE|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
58443218|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
58443219|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
58443220|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
58443221|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
58443222|NCT02023996|DEVICE|PET imaging|
58443223|NCT05257629|COMBINATION_PRODUCT|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
58443224|NCT05257629|OTHER|Varenicline Plus Counseling|Varenicline plus counseling
58443225|NCT03286452|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
58443226|NCT00369213|DEVICE|Additional spermicidal lubricant to condoms|
58443227|NCT05181644|DEVICE|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
58443228|NCT05181644|PROCEDURE|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
58443229|NCT03674632|BEHAVIORAL|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
58443230|NCT03208634|DEVICE|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
57739998|NCT06500481|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57739999|NCT06500481|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
57740000|NCT06500481|PROCEDURE|Lumbar Puncture|Undergo LP
57740001|NCT06500481|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57740002|NCT06500481|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57740003|NCT06500481|RADIATION|Proton Beam Craniospinal Irradiation|Undergo pCSI
57740004|NCT06500481|OTHER|Quality-of-Life Assessment|Ancillary studies
57740005|NCT01850225|DEVICE|Auditory brainstem implant|
57740006|NCT01152580|DIETARY_SUPPLEMENT|melatonin|3mg p.o. at bedtime daily
57740007|NCT01152580|DIETARY_SUPPLEMENT|sugar pill|lactose p.o. at bedtime daily
57740008|NCT05326464|DRUG|Tofacitinib 10mg|10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
57740009|NCT00092534|BIOLOGICAL|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
58443231|NCT06017726|OTHER|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
58443232|NCT00592904|DRUG|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
58109969|NCT05456828|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
58109970|NCT00879554|BIOLOGICAL|CVX-045|Weekly, intravenous dose
58109971|NCT01714505|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
58109972|NCT03877874|DRUG|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
57740010|NCT00092534|BIOLOGICAL|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
57740011|NCT02657980|DEVICE|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
57740012|NCT02657980|DEVICE|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
58109973|NCT02262949|DEVICE|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
58109974|NCT01710306|BEHAVIORAL|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
58109975|NCT01984281|BEHAVIORAL|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
58109976|NCT01181661|BEHAVIORAL|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
58109977|NCT01181661|BEHAVIORAL|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
57740013|NCT06333925|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)|10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)
57740014|NCT06333925|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)|inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)
57740015|NCT06333925|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
58109978|NCT00459082|DRUG|Dexmedetomine|
58109979|NCT03559764|BIOLOGICAL|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
58109980|NCT05745064|DRUG|TL-925|TL-925 is an eye drop.
58109981|NCT05745064|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
58109982|NCT04929197|DEVICE|PERSBRA|"After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA."
58443233|NCT03078894|DIAGNOSTIC_TEST|Zika|Zika Diagnostic test
58443234|NCT03078894|DIAGNOSTIC_TEST|Chikagunya|Chikagunya Diagnostic test
58443235|NCT03078894|DIAGNOSTIC_TEST|Dengue|Dengue Diagnostic test
57740016|NCT01362140|DRUG|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
57740017|NCT01362140|DRUG|Placebo|Administered by subcutaneous injection every 3 weeks
57740018|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo lower dose platelet transfusion
57740019|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo higher dose platelet transfusion
57769642|NCT05266105|DRUG|Palbociclib|Palbociclib is an approved CDK 4/6 Inhibitor drug
58109983|NCT05380830|OTHER|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
58109984|NCT05206136|DEVICE|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
58109985|NCT05687656|DEVICE|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
58109986|NCT00636428|DRUG|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
58109987|NCT00644371|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
58109988|NCT05824299|PROCEDURE|General Anesthesia|Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.
58312149|NCT00522834|DRUG|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
58312150|NCT00522834|DRUG|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
58312151|NCT02136693|DRUG|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
58312152|NCT02136693|DRUG|Placebo|3.5 g /day of inert compound for 180 days after STARR
58312153|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
58312154|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
58312155|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
58312156|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
58312157|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
58312158|NCT00877968|DIETARY_SUPPLEMENT|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
58443236|NCT01378442|OTHER|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
58443237|NCT03308708|DRUG|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
58312159|NCT00877968|DIETARY_SUPPLEMENT|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
58312160|NCT00877968|DIETARY_SUPPLEMENT|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --\> 250 g cooked Available CHO: 52.8 g"
58443238|NCT00780416|DRUG|MP-424|750 mg every 8 hours for 12 weeks
58312161|NCT06269783|BEHAVIORAL|sipIT|Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
58312162|NCT03513419|BEHAVIORAL|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
58443239|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
58443240|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
58443241|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
58443242|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
58443243|NCT02705196|GENETIC|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
58443244|NCT02705196|DRUG|gemcitabine|chemotherapy
58443245|NCT02705196|DRUG|nab-paclitaxel|chemotherapy
58109989|NCT05824299|PROCEDURE|Spinal Anesthesia|Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
58109990|NCT00525031|DRUG|Temozolomide (TMZ)|150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
58109991|NCT00525031|DRUG|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
58443246|NCT02705196|BIOLOGICAL|atezolizumab|anti-PD-L1 antibody
58443247|NCT04741919|PROCEDURE|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
58443248|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
58443249|NCT06704724|DRUG|PF-07985045|KRAS inhibitor
58443250|NCT06704724|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
58443251|NCT06704724|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
58443252|NCT06704724|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
58443253|NCT06704724|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
58443254|NCT06704724|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
58443255|NCT06704724|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
58109992|NCT00368329|DRUG|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
57740020|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
57740021|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
58109993|NCT00368329|DRUG|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
58109994|NCT00368329|DRUG|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
58109995|NCT00368329|DRUG|Carboplatin|AUC 2, based onCalvert formula IV infusion
58109996|NCT03157063|DIAGNOSTIC_TEST|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
58109997|NCT03569163|DEVICE|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
58109998|NCT05168059|DRUG|Clevidipine 0.5 MG/ML Intravenous Emulsion|Effectiveness and safety of clevidipine
58443256|NCT06704724|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
58443257|NCT06704724|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor
57740022|NCT03088267|DRUG|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
58109999|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
58110000|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
58443258|NCT06704724|COMBINATION_PRODUCT|Sasanlimab|immune checkpoint inhibitor (PD-1 inhibitor)
58443259|NCT06704724|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
58443260|NCT06704724|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
58443261|NCT06704724|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
58443262|NCT06704724|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
58443263|NCT06704724|COMBINATION_PRODUCT|PF-07284892|SHP2 Inhibitor
58443264|NCT05133765|DEVICE|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
58443265|NCT04759157|BEHAVIORAL|Couples-based treatment|Couples will attend 3, video based sessions for couples-based treatment
58443266|NCT04759157|OTHER|Standardized education|Patients will receive standardized educational materials
58443267|NCT03266406|DRUG|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
58110001|NCT04221581|DEVICE|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
58110002|NCT01975090|DEVICE|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
58110003|NCT02700802|OTHER|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
58110004|NCT01508156|DRUG|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
58110005|NCT01508156|DRUG|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
58110006|NCT04199780|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
58110007|NCT04199780|BEHAVIORAL|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
58110008|NCT03520621|OTHER|No intervention|no intervention
58110009|NCT01004692|DEVICE|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
58110010|NCT02101320|DEVICE|TRECAM|using the camera during the surgery
58110011|NCT00436878|BEHAVIORAL|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
58110012|NCT01294878|DRUG|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
58110013|NCT00864487|DRUG|Neratinib|HKI-272
57740023|NCT03088267|DRUG|Placebo extended-release oral suspension|6, 7 or 8 mL PO
57740024|NCT00608582|DEVICE|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
58110014|NCT03659968|OTHER|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
58110015|NCT03806322|OTHER|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
58110016|NCT03806322|OTHER|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
58312163|NCT06243445|DIAGNOSTIC_TEST|Transthoracic echocardiography for central venous catheter tip location|Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
57740025|NCT04789668|DRUG|Bintrafusp Alfa|Given IV
57740026|NCT04789668|DRUG|Pimasertib|Given PO
57740027|NCT04789668|OTHER|Quality-of-Life Assessment|Ancillary studies
57740028|NCT06724991|PROCEDURE|Lower Dose Therapy|The group receiving the lower-dose therapy consists of 5 units of Actrapid (insulin) with 25cc of Dextrose 50%. This intervention is the focus of the clinical trial and is being investigated to determine if it achieves a comparable reduction in potassium levels with fewer potential complications. The aim is to establish it as a non-inferior alternative to conventional-dose therapy in the management of mild and moderate hyperkalemia.
57769643|NCT01526811|DEVICE|Endurant Stent graft|Endurant Stent graft implantation
58110017|NCT01503359|DIETARY_SUPPLEMENT|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
58312164|NCT05916209|PROCEDURE|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
58312165|NCT04297592|DRUG|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
58312166|NCT04297592|DRUG|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
57769644|NCT04855292|DRUG|TG103 injection|TG103 injection, SC, once weekly
57769645|NCT04855292|DRUG|Placebo|Placebo control, SC, once weekly
57740029|NCT06724991|PROCEDURE|Conventional Dose Therapy|The group receiving the conventional-dose therapy, consisting of 10 units of Actrapid (insulin) with 50cc of Dextrose 50%, which is currently in use as a standard practice in emergency departments for managing mild and moderate hyperkalemia. This dosing regimen aligns with established clinical guidelines and is widely accepted as an effective approach in controlling potassium levels.
57740030|NCT02776358|OTHER|High Fidelity Simulation|"A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
57740031|NCT02776358|OTHER|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
58312167|NCT04297592|DRUG|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
58443268|NCT05452733|BEHAVIORAL|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
58443269|NCT01310764|PROCEDURE|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
58443270|NCT02502942|BEHAVIORAL|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
58443271|NCT02502942|BEHAVIORAL|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
58443272|NCT00704704|DRUG|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
57740032|NCT02154763|DRUG|Ropivacaine|
58312168|NCT03442452|OTHER|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
58312169|NCT02243748|OTHER|Palliative Therapy|Receive individualized palliative care
58312170|NCT02243748|OTHER|quality-of-life assessment|Ancillary studies
58312171|NCT02243748|OTHER|questionnaire administration|Ancillary studies
58312172|NCT05449665|OTHER|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
58312173|NCT05449665|OTHER|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
58312174|NCT05449665|OTHER|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
58312175|NCT04425317|DIAGNOSTIC_TEST|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
58312176|NCT04040439|DRUG|Dexmedetomidine Hydrochloride|"\[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
58312177|NCT04689542|OTHER|Sit-To-Stand test|The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
58312178|NCT00524498|DRUG|OPC-18|OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
58312179|NCT00524498|DRUG|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
58312180|NCT06436716|RADIATION|MRI|Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
58312181|NCT02427867|OTHER|Remote ischemic preconditioning|
58312182|NCT02427867|OTHER|no ischemic preconditioning|
58443273|NCT02094092|OTHER|ProTectis drops (five drops per day) for 21 days|
58443274|NCT02094092|OTHER|Placebo drops (five drops per day) for 21 days|
58443275|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58443276|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
58443277|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
57740033|NCT02154763|DRUG|Normal Saline|
57740034|NCT05526105|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
57740035|NCT01959724|OTHER|Vitrectomy|
58312183|NCT00701363|DRUG|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
58110018|NCT05733650|BIOLOGICAL|Epcoritamab|Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
58110019|NCT05700357|PROCEDURE|TPVB with 20 ml|The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
58110020|NCT05700357|PROCEDURE|TPVB with 25 ml|The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
58443278|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
58110021|NCT05700357|PROCEDURE|TPVB with 30 ml|The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
57769646|NCT02490618|OTHER|Probiotic tablet- Biogaia|
58110022|NCT03826485|DRUG|PRIC|Pranlukast hydrate 50mg
58110023|NCT03826485|DRUG|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
58110024|NCT02429401|BEHAVIORAL|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
58110025|NCT02429401|BEHAVIORAL|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
58110026|NCT03469271|DRUG|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
58110027|NCT03469271|OTHER|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
58110028|NCT03469271|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
58110029|NCT03469271|OTHER|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
58110030|NCT03469271|DEVICE|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
57769647|NCT02490618|OTHER|Placebo tablet|
58110031|NCT05744661|OTHER|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
58110032|NCT05744661|OTHER|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
58110033|NCT01792284|DRUG|LY2605541|
58110034|NCT01792284|DRUG|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
58312184|NCT05157373|DIAGNOSTIC_TEST|Endometrial sampling and Peripheral blood collection|The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.
58443279|NCT05930496|OTHER|Interview|Ancillary studies
58443280|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
58443281|NCT05970991|BEHAVIORAL|Brief Online Training (BOLT) for measurement-based care (MBC)|Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.
58110035|NCT03119064|DRUG|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
58110036|NCT03119064|DRUG|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
58110037|NCT03269175|OTHER|Brain MRI|Brain MRI will be performed
58110038|NCT03269175|OTHER|Blood sampling|Blood samples will be taken
57740036|NCT04340206|BEHAVIORAL|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
57740037|NCT04340206|BEHAVIORAL|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
57956019|NCT03658486|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
57956020|NCT01224184|BEHAVIORAL|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
57956021|NCT01224184|BEHAVIORAL|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
57956022|NCT03074474|DEVICE|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
58443282|NCT05970991|BEHAVIORAL|Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)|The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.
58443283|NCT05970991|BEHAVIORAL|Live Post-Training Consultation|Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.
58443284|NCT05970991|BEHAVIORAL|Asynchronous Discussion Board|An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
58443285|NCT02560272|BIOLOGICAL|Minhai-HIB|0.5ml, intramuscular
58110039|NCT05961254|DEVICE|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
58110040|NCT06206733|DRUG|ASKB589|ASKB589 will be administered as a minimum 3-hour IV infusion
58443286|NCT02560272|BIOLOGICAL|Act-HIB®|0.5ml, intramuscular
58443287|NCT01481337|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
58443288|NCT02270112|DEVICE|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
58443289|NCT04543227|BEHAVIORAL|Opioid Use 90-Days Post Treatment|Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
58443290|NCT01332253|DRUG|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
58443291|NCT01332253|OTHER|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
58443292|NCT05785429|DRUG|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
58443293|NCT05785429|DRUG|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
58110041|NCT06206733|DRUG|Oxaliplatin|Oxaliplatin will be administered as a minimum 2-hour IV infusion
58110042|NCT06206733|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
58443294|NCT04325828|DRUG|Apalutamide|Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
58443295|NCT04325828|DRUG|GnRH Agonist|A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
58443296|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
58110043|NCT06206733|DRUG|Tislelizumab|Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
58110044|NCT06206733|DRUG|Placebo|Placebo will be administered as a minimum 3-hour IV infusion
58110045|NCT01164735|OTHER|Laboratory Biomarker Analysis|Correlative studies
58110046|NCT06319391|OTHER|CYP3A5*1*、CYP3A5*1*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
58110047|NCT06319391|OTHER|CYP3A5*3*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
58110048|NCT00707174|DRUG|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
57740038|NCT04340206|BEHAVIORAL|Control group, no intervention|Behavioral: No intervention
57740039|NCT03602131|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
57740040|NCT03602131|DRUG|Cladribine|6 mg/m2 intravenously once daily for 5 days
57740041|NCT03602131|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
57740042|NCT03602131|DRUG|Busulfan|3.2 mg/kg intravenously once daily for 4 days
57740043|NCT03602131|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
57740044|NCT05214872|DIAGNOSTIC_TEST|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~* hemoglobin (HGB) \[g/dl\];~* red blood count (RBC) \[10\^12/l\];~* hematocrit (HCT) \[l/l\];~* white blood cells (WBC) \[10\^9/l\];~* platelet count (PLT) \[10\^9/l\]"
58110049|NCT00707174|DRUG|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
58110050|NCT03221946|DRUG|Diclofenac Sodium|tablet of 50mg,
58110051|NCT03221946|DRUG|Diclofenac sodium|Transdermal patch 100 mg
58110052|NCT03221946|DRUG|Diclofenac|intra muscular injection 100mg
58110053|NCT00323674|DEVICE|Polysoft Mesh|Polysoft Mesh is used.
58110054|NCT00323674|DEVICE|Light Weight Mesh|Light Weight Mesh is used.
58110055|NCT06186167|PROCEDURE|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
57740045|NCT05214872|OTHER|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) \[kg/m\^2\] was calculated by dividing a person's weight (post-HD weight in HD group) \[kg\] by the squared their body height \[m\]
58110056|NCT02602340|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
58312185|NCT05157373|BEHAVIORAL|FSFI Scale|"The participants will fill up the Female Sexual Function Index (FSFI) questionnaire.~The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration)."
57740046|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (1)|"Serum concentration of:~* advanced glycation ends products (AGE) \[µg/mg protein\];~* 3-nitrotyrosine (3-NT) \[µmol/mg protein\];~* advanced oxidation protein products (AOPP) \[µmol/mg protein\];~* carboxymethyle(lysine) (CML) \[µg/mg protein\]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
57956023|NCT00717171|DEVICE|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
58110057|NCT01716754|DRUG|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
58110058|NCT01716754|DRUG|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
58110059|NCT01716754|DRUG|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
58110060|NCT06527053|DEVICE|obturator|special maxillofacial device to close hollow defects
58312186|NCT05541705|BEHAVIORAL|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
58312187|NCT02414061|DIETARY_SUPPLEMENT|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
58312188|NCT02414061|OTHER|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
58312189|NCT03336346|DRUG|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
58110061|NCT03145610|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
58110062|NCT03145610|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
58110063|NCT01811797|DEVICE|Low Intensity Shockwave by Renova|
58110064|NCT01811797|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
58312190|NCT03336346|DEVICE|ENG implant|Reversible contraception implant
58443297|NCT00600210|DRUG|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
57740047|NCT05214872|DIAGNOSTIC_TEST|metalloproteinases|"metalloproteinases in the serum \[ng/ml\]:~* metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R\&D Systems, Canada;~* tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R\&D Systems, Canada;~* the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
57740048|NCT05214872|DIAGNOSTIC_TEST|parameters of lipids metabolism in the serum|"* total cholesterol (T-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* low-density lipoprotein cholesterol (LDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* high-density lipoprotein cholesterol (HDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* triglycerides (TG) \[mg/dl\] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C \[mg/dl\] = total cholesterol (T-C) \[mg/dl\]- HDL-C \[mg/dl\]- TG\[mg/dl\]/5)."
57740049|NCT05214872|DIAGNOSTIC_TEST|parameters of iron metabolism|"* iron concentration \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* total iron-binding capacity (TIBC) \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* the unsaturated iron-binding capacity (UIBC) \[mg/dl\] was determined by an equation in which iron concentration in plasma is subtracted from TIBC \[mg/dl\];~* ferritin \[ng/ml\] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
58443298|NCT00600210|DRUG|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
58443299|NCT00600210|RADIATION|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
58443300|NCT01667653|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule once daily
58443301|NCT01667653|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
58312191|NCT03336346|DRUG|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
58312192|NCT05716464|BEHAVIORAL|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
58443302|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
58443303|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
58443304|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
58110065|NCT06360731|OTHER|4-7-8 breathing exercise technique and informative session on tinnitus|Participants in experimental group will be individually provided with informative session on tinnitus for one hour by researchers. During the informative session, the participants will be given general information about tinnitus and will be informed about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus. In the same session, after one hour of informative session, the 4-7-8 breathing exercise method will be demonstrated by the same researchers. In addition, a video showing how to perform the 4-7-8 breathing exercise technique will be sent as a text message to their cell phones.
58110066|NCT06360731|OTHER|Informative session on tinnitus|Participants in control group will be individually provided with informative session on tinnitus only for one hour by researchers G.K. and G.S.U. from both clinics. During the informative session, the participants will be given general information about tinnitus and inform about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus.
58110067|NCT01637025|DEVICE|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
58110068|NCT01637025|DEVICE|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
58110069|NCT06462001|BIOLOGICAL|Bacillus Calmette-Guerin Vaccine Intravesical|BCG (Oncotice) is administered intravesically as per usual standard of care
58110070|NCT06462001|DRUG|Mitomycin|MMC is administered intravesically as per usual standard of care
58110071|NCT01072019|OTHER|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
58443305|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
58443306|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
58110072|NCT05059782|DRUG|chemotherapy, targeted therapeutics, immunotherapy|Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
58110073|NCT05059782|RADIATION|IFRT, IMRT or SBRT|IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）
58110074|NCT04304950|DRUG|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
58110075|NCT04304950|DRUG|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
58110076|NCT04918615|PROCEDURE|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
58110077|NCT05278585|PROCEDURE|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
58110078|NCT00164203|BEHAVIORAL|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
58110079|NCT00164203|BEHAVIORAL|School-based CBT|12 sessions, weekly
58110080|NCT00164203|BEHAVIORAL|activity control condition|weekly games \& activities x 12 weeks
58110081|NCT05293587|BEHAVIORAL|Physical Activity|Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
58110082|NCT03453502|BEHAVIORAL|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
58110083|NCT03093545|BIOLOGICAL|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
58110084|NCT03093545|BIOLOGICAL|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
58110085|NCT03473834|OTHER|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
58443307|NCT02777489|DRUG|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
58443308|NCT01870505|DRUG|BYL719|
58110086|NCT03473834|BEHAVIORAL|Medication|The control group will be received the normal medication from their doctor.
58110087|NCT04090684|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
58443309|NCT01870505|DRUG|Letrozole|
58443310|NCT01870505|DRUG|Exemestane|
58443311|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
58443312|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
58443313|NCT04784832|DEVICE|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
58443314|NCT04784832|DEVICE|Peripheral Nerve Stimulation|Electric stimulation of the nerves
58443315|NCT04784832|DEVICE|Transcranial direct current stimulation|Electric stimulation of the cortex
58443316|NCT04784832|DEVICE|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
58443317|NCT04784832|DEVICE|Wrist|Short-term immobilization of the arm
58110088|NCT05443555|DRUG|Gabapentin|Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
58110089|NCT05443555|DRUG|Placebo|Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
58110090|NCT05516212|DIETARY_SUPPLEMENT|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
58443318|NCT04784832|DEVICE|Robotic arm|External perturbation of force field induced by robotic arm
58443319|NCT04784832|DEVICE|Cervicomedullar stimulation|Electric stimulation of the muscle
58110091|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_1 supplementation|"CAFMIPS_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
58110092|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_2 supplementation|"CAFMIPS_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
58110093|NCT05516212|DIETARY_SUPPLEMENT|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
58110094|NCT06531291|DRUG|Surufatinib|250 mg, po, qd, q3w
58443320|NCT04784832|OTHER|Physical training|Training to perform the task by actually doing the task
58443321|NCT04784832|OTHER|Mental training|Training to perform the task by imaging doing the task
58443322|NCT00987311|DIETARY_SUPPLEMENT|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
58443323|NCT00987311|DIETARY_SUPPLEMENT|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
58110095|NCT06531291|DRUG|Serplulimab|200 mg, iv, d1, q3w
58110096|NCT06531291|DRUG|standard chemotherapy|Decided by PI
58443324|NCT00987311|DIETARY_SUPPLEMENT|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
58443325|NCT00610311|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
58443326|NCT00610311|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
58443327|NCT00610311|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
58443328|NCT00610311|BIOLOGICAL|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)
58443329|NCT00610311|BIOLOGICAL|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.
58443330|NCT04475120|DRUG|liposomal lactoferrin|oral and intra-nasal formulation
58443331|NCT04475120|DRUG|SOC therapy|oral administration
58443332|NCT00274508|DRUG|tiotropium bromide|
58443333|NCT05179148|BEHAVIORAL|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
58110097|NCT00703378|DRUG|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
58443334|NCT04891380|DEVICE|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
58443335|NCT04891380|OTHER|Hypotension|measurement of physiological parameters
58443336|NCT04891380|OTHER|Intensive care transport|Measurement of physiological parameters
58443337|NCT06059989|DRUG|Infliximab subcutaneous|Mono and combination therapy group
58443338|NCT06059989|DRUG|Immunosuppressive Agents|Combination group only
58443339|NCT01621711|BEHAVIORAL|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
58443340|NCT01567111|PROCEDURE|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
58443341|NCT03982680|DRUG|Toripalimab|3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total
58443342|NCT03982680|DRUG|Gemcitabine|1250mg/m2 on d1 and d15 q4W\*4cycles
58443343|NCT03982680|DRUG|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
58443344|NCT01633658|DIETARY_SUPPLEMENT|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
58443345|NCT01633658|DIETARY_SUPPLEMENT|25(OH)D|a single dose of 625 micrograms of 25(OH)D
58443346|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
58443347|NCT02154919|PROCEDURE|Percutaneous coronary intervention|
58110098|NCT01724476|DRUG|folate with B12|
58110099|NCT01724476|DRUG|placebo|
58443348|NCT00226486|OTHER|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
58443349|NCT00226486|OTHER|Usual care|No intervention, but ususal care after an accidental fall.
57740050|NCT05214872|DIAGNOSTIC_TEST|selected inflammatory markers|"* high-sensitivity C-reactive protein (hsCRP) \[mg/l\] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~* neopterin \[nmol/l\] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~* interleukin 18 (IL-18) \[pg/ml\] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R\&D Inc., USA."
58110100|NCT04993781|BEHAVIORAL|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
58110101|NCT02758093|BEHAVIORAL|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
58110102|NCT02758093|OTHER|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
58110103|NCT04157270|DEVICE|Penumbra System|Penumbra System
58110104|NCT04275219|DRUG|Tongfu capsules|Tongfu capsules include 5 herbals
58110105|NCT04275219|DRUG|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
58110106|NCT05603078|RADIATION|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
58443350|NCT01068574|OTHER|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
58443351|NCT05432752|DEVICE|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
58110107|NCT06541275|DIAGNOSTIC_TEST|brain MRI and CT|The diagnostic tests will be conducted at 6, 12, and 24 months of follow-up.
58110108|NCT06545734|PROCEDURE|Direct Ischemic Post-conditioning|After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
58110109|NCT06545734|PROCEDURE|Endovascular therapy|Thrombectomy alone.
58443352|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
58443353|NCT03336294|RADIATION|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
58443354|NCT02289807|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
58443355|NCT02289807|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
58443356|NCT01401517|DRUG|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
58443357|NCT00873600|DRUG|chemotherapy|
58443358|NCT00873600|OTHER|medical chart review|
58110110|NCT01301131|OTHER|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
58110111|NCT01301131|OTHER|control|usual oral care
58110112|NCT04190238|OTHER|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
58110113|NCT04190238|OTHER|Physical therapy|specific for spasticity
58110114|NCT02196506|DRUG|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
58110115|NCT02196506|DRUG|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
58110116|NCT01974570|DIETARY_SUPPLEMENT|Marealis refined peptide concentrate|2 tablets, once per day before noon
58110117|NCT01974570|DIETARY_SUPPLEMENT|Placebo|2 tablets, once per day before noon
58110118|NCT05842083|BEHAVIORAL|On-site supportive communication training|On-site supportive communication training
58110119|NCT04670822|BEHAVIORAL|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
58110120|NCT04670822|BEHAVIORAL|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
58110121|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
58110122|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
58110123|NCT02587156|DIETARY_SUPPLEMENT|Meal serving|To investigate impact of habituated protein level
58110124|NCT02569840|DIETARY_SUPPLEMENT|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
58110125|NCT05399719|OTHER||no intervention
58110126|NCT03935659|DEVICE|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
58110127|NCT03935659|PROCEDURE|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
58110128|NCT02880215|BEHAVIORAL|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
57740051|NCT05214872|DEVICE|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) \[mm\] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
58110129|NCT02880215|BEHAVIORAL|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
58110130|NCT01708876|DRUG|Artesunate-mefloquine|
58110131|NCT01708876|DRUG|Chloroquine|
58110132|NCT01708876|DRUG|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
58110133|NCT03476915|OTHER|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
58110134|NCT05024071|DEVICE|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
58110135|NCT05024071|DEVICE|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
58110136|NCT04634721|DRUG|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
58110137|NCT00012584|DRUG|methylphenidate|
58110138|NCT00012584|DRUG|fluvoxamine|
58110139|NCT03998228|DIAGNOSTIC_TEST|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~* Radiological examination of BMD;~* Calculation of the FRAX® score;~* Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
58110140|NCT03995303|OTHER|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
58443359|NCT00873600|OTHER|questionnaire administration|
58443360|NCT00873600|PROCEDURE|adjuvant therapy|
58443361|NCT00873600|PROCEDURE|assessment of therapy complications|
58443362|NCT00873600|PROCEDURE|cognitive assessment|
58443363|NCT00873600|PROCEDURE|psychosocial assessment and care|
58443364|NCT00873600|PROCEDURE|quality-of-life assessment|
58110141|NCT04697355|DIETARY_SUPPLEMENT|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
58110142|NCT02768740|DRUG|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
58110143|NCT06530082|BIOLOGICAL|CircFam53B-219aa DC vaccine|Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.
58110144|NCT06530082|DRUG|camrelizumab|Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
58110145|NCT00592020|PROCEDURE|Short Transverse Incision|Short Transverse Incision for kidney transplantation
58110146|NCT00592020|PROCEDURE|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
58110147|NCT04749186|DEVICE|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
58110148|NCT01965652|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
58110149|NCT01965652|DRUG|Placebo|Placebo tablet taken orally once a day
58110150|NCT04314427|PROCEDURE|Roux-en-Y gastric bypass|
58110151|NCT04314427|PROCEDURE|Sleeve gastrectomy|
58443365|NCT05095259|DRUG|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
58443366|NCT05095259|DRUG|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
58443367|NCT05095259|PROCEDURE|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
57956024|NCT00717171|DEVICE|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
58110152|NCT01042496|DRUG|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
58110153|NCT01042496|PROCEDURE|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
58110154|NCT02102490|DRUG|Abemaciclib|Administered orally
58110155|NCT06469346|OTHER|Nordic Hamstring Eccentric Exercise Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~Nordic eccentric exercise protocol:~* Week 1: 2 sets x 5 repetitions~* Week 2: 2 sets x 6 repetitions~* Week 3: 3 sets x 6 repetitions~* Week 4-6: 3 sets x 8 repetitions"
58110156|NCT06469346|OTHER|Passive Hamstring Static Stretching Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~* Week 1-2: 1 set x 2 repetitions of 30 seconds~* Week 3: 1 set x 3 repetitions of 30 seconds~* Week 4-6: 1 set x 3 reps of 40 seconds"
58110157|NCT06469346|OTHER|Control Group|No intervention
58110158|NCT00002273|DRUG|Ganciclovir|
58110159|NCT01222806|DEVICE|Repetitive Transcranial Magnetic Stimulation|
58110160|NCT02476552|DRUG|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
58110161|NCT02476552|DRUG|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)
58110162|NCT02476552|DRUG|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
58110163|NCT01730859|OTHER|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
58110164|NCT05704218|BIOLOGICAL|blood sample|the patient will have a blood sample in order to perform serology tests
57956025|NCT06063200|DRUG|Methylphenidate Pill|Single encapsulated pill
58443368|NCT05095259|PROCEDURE|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
58443369|NCT05095259|DRUG|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
57740052|NCT05214872|DEVICE|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) \[beats per minute \[bpm\]\]; ejection duration (ED) \[millisecons\]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) \[mm Hg\]; peripheral mean arterial pressure (pMAP) \[mm Hg\]; peripheral end-systolic pressure (pESP) \[mm Hg\]; central systolic (cSBP) and diastolic blood pressure (cDBP) \[mm Hg\]; central mean arterial pressure (cMAP) \[mm Hg\]; central augmented pressure (cAP) \[mmHg\]; central mean pressure of diastole (cMPD)\[mm Hg\]; central mean pressure of systole (cMPS) \[mm Hg\]; central end-systolic pressure (cESP) \[mm Hg\]."
57956026|NCT06164379|DRUG|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
58312193|NCT05716464|BEHAVIORAL|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
58312194|NCT00478959|DRUG|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
58312195|NCT03208153|PROCEDURE|Invasive|Coronary angiogram and revascularization if anatomically feasible
58312196|NCT03208153|PROCEDURE|Conservative|Conservative
58312197|NCT01774526|OTHER|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
58443370|NCT05095259|DEVICE|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
58110165|NCT06090578|OTHER|TabCAT Brain Health Assessment Clinical Pathway|Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates who will then perform the TabCAT-BHA tablet-based test. The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline. The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate. Nursing support is available to support the PCP in making the diagnosis and to consult to the family via telephone post-diagnosis to address immediate care needs.
58110166|NCT04499456|OTHER|Personalised Normative Feedback|The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
58110167|NCT02903576|PROCEDURE|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
58110168|NCT02903576|PROCEDURE|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
58110169|NCT02033876|DRUG|Ursodiol|
58110170|NCT00160030|DRUG|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
58110171|NCT00160030|DRUG|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
58110172|NCT01872689|DRUG|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
58110173|NCT01872689|DRUG|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
58110174|NCT01872689|DRUG|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
58110175|NCT01478633|DRUG|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
58110176|NCT03582371|PROCEDURE|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
58110177|NCT03582371|PROCEDURE|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
57956027|NCT06164379|DRUG|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
58110178|NCT02088528|DEVICE|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
58110179|NCT02088528|PROCEDURE|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
58312198|NCT03251417|DRUG|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
58110180|NCT05723822|DEVICE|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
58110181|NCT05349331|PROCEDURE|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
58110182|NCT03101423|DRUG|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
58110183|NCT03101423|DRUG|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
58110184|NCT00618423|DRUG|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
58110185|NCT00618423|DRUG|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
58110186|NCT06290414|DIAGNOSTIC_TEST|infrared thermal camera|capturing thermographic imaging of gingiva to detect thermal changes due to inflammation as a result of periodontal disease
58110187|NCT03695133|BEHAVIORAL|Group-based interventions|"1. Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~2. Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
58110188|NCT01735591|DIETARY_SUPPLEMENT|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
58110189|NCT01735591|DIETARY_SUPPLEMENT|Probiotic|Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
58110190|NCT00769899|DRUG|AZD7325|Capsule for oral, single dose
58110191|NCT00769899|DRUG|Placebo|Placebo capsule for oral, single dose
58110192|NCT00002119|DRUG|WF10|
58110193|NCT03974581|OTHER|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
58110194|NCT03974581|OTHER|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
58110195|NCT02151461|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
58110196|NCT02151461|DRUG|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
58110197|NCT02151461|DRUG|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
58312199|NCT03251417|DRUG|Apatinib|Apatinib 500 mg oral take, daily
57740053|NCT05214872|DEVICE|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~* reflection index (RI) \[in percentages \[%\]\];~* vascular stiffness index (SI) \[m/s\];~* peripheral pulse pressure (pPP) \[mm Hg\];~* central puls pressure (cPP) \[mm Hg\]~* peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
57740054|NCT05214872|OTHER|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
57740055|NCT05214872|DIAGNOSTIC_TEST|glucose (Glu)|glucose (Glu) \[mg/dl\] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
57740056|NCT05214872|DIAGNOSTIC_TEST|klotho|klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
57740057|NCT05214872|DIAGNOSTIC_TEST|fibroblast growth factor 23 (FGF-23)|FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
57956028|NCT05182151|DRUG|Istradefylline 40 mg|adenosine A2A receptor antagonist
58110198|NCT02151461|DRUG|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
58110199|NCT00017030|DRUG|trabectedin|
58110200|NCT02273206|BEHAVIORAL|Prevention Care Management for Depression and Cancer Screening|
57740058|NCT05214872|DIAGNOSTIC_TEST|parameters of calcium and phosphate metabolism|"* total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
57740059|NCT05214872|DIAGNOSTIC_TEST|liver enzymes activity assessment|"activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
57740060|NCT05214872|DIAGNOSTIC_TEST|total protein and albumin|"* total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
58110201|NCT02273206|BEHAVIORAL|Prevention Care Management for Cancer Screening|
58110202|NCT00796159|DRUG|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
58110203|NCT01938300|DRUG|Magnesium Sulfate|
58110204|NCT01938300|DRUG|Normal saline|
58110205|NCT01491659|DIETARY_SUPPLEMENT|Idoform Plus|orally once daily
58110206|NCT01491659|DIETARY_SUPPLEMENT|Placebo|orally once daily
58110207|NCT02693678|OTHER|Massage|
58312200|NCT02550795|DRUG|Dexmedetomidine|administration of dexmedetomidine only
57740061|NCT05214872|DIAGNOSTIC_TEST|creatinine and urea|"* creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
57740062|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.
57956029|NCT03098823|DRUG|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
58110208|NCT02693678|DEVICE|DIathermy|
58110209|NCT02693678|DEVICE|Sham diathermy|
58110210|NCT00767689|DRUG|Vitamin B 6|vitamin b6 100 mg po daily
58110211|NCT00767689|DRUG|placebo|placebo is given in the placebo arm
58110212|NCT03526107|OTHER|CF Control|CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine
58110213|NCT03526107|OTHER|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
57956030|NCT03098823|DRUG|Prednisone|FDA approved corticosteroid frequently used for SLE.
57956031|NCT06061861|OTHER|Financial support for healthy foods and free home delivery|Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
57956032|NCT06061861|OTHER|Free home delivery|Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
58110214|NCT03526107|OTHER|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
58110215|NCT04214951|DRUG|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
58110216|NCT04214951|DRUG|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
58110217|NCT03378349|BEHAVIORAL|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
58110218|NCT03378349|BEHAVIORAL|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
58110219|NCT02432261|DRUG|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
58110220|NCT02432261|DRUG|Testosterone only gel|Testosterone only gel
58110221|NCT01735045|DEVICE|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
58110222|NCT01735045|DEVICE|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
58110223|NCT01484665|OTHER|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
58110224|NCT02722824|DEVICE|Electro-stimulation|
58110225|NCT02722824|OTHER|Placebo|
58110226|NCT04809428|PROCEDURE|vNOTES salpingectomy|Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
58110227|NCT04809428|PROCEDURE|Laparoscopic salpingectomy|Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
58110228|NCT05058937|DIAGNOSTIC_TEST|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
58110229|NCT05686278|DEVICE|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
58110230|NCT03189264|PROCEDURE|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
58312201|NCT02550795|DRUG|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
58312202|NCT02550795|DRUG|Control|administration of normal saline
58312203|NCT05259917|DRUG|Placebo|Placebo to KVD900 Tablet
58312204|NCT05259917|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
58312205|NCT05259917|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
58312206|NCT01675609|DRUG|Placebo|1 drop in each eye daily for up to 35 days
58110231|NCT02415361|OTHER|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
58110232|NCT02356081|OTHER|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
58110233|NCT02189395|DRUG|NPH and regular insulin|
58110234|NCT02189395|DRUG|glargine and humalog|
58110235|NCT03792971|DRUG|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
58110236|NCT03792971|DRUG|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
58110237|NCT02494687|DRUG|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
58110238|NCT02494687|DRUG|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
58110239|NCT02494687|DRUG|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
58110240|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
57740063|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.
57740064|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"* methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
57740065|NCT05214872|DIAGNOSTIC_TEST|selected electrolytes assessment|"* potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
57740066|NCT05214872|DIAGNOSTIC_TEST|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
57740067|NCT05214872|OTHER|estimated glomerular filtration rate (eGFR) calculation|eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.
57740068|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
57740069|NCT06176196|DRUG|VX-548|Tablets for oral administration.
57740070|NCT06176196|DRUG|Placebo|Tablets for oral administration.
57740071|NCT01557413|PROCEDURE|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
57740072|NCT01557413|PROCEDURE|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
57740073|NCT03671837|OTHER|Oxygen|15 L/min O2
57740074|NCT03671837|OTHER|Air|15 L/min air
58110241|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
58110242|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
58110243|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
58110244|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
58110245|NCT05940883|DRUG|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
58110246|NCT03706677|DEVICE|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
58110247|NCT03706677|DEVICE|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
58110248|NCT01398592|DRUG|Vildagliptin|50mg vildagliptin bid
58110249|NCT01398592|DRUG|Sitagliptin|100mg sitagliptin po qd
58110250|NCT03500965|BEHAVIORAL|text-only PWL|control condition (no image)
58110251|NCT03500965|BEHAVIORAL|graphic PWL|pictorial warning
58110252|NCT03500965|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
58110253|NCT03500965|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
57740075|NCT00251953|DRUG|Tesaglitazar|
57740076|NCT00251953|DRUG|Metformin|
58110254|NCT04684810|BEHAVIORAL|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
57740077|NCT03545854|PROCEDURE|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
58110255|NCT03111888|DEVICE|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
58312207|NCT01675609|DRUG|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
57740078|NCT03538015|DRUG|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
58110256|NCT02685956|DEVICE|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
58110257|NCT03121781|OTHER|respiratory support- interface|change interface to RAM cannula
58110258|NCT03121781|OTHER|respiratory support- interface|change interface to binasal prongs
58110259|NCT04605523|PROCEDURE|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
58110260|NCT02100566|BEHAVIORAL|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
58110261|NCT02100566|BEHAVIORAL|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
58110262|NCT06529991|DEVICE|Occipivot suboccipital pillow self-myofascial release|"Subjects will be instructed in the use of the Occipivot suboccipital pillow and how it should feel. They will be supervised as it is placed. Once verbal verification is obtained regarding the feel and placement of the wedge, the treatment time will begin and continue for 5 minutes."
58110263|NCT03855319|BEHAVIORAL|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
57740079|NCT03538015|DRUG|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
57956033|NCT00684788|COMBINATION_PRODUCT|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
57956034|NCT04320407|DEVICE|Osia 2 System|The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
57956035|NCT01178775|BEHAVIORAL|walking|use a pedometer for records steps.
57956036|NCT02567487|DRUG|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
57956037|NCT02209077|DEVICE|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
57956038|NCT03500432|PROCEDURE|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
57956039|NCT04212676|OTHER|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
57956040|NCT04212676|OTHER|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
57956041|NCT03475459|DRUG|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
57956042|NCT03482414|OTHER|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
57956043|NCT03482414|OTHER|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
57956044|NCT03482414|OTHER|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
58110264|NCT00251628|OTHER|Standard Care|standard care
58110265|NCT00251628|OTHER|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
58110266|NCT00251628|OTHER|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
57740080|NCT03538015|DRUG|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
57956045|NCT06061549|BIOLOGICAL|AAV1/SERCA2a|3E13 viral genomes fixed dose
57956046|NCT03490305|PROCEDURE|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
57956047|NCT02883946|OTHER|Data collection|
58110267|NCT00251628|OTHER|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
58110268|NCT01555281|DRUG|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
58110269|NCT01555281|DRUG|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
58110270|NCT01555281|DRUG|Dexamethasone|40 mg (for patients \<75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
58110271|NCT01170260|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
58110272|NCT01170260|BEHAVIORAL|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
58110273|NCT01170260|BEHAVIORAL|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
58110274|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
58110275|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
58110276|NCT05329428|OTHER|Usual Antenatal Care|In early pregnancy (gestational week \<15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
58110277|NCT01433900|DRUG|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
58110278|NCT01433900|DRUG|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
58110279|NCT03214458|DEVICE|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
58110280|NCT02629133|BEHAVIORAL|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
58110281|NCT06460428|BEHAVIORAL|Interactive video usage|The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
58443371|NCT05095259|PROCEDURE|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
58443372|NCT05095259|PROCEDURE|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
58443373|NCT05095259|PROCEDURE|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
58443374|NCT05095259|DEVICE|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
58443375|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
58443376|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
57740081|NCT04461951|OTHER|Lifestyles (exposure)|no intervention
57956048|NCT06428578|OTHER|FBM-In person|Participants will receive two home visits by a CHW. Each home visit will last about 30 minutes, during which the CHW will assist the woman with community resources and help with enrolling in any state or federal nutrition and medical programs. Furthermore, the participants will be given access to a private Facebook group for nutrition, health education, and social support. Home visits will occur during the second and fifth weeks of the study.
57956049|NCT06428578|OTHER|FBM-Virtual|Participants will receive access to a virtual platform which will have information on national, state, and local food and medical resources, as well as local community resources, and will have access to a private Facebook group for nutrition, health education, and social support.
58443377|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
57740082|NCT01818479|BIOLOGICAL|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
58110282|NCT04229316|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
58110283|NCT03299530|OTHER|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
58443378|NCT05783414|BEHAVIORAL|f2f CST|An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
58443379|NCT05783414|BEHAVIORAL|f2f carer support|Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
58443380|NCT05783414|BEHAVIORAL|vCST|A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
58443381|NCT05783414|BEHAVIORAL|online carer support|A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
58443382|NCT03116685|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
58443383|NCT03116685|OTHER|Placebo|Placebo
58443384|NCT05432492|DRUG|AK112|IV infusion, specified dose on specified days
58443385|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
58443386|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
58443387|NCT03080948|BEHAVIORAL|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
58443388|NCT03080948|OTHER|Saliva samples|Germline DNA analysis
58443389|NCT00731679|DRUG|Rifaximin|
58443390|NCT00731679|DRUG|Placebo|
57740083|NCT01818479|PROCEDURE|Stem cell transplant|
57740084|NCT04662554|DEVICE|1-mm Resolution Clinical PET camera|1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
57740085|NCT03479320|DRUG|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
58443391|NCT04277065|PROCEDURE|BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection|Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
57956050|NCT06428578|OTHER|home delivered food boxes|Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
57956051|NCT04517487|BIOLOGICAL|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
57956052|NCT04517487|BIOLOGICAL|Placebo|Placebo
57956053|NCT02777671|DRUG|BIA 2-093|
57956054|NCT02777671|DRUG|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
57956055|NCT05138809|BEHAVIORAL|Exercise|Use online exercise platform
57956056|NCT03991351|OTHER|Exposure to images|Exposure to images
57956057|NCT05314205|PROCEDURE|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
57956058|NCT00964977|RADIATION|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
57956059|NCT00464412|BEHAVIORAL|Education|
57956060|NCT02803944|DRUG|Azithromycin|
57956061|NCT03072056|DRUG|MIN-101|
57956062|NCT00343421|BIOLOGICAL|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
58443392|NCT04277065|PROCEDURE|cotton tourniquet|cotton tourniquet
57956063|NCT00343421|BIOLOGICAL|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
57956064|NCT06168032|BIOLOGICAL|Any Chinese government-recommended COVID-19 booster vaccine|Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.
58110284|NCT05500495|OTHER|no intervention|no intervention
57956065|NCT03380689|DRUG|S-1|- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
58110285|NCT04539002|BEHAVIORAL|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
57740086|NCT03479320|DRUG|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
57740087|NCT00435604|DRUG|Hylenex|
57740088|NCT02497573|OTHER|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
57740089|NCT05271864|DEVICE|Apple Watch|Apple Watch
58443393|NCT01400568|DRUG|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
58110286|NCT04539002|BEHAVIORAL|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
58110287|NCT03056326|DRUG|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
58110288|NCT03056326|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
58110289|NCT03056326|DRUG|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
58110290|NCT03056326|DRUG|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
58110291|NCT02106169|BEHAVIORAL|Therapeutic education group|
58443394|NCT01400568|DRUG|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
58110292|NCT03413527|DEVICE|rTMS|rTMS Treatment
58443395|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
58110293|NCT05771831|BIOLOGICAL|Thrombosomes®|The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
58110294|NCT05771831|BIOLOGICAL|Standard platelet concentrate|The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
58110295|NCT04948307|DEVICE|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
58443396|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
58110296|NCT04948307|OTHER|Standard of Care|sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
58110297|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
58110298|NCT02218359|DRUG|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
58110299|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
58110300|NCT00146289|DRUG|MICARDIS® (telmisartan)|
58110301|NCT00740259|DRUG|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
58110302|NCT03179475|DRUG|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
58110303|NCT03563027|BEHAVIORAL|Social Incentive Gamification|Game-based intervention with points and levels
57740090|NCT02040116|DRUG|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
58110304|NCT03563027|BEHAVIORAL|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
58110305|NCT03563027|BEHAVIORAL|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
58312208|NCT00774475|DRUG|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
58312209|NCT00774475|DRUG|doubled therapy|clopidogrel 150 mg/day
58312210|NCT06402019|DRUG|Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)|Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
58312211|NCT06402019|DRUG|normal saline|Group went under multiple sessions of normal saline injection.
58443397|NCT02474420|DRUG|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
58443398|NCT02474420|DRUG|Deferasirox|Deferasirox administered per standard of care by the treating physician
57740091|NCT06113250|DEVICE|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
57956066|NCT03380689|DRUG|Irinotecan|- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
58312212|NCT01092377|DIETARY_SUPPLEMENT|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
58312213|NCT01092377|DIETARY_SUPPLEMENT|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
58312214|NCT01092377|OTHER|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
58312215|NCT01092377|OTHER|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
58312216|NCT06155435|BEHAVIORAL|solution focused approach training|To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
58312217|NCT03159637|PROCEDURE|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
58312218|NCT03632824|DRUG|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
58312219|NCT02745106|PROCEDURE|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
58312220|NCT02745106|DEVICE|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
58443399|NCT03777761|DRUG|tucatinib|300mg oral dose
58443400|NCT03777761|DRUG|placebo|Matching placebo for tucatinib
58443401|NCT03777761|DRUG|moxifloxacin|400mg single oral dose
57956067|NCT03380689|DRUG|Bevacizumab|- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
57956068|NCT01960621|DRUG|cyclodextrin|intravenous
57740092|NCT06113250|DEVICE|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
57740093|NCT06113250|OTHER|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
57740094|NCT06258967|DRUG|ciprofol|Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
58443402|NCT00195039|DRUG|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
58443403|NCT02123849|DRUG|Aspirin|Given PO
58443404|NCT02123849|OTHER|Laboratory Biomarker Analysis|Correlative studies
58443405|NCT02123849|OTHER|Placebo|Given PO
58443406|NCT00646360|DIETARY_SUPPLEMENT|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
58443407|NCT00646360|DIETARY_SUPPLEMENT|Placebo|2 tablets daily during pregnancy
58443408|NCT06110208|DRUG|CLL1 and CD38 dual-target CAR-T injection|CLL1 and CD38 dual-target CAR-T injection
58443409|NCT02942758|DRUG|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
58443410|NCT02942758|DRUG|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
58443411|NCT02942758|DRUG|ATRA|ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
58443412|NCT02942758|DRUG|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
58443413|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
58443414|NCT03349125|BEHAVIORAL|Collar On|
58443415|NCT03349125|BEHAVIORAL|Collar Off|
58443416|NCT03864302|BEHAVIORAL|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
58443417|NCT06725862|PROCEDURE|Retrolaminar Block (RLB)|This intervention involves administering 0.25% bupivacaine (0.1 mL/kg) into the retrolaminar space at the L4 vertebral level using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
57740095|NCT06258967|DRUG|propofol|Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
57740096|NCT01595295|OTHER|non interventional|
57740097|NCT05245929|DEVICE|Distalization|Distalizing the posterior maxillary segment
57740098|NCT02449200|OTHER|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
57740099|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
57740100|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
57740101|NCT00739349|DRUG|vehicle/placebo|vehicle/placebo
57740102|NCT05130151|BEHAVIORAL|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
58443418|NCT06725862|PROCEDURE|Caudal Block (CB)|This intervention involves administering 0.125% bupivacaine (1 mL/kg, maximum 20 mL) into the sacral canal using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
58443419|NCT06725329|BEHAVIORAL|A tailored psychosocial education intervention|"Participants will get ten 60-minute psychoeducational group sessions about chronic pain and its management. The group sessions will be conducted by the PI and a bilingual project director at Korean churches or daycare centers in Baltimore-Washington Metropolitan area.~The psychoeducational group session will be adapted from LAMP intervention that has been previously developed. The intervention provides biopsychosocial education sessions about chronic pain and its management. For example, sessions focus on providing information regarding: (1) pain and the biological stress response and the gate control theory of pain, (2) the psychological impact of thoughts and emotions on pain and (3) facilitated group discussions to help participants develop a new understanding of pain through shared social experiences, all of which have been shown to improve pain outcomes."
58443420|NCT00002357|DRUG|HBY 097|
58443421|NCT00002357|DRUG|Zidovudine|
58443422|NCT03167775|DRUG|Elemene Injection/Elemene Oral Emulusion|
58443423|NCT00931606|BIOLOGICAL|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
58443424|NCT00931606|DRUG|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
58443425|NCT01103583|DRUG|Hydroxyurea|500 mg/die per os for two years
58443426|NCT01103583|OTHER|placebo|500 mg/die per os for two years
57740103|NCT01711203|OTHER|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
58443427|NCT05477784|OTHER|Educational Intervention|Receive EC-PC program
58443428|NCT05477784|OTHER|Informational Intervention|Receive education booklet
58443429|NCT05477784|OTHER|Questionnaire Administration|Ancillary studies
58443430|NCT06527781|DRUG|PD5K3|Six dose levels will be evaluated. intravenous injection
57740104|NCT01711203|OTHER|General Strengthening|General abdominal and lower quarter musculature strengthening
57740105|NCT04819269|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
57740106|NCT04819269|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
57740107|NCT03822533|OTHER|Physiotherapist as primary assessor|Physiotherapist diagnose and treat the patient.
57740108|NCT03822533|OTHER|Physician as primary assessor|Physician diagnose and treat the patient.
57740109|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
57740110|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
57740111|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
57740112|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
57740113|NCT01567618|DRUG|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
58312221|NCT02745106|DEVICE|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)"
58443431|NCT06527781|DRUG|Placebo|intravenous injection
58443432|NCT06527781|DRUG|Pegaspargase|Six dose levels will be evaluated. intramuscular injection
58443433|NCT06308198|DRUG|AGN-151586|Intramuscular Injections
57956069|NCT02585505|PROCEDURE|stem cells|stem cell will be injected
57740114|NCT01567618|DRUG|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
57740115|NCT01114854|DRUG|Topiramate IR|
57740116|NCT01114854|DRUG|Topiramate ER|
57740117|NCT00755482|DRUG|Aquamin F|
57740118|NCT00755482|DRUG|Placebo (maltodextran)|
57740119|NCT02965950|DRUG|Cyclophosphamide|I.v. infusion
57956070|NCT05956795|DIAGNOSTIC_TEST|Ultrasound|Sonographic imaging will be performed of lymph node basins
57956071|NCT04469413|DRUG|Paracetamol Infusion|Continuous and Standard Intermittent Boluses Paracetamol Infusion
57956072|NCT03014401|PROCEDURE|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
58443434|NCT06308198|DRUG|Placebo|Intramuscular Injections
58443435|NCT05761990|OTHER|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
58443436|NCT05761990|OTHER|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
58443437|NCT01128244|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will receive vitamin B6 supplementation.
58443438|NCT01128244|PROCEDURE|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
58443439|NCT05839808|OTHER|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
58443440|NCT02124694|BEHAVIORAL|HTUG|HTUG is a group psychotherapy...
58443441|NCT04936815|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
58443442|NCT06726395|DRUG|Penicillin G_1200mg|benzylpenicillin preferred dosing 1gx4
57956073|NCT03014401|PROCEDURE|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
57740120|NCT05956301|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
57740121|NCT05956301|DEVICE|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
58312222|NCT06342232|BEHAVIORAL|Neurofeedback mindfulness|The participants used a portable EEG headband to complete 10 minutes of neurofeedback mindfulness practice for 8 weeks. While being seated comfortably, they could modify their brains rates based on the audio neurofeedback they received.
58312223|NCT06342232|BEHAVIORAL|Simple attention controlled task|The controlled group of this project also received an intervention which included an audiobook. While wearing the headband, the controlled participants muted their neurofeedback sounds and only focused on an audiobook while remaining relaxed. A summary of their brain states was given to them when completing their practice every day.
57740122|NCT05956301|DEVICE|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
58312224|NCT03937778|BEHAVIORAL|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
58312225|NCT03256578|DEVICE|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
58312226|NCT06192732|BEHAVIORAL|A more plant-based diet during weight loss|Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
58312227|NCT02528032|OTHER|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
58312228|NCT05672719|DIAGNOSTIC_TEST|Right Heart Catheterization|Procedure
58312229|NCT00170443|BIOLOGICAL|rHAO Trivalent Influenza Vaccine|
58443443|NCT06726395|DRUG|cloxacillin|cloxacillin 2gx4
58443444|NCT05767112|OTHER|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
58443445|NCT00596752|DRUG|Alprostadil|"* Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
58443446|NCT00596752|OTHER|Placebo|"* Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
58443447|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
58443448|NCT01973998|DRUG|Roflumilast|PDE4 inhibitor
58443449|NCT01973998|DRUG|Placebo|Inactive substance.
58443450|NCT00183625|BEHAVIORAL|Individual Placement and Support (Supported Employment)|
58312230|NCT03184740|DEVICE|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
58312231|NCT03184740|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
58312232|NCT00512434|PROCEDURE|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
58312233|NCT02961842|DRUG|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
58312234|NCT02961842|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
58312235|NCT02961842|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
58312236|NCT02961842|DRUG|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
58312237|NCT02961842|DRUG|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
58312238|NCT02961842|DRUG|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
58312239|NCT02961842|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
58312240|NCT02961842|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
58312241|NCT02961842|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
58443451|NCT00183625|BEHAVIORAL|Social Skills Training|
58443452|NCT00183625|DRUG|Olanzapine|
58443453|NCT00183625|DRUG|Risperidone|
58443454|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
58443455|NCT01874080|DRUG|Saxagliptin/Metformin|
58443456|NCT06725589|OTHER|metabolic disease|metabolic disease
58443457|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
58443458|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
58443459|NCT05878847|DIETARY_SUPPLEMENT|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
58443460|NCT05878847|DIETARY_SUPPLEMENT|Placebo|Placebo
58443461|NCT06725940|DEVICE|68Ga-GZMB PET/CT|68Ga-GZMB PET/CT
58443462|NCT00001379|BIOLOGICAL|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
58443463|NCT00001379|DRUG|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
58443464|NCT02916901|DRUG|CKD-519 200mg|
58312242|NCT05462600|OTHER|Position change|Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
57740123|NCT06236503|BEHAVIORAL|Real Stimulation|"Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months."
57740124|NCT06236503|BEHAVIORAL|Placebo Stimulation|Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
57740125|NCT00005076|BIOLOGICAL|cetuximab|
57740126|NCT00005076|DRUG|irinotecan hydrochloride|
57740127|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
57740128|NCT02519010|DRUG|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
57740129|NCT02519010|DRUG|Exforge|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
57956074|NCT06206174|DRUG|TGRX-814|Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
57956075|NCT01531920|DRUG|alcohol + placebo|Part A alcohol + placebo
57956076|NCT01531920|DRUG|alcohol + perampanel|Part A: alcohol + perampanel
57956077|NCT01531920|DRUG|perampanel + alcohol|Part B: perampanel + alcohol
57956078|NCT01531920|DRUG|placebo + alcohol|Part B: placebo + alcohol
58312243|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
58312244|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
58443465|NCT02916901|DRUG|Placebo|
58443466|NCT01969955|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
58443467|NCT01336140|DRUG|Aminophylline|75 mg of intravenous aminophylline
58443468|NCT01336140|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
58443469|NCT05490030|DRUG|TNO155|Single oral dose of TNO155 on Day 1
58443470|NCT00003967|DRUG|etoposide|
58443471|NCT00003967|DRUG|topotecan hydrochloride|
57740130|NCT00646477|DEVICE|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
57740131|NCT01308242|DRUG|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
58110306|NCT03932084|BEHAVIORAL|Control group|"During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
58110307|NCT03932084|BEHAVIORAL|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
58110308|NCT00637442|DRUG|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
58110309|NCT03557710|BEHAVIORAL|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
57740132|NCT05377580|DRUG|Period 1 IBI112 Placebo|Intravenous Injection
57740133|NCT05377580|DRUG|Period 2 IBI112 dose 3|Subcutaneous injections
57740134|NCT05377580|DRUG|Period 1 IBI112 dose 1|Intravenous Injection
57740135|NCT05377580|DRUG|Period 1 IBI112 dose 2|Intravenous Injection
57740136|NCT05377580|DRUG|Period 2 IBI112 dose 4|Intravenous Injection
57740137|NCT05377580|DRUG|Period 2 IBI112 Placebo|Subcutaneous injections
57740138|NCT01835457|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
57740139|NCT01835457|BEHAVIORAL|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
57740140|NCT05418036|DRUG|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
58110310|NCT04132739|BEHAVIORAL|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
58443472|NCT04200690|OTHER|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
57740141|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
57740142|NCT02457039|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
58110311|NCT04132739|BEHAVIORAL|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
57740143|NCT02457039|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
57740144|NCT02457039|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
57740145|NCT02457039|DRUG|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\]."
57740146|NCT03549910|PROCEDURE|APRVplus protocol|Physiology-driven APRVplus protocol
57740147|NCT03549910|PROCEDURE|Low tidal volume ventilation|Low tidal volume lung protective ventilation
57740148|NCT02666547|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
57740149|NCT02666547|RADIATION|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
58443473|NCT04200690|OTHER|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
57740150|NCT02666547|RADIATION|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
58443474|NCT02334293|DRUG|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
58443475|NCT06451991|OTHER|Use of concept map in clinical practice in nursing students|Concept map will be used in clinical practice in nursing students.
58443476|NCT00811681|DRUG|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
58443477|NCT00811681|DRUG|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
58443478|NCT00193206|DRUG|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
58443479|NCT00193206|DRUG|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
58443480|NCT00193206|DRUG|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
57740151|NCT01295554|OTHER|NCE MRA and CE MRA|"Each patient will receive on the same day:~* NCE MRA~* CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
57769648|NCT05603988|DEVICE|Intracanal Diode laser irradiation|After endodontic retreatment, root canals will be irradiated with a 980 nm diode laser coupled with optical fibre 200 μm (Litemedics, Italy) with setting 1.2-watt power, in pulsed mode. The irradiation protocol will be of 5-sec irradiation followed by a 10-sec pause, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth. The tip will be positioned 1 mm short of the apex. Followed by activation during which it will be slowly dragged at a speed of approximately 2 mm/ sec in a way that the root canals will be irradiated from the apical to the coronal portion, in a helicoidal movement touching the canal walls.
58110312|NCT04132739|BEHAVIORAL|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
58443481|NCT00837213|DRUG|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
58443482|NCT00837213|DRUG|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
58443483|NCT00123123|DRUG|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
58443484|NCT00123123|DRUG|placebo|
58443485|NCT02037516|DEVICE|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
58443486|NCT02037516|DRUG|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
58443487|NCT02037516|DEVICE|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
58458458|NCT04944459|DEVICE|Muse-S headband; InteraXon Inc., RRID:SCR_014418|"Muse-S is used as a technology-supported Mindfulness Training (tsMT) device as a way to introduce meditation as a method for managing chronic pain in individuals as it facilitates the learning process, requires minimal training to use and provides mechanisms to enhance compliance and track progress. The availability of direct feedback data from Muse-S may encourage the participant to perform meditation sessions and may increase time spent in the calm brain state."
58458459|NCT00285909|BEHAVIORAL|Alcohol: 25 gday (white wine)|
58458460|NCT03839368|PROCEDURE|fixation of angle fracture|open reduction and internal fixation of angle fracture
58458461|NCT05608603|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
57769649|NCT05603988|OTHER|Placebo|"After endodontic retreatment, mock laser application (Placebo group) will be applied:~The fiberoptic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated"
58312245|NCT03715062|OTHER|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
58312246|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally.
58312247|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally
58312248|NCT05298241|OTHER|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
58312249|NCT01943604|OTHER|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
58312250|NCT01943604|OTHER|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
58312251|NCT00193453|DRUG|Gemcitabine|1000mg/m2 30min IV, Day 1 \& 8
58312252|NCT00193453|DRUG|Docetaxel|30mg/m2, 30min IV, day 1 \& 8
58312253|NCT00193453|DRUG|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
58312254|NCT05149339|DRUG|Cholecalciferol 2800 I.U. ml oral drops|"(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3)."
58312255|NCT04638062|OTHER|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
58312256|NCT04638062|OTHER|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
58312257|NCT06054711|OTHER|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
58312258|NCT01911741|DRUG|MDV3100|Oral
58312259|NCT01739335|DRUG|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
58312260|NCT01739335|DRUG|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
58312261|NCT06147271|DRUG|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
58312262|NCT02750631|OTHER|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
57769650|NCT03183583|PROCEDURE|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
57956079|NCT05059314|OTHER|Brisk walking (moderate physical activity)|"1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6"
58443488|NCT06277661|BEHAVIORAL|MOMI PODS|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
58443489|NCT06277661|BEHAVIORAL|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
58443490|NCT03397342|DEVICE|CPAP machine|Use of CPAP machine during MRI
58443491|NCT04294030|DEVICE|Diagnostic Test: NOWDx HSV-2 Test|For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
58443492|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
58443493|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
58443494|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
58443495|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
58443496|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
58443497|NCT05148806|DIAGNOSTIC_TEST|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
57769651|NCT02387437|BEHAVIORAL|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
57956080|NCT01595776|OTHER|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
57740152|NCT06378554|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
58443498|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
58443499|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
58443500|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
58443501|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
58443502|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
58443503|NCT03430934|COMBINATION_PRODUCT|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
58443504|NCT02186665|DRUG|calcitriol ointment|
58443505|NCT02186665|DRUG|placebo comparator|
58443506|NCT05668598|DIAGNOSTIC_TEST|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
58443507|NCT04903535|DEVICE|Alonefire SV003 10W 365nm UV Flashlight|Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
58443508|NCT05842252|PROCEDURE|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
58443509|NCT00756418|DRUG|montelukast|montelukast 5 mg QD 4-weeks.
58443510|NCT00756418|DRUG|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
57740153|NCT05972096|BEHAVIORAL|Combination DBT, self-compassion and contextual-based skills|Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
57740154|NCT02575885|OTHER|Electronic Cigarette|Receive different type of ENDS product at each visit
58443511|NCT01389492|OTHER|frozen meat cutlets meal|250 g of meat cutlets
58443512|NCT01389492|OTHER|meat meals|250 g of meat meal for 4 days
58443513|NCT04309474|DRUG|Elezanumab|Intravenous (IV) infusion
58443514|NCT04309474|DRUG|Placebo|Intravenous (IV) infusion
58443515|NCT03348839|DEVICE|NeLLY service|Telesurveillance and therapeutic support
58443516|NCT03790059|DRUG|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
58443517|NCT03790059|PROCEDURE|RFA|Treat the samll HCC with the RFA.
58443518|NCT03319823|DRUG|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment"
58443519|NCT03319823|DRUG|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
58443520|NCT03319823|DRUG|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
58443521|NCT04044339|DRUG|TD-5202|Study Drug to be administered orally
58443522|NCT04044339|DRUG|Placebo|Placebo to be administered orally
58443523|NCT00749723|DRUG|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
58443524|NCT00749723|DRUG|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
58443525|NCT00749723|DRUG|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
58443526|NCT00749723|DRUG|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
58443527|NCT00749723|DRUG|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
58443528|NCT00749723|PROCEDURE|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
58443529|NCT00749723|DRUG|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
58443530|NCT00749723|DRUG|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
58443531|NCT02548338|PROCEDURE|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
58443532|NCT03755882|DEVICE|ACUVUE® DEFINE™ Vivid Style|TEST Lens
58443533|NCT03755882|DEVICE|LACELLE™ Sparkling Brown|CONTROL Lens
58443534|NCT03949608|OTHER|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
58443535|NCT00271102|PROCEDURE|anterior vaginal repair (colporrhaphy)|vaginal repair
57740155|NCT02575885|OTHER|Electronic Cigarette|Receive BLU e-cigarette ENDS product
58443536|NCT00271102|PROCEDURE|abdominal paravaginal defect repair|abdominal repair
57740156|NCT02575885|OTHER|Laboratory Biomarker Analysis|Correlative studies
57740157|NCT02575885|OTHER|Pharmacological Study|Correlative studies
58443537|NCT04804163|DEVICE|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
58443538|NCT02154841|BEHAVIORAL|Questionnaire, taste test, visual food test|
58443539|NCT00211328|DRUG|anecortave acetate|
58443540|NCT00308854|PROCEDURE|Photodynamic Therapy|
58443541|NCT03912779|BEHAVIORAL|C2Hear RLOs|Freely available online RLOs
58443542|NCT03912779|BEHAVIORAL|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
58443543|NCT02360891|OTHER|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
58443544|NCT03813264|OTHER|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
58443545|NCT03850028|OTHER|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
58110313|NCT00583869|DRUG|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
57740158|NCT02575885|OTHER|Questionnaire Administration|Ancillary studies
57740159|NCT05632146|PROCEDURE|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
57740160|NCT05632146|PROCEDURE|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
57740161|NCT01708850|DRUG|Rivaroxaban|All specified in arm description. One arm study.
57740162|NCT03816748|DEVICE|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
57740163|NCT00908479|BEHAVIORAL|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
57740164|NCT00908479|BEHAVIORAL|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
58110314|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
58110315|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
58110316|NCT01862328|DRUG|MLN4924|"MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle"
58110317|NCT01862328|DRUG|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle"
57740165|NCT06683742|DRUG|EYP-1901|Intravitreal Injection
57740166|NCT06683742|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
57740167|NCT04219670|DIAGNOSTIC_TEST|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
57740168|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
57740169|NCT00019916|BIOLOGICAL|aldesleukin|
57740170|NCT00019916|BIOLOGICAL|p53 peptide vaccine|
57740171|NCT00019916|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58110318|NCT01862328|DRUG|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
58110319|NCT01862328|DRUG|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle"
57740172|NCT06161675|BEHAVIORAL|QuitAid|Participants will receive the QuitAid intervention, based on a medication adherence intervention, which addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician. Smokers not ready to quit will receive up to two sessions focused on using NRT to cut down cigarette use. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the full QuitAid intervention.
57740173|NCT06161675|BEHAVIORAL|SmokefreeTXT|All participants will receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment. For smokers not ready to quit, participants will receive two week-long pre-quit modules, Practice Quit and Daily Challenges. These modules will help the smoker become comfortable with not smoking for short periods of time and build skills before they attempt to quit. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the ready to quit treatment.
58110320|NCT01862328|DRUG|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle"
58110321|NCT00366379|DRUG|GK Activator (2)|25-200mg po bid for 20 weeks
58110322|NCT03250910|DRUG|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
58110323|NCT03250910|DRUG|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
58110324|NCT06373406|DRUG|MHB036C|An antibody-drug conjugate therapy
58110325|NCT04261478|DEVICE|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
58110326|NCT04261478|DRUG|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
58110327|NCT05256732|DRUG|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
58110328|NCT05256732|OTHER|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
58312263|NCT01528371|DRUG|Midazolam|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
58110329|NCT05256732|DRUG|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
58110330|NCT05256732|OTHER|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
58110331|NCT05256732|DRUG|AT-527|AT-527 administered twice daily (BID)
58110332|NCT05256732|DRUG|AT-527 single dose|AT-527 single dose fasted/fed cross-over
58312264|NCT01528371|DRUG|Normal Saline Solution (NSS)|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
58312265|NCT03588338|DRUG|Perfalgan|For postoperative pain
58312266|NCT03588338|DRUG|Control|For postoperative nausea and vomiting
58312267|NCT03747471|BEHAVIORAL|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
58312268|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
58312269|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
58110333|NCT05357794|DRUG|Brentuximab vedotin|Given by Vein (IV)
58110334|NCT00003637|DRUG|cisplatin|
58110335|NCT00003637|DRUG|fluorouracil|
58110336|NCT00003637|RADIATION|radiation therapy|
58110337|NCT04696562|BEHAVIORAL|Deep Breathing Exercise with Triflo|The investigators will do deep breathing exercises 5-10 times an hour with the triflo device.
58110338|NCT01212783|BEHAVIORAL|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
58110339|NCT01212783|BEHAVIORAL|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
58110340|NCT00040859|DRUG|capecitabine|
58110341|NCT00040859|DRUG|oxaliplatin|
58110342|NCT00094783|PROCEDURE|MRI|
57740174|NCT06161675|DRUG|Nicotine Replacement Therapy Patch|All participants will receive up to 8 weeks of NRT in the form of patch. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
57740175|NCT06161675|DRUG|Nicotine lozenge|All participants will receive up to 8 weeks of NRT in the form of lozenge. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
58110343|NCT00002582|DRUG|CMF regimen|
58110344|NCT00002582|DRUG|cyclophosphamide|
58110345|NCT00002582|DRUG|doxorubicin hydrochloride|
58110346|NCT00002582|DRUG|fluorouracil|
58110347|NCT00002582|DRUG|goserelin acetate|
58110348|NCT00002582|DRUG|leuprolide acetate|
58110349|NCT00002582|DRUG|methotrexate|
58110350|NCT00002582|DRUG|tamoxifen citrate|
58110351|NCT00002582|PROCEDURE|oophorectomy|
58110352|NCT00002582|RADIATION|radiation therapy|
58110353|NCT04363736|DRUG|Tociliuzumab|Participants will receive IV TCZ.
58110354|NCT01581983|BEHAVIORAL|Internet Mindfulness Meditation|one hour session each week for six weeks
58110355|NCT01581983|BEHAVIORAL|Individual Mindfulness Meditation|one hour session each week for six weeks
58110356|NCT02348970|DEVICE|ONIRIS®|sleeping test
58110357|NCT02348970|DEVICE|TALI|sleeping test
58110358|NCT00560547|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
58110359|NCT04926896|PROCEDURE|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
58110360|NCT04926896|PROCEDURE|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
58110361|NCT04576793|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
58110362|NCT04576793|DRUG|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
58443546|NCT05350449|BEHAVIORAL|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
58443547|NCT04522596|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
58443548|NCT04522596|OTHER|Placebo|Placebo inhaled once a day
58443549|NCT00321464|BIOLOGICAL|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
58443550|NCT00321464|DRUG|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
58443551|NCT04703426|DRUG|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
58443552|NCT04703426|DRUG|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
58443553|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
58443554|NCT04841616|PROCEDURE|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
58443555|NCT04841616|PROCEDURE|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
58443556|NCT06149871|BEHAVIORAL|Physical activity|resistance, aerobic, and flexibility exercises
58443557|NCT04311125|PROCEDURE|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
58443558|NCT04311125|PROCEDURE|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
57740176|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
58110363|NCT04576793|DRUG|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
57740177|NCT02560948|BIOLOGICAL|Placebo solution|4 x 2 injections over 21 days
57740178|NCT02560948|BIOLOGICAL|gpASIT+TM|4 x 2 injections over 21 days
57740179|NCT05349617|BIOLOGICAL|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
58110364|NCT04576793|PROCEDURE|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
58443559|NCT04311125|PROCEDURE|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
58443560|NCT01694056|OTHER|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
58443561|NCT01694056|OTHER|Control diet|4 weeks high mixed protein diet (20 en%)
58443562|NCT02478099|DRUG|MPDL3280A|Anti-PD-L1 antibody
58443563|NCT03787550|DRUG|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
58443564|NCT06284655|BEHAVIORAL|group-based combined with innovative technology education|The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.
58443565|NCT06284655|OTHER|Standard treatment|Treatment as usual.
58443566|NCT06726278|DRUG|Misoprostol 400mcg Tab|Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
57740180|NCT05349617|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
58110365|NCT04267796|OTHER|Aerobic Exercise|Complete aerobic training
57740181|NCT01049126|OTHER|ChemoFx|Chemoresponse Marker Assay
57740182|NCT04892355|DEVICE|Root canal irrigation|Devices used during root canal irrigation
58443567|NCT06726278|DRUG|Placebo|participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
58443568|NCT00930930|DRUG|cisplatin|Given IV
58443569|NCT00930930|DRUG|everolimus|Given orally
58443570|NCT00930930|DRUG|paclitaxel|Given IV
58443571|NCT00930930|OTHER|placebo|Given orally
58443572|NCT00930930|PROCEDURE|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
58443573|NCT03744949|DRUG|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
58443574|NCT03744949|DRUG|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
58443575|NCT03744949|DRUG|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
58443576|NCT03744949|DRUG|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
58443577|NCT06166966|OTHER|Flipped Education Model|The effect of the Inside Out Education Model on the course success of nursing students.
58443578|NCT00994006|DIETARY_SUPPLEMENT|Magnesium oxide|520 mg of elemental magnesium q.d.
57740183|NCT01654549|DRUG|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
57740184|NCT04231812|DEVICE|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
57740185|NCT06534632|OTHER|Mother's colostrum|Oropharyngeal administration of mother's colostrum
58312270|NCT01610518|DIETARY_SUPPLEMENT|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
58443579|NCT00994006|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
57740186|NCT06534632|OTHER|Placebo|Oropharyngeal administration of sterile water
57740187|NCT01993069|BEHAVIORAL|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
57740188|NCT05175755|OTHER|Patients|The procedure involves taking a total of 12 ml of blood.
58443580|NCT00640848|DRUG|almorexant|1 dose of 400 mg in two treatment sequences
57740189|NCT05684328|PROCEDURE|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
58110366|NCT04267796|OTHER|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
58110367|NCT04267796|OTHER|Quality-of-Life Assessment|Ancillary studies
58110368|NCT04267796|OTHER|Questionnaire Administration|Ancillary studies
58443581|NCT00640848|DRUG|almorexant|1 dose of 200 mg in two treatment sequences
58110369|NCT04267796|OTHER|Resistance Training|Complete high-resistance circuit training sessions
58312271|NCT01610518|DIETARY_SUPPLEMENT|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
58312272|NCT04113603|DIAGNOSTIC_TEST|Urinary malignancy|Single bolus three phase CTU
58443582|NCT00640848|DRUG|almorexant|1 dose of 100 mg in two treatment sequences
58443583|NCT00640848|DRUG|almorexant|1 dose of 50 mg mg in two treatment sequences
58443584|NCT00640848|DRUG|almorexant|1 dose of 1000 mg in two treatment sequences
58443585|NCT05117190|PROCEDURE|Facial Allotransplantation|
58443586|NCT01758913|DRUG|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
58443587|NCT01582711|BEHAVIORAL|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
58443588|NCT01582711|BEHAVIORAL|SMS reminders|Short Message Service (SMS) text reminders
58443589|NCT01582711|DRUG|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
58443590|NCT06119113|OTHER|Evaluation of the wound infection at the 10th day post-op check-up among all groups|Discharge, redness, increased temperature, and dehiscence were accepted as wound infection.
58458462|NCT05608603|DIAGNOSTIC_TEST|Cardiorespiratory stress test|Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.
57740190|NCT05684328|PROCEDURE|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
57740191|NCT04408573|OTHER|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
58110370|NCT01082445|DRUG|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
57740192|NCT00403832|DEVICE|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
58110371|NCT01082445|DRUG|Placebo|Placebo
58110372|NCT05935800|BEHAVIORAL|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
58110373|NCT02235428|DRUG|Ipratropium bromide|
58110374|NCT02235428|DRUG|Placebo|
58110375|NCT02235428|DRUG|Salbutamol|
58110376|NCT05528926|OTHER|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
58110377|NCT05528926|OTHER|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
58110378|NCT05528926|DRUG|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
58443591|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 2nd month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
58443592|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 6th month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
58443593|NCT03472326|DRUG|GS-9131|Tablet(s) administered orally once daily
58443594|NCT03472326|DRUG|BIC|Tablet(s) administered orally once daily
58443595|NCT03472326|DRUG|TAF|Tablet(s) administered orally once daily
58443596|NCT03472326|DRUG|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
58443597|NCT03472326|DRUG|DRV|Tablet(s) administered orally once daily
58443598|NCT03472326|DRUG|RTV|Tablet(s) administered orally once daily
58443599|NCT06010342|DRUG|TL118 Capsule|Oral administration
57740193|NCT04518878|DRUG|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
57740194|NCT04518878|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
57740195|NCT02464189|OTHER|Q-Kap|
58110379|NCT00635388|OTHER|Placebo|oral, placebo, once/day for 12 weeks
58110380|NCT00635388|OTHER|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
58110381|NCT00635388|OTHER|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
58110382|NCT02974374|DRUG|PF-06835919|Single or repeated, escalating dose
58110383|NCT02974374|OTHER|Placebo|Single or repeated, escalating dose
58110384|NCT04860635|DRUG|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
58110385|NCT01677559|DRUG|MLN8237|
58110386|NCT01677559|DRUG|nab-Paclitaxel|
58443600|NCT05160896|DRUG|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
58443601|NCT05160896|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
58443602|NCT05160896|DRUG|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
58443603|NCT05160896|DRUG|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
58312273|NCT04357795|DRUG|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
58443604|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
57740196|NCT05227742|DRUG|Psilocybin|Participants will receive oral psilocybin once per week for 5 weeks.
58312274|NCT04240873|BIOLOGICAL|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis
58443605|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
58443606|NCT03910972|BIOLOGICAL|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
58443607|NCT02825524|DEVICE|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
58443608|NCT05695885|BEHAVIORAL|STEPS|behavioral counseling
58443609|NCT05695885|BEHAVIORAL|Services as usual (SAU)|behavioral counseling normally provided
57740197|NCT05227742|DRUG|Placebo|Participants will receive inert placebo once per week for 5 weeks.
57740198|NCT02962687|BEHAVIORAL|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
57740199|NCT02962687|BEHAVIORAL|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
57740200|NCT02285946|PROCEDURE|major spine surgery|
57740201|NCT02380547|OTHER|Sonographic diaphragmatic measurements|
57740202|NCT03084055|BEHAVIORAL|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
58312275|NCT04240873|OTHER|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
58312276|NCT02349412|OTHER|Early palliative care|
58312277|NCT04115813|BEHAVIORAL|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
58443610|NCT04930900|DRUG|ARS-1 with URTI|ARS-1
58443611|NCT04930900|DRUG|ARS-1 without URTI|ARS-1 without URTI
58443612|NCT06245733|OTHER|Compassion-Based Education Program Adapted for Adults|Training will be given once a week. This training will last 10 weeks in total.
58443613|NCT06401863|OTHER|Shared Decision Making Tool|EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
58110387|NCT04366388|DEVICE|ActivPAL3 VT (PAL Technologies Ltd).|. The ActivPAL will be fitted by a trained research assistant on the mid-thigh of the participants' dominant leg. ActivPALs have an inclinometer that detects the joint angle of the thigh to capture lying, sitting, standing, and stepping activities.
58110388|NCT02947061|DRUG|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
58443614|NCT05363189|PROCEDURE|Venous augmentation|Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
58443615|NCT05363189|PROCEDURE|Traditional ERAS (enhanced recovery after surgery) protocol|Pre-, peri-, and post-operative care as described in the ERAS protocol
58443616|NCT05363189|PROCEDURE|Sahlgrenska recovery protocol|Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
58443617|NCT05363189|PROCEDURE|No venous augmentation|Traditional deep inferior epigastric artery perforator flap (DIEP)
58443618|NCT03040674|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
58443619|NCT00043511|BIOLOGICAL|pGA2/JS2 Plasmid DNA Vaccine|
58443620|NCT00828230|DRUG|budesonide|One application of 2mg budesonide once daily for 8 weeks
58443621|NCT00828230|DRUG|Placebo foam|One application of placebo foam once daily for 8 weeks
58443622|NCT04379206|DIAGNOSTIC_TEST|HIV self-test kit|fingerprick and oral fluid HIV self-tests with optional on-site or hotline staff assistance
57956081|NCT04699487|DEVICE|Photobiomodulation|"Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session."
57956082|NCT00832728|OTHER|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
57956083|NCT00832728|DEVICE|ELAD®|ELAD therapy
57956084|NCT05405179|PROCEDURE|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized bone flaps for jaw reconstruction using patient-specific surgical guides and titanium plates
57956085|NCT04962360|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
57956086|NCT04962360|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
57956087|NCT04360902|OTHER|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
57956088|NCT00745563|DEVICE|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
57956089|NCT05543473|OTHER|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
58110389|NCT02947061|DRUG|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
58110390|NCT06371547|OTHER|Stretching Exercise|Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.
58110391|NCT03998085|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
58110392|NCT05682794|PROCEDURE|transanal total mesorectal excision|transanal TME
58443623|NCT04379206|OTHER|Graphical User Interface|Gamification or neumorphism user interface
58443624|NCT04430504|BEHAVIORAL|multidisciplinary telerehabilitation|weekly video meetings to instruct and monitor self-exercises at home
58443625|NCT03796117|DEVICE|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
58110393|NCT04804332|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
58110394|NCT04804332|OTHER|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
58110395|NCT04433845|DRUG|Psilocybin|Open-label
58110396|NCT02917954|DEVICE|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
58458463|NCT05608603|DIAGNOSTIC_TEST|Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer|The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
58110397|NCT02889328|DRUG|Regorafenib|Regorafenib 100mg continuous dosing arm
58110398|NCT00680576|BEHAVIORAL|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
58110399|NCT00680576|BEHAVIORAL|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
58110400|NCT06204172|DEVICE|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
58110401|NCT06204172|OTHER|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
58110402|NCT05521750|PROCEDURE|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
58110403|NCT00794326|DRUG|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
58110404|NCT04905654|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
58110405|NCT04905654|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
58110406|NCT03676959|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
58110407|NCT03676959|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
58110408|NCT03676959|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
58110409|NCT01218620|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
58110410|NCT01218620|DRUG|Ketoconazole|Given PO
58110411|NCT01218620|DRUG|Rifampin|Given PO
58110412|NCT01218620|DRUG|Midazolam Hydrochloride|Given IV
58110413|NCT01218620|DRUG|Omeprazole|Given PO
58110414|NCT01218620|DRUG|Tolbutamide|Given PO
58110415|NCT01218620|DRUG|Dextromethorphan Hydrobromide|Given PO
58110416|NCT01218620|OTHER|Pharmacological Study|Correlative studies
58110417|NCT01218620|OTHER|Laboratory Biomarker Analysis|Correlative studies
58110418|NCT04956406|BEHAVIORAL|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
58110419|NCT04956406|OTHER|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
58110420|NCT05701267|DEVICE|MRI research|3T MRI protocol of \~1 hour
58110421|NCT00457379|BEHAVIORAL|physical exercise|
58110422|NCT02867020|DRUG|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
58110423|NCT02867020|DRUG|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
58110424|NCT02867020|DRUG|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
58443626|NCT03796117|DEVICE|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
58110425|NCT02867020|DRUG|Prednisone|Subjects will receive prednisone 10mg/day.
58110426|NCT00580983|RADIATION|IMRT|
58110427|NCT00580983|DRUG|Paclitaxel|
58110428|NCT00580983|DRUG|Carboplatin|
58110429|NCT00580983|DRUG|Cisplatin|
58110430|NCT00580983|DRUG|5-Fluorouracil|
58110431|NCT06278402|DRUG|Tofacitinib|Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
58110432|NCT02791659|RADIATION|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
58110433|NCT00660790|OTHER|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
58110434|NCT05817526|DRUG|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
58110435|NCT05817526|PROCEDURE|Autograft harvesting from chin|Autograft
58110436|NCT03658278|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
58110437|NCT02945280|DRUG|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
58110438|NCT00300092|DRUG|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
58110439|NCT02048397|OTHER|Pulmonary Rehabilitation|
58110440|NCT02048397|DIETARY_SUPPLEMENT|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
58110441|NCT04203706|OTHER|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
58110442|NCT00830063|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
58110443|NCT00830063|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
58110444|NCT00830063|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
58110445|NCT00830063|OTHER|placebo|placebo to match tanezumab and naproxen dosing
58110446|NCT01676584|DRUG|RO6811135|single ascending doses sc
58110447|NCT01676584|DRUG|placebo|single doses sc
58110448|NCT03365921|BIOLOGICAL|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
58110449|NCT06537492|PROCEDURE|REBOA|"The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant."
58110450|NCT06537492|DEVICE|Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)|Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).
58110451|NCT06537492|DEVICE|Mechanical Chest Compression Device with Active Chest Decompression|In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.
58110452|NCT06537492|DEVICE|Impedance Threshold Device|In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
58110453|NCT02177097|BIOLOGICAL|Blood samples|4 x 10 ml blood samples.
58110454|NCT05947552|DRUG|Serum ferritin|Serum ferritin in CKD patients
58110455|NCT06048328|BEHAVIORAL|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 6 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
58110456|NCT00586300|OTHER|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
57740203|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
58110457|NCT00586300|BEHAVIORAL|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
58110458|NCT00586300|OTHER|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
58110459|NCT04854694|DEVICE|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
58110460|NCT04854694|DEVICE|conventional surgical N95 respirator|standard N95 respirator
58110461|NCT02971605|DRUG|Psilocybin|25 mg/70 kg Psilocybin
58443627|NCT03915314|DIAGNOSTIC_TEST|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
58443628|NCT02037334|DEVICE|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
58443629|NCT00351065|DRUG|SK3530|
58443630|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
58443631|NCT01159015|DRUG|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
57740204|NCT01832116|DRUG|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
57740205|NCT03502382|DIAGNOSTIC_TEST|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
57740206|NCT03381495|DRUG|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
57740207|NCT03078270|DRUG|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
57740208|NCT03078270|OTHER|Placebo|single treatment visit for 5 injections of normal saline
57740209|NCT06041035|DRUG|QLS31905|Administered as an intravenous infusion.
58443632|NCT01159015|DRUG|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
58443633|NCT00003346|DRUG|acetaminophen|
58443634|NCT00003346|DRUG|acetylcysteine|
58443635|NCT00003346|DRUG|carmustine|
58443636|NCT01278992|DIETARY_SUPPLEMENT|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
58443637|NCT01942174|BIOLOGICAL|Prevenar 13|Vaccination at the beginning of the study (day 0)
58443638|NCT01942174|BIOLOGICAL|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
58443639|NCT01942174|DRUG|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
57740210|NCT06041035|DRUG|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
57740211|NCT06041035|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
57740212|NCT06041035|DRUG|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
57740213|NCT06041035|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
57740214|NCT06041035|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
58110462|NCT00111189|DRUG|Placebo|Placebo every 4 wk up to 24 mo
58110463|NCT00111189|DRUG|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
58443640|NCT01942174|DRUG|Methotrexate - Delay|"For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13"
58443641|NCT05581459|OTHER|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
57740215|NCT03939052|DIETARY_SUPPLEMENT|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
57740216|NCT01284465|BEHAVIORAL|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
58110464|NCT05478811|DEVICE|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
58110465|NCT05478811|DEVICE|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
58110466|NCT00001622|PROCEDURE|investigate the relationship between in vivo and in vitro vascular responses|
58443642|NCT05581459|OTHER|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
58443643|NCT05581459|OTHER|Sham vibration|Handheld device was applied to the participants without any vibrations.
58443644|NCT05427240|OTHER|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
58443645|NCT05427240|OTHER|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
58443646|NCT05427240|OTHER|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
58443647|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
58443648|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
58443649|NCT06540794|OTHER|PEEP TITRATION|Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
58443650|NCT06182969|DRUG|APG-2575|Take orally once daily (QD) for 12 weeks.
58443651|NCT06182969|OTHER|Placebo|Take orally once daily (QD) for 12 weeks.
58443652|NCT00668837|DRUG|Paliperidone|
58443653|NCT02628561|DEVICE|Transcranial direct current stimulation|
58443654|NCT02628561|BEHAVIORAL|Constraint-Induced Movement Therapy|
58443655|NCT04575571|OTHER|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
58443656|NCT00950313|OTHER|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
58443657|NCT00950313|OTHER|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
58443658|NCT05022966|OTHER|No intervention|Individuals did not received any intervention.
58443659|NCT01259180|PROCEDURE|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
58110467|NCT03843437|DEVICE|Tencel Therapeutic Garments|Children age 6 months to 3 years will wear a Tencel full body suit with feet and mittens, while children age 3-6 years will wear Tencel long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
58110468|NCT03843437|DEVICE|Cotton Therapeutic Garments|Children age 6 months to 3 years will wear a cotton full body suit with feet and mittens, while children age 3-6 years will wear cotton long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
58110469|NCT05326087|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
58110470|NCT05326087|DRUG|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
58110471|NCT04409002|DRUG|Niraparib|Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
58110472|NCT04409002|DRUG|Dostarlimab|Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
58110473|NCT04409002|RADIATION|Radiation|Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
58110474|NCT00461500|DRUG|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
58110475|NCT00461500|DRUG|Fluticasone propionate|FP 100
58110476|NCT03113058|COMBINATION_PRODUCT|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
58443660|NCT01259180|PROCEDURE|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
58443661|NCT05044871|DRUG|Pamiparib|40mg PO. bid.
58443662|NCT05044871|DRUG|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
58443663|NCT05044871|DRUG|Tislelizumab|200mg IV. D1
58443664|NCT05044871|DRUG|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
58443665|NCT05044871|DRUG|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
58443666|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
58443667|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
58443668|NCT02343406|DRUG|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
58110477|NCT05452538|DEVICE|Transfusion|Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
58110478|NCT03465228|DEVICE|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
58110479|NCT03465228|DEVICE|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
58110480|NCT03465228|OTHER|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
58443669|NCT02343406|DRUG|Temozolomide|Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
58443670|NCT02343406|DRUG|Lomustine|Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
58110481|NCT02958540|BIOLOGICAL|SynGEM|Prime / boost vaccination in each group
58110482|NCT02958540|OTHER|placebo|prime /boost vaccination
58110483|NCT04088578|OTHER|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
58110484|NCT04088578|OTHER|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
58110485|NCT04088578|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
58110486|NCT04878978|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis will be used to sample the amniotic fluid for Biofire detection of microorganism and to direct antibiotic treatment
58110487|NCT04878978|OTHER|Routine care without amniocentesis|Routine clinical care
58110488|NCT01614613|DEVICE|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
58110489|NCT01614613|DEVICE|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
58110490|NCT01614613|DEVICE|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
58110491|NCT01614613|DEVICE|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
57740217|NCT01284465|BEHAVIORAL|Control group|Group education sessions at baseline, 3 and 6 months
58110492|NCT01614613|DEVICE|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
58110493|NCT01614613|DEVICE|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
58110494|NCT02370784|DRUG|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
58110495|NCT02370784|DRUG|Placebo|oral drug of similar appearance to atorvastatin
58443671|NCT05478083|DRUG|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
58443672|NCT04823442|DRUG|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
58443673|NCT04823442|DRUG|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
58443674|NCT04207749|DEVICE|LID015385 contact lenses|Investigational soft contact lenses
58443675|NCT04207749|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses
58443676|NCT04207749|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
57740218|NCT02522494|BEHAVIORAL|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
57740219|NCT02522494|BEHAVIORAL|Video|An educational intervention delivered prior to patients' visits with primary care providers.
57740220|NCT05602714|OTHER|Collection Data|
58110496|NCT00059995|BIOLOGICAL|iratumumab|
58110497|NCT01916564|OTHER|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
58110498|NCT01916564|OTHER|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
58110499|NCT00097019|DRUG|bevacizumab|
58110500|NCT01569503|DEVICE|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
58110501|NCT01698320|DRUG|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
58110502|NCT01698320|DRUG|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
58443677|NCT03433417|DEVICE|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
58443678|NCT06042634|BEHAVIORAL|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
58443679|NCT06042634|BEHAVIORAL|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
58443680|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
58443681|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
58443682|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
57740221|NCT03577210|PROCEDURE|augmentation genioplasty|augmentation genioplasty with patient-specific PEEK implant
57740222|NCT06644573|PROCEDURE|PROSOMNIA Sleep Therapy™ (PSTx)|PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
58443683|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
57769652|NCT02387437|BEHAVIORAL|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
58110503|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
58110504|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
58110505|NCT01261520|BEHAVIORAL|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
58110506|NCT06307808|DRUG|Tacrolimus|Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus
58110507|NCT06307808|DRUG|Belatacept|Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
58110508|NCT05470790|OTHER|patient reported outcome measures|Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
58110509|NCT04405206|DRUG|Oxaliplatin|OXA 130mg/m2
58443684|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
58443685|NCT00974623|DEVICE|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
58443686|NCT03956966|DRUG|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
58443687|NCT03956966|DRUG|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
58458464|NCT01796925|DEVICE|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
58458465|NCT01464086|OTHER|whole body MRI|whole body MRI at inclusion, one and two years
58458466|NCT05478421|PROCEDURE|Collagen sponge|The bone cavity will be filled with collagen sponge.
58458467|NCT05478421|PROCEDURE|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
57769653|NCT02387437|BEHAVIORAL|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
58110510|NCT04405206|DRUG|Capecitabine|Cape 1000mg/m2
58110511|NCT04405206|RADIATION|intensity modulated radiotherapy|IMRT 50.4Gy/22f
58110512|NCT04405206|PROCEDURE|DRE-Endoscopy-MRI-CEA|examination process in follow up
58110513|NCT04405206|PROCEDURE|Nonoperative Management|Watch and Wait
58110514|NCT04405206|PROCEDURE|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
58110515|NCT04405206|PROCEDURE|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
58110516|NCT04405206|BEHAVIORAL|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
58110517|NCT06391905|DRUG|PCSK9 inhibitor in combination with standard advanced first-line regimen group|Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
58110518|NCT06391905|DRUG|standard advanced first-line regimen group|Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
58110519|NCT00686374|BIOLOGICAL|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
58110520|NCT06529835|DEVICE|NeuroSpan Bridge|"The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump."
58110521|NCT06529835|DEVICE|NeuroGen Nerve Guide|The NeuraGen Nerve Guide is a resorbable implant for the repair of 0.5-1.0cm peripheral nerve discontinuities. NeuraGen Nerve Guide provides a protective environment for peripheral nerve repair after injury. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap. The semi-permeable type 1 collagen membrane allows for controlled resorption, appropriate nutrient diffusion and retention of representative Nerve Growth Factor.
58110522|NCT06529835|DEVICE|Nerve Autograft|A nerve autograft is a surgical procedure that involves transplanting a segment of a patient's own sensory nerve tissue to repair a damaged peripheral nerve injury measuring 1.1-3.0cm. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap
58110523|NCT06536712|BIOLOGICAL|Mesenchymal Stem Cells Derived Exosomes|Mesenchymal Stem Cells Derived Exosomes will be administered intraperitoneally to patients at the end of their surgery
58110524|NCT06536712|OTHER|Placebo|10 patients will receive intraperitoneal placebo at the end of their surgery
58110525|NCT02367079|DEVICE|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
58110526|NCT00648856|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
58110527|NCT00648856|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fed
58110528|NCT05658614|BIOLOGICAL|Sm14 recombinant vaccine+ GLA-SE adjuvant|rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
58110529|NCT05366556|BEHAVIORAL|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
58110530|NCT06025175|RADIATION|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
58312278|NCT05766241|BEHAVIORAL|Sensory Strategies Training|In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
58312279|NCT00177411|DRUG|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
58443688|NCT03956966|DRUG|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
58443689|NCT02870153|DRUG|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
58443690|NCT02870153|DRUG|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
58443691|NCT04891133|DRUG|Baricitinib|4 mg baricitinib (2 tablets of 2 mg) once daily
58312280|NCT00314405|DRUG|Methylene blue (1%)|
58312281|NCT00314405|DRUG|Rhenium sulfure|
58312282|NCT00314405|PROCEDURE|Surgical procedure|
58443692|NCT04891133|DRUG|Placebo|4 mg placebo (2 tablets of 2 mg) once daily
58443693|NCT03636126|DEVICE|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
58443694|NCT01483183|DRUG|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
57769654|NCT03975426|PROCEDURE|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
58110531|NCT06025175|OTHER|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
58110532|NCT05213078|OTHER|Educational Intervention|Receive teaching intervention
58443695|NCT01483183|DRUG|Placebo|Placebo dose, 10-minute constant rate IV infusion
58458468|NCT05478421|PROCEDURE|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
58458469|NCT01446627|OTHER|There is no intervention for this study|None, no intervention made.
58110533|NCT05213078|OTHER|Quality-of-Life Assessment|Ancillary studies
58110534|NCT05213078|OTHER|Questionnaire Administration|Ancillary studies
58110535|NCT05684250|BEHAVIORAL|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
58110536|NCT04193722|DRUG|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
58110537|NCT06331078|OTHER|Square Stepping Exercise training|The experimental group will have Square Stepping Exercise training.
58110538|NCT06331078|OTHER|Aerobic Exercise Training|Individuals in the aerobic control cohort will partake in a treadmill walking session.
58110539|NCT03952910|OTHER|Online pain education program|Online pain education program
58110540|NCT01956279|DRUG|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
58110541|NCT01956279|DRUG|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
58110542|NCT00401882|DRUG|Epinephrine|Epinephrine (1 mg) IV additional doses
58110543|NCT00401882|DRUG|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
58110544|NCT01846247|OTHER|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
58312283|NCT00314405|PROCEDURE|Anatomo-pathologic procedure|
58443696|NCT05809193|BEHAVIORAL|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
58443697|NCT01797055|DRUG|Human apotransferrin|intravenous infusion
58443698|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
58443699|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
57769655|NCT06251037|BEHAVIORAL|Youth Aware of Mental Health in Galicia|"The program follows a manualized protocol, comprising five interactive one-hour class sessions with adaptations to the Galician school population.~The Inaugural Session consists of an interactive slide presentation, an introduction of materials, the delivery of the manual, and the poster's display. The Second Session involves group discussions on real-life dilemmas. The Third and Fourth Sessions focus on crisis situations, depression, suicidal ideation, and help-seeking behaviors through role-playing games. The Closing Session includes a collective summary of topics and addresses dynamic aspects emerging during the group experience."
58110545|NCT01846247|OTHER|Standard care|
58110546|NCT05127603|BEHAVIORAL|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
58110547|NCT00003633|DRUG|docetaxel|
58110548|NCT00003633|DRUG|estramustine phosphate sodium|
58110549|NCT00003633|DRUG|mitoxantrone hydrochloride|
58110550|NCT00003633|DRUG|prednisone|
58110551|NCT00670878|DRUG|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
58110552|NCT00670878|DRUG|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
58110553|NCT03446274|DRUG|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
58110554|NCT01986842|DIETARY_SUPPLEMENT|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
58110555|NCT06353035|OTHER|Rewilding|Private yards of the intervention study subjects will be modified with vegetation and deadwood.
58110556|NCT03090009|DRUG|Flurbiprofen|100 mg twice a day for 14 days
58110557|NCT03090009|DRUG|Placebo Oral Tablet|placebo group
58312284|NCT04413045|OTHER|Prevalence of COVID-19|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
58312285|NCT05883982|PROCEDURE|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
58312286|NCT05378503|DRUG|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
58312287|NCT05378503|DRUG|Qsymia 7.5Mg-46Mg Extended Release Capsule|"1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
58312288|NCT05378503|DRUG|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
58110558|NCT06374381|BEHAVIORAL|PEACE Online Resources|The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.
58110559|NCT06374381|BEHAVIORAL|PEACE Weekly Group Facilitation|Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.
58110560|NCT06374381|BEHAVIORAL|PEACE Weekly Individual Facilitation|Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
58110561|NCT00002189|DRUG|Paclitaxel|
58110562|NCT04664608|DEVICE|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
58110563|NCT01987700|DEVICE|FLEX-HD|
58110564|NCT01987700|DEVICE|Strattice|
58110565|NCT02189694|DEVICE|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
58110566|NCT02189694|DEVICE|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
58110567|NCT02189694|DEVICE|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
58110568|NCT04618835|DIAGNOSTIC_TEST|40-Steps-test|40 steps performed on the spot
58110569|NCT03764410|PROCEDURE|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
58110570|NCT03654690|DIAGNOSTIC_TEST|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
58110571|NCT03654690|BEHAVIORAL|Counseling|Post-Test HIV Risk ReductionCounseling
58110572|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA
58110573|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
58110574|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
58110575|NCT03951870|BEHAVIORAL|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
58110576|NCT03951870|BIOLOGICAL|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
58110577|NCT02891564|BEHAVIORAL|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
58110578|NCT02891564|OTHER|Control Mobile 3D video game|expectancy-matched control game
58110579|NCT04733352|OTHER|acupuncture|to conduct acupuncture on different acupoints
58110580|NCT01548950|DRUG|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
58443700|NCT02683434|DEVICE|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
58443701|NCT03828331|OTHER|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
58443702|NCT06169982|DRUG|LY3209590|Administered SC
58110581|NCT00198978|DRUG|Cyclophosphamide|
58110582|NCT00198978|DRUG|Dexamethasone / Prednisolone|
58110583|NCT00198978|DRUG|Cytarabine|
58110584|NCT00198978|DRUG|Idarubicin|
58110585|NCT00198978|DRUG|Granulocyte-Colony-Stimulating Factor|
58110586|NCT00198978|DRUG|Mercaptopurine|
58110587|NCT00198978|DRUG|Methotrexate|
58443703|NCT05349786|OTHER|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
58443704|NCT03154996|DRUG|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
58443705|NCT03154996|DRUG|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
58443706|NCT03154996|DEVICE|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
58443707|NCT03055520|OTHER|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
58110588|NCT00198978|DRUG|Rituximab|
58110589|NCT00198978|DRUG|HDARAC|
58110590|NCT00198978|DRUG|Vincristine|
58110591|NCT00198978|DRUG|Depocyte|
58312289|NCT05378503|DRUG|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
58110592|NCT00198978|DRUG|Asparaginase|
58110593|NCT00662714|DRUG|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
58110594|NCT00662714|DRUG|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
58110595|NCT02838290|OTHER|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
58110596|NCT02838290|OTHER|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
58110597|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
58110598|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
58110599|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
58110600|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
58110601|NCT02678221|DRUG|Sildenafil citrate|
58110602|NCT02678221|DRUG|Aspirin|
58110603|NCT03455023|OTHER|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
58110604|NCT03706326|BIOLOGICAL|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
58110605|NCT03706326|BIOLOGICAL|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
58110606|NCT03706326|COMBINATION_PRODUCT|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
58110607|NCT04318652|DRUG|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
58110608|NCT00967200|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
58110609|NCT00967200|OTHER|pharmacogenomic studies|pharmacogenomic studies
58312290|NCT05378503|DRUG|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
58312291|NCT06033469|DRUG|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
58312292|NCT06033469|DRUG|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
58312293|NCT02530385|OTHER|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
58312294|NCT02530385|BIOLOGICAL|FMT Capsules|Capsules will be generated as per FDA-approved procedures
58312295|NCT04596293|DRUG|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
58110610|NCT04928911|BIOLOGICAL|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
58110611|NCT05127811|DRUG|ZN-d5|BION design
58443708|NCT03055520|OTHER|placebo|nonspecific recreation including befriending and free simple activities.
58443709|NCT03261219|DEVICE|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
57956090|NCT06296862|OTHER|Dietary Approaches to Stop Hypertension Diet|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
58110612|NCT02448472|OTHER|Observational study, none intervention|
58443710|NCT03261219|DEVICE|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
58443711|NCT00924768|BIOLOGICAL|20K EU CCRE|Inhalation of CCRE
58110613|NCT01919957|OTHER|No intervention|
58110614|NCT02767622|PROCEDURE|Liver transplantation|
58443712|NCT03692702|BEHAVIORAL|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
58443713|NCT02816801|OTHER|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
58443714|NCT01032720|PROCEDURE|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
57956091|NCT00276172|DRUG|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
58110615|NCT04323007|DIAGNOSTIC_TEST|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
58110616|NCT03973996|DIETARY_SUPPLEMENT|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
58110617|NCT03973996|DIETARY_SUPPLEMENT|Placebo|A matched gummy confection formulated without green tea extract
58110618|NCT00270699|BIOLOGICAL|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
58110619|NCT00270699|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-200,201
58110620|NCT04134975|PROCEDURE|Spine surgery|surgery with pedicle screw placement between L1 and S1
58443715|NCT01032720|PROCEDURE|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
58443716|NCT05831488|OTHER|Non-Interventional|Non Interventional
58443717|NCT03113994|DRUG|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
58443718|NCT03113994|DRUG|Placebo Oral Tablet|Placebo, daily for 12 months
58443719|NCT03113994|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg CoQ10, daily for 12 months
57740223|NCT06644573|PROCEDURE|Anesthesia-Induced Sleep Therapy|"1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy."
57740224|NCT06644573|DRUG|Diprivan (propofol), Astra-Zeneca|Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
58443720|NCT03113994|DIETARY_SUPPLEMENT|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
58443721|NCT03113994|DIETARY_SUPPLEMENT|Vitamin D|2000IU Vitamin D, daily for 12 months
58443722|NCT02233972|DRUG|Midazolam|
58443723|NCT02233972|DRUG|Ginkgolides Meglumine Injection|
58443724|NCT02233972|DRUG|placebo|
57740225|NCT06644573|DEVICE|Continuous EEG Monitoring|Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
57956092|NCT00872105|PROCEDURE|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
58110621|NCT05482672|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
58110622|NCT05482672|BEHAVIORAL|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
58443725|NCT01415141|DRUG|Peginterferon alfa-2a|180ug subcutaneously, weekly
58443726|NCT01415141|DRUG|Ribavirin|"Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg"
58443727|NCT01415141|DRUG|telaprevir|750mg every 8 hours, orally
58443728|NCT00120965|DEVICE|AutoPulse|Standard device settings
58443729|NCT00120965|OTHER|Manual CPR|Manual CPR
58443730|NCT03315039|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
58443731|NCT05282771|DRUG|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
58443732|NCT05282771|DRUG|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
58443733|NCT05282771|DRUG|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
58443734|NCT04206371|DIAGNOSTIC_TEST|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
58110623|NCT05482672|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
58110624|NCT05482672|BEHAVIORAL|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
58458470|NCT05326451|DEVICE|active tDCS|Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
57740226|NCT05396248|BEHAVIORAL|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
57740227|NCT05396248|BEHAVIORAL|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
57740228|NCT03755830|OTHER|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
57956093|NCT00872105|PROCEDURE|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
57956094|NCT02173743|OTHER|PRP|platelet enriched autologous blood plasma
57956095|NCT02173743|OTHER|Control|Regular barbotage/care as usual
57956096|NCT00202735|PROCEDURE|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
57956097|NCT00202735|PROCEDURE|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
57956098|NCT03828929|DRUG|Vitamin C|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
57956099|NCT03828929|DRUG|Normal saline|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
57956100|NCT01266863|OTHER|E test method|E test strips directly applied to BAL
57956101|NCT05837637|DIAGNOSTIC_TEST|The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)|"* The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12"
57956102|NCT02755857|DRUG|Lozanoc|65 mg
57956103|NCT04686630|OTHER|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
57956104|NCT02877342|OTHER|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
57956105|NCT03821857|DRUG|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
57956106|NCT00281398|BEHAVIORAL|Questionnaire|
57956107|NCT00385645|DRUG|Combivir+Kaletra|
57956108|NCT00385645|DRUG|Combivir+Reyataz|
57956109|NCT05182554|BEHAVIORAL|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
58110625|NCT01810926|BIOLOGICAL|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
58110626|NCT01810926|DRUG|Rituximab|single infusion of200 mg/m2 on day -1
58110627|NCT01810926|DRUG|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
58110628|NCT01810926|DRUG|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
57740229|NCT05245344|PROCEDURE|Peripheral blood withdrawal|25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
57740230|NCT06003803|BEHAVIORAL|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
57740231|NCT01352338|DRUG|Lenalidomide, endoxan, prednisone|dose-finding
58110629|NCT01810926|DRUG|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
58110630|NCT01810926|DRUG|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
58110631|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
58110632|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
58110633|NCT06232863|DRUG|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
58110634|NCT01305317|DRUG|Lipitor|Atorvastatin 20mg daily for 6 months
58110635|NCT03622333|GENETIC|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
58110636|NCT01574599|OTHER|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
58110637|NCT04362033|DIAGNOSTIC_TEST|Passive Leg Raising (PLR) and PEEP increment (PEEP)|PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position
57740232|NCT01352338|DRUG|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
57740233|NCT04756687|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
57740234|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via prepared syringe
58443735|NCT01255618|DEVICE|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
57956110|NCT05182554|BEHAVIORAL|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
58110638|NCT01513785|DRUG|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
58443736|NCT05449691|PROCEDURE|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
57956111|NCT05182554|BEHAVIORAL|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
58110639|NCT01513785|DRUG|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
58110640|NCT01418729|DRUG|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
58110641|NCT00103103|DRUG|bortezomib|
58110642|NCT00103103|DRUG|fluorouracil|
58443737|NCT05604027|DIAGNOSTIC_TEST|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
58443738|NCT03532126|DEVICE|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
57740235|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via syringe pump
57740236|NCT04299672|PROCEDURE|Postural reconstruction|Interventions are described in group descriptions
57740237|NCT01053182|PROCEDURE|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
57740238|NCT01053182|PROCEDURE|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
57740239|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
57740240|NCT06123286|DRUG|Tart Cherry|1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
57740241|NCT06123286|DRUG|Omega 3 FA (Fish Oil)|2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks
57740242|NCT00239174|DRUG|SR147778|
57740243|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
58110643|NCT00103103|DRUG|leucovorin calcium|
58110644|NCT00437281|DRUG|Placebo|Placebo
58110645|NCT00437281|DRUG|Pregabalin|Orally-administered pregabalin
58110646|NCT04728087|DEVICE|ACCEL® Absorbable Hemostat Powder|Up to 2 bellows (10 grams nominal) of ACCEL®
58110647|NCT04728087|DEVICE|Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)|Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
58110648|NCT06544772|DEVICE|Pivot cigarette smoking cessation program|The Pivot cigarette smoking cessation program comprises a mobile personal breath carbon monoxide sensor (Pivot Breath Sensor) and a smartphone app (Pivot app) with in-app asynchronous SMS text-based coaching with a certified human tobacco cessation coach.
58110649|NCT00310778|DRUG|high sodium diet|high sodium diet
58110650|NCT00310778|DRUG|low sodium diet|low sodium diet
58110651|NCT00310778|DRUG|ramipril 10 mg|ramipril 10 mg
58110652|NCT00310778|DRUG|valsartan 160 mg|valsartan 160 mg
58110653|NCT00310778|DRUG|candesartan 8 mg|candesartan 8 mg
57740244|NCT03343236|RADIATION|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
57956112|NCT05182554|BEHAVIORAL|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
57956113|NCT05182554|BEHAVIORAL|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
57956114|NCT05182554|BEHAVIORAL|Video order|The order in which videos appear on the vaccine content website will be randomized.
57956115|NCT03373604|DRUG|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
57956116|NCT03373604|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
57956117|NCT03044340|OTHER|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
57740245|NCT05898867|OTHER|Saline|Open label intra-articular injection of isotonic saline.
57956118|NCT05011708|DEVICE|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
57956119|NCT05011708|DEVICE|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
57956120|NCT00283595|DRUG|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
58110654|NCT00310778|DRUG|atenolol 50 mg|atenolol 50 mg
58110655|NCT00475852|DRUG|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
58110656|NCT00475852|DRUG|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
58110657|NCT05017493|COMBINATION_PRODUCT|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
58110658|NCT04351282|RADIATION|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
58110659|NCT00911859|DRUG|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
57740246|NCT05938647|OTHER|Risk factor: group 3|Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
57956121|NCT00283595|DRUG|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
57956122|NCT00397826|DRUG|MK0733|Duration of Treatment: 12 Weeks
57956123|NCT00338871|PROCEDURE|home exercise|
57956124|NCT01891331|DRUG|VT-1161|
57956125|NCT01891331|DRUG|Fluconazole|
57956126|NCT00000859|DRUG|Indinavir sulfate|
57956127|NCT00000859|DRUG|Ritonavir|
57956128|NCT00000859|DRUG|Nelfinavir mesylate|
57956129|NCT05183750|PROCEDURE|High tibial osteotomy|Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
57956130|NCT01796405|DRUG|Clofarabine|
57956131|NCT05220527|DRUG|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
57956132|NCT05220527|DRUG|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
58110660|NCT00911859|DRUG|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
58110661|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
58110662|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
58443739|NCT02406911|DRUG|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
58443740|NCT04054141|DEVICE|Mag Stim|rTMS
57956133|NCT05220527|DRUG|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
57956134|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal powder
57956135|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intramuscular injection
57956136|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal spray
57956137|NCT02692066|BIOLOGICAL|varicella vaccine|
57956138|NCT03119792|OTHER|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
57956139|NCT03119792|OTHER|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
57956140|NCT01431664|DRUG|multikinase inhibitor AT9283|
57956141|NCT01431664|OTHER|laboratory biomarker analysis|
57956142|NCT01431664|OTHER|pharmacological study|
57956143|NCT02107586|PROCEDURE|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
57956144|NCT02107586|PROCEDURE|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
57956145|NCT01197326|DEVICE|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
57956146|NCT01051427|DEVICE|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
57956147|NCT01051427|DEVICE|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
57956148|NCT01121393|DRUG|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
57956149|NCT01121393|DRUG|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
57956150|NCT00878371|DRUG|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
57956151|NCT03824808|DRUG|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
57956152|NCT03824808|DRUG|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
57956153|NCT00525655|BEHAVIORAL|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
57956154|NCT00525655|BEHAVIORAL|Questionnaire|Questionnaires taking 10-15 minutes to complete.
57956155|NCT04464161|DIETARY_SUPPLEMENT|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
57956156|NCT06042803|OTHER|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
57956157|NCT06042803|OTHER|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
58443741|NCT01511068|DRUG|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
58443742|NCT05109624|PROCEDURE|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
57956158|NCT06042803|OTHER|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
57956159|NCT04356560|DIAGNOSTIC_TEST|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
57956160|NCT02742038|OTHER|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
57956161|NCT06044688|DEVICE|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
58443743|NCT03643627|DRUG|SYNT001|single IV infusion
58443744|NCT03643627|DRUG|Placebo|single IV infusion
58443745|NCT03005132|OTHER|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
58443746|NCT04612257|OTHER|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
57740247|NCT05938647|OTHER|Risk factor: group 4|Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
58443747|NCT02923856|DEVICE|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
58443748|NCT02923856|DEVICE|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
58443749|NCT02923856|DEVICE|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
57740248|NCT02628210|OTHER|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
57740249|NCT01527929|DRUG|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
57740250|NCT01921673|DRUG|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
57740251|NCT03364127|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
57740252|NCT03364127|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
57956162|NCT06044688|DEVICE|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
57956163|NCT02698735|DRUG|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
57956164|NCT02698735|DRUG|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
57956165|NCT01445028|DRUG|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
57956166|NCT00723970|DRUG|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
57956167|NCT02019407|PROCEDURE|PVI, CTI block|"* PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
57956168|NCT02019407|PROCEDURE|PVI|PVI (pulmonary isolation)
57956169|NCT02428257|PROCEDURE|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
57956170|NCT02428257|DRUG|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
57956171|NCT02428257|DRUG|isobaric bupivacaine|0.5% isobaric bupivacaine
57956172|NCT02428257|DRUG|ephedrine|
57956173|NCT00375726|BIOLOGICAL|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
57956174|NCT00375726|BIOLOGICAL|Placebo|Placebo for rDEN3/4delta30(ME)
57956175|NCT02911480|DRUG|Oxytocin|
57956176|NCT05874973|OTHER|Time-controlled adaptative ventilation (TCAV)|Ventilation with TCAV set on the APRV mode on the ventilator.
57956177|NCT05874973|OTHER|Volume-controlled ventilation (VCV)|Ventilation with the VCV mode set on the ventilator.
57956178|NCT04670640|DEVICE|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
58110663|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
58110664|NCT00911859|DRUG|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
58443750|NCT01937260|DRUG|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
58443751|NCT01224717|DRUG|PTH134|
57956179|NCT04670640|BEHAVIORAL|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
58110665|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
57740253|NCT02739438|OTHER|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
57956180|NCT04670640|BEHAVIORAL|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
57956181|NCT00751777|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
57956182|NCT00751777|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
57956183|NCT03519893|DRUG|Losartan|Patients are tested for their normal prescription losartan medication
57956184|NCT01420237|DEVICE|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
57956185|NCT03645993|GENETIC|Genetic Testing|A one time blood sample will be taken.
57956186|NCT01383837|BEHAVIORAL|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
57956187|NCT01383837|BEHAVIORAL|Health Promotion|Health Promotion Intervention
58110666|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
58110667|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
58110668|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
58110669|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
58110670|NCT01306461|DRUG|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
58443752|NCT01224717|DRUG|Placebo|
58443753|NCT01224717|DRUG|Forsteo|
58110671|NCT01306461|DRUG|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
58110672|NCT03016182|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
58110673|NCT03016182|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
58110674|NCT03569254|DEVICE|Neomedlight Phototherapy Blanket|The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
57956188|NCT05422807|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
57956189|NCT01175109|DRUG|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
57956190|NCT03111784|OTHER|Fish consumption and lipid profiles|
58443754|NCT03827603|DRUG|Ibrutinib|Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
58443755|NCT05503342|OTHER|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
57956191|NCT05266235|DEVICE|Validation of the Withings bodyscan scale WBS08|Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
58110675|NCT03569254|DEVICE|Ohmeda-Fiber Optic Phototherapy Blanket|This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
58110676|NCT03645070|DEVICE|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
58110677|NCT03645070|DEVICE|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
58110678|NCT01255228|OTHER|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
58110679|NCT04468087|DRUG|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
58110680|NCT04468087|DRUG|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
58110681|NCT04468087|DRUG|Sofusbuvir + Daclastavir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
58110682|NCT04468087|DRUG|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
58110683|NCT04468087|DRUG|Placebo Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
58110684|NCT04468087|DRUG|Placebo Sofusbuvir + Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
58110685|NCT00657878|DRUG|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
58110686|NCT00657878|DRUG|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
58110687|NCT00657878|DRUG|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
58110688|NCT00657878|DRUG|Topotecan|dosing and schedule according to Institutional guidelines
58110689|NCT00657878|DRUG|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
57740254|NCT02739438|OTHER|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
58110690|NCT04675060|DRUG|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
58110691|NCT03187483|PROCEDURE|orthodontic treatment|orthodontic treatment in maxillary crowding
58110692|NCT00440375|DRUG|Rosiglitazone|
58110693|NCT02207647|OTHER|no intervention|
58110694|NCT01502345|BIOLOGICAL|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
58110695|NCT02947282|OTHER|Educational Workshop|They will attend a 2 hour class on pelvic floor health
58110696|NCT05729256|BEHAVIORAL|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
58110697|NCT05729256|BEHAVIORAL|Brief Advice and Information|Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
57740255|NCT02739438|OTHER|Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
57740256|NCT03961568|DRUG|Cenobamate|active drug
57740257|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
57740258|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
58110698|NCT04733235|DRUG|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
58110699|NCT00190307|DRUG|aspirin 75 mg/day|aspirin 75 mg/day
58110700|NCT01991977|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
58110701|NCT01991977|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
58110702|NCT01991977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57740259|NCT06455462|DRUG|Tezepelumab|tezepelumab treatment initiated as part of the tezepelumab patient access programme (TPAP) between 1st January 2023 and 19th July 2023
58110703|NCT01991977|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
58110704|NCT01991977|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET
58110705|NCT01991977|OTHER|Quality-of-Life Assessment|Ancillary studies
58110706|NCT01991977|DRUG|Temozolomide|Receive temozolomide
58110707|NCT02292433|DRUG|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
58110708|NCT02292433|DRUG|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
58110709|NCT02292433|DRUG|Placebo|tablets, breakfast plus lunch, 7 days
58110710|NCT05547815|BIOLOGICAL|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
58110711|NCT03342508|DEVICE|Fetal Pillow|see arm description
58110712|NCT02725671|DEVICE|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
58110713|NCT01344408|PROCEDURE|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
58110714|NCT03574246|DRUG|chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15|chlorhexidine gluconate + benzydamine hydrochloride oral rinse
58110715|NCT03574246|OTHER|%0.9 NaCl Solution|isotonic sodium chloride
58443756|NCT05503342|OTHER|Asthma control assessment|Asthma control assessment questionnaire application in paper format
57740260|NCT04321226|DEVICE|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
57956192|NCT05378386|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
58110716|NCT00889785|BEHAVIORAL|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
58110717|NCT00889785|BEHAVIORAL|Usual Care|Will receive usual care and monthly phone calls as an active control.
58110718|NCT02962882|DEVICE|Mepilex Border|Multi-layer Foam Dressings
58110719|NCT04014400|OTHER|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
58110720|NCT04360603|DEVICE|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
58110721|NCT04360603|DEVICE|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
58110722|NCT02808806|OTHER|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
58110723|NCT02145403|DRUG|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
58110724|NCT02145403|DRUG|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
58110725|NCT03065283|PROCEDURE|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
58110726|NCT03065283|PROCEDURE|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
58110727|NCT04440345|DRUG|IBI362|Administered by subcutaneous injection
58110728|NCT04440345|DRUG|Placebo|Administered by subcutaneous injection
58110729|NCT06204926|DIAGNOSTIC_TEST|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
58110730|NCT00328237|PROCEDURE|Cord Blood Transplant|
58110731|NCT06502041|PROCEDURE|MARPE with MOP|mini-screw assisted rapid palatal expansion with micro-osteoperforation
58110732|NCT06502041|PROCEDURE|MARPE without MOP|mini-screw assisted rapid palatal expansion without micro-osteoperforation
58443757|NCT01980381|OTHER|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
58443758|NCT05447481|DIETARY_SUPPLEMENT|chicory inulin-type fructan|Dietary supplement: chicory inulin-type fructan
58443759|NCT00767806|DRUG|Duloxetine|60 mg orally once daily for 12 weeks
58110733|NCT03286647|PROCEDURE|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
58110734|NCT00602550|DRUG|Zidovudine|
58443760|NCT00767806|DRUG|Placebo|Placebo once daily orally for 12 weeks
58443761|NCT02318966|DIETARY_SUPPLEMENT|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
57769656|NCT04109638|DEVICE|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
58443762|NCT04156035|DRUG|Lamotrigine|Orally; 300 mg
57956193|NCT03065348|DIETARY_SUPPLEMENT|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
58443763|NCT04156035|DRUG|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
58443764|NCT04156035|DRUG|Placebo Pretreatment|Lamotrigine Placebo
58443765|NCT04156035|DRUG|Placebo Infusion|Ketamine Placebo
58110735|NCT01936168|DEVICE|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
58110736|NCT01936168|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
58110737|NCT03978702|OTHER|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
58110738|NCT04252352|DEVICE|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
58110739|NCT03139747|DRUG|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
58110740|NCT03139747|DRUG|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
58110741|NCT05189561|OTHER|near-infrared scanner|"Tests to be administered: Near Infra-Red Scanning of the head at the bedside.~Time taken for testing: Two minutes~Biological samples collected: None~Frequency of testing/collection: Once~Risks for the participants while being tested: None"
57740261|NCT01835626|DRUG|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
57740262|NCT01835626|RADIATION|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
57740263|NCT02228265|OTHER|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
57740264|NCT02228265|DRUG|Enzalutamide|Given PO
58110742|NCT00276874|DRUG|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
58110743|NCT00276874|DRUG|Placebos|Placebo; 0 mg; oral; daily
58110744|NCT01151787|DRUG|cyclobenzaprine hydrochloride|15mg daily for 3 months
58110745|NCT01151787|DRUG|placebo|placebo
58443766|NCT04647968|PROCEDURE|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
57740265|NCT02228265|OTHER|Laboratory Biomarker Analysis|Correlative studies
58110746|NCT01132716|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
58443767|NCT04647968|PROCEDURE|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
58110747|NCT03765671|DRUG|Elafibranor|120mg oral single dose
58110748|NCT04147728|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
58110749|NCT04147728|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
58110750|NCT05313620|DRUG|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
58110751|NCT05313620|DRUG|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
58110752|NCT00955747|DRUG|Tagatose|powder; 15 grams three times daily; one year
58110753|NCT00955747|DRUG|Sugar Substitute Splenda|1.5 g powder tid
58110754|NCT00544557|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
58110755|NCT00732329|BEHAVIORAL|Occupational Therapy|"optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy"
57740266|NCT04999813|COMBINATION_PRODUCT|Comprehensive intensive intervention|"* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance."
57740267|NCT00651664|DRUG|alisertib|Alisertib (MLN8237) capsules
57740268|NCT01597050|DRUG|R932333|R393233 6% (60 mg/g), bid
58110756|NCT00204750|PROCEDURE|Bougie Dilation|Bougie dilation will be performed as standard
58110757|NCT00204750|PROCEDURE|Needle-knife incision|Needle-knife incision will be performed
58443768|NCT04160858|OTHER|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
58443769|NCT04160858|OTHER|Control|Wait-list control
58443770|NCT01382238|DRUG|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
58443771|NCT01382238|DRUG|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
57740269|NCT01597050|DRUG|Placebo|Placebo, bid
57740270|NCT04594161|DEVICE|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
57740271|NCT04594161|DEVICE|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
57740272|NCT01208454|DRUG|Isotretinoin|Given PO
57740273|NCT01208454|OTHER|Laboratory Biomarker Analysis|Correlative studies
57740274|NCT01208454|OTHER|Pharmacological Study|Correlative studies
57740275|NCT01208454|DRUG|Vorinostat|Given PO
57740276|NCT05188001|OTHER|Not an Interventional Study|Not an interventional Study
57740277|NCT00135148|PROCEDURE|Filling out a questionnaire on libido and possible partner relationship|
57740278|NCT00135148|PROCEDURE|Sex steroid analysis|
57740279|NCT01192438|PROCEDURE|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
57740280|NCT05414591|DRUG|DWP16001 drug A|1 tablet, Oral, once daily single dose
57740281|NCT05414591|DRUG|DWP16001 drug B|3 tablet, Oral, once daily single dose
58110758|NCT03294161|DRUG|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
58110759|NCT03294161|DRUG|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
58110760|NCT04861896|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
58110761|NCT05692921|OTHER|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
58110762|NCT05692921|OTHER|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
58110763|NCT04837625|OTHER|no interventions|no interventions
58110764|NCT01792258|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
58110765|NCT06152159|OTHER|data collection|Data collection
58110766|NCT05001490|OTHER|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
58110767|NCT03779399|OTHER|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
58110768|NCT02555709|DRUG|VTP-43742|VTP-43742 administered as an oral capsule once daily
58110769|NCT02555709|DRUG|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
58110770|NCT02555709|DRUG|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
58110771|NCT02501109|DRUG|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
58110772|NCT01470794|BIOLOGICAL|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
58110773|NCT01470794|DRUG|Toca FC|
58110774|NCT01786811|BEHAVIORAL|Training|"1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
58110775|NCT00683150|OTHER|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
58110776|NCT02925065|OTHER|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
58443772|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
58443773|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
57740282|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
57740283|NCT04395105|DRUG|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
57740284|NCT04335682|DRUG|Darolutamide|Patients randomized to darolutamide.
57956194|NCT03065348|DIETARY_SUPPLEMENT|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
57956195|NCT03065348|DIETARY_SUPPLEMENT|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal"
57956196|NCT03065348|OTHER|Preoperative hydration|If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
57956197|NCT03065348|OTHER|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
57956198|NCT02824705|PROCEDURE|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
57740285|NCT04335682|DRUG|Enzalutamide|Patients randomized to enzalutamide.
57740286|NCT00473798|BEHAVIORAL|Questionnaire|Questionnaire
57956199|NCT06416904|DEVICE|archwire stopper mesial to the maxillary first molar group|canine retraction after the extraction of the maxillary first premolars with archwire stoppers is mesial to the maxillary first molars.
57956200|NCT06416904|DEVICE|inter-radicular mini-screw|canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
57956201|NCT04141332|DIAGNOSTIC_TEST|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
57740287|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
57740288|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
57740289|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
57956202|NCT03212833|DIAGNOSTIC_TEST|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
57956203|NCT02431572|OTHER|PBR PET|
57956204|NCT02431572|BIOLOGICAL|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
57956205|NCT02431572|RADIATION|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
57956206|NCT05766995|DEVICE|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
57956207|NCT05766995|DEVICE|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
57956208|NCT05766995|DEVICE|Waxed Dental Floss|Nylon string used to clean between the teeth manually
58110777|NCT05925322|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
58110778|NCT05925322|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
58110779|NCT01020305|DRUG|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
58110780|NCT01020305|DRUG|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
58443774|NCT02270554|DEVICE|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
58443775|NCT04477577|BEHAVIORAL|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
58443776|NCT04477577|BEHAVIORAL|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
57740290|NCT04989790|OTHER|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
57956209|NCT02398591|DRUG|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
57956210|NCT02398591|DRUG|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
58443777|NCT03723772|DRUG|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
58443778|NCT03723772|DRUG|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
58110781|NCT01675908|PROCEDURE|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
58110782|NCT01675908|PROCEDURE|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
58443779|NCT00797277|DRUG|IM olanzapine|10mg olanzapine IM
58443780|NCT00797277|DRUG|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
58443781|NCT01885676|DEVICE|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
58443782|NCT01885676|OTHER|Saline Solution|Saline Solution mesotherapy micro injection
58443783|NCT05527444|DRUG|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
58443784|NCT05527444|DRUG|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
58443785|NCT05527444|DRUG|NSAID|stable dose
58110783|NCT03387410|DRUG|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
58110784|NCT01266382|DEVICE|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
58110785|NCT00443352|DRUG|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
58443786|NCT05527444|DRUG|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
58443787|NCT06024603|DIAGNOSTIC_TEST|Drug Sensitivity Test (DST)|Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
57956211|NCT03431155|OTHER|Nursing intervention|Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
57956212|NCT05095207|DRUG|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
57956213|NCT05095207|DRUG|Bicalutamide|150 mg orally daily, day 1 to 28.
58110786|NCT01512979|DRUG|metformin|1000 mg to 2000 mg per day
58110787|NCT01512979|DRUG|linagliptin|5 mg daily
58443788|NCT01860313|BEHAVIORAL|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
57740291|NCT04635553|DRUG|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
58110788|NCT01512979|DRUG|metformin placebo|0 to 2 tablets daily
58443789|NCT01860313|BEHAVIORAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
58443790|NCT01071421|DEVICE|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
58443791|NCT02598440|DRUG|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
58443792|NCT02598440|DRUG|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
58443793|NCT04538417|DEVICE|Cooled Radiofrequency Ablation|RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
58443794|NCT05904067|BIOLOGICAL|COVID Convalescent Plasma|200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
58443795|NCT02110667|DEVICE|Transperineal Ultrasound|
58443796|NCT04055909|DRUG|nangibotide low dose|nangibotide 0.3 mg/kg/h
58443797|NCT04055909|DRUG|nangibotide high dose|nangibotide 1.0 mg/kg/h
58443798|NCT04055909|DRUG|placebo|matching placebo
58443799|NCT05336747|BEHAVIORAL|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
58443800|NCT02636530|BEHAVIORAL|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
58443801|NCT02636530|BEHAVIORAL|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
58443802|NCT04331470|DRUG|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
58443803|NCT04331470|DRUG|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
58458471|NCT01803425|OTHER|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
57740292|NCT06564441|DRUG|Survodutide|Survodutide
57740293|NCT06564441|DRUG|Bupropion|Bupropion
57740294|NCT06564441|DRUG|Caffeine|Caffeine
57740295|NCT06564441|DRUG|Midazolam|Midazolam
57740296|NCT02172755|DRUG|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
57956214|NCT00685503|DRUG|Ranibizumab|
58110789|NCT01512979|DRUG|metformin placebo|4 tablets daily
58443804|NCT05081232|DEVICE|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
58443805|NCT05144139|BIOLOGICAL|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
58443806|NCT00321451|BEHAVIORAL|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
58443807|NCT00321451|BEHAVIORAL|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
58443808|NCT00321451|OTHER|Usual care|3 outpatient visits with study physician
58443809|NCT04807335|DRUG|CT001|nasal spray
58443810|NCT04807335|DRUG|Ketamine|iv single dose
58443811|NCT04807335|DRUG|sufentanil|iv single dose
58443812|NCT02378324|OTHER|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
58443813|NCT05434390|BEHAVIORAL|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
58443814|NCT05434390|BEHAVIORAL|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
58443815|NCT04197180|PROCEDURE|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
58443816|NCT02292446|DRUG|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
58443817|NCT03902314|DRUG|Lidocaine Iv|Intravenous infusion
58443818|NCT03902314|DRUG|Saline Solution|Intravenous infusion
58443819|NCT05681702|DRUG|aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
58443820|NCT05681702|DRUG|prasugrel or ticagrelor|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
58443821|NCT00513149|DRUG|Clopidogrel|Clopidogrel 600 mg loading
58443822|NCT03822767|BIOLOGICAL|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
58443823|NCT03822767|BIOLOGICAL|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
58443824|NCT00941915|RADIATION|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
58443825|NCT03151733|PROCEDURE|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
58443826|NCT03151733|PROCEDURE|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
58443827|NCT02639442|DEVICE|ClearRing™|
58443828|NCT04042961|OTHER|Reactive balance training|A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance \~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).
58458472|NCT01013129|GENETIC|DNA analysis|saliva samples will be collected from men (probands) who join the study.
58458473|NCT01013129|GENETIC|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
57956215|NCT06089642|DEVICE|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
58458474|NCT01013129|OTHER|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
58458475|NCT01013129|OTHER|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
58110790|NCT04800055|OTHER|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
58110791|NCT03790085|DRUG|Risperidone|Risperidone tablet
58110792|NCT03790085|DRUG|Olanzapine|Olanzapine tablet
58110793|NCT03790085|DRUG|Aripiprazole|Aripiprazole tablet
58110794|NCT03244397|OTHER|Physical therapy + educational strategy|See arm/group descriptions
58110795|NCT03244397|BEHAVIORAL|Educational strategy|See arm/group descriptions
58110796|NCT04697511|DRUG|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
58110797|NCT04697511|DRUG|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
58110798|NCT05450497|DRUG|Propofol|comparing sedative agents
58110799|NCT05450497|DRUG|Dexmedetomidine|comparing sedative agents
58110800|NCT05450497|DRUG|Dexmedetomidine and propofol|comparing sedative agents
58110801|NCT02154113|DEVICE|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
58110802|NCT02154113|DEVICE|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
58110803|NCT03276910|DRUG|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
58110804|NCT03276910|DRUG|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
58110805|NCT03334487|DRUG|Dexamethasone|Oral
57740297|NCT02540018|DEVICE|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
57740298|NCT02540018|DEVICE|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
58110806|NCT03334487|DRUG|Rovalpituzumab tesirine|Intravenous
58110807|NCT00435695|DRUG|GSK163090|
58110808|NCT03582293|DRUG|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
58110809|NCT03582293|DRUG|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
58110810|NCT00756847|DRUG|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
58110811|NCT00756847|DRUG|paclitaxel|Intravenous injection dosed once every three weeks
58110812|NCT00756847|DRUG|carboplatin|Intravenous injection dosed once every three weeks
58110813|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
58110814|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
57740299|NCT03541070|DEVICE|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
58110815|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
58110816|NCT00796289|DRUG|clomiphene citrate|Oral, 50 mg daily for 5 days
58110817|NCT00796289|DRUG|placebo clomiphene citrate|oral, taken for 5 days
58110818|NCT00796289|DRUG|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
58110819|NCT02344134|BIOLOGICAL|NBP607|0.5 mL, intramuscular, a single dose
58110820|NCT02344134|BIOLOGICAL|Agrippal S1|0.5 mL, intramuscular, a single dose
58110821|NCT03372499|DIETARY_SUPPLEMENT|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
58110822|NCT02693184|OTHER|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
58110823|NCT02693184|OTHER|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
58110824|NCT06539299|PROCEDURE|Socket Preservation|After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.
58110825|NCT02675426|DRUG|Placebo|Tablet; Oral
58110826|NCT02675426|DRUG|Upadacitinib|Tablet; Oral
58110827|NCT01050231|DEVICE|Functional/ Multi-joints activities|Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
58110828|NCT01050231|DEVICE|Individual Joint Training|Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
58110829|NCT00306631|DRUG|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
58110830|NCT02720315|PROCEDURE|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
58110831|NCT03986749|PROCEDURE|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
58110832|NCT00600288|DRUG|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
58110833|NCT00600288|DRUG|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
58110834|NCT00609778|DEVICE|LUCAS|Mechanical chest compression
58110835|NCT00609778|OTHER|Conventional manual resuscitation method|Manual compression
58110836|NCT00775983|DEVICE|laminaria|place device in cervix for dilation
58110837|NCT00775983|DEVICE|Dilapan-S|Place in cervix for dilation.
58110838|NCT01165242|BIOLOGICAL|Meningococcal vaccine GSK 134612|One intramuscular injection
58110839|NCT01165242|BIOLOGICAL|Menactra®|One intramuscular injection
58110840|NCT04456465|OTHER|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
58110841|NCT02001428|DRUG|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
58110842|NCT01859702|DRUG|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
58110843|NCT03564899|BEHAVIORAL|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
58110844|NCT03564899|BEHAVIORAL|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
58110845|NCT06546436|DRUG|CARC-101C|Subjects enrolled in the project will received a one-dose injection of CARC-101C
58110846|NCT05377333|DRUG|LY3457263|Administered SC.
58110847|NCT05377333|DRUG|Placebo|Administered SC.
58110848|NCT05377333|DRUG|Dulaglutide|Administered SC.
58110849|NCT04886570|DEVICE|hip arthroplasty|Hip arthroplasty is a kind of joint reconstruction surgery, which has been successfully utilized for treatment of osteoarthritis or hip fracture for decades. In this surgery, implants is applied to reconstruct hip joint, and usually comprised of four components, including femoral stem, femoral head, acetabular cup and liner.
58110850|NCT01740492|DRUG|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
58110851|NCT01740492|DRUG|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
58110852|NCT01740492|OTHER|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
58443829|NCT04042961|OTHER|Aerobic and strength training (AST)|"AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum."
58443830|NCT00413036|DRUG|lenalidomide|once daily oral capsule
58110853|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
58443831|NCT03350815|DRUG|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
57740300|NCT03492281|DRUG|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
57740301|NCT03492281|DRUG|Vibegron placebo|placebo to match vibegron (experimental drug)
57740302|NCT03492281|DRUG|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
58110854|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
58110855|NCT02481479|DRUG|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
58110856|NCT02957786|DRUG|Cytisine|Cytisine tablets
58110857|NCT02957786|BEHAVIORAL|Behavioural support|Withdrawal-orientated cessation support
58110858|NCT02957786|DRUG|Varenicline|Varenicline tablets
58110859|NCT02580890|DEVICE|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
58110860|NCT02580890|DEVICE|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
58110861|NCT03785483|BEHAVIORAL|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
58110862|NCT01841359|DRUG|Pramlintide|See description above (arm description).
58110863|NCT04101474|DRUG|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
58110864|NCT04344054|BIOLOGICAL|RV3-BB|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
58443832|NCT03350815|DRUG|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
58443833|NCT03350815|DRUG|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
57740303|NCT03492281|DRUG|Tolterodine placebo|placebo to match tolterodine (active comparator)
57740304|NCT05197894|DEVICE|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
58110865|NCT04344054|BIOLOGICAL|Trivalent P2-VP8|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
58110866|NCT04344054|BIOLOGICAL|Rotarix|1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
58110867|NCT04344054|BIOLOGICAL|RV3-BB birth dose|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
58110868|NCT04344054|BIOLOGICAL|Trivalent P2-VP8 Booster dose|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
58443834|NCT00445185|BIOLOGICAL|Henogen HB vaccine|Month 12, 24 and 36
58443835|NCT00445185|BIOLOGICAL|Fendrix vaccine|Month 12, 24 and 36
58443836|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
58443837|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
58443838|NCT02100475|DRUG|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
58443839|NCT02100475|DRUG|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
57740305|NCT05074628|DRUG|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
57740306|NCT03328754|DEVICE|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
57740307|NCT03328754|DEVICE|Group 2 Forsus|Forsus placed bilaterally for class II correction
58443840|NCT04832191|DEVICE|CE-SM|contrast enhanced spectral mammography \&contrast enhanced magnetic resonance imaging
58443841|NCT04241484|DEVICE|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
58443842|NCT01288001|DRUG|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
58443843|NCT02161835|OTHER|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
57740308|NCT01108848|BIOLOGICAL|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
57740309|NCT01460940|DRUG|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
57740310|NCT01460940|DRUG|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
57740311|NCT00974324|DRUG|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
57740312|NCT02157805|OTHER|beef meat|"Meat cooking conditions~1. st condition : beef meat cooked during 5 minutes at 55°C~2. nd condition : beef meat cooked during 30 minutes à 90°C"
57740313|NCT04656834|PROCEDURE|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
57740314|NCT04656834|PROCEDURE|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
58443844|NCT04995211|DEVICE|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
57740315|NCT03214562|DRUG|Cytarabine|Given IV
57956216|NCT00746252|DRUG|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
57956217|NCT00746252|DRUG|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
57956218|NCT03102905|OTHER|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
57956219|NCT02289222|DRUG|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
57956220|NCT02289222|DRUG|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
57956221|NCT02289222|DRUG|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
57956222|NCT03713164|DIETARY_SUPPLEMENT|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
58443845|NCT01374633|DRUG|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
57956223|NCT03713164|DIETARY_SUPPLEMENT|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
57740316|NCT03214562|BIOLOGICAL|Filgrastim|Given SC
58110869|NCT04656951|DRUG|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
58443846|NCT05112562|BEHAVIORAL|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
57956224|NCT01464307|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
57956225|NCT01464307|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
58458476|NCT01013129|OTHER|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
57740317|NCT03214562|DRUG|Fludarabine|Given IV
57740318|NCT03214562|DRUG|Idarubicin|Given IV
57740319|NCT03214562|BIOLOGICAL|Pegfilgrastim|Given SC
57740320|NCT03214562|DRUG|Venetoclax|Given PO
57740321|NCT01774149|DEVICE|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
57740322|NCT01774149|DEVICE|Diastat|Users get the Few Touch Application with Diastat module activated.
57740323|NCT05662033|DRUG|AZD6793|AZD6793 will be administered orally
57740324|NCT05662033|DRUG|Placebo|Placebo will be administered orally
57956226|NCT05561660|DEVICE|PFO device closure|Participants randomized into this group will take PFO device closure.
57956227|NCT05561660|DRUG|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
58110870|NCT06168071|DEVICE|taVNS|Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
58443847|NCT05112562|BEHAVIORAL|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
58110871|NCT03256175|PROCEDURE|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
58110872|NCT01188928|DRUG|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
58110873|NCT01188928|DRUG|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
58110874|NCT01188928|DRUG|Calcipotriene|Topical suspension once daily for up to 8 weeks.
57740325|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
57740326|NCT05931692|DIAGNOSTIC_TEST|Virtual reality|Virtual environment that triggers fear of falling
58110875|NCT01188928|DRUG|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
58110876|NCT02506725|OTHER|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
58110877|NCT05610930|OTHER|Front-of-pack label NutriScore 2.0|"Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire."
58458477|NCT01013129|PROCEDURE|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
58458478|NCT01013129|PROCEDURE|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
58458479|NCT01958996|DRUG|idarubicin|
57740327|NCT05931692|DIAGNOSTIC_TEST|Electroencephalogram|Detect brain waves in response to fear of falling
57740328|NCT05931692|DIAGNOSTIC_TEST|Electromyography|Measures muscle activity and response to fear of falling
57740329|NCT05931692|DIAGNOSTIC_TEST|Motion Capture system|Measures postural and gait responses to fear of falling
57740330|NCT05931692|DIAGNOSTIC_TEST|Polar H10 Heart Sensor|Heart rate monitor
57740331|NCT05931692|DIAGNOSTIC_TEST|Inertial measurement Unite|Measure Postural sway
58443848|NCT05380440|BEHAVIORAL|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
58443849|NCT05380440|BEHAVIORAL|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
58443850|NCT03130920|PROCEDURE|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
58443851|NCT04951622|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
58443852|NCT04951622|DRUG|Placebo|Matching placebo will be administered as an IV infusion.
58443853|NCT01285934|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
58443854|NCT01285934|DRUG|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
58443855|NCT00001212|DRUG|prednisone|
58443856|NCT00001212|DRUG|cyclophosphamide|
58443857|NCT00001212|DRUG|cyclosporin A|
58443858|NCT04996251|DRUG|Bupivacaine Injection|0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
58443859|NCT03910088|DRUG|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
58443860|NCT03910088|DRUG|Hydrocortisone|Giving drug to relieve post-dural puncture headache
58443861|NCT03910088|DRUG|Acetaminophen|giving a drug to relieve post-dural puncture headache
58443862|NCT03910088|OTHER|oral fluids|giving oral fluids to maintain good hydration
58443863|NCT03910088|DRUG|Caffeine|giving a drug to relieve post-dural puncture headache
58443864|NCT03910088|DRUG|Diclofenac|giving a drug to relieve post-dural puncture headache
58458480|NCT03095079|DRUG|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
57740332|NCT00002574|BIOLOGICAL|recombinant interferon alfa|
57740333|NCT00002574|DRUG|omacetaxine mepesuccinate|
57740334|NCT05729763|OTHER|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
57740335|NCT05729763|OTHER|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
57740336|NCT02280044|BIOLOGICAL|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
57740337|NCT02280044|BIOLOGICAL|Placebo intervention|Placebo administered then Challenge with C jejuni
58443865|NCT04692519|BEHAVIORAL|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
57740338|NCT02650869|DIETARY_SUPPLEMENT|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
57740339|NCT02650869|DIETARY_SUPPLEMENT|Breast milk|Normal breast milk will be given as part of standard care
58443866|NCT02429830|DEVICE|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
57740340|NCT04681339|OTHER|Antibiotic treatment|Antibiotic treatment
57740341|NCT04681339|OTHER|No antibiotic treatment|No antibiotic treatment
57740342|NCT04618185|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
57740343|NCT05735067|OTHER|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
57956228|NCT00634153|OTHER|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
57740344|NCT02100176|OTHER|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
57740345|NCT02100176|DRUG|Rotigotine|Rotigotine 2-8 mg/24 h
57740346|NCT03025906|DRUG|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
57740347|NCT03025906|DRUG|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
57740348|NCT06236022|DRUG|Sirolimus|at a dose of 2 mg once daily
57740349|NCT02394782|DEVICE|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
57740350|NCT02394782|DEVICE|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
58443867|NCT05711134|BEHAVIORAL|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
57740351|NCT05861934|BEHAVIORAL|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
57740352|NCT04546581|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
57740353|NCT04546581|OTHER|Placebo|Participants will receive a single infusion of the placebo (saline).
57740354|NCT04546581|DRUG|Remdesivir|Remdesivir will be given to participants in both groups as standard of care (SOC).
57956229|NCT00730938|DRUG|cefuroxime|intracameral cefuroxime 0.1 ml
57956230|NCT00730938|DRUG|Saline placebo|0.1 ml of Ringers lactate
58110878|NCT01507831|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
58443868|NCT00961363|DRUG|Sitagliptin|sitagliptin 100 mg per day
58443869|NCT00961363|DRUG|Placebo|Placebo
57740355|NCT06665308|OTHER|No intervention|No intervention will be administered to study participants. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.
57740356|NCT00109616|BEHAVIORAL|Newborn skin cleansing with 0.25% chlorhexidine solution|
57740357|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with soap and water solution|
57740358|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with 4% chlorhexidine|
57740359|NCT05103020|DRUG|intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
58443870|NCT02644343|DEVICE|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
58443871|NCT03986528|DRUG|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
58443872|NCT03986528|DRUG|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
58443873|NCT04524364|DEVICE|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
58443874|NCT00013741|BEHAVIORAL|Tailored Education Messages|
57740360|NCT05103020|DRUG|IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
58443875|NCT05906836|DRUG|Rosuvastatin|Administered orally.
58443876|NCT05906836|DRUG|Selpercatinib|Administered orally.
58443877|NCT04078347|PROCEDURE|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
58443878|NCT00493259|BEHAVIORAL|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
58443879|NCT00493259|BEHAVIORAL|Depression Scale for Children (CES-DC)|questionnaire
58443880|NCT03965741|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
58443881|NCT03965741|DRUG|Apixaban(Eliquis)|Follow clinical administration
58443882|NCT03965741|DRUG|Pradaxa (Dabigatran etexilate)|Follow clinical administration
58443883|NCT02709330|DRUG|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
58443884|NCT02709330|OTHER|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
58443885|NCT06310616|DRUG|VH4524184|VH4524184 will be administered.
57740361|NCT01489033|BIOLOGICAL|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
57740362|NCT04760418|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
57740363|NCT04087538|DIAGNOSTIC_TEST|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
57740364|NCT02372201|OTHER|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
57740365|NCT01625897|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
57956231|NCT04986462|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
58443886|NCT06310616|DRUG|Loestrin|Loestrin will be administered.
58443887|NCT01435486|DRUG|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
58443888|NCT01435486|DRUG|Normal saline|Placebo with an equivalent volume of normal saline.
57740366|NCT01625897|DRUG|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
58443889|NCT06075589|BEHAVIORAL|Education for Intervention|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
58443890|NCT06075589|BEHAVIORAL|Best Practice|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
58443891|NCT04141423|DRUG|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
58443892|NCT03738618|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed"
58443893|NCT03738618|DRUG|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
58443894|NCT05722548|DRUG|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
58443895|NCT05722548|OTHER|Standard Medical Treatment|Standard Medical Treatment
58443896|NCT01835158|DRUG|Cabozantinib S-malate|Given PO
58443897|NCT01835158|OTHER|Laboratory Biomarker Analysis|Correlative studies
58443898|NCT01835158|DRUG|Sunitinib Malate|Given PO
58443899|NCT00018967|DRUG|glucarpidase|
58443900|NCT05786508|OTHER|Partners4Pain program|"Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
58443901|NCT05786508|OTHER|Key to Wellbeing program|"Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
58443902|NCT06482541|COMBINATION_PRODUCT|5 billion exosomes and saline solution microneedling|Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
58443903|NCT06482541|COMBINATION_PRODUCT|50 billion exosomes and saline solution microneedling|Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
58443904|NCT01833559|DIETARY_SUPPLEMENT|Dietary control|
58443905|NCT01833559|DRUG|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
58443906|NCT02352623|RADIATION|DXA scan|DXA scan
57956232|NCT05700162|BEHAVIORAL|Photograph|As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.
58110879|NCT01507831|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
58110880|NCT01507831|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
58443907|NCT02352623|PROCEDURE|Clinical examination|Clinical examination
58443908|NCT05391906|OTHER|Diffusion-weighted magnetic resonance imaging|Diffusion-weighted magnetic resonance imaging
58443909|NCT00337207|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
57740367|NCT02901457|OTHER|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
57740368|NCT06361147|OTHER|Psychoeducational program for ASD|6 psychoeducation trainings for Autism Spectrum Disorder
57740369|NCT04644250|DRUG|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
58110881|NCT00927888|DRUG|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
58110882|NCT00927888|DRUG|Placebo|placebo is identical in appearance in comparison to active drug.
58110883|NCT00776633|DRUG|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
58110884|NCT00776633|DRUG|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
58110885|NCT00776633|DRUG|oral anticoagulation|
58110886|NCT01504828|DRUG|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
58110887|NCT06177041|DRUG|M108 monoclonal antibody|M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
58110888|NCT06177041|DRUG|Placebo|Placebo will be administered as a minimum 2-hour IV infusion.
58110889|NCT06177041|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
58110890|NCT06177041|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
58110891|NCT00868114|BIOLOGICAL|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
58110892|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
58110893|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
58110894|NCT03974152|OTHER|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
58110895|NCT02922959|BEHAVIORAL|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
58110896|NCT02922959|DRUG|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
58110897|NCT02922959|BEHAVIORAL|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
58110898|NCT01652118|DRUG|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
58443910|NCT03226834|DEVICE|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
57740370|NCT04644250|DRUG|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
58110899|NCT01652118|DRUG|Saline|
58110900|NCT03892148|DRUG|Furosemide|Protocol for the use of diuretics
58110901|NCT03892148|DRUG|Hydrochlorothiazide|Protocol for the use of diuretics
58443911|NCT03226834|OTHER|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
57740371|NCT04644250|RADIATION|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
57740372|NCT04806880|DEVICE|Web-application|support for olfactory coaching consisting of the inhalation of fragrant essential oils.
57956233|NCT05700162|BEHAVIORAL|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
57956234|NCT05700162|BEHAVIORAL|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
57956235|NCT05700162|BEHAVIORAL|Control Group|She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
57956236|NCT04480177|DEVICE|foot insole|the subject was instructed to wear foot insole for 8 hours.
57956237|NCT04480177|OTHER|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
58110902|NCT04645238|OTHER|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
58110903|NCT04645238|OTHER|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
58110904|NCT04166981|PROCEDURE|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
58110905|NCT04166981|PROCEDURE|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
58110906|NCT04033133|DEVICE|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
58110907|NCT00520351|DRUG|ClearCare|contact lens care system
58110908|NCT00520351|DRUG|Optifree Replenish|contact lens care system
58110909|NCT03760510|DEVICE|Tube Fastener|Endotrachel tube secured with tube fastener
58110910|NCT03760510|DEVICE|Adhesive Tape|Endotracheal tube secured with adhesive tape.
58443912|NCT04406649|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
58443913|NCT01107665|DRUG|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
57740373|NCT03694639|OTHER|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
57740374|NCT02477696|DRUG|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
58110911|NCT05642559|OTHER|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
58443914|NCT00945256|OTHER|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
58443915|NCT00945256|DRUG|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
58443916|NCT00945256|DIETARY_SUPPLEMENT|Amino Acid Drink|7.5 gram Amino Acid drink
58443917|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
58443918|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
58443919|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
58443920|NCT05783336|BEHAVIORAL|Stepping Stones and Creating Futures Plus (SSCF+)|Group-based intervention delivered to small friendship networks, by a facilitator.
58443921|NCT06025006|OTHER|alternative to incarceration|place of respite with housing plus intensive follow-up
57740375|NCT02477696|DRUG|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
57740376|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
57740377|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
58443922|NCT00010283|DRUG|beclomethasone dipropionate|
58443923|NCT01085370|OTHER|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
58443924|NCT06675955|DRUG|Ocrelizumab|Ocrelizumab will be administered according to the regimen in the parent study.
58443925|NCT03070535|OTHER|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
58443926|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
58443927|NCT06124378|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
58443928|NCT06124378|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
58443929|NCT06124378|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
58443930|NCT06124378|PROCEDURE|Colectomy|The specific surgical approach is laparoscopic. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
58443931|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
58443932|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
58443933|NCT01365169|BEHAVIORAL|Exercise Intervention|Participate in walking and/or strengthening program
58443934|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
58443935|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
58443936|NCT01365169|OTHER|Health Telemonitoring|Use smart phone
58110912|NCT04460989|PROCEDURE|arthroplasty|total knee replacement
57956238|NCT02257983|DRUG|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
57956239|NCT02257983|DRUG|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
57956240|NCT00261872|DRUG|Methylphenidate|
57956241|NCT03425032|DEVICE|CT scanner|Regular CT imaging of the abdomen and pelvis
57956242|NCT02636088|DRUG|Cetuximab|
57956243|NCT02108431|DEVICE|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
57956244|NCT02108431|DEVICE|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
57956245|NCT02698488|PROCEDURE|Morphology|
57956246|NCT02698488|PROCEDURE|Morphology and Mass Spectroscopy|
58110913|NCT01400269|BEHAVIORAL|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
58443937|NCT01365169|OTHER|Health Telemonitoring|Use CO monitor and smart phone
58443938|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
58443939|NCT01365169|OTHER|Quality-of-Life Assessment|Ancillary studies
57740378|NCT02808364|BIOLOGICAL|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
57956247|NCT03389971|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
57956248|NCT05091398|OTHER|Regional analgesia of thoracic surgical patients|ultrasound-guided erector spinae block on T4 and T6 levels ,paravertebral block or intercostal nerve block after the anesthesia induction and turning the patient in the lateral position with 30 mL 0.5% bupivacaine +50 µ adrenaline will be injected by the surgeon through the thoracoscope .
57956249|NCT05799456|DIAGNOSTIC_TEST|Free glycosaminoglycan profiling|Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
58110914|NCT00274014|DRUG|Tiotropium|
58110915|NCT00274755|DRUG|chemotherapy|
58110916|NCT00274755|PROCEDURE|conventional surgery|
58110917|NCT00274755|PROCEDURE|magnetic resonance imaging|
57956250|NCT01505621|OTHER|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine
58110918|NCT00274755|PROCEDURE|magnetic resonance spectroscopic imaging|
58110919|NCT00274755|RADIATION|radiation therapy|
58110920|NCT02880904|OTHER|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
58110921|NCT03825952|DEVICE|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
58110922|NCT02832908|OTHER|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
58110923|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
58443940|NCT01365169|OTHER|Questionnaire Administration|Ancillary studies
58443941|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit and Actigraph
57740379|NCT05596370|DIAGNOSTIC_TEST|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
58110924|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
58110925|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
58110926|NCT03208959|DRUG|HTI-1090|IDO/TDO inhibitor
58110927|NCT04866485|DRUG|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
57740380|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization
58110928|NCT04468776|DRUG|Zolpidem|Zolpidem, as prescribed by physician
58110929|NCT04468776|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
58110930|NCT04468776|DRUG|Trazodone|Trazodone, as prescribed by physician
58110931|NCT02382978|OTHER|nurse-provided well child visit|
58110932|NCT05061667|PROCEDURE|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
57740381|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
58110933|NCT05061667|PROCEDURE|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
58110934|NCT03618966|DEVICE|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
58110935|NCT00744510|OTHER|Reflexology|10 weekly sessions of 45 minutes each
58110936|NCT02238977|DRUG|Fluoxetine|Antidepressant
58110937|NCT02238977|DRUG|Bupropion|Antidepressant
58110938|NCT00134888|DRUG|Buprenorphine/naloxone|
58110939|NCT04520035|DRUG|camrelizumab|Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
58110940|NCT04520035|DRUG|Paclitaxel|Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
58110941|NCT04520035|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy
58110942|NCT02280421|DRUG|ASP2151 400mg + 100mg ciclosporin|
57740382|NCT02450318|OTHER|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
57740383|NCT00858065|BEHAVIORAL|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
58110943|NCT02280421|DRUG|ASP2151 1200mg + 100mg ciclosporin|
58110944|NCT02609282|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|
58110945|NCT00789802|DRUG|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
58110946|NCT00789802|DRUG|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
58110947|NCT00789802|DRUG|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
58110948|NCT02552381|OTHER|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
58110949|NCT00989079|DRUG|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
58110950|NCT00989079|DRUG|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
58110951|NCT06330311|OTHER|Physiotherapy|Evidence-based multimodal physiotherapy treatment based on learning and motor control
58110952|NCT05249010|PROCEDURE|acupuncture and moxibustion|Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
58110953|NCT03567915|OTHER|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
58110954|NCT01745978|PROCEDURE|Precut papillotomy|
58110955|NCT06340542|OTHER|Thoracic Mobility exercises|Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.
58110956|NCT06340542|OTHER|Manual Release technique|Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
58110957|NCT03967483|DRUG|Indometacin|patient who are taken indomatacin for headaches and migraine
58110958|NCT06530485|DIETARY_SUPPLEMENT|Microbiota-directed food|MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.
58110959|NCT06530485|DIETARY_SUPPLEMENT|Khichuri|Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.
57740384|NCT00858065|BEHAVIORAL|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
57740385|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
58312296|NCT05989581|DRUG|Labetalol or Nifedipine|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs \<130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP\<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
58443942|NCT03274544|OTHER|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g"
57740386|NCT05598216|DIAGNOSTIC_TEST|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
57740387|NCT05050136|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
57740388|NCT05050136|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
57740389|NCT03044379|DRUG|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
58312297|NCT04830280|PROCEDURE|posterior quadratus lumborum block|administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
58312298|NCT05375916|DRUG|Hydromorphone|Sustained-release hydromorphone is a long-acting preparation opioid
57740390|NCT03044379|OTHER|Universal HEC placebo gel|
58443943|NCT01591187|OTHER|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
58443944|NCT01591187|OTHER|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
58443945|NCT01591187|OTHER|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
58443946|NCT04655573|PROCEDURE|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
58443947|NCT02041845|RADIATION|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
58443948|NCT02041845|RADIATION|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
58443949|NCT01330329|BEHAVIORAL|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
58110960|NCT03652961|DRUG|Abatacept|Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
58110961|NCT03652961|DRUG|DMARDs|Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
58110962|NCT02447510|PROCEDURE|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
58443950|NCT01330329|BEHAVIORAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
57740391|NCT01188434|BEHAVIORAL|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
57740392|NCT01188434|BEHAVIORAL|Services as Usual|Services as usual referred by child welfare
57740393|NCT05282238|DIAGNOSTIC_TEST|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
57740394|NCT01640522|OTHER|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
58443951|NCT01970306|DEVICE|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
58443952|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
58443953|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
58443954|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
57740395|NCT01640522|OTHER|Enhanced usual Care|
57740396|NCT00884585|DRUG|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
58312299|NCT05623800|OTHER|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
58312300|NCT02239289|OTHER|Biofeedback|Idem as described in the arm section (above)
57740397|NCT00884585|DRUG|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
57740398|NCT04524468|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
57740399|NCT00000154|PROCEDURE|Vitrectomy|
57740400|NCT00913484|DRUG|Disulfiram|Disulfiram 250 mg per day
57740401|NCT00913484|DRUG|Placebo|Placebo daily
58312301|NCT00004497|DRUG|UT-15|
58110963|NCT02447510|PROCEDURE|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
57740402|NCT05812651|OTHER|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
58110964|NCT02447510|PROCEDURE|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
58110965|NCT00125567|DRUG|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
58110966|NCT00125567|DRUG|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
58110967|NCT01816971|DRUG|dexamethasone|Given IV or PO
58110968|NCT01816971|DRUG|carfilzomib|Given IV
58110969|NCT01816971|DRUG|lenalidomide|Given PO
58443955|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
58110970|NCT01816971|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
58110971|NCT01816971|OTHER|laboratory biomarker analysis|Correlative studies
58110972|NCT02324985|DRUG|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
57740403|NCT01801020|OTHER|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
58110973|NCT02324985|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
58110974|NCT04418427|BIOLOGICAL|6E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
58110975|NCT04418427|BIOLOGICAL|2E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
58110976|NCT04418427|BIOLOGICAL|Aflibercept|Commercially available Active Comparator
58110977|NCT00509210|DRUG|telaprevir (VX-950)|
58110978|NCT06462157|OTHER|Compassionate Mind Training|Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
58312302|NCT06352606|DIAGNOSTIC_TEST|Spinal anesthesia|Oxygen supply will be done via nasal prong (2 L/min) when necessary. The local anesthetic used will be bupivacaine 0.6 mg/kg.
57740404|NCT01801020|OTHER|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
57740405|NCT00070902|PROCEDURE|Lumbar side-posture spinal adjusting|
57740406|NCT01107184|PROCEDURE|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
57740407|NCT01107184|PROCEDURE|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
58110979|NCT06129552|PROCEDURE|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
58110980|NCT05165251|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
58110981|NCT05165251|DRUG|Amlodipine 5mg|amlodipine 5mg QD
58110982|NCT05165251|OTHER|Lifestyle intervention|Lifestyle intervention
58312303|NCT06352606|DIAGNOSTIC_TEST|General anesthesia|Patients will receive sevoflurane for induction and maintenance in an air/oxygen mixture along. Endotracheal tube will be inserted. No opioids or nitrous oxide was used intraoperatively.
58312304|NCT06525168|DRUG|DA414 Granules|DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
58312305|NCT06525168|DRUG|DA414 placebo|DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
58110983|NCT04698122|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
58110984|NCT04698122|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
58110985|NCT04698122|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
58110986|NCT00382330|DRUG|Ciclopirox|
58110987|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
58110988|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System Containing Placebo Product
58312306|NCT03179384|DRUG|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
58443956|NCT05528393|DIAGNOSTIC_TEST|Blood sampling|blood sampling
58443957|NCT06726343|DEVICE|Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
58110989|NCT06527482|PROCEDURE|Autologous Osteoperiosteal Transplantation|After full exposure of the lesion, the center of the cystic lesion was determined and drilled perpendicularly using a 2-mm pin. Then, a 4.5-mm cannulated bore was used to drill the lesion until the cyst was reached, and a small bone socket was created. A harvester tube matching the diameter of the cyst was used to enlarge the bone socket with care to avoid damage to the adjacent normal cartilage. The cystic lesion was debrided thoroughly, and the sclerotic wall of the cyst was freshened using a curette. The harvester tube with a matched diameter was driven in to a depth of 15 to 20 mm at the 2-cm proximal part of the anterior superior iliac spine perpendicularly without violation of the lateral wall of the crest. When necessary, small pieces of cancellous bone were also harvested from the iliac crest using a bone curette then grafted into the peripheral area of the cyst to fill up the remaining space of the cyst around the bone socket in the talus.
58110990|NCT00263081|DRUG|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
58110991|NCT00263081|DRUG|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
58312307|NCT01669239|DRUG|Liposomal Doxorubicin|"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
58312308|NCT02748772|DRUG|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
58443958|NCT06726343|DEVICE|Investigational Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
58443959|NCT02388334|OTHER|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~* identify the specific support needs of the caregivers~* study the links between the quality of care as perceived by the professionals, patients and caregivers~* identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
58443960|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
58443961|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
58443962|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
57740408|NCT04110613|DIETARY_SUPPLEMENT|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
58110992|NCT06468683|BIOLOGICAL|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
57740409|NCT04230499|DRUG|Encapsulated Rapamycin (eRapa)|eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
57740410|NCT06194227|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
57740411|NCT06194227|BEHAVIORAL|Traditional Yoga|Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
57740412|NCT03528018|DEVICE|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
57740413|NCT03528018|OTHER|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
57740414|NCT01016210|DRUG|Leuveris|IV
58110993|NCT04340414|DEVICE|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
58110994|NCT01070394|DRUG|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
58110995|NCT03522740|OTHER|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
58110996|NCT00502541|DRUG|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
58110997|NCT00502541|PROCEDURE|Standard of Care|Repeat macular grid laser or observation
58110998|NCT03989115|DRUG|RMC-4630|RMC-4630 for oral administration
58110999|NCT03989115|DRUG|Cobimetinib|Cobimetinib for oral administration
58111000|NCT03989115|DRUG|Drug: Osimertinib|Osimertinib for oral administration
58111001|NCT06529640|PROCEDURE|SCTG followed by coronally postionting flap|The SCTG will be harvested from the palate followed by coronally postionting flap
58111002|NCT06529640|PROCEDURE|periosteal flap followed by coronally postionting flap|he periosteal pedicle graft obtained is then turned over the exposed root surface then followed by coronally postionting flap
58111003|NCT01456052|DRUG|Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally.
58111004|NCT01456052|DRUG|Placebo|Matching placebo administered orally.
57740415|NCT01016210|DRUG|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
58111005|NCT04485286|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
58111006|NCT04514029|DRUG|Simvastatin|Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
58111007|NCT04514029|DRUG|Dexamethasone|Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
58111008|NCT01696383|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
58111009|NCT04478071|DRUG|vadadustat|Participants will receive vadadustat once daily for 14 days.
58111010|NCT04478071|DRUG|placebo|Participants will receive matching placebo once daily for 14 days.
58111011|NCT02905721|PROCEDURE|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
58111012|NCT01259401|BEHAVIORAL|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
58111013|NCT01259401|BEHAVIORAL|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
57740416|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
58111014|NCT04837755|DIAGNOSTIC_TEST|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
58111015|NCT03833453|BEHAVIORAL|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
58111016|NCT03833453|BEHAVIORAL|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
58111017|NCT00756028|DRUG|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
58111018|NCT00756028|DRUG|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
58111019|NCT06180967|DRUG|Midazolam Syrup|Administered Orally.
58111020|NCT06180967|DRUG|Midazolam Solution|Administered IV bolus.
58111021|NCT06180967|DRUG|Pirtobrutinib|Administered Orally.
58111022|NCT02599883|RADIATION|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
58111023|NCT03336632|DRUG|Chidamide|20 mg orally, twice weekly from D-7 to D+14
58111024|NCT03336632|DRUG|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
57740417|NCT06496048|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
57740418|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
57740419|NCT06496048|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
57740420|NCT04118530|OTHER|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
57740421|NCT01669629|DEVICE|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
58111025|NCT03336632|DRUG|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
58111026|NCT04352491|OTHER|No intervention|No intervention
58443963|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
58443964|NCT05370131|OTHER|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
58111027|NCT02935075|DRUG|Tenofovir disoproxil fumarate|Oral daily
58111028|NCT02935075|DRUG|Lamivudine|Oral daily
57740422|NCT01669629|DEVICE|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
57740423|NCT05704075|PROCEDURE|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
57740424|NCT05704075|PROCEDURE|Conventional|Dressing + Negative Pressure Wound Therapy
57740425|NCT06534398|DEVICE|Dental implant prosthesis with cantilever extension|A retrospective study on the radiographic and clinical findings of implant-supported dental prostheses with cantilever extensions in place and function for at least 10 years
58111029|NCT02935075|DRUG|Efavirenz|Oral daily
58111030|NCT04905979|DRUG|AD113|Two oral capsules administered before bed
58111031|NCT04905979|DRUG|Atomoxetine|Two oral capsules administered before bed
58111032|NCT04148183|DRUG|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
58111033|NCT04148183|DRUG|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
58111034|NCT04148183|DRUG|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
58443965|NCT05467384|DRUG|Amlodipine|5mg/day in two divided doses
58443966|NCT00297323|DRUG|Topiramate|75 patients over the age of 2 years old with epilepsy.
58111035|NCT02565485|DRUG|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
58111036|NCT01498419|DRUG|Moxifloxacin (M)|
58111037|NCT01498419|DRUG|Pretomid (Pa)|
58443967|NCT00475566|DEVICE|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
58443968|NCT00475566|DEVICE|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
58111038|NCT01498419|DRUG|Pyrazinamide (Z)|
58443969|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
58111039|NCT01498419|DRUG|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
58111040|NCT05181137|DRUG|SHR0302|Oral tablets taken once daily (QD)
58111041|NCT05181137|DRUG|Placebo|Oral tablets taken once daily (QD)
58111042|NCT03780933|DIETARY_SUPPLEMENT|vitamin c|vitamin c IV 10 G
58111043|NCT02220140|BEHAVIORAL|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
58111044|NCT03281434|DIETARY_SUPPLEMENT|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
58111045|NCT03281434|DIETARY_SUPPLEMENT|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
58312309|NCT02748772|DRUG|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
58111046|NCT00500409|DRUG|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
58111047|NCT00500409|DRUG|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
58111048|NCT05268731|PROCEDURE|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
58111049|NCT05268731|PROCEDURE|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
58312310|NCT00002703|RADIATION|high-LET heavy ion therapy|
58312311|NCT00002703|RADIATION|low-LET photon therapy|
58312312|NCT00021242|DRUG|docetaxel|Continuous IV infusion
58312313|NCT03915743|OTHER|palliative care|complex and multi-faceted individualized palliative care
58312314|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
58312315|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
58312316|NCT05916170|BEHAVIORAL|Health Warnings|Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
58312317|NCT05916170|BEHAVIORAL|No Warnings|No warnings posted in the hookah café
58312318|NCT00006022|BIOLOGICAL|aldesleukin|
58312319|NCT00006022|DRUG|bryostatin 1|
58312320|NCT05458778|DEVICE|Daily test with urine by the product|Women perform the hCG test and share the test results
58312321|NCT02372461|DRUG|Placebo|This is an non inferiority trial, the intervention is a placebo
58312322|NCT02372461|DRUG|Amoxicillin|Amoxicillin Liquid
58312323|NCT03153657|DRUG|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
58111050|NCT05268731|PROCEDURE|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
58111051|NCT02163811|BEHAVIORAL|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
58111052|NCT02163811|BEHAVIORAL|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
58111053|NCT04262310|OTHER|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
58111054|NCT03242122|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
58111055|NCT03242122|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
58111056|NCT03242122|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
58111057|NCT03242122|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
58111058|NCT03242122|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
58111059|NCT00384696|DRUG|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke \>10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
57740426|NCT01995461|DRUG|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
57740427|NCT03302338|DRUG|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
58111060|NCT00384696|BEHAVIORAL|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
57740428|NCT03302338|DRUG|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
58111061|NCT06075914|OTHER|Ketogenic Intervention|Participants will receive ready-to-eat Ketogenic Diet meals.
58111062|NCT06075914|OTHER|Mediterranean Intervention|Participants will receive ready-to-eat Mediterranean Diet meals.
58111063|NCT06075914|DIETARY_SUPPLEMENT|Placebo|Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.
58111064|NCT06075914|DIETARY_SUPPLEMENT|Ketone Ester|Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
58111065|NCT01623830|BEHAVIORAL|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
58111066|NCT03707483|COMBINATION_PRODUCT|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
58111067|NCT00463892|PROCEDURE|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
58111068|NCT04486183|OTHER|capillary blood samples|The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
58111069|NCT04791735|PROCEDURE|Laparoscopy|"* Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~* Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~* Use of laparoscopic specific devices:~  * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~ * Use of a laparoscopic camera system with 0° or 30°~ * Use of a dedicated laparoscopic ultrasound probe.~ * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~* Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
58312324|NCT03153657|DRUG|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
58312325|NCT00300599|DEVICE|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
58111070|NCT04791735|PROCEDURE|Laparotomy|"* Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~* Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~* Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~* Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
58111071|NCT04053881|DRUG|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
58111072|NCT03028194|PROCEDURE|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
58111073|NCT03028194|PROCEDURE|Placebo|No procedure after delivery of the placenta
58111074|NCT02512770|PROCEDURE|endoscopic dilatation|
58111075|NCT04366466|OTHER|suicide attempt patient using PEPS Program|"The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group."
58111076|NCT05081674|DRUG|Alectinib|600mg 1OD
58111077|NCT05081674|DRUG|Pembrolizumab|200mg every 21 days
58111078|NCT05081674|DRUG|Nivolumab|6mg/kg every 4 weeks
58111079|NCT05081674|DRUG|Erlotinib|150mg
58111080|NCT00949390|BEHAVIORAL|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
58111081|NCT00871169|DRUG|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
58111082|NCT03935581|DEVICE|ExAblate|Auto Focusing (AF) echo imaging
58111083|NCT01114113|DRUG|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
58111084|NCT01114113|DEVICE|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
58111085|NCT01114113|DEVICE|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
58111086|NCT01114113|DEVICE|SmartPill capsule|SmartPill capsule
58111087|NCT05028101|PROCEDURE|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
58111088|NCT05028101|BEHAVIORAL|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
58111089|NCT02140489|DRUG|amosartan|
58111090|NCT02140489|DRUG|rosuvastatin|
57740429|NCT03588026|DRUG|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
57740430|NCT03588026|OTHER|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
58111091|NCT02140489|DRUG|amosartan and rosuvastatin|
58111092|NCT06282796|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software
57740431|NCT00169169|DRUG|ACVBP|
57740432|NCT00169169|DRUG|ACE|
57740433|NCT00169169|DRUG|rituximab|
58111093|NCT06175702|DRUG|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
58111094|NCT06175702|DRUG|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
58111095|NCT06175702|DRUG|Imatinib|600 mg per day from 1 to up to 5 years
58111096|NCT06175702|DRUG|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
57740434|NCT00169169|PROCEDURE|Autologous stem cell transplant|
57740435|NCT05895266|DRUG|ABBV-903|Oral Tablet
57740436|NCT05895266|DRUG|Midazolam|Oral Liquid
58111097|NCT06175702|DRUG|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
58111098|NCT06175702|DRUG|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
58111099|NCT06175702|DRUG|Ponatinib|15 mg per day from consolidation start up to 5 years
58111100|NCT06175702|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
58111101|NCT06175702|PROCEDURE|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
58111102|NCT06175702|DRUG|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
58111103|NCT06175702|DRUG|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
58111104|NCT01643083|DRUG|Rifaximin|Rifaximin 400mg tid for 2 wk
58111105|NCT01643083|DRUG|Placebo|Placebo for 2 week
58111106|NCT01499927|OTHER|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
58111107|NCT06298279|BEHAVIORAL|Tunneled Delivery|Participants will be offered a pre-determined pathway to completing the 8-week course
58111108|NCT06298279|BEHAVIORAL|Personalized Delivery|Participants will be able to complete course modules at their own pace and in the order that most interests them.
57740437|NCT05155865|DEVICE|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
57740438|NCT05155865|DEVICE|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
57740439|NCT01683864|DRUG|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
57740440|NCT00707031|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
57740441|NCT00707031|DEVICE|Pen auto-injector|
58111109|NCT06298279|BEHAVIORAL|Standard Resources|Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.
58111110|NCT06298279|BEHAVIORAL|Enhanced Social Learning Resources|Participants will receive additional intervention content.
58111111|NCT06298279|BEHAVIORAL|Transdiagnostic Self-Guided ICBT|An ICBT course that is completed without the guidance of a therapist.
58111112|NCT02006966|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
58111113|NCT02006966|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
58111114|NCT04961229|BIOLOGICAL|The Pfizer mRNA-based BNT162b2 vaccine|"participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response)."
58111115|NCT06541782|BEHAVIORAL|Dyadic CAT-based Intervention|The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.
58111116|NCT06541782|BEHAVIORAL|Psycho-Educational Parent Counseling|This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
58111117|NCT02754791|DEVICE|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
58312326|NCT00300599|OTHER|Placebo|Placebo
58111118|NCT02754791|DEVICE|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
58111119|NCT03254719|OTHER|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
58111120|NCT02991261|DRUG|SPARC001 type I|Treatment type I
58111121|NCT02991261|DRUG|SPARC001 type II|Treatment type II
58111122|NCT02991261|DRUG|Reference001 type I|Hydrocodone-acetaminophen
58111123|NCT02991261|DRUG|Reference001 type II|Hydrocodone Acetaminophen
58111124|NCT04523415|OTHER|without intervention, just retrospectively review the data about patients|without intervention
58111125|NCT03351413|OTHER|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
58111126|NCT05077306|OTHER|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
58111127|NCT04170959|DRUG|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
58111128|NCT04170959|OTHER|No metformin|Standard of care without metformin.
58111129|NCT00206466|DRUG|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
58111130|NCT00206466|DRUG|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
58111131|NCT02229266|BIOLOGICAL|NK cells|
58111132|NCT02229266|DRUG|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
58111133|NCT04901754|DRUG|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
58111134|NCT05936736|RADIATION|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
58111135|NCT01535248|OTHER|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
58111136|NCT03222167|DRUG|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
58111137|NCT02872181|PROCEDURE|Supine|Placed in Supine position
58111138|NCT02872181|PROCEDURE|Left uterine displacement|Placed in 15 degrees left uterine displacement
57740442|NCT00707031|DRUG|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
57740443|NCT00707031|DEVICE|Prefilled pen injector|
57740444|NCT00707031|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
58312327|NCT04164238|DRUG|Toripalimab|Toripalimab Injection
58312328|NCT04164238|DRUG|Paclitaxel|Paclitaxel Injection
58111139|NCT04364165|BEHAVIORAL|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
58111140|NCT04364165|BEHAVIORAL|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
58111141|NCT03349177|DRUG|Epirubicin|100mg/m2
58111142|NCT03349177|DRUG|Fluorouracil|500mg/m2
58443970|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
58111143|NCT03349177|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
58443971|NCT03783299|DRUG|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
58443972|NCT03783299|DRUG|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
58443973|NCT00653588|DRUG|Rosuvastatin|40mg
58443974|NCT00653588|DRUG|Atorvastatin|80mg
58443975|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
57740445|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
57740446|NCT05986175|OTHER|Motor Imagery Training|The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
58111144|NCT03349177|DRUG|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
58312329|NCT04164238|DRUG|Carboplatin|Carboplatin Injection
58312330|NCT04164238|DRUG|Cisplatin|Cisplatin injection
58312331|NCT04164238|DRUG|5-fu|5-fu injection
58312332|NCT04635839|DRUG|Standard Dose of Unfractionated Heparin|5,000 units subcutaneous unfractionated heparin every 12 hours
58312333|NCT04635839|DRUG|Gestational Age-Based Dose of Unfractionated Heparin|"* First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours"
58111145|NCT04229303|DRUG|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily \[BID\]) or 4 \[20mg BID\]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily \[QD\]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 \[20mg BID\] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
58111146|NCT04229303|DRUG|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
58111147|NCT04528628|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
58111148|NCT04528628|DRUG|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
58111149|NCT04528628|COMBINATION_PRODUCT|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
58111150|NCT04650100|PROCEDURE|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
58111151|NCT03751020|BEHAVIORAL|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
58111152|NCT03751020|BEHAVIORAL|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
58111153|NCT03751020|OTHER|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
58111154|NCT04711629|OTHER|Clinical Tests|Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
58111155|NCT01381822|DRUG|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
58111156|NCT00032708|BIOLOGICAL|Dryvax|
58111157|NCT04965610|OTHER|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
58111158|NCT04965610|OTHER|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
58111159|NCT04283747|DIAGNOSTIC_TEST|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
58111160|NCT05751395|DEVICE|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
58443976|NCT06022796|OTHER|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
58443977|NCT06022796|OTHER|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
57740447|NCT05986175|OTHER|Core Stabilization Exercises|Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
58443978|NCT04397744|BEHAVIORAL|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
58111161|NCT06232356|DIAGNOSTIC_TEST|Mobile Web App|all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
58111162|NCT04127591|OTHER|exosome|Collect exosomes in peripheral blood of patients and extract miRNAs from them.
58111163|NCT06530290|DRUG|Mirtazapine 15 MG|Mirtazapine (15 mg), once a day for 12 weeks
58111164|NCT06530290|DRUG|Placebo|Placebo, once a day, for 12 weeks
58111165|NCT04281056|PROCEDURE|Tooth removal and their replacement by means of a denture|Teeth have been removed and replaced by means of dentures for at least one year
58111166|NCT04335110|BEHAVIORAL|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
58111167|NCT02775253|OTHER|Chronic cold acclimation|
58111168|NCT02947373|DRUG|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
58111169|NCT02977442|BEHAVIORAL|exercise|
58111170|NCT02451670|BEHAVIORAL|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
58111171|NCT02410837|PROCEDURE|Electromagnetic Navigation Bronchoscopy|
58111172|NCT05967312|DIAGNOSTIC_TEST|Minuteful Kidney Test Kit|The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
58111173|NCT06547879|BEHAVIORAL|Hypertension Self Management Program|The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
58111174|NCT01423838|DRUG|Solifenacin|5 mg, oral, once in a day
58111175|NCT01423838|DRUG|Oxybutynin|5 mg, oral, three times in a day
58443979|NCT04774263|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
58443980|NCT02449161|DRUG|MPA|
58111176|NCT04072978|DEVICE|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
58443981|NCT02449161|DRUG|placebo|
58111177|NCT01557452|DRUG|Givinostat|ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
58111178|NCT00691145|DRUG|tacrolimus ointment|transdermal
58111179|NCT00764803|DEVICE|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
58111180|NCT00764803|DEVICE|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
58111181|NCT00903890|OTHER|Survey|Survey asking questions regarding the subjects cardiac and general health.
58111182|NCT00133315|DRUG|Infliximab|
58111183|NCT00133315|DRUG|Etanercept|
58111184|NCT00133315|DRUG|Adalimumab|
58111185|NCT01768078|PROCEDURE|Intravitreal injection of Betamethasone + antibiotics|
58111186|NCT01768078|PROCEDURE|Intravitreal injection of antibiotics|
58111187|NCT01797419|DRUG|GS-5806|Single dose, oral liquid, .5 mL/kg
58111188|NCT01797419|DRUG|Placebo|Single dose, oral liquid, .5 mL/kg
58443982|NCT05881954|PROCEDURE|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
58443983|NCT03349788|PROCEDURE|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
58443984|NCT03349788|PROCEDURE|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
58443985|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
58443986|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
58111189|NCT02281071|PROCEDURE|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
58111190|NCT00227656|BIOLOGICAL|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
58443987|NCT04488926|DIETARY_SUPPLEMENT|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
58443988|NCT04488926|OTHER|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
58443989|NCT04488926|DRUG|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
58443990|NCT04488926|DRUG|Rescue Drug|Use as needed allowed
58111191|NCT00227656|DRUG|Capecitabine|1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
58111192|NCT06467500|DRUG|Cadonilimab (AK104)|Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
58111193|NCT03400371|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
58111194|NCT03400371|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
58111195|NCT06171997|OTHER|Swaddling after bath group|"The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale."
58111196|NCT03990389|DEVICE|Chatbot Intervention|a chatbot will be used to monitor depression severity
58111197|NCT04733131|DRUG|Conversion to a belatacept regimen|belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
58111198|NCT00912418|BIOLOGICAL|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
58111199|NCT03953365|PROCEDURE|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
58111200|NCT00280787|DRUG|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
58111201|NCT00280787|DRUG|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
58111202|NCT00280787|DRUG|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
58111203|NCT00280787|DRUG|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
58111204|NCT00280787|RADIATION|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
58111205|NCT00947011|DRUG|Placebo|1 tablet 100 mg once a day
58111206|NCT00947011|DRUG|Januvia|1 tablet 100 mg once a day
58111207|NCT03503708|DRUG|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
58111208|NCT00133107|DRUG|efalizumab|
58111209|NCT06010056|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
58111210|NCT06010056|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
58111211|NCT01333176|PROCEDURE|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If \< 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result \>6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~1. Did the clients who were counseled to do so get follow-up blood tests?~2. Were all the formal diagnostic tests performed?~3. Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~4. Did the family physicians find this useful?"
58111212|NCT01333176|PROCEDURE|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
57740448|NCT02446158|DRUG|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
58111213|NCT01333176|PROCEDURE|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
58111214|NCT01333176|PROCEDURE|Blood test|HbA1c blood test
58111215|NCT01333176|PROCEDURE|Blood test|HbA1c finger poke blood test
57740449|NCT05770999|OTHER|Lavender application|Lavender application
58111216|NCT03618459|OTHER|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
58111217|NCT05418478|BEHAVIORAL|Intervention transtheoretical model group|"The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change)."
58111218|NCT03080194|DRUG|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
57740450|NCT03511755|DEVICE|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
57740451|NCT02683096|OTHER|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
57740452|NCT02405221|BIOLOGICAL|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
58111219|NCT03080194|DRUG|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
58111220|NCT01783496|DEVICE|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
58111221|NCT05791942|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
58111222|NCT05791942|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
58111223|NCT05791942|BEHAVIORAL|Behavioral: Action prompt|The message will prompt people to take care of the health gap right away before it slips their mind.
58111224|NCT03423706|PROCEDURE|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
58111225|NCT04881890|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
58111226|NCT04133571|DRUG|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
58111227|NCT04476732|OTHER|Paraben-free skincare product|Paraben-free lotion will be applied twice a day for one week.
58111228|NCT04476732|OTHER|Paraben-containing skincare product|Paraben-containing lotion will be applied twice a day for one week.
58111229|NCT02647554|DRUG|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
58111230|NCT02647554|DRUG|Placebo|matching placebo every 8 hours for 10 days
57740453|NCT02405221|BIOLOGICAL|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
57740454|NCT01525732|PROCEDURE|Per Oral Endoscopic Myotomy|
57740455|NCT01791933|DRUG|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
58111231|NCT04074213|DRUG|Clozapine|Clozapine treatment
58111232|NCT02659878|PROCEDURE|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
58111233|NCT03796299|DIAGNOSTIC_TEST|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
58111234|NCT06140511|DIAGNOSTIC_TEST|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study \[Ferri et al. Sleep 2018:zsy187\] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
58111235|NCT04136197|DIAGNOSTIC_TEST|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
58111236|NCT02086656|DRUG|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
58111237|NCT00376779|BIOLOGICAL|Infanrix hexa Vaccine|
58111238|NCT06410040|DRUG|Lorlatinib|lolatinib 100mg qd po
58111239|NCT02540707|DRUG|solifenacin|solifenacin 5 mg per day for 12 weeks
58111240|NCT02540707|DRUG|mirabegron|mirabegron 25 mg per day for 12 weeks
58111241|NCT00188695|PROCEDURE|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
58111242|NCT03058978|DEVICE|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
58111243|NCT05255133|OTHER|Liquid biopsies|Blood sampling will be done at regular intervals
58111244|NCT05255133|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
58443991|NCT05097443|DRUG|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
58443992|NCT02538042|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
58443993|NCT02538042|DRUG|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
58443994|NCT02538042|BEHAVIORAL|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
57956251|NCT04309227|OTHER|Strength Training|"Strength training traditionally requires use of high intensity loads to stimulate muscle growth and strength improvements. Some participants will be randomized to a traditional strength training program.~Blood Flow Restriction (BFR) training is used to stimulate muscle hypertrophy and strength improvements in a variety of populations. Results of BFR training are comparable to traditional high intensity training (HIT) despite using weight that are at a low intensity (low percent of 1 repetition maximum). This intervention has not been extensively studies in the rheumatoid or osteoarthritis populations, nor the myositis populations despite idealogical benefit for each group of low-load strengthening."
57956252|NCT02733666|PROCEDURE|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
57956253|NCT04994119|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
57956254|NCT04994119|DRUG|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
57956255|NCT04607200|DRUG|AGEN2034|Anti-PD-1 Monoclonal Antibody
58111245|NCT04638855|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
58111246|NCT04638855|DEVICE|Placebo|No device after hysteroscopy surgery
58111247|NCT00884130|PROCEDURE|laparoscopic colorectal resection|
58111248|NCT00884130|PROCEDURE|open colorectal resection|
58111249|NCT02555059|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
58111250|NCT03862625|DEVICE|a modular adaptive seating system|
58111251|NCT03862625|OTHER|home exercise program for scoliosis|
58111252|NCT04405934|OTHER|Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures|Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
58111253|NCT05245773|OTHER|Automated SMS program to support post-discharge transitions of care|The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
58111254|NCT05890105|DRUG|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
58111255|NCT05890105|DRUG|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
57956256|NCT04607200|DRUG|AGEN1884|Anti-CTLA-4 Monoclonal Antibody
57956257|NCT01178060|OTHER|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
57956258|NCT01178060|OTHER|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
57956259|NCT02779374|OTHER|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
57956260|NCT01773109|DRUG|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
57956261|NCT04621370|DRUG|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
57956262|NCT04621370|DRUG|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
57956263|NCT04621370|RADIATION|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
57956264|NCT04621370|RADIATION|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
57956265|NCT04621370|DRUG|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
57956266|NCT03033355|DRUG|Intradetrusor injection of Botulinum Toxin-A|Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
57956267|NCT06461260|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
57956268|NCT00418197|DEVICE|Total Facet Arthroplasty System® (TFAS®)|
57956269|NCT04116112|DRUG|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
57956270|NCT04116112|DRUG|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
57956271|NCT04116112|DRUG|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
57956272|NCT05694351|BEHAVIORAL|Healthy meals and physical activity in families with type 2 diabetes|Families will participate in telehealth family education on diabetes management and prevention through lifestyle modifications in their everyday occupations regarding current recommendations for physical activity, grocery shopping, meal preparation, and family meal routines. Each family will be assisted in setting tailored goals for the family as a whole and individually regarding physical activity and dieting habits. The goals will be incorporated into family daily routines, to secure manageability and sustainability of the new lifestyle habits. Local facilities and communy networks will be engaged in this process to empower and motivate the participants. Working with the goals will be monitored and facilitated throughout the intervention period of 3 months. Before discharge, each family will co-produce a maintenance plan for physical activity and healthy dieting.
57956273|NCT04864665|DIETARY_SUPPLEMENT|a formula with prebiotics and milk fat|Provided in a formula added with prebiotics and milk fat for 1 month
58111256|NCT02748005|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|one cap once a day
58312334|NCT04762186|DRUG|human SARS-CoV 2 specific T lymphocytes|"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
58312335|NCT01294046|DEVICE|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
57956274|NCT03730116|DRUG|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
57956275|NCT04008407|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
58312336|NCT06072638|BEHAVIORAL|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
58312337|NCT03976908|DEVICE|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
57740456|NCT01791933|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
57740457|NCT01791933|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10\~20 acupoints 1-2times a week for more than 2 months
57956276|NCT04008407|PROCEDURE|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
57956277|NCT02553512|OTHER|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
58111257|NCT06078488|OTHER|Individualized and Protocolized Nutritional Care Bundle|"Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks."
57956278|NCT02474966|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
57956279|NCT04197115|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
58111258|NCT06078488|OTHER|Optimized Standard Care|Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
58111259|NCT01380314|DRUG|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
58111260|NCT01380314|DRUG|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
58111261|NCT04821882|DRUG|Dextrose|10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
58111262|NCT03491605|OTHER|peripheral EBV-DNA load|No intervention
58111263|NCT06455189|OTHER|Control Group - Standard of care neurosurgical resection|The control group will include only standard of care tools. - Standard of care neurosurgical resection will include the use of all standard neurosurgical instruments and techniques (eg, microscope, intraoperative ultrasound, 5-ALA fluorescence guided surgery and neuronavigation system).
58111264|NCT06455189|PROCEDURE|MRF/MRI infiltration guidance for extended resection|Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body
58111265|NCT04391556|DRUG|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
58111266|NCT03361956|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
58111267|NCT03361956|DRUG|Placebo|Participants will receive matching placebo tablet orally.
58111268|NCT03361956|DRUG|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
58111269|NCT04281368|OTHER|Analysis of IUFD|Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy
58111270|NCT02025582|DEVICE|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
58111271|NCT05709106|DRUG|Rimegepant 75 MG|Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
58111272|NCT00077688|DRUG|TOCOSOL Paclitaxel|
58111273|NCT05624359|DRUG|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
58312338|NCT05408637|DEVICE|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
58312339|NCT00115388|PROCEDURE|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
58312340|NCT03740464|DRUG|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
58443995|NCT02538042|BEHAVIORAL|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
57740458|NCT01791933|PROCEDURE|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
57740459|NCT04037501|OTHER|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
58312341|NCT03740464|DRUG|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
58312342|NCT01988324|OTHER|FDHT-PET scan|
58312343|NCT01988324|OTHER|FES-PET scan|
58312344|NCT01988324|OTHER|CT-scan|
58312345|NCT01988324|OTHER|Bone scintigraphy|
58312346|NCT01988324|OTHER|Tumor biopsy|
58312347|NCT00120978|DRUG|Advair|
58312348|NCT00120978|DRUG|Flovent|
58312349|NCT02623192|OTHER|Patients who have performed the ARDS pulmonary function test|
58312350|NCT04556266|BIOLOGICAL|CAR T-Cell Infusion|Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
58312351|NCT02774889|BEHAVIORAL|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources"
58443996|NCT05357222|BEHAVIORAL|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
58443997|NCT06434181|DIETARY_SUPPLEMENT|Beetroot Juice|Beet-It Sports Shot, 70mL, containing 6.5 mmol nitric oxide (taking two shots per day in active group)
58111274|NCT05624359|DRUG|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
58111275|NCT06272851|DEVICE|optical coherence tomography|measuring choroidal thickness using optical coherence tomography
58111276|NCT04053478|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
58111277|NCT04053478|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
58111278|NCT04053478|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
58111279|NCT04053478|DRUG|Vasopressin|Vasopressin, at applicable concentrations based on literature
58111280|NCT06316947|RADIATION|CHW-delivered intervention|WellShare CHWs will then deliver the brief, approximately 15-minute intervention to the participating parent. The new intervention components will build off existing tobacco education outreach using verbal instruction and images developed by WellShare CHWs and layer in home smoke-free rules, potential biomarker feedback about smoke exposure, and other educational intervention components that align. Additionally there will be pre and post-intervention surveys and urine samples collection for cotinine levels.
58111281|NCT03575559|BEHAVIORAL|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
58111282|NCT03575559|BEHAVIORAL|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
58111283|NCT03575559|BEHAVIORAL|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
58111284|NCT01993433|DRUG|DRM02|
58111285|NCT01993433|OTHER|Vehicle|
58111286|NCT01893502|BEHAVIORAL|Telephone counselling from Quitline|
58111287|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine A dose|Inactivated vaccine against EV71, three doses, 28 days interval
58111288|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine B dose|Inactivated vaccine against EV71, three doses, 28 days interval
58111289|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine C dose|Inactivated vaccine against CVA16, three doses, 28 days interval
58443998|NCT06434181|DIETARY_SUPPLEMENT|Placebo Control|Beet-It Placebo Shot, 70mL (taking two shots per day in placebo group)
58111290|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine D dose|Inactivated vaccine against CVA16, three doses, 28 days interval
58111291|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine E dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
58111292|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine high dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
58111293|NCT04182932|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
58111294|NCT03780894|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
58443999|NCT00497406|PROCEDURE|Salivary gland transfer|Retrograde flow method
58444000|NCT00497406|PROCEDURE|Helical Tomotherapy treatment|total of 30 fractions
58444001|NCT01377662|DRUG|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
58444002|NCT01377662|OTHER|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
58444003|NCT04090411|DRUG|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
58444004|NCT04090411|DRUG|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
58444005|NCT04090411|DRUG|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
58444006|NCT04090411|OTHER|Induction- Placebo SC Q4W|0 mg Placebo
58444007|NCT04090411|DRUG|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
58111295|NCT03780894|BIOLOGICAL|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
58111296|NCT03780894|DRUG|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
58111297|NCT02801448|DRUG|sulforaphane|sulforaphane-containing broccoli sprout extracts
58111298|NCT02801448|DRUG|Placebo|Maltodextrine-based placebo without sulforaphane
58111299|NCT03526367|DRUG|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
58111300|NCT03526367|DRUG|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
58111301|NCT06045416|PROCEDURE|venous blood puncture|"Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons."
58111302|NCT04800445|DIAGNOSTIC_TEST|Salivary CRP|Salivary C reactive protein in neonatal sepsis
58111303|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
58111304|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
58111305|NCT02673671|DEVICE|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
58111306|NCT06281119|BIOLOGICAL|Cervavac as three dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
58111307|NCT06281119|BIOLOGICAL|Cervavac as two dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
58111308|NCT06281119|BIOLOGICAL|Gardasil as three dose regimen|Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
58312352|NCT04577508|BEHAVIORAL|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
58312353|NCT04577508|OTHER|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
58312354|NCT01142336|DRUG|Simvastatin|Simvastatin 40mg qHS for 1 year
58312355|NCT01142336|DRUG|Placebo|Placebo 1 tablet qHS for 1 year
57740460|NCT00226239|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
57956280|NCT04197115|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
58312356|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, on day 1.
58312357|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
57740461|NCT00226239|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
57740462|NCT00226239|DRUG|Cetuximab|Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
58312358|NCT04877600|OTHER|dual task performance|dual task performance measurement
58444008|NCT04090411|DRUG|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
57956281|NCT04197115|DRUG|Complex B|Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
58444009|NCT04090411|DRUG|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
57956282|NCT03132337|OTHER|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
57956283|NCT00915681|DRUG|Silibinin|20 mg/kg continuous IV is over 24 hours
57956284|NCT00546052|DRUG|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
58111309|NCT03335020|DEVICE|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
58111310|NCT03335020|DEVICE|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
58111311|NCT03335020|DRUG|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
58111312|NCT03335020|OTHER|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
58111313|NCT03335020|DEVICE|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
58444010|NCT01849406|DRUG|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
58444011|NCT01849406|DRUG|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
57740463|NCT00226239|PROCEDURE|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
57956285|NCT02975544|BEHAVIORAL|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
57956286|NCT05088304|OTHER|no intervention|
57956287|NCT04423497|OTHER|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
57956288|NCT00209378|OTHER|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
57956289|NCT00209378|OTHER|HfCitPre|regional anticoagulation with citrate containing replacement solution
57956290|NCT01347151|DEVICE|The glidescope video laryngoscopy|
57956291|NCT01347151|DEVICE|The Pentax airwayscope|
57956292|NCT03326843|DRUG|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
57956293|NCT04434495|BIOLOGICAL|PRP|PRP injection into uterine cavity
57956294|NCT00186550|BEHAVIORAL|Supportive Expressive Group Psychotherapy|
57956295|NCT00186550|BEHAVIORAL|Education|
57956296|NCT02342015|DRUG|Atorvastatin|Atorvastatin 40mg/day for three months
57956297|NCT02284282|DRUG|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
57956298|NCT02284282|DRUG|subcutaneum injection lidocaine|placebo injection
57956299|NCT00362089|DIETARY_SUPPLEMENT|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
57956300|NCT04887493|DRUG|Misoprostol|Misoprostol 25µg will be used for both the study arms
57956301|NCT02562742|DRUG|SOF|SOF 400 mg tablets administered orally once daily
57956302|NCT02562742|DRUG|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
57956303|NCT04937556|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
57956304|NCT04937556|DIETARY_SUPPLEMENT|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
57740464|NCT06700915|DIETARY_SUPPLEMENT|Diaberine|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
57740465|NCT06700915|DIETARY_SUPPLEMENT|Placebo Capsule|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
57740466|NCT06580834|DEVICE|Cergenx Wave|Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.
58111314|NCT04078230|PROCEDURE|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
58444012|NCT00002984|DRUG|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
57956305|NCT01514227|DRUG|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
58111315|NCT01653483|DRUG|GSK573719|Novel Dry-Powder Inhaler
58111316|NCT01653483|DRUG|GSK573719matched-placebo|Novel Dry-Powder Inhaler
58111317|NCT00468923|DRUG|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
58111318|NCT00468923|DRUG|Rosuvastatin|Rosuvastatin 10 mg once daily
58111319|NCT00814658|DRUG|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
58111320|NCT00814658|DRUG|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
58111321|NCT00814658|DRUG|Placebo|Matching placebo three times a day (tid).
58444013|NCT00002984|DRUG|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
58444014|NCT00002984|DRUG|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
58444015|NCT00002984|PROCEDURE|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
58444016|NCT00002984|RADIATION|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
57740467|NCT00285142|DRUG|rosiglitazone|
58444017|NCT00080301|DRUG|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
58111322|NCT05707429|OTHER|The Arabic version of The International Index of Erectile Function (IIEF-5)|The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of \< 22 is defined as ED .
58111323|NCT05707429|OTHER|The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)|was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
58111324|NCT05707429|OTHER|Assessment of depression and anxiety|Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
58111325|NCT05707429|OTHER|The Fatigue assessment scale (16)|It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
58111326|NCT05707429|OTHER|• Quality of life assessment|Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
58444018|NCT00080301|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
58444019|NCT02291419|DRUG|ticagrelor|ticagrelor 90 mg bid
58444020|NCT02291419|DRUG|aspirin|aspirin 81 mg daily
57956306|NCT01514227|DRUG|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
57740468|NCT03610126|PROCEDURE|volume controlled ventilation|the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
57956307|NCT01069562|OTHER|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
57956308|NCT01069562|OTHER|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
57956309|NCT02870309|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
57956310|NCT00753870|BIOLOGICAL|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
57956311|NCT04476303|DRUG|BEY2153|Capsule
57956312|NCT00825500|DRUG|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
57956313|NCT00825500|DRUG|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
57956314|NCT00825500|DRUG|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
57956315|NCT00489567|PROCEDURE|Blood sample collection|
57956316|NCT06330038|DRUG|Propofol|Propofol will be used for the induction and maintenance of general anesthesia.
57956317|NCT06330038|DRUG|Inhaled anesthetics|Inhaled anesthetics will be used for the maintenance of general anesthesia.
57956318|NCT03477760|BIOLOGICAL|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
57956319|NCT05683444|DRUG|Octreotide infusion|Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
57956320|NCT05683444|DRUG|Saline infusion|Saline Infusion
57956321|NCT05080465|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
57956322|NCT05990673|DRUG|Remimazolam|remimazolam is given intravenously
57956323|NCT05024955|PROCEDURE|Discussion|Attend a focus group
57956324|NCT05024955|OTHER|Interview|Attend interview
57956325|NCT05568511|OTHER|App-based exercise program|Remotely-controlled, app-guided exercise program
57956326|NCT05568511|OTHER|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
57956327|NCT01509963|OTHER|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
57956328|NCT00166608|PROCEDURE|Blood sampling|
57956329|NCT02916940|DRUG|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
57956330|NCT04788355|DRUG|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
57956331|NCT04788355|DRUG|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
57956332|NCT04788355|DRUG|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
58111327|NCT05707429|OTHER|The Female Sexual Function Index (FSFI)|The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
58111328|NCT03955666|BIOLOGICAL|PRV-3279 or placebo|bi-specific antibody-based molecule
58111329|NCT04621942|OTHER|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
58111330|NCT04621942|OTHER|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
58111331|NCT00229112|DRUG|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
58111332|NCT00229112|DRUG|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
57740469|NCT03610126|PROCEDURE|pressure controlled ventilation|the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
57740470|NCT04597853|DIAGNOSTIC_TEST|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
57956333|NCT04788355|DRUG|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
57956334|NCT03637933|PROCEDURE|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
57956335|NCT02905474|OTHER|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
57956336|NCT02905474|DEVICE|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
57956337|NCT02905474|DEVICE|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
57956338|NCT00153582|BIOLOGICAL|WT1 126-134 peptide|
57956339|NCT00005112|DRUG|Human recombinant growth hormone|
57956340|NCT00866307|DRUG|Cyclophosphamide|Given IV
57956341|NCT00866307|DRUG|Cytarabine|Given IT and IV or SC
57956342|NCT00866307|DRUG|Daunorubicin Hydrochloride|Given IV
57956343|NCT00866307|DRUG|Dexamethasone|Given IV
57956344|NCT00866307|DRUG|Doxorubicin Hydrochloride|Given IV
57956345|NCT00866307|OTHER|Laboratory Biomarker Analysis|Correlative studies
57956346|NCT00866307|DRUG|Mercaptopurine|Given PO
57956347|NCT00866307|DRUG|Methotrexate|Given IT and PO
57956348|NCT00866307|DRUG|Pegaspargase|Given IV
57956349|NCT00866307|DRUG|Prednisone|Given IV or PO
57956350|NCT00866307|RADIATION|Prophylactic Cranial Irradiation|Undergo radiation
57956351|NCT00866307|DRUG|Thioguanine|Given PO
57956352|NCT00866307|DRUG|Vincristine Sulfate|Given IV
57956353|NCT06275503|BEHAVIORAL|Screening invitation mode|Cluster randomized study to compare mode of invitation
57956354|NCT03021642|DRUG|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
57956355|NCT03021642|DRUG|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
57956356|NCT03021642|DRUG|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
58111333|NCT05270187|OTHER|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
57740471|NCT03625570|BEHAVIORAL|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
57740472|NCT03625570|BEHAVIORAL|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
58111334|NCT05270187|OTHER|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
58111335|NCT00736619|OTHER|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
58111336|NCT02419859|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
58111337|NCT02419859|DRUG|Insulin, Asp(B28)-|a fast-acting analog of human insulin
58111338|NCT03705169|BIOLOGICAL|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
58312359|NCT05348434|PROCEDURE|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
58312360|NCT05675670|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
57740473|NCT02234869|DRUG|Interferon Beta|Subcutaneous injection
57740474|NCT02234869|DRUG|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
57740475|NCT05420155|PROCEDURE|Surgical resection|Surgical treatment of hepatic hydatidic cyst
57740476|NCT02242474|DRUG|Anti-TNF suspended perioperatively|
57740477|NCT02242474|DRUG|Anti-TNFα continued perioperatively|
57956357|NCT03021642|DRUG|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
57956358|NCT05028400|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
57956359|NCT05712512|BEHAVIORAL|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
57956360|NCT05712512|OTHER|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
57956361|NCT03355300|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
57956362|NCT01895322|DRUG|OPC-41061|
57956363|NCT02868242|DRUG|LDV/SOF|Tablet(s) administered orally once daily
57956364|NCT05061173|OTHER|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
57956365|NCT05061173|OTHER|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
58111339|NCT03705169|BIOLOGICAL|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
58111340|NCT03575039|DEVICE|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
58111341|NCT01718210|DRUG|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
57740478|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
57740479|NCT01467180|DEVICE|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
58111342|NCT01718210|DRUG|CONTROL|group of controls treated with a standard IVF medium
58111343|NCT03867227|DEVICE|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
58111344|NCT03524937|DRUG|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
57740480|NCT01467180|DEVICE|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
57740481|NCT06613217|DRUG|zelenirstat|Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
57740482|NCT04253743|OTHER|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
57740483|NCT04546308|OTHER|Resistance exercise training|Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
58111345|NCT03524937|DRUG|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
58111346|NCT03524937|DRUG|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
58111347|NCT03208348|OTHER|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
58111348|NCT02130206|OTHER|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
58111349|NCT02130206|OTHER|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
58111350|NCT02130206|OTHER|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
58312361|NCT05395442|DIAGNOSTIC_TEST|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
57740484|NCT06164717|BEHAVIORAL|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
58111351|NCT02130206|OTHER|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
58111352|NCT02804269|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
58111353|NCT02804269|OTHER|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
58111354|NCT05209490|PROCEDURE|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed."
58111355|NCT05209490|PROCEDURE|femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
58111356|NCT02706002|DEVICE|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
58111357|NCT02706002|PROCEDURE|hip prosthesis|all patients in the study will undergo hip prosthesis
58111358|NCT00787566|DRUG|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
58111359|NCT03717285|PROCEDURE|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
58111360|NCT03717285|PROCEDURE|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
58111361|NCT05933525|BIOLOGICAL|Travelan|6 Travelan tablets (1200mg) administered orally for 7 days
58111362|NCT05933525|OTHER|Placebo|6 tablets of placebo (1200mg) administered orally for 7 days
58111363|NCT00122850|DRUG|Duloxetine|
58111364|NCT00122850|DRUG|venlafaxine|
58111365|NCT00122850|DRUG|placebo|
58111366|NCT00708630|BEHAVIORAL|Extended information on side effects|More detailed information on possible side effects of vaccine
58111367|NCT03082456|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
58111368|NCT03082456|DIAGNOSTIC_TEST|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
58111369|NCT03082456|DIAGNOSTIC_TEST|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
58111370|NCT05451043|BIOLOGICAL|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
58111371|NCT05451043|DRUG|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
58111372|NCT05451043|DRUG|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
58111373|NCT05451043|BIOLOGICAL|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
58111374|NCT05451043|DRUG|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
58111375|NCT05451043|DRUG|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
58111376|NCT06503042|DRUG|Chemotherapy combined with immunotherapy|Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
58111377|NCT06503042|DRUG|Chemotherapy only|Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
58111378|NCT00003782|DRUG|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
58111379|NCT00003782|DRUG|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
58111380|NCT00003782|DRUG|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
58111381|NCT01154153|DRUG|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
58312362|NCT01344135|DIETARY_SUPPLEMENT|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
58111382|NCT01154153|DRUG|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
57740485|NCT06164717|BEHAVIORAL|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
57740486|NCT06164717|OTHER|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
57740487|NCT01542918|DRUG|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
58111383|NCT01154153|DRUG|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
58111384|NCT01154153|DRUG|Claritin® Syrup|Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
58111385|NCT01146730|BEHAVIORAL|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
58111386|NCT01146730|BEHAVIORAL|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
58111387|NCT05261425|DEVICE|Monocryl buried|Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
58312363|NCT01344135|DIETARY_SUPPLEMENT|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
57740488|NCT01542918|DRUG|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
58111388|NCT05261425|DEVICE|Nylon (FDA Approved) not buried|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
58111389|NCT05654610|DEVICE|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
58111390|NCT02168075|DRUG|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
58111391|NCT02168075|DRUG|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
58111392|NCT02168075|DRUG|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
58111393|NCT02168075|DRUG|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
58111394|NCT00595426|DRUG|YM150|Oral
58111395|NCT00595426|DRUG|Warfarin|Oral
58111396|NCT04882111|BEHAVIORAL|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
58111397|NCT06012591|OTHER|Quality improvement recommendations (action plans)|Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
58111398|NCT02036528|DRUG|Gentamicin Topical Gel|
58111399|NCT02036528|DRUG|Ciprofloxacin|
58111400|NCT02036528|DRUG|Doxycycline|
58111401|NCT05064202|DEVICE|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
58111402|NCT05064202|DRUG|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
58111403|NCT05252078|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
58111404|NCT05252078|DRUG|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
58111405|NCT03108079|DEVICE|Cystosure Urinary Access System|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
58458481|NCT02422498|RADIATION|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
57740489|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
57956366|NCT05061173|OTHER|Combined Exercise Training Group|"Combined Exercise training includes \[Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction\] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
58111406|NCT03108079|DEVICE|Foley Catheter|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
58111407|NCT05618483|DEVICE|Nasal Spray|The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
58111408|NCT04484922|DRUG|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
58111409|NCT04484922|DRUG|Normal saline|continuous infusion of normal saline during the surgery
58111410|NCT03492073|BEHAVIORAL|Emotional Supportive Mindfulness-based Program|Mindfulness training
58111411|NCT03492073|BEHAVIORAL|Emotional Supportive Program|Narrative-orientated therapy.
58111412|NCT01252628|DRUG|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
58111413|NCT01252628|DRUG|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
58111414|NCT01252628|DRUG|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
58111415|NCT01252628|DRUG|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
58111416|NCT04846556|OTHER|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
58458482|NCT02422498|DRUG|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
58111417|NCT02308111|DRUG|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
58111418|NCT02308111|DRUG|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
58111419|NCT04511351|DRUG|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
58111420|NCT03518710|OTHER|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~* Process evaluation:~* Oculomotors: DEM test (5min)~* Visuo-attention: computerized STROOP (15min)~* Visuo-Perceptive: DTVP3 (30min)~* Phonological \& lexical: Exalang (10min)"
58111421|NCT03518710|OTHER|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
58111422|NCT05499156|OTHER|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
58111423|NCT01916785|DRUG|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
58111424|NCT02600169|DRUG|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
58111425|NCT03911609|OTHER|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
58111426|NCT03911609|OTHER|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
58111427|NCT06503341|OTHER|Cardiovascular risk assesment|ASCVD Score and WHO Cardiovascular Risk score.
58111428|NCT02758366|DRUG|Doxorubicin|
58111429|NCT02447484|BEHAVIORAL|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
58111430|NCT02447484|BEHAVIORAL|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
57740490|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
58111431|NCT04449159|DIETARY_SUPPLEMENT|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
58111432|NCT04449159|DIETARY_SUPPLEMENT|Placebo|Placebo
58111433|NCT03754816|PROCEDURE|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
58111434|NCT03754816|DRUG|Levobupivacaine|Levobupivacaine
58111435|NCT01681771|BEHAVIORAL|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
58111436|NCT01681771|BEHAVIORAL|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
58111437|NCT02960815|BIOLOGICAL|Intanza|
58111438|NCT02960815|BIOLOGICAL|Mutagrip|
58111439|NCT02960815|DRUG|Aldara|
57740491|NCT04938245|DEVICE|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
58111440|NCT04976868|DRUG|Pimecrolimus 1% Top Cream|Elidel® as prescribed within routine clinical practice
58111441|NCT04078919|DIETARY_SUPPLEMENT|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
58111442|NCT04078919|OTHER|Low calorie diet|Low calorie diet
58111443|NCT00863057|DRUG|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
58111444|NCT00863057|DRUG|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
57740492|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
58111445|NCT00863057|DRUG|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
58111446|NCT00863057|DRUG|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
58111447|NCT00006721|BIOLOGICAL|rituximab|Given IV
58111448|NCT00006721|DRUG|cyclophosphamide|Given IV
58111449|NCT00006721|DRUG|doxorubicin|Given IV
58111450|NCT00006721|DRUG|prednisone|Given orally
58111451|NCT00006721|DRUG|vincristine|Given IV
58111452|NCT00006721|RADIATION|tositumomab|Given IV
58111453|NCT02967133|DRUG|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
58111454|NCT02967133|DRUG|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
58111455|NCT01072032|DEVICE|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
58111456|NCT01670461|BEHAVIORAL|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
58111457|NCT01670461|BEHAVIORAL|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  ... regarding advance directives ... to honor each non-minor patient's wishes ... to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
57740493|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
57740494|NCT01261611|DRUG|Placebo|I.M. injection on day 1 of treatment cycle 1.
57740495|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
58111458|NCT02638857|PROCEDURE|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
58111459|NCT02638857|BIOLOGICAL|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
58111460|NCT02638857|DRUG|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
58111461|NCT02638857|DRUG|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
58111462|NCT02638857|DRUG|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
58111463|NCT02638857|BIOLOGICAL|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
58111464|NCT04857385|DEVICE|Radial artery hemostasis|Each of the devices will be assessed for radial artery hemostasis.
58111465|NCT01004081|DRUG|BIIB021|BID orally for 28 days
58111466|NCT01004081|DRUG|BIIB021|TIW orally for 28 days
58111467|NCT01004081|DRUG|exemestane (Aromasin)|Daily in tablet form for 28 days
58111468|NCT04597762|DRUG|Cyclosporin|Cyclosporin eyedrops
58111469|NCT04597762|DRUG|Hydrocortisone|Hydrocortisone eyedrops
58111470|NCT00022425|DRUG|perillyl alcohol|
58111471|NCT01766011|OTHER|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
58312364|NCT01344135|BEHAVIORAL|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~1. Optimising dietary intake to physical activity pattern and energy expenditure.~2. Minimize deterioration of dietary intake during acute exacerbations.~3. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~4. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
57740496|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
57740497|NCT02546661|DRUG|MEDI4736|MEDI4736
57740498|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
57740499|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
57740500|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
57740501|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
57740502|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
57740503|NCT00362518|DIETARY_SUPPLEMENT|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
57740504|NCT00362518|DIETARY_SUPPLEMENT|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
57740505|NCT00362518|DIETARY_SUPPLEMENT|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
58111472|NCT01078623|DRUG|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
58111473|NCT01078623|DRUG|Placebo|Placebo control twice daily
58111474|NCT01078623|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
58111475|NCT01078623|DRUG|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
58111476|NCT01078623|DRUG|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
58111477|NCT02005354|DEVICE|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).
58111478|NCT02005354|DRUG|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
58111479|NCT04611035|DEVICE|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
58111480|NCT01369251|BEHAVIORAL|Hygiene|
58111481|NCT01369251|PROCEDURE|Usual alcohol care|
58111482|NCT00803946|DRUG|Ibuprofen Tablets, 800 mg|
58111483|NCT01428024|DEVICE|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
57740506|NCT00362518|DIETARY_SUPPLEMENT|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
58111484|NCT01428024|DEVICE|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
58111485|NCT03074279|OTHER|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
58111486|NCT04156191|DRUG|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
58111487|NCT04156191|DRUG|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
57740507|NCT02439710|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
57740508|NCT01751438|OTHER|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
57740509|NCT01751438|OTHER|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
58458483|NCT02422498|PROCEDURE|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
57740510|NCT01751438|BEHAVIORAL|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
58111488|NCT00685971|DIETARY_SUPPLEMENT|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
58111489|NCT00685971|DIETARY_SUPPLEMENT|placebo|5 drops once daily for 12 weeks
58111490|NCT03287466|DRUG|Oxygen|targeted oxygen therapy
58111491|NCT01608633|OTHER|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
58111492|NCT04586790|DRUG|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
58111493|NCT04586790|DRUG|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
58111494|NCT04586790|DRUG|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
58111495|NCT01306253|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
58111496|NCT03058497|DEVICE|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
58111497|NCT01034137|DRUG|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
58111498|NCT01034137|DRUG|placebo MTX|orally weekly
58111499|NCT01034137|DRUG|placebo TCZ|iv every 4 weeks
58111500|NCT01034137|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
58111501|NCT04312659|DRUG|Infliximab|Participants will be observed who were treated with Infliximab.
58111502|NCT06540729|DRUG|Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer|Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
58111503|NCT01323998|DRUG|5ARI|Dutasteride or Finasteride
58111504|NCT01323998|DRUG|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
57740511|NCT01751438|OTHER|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
57740512|NCT05572138|DIAGNOSTIC_TEST|Body Impedance Analysis|Body Impedance Analysis
58111505|NCT00367406|DEVICE|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
58111506|NCT03988725|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800 IU once daily
58111507|NCT03539315|BEHAVIORAL|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
58111508|NCT00130481|DRUG|Atorvastatin 20 mg daily for 3 months|
58111509|NCT06240845|OTHER|High-level laser therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
58458484|NCT03701139|PROCEDURE|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
57740513|NCT05378633|RADIATION|SRS|Stereotactic Radiotherapy (SRS)
57740514|NCT05378633|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
57740515|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
57740516|NCT00504270|DRUG|Placebo|po daily
57740517|NCT00504270|DRUG|RG3421 120mg|120mg po daily
57740518|NCT00504270|DRUG|RG3421 20mg|20mg po daily
57740519|NCT03254082|OTHER|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
57740520|NCT03254082|OTHER|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
57740521|NCT03254082|OTHER|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
58111510|NCT06240845|OTHER|Low-level laser therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
58111511|NCT05250349|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography with standard measurements
58111512|NCT05250349|DIAGNOSTIC_TEST|Doppler sonography|Transcarotid and transcranial Doppler sonography
58111513|NCT05250349|DIAGNOSTIC_TEST|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
58111514|NCT05491174|BEHAVIORAL|DBT-Informed skills group|10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
58111515|NCT03518697|BEHAVIORAL|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
58111516|NCT02415010|DEVICE|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
58111517|NCT06481696|DIETARY_SUPPLEMENT|Resveratrol-based multivitamin supplement|Natural polyphenol and vitamins
58111518|NCT06481696|DIETARY_SUPPLEMENT|Folic acid|Supplementation with folic acid at the standard dosage of 0.4 mg/die
58111519|NCT06481696|PROCEDURE|IVF/ICSI|In vitro fertilization/IntraCytoplasmic Sperm Injection
58111520|NCT06481696|DRUG|Follitropin Alfa|Controlled Ovarian Stimulation
58111521|NCT06481696|DRUG|Ganirelix Acetate 0.5 MG/ML [Fyremadel]|GnRH Antagonist
58111522|NCT06481696|DRUG|hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously|For the induction of oocyte maturation
58458485|NCT03701139|PROCEDURE|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
58458486|NCT00004925|BIOLOGICAL|trastuzumab|
58458487|NCT00004925|DRUG|pegylated liposomal doxorubicin hydrochloride|
58111523|NCT04607642|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
58111524|NCT04607642|RADIATION|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
58111525|NCT04607642|DRUG|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
58111526|NCT04607642|OTHER|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
58111527|NCT01510665|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
58111528|NCT01510665|DIETARY_SUPPLEMENT|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
58111529|NCT01510665|BEHAVIORAL|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
58111530|NCT02557672|DRUG|Prothrombin complex concentrate (Human)|PCC (Kcentra)
58111531|NCT02557672|BIOLOGICAL|Fresh frozen plasma (FFP)|FFP
58111532|NCT03125057|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
58111533|NCT03187054|PROCEDURE|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
58111534|NCT05907200|OTHER|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
58111535|NCT05907200|OTHER|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
58111536|NCT02152787|DRUG|Injection of propofol 1.0mg/kg|
58111537|NCT02152787|DRUG|propofol 0.5mg/kg|
58111538|NCT02152787|DRUG|normal saline|
58111539|NCT04108481|DRUG|Durvalumab|Immunotherapy
58111540|NCT04108481|RADIATION|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
58111541|NCT02561988|DRUG|Avapritinib|
58111542|NCT00718965|DRUG|AVE5530|one tablet in the evening with dinner
58111543|NCT00718965|DRUG|Placebo|one tablet in the evening with dinner
58111544|NCT03824210|OTHER|App|Mobile phone app
58111545|NCT00872560|DEVICE|NovoFine® needle 6 mm|
58111546|NCT00872560|DEVICE|NovoFine® needle 8 mm|
58111547|NCT04324879|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
58111548|NCT01226147|DRUG|Tamibarotene|4mg/day for 24 weeks.
58111549|NCT01159769|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
58111550|NCT02198677|PROCEDURE|Anterior to posterior pressures|Anterior to posterior pressures
58111551|NCT02198677|PROCEDURE|Lateral glide|Lateral glide
58111552|NCT02525328|OTHER|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
58111553|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
58111554|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
58111555|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
58111556|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
58111557|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
58111558|NCT04460352|DRUG|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
58111559|NCT04460352|DRUG|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
58111560|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
58111561|NCT05898282|OTHER|observation|since this is a cross sectional observational study any form of intervention was not applicable
58111562|NCT06318481|DRUG|Ticagrelor 90 MG|Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
58111563|NCT06318481|DRUG|Clopidogrel|Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
58111564|NCT03564756|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C per day
58111565|NCT05639387|PROCEDURE|actual tVNS|Active tVNS (stimulation on cymba conchae --\> nervus vagus stimulation)
58111566|NCT05639387|PROCEDURE|sham tVNS|Sham tVNS (stimulation on earlobe --\> no nervus vagus stimulation)
58111567|NCT04164485|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
58111568|NCT04164485|BIOLOGICAL|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
58111569|NCT03574883|DEVICE|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
58111570|NCT03574883|DEVICE|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
58111571|NCT03569319|BEHAVIORAL|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
58111572|NCT03569319|BEHAVIORAL|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
58111573|NCT03569319|BEHAVIORAL|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
58111574|NCT00062309|RADIATION|radiation therapy|
58312365|NCT01344135|BEHAVIORAL|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
58312366|NCT00651209|DRUG|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
58312367|NCT00626145|PROCEDURE|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
58312368|NCT00626145|PROCEDURE|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
58312369|NCT03143452|DRUG|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
58312370|NCT03143452|DRUG|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
58111575|NCT05299229|DIAGNOSTIC_TEST|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
58111576|NCT01361399|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
58111577|NCT01361399|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
58111578|NCT01361399|DRUG|Lidocain|Single oral application of Lidocain (as lozenge)
58111579|NCT01361399|DRUG|Placebo|Single oral application of Placebo (as lozenge)
58111580|NCT05557578|DRUG|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
58111581|NCT00495118|DRUG|risperidone|
58111582|NCT03010202|DRUG|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
58111583|NCT03010202|DRUG|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
58111584|NCT05126875|RADIATION|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
58111585|NCT04890275|OTHER|Blood flow restricted resistance exercise (BFR)|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
58312371|NCT04215835|DRUG|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
58312372|NCT04215835|DRUG|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
58312373|NCT06494657|OTHER|Corticosteroid injection|Corticosteroid injection for frozen shoulder
58312374|NCT02832037|DRUG|BI 425809 dose 1|
58111586|NCT04890275|OTHER|Resistance exercise without blood flow restricted (NON-BFR)|Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
58111587|NCT06463938|OTHER|Active comparator|CPP-ACP paste will be applied on exposed area
58111588|NCT06463938|DEVICE|Experimental group|Lasotronix will be applied following its protocol
58111589|NCT06463938|COMBINATION_PRODUCT|Combination of laser and paste|This group will receive the combination of above two treatments
58111590|NCT06463938|BEHAVIORAL|Control group|this will be a control group
58111591|NCT03016585|OTHER|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
58111592|NCT00305370|DRUG|Aripiprazole|
58111593|NCT04897971|DIAGNOSTIC_TEST|Medium enriched for newly synthesized antibodies in spine infection|Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
58111594|NCT05455970|OTHER|Rhythmic auditory stimulation (RAS)|A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
58111595|NCT00902824|BIOLOGICAL|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)
58111596|NCT00902824|BIOLOGICAL|TBC-M4|Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
58111597|NCT00902824|OTHER|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
58111598|NCT02110706|DRUG|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
58111599|NCT02110706|DRUG|Placebo|The placebo group will receive a vehicle control infusion
58111600|NCT06447220|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
58111601|NCT02362854|PROCEDURE|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
58111602|NCT02362854|DEVICE|DL application in peri-implantitis|Diode laser application in the diseased implants.
58111603|NCT04908722|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
58111604|NCT00609895|DRUG|INSULIN GLARGINE|
58111605|NCT05514847|DRUG|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
58111606|NCT05514847|DRUG|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
58111607|NCT03704779|BEHAVIORAL|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
58312375|NCT02832037|DRUG|BI 425809 dose 2|
57740522|NCT03254082|OTHER|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
58111608|NCT03900546|DEVICE|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
58312376|NCT02832037|DRUG|BI 425809 dose 3|
58312377|NCT02832037|DRUG|BI 425809 dose 4|
58111609|NCT01773694|BEHAVIORAL|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
58111610|NCT00147264|DRUG|Telmisartan (Micardis®) vs. Placebo|
58111611|NCT00147264|BEHAVIORAL|Low-Glycemic Index Diet vs. Control Diet|
58111612|NCT01742325|BEHAVIORAL|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
58111613|NCT04189094|DRUG|Sintilimab|Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
58111614|NCT04189094|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
58111615|NCT04189094|DRUG|Cisplatin|cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
58111616|NCT04189094|RADIATION|radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
58312378|NCT02832037|DRUG|Placebo|
58444021|NCT04975178|BIOLOGICAL|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
58111617|NCT02496260|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
58111618|NCT02496260|PROCEDURE|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
57740523|NCT03254082|OTHER|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
57740524|NCT04568434|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
58111619|NCT01261325|DRUG|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
58111620|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
58111621|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
57956367|NCT04312490|DIAGNOSTIC_TEST|endomyocardial biopsy|Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
57956368|NCT04683965|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
57956369|NCT04683965|DRUG|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
57956370|NCT04683965|DRUG|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
57956371|NCT02922140|BEHAVIORAL|pharmaceutical care service|
57956372|NCT02914262|DRUG|AKB-4924|Comparison of different dosages of AKB-4924
57956373|NCT02914262|OTHER|Placebo|Placebo comparator
57956374|NCT00589446|DEVICE|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
57956375|NCT04806607|PROCEDURE|19G FNB|Biopsy specimen adequacy using the 19G FNB
57956376|NCT04806607|PROCEDURE|22G FNB|Biopsy specimen adequacy using the 22G FNB.
57956377|NCT00217815|DRUG|Mycograb, Docetaxel|
57956378|NCT00525538|RADIATION|conformal radiotherapy|
57956379|NCT00105937|DRUG|OraVescent fentanyl citrate|
58111622|NCT01261325|DRUG|Antiepileptic drugs with market authorization available per country|
58111623|NCT04694040|DEVICE|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
58111624|NCT00701766|DRUG|BI 2536|
58111625|NCT06529029|DEVICE|Sigma-Stim|Right Ultra-Brief Low Amplitude Seizure Therapy at 600mA or 700mA vs Right Unilateral Ultra-Brief Standard ECT at 800mA.
58444022|NCT04975178|BIOLOGICAL|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
57740525|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
57740526|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
57956380|NCT04755634|DEVICE|Hyaluronic Acid|Injectable
57956381|NCT06417619|BEHAVIORAL|Mindfulness-Based Psychoeducation|The Effect of Mindfulness-Based Psychoeducation on Depression Level of Depression Patients
57956382|NCT05966285|OTHER|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
57956383|NCT05966285|OTHER|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
57956384|NCT01459458|BEHAVIORAL|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
57956385|NCT04957771|OTHER|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
57956386|NCT03194373|DRUG|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
57956387|NCT03194373|DRUG|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
57956388|NCT03535753|DRUG|Decitabine and R-GDP|Decitabine and R-GDP
57956389|NCT00953758|DRUG|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
57956390|NCT02918864|DRUG|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
58111626|NCT00551486|PROCEDURE|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
58111627|NCT06052878|OTHER|"Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)"|"The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions."
58111628|NCT06052878|OTHER|Parental questionnaire about their child's cognitive functioning in their daily life and medical history.|Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.
58111629|NCT03358394|BEHAVIORAL|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
58111630|NCT00231049|DRUG|AG-707|
58111631|NCT06021262|OTHER|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
58111632|NCT04387110|DRUG|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
58111633|NCT02450942|DRUG|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
58111634|NCT04807127|DRUG|Immune checkpoint blockade|ICI, administered as standard-of-care treatment
58111635|NCT04807127|DRUG|Targeted therapy|TKI, administered as standard-of-care treatment
57740527|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
58111636|NCT04807127|RADIATION|Radiotherapy|RT, administered as standard-of-care treatment
58111637|NCT04155788|BEHAVIORAL|Food Exposure|Participants will complete a meal exposure using one of their feared foods.
58111638|NCT00661674|DRUG|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
58111639|NCT00661674|DRUG|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
58111640|NCT00661674|OTHER|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
58111641|NCT05969795|DIAGNOSTIC_TEST|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
58111642|NCT05969795|DIAGNOSTIC_TEST|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
58111643|NCT05969795|DRUG|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
58111644|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
58111645|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
58444023|NCT00512876|DRUG|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
58444024|NCT02515734|DRUG|fluorouracil|
58444025|NCT02515734|DRUG|Leucovorin|
58444026|NCT02515734|DRUG|irinotecan|
57740528|NCT05686070|DRUG|Asundexian (BAY2433334)|Once daily, oral
57740529|NCT05686070|DRUG|Placebo|Placebo to asundexian, once daily, oral
58111646|NCT05969795|PROCEDURE|Embryo transfer|The procedure in which embryo is placed in the uterus.
58111647|NCT05969795|DIAGNOSTIC_TEST|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of \> 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
58444027|NCT02515734|DRUG|oxaliplatin|
58444028|NCT02515734|BIOLOGICAL|bevacizumab|
58444029|NCT02515734|BIOLOGICAL|cetuximab|
58444030|NCT04891523|DIETARY_SUPPLEMENT|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
57740530|NCT03169387|BEHAVIORAL|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
57740531|NCT03169387|BEHAVIORAL|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
58111648|NCT05969795|DIAGNOSTIC_TEST|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
58111649|NCT02060656|DRUG|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
58111650|NCT02060656|DRUG|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
58111651|NCT02060656|DRUG|Rituximab|375mg/m2 IV D1, D15 every 28 days
58111652|NCT02060656|DRUG|Cisplatin|100mg/m2 IV D15 every 28 days
58111653|NCT02060656|DRUG|Lenalidomide|25mg PO D1-21 every 28 days
58111654|NCT06200389|DIAGNOSTIC_TEST|microbiology testing|Vulvovaginal Candidiases patients diagnosed by microbiology testing can be included
58111655|NCT03037684|DIAGNOSTIC_TEST|neurophysiology|electrophysiologic measurements of peripheral nerves
58111656|NCT03272867|DIETARY_SUPPLEMENT|ProManna|
58111657|NCT01312779|DEVICE|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
58111658|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
57740532|NCT02216175|OTHER|SLIT to cow's milk|Sublingual immunotherapy
57740533|NCT02216175|OTHER|Low dose OIT|Oral Immunotherapy (low dose)
57740534|NCT02216175|OTHER|Conventional OIT to cow's milk|Oral Immunotherapy
57740535|NCT06085248|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
57740536|NCT06085248|BEHAVIORAL|Active walking|walking without RAS cue
58111659|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
58111660|NCT02910310|OTHER|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
58111661|NCT06523088|DRUG|PN20|Six dose levels of PN20 will be evaluated
58111662|NCT06523088|DRUG|Placebo|Placebo of PN20
58111663|NCT00276705|DRUG|cisplatin|
58111664|NCT00276705|DRUG|cyclophosphamide|
58111665|NCT00276705|DRUG|doxorubicin hydrochloride|
58111666|NCT00276705|DRUG|thalidomide|
58111667|NCT00276705|PROCEDURE|adjuvant therapy|
58111668|NCT00276705|PROCEDURE|conventional surgery|
58111669|NCT00276705|PROCEDURE|neoadjuvant therapy|
58111670|NCT02938806|OTHER|No intervention|No intervention
58111671|NCT02624518|DRUG|68Ga-RM2|Imaging with PET/MRI
58111672|NCT02624518|PROCEDURE|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
58111673|NCT02624518|PROCEDURE|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
58111674|NCT04706871|DEVICE|taVNS|"taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear."
58111675|NCT04706871|DEVICE|tnVNS|"tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear."
58111676|NCT00706706|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
57740537|NCT04913753|PROCEDURE|CBEU|Patients in the control group will have bacterial culture and double J removal will be performed as usual. .
58111677|NCT02658682|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
58111678|NCT02658682|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
58111679|NCT03813485|OTHER|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
58444031|NCT04891523|OTHER|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo \[inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)\] in form of a lozenge, daily, during 3 weeks.
58444032|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue
58444033|NCT00328367|DRUG|aripiprazole|aripiprazole augmentation of clozapine
57740538|NCT04913753|PROCEDURE|No CBEU|Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
57740539|NCT05339529|DRUG|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
57740540|NCT05339529|DRUG|Blank control|Blank control
57740541|NCT00450411|RADIATION|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
58444034|NCT00328367|DRUG|placebo|placebo
58444035|NCT01731366|OTHER|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
57740542|NCT00450411|RADIATION|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
57740543|NCT05371496|DRUG|Semaglutide|3.0 mg/ml (titrated to 2.4 mg) subcutaneous once weekly for 12 months
57740544|NCT05371496|DRUG|Placebo|Matched placebo with no active drug once weekly for 12 months
57740545|NCT05371496|BEHAVIORAL|Counselling on healthy lifestyle intervention|All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.
57740546|NCT06462989|OTHER|ECHONEXT|ECHONEXT Artificial intelligence algorithm
58444036|NCT01731366|OTHER|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
58458488|NCT02472860|BEHAVIORAL|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
57740547|NCT01782066|BIOLOGICAL|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
57740548|NCT05319067|OTHER|Stool sampling|Stool sample taken at home 24 hours before hospital visit
57740549|NCT04642508|PROCEDURE|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
57740550|NCT05646186|DIETARY_SUPPLEMENT|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
58444037|NCT05395325|OTHER|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
57740551|NCT05646186|DIETARY_SUPPLEMENT|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
57740552|NCT06061510|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
57740553|NCT06061510|DIETARY_SUPPLEMENT|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
57740554|NCT04769427|DEVICE|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
57740555|NCT00712023|DEVICE|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
57740556|NCT03919383|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
57740557|NCT03919383|DRUG|Toripalimab|240mg intravenously every 3 weeks
57740558|NCT06670664|OTHER|No intervention|No intervention. This is a single-group study.
57740559|NCT02024906|DIETARY_SUPPLEMENT|soy protein isolate (SPI)|
57740560|NCT02024906|DIETARY_SUPPLEMENT|milk protein isolate (MPI)|
57740561|NCT00862134|DRUG|PR104|770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
57740562|NCT00862134|DRUG|docetaxel|75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
58458489|NCT02472860|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition
58312379|NCT06472648|OTHER|Proprioception training exercise plan with BOSU|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises."
58312380|NCT06472648|OTHER|Proprioception training exercise plan with Blackboard (BB)|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises."
58312381|NCT04329065|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
58312382|NCT04329065|DRUG|Paclitaxel|Given via infusion
58312383|NCT04329065|BIOLOGICAL|Trastuzumab|Given IV
58312384|NCT04329065|BIOLOGICAL|Pertuzumab|Given IV
58444038|NCT05395325|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
58444039|NCT05395325|OTHER|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
58444040|NCT02919046|BIOLOGICAL|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
58444041|NCT04014985|OTHER|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
57740563|NCT00862134|DRUG|docetaxel|60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
58444042|NCT02255994|DEVICE|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
58444043|NCT02255994|PROCEDURE|No mesh.|Patients in this arm had subvesical plication without reinforcement.
58444044|NCT02862873|PROCEDURE|Spinal anaesthesia|
58444045|NCT02862873|DRUG|Ondansetron|
58444046|NCT02862873|OTHER|saline solution|
58444047|NCT02722954|DRUG|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
58444048|NCT02722954|DRUG|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
58444049|NCT01584310|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
57956391|NCT02918864|BEHAVIORAL|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
58312385|NCT00477685|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
58312386|NCT02474186|RADIATION|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
58312387|NCT02474186|DRUG|Xeloda|chemotherapy agent daily for two weeks
58312388|NCT02474186|DRUG|paclitaxel|chemotherapy agent weekly for two weeks
58312389|NCT01838876|DRUG|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
58312390|NCT01838876|DRUG|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
58312391|NCT01104649|DRUG|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
58312392|NCT01104649|DRUG|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
58312393|NCT01138735|DRUG|adapalene/benzoyl peroxide|daily topical application for 12 weeks
58312394|NCT01138735|DRUG|Topical Gel Vehicle|daily topical application for 12 weeks
58444050|NCT01584310|OTHER|No STAMP using|No intervention
58444051|NCT03343834|BIOLOGICAL|biological collection|"At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
58444052|NCT05137028|OTHER|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
58444053|NCT05484011|BIOLOGICAL|odetiglucan|Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
58444054|NCT05484011|BIOLOGICAL|CDX-1140|A fully human agonist anti-CD40 monoclonal antibody
58444055|NCT00149903|DRUG|Mycophenolate sodium (enteric coated)|
58444056|NCT02682732|PROCEDURE|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
58444057|NCT03553524|OTHER|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
58444058|NCT03553524|OTHER|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
58458490|NCT01026012|DRUG|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
58458491|NCT01859234|DRUG|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
58458492|NCT01507922|DRUG|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
58458493|NCT01507922|DRUG|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
58312395|NCT03282864|DEVICE|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
58312396|NCT01963611|DRUG|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
58312397|NCT01963611|DRUG|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
58312398|NCT01963611|DRUG|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
57956392|NCT02918864|BEHAVIORAL|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
57740564|NCT00862134|DRUG|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
57956393|NCT05291494|BEHAVIORAL|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
57956394|NCT05291494|BEHAVIORAL|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
57956395|NCT03468855|DRUG|ATI-50002 topical solution|Topical Solution administered twice daily
57956396|NCT03353870|OTHER|qualitative interview|individual qualitative interview
57956397|NCT02887391|OTHER|No intervention - observational study|No intervention - observational study
57956398|NCT03439865|DRUG|Ivacaftor|150 mg tablet PO BID x 14 days
57956399|NCT03439865|DRUG|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
57956400|NCT03807713|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
57956401|NCT03728309|DEVICE|JUVÉDERM VOLITE™ XC|Intradermal, needle in multiple microdepot injections across both cheeks.
58111680|NCT03813485|OTHER|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
58111681|NCT02439606|DEVICE|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
57956402|NCT00034372|DRUG|oregovomab|
57956403|NCT01180660|DRUG|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
58111682|NCT02439606|DEVICE|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
58111683|NCT04253925|OTHER|Kegel exercises|global postural correction exercises
58111684|NCT04932733|OTHER|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
58111685|NCT04932733|OTHER|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
58111686|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
58111687|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
57740565|NCT04180618|OTHER|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
58111688|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
58111689|NCT00000452|DRUG|naltrexone (Revia)|
58111690|NCT00000452|BEHAVIORAL|Compliance Enhancement Tech.|
58111691|NCT00000452|BEHAVIORAL|Cognitive Behavior Therapy|
58111692|NCT05600179|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
58111693|NCT02058810|DEVICE|Nasal high flow|
58111694|NCT02058810|DEVICE|Conventional nasal oxygen|
57740566|NCT05656950|PROCEDURE|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
57956404|NCT01180660|DRUG|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
57956405|NCT05399537|DRUG|Prismocitrate 18|Prismocitrate 18 solution will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. A BFR between 100 - 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight.
57956406|NCT05912465|OTHER|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
57956407|NCT02289183|PROCEDURE|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
57956408|NCT02289183|PROCEDURE|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
57956409|NCT05574205|OTHER|Resistance Exercise|Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
57956410|NCT05574205|DIETARY_SUPPLEMENT|Protein supplementation|Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
58111695|NCT02809534|DRUG|Anlotinib|Anlotinib p.o. qd
58111696|NCT04503252|OTHER|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
58312399|NCT01963611|DRUG|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
57956411|NCT04473456|PROCEDURE|Simultaneous EGD and colonoscopy|Patients are examined simultaneously by EGD and colonoscopy
57956412|NCT06193590|DEVICE|Carevix|Cervical stabilization device that uses vacuum
57956413|NCT06193590|DEVICE|Tenaculum|standard of care cervical stabilization device
58111697|NCT04503252|OTHER|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
58111698|NCT04503252|OTHER|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
58111699|NCT04503252|OTHER|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
58312400|NCT01963611|DRUG|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
58312401|NCT00775879|DRUG|Induction with Sevoflurane|
57740567|NCT01702337|OTHER|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
57740568|NCT04117035|PROCEDURE|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
57740569|NCT04117035|PROCEDURE|GKRS standard care|Standard GKRS treatment
57740570|NCT02573974|OTHER|Samples|Blood samples, muscle biopsy and sample of hair
57740571|NCT05346289|PROCEDURE|Elective surgery for intact AAA|Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
58111700|NCT04503252|OTHER|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
58312402|NCT01258374|DRUG|Raltegravir|Raltegravir, 400 mg bid
58111701|NCT02544633|DRUG|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
58111702|NCT01475656|DRUG|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
58111703|NCT01362114|DRUG|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
58111704|NCT01362114|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
58111705|NCT01182714|PROCEDURE|immediate removal of in-dwelling catheter|
58111706|NCT01182714|PROCEDURE|24 hours delayed removal of catheter|
58111707|NCT00686478|DRUG|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
58111708|NCT04296383|DRUG|Azithromycin plus Xiyanping injection|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
58111709|NCT04296383|DRUG|Azithromycin|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
58111710|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
58111711|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
58111712|NCT00140998|DRUG|17 beta estradiol|
58111713|NCT02685605|PROCEDURE|Standard surgery|
58111714|NCT02685605|RADIATION|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
58111715|NCT02685605|RADIATION|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
58111716|NCT02685605|DRUG|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
58111717|NCT04543045|OTHER|not an intervention|not an intervention
58111718|NCT05326152|BIOLOGICAL|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
58111719|NCT05326152|BIOLOGICAL|Intralesional saline|Intralesional saline
58111720|NCT06189261|OTHER|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
57740572|NCT06501781|BEHAVIORAL|Peer Activate-LAI|Peer Activate-LAI is a Peer Recovery Specialist-delivered behavioral activation and problem solving intervention, based on our team's formative work. The intervention focuses on problem-solving skills to improve adherence to ART and/or PrEP both at the individual level and environmental barriers to care (i.e., transportation, housing).
58111721|NCT00303992|BIOLOGICAL|trastuzumab|
58111722|NCT00303992|DRUG|irinotecan hydrochloride|
58111723|NCT01186783|DRUG|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
57740573|NCT06501781|OTHER|Standard of Care HIV treatment or prevention with LAI-PrEP/ART|Standard of care HIV treatment or prevention with LAI-PrEP/ART
58111724|NCT05727293|OTHER|noting|Non intervention
58111725|NCT02140073|DRUG|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
58111726|NCT02140073|DRUG|omeprazole|40mg in the morning
58111727|NCT01422733|DRUG|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
58111728|NCT01422733|DRUG|dexamethasone|1 mg PO twice
58111729|NCT01422733|DRUG|Cosyntropin|250 micrograms IV twice
58111730|NCT01422733|DRUG|rhCG|25 mcg IV twice
58111731|NCT00569283|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58111732|NCT02162329|BEHAVIORAL|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
58111733|NCT02162329|PROCEDURE|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
58111734|NCT02162329|PROCEDURE|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
58111735|NCT02162329|BEHAVIORAL|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
58111736|NCT05809583|DRUG|Ozanimod|Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
58111737|NCT01672372|DIETARY_SUPPLEMENT|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
58312403|NCT01258374|DRUG|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
58111738|NCT01672372|DIETARY_SUPPLEMENT|Placebo Max Stress B|
58111739|NCT00384891|DEVICE|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
58111740|NCT00384891|DRUG|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
58111741|NCT05903599|OTHER|Anodal transcranial direct current stimulation|The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.
58111742|NCT05903599|OTHER|Sham Stimulation|"postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises."
58111743|NCT05946642|DRUG|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
58111744|NCT05946642|DRUG|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
58111745|NCT05474612|OTHER|kinesiology taping with conventional therapy|Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
58111746|NCT05474612|OTHER|Instrument assisted soft tissue mobilization with conventional therapy|IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
58111747|NCT01538706|OTHER|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
58111748|NCT00072033|DRUG|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
58444059|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
58444060|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
58444061|NCT04977401|PROCEDURE|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
57740574|NCT02212028|DRUG|prasugrel|the effects of whole tablets versus crushed tablets will be compared
58312404|NCT05186480|DIETARY_SUPPLEMENT|Neo Mune|"Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)"
58312405|NCT05968235|OTHER|Collecting blood samples|Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
57740575|NCT00003298|DRUG|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
57740576|NCT00003298|DRUG|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
57740577|NCT00003298|DRUG|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
58111749|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
58111750|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
58111751|NCT02832297|OTHER|Vectra DA|
58111752|NCT02832297|OTHER|Usual Care|
58111753|NCT01494220|DEVICE|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
58111754|NCT00912470|PROCEDURE|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
58312406|NCT00995878|PROCEDURE|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
58312407|NCT00995878|PROCEDURE|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
58312408|NCT01117870|OTHER|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
58312409|NCT01117870|OTHER|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
58312410|NCT04587713|DRUG|TD-1473 [Tablet A]|TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
57740578|NCT00003298|DRUG|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
58312411|NCT04587713|DRUG|TD-1473 [Tablet B]|TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
57740579|NCT00003298|PROCEDURE|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
57740580|NCT00003298|RADIATION|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
57740581|NCT06732908|DIETARY_SUPPLEMENT|LipoMicel Berberine|Berberine powder in a LipoMicel matrix encapsulated in soft gel.
57740582|NCT06732908|OTHER|Placebo|microcrystalline cellulose
58111755|NCT01207063|OTHER|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
58111756|NCT04036578|DEVICE|A 12-week PFMT bio-assisted surface electromyographic program|
58111757|NCT03493698|DRUG|Midazolam|Midazolam
58111758|NCT03493698|DRUG|Inarigivir|Inarigivir
58312412|NCT03678740|OTHER|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
58312413|NCT04264741|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
57740583|NCT05231798|DRUG|[18F]-FEOBV Radiotracer|Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
57740584|NCT00145093|DRUG|Baker's yeast (Bio Chromium)|
57740585|NCT05885672|BEHAVIORAL|Online psychoeducational lifestyle intervention|A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
58312414|NCT04264741|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
58312415|NCT06284473|DRUG|Ketamine|Ketamine is an N-methyl-D aspartate receptor agonist
58312416|NCT06284473|OTHER|Saline|Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
58444062|NCT04977401|DEVICE|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
58312417|NCT01789268|DEVICE|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
58444063|NCT04977401|DEVICE|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
58444064|NCT01387841|BEHAVIORAL|yoga|Postures,relaxation techniques
58444065|NCT01387841|BEHAVIORAL|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
58444066|NCT04359160|DEVICE|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
58444067|NCT04359160|OTHER|Questionnaire|Paper questionnaire follow-up, with questions and score
58444068|NCT02430857|OTHER|OMT|Manuel osteopathic treatment of the spine
58444069|NCT03237715|OTHER|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
58444070|NCT05900544|OTHER|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
58444071|NCT02848534|BIOLOGICAL|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
58444072|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium and saffron extract|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
58444073|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
58444074|NCT06409143|DEVICE|HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
58444075|NCT06409143|DEVICE|Sham HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
57956414|NCT05207007|PROCEDURE|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
58312418|NCT00623675|DIETARY_SUPPLEMENT|Mineralox C|Mineralox C 2 capsules three times a day.
57956415|NCT05409261|BIOLOGICAL|Ad26.COV2.S|Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
58312419|NCT00838851|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
58312420|NCT04194632|PROCEDURE|Temporary right ventricular pacing|As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
58312421|NCT05861908|OTHER|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
58312422|NCT05861908|OTHER|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
58312423|NCT05861908|OTHER|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
57740586|NCT06426550|PROCEDURE|Periodontal treatment|"An experienced periodontist will access clinical periodontal parameters, including plaque index, bleeding on probing, pocket probing depth, gingival recession, clinical attachment level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed."
58312424|NCT05861908|OTHER|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
58312425|NCT02130609|DEVICE|Skintel|
57740587|NCT01577979|BEHAVIORAL|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
57740588|NCT01577979|BEHAVIORAL|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
58312426|NCT02807922|DRUG|Zopiclone|
58312427|NCT02807922|DRUG|Placebo|
58312428|NCT00808340|DEVICE|balafilcon A|multifocal contact lens
58312429|NCT00808340|DEVICE|senofilcon A production|multifocal contact lens
58312430|NCT00808340|DEVICE|senofilcon A test|multifocal contact lens
58444076|NCT06409143|OTHER|UE rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
57956416|NCT02436876|DRUG|MBN-101|MBN-101 is a locally administered, anti-infective drug product
58444077|NCT06409143|DEVICE|HD-tES (Bilateral)|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
58444078|NCT01036321|DRUG|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
58444079|NCT01036321|DRUG|Methyl cellulose blend|Placebo - Take 2 capsules daily
58444080|NCT03629522|DRUG|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
58444081|NCT04648683|BEHAVIORAL|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
58444082|NCT04648683|BEHAVIORAL|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
58444083|NCT00818051|RADIATION|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
58444084|NCT04131946|OTHER|Community-Based (Intervention Arm)|Community dispensed FIT
58444085|NCT02133781|BIOLOGICAL|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
58444086|NCT02133781|BIOLOGICAL|FluMist® 2009-2010 Formula|This vaccine is given intranasally
58444087|NCT01011140|BEHAVIORAL|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
58444088|NCT03859271|BEHAVIORAL|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
58444089|NCT03859271|BEHAVIORAL|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
58444090|NCT00007358|DRUG|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
58444091|NCT05330832|DIAGNOSTIC_TEST|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
58444092|NCT06727344|OTHER|Blood Flow Restriction|Exercise with restriction of blood flow supply
58444093|NCT06727344|OTHER|Brace|Knee brace to restrict range of motion
58444094|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
58444095|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
58444096|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
58444097|NCT01112787|DRUG|Tazarotene Foam|Tazarotene Foam
58444098|NCT01112787|DRUG|Vehicle Foam|Vehicle Foam
58444099|NCT01112787|DRUG|Sodium Laural Sulfate|Sodium Laural Sulfate
57956417|NCT02436876|OTHER|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
57956418|NCT04315519|OTHER|Exercise|Aerobic Exercise
57956419|NCT00820898|DRUG|Gemcitabine Hydrochloride|Given IV
58444100|NCT01112787|DRUG|Distilled Water|Distilled Water
58444101|NCT03801174|BEHAVIORAL|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
58444102|NCT03801174|BEHAVIORAL|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
58444103|NCT04137731|DEVICE|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
57956420|NCT02065752|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
58444104|NCT01631994|DRUG|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
58444105|NCT04057807|DRUG|LPS|LPS (0.4 ng/kg)
58444106|NCT06295861|OTHER|no different intervention between the two cohort.|no different intervention between the two cohort.
58444107|NCT02089074|BEHAVIORAL|Drug use counselling|
58444108|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
58444109|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
58111759|NCT04525690|BEHAVIORAL|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
58111760|NCT01860482|DRUG|Newrabell® Tablet 10mg|
58444110|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
58444111|NCT04674722|DRUG|Injection of 99mTc-NM-02|A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
58444112|NCT04674722|DRUG|Injection of 188Re-NM-02|A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
58444113|NCT00908804|PROCEDURE|open appendectomy|
58444114|NCT00908804|PROCEDURE|laparoscopic appendectomy|
58444115|NCT00346788|PROCEDURE|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
58444116|NCT06360848|OTHER|surgery|SURGICAL TREATMENT OF PSEUDARTHROSIS OF THE HUMERUS
58444117|NCT00330005|BEHAVIORAL|Group Psychotherapy|
58444118|NCT02125084|DRUG|Everolimus|
58444119|NCT02125084|DRUG|Enzalutamide|
58111761|NCT00548990|BEHAVIORAL|cardiovascular exercise training|
58111762|NCT00548990|BEHAVIORAL|flexibility/balance control|
58111763|NCT05479968|DEVICE|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
58111764|NCT01724359|DRUG|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
58111765|NCT02436135|DRUG|Idelalisib|Idelalisib tablets administered orally for 24 weeks
58111766|NCT02436135|DRUG|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
58111767|NCT00686803|DRUG|PL3994|Study drug
58111768|NCT00686803|DRUG|Placebo|Placebo
58312431|NCT03356717|BEHAVIORAL|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
58312432|NCT03356717|BEHAVIORAL|educational intervention|without observer tool
58312433|NCT01794468|OTHER|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
58312434|NCT02939352|DEVICE|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
58312435|NCT02939352|DEVICE|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
58312436|NCT04009837|BEHAVIORAL|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
58312437|NCT04009837|BEHAVIORAL|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
58312438|NCT02156258|DEVICE|FFDM Mammography|Standard mammography image collection
58312439|NCT02156258|DEVICE|DBT Mammography|Collection of breast images using DBT mammography
58312440|NCT02926014|DEVICE|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
58444120|NCT03009474|DRUG|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
58444121|NCT03009474|DRUG|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
58444122|NCT01292187|DRUG|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
58444123|NCT01292187|DRUG|Oral placebo at dinnertime|Oral placebo at dinnertime.
58444124|NCT01292187|DRUG|Oral calcitonin at bedtime|Oral calcitonin at bedtime
58444125|NCT01292187|DRUG|Oral placebo at bedtime|Oral placebo at bedtime
58111769|NCT04656522|BEHAVIORAL|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
58111770|NCT04116346|OTHER|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
58111771|NCT00747747|BIOLOGICAL|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
58111772|NCT00747747|DEVICE|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
58111773|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine Needle aspiration
58111774|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
58444126|NCT04869865|DIETARY_SUPPLEMENT|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
58444127|NCT06531070|DIETARY_SUPPLEMENT|Nitrate|"A four-day supplementation period, separated by one week including a 3-day washout period between conditions will be applied before conducting strength and endurance assessments~Days 1 to 3 the randomly assigned supplement (N, NC, or PLA) will be ingested 2 hr before a standard low-volume training session including 3 sets of 8 to 10 reps of squat and deadlift using a very light load (e.g., own body mass) and flexibility exercises following by 5 min of running at self-paced intensity rated as light (12) with the rating of perceived exertion Borg Scale.~Day 4: the assigned supplement will be ingested 2.5 h before the assessments~Assessment of strength and endurance will be conducted"
58444128|NCT04200118|OTHER|Observational|non intervention
58444129|NCT00966615|OTHER|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
58444130|NCT00966615|OTHER|glucose-based dialysis solution|2-L exchange; three times a day
58444131|NCT05483075|BEHAVIORAL|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
58444132|NCT04664374|OTHER|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
58444133|NCT00651716|OTHER|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
58444134|NCT00651716|OTHER|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
57740589|NCT01903473|DRUG|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
58111775|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
58111776|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
58111777|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
58111778|NCT03716102|DEVICE|PCI with implantation with DES|PCI with implantation with DES
58111779|NCT03628352|DRUG|Tricaprilin|Tricaprilin with flavoring agents added
57740590|NCT01903473|OTHER|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
58444135|NCT00651716|OTHER|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
57740591|NCT03883633|BEHAVIORAL|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
57740592|NCT04847869|DEVICE|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
57740593|NCT05545553|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
57740594|NCT05545553|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
57740595|NCT01318226|DRUG|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
57740596|NCT01318226|DRUG|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
57740597|NCT00605280|DRUG|Standard of Care|Clinicians decision to use optional laser therapy.
58111780|NCT04101136|DRUG|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
58111781|NCT02513459|DRUG|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
58111782|NCT02513459|DRUG|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
58111783|NCT01785875|DRUG|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
58444136|NCT02135510|DRUG|metoclopramide|
58444137|NCT02135510|DRUG|dexamethason|
58444138|NCT02135510|DRUG|palonosetron|
58444139|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
58444140|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
57740598|NCT00605280|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
57740599|NCT05712590|OTHER|dietary habit|As it is observational study, women that follow three different dietary patterns will be inlcuded .
57740600|NCT00546585|BIOLOGICAL|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
57740601|NCT00546585|DRUG|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
58444141|NCT01132313|DRUG|BI 201335|40 weeks, QD
58444142|NCT01132313|DRUG|BI 207127|4 weeks, low dose TID
58444143|NCT01132313|DRUG|BI 201335|24 weeks, QD
58444144|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
58444145|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
58444146|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
58444147|NCT01132313|DRUG|BI 207127|40 weeks, high dose, TID
58444148|NCT01132313|DRUG|BI 207127|24 weeks, very high dose, BID
58444149|NCT01132313|DRUG|BI 207127|16 weeks, standard dose, BID
58444150|NCT01132313|DRUG|BI 201335|24 weeks, QD
58444151|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
58444152|NCT01132313|DRUG|Ribavirin|40 weeks, according to label
58444153|NCT01132313|DRUG|BI 207127|16 weeks, high dose, TID
58312441|NCT02926014|OTHER|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
58312442|NCT02926014|OTHER|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
58444154|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
58444155|NCT01132313|DRUG|BI 201335|28 weeks, QD
57956421|NCT02065752|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
58444156|NCT01132313|DRUG|BI 201335|16 weeks, QD
58444157|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
58444158|NCT01132313|DRUG|BI 201335|24 weeks, QD
57740602|NCT02829853|GENETIC|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
57740603|NCT03283774|OTHER|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
57740604|NCT04591522|OTHER|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
58312443|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 1
58312444|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 180
58312445|NCT02655874|BIOLOGICAL|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
58312446|NCT03315260|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
58312447|NCT03271697|DRUG|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
58312448|NCT03271697|DRUG|Placebo|as a comparator comparing with AM group
58312449|NCT03423771|DRUG|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
58312450|NCT01022606|OTHER|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
58312451|NCT05201937|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
58444159|NCT01132313|DRUG|BI 201335|28 weeks, QD
58444160|NCT01132313|DRUG|BI 207127|24 weeks, standard dose, BID
58312452|NCT02849028|BEHAVIORAL|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
58444161|NCT01132313|DRUG|BI 201335|24 weeks, QD
58444162|NCT01132313|DRUG|BI 201335|16 weeks, QD
57740605|NCT00959933|DRUG|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
57740606|NCT00959933|DRUG|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
57740607|NCT03986112|BIOLOGICAL|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
57740608|NCT04091074|DRUG|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
57740609|NCT04091074|DRUG|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
57740610|NCT04091074|PROCEDURE|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
57740611|NCT02019160|DRUG|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
57740612|NCT02019160|DRUG|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
57740613|NCT05920629|BEHAVIORAL|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 12 months. We will perform a first echocardiography at randomization and a second at 12 months' follow-up.
58312453|NCT04694092|DRUG|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
58444163|NCT01132313|DRUG|BI 207127|16 weeks, high dose, BID
58444164|NCT01132313|DRUG|BI 201335|24 weeks, QD
58444165|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
57740614|NCT04368429|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
57740615|NCT04368429|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
58312454|NCT04694092|DRUG|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
58312455|NCT05964062|DEVICE|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
58312456|NCT05964062|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
58444166|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
57740616|NCT05028218|DRUG|TQB3824 tablets|TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
58444167|NCT01132313|DRUG|BI 207217|28 weeks, high dose BID
58444168|NCT01132313|DRUG|BI 201335|16 weeks, QD
57740617|NCT04184791|DEVICE|Deep Brain Stimulation|Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
57740618|NCT00001768|DRUG|Intravenous immunoglobulin|
57740619|NCT00455065|BEHAVIORAL|Whole Grain Foods|
57740620|NCT05653999|DEVICE|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
57740621|NCT04427202|BEHAVIORAL|Referral to harm reduction services|Participants are referred to harm reduction services
58444169|NCT01132313|DRUG|BI 207127|24 weeks, high dose, TID
58444170|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
58444171|NCT01132313|DRUG|BI 207127|4 weeks, high dose, TID
58444172|NCT01132313|DRUG|BI 201335|28 weeks, QD
58444173|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
58444174|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
58444175|NCT04642391|DRUG|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
58444176|NCT04175028|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
58444177|NCT05799131|DEVICE|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
58312457|NCT01324297|OTHER|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
58312458|NCT02106507|DRUG|apalutamide|apalutamide, 240 mg/day, oral
58312459|NCT02106507|DRUG|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
58312460|NCT00570947|OTHER|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
58444178|NCT04206488|DRUG|JNJ-70033093|Participants will receive JNJ-70033093 orally.
58444179|NCT04206488|DRUG|Digoxin|Participants will receive digoxin orally.
58444180|NCT01375023|RADIATION|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
58312461|NCT06018090|OTHER|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
58312462|NCT04410393|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
58312463|NCT00325416|DRUG|melphalan|(Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
58444181|NCT01375023|BIOLOGICAL|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
58444182|NCT01442714|DRUG|Azacitidine|Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
58312464|NCT00325416|DRUG|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)"
58444183|NCT01442714|DRUG|Lenalidomide|Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
58444184|NCT00930553|BIOLOGICAL|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
58444185|NCT06064071|DEVICE|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
58111784|NCT05510713|DEVICE|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
58111785|NCT04988945|PROCEDURE|TACE|Procedure of TACE will be standardized.
58111786|NCT04988945|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
58111787|NCT04988945|DRUG|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
58111788|NCT04988945|DRUG|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
58111789|NCT03455179|OTHER|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
58111790|NCT03455179|OTHER|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
57740622|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
57740623|NCT05614349|DRUG|Other|Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
58111791|NCT03455179|OTHER|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
58444186|NCT06064071|PROCEDURE|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
58444187|NCT06064071|DEVICE|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
58458494|NCT02854085|BEHAVIORAL|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
57740624|NCT05614349|OTHER|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
58111792|NCT03944785|DRUG|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
58111793|NCT02307409|OTHER|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
58111794|NCT02052128|DRUG|onapristone|
58111795|NCT03280537|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
57740625|NCT01744522|PROCEDURE|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
57740626|NCT06265597|OTHER|Healthy Nutrition and Yoga Program|"* Healthy Nutrition Program~  * Providing individual counseling to children every 2 weeks from the start of the program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~ * In the 2nd, 4th, 6th, 8th and 10th weeks from the start of the program, children are asked to keep nutrition diaries for 2 weekdays and 1 weekend, and planning is made according to achieving basic healthy nutrition behavior goals.~ * Sending reminder messages regarding the basic healthy eating behavior target via Whatsapp every week in order to maintain interaction and ensure motivation.~* Yoga Program Children's yoga is applied to each group twice a week for 12 weeks.~* The time points at which outcome measures will be evaluated and data reported are as follows:~  * From the start of the program, on the 1st day,~ * From the start of the program, in the 2nd, 4th, 6th, 8th, 10th, and 12th weeks~ * 3 months after completion of study"
58111796|NCT03280537|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
58111797|NCT01179633|DEVICE|OPLON active patch|
58111798|NCT01179633|DEVICE|Sham patch|
58111799|NCT00002196|DRUG|CI-1012|
58312465|NCT00325416|PROCEDURE|Autologous Stem Cell Rescue|Day 0
58111800|NCT04549259|BEHAVIORAL|Group-Based Social Support|This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
58111801|NCT04549259|BEHAVIORAL|HIV Stigma Reduction|"This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011)."
58111802|NCT04549259|BEHAVIORAL|Strengths-Based Case Management (SBCM)|The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
58111803|NCT04549259|BEHAVIORAL|Personalized Technology Detailing|Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
58111804|NCT05664191|DRUG|Levosimendan|Infusion at 0.1 µg/kg/min at day 1 and day 8
58111805|NCT05664191|OTHER|Placebo|Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
58111806|NCT04648293|DEVICE|Starling|Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
58111807|NCT03107949|DEVICE|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
58111808|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
58111809|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
58111810|NCT03729752|DRUG|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
58111811|NCT02571725|DRUG|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
58111812|NCT02571725|DRUG|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
58111813|NCT03233282|OTHER|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
58312466|NCT04585997|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
57740627|NCT01792063|DRUG|Sevoflurane|
57740628|NCT01792063|DRUG|Sevoflurane|
58111814|NCT03233282|OTHER|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
58111815|NCT03233282|OTHER|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
58111816|NCT03233282|OTHER|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
58111817|NCT03233282|OTHER|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
58444188|NCT05936073|DIAGNOSTIC_TEST|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
58444189|NCT02033746|DEVICE|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
57740629|NCT03662204|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
58111818|NCT03233282|OTHER|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111819|NCT03233282|OTHER|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111820|NCT03233282|OTHER|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111821|NCT03233282|OTHER|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111822|NCT03233282|OTHER|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111823|NCT03233282|OTHER|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
58111824|NCT02926378|PROCEDURE|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
58111825|NCT01671384|DRUG|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
58111826|NCT01671384|DRUG|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
58111827|NCT04513340|DRUG|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
58312467|NCT04585997|DRUG|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
58444190|NCT01247961|DRUG|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
58444191|NCT01247961|OTHER|Placebo|Normal saline
57740630|NCT05071157|BEHAVIORAL|echocardiography|"* speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)"
57740631|NCT02369094|OTHER|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
57740632|NCT03683485|PROCEDURE|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
58111828|NCT02687477|PROCEDURE|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
58111829|NCT02687477|PROCEDURE|Sham procedure|patient in the sham group will receive sham procedure
58111830|NCT06530381|OTHER|Pilates Exercises With Face-to-Face|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed face to face.
57740633|NCT03683485|PROCEDURE|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
57740634|NCT05865106|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
57740635|NCT05865106|OTHER|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
57740636|NCT00114868|DRUG|Vitamin A|
57740637|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
57740638|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
57740639|NCT01603264|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
57740640|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
57740641|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
57740642|NCT06359938|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
58111831|NCT06530381|OTHER|Pilates Exercises With Telerehabilitation|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed as telerehabilitation.
58312468|NCT03076463|DIETARY_SUPPLEMENT|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
58444192|NCT01563263|BIOLOGICAL|IC43|100 mcg
57740643|NCT06359938|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
57740644|NCT05441072|DEVICE|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
57740645|NCT00863174|DRUG|SPARC147709|SPARC147709 injection
57740646|NCT00863174|DRUG|Reference147709|Reference147709 injection
57740647|NCT00369330|DEVICE|external electrical cardioversion|
57740648|NCT04414267|BIOLOGICAL|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
58111832|NCT02042690|PROCEDURE|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
58111833|NCT02042690|DRUG|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
58111834|NCT02595333|DRUG|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
58111835|NCT02595333|DRUG|Group S1|sufentanil was administered for analgesia in primary cesarean section
57740649|NCT04414267|BIOLOGICAL|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
57740650|NCT04150679|PROCEDURE|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
57740651|NCT04150679|PROCEDURE|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
57740652|NCT05154682|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
57740653|NCT05154682|DRUG|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
57740654|NCT05154682|DRUG|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
57740655|NCT05787639|DRUG|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
57740656|NCT02947126|DRUG|Hypertonic Saline|Inhaled 7% Hypertonic saline
58111836|NCT02595333|DRUG|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
58111837|NCT02595333|DRUG|Group S2|sufentanil was administered for analgesia in repeated cesarean section
58111838|NCT01531348|OTHER|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
57740657|NCT02947126|DRUG|Isotonic Saline|Inhaled 0.9% Isotonic saline
57740658|NCT02947126|DRUG|Indium-DTPA|Inhaled Indium 111 DTPA
57740659|NCT02947126|DRUG|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
57740660|NCT03221387|DEVICE|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
57740661|NCT02375620|BIOLOGICAL|PEG-somatropin|
57740662|NCT03880305|DIAGNOSTIC_TEST|complete blood count|complete blood count
57740663|NCT02293044|DEVICE|Crest® Sensi-Stop™ Strips|
57740664|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
58111839|NCT04563078|DEVICE|Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
58111840|NCT04563078|PROCEDURE|Sham Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
57740665|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
57740666|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
57740667|NCT02339831|DEVICE|CAMOPED|Camoped given after surgery
57740668|NCT02339831|DEVICE|CPM passive motion device|passive motion device given after surgery
58111841|NCT02521948|DEVICE|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
58111842|NCT03171714|DEVICE|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
58111843|NCT03171714|DEVICE|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
58111844|NCT04009967|DRUG|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
58111845|NCT01169649|DRUG|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
58111846|NCT05938153|OTHER|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
58111847|NCT04805281|OTHER|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
58111848|NCT04805281|OTHER|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
58111849|NCT02514187|DRUG|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
58111850|NCT02514187|DRUG|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
58111851|NCT01429402|DRUG|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
58312469|NCT01962675|DEVICE|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
58444193|NCT01563263|DRUG|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
57740669|NCT03096405|DIAGNOSTIC_TEST|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
57740670|NCT02046330|DEVICE|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
57740671|NCT01954979|DRUG|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
57740672|NCT01072461|BEHAVIORAL|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
57740673|NCT01072461|BEHAVIORAL|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
57740674|NCT01072461|BEHAVIORAL|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
58312470|NCT01962675|BEHAVIORAL|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
58312471|NCT03051711|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
58458495|NCT02854085|BEHAVIORAL|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
58458496|NCT01283555|DRUG|Tenofovir|Delivered using prefilled and user-filled applicator
57740675|NCT02901015|BEHAVIORAL|Assessment battery A|"Social cognition tests version A are administered to the patients"
58111852|NCT01429402|DRUG|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
58111853|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
58111854|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
58111855|NCT04236310|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
58111856|NCT04236310|DRUG|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
58111857|NCT04236310|DRUG|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
58111858|NCT04236310|DRUG|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
58458497|NCT05563610|DRUG|Amoxicillin 500mg|Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
58111859|NCT01365845|RADIATION|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
58111860|NCT01365845|RADIATION|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
57740676|NCT02901015|BEHAVIORAL|Assessment battery B|"Social cognition tests version B are administered to the patients"
58111861|NCT01783483|DEVICE|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
58111862|NCT01783483|DEVICE|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
58111863|NCT01753479|OTHER|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
58111864|NCT04063566|PROCEDURE|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
58111865|NCT04063566|PROCEDURE|Prostate-specific antigen (PSA) test|Blood test for PSA levels
58111866|NCT01189240|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
58111867|NCT01189240|BIOLOGICAL|bevacizumab|Given IV
58111868|NCT01189240|OTHER|laboratory biomarker analysis|Correlative studies
58111869|NCT01189240|OTHER|pharmacological study|Correlative studies
58111870|NCT06417957|OTHER|cultural competence training|The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
58111871|NCT05826106|PROCEDURE|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
58111872|NCT03601247|DEVICE|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
58111873|NCT02509871|OTHER|Body composition measurement|DXA, impedance
58111874|NCT06527495|DRUG|Sorafenib|Sorafenib Tablets (200 -400 mg) twice daily
58458498|NCT02251626|DIETARY_SUPPLEMENT|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
57740677|NCT05356858|DRUG|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
57740678|NCT05607095|BIOLOGICAL|Lifileucel (LN-144/LN-145)|Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
57740679|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
58458499|NCT02251626|DIETARY_SUPPLEMENT|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
58458500|NCT02925897|BEHAVIORAL|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
58458501|NCT00265564|BEHAVIORAL|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
58458502|NCT00265564|BEHAVIORAL|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
57740680|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
57740681|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
57956422|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
57956423|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
57956424|NCT04210609|DEVICE|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
57956425|NCT02764827|BIOLOGICAL|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
57956426|NCT05733871|DIETARY_SUPPLEMENT|meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
57956427|NCT05733871|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
57956428|NCT00387114|DRUG|Vitamin C|
57956429|NCT05301946|OTHER|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
58458503|NCT03211468|BEHAVIORAL|Clinical intervention program to prevent eating disorders|See previous
57956430|NCT00425386|DRUG|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily"
57956431|NCT00425386|DRUG|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
57956432|NCT00425386|PROCEDURE|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
57956433|NCT00971945|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
57956434|NCT05360056|DEVICE|DexCom G6|Wearable continuous glucose monitor
57956435|NCT00014183|DRUG|gefitinib|
57956436|NCT01876407|DEVICE|Low intensity laser for oral mucositis|
58111875|NCT01396759|PROCEDURE|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
57740682|NCT05355974|DRUG|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
57740683|NCT05355974|DRUG|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
58111876|NCT01396759|PROCEDURE|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
57740684|NCT05355974|DRUG|normal saline|500mL infusion run at 999mL/hr
57740685|NCT05355974|DRUG|Plasma-lyte|500mL infusion run at 999mL/hr
57740686|NCT05101239|DEVICE|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
57740687|NCT03516448|DRUG|Gan Fu Le Tablets|6 Tablets，tid,po
57740688|NCT03516448|DRUG|Tyroserleutide for injection|6mg/d, 5days,ivgtt
57740689|NCT03516448|DRUG|Placebo|0mg/d, 5days,ivgtt
57740690|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
57740691|NCT04298593|DEVICE|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
57740692|NCT02696655|BEHAVIORAL|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
57956437|NCT01876407|DEVICE|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
57956438|NCT03922698|OTHER|No interventions|No interventions - observational study
57956439|NCT00661531|DRUG|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
57956440|NCT00661531|DRUG|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
57956441|NCT01537757|DRUG|MK-8931|Single dose, administered as oral capsules
57956442|NCT02695628|DRUG|18F-Fluoromisonidazole|Undergo \[18F\] FMISO PET/CT
57956443|NCT02695628|PROCEDURE|Arterial Embolization|Undergo transcatheter arterial embolization
57956444|NCT02695628|DIAGNOSTIC_TEST|Computed Tomography|Undergo \[18F\] FMISO PET/CT
57956445|NCT02695628|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo \[18F\] FMISO PET/CT
58458504|NCT06237582|PROCEDURE|epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
58458505|NCT01031719|BIOLOGICAL|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
58458506|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
57956446|NCT00875745|DRUG|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
57956447|NCT04069065|DRUG|Conversion to Once-daily Tacrolimus|"* Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml."
57740693|NCT04294966|DRUG|Dextrose|Administering dextrose to healthy volunteers for our placebo group
57740694|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
57740695|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
58111877|NCT01396759|PROCEDURE|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
58111878|NCT00293969|DRUG|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
58111879|NCT05987657|DIAGNOSTIC_TEST|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
58111880|NCT01567371|DEVICE|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
58111881|NCT04368052|DIAGNOSTIC_TEST|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
58111882|NCT04497324|BIOLOGICAL|Convalescent plasma|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
58111883|NCT01203774|DRUG|Glargine insulin|20-180 units per day
58111884|NCT04262375|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
58111885|NCT04262375|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
58111886|NCT06481553|DRUG|first line treatment|Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
58111887|NCT03952156|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
58111888|NCT03952156|GENETIC|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
58111889|NCT00287287|DRUG|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
58111890|NCT03348982|BEHAVIORAL|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
58111891|NCT06530069|OTHER|exposures|exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
57740696|NCT02852551|DRUG|PAT-1251|
57740697|NCT02852551|DRUG|Placebo|
57740698|NCT02063126|DIETARY_SUPPLEMENT|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
57740699|NCT02063126|DIETARY_SUPPLEMENT|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
57740700|NCT01830127|DRUG|Ribavirin|24 Weeks
57740701|NCT01830127|DRUG|BI 207127 high dose|24 Weeks
57740702|NCT01830127|DRUG|Faldaprevir|24 Weeks
57740703|NCT01830127|DRUG|Ribavirin|24 Weeks
57740704|NCT01830127|DRUG|BI 207127 low dose|24 Weeks
57740705|NCT01830127|DRUG|Faldaprevir|24 Weeks
58111892|NCT05483439|DRUG|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
58111893|NCT05483439|DRUG|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
58111894|NCT05483439|DRUG|traditional herbal medicine|traditional herbal medicine
58458507|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
57740706|NCT00003954|DRUG|melphalan|Given IV
57740707|NCT00003954|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
58111895|NCT06089135|DEVICE|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
58111896|NCT06089135|DEVICE|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
58111897|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
58111898|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
58458508|NCT06066216|DRUG|Cadonilimab|Injectable solution
57740708|NCT00003954|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
57740709|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
57740710|NCT00003954|RADIATION|total-body irradiation|Undergo TBI
58458509|NCT06066216|DRUG|Carboplatin|Injectable solution
58458510|NCT06066216|DRUG|Cisplatin|Injectable solution
57740711|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo donor PBSCT
57740712|NCT00003954|DRUG|cyclosporine|Given IV and PO
57740713|NCT00003954|DRUG|mycophenolate mofetil|Given PO
57740714|NCT00003954|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
57740715|NCT00598429|DRUG|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
57740716|NCT06091865|DRUG|Odronextamab|Odronextamab will be administered by intravenous (IV) infusion
57740717|NCT06091865|DRUG|Rituximab|Rituximab will be administered IV, or subcutaneously (SC)
57740718|NCT06091865|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV as part of chemotherapy
57740719|NCT06091865|DRUG|Doxorubicin|Doxorubicin will be administered IV as part of chemotherapy
58111899|NCT02277314|PROCEDURE|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
58111900|NCT03453359|DEVICE|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
58111901|NCT03453359|DEVICE|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
58111902|NCT00994032|PROCEDURE|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
58111903|NCT00994032|OTHER|Medical treatment|standard antalgic medical treatment
58111904|NCT02659267|BEHAVIORAL|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
58111905|NCT03310203|DIAGNOSTIC_TEST|Iron|Labelled iron
58111906|NCT01001897|DRUG|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
58111907|NCT01001897|DRUG|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
58111908|NCT02099968|BEHAVIORAL|Comprehensive Lifestyle Modification|"* Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
58111909|NCT02099968|BEHAVIORAL|Standard Lifestyle Modification / modified DASH|"* Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation"
57740720|NCT06091865|DRUG|Vincristine|Vincristine will be administered IV as part of chemotherapy
57740721|NCT06091865|DRUG|Prednisone/Prednisolone|Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
57740722|NCT05774366|DRUG|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
57740723|NCT05774366|DRUG|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
57740724|NCT04223518|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of \>90% protein which consists primarily of immunoglobulins (\>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
58111910|NCT04621890|BEHAVIORAL|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
58111911|NCT03001609|DRUG|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
58111912|NCT03720795|BEHAVIORAL|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
58111913|NCT01847183|BEHAVIORAL|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
58111914|NCT02025309|DEVICE|Neuromuscular monitorisation|
58111915|NCT03646253|OTHER|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
58312472|NCT05828342|PROCEDURE|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
58312473|NCT05441189|PROCEDURE|Resection|radical R0 resection of pancreatic adenocarcinoma
57740725|NCT04223518|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed Collagen
58458511|NCT06066216|DRUG|Paclitaxel|Injectable solutionS
57740726|NCT06058650|PROCEDURE|Biopsy of Breast|Undergo biopsy of breast
57740727|NCT06058650|OTHER|Medical Device Usage and Evaluation|Utilization of the Stereo Navigator accessory
57740728|NCT06058650|RADIATION|Scintimammography|Undergo MBI
57740729|NCT06058650|OTHER|Technetium Tc-99m Sestamibi|Given IV
57740730|NCT06088264|DRUG|BMS-986322|Specified dose on specified days.
57740731|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
57740732|NCT06624137|DRUG|Placebo|Matched Placebo
57740733|NCT03784339|OTHER|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
58111916|NCT02608359|DRUG|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
58111917|NCT00376142|BEHAVIORAL|Psychological theory-based behaviour change interventions|
58111918|NCT06482710|DEVICE|Pinwheel|The children in the intervention group were given breathing exercises with pinwheels.
58111919|NCT01753531|DEVICE|Flu Symptoms|
58111920|NCT00955032|DEVICE|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
58111921|NCT00955032|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
58111922|NCT00077428|DRUG|bortezomib|Given IV
58111923|NCT00077428|DRUG|doxorubicin hydrochloride|Given IV
58111924|NCT00077428|OTHER|laboratory biomarker analysis|Correlative studies
58111925|NCT04038151|DEVICE|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
58444194|NCT01761448|DEVICE|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
58444195|NCT01761448|DEVICE|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
58444196|NCT01761448|DEVICE|Control group training without Guided Exercise system at home|
58444197|NCT03602365|DEVICE|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
58444198|NCT05257291|DRUG|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
58444199|NCT06154707|DRUG|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
58444200|NCT06154707|OTHER|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
58444201|NCT03053570|DEVICE|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
58444202|NCT03053570|DEVICE|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
57740734|NCT03784339|OTHER|Physiotherapy|Standard physiotherapy care
57740735|NCT04575636|DIAGNOSTIC_TEST|Magnetic Resonance Lymphography|Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system
57740736|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
57956448|NCT03183895|DEVICE|Left ventricular restoration|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
58312474|NCT03069989|DRUG|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
58312475|NCT03069989|DRUG|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
58444203|NCT00119470|PROCEDURE|EUS-FNA|
58444204|NCT00119470|PROCEDURE|Conventional Surgical Technique|
58458512|NCT05947188|OTHER|prostate cancer diagnosis|prostate cancer diagnosis
57956449|NCT03124823|DEVICE|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
58111926|NCT04038151|DEVICE|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
58111927|NCT06370299|OTHER|(exposure of) MDR carriage|The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
58111928|NCT03548714|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
58111929|NCT03548714|OTHER|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
58111930|NCT04873674|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
58444205|NCT04486014|PROCEDURE|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
57740737|NCT04857268|DEVICE|wearable continuous ECG monitoring patch, ATP-C120|"ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside."
58444206|NCT04486014|PROCEDURE|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
58444207|NCT03798327|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
58444208|NCT01505374|PROCEDURE|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
57740738|NCT03875027|PROCEDURE|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
57740739|NCT04166409|PROCEDURE|Biospecimen Collection|Correlative studies
57740740|NCT04166409|DRUG|Carboplatin|Given IV
58312476|NCT03069989|DRUG|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
58312477|NCT02445469|OTHER|MRI exam of the brain|MRI exam of the brain
58444209|NCT01505374|PROCEDURE|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
58444210|NCT00904488|DRUG|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
58312478|NCT04260113|DRUG|Apatinib Mesylate|Apatinib orally 500mg once daily half an hour after meal
58312479|NCT01434511|BIOLOGICAL|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
58312480|NCT01855269|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
57740741|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58111931|NCT04873674|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
58111932|NCT05863156|DIAGNOSTIC_TEST|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
57740742|NCT04166409|OTHER|Quality-of-Life Assessment|Ancillary studies
57740743|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
57740744|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
57740745|NCT04166409|DRUG|Vincristine Sulfate|Given IV
57740746|NCT06732765|OTHER|Pilates exercise program|Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
57740747|NCT06732765|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
57740748|NCT03717961|DRUG|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
57740749|NCT03717961|DRUG|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
57740750|NCT04163705|DIAGNOSTIC_TEST|blood sample collection|Routine Laboratory Analysis
57740751|NCT02223923|DRUG|AZD6738|
57740752|NCT02223923|RADIATION|Palliative radiotherapy|
57740753|NCT02085408|DRUG|Daunorubicin|Given IV
57740754|NCT02085408|DRUG|Cytarabine|Given IV
57740755|NCT02085408|DRUG|Clofarabine|Given IV
57740756|NCT02085408|DRUG|Decitabine|Given IV
57740757|NCT02085408|OTHER|Observation|Undergo clinical observation
57740758|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
57740759|NCT04066348|BIOLOGICAL|Etanercept|To treat blast or noise induced tinnitus
57740760|NCT04066348|OTHER|Saline|Placebo
57740761|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro|
57740762|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro FreeD|
57740763|NCT05579418|DRUG|Evolocumab|Evolocumab is an injection for management of dyslipidemia
57740764|NCT01214772|DRUG|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
57740765|NCT00636610|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
58111933|NCT05863156|DIAGNOSTIC_TEST|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
58111934|NCT05863156|DIAGNOSTIC_TEST|left side lying position|In the study, 120 participants in the left side lying position (control group).
58111935|NCT01280799|BEHAVIORAL|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
57740766|NCT00636610|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
57740767|NCT00636610|DRUG|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
57740768|NCT00636610|DRUG|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
58111936|NCT05053178|BEHAVIORAL|Mindfulness-based mandala activity|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented
58111937|NCT01428726|DRUG|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
58111938|NCT03476356|DRUG|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
58111939|NCT03476356|DRUG|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
58111940|NCT02881476|OTHER|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
58111941|NCT03770871|DRUG|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
58111942|NCT03770871|DRUG|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
58111943|NCT06112535|DEVICE|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
58444211|NCT00904488|DRUG|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
58444212|NCT00091091|OTHER|medical chart review|
58444213|NCT00091091|OTHER|questionnaire administration|
58111944|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
58111945|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
57740769|NCT00636610|DRUG|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
58111946|NCT00133302|DRUG|Standard CHOP|
58111947|NCT00133302|DRUG|Bi-CHOP (dose intensified CHOP)|
58444214|NCT00091091|PROCEDURE|management of therapy complications|
58444215|NCT01076530|DRUG|vorinostat|
58444216|NCT01076530|DRUG|temozolomide|
58444217|NCT01076530|OTHER|diagnostic laboratory biomarker analysis|
58444218|NCT01076530|OTHER|pharmacological study|
58111948|NCT06450600|BEHAVIORAL|Multiple Sclerosis Therapeutic Education Program|"The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience."
58111949|NCT03103009|DRUG|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
58111950|NCT03873519|OTHER|Chromatic Environment|Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
58111951|NCT03873519|OTHER|Room Orientation|Room will be facing North or South
58111952|NCT05953922|OTHER|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
58111953|NCT02756000|PROCEDURE|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
58111954|NCT02756000|PROCEDURE|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
58111955|NCT02179684|PROCEDURE|Baby-sitter surgery N. fascialis|
58111956|NCT02179684|OTHER|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
58111957|NCT00824460|DRUG|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
58111958|NCT00824460|DRUG|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
58444219|NCT02362750|OTHER|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
58444220|NCT02362750|OTHER|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
57740770|NCT04678492|DRUG|Esomeprazole|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
57740771|NCT04678492|DRUG|Amoxicillin|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
57740772|NCT04678492|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
58444221|NCT02362750|OTHER|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
58444222|NCT02362750|OTHER|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
57740773|NCT04678492|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
57740774|NCT04678492|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
57740775|NCT04678492|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
57740776|NCT00439868|DRUG|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
57740777|NCT00439868|DRUG|placebo|Matching placebo tablets to WELLBUTRIN XL.
58444223|NCT02362750|OTHER|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
58111959|NCT00824460|DRUG|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
58111960|NCT00824460|DRUG|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
58111961|NCT00824460|DRUG|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
58111962|NCT00824460|DRUG|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
58111963|NCT00036777|DRUG|carboplatin|Given IV
58111964|NCT00036777|DRUG|7-hydroxystaurosporine|Given IV
58111965|NCT00036777|OTHER|pharmacological study|Correlative studies
58111966|NCT03040076|BEHAVIORAL|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
58111967|NCT03040076|BEHAVIORAL|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
58111968|NCT03231527|PROCEDURE|coronary artery bypass grafting (CABG)|myocardial revascularization
58111969|NCT01990885|DRUG|BL-7010|
58111970|NCT01990885|DRUG|Placebo|
58111971|NCT02708290|OTHER|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
58111972|NCT02762565|DEVICE|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
58111973|NCT02792413|DRUG|Denosumab|Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
57740778|NCT02711774|DEVICE|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
57740779|NCT03461003|OTHER|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
58111974|NCT02792413|DRUG|NaCl (placebo)|Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
58111975|NCT04036227|DRUG|GS-248|GS-248 oral solution
58312481|NCT01855269|DIETARY_SUPPLEMENT|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
58312482|NCT01855269|DIETARY_SUPPLEMENT|placebo sterile water|
58312483|NCT00677222|BIOLOGICAL|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
57740780|NCT03461003|OTHER|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
57740781|NCT03461003|DRUG|Amlodipine|Calcium-channel blocker; antihypertensive
57740782|NCT03461003|DRUG|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
58111976|NCT04036227|DRUG|Placebo|Placebo oral solution with the same composition to match active drug
58111977|NCT00254397|DRUG|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
58111978|NCT00254397|BIOLOGICAL|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
58111979|NCT00254397|BIOLOGICAL|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
58111980|NCT05197010|OTHER|Home based exercise program via a smartphone application|Daily home based exercise program (30min/day, 7days/week for 6 weeks).
58312484|NCT05555680|OTHER|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
58312485|NCT04301050|OTHER|Yoga Intervention|Weekly 75-minute yoga classes.
57740783|NCT03461003|DRUG|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
57740784|NCT03461003|DRUG|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
57740785|NCT01835951|OTHER|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
58111981|NCT01039220|BIOLOGICAL|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
58312486|NCT05203315|DRUG|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
58312487|NCT05203315|DRUG|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
58312488|NCT01029756|DEVICE|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
58312489|NCT01029756|DEVICE|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
58312490|NCT06372561|DRUG|Mineral trioxide aggregate (dressing material)|MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
58312491|NCT06372561|DRUG|Melatonin (dressing material)|melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
58444224|NCT02362750|OTHER|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
58444225|NCT02362750|OTHER|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
57740786|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
57769657|NCT02875301|BEHAVIORAL|150 Minutes Week|This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
58111982|NCT01483976|OTHER|Oral medical nutritional supplement|orally over a three hour period
58111983|NCT01483976|OTHER|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
58111984|NCT06482866|OTHER|Cottle's septoplasty and radiocoagulation conchoplasty|Cottle's septoplasty and radiocoagulation conchoplasty Study group - added nasal splits; Control group - nasal splits weren't used.
58111985|NCT01102777|BEHAVIORAL|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
58111986|NCT01102777|OTHER|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
58111987|NCT01336010|DRUG|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
58111988|NCT01336010|DRUG|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
58111989|NCT05954078|DRUG|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
58111990|NCT05954078|DRUG|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
58111991|NCT05300932|DRUG|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
58111992|NCT05300932|DRUG|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
57740787|NCT03977038|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
58111993|NCT00581594|PROCEDURE|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
58111994|NCT00581594|PROCEDURE|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
58111995|NCT01955603|DRUG|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
58111996|NCT01955603|DRUG|placebo|Placebo administered corresponding to NNC0215-0384 treatment
58111997|NCT00206206|PROCEDURE|Hyperglycemia Protocol Procedure|
58111998|NCT06547905|DEVICE|Ostomy Leakage Detection System|A system that is used to detect ostomy leaks
58111999|NCT02914366|DRUG|Ambroxol|
58112000|NCT02914366|OTHER|Placebo|
58112001|NCT01402583|DRUG|PEG IFN/Ribavirin|PEG IFN/Ribavirin
58112002|NCT04070456|OTHER|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
58112003|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
58312492|NCT01898416|DRUG|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
58444226|NCT05637788|DIAGNOSTIC_TEST|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
58444227|NCT01594619|DRUG|Naloxegol|Oral 25mg tablet
58444228|NCT01594619|DRUG|Diltiazem XR|Oral 240mg tablet
58112004|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
58112005|NCT04372433|BIOLOGICAL|IO-202|IO-202 as monotherapy
58112006|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
58112007|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine + Venetoclax|IO-202 and azacitidine + venetoclax combination therapy
58112008|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
58312493|NCT01258049|DRUG|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
58312494|NCT01258049|DRUG|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
58312495|NCT03255187|DIETARY_SUPPLEMENT|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].
58312496|NCT03255187|DIETARY_SUPPLEMENT|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
57956450|NCT03202966|OTHER|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
57956451|NCT02187471|DRUG|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
57956452|NCT02187471|DRUG|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
57956453|NCT02187471|DRUG|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
57956454|NCT02187471|DRUG|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
57956455|NCT03970187|OTHER|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
58312497|NCT04794907|OTHER|Observation|Patient data will be collected from eye exams, surveys and medical record review.
58312498|NCT06048224|DRUG|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
58444229|NCT05743088|BEHAVIORAL|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
58312499|NCT06048224|DRUG|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
58444230|NCT01436786|OTHER|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
58312500|NCT05280990|DIAGNOSTIC_TEST|mHBS|Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
58458513|NCT05252897|PROCEDURE|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
58112009|NCT03826381|DIAGNOSTIC_TEST|Magnetic resonance (MR) spectroscopy of the liver|Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
58112010|NCT03826381|DIAGNOSTIC_TEST|Fibroscan|Transient Elastography for Measurement of liver fibrosis.
58112011|NCT03826381|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
58112012|NCT03826381|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
58112013|NCT03826381|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
58112014|NCT03826381|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
58112015|NCT00001128|DRUG|Interleukin-12|
58112016|NCT00001128|DRUG|Paromomycin sulfate|
58112017|NCT00001128|DRUG|Azithromycin|
58112018|NCT04823000|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
58444231|NCT03517761|BIOLOGICAL|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
58444232|NCT03517761|OTHER|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
58444233|NCT06139744|DRUG|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
58444234|NCT06139744|DRUG|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
58458514|NCT05252897|PROCEDURE|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
58312501|NCT05280990|DIAGNOSTIC_TEST|CT/MRI volumetry|Preoperative FLRF assessment using CT/MRI volumetry
58112019|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 1.5mg/ day|Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
58312502|NCT03171090|OTHER|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
58312503|NCT03171090|OTHER|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
58312504|NCT01114724|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
58112020|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 2.0mg/ day|Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
58112021|NCT05583175|DRUG|Venetoclax plus RIC|Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.
58112022|NCT05678985|BEHAVIORAL|Choose to Move|As described under study arm description.
58312505|NCT04636047|OTHER|The method of gene mutation detection|All samples were detected by NGS CGP panel.
58112023|NCT02854683|DRUG|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
58112024|NCT02854683|DIETARY_SUPPLEMENT|Oral Rehydration Solution|1 liter of ORS solution given by mouth
58112025|NCT01545687|DIETARY_SUPPLEMENT|Lactobacillus brevis CD2 lozenge|Dissolved orally
58112026|NCT01545687|OTHER|placebo|Dissolved orally
58112027|NCT00526773|OTHER|telephone management plus a motivational intervention|heart failure intervention
58112028|NCT00526773|OTHER|telephone management with standard patient education|heart failure intervention
58312506|NCT01513655|DEVICE|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
58112029|NCT04269278|DRUG|0 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
58312507|NCT00732914|DRUG|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
58312508|NCT00732914|DRUG|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
58312509|NCT05540431|DRUG|Activated Charcoal|RCT
57740788|NCT05265611|BEHAVIORAL|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
58312510|NCT05540431|DIETARY_SUPPLEMENT|Probiotic|RCT
58312511|NCT05540431|OTHER|No intervention|RCT
58312512|NCT00139529|BEHAVIORAL|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
58312513|NCT00139529|BEHAVIORAL|Educational Intervention|Educational intervention will be completed during pregnancy.
58444235|NCT05082246|OTHER|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
58444236|NCT05082246|OTHER|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
58458515|NCT04133558|OTHER|tracheal aspirate during routine care|tracheal aspirate during routine care
58458516|NCT05136508|DRUG|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
57740789|NCT05265611|BEHAVIORAL|Tutoring|Young adults will be trained to tutor students in elementary school.
57740790|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
57956456|NCT03320122|OTHER|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
57956457|NCT03320122|OTHER|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
57956458|NCT03320122|OTHER|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
57956459|NCT02071407|DRUG|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
57956460|NCT02071407|DRUG|Placebo|
57956461|NCT01028846|DRUG|Diazoxide|1-2 mg/kg total dose given intravenously
57956462|NCT01028846|DRUG|Placebo|Intravenous normal saline
57956463|NCT06131879|DEVICE|Laser acupuncture|Biostimulation of temporalis and masseter muscles
57956464|NCT06131879|BEHAVIORAL|Modified physical therapy|Progressive muscle relaxation of temporalis and masseter muscles
58312514|NCT03211507|OTHER|Computer-assisted telephone interview|Occupational history
58312515|NCT03211507|GENETIC|Genetic analysis|To include analysis of known susceptibility markers
57956465|NCT01594853|BEHAVIORAL|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
57956466|NCT05813080|DEVICE|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
58112030|NCT04269278|DRUG|0.25 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
58112031|NCT04269278|DRUG|0.5 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
58112032|NCT04269278|DRUG|0.75 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
58112033|NCT03031899|PROCEDURE|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
58112034|NCT03031899|DIAGNOSTIC_TEST|Rose Bengal|the lesions stained positive were subjected to biopsy
58112035|NCT03031899|DIAGNOSTIC_TEST|toluidine blue|the lesions stained positive were subjected to biopsy
58112036|NCT04546906|BIOLOGICAL|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
58112037|NCT02449603|DRUG|Exenatide|
58112038|NCT02449603|DRUG|Biphasic insulin Aspart 30|
58112039|NCT01835132|DEVICE|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
58112040|NCT02730065|BEHAVIORAL|Structured Aerobic Dance Training Group|Systematic physical activity
58112041|NCT02730065|BEHAVIORAL|Stretching plus education|Weekly group based stretching with psychoeducation and health education
58112042|NCT03459326|OTHER|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)"
58112043|NCT00200395|DRUG|Tarceva|OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
58112044|NCT06543823|DEVICE|SupraTHEL 250|the membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures
58112045|NCT06543823|OTHER|Comparator|no membrane is placed onto the wound bed , left bare to heal
57956467|NCT05813080|OTHER|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
57956468|NCT06543108|DIAGNOSTIC_TEST|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
57956469|NCT04422860|DRUG|Gum Arabic varnish|Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
57956470|NCT04422860|DRUG|Proflourid Varnish,VOCO|5% NaF varnish
57956471|NCT04422860|DRUG|MI Varnish,GC Japan Inc.|CPP-ACP with fluoride based varnish
57956472|NCT05716880|DRUG|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
57956473|NCT05716880|OTHER|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
57956474|NCT00290966|DRUG|XRP6976|
57956475|NCT04020250|DEVICE|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
57956476|NCT03389035|BIOLOGICAL|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
58112046|NCT00425659|DEVICE|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
58112047|NCT00425659|DEVICE|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
58112048|NCT00425659|DEVICE|CPAP|usual practice
58112049|NCT04390139|DRUG|XCEL-UMC-BETA|Administration on top of the standard administered treatment
58312516|NCT00300053|BIOLOGICAL|CLBS14 (low-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
57956477|NCT03823469|BEHAVIORAL|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
57956478|NCT03823469|BEHAVIORAL|Nutritional counseling|Two 30-minute nutritional counseling sessions
57956479|NCT05230186|PROCEDURE|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
58112050|NCT04390139|OTHER|Placebo|Administration on top of the standard administered treatment
58112051|NCT00510549|PROCEDURE|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
58112052|NCT03392376|DRUG|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
58112053|NCT03392376|OTHER|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
58112054|NCT03107351|DEVICE|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
58112055|NCT03107351|DEVICE|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
58112056|NCT03124381|DEVICE|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
58112057|NCT03124381|DEVICE|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
58112058|NCT02400710|BEHAVIORAL|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
58112059|NCT02400710|BEHAVIORAL|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
58112060|NCT05641272|BIOLOGICAL|3,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
58112061|NCT05641272|BIOLOGICAL|9,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
58112062|NCT05641272|OTHER|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
58112063|NCT00189397|DRUG|azathioprine and corticosteroids for Parthenium dermatitis|
58112064|NCT02688127|DRUG|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
58112065|NCT05574582|PROCEDURE|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
58444237|NCT05082246|OTHER|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
58444238|NCT03293030|DRUG|Dupilumab|Dupilumab treatment
58112066|NCT02850523|OTHER|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
58112067|NCT03668028|BIOLOGICAL|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
58112068|NCT03668028|PROCEDURE|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
58112069|NCT02529800|DRUG|HIP1402|Tamsulosin HCl 0.4mg
58112070|NCT02529800|DRUG|HGP0412|Tamsulosin HCl 0.2mg
58112071|NCT00006170|DRUG|Bupropion|smoking cessation medication aid
57740791|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
58112072|NCT00006170|DRUG|Placebo|A matched placebo pill
58444239|NCT03685227|OTHER|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
58444240|NCT05140460|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
58112073|NCT00006170|BEHAVIORAL|weight concerns intervention|cognitive behavioral treatment to address weight concners
58112074|NCT00006170|BEHAVIORAL|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
58112075|NCT01871987|DRUG|FK949E|oral
58112076|NCT06377358|DEVICE|Tecar Therapy|Tecar Therapy at 1Mhz radiofrequency by the use of a C-400 device. The duration of the treatment will be 5 weeks, where 10 sessions will be carried out, 2 per week
58112077|NCT05093777|OTHER|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
58112078|NCT05093777|OTHER|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
58112079|NCT03651661|DRUG|human insulin|human insulin administered as nasal spray
58112080|NCT03651661|DRUG|placebo|placebo administered as nasal spray
58112081|NCT03651661|DIAGNOSTIC_TEST|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
58112082|NCT03417622|PROCEDURE|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
58112083|NCT03417622|DRUG|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
58112084|NCT03417622|PROCEDURE|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
58112085|NCT03417622|PROCEDURE|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
58112086|NCT05515809|DRUG|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
58112087|NCT05515809|DRUG|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
58112088|NCT06528587|PROCEDURE|narrow diameter implant|Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
58112089|NCT05079893|OTHER|Case control study|Observational case control study
58112090|NCT05802095|DEVICE|Supplemental Feeding Tube Device|One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
58112091|NCT00273195|DEVICE|Implantable Cardioverter Defibrillator|
58112092|NCT03641118|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
58112093|NCT06178679|DRUG|ST-100 (vezocolmitide)|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
58112094|NCT06178679|DRUG|Vehicle|Vehicle Ophthalmic Solution
58444241|NCT05140460|BEHAVIORAL|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
57740792|NCT03528538|OTHER|Placebo|rice flour in a vegetable/ cellulose capsule
57740793|NCT03919422|PROCEDURE|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
58112095|NCT04376723|OTHER|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
58112096|NCT01353924|BIOLOGICAL|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
58112097|NCT01353924|BIOLOGICAL|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
58112098|NCT04050332|BEHAVIORAL|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
58112099|NCT04525742|OTHER|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
58112100|NCT03086239|DRUG|Rovalpituzumab tesirine|Intravenous
58112101|NCT01597895|DRUG|Maraviroc|Maraviroc 150 mg BID x 5 days with food
58112102|NCT01597895|DRUG|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
58112103|NCT01597895|DRUG|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
58444242|NCT01792037|DRUG|Etomidate|
58444243|NCT01792037|DRUG|Midazolam|
58444244|NCT01792037|DRUG|methylprednisolone|
57740794|NCT03919422|PROCEDURE|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
57740795|NCT06443775|DRUG|Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)|Eye Drops
58444245|NCT05215834|DRUG|Remifentanil|"1. Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~2. Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery."
58444246|NCT01327677|DRUG|Fentanyl|25-50 mcg every 20 minutes
58112104|NCT02909725|OTHER|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
58312517|NCT00300053|BIOLOGICAL|CLBS14 (high-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
58312518|NCT00300053|BIOLOGICAL|placebo injection|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
58312519|NCT03706846|PROCEDURE|fasting|fasting before gastrointestinal endoscopy
58312520|NCT00413517|PROCEDURE|Epi-Lasik|A vision correcting surgery
58444247|NCT01327677|DRUG|Fentanyl|20mcg/demand dose with an 8 minute lock out
58444248|NCT01006759|OTHER|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
58444249|NCT01362894|DEVICE|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
58444250|NCT01362894|DEVICE|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
58444251|NCT00102128|DRUG|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
57740796|NCT05181163|DIAGNOSTIC_TEST|swab|Swabs from site of infection will be taken
58112105|NCT02909725|OTHER|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
58112106|NCT02909725|OTHER|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
58112107|NCT02048254|RADIATION|brachytherapy|
58112108|NCT02048254|RADIATION|IMRT|
58112109|NCT04663880|OTHER|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
58112110|NCT04663880|OTHER|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
58112111|NCT04663880|OTHER|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
58112112|NCT04636749|DEVICE|Erbium laser|Vaginal laser therapy
58312521|NCT01654887|OTHER|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
58312522|NCT01654887|RADIATION|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
58312523|NCT00668616|DRUG|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
58312524|NCT00668616|DRUG|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
58444252|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
58112113|NCT04636749|DEVICE|Sham laser|Sham laser therapy
58112114|NCT05548933|PROCEDURE|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
58112115|NCT06529718|DRUG|Ivonescimab|20 mg/kg IV infusion every 3 weeks
58112116|NCT06529718|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks
58112117|NCT01901991|PROCEDURE|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
58444253|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
57740797|NCT00689767|DEVICE|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
58112118|NCT01901991|PROCEDURE|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
58112119|NCT02660385|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
57740798|NCT00689767|DEVICE|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
58112120|NCT02660385|BEHAVIORAL|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
58112121|NCT00000531|DEVICE|defibrillators, implantable|
58112122|NCT00000531|DRUG|amiodarone amiodarone|
58312525|NCT02173613|OTHER|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~* It is highly recommended to stop antibiotics if PCT \<0.1ng/ml, and the recommended stop if 0.1ng/ml \<PCT \<0.25 ng / ml.~* It is recommended to continue treatment if 0.25 ng / ml \<PCT ng / ml.~* Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
58312526|NCT05664516|DRUG|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
58312527|NCT05664516|DRUG|Placebo|Nasal solution without oxytocin
58444254|NCT02708810|DEVICE|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
58444255|NCT02708810|RADIATION|80 Gy Radiation|
58444256|NCT05639140|OTHER|Data collection|Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
58444257|NCT06308666|DEVICE|Delefilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
58444258|NCT01057186|DIETARY_SUPPLEMENT|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
57740799|NCT00908154|DRUG|Placebo|Tablets to match GSK1014802
58444259|NCT01057186|DRUG|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
58444260|NCT04323072|PROCEDURE|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
58444261|NCT04323072|PROCEDURE|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
57740800|NCT00908154|DRUG|GSK1014802|Sodium channel blocker
57740801|NCT05261633|DEVICE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
57740802|NCT05476328|DEVICE|OPAL Sound Processing Strategy.|OPAL Sound Processing Strategy. OPAL sound processing strategy designed to improve perception of fundamental frequency (F0) as cue to lexical tone in tonal languages and to pitch in music. This research strategy will be implemented in the Nucleus 6 CP900 sound processors. The programming will be performed by the investigational software Cochlear Device Interface Tool (CDI Tool). Investigational firmware will be written on a commercially available N6 sound processor sound processor.
58112123|NCT00000531|DRUG|sotalol|
58112124|NCT01084603|DRUG|Oral Nicotine|A new l mg oral nicotine product
58112125|NCT01084603|DRUG|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
58112126|NCT01084603|DRUG|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
58112127|NCT00481247|DRUG|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
58112128|NCT00481247|DRUG|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
58112129|NCT03000400|BEHAVIORAL|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
58112130|NCT03000400|BEHAVIORAL|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
58444262|NCT04814121|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
58112131|NCT03999346|OTHER|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
58312528|NCT03257579|OTHER|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
58444263|NCT04814121|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
58444264|NCT03863431|OTHER|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
58444265|NCT03863431|OTHER|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
58444266|NCT03667469|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
58444267|NCT03667469|DIETARY_SUPPLEMENT|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
58112132|NCT03392090|OTHER|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
58112133|NCT01605461|DRUG|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
58444268|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
58444269|NCT06078059|OTHER|Knee aspiration|Knee aspiration
57740803|NCT05476328|DEVICE|OPAL-EM|OPAL-EM (Enhanced Modulation) is a version of OPAL that improves temporal accuracy in the coding of F0 amplitude-modulation in the stimulus envelope. It is specifically designed to address the need for use of low stimulation rates (i.e., lower than the recommended OPAL rate of around 1200 pps/ch) but it is also expected to provided improvements for all stimulation rates by virtue of the improved temporal accuracy it provides.
58112134|NCT04379661|BEHAVIORAL|Online support Group|12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
58312529|NCT03257579|BEHAVIORAL|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
58444270|NCT02755220|DEVICE|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
58444271|NCT03605446|DIETARY_SUPPLEMENT|Biscuit acceptance|Acceptance of high protein biscuits
58444272|NCT01797263|OTHER|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
58444273|NCT01797263|OTHER|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
58458517|NCT05136508|DRUG|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
58458518|NCT01106599|DRUG|GDC-0623|Repeating oral dose
57740804|NCT05476328|DEVICE|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
57740805|NCT05476328|DEVICE|FAST|FAST (Fundamental Asynchronous Stimulus Timing) is a low- and variable-rate coding strategy that has been shown to be power efficient and significantly increase sensitivity to ITD cues in bilateral subjects. It also explicitly codes low F0s as the rate of stimulation and may have tone and music benefits. It has been implemented on the Nucleus 5 CP800 sound processor for CIC4-based implants.
58112135|NCT06401200|OTHER|bar retained implant overdenture|use of bar attachment in completely edentulous patient
58112136|NCT05986071|DRUG|M1774|• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
58112137|NCT05986071|DRUG|Fulvestrant injection|Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
58112138|NCT02741271|DRUG|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
58312530|NCT01160302|DRUG|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
58312531|NCT04056468|DRUG|Mobocertinib|Mobocertinib capsule.
58312532|NCT04100213|BEHAVIORAL|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
58112139|NCT02741271|DRUG|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
58112140|NCT02741271|DRUG|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
58112141|NCT02741271|DRUG|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
58112142|NCT02741271|DRUG|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
58112143|NCT05125783|OTHER|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
58112144|NCT02189876|BEHAVIORAL|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
58112145|NCT02189876|BEHAVIORAL|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
58112146|NCT05023954|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
58112147|NCT06231797|DIAGNOSTIC_TEST|AI algorithm conducted on 12-lead ECG and transthoracic echocardiography|12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.
58112148|NCT01879800|BEHAVIORAL|Acceptance and Commitment Therapy plus Illness Management|
57740806|NCT05476328|DEVICE|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
58112149|NCT02887612|OTHER|ctDNA test|
58112150|NCT00698178|OTHER|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
58112151|NCT01612156|DRUG|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
58112152|NCT01612156|DRUG|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
58112153|NCT01352247|PROCEDURE|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
58112154|NCT01352247|PROCEDURE|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
58112155|NCT06458725|DEVICE|Magnetic Resonance Imaging (MRI)|"- Three MRI :~* two on an MR-Linac 1.5 Tesla (10 to 17 days apart)~* one on a standard 1.5 Tesla MRI"
58112156|NCT06047158|DRUG|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
58112157|NCT01097161|BEHAVIORAL|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
57956480|NCT04475055|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen (DIPS)|The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
57956481|NCT03699007|BEHAVIORAL|Graded Exposure Therapy (GET Living)|The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
58112158|NCT01563432|DRUG|Feburic®|80 mg\*1 tablet
58112159|NCT01563432|DRUG|TMX-67|40 mg\*2 tablets
58112160|NCT01555606|OTHER|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
58112161|NCT00629486|GENETIC|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
58112162|NCT02109926|OTHER|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
58112163|NCT00851045|DRUG|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
58112164|NCT00851045|DRUG|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
58112165|NCT00851045|DRUG|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
58112166|NCT00851045|DRUG|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
57956482|NCT03699007|BEHAVIORAL|Multidisciplinary Pain Management (MPM)|The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
58112167|NCT00851045|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
58112168|NCT00851045|DRUG|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
58112169|NCT00851045|DRUG|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
58112170|NCT01951183|DRUG|Placebo|RO681135 placebo subcutaneously daily
58112171|NCT01951183|DRUG|RO6811135|Subcutaneously daily
58112172|NCT00140556|RADIATION|Chemoradiotherapy|External beam radiation daily (M-F)
58112173|NCT00140556|DRUG|Cisplatin|Cisplatin week 1 and 5 of radiation
58112174|NCT00140556|DRUG|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
58112175|NCT00140556|DRUG|Erlotinib|Erlotinib daily during radiation
58312533|NCT02728336|PROCEDURE|Cardiac MRI|
58444274|NCT04988529|BEHAVIORAL|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
57956483|NCT04293861|DEVICE|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
57956484|NCT04388150|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
58112176|NCT00418782|DRUG|naproxen|
58112177|NCT00418782|DRUG|CE-224535|
58112178|NCT00418782|DRUG|placebo|
58112179|NCT05305183|DRUG|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
58112180|NCT02804828|DIETARY_SUPPLEMENT|Individualized mitochondrial cocktail|Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
58312534|NCT00067080|DRUG|ICL670, deferoxamine|
58312535|NCT06069102|DRUG|Usual care|The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
58112181|NCT02804828|DIETARY_SUPPLEMENT|Placebo|6 months for the double-blind phase
58312536|NCT06069102|DRUG|Tight blood pressure control|The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
58444275|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
57956485|NCT06317194|DEVICE|kTMP|A new non-invasive brain stimulation tool
57956486|NCT06317194|DEVICE|Sham kTMP|A new non-invasive brain stimulation tool with sham setting selected
57956487|NCT05800249|DRUG|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
58112182|NCT02915510|DIETARY_SUPPLEMENT|Glycomacropeptide-based protein substitute|
58112183|NCT01556685|OTHER|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
58112184|NCT01556685|OTHER|Blood Sample|For evaluation of interferon-related Nab
58112185|NCT01556685|GENETIC|Blood Sample|genetic evaluation - predisposition to Nab generation
58112186|NCT04147481|OTHER|Group Abdominal Nerve Block with local anesthetics|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
58112187|NCT04147481|OTHER|Group Abdominal Nerve Block with saline|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
58112188|NCT04999228|DRUG|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
58112189|NCT04999228|DRUG|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
58112190|NCT00103870|PROCEDURE|Electrodermal stimulation|
58112191|NCT00103870|PROCEDURE|Music listening task|
58112192|NCT06182007|PROCEDURE|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
58312537|NCT04583501|BIOLOGICAL|Omalizumab|Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
58444276|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
58444277|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
58444278|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
57956488|NCT06340932|DEVICE|Iovera|Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration
57956489|NCT06340932|DRUG|Celecoxib|200mg BID
57956490|NCT06340932|DRUG|Acetaminophen|1000mg q8h
57956491|NCT06340932|DRUG|Oxycodone|As needed
57956492|NCT06340932|DRUG|Tramadol|As needed
57740807|NCT05476328|DEVICE|FAST-OPAL|FAST-OPAL (combined FAST and OPAL strategy) strategy was developed to improve FAST strategy performance in noisy environments. The processing techniques employed by FAST-OPAL retain the sparse, yet temporally precise coding of temporal envelope information, while improving coding of that information in noise and coding of relative across-channel intensity in noise.
57956493|NCT06340932|DRUG|Bupivacaine Hydrochloride|20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK
57956494|NCT06340932|DRUG|Acetaminophen 500Mg Cap|500mg q6h prn
57956495|NCT02949752|DRUG|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
57956496|NCT04509310|DEVICE|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
57956497|NCT04674592|OTHER|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
57956498|NCT05395065|DEVICE|Silver Diamine Fluoride/Sodium Fluoride Varnish|Application of dental caries arresting topical medication
57956499|NCT01421550|PROCEDURE|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
57956500|NCT01421550|PROCEDURE|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
57956501|NCT04655664|DIAGNOSTIC_TEST|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
57956502|NCT04655664|DIAGNOSTIC_TEST|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
57956503|NCT02849795|OTHER|bone densitometry|
58444279|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
57956504|NCT02849795|OTHER|questionnaires|
57956505|NCT02849795|OTHER|biological analyses|
57956506|NCT00646542|DRUG|Vildagliptin|
57956507|NCT00646542|DRUG|Placebo|
58444280|NCT01035619|DRUG|moxidectin|Single Dose Moxidectin 4 mg
58444281|NCT02402582|OTHER|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
58444282|NCT02402582|OTHER|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
58112193|NCT01475188|DRUG|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
58112194|NCT01475188|OTHER|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
58112195|NCT04916171|OTHER|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
58112196|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
58444283|NCT05988879|DRUG|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
58444284|NCT03994666|BIOLOGICAL|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
58444285|NCT03994666|BIOLOGICAL|Placebo (NaCl)|Placebo injection
58444286|NCT01814124|OTHER|Manual therapy plus exercise|
58444287|NCT01814124|OTHER|Advice and home exercise|
58444288|NCT02458053|BEHAVIORAL|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
58444289|NCT02458053|BEHAVIORAL|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
58444290|NCT02458053|BEHAVIORAL|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
58444291|NCT02458053|BEHAVIORAL|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
58444292|NCT02458053|OTHER|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
58444293|NCT02458053|BEHAVIORAL|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
58444294|NCT03763019|PROCEDURE|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
58444295|NCT03763019|PROCEDURE|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
58444296|NCT02842164|OTHER|Tension group|
58444297|NCT02842164|OTHER|No tension group|
58444298|NCT02842164|OTHER|Foley catheter Balloon|
58444299|NCT04498442|BEHAVIORAL|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
57740808|NCT05476328|DEVICE|Cochlear Device Interface Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
58444300|NCT04498442|BEHAVIORAL|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
58444301|NCT04651868|OTHER|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
58444302|NCT04651868|OTHER|Placebo|A 210 mins intravenous infusion with isotonic NaCl
58112197|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
58444303|NCT04651868|OTHER|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)
58444304|NCT04651868|OTHER|Placebo|A 180 mins intravenous infusion with isotonic NaCl
58444305|NCT05125406|BEHAVIORAL|Exposure therapy with Virtual Reality.|Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
57740809|NCT06670625|BEHAVIORAL|IDAC+|Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.
58112198|NCT02002156|BIOLOGICAL|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
57740810|NCT02291887|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab
58444306|NCT04402879|PROCEDURE|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements."
58444307|NCT05563272|DRUG|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
57740811|NCT02291887|DRUG|Aflibercept|Intravitreal injection of Aflibercept
58112199|NCT01527539|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
58112200|NCT02885935|OTHER|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
58112201|NCT02885935|OTHER|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
58112202|NCT03237611|DRUG|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
58444308|NCT05441267|DRUG|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
58444309|NCT05441267|DRUG|Placebo oral tablet|Placebo oral semaglutide
58458519|NCT04772703|DIAGNOSTIC_TEST|COMET ASSAY|The description in the detailed description of the study
57740812|NCT02045238|DRUG|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
57740813|NCT02045238|RADIATION|Chest X-Ray|
58112203|NCT03237611|DRUG|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
58112204|NCT03237611|DRUG|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
58312538|NCT05229913|DRUG|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
58312539|NCT05229913|DRUG|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
58312540|NCT05229913|DRUG|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
58312541|NCT05229913|DRUG|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
58312542|NCT05229913|DRUG|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
57740814|NCT02045238|OTHER|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
58312543|NCT00301834|BIOLOGICAL|alemtuzumab|
58312544|NCT00301834|DRUG|busulfan|
58312545|NCT00301834|DRUG|cyclosporine|
58312546|NCT00301834|DRUG|fludarabine phosphate|
58312547|NCT00301834|DRUG|methotrexate|
58312548|NCT00301834|DRUG|methylprednisolone|
58312549|NCT00301834|PROCEDURE|allogeneic bone marrow transplantation|
58312550|NCT00301834|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58312551|NCT00301834|PROCEDURE|peripheral blood stem cell transplantation|
58312552|NCT00301834|PROCEDURE|umbilical cord blood transplantation|
58312553|NCT01445340|DRUG|Romidepsin (FR901228)|
58312554|NCT00216372|DRUG|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
58312555|NCT00216372|OTHER|Placebo|A single intra-muscular injection on day 0.
58312556|NCT02924155|DRUG|SJP002|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
58312557|NCT02924155|DRUG|Placebo|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
58312558|NCT06216496|OTHER|dynamic test for amino acid metabolism|"Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate."
58312559|NCT03118180|BIOLOGICAL|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
58112205|NCT03237611|DRUG|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
58112206|NCT01847196|DEVICE|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
58444310|NCT05314907|DEVICE|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
58444311|NCT05314907|OTHER|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
58444312|NCT05355662|OTHER|Age|The study was retrospective and did not involve the application of interventions.
58444313|NCT04602117|DRUG|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
58444314|NCT03467711|OTHER|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
58444315|NCT03467711|OTHER|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
58444316|NCT05200676|DEVICE|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
58444317|NCT05200676|DEVICE|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
58444318|NCT02292719|DRUG|OBV/PTV/r|Tablet
58444319|NCT02292719|DRUG|Sofosbuvir|Tablet
58444320|NCT02292719|DRUG|Ribavirin (RBV)|Tablet
58444321|NCT05922371|DIAGNOSTIC_TEST|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
58444322|NCT04205682|DRUG|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
58444323|NCT04205682|DRUG|Placebo|Placebo capsules administered BD for 5 days
58444324|NCT04768621|OTHER|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
58444325|NCT02969356|BIOLOGICAL|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
58444326|NCT02969356|OTHER|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
58112207|NCT03368495|BIOLOGICAL|Co-administration of MMR/YF|Both MMR \& yellow fever vaccines administered on Day 0.
58112208|NCT03368495|BIOLOGICAL|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
58112209|NCT03368495|BIOLOGICAL|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
58444327|NCT04328220|DIAGNOSTIC_TEST|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
58444328|NCT01969006|DRUG|Marcaine ½%|
58444329|NCT01969006|PROCEDURE|Needle prick|
58444330|NCT03160898|DRUG|Reldesemtiv|Oral tablet
58444331|NCT03160898|DRUG|Placebo|Oral tablet
58444332|NCT04879966|DRUG|Infliximab|Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
58444333|NCT04879966|DRUG|Corticosteroid|Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
58444334|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
58444335|NCT06262113|OTHER|Letters about NF1 Care (Content Type 1)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
58112210|NCT04027010|OTHER|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
58112211|NCT01201954|DRUG|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
58112212|NCT04235647|OTHER|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
58444336|NCT06262113|OTHER|Letters about NF1 Care (Content Type 2)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
58444337|NCT02057172|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
58444338|NCT02057172|DRUG|liraglutide|Liraglutide is a GLP-1 agonist.
58444339|NCT02057172|DRUG|Placebo|Placebo
58444340|NCT01959841|DRUG|ASP2151|200 mg once daily or 400 mg once daily
58444341|NCT01959841|DRUG|valaciclovir|1000 mg three times daily
58444342|NCT03737539|DIAGNOSTIC_TEST|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
58444343|NCT00502554|PROCEDURE|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
58444344|NCT00742417|BIOLOGICAL|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"
58444345|NCT00742417|OTHER|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
58444346|NCT05185999|DRUG|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
58444347|NCT00799903|DRUG|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
58444348|NCT00799903|DRUG|Placebo|Placebo administered in addition to standard therapy
58444349|NCT05164627|DRUG|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
58444350|NCT05164627|DRUG|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
58112213|NCT04235647|OTHER|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
58112214|NCT04985214|OTHER|Questionnaire|Questionnaire on the quality of life
58444351|NCT05164627|DRUG|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
58112215|NCT02257632|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
58112216|NCT02257632|DRUG|Aflibercept 2 mg|Administered as an intravitreal injection
58112217|NCT05002465|DRUG|68Ga-PSMA-11|Injection of 68Ga PSMA-11
58112218|NCT05002465|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
58112219|NCT03031457|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
58444352|NCT03201419|DRUG|FE 201836|Oral solution for daily intake
58444353|NCT03201419|DRUG|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
58112220|NCT01956357|OTHER|Aquatic exercise|
58112221|NCT01956357|OTHER|Land Exercise|
58112222|NCT02494245|OTHER|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
58444354|NCT03201419|DRUG|Placebo oral solution|Manufactured to mimic experimental drug
58444355|NCT03201419|DRUG|Placebo ODT|Manufactured to mimic experimental drug
58444356|NCT04763941|DIAGNOSTIC_TEST|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
58444357|NCT03960112|DEVICE|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
58112223|NCT03196791|DRUG|Sugammadex Sodium|"1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
58112224|NCT00421785|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
58112225|NCT04969952|OTHER|For interventional module|Using vedio to assist physicians introducing advance care planning to cancer patients
58444358|NCT00640965|DRUG|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
58444359|NCT00640965|DRUG|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
58444360|NCT02925624|PROCEDURE|Pulmonary vein isolation|
58444361|NCT03097536|OTHER|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
58444362|NCT05217394|OTHER|OTHIG|Occupational Therapy Handwriting Intervention Guideline
58444363|NCT03088488|DIAGNOSTIC_TEST|fasting venous blood samples|
58444364|NCT04270799|DIAGNOSTIC_TEST|Machine Learning Classification|Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
58444365|NCT02525588|DEVICE|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
58444366|NCT01409876|RADIATION|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
58444367|NCT05642520|PROCEDURE|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
58444368|NCT05642520|PROCEDURE|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
58444369|NCT05979519|BEHAVIORAL|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
58444370|NCT05979519|BEHAVIORAL|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
58444371|NCT05979519|BEHAVIORAL|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
58444372|NCT03871244|PROCEDURE|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
58444373|NCT03871244|PROCEDURE|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
58444374|NCT02002741|DRUG|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
58444375|NCT02002741|DRUG|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
58112226|NCT02622074|BIOLOGICAL|Pembrolizumab|200 mg administered Q3W as an IV infusion.
58312560|NCT03116230|DEVICE|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
58312561|NCT03116230|DEVICE|Knee Sleeve|Commercially-available knee sleeve.
58444376|NCT05375227|OTHER|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
58444377|NCT00110500|GENETIC|hVEGF-A|
58444378|NCT01897948|OTHER|Milk-based beverage without DHA|
58444379|NCT01897948|OTHER|Milk-based beverage with DHA at mid level|
58444380|NCT01897948|OTHER|Milk-based beverage with DHA at high level|
58112227|NCT02622074|DRUG|Nab-paclitaxel|125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.
58444381|NCT03430960|OTHER|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
58444382|NCT03430960|OTHER|Mobile App Survey|Participants will be followed-up via mCare mobile app
58112228|NCT02622074|DRUG|Anthracycline (doxorubicin)|60 mg/m\^2 administered Q3W as an IV injection.
58444383|NCT01458262|OTHER|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
58444384|NCT02757144|DRUG|DWP14012|DWP14012 tablets
58112229|NCT02622074|DRUG|Cyclophosphamide|600 mg/m\^2 administered Q3W as an IV infusion.
58312562|NCT01408472|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
58312563|NCT05215288|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
58444385|NCT02757144|DRUG|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
58444386|NCT02757144|DRUG|Esomeprazole|Nexium®
58444387|NCT01277874|DEVICE|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
58444388|NCT01277874|DEVICE|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
58444389|NCT01008943|BIOLOGICAL|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
58444390|NCT01493973|DRUG|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
58444391|NCT01493973|DRUG|Placebo|Placebo
58444392|NCT04161937|BEHAVIORAL|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
58444393|NCT00003864|DRUG|carboplatin|
58112230|NCT02622074|DRUG|Carboplatin|AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
58112231|NCT02622074|DRUG|Paclitaxel|80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.
58112232|NCT00313053|DRUG|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
58444394|NCT00003864|DRUG|docetaxel|
58444395|NCT02488005|DEVICE|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
58444396|NCT01822418|DRUG|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
58444397|NCT01822197|DEVICE|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
58444398|NCT04744922|DIETARY_SUPPLEMENT|Extracts of citrus peels standardized in AUR and NAR (phytocomplex).|One capsule a day for 9 months
58444399|NCT02742545|BEHAVIORAL|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
58444400|NCT02551822|DEVICE|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
57740815|NCT05616988|OTHER|psychological-clinical intervention with three days of expressive writing by Pennebaker|"The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~* Emotions and expectations related to the breast reconstruction process.~* Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~* Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days)."
57740816|NCT03204279|DRUG|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
57740817|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
58444401|NCT02303249|OTHER|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
58444402|NCT00350688|RADIATION|Helical tomotherapy IMRT|Helical tomotherapy IMRT
58444403|NCT05331586|BEHAVIORAL|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
58444404|NCT04463342|COMBINATION_PRODUCT|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
58444405|NCT04463342|COMBINATION_PRODUCT|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
58444406|NCT03056742|BIOLOGICAL|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
58444407|NCT02665572|BEHAVIORAL|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
58112233|NCT00313053|DRUG|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
58112234|NCT00728559|DRUG|bupivacain 0.5%|trocar site injection
58312564|NCT01189448|DRUG|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
58312565|NCT01189448|DRUG|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
58312566|NCT05627804|OTHER|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
58312567|NCT05627804|OTHER|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
58312568|NCT05627804|OTHER|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
58312569|NCT05627804|OTHER|Control|No exercise will be performed.
58312570|NCT04560842|DEVICE|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
58312571|NCT04560842|DEVICE|Conventional oxygen therapy|Conventional oxygen device
58312572|NCT04480879|DRUG|AZD8154 nebuliser|Nebuliser suspension
58312573|NCT04480879|DRUG|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
58312574|NCT04480879|DRUG|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
58312575|NCT05453383|DRUG|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
58444408|NCT05674058|OTHER|No intervention|According to clinical practice.
58444409|NCT00858624|DRUG|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
58112235|NCT02732587|DRUG|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
58312576|NCT04748978|PROCEDURE|hysteroscopy|OPPIum and Myolysis
58444410|NCT05314335|OTHER|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
58444411|NCT05314335|OTHER|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
58312577|NCT05692440|DEVICE|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
58312578|NCT04096131|PROCEDURE|cataract surgery|phacoemulsification
58312579|NCT03736018|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
58312580|NCT06550921|PROCEDURE|ablation of oligometastasis|The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
58312581|NCT03410316|OTHER|No intervention|
58312582|NCT05687539|DIETARY_SUPPLEMENT|Mastiha water|10ml of mastiha water before every meal for one month
58312583|NCT05687539|DIETARY_SUPPLEMENT|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
58112236|NCT03111147|DEVICE|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
58444412|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
58444413|NCT04966260|OTHER|Standardized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
58444414|NCT04966260|OTHER|Control|This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
58444415|NCT04966260|OTHER|Personalized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
58444416|NCT06383416|OTHER|Neck pain by VAS|chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index.
58444417|NCT00406172|DRUG|Bevacizumab|
58444418|NCT00314964|DRUG|PD-0299685|
58444419|NCT03418636|BEHAVIORAL|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
58444420|NCT03418636|BEHAVIORAL|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
58444421|NCT04730856|DRUG|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
58444422|NCT03216408|DRUG|Neuronox|
58444423|NCT03216408|DRUG|Botox|
58444424|NCT02652351|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
57740818|NCT03204279|DRUG|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
58112237|NCT03111147|DEVICE|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
58112238|NCT01430182|DRUG|Methadone|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
58444425|NCT01744548|BEHAVIORAL|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
58444426|NCT03825302|DIAGNOSTIC_TEST|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
58444427|NCT03825302|DIAGNOSTIC_TEST|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
58444428|NCT04589442|BIOLOGICAL|Split thickness skin graft|standard of care graft
58444429|NCT04589442|BIOLOGICAL|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
58444430|NCT04311762|DRUG|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
58444431|NCT04736381|DRUG|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
57740819|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
58312584|NCT02576496|DRUG|Tinostamustine|
57740820|NCT02739581|PROCEDURE|Endoscopic Variceal Ligation|
57740821|NCT02739581|DRUG|Non selective beta blocker|
58312585|NCT04501900|DRUG|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
58312586|NCT03357757|DRUG|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
58112239|NCT01430182|DRUG|Morphine|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
57740822|NCT02739581|OTHER|Placebo|
57740823|NCT01495429|PROCEDURE|Central venous catheter|Placement of a peripherally inserted central venous catheter
57740824|NCT01495429|PROCEDURE|Central venous catheter|Placement of a centrally inserted central venous catheter
58112240|NCT00412815|BEHAVIORAL|Exercise training|
57740825|NCT03553810|DRUG|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
58312587|NCT03357757|BIOLOGICAL|Avelumab|10 mg/kg IV
58444432|NCT01793766|DEVICE|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
58444433|NCT01793766|DEVICE|Sham modulation|
58444434|NCT03028610|DEVICE|radiofrequency generator|
58444435|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
58444436|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
58444437|NCT04492501|PROCEDURE|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
58312588|NCT03252158|BEHAVIORAL|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
58312589|NCT00440843|DRUG|Olanzapine (Zyprexa)|OLZ
58312590|NCT00440843|DRUG|Typicals|Stay on typicals regimen
58312591|NCT00297401|DRUG|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
58312592|NCT00297401|DRUG|placebo|QD, PO, up to 8 weeks
58312593|NCT06132802|PROCEDURE|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
58112241|NCT01606137|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
57740826|NCT03553810|DRUG|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
58112242|NCT00468533|DRUG|Aripiprazole|
58444438|NCT04492501|BIOLOGICAL|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
57740827|NCT01914094|BEHAVIORAL|Prehab|
57740828|NCT05156918|OTHER|Exercise|Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
58112243|NCT06107088|DIETARY_SUPPLEMENT|Active 1|lactase enzyme
58444439|NCT04492501|DRUG|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level \> 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC \< 1000, Platelets \< 50, ALT or AST \> 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
57740829|NCT05156918|OTHER|Non Exercise|There are no modifications to regular diet or exercise habits for 30 days.
58112244|NCT06107088|DIETARY_SUPPLEMENT|Active 2|lactase-bacterial strain combination
58112245|NCT06107088|DIETARY_SUPPLEMENT|Active 3|bacterial strain alone
58112246|NCT06107088|DIETARY_SUPPLEMENT|Placebo|placebo
58112247|NCT03201471|DRUG|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
57740830|NCT02726451|OTHER|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
57740831|NCT02726451|OTHER|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
58112248|NCT01677910|DRUG|Telotristat etiprate|Telotristat etiprate tablets.
58112249|NCT01677910|DRUG|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
57740832|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.
58112250|NCT00877682|PROCEDURE|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
58112251|NCT02922114|OTHER|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
58112252|NCT06544577|DRUG|ELacestrant|345 mg/day once daily oral dosing
58112253|NCT03876756|OTHER|postpartum acute urinary retention|Collection of risk factors
58112254|NCT03876756|OTHER|no postpartum acute urinary retention|Collection of risk factors
58112255|NCT05175456|OTHER|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
58112256|NCT05175456|DEVICE|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
58112257|NCT04177810|DRUG|Cemiplimab|Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
58112258|NCT04177810|DRUG|Plerixafor|Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
58112259|NCT01501383|DRUG|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
58112260|NCT01501383|DRUG|Placebo|Matching placebo
58112261|NCT01501383|DRUG|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
58112262|NCT04725526|DEVICE|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
58112263|NCT03787485|BEHAVIORAL|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
58112264|NCT01875445|DRUG|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
58112265|NCT01875445|DRUG|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
58112266|NCT05767255|DRUG|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
58112267|NCT05767255|DRUG|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
58112268|NCT02454972|DRUG|lurbinectedin (PM01183)|
57740833|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.
57740834|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
57740835|NCT05652062|DEVICE|Prizvalve® system|Transcatheter valve-in-valve replacement
57740836|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
57740837|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
57740838|NCT06669169|DRUG|Jia Shen Tablet Placebo|Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
57740839|NCT06669169|DRUG|Low dose Jia Shen Tablet|Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
58112269|NCT01737177|DRUG|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
58444440|NCT04492501|DRUG|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT \> 5 times ULN and GFR \< 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
58444441|NCT04492501|BIOLOGICAL|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
58444442|NCT00648362|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fasting
58444443|NCT00648362|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fasting
57740840|NCT06669169|DRUG|High dose Jia Shen Tablet|High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
57740841|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
57740842|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
57740843|NCT02833168|OTHER|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
58444444|NCT00965575|DRUG|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
58444445|NCT00965575|DRUG|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
58444446|NCT02798978|DRUG|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
58444447|NCT02798978|DRUG|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
57740844|NCT02833168|DEVICE|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
57740845|NCT06701994|BEHAVIORAL|Innovative Kinesiotaping Bandage Group|This group will receive an innovative kinesiotaping bandage developed specifically for this study. The kinesiotape will be applied directly to the skin on the ankle, combining water resistance with restrictive properties to stabilise the joint while maintaining flexibility. Unlike traditional tape, the kinesiotape is designed to perform well in aquatic conditions, making it suitable for triathlon demands. It provides joint support while allowing a greater range of motion, aiming to enhance performance across all phases of the sport. To maintain blinding, the bandage will also be covered with an opaque stocking.
58444448|NCT02094651|DRUG|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
58444449|NCT02094651|OTHER|Placebo|The placebo is an inactive substance that looks like the active drug.
58444450|NCT01199224|DRUG|veliparib|veliparib formulation A
58444451|NCT01199224|DRUG|veliparib|veliparib formulation B
58444452|NCT01199224|DRUG|veliparib|veliparib formulation C
58444453|NCT01199224|DRUG|veliparib|veliparib formulation C
58444454|NCT04394065|DEVICE|ultrasensitive positron emission tomography|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
58444455|NCT05030168|DRUG|Ketosteril|ketoanalogues of essential amino acid
58444456|NCT03583970|DEVICE|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
58444457|NCT01511016|DRUG|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
58444458|NCT01511016|DRUG|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
58444459|NCT00241345|DRUG|Valganciclovir|
58444460|NCT00241345|DRUG|Ganciclovir|
58444461|NCT01940835|PROCEDURE|Upper endoscopy with small bowel biopsies and brushings.|
58444462|NCT01940835|OTHER|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
58444463|NCT01940835|OTHER|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
57740846|NCT06701994|BEHAVIORAL|Traditional Tape Bandage Group|Participants in this group will receive a traditional ankle bandage using functional tape. The bandage is applied directly to the skin and is designed to restrict ankle inversion and plantar flexion, providing stability to prevent recurrent injuries. Traditional tape bandages are widely used in sports due to their effective joint stabilisation. However, they have significant limitations in aquatic environments as they lack water resistance, which makes them less effective during the swimming phase of triathlons. The bandage will be covered with an opaque stocking to ensure blinding, preventing participants or evaluators from identifying the type of intervention.
57740847|NCT06701994|BEHAVIORAL|Placebo Bandage Group|Participants in this group will receive a placebo bandage consisting of a simple gauze wrap applied directly to the ankle. The gauze lacks stabilising or therapeutic properties and is used as a control to account for potential placebo effects. Although it mimics the application process of the other bandages, it does not provide functional or structural support to the ankle joint. An opaque stocking will cover the gauze to ensure that neither participants nor evaluators can distinguish the placebo bandage from the others, maintaining the integrity of the blinding process.
58444464|NCT06023706|DRUG|Capsaicin 179 Mg Cutaneous Patch|1 patch applied once for 1 hour
58444465|NCT06023706|DRUG|Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)|1 patch applied once for 1 hour
57740848|NCT00274638|DRUG|Telmisartan & Hydrochlorothiazide|
58444466|NCT01599013|DRUG|Vinflunine, Gemcitabine|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
58444467|NCT01599013|DRUG|Vinflunine, Carboplatin|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
58444468|NCT03826238|DIAGNOSTIC_TEST|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
58444469|NCT03410563|BEHAVIORAL|Auditory inputs|Three different auditory inputs
58444470|NCT00895115|DIETARY_SUPPLEMENT|vitamin E|Given once daily
58444471|NCT00895115|PROCEDURE|sham intervention|No supplementation
58444472|NCT01897363|OTHER|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
57740849|NCT00274638|DRUG|Losartan & Hydrochlorothiazide|
57740850|NCT00274638|PROCEDURE|ABPM|
57740851|NCT05956119|DEVICE|dry needling + physiotherapy (standard/usual care)|same that arm descrption
57740852|NCT05956119|OTHER|sham dry needling + physiotherapy (standard/usual care)|same that arm description
57740853|NCT02660827|DEVICE|Insulin Pump|Closed Loop Algorithm
57740854|NCT00260468|OTHER|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
58112270|NCT06285721|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
58112271|NCT06285721|DEVICE|Sham transcranial alternating current stimulation (tACS)|Sham-tACS is a form of non-effective stimulation which can mimic the subjective sensation of active tACS treatment. During sham-tACS, the device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.The sham-tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
58112272|NCT04479657|DRUG|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
58112273|NCT04479657|DRUG|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
58112274|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
58112275|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
58112276|NCT05716191|OTHER|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
58112277|NCT04797715|DRUG|AXS-05|AXS-05 tablets, taken twice daily
58112278|NCT04797715|DRUG|Placebo|Placebo tablets, taken twice daily
58444473|NCT05326646|DIETARY_SUPPLEMENT|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
58444474|NCT05211206|OTHER|IV fluids|Amount of intravenous fluids delivered
58444475|NCT03920943|OTHER|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
58444476|NCT05509426|BEHAVIORAL|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
58444477|NCT03654937|BIOLOGICAL|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB."
58444478|NCT00924248|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
58444479|NCT01789437|DEVICE|Dexamethasone Intravitreal Implant (Ozuredex)|
58444480|NCT03592368|DEVICE|IBT|Interpretation bias training
58444481|NCT00713544|DRUG|AZD5672|20 mg oral, once daily
58112279|NCT01308281|PROCEDURE|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
58112280|NCT01308281|PROCEDURE|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
58112281|NCT06382181|BEHAVIORAL|Music therapy for community-dwelling individuals with unwanted loneliness|Music therapy workshops were implemented. The enjoyment and expression of feelings were encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. There was one session per week. Total 12 sessions.
58112282|NCT06382181|BEHAVIORAL|Health education for community-dwelling individuals with unwanted loneliness|Twelve health education workshops were carried out. They included group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others.
58112283|NCT06382181|BEHAVIORAL|Physical exercise for community-dwelling individuals with unwanted loneliness|This intervention was implemented with 2 group sessions each week for 13 weeks. It included physical exercise adapted to the physical conditions of each participant.
58112284|NCT05949281|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
58112285|NCT05949281|DRUG|Placebo|Placebo tablet once-daily
58112286|NCT00754195|OTHER|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
58112287|NCT04562025|DRUG|UC-MSCs|3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
58112288|NCT04562025|DRUG|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
58112289|NCT02046785|OTHER|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
58112290|NCT05425108|DEVICE|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
58112291|NCT06252194|DRUG|Metformin and doxycycline|Metformin 500 mg tablet twice daily
58112292|NCT04716959|PROCEDURE|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
58444482|NCT00713544|DRUG|Etanercept|50 mg, subcutaneous injection, weekly
58112293|NCT04716959|PROCEDURE|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
58112294|NCT00752856|DRUG|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
58112295|NCT00752856|DRUG|Atripla|Atripla 1 tab once a day
58112296|NCT05605028|BEHAVIORAL|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
58112297|NCT05605028|OTHER|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
58112298|NCT06091774|DEVICE|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
58112299|NCT01402115|DIETARY_SUPPLEMENT|Polycan|polycan 150 mg/d for 12 weeks
58112300|NCT01402115|DIETARY_SUPPLEMENT|Placebo|Placebo 150mg/d for 12 weeks
58112301|NCT02023632|BEHAVIORAL|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
58444483|NCT00713544|DRUG|Placebo|placebo, oral, once daily
58444484|NCT00713544|DRUG|AZD5672|50 mg oral, once daily
58444485|NCT00713544|DRUG|AZD5672|100 mg oral, once daily
58444486|NCT00713544|DRUG|AZD5672|150 mg oral, once daily
58444487|NCT05546476|DRUG|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
58444488|NCT05546476|DRUG|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
58444489|NCT02398604|DRUG|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
58444490|NCT02398604|DRUG|Placebo|Placebo
58444491|NCT02737475|DRUG|BMS-986178|Specified dose on specified days
58444492|NCT02737475|DRUG|Nivolumab|Specified dose on specified days
58444493|NCT02737475|DRUG|Ipilimumab|Specified dose on specified days
58444494|NCT02737475|BIOLOGICAL|Tetanus vaccine|Specified dose on specified days
58444495|NCT02737475|BIOLOGICAL|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
58444496|NCT02737475|DRUG|Cyclophosphamide|Specified dose on specified days
58112302|NCT02023632|BEHAVIORAL|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
58112303|NCT02023632|BEHAVIORAL|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
58112304|NCT03763331|DEVICE|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
58112305|NCT03763331|DEVICE|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
58112306|NCT03812068|BEHAVIORAL|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
58112307|NCT03812068|BEHAVIORAL|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
58112308|NCT02123459|DRUG|Cephalexin|Administered orally
58112309|NCT01475669|BIOLOGICAL|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
58112310|NCT01475669|BIOLOGICAL|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
58112311|NCT04898985|DIAGNOSTIC_TEST|ImmunoSEQ|experiment assay
58112312|NCT02683733|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
58112313|NCT02683733|DRUG|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
58112314|NCT01025193|DRUG|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
58112315|NCT05585502|OTHER|Training (minute oscillation stretching)|The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
58112316|NCT02971410|OTHER|Laboratory Biomarker Analysis|Correlative studies
58112317|NCT02971410|OTHER|Quality-of-Life Assessment|Ancillary studies
58112318|NCT02971410|DRUG|Simvastatin|Given PO
58112319|NCT04890600|BEHAVIORAL|well-being assessment|exploration of emotional, cognitive and behavioural resources of healthcare professionals
58112320|NCT04873349|DIETARY_SUPPLEMENT|Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)|two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
58112321|NCT03215485|BEHAVIORAL|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
58112322|NCT03215485|BEHAVIORAL|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
58112323|NCT03215485|OTHER|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
58112324|NCT00354510|DRUG|GW842470X cream|
58112325|NCT03615456|PROCEDURE|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
58112326|NCT03615456|PROCEDURE|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
58112327|NCT00003102|BIOLOGICAL|Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)|cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.
58112328|NCT00739479|DIETARY_SUPPLEMENT|Weight Loss|Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
58312594|NCT06132802|PROCEDURE|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
58112329|NCT00334620|PROCEDURE|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
58112330|NCT03872960|PROCEDURE|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
58112331|NCT04639687|BEHAVIORAL|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
58112332|NCT03348046|DRUG|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
58112333|NCT04193059|DRUG|Paclitaxel|paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
58112334|NCT04193059|DRUG|Carboplatin|carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
58112335|NCT04193059|DRUG|Epirubicin|epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
58112336|NCT04193059|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
58112337|NCT04193059|DRUG|Trastuzumab|trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
58112338|NCT04193059|DRUG|Pertuzumab|pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
58112339|NCT04193059|DRUG|Docetaxel|docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
58112340|NCT00325494|DRUG|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
58112341|NCT05448859|PROCEDURE|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
58112342|NCT02081170|PROCEDURE|Autologous platelet concentrate|"1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery"
58112343|NCT02352740|DIETARY_SUPPLEMENT|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
58112344|NCT02352740|DIETARY_SUPPLEMENT|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
58444497|NCT02643238|DEVICE|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
58444498|NCT00991939|DRUG|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
57740855|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
57740856|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
57740857|NCT04432597|BIOLOGICAL|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
57740858|NCT04432597|DIAGNOSTIC_TEST|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
57740859|NCT04432597|DIAGNOSTIC_TEST|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
57740860|NCT04432597|DIAGNOSTIC_TEST|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
58112345|NCT04400695|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
58112346|NCT04400695|DRUG|Paclitaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
58112347|NCT04400695|DRUG|Docetaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
58112348|NCT04400695|DRUG|Vinorelbine Tartrate Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
58112349|NCT04400695|DRUG|Capecitabine Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
58112350|NCT04678453|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
58112351|NCT04582227|DEVICE|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
58112352|NCT00135642|BIOLOGICAL|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
58112353|NCT00135642|PROCEDURE|Venepuncture: 20 ml blood sample taken on 2 separate visits|
58112354|NCT05508451|PROCEDURE|Double jaw surgery|A type of orthognathic surgery
58112355|NCT01016860|DRUG|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
58112356|NCT01016860|DRUG|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
58112357|NCT03521999|BEHAVIORAL|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
58112358|NCT03521999|OTHER|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
58112359|NCT04086706|PROCEDURE|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
58444499|NCT00991939|DRUG|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
58444500|NCT04279535|DRUG|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
58444501|NCT05421481|OTHER|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
58444502|NCT03374371|DIAGNOSTIC_TEST|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
58444503|NCT01862913|OTHER|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
58444504|NCT01862913|OTHER|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
58444505|NCT02451020|OTHER|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
58444506|NCT03589261|DEVICE|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
57740861|NCT04432597|DIAGNOSTIC_TEST|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
57740862|NCT04432597|DIAGNOSTIC_TEST|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
57740863|NCT04432597|PROCEDURE|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
58112360|NCT01090128|DRUG|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
58112361|NCT01090128|DRUG|doxorubicin|50 mg/m2 every 3 weeks
58112362|NCT01090128|DRUG|cyclophosphamide|500 mg/m2 given every 3 weeks
58112363|NCT02059733|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
58112364|NCT02260765|DEVICE|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
58112365|NCT01882400|DRUG|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
58112366|NCT02232503|GENETIC|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
58112367|NCT03476447|OTHER|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
58112368|NCT03476447|OTHER|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
58112369|NCT00796484|DRUG|XL888|Administered orally
58444507|NCT04679974|BEHAVIORAL|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
58444508|NCT02440243|DRUG|Purethal|prerseasonal course of SCIT - three years
58444509|NCT02440243|DRUG|Purethal -placebo|preseasonal course of SCIT - three years
58444510|NCT00943930|DRUG|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
58444511|NCT05447208|DRUG|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
58444512|NCT05447208|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
58444513|NCT02473900|DRUG|HIP1403|Oseltamivir 75mg
58444514|NCT02473900|DRUG|HGP0919|Oseltamivir phosphate 75mg
58444515|NCT01736670|DRUG|Triamcinolone Acetonide spray|
58444516|NCT01736670|DRUG|Triamcinolone acetonide cream|
58444517|NCT01736670|DRUG|Alcohol spray|
58444518|NCT00832416|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
58444519|NCT00832416|DRUG|Placebo|One Placebo tablet daily.
58444520|NCT06280508|DRUG|Adebrelimab, Apatinib, Gemcitabine, cisplatin|Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
58444521|NCT02951494|OTHER|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
58444522|NCT02694302|DEVICE|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
58444523|NCT02694302|DEVICE|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
58112370|NCT06334926|OTHER|no intervention, retrospective data analysis|not applicable, retrospective data analysis
58444524|NCT02446717|DRUG|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
58444525|NCT02446717|DRUG|ribavirin (RBV)|Tablet
58444526|NCT02446717|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
58112371|NCT04200703|OTHER|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
58112372|NCT03681106|DEVICE|Kinesio Tex|Kinesio Tex tape on the operated limb
58112373|NCT02607761|OTHER|Video|Video-Audio Media
58112374|NCT01223196|DRUG|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
58112375|NCT01223196|DRUG|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
58444527|NCT02780284|BEHAVIORAL|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
58444528|NCT03316144|BIOLOGICAL|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
58444529|NCT01522300|OTHER|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
58444530|NCT01522300|OTHER|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
58444531|NCT05287828|OTHER|Surgeons CT scan analysis|Surgeons extract indicators using standard methods of analysis
58444532|NCT05287828|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed using PRAEVAorta Suite which is composed of the software PRAEVAorta 2 and PRAEVAorta Web. Indicators extraction is fully automatic.
58444533|NCT02607943|DRUG|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
58112376|NCT05824312|DRUG|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
58112377|NCT03909321|BEHAVIORAL|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
58112378|NCT00299585|PROCEDURE|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
58112379|NCT04211298|DRUG|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
58112380|NCT04211298|DRUG|Propofol|Propofol
58112381|NCT03213561|DEVICE|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
57740864|NCT04432597|PROCEDURE|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
57740865|NCT06302101|BEHAVIORAL|chair-based exercises|"Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises."
58112382|NCT02951663|DIETARY_SUPPLEMENT|Protein|
58112383|NCT01205698|OTHER|Nutritional drink|
58444534|NCT02607943|DRUG|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
58444535|NCT04713163|DRUG|covid19 vaccine|Vaccine
58112384|NCT00217412|DRUG|vorinostat|Given orally
58112385|NCT00217412|DRUG|isotretinoin|Given orally
57740866|NCT06302101|BEHAVIORAL|cognitive exercises|Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
58112386|NCT03251183|DIAGNOSTIC_TEST|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
58112387|NCT03251183|DIAGNOSTIC_TEST|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
58112388|NCT03251183|DIAGNOSTIC_TEST|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
58112389|NCT03251183|DIAGNOSTIC_TEST|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
58444536|NCT01709370|DRUG|Letrozole, PD 0332991|
57740867|NCT06672471|OTHER|No Post Operative Antibiotics for intervention group|No Post Operative Antibiotics in patients going clean contaminated head and neck surgery
57740868|NCT06672471|OTHER|Post Operative Antibiotics for one day|Control group will receive perioperative as well as post operative antibiotics for one day
57740869|NCT01018394|DRUG|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
57740870|NCT01018394|DRUG|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
57740871|NCT02301312|DEVICE|POSS-PCU vascular graft|New vascular access graft
57740872|NCT04996758|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
57740873|NCT05920551|OTHER|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
57740874|NCT05920551|OTHER|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
57740875|NCT06369389|OTHER|Patients eligible for CAR-T treatment|Patients eligible for CAR-T treatment for their hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
57956508|NCT04951037|BEHAVIORAL|Fully Asynchronous Online Savvy Program|"The intervention is a fully online, self-administered psychoeducational program designed to enhance caregiver mastery for family and friends providing unpaid care for living with Alzheimer's and similar dementia disorders. Participants will be asked to engage with a fully online version of Tele-Savvy for 42 days.~Participants will receive a series of daily video lessons related to caregiving. These lessons are generally 8-15 minutes in length and are emailed to participants. Participants can watch the lessons whenever and as often as they wish over the course of the study. There will also be self-guided learning strategies and exercises to accomplish skill and mastery related to the caregiving role. The lessons cover a variety of topics including:~* Facts about dementing Illnesses~* Caregiving Strategies - guiding the person through days that are as safe, calm, and pleasant as possible~* Self-Care for the Caregiver"
57956509|NCT05097456|DEVICE|carbon dioxide laser|carbon dioxide laser
57956510|NCT05097456|DEVICE|sham laser|sham laser
57956511|NCT00480610|DRUG|tacrolimus ointment|Topical application
57956512|NCT00480610|DRUG|Placebo ointment|Topical application
57956513|NCT06216665|OTHER|Continuous Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test
57956514|NCT06216665|OTHER|Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test
58112390|NCT03251183|DIAGNOSTIC_TEST|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
58112391|NCT05151978|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
58112392|NCT01492257|OTHER|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
58112393|NCT02102581|PROCEDURE|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
58112394|NCT01585233|DRUG|ASKP1240|Intravenous
58112395|NCT01585233|DRUG|Placebo|Intravenous
58112396|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
58112397|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
58112398|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
58112399|NCT04965220|DRUG|HLX 208|take orally
58112400|NCT05362058|DRUG|Insulin Efsitora Alfa|Administered SC
58112401|NCT05362058|DRUG|Insulin Degludec|Administered SC
58112402|NCT00798083|DRUG|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
58112403|NCT01577537|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
58444537|NCT00881114|DRUG|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
58444538|NCT00881114|DRUG|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
58444539|NCT00398840|DRUG|ARQ 171|
58444540|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
58444541|NCT01397461|DRUG|ozenoxacin placebo|cream
58444542|NCT01397461|DRUG|retapamulin 1% ointment|ointment
58444543|NCT01397461|DRUG|ozenoxacin 1% cream|1% cream
58444544|NCT01743443|OTHER|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
58444545|NCT05836168|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair|multispecies probiotic
57740876|NCT01952327|DEVICE|The pleurapump system|Implantation of the pleurapump system
58444546|NCT05836168|DIETARY_SUPPLEMENT|Placebo|Placebo
58112404|NCT01577537|DRUG|Placebo|Vaginal gel, daily for 7 days
58112405|NCT04450290|DEVICE|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
58444547|NCT03772262|DIETARY_SUPPLEMENT|goldenseal|Oral 500 mg capsules
58444548|NCT03772262|DRUG|Metformin|Oral solution
58112406|NCT00811200|DRUG|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
58112407|NCT00811200|DRUG|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
58444549|NCT03772262|DRUG|Furosemide|Oral solution
58444550|NCT03772262|DRUG|Midazolam oral solution|Oral syrup
58444551|NCT03772262|DRUG|Rosuvastatin Oral Tablet|Oral tablet
58444552|NCT04034004|BEHAVIORAL|Mindfulness|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
58444553|NCT04034004|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
58444554|NCT04034004|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
58444555|NCT04034004|BEHAVIORAL|Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
58444556|NCT06298136|BEHAVIORAL|mindfulness-based intervention|Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided
58444557|NCT06298136|BEHAVIORAL|child behavior management|worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
58444558|NCT03698227|DRUG|Olaratumab|iv infusion
58444559|NCT03698227|DRUG|Dexrazoxane|iv infusion
57740877|NCT05725317|DEVICE|LID220365 contact lens|Investigational delefilcon A spherical contact lens made with a modified manufacturing process
58444560|NCT03698227|DRUG|Doxorubicin|iv infusion
58444561|NCT03580681|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
58444562|NCT03580681|DIETARY_SUPPLEMENT|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
58444563|NCT02586623|DRUG|Droxidopa capsules|100, 200 or 300 mg
58444564|NCT02586623|DRUG|Placebo capsules|
58444565|NCT05980585|DEVICE|CPM Device|Daily use of the CPM wearable device
58444566|NCT03724929|PROCEDURE|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
57740878|NCT05725317|DEVICE|LID006961 contact lens|Commercially available delefilcon A spherical contact lens
57956515|NCT05547178|OTHER|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
57956516|NCT05547178|OTHER|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
57956517|NCT05547178|OTHER|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
58444567|NCT03724929|DEVICE|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
58444568|NCT03309423|DIAGNOSTIC_TEST|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
58444569|NCT02053636|DRUG|lucitanib|
58444570|NCT06051903|OTHER|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
58444571|NCT03357562|DEVICE|lung MRI|lung MRI without contrast injection
58444572|NCT02521922|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
58444573|NCT02521922|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
58444574|NCT00005617|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
58444575|NCT00005617|PROCEDURE|leukapheresis|Patients require a single leukapheresis to obtain 2x10\^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
57956518|NCT04734912|OTHER|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
57956519|NCT05860062|DIETARY_SUPPLEMENT|Vitamin D|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
58112408|NCT00811200|OTHER|sham|at baseline one sham-injection
58112409|NCT06440811|DRUG|SOX+PD-1 antibody|Patients would be allocated to the SOX+PD-1 antibody group.
58112410|NCT06440811|DRUG|FLOT+PD-1 antibody|Patients would be allocated to the FLOT+PD-1 antibody group
58112411|NCT00583596|DEVICE|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
58444576|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
58444577|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
58444578|NCT05981482|DIAGNOSTIC_TEST|OxVPS|Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
58312595|NCT05041686|COMBINATION_PRODUCT|CADISS® System|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2.~2. Reusable stainless steel noncutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
58312596|NCT06014645|OTHER|Rehabilitation|The study group will be given a core stabilization program in addition to education.
58444579|NCT05650281|OTHER|NO INTERVENTION|NO INTERVENTION
58444580|NCT01979952|DRUG|Matching Placebo|twice daily dosing
58444581|NCT01979952|DRUG|Nintedanib|gelating capsule
58444582|NCT04737018|OTHER|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
58444583|NCT04737018|OTHER|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
58444584|NCT04737018|OTHER|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
58444585|NCT04737018|OTHER|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
58444586|NCT04737018|OTHER|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
58444587|NCT04737018|OTHER|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
57956520|NCT05860062|OTHER|Calcium|3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
58112412|NCT00583596|OTHER|Objective Performance Criteria|Compare results of device closure to objective performance criteria
58112413|NCT00563303|DRUG|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
58444588|NCT04737018|DEVICE|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
58444589|NCT04737018|OTHER|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
58444590|NCT04737018|OTHER|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
58444591|NCT06407050|BEHAVIORAL|4 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
58444592|NCT06407050|BEHAVIORAL|8 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
58112414|NCT00563303|DRUG|NaCl|48mL from Day 1 to Day 6
58112415|NCT05357560|BIOLOGICAL|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
58112416|NCT01203683|BEHAVIORAL|Active computer-based training|8 sessions across 4 weeks.
58112417|NCT01203683|BEHAVIORAL|Inert computer training|8 sessions across 4 weeks.
58112418|NCT00194818|DRUG|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
58112419|NCT05692674|RADIATION|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
58312597|NCT06014645|OTHER|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
58312598|NCT01770964|DRUG|Pregabalin|
58312599|NCT01770964|DRUG|placebo|
58444593|NCT06407050|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
58112420|NCT06263309|DIAGNOSTIC_TEST|Femoral neck shortening measurement|We examine femoral neck shortening in patients with femoral neck fractures.
58112421|NCT04705909|DRUG|Pitavastatin|Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
58112422|NCT04705909|DRUG|placebo|patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
58112423|NCT03821324|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
58112424|NCT05752305|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
58112425|NCT05752305|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
58112426|NCT01928914|DRUG|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
58112427|NCT01928914|DRUG|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
58112428|NCT01928914|DRUG|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
58112429|NCT01928914|DRUG|moxifloxacin|moxifloxacine given on Day 3 only
58112430|NCT01928914|DRUG|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
58112431|NCT01928914|DRUG|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
58112432|NCT05823311|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
58112433|NCT05823311|DRUG|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
58112434|NCT00373685|DRUG|Celecoxib|open-label
58112435|NCT00373685|DRUG|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
58112436|NCT03052166|DEVICE|QT Ultrasound scan|QT Ultrasound scan
58112437|NCT03840811|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
58112438|NCT03840811|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
58112439|NCT03840811|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
58112440|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
58112441|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
58444594|NCT04656457|DEVICE|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
58444595|NCT04656457|OTHER|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
58444596|NCT06090565|DRUG|Cefixime|Two 400 mg tablets will be administered orally to equal a 800 mg dose.
58444597|NCT06090565|DRUG|Doxycyclin|One 100 mg tablet will be administered orally twice a day for 7 days
58444598|NCT06090565|DRUG|Ceftriaxon|Dose of 1 g intramuscular one time
58444599|NCT06090565|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 g dose.
58444600|NCT02517697|DRUG|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
58444601|NCT02517697|DRUG|Placebo|oral formulation of matching placebo three times daily for 12 weeks
58312600|NCT01770964|BEHAVIORAL|Training Type A|
58312601|NCT01770964|BEHAVIORAL|Training Type B|
58444602|NCT02759250|DRUG|ARGX-110|
58444603|NCT02134717|DRUG|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
58444604|NCT02134717|PROCEDURE|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
58444605|NCT02134717|PROCEDURE|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
58444606|NCT02134717|PROCEDURE|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
57956521|NCT05656924|DEVICE|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
57956522|NCT04828057|DRUG|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
57956523|NCT03579355|BEHAVIORAL|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
57956524|NCT01309074|DRUG|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
58312602|NCT03932708|BEHAVIORAL|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
58312603|NCT03912272|BEHAVIORAL|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
58312604|NCT03912272|BEHAVIORAL|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
57956525|NCT01309074|DRUG|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
58312605|NCT04202835|DRUG|Cyclophosphamide|Post Transplant Cyclophosphamide
58312606|NCT04202835|DRUG|Anti-Thymocyte globulin (rabbit)|Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
58312607|NCT00864318|DRUG|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
58444607|NCT00620724|DRUG|Placebo|Placebo three times daily
58312608|NCT00864318|DRUG|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
58312609|NCT00864318|DRUG|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
58312610|NCT00864318|DRUG|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
58444608|NCT00620724|DRUG|Nifedipine|20 mg of slow-release Nifedipine three times daily
58444609|NCT02770924|DEVICE|AT LISA TRI TORIC|phacoemulsification with IOL implantation
58444610|NCT02770924|DEVICE|AT LISA TRI|phacoemulsification with IOL implantation
58444611|NCT00891228|DRUG|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
58112442|NCT05844683|OTHER|2% chlorhexidine digluconate solution|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
58112443|NCT05844683|OTHER|usual baths|Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
58112444|NCT02982382|OTHER|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
58112445|NCT02982382|OTHER|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
58112446|NCT02982382|OTHER|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
58112447|NCT04746014|DIAGNOSTIC_TEST|Clearblue Pregnancy Test|Urine Pregnancy Test
58112448|NCT02383147|DEVICE|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
58112449|NCT02383147|DEVICE|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
58112450|NCT00373724|PROCEDURE|radiofrequency denervation|
58112451|NCT05881109|DRUG|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
58112452|NCT02141386|OTHER|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
58112453|NCT06286566|DEVICE|Implant placement with soi surface in diabetic subjects|Implants placement with SOI surface in subjects with diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
58112454|NCT06286566|DEVICE|Implant placement with soi surface in healthy subjects|Implants placement with SOI surface in subjects without diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
58444612|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
58444613|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
58112455|NCT01724970|DEVICE|ProSeal|Patients will be ventilated with PLMA
58112456|NCT01724970|DEVICE|Supreme LMA|Patients will be ventilated with SLMA
58112457|NCT06405776|DRUG|lidocaine|Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
58112458|NCT06405776|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
58312611|NCT00864318|PROCEDURE|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
58312612|NCT01697579|DRUG|Fosaprepitant|Administered intravenously (IV) as a single dose
58312613|NCT01697579|DRUG|Fosaprepitant Placebo|Administered IV as a single dose
58312614|NCT01697579|DRUG|Ondansetron|Administered IV according to local labeling and/or local standard of care
58312615|NCT01697579|DRUG|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
58312616|NCT01290328|DRUG|Epoetin Alfa|150 units/kg/weekly
58312617|NCT06406504|OTHER|in-laboratory simulation group|The students in-laboratory group performed the simulation applications in the patient room in the simulation laboratory. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
58312618|NCT06406504|OTHER|in-situ simulation group|Students in the in-situ simulation group performed the simulation practices in a patient room in a clinic at a university hospital. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
58312619|NCT03710954|DIAGNOSTIC_TEST|Experimental Group|All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
58312620|NCT03540459|DIAGNOSTIC_TEST|sleep polygraphy|sleep polygraphy (one night) in all included patients
58112459|NCT05551728|BEHAVIORAL|ESDM-informed caregiver coaching|The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
58112460|NCT01279642|DEVICE|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
58112461|NCT01279642|OTHER|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
58112462|NCT06530537|DRUG|Cilostazol|Cilostazol 100mg twice daily
58112463|NCT06530537|DRUG|Aspirin|Aspirin 100mg once daily
58112464|NCT05617820|DRUG|Estradiol|Vaginal Insert, 4 mcg tablet
58112465|NCT05617820|DRUG|Imvexxy|Estradiol 4 mcg Vaginal Insert
58112466|NCT05617820|DRUG|Placebo|Vehicle Vaginal Insert
58444614|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
58444615|NCT01388907|OTHER|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
58444616|NCT01388907|DEVICE|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
58112467|NCT05447585|DEVICE|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
58112468|NCT05447585|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
58112469|NCT03058939|DRUG|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
58112470|NCT03058939|DRUG|Perjeta|Only administered to patients with HER2-positive disease.
58112471|NCT03058939|DRUG|Herceptin SC|Only administered to patients with HER2-positive disease.
58112472|NCT03058939|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
58444617|NCT00224588|DRUG|Ketamine (or placebo : isotonic saline solution)|
58444618|NCT00306085|GENETIC|Autologous bone marrow cells|
58444619|NCT05431478|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
58112473|NCT03058939|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
58112474|NCT03058939|DRUG|LHRH agonist|Administered to all premenopausal patients.
58312621|NCT01582347|DRUG|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
58312622|NCT01582347|DRUG|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
58444620|NCT05431478|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
58444621|NCT05431478|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
58444622|NCT05651906|PROCEDURE|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
58444623|NCT03265236|DIAGNOSTIC_TEST|Anti - modified citrullinate vimentin|patients with early and late RA
58112475|NCT03058939|DRUG|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
58112476|NCT03058939|DRUG|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
58112477|NCT01748500|DRUG|Pantoprazole|
58112478|NCT03058536|DEVICE|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
58112479|NCT03058536|DRUG|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
58444624|NCT02083536|RADIATION|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
58444625|NCT02083536|DRUG|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
58444626|NCT03054649|DEVICE|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
57956526|NCT03442543|DEVICE|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
57956527|NCT01903512|PROCEDURE|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
57956528|NCT04956159|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
58444627|NCT03054649|PROCEDURE|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
58444628|NCT02837029|OTHER|Laboratory Biomarker Analysis|Correlative studies
58444629|NCT02837029|BIOLOGICAL|Nivolumab|Given IV
58444630|NCT02837029|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
58444631|NCT01420926|DRUG|Bortezomib|Given SC
58444632|NCT01420926|DRUG|Decitabine|Given IV
58112480|NCT03058536|OTHER|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
58112481|NCT01806597|BIOLOGICAL|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
57740879|NCT06059495|DRUG|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
57740880|NCT03547089|DEVICE|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
57740881|NCT04437654|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
57740882|NCT06213532|BEHAVIORAL|Smoking Cessation Intervention|Multimedia program administered either remotely or in person
57740883|NCT06213532|OTHER|Saliva Collection|Saliva samples will be collected from each participant
57740884|NCT06213532|OTHER|Survey Administration|Ancillary studies
57740885|NCT03595644|RADIATION|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
57956529|NCT04956159|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
58112482|NCT01806597|BIOLOGICAL|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
58444633|NCT01420926|OTHER|Laboratory Biomarker Analysis|Correlative studies
57740886|NCT03595644|DRUG|TKI|Received EGFR-TKI treatment
57740887|NCT06143826|OTHER|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
57956530|NCT03762759|PROCEDURE|Computed Tomography|Undergo PET/CT
57956531|NCT03762759|DRUG|Fluciclovine F18|Given IV
57956532|NCT03762759|RADIATION|Gallium Ga68-labeled PSMA-11|Given IV
57956533|NCT03762759|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57956534|NCT06141278|BEHAVIORAL|Care cascade intervention|Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
58112483|NCT01806597|BIOLOGICAL|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
58112484|NCT01017679|DRUG|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
58112485|NCT00800098|DRUG|herbal topical cream|
58112486|NCT02499354|DRUG|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
58444634|NCT01420926|OTHER|Pharmacological Study|Correlative studies
58444635|NCT01420926|OTHER|Quality-of-Life Assessment|Ancillary studies
58112487|NCT02499354|DRUG|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
58112488|NCT01432132|BEHAVIORAL|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
58112489|NCT01432132|BEHAVIORAL|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
58112490|NCT02159859|DRUG|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
58112491|NCT05087394|OTHER|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
58112492|NCT05842395|DRUG|Vitamin C|Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.
58112493|NCT05842395|DRUG|Placebo|Participants with distal radius fractures will take daily Placebo orally for three months.
58444636|NCT01420926|OTHER|Questionnaire Administration|Ancillary studies
58444637|NCT01440855|OTHER|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
58444638|NCT01440855|OTHER|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
58444639|NCT05001204|DRUG|68Ga-NOTA-RM26|68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
58444640|NCT05984043|BEHAVIORAL|Biofeedback|Heart-rate Variability Biofeedback
58444641|NCT05984043|OTHER|Waitlist|Waitlist control group
58444642|NCT00646425|DRUG|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
57956535|NCT05779826|OTHER|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
58112494|NCT00852085|BEHAVIORAL|Enhanced community service|Two educational sessions and volunteering at a local community service site
58112495|NCT00852085|BEHAVIORAL|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
58112496|NCT01690065|DRUG|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
58112497|NCT03676374|DRUG|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
58112498|NCT03676374|DRUG|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
58112499|NCT04274192|OTHER|Synchronized HFNC at 6 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
58112500|NCT04274192|OTHER|Continuous HFNC at 6 liters per minute (LPM)|Standard HFNC therapy at 6 LPM
58112501|NCT04274192|OTHER|Synchronized HFNC at 8 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
58112502|NCT04274192|OTHER|Continuous HFNC at 8 liters per minute (LPM)|Standard HFNC therapy at 8 LPM
58112503|NCT04383002|DRUG|Nitric Oxide|iNO will be given at 160ppm for 6 hours, once a day, for 2 days
58112504|NCT00950833|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
58112505|NCT04434859|OTHER|No intervention|No intervention
58112506|NCT02947932|DRUG|Resveratrol|pre-ERCP intervention
58112507|NCT02947932|DRUG|Indomethacin|post-ERCP intervention in high risk patients
58444643|NCT00646425|DRUG|Placebo|Placebo to match basiliximab
58444644|NCT03734003|DEVICE|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
58444645|NCT03734003|DEVICE|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
58444646|NCT03237793|PROCEDURE|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
58112508|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
58112509|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
58112510|NCT04189276|BIOLOGICAL|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
58112511|NCT04189276|BIOLOGICAL|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
58112512|NCT05077852|DIAGNOSTIC_TEST|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
58112513|NCT02212431|DRUG|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
58112514|NCT02580578|OTHER|No Intervention|No intervention is administered in this study.
58112515|NCT03154528|DIAGNOSTIC_TEST|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
58112516|NCT02158910|DRUG|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
58444647|NCT03237793|PROCEDURE|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
58444648|NCT06114186|DEVICE|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
58444649|NCT06114186|OTHER|standard of care|self reported HbA1C or GMI
58444650|NCT05961657|DIAGNOSTIC_TEST|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
57956536|NCT01707472|BIOLOGICAL|Simtuzumab|700 mg intravenously for a total of 12 infusions.
57956537|NCT02298764|OTHER|Standard back pain treatment|Standard back pain treatment
58112517|NCT01893866|DRUG|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
58112518|NCT01893866|DRUG|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
58112519|NCT04898725|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 4800IU daily
58112520|NCT02785133|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
58112521|NCT02785133|DRUG|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
58112522|NCT02785133|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
58112523|NCT01074021|DRUG|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
58444651|NCT06532084|DRUG|Sorafenib|Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
58444652|NCT00921791|DEVICE|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
58444653|NCT00921791|DEVICE|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
58444654|NCT00921791|BEHAVIORAL|Pharmaceutical care|consultations with the pharmacists
57956538|NCT02298764|OTHER|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
57956539|NCT04063371|OTHER|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
58444655|NCT00921791|OTHER|Usual care|Consultation with the physician.
58444656|NCT03811314|DEVICE|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
57956540|NCT04063371|OTHER|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
57956541|NCT04204252|DRUG|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
57956542|NCT04204252|DRUG|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
58444657|NCT03811314|DEVICE|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
58444658|NCT03811314|DEVICE|Isokinetic trinaing|Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second
57956543|NCT05873244|DRUG|Zabadinostat (CXD101) and Geptanolimab|"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
58444659|NCT03811314|DEVICE|Isotonic training|Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
58444660|NCT01902329|DRUG|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
58444661|NCT01902329|DRUG|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
58444662|NCT03948334|DRUG|ZPL389 30mg|30mg of ZPL389; once daily
57956544|NCT05873244|DRUG|Lenvatinib and Sorafenib|"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
57956545|NCT00783094|DRUG|Tadalafil 2.5 mg|oral, daily
57956546|NCT00783094|DRUG|Tadalafil 5 mg|oral, daily
57956547|NCT00783094|DRUG|Placebo|oral, daily
57956548|NCT01731652|DRUG|TMX-101|
58444663|NCT03948334|DRUG|ZPL389 50mg|50mg of ZPL389; once daily
58444664|NCT03948334|DRUG|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
58444665|NCT05692544|PROCEDURE|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
58444666|NCT04577469|DRUG|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
58444667|NCT04577469|DRUG|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
58444668|NCT01648972|DRUG|Gastrografin|
58444669|NCT01648972|DRUG|Placebo|
58444670|NCT00464503|DRUG|Rosuvastatin-Crestor|
58444671|NCT00464503|DRUG|Pravastatin-Pravasine|
58112524|NCT01074021|DRUG|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
58112525|NCT03741218|OTHER|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
58112526|NCT03645083|BEHAVIORAL|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
58112527|NCT03645083|BEHAVIORAL|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
58112528|NCT03982056|OTHER|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
58312623|NCT01582347|DRUG|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
58444672|NCT02984917|PROCEDURE|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
58444673|NCT02984917|PROCEDURE|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
58444674|NCT02039284|DEVICE|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
58312624|NCT01582347|DRUG|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
57956549|NCT04640883|BEHAVIORAL|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (\>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.
58312625|NCT01031082|PROCEDURE|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
58444675|NCT02039284|DEVICE|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
57956550|NCT04640883|BEHAVIORAL|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (\>four hours per session), distance-matched to sprint group.
58444676|NCT02039284|DEVICE|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
58444677|NCT02039284|DEVICE|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
58444678|NCT01919229|DRUG|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
57740888|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
58112529|NCT04246970|OTHER|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
58112530|NCT04246970|OTHER|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
58112531|NCT02770716|DRUG|Terlipressin|Terlipressin solution for injection
58112532|NCT02770716|OTHER|Placebo|Matching placebo solution for injection
58112533|NCT05527210|DIETARY_SUPPLEMENT|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
58112534|NCT05527210|DIETARY_SUPPLEMENT|Placebo Prebiotic|Placebo prebiotic mixed into water
58112535|NCT00123383|DRUG|Modafinil|
58112536|NCT05631899|BIOLOGICAL|KRAS-EphA-2-CAR-DC|5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.
58112537|NCT05631899|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
58112538|NCT05631899|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
58112539|NCT05631899|DRUG|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
58112540|NCT05631899|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
58112541|NCT05443490|DIETARY_SUPPLEMENT|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10\^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
58112542|NCT05443490|OTHER|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
58112543|NCT03492983|DIETARY_SUPPLEMENT|Intervention group|10 g/day of high cocoa content chocolate for six months.
58112544|NCT02040428|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|
58112545|NCT02040428|BIOLOGICAL|Topical hemostat|
58444679|NCT01919229|DRUG|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
57956551|NCT04640883|BEHAVIORAL|Recovery for 10 days (low training load)|Habitual low-intensity cycling (\>0.5-2 hours per session)
57956552|NCT03826732|BEHAVIORAL|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
57956553|NCT02965495|DRUG|YYD302 2ml|YYD302 2ml
57956554|NCT02965495|DRUG|YYD302 3ml|YYD302 3ml
57956555|NCT02965495|DRUG|Placebo 3ml|phosphate buffered saline 3ml
57956556|NCT01368835|DEVICE|Ulthera treatment|treatment of cheeks and upper neck area of face
57956557|NCT04590092|DEVICE|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
57956558|NCT02686515|DEVICE|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
57956559|NCT02686515|DEVICE|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
58112546|NCT05567757|BIOLOGICAL|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
58112547|NCT01521728|OTHER|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
58112548|NCT01521728|OTHER|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
58112549|NCT01521728|OTHER|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
58112550|NCT06253468|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
58112551|NCT04967716|OTHER|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
58112552|NCT04967716|OTHER|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
58112553|NCT06286839|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L.
58112554|NCT01360450|DRUG|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.
58444680|NCT02097030|DEVICE|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
58112555|NCT01360450|DRUG|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
58112556|NCT02468557|DRUG|Idelalisib|Tablets administered orally twice daily
58112557|NCT02468557|DRUG|Nab-paclitaxel|125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
58112558|NCT02468557|DRUG|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
58112559|NCT04868409|DRUG|Suxamethonium|1 mg/kg for tracheal intubation after 60 seconds
58112560|NCT04868409|DRUG|Rocuronium|1 mg/kg for tracheal intubation after 60 seconds
58312626|NCT03539510|BEHAVIORAL|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
58312627|NCT04937868|OTHER|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
58312628|NCT05489042|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
58312629|NCT05489042|DEVICE|sham rTMS|5 sessions of sham rTMS
58312630|NCT04581915|DRUG|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
58312631|NCT04581915|OTHER|Placebo|Placebo capsule
58312632|NCT05033132|DRUG|Balstilimab|Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
58312633|NCT05033132|DRUG|Balstilimab + Zalifrelimab|An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
58312634|NCT02902926|BEHAVIORAL|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
58312635|NCT02902926|BEHAVIORAL|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
58312636|NCT03555799|DIAGNOSTIC_TEST|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
58312637|NCT03527264|DRUG|Nivolumab induction|2 doses Nivolumab 240mg IV
58312638|NCT03527264|DRUG|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
58312639|NCT03527264|RADIATION|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
58312640|NCT03527264|DRUG|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
58312641|NCT03527264|DRUG|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
58312642|NCT03752892|OTHER|intervention -1-leg cycle training|partitioned aerobic exercise training
58312643|NCT03752892|OTHER|usual care - 2-leg cycle training|conventional aerobic exercise training
58312644|NCT00128063|DRUG|succinylated human serum albumin|
58312645|NCT05793658|PROCEDURE|Standard capnography|Patients undergoing colonoscopy under sedation were randomly assigned to receive standard capnography monitoring or modified capnography monitoring which can be achieved by tucking capnography probe under the face mask.74 patients were enrolled. Patient characteristics were well balanced between the two groups 37 patients in each group.
57956560|NCT03127371|DRUG|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
58112561|NCT04573400|OTHER|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
58112562|NCT01907737|OTHER|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
58112563|NCT01907737|OTHER|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
58112564|NCT01907737|OTHER|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
58112565|NCT01907737|OTHER|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
58112566|NCT05863988|OTHER|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
58112567|NCT05863988|OTHER|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
58112568|NCT00571922|DRUG|Acamprosate|2 gr/day (333 mg, TID)
58112569|NCT00571922|DRUG|placebo|matching placebo
58112570|NCT04398394|DEVICE|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
58112571|NCT03676023|DRUG|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
58112572|NCT02763579|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
58112573|NCT02763579|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
58444681|NCT02097030|DEVICE|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
58112574|NCT02763579|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
58112575|NCT02763579|DRUG|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
58112576|NCT05776966|BEHAVIORAL|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
58112577|NCT05776966|OTHER|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
58112578|NCT01779947|DRUG|Estradiol Vaginal Tablets 10 mcg|
58112579|NCT01779947|DRUG|placebo|
58112580|NCT02381509|DEVICE|IVC Filter|
58112581|NCT05779319|DEVICE|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
58112582|NCT04202900|OTHER|phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
58112583|NCT06524024|BIOLOGICAL|Tumor polypeptide pool induced DC-CTL cell injection|In this study, DC-CTL cells were injected once a day for two consecutive days, 1-2 days after study participants received a conventional antitumor regimen, and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells. A total of about 4-6 cycles of cell infusion are required
58112584|NCT03818490|OTHER|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
58112585|NCT02539095|DEVICE|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
58444682|NCT02097030|DEVICE|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
57740889|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
58444683|NCT00036634|DRUG|Tenofovir DF|Tenofovir DF tablet administered orally once daily
58444684|NCT00036634|DRUG|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
58444685|NCT03499314|DEVICE|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
58444686|NCT03499314|DEVICE|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
58112586|NCT02539095|DEVICE|Normal saline|"1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
58112587|NCT03717610|PROCEDURE|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
58112588|NCT02373475|OTHER|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
57740890|NCT03166761|DRUG|Dexamethasone|Dexamethasone injection into the sacroiliac joint
58112589|NCT02373475|OTHER|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
58112590|NCT04022070|OTHER|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
58112591|NCT02532777|DRUG|Prednisone|
58112592|NCT02532777|DRUG|Cyclophosphamide(CTX)|
58112593|NCT02532777|DRUG|Mycophenolate mofetil(MMF)|
58112594|NCT02532777|DRUG|Leflunomide(LEF)|
58112595|NCT02532777|DRUG|Angiotensin-converting enzyme inhibitor(ACEI)|
58112596|NCT02532777|DRUG|Methylprednisolone|
58112597|NCT00900809|BIOLOGICAL|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
58112598|NCT04422847|DEVICE|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
58112599|NCT01190306|DEVICE|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
58112600|NCT01190306|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
57740891|NCT03166761|DRUG|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
57740892|NCT02187991|DRUG|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
57740893|NCT02187991|DRUG|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
57740894|NCT02161133|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
57740895|NCT02161133|BEHAVIORAL|Health Education|Health Education provides didactic information about Gulf War Illness
57740896|NCT06128109|DEVICE|Thioderm Strong|Test Device
57740897|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
58112601|NCT06542042|DIAGNOSTIC_TEST|NAS, NGS and Laboratory tests|Using three diffrent detection methods and comparing their efficiency
58112602|NCT03575429|BEHAVIORAL|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
58312646|NCT05793658|PROCEDURE|Modified capnography|If Respiratory rate below 14 b/m: more sedation isn't not advised and the patient may develop airway obstruction and needs airway intervention ( like jaw thrust or oral airway) If respiratory rate more than 20 b/m it means this patient is prone to awake or to move and this patient in need for incremental dose of sedative drug ( e.g 20 to 30 mg propofol) Also roughly speaking respiratory rate from 16 to 18 b/m is the target
58312647|NCT00576082|OTHER|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
58312648|NCT02253264|DRUG|Rituximab|
57740898|NCT06269770|DRUG|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
57740899|NCT06269770|DRUG|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
57740900|NCT03711773|OTHER|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
57740901|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
57740902|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
58112603|NCT03575429|BEHAVIORAL|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
58112604|NCT00162383|DRUG|Debrisoquine|
58112605|NCT00162383|DRUG|Mephenytoin|
58112606|NCT00162383|DRUG|Dapsone|
58112607|NCT00162383|DRUG|Caffeine|
57740903|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
57740904|NCT01443481|DRUG|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
57740905|NCT06473896|DRUG|Ketalar|a dissociative anesthetic used medically for induction and maintenance of anesthesia
58112608|NCT00623025|DRUG|Creon 25000|6 to 9 capsules Creon 25000 per day
58112609|NCT00623025|DRUG|Placebo|6 to 9 capsules placebo per day
58112610|NCT02934269|DRUG|Placebo|
58112611|NCT02934269|DRUG|CC-90006|
58112612|NCT02793063|OTHER|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
58112613|NCT03202628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
58112614|NCT03202628|DRUG|Dexamethasone|Given PO
58112615|NCT03202628|DRUG|Ixazomib Citrate|Given PO
58112616|NCT03202628|OTHER|Laboratory Biomarker Analysis|Correlative studies
58112617|NCT03202628|DRUG|Pomalidomide|Given PO
58112618|NCT03740100|DRUG|Bimiralisib|Bimiralisib capsules
58112619|NCT05803278|OTHER|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
58112620|NCT01849939|DRUG|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
58112621|NCT06267599|PROCEDURE|ACAR-Style Bladder Suture|In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
58112622|NCT03724721|PROCEDURE|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
58444687|NCT03499314|OTHER|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
58444688|NCT03887273|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
58444689|NCT03529968|PROCEDURE|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
58112623|NCT01998685|DRUG|Propofol|
58112624|NCT01998685|DRUG|remifentanyl|
58112625|NCT01998685|DRUG|Midazolam|
58112626|NCT01998685|DRUG|Fentanyl|
58112627|NCT01998685|DRUG|Sevoflurane|
58112628|NCT04256993|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
58112629|NCT04256993|DRUG|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
58112630|NCT03158428|OTHER|CSD170202AA|A moist snuff product
58112631|NCT03158428|OTHER|CSD170202AB|A moist snuff product
58112632|NCT03899337|DRUG|Acalabrutinib|100mg capsule, PO, BD
58112633|NCT03899337|DRUG|Cyclophosphamide|750mg/m\^2, IV bolus
58112634|NCT03899337|DRUG|Doxorubicin|50mg/m\^2, IV bolus
58112635|NCT03899337|DRUG|Vincristine|1.4mg/m\^2, IV infusion
58112636|NCT03899337|DRUG|Prednisolone|40mg/m\^2, PO, OD
58112637|NCT03899337|DRUG|Rituximab|375mg/m\^2, IV infusion
57956561|NCT03127371|DRUG|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
58112638|NCT01129154|DRUG|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
58112639|NCT04421794|DEVICE|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
58112640|NCT04421794|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
58112641|NCT05806333|DIAGNOSTIC_TEST|FAPI PET|Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
58112642|NCT00213954|PROCEDURE|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
57740906|NCT06473896|DRUG|Dexmedetomidine|an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
57740907|NCT03717896|DRUG|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
57740908|NCT03717896|DRUG|Placebo|50mL 0.9% saline
57740909|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
57740910|NCT00435773|PROCEDURE|Single Leeching|
57740911|NCT00435773|PROCEDURE|Repeated Leeching after 4 weeks|
57956562|NCT05393609|PROCEDURE|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
57956563|NCT05393609|DIETARY_SUPPLEMENT|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
58112643|NCT00650559|PROCEDURE|Chest wall enlargement|Widening sternotomy
58112644|NCT02393534|OTHER|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
58112645|NCT06226454|DRUG|VX-993|Suspension for oral administration.
58112646|NCT06226454|DRUG|Placebo|Suspension for oral administration.
58112647|NCT01357356|DRUG|SER120 (750 ng/day)|
58112648|NCT01357356|DRUG|SER120 (1000 ng/day)|SER120 (1000 ng/day)
58112649|NCT01357356|DRUG|SER120 (1500 ng/day)|
58112650|NCT01357356|DRUG|Placebo|
58112651|NCT00007241|DEVICE|Isometric exercise|
58112652|NCT02619994|DRUG|Linezolid|
58112653|NCT02619994|DRUG|Delamanid|
58112654|NCT02619994|DRUG|Levofloxacin|
58112655|NCT02619994|DRUG|Pyrazinamide|
58112656|NCT02619994|DRUG|Locally-used WHO-approved MDR-TB regimen in Korea|
58112657|NCT04605952|DIAGNOSTIC_TEST|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
58112658|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
58112659|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
58112660|NCT06016933|DRUG|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
58112661|NCT06016933|PROCEDURE|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
58112662|NCT05774106|BEHAVIORAL|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
57740912|NCT00435773|PROCEDURE|Placebo Leeching|
57956564|NCT02393729|BEHAVIORAL|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour"
57740913|NCT01983748|BIOLOGICAL|Autologous Dendritic Cells loaded with autologous Tumor RNA|
57740914|NCT03923348|DEVICE|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
57740915|NCT04877522|DRUG|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
57740916|NCT04877522|DRUG|Imatinib|Taken orally, once daily, in the morning with low-fat meal
57740917|NCT04877522|DRUG|Nilotinib|Taken orally, twice daily, on an empty stomach
57740918|NCT04877522|DRUG|Bosutinib|Taken orally, once daily, with food
57740919|NCT04877522|DRUG|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
57956565|NCT02393729|OTHER|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
57956566|NCT03718507|DRUG|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
57956567|NCT03718507|DRUG|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
57956568|NCT04100330|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
57956569|NCT04100330|DRUG|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
57956570|NCT03713944|DRUG|Carboplatin|Carboplatin, AUC 5
57956571|NCT03713944|DRUG|Pemetrexed|Pemetrexed 500mg/m2
57956572|NCT03713944|DRUG|Atezolizumab|Atezolizumab 1200mg
57740920|NCT06171191|BEHAVIORAL|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
58112663|NCT05907395|DRUG|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
58112664|NCT05907395|DRUG|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
57740921|NCT05707533|PROCEDURE|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
58112665|NCT00003966|DRUG|defibrotide|
58112666|NCT03985501|OTHER|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
58112667|NCT02528578|DEVICE|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
58112668|NCT02528578|OTHER|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
58112669|NCT05446090|DIAGNOSTIC_TEST|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
57740922|NCT06095726|BEHAVIORAL|Peppermint Inhalation|The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
57740923|NCT06095726|BEHAVIORAL|Swedish Massage|Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
57956573|NCT03713944|DRUG|Bevacizumab|Bevacizumab 15mg/kg
57956574|NCT02833103|DRUG|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
57956575|NCT02833103|DRUG|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
57956576|NCT01680900|DRUG|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
58112670|NCT05446090|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
58112671|NCT05446090|DIAGNOSTIC_TEST|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
58312649|NCT06393231|OTHER|acupuncture|Acupuncture is applied to ST8, GB14, BL12, SJ23, ST2, SI18, ST4, ST7, RN24, Ex-HN16, SJ17 and LI4 on the affected side and needles are retained for half an hour.Add infrared irradiation therapy in the same time
58312650|NCT01879267|BEHAVIORAL|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
57956577|NCT01680900|DRUG|placebo capsules|placebo capsules matched to drug capsules.
57956578|NCT01280136|BEHAVIORAL|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game...Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
58112672|NCT05446090|PROCEDURE|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
58112673|NCT05446090|DIAGNOSTIC_TEST|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
58112674|NCT05446090|DIAGNOSTIC_TEST|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
58112675|NCT05446090|DIAGNOSTIC_TEST|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
58112676|NCT05446090|DIAGNOSTIC_TEST|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
58112677|NCT05446090|DIAGNOSTIC_TEST|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
58312651|NCT05081687|DRUG|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
58444690|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
58444691|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
58444692|NCT04800601|OTHER|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
58444693|NCT04800601|OTHER|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
57740924|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
57740925|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
57740926|NCT05888636|OTHER|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
57740927|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
57956579|NCT06454253|DEVICE|Da Vinci Robot Surgical System|Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system
57956580|NCT03691792|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
57740928|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
57740929|NCT04617639|BEHAVIORAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
57740930|NCT04617639|BEHAVIORAL|Standard care|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
57740931|NCT04617639|BEHAVIORAL|Observation group|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
57956581|NCT03691792|OTHER|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
57956582|NCT01686620|DRUG|BIOD-123|
57956583|NCT01686620|DRUG|Lispro (Humalog)|
57740932|NCT05817695|DEVICE|Leadless pacemaker|To observe the effect of pacemaker implantation at different sites on cardiac synchronization and tricuspid regurgitation
57740933|NCT03948568|COMBINATION_PRODUCT|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
57740934|NCT04301778|DRUG|Durvalumab|"1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV"
57956584|NCT02294240|DIETARY_SUPPLEMENT|Energy dense biscuits|Energy dense biscuits will be provided
57956585|NCT02294240|OTHER|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
58444694|NCT02722200|DRUG|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
58444695|NCT02722200|OTHER|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
58444696|NCT01456169|DRUG|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
58444697|NCT01456169|DRUG|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
58444698|NCT01199809|DRUG|Placebo|multiple doses
58444699|NCT01199809|DRUG|RO5310074|multiple ascending doses
58444700|NCT00756431|DEVICE|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
58444701|NCT00756431|DEVICE|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
58444702|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
57740935|NCT04301778|DRUG|SNDX-6352|"1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV"
57956586|NCT00810979|DRUG|SLx-4090|tablet
57956587|NCT00810979|DRUG|SLx-4090|tablet
58444703|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
58444704|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
58444705|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
58444706|NCT04875052|DEVICE|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
58444707|NCT04875052|DEVICE|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
57740936|NCT00146575|DEVICE|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
57740937|NCT00146575|DEVICE|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
57740938|NCT00558428|DRUG|fixed dose combination of telmisartan+amlodipine|
57740939|NCT00558428|DRUG|amlodipine|
57740940|NCT03681158|DRUG|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
57740941|NCT02196649|DEVICE|Endoscopic Clip|
57956588|NCT00810979|OTHER|Placebo|matching tablet
57956589|NCT00810979|DRUG|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
57956590|NCT00896376|BIOLOGICAL|trastuzumab|
57956591|NCT00896376|OTHER|laboratory biomarker analysis|
57956592|NCT00896376|OTHER|pharmacological study|
57956593|NCT01858181|BIOLOGICAL|ocaratuzumab|
57956594|NCT05087069|DRUG|BV100|Rifabutin for Infusion
57956595|NCT05087069|DRUG|Placebo|Saline intravenous infusion
57956596|NCT05331014|DRUG|LivaloVA|For 8 weeks(PO, QD)
57956597|NCT05331014|DRUG|LivaloV|For 8 weeks(PO, QD)
57956598|NCT05331014|DRUG|VA|For 8 weeks(PO, QD)
57956599|NCT00164294|BEHAVIORAL|Brief intervention|
57956600|NCT00874978|DRUG|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
57956601|NCT00334022|DRUG|enfuvirtide|1ml BID
57956602|NCT06425003|DRUG|[14C] ABBV-CLS-7262|Oral Solution
58444708|NCT04875052|OTHER|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
58112678|NCT05446090|OTHER|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
58112679|NCT05446090|OTHER|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
58112680|NCT05446090|OTHER|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
58112681|NCT05446090|OTHER|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
58112682|NCT05446090|OTHER|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
58112683|NCT05446090|OTHER|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
57740942|NCT05427461|OTHER|Blood samples will be collected at different times.|"For patients with localized leiomyosarcoma, samples will be collected:~* At Baseline.~* Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).~* After surgery.~* At each control visit.~* At local or metastatic recurrence (or at 24 months post inclusion if no progression).~For patients with metastatic leiomyosarcoma, samples will be collected:~* At Baseline.~* At each therapeutic line.~* At progression (or at 24 months post inclusion if no progression)."
57740943|NCT03249519|RADIATION|Radiation|50.4 Gy
57740944|NCT03249519|RADIATION|brachytherapy|35-40 Gy
57740945|NCT03249519|DRUG|Cisplatin|weekly 40 mg/m\^2 (6cycles)
57740946|NCT03249519|OTHER|Hyperthermia|10 times
57740947|NCT00323596|BEHAVIORAL|physical activity program of strength and balance retraining|
57740948|NCT06025565|DIAGNOSTIC_TEST|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
57956603|NCT02566746|DEVICE|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
57956604|NCT02566746|DRUG|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
58112684|NCT05446090|OTHER|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
58112685|NCT05446090|OTHER|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
58312652|NCT02982759|BEHAVIORAL|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
57740949|NCT02541708|DRUG|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
57740950|NCT02541708|DRUG|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
57740951|NCT02858895|DRUG|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
57740952|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
57740953|NCT03584451|BEHAVIORAL|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
57740954|NCT01900938|PROCEDURE|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
58312653|NCT02982759|BEHAVIORAL|Genetic Newsletters|The comparison will receive generic newsletters
58312654|NCT02991807|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
57740955|NCT01900938|PROCEDURE|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
57740956|NCT01900938|DRUG|Midazolam|
57740957|NCT01900938|DRUG|Propofol|
57740958|NCT01190592|OTHER|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
57740959|NCT05065866|DRUG|BMS-986345|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
57740960|NCT05065866|DRUG|Duvelisib|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
57740961|NCT03818672|DRUG|Rifaximin|Rifaximin 550 MG BID
57740962|NCT04110769|DIAGNOSTIC_TEST|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
58112686|NCT03607006|PROCEDURE|Patient specific PEEK sheets|Computer aided sheet design
58112687|NCT03607006|PROCEDURE|Autogenous bone shell|autogenous retromolar/chin bone graft
58112688|NCT02287337|PROCEDURE|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
58112689|NCT02287337|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
58112690|NCT03047382|OTHER|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
58112691|NCT06526897|PROCEDURE|Biopsy|Undergo biopsy
58112692|NCT06526897|PROCEDURE|Chest Computed Tomography|Undergo chest CT
58112693|NCT06526897|PROCEDURE|Chest Radiography|Undergo CXR
58112694|NCT06526897|OTHER|Quality-of-Life Assessment|Ancillary studies
58112695|NCT06526897|OTHER|Questionnaire Administration|Ancillary studies
58112696|NCT05148546|DRUG|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
58112697|NCT05148546|DRUG|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
58112698|NCT05148546|DRUG|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
58112699|NCT06270030|DRUG|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
58112700|NCT06270030|DRUG|LNZ100 (Aceclidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
58112701|NCT06270030|DRUG|Placebo (Vehicle) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
58112702|NCT05141578|BEHAVIORAL|Luci Coach Assisted Intervention|"The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24."
58112703|NCT04119583|DEVICE|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
57740963|NCT04110769|DIAGNOSTIC_TEST|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
58112704|NCT04119583|OTHER|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
58112705|NCT04119583|OTHER|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
58112706|NCT01244815|DRUG|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
58112707|NCT01244815|DRUG|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
57740964|NCT02210364|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
58112708|NCT01244815|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
57740965|NCT02210364|DRUG|capecitabine|capecitabine 150 mg tablets
57740966|NCT00574587|DRUG|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
57740967|NCT00574587|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
57740968|NCT00574587|DRUG|Trastuzumab|Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
57740969|NCT00574587|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
57740970|NCT00574587|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
57740971|NCT00574587|PROCEDURE|Surgery|Surgical excision of tumor from breast
57740972|NCT03232970|OTHER|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
58112709|NCT04460599|OTHER|Observation|Observation of recorded neurological signs
58112710|NCT02314533|DRUG|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
58112711|NCT01741480|OTHER|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
58112712|NCT01741480|OTHER|routine care|
58112713|NCT02912013|DEVICE|Me Mini|Home use hair removal device
58112714|NCT05245981|DEVICE|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
58112715|NCT04835766|DIAGNOSTIC_TEST|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
58112716|NCT05608590|DRUG|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
58112717|NCT03154333|DRUG|diacerein 1% ointment|diacerein 1% ointment administered topically
58112718|NCT03154333|DRUG|A placebo ointment|vehicle ointment administered topically
58112719|NCT05378087|RADIATION|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
58112720|NCT05378087|PROCEDURE|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
58112721|NCT02807766|BEHAVIORAL|Behavior modification|Each group has 30 subjects and experiences six months' training.
58444709|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
57956605|NCT01406834|BEHAVIORAL|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
58112722|NCT02807766|BEHAVIORAL|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
58112723|NCT02807766|BEHAVIORAL|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
58112724|NCT02807766|BEHAVIORAL|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
58112725|NCT05683470|DRUG|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
58112726|NCT04756141|DEVICE|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
58112727|NCT05202691|OTHER|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
58112728|NCT05202691|OTHER|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
58112729|NCT05272098|OTHER|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
58444710|NCT03211975|OTHER|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
58112730|NCT05272098|OTHER|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
58112731|NCT06172010|DRUG|Clindamycin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
58112732|NCT06172010|DRUG|Rifampicin and levofloxacin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
58112733|NCT02208583|DRUG|Docetaxel & Prednisone|Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
58112734|NCT02208583|DRUG|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
58112735|NCT02208583|DRUG|cisplatin & Etoposide|cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
58112736|NCT02208583|DRUG|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
58112737|NCT04426526|DEVICE|BTL 799-2|High power magnet system
58444711|NCT04472299|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
58444712|NCT03189160|BIOLOGICAL|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
58444713|NCT03189160|BIOLOGICAL|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
58444714|NCT03189160|OTHER|Non-treatment control group|
58444715|NCT04701190|DRUG|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
58444716|NCT04701190|DRUG|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
58112738|NCT05058859|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
58444717|NCT04701190|DRUG|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
57740973|NCT05622669|OTHER|Observational|Sensed and lived experience data from all groups without a specific behavioural or drug intervention
57740974|NCT02756767|OTHER|Survey|
57740975|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
57740976|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
58112739|NCT04881526|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
58112740|NCT04881526|DIETARY_SUPPLEMENT|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
58112741|NCT00146237|DRUG|phenytoin|
58112742|NCT00202553|DRUG|Perindopril|
58112743|NCT04646122|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography parameters
58112744|NCT02903433|OTHER|High-intake avocados|Families will receive 14 avocados on a weekly basis.
58112745|NCT02903433|OTHER|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
58112746|NCT02903433|BEHAVIORAL|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
58112747|NCT02903433|BEHAVIORAL|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
58112748|NCT03013166|OTHER|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
58112749|NCT05118282|BEHAVIORAL|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
58112750|NCT05118282|BEHAVIORAL|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
57740977|NCT01431625|OTHER|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. - Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
58112751|NCT04283383|OTHER|Primary Care Clinical Ultrasound Classroom (AECAP)|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
58112752|NCT04520854|OTHER|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
58112753|NCT04520854|OTHER|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
58112754|NCT06528483|DRUG|Sacituzumab Govitecan + Zimberelimab|"Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice."
57740978|NCT03282318|DRUG|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
57740979|NCT03282318|DRUG|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
58112755|NCT01042977|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
58112756|NCT01042977|DRUG|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
58444718|NCT04701190|DRUG|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
57740980|NCT04075500|DEVICE|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
58112757|NCT03145883|OTHER|Home-Based Aerobic Exercise|
58112758|NCT00377026|BEHAVIORAL|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
58112759|NCT06527989|DRUG|Ceftriaxone 2000 mg|antibiotic prophylaxis
58112760|NCT04365283|PROCEDURE|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
58112761|NCT04365283|OTHER|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
58112762|NCT00171782|DRUG|VALSARTAN+HYDROCHLOROTHIAZIDE|
58444719|NCT04701190|DRUG|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
57740981|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
57740982|NCT04016090|OTHER|Placebo|Placebo capsule
58112763|NCT01167855|OTHER|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
58444720|NCT04701190|PROCEDURE|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
58444721|NCT06727383|PROCEDURE|peripheral blood collection|standard blood test procedures
57740983|NCT02043496|BEHAVIORAL|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
58112764|NCT01167855|OTHER|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
58112765|NCT01167855|OTHER|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
58112766|NCT01167855|OTHER|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
58112767|NCT01167855|OTHER|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
58112768|NCT01795703|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
57740984|NCT02043496|BEHAVIORAL|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
57740985|NCT02268201|DRUG|Advagraf|oral
57740986|NCT02268201|DRUG|Prograf|oral
57740987|NCT00535730|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
57740988|NCT00535730|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
57740989|NCT00535730|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
57740990|NCT03120962|DRUG|Oxycodone|Oxycodone 20mg/day, for 4 weeks
57740991|NCT03120962|DRUG|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
57740992|NCT03120962|DRUG|Famciclovir|Famciclovir 500mg three-times daily for 7 days
58112769|NCT01795703|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
58112770|NCT04719247|PROCEDURE|Pulpotomy|Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
58112771|NCT04115449|DRUG|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
58112772|NCT04115449|DRUG|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
58112773|NCT05481060|OTHER|Screen-based simulation|In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
58112774|NCT04182750|OTHER|Pharmacist consultation|"The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use."
58112775|NCT04317781|BIOLOGICAL|Tagraxofusp-erzs|Given IV
58112776|NCT03028883|OTHER|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
58112777|NCT03456869|DEVICE|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
58112778|NCT02657720|DEVICE|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
58112779|NCT02657720|DEVICE|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
58112780|NCT02657720|DEVICE|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
58112781|NCT01328392|DRUG|Dexlansoprazole|30mg a day, 3 months
58112782|NCT03422783|DEVICE|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
58112783|NCT03422783|DIAGNOSTIC_TEST|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
58112784|NCT03422783|DIAGNOSTIC_TEST|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
58112785|NCT03422783|BIOLOGICAL|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
58112786|NCT01224210|DRUG|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
58112787|NCT03536676|OTHER|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
58112788|NCT03536676|OTHER|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
58112789|NCT02274467|DEVICE|Trans-catheter electric stimulation test|
58112790|NCT03263520|DRUG|Nandrolone Decanoate|Drug administration
58112791|NCT03263520|DRUG|Dexamethasone|Drug administration
58112792|NCT02801591|PROCEDURE|Conventional ovarian stimulation proctol without rhGH|
58112793|NCT02424565|DRUG|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
58444722|NCT06727383|PROCEDURE|leukapheresis|"Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma."
58444723|NCT02859103|DRUG|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
58444724|NCT02732964|OTHER|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
58444725|NCT02732964|OTHER|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
58444726|NCT06727435|DRUG|non-sedation strategy|Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
58444727|NCT02866227|DRUG|TOL-463|TOL-463 vaginal gel
58112794|NCT02424565|OTHER|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
58112795|NCT01181856|BIOLOGICAL|MVA 85A|Single injection of 1 x 108 pfu MVA85A
58112796|NCT00568269|PROCEDURE|Open repair|Open repair is according to the Lichtenstein technique
58112797|NCT00568269|PROCEDURE|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
58112798|NCT00326885|DRUG|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
58112799|NCT02568995|DRUG|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
58444728|NCT02866227|DRUG|TOL-463|TOL-463 vaginal insert
58444729|NCT05195541|DRUG|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
58444730|NCT01587040|DRUG|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
58444731|NCT01587040|DRUG|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
58444732|NCT05737654|OTHER|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
58444733|NCT01327599|DRUG|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
57956606|NCT05021783|DIAGNOSTIC_TEST|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
58112800|NCT04249206|PROCEDURE|Root Canal Treatment|
58112801|NCT02625766|PROCEDURE|LC fracture surgical fixation|
58112802|NCT02625766|PROCEDURE|LC fracture non-operative management|
58112803|NCT04206852|PROCEDURE|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
58112804|NCT02166242|DRUG|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
58112805|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
57740993|NCT01843426|DRUG|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
57740994|NCT03876080|OTHER|Dry needling|The use of a solid filiform needle to treat trigger points
57740995|NCT03876080|OTHER|Sham needling|Simulated needling
57740996|NCT03254680|DIETARY_SUPPLEMENT|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
57740997|NCT06724757|OTHER|Health questionnaire|The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
58444734|NCT02629120|DRUG|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
58444735|NCT02629120|DRUG|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
58444736|NCT02629120|DRUG|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
58444737|NCT02629120|DRUG|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
58444738|NCT02629120|RADIATION|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
58444739|NCT02629120|BIOLOGICAL|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
58444740|NCT03570814|DRUG|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
58444741|NCT03570814|DRUG|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
58444742|NCT03570814|DRUG|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
57740998|NCT01099904|DRUG|RO5024048|multiple oral doses for 5 days
57740999|NCT04729322|PROCEDURE|Biopsy|Undergo biopsy
57741000|NCT04729322|PROCEDURE|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
57741001|NCT04729322|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
57741002|NCT04729322|DRUG|Metronidazole|Given PO
58112806|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
58112807|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
58112808|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
58112809|NCT03705351|DEVICE|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
58112810|NCT03705351|DRUG|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
58112811|NCT03705351|RADIATION|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
58112812|NCT01142297|DEVICE|dental implant and modified dental implant|standard SLA surface and chemically modified surface
58112813|NCT03339791|PROCEDURE|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
58112814|NCT03339791|PROCEDURE|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
58112815|NCT02468479|OTHER|No relevant intervention.|No relevant intervention.
58112816|NCT06234046|DRUG|Rifaximin 550Mg Tab|group (1) received Rifaximin as 550 mg twice daily dosage for six months.
58112817|NCT06234046|DRUG|Ciprofloxacin 750 MG|group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.
58312655|NCT02991807|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
57956607|NCT05021783|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
58112818|NCT06234046|DIAGNOSTIC_TEST|ascitic fluid sample|aspiration of ascitic fluid sample and analysis for differential cell count
58112819|NCT01196481|DRUG|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
58112820|NCT01196481|PROCEDURE|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
58112821|NCT04647344|DRUG|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
58112822|NCT04647344|DRUG|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
58112823|NCT01002157|DIETARY_SUPPLEMENT|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
58112824|NCT01002157|OTHER|Placebo capsules|Capsules containing no Menaquinone-7
58112825|NCT03172585|OTHER|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
58112826|NCT03172585|OTHER|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
58112827|NCT04767490|PROCEDURE|Standard Duodenal Switch|
58112828|NCT04767490|PROCEDURE|Single Anastomosis Duodenal Switch|
58112829|NCT06480994|DIAGNOSTIC_TEST|Routine Assays on fresh plasma|"Routine coagulation tests using STA-R Max analyzer :~Prothrombin Time (PT) activated Partial Thromboplastin Time (aPTT Thrombin Time (TT) Fibrinogen Anti-Xa activity"
58312656|NCT03168945|OTHER|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
58312657|NCT03168945|OTHER|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
58112830|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on fresh plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
58112831|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on frozen plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
58112832|NCT05921084|BEHAVIORAL|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
58112833|NCT05921084|BEHAVIORAL|General dietary advice|General dietary advice
58112834|NCT05923177|DRUG|SPECT|One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
58112835|NCT00676585|DRUG|Normal Saline|Normal Saline
58112836|NCT00676585|DRUG|Hydrocortisone|Hydrocortisone 100mg
58112837|NCT05044403|PROCEDURE|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
58112838|NCT05044403|PROCEDURE|Conventional treatment|Conventional treatment
58112839|NCT06382467|DRUG|Remimazolam besylate + propofol MCT|remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
58112840|NCT06382467|DRUG|Propofol MCT|Propofol MCT 2-8 mcg/ml using target-controlled infusion
58112841|NCT00177112|PROCEDURE|clean patient preparation for cystoscopy|
58112842|NCT00177112|PROCEDURE|sterile patient preparation for cystoscopy|
58112843|NCT02186808|DEVICE|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
58112844|NCT02907008|OTHER|Polysomnography|
58112845|NCT06417606|DRUG|Lenvatinib|Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
58112846|NCT04450498|BIOLOGICAL|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects \> 2 years of age and have shown to be safe and immunogenic.
58112847|NCT04450498|BIOLOGICAL|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
58112848|NCT02182011|DRUG|Tenecteplase|
58112849|NCT02182011|DRUG|Alteplase|
58112850|NCT02182011|DRUG|Streptokinase|
58112851|NCT05840003|RADIATION|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
58444743|NCT03570814|DRUG|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
58444744|NCT01965730|DRUG|epsilon-aminocaproic acid (EACA)|
58444745|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
58444746|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
58444747|NCT00824473|DRUG|Placebo|Placebo
58112852|NCT02986152|BEHAVIORAL|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
58112853|NCT03408600|OTHER|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
58444748|NCT00824473|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
58444749|NCT03057015|DRUG|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
57741003|NCT04729322|DRUG|Neomycin|Given PO
58112854|NCT00624403|DEVICE|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
58112855|NCT00624403|DEVICE|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
57741004|NCT04729322|BIOLOGICAL|Nivolumab|Given IV
58312658|NCT05474001|DRUG|Fentanyl|10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
58444750|NCT03057015|DRUG|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
58444751|NCT03057015|DRUG|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
58444752|NCT03057015|DRUG|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
58444753|NCT03057015|DRUG|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
58312659|NCT05474001|DRUG|Bupivacain|10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
58444754|NCT04597385|OTHER|Long-term Follow-Up|No intervention
58444755|NCT06238778|DRUG|HDV-Lispro|HDV-L will be used as the mealtime insulin
58444756|NCT06238778|DRUG|Lispro|Lispro will be used as the mealtime insulin
58312660|NCT05474001|DRUG|intravenous graniseton|10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
58312661|NCT00797758|OTHER|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
57741005|NCT04729322|BIOLOGICAL|Pembrolizumab|Given IV
57741006|NCT04729322|OTHER|Questionnaire Administration|Ancillary studies
58112856|NCT01294592|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
57741007|NCT04729322|DRUG|Vancomycin|Given PO
57741008|NCT00999375|BEHAVIORAL|Education|
57741009|NCT00999375|BEHAVIORAL|Problem Solving|
57741010|NCT00999375|BEHAVIORAL|Social Learning|
58312662|NCT06296511|BEHAVIORAL|Exercise|60 min of treadmill exercise performed at 70% of peak oxygen uptake.
58312663|NCT04084015|DEVICE|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
58112857|NCT01294592|DRUG|tamsulosin|Take 1 capsule daily when escalation criteria met
58112858|NCT00139204|PROCEDURE|C11 Methionine PET scan|
58112859|NCT05438290|DRUG|DPCP|topical immunomodulator
58112860|NCT05559554|DRUG|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
58112861|NCT05559554|DRUG|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
58112862|NCT02858856|DRUG|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
58444757|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
58444758|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
58444759|NCT06727123|OTHER|motivational interviewing|Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
58444760|NCT06727123|OTHER|Control|No application will be made. Routine follow-ups will be made.
58444761|NCT05293639|DEVICE|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
58444762|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
58444763|NCT01361100|DEVICE|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
58444764|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
58444765|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
58444766|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
58444767|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
58444768|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
58444769|NCT02960607|DRUG|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
58444770|NCT02779049|OTHER|Blood examination|blood sampling
58444771|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
58444772|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
58444773|NCT06446986|OTHER|Single and Dual-Task Timed Up and Go Test|Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.
58444774|NCT06446986|OTHER|Single and Dual-Task Tandem Walking Test|"The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards"
57741011|NCT00999375|BEHAVIORAL|Behavior Modification|
58112863|NCT05080777|BEHAVIORAL|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
58112864|NCT05080777|BEHAVIORAL|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
58444775|NCT06446986|OTHER|Simple Shoulder Test|Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
57741012|NCT02002481|OTHER|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
57741013|NCT03788837|DRUG|ILOPROST|The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
57741014|NCT03788837|DRUG|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
58112865|NCT04382456|DIETARY_SUPPLEMENT|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
58112866|NCT03110952|BIOLOGICAL|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
57741015|NCT04984148|DIAGNOSTIC_TEST|CT|Contrast-enhanced thoracic computed tomography
57741016|NCT06489743|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
57741017|NCT01049048|DIETARY_SUPPLEMENT|Vitamin D3|2500 IU Vitamin D3
57741018|NCT01049048|DIETARY_SUPPLEMENT|Placebo|No (0 IU) vitamin D3 added to cookie.
57741019|NCT00454051|DRUG|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
58112867|NCT03110952|BIOLOGICAL|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
58112868|NCT03110952|OTHER|Placebo|0.5 mL vial
57741020|NCT00454051|DRUG|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
57741021|NCT03519854|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
57741022|NCT03519854|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
57741023|NCT03519854|DRUG|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
57741024|NCT00862160|DEVICE|ROCsafeTM|using minimized perfusion circuit while CABG
57741025|NCT00229333|DRUG|Escitalopram|
57741026|NCT04149405|PROCEDURE|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
58112869|NCT01877759|BIOLOGICAL|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
58112870|NCT04121000|PROCEDURE|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
58312664|NCT01369433|DRUG|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
58312665|NCT01369433|DRUG|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
58444776|NCT01094535|DRUG|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
58444777|NCT04047251|DRUG|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
58458520|NCT06301230|DEVICE|Portable Laparoscopic Trainer (PLET)|"The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation."
58458521|NCT04840446|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Sensor
58458522|NCT04643275|DEVICE|BTL-899|Treatment with study device.
57741027|NCT04149405|DRUG|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
57741028|NCT03651089|DRUG|SP16|subcutaneous injection of experimental anti-inflammatory drug
58112871|NCT00411697|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
58112872|NCT03307512|DRUG|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
58112873|NCT03307512|DRUG|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
58112874|NCT03504332|PROCEDURE|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
58112875|NCT04534647|DIAGNOSTIC_TEST|different serum and urine biomarkers|urine exosomes and serum biomarkers
58112876|NCT03495193|OTHER|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
58312666|NCT01369433|DRUG|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
58312667|NCT01369433|DRUG|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
57741029|NCT03651089|DRUG|Placebos|subcutaneous injection of sterile saline
58444778|NCT03499093|OTHER|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
58444779|NCT05802043|BEHAVIORAL|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
58444780|NCT00171171|DRUG|deferasirox|
58444781|NCT00974649|BEHAVIORAL|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
58444782|NCT06461832|PROCEDURE|Group 1|In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.
57741030|NCT05794542|DEVICE|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
57741031|NCT04178733|DRUG|LY3493269 - SC|Administered SC
57741032|NCT04178733|DRUG|Placebo - SC|Administered SC
57741033|NCT04178733|DRUG|LY3493269 - IV|Administered IV
57741034|NCT02693743|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
57741035|NCT04958018|DIETARY_SUPPLEMENT|Almonds|almond (Prunus dulcis) consumption
57741036|NCT04958018|DIETARY_SUPPLEMENT|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
57741037|NCT03707977|DRUG|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
57741038|NCT03707977|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
57741039|NCT03707977|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
57741040|NCT02541552|DRUG|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
57741041|NCT05505656|DIAGNOSTIC_TEST|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
57741042|NCT03036358|OTHER|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
57741043|NCT03036358|OTHER|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
57741044|NCT04949373|DEVICE|High-intensity laser therapy (HILT)|"High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
57741045|NCT04949373|DEVICE|Sham High-intensity laser therapy (sham HILT)|"Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
57741046|NCT02275676|OTHER|bioelectrical impedance analysis|
57741047|NCT02275676|OTHER|indirect calorimetry|
57741048|NCT06450132|DRUG|Atropine Ophthalmic|0.05% atropine ophthalmic solution
57741049|NCT06450132|DEVICE|MiSight 1-day disposable contact lenses|soft multifocal contact lenses
57741050|NCT05703568|OTHER|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
57741051|NCT05703568|OTHER|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
58312668|NCT01369433|DRUG|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
58444783|NCT06461832|PROCEDURE|Group 2|In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
58444784|NCT06725524|BIOLOGICAL|JMT601|intravenous infusion on day 1 once a week
58444785|NCT00755495|DRUG|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
58444786|NCT00755495|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
58444787|NCT00755495|DRUG|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
58444788|NCT00755495|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
58444789|NCT01680666|PROCEDURE|central line placement|central line placement
58444790|NCT01680666|DEVICE|Ultrasound|Ultrasound guided central venous access
58444791|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
58312669|NCT01369433|DRUG|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
57741052|NCT01592318|DRUG|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
57741053|NCT01592318|DRUG|danoprevir|Reference tablet, single oral dose
57741054|NCT01592318|DRUG|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
58444792|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
58444793|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
57741055|NCT01592318|DRUG|ritonavir|Reference tablet, single oral dose
57741056|NCT06579222|OTHER|Primary Care Rheumatology Family Physician Consultation|The participant will be booked with a primary care rheumatology family physician for rheumatoid arthritis comorbidity screening. They will complete weight, height, blood pressure measurement, assess for risk factors for dyslipidemia, type 2 diabetes, hypertension, bone mineral density loss and vaccine preventable infectious diseases.
58312670|NCT02888054|DRUG|lesinurad/allopurinol 200/300 FDC tablet|
58312671|NCT02888054|DRUG|lesinurad 200 mg|
58312672|NCT02888054|DRUG|allopurinol 300 mg|
58312673|NCT03000972|PROCEDURE|Cement augmentation|
58312674|NCT03000972|PROCEDURE|PFN-A Nail|
58312675|NCT03555162|OTHER|fMRI|Imaging examination
58312676|NCT00942136|DRUG|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
58312677|NCT00942136|DRUG|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
58312678|NCT00942136|DRUG|Placebo|Placebo Suspension as a single dose.
58312679|NCT00942136|DRUG|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
58112877|NCT03495193|BEHAVIORAL|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
58112878|NCT01004120|DIETARY_SUPPLEMENT|Bimuno|5.5g daily intake
58112879|NCT01004120|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily intake
58112880|NCT00593333|DEVICE|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
58444794|NCT02318342|DRUG|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
58444795|NCT04985461|DEVICE|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
58312680|NCT02990000|BEHAVIORAL|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
57741057|NCT01045746|DEVICE|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
57741058|NCT01045746|DEVICE|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
58444796|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
57741059|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
58112881|NCT00593333|DEVICE|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
58112882|NCT03309410|DIAGNOSTIC_TEST|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
58112883|NCT04986696|DEVICE|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
58312681|NCT04113694|DEVICE|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
58312682|NCT00658853|BEHAVIORAL|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
58312683|NCT04132765|OTHER|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
58312684|NCT04132765|OTHER|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
58444797|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
57741060|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
57741061|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
58444798|NCT00933322|DIETARY_SUPPLEMENT|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
58444799|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
58444800|NCT05516758|DRUG|Placebo|Administered SC
58444801|NCT03353480|DRUG|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
58312685|NCT04132765|OTHER|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
58444802|NCT03353480|DRUG|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
58444803|NCT05672706|PROCEDURE|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
58444804|NCT03954080|DEVICE|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
58444805|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
58444806|NCT00821496|DRUG|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
58312686|NCT04132765|OTHER|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
58312687|NCT04132765|OTHER|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
58444807|NCT06725420|OTHER|Ultrasound-guided local Injection|Ultrasound-Guided steroid injection and splinting in patients with carpal tunnel syndrome
58444808|NCT06725420|OTHER|Intramuscular Steroid Injection|Intramuscular gluteal steroid injection and Splinting in Patients With Carpal Tunnel Syndrome
58444809|NCT06725420|DEVICE|Splinting|wrist night splint
58444810|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
58312688|NCT04132765|OTHER|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
58312689|NCT04132765|OTHER|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
58312690|NCT04132765|OTHER|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
58312691|NCT04132765|OTHER|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
58312692|NCT04132765|OTHER|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
58312693|NCT04132765|OTHER|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
58312694|NCT04132765|OTHER|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
57741062|NCT06303050|OTHER|Mental Imagery with task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. During each 45 minutes of session, the participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance. Regular breaks will give to the participants to avoid overexertion and fatigue during 45 minutes of continues practice. The 2 minutes rest period will provide to the partici-pants during each practice session
57741063|NCT06303050|OTHER|Task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will receive the Task oriented training for 25-30 minutes, 05 days a week for 06 weeks consisting of Warm up Period, Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
57741064|NCT03691467|DEVICE|immediate dental implant|immediate dental implant placement in freshly extracted socket.
58312695|NCT04456686|DRUG|LY3016859|LY3016859 given IV.
57741065|NCT03691467|DRUG|Hyaluronic Acid|topical application of hyaluronic acid
58312696|NCT04456686|DRUG|Placebo|Placebo given IV.
58312697|NCT05759572|DRUG|Apatinib|TKI
58312698|NCT05759572|DRUG|Dalpiciclib|CDK4/6 inhibitor
58312699|NCT05759572|DRUG|Fulvestrant/AI|Endocrine therapy
58312700|NCT00363740|DRUG|GW685698X Aqueous Nasal Spray|
58444811|NCT04407988|DRUG|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
58112884|NCT04596449|OTHER|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
58112885|NCT03807154|BEHAVIORAL|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
58444812|NCT03736941|OTHER|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
58112886|NCT03807154|BEHAVIORAL|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
58112887|NCT03376074|DEVICE|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
58112888|NCT03376074|OTHER|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
58112889|NCT06529822|BIOLOGICAL|Synthetic long peptide personalized cancer vaccine|Neoantigen vaccines will be provided on a patient-specific basis
58112890|NCT06529822|DRUG|Poly ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
58112891|NCT06529822|BIOLOGICAL|Nivolumab|Standard of care, not required to be given by the protocol
58112892|NCT06529822|DEVICE|Signatera assay|Signatera is a clinically validated, personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS) based clinical trial assay targeting 16 tumor-specific mutations. It is intended for the detection of ctDNA isolated from anticoagulated peripheral whole blood from post-surgical patients previously diagnosed with localized or advanced solid tumors to aid physician assessment and treatment decision-making, together with other clinical factors
58112893|NCT02265952|DRUG|REGN1500 250 mg SC/15 mg/kg IV/450 mg SC|Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
58112894|NCT05004857|BEHAVIORAL|Book reading|Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
58112895|NCT00308373|DRUG|Metformin vs Thiazolidinedione (Pioglitazone)|
58112896|NCT01208142|OTHER|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
58112897|NCT01208142|DEVICE|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
57741066|NCT01461876|DRUG|antiretroviral therapy|Standard of care antiretroviral therapy
58112898|NCT05158491|DRUG|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
58112899|NCT05972850|BEHAVIORAL|Vivo Heart|Vivo is an online, live, small group fitness program developed for older adults that uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session for 45 min, 2-3 times/week.
58112900|NCT02297906|DRUG|Ketorolac|Non-steroidal anti-inflammatory drug
58112901|NCT01446913|DEVICE|Standard CPAP Intervention|
58112902|NCT01446913|BEHAVIORAL|Enhanced CPAP Intervention|
58112903|NCT00891683|DRUG|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
58444813|NCT06406023|OTHER|Conventional treatment|"Hot pack will be applied for 10 minutes. AROM's of Hip (5 reps x 2 sets each). Piriformis stretch 3 reps x 20 sec hold x 2 sets. SLR (5reps x 10 sec hold x 2 sets). Sciatic nerve stretch (5 reps x 10 sec hold x 2 sets) for 3 days/ week for 2 weeks.~Strengthening exercises will be performed after 2 weeks of previous intervention of Hip abductors (Hip abduction with band in sitting, standing, side-lying hip raise), and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each).~SLR (5 reps x 10 sec hold x 2 sets) each exercise will be performed 3 days/ week for 2 weeks.~Total treatment protocol will be followed for 4 weeks. Each session will be of 30 minutes."
57741067|NCT06249932|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
58312701|NCT02857504|DEVICE|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
58312702|NCT02857504|DEVICE|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
58312703|NCT03389165|DEVICE|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
58312704|NCT02854462|BEHAVIORAL|Language comprehension intervention|
58312705|NCT02854462|BEHAVIORAL|Counting intervention|
58312706|NCT03287544|OTHER|Combined rehabilitation|Linguistic training as well as communication training.
58312707|NCT03287544|OTHER|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
58312708|NCT02301455|BEHAVIORAL|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
58444814|NCT06406023|OTHER|Instrument assisted soft tissue mobilization|Instrument assisted soft tissue mobilization IASTM with Graston tool along with conventional treatment in first 6 sessions. Apply hot pack for 10 mins on low back as passive warm up then AROM's of Hip (5 reps x 2 sets each) will be performed. Apply Graston tool at 30-60 degrees angle along the length of following muscles Piriformis, Gluteus medius and Hamstrings after applying emollient for 40-120 seconds.
58444815|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
58444816|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
58444817|NCT01110356|DRUG|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
58444818|NCT01110356|OTHER|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
58444819|NCT01012258|BIOLOGICAL|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
58444820|NCT02557737|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
58444821|NCT01721226|DEVICE|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
58444822|NCT01721226|OTHER|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
58444823|NCT02008344|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
58444824|NCT02008344|DRUG|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
58444825|NCT04574401|DRUG|IS-002|Intravenous injection of IS-002 Investigational Drug
58312709|NCT04152499|DRUG|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
57741068|NCT06249932|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
58444826|NCT01915173|DRUG|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
58444827|NCT01915173|DRUG|Placebo|Lactose tablets
58444828|NCT01915173|BEHAVIORAL|Expanded Interview|
58444829|NCT01915173|BEHAVIORAL|Standard Interview|
58444830|NCT06263478|DRUG|INCA034176|IV infusion
58444831|NCT03843892|DRUG|OFEV|twice daily
58444832|NCT03718767|DRUG|Nivolumab|IV Nivolumab
58444833|NCT03670563|OTHER|Short foot exercise protocol|Exercises that target intrinsic foot muscles
58444834|NCT03670563|OTHER|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
58444835|NCT03874117|OTHER|Twice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
58444836|NCT03874117|OTHER|Thrice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
57741069|NCT06150547|DIAGNOSTIC_TEST|FDG Positron Emission Tomography|Imaging using an FDG radioactive tracer to look at the head.
58312710|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
58112904|NCT03323632|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
58112905|NCT03983707|DEVICE|Purastat®|Use of Purastat®
58112906|NCT05559294|BEHAVIORAL|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
58112907|NCT05559294|BEHAVIORAL|Education and care as Usual (ECAU)|Active control
58112908|NCT02175966|DRUG|DCV/ASV/BMS-791325|
58112909|NCT02175966|DRUG|Ribavirin|
58112910|NCT02175966|DRUG|Sofosbuvir|
58112911|NCT02175966|DRUG|Peginterferon α-2a|
58112912|NCT00048971|GENETIC|mutation analysis|
58112913|NCT00048971|GENETIC|polymorphic microsatellite marker analysis|
58444837|NCT01404780|DEVICE|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
58112914|NCT01403883|BEHAVIORAL|Standard Care|Psychological \& enterostomal therapy clinics on demand only
58112915|NCT01403883|BEHAVIORAL|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
58112916|NCT05956197|OTHER|No intervention|No intervention. This is a cohort study
58312711|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
58444838|NCT01404780|DEVICE|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
58112917|NCT06504108|PROCEDURE|Calcium silicate-based sealer full Pulpotomy|Using calcium silicate-based sealer as a capping agent after full pulpotomy
58112918|NCT06504108|PROCEDURE|Calcium silicate-based premixed putty full Pulpotomy|Using calcium silicate-based premixed putty as a capping agent after full pulpotomy
58112919|NCT06504108|PROCEDURE|Full Pulpotomy|Using combination between calcium silicate-based sealer and calcium silicate-based premixed putty as a capping agent after full pulpotomy
58112920|NCT05924971|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
58112921|NCT03063632|BIOLOGICAL|Interferon Gamma-1b|Given SC
58112922|NCT03063632|OTHER|Laboratory Biomarker Analysis|Ancillary studies
58112923|NCT03063632|BIOLOGICAL|Pembrolizumab|Given IV
58112924|NCT03760133|DRUG|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
58112925|NCT01840683|DEVICE|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
58112926|NCT02903927|DEVICE|Implantation of CT LUCIA IOL|
58112927|NCT02903927|DEVICE|Implantation of Acrysof IQ SN60WF IOL|
58112928|NCT05586620|PROCEDURE|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
58112929|NCT05586620|PROCEDURE|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
58112930|NCT02904200|DEVICE|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
58112931|NCT02904200|DEVICE|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
58112932|NCT01113710|DRUG|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
58112933|NCT04517006|BEHAVIORAL|Self-focused acts|Completion of daily acts for personal enjoyment.
58112934|NCT04517006|BEHAVIORAL|Prosocial acts|Completion of daily acts for the benefit of others.
58312712|NCT01331564|BEHAVIORAL|Control|Control women will receive non-weight related content during both time periods at the project website.
58112935|NCT01363791|OTHER|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
58112936|NCT00770991|DRUG|Black raspberry (BRB) Slurry|20 grams BRB Slurry
58312713|NCT05106907|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
58312714|NCT03803826|DEVICE|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
58112937|NCT00770991|DRUG|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
58112938|NCT00770991|DRUG|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
58112939|NCT04033939|DRUG|HSK3486|
58112940|NCT04033939|DRUG|Propofol|
58112941|NCT04033939|DRUG|Placebo|
58112942|NCT02659202|DEVICE|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
58112943|NCT04467333|OTHER|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
58112944|NCT00748007|DRUG|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
58112945|NCT05852782|OTHER|White Light therapy|Participants will be exposed to broadband light for one hour
58112946|NCT05852782|OTHER|Blue light therapy|Participants will be exposed to blue light for one hour
58112947|NCT05852782|OTHER|Red light therapy|Participants will be exposed to re light for one hour
58112948|NCT05852782|OTHER|Darkness|Participants will be in complete darkness for one hour
58444839|NCT00323648|DRUG|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
58444840|NCT05541679|DEVICE|Right ventricular septal pacing followed by left bundle branch area pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
57741070|NCT06150547|DIAGNOSTIC_TEST|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
58112949|NCT00469820|BIOLOGICAL|autologous tumor cell vaccine|
58112950|NCT00469820|BIOLOGICAL|peripheral blood lymphocyte therapy|
58112951|NCT02687282|OTHER|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
58112952|NCT03404206|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
58112953|NCT03404206|DRUG|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
58112954|NCT03404206|DRUG|Placebo|Matching placebo, 2 tablets, oral, single dose
57741071|NCT04292626|DIAGNOSTIC_TEST|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
57741072|NCT01936584|PROCEDURE|TAPP repair for inguinal hernias|
58112955|NCT02657993|BEHAVIORAL|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
58112956|NCT02657993|BEHAVIORAL|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
58112957|NCT01038583|DRUG|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
58112958|NCT01038583|DRUG|Placebo|100 mg enteric-coated placebo
58112959|NCT04809779|DRUG|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
58112960|NCT05994456|DRUG|PD-1 inhibitor|240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
58112961|NCT00224250|PROCEDURE|One- versus two-layer hysterotomy closure|
58112962|NCT02387814|DRUG|Abemaciclib|Administered Orally
58112963|NCT01993394|OTHER|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
58112964|NCT01993394|OTHER|gas mixture|breathing air, 44.5%O2 or 100%O2
58112965|NCT04292574|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
58112966|NCT01138150|DRUG|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
58112967|NCT01138150|DRUG|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
58112968|NCT00996554|PROCEDURE|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
58112969|NCT00996554|PROCEDURE|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
57956608|NCT05021783|OTHER|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
58112970|NCT02531022|BEHAVIORAL|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
58112971|NCT02531022|BEHAVIORAL|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
58112972|NCT03360201|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
58112973|NCT02517359|DRUG|RV6153 single dose|Safety and tolerability of single doses
58312715|NCT03803826|DIAGNOSTIC_TEST|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
58312716|NCT04432480|PROCEDURE|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
58312717|NCT05155319|BIOLOGICAL|UFluA 20 µg each antigen/dose|Low dose
57741073|NCT01936584|PROCEDURE|TEP repair for inguinal hernia|
57741074|NCT01936584|OTHER|EuraHS-QoL questionnaire|questionnaire administration
57741075|NCT01936584|OTHER|Carolina Comfort Scale|questionnaire administration
57956609|NCT05021783|DIAGNOSTIC_TEST|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
58112974|NCT02517359|DRUG|RV6153 matching placebo single dose|Safety and tolerability of single doses
58112975|NCT02517359|DRUG|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
58112976|NCT02517359|DRUG|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
58112977|NCT02517359|DRUG|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
57741076|NCT02806375|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
57741077|NCT02806375|DRUG|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
57741078|NCT02806375|DRUG|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
57741079|NCT02806375|DRUG|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
57741080|NCT02806375|DRUG|Ruxolitinib|Days -8 through -2 15 mg tid
58112978|NCT02517359|DRUG|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
58112979|NCT02330679|DRUG|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
58112980|NCT02330679|DRUG|Placebo|
58112981|NCT00497367|DEVICE|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
58112982|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
58112983|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
58112984|NCT05554510|OTHER|Observational|No interventions planned. Observational data collection only.
58112985|NCT02546284|DRUG|lenzilumab|
58112986|NCT02071381|DRUG|DW330SR 45mg|
58112987|NCT02071381|DRUG|DW1030 75mg|
58444841|NCT05541679|DEVICE|Left bundle branch area pacing followed by right ventricular septal pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
57741081|NCT02806375|DRUG|Ruxolitinib|Days +5 through +100: 7.5 mg bid
58444842|NCT02964000|DEVICE|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
58444843|NCT02964000|DEVICE|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
58444844|NCT02964000|DEVICE|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
58444845|NCT02630472|DRUG|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
57956610|NCT05021783|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
58112988|NCT03964454|BEHAVIORAL|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
58112989|NCT03964454|BEHAVIORAL|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
58112990|NCT00785122|DRUG|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
58112991|NCT00785122|DRUG|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
58112992|NCT06358313|DRUG|Atorvastatin 40mg|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
58312718|NCT05155319|BIOLOGICAL|UFluA 60 µg each antigen/dose|High Dose
58312719|NCT05155319|BIOLOGICAL|Placebo|Placebo
58312720|NCT02723240|DRUG|NUC-3373|
58312721|NCT05457959|BIOLOGICAL|Dendritic Cell Tumor Peptide Vaccine|Given ID
58312722|NCT05457959|BIOLOGICAL|Ipilimumab|Given IV
57741082|NCT01296451|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
57741083|NCT01296451|BIOLOGICAL|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
57741084|NCT01296451|BIOLOGICAL|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
57741085|NCT01764737|DRUG|VX15/2503|single dose intravenous administration
57741086|NCT01764737|DRUG|Placebo|single dose intravenous administration
57741087|NCT00000779|BIOLOGICAL|Aluminum hydroxide|
58112993|NCT06358313|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
58112994|NCT03666182|OTHER|No Intervention|No Intervention
58112995|NCT00207714|DRUG|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
58312723|NCT05457959|PROCEDURE|Leukapheresis|Undergo leukapheresis
58312724|NCT05457959|BIOLOGICAL|Nivolumab|Given IV
58312725|NCT05457959|DRUG|Placebo Administration|Given ID
58312726|NCT05457959|DRUG|Placebo Administration|Given IV
58112996|NCT00207714|DRUG|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
58112997|NCT00207714|DRUG|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
58112998|NCT00207714|DRUG|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
58112999|NCT03120585|OTHER|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR \>4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
58113000|NCT04275947|OTHER|nCapp, a cell phone-based auto-diagnosis system|Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
58113001|NCT03406689|DRUG|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
58113002|NCT03406689|DRUG|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
58113003|NCT03406689|DRUG|Artificial tear|One drop Artificial Tears will be instilled 45' prior to the IVI.
58113004|NCT01094366|PROCEDURE|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
58113005|NCT01094366|PROCEDURE|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
58113006|NCT02542306|DRUG|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
58113007|NCT00936975|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
58113008|NCT05012137|PROCEDURE|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
58113009|NCT05012137|DRUG|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
58113010|NCT03774979|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
58113011|NCT01324245|DRUG|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
58113012|NCT03109873|RADIATION|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
58113013|NCT03109873|DRUG|Metformin Hydrochloride|Given orally
58113014|NCT03109873|OTHER|Placebo|Given orally
58113015|NCT02271815|OTHER|Oral Hygiene|Oral Hygiene
58312727|NCT05457959|DRUG|Poly ICLC|Given IM
58312728|NCT05457959|PROCEDURE|Resection|Undergo standard of care surgical resection
57741088|NCT00000779|BIOLOGICAL|MF59|
58312729|NCT01515839|DIETARY_SUPPLEMENT|Multivitamin Supplement intervention|"We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss"
58312730|NCT06351046|BEHAVIORAL|Online Mindfullness Based Stress Reduction Program|Online group class/week for eight consecutive weeks with 8 sessions
57741089|NCT00000779|BIOLOGICAL|rgp120/HIV-1IIIB|
57741090|NCT00000779|BIOLOGICAL|rgp120/HIV-1MN|
57741091|NCT00000779|BIOLOGICAL|rgp120/HIV-1 SF-2|
57741092|NCT00000779|BIOLOGICAL|Env 2-3|
58113016|NCT04352842|OTHER|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
58113017|NCT00567944|DEVICE|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
58113018|NCT04195984|DEVICE|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
58113019|NCT00170885|DRUG|Everolimus|
58113020|NCT03139565|BIOLOGICAL|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
58113021|NCT03139565|BIOLOGICAL|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
58113022|NCT02373384|DRUG|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
58113023|NCT02373384|BEHAVIORAL|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
57741093|NCT04822038|DIETARY_SUPPLEMENT|Vitamin D3|5000 UI Vitamin D3 daily by 4 weeks
58113024|NCT02373384|DIETARY_SUPPLEMENT|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
58113025|NCT05676333|DRUG|Secukinumab|
58113026|NCT04025970|GENETIC|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
58444846|NCT02630472|DRUG|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
57741094|NCT04822038|OTHER|Dietary recommendations|Dietary recommendations based on food rich in 25 (OH) vitamin D
57741095|NCT03626597|DIAGNOSTIC_TEST|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
57741096|NCT03626597|BEHAVIORAL|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling \& referral to care
57741097|NCT03626597|BEHAVIORAL|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
58113027|NCT00580359|DRUG|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
58113028|NCT05343949|OTHER|HIIT exercise program ABC|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
58113029|NCT05343949|OTHER|HIIT exercise program CAB|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
58113030|NCT05343949|OTHER|HIIT exercise program BCA|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
58113031|NCT02281630|DRUG|KWA-0711|
58113032|NCT02281630|DRUG|Placebo|
58113033|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
58113034|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
58113035|NCT06527313|BEHAVIORAL|Movement Mobilization Concept, Exercise and Tape|Mulligan Concept MWM Mulligan Taping Mulligan Self Home Workout
57741098|NCT03436394|DRUG|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
57741099|NCT00930293|BEHAVIORAL|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
58113036|NCT06527313|BEHAVIORAL|Sham Movement Mobilization Concept, Exercise and Tape|The technique will be applied to cases in the sham group with only hand contact, without any slippage or rotation in any direction. Then, rigid taping will be applied without any tension or direction, and home exercises will be given.
58312731|NCT06351046|DEVICE|Virtual Reality-based Pain Self-management program|The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
58312732|NCT06422533|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days
58312733|NCT06422533|DRUG|Piperacillin/tazobactam|Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
57741100|NCT00930293|BEHAVIORAL|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
57741101|NCT00930293|DRUG|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
58312734|NCT00345306|DRUG|Comparison between two different progesterone administration|
58444847|NCT04724915|PROCEDURE|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
58113037|NCT06527313|BEHAVIORAL|Special Exercises|"Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips"
58113038|NCT06410937|PROCEDURE|thyroidectomy without drain|thyroidectomy without subcutaneous suction drain
58113039|NCT06410937|PROCEDURE|thyroidectomy with drain|hyroidectomy with subcutaneous suction drain
58113040|NCT02134574|BIOLOGICAL|hematologic malignancy|hematologic malignancy with a sampling of blood
58113041|NCT03874806|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
58113042|NCT03874806|DRUG|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
58113043|NCT03847883|DRUG|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
58113044|NCT06279897|OTHER|Skin Surface Rewarming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~90°F and held here for the duration of the LBNP test.
58113045|NCT06279897|OTHER|Skin Surface Warming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~93°F and held here for the duration of the LBNP test.
58113046|NCT06279897|OTHER|Skin Surface Heating|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~95°F and held here for the duration of the LBNP test.
58113047|NCT06279897|OTHER|Skin Surface Cooling|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will remain lowered to \~82°F for the duration of the LBNP test.
58312735|NCT04418960|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
58312736|NCT04519424|BIOLOGICAL|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
57741102|NCT02597400|DRUG|Metformin|"* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
57741103|NCT02597400|DRUG|HMS5552|"* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
58312737|NCT04519424|DRUG|Placebo|Normal saline (0.9% sodium chloride)
57741104|NCT06402734|BEHAVIORAL|Adherence to Gluten Free Diet|Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
57741105|NCT05775614|DEVICE|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
57741106|NCT05775614|DEVICE|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
58113048|NCT01381900|DRUG|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
58113049|NCT01381900|DRUG|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
58312738|NCT06192316|BEHAVIORAL|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
58312739|NCT02757196|DRUG|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
58312740|NCT02757196|DRUG|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
58444848|NCT04724915|PROCEDURE|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
58444849|NCT02915263|DRUG|IGIV-C|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
57956611|NCT00957008|BEHAVIORAL|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
58113050|NCT01381900|DRUG|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
58113051|NCT01381900|DRUG|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
58113052|NCT01381900|DRUG|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
58113053|NCT04645290|BEHAVIORAL|"Intervention group: Educational Intervention KARER"|"Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~* Module 0: the introduction~* Module 1: called Identifying my role as a caregiver~* Module 2: called Strategies to strengthen care~* Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~- One season of practices abilities of 4 hours."
58312741|NCT00058591|BIOLOGICAL|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
58312742|NCT02525068|DRUG|AZD5363|Until confirmed disease progression.
58444850|NCT02915263|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
57956612|NCT00957008|OTHER|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
58113054|NCT03712969|DRUG|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
58312743|NCT02525068|DRUG|Enzalutamide|Until confirmed disease progression.
58312744|NCT01351636|DRUG|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
58312745|NCT01351636|DRUG|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
58312746|NCT00719901|DRUG|obatoclax mesylate|Given IV
58312747|NCT00719901|DRUG|bortezomib|Given IV
58312748|NCT00719901|OTHER|laboratory biomarker analysis|Correlative studies
58312749|NCT01641536|GENETIC|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
58312750|NCT01963234|BEHAVIORAL|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
58312751|NCT01981252|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
58312752|NCT05203185|OTHER|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
58444851|NCT04770116|DEVICE|Auditory Stimulation|The device records biosignals and precisely plays tones to enhance sleep slow waves.
58444852|NCT01284023|OTHER|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
58444853|NCT03760523|DRUG|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
58444854|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
58444855|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
58444856|NCT00214539|PROCEDURE|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
58113055|NCT05344066|OTHER|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
58113056|NCT05344066|OTHER|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
58113057|NCT01478503|DRUG|mirabegron OCAS|oral
58113058|NCT01478503|DRUG|Placebo|oral
57741107|NCT03757000|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
58113059|NCT03549130|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
58113060|NCT03549130|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
58444857|NCT00214539|DRUG|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
58444858|NCT02497729|PROCEDURE|Written Checklist|Use of a written checklist pre and peri-intubation
58444859|NCT02497729|PROCEDURE|Head of Bed Up|Raising the patient's head of bed to 25 degrees
58444860|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
57741108|NCT02895087|OTHER|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
58113061|NCT04131361|OTHER|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
58113062|NCT01857791|BEHAVIORAL|multidisciplinary, behavior modification|
58444861|NCT05408390|OTHER|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
58444862|NCT05408390|OTHER|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
58444863|NCT05408390|OTHER|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
58444864|NCT05408390|OTHER|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
58444865|NCT00490958|DRUG|telmisartan|
58444866|NCT04811846|DEVICE|Bipolar transurethral resection of bladder tumor (TURBT)|Standard resection in piecemeal technique with standard bipolar cutting loop. (Storz medical, 27040 GP1)
58444867|NCT04811846|DEVICE|Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)|Vaporization of bladder tumor with standard bipolar vaporization electrode. (Storz medical, 27040 NB)
58444868|NCT03712683|DRUG|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
58444869|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
57741109|NCT02895087|OTHER|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
57741110|NCT04026776|DRUG|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
57741111|NCT04026776|OTHER|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
57741112|NCT06530862|OTHER|ESWT+stretching exercises|Participants in this group will receive ESWT treatment
58113063|NCT02247570|PROCEDURE|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
58113064|NCT05678920|OTHER|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
58444870|NCT06625905|DIAGNOSTIC_TEST|Ultrasound imaging|Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).
58444871|NCT03692559|OTHER|full aseptic dressing|Replacement of the central venous catheters in the dressing process
58444872|NCT05024734|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
58444873|NCT05024734|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
58444874|NCT05024734|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
58444875|NCT05024734|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
58444876|NCT04269213|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
58444877|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
57741113|NCT06530862|OTHER|Dry needling+stretching exercises|Participants in this group will receive Dry needling treatment
58113065|NCT01818570|DRUG|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
58113066|NCT01818570|DRUG|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
58113067|NCT01372787|PROCEDURE|Assessment of Therapy Complications|Ancillary studies
58113068|NCT01372787|OTHER|Medical Chart Review|Ancillary studies
58444878|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
58444879|NCT05179239|DRUG|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
58444880|NCT03758534|OTHER|No intervention|This is a retrospective chart review study.
58444881|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
58444882|NCT00785980|DRUG|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
57741114|NCT03009045|DRUG|Tedizolid|200mg oral tedizolid one pill per day
57741115|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
58113069|NCT01372787|OTHER|Quality-of-Life Assessment|Ancillary studies
58113070|NCT01372787|OTHER|Questionnaire Administration|Ancillary studies
58113071|NCT02524106|DRUG|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
58113072|NCT02524106|DRUG|Placebo|placebo
58113073|NCT05871879|DIAGNOSTIC_TEST|The 5-item modified frailty index|The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
58113074|NCT04466449|DIAGNOSTIC_TEST|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
58113075|NCT00672022|DRUG|Zavesca (Miglustat)|
58113076|NCT06433349|OTHER|Survey and interviews|Questionnaires and interviews
58113077|NCT04303845|DRUG|Erenumab|140 mg of erenumab via subcutaneous injection
58113078|NCT03639428|DRUG|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
58113079|NCT01166971|DEVICE|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
58113080|NCT01166971|DEVICE|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
58113081|NCT01567215|PROCEDURE|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
58113082|NCT01567215|DRUG|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
58113083|NCT01567215|PROCEDURE|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
58113084|NCT01590433|DRUG|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
58113085|NCT01590433|DRUG|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
58113086|NCT01590433|BEHAVIORAL|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
58113087|NCT04028583|OTHER|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
58113088|NCT04028583|OTHER|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
58444883|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
58444884|NCT00307905|DRUG|Traumeel S|homeopathic remedy
58444885|NCT00307905|DRUG|Placebo remedy|identical size, shape and taste of treatment medication
58444886|NCT06727409|DRUG|Finerenone|Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy
57741116|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
57741117|NCT00760929|DRUG|Placebo|iv 9mg/kg weekly
57741118|NCT00760929|DRUG|Placebo|iv 16mg/kg every 3 weeks
57741119|NCT00760929|DRUG|RG1507|iv 9mg/kg weekly
57741120|NCT00760929|DRUG|RG1507|iv 16mg/kg every 3 weeks
57741121|NCT00760929|DRUG|erlotinib [Tarceva]|150mg oral daily
58113089|NCT00873210|DRUG|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
58113090|NCT00493753|PROCEDURE|Acupuncture|
58113091|NCT04980521|OTHER|The radon app|Participants will be asked to use the radon app.
58113092|NCT04980521|OTHER|Print brochure|Participants will receive print brochures.
58113093|NCT04363411|OTHER|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
58113094|NCT05773690|OTHER|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
58113095|NCT05773690|OTHER|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
58113096|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
58113097|NCT01598649|DIETARY_SUPPLEMENT|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
58113098|NCT01598649|DIETARY_SUPPLEMENT|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
58113099|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
58113100|NCT01735058|DRUG|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
58113101|NCT01735058|DRUG|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
58113102|NCT05221606|BEHAVIORAL|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
58113103|NCT05221606|BEHAVIORAL|Usual Care|Binder of written supportive care materials
58113104|NCT00618774|DRUG|telmisartan40/amlodipine5|
58113105|NCT00618774|DRUG|telmisartan80/amlodipine5|
58113106|NCT03266549|PROCEDURE|botulinum toxin augmented surgery|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
58113107|NCT03266549|PROCEDURE|conventional surgery|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia. The standard correction tables will be used as a guide for the amount of muscle recession and, or resection.
58444887|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
57956613|NCT00957008|DEVICE|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
58113108|NCT04382157|DRUG|Mablet 360 mg|Slow-released magnesium hydroxide
58113109|NCT04382157|DRUG|Placebo|Placebo
58113110|NCT04665479|OTHER|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
58113111|NCT00910858|DRUG|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
58113112|NCT00910858|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
58113113|NCT00939705|DRUG|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
58113114|NCT03920436|DIETARY_SUPPLEMENT|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
58113115|NCT03920436|DIETARY_SUPPLEMENT|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
58113116|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
58113117|NCT04403100|DRUG|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
58113118|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
58113119|NCT04403100|DRUG|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
58113120|NCT02266706|DRUG|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
58113121|NCT02266706|DRUG|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
58113122|NCT02266706|DRUG|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
58113123|NCT02266706|DRUG|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
58113124|NCT02266706|DRUG|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
58113125|NCT01140178|DRUG|HPPH|Given IV
58113126|NCT01880710|PROCEDURE|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
58113127|NCT01880710|PROCEDURE|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
57741122|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
58113128|NCT04897100|PROCEDURE|Achilles tendon tenotomy|Achilles tendon tenotomy during Ponseti treatment for clubfoot
58113129|NCT01851590|DEVICE|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
58113130|NCT01851590|DRUG|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
58113131|NCT01851590|DRUG|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
58113132|NCT06528756|PROCEDURE|shockwave therapy|ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.
58113133|NCT06528756|PROCEDURE|Barbotage|"US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way."
58113134|NCT04387747|OTHER|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
58113135|NCT02615327|DIETARY_SUPPLEMENT|8 g Polydextrose|8g of Polydextrose
58113136|NCT02615327|DIETARY_SUPPLEMENT|12 g Polydextrose|12 g of Polydextrose
58312753|NCT03652896|PROCEDURE|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
58312754|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58113137|NCT02615327|DIETARY_SUPPLEMENT|16 g Polydextrose|16 g of Polydextrose
58113138|NCT02615327|DIETARY_SUPPLEMENT|Placebo|0 g of Polydextrose
58113139|NCT02642627|DEVICE|Bellafill|
58113140|NCT05747365|DIAGNOSTIC_TEST|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
58113141|NCT00055874|BIOLOGICAL|recombinant interferon alfa|
58113142|NCT00055874|DRUG|cytarabine|
58113143|NCT00055874|DRUG|hydroxyurea|
58113144|NCT00055874|DRUG|imatinib mesylate|
58113145|NCT00055874|PROCEDURE|allogeneic bone marrow transplantation|
58113146|NCT00055874|PROCEDURE|autologous bone marrow transplantation|
58113147|NCT00055874|PROCEDURE|peripheral blood stem cell transplantation|
58312755|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58312756|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
58113148|NCT01360957|DIETARY_SUPPLEMENT|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
57741123|NCT01544322|DRUG|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
58113149|NCT04146220|DRUG|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
57741124|NCT01147224|DRUG|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
57741125|NCT03453268|OTHER|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
57741126|NCT03453268|OTHER|Control|usual treatment
57741127|NCT01509898|DEVICE|Water jet|use of water jet for a month
57741128|NCT05071118|DRUG|Pregabalin 150mg|pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
57741129|NCT05071118|DRUG|Placebo|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
57741130|NCT00796380|DRUG|Xingnaojing|injection
57741131|NCT02077257|DRUG|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
58113150|NCT04503798|BEHAVIORAL|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
58113151|NCT03103659|OTHER|personalised care plan|Quality of life assessement in elderly cancer patients
57741132|NCT01773070|DRUG|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
57741133|NCT01773070|DRUG|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
57741134|NCT01773070|DRUG|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
57741135|NCT03905889|DRUG|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
57741136|NCT03905889|DRUG|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
58113152|NCT04841239|OTHER|Herbal topical formulation|
58113153|NCT02500017|DIETARY_SUPPLEMENT|Melatonin|5mg rapid release melatonin capsule
58113154|NCT02500017|OTHER|Placebo|matching placebo capsule
58113155|NCT00180830|DRUG|Glivec|
58312757|NCT03636256|DRUG|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
57741137|NCT01201590|DIETARY_SUPPLEMENT|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
57741138|NCT01201590|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
57741139|NCT02742948|DRUG|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
57741140|NCT05597969|BEHAVIORAL|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
58113156|NCT00180830|DRUG|Gleevec|
58113157|NCT00063960|DRUG|floxuridine|
58113158|NCT00063960|DRUG|irinotecan hydrochloride|
58113159|NCT00408876|DRUG|Duloxetine|
58113160|NCT00408876|DRUG|Placebo|
58113161|NCT00443950|DRUG|Etanercept|
58113162|NCT03381885|BEHAVIORAL|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
58113163|NCT03381885|BEHAVIORAL|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
58113164|NCT04782115|BIOLOGICAL|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
57741141|NCT00127101|DRUG|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
58113165|NCT04782115|BIOLOGICAL|Conbercept|KH902(Conbercept）
58113166|NCT01239147|OTHER|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
58113167|NCT01239147|OTHER|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
58113168|NCT05036915|PROCEDURE|Pacifier randomly|"Common Action Steps:~1. Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~2. Inclusion and exclusion criteria are evaluated.~3. Study group is determined in line with the randomization order of the newborn to be included in the study.~4. First part of the patient information and follow-up form is completed.~5. Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~\* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~1. Common procedure steps are applied.~2. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~3. Second part of the patient information and follow-up form is completed daily."
58113169|NCT05036915|PROCEDURE|Pacifier other|"Procedure Steps of the Experimental Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~  1. Common procedure steps are applied.~ 2. Pacifier is given for 5 min before each feeding.~ 3. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~ 4. Second part of the patient information and follow-up form is completed daily."
58113170|NCT04728113|OTHER|Supportive care visit with questionnaires|5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
58113171|NCT04728113|OTHER|Oncological standard visit|Oncological standard visit
58113172|NCT01901315|PROCEDURE|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
58444888|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
58444889|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
57741142|NCT00127101|DRUG|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
57741143|NCT00408473|DRUG|Flecainide|
57741144|NCT05278910|OTHER|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
57741145|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
58113173|NCT01901315|PROCEDURE|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
58113174|NCT05122585|PROCEDURE|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
58113175|NCT01743677|DRUG|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
58113176|NCT01743677|DRUG|Placebo|Single dose placebo tablets (5 tablets)
58312758|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
58312759|NCT03636256|OTHER|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
58312760|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
58312761|NCT03823144|DEVICE|Diagnostic Microscopy|Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
58312762|NCT03823144|DRUG|Fluorescein Sodium Injection|Given IV as part of IVM procedure
58312763|NCT03963440|OTHER|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
58312764|NCT01457794|OTHER|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
58444890|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
58444891|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
58444892|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
58113177|NCT01743677|DRUG|Moxifloxacin|Single dose Avelox 400 mg tablet
58113178|NCT01403350|DEVICE|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
58444893|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
57741146|NCT05278910|DIETARY_SUPPLEMENT|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
57741147|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
57741148|NCT04118153|DRUG|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
57741149|NCT05856448|DRUG|GLPG3667|Capsule
57741150|NCT05856448|DRUG|Placebo|Capsule
58113179|NCT03548376|OTHER|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
57741151|NCT05564234|PROCEDURE|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
57741152|NCT05564234|PROCEDURE|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
57741153|NCT05537220|DRUG|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
57741154|NCT05537220|DRUG|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
57741155|NCT03273634|DRUG|Lansoprazole Pill|once daily at night time
58444894|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
58113180|NCT01317732|DEVICE|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
58113181|NCT05211050|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
58113182|NCT05211050|DRUG|Sumatriptan|10 min infusion of 4 mg sumatriptan.
58113183|NCT05211050|DRUG|Saline|10 min infusion of isotonic saline (placebo).
58113184|NCT01513057|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
58113185|NCT01513057|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
58113186|NCT02541695|BIOLOGICAL|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
58312765|NCT02524938|DIETARY_SUPPLEMENT|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
58444895|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
58444896|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
58444897|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
58444898|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
58444899|NCT03295760|DRUG|Q10 Coenzyme|
58444900|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
58444901|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
58444902|NCT05699824|DRUG|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
58444903|NCT05699824|OTHER|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
58113187|NCT04835298|OTHER|Dyspnea|questionnaires
58113188|NCT02334956|OTHER|Brain MRI|
58113189|NCT01696474|DRUG|Bortezomib|
58113190|NCT01997528|DEVICE|Change of blood flow or sweep gas flow ( ILA Activve)|
58113191|NCT00833781|BIOLOGICAL|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
58312766|NCT02524938|DIETARY_SUPPLEMENT|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
58312767|NCT05299749|OTHER|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
58312768|NCT05299749|OTHER|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
58312769|NCT00467766|BEHAVIORAL|Psychosocial information, counseling, and support|
58444904|NCT05699824|DRUG|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
58444905|NCT00625079|DRUG|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
58444906|NCT04115631|DRUG|Acalabrutinib|Given PO
58444907|NCT04115631|DRUG|Bendamustine|Given IV
58444908|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
58444909|NCT04115631|DRUG|Cytarabine|Given IV
57741156|NCT03273634|DRUG|Placebo|Placebo
57741157|NCT06237205|DRUG|Niraparib|a highly selective PARP1 and PARP2 inhibitor
57741158|NCT03422250|DEVICE|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks.
58444910|NCT04115631|BIOLOGICAL|Rituximab|Given IV
58444911|NCT01391624|DRUG|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
58444912|NCT01391624|DRUG|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
58444913|NCT05007756|RADIATION|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
58444914|NCT06124963|DRUG|WX390|WX390 tablet, 0.9 mg once a day
58444915|NCT06124963|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
58444916|NCT00242541|DRUG|Octreotide acetate|
58444917|NCT05693350|DIAGNOSTIC_TEST|DUS|Duplex ultrasound
58113192|NCT00833781|BIOLOGICAL|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
58113193|NCT00231296|DEVICE|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
58113194|NCT00231296|DRUG|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
58113195|NCT00514995|DRUG|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
58113196|NCT02112903|DRUG|Encapsulated vortioxetine IR tablet, 20 mg|
58444918|NCT05396911|BEHAVIORAL|UP2UTobacco|The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. UP2UTobacco targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
58444919|NCT00773513|DRUG|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
58444920|NCT00773513|DRUG|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
58444921|NCT00773513|DRUG|Epoetin Beta|Epoetin beta will be administered as per approved label.
57956614|NCT04821427|BEHAVIORAL|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
58444922|NCT00773513|DRUG|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
58444923|NCT05755139|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
57956615|NCT04361591|OTHER|Observational only|Observational Study
57956616|NCT06296732|PROCEDURE|Duration of surgery intervention|Intraoperative- duration from the beginning of the skin incision to skin suture (min)
57956617|NCT02141711|DRUG|TAK-438|TAK-438 tablets
57956618|NCT02141711|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
58113197|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 5.5)|
58312770|NCT00467766|DRUG|Donepezil (Aricept)|
58312771|NCT01243281|DRUG|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
58312772|NCT02805023|BIOLOGICAL|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
58312773|NCT02805023|BIOLOGICAL|Control medium|Intramuscular injections - single treatment session
58312774|NCT01426529|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
58312775|NCT01426529|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
58312776|NCT01426529|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
57956619|NCT03064477|BEHAVIORAL|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
58113198|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 6.0)|
58113199|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 7.0)|
58113200|NCT00618969|OTHER|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
58113201|NCT03902756|OTHER|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
58113202|NCT02327520|OTHER|Colitis with CDI treatment|All patients will be treated with standard treatment
58113203|NCT02131896|OTHER|Interventional arm-Mediterranean diet|
58113204|NCT02131896|OTHER|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
58312777|NCT01963468|BEHAVIORAL|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
58444924|NCT04895241|DRUG|Litifilimab|Administered as specified in the treatment arm.
58444925|NCT04895241|DRUG|Placebo|Administered as specified in the treatment arm.
58444926|NCT04869540|OTHER|Usual care|Evidence based care for transition-aged youth (TAY) with ASD.
58444927|NCT04869540|OTHER|'Got Transition' toolkit and resources|Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.
58444928|NCT04869540|BEHAVIORAL|PSE intervention|A family-based problem solving education (PSE) intervention.
58444929|NCT00855816|BEHAVIORAL|Breathing training|relaxation training
58444930|NCT01142882|BEHAVIORAL|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
58444931|NCT01142882|BEHAVIORAL|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
58444932|NCT05984680|OTHER|Surveys and Interviews - Arm A|For Arm A, this outpatient study will administer surveys, interviews, concept mapping exercises, guided tours of oncology clinics, design team workshops, and phone calls for follow-up questions
58312778|NCT02941640|PROCEDURE|E group|The securing the base of appendix by endoloop.
58444933|NCT05984680|OTHER|COPD Care Pathway|The COPD care pathway will consist of an initial assessment followed by monthly follow-up assessments, which occur during regularly scheduled immunotherapy infusions. At each of these three visits, the study team will administer symptom measures, counsel participants on the management of COPD, and give algorithm-generated general recommendations to the patient and provider regarding possible options for COPD-directed care.
57741159|NCT00990691|DRUG|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg."
57741160|NCT00990691|DRUG|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg."
57741161|NCT00990691|DRUG|Administration of a placebo|Administration of a daily dose of placebo
58444934|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
58444935|NCT05663203|OTHER|Interview|Complete interview
58444936|NCT05663203|OTHER|Survey Administration|Complete survey
58444937|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
58113205|NCT06038188|BEHAVIORAL|SIT LESS Booster|"Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote"
58113206|NCT06338020|OTHER|Adaptive variable-resistance training|"The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
58312779|NCT02941640|PROCEDURE|S group|The securing the base of appendix by Stapler.
58312780|NCT02941640|PROCEDURE|H group|The securing the base of appendix by Hem-o-lok clip.
58312781|NCT02941640|PROCEDURE|DS group|The securing the base of appendix by DS clip.
58312782|NCT02941640|DEVICE|Endoloop|
58444938|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
57741162|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
57741163|NCT06205602|DRUG|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
57741164|NCT06205602|DRUG|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
57741165|NCT06205602|DRUG|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
58312783|NCT02941640|DEVICE|Stapler|
58444939|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
58444940|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
58444941|NCT04439539|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
58444942|NCT04439539|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
58444943|NCT04439539|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
58444944|NCT04439539|DRUG|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
57741166|NCT06205602|DRUG|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
57956620|NCT03064477|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
57956621|NCT06345677|COMBINATION_PRODUCT|ViXe Xombination|Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure
57956622|NCT06345677|COMBINATION_PRODUCT|Placebo + Sham|Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
57956623|NCT03303950|DRUG|Busulfan|Given IV
57956624|NCT03303950|DRUG|Cyclophosphamide|Given IV
57956625|NCT03303950|DRUG|Fludarabine|Given IV
57956626|NCT03303950|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
57956627|NCT03303950|OTHER|Laboratory Biomarker Analysis|Correlative studies
57956628|NCT02987621|DEVICE|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
58312784|NCT02941640|DEVICE|Hem-o-lok clip|
58312785|NCT02941640|DEVICE|DS clip|
58312786|NCT04796857|DRUG|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
58312787|NCT04796857|DRUG|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
58312788|NCT02603900|DRUG|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
58444945|NCT04439539|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally.
58444946|NCT05871099|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Experimental group receive HIPEC two times after laproscopic gastrectomy
58444947|NCT03376737|DRUG|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
58444948|NCT00971074|DRUG|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
58444949|NCT00971074|OTHER|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
58444950|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
58444951|NCT02645292|DEVICE|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
58113207|NCT06338020|OTHER|Standard physical therapy|The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
57956629|NCT02960620|DEVICE|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
57956630|NCT01496066|DEVICE|LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|LAL implanted and adjusted with LDD
57956631|NCT01496066|DEVICE|Monofocal control IOL|Commercially available monofocal intraocular lens (IOL)
57956632|NCT00002953|DRUG|cyclophosphamide|
58113208|NCT02922803|DRUG|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
58113209|NCT02922803|DRUG|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
58113210|NCT02531828|DEVICE|Application of dressings for surgical correction.|Dressing for surgical correction
58113211|NCT02531828|DEVICE|POLYSHAFT®|
58113212|NCT05935774|BIOLOGICAL|Atezolizumab|Given IV
58444952|NCT02645292|DEVICE|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
58444953|NCT06669117|DRUG|VERT-002|Route of Administration: Intravenous
58444954|NCT06587490|RADIATION|stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
58444955|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
58444956|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
58444957|NCT02354014|DRUG|Bedaquiline (TMC207)|TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.
57741167|NCT05876546|DEVICE|Liquid bandage|The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.
57741168|NCT05876546|DEVICE|Saline Solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
57741169|NCT02464449|BEHAVIORAL|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
57956633|NCT00002953|DRUG|epirubicin hydrochloride|
57956634|NCT00002953|DRUG|paclitaxel|
57956635|NCT01242449|DRUG|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
58113213|NCT05935774|PROCEDURE|Biopsy|Undergo biopsy
58113214|NCT05935774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58113215|NCT05935774|PROCEDURE|Computed Tomography|Undergo CT
58113216|NCT05935774|OTHER|Electronic Health Record Review|Ancillary studies
58113217|NCT05935774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58113218|NCT05935774|DRUG|Trabedersen (OT-101)|Given IV
58113219|NCT03654534|DIETARY_SUPPLEMENT|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
58113220|NCT05126381|BEHAVIORAL|Smoking|The Study contains patients who are allowed to smoke
58312789|NCT02603900|DRUG|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
58312790|NCT02603900|DEVICE|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
58113221|NCT05126381|BEHAVIORAL|non-somking|The Study contains patients who are not allowed to smoke
58312791|NCT02603900|DEVICE|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
58312792|NCT04730011|BEHAVIORAL|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
57741170|NCT02464449|BEHAVIORAL|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
57956636|NCT01242449|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
58312793|NCT06530810|DRUG|HS-10382+Flumatinib|Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily
57956637|NCT00987038|DRUG|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
57956638|NCT00987038|DRUG|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
57956639|NCT04179383|OTHER|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
58312794|NCT01578291|BEHAVIORAL|Parental information|An informational brochure indicating the study details
58312795|NCT01578291|BEHAVIORAL|Play therapy|Play therapy with a child life specialist
57956640|NCT02078687|DIETARY_SUPPLEMENT|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
58444958|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
58444959|NCT04770038|BEHAVIORAL|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
58312796|NCT03409380|DIETARY_SUPPLEMENT|Arginine Drink|10 g of arginine in a formulated drink
58444960|NCT06674525|DRUG|626|Single subcutaneous injection
58444961|NCT06674525|DRUG|Placebo|Single subcutaneous injection
57956641|NCT02078687|DIETARY_SUPPLEMENT|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
57956642|NCT02078687|DIETARY_SUPPLEMENT|Mothers own milk|Group 1 received mothers own milk without fortification
57956643|NCT04677712|DRUG|CCH-aaes|Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
58444962|NCT03545438|BIOLOGICAL|LIB003|LIB003 or placebo
58444963|NCT02246959|BEHAVIORAL|Process Incentive|Daily sweepstake conditional on daily medication adherence
58444964|NCT02246959|BEHAVIORAL|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
58444965|NCT01675518|DRUG|ASP7991|oral
58444966|NCT01675518|DRUG|Placebo|oral
58444967|NCT03263624|DEVICE|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
58444968|NCT03263624|DRUG|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
58444969|NCT05683834|DRUG|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
58444970|NCT05683834|DRUG|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
57956644|NCT04677712|OTHER|Compression|Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.
57956645|NCT04677712|OTHER|Cold Packs|Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.
57956646|NCT04677712|DRUG|Arnica Gel|Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
57956647|NCT04677712|DRUG|INhance®|Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
57956648|NCT04677712|OTHER|PDL|Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
58444971|NCT05683834|OTHER|Placebo Comparator|Normal Saline
58444972|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
58444973|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
58444974|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
58312797|NCT03409380|DIETARY_SUPPLEMENT|Plain Drink|formulated drink
58312798|NCT05639036|DEVICE|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
58312799|NCT05639036|PROCEDURE|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
58312800|NCT05042492|DEVICE|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
58444975|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
58444976|NCT05421013|DRUG|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
58444977|NCT06577597|DRUG|GSK3923868|Participants will receive single dose of GSK3923868.
57741171|NCT02625896|BEHAVIORAL|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
58312801|NCT01214122|DRUG|AZD9668|60 mg orally twice daily for 11 days
58444978|NCT06577597|DRUG|Placebo|Participants will receive single dose of Placebo.
57741172|NCT04166994|BEHAVIORAL|Exercise and diet|IMPACT Intervention
57741173|NCT04166994|OTHER|No Intervention: Usual Care|No exercise or diet specialization.
58312802|NCT01214122|DRUG|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
58444979|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
58444980|NCT02784171|DRUG|Cisplatin|
58444981|NCT02784171|DRUG|Pemetrexed|
58444982|NCT02784171|DRUG|Pembrolizumab|
58444983|NCT04227093|DRUG|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
57741174|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
57956649|NCT05076539|OTHER|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
58113222|NCT04597606|OTHER|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
58444984|NCT04227093|DRUG|Placebo|Matching placebo tablets taken twice daily.
58444985|NCT05590728|DRUG|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
58444986|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
58444987|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
58444988|NCT06114888|DIAGNOSTIC_TEST|MeMed BV + Usual Care|We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
57741175|NCT02102087|DEVICE|Initial Specimen Diversion Device (ISDD)|
57741176|NCT02102087|DEVICE|Lab standard practice (LSP)|
57741177|NCT02160587|DRUG|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
57956650|NCT04992520|BIOLOGICAL|S. sonnei 53G|Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast
57956651|NCT04992520|BIOLOGICAL|S. flexneri 2a 2457T|Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
57956652|NCT05808400|BIOLOGICAL|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.
57956653|NCT03678480|DRUG|HTD1801|HTD1801 capsules, 250mg
57956654|NCT03678480|DRUG|Ursodeoxycholic Acid|UDCA capsules, 125mg
57741178|NCT02160587|DRUG|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
57956655|NCT01928381|DRUG|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
58444989|NCT06114888|OTHER|Usual Care Alone|Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
58444990|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR)|Imagery rescripting (IR) is a technique where the individual is instructed to imagine a negative memory or image as vividly as possible, and to change it in a direction that he/she desires. IR seems particularly efficient because it is based on the experienced emotions during perceptual information processing, thereby eliciting stronger emotional responses than verbal processing.
57741179|NCT02160587|OTHER|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
57741180|NCT03993769|OTHER|A19010-F|A snus product
57956656|NCT01928381|DRUG|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
58444991|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR) and Targeted Memory Reactivation (TMR) during sleep|Targeted Memory Reactivation (TMR) is a technique used to strengthen a memory trace during sleep. TMR is used to modify memory formation through the application of cues during sleep. In this TMR protocol, an olfactory cue is associated with the imagery rescripting (IR) during the day, and then administered during sleep. In that way, the replay of the associated memory and its corresponding neural representation in memory networks are artificially promoted, a procedure which usually strengthens memory consolidation. Previous studies have shown that TMR in sleep reduces emotional arousal, making it a promising technique for insomnia.
58444992|NCT06335784|BEHAVIORAL|Sleep Hygiene|Sleep hygiene education includes modifications in the behavior (e.g., exercise, coffee, alcohol intake) and environment (e.g., light, noise, temperature conditions) that offer to the individual the foundation for healthy sleep. Sleep hygiene is an important component in treating ID, but insufficient and less effective than CBT-I when offered alone.
58444993|NCT06335784|BEHAVIORAL|Sleep Hygiene + Odor|Sleep hygiene instructions will be applied in the presence of an odor, which will be also used during the night.
58444994|NCT06335784|OTHER|"Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention"|Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.
58444995|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
58444996|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
58444997|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
58444998|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
58444999|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
58445000|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
58445001|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
58445002|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
58445003|NCT02968342|DEVICE|Vaginal progesterone 8%|vaginal self application
58445004|NCT03081884|DRUG|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
58445005|NCT02346461|DRUG|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
57741181|NCT03993769|OTHER|B19010-F|A snus product
57741182|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
57741183|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
57741184|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
57741185|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
58312803|NCT00566826|BEHAVIORAL|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
57741186|NCT01384994|DRUG|Panitumumab|6 mg/kg BW every 2 weeks
57741187|NCT01384994|DRUG|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
57741188|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
57741189|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
57741190|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
57741191|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
57741192|NCT03568864|OTHER|Low nucleotide meal|The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
58312804|NCT00566826|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
58312805|NCT03057418|DRUG|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
58312806|NCT04491799|DIAGNOSTIC_TEST|Fecal calprotectin|Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
58312807|NCT02106481|DRUG|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
58312808|NCT02106481|DRUG|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
58312809|NCT04445168|BEHAVIORAL|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
58312810|NCT05513911|OTHER|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
58312811|NCT04628624|DIETARY_SUPPLEMENT|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
58445006|NCT02346461|DRUG|ManNAc|At doses of 6 g twice daily (12 g per day).
58445007|NCT03420547|BEHAVIORAL|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
57741193|NCT03568864|OTHER|High nucleotide meal|The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
58445008|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
57741194|NCT04954118|PROCEDURE|Internal jugular vein cannulation|The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.
57741195|NCT01692782|DRUG|SEP-225289|SEP-225289 4mg once daily
57956657|NCT01928381|DRUG|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
57956658|NCT00505466|BEHAVIORAL|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
57741196|NCT01692782|DRUG|SEP-225289|SEP-225289 8mg once daily
57741197|NCT01692782|DRUG|Placebo|Placebo once daily
57741198|NCT03686852|OTHER|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
57741199|NCT06530940|DIAGNOSTIC_TEST|Buccal Schirmer Test|"For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) ."
57741200|NCT06540066|DRUG|BGB-B3227|Administered intravenously.
57741201|NCT06540066|DRUG|Tislelizumab|Administered intravenously.
57741202|NCT06540066|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
58312812|NCT04628624|DIETARY_SUPPLEMENT|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
58312813|NCT04628624|DIETARY_SUPPLEMENT|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
58312814|NCT01088087|DIETARY_SUPPLEMENT|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
58312815|NCT05869474|PROCEDURE|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
58312816|NCT05869474|DRUG|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
58445009|NCT04047628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|"1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
57741203|NCT00002538|PROCEDURE|laparoscopic surgery|
57741204|NCT04681612|DIAGNOSTIC_TEST|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
57741205|NCT04681612|DIAGNOSTIC_TEST|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
57956659|NCT05461950|PROCEDURE|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
57956660|NCT05461950|PROCEDURE|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
57956661|NCT05461950|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
57956662|NCT04583033|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
57956663|NCT05152550|OTHER|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
57956664|NCT05137327|BEHAVIORAL|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
57956665|NCT05137327|BEHAVIORAL|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
57956666|NCT03308656|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
57956667|NCT05026307|PROCEDURE|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
57956668|NCT01472497|DRUG|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
57956669|NCT02798536|DRUG|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
57956670|NCT02798536|DRUG|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
57956671|NCT05117775|OTHER|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
57956672|NCT04427215|OTHER|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
57956673|NCT00278993|DRUG|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
57956674|NCT00326365|DRUG|Kali bichromicum 10-60 (C30)|
57956675|NCT06253156|BEHAVIORAL|virtual reality|It is planned to provide 4 sessions of standard disaster preparedness training to nursing students in the intervention group. After the standard training sessions are completed, nursing students will be shown disaster simulation videos and visuals using virtual reality glasses within the scope of the virtual reality-based disaster preparedness training program.
57956676|NCT04368156|DEVICE|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
58312817|NCT01870596|DRUG|Cytarabine|Given IV
58312818|NCT01870596|DRUG|CHK1 Inhibitor SCH 900776|Given IV
58312819|NCT01870596|OTHER|Laboratory Biomarker Analysis|Correlative studies
58312820|NCT04832035|OTHER|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
58312821|NCT04832035|BEHAVIORAL|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
57956677|NCT02931058|OTHER|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
58113223|NCT04597606|DEVICE|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
58113224|NCT04597606|DEVICE|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
58113225|NCT02006147|DRUG|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
58113226|NCT00411047|DRUG|gefitinib|oral drug taken daily around the same time
58312822|NCT05545735|DRUG|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
58445010|NCT04047628|BIOLOGICAL|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab"
57741206|NCT04681612|DIAGNOSTIC_TEST|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
57741207|NCT04681612|DIAGNOSTIC_TEST|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
58312823|NCT02641834|OTHER|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
58312824|NCT02641834|OTHER|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
58312825|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
58445011|NCT02855268|DRUG|lademirsen (SAR339375)|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
58445012|NCT02855268|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
58445013|NCT02883374|DRUG|Chidamide|
58445014|NCT05639257|DRUG|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
58445015|NCT05639257|DRUG|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
58445016|NCT06725498|DRUG|Tislelizumab-jsgr|200mg, Q3W
57741208|NCT04681612|DIAGNOSTIC_TEST|History, Lab, clinical and hemodynamic parameters|1. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
57741209|NCT03798938|OTHER|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
57741210|NCT02261493|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
57741211|NCT02261493|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
57741212|NCT03432975|DRUG|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
58445017|NCT06725498|DRUG|Cisplatin|60-75 mg/㎡, Q3W
58445018|NCT06725498|DRUG|Albumin-Bound Paclitaxel|260 mg/㎡, Q3W
58445019|NCT06725498|RADIATION|Radiotherapy|Radical Radiotherapy or adjuvant Radiotherapy per guidelines.
57741213|NCT03432975|DRUG|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
58113227|NCT05454423|OTHER|the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication|"-Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding"
58312826|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
58312827|NCT05043935|PROCEDURE|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
58312828|NCT05043935|PROCEDURE|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
57741214|NCT00508066|DRUG|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
57741215|NCT00508066|DRUG|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
58312829|NCT02759640|DRUG|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
58312830|NCT05303714|COMBINATION_PRODUCT|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
58312831|NCT05594082|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
58312832|NCT05498727|DIAGNOSTIC_TEST|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
58312833|NCT06275269|PROCEDURE|Ultrasound-Guided|Ultrasound-Guided Triamcinolone Injection
58312834|NCT06275269|PROCEDURE|Translaryngeal Endoscopic Mucosal Injection|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
58312835|NCT03226587|PROCEDURE|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
58312836|NCT03226587|PROCEDURE|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
58312837|NCT01260909|DEVICE|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
58312838|NCT01715298|DRUG|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
58312839|NCT01715298|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
58312840|NCT03502798|DEVICE|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
58312841|NCT01508000|DRUG|FOLFOX6|5-FU, folinic acid, oxaliplatin
58312842|NCT01508000|BIOLOGICAL|Bevacizumab|Targeted therapy
58312843|NCT01508000|BIOLOGICAL|Panitumumab|Targeted therapy
58312844|NCT01508000|PROCEDURE|Surgery|
58312845|NCT03479905|OTHER|Salter nasal cannula|Oxygen will be delivered via standard nasal cannula during colonoscopy
58312846|NCT03479905|OTHER|Face mask|Oxygen will be delivered via face mask during colonoscopy
58312847|NCT03479905|DEVICE|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
58312848|NCT03238131|DRUG|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
58312849|NCT03238131|DRUG|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
58312850|NCT02354326|RADIATION|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
58312851|NCT02354326|RADIATION|computed tomography|Undergo CT without VNC
58312852|NCT04754295|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
58312853|NCT04754295|OTHER|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
58445020|NCT00402870|DEVICE|ProSeal LMA|ProSeal LMA vs Tracheal Tube
58445021|NCT00402870|DEVICE|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
58445022|NCT02822898|DRUG|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
58445023|NCT02822898|DRUG|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
57956678|NCT02931058|OTHER|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
58458523|NCT03502837|OTHER|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
57956679|NCT02931058|OTHER|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
57956680|NCT06463600|DEVICE|Magseed|Tumour localizer
57956681|NCT06463600|DEVICE|Metallic clip and guide wire|Tumour localizers
57956682|NCT00604604|BEHAVIORAL|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
57956683|NCT04434521|BEHAVIORAL|Questionnaire|Questionnaire about habits in terms of near vision activities
57956684|NCT04434521|OTHER|Eye examination|"The eye examination involves the following measurements:~* Distant vision phoria with Thorington method~* Close vision with Thorington method~* Objective eye-to-eye refraction with self-refractometer~* Binocular objective refraction with autorefractometer~* Monocular/biocular/binocular refraction with Nidek TS610~* SiView automatic refraction~* Humphriss binocular refraction~* MOU Binocular refraction"
57956685|NCT05208151|OTHER|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
57956686|NCT01632566|DRUG|Placebo|Capsules administered orally
57956687|NCT01632566|DRUG|LY3031207|Administered orally
57956688|NCT01632566|DRUG|Celecoxib|Administered orally
57956689|NCT01632566|DRUG|Simvastatin|Administered orally
57956690|NCT06446440|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis
57956691|NCT06446440|PROCEDURE|Open adhesiolysis|Open adhesiolysis
58458524|NCT01033240|DRUG|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
58445024|NCT03918421|OTHER|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
58445025|NCT00742183|DEVICE|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
58445026|NCT00742183|DEVICE|Silvadene|Silvadene - dressing changes every day, more frequently if needed
58445027|NCT00511134|DRUG|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
58445028|NCT00511134|DRUG|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
57741216|NCT04899830|DEVICE|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,...)
58458525|NCT01033240|DRUG|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
58458526|NCT01033240|DRUG|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
58113228|NCT05454423|OTHER|traditional physical therapy + anti-hyperuricemia medication|"traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17."
58445029|NCT03550274|DEVICE|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
58445030|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
58445031|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
58445032|NCT06128369|DRUG|Dexamethasone Ophthalmic Suspension|Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
58445033|NCT06128369|OTHER|Vehicle of OCS-01|inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
58445034|NCT00733915|DEVICE|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
58445035|NCT01770574|DEVICE|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
58445036|NCT01770574|PROCEDURE|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
58445037|NCT06727149|OTHER|Control Group|No intervention was performed to reduce pain, fear and anxiety in the control group
58445038|NCT06727149|OTHER|Virtual Reality Group|The children in the VR group were informed about the virtual reality glasses and told that they could remove the glasses at any time if they felt uncomfortable during the procedure
58445039|NCT05509803|BEHAVIORAL|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
58445040|NCT02771717|DRUG|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
58113229|NCT01238822|DRUG|Methylphenidate|18 mg methylphenidate
58113230|NCT01238822|DRUG|placebo|Placebo
58113231|NCT01238822|DRUG|Methylphenidate|36 mg methylphenidate
58113232|NCT01238822|DRUG|Methylphenidate|54 mg methylphenidate
58445041|NCT02771717|DRUG|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
57956692|NCT04011020|COMBINATION_PRODUCT|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
57956693|NCT04255056|DRUG|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
58445042|NCT05759858|OTHER|None of intervention|None of the interventions was applied.
58445043|NCT04243993|OTHER|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
58445044|NCT05904574|OTHER|Autologous blood patch|Approximately 3-4 pieces were taken with the 18 G core biopsy needle until sufficient tissue was obtained. In the autologous blood patch technique, approximately 6-7 ml of blood was taken from the patient with a 10 ml syringe before the procedure. By attaching a 3-way tap to the injector from which the blood is drawn, blood is drawn into a second injector to ensure that the clotted blood is dispersed and homogenized. The prepared autologous blood patch was given through the coaxial needle (approximately 1 ml of autologous blood patch was applied for every 1 cm when the coaxial needle was withdrawn) and the tract formed by the biopsy needle in the parenchyma, pleura, and under the skin was closed with the patient's autologous blood.
58445045|NCT05904574|OTHER|Percutaneous transthoracic biopsy|After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.
57956694|NCT00980200|DRUG|Dose 4 QD|QD once daily
57956695|NCT00980200|DRUG|Dose 3 QD|QD once daily
57956696|NCT00980200|DRUG|placebo|placebo
57956697|NCT00980200|DRUG|Dose 2 QD|QD once daily
58445046|NCT03234413|DRUG|Botulinum toxin type A|Botulinum toxin type A
58445047|NCT01908530|DEVICE|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
57956698|NCT00980200|DRUG|Dose 1 BD|BD twice daily
57956699|NCT05865678|OTHER|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
57956700|NCT03357627|DRUG|TAK-659|TAK-659 tablets.
57956701|NCT03357627|DRUG|Venetoclax|Venetoclax tablets.
57956702|NCT00502762|DRUG|topotecan|
57956703|NCT06076655|OTHER|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
57956704|NCT05940792|OTHER|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
58113233|NCT02558426|PROCEDURE|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
58113234|NCT00439764|BEHAVIORAL|General health talk|Routine clinical practice and talk on general health
58113235|NCT00439764|BEHAVIORAL|Handout of The Back Book|Talk on health of the back and handout of The Back Book
58445048|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
58445049|NCT05727813|DEVICE|cryoablation|cryoablation of breast cancer smaller than 2 cm
57741217|NCT03047200|BIOLOGICAL|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
57741218|NCT04468438|DIAGNOSTIC_TEST|serum estrogen and urinary albumin creatinine ratio|serum estrogen and urinary albumin creatinine ratio
57741219|NCT04943198|DRUG|Vemurafenib|20 mg/kg/day
57741220|NCT03491761|BIOLOGICAL|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
57741221|NCT03491761|BIOLOGICAL|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
58445050|NCT05433155|DEVICE|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
58458527|NCT01033240|DRUG|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
57741222|NCT01855776|DEVICE|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
57741223|NCT01855776|BEHAVIORAL|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
57741224|NCT01855776|BEHAVIORAL|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
57741225|NCT01855776|OTHER|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
57741226|NCT06487455|DRUG|SPH7485|SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
57741227|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)
57741228|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
57741229|NCT02031887|DIETARY_SUPPLEMENT|formula with synbiotics|
57741230|NCT02031887|DIETARY_SUPPLEMENT|formula without synbiotics|
57741231|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
57741232|NCT05799755|DRUG|Placebo|Placebo comparator
57741233|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
57741234|NCT05836493|PROCEDURE|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
57741235|NCT05836493|PROCEDURE|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
57741236|NCT06071962|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
57741237|NCT06071962|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
57741238|NCT05671848|OTHER|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
57741239|NCT04850846|DRUG|Metformin XR|Orally by mouth
57741240|NCT04850846|OTHER|Placebo|Orally by mouth
57741241|NCT02519348|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
57741242|NCT02519348|BIOLOGICAL|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
57741243|NCT02519348|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
57741244|NCT03536806|DRUG|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
57741245|NCT03536806|DRUG|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
57741246|NCT03750552|DRUG|ampreloxetine|Oral tablet, QD
57741247|NCT03750552|DRUG|Placebo|Oral tablet, QD
57741248|NCT01037348|DRUG|ranibizumab 0.5mg|
57741249|NCT03934398|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
57741250|NCT03934398|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
57741251|NCT03934398|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
57741252|NCT03934398|DIAGNOSTIC_TEST|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
57741253|NCT03877094|BEHAVIORAL|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
57741254|NCT03385928|DRUG|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
57741255|NCT03385928|DRUG|Normal saline|Placebo given within 2 hours of symptom onset
57741256|NCT01440491|OTHER|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
57741257|NCT01387139|DRUG|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
57741258|NCT01387139|DRUG|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
57741259|NCT05777226|DRUG|Epalrestat|Patients in the treatment group are intervened with Epalrestat tablets.
57741260|NCT05118685|DRUG|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
57741261|NCT05118685|COMBINATION_PRODUCT|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
58445051|NCT03605108|DIETARY_SUPPLEMENT|Probiotic|"• Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
58445052|NCT03605108|OTHER|Placebo|Rice flour only
58445053|NCT00988013|RADIATION|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
58445054|NCT00988013|RADIATION|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
57741262|NCT00605293|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
57741263|NCT00605293|DRUG|Epoetin alfa|As prescribed
57741264|NCT05890599|BEHAVIORAL|Yoga Therapy|"The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume."
57741265|NCT05890599|BEHAVIORAL|Health Education|Health education courses are conducted on-site once a week for 90 minutes over 12 weeks by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
57741266|NCT03217110|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
57956705|NCT05940792|OTHER|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
58312854|NCT00769561|BEHAVIORAL|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
58445055|NCT00988013|RADIATION|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
58445056|NCT00988013|RADIATION|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
58445057|NCT02837458|DEVICE|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
57956706|NCT01549236|DRUG|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
58445058|NCT02837458|DEVICE|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
58445059|NCT02396212|BIOLOGICAL|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
58445060|NCT06727097|DIAGNOSTIC_TEST|Posturography|"Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns."
58445061|NCT06727097|DIAGNOSTIC_TEST|Walking Speed|The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.
58445062|NCT06727097|DIAGNOSTIC_TEST|Instrumented 7M Timed UP and GO|This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.
58445063|NCT06727097|OTHER|Fall Event Records|A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.
58445064|NCT06727097|DIAGNOSTIC_TEST|MRI (3T)|Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
58445065|NCT00398034|DRUG|Testosterone Gel|
58445066|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
58445067|NCT06088979|OTHER|Placebo|Placebo
58445068|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
58445069|NCT00196664|DRUG|Paroxetine|
58445070|NCT05006261|DEVICE|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
58445071|NCT05523817|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
58445072|NCT06725238|OTHER|Acute-to-chronic glycemic ratio|This ratio could be related to diabetic foot ulcer
58445073|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
57956707|NCT03956095|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
57956708|NCT03956095|OTHER|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
57956709|NCT03757910|DRUG|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
57956710|NCT03757910|DRUG|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
57956711|NCT06180954|DRUG|[14C]-LOXO-305|Administered orally
57956712|NCT06180954|DRUG|LOXO-305|Administered orally
58445074|NCT02470598|OTHER|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
58445075|NCT00899756|GENETIC|molecular diagnostic method|
58445076|NCT00899756|GENETIC|mutation analysis|
57741267|NCT03217110|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
57741268|NCT00490893|DRUG|Detemir|
57741269|NCT05190991|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
57741270|NCT03195933|OTHER|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
57956713|NCT06180954|DRUG|[14C]-LOXO-305|Administered IV
58113236|NCT00439764|BEHAVIORAL|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
58113237|NCT04496089|DIAGNOSTIC_TEST|89Zr-girentuximab|A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
58113238|NCT04035837|DRUG|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
58445077|NCT04953130|BIOLOGICAL|Gardasil® HPV vaccine|Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
58445078|NCT04354324|DRUG|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
58445079|NCT05337800|BEHAVIORAL|stress managment program|A four-session stress management program will be applied to the experimental group students.
58445080|NCT03797846|PROCEDURE|combined glaucoma surgery|combined procedure with trabeculectomy and cataract removal
58445081|NCT06108154|BEHAVIORAL|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
58445082|NCT05867212|DRUG|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
58445083|NCT06468995|OTHER|Surveys completion|Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
58445084|NCT06468995|DRUG|Home administration of CAB+RPV|Drug treatment and follow-up at home (home arm).
58445085|NCT06468995|DRUG|Hospital administration of CAB+RPV|Drug treatment and follow-up in hospital (hospital arm)
58445086|NCT00318799|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
58445087|NCT00318799|DRUG|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
58445088|NCT00856765|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
58445089|NCT00856765|DEVICE|Bare metal stent|Bare metal stent
58445090|NCT00856765|DEVICE|Drug eluting stent|Paclitaxel eluting stent
58445091|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
58445092|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
58445093|NCT04046900|BIOLOGICAL|Vaginal microbiome transplant|Vaginal fluid from healthy donors
58445094|NCT04046900|DRUG|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
58445095|NCT04046900|OTHER|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
57741271|NCT03195933|OTHER|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
57741272|NCT04099108|COMBINATION_PRODUCT|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
57741273|NCT01483924|DRUG|Apo805K1|Sequential parallel dose escalation.
57741274|NCT05865431|DRUG|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
57956714|NCT03098329|OTHER|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
57956715|NCT02052271|DEVICE|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
57956716|NCT05319392|DIAGNOSTIC_TEST|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
57956717|NCT01344876|DRUG|OPB-51602|once daily during the treatment period
57956718|NCT03798158|OTHER|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
57956719|NCT05562375|DEVICE|GOCCLES|"Inspection using GOCCLES®. An UV light source will be administered, with polymerization lamp sdi radii xpert, with a potency of 1500 mW/cm2 and a wavelength of 440-480nm, applied at 20cm of the injury.~Notes will be taken on the location and size of the injury observed with the device.~Image register using the GOCCLES® photographic filter for mobile devices. The same light source will be used."
58445096|NCT06490133|DIETARY_SUPPLEMENT|Polyhpenol extract|Three capsules in fasting conditions 15 minutes prior breakfast
58445097|NCT06490133|DIETARY_SUPPLEMENT|Placebo|Three capsules in fasting conditions 15 minutes before breakfast
58458528|NCT01033240|DRUG|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
58113239|NCT01853007|BEHAVIORAL|COACH Program|
58113240|NCT03673384|DEVICE|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
58113241|NCT03673384|DEVICE|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
57741275|NCT00103246|DRUG|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
57741276|NCT04216316|DRUG|Berzosertib|Given IV
57741277|NCT04216316|PROCEDURE|Biospecimen Collection|Correlative studies
57956720|NCT05562375|DIAGNOSTIC_TEST|Toluidine blue stain|"To value the toluidine blue diagnosis capacity, the sequence described by Mashberg will be followed: The patient will realize a mouthwash with acetic acid at 1% for 20 seconds. Two using water for 20 seconds. Toluidine blue at 1% will be applied for 20 seconds. New mouthwash with acetic acid for 60 seconds and a final mouthwash with water.~Notes on the and pictures will be taken on the location and size of the injury."
57956721|NCT05562375|PROCEDURE|Biopsy|The area to biopsy will be chosen, and, using local anaesthesia, it will be resected. The specimens will be sent to the oral and maxillofacial pathology diagnostic service of the University of Basque Country for anatomopathological study
58113242|NCT03673384|DRUG|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
58113243|NCT03673384|DRUG|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
58445098|NCT02891395|DRUG|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
57956722|NCT03189446|RADIATION|Vaginal Cuff Brachytherapy|Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
57741278|NCT04216316|DRUG|Carboplatin|Given IV
57741279|NCT04216316|PROCEDURE|Computed Tomography|Undergo CT
57741280|NCT04216316|DRUG|Gemcitabine Hydrochloride|Given IV
57741281|NCT04216316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57956723|NCT03189446|DRUG|Carboplatin|Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
57741282|NCT04216316|BIOLOGICAL|Pembrolizumab|Given IV
57956724|NCT03189446|DRUG|Paclitaxel|Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
58113244|NCT00996528|BEHAVIORAL|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
57741283|NCT04572048|OTHER|Single-day NRP Training|NRP training course completed in one single day of 8 hours
58113245|NCT01445132|DRUG|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
57741284|NCT04572048|OTHER|longitudinal NRP training|NRP training course completed over one year by attending nine 30-minute modules.
57741285|NCT01628029|OTHER|Counseling|Undergo CBT
57741286|NCT01628029|DRUG|Methylphenidate Hydrochloride|Given PO
57741287|NCT01628029|PROCEDURE|Phototherapy|Undergo light therapy
57741288|NCT01628029|OTHER|Placebo Administration|Given PO
58113246|NCT01337154|DRUG|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
58113247|NCT01337154|DRUG|Placebo|Tablets, orally, daily
58113248|NCT02241681|DIETARY_SUPPLEMENT|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
58113249|NCT03799978|DRUG|ACT-541468|ACT-541468 50 mg film-coated tablets
57741289|NCT01628029|OTHER|Quality-of-Life Assessment|Ancillary studies
57741290|NCT01628029|PROCEDURE|Sham Intervention|Undergo sham light therapy
57741291|NCT01628029|DRUG|Therapeutic Melatonin|Given PO
58458529|NCT01033240|DRUG|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
58445099|NCT03728010|DIAGNOSTIC_TEST|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
58445100|NCT06576076|BEHAVIORAL|Contingency management for cannabis abstinence|Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
58445101|NCT05534399|PROCEDURE|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
57741292|NCT01508039|OTHER|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
57741293|NCT01516047|DRUG|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
58113250|NCT02987595|OTHER|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
58445102|NCT04516109|DEVICE|Modified hip capsule side fixed slotted cannula|Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
58445103|NCT04516109|DEVICE|Modified bone graft delivery tool set|Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
58445104|NCT06727045|OTHER|Mandala Coloring|"A literature review was conducted to determine the frequency and number of mandalas to be applied to the patients in the intervention group, and the average of the number of mandala sessions applied to different patient groups was obtained, and mandala application was performed during a total of eight hemodialysis sessions, every other day. Mandala painting was performed approximately 30 minutes after the start of HD treatment, considering the art therapist's recommendation and the symptoms that may develop during HD. Each mandala painting was performed with a structured and different mandala pattern. Since it was stated that the use of round patterns instead of square patterns was effective in increasing the comfort level, the booklet called Mandala Booklet, consisting of 8 structured mandala patterns with round shapes and containing general information about mandala, was used in the study. The group was informed about the content of the booklet face to face. Dry pencils were prefer"
58445105|NCT01708317|BEHAVIORAL|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
58445106|NCT06402123|DRUG|zagociguat 15mg|Once-daily oral tablets
58445107|NCT06402123|DRUG|zagociguat 30mg|Once-daily oral tablets
58445108|NCT06402123|DRUG|Placebo|Once-daily oral tablets
58113251|NCT02987595|OTHER|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
58445109|NCT06123078|BEHAVIORAL|CaCBT|Culturally adapted Self help guide and modules total eight 80 hour session per week
58445110|NCT03894618|DRUG|SL-279252|The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
57741294|NCT01516047|DRUG|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
57741295|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
57741296|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
57741297|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
57741298|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
57741299|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
58113252|NCT00682383|DRUG|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
58113253|NCT03184103|DIAGNOSTIC_TEST|anti streptolysin o titre and serum complement test|diagnostic lab test
58113254|NCT00318552|DRUG|Meropenem|
58113255|NCT04302766|DRUG|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
58113256|NCT02785172|DRUG|IDP-118 Vehicle Lotion|Vehicle
58113257|NCT02785172|DRUG|IDP-118 Vehicle Cream|Vehicle
58445111|NCT04293185|GENETIC|bb1111|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
58445112|NCT00730808|DIETARY_SUPPLEMENT|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
58445113|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
58445114|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
58312855|NCT00769561|DEVICE|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
58445115|NCT05766826|OTHER|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
58445116|NCT05766826|OTHER|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
57741300|NCT04315077|DIETARY_SUPPLEMENT|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
57741301|NCT04315077|OTHER|Resistance Training|5 days of supervised and programmed whole-body resistance training.
57741302|NCT04193800|OTHER|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
57741303|NCT04866212|BEHAVIORAL|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
57741304|NCT04866212|BEHAVIORAL|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
57956725|NCT01415427|DRUG|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
57956726|NCT01415427|DRUG|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
57956727|NCT02121457|DIETARY_SUPPLEMENT|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
57956728|NCT02121457|DIETARY_SUPPLEMENT|selenium|
57956729|NCT04041882|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
57956730|NCT05572775|PROCEDURE|Quadratus lumborum (QL) block|bilateral anterior subcostal quadratus lumborum block
57956731|NCT05572775|PROCEDURE|Erector Spinae Plane (ESP) Block|bilateral erector spinae plane block
57956732|NCT02302898|BEHAVIORAL|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
57956733|NCT02302898|OTHER|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
57956734|NCT02302898|OTHER|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
57956735|NCT06308276|OTHER|Aerobic Training|Aerobic Training: Brisk walking, jogging, cycling, or low-impact aerobics
57956736|NCT06308276|OTHER|Resistance Training|Resistance Training: Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
58113258|NCT02785172|DRUG|IDP-118 Lotion|Lotion
58113259|NCT02785172|DRUG|Ultravate Cream|Cream
58312856|NCT06551753|OTHER|virtual reality app|virtual reality app
58312857|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
58312858|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
58445117|NCT01693536|BEHAVIORAL|Lifestyle counselling|as in Arm Description
58445118|NCT06457867|PROCEDURE|microfragmented adipose tissue loaded on bovine graft|microfragmented adipose tissue loaded on bovine graft on ridge preservation
58445119|NCT05838157|BIOLOGICAL|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
58445120|NCT02509923|DRUG|Z-215 10mg|Z-215 10mg, capsules
57956737|NCT04223934|OTHER|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
58445121|NCT02509923|DRUG|Z-215 20mg|Z-215 20mg, capsules
57956738|NCT05069857|DRUG|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
57956739|NCT05069857|DRUG|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
57956740|NCT06310980|DEVICE|smartpen|use of a smartpen connected with glucose sensor by an digital application
57956741|NCT03946709|OTHER|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
57956742|NCT00419380|DRUG|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
57956743|NCT05558839|BEHAVIORAL|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
57956744|NCT02958488|DEVICE|High Flow Nasal Cannula|
57956745|NCT00220012|PROCEDURE|Folate depletion and supplementation|
57956746|NCT06130267|OTHER|Endocare|Virtual paradigm (calming environnement)
57956747|NCT02150577|BEHAVIORAL|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
57956748|NCT02224859|DEVICE|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
57956749|NCT02224859|OTHER|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
57956750|NCT03864653|BEHAVIORAL|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
57956751|NCT00806559|OTHER|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
57956752|NCT00806559|OTHER|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
57956753|NCT02127190|DRUG|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
57956754|NCT02127190|DRUG|Placebo|
57956755|NCT04865068|DIAGNOSTIC_TEST|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
58312859|NCT04243278|DRUG|Low-dose aspirin|81 mg of low dose aspirin PO for 6 months
58312860|NCT04243278|DRUG|Placebo oral tablet|placebo PO for 6 months
58445122|NCT02509923|DRUG|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
58445123|NCT02509923|DRUG|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
58445124|NCT02820454|DRUG|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
58445125|NCT02820454|RADIATION|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
58445126|NCT04685265|DRUG|anle138b|capsule containing excipient and anle138b
58113260|NCT04076306|OTHER|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
58113261|NCT04810195|DEVICE|Boston Scientific Acurate neo2 TAVR device|The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.
58113262|NCT06544213|BEHAVIORAL|Control Group|60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.
58113263|NCT06544213|BEHAVIORAL|Countermeasure Supine Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position."
58113264|NCT06544213|BEHAVIORAL|Countermeasure AG-Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.~The supine bike exercise is performed in a short arm centrifuge in rotation. Volunteers will start pedalling and the centrifuge will start at 0.15 Gz less than individual's threshold.~Every 4 minutes thereafter, the AG will be increased by 0.15 Gz, synchronized with the ramping up of cycle ergometer interval intensity. The AG will increase only up to 70 % of their tolerance level,.~It will then decrease by 0.15 Gz every 4 minutes, and until the 30-minute exercise is completed."
58113265|NCT03535883|DRUG|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
58113266|NCT01263899|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
58445127|NCT04685265|DRUG|Placebo|matching placebo capsule containing excipient
58113267|NCT03428659|OTHER|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
58113268|NCT04555525|DRUG|sarecycline|sarecycline tablet
58113269|NCT04555525|DIETARY_SUPPLEMENT|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
58113270|NCT02815904|OTHER|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
58312861|NCT04130841|PROCEDURE|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
58312862|NCT02171624|DRUG|dabigatran etexilate|
57741305|NCT04866212|DIAGNOSTIC_TEST|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
57741306|NCT02247609|GENETIC|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
57956756|NCT03847701|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
57956757|NCT03847701|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
57956758|NCT01061814|DRUG|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
57956759|NCT01061814|DRUG|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
57956760|NCT00128544|DRUG|telbivudine|
58113271|NCT02815904|OTHER|Conventional handling|Positioning of preterm infants for optimal physiological development
58113272|NCT02815904|OTHER|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
58113273|NCT02815904|OTHER|Kangaroo Mother Care|Providing skin to skin human touch
58312863|NCT02171624|DRUG|quinidine|
58445128|NCT06291480|BEHAVIORAL|Neurologic Music Therapy|Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
58445129|NCT05676112|DRUG|nintedanib|nintedanib
58445130|NCT05676112|DRUG|pirfenidone|pirfenidone
58445131|NCT05270837|DRUG|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
58445132|NCT05270837|OTHER|Diet Only|Diet Control
58445133|NCT02152709|BIOLOGICAL|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
58445134|NCT02152709|BIOLOGICAL|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
58445135|NCT01597336|PROCEDURE|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
58445136|NCT01597336|PROCEDURE|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
58445137|NCT06206161|BEHAVIORAL|Indicated Prevention, Clinical Staff|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
58445138|NCT06206161|BEHAVIORAL|Selective Prevention|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
58445139|NCT06206161|BEHAVIORAL|Expanded Paraprofessional Workforce|Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
58445140|NCT02470520|PROCEDURE|CRRT|continuous renal replacement therapy
58445141|NCT00227409|DRUG|calcium disodium EDTA (edetate calcium disodium)|
58445142|NCT06727175|BEHAVIORAL|non-invasive neuromodulation therapy|Patients with subjective tinnitus were treated using non-invasive neuroregulation therapy. That is, to generate personalized, non-invasive acoustically stimulated neuroregulation regimens for six montns. Each participant was treated three times a day (morning, noon and bedtime) for 30 minutes each time.
58445143|NCT06727175|OTHER|before any intervention|before any intervention
58445144|NCT05092945|OTHER|Cold exposure|The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
57741307|NCT03280758|BEHAVIORAL|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
58445145|NCT05092945|DRUG|Oral Nicotinic acid|A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
57741308|NCT05011851|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
57741309|NCT03278418|PROCEDURE|Tricuspid Valve Repair|It will be performed according to the surgeon preference
57956761|NCT00128544|DRUG|valtorcitabine|
58445146|NCT04131179|BEHAVIORAL|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
58113274|NCT01023269|DEVICE|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
58113275|NCT01332110|DEVICE|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
58113276|NCT05778149|DRUG|Aumolertinib,Anlotinib|Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
57741310|NCT03278418|PROCEDURE|Left-sided valve surgery|It will be performed according to the surgeon preference
57741311|NCT03015402|DRUG|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
57956762|NCT02326415|OTHER|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
57956763|NCT02326415|OTHER|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
58113277|NCT01109459|OTHER|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
58113278|NCT01109459|OTHER|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
58113279|NCT05571761|BEHAVIORAL|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
58113280|NCT00979628|DRUG|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
58113281|NCT00979628|DRUG|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
58113282|NCT00979628|DRUG|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
58113283|NCT00857025|BIOLOGICAL|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
58312864|NCT06147674|DEVICE|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~* Pulmonary Blood Flow (PBF)~* Shunt Fraction (Qsi)~* Dead space (VD):~* Functional Residual Capacity (FRC)"
58312865|NCT00819039|DRUG|Aprepitant|Aprepitant administered orally or intraveously.
58312866|NCT00819039|DRUG|Ondansetron|Ondansetron administered intravenously.
58445147|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
58113284|NCT00857025|OTHER|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
58113285|NCT00857025|OTHER|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
58113286|NCT00857025|OTHER|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
58113287|NCT03786289|BIOLOGICAL|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
58113288|NCT03786289|BIOLOGICAL|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
58113289|NCT00004797|DRUG|fructose|
58113290|NCT00004797|DRUG|placebo|
58312867|NCT05225740|BEHAVIORAL|Standard Exposure|The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
58312868|NCT05225740|BEHAVIORAL|Stress Management Training|Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
58113291|NCT04611659|BEHAVIORAL|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
58113292|NCT00549198|DRUG|Abacavir/lamivudine and efavirenz|
58113293|NCT00549198|DRUG|Tenofovir/Emtricitabine and efavirenz|
58113294|NCT00929903|DRUG|pazopanib hydrochloride|Given orally
58113295|NCT00929903|OTHER|pharmacological study|Correlative studies
58113296|NCT05555082|OTHER|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
58113297|NCT05063019|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging and enterography before surgery
58113298|NCT03686800|DEVICE|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
58113299|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
58113300|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
58113301|NCT01066481|DRUG|Placebo|Placebo three times daily for 6 months
58113302|NCT01637311|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
58113303|NCT02972411|BEHAVIORAL|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
58113304|NCT02972411|DRUG|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
58113305|NCT02880072|DIETARY_SUPPLEMENT|phosphate orally|4 different preparations of phosphate
58113306|NCT04532541|OTHER|Monogenic lupus screening|This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
58113307|NCT05334654|DRUG|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
58113308|NCT05334654|DRUG|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
58113309|NCT00819650|DRUG|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
57741312|NCT03015402|DRUG|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
58113310|NCT02139306|DRUG|Ataluren (PTC124®)|Oral Ataluren TID
58113311|NCT02139306|DRUG|Placebo|Oral Placebo TID
58113312|NCT03124485|PROCEDURE|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
58113313|NCT03124485|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
58113314|NCT01548469|OTHER|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
58113315|NCT01548469|OTHER|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
58113316|NCT06066385|PROCEDURE|Small bites technique|Closure of the fascia after midline laparotomy using a slowly resorbalbe 2.0 suture, with 0.5 cm bites, and 0.5 cm between the stitches, at least resulting in a 1:4 wound length:suture length ratio.
58113317|NCT06066385|PROCEDURE|Conventional large bites closure|Closure of a midline laparotomy using a slowy resorbable thick suture (e.g. PDS loop) with large bites and large steps (\>= 1 cm).
58113318|NCT01832090|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
58113319|NCT05777265|OTHER|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
58113320|NCT00248339|DRUG|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
58113321|NCT00248339|DRUG|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
58113322|NCT00248339|DRUG|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
58113323|NCT06365827|OTHER|observational study|no intervention of interest
58113324|NCT01873768|DRUG|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
58113325|NCT01873768|DRUG|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
58113326|NCT00208910|BEHAVIORAL|Odorant Cue|
58113327|NCT05232578|RADIATION|Early salvage radiotherapy (eSRT)|"eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
58113328|NCT05232578|RADIATION|Delayed Salvage radiotherapy (dSRT)|"dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
58113329|NCT03440281|DIAGNOSTIC_TEST|Uterine artery doppler|Uterine artery Doppler pulsatility indices
58113330|NCT03440281|DIAGNOSTIC_TEST|Maternal serum homocysteine estimation|
58113331|NCT05544383|BEHAVIORAL|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
57741313|NCT04750746|OTHER|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
57741314|NCT04750746|OTHER|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
58113332|NCT05544383|OTHER|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
58113333|NCT05206032|OTHER|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
58113334|NCT01401920|OTHER|leg elevation|bilateral passive leg elevation for 30 seconds
58113335|NCT01401920|OTHER|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
58113336|NCT01401920|OTHER|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
58113337|NCT01401920|OTHER|control group|supine position without passive leg elevation or trendelenburg position
58113338|NCT00721461|BIOLOGICAL|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
58113339|NCT02831530|DRUG|Abemaciclib|
58113340|NCT06294171|DEVICE|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
58113341|NCT01538316|DIETARY_SUPPLEMENT|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
57741315|NCT01624038|DRUG|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
58113342|NCT01538316|DIETARY_SUPPLEMENT|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
58445148|NCT01462240|DEVICE|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
57741316|NCT01624038|DRUG|hydroxyurea, blood transfusion|* Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
58113343|NCT01538316|DIETARY_SUPPLEMENT|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
58113344|NCT04801602|DIAGNOSTIC_TEST|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
58445149|NCT06088719|PROCEDURE|axillary surgery|one group undergoes axillary surgery
58458530|NCT02900794|DEVICE|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
57741317|NCT04948099|DRUG|VIB1116|VIB1116
57741318|NCT04948099|DRUG|Placebo|Placebo
57741319|NCT00262821|DRUG|cisplatin|Given IV
57741320|NCT00262821|DRUG|tirapazamine|Given IV
58458531|NCT02900794|PROCEDURE|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
58113345|NCT04602351|BEHAVIORAL|Communication|policies on communication and informed consent in ICU
58113346|NCT02415166|BIOLOGICAL|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
58113347|NCT02415166|OTHER|NaCl-saline placebo|placebo
58113348|NCT04393805|DRUG|Low Molecular Weight Heparin|Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
58113349|NCT01088152|BEHAVIORAL|Celiac school|Structured education of adult celiac patients at 10 sessions.
58445150|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
58445151|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
58445152|NCT01011543|PROCEDURE|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
58445153|NCT03634163|BEHAVIORAL|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
58113350|NCT01088152|BEHAVIORAL|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
57741321|NCT01625221|DEVICE|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
57741322|NCT04696666|DEVICE|INSTYLAN (Sodium Hyaluronate 80mg/50ml)|The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
57956764|NCT04336631|BEHAVIORAL|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
57956765|NCT02423915|DRUG|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
58113351|NCT02056730|DRUG|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
58113352|NCT01026610|DRUG|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
58113353|NCT01026610|DRUG|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
58113354|NCT01026610|DRUG|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
58113355|NCT03947047|DIAGNOSTIC_TEST|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
58113356|NCT02630745|PROCEDURE|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
58113357|NCT02630745|PROCEDURE|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
58113358|NCT05214807|DEVICE|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
58113359|NCT05214807|DEVICE|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
58113360|NCT04674176|DRUG|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
58113361|NCT00528437|DRUG|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
58113362|NCT01391182|OTHER|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
58113363|NCT01391182|OTHER|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
58113364|NCT02172716|PROCEDURE|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
58113365|NCT03501550|DRUG|CDI-31244|investigational drug
58113366|NCT03501550|DRUG|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
58113367|NCT03491878|PROCEDURE|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
58113368|NCT03491878|PROCEDURE|Open|Open cholecystectomy including segments IVB and V
58113369|NCT01131728|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
58113370|NCT03085082|DIAGNOSTIC_TEST|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
58113371|NCT01909583|OTHER|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
58113372|NCT05004818|PROCEDURE|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
58113373|NCT05004818|PROCEDURE|Sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
58113374|NCT01892995|DRUG|Ketamine|
58113375|NCT06528678|DEVICE|Intraocular lens|Lens exchange with an intraocular lens
58113376|NCT05687045|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
58113377|NCT05687045|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
58113378|NCT01563471|DRUG|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
58113379|NCT01563471|DRUG|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
58445154|NCT03634163|BEHAVIORAL|Quality of Life Assessment|Completion of baseline measures
58445155|NCT04236752|RADIATION|Stereotactic Ablative Body Radiation (SBRT)|
58445156|NCT01174121|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
58445157|NCT01174121|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
58445158|NCT01174121|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
58445159|NCT01174121|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
58445160|NCT01174121|DRUG|Pembrolizumab (Keytruda)|Arm 3: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks).
58445161|NCT00125957|DRUG|Wellbutrin|
58445162|NCT00125957|DRUG|Placebo|
58458532|NCT02750189|OTHER|Direct cost|Money spent to treat COPD in medical institute based on HIRA
57956766|NCT02423915|DRUG|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
57956767|NCT02423915|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -8.
57956768|NCT02423915|RADIATION|Total Body Radiation|2 Gy delivered on Day -4.
58113380|NCT01314703|DRUG|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
58113381|NCT01314703|DRUG|70% isopropyl alcohol|10.5 ml applicator
58113382|NCT01907659|OTHER|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
58113383|NCT02184494|DEVICE|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
58113384|NCT04289220|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
58113385|NCT03435432|DIETARY_SUPPLEMENT|Glucose|Glucose drink
58113386|NCT03435432|DIETARY_SUPPLEMENT|Water|Control
58113387|NCT00950183|DEVICE|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
57956769|NCT02423915|PROCEDURE|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Fucosylated T-reg cells on Day -1."
58113388|NCT00950183|OTHER|Ice|postoperative cold therapy
58113389|NCT00249457|BEHAVIORAL|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
58113390|NCT02632656|OTHER|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
58113391|NCT01907087|BIOLOGICAL|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
58113392|NCT02600806|DRUG|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
58113393|NCT02600806|DRUG|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
58113394|NCT01527825|BIOLOGICAL|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
58113395|NCT01527825|BIOLOGICAL|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
58113396|NCT06093256|DEVICE|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
58113397|NCT01859390|DRUG|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
58113398|NCT01859390|DIETARY_SUPPLEMENT|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
58113399|NCT05278377|BEHAVIORAL|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
58113400|NCT05953428|OTHER|Opioid Sparing Anesthesia Protocol (OSA)|OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
58113401|NCT05953428|OTHER|Opioid Based Anesthesia Protocol (OBA)|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
58312869|NCT05225740|BEHAVIORAL|Enhanced Exposure|The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.
58312870|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
58113402|NCT04928833|OTHER|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
58113403|NCT04928833|OTHER|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
57741323|NCT06276868|DRUG|Dalcilib+letrozole+HP treatment group|"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks."
57741324|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
58113404|NCT00272337|DRUG|Aspirin|Dosage
58113405|NCT01078415|DEVICE|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
58113406|NCT03846921|DIAGNOSTIC_TEST|Laboratory blood test|Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
58113407|NCT01210183|DRUG|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
58113408|NCT02856074|BIOLOGICAL|prise de sang|
58113409|NCT02856074|OTHER|quality of life questionnaire|
58113410|NCT04202302|PROCEDURE|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
58113411|NCT05874869|DRUG|Dihydroartemisinin-piperaquine|The drug will be administered once a day for three consecutive days for three months (March, April, and May)
57741325|NCT01039701|DRUG|AZD1446|capsules, oral, 3 times daily
58445163|NCT04788394|OTHER|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
57741326|NCT01039701|DRUG|Placebo|capsules, oral, 3 times daily, 4 weeks
57741327|NCT02332590|DRUG|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
57741328|NCT02332590|DRUG|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
58113412|NCT02833857|DRUG|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
58113413|NCT01093859|DRUG|PRX-105|Sterile solution for intravenous injection
58113414|NCT01234259|DEVICE|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
58113415|NCT02478593|BEHAVIORAL|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
58113416|NCT01708928|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
57741329|NCT02332590|DRUG|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
57741330|NCT02332590|DRUG|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
57741331|NCT01618162|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
57741332|NCT01618162|DRUG|placebo|Injected subcutaneously (under the skin) once daily.
57741333|NCT03322969|DRUG|Paclitaxel/DDP|receiving the modified chemotherapy
57741334|NCT03322969|DRUG|XELOX/SOX|receiving the original chemotherapy
57741335|NCT03907124|DRUG|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
57956770|NCT02423915|PROCEDURE|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
58113417|NCT00813371|DEVICE|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
58113418|NCT00813371|DEVICE|ARDSnet protocol|ARDSnet protocol
58113419|NCT05360433|DRUG|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
58113420|NCT01232257|DRUG|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
58113421|NCT02277821|DEVICE|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
58113422|NCT03591978|DIAGNOSTIC_TEST|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
58113423|NCT02533999|DEVICE|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
58113424|NCT02533999|DEVICE|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
58113425|NCT05481580|DIAGNOSTIC_TEST|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
58113426|NCT03947788|BEHAVIORAL|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
58113427|NCT01657487|DRUG|Fluticasone/Salmeterol high dose|
58113428|NCT01261533|DEVICE|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
58113429|NCT06449079|OTHER|Machine learning|Analysis of data with machine learning methods
58113430|NCT01799733|OTHER|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
58113431|NCT01799733|OTHER|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
58113432|NCT04950283|DIAGNOSTIC_TEST|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
58113433|NCT04951388|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
58113434|NCT04951388|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
58113435|NCT04882683|DRUG|Prednisone|0.75 mg per kilogram per day for three months
58113436|NCT04882683|DRUG|Azathioprine|1 mg per kilogram per day for three months
58113437|NCT04882683|DRUG|Adalimumab|40mg every two weeks for three months
58113438|NCT04882683|BIOLOGICAL|umbilical cord blood mononuclear cells|Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10\^8).
58113439|NCT01084005|DRUG|linagliptin|patients receive linagliptin 5 mg tablets once daily
58113440|NCT01084005|DRUG|placebo|patients receive placebo matching linagliptin 5 mg once daily
58113441|NCT00005615|BIOLOGICAL|Interferon alfa|Interferon alfa as outlined in treatment arm.
58113442|NCT00005615|RADIATION|Radiation therapy|Radiation therapy as outlined in treatment arm.
58113443|NCT06527183|DIAGNOSTIC_TEST|Skin punch biopsy to demonstrate small fiber neuropathy|Skin punch biopsy to assess intrapidermal nerve fiber density
58458533|NCT02750189|OTHER|Indirect cost|extra-expanses excluding hospital fees
58458534|NCT01310465|DRUG|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
58458535|NCT01310465|DRUG|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
58113444|NCT00774332|DRUG|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
58113445|NCT02988752|DEVICE|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
58113446|NCT02988752|DEVICE|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
58113447|NCT02462070|DRUG|IDP-118 Lotion|Lotion
58113448|NCT02462070|DRUG|IDP-118 Vehicle Lotion|Lotion
58113449|NCT05142436|OTHER|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
58113450|NCT05142436|OTHER|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
58113451|NCT05142436|OTHER|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
58113452|NCT05142436|OTHER|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
58113453|NCT05142436|OTHER|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
58113454|NCT00736528|DRUG|PF-04447943|05 mg BID for 14 days
58113455|NCT00736528|DRUG|PF-04447943|15 mg BID for 14 days
58113456|NCT00736528|DRUG|PF-04447943|45mg BID for 14 days
58458536|NCT00866177|OTHER|Laboratory Biomarker Analysis|Correlative studies
58458537|NCT00866177|DRUG|Selumetinib|Given orally
58113457|NCT00736528|DRUG|Placebo|Placebo for 14 days
58113458|NCT02798068|DRUG|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
58113459|NCT05426122|OTHER|Barley rice protein concentrate shake|At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
58113460|NCT05426122|OTHER|Pea protein concentrate shake|At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
58113461|NCT05426122|OTHER|Whey protein concentrate shake|At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
58113462|NCT02257359|DRUG|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
58113463|NCT00463866|DRUG|Budesonide/formoterol|
58113464|NCT03619161|OTHER|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
58113465|NCT03619161|OTHER|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
58445164|NCT04788394|OTHER|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
57741336|NCT03907124|DRUG|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
58445165|NCT04561258|BIOLOGICAL|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
58445166|NCT03507673|DIAGNOSTIC_TEST|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
58445167|NCT05870423|DRUG|olaparib|18 days olaparib during each cycle of PRRT
58445168|NCT04979676|BEHAVIORAL|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
57956771|NCT02423915|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
57956772|NCT02423915|DRUG|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
58113466|NCT04988659|OTHER|Exposures|Exposures
58445169|NCT04979676|BEHAVIORAL|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
58445170|NCT04979676|BEHAVIORAL|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
58113467|NCT04900506|PROCEDURE|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
58445171|NCT00813189|DEVICE|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
58445172|NCT01180686|DEVICE|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
58445173|NCT01180686|DEVICE|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
58445174|NCT04585841|DRUG|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
58445175|NCT05037474|PROCEDURE|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
58445176|NCT05952557|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
58445177|NCT05952557|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered orally
58113468|NCT05472610|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
58312871|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
57956773|NCT02423915|PROCEDURE|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
58113469|NCT03005470|DEVICE|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
58113470|NCT03005470|DEVICE|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
58113471|NCT03005470|DEVICE|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
58113472|NCT03005470|OTHER|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
58113473|NCT03077633|PROCEDURE|Cervical Cerclage placement|Cervical Cerclage placement
58113474|NCT03077633|DRUG|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
58113475|NCT04140006|DRUG|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
58113476|NCT04140006|DRUG|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
58113477|NCT04140006|DRUG|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
58113478|NCT04140006|DRUG|Control|Flapped surgery for insertion of dental implant without topical application of any gel
58113479|NCT05226156|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
58113480|NCT04371783|PROCEDURE|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
58113481|NCT04371783|PROCEDURE|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
58113482|NCT01410383|DRUG|Placebo|Tablets taken daily
58113483|NCT01410383|DRUG|Eprotirome|Tablets taken daily
58113484|NCT01410383|DRUG|Eprotirome|Tablets taken daily
58445178|NCT05952557|DRUG|Anastrozole|Anastrozole. Comparator. Administered orally
58113485|NCT02060461|DEVICE|FS200 femtosecond laser LASIK|
58113486|NCT02060461|DEVICE|IntraLase femtosecond laser LASIK|
58113487|NCT06528353|DIAGNOSTIC_TEST|HPV16-E6 serology and HPV ctDNA|"In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance."
58113488|NCT01620489|DRUG|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
58445179|NCT05952557|DRUG|Letrozole|Letrozole. Comparator. Administered orally
58445180|NCT05952557|DRUG|Exemestane|Exemestane. Comparator. Administered orally
58445181|NCT05952557|DRUG|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
58445182|NCT02316496|DRUG|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
58445183|NCT02316496|DRUG|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
58113489|NCT01620489|DRUG|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
58113490|NCT01976390|DRUG|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
58113491|NCT01976390|DRUG|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
58113492|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
58113493|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
58113494|NCT02039479|DRUG|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
58113495|NCT02039479|DRUG|Placebo|Placebo as ADD-on to every necessary treatment as usual
58113496|NCT03552120|BEHAVIORAL|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
58445184|NCT03319004|DEVICE|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
58113497|NCT03552120|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
58113498|NCT05101499|PROCEDURE|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
58113499|NCT05101499|PROCEDURE|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
58113500|NCT00004316|DRUG|capsaicin|
58113501|NCT06324214|DIETARY_SUPPLEMENT|Urolithin A (Mitopure)|Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
58113502|NCT06324214|OTHER|Placebo|Placebo.
58113503|NCT03094806|DEVICE|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
58445185|NCT05899400|DIAGNOSTIC_TEST|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
58445186|NCT06726408|OTHER|Neuromonitoring with 10 electrodes|"In case of no parental objection, the clinician may begin neuromonitoring according to standard indications. The number of electrodes applied to the child's skull will be 10 electrodes (8 recording electrodes, 1 reference electrode, and 1 ground electrode) instead of the current 5.~The intensivist will analyze the quantitative EEG trace as they currently do but will also have access to additional tools for seizure detection support (CDSA and seizure detection software) and targeted review of part of the recording by a neurophysiologist in case of doubt. Access to the neurophysiologist will be available during current working hours on weekdays. Data will be collected in 12-hour periods."
58445187|NCT03407755|PROCEDURE|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
58113504|NCT03094806|DEVICE|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
58113505|NCT03334565|DEVICE|Low efficiency air filtration systems|Subjects were exposed to low-efficiency filtered air.
58445188|NCT06725550|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
58445189|NCT06725550|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
58445190|NCT05730413|DRUG|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
58113506|NCT03334565|DEVICE|High efficiency air filtration systems|Subjects were exposed to high-efficiency filtered air.
58113507|NCT03334565|DEVICE|Air filtration systems without filters (sham)|Subjects were exposed to unfiltered air.
58445191|NCT05730413|DRUG|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
58113508|NCT03655210|DRUG|HL151|HL151(1Tab) once a day for 4 weeks of treatments
58113509|NCT03655210|DRUG|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
58113510|NCT02416583|DRUG|Oxytocin|
58113511|NCT02416583|DRUG|Dinoprostone|
58113512|NCT02416583|PROCEDURE|Membrane sweeping|
58113513|NCT02874963|PROCEDURE|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
58113514|NCT02874963|DEVICE|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
58445192|NCT05721170|DRUG|Beta blocker|Investigation on beta-blockers in TAVI and brief post-TAVI period.
58445193|NCT01540357|BEHAVIORAL|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
58445194|NCT01540357|BEHAVIORAL|Treatment after waiting time|Treatment was performed after completion of the active arm.
58113515|NCT02874963|DRUG|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
58113516|NCT03994445|BEHAVIORAL|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
58113517|NCT04193631|DRUG|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
58113518|NCT03910803|DRUG|Brodalumab|"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."
58113519|NCT00337805|OTHER|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
58113520|NCT02847533|PROCEDURE|blood sample|blood sample for concentration levels of inflammatory markers
58113521|NCT02847533|BEHAVIORAL|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
58445195|NCT05712720|DRUG|Experimental: Group 1|RZ402 50 mg oral tablet, once daily for 3 months
58113522|NCT03295799|OTHER|Patient Self-Management|Patient will manage their own warfarin therapy.
58113523|NCT01732965|OTHER|Phototherapy|
58445196|NCT05712720|DRUG|Experimental: Group 2|RZ402 200mg oral tablet, once daily for 3 months
58445197|NCT05712720|DRUG|Experimental: Group 3|RZ402 400mg oral tablet, once daily for 3 months
58113524|NCT01732965|OTHER|Phototherapy and Photochemotherapy|
58113525|NCT02143947|DEVICE|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
58113526|NCT02143947|DEVICE|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
58113527|NCT00116415|DRUG|efavirenz; didanosine EC; lamivudine|
58113528|NCT05524987|BEHAVIORAL|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months
58113529|NCT02970669|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
58113530|NCT02970669|DRUG|enalapril|Enalapril tablet taken orally.
58113531|NCT02970669|DRUG|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
58445198|NCT05712720|OTHER|Placebo: Group 4|Placebo, once daily for 3 months
58445199|NCT01950403|DRUG|linaclotide acetate|Given PO
58445200|NCT01950403|OTHER|placebo|Given PO
58445201|NCT01950403|OTHER|pharmacological study|Correlative studies
58445202|NCT01950403|OTHER|laboratory biomarker analysis|Correlative studies
58445203|NCT06113211|DRUG|Narcotic pain medication|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
58113532|NCT02970669|DRUG|matching placebo enalapril|matching placebo enalapril tablet taken orally
58113533|NCT03999281|OTHER|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
58113534|NCT05153356|DEVICE|Personal Kinetigraph, Kinesia 360|10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
58445204|NCT06113211|DRUG|Nonnarcotic pain medications|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
58445205|NCT01637155|DRUG|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
58445206|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
58445207|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
58445208|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
58113535|NCT01155583|DRUG|azacitidine|Given by subcutaneous injection (SC)
58113536|NCT01155583|DRUG|lenalidomide|Given orally
58113537|NCT01155583|DRUG|dexamethasone|Given orally
58113538|NCT01155583|OTHER|DNA methylation analysis|Correlative studies
58113539|NCT01155583|OTHER|gene expression analysis|Correlative studies
58113540|NCT01155583|OTHER|bone marrow aspiration|Correlative studies
58445209|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
58445210|NCT06137976|PROCEDURE|Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)|Placement of tube through the nose or mouth into the stomach for gastric decompression
58445211|NCT04305366|OTHER|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
58445212|NCT06726746|DEVICE|Fractional CO2 laser|". Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic."
58445213|NCT00584519|OTHER|non-interventional|non-interventional
58445214|NCT03502447|DEVICE|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
58445215|NCT03502447|DEVICE|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
58445216|NCT04721210|OTHER|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
58445217|NCT00181662|DRUG|Curcumin|
58113541|NCT01155583|OTHER|immunohistochemistry staining method|Correlative studies
58113542|NCT01155583|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
58113543|NCT01155583|OTHER|flow cytometry|Correlative studies
58445218|NCT04661007|DRUG|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
58113544|NCT04147715|DRUG|S-648414|Tablet for oral administration
58113545|NCT04147715|DRUG|Placebo|Tablet for oral administration
58113546|NCT04147715|DRUG|Midazolam|Solution for oral administration
58113547|NCT04147715|DRUG|Dolutegravir|Tablet for oral administration
58113548|NCT00756964|DRUG|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
58113549|NCT00756964|DRUG|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
58113550|NCT01486706|DRUG|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
58113551|NCT01486706|DRUG|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
58113552|NCT01486706|DRUG|Placebo drugs|will titrate medications similar to the active drug group
58113553|NCT06254209|DIETARY_SUPPLEMENT|Botanicals extracts|Powder included in capsules for daily administration
58113554|NCT06254209|DIETARY_SUPPLEMENT|Placebo|Maltodextrin included in capsules for daily administration
58113555|NCT05008237|DRUG|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
58445219|NCT04661007|DRUG|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
58445220|NCT04661007|DRUG|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
58445221|NCT04661007|DRUG|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
58445222|NCT04046146|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
58113556|NCT04377178|DEVICE|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
58113557|NCT04377178|DEVICE|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
58113558|NCT02917200|DRUG|Moxifloxacin|Oral route
58113559|NCT02917200|DEVICE|DAV132|Oral route
58113560|NCT02917200|OTHER|Negative control|Oral route
58113561|NCT06312332|BEHAVIORAL|Pulmonary Embolism (PE) Care in Emergency Department (ED)|Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
58445223|NCT04046146|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
58445224|NCT04220554|OTHER|Improved support by health-care professionals|Improved support to patients prescribed topical antipsoriatic drugs
58445225|NCT04249817|OTHER|Video Conferencing with Exteneded Role Practitioner (VC-ERP)|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
58445226|NCT04208555|DRUG|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
58445227|NCT04208555|DRUG|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
58445228|NCT00636285|DRUG|Placebo|Placebo
58445229|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
57956774|NCT02423915|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
57956775|NCT02423915|PROCEDURE|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1."
57956776|NCT06391671|OTHER|Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)|Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
58113562|NCT03246568|PROCEDURE|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
58113563|NCT03246568|PROCEDURE|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
58113564|NCT03502421|DRUG|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
58113565|NCT03895593|OTHER|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
58113566|NCT00003747|DRUG|carboplatin|
58113567|NCT00003747|DRUG|temozolomide|
58113568|NCT01140984|DRUG|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
58113569|NCT00318266|DEVICE|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
58113570|NCT06118359|BEHAVIORAL|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
58113571|NCT01339195|BEHAVIORAL|French adaptation of NINDS-Canadian Stroke Network battery|"* clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI"
58113572|NCT00376428|DRUG|Gentamicin|
58113573|NCT03137082|DRUG|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
58113574|NCT03137082|DRUG|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
58113575|NCT01844934|OTHER|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
58445230|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
57956777|NCT05034965|DRUG|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
57956778|NCT06110130|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
57956779|NCT06110130|DRUG|Placebo|Take Placebo 10 mg orally daily for 4 months
58113576|NCT03555721|OTHER|Oral examination with incandescent light|Suspicious oral lesions will be identified by oral examination with incandescent light.
58113577|NCT03555721|OTHER|Oral examination with OralID|OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
58113578|NCT03555721|DIAGNOSTIC_TEST|Biopsy|Tissue will be collected to identify pre-cancerous or cancerous cells
58113579|NCT03555721|DIAGNOSTIC_TEST|CytID|CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
57956780|NCT00264706|DRUG|Nona-L-arginine|
58445231|NCT00779493|DIETARY_SUPPLEMENT|curcumin|curcumin 900mg twice daily by mouth
58445232|NCT00779493|DIETARY_SUPPLEMENT|placebo|placebo capsule to simulate 900mg curcumin capsule
58445233|NCT01383226|PROCEDURE|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
57956781|NCT01259609|PROCEDURE|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
57956782|NCT01733472|DRUG|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
57956783|NCT01733472|DRUG|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
57956784|NCT03106038|DRUG|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
57956785|NCT03289650|DRUG|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
57741337|NCT01575366|BEHAVIORAL|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
58113580|NCT03555721|DIAGNOSTIC_TEST|hpvID|hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
58113581|NCT01416376|DRUG|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
58445234|NCT04747899|OTHER|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
58445235|NCT04747899|OTHER|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
58445236|NCT00016328|DRUG|temsirolimus|Given IV
58445237|NCT00016328|OTHER|laboratory biomarker analysis|Correlative studies
58445238|NCT00016328|OTHER|pharmacological study|Correlative studies
58445239|NCT05661604|OTHER|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
58445240|NCT02613585|OTHER|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
58445241|NCT03539718|DRUG|Taurolidine heparin|Taurolock-hep 500 at end of session
58445242|NCT03539718|DRUG|Heparin Sodium|Heparin sodium 5000 at end of session
58445243|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
57741338|NCT06533228|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)|Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
57741339|NCT03265600|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
58113582|NCT01416376|DRUG|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
58113583|NCT00490061|DRUG|Lapatinib|1500 mg po daily orally
58113584|NCT00490061|PROCEDURE|Radiotherapy (radiation)|Standard of Care
58445244|NCT05059509|BIOLOGICAL|FB825|FB825, 5mg/kg, by 1 hour IV infusion on Day 1
58445245|NCT04515901|DRUG|2% lidocaine|Viscous lidocaine
58445246|NCT04515901|OTHER|Placebo|Methylcellulose and cherry flavouring
58445247|NCT03792256|DRUG|Palbociclib|Given PO (or via NG- tube)
58445248|NCT03792256|DRUG|Cytarabine|Given intrathecally (IT)
58445249|NCT03792256|DRUG|Methotrexate|Given intrathecally (IT)
58445250|NCT03792256|DRUG|Hydrocortisone|Given IT
58445251|NCT03792256|DRUG|Doxorubicin|Given intravenously (IV)
58445252|NCT03792256|DRUG|Prednisolone|Either prednisone or prednisolone is given PO
58445253|NCT03792256|DRUG|Vincristine|Given IV
58445254|NCT03792256|DRUG|Pegaspargase|Given IV
58445255|NCT03792256|DRUG|Hydrocortisone|Given intrathecally (IT)
58445256|NCT03792256|DRUG|Prednisone|Either prednisone or prednisolone is given PO
58445257|NCT02031263|PROCEDURE|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
58445258|NCT05350644|OTHER|Primary exposure variable|"1. Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~2. Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
58445259|NCT05350644|OTHER|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
58445260|NCT02345473|GENETIC|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
58445261|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
58445262|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
58445263|NCT06725576|PROCEDURE|Ablation|Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
58445264|NCT02353715|DRUG|Enzalutamide|
57741340|NCT03265600|BEHAVIORAL|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
57741341|NCT04823884|PROCEDURE|open distal chevron osteotomy|Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.
57741342|NCT04823884|PROCEDURE|minimally invasive distal chevron osteotomy|The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
57741343|NCT00381940|DRUG|ifosfamide|Given IV
57741344|NCT00381940|DRUG|bortezomib|Given IV
57741345|NCT00381940|DRUG|vinorelbine tartrate|Given IV
58113585|NCT00490061|DEVICE|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
58113586|NCT00490061|DEVICE|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
58113587|NCT05425966|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
58113588|NCT01005550|DRUG|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
58113589|NCT01005550|DRUG|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
58113590|NCT01005550|DRUG|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
58113591|NCT01005550|DRUG|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
58113592|NCT01331785|DRUG|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
58113593|NCT05583890|DEVICE|Continuous glucose monitors|Participants will wear continuous glucose monitors for a 7 day period.
58113594|NCT05583890|DEVICE|Activity tracker|Participants will wear the activity tracker for a 7 day period.
58113595|NCT05583890|BEHAVIORAL|Food Diary|Participants will complete a food diary of everything they eat for 7 days.
58113596|NCT05583890|BEHAVIORAL|Questionnaires|Participants will complete FACT-Hep, DiPcare-Q and health inequality related questions.
58445265|NCT02353715|DRUG|Abiraterone acetate|
58113597|NCT03546582|DRUG|Pembrolizumab|Anti-PD-1 targeted immunotherapy
58113598|NCT03546582|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
58113599|NCT01907724|DRUG|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
58113600|NCT01907724|DRUG|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
58113601|NCT01907724|DRUG|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
58113602|NCT01907724|DRUG|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
58113603|NCT05798403|DEVICE|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
58113604|NCT05798403|DRUG|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
58113605|NCT01288833|DEVICE|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
58113606|NCT01987804|DRUG|Oxytocin 100 i.u.|
58113607|NCT01987804|DRUG|Oxytocin 400 i.u.|
58113608|NCT01987804|DRUG|Placebo|
58113609|NCT00058357|DRUG|lidocaine|
58113610|NCT00058357|OTHER|placebo|
58445266|NCT02353715|DRUG|Sipuleucel-T|
58445267|NCT02728453|DRUG|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
58445268|NCT02728453|DRUG|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
58445269|NCT05233033|DRUG|KT-413|KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
58113611|NCT06378983|DRUG|Oral isotretinoin|Oral isotretinoin
58113612|NCT06378983|OTHER|Oral isotretinoin combined with microneedle radiofrequency therapy|Oral isotretinoin combined with microneedle radiofrequency therapy
58113613|NCT05307263|PROCEDURE|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
58113614|NCT05307263|PROCEDURE|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
58113615|NCT03207659|PROCEDURE|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
58113616|NCT03207659|PROCEDURE|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
58113617|NCT02058433|OTHER|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
58113618|NCT02058433|OTHER|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
57956786|NCT03289650|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
57956787|NCT06116825|OTHER|1450ppm Fluoride toothpaste|1450ppm Fluoride toothpaste
58113619|NCT05114226|DRUG|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
58445270|NCT04936633|OTHER|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~- Intervention contents~1. Diet, exercise pattern~2. Causes of hypoglycemia~3. Causes of hyperglycemia~4. Causes of glycemic variability~5. Counseling for improvement plans for the cause~6. Counseling to strengthen lifestyle modification~7. Counseling for insulin administration~8. Counseling for Insulin dose adjustment (adjusted dose)~9. Counseling for how to use a FSGM"
57956788|NCT06116825|OTHER|1000Pppm Fluoride toothpaste|1000Pppm Fluoride toothpaste
57956789|NCT04519892|OTHER|PDRC|Personalized depression risk communication.
58113620|NCT01952574|DRUG|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
58113621|NCT01952574|DRUG|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
58113622|NCT01952574|DRUG|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
58113623|NCT01952574|DRUG|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
58113624|NCT04765033|DRUG|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
58113625|NCT04023630|DRUG|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
58458538|NCT03043534|OTHER|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
58458539|NCT03043534|OTHER|Brush|All subjects randomized to brush will use the brush with each shave
57741346|NCT00381940|BIOLOGICAL|filgrastim|Given IV or SC
57741347|NCT01168284|BEHAVIORAL|Coping Effectiveness Training|
57956790|NCT04519892|OTHER|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
57956791|NCT01783327|BEHAVIORAL|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
57741348|NCT04319510|PROCEDURE|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
57956792|NCT01783327|BEHAVIORAL|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
57956793|NCT00027339|DRUG|lopinavir/ritonavir|
57956794|NCT00027339|DRUG|indinavir sulfate|
57956795|NCT00027339|DRUG|tenofovir disoproxil fumarate|
57956796|NCT00027339|DRUG|ritonavir|
57956797|NCT00027339|DRUG|fosamprenavir|
57956798|NCT05204264|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
57956799|NCT05204264|BEHAVIORAL|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
57956800|NCT05284760|DRUG|Soticlestat|Soticlestat T4 tablets.
57956801|NCT05284760|DRUG|Soticlestat|Soticlestat T3 mini-tablets.
57956802|NCT05284760|DRUG|Soticlestat|Soticlestat commercial tablets.
57956803|NCT05135650|OTHER|Questionnaire Administration|Ancillary studies
57956804|NCT05135650|BIOLOGICAL|Sotrovimab|Given IV
57956805|NCT05135650|PROCEDURE|Biospecimen Collection|Undergo blood and nasal swab sample collection
57956806|NCT00405197|BEHAVIORAL|Isocaloric diet high in MUFA or Mediterranean diet|
57956807|NCT00916253|DRUG|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
57956808|NCT00916253|DRUG|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
57956809|NCT06499987|PROCEDURE|resection anastomosis|resection of stenotic part of trachea and reanastmosis
58113626|NCT04023630|DRUG|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
58113627|NCT04023630|DRUG|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
58113628|NCT05975021|DRUG|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 1.0 or 0.5 µg/kg/min for 18 hours, 0.5 µg/kg/min for 24 hours. Total duration 48 hours.
58113629|NCT05975021|DRUG|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
58113630|NCT06399419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58113631|NCT06399419|PROCEDURE|Bone Scan|Undergo bone scan
58113632|NCT06399419|BIOLOGICAL|CBM588 Capsules|Given PO
58445271|NCT04440748|DEVICE|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
58445272|NCT04440748|OTHER|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
58445273|NCT03565536|DRUG|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
58113633|NCT06399419|PROCEDURE|Computed Tomography|Undergo CT
58445274|NCT03565536|PROCEDURE|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
58445275|NCT03565536|RADIATION|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
57956810|NCT06076915|BEHAVIORAL|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
57956811|NCT04791046|DRUG|antihypertensive therapy|Personalized evidence-based antihypertensive therapy in patients with comorbidities
57956812|NCT00406302|DRUG|Docetaxel|75mg/m², day 1,22
57956813|NCT00406302|DRUG|oxaliplatin|40mg/m², d1,2,22,23
58113634|NCT06399419|BIOLOGICAL|Ipilimumab|Given IV
58113635|NCT06399419|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58113636|NCT06399419|BIOLOGICAL|Nivolumab|Given IV
58113637|NCT06142656|DRUG|Metformin Hydrochloride tablet|Metformin Hydrochloride 850 mg oral tablet
57741349|NCT04319510|PROCEDURE|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
57956814|NCT00406302|DRUG|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
57956815|NCT00406302|PROCEDURE|surgery|28 days after end of induction chemotherapy
58113638|NCT06142656|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG oral tablets
58113639|NCT00863369|BIOLOGICAL|rituximab|Given IV
58113640|NCT00863369|DRUG|bortezomib|Given IV
58113641|NCT00863369|DRUG|gemcitabine hydrochloride|Given IV
58113642|NCT00863369|OTHER|questionnaire administration|Ancillary studies
58113643|NCT04537247|PROCEDURE|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
58113644|NCT03104205|BEHAVIORAL|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
57956816|NCT00287625|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation
57741350|NCT04319510|PROCEDURE|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered 2 treatments (4TUS) of 1:1 CST and the participation in the group training.
57956817|NCT05822687|BEHAVIORAL|Education|This is a constant component; all participants will get a psychoeducation digital module.
57956818|NCT05822687|BEHAVIORAL|Reappraisal Coping|This digital module will teach reappraisal coping skills.
57956819|NCT05822687|BEHAVIORAL|Distraction Coping|This digital module will teach distraction coping skills.
57956820|NCT05822687|BEHAVIORAL|Relaxation Coping|This digital module will teach relaxation coping skills.
58445276|NCT00856063|DRUG|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
58445277|NCT06025539|BEHAVIORAL|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
58445278|NCT04515758|OTHER|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
58445279|NCT04515758|OTHER|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
58445280|NCT06385483|DRUG|Afatinib|Given PO
57741351|NCT00214357|BEHAVIORAL|Mindfulness-based stress reduction|
57741352|NCT00162370|DRUG|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
57956821|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
57956822|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
57956823|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
57956824|NCT01052298|DRUG|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
57956825|NCT03354754|DRUG|LYS228|LYS228 IV infusion every 6 hours
57956826|NCT03354754|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
57956827|NCT03346460|OTHER|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
57956828|NCT03346460|RADIATION|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
58113645|NCT02382471|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
58113646|NCT02382471|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
58113647|NCT01035320|DRUG|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
58113648|NCT00603343|DRUG|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
58113649|NCT00603343|DRUG|placebo|placebo corresponding to body weight
58113650|NCT04923529|DRUG|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
58113651|NCT05765110|OTHER|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
58113652|NCT05765110|OTHER|DBS OFF state|Turning off the stimulation during experiment
58113653|NCT05765110|OTHER|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
58113654|NCT05765110|OTHER|DBS ON state|Experiment will be performed with stimulation (ON condition)
58113655|NCT04362774|DEVICE|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
58113656|NCT00256542|DRUG|Alkalinized Lidocaine-Heparin|
57741353|NCT02190539|OTHER|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
57741354|NCT04654780|BEHAVIORAL|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
58113657|NCT04607603|DRUG|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
58113658|NCT04607603|DRUG|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
58113659|NCT06111456|OTHER|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
58113660|NCT06111456|OTHER|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
58113661|NCT04780737|PROCEDURE|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
58113662|NCT00494806|OTHER|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
58113663|NCT05730777|DRUG|Bifidobacterium Bifidum Oral Capsule|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
58113664|NCT05730777|DRUG|Cisplatin|Patients in the control group will receive conventional antitumor treatment only.
58113665|NCT05730777|DRUG|Carboplatin|Patients in the control group will receive conventional antitumor treatment only.
58113666|NCT05730777|DRUG|Paclitaxel|Patients in the control group will receive conventional antitumor treatment only.
58113667|NCT05730777|DRUG|Atlizumab|Patients in the control group will receive conventional antitumor treatment only.
58113668|NCT06546280|DRUG|Camrelizumab|Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
58113669|NCT06546280|DRUG|Apatinib|Apatinib 250 mg will be taken orally once daily.
58113670|NCT01439841|DIETARY_SUPPLEMENT|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
58113671|NCT01439841|DIETARY_SUPPLEMENT|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
58312872|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
58312873|NCT02687672|BIOLOGICAL|Stem Cell Transplantation|Transplantation of autologous stem cells
58445281|NCT06385483|PROCEDURE|Biopsy|Undergo biopsy
58445282|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58113672|NCT03283865|DIAGNOSTIC_TEST|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
58113673|NCT05170425|DEVICE|Prospera|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
57741355|NCT04654780|BEHAVIORAL|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
58113674|NCT01589003|OTHER|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
58113675|NCT01589003|OTHER|High GI growing up milk|High glycaemic index growing up milk
58113676|NCT03080181|DRUG|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
58113677|NCT05934032|OTHER|observational, non-interventional|observational, non-interventional
58113678|NCT01303991|OTHER|Hexvix PDT with Karl Storz T-Light|
58445283|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
58445284|NCT06385483|PROCEDURE|Echocardiography|Undergo ECHO
58445285|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58445286|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
58445287|NCT06548100|DRUG|mibavademab|Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
58445288|NCT03335774|DRUG|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
58445289|NCT03335774|DRUG|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
58445290|NCT06500988|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement a comprehensive digital atrial fibrilation guideline-recommended toolkit
57741356|NCT04654780|BEHAVIORAL|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
58113679|NCT03108105|DEVICE|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
58113680|NCT06277791|DRUG|Adebrelimab|Adebrelimab：20mg/kg, ivdrip, D1，Q3W
58113681|NCT04669899|DRUG|JTX-8064|Specified dose on specified days
58113682|NCT04669899|DRUG|pimivalimab|Specified dose on specified days
58113683|NCT05743283|DEVICE|SynEx Wound Cleanser|SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
57741357|NCT05698810|OTHER|CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability|tests
57741358|NCT05698810|OTHER|CE marked Medical Device Magnetic Resonance Imaging (MRI) usability|tests
57741359|NCT05698810|OTHER|CE marked Medical Device ElectroEncephaloGraphy (EEG) usability|tests
57741360|NCT05698810|OTHER|CE marked Medical Device ElectroCardioGraphy (ECG) usability|tests
57741361|NCT00380848|PROCEDURE|Hemodiafiltration|
58445291|NCT06726161|DIAGNOSTIC_TEST|RYZ811|Ga-68
58445292|NCT06726161|DRUG|RYZ801|Ac-225
58445293|NCT03477396|DRUG|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
58445294|NCT03477396|OTHER|Laboratory Biomarker Analysis|Correlative studies
58445295|NCT03477396|OTHER|Pharmacokinetic Study|Correlative studies
58445296|NCT03477396|OTHER|Questionnaire Administration|Ancillary studies
58445297|NCT03477396|DRUG|Ribociclib|Given PO
58445298|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
58445299|NCT05090891|DRUG|placebo|placebo will be administered QD orally
58445300|NCT01156103|BEHAVIORAL|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
58445301|NCT01645254|DRUG|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
58445302|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
58445303|NCT05730036|DRUG|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
58445304|NCT05730036|DRUG|Elotuzumab|Elotuzumab will be administered by IV infusion
58445305|NCT05730036|DRUG|Pomalidomide|Pomalidomide capsules will administered by mouth (PO)
58445306|NCT05730036|DRUG|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
58113684|NCT05743283|OTHER|Saline|The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.
58113685|NCT02393196|DRUG|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
58113686|NCT02393196|DRUG|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
58113687|NCT01173159|DRUG|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
58113688|NCT05950724|DRUG|Etanercept Injection [Enbrel]|25 mg subcutaneous injection
58113689|NCT01483872|DRUG|NAC/Tigecycline/Heparin combination lock solution|
58113690|NCT01483872|DRUG|Standard anticoagulant (Heparin or Citrate)|
58113691|NCT00003833|GENETIC|DNA stability analysis|
58113692|NCT00003833|GENETIC|gene mapping|
58113693|NCT00526890|DIETARY_SUPPLEMENT|selenomethionine|Oral Twice daily
58113694|NCT00526890|DRUG|carboplatin|Weekly IV
58113695|NCT00526890|DRUG|paclitaxel|Weekly IV
58113696|NCT00526890|OTHER|laboratory biomarker analysis|Correlative Study
58113697|NCT00526890|RADIATION|radiation therapy|Undergoing radiation Therapy
58113698|NCT05893212|BEHAVIORAL|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
58113699|NCT05893212|BEHAVIORAL|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
58113700|NCT05436158|OTHER|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
58113701|NCT02942251|OTHER|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
58113702|NCT02942251|OTHER|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
58113703|NCT02942251|OTHER|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
58113704|NCT02942251|OTHER|Laboratory abnormality|This group will be suggested to more safety antidepressants.
58113705|NCT02942251|OTHER|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
58113706|NCT02942251|OTHER|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
58113707|NCT00163410|DRUG|Ciclesonide|
58113708|NCT04052399|DEVICE|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
58113709|NCT04052399|DEVICE|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
58113710|NCT04052399|DEVICE|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
58113711|NCT03567057|DRUG|ADS-5102, 274 mg|Oral capsules
58113712|NCT03397563|DEVICE|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
58445307|NCT06097663|DRUG|MAS825|Active MAS825 single dose
58445308|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
58113713|NCT03397563|DEVICE|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
58113714|NCT05724433|OTHER|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
58113715|NCT05724433|OTHER|Routine HF Care|Care as determined by the treating physician
58113716|NCT02370966|DIETARY_SUPPLEMENT|Berry powder|Berry and gingivitis trial
58113717|NCT00762671|DRUG|Ebselen|150 mg BID for 2 weeks
58113718|NCT00762671|DRUG|Placebo|Placebo 1 po BID for 2 weeks
58312874|NCT06237179|BEHAVIORAL|Exercise Training Intervention|5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
58445309|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
58445310|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
58445311|NCT02021643|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
58113719|NCT04482010|OTHER|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
58113720|NCT04876898|OTHER|prospective cohort in high body mass index patient with covid 19|A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels
58113721|NCT03129737|PROCEDURE|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
58113722|NCT03129737|PROCEDURE|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
58113723|NCT02878850|OTHER|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
58113724|NCT05222815|OTHER|CGM|Continuous glucose monitor (CGM)-based glucose monitoring
58113725|NCT05222815|OTHER|SMBG|Self-monitoring of blood glucose (SMBG)-based glucose monitoring
58113726|NCT03480828|DIAGNOSTIC_TEST|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
58113727|NCT00437151|OTHER|More frequent than normal office visits|Mode of patient reminder
58113728|NCT00437151|OTHER|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
58113729|NCT00437151|OTHER|Parenteral involvement / intervention reminders|Mode of patient reminder
58113730|NCT00437151|OTHER|No intervention or reminders|Mode of patient reminder
58113731|NCT01374399|BEHAVIORAL|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
58445312|NCT02021643|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
58445313|NCT02021643|DRUG|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
58113732|NCT02956720|DEVICE|UltraShape Power|non-invasive body contouring procedure
58445314|NCT06007820|PROCEDURE|Large Volume Thoracocentesis|Large Volume Thoracocentesis
58113733|NCT01983956|BEHAVIORAL|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
58113734|NCT05445115|DEVICE|Mollie device|medical device
58113735|NCT03588156|DRUG|Benapenem|Dose-escalation For 11 level dose groups A1 \~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
58113736|NCT03588156|DRUG|Placebo|Placebo
58113737|NCT03104153|PROCEDURE|Early-drain removal|Drain removal at hospital discharge
58113738|NCT06542926|PROCEDURE|liver resection|Resection of non-colorectal liver metastases
58113739|NCT03500939|DRUG|Medical oxygen|inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
58445315|NCT06007820|PROCEDURE|Pigtail Catheter|Pigtail Catheter
58445316|NCT01458483|DEVICE|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
58445317|NCT03655561|OTHER|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
58445318|NCT06264011|BEHAVIORAL|Salaat|While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
58445319|NCT06264011|OTHER|Sham comparator|Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
58445320|NCT02442440|DRUG|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
58113740|NCT03500939|OTHER|Standard of care|e.g. thrombectomy, thrombolysis
58113741|NCT05342090|OTHER|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
58113742|NCT02058628|DRUG|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
58113743|NCT02058628|DRUG|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
58113744|NCT00235859|DRUG|adalimumab|
58113745|NCT00235859|DRUG|methotrexate|
58445321|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
58113746|NCT03170505|PROCEDURE|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
58113747|NCT02621515|DRUG|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
58113748|NCT02711150|DEVICE|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
58113749|NCT01006668|DRUG|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
58113750|NCT01006668|DRUG|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
58445322|NCT04218409|DRUG|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
58445323|NCT04218409|DRUG|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
57741362|NCT05917795|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
57741363|NCT02621931|DRUG|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
58113751|NCT05960851|DRUG|LY3871801|Administered orally.
58113752|NCT05960851|DRUG|Placebo|Administered orally.
58113753|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
58113754|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
58445324|NCT04218409|OTHER|Placebo Oxycodone|Oxycodone 0 mg orally
58445325|NCT04218409|OTHER|Placebo oxytocin|Intranasal placebo administration
58445326|NCT04218409|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
58113755|NCT04813822|DRUG|Miconazole Nitrate 2%|Active Comparator
58113756|NCT03773094|DRUG|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
58113757|NCT03773094|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
58445327|NCT04142294|DIETARY_SUPPLEMENT|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
58113758|NCT06190847|OTHER|regular chemoradiotherapy|regular chemoradiotherapy
58113759|NCT04654728|PROCEDURE|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
57741364|NCT02621931|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
57741365|NCT03150472|DEVICE|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
58113760|NCT05687305|OTHER|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
58113761|NCT05837364|OTHER|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
58113762|NCT01992289|DRUG|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
58113763|NCT00350857|DRUG|Extended-Release Carbamazepine|
58113764|NCT01337050|DRUG|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
58113765|NCT04605419|PROCEDURE|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
58113766|NCT01299038|DRUG|rosuvastatin|Taken orally once a day for 4 weeks
58113767|NCT03753854|DIAGNOSTIC_TEST|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
58113768|NCT03753854|BIOLOGICAL|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
58113769|NCT03753854|BIOLOGICAL|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
58113770|NCT03753854|OTHER|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
58113771|NCT03753854|OTHER|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
58113772|NCT05021627|PROCEDURE|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
58312875|NCT06237179|BEHAVIORAL|Healthy Living Education|During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
58312876|NCT02020642|PROCEDURE|Renal transplantation|Renal transplantation from cadaveric or live donor
57741366|NCT03399695|PROCEDURE|preoxygenation|spontaneous breathing
57741367|NCT00478348|PROCEDURE|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
58445328|NCT06029049|DRUG|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
58445329|NCT06029049|DRUG|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
58445330|NCT01565681|DRUG|ASP1240|infusion
57741368|NCT05488392|PROCEDURE|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
58113773|NCT05021627|PROCEDURE|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
58113774|NCT00240357|PROCEDURE|Lifestyle Regulation|
58113775|NCT00767325|DRUG|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
58445331|NCT01565681|DRUG|Placebo|infusion
58445332|NCT00627250|DRUG|Amantadine|Amantadine 100 mg every morning and 12 noon
58113776|NCT00767325|DRUG|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
57741369|NCT05803226|BEHAVIORAL|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
58312877|NCT02873689|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule
58445333|NCT05054426|DRUG|Methotrexate|intravenous versus intrathecal methotrexate
58445334|NCT06726187|OTHER|Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).|Screening questionnaire
58445335|NCT02132819|OTHER|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
58445336|NCT02132819|OTHER|feeding during transfusion|The feeding process will be continued during the transfusion
58458540|NCT04024917|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~- The program cardiac coherence will be performed during 90 days after the surgery"
58113777|NCT05686733|DEVICE|SEAL Device|Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
58113778|NCT03164590|DRUG|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
57741370|NCT02234674|OTHER|Current intensive CDP|"Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging"
57741371|NCT02234674|OTHER|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
58113779|NCT03164590|DRUG|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
58113780|NCT03164590|DRUG|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
58113781|NCT03717766|DEVICE|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
58113782|NCT00864942|DRUG|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
58113783|NCT00864942|DRUG|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
58113784|NCT00864942|DRUG|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
58312878|NCT02873689|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
58458541|NCT04024917|OTHER|Standard care|Standard care
58458542|NCT05075330|BEHAVIORAL|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
57741372|NCT02089880|DEVICE|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
57741373|NCT02089880|DEVICE|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
57956829|NCT03346460|RADIATION|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
57956830|NCT04448587|DRUG|Sitagliptin 100mg|Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
57956831|NCT02706730|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
57956832|NCT04422249|PROCEDURE|laparoscopic middle hepatic vein guidance anatomic hemihepatectomy|95 patients with primary HCC were divided into the middle hepatic vein guidance group(n=45) and the traditional group(n=45) according to the odd and even Numbers, and sealed into envelopes.Outcomes were monitored and evaluated during the 3-year follow-up period
57956833|NCT02899039|BIOLOGICAL|extra blood draw samples|
58113785|NCT00864942|DRUG|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
58113786|NCT00511563|DRUG|GW876008 and GSK561679|GW876008 and GSK561679
58113787|NCT02070848|OTHER|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
58113788|NCT02070848|OTHER|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
57741374|NCT03326375|RADIATION|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
57741375|NCT01508468|DRUG|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
58113789|NCT02070848|OTHER|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
58113790|NCT04570410|PROCEDURE|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
58445337|NCT01440088|DRUG|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
58113791|NCT04570410|DRUG|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
58113792|NCT04570410|DRUG|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
58113793|NCT00200005|DEVICE|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
58113794|NCT05574426|BEHAVIORAL|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
58113795|NCT01193517|DRUG|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
58113796|NCT01193517|DRUG|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
58113797|NCT01193517|DRUG|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
58113798|NCT01193517|DRUG|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
57741376|NCT01508468|DRUG|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
57741377|NCT04552964|OTHER|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
57741378|NCT02828722|OTHER|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
57741379|NCT02828722|OTHER|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
58113799|NCT06306495|OTHER|International Physical Activity Survey|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
58113800|NCT06104930|OTHER|Explorative biomarker study|Analysis of blood biomarker
58113801|NCT04771819|DEVICE|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
58113802|NCT04945720|PROCEDURE|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
58113803|NCT04945720|DRUG|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
58113804|NCT00000372|DRUG|D-cycloserine|
58113805|NCT00000372|DRUG|Glycine|
58113806|NCT00000372|DRUG|Clozapine|
58113807|NCT00000372|DRUG|Placebo|
58113808|NCT04641481|BIOLOGICAL|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
58113809|NCT04641481|BIOLOGICAL|Placebo|Placebo (PBS+Alum, without antigen)
58113810|NCT00840983|PROCEDURE|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
58113811|NCT06379399|DRUG|Cetuximab|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;
58312879|NCT04987073|PROCEDURE|skin biopsy|A skin biopsy to cultivate fibroblasts.
58312880|NCT00070434|DRUG|capecitabine|825mg/m2 BID, PO, daily
58312881|NCT00070434|DRUG|fluorouracil|Bolus + IV for 46 hrs on Day 1
58312882|NCT00070434|DRUG|irinotecan hydrochloride|IV infusion over 90 min on Day 1
58312883|NCT00070434|DRUG|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
58312884|NCT00070434|DRUG|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
57741380|NCT03468010|RADIATION|chemoradiation|radiation with concurrent ciplatin
58113812|NCT06379399|DRUG|Trifluridine/Tipiracil|"Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;"
58113813|NCT06189755|DEVICE|Positive Airway Pressure|Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
58113814|NCT05702359|OTHER|Glucose as reference food|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113815|NCT05702359|OTHER|Control juice|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113816|NCT05702359|OTHER|Juice with vitamin D3|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113817|NCT05702359|OTHER|Juice with n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113818|NCT05702359|OTHER|Juice with probiotics|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113819|NCT05702359|OTHER|Juice with probiotics, vitamin D3, and n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
58113820|NCT00630669|PROCEDURE|Rubber band ligation|placing rubber bands around the internal hemorrhoids
58113821|NCT00630669|PROCEDURE|Bipolar coagulation|using electricity to cauterize
58113822|NCT02452060|DRUG|Ketamine|0.4mg/kg infusion
58113823|NCT02452060|OTHER|Placebo Comparator|0.4mg/kg infusion
58113824|NCT03306056|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
58445338|NCT01440088|DRUG|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
57741381|NCT03468010|DRUG|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
57741382|NCT04986176|DRUG|HC-1119|oral
57741383|NCT04986176|DRUG|Placebo|oral
57741384|NCT01967732|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
58113825|NCT03306056|OTHER|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
58445339|NCT03818191|DRUG|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
58445340|NCT03818191|OTHER|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
58445341|NCT00505557|PROCEDURE|Transaxillary dual plane technique|
57741385|NCT01967732|OTHER|CC|Single use of subject's own conventional cigarette (CC)
57741386|NCT01967732|OTHER|NNS|Single administration of 1 mg of nicotine
57741387|NCT05366777|DRUG|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
57741388|NCT05366777|DRUG|Saline|100 ml of normal saline
57741389|NCT06200766|DRUG|Mometasone furoate as a nasal spray|Subjects received 2 presses in each side nostrils at the same time point (± 1h).
57741390|NCT02137161|DRUG|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
57741391|NCT02137161|DRUG|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
57741392|NCT01435083|DRUG|Desmopressin|120 µg, oral lyophilisate, sublingual use
57956834|NCT06493994|OTHER|transaxillary (TAX) transcatheter aortic valve replacement|Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval Octacor transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
57956835|NCT03615183|DRUG|MK-8527|Single oral capsule
57956836|NCT01797211|DIETARY_SUPPLEMENT|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
57956837|NCT02236052|BIOLOGICAL|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
57956838|NCT02236052|BIOLOGICAL|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
57956839|NCT02236052|BIOLOGICAL|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
57956840|NCT02236052|BIOLOGICAL|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
57956841|NCT02236052|BIOLOGICAL|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
57956842|NCT02236052|BIOLOGICAL|Placebo|A single dose of placebo
57956843|NCT02355561|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
57956844|NCT02355561|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
57956845|NCT02355561|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
57956846|NCT05299437|DRUG|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
57956847|NCT04455373|PROCEDURE|pediatric vascular bypass grafting|pediatric vascular bypass grafting
57956848|NCT05598372|BEHAVIORAL|shotblocker|infant pain during vaccination and mother anxiety
57956849|NCT05598372|BEHAVIORAL|lullaby|infant pain during vaccination and mother anxiety
57956850|NCT03183882|BEHAVIORAL|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
57956851|NCT03183882|BEHAVIORAL|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
57956852|NCT04854681|DRUG|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
57956853|NCT03393767|DRUG|Ranibizumab|Intravitreal injection
57956854|NCT05269758|BEHAVIORAL|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
57956855|NCT02271503|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
57956856|NCT02271503|DRUG|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
57956857|NCT02271503|DRUG|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
57956858|NCT02271503|DRUG|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
57956859|NCT02271503|DRUG|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
57956860|NCT06471868|DRUG|IY-HCR21|Betanechol 50mg
57956861|NCT06471868|DRUG|IY-MIC|Betanechol 25mg
57956862|NCT01776073|BEHAVIORAL|Patient Navigation|
57956863|NCT02057783|OTHER|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
58445342|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
58445343|NCT04140630|OTHER|No intervention|No intervention; 1 week observational study
58445344|NCT02293798|DEVICE|silk surgical scaffold|surgical implant
58113826|NCT03306056|OTHER|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
58113827|NCT03306056|OTHER|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks"
58113828|NCT05138198|BEHAVIORAL|Mediterranean Diet & Physical Activity|"At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals"
58445345|NCT00546546|DRUG|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
58445346|NCT02392572|DRUG|Akt/ERK Inhibitor ONC201|Given PO
58445347|NCT01887132|DRUG|Donepezil|
57741393|NCT03832595|OTHER|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
57741394|NCT03832595|OTHER|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
57741395|NCT01089426|DRUG|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
57741396|NCT01089426|OTHER|Historical Controls|Standard of Care
58445348|NCT01887132|DRUG|Placebo|
58445349|NCT04881617|BEHAVIORAL|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
58445350|NCT04881617|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
58445351|NCT02756676|PROCEDURE|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
58445352|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
57741397|NCT06540339|OTHER|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
57741398|NCT03932604|DEVICE|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
57741399|NCT00636649|DRUG|Escitalopram|10-20 mg
57741400|NCT00636649|DRUG|Placebo|Placebo
57741401|NCT04656535|DRUG|Zimberelimab|Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
57741402|NCT04656535|DRUG|Domvanalimab|Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
57741403|NCT04656535|DRUG|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
57741404|NCT02605486|DRUG|Palbociclib|
58113829|NCT05138198|BEHAVIORAL|Usual Care|As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
58113830|NCT04175327|DEVICE|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
58113831|NCT00499720|DRUG|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
58113832|NCT00752661|DRUG|Tramadol Hydrochloride; JNS013|
58113833|NCT04933578|BEHAVIORAL|Dental anxiety scales|"* The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (\>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25."
57741405|NCT02605486|DRUG|Bicalutamide|
57741406|NCT01611701|PROCEDURE|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
57741407|NCT01611701|PROCEDURE|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
58113834|NCT05873777|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
58113835|NCT00717210|DRUG|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
58113836|NCT00717210|RADIATION|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
58113837|NCT01892423|OTHER|Cetaphil Moisturizing Lotion Daily Advance|
58113838|NCT00417027|PROCEDURE|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
58113839|NCT01904383|DRUG|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
57741408|NCT01163370|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
57741409|NCT01163370|OTHER|exercise training|resistance training twice a week for 24 weeks
57741410|NCT01163370|OTHER|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
57741411|NCT00330083|BIOLOGICAL|ALK Ragweed Tablet|
57741412|NCT06683508|DRUG|LY3549492|Administered orally
57741413|NCT06683508|DRUG|Placebo|Administered orally
57741414|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
57741415|NCT02930733|DRUG|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
57741416|NCT02930733|DRUG|Saline|2 ml saline subcutaneously bilaterally
57741417|NCT06649292|DRUG|SHR-A1904|SHR-A1904
57741418|NCT06649292|DRUG|Paclitaxel, Docetaxel, Irinotecan|Paclitaxel, Docetaxel, Irinotecan
57741419|NCT03816774|DRUG|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
57741420|NCT06398327|PROCEDURE|PULPOTOMY TREATMENT|During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
57741421|NCT00599612|DRUG|GW856553|A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
57741422|NCT02246127|DRUG|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
58113840|NCT01271764|OTHER|no drug|The role of G9a protein in patients with endometrial cancer
57741423|NCT02246127|DRUG|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops."
57741424|NCT05245669|BIOLOGICAL|ENZ215|healthy volunteers receive ENZ215 (60mg) once
57741425|NCT05245669|BIOLOGICAL|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
57741426|NCT05245669|BIOLOGICAL|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
57741427|NCT01022762|DRUG|repaglinide|Individually adjusted dose for 16 weeks
58113841|NCT04120220|OTHER|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
57741428|NCT01022762|DRUG|gliclazide|Individually adjusted dose for 16 weeks
58113842|NCT04120220|OTHER|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
58113843|NCT02061085|DRUG|Eribulina|
58113844|NCT04627220|DIAGNOSTIC_TEST|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
58113845|NCT03164863|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
58113846|NCT04427709|DRUG|Oxytocin|Intramuscular injection of Oxytocin (Pitocin®)
58113847|NCT04427709|DRUG|Placebo|Intramuscular placebo injection
58113848|NCT02754323|DEVICE|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
58113849|NCT04523142|DRUG|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
58113850|NCT05171803|OTHER|No intervention|No intervention, prospective, cohort study.
58445353|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
58445354|NCT04303572|DRUG|Eloctate ITI|This is a factor VIII-Fc infusion protein.
58445355|NCT04303572|DRUG|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
58445356|NCT04789915|DRUG|Memantine|Add on treatment with memantine to aripiprazole.
58445357|NCT04789915|DRUG|Placebo|Placebo add on to aripiprazole
58445358|NCT00288678|PROCEDURE|Health Education|
58445359|NCT06230224|DRUG|Odronextamab|Administered by intravenous (IV) infusion
58445360|NCT06230224|DRUG|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
58113851|NCT02760550|OTHER|No intervention|Participants of all three groups completed a questionnaire.
58113852|NCT01913730|DRUG|Bortezomib|
58113853|NCT01913730|DRUG|Dexamethasone|
58113854|NCT03903640|DEVICE|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
58113855|NCT03903640|BIOLOGICAL|Nivolumab|-Standard of care
58113856|NCT03903640|BIOLOGICAL|Ipilimumab|-Standard of care
58113857|NCT02444533|DRUG|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
58445361|NCT06230224|DRUG|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
57741429|NCT06393348|DRUG|HRS-7535|HRS-7535
57741430|NCT06393348|DRUG|Placebo|Placebo
58113858|NCT02780661|DEVICE|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
58445362|NCT06230224|DRUG|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
58445363|NCT06230224|DRUG|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
58445364|NCT06230224|DRUG|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
58445365|NCT06230224|DRUG|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
58113859|NCT02780661|DEVICE|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
58113860|NCT02780661|OTHER|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
58113861|NCT01643369|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
58113862|NCT01643369|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
58445366|NCT06230224|DRUG|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
58445367|NCT06230224|DRUG|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
58445368|NCT05479240|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
58445369|NCT05479240|DRUG|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
58445370|NCT05479240|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
58445371|NCT05479240|RADIATION|short-range radiotherapy|5\*5Gy，d1-d5
58113863|NCT01643369|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
58113864|NCT03650933|BIOLOGICAL|G-CHOP|6 cycles(each cycle is 3 weeks)
58445372|NCT00687804|DRUG|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
58445373|NCT00687804|PROCEDURE|Laser|Laser photocoagulation treatment
58445374|NCT00687804|PROCEDURE|Sham laser|Sham to laser procedure.
58445375|NCT00687804|DRUG|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
58445376|NCT06176768|DRUG|LY3972406|Administered orally
58445377|NCT06176768|DRUG|Placebo|Administered orally
57741431|NCT01839110|DRUG|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
57741432|NCT01839110|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
57741433|NCT03430674|BEHAVIORAL|Exercise|Exercise, questionnaires and blood draws.
58113865|NCT03650933|BIOLOGICAL|R-CHOP|6 cycles(each cycle is 3 weeks)
58113866|NCT02579330|DEVICE|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
58113867|NCT02579330|OTHER|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
58445378|NCT03257033|DRUG|Gemcitabine|Chemotherapy
58445379|NCT03257033|DRUG|nab-paclitaxel|Chemotherapy
58445380|NCT03257033|DEVICE|RenovoCath|Intra-arterial catheter
58445381|NCT00795236|DRUG|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
58445382|NCT06725316|BEHAVIORAL|4-7-8 breathing exercises|Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
58445383|NCT03261609|OTHER|preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
58445384|NCT01187628|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
58113868|NCT03367026|DRUG|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
58113869|NCT06484192|DRUG|Naproxen 500 Mg|participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
58113870|NCT06484192|DRUG|Ketorolac|participants will receive Ketorolac (15 mg) immediately after surgery
58113871|NCT06484192|DRUG|OxyCODONE 5 mg Oral Tablet|participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
58113872|NCT06484192|DRUG|Metaxalone 800 MG|participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
58113873|NCT04093947|OTHER|Observational study|Observational and prospective study
58113874|NCT02057952|BEHAVIORAL|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
57956864|NCT04258943|DRUG|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
57956865|NCT05105490|DRUG|PerQdisc|Observational trial to collect post-market safety and efficacy information in a limited number of human patients
57956866|NCT01700556|OTHER|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
57956867|NCT01700556|OTHER|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
57741434|NCT04218461|DIAGNOSTIC_TEST|PRE-DELIRIC model|To predict delirium according to risk factors in the PRE-DELIRIC model
57956868|NCT01700556|OTHER|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
57956869|NCT01700556|OTHER|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
57956870|NCT05051774|BEHAVIORAL|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
58113875|NCT02947113|DRUG|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
58113876|NCT02947113|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
58113877|NCT02947113|DRUG|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
58113878|NCT02947113|DRUG|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
58113879|NCT04823871|PROCEDURE|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
58113880|NCT01044147|BEHAVIORAL|VLM-S|Online program for weight loss - standard
58113881|NCT01044147|BEHAVIORAL|VLM-M|Online program for weight loss - modulated
58113882|NCT01044147|BEHAVIORAL|OGR|Online program for weight loss - resources
58113883|NCT05321810|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
58445385|NCT03610191|DIAGNOSTIC_TEST|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
58445386|NCT03610191|BEHAVIORAL|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
58445387|NCT03610191|PROCEDURE|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
58445388|NCT05307692|DRUG|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
58445389|NCT05307692|DRUG|Placebo|Matching placebo will be administered orally as a tablet.
58445390|NCT04223713|PROCEDURE|TriRec|Trileaflet Reconstruction of the Aortic Valve
58445391|NCT04223713|PROCEDURE|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
57956871|NCT05051774|BEHAVIORAL|2. Exercise|"The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
57956872|NCT05051774|BEHAVIORAL|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
57956873|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine|
57956874|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine + adjuvant|
57956875|NCT02797236|BIOLOGICAL|Placebo|
57956876|NCT02797236|BIOLOGICAL|Placebo + adjuvant|
58445392|NCT00676013|PROCEDURE|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
57956877|NCT02161679|DRUG|IMMU-132 infusion is administered to participants in one arm for the study|
57956878|NCT02161679|DRUG|IMMU-132 plus Carboplatin infusion|
57956879|NCT05616260|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
57956880|NCT05616260|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
57956881|NCT05616260|DEVICE|Continuous Positive Airway Pressure|Standard CPAP device
58113884|NCT05321810|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
58113885|NCT00440154|DRUG|AVE5530|
58113886|NCT00440154|DRUG|placebo|
57956882|NCT02875639|DRUG|Yiqi prescription|
57956883|NCT02875639|DRUG|Huoxue prescription|
58113887|NCT00440154|DRUG|ezetimibe|
58113888|NCT03806894|DIAGNOSTIC_TEST|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
58445393|NCT00676013|PROCEDURE|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
58445394|NCT00676013|PROCEDURE|Homograft|Grafting using homograft as a skin substitute
58445395|NCT00676013|PROCEDURE|Autograft|grafting using patients own skin from a separate donor site
58445396|NCT01496469|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
58445397|NCT01496469|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
58445398|NCT05121948|DRUG|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
58113889|NCT00865982|DRUG|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
58113890|NCT01725477|DRUG|methylen blue &normal saline|Washing after dye injection
58445399|NCT04187495|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
58445400|NCT00871338|BIOLOGICAL|GSK2197870A|3 doses given at 2, 3 and 4 months of age
58445401|NCT00871338|BIOLOGICAL|Prevenar™|3 co-administered doses, intramuscular into right thigh
58445402|NCT00871338|BIOLOGICAL|Menitorix™|1 booster dose at 12 months of age
58445403|NCT00871338|BIOLOGICAL|Pediacel™|3 doses given at 2, 3 and 4 months of age
57956884|NCT02875639|DRUG|Buyang huanwu decoction|
57956885|NCT02875639|DRUG|QISHEN YIQI DRIPPING PILLS|
57956886|NCT02875639|DRUG|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
57956887|NCT02875639|DRUG|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
58445404|NCT00871338|BIOLOGICAL|Menjugate™|2 doses given at 3 and 4 months of age
58445405|NCT05993923|OTHER|GPOU|"Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report"
58445406|NCT05809843|DEVICE|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
57956888|NCT02329769|DRUG|PRO044 SC 6 mg/kg|
57956889|NCT02329769|DRUG|PRO044 IV 6 mg/kg|
57956890|NCT02329769|DRUG|PRO044 IV 9 mg/kg|
57956891|NCT01477242|DRUG|Ondansetron|2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
57956892|NCT05754346|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
57956893|NCT05754346|OTHER|Upper extremity exercises combined with diaphragmatic breathing exercises|"Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises."
57956894|NCT04793295|DRUG|MT-7117|MT-7117
57956895|NCT03740256|BIOLOGICAL|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
57956896|NCT05680363|DEVICE|HyperSperm|Multi-step sperm preparation
57956897|NCT05680363|DEVICE|Standard Sperm Preparation|Standard sperm preparation
57956898|NCT02370875|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
57956899|NCT02370875|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
57956900|NCT04312009|DRUG|Losartan|Losartan; 50 mg daily; oral administration
57956901|NCT04312009|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
57956902|NCT04441229|BEHAVIORAL|ABMT mobile application|"After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required."
57956903|NCT04145414|DEVICE|MRI|Reproductibility test assessed with MRI for cerebrospinal fluid movements
58113891|NCT01725477|DRUG|methylene blue|
58113892|NCT01725477|DRUG|metheylne blue with normal saline|
58113893|NCT06334523|DEVICE|ventilation|"the premature infant will be ventillad by respirator and medical device S-lem for reduce the Continuous Tracheal Gas Insufflation (CTGI). The CTGI is a ventilation option conventional to reduce or even cancel space anatomical death due to respiratory prostheseses."
58113894|NCT03805204|PROCEDURE|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
58113895|NCT01740856|OTHER|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
57741435|NCT01280279|OTHER|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
57956904|NCT05472727|OTHER|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
57956905|NCT05472727|OTHER|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
57956906|NCT04517188|DRUG|Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP|Single topical administration
57956907|NCT00881777|PROCEDURE|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
57956908|NCT00881777|PROCEDURE|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
58113896|NCT01740856|OTHER|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
58113897|NCT03944486|DEVICE|Feasibility of OnTrack|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
58113898|NCT02919137|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
58113899|NCT03679754|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
58113900|NCT03679754|DRUG|veledimex|"* 20mg/day~* 15 oral daily doses of veledimex"
57741436|NCT01085851|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
57741437|NCT01085851|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
57956909|NCT06198673|DRUG|Antiplatelet Agents|Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
57956910|NCT01826552|DEVICE|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
57956911|NCT01826552|DEVICE|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
58113901|NCT05085964|DRUG|RNA antisense oligonucleotide for intravitreal injection|"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
58113902|NCT00192127|BIOLOGICAL|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
57956912|NCT03466177|DIAGNOSTIC_TEST|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
57956913|NCT04245020|OTHER|Text message follow up|A text message will be sent to the patient 6-8 weeks following discharge
57956914|NCT04245020|OTHER|Telephone follow up|The patient will be followed up at 6-8 weeks following discharge with a telephone call
58445407|NCT06165042|OTHER|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
58445408|NCT06165042|OTHER|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
57956915|NCT04245020|OTHER|In person follow up|The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
57956916|NCT03156400|OTHER|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
58445409|NCT02641028|DRUG|CERC-501|CERC-501
58445410|NCT02641028|DRUG|Placebo|Placebo
58445411|NCT00934219|DRUG|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
58445412|NCT05263557|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
58445413|NCT05263557|DIETARY_SUPPLEMENT|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
58445414|NCT04107532|OTHER|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
58445415|NCT00226811|DRUG|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
58445416|NCT04418258|DEVICE|Capillary Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter\[#CSL2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
58445417|NCT04418258|DEVICE|Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter\[#2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
58445418|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
58445419|NCT03259087|DRUG|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
58445420|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
58445421|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
58445422|NCT00604630|DRUG|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
58445423|NCT00604630|DRUG|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
58445424|NCT01220739|DEVICE|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
58445425|NCT04266132|PROCEDURE|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
57956917|NCT06047548|DRUG|Tirzepatide|Administered SC
57956918|NCT06047548|DRUG|Placebo|Administered SC
57956919|NCT05880342|DRUG|Reboxetine Pill|8 mg
57956920|NCT05880342|DRUG|Methylphenidate Oral Product|20 mg
57956921|NCT05080010|DRUG|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
57956922|NCT03042208|OTHER|Self guided handout|Written handout with basic weight management strategies
57956923|NCT03042208|BEHAVIORAL|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
58113903|NCT00192127|OTHER|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
58445426|NCT04266132|PROCEDURE|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
58113904|NCT03859661|DIETARY_SUPPLEMENT|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
58113905|NCT05774509|BIOLOGICAL|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
58113906|NCT02089542|OTHER|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
58113907|NCT03685019|RADIATION|Valgus Stress|Valgus stress radiograph
58113908|NCT03685019|RADIATION|Varus stress|Varus stress radiograph
58445427|NCT04266132|PROCEDURE|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
58445428|NCT04266132|DRUG|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
58445429|NCT00002043|DRUG|Dapsone|
57741438|NCT06372769|DIAGNOSTIC_TEST|electromyograph and kinesiograph|"The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities."
57741439|NCT06668376|DEVICE|Leg Sleeve|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
58113909|NCT03685019|RADIATION|0 degree flexion radiograph|0 degree flexion radiograph
58113910|NCT03685019|RADIATION|20 degree flexion radiograph|20 degree flexion radiograph
58113911|NCT03685019|RADIATION|45 degree flexion radiograph|45 degree flexion radiograph
58445430|NCT03370718|DRUG|Cabozantinib|Given PO
58445431|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
58445432|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
58445433|NCT03567876|DRUG|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
58445434|NCT01766180|DRUG|Fruitflow-II|150 mg/day for 3 months, orally
58445435|NCT01766180|DRUG|resVida|150 mg/day for 3 months, orally
58445436|NCT02053090|BEHAVIORAL|Group Education and Stretching|
58445437|NCT02053090|PROCEDURE|Group Acupuncture|
58445438|NCT00068757|BIOLOGICAL|trastuzumab|
58445439|NCT00068757|DRUG|lonafarnib|
58445440|NCT00068757|DRUG|paclitaxel|
58445441|NCT00068757|OTHER|pharmacological study|
58445442|NCT05733156|RADIATION|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
58113912|NCT05030857|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
58113913|NCT05030857|DRUG|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
58113914|NCT01080105|BEHAVIORAL|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
58113915|NCT01080105|BEHAVIORAL|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
57741440|NCT06668376|DEVICE|Placebo|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
57741441|NCT05822115|DEVICE|Reduction of breast hypertrophy by means of laparoscopic|"The research procedure is a breast reduction performed by means of laparoscopic surgery.~The project consists of removing a disc from the breast at the level of the base, thus causing peripheral skin slackening of 2 to 3 cm but circular. Both breasts are usually operated on at the same time. In case of asymmetry, only one side will be treated."
57741442|NCT06270966|DEVICE|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
57741443|NCT03583216|DIAGNOSTIC_TEST|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
57741444|NCT03583216|DIAGNOSTIC_TEST|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
57741445|NCT05446168|DRUG|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
58113916|NCT01080105|BEHAVIORAL|Educational website|Participants will receive access to a static educational website for 12 weeks.
58113917|NCT06093828|DEVICE|TriFlo Tricuspid Flow Optimizer|An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
58113918|NCT01815411|DIETARY_SUPPLEMENT|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
58445443|NCT02134444|BEHAVIORAL|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
58445444|NCT02134444|BEHAVIORAL|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
58445445|NCT00079560|DRUG|dronabinol|dronabinol to prevent development of marijuana withdrawal
58445446|NCT01588561|DRUG|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
58445447|NCT01588561|OTHER|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
57741446|NCT00313404|BIOLOGICAL|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
57741447|NCT04435665|DRUG|NFX-179 Gel|gel for topical administration
58445448|NCT05971069|PROCEDURE|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
57741448|NCT04435665|DRUG|Vehicle Gel|vehicle gel for topical administration
57741449|NCT04789538|OTHER|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
57741450|NCT06723951|OTHER|QUALAS survey|Participants will be asked to complete the surveys at one (controls) and two (patients) timepoints.
57741451|NCT00006123|BIOLOGICAL|trastuzumab|
57741452|NCT00006123|DRUG|carboplatin|
57741453|NCT00006123|DRUG|carmustine|
57741454|NCT00006123|DRUG|cisplatin|
57741455|NCT00006123|DRUG|cyclophosphamide|
57741456|NCT00006123|DRUG|thiotepa|
57741457|NCT00006123|PROCEDURE|peripheral blood stem cell transplantation|
57741458|NCT01915615|OTHER|None - this is an observational study|None - this is an observational study
57741459|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Medicine Diet|Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
57741460|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Diet|Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
58113919|NCT03506009|DRUG|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
58113920|NCT03506009|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
58113921|NCT02277223|DIETARY_SUPPLEMENT|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
58113922|NCT02277223|DRUG|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
58113923|NCT06201481|PROCEDURE|anterior and posterior full coverage crowns|Teeth preparation,crown fitting and cementation
58113924|NCT01275313|DEVICE|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
58113925|NCT01275313|DEVICE|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
58113926|NCT02541656|PROCEDURE|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
58113927|NCT00097123|DRUG|Misoprostol|
58113928|NCT00367185|DRUG|Thalidomide|
58113929|NCT05849428|DEVICE|Freestyle Libre 3|Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
58113930|NCT00909077|DRUG|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
58113931|NCT00909077|DRUG|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
58113932|NCT03564925|PROCEDURE|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
58113933|NCT03564925|PROCEDURE|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
58113934|NCT06114433|OTHER|3D printed educational model|Slide-based presention plus 3D printed educational model
58113935|NCT06114433|OTHER|Traditional model education|Slide-based presention plus traditional model
58113936|NCT00503126|DRUG|bivalirudin|anticoagulation
58113937|NCT04165278|OTHER|hyperthermic baths|Taking hyperthermic baths
58113938|NCT02519426|PROCEDURE|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
57741461|NCT03529474|OTHER|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE"
57741462|NCT03529474|OTHER|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
57741463|NCT03345238|PROCEDURE|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
57741464|NCT01895972|DRUG|Latanoprostene bunod|
57741465|NCT03131557|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
57741466|NCT03131557|DEVICE|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
58113939|NCT06016855|PROCEDURE|Tumor Debulking|Undergo surgical debulking
58445449|NCT05971069|PROCEDURE|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
57741467|NCT05618795|OTHER|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
57741468|NCT03235167|DRUG|CpG DNA|CpG DNA concentrate
57741469|NCT03235167|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
57741470|NCT03235167|DRUG|Placebo - Concentrate|CpG DNA vehicle
58445450|NCT05971069|PROCEDURE|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
58445451|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58445452|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
58445453|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
58445454|NCT04659616|DRUG|Cytarabine|Given IV
58445455|NCT04659616|DRUG|Daunorubicin|Given IV
57741471|NCT05582720|BEHAVIORAL|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
57741472|NCT05582720|BEHAVIORAL|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
57741473|NCT05403866|DRUG|LT3001 Drug Product|Administered by intravenous infusion
57741474|NCT05403866|DRUG|Placebo|Administered by intravenous infusion
57741475|NCT03239119|BIOLOGICAL|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
57741476|NCT03239119|BIOLOGICAL|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
57741477|NCT03239119|BIOLOGICAL|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
58113940|NCT06016855|DRUG|Lutetium Lu 177 Dotatate|Given by IV
58113941|NCT06016855|PROCEDURE|Computed Tomography|Undergo Computed Tomography
58113942|NCT06016855|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
58113943|NCT06016855|DRUG|Copper Cu 64 Dotatate|Given by IV
58113944|NCT06016855|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
58113945|NCT03350022|PROCEDURE|Sham Feeding|Sham feeding will be offered to participants.
58445456|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
58445457|NCT04659616|DRUG|Pemigatinib|Given PO
58445458|NCT05987696|DRUG|CD33/CLL1 dual CAR-NK cell|NK cell therapy
58445459|NCT05987696|DRUG|Cyclophosphamid|Lympho-conditioning Agent
58445460|NCT05987696|DRUG|Fludarabine|Lympho-conditioning Agent
58445461|NCT05987696|DRUG|Cytarabine|Lympho-conditioning Agent
58113946|NCT02361021|OTHER|- Weaning from mechanical ventilation|
58113947|NCT02132299|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
58113948|NCT02132299|BIOLOGICAL|Normal Saline (Placebo)|
58445462|NCT05987696|DRUG|CD33 CAR-NK cell|NK cell therapy
58445463|NCT05987696|DRUG|super NK cell|NK cell therapy
58445464|NCT00033488|OTHER|cytology specimen collection procedure|
58445465|NCT00033488|PROCEDURE|annual screening|
58445466|NCT00033488|PROCEDURE|comparison of screening methods|
58445467|NCT02442024|BEHAVIORAL|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
58445468|NCT02442024|BEHAVIORAL|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
58445469|NCT02491983|DRUG|Palbociclib|
58445470|NCT02491983|DRUG|Fulvestrant|
58445471|NCT02491983|DRUG|Letrozole|
58445472|NCT00612755|DRUG|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
58445473|NCT03441061|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
58445474|NCT00910780|DRUG|Aripiprazole|via oral tablets, everyday
58445475|NCT00910780|DRUG|Zyprexa|via oral tablets, taken once daily
58445476|NCT00910780|DRUG|Risperdal|via oral tablets, taken once daily
57962239|NCT06549829|OTHER|Nutritional optimization-led triple prehabilitation Intervention|The nutritional status of the patients was assessed together with the clinical nutritionist to develop an individualized nutritional plan. The experimental group used ordinary dietary supplementation + transoral nutritional supplementation, and the control group used ordinary dietary supplementation. The target energy was basal energy metabolism level \* physical activity level, physical activity level was male: 1.55 female: 1.56; basal energy level was basal metabolism standardized value \* body weight (basal metabolism standardized value for obese patients was 25; basal metabolism standardized value for normal or emaciated patients was 30). Add 600kcal capacity supplement to this. Exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance. Specialized psychological interventions.
57962240|NCT06549829|OTHER|Conventional triple prehabilitation Intervention|Conventional triple prehabilitation: ordinary dietary supplementation; exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance; specialized psychological interventions.
57741478|NCT03239119|BIOLOGICAL|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
57741479|NCT02371954|BEHAVIORAL|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
57962241|NCT00526682|DIETARY_SUPPLEMENT|Irvingia/cissus combo|
57962242|NCT05439499|DRUG|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
57962243|NCT05439499|DRUG|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
57741480|NCT02371954|OTHER|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
57962244|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
57962245|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
57962246|NCT02068547|BIOLOGICAL|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
57962247|NCT02068547|BIOLOGICAL|Bone Marrow Aspirate|
57962248|NCT02485145|DRUG|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
57962249|NCT02485145|DRUG|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
57962250|NCT02485145|DRUG|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
57962251|NCT05117359|DEVICE|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
57962252|NCT00327522|BIOLOGICAL|pneumococcal vaccine|
57962253|NCT04307108|DEVICE|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy \[29\] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
57962254|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training|"The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure."
57962255|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage|"Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
57962256|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise|"Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
57962257|NCT02494531|RADIATION|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
57962258|NCT02494531|RADIATION|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
57962259|NCT02014064|DRUG|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)"
57962260|NCT02014064|OTHER|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
57962261|NCT02290795|OTHER|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
58113949|NCT02132299|BIOLOGICAL|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
58113950|NCT04551482|DRUG|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
58113951|NCT04551482|DRUG|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
58113952|NCT00057447|DRUG|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
58113953|NCT00057447|DRUG|Rituximab|375 mg per square meters, IV, 1x per week
58113954|NCT05208411|BEHAVIORAL|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll \& Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
58113955|NCT01774006|OTHER|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
58113956|NCT02579083|DRUG|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
58113957|NCT02579083|DRUG|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
58113958|NCT01573247|DRUG|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
58113959|NCT04526678|DIETARY_SUPPLEMENT|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
58113960|NCT00633152|DRUG|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
58113961|NCT00633152|DRUG|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
58113962|NCT00633152|DRUG|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
58113963|NCT01745328|DRUG|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
58113964|NCT01745328|DRUG|TCM|Subject is treated with TCM for 4 weeks.
58113965|NCT01745328|DRUG|LVX-AMX|treatment with placebo from 2 to 4 weeks.
58113966|NCT05566379|OTHER|Mindfulness - Mindful Awareness Practices ( MAPs)|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
58113967|NCT00860106|OTHER|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
58445477|NCT05142605|BEHAVIORAL|Meaning-Centered Grief Therapy|Meaning-Centered Grief Therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in participants' life after participants' loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
58113968|NCT03764059|DEVICE|Filtek™ Bulk Fill Posterior Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
58113969|NCT03764059|DEVICE|Filtek™ Z350XT Universal Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
58113970|NCT01889862|DRUG|BMN165 20mg/day|BMN165 20mg/day self-administered daily
58113971|NCT01889862|DRUG|BMN165 40mg/day|BMN165 40mg/day self-administered daily
58113972|NCT01889862|DRUG|Placebo|Non-drug placebo, self-administered daily
58113973|NCT03562299|DEVICE|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
57741481|NCT04973865|OTHER|Validation & reliability|Translated version of IPAQ(SF) validation \& Reliability
57741482|NCT05066724|DRUG|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
58113974|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
58113975|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
58113976|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
58113977|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
58113978|NCT04676932|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
58113979|NCT02328599|PROCEDURE|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
58113980|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
58113981|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
58113982|NCT04689958|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
58113983|NCT04689958|DRUG|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
58113984|NCT06422611|DEVICE|Impression methods|Both digital and conventional impressions were taken from same patients
58113985|NCT00626483|BIOLOGICAL|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10\^7) is being assessed.
58113986|NCT00626483|DRUG|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
58113987|NCT00735683|DRUG|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
58113988|NCT00735683|DRUG|Placebo|includes diet, physical activity, and lifestyle modification
58113989|NCT00154037|DRUG|Pioglitazone (drug) and/or candesartan (drug)|
58113990|NCT01371578|DRUG|GS-5885 tablet|30 mg active tablet
58113991|NCT01371578|DRUG|GS-9451 tablet|two active 100 mg tablets
58113992|NCT01371578|BIOLOGICAL|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
58113993|NCT01371578|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
58113994|NCT05585359|OTHER|injectable platelet rich fibrin augmented with Vitamin C|According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
58113995|NCT04132232|DIAGNOSTIC_TEST|knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels|Will use the Smokerlyzer® device at each visit and be provided information on exhaled carbon monoxide and fetal carboxyhemoglobin. Risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin level will be provided.
58113996|NCT02307474|RADIATION|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
58113997|NCT02307474|DRUG|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
58113998|NCT03314129|BEHAVIORAL|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
58113999|NCT03314129|BEHAVIORAL|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
58114000|NCT03314129|BEHAVIORAL|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
58114001|NCT03314129|BEHAVIORAL|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
58445478|NCT05142605|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy will help participants cope with participants' loss by giving them a place to express participants' feelings and providing participants with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
58445479|NCT05142605|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of participants' standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
58114002|NCT00692926|BIOLOGICAL|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
58114003|NCT01081028|OTHER|First-line therapy|As prescribed by treating physician
58114004|NCT01081028|DRUG|Second-line Multiple Myeloma treatments|As prescribed by the treating physician
58114005|NCT03417349|DEVICE|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
58114006|NCT02152020|BEHAVIORAL|Survey|
58114007|NCT03154879|DEVICE|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
58114008|NCT00924066|DRUG|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
58114009|NCT02116686|DEVICE|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
58114010|NCT00638157|DRUG|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
58114011|NCT00638157|DRUG|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
58114012|NCT00030173|DRUG|Epothilone D (KOS-862)|
58114013|NCT03846271|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
58114014|NCT03846271|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
58114015|NCT02884206|DRUG|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
58114016|NCT02884206|DRUG|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
58114017|NCT02884206|DRUG|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
58114018|NCT02884206|DRUG|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
58114019|NCT01075139|BEHAVIORAL|Brief Motivational Intervention|30 minute one-on-one meeting
58114020|NCT01075139|BEHAVIORAL|Educational information|Educational handouts/brochures
58114021|NCT00686920|DRUG|Rifaximin|Oral
58114022|NCT01536756|OTHER|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
58114023|NCT01536756|OTHER|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
58114024|NCT03588325|DIAGNOSTIC_TEST|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
58114025|NCT00645775|DIETARY_SUPPLEMENT|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
58114026|NCT06479759|DRUG|LM-108 antibody and sintilimab|Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
58114027|NCT06479759|DRUG|LM-108 antibody and sintilimab and chemotherapy|Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
58114028|NCT03532256|BEHAVIORAL|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
58114029|NCT03532256|BEHAVIORAL|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
58114030|NCT03532256|BEHAVIORAL|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
58114031|NCT03803722|DEVICE|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
58114032|NCT03096613|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
58114033|NCT01854788|OTHER|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
58445480|NCT03009422|DRUG|Local application pentostam|
58114034|NCT01854788|OTHER|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
58114035|NCT01854788|OTHER|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
58114036|NCT03624270|DRUG|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
58114037|NCT00094133|PROCEDURE|hot flashes attenuation|
58114038|NCT00094133|PROCEDURE|hypnotherapy|
58114039|NCT00541281|DRUG|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
58114040|NCT00541281|DRUG|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
58114041|NCT00541281|DRUG|prednisone|2x5 mg a day
58114042|NCT04859855|PROCEDURE|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
58114043|NCT04859855|PROCEDURE|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
58114044|NCT00647608|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
58114045|NCT00647608|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fed
58114046|NCT05660057|DEVICE|New computer monitor|The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.
58114047|NCT03967132|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
58114048|NCT03967132|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
58114049|NCT03967132|OTHER|Reference Group|Human milk, breast feeding ad libitum
58114050|NCT02818283|DIETARY_SUPPLEMENT|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
58445481|NCT03009422|DRUG|intra-lisional pentostam|
58445482|NCT03009422|DEVICE|fractional CO2 laser|
58114051|NCT02818283|OTHER|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
58114052|NCT06021548|OTHER|Blood sample|Finger stick blood spots will be collected at V0 and M12
58114053|NCT06021548|OTHER|Saliva sample|Saliva sample will be collected at V0
58114054|NCT06021548|OTHER|Hair sample|Hair sample will be collected at V0 (optional)
58114055|NCT04480099|DRUG|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
58114056|NCT04480099|DRUG|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
58114057|NCT02019979|DRUG|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
58114058|NCT02019979|BEHAVIORAL|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
58114059|NCT06539364|DIAGNOSTIC_TEST|Quality of life surveys were conducted|Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
58114060|NCT00086879|DRUG|carmustine|
58114061|NCT00086879|DRUG|erlotinib hydrochloride|
58114062|NCT00086879|DRUG|temozolomide|
58114063|NCT03214757|OTHER|treatment of anemia.|drug treatment of anemia.
58114064|NCT03339635|DRUG|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
58114065|NCT03339635|DRUG|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
58114066|NCT02008110|DRUG|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
58445483|NCT05832879|BEHAVIORAL|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
58445484|NCT03786536|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
57741483|NCT05521516|DEVICE|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
58114067|NCT02008110|DRUG|CA125 guided strategy|Consider statins in all patients in the active arm
58114068|NCT02008110|DRUG|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
58114069|NCT02008110|OTHER|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
58114070|NCT02008110|DRUG|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
58114071|NCT02008110|DRUG|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
58114072|NCT02627014|OTHER|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
58114073|NCT02627014|OTHER|Home physical therapy|once a day: 15 minutes
58445485|NCT05648292|BEHAVIORAL|Neuropsychological tests and psychological questionnaires|"* The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
58445486|NCT04728386|OTHER|curcumin solution|2 % curcumin solution as root canal irrigant
57741484|NCT05521516|DEVICE|Sham Treatment|Application of 5 days of a nonfunctional sham device
58114074|NCT02627014|OTHER|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
58114075|NCT02627014|OTHER|Home physical therapy in cervical region|once a day: 15 minutes
58114076|NCT01075620|DEVICE|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
58114077|NCT01075620|DEVICE|LPS RP|non-posterior stabilized rotating platform design
58114078|NCT04718220|DIAGNOSTIC_TEST|Antibody testing for SARS-CoV-2 IgG|Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.
58445487|NCT04728386|OTHER|sodium hypochlorite|2.5% sodium hypochlorite solution as root canal irrigant
58445488|NCT05303623|OTHER|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
57741485|NCT02738866|DRUG|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
57741486|NCT02738866|DRUG|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
57956924|NCT05149690|OTHER|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
57956925|NCT05149690|OTHER|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
57956926|NCT01210339|DRUG|Clopidogrel|Clopidogrel
57956927|NCT01210339|DRUG|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
57956928|NCT01307475|OTHER|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
57956929|NCT01307475|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
57956930|NCT01307475|OTHER|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
57956931|NCT01307475|OTHER|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
57956932|NCT01307475|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
57956933|NCT01307475|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
57956934|NCT01307475|OTHER|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
57956935|NCT01307475|OTHER|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
57956936|NCT01307475|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
57956937|NCT01148446|DRUG|Cyclophosphamide|750 mg/mq IV, day 1
57956938|NCT01148446|DRUG|Cyclophosphamide|50 mg/mq IV, day 1
57956939|NCT01148446|DRUG|Doxorubicin|50 mg/mq IV, day1
57956940|NCT01148446|DRUG|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
57956941|NCT01148446|DRUG|Prednisone|75 mg/mq IV, days 1-5
57956942|NCT01148446|DRUG|Prednisone|60 mg/mq IV/PO, days 1-5
57956943|NCT01148446|DRUG|Epirubicin|50 mg/mq IV, day 1
57956944|NCT01148446|DRUG|Vinblastine|5 mg/mq IV, day 1
57956945|NCT01148446|DRUG|Rituximab|375 mg/mq IV, day 1
58445489|NCT05303623|OTHER|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
57956946|NCT01148446|DRUG|G-CSF|300 µg tot., SC; days 7-11
57956947|NCT02435355|BEHAVIORAL|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
57956948|NCT05136937|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
57956949|NCT04650373|PROCEDURE|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
57956950|NCT02148380|DRUG|pemetrexed plus carboplatin|
57956951|NCT02148380|DRUG|gefitinib|
57956952|NCT00486408|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5x10\^10 Ad vg
57956953|NCT00006142|BEHAVIORAL|phenylalanine restricted diet|
57956954|NCT00485212|DEVICE|compression bandage|
58114079|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 RNA|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.
58114080|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 IgM/IgG|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
58114081|NCT04179071|DRUG|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
58114082|NCT04179071|DRUG|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
58114083|NCT02990832|DEVICE|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
58114084|NCT00289458|BEHAVIORAL|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
58114085|NCT00289458|BEHAVIORAL|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
58114086|NCT00289458|BEHAVIORAL|Control|no exercise
58445490|NCT05303623|OTHER|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
57741487|NCT05646667|OTHER|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
57956955|NCT01751308|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
58114087|NCT00374543|DRUG|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
58114088|NCT00374543|DRUG|Placebo|Placebo administered daily for 8 weeks
58114089|NCT00470444|PROCEDURE|Transfusion with Red Blood Cells|Units of donated Red blood cells
58114090|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of red blood cells
58445491|NCT02240641|DRUG|Lacidipine|
58445492|NCT02240641|DRUG|Diuretics|
58445493|NCT02240641|DRUG|antihypertensive drugs|
58445494|NCT02240641|DRUG|alpha blockers|
58445495|NCT02240641|DRUG|Angiotensin-Converting Enzyme Inhibitors|
58445496|NCT02240641|DRUG|beta blockers|
58445497|NCT06393972|DRUG|Tofacitinib 5 MG BID|Tofacitinib 5 MG BID
58445498|NCT03874572|BIOLOGICAL|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
58445499|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
57741488|NCT05646667|OTHER|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
57741489|NCT06166927|DEVICE|Cuffed endotracheal tube|Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
57956956|NCT06309459|DIAGNOSTIC_TEST|Carbonic anhydrase staining levels|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
57956957|NCT01324232|DRUG|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
57956958|NCT01324232|DRUG|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
57956959|NCT01324232|DRUG|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
57956960|NCT01324232|DRUG|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
57956961|NCT01029067|BEHAVIORAL|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
57956962|NCT01029067|BEHAVIORAL|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
57956963|NCT01056146|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
57956964|NCT01056146|BEHAVIORAL|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
58114091|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of donated red blood cells
58114092|NCT03961776|DEVICE|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
58114093|NCT00425789|PROCEDURE|Treatment with Hyperbaric oxygen|
58114094|NCT02049359|OTHER|Texting|Bidirectional texting once weekly for 12 weeks
58114095|NCT04345471|DRUG|Desvenlafaxine 100 mg|once daily dosing for 8 weeks
58114096|NCT04345471|DRUG|Desvenlafaxine 50 mg|once daily dosing for 8 weeks
58114097|NCT04345471|DRUG|Placebo|once daily dosing for 8 weeks
58114098|NCT06329596|DIETARY_SUPPLEMENT|Xylitol gum|Two pieces of xylitol gum after meals, thrice a day.
58114099|NCT06329596|DIETARY_SUPPLEMENT|Sorbitol gum|Two pieces of sorbitol gum after meals, thrice a day.
58114100|NCT03918551|DRUG|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
58114101|NCT03918551|DRUG|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
58114102|NCT04046042|OTHER|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
58114103|NCT04046042|OTHER|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
58114104|NCT05442983|DRUG|PanCytoVir™ (probenecid)|Active drug
58114105|NCT05442983|DRUG|Placebo|Matching placebo
58445500|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
58445501|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
58445502|NCT04976686|OTHER|Diet modification|Participants will reduce their carbohydrate consumption to 80g daily
58445503|NCT03310814|OTHER|Personalized nutrition|Receives individualized nutrition information
58445504|NCT05175586|DIAGNOSTIC_TEST|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
58445505|NCT05175586|PROCEDURE|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
57741490|NCT06166927|DEVICE|UnCuffed ETT|Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
58114106|NCT02002117|OTHER|DNA mass|DNA mass spectrometry
58114107|NCT03277183|DRUG|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
58114108|NCT03277183|DRUG|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
57741491|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
57741492|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
57741493|NCT05844813|DRUG|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
57741494|NCT05844813|PROCEDURE|Radical Surgery|Radical sarcoma resectional surgery
57741495|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 100 ug/kg
58114109|NCT00626925|DRUG|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
58114110|NCT00626925|DRUG|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
58114111|NCT03822962|DRUG|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
58114112|NCT03822962|OTHER|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
58114113|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
58114114|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
58114115|NCT05584527|OTHER|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
58114116|NCT05584527|OTHER|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
58114117|NCT05584527|OTHER|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
58114118|NCT05353374|DRUG|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
58114119|NCT05353374|DRUG|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
58114120|NCT02558933|DIETARY_SUPPLEMENT|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
58114121|NCT02319681|BEHAVIORAL|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
58114122|NCT02319681|BEHAVIORAL|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
58114123|NCT01891591|PROCEDURE|Roux-en-Y gastric bypass (RYGP)|
58114124|NCT01079676|DRUG|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
58114125|NCT01079676|DRUG|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
58114126|NCT04676191|DEVICE|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
58114127|NCT04676191|DEVICE|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
58114128|NCT00673790|DRUG|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
58114129|NCT00673790|DRUG|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
58114130|NCT00673790|DRUG|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
58114131|NCT03618979|BIOLOGICAL|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
58445506|NCT05175586|OTHER|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
58445507|NCT06172647|DIAGNOSTIC_TEST|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
58445508|NCT04987502|OTHER|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
58445509|NCT04987502|BEHAVIORAL|Standard treatment|counselling, relaxation techniques, sound enrichment
58445510|NCT06722677|DEVICE|VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
58445511|NCT06722677|DEVICE|Sham VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
58445512|NCT06722677|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke.
58445513|NCT03805789|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
58445514|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
58445515|NCT06046729|DRUG|Eltrekibart|Administered SC
58445516|NCT06046729|DRUG|Placebo|Administered SC
58114132|NCT03618979|BIOLOGICAL|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
58445517|NCT04601896|OTHER|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
58445518|NCT04403451|BEHAVIORAL|True North|Love Notes, Financial Stability, Jobs
58114133|NCT03618979|BIOLOGICAL|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
58114134|NCT05832606|OTHER|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
58114135|NCT04648579|DEVICE|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
58114136|NCT04648579|OTHER|Control|Hospital usual care regarding vital signs collection and TRR activation.
58114137|NCT00225082|DRUG|Nucleoside analogue switch|stavudine switched to tenofovir
58114138|NCT01302314|BEHAVIORAL|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
58114139|NCT05539183|PROCEDURE|Blood withdrawal|Blood withdrawal
58114140|NCT00460473|DRUG|Dexmedetomidine|
58114141|NCT00460473|DRUG|Placebo|
58114142|NCT04504864|DRUG|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
58114143|NCT04504864|DRUG|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
58114144|NCT00851032|OTHER|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
58114145|NCT01564758|DRUG|Linezolid|"1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
58114146|NCT03411590|OTHER|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
58114147|NCT03218735|PROCEDURE|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
58114148|NCT03218735|PROCEDURE|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
58114149|NCT05480878|DRUG|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58114150|NCT05480878|DRUG|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58114151|NCT05480878|DRUG|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58114152|NCT02181257|COMBINATION_PRODUCT|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
58114153|NCT02181257|OTHER|No intervention in the SOC / Retrospective Chart review.|SOC Retrospective chart review similar to a control group
58114154|NCT06074120|DEVICE|Low-level laser therapy|Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.
58114155|NCT01216111|DRUG|Paclitaxel Cisplatin|"Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6"
58114156|NCT01216111|DRUG|fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
58114157|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
58114158|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
58114159|NCT00377728|DRUG|GSK256066|
58114160|NCT03750474|DIAGNOSTIC_TEST|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
58114161|NCT05535712|DEVICE|Lung Anatomic Resection (Da Vinci SP)|To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
58114162|NCT04436328|PROCEDURE|Surgical treatment|Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).
58114163|NCT04436328|OTHER|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
58114164|NCT04780659|BIOLOGICAL|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
58114165|NCT01713153|DRUG|Misoprostol|600 mcg misoprostol oral
58114166|NCT01713153|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
58114167|NCT06182683|DIAGNOSTIC_TEST|optical coherence tomography and fractional flow reserve|The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.
58114168|NCT06182683|DIAGNOSTIC_TEST|Coronary angiography|The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography
58114169|NCT03958981|DRUG|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
58445519|NCT04688749|DIAGNOSTIC_TEST|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
58445520|NCT06009094|DRUG|VC005|VC005 group with Local topical application
58445521|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
58114170|NCT03958981|DRUG|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
58445522|NCT06091735|DRUG|OSS|experimental
58445523|NCT06091735|DRUG|OSS+Linzess|experimental
58114171|NCT02843074|DRUG|elotuzumab|Given intravenously (IV)
58114172|NCT02843074|DRUG|Lenalidomide|Given by IV
58114173|NCT02843074|DRUG|Dexamethasone|Given orally (PO) or by IV
58114174|NCT02843074|PROCEDURE|autologous stem cell transplantation|
58114175|NCT00277680|PROCEDURE|Laparoscopic bilateral occlusion of uterine artery|
58114176|NCT00277680|PROCEDURE|Radiological embolization (UFE)|
58114177|NCT01561183|PROCEDURE|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
58114178|NCT01561183|PROCEDURE|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
58114179|NCT01561183|PROCEDURE|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
58445524|NCT06091735|DRUG|PEG-Interferon Alfa|Placebo Comparator
58445525|NCT03329092|DRUG|ATM-AVI|"(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
58445526|NCT03329092|DRUG|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
58114180|NCT01561183|PROCEDURE|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
58445527|NCT03329092|DRUG|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
58114181|NCT06543368|BIOLOGICAL|Intra articular PRP Injection|A total of 20 joints (estimated 10-15 patients) will receive injections, performed at day 0 and 3 weeks, for a total of two injections - two injections have demonstrated superior outcomes to one, and will increase our number of injections to improve the proof of feasibility. All subjects will receive ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort.
58114182|NCT00418873|DRUG|Zotepine|Oral
58114183|NCT00418873|DRUG|Risperidone|Oral
58114184|NCT05539573|DEVICE|Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.|"The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure."
58445528|NCT03329092|DRUG|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
58114185|NCT04502758|DEVICE|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
58445529|NCT02298400|DEVICE|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
58445530|NCT02298400|DEVICE|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
58445531|NCT02298400|DEVICE|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
58445532|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
58445533|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
57741496|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 300 ug/kg
57741497|NCT00771810|DRUG|Placebo|Once daily subcutaneous injection of placebo
57741498|NCT03732183|BEHAVIORAL|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
57741499|NCT02212756|DRUG|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
57741500|NCT02212756|DRUG|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
57956965|NCT02238444|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
58114186|NCT04502758|DEVICE|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
58114187|NCT05235594|DEVICE|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
58114188|NCT00217828|DRUG|citalopram|
58114189|NCT00197756|DIETARY_SUPPLEMENT|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
58114190|NCT00197756|DIETARY_SUPPLEMENT|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
58114191|NCT00197756|DIETARY_SUPPLEMENT|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
58114192|NCT00197756|OTHER|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
58114193|NCT02410512|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
58445534|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
58445535|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
57741501|NCT04068337|PROCEDURE|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
58114194|NCT02410512|DRUG|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
58114195|NCT05896059|DRUG|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
58114196|NCT05896059|DRUG|Anlotinib|Anlotinib，12mg，oral administration，QD.
58114197|NCT06543602|DIAGNOSTIC_TEST|multi-model monitoring and alert|All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
58114198|NCT01156571|DRUG|cangrelor P2Y12 (platelet) inhibitor|
58114199|NCT01156571|DRUG|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
58114200|NCT01156571|DRUG|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
58114201|NCT06251128|BEHAVIORAL|Stroke Self management Program|"Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants"
58114202|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
58114203|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
58445536|NCT05314998|DRUG|Oxaliplatin|85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
58445537|NCT05314998|DRUG|Irinotecan|150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
57956966|NCT02238444|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
57956967|NCT02238444|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
58114204|NCT04156074|DIETARY_SUPPLEMENT|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
58114205|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
58114206|NCT02189616|BEHAVIORAL|SMS reminder|send weekly mobile phone short message reminders to the intervention group
58114207|NCT02189616|OTHER|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
58114208|NCT02189616|OTHER|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
58114209|NCT05058742|DEVICE|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
58114210|NCT03467412|DRUG|FOL-005|intradermal injection
58114211|NCT03467412|DRUG|Placebo|intradermal injection
57741502|NCT06034587|DIAGNOSTIC_TEST|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
57741503|NCT06034587|RADIATION|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
57741504|NCT04777500|DEVICE|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
58445538|NCT05314998|DRUG|Folinic acid|400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
58445539|NCT05314998|DRUG|5-fluorouracil|2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
58114212|NCT06346236|DRUG|L-thyroxine at a dose of 7.5 µg/kg/d for THOP|Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
58114213|NCT06346236|OTHER|THOP without treatment|Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.
58114214|NCT06346236|OTHER|NoTHOP|Subjects diagnosed no-THOP (as previously defined)
57741505|NCT00840853|GENETIC|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
58114215|NCT02343887|OTHER|neuropsychological tests|
58114216|NCT02343887|OTHER|STAI-Y scale for anxiety|
58114217|NCT02343887|OTHER|Beck scale for depression|
58445540|NCT05314998|DRUG|Gemcitabine|1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
58445541|NCT05314998|DRUG|Capecitabine|1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
57741506|NCT00840853|DRUG|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
58445542|NCT02259465|BEHAVIORAL|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
57741507|NCT05099042|OTHER|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
57741508|NCT01211925|PROCEDURE|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
57741509|NCT01211925|DRUG|Aspirin|100 mg per day continuous
57956968|NCT02238444|DRUG|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
58114218|NCT02343887|OTHER|without intervention|
58114219|NCT03483285|DEVICE|airtraq|airtraq videolaryngoscope
58114220|NCT03483285|DEVICE|storz|storz videolaryngoscope
58114221|NCT00624871|DRUG|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
58114222|NCT00624871|DRUG|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
58114223|NCT00624871|DRUG|Placebo|
58114224|NCT01284595|DRUG|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
58114225|NCT00029185|DRUG|Dehydrex|
58445543|NCT02259465|DIETARY_SUPPLEMENT|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
58445544|NCT02259465|DIETARY_SUPPLEMENT|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
58445545|NCT05142826|BEHAVIORAL|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
58114226|NCT01283633|DEVICE|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
57741510|NCT00233077|BEHAVIORAL|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
58312885|NCT00070434|RADIATION|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
58445546|NCT05142826|OTHER|School as Usual|Interventions and supports as provided through usual care
58445547|NCT00534859|DEVICE|High Risk PCI|High Risk Percutaneous Coronary Intervention
57741511|NCT00233077|BEHAVIORAL|Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
57741512|NCT06733038|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at first infusion) day 1
57741513|NCT06733038|DRUG|Bevacizumab|5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
57741514|NCT06733038|DRUG|Irinotecan (CPT-11)|165 mg/sqm iv over 60 minutes day 1
57741515|NCT06733038|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
57741516|NCT06733038|DRUG|Leucovorin|200 mg/sqm iv over 2 hours day 1
57741517|NCT06733038|DRUG|Fluorouracil (5-FU)|3200 mg/sqm 48 h-continuous infusion, starting on day 1
58312886|NCT00070434|DRUG|Pyridoxine|50mg TID, PO daily
58114227|NCT00622141|DRUG|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
58114228|NCT06150378|DRUG|Corticosteroid|Patients that receive an injection with corticosteroid
58114229|NCT06150378|BIOLOGICAL|Plathet rich plasma|Patients that receive an injection with Plathet-rich plasma
58114230|NCT06388291|DEVICE|Deep Brain Stimulation|ON/OFF stimulation vs OFF/ON stimulation
58114231|NCT02625545|DEVICE|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
58114232|NCT04061564|DEVICE|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
58114233|NCT02408406|OTHER|Communication Intervention|Use PatientCareAnywhere system
58114234|NCT02408406|OTHER|Educational Intervention|Use PatientCareAnywhere system
58114235|NCT02408406|OTHER|Internet-Based Intervention|Use PatientCareAnywhere system
58114236|NCT02408406|OTHER|Quality-of-Life Assessment|Ancillary studies
58445548|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
58114237|NCT02408406|OTHER|Questionnaire Administration|Ancillary studies
58114238|NCT01186978|RADIATION|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
58114239|NCT00655421|OTHER|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
58114240|NCT00655421|DEVICE|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
57741518|NCT06128668|BEHAVIORAL|Yoga|Yoga will be applied
57741519|NCT01785966|BEHAVIORAL|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
58114241|NCT00655421|OTHER|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
58114242|NCT05494775|DRUG|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
58114243|NCT03165890|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
58114244|NCT03165890|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
58114245|NCT04784481|DRUG|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
58114246|NCT06185712|BEHAVIORAL|Nurse-led disease management education|Nurse-led disease management education was applied to the intervention group
58114247|NCT00740727|DRUG|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
58114248|NCT00740727|PROCEDURE|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
58114249|NCT03410381|OTHER|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
58445549|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
58445550|NCT03148041|OTHER|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
58114250|NCT05661877|OTHER|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
58114251|NCT05661877|OTHER|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
58114252|NCT00182221|PROCEDURE|MDA D-Dimer Testing|
58114253|NCT01785784|DRUG|rhGM-CSF Gel|
58114254|NCT00576199|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
58114255|NCT00576199|PROCEDURE|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
58114256|NCT02628340|OTHER|Ex-vivo analysis|
58114257|NCT02268045|BIOLOGICAL|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
58114258|NCT02268045|BIOLOGICAL|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
58114259|NCT06527820|BEHAVIORAL|Talk About It (conversation aid)|"Talk About It is a conversation aid aimed to increase awareness of options and prompt discussion."
58114260|NCT02427373|DIETARY_SUPPLEMENT|fish oil ethyl ester|
58114261|NCT02427373|DIETARY_SUPPLEMENT|fish oil triglyceride|
58114262|NCT02427373|DIETARY_SUPPLEMENT|krill oil|
58114263|NCT01373892|PROCEDURE|Bariatric surgery|
58114264|NCT00218686|BEHAVIORAL|psychoeducational|psychoeducational
58114265|NCT00218686|BEHAVIORAL|control|VTC
58114266|NCT03857685|PROCEDURE|In-vitro model|In-vitro model of posterior capsule opacification by culturing the lens capsule
58114267|NCT02304575|OTHER|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
58114268|NCT02304575|OTHER|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
58114269|NCT03387059|DEVICE|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
58114270|NCT05168956|OTHER|Collect data of medical record|"Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
58114271|NCT00896818|GENETIC|DNA analysis|
58114272|NCT00896818|GENETIC|genetic linkage analysis|
58114273|NCT00896818|GENETIC|loss of heterozygosity analysis|
58114274|NCT00896818|GENETIC|polymorphism analysis|
58114275|NCT00896818|OTHER|laboratory biomarker analysis|
58114276|NCT00896818|OTHER|medical chart review|
58114277|NCT00896818|OTHER|questionnaire administration|
58114278|NCT05796622|BEHAVIORAL|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIVST-Chatbot
57741520|NCT05601102|BEHAVIORAL|danceSing Care|- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
57741521|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
58114279|NCT05796622|BEHAVIORAL|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIVST-OIC
58114280|NCT03123211|DRUG|Veliparib|Veliparib will be administered orally.
58114281|NCT01199432|DRUG|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
58114282|NCT01199432|DRUG|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
58114283|NCT01199432|DRUG|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
58114284|NCT02340156|GENETIC|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
57741522|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
58114285|NCT02340156|DRUG|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
58114286|NCT04598672|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
58114287|NCT01759537|DEVICE|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
58114288|NCT01759537|DEVICE|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
57741523|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
57741524|NCT00322348|DRUG|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
57741525|NCT00322348|DRUG|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
57741526|NCT01261338|DRUG|olestra|non-absorbable dietary fat
57741527|NCT05717868|OTHER|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
57956969|NCT02905786|DEVICE|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
57956970|NCT02905786|OTHER|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
58114289|NCT01780727|PROCEDURE|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
58114290|NCT05743790|DIETARY_SUPPLEMENT|RS2-control-RS4|Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
58114291|NCT05743790|DIETARY_SUPPLEMENT|RS4-control-RS2|Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
58114292|NCT04052100|OTHER|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
58114293|NCT04052100|OTHER|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
58445551|NCT00940901|DRUG|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
58445552|NCT00940901|OTHER|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
58445553|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
58445554|NCT01931306|DRUG|Afatinib|BIBW2992 low to medium dose once daily
58445555|NCT01518374|DRUG|Florbetapir F 18|370 MBq (10 mCi)
58445556|NCT06654752|OTHER|Immediate Oral Antibiotics|Increase airway clearance and start 14 days of preselected oral antibiotics right away
58445557|NCT06654752|OTHER|Tailored Treatment: Oral Antibiotics only if Additional Treatment needed|Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
58445558|NCT01824550|OTHER|home-based exercise training condition|Home based endurance exercise training
58445559|NCT00955396|DRUG|GSK1014802|Tablets
58445560|NCT00955396|DRUG|Placebo|Tablets
57741528|NCT05717868|OTHER|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
57956971|NCT02905786|OTHER|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
57956972|NCT03258112|PROCEDURE|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
57956973|NCT04051437|PROCEDURE|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
57956974|NCT04051437|DRUG|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
57956975|NCT03516760|DRUG|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
57956976|NCT01727609|DIETARY_SUPPLEMENT|Milk feed (breast milk or formula milk)|
58445561|NCT02595424|DRUG|Capecitabine|Given PO
58445562|NCT02595424|DRUG|Carboplatin|Given IV
58445563|NCT02595424|DRUG|Cisplatin|Given IV
57956977|NCT01018498|BEHAVIORAL|Restricted FODMAPs diet|Restricted fermentable substrate diet
57956978|NCT05218785|DRUG|Botox|75 U in medial gastrocbemius head. x 3
57956979|NCT02278172|DIETARY_SUPPLEMENT|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
57956980|NCT02278172|DIETARY_SUPPLEMENT|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
57956981|NCT02098174|DRUG|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
57956982|NCT02098174|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
58445564|NCT02595424|DRUG|Etoposide|Given IV
58445565|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
58445566|NCT02595424|DRUG|Temozolomide|Given PO
58445567|NCT06141863|OTHER|questionnaire|Neck Disability Index, The Fonseca Anamnestic Index (FAI) and Visual Analogue Scale (VAS)
57956983|NCT04222166|BIOLOGICAL|CAM|Cryopreserved Amniotic Membrane
57956984|NCT00401752|DRUG|Esomeprazole|
57956985|NCT00401752|DRUG|Ranitidine|
57956986|NCT02420873|DRUG|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
57956987|NCT00307151|DRUG|Lamivudine|4 mg/kg twice daily
58445568|NCT03863119|DRUG|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
58445569|NCT06340945|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
58445570|NCT05943249|PROCEDURE|magnetic resonance|
58445571|NCT01015781|PROCEDURE|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
58114294|NCT05499364|BEHAVIORAL|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
58445572|NCT01015781|PROCEDURE|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
58114295|NCT05499364|BEHAVIORAL|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
58114296|NCT01532882|DRUG|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
58114297|NCT01532882|DRUG|Placebo|tablet, PO, 1 per day during 28 days
58445573|NCT04184297|DRUG|Tiotropium and Olodaterol (Tio+Olo)|drug
58445574|NCT04184297|DRUG|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
58445575|NCT03018691|DRUG|OPA-15406|
58445576|NCT03018691|DRUG|Placebos|
58445577|NCT03928795|PROCEDURE|elective caesarean section|elective caesarean section
58445578|NCT03077919|DRUG|Ropivacaine|0.5% ropivacaine
58445579|NCT03077919|DRUG|Sham treatment|preservative-free normal saline
58445580|NCT06726629|OTHER|Version Of The New Knee Society Knee Scoring System|All patients will be subjected to the same clinical and radiographic checks, the data of which will be collected in the different centres
57741529|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
57956988|NCT00307151|DRUG|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
57741530|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
57956989|NCT00307151|DRUG|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
57956990|NCT00307151|DRUG|Zidovudine|180 mg/m\^2 twice daily
57956991|NCT01725009|DRUG|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
57956992|NCT01864538|DRUG|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
57962262|NCT01578980|DEVICE|Outpatient Control-to-Range|Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
57962263|NCT00274365|PROCEDURE|videoconference|
57962264|NCT02792842|DRUG|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
57962265|NCT02792842|DRUG|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
57962266|NCT02792842|DRUG|Placebo|Placebo infusion once daily on days 1-3 in each cycle
57962267|NCT02757170|DEVICE|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
57962268|NCT02700737|OTHER|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
57962269|NCT02700737|OTHER|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
57962270|NCT00892632|PROCEDURE|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
57962271|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
57962272|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
57962273|NCT03390062|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
57962274|NCT02436850|PROCEDURE|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
57962275|NCT02407678|GENETIC|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
57962276|NCT04949100|DEVICE|Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
58114298|NCT00624481|DRUG|Teriparatide|20ug subcutaneous injection daily for 24 weeks
58114299|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
58114300|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
58114301|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
58445581|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
58445582|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
57741531|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
57741532|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
57741533|NCT01639885|BIOLOGICAL|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
57741534|NCT04203693|DRUG|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
57741535|NCT06733064|DIETARY_SUPPLEMENT|Supplementation of vitamin D3|Supplementation of vitamin d3 at a dose of 4000 iu / day
57741536|NCT06733064|DIETARY_SUPPLEMENT|Placebo|Vegetable oil as a placebo
57956993|NCT01653288|BEHAVIORAL|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
57956994|NCT02830880|DRUG|FACBC PET-CT|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
57956995|NCT02830880|OTHER|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
57956996|NCT06394713|DRUG|QLF31907|intravenous administration, once every 3 weeks
57956997|NCT06394713|DRUG|Irinotecan|intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
57956998|NCT06394713|DRUG|Docetaxel|intravenous administration, 75mg/m2, d1, every 3 weeks
58114302|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
58114303|NCT02363751|DRUG|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
58114304|NCT00416403|DRUG|fluvastatin sodium|Given orally
58114305|NCT00416403|PROCEDURE|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
58114306|NCT00604110|OTHER|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF\<45%), is hemodynamically favourable.
58114307|NCT06186440|DRUG|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
58114308|NCT06186440|DRUG|Temozolomide|Temozolomide
58114309|NCT04758871|DRUG|Dydrogesterone 10 MG Oral Tablet|10 mg three times daily
57741537|NCT06462508|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
58114310|NCT04758871|DRUG|Micronized progesterone|2x 200 mg vaginal tablets two times daily
58114311|NCT01388647|DRUG|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
58114312|NCT01388647|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
58114313|NCT01388647|DRUG|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
58114314|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
58114315|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
58445583|NCT04523207|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
58445584|NCT04523207|DRUG|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
58445585|NCT04523207|DRUG|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
58114316|NCT05494554|DEVICE|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
58445586|NCT00112372|DRUG|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
58445587|NCT05880381|DEVICE|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
58445588|NCT05880381|OTHER|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
58445589|NCT04067258|DIAGNOSTIC_TEST|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
57741538|NCT06462508|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
57741539|NCT05261152|DRUG|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
57741540|NCT02405520|BIOLOGICAL|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
57741541|NCT02405520|BIOLOGICAL|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
58114317|NCT06302855|DIAGNOSTIC_TEST|dental expertise|dental visit based on dental expertise
58114318|NCT04155983|DRUG|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
57741542|NCT02405520|BIOLOGICAL|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
57741543|NCT02405520|BIOLOGICAL|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
58445590|NCT00200720|BEHAVIORAL|Atkins diet (low carbohydrate diet)|
58445591|NCT00200720|BEHAVIORAL|DASH diet (high carbohydrate diet)|
58445592|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
58445593|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
58445594|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
58445595|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
58445596|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
58445597|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
58445598|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
58445599|NCT00109824|DRUG|decitabine|Given IV
58445600|NCT00109824|DRUG|valproic acid|Given PO
58445601|NCT00109824|OTHER|pharmacological study|Correlative studies
58445602|NCT00109824|OTHER|laboratory biomarker analysis|Correlative studies
58445603|NCT05865470|DRUG|Cannabis|smoked cannabis
58445604|NCT05865470|DRUG|Dronabinol|Oral delta-9-THC
58114319|NCT05295693|DEVICE|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
58445605|NCT05865470|DRUG|Smoked Placebo|Placebo Cannabis
58445606|NCT05865470|DRUG|Oral Placebo|Oral Placebo
58445607|NCT00550407|DRUG|lamotrigine|lamotrigine 100mg/day or 200mg/day
58445608|NCT00550407|DRUG|Placebo|placebo once daily
58445609|NCT00669708|DEVICE|cooling compound (ph5 Eucerin)|application twice daily to the skin
58445610|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
58445611|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
58445612|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
58445613|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
58445614|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (active treatment)|
58445615|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (placebo treatment)|
58114320|NCT00988234|PROCEDURE|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
58114321|NCT00988234|PROCEDURE|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
58445616|NCT05708495|OTHER|posterior ilium mobilization|the therapist will mobilize the innominate on the affected side posteriorly
58445617|NCT05708495|OTHER|strengthening and stretching exercises|the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
58445618|NCT02171442|DRUG|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
58445619|NCT02171442|DRUG|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
58445620|NCT03415945|DEVICE|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
58445621|NCT06706219|DRUG|Sacituzumab tirumotecan plus pembrolizumab|"Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients."
58445622|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
58445623|NCT03354273|DRUG|PET MPI|Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
58445624|NCT03354273|DRUG|SPECT MPI|SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
58445625|NCT03354273|DRUG|Pharmacological stress agents|Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
58445626|NCT01933490|OTHER|high carbohydrate test meal|
58445627|NCT01933490|OTHER|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
58445628|NCT01933490|OTHER|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
58445629|NCT02791230|DRUG|Tafamidis|Soft gel capsules administered once a day for 60 months
58445630|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
58445631|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58445632|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58445633|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
58445634|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
58445635|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
58445636|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58445637|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
58445638|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
58445639|NCT05865522|OTHER|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
58445640|NCT05865522|OTHER|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
58445641|NCT01908452|DRUG|Pyridoxine|1200 mg/d during 12 weeks
58445642|NCT00096434|DRUG|sorafenib tosylate|Given orally
58445643|NCT00096434|OTHER|laboratory biomarker analysis|Correlative studies
58445644|NCT00988988|DRUG|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
58445645|NCT00988988|DRUG|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
58445646|NCT00988988|DRUG|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
58445647|NCT05286502|DEVICE|fundus photography|color fundus photography
58445648|NCT04094857|DRUG|HBN-1|Intravenous infusion
58445649|NCT04331717|DEVICE|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
57962277|NCT04949100|DEVICE|PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
57962278|NCT02266693|BEHAVIORAL|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
57962279|NCT05556499|DIAGNOSTIC_TEST|Biomarker assays|Circulating bone biomarkers assays
57962280|NCT06189937|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|"In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~1. Education on psychological trauma and its treatment, and basics of emotion regulation techniques~2. Education on anxiety and depressive disorders and their treatment~3. Muscle relaxation and stretching exercises~4. Education about depressive and grief-related disorders and disturbing memories protocol~5. Interoceptive exposure: head rotation and hyperventilation~6. Anxiety, worry, and stress~7. Anger and anger protocol; breathing exercises~8. Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants."
57962281|NCT05483530|BIOLOGICAL|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
57962282|NCT01249352|DRUG|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
57962283|NCT01249352|DRUG|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
57962284|NCT01249352|DRUG|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
57962285|NCT01249352|RADIATION|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
58114322|NCT00988234|PROCEDURE|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
58114323|NCT00988234|PROCEDURE|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
57741544|NCT03724643|OTHER|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
57962286|NCT01726946|DRUG|VX-135|12 weeks of VX-135
57962287|NCT01726946|DRUG|ribavirin|12 weeks of ribavirin
57962288|NCT03063580|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
57962289|NCT03063580|DRUG|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
57962290|NCT04438174|DRUG|Processed Amniotic Fluid|Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
57962291|NCT04438174|OTHER|Standard of Care Wound Treatment Regimen|ointment-based dressing and non-ointment-based dressings
57962292|NCT03064841|DRUG|No Treatment|No treatment
57962293|NCT03861143|DRUG|BT-11 (440 mg)|Oral, once daily tablet
57962294|NCT03861143|DRUG|BT-11 (880 mg)|Oral, once daily tablet
57962295|NCT03861143|DRUG|Placebo|Oral, once daily tablet
57962296|NCT06286748|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
57962297|NCT06286748|OTHER|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
57962298|NCT03766880|PROCEDURE|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
57962299|NCT03766880|PROCEDURE|MR imaging|MR images for the post-processing analysis
57962300|NCT04163068|OTHER|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
57962301|NCT05304507|BEHAVIORAL|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
57962302|NCT05304507|BEHAVIORAL|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
57962303|NCT01088581|DRUG|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
57962304|NCT05878652|DEVICE|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
57962305|NCT05878652|OTHER|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
57962306|NCT02750787|OTHER|Nutritional Study Product|Two 220 ml servings per day
57962307|NCT02527980|OTHER|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
57962308|NCT02561091|OTHER|Placebo|
57962309|NCT02561091|DRUG|AM-111 0.4 mg/ml|
57962310|NCT02561091|DRUG|AM-111 0.8 mg/ml|
57962311|NCT04808856|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic Hormone Injection 25u qd iv \*3d
57962312|NCT04808856|DRUG|Methylprednisolone Injection|Methylprednisolone Injection 40mg qd iv \*3d
57962313|NCT02750163|DRUG|paracetamol|Paracetamol will be given to febrile septic patients
57962314|NCT00104546|PROCEDURE|Acupuncture point injection of vitamin K|
57962315|NCT02613598|DRUG|Bortezomib|
57962316|NCT02613598|DRUG|Ruxolitinib|
57962317|NCT01179074|PROCEDURE|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
57962318|NCT01179074|PROCEDURE|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
57962319|NCT05276479|OTHER|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
57962320|NCT02650037|PROCEDURE|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
57741545|NCT05736848|DEVICE|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
57741546|NCT00990834|DRUG|simvastatin|simvastatin 80 mg PO daily for one to eight months.
58114324|NCT03599310|BEHAVIORAL|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
58114325|NCT03599310|BEHAVIORAL|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
58114326|NCT03409679|DRUG|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
58114327|NCT03409679|DRUG|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
58114328|NCT05464732|DEVICE|Vivity IOL|The Vivity IOL will be implanted bilaterally in all subjects.
58114329|NCT01438554|DRUG|Pazopanib|
58445650|NCT04331717|BEHAVIORAL|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
58445651|NCT04331717|DRUG|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
58445652|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
58445653|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
58445654|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
58445655|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
58445656|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
58445657|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
57741547|NCT06268574|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
57741548|NCT01229761|DRUG|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
57741549|NCT01229761|DRUG|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
58114330|NCT01438554|DRUG|GSK1120212|
58114331|NCT06091410|BIOLOGICAL|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
58114332|NCT06091410|BIOLOGICAL|influenza vaccine|inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
58114333|NCT01944228|DEVICE|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
58114334|NCT01944228|DEVICE|Sham Stimulation|Catheter placed in the IJV without stimulation
58114335|NCT06011421|DEVICE|Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant
58114336|NCT00004110|BIOLOGICAL|monoclonal antibody 3F8|
58114337|NCT00004110|DRUG|etoposide|
58114338|NCT00004110|DRUG|isotretinoin|
58114339|NCT04207086|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58114340|NCT04207086|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
58114341|NCT04576806|OTHER|Body temperature|Warming of administered fluid bolus
58114342|NCT04576806|DRUG|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
58114343|NCT04576806|OTHER|Room temperature|Cooling of administered fluid bolus
58114344|NCT04402749|OTHER|Nephrectomy|Patients underwent nephrectomy
58114345|NCT03670979|PROCEDURE|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
58114346|NCT00669578|DRUG|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
58114347|NCT05794399|DRUG|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
57741550|NCT01229761|BEHAVIORAL|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
57741551|NCT01229761|BEHAVIORAL|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
58114348|NCT05794399|DRUG|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
58445658|NCT02436616|DEVICE|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
58445659|NCT04041154|BEHAVIORAL|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
58445660|NCT04041154|BEHAVIORAL|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
58445661|NCT04041154|BEHAVIORAL|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
58445662|NCT06474637|DEVICE|AEON Endoscopic Powered Stapler Handle and Reload|The AEON™ Endoscopic Stapler places two triple-staggered rows of titanium staples while simultaneously transecting between the two triple-staggered rows of staples. The size of the staples and staple line length are based on the selection of the Stapler Reload (2.0mm, 2.5mm, 3.25mm, 4.0mm, 5.0mm and 5.5mm).
58445663|NCT01385657|DRUG|Placebo|A total of 4 doses were administered.
58445664|NCT01385657|DRUG|Dupilumab|A total of 4 doses were administered.
58445665|NCT01385657|OTHER|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
57741552|NCT06731959|DRUG|Flexlamose|Fexlamose solution via nebulizer for 28 days
57741553|NCT06731959|DRUG|Placebo|Placebo solution via nebulizer for 28 days
57741554|NCT00436657|DRUG|CHPP of Cisplatin|Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
57741555|NCT00436657|PROCEDURE|Abdominal Surgery|Surgical removal of abdominal tumors.
58445666|NCT01804881|BEHAVIORAL|Lifestyle counseling|Six week program to address problematic eating
58445667|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
58445668|NCT05073926|OTHER|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
58114349|NCT06045585|BIOLOGICAL|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
58114350|NCT04511364|OTHER|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
58114351|NCT03715595|OTHER|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
58114352|NCT04551079|DRUG|TAK-994|TAK-994 tablets.
58114353|NCT04551079|DRUG|Placebo|TAK-994 placebo-matching tablets.
58114354|NCT03119532|OTHER|Receive metric feedback email|If the provider received an email about the participants performance metrics
58114355|NCT06438783|DRUG|1200mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
58114356|NCT06438783|DRUG|1800mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
58114357|NCT02400905|DEVICE|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
58114358|NCT05781477|BEHAVIORAL|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
58114359|NCT02468661|DRUG|INC280 single agent|
58445669|NCT05043753|OTHER|Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)|"Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016)."
58445670|NCT04190901|BEHAVIORAL|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
58445671|NCT04190901|BEHAVIORAL|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
58445672|NCT04190901|BEHAVIORAL|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
58445673|NCT04190901|BEHAVIORAL|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
57741556|NCT05095818|OTHER|PrEP-RN|Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
58445674|NCT03052244|DEVICE|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
58445675|NCT03052244|DEVICE|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
58445676|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
58114360|NCT02468661|DRUG|erlotinib|
58114361|NCT06442683|DIAGNOSTIC_TEST|TTE simulation-based medical training|half-day simulation-based neonatal echocardiography training.
58114362|NCT01821027|DRUG|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
58114363|NCT01821027|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
58114364|NCT04653870|OTHER|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
58114365|NCT04653870|OTHER|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
58114366|NCT04008342|OTHER|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
58114367|NCT03429296|OTHER|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
57741557|NCT06579716|OTHER|Traditional balance exercise|All patients in both group received a traditional balance exercise program, 3 sessions per week, for 6 weeks. Each session of exercise comprised 10 min of warm-up, 40min of balance exercise, and 5min of cool down. Warm-up included treadmill walking. Balance exercise comprised two sets of sit to stand, one leg stance, tandem stance and 30 squats. The first set of exercises was performed on a stable surface, whereas the second set of exercises was performed on an unstable surface by using Thera band stability trainer. Each set of each exercise was performed for 3 min, with 1-2 min of rest in between the exercises. Cool-down included deep breathing, abdominal breathing, and mild stretching.
58114368|NCT00737321|PROCEDURE|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
58114369|NCT05906264|BEHAVIORAL|Tele-intervention|Tele-intervention every week to check compliance and encourage the rehabilitation
58114370|NCT03357432|OTHER|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
58114371|NCT00548353|DRUG|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
58114372|NCT00548353|DRUG|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
58114373|NCT02472977|DRUG|Ulocuplumab|
58114374|NCT02472977|DRUG|Nivolumab|
58114375|NCT03534297|DRUG|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
58114376|NCT03534297|DRUG|Placebo capsules|Hard opaque capsules containing 0 mg of API.
58114377|NCT05124756|DEVICE|Bioelectric stimulation|The sessions will include 20 minutes for stimulation of the thigh muscles and 45 minutes for stimulation of the kidneys. The electrodes will be placed on the motor point of the quadriceps muscle in both lower limbs. The neuromuscular electric stimulation will be applied by symmetrical biphasic pulsed current, at an 80 Hz frequency, 400 ms pulse width, 10 s contraction time, rest time decreasing as the protocol advanced, at reciprocal mode. The intensity will be individually adjusted to produce visible muscle contraction. Concomitant, two electrodes will be placed in the abdominal corresponding to the kidney anatomical site and two electrodes on the dorsal region at the level of the 10th thoracic vertebra. The stimulation of the kidneys will include in addition to Klotho, precise signals for several pro-regenerative proteins. The intensity of the electric current will be individually adjusted to sensory stimulation.
58114378|NCT01148290|PROCEDURE|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
58114379|NCT01148290|PROCEDURE|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
58114380|NCT03216733|DEVICE|COMBO|PCI with COMBO stent
58114381|NCT03216733|DEVICE|ORSIRO|PCI with ORSIRO stent
58114382|NCT04788589|OTHER|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
58114383|NCT01694511|PROCEDURE|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
58114384|NCT01694511|PROCEDURE|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
58114385|NCT01434459|DRUG|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
58114386|NCT03799887|BEHAVIORAL|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
58114387|NCT03799887|BEHAVIORAL|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
58114388|NCT03799887|BEHAVIORAL|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
58114389|NCT02245191|DRUG|Ephedrine|5mg after Spinal Anesthesia
58114390|NCT02245191|DRUG|Phenylephrine|100mcg after Spinal Anesthesia
58114391|NCT02245191|DRUG|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
58114392|NCT02415959|DRUG|Creon IR|
58114393|NCT02415959|DRUG|Creon® (DR/GR)|
58114394|NCT00905489|DRUG|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
58114395|NCT00905489|DRUG|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
58114396|NCT06441565|DRUG|Fruquintinib|A treatment cycle of 4 weeks, with 4 mg orally once daily for 3 weeks, followed by a 1-week break
58114397|NCT06441565|DRUG|Fluorouracil|2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
58114398|NCT06441565|DRUG|Oxaliplatin|85 mg/m² given every 2 weeks through hepatic arterial infusion
58114399|NCT04648761|BIOLOGICAL|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
58114400|NCT04188925|DEVICE|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
58114401|NCT04188925|DEVICE|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
58114402|NCT05353556|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
58114403|NCT05353556|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
58114404|NCT04184375|BEHAVIORAL|cognitive stimulation|"Patients participate in one session per week according to the following schedule:~* 2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~* 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~* 2 voluntary attention sessions: improve daily attention.~* 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~* 2 sessions of structuring through language: impact on social life.~* 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips."
58114405|NCT05588206|RADIATION|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
58114406|NCT02011594|DRUG|Nimotuzumab|400mg Q2W intravenously
58114407|NCT02011594|DRUG|Placebo|Normal saline
58114408|NCT04524533|BEHAVIORAL|Experimental smoking cessation video|Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.
58114409|NCT04524533|BEHAVIORAL|Control video|Participants randomized to the control group will watch a 10 minute video.
58114410|NCT04524533|OTHER|Brochure of smoking cessation EBTs|All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.
58114411|NCT04524533|BEHAVIORAL|Tailored text message program|Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.
58114412|NCT04524533|OTHER|Assessment text messages|Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
58114413|NCT00544583|PROCEDURE|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
58114414|NCT00544583|PROCEDURE|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
58114415|NCT02141178|DRUG|Bupivacaine|
58114416|NCT02141178|DRUG|Exparel|
58114417|NCT01132599|DIETARY_SUPPLEMENT|C-11 choline|
58114418|NCT01132599|RADIATION|18F-fluoromethylcholine|
58114419|NCT00697112|DRUG|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
58114420|NCT05092334|OTHER|proprioceptive exercises|proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
58114421|NCT05092334|OTHER|Strengthening exercise|strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
58114422|NCT05720481|OTHER|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
58114423|NCT05720481|OTHER|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
58114424|NCT05740670|OTHER|Dr. Kellyann's Bone Broth|Participants will have two bone broth phases, each three weeks in length. Bone broth phases will be separated by a one-week maintenance phase. A one-week maintenance phase will also occur after the second bone broth phase. Each week of a broth phase will consist of five feeding days and five fasting days. On feeding days, participants will consume one packet of bone broth, twice each day, as snacks between meals. On fasting days, participants will consume one packet of bone broth every two hours for a total of seven packets each day.
58114425|NCT02873481|BEHAVIORAL|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
58114426|NCT03094208|OTHER|dual task balance training|balance exercises with cognitive and motor dual tasks
58114427|NCT03094208|OTHER|traditional balance training|balance exercises
58114428|NCT03238027|DRUG|Axatilimab|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
58114429|NCT03238027|DRUG|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
58114430|NCT02532010|DRUG|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
58114431|NCT02532010|DRUG|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
58445677|NCT03718026|OTHER|The timed 360° turn test|"* The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
58114432|NCT02532010|DRUG|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
58114433|NCT00410722|DIETARY_SUPPLEMENT|Whole wheat and bran muffin|
58114434|NCT00410722|DIETARY_SUPPLEMENT|Mixed tree nuts|
58114435|NCT04854720|DEVICE|Fuji® II LC CAPSULE|"Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions."
58114436|NCT04854720|DEVICE|Clinpro™ XT Varnish|"Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions."
58114437|NCT04854720|DEVICE|Beautifil Flow|"Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions."
58445678|NCT04981379|DRUG|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
58445679|NCT04981379|DRUG|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
58445680|NCT04981379|DRUG|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
58114438|NCT04854720|DEVICE|Fuji Triage® CAPSULE|"Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions."
58445681|NCT04981379|DRUG|Placebo|Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
58445682|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)"
58445683|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
57741558|NCT06579716|OTHER|Resistance exercise|All patients in both group received a resistance exercise program, 3 sessions per week, for 6 weeks. Each patient was seated in sitting position and the weight sandbags was applied at the dorsum of the foot. The resistance was set to be around 40%-60% of the 1RM. The patient performed the exercise for 3 bouts, every bout 10 repetitions. The one repetition maximum (1RM) was established prior to the training period using the following equation: 1 RM = Weight (kg) X (1 + {0.033 X number of repetitions)}.
57741559|NCT06579716|OTHER|Whole-body vibration (WBV)|Patients were asked to stand barefoot on the vibratory platform with an even distribution of weight on both feet and familiarized with WBV at a lesser frequency and amplitude. Then, they were asked to bend their knee 30º to the vertical; thereafter, to obtain a greater muscular response, WBV training was performed at a frequency of 30 Hz and an amplitude of 2mm. The exercise comprised five bouts of a 30-sec vibration with a 1-min elapse between the bouts.
58114439|NCT01191255|DRUG|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
58114440|NCT06531096|BEHAVIORAL|v-DOT|Video directly observed therapy
58114441|NCT01968616|DRUG|Ranibizumab, 0.5mg, Intravitreal|
58114442|NCT05581186|OTHER|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
58114443|NCT05581186|OTHER|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
58114444|NCT05581186|OTHER|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
58114445|NCT03209830|DRUG|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
58114446|NCT03209830|DRUG|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
58114447|NCT00002185|DRUG|Nelfinavir mesylate|
58114448|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
58114449|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
58114450|NCT05517512|DIAGNOSTIC_TEST|Estimation of Protein 13|"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."
58114451|NCT03932487|OTHER|urinary iodine and urine BPA|urinary iodine and urine BPA
58114452|NCT02702206|DRUG|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
58114453|NCT02702206|DRUG|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
58114454|NCT02702206|DRUG|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
58114455|NCT02098356|OTHER|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
58114456|NCT02419638|DRUG|Rebif (IFN β-1a subcutaneous three times per week)|
58114457|NCT02419638|DRUG|Tecifdera (dimethyl fumarate)|
58445684|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
58114458|NCT05941091|BEHAVIORAL|HafifMod Programme|"MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos."
58114459|NCT05941091|BEHAVIORAL|Distribution of printed material|In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
58114460|NCT02742181|DRUG|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
58114461|NCT02742181|OTHER|Control Group|Standard postoperative care
58114462|NCT05512325|DRUG|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
58114463|NCT05485181|BEHAVIORAL|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
58114464|NCT00570856|DRUG|Folic acid|Folic acid 5 mg/day
58114465|NCT00570856|DRUG|Placebo|Placebo similar to the folic acid tablets, 1/day
58445685|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
57956999|NCT05933369|BEHAVIORAL|Clincal pharmacist intervention|Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
57957000|NCT06203990|BEHAVIORAL|Barre exercise|Group barre exercise class
57957001|NCT04677244|PROCEDURE|Blood sample in portal vein|A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
57957002|NCT01018875|DRUG|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
57957003|NCT01018875|DRUG|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
57957004|NCT01018875|DRUG|placebo|Subjects will take 4 capsules once daily for 12 weeks.
57957005|NCT02179333|OTHER|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
57957006|NCT01957358|BEHAVIORAL|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
57957007|NCT05706389|DIETARY_SUPPLEMENT|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
57741560|NCT06579716|OTHER|Kineso tape|Kineso tape was applied to dorsiflexors 24 hours a day and was replaced every 5 days for patients who were taped in accordance with Kenzo Kase's Kinesio taping Manual. For taping, each patient's leg was placed in a relaxed position while he sat on a taping table. The skin was to be free of oils and lotions, to avoid anything that might limit the acrylic adhesive's ability to adhere to the skin. So, the subject's skin was cleaned with alcohol prior to tape application. For the Tibialis anterior, tape was measured from the muscle origin to the insertion while the muscle was stretched. The base of the tape was applied to the origin at the lateral condyle and superior 2/3 of anterolateral surface of tibia. Then the subject was asked to stretch the foot into plantar flexion and eversion; taping was then finished toward the insertion at the medial and plantar surface of medial cuneiform and base of the first metatarsal.
57741561|NCT01311960|DRUG|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
57741562|NCT01311960|DRUG|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
57741563|NCT05918068|DRUG|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
57741564|NCT05918068|COMBINATION_PRODUCT|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
57741565|NCT05918068|OTHER|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
58445686|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
58445687|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
57741566|NCT00206791|DEVICE|MBCP-Gel (tm)|
57741567|NCT05940532|DRUG|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
57741568|NCT00002411|DRUG|Nelfinavir mesylate|
57741569|NCT00002411|DRUG|Lamivudine|
57741570|NCT00002411|DRUG|Stavudine|
57741571|NCT00002411|DRUG|Zidovudine|
57741572|NCT00002411|DRUG|Didanosine|
57741573|NCT06288906|OTHER|mechanical thrombectomy of caval and iliofemoral veins|investigate efficacy, safety of mechanical thrombectomy systems used in symptomatic acute and subacute ileofemoral and caval thrombosis
58114466|NCT05426252|DRUG|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
58114467|NCT05426252|DRUG|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
58114468|NCT01881399|DEVICE|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
58114469|NCT01881399|OTHER|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
57741574|NCT03475550|OTHER|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
57741575|NCT01928719|DRUG|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
58114470|NCT01881399|PROCEDURE|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
58114471|NCT02449291|DRUG|APD421|
58114472|NCT02449291|DRUG|Placebo|
57741576|NCT01928719|DRUG|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
57741577|NCT05086133|DEVICE|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
57741578|NCT05086133|DEVICE|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
58114473|NCT00087061|DRUG|gimatecan|
58114474|NCT01789281|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
58114475|NCT01789281|DRUG|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
58114476|NCT06153524|BEHAVIORAL|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
58114477|NCT06153524|BEHAVIORAL|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
58114478|NCT01405976|DEVICE|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
58114479|NCT06527092|DEVICE|Virtual Reality|VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems
58114480|NCT06527092|DEVICE|Bubbles|A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
58114481|NCT02109133|PROCEDURE|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
58114482|NCT02109133|PROCEDURE|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
58114483|NCT02109133|DRUG|Rocuronium|
58114484|NCT02109133|DRUG|Sugammadex|
58114485|NCT02109133|DRUG|Atracurium|
58114486|NCT02109133|DRUG|Neostigmine|
58114487|NCT05073900|PROCEDURE|Rhomboid intercostal block|two regional anesthesia block techniques are applied
58114488|NCT00406198|PROCEDURE|venovenous hemofiltration|
58114489|NCT04872426|OTHER|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
58114490|NCT03043274|DRUG|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
58114491|NCT04572620|DRUG|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
58114492|NCT04572620|DRUG|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
58114493|NCT00593996|OTHER|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
58114494|NCT03158259|OTHER|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
58114495|NCT04867161|DIAGNOSTIC_TEST|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
57957008|NCT06492096|DEVICE|Bibloc Mandibular Advancement device|Each patient received a CAD/CAM designed Bibloc Mandibular Advancement device
57957009|NCT04220996|DRUG|Vortioxetine|Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
57957010|NCT00299832|DRUG|Aliskiren|
57957011|NCT03776175|DRUG|PF-05221304 Monotherapy|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
57957012|NCT03776175|DRUG|PF-06865571 Monotherapy|Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
57957013|NCT03776175|DRUG|Placebo|Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
58114496|NCT05340556|GENETIC|Blood sample|Blood sample of 12 ml EDTA plasma.
58114497|NCT05340556|GENETIC|Swap test|receive swab tests for collecting cells from the oral mucosa
58114498|NCT05778370|DEVICE|Swept Source Optical Coherence Tomography(Topcon DRI Triton)|Topcon DRI Triton
58114499|NCT02193984|BEHAVIORAL|Peer support|
57957014|NCT03776175|DRUG|PF-05221304 and PF-06865571 Combination|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
57957015|NCT04793425|BEHAVIORAL|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
57957016|NCT05099692|BEHAVIORAL|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
57957017|NCT01000662|RADIATION|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
57957018|NCT01000662|RADIATION|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
57957019|NCT02556398|BEHAVIORAL|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
57957020|NCT04336761|DIAGNOSTIC_TEST|nasopharyngeal swab|Data collection and nasopharyngeal swab
57957021|NCT04978207|BEHAVIORAL|A Faithful Response to COVID-19|See previous description
57957022|NCT00886301|PROCEDURE|liver biopsy|liver biopsy
57957023|NCT01817309|OTHER|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
57957024|NCT05779072|DEVICE|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
57957025|NCT01931358|BIOLOGICAL|ALVAC-HIV|1 mL intramuscular injection containing 10\^6 CCID50/dose
57957026|NCT01931358|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
57957027|NCT01931358|BIOLOGICAL|ALVAC-HIV Placebo|1 mL per injection
57957028|NCT01931358|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
57957029|NCT02286947|DRUG|Eteplirsen|Eteplirsen solution for IV infusion
58114500|NCT00008099|BIOLOGICAL|MUC1 antigen/SB AS-2|
58114501|NCT02561390|PROCEDURE|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
58114502|NCT02561390|OTHER|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
58114503|NCT00663910|DRUG|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
58114504|NCT00663910|PROCEDURE|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
58114505|NCT00663910|PROCEDURE|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
58114506|NCT00663910|PROCEDURE|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
58114507|NCT01506089|OTHER|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
58114508|NCT04468971|BIOLOGICAL|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
58114509|NCT04468971|DRUG|Placebo|Expicient
58114510|NCT02459613|DRUG|99mTc-Annexin V-128 SPECT|
58114511|NCT06479694|BEHAVIORAL|Real-life Dual-Task Training|The intervention is Real-life Dual-Task Training (Real-DTT) which uses instrumental activities of daily living training with explicit focus on the cognitive and motor elements and when to focus attention to one vs. the other to reduce fall risk. The Real-DTT sessions will be delivered once a week for 10 weeks during their occupational therapy sessions, delivered by a licensed occupational therapist. Real-DTT is a modified version of occupational therapy, with a protocol tailored to the participants.
58114512|NCT02323906|DRUG|CC-122|Investigational new drug
58114513|NCT02323906|DRUG|Sorafenib|Kinase inhibitor
58114514|NCT01087879|DRUG|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
58114515|NCT01087879|DRUG|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
58114516|NCT01087879|DRUG|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
58114517|NCT00401856|DRUG|Eplerenone|50mg oral route
58114518|NCT00401856|DRUG|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
58114519|NCT01249105|DRUG|MK-2206|Taken orally once a week
58114520|NCT03232528|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
58114521|NCT03232528|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
58114522|NCT00877175|DRUG|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
58114523|NCT05580926|BEHAVIORAL|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
58114524|NCT05580926|OTHER|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
58114525|NCT05188040|OTHER|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
58114526|NCT02047942|BEHAVIORAL|Center-based cardiac rehabilitation|
58114527|NCT02047942|BEHAVIORAL|Home-based training with telemonitoring guidance|
58114528|NCT04091542|DEVICE|Optiflow/Ventilator|Participants will have 2 days with optiflow, 2 days with ventilator.
58114529|NCT02600728|BEHAVIORAL|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
58114530|NCT02600728|BEHAVIORAL|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
58114531|NCT03673189|DEVICE|sensors|Acquisition and transmission of exploitable recordings in the public targeted by the DS, that is to say which allow to draw clinical information in relation to the objectives of the DS (detection of the cardiac rhythm): data without artefact (saturation), in a good signal to noise ratio.
58114532|NCT02588625|DRUG|BMS-986020|
58114533|NCT02588625|OTHER|Placebo|
58114534|NCT00479310|DRUG|Summers 5% L.A.|
58114535|NCT00896285|OTHER|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
57741579|NCT00728390|DRUG|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
58114536|NCT00896285|OTHER|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
58114537|NCT00896285|OTHER|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
58445688|NCT06419712|DRUG|vitamin D (cholecalciferol) supplementation|This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
58445689|NCT05975645|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
58445690|NCT05975645|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
57741580|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
57741581|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
58445691|NCT05975645|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
58445692|NCT01543074|DIETARY_SUPPLEMENT|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
57741582|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
57741583|NCT03392714|DRUG|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
57741584|NCT05357612|DRUG|Pimavanserin|PD related Psychosis
58114538|NCT00896285|OTHER|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
58114539|NCT00521898|PROCEDURE|Descemet Membrane Endothelial Keratoplasty (DMEK)|
58445693|NCT01543074|DIETARY_SUPPLEMENT|Garlic oil|1 pill = 30 mg garlic oil/day
58445694|NCT01543074|DRUG|BSE|2 pills = 200 micromoles of Sulforaphane/day
58445695|NCT01543074|DIETARY_SUPPLEMENT|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
58445696|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
58114540|NCT03201783|OTHER|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
58114541|NCT03201783|OTHER|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
58114542|NCT02614703|DRUG|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
58114543|NCT02614703|OTHER|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
58114544|NCT04914793|DEVICE|Antimicrobial prescribing guideline mobile phone application (MicroGuide)|This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
58445697|NCT02529163|OTHER|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
57957030|NCT03937856|BEHAVIORAL|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
57957031|NCT03900871|DRUG|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
57957032|NCT04797143|DEVICE|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
57957033|NCT04004884|DRUG|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
57957034|NCT01452399|PROCEDURE|Shave margins|Partial mastectomy with shave margins.
57957035|NCT01452399|PROCEDURE|No Shave Margins|Partial mastectomy without shave margins.
57957036|NCT00744874|PROCEDURE|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
57957037|NCT01803360|DRUG|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
57957038|NCT04440995|PROCEDURE|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
57957039|NCT05721235|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
57957040|NCT06500364|DEVICE|LoopLoc Arm|Patients in this intervention will have had a capsular closure performed using a LoopLoc device after their hip arthroscopy.
57957041|NCT06500364|DEVICE|Control Arm|Patients in this intervention will have not had a capsular closure using a LoopLoc device after their hip arthroscopy.
57957042|NCT00630630|DRUG|Levetiracetam|
57957043|NCT00630630|OTHER|Placebo|
57957044|NCT05073809|DIAGNOSTIC_TEST|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
57957045|NCT01578733|DIETARY_SUPPLEMENT|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
57957046|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
57957047|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
57957048|NCT05376176|DRUG|Placebo (Vehicle) BID|Placebo (vehicle) BID
57957049|NCT04001361|PROCEDURE|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
57957050|NCT02997579|PROCEDURE|patellar resurfacing|patellar component insert with cement
57957051|NCT01544946|DRUG|88% sucrose po|88% sucrose solution (Syrup B.P.)
57957052|NCT01544946|DRUG|placebo po|sterile water
57957053|NCT03783390|BEHAVIORAL|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
58114545|NCT03239275|PROCEDURE|Biocreative therapy|
58114546|NCT03830047|DEVICE|nd yag laser|nd yag laser will be applied on the vulval warts
58114547|NCT00359229|DRUG|Zolpidem|Administration of Zolpidem 5mg
58114548|NCT05433337|DEVICE|Digital ACT|Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
57957054|NCT03783390|BEHAVIORAL|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
58114549|NCT04652921|DIETARY_SUPPLEMENT|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
58114550|NCT04652921|OTHER|Inulin|A dietary supplement provided as powder dissolved in a glass of water
58114551|NCT04820959|BIOLOGICAL|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
58114552|NCT04820959|BIOLOGICAL|Blood sampling|Pre-operative blood sampling
58114553|NCT03091530|OTHER|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
58114554|NCT03091530|OTHER|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
58114555|NCT03607630|OTHER|Imagery Rescripting|psychological therapy
58114556|NCT05085054|DRUG|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
58114557|NCT03136783|OTHER|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
58114558|NCT00314379|DRUG|Vitamin E 400IU/day|
58114559|NCT01247896|DRUG|PF-05190457|Single Dose 2 mg
58114560|NCT01247896|DRUG|PF-05190457|Single Dose 10 mg
58114561|NCT01247896|DRUG|PF-05190457|Single Dose 30 mg
58114562|NCT01247896|DRUG|PF-05190457|Single Dose 100 mg
58114563|NCT01247896|DRUG|PF-05190457|Single Dose 300 mg
58114564|NCT01247896|DRUG|PF-05190457|Single Dose 600 mg
58114565|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined with food
58114566|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined
57957055|NCT02626195|DIETARY_SUPPLEMENT|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse"
57957056|NCT03638232|OTHER|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
57957057|NCT03638232|OTHER|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
57957058|NCT03638232|OTHER|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
57957059|NCT01029366|BIOLOGICAL|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
58114567|NCT01247896|DRUG|Placebo|Single Dose Placebo
58114568|NCT00000606|PROCEDURE|Lung volume reduction surgery|
58114569|NCT04094194|OTHER|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
58114570|NCT05330845|BIOLOGICAL|IL6 assessment|Blood IL6 will be assessed during trial
57957060|NCT00083993|DRUG|Temsirolimus (CCI-779) for 34 months|
57957061|NCT00083993|DRUG|Letrozole for 34 months|
57957062|NCT03603496|BEHAVIORAL|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
57957063|NCT03603496|BEHAVIORAL|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
57957064|NCT03603496|DRUG|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
58114571|NCT05330845|BIOLOGICAL|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
58114572|NCT01166854|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
58114573|NCT04221555|DRUG|Docetaxel, Oxaliplatin, S-1 and Durvalumab|"1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
58114574|NCT04221555|DRUG|Durvalumab and Tremelimumab|"1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment."
58114575|NCT00947856|DRUG|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
58445698|NCT02529163|OTHER|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
58445699|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
58445700|NCT06726811|DRUG|Droperidol injection|2.5 mg
58445701|NCT05335876|BIOLOGICAL|onasemnogene abeparvovec|Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
58445702|NCT02068794|OTHER|Laboratory Biomarker Analysis|Correlative studies
58445703|NCT02068794|PROCEDURE|Mesenchymal Stem Cell Transplantation|Given IP
58114576|NCT05994781|DEVICE|EasyDew MD regen cram|No intervention
57957065|NCT02135692|BIOLOGICAL|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
57957066|NCT02135692|DRUG|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
57957067|NCT05687461|OTHER|Build a national diagnosis and treatment quality control platform for major respiratory diseases|"1. Build a national diagnosis and treatment quality control platform for major respiratory diseases~2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases~3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases"
57957068|NCT00428974|DRUG|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
57957069|NCT00428974|DRUG|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
57957070|NCT00428974|DRUG|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
57957071|NCT00428974|DRUG|Placebo|Placebo tablets q12 hours for 12 weeks
57957072|NCT02634723|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|
57957073|NCT05446545|OTHER|ND-EOC or platinum-sensitive rEOC|platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
58114577|NCT03745625|DRUG|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
58114578|NCT03745625|DRUG|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
58114579|NCT01898910|PROCEDURE|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
58114580|NCT01898910|PROCEDURE|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
58114581|NCT01898910|DRUG|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
58114582|NCT00006031|PROCEDURE|Needle localized breast biopsy with specimen x-ray|
58114583|NCT00006031|PROCEDURE|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
58114584|NCT05660083|DRUG|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
58114585|NCT02826603|DRUG|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
58114586|NCT02826603|DRUG|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
58114587|NCT03421652|DRUG|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
58114588|NCT03421652|RADIATION|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
58114589|NCT01977326|BEHAVIORAL|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
58114590|NCT01977326|OTHER|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
58114591|NCT02684695|OTHER|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
58114592|NCT02684695|OTHER|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
58445704|NCT02068794|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
58445705|NCT02068794|PROCEDURE|Echocardiography|Undergo ECHO
57957074|NCT05453331|PROCEDURE|bilateral STN deep brain stimulation|bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
58445706|NCT02068794|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58445707|NCT02068794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58445708|NCT02068794|PROCEDURE|Chest Radiography|Undergo chest X-ray
58445709|NCT02068794|PROCEDURE|Single Photon Tomography and Computed Tomography Scan|Undergo SPECT/CT
58445710|NCT02068794|PROCEDURE|Computed Tomography|Undergo CT
58445711|NCT02068794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58445712|NCT03660761|DRUG|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
57957075|NCT01665144|DRUG|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
57957076|NCT01665144|DRUG|Placebo|Film-coated tablets
57957077|NCT01113827|DIETARY_SUPPLEMENT|Olive Extract|Capsule form ingested 1x/day for 6 weeks
57957078|NCT01113827|DIETARY_SUPPLEMENT|Placebo|Placebo
57957079|NCT06479655|DRUG|Fentanyl|Intravenous fentanyl infusion with dilution of 10mcg/ml
57957080|NCT06479655|DRUG|Morphine|Intravenous morphine infusion with dilution 1mg/ml
58114593|NCT05102799|OTHER|No intervention|No intervention
58445713|NCT03660761|DRUG|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
58445714|NCT04254484|BEHAVIORAL|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
58445715|NCT04254484|DIAGNOSTIC_TEST|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
58445716|NCT03282890|OTHER|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
58445717|NCT02920749|DRUG|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
58445718|NCT02920749|DRUG|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
57741585|NCT05858996|BEHAVIORAL|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
57741586|NCT05858996|OTHER|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
57957081|NCT01263639|OTHER|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
57957082|NCT01263639|OTHER|Standard of care - No biosketch card|Standard of care
57957083|NCT05104580|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
58114594|NCT00477828|DEVICE|Continuous positive airway pressure|
58114595|NCT05092711|BEHAVIORAL|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
58445719|NCT02920749|DRUG|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
58445720|NCT02920749|DRUG|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
58445721|NCT06419088|OTHER|Preoperative individualized education|Based on the identified individual education needs, the researcher implemented audio-visual education to the intervention group in the ward.
58445722|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
58114596|NCT05092711|DRUG|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
58114597|NCT03602898|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
58114598|NCT03602898|DRUG|Busulfan|Given IV or PO
58445723|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
58445724|NCT01308697|PROCEDURE|Operative fixation of flail chest|Plate fixation
58445725|NCT01308697|OTHER|Non Operative management|Non Operative treatment of Flail Chest
58445726|NCT04927065|BIOLOGICAL|mRNA-1273.211|Sterile liquid for injection
58445727|NCT04927065|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
57957084|NCT02884778|DIAGNOSTIC_TEST|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
57957085|NCT05319639|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
58114599|NCT03602898|DRUG|Cyclophosphamide|Given IV
58114600|NCT03602898|DRUG|Cyclosporine|Given IV or PO
58114601|NCT03602898|DRUG|Fludarabine Phosphate|Given IV
58445728|NCT04927065|BIOLOGICAL|mRNA-1273.617.2|Sterile liquid for injection
58445729|NCT04927065|BIOLOGICAL|mRNA-1273.213|Sterile liquid for injection
58445730|NCT04927065|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
58445731|NCT04927065|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
58445732|NCT04927065|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
58114602|NCT03602898|DRUG|Methotrexate|Given IV
58114603|NCT03602898|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
58114604|NCT03602898|OTHER|Quality-of-Life Assessment|Ancillary studies
58114605|NCT03602898|OTHER|Questionnaire Administration|Ancillary studies
58114606|NCT03602898|DRUG|Tacrolimus|Given IV or PO
58114607|NCT03602898|RADIATION|Total-Body Irradiation|Undergo TBI
58114608|NCT02269202|DRUG|Midazolam, tablet|
58114609|NCT02269202|DRUG|Crobenetine, i.v. infusion|
58114610|NCT02269202|DRUG|Placebo|
58445733|NCT04927065|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
58445734|NCT04927065|BIOLOGICAL|mRNA-1273.231|Sterile liquid for injection
58445735|NCT06465004|DIETARY_SUPPLEMENT|Consumption of protein - rich drink|The participants will drink on of three protein - rich drinks
58445736|NCT04503265|DRUG|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
58114611|NCT03032497|DEVICE|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
57741587|NCT04884438|BEHAVIORAL|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~1. Psychoeducation about gratitude and its effects on health (both physical and psychological).~2. Gratitude towards life:~   1. Gratitude walk~  2. Three positive things~  3. Sharing gratitude~3. Social gratitude:~   1. Daily thanks to others~  2. Gratitude letter~  3. Proof of gratitude~4. Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~   1. Gratitude for the things I do to take care of my physical health.~  2. Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~  3. Gratitude for what I do to take care of others."
57741588|NCT00211679|DRUG|Botulinum Toxin Type A|
57741589|NCT00091481|DRUG|Zemplar|
58114612|NCT02911389|OTHER|Home PT via web-based platform|
58114613|NCT02911389|OTHER|Home PT via paper manual|
58114614|NCT02911389|OTHER|outpatient PT|
57741590|NCT03958370|OTHER|Fitbit|Fitbit use during physical therapy session
57741591|NCT06073821|DRUG|Sonrotoclax|Administered orally
57741592|NCT06073821|DRUG|Zanubrutinib|Administered orally
57741593|NCT06073821|DRUG|Venetoclax|Administered orally
57741594|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
57741595|NCT03152526|DEVICE|Interventions|CliniMACS® CD3 and CD19 Reagent System
57957086|NCT05319639|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
57957087|NCT05319639|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
58114615|NCT05448703|OTHER|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
58114616|NCT06324253|PROCEDURE|bilateral Erector spine block,A dose of 30 ml 0.125% Bupivacaine will be injected.|will receive bilateral Erector Spinae Block after induction of anesthesia
58114617|NCT06324253|PROCEDURE|Thoracic epidural analgesia|will receive Thoracic Epidural Block before induction of anesthesia .a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour
58114618|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
58114619|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
58114620|NCT00669955|DRUG|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
58445737|NCT04503265|DRUG|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
58114621|NCT00669955|DRUG|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
58114622|NCT02100956|DRUG|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
58114623|NCT02100956|DRUG|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
58114624|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product|Coated Tablets
58114625|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product|Coated Tablets
58114626|NCT01953159|OTHER|Blood Collection|
58114627|NCT01953159|OTHER|Patient Questionnaires|
58114628|NCT01207128|DRUG|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
58114629|NCT06024863|DIAGNOSTIC_TEST|Screening stress test on a bicycle ergometer (usual practise)|
58114630|NCT02629952|OTHER|Blueberry Tea|Blueberry Tea
58114631|NCT04922398|BIOLOGICAL|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
58114632|NCT04922398|DRUG|Normal saline|0.9% normal saline will be injected in each ovary
58114633|NCT04380571|DEVICE|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
58114634|NCT04380571|DEVICE|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
58445738|NCT06727279|OTHER|Specialized food - Plant-Based Meat Analog|Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.
58445739|NCT06727279|OTHER|standard isocalorie diet|Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
58445740|NCT02968368|DRUG|Ferric maltol|
58445741|NCT02968368|OTHER|Placebo|
57741596|NCT03876405|DEVICE|smartskin non-invasive sensory feedback|"The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket."
57741597|NCT04137042|DRUG|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
58114635|NCT04380571|OTHER|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
58114636|NCT05578573|DEVICE|KARAHOC device|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.
58114637|NCT05578573|DEVICE|Angiocatheter|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
58114638|NCT01269983|OTHER|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
58114639|NCT02917447|BEHAVIORAL|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
58114640|NCT02917447|BEHAVIORAL|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
58114641|NCT04566783|DIAGNOSTIC_TEST|Psychological/psychiatric examination|Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
58114642|NCT04566783|DIAGNOSTIC_TEST|Neurological examination|Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
58114643|NCT04566783|DIAGNOSTIC_TEST|Gynecological/urological examination|Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
58114644|NCT04566783|DIAGNOSTIC_TEST|Laboratory assessment|Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
58445742|NCT06493058|OTHER|Prone positioning|The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
58445743|NCT01416948|DRUG|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
58445744|NCT01416948|DRUG|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
58445745|NCT01416948|DRUG|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
58445746|NCT04142801|DEVICE|MeMo web application|The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
57741598|NCT04137042|DRUG|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
57741599|NCT05349344|OTHER|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
58114645|NCT04566783|DIAGNOSTIC_TEST|Structural and Functional Magnetic Resonance Imaging|"1. Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~2. Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~3. High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~4. Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~5. Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~6. Functional MRI to assess brain response towards sexual cue reactivity."
58114646|NCT04902339|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
58114647|NCT04902339|OTHER|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
58114648|NCT04902339|BEHAVIORAL|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
58114649|NCT01060774|DRUG|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
58114650|NCT01060774|DRUG|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
58114651|NCT00799006|DRUG|Placebo|Subjects will be given placebo or PF-04620110
58114652|NCT00799006|DRUG|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
58114653|NCT04108169|PROCEDURE|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
58114654|NCT05442333|PROCEDURE|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures."
58114655|NCT02517710|PROCEDURE|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
58114656|NCT06222463|DEVICE|Evone|Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
58445747|NCT04142801|OTHER|Control group|the patient have the classical follow up at the memory center (consultation)
58445748|NCT00410956|BIOLOGICAL|bevacizumab|
58445749|NCT00410956|DRUG|dexamethasone|
58445750|NCT00410956|DRUG|floxuridine|
58445751|NCT00410956|GENETIC|protein expression analysis|
58445752|NCT00410956|OTHER|flow cytometry|
57741600|NCT05349344|OTHER|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
57741601|NCT06603220|DRUG|Oral EVO756|Oral EVO756, once daily
58114657|NCT01412671|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
58114658|NCT05091814|RADIATION|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
58114659|NCT03979677|BEHAVIORAL|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
58114660|NCT00101972|BIOLOGICAL|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
58445753|NCT00410956|OTHER|immunoenzyme technique|
58445754|NCT00410956|OTHER|immunohistochemistry staining method|
58445755|NCT00410956|OTHER|immunologic technique|
58445756|NCT00410956|OTHER|laboratory biomarker analysis|
58445757|NCT00410956|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
58445758|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Squamous NSCLC
58445759|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Non-Squamous NSCLC
58445760|NCT06344299|OTHER|potential predictors|Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
58445761|NCT05171192|BEHAVIORAL|CMAP Plus LTP|The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
58445762|NCT06367348|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention. Sessions consist of incentivized savings accounts, financial literacy training, and relationships skills building, including couple communication.
58445763|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
58445764|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
58445765|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
58445766|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
58445767|NCT00921349|PROCEDURE|Ligation of varices|all varices are ligated until obliteration
58114661|NCT04119661|DEVICE|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
58114662|NCT04119661|DEVICE|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
58114663|NCT03321747|RADIATION|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
58114664|NCT05216614|DRUG|Fluvoxamine|Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
58114665|NCT05216614|DRUG|Placebo|lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
58114666|NCT01424982|DRUG|Cyclophosphamide|Given IV
58114667|NCT01424982|DRUG|Cytarabine|Given IV
58114668|NCT01424982|DRUG|Dexamethasone|Given IV or PO
58114669|NCT01424982|DRUG|Doxorubicin|Given IV
58114670|NCT01424982|DRUG|Doxorubicin Hydrochloride|Given IV
58114671|NCT01424982|OTHER|Laboratory Biomarker Analysis|Correlative studies
58114672|NCT01424982|DRUG|Methotrexate|Given IV
58114673|NCT01424982|DRUG|Ponatinib|Given PO
58114674|NCT01424982|DRUG|Ponatinib Hydrochloride|Given PO
58114675|NCT01424982|DRUG|Prednisone|Given PO
58445768|NCT00921349|DRUG|Nadolol|Nadolol (beta-blocker)
58445769|NCT01062152|DRUG|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
58445770|NCT01062152|DRUG|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
58445771|NCT02566317|DEVICE|Sit-Stand workstation|Installation of a sit-stand desk at work
58445772|NCT02566317|BEHAVIORAL|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
58445773|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
58114676|NCT01424982|BIOLOGICAL|Rituximab|Given IV
58114677|NCT01424982|DRUG|Vincristine|Given IV
58114678|NCT01424982|DRUG|Vincristine Sulfate|Given IV
58114679|NCT04032678|DEVICE|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
58114680|NCT04032678|DEVICE|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
58114681|NCT00229541|PROCEDURE|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
58114682|NCT03182920|DRUG|Lasmiditan|Oral administration
58114683|NCT03182920|DRUG|Placebo|Oral administration
58114684|NCT05242419|DRUG|Sodium Chloride Injection|0.9% Sodium Chloride Injection
58114685|NCT05242419|DRUG|Huperzine A Injection|Huperzine A Injection
58114686|NCT02139345|DEVICE|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
58114687|NCT02139345|DEVICE|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
58114688|NCT03282435|BIOLOGICAL|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
58114689|NCT03282435|OTHER|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
58114690|NCT03282435|BIOLOGICAL|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
58114691|NCT02099266|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
58114692|NCT02261571|OTHER|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
58114693|NCT05062109|BEHAVIORAL|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~* Muscle rehabilitation developed with a physiotherapist or physical activity monitor~* Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~* Cognitive and physical stimulation Exergame~* Psychological support by a psychologist~* Information in the form of videos on the main risks and important points to know and prepare before and after surgery~* Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~* One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
58114694|NCT02222142|DRUG|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
58114695|NCT04093180|PROCEDURE|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
58114696|NCT04093180|PROCEDURE|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
58114697|NCT02376985|PROCEDURE|Oral management|
58114698|NCT02376985|DRUG|Everolimus|
58114699|NCT06528574|DEVICE|Conventional root canal treatment|Root canals will be irrigated by only side perforated needle
58114700|NCT06528574|DEVICE|Ultrasonic|Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
58114701|NCT06528574|DEVICE|Apical negative pressure|Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system
58445774|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
58445775|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
58114702|NCT06528574|DEVICE|Combined Ultrasonic and negative pressure|Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
58114703|NCT04098874|DRUG|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
58114704|NCT04098874|DRUG|Placebo oral tablet|12 weeks postpartum of blinded placebo
58114705|NCT04763837|DEVICE|Intraureteral stent|This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
58114706|NCT04763837|DEVICE|Conventional Double-J stent|This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
58114707|NCT05625711|DEVICE|The endovascular interventional surgical instrument control system|The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
58114708|NCT03316079|OTHER|Chest physiotherapy techniques|Respiratory manual CPT
58114709|NCT03316079|DEVICE|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
58114710|NCT02965820|DEVICE|Opti-Free® PureMoist® contact lens solution|
58114711|NCT02965820|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
58114712|NCT02965820|DEVICE|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
58114713|NCT03779191|DRUG|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
58114714|NCT03779191|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
58445776|NCT02579967|DRUG|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
57741602|NCT03285139|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
58114715|NCT03501784|DEVICE|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
58114716|NCT03501784|DEVICE|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
58114717|NCT05074589|DRUG|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
58114718|NCT05074589|DRUG|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
57741603|NCT02119507|DEVICE|Curodont Repair|Single application on Day 0
58114719|NCT05121181|OTHER|delphi project|delphy study
58114720|NCT00534625|DRUG|zileuton|Single injection of zileuton 150 mg
58114721|NCT00534625|DRUG|placebo|Single injection of placebo
58114722|NCT00534625|DRUG|zileuton|Single injection of zileuton 300 mg
57741604|NCT02119507|OTHER|No treatment - control|
57741605|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
57957088|NCT05319639|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
57957089|NCT05319639|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
57957090|NCT05319639|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
57957091|NCT03261622|DEVICE|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
58114723|NCT03294083|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
58114724|NCT03294083|BIOLOGICAL|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
58114725|NCT06162403|OTHER|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
58114726|NCT05699707|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Participants will consume a ketone monoester drink (0.75 k/kg body mass) with venous blood samples obtained before and after (30, 60 and 90 minutes) drink consumption.
58445777|NCT02579967|DRUG|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
58445778|NCT02579967|DRUG|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
58445779|NCT02579967|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
58445780|NCT02579967|PROCEDURE|Allo BMT|Allogeneic blood or marrow transplantation
58445781|NCT06725303|DEVICE|Excimer|Light energy
58445782|NCT02673463|DRUG|Spironolactone|25 mg once daily
58114727|NCT01297647|PROCEDURE|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
58114728|NCT04495777|OTHER|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
58114729|NCT02577081|OTHER|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
58114730|NCT05694988|DEVICE|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
58114731|NCT03343106|BEHAVIORAL|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
58445783|NCT02673463|DRUG|Placebo|Visually identical to spironolactone, once daily
58114732|NCT03343106|BEHAVIORAL|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
58114733|NCT06503744|PROCEDURE|ablation|ablation
58445784|NCT00981461|DEVICE|HairMax LaserComb|Device application 3 times week, for 26 weeks
58445785|NCT00981461|DEVICE|Control Device|Device application 3 times week, for 26 weeks
58445786|NCT00776854|DEVICE|Noveon laser|870 and 930nm wavelengths
58445787|NCT01632020|DRUG|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
58445788|NCT01632020|DRUG|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
58445789|NCT05042583|PROCEDURE|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
58445790|NCT03097965|DIETARY_SUPPLEMENT|PROGRAM|
58445791|NCT03097965|OTHER|DIET|
58445792|NCT00622505|DRUG|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
58445793|NCT06725758|DRUG|ODM-212|ODM-212 5mg and/or 40mg tablets
58445794|NCT03275285|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58445795|NCT03275285|DRUG|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58445796|NCT03275285|DRUG|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
58445797|NCT01815827|DRUG|inclacumab|single intravenous doses
58445798|NCT03636789|OTHER|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
58445799|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
57957092|NCT00689871|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
58114734|NCT02514590|DEVICE|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
57957093|NCT01068028|DRUG|ORM-12741|Ascending multiple doses to sequential panels
57957094|NCT01068028|DRUG|Placebo for ORM-12741|
57957095|NCT05259982|PROCEDURE|Vital root resection|Vital resection of root with attachment loss exceeding 2/3 of the root with the use of calcium silicate cement in the pulpal wound
57957096|NCT03801668|DRUG|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
57957097|NCT03801668|DRUG|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
57957098|NCT02733770|PROCEDURE|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
57957099|NCT02733770|PROCEDURE|Laparoscopic mini gastric bypass|Doppler ultrasound.
57957100|NCT03691974|DRUG|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
57957101|NCT03691974|OTHER|Placebo|Subcutaneous (SC) every four weeks (Q4W)
57957102|NCT02171585|DRUG|Dabigatran etexilate|
57957103|NCT02171585|DRUG|Clarithromycin|
57957104|NCT00005870|DRUG|fluorouracil|
57957105|NCT00005870|DRUG|gemcitabine hydrochloride|
57957106|NCT00005870|DRUG|mitomycin C|
57957107|NCT00005870|DRUG|rubitecan|
57957108|NCT00381264|DRUG|Cesamet™ (nabilone)|
57957109|NCT02103569|DRUG|FDC of Daclatasvir, Asunaprevir and BMS-791325|
57957110|NCT02103569|DRUG|FDC of Norethindrone and Ethinyl Estradiol|
57957111|NCT02103569|DRUG|BMS-791325|
57957112|NCT06407180|DRUG|Triamcinolone Acetonide|receive intraarticular triamcinolone injection
57957113|NCT06407180|DRUG|Normal saline|receive intraarticular normal saline injection
57957114|NCT05903846|OTHER|Oketani massage|"The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless."
57957115|NCT02902952|BEHAVIORAL|Physical Exercise|An eight week physical exercise intervention
57741606|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
58114735|NCT01093742|DRUG|HM10560A|Subcutaneously administrate at 0 hour on Day 1
58114736|NCT01093742|DRUG|Placebo|Placebo
58114737|NCT02592694|DRUG|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
58114738|NCT02592694|DEVICE|thrombus aspiration|manual thrombus aspiration
58114739|NCT04931628|DRUG|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
57957116|NCT02902952|BEHAVIORAL|Control Intervention|An eight week sedentary control intervention
57957117|NCT04712929|OTHER|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
57957118|NCT04307290|DRUG|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
57957119|NCT00928551|DRUG|vabicaserin|
57957120|NCT05324046|DIAGNOSTIC_TEST|contrast-enhanced abdomen CT|"contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation).~* full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional)~* low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software.~* images are reconstructed using full dose (A- \& B- tubes) and smaller dose (A-tube only, B-tube only)"
57957121|NCT04270474|OTHER|Deprescribing of target anticholinergics|The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
58114740|NCT04931628|DRUG|0.9% NaCl|0.9% NaCl
58114741|NCT04011969|DIAGNOSTIC_TEST|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
58114742|NCT04011969|DIAGNOSTIC_TEST|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~1. Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~2. NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
58114743|NCT04011969|DIAGNOSTIC_TEST|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~1. Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~2. Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
58445800|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
58445801|NCT06725381|DRUG|SKB571|SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
58445802|NCT04837573|BEHAVIORAL|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
58445803|NCT03291717|BEHAVIORAL|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
58445804|NCT05565703|OTHER|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
58445805|NCT05565703|OTHER|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
58445806|NCT04789876|OTHER|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
58445807|NCT04789876|BEHAVIORAL|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
57741607|NCT00498719|BEHAVIORAL|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
58114744|NCT02242513|DEVICE|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
58114745|NCT02242513|DRUG|Xylocaine|
58445808|NCT02956694|BEHAVIORAL|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
58445809|NCT06439277|DRUG|Tirzepatide|Administered SC
58445810|NCT06439277|DRUG|Placebo|Administered SC
57741608|NCT00498719|OTHER|Control Group|Standard educational support.
57741609|NCT02859792|DRUG|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
57741610|NCT02859792|DRUG|Placebo|placebo capsules 25 or 50 mg
57741611|NCT02859792|BIOLOGICAL|Blood Samples|v1;v2;v3;v4
57741612|NCT03971682|BEHAVIORAL|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
58114746|NCT04966897|DIETARY_SUPPLEMENT|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
58445811|NCT05956899|DRUG|Palonosetron|IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia
58445812|NCT05956899|DRUG|Ondansetron|IV ondansetron 0.15mg/kg at the start of wound closure
58445813|NCT00585520|DRUG|Progesterone|200mg BID for 5 days
58445814|NCT00585520|DRUG|Placebo|Placebo
58445815|NCT01186991|DRUG|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
58445816|NCT01186991|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
58114747|NCT04966897|DIETARY_SUPPLEMENT|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
58114748|NCT06157281|BEHAVIORAL|Connect|A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
58445817|NCT01186991|DRUG|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
58445818|NCT01186991|DRUG|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
58114749|NCT05896293|DRUG|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
58445819|NCT01186991|DRUG|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
57741613|NCT03971682|OTHER|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
57741614|NCT03932851|OTHER|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
57741615|NCT00057668|BEHAVIORAL|Multi-Setting Early Intervention|
57741616|NCT00057668|BEHAVIORAL|Community Intervention|
57741617|NCT00265889|BIOLOGICAL|filgrastim|480 mcg beginning day +5
58114750|NCT05896293|DRUG|leuprolide acetate|Single SC bolus
58445820|NCT05813964|DRUG|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
58445821|NCT05813964|DRUG|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
58445822|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
58445823|NCT01581398|DRUG|Pegasys|sc, qw, 24 weeks.
58445824|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
57741618|NCT00265889|DRUG|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
58445825|NCT01581398|DRUG|Pegasys|sc, qw, 48 weeks.
58445826|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
58445827|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
58445828|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
58445829|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
58114751|NCT05971121|DRUG|ciprofol|Ciprofol were used for sedation in ICU hypotensive patients
58114752|NCT03480711|PROCEDURE|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
58114753|NCT03480711|PROCEDURE|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
58114754|NCT00415532|DRUG|Medical Standard of Care for ITP|
58114755|NCT00415532|BIOLOGICAL|Romiplostim|
58114756|NCT01767441|PROCEDURE|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
58445830|NCT01034930|PROCEDURE|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
58445831|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
58114757|NCT01767441|PROCEDURE|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
57741619|NCT00265889|DRUG|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
57741620|NCT00265889|DRUG|etoposide|60 mg/kg, IV
57741621|NCT00265889|DRUG|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
58114758|NCT01767441|PROCEDURE|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
58114759|NCT01767441|OTHER|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
58114760|NCT05895084|BEHAVIORAL|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
58445832|NCT05898126|PROCEDURE|Usual care|Standard of care
57741622|NCT00265889|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
57957122|NCT04270474|OTHER|Usual Care|Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
57957123|NCT01227330|BEHAVIORAL|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
57957124|NCT01227330|BEHAVIORAL|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
57957125|NCT03433014|PROCEDURE|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
57957126|NCT03433014|OTHER|Control|No infiltration
57741623|NCT00265889|RADIATION|radiation therapy|radiation therapy
57741624|NCT06511141|DEVICE|Axonics SNM System|To assess clinical outcomes of the Axonics SNM System in the male OAB population.
57957127|NCT02442973|PROCEDURE|Control group (CG): standard practice|Standard practice group
57957128|NCT02442973|PROCEDURE|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
57957129|NCT02442973|DEVICE|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
57957130|NCT03119519|RADIATION|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
57957131|NCT03119519|DRUG|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
57957132|NCT03375450|OTHER|Standard of Care|Participants will be followed as per local routine primary healthcare practice
57957133|NCT04609852|DRUG|E8001|Intravenous infusion.
57741625|NCT06731933|DRUG|BVEC|The study drug will be administered by home nurse at Subjects home for the participants residing in US. No drug will be applied when at study site. The subjects enrolled in Bari, Italy will not be administered BVEC.
58445833|NCT01646281|DRUG|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
58114761|NCT00423800|DRUG|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
58114762|NCT05885360|DRUG|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
58114763|NCT04721457|DRUG|Distilled Water|Control group
58114764|NCT04721457|DRUG|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
58114765|NCT04721457|DRUG|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
58445834|NCT01646281|DRUG|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
58445835|NCT04726722|BEHAVIORAL|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
58445836|NCT05594719|DEVICE|Shorter-wavelength dominant light|Shorter-wavelength dominant light
58445837|NCT05594719|DEVICE|Light similar to the solar spectrum proportion|Light similar to the solar spectrum proportion with no specific wavelength dominant
58445838|NCT05594719|DEVICE|Longer-wavelength dominant light|Longer-wavelength dominant light
58445839|NCT02021669|DRUG|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
58445840|NCT02021669|DRUG|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
58445841|NCT02545218|PROCEDURE|Perineorraphy|Surgery for improperly healed perineal tear
57741626|NCT01877538|OTHER|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
57741627|NCT02738268|DEVICE|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
57741628|NCT02738268|DEVICE|sham laser|
57957134|NCT04609852|DRUG|Placebo|Intravenous infusion.
57957135|NCT02813200|DRUG|Seretide® Diskus® 500/550 μg|Every day during 7 days
57957136|NCT02813200|DRUG|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
57957137|NCT02813200|DRUG|Spiriva® Respimat® 2,5 μg|Every day during 7 days
57957138|NCT00812214|DRUG|eszopiclone|3 mg tablet every night at bedtime
58114766|NCT04721457|DRUG|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
58114767|NCT04721457|DRUG|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
58114768|NCT04721457|OTHER|No rinse group|second control group
58445842|NCT02545218|OTHER|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
58445843|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
58445844|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
57741629|NCT00430768|BIOLOGICAL|rAAV1-CB-hAAT|
57957139|NCT00812214|DRUG|placebo|1 tablet every night at bedtime
58445845|NCT01880658|DRUG|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
58445846|NCT04890470|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
58445847|NCT04890470|DRUG|Vasopressin|intranasal administration of vasopressin (20 IU)
58445848|NCT04890470|DRUG|Placebo|intranasal administration of placebo
58445849|NCT06280716|DRUG|Placebo|Subcutaneous injection
58445850|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
58445851|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
58445852|NCT02795585|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
58445853|NCT04385186|DRUG|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
58445854|NCT04385186|DRUG|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
57741630|NCT05903417|DRUG|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
57741631|NCT05903417|OTHER|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
57741632|NCT03078348|OTHER|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
57741633|NCT03078348|BEHAVIORAL|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
57741634|NCT03078348|BEHAVIORAL|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
58445855|NCT06411574|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
57741635|NCT06580262|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
57741636|NCT03902704|DEVICE|Cleverscope|the device is used in patients without difficult airways predictors
58445856|NCT03243136|OTHER|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
58445857|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
58445858|NCT00655616|DRUG|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
57957140|NCT03621371|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
57957141|NCT03621371|BEHAVIORAL|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
57957142|NCT05915442|DRUG|Quemliclustat|100mg IV once every two weeks
58445859|NCT00655616|DRUG|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
58445860|NCT06725134|BEHAVIORAL|Therapy dog presence|A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
58445861|NCT06725134|BEHAVIORAL|Standard-of-care basic behavior guidance|Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
58445862|NCT00369577|DRUG|Inhaled Placebo|Inhaled Placebo, single dose
58445863|NCT00369577|DRUG|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
58445864|NCT00369577|DRUG|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
58445865|NCT04457063|PROCEDURE|PKP|"1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
58445866|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
58445867|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
57741637|NCT03902704|DEVICE|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
57741638|NCT04204629|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, PO
57741639|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
58445868|NCT06143267|OTHER|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
58445869|NCT05564455|OTHER|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
57741640|NCT00695669|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
57741641|NCT05847426|OTHER|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
57741642|NCT05847426|OTHER|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
57957143|NCT05915442|DRUG|Etrumadenant|150 mg orally (PO) once a day (QD)
57957144|NCT05915442|DRUG|Zimberelimab|240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
57957145|NCT05915442|RADIATION|Stereotactic Body Radiation Therapy|Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
57957146|NCT03986489|BEHAVIORAL|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
58445870|NCT05564455|OTHER|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
58445871|NCT03231007|OTHER|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
58445872|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
58445873|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
58445874|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
57741643|NCT00726726|DRUG|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
57741644|NCT00726726|DRUG|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
57957147|NCT03986489|BEHAVIORAL|Chronic pain social support group|"The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session."
57957148|NCT04096911|DRUG|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
58445875|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
58445876|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
57957149|NCT04096911|DRUG|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
58114769|NCT02886975|BEHAVIORAL|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
58445877|NCT05026359|DEVICE|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
58114770|NCT02042911|DRUG|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
58445878|NCT06713330|DEVICE|BioFLX crown|Device: BioFLX crown
58445879|NCT06713330|DEVICE|3M Stainless Steel Crown|3M Stainless Steel Crown
57957150|NCT04942925|DEVICE|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
57741645|NCT00726726|DRUG|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
57957151|NCT04942925|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
57957152|NCT03086733|DRUG|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
57957153|NCT04695964|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
58114771|NCT04186390|OTHER|Simulation training in small bowel capsule endoscopy|Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
58114772|NCT03720483|DRUG|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
58445880|NCT04236388|DIETARY_SUPPLEMENT|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
58445881|NCT04236388|DIETARY_SUPPLEMENT|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
57741646|NCT03606330|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT."
57741647|NCT03606330|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
57741648|NCT05029765|DIETARY_SUPPLEMENT|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
57741649|NCT05029765|DIETARY_SUPPLEMENT|Healthy diet (WHO recommendations)|Recommendations according to WHO
57741650|NCT05029765|DIETARY_SUPPLEMENT|Placebo|Placebo
57741651|NCT05029765|DIETARY_SUPPLEMENT|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
57741652|NCT03873948|OTHER|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
57957154|NCT03837080|OTHER|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
57741653|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
57957155|NCT00653003|DRUG|Leflunomide|tablets, 20mg, single-dose
57957156|NCT00653003|DRUG|ARAVA|Tablets, 20mg, single-dose
57957157|NCT03473496|BIOLOGICAL|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
57957158|NCT01993693|DEVICE|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
57957159|NCT01993693|DEVICE|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
58445882|NCT04345562|PROCEDURE|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
58445883|NCT01890837|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
57741654|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
57741655|NCT02274714|OTHER|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
57741656|NCT05614102|DRUG|BAY2965501|Daily oral application
57741657|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
57741658|NCT05614102|DRUG|Platinum-based Chemotherapy|Standard of care doses per tumor type will be administered.
57741659|NCT05881759|BEHAVIORAL|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
57741660|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
57957160|NCT00973076|DRUG|AZD8055|Tablets, orally administered, twice daily
57957161|NCT03502993|DIAGNOSTIC_TEST|Validation of biomarker|
57957162|NCT02823977|DRUG|Ketamine|Blinded study drug administered to experimental arm
57957163|NCT02823977|DRUG|Dexmedetomidine|Open-label study drug administered to both arms
57957164|NCT02823977|DRUG|Normal saline|Blinded comparator administered to control arm
58445884|NCT01890837|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
58445885|NCT05616481|PROCEDURE|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
58114773|NCT03720483|DRUG|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
58114774|NCT01164033|DRUG|RO5045337|single oral dose
58114775|NCT04251182|DRUG|15mg T3D-959|Oral administration once daily in the morning
58445886|NCT05616481|PROCEDURE|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
58445887|NCT05700877|OTHER|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
58445888|NCT05700877|OTHER|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
58445889|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
58445890|NCT06727071|PROCEDURE|Hyperglycemic clamp|A continuous infusion of 20% dextrose will be maintained throughout the procedure, while a variable rate of insulin infusion will be used to control participants blood glucose level.
58445891|NCT04587050|DIAGNOSTIC_TEST|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
58445892|NCT04587050|DIAGNOSTIC_TEST|Cervical cytology|Cervical cytology
58445893|NCT04587050|DIAGNOSTIC_TEST|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
58445894|NCT06122506|PROCEDURE|Laparoscopic cerclage|Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
58445895|NCT06122506|PROCEDURE|Vaginal cerclage|Transvaginal cerclage in pregnant women.
58445896|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
58445897|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine|standart support
58445898|NCT03777059|DRUG|Atogepant|Atogepant tablet
58445899|NCT03777059|DRUG|Placebo|Placebo-matching atogepant tablets
58445900|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
57741661|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
57741662|NCT02019368|DIETARY_SUPPLEMENT|Placebo|
57741663|NCT02019368|DIETARY_SUPPLEMENT|Aged garlic extract|
58114776|NCT04251182|DRUG|30 mg T3D-959|Oral administration once daily in the morning
58114777|NCT04251182|DRUG|45 mg T3D-959|Oral administration once daily in the morning
58114778|NCT04251182|DRUG|Placebos|Oral administration once daily in the morning
58114779|NCT00095290|DRUG|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
58114780|NCT00095290|DRUG|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
58445901|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
58445902|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
58445903|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
58445904|NCT06726967|DIAGNOSTIC_TEST|vitamin D 25(OH)D|Thyroid functions (thyroid-stimulating hormone (TSH), serbest triiodothyronine (fT3), serbest thyroxine (fT4)); Thyroid antibodies (Anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG))
58445905|NCT03384368|DEVICE|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
58445906|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
58445907|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
58114781|NCT04109157|DIAGNOSTIC_TEST|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
58114782|NCT03786666|PROCEDURE|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
58114783|NCT05332561|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
58114784|NCT05332561|DRUG|Inavolisib|Arm 2
58114785|NCT05332561|DRUG|Ipatasertib|Arm 3
58114786|NCT05332561|DRUG|Olaparib|Arm 4
58114787|NCT05332561|DRUG|Sacituzumab govitecan|Arm 5
58445908|NCT02564458|BEHAVIORAL|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
58445909|NCT06726356|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
58445910|NCT01509755|DRUG|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
58445911|NCT01509755|DRUG|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
58445912|NCT01509755|DRUG|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
57957165|NCT04251637|OTHER|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
57957166|NCT00561197|DRUG|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
57957167|NCT00779376|DRUG|Zidovudine 300mg tablets|
57957168|NCT02911922|DEVICE|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
57957169|NCT02911922|DEVICE|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
57957170|NCT02911922|RADIATION|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
58445913|NCT01687296|DRUG|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
58445914|NCT01687296|DRUG|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
58445915|NCT01687296|DRUG|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
58445916|NCT01687296|DRUG|placebo tablet|placebo soluble tablet, oral ,once daily
58445917|NCT01687296|DRUG|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
57957171|NCT06100341|OTHER|Virtual reality|A role-playing game set in a spaceship in outer space where a user will need to accomplish three activities to complete the game. These activities were designed based on typical therapy goals for children with cerebral palsy of improving balance, gross motor performance, walking speed, and functional mobility.
57957172|NCT04360759|DRUG|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
57957173|NCT00899184|GENETIC|polymorphism analysis|
58445918|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
57957174|NCT00899184|OTHER|laboratory biomarker analysis|
57957175|NCT03759535|DIAGNOSTIC_TEST|Acute rejection|Donor derived cell free DNA
58114788|NCT05332561|DRUG|Trastuzumab/pertuzumab|Arm 6
58114789|NCT06529315|OTHER|Point-of-Care Ultrasound|The investigators will use point-of-care ultrasound to exam participants including lungs, heart, liver, spleen, kidney and bladder, etc.
58114790|NCT02765828|OTHER|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
58114791|NCT00306384|DRUG|Alogliptin|Alogliptin tablets.
58445919|NCT00028704|PROCEDURE|conventional surgery|
58445920|NCT00028704|RADIATION|radiation therapy|
58445921|NCT02459444|DEVICE|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
58445922|NCT02459444|OTHER|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
58445923|NCT06121089|PROCEDURE|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
58445924|NCT06121089|PROCEDURE|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
58445925|NCT06725277|DRUG|Spravato|Intranasal esketamine
58445926|NCT06725277|DRUG|IV Ketamine|IV ketamine
58445927|NCT01217463|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
58445928|NCT00389493|DRUG|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
58445929|NCT00389493|BEHAVIORAL|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
58445930|NCT00389493|DRUG|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
58445931|NCT03171337|DEVICE|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
58445932|NCT03171337|DEVICE|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
58445933|NCT03171337|DEVICE|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
58445934|NCT01695434|OTHER|MRI|All subjects will undergo a MRI.
58445935|NCT02363621|DRUG|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
58445936|NCT02363621|DRUG|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
58445937|NCT05189119|DIAGNOSTIC_TEST|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
58445938|NCT04428229|OTHER|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
58445939|NCT00287508|DEVICE|Carotid artery stenting with filter (interventional)|
58445940|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
58445941|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
58445942|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
58445943|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
58445944|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
58114792|NCT04316052|OTHER|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
58114793|NCT04316052|OTHER|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
58114794|NCT03237585|BEHAVIORAL|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
58114795|NCT00594633|OTHER|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
58114796|NCT04378010|DRUG|EDP-305 1.5 mg|Tablet
58114797|NCT04378010|DRUG|EDP-305 2 mg|Tablet
58114798|NCT04378010|DRUG|Placebo|Tablet
58114799|NCT01942798|DEVICE|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
58114800|NCT01942798|DEVICE|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
58114801|NCT00796237|DEVICE|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
58114802|NCT00796237|OTHER|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
58114803|NCT03210675|DIAGNOSTIC_TEST|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
58114804|NCT03293927|DRUG|Fentanyl|The patient will receive IV fentanyl
58114805|NCT03293927|DRUG|Dexmedetomidine|The patient will receive IV dexemedetomidine
58114806|NCT00585091|DRUG|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
58114807|NCT00539539|OTHER|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
58114808|NCT01696864|DEVICE|Hand tutor rehabilitation device|A rehabilitation device for the hand
58445945|NCT04182841|DEVICE|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
58114809|NCT01696864|DEVICE|Arm tutor rehabilitation device|A rehabilitation device for the arm
58114810|NCT05673187|DRUG|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
58114811|NCT01199601|BEHAVIORAL|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
58114812|NCT00004451|DRUG|Glucose|
58114813|NCT01162499|DRUG|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
58445946|NCT04212598|DRUG|Sintilimab|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
58114814|NCT01162499|OTHER|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
58114815|NCT05989360|DIAGNOSTIC_TEST|Lung Clearance Index|Normative values in healthy children from ethnic backgrounds
58114816|NCT02797964|DRUG|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
58114817|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative PPI|sleeve + preoperative PPI
58114818|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative Placebo|sleeve + preoperative Placebo
58114819|NCT00000616|BEHAVIORAL|diet, sodium-restricted|
58445947|NCT01557088|OTHER|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
58114820|NCT00000616|BEHAVIORAL|diet, fat-restricted|
58114821|NCT00000616|BEHAVIORAL|exercise|
58114822|NCT00000616|BEHAVIORAL|diet, reducing|
58114823|NCT00000616|BEHAVIORAL|alcohol drinking|
58114824|NCT02974413|BEHAVIORAL|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
58114825|NCT03136692|BEHAVIORAL|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
58114826|NCT06073795|PROCEDURE|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
58114827|NCT05822700|PROCEDURE|Kirschner wire|Transfixing femoral head Kirschner wire
58114828|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
58445948|NCT01557088|PROCEDURE|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
58445949|NCT00684775|COMBINATION_PRODUCT|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
58445950|NCT02475278|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
58445951|NCT02418052|PROCEDURE|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
58445952|NCT02678351|DRUG|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
58445953|NCT02678351|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
58445954|NCT02678351|PROCEDURE|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
58445955|NCT01154777|BEHAVIORAL|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
58445956|NCT00082407|DRUG|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
58445957|NCT00082407|DRUG|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
58445958|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
58445959|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
58445960|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
58445961|NCT01363089|DRUG|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
58445962|NCT01363089|DRUG|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
58114829|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
58114830|NCT06107361|DEVICE|B. Braun 6.35cm 20 gauge ultralong intravenous catheter|B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter
58114831|NCT06107361|DEVICE|BD 5.71 cm 20 gauge Accucath|Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire
58114832|NCT02429700|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
58114833|NCT02429700|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
58114834|NCT02429700|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
58114835|NCT02429700|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
58445963|NCT00123318|DRUG|epirubicin|50mg/m2 IV day 1
58445964|NCT00123318|DRUG|cisplatin|60mg/m2 IV day 1
58445965|NCT00123318|DRUG|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
58445966|NCT00123318|RADIATION|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
58114836|NCT02429700|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
58114837|NCT01772368|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
58114838|NCT01772368|DRUG|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
58445967|NCT00747084|PROCEDURE|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
57741664|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
57741665|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
57741666|NCT01064232|DRUG|Risperidone|Risperidone Tablets 1 mg
57957176|NCT04381910|DRUG|LY01610( Irinotecan hydrochloride liposome injection )|LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
57957177|NCT05300178|PROCEDURE|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
57957178|NCT00096863|DRUG|Ziprasidone|
57957179|NCT00096863|DRUG|Haloperidol|
57957180|NCT00096863|OTHER|Placebo|
58114839|NCT01772368|DRUG|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
58114840|NCT01772368|DRUG|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
58445968|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
58114841|NCT03619499|DEVICE|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
58114842|NCT06479044|DIAGNOSTIC_TEST|Herrmann Brain Model|The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
58114843|NCT01798485|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
58114844|NCT01798485|DRUG|Ganetespib|Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
58445969|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
58445970|NCT05039957|OTHER|joint preparation|fixation of fracture with joint preparation
58445971|NCT05039957|OTHER|without joint preparation|fixation of fracture without joint preparation
58445972|NCT04661982|OTHER|Long-term Follow-up|Undergo long term follow-up
58445973|NCT04661982|OTHER|Questionnaire Administration|Ancillary studies
58445974|NCT04661982|OTHER|Quality-of-Life Assessment|Ancillary studies
58445975|NCT06222580|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58445976|NCT06222580|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
58445977|NCT06222580|DRUG|Gilteritinib|Given PO
57741667|NCT00673972|RADIATION|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
57741668|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
57741669|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
57741670|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
57741671|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
57741672|NCT05945433|DEVICE|anovo™ Surgical System|The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
57741673|NCT05257096|BEHAVIORAL|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
58114845|NCT06419348|DRUG|99mTc-QULIC-5-P1|Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
58114846|NCT06528041|OTHER|Inulin|12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
58445978|NCT06222580|DRUG|Revumenib|Given PO
58445979|NCT02379169|DIETARY_SUPPLEMENT|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
58445980|NCT02379169|DIETARY_SUPPLEMENT|Placebo|Triglycerides of medium chain fatty acids
58445981|NCT04880096|OTHER|eDOL|e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
58445982|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
58445983|NCT00532688|DRUG|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
58445984|NCT02851706|OTHER|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
58114847|NCT06528041|OTHER|Maltodextrin|6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
58114848|NCT01231061|RADIATION|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
58114849|NCT01231061|RADIATION|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
58114850|NCT05606692|DRUG|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
58114851|NCT05606692|DRUG|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
58114852|NCT05139966|DRUG|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
58114853|NCT04091269|DEVICE|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
58114854|NCT02613637|OTHER|Registry|
58114855|NCT03843177|OTHER|No intervention|No intervention will be performed. Only assessment will be done.
57957181|NCT04901143|DEVICE|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
57957182|NCT01339559|DRUG|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
57957183|NCT04800198|PROCEDURE|non-invasive ventilation|none, measurements only
57957184|NCT04325542|DIAGNOSTIC_TEST|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
57957185|NCT04901299|DRUG|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
57957186|NCT04901299|DRUG|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
58114856|NCT00164606|BEHAVIORAL|Positive Parenting Program (Triple-P)|
58114857|NCT02911883|DEVICE|Optical Coherence Tomography Angiography|
58114858|NCT02611752|DRUG|CAM2038|CAM2038 subcutaneous injection
58114859|NCT04866797|OTHER|cyclic merocyanine|long-UVA absorber
58114860|NCT04866797|OTHER|Placebo|Placebo
58114861|NCT01007916|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
58114862|NCT01007916|DEVICE|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
57957187|NCT05018234|DEVICE|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
57957188|NCT05417854|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
57957189|NCT01440621|DRUG|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
57957190|NCT01440621|DRUG|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
57957191|NCT05787262|PROCEDURE|upper endoscopy|Upper endoscopy , biopsy and histopathological examination of taken biopsies.
57957192|NCT03445091|DEVICE|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
57957193|NCT04242082|DIAGNOSTIC_TEST|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
57957194|NCT06424782|OTHER|medicinal water|Medicinal water treatment in bath tub once daily.
57957195|NCT00211146|DRUG|epoetin alfa|
57957196|NCT01332539|OTHER|no intervention|non-interventional study
57957197|NCT01902290|BIOLOGICAL|Placebo|Placebo administered subcutaneously
58114863|NCT05364099|DRUG|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
58114864|NCT05364099|DRUG|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
58114865|NCT05364099|PROCEDURE|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
58114866|NCT03355378|PROCEDURE|gum chewing|chewing gum orally for 30 minutes
58114867|NCT05025423|DRUG|Venetoclax Oral Tablet [Venclexta]|Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
57957198|NCT01902290|BIOLOGICAL|Brodalumab|Brodalumab administered subcutaneously
57957199|NCT06301880|DRUG|The topical application of a vasodilator on the LIMA graft|Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
57957200|NCT00457327|PROCEDURE|protective ileostomy|
57957201|NCT04363775|DEVICE|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
57957202|NCT04363775|DEVICE|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
57957203|NCT01606111|DRUG|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
57957204|NCT01606111|DRUG|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
57957205|NCT04429178|OTHER|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
57957206|NCT00978029|DRUG|Placebo|Placebo sublingual tablet, once daily
57957207|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
57957208|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
57957209|NCT03269123|DEVICE|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
57957210|NCT04345744|PROCEDURE|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
57957211|NCT04345744|DEVICE|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
57957212|NCT04345744|DEVICE|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
57957213|NCT04807348|DRUG|Chiglitazar 32mg|Administrated once daily
57957214|NCT04807348|DRUG|Chiglitazar 48mg|Administrated once daily
57957215|NCT04807348|DRUG|Placebo|Placebo of Chiglitazar
57957216|NCT04807348|DRUG|Metformin Hydrochloride|most tolerable dose
57957217|NCT04780620|OTHER|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
57957218|NCT01784861|DRUG|X-82|
57957219|NCT01784861|DRUG|Everolimus|
57957220|NCT00704782|DRUG|dimebon|
57957221|NCT04319328|DRUG|Cefazolin|Non-interventional pharmacokinetic evaluation
57957222|NCT04319328|DRUG|Ceftazidime|Non-interventional pharmacokinetic evaluation
57957223|NCT01762852|DRUG|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
57957224|NCT01762852|DRUG|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
57957225|NCT00062335|RADIATION|radiation therapy|
57957226|NCT06115187|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
57957227|NCT06115187|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
57957228|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 without adjuvant
57957229|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 with adjuvant
57957230|NCT05903183|BIOLOGICAL|Placebo|Diluent
57957231|NCT02105532|OTHER|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
58114868|NCT03035838|DRUG|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
58114869|NCT04359992|OTHER|Extra blood sample|3 extra blood samples at day 0, 2 and 7
58114870|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium"
58114871|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS)|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected"
58114872|NCT03878355|PROCEDURE|functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique with middle turbinate preservation
58114873|NCT00564369|OTHER|CDC HIV testing recommendations|Current vs. prior CDC recommendations
58114874|NCT02561312|OTHER|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
58114875|NCT02561312|OTHER|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
57957232|NCT02105532|OTHER|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
57957233|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
57957234|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
57957235|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
57957236|NCT03401528|DRUG|AVB-S6-500|AVB-S6-500 is an investigational drug.
57957237|NCT03401528|OTHER|Placebo|Matching placebo
57957238|NCT03436862|DRUG|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
57957239|NCT01849874|DRUG|MEK162, MEK inhibitor; oral|multiple dose, single schedule
57957240|NCT01849874|DRUG|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
57957241|NCT04110847|DRUG|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
57957242|NCT02891304|OTHER|Quarterly Feedback|Learning curves received quarterly vs. annually
57957243|NCT01687764|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
58114876|NCT03801096|BEHAVIORAL|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).
58114877|NCT03801096|BEHAVIORAL|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
58114878|NCT05816733|DRUG|Dapagliflozin|Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
58114879|NCT05816733|DRUG|Placebo|Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
58114880|NCT03815357|OTHER|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
58445985|NCT06725875|OTHER|White Noise Group|During the procedure, a mobile white noise (WN) application called Noise: White, Pink, Brown will be played via over-the-ear headphones to provide the individual with a sense of comfort. The intensity of the white noise will be determined using sound samples for patient comfort. The mobile WN application will be played to the patient by selecting white from among the color options. The sound level will be adjusted below 50 dB using a measuring device to prevent possible hearing damage (12). At the end of the procedure, the listening process will be terminated and the headphones will be removed. At the end of the procedure, the outer and inner surfaces of the headphones will be cleaned with disposable disinfectant wipes to prevent decontamination when used by another patient.
58445986|NCT06725875|OTHER|Earplug group|2. Earplug group: An earplug that prevents patients from hearing outside sounds will be used during the procedure. Features: Smooth, dirt-resistant surface provides better hygiene. Earplugs are easy to roll for quick and easy insertion. Conical design fits comfortably in ear canals. Soft polyurethane foam is hypoallergenic. Similar earplugs were used in a previous study
58445987|NCT06538116|DRUG|Mevidalen|Administered orally
58445988|NCT06538116|DRUG|Placebo|Administered orally
57741674|NCT03900468|DEVICE|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
58114881|NCT04921683|DEVICE|BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation|"Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total \~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA \<= 190W/cm2, ISPTA \<= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface."
58114882|NCT05778279|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
58114883|NCT02684500|DEVICE|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
58114884|NCT01787214|DIETARY_SUPPLEMENT|Full dose|20% of daily energy needs supplied by walnuts
58445989|NCT00398099|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
58445990|NCT01866358|PROCEDURE|Intraosseous infusion|Using intraosseous infusion for resustation in this group
58445991|NCT01866358|PROCEDURE|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
58445992|NCT06322888|BEHAVIORAL|Exercise Training Program|A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
58445993|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
58445994|NCT03856216|DRUG|Bendamustine|Given IV
58445995|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
58445996|NCT03856216|DRUG|Fludarabine|Given IV
58445997|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
58445998|NCT03856216|DRUG|Melphalan|Given IV
58114885|NCT01787214|DIETARY_SUPPLEMENT|Half dose|10% of daily energy needs supplied by walnuts
57741675|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
57957244|NCT01687764|OTHER|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
58114886|NCT01787214|DIETARY_SUPPLEMENT|Control|Walnut free meals
58445999|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
58446000|NCT03856216|BIOLOGICAL|Rituximab|Given IV
58446001|NCT03856216|DRUG|Tacrolimus|Given IV and PO
58446002|NCT05184634|OTHER|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
58446003|NCT05184634|OTHER|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
58446004|NCT05184634|OTHER|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
58446005|NCT05184634|OTHER|QUALITY OF LIFE|To determine the quality of life of MetS individuals
58446006|NCT02152306|DRUG|Fimasartan and Amlodipine|
58446007|NCT02152306|DRUG|Fimasartan|
58446008|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
58446009|NCT01737125|RADIATION|Magnetic Resonance Imaging (MRI)|"* spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~* MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
57741676|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
57741677|NCT04728321|BIOLOGICAL|AK104 lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
57741678|NCT04728321|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
57741679|NCT01952535|DRUG|HMS5552|
57741680|NCT01952535|DRUG|Placebo|
57741681|NCT04708444|DIAGNOSTIC_TEST|CD318|Flowcytometric marker
57957245|NCT01687764|BEHAVIORAL|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
57957246|NCT01687764|BEHAVIORAL|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
57957247|NCT02905565|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
57957248|NCT02905565|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
57957249|NCT00248248|DRUG|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
57957250|NCT00683033|BEHAVIORAL|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
57957251|NCT00683033|BEHAVIORAL|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
57957252|NCT05672342|DRUG|Cannabidiol|Given PO
57957253|NCT05672342|DRUG|Delta-8-Tetrahydrocannabinol|Given PO
57957254|NCT05672342|DRUG|Placebo Administration|Given PO
57957255|NCT05672342|OTHER|Questionnaire Administration|Ancillary studies
57957256|NCT03449823|DIAGNOSTIC_TEST|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
57957257|NCT02205749|BEHAVIORAL|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
57957258|NCT02205749|BEHAVIORAL|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
57957259|NCT02205749|BEHAVIORAL|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
58114887|NCT00977964|OTHER|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
58114888|NCT00977964|OTHER|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
58114889|NCT00977964|OTHER|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
58114890|NCT00977964|OTHER|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
58114891|NCT00977964|OTHER|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
58114892|NCT00977964|OTHER|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
58114893|NCT05544851|OTHER|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
58114894|NCT01534975|DIAGNOSTIC_TEST|contrast agent|we are randomizing patients to different contrast agents.
58114895|NCT00772577|DRUG|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
58114896|NCT00772577|DRUG|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
58114897|NCT04822662|BEHAVIORAL|Epilepsy Education Programme|Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
58114898|NCT04579328|BEHAVIORAL|Exposure to Growth Mats|see arm/group descriptions for description of intervention
58114899|NCT01945099|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
58114900|NCT01945099|DRUG|hyaluronidase|
58114901|NCT01945099|DRUG|Lispro-PH20|
58446010|NCT05948631|BEHAVIORAL|MISC intervention|MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
58446011|NCT05948631|BEHAVIORAL|Treatment as Usual (TAU)|TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
58446012|NCT05582993|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
57957260|NCT04558814|DIAGNOSTIC_TEST|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
57957261|NCT01140360|DRUG|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
57957262|NCT00940407|DEVICE|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
57957263|NCT06495632|DRUG|Motrin and narcotic|See described earlier
57957264|NCT02961335|PROCEDURE|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
57957265|NCT02961335|PROCEDURE|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
57957266|NCT02961335|PROCEDURE|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
57957267|NCT06407310|DRUG|Pembrolizumab|I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
57957268|NCT06407310|DRUG|Carboplatin|I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
57957269|NCT06407310|DRUG|Paclitaxel|I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
57957270|NCT03976973|DRUG|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
57957271|NCT03976973|DRUG|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
58114902|NCT04749524|DIAGNOSTIC_TEST|Medial-Olivocochlear Reflex (MOCR) Strength Measurement|Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.
58114903|NCT03035227|PROCEDURE|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
58114904|NCT03035227|DRUG|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
58114905|NCT05383274|COMBINATION_PRODUCT|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
58114906|NCT00919958|BIOLOGICAL|PLX-PAD IM injection|Single treatment; multiple injections
58114907|NCT01692158|DRUG|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
58114908|NCT03054025|DEVICE|Smart Phone Monitoring Device|Use activity tracker application
58114909|NCT02243020|DEVICE|Vagus Nerve Stimulation (VNS)|
58114910|NCT03414164|DIETARY_SUPPLEMENT|procyanidine|natural antioxidants
58114911|NCT04342403|DIAGNOSTIC_TEST|Quality of Life|Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
58114912|NCT03720756|OTHER|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
58114913|NCT02967198|DEVICE|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
58114914|NCT02967198|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
58446013|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
58114915|NCT03989960|PROCEDURE|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
58114916|NCT03989960|PROCEDURE|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
58446014|NCT00458120|BIOLOGICAL|rDEN1delta30|Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
58446015|NCT00458120|BIOLOGICAL|rDEN2/4delta30(ME)|Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
58446016|NCT00458120|BIOLOGICAL|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
58446017|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
58446018|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
58446019|NCT03545074|BEHAVIORAL|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
58114917|NCT06544317|BEHAVIORAL|physical training|All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
58114918|NCT00076323|DRUG|Primaquine|
58114919|NCT00827827|OTHER|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
58446020|NCT03545074|BEHAVIORAL|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
58446021|NCT06069336|DRUG|Hypertonic saline|Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
58446022|NCT06069336|DRUG|Normal saline|0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
57741682|NCT04588350|DEVICE|i-SEP autotransfusion system|Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
58114920|NCT00827827|OTHER|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
58114921|NCT04889183|DRUG|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
58114922|NCT04889183|DRUG|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
58114923|NCT02961920|DEVICE|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
58446023|NCT00001595|PROCEDURE|MRI|
58446024|NCT00001595|PROCEDURE|Tissue specimen collection|
58446025|NCT02370420|BIOLOGICAL|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
58446026|NCT02370420|BEHAVIORAL|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
58446027|NCT02114606|DEVICE|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
58446028|NCT00940758|DRUG|PEP02|Dose escalation: 50-100 mg/m2 biweekly
58446029|NCT00592488|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
58446030|NCT03316638|DRUG|W0101 - Cohort A1|Administered once every 2 weeks
58446031|NCT03316638|DRUG|W0101 - Cohort A2|Administered every 3 weeks
58446032|NCT03316638|DRUG|W0101 - Expansion Phase|Administered according to the recommended dose for expansion
58114924|NCT02961920|DEVICE|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
58114925|NCT05269719|PROCEDURE|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
58114926|NCT02509728|DIETARY_SUPPLEMENT|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
58114927|NCT02509728|DIETARY_SUPPLEMENT|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
58114928|NCT02509728|DIETARY_SUPPLEMENT|standard nutrition|standard nutrition
58114929|NCT01427920|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
58114930|NCT05977270|DEVICE|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
58114931|NCT01091376|DRUG|Erlotinib|Erlotinib 150mg/day
58114932|NCT01091376|RADIATION|Thoracic radiotherapy|60-70Gy/30-35f
58114933|NCT03430700|DRUG|Pembrolizumab|Intravenous infusion
58114934|NCT00003860|BIOLOGICAL|filgrastim|
58114935|NCT00003860|DRUG|carboplatin|
58114936|NCT00003860|DRUG|etoposide|
58114937|NCT00003860|DRUG|ifosfamide|
58114938|NCT00003860|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58114939|NCT00643110|DRUG|D50 glucose|D50 glucose would be administered, if necessary.
58114940|NCT02883829|BEHAVIORAL|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
58114941|NCT02883829|BEHAVIORAL|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
58114942|NCT00441584|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
58114943|NCT00441584|DRUG|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
58446033|NCT06312202|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
57957272|NCT03976973|PROCEDURE|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
57957273|NCT03695003|DIETARY_SUPPLEMENT|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
57957274|NCT03695003|DIETARY_SUPPLEMENT|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
57957275|NCT03389854|DEVICE|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
57957276|NCT03389854|DEVICE|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
57957277|NCT02091570|OTHER|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
57957278|NCT03259074|BIOLOGICAL|Placebo|Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes
57957279|NCT03259074|BIOLOGICAL|GP2017 (adalimumab biosimilar)|40 mg in pre-filled syringes was administered subcutaneously
57957280|NCT03259074|BIOLOGICAL|AIN457 150 mg|150 mg in pre-filled syringes was administered subcutaneously
57957281|NCT06046261|OTHER|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
57957282|NCT04392115|BEHAVIORAL|The PREPARE program|"A home-based exercise program guided by paper materials, weekly phone calls, and a DVD.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
57957283|NCT04163809|DEVICE|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
57957284|NCT01314716|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
57957285|NCT01314716|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
57957286|NCT03054376|OTHER|Immobilization|Full length cast of one leg R/L randomized
57957287|NCT03054376|OTHER|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
58114944|NCT06259942|OTHER|İntervention 1 group (underbody heater group only)|Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
58114945|NCT06259942|OTHER|İntervention 2 group (group using both underbody heater and heated iv liquid)|IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
58114946|NCT06259942|OTHER|Control Group|no active heating treatment was applied in this group
58114947|NCT00084539|RADIATION|Radiation therapy|
58114948|NCT02144584|DRUG|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
58114949|NCT02144584|DRUG|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
58114950|NCT02423174|PROCEDURE|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
58114951|NCT02423174|DEVICE|FMwand Surgical System|
58114952|NCT01040221|DRUG|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
58114953|NCT04849026|DRUG|Clozaril 100 mg (Clozapine)|2 Doses/Day for 10 days
58114954|NCT04849026|DRUG|WID-CLZ18|2 Doses/Day for 10 days
58446034|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
58446035|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
58446036|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
58446037|NCT03502473|DEVICE|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer"
58446038|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
58446039|NCT06726369|DRUG|MK-6204 (SKB535) for Injection|MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
58446040|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
58446041|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
58446042|NCT06529913|DIAGNOSTIC_TEST|Collection of environmental, biological, and clinical data|"All enrolled patients/healthy volunteers will undergo:~* measurement of serum and urine concentration of metals (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).~* Patch test to metals.~* Within-breath analysis of oscillometry parameters.~* Measurement of serum zonulin.~* Measurement of serum levels of protein oxidation products."
58446043|NCT06141707|OTHER|Arabic pediatric sleep questionnaire|Pediatric Sleep Questionnaire (PSQ) developed and validated by chervil et al. (2000) is a 22 item questionnaire which had been shown to have a sensitivity of 81% and specificity of 87% for SRBD.These scales for childhood SRBDs, snoring, sleepiness, and behavior are valid and reliable instruments that can be used to identify SRBDs or associated symptom-constructs in clinical research when polysomnography is not feasible.
58446044|NCT01078610|BIOLOGICAL|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
58114955|NCT04574310|OTHER|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
58446045|NCT05896527|DRUG|DC-806|DC-806 will be supplied as tablets to be administered orally.
58446046|NCT05896527|OTHER|Placebo|Matching placebo will be supplied as tablets to be administered orally.
58446047|NCT05583916|PROCEDURE|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
58446048|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
58446049|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
58114956|NCT05926908|BEHAVIORAL|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
58446050|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
58446051|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
58446052|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
58446053|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
58446054|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
58114957|NCT05926908|BEHAVIORAL|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
58446055|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
58446056|NCT06680817|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
58446057|NCT03045523|DRUG|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
58446058|NCT03045523|DRUG|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
58446059|NCT03045523|DRUG|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
58446060|NCT05340738|OTHER|LyssnCBT|LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
58446061|NCT06727448|OTHER|SRQ questionnaire|SRQ questionnaire administered at inclusion visit and 14 days after inclusion
58446062|NCT02858310|BIOLOGICAL|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
58446063|NCT02858310|DRUG|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
58446064|NCT02858310|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
58446065|NCT02858310|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
57741683|NCT06496633|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
57957288|NCT03054376|OTHER|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
57957289|NCT03670875|DIETARY_SUPPLEMENT|Agave inulin|Will be provided in dehydrated apple cubes
58446066|NCT04914533|DEVICE|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
58446067|NCT06127589|BEHAVIORAL|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
58446068|NCT06127589|DRUG|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
58446069|NCT06127589|BEHAVIORAL|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
57957290|NCT03670875|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
57957291|NCT03670875|DIETARY_SUPPLEMENT|O3FA|Will be provided in capsules
57957292|NCT03670875|BEHAVIORAL|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
57957293|NCT03220828|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets)
57957294|NCT04458142|OTHER|Single buccal infiltration|painless technique for palatal anesthesia,single injection,single puncture given
57957295|NCT05823597|BEHAVIORAL|Sugar Intensive Treatment|see arm description
57957296|NCT05823597|BEHAVIORAL|General Health Control|see arm description
57741684|NCT03599648|BEHAVIORAL|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
57957297|NCT03651596|BEHAVIORAL|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
57957298|NCT03651596|BEHAVIORAL|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
58446070|NCT06127589|BEHAVIORAL|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for \>2 times) at 3-month follow-up.
58446071|NCT06127589|BEHAVIORAL|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
58446072|NCT06127589|BEHAVIORAL|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
58446073|NCT02098798|PROCEDURE|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
58446074|NCT02098798|PROCEDURE|HD Colonoscopy + iSCAN|
58446075|NCT02098798|PROCEDURE|HD Colonoscopy + dye spray|
58446076|NCT05287646|DEVICE|Suction Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
58446077|NCT05287646|DEVICE|Elevated Vacuum Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
58446078|NCT01484535|PROCEDURE|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
58446079|NCT01484535|PROCEDURE|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
58446080|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
57741685|NCT03599648|BEHAVIORAL|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
57741686|NCT04221997|DRUG|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
57741687|NCT02570126|BIOLOGICAL|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
57741688|NCT02570126|BIOLOGICAL|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
58114958|NCT05926908|BEHAVIORAL|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
58114959|NCT05926908|BEHAVIORAL|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
58114960|NCT05926908|BEHAVIORAL|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
58114961|NCT05926908|BEHAVIORAL|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
58114962|NCT01860391|DEVICE|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
58446081|NCT00799435|DRUG|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
58446082|NCT02305212|BEHAVIORAL|Cogmed|
58446083|NCT05100914|OTHER|Couple-based family nursing|Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
58446084|NCT06726980|DRUG|dextrose 5%|patients will receive 5 % dextrose infusion
58114963|NCT05465915|DEVICE|Electroconvulsive therapy|Patients are treated with ECT.
58446085|NCT06726980|DRUG|Dextrose 10%|patients will receive 10 % dextrose infusion (25gm/ 250 mL)
58446086|NCT06726980|DRUG|0.9% saline|patients will receive infused IV 0.9 % saline
57957299|NCT04248413|DEVICE|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
57957300|NCT04248413|OTHER|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
58446087|NCT04071769|DRUG|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
58446088|NCT05999266|DIAGNOSTIC_TEST|Ultrasonographic Measurements|In patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
57957301|NCT05875870|BEHAVIORAL|Daylight exposure combine walking|"1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
57957302|NCT05875870|BEHAVIORAL|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
57957303|NCT03673683|BEHAVIORAL|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
57957304|NCT03673683|BEHAVIORAL|Usual care|Usual sedation and weaning management that is not protocol based
57957305|NCT03156088|DEVICE|"Sacral Neuromodulator InterStim"|
58114964|NCT03770000|DRUG|Tenalisib|Tenalisib, BID orally daily
58114965|NCT03770000|DRUG|Romidepsin|Romidepsin IV
58446089|NCT02468726|DEVICE|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
58446090|NCT02468726|DRUG|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
58446091|NCT05246800|OTHER|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
57957306|NCT06494995|DRUG|Cadonilimab|a PD-1/CTLA-4 dual antibody
57957307|NCT06494995|RADIATION|Low-dose radiotherapy|Low-dose radiation
57957308|NCT06494995|RADIATION|SBRT|selected leisions to treat with stereotactic radiotherapy
57957309|NCT06494995|DRUG|Capecitabine|Capecitabine metronomic chemotherapy
57957310|NCT05564065|PROCEDURE|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
58114966|NCT02066584|OTHER|Sibling oocyte incubation|
58114967|NCT03381066|DRUG|gefitinib, pemetrexed,cisplatin|"* Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~* Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
57957311|NCT05564065|PROCEDURE|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
57957312|NCT05541965|OTHER|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
58114968|NCT03381066|DRUG|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
58446092|NCT06140173|PROCEDURE|Low osmolar contrast|100 mL of 350 mg omnipaque will be administered via nasogastric tube
58446093|NCT06140173|PROCEDURE|Sterile water|100 mL of sterile water will be administered via nasogastric tube
58446094|NCT06472115|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE) for insistence on sameness (IS)|This study will examine the potential effectiveness of a virtually delivered parent-mediated intervention for insistence on sameness behaviors in autism. This includes a 16 week protocol where caregivers meet weekly for one hour with a study therapist.
58446095|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
58446096|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
58446097|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
58446098|NCT04366661|DIAGNOSTIC_TEST|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
58446099|NCT02995317|OTHER|Number of falls based on an one year follow-up|
58446100|NCT02598297|DRUG|Ruxolitinib|5 mg tablet for oral use
58446101|NCT02598297|DRUG|Ruxolitinib Placebo|5 mg placebo tablet for oral use
58114969|NCT04437069|OTHER|Decision Aid|Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).
58446102|NCT05455476|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
58446103|NCT05455476|BEHAVIORAL|CBT for Chronic Pain|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
58446104|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
58446105|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
58446106|NCT01136408|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
58446107|NCT06262100|DEVICE|Carragelose|Application of Carragelose containing eye drops
58446108|NCT02772744|DRUG|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
58446109|NCT02772744|DRUG|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
58446110|NCT02772744|DRUG|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
58446111|NCT03084692|BEHAVIORAL|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
58446112|NCT06236919|BEHAVIORAL|VR cognitive training|The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
58446113|NCT06236919|BEHAVIORAL|VR nature exposure relaxation|The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
57957313|NCT03731962|PROCEDURE|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
57957314|NCT00210210|DRUG|Ketamine|
58446114|NCT06725966|PROCEDURE|Conventional Epley maneuver|Epley maneuver using a mechanized chair
58446115|NCT06725966|PROCEDURE|Personalized Epley maneuver|Personalized Epley maneuver, using a mechanized chair
58446116|NCT04699383|DRUG|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
58446117|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
58446118|NCT01366482|DEVICE|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
58446119|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
58114970|NCT04437069|OTHER|Values Clarification Exercise|The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
58114971|NCT04927754|BEHAVIORAL|Behavioral guidance|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
58446120|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
57741689|NCT00925613|DEVICE|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
58446121|NCT05733442|OTHER|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
58446122|NCT05733442|OTHER|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
58446123|NCT04198792|OTHER|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
58446124|NCT05030207|DIAGNOSTIC_TEST|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
58446125|NCT05030207|DIAGNOSTIC_TEST|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
58446126|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
58446127|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
58446128|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
57741690|NCT00925613|DEVICE|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
57741691|NCT01798329|DIETARY_SUPPLEMENT|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine"
57741692|NCT06733363|BEHAVIORAL|Behavioral Dietary Intervention|Participate in POW-R Health Only/Core program
57741693|NCT06733363|BEHAVIORAL|Telephone- Based Intervention|Receive live phone calls
57741694|NCT02303184|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
57741695|NCT02303184|DRUG|Sham|suprachoroidal sham procedure
57741696|NCT02303184|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
58114972|NCT04927754|OTHER|Pain assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was assessed the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's pain during dental care.
58114973|NCT04927754|OTHER|Dental anxiety assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was evaluated the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's dental anxiety during treatment sessions.
58114974|NCT03594877|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
58446129|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
58446130|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
58446131|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
58446132|NCT04915729|DRUG|tenecteplase|tenecteplase
58446133|NCT04915729|DRUG|alteplase|alteplase
58446134|NCT02957734|PROCEDURE|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
58446135|NCT00278733|BEHAVIORAL|Brief intervention (physician advice)|
58446136|NCT06018948|DRUG|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
58446137|NCT06018948|DRUG|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
58446138|NCT06018948|DRUG|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
58446139|NCT04438317|PROCEDURE|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
58446140|NCT04438317|PROCEDURE|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
58446141|NCT02828475|OTHER|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
58446142|NCT02828475|BEHAVIORAL|Standard Care|Previous standard of care based on surgeon judgement alone.
58446143|NCT03357536|PROCEDURE|Human biological samples|"* Blood sample~* Skin biopsy~* Saliva"
58446144|NCT01107314|OTHER|Phlebotomy|Blood draws (total 48 cc blood)
58446145|NCT02246907|OTHER|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
58446146|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
58446147|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
57957315|NCT06329583|DIAGNOSTIC_TEST|diaphragmatic breathing|Different positions and techniques for diaphragmatic breathing
57957316|NCT00118014|DRUG|Sertraline|
57957317|NCT00118014|BEHAVIORAL|Habit Reversal Training|
58446148|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
58446149|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
58446150|NCT01574235|BIOLOGICAL|Nivestim®|
58446151|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
57957318|NCT00769002|BIOLOGICAL|FluShield|Flu vaccine
57957319|NCT00769002|BIOLOGICAL|FluShield - same arm|Flu vaccine
57957320|NCT00769002|BIOLOGICAL|FluShield - opposite arm|Flu vaccine
57957321|NCT00769002|PROCEDURE|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
57957322|NCT00769002|PROCEDURE|FDG PET-CT Scan|PET scan
57957323|NCT00769002|GENETIC|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
57957324|NCT05450146|OTHER|Partner in Balance|"The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals."
58114975|NCT04561310|OTHER|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
58114976|NCT04561310|OTHER|Active release technique|"Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
58114977|NCT03623256|DRUG|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
58114978|NCT03623256|DRUG|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
58114979|NCT03623256|DRUG|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
58114980|NCT03623256|DRUG|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
58114981|NCT06461923|DEVICE|Insole wearing|The insole-wearing group is instructed to wear the insole gait analysis device as frequently and for as long as possible during outdoor activities. Participants receive feedback during 3rd to 4th week via telephone. Following a period of 6 weeks, an evaluation of the usability and satisfaction of the insole gait analysis device will be conducted.
58114982|NCT02702752|OTHER|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
58114983|NCT06546683|OTHER|Short-Chain Fatty Acids|Colon-delivery capsules of Short-Chain Fatty Acids will be administered in a ratio of 60:20:20, thus 150 mmol of acetate, 50 mmol of propionate and 50 mmol of butyrate equivalent to 20g of fibers, once daily, one week
58114984|NCT06546683|OTHER|Placebo|Microcrystalline Cellulose will be used as placebo, one daily, one week
58114985|NCT03778047|DRUG|Enzalutamide|oral
58114986|NCT03778047|DRUG|HC1119|oral
58114987|NCT03873779|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
58114988|NCT02827903|DRUG|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
58114989|NCT02827903|DRUG|Metformin + placebo|Group II: Metformin + placebo,
58114990|NCT02827903|DRUG|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
58114991|NCT04888650|OTHER|questionnaire|electronic questionnaire
58446152|NCT03877211|OTHER|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
58446153|NCT03877211|OTHER|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
58446154|NCT03877211|OTHER|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
58114992|NCT04699981|OTHER|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
58114993|NCT04699981|OTHER|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
58114994|NCT00757666|DEVICE|Rate adaptive pacemaker|Accelerometer sensor
58114995|NCT00757666|DEVICE|Rate adaptive pacemaker|Minute ventilation sensor
58114996|NCT03449043|OTHER|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
58114997|NCT05562336|DEVICE|Optical coherence tomography angiography|Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
58114998|NCT02273674|DEVICE|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
58114999|NCT02273674|DEVICE|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
58446155|NCT03877211|OTHER|Tonal audiometry|Tonal audiometry will be performed with headphones
58446156|NCT03877211|OTHER|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
58446157|NCT00217217|DEVICE|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
58446158|NCT04533529|DRUG|Seltorexant|Seltorexant tablet will be administered orally once daily.
58446159|NCT04533529|DRUG|Placebo|Matching placebo tablet will be administered orally once daily.
58446160|NCT06553495|OTHER|Nerve block|Analgesic effect of different nerve blocks
58446161|NCT01922271|DRUG|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
58446162|NCT01922271|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
58446163|NCT01922271|DRUG|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
58115000|NCT00737230|OTHER|educational intervention|
58115001|NCT00737230|OTHER|questionnaire administration|
58115002|NCT00737230|PROCEDURE|assessment of therapy complications|
58446164|NCT01922271|DRUG|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
58446165|NCT01922271|DRUG|Salbutamol|Used as resuce medication
58446166|NCT05176236|OTHER|Pictographic tracheostomy care handouts|The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
58446167|NCT01041313|DRUG|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
57741697|NCT00501176|PROCEDURE|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
58115003|NCT00737230|PROCEDURE|gastrointestinal complications management/prevention|
58446168|NCT01041313|DRUG|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
58446169|NCT04400565|BEHAVIORAL|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
58446170|NCT04270708|DRUG|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
58446171|NCT04270708|DRUG|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
58446172|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid administration. Oxytocin delivered 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
58446173|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \< 40 kg will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
58446174|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \> 40 kg will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
58446175|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.
58446176|NCT01453010|OTHER|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
58446177|NCT02326597|OTHER|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
58115004|NCT00737230|PROCEDURE|management of therapy complications|
58115005|NCT00737230|PROCEDURE|quality-of-life assessment|
58446178|NCT02326597|OTHER|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
58446179|NCT02306798|DRUG|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
57741698|NCT02192502|DRUG|human albumin 5%|
57741699|NCT02192502|DRUG|HES 130/0.4 (Voluven)|
57741700|NCT06185764|DRUG|VX-670|Solution for intravenous administration.
58115006|NCT05494905|OTHER|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
58446180|NCT00491127|DRUG|gemcitabine|
58446181|NCT00491127|DRUG|cisplatin|
58446182|NCT00491127|DRUG|dexamethasone|
58446183|NCT02880098|BIOLOGICAL|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
58446184|NCT06725784|DEVICE|ReHandyBot|"The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.~The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions."
58446185|NCT06726096|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|"The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control"
58446186|NCT03943641|OTHER|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
58446187|NCT01810003|DIETARY_SUPPLEMENT|High DHA|10 week supplementation period
58446188|NCT01810003|DIETARY_SUPPLEMENT|High EPA|10 week supplementation period
58446189|NCT01810003|DIETARY_SUPPLEMENT|Placebo|10 week supplementation period
58115007|NCT05494905|OTHER|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
58115008|NCT04523493|COMBINATION_PRODUCT|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
58115009|NCT04523493|COMBINATION_PRODUCT|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
58115010|NCT06288165|DEVICE|Coronary Sinus Reducer Implantation|Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
58446190|NCT01428908|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
58446191|NCT01428908|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
58446192|NCT01428908|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
58446193|NCT01428908|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
58446194|NCT03742973|DRUG|Baricitinib|Administered orally.
58446195|NCT03742973|DRUG|Placebo|Administered orally.
58446196|NCT00554450|DRUG|Dapagliflozin|Tablets, Oral, once daily
58446197|NCT05314465|OTHER|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times \& repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
58446198|NCT06725602|DEVICE|"TQ - Proximal Application (high and tight)"|"Tourniquet application: proximal (high and tight) on arms and thighs."
58446199|NCT06725602|DEVICE|TQ - Controlled application (2-3 inches)|TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.
57741701|NCT06185764|DRUG|Placebo|Solution for intravenous administration.
58115011|NCT01110980|OTHER|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
58446200|NCT01870115|DIETARY_SUPPLEMENT|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
58446201|NCT01870115|DIETARY_SUPPLEMENT|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
58446202|NCT02563236|OTHER|Parabolic flight|
58446203|NCT00380731|BEHAVIORAL|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
58446204|NCT06514547|BIOLOGICAL|Conjugate Pneumococcal Vaccine 20 (PCV20)|Vaccine
58446205|NCT00583687|DEVICE|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
58446206|NCT00583687|OTHER|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
58446207|NCT00583687|OTHER|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
58446208|NCT00583687|DEVICE|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
58446209|NCT03275324|DEVICE|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
58446210|NCT03271502|PROCEDURE|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
58446211|NCT03271502|PROCEDURE|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
58446212|NCT06726304|BEHAVIORAL|Baby Carrier Intervention|Mothers in the intervention group will have the opportunity to choose between two different soft ergonomic baby carriers and will receive instructions on how to use the carrier of their choice. Infants will be placed chest-to-chest in the carrier, supported by the mother's upper torso for a prescribed amount of time during the period of six weeks.
58446213|NCT02934165|BEHAVIORAL|Family Safety 123|Theoretically-based injury prevention videos for families
58446214|NCT02934165|BEHAVIORAL|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
57957325|NCT06420505|DEVICE|Percutaneous Coronary Intervention|The Vivo ISAR is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
57957326|NCT02658123|OTHER|Pre-operative education (standard of care)|
57957327|NCT02658123|OTHER|Home health care visits (standard of care)|
58115012|NCT01110980|OTHER|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
58115013|NCT03198702|DRUG|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
57957328|NCT02658123|OTHER|Follow-up post-operative visits|
57957329|NCT02658123|OTHER|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
57957330|NCT02658123|OTHER|Healthcare Utilization Form|"* Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit"
58115014|NCT03198702|OTHER|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
58115015|NCT06546397|DRUG|17β-estradiol/dydrogesterone tablets|The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
58115016|NCT00430157|DRUG|GSK256066|
58446215|NCT05413408|OTHER|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
58446216|NCT06395038|DRUG|Abatacept plus Aldesleukin|CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
58446217|NCT02664506|BEHAVIORAL|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
58446218|NCT06726460|DIAGNOSTIC_TEST|Nova Stat Profile pHOx Ultra Analyzer System(Nova)|This group involves the use of Nova for measuring serum and whole blood samples. The results from Nova will be compared with those obtained from P1.
58446219|NCT06726460|DIAGNOSTIC_TEST|Novel POCT dry electrolyte analysis system(P1)|This group involves the use of P1 for measuring serum and whole blood samples. The results from P1 will be compared with those obtained from Nova.
58446220|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
58446221|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
58446222|NCT05556668|DEVICE|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
58446223|NCT04977713|OTHER|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
58446224|NCT04977713|OTHER|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
58446225|NCT06467916|BEHAVIORAL|PATH|anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
58446226|NCT06726031|DEVICE|wearing VR glass|The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
58446227|NCT06725407|BEHAVIORAL|Cesarean section|In the study, the participants' postoperative hypothermia development status was monitored.
58446228|NCT04314986|DRUG|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
58446229|NCT04314986|DRUG|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
58446230|NCT04314986|DRUG|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
58446231|NCT04314986|DRUG|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
58446232|NCT05185726|BEHAVIORAL|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
58115017|NCT00394745|DRUG|Valsartan|
58115018|NCT03308110|DRUG|PF-06650833|Two formulations of PF-006650833
58115019|NCT01810796|DRUG|Ranolazine|Ranolazine versus placebo
58115020|NCT03366285|DIAGNOSTIC_TEST|Attachment story completion taks (ASCT)|Bonding quality
58115021|NCT04550468|OTHER|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
58115022|NCT04550468|OTHER|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
58115023|NCT01208558|BEHAVIORAL|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
58115024|NCT01208558|BEHAVIORAL|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
58115025|NCT01208558|BEHAVIORAL|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
58115026|NCT03804099|DRUG|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
58446233|NCT05185726|BEHAVIORAL|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
58446234|NCT05185726|BEHAVIORAL|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
58446235|NCT05376631|PROCEDURE|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
58446236|NCT05376631|PROCEDURE|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
58446237|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
58446238|NCT04662359|DIAGNOSTIC_TEST|Ultrasound Assessment|Patients will undergo an ultrasound scan to assess the severity of their rheumatoid arthritis.
58446239|NCT05271916|DRUG|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
58446240|NCT05271916|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
58446241|NCT04119180|DRUG|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
58446242|NCT04119180|DRUG|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
58446243|NCT04119180|PROCEDURE|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
58446244|NCT01200368|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
58446245|NCT01200368|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
58446246|NCT01200368|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
58446247|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
58446248|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
58446249|NCT05575362|OTHER|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
58446250|NCT05575362|OTHER|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
58446251|NCT04311255|PROCEDURE|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
58446252|NCT03988764|OTHER|None AHT|No further intervention planned for either group as part of the current study.
58115027|NCT03740698|DEVICE|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
58115028|NCT03740698|DEVICE|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
58115029|NCT03309891|DRUG|GX-H9|subcutaneous injection (weekly or twice-monthly)
58115030|NCT03309891|DRUG|Genotropin|subcutaneous injection (daily)
58115031|NCT03522584|BIOLOGICAL|Durvalumab|Given IV
58115032|NCT03522584|OTHER|Laboratory Biomarker Analysis|Correlative studies
58115033|NCT03522584|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58115034|NCT03522584|BIOLOGICAL|Tremelimumab|Given IV
58115035|NCT03522584|PROCEDURE|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
58115036|NCT02044978|DEVICE|Zoledronate-coated dental implant|
58115037|NCT04642573|OTHER|non interventional|non interventional
58115038|NCT04636528|DEVICE|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
58115039|NCT04636528|DEVICE|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, PTs will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
58115040|NCT00312000|DRUG|capecitabine-irinotecan|"1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
58115041|NCT00312000|DRUG|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
58115042|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
58115043|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
58115044|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
58115045|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
58115046|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
58115047|NCT00525967|DRUG|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
58115048|NCT03325647|DRUG|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
58115049|NCT03325647|DRUG|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
58115050|NCT00564174|DRUG|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
58446253|NCT02426840|DIETARY_SUPPLEMENT|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
58446254|NCT02426840|DIETARY_SUPPLEMENT|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
58115051|NCT00564174|DRUG|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
58115052|NCT04480411|BEHAVIORAL|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
58115053|NCT01518452|BEHAVIORAL|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
58115054|NCT01518452|BEHAVIORAL|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
58115055|NCT05974410|DRUG|AVM0703|small molecule immunomodulatory drug
58115056|NCT05974410|DRUG|Hydrocortisone|physiologic circadian glucocorticoid
58446255|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
58446256|NCT06654440|DRUG|SHR-A2102 for injection|SHR-A2102 for injection
58446257|NCT02289638|DEVICE|Intubrite|Video-Laryngoscopy
58446258|NCT02289638|DEVICE|MIL|Direct-Laryngoscopy
58446259|NCT02527590|OTHER|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
58446260|NCT02527590|OTHER|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
58115057|NCT05974410|DRUG|Proton pump inhibitor|
58115058|NCT04766918|PROCEDURE|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
58115059|NCT04766918|PROCEDURE|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
58446261|NCT02527590|OTHER|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
58446262|NCT02527590|OTHER|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
58446263|NCT02527590|OTHER|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
58446264|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
58446265|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
58446266|NCT06150482|OTHER|No intervention|No intervention
58115060|NCT05965193|DEVICE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
58115061|NCT05965193|DEVICE|Nasal oxygen|For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
58446267|NCT03386721|DRUG|simlukafusp alfa|simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
58446268|NCT03386721|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
58446269|NCT03386721|DRUG|Gemcitabine|Single-agent treatment administered as per approved protocol.
58115062|NCT05965193|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
58115063|NCT03055533|BEHAVIORAL|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
58115064|NCT03036033|DEVICE|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
58446270|NCT03386721|DRUG|Vinorelbine|Single-agent treatment administered as per approved protocol.
58446271|NCT06726005|DEVICE|functional appliance twin block|3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
58446272|NCT00602420|DRUG|naproxen|Oral naproxen twice daily for 5-8 days.
58446273|NCT00602420|OTHER|placebo|Oral placebo twice daily for 5-8 days.
58115065|NCT05644691|OTHER|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
58446274|NCT04104607|DRUG|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
58446275|NCT05609435|OTHER|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
58446276|NCT03117855|DRUG|Capecitabine|Given PO
58446277|NCT03117855|OTHER|Laboratory Biomarker Analysis|Correlative studies
58446278|NCT03117855|RADIATION|Radioembolization|Undergo yttrium Y-90 radioembolization
58115066|NCT05644691|OTHER|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
58115067|NCT00015106|DRUG|Lamotrigine|
58115068|NCT01312610|DIETARY_SUPPLEMENT|High flavanone orange juice|High flavonone orange juice drink.
58446279|NCT05178199|BEHAVIORAL|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
58446280|NCT05178199|BEHAVIORAL|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
58446281|NCT01002651|DIETARY_SUPPLEMENT|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
58446282|NCT01002651|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
58446283|NCT05120414|OTHER|balanace exercises|Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
58446284|NCT05120414|OTHER|Balance Exercises plus Ankle strategy|ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
58446285|NCT02486536|DRUG|polyethylene glycol|
58446286|NCT02486536|DEVICE|capsule endoscopy|
58446287|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
58446288|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
58446289|NCT00180388|PROCEDURE|endoscopic vein harvesting|
58115069|NCT01312610|DIETARY_SUPPLEMENT|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
58115070|NCT01554761|PROCEDURE|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
58115071|NCT01554761|DEVICE|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
58115072|NCT02482805|BEHAVIORAL|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
58446290|NCT00180388|PROCEDURE|open vein harvesting|
57741702|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
57957331|NCT02658123|OTHER|The City of Hope QOL Survey for Ostomy Patients|"* Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
57957332|NCT02658123|OTHER|Phone call with CWOCN or PA|
57741703|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
57741704|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
57741705|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
57741706|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
57741707|NCT02543034|DEVICE|Betafoam Wound Dressing|Foam dressing including Betadine iodine
57741708|NCT02543034|DEVICE|Petrolatum Gauze|Gauze dressing
57741709|NCT02543034|DEVICE|Allevyn Wound Dressing|Foam dressing
57741710|NCT03484975|DEVICE|Observation group|Collect coronary images with a hybrid IVUS OCT system.
57957333|NCT01436539|DRUG|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
57957334|NCT01436539|DRUG|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
57957335|NCT06168838|DRUG|Anticoagulant|Know the casuistry of spontaneous intracranial hemorrhages and secondary to the use of both oral and parenteral anticoagulants
57957336|NCT04036708|BEHAVIORAL|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
57957337|NCT04036708|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
57957338|NCT05101603|DEVICE|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
57957339|NCT05101603|DEVICE|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
57957340|NCT05101603|PROCEDURE|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
57957341|NCT03189875|OTHER|Standard of Care|Participants will be followed as per local routine clinical practice
57957342|NCT00506883|DRUG|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
57957343|NCT00506883|DRUG|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
57957344|NCT00506883|OTHER|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
57957345|NCT03716349|DIAGNOSTIC_TEST|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
57957346|NCT03716349|OTHER|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
57957347|NCT03716349|DRUG|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
57957348|NCT03716349|DEVICE|rubber dam|The area will be isolated with rubber dam isolation
57957349|NCT03716349|OTHER|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
58115073|NCT06545136|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
58115074|NCT03719183|DIAGNOSTIC_TEST|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
58115075|NCT03719183|DIAGNOSTIC_TEST|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements"
58115076|NCT03719183|DIAGNOSTIC_TEST|Multiplex FISH (M-FISH)|24-color karyotyping
58115077|NCT02493725|DRUG|Eculizumab|
58115078|NCT02493725|DRUG|Placebo|
58115079|NCT03169777|BIOLOGICAL|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
58115080|NCT03169777|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
58115081|NCT03169777|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
58115082|NCT03169777|BIOLOGICAL|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
58115083|NCT03169777|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
58115084|NCT03169777|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
57741711|NCT04089033|PROCEDURE|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
58115085|NCT03169777|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
58115086|NCT03169777|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
58115087|NCT03169777|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
58115088|NCT03169777|BIOLOGICAL|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
58115089|NCT03169777|DRUG|Lovaza|Omega-3-acid ethyl esters
58115090|NCT03169777|DRUG|oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
58115091|NCT03169777|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
58115092|NCT03169777|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
58115093|NCT03169777|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
58115094|NCT03169777|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
58115095|NCT03169777|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
58115096|NCT03169777|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
57741712|NCT04089033|PROCEDURE|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
58446291|NCT04992663|DEVICE|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~* Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~* Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~* Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~* Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~* Counseling video (cesarean section, epidural anesthesia)"
58446292|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
58446293|NCT06333665|OTHER|Whether there is type 2 diabetes mellitus before surgery|Patients were grouped according to whether they had type 2 diabetes mellitus before surgery
58446294|NCT06693089|OTHER|MIT-ED|The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
58446295|NCT05066386|OTHER|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
57741713|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
57741714|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
57741715|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
57741716|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
58446296|NCT06457789|DRUG|[18F]F-AraG PET imaging|Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
58446297|NCT06457789|DRUG|[89Zr]Zr-Df-Crefmirlimab PET imaging|Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
57741717|NCT05467891|DRUG|Exemestane|25 mg orally once daily
57741718|NCT00223834|BEHAVIORAL|single session of Motivational Interviewing|
58446298|NCT03261388|BEHAVIORAL|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
57741719|NCT03886532|OTHER|Medical Marijuana|registry and blood samples
57741720|NCT02133534|DRUG|Atorvastatin|
57741721|NCT02738567|PROCEDURE|patients undergoing surgery or medical procedure|
57741722|NCT06732310|BEHAVIORAL|Pregnant Moms' Empowerment Program|Women who receive the PMEP complete a structured set of sessions delivered over the course of 5 weeks, each session lasts 2 hours in duration: (1) becoming a group \& safety planning, (2) identifying and understanding sources of stress, (3) strategies to build resilience and resolve conflict, (4) perinatal health and infant care, and (5) positive parenting.
57741723|NCT06732310|BEHAVIORAL|Reminiscing and Emotion Training|Each of the 5 RET sessions are 1 hour in duration. The program is manualized and each session includes teaching/review of skills, instructions/activity with rationale, reminiscing practice, and immediate video feedback by a family coach.
57741724|NCT06732310|BEHAVIORAL|Pregnancy - Active Control|Women who are not randomized to the PMEP participate in a contact-equivalent, nondirective social support group.
57957350|NCT03716349|PROCEDURE|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
58115097|NCT03169777|BIOLOGICAL|GI-4000|RAS yeast vaccine
58115098|NCT03169777|BIOLOGICAL|GI-6207|CEA yeast vaccine
58115099|NCT03169777|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
57957351|NCT03716349|PROCEDURE|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
58115100|NCT03169777|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
58115101|NCT03179683|DEVICE|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
58446299|NCT05767840|OTHER|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
57957352|NCT03716349|PROCEDURE|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
57957353|NCT03716349|OTHER|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
58115102|NCT00832078|DEVICE|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
58115103|NCT00832078|DEVICE|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
58115104|NCT02404740|DEVICE|Pulse oximetry|Pulse oximetry
58115105|NCT05305521|PROCEDURE|transcrestal sinus floor elevation|Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
58446300|NCT05833438|DRUG|VEN+AZA-5|Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
58446301|NCT01066728|OTHER|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
58446302|NCT01066728|DRUG|Theophylline|
58446303|NCT05081895|DEVICE|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
58446304|NCT05081895|OTHER|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
58115106|NCT05305521|PROCEDURE|Implant placement|"Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament"
58115107|NCT03139214|BEHAVIORAL|Parenting Intervention|
58115108|NCT00164879|PROCEDURE|Endoscopic stenting followed by elective laparoscopic resection|
58115109|NCT03917628|DRUG|SCT630|SCT630 single s.c. injection
58115110|NCT03917628|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
58115111|NCT00270374|DRUG|nesiritide|
58115112|NCT02870712|PROCEDURE|Suture of perineum|suture of the tear to obtain hemostasis
58115113|NCT02870712|PROCEDURE|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
58115114|NCT04822766|PROCEDURE|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
58446305|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
58446306|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
58446307|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
58446308|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
58446309|NCT00997802|DEVICE|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
58446310|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
58446311|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
58115115|NCT04822766|DRUG|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
58115116|NCT00088777|BEHAVIORAL|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
58115117|NCT00088777|BEHAVIORAL|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
58115118|NCT03840746|OTHER|Tomato, onion and lovage soup (TOL)|Soup
58115119|NCT03840746|OTHER|TOL soup with inulin|Soup
58115120|NCT00268710|DRUG|docetaxel|
58115121|NCT00003390|DRUG|irofulven|
58115122|NCT00129779|BEHAVIORAL|Intermediate care package|
58115123|NCT05551078|BIOLOGICAL|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
58115124|NCT03111979|DIETARY_SUPPLEMENT|beta-alanine|
58115125|NCT03111979|DIETARY_SUPPLEMENT|Placebo|
58115126|NCT03773328|BIOLOGICAL|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
58115127|NCT02666430|DRUG|Mylan's insulin glargine|
58115128|NCT02666430|DRUG|Lantus®|
58115129|NCT03135379|DEVICE|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
58115130|NCT03135379|DEVICE|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
58115131|NCT00419926|DRUG|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
58115132|NCT00419926|DRUG|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
58115133|NCT00419926|DRUG|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
58115134|NCT01654146|DRUG|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
58115135|NCT01654146|DRUG|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
58115136|NCT01654146|DRUG|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
58115137|NCT01654146|DRUG|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
58115138|NCT02044471|OTHER|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
58115139|NCT02788123|DRUG|bismuth tripotassium dicitrate|oral
58115140|NCT02788123|DRUG|pantoprazole|oral
58115141|NCT01847573|DRUG|HT-100|May be administered in either fed or fasted state
58115142|NCT02537132|OTHER|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
58115143|NCT04108377|DRUG|Roflumilast|Roflumilast capsule
58115144|NCT04108377|DRUG|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
58115145|NCT04090996|DIAGNOSTIC_TEST|Dual TAsk|"Motor assessment includes:~* posturographic examination in Single-task (ST) and Double-task (DT)~* an analysis of ST and DT walking;~* Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
58115146|NCT05427565|OTHER|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
58115147|NCT05427565|OTHER|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
58115148|NCT00746668|BEHAVIORAL|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
58115149|NCT00746668|BEHAVIORAL|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
58115150|NCT00746668|BEHAVIORAL|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
58115151|NCT01672346|PROCEDURE|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
58115152|NCT00005042|DRUG|semaxanib|
58115153|NCT02565342|PROCEDURE|Interscalene brachial plexus block|
58115154|NCT00151294|DRUG|escitalopram oxalate antidepressant|
58115155|NCT02400320|DRUG|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
58115156|NCT02400320|DRUG|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
58115157|NCT02400320|OTHER|Saline|Saline
58115158|NCT05070520|DRUG|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
58115159|NCT02303561|BEHAVIORAL|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
58115160|NCT02303561|BEHAVIORAL|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
58115161|NCT04853810|OTHER|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
58115162|NCT00809809|DRUG|Zicam (Ionic zinc)|33mmol/l of ionic zinc
58115163|NCT00809809|DRUG|placebo|placebo swab
58115164|NCT00301106|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
58115165|NCT02639208|OTHER|PatientsLikeMe (PLM)|
58115166|NCT05267574|DRUG|REN001|Once daily dosing
58115167|NCT05999981|PROCEDURE|Transversalis Fascia Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance between transversus abdominis muscle and transversalis fascia bilaterally
58458543|NCT03057496|DEVICE|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
58115168|NCT05999981|PROCEDURE|Transversus Abdominis Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally
58115169|NCT03192683|DEVICE|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
58115170|NCT03192683|DEVICE|Regular sling|
58115171|NCT05144620|DIAGNOSTIC_TEST|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
58115172|NCT03717389|OTHER|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
58115173|NCT04485000|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
58115174|NCT03131999|DRUG|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
58115175|NCT03131999|DRUG|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
58115176|NCT06054906|DRUG|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
58115177|NCT06135285|DEVICE|Control subjects|The subject will be repositioned from the prone to recovery position
58115178|NCT02480010|DRUG|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
58115179|NCT01211847|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
58115180|NCT01211847|DRUG|Placebo|Placebo matching DCCR
58115181|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
58115182|NCT05621538|DEVICE|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
58115183|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
58115184|NCT05621538|DEVICE|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
58115185|NCT04385810|PROCEDURE|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
58115186|NCT01683253|DRUG|Levodopa/Carbidopa(200mg/50mg)|
58115187|NCT01683253|DRUG|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
58115188|NCT02122094|BEHAVIORAL|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
58115189|NCT00788957|DRUG|Panitumumab|Panitumumab for intravenous infusion
58115190|NCT00788957|DRUG|Ganitumab|Ganitumab for intravenous infusion
58115191|NCT00788957|DRUG|Rilotumumab|Rilotumumab for intravenous infusion
58115192|NCT00788957|DRUG|Placebo|Placebo intravenous infusion
58115193|NCT03814109|DRUG|LENINGRADO association|1 coated sustained-release tablet, oral, once a day.
58115194|NCT03814109|DRUG|Indapamide SR 1.5 MG|1 coated sustained-release tablet, oral, once a day.
58115195|NCT03814109|DRUG|Levamlodipine 2.5/ 5 mg|1 tablet, oral, once a day.
58115196|NCT03814109|OTHER|Leningrado association Placebo|1 coated sustained-release tablet, oral, once a day.
58115197|NCT03814109|OTHER|Indapamide SR Placebo|1 coated sustained-release tablet, oral, once a day.
58115198|NCT03814109|OTHER|Levamlodipine placebo|1 tablet, oral, once a day.
58115199|NCT01178359|DRUG|nitrite|
57741725|NCT06732310|BEHAVIORAL|Enhanced Case Management|Families randomized to this attentional control condition will receive enhanced case management. They will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials (e.g., Adventures in Parenting curriculum developed by NICHD) that were selected to not overlap with RET content (e.g., reading together, fitness, etc.). Using mothers' responses regarding access to resources on the Family Resource Scale (Dunst \& Leet, 1987), which is completed during the baseline visit, mothers will also receive referrals to community resources for items rated as inadequate.
58115200|NCT03867903|DEVICE|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
58115201|NCT03867903|OTHER|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
58115202|NCT01918111|PROCEDURE|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
58115203|NCT01918111|DRUG|adenosine infusion treatment|Continue hypertensive medication
58115204|NCT05205785|DIETARY_SUPPLEMENT|Human Milk Oligosaccharide Mix|Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.
58115205|NCT05205785|OTHER|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
58115206|NCT03626610|BEHAVIORAL|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
58115207|NCT04736979|DRUG|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
58115208|NCT01190683|DRUG|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
58115209|NCT01190683|DRUG|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
58115210|NCT01190683|DRUG|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
58115211|NCT01190683|OTHER|lactose placebo|similar number of granules and tablets as active group
58115212|NCT01190683|OTHER|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
58115213|NCT01133392|DRUG|Insulin lispro A|20 units (U) subcutaneously (SC).
58115214|NCT01133392|DRUG|Insulin lispro B|20 U subcutaneously (SC).
58115215|NCT03584737|DIAGNOSTIC_TEST|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
57957354|NCT03716349|PROCEDURE|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
57957355|NCT03716349|PROCEDURE|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
57957356|NCT03716349|OTHER|Consent|The consent form will be signed, copy will be provided to the patient
57957357|NCT03716349|OTHER|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
58115216|NCT03584737|DIAGNOSTIC_TEST|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
58115217|NCT03584737|DIAGNOSTIC_TEST|PCR assay|Semiquantitative real-time PCR assay
58115218|NCT04915586|DRUG|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
58446312|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
58446313|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
58446314|NCT00398567|DRUG|HKI-272|HKI-272 by mouth
58446315|NCT00398567|DRUG|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
58458544|NCT02267239|DRUG|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
57741726|NCT03540914|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
57741727|NCT03540914|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
57741728|NCT00686881|BIOLOGICAL|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
57741729|NCT00686881|DRUG|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
57741730|NCT01752673|OTHER|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
57741731|NCT01752673|OTHER|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
57741732|NCT02053818|DRUG|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
57741733|NCT02053818|DRUG|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
57741734|NCT05758844|PROCEDURE|safe-line technique|Safe-line approach
57741735|NCT04510805|DEVICE|NextDose (nextdose.org)|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
57741736|NCT00275197|DRUG|Sertraline and Elzasonan Combination|
57741737|NCT00275197|DRUG|Sertraline|
57957358|NCT03716349|RADIATION|xray|When necessary a radiograph (xray) will be obtained
57957359|NCT03716349|OTHER|Release of medical information signed|The release of medical information form will be signed
57957360|NCT03716349|OTHER|Oral Exam|An Oral Exam will be completed
57957361|NCT03716349|OTHER|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
57957362|NCT03716349|OTHER|Clinical Assessment|A clinical assessment will be completed by the evaluators
57957363|NCT03716349|DEVICE|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
57957364|NCT03716349|DEVICE|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
57957365|NCT00160459|DRUG|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
57957366|NCT00160459|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
57957367|NCT00160459|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
57957368|NCT00160459|DRUG|Placebo|Tablet, oral Daily for 12 weeks
58115219|NCT03114189|PROCEDURE|footbath|
58115220|NCT03114189|BEHAVIORAL|care of sleep|
58115221|NCT06528262|DRUG|Enavogliflozin|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
58446316|NCT06726083|BEHAVIORAL|Nutrition Intervention|Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
58115222|NCT06528262|DRUG|Placebo|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
58115223|NCT04979130|DRUG|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
58446317|NCT06726083|BEHAVIORAL|Contact Control|Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
58446318|NCT01871519|DEVICE|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
58446319|NCT05841875|OTHER|C reactive protein algorithm|"Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement.~Before discontinuing antibiotic therapy, physicians should confirm that the patient is clinically improving, with no signs of a persistent infectious focus. Additionally, they will be encouraged to verify that the Sequential Organ Failure Assessment (SOFA) score is stable or decreasing. These factors will assist in determining the appropriateness of stopping antibiotics."
58446320|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
58446321|NCT01668225|PROCEDURE|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
58446322|NCT00431015|DRUG|IPI-504|IV Hsp90 inhibitor
58446323|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
58446324|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
57741738|NCT00275197|DRUG|Placebo|
58115224|NCT04979130|DRUG|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
58115225|NCT03016559|OTHER|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
57741739|NCT06682299|DEVICE|Transmagnetic Stimulation|TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).
57741740|NCT06682299|DEVICE|Electroconvulsive Therapy|Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression
57741741|NCT06733662|BEHAVIORAL|Experimental: Education-based motivational interviewing Group|The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
57741742|NCT02200718|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
57957369|NCT02961556|DRUG|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
58115226|NCT04569955|BEHAVIORAL|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
58115227|NCT04559295|BIOLOGICAL|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
58115228|NCT05821712|DRUG|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
58115229|NCT05821712|DRUG|0.057% sodium fluoride Mouthwash|mouthwash
58115230|NCT05030090|BEHAVIORAL|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
58115231|NCT05030090|DIETARY_SUPPLEMENT|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
58115232|NCT05030090|COMBINATION_PRODUCT|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
58446325|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
58446326|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
58446327|NCT05206812|DRUG|durvalumab|"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
58115233|NCT01106872|DRUG|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
58115234|NCT05431283|DRUG|Tofacitinib|This study aims to assess the effectiveness of TOFA
58115235|NCT03848585|DEVICE|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
58446328|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
58446329|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
58446330|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
57741743|NCT02200718|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
57741744|NCT03141320|OTHER|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
58115236|NCT03848585|OTHER|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
57741745|NCT00447057|DRUG|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
57741746|NCT00447057|DRUG|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
58115237|NCT05480917|OTHER|Patients receiving PsoPlus care|As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
58115238|NCT01764620|OTHER|Elastic taping applied with tension|
58115239|NCT01764620|OTHER|Elastic taping applied without tension|
58115240|NCT01764620|OTHER|Fatigue protocol|
58115241|NCT06080984|DRUG|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL)."
58115242|NCT06080984|DRUG|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
58115243|NCT04656015|DEVICE|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~* Regional or global myocardial signal intensity increase in T2-weighted images~* Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~* There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
58115244|NCT06101121|DEVICE|Lubri-Cream|Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
58115245|NCT00974883|PROCEDURE|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
58115246|NCT00974883|PROCEDURE|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
58115247|NCT03511352|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
58115248|NCT03511352|BEHAVIORAL|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
58446331|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
58446332|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
58446333|NCT01688375|DRUG|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
58446334|NCT06558838|DRUG|acyclovir-penciclovir cream|Patients will treat their cold sore with active study drug based upon their randomization
58446335|NCT06558838|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
58446336|NCT01082692|BIOLOGICAL|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
58446337|NCT02068625|DRUG|Rasagiline|Rasagiline 1mg daily orally for 7 days
58446338|NCT02068625|DRUG|Placebo|Oral treatment with placebo for 7 days
58446339|NCT02071199|DRUG|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
57741747|NCT00447057|DRUG|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
57741748|NCT00447057|DRUG|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
58115249|NCT01858246|DEVICE|Bonebridge|
58115250|NCT01858246|DEVICE|Bone Anchored Hearing Aid|
58115251|NCT05655702|OTHER|Community based TB intervention|"* 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts."
58115252|NCT01617564|DRUG|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
58115253|NCT01617564|OTHER|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
58115254|NCT01664052|DEVICE|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
58115255|NCT01664052|DEVICE|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
58115256|NCT01664052|DEVICE|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
58115257|NCT00593138|DRUG|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
58115258|NCT05219396|DEVICE|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
58115259|NCT00704223|DRUG|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
58115260|NCT02655172|OTHER|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
58115261|NCT02655172|OTHER|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
58115262|NCT03170206|DRUG|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
58115263|NCT03170206|DRUG|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
58115264|NCT06347757|PROCEDURE|Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy|laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).
58115265|NCT01877928|DEVICE|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
58115266|NCT01877928|DEVICE|standard CPAP|Standard of care postoperative treatment for OSA.
58115267|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
58115268|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
58115269|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
58446340|NCT02071199|DRUG|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
58115270|NCT00323583|DRUG|paclitaxel|
58115271|NCT00323583|DRUG|oxaliplatin|
57741749|NCT04247672|DEVICE|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
58115272|NCT00323583|DRUG|leucovorin|
58115273|NCT00323583|DRUG|5-fluorouracil|
58115274|NCT00323583|DRUG|glutathione|
58115275|NCT00323583|DRUG|calcium and magnesium|
58115276|NCT00323583|PROCEDURE|Chemotherapy|
58115277|NCT00323583|PROCEDURE|Chemoprotection|
58115278|NCT00323583|PROCEDURE|Complementary and alternative therapy|
58115279|NCT00398359|BEHAVIORAL|Motivational Interviewing (physicians)|Identifying and referring children with BMI \>93%.
58115280|NCT00398359|BEHAVIORAL|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
58115281|NCT03772639|OTHER|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
58115282|NCT05084690|OTHER|Unilateral resistance training|Unilateral resistance training of the elbow flexors
58115283|NCT05084690|OTHER|Illusionary mirror visual feedback|Modified Ramachandran's mirror box
58115284|NCT05482984|OTHER|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
58115285|NCT06544018|GENETIC|Genetic analysis of NLRP3|Blood test for genetic analysis of NLRP3
58115286|NCT06544018|DEVICE|Circadian rhythm measurement|Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
58115287|NCT06544018|BIOLOGICAL|Saliva sampling|Saliva sampling for salivary melatonin determination
58115288|NCT06544018|OTHER|Questionnaire|Questionnaire to determine chronotype
58115289|NCT06544018|OTHER|AIDAI score|Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
58115290|NCT06544018|BIOLOGICAL|Blood sampling|"1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways"
58115291|NCT00600626|DRUG|biphasic insulin aspart|
58446341|NCT02071199|DRUG|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
58446342|NCT02871635|DRUG|BI 695501|
58446343|NCT02871635|DRUG|HUMIRA|
58446344|NCT06725992|DRUG|IY-NS250|Ilaprazole 20mg + Sodium bicarbonate 500mg
58446345|NCT06725992|DRUG|IY-NT-SR|Ilaprazole 10mg
58446346|NCT05974098|OTHER|Observational study|This study intends to use correlation analysis and mediation analyses to assess the mediating effects of self-efficacy, coping, depression and anxiety on the quality of life of patients with paroxysmal atrial fibrillation.
58115292|NCT00600626|DRUG|insulin NPH|
58115293|NCT00600626|DRUG|insulin aspart|
58115294|NCT01991587|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
58115295|NCT01991587|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
58115296|NCT01991587|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
58115297|NCT01991587|BIOLOGICAL|Placebo|A single dose of placebo
58115298|NCT00132431|DRUG|Sensipar|
58115299|NCT01688037|DRUG|NBI-98854|25 mg capsule
58446347|NCT00476827|DRUG|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
57741750|NCT04609033|DRUG|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
57741751|NCT04609033|DRUG|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
57741752|NCT04609033|DRUG|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
58115300|NCT01688037|DRUG|NBI-98854|50 mg capsule
58115301|NCT01688037|DRUG|Placebo|
58115302|NCT04682275|OTHER|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
58115303|NCT04193891|OTHER|Modified Atkins Diet|The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
58115304|NCT00260325|DRUG|valdecoxib|
58115305|NCT02854566|DEVICE|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
58115306|NCT00130520|DRUG|bevacizumab|10mg/kg every two weeks IV-bevacizumab
58115307|NCT00130520|DRUG|erlotinib|150mg daily by mouth-erlotinib
58115308|NCT05235308|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
58446348|NCT00476827|DRUG|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
58446349|NCT00476827|DRUG|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
58446350|NCT00476827|DRUG|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
58115309|NCT01618305|DRUG|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
58115310|NCT01618305|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
58115311|NCT01618305|DRUG|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
58115312|NCT01152281|BEHAVIORAL|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
58115313|NCT01152281|BEHAVIORAL|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
58446351|NCT00476827|DRUG|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
58446352|NCT00476827|DRUG|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
58446353|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
58446354|NCT05635513|DEVICE|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
58446355|NCT01434849|DRUG|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
58446356|NCT01434849|DRUG|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
58446357|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
58446358|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
58446359|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
58446360|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
58115314|NCT01152281|BEHAVIORAL|Minimal Control|Control messages to increase awareness of HIV risk
58115315|NCT01152281|BEHAVIORAL|Instrumental|Instrumental messages with stories of people living with HIV
58446361|NCT05274958|BEHAVIORAL|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
58446362|NCT05205291|DRUG|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
58446363|NCT05205291|RADIATION|PET/MR with [11C]PBR28|A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
58446364|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
58446365|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
57741753|NCT04609033|DRUG|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
57741754|NCT04329039|DRUG|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
58115316|NCT01152281|BEHAVIORAL|Empowering|Empowering messages with stories of people living with HIV
58115317|NCT04767789|DIETARY_SUPPLEMENT|NZ-GHMH-01|Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
58115318|NCT04767789|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
58115319|NCT05661929|OTHER|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
58115320|NCT02351128|DRUG|Lanreotide|
58115321|NCT03782857|BEHAVIORAL|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
58115322|NCT05731102|DIAGNOSTIC_TEST|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
58115323|NCT00892827|DRUG|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
58115324|NCT05678621|DRUG|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
58446366|NCT06726473|DIAGNOSTIC_TEST|Wet Blood Gas Analyzer (ABL90)|This group involves the use of the ABL90 wet blood gas analyzer for measuring arterial whole blood samples. The results obtained from the ABL90 analyzer will be compared with those obtained from the EG-i30 dry blood gas analyzer
58446367|NCT06726473|DIAGNOSTIC_TEST|Dry Blood Gas Analyzer (EG-i30)|This group involves the use of the EG-i30 dry blood gas analyzer for measuring arterial whole blood samples. The results obtained from the EG-i30 analyzer will be compared with those obtained from the ABL90 wet blood gas analyzer.
58446368|NCT01450761|BIOLOGICAL|Ipilimumab|
58446369|NCT01450761|BIOLOGICAL|Placebo matching Ipilimumab|
58446370|NCT01450761|DRUG|Etoposide|
58446371|NCT01450761|DRUG|Cisplatin|
58446372|NCT01450761|DRUG|Carboplatin|
58446373|NCT06725745|OTHER|Survey|Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
58115325|NCT05678621|DRUG|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
58115326|NCT05678621|DRUG|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
58115327|NCT06436924|DEVICE|Left Atrial Appendage Device Implant|The Watchman Device is implanted into the left atrial appendage and is designed to close it off and keep blood clots from escaping that area.
58115328|NCT02300025|DRUG|cobimetinib|single oral 10-mg dose of cobimetinib
58115329|NCT00653497|BEHAVIORAL|Aquatic exercise|"Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration"
58115330|NCT02916381|PROCEDURE|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
58115331|NCT02916381|PROCEDURE|General anaesthesia|
57741755|NCT01795833|OTHER|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
58115332|NCT00876278|DEVICE|*AT.Smart 46LC|Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
58115333|NCT02248337|DRUG|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
58115334|NCT04183790|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
58115335|NCT04183790|DRUG|IVA|Mono tablet for oral administration.
58115336|NCT04832074|OTHER|Dry Needling|Real Dry Needling in the most active Myofascial Trigger Point
58115337|NCT04832074|OTHER|Sham Dry Needling|Sham Dry Needling in the same location, but not piercing the skin
58446374|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
58446375|NCT01181466|DEVICE|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
58446376|NCT06540144|DRUG|rozanolixizumab|rozanolixizumab solution for injection
58446377|NCT06533579|GENETIC|Dose Level 1, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
58446378|NCT06533579|GENETIC|Dose Level 2, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
58446379|NCT06533579|GENETIC|Dose Level 3, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
57957370|NCT00797823|DRUG|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
57957371|NCT00797823|DRUG|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
57957372|NCT00797823|DRUG|Placebo|Saline solution 0.9%
57957373|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
58115338|NCT01847313|DRUG|Liraglutide|Daily administration of liraglutide for 6 months
58115339|NCT01653574|DRUG|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
58115340|NCT04312555|DRUG|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
58115341|NCT04123041|OTHER|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
58115342|NCT00001564|DRUG|EF-1 Peptide|
58115343|NCT00001564|DRUG|EF-2 Peptide|
58115344|NCT00001564|DRUG|PXFK Peptide|
58115345|NCT00001564|DRUG|E7 Peptide|
58115346|NCT00001564|DRUG|IL-2|
58115347|NCT00001564|DRUG|IL-4|
58115348|NCT00001564|DRUG|GM-CSF|
58115349|NCT00001564|DRUG|CD40 Ligand|
58446380|NCT06533579|GENETIC|Dose Level 4, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
58446381|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
58446382|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
58446383|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
58446384|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58446385|NCT05088057|DRUG|Camrelizumab|200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
58446386|NCT05088057|DRUG|Doxorubicin|60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
58446387|NCT05088057|DRUG|Cyclophosphamide|600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
58446388|NCT05088057|DRUG|Docetaxel|75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
58446389|NCT02203994|DEVICE|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
58446390|NCT03387865|PROCEDURE|tissue biopsies|additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.
58446391|NCT03387865|PROCEDURE|blood sampling|additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)
58446392|NCT03387865|GENETIC|DNA banking|constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation
58446393|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
57741756|NCT04196179|DRUG|ANG3070|ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
58115350|NCT06144359|OTHER|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
58446394|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
58446395|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
58446396|NCT04320355|OTHER|Soft tissue manual therapy|The intervention is a type of massage.
58115351|NCT02394132|DRUG|Imiquimod|
58115352|NCT02394132|RADIATION|Radiotherapy|
58115353|NCT03109990|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
58115354|NCT03109990|DRUG|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
58446397|NCT03372967|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
58446398|NCT03372967|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
58446399|NCT03372967|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
58446400|NCT02591108|DEVICE|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
58446401|NCT02591108|DEVICE|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
57741757|NCT04196179|DRUG|Placebo oral capsule|ANG-3070 placebo capsules visually match the drug product.
57741758|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
57741759|NCT06083207|DRUG|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
57741760|NCT03598413|DIETARY_SUPPLEMENT|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
57741761|NCT00067015|DRUG|bicalutamide|
58115355|NCT00542516|DRUG|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
57741762|NCT00067015|DRUG|goserelin acetate|
57741763|NCT00067015|PROCEDURE|assessment of therapy complications|
57741764|NCT00067015|PROCEDURE|quality-of-life assessment|
58115356|NCT00542516|DRUG|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
58115357|NCT02957409|DRUG|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
58115358|NCT05729750|DIAGNOSTIC_TEST|Trans abdominal ultrasound for assess biophysical profile|The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
58115359|NCT03834584|DRUG|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
58115360|NCT06168955|OTHER|skin biopsy|skin biopsy for cell culture and N-homocysteinylation study
58115361|NCT03462329|DRUG|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
57741765|NCT00067015|RADIATION|radiation therapy|
57741766|NCT03213158|DRUG|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
57741767|NCT03677713|PROCEDURE|No nasal packing.|No nasal packing at the end of the surgery
58446402|NCT05659927|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
58446403|NCT05659927|DRUG|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
57741768|NCT03677713|PROCEDURE|Nasal Packing|Patients will have nasal packing at the end of the surgery
58115362|NCT04948190|BEHAVIORAL|Testing with medical detection dogs|Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
58115363|NCT01021150|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
58115364|NCT01021150|DRUG|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
58115365|NCT01816152|OTHER|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
58115366|NCT01816152|OTHER|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
58115367|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
58115368|NCT02207621|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
58115369|NCT02207621|OTHER|Placebo|1 drop QD, AM, OU
58115370|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
57741769|NCT05143827|OTHER|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
57741770|NCT05143827|OTHER|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
57741771|NCT03731468|DRUG|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
57741772|NCT03731468|DRUG|Dexamethasone|dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
57741773|NCT05045625|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
57741774|NCT00030719|BIOLOGICAL|filgrastim|
57741775|NCT00030719|BIOLOGICAL|monoclonal antibody Ch14.18|
57741776|NCT00030719|DRUG|busulfan|
57741777|NCT00030719|DRUG|carboplatin|
57741778|NCT00030719|DRUG|cyclophosphamide|
57741779|NCT00030719|DRUG|etoposide|
57741780|NCT00030719|DRUG|isotretinoin|
57741781|NCT00030719|DRUG|melphalan|
57741782|NCT00030719|DRUG|vincristine sulfate|
57741783|NCT00030719|PROCEDURE|bone marrow ablation with stem cell support|
57741784|NCT00030719|PROCEDURE|conventional surgery|
57741785|NCT00030719|PROCEDURE|peripheral blood stem cell transplantation|
57741786|NCT00030719|RADIATION|radiation therapy|
57741787|NCT05151302|DIAGNOSTIC_TEST|computer vision symptom scale (CVSS) questionnaire|Subjects working at VDT for \>20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
57741788|NCT03178266|DEVICE|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
57741789|NCT03141359|RADIATION|SBRT|Primary tumor SBRT
57741790|NCT03141359|DRUG|Carboplatin|concurrent chemotherapy
58115371|NCT05825118|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
58115372|NCT04998643|DIAGNOSTIC_TEST|Muscle ultrasound to estimate lean body mass|The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
58115373|NCT05172856|DRUG|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
58115374|NCT01823549|OTHER|questionnaire administration|Ancillary studies
58446404|NCT06727162|PROCEDURE|Contrast-Enhanced Ultrasound|"Participants are scanned in a supine position with the neck fully exposed. A routine ultrasound examination is first performed to assess the cervical lymph nodes. Assessment includes: number, size, location (zones I-VII), structure, echogenicity, margin, shape, hilum, calcification, and vascular distribution.~After the routine ultrasound scan, the ultrasound system is switched to dual contrast-enhanced ultrasound mode. Sonazoid (GE Healthcare) is then administered intravenously through the antecubital vein at a dose of 0.015 mL/kg, followed by an injection of 5 mL of physiological saline. A timer is started after the injection, and video recording is made during the vascular phase from 5 to 60 seconds."
58446405|NCT06726863|DRUG|Vamifeport IRF|Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.
58446406|NCT06726863|DRUG|Vamifeport PR1|Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.
58446407|NCT06726863|DRUG|Vamifeport PR2|Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
58446408|NCT02277444|DRUG|Golimumab|Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
58446409|NCT02277444|DRUG|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
58446410|NCT01569620|BEHAVIORAL|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
58446411|NCT01569620|BEHAVIORAL|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
58446412|NCT01569620|BEHAVIORAL|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
58446413|NCT05958849|DRUG|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
58446414|NCT05054998|RADIATION|Fludeoxyglucose F-18|Given IV
58446415|NCT05054998|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58446416|NCT05054998|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
58446417|NCT04198480|DRUG|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
58446418|NCT05596604|OTHER|survey- no intervention|survey- no intervention
58446419|NCT04519463|DRUG|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
58446420|NCT04519463|DRUG|Placebo|Sodium Chloride 0.9%
58446421|NCT01726582|DRUG|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
58446422|NCT01726582|RADIATION|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
57741791|NCT03141359|DRUG|Paclitaxel|concurrent chemotherapy
58115375|NCT02345278|DRUG|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
58115376|NCT02345278|OTHER|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
58446423|NCT01726582|DRUG|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
57741792|NCT03141359|DRUG|cis Platinum|concurrent chemotherapy
57741793|NCT03141359|DRUG|Etoposide|concurrent chemotherapy
57741794|NCT03141359|RADIATION|IMRT|mediastinal radiation
57741795|NCT03141359|DRUG|Durvalumab|adjuvant immunotherapy
57741796|NCT04085328|DEVICE|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
58312887|NCT06158581|BEHAVIORAL|The Emotion Awareness and Skills Enhancement Program|"EASE is a cutting-edge program created by researchers at the University of Alabama and the University of Pittsburgh in collaboration with autistic individuals, caregivers of autistic youth, and therapists. The overarching goal of the program is to support autistic clients who want to work on emotion regulation. EASE is unique because it targets emotional distress in autistic youth and adults, instead of targeting the core symptoms of autism (i.e., it is not a social skills intervention).~The program is a 16-session, mindfulness-based intervention. Each session is 1:1 for 45 minutes to one hour. While the program is designed for individual intervention, caregivers are also invited to play an active role on the care team."
58446424|NCT01726582|RADIATION|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
58446425|NCT01726582|DRUG|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
57741797|NCT04085328|DEVICE|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
58115377|NCT05396820|OTHER|Experimental pain|Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
58115378|NCT00439608|DRUG|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
58446426|NCT01726582|RADIATION|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
58446427|NCT01726582|DRUG|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
58115379|NCT04283578|DRUG|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
58115380|NCT04283578|DRUG|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
58446428|NCT01726582|RADIATION|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
58446429|NCT01726582|DRUG|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
58115381|NCT00621179|DRUG|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
58115382|NCT00621179|OTHER|No intervention|
58446430|NCT01726582|RADIATION|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
58115383|NCT02260492|DRUG|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
58446431|NCT01726582|RADIATION|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
58446432|NCT01726582|DRUG|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
58446433|NCT01726582|DRUG|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
58446434|NCT01726582|OTHER|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
58446435|NCT02949999|DRUG|Voclosporin|
58115384|NCT02260492|DRUG|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
58115385|NCT02260492|DRUG|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
58446436|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
58458545|NCT02267239|DRUG|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
57957374|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
58115386|NCT06175195|BEHAVIORAL|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
58115387|NCT02918838|BEHAVIORAL|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
58446437|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
58446438|NCT00363636|DRUG|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
58446439|NCT00363636|DRUG|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
58446440|NCT04201106|BEHAVIORAL|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
58446441|NCT04201106|BEHAVIORAL|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
58446442|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
58446443|NCT04524234|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of cardiac function
58446444|NCT06177600|BEHAVIORAL|Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers|"Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked."
58446445|NCT04862247|BEHAVIORAL|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
58446446|NCT04862247|BEHAVIORAL|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
58446447|NCT05706571|OTHER|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
58446448|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
58446449|NCT01818596|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
58446450|NCT05864326|DEVICE|Warm group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.
58446451|NCT05864326|DEVICE|Room temperature group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
58115388|NCT02918838|BEHAVIORAL|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
58115389|NCT02918838|BEHAVIORAL|Control Group|
58446452|NCT02506634|DRUG|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
58446453|NCT02458573|OTHER|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
57957375|NCT00372502|PROCEDURE|Modified EGDT|Early goal directed therapy with lactate clearance
58115390|NCT01606566|DRUG|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
58446454|NCT02458573|OTHER|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
58446455|NCT03725384|DRUG|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
58446456|NCT03725384|DRUG|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
58446457|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
58446458|NCT03214354|DRUG|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
58446459|NCT03214354|RADIATION|Total Body Irradiation|TBI 300 cGy on Day -2
58446460|NCT03214354|DRUG|Sirolimus|Sirolimus is used for GVHD prophylaxis
58446461|NCT04494620|DIAGNOSTIC_TEST|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
58446462|NCT06357039|DEVICE|Sleep tracking device|In addition to polysomnography, a device containing EEG+PPG sensors for sleep classification was placed on the forehead, and another device containing PPG and accelerometer sensors was placed on the wrist. The wrist to which the device is attached is randomly assigned.
58446463|NCT03335410|OTHER|Non- interventional|Non- interventional
58446464|NCT03343626|DRUG|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
58446465|NCT03343626|BIOLOGICAL|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
57957376|NCT00372502|PROCEDURE|Standard EGDT|Early goal directed therapy
57957377|NCT01535781|DRUG|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
57957378|NCT01535781|DRUG|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
58446466|NCT03590314|DEVICE|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
58446467|NCT03590314|OTHER|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
58446468|NCT06723665|DRUG|18F-PSMA-1007|18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
58446469|NCT06723665|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
58446470|NCT05919511|OTHER|Non-Interventional|This is an observational study
58446471|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
58446472|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
58446473|NCT01131910|BIOLOGICAL|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
57957379|NCT06426069|OTHER|Masticatory efficiency assessment|Masticatory efficiency will be assessed for each group.
58446474|NCT03420872|OTHER|Nutrient mixtures|consumption of a mixture of beneficial nutrients
58446475|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
58446476|NCT00986843|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
58446477|NCT05697341|PROCEDURE|Ultra-Mini-PCNL|treatment to extract or disintegrate renal stones
58446478|NCT05697341|PROCEDURE|Stented SWL|treatment to disintegrate renal stones in the presence of a JJ
58115391|NCT03306108|DEVICE|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
58115392|NCT00903383|DRUG|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
58115393|NCT00903383|DRUG|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
58115394|NCT00903383|DRUG|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
57741798|NCT05870748|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
57741799|NCT05870748|DRUG|Pegfilgrastim|Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.
57741800|NCT05870748|DRUG|Gemcitabine|Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.
58115395|NCT00903383|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
58115396|NCT03433001|DRUG|Ixazomib|Ixazomib capsules
58115397|NCT03433001|DRUG|Lenalidomide|Lenalidomide capsules
58115398|NCT03433001|DRUG|Dexamethasone|Dexamethasone tablets
58115399|NCT03640936|BEHAVIORAL|Induced Sputum|Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
58115400|NCT03445559|BEHAVIORAL|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
58446479|NCT05373862|DEVICE|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
58458546|NCT02267239|DRUG|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
57741801|NCT05870748|DRUG|Paclitaxel|Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.
57741802|NCT05870748|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
57741803|NCT05870748|DRUG|Topotecan|Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
57741804|NCT04197843|DEVICE|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
58458547|NCT02267239|DRUG|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
57741805|NCT00726206|OTHER|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
58115401|NCT03445559|BEHAVIORAL|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
58458548|NCT02267239|PROCEDURE|professional oral cleaning|scaling and polishing teeth of the volunteers
58458549|NCT02267239|PROCEDURE|Plaster cast|Taking a plaster cast of the volunteers' mouth
58458550|NCT02267239|DEVICE|IDODS|Specific intraoral device which carries six glass disks
58115402|NCT03445559|BEHAVIORAL|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
58115403|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
58115404|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
58115405|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
58115406|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
58115407|NCT00236327|DRUG|fentanyl|
58115408|NCT05431309|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
58115409|NCT05431309|OTHER|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
58115410|NCT05957718|DRUG|TKTX cream|TKTX cream was used in several studies on Tatto and laser
58115411|NCT03896490|BEHAVIORAL|Attention Control Training|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
58115412|NCT03896490|BEHAVIORAL|Control|The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
58115413|NCT05730985|DIETARY_SUPPLEMENT|Miotrof® formula|1 sachet per day for 4 months
58115414|NCT05730985|DIETARY_SUPPLEMENT|Placebo formula|1 sachet per day for 4 months
58115415|NCT00624767|DRUG|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
58115416|NCT00624767|DRUG|NovoLog|NovoLog at doses up to 30 IU
58115417|NCT05621083|DIETARY_SUPPLEMENT|Omega- 3|In the fish oil supplement period, the participants will receive concentrated fish oil which is equal to in total 2.3 g EPA+DHA per day during 6 weeks.
58115418|NCT05621083|DIETARY_SUPPLEMENT|HOSO|In the HOSO period, the participants will receive similar amount of HOSO per day during 6 weeks.
58115419|NCT00681408|DRUG|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
58115420|NCT00681408|DRUG|Placebo|Fish oil placebo pills
58115421|NCT05868057|DRUG|SHR7280 tablets|SHR7280 tablets 1 time
58446480|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
58446481|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
58446482|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
58446483|NCT00312026|DRUG|efalizumab|
58446484|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
58115422|NCT05868057|DRUG|SHR7280 dry suspension|SHR7280 dry suspension 1 time
58115423|NCT05226520|DIETARY_SUPPLEMENT|Experimental probiotic product|Probiotic supplementation
58115424|NCT05226520|OTHER|Placebo comparator|Placebo
58446485|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
58446486|NCT06726252|DEVICE|FFR measurement and intravascular imaging|Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement, and intravascular imaging, including IVUS and integrated OCT-IVUS using a single cathete to assess the accurary of OUFR, using wire-based FFR measurement as the gold standard.
57741806|NCT06498765|OTHER|Pacifier Use|The newborns in the experimental group were given a pacifier, unlike the control group. The newborns were placed in a phototherapy incubator and each time they were placed in a phototherapy incubator, the newborns were given a pacifier for an average of 5 minutes. The researcher encouraged the babies to take the pacifier.
58115425|NCT05287984|DRUG|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
58115426|NCT05287984|DRUG|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
58115427|NCT03877055|DRUG|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
58115428|NCT03877055|DRUG|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
58115429|NCT00548977|OTHER|Drawing blood to study genetic polymorphism|
58115430|NCT04877392|DIETARY_SUPPLEMENT|Lavender essential oil|Use of inhaled lavender essential oil
58115431|NCT04735237|PROCEDURE|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
58115432|NCT04735237|PROCEDURE|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
58115433|NCT01868009|DEVICE|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
58115434|NCT01868009|DEVICE|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
58115435|NCT04434313|DEVICE|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
58115436|NCT05871697|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
58446487|NCT05658588|DEVICE|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
58446488|NCT04273893|RADIATION|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
58446489|NCT04273893|RADIATION|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
58446490|NCT04273893|DIAGNOSTIC_TEST|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
58446491|NCT02223338|DRUG|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
57741807|NCT01992380|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
58446492|NCT02223338|DRUG|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
57741808|NCT01992380|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
57741809|NCT05549973|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
57741810|NCT00000502|PROCEDURE|cardiopulmonary resuscitation|
57741811|NCT01420055|DRUG|fingolimod|
57741812|NCT03386279|DRUG|PF-04965842|one single dose of 600 mg by mouth
58115437|NCT05871697|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
58115438|NCT06454500|OTHER|Clinical decision support|A 48 hour expiration on orders placed for indwelling urinary catheters.
58115439|NCT01760278|DRUG|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
58115440|NCT01264211|DRUG|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
58115441|NCT01264211|DRUG|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
58115442|NCT02254733|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
58115443|NCT02254733|OTHER|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
58115444|NCT01593527|DRUG|ACZ885|Canakinumab 150 mg s.c.
58115445|NCT01593527|DRUG|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
58115446|NCT04138849|DRUG|BBT-877 single dose|Oral capsule, single dose.
58446493|NCT01151371|DEVICE|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
58446494|NCT01151371|DEVICE|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
58446495|NCT01151371|DEVICE|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
58446496|NCT06725485|DRUG|Low-Dose Lidocaine|Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
58446497|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
58446498|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
58115447|NCT04138849|DRUG|Placebo single dose|Oral capsule, single dose.
58115448|NCT05886699|OTHER|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
58115449|NCT05886699|OTHER|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
58115450|NCT03397628|OTHER|FIFA 11 for health|
58115451|NCT06483958|BEHAVIORAL|palliative care protocol|"1. Symptom management~2. Respect for patient and family autonomy.~3. Respectful management of clinical information.~4. Provision of holistic care and support."
58446499|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
58446500|NCT06462183|DRUG|RGT-61159|Oral MYB inhibitor
58446501|NCT05681065|DEVICE|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
58446502|NCT02534363|DRUG|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
58446503|NCT02534363|DRUG|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
58446504|NCT02534363|DRUG|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
58446505|NCT02534363|BEHAVIORAL|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
58446506|NCT02327676|DRUG|Emtricitabine|emtricitabine were given to each patients for 48 weeks
58446507|NCT02782286|DRUG|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
58115452|NCT00533520|DRUG|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
58446508|NCT02782286|DRUG|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
58446509|NCT03374579|DIAGNOSTIC_TEST|Fluid challenge|Fluid challenge and measure change in co2 gap
58446510|NCT03162822|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
58446511|NCT03162822|OTHER|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
58458551|NCT00325455|DRUG|MK0859|
58115453|NCT04960475|OTHER|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
57741813|NCT03386279|DRUG|Moxifloxacin|one single dose of 400 mg by mouth
58115454|NCT04960475|OTHER|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
58115455|NCT04960475|OTHER|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
58115456|NCT00927459|DRUG|PRO-040201|Single dose IV infusion
58115457|NCT00927459|DRUG|Placebo|placebo
58446512|NCT03162822|OTHER|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
57741814|NCT03386279|DRUG|Placebo|one single dose by mouth
57957380|NCT01423799|DIETARY_SUPPLEMENT|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
58115458|NCT06547593|BEHAVIORAL|multifaceted nutrition intervention|"In this group, a 3-month multifaceted nutrition intervention will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: WeChat groups will be established to record the dietary status of the research subjects. The research subjects will be asked to keep a dietary diary and take photos of their diet daily. Trained researchers will record their daily diet and provide timely feedback to the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks. The content will include basic knowledge of frailty, prevention and treatment guidance, health outcomes, medication management, and healthy behaviors."
58115459|NCT06547593|BEHAVIORAL|Nutritional and Exercise Combined Intervention|To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
58115460|NCT06547593|BEHAVIORAL|Control Group|The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.
58115461|NCT05473156|DRUG|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses."
58115462|NCT05473156|DRUG|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
58115463|NCT02165228|BEHAVIORAL|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
58115464|NCT02165228|BEHAVIORAL|Nutrition Enhancement|Nutrition education class and behavioral intervention
58115465|NCT00390156|BIOLOGICAL|bevacizumab|5 mg/kg
58115466|NCT00390156|DRUG|cyclophosphamide|Current dose 50 mg
58115467|NCT00390156|DRUG|imatinib|Current dose 400 mg
58115468|NCT05547230|OTHER|questionnaires|The same tests will be applied to all participants in an objective way.
58115469|NCT01211574|BEHAVIORAL|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
58115470|NCT01211574|BEHAVIORAL|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
58115471|NCT01211574|BEHAVIORAL|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
58115472|NCT03723291|COMBINATION_PRODUCT|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care \[a structured programme of rehabilitation exercises\] for 6 months
58115473|NCT03723291|PROCEDURE|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
58115474|NCT05464290|PROCEDURE|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
58446513|NCT03162822|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
58446514|NCT02035527|DRUG|sorafenib tosylate|Given daily PO in the a.m.
58446515|NCT02035527|DRUG|cisplatin|Given IV over 1 hour following Docetaxel administration
58446516|NCT02035527|DRUG|docetaxel|Given IV 1 hour prior to cisplatin administration
58458552|NCT03284463|DRUG|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
58446517|NCT02035527|OTHER|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
58115475|NCT03101163|BIOLOGICAL|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
58115476|NCT03101163|OTHER|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
58115477|NCT01814761|DRUG|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
58115478|NCT02168270|DIETARY_SUPPLEMENT|ascorbic acid|Given IV
58446518|NCT06708559|OTHER|Breast-fed infants|Immune system characterization via blood and stool samples collection
58446519|NCT04182815|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
58115479|NCT02168270|DRUG|temozolomide|Given PO
58115480|NCT02168270|OTHER|quality-of-life assessment|Ancillary studies
58115481|NCT02168270|OTHER|laboratory biomarker analysis|Correlative studies
58446520|NCT06655155|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
58446521|NCT06655155|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
58446522|NCT05720390|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
58446523|NCT05720390|OTHER|L-leucine|L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
57957381|NCT01423799|DIETARY_SUPPLEMENT|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
57957382|NCT04839731|DRUG|Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream|Apply twice per day for allotted time
57957383|NCT04839731|DRUG|Nourivan Base Cream|Apply twice per day for allotted time
57957384|NCT01070264|DIETARY_SUPPLEMENT|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
57957385|NCT03910556|DRUG|Propofol|intraoperative factors
57957386|NCT01412593|BIOLOGICAL|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
57957387|NCT01294670|DRUG|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
58115482|NCT01943461|DRUG|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
58446524|NCT05720390|OTHER|Combination of quinine and L-leucine|In this condition, both quinine and L-leucine will be administered as 'active'.
58446525|NCT05720390|OTHER|Control|In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
58446526|NCT04502563|OTHER|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
58115483|NCT01943461|DRUG|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
58115484|NCT01943461|DRUG|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
58115485|NCT06400849|DEVICE|cryotherapy alone of the upper or lower limbs|Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
58115486|NCT06400849|DEVICE|cryotherapy and crompression of the upper or lower limbs|Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
58115487|NCT04755322|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
58115488|NCT04755322|DRUG|Folic acid|5 mg
58115489|NCT04755322|DRUG|Low-dose aspirin|75 mg
58115490|NCT00001683|DRUG|COL-3|
58446527|NCT04502563|OTHER|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
58446528|NCT06726239|OTHER|Progressive relaxation exercises|"The aim of relaxation exercises is for individuals to understand the difference between tension and relaxation and to be able to relax themselves in situations of tension. Relaxation exercises are performed with light music in the background and instructions for relaxation exercises so that patients can focus mentally. The progressive relaxation technique involves voluntary stretching and relaxation of human muscle groups (muscle groups starting with the hand and ending with the foot) (5-10 seconds) 1 repetition for each muscle group. The total duration of the exercises is 20 minutes. The instructions and exercise steps in the Turkish Psychologists Association Publications (TPDY, 2010) Relaxation Exercises CD given to the patient during the exercise will be followed."
58446529|NCT05947864|BIOLOGICAL|Biological samples (blood and oral fluid)|"For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)"
58446530|NCT04249843|DRUG|BGB-3245|administered orally (PO)
58446531|NCT05276817|DEVICE|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
58446532|NCT05276817|DRUG|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
58115491|NCT03730324|DIAGNOSTIC_TEST|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
58115492|NCT03730324|DIAGNOSTIC_TEST|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
58115493|NCT04485247|PROCEDURE|Transumbilical Laparoscopic-Assisted Appendectomy|appendectomy performed extracorporeally through umbilical port
58115494|NCT04485247|PROCEDURE|3-port laparoscopic appendectomy|appendectomy performed intracorporeally with 3-port
58115495|NCT02934828|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
58115496|NCT02934828|DRUG|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
58115497|NCT05072691|DIAGNOSTIC_TEST|CSF immunoglobulin (Ig) free light chains (FLC) dosage|CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
58446533|NCT05276817|DEVICE|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
58446534|NCT00746863|DRUG|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
58458553|NCT03284463|DRUG|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
57741815|NCT00853814|BEHAVIORAL|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
57741816|NCT02877043|PROCEDURE|resection pulmonaire|
58115498|NCT02144259|DRUG|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
58115499|NCT02144259|DRUG|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
58115500|NCT03004690|DEVICE|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
58115501|NCT03004690|DEVICE|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
58446535|NCT06725043|DEVICE|Therapeutic ultrasound|Pulsed therapeutic ultrasound (1 MHz , 50% duty cycle and intensity gradually increased till the patient felt a deqi sensation).Each point was stimulated by ultrasound for 5 minutes at bilateral acupuncture points of PC6, PC7, BL60 and KI1(3 times / week for 4 weeks).
58446536|NCT06725043|DEVICE|Placebo therapeutic ultrasound|patients were received placebo therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI.
58446537|NCT06725043|OTHER|Traditional physical therapy program|Strengthing exercise, balance training, stretching exercises and home exercise program and education
58446538|NCT03496675|BEHAVIORAL|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
58446539|NCT03496675|BEHAVIORAL|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
58446540|NCT03496675|OTHER|Standard care|May include pharmacological and non-pharmacological interventions as locally available
58446541|NCT06526988|BEHAVIORAL|EPIC-HF Patient-facing Tool|A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.
58446542|NCT06526988|BEHAVIORAL|PROMPT-HF Clinician-facing Alert|A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
58115502|NCT05555589|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
58446543|NCT05838768|DRUG|HRO761|Tablet
58446544|NCT05838768|BIOLOGICAL|pembrolizumab|Concentrate for solution for infusion
58446545|NCT05838768|DRUG|irinotecan|Concentrate for solution for infusion
58115503|NCT05555589|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
58115504|NCT03729765|DEVICE|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
58115505|NCT04449042|PROCEDURE|airway management during sedation or general anesthesia|airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
58115506|NCT01988311|DRUG|psilocybin|dose manipulation as described in the protocol
58446546|NCT02118974|PROCEDURE|Hysterectomy|Hysterectomy
58446547|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
58446548|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
58446549|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
58446550|NCT03828617|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
58446551|NCT05432401|BIOLOGICAL|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
58446552|NCT06410014|OTHER|No intervention is performed|The study is observational
58446553|NCT06725056|OTHER|DS-MCE and EGD examinations|sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
58446554|NCT06337695|BIOLOGICAL|Vedolizumab|300 mg IV at weeks 0, 3, 6, 14, and 22
58115507|NCT02789111|DRUG|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
58115508|NCT02789111|DRUG|Placebo|Placebo twice daily up to 15 doses
58115509|NCT00652873|DRUG|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
58115510|NCT00652873|DRUG|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
58446555|NCT06337695|BIOLOGICAL|Placebo|300 mg IV at weeks 0, 3, 6, 14, and 22
58115511|NCT01507896|BIOLOGICAL|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
58115512|NCT06290583|DRUG|Bupivacaine|Spinal anesthesia with standard dose of bupivacaine
58115513|NCT06290583|DRUG|Prilocaine|Spinal anesthesia with 50 mg dose of Prilocaine.
58115514|NCT05610501|PROCEDURE|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
58115515|NCT01387100|BEHAVIORAL|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
58115516|NCT02386059|DRUG|PLACEBO|received normal saline, intravenously
58115517|NCT02386059|DRUG|Dexamethasone|4 mg, intravenously, at the start of surgery
58115518|NCT02386059|DRUG|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
58115519|NCT02386059|DRUG|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
58115520|NCT01682161|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
58115521|NCT02872402|BEHAVIORAL|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
58115522|NCT02872402|BEHAVIORAL|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
58115523|NCT03969459|BIOLOGICAL|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
58115524|NCT03969459|BIOLOGICAL|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
58115525|NCT03969459|BIOLOGICAL|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
58115526|NCT03969459|OTHER|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
58115527|NCT01480856|PROCEDURE|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
58115528|NCT01480856|PROCEDURE|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
58115529|NCT02345486|OTHER|0.9% sodium chloride|
58115530|NCT02345486|OTHER|Physiologically balanced fluid|
58115531|NCT05085314|PROCEDURE|Ngenuity digital 3D microscope|Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX
58115532|NCT05085314|PROCEDURE|Conventional microscope|Cataract surgery under topical anesthesia with a conventional microscope
58115533|NCT03496454|OTHER|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
58115534|NCT05381259|BEHAVIORAL|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
58446556|NCT05408715|OTHER|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
58458554|NCT02942212|BEHAVIORAL|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
58115535|NCT03746678|OTHER|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
58115536|NCT04051138|OTHER|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
58115537|NCT03645226|DIAGNOSTIC_TEST|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
58115538|NCT03089632|OTHER|Gluten-free diet|One-month gluten-free diet
58115539|NCT01254045|DRUG|placebo|intranasal placebo (48 international units)
58115540|NCT01254045|DRUG|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
58115541|NCT01254045|DRUG|oxytocin 48IU|intranasal oxytocin (48 international units)
58115542|NCT02570165|DRUG|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
58115543|NCT02570165|DRUG|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
58115544|NCT02570165|DRUG|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
58115545|NCT06126042|DRUG|Test Product|DRL_AB, Pre Filled Syringe; Solution for injection
58115546|NCT06126042|DRUG|Reference product|USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
58115547|NCT06126042|DRUG|Reference Medicinal Product|EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
58115548|NCT00729196|BEHAVIORAL|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
58446557|NCT06137586|OTHER|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
58446558|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
58446559|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
58446560|NCT02999906|DRUG|Oral Treprostinil|Sustained release oral tablets for three times daily administration
58115549|NCT04277195|DIAGNOSTIC_TEST|SPAG5 Assay|Testing for SPAG5 expression in the tumour.
58446561|NCT02999906|DRUG|Placebo|Placebo (sugar pill) for three times daily oral administration
58446562|NCT00004561|BEHAVIORAL|exercise|
58115550|NCT02648373|BEHAVIORAL|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
58115551|NCT02648373|OTHER|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
58115552|NCT04083339|DRUG|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
58446563|NCT03368586|DEVICE|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (\<4.0 mmol/L) or high (\>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
58446564|NCT03791970|DEVICE|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
58446565|NCT03791970|DEVICE|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
58446566|NCT04322188|OTHER||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
58446567|NCT03494296|DRUG|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
58115553|NCT04083339|DRUG|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
58115554|NCT05705583|OTHER|Other: Blood and Urine Collection|Blood and Urine Collection
58115555|NCT06123403|DIAGNOSTIC_TEST|blood methotrexate level and Cystatin C level|blood methotrexate level and Cystatin C level
58115556|NCT06200961|DEVICE|Transnasal Endoscopy|Unsedated endoscopic evaluation through the nose.
58115557|NCT06200961|PROCEDURE|Esophagogastroduodenoscopy|Sedated endoscopic evaluation through the mouth.
58115558|NCT04111133|DRUG|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
58115559|NCT04111133|DRUG|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
58115560|NCT02619604|OTHER|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
58115561|NCT04510220|DRUG|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
58115562|NCT04510220|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
58115563|NCT04625920|DEVICE|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
58115564|NCT04633759|OTHER|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
58115565|NCT04568928|DEVICE|OLTP/PE + FES|12 sessions OLTP/PE + FES
58115566|NCT04574778|DRUG|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
58115567|NCT04596501|OTHER|Early and late postmenopausal women|The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.
58115568|NCT01824771|OTHER|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
58115569|NCT06051396|PROCEDURE|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
58115570|NCT01004770|DRUG|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
58115571|NCT01004770|DRUG|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
58115572|NCT04079842|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
58115573|NCT01859325|BIOLOGICAL|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
58115574|NCT01859325|BIOLOGICAL|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
58115575|NCT01859325|BIOLOGICAL|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
58115576|NCT01859325|DRUG|Placebo|
58115577|NCT02501239|BEHAVIORAL|Accept Yourself!|
58115578|NCT02501239|BEHAVIORAL|Weight Watchers|
58115579|NCT04370145|DRUG|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
58115580|NCT04370145|DRUG|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
58115581|NCT04370145|DRUG|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
58115582|NCT04847609|DEVICE|GentleCath™ Air catheter|Patients
58115583|NCT04228302|DRUG|EC5026 oral capsule|"5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo."
58115584|NCT04228302|OTHER|Placebo oral capsule|5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
58115585|NCT02333409|PROCEDURE|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
58115586|NCT01677455|DRUG|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
58115587|NCT01583387|OTHER|1-Increased water intake regimen|Arm 1-Intervention
58115588|NCT01583387|OTHER|2-Non-modified water intake regimen|Arm 2-Control
58115589|NCT06234852|BEHAVIORAL|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
58115590|NCT06234852|BEHAVIORAL|Glucocorticoid maintenance group|Daily 5-mg prednisolone over 24 weeks
58115591|NCT03369756|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
58115592|NCT05485428|OTHER|High-intensity interval training|12-weeks of high intensity interval exercise, 30 minutes thrice weekly
58115593|NCT01706198|DRUG|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
58115594|NCT01706198|DRUG|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
58115595|NCT02217722|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
58115596|NCT02217722|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
58115597|NCT04066179|DRUG|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
58115598|NCT04066179|DRUG|Prednisolone|Prednisolone 40 mg for initial 7 days
58115599|NCT04224779|BIOLOGICAL|Biological collection|The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
58115600|NCT05163002|BEHAVIORAL|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
58115601|NCT02523365|PROCEDURE|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
58115602|NCT01525706|DRUG|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
58446568|NCT01646086|BEHAVIORAL|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
58446569|NCT06091150|PROCEDURE|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
58446570|NCT06106802|DRUG|Lazertinib|Lazertinib 240mg/day
58446571|NCT06106802|DRUG|Tepotinib|Tepotinib 500mg/day
58446572|NCT04083365|DRUG|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
58115603|NCT02945462|BIOLOGICAL|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
58115604|NCT00551122|BIOLOGICAL|filgrastim|
58115605|NCT00551122|BIOLOGICAL|lenograstim|
58115606|NCT00551122|BIOLOGICAL|pegfilgrastim|
58446573|NCT04083365|DRUG|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
58446574|NCT04083365|DRUG|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
58446575|NCT04783909|PROCEDURE|Phacoemulsification cataract surgery|All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
58115607|NCT00551122|DRUG|cisplatin|
58115608|NCT00551122|DRUG|gemcitabine hydrochloride|
58115609|NCT00551122|DRUG|ifosfamide|
58115610|NCT00551122|DRUG|paclitaxel|
58115611|NCT06544486|PROCEDURE|Caries Removal|The cavity preparation and restoration were performed by a single operator. Infected dentin tissue was selectively removed. The differentiation between infected and affected dentin was determined by the clinician through the visual-tactile method.Isolation was achieved with cotton rolls and suction.
58115612|NCT06544486|PROCEDURE|Filling|Sectional matrix systems and interdental wedges were used to achieve an anatomical contour and contact. Then, the selected materials were placed in the cavity according to the manufacturers' recommendations.
58115613|NCT04900233|OTHER|surgery|emergency surgery
58446576|NCT03010033|OTHER|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
58115614|NCT06161597|BEHAVIORAL|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
58115615|NCT02888769|BEHAVIORAL|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
58115616|NCT04996810|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
58115617|NCT04996810|BIOLOGICAL|Botox®|Botulinum toxin Type A
58115618|NCT04657510|OTHER|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
58115619|NCT02749019|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
58115620|NCT01584778|OTHER|eosinophil cationic protein|Serum eosinophil cationic protein levels
58446577|NCT03029910|OTHER|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
58446578|NCT03029910|OTHER|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
58115621|NCT00006081|DRUG|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
58115622|NCT00006081|DRUG|Paclitaxel (Taxol)|80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
58446579|NCT00237497|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
58446580|NCT00237497|DRUG|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
58115623|NCT03982758|OTHER|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
58446581|NCT00237497|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
58446582|NCT05392309|OTHER|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
58115624|NCT03982758|OTHER|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
58115625|NCT05031481|DRUG|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
58115626|NCT05031481|DRUG|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
58115627|NCT05031481|DRUG|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
58446583|NCT05392309|OTHER|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
58446584|NCT05569447|PROCEDURE|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
58115628|NCT05031481|DRUG|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
58115629|NCT06480448|OTHER|Traditional physical herapy|core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.
58115630|NCT06480448|OTHER|Treadmill training|Treadmill training for 20 minutes three time a week.
58115631|NCT00881959|DEVICE|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
58115632|NCT01541462|OTHER|Weaning|Decrease assistance provided by the ventilator
58115633|NCT02223026|DRUG|Linagliptin/metformin FDC|
58115634|NCT02223026|OTHER|high-fat, high caloric meal|
58115635|NCT04305223|PROCEDURE|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
58115636|NCT04305223|OTHER|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
58115637|NCT02439242|DRUG|fluid challenge of saline|250 ml of saline
58115638|NCT01900873|DEVICE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
58115639|NCT01900873|DEVICE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
58115640|NCT03804645|DRUG|Treatment A|Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
58115641|NCT03804645|DRUG|Treatment B|Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
57957388|NCT02592850|OTHER|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
57957389|NCT02592850|OTHER|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
58115642|NCT03804645|DRUG|Treatment C|Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
58115643|NCT03804645|DRUG|Treatment D|Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
58115644|NCT06205303|OTHER|Patient Decision Aid (Video)|Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
58115645|NCT00891774|DEVICE|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
58115646|NCT02265887|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
58115647|NCT00075894|DRUG|L-alanosine|
58115648|NCT04813900|OTHER|Lung ultrasound|Lung ultrasound in order to calculate lung ultrasound score
58115649|NCT01080430|OTHER|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
58115650|NCT02300376|DRUG|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
58115651|NCT01097356|DIETARY_SUPPLEMENT|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
57741817|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
58115652|NCT05296512|DRUG|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
58115653|NCT05296512|DRUG|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
58115654|NCT02788331|OTHER|No intervention|
57741818|NCT05845138|DRUG|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
57741819|NCT01846182|DRUG|Duloxetine|serotonin norepinephrine reuptake inhibitor
58115655|NCT02727140|BEHAVIORAL|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
58115656|NCT02727140|BEHAVIORAL|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
58115657|NCT02024828|OTHER|Early/Slow|
58115658|NCT02024828|OTHER|Early/Fast|
58115659|NCT02024828|OTHER|Late/Slow|
58115660|NCT02024828|OTHER|Late/Fast|
58115661|NCT04443322|DRUG|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
58115662|NCT04443322|DRUG|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
58446585|NCT02052752|DRUG|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
58446586|NCT02052752|DRUG|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
57741820|NCT01846182|DRUG|Pregabalin|alpha-2-alpha subunit calcium channel ligand
58115663|NCT02448628|DRUG|CS-3150|
58115664|NCT00325533|BEHAVIORAL|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
58115665|NCT00325533|OTHER|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
58115666|NCT00621686|BIOLOGICAL|bevacizumab|
58115667|NCT00621686|DRUG|sorafenib tosylate|
58115668|NCT01702350|DRUG|GSK2251052|Oral formulation of an an antibacterial
58446587|NCT02052752|DRUG|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
58458555|NCT02942212|BEHAVIORAL|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
57741821|NCT01846182|DRUG|Placebo|Placebo
57741822|NCT06133400|OTHER|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
57741823|NCT06133400|OTHER|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
57741824|NCT06133400|OTHER|Biological samples|Collect venous blood, saliva and stool samples
57741825|NCT03118583|DIETARY_SUPPLEMENT|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
57741826|NCT05574569|BEHAVIORAL|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
58115669|NCT06106503|RADIATION|chest x-ray|chest x-ray after rigid bronchoscopy for patient with foreign body inhalation
58115670|NCT06106503|OTHER|clinical examination|no investigations well be done unless needed
58115671|NCT01129999|BEHAVIORAL|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
58115672|NCT01129999|BEHAVIORAL|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
58115673|NCT03252288|BEHAVIORAL|Reminders|Text of phone-call based reminders to mobile phones
58115674|NCT03252288|BEHAVIORAL|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs \>1 week but within 4 weeks of the scheduled visit
58115675|NCT03432299|PROCEDURE|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
58115676|NCT00195806|DRUG|divalproex sodium|
58115677|NCT00560183|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
58115678|NCT00560183|DRUG|Placebo|Capsules
58115679|NCT01227668|DRUG|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
58115680|NCT01227668|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
58115681|NCT02371083|OTHER|Extended timing of pessary care|
58115682|NCT04659733|DRUG|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
58115683|NCT03754491|BEHAVIORAL|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
58115684|NCT03929224|DRUG|Medicinal honey|Treat healing surgical site with medicinal honey
58115685|NCT03929224|DRUG|Bacitracin|Treat healing surgical site with bacitracin
58115686|NCT02751333|PROCEDURE|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
58115687|NCT02751333|PROCEDURE|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
58115688|NCT02751333|DEVICE|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
58115689|NCT02751333|DEVICE|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
58115690|NCT00125996|DRUG|Venofer (intravenous iron sucrose)|
58458556|NCT02942212|OTHER|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
57741827|NCT05574569|BEHAVIORAL|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
57741828|NCT05574569|BEHAVIORAL|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
58115691|NCT01809314|DRUG|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
58115692|NCT01664195|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
58115693|NCT04014959|DEVICE|Transcranial Magnetic Stimulation|"Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. Repetitive TMS (rTMS) is FDA-approved for depression treatment.~TMS is administered over 5 study visits: an initial TMS/fMRI session, a 3-day TMS intervention regimen, and a post-intervention TMS/fMRI session. During TMS/fMRI sessions, participants receive single pulses of TMS pre/post a short round of Intermittent Theta Burst Stimulation (iTBS), a modified rTMS protocol. Throughout the 3-day intervention regimen, participants receive two full rounds of iTBS daily.~All study participants receive active TMS."
58115694|NCT06243978|BEHAVIORAL|liebria|Participants will receive access to the digital health intervention liebria in addition to TAU
58115695|NCT06243978|OTHER|information brochure on hypertension|Participants will receive an information brochure on hypertension
58115696|NCT03175237|OTHER|Mirror Therapy|
58115697|NCT02081261|PROCEDURE|Coronary artery bypass surgery|coronary artery bypass surgery
58115698|NCT06483672|DRUG|Furmonertinib|Furmonertinib 80mg, once daily, orally
58115699|NCT06483672|DRUG|Anlotinib|Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
58115700|NCT02610049|BEHAVIORAL|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson \& Chard (11/2010)
58115701|NCT02610049|BEHAVIORAL|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson \& Chard (11/2010)
58115702|NCT02610049|BEHAVIORAL|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson \& Chard (1/2010) CPT + Art Therapy of mixed individual techniques
58115703|NCT05496088|PROCEDURE|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
58115704|NCT05496088|PROCEDURE|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
58115705|NCT03605615|OTHER|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
58115706|NCT06389279|OTHER|PENG block group|Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
58115707|NCT06389279|OTHER|FIC block group|Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
58115708|NCT06389279|OTHER|Femoral block group|Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
58115709|NCT06389279|OTHER|Control group|No intervention
58115710|NCT01464359|DRUG|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
58115711|NCT01464359|DRUG|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.
58115712|NCT01464359|RADIATION|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
58115713|NCT01464359|DRUG|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
58115714|NCT01464359|DRUG|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
58115715|NCT01464359|DRUG|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours
58115716|NCT01464359|BIOLOGICAL|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
58115717|NCT01464359|BIOLOGICAL|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
58115718|NCT00226694|DRUG|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
58115719|NCT00226694|OTHER|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
58115720|NCT00092079|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
58115721|NCT04497610|DIAGNOSTIC_TEST|Breath sample|Patient will blow into a tube 5 times.
58115722|NCT04661462|OTHER|online survey|We invite volunteers after COVID-19 to participate in an online survey.
58115723|NCT04604483|DEVICE|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
58115724|NCT00377052|DRUG|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
58115725|NCT00377052|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
58115726|NCT02743442|DEVICE|da Vinci® Si™|
58115727|NCT00887003|DRUG|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
58115728|NCT00887003|DRUG|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
58115729|NCT00887003|DRUG|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
58115730|NCT00887003|DRUG|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
58115731|NCT00887003|DRUG|Depo-Medrol|80mg Depo-Medrol
58115732|NCT06367556|BEHAVIORAL|Emotion and Symptom-Focused Engagement (EASE)|EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.
57741829|NCT03722186|DRUG|SHR-1603|SHR-1603 monotherapy
58115733|NCT06103526|DIETARY_SUPPLEMENT|Immunonutrition|enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
58115734|NCT06546306|DEVICE|TOUCH® CMC 1|TOUCH® prosthesis is a total CMC 1 (1st Carpo-metacarpal) joint replacement prosthesis.
58115735|NCT01271114|DRUG|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
58115736|NCT01271114|DRUG|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
57741830|NCT05646875|OTHER|hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
58115737|NCT06109662|DIAGNOSTIC_TEST|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
58115738|NCT06109662|OTHER|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
57741831|NCT03333850|DEVICE|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
58115739|NCT04487756|DRUG|Atezolizumab 1200 mg in 20 ML Injection|"- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)"
58115740|NCT04487756|BIOLOGICAL|ADC Vaccine|- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
58115741|NCT04487756|DRUG|Carboplatin|- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
58115742|NCT01869322|DEVICE|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
58115743|NCT01869322|DEVICE|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
58115744|NCT05875415|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
58115745|NCT05875415|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
58115746|NCT04044846|BEHAVIORAL|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
58446588|NCT03434548|RADIATION|PET imaging|"PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
58446589|NCT03434548|OTHER|Multi-modal MRI imaging|Multi-modal MRI imaging
58446590|NCT01615016|OTHER|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
58446591|NCT04859088|DIETARY_SUPPLEMENT|Partial Enteral Nutrition|Dietary intervention (Liquid food replacement intervention)
57741832|NCT03333850|DEVICE|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
57741833|NCT03333850|DEVICE|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
57741834|NCT03201939|DRUG|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
57741835|NCT03201939|OTHER|Placebo Oral Tablet|Comparator placebo (control arm)
58115747|NCT04372498|DRUG|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
58115748|NCT03720184|PROCEDURE|HAR|"HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk"
58115749|NCT06102889|DIAGNOSTIC_TEST|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
58115750|NCT03256513|OTHER|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
58115751|NCT03256513|OTHER|conventional controlling|control blood pressure by conventional strategy
58115752|NCT00717977|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
58115753|NCT01247688|DRUG|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
58115754|NCT01247688|DRUG|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
57741836|NCT05214833|BEHAVIORAL|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
57741837|NCT05214833|BEHAVIORAL|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
57741838|NCT06579118|OTHER|Laughter yoga|The women in the experimental group were given laughter yoga sessions by the researcher.
58115755|NCT01247688|RADIATION|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
58446592|NCT01324661|BEHAVIORAL|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
58115756|NCT01247688|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
58446593|NCT05143034|DIETARY_SUPPLEMENT|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
58446594|NCT05143034|DIETARY_SUPPLEMENT|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
58446595|NCT06706141|BEHAVIORAL|PowerPoint presentation.|The training included topics such as breast anatomy; breast cancer incidence in Somalia, mortality, morbidity rates; breast cancer risk factors, importance of screening methods; The messages on breast self-examination, health belief models, breast cancer awareness, confidence for BSE, and perceived barriers/benefits for BSE were presented in a PowerPoint presentation. The procedure for performing breast self-examination was described using the English edition of Bristol-Myers Squibb Oncology. In the movie, BSE was made simpler with schematics showing the breast area that needed to be covered. Simple directions on which fingers to use and how to move them over the breast were provided. After the film, the emphasis shifted to helping students gain more self-assurance in their ability to accurately complete each BSE step. Students were encouraged to use proper palpation technique to find lumps by performing a breast examination on a silicone breast model.
58446596|NCT01578681|PROCEDURE|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
58446597|NCT01578681|PROCEDURE|Stretching|Patient will be instructed to do muscle stretching of the thorax
57741839|NCT05517317|COMBINATION_PRODUCT|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
57741840|NCT03597568|DIETARY_SUPPLEMENT|Resveratrol|Oral supplementation for 6 weeks
58115757|NCT02099461|DRUG|Denosumab|Single sucutaneous dose
57741841|NCT03597568|OTHER|Placebo|Oral supplementation for 6 weeks
58115758|NCT02099461|PROCEDURE|Percutaneous core needle breast biopsy|
58115759|NCT01465776|OTHER|laboratory biomarker analysis|Correlative studies
58115760|NCT01465776|OTHER|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
58115761|NCT00410410|DRUG|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
58115762|NCT00410410|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
58115763|NCT00410410|DRUG|abatacept|"\~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
58115764|NCT02370706|DRUG|PIM447|pan-pim inhibitor
58115765|NCT02370706|DRUG|Ruxolitinib|JAK1/JAK2 inhibitor
58446598|NCT04758065|OTHER|Radial pressure waves Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Experimental Group: Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves."
58446599|NCT04758065|OTHER|Therapeutic Exercise and Manual Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy."
58446600|NCT03038295|DRUG|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
58446601|NCT03038295|DRUG|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
58446602|NCT01488526|DRUG|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
58446603|NCT01115673|DRUG|Acetaminophen|Acetaminophen Caplet - single dose
58446604|NCT01115673|DRUG|Placebo Control|0 mg Caplet - single dose
58446605|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
58446606|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
58446607|NCT06726564|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
58446608|NCT03334032|OTHER|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
58446609|NCT06726213|OTHER|Walk and talk|An hour long walk at a slow pace lead by a trained walking leader.
58446610|NCT02588261|DRUG|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
58446611|NCT02588261|DRUG|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
58446612|NCT02588261|DRUG|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
58446613|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
58446614|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
58115766|NCT02370706|DRUG|LEE011|CDK4/6 inhibitor
58115767|NCT03718156|OTHER|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
58115768|NCT05108883|DEVICE|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
58115769|NCT00349895|DEVICE|Coronary stent implantation|Percutaneous Coronary Intervention
58115770|NCT04413747|BEHAVIORAL|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
58115771|NCT04413747|BEHAVIORAL|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
57741842|NCT00204048|BEHAVIORAL|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
57741843|NCT03882333|OTHER|Acute exercise|30 min acute exercise (bicycle at stationary cycle)
57741844|NCT00126412|DRUG|123I-mIBG (meta-iodobenzylguanidine)|
57957390|NCT03393273|DRUG|Elotuzumab|"* Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
57957391|NCT06319105|OTHER|Standard intervention: Offer PrEP choice|This hybrid observational-implementation study will observe the implementation of a choice of oral pre-exposure prophylaxis or long-acting injectable cabotegravir for pre-exposure prophylaxis for all participants.
57957392|NCT00757250|DRUG|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
58312888|NCT06158581|BEHAVIORAL|The Unified Protocol|"UP is a thoroughly-studied, manualized intervention created by researchers at the University of Miami in conjunction with researchers at Boston University. The program was designed to be customizable to meet the needs of people with a variety of diagnoses, allowing more individuals to access emotion regulation resources. The protocol also has different modules to accommodate different developmental levels (UP-Children, UP-Adolescent, UP-Adult). The overall goal of UP is to help clients identify emotions and build new strategies to cope with stressful life situations and distressing emotions.~The protocol is flexible, with each session is about 45 to 60 minutes and the number of sessions varying between 12 - 21 sessions. For the current study, the treatment will take place over 16 sessions. The intervention is cognitive behavioral therapy (CBT) based but also includes hints of mindfulness-based intervention strategies."
58312889|NCT03462680|DIETARY_SUPPLEMENT|niacin|Niacin or nicotinic acid 250 mg tablets
58312890|NCT03462680|OTHER|placebo|placebo tablet
58312891|NCT01030900|BIOLOGICAL|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
58312892|NCT01030900|BIOLOGICAL|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
58312893|NCT01030900|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
58312894|NCT00988780|DRUG|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
58312895|NCT00988780|DRUG|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
58312896|NCT02340949|DRUG|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
58312897|NCT02340949|DRUG|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
58312898|NCT02340949|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
58312899|NCT02340949|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
58312900|NCT05052840|OTHER|Muscle endurance training (MET)|Experimental group will be given MET Program, stretching \& strengthening exercises and Hot packs (for 15 minutes). MET program will include warm up, endurance and cool down exercises. The warm up and cool down period will be consisted of 5-minute walking, and 10 repetitions of stretching exercises. Endurance exercises will consist of 4 levels.
57741845|NCT01632748|DEVICE|Neurotech Vital Device|5 minute treatment
57741846|NCT01632748|DEVICE|Modified Neurotech Vital Device|5 minute stimulation
57741847|NCT00408213|DRUG|mycophenolate mofetil [CellCept]|1g po bid
58115772|NCT04413747|BEHAVIORAL|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
58115773|NCT03892681|OTHER|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
58115774|NCT01671787|DRUG|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
58115775|NCT01671787|DRUG|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
58115776|NCT05127083|RADIATION|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
58115777|NCT04958083|DIAGNOSTIC_TEST|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
58115778|NCT02501850|DRUG|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
58115779|NCT02501850|DRUG|metformin|Treatment with metformin and/or sulphonilurea
58115780|NCT00497471|DRUG|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
58115781|NCT00497471|DRUG|iron (2 mg/kg/daily)|
58446615|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
58446616|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
58115782|NCT03522779|DIETARY_SUPPLEMENT|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
58115783|NCT03522779|OTHER|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
58115784|NCT03522779|OTHER|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
58115785|NCT01347710|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
58115786|NCT01347710|DRUG|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
58115787|NCT06044558|DRUG|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
58115788|NCT06044558|DRUG|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
58446617|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
58446618|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
58446619|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
58446620|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
57741848|NCT00408213|DRUG|Placebo|po bid
57741849|NCT05386888|DRUG|GFH018|Administered as oral
57741850|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
58115789|NCT06044558|DRUG|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
58115790|NCT02406833|DRUG|TGF-β2 antisense oligonucleotide|intravitreal injection
58115791|NCT02406833|PROCEDURE|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
58115792|NCT00395707|DRUG|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
58115793|NCT00395707|DRUG|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
58115794|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
58446621|NCT00203489|DEVICE|KERLIX A.M.D. Gauze|
58115795|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.5mg/0.05 ml
58446622|NCT01994616|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
58446623|NCT02426736|DRUG|Dexamethasone|
58446624|NCT02426736|DRUG|Bupivacaine|
58446625|NCT02426736|PROCEDURE|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
58446626|NCT04112966|PROCEDURE|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
58446627|NCT04112966|OTHER|the health education|The health education for lymphedema prevention.
58115796|NCT05723640|DRUG|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
58115797|NCT05723640|DRUG|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
58115798|NCT05723640|DRUG|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
58115799|NCT05723640|DRUG|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
58115800|NCT01765556|DRUG|ketoconazole|multiple doses of ketoconazole in Period B and C
58115801|NCT01765556|DRUG|vemurafenib|single dose of vemurafenib in Period A and C
58115802|NCT05198128|DRUG|Calcium intravenous infsuion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
58115803|NCT05198128|DRUG|0.9 % saline|0.9 % saline
58115804|NCT06220461|DIETARY_SUPPLEMENT|Folic acid|Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
58115805|NCT00545337|DRUG|Insuline glulisine|
58446628|NCT03833024|DRUG|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
58446629|NCT03833024|DRUG|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
57741851|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
57741852|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
57741853|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
57741854|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
57741855|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
57741856|NCT05386888|DRUG|GFH018|Administered as an IV infusion
57741857|NCT01894295|DIETARY_SUPPLEMENT|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
58115806|NCT05772299|RADIATION|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
58115807|NCT05772299|DEVICE|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
58115808|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
58115809|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
58115810|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
58115811|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
58115812|NCT04373109|BEHAVIORAL|Observation|Observation of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
58115813|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
58115814|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
58115815|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
58115816|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
58115817|NCT00403286|DRUG|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
58115818|NCT00403286|DRUG|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
58115819|NCT00403286|DRUG|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
58115820|NCT00403286|DRUG|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
58115821|NCT01961791|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
58115822|NCT03281421|OTHER|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
58446630|NCT03191266|DEVICE|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
58446631|NCT03191266|DEVICE|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
58446632|NCT01486966|DRUG|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
58446633|NCT01486966|DRUG|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
58446634|NCT01486966|DRUG|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
57741858|NCT01894295|DIETARY_SUPPLEMENT|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
57741859|NCT01911403|PROCEDURE|Manual compression|Closure procedure by Manual compression
58446635|NCT01486966|DRUG|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
58446636|NCT01486966|DRUG|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
58446637|NCT01533506|DRUG|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
58446638|NCT00250237|DRUG|Haloperidol|Haloperidol 1mg twice daily during 72hours
58446639|NCT00250237|DRUG|placebo|Placebo 1mg twice daily during 72hours
58446640|NCT03832335|DIAGNOSTIC_TEST|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
58446641|NCT00063778|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
58446642|NCT00063778|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
57741860|NCT01911403|DEVICE|Angio-Seal|Closure procedure by angio-Seal
57741861|NCT05530213|DEVICE|3D gait analysis on the GRAIL|3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)
58446643|NCT05937061|BIOLOGICAL|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
58446644|NCT05937061|OTHER|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
58446645|NCT05937061|RADIATION|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
58446646|NCT05937061|OTHER|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
58446647|NCT04094974|DEVICE|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
57741862|NCT05530213|OTHER|Weight and height|The subject's body weight and height will be assessed
57741863|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
57741864|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
57741865|NCT01461668|DRUG|Retapamulin|Two times a day for 5 days
57741866|NCT01461668|DRUG|Placebo|Two times a day for 5 days
57957393|NCT03991689|BEHAVIORAL|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
57957394|NCT05442307|BEHAVIORAL|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
57957395|NCT05442307|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
57957396|NCT06128460|DRUG|Zimberelimab|240mg, q3w，8 cycles
57957397|NCT06128460|DRUG|Platinum|cisplatin 40mg/m2 for 5-6 cycles
57957398|NCT06128460|RADIATION|radiotherapy|45-50Gy/1.8Gy/25-28f
57957399|NCT00950508|PROCEDURE|High volume plasma exchange|3 high volume plasma exchanges over 3 days
57957400|NCT00950508|PROCEDURE|Standard medical treatment|Standard medical treatment
57957401|NCT03248401|DRUG|Cilostazol|Cilostazol 200 mg/day
57957402|NCT03248401|DRUG|Aspirin|Aspirin 100 mg/day
57957403|NCT02057315|DRUG|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
57957404|NCT02057315|DRUG|Placebo|One dose of matching placebo over 3 bilateral applications.
57957405|NCT05988476|OTHER|Exercise|5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
58115823|NCT00386724|DEVICE|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
58115824|NCT00386724|DEVICE|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
58115825|NCT00782002|BIOLOGICAL|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
58115826|NCT02768623|OTHER|Pharmacist led Asthma Management|
58115827|NCT02768623|OTHER|Pharmacist Intervention (when requested by patient)|
58115828|NCT00146770|BIOLOGICAL|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
58115829|NCT00146770|BIOLOGICAL|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
58115830|NCT00146770|BIOLOGICAL|placebo|Placebo for 26 weeks
58115831|NCT05937113|BIOLOGICAL|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
58115832|NCT01211769|DRUG|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
58115833|NCT01211769|DRUG|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
58115834|NCT01211769|DRUG|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
58115835|NCT01211769|DRUG|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
58115836|NCT00225199|DRUG|Visanne (BAY86-5258, SH T00660AA)|orally once daily
58115837|NCT00225199|DRUG|Placebo|orally once daily
58446648|NCT04508426|DRUG|[14C]AR882|Single dose of \[14C\]AR882
57957406|NCT05988476|DEVICE|Pulsed Electromagnetic Field Therapy|5 day/week, two week,two sessions consisting of 180 minutes
58446649|NCT06719804|DRUG|Propranolol|Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
58446650|NCT01450865|DRUG|flupirtine|Potassium channel opener (SNEPCO)
58446651|NCT01800097|DRUG|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
58446652|NCT01800097|DRUG|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
57957407|NCT00152542|DRUG|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
57957408|NCT00152542|DRUG|Placebo|No iNO given for days 1-7
57957409|NCT00018265|BEHAVIORAL|Task specific endurance training|
57957410|NCT00018265|BEHAVIORAL|Tai Chi|
57957411|NCT00411554|DRUG|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
57957412|NCT00411554|DRUG|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
57957413|NCT00641498|BEHAVIORAL|Psychotherapy|Individual supportive
57957414|NCT02061865|DRUG|REGN2176-3|
57957415|NCT00262873|DRUG|bortezomib|
57957416|NCT01856881|DRUG|AMG 876|Ascending multiple doses of study drug administered SC
57957417|NCT00003338|PROCEDURE|immunoscintigraphy|
57957418|NCT00003338|RADIATION|technetium Tc 99m epratuzumab|
57957419|NCT03608943|OTHER|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
57957420|NCT05980442|DEVICE|Navigated total knee arthroplasty|Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
57957421|NCT05980442|DEVICE|Robot assisted total knee arthroplasty|Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
58115838|NCT05338086|DRUG|MB09 (denosumab biosimilar)|PFS 60 mg/mL solution,
58115839|NCT05338086|DRUG|EU-Prolia|PFS 60 mg/mL solution, administered as subcutaneous injection
58115840|NCT05338086|DIETARY_SUPPLEMENT|Elemental Calcium|at least 1000 mg daily
58115841|NCT05338086|DIETARY_SUPPLEMENT|Vitamin D|at least 400 IU daily
58115842|NCT01930084|OTHER|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
58115843|NCT01930084|OTHER|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
58115844|NCT01930084|BEHAVIORAL|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
58115845|NCT01930084|OTHER|Non-cash Financial Incentives|Non-cash Financial Incentives
58115846|NCT01467063|DIETARY_SUPPLEMENT|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
58115847|NCT01467063|DIETARY_SUPPLEMENT|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
58115848|NCT04505410|DRUG|Tofacitinib|10mg tofacitinib tablets taken twice daily for eight weeks
58115849|NCT04505410|OTHER|Fast Mimicking Diet|FMD is a five day meal plan that includes foods such as soups, snacks, bards, teas and supplements (omega-3 fatty acids) for a total of 66 items per box. The diet is plant-based, gluten free and dairy free without any artificial preservatives, chemicals or biologically active ingredients.
58115850|NCT04505410|DRUG|Ustekinumab induction|Participant will be initiated with ustekinumab induction therapy as second line biologic therapy
58115851|NCT04505410|DRUG|Infliximab induction|Participant will be initiated with infliximab induction therapy as second line biologic therapy
58446653|NCT03222687|DRUG|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
57957422|NCT02239276|DRUG|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
58115852|NCT00634179|DRUG|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
58115853|NCT00634179|BIOLOGICAL|Rituximab|Rituximab 375 mg/m²
58115854|NCT00634179|DRUG|Doxorubicin|Doxorubicin 50 mg/m²
58115855|NCT00634179|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m²
58446654|NCT03222687|DRUG|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
58446655|NCT03415282|DRUG|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
58458557|NCT02942212|DRUG|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke \>10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
57957423|NCT01617460|DRUG|Aripiprazole|Flexibly dose administered orally once daily
57957424|NCT04672759|DRUG|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
57957425|NCT04672759|DRUG|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
58115856|NCT00634179|DRUG|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
58115857|NCT00634179|DRUG|Prednisone|Prednisone 100 mg/day given orally on days 1-5
58115858|NCT01452529|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
58115859|NCT01452529|DRUG|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
58115860|NCT03980795|OTHER|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
58115861|NCT02981797|OTHER|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
58115862|NCT01830556|DRUG|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
58115863|NCT01073020|DEVICE|Allergan Adjustable Gastric Band Surgery|
58115864|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group
58115865|NCT01073020|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) Surgery|
58115866|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
58115867|NCT02469974|DRUG|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
58115868|NCT02469974|DRUG|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
58115869|NCT02469974|DRUG|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
58115870|NCT00319449|DRUG|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
58115871|NCT00319449|DRUG|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
58115872|NCT00319449|DRUG|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
58115873|NCT01577095|OTHER|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
58115874|NCT01577095|DRUG|TZD|Rosiglitazone 8 mg single dose
58115875|NCT04929496|PROCEDURE|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
58115876|NCT01573923|BIOLOGICAL|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
58115877|NCT01573923|BIOLOGICAL|Conventional therapy|Conventional therapy without cell therapy
58115878|NCT02896660|DEVICE|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
58115879|NCT06528444|DRUG|Grup 1 placebo|placebo 1 capsule (6 mg) /day for 7 days.
58115880|NCT06528444|DRUG|Grup 2 dexametasona|dexamethasone 1 capsule (6 mg)/day for 7 days
58115881|NCT06113523|BIOLOGICAL|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
58115882|NCT05497011|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
58115883|NCT03216330|OTHER|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
58115884|NCT05925101|BEHAVIORAL|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
58115885|NCT05925101|BEHAVIORAL|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
58115886|NCT05925101|BEHAVIORAL|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
58458558|NCT02942212|BEHAVIORAL|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
57957426|NCT04693962|DIAGNOSTIC_TEST|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
57957427|NCT03377907|DRUG|ketamine in hematoma block|ketamine used in local hematoma block only
57957428|NCT03377907|DRUG|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
58458559|NCT02942212|BEHAVIORAL|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
58115887|NCT05925101|BEHAVIORAL|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
58115888|NCT05925101|BEHAVIORAL|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
58115889|NCT05925101|BEHAVIORAL|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
58115890|NCT05925101|BEHAVIORAL|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
58115891|NCT05925101|BEHAVIORAL|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
58115892|NCT00002806|DRUG|lomustine|
58115893|NCT00002806|DRUG|procarbazine hydrochloride|
58115894|NCT00002806|DRUG|vincristine sulfate|
58115895|NCT00002806|RADIATION|low-LET photon therapy|
58115896|NCT00119977|PROCEDURE|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
58115897|NCT05261113|PROCEDURE|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
58115898|NCT00788528|DRUG|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
58115899|NCT01592799|PROCEDURE|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
58115900|NCT01592799|OTHER|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: \< 6 months; 6-23 months; 24-59 months; \> 5 years.
58115901|NCT03562403|DEVICE|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
58115902|NCT00698022|DRUG|Risperidone|risperidone daily for 28 days
58115903|NCT00698022|DRUG|Mifepristone|mifepristone daily for 28 days
58115904|NCT00698022|DRUG|Risperidone-matched placebo|risperidone-matched placebo daily for 28 days
58115905|NCT00698022|DRUG|Mifepristone-matched placebo|mifepristone-matched placebo daily for 28 days
58115906|NCT04938206|PROCEDURE|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
58115907|NCT01518491|DRUG|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
58115908|NCT01518491|OTHER|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
58115909|NCT00943800|DRUG|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
58115910|NCT00943800|PROCEDURE|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
58115911|NCT00943800|PROCEDURE|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
58115912|NCT00943800|DRUG|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
58115913|NCT00943800|DRUG|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
58115914|NCT03639597|DEVICE|VytronUS Ablation System|
58115915|NCT00034515|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|
58115916|NCT01768000|BEHAVIORAL|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
58458560|NCT02942212|BEHAVIORAL|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
58115917|NCT01736410|DRUG|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
58115918|NCT05958277|DRUG|Vitamin B3|Vitamin B3 upto 16 mg/day
58115919|NCT05958277|DRUG|Vitamin B12|Vit B12 upto 250 mcg per day
58312901|NCT05052840|OTHER|Conventional Treatment|"Conventional treatment group will be given hot packs (for 15 minutes) and Strengthening \& stretching exercise program including:~STRETCHING EXERCISES (lumbar extensor muscles, iliopsoas muscles, hamstring muscles, gastrocnemius muscles and pectoral muscles).~STRENGTHENING EXERCISES (rectus abdominus crunch, oblique crunch, pelvic elevation, single leg pelvic elevation, lumbal spine extension, on hands and knees position with the raise of one leg, on hands and knees position with the raise of opposite arm and leg). Each exercise will be repeated 10 times."
58312902|NCT04530071|BIOLOGICAL|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10\^7 cells)
58312903|NCT04530071|BIOLOGICAL|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10\^7 cells)
58312904|NCT04530071|BIOLOGICAL|Placebo|HA + saline + placebo comparator
58115920|NCT01858714|BEHAVIORAL|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
58312905|NCT03720561|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
58312906|NCT04399681|DEVICE|Bedside lung ultrasound|Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.
58458561|NCT01131988|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
58115921|NCT01858714|BEHAVIORAL|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
58115922|NCT01858714|BEHAVIORAL|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
58115923|NCT01962883|OTHER|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
58115924|NCT00831727|BEHAVIORAL|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
57957429|NCT03377907|DRUG|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
57957430|NCT00934986|OTHER|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~* Stage A patient who does not require a treatment: one sample the day of enrollment.~* Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
57957431|NCT00568646|DRUG|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
58115925|NCT00831727|BEHAVIORAL|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
58312907|NCT02225587|BIOLOGICAL|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
58312908|NCT02225587|BIOLOGICAL|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
58312909|NCT02225587|BIOLOGICAL|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
58312910|NCT01380366|DRUG|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
58446656|NCT04017091|DIAGNOSTIC_TEST|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
58446657|NCT06527521|PROCEDURE|Traumatologic surgery|Patients undergoing trauma surgery
58446658|NCT01553019|RADIATION|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
58312911|NCT01380366|PROCEDURE|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
58446659|NCT01553019|DRUG|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
58446660|NCT02650180|DEVICE|Soberlink Cellular Device|Alcohol Breath Analyzer
58446661|NCT02691559|DEVICE|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
58446662|NCT06342518|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.
58446663|NCT06342518|DEVICE|Sham ESWT|The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock
57957432|NCT00085761|DRUG|Capsaicin Dermal Patch|
57957433|NCT02303379|OTHER|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
58115926|NCT02232048|OTHER|Transthoracic Echocardiogram|
58115927|NCT02739984|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection with an automated mini doser
58115928|NCT02739984|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
58115929|NCT02658409|BIOLOGICAL|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
58115930|NCT02658409|BIOLOGICAL|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
58115931|NCT01167920|OTHER|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
58312912|NCT01380366|PROCEDURE|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
58312913|NCT01380366|OTHER|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
58312914|NCT01380366|OTHER|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
58312915|NCT01380366|OTHER|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
58312916|NCT01922583|DRUG|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
58312917|NCT03413735|OTHER|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
58312918|NCT03413735|OTHER|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
58312919|NCT02576600|DEVICE|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
58312920|NCT02576600|OTHER|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
58312921|NCT02576600|DRUG|Propofol|TCI
58312922|NCT02576600|DRUG|Remifentanil|TCI
58312923|NCT02699164|DEVICE|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
58312924|NCT02699164|OTHER|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
58312925|NCT02699164|OTHER|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
58312926|NCT05668273|OTHER|education with simulated patient|Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
58312927|NCT05668273|OTHER|education with simulator|Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
58312928|NCT05668273|OTHER|control group|Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
58312929|NCT03287765|DRUG|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
58312930|NCT00758888|PROCEDURE|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
58312931|NCT00758888|PROCEDURE|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
58115932|NCT03863275|DEVICE|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
58312932|NCT00758888|OTHER|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
58312933|NCT02130440|DRUG|Resveratrol nasal spray|
58312934|NCT01969526|OTHER|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
58312935|NCT02646085|DRUG|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
58312936|NCT01113099|OTHER|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
57741867|NCT06477575|DEVICE|neurocognitive therapy based on new technologies|"The cognitive neurorehabilitation program is based on gaming through the use of the Nintendo Switch device. The following games have been chosen: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder, since they are games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Hardware: Nintendo Switch Software: 60 in 1 game Games: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder. Therapy time: 30 minutes effective. Number of Sessions: 2 per week / Number of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
58115933|NCT03863275|OTHER|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
58115934|NCT04013256|OTHER|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
58115935|NCT04013256|OTHER|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
58115936|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
58115937|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
58115938|NCT04047212|DIAGNOSTIC_TEST|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
58115939|NCT04047212|DIAGNOSTIC_TEST|periodontal examination|Periodontal clinical examination to all by periodontal charting
58115940|NCT02002247|DRUG|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
58115941|NCT02002247|DRUG|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
58115942|NCT02585258|DRUG|Prednisolone|1 capsule containing a tablet of 5 mg prednisolone/ day
58115943|NCT02585258|DRUG|Placebo|1 capsule containing a placebo tablet / day
58115944|NCT03867591|OTHER|Gastro-AD®|"The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents."
58115945|NCT03867591|OTHER|Placebo|The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
58115946|NCT03871400|PROCEDURE|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
58312937|NCT06163859|BEHAVIORAL|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
58446664|NCT06342518|BEHAVIORAL|Resting Splint , Exercises and ice|Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
58458562|NCT01416818|DRUG|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
58458563|NCT01416818|DRUG|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
58458564|NCT01416818|DRUG|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
58115947|NCT03818737|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
58115948|NCT03818737|BIOLOGICAL|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
58115949|NCT03818737|BIOLOGICAL|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
58115950|NCT03818737|DRUG|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
58115951|NCT04417790|DIAGNOSTIC_TEST|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
58115952|NCT02902731|DRUG|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
58115953|NCT02902731|DRUG|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
58115954|NCT02779582|DRUG|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
58115955|NCT02779582|DRUG|Placebo|pill with no effect
58115956|NCT05237700|OTHER|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
58446665|NCT02950480|DRUG|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
58446666|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
58446667|NCT05187078|PROCEDURE|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
57741868|NCT06477575|OTHER|conventional neurocognitive therapy|"The cognitive neurorehabilitation program for group active comparator is based on playing more conventional board games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Traditional games and token book. Games: Dobble, Lynx, Crazy cups, Jungle speed, animalea, ghost. Card: Stimulate and learn level 3 and 4. Therapy time: 30 minutes effective. No. of sessions: 2 per week / No. of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
57741869|NCT01881126|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
57741870|NCT01881126|DRUG|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
57957434|NCT02303379|OTHER|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
57957435|NCT02303379|OTHER|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
57957436|NCT03451773|DRUG|M7824|1,200 or 500mg every 2 weeks by intravenous (IV) infusion
57957437|NCT03451773|DRUG|Gemcitabine|Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
57957438|NCT02242955|DRUG|Diazepam|40 mg per day.
57957439|NCT03306732|DRUG|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
57957440|NCT03306732|DRUG|Normal saline (100ml)|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
57957441|NCT05318391|DIAGNOSTIC_TEST|Gene expression profile|"Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)"
57957442|NCT00002655|PROCEDURE|cryosurgery|
57957443|NCT03958448|PROCEDURE|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
57957444|NCT03958448|PROCEDURE|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
57957445|NCT03958448|PROCEDURE|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
57957446|NCT04434274|DRUG|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
57957447|NCT02277509|BEHAVIORAL|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
57957448|NCT02277509|BEHAVIORAL|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
57957449|NCT05832281|DRUG|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
57957450|NCT05832281|DRUG|Placebo|Placebo for Purysis
57957451|NCT04442230|BIOLOGICAL|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
57957452|NCT04442230|OTHER|Placebo|Normal saline
57957453|NCT03632421|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58115957|NCT01814579|DEVICE|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
58115958|NCT01814579|DEVICE|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
58115959|NCT02705079|OTHER|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
57741871|NCT01881126|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
57741872|NCT01881126|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
57741873|NCT01380340|OTHER|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
57741874|NCT06542874|DRUG|NNC0487-0111 subcutanous|NNC0487-0111 administered subcutanously (under the skin)
57741875|NCT06542874|DRUG|Placebo (NNC0487-0111 subcutanous)|NNC0487-0111 placebo administered subcutanously (under the skin)
57741876|NCT06542874|DRUG|NNC0487-0111 oral|NNC0487-0111 administered orally (in the mouth)
58115960|NCT04936620|PROCEDURE|Duroplasty|Expansion Duroplasty
57741877|NCT06542874|DRUG|Placebo (NNC0487-0111 oral)|NNC0487-0111 placebo administered orally (in the mouth)
57741878|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
57741879|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
57741880|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
57741881|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
57741882|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
57741883|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
58115961|NCT04936620|PROCEDURE|Spinal surgery|Spinal surgery including laminectomy
58115962|NCT06429098|DRUG|Venetoclax|Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
58115963|NCT06429098|DRUG|azacitidine|Given SC
58446668|NCT05187078|PROCEDURE|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
58446669|NCT06328673|DRUG|DM919|Anti-MICA/MICB monoclonal antibody
58446670|NCT06328673|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
58446671|NCT04303559|DRUG|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
58446672|NCT04303559|DRUG|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
58458565|NCT03284177|DRUG|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
58458566|NCT03284177|DRUG|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
57741884|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
58115964|NCT06429098|DRUG|decitabine|Given IV
58115965|NCT06429098|DRUG|Cytarabine|Given IV
58115966|NCT06019325|PROCEDURE|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
58115967|NCT02275988|DRUG|K-877|
58115968|NCT02275988|DRUG|Clarithromycin|
58458567|NCT03284177|OTHER|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
58458568|NCT03432507|OTHER|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
58115969|NCT00673361|DRUG|Concurrent decrescendo biochemotherapy regimen|"* Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days"
58115970|NCT00673361|DRUG|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
58446673|NCT04671264|DEVICE|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
58115971|NCT00878345|DRUG|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
58115972|NCT00878345|DRUG|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
58312938|NCT05232617|OTHER|Rheumatological rehabilitation training|Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
58312939|NCT02313051|DRUG|Everolimus|mTOR inhibitor
58312940|NCT02313051|DRUG|Goserelin|
58312941|NCT02313051|DRUG|Letrozole|
58446674|NCT02275663|DRUG|Azacytidine|
58446675|NCT02275663|DRUG|Fludarabine|
58446676|NCT02275663|DRUG|Cytarabine|
58446677|NCT02275663|DRUG|Filgrastim|G-CSF
58446678|NCT01314001|DRUG|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
58446679|NCT01314001|DRUG|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
58446680|NCT01314001|DRUG|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
58446681|NCT03841422|PROCEDURE|video-assisted nasal self-packing|video-assisted nasal self-packing
58446682|NCT04713956|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
58446683|NCT04713956|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
58446684|NCT04713956|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
57741885|NCT06140524|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
58115973|NCT05757492|DRUG|CHS-006 (anti-TIGIT)|Arm A participants will receive CHS-006 administered via IV Q3W.
58115974|NCT05757492|DRUG|toripalimab (anti-PD-1)|Arm B participants will receive toripalimab administered via IV Q3W.
58115975|NCT01626885|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
58115976|NCT05962177|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
58115977|NCT05962177|OTHER|Blood withdrawal|Blood withdrawal
58115978|NCT05962177|OTHER|Neuropsychological tests|Neuropsychological tests
58115979|NCT01541956|DRUG|Metformin|500 mg twice daily
58446685|NCT04713956|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
58446686|NCT04713956|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
58446687|NCT06009835|OTHER|Recommended treatment plan|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
58446688|NCT01862523|BIOLOGICAL|Capsaicin|Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
58115980|NCT01541956|DRUG|vildagliptin|Vildagliptin 50 mg twice daily
58446689|NCT01862523|BIOLOGICAL|diluent|diluent
58446690|NCT06466460|OTHER|Motion based - Virtual cycling|To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment. (Intervention study)
58446691|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
57741886|NCT06733480|DEVICE|Band Connect|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
57741887|NCT03129828|DRUG|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
57741888|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
58115981|NCT02041494|DEVICE|Ventralight|
58115982|NCT02041494|DEVICE|Strattice|
58115983|NCT04776174|DEVICE|Ultrasound using the telerobotic Melody system|The children will first have a telerobotic ultrasound abdominal, pulmonary or cardiac followed by a classical ultrasound.
58115984|NCT04912466|DRUG|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
58115985|NCT01517724|DRUG|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
58115986|NCT05480618|BEHAVIORAL|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~1. frequency (between 0.25 and 0.1 Hz)~2. Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~3. with and without ujjayi (yogic throat restriction)~4. with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
58115987|NCT05851235|OTHER|Prehabilitation course|During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
58312942|NCT00992888|DEVICE|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
58312943|NCT01508312|DRUG|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
58312944|NCT01508312|DRUG|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
58446692|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
58446693|NCT04851054|PROCEDURE|Surgery for colon cancer with intention to cure|Surgery by open or laparoscopic approach
57741889|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
58115988|NCT03946215|OTHER|Each participant will perform:|Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
58312945|NCT00599001|DRUG|SD-101|Single subcutaneous escalating dose
58312946|NCT00599001|DRUG|placebo|placebo
58446694|NCT04444466|DRUG|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
58446695|NCT04444466|OTHER|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
57741890|NCT00797654|BEHAVIORAL|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
57741891|NCT00797654|BEHAVIORAL|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
58312947|NCT03612219|DRUG|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
58312948|NCT03612219|RADIATION|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
58446696|NCT03625284|DIETARY_SUPPLEMENT|Placebo|Edible oil
58446697|NCT03625284|DIETARY_SUPPLEMENT|FucoVital|Microalgae oil extract
58446698|NCT06727396|DRUG|CKD-508 Tablet|Investigational drug
58446699|NCT06727396|DRUG|Placebo Tablet|Placebo
58458569|NCT00350025|DRUG|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
57741892|NCT06282809|DEVICE|HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy|Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
57741893|NCT00421551|DRUG|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
58312949|NCT03612219|DRUG|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
58312950|NCT06515275|OTHER|Education via video (QR code links)|Video education on self-administered medications for women undergoing IVF treatment
58458570|NCT00350025|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
58115989|NCT03787745|PROCEDURE|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
58115990|NCT03787745|PROCEDURE|Conventional|State of the art primary PCI, however thrombectomy is not allowed
58115991|NCT01280370|PROCEDURE|Abdominal surgery|intraoperative mesh implantation
58115992|NCT05887830|DRUG|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
58115993|NCT05887830|OTHER|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
57741894|NCT00421551|DRUG|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
58115994|NCT03140306|DIAGNOSTIC_TEST|Patients who have had split dose CT|Computed tomography
58115995|NCT00631111|DRUG|effervescent ibuprofen tablets|
58115996|NCT00631111|DRUG|effervescent Aspirin plus Vitamin C tablets|
58115997|NCT00631111|DRUG|ibuprofen tablets|
58115998|NCT00631111|DRUG|placebo|
58115999|NCT03940313|PROCEDURE|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
58116000|NCT02413073|PROCEDURE|Whole Body Vibration|We wil use vibration in patients with kidney disease
58116001|NCT02976012|DRUG|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
58116002|NCT02976012|PROCEDURE|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
58116003|NCT03220685|BIOLOGICAL|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
58116004|NCT03363282|PROCEDURE|Pterygium Excision|Pterygium excision is the first step for repair
57741895|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using NuSmile Zirconia crowns|Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect. These crowns have high flexural strength, allowing them to resist crack propagation. The additional benefits of these crowns are the ability to replace metals due to extremely high strength and toughness, higher resistance to chemicals, and superior erosion resistance
58116005|NCT03070210|PROCEDURE|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
58116006|NCT03070210|PROCEDURE|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
58116007|NCT05751655|OTHER|Prehospital care following drowning accident|Prehospital care provided by the emergency medical service 83 (SAMU 83)
58116008|NCT02778178|DRUG|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
58116009|NCT02778178|DRUG|Placebo|20 mL saline 0.9%, per side
58116010|NCT02778178|DEVICE|ultrasound|
58116011|NCT00865553|BEHAVIORAL|computer-assisted smoking cessation intervention|
58116012|NCT00865553|OTHER|cancer prevention|
58116013|NCT00865553|OTHER|educational intervention|
58116014|NCT00865553|OTHER|survey administration|
58116015|NCT06039670|PROCEDURE|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
58116016|NCT04543981|DIAGNOSTIC_TEST|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
58116017|NCT01104233|DEVICE|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
58116018|NCT03776851|DRUG|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
58116019|NCT05668871|DRUG|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
58116020|NCT00038883|DRUG|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
58116021|NCT03355742|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
58116022|NCT03355742|DRUG|DAPT|1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
58116023|NCT02933983|OTHER|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
58116024|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
58116025|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
58116026|NCT01313728|DRUG|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
58446700|NCT04104737|DEVICE|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
58446701|NCT05367791|OTHER|POSTUR|Training sessions without any stimulation
58446702|NCT05367791|OTHER|Localised Vibration|Training sessions with localized vibration
57741896|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using BioFlx crowns|The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns. The Bioflex crown may provide a promising result in terms of the clinician's and parental satisfaction as aesthetic is a prime concern for parents and children in this era. The limitations of the studies on this type of crowns will require more studies with more detailed clinical observation and larger sample size to provide more rigorous results.
57741897|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using Digital VITA ENAMIC crowns (CAD/CAM blanks)|is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
58116027|NCT01313728|DRUG|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
58116028|NCT02224521|DRUG|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
58116029|NCT02224521|DRUG|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
58446703|NCT05367791|OTHER|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
58116030|NCT02224521|DRUG|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
57741898|NCT06733753|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
58116031|NCT02224521|DRUG|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
58116032|NCT02224521|DRUG|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
58116033|NCT02224521|DRUG|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
58116034|NCT00783679|DEVICE|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
58116035|NCT02346539|DRUG|Nicotine polacrilex|Single Acute dose
58116036|NCT01497938|DEVICE|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
58312951|NCT00712504|DRUG|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
58312952|NCT00712504|DRUG|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
58312953|NCT01041911|DRUG|Euphorbia tablets|50 mg, tablet, once daily, 14 days
58312954|NCT01041911|DRUG|Euphorbia tablets|100 mg, tablet, once daily, 14 days
58312955|NCT01041911|DRUG|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
58312956|NCT01041911|DRUG|Placebo tablets|placebo, tablet, once daily, 14 days
58312957|NCT04582799|DEVICE|ECCO2R|Extracorporeal CO2 Removal
58312958|NCT04582799|DEVICE|NIV|Non-invasive ventilation
58312959|NCT04121143|BIOLOGICAL|IL-17A Antagonist|SHR-1314 subcutaneous injection
58312960|NCT04121143|BIOLOGICAL|Placebos|placebo subcutaneous injection to maintain consistency and to prevent blindness
58312961|NCT00984867|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
58312962|NCT00984867|DRUG|Placebo|Matching placebo tablet
58116037|NCT01497938|DEVICE|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
58116038|NCT02397200|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
58116039|NCT02397200|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
58116040|NCT05296681|DRUG|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
58116041|NCT05025332|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
58116042|NCT00472446|DRUG|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
58116043|NCT00472446|DRUG|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
58116044|NCT00275028|DRUG|cediranib maleate|Given orally
58116045|NCT06302712|BEHAVIORAL|Traditional Islamically Integrated Psychotherapy|Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.
58116046|NCT02783391|DEVICE|ECoG and intracortical electrodes|
58116047|NCT00647049|DRUG|methotrexate|8000mg/m2 i.v., max. 2 cycles
58116048|NCT00647049|DRUG|Rituximab|375mg/m2, max. 8 times
58116049|NCT00647049|DRUG|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
58116050|NCT00647049|DRUG|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
58116051|NCT00647049|DRUG|Carmustin|400mg/m2 i.v. for 1 day
58116052|NCT03011463|DRUG|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
58116053|NCT03011463|DRUG|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
58116054|NCT03011463|DRUG|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
58116055|NCT03011463|DRUG|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
58116056|NCT00623623|PROCEDURE|primary PCI|Standard primary PCI
58116057|NCT00623623|DRUG|enoxaparin|Adjunctive treatment
57741899|NCT04887454|BEHAVIORAL|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
57741900|NCT04887454|BEHAVIORAL|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
58116058|NCT00623623|PROCEDURE|catheterisation|Routine or rescue coronary intervention
58116059|NCT00623623|DRUG|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
58116060|NCT00623623|DRUG|clopidogrel|Adjunctive treatment
58116061|NCT03349606|DRUG|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
58116062|NCT03349606|RADIATION|[C-11]FLB 457|PET radiotracer
58116063|NCT03205514|DIAGNOSTIC_TEST|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
58116064|NCT02036281|DRUG|Substance P-Saporin|
58116065|NCT01723956|PROCEDURE|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
58116066|NCT01723956|PROCEDURE|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
58116067|NCT05612347|DIAGNOSTIC_TEST|FIT|Annual FIT
58116068|NCT05612347|DIAGNOSTIC_TEST|Colonoscopy|One time surveillance colonoscopy
58116069|NCT03797976|DEVICE|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
58116070|NCT03418883|OTHER|Mirror therapy|
58116071|NCT00362700|DRUG|Clevudine|
58116072|NCT00004498|GENETIC|Adenoviral Vector-Mediated Gene Transfer|
58116073|NCT06484023|OTHER|Survey|quality of life questionnaire
58116074|NCT01172353|DRUG|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
58116075|NCT01172353|DRUG|saline|hydration with saline 1ml/Kg/h for 6 hours
58116076|NCT03315156|DIAGNOSTIC_TEST|Electrogustometery|Taste assessment using EGM
58116077|NCT03158337|BEHAVIORAL|Aerobic exercise|
58116078|NCT03502629|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
58312963|NCT00065871|BEHAVIORAL|Contraceptive Screening by Pharmacist|
58312964|NCT00065871|BEHAVIORAL|Contraceptive Prescribing by Pharmacist|
58116079|NCT02473991|RADIATION|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
58116080|NCT00947427|DRUG|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
58116081|NCT00947427|DRUG|Placebo|Placebo subcutaneous injections
58116082|NCT00945425|DRUG|AZD7325|oral capsule, once or twice daily, 7 days
58116083|NCT00945425|DRUG|Placebo|oral capsule, once or twice daily, 7 days
58116084|NCT05890456|BEHAVIORAL|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
58116085|NCT05890456|BEHAVIORAL|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
58116086|NCT03603236|DIAGNOSTIC_TEST|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
58116087|NCT03603236|DIAGNOSTIC_TEST|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
58116088|NCT02649231|DRUG|Ketamine|0.8 mg/kg ketamine
58116089|NCT02649231|DRUG|Placebo|0.9% saline
58312965|NCT01200641|DRUG|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
58116090|NCT02649231|BEHAVIORAL|Psychological Therapy|Manualised relapse prevention based CBT
58116091|NCT02649231|BEHAVIORAL|Alcohol Education|Simple education about alcohol effects
58116092|NCT02495597|OTHER|no intervention - just observational|
58116093|NCT02231320|DRUG|Berodual® Respimat® - inhaler|
58116094|NCT00681863|DRUG|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
57741901|NCT04887454|OTHER|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
57741902|NCT02110641|BEHAVIORAL|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
58312966|NCT01200641|DRUG|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
58312967|NCT01200641|DRUG|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
58116095|NCT00681863|DRUG|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
58116096|NCT00681863|DRUG|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
58116097|NCT00681863|DRUG|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
58116098|NCT00681863|DRUG|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
58312968|NCT00754741|BEHAVIORAL|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
58116099|NCT02505776|DRUG|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
58116100|NCT01165814|DRUG|Naproxen Tramadol|
58116101|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
58116102|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
58116103|NCT06057298|PROCEDURE|Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)|"Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model:~* Oxaliplatin 360 mg/mq for 30 min.~* Oxaliplatin 200 mg/mq for 120 min.~* Mitomycin-C 35mg/mq for 60 min.~* Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)"
58446704|NCT01691157|OTHER|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
57741903|NCT05835297|OTHER|Physical exercise interventions|Participants will undergo a 12-week multicomponent exercise regimen, twice per week on non-consecutive days for 45-60 min each. The session will be divided into 4 min of warm-up; range of motion exercises of upper and lower extremities, followed by light walking, then 8 min balance exercises, followed by 15 min strength exercises; two sets of 13-15 repetitions maximum of chair rises with progression, two sets of 13-15 repetitions of modified squats (holding a chair backrest if needed) with progression, 2 sets of 20-30 repetitions of seated or 2 sets of 13-15 repetitions of standing calf raises, then 15 min aerobic exercises; five 3-min bouts of walking between two strengthening exercises and/or 2 balance exercises, finally 3 min cool down exercises of light walking and stretching exercises.
57741904|NCT04101305|DIAGNOSTIC_TEST|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
57741905|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
57741906|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
57741907|NCT05909332|DRUG|Antivascular therapy|BP102 (anti VEGFR)
58116104|NCT01923246|BEHAVIORAL|Single WEB intervention|Brief WEB intervention recieved once
58446705|NCT01691157|OTHER|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
58446706|NCT04276233|DRUG|Mepolizumab|Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
58446707|NCT04276233|DRUG|Salbutamol|Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
58446708|NCT06514001|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
58446709|NCT02842294|DRUG|Bevacizumab|
58116105|NCT01923246|BEHAVIORAL|Repeated WEB intervention|WEB intervention recieved twice.
58116106|NCT01923246|BEHAVIORAL|Single IVR intervention|IVR intervention recieved once
57741908|NCT05909332|DRUG|Chemotherapy|ddEC-P
57741909|NCT03215797|DRUG|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
58116107|NCT01923246|BEHAVIORAL|Repeated IVR intervention|IVR intervention recieved twice
58116108|NCT02758054|BEHAVIORAL|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
58116109|NCT02742779|DRUG|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
58446710|NCT00195533|DRUG|piperacillin-tazobactam|
58446711|NCT00195533|DRUG|glycopeptide|
58446712|NCT06169553|OTHER|Holistic injection-related injection treatment|Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
58446713|NCT04451941|DEVICE|Experimental: RecoveriX with individual EEG calibration|RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
58116110|NCT02742779|DRUG|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
58116111|NCT02245776|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
58116112|NCT04160078|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) Intervention|"* 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
58116113|NCT01982383|DEVICE|Micropulse Laser Treatment|
58116114|NCT01982383|OTHER|No treatment|
58116115|NCT06503796|DRUG|Lamivudine|4mg/kg/d, oral
58116116|NCT06503796|DRUG|Interferon|Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
58116117|NCT01423435|DRUG|TRK-100STP|oral
58116118|NCT03154320|OTHER|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
58116119|NCT03154320|OTHER|Standard treatment|Standard treatment
58116120|NCT03945565|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
58116121|NCT03015142|DEVICE|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
58116122|NCT01752920|DRUG|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
57741910|NCT03215797|DRUG|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
57741911|NCT02498483|DRUG|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
57741912|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
58116123|NCT01752920|DRUG|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
58116124|NCT01752920|DRUG|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
58116125|NCT01752920|DRUG|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
58116126|NCT02462421|DRUG|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
58116127|NCT00667927|DRUG|Busulfan|See Detailed Description section for description of treatment plan.
57741913|NCT06331884|DRUG|Placebo|Application of placebo
57741914|NCT04837066|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
58116128|NCT00667927|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
58116129|NCT00667927|DRUG|Mesna|See Detailed Description section for description of treatment plan.
58116130|NCT01214330|DEVICE|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
58116131|NCT06259110|DIAGNOSTIC_TEST|Multiplex PCR|multiplex PCR is a molecular biology technique that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample
58116132|NCT01045499|DEVICE|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
58116133|NCT04638985|BIOLOGICAL|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
58116134|NCT04638985|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
58116135|NCT04638985|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
58116136|NCT04638985|BIOLOGICAL|MMR|MMR at the age of 18 month old
58116137|NCT05042336|DRUG|camrelizumab/lenvatinib combined with TACE|"Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w"
58116138|NCT05048732|DRUG|18F-FluorApoTrace|-The dose of 18F-FluorApoTrace to be given is 5 mCi
58312969|NCT00754741|BEHAVIORAL|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
58446714|NCT04451941|DEVICE|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
57741915|NCT04936152|OTHER|mime therapy using tablet PC mirror application|"After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present."
57957454|NCT03632421|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58446715|NCT04724863|PROCEDURE|Angioscan|"The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination."
57741916|NCT04936152|OTHER|the control intervention including the mime therapy|After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
57957455|NCT03217838|DRUG|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
58446716|NCT05062135|DRUG|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
57957456|NCT03217838|DRUG|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
58312970|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
57741917|NCT01570829|DRUG|Dietressa|Oral administration.
57741918|NCT01570829|DRUG|Placebo|Oral administration.
57741919|NCT06732583|BIOLOGICAL|Tuberculosis (TB) vaccine (Ad5-105K)|1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth
57741920|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
58312971|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
57741921|NCT06732583|BIOLOGICAL|Ad5-105K|1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH
57741922|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
57741923|NCT04726020|OTHER|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
57741924|NCT04726020|OTHER|Standard monitoring|standard monitoring of adverse event reaction
57741925|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
57957457|NCT03217838|DRUG|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
57957458|NCT04160507|OTHER|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
57957459|NCT06171438|DIAGNOSTIC_TEST|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
58312972|NCT05668559|PROCEDURE|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
58446717|NCT02472301|DIETARY_SUPPLEMENT|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
57741926|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
58312973|NCT05668559|PROCEDURE|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
58312974|NCT04031170|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
58312975|NCT04031170|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
58312976|NCT05363774|DRUG|NNC0519-0130|"SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels."
58312977|NCT05363774|DRUG|Placebo (NNC0519-0130)|"SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels."
58446718|NCT02472301|DIETARY_SUPPLEMENT|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
58446719|NCT02472301|DIETARY_SUPPLEMENT|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
57957460|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
58312978|NCT01066234|RADIATION|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
58312979|NCT01066234|DRUG|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
58312980|NCT01694680|DIETARY_SUPPLEMENT|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
58312981|NCT01694680|DIETARY_SUPPLEMENT|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
58312982|NCT02232867|BEHAVIORAL|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
58312983|NCT02820662|OTHER|RETCAM|
58312984|NCT02820662|BIOLOGICAL|Blood samples|
58312985|NCT03188822|DEVICE|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
58312986|NCT03188822|DEVICE|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
58312987|NCT03316105|DEVICE|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
58312988|NCT01346098|PROCEDURE|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
58312989|NCT01346098|PROCEDURE|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
58446720|NCT02034877|BIOLOGICAL|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
57741927|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
57741928|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
58446721|NCT02034877|PROCEDURE|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
58446722|NCT01111617|PROCEDURE|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
58446723|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
58446724|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
58446725|NCT05529693|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
57741929|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
57741930|NCT04940429|DEVICE|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
57741931|NCT04940429|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
57741932|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
58116139|NCT06354244|DEVICE|Electroacupuncture of 2 sessions per week|Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.
58116140|NCT06354244|DEVICE|Electroacupuncture of 3 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
58116141|NCT06354244|DEVICE|Electroacupuncture of 4 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
58116142|NCT01566292|DRUG|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
58116143|NCT05558722|DRUG|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
58116144|NCT05511285|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
58116145|NCT00051428|PROCEDURE|Reiki (distant and direct-contact)|
58116146|NCT00001427|DRUG|9-aminocamptothecin|
58116147|NCT02056899|DRUG|Gabapentin|
58116148|NCT05710302|OTHER|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
58116149|NCT06343051|DEVICE|USCOM|Device that measures how much blood is being pumped in and out of the heart.
58116150|NCT01426256|DIETARY_SUPPLEMENT|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
58116151|NCT03999125|DRUG|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
58116152|NCT03999125|DRUG|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
58116153|NCT03999125|DRUG|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
58116154|NCT01612000|BIOLOGICAL|PanBlok|Intramuscular injection
58116155|NCT01612000|BIOLOGICAL|rHA adjuvant|Intramuscular injection
58116156|NCT01725815|BEHAVIORAL|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
58116157|NCT05297747|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
58116158|NCT05297747|DIAGNOSTIC_TEST|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
58116159|NCT00631176|BEHAVIORAL|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
58446726|NCT06149078|DIAGNOSTIC_TEST|serum uric acid|to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
58446727|NCT04522167|DRUG|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
58446728|NCT04522167|DRUG|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
58116160|NCT02950753|DRUG|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
58116161|NCT02950753|DRUG|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
58116162|NCT01572961|DRUG|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
58446729|NCT00782717|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
58446730|NCT00782717|OTHER|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
58446731|NCT00782717|DRUG|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
58446732|NCT01324791|PROCEDURE|anti-reflux surgery|
58446733|NCT04423055|DRUG|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
58446734|NCT03128242|DRUG|Oxytocin|intranasal administration of oxytocin (24IU)
58446735|NCT03128242|DRUG|placebo|intranasal administration of placebo (24IU)
58446736|NCT06726434|PROCEDURE|Surgical neurotomy (SN)|"Surgical neurotomy will be performed under general anesthesia according to the previous description. Muscle relaxant drugs will not be used in order to prevent any interference with the intraoperative electrical stimulation.~The patient will be placed in a prone position and a vertical cutaneous incision will be made at the popliteal fossa location.~The tibial nerve will be dissected and the motor nerve branches of the soleus, gastrocnemius, tibialis posterior and flexor hallucis longus will be identified with intraoperative tripolar electrical stimulation. The selected motor nerve branches will be partially sectioned over a 5mm length under the microscope. The extent of nerve section will be determined according to the degree of spasticity and to the intraoperative residual muscular contraction under electrical stimulation"
58446737|NCT06726434|PROCEDURE|Cryoneurotomy (CN)|"After the use of an aseptic technique with 2% chlorhexidine, betadine application and a local anesthesia with lidocaine 1% (3ml), percutaneous cryoneurotomy will be performed with METRUM CRYOFLEX device guided by ultrasound with 1.2mm cryoprobe at -89°C placed through a #16 angio guide. Electrical stimulation will be performed to confirm tibial nerve contact at 0.8 mV.~The ice ball will be repositioned to two spots along the nerve. Each lesion will be treated for 2min cryoneurolysis at -89°C, followed by 2min without freezing (passive defreezing period) and 2min of cryoneurolysis at -89°C, based on cryotherapy for pain management."
58446738|NCT04372420|DRUG|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
58446739|NCT04372420|PROCEDURE|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
58446740|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
57741933|NCT03901326|DIAGNOSTIC_TEST|CT-FFR assessment|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
58116163|NCT01572961|DRUG|Placebo|
57741934|NCT04497168|DRUG|Citalopram 20mg|20mg daily
57741935|NCT04497168|DRUG|Placebo|matching placebo pills
57741936|NCT02002169|OTHER|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
57957461|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
57957462|NCT01598038|OTHER|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
57957463|NCT01437020|DRUG|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
58116164|NCT03919955|DRUG|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed
58116165|NCT03919955|DRUG|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed
58116166|NCT03919955|DRUG|Placebo|Placebo, per mouth, before bed
58116167|NCT03179982|BEHAVIORAL|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills"
58446741|NCT03133507|BEHAVIORAL|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
58446742|NCT03133507|BEHAVIORAL|Reassurance Condition|Children will be reassured by the experimenter .
58446743|NCT03133507|BEHAVIORAL|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
58446744|NCT05941234|OTHER|Biological biomarker analysis|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
57741937|NCT02002169|OTHER|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
58116168|NCT06352320|BIOLOGICAL|Diagnosis of HCM|Hypertrophic cardiomyopathy (HCM) is defined as the presence of increased LV wall thickness (with or without RV hypertrophy) or mass that is not solely explained by abnormal loading conditions.
58116169|NCT06352320|BIOLOGICAL|Diagnosis of DCM|Dilated cardiomyopathy (DCM) is defined as the presence of LV dilatation and global or regional systolic dysfunction unexplained solely by abnormal loading conditions (e.g. hypertension, valve disease, CHD) or CAD.Very rarely, LV dilatation can occur with normal ejection fraction (EF) in the absence of athletic remodelling or other environmental factors; this is not in itself a cardiomyopathy, but may represent an early manifestation of DCM. The preferred term for this is isolated left ventricular dilatation. Right ventricular dilatation and dysfunction may be present but are not necessary for the diagnosis.
58116170|NCT06352320|BIOLOGICAL|Diagnosis of ARVC|Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined as the presence of predominantly RV dilatation and/or dysfunction in the presence of histological involvement and/or electrocardiographic abnormalities in accordance with published criteria.
58116171|NCT06352320|BIOLOGICAL|Diagnosis of NDLVC|The NDLVC phenotype is defined as the presence of non-ischaemic LV scarring or fatty replacement regardless of the presence of global or regional wall motion abnormalities (RWMAs), or isolated global LV hypokinesia without scarring.
58116172|NCT06352320|BIOLOGICAL|Diagnosis of RCM|Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness.Restrictive cardiomyopathy commonly presents as biatrial enlargement. Left ventricular systolic function can be preserved, but it is rare for contractility to be completely normal. Restrictive pathophysiology may not be present throughout the natural history, but only at an initial stage (with an evolution towards a hypokinetic-dilated phase). Restrictive physiology can also occur in patients with end-stage hypertrophic and dilated cardiomyopathy; the preferred terms are 'hypertrophic' or 'dilated cardiomyopathy with restrictive physiology'. Restrictive ventricular physiology can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic function
58116173|NCT06352320|BIOLOGICAL|Diagnosis of LVNC|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickerendocardial layer. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope. Left ventricular non-compaction has also been used to describe an acquired and sometimes transient phenomenon of excessive LV trabeculation (e.g. in athletes, during pregnancy, or following vigorous activity)that must reflect increased prominence of an otherwise normal myocardial architecture, given that cardiomyocytes are terminally differentiated and the formation of new cardiac structures is impossible.The Task Force does not consider LVNC to be a cardiomyopathy in the general sense.
58116174|NCT02891200|OTHER|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
58116175|NCT02891200|OTHER|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
58116176|NCT04259411|DEVICE|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
58116177|NCT00566709|PROCEDURE|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
58116178|NCT02818556|DRUG|Restalyne Silk|
58116179|NCT02818556|DRUG|Belotero Balance|
58116180|NCT01897597|DRUG|BI 144807 high dose|oral solution
58116181|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
58116182|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
58116183|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
58116184|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
57741938|NCT06258590|DEVICE|Transcutaneous auricular vagus nerve stimulation|Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
58116185|NCT01897597|DRUG|BI 144807 intermediate dose|oral solution
57741939|NCT02917707|OTHER|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
57741940|NCT01978613|DRUG|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
57741941|NCT01978613|DRUG|placebo|Tablets for one-daily oral administration.
57741942|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
57741943|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
57741944|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
58116186|NCT01897597|DRUG|BI 144807 high dose|tablet
58116187|NCT04818021|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
58116188|NCT04818021|BEHAVIORAL|Facial Skin Stretch|Facial skin stretch
58116189|NCT01754259|DRUG|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
58116190|NCT01754259|DRUG|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
57741945|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
57741946|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
57741947|NCT06105632|DRUG|Everolimus|Active Comparator
57741948|NCT06105632|DRUG|Exemestane|Active Comparator
57741949|NCT04677972|DRUG|Ebselen|Glutathione peroxidase mimetic
58116191|NCT01798459|DRUG|Methylphenidate|
58116192|NCT00287027|DRUG|Risperdal Long Acting Injectable Antipsychotic Medication|
58116193|NCT04330300|DRUG|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
58116194|NCT04330300|DRUG|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
58116195|NCT04330300|DRUG|ACE inhibitor|Anti-hypertensive (Control Arm)
58116196|NCT04330300|DRUG|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
58116197|NCT03449056|DRUG|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
58116198|NCT01565083|DRUG|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
58116199|NCT01565083|DRUG|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
58116200|NCT01565083|DRUG|Vinorelbine|A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
58446745|NCT02928575|DRUG|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
58446746|NCT02928575|DRUG|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
58446747|NCT02928575|RADIATION|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
57741950|NCT04677972|DRUG|Placebo|Matching placebo containing excipients
57741951|NCT02690064|DIETARY_SUPPLEMENT|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
57741952|NCT02690064|DIETARY_SUPPLEMENT|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
58116201|NCT01466686|RADIATION|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
58116202|NCT01466686|DRUG|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
58446748|NCT05180383|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
58458571|NCT03090477|BEHAVIORAL|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
57741953|NCT02690064|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
57741954|NCT04712942|DRUG|Pevonedistat|Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
57741955|NCT04712942|DRUG|Azacitidine|azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
57741956|NCT02868359|OTHER|No Intervention|The study is observational.
57741957|NCT06481709|DRUG|RLF-OD032|100 mg/mL oral suspension
57741958|NCT06481709|DRUG|Kuvan|100 mg powder for oral solution
57741959|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
57741960|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
57741961|NCT06620042|DRUG|Ketamine|Open-label Ketamine
57741962|NCT06620042|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) of the brain
57957464|NCT01437020|DRUG|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
57957465|NCT05712187|DRUG|ALTO-100|ALTO-100 tablet BID
57957466|NCT05712187|DRUG|Placebo|Placebo tablet BID
57957467|NCT01732887|OTHER|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
57957468|NCT03397407|OTHER|No intervention|
57957469|NCT05345600|OTHER|MILTA probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
58116203|NCT06546605|DEVICE|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training is a novel training modality that involves the simultaneous electrical stimulation of multiple muscle groups while performing dynamic exercises. Participants in the WB-EMS Training Group will use the miha bodytec device (Augsburg, Germany), which consists of a special suit with integrated electrodes covering major muscle groups. The device generates electrical impulses (85 Hz, 350 μs) that cause involuntary muscle contractions during exercises like squats, lunges, and trunk rotations.Each 20-25-minute WB-EMS session will be conducted twice a week during the two 8-week intervention periods. Sessions will include a warm-up followed by 4-6 WB-EMS exercises performed for 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the stimulation and exercises will be progressively increased based on individual adaptation and tolerance, with the stimulation intensity set at 70-85% of the maximal tolerable level.
58116204|NCT06546605|BEHAVIORAL|Plyometric Training|"Plyometric Training is a high-intensity, explosive strength training modality that involves quick, powerful movements designed to increase muscle power, speed, and agility. Participants in the Plyometric Training Group will engage in a progressive plyometric training program that emphasizes eccentric muscle loading followed by rapid concentric contractions.~The plyometric exercises will include various types of jumps, hops, and bounds, such as box jumps, depth jumps, split squat jumps, and single-leg hops. Each training session will begin with a dynamic warm-up, followed by 4-6 plyometric drills performed for 3-5 sets of 8-12 repetitions, with 60-90 seconds of rest between sets. The intensity and volume of the exercises will be gradually increased over the two 8-week intervention periods."
57741963|NCT06205420|OTHER|Injectable composite resin restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
57741964|NCT06205420|OTHER|Injectable giomer restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
57741965|NCT05821309|DRUG|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
57741966|NCT05821309|DRUG|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
57741967|NCT05821309|DRUG|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
57741968|NCT04821778|RADIATION|Radiotherapy|50-66Gy/1.8-2.2Gy/25-30f
57741969|NCT04821778|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
57741970|NCT04821778|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
57741971|NCT04821778|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
57957470|NCT05345600|OTHER|placebo probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
57957471|NCT04737577|PROCEDURE|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
57957472|NCT04737577|PROCEDURE|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
57957473|NCT00371930|PROCEDURE|application of a dye suspension followed by a laser intervention|
57741972|NCT04821778|DRUG|5-FU Analog based chemotherapy|W1-5 qW or d1-14, q3W according to physician's preference
57957474|NCT06288087|OTHER|VR Based Training with Machine Guidance (MG Group)|The members of both groups will undertake a VR based basic training for ALS. Afterwards MG group were trained with VR based Advanced Training Module, which provides training with full machine guidance. The knowledge level will then be evaluated by the exam mode of the VR based training module
58116205|NCT06546605|BEHAVIORAL|Functional Training|"Functional Training is a training approach that focuses on exercises that simulate the demands of specific sports or daily activities, targeting multiple muscle groups and movement patterns simultaneously. Participants in the Functional Training Group will engage in a tailored functional training program designed to enhance their performance in basketball or volleyball.~The functional training exercises will incorporate multi-joint, multi-planar movements that mimic game-specific actions, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills. Each session will start with a dynamic warm-up, followed by 6-8 functional exercises performed for 3-4 sets of 8-12 repetitions, with 60 seconds of rest between sets. The program will also include core stability and injury prevention exercises."
58116206|NCT05455749|DIETARY_SUPPLEMENT|holoBLG|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)
58116207|NCT06031311|DIAGNOSTIC_TEST|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
58116208|NCT05806359|DRUG|Danicamtiv|Specified dose on specified days
58116209|NCT05806359|DRUG|Placebo|Specified dose on specified days
58446749|NCT06147141|BEHAVIORAL|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
58446750|NCT06147141|BEHAVIORAL|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
58446751|NCT04781686|DRUG|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
58446752|NCT04781686|DRUG|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
58446753|NCT04781686|DRUG|S1|S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
58446754|NCT04781686|DRUG|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
57957475|NCT06288087|OTHER|VR Based Training with Educator Guidance in Metaverse (EG Group)|The members of both groupswill undertake a VR based basic training for ALS. Afterwards EG group will attend at VR based Educator guided training in metaverse. The knowledge level will then be evaluated by the exam mode of the VR based training module
57957476|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
57957477|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
57957478|NCT04842084|BIOLOGICAL|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
57741973|NCT04821778|DRUG|Nimotuzumab|200-400mg, d1,qW
57741974|NCT02998073|BEHAVIORAL|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
57957479|NCT00179309|DRUG|Docetaxel|35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
57957480|NCT00179309|BIOLOGICAL|PANVAC-V|2 x 10\^8 PFU
57957481|NCT00179309|BIOLOGICAL|PANVAC-F|1 x 10\^9 PFU
58116210|NCT01038557|BIOLOGICAL|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
58116211|NCT00228462|DRUG|Seroquel (quetiapine)|
58116212|NCT03657199|DIAGNOSTIC_TEST|Cardiac computed tomography|Routine computed tomography of the heart before discharge
58116213|NCT02330081|DEVICE|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood."
58116214|NCT04117308|PROCEDURE|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
57741975|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
58116215|NCT04117308|PROCEDURE|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
58116216|NCT04437693|DRUG|Hydroxychloroquine|The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
58116217|NCT02325700|PROCEDURE|Aortic repair|Aortic bypass
58116218|NCT03393442|DIAGNOSTIC_TEST|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
58116219|NCT00359437|DRUG|Satavaptan|oral administration once daily
58116220|NCT00359437|DRUG|placebo|oral administration once daily
58116221|NCT00050661|DRUG|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
58116222|NCT00050661|DEVICE|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
58116223|NCT02497391|DRUG|Evacetrapib|administered orally
58116224|NCT04938778|OTHER|PNF|PNF Participants will engage in 8 weeks of 14 hours per night fasting
58116225|NCT05085613|BEHAVIORAL|Corrective message framing and humor|The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
57957482|NCT00179309|BIOLOGICAL|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
57957483|NCT02834468|DRUG|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
58116226|NCT00152321|BEHAVIORAL|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
58116227|NCT00152321|BEHAVIORAL|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
58116228|NCT00152321|OTHER|Usual Care|
58116229|NCT00077779|DRUG|Adalimumab|
58116230|NCT03995069|BEHAVIORAL|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
57957484|NCT05700695|DRUG|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
57957485|NCT05700695|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
57957486|NCT03592446|DEVICE|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
57957487|NCT03592446|DEVICE|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
57957488|NCT01738334|BEHAVIORAL|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
57957489|NCT01738334|BEHAVIORAL|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
57957490|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 4mg|
57957491|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 6mg|
57957492|NCT05939895|DEVICE|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
57741976|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
58446755|NCT06503666|BEHAVIORAL|ZAIMARA|"The ZAIMARA curriculum focuses on strengthening communication between adolescent girls and young women (AGYW) and their mother figures (MF) to make healthy sexual decisions, to learn more about HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP). The topics in the curriculum focus on effective communication, mothers talking to daughters on sex, HIV, STIs and PrEP. The intervention consists of participants attending a two day workshops with their MF.~Other names:~ZAIMARA"
57741977|NCT00688818|DRUG|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
58116231|NCT03995069|BEHAVIORAL|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
58116232|NCT01405820|DRUG|natalizumab IV|natalizumab for IV Infusion
58446756|NCT06503666|BEHAVIORAL|Health Promotion|"The health promotion (HP) curriculum focuses on healthy living by encouraging good nutrition, improving knowledge on violence recognition, management and support/resources, exercise, informed consumer behavior, alcohol and substance use.The intervention consists of participants attending a two day workshops with their MF.~Other names:~HP"
58446757|NCT02668458|PROCEDURE|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
58446758|NCT02668458|PROCEDURE|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
58446759|NCT03826069|OTHER|Augmented reality-based curriculum|Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
58446760|NCT03826069|OTHER|Conventional Simulation Curriculum|Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
58446761|NCT01362829|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
58446762|NCT04975776|BEHAVIORAL|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
58446763|NCT04975776|BEHAVIORAL|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
58446764|NCT01359345|DRUG|gadollinum|use of on injection gadollinum Iv for imaging
58446765|NCT04015206|OTHER|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
58446766|NCT03468244|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
58446767|NCT02085694|DRUG|Lactobacillus brevis CD2|
58446768|NCT04998955|BEHAVIORAL|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
58446769|NCT00249509|DRUG|Nefazodone|
58446770|NCT00249509|DRUG|Bupropion|
58116233|NCT01405820|DRUG|natalizumab SC|natalizumab for Subcutaneous Injection
58116234|NCT01405820|DRUG|IV Placebo|Intravenous placebo to natalizumab
58116235|NCT01405820|DRUG|SC Placebo|Subcutaneous placebo to natalizumab
58116236|NCT00252187|DRUG|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
57741978|NCT00688818|DRUG|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
57741979|NCT03923933|DRUG|Chlorthalidone|Chlorthalidone
58116237|NCT00252187|OTHER|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
58116238|NCT06316583|OTHER|TrP-DN and Acupuncture|Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
58116239|NCT00306969|DRUG|bexarotene|
58116240|NCT00306969|DEVICE|photopheresis|
58116241|NCT00543361|DRUG|MK0767|Duration of Treatment: 52 Weeks
58116242|NCT00543361|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
58446771|NCT05759494|DIAGNOSTIC_TEST|rapid diagnostic test (multiplex PCR filmArray)|"novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis."
58446772|NCT04329910|OTHER|no intervention|no intervention - observational only
58446773|NCT00226382|DRUG|Pegylated Interferon-alfa-2a|Pegasys once weekly
58446774|NCT03263273|DRUG|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
58116243|NCT00543361|DRUG|Comparator: metformin|Duration of Treatment: 52 Weeks
58116244|NCT02959775|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
58116245|NCT02959775|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
58116246|NCT04031027|DRUG|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
57741980|NCT03923933|DRUG|Bumetanide|Bumetanide
57741981|NCT06719505|OTHER|ME|Exercises selected with a focus on the major muscle groups. There will be one protocol for the first 3 months and a second protocol for months 4-6, with the number of repetitions for each exercise varying from 3 sets of 8 to 10 repetitions, totaling 18 exercises.
58116247|NCT00112489|DRUG|carboplatin|
58116248|NCT00112489|DRUG|paclitaxel|
58446775|NCT03263273|DRUG|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
58116249|NCT04009330|DIAGNOSTIC_TEST|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
58116250|NCT03662386|PROCEDURE|OCT-A|Optical coherence tomography angiography (OCT-A)
58116251|NCT03662386|PROCEDURE|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
58116252|NCT04083014|DRUG|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
58116253|NCT02753400|DRUG|emixustat hydrochloride|Tablet for oral administration
58116254|NCT02753400|OTHER|Placebo|Placebo tablets for oral administration contain only inactive ingredients
58446776|NCT03263273|OTHER|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
58116255|NCT05484375|DRUG|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
58116256|NCT02786498|DRUG|Vitamin D3|
58116257|NCT02786498|OTHER|Placebo|
58116258|NCT04577274|DIETARY_SUPPLEMENT|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
58446777|NCT01922141|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
58116259|NCT04577274|DIETARY_SUPPLEMENT|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
58116260|NCT04577274|DIETARY_SUPPLEMENT|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
58116261|NCT00627718|DEVICE|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
58446778|NCT01922141|DRUG|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
58116262|NCT04014998|OTHER|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
58116263|NCT05057156|BEHAVIORAL|cognitive rehabilitation|patients have to use an app with cognitive games
58446779|NCT01922141|DRUG|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
58446780|NCT01922141|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
57741982|NCT06719505|OTHER|PE|The stretching and strengthening exercises will target the major muscle groups, and at the end of each session (lasting approximately 60 minutes), the instructor will guide the participant through a relaxation exercise using an EVA foam roller. The exercises were selected to improve overall muscle strength, as traditionally applied in Pilates. There will be one protocol for the first 3 months and a second protocol for months 4-6, with 17 exercises in each protocol, varying from 3 sets of 8 to 10 repetitions.
57741983|NCT03532295|DRUG|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
58116264|NCT00001228|DRUG|Interferon|
58116265|NCT01694615|PROCEDURE|Cryoprobe biopsy|
58116266|NCT01694615|PROCEDURE|Forceps Biopsy|
58116267|NCT03819933|BEHAVIORAL|Educational intervention|Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
58116268|NCT04984850|OTHER|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
58116269|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
58116270|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
58116271|NCT01876862|OTHER|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
58116272|NCT03810833|DEVICE|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
58446781|NCT06725511|BEHAVIORAL|Opt-out framing|Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.
58446782|NCT06725511|BEHAVIORAL|Opt-in framing|Eligible participants are invited to enroll
58446783|NCT05192993|OTHER|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
58446784|NCT05192993|OTHER|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
58446785|NCT05192993|OTHER|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
58446786|NCT03524014|OTHER|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
58446787|NCT03123666|DRUG|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
58446788|NCT03123666|OTHER|Placebo|Placebo identical to GMCSF will be given
58446789|NCT00860171|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
58446790|NCT00860171|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV
58446791|NCT00860171|OTHER|Laboratory Biomarker Analysis|Correlative studies
58446792|NCT06725888|DEVICE|Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:|"Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days"
57957493|NCT05639855|OTHER|Mental Health Literacy Programme|Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
58446793|NCT03884790|DEVICE|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
58446794|NCT05152108|DEVICE|BCI feasibility test|Testing the feasibility of BCI device by determining the accuracy of BCI control
58446795|NCT03174366|DRUG|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
58446796|NCT03109639|DEVICE|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
58446797|NCT03109639|DEVICE|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
58446798|NCT03066193|DRUG|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
57957494|NCT04892836|OTHER|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
58446799|NCT01460134|DRUG|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
58446800|NCT01460134|DRUG|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
58446801|NCT01460134|DRUG|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
58446802|NCT03306940|DRUG|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
58446803|NCT06725095|OTHER|Placebo gel|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
58446804|NCT06725095|OTHER|Enamel Matrix Proteins Derivative|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
58446805|NCT05028452|OTHER|Internet based support|Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.
58446806|NCT01673997|DRUG|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
57957495|NCT04755049|DIAGNOSTIC_TEST|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire
57957496|NCT01137773|DRUG|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
57957497|NCT01137773|DRUG|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
57957498|NCT04899232|DRUG|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
57957499|NCT03300466|DEVICE|GP0045|Hyaluronic acid gel
57957500|NCT03300466|DEVICE|Comparator|Hyaluronic acid gel
57957501|NCT03877887|DIAGNOSTIC_TEST|echo cardiogram|Assessment of left ventricular systolic and diastolic function
57957502|NCT02555670|OTHER|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
58446807|NCT03078556|DRUG|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
57957503|NCT04048915|BEHAVIORAL|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
57957504|NCT04048915|BEHAVIORAL|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
57957505|NCT01923129|DRUG|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
57957506|NCT02757664|DEVICE|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
58116273|NCT06344442|DRUG|Arginine vasopressin|low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
58116274|NCT06344442|DRUG|Norepinephrine|Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
58116275|NCT01759381|DEVICE|Negative pressure wound therapy (NPWT)|
58116276|NCT05480397|OTHER|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~* Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~* Group (3): Will receive (cryotherapy and conventional physical therapy )"
58116277|NCT04110795|OTHER|No Intervention|No Intervention
58116278|NCT01508585|BEHAVIORAL|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
58116279|NCT02733237|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
58116280|NCT02733237|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
58116281|NCT00685919|DRUG|Carbidopa|200 mg every 6 hours for 5 doses given orally
58116282|NCT00685919|DRUG|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
58116283|NCT03346395|BEHAVIORAL|Problem solving based intervention|Problem solving based intervention
58116284|NCT03346395|BEHAVIORAL|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
58116285|NCT02362906|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
58116286|NCT02362906|DRUG|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
58116287|NCT02362906|DRUG|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
58116288|NCT02362906|DRUG|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
58116289|NCT02362906|DRUG|second generation cephalosporin|
58116290|NCT02362906|DRUG|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
58116291|NCT02362906|DRUG|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
58116292|NCT01720186|DEVICE|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
58116293|NCT00000295|DRUG|Micronized Progesterone|
58116294|NCT04670757|DRUG|CPL409116|IMP administration, tablets contain CPL409116 as an active ingredient
58116295|NCT04670757|DRUG|Placebo|Placebo comparator
58116296|NCT05146466|BEHAVIORAL|E-MATVR|It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
58116297|NCT05146466|BEHAVIORAL|E-MATE|It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
58116298|NCT05303142|OTHER|Heat Tolerance Assessment|60-90 minutes exercise in hot (34 °C; 45% R.H.) conditions at 60%VO2max
58116299|NCT04057781|PROCEDURE|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
58116300|NCT04057781|PROCEDURE|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
58446808|NCT03078556|DRUG|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
58116301|NCT00002571|BIOLOGICAL|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
57741984|NCT03532295|DRUG|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
57741985|NCT03532295|RADIATION|Radiation therapy|-The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.
58116302|NCT00002571|BIOLOGICAL|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
58116303|NCT00002571|DRUG|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
58116304|NCT00002571|DRUG|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
58116305|NCT00002571|DRUG|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
58116306|NCT00002571|DRUG|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
58116307|NCT00002571|DRUG|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
58116308|NCT00002571|DRUG|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
58116309|NCT00002571|DRUG|prednisone|60 mg/m2 po QD x 14days for 6 cycles
58116310|NCT00002571|DRUG|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
58116311|NCT00002571|DRUG|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
58116312|NCT00002571|RADIATION|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
58116313|NCT00002571|DRUG|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
58116314|NCT03507439|DEVICE|AVIVO Mobile Patient Management (MPM) System|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
58116315|NCT03507439|DEVICE|VitalPatch biosensor|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
58116316|NCT03507439|DEVICE|DynaPort Move Monitor|Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study
58116317|NCT01493297|OTHER|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
58116318|NCT02758002|PROCEDURE|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
58116319|NCT03475732|DRUG|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
58116320|NCT05612386|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
58116321|NCT04468256|OTHER|COVID-19 experience surveys|Serial online surveys recording experiences of the COVID-19 pandemic.
58116322|NCT04125004|DEVICE|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
58116323|NCT03867383|DRUG|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
58116324|NCT03867383|DRUG|Placebo|60 milliliters normal saline
58446809|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
58116325|NCT00308022|DEVICE|High Frequency Percussive Ventilation|
58116326|NCT03831633|DRUG|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
58116327|NCT03831633|DRUG|Standard of Care|"* oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
58116328|NCT04716114|DRUG|SKLB1028|SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
58116329|NCT04716114|DRUG|Salvage Chemotherapy|Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
58116330|NCT06178146|DRUG|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
58116331|NCT06178146|DRUG|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
58116332|NCT00200031|DEVICE|Interstim therapy|
58116333|NCT03141177|BIOLOGICAL|Nivolumab|Specified dose on specified day
58116334|NCT03141177|DRUG|Cabozantinib|Specified dose on specified days
58116335|NCT03141177|DRUG|Sunitinib|Specified dose on specified days.
58116336|NCT03141177|BIOLOGICAL|Ipilimumab|Specified dose on specified days
58116337|NCT03649737|BEHAVIORAL|Exercise Intervention|Attend supervised and unsupervised exercise sessions
58116338|NCT03649737|OTHER|Survey Administration|Ancillary studies
58116339|NCT03649737|OTHER|Quality-of-Life Assessment|Ancillary studies
58116340|NCT00200928|BIOLOGICAL|BCG|
58116341|NCT03731182|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
58116342|NCT03731182|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
58116343|NCT06402747|DRUG|Clopidogrel|Clopidogrel 75mg once daily
58116344|NCT06402747|DRUG|Cilostazol|Cilostazol 200mg per day
58116345|NCT06201624|DRUG|Isotretinoin|Patients will receive 1mg/kg/day for 3 months
58116346|NCT06201624|DRUG|Triple combination formula|Patients are instructed to apply the triple combination formula at night daily for 3 months
58116347|NCT03922477|DRUG|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
58446810|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
57741986|NCT03532295|PROCEDURE|Peripheral blood draw|"* Baseline (prior to administration of any study treatment)~* Before initiation of RT (up to 7 days prior to start of RT; may be on the same day as RT before RT treatment)~* At the end of RT and/or Cycle 2 Day 1 prior to administration of INCMGA00012 with our without epacadostat~* Cycle 3 Day 1 prior to administration of INCMGA00012 with or without epacadostat (+/- 7 days)~* Cycle 5 Day 1 prior to administration of INCMGA00012 with our without epacadostat (+/- 7 days)~* Time of disease progression"
57957507|NCT02757664|OTHER|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
57957508|NCT02757664|DEVICE|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
57957509|NCT00313209|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
57957510|NCT00313209|DRUG|Placebo|once daily
57957511|NCT03245931|OTHER|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
57957512|NCT00941265|DRUG|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
57957513|NCT00941265|DRUG|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
57957514|NCT05448872|DRUG|Sacubitril/Valsartan|HF patients treated with Sac/Val
57957515|NCT05729412|OTHER|Mentioned|If prescription is properly filled for specific details than it is compliance
57957516|NCT04041284|DRUG|Fremanezumab|Monthly 225 mg subcutaneous
57957517|NCT04041284|DRUG|Placebo|Matching Placebo
57957518|NCT01897636|PROCEDURE|EUS-guided fine-needle injection of DCs vaccinations|
57957519|NCT03344003|DRUG|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
57957520|NCT00606086|DRUG|GI-5005|40YU, subcutaneous
57957521|NCT00606086|DRUG|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
57957522|NCT03612687|DEVICE|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
57957523|NCT04029012|DRUG|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
57957524|NCT02135718|DEVICE|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
57957525|NCT02135718|DEVICE|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
58116348|NCT03922477|DRUG|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
58116349|NCT03341286|DRUG|TK3|Tryptophan and thiamine as on oral supplement
58116350|NCT05619146|DEVICE|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
58446811|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI|
58116351|NCT03441542|BEHAVIORAL|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
58116352|NCT03441542|BEHAVIORAL|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
58116353|NCT03117673|OTHER|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
58116354|NCT05088512|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
58116355|NCT05723497|OTHER|Elderberry juice|Participants will consume elderberry juice 1-week.
58116356|NCT05723497|OTHER|Placebo beverage|Participants will consume placebo for 1-week.
58116357|NCT04690413|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
58116358|NCT02089828|OTHER|autologous purified CD34+ cells|
58116359|NCT02089828|OTHER|autologous peripheral blood mononuclear cells|
58116360|NCT00321711|DRUG|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
58116361|NCT00321711|BIOLOGICAL|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
57741987|NCT03532295|DRUG|Retifanlimab|-Will be supplied by Incyte
58116362|NCT00321711|DRUG|Azacitidine|hypomethylating agent
58116363|NCT00321711|DRUG|Decitabine|hypomethylating agent
58116364|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
57741988|NCT01717118|BIOLOGICAL|Bivalent Vaccines|
58446812|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 1|
58446813|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 2|
58446814|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI replicate|
58116365|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
58116366|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
58446815|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
58446816|NCT03308006|BIOLOGICAL|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
57741989|NCT01717118|BIOLOGICAL|Tetravalent Vaccine|
57741990|NCT06732115|PROCEDURE|One-step polishing system with nanohybrid resin composite restorations.|one-step polishing system using OneGloss by Shofu
57741991|NCT06732115|PROCEDURE|Multistep system polishing system Super-Snap X-treme (Shofu) with nanohybrid resin composite restorations.|A multi-step polishing system
57741992|NCT02207816|PROCEDURE|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
57741993|NCT02207816|BIOLOGICAL|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
57741994|NCT02207816|BIOLOGICAL|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
57741995|NCT02207816|BIOLOGICAL|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
58116367|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
58116368|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
58116369|NCT01567306|BIOLOGICAL|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
58116370|NCT02035137|RADIATION|131I-MIBG|
58446817|NCT00114855|DRUG|HYPOCOL®|
58446818|NCT06162780|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.
57741996|NCT02207816|BIOLOGICAL|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
57741997|NCT02207816|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
57741998|NCT05668117|DEVICE|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
57741999|NCT05289362|DEVICE|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
58116371|NCT02035137|DRUG|Vincristine|
58116372|NCT02035137|DRUG|Irinotecan|
58116373|NCT02035137|DRUG|Vorinostat|
58116374|NCT00751374|DRUG|gentamicin|topical gentamicin cream on daily basis
58116375|NCT00751374|DRUG|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
58116376|NCT02761369|DEVICE|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
58446819|NCT06162780|PROCEDURE|TEER|Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.
58446820|NCT00819936|PROCEDURE|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
58446821|NCT00819936|PROCEDURE|backward walking|physiotherapy with use a backward walking type of physiotherapy
58446822|NCT03158194|BEHAVIORAL|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
58446823|NCT01243723|DRUG|Eductyl suppository|One suppository every morning during 21 days
58446824|NCT01243723|DRUG|Placebo suppository|One suppository every morning during 21 days
58446825|NCT01851629|BEHAVIORAL|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
57957526|NCT04788628|OTHER|Baseline|Hippocampal and scalp EEG monitoring during overnight sleep
57957527|NCT04788628|OTHER|Motor procedural memory task|Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning
57957528|NCT04788628|OTHER|Motor procedural memory task plus auditory stimulation|Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
57957529|NCT05583929|OTHER|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
57957530|NCT04223310|DRUG|Virtual AAD TEST group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design."
57957531|NCT04223310|DRUG|Empirical AAD group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design."
57957532|NCT00159861|DRUG|Sildenafil citrate|
57957533|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
57957534|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
57957535|NCT00301340|DRUG|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
58116377|NCT03520283|OTHER|Interview|Ancillary studies
58446826|NCT01851629|OTHER|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
58446827|NCT03068702|DEVICE|Optical Coherence Tomography Angiography|
58116378|NCT03520283|OTHER|Questionnaire Administration|Ancillary studies
58116379|NCT03520283|BEHAVIORAL|System Support Mapping|Complete MAP
58116380|NCT00745251|DRUG|VI-0521|15 mg Phentermine and 92 mg Topiramate
58116381|NCT00745251|DRUG|placebo|placebo
58116382|NCT02038478|BIOLOGICAL|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
58116383|NCT01070641|DRUG|Carvedilol|Carvedilol 12.5mg QD
58116384|NCT01070641|PROCEDURE|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
58116385|NCT05986877|DRUG|STSA-1201 Subcutaneous injection|Subcutaneous injection
58116386|NCT05986877|DRUG|Placebo|Subcutaneous injection
58116387|NCT00367315|DRUG|Lumiracoxib|
58116388|NCT04035590|PROCEDURE|No drain|Mastectomy with flap fixation without low vacuum drainage
58116389|NCT04035590|PROCEDURE|With drain|Mastectomy with flap fixation with low vacuum drainage
58116390|NCT02711956|DRUG|ZEN003694|
58116391|NCT02711956|DRUG|Enzalutamide|
58116392|NCT00087191|DRUG|EF5|Given IV
58446828|NCT05187039|OTHER|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
58446829|NCT02245945|DRUG|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
57742000|NCT05289362|DEVICE|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
58116393|NCT00087191|DRUG|motexafin lutetium|Given IV
58116394|NCT00087191|OTHER|pharmacological study|Correlative studies
58446830|NCT02245945|DRUG|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
58446831|NCT01698814|DRUG|AL-4943A Ophthalmic Solution|
58446832|NCT01698814|DRUG|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
58446833|NCT02294058|DRUG|Ozanimod|Capsules for oral administration once a day
58446834|NCT02294058|DRUG|Interferon beta-1a|Administered by intramuscular injection once a week
58116395|NCT03592381|PROCEDURE|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
58116396|NCT03592381|PROCEDURE|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
58446835|NCT02294058|DRUG|Placebo to ozanimod|Matching placebo capsules administered orally once a day
58446836|NCT02294058|DRUG|Placebo to interferon beta-1a|Placebo intramuscular injection once a week
58446837|NCT06056661|BEHAVIORAL|WMR|Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
58446838|NCT05330208|DRUG|SHR-1816|SHR-1816
58446839|NCT05330208|DRUG|Placebo|Placebo
58446840|NCT06277063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The vagus nerve's auricular branch is primarily distributed in the tragus, tragus sulcus, and concha cavity. It can activate the nucleus tractus solitarius through the vagus afferent fibers, thereby activating various areas of the vagus nerve in the central nervous system. This stimulation technique involves applying a constant current of around 2-3mA to the epidermal terminals of the ear using an electrode. It aims to regulate the vagus nerve, modulate the autonomic nervous system, release neurotransmitters, improve cerebral blood flow, and alleviate headache symptoms. In the implementation, non-invasive transcutaneous vagus nerve stimulation was performed by having the subject wear a vagus stimulator and adjusting the appropriate stimulation intensity.
58446841|NCT06277063|DEVICE|Sham transcutaneous auricular vagus nerve stimulation|The subjects in the sham stimulation group will wera a stimulator with the same appearance as the experimental group. However, the electrode of the stimulator will be located near the auricle and earlobe, and the intensity of the stimulator will be adjusted.
58446842|NCT04526626|DEVICE|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
58446843|NCT03406637|DEVICE|BPK-S Integration|primary total knee endoprosthesis
58446844|NCT04484818|DRUG|Darolutamide|Given PO
58446845|NCT04484818|DRUG|Goserelin Acetate|Given via injection
58446846|NCT04484818|DRUG|Leuprolide Acetate|Given IV
58446847|NCT04484818|DRUG|Placebo Administration|Given PO
58446848|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
57742001|NCT04530292|BEHAVIORAL|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
58116397|NCT00850278|OTHER|FLT-PET imaging|Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
58116398|NCT03231618|DIETARY_SUPPLEMENT|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
58116399|NCT03980379|DRUG|304 injection|Monoclonal antibodies, 100mg/10ml per injection
58116400|NCT03980379|DRUG|rituximab injection|100mg/10ml per injection ，manufactured by Roche
58116401|NCT01828255|DEVICE|SENSIMED Triggerfish®|
58116402|NCT03020472|BIOLOGICAL|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
58116403|NCT01488578|DRUG|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
58116404|NCT03790787|DRUG|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
58116405|NCT03790787|DRUG|Dorzagliatin|Glucokinase activator currently under development
58446849|NCT04484818|DRUG|Triptorelin|Given via injection
58446850|NCT04007263|DRUG|Placebo|Placebo via 30 minute infusion once daily for 5 days
58446851|NCT04007263|DRUG|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
58446852|NCT06172179|OTHER|No interventions|All procedures are observation. No intervention in this study.
57742002|NCT06200181|DRUG|Olanzapine|Given by PO
57742003|NCT06200181|DRUG|Olanzapine|Given by PO
58116406|NCT04484597|DIAGNOSTIC_TEST|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
58116407|NCT04111237|BEHAVIORAL|Two Finger technique|two finger method for chest compression provuision
58116408|NCT04111237|BEHAVIORAL|Two Thumb Technique|Two thumb technique
58116409|NCT01414946|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
58116410|NCT01414946|OTHER|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
58116411|NCT05455242|BEHAVIORAL|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
58116412|NCT02203136|PROCEDURE|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
58116413|NCT02203136|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
58116414|NCT03979209|DRUG|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
58116415|NCT01093079|PROCEDURE|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
58116416|NCT01093079|PROCEDURE|Open partial nephrectomy|Open partial nephrectomy
58116417|NCT04184310|OTHER|Modified perineal linear stapler resection for external rectal prolapse|After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
58116418|NCT02356965|DRUG|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
58116419|NCT02356965|DRUG|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
58446853|NCT00233766|DEVICE|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
58446854|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
58446855|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
58446856|NCT00740584|DRUG|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
58446857|NCT06538155|DEVICE|Wearable device|Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked
58446858|NCT06538155|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
58446859|NCT06538155|OTHER|CT scan, TEE exam, or chest X ray|Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
58446860|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
58446861|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
58446862|NCT00240461|OTHER|Placebo|crystalline substance 200 mg twice daily for 6 months
58446863|NCT05423314|PROCEDURE|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
58446864|NCT01373658|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
58116420|NCT06087809|BEHAVIORAL|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
58116421|NCT06087809|BEHAVIORAL|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
58116422|NCT00395083|BEHAVIORAL|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
58116423|NCT04899856|DEVICE|TransAeris|TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
58446865|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
58446866|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
58446867|NCT04236362|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
58446868|NCT04236362|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
58446869|NCT03959059|DEVICE|Mixed Reality technology|combine image with real body
58446870|NCT01558947|DRUG|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
58446871|NCT01558947|DRUG|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
58446872|NCT02768779|OTHER|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
58446873|NCT02733523|BEHAVIORAL|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
58446874|NCT03306992|BEHAVIORAL|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
58446875|NCT06727136|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets
58446876|NCT06243640|DRUG|Buagafuran capsules, 15mg/ capsule|Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
58446877|NCT06243640|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
57742004|NCT06200181|DRUG|Placebo|Given by PO
58116424|NCT02087046|DEVICE|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
58116425|NCT00935987|DRUG|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
58116426|NCT02770183|DEVICE|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
58116427|NCT03112356|DRUG|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
58116428|NCT03954561|PROCEDURE|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
58446878|NCT05102864|DEVICE|Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex|iTBS will be administered to the left DLPFC for 10 consecutive days
58446879|NCT04751318|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
58446880|NCT04751318|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
58446881|NCT01054456|DRUG|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
58446882|NCT05848895|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
58446883|NCT05848895|BEHAVIORAL|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
58446884|NCT05711732|DIAGNOSTIC_TEST|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
58446885|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
58446886|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
58446887|NCT01223729|DRUG|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
58446888|NCT01223729|OTHER|placebo|placebo twice per day
58446889|NCT03491514|OTHER|Test Granola|51 g Test Granola
58446890|NCT03491514|OTHER|Control Granola|54.1 Control Granola
57742005|NCT05225246|OTHER|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
58116429|NCT03954561|PROCEDURE|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
58116430|NCT05966857|DEVICE|Wearable: Smartwatch|The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
58116431|NCT06544798|GENETIC|AAV2-hAQP1|Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
58116432|NCT02287454|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
58116433|NCT00790374|DRUG|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
58116434|NCT00790374|DRUG|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
58116435|NCT00790374|DRUG|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
58116436|NCT01396642|OTHER|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
58312990|NCT01978756|OTHER|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
58116437|NCT05729100|OTHER|Oral carbohydrate-electrolyte solution|Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)
58116438|NCT05729100|OTHER|Control|Standard clear fluid (water)
58446891|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
58446892|NCT02766868|DRUG|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
58446893|NCT00482625|DRUG|erlotinib hydrochloride|Given PO
58446894|NCT00482625|PROCEDURE|conventional surgery|Undergo pancreatectomy
58116439|NCT04085081|OTHER|E-mail|Receive brief motivational text or email messages
58116440|NCT04085081|BEHAVIORAL|Exercise Intervention|Receive personalized walking program plus strength exercises
58312991|NCT03163628|BIOLOGICAL|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~* A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~* A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
58312992|NCT04553718|OTHER|experimental group|provide mHealth program, which has pregnant women using wearable device and app
58312993|NCT04010305|DRUG|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
58312994|NCT04010305|DRUG|Placebo film|Placebo film for BXCL501
58312995|NCT06550648|PROCEDURE|Right Heart Catheterization (Swan Ganz Catheter)|Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer
58446895|NCT00482625|OTHER|immunohistochemistry staining method|Correlative studies
58446896|NCT00482625|GENETIC|protein expression analysis|Correlative studies
58446897|NCT00482625|PROCEDURE|biopsy|Correlative studies
58446898|NCT00482625|OTHER|pharmacological study|Correlative studies
58446899|NCT00482625|OTHER|laboratory biomarker analysis|Correlative studies
58446900|NCT02404818|PROCEDURE|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
58446901|NCT02404818|PROCEDURE|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
58446902|NCT06725264|DRUG|Deucravacitinib|6 mg twice daily
57742006|NCT04109703|DEVICE|High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.|The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
58446903|NCT03618420|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
58446904|NCT03618420|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
58116441|NCT04085081|OTHER|Quality-of-Life Assessment|Ancillary studies
58116442|NCT04085081|OTHER|Questionnaire Administration|Ancillary studies
58116443|NCT04085081|BEHAVIORAL|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
58116444|NCT04085081|OTHER|Text Message|Receive brief motivational text or email messages
58116445|NCT05007691|DEVICE|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
58116446|NCT03458507|DEVICE|Switch of nocturnal NIV interface|"1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
58116447|NCT02197728|DEVICE|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
58116448|NCT05228119|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
58116449|NCT02386592|DRUG|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
58116450|NCT02386592|BEHAVIORAL|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
58116451|NCT02386592|BEHAVIORAL|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
58116452|NCT02386592|OTHER|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
58116453|NCT06002295|DRUG|Chlorhexidine Topical Cream|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
58116454|NCT06002295|DRUG|Methylated Spirit|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
58116455|NCT04544891|OTHER|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
58116456|NCT04180345|OTHER|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
58446905|NCT03191630|BEHAVIORAL|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
58116457|NCT02631109|DRUG|Pegaspargase|2000U/m2 day5
58116458|NCT02631109|DRUG|doxorubicin|25mg/m2 day1
58116459|NCT02631109|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
58116460|NCT02631109|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
58116461|NCT01373606|DRUG|Terlipressin|
58116462|NCT02448459|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
58312996|NCT01592955|DEVICE|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
58312997|NCT01206764|DRUG|RAD001|
58312998|NCT00072553|DRUG|celecoxib|
58116463|NCT05141266|BEHAVIORAL|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
58312999|NCT00072553|DRUG|fluorouracil|
58313000|NCT00072553|DRUG|leucovorin calcium|
58313001|NCT00072553|DRUG|oxaliplatin|
58313002|NCT00072553|PROCEDURE|adjuvant therapy|
58313003|NCT00072553|PROCEDURE|conventional surgery|
58313004|NCT00072553|PROCEDURE|neoadjuvant therapy|
58313005|NCT00295802|DEVICE|Integrated Imaging High Intensity Focused Ultrasound|
58313006|NCT00295802|DEVICE|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
58313007|NCT00410163|DRUG|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
58313008|NCT00410163|DRUG|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
58313009|NCT00410163|DRUG|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
58446906|NCT03191630|BEHAVIORAL|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
58446907|NCT02544659|DRUG|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
58446908|NCT03782701|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
58446909|NCT03782701|OTHER|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
58116464|NCT05141266|OTHER|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
58313010|NCT00410163|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
58313011|NCT00003297|DRUG|mitoxantrone hydrochloride|
57742007|NCT04109703|DEVICE|Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
58116465|NCT02429869|DRUG|everolimus|
58116466|NCT02115191|DEVICE|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
58313012|NCT00003297|DRUG|thiotepa|
58313013|NCT00003297|DRUG|topotecan hydrochloride|
58313014|NCT00003297|PROCEDURE|peripheral blood stem cell transplantation|
57742008|NCT04534374|BEHAVIORAL|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
57742009|NCT04534374|BEHAVIORAL|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
57742010|NCT00817362|DRUG|IPI-504|IPI-504 IV infusion 300 mg/m2
57742011|NCT00817362|DRUG|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
57742012|NCT06561529|DEVICE|Gastric Bypass Stent System|The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
58116467|NCT02115191|PROCEDURE|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
58116468|NCT05064813|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR Intervention|MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.
58116469|NCT05064813|BEHAVIORAL|Stress Education Control Condition (SE)|Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
58116470|NCT04280172|OTHER|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
58116471|NCT04280172|OTHER|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
58116472|NCT03008460|DRUG|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
58116473|NCT03008460|DRUG|Klean-Prep®|Oral solution taken the evening before the colonoscopy
58116474|NCT02735083|BIOLOGICAL|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
58116475|NCT00021502|DRUG|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
58116476|NCT00820235|DEVICE|OsseoSpeed™|OsseoSpeed™ implant
58116477|NCT00820235|DEVICE|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
58116478|NCT00820235|DEVICE|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
58116479|NCT00004812|BEHAVIORAL|Exercise|
58116480|NCT02643901|BIOLOGICAL|GW003|single SC injection
58116481|NCT05727267|BIOLOGICAL|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
58116482|NCT05727267|BIOLOGICAL|TherVacB|Administration of the described combinations via the intramuscular route
58116483|NCT04499183|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|15 gram/day fructo- and galacto-oligosaccharides
58116484|NCT01636297|BEHAVIORAL|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
58116485|NCT01636297|BEHAVIORAL|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
58116486|NCT03297359|BIOLOGICAL|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
58116487|NCT01066494|DRUG|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
58116488|NCT03205384|PROCEDURE|surgery|
58116489|NCT05928000|DRUG|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
58116490|NCT03832933|BEHAVIORAL|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
58116491|NCT03832933|BEHAVIORAL|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
58116492|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
58116493|NCT00386672|BEHAVIORAL|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
58116494|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
58116495|NCT01703741|DRUG|Testosterone Gel (FE 999093)|
58116496|NCT00102869|DRUG|levodopa|100mg levodopa per day over 10 days/ treatment phase
58116497|NCT03654898|BEHAVIORAL|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
58116498|NCT03654898|BEHAVIORAL|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
58116499|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
58116500|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
58116501|NCT04521400|DRUG|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
58116502|NCT04521400|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
58116503|NCT04521400|DRUG|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
58116504|NCT00310856|BIOLOGICAL|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
58116505|NCT00310856|BIOLOGICAL|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
58116506|NCT00310856|BIOLOGICAL|DTaP-Hib-IPV|
58116507|NCT00310856|BIOLOGICAL|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
58116508|NCT00310856|BIOLOGICAL|MMR|
58116509|NCT00310856|BIOLOGICAL|Varicella|
58116510|NCT05113225|PROCEDURE|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
58116511|NCT05785520|DEVICE|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
58446910|NCT03708978|DIAGNOSTIC_TEST|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
58116512|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
58116513|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
58116514|NCT02278679|PROCEDURE|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
58446911|NCT01751100|BEHAVIORAL|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
58446912|NCT01751100|BEHAVIORAL|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
58446913|NCT06725615|OTHER|Regular Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
57957536|NCT02565407|BEHAVIORAL|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
57957537|NCT02565407|BEHAVIORAL|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
57957538|NCT03108950|BEHAVIORAL|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
57957539|NCT01278498|DRUG|Escitalopram|first week:5mg 2nd week\~12 week:10mg
57957540|NCT01278498|DRUG|sugar pill|first week:5mg 2nd week\~12 weeks:10mg
57957541|NCT05190003|OTHER|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
57957542|NCT00107237|DRUG|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
57957543|NCT00107237|DRUG|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
57957544|NCT01123863|OTHER|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
57957545|NCT01123863|OTHER|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
58446914|NCT06725615|OTHER|High Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
58446915|NCT06725615|OTHER|Low Umami exposure|This group will receive the basic diet without added MSG.
58446916|NCT06725615|OTHER|one-week run-in period|During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
58446917|NCT01004289|PROCEDURE|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
58446918|NCT01004289|PROCEDURE|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
58116515|NCT04625582|BEHAVIORAL|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
58116516|NCT04625582|BEHAVIORAL|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
58116517|NCT02259842|DRUG|BI 34021 FU2 solution|
58116518|NCT02259842|DRUG|BI 34021 FU2 tablet|dose group 4 only
58116519|NCT02259842|DRUG|Placebo|
58116520|NCT02259842|OTHER|High fat, high calorie breakfast|only for dose groups 3 and 5
58116521|NCT03339882|DRUG|Remifemin|Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
58116522|NCT05423756|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
58116523|NCT05423756|OTHER|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
58116524|NCT04237571|BEHAVIORAL|CANE Meal Program|Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
58116525|NCT00987987|PROCEDURE|donor lymphocyte infusion|regulatory T cells depletion
58116526|NCT05628623|DRUG|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
58116527|NCT05628623|DRUG|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
58116528|NCT05628623|DRUG|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
58446919|NCT01019070|DRUG|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
58446920|NCT02669459|DRUG|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
58446921|NCT02669459|PROCEDURE|LLETZ|surgical treatment for CIN, current gold standard
58446922|NCT05605106|DIAGNOSTIC_TEST|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
58446923|NCT05605106|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
58446924|NCT00089037|DRUG|methotrexate|
58446925|NCT00089037|DRUG|sirolimus|
58446926|NCT00089037|DRUG|tacrolimus|
58116529|NCT05628623|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
58116530|NCT00352079|BIOLOGICAL|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
58116531|NCT00352079|DRUG|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
58116532|NCT00352079|PROCEDURE|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
58116533|NCT05024461|DIAGNOSTIC_TEST|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~* Pre-analytical particularities and analytical particularities~* Cycle threeshold~* Demographic variables~* Clinical variables~* Clinical criteria~* Questionnaire on the perception of the 2 sampling methods"
58446927|NCT01988714|OTHER|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
58446928|NCT01988714|OTHER|(CG) plus evidence-based SE|(CG) plus evidence-based SE
58446929|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
58446930|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
58446931|NCT00829842|OTHER|oral hygiene|oral hygiene with 0.12% chlorexidine
58446932|NCT00829842|OTHER|placebo|oral hygiene placebo
58446933|NCT06342908|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
58446934|NCT06342908|BIOLOGICAL|Dendritic Cell Therapy|Given PpDC vaccine ID
58116534|NCT02473328|DRUG|Atazanavir 200 mg/r|"1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
58116535|NCT03074526|OTHER|Amniotic Fluid|Amniotic Fluid
58116536|NCT03074526|OTHER|Saline Placebo|Saline Placebo
58116537|NCT01749176|BEHAVIORAL|SMS texting intervention|
58116538|NCT01749176|BEHAVIORAL|Control-Usual Care|
58116539|NCT00496184|DRUG|Nifedipine cream topical application|
58116540|NCT01056757|DRUG|Ribavirin|1000 mg bid, po, q28days
58116541|NCT04606563|DRUG|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
58116542|NCT04606563|DRUG|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
58116543|NCT04606563|DRUG|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
58116544|NCT04606563|DRUG|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
58116545|NCT04606563|DRUG|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
58116546|NCT04606563|DRUG|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
58116547|NCT04606563|DRUG|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
58116548|NCT04606563|DRUG|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
58116549|NCT05751681|OTHER|progestin primed ovarian stimulation protocol|progestin primed ovarian stimulation protocol
58116550|NCT05751681|DRUG|dydrogesterone (Duphaston, Abbott)|20 mg oral dose of dydrogesterone (Duphaston, Abbott)
58116551|NCT05751681|DRUG|Cetrotide|0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
58116552|NCT00956228|RADIATION|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
58116553|NCT02999464|OTHER|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
58116554|NCT02999464|OTHER|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
58116555|NCT03150121|PROCEDURE|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
58116556|NCT03150121|PROCEDURE|Blood sample|5-10mL of blood will be drawn from participants.
58116557|NCT03150121|DEVICE|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
58116558|NCT04712435|DRUG|N-acetylcysteine|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
58116559|NCT04712435|DRUG|Placebo|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
58116560|NCT03449082|BIOLOGICAL|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
58116561|NCT03449082|BIOLOGICAL|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
58116562|NCT03449082|DRUG|Fibrin glue|Fibrin glue 0.5cc
58116563|NCT03449082|DRUG|Normal saline|Normal saline 0.5cc
58116564|NCT00708929|PROCEDURE|Squatting|Squatting for 6 minutes
58116565|NCT04612920|DRUG|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
58116566|NCT03273387|DRUG|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
58116567|NCT03273387|DRUG|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
58446935|NCT06342908|PROCEDURE|Leukapheresis|Undergo leukapheresis
58446936|NCT06342908|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58446937|NCT06342908|DRUG|Poly ICLC|Given IM
58446938|NCT01051336|DEVICE|TARIS Placebo|
58446939|NCT01051336|PROCEDURE|Sham Procedure|
58446940|NCT01961271|DRUG|Buprenorphine transdermal patch|Please see Arm Description.
57769658|NCT02875301|BEHAVIORAL|225 Minutes Week|This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
58116568|NCT02095847|PROCEDURE|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
58116569|NCT02095847|DRUG|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
58116570|NCT00322907|DRUG|Cotrifazid vs mefloquine or quinine+SP|
58116571|NCT02737306|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
58116572|NCT02737306|DRUG|Placebo|Placebo in parenteral solution.
58116573|NCT00785525|DRUG|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
58116574|NCT03943342|DRUG|Ibrutinib|Given PO
58116575|NCT03943342|DRUG|Venetoclax|Given PO
58116576|NCT03267030|DRUG|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
58116577|NCT03419663|DIETARY_SUPPLEMENT|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
58446941|NCT04062591|DRUG|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
58116578|NCT01841606|DRUG|Ondansetron|4mg of IV ondansetron
58116579|NCT01841606|OTHER|Normal saline|10mL of IV normal saline
58446942|NCT04062591|DRUG|Placebo|saline IM in the same dose of piroxicam
58116580|NCT00712010|OTHER|Whey protein native|Whey protein native against the 6 other arms
58116581|NCT00712010|OTHER|Whey protein microgels|Whey protein microgels versus the six other arms
58116582|NCT00712010|OTHER|Hydrolyzed whey protein|versus the six other arms
58116583|NCT00712010|OTHER|Casein native|versus the six other arms
58116584|NCT00712010|OTHER|Hydrolyzed casein|versus the six other arms
58116585|NCT00712010|OTHER|Total milk protein native|versus the six other arms
58116586|NCT00712010|OTHER|Hydrolyzed milk protein|versus the six other arms
58446943|NCT03170661|DRUG|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
58116587|NCT00991198|DRUG|Topical oxygen|0.5% concentration of Topical oxygen
57742013|NCT06732817|DEVICE|Active rTMS was administered using a transcranial magnetic stimulator (Rapid2; MagStim).|Active rTMS was sequentially administered over the left DLPFC and left TPJ sites one hour apart, for 3 weeks (21 consecutive days), using a transcranial magnetic stimulator (Rapid2; MagStim) with a 70-mm air-cooled figure-of-eight coil. Stimulation at 20 Hz (2 seconds on, 28 seconds off) was applied over the left DLPFC with an intensity set at 100% of the individual resting motor threshold (RMT), delivering a total of 1,600 pulses daily. Continuous theta burst stimulation (cTBS) was applied over the left TPJ at either 100% of the individual RMT or at the highest intensity that the stimulator could deliver for this protocol (50% of maximum output). Three daily sessions of cTBS were administered, separated by two 15-minute breaks, delivering a total of 1,800 pulses daily. The coil was navigated in real-time using a frameless neuro-navigation system (Brainsight; Rogue Research, Montreal, Quebec, Canada).
57742014|NCT05109299|OTHER|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
57742015|NCT05109299|OTHER|Fluoride toothpaste|1450 ppm fluoride toothpaste
57742016|NCT04495179|DRUG|AZD4635|Subjects will receive AZD4635 orally daily
57742017|NCT04495179|DRUG|Durvalumab|Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
57742018|NCT04495179|DRUG|Cabazitaxel|Subjects will receive intravenous cabazitaxel every 3 weeks
57742019|NCT01374542|PROCEDURE|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
57957546|NCT02869386|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
57957547|NCT02869386|PROCEDURE|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
57957548|NCT01462266|DRUG|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
57957549|NCT01462266|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
57957550|NCT01462266|BIOLOGICAL|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
57957551|NCT01462266|DRUG|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
57957552|NCT03652532|BEHAVIORAL|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
57957553|NCT03652532|BEHAVIORAL|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
57957554|NCT04232579|OTHER|Therapeutic strategy|Therapeutic strategy compatible with the guidelines and development of predictive biomarkers of the response to treatment.
57957555|NCT00937300|BIOLOGICAL|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
58116588|NCT00991198|DRUG|Topical oxygen|0.25% concentration topical oxygen
58116589|NCT00991198|DRUG|placebo|no O2
58446944|NCT04555460|PROCEDURE|Hemicraniectomy|Large hemicraniectomy and duraplasty
57957556|NCT02870361|DRUG|intranasal insulin|
57957557|NCT02870361|DRUG|Placebo|
58116590|NCT01035528|DRUG|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
57957558|NCT00862264|DRUG|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
57957559|NCT05662423|BEHAVIORAL|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
57957560|NCT05662423|BEHAVIORAL|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
57957561|NCT02526004|DRUG|Ceftazidime|
57957562|NCT02526004|DRUG|Tobramycin|
58116591|NCT01035528|DRUG|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
58116592|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered as a single dose
58116593|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered as a single dose
58446945|NCT04555460|OTHER|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
58116594|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered as a single dose
58116595|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered as a single dose
58446946|NCT02432417|DRUG|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
58446947|NCT06727201|DRUG|Ondansetron (Zofran)|Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.
58446948|NCT06727201|DRUG|Saline (NaCl 0,9 %) (placebo)|normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia
58446949|NCT03233113|BEHAVIORAL|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
58446950|NCT01702025|DRUG|Placebo|Yellow corn meal in gel capsules
58446951|NCT01702025|DRUG|Aminophylline|National Drug Code (NDC) 0143-1020-01
58446952|NCT01702025|DRUG|Methazolamide|NDC 0781-1072-01
58446953|NCT01702025|DRUG|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
58116596|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered as a single dose
58116597|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered daily for 14 days
58116598|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered daily for 14 days
58116599|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered daily for 14 days
58116600|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered daily for 14 days
58446954|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
58446955|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
58116601|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered daily for 14 days
58116602|NCT02110420|DRUG|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
58116603|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered as a single oral dose
58116604|NCT02110420|DRUG|CC-90001|CC-90001 720mg will be administered as a single oral dose
58116605|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered daily for 14 days
58446956|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
58116606|NCT03775356|OTHER|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
58116607|NCT03136991|DRUG|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
58446957|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
58446958|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
58446959|NCT01684202|DRUG|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
58446960|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
58446961|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
58446962|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
58446963|NCT04428151|DRUG|Lenvatinib|20 mg once daily, taken as oral capsules
58446964|NCT04428151|BIOLOGICAL|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
58446965|NCT04428151|DRUG|Docetaxel|75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle
58116608|NCT03136991|DRUG|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
58446966|NCT04428151|DRUG|Capecitabine|1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
58446967|NCT04428151|DRUG|Paclitaxel|80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
58446968|NCT04428151|DRUG|Cetuximab|400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
58446969|NCT04428151|DRUG|Lenvatinib|24 mg once daily, taken as oral capsules
58446970|NCT06554379|OTHER|Periodontal health and gingivitis|The presence or absence of periodontal disease in the gingiva was determined.
58446971|NCT01837277|DRUG|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
58446972|NCT01837277|DRUG|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
58446973|NCT05524779|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
58446974|NCT06727058|BIOLOGICAL|Pandemic flu H5 mRNA vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)"
58446975|NCT06727058|OTHER|Placebo|"Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)"
57742020|NCT05612490|DRUG|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
58116609|NCT05097885|OTHER|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
58116610|NCT00962299|DRUG|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
58116611|NCT00962299|DRUG|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
58116612|NCT02572583|DRUG|Liugan Shuangjie Heji|
58116613|NCT02572583|DRUG|Shufeng Jiedu Capsule|
58116614|NCT02572583|DRUG|Oseltamivir Phosphate Capsule|
58116615|NCT02724137|BEHAVIORAL|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
58116616|NCT02724137|OTHER|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
58116617|NCT05876702|DEVICE|endoscopy|use of upper endoscopy with i-scan specially , in diagnosis of esophageal lesions and comparison of results with histopathology.
58116618|NCT05945394|OTHER|No intervention|This is an obvertional study, and there is no intervention.
58116619|NCT03687125|DRUG|Tinostamustine|Participants received tinostamustine IV injection.
58446976|NCT04627363|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
57742021|NCT01041638|BIOLOGICAL|Aldesleukin|Given IV
57742022|NCT01041638|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
57742023|NCT01041638|BIOLOGICAL|Dinutuximab|Given IV
57742024|NCT01041638|DRUG|Isotretinoin|Given PO
57742025|NCT01041638|BIOLOGICAL|Sargramostim|Given IV or SC
57742026|NCT02374905|DEVICE|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
57742027|NCT02374905|BEHAVIORAL|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
58116620|NCT03687125|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
58116621|NCT06278285|OTHER|Blood GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
58446977|NCT04627363|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
58446978|NCT04627363|DRUG|Toripalimab|240mg intravenously every 3 weeks
58116622|NCT06278285|OTHER|Blood No treated GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
58446979|NCT03713281|DEVICE|Toric Multifocal etafilcon A with PVP|Investigational
57742028|NCT00088231|DRUG|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
57742029|NCT00088231|DRUG|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
57742030|NCT02656433|DEVICE|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
57742031|NCT02656433|OTHER|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
57742032|NCT02862457|DRUG|Epacadostat 25 mg|Oral administration
57742033|NCT02862457|DRUG|Epacadostat 100 mg|Oral administration
57742034|NCT02862457|BIOLOGICAL|pembrolizumab 200 mg|Intravenous (IV) infusion
57742035|NCT02862457|DRUG|Cisplatin 75 mg/m^2|IV infusion
57742036|NCT02862457|DRUG|Carboplatin Area Under the Curve (AUC) 5|IV infusion
57742037|NCT02862457|DRUG|Pemetrexed 500 mg/m^2|IV infusion
57742038|NCT02862457|DRUG|Paclitaxel 200 mg/m^2|IV infusion
57742039|NCT02862457|DRUG|Carboplatin AUC 6|IV infusion
57742040|NCT04687891|DIAGNOSTIC_TEST|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
57742041|NCT04941599|DRUG|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
57742042|NCT04941599|OTHER|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
57742043|NCT02654626|DRUG|KBP-7072|Drug Intervention
57742044|NCT02654626|OTHER|Placebo|
57742045|NCT02724943|BEHAVIORAL|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
57742046|NCT02724943|BEHAVIORAL|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
57742047|NCT02724943|BEHAVIORAL|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
57957563|NCT03867578|DIAGNOSTIC_TEST|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
57957564|NCT03867578|DIAGNOSTIC_TEST|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
58116623|NCT01851161|PROCEDURE|computed tomography|Undergo conventional CT scan in both supine and prone positioning
58116624|NCT01851161|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
58116625|NCT01851161|RADIATION|radiation therapy|Undergo radiation therapy
58116626|NCT01314755|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
58446980|NCT02290015|OTHER|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
58446981|NCT06420271|DEVICE|Real (real iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 190 seconds with a frequency of 5 Hz coupled with iTBS (coil positioned tangentially with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
58446982|NCT06420271|DEVICE|Sham (sham iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 10 seconds with a frequency of 5 Hz coupled with sham iTBS (coil positioned perpendicularly with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
58446983|NCT04041271|OTHER|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
58446984|NCT04041271|OTHER|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
58446985|NCT04041271|OTHER|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
58446986|NCT04041271|OTHER|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
58446987|NCT04041271|OTHER|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
58116627|NCT01314755|DIETARY_SUPPLEMENT|An iso-caloric, iso-nitrogenous control feed|
58116628|NCT02489890|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
58116629|NCT05852548|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
57957565|NCT03867578|DIAGNOSTIC_TEST|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
57957566|NCT04431713|DRUG|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
57957567|NCT02161211|BEHAVIORAL|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
57957568|NCT02161211|BEHAVIORAL|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
58116630|NCT02184949|PROCEDURE|Percutaneous Coronary Intervention|
58116631|NCT02184949|PROCEDURE|Primary Percutaneous Coronary Intervention|
58116632|NCT01693484|DRUG|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
58313015|NCT04400994|DRUG|Rituximab|"Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
58446988|NCT03958357|DEVICE|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
58446989|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
58446990|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
58446991|NCT03523767|BIOLOGICAL|S.typhi Injection|0.5 ml of S.typhi injection
58446992|NCT03523767|BIOLOGICAL|Normal Saline Injection|0.5 ml of normal saline injection
58446993|NCT03513276|DRUG|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
58446994|NCT03513276|DRUG|Saline Solution|Multimodal analgesia + Saline solution
58446995|NCT03513276|DRUG|Adrenaline 10mcg/ml|
58446996|NCT02750488|DRUG|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
58446997|NCT02750488|OTHER|Untreated skin|One site is patched without treatment as control
58446998|NCT04891289|DRUG|Gemcitabine|See arm for details.
58446999|NCT04891289|DRUG|Oxaliplatin|See arm for details.
58447000|NCT04891289|DRUG|Dexamethasone|See arm for details.
58447001|NCT04891289|DRUG|Floxuridine (FUDR)|See arm for details.
58313016|NCT04400994|OTHER|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour"
58447002|NCT04891289|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
58447003|NCT01311336|DRUG|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
58447004|NCT01311336|DRUG|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
58313017|NCT01409473|RADIATION|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
58313018|NCT01092468|PROCEDURE|Diathermy|flap dissection with conventional diathermy
58313019|NCT01092468|PROCEDURE|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
58447005|NCT00183326|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
58447006|NCT00183326|BEHAVIORAL|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
58447007|NCT02220829|DRUG|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
58447008|NCT02220829|DRUG|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
58447009|NCT01124279|DRUG|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
58447010|NCT05159466|PROCEDURE|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
58447011|NCT04515212|OTHER|Optic Nerve Ultrasounds|Patients will have up to four ultrasounds of the optic nerve.
58447012|NCT00003411|DRUG|motexafin gadolinium|
58447013|NCT00003411|RADIATION|radiation therapy|
58447014|NCT06725810|DRUG|enadustat|Patients are administered with enarodustat with dosage adjusted according to hemoglobin levels to achieve and maintain hemoglobin target over 96 weeks.
58447015|NCT05440734|DRUG|Melatonin|2 Mg Oral Tablet, slow release
58447016|NCT05440734|DRUG|Placebo|placebo pill identical to the treatment pill
58447017|NCT02962661|OTHER|Best Practice|Given standard of care
58447018|NCT02962661|OTHER|Laboratory Biomarker Analysis|Correlative studies
58447019|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given IV
58447020|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given transendocardially
58447021|NCT00985868|DRUG|multikinase inhibitor AT9283|
58447022|NCT00985868|OTHER|enzyme-linked immunosorbent assay|
58447023|NCT00985868|OTHER|immunohistochemistry staining method|
58447024|NCT00985868|OTHER|laboratory biomarker analysis|
58447025|NCT00985868|OTHER|pharmacological study|
58447026|NCT04146350|PROCEDURE|PPV+/-Cat|pars plana vitrectomy+/-cataract
58447027|NCT04146350|PROCEDURE|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
58447028|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
58447029|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
58447030|NCT04146350|PROCEDURE|PSR|posterior scleral reinforcement
57957569|NCT02161211|BEHAVIORAL|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
58447031|NCT04146350|PROCEDURE|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
57957570|NCT04479163|BIOLOGICAL|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
57957571|NCT04479163|OTHER|Placebo|Normal Saline 0.9%
57957572|NCT03020732|PROCEDURE|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
57957573|NCT03020732|PROCEDURE|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
57957574|NCT03933865|DRUG|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
58447032|NCT04146350|PROCEDURE|Gas|gas tamponade alone
58447033|NCT05899140|DRUG|Clindamycin|Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
58447034|NCT05899140|OTHER|Standard of care|Standard of care
58447035|NCT06618118|DRUG|Fosigotifator|Oral Use
58447036|NCT06618118|DRUG|Placebo|Oral Use
58447037|NCT01907464|OTHER|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
58447038|NCT01907464|OTHER|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
58447039|NCT01907464|OTHER|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
58447040|NCT01907464|OTHER|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
58447041|NCT01359904|OTHER|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
58447042|NCT05614037|DRUG|Felodipine sustained release tablets (trade name: plendil®)|Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
58447043|NCT05614037|DRUG|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
58116633|NCT02140957|BEHAVIORAL|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
58116634|NCT02693496|OTHER|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
58116635|NCT02598648|OTHER|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
58447044|NCT05213702|DEVICE|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
58116636|NCT02598648|OTHER|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
58116637|NCT02542124|BIOLOGICAL|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
58116638|NCT05683795|OTHER|Consensus study|Modified-Delphi study and consensus meetings
58116639|NCT00062140|DRUG|cyclophosphamide|
58116640|NCT00062140|PROCEDURE|allogeneic bone marrow transplantation|
58447045|NCT03738488|DEVICE|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
58116641|NCT00062140|PROCEDURE|peripheral blood stem cell transplantation|
58116642|NCT00062140|RADIATION|radiation therapy|
58116643|NCT05313828|DRUG|Acyclovir|acyclovir 4 times /day
58116644|NCT05313828|DRUG|Tobramycin|tobramycin 4 times /day
58116645|NCT05313828|DRUG|Fluorometholone|Fluorometholone 4 times/ day
58116646|NCT05313828|DRUG|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
58116647|NCT02925767|DEVICE|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
58116648|NCT02925767|DEVICE|308-nm excimer laser|XTRAC, PhotoMedex, US
58116649|NCT06483581|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
58116650|NCT06483581|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
58313020|NCT00426270|DRUG|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
58313021|NCT00879190|DRUG|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
58313022|NCT00879190|DRUG|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
58313023|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
58313024|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
58313025|NCT04992247|BIOLOGICAL|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
58313026|NCT04992247|BIOLOGICAL|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
58116651|NCT00121654|DEVICE|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
58116652|NCT02295774|PROCEDURE|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
58116653|NCT02295774|DRUG|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
58116654|NCT01018888|DEVICE|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
58116655|NCT06121869|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
58116656|NCT06121869|DIETARY_SUPPLEMENT|Leucine|Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
58116657|NCT06121869|DIETARY_SUPPLEMENT|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
58116658|NCT01092520|DRUG|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
58116659|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 1|54/ 59,4 Gy
58447046|NCT03738488|OTHER|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
58447047|NCT06135974|DRUG|LC106|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
58447048|NCT06135974|DRUG|LC115|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
58116660|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 2|48,8/ 55 Gy
58116661|NCT03396718|RADIATION|Standard radio(chemotherapy)|60/ 66 Gy
58116662|NCT00590356|DEVICE|StarClose®|Closure device for femoral artery suture site occlusion
58116663|NCT00590356|DEVICE|AngioSeal®|Closure device for femoral artery suture site occlusion
58116664|NCT01885637|OTHER|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
58116665|NCT03801733|DRUG|Vadadustat|Oral dose of 600 mg QD
58116666|NCT03801733|DRUG|Simvastatin|Oral Simvastatin
58116667|NCT03801733|DRUG|Rosuvastatin|Oral Rosuvastatin
58116668|NCT03801733|DRUG|Atorvastatin|Oral Atorvastatin
58447049|NCT06135974|DRUG|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
58447050|NCT06135974|DRUG|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
58447051|NCT01987102|DRUG|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
58116669|NCT03801733|DRUG|Pravastatin|Oral Pravastatin
58116670|NCT03801733|DRUG|Sulfasalazine|Oral Sulfasalazine
58116671|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|15 Gy in one treatment
58116672|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
58116673|NCT04163692|OTHER|Progressive relaxation exercises|"Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things."
58116674|NCT05216978|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
58116675|NCT04944602|BIOLOGICAL|SYN008|injection of 300 mg
58116676|NCT04944602|BIOLOGICAL|Omalizumab for injection|injection of 300 mg
58116677|NCT04871217|DIAGNOSTIC_TEST|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
58116678|NCT01037166|DRUG|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
58116679|NCT01620983|BEHAVIORAL|Pain Coping Skills Training|
58116680|NCT01620983|BEHAVIORAL|Arthritis Education|
58116681|NCT01620983|OTHER|Usual Care|
58116682|NCT03888833|DEVICE|ECMO|ECMO installation
58116683|NCT00359970|DRUG|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
58116684|NCT00359970|DRUG|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
58116685|NCT00359970|DRUG|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
58116686|NCT00359970|OTHER|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
58116687|NCT02739815|DRUG|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
58116688|NCT02739815|DRUG|Tranexamic Acid|Tranexamic acid
58116689|NCT02802514|DRUG|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
58313027|NCT01464567|PROCEDURE|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
58116690|NCT02802514|DRUG|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
58447052|NCT01987102|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
58447053|NCT05894447|DRUG|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
58447054|NCT05894447|DRUG|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
58447055|NCT05894447|DRUG|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
58447056|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
58447057|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
58447058|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
58447059|NCT05488457|DRUG|deuterated oxytocin (d5OT)|Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
58447060|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
58447061|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
57957575|NCT03933865|DRUG|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
57957576|NCT03933865|DRUG|Placebos|Placebo will be normal saline solution given via intramuscular injection.
58116691|NCT02802514|DRUG|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
58116692|NCT02802514|DRUG|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
58313028|NCT01464567|PROCEDURE|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
58447062|NCT06440005|DRUG|AGX101|Antibody Drug Conjugate
58116693|NCT05325892|COMBINATION_PRODUCT|This is an observational study|This is an observational study
58447063|NCT02552134|OTHER|exercise training|
58313029|NCT02354118|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
58313030|NCT02354118|OTHER|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
58447064|NCT02552134|OTHER|recommendation to be active|
58447065|NCT01391663|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
58447066|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
58447067|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
58313031|NCT05248789|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
58313032|NCT02327455|PROCEDURE|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
58447068|NCT03919357|BEHAVIORAL|BMT-i|Passing the BMT-i test
58447069|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
57742048|NCT02724943|BEHAVIORAL|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
58447070|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
58447071|NCT01905878|DRUG|DLBS1033|
58313033|NCT06264713|DEVICE|Immersive Virtual Reality|Patients wear a head-mounted-display and will be immersed in a virtual environment. The stimuli will be provided in the left, center and right visual fields. Eye-tracking biofeedback will be provided about the real-time performance during each exercise.
58313034|NCT06264713|DEVICE|Sham Immersive Virtual Reality|The patients performed the same protocol of the experimental group, differently to the immersive virtual reality group, from session 2 to session 8 (7 sessions), the stimuli will be provided in the center and right visual fields.
58447072|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
58447073|NCT02416739|DRUG|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
58447074|NCT00200603|DEVICE|calcium phosphate macroporous bioceramics|
58313035|NCT01525953|DRUG|Chemotherapy|Chemotherapy according to standard
58447075|NCT03507205|DEVICE|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
58447076|NCT03507205|DEVICE|Xience Prime|Durable polymer-coated everolimus-eluting stents
58447077|NCT03507205|DEVICE|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
57742049|NCT02724943|BEHAVIORAL|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
58116694|NCT04192825|PROCEDURE|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
58116695|NCT04023565|DRUG|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
58116696|NCT04896385|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
58447078|NCT03507205|DEVICE|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
58447079|NCT03507205|DEVICE|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
58447080|NCT03500640|BEHAVIORAL|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
58313036|NCT01525953|RADIATION|Radiotherapy|Radiotherapy according to local standard
58313037|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
58313038|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
58313039|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
58313040|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
58447081|NCT03500640|BEHAVIORAL|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
58447082|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
58447083|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
58447084|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
58447085|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
58447086|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
58447087|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
58447088|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
58447089|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
58116697|NCT04896385|DRUG|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
58116698|NCT03187652|DIAGNOSTIC_TEST|CT Perfusion Study|Brain and cardiac CT perfusion scan
58313041|NCT01526980|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
57742050|NCT06221566|OTHER|Muscle Energy Technique|"Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
58116699|NCT03187652|DIAGNOSTIC_TEST|Echocardiogram|Speckle tracking Echocardiography
58116700|NCT03187652|DIAGNOSTIC_TEST|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
58116701|NCT03187652|DIAGNOSTIC_TEST|MRI|MRI to assess white matter changes
58313042|NCT01526980|DRUG|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
57742051|NCT06221566|OTHER|Stretching Exercises|"Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
57742052|NCT03181100|DRUG|Atezolizumab|Given IV
57742053|NCT03181100|BIOLOGICAL|Bevacizumab|Given IV
58116702|NCT05124691|COMBINATION_PRODUCT|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
58116703|NCT05124691|DRUG|Albendazole|Albendazole 400mg single dose
58116704|NCT02012647|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
58116705|NCT02012647|PROCEDURE|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
58116706|NCT06218420|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
58116707|NCT04517656|OTHER|Blood samples|"A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment."
58116708|NCT04039581|OTHER|Kinesio Taping|Kinesio Taping relaxation technique (muscle inhibition technique)
58116709|NCT04039581|OTHER|Conventional treatment|Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
58116710|NCT04778527|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
58116711|NCT04778527|DRUG|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
57742054|NCT03181100|DRUG|Cobimetinib|Given PO
58116712|NCT01725113|DRUG|Calcitriol|3 times weekly
58447090|NCT06725563|PROCEDURE|Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures|We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \&lt;6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.
58447091|NCT00377858|DRUG|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
58447092|NCT00377858|DRUG|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
58447093|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
58447094|NCT05067387|DRUG|Placebo|Oral placebo
58447095|NCT05067387|DRUG|THC|Oral THC (20 mg)
58447096|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
58447097|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
58116713|NCT01725113|DRUG|Paricalcitol|3 times weekly
58116714|NCT00190853|DRUG|Duloxetine|
58116715|NCT06359678|DEVICE|NorthStar|Throughout the real-time MRI-guided ablation procedure, the operator will assess the precision of the NorthStar 3D navigation software. Before commencing the actual ablation, the operator will confirm the alignment of the 3D anatomical shell, generated in NorthStar through specific electrical signals. Post the ablation procedure, a secondary alignment verification will be conducted to detect any potential drift or shift.
58447098|NCT06725901|DEVICE|Web-Based Application|The intervention involves the DIAGEN-IA platform, a diagnostic support tool designed to identify pediatric neurological diseases with a genetic basis. Using a Bayesian network model and integrating ontologies such as ORDO, HPO, and HOOM, DIAGEN-IA links phenotypic data entered by physicians to suggested diagnoses and tests. Pediatric neurologists will be trained to use the platform during a 12-month intervention. DIAGEN-IA allows clinicians to input clinical and diagnostic data, generating differential diagnoses and recommended tests, with results exportable in PDF for integration into medical records. Platform usage will be tracked, including login frequency, time spent, and evaluations performed.
58447099|NCT06128304|OTHER|Core Implementation strategies|"Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants"
58447100|NCT06128304|OTHER|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement"
58116716|NCT01117883|OTHER|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
58116717|NCT05899465|DRUG|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
58116718|NCT05899465|DRUG|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
58116719|NCT03551730|COMBINATION_PRODUCT|PRT064445/Enoxaparin|
58116720|NCT03551730|COMBINATION_PRODUCT|Placebo/Enoxaparin|
58116721|NCT03551730|DRUG|Placebo|
58313043|NCT01526980|DRUG|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
57742055|NCT03181100|DRUG|Nab-paclitaxel|Given IV
57742056|NCT03181100|DRUG|Paclitaxel|Given IV
57742057|NCT03181100|DRUG|Vemurafenib|Given PO
57742058|NCT04082546|PROCEDURE|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
57742059|NCT01175603|BEHAVIORAL|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
57742060|NCT03209804|PROCEDURE|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
58116722|NCT05824182|DEVICE|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
58116723|NCT01270022|OTHER|Implementation|
58116724|NCT01270022|OTHER|dissemination|
58116725|NCT03931096|OTHER|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
58116726|NCT04059666|OTHER|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
58116727|NCT04059666|OTHER|Control|Cow's milk-based Infant Formula
58116728|NCT00974493|DRUG|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
58116729|NCT01788722|DRUG|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
58313044|NCT03259893|OTHER|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
57742061|NCT03725917|OTHER|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
58116730|NCT03391297|BEHAVIORAL|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
58116731|NCT03436628|DEVICE|MyT1DHero|A mobile phone application
58116732|NCT04878406|DRUG|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
58116733|NCT04878406|DRUG|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
58116734|NCT04878406|DRUG|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
58313045|NCT03259893|BEHAVIORAL|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
58313046|NCT03259893|OTHER|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
58313047|NCT04938050|DIAGNOSTIC_TEST|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
58313048|NCT02057770|DRUG|busulfan|
58313049|NCT02057770|DRUG|fludarabine phosphate|
58313050|NCT02057770|RADIATION|total-body irradiation (TBI)|
58313051|NCT02057770|PROCEDURE|Stem cell transplant|
58313052|NCT02057770|DRUG|cyclophosphamide|
58313053|NCT02057770|DRUG|tocilizumab|
58313054|NCT03907345|BEHAVIORAL|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
58313055|NCT01180062|DRUG|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
58313056|NCT01180062|DRUG|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
58313057|NCT01180062|DRUG|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
58116735|NCT04878406|DRUG|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
58116736|NCT00278512|BIOLOGICAL|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
58116737|NCT00278512|BIOLOGICAL|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
58116738|NCT00278512|DRUG|Cyclophosphamide|Causes prevention of the cell division
58116739|NCT00278512|DRUG|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
58116740|NCT00278512|DRUG|G-CSF|Hematopoietic growth factor
58116741|NCT00278512|DRUG|Campath-1h|Humanized monoclonal antibody against CD52 antigen
58116742|NCT00278512|DRUG|Fludarabine|inhibits DNA synthesis or repair
58116743|NCT00278512|DRUG|Tacrolimus|immune suppressive drug
58116744|NCT00278512|DRUG|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
58116745|NCT00005910|PROCEDURE|Intraoperative ultrasound|
58116746|NCT00092859|DRUG|MK0557|
58116747|NCT01424956|DEVICE|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
58116748|NCT05864625|DRUG|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
57742062|NCT03704766|DIAGNOSTIC_TEST|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
57742063|NCT03704766|DIAGNOSTIC_TEST|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
58116749|NCT05864625|DRUG|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
58116750|NCT01953783|DRUG|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
58116751|NCT04340232|DRUG|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
58116752|NCT02492958|BIOLOGICAL|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
58116753|NCT02492958|BIOLOGICAL|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
58116754|NCT06524791|OTHER|bacteriophage detection|bacteriophage detection
58116755|NCT02875171|DRUG|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
58313058|NCT01327794|GENETIC|polymorphism analysis|
58313059|NCT01327794|OTHER|immunologic technique|
58313060|NCT01327794|OTHER|laboratory biomarker analysis|
58313061|NCT01327794|OTHER|medical chart review|
58313062|NCT03394937|BIOLOGICAL|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
58313063|NCT00380900|DRUG|AGG-523|
58313064|NCT01800253|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
57742064|NCT03704766|DIAGNOSTIC_TEST|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
57742065|NCT03704766|DIAGNOSTIC_TEST|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
57742066|NCT03704766|DIAGNOSTIC_TEST|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
57742067|NCT03704766|DIAGNOSTIC_TEST|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
58313065|NCT01800253|PROCEDURE|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
58313066|NCT01800253|PROCEDURE|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
58116756|NCT06546878|PROCEDURE|Cardiac Rehabilitation (Phase I) - nurse intervention|"The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver."
58116757|NCT04178915|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
58116758|NCT04178915|DIAGNOSTIC_TEST|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
58116759|NCT02363010|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
58116760|NCT02363010|BEHAVIORAL|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
58116761|NCT02363010|BEHAVIORAL|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
58116762|NCT04799210|DEVICE|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
58116763|NCT04038970|BIOLOGICAL|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
58116764|NCT04038970|BIOLOGICAL|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
58116765|NCT04038970|BIOLOGICAL|Placebo|Solution, intravenous, Placebo
58116766|NCT04038970|COMBINATION_PRODUCT|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
58116767|NCT01125995|RADIATION|early CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
58116768|NCT01125995|RADIATION|late CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
58116769|NCT05107284|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
58116770|NCT05107284|BEHAVIORAL|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
58116771|NCT00222677|DRUG|aspirin|100 mg daily
58116772|NCT01957683|DEVICE|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
58116773|NCT03027336|DIETARY_SUPPLEMENT|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
58116774|NCT03027336|DIETARY_SUPPLEMENT|Placebo|patients will take one tablet daily for 12 weeks.
58116775|NCT01717456|OTHER|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
58116776|NCT01717456|DIETARY_SUPPLEMENT|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
58116777|NCT01717456|DRUG|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
58116778|NCT01717456|BEHAVIORAL|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
58116779|NCT01717456|BEHAVIORAL|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
58116780|NCT01717456|BEHAVIORAL|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
58116781|NCT01717456|OTHER|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
58116782|NCT03905291|DRUG|MT921|Formulated as an injectable solution
58116783|NCT03905291|DRUG|Placebo|normal saline
58116784|NCT05170828|DRUG|Cyclophosphamide|pre-transplant conditioning treatment
58116785|NCT05170828|DRUG|Fludarabine|pre-transplant conditioning treatment
58116786|NCT05170828|RADIATION|Total Body Irradiation|pre-transplant conditioning treatment
58116787|NCT05170828|DRUG|Busulfan|pre-transplant conditioning treatment
58116788|NCT05170828|DRUG|Mesna|given with cyclophosphamide
58116789|NCT05170828|DRUG|Sirolimus|post-transplant treatment for GVHD
58116790|NCT05170828|DRUG|Mycophenolate Mofetil|post-transplant treatment for GVHD
58447101|NCT03766126|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg."
58447102|NCT06204250|DRUG|GS1-144|Oral tablets.
58447103|NCT06204250|DRUG|Placebo|Matching placebo tablets.
58447104|NCT06725693|DIAGNOSTIC_TEST|18F/68Ga-Exendin 4|Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
58116791|NCT05170828|DRUG|Filgrastim|post-transplant treatment for GVHD
58116792|NCT05170828|DRUG|Cyclophosphamide|post-transplant treatment for GVHD
58116793|NCT05170828|PROCEDURE|Bone Marrow Transplant|Transplant with investigational bone marrow product
58116794|NCT04512768|BEHAVIORAL|Transdiagnostic Internet-delivered Cognitive Behaviour Therapy|All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
58313067|NCT01800253|PROCEDURE|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
58313068|NCT01800253|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
58447105|NCT06726798|PROCEDURE|Endoscopic submucosal dissection with EndoRobotics traction device|All patients received robotic ESD under general anesthesia or monitored anaesthetic care at the endoscopy center of Prince of Wales Hospital. The targeted lesion would first be localized and pre-injected using a mixture of normal saline, indigocarmine, epinephrine and sodium hyaluronate. The robotic endoscopic traction device was then inserted to reach the target. Mucosal incision first started from the anal side followed by lifting with the grasper\[Figure 1; Video 1\]. Vio 3 diathermy system (ERBE, Germany) was used with endocut Q effect 3 and forced coagulation effect 3. Further submucosal dissection would be performed by electrocautery knife with traction achieved via EndoRobotics traction. Upon completion, the specimen would be retrieved upon withdrawal of the whole system.
58447106|NCT06447415|DRUG|HRS-7450|HRS-7450 Injection
58447107|NCT06447415|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection
58313069|NCT05466058|DIAGNOSTIC_TEST|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
58116795|NCT04512768|BEHAVIORAL|Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia|A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
58116796|NCT06223581|OTHER|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
58116797|NCT03128593|DRUG|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
58116798|NCT02114931|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
58116799|NCT04104646|DRUG|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
58116800|NCT04104646|DRUG|Morphine|Oral morphine administration at starting dose of 0.07 mg/kg q4
58116801|NCT04104646|DRUG|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
58447108|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
57742068|NCT03704766|DIAGNOSTIC_TEST|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
57742069|NCT03704766|DIAGNOSTIC_TEST|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
57742070|NCT03704766|DIAGNOSTIC_TEST|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
57742071|NCT03704766|DIAGNOSTIC_TEST|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
57742072|NCT03704766|DIAGNOSTIC_TEST|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
57742073|NCT03704766|DIAGNOSTIC_TEST|Synovial PCR for Kingella kingae|In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
58116802|NCT04104646|DRUG|Morphine matched placebo|Oral morphine matched placebo administration
58447109|NCT06020781|DRUG|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
58447110|NCT06020781|DRUG|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
58447111|NCT06020781|DRUG|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
58447112|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
57742074|NCT03704766|DIAGNOSTIC_TEST|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
57742075|NCT03704766|DIAGNOSTIC_TEST|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
57742076|NCT03704766|DIAGNOSTIC_TEST|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
57742077|NCT03704766|DIAGNOSTIC_TEST|Serum D-dimer|A blood test performed at the hospital.
57742078|NCT03704766|DIAGNOSTIC_TEST|Serum Procalcitonin|A blood test performed at the hospital.
57742079|NCT03704766|DIAGNOSTIC_TEST|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
57742080|NCT03704766|DIAGNOSTIC_TEST|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
57742081|NCT06732544|OTHER|snoezelen room|During the travail, projectors, starry ceiling visuals and blue light LEDs will be used for visual stimuli, speakers will be used as auditory stimuli, diffusers will be used for olfactory stimuli, and therapy dough will be used for touch stimuli.
57742082|NCT06732544|OTHER|routine delivery room|General practice
57742083|NCT03602118|DRUG|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
57742084|NCT04088409|DRUG|Baricitinib|Administered orally
58447113|NCT05013359|OTHER|No treatment given|No treatment given
58447114|NCT02009488|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
58447115|NCT02009488|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
58116803|NCT04919928|DEVICE|Cochlear Implant and Hearing aid in bimodal solution|"Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear."
58116804|NCT04919928|DEVICE|Bilateral hearing aids|Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
58116805|NCT00190866|DRUG|Duloxetine|
58116806|NCT00190866|DRUG|placebo|
58116807|NCT02844374|OTHER|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
58447116|NCT02009488|DRUG|Placebo|One placebo capsule (inactive medication) once daily.
58116808|NCT01873859|DRUG|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
58447117|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
57742085|NCT04088409|DRUG|Adalimumab|Administered SC
57742086|NCT02612948|DRUG|Quetiapine|escalating dose to prevent delerium.
58116809|NCT06437132|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
58447118|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
58447119|NCT04372823|BEHAVIORAL|Policy/program|Policy/program to improve nutrition and increase physical activity
58447120|NCT02551263|DRUG|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
58447121|NCT05027867|DRUG|KRT-232|Administered by mouth
58447122|NCT03785704|DRUG|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
58447123|NCT00287716|DRUG|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
58447124|NCT00287716|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
58447125|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
58447126|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
58447127|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
57742087|NCT06670261|OTHER|Data collection|Retrospective pseudo-anonymized clinical and scannographic data from the routine management of patients in rhino-sinusology consultations.
58447128|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
57742088|NCT01912612|DRUG|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
57742089|NCT05363566|DEVICE|airway divice|inserted airway device
57742090|NCT04321538|DEVICE|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
57742091|NCT04321538|DEVICE|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
58313070|NCT01204242|DRUG|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
57742092|NCT04321538|DIAGNOSTIC_TEST|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
58313071|NCT01204242|DRUG|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
58313072|NCT04472572|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients with COVID-19 infection
57742093|NCT05318794|DRUG|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
57742094|NCT03863340|BEHAVIORAL|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch"
58313073|NCT01790399|PROCEDURE|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
58313074|NCT00447681|DRUG|ILV-094|
58313075|NCT01738958|BIOLOGICAL|L. retueri|two tablets a day for 6 weeks
58447129|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
57742095|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
57742096|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
57742097|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
57742098|NCT01088932|DRUG|SRX246|capsules
57742099|NCT04906395|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
58313076|NCT01738958|BIOLOGICAL|Placebo|
58313077|NCT00703534|DRUG|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
58313078|NCT00703534|DRUG|Placebo|capsule. administered as a single dose twice daily for 4 weeks
58313079|NCT00703534|DRUG|Gelusil®|Chewable tablets taken as needed
58447130|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
58447131|NCT02780492|OTHER|Set of assessment tools|
58116810|NCT03760393|BEHAVIORAL|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
58116811|NCT01934374|BEHAVIORAL|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
58116812|NCT00671879|DRUG|Carisoprodol SR 700 mg|700 mg twice daily tablet
58116813|NCT00671879|DRUG|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
58116814|NCT00671879|DRUG|Placebo|placebo tablet
58116815|NCT02251587|OTHER|Standard Weight Management Program|Standard Diet program based on diet and exercise.
58116816|NCT02251587|OTHER|Sensible Weigh Program|Weight loss program designed for low income women.
58116817|NCT00001728|DRUG|Fosamax (Alendronate)|
58313080|NCT00408499|DRUG|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
58313081|NCT00408499|DRUG|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
58313082|NCT01375101|DRUG|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
58313083|NCT01375101|DRUG|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
58447132|NCT00649506|DRUG|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
58447133|NCT00649506|DRUG|Macrodantin® 100 mg Capsules|100mg, single dose fed
58447134|NCT03337334|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
58447135|NCT04320784|OTHER|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
58447136|NCT04320784|OTHER|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
58447137|NCT04661046|DRUG|Traditional Chinese Medicine|Chinese medicine prescription
58447138|NCT01550757|BEHAVIORAL|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
58447139|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
58447140|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
58447141|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
58447142|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
58447143|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
58447144|NCT01011374|DRUG|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
58447145|NCT06726200|DRUG|Buprenorphine + naloxone (Suboxone)|Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care
58447146|NCT06726200|DRUG|Buprenorphine Injection|Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
58313084|NCT03962361|OTHER|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
58313085|NCT01409668|DIETARY_SUPPLEMENT|L. Amylovorus|L. Amylovorus
58116818|NCT03069079|PROCEDURE|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
58116819|NCT03027570|BEHAVIORAL|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
58116820|NCT03027570|BEHAVIORAL|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
58116821|NCT03027570|OTHER|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
58116822|NCT05092061|OTHER|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
58116823|NCT05092061|OTHER|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
58116824|NCT04161794|OTHER|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
58116825|NCT04622384|OTHER|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
58116826|NCT03336983|DRUG|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
58116827|NCT03336983|DRUG|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
58116828|NCT03974594|DRUG|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
58116829|NCT03974594|DRUG|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
58116830|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
58116831|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
58116832|NCT00384033|DRUG|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
58116833|NCT00384033|DRUG|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
58116834|NCT02669264|DRUG|ADCT-402|Intravenous infusion
58116835|NCT00991770|OTHER|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
58116836|NCT00991770|OTHER|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
58447147|NCT06725368|DRUG|PCC|"PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death."
58447148|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
58447149|NCT01372566|DEVICE|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
58447150|NCT01372566|OTHER|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
58447151|NCT04528719|BIOLOGICAL|mRNA-1345|Formulation for injection
58116837|NCT02456233|PROCEDURE|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
58447152|NCT04528719|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
58447153|NCT03325959|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 HBOT sessions at 2 ATA 100% oxygen
58116838|NCT02456233|PROCEDURE|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
58116839|NCT00368537|DRUG|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
58116840|NCT00368537|DRUG|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
58313086|NCT01409668|DIETARY_SUPPLEMENT|L. Fermentum|L. Fermentum
58313087|NCT03883386|DRUG|Loratadine|10 mg in a capsule
58313088|NCT03883386|DRUG|Placebo|Administered via capsule
58313089|NCT05264116|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
58447154|NCT03325959|DRUG|Cymbalta / Lyrica treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
58447155|NCT03325959|DEVICE|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
58447156|NCT02754726|DRUG|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
58447157|NCT02754726|DRUG|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
58447158|NCT02754726|DRUG|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
58447159|NCT02754726|DRUG|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
58116841|NCT00843453|OTHER|blood collection|blood collection
58116842|NCT00843453|DRUG|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
58447160|NCT02754726|DRUG|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
58447161|NCT04514822|DIAGNOSTIC_TEST|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
58447162|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
58447163|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
58116843|NCT00701428|DRUG|Losartan|Losartan 50 mg daily during 6 + 6 weeks
58116844|NCT00701428|OTHER|CPAP|CPAP during the second 6 week-period
58116845|NCT03801837|DIETARY_SUPPLEMENT|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\]
58447164|NCT04579471|DIAGNOSTIC_TEST|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
58447165|NCT05481775|DRUG|Anlotinib|Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
58447166|NCT05481775|DRUG|Chemotherapy|Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
58447167|NCT05481775|RADIATION|Radiotherapy|Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
58447168|NCT05481775|DRUG|Immunotherapy|consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
58447169|NCT02548208|DEVICE|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
58313090|NCT04049461|DIAGNOSTIC_TEST|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
58313091|NCT04049461|RADIATION|Abdominal CT scan|Observe whether HOAI occurs.
58313092|NCT00318396|PROCEDURE|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
58447170|NCT02548208|DEVICE|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
58313093|NCT00318396|PROCEDURE|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
58313094|NCT02346864|BEHAVIORAL|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
58116846|NCT03801837|DIETARY_SUPPLEMENT|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
58116847|NCT01532245|OTHER|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
58116848|NCT01532245|OTHER|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
58116849|NCT01532245|OTHER|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
58116850|NCT02796196|OTHER|Medical Chart Review|Review of medical chart
58116851|NCT02796196|DEVICE|Monitoring Device|Wearable physical activity monitoring device
58116852|NCT02796196|PROCEDURE|Physical Therapy|Undergo primarily self-directed physical therapy
58116853|NCT03929211|DRUG|CPI-613|Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
58116854|NCT03929211|DRUG|Hydroxychloroquine|Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
58116855|NCT00371800|DRUG|cinnamon|
58116856|NCT02668783|DRUG|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
58116857|NCT02668783|DRUG|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
58116858|NCT02668783|DRUG|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
58116859|NCT01857193|DRUG|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
58116860|NCT01857193|DRUG|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
58116861|NCT01857193|DRUG|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
58116862|NCT04248855|DRUG|KAN-101|Intravenous (IV) infusion
58116863|NCT04248855|DRUG|Placebo|Intravenous (IV) infusion
58116864|NCT02352506|OTHER|Blood draw for measurement of MIF|Observational study, no intervention
58116865|NCT03244956|DRUG|Trametinib|2mg daily for a maximum of 6 weeks of treatment
58116866|NCT03244956|DRUG|Dabrafenib|150mg twice daily
58116867|NCT03244956|RADIATION|131I|5.5 GBq
58116868|NCT03244956|DRUG|rhTSH|0.9mg on two consecutive days after 35 days of treatment
58116869|NCT01241409|DRUG|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
58313095|NCT02346864|BEHAVIORAL|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
58447171|NCT05404048|OTHER|89Zr-atezolizumab PET-imaging|89Zr-atezolizumab tracer injection + PET/CT-scan
58447172|NCT01424501|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
58447173|NCT01424501|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
58116870|NCT01241409|DRUG|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
58116871|NCT01241409|DRUG|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
58116872|NCT03192059|DRUG|Pembrolizumab|Efficacy of the combined treatment
58116873|NCT03192059|RADIATION|Radiation|Efficacy of the combined treatment
58116874|NCT03192059|DRUG|Vitamin D|Efficacy of the combined treatment
58116875|NCT03192059|DRUG|Aspirin|Efficacy of the combined treatment
58116876|NCT03192059|DRUG|Lansoprazole|Efficacy of the combined treatment
58116877|NCT03192059|DRUG|Cyclophosphamide|Efficacy of the combined treatment
58116878|NCT03192059|DIETARY_SUPPLEMENT|Curcumin|Efficacy of the combined treatment
58313096|NCT03707002|DIETARY_SUPPLEMENT|scFOS|daily intake for 6 weeks
58116879|NCT03249090|OTHER|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
58116880|NCT03249090|OTHER|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
58116881|NCT04739449|BEHAVIORAL|Coaching, Cleaning, Communication, Collaboration|"1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise"
58116882|NCT01266174|DRUG|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
58116883|NCT01266174|DRUG|Placebo|Placebo to match eltoprazine
58116884|NCT00192296|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
58116885|NCT00192296|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
57742100|NCT04906395|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet or solution
58116886|NCT00192296|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
58116887|NCT00192296|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
58116888|NCT00424658|PROCEDURE|SAHS diagnosis|
58116889|NCT00557882|DEVICE|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
58313097|NCT03707002|DIETARY_SUPPLEMENT|Maltodextrin|daily intake for 6 weeks
58447174|NCT01301313|DRUG|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
58447175|NCT01301313|DRUG|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
58447176|NCT06280092|DRUG|AMSCs|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
58447177|NCT00391144|PROCEDURE|intravitreal triamcinolone injection of avastin (1.25 mg)|
58447178|NCT04358692|DEVICE|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
58447179|NCT01128426|OTHER|No Intervention|No Intervention
58447180|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
58447181|NCT05597033|BEHAVIORAL|Control|seated rest
58447182|NCT02331186|PROCEDURE|bariatric surgery|bariatric surgery for obese women
57742101|NCT04906395|DRUG|Letrozole Tablets|One 2.5 mg tablet taken orally once daily
57742102|NCT04906395|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
57742103|NCT04906395|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
57742104|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
57742105|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
57742106|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
57742107|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
58116890|NCT03758833|DIAGNOSTIC_TEST|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
58116891|NCT03758833|PROCEDURE|Single embryo transfer|Transfer of single embryo
58116892|NCT03758833|PROCEDURE|Double embryo tranfer|Transfer of two embryos
58116893|NCT06355739|DEVICE|CAR T cell injection|intravenous injection
58116894|NCT04711525|BEHAVIORAL|Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
58116895|NCT04711525|BEHAVIORAL|Control Group: Standard health education|The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
58116896|NCT05252416|DRUG|BLU-222|Oral administration
58116897|NCT05252416|DRUG|Carboplatin|IV Infusion
57742108|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
57742109|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
58116898|NCT05252416|DRUG|Ribociclib|Oral administration
58116899|NCT05252416|DRUG|Fulvestrant|Intra muscular administration
58116900|NCT04388059|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
58116901|NCT02397681|OTHER|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
58116902|NCT02153047|BEHAVIORAL|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
58116903|NCT03389984|DIAGNOSTIC_TEST|cutaneous|SKIN BIOPSY
58116904|NCT06064253|BEHAVIORAL|health education|adherence to treatment
58116905|NCT01514266|DRUG|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
58116906|NCT01514266|DRUG|Placebo|
58116907|NCT05765955|DRUG|POLB 001|Investigational Medicinal Product
58116908|NCT05765955|DRUG|Placebo|Matching Placebo
58116909|NCT00021658|PROCEDURE|Pesticide application procedures|
58116910|NCT00406978|DRUG|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
58116911|NCT00406978|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
58116912|NCT00406978|DRUG|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
58116913|NCT00406978|DRUG|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
58116914|NCT00020891|PROCEDURE|computed tomography|
58116915|NCT00020891|RADIATION|radiation therapy|
58116916|NCT01519128|DRUG|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
58116917|NCT01519128|DRUG|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
57742110|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
57742111|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
57742112|NCT03845153|DRUG|Metformin Retard 850 mg|tablet
57742113|NCT03845153|OTHER|Placebo|placebo tablet
58116918|NCT04615442|DEVICE|Epihunter|Subjects wear epihunter during routine video EEG
58116919|NCT01615081|OTHER|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
58313098|NCT06381232|OTHER|No Intervention|This is an observational study, there are no interventions.
58313099|NCT04861792|BEHAVIORAL|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
58313100|NCT04673773|BEHAVIORAL|A Massive Open Online Course|Same as intervention
58116920|NCT06141915|OTHER|Aerobic training|"patients will be engaged in aerobic training using treadmill three times per week, for 12 weeks. The exercise intensity will be 50-70% of each patient's maximum heart rate. Each exercise session will consist of three phases; five-minutes warming up phase in form of stretching exercises and walking on the treadmill at the slowest speed, 20-minutes conditioning phase in form of walking on the treadmill at 50% of participants' maximum heart rate in the first two weeks then progressed gradually to reach the 70% of maximum heart rate by the 12th weeks, and five-minutes cool down phase that will be constant as warming up phase. During the training, the patient's blood pressure, heart rate, and breathing pattern will be frequently monitored"
58116921|NCT06141915|OTHER|diet protocol|diet protocol
58313101|NCT03913039|PROCEDURE|Transperineal biopsy Protocol|"1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
58313102|NCT01381120|DRUG|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
57742114|NCT03088826|DRUG|Morphine Sulfate|15mg PO morphine sulfate
57742115|NCT03088826|DRUG|Oxycodone|10mg Oxycodone
57742116|NCT03088826|DRUG|Acetaminophen|650 mg Acetaminophen
58116922|NCT03776409|DRUG|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
58116923|NCT03776409|DRUG|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
58116924|NCT02611284|PROCEDURE|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
58116925|NCT02611284|PROCEDURE|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
57742117|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
58116926|NCT02701075|DEVICE|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
58116927|NCT02701075|DEVICE|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
58116928|NCT01738581|DEVICE|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
57742118|NCT03678753|DRUG|Placebo|Matching Placebo
57742119|NCT05895461|BEHAVIORAL|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
57742120|NCT05895461|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
57742121|NCT00002803|DRUG|cyclophosphamide|
57742122|NCT00002803|DRUG|doxorubicin hydrochloride|
57742123|NCT00002803|DRUG|vincristine sulfate|
58313103|NCT01381120|DRUG|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
58313104|NCT00155987|PROCEDURE|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
58313105|NCT00398229|DRUG|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
57742124|NCT00002803|PROCEDURE|conventional surgery|
57742125|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
58447183|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by packs|GROUP A: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by packs on non woven gauzes entirely covering the area. Eventually, if dried, gauzes are externally watered with additional sulphurous thermal water during the 20 minutes. After water application the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
58447184|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by limb full immersion|GROUP B: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by limb full immersion in a limb tub. After the immersion, the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
58447185|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
58447186|NCT05633472|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
58447187|NCT05633472|OTHER|Placebo|Placebo
58447188|NCT05859074|BIOLOGICAL|MQ719|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
58447189|NCT05859074|DRUG|Pembrolizumab|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
58447190|NCT04647240|BIOLOGICAL|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
58447191|NCT01964963|DRUG|Alogliptin|Alogliptin tablets
58447192|NCT06319534|BEHAVIORAL|Comprehensive rehabilitation|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
58447193|NCT06319534|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58447194|NCT06319534|DRUG|Lidocaine Hydrochloride|the patients are provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58447195|NCT06319534|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58447196|NCT01594229|DRUG|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
58447197|NCT01594229|DRUG|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
57742126|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
58447198|NCT01594229|DRUG|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
58447199|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
58447200|NCT00889512|DRUG|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
58447201|NCT00889512|DRUG|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
58116929|NCT01738581|BEHAVIORAL|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
58116930|NCT01738581|BEHAVIORAL|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
57742127|NCT06053476|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
58116931|NCT04989062|DIAGNOSTIC_TEST|Fibroscan|Controlled attenuation parameter and liver stiffness measurement are measured.
58116932|NCT04989062|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
57742128|NCT06053476|PROCEDURE|Single-shot paravertebral block|At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
58447202|NCT03030417|DRUG|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
58447203|NCT03030417|OTHER|Ondansetron|Anti-emetic for nausea or vomiting.
57742129|NCT06053476|PROCEDURE|Late chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system"
57742130|NCT06053476|PROCEDURE|Early chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system"
57742131|NCT01587508|DRUG|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
57742132|NCT01587508|DRUG|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
57742133|NCT01587508|DRUG|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
57742134|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
57742135|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
57742136|NCT06722222|PROCEDURE|Gao's triple eversion carotid endarterectomy|The carotid sheath is dissected in front of the sternocleidomastoid muscle to expose sufficient lengths of the CCA, ECA, and ICA. After raising the systolic blood pressure to 180 mmHg and intravenously injecting 1 mg/kg heparin, the superior thyroid artery is lapped and severed, and the CCA is occluded proximally to the CCA plaque, based on the plaque location shown by preoperative CTA and by intraoperative arterial exploration. Subsequently, the ECA and ICA are blocked individually. The ICA is cut diagonally at the CCA fork and the ECA is transected approximately 5 mm above its beginning. The plaque is removed with tweezers after eversion of the ICA. This process is repeated for the ECA. Finally, the long segment of plaque in the CCA is stripped proximally, followed by thorough removal of the debris on the peeling surface using heparin irrigation.
57742137|NCT00259051|DRUG|Omeprazole|
57742138|NCT01568333|DRUG|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
57742139|NCT05824026|DEVICE|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
57742140|NCT00149513|BEHAVIORAL|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
58447204|NCT03030417|OTHER|Olanzapine|Persistent nausea or vomiting.
57742141|NCT00149513|BEHAVIORAL|Usual care|Participants will receive usual care.
57742142|NCT00898885|PROCEDURE|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
57742143|NCT02264028|DRUG|[14C]-DK-AH 269 CL, solution for infusion|
57742144|NCT02264028|DRUG|[14C]-DK-AH 269 CL, drinking solution|
58116933|NCT04989062|DIAGNOSTIC_TEST|Urine unclear magnetic resonance metabolomics|Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
58116934|NCT04989062|DIAGNOSTIC_TEST|Hand grip strength|Hand grip strength in both hands is measured by hand-held dynamometer.
57742145|NCT01464541|PROCEDURE|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
57742146|NCT01464541|PROCEDURE|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
57742147|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
57742148|NCT05198830|DRUG|Carboplatin|Given IV
58313106|NCT05246995|DRUG|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
57742149|NCT05198830|DRUG|Cisplatin|Given IV
57742150|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
57742151|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
57742152|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
57742153|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57742154|NCT05198830|DRUG|Methoxyamine|Given PO
57742155|NCT05198830|DRUG|Pemetrexed|Given IV
57742156|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
58116935|NCT05379543|OTHER|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
58116936|NCT03903484|OTHER|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
58116937|NCT03836781|DRUG|Ketorolac|Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
58116938|NCT03836781|DRUG|Chlorhexidine 2%|Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
58116939|NCT05361148|OTHER|no interventions will be used|This is a cohort study with no interventions.
58116940|NCT01995617|BIOLOGICAL|Placebo|normal saline, 0.5 mL per dose
58116941|NCT01995617|BIOLOGICAL|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
58116942|NCT01995617|BIOLOGICAL|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
58116943|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
58116944|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
58116945|NCT01995617|BIOLOGICAL|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
57742157|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
57742158|NCT02630628|DRUG|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
57742159|NCT02630628|DRUG|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
58313107|NCT06514235|OTHER|Observational study (Non-interventional study)|This is an observational study.
58313108|NCT03931564|PROCEDURE|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
58313109|NCT03931564|PROCEDURE|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
57742160|NCT06118411|DRUG|Upadacitinib|Oral Tablets
57742161|NCT06118411|DRUG|Placebo|Oral Tablets
57742162|NCT06118411|OTHER|NB-UVB (narrow-band ultraviolet B) Phototherapy|NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
57742163|NCT03731273|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
57742164|NCT06733285|DRUG|Sensodyne Rapid Relief|Toothpaste containing 0.454 % weight/weight (w/w) SnF2 (1100 parts per million \[ppm\] fluoride).
57742165|NCT06733285|DRUG|Colgate Cavity Protection|A regular fluoride toothpaste containing 1000 ppm fluoride.
57742166|NCT06240442|OTHER|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
57742167|NCT06240442|OTHER|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
57742168|NCT06701539|DRUG|Liposome bupivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.
58116946|NCT01995617|BIOLOGICAL|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
58116947|NCT03086720|PROCEDURE|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
58116948|NCT03086720|PROCEDURE|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
58116949|NCT05332210|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
58116950|NCT03713710|BEHAVIORAL|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
58116951|NCT03713710|BEHAVIORAL|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
58116952|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
58116953|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
58116954|NCT00614055|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
58116955|NCT00614055|DRUG|metformin|Tablets, 1500-2000 mg/day
58313110|NCT00142415|DRUG|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
58313111|NCT00142415|DRUG|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
58313112|NCT02188160|DRUG|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
58313113|NCT02188160|DRUG|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
58313114|NCT04440488|BIOLOGICAL|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
58116956|NCT02853929|BIOLOGICAL|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
58116957|NCT05593406|DEVICE|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
58116958|NCT05593406|OTHER|Control Group|NDT treatment 2 sessions per week
58116959|NCT01523795|OTHER|Motion-controlled video gaming|Play of motion-controlled video games for one hour
58116960|NCT01523795|OTHER|Traditional video gaming|Participants played traditional video games for one hour
58116961|NCT01523795|OTHER|Television watching|Participants watched television for one hour
58116962|NCT03348709|DIETARY_SUPPLEMENT|Isoosmolar|48 hours, 800 ml per 24 hours
58116963|NCT03348709|DIETARY_SUPPLEMENT|Hyperosmolar|48 hours, 800 ml per 24 hours
58116964|NCT02531542|DEVICE|Echocardiography according to the READ method.|"* Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
58116965|NCT01684566|DEVICE|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
58116966|NCT01684566|OTHER|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
58116967|NCT01808209|DEVICE|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
58116968|NCT01808209|DEVICE|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
58116969|NCT01178983|DEVICE|surface electromyography|Surface electromyography (SEMG) telebiofeedback
58116970|NCT01178983|DEVICE|surface electromyography|conventional biofeedback
58116971|NCT03811041|OTHER|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
58116972|NCT03811041|OTHER|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
58116973|NCT03811041|OTHER|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
58116974|NCT02062606|DEVICE|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
58116975|NCT05273385|DEVICE|Nanodropper|Device to apply liquid medication to eyes
58447205|NCT03030417|OTHER|Lorazepam|Persistent nausea or vomiting.
58116976|NCT04783363|OTHER|Snoezelen session|before one of two repeated invasive care
58116977|NCT01816698|DRUG|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
58116978|NCT01816698|DRUG|Placebo|Placebo: 1 package once a day after meals, 12 weeks
58447206|NCT03030417|OTHER|Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate|Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.
58116979|NCT01063478|DRUG|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
58116980|NCT04877184|DEVICE|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~* transcranial ultrasound stimulation: during 4 weeks~* rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
58447207|NCT03030417|OTHER|Loperamide|Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.
58447208|NCT03030417|OTHER|Diphenhydramine|Diphenhydramine 50 mg intravenous (IV) for allergic reaction.
58116981|NCT04877184|DEVICE|Rehabilitation|"The participants in control group would received rehabilitation therapy.~- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
58116982|NCT05139693|DEVICE|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
58116983|NCT06169774|OTHER|Educational video|Watch the 17-minute educational video as many times as needed within a 12-month period.
58116984|NCT00002315|DRUG|Netivudine|
58116985|NCT00002315|DRUG|Acyclovir|
58116986|NCT03164954|DIAGNOSTIC_TEST|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
58116987|NCT02646345|PROCEDURE|Surgical checklist|Use of the World Health Organization Surgical checklist
58116988|NCT06014450|RADIATION|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
58116989|NCT06173245|PROCEDURE|Intravitreal injection of ranibizumab|"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."
58116990|NCT01080027|DRUG|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
58116991|NCT02115256|DRUG|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
58116992|NCT02115256|DRUG|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
58447209|NCT03030417|OTHER|Steroid|For allergic reaction at discretion of principal investigator.
58116993|NCT01441271|PROCEDURE|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.
58116994|NCT01441271|PROCEDURE|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
58116995|NCT04473079|DIETARY_SUPPLEMENT|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
57742169|NCT06701539|DRUG|Ropivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
58447210|NCT03030417|OTHER|Epinephrine|For allergic reaction at discretion of principal investigator.
58447211|NCT06727422|DRUG|rifaximin 66mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
58447212|NCT06727422|DRUG|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
58116996|NCT04473079|DIETARY_SUPPLEMENT|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
58116997|NCT01793610|DRUG|Comparative-dose (40mg) MDMA|An initial comparator-dose of 40 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg MDMA).
58447213|NCT06727422|DRUG|Placebo|placebo three times daily
58447214|NCT01930942|RADIATION|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
58447215|NCT04705246|BEHAVIORAL|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
58447216|NCT01299181|DRUG|Atorvastatin|80mg once daily orally
58447217|NCT00041379|DRUG|beta alethine|
58447218|NCT04458909|DRUG|Carboplatin|Given IV
58447219|NCT04458909|DRUG|Cisplatin|Given IV
58447220|NCT04458909|DRUG|Gemcitabine|Given IV
58447221|NCT04458909|BIOLOGICAL|Nivolumab|Given IV
58447222|NCT04458909|OTHER|Questionnaire Administration|Ancillary studies
58447223|NCT06726538|BIOLOGICAL|Intravenous administration of Autologous, adipose-derived mesenchymal stem cells|"Patients in group A will receive two infusions of autologous, adipose-derived mesenchymal stem cells at day 0 and day 90 ± 14 at a dose of 10\^6 cells/kg.~Autologous, adipose-derived mesenchymal stem cells used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5%. For clinical use, cells at passage 3 will be harvested in 100 mL Ringer's lactate. Therapeutic ASC products must pass the following releasing criteria: (1) negative for bacteria, fungi and mycoplasma; (2) more than 90% viability; (3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and (4) endotoxin \<5 EU/kg. The patient will be infused with 1x106 cells/kg body weight within 60 minutes via the intravenous route."
58447224|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
58447225|NCT03458949|OTHER|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
58447226|NCT05902598|DRUG|VSA001 injection|also referred to as ARO-APOC3
58447227|NCT05902598|DRUG|Placebo|Matching VSA001 injection
58447228|NCT05684068|PROCEDURE|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
57742170|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
57742171|NCT05338970|DRUG|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
57742172|NCT05338970|DRUG|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W
57742173|NCT05289726|DRUG|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
57742174|NCT05289726|DRUG|Placebo|he control group received placebo granules mixed with dextrin and food coloring
57742175|NCT02362529|DRUG|Minocycline|50 mg and 100 mg capsule, oral administration
57742176|NCT02362529|DRUG|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
57742177|NCT02362529|DRUG|Celecoxib|100 mg and 200 mg capsules, oral administration.
57957577|NCT01019382|DRUG|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
58116998|NCT01793610|DRUG|Active Dose 2 (100 mg) MDMA|An initial dose of full-dose 100 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg MDMA).
58447229|NCT05684068|PROCEDURE|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
58447230|NCT03896321|DRUG|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
58447231|NCT03896321|DRUG|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
58447232|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
58447233|NCT03784677|DRUG|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
58447234|NCT02509845|DRUG|C16G2|Antimicrobial peptide
58447235|NCT02509845|OTHER|Placebo|Placebo
58447236|NCT06577987|DRUG|CID-078 Monotherapy|Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
58447237|NCT05734755|BEHAVIORAL|The Individualized Dietary Behavioural Change Programme (IDBC)|The first three weekly face-to-face sessions will be during the 'goal initiation' and 'planning' phases. The remaining seven face-to-face sessions will be offered once to twice per month between weeks 4 and 24 during the program at the 'action execution' phase. Family members will be encouraged to join the dietary consultations. Strategies will be discussed with the family members to facilitate the participant's adherence to the recommended diet regimen.Phase I Goal Initiation is aimed at motivating the participants to actively manage their sarcopenic obesity. Phase II Plan Formulation is aimed at guiding the participants in transforming their (sub-) goals into detailed individualized action plans.Phase III Action Execution is aimed at encouraging the participants to continually execute the action plan. The IDBC guidebook will be given to the participants to guide them on how to gradually adopt our dietary recommendations in their daily life.
58447238|NCT05734755|BEHAVIORAL|The Exercise Training|The group size will be \< 10. They will be used in the resistance exercise in this study to improve muscle strength (20 mins). Brisk walking (20 mins) will be employed in the aerobic exercise in this study. Each session will include 10 minutes of warm-up and cool-down exercises at the beginning and at the end. A YouTube video and a pamphlet describing the different types of exercises used in this programme will be disseminated to all participants to encourage them to continually practise their exercises at home for 30 minutes at least 5 times per week.
58447239|NCT02538601|BEHAVIORAL|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
57957578|NCT06307912|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
57957579|NCT06307912|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
57957580|NCT04864730|OTHER|No intervention|No intervention
57957581|NCT04749459|DRUG|ChapStick Moisturizer, Strawberry Flavor|A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.
57957582|NCT04749459|DRUG|ChapStick Moisturizer, Classic Flavor|A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
57957583|NCT04749459|DRUG|ISO 24444:2010 P2 Standard Reference Sunscreen|A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
57957584|NCT05469347|DRUG|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
57957585|NCT05469347|DRUG|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
58116999|NCT01793610|DRUG|Active Dose 1 (125 mg) MDMA|An initial dose of full-dose 125 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg MDMA).
58117000|NCT01793610|BEHAVIORAL|Psychotherapy|Psychotherapy conducted throughout experimental sessions.
58313115|NCT02745288|PROCEDURE|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
58447240|NCT02538601|BEHAVIORAL|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
57957586|NCT03755648|OTHER|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
57957587|NCT03755648|OTHER|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
57957588|NCT03755648|OTHER|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
57957589|NCT04019730|OTHER|diet|low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)
57957590|NCT01465906|DRUG|tulobuterol|patch, 2mg, qN, 3 months
57957591|NCT01465906|DRUG|Tiotropium Bromide|18ug, inhale, qD, 3 months
57957592|NCT01465906|DRUG|tiotropium bromide|18ug, inhale, qD, 3 months
57957593|NCT03595553|DRUG|Ridinilazole|ridinilazole (200 mg bid)
57957594|NCT03595553|DRUG|Vancomycin|vancomycin (125 mg qid)
57957595|NCT02826109|DEVICE|PeriAcryl®90 HV|
57957596|NCT04417478|OTHER|Scaling and root planning|Periodontal debridement was performed in all patients.
57957597|NCT01040052|BIOLOGICAL|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
57957598|NCT00091832|BIOLOGICAL|Denosumab|Denosumab administered by subcutaneous injection
57957599|NCT00091832|DRUG|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
57957600|NCT05801380|DRUG|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
57957601|NCT05801380|DRUG|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
57957602|NCT01195129|DEVICE|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
57957603|NCT01195129|DEVICE|Non-hydrogel coils|Cerecyte or bare platinum coils
57957604|NCT04500327|OTHER|Drive app|The Drive app will be used to monitor sleep metrics for users of CPAP therapy.
57957605|NCT04500327|DEVICE|Non contact motion sensor|The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
57957606|NCT04797065|PROCEDURE|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
57957607|NCT04797065|PROCEDURE|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
57957608|NCT05598918|PROCEDURE|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
57957609|NCT05598918|PROCEDURE|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
57957610|NCT00257803|DRUG|Oxytocin|See detailed description
57957611|NCT00257803|DRUG|Saline solution|See detailed description
57957612|NCT01986543|DRUG|drug administration|
57957613|NCT01076582|DRUG|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
57957614|NCT01076582|DRUG|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
57957615|NCT04016311|BEHAVIORAL|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
58117001|NCT02226796|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
58117002|NCT02958657|OTHER|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
57742178|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
58117003|NCT01618266|DRUG|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
58117004|NCT01243996|DRUG|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
57742179|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
57742180|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
57742181|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
57742182|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
57742183|NCT02444390|PROCEDURE|Biopsy|biopsy of a metastasis
57742184|NCT06231862|DIAGNOSTIC_TEST|SeptiCyte (various)|mRNA expression scores
57742185|NCT06021301|OTHER|Platelet-Rich Fibrin and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
57742186|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
57742187|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks.
57742188|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks.
57742189|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks.
57742190|NCT03031652|DEVICE|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
57742191|NCT04431596|DEVICE|Forearm cooling|forearm immersion will be performed for active cooling assessment.
57742192|NCT04431596|OTHER|Mist-fan cooling|A mist-fan will be placed in front of the participant for active cooling.
57742193|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
58117005|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
58117006|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
58117007|NCT02971956|DRUG|Pembrolizumab|Immune checkpoint inhibitor
58117008|NCT03991832|DRUG|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
58117009|NCT03991832|DRUG|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
58117010|NCT03317236|DRUG|Quetiapine|A fixed 50 mg exteded release formulation.
58117011|NCT01215123|DRUG|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
58117012|NCT03853577|OTHER|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
58117013|NCT00820456|OTHER|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
58447241|NCT06725173|GENETIC|Targeted Long-read sequencing|All patient's will undergo targeted long-read sequencing to resolve genomic and epigenomic signatures of the RB1 gene
58313116|NCT06058819|DIAGNOSTIC_TEST|Newborns suspected of Infections|This study will include NICU newborns of at least 7 days of life with suggestive signs of neonatal sepsis. The results will be extrapolated to this same population.
57742194|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
57742195|NCT04988451|BEHAVIORAL|ASL Services|ASL specialist meets with participants and provides ASL instruction
58117014|NCT03735784|BEHAVIORAL|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
58117015|NCT05448716|DIAGNOSTIC_TEST|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
58447242|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
58447243|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
57742196|NCT05690386|BIOLOGICAL|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
57742197|NCT05690386|DRUG|Somatropin|Once-daily subcutaneous injection of Somatropin
57742198|NCT02707835|OTHER|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
57742199|NCT02707835|OTHER|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
57742200|NCT02707835|OTHER|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
57742201|NCT06733922|DEVICE|ETNATM-ProgMS|To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
57742202|NCT05971719|DIAGNOSTIC_TEST|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
57742203|NCT05599828|DRUG|AMG 510|Oral Tablet
57742204|NCT05599828|DRUG|Omeprazole|Capsule
58117016|NCT05448716|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
58447244|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
58447245|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
58117017|NCT01095757|DRUG|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
58117018|NCT01161654|DRUG|naratriptan hydrochoride|2.5 mg tablet
58117019|NCT00050895|DRUG|Lopinavir/ritonavir|
58117020|NCT00050895|DRUG|Efavirenz|
58447246|NCT03986203|DEVICE|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
57742205|NCT05599828|DRUG|Famotidine|Tablet
57742206|NCT04064034|OTHER|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
57742207|NCT02566954|OTHER|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
58117021|NCT00050895|DRUG|Stavudine|
58117022|NCT00050895|DRUG|Zidovudine|
58447247|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
58447248|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
58447249|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
58447250|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
57742208|NCT05418699|DEVICE|closed-loop insulin pump|Follow up of patients with real-time closed-loop insulin delivery systems
58117023|NCT00050895|DRUG|Lamivudine|
58117024|NCT00050895|DRUG|Tenofovir disoproxil fumarate|
58117025|NCT02001779|DEVICE|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
58117026|NCT02001779|DEVICE|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
58447251|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
58447252|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
58447253|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
58447254|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
58447255|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
58447256|NCT00570310|DRUG|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
58117027|NCT03065127|BEHAVIORAL|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
58447257|NCT00570310|DRUG|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
58447258|NCT05065788|OTHER|data collection|data collection
58447259|NCT01598909|DRUG|Arnica|Application of Arnica ointment periorbitally
58447260|NCT01598909|DRUG|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
58447261|NCT00674674|DRUG|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
58447262|NCT00674674|DRUG|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
58447263|NCT00674674|DRUG|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
58447264|NCT05549830|OTHER|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
58447265|NCT05120362|DRUG|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
58447266|NCT00970437|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
58447267|NCT00970437|BEHAVIORAL|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
58447268|NCT03202563|DRUG|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
58117028|NCT03065127|BEHAVIORAL|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
58447269|NCT03202563|DRUG|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
58447270|NCT03202563|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
58447271|NCT03202563|DEVICE|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
58447272|NCT03202563|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
58447273|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
58447274|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
58447275|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
58447276|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
58447277|NCT03035604|OTHER|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
58447278|NCT05184582|BEHAVIORAL|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
58447279|NCT00806039|OTHER|Early Renal Involvement|Renal Consultation
58447280|NCT00855244|OTHER|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
58447281|NCT00277771|BEHAVIORAL|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
58447282|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
58117029|NCT03065127|BEHAVIORAL|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
58117030|NCT01831063|BEHAVIORAL|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
58117031|NCT00988169|DRUG|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
58117032|NCT06325085|OTHER|compensatory and restorative rehabilitation techniques|"compensatory and restorative rehabilitation techniques Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
58117033|NCT06325085|OTHER|Traditional cognitive rehabilitation training|"Naming words ( ask patient to name food, states, family members) Counting numbers backwards, backward counting of days and months) Spell the word backwards, remembering a piece of information Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
58117034|NCT03381547|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
58117035|NCT00317954|DRUG|Spironolactone|
58117036|NCT03827213|DRUG|Exparel|A shot of long acting local anesthetic for post operative pain management
58447283|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
58117037|NCT03827213|DEVICE|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
57742209|NCT03637205|PROCEDURE|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
57742210|NCT03637205|OTHER|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
58117038|NCT00753714|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58117039|NCT00753714|DRUG|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58117040|NCT00753714|DRUG|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
58117041|NCT04990622|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
58117042|NCT04773093|DRUG|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
58117043|NCT04773093|DRUG|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
58117044|NCT04537676|OTHER|No intervention, this is an observational study|No intervention
58117045|NCT04141410|DRUG|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
58447284|NCT00765180|DEVICE|TRE vs. NBI|TRE NBI
58447285|NCT06039709|COMBINATION_PRODUCT|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given \~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
58447286|NCT00965250|DRUG|IMC-12|20 mg/kg intravenously once every three weeks
58447287|NCT02934724|PROCEDURE|Self sample from vagina|Self sample using The Rover's Evalyn Brush
57742211|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
58117046|NCT04141410|DEVICE|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
58117047|NCT01405950|DRUG|Zanaflex Capsules|0.025 mg/kg
58117048|NCT01405950|DRUG|Zanaflex Capsules|0.05 mg/kg
58117049|NCT01405950|DRUG|Zanaflex Capsules|0.075 mg/kg
58117050|NCT01405950|DRUG|Zanaflex Capsules|0.1 mg/kg
58447288|NCT02934724|PROCEDURE|Self sample from the oral cavity|Self sample using COPAN FloqSwab
58447289|NCT02934724|OTHER|Questionnaire|Questionnaire about vaccination status and sexual behaviour
58447290|NCT02396706|DRUG|Ivy Leaves Cough Liquid|
58447291|NCT02396706|DRUG|Placebo|
58117051|NCT05692882|DEVICE|Drug-Eluting Stents|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
57742212|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
58117052|NCT02585674|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
58117053|NCT02585674|DEVICE|MyStar DoseCoach|Glucose meter
58117054|NCT05788042|DEVICE|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
58117055|NCT05788042|DEVICE|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
58117056|NCT00186914|BIOLOGICAL|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
58117057|NCT00887627|DRUG|conivaptan hydrochloride|intravenous
58117058|NCT02535819|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
58117059|NCT02535819|PROCEDURE|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
58447292|NCT04742452|PROCEDURE|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
58447293|NCT04742452|PROCEDURE|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
58447294|NCT03827525|BEHAVIORAL|Cognitive and Behavioral Therapy|9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
58447295|NCT05112939|DRUG|RPV LA|RPV LA will be administered at different formulations.
58117060|NCT03331965|DRUG|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
58117061|NCT03331965|DRUG|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
58117062|NCT01497483|DRUG|Pravastatin alone|Pravastatin 40 mg with placebo.
58117063|NCT01497483|DRUG|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
58117064|NCT03057587|DEVICE|NIRS Monitoring|NIRS data will be collected throughout the surgery
58447296|NCT05112939|DRUG|CAB LA|CAB LA will be administered at formulation 3.
58447297|NCT06725914|BEHAVIORAL|kangaroo care|Transport practice with paternal kangaroo care in preterm infants
58447298|NCT06004986|DRUG|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
58447299|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
57742213|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
57742214|NCT03583554|DRUG|Placebo|Single dose of 4 placebo oral capsules
57742215|NCT03583554|DRUG|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
57742216|NCT03583554|DRUG|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
57742217|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
57742218|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
57742219|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
57742220|NCT05920369|OTHER|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
57742221|NCT05920369|OTHER|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
57742222|NCT05920369|OTHER|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
57742223|NCT00626431|DRUG|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
57742224|NCT00626431|DRUG|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
57742225|NCT04632875|BEHAVIORAL|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
57742226|NCT04632875|BEHAVIORAL|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
57742227|NCT00269490|BEHAVIORAL|Yoga Nidra|
57742228|NCT05809752|BIOLOGICAL|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
58117065|NCT04709900|DIAGNOSTIC_TEST|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
58117066|NCT00003557|DRUG|dolastatin 10|
58117067|NCT00445289|DEVICE|SmartCare/PS|
58117068|NCT00310427|DRUG|LY686017|50 mg administered orally on a daily basis
57742229|NCT05531773|OTHER|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
57742230|NCT01751828|DRUG|Sertraline|
57742231|NCT03921515|OTHER|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
58117069|NCT00310427|DRUG|Placebo|Administered on a daily basis
58117070|NCT03362151|OTHER|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
58117071|NCT03362151|OTHER|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
58117072|NCT03362151|OTHER|White rice|White rice (Approximately 43 grams carbohydrate per meal)
58117073|NCT02087059|DRUG|Ruxolitinib|
58117074|NCT02689895|OTHER|modified directly administered anti-retroviral therapy (mDAART)|As described before
58117075|NCT00508378|BEHAVIORAL|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
58117076|NCT00508378|BEHAVIORAL|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
58117077|NCT03103581|DRUG|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
57742232|NCT03921515|OTHER|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
58313117|NCT05338632|DRUG|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
58117078|NCT03496792|OTHER|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
58117079|NCT03496792|OTHER|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
57742233|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
58117080|NCT03496792|OTHER|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
58117081|NCT03496792|OTHER|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
58117082|NCT01938976|BEHAVIORAL|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
58117083|NCT00063128|DRUG|insulin|"* Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only."
58117084|NCT00063128|DRUG|human insulin inhalation powder (HIIP)|"* Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
58117085|NCT01234779|DRUG|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
58117086|NCT01234779|DRUG|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
58117087|NCT01234779|DRUG|olanzapine|15 mg orally daily, 4 weeks
58447300|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
58447301|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
57742234|NCT02069444|PROCEDURE|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
58117088|NCT01234779|DRUG|placebo|orally daily, 4 weeks
58117089|NCT02003495|BIOLOGICAL|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
58117090|NCT02003495|BIOLOGICAL|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
58117091|NCT02003495|BIOLOGICAL|MPV-A Vaccine Group|0.5ml, intramuscular
58117092|NCT02003495|BIOLOGICAL|MCV-AC Vaccine Group|0.5ml, intramuscular
58117093|NCT02003495|BIOLOGICAL|Hib Vaccine Group|0.5ml, intramuscular
58117094|NCT03183466|PROCEDURE|arthroscopic repair|
58117095|NCT03183466|PROCEDURE|arthroscopic debridement|
58117096|NCT02224209|DEVICE|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~1. The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~2. Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
58117097|NCT02224209|DEVICE|a balloon, stent|"Routine stenting procedure:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
58447302|NCT00835250|PROCEDURE|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
57742235|NCT02069444|PROCEDURE|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
57742236|NCT06732232|DRUG|CD19/CD20/BCMA CAR-T|CD19/CD20/BCMA CAR T therapy
57742237|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (blinded)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
58117098|NCT04579874|DIAGNOSTIC_TEST|LIVERFASt|blood draw
58313118|NCT05338632|DRUG|Naloxone Hydrochloride|naloxone 0.4mg/ml, up to 4 doses 2mg intramuscularly, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
58447303|NCT00835250|PROCEDURE|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
58447304|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
58117099|NCT05117008|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
58117100|NCT04624191|OTHER|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
58117101|NCT04261257|OTHER|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out."
58117102|NCT06463964|DIAGNOSTIC_TEST|Serum Creatinine|Laborataries for prediction of AKi in patients with ADHF
58117103|NCT01273103|DRUG|200mg [14C]- GSK2248761|single oral suspension dose of \[14C\]- GSK2248761 200 mg
58117104|NCT03349333|DRUG|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
58117105|NCT03349333|DIETARY_SUPPLEMENT|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
58117106|NCT05186610|PROCEDURE|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
58117107|NCT03309800|DRUG|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
58117108|NCT03309800|DRUG|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
58117109|NCT04288596|OTHER|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
58117110|NCT03028272|OTHER|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
58117111|NCT03028272|OTHER|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
58117112|NCT04158856|DRUG|Pyrotinib|400mg po every day
58117113|NCT04158856|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
58117114|NCT02419313|DRUG|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
58117115|NCT02419313|DRUG|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
58117116|NCT04275687|RADIATION|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost."
57742238|NCT06542198|DIAGNOSTIC_TEST|Placebo Infusion (blinded)|0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).
58117117|NCT04275687|DRUG|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
58117118|NCT02214927|DRUG|BI 11634 tablet|
58117119|NCT02214927|DRUG|BI 11634 drinking solution|
58313119|NCT04546646|OTHER|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
58313120|NCT03720587|OTHER|Semi-structured interviews|Semi-struuctured telephone interviews
57742239|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (open label)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
57742240|NCT00072267|DRUG|7-hydroxystaurosporine|
58117120|NCT01393990|DRUG|LY2228820|Administered orally
58117121|NCT01393990|DRUG|Midazolam|
58117122|NCT01393990|DRUG|Tamoxifen|
58117123|NCT04669821|DRUG|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
58117124|NCT04669821|DRUG|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
58117125|NCT03500770|DEVICE|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
58117126|NCT01623661|OTHER|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
58117127|NCT04297683|DRUG|Zilucoplan|"Drug: Zilucoplan~Administration: Subcutaneous injection~Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight"
58117128|NCT04297683|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
58117129|NCT04297683|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dose: 30 mg or 60 mg daily"
58117130|NCT04297683|DRUG|Pridopidine|"Drug: Pridopidine~Administration: Oral~Dose: 45mg twice daily"
58117131|NCT04297683|DRUG|SLS-005 Trehalose|"Drug: SLS-005 Trehalose~Administration: Infusion~Dose: 0.75 g/kg weekly"
58117132|NCT04297683|DRUG|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
58117133|NCT04297683|DRUG|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
58117134|NCT06544343|OTHER|Remote Monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
58313121|NCT00613795|DIETARY_SUPPLEMENT|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
58313122|NCT00613795|DIETARY_SUPPLEMENT|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
58447305|NCT04106609|OTHER|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
57742241|NCT00072267|DRUG|topotecan hydrochloride|
57742242|NCT03341793|DIAGNOSTIC_TEST|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
57742243|NCT05500469|DEVICE|Paul glaucoma drainage device (GDD)|Implantation of the GDD
57742244|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
57742245|NCT04360733|OTHER|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
57742246|NCT02427126|DRUG|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
57742247|NCT02427126|DRUG|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
57957616|NCT04344587|OTHER|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
57957617|NCT04344587|OTHER|Usual care|"The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
57957618|NCT03130244|DEVICE|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
57957619|NCT03130244|DRUG|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
57957620|NCT05748093|DRUG|Cobicistat|Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
57957621|NCT00356941|DRUG|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
58117135|NCT06544343|OTHER|On site monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
57957622|NCT00356941|DRUG|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
57957623|NCT00356941|PROCEDURE|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
57957624|NCT01497015|BEHAVIORAL|memory training|10 1-hour sessions over 6-8 weeks
57957625|NCT01497015|BEHAVIORAL|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
58117136|NCT04978454|BIOLOGICAL|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
58117137|NCT04978454|OTHER|Placebo|Sucrose phosphate glutamate (SPG) inoculum
58117138|NCT00861237|DRUG|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
57742248|NCT01402453|BEHAVIORAL|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
57742249|NCT01402453|BEHAVIORAL|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
57742250|NCT05243758|DEVICE|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
57742251|NCT05243758|DEVICE|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
57742252|NCT05243758|DEVICE|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
57742253|NCT05243758|DEVICE|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH \&Co. KG, Tuttlingen, Germany)
58117139|NCT00861237|DRUG|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
58117140|NCT00906347|DRUG|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
58117141|NCT00906347|DRUG|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
58117142|NCT01834521|OTHER|Web-based screening and tailored support|
58117143|NCT00003361|DRUG|decitabine|
57742254|NCT06052696|DRUG|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
57742255|NCT06052696|DRUG|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
58117144|NCT03555370|BEHAVIORAL|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
58117145|NCT03555370|BEHAVIORAL|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
58117146|NCT01775761|DRUG|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
58117147|NCT01775761|DRUG|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
58117148|NCT01775761|DRUG|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
58117149|NCT02209779|DRUG|BIBR 796 BS|
58117150|NCT02209779|DRUG|Placebo|
58117151|NCT02593981|DIETARY_SUPPLEMENT|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
57742256|NCT06311695|DEVICE|Contrast Enhanced Mammography|Contrast Enhanced Mammography
57742257|NCT04274907|DRUG|Venetoclax|Tablet: Oral
58117152|NCT02593981|DIETARY_SUPPLEMENT|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
58117153|NCT04435613|OTHER|protective mechanical ventilation strategies|1. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
58117154|NCT04648410|OTHER|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
58447306|NCT04106609|OTHER|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
58447307|NCT00059345|PROCEDURE|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
58447308|NCT00059345|PROCEDURE|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
58447309|NCT00059345|OTHER|Usual Care|Usual care for knee osteoarthritis
58447310|NCT04346329|DRUG|Hydroxychloroquine|Treated group
58447311|NCT04346329|DRUG|Placebo oral tablet|Placebo Group
58447312|NCT03535129|BEHAVIORAL|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
57742258|NCT04274907|DRUG|Pembrolizumab|Intravenous (IV) Infusion
57742259|NCT00038051|DRUG|Hum-195/rGel|Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
57742260|NCT00071617|BEHAVIORAL|Youth-Nominated Support Team|
57742261|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
57742262|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
57742263|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
57742264|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
57742265|NCT03937154|DRUG|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
57742266|NCT03937154|DRUG|Placebo|Placebo comparator
57742267|NCT03912558|PROCEDURE|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
57742268|NCT04453631|DEVICE|active tDCS|26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
57742269|NCT04453631|DEVICE|sham tDCS|tDCS is controlled in this intervention: sham mode.
57742270|NCT04453631|BEHAVIORAL|CBT-UP|15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
57742271|NCT04453631|BEHAVIORAL|Psychoeducation|To control for the cognitive-behavioral intervention we will use psychoeducation materials.
57957626|NCT01497015|BEHAVIORAL|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
57957627|NCT00832559|BIOLOGICAL|CVA21|1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
57957628|NCT03548558|BEHAVIORAL|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
57957629|NCT03548558|BEHAVIORAL|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
57957630|NCT03548558|BEHAVIORAL|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
57957631|NCT03548558|BEHAVIORAL|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
57957632|NCT05840744|DIAGNOSTIC_TEST|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
57957633|NCT03193398|DRUG|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
57957634|NCT03193398|DRUG|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
57957635|NCT00373204|DRUG|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
57957636|NCT04332588|DRUG|[18F]FMISO PET/MRI imaging|\[18F\]FMISO PET/MRI imaging
57957637|NCT01394588|DEVICE|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
57957638|NCT03687216|PROCEDURE|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
57957639|NCT03687216|PROCEDURE|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
58117155|NCT03191721|PROCEDURE|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
58117156|NCT03191721|PROCEDURE|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
58447313|NCT05639296|OTHER|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
58447314|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
58447315|NCT03468868|BEHAVIORAL|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
57742272|NCT05198466|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
58447316|NCT06672549|DRUG|Orforglipron|Administered orally. ISA specific interventions will be listed in the ISA.
57742273|NCT05198466|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
57742274|NCT01684748|DRUG|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
57957640|NCT06264570|DIETARY_SUPPLEMENT|B-TMG supplementation|B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
57957641|NCT06264570|DIETARY_SUPPLEMENT|B-SAM supplementation|B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
57957642|NCT06264570|OTHER|B-TMG placebo|B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
57957643|NCT06264570|OTHER|B-SAM placebo|B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
57742275|NCT05916326|BIOLOGICAL|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
57742276|NCT05916326|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
57742277|NCT05156190|OTHER|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
57742278|NCT06112756|DRUG|Elinzanetant|Oral
57742279|NCT06112756|OTHER|Placebo|Oral
57742280|NCT06519968|DRUG|AZD4604|AZD4604 will be administered as Dry Powder Inhalation (DPI).
57742281|NCT06519968|DRUG|Placebo|Placebo will be administered as DPI.
57742282|NCT02471196|DRUG|ORM-12741|ORM-12741 low dose twice a day
57742283|NCT02471196|DRUG|ORM-12741|ORM-12741 high dose twice a day
57957644|NCT00630955|DRUG|memantine|Memantine 20 mg once per day for 7 days
57957645|NCT00630955|DRUG|Memantine|Memantine 40 mg once per day for 7 days
57957646|NCT00630955|DRUG|Placebo|Placebo once per day for 7 days
57957647|NCT03901950|DRUG|XNW7201 tablets|A wnt pathway inhibitor
57957648|NCT01171846|OTHER|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
57957649|NCT00439582|DIETARY_SUPPLEMENT|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
57957650|NCT00439582|DIETARY_SUPPLEMENT|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
57957651|NCT01791192|DRUG|FTY720|Fingolimod
57957652|NCT01791192|DRUG|Oral Corticosteroid|Oral Corticosteroid
57957653|NCT00003683|DRUG|doxorubicin hydrochloride|
57957654|NCT00003683|DRUG|ifosfamide|
57957655|NCT02556255|DEVICE|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
57957656|NCT05686174|DIETARY_SUPPLEMENT|MBS217|Soybean Fermented Extract (MBS217)
57957657|NCT05686174|DIETARY_SUPPLEMENT|Placebo|Without active ingredient
57957658|NCT05166694|OTHER|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
57957659|NCT05166694|OTHER|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
57957660|NCT05166694|OTHER|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
57957661|NCT00731250|DRUG|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
57742284|NCT02471196|DRUG|Placebo|Placebo twice a day
57742285|NCT06662227|BIOLOGICAL|Single dose injection of certain dose of UWD-19|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells
57742286|NCT03969862|DEVICE|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
58447317|NCT06672549|DRUG|Placebo|Administered orally. ISA specific interventions will be listed in the ISA.
57742287|NCT01016665|DRUG|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
57742288|NCT06685861|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
57742289|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
58117157|NCT03191721|PROCEDURE|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
58117158|NCT03191721|DRUG|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
58117159|NCT03191721|DRUG|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
58117160|NCT03191721|PROCEDURE|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
58117161|NCT00417599|BEHAVIORAL|Lifestyle Intervention|lifestyle intervention .
58117162|NCT00417599|OTHER|control group|waiting list control group
58447318|NCT05244746|PROCEDURE|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
58447319|NCT04656743|PROCEDURE|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
57742290|NCT04576091|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57742291|NCT04576091|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT scan
57742292|NCT04576091|DRUG|Elimusertib|Given PO
57742293|NCT04576091|BIOLOGICAL|Pembrolizumab|Given IV
57742294|NCT04576091|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
57742295|NCT04576091|OTHER|Quality-of-Life Assessment|Ancillary studies
57742296|NCT04576091|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58117163|NCT03978871|BEHAVIORAL|Growth Mindset|Growth emotion mindset induction
58117164|NCT03978871|BEHAVIORAL|Control|Brain education
58117165|NCT06547528|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
58447320|NCT04656743|PROCEDURE|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
57742297|NCT06095570|DRUG|Ciprofol|For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
57742298|NCT06095570|DRUG|Remimazolam|For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
58117166|NCT00682721|DRUG|Placebo|Matching placebo two pills once daily
58117167|NCT00682721|DRUG|Valacyclovir|1 gram daily x number of days active in the study
57742299|NCT04781374|DRUG|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
57742300|NCT05410938|DRUG|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
57957662|NCT00731250|DRUG|Placebo|Subjects will be administered SB-705498 matching placebo tablets
58117168|NCT04556669|BIOLOGICAL|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
57957663|NCT00731250|OTHER|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
57742301|NCT05113628|DIAGNOSTIC_TEST|methylene blue identification|"After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl."
57742302|NCT05644977|DRUG|Emraclidine|Oral tablets
57742303|NCT05644977|DRUG|Placebo|Oral tablets
57742304|NCT00783926|BIOLOGICAL|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
57742305|NCT06443463|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
57742306|NCT06443463|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
57742307|NCT06732505|DRUG|[225Ac]Ac-DOTATATE|The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.
57742308|NCT03332368|OTHER|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
57742309|NCT05875181|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
57742310|NCT05875181|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
57742311|NCT06124209|DRUG|TachoSil|TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
57742312|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
57742313|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
57742314|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
57742315|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
58117169|NCT05089994|PROCEDURE|US guided injection|using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
57742316|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
57742317|NCT00127374|BEHAVIORAL|Dietary and physical activity modifications|
57742318|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
57742319|NCT03292250|DRUG|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
57742320|NCT03292250|DRUG|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
57742321|NCT03292250|DRUG|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
57742322|NCT03292250|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
57742323|NCT03292250|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
57742324|NCT03175133|OTHER|Strength exercise|Strengthening exercises performed with physical therapist.
57742325|NCT03715933|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
57742326|NCT03715933|DRUG|Carboplatin|Chemotherapy
57742327|NCT03715933|DRUG|Cisplatin|Chemotherapy
57742328|NCT03715933|DRUG|Pemetrexed|Chemotherapy
57742329|NCT03715933|DRUG|5-fluorouracil|Chemotherapy
57742330|NCT03715933|DRUG|Irinotecan|Chemotherapy
57742331|NCT03715933|DRUG|Temozolomide|Chemotherapy
58117170|NCT02623790|OTHER|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
58117171|NCT02623790|OTHER|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
58117172|NCT02623790|OTHER|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
58117173|NCT01117961|BEHAVIORAL|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
57742332|NCT00737165|BEHAVIORAL|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems"
57742333|NCT00737165|BEHAVIORAL|Suicide prevention program as usual|Usual suicide prevention program
57742334|NCT04840589|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
57742335|NCT04840589|PROCEDURE|Biopsy|Undergo a biopsy
57742336|NCT04840589|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57742337|NCT04840589|PROCEDURE|Computed Tomography|Undergo a CT scan
57742338|NCT04840589|BIOLOGICAL|Ipilimumab|Given IV
57742339|NCT04840589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57742340|NCT04840589|BIOLOGICAL|Nivolumab|Given IV
57742341|NCT04840589|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
57742342|NCT04840589|PROCEDURE|X-Ray Imaging|Undergo x-ray
57742343|NCT01320046|OTHER|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
57742344|NCT04347551|OTHER|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
57742345|NCT06670235|BEHAVIORAL|Upright Birthing Position|This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.
57742346|NCT06670235|BEHAVIORAL|Lithotomy Birthing Position|Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
57742347|NCT01627327|DRUG|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
57742348|NCT01627327|DRUG|tiotropium bromide 18mcg|inhalation powder
57742349|NCT03146624|OTHER|attachment retained obturator|obturator which retained by attachment
57742350|NCT03146624|OTHER|clasp retained obturator|obturator which retained by clasp
57742351|NCT02525874|DRUG|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
57742352|NCT04930068|OTHER|low caloric diet|A low-calorie diet is a structured eating plan that restricts daily caloric intake, commonly for weight loss. Following a low-calorie diet typically means consuming around 1,200 to 1,500 calories per day, which creates a calorie deficit that can lead to weight loss. A low-calorie diet can be effective, but it requires a lot of discipline to work and be safe.
57742353|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
57742354|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
57742355|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
58117174|NCT04084756|BEHAVIORAL|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
58117175|NCT04084756|BEHAVIORAL|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
58117176|NCT03419195|OTHER|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
57742356|NCT04461002|OTHER|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
57742357|NCT04719780|BEHAVIORAL|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
57742358|NCT04719780|BEHAVIORAL|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
57742359|NCT05805592|BEHAVIORAL|Screen-to-Move-Program (STEP)|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP)."
57742360|NCT00951275|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
58447321|NCT01156766|DEVICE|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
57742361|NCT00951275|DRUG|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
57742362|NCT06421012|PROCEDURE|Experimental : Patients without additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will not receive additional preoxygenation before any endotracheal suctioning; their FiO2 value will be maintained constant
58117177|NCT05358210|BEHAVIORAL|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
58117178|NCT05358210|BEHAVIORAL|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
58117179|NCT04559620|OTHER|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
58447322|NCT06355453|DEVICE|Goldcrest Patch and Three Patch Coupons|Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
58447323|NCT06355453|DEVICE|Goldcrest Patch and Novii Patch|Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
58447324|NCT04245839|DRUG|Fludarabine|Fludarabine
58447325|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
58447326|NCT04245839|DRUG|JCAR017|JCAR017
58447327|NCT02073994|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
57742363|NCT06421012|PROCEDURE|Active Comparator : Patients with additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will receive additional preoxygenation at 100% FiO2 for a systematic 2-minute duration prior to any endotracheal suction. Subsequently, the FiO2 will be reset to the previous default value.
57742364|NCT00712361|DEVICE|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
57742365|NCT03043508|OTHER|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
57742366|NCT03043508|BEHAVIORAL|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
57742367|NCT03162224|DRUG|MEDI0457|MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
57742368|NCT03162224|DEVICE|CELLECTRA®5P device|MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.
57742369|NCT03162224|DRUG|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
58117180|NCT02212405|DEVICE|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
58117181|NCT02212405|OTHER|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
58447328|NCT04818970|DEVICE|Narrow Band ultraviolet B-Band Light|Daily doses of NB-UVB for 8 consecutive days.
58447329|NCT04818970|DEVICE|non Narrow Band ultraviolet B-Band Light|Daily doses of non-NB-UVB for 8 consecutive days.
57742370|NCT03119467|DRUG|RP4010|Escalating doses starting at 25 mg
57742371|NCT00527566|BIOLOGICAL|Mepolizumab|IV mepolizumab, 750 mg
58447330|NCT00034294|DRUG|GT160-246|
58447331|NCT04170543|DRUG|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
58447332|NCT04170543|DRUG|Placebo|Placebo
58447333|NCT04170543|DRUG|Dapagliflozin|Dapagliflozin 10 mg
57742372|NCT02495272|DRUG|Oxytocin|Oxytocin 10IU Administered intramuscularly.
57742373|NCT05402280|BEHAVIORAL|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
57742374|NCT05152680|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
57742375|NCT05566041|DRUG|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
57742376|NCT05566041|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
57742377|NCT04606355|DIAGNOSTIC_TEST|Visual Acuity|autostereoscopic, monocular dynamic force choice test
57742378|NCT04606355|DIAGNOSTIC_TEST|stereopsis|autostereoscopic dynamic forced-choice depth perception test
57742379|NCT04606355|DIAGNOSTIC_TEST|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
57742380|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
57742381|NCT06440915|DRUG|Isavuconazole|Isavuconazole
57742382|NCT01920451|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
57742383|NCT05946811|DRUG|Macitentan 10mg|Macitentan 10 mg oral once daily for 3 months. vs placebo
57742384|NCT01187693|OTHER|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
57742385|NCT02065336|DRUG|ARC-520|
57742386|NCT02065336|DRUG|Placebo|
57742387|NCT02065336|DRUG|entecavir|
58117182|NCT05314569|DRUG|Ketamine- dexmedetomidine|ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery
58447334|NCT06725836|PROCEDURE|Implantation of electrodes into the epidural space for spinal cord stimulation|Under X-ray guidance and with neurophysiological supervision, the electrode is implanted. The stimulator is surgically placed in a pocket formed in the iliac crest area on the left side, where it is secured. The generator is connected to an electrode array positioned on the dorsal epidural surface of the spinal cord at the appropriate level (sacral-lumbar/cervical region), as confirmed by intraoperative fluoroscopy.
58447335|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for spastic syndrome suppression|During the selection of the optimal stimulation program for spasticity suppression, spinal cord stimulation (SCS) is performed at various sites on the electrode array. Stimulation is initiated at a specific site with a frequency of 60 Hz, and the intensity is gradually increased until the spasticity is alleviated (i.e., the limb can flex and extend without restriction). If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is again adjusted from 0 to comfortable values. Stimulation is sequentially applied at different sites, and those sites where muscle spasticity is most effectively suppressed are selected.
57742388|NCT02065336|DRUG|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
57742389|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
57742390|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
57742391|NCT03821168|DRUG|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
57742392|NCT03821168|DRUG|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
57742393|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
57742394|NCT05483504|DRUG|F61 injection|Colorless or slightly yellow liquid, may be slightly opalescent
57742395|NCT05483504|DRUG|F61 Placebo|Colorless or slightly yellow liquid, may be slightly opalescent
57742396|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
57742397|NCT05027139|DRUG|Evorpacept|Administered IV
57742398|NCT00000179|DRUG|Trazodone|
57742399|NCT00000179|DRUG|Haloperidol|
57742400|NCT00698646|DRUG|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
57742401|NCT00698646|DRUG|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
57742402|NCT00698646|DRUG|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
57742403|NCT00810264|DEVICE|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
57742404|NCT03306212|DRUG|Botulinum toxin A|
57742405|NCT03306212|OTHER|Occupational Therapy|
57742406|NCT03306212|OTHER|Intermittent serial casting|
58447336|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for volitional motor control|Over the course of two weeks, the configuration of the electrodes and the intensity of the stimulation are adjusted to ensure optimal voluntary muscle control. A systematic approach is used to determine the most suitable settings. First, the anodes and cathodes on the electrode array are identified. The desired frequency range is 20-40 Hz. The pulse width is determined empirically. The adjustment begins at 20 Hz, with the stimulation intensity gradually increased. If unpleasant sensations (such as muscle spasms or pain) occur, the intensity is reduced to comfortable values. If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is adjusted again from 0 to comfortable levels. Stimulation is sequentially applied at different sites, with the sites that provide the most effective voluntary muscle control being selected.
57742407|NCT02341430|DEVICE|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
57742408|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
58447337|NCT06725836|DIAGNOSTIC_TEST|Resting electroencephalography for identifying neurocorrelates of spinal cord stimulation.|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. Initially, the participant is recorded in a resting state before the implantation of the stimulator for 20 minutes (5 minutes with eyes open, followed by 5 minutes with eyes closed). After the surgery, the participant is recorded in the same manner before the first activation of the stimulator. After selecting the programs, the participant is recorded without stimulation (eyes open, then closed), followed by recordings with the spinal cord stimulator (SCS) activated (eyes open, then closed). The stimulation is then turned off again, and recording is conducted with eyes open and closed. Before discharge, the participant is recorded in a resting state for 20 minutes with the stimulation program active.
58447338|NCT06725836|DIAGNOSTIC_TEST|Electroencephalography within the motor imagery paradigm|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. During the experiment, with the stimulator turned off, the participant views a fixation cross on a computer screen. Then, they hear an auditory signal and see a sign indicating a specific movement (complete flexion and extension of the left arm, complete flexion and extension of the right arm, complete flexion and extension of the left leg, complete flexion and extension of the right leg). The participant imagines the movements according to the auditory and visual signals on the screen. Subsequently, the participant performs the same movements in the same order. The motor control stimulation program is then activated, and the entire sequence is repeated (first imagining the movement, then performing the imagined movements). The timing of the command presentations is recorded with marker placements.
58447339|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
58447340|NCT04391114|PROCEDURE|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
57742409|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
57742410|NCT02645734|DRUG|bevacizumab|1.25 mg of bevacizumab is injected
57742411|NCT02645734|DRUG|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
57742412|NCT02645734|DRUG|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
57742413|NCT03387553|BIOLOGICAL|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
57742414|NCT03387553|DRUG|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
57742415|NCT03387553|PROCEDURE|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
57742416|NCT03733262|OTHER|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
57742417|NCT00344461|DRUG|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
57742418|NCT06109987|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
57742419|NCT00538135|BEHAVIORAL|Cognitive Behavioural Therapy|
57742420|NCT00538135|OTHER|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
57742421|NCT04062266|DRUG|Azacitidine|Given SC or IV
57742422|NCT04062266|DRUG|Venetoclax|Given PO
58117183|NCT05314569|DRUG|Fentanyl- midazolam|Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
57742423|NCT05502432|DEVICE|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
57742424|NCT05502432|DEVICE|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
57742425|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
57742426|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
57742427|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
57742428|NCT01692340|OTHER|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
57742429|NCT03692533|DIAGNOSTIC_TEST|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
57742430|NCT03532074|DIAGNOSTIC_TEST|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
57742431|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
57742432|NCT03532074|DIAGNOSTIC_TEST|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
57742433|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
57957664|NCT03955133|OTHER|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
58117184|NCT05314569|DRUG|Isoflurane|Anesthetic inhalational gas
58117185|NCT00979160|DRUG|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
58117186|NCT00674219|DRUG|Memantine|Namenda 10mg BID for 12 weeks
58117187|NCT06546579|DIAGNOSTIC_TEST|Skin sampling|All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
58117188|NCT06398470|DIAGNOSTIC_TEST|NeuroSAFE procedure|Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.
58117189|NCT06398470|DIAGNOSTIC_TEST|LaserSAFE procedure|The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
58117190|NCT04371614|BEHAVIORAL|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
58117191|NCT02831062|OTHER|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
58117192|NCT02655354|BEHAVIORAL|Motivational Interviewing|
58117193|NCT02655354|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
58117194|NCT02655354|BEHAVIORAL|Care Management|
58117195|NCT02655354|DRUG|Fluoxetine|Anti-depressant
58117196|NCT02655354|DRUG|Fluvoxamine|Anti-depressant
58447341|NCT04391114|PROCEDURE|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
58447342|NCT00356967|DRUG|dianicline|
57742434|NCT06732739|OTHER|percussions with teach-back breathing exercise|"patient will receive Teach Back Breathing Exercises like pursed lip breathing, DE breathing and diaphragmatic breathing Teach-back breathing exercises refer to a method of instructing individuals in breathing techniques and then having them demonstrate or teach back the instructions to ensure comprehension and mastery. This educational approach is commonly used in healthcare settings, particularly when teaching patients how to perform various breathing exercises for therapeutic purposes. Patients were informed about the importance of regular chest percussion I will use the clapping technique which provided by cupped hand for 3 minutes in 5 positions of drainage (upper lobes-apical and posterior segment, apical and anterior segment, right upper lobe-posterior segment, left upper lobe-posterior segment, lower lobes- apical segment) with assisted suction three times/shift for four days, and then each patient will be observed."
58117197|NCT02655354|DRUG|Paroxetine|Anti-depressant
58117198|NCT02655354|DRUG|Sertraline|Anti-depressant
58447343|NCT00060632|DRUG|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
58447344|NCT04234867|DRUG|Dapagliflozin|once daily for 5 days
58447345|NCT04234867|DRUG|Placebo oral tablet|once daily for 5 days
58447346|NCT04234867|OTHER|Stress|single dose after last administration of experimental drug
58447347|NCT04234867|OTHER|Placebo Stress|single dose after last administration of experimental drug
58447348|NCT06725394|OTHER|Filling out the survey|Data were collected using an information form, the Smartphone Addiction Scale-Short Version (SAS-SV), the Perceived Stress Scale (PSS-10), and the Neck Disability Index (NDI).
58447349|NCT01568840|OTHER|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
58447350|NCT01568840|OTHER|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
58447351|NCT06433323|OTHER|Anti-aging cosmetic care product|"This is an intra-individual comparison study.~* frequency of application: Once a day (in the evening)~* modalities of application: Apply the cream on the tested area determined by the randomization~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)"
58447352|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
58447353|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
58447354|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
58447355|NCT03668002|PROCEDURE|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
58447356|NCT03668002|PROCEDURE|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
57742435|NCT06732739|OTHER|PERCUSSION|similar to Group A, each patient underwent individual interviews. Patients were educated on the significance of regular chest percussion. The clapping technique, executed with cupped hands, was applied for 3 minutes in five drainage positions (upper lobes - apical and posterior segment, apical and anterior segment, right upper lobe - posterior segment, left upper lobe - posterior segment, lower lobes - apical segment). This procedure, including assisted suction three times per shift, was administered for four consecutive days.
58117199|NCT02655354|DRUG|Citalopram|Anti-depressant
58117200|NCT02655354|DRUG|Venlafaxine|Anti-depressant
58117201|NCT02655354|DRUG|Duloxetine|Anti-depressant
58117202|NCT02655354|DRUG|Mirtazapine|Anti-depressant
58117203|NCT02655354|DRUG|Diphenhydramine|Sleep medication
58117204|NCT02655354|DRUG|Trazodone|Sleep medication
58117205|NCT02655354|DRUG|Prazosin|Sleep medication
58117206|NCT04139174|PROCEDURE|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
58117207|NCT05044442|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
58117208|NCT05044442|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
58117209|NCT04058483|OTHER|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
58117210|NCT01720628|OTHER|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
58117211|NCT03642574|PROCEDURE|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
58447357|NCT06017180|OTHER|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
58447358|NCT06017180|OTHER|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
58117212|NCT02322879|DRUG|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
58117213|NCT02322879|OTHER|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
58447359|NCT06726317|BEHAVIORAL|Early palliative care integration|The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
58447360|NCT06059404|BEHAVIORAL|Meals + RD services only|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
58447361|NCT06059404|BEHAVIORAL|Meals + OT services only|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
58447362|NCT06059404|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
58447363|NCT05821244|BEHAVIORAL|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
58447364|NCT02112617|RADIATION|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
58447365|NCT06725927|BIOLOGICAL|Influenza vaccination|Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
58447366|NCT03472950|DRUG|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
58447367|NCT03472950|DRUG|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
58447368|NCT06054607|DIETARY_SUPPLEMENT|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
58447369|NCT06054607|OTHER|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
58447370|NCT06281535|DEVICE|Implant loading|Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
58447371|NCT03251937|DEVICE|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
58447372|NCT00932906|OTHER|Different self-training methods|Self training with MiniAnne Training Kit
57957665|NCT05427266|OTHER|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
58117214|NCT02322879|DRUG|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
58117215|NCT05359432|DRUG|Empagliflozin|Receiving allocated drug dosage as per clinical needs
58117216|NCT05359432|DRUG|Vildagliptin|Receiving allocated drug dosage as per clinical needs
58117217|NCT00242762|DRUG|ZD1839 (IRESSA™)|
58447373|NCT00932906|OTHER|Standard training|Instructor-based training meeting ERC directions
58117218|NCT00242762|DRUG|Docetaxel|
58117219|NCT00242762|DRUG|Cisplatin|
58117220|NCT01811446|DEVICE|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
58117221|NCT02780778|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
58117222|NCT02780778|DRUG|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
58117223|NCT03409185|DEVICE|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
58117224|NCT03409185|DEVICE|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
58117225|NCT01108900|DRUG|sildenafil|tables, 25,50,100 mg, on demand, 1 month
58447374|NCT04951752|DRUG|Ropivacaine injection|Transmuscular quadratus lumborum block - active
58447375|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
58447376|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
58117226|NCT05326022|DEVICE|Microcurrent therapy|Microcurrent therapy
57742436|NCT02744534|DRUG|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
57742437|NCT02744534|PROCEDURE|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
57742438|NCT02744534|PROCEDURE|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
57742439|NCT02446405|DRUG|Enzalutamide|
57742440|NCT02446405|DRUG|NSAA|
58117227|NCT05326022|DEVICE|Low Level Laser Therapy|Laser therapy
58117228|NCT05326022|OTHER|Medical therapy|Medical therapy
58117229|NCT06395649|DEVICE|Classical rTMS to M1|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.
58117230|NCT06395649|DEVICE|rTMS to the High connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.
58117231|NCT06395649|DEVICE|rTMS to the low connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
58117232|NCT06395649|DEVICE|Sham rTMS|Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
58117233|NCT03824522|BIOLOGICAL|ADYNOVATE|Pegylated recombinant human factor VIII
58117234|NCT00793845|DRUG|Cyclophosphamide|First HDCT
58117235|NCT00793845|DRUG|Etoposide|First HDCT
58117236|NCT00793845|DRUG|Carboplatin|First HDCT
58447377|NCT04807933|BEHAVIORAL|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
57742441|NCT02446405|DRUG|LHRHA or Surgical Castration|
57742442|NCT00554970|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
57742443|NCT00554970|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
57742444|NCT00554970|DRUG|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
58117237|NCT00793845|DRUG|Thiotepa|Second HDCT
58447378|NCT05349357|OTHER|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
58117238|NCT00793845|DRUG|Melphalan|Second HDCT
58117239|NCT00793845|RADIATION|Total body irradiation|Second HDCT
58447379|NCT05349357|OTHER|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
57742445|NCT00554970|DRUG|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
58117240|NCT05645458|OTHER|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
58117241|NCT01252433|OTHER|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
58117242|NCT00064181|DRUG|FOLFIRI regimen|
58117243|NCT00064181|DRUG|capecitabine|
58117244|NCT00064181|DRUG|celecoxib|
58117245|NCT00064181|DRUG|fluorouracil|
58117246|NCT00064181|DRUG|irinotecan hydrochloride|
58117247|NCT00064181|DRUG|leucovorin calcium|
58117248|NCT01760122|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
58117249|NCT01760122|DRUG|Pegasys|sc, qw, 48 weeks.
58117250|NCT04588428|DRUG|INO-4700|INO-4700 was administered ID.
58447380|NCT05349357|OTHER|Stretching exercises|Stretching exercises
58447381|NCT05349357|DEVICE|TENS|TENS
58117251|NCT04588428|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
58117252|NCT04588428|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device was administered following ID drug administration
58117253|NCT01987284|DRUG|SER100|
58117254|NCT01987284|DRUG|Placebo|
58117255|NCT03781856|BEHAVIORAL|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
58117256|NCT03781856|BEHAVIORAL|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
58117257|NCT03949556|OTHER|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
58117258|NCT03286413|PROCEDURE|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
58117259|NCT00289627|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
58117260|NCT02140684|DEVICE|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
58117261|NCT02676219|OTHER|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
58117262|NCT02676219|OTHER|Water|
58117263|NCT03114956|PROCEDURE|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
58117264|NCT03114956|PROCEDURE|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
58117265|NCT03114956|PROCEDURE|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
58117266|NCT03114956|PROCEDURE|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
58117267|NCT03849365|DRUG|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
58117268|NCT04433481|DRUG|Dabigatran|T. Dabigatran 150 mg twice a day
58447382|NCT03374787|DEVICE|Fusion Sound Processor|Sound Processor
58447383|NCT04949594|DEVICE|TENS|application on muscles where pain is situated (cervical)
57742446|NCT04720079|PROCEDURE|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
58117269|NCT04433481|OTHER|Placebo|placebo
58117270|NCT01777685|DRUG|Sulpiride|
58117271|NCT04712006|DRUG|JNJ-64304500|Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
58117272|NCT02135874|DRUG|Clofarabine|Given IV
58117273|NCT02135874|DRUG|Cytarabine|Given IV
58117274|NCT02135874|DRUG|Dexamethasone|Given IV
58117275|NCT02135874|DRUG|Idarubicin|Given IV
58117276|NCT02135874|BIOLOGICAL|Rituximab|Given IV
58117277|NCT02135874|DRUG|Sorafenib|Given PO
58117278|NCT02135874|DRUG|Sorafenib Tosylate|Given PO
57742447|NCT04720079|PROCEDURE|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
57742448|NCT01567384|DRUG|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
58117279|NCT02135874|DRUG|Vincristine|Given IV
58117280|NCT02135874|DRUG|Vincristine Sulfate|Given IV
58117281|NCT02473510|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
58117282|NCT02473510|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
58117283|NCT02588183|DEVICE|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
58117284|NCT02286518|DRUG|TAK-114 10 mg capsule|
58117285|NCT02286518|DRUG|TAK-114 matched placebo|
58117286|NCT06547853|BEHAVIORAL|Physical exercise|Groups will be enrolled in a 12-week exercise program. The intervention will be carried out in a highly complex oncology center in Maceió-AL, using the FITT components of the prescription: frequency (4 days a week), intensity (aerobic part through musical beats, subjective perception scale and resistance exercises through a number of maximum repetitions), the time of each session will be 45 minutes, the type of activity offered will be combined exercise training and aerobic exercise training (i.e., walking).
58117287|NCT00708331|DEVICE|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
58117288|NCT03693690|PROCEDURE|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
58117289|NCT03807323|BEHAVIORAL|Lifestyle counselling and exercise|"The program consists of:~1. Instructor-led training twice a week,~2. One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~3. Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
58117290|NCT01729416|OTHER|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
58117291|NCT01729416|OTHER|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
58117292|NCT06543836|DRUG|Sintilimab|Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
58117293|NCT06543836|DRUG|Fruquintinib or Regorafenib|"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
58117294|NCT06543836|DRUG|Fruquintinib|Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
57742449|NCT04324944|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
57742450|NCT04324944|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation around befriending. Each session is 60 minutes long.
58117295|NCT04887883|BEHAVIORAL|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
58117296|NCT00606684|DRUG|GW642444 6.25|GW642444 6.25
58117297|NCT00606684|DRUG|GW642444 3mcg|once daily
58117298|NCT00606684|DRUG|GW642444 12.5mcg|GW642444 12.5mcg
58117299|NCT00606684|DRUG|GW642444 25mcg|GW642444 25mcg
58117300|NCT00606684|DRUG|GW642444 50mcg|GW642444 50mcg
58117301|NCT00606684|OTHER|placebo|placebo
57742451|NCT04956302|DRUG|Bortezomib|Given SC
57742452|NCT04956302|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
58117302|NCT01680185|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
58117303|NCT01680185|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
58117304|NCT01680185|OTHER|Standard of care|all covered above
58117305|NCT01626378|DRUG|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
58117306|NCT01626378|DRUG|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
58117307|NCT03487796|BEHAVIORAL|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
57742453|NCT04956302|DRUG|Dexamethasone|Given PO or IV
57742454|NCT04956302|DRUG|Panobinostat Lactate|Given PO
57742455|NCT05390840|DRUG|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
57742456|NCT05390840|OTHER|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
57742457|NCT01273454|DRUG|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
58117308|NCT03487796|OTHER|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
58313123|NCT03884764|PROCEDURE|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
57742458|NCT00430794|DRUG|Spironolactone|
57742459|NCT04474236|OTHER|thoracic lung ultrasound|Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
57742460|NCT06732999|BEHAVIORAL|Gaze-Contingent Music Reward Therapy (GC-MRT|Gaze-Contingent Music Reward Therapy (GC-MRT) is a treatment method for adults with social anxiety disorder found to be effective in reducing social anxiety in various RCTs. This method includes a computerized cognitive training to redirect threat-related attention patterns.
58313124|NCT03884764|PROCEDURE|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
58313125|NCT03897335|DRUG|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
58447384|NCT05813457|OTHER|PRESTO Early Identification Program|"The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
58447385|NCT00352677|DRUG|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
57742461|NCT06495853|PROCEDURE|Continuous Circumferential Reinforcement of the Anastomotic|The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
57742462|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
57742463|NCT04769037|DIETARY_SUPPLEMENT|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
57742464|NCT04769037|DIETARY_SUPPLEMENT|Placebo|Lactose identical in appearance and taste to the active supplement
57957666|NCT03759626|BEHAVIORAL|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
57957667|NCT03759626|BEHAVIORAL|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
57957668|NCT02575521|DRUG|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
57957669|NCT02575521|DRUG|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
57957670|NCT01329393|BEHAVIORAL|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
57957671|NCT01329393|BEHAVIORAL|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
57957672|NCT04299295|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
57957673|NCT04299295|DEVICE|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
57957674|NCT02368054|DRUG|Bupivacaine|Infiltration anesthesia
57957675|NCT02368054|DRUG|Adrenaline|Infiltration anesthesia
57957676|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
57957677|NCT01340209|DRUG|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
57957678|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
57957679|NCT03912077|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
57957680|NCT05501353|OTHER|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
57957681|NCT00648375|DRUG|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
57957682|NCT00648375|DRUG|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
58447386|NCT06472245|DRUG|OSE2101|OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
58117309|NCT04675177|DRUG|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
58117310|NCT04675177|PROCEDURE|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
58117311|NCT00530400|DRUG|cefuroxime|preoperative intravenous 1.5g cefuroxime
58117312|NCT00530400|DRUG|placebo|preoperative intravenous placebo
58117313|NCT05266781|PROCEDURE|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
58117314|NCT05266781|PROCEDURE|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
58117315|NCT02757586|GENETIC|shRNA|Using shRNA interfered the expression of the gene of CLL
58117316|NCT01128647|DIETARY_SUPPLEMENT|Fructose:glucose drink|
58117317|NCT01128647|DIETARY_SUPPLEMENT|glucose drink|
58117318|NCT02563483|BEHAVIORAL|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
58117319|NCT01513668|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
58117320|NCT06098170|BEHAVIORAL|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
58117321|NCT06098170|BEHAVIORAL|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
58117322|NCT03958279|DIAGNOSTIC_TEST|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
58117323|NCT03958279|DIAGNOSTIC_TEST|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
58447387|NCT06472245|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
58117324|NCT06114056|BIOLOGICAL|JWK007 Single intravenous infusion administration|"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."
58117325|NCT03075033|DEVICE|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
58447388|NCT06472245|DEVICE|NGS HLAA2 assay|Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
58447389|NCT00657163|DRUG|fluoxetine|fluoxetine per os 20 mg daily
57742465|NCT04392765|DEVICE|eXciteOSA|eXciteOSA transoral neurostimulation device
57742466|NCT05090579|PROCEDURE|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
57742467|NCT05090579|PROCEDURE|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
58117326|NCT03075033|DEVICE|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
58313126|NCT03897335|DRUG|Placebo|The placebo group will not receive any aminophylline treatments for the first post-op five days
58313127|NCT01693952|BIOLOGICAL|blood draw|
58313128|NCT04151459|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
58313129|NCT05545501|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
58447390|NCT00657163|DRUG|placebo|placebo per os daily
58447391|NCT03544255|PROCEDURE|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
58447392|NCT06085599|BEHAVIORAL|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
57742468|NCT05090579|PROCEDURE|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
57742469|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
57742470|NCT04326543|DIAGNOSTIC_TEST|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"* Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
57742471|NCT01527734|DRUG|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
57742472|NCT01527734|DRUG|placebo|1ml once or twice a day for 1 or 2 days.
58117327|NCT04654403|DRUG|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
58447393|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.
58447394|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants initiating a CDK 4/6 i after progression on ET.
58447395|NCT02649556|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
58447396|NCT02649556|OTHER|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
58447397|NCT01643382|DRUG|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
58447398|NCT01643382|DRUG|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
58447399|NCT05128578|BEHAVIORAL|Liver Education About Pain (LEAP)|LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
58447400|NCT05128578|BEHAVIORAL|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
58447401|NCT06487091|DIAGNOSTIC_TEST|Analysis of platelet function|Blood withdrawal, platelet separation and analysis of the expression levels of markers of platelet function
58447402|NCT03551626|DRUG|Dabrafenib|Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration
58447403|NCT03551626|DRUG|Trametinib|Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
58447404|NCT00934765|BEHAVIORAL|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
58447405|NCT06725342|GENETIC|Combined DNA/RNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.|"Dual extractions (DNA/RNA) will be carried out from macrodissected thick unstained FFPE sections; samples will be measured for adequate quality / quantity; libraries will be constructed separately with each panel and samples will be sequenced in the same chip in an Ion Torrent Proton System, according to the manufacturer's instructions.~Sequencing results will be called with the Variant Caller for each panel and submitted for initial analysis and annotation to the Ion Reporter pipeline with each DNA and RNA panel"
58447406|NCT06725979|DEVICE|maxillary expansion using hyrax expander|The rapid expansion of the upper jaw will be performed using palatal expander with hyrax screw, which will be activated 2x a day, until the needed width is reached (according to the cast analysis).
58447407|NCT01317251|OTHER|Dietary intervention (without dairy products)|Control diet without dairy products
57742473|NCT03074630|DRUG|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
57742474|NCT03074630|DRUG|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
57742475|NCT05958121|BIOLOGICAL|IMA402 (Phase Ia)|Intravenous infusions in escalating dose levels
57742476|NCT05958121|BIOLOGICAL|IMA402 (Phase Ib)|Treatment at MTD and/or RDE (Phase Ib)
57742477|NCT05958121|BIOLOGICAL|IMA402 (Phase II)|Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
57742478|NCT04609891|DRUG|Avatrombopag|10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
57742479|NCT06733090|DRUG|0.12% chlorhexidine glucanate solution|The superiority of two different solutions over each other will be examined with a standard maintenance.
57742480|NCT06733090|DRUG|0.2% chlorhexidine glucanate solution|0.2% chlorhexidine glucanate solution
57957683|NCT00648375|BEHAVIORAL|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
57742481|NCT03229954|DRUG|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
57742482|NCT03229954|DRUG|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
57742483|NCT01039051|BEHAVIORAL|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
57742484|NCT00000727|DRUG|Pentamidine isethionate|
57742485|NCT00000727|DRUG|Pyrimethamine|
57742486|NCT00000727|DRUG|Sulfamethoxazole/Trimethoprim|
57742487|NCT00000727|DRUG|Sulfadoxine/Pyrimethamine|
57742488|NCT00000727|DRUG|Zidovudine|
57742489|NCT01845675|DRUG|temozolomide or dacarbazine-based chemotherapy, endostatin|
57742490|NCT01579591|OTHER|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
57742491|NCT01579591|OTHER|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
57742492|NCT04879901|DIAGNOSTIC_TEST|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
57742493|NCT05185531|COMBINATION_PRODUCT|PD-1 plus stereotactic body radiotherapy|neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
57742494|NCT01257906|DRUG|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
57742495|NCT01257906|DRUG|ZIANA®|Topical Gel applied in the evening for 84 days
57742496|NCT01257906|DRUG|Vehicle Control|Topical Gel applied in the evening for 84 days.
57742497|NCT06733051|DRUG|Golidocitinib|150 mg, administered once daily from Day 1 to Day 21 (D1-D21)
57742498|NCT06733051|DRUG|Benmelstobart|1200 mg, administered on Day 1 (D1) of every cycle
57742499|NCT03340519|DEVICE|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
58117328|NCT02414880|DRUG|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
57742500|NCT02429882|DRUG|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
57742501|NCT02429882|DRUG|Placebo|Placebo will be administered subcutaneously
57742502|NCT06109870|BEHAVIORAL|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
57742503|NCT04876729|BEHAVIORAL|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
57742504|NCT05972551|DRUG|Romosozumab|Subcutaneous (SC) injection
57742505|NCT05972551|DRUG|Bisphosphonate|Administration determined by investigator according to the local standard of care
57742506|NCT03722134|PROCEDURE|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
57742507|NCT03722134|PROCEDURE|EVLA|Great saphenous vein occlusion with a thermal laser chateter
58117329|NCT02414880|DRUG|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
58117330|NCT02414880|DRUG|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
58117331|NCT05702281|DEVICE|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
57742508|NCT03722134|PROCEDURE|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
57742509|NCT06133387|DEVICE|Endoscopic submucosal dissection using the ELS System|All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
57742510|NCT01154920|DRUG|Paclitaxel|135 mg/m\^2 weekly, Weeks 1 - 6
57742511|NCT01154920|DRUG|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
57742512|NCT01154920|DRUG|Cetuximab|"PCC Arm: 400 mg/m\^2 by vein over about 1-2 hours on Day 1; 250 mg/m\^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
57742513|NCT01154920|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
57742514|NCT01154920|DRUG|Cisplatin|100 mg/m\^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
57742515|NCT01154920|DRUG|Fluorouracil|700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
57742516|NCT01154920|RADIATION|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
58117332|NCT05071547|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
58117333|NCT05071547|OTHER|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
58117334|NCT06432621|PROCEDURE|using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation|patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
58117335|NCT04919083|OTHER|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
58117336|NCT04919083|OTHER|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
58117337|NCT05924711|OTHER|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
58117338|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
58117339|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
58117340|NCT06163833|OTHER|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
58117341|NCT04841278|DEVICE|EUS/ERCP|EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
58117342|NCT02008721|DRUG|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
58117343|NCT02008721|DRUG|Placebo|Placebo
58117344|NCT06544876|BEHAVIORAL|sit-to-stand|test for balance during movement from sitting to standing
58117345|NCT06544876|BEHAVIORAL|stand to sit|test for balance during movement from standing to sitting
58117346|NCT06544876|BEHAVIORAL|standing perturbation|test for balance recovery following perturbation
57742517|NCT01154920|OTHER|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m\^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
58117347|NCT06544876|OTHER|MRI of sciatic nerve|measure of peripheral nerve diameter
58117348|NCT05118321|DEVICE|Custom-made upper limb exosuit and hand exoskeleton|Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
58117349|NCT06229600|OTHER|Standard rehabilitation|Respiratory rehabilitation
58117350|NCT00472550|DRUG|esomeprazole 20 mg|
58447408|NCT01317251|OTHER|Dietary intervention (high milk content)|Diet with a high content of milk (\~1200 mg Ca/d from milk)
58447409|NCT01317251|OTHER|Dietary intervention (high cheese content)|Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
57742518|NCT06666491|DRUG|Tafenoquine|A single dose of TQ will be administered orally on Day 1 or Day 2.
58447410|NCT03826186|DEVICE|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
58447411|NCT03826186|DEVICE|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
57742519|NCT06666491|DRUG|Primaquine|A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
57742520|NCT06666491|DRUG|Chloroquine|A single dose of CQ will be administered orally, daily, on Days 1 to 3.
57742521|NCT06010082|BEHAVIORAL|Music Therapy|Music Therapy intervention will be delivered through instructed participants to empty their bladder and then listen to music for 30 min in a semi-fowler's position with their head and shoulders raised 30° in a quiet and dim environment, listening to the music of symphonic music.
58447412|NCT00854880|DRUG|PDC339|
58447413|NCT00854880|DRUG|Placebo|
58447414|NCT00671489|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
57742522|NCT01923259|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
57742523|NCT06636877|DRUG|BR1019|One tablet administered alone
58313130|NCT05545501|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
58313131|NCT05545501|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
58313132|NCT02209064|DEVICE|Pericardial access|Access to the pericardium to enable further treatments.
58447415|NCT02255227|BIOLOGICAL|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
57957684|NCT01936532|DRUG|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
57957685|NCT01936532|DRUG|Lenalidomide|
57957686|NCT01936532|DRUG|Dexamethasone|
57957687|NCT04348409|DRUG|Nitazoxanide Tablets|Patients will receive nitazoxanide 600 mg BID for 7 days
57957688|NCT04348409|DRUG|Placebo|Patients will receive placebo BID for 7 days
57957689|NCT02540486|OTHER|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
57957690|NCT02540486|OTHER|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
57957691|NCT02776800|DEVICE|Allevyn Life|
57957692|NCT02776800|DEVICE|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
57957693|NCT00429858|DRUG|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
58313133|NCT04663113|OTHER|Control Group/1st group ( standard physiotherapy|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
58313134|NCT04663113|OTHER|2nd group- Standard physiotherapy + bicycle ergometer|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given."
58313135|NCT04663113|OTHER|3rd group- Standard physiotherapy + exercise protocol to be developed|"Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction"
58313136|NCT04168957|DRUG|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
58313137|NCT04994964|DIAGNOSTIC_TEST|Electromyography|Needle vocal cord electromyography using Medtronic NIM monitor
58313138|NCT03777241|BEHAVIORAL|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
58313139|NCT03777241|BEHAVIORAL|Standard of care|Participants in this group will receive standard of care.
58447416|NCT02255227|BIOLOGICAL|Pneumo 23|one dose
58447417|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
58447418|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
58447419|NCT02177188|DEVICE|LBNP Lower Bodi Negative Pressure Chamber|
58447420|NCT03740659|DRUG|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
57957694|NCT00429858|DRUG|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
57957695|NCT02103530|OTHER|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
58447421|NCT03740659|DRUG|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
58447422|NCT03740659|DRUG|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
58447423|NCT00801229|DRUG|Vyvanse|Vyvanse 30, 50, or 70 mg daily
58447424|NCT00801229|DRUG|Placebo|Placebo 30, 50, 70 mg daily
58117351|NCT05466890|DRUG|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
58117352|NCT05466890|DRUG|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
58117353|NCT05420428|DEVICE|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
58117354|NCT05420428|DEVICE|endotracheal intubation|under general anesthesia, patients received endotracheal intubation
58117355|NCT02960074|BIOLOGICAL|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
58117356|NCT04666766|DEVICE|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
58117357|NCT05718388|OTHER|Physical therapy exercises|For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
58447425|NCT02682368|DIAGNOSTIC_TEST|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
57742524|NCT06636877|DRUG|BR1019-2|One tablet administered alone
57742525|NCT06636877|DRUG|BR1019-3|One tablet administered alone
57742526|NCT00002564|OTHER|educational intervention|
57957696|NCT03756311|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
57957697|NCT02224378|PROCEDURE|peep induced CVP|
57957698|NCT02224378|PROCEDURE|passive leg raising(PLR)|
57957699|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
57957700|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
57957701|NCT02101723|DIETARY_SUPPLEMENT|Placebo|Placebo powder without micronutrients
57957702|NCT00777010|OTHER|Ketogenic diet|carbohydrate restricted diet
57957703|NCT00777010|OTHER|Healthy high carbohydrate diet|higher carbohydrate diet
58117358|NCT05718388|OTHER|Isokinetic training|Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
58117359|NCT01297257|DEVICE|Stent implantation|Single arm, open label stent implantation
58117360|NCT03974633|COMBINATION_PRODUCT|Injection|All information is included in the Arm/group descriptions
58117361|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
58117362|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
58117363|NCT00219856|DRUG|Propofol|"* Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~* Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
58117364|NCT00219856|DRUG|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
58117365|NCT00219856|DRUG|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
57742527|NCT00002564|PROCEDURE|therapeutic dietary intervention|
57742528|NCT03045666|OTHER|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
57957704|NCT01330238|DRUG|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
57957705|NCT05405283|BIOLOGICAL|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
57957706|NCT05405283|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
57957707|NCT06130293|DEVICE|VR game intervention|Using self-paced VR game to train.
58117366|NCT02355548|OTHER|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
58117367|NCT05728177|COMBINATION_PRODUCT|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
58117368|NCT03130205|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
58117369|NCT03130205|RADIATION|Computed Tomography|Computed Tomography
58117370|NCT03130205|RADIATION|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
58117371|NCT03130205|PROCEDURE|Phlebotomy|3 EDTA tubes drawn from peripheral vein
57742529|NCT03321331|COMBINATION_PRODUCT|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
58117372|NCT03130205|GENETIC|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
58117373|NCT03749655|BEHAVIORAL|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
58117374|NCT01548781|BEHAVIORAL|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
58117375|NCT05946083|DIETARY_SUPPLEMENT|Inulin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
58117376|NCT05946083|DIETARY_SUPPLEMENT|Maltodextrin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
58117377|NCT03118739|DRUG|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
58117378|NCT03118739|DRUG|Placebo|Capsule administered orally, once daily for 24 weeks
58117379|NCT01415921|DRUG|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
57742530|NCT03321331|COMBINATION_PRODUCT|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
57957708|NCT04851951|PROCEDURE|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
58117380|NCT00322556|DRUG|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
57742531|NCT00818116|DEVICE|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
57742532|NCT06490562|DRUG|PDCy|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
58117381|NCT03253978|RADIATION|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
58447426|NCT02682368|DIAGNOSTIC_TEST|Radiology report|Radiologist report compared to the point of care ultrasound impression.
57742533|NCT06490562|DRUG|Non Cy|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
57957709|NCT00540189|PROCEDURE|Initial appendectomy|
57957710|NCT00540189|PROCEDURE|Interval appendectomy|
57957711|NCT05211479|BEHAVIORAL|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
57957712|NCT02418416|OTHER|Oocyte double chemical activation|Oocyte double chemical activation
57957713|NCT01698346|BIOLOGICAL|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
58117382|NCT02202018|OTHER|Active KT intervention|"1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
58447427|NCT02682368|PROCEDURE|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
58447428|NCT00414141|BIOLOGICAL|Grass MATA MPL|4 subcutaneous injections
58447429|NCT00414141|BIOLOGICAL|Placebo|4 subcutaneous injections
57957714|NCT06027359|OTHER|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~* Therapeutic play activities will not be performed with the children in the control group.~* One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
57957715|NCT06349395|OTHER|MBSR surgical nursing care|This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
57957716|NCT02419287|DRUG|crizotinib|
57957717|NCT02308683|DIETARY_SUPPLEMENT|Moringa oleifera|12 weeks supplementation
57742534|NCT01704170|DEVICE|Kona Externally Focused Ultrasound Therapy|
58117383|NCT06406647|OTHER|retrocalvicular block|retrocalvicular block in upper limb orthopedic Surgey
58117384|NCT02924857|DEVICE|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
58117385|NCT02924857|DEVICE|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
58117386|NCT04124861|DRUG|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
58117387|NCT04089683|OTHER|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
58447430|NCT06726499|DEVICE|Spherical CRT|Contact lens for myopia progression
58447431|NCT06726499|DEVICE|Toric CRT|Contact lens for myopia progression
58447432|NCT06726330|PROCEDURE|Fimbriectomy Followed by Delayed Oophorectomy (F-DO)|"This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis"
58447433|NCT06726330|PROCEDURE|Bilateral Salpingo-Oophorectomy|This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
57742535|NCT06445491|OTHER|Control order|Participants will perform an initial baseline of tests, order of 1- 2- 3
57742536|NCT06445491|OTHER|Randomized sequence|the testing order will be randomized for follow up testing.
57742537|NCT06488859|BEHAVIORAL|Positive Affect Treatment|Sessions 1-8: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects
58117388|NCT01853306|DRUG|Veliparib|veliparib
58117389|NCT01830920|DRUG|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
58117390|NCT01830920|DRUG|Placebo|A normal saline solution identical in appearance to the active drug solution
58117391|NCT02233790|DRUG|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
58117392|NCT02233790|DRUG|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
58117393|NCT06417996|OTHER|Digital Group|Once patients are ready for discharge, patients in the digital group will be sent home with the Biobeat digital monitoring kit with written \& oral instructions on how it will be used in maintaining continuity of care which will track ECG (electrocardiogram), HR, NIBP, SPO2, and pain scores. A continuous recording and two-lead ECG patch will be applied and activated at the time of discharge to identify any paroxysmal atrial fibrillation.
58117394|NCT03440203|OTHER|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
58447434|NCT05693363|DEVICE|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
57742538|NCT06488859|BEHAVIORAL|Positive Affect Treatment and Negative Affect Treatment|Sessions 1-4: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects Sessions 5-8: Exposure therapy to feared or avoided situations, sensations, or memories
57742539|NCT00528775|DRUG|HPPH|4 mg/m2 IV
57742540|NCT00528775|PROCEDURE|endoscopic procedure|Treatment with 150 joules from laser
57742541|NCT01410773|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
57742542|NCT05300425|OTHER|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
57742543|NCT05300425|OTHER|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
57742544|NCT05703100|OTHER|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
57742545|NCT05703100|OTHER|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
57742546|NCT05703100|OTHER|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
57742547|NCT02308748|DRUG|Dofetilide|"* 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg"
57742548|NCT02308748|DRUG|Mexiletine|"* 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am"
58117395|NCT06170814|OTHER|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
58117396|NCT05861609|PROCEDURE|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
57742549|NCT02308748|DRUG|Lidocaine|"* 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
57742550|NCT02308748|DRUG|Moxifloxacin|"* 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
57742551|NCT02308748|DRUG|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
57742552|NCT02308748|DRUG|Placebo|Placebo (#2 Gelcap or IV saline)
58117397|NCT05861609|PROCEDURE|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
58117398|NCT05861609|PROCEDURE|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
58117399|NCT05585463|PROCEDURE|acupuncture|Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
58117400|NCT04843085|OTHER|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
58117401|NCT04738877|DIAGNOSTIC_TEST|Body fat measurement|Body fat measurement using skinfolds
58447435|NCT02641431|PROCEDURE|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
58447436|NCT02641431|DRUG|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
58447437|NCT02641431|PROCEDURE|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
57742553|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
57742554|NCT04429516|DRUG|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
57742555|NCT04429516|DRUG|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
57742556|NCT00542802|DRUG|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
57742557|NCT00542802|DRUG|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
57742558|NCT06578962|OTHER|Phase 1: short intensive treatment phase|During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.
57742559|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with gentle balancing shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the gentle balancing shampoo RD1089O was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
58117402|NCT04738877|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
58117403|NCT04738877|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography
58117404|NCT04738877|DIAGNOSTIC_TEST|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
58117405|NCT06379074|BEHAVIORAL|Improving sleep health and resilience during pregnancy|"Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician.~Sessions' contents:~1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy;~2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques;~3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques;~4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques;~5. Sleep in the postpartum and the development of sleep regulation in children;~6. Relapse prevention and focus on acquired skills and how to prioritize sleep."
58447438|NCT02641431|PROCEDURE|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
58447439|NCT02414685|DRUG|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
58447440|NCT02414685|DRUG|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
58447441|NCT02414685|DRUG|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
57742560|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with neutral shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the neutral shampoo RD0057H was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
57742561|NCT06578962|OTHER|Phase 2 : neutral shampoo|"During maintenance phase (phase 2):~the neutral shampoo RD0057H was applied thrice a week for 8 weeks."
57742562|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally (PO) QD
57742563|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
57742564|NCT03062969|PROCEDURE|Cleavage stage biopsy group|"* intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer"
57742565|NCT03062969|PROCEDURE|Trophectoderm biopsy group|"* ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer"
57742566|NCT01725828|DEVICE|Ultrasound|Using the Ultrasound to determine the location of the CTM.
57742567|NCT01725828|OTHER|External Palpation|Using External Palpation to identify cricothyoid membrane
57742568|NCT06724510|DEVICE|HIFU treatment with ULTRAFOMER MPT|The high-intensity focused ultrasound (HIFU) treatment, which is the primary intervention being evaluated for efficacy and safety in eyebrow lifting.
57742569|NCT06285877|PROCEDURE|Conventional therapy sessions|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
57742570|NCT06285877|PROCEDURE|Conventional therapy sessions plus Nintendo Switch|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
57742571|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
57742572|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
57742573|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
57742574|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
57742575|NCT06654089|DIETARY_SUPPLEMENT|Emergen-C Core Super Orange Powder|A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.
57742576|NCT06654089|DIETARY_SUPPLEMENT|Placebo|A study product identical to the test product without active ingredients.
57742577|NCT01886898|OTHER|Infant formula|infant formula
57742578|NCT01886898|OTHER|Breastfeeding|
57742579|NCT03158883|DRUG|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).
57742580|NCT03158883|RADIATION|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
57742581|NCT02353650|DIETARY_SUPPLEMENT|Q10|
57742582|NCT02353650|DIETARY_SUPPLEMENT|placebo|
57742583|NCT03199222|DEVICE|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
57742584|NCT01397838|DRUG|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
57742585|NCT00299650|DRUG|cisatracurium|
57742586|NCT00299650|DRUG|Placebo|physiological serum infusion
57742587|NCT00299650|DRUG|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
57742588|NCT04514341|OTHER|Short Message Service (SMS)|Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.
58447442|NCT06609057|OTHER|Nutritional Intervention|Receive Cooking for Your Health in Southern New Mexico intervention
57742589|NCT04514341|OTHER|Remote Patient Navigation|Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
57742590|NCT00003532|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57742591|NCT06219746|DIAGNOSTIC_TEST|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
57742592|NCT02975973|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
57742593|NCT01088139|DIETARY_SUPPLEMENT|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
58447443|NCT06609057|OTHER|Questionnaire Administration|Ancillary studies
57742594|NCT01814592|PROCEDURE|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
57742595|NCT01814592|PROCEDURE|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
57742596|NCT01395381|DRUG|Placebo|placebo given once
57742597|NCT01395381|DRUG|Albendazole|single dose albendazole given at the time of enrollment
57742598|NCT02224768|DRUG|Ipilimumab|
57742599|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
57742600|NCT04084314|BIOLOGICAL|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
58447444|NCT06609057|OTHER|Survey Administration|Ancillary studies
58117406|NCT06379074|BEHAVIORAL|Information on pregnancy-related issues|"Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions."
58117407|NCT02837510|BEHAVIORAL|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
58117408|NCT00670475|DRUG|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
58117409|NCT00670475|DIETARY_SUPPLEMENT|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
58117410|NCT00290745|DRUG|letrozole|
58117411|NCT00290745|DRUG|tamoxifen citrate|
58117412|NCT00290745|PROCEDURE|conventional surgery|
58447445|NCT06609057|OTHER|Discussion|Ancillary studies
58447446|NCT05663580|DRUG|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
58447447|NCT01466127|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
58447448|NCT01466127|DRUG|Placebo|Matched nasal spray placebo
58447449|NCT06725355|DRUG|IN-R00002|Single administration of IN-R00002 60mg
58447450|NCT06725355|DRUG|IN-G00002|Single administration of IN-G00002 60mg
57742601|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
57742602|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
57742603|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
57742604|NCT06373432|OTHER|Fingerstick|Fingerstick to check glucose value during labor.
57957718|NCT01849861|DRUG|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity"
57957719|NCT02326805|OTHER|Laboratory Biomarker Analysis|Correlative studies
57957720|NCT02326805|OTHER|Placebo Administration|Given SC
57957721|NCT02326805|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
57957722|NCT01656031|DRUG|clofarabine|
57957723|NCT01656031|DRUG|cytarabine|
58117413|NCT00290745|PROCEDURE|neoadjuvant therapy|
58117414|NCT04368585|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
58447451|NCT01405300|DIETARY_SUPPLEMENT|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.
58447452|NCT01405300|DIETARY_SUPPLEMENT|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
58447453|NCT05849168|BEHAVIORAL|Exercise training|Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
58447454|NCT00798525|DRUG|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
57742605|NCT05256589|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
57957724|NCT01966133|DRUG|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
57957725|NCT04243330|BEHAVIORAL|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
57957726|NCT04243330|BEHAVIORAL|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
58117415|NCT04368585|DRUG|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
57742606|NCT03580733|DRUG|caspofungin antifungal therapy|caspofungin
57742607|NCT03580733|OTHER|placebo|placebo
57742608|NCT06580678|DRUG|KH001|topical application of KH001
57742609|NCT06580678|DRUG|Placebo|topical application of Water for Injection
57742610|NCT01659931|DRUG|Montelukast|10 mg Tablet
57742611|NCT01659931|DRUG|Singulair|10 mg Tablet
57742612|NCT01285583|DRUG|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
58117416|NCT04368585|DRUG|Omeprazole|40 mg (1 x 40 mg capsule) omeprazole administered QD
58117417|NCT00798889|DRUG|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
58117418|NCT01492582|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
58117419|NCT01492582|OTHER|laboratory biomarker analysis|Correlative studies
58117420|NCT01492582|OTHER|survey administration|Ancillary studies
58117421|NCT01492582|OTHER|medical chart review|Ancillary studies
58447455|NCT00798525|DRUG|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
58447456|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
58447457|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
58447458|NCT02226718|OTHER|Administration of questionnaire|
57742613|NCT05554952|COMBINATION_PRODUCT|MTA|Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
57742614|NCT01656551|DRUG|Gemcitabine|
57742615|NCT01656551|DRUG|Pemetrexed|500 mg/m2 day 1 every 3 weeks
57742616|NCT01656551|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks
57742617|NCT04732455|DRUG|Lidocaine in Saline|Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
57742618|NCT04732455|DRUG|Duloxetine 30 MG|Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
57742619|NCT04732455|DRUG|Normal saline|200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
57742620|NCT01972958|OTHER|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
57742621|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
57742622|NCT00879138|DRUG|VA106483|
57742623|NCT00879138|DRUG|Sugar pill|
57742624|NCT03577717|OTHER|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
57742625|NCT03577717|OTHER|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
57742626|NCT02477111|DEVICE|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
57742627|NCT01258608|DRUG|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
57742628|NCT01258608|DRUG|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
57742629|NCT01258608|DRUG|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
57742630|NCT06305338|OTHER|Optical Coherence Tomography|the study releated measurements will be performed: IOLMaster 700, Casia 2 and Pentacam HR.
57742631|NCT02535910|DIETARY_SUPPLEMENT|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
58117422|NCT04738747|BEHAVIORAL|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
58117423|NCT04875156|OTHER|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
58117424|NCT00275535|DRUG|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
58117425|NCT00275535|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
58117426|NCT00275535|DRUG|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
58117427|NCT00275535|DRUG|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
58117428|NCT00275535|DRUG|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
58117429|NCT02585882|OTHER|Fluoride table salt|
58117430|NCT03198299|DEVICE|MEI BIN insoles|wearing insoles for 12 weeks
57742632|NCT02535910|DIETARY_SUPPLEMENT|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
57742633|NCT02535910|DIETARY_SUPPLEMENT|Control|Subjects are asked to consume a breakfast without vitamin D
57742634|NCT00965432|DRUG|STX107|Single dose of an oral suspension
57742635|NCT05275192|DEVICE|Videoscope-assisted periodontal regeneration minimally invasive surgery|Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
57742636|NCT05275192|PROCEDURE|Periodontal regeneration minimally invasive surgery|Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
57742637|NCT05275192|PROCEDURE|Guided tissue regeneration surgery|Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
57742638|NCT02067260|DEVICE|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
57742639|NCT02067260|DEVICE|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
57742640|NCT00175604|DRUG|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
57742641|NCT03355326|DRUG|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
57742642|NCT01271322|RADIATION|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
57742643|NCT06576726|OTHER|This study involves no intervention.|This study involves no intervention.
58447459|NCT01013194|OTHER|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2."
58117431|NCT00202137|BEHAVIORAL|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
58117432|NCT00202137|BEHAVIORAL|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
58117433|NCT02764489|BIOLOGICAL|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
58447460|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
58447461|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
57742644|NCT04398277|BEHAVIORAL|Daily Coping Toolkit|"1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box."
57742645|NCT02250612|DRUG|1 drop of 0.375% SYL040012 (bamosiran)|
57742646|NCT02250612|DRUG|1 drop of 0.750% SYL040012 (bamosiran)|
57742647|NCT02250612|DRUG|1 drop of 1.125% SYL040012 (bamosiran)|
57742648|NCT02250612|DRUG|1 drop of 1.5% SYL040012 (bamosiran)|
57742649|NCT02250612|DRUG|1 drop of 0.5 % timolol maleate|
57742650|NCT05560854|BEHAVIORAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
58117434|NCT00892697|DRUG|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
58117435|NCT00892697|DRUG|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
58447462|NCT02155777|DRUG|OrthoNovum 1/35|
57742651|NCT01838798|OTHER|Baseline activities|Initial consent procedures and baseline data collection.
57742652|NCT01838798|OTHER|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire"
57742653|NCT01838798|OTHER|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts"
57742654|NCT01838798|OTHER|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress"
57742655|NCT04432987|DRUG|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
58447463|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
58447464|NCT01153737|OTHER|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
57742656|NCT03105310|DRUG|Pegylated interferon alfa|Pegylated interferon alfa
57742657|NCT03105310|DRUG|Ezetimibe|Ezetimibe
57742658|NCT02650648|DRUG|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
57742659|NCT02650648|BIOLOGICAL|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10\^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
57742660|NCT02650648|BIOLOGICAL|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over \~30-90 minutes
57742661|NCT02650648|DRUG|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10\^5 U/m\^2/day.
57742662|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
57742663|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
57742664|NCT06733142|DIETARY_SUPPLEMENT|Test Product: Yoghurt|High protein spoonable yoghurt
57742665|NCT06733142|DIETARY_SUPPLEMENT|Micellar casein drink|Micellar casein drink made from water, casein powder and fruit syrup
57742666|NCT06733142|DIETARY_SUPPLEMENT|Placebo|Placebo sugar free jelly
57742667|NCT03752684|OTHER|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate
57742668|NCT03752684|OTHER|Moderately high oxalate/low calcium diet|Subjects will be instructed to ingest a controlled diet moderately high in oxalate
57742669|NCT03752684|OTHER|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
57742670|NCT05480475|DRUG|Dabigatran etexilate|On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
57742671|NCT05480475|DRUG|Rosuvastatin|On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
57742672|NCT05480475|DRUG|Daridorexant|On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
57957727|NCT06063421|DEVICE|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
57957728|NCT06063421|DRUG|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
58447465|NCT01153737|OTHER|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
58447466|NCT01470456|DRUG|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
58447467|NCT01470456|DRUG|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
57742673|NCT04585932|DRUG|Apalutamide|Given PO
57957729|NCT04739046|DRUG|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
57957730|NCT02206646|DRUG|Metalyse|
57742674|NCT04585932|DRUG|Degarelix|Given SC
58117436|NCT00892697|DRUG|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
58447468|NCT05661851|DRUG|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
57742675|NCT04585932|DRUG|Leuprolide Acetate|Given IM
57742676|NCT04585932|OTHER|Quality-of-Life Assessment|Ancillary studies
57742677|NCT04585932|OTHER|Questionnaire Administration|Ancillary studies
57742678|NCT04585932|RADIATION|Radiation Therapy|Undergo RT
58447469|NCT05661851|DRUG|Blink® Tears eye Drops|Control Product
58447470|NCT04537026|DRUG|Amniotic Fluid Allograft|Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
58447471|NCT04537026|DRUG|Dexamethasone sodium phosphate|Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
58447472|NCT02695251|OTHER|low AGE meal|Patients will receive a low AGE (eggs) meal
58447473|NCT02695251|OTHER|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
58447474|NCT04258826|DRUG|LY3154207|LY3154207 administered orally.
58447475|NCT04258826|DRUG|Placebo|Placebo administered orally.
58447476|NCT06074562|DRUG|LY3556050|Administered orally.
58447477|NCT06074562|DRUG|Placebo|Administered orally.
58447478|NCT04338308|DEVICE|new-DES|with ot without embolic protection device
58447479|NCT04338308|DEVICE|BMS|with ot without embolic protection device
57742679|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
57742680|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
57742681|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
57742682|NCT05381974|DRUG|Psilocybin|Open-Label
57742683|NCT00931372|DRUG|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
57742684|NCT00931372|DRUG|Placebo|Subcutaneous injection
57742685|NCT03818412|PROCEDURE|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
57742686|NCT02127424|PROCEDURE|Nurse-driven HIV targeted screening|
57742687|NCT02127424|PROCEDURE|Current practice|
57742688|NCT04653766|DRUG|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
57742689|NCT04653766|DRUG|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
57742690|NCT04653766|DRUG|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
57742691|NCT04653766|DRUG|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
57742692|NCT04653766|DRUG|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
57742693|NCT02654808|DEVICE|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
57742694|NCT02654808|DEVICE|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
57742695|NCT00205283|DRUG|Nelfinavir|
57742696|NCT02677116|DRUG|Olaratumab|Olaratumab administered IV.
57742697|NCT02677116|DRUG|Doxorubicin|Doxorubicin administered IV.
57742698|NCT02677116|DRUG|Vincristine|Vincristine administered IV.
57742699|NCT02677116|DRUG|Irinotecan|Irinotecan administered IV.
57742700|NCT02677116|DRUG|Ifosfamide|Ifosfamide administered IV.
57742701|NCT02821273|OTHER|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
57742702|NCT02821273|OTHER|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
57742703|NCT04326270|DEVICE|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
57742704|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
58117437|NCT06320379|DIETARY_SUPPLEMENT|Zypan|The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosol™ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals
57742705|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
57742706|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
58117438|NCT06320379|DIETARY_SUPPLEMENT|Placebo Comparator|The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%\*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)
57742707|NCT05699733|DEVICE|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
57742708|NCT02141126|OTHER|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
57742709|NCT02141126|OTHER|Usual care|Standard inpatient 'usual care' physiotherapy
57742710|NCT04070924|OTHER|Bandaid|Bandaid dressing
58313140|NCT01632319|BEHAVIORAL|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
57742711|NCT04070924|OTHER|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
57742712|NCT00591890|DRUG|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
57742713|NCT02434692|DEVICE|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
57742714|NCT01945606|DRUG|Placebo (treatment 1)|Oral administration of placebo tablets
57742715|NCT01945606|DRUG|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
57742716|NCT03190473|DEVICE|DES|PCI with implantation of a DES
57742717|NCT04171466|OTHER|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
57957731|NCT00193895|DRUG|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
57957732|NCT00193895|RADIATION|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
57957733|NCT04481529|OTHER|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
57742718|NCT04171466|OTHER|SH-DS01|SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
57742719|NCT04171466|OTHER|Placebo|Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
57742720|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
57742721|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
57957734|NCT03631836|DRUG|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
57957735|NCT03631836|DRUG|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
57957736|NCT03631836|BIOLOGICAL|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
57742722|NCT04656054|PROCEDURE|liposuction|liposuction procedure and observation of the hematological changes on the patients
57742723|NCT06732193|PROCEDURE|On-site respiratory physiotherapy|The patient attends face-to-face physiotherapy sessions prescribed by the doctor.
57742724|NCT06732193|DEVICE|Fissios App|The patient uses the Fissios App to perform respiratory physiotherapy exercises.
57742725|NCT05911204|OTHER|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
57742726|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
57742727|NCT06480773|DRUG|standard of care chemotherapy|intravenous Paclitaxel or the combination of Bleomycin and Vincristine.
57742728|NCT04866017|DRUG|Tislelizumab|200 mg intravenously every three weeks
57742729|NCT04866017|DRUG|Durvalumab|10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
57957737|NCT03631836|DEVICE|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
57957738|NCT00222183|DRUG|Elidel (pimecrolimus)|
57957739|NCT04804189|BEHAVIORAL|Guardians 4 Health|Clubs will implement Guardians 4 Health's intervention into their community by (1) incorporating Guardians 4 Health materials into standard Club educational activities; (2) conducting a community- level Reframe event, led by Club adult and teen leaders; and (3) using social norms digital marketing materials.
57742730|NCT04866017|DRUG|Ociperlimab|900 milligrams (mg) intravenously every three weeks
57742731|NCT04866017|DRUG|Chemotherapy|"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
57742732|NCT04866017|RADIATION|Radiotherapy|All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
57742733|NCT02275104|DEVICE|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
57742734|NCT02275104|DEVICE|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
58117439|NCT03639272|PROCEDURE|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
58117440|NCT03404661|DRUG|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
58117441|NCT04328948|RADIATION|Chemoradiotherapy|Chemoradiotherapy
58117442|NCT01195922|DRUG|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
57742735|NCT02275104|DEVICE|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
57742736|NCT02275104|DEVICE|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
58117443|NCT05507554|DRUG|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
58447480|NCT06465511|BEHAVIORAL|Supportive clinic|During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.
58447481|NCT06465511|BEHAVIORAL|Control: Self-management|Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
57957740|NCT04639622|DIAGNOSTIC_TEST|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
57957741|NCT03740750|DEVICE|Thermacare heat wraps|low level continuous heat wrap
57957742|NCT03740750|DEVICE|TENS|electrical stimulation
57957743|NCT03740750|DEVICE|sham heat|expended heat wrap
57957744|NCT03740750|DEVICE|sham Tens|tens applied but unit not turned on
57957745|NCT02269527|OTHER|Live music|Providing 1-hour live music 5 days/ week.
57957746|NCT05627219|BEHAVIORAL|Training and Education|Undergo training and education
57957747|NCT05627219|OTHER|Educational Intervention|Receive educational booklet
57957748|NCT05627219|PROCEDURE|Discussion|Attend discussion with peer genetic coach
57957749|NCT06372964|DRUG|Lumateperone|Lumateperone administered orally, once daily.
57957750|NCT06372964|DRUG|Placebo|Matching placebo administered orally, once daily.
57957751|NCT00267748|DRUG|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
57742737|NCT02275104|PROCEDURE|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
58117444|NCT05507554|DRUG|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
58117445|NCT05507554|DRUG|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
58117446|NCT04894422|OTHER|Observational intervention|Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
58117447|NCT03611114|DIETARY_SUPPLEMENT|Blood orange juice|
58117448|NCT03611114|DIETARY_SUPPLEMENT|Control drink|
58117449|NCT00417313|DEVICE|periosteal electro-acupuncture (osteopuncture).|
58117450|NCT05979181|PROCEDURE|Cesarean hysterectomy|Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
58117451|NCT04402515|DRUG|TIO/OLO|Tiotropium/Olodaterol
58117452|NCT04402515|DRUG|ICS|inhaled cortocosteroids
58117453|NCT02687256|DEVICE|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
58117454|NCT02687256|DEVICE|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
58117455|NCT02687256|DRUG|Heparin|
58117456|NCT00818714|RADIATION|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
58117457|NCT03275701|DRUG|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
58117458|NCT01691755|DRUG|Placebo|oral doses once a day for 26 weeks
58117459|NCT01691755|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
58117460|NCT06207825|DIAGNOSTIC_TEST|Test images and videos|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.
58117461|NCT01077206|DRUG|Simvastatin|80mg daily versus 40mg daily, for 21 days.
58117462|NCT06481800|OTHER|Progressive muscle relaxation (PMR)|patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
58447482|NCT06105840|PROCEDURE|Acupressure and Standardized Curcuminoid from Turmeric Extract|capsules containing curcuminoid from Tumeric Extract three times a day for 3 weeks and acupressure massage at points provide comfort for knee pain twice a week for 3 weeks
57742738|NCT03188848|DRUG|BPI-3016|Single-dose subcutaneous injection of BPI-3016
57742739|NCT03188848|DRUG|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
57742740|NCT04804553|DRUG|Apremilast|Participants will receive apremilast orally.
58117463|NCT06481800|OTHER|cnotrol group|Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests
58117464|NCT06481800|OTHER|Manual lymphatic drainage (MLD)|Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
58117465|NCT01100684|DRUG|Asimadoline|0.5 mg Asimadoline BID
58117466|NCT01100684|DRUG|Placebo|Placebo
58117467|NCT01629875|DRUG|Generic equivalent of Clostridium Botulinum A Toxin|
58117468|NCT01629875|DRUG|Botox (Clostridium Botulinum A Toxin)|
58117469|NCT06541470|PROCEDURE|Cutting needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
58117470|NCT06541470|PROCEDURE|Abrams needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
58117471|NCT05936528|DRUG|Lactoferrin|antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
58117472|NCT02549742|PROCEDURE|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
58117473|NCT02549742|DEVICE|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
58117474|NCT02549742|DRUG|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
58117475|NCT02791776|OTHER|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
58117476|NCT00000614|DRUG|warfarin|
58117477|NCT03508895|OTHER|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
58117478|NCT03508895|OTHER|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
58117479|NCT03508895|OTHER|Casein protein|The intervention was provided in the form of a smoothie.
58313141|NCT01632319|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
58447483|NCT06105840|PROCEDURE|Sham Acupressure and Placebo|capsules containing starch three times a day for 3 weeks and acupressure massage at points that are not to provide comfort for knee pain twice a week for 3 weeks
58447484|NCT03461146|DRUG|MT-6548|Oral tablet
57742741|NCT04804553|DRUG|Placebo|Participants will receive the matching placebo orally.
57742742|NCT00572741|DIETARY_SUPPLEMENT|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
57742743|NCT00572741|DIETARY_SUPPLEMENT|Placebo|cellulose
57742744|NCT00572741|DIETARY_SUPPLEMENT|folate|Folinic acid: Dose: 400 µg twice a day (BID)
57742745|NCT00572741|DIETARY_SUPPLEMENT|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
57742746|NCT00572741|DIETARY_SUPPLEMENT|vitamin C|Vitamin C 500 mg
58117480|NCT02168647|BEHAVIORAL|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
58117481|NCT02168647|OTHER|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
58117482|NCT05784571|OTHER|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
58117483|NCT05784571|OTHER|Modified Physical Performance Test|A test of physical functioning
57742747|NCT00572741|DIETARY_SUPPLEMENT|cod liver oil|Cod liver oil 1/2 teaspoon
57742748|NCT00572741|DIETARY_SUPPLEMENT|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
57742749|NCT00572741|DIETARY_SUPPLEMENT|carnitine|Acetyl L-Carnitine Dose: 250 mg
57742750|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
58447485|NCT02466932|DEVICE|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
58447486|NCT04066478|DRUG|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
57742751|NCT05293080|OTHER|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
57742752|NCT05293080|OTHER|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
57742753|NCT05108792|OTHER|NO INTERVENTION|observational study, no intervention performed
57957752|NCT00267748|DRUG|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
57957753|NCT00352651|DRUG|Pregabalin|
57957754|NCT03343587|DRUG|LY3375880 IV|administered IV
57957755|NCT03343587|DRUG|LY3375880 SC|administered SC
57957756|NCT03343587|DRUG|Placebo IV|administered IV
58447487|NCT04066478|DRUG|Placebo|Placebo
57742754|NCT00000648|DRUG|Penicillin G potassium|
57742755|NCT00000648|DRUG|Ceftriaxone sodium|
57742756|NCT01930110|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
57742757|NCT01930110|OTHER|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
57742758|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
57742759|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
57742760|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
57742761|NCT01588184|DRUG|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
57957757|NCT03343587|DRUG|Placebo SC|administered SC
57957758|NCT04495738|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
57957759|NCT04495738|OTHER|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
57957760|NCT04495738|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
57957761|NCT04495738|OTHER|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
57957762|NCT04495738|OTHER|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
57742762|NCT06211205|DEVICE|Customized 3D printed nostril retainer combined with lip taping|the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments
57742763|NCT06211205|PROCEDURE|Lip taping|the infants will receive lip tape to approximate the labial and alveolar segments
57957763|NCT04495738|OTHER|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
57957764|NCT02706873|DRUG|Placebo to Upadacitinib|Tablet; Oral
57957765|NCT02706873|DRUG|Methotrexate|Capsule or Tablet; Oral
57957766|NCT02706873|DRUG|Placebo to Methotrexate|Capsule or Tablet; Oral
57957767|NCT02706873|DRUG|Upadacitinib|Tablet; Oral
57957768|NCT03797625|DRUG|Irinotecan|60mg/m2，D1，8
57957769|NCT03797625|DRUG|DDP|60mg/m2，D1
57742764|NCT04592770|BEHAVIORAL|Nature based walk therapy|10 minutes stretching exercises followed by walk in nature for 50 minutes
57742765|NCT04592770|BEHAVIORAL|Sit in nature|Sit in nature for 60 minutes
57742766|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
57742767|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
57742768|NCT04763902|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
57742769|NCT04439526|DRUG|Guselkumab|Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
57742770|NCT03632382|DIAGNOSTIC_TEST|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
58117484|NCT05784571|OTHER|Hand grip strength|A test of hand grip strength using a hand dynamometer.
58447488|NCT00439296|DRUG|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
57742771|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
57742772|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
58117485|NCT05784571|OTHER|6-minute walk test|Self-paced test of walking capacity.
58117486|NCT05784571|PROCEDURE|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
58117487|NCT03465410|DRUG|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
58117488|NCT03465410|DRUG|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
57742773|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
58117489|NCT00936377|DRUG|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
58117490|NCT00936377|OTHER|Placebo|Normal saline for five days.
58117491|NCT02038634|DRUG|Betamethasone|
58117492|NCT02038634|DEVICE|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
57742774|NCT06246396|DRUG|Placebo|Placebo
57957770|NCT03797625|DRUG|Endostar|15mg/d，d1-d7 civ
57957771|NCT00584480|OTHER|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
57957772|NCT05713097|DIAGNOSTIC_TEST|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
58117493|NCT02082613|PROCEDURE|Lord´s procedure|
58117494|NCT02082613|PROCEDURE|Sclerotherapy|
58117495|NCT03926078|OTHER|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
58117496|NCT03926078|RADIATION|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
58117497|NCT03926078|RADIATION|CT scan|CT scans will be acquired and used to calculate the HI and EHI
58117498|NCT04351295|DRUG|Favipiravir|Favipiravir
58117499|NCT04351295|DRUG|Chloroquine|chloroquine oral tablets
58117500|NCT01380028|DRUG|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
58117501|NCT01380028|DRUG|placebo|placebo
58117502|NCT04626427|DEVICE|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
58313142|NCT06082739|OTHER|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
58447489|NCT00439296|DRUG|Dexamethasone|"In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14."
58447490|NCT00439296|DRUG|PEG-asparaginase|"In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15."
58447491|NCT00439296|DRUG|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
57742775|NCT06491147|OTHER|Emergency front of neck access|"The algorithm in the DAS manual will be explained. Following this, the researcher will demonstrate the scalpel spark plug technique with a 4-step approach that is frequently used in skill teaching.~In step 1 of this approach, the technique will be demonstrated without any verbal explanation.~In the 2nd step, the technique will be demonstrated with verbal expression. In the 3rd step, the participant will be asked to have the trainer do it. In the 4th and last step, the participant will apply eFONA from start to finish."
57742776|NCT02794285|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
57742777|NCT02794285|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
57742778|NCT03686046|OTHER|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
57742779|NCT06265428|DRUG|DB-1303/BNT323|Administered I.V.
57742780|NCT06265428|DRUG|T-DM1|Administered I.V.
57742781|NCT03520322|DEVICE|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
57742782|NCT03520322|DEVICE|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
57742783|NCT03885531|DEVICE|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
57742784|NCT04092374|PROCEDURE|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
57742785|NCT03178149|DRUG|ASP7317|subretinal injection
58117503|NCT04931420|DRUG|Standard of Care Chemotherapy|"* If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
57742786|NCT03178149|DRUG|tacrolimus|oral
57742787|NCT03178149|DRUG|trimethoprim-sulfamethoxazole|oral
57742788|NCT03178149|DRUG|Acyclovir|oral
57742789|NCT03178149|DRUG|Nystatin|oral
57742790|NCT06536127|DIAGNOSTIC_TEST|Blood samples|Nk cells and ImmunoScore
57742791|NCT06140199|PROCEDURE|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
58117504|NCT04931420|PROCEDURE|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
58117505|NCT04931420|PROCEDURE|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
58447492|NCT00439296|DRUG|Cytarabine|"* Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
57742792|NCT06140199|PROCEDURE|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
57742793|NCT06733649|OTHER|substance abuse treatment education|Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
57742794|NCT06734039|DEVICE|Programming of cochlear implant audio processor frequency settings|Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software
58313143|NCT01093508|DRUG|APD916|
58313144|NCT05107115|DRUG|rilzabrutinib|Tablet, oral use
58313145|NCT05107115|DRUG|placebo|Tablet, oral use
58313146|NCT00851149|DEVICE|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
57742795|NCT06733181|OTHER|REMINDER intervention|The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
57742796|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
57742797|NCT02696148|DRUG|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
57742798|NCT02696148|DRUG|placebo|For subcutaneous (s.c., under the skin) injection once daily.
58313147|NCT03416101|PROCEDURE|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification \[39\] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
58313148|NCT05085145|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
58313149|NCT03327974|OTHER|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
58313150|NCT06157476|OTHER|Stretch-shortening exercise|The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
58313151|NCT06157476|OTHER|Standard exercise program|The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
58313152|NCT06060470|BEHAVIORAL|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
58313153|NCT06060470|BEHAVIORAL|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
58313154|NCT02856958|PROCEDURE|Nerve decompression|
58313155|NCT02856958|OTHER|Non-operative|Physical therapy
58313156|NCT05502029|BEHAVIORAL|Extended translation|Translation extended beyond the preoperative area
58313157|NCT05502029|BEHAVIORAL|Standard translation|Translation in the preoperative area
58313158|NCT03885063|BEHAVIORAL|Benjamin Rose Institute Care Consultation (BRI-CC)|The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
58313159|NCT01635088|DRUG|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
58313160|NCT01635088|DEVICE|KoKo Spirometry|
58313161|NCT01635088|DRUG|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
58313162|NCT01635088|DEVICE|Oscillometry|
57742799|NCT02265562|DRUG|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
57742800|NCT02265562|DRUG|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
57742801|NCT01329367|BEHAVIORAL|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
57742802|NCT01329367|BEHAVIORAL|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
57742803|NCT01329367|BEHAVIORAL|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
58117506|NCT04931420|RADIATION|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
58447493|NCT00439296|DRUG|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
57742804|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
57742805|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
57742806|NCT06018480|OTHER|Creatine Monohydrate|The supplementation is the intervention.
58117507|NCT04931420|RADIATION|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
58117508|NCT04931420|PROCEDURE|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
58117509|NCT04931420|PROCEDURE|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
58313163|NCT06140134|PROCEDURE|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
58313164|NCT04019639|DEVICE|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
58447494|NCT00439296|DRUG|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
57742807|NCT06018480|OTHER|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
57742808|NCT03335462|OTHER|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
57742809|NCT03335462|OTHER|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
57742810|NCT00827918|DRUG|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
57742811|NCT00827918|DRUG|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
58447495|NCT00439296|DRUG|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
58447496|NCT05560685|OTHER|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
58447497|NCT05560685|OTHER|Semi-structured interview|Team member participants will complete a semi-structured interview.
58447498|NCT01526213|DRUG|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
58447499|NCT02109991|DEVICE|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
58447500|NCT04295525|DIETARY_SUPPLEMENT|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
58447501|NCT04295525|DIETARY_SUPPLEMENT|placebo mucoadhesive oral tablet|placebo
58447502|NCT05379465|OTHER|No intervention|No intervention was done.
57742812|NCT00827918|DRUG|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
57742813|NCT00006155|DRUG|SU5416 and carboplatin|
57742814|NCT06426537|DRUG|Colchicine 0.5 MG Oral Tablet|Oral administration of Colchicine in STEMI patients
58447503|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
58447504|NCT06671782|OTHER|Kegel exercises|Kegel exercises without any formal training
57742815|NCT02634411|DRUG|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
57742816|NCT02634411|DRUG|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
57742817|NCT05706506|DRUG|Tirzepatide|Administered SC
57742818|NCT01913418|DRUG|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
57742819|NCT01913418|DRUG|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
57742820|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
57742821|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
57742822|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
57742823|NCT00324870|DRUG|vorinostat|Given orally
58117510|NCT04931420|OTHER|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
58117511|NCT02861183|DEVICE|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
58117512|NCT02861183|DEVICE|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
58117513|NCT05731154|OTHER|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
58447505|NCT06671782|OTHER|Pelvic Floor Muscle Exercise Program with biofeedback|Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
58447506|NCT06671782|OTHER|Questionnaires|All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
57742824|NCT00324870|DRUG|bevacizumab|Given IV
57742825|NCT06386588|OTHER|Closed loop auditory stimulation during sleep|Short bursts of pink noise delivered at precise times during overnight sleep at home.
57742826|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
57742827|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
57742828|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
57742829|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
57742830|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
57742831|NCT05637840|OTHER|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
57742832|NCT05637840|OTHER|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
57742833|NCT03565887|DRUG|RVL-1201|RVL-1201 ophthalmic solution 0.1%
57742834|NCT03565887|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
57742835|NCT03526822|BIOLOGICAL|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
58447507|NCT06671782|OTHER|Interviews|A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
58447508|NCT02221674|DRUG|Tapentadol|
58117514|NCT03828461|BEHAVIORAL|Facilitated group therapy with behavioral practice; 16 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
58117515|NCT06528249|DRUG|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
58117516|NCT06022133|BEHAVIORAL|Dietary sodium restriction|Selfemployed dietary sodium restriction
58117517|NCT01431755|DEVICE|Restylane SubQ|Treatment with up to 2 ml of the product
58117518|NCT01431755|DEVICE|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
58447509|NCT06726421|RADIATION|Stereotactic body radiotherapy (SBRT)|The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.
57742836|NCT03526822|BIOLOGICAL|Tumor sample|One tumor sample in operative period
58117519|NCT06547723|OTHER|MBSR and physiotherapy|"In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures."
58313165|NCT04019639|DEVICE|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
57742837|NCT00499031|BIOLOGICAL|Cetuximab|Given IV
57742838|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
57742839|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
57742840|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
57742841|NCT02118220|OTHER|Concussion Questionnaire|
57742842|NCT04195308|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
57742843|NCT04195308|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
58447510|NCT06726421|DRUG|axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib|Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
57742844|NCT04195308|DEVICE|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
57742845|NCT06233279|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
57742846|NCT06233279|DEVICE|Sham Stimulation|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
57742847|NCT05832138|BEHAVIORAL|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
57742848|NCT01970982|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
58447511|NCT00044772|DRUG|Venlafaxine ER|
57742849|NCT01970982|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
57742850|NCT01970982|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
57742851|NCT01928368|DRUG|AMG 282|Single dose either subcutaneously or intravenously on day 1.
57742852|NCT01928368|DRUG|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
57742853|NCT05121519|OTHER|Consume coffee|Drink coffee regularly (recommend at least 1 cup of coffee per day)
57742854|NCT05121519|OTHER|Avoid coffee|Abstain from coffee and other caffeinated beverages
57742855|NCT02429765|DRUG|ACL/FOR|
57742856|NCT02429765|DRUG|Placebo|
58447512|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
57742857|NCT06732557|OTHER|Traditional treatments|Isometric exercise for deep neck flexors and sub occipital release
57742858|NCT06732557|OTHER|muscle energy technique|Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
57742859|NCT06732557|OTHER|Mulligan Mobilization|Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
57742860|NCT02099474|OTHER|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
57742861|NCT05615415|DRUG|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
57742862|NCT05615415|DRUG|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
58117520|NCT06547723|OTHER|physiotherapy|In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
58117521|NCT03644095|DRUG|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
58117522|NCT03644095|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
58117523|NCT00859469|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
58117524|NCT00859469|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
57742863|NCT05615415|DEVICE|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
57742864|NCT05395091|BIOLOGICAL|AVT03|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm will receive AVT03 60mg administered s.c. At Month 12, subjects in the AVT03 arm will receive a third dose of AVT03 60 mg.
58117525|NCT01842958|DEVICE|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
58117526|NCT01842958|DEVICE|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
58117527|NCT06026982|DIETARY_SUPPLEMENT|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
58117528|NCT05175079|DEVICE|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
58447513|NCT03516422|PROCEDURE|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
57742865|NCT05395091|BIOLOGICAL|Denosumab|"Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection.~Subjects will receive 60mg of commercially available US-Prolia, administered s.c At Month 12, subjects in the Prolia treatment group will be re-randomized in a 1:1 ratio to receive either:~* Group 2a: Subjects will receive AVT03 60 mg administered s.c. on Day365.~* Group 2b: Subjects will receive Prolia 60 mg administered s.c. on Day365."
57742866|NCT03339674|BEHAVIORAL|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
57742867|NCT03339674|BEHAVIORAL|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
57742868|NCT05758337|DEVICE|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
58447514|NCT03516422|OTHER|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
58447515|NCT03789916|DRUG|Ticagrelor|90 mg bis in die
58117529|NCT05175079|OTHER|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
58117530|NCT01753037|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
58117531|NCT01753037|OTHER|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
58117532|NCT03426930|OTHER|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
58117533|NCT03426930|OTHER|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
58117534|NCT01159327|DRUG|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
58117535|NCT00324415|BIOLOGICAL|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
58117536|NCT00324415|DRUG|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
58117537|NCT00324415|DRUG|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
58117538|NCT00324415|RADIATION|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
58117539|NCT01274728|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
58117540|NCT04984109|PROCEDURE|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
58117541|NCT04984109|PROCEDURE|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
58117542|NCT01501695|DRUG|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
58117543|NCT01501695|DRUG|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
58117544|NCT01501695|DRUG|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
57742869|NCT04098133|OTHER|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
57742870|NCT04098133|OTHER|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
57742871|NCT04098133|OTHER|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
57742872|NCT04098133|OTHER|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
57742873|NCT05196464|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
58117545|NCT06544187|DIAGNOSTIC_TEST|MRS scan|Magnetic Resonance Spectroscopy scan on the thigh
58117546|NCT06544187|DIAGNOSTIC_TEST|CPET|Cardiopulmonary Exercise Test
58117547|NCT00328874|DRUG|Coenzyme Q10|
58117548|NCT02742090|DRUG|Umbralisib|Umbralisib was administered as a tablet(s), orally once daily.
58117549|NCT04935827|OTHER|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November"
58117550|NCT04935827|OTHER|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
58117551|NCT04066881|BIOLOGICAL|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
58313166|NCT05767385|PROCEDURE|Single Arm|"* Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
58447516|NCT03789916|DRUG|acetylsalicylic acid|100 mg die
58447517|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
58447518|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
58447519|NCT00066677|DRUG|rhuMAB-VEGF|
58447520|NCT00066677|DRUG|docetaxel|
58447521|NCT05855772|DEVICE|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
58117552|NCT04066881|BIOLOGICAL|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
58117553|NCT04066881|BIOLOGICAL|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
58117554|NCT04066881|DRUG|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
57742874|NCT05196464|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
57742875|NCT05331170|BIOLOGICAL|Research Grade RG-RV|Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
58117555|NCT04066881|DRUG|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
58117556|NCT06301555|BEHAVIORAL|Reinforcement learning algorithm powered cognitive and behavioral intervention|Reinforcement learning algorithm powered cognitive and behavioral intervention
58117557|NCT06301555|BEHAVIORAL|cognitive and behavioral intervention|cognitive and behavioral intervention
58117558|NCT01761526|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
58117559|NCT04633837|DEVICE|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
58117560|NCT00004686|DRUG|methotrexate|
57742876|NCT05227001|BIOLOGICAL|PF-07852352 Influenza saRNA 1|Intramuscular injection
57742877|NCT05227001|BIOLOGICAL|PF-07836391 Influenza saRNA|Intramuscular injection
57742878|NCT05227001|BIOLOGICAL|PF-07836394 Influenza saRNA|Intramuscular injection
57742879|NCT05227001|BIOLOGICAL|PF-07836395 Influenza saRNA|Intramuscular injection
57742880|NCT05227001|BIOLOGICAL|PF-07836396 Influenza saRNA|Intramuscular injection
57742881|NCT05227001|BIOLOGICAL|PF-07867246 Influenza saRNA|Intramuscular injection
57957773|NCT01238458|DRUG|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
57742882|NCT05227001|BIOLOGICAL|Placebo|Intramuscular injection
57742883|NCT05227001|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
57957774|NCT06457386|PROCEDURE|systematic echocardiography|"transthoracic echocardiography (TTE) will be performed as soon as possible within 14 days following the first blood sample collection for SAB diagnosis, completed, if required, by a transoesophageal (TEE) echocardiography based on the judgment of the echocardiographist.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
57957775|NCT06457386|PROCEDURE|no echocardiography arm|"no echocardiography will be performed unless occurrence of new events evocating IE (extra-cardiac events or positive Staphylococcus aureus blood culture), based on the clinical judgment of the investigator.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
57957776|NCT02239939|BEHAVIORAL|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
57957777|NCT02239939|BEHAVIORAL|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
57957778|NCT03703973|DIAGNOSTIC_TEST|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
57957779|NCT01334034|DRUG|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
58117561|NCT00004686|DRUG|prednisone|
58117562|NCT02244437|DRUG|Ibuprofen|
57742884|NCT05227001|BIOLOGICAL|PF-07871987 Influenza saRNA|Intramuscular injection
57742885|NCT05227001|BIOLOGICAL|PF-07914705 Influenza saRNA|Intramuscular injection
57742886|NCT05227001|BIOLOGICAL|PF-07915048 Influenza saRNA|Intramuscular injection
57742887|NCT00142441|DEVICE|Pulsed dye laser|
57742888|NCT01398150|DIETARY_SUPPLEMENT|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
57742889|NCT01398150|DIETARY_SUPPLEMENT|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
57742890|NCT02145546|DRUG|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
57742891|NCT02145546|DRUG|Propafenone|150mg per 8 hours, 3 times per day
57742892|NCT02145546|DRUG|Sotalol|80mg twice per day.
57742893|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
57742894|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
57742895|NCT04262518|DEVICE|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
57742896|NCT03494387|DRUG|Oxygen|80% versus 30% inspiratory oxygen concentration
57742897|NCT03494387|DRUG|Antioxidants|Antioxidants versus placebo
57742898|NCT06614127|DEVICE|Dexcom G7® sensor placed in upper arm and positioned over deltoid|"For the subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh."
57742899|NCT06614127|DEVICE|Dexcom G7® sensor placed in anterior thigh|"For the subjects with Dexcom G7® sensor place in anterior thigh cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh."
57742900|NCT06388694|OTHER|Pharmacist Care|Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
57742901|NCT06388694|OTHER|Primary Care Physician Care|Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
57742902|NCT01584622|DEVICE|CADence System|Non-invasive detection of \> or equal to 50% stenosis in any of the major coronary arteries.
57742903|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
57742904|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
57742905|NCT00083018|GENETIC|cytogenetic analysis|
57742906|NCT00083018|GENETIC|proteomic profiling|
57742907|NCT00083018|OTHER|cytology specimen collection procedure|
57742908|NCT00083018|OTHER|immunohistochemistry staining method|
57742909|NCT00083018|OTHER|laboratory biomarker analysis|
57742910|NCT00083018|PROCEDURE|breast duct lavage|
57742911|NCT03474341|DIAGNOSTIC_TEST|MRI|"* Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
57742912|NCT03474341|DIAGNOSTIC_TEST|PET-CT|"* According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
57742913|NCT03474341|DIAGNOSTIC_TEST|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
57742914|NCT03474341|DIAGNOSTIC_TEST|Blood samples|"* Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT"
58117563|NCT02244437|DRUG|Acetaminophen|
58117564|NCT02545413|DRUG|Probiotic VSL#3|
58447522|NCT05855772|BEHAVIORAL|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
57742915|NCT02554968|OTHER|Questionnaires|
57742916|NCT02614716|DRUG|LY3090106|Administered SC
57742917|NCT02614716|DRUG|Placebo|Administered SC
57742918|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Interscalene nerve block with 20 mL 0.5% bupivacaine.
57742919|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
57742920|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
57742921|NCT03321916|DEVICE|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
57742922|NCT06411067|DRUG|Erenumab|Monthly injection of erenumab for fibromyalgia
57742923|NCT06411067|DRUG|Saline|Monthly injection of 0.9% saline for control
57742924|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
57742925|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
57742926|NCT04801550|DEVICE|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
57742927|NCT00066248|DRUG|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
57957780|NCT01334034|DRUG|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
58117565|NCT02545413|DRUG|Placebo|
57742928|NCT00066248|DRUG|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
57742929|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
57742930|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
58117566|NCT01288859|OTHER|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
57742931|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
58117567|NCT01288859|OTHER|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
58117568|NCT01288859|OTHER|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
57742932|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
57742933|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
57742934|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
57742935|NCT06582745|DRUG|Trametinib|Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
57742936|NCT06307587|PROCEDURE|dry needling|The vastus intermedius will be approached with DN from the lateral aspect and the pincer approach will be followed. The Hong fast-in and fast out technique with multiple rapid needle insertions will be performed following previous recommendations (Chou, et al., 2014). The control group will receive the rehabilitation program alone. A headless 0.25 × 25-mm needle (Stainless steel, Agupunt A1038P, 158 Caspe, Barcelona, Spain) will be used. The penetration depth will be varied according to the patient. Hemostasis will be performed for 1 minutes. DN will be performed medial to the sartorius muscle limit to avoid saphenous nerve adverse effects during DN (Henry et al., 2016).
57742937|NCT01605513|DRUG|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
58117569|NCT01288859|OTHER|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
58117570|NCT01288859|OTHER|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
58117571|NCT01288859|OTHER|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
58117572|NCT00654485|DRUG|Rosuvastatin|
57742938|NCT06732622|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
57742939|NCT06732622|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
57742940|NCT06732622|DEVICE|Sham laser acupuncture|"Patients in the laser acupuncture group (Sham group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
57742941|NCT03889743|DRUG|Dexamethasone treatment during 3 days|Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
58117573|NCT00654485|DRUG|Atorvastatin|
58117574|NCT06165120|PROCEDURE|Bracka's repair using preputial graft|"Staged repair:~1. Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~3. Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
58447523|NCT06726291|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
58447524|NCT06389578|DRUG|Teprotumumab|SC administration and IV infusion
58447525|NCT01858363|DEVICE|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
57957781|NCT01334034|DRUG|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
58447526|NCT01858363|DEVICE|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
58447527|NCT00091234|DRUG|gemtuzumab ozogamicin|
57742942|NCT03889743|DRUG|placebo treatment during 3 days|1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
57742943|NCT06315556|DRUG|Aflibercept (Eylea)|Eylea 40 mg/mL solution for injection in pre-filled syringe.
57742944|NCT03943030|OTHER|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
57742945|NCT00353717|DRUG|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
57742946|NCT05268679|OTHER|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
57742947|NCT05268679|OTHER|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
57742948|NCT05268679|OTHER|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
57742949|NCT02666950|DRUG|Cytarabine|Given SC
57742950|NCT02666950|OTHER|Laboratory Biomarker Analysis|Correlative studies
57742951|NCT02666950|OTHER|Pharmacological Study|Correlative studies
57742952|NCT02666950|OTHER|Quality-of-Life Assessment|Ancillary studies
57742953|NCT02666950|OTHER|Questionnaire Administration|Ancillary studies
58447528|NCT02688686|BIOLOGICAL|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
57742954|NCT02666950|DRUG|WEE1 Inhibitor AZD1775|Given PO
57742955|NCT02846974|DEVICE|Pulse oximeter|A pulse oximeter will be used for calibration
58117575|NCT06165120|PROCEDURE|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~1. Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~3. Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
58117576|NCT01855126|OTHER|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
58313167|NCT05767385|PROCEDURE|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
58447529|NCT03641170|BEHAVIORAL|Physical activity|Interval walking performed after each main meal.
58447530|NCT03641170|BEHAVIORAL|Inactivity|Inactivity after each main meal.
57742956|NCT06732180|DRUG|GT-02287|Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
57742957|NCT06733519|DRUG|Nalmefene|Th-104 Nalmefene Mucoadhesive Buccal strip
57742958|NCT06733519|DRUG|Placebo|Matching placebo to TH-104
58313168|NCT01353534|BIOLOGICAL|A/H5N1 Antigen|A/H5N1 Antigen
58313169|NCT01353534|DRUG|Vaccine Enhancement Patch|Vaccine Enhancement Patch
57742959|NCT02970500|DRUG|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
58313170|NCT00329316|DRUG|Crinone Gel 8%|
58447531|NCT03641170|OTHER|Fixed diet.|Participants will receive a fixed diet through out the intervention period and control period.
57742960|NCT02970500|DRUG|Placebo Group|Placebo
57742961|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
57742962|NCT04729114|DRUG|prednisone|Oral dose
57742963|NCT04729114|DRUG|dexamethasone|Oral dose
57742964|NCT04729114|DRUG|enzalutamide|Oral capsule
57742965|NCT05981768|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
57742966|NCT00398008|DRUG|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
57742967|NCT00398008|DRUG|Naltrexone|Opioid antagonist medication to treat opiate dependence
57742968|NCT00398008|BEHAVIORAL|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
57742969|NCT03734731|DEVICE|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
58117577|NCT01855126|OTHER|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
58117578|NCT01802346|DIETARY_SUPPLEMENT|dietary intervention|Consume a low-calorie diet
58117579|NCT01802346|PROCEDURE|nutritional support|Receive dietary advice
58117580|NCT01802346|OTHER|laboratory biomarker analysis|Correlative studies
58117581|NCT03857113|PROCEDURE|PSMA-radioguided surgery|PSMA-radioguided surgery
58117582|NCT04531033|DIETARY_SUPPLEMENT|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
58117583|NCT04531033|DIETARY_SUPPLEMENT|Placebo|placebo made to match dietary supplement being tested.
58447532|NCT02416596|PROCEDURE|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
58447533|NCT02416596|DEVICE|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
58447534|NCT06422884|DRUG|ENV-101|oral tablet, dosed once a day
58447535|NCT06422884|DRUG|Placebo|oral tablet, dosed once a day
58447536|NCT00834665|BIOLOGICAL|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
58447537|NCT00834665|BIOLOGICAL|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
58447538|NCT01946152|DRUG|Dexamethasone|Given PO
58447539|NCT01946152|BIOLOGICAL|Filgrastim-sndz|Given SC
58447540|NCT01946152|OTHER|Laboratory Biomarker Analysis|Correlative studies
58447541|NCT01946152|DRUG|Pomalidomide|Given PO
57742970|NCT03734731|DEVICE|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
57742971|NCT03734731|DRUG|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
58117584|NCT00213811|BEHAVIORAL|clinical, biological, and radiological|
58117585|NCT03013933|DRUG|Brentuximab Vedotin|Given IV
58447542|NCT02734745|DEVICE|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
58447543|NCT01436578|DRUG|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
58447544|NCT00672919|DRUG|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
58447545|NCT00376792|DRUG|docetaxel|
58447546|NCT00376792|OTHER|active surveillance|
58117586|NCT03013933|DRUG|Cyclosporine|Given PO
57742972|NCT03734731|DRUG|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
58117587|NCT03013933|OTHER|Pharmacokinetic Study|Correlative studies
58117588|NCT03013933|DRUG|Verapamil|Given PO
57742973|NCT06124040|BEHAVIORAL|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
57742974|NCT06539429|BIOLOGICAL|ANT-301|Administration on Day 1
58117589|NCT03013933|DRUG|Verapamil Hydrochloride|Given PO
57742975|NCT01198080|BIOLOGICAL|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
58117590|NCT01616303|DRUG|Carboplatin|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
58117591|NCT01616303|DRUG|Paclitaxel|Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
58117592|NCT01616303|BIOLOGICAL|oregovomab|oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
58117593|NCT00281619|DRUG|CellCept (mycophenolate mofetil)|
58117594|NCT00281619|BEHAVIORAL|Dietary Monitoring|
58117595|NCT00281619|BEHAVIORAL|Drug Diary|
58117596|NCT00281619|PROCEDURE|Blood Sampling|
58117597|NCT05768828|DIAGNOSTIC_TEST|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
58447547|NCT00376792|PROCEDURE|adjuvant therapy|
58447548|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
58447549|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
58447550|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
58117598|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
58117599|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
58117600|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
58117601|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
58117602|NCT00711503|DRUG|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
58117603|NCT00711503|DRUG|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
58117604|NCT05720533|DRUG|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
58117605|NCT05517850|BEHAVIORAL|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
58117606|NCT05517850|BEHAVIORAL|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
58313171|NCT05901220|BEHAVIORAL|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
58447551|NCT03349658|OTHER|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
58313172|NCT01799941|DRUG|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
58313173|NCT05998967|BEHAVIORAL|Mobile Mantram Repetition Program|Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
58313174|NCT03163732|GENETIC|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
58313175|NCT03299985|OTHER|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
58313176|NCT03299985|OTHER|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
58313177|NCT01292902|OTHER|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.
58313178|NCT01292902|OTHER|inspiratory muscle exercise|Equal to the group with chronic heart failure.
58447552|NCT03349658|OTHER|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
58447553|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
58447554|NCT01449006|DRUG|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
58447555|NCT03147352|DEVICE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
57742976|NCT04166357|DIAGNOSTIC_TEST|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
58313179|NCT05397418|BEHAVIORAL|Supervised resistance exercise program|12 week supervised low impact resistance training program
58447556|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
58447557|NCT05917613|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
58447558|NCT04311684|DEVICE|hybrid Brillouin-Raman spectroscopy|Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
57742977|NCT05973110|BEHAVIORAL|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
58117607|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
58117608|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
58117609|NCT01562795|DRUG|corticosteroids|corticosteroids plus artificial tear substitute
58117610|NCT01562795|DRUG|artificial tear substitute|artificial tear substitute alone
58117611|NCT01195571|BIOLOGICAL|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
58117612|NCT05452577|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
58117613|NCT05452577|DRUG|Estazolam 1Mg Tab|1mg tablet once daily
58117614|NCT03432000|OTHER|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
58117615|NCT00208390|DEVICE|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
57742978|NCT05973110|BEHAVIORAL|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
58117616|NCT05522010|PROCEDURE|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
58117617|NCT01162590|BIOLOGICAL|Rotarix ™|Oral, single dose
58117618|NCT01162590|BIOLOGICAL|Placebo|Oral, single dose
58117619|NCT00614159|DRUG|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
58117620|NCT00614159|DRUG|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
58117621|NCT00001074|DRUG|Hydroxyurea|
58117622|NCT00001074|DRUG|Didanosine|
58313180|NCT05397418|BEHAVIORAL|Unsupervised resistance exercise program|12 week unsupervised low impact resistance training program
58447559|NCT04339517|PROCEDURE|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
58447560|NCT03980730|DRUG|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
57742979|NCT02897713|OTHER|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
57742980|NCT02897713|OTHER|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
57742981|NCT03085485|DRUG|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
57742982|NCT03085485|DRUG|Placebo|placebo pills
57742983|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
58117623|NCT06527716|OTHER|Teaching Strategy|"Experimental group:~Get involved in the LINE digital media course learning platform.~1. LINE digital media course study period:~   Research subjects need to complete the aforementioned three pre-measurement forms before they can join the LINE digital media course. In this lesson plan design, at the end of a single class, there will be a summary of the key points of the class; after the end of a single class, there will be 5 to 10 questions accompanying the class. When the research subjects have finished answering, Regardless of whether the answer is correct or not, the system will display Problem Solution Analysis. The study time for this stage is 1 month.~2. WorkShop Learning~Control group:~Intervention in regular education course learning platform. The above-mentioned digital media courses will be placed on the educational platform of the college for research subjects to watch and learn."
57742984|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
57742985|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
57742986|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
57742987|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
57742988|NCT03712644|DEVICE|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
58117624|NCT01653197|BEHAVIORAL|Control|No scratch off element
58117625|NCT01653197|BEHAVIORAL|Curiosity|The recipient will be prompted to scratch off for answer to question.
58117626|NCT01653197|BEHAVIORAL|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
58117627|NCT06224582|DRUG|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
58447561|NCT03980730|DRUG|Placebo|Matching placebo capsule administered orally, once daily
58447562|NCT05924945|DEVICE|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
58117628|NCT06224582|DRUG|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
58117629|NCT03875183|DRUG|INL1|Capsules
58117630|NCT03875183|OTHER|Placebo|Capsules
58117631|NCT06287697|OTHER|No intervention|No intervention
58117632|NCT05713877|DRUG|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
58117633|NCT05713877|DRUG|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
58117634|NCT04740684|OTHER|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
58117635|NCT04801979|DIAGNOSTIC_TEST|Incremental Step Test|"Performance of the incremental step test (number of steps) for the assessment of exercise capacity. The step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
58117636|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test|Skin Prick Testing with inhalant allergens
58117637|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
58117638|NCT02161952|DRUG|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
58117639|NCT02161952|DRUG|Matched equivalent placebo|
58117640|NCT05653791|DIAGNOSTIC_TEST|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
58117641|NCT06230471|DRUG|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
57742989|NCT01494831|BEHAVIORAL|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
58117642|NCT06230471|DRUG|Pembrolizumab and Lenvatinib|Pembrolizumab and Lenvatinib
58117643|NCT06230471|DRUG|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
58117644|NCT03776032|DRUG|Darbepoetin alfa|Administered by subcutaneous injection once a week
58117645|NCT03776032|DRUG|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
58117646|NCT06545422|OTHER|St. John's wort oil|To examine the effect of regularly applied St. John's Wort oil on skin moisture.
58117647|NCT06545422|OTHER|Barrier Cream|To examine the effect of regularly applied barrier cream on skin moisture.
58117648|NCT03333525|OTHER|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
58117649|NCT02367053|DRUG|ZP4207|
58117650|NCT02367053|DRUG|Glucagon|
58117651|NCT00783757|DEVICE|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
58117652|NCT05220670|OTHER|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
58117653|NCT05220670|OTHER|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
58117654|NCT01823445|OTHER|Xylitol disk|
58117655|NCT01104857|PROCEDURE|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
58117656|NCT01104857|PROCEDURE|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
58117657|NCT00171509|DRUG|Cyclosporine microemulsion|
58117658|NCT02429154|OTHER|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
58117659|NCT02429154|OTHER|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
58313181|NCT04523376|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
57742990|NCT01834131|BEHAVIORAL|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
57742991|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
58117660|NCT00373659|DRUG|Ranibizumab (Lucentis)|
58117661|NCT05373875|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
57742992|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
57742993|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
58117662|NCT03446560|DEVICE|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
58313182|NCT04969289|BEHAVIORAL|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
57742994|NCT06145763|OTHER|Survey Administration|Ancillary studies
57742995|NCT04731779|DRUG|cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
57742996|NCT04731779|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
57742997|NCT06179524|BIOLOGICAL|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
57742998|NCT04421781|OTHER|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
57742999|NCT06386315|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57743000|NCT06386315|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
57743001|NCT06386315|RADIATION|Involved-site Radiation Therapy (3 Fractions)|Undergo ISRT in 3 fractions
57743002|NCT06386315|RADIATION|Involved-site Radiation Therapy (12 Fractions)|Undergo ISRT in 12 fractions
57743003|NCT06386315|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57743004|NCT06386315|OTHER|Questionnaire Administration|Ancillary studies
57743005|NCT01986465|DRUG|Depomedrol|
57743006|NCT01986465|DRUG|Placebo|
57743007|NCT01429532|PROCEDURE|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
57743008|NCT05574660|DIETARY_SUPPLEMENT|High-Fat/High-Sugar (HF/HS) Diet|
57957782|NCT01493453|GENETIC|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10\*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
57743009|NCT05574660|DIETARY_SUPPLEMENT|Low-Fat/Low-Sugar (LF/LS) Diet|
57743010|NCT02610348|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
57743011|NCT02610348|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
57743012|NCT00796302|DRUG|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
57743013|NCT00796302|DRUG|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
57743014|NCT00796302|BEHAVIORAL|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
57743015|NCT00796302|DRUG|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
57743016|NCT01335204|DRUG|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
57743017|NCT03728829|DRUG|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
57743018|NCT01988779|DRUG|oral levofloxacin|
57743019|NCT01988779|DRUG|nebulized levofloxacin|
57957783|NCT03328663|OTHER|CARE|Promote effective coping and reduce caregiving burden.
57957784|NCT03328663|OTHER|Standard Transplant Care|Standard cared administered by the hospital.
57957785|NCT05134961|PROCEDURE|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
58117663|NCT03446560|DEVICE|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
58117664|NCT04396470|DEVICE|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
58117665|NCT02022501|DRUG|DE-120|
58117666|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
58117667|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
58117668|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
57743020|NCT06723912|OTHER|Health Action Process Approach-Based Program|Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.
57743021|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
57743022|NCT02061202|DRUG|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
57743023|NCT02061202|DRUG|Placebo|placebo training inhaler with the same instructions as the experimental group.
57957786|NCT00416247|BEHAVIORAL|Hypnosis|Hypnosis
57957787|NCT02355288|PROCEDURE|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
57957788|NCT02355288|PROCEDURE|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
57957789|NCT00278421|BIOLOGICAL|rituximab|
57957790|NCT00278421|DRUG|cyclophosphamide|
57957791|NCT00278421|DRUG|doxorubicin hydrochloride|
57957792|NCT00278421|DRUG|prednisone|
57957793|NCT00278421|DRUG|vincristine sulfate|
57957794|NCT03747601|DEVICE|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
57957795|NCT04583397|OTHER|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
57957796|NCT01568606|DEVICE|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
57957797|NCT04813471|DRUG|Endothelial Protocol|Endothelial Protocol
57957798|NCT03075566|BIOLOGICAL|Healthy subjects|- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
57957799|NCT03075566|BIOLOGICAL|Patients|- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
57957800|NCT04069845|DRUG|liposomal doxorubicin|intravenous liposomal doxorubicin
57957801|NCT05219188|RADIATION|3.7 mS, CT radiation|Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
58117669|NCT01033383|DIETARY_SUPPLEMENT|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
58117670|NCT01033383|DIETARY_SUPPLEMENT|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
58117671|NCT05736081|DRUG|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
58117672|NCT00891293|DRUG|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
58117673|NCT01573520|OTHER|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
58117674|NCT05079737|OTHER|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
57743024|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
57743025|NCT06647836|OTHER|Efficacy observation|Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
57743026|NCT04321239|BEHAVIORAL|Positive STEPS|Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
57743027|NCT00006136|DRUG|arginine butyrate|
57743028|NCT00006136|DRUG|epoetin alfa|
57743029|NCT00740948|DRUG|Rituximab (mabthera) Injection|2 \* 1g of Rituximab at the 1st day and at the 14th day.
57743030|NCT00740948|DRUG|Placebo: NaCl 0.9% or Glucose 5%|2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
57743031|NCT00177554|DRUG|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
57743032|NCT03001284|OTHER|NO intervention|
57743033|NCT01727739|DEVICE|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
57743034|NCT01727739|DEVICE|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
57743035|NCT03352791|BEHAVIORAL|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
57743036|NCT03352791|BEHAVIORAL|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
58117675|NCT00793052|DRUG|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
57743037|NCT05016505|BEHAVIORAL|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
57743038|NCT05016505|BEHAVIORAL|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
57743039|NCT01550458|DRUG|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
57743040|NCT01550458|OTHER|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
57743041|NCT05653219|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
57743042|NCT05653219|DRUG|Eltrombopag|Film-coated tablet for oral use
58117676|NCT03561259|DRUG|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
58313183|NCT01493622|DRUG|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
58313184|NCT01493622|DRUG|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
58313185|NCT05096715|DRUG|Atezolizumab|Intravenous Infusion
58313186|NCT05096715|DRUG|Bevacizumab|Intravenous Infusion
58313187|NCT05096715|RADIATION|Stereotactic body radiation therapy (SBRT)|External Beam Radiation
57743043|NCT05653219|DRUG|Placebo|Concentrate for solution for infusion for intravenous use.
57743044|NCT04975516|DRUG|Chemotherapy|Given chemotherapy
57743045|NCT04975516|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57743046|NCT04975516|PROCEDURE|Computed Tomography|Undergo CT
57743047|NCT04975516|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58117677|NCT03561259|DRUG|131-MIBG + Vorinostat|Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
58117678|NCT00545558|DRUG|Efavirenz|600 mg tablet taken orally daily
58117679|NCT00545558|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
58117680|NCT01214603|DRUG|LY2090314|Administered intravenously
58117681|NCT02056275|OTHER|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
58117682|NCT02056275|OTHER|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
58117683|NCT01692171|DRUG|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
58117684|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
58117685|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
58117686|NCT02405611|BEHAVIORAL|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
58117687|NCT04585555|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
58117688|NCT04476082|OTHER|No intervention - observational study only|No intervention - observational study only
58117689|NCT06245616|DIETARY_SUPPLEMENT|Consumption of olive pomace olive oil by alzheimer's patients|Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
58117690|NCT06245616|DIETARY_SUPPLEMENT|Consumption of high-oleic sunflower oil by alzheimer's patients|Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
58117691|NCT00447603|DRUG|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
58117692|NCT00447603|DRUG|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
58117693|NCT00447603|DRUG|Placebo for Losartan|
58117694|NCT00447603|DRUG|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
58117695|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
58117696|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
58447563|NCT05924945|DEVICE|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
57743048|NCT04975516|PROCEDURE|Biospecimen Collection|Undergo blood collection
57743049|NCT04975516|OTHER|Questionnaire Administration|Ancillary studies
58117697|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
58117698|NCT00209209|DRUG|Rituximab|antibody
58117699|NCT00209209|DRUG|Cyclophosphamide|chemotherapy
57743050|NCT06733779|OTHER|observation|cross-sectional study
57743051|NCT04004611|DRUG|Mirikizumab|Administered IV and SC
57743052|NCT06099626|OTHER|Different types of disease|Groups were observed according to disease type
58117700|NCT00209209|DRUG|Doxorubicin|chemotherapy
58117701|NCT00209209|DRUG|Vincristine|chemotherapy
58117702|NCT00209209|DRUG|Prednisone|coricosteroide
58117703|NCT00209209|DRUG|Fludarabine|chemotherapy
58117704|NCT00209209|DRUG|Interferon-alpha|cytokine
58117705|NCT00209209|DRUG|pegylated formula Interferon-alpha 2b|cytokine
58117706|NCT00209209|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
58117707|NCT00209209|PROCEDURE|chemotherapy: R-FC|immuno-chemotherapy
58117708|NCT00209209|PROCEDURE|Interferon maintenance|cytokine
57957802|NCT05435456|OTHER|Exercise|Strengthening and Relaxation Exercises
58117709|NCT00209209|PROCEDURE|Rituximab maintenance|antibody
58447564|NCT03897556|DIETARY_SUPPLEMENT|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
58447565|NCT03897556|OTHER|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
58117710|NCT04875234|DEVICE|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
58117711|NCT06240962|OTHER|Strength Training|They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
58117712|NCT06240962|OTHER|Mindfulness Exercise|They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
58117713|NCT06546111|DRUG|Placebo|Drug :placebo tab PO BID for 14 days.
58117714|NCT06546111|DRUG|Daflon|Daflon 500 mg tab PO BID for 14 days.
58117715|NCT05416658|OTHER|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
58117716|NCT05729633|OTHER|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
58117717|NCT03788681|DRUG|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
58117718|NCT03788681|DRUG|Placebo Oral Tablet|placebo
58117719|NCT01464827|DRUG|ABT-450|ABT-450 tablets
58117720|NCT01464827|DRUG|ABT-333|ABT-333 tablets
58117721|NCT01464827|DRUG|ABT-267|ABT-267 tablets
58117722|NCT01464827|DRUG|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
58117723|NCT01464827|DRUG|Ritonavir|Ritonavir capsules
58117724|NCT04050397|OTHER|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
58117725|NCT04050397|OTHER|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
58117726|NCT00131989|DRUG|sorafenib tosylate|Given orally
58447566|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
57957803|NCT03580421|PROCEDURE|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
57957804|NCT03580421|PROCEDURE|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
58117727|NCT00131989|OTHER|pharmacological study|Correlative studies
58117728|NCT00131989|OTHER|laboratory biomarker analysis|Correlative studies
58117729|NCT04548895|DEVICE|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
58117730|NCT03273985|OTHER|Dry needling|Trigger point deep dry needling
58117731|NCT03273985|OTHER|Ischemic compression|Trigger point ischemic compression
58117732|NCT02200133|OTHER|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
58117733|NCT05057195|RADIATION|Interstitial radiation therapy|From 30 to 50 Gy,
58117734|NCT05057195|RADIATION|Postoperative external beam therapy|50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
58117735|NCT04604639|DIAGNOSTIC_TEST|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
58117736|NCT00819728|DRUG|Docetaxel|35mg/m2 IV each week for 4 weeks
58117737|NCT00819728|DRUG|Irinotecan|50mg/m2 IV each week for 4 weeks
58447567|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
58447568|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
58447569|NCT01684319|DIETARY_SUPPLEMENT|Formula milk free of cow's milk protein|
58447570|NCT01684319|DIETARY_SUPPLEMENT|Placebo|Infant formula milk
58447571|NCT04219241|BIOLOGICAL|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
58447572|NCT02133898|OTHER|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
58117738|NCT03753997|BEHAVIORAL|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
58117739|NCT06527352|DEVICE|glottis mask airway|the glottis mask airway is used for maintaining ventilation during general anesthesia
58117740|NCT06527352|OTHER|tulip shaped|the tulip shaped mask airway is with a tulip shaped tip
58117741|NCT06527352|OTHER|classical shaped|the classical shaped mask airway is with a water-drop shaped tip
58117742|NCT03316859|DRUG|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
58117743|NCT03316859|OTHER|Placebo pill|Placebo pill administered 1 hour pre-operatively
57743053|NCT05156658|DRUG|Etonogestrel (ENG) Subdermal Implants|Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
57743054|NCT06008717|DEVICE|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
58117744|NCT05642026|DRUG|Ropivacaine|Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
58117745|NCT05642026|DRUG|Non steroidal anti-inflammatory drug and opioids|Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
58117746|NCT00214630|DRUG|rosuvastatin calcium|
58117747|NCT00214630|DRUG|atorvastatin|
57743055|NCT06008717|DEVICE|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
58117748|NCT01856985|DRUG|Misoprostol|
58117749|NCT01856985|DRUG|Mifepristone|
58117750|NCT04741360|OTHER|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
58117751|NCT04354194|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
58117752|NCT04354194|PROCEDURE|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
58117753|NCT04634409|DRUG|Bamlanivimab|Administered IV.
58117754|NCT04634409|DRUG|Etesevimab|Administered IV.
58117755|NCT04634409|DRUG|Placebo|Administered IV.
58447573|NCT06725251|BEHAVIORAL|Art Therapy|Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
57743056|NCT06733740|PROCEDURE|ultrasound-guided thermal ablation|ultrasound-guided thermal ablation to treat tumor
57743057|NCT00977353|DRUG|citalopram|20-60 mg/day, oral, for 6 weeks
57743058|NCT00977353|DRUG|sarcosine|500-1500 mg/day, oral, for 6 weeks
57743059|NCT02660632|OTHER|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
58117756|NCT04634409|DRUG|VIR-7831|Administered IV.
58117757|NCT04634409|DRUG|Bebtelovimab|Administered IV.
58117758|NCT04775784|DIAGNOSTIC_TEST|Determination of SARS-CoV2 presence in CNS|Brain tissue sampling
58117759|NCT06545240|DIAGNOSTIC_TEST|Mid-upper arm circumference|Mid-upper arm circumference was taken using non-stretchable band SECA 202
58117760|NCT02136732|OTHER|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
58117761|NCT02136732|OTHER|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
58117762|NCT00169936|DEVICE|Magnetocardiograph|
58117763|NCT02231710|BIOLOGICAL|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
58117764|NCT00405977|DRUG|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
58117765|NCT00405977|DRUG|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
58117766|NCT04098081|DRUG|galeterone|Therapeutic
58117767|NCT04098081|DRUG|Gemcitabine|Therapeutic
58313188|NCT04393727|BIOLOGICAL|CONVALESCENT PLASMA|Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
58313189|NCT00900562|DRUG|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
58117768|NCT01806974|OTHER|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
57743060|NCT02660632|OTHER|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
57743061|NCT00403416|DRUG|AEB071|
57743062|NCT00403416|DRUG|Mycophenolic Acid|
58117769|NCT04025385|OTHER|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
58117770|NCT01319097|OTHER|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
57743063|NCT01421563|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
57743064|NCT06722248|BEHAVIORAL|high fidelity simulation-based training|"The intervention is a two-hour high-fidelity simulation training session focusing on newborn assessment, care practices, skin-to-skin contact, and breastfeeding. It uses SimBaby mannequins and breastfeeding models to mimic the hospital environment. Scenarios are tailored to nursing students' learning levels and reviewed by experienced midwives.~The training includes:~Prebriefing: Introduction of learning objectives, scenario background, simulation familiarization, confidentiality discussions, and ground rules.~Intervention: Scenario-based training on baby care and breastfeeding. Debriefing: Plus-delta debriefing model reviewed by simulation educators. The training will be conducted in the nursing simulation laboratory."
57743065|NCT06722248|BEHAVIORAL|conventional training|Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.
58447574|NCT02115295|DRUG|Cladribine|Given IV
57743066|NCT02242864|DRUG|Micardis®|
57743067|NCT02242864|DRUG|MicardisPlus®|
57743068|NCT05536362|DRUG|TCI Propofol Injection|To decrease postoperative pain after cancer colon surgery
57743069|NCT02460718|BEHAVIORAL|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
57743070|NCT00195910|DRUG|Morphine|0.1 mg/kg IV morphine
58117771|NCT04049552|DRUG|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
58117772|NCT04049552|DRUG|Placebo|Petrolatum ointment placebo
58447575|NCT02115295|DRUG|Cytarabine|Given IV
57743071|NCT00195910|DRUG|Hydromorphone|0.015 mg/kg IV hydromorphone
57743072|NCT03552874|OTHER|The Performance of Upper Limb Questionnaire (PUL)|
58313190|NCT05812404|DRUG|DWP14012|Potassium-competitive acid blocker
57743073|NCT03871595|DRUG|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
57743074|NCT03896646|PROCEDURE|Computed Tomography|Undergo SPECT/CT HIDA scan
57743075|NCT03896646|OTHER|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
58313191|NCT05812404|DRUG|DWC202201|Atorvastatin Calcium Trihydrate
58313192|NCT03625128|DRUG|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
58447576|NCT02115295|DRUG|Gilteritinib|Given PO
57743076|NCT03896646|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
57743077|NCT03896646|RADIATION|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
57743078|NCT03896646|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
57743079|NCT00256581|PROCEDURE|Additional rest and stress image sets on new camera|
57743080|NCT02952352|BEHAVIORAL|Diabetes Prevention Program|Culturally adapted diabetes prevention program
57743081|NCT01659190|OTHER|Oiled-limestone liniment|
57743082|NCT03505112|OTHER|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
57743083|NCT04820855|BEHAVIORAL|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
57743084|NCT04820855|OTHER|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
58117773|NCT06091800|OTHER|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
58117774|NCT05943925|OTHER|No intervention|no intervention
58313193|NCT04704050|DRUG|dronedarone 400 mg Oral Tablet|"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
58313194|NCT04704050|DRUG|Placebo|Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
58313195|NCT04753515|DRUG|dexmedetomidine combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
58447577|NCT02115295|DRUG|Idarubicin|Given IV
58447578|NCT02115295|OTHER|Laboratory Biomarker Analysis|Correlative studies
58447579|NCT02115295|DRUG|Midostaurin|Given PO
58447580|NCT02115295|DRUG|Venetoclax|Given PO
58313196|NCT04753515|DRUG|propofol combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
57743085|NCT05214274|OTHER|No intervention would be taken|No intervention would be taken
58313197|NCT05778565|PROCEDURE|Extraocular muscle stretching|Extraocular muscle stretching to test its efficacy as a weakening procedure
58447581|NCT04184570|OTHER|Observational Trial|Observational Trial
58447582|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
57743086|NCT01012830|DRUG|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
57743087|NCT06732596|OTHER|Embodied conversational agent (ECA)|The app with the ECA will be provided.
57743088|NCT06732596|OTHER|Technical support|Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.
57743089|NCT06732596|OTHER|Additional ECA messages|Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.
57743090|NCT06732596|OTHER|Additional incentives|Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
57743091|NCT02526732|OTHER|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
57743092|NCT06308510|OTHER|collection additional peritoneal lavage fluid|collection additional peritoneal lavage fluid
57743093|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
58313198|NCT03962829|DRUG|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
58313199|NCT03962829|DRUG|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
57743094|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
57743095|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
57743096|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
57743097|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
58117775|NCT05943925|DIETARY_SUPPLEMENT|Probiotic supplement|A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.
58117776|NCT05892757|DRUG|Atogepant|Oral Tablet
57743098|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
57957805|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
58117777|NCT05892757|DRUG|Ubrogepant|Oral Tablet
58117778|NCT01533857|DIETARY_SUPPLEMENT|hot water|Hot water and placebo capsule
58313200|NCT00695019|DRUG|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
58313201|NCT00695019|DRUG|placebo lozenges|200 mg matching placebo lozenges
58313202|NCT03451045|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
58117779|NCT01533857|DIETARY_SUPPLEMENT|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
58313203|NCT03451045|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
58313204|NCT03451045|OTHER|Placebo|Subjects will receive placebo twice daily.
58313205|NCT03371550|DRUG|Docetaxel|Induction chemotherapy
58313206|NCT03371550|RADIATION|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
58313207|NCT03371550|DRUG|Cisplatin|Induction chemotherapy
58313208|NCT00706563|BIOLOGICAL|Fluarix™|Single intramuscular dose on Day 0
58447583|NCT02872246|DRUG|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58313209|NCT03578042|DRUG|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
58447584|NCT02872246|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
58447585|NCT04583527|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
58313210|NCT03578042|DRUG|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
58313211|NCT05408364|DIETARY_SUPPLEMENT|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
58313212|NCT05408364|PROCEDURE|SRP|Scalling and root planing
58447586|NCT03953469|DIETARY_SUPPLEMENT|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
58447587|NCT01101789|PROCEDURE|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
58447588|NCT01101789|PROCEDURE|regular sutures for surgical wound closure|
57743099|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
57743100|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
57743101|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
57743102|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
57743103|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
57743104|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
58313213|NCT05518721|PROCEDURE|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
58313214|NCT04941989|DRUG|HTL0022562|HTL0022562
58313215|NCT04941989|DRUG|Placebo|Placebo
58313216|NCT05776992|DEVICE|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
58313217|NCT05776992|DEVICE|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
58313218|NCT04643886|DRUG|GEM103|Biological
58313219|NCT00931424|PROCEDURE|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
58313220|NCT02035124|DRUG|BKM 120|
58313221|NCT02035124|DRUG|Cabazitaxel|
58447589|NCT00699608|DRUG|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
58447590|NCT01928927|DRUG|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
57743105|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
57743106|NCT00694603|DRUG|Cetuximab|Given intravenously once per week.
57743107|NCT01475968|OTHER|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
57743108|NCT01475968|OTHER|Filtered Air|Filtered Air
57957806|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
58313222|NCT06274827|DIAGNOSTIC_TEST|Superficial Electromyography|For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
58313223|NCT04400318|DRUG|Dupilumab|solution for injection subcutaneous
58313224|NCT04400318|DRUG|Placebo|Solution for injection subcutaneous
58313225|NCT01668797|DRUG|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
58313226|NCT01668797|DRUG|Placebo|Placebo comparator for 52 weeks
58313227|NCT05494528|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
58313228|NCT05494528|DRUG|Entecavir|Entecavir 0.5 mg once per day
58313229|NCT03153670|OTHER|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
58313230|NCT01162200|RADIATION|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
58313231|NCT00990886|DRUG|Placebo|Once daily for 12 weeks
58313232|NCT00990886|DRUG|Oxybutynin chloride|15 mg once daily for 12 weeks
58313233|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
58313234|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
58313235|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
58313236|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
58447591|NCT00687739|DRUG|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
58447592|NCT00687739|DRUG|Estradiol Transdermal|0.075 mg patch per day for 5 months
58447593|NCT00687739|BEHAVIORAL|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
58447594|NCT03353805|BEHAVIORAL|questionnaire|questionnaire
58117780|NCT00672828|BEHAVIORAL|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
58117781|NCT00672828|BEHAVIORAL|Interactive computer intervention|
58447595|NCT06726603|PROCEDURE|Assisted Reproductive Technology|Assisted Reproductive Technology for the purposes of this study include IVF and IVF+ICSI. Ovulation induction methods are not considered Assisted Reproductive Technology
57743109|NCT05618574|DIETARY_SUPPLEMENT|210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
57743110|NCT03801785|OTHER|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
57743111|NCT01702727|DEVICE|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
57743112|NCT01702727|DEVICE|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
57743113|NCT01702727|DEVICE|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
57743114|NCT06304831|BEHAVIORAL|Quality ratings of health care providers for children|Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
57743115|NCT06727513|PROCEDURE|A single-operator technique for GlideScope intubation.|A single-operator technique where the senior resident will insert the GlideScope and perform the endotracheal intubation using an angulated stylet.
57743116|NCT06727513|PROCEDURE|A double-operator technique for GlideScope intubation|A double-operator technique where the senior resident will insert the GlideScope until visualizing an optimal glottic view, then the attending physician will take over the GlideScope keeping it in the same fixed position, while the resident performs the endotracheal intubation using an angulated stylet.
57743117|NCT04435366|DRUG|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
57743118|NCT04435366|DRUG|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
57743119|NCT06241248|DIAGNOSTIC_TEST|Rapid sepsis diagnostic test|The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
57743120|NCT03756428|PROCEDURE|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
57743121|NCT03756428|PROCEDURE|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
57743122|NCT05203926|PROCEDURE|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
58117782|NCT00522288|DEVICE|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
58117783|NCT00522288|DEVICE|Spectacle|Spectacles for the treatment of myopia
58117784|NCT01371513|OTHER|continuous screening|practice patterns for screening prostate cancer
58117785|NCT05725590|PROCEDURE|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
58447596|NCT06161129|DEVICE|Lenses|The filter lenses will be worn by participants for one month all day.
58313237|NCT06179459|PROCEDURE|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
58447597|NCT03311165|OTHER|no intervention|no intervention was given
58447598|NCT01337336|DRUG|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
57743123|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
57743124|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
57743125|NCT06733506|DRUG|Chlorhexidine gluconate|"Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml)."
58447599|NCT01337336|DRUG|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
58447600|NCT05491382|PROCEDURE|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
58447601|NCT05491382|PROCEDURE|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
58447602|NCT05491382|PROCEDURE|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
58447603|NCT05519514|DRUG|Cortiment|Budesonide 9 mg prolonged release tablets
58447604|NCT05519514|DRUG|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
58447605|NCT05338034|DRUG|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
58447606|NCT05338034|DRUG|Placebo|Capsule
57743126|NCT06733506|DRUG|Isopropyl Alcohol 70% Topical Application Solution|Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
57743127|NCT06733506|BEHAVIORAL|Skin Prep Before Injecting Recreational/Street Drugs|During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
57743128|NCT06291428|DIAGNOSTIC_TEST|Raman spectroscopy|Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
57743129|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A1|Suspension for injection. Route of administration: IM injection
57743130|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A2|Suspension for injection. Route of administration: IM injection
57743131|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A3|Suspension for injection. Route of administration: IM injection
57743132|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B1|Suspension for injection. Route of administration: IM injection
58447607|NCT01396213|DRUG|Larazotide Acetate|gelatin capsule
58447608|NCT01396213|DRUG|placebo|gelatin capsule
58447609|NCT04171050|DRUG|Local anaesthetic|Local anesthesia injections
58447610|NCT04171050|DRUG|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
58447611|NCT06725433|PROCEDURE|Nissen fundoplication|Hiatal hernia repair and Nissen fundoplication
58447612|NCT06725433|PROCEDURE|Dor fundoplication|Hiatal hernia repair and Dor fundoplication
58447613|NCT04958889|OTHER|No intervention|(observational study)
58447614|NCT01669317|OTHER|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
58447615|NCT01669317|OTHER|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
58447616|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
58447617|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
58447618|NCT02784847|DRUG|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
58447619|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
57743133|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B2|Suspension for injection. Route of administration: IM injection
58117786|NCT05725590|PROCEDURE|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
58117787|NCT02478060|BIOLOGICAL|Birch-SPIRE|
57743134|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B3|Suspension for injection. Route of administration: IM injection
57743135|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C1|Suspension for injection. Route of administration: IM injection
57743136|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C2|Suspension for injection. Route of administration: IM injection
57743137|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C3|Suspension for injection. Route of administration: IM injection
57743138|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 1|Suspension for injection. Route of administration: IM injection
57743139|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 2|Suspension for injection. Route of administration: IM injection
57743140|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 3|Suspension for injection. Route of administration: IM injection
57743141|NCT06583031|BIOLOGICAL|Monovalent RSV Vaccine|Suspension for injection. Route of administration: IM injection
57743142|NCT00485290|BEHAVIORAL|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
57743143|NCT02415101|PROCEDURE|Resective surgery|
58117788|NCT02478060|BIOLOGICAL|Placebo|
58447620|NCT03812536|OTHER|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
57743144|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
57743145|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
58447621|NCT02555176|DIETARY_SUPPLEMENT|Dietary intervention|Follow a low-carbohydrate diet
57743146|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
57743147|NCT03144713|DRUG|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
57743148|NCT03144713|DRUG|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
57743149|NCT03144713|DRUG|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
57743150|NCT03657277|DEVICE|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
57743151|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
57743152|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
57743153|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
57743154|NCT05321498|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
57743155|NCT05321498|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
57743156|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
57743157|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
57743158|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
57743159|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
58117789|NCT01472588|BEHAVIORAL|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
58117790|NCT01472588|BEHAVIORAL|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
58117791|NCT01472588|OTHER|Self Help|Public education/information booklet on weight management.
58117792|NCT02140164|DRUG|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
57743160|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
57743161|NCT01499004|DRUG|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
57743162|NCT04197713|DRUG|Adavosertib|Given PO
57743163|NCT04197713|DRUG|Olaparib|Given PO
57743164|NCT06580639|OTHER|No intervention.|Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.
57743165|NCT00231634|DRUG|topiramate|
57743166|NCT05830162|DRUG|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
57743167|NCT05830162|DRUG|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
57743168|NCT03781752|DRUG|Methylphenidate|study to determine dose
57957807|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD."
57957808|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD."
58447622|NCT06726265|BIOLOGICAL|eftilagimod alfa|30 mg of efti every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
57743169|NCT06732297|BEHAVIORAL|dyadic art therapy intervention for parent-child relationship in vulnerable families|The Stronger Family Through Art Therapy (SFAT) is a dyadic art therapy intervention developed to improve the parent-child relationship in vulnerable families. Service users of the SFAT programme will receive a progressive support from workshops, dyad art therapy, and an innovative art-based self-care tool developed with a multidisciplinary team to meet the needs of enhancing family communication and strengthening emotional bonding.
57743170|NCT01515410|DRUG|DM-1992|72.5mg carbidopa/230mg levodopa
57743171|NCT01515410|DRUG|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
57743172|NCT04348305|DRUG|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
57743173|NCT04348305|DRUG|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
57743174|NCT02934490|DEVICE|Mesh|Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
57743175|NCT05663424|OTHER|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
57743176|NCT05663424|OTHER|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (\>2hr)
57743177|NCT05663424|OTHER|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
57743178|NCT02990533|DRUG|Testosterone|
57743179|NCT02990533|DIETARY_SUPPLEMENT|Protein Supplement|
57743180|NCT02990533|OTHER|Placebo Injection|
57743181|NCT02990533|OTHER|Placebo supplement|
57743182|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
57743183|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
57743184|NCT00798720|DRUG|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
57743185|NCT00798720|DRUG|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
57743186|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
57743187|NCT03609112|OTHER|The WISC-V|The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
57743188|NCT03609112|OTHER|The NEPSY-II|The NEPSY-II (Korkman et al., 2012). The Narrative Memory subtest is designed to assess verbal memory using organised language material.
57743189|NCT03609112|OTHER|The Child Executive Function Evaluation Battery CEF|The Child Executive Function Evaluation Battery CEF (Roy et al., 2021), which aims to evaluate the four main components of executive function (inhibition, working memory, flexibility and planning).
57743190|NCT03609112|OTHER|"The CONNERS 3 long version"|"The  CONNERS 3 long version  (Conners, 2008), which assesses attentional skills by means of a questionnaire to be completed by parents."
57743191|NCT03609112|OTHER|"The BRIEF"|The 'BRIEF' (Gioia et al., 2013; parent version, teacher version), which is a behavioural evaluation inventory of executive functions completed by parents and teachers and which makes it possible to determine whether the child has, for example, difficulties with organisation, planning or behavioural regulation.
57743192|NCT03609112|OTHER|"The PEDS-QL quality of life"|"The PEDS-QL quality of life (Tessier et al., 2009) that will be completed by the parents and the patient concerns the day to- day functioning of the child (in school, relationships to others, physical abilities and emotional state)."
57743193|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort) which assesses fatigue in everyday life.
57743194|NCT03609112|OTHER|The Family Functioning Inventory FAD)|The Family Functioning Inventory FAD (Speranza et al., 2006) is used to assess the family functioning of the child and his/her family. The short version is used as an indicator of general functioning.
58447623|NCT06726265|DRUG|carboplatin plus paclitaxel|For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2
57743195|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
57743196|NCT06733246|DEVICE|Aspiration 0|Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
57743197|NCT04064489|OTHER|TRIPscore|TRIPcast score calculation
57743198|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
57743199|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
58447624|NCT06726265|DRUG|cisplatin or carboplatin + pemetrexed|For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks
57743200|NCT01001052|DRUG|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
57743201|NCT04080804|DRUG|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
57743202|NCT04080804|DRUG|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
57743203|NCT04080804|DRUG|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
57743204|NCT04762368|DEVICE|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
57743205|NCT04762368|DEVICE|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
57743206|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
58117793|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
58117794|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
58117795|NCT00288171|DRUG|Placebo|placebo capsule twice daily for one month
57743207|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
57743208|NCT03902054|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
57743209|NCT03902054|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
57743210|NCT03902054|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
57743211|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
57743212|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
57743213|NCT01087892|DIETARY_SUPPLEMENT|Probiotic drink containing the live strain|Probiotic drink contains no strain
57743214|NCT01087892|DIETARY_SUPPLEMENT|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
57743215|NCT05808101|OTHER|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
57743216|NCT01506193|BIOLOGICAL|PriorixTetra™|One dose administered subcutaneously
57743217|NCT01506193|BIOLOGICAL|Meningitec|One dose administered intramuscularly
57743218|NCT05800535|DRUG|Study of the adverse effects of long-term oncological treatments|Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
57743219|NCT05800535|BEHAVIORAL|Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients|Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
57743220|NCT00400335|DRUG|Nanomilled testosterone|
57743221|NCT00400335|DRUG|commercially available dutasteride|
57957809|NCT06081907|DRUG|IBI363|The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
57957810|NCT00951730|OTHER|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
58117796|NCT00288171|DRUG|Allopurinol|Allopurinol 200mg twice daily for one month
58117797|NCT01451905|DRUG|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
58117798|NCT01451905|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
57743222|NCT00400335|DRUG|Nanomilled dutasteride|
57743223|NCT02823951|DRUG|Rebif|
57743224|NCT02823951|DRUG|Tecfidera|
57743225|NCT06733467|OTHER|Stimulus properties: remembered feature|The feature used to determine which stimulus feature to remember to will be varied across trials using a letter cue (M = remember-motion; C = remember-color; 0 = remember nothing)
57743226|NCT02703922|OTHER|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
57743227|NCT05308329|DEVICE|Intra-coronary imaging device|Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
57743228|NCT05308329|BEHAVIORAL|PCI procedural characteristics|Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
57743229|NCT02306070|DRUG|Metformin|metformin treatment + standard of care dietary and exercise advice
57743230|NCT02306070|DRUG|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
57743231|NCT00006257|DRUG|paclitaxel|
57743232|NCT00006257|DRUG|semaxanib|
57743233|NCT00006213|DRUG|BMS-214662|Given IV
57743234|NCT00006213|OTHER|pharmacological study|Correlative studies
57743235|NCT00006213|OTHER|laboratory biomarker analysis|Correlative studies
57743236|NCT05061238|DEVICE|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
57743237|NCT04492254|DRUG|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
57957811|NCT00919503|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infused IV
57957812|NCT00919503|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57957813|NCT00919503|DRUG|Cyclosporine|Given IV or PO
57957814|NCT00919503|DRUG|Fludarabine Phosphate|Given IV
57957815|NCT00919503|OTHER|Laboratory Biomarker Analysis|Correlative studies
57957816|NCT00919503|DRUG|Methotrexate|Given IV
57957817|NCT00919503|DRUG|Mycophenolate Mofetil|Given IV or PO
57957818|NCT00919503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infused IV
57957819|NCT00919503|DRUG|Tacrolimus|Given IV or PO
58117799|NCT01729702|OTHER|blood sample collection|
58117800|NCT01839084|DRUG|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
58117801|NCT01839084|DRUG|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
58117802|NCT04767269|DRUG|Cuminum Cyminum|Cuminum Cyminum mouthwash in chronic gingivitis patients
57743238|NCT00440531|BIOLOGICAL|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
57743239|NCT00440531|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
57743240|NCT00440531|BIOLOGICAL|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
57743241|NCT00514735|PROCEDURE|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
57743242|NCT00514735|DRUG|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
57743243|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
57743244|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
57743245|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
57743246|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
58313238|NCT02346747|BIOLOGICAL|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
58447625|NCT06726265|BIOLOGICAL|Pembrolizumab (KEYTRUDA®)|200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months
57743247|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
57743248|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
57743249|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
57743250|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
57743251|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
57743252|NCT06283472|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
57743253|NCT06283472|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
57743254|NCT04886024|OTHER|Advanced Glycation End Products (AGEs)|Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
57743255|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
57743256|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
57743257|NCT01140217|DRUG|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
57743258|NCT06296550|OTHER|Dulce Digital Text Messaging Intervention|"Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading."
57743259|NCT06296550|OTHER|CGM Device|Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
58313239|NCT02346747|OTHER|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
58313240|NCT01612013|DRUG|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
58117803|NCT04767269|DRUG|herbal Mouthwash|herbal mouthwash in chronic gingivitis patients
58447626|NCT06726265|OTHER|Placebo|efti-matching placebo every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
58447627|NCT04883866|BEHAVIORAL|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
58447628|NCT04883866|BEHAVIORAL|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
58447629|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
57743260|NCT04504487|OTHER|Drain Removal|Abdominal drain placed during surgery removal
57743261|NCT02598492|OTHER|arterial blood gas|Just record clinical lab data
57743262|NCT06113848|DRUG|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
57743263|NCT06113848|DRUG|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
57743264|NCT06113848|DRUG|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
57743265|NCT06113848|OTHER|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
57743266|NCT06367166|DRUG|"Venarus® (diosmin and hesperidin)"|"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
57743267|NCT06367166|PROCEDURE|Endovenous laser ablation (EVLA) with miniphlebectomy|Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
57743268|NCT06367166|OTHER|Elastic compression|All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
57743269|NCT06367166|OTHER|Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores|The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
57743270|NCT06205342|DRUG|Mesenchymal Stem Cells|Autologous bone marrow derived MSCs
57743271|NCT06205342|OTHER|Other: Placebo|Control
57743272|NCT02444065|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
57743273|NCT02444065|BEHAVIORAL|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter \& Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
57743274|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder|
57743275|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder (containing FeSO4), phytase|
57743276|NCT01991626|DIETARY_SUPPLEMENT|Iron pyrophosphate (FePP)|
57743277|NCT01991626|DIETARY_SUPPLEMENT|Iron sulphate|
57743278|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
57743279|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
57743280|NCT04737460|GENETIC|AAV9/CLN7|Enrollees will receive gene therapy via a viral vector
57743281|NCT03089684|OTHER|No intervention|No intervention
57743282|NCT06732895|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
57743283|NCT06732895|DRUG|Placebo for navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
57743284|NCT02373800|DEVICE|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
57743285|NCT04710810|OTHER|umbilical cord blood mononuclear stem cells|UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
57743286|NCT00952367|OTHER|Nasopharyngeal swab|Nasopharyngeal swab
57743287|NCT03983512|DEVICE|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
57743288|NCT02319811|PROCEDURE|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
57743289|NCT02496624|OTHER|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
57743290|NCT03230708|OTHER|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
57743291|NCT03230708|DRUG|convention drugs|according to usage method of drugs
57743292|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
57743293|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
57957820|NCT00919503|RADIATION|Total-Body Irradiation|Undergo total body irradiation
57957821|NCT00919503|DRUG|Treosulfan|Given IV
57743294|NCT06062680|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
57957822|NCT00919503|PROCEDURE|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
58447630|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
57743295|NCT01353352|OTHER|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
57743296|NCT06732024|PROCEDURE|Vaccum assisted closure|close skin and SC tissue by vaccum device
57743297|NCT06732024|PROCEDURE|primary wound closure|close skin and SC tissue by primary closure
57743298|NCT05620875|DIAGNOSTIC_TEST|Cerebral injury markers|Blood tests at given time points perioperatively.
57743299|NCT05620875|DIAGNOSTIC_TEST|Cerebral oximetry index|Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
57743300|NCT03206203|DRUG|Atezolizumab|Given by vein
57743301|NCT03206203|DRUG|Carboplatin|Given by vein
57743302|NCT03206203|OTHER|Laboratory Biomarker|Correlative study
57743303|NCT03206203|OTHER|Quality-of-Life Assessment|Ancillary studies
57743304|NCT05195931|DIAGNOSTIC_TEST|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
57743305|NCT05195931|DIAGNOSTIC_TEST|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
57743306|NCT05195931|DIAGNOSTIC_TEST|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
57743307|NCT06733974|OTHER|Multi-faceted Intervention|The participant, i.e. relative, will receive the multifaceted intervention which include: a first meeting with the healthcare team including written information about palliative care for dying patients, information on possibility to participate in care, pro-active communication, and dedicated interview and brochure after the patient's death with possibility of psychological follow up.
57743308|NCT02270333|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
57743309|NCT02270333|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
57743310|NCT03154216|BEHAVIORAL|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
57743311|NCT03154216|OTHER|Drink|Beverage to be consumed after exercise
57743312|NCT02961465|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
57743313|NCT05251051|BEHAVIORAL|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
57743314|NCT05251051|OTHER|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
57743315|NCT06372470|OTHER|Zestril|N/A, this is an observational study.
57743316|NCT00772226|DEVICE|music pillow|according to randomisation patients will receive with/without music.
57743317|NCT00772226|DEVICE|pillow without music|According to randomisation patients will receive a pillow with/without music
57743318|NCT03974620|BEHAVIORAL|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
57743319|NCT03974620|BEHAVIORAL|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
57743320|NCT03671005|BEHAVIORAL|Mindfulness-based group therapy|see above
57743321|NCT03671005|OTHER|Treatment as usual|see above
57743322|NCT01724138|DRUG|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
57743323|NCT00070473|DRUG|pemetrexed disodium|
57743324|NCT06211569|OTHER|Usual follow-up|Usual follow-up
57743325|NCT03073148|DEVICE|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
57743326|NCT03073148|OTHER|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
57743327|NCT02381886|DRUG|IDH305|
57743328|NCT01851148|OTHER|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
57743329|NCT01851148|OTHER|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
57743330|NCT01851148|DRUG|triptans|administration of triptans drug treatment according to international guidelines
57957823|NCT03506555|PROCEDURE|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
57957824|NCT04044131|DRUG|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
57743331|NCT04602728|BEHAVIORAL|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
57743332|NCT05465161|DEVICE|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
57743333|NCT04354467|DIAGNOSTIC_TEST|urine neutrophil gelatinase -associated lipocalin|urine biomarker is measured and batched procesessed
57743334|NCT03018405|BIOLOGICAL|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
57743335|NCT04929769|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
57743336|NCT04929769|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
57743337|NCT04364373|PROCEDURE|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
57743338|NCT04364373|PROCEDURE|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
57743339|NCT04364373|PROCEDURE|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
57743340|NCT02680873|OTHER|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
57743341|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
57743342|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
57743343|NCT04049175|DRUG|Treatment A|Tablet of CHF 6532
57743344|NCT04049175|DRUG|Treatment B|Tablet of CHF 6532
57743345|NCT04049175|DRUG|Treatment C|Tablet of CHF 6532
57743346|NCT04049175|DRUG|Treatment D|Tablet of CHF 6532 placebo
57743347|NCT06733857|BEHAVIORAL|VEG2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
57957825|NCT04044131|DRUG|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
57957826|NCT03329235|DRUG|PRP|platelet rich plasma
57957827|NCT03329235|DRUG|HA|hyaluronic acid
57957828|NCT03094871|BEHAVIORAL|FACE-PC|
57957829|NCT04901208|DRUG|Nicotine pod|Nicotine pods administered to individuals who use Juul
58117804|NCT01887509|DEVICE|Probe-based confocal laser endomicroscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
58117805|NCT01887509|PROCEDURE|Rectoscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
57743348|NCT06733857|BEHAVIORAL|OMNI2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
57743349|NCT06720259|DRUG|Oxantel Pamoate|Tablets containing 250 mg oxantel pamoate
57743350|NCT06720259|DRUG|Mebendazole|Tablets containing 500 mg mebendazole
57743351|NCT03583255|DRUG|Dexamethasone|Given PO
57743352|NCT03583255|BEHAVIORAL|Exercise Intervention|Complete resistance training and moderate intensity walking
57743353|NCT03583255|OTHER|Placebo Administration|Given PO
57743354|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
58117806|NCT01887509|PROCEDURE|EUS|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
58117807|NCT01887509|PROCEDURE|Biopsy and resection|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
58117808|NCT01409356|BEHAVIORAL|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
57743355|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
57743356|NCT01175850|DEVICE|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
57743357|NCT01175850|DEVICE|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
57743358|NCT06732648|DRUG|HRS8179 injection|HRS8179 injection; high dose
57743359|NCT06732648|DRUG|HRS8179 blank preparation.|HRS8179 blank preparation.
57743360|NCT05394246|DRUG|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
57743361|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
57743362|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
57743363|NCT03533712|DIETARY_SUPPLEMENT|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~* Total energy: 250-500 kcal per daily serving~* Fat content: 10-60% of energy intake~* Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~* Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~* Trans Fats: \<1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
57743364|NCT03533712|DIETARY_SUPPLEMENT|Fe and folic acid supplement|Routine iron and folic acid supplementation.
57743365|NCT04088552|OTHER|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
57957830|NCT04901208|DRUG|Placebo pod|Nicotine-free pods administered to individuals who use Juul
57743366|NCT04088552|BEHAVIORAL|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
57743367|NCT05095610|DEVICE|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
57743368|NCT05722002|DRUG|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
57743369|NCT05722002|DRUG|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
57743370|NCT05722002|DRUG|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
58313241|NCT01612013|DRUG|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
58447631|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
58447632|NCT01367834|DRUG|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
58447633|NCT01225094|DRUG|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
57743371|NCT06431503|OTHER|Tok-Sen Massage|Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.
57743372|NCT06431503|OTHER|Pressure Massage|Press the wedge: the strength for pressing the wedge is 1500g±50g,
57743373|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
57743374|NCT04711889|DRUG|Blank control|Blank control
57743375|NCT06733818|OTHER|Functional assessment of physical performance|Functional assessment of physical performance was performed with the Alusti test. This 10-question test was developed to assess physical performance in the geriatric population 13 and has been validated in Turkish 14. This test evaluates limb range of motion and muscle strength, ability to move from supine to sitting position, sitting balance, ability to stand up from sitting position, standing, walking, walking distance, ability to stand on tandem and single leg with eyes closed. The results of this test, which is scored out of 100, indicate the level of activity. 0-30, interpreted as totally dependent; 31-40, highly dependent; 41-50, moderately dependent; 51-60, slightly dependent; 61-75, good activity; 76-90, very good activity; and 91-100, excellent activity.
57743376|NCT06722183|DRUG|Futibatinib orally administered|Futibatinib will be administered 20mg orally, once daily, continously
57743377|NCT06722183|DRUG|Tislelizumab (i.v. 200mg)|Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle
57743378|NCT06441968|BIOLOGICAL|MPV/S-2P|A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.
57743379|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
57743380|NCT04702568|DRUG|Eculizumab|Administered at stable dose at the time of study entry
57743381|NCT04702568|DRUG|Ravulizumab|Administered at stable dose at the time of study entry
57743382|NCT01320007|DRUG|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
58447634|NCT01225094|OTHER|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
58447635|NCT01949974|DRUG|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
58447636|NCT01949974|OTHER|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
58447637|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
58447638|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
57957831|NCT02564315|DRUG|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
57957832|NCT02564315|BEHAVIORAL|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
58313242|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
58313243|NCT01612013|DRUG|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
58447639|NCT01814475|DRUG|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
58313244|NCT01612013|DRUG|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
58447640|NCT01814475|DRUG|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
58447641|NCT05167565|OTHER|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (\~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
57743383|NCT01320007|OTHER|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
57743384|NCT06733805|BEHAVIORAL|Portrait + Therapeutics Letter|"In the context of audit and feedback interventions, Portrait is a document produced by the physician organization Therapeutics Initiative that provides personalized prescribing feedback for BC clinicians. Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual prescriber's prescribing practice, benchmarks or targets, a succinct review of the best-available evidence on the topic, and recommendations for future action.~The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and provide reference for the data presented in the Portraits."
57743385|NCT00773968|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
57743386|NCT04212091|BIOLOGICAL|PGT121.414.LS|Administered via IV infusion or SC infusion, depending on the arm
57743387|NCT04212091|BIOLOGICAL|VRC07-523LS|Administered via IV infusion or SC infusion, depending on the arm
57743388|NCT05884346|OTHER|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
57743389|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
57743390|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Medical management
57743391|NCT06722976|OTHER|Multicomponent exercise programs|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each session.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
58313245|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
58447642|NCT05167565|OTHER|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
57743392|NCT06253494|BIOLOGICAL|AdHER2DC vaccine|AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12
57743393|NCT06253494|BIOLOGICAL|Pembrolizumab|Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16
57743394|NCT06253494|BIOLOGICAL|N-803|N-803 is given by subcutaneous injections on Day 1 of cycles 1-16
57743395|NCT06253494|DRUG|Lenvatinib|Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16
57743396|NCT06253494|DEVICE|PATHWAY HER2 (4B5) assay|Used during screening to estimate eligibility
57743397|NCT03064568|DRUG|Misoprostol 100Mcg Tab|
57743398|NCT03064568|DRUG|Placebo|
57743399|NCT01832948|DRUG|Endostar|
58447643|NCT05167565|OTHER|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
58447644|NCT05167565|OTHER|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
58447645|NCT05167565|OTHER|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
58447646|NCT05167565|OTHER|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
58447647|NCT05167565|OTHER|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
58447648|NCT05167565|OTHER|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
58447649|NCT01150097|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
58447650|NCT01150097|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
58447651|NCT01150097|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
57743400|NCT01832948|DRUG|Oxaliplatin|
57743401|NCT01832948|DRUG|Folinic acid|
57743402|NCT01832948|DRUG|5-FU|
57743403|NCT06202287|OTHER|Balance measurements using the HUR Smart balance device, balance tests, and other surveys.|50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
57743404|NCT04957537|BEHAVIORAL|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
57743405|NCT06470165|PROCEDURE|Priority-matching correction technique in DLS|"For Type 1 global coronal malalignment (GCM), TL/L curve makes the primary contri- bution on C7PL shifting. First, inserting pedicle screws bilaterally. Second, aggressively decreasing the magnitude of TL/L curve. Third, moderately leveling L4 endplate to pull the fusion segments to the middle line with hand pressure on the convexity of TL/L curve. If the correctability of the key curve was limited, the correction of the minor curve would be con- vergent.~For Type 2 GCM, LS curve makes the primary contribution on C7PL shifting. First, releasing LS curve from the concave side using facetectomy after screws inserted. Second, performing L4-5 or L5-S1 trans- foraminal lumbar interbody fusion (TLIF) from the con- vexity of the fractional curve, with cages inserted at the concave side to assist deformity correction. Third, compressing the convexity of LS to horizontalize L4 endplate, followed by moderate manipulative reduction of TL/L curve to adjust intraoperative coronal balance."
57957833|NCT02564315|BEHAVIORAL|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
57743406|NCT06470165|PROCEDURE|Traditional correction technique in DLS|"In concave coronal malalignment (CM), the correction of the main curve improves the CM, thus we can talk about convergent corrective objectives. The ability to correct the CM depends on the correctability of the main curve. The need of three-column osteotomies in order to obtain correction of CM depends on the location and flexibility of the main curve.~The correction of convex CM depends on the correction of the lumbosacral curve. The correction strategy will depend on many factors including the driver of the deformity, which should always be fused, but also the degeneration and stiffness of the compensatory curve which can lead to more extended fusion. The need of three-column osteotomies depends mainly on the stiffness of the lumbosacral curve."
57743407|NCT06064396|OTHER|Gong's Mobilization|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Gong's Mobilization.
57743408|NCT06064396|OTHER|Stecco Fascial Therapy|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with stecco fascial therapy.
57743409|NCT05845320|OTHER|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
57743410|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
57743411|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
57743412|NCT05229068|BIOLOGICAL|RSV MAT|Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
57743413|NCT06720662|DIETARY_SUPPLEMENT|Icosapent-ethyl ester capsules|Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.
57743414|NCT06720662|DIETARY_SUPPLEMENT|Corn oil Control|Corn oil twice a day (2.0 g/day x 2) for six months.
57957834|NCT02564315|BEHAVIORAL|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
57743415|NCT06221189|BEHAVIORAL|ACT-CSP|The ACT treatment will consist of three 45 to 60-min weekly sessions to be delivered to the caregiver in an individual format via online videoconferencing application e.g. ZOOM or WhatsApp within 3 weeks. The ACT-CSP can be delivered via face-to-face on request. Each session has a specific content with pre-planned materials and mindfulness exercises and metaphors. Psychological-based homework will be assigned at the end of each session. The components of ACT process will be emphasized in the intervention programme, which include perspective taking, self-as-context and defusion (i.e. recognizing worry thoughts as thoughts only), identifying values and acceptance of present-moment experience with respect to the values, and committed action.
57957835|NCT02564315|BEHAVIORAL|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
57957836|NCT02564315|BEHAVIORAL|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
57957837|NCT02564315|BEHAVIORAL|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
58117809|NCT05684926|OTHER|Telerehabilitation yoga|Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
58117810|NCT04290078|DEVICE|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
58117811|NCT04290078|OTHER|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
58117812|NCT01193621|DRUG|haloperidol, PET|"1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
57743416|NCT06723301|BEHAVIORAL|Chatbot-base problem-solving skills training(PSST)|The intervention incorporates eight sessions: Session 1 involves rapport building, understanding relevant personal and medical history, and introducing the Chatbot-based program and worksheet; Session 2 focuses on maintaining brightness and optimism when faced with a specific obstacle; Sessions 3-7 involve the continued application of problem-solving skills training(PSST) to identify problems and the promotion of problem-solving strategies and skills in vivo, including (a) identifying the problem, (b) determining the options, (c) evaluating and choosing the best option, (d) acting according to the best option, and (e) seeing if it works; and Session 8 involves a review of PSST principles and termination.
57743417|NCT01696201|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
57743418|NCT06443268|DIAGNOSTIC_TEST|questionnaire, hair samples, blood samples, clinical exam|The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
57743419|NCT05661734|DRUG|VX-548|Tablets for oral administration.
57743420|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
57743421|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
58117813|NCT02078063|DRUG|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
58117814|NCT02078063|DRUG|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
58117815|NCT01449058|DRUG|BYL719|taken orally
58117816|NCT01449058|DRUG|MEK162|taken orally
58117817|NCT02598102|DRUG|Diclofenac sodium|Diclofenac for pain relief
57743422|NCT04733040|DRUG|MOR202|MOR202 will be administered as an intravenous infusion
57743423|NCT01413568|DRUG|POL6326|
57743424|NCT01413568|PROCEDURE|Leukapheresis|
57743425|NCT01413568|PROCEDURE|PBSC Transplant|
57743426|NCT04376138|OTHER|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
58117818|NCT02598102|DRUG|Placebo|Placebo for comparison
58117819|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
58117820|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
58117821|NCT00996866|DRUG|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
58117822|NCT00996866|DRUG|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
58117823|NCT00217854|PROCEDURE|Bronchoscopic|Bronchoscopic procedure
58117824|NCT00901368|DRUG|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
57743427|NCT04376138|OTHER|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
58117825|NCT00901368|DRUG|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
58117826|NCT02248532|BIOLOGICAL|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
57743428|NCT04728529|PROCEDURE|USSM protocol|"In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2"
57743429|NCT04728529|PROCEDURE|ACCM protocol|In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
57743430|NCT04269499|DEVICE|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
57743431|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
57743432|NCT05318287|BEHAVIORAL|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
57743433|NCT00291967|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
57743434|NCT03136445|DRUG|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
57743435|NCT03136445|DRUG|Placebo|IV (saline) or oral placebo tablets
57957838|NCT02564315|DRUG|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke \>10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke \<=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
57957839|NCT04455529|OTHER|ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
58117827|NCT06286553|BEHAVIORAL|Trunk exercise|Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.
58447652|NCT01150097|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
58447653|NCT01150097|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
58447654|NCT01150097|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
58313246|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
58447655|NCT06369974|DRUG|Antisense oligonucleotide treatment (ASO)|Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
57743436|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
57743437|NCT04491448|BEHAVIORAL|Social needs screening|Interview and referral for non-medical health-related social needs
57743438|NCT01358695|BIOLOGICAL|ANT-1207|The interventions differ by dose of investigational product applied.
57957840|NCT06329037|DRUG|Vasopressin|Administration of Vasopressin (20 IU) (oral spray)
57957841|NCT06329037|DRUG|Placebo|Administration of Placebo (oral spray)
58313247|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
57957842|NCT04547205|DRUG|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
58313248|NCT05986110|PROCEDURE|A training intervention on clinical ultrasound|To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
58313249|NCT00002791|BIOLOGICAL|filgrastim|
58313250|NCT00002791|DRUG|dacarbazine|
58313251|NCT00002791|DRUG|doxorubicin hydrochloride|
58313252|NCT00002791|DRUG|ifosfamide|
58313253|NCT00002791|DRUG|mesna|
58313254|NCT00002791|PROCEDURE|conventional surgery|
58447656|NCT03965494|DRUG|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
58447657|NCT03965494|DRUG|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
57743439|NCT01358695|BIOLOGICAL|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
57743440|NCT01358695|BIOLOGICAL|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
57743441|NCT04907708|DRUG|Metformin|Euglycemic agent
58117828|NCT06286553|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Inspiratory muscle strengthening exercises using inspiratory resistance (IMT devices)
58117829|NCT06286553|BEHAVIORAL|Control Group|Participants in the Control Group will receive general management information for DRA, written instructions and a single educational exercise session for contracting the deeper abdominals and pelvic floor muscles.
58117830|NCT00648453|DRUG|Clopidogrel (Plavix)|
58117831|NCT03361514|BEHAVIORAL|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
58117832|NCT03361514|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
58117833|NCT04779619|OTHER|Online self-report questionnaire completion|After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
58117834|NCT04120168|GENETIC|Laboratory Tests|"* Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
58117835|NCT02180061|BIOLOGICAL|Pembrolizumab|IV infusion
58117836|NCT05781659|PROCEDURE|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
58117837|NCT05781659|PROCEDURE|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
57957843|NCT06501664|DRUG|liposomal irinotecan|Liposomal irinotecan 70 mg/m²
58117838|NCT04448171|DEVICE|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
58447658|NCT02495129|DRUG|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
58447659|NCT02495129|DRUG|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
57743442|NCT04907708|DRUG|Insulin|Hypoglycemic agent
57743443|NCT04891419|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
57743444|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
57957844|NCT06501664|DRUG|5-FU|5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
57957845|NCT06501664|DRUG|LV|LV 400 mg/m²
57957846|NCT06501664|DRUG|Irinotecan|Irinotecan 180 mg/m²
57743445|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
57743446|NCT06722170|GENETIC|EH002 administration|EH002 was administered into one or both ears via intracochlear injection.
57743447|NCT06597487|PROCEDURE|Full pulpotomy|"The patients will receive full pulpotomy as follows:~-Under rubber dam isolation, the operator will perform caries removal, complete the access cavity preparation, achieve hemostasis from all canals, and apply the bioceramic material. The operator will seal the cavity with glass ionomer restoration."
57743448|NCT06597487|PROCEDURE|Conventional root canal treatment|The patients will receive conventional root canal treatment, which is the gold standard treatment protocol in cases with irreversible pulpitis.
57743449|NCT06542536|DRUG|Monlunabant|Oral monlunabant
57743450|NCT06542536|DRUG|Placebo (monlunabant)|Oral placebo (monlunabant)
57743451|NCT00695643|DRUG|Mesalazine|3 g per day
57743452|NCT00695643|DRUG|Placebo|0 g per day
57743453|NCT02855931|PROCEDURE|Middle turbinate resection|
57743454|NCT01689064|PROCEDURE|Stamm Approach|
57743455|NCT01689064|PROCEDURE|Posterior Septectomy|
57743456|NCT04715568|DRUG|Losartan|50 mg tablets taken orally
57743457|NCT04715568|DRUG|Placebo|Tablets taken orally
57957847|NCT03530371|DRUG|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
57957848|NCT01622881|DRUG|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
57957849|NCT01622881|DRUG|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
57957850|NCT04489966|BEHAVIORAL|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
57743458|NCT04861987|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
57743459|NCT05506787|DRUG|Esketamine|Esketamine
57743460|NCT05506787|DRUG|Placebo|Placebo
57743461|NCT05082038|DEVICE|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
57743462|NCT05082038|DEVICE|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
57743463|NCT02626780|DEVICE|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
57743464|NCT06733948|DEVICE|Dental stent|Dental stent is personalised device for tongue depressing and immobilisation during RT. The aims are to reduce unnecessary RT doses to adjacent non-target healthy tissue, including the tongue, adjacent oral mucosa, parotid glands/ submandibular glands, and temporomandibular joints. Dentists will take impression of the teeth on moulds, and measure the height to raise the bite, the stent is then fabricated as methyl methacrylate resin in the dental laboratory. The resin base extends to the tongue and a flat plate depresses the tongue. This device will be placed before each RT fraction.
57743465|NCT06733948|OTHER|No dental stent|No dental stent used during chemoradiation treatment
57743466|NCT01394965|PROCEDURE|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
57743467|NCT05682053|DIAGNOSTIC_TEST|Multiparametic MRI|patients will have a Multiparametric MRI
58447660|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
57743468|NCT05645328|OTHER|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
57743469|NCT00211705|BEHAVIORAL|Diet|
57743470|NCT00211705|DRUG|Diet+pravastatin|
57743471|NCT04235036|DRUG|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
57743472|NCT04235036|DRUG|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
57743473|NCT06401356|DRUG|Pelabresib|Small molecule inhibitor of bromodomain and extraterminal (BET) protein
58447661|NCT03932695|DIETARY_SUPPLEMENT|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
58447662|NCT03932695|DIETARY_SUPPLEMENT|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
58447663|NCT03932695|DIETARY_SUPPLEMENT|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
58447664|NCT02303093|BIOLOGICAL|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
57957851|NCT01355939|PROCEDURE|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
58117839|NCT04448171|DEVICE|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
58117840|NCT05642156|PROCEDURE|isolated Ultrafiltration (iso-UF)|isolated Ultrafiltration
58313255|NCT00002791|RADIATION|brachytherapy|
58447665|NCT02303093|BIOLOGICAL|Panzyga|Panzyga
57743474|NCT05420103|OTHER|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
57743475|NCT03621605|BIOLOGICAL|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
58447666|NCT03655041|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
57743476|NCT03621605|DRUG|Placebos|Placebo administered by slow IV infusion or SC injection.
57743477|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
57957852|NCT04344678|DRUG|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
57957853|NCT04344678|DRUG|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
57957854|NCT06293612|OTHER|No intervention was administrated to the two cohorts.|
57957855|NCT02031705|PROCEDURE|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
57957856|NCT02031705|PROCEDURE|control group|Control group was performed no additional cavotricuspid isthmus ablation.
57957857|NCT03091309|OTHER|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
57957858|NCT03091309|BEHAVIORAL|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
58447667|NCT03655041|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
57743478|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
57743479|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
57743480|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
57743481|NCT05304169|DRUG|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
57743482|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
57743483|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
57743484|NCT06731881|DEVICE|Nasal PDT|Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.
57743485|NCT06731881|COMBINATION_PRODUCT|Photosensitizer formulation only|Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).
57743486|NCT06731881|OTHER|Standard follow-up|All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.
57743487|NCT06731881|DIAGNOSTIC_TEST|Nasal culture|Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).
57957859|NCT03091309|BEHAVIORAL|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
58117841|NCT04939974|DIETARY_SUPPLEMENT|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
58447668|NCT01372969|DRUG|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
58447669|NCT01564563|DRUG|standard therapy|Standard treatment of bleeding
57743488|NCT06731881|DIAGNOSTIC_TEST|Flexible nasendoscopy|Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).
57743489|NCT06731881|OTHER|In-person review|On Week 2 (±7 days), the participant will undergo an in-person review conducted in the ENT Outpatient department, 2nd floor Southwark wing, Guy's Hospital by the CI, PI or Co-investigator. During this appointment, concomitant medications and use of post-operative antibiotics will be reviewed.
57743490|NCT06731881|OTHER|Telephone Follow-up|"On day 30, the research nurse will telephone participants from the ENT research office.~* Review of adverse events/adverse device effects~* Review of concomitant medications~* Signs and symptoms post-surgery~* Nasal washout~* Record any use of post-operative antibiotics, both local and systemic"
57957860|NCT03091309|BEHAVIORAL|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
57957861|NCT03091309|OTHER|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence \[self-reported using the 5 item Medication Adherence Report Scale (MARS-5)\] and IBD related disease activated \[self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity\].
58117842|NCT03385746|OTHER|polyamide|metal reinforced polyamide denture base material
58447670|NCT01564563|DRUG|placebo|Placebo
58117843|NCT03385746|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
58117844|NCT00016055|BIOLOGICAL|lymphokine-activated killer cells|
58117845|NCT00016055|DRUG|temozolomide|
58117846|NCT05615623|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
58117847|NCT05615623|DRUG|Doxorubicin|Doxorubicin infusion
58313256|NCT00002791|RADIATION|intraoperative radiation therapy|
58313257|NCT00002791|RADIATION|radioisotope therapy|
58313258|NCT00122603|DRUG|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
58313259|NCT00122603|DRUG|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
58313260|NCT06550596|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58447671|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
58447672|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
57743491|NCT04594031|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)
58117848|NCT02716883|PROCEDURE|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
58447673|NCT04907474|DRUG|tropicamide-phenylephrine fixed combination ophthalmic solution|Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
58447674|NCT04406675|OTHER|neuropsychological test|neuropsychological test
58447675|NCT02766712|PROCEDURE|Pace During 1st Half of Lesion|
58447676|NCT02766712|PROCEDURE|Pace During 2nd Half of Lesion|
57743492|NCT01177904|OTHER|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
57743493|NCT01177904|OTHER|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
57743494|NCT06722846|BEHAVIORAL|Randomized Case Vignette Study|Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.
57957862|NCT03091309|OTHER|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
57957863|NCT05477290|PROCEDURE|Trigger Finger Release through Transverse Incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
57957864|NCT05477290|PROCEDURE|Trigger Finger Release through Oblique Incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
57957865|NCT05477290|PROCEDURE|Trigger Finger Release through Vertical Incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
57957866|NCT02966691|OTHER|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
57957867|NCT05655338|DEVICE|antimicrobial photodynamic therapy|
57957868|NCT05655338|DRUG|systemic antibiotics|
57957869|NCT00544609|DRUG|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
58117849|NCT01815021|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
58313261|NCT06550596|OTHER|Axolotl DualGraft + SOC|Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58313262|NCT00300196|BIOLOGICAL|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
58313263|NCT00300196|DRUG|Placebo|0.6 mL/kg/hr
58313264|NCT01458587|DRUG|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
58313265|NCT01458587|DRUG|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
58313266|NCT00077818|DRUG|Enoxaparin sodium|
57743495|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
57743496|NCT05110742|DRUG|Cyclophosphamide|Given by IV
57743497|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
57769659|NCT02875301|BEHAVIORAL|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
57957870|NCT00544609|PROCEDURE|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
57957871|NCT00207051|DRUG|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
58117850|NCT01815021|DIETARY_SUPPLEMENT|crystalline calcium supplements|
58117851|NCT00565981|DRUG|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
58313267|NCT01867775|DRUG|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
58447677|NCT04909866|COMBINATION_PRODUCT|TACE+Lenvatininb+Camrelizumab|Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
58447678|NCT01083823|OTHER|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
58447679|NCT00437424|DRUG|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
57743498|NCT04499092|OTHER|Personalized Neuropsychological treatment (CORE-ABI)|Personalized neuropsychological treatment. In the CORE-ABI intervention, the stimulation of cognitive functions will be provided based on a weekly evaluation of child's cognitive profile by a qualified neuropsychologist. Each session will have a duration of 45 min. While the first 30 minutes will be devoted to the stimulation of the most impaired cognitive function(s), the remaining 15 minutes will ensure the stimulation of the other cognitive subdomains. Domains addressed by the intervention will be the following: selective attention, sustained and divided attention, inhibition and shifting, visual-perceptual abilities, visual-spatial abilities, visual-constructional abilities, short-term memory, long-term memory, working-memory, categorization/reasoning/abstraction, problem-solving/planning and socio-emotional skills.
57743499|NCT04499092|OTHER|Sequential Neuropsychological treatment (SET-ABI)|"Sequential Neuropsychological Treatment. In the SET-ABI intervention, the stimulation of cognitive functions will be provided following a sequential order, identical for each child and for each session in each setting (neuropsychological treatment, speech therapy treatment and psychoeducational treatment). Each session will have a duration of 45 min.~Specifically, the first three weeks (weeks 1-3) of treatment will target attention; in weeks 4-6, the domain of visual-spatial and visual-constructional abilities will be addressed; in weeks 7-9, memory will be the target domain; in weeks 10-12, executive functions and socio-emotional skills will be addressed."
57743500|NCT06665386|PROCEDURE|hypothermia|"Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL"
57769660|NCT02626221|OTHER|Non Interventional Study|Non Interventional Study
57769661|NCT03075956|DRUG|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
58447680|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
58447681|NCT04112303|DRUG|SOF/VEL|Tablets administered orally once daily
57769662|NCT03075956|DRUG|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
57769663|NCT03075956|DRUG|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
58117852|NCT00565981|DRUG|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
58313268|NCT05031767|OTHER|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
58313269|NCT05031767|OTHER|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
58313270|NCT05031767|OTHER|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
58313271|NCT00003723|DRUG|gemcitabine hydrochloride|Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
58313272|NCT04424602|DRUG|cyclo phosphamide|500mg vial
58313273|NCT04424602|DRUG|mycophenolate|500mg film-coated tablets.
58313274|NCT02908334|DRUG|Sertraline|400 mg/day sertraline
58313275|NCT03998072|OTHER|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
58313276|NCT05385406|DIAGNOSTIC_TEST|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
58313277|NCT05385406|DIAGNOSTIC_TEST|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter \> 5mm of acetowhite lesion)."
58313278|NCT05684770|OTHER|4G tablet|Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
58313279|NCT03727282|PROCEDURE|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
58447682|NCT06725654|OTHER|Diagnostic Procedures|To evaluation the oral and dental health of orphaned children, DMFT, deft, GI, PI and CPITN indices were used to assess dental caries experience, gingival inflammation, the amount of plaque on the tooth surface and periodontal status, respectively.
58447683|NCT03121365|BEHAVIORAL|Digital/E-Book Arm|Promotion of early reader digital e-book reading
57743501|NCT06733077|DEVICE|gait with cueing wearable device and neuro-ocular performance|"Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home."
57743502|NCT06733428|DEVICE|Pachymeter|Measure the thickness of the cornea
57743503|NCT06506435|BEHAVIORAL|Two Dimensional (2D) Informational Video|A 30-minute informational video. The two dimensional (2D) video provides information about the radiotherapy process. Participants will receive this one-time intervention in-person, prior to treatment.
57743504|NCT06506435|BEHAVIORAL|First-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a first-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
57743505|NCT06506435|BEHAVIORAL|Third-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a third-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
58117853|NCT06036758|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14 Test|Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
58117854|NCT02539030|PROCEDURE|Microfracture|simple microfracture
57743506|NCT06621238|BEHAVIORAL|Music|Listen to Music
57743507|NCT00449176|DRUG|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
57743508|NCT00449176|DRUG|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
57743509|NCT00449176|DRUG|placebo|matching placebo twice daily for 15 weeks
57743510|NCT02352038|DEVICE|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
57743511|NCT02352038|OTHER|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
57743512|NCT06663722|BIOLOGICAL|Axatilimab|Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.
57743513|NCT06663722|PROCEDURE|Extracorporeal Photopheresis|"Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7.~Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7.~After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months."
57743514|NCT06731946|DEVICE|Flow diverting|Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
57743515|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
57743516|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
57743517|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
57743518|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
58447684|NCT03121365|BEHAVIORAL|Standard/Board Book Arm|Promotion of early reader board book reading
57743519|NCT05911503|DRUG|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
57743520|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
58117855|NCT02539030|DEVICE|CartiFill|add collagen when doing microfracture
58117856|NCT00093639|DRUG|everolimus|
57957872|NCT05144607|OTHER|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
57957873|NCT06162910|DIAGNOSTIC_TEST|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
58117857|NCT00093639|DRUG|imatinib mesylate|
58117858|NCT01396044|OTHER|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
58313280|NCT03727282|PROCEDURE|adjust dobutamine according to the attending physician|adjust dobutamine dose
58447685|NCT05114408|OTHER|4 week trimodal prehabilitation course|"trimodal prehabilitation in mixed: stationary and at-home structure"
58447686|NCT06530199|PROCEDURE|Enamel matrix derivative|connective tissue graft and Enamel matrix derivative in the defect area
57957874|NCT06162910|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
57957875|NCT03920670|DEVICE|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
58117859|NCT01396044|OTHER|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
58117860|NCT03587181|PROCEDURE|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
58117861|NCT01021995|DRUG|echinacea|drops, 0.9 ml, tid for 4 months
58117862|NCT01021995|DRUG|placebo|drops, 0.9 ml tid for 4 months
58117863|NCT00004576|DRUG|LY300164|
58117864|NCT05017233|DEVICE|Spectral CT|Using Spectral CT to scan Breast
57957876|NCT03920670|DEVICE|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
57957877|NCT01103674|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
57957878|NCT05934500|DRUG|Cannabidiol Oil|Subjects will self administer CBD sublingually
58117865|NCT05635825|OTHER|Observational Survey|Collection of a 4-day food record
58117866|NCT05877820|BIOLOGICAL|Tislelizumab|Intravenous infusion
58117867|NCT05877820|DRUG|Lenvatinib|Oral tablet
58117868|NCT00106028|DRUG|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
58117869|NCT00106028|DRUG|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
58117870|NCT05477979|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
58117871|NCT06399770|DEVICE|Muscle ultrasound|Role of muscle ultrasound in LGMD
58117872|NCT04829695|DRUG|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
58117873|NCT04829695|DRUG|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
58117874|NCT04431986|OTHER|No intervention: secondary use of a database|Statistical analyses
58117875|NCT00969332|DRUG|Omegaven|0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
58117876|NCT05763433|OTHER|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
58117877|NCT03058510|PROCEDURE|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
58117878|NCT03588390|DRUG|BI 1323495|Low strength tablet
57957879|NCT06258070|OTHER|Abobotulinumtoxin A injection for bruxism|Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
58117879|NCT03588390|DRUG|BI 1323495|Middle strength tablet
58117880|NCT03588390|DRUG|BI 1323495|High strength tablet
58117881|NCT03588390|DRUG|Placebo|Placebo to low strength tablet
58117882|NCT03588390|DRUG|Placebo|Placebo to middle strength tablet
58117883|NCT03588390|DRUG|Placebo|Placebo to high strength tablet
58117884|NCT02566135|DEVICE|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
58117885|NCT02566135|DEVICE|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
58117886|NCT01896297|DRUG|Pradaxa, dabigatran etexilate|75mg BID by oral
58117887|NCT01666886|DEVICE|Mandibular Advancement Device (MAD)|
58117888|NCT06321081|DRUG|irinotecan, cetuximab, envafolimab|rechallenge treatment
58117889|NCT02517190|OTHER|Parabolic flight|
58117890|NCT02517190|OTHER|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
58117891|NCT02517190|OTHER|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
58117892|NCT02517190|OTHER|cellular energy metabolism measurements|purines, lactate
58117893|NCT05653713|DRUG|CSL324|Single intravenous (IV) dose of CSL324
58117894|NCT05653713|DRUG|Placebo|IV dose of 0.9% saline
57743521|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
58117895|NCT01686178|BEHAVIORAL|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
58117896|NCT03338465|DEVICE|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
58117897|NCT01861327|DRUG|CO2|carbon dioxide (CO2) as arterial contrast media
58313281|NCT04562376|OTHER|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
58313282|NCT04562376|OTHER|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
58313283|NCT00293592|DRUG|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
58313284|NCT05784675|DEVICE|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
58313285|NCT00348257|DEVICE|Hair removal by laser/IPL device|
58313286|NCT04698434|DRUG|Esketamine|each group was given a single intravenous dose of the corresponding esketamine.
58313287|NCT01082471|DRUG|Morphine 6-glucuronide|
58458572|NCT06074848|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
57743522|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
57743523|NCT06333587|PROCEDURE|image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
57743524|NCT03204253|DRUG|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
57957880|NCT05595044|DRUG|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
57957881|NCT05595044|OTHER|Habilitation|Habilitation
57957882|NCT04513431|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
57957883|NCT03594188|PROCEDURE|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
57957884|NCT00935168|DRUG|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
57957885|NCT00935168|DRUG|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
57957886|NCT05470907|DEVICE|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
57957887|NCT06241040|OTHER|Aerobic Exercises with core Muscle strengthening|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
57957888|NCT06241040|OTHER|Aerobic Exercise without Core Muscle Strengthening|Aerobic Exercise without Core Muscle Strengthening
57957889|NCT03668483|OTHER|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
57957890|NCT00767377|DRUG|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
57957891|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
57957892|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
58117898|NCT01861327|DRUG|Iodine contrast media|Iodine as arterial contrast media
58117899|NCT00132509|DRUG|DFIL|Alteplase : 0.8mg/kg over 90 minutes
58117900|NCT00132509|DRUG|NINDS|Alteplase : 0.9mg/kg over 60 minutes
58313288|NCT01082471|DRUG|Morphine|
58313289|NCT06551857|OTHER|Chemotherapy, chemoradiation, radiation therapy|Cancer treatment
58313290|NCT06208397|DIAGNOSTIC_TEST|Magnetic Resonance Elastography and routine MRI|Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.
58313291|NCT00187551|OTHER|Interruption of enfuvirtide|treatment interruption
58313292|NCT00187551|OTHER|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
58313293|NCT05604417|DRUG|TAZEMETOSTAT|Dosage and treatment timings per protocol
58313294|NCT05604417|DRUG|Zandelisib|Dosage and treatment timings per protocol
58313295|NCT02937441|OTHER|Ultrasonic Measurement|"How we measure;~1. First measurement shall be taken in 4 hours.~2. Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~3. Third measurement shall be taken after fluid treatment.~4. Fourth measurement shall be taken at patients polyclinic control."
58313296|NCT02255747|DRUG|Lactulose|
58313297|NCT03173339|PROCEDURE|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
58447687|NCT05922189|OTHER|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
58447688|NCT05922189|OTHER|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
57743525|NCT03204253|DRUG|rFSH alone|32 women who were stimulated with recombinant FSH alone
57743526|NCT03155997|DRUG|Abemaciclib|Administered orally.
57743527|NCT03155997|DRUG|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
57743528|NCT03581981|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)
57743529|NCT03581981|BEHAVIORAL|Treatment as Usual|Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
57743530|NCT02285439|DRUG|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
57743531|NCT06682234|DRUG|obeldesivir|Tablets administered orally
57743532|NCT06508281|OTHER|experimental group|. Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want
57743533|NCT04205838|BIOLOGICAL|Anakinra|Given SC
58447689|NCT00783614|DRUG|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
57743534|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
57743535|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
57743536|NCT04205838|DRUG|Fludarabine|Given via infusion
57743537|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
57743538|NCT02351804|DRUG|Ropivacaine + dexamethasone|Adductor canal block, single bolus
57743539|NCT02351804|DRUG|Ropivacaine + placebo|Adductor canal block, single bolus
57743540|NCT06733402|DRUG|Trifarotene Cream 0.005%|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
57743541|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
57743542|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
57743543|NCT06733402|DRUG|Placebo|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
57743544|NCT06229860|OTHER|Interview|In-person interview with the study coordinator to complete study questionnaire.
57743545|NCT00313820|DRUG|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
58313298|NCT03173339|DRUG|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
58313299|NCT03173339|DRUG|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
57769664|NCT03075956|DRUG|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
57769665|NCT01274065|GENETIC|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
58313300|NCT03173339|DRUG|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
58313301|NCT03173339|DRUG|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
58117901|NCT06304870|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
58117902|NCT06304870|DRUG|Lidocaine|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
58313302|NCT00737048|DRUG|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
58447690|NCT00783614|DRUG|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
57743546|NCT00313820|DRUG|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
57743547|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
57743548|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
57743549|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
57957893|NCT03798821|DIETARY_SUPPLEMENT|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
57957894|NCT00303251|DRUG|TKI258|
57957895|NCT02415712|DRUG|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
57957896|NCT00944164|BEHAVIORAL|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
57957897|NCT00944164|BEHAVIORAL|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
57957898|NCT05186207|OTHER|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
57957899|NCT05986526|PROCEDURE|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
57957900|NCT05986526|PROCEDURE|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
57957901|NCT04800536|OTHER|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
57957902|NCT04800536|OTHER|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
57957903|NCT02851004|DRUG|Napabucasin|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
57957904|NCT02851004|DRUG|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
57957905|NCT03155594|DEVICE|Freestyle Libre|Continuous glucose monitoring patch
57957906|NCT01602692|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
57743550|NCT04359472|DEVICE|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
57769666|NCT00004585|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
57957907|NCT01602692|DRUG|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
57957908|NCT05294744|DRUG|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
58313303|NCT00737048|DRUG|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
58313304|NCT00737048|DRUG|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
58447691|NCT00718510|DRUG|L-Arginine|3 grams, twice daily, oral administration
57769667|NCT00004585|DRUG|Lamivudine/Zidovudine|
58117903|NCT06304870|PROCEDURE|Injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process.
58117904|NCT03271528|DRUG|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
57957909|NCT00042861|DRUG|7-hydroxystaurosporine|
57957910|NCT00042861|DRUG|fluorouracil|
58117905|NCT03271528|DRUG|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
58117906|NCT01188733|DRUG|Long acting octreotide 10mg|Comparison of different doses
57743551|NCT06482359|BIOLOGICAL|coformulated CIC Vaccine|SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)
57743552|NCT06482359|BIOLOGICAL|Fluzone HD trivalent|60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
57743553|NCT06717295|DIAGNOSTIC_TEST|DiNanoQ: A multi-cancer early detection (MCED) blood test|"Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer."
57957911|NCT00042861|DRUG|leucovorin calcium|
57957912|NCT00003460|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
57957913|NCT06194591|DEVICE|NephrospecTM, low-intensity extracorporal shockwave therapy device|"Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter."
57957914|NCT06194591|DEVICE|Sham-Device|The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
57957915|NCT00272974|BEHAVIORAL|Clinic-based counseling|
57957916|NCT01479543|OTHER|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
57957917|NCT01479543|OTHER|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
57957918|NCT01479543|OTHER|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
57957919|NCT01479543|OTHER|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
57957920|NCT01479543|OTHER|Placebo|Placebo capsule for 28 days.
57957921|NCT00127907|DRUG|epinephrine (1 mg/1 mL)|
57957922|NCT00127907|DRUG|arginine-vasopressin (40 UI/2 mL)|
57957923|NCT03919708|DEVICE|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
57957924|NCT01017393|DRUG|Ketamine|
57957925|NCT01017393|DRUG|ketamine free|
58117907|NCT01188733|DRUG|Long acting Octreotide 30mg|Comparison of drug doses
57957926|NCT01347034|PROCEDURE|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
57957927|NCT01347034|BIOLOGICAL|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
57957928|NCT01451710|DRUG|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
57957929|NCT04943705|DEVICE|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
57957930|NCT01182428|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
58117908|NCT01188733|DRUG|Saline|Comparison of drug doses
57769668|NCT00004585|DRUG|Abacavir sulfate|
58117909|NCT05785455|OTHER|COGMO Intervention|Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy
58117910|NCT05785455|OTHER|Usual Care|Usual Primary Care health education and treatment for patients with chronic neck pain
58117911|NCT02617108|DEVICE|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
58117912|NCT02302573|DRUG|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
58313305|NCT00737048|DRUG|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
58313306|NCT04156659|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
58313307|NCT05530005|OTHER|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
58447692|NCT05149534|BEHAVIORAL|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
58447693|NCT05149534|DEVICE|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
58447694|NCT00488540|DRUG|Paracetamol|Suppository
58447695|NCT00488540|DRUG|Placebos|Suppository
57743554|NCT06717295|OTHER|DiNanoTrack: Therapeutic Response Monitoring Blood Test|"Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance."
57743555|NCT01130948|OTHER|altitude exposure|exposure to 490m, 1700m and 2590m
57743556|NCT01750073|DRUG|Cyclophosphamide|Given IV
57743557|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
57957931|NCT01182428|DEVICE|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
57957932|NCT02465073|DEVICE|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
57957933|NCT02465073|DEVICE|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
57957934|NCT02465073|DEVICE|Standard of Care Group|Subjects will receive Standard of Care only.
57957935|NCT04103437|DIAGNOSTIC_TEST|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
57957936|NCT04103437|DIAGNOSTIC_TEST|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
57957937|NCT04103437|OTHER|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
57957938|NCT03597048|BEHAVIORAL|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
57957939|NCT03597048|BEHAVIORAL|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
57957940|NCT03597048|BEHAVIORAL|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
57957941|NCT00084123|BEHAVIORAL|Healing Touch Therapy|
58447696|NCT05940701|COMBINATION_PRODUCT|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
57743558|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
57743559|NCT01750073|DRUG|Paclitaxel|Given IV
57743560|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
58313308|NCT03733964|PROCEDURE|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
58447697|NCT05940701|OTHER|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
58447698|NCT05309902|DRUG|Soticlestat|Soticlestat tablet.
58447699|NCT05309902|DRUG|Placebo|Soticlestat placebo-matching tablet.
58447700|NCT05309902|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
58447701|NCT05309902|DRUG|Placebo|Moxifloxacin placebo-matching capsule.
58447702|NCT05547126|DEVICE|Transcranial direct current stimulation|"It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy."
57769669|NCT00004585|DRUG|Efavirenz|
57957942|NCT00084123|BEHAVIORAL|Relaxation Therapy|
58117913|NCT05923164|DIAGNOSTIC_TEST|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
57743561|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
57743562|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
58117914|NCT05923164|DIAGNOSTIC_TEST|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
57957943|NCT00084123|BEHAVIORAL|Standard Care|Standard Care
58117915|NCT06154382|DRUG|Eltroxin administration|eltroxin administration
58117916|NCT05781698|DRUG|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
58117917|NCT05781698|DRUG|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
58117918|NCT05921903|BIOLOGICAL|RSVPreF3 OA Investigational Vaccine|The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).
58117919|NCT04820842|DRUG|TAK-994|TAK-994 tablets.
58313309|NCT03733964|PROCEDURE|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
57743563|NCT00743366|DRUG|Marijuana|0,6.2% THC
57743564|NCT00743366|DRUG|Quetiapine|200 mg/day
57743565|NCT00743366|DRUG|Placebo oral capsule|
57957944|NCT00185978|BEHAVIORAL|diet, physical activity, reduced sedentary behavior|
57957945|NCT05522439|DRUG|SHR-1703|SHR-1703 will be administered by SC injection.
57957946|NCT05522439|DRUG|SHR-1703 Placebo|Matching Placebo will be administered by the SC route.
57957947|NCT00187421|PROCEDURE|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
57957948|NCT05133635|DRUG|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
57957949|NCT05133635|DRUG|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
57957950|NCT03872986|DEVICE|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
57957951|NCT03872986|DEVICE|Giomer|Beautifil II dental restorative material
57957952|NCT03872986|DEVICE|GIC|Equia forte dental restorative material
58117920|NCT04820842|DRUG|Placebo|Placebo-matching tablets.
58117921|NCT01890707|PROCEDURE|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
58117922|NCT01890707|PROCEDURE|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
58117923|NCT05363124|OTHER|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
58313310|NCT03733964|PROCEDURE|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
58313311|NCT03733964|PROCEDURE|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
58447703|NCT04236674|DEVICE|Buzzy thermomechanical device|Buzzy thermomechanical device placed near intervention site.
57743566|NCT02503748|OTHER|Online tutorial|website informing about treatment options in localized prostate cancer
57743567|NCT06733883|OTHER|psychotherapy|Music therapy
57743568|NCT05830955|OTHER|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
57743569|NCT05830955|OTHER|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
57743570|NCT05830955|OTHER|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
57743571|NCT06359665|DRUG|Curcumin|500 mg capsule twice daily
57743572|NCT06359665|DRUG|Placebo|capsule twice daily
57743573|NCT03101748|DRUG|Cyclophosphamide|Given IV
57743574|NCT03101748|DRUG|Doxorubicin|Given IV
57743575|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
57743576|NCT03101748|DRUG|Neratinib|Given PO
57743577|NCT03101748|DRUG|Paclitaxel|Given IV
57743578|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
57743579|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
57957953|NCT03578120|BIOLOGICAL|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
58313312|NCT02014623|OTHER|Grass pollen sublingual immunotherapy tablet|
58117924|NCT05363124|OTHER|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
58117925|NCT03317197|DRUG|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
58117926|NCT03317197|DRUG|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
58117927|NCT03317197|DRUG|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
58117928|NCT03317197|DRUG|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
58117929|NCT02506790|DRUG|metformin|
58117930|NCT02506790|DRUG|Melatonin|
58117931|NCT02506790|DRUG|Toremifene|
58117932|NCT06194097|PROCEDURE|adenoidectomy versus endoscopic sinus surgery with adenoidectomy|adenoidectomy versus endoscopic sinus surgery
58117933|NCT00389506|BIOLOGICAL|LMB-2 immunotoxin|
58117934|NCT00389506|DRUG|cyclophosphamide|
58117935|NCT00389506|DRUG|fludarabine phosphate|
58117936|NCT00389506|OTHER|pharmacological study|
58117937|NCT01169090|DRUG|SK-0403|SK-0403
58117938|NCT01169090|DRUG|Placebo|Placebo
58117939|NCT01169090|DRUG|Sitagliptin|Sitagliptin
58117940|NCT02171936|OTHER|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
58117941|NCT05964647|DRUG|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
58117942|NCT05964647|DRUG|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
58117943|NCT05964647|DRUG|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
58117944|NCT05964647|DRUG|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
58117945|NCT05964647|DRUG|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
58447704|NCT04236674|BEHAVIORAL|Music Selection|Patient specified procedural music
57743580|NCT02767258|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
58117946|NCT00729235|DEVICE|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
58117947|NCT00729235|DEVICE|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
58117948|NCT04023331|DRUG|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
58117949|NCT04023331|DRUG|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
57743581|NCT02767258|DEVICE|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
58117950|NCT00036413|DRUG|TCH346|
58117951|NCT04744844|PROCEDURE|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
58117952|NCT03246542|DIAGNOSTIC_TEST|shistocytes percentage|
58117953|NCT03957733|DRUG|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
58117954|NCT03475797|DEVICE|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
58117955|NCT03475797|OTHER|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
58117956|NCT06152913|BEHAVIORAL|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
58117957|NCT00268320|DEVICE|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
58117958|NCT01014390|DEVICE|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
58117959|NCT05555459|PROCEDURE|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
58117960|NCT05287659|DIETARY_SUPPLEMENT|meal replacements or supplementation with leucine|meal replacements or animal protein or supplementation with leucine
58117961|NCT02402868|DRUG|Ketamine and saline|Ketamine intravenous and intranasal
58313313|NCT02014623|DRUG|Control|
58313314|NCT00522665|DRUG|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
58313315|NCT00522665|BIOLOGICAL|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
58447705|NCT03348280|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
58447706|NCT06543888|BEHAVIORAL|passive exoskeleton- assisted gait training programs|Participants will wear an exoskeleton during the training. Each 30-minute Passive exoskeleton-assisted gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living
58117962|NCT01508273|BEHAVIORAL|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
58117963|NCT01508273|BEHAVIORAL|Website|Website access given that allows participant to track exercise behavior and help to set goals.
58117964|NCT01508273|BEHAVIORAL|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
58117965|NCT01508273|BEHAVIORAL|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
58117966|NCT01508273|BEHAVIORAL|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
58117967|NCT04558216|DRUG|Vonoprazan|20 mg tablets administered orally
58117968|NCT04558216|DRUG|Rifampin|600 mg (Two 300 mg capsules)
58117969|NCT00636831|DRUG|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
58117970|NCT04951128|DRUG|Tranexamic acid injection|Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
58117971|NCT04951128|OTHER|Local anesthetic control|Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).
58117972|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
58117973|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
58117974|NCT01965561|DEVICE|CRoC|Use of Combat Ready Clamp (CRoC)
58117975|NCT01965561|DEVICE|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
58117976|NCT01965561|DEVICE|JETT|Use of Junctional Emergency Treatment Tool (JETT)
58313316|NCT00522665|BIOLOGICAL|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
58447707|NCT06543888|BEHAVIORAL|Conventional gait training|Each 30-minute conventional gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living.
57743582|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
57743583|NCT05620823|DRUG|Placebo|Oral; Tablet
58117977|NCT01965561|DEVICE|SJT|Use of SAM Junctional Tourniquet (SJT)
58313317|NCT03184246|DEVICE|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
58447708|NCT04684069|DEVICE|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
57743584|NCT06733324|BEHAVIORAL|SCERTS (Social Communication, Emotional Regulation, Transactional Support)|"The SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention is a comprehensive, multidisciplinary approach specifically tailored to address the unique needs of children with Autism Spectrum Disorder (ASD) aged 3-6 years. Unlike traditional behavioral therapies such as Applied Behavior Analysis (ABA), SCERTS emphasizes a developmental framework, focusing on enhancing social communication, emotional regulation, and environmental support. It incorporates family involvement and integrates strategies into naturalistic settings, ensuring skill generalization across home, school, and community environments.~This intervention is distinguished by its individualized goals based on each child's developmental profile and its emphasis on fostering meaningful interactions rather than relying on compliance-based methods. SCERTS also incorporates transactional supports, such as modifying the physical and social environment to promote engagement and reduce stress, w"
57743585|NCT06733324|BEHAVIORAL|Behavioral Treatment, Speech Therapy|The control group will be the treatment as usual group receiving conventional behavior therapy and speech therapy
57743586|NCT00765674|DRUG|Aliskiren|150 and 300 mg tablets
57743587|NCT00765674|DRUG|Amlodipine|5 and 10 mg capsules
58117978|NCT05503849|BEHAVIORAL|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
58117979|NCT05635045|DRUG|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
58117980|NCT05436821|DEVICE|Auricular vagus nerve stimulation|Autonomic nerve system regulation
58117981|NCT05436821|DEVICE|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
58117982|NCT01748890|DEVICE|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
58117983|NCT03887689|BEHAVIORAL|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
58117984|NCT02729155|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
58117985|NCT02729155|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
58117986|NCT02729155|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
58447709|NCT04684069|DEVICE|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
58117987|NCT02729155|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
58117988|NCT00244920|DRUG|bicalutamide|
58117989|NCT00244920|DRUG|leuprolide acetate|
58447710|NCT01757106|DRUG|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
58447711|NCT01757106|DRUG|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
58117990|NCT00244920|DRUG|squalamine lactate|
58117991|NCT00244920|PROCEDURE|adjuvant therapy|
58117992|NCT00244920|PROCEDURE|antiandrogen therapy|
58117993|NCT00244920|PROCEDURE|antiangiogenesis therapy|
58313318|NCT03184246|DEVICE|Direct laryngoscopy|direct laryngoscopy will be used for intubation
58447712|NCT00550017|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
57743588|NCT00765674|DRUG|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
57743589|NCT00765674|DRUG|Placebo|tablet
57743590|NCT00765674|DRUG|Placebo|capsules
58447713|NCT04448977|DRUG|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
58447714|NCT05924347|DIAGNOSTIC_TEST|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
58447715|NCT05924347|DIAGNOSTIC_TEST|Scolioscan|3D ultrasound of the spine
58447716|NCT05924347|DIAGNOSTIC_TEST|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
58313319|NCT02600260|DRUG|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
58447717|NCT03203252|OTHER|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
58447718|NCT03203252|OTHER|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
58447719|NCT03203252|OTHER|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
58447720|NCT03232346|DRUG|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
58447721|NCT03232346|DRUG|Buprenorphine|5-week buprenorphine taper
58447722|NCT06100679|BEHAVIORAL|Responsible Engaged and Loving (REAL) Fathers Initiative|REAL Fathers is a multilevel norms-shifting intervention among: young fathers (ages 16-25 whose oldest child is under the age of 3); couple dyads (fathers and wives); mentoring dyads and groups; and communities. Respected men in the community are identified by participating young fathers, their partners and community members to become mentors. Mentors participate in a training and mentor young fathers through home and group sessions on conflict resolution, non-violent discipline, family planning, and couple communication. Mentoring is supplemented with a monthly poster campaign designed to reinforce messages from the home and group mentoring sessions and a community celebration. REAL Fathers aims to build positive partnerships and parenting practices among young fathers to: 1) reduce incidence of intimate partner violence; 2) reduce harsh physical punishment of children; 3) improve early childhood development; 4) decrease unmet need for family planning.
58447723|NCT05038865|OTHER|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
57743591|NCT04593433|OTHER|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
57743592|NCT05708612|PROCEDURE|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
57743593|NCT06733766|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radiofrequency ablation, laser ablation
57743594|NCT04473885|OTHER|Perturbation-based balance training|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
57743595|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
57743596|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
57743597|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
57743598|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
57743599|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
58313320|NCT02600260|OTHER|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
58313321|NCT01122173|DEVICE|Ablation|Atrial fibrillation ablation procedure
58447724|NCT04483726|PROCEDURE|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
58447725|NCT04483726|PROCEDURE|open distal pancreatectomy|open distal pancreatectomy
58447726|NCT03400826|DRUG|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
58447727|NCT03400826|DRUG|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
58313322|NCT05055765|PROCEDURE|Microneedling|MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
57743600|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
57743601|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
58117994|NCT00244920|PROCEDURE|conventional surgery|
58117995|NCT00244920|PROCEDURE|neoadjuvant therapy|
58313323|NCT05055765|PROCEDURE|injectable- platelet rich fibrin|I-PRF will be prepared according to Choukroun PRF method.
58117996|NCT00244920|PROCEDURE|releasing hormone agonist therapy|
58447728|NCT03255317|BEHAVIORAL|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
58447729|NCT03255317|BEHAVIORAL|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
58447730|NCT05065359|DRUG|Rodatristat Ethyl 300 mg BID|Tablets, oral, 300 mg, BID 14 days
58447731|NCT05065359|DRUG|Rodatristat Ethyl 600 mg BID|Tablets, oral, 600 mg, BID 14 days
58447732|NCT05065359|DRUG|Placebo|Tablets, oral, 0 mg, BID for 14 days
58447733|NCT01504022|OTHER|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
58447734|NCT04427865|DRUG|prophylactic lactoferrin daily|200 mg oral lactoferrin daily
58447735|NCT04990258|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.
58447736|NCT03776799|DEVICE|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
57957954|NCT02457871|BEHAVIORAL|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
57957955|NCT04482335|OTHER|No intervention|No intervention
57957956|NCT03224897|DEVICE|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
57957957|NCT03224897|DEVICE|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
57957958|NCT03224897|DEVICE|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
57957959|NCT06409676|PROCEDURE|ERAS protocols|Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
58117997|NCT01743365|DRUG|Cisplatin-5FU-Afatinib|
58117998|NCT03908255|DRUG|Branch Chain Amino Acid|Nutritional supplementation
58117999|NCT03908255|OTHER|maltodextrin|Placebo
58118000|NCT01566799|DRUG|Metformin|metformin 500 mg/day po for 24 weeks.
58118001|NCT03265899|DRUG|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
58118002|NCT03265899|DRUG|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
58118003|NCT04658875|DIETARY_SUPPLEMENT|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
58118004|NCT04658875|OTHER|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
58118005|NCT04658875|OTHER|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
58447737|NCT03776799|DEVICE|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
58447738|NCT04363879|PROCEDURE|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
58447739|NCT04363879|PROCEDURE|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
58447740|NCT05897606|COMBINATION_PRODUCT|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
58447741|NCT05897606|COMBINATION_PRODUCT|Placebo|Placebo
58447742|NCT04947241|DRUG|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
58447743|NCT04132310|OTHER|N/A This is an observational study.|This is an observational study.
58447744|NCT00191308|DRUG|pemetrexed|500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
58447745|NCT00191308|DRUG|cisplatin|75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
58447746|NCT00191308|PROCEDURE|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
58447747|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
58118006|NCT04658875|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
58118007|NCT04658875|OTHER|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
58118008|NCT00613574|DRUG|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
58118009|NCT00279942|DIETARY_SUPPLEMENT|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
57957960|NCT03664999|DIAGNOSTIC_TEST|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
58118010|NCT00279942|OTHER|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
58118011|NCT06354985|DRUG|Modafinil 200mg|Modafinil 200mg daily for 8 weeks.
58118012|NCT06354985|DRUG|Placebo|Placebo daily for 8 weeks.
58118013|NCT06354985|BEHAVIORAL|Exercise Program One|Exercise Program One three times per week for 8 weeks.
57743602|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
57743603|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
58118014|NCT06354985|BEHAVIORAL|Exercise Program Two|Exercise Program Two three times per week for 8 weeks.
58118015|NCT02010723|PROCEDURE|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
57957961|NCT04648384|DIETARY_SUPPLEMENT|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
57957962|NCT04648384|DIETARY_SUPPLEMENT|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
58118016|NCT02010723|DRUG|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
58118017|NCT03517852|DEVICE|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
58118018|NCT01289509|DRUG|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
58118019|NCT01289509|DRUG|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
58118020|NCT00859625|PROCEDURE|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
58118021|NCT00938652|DRUG|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
58118022|NCT00938652|DRUG|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
57957963|NCT04648384|OTHER|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
58118023|NCT02472678|OTHER|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
58118024|NCT02472678|OTHER|Standard care|The control group will receive standard care.
58118025|NCT00006291|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58118026|NCT00006291|DRUG|Aldesleukin|
58118027|NCT02714686|BEHAVIORAL|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
58313324|NCT00941551|DRUG|levothyroxine|levothyroxine 75-125 ug/day
57743604|NCT00225654|DEVICE|coronary stent|
57743605|NCT00233922|DEVICE|Osteosheet(r)|
57743606|NCT02385305|DEVICE|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
57743607|NCT01982357|DEVICE|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
58118028|NCT03724110|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
58118029|NCT04096391|DEVICE|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
58313325|NCT00941551|DRUG|no levothyroxine|observation only without prophylactic levothyroxine
58313326|NCT00207740|DRUG|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
57743608|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
57957964|NCT02095535|DRUG|Chlorhexidine gluconate|antiseptic
58118030|NCT04096391|DRUG|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
58118031|NCT00004584|DRUG|Atazanavir|
58313327|NCT00207740|DRUG|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
57743609|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
57743610|NCT06005766|BEHAVIORAL|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
58313328|NCT06430489|DRUG|Nitrous oxide|inhaled nitrous oxide (1 hour at 50% concentration)
57743611|NCT06005766|OTHER|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
57743612|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (I)|"1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g"
57957965|NCT01596998|DRUG|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
57957966|NCT01596998|DRUG|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
57957967|NCT01596998|OTHER|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
57957968|NCT01596998|OTHER|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
57957969|NCT02573155|DRUG|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
57957970|NCT02573155|DRUG|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
57957971|NCT02573155|DRUG|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
57957972|NCT02573155|DRUG|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
57957973|NCT02573155|DRUG|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
57957974|NCT02573155|DRUG|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
58313329|NCT06430489|DRUG|Medical air|inhaled medical air (1 hour)
58313330|NCT04611815|PROCEDURE|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
58313331|NCT04611815|DIAGNOSTIC_TEST|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
58313332|NCT04611815|DIAGNOSTIC_TEST|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
57957975|NCT02573155|DRUG|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
58118032|NCT00004584|DRUG|Ritonavir|
58118033|NCT00004584|DRUG|Saquinavir|
58118034|NCT06376032|DEVICE|EndeavorOTC®|EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
58118035|NCT02004847|DEVICE|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
58118036|NCT05291845|BIOLOGICAL|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
58118037|NCT05291845|BIOLOGICAL|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
58118038|NCT00855452|PROCEDURE|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
58118039|NCT03801629|DRUG|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
58118040|NCT03801629|DRUG|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
58118041|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
58118042|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
58118043|NCT04895618|DEVICE|Erchonia GVL|Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
58118044|NCT05885230|PROCEDURE|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
58118045|NCT05885230|DRUG|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
58118046|NCT02840656|OTHER|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
58118047|NCT02840656|OTHER|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
58118048|NCT06486363|DRUG|Aspirin combined with clopidogrel|Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
58118049|NCT06486363|DRUG|Aspirin combined with half-dose ticagrelor|Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
58118050|NCT00781755|DRUG|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
58118051|NCT00781755|BEHAVIORAL|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
58313333|NCT02610010|DRUG|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
58447748|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
57743613|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (II)|Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
58313334|NCT02610010|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
58118052|NCT06544525|OTHER|Physical therapy|The intervention will be physical therapy standard of care.
58118053|NCT02447536|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
58118054|NCT02447536|BIOLOGICAL|BCG-Russia-I (Serum Institute of India)|See above
58313335|NCT06069089|RADIATION|Dexa scan|No intervention
58447749|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
58118055|NCT00927121|DEVICE|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
58118056|NCT00545233|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
58118057|NCT00545233|DRUG|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
58118058|NCT00545233|DRUG|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
58118059|NCT02588573|DEVICE|etafilcon A (control)|contact lens
58313336|NCT00248053|DRUG|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
58447750|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
58447751|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
58447752|NCT00298974|DRUG|hydrocodone / acetaminophen extended release|2 tablets twice daily
58447753|NCT00298974|DRUG|Placebo|2 tablets twice daily
57743614|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (III)|"1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g"
58118060|NCT02588573|DEVICE|somofilcon A (test)|contact lens
58118061|NCT02616692|DRUG|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
58118062|NCT04485988|DRUG|Beta blocker|Duration of medication
58118063|NCT05764889|OTHER|wrapped with the Flexible Sleeve Penis Protection Device|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
58118064|NCT05764889|OTHER|wrapped with traditional gauze|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
58118065|NCT02539563|OTHER|peanut shaped birthing ball|peanut ball will be utilized
58118066|NCT03085446|BEHAVIORAL|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
58313337|NCT04225975|DIAGNOSTIC_TEST|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
58313338|NCT04225975|DIAGNOSTIC_TEST|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
58313339|NCT05673122|DEVICE|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
58313340|NCT04011852|DEVICE|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
57743615|NCT04790240|DRUG|Standard of care|remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
57743616|NCT00765388|DEVICE|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
57743617|NCT00765388|DEVICE|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
57743618|NCT02380092|DEVICE|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
57743619|NCT05925127|BIOLOGICAL|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
57743620|NCT05925127|BIOLOGICAL|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
57743621|NCT05925127|BIOLOGICAL|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
57743622|NCT05925127|BIOLOGICAL|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
57743623|NCT05925127|BIOLOGICAL|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
57743624|NCT05925127|BIOLOGICAL|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
57743625|NCT05925127|BIOLOGICAL|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
57957976|NCT02573155|DRUG|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
58447754|NCT06500884|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
58447755|NCT06500884|DRUG|Prophylaxis A|Prophylaxis A will be administered orally.
57957977|NCT02573155|DRUG|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
57957978|NCT02573155|DRUG|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
58118067|NCT03085446|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
58118068|NCT04297852|DIETARY_SUPPLEMENT|Vegan drink|Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
58118069|NCT04297852|DIETARY_SUPPLEMENT|Control|Placebo drink Dose: 500 mL a day
58118070|NCT04383704|OTHER|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
58313341|NCT04632485|DEVICE|Ultrasound imaging|Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.
57957979|NCT02573155|DRUG|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
57957980|NCT04485520|OTHER|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
57957981|NCT04485520|OTHER|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
57957982|NCT04884230|PROCEDURE|Oversewing|Oversewing of the gastric remnant
58118071|NCT04973956|OTHER|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
58118072|NCT04973956|OTHER|Control|No intervention
58118073|NCT01928446|DRUG|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
58118074|NCT01928446|DRUG|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
58118075|NCT01225328|BEHAVIORAL|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
58118076|NCT05954715|OTHER|Ischaemic Preconditioning|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
58118077|NCT05954715|OTHER|Sham|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
58118078|NCT02801058|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
58313342|NCT04632485|DEVICE|Magnetic Resonance Imaging (MRI)|Head and Neck MRI exam with contrast
58447756|NCT06500884|DRUG|Prophylaxis B|Prophylaxis B will be administered orally.
58447757|NCT06500884|DRUG|Prophylaxis C|Prophylaxis C will be administered orally.
57743626|NCT06132880|DRUG|Human Urinary Kallidinogenase|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
57743627|NCT06132880|OTHER|Clinical Routine Treatment|Conventional therapy of acute ischemic stroke after based on Chinese guidelines
57743628|NCT04406493|DIAGNOSTIC_TEST|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
57743629|NCT06582706|DRUG|Placebo Comparator|a readily available inert placebo will be used
57957983|NCT00097760|DRUG|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
57743630|NCT06582706|DRUG|Extended Release Niacin|500 mg
57743631|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
57743632|NCT06710834|DEVICE|Hemoadsorption cartridge|HA 130 cartridge
57743633|NCT06710834|DEVICE|Hemodiafiltration|Postdilutional hemodiafiltration
57743634|NCT03746366|RADIATION|[C-11]|Radiolabel
57743635|NCT03746366|DRUG|Pittsburgh Compound B|Tracer
57743636|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Oral administration
57743637|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Oral administration
57769670|NCT04002219|DIETARY_SUPPLEMENT|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
57769671|NCT02926235|DRUG|Amino Acid|Treatment arm
57769672|NCT02926235|OTHER|Placebo|
57769673|NCT00584701|DRUG|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
57957984|NCT00097760|DRUG|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
57957985|NCT00097760|DRUG|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
57957986|NCT06539923|OTHER|retrieving data|Data will be retrieved retrospectively
57957987|NCT05701332|BIOLOGICAL|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
57957988|NCT04321759|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
57957989|NCT04321759|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
57957990|NCT00590590|DRUG|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
57957991|NCT00590590|DRUG|lidocaine|semi solid, twice weekly for 4 months
57957992|NCT00590590|DRUG|placebo|semi solid, twice weekly for 4 months
57957993|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment|Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
57957994|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention|Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
58118079|NCT05349903|OTHER|Rice flour|Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118080|NCT05349903|OTHER|Alternanoligosaccharide 15|Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118081|NCT05349903|OTHER|Inulin|Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118082|NCT05349903|OTHER|Waxy potato starch|Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118083|NCT05349903|OTHER|Waxy potato starch + epigallocatechin gallate (EGCG)|A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118084|NCT05349903|OTHER|Chickpea flour + epigallocatechin gallate (EGCG)|A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
58118085|NCT03465891|DRUG|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
58447758|NCT05585840|DEVICE|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
58447759|NCT00990743|DRUG|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
58447760|NCT00189839|DRUG|tacrolimus|Immunosuppression
58447761|NCT00203229|DRUG|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
58447762|NCT00203229|DRUG|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
58447763|NCT01658007|DRUG|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
58118086|NCT03465891|RADIATION|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
58118087|NCT05429203|DEVICE|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
58118088|NCT05429203|DEVICE|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
58118089|NCT02347930|OTHER|kidney ultrasound|kidney ultrasound
58118090|NCT02463617|OTHER|magnetic resonance imaging|
58447764|NCT06703034|OTHER|Biological Sampling|"The procedures specifically carried out for the study during a single visit are as follows:~* One nasopharyngeal swab for the baseline measurement of the nasal IFN-I score~* Venous blood sample collection in:~  * One yellow tube (5 mL) for anti-interferon antibody measurement~ * One PAXgene tube (2.5 mL) for the baseline IFN score without stimulation~ * Two green heparin tubes (8 mL) for performing immune-functional tests~ * Two large purple tubes (20 mL) for biological collection (if the patient provides specific consent)~ * A total of 35.5 mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Northern Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota."
57743638|NCT06479070|OTHER|Blood samples|"A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment."
58118091|NCT04466150|DRUG|Ocrelizumab|open label biomarker study
58118092|NCT04580056|PROCEDURE|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
58118093|NCT04137263|OTHER|DOSE formulation|over-the-counter topical
58118094|NCT03276975|DRUG|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
58118095|NCT02919475|DRUG|JTE-051|Active drug tablets containing JTE-051
58118096|NCT02919475|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
58313343|NCT04632485|OTHER|Neurocognitive testing|Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills
58447765|NCT06263894|OTHER|Experimental group|Alexander technique will be applied to the experimental group.
58447766|NCT06206525|OTHER|Initial insulin dosing using the calculator|Participants will receive initial insulin doses by the calculator on hospital admission.
58447767|NCT02196155|DRUG|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
58447768|NCT02196155|DRUG|cortisone|
58118097|NCT05043532|PROCEDURE|2 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
58447769|NCT02196155|DRUG|Saline|
58447770|NCT05177497|DRUG|SHR-1701|SHR-1701 administered by iv
58447771|NCT05801666|OTHER|Acupuncture|Acupuncture 5 points
58447772|NCT02532465|DEVICE|Air-Q|
58447773|NCT02532465|DEVICE|i-gel|
58447774|NCT04726683|PROCEDURE|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
58447775|NCT04726683|PROCEDURE|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
58447776|NCT04726683|PROCEDURE|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
58447777|NCT04726683|PROCEDURE|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
58447778|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
58447779|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
58313344|NCT04632485|DEVICE|Transcranial Doppler (TCD)|Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes
58313345|NCT04632485|DEVICE|Pulse Wave Doppler|Pulse wave Doppler will be used to acquire a Doppler waveform in the right common carotid artery and the right femoral artery
58313346|NCT03889288|DEVICE|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
58313347|NCT04397978|RADIATION|Stereotactic radiotherapy|Local ablative therapy with SRT
58313348|NCT05111717|DRUG|Desflurane|Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
58313349|NCT00255580|DRUG|Smoked cannabis|
58447780|NCT01988675|RADIATION|Whole Brain Irradiation|
58447781|NCT01988675|RADIATION|Partial Brain Irradiation|
58447782|NCT01988675|BEHAVIORAL|Neuropsychological Testing|
58447783|NCT01988675|BEHAVIORAL|Quality of Life Questionnaire|
58447784|NCT01988675|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
58447785|NCT00941408|PROCEDURE|Diagnostic tumor core biopsy|
58447786|NCT04163575|BIOLOGICAL|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
58447787|NCT03754517|DIAGNOSTIC_TEST|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
58447788|NCT04757116|DEVICE|iTind|The iTind is implemented for 5-7 days
58447789|NCT04757116|PROCEDURE|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
58447790|NCT02504489|DRUG|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
58447791|NCT02504489|DRUG|Docetaxel (D)|Docetaxel 75 mg/m2 IV
58447792|NCT03869554|DIAGNOSTIC_TEST|Detection of Fabry disease|Systematic detection of Fabry disease
58447793|NCT00704886|OTHER|video|video of dementia
58447794|NCT05276258|DEVICE|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
58447795|NCT05276258|DRUG|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
58313350|NCT04657913|OTHER|cold water spray application|It will be sprayed into the mouth of patients every hour.
58313351|NCT04657913|OTHER|cold saline spray application|It will be sprayed into the mouth of patients every hour.
58313352|NCT01767337|DEVICE|FLUGEN 101.2 device|
58447796|NCT00128310|DRUG|Vinorelbine|
57743639|NCT01417572|DRUG|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
57743640|NCT03783182|DRUG|Betamethason Sodium Phosphate|Glucocorticoid
57743641|NCT03783182|DRUG|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
57743642|NCT00575575|BEHAVIORAL|cognitive behavior therapy|cognitive behavior therapy once a week
57743643|NCT04224077|DIAGNOSTIC_TEST|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
57743644|NCT05258110|DRUG|midazolam|midazolam
57743645|NCT05258110|DRUG|BI 425809|BI 425809
57743646|NCT03163758|DEVICE|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
57743647|NCT03163758|DEVICE|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
57743648|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
57743649|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
57743650|NCT03154008|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
57743651|NCT06088290|DRUG|Lurbinectedin|Intravenous Infusion
57743652|NCT06088290|DRUG|Doxorubicin|Short intravenous push or bolus (according to label)
57743653|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
57743654|NCT02530489|DRUG|Atezolizumab|Given IV
57743655|NCT02530489|DRUG|Nab-paclitaxel|Given IV
57743656|NCT06571266|DRUG|Risankizumab|• Subcutaneous Injection via prefilled syringe
57743657|NCT05592275|DRUG|LY3540378|Administered SC
57743658|NCT05592275|DRUG|Placebo|Administered SC
57743659|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
57743660|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
57743661|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
57743662|NCT05351801|DRUG|Placebo|Placebo
58313353|NCT03160950|DEVICE|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
58313354|NCT05650502|DRUG|saisonal malaria chimoprevention|Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
58313355|NCT03658525|DEVICE|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
58313356|NCT00478621|BIOLOGICAL|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
57743663|NCT05670899|PROCEDURE|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
58313357|NCT00478621|BIOLOGICAL|Cervarix TM|Intramuscular administration
57743664|NCT06723717|DRUG|Daily infusion of dornase alfa|Daily infusion of dornase alfa at a dose of 125 microg/kg as an intravenous bolus until day 14 after SAH
57743665|NCT06732804|BIOLOGICAL|AVT80|Single subcutaneous injection of AVT80 (108mg)
57743666|NCT06732804|BIOLOGICAL|Geographical region 1 Entyvio|Single subcutaneous injection of Geographical region 1 Entyvio (108mg)
57743667|NCT06732804|BIOLOGICAL|Geographical region 2 Entyvio|Single subcutaneous injection of Geographical region 2 Entyvio (108mg)
57743668|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
57743669|NCT05275257|DEVICE|Use of Uricap Female, a New Urine Collecting Device|The uridome is changed daily by trained staff
57743670|NCT05514353|DRUG|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
57743671|NCT05514353|DRUG|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
57743672|NCT06205667|PROCEDURE|Computer Guided Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
57743673|NCT06205667|PROCEDURE|Conventional Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
57743674|NCT00148967|DEVICE|Implantable Cardioverter Defibrillator|
57743675|NCT05011760|RADIATION|Baseline [C-11]NPA PET Scan|Radiotracer
57743676|NCT05011760|DRUG|d-amphetamine|Oral, 0.5 mg/Kg
57743677|NCT05011760|RADIATION|Post-amphetamine [C-11]NPA PET Scan|Radiotracer
57743678|NCT05534009|OTHER|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
57743679|NCT03859635|DRUG|Liposomal Bupivacaine|20 ml
57743680|NCT03859635|DRUG|Bupivacaine, 0.25%|10 ml
57743681|NCT03859635|DRUG|Bupivacaine, 0.5%|30 ml
57743682|NCT06647550|DRUG|HD-6277 100mg|PO, QD
57743683|NCT06647550|DRUG|HD-6277 50mg|PO, QD
57743684|NCT06647550|DRUG|HD-6277 25mg|PO, QD
57743685|NCT06647550|DRUG|Placebo|PO, QD
57743686|NCT02170740|DRUG|BIBR 1048 MS - low dose|
57743687|NCT02170740|DRUG|BIBR 1048 MS - high dose|
57743688|NCT02170740|DRUG|BIBR 1048 MS + Pantoprazole|
57743689|NCT06733558|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy (ECT) is a medical treatment that uses controlled electrical stimulation to induce a brief, generalized seizure in the brain. This intervention is performed under general anesthesia with muscle relaxants to ensure patient comfort and safety. ECT is typically used to treat severe depression, bipolar disorder, and other mental health conditions when other treatments, such as medication and psychotherapy, have not been effective.
57743690|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
57743691|NCT03372200|DRUG|FYU-981|Oral daily dosing for 14 weeks
57743692|NCT03372200|DRUG|Febuxostat|Oral daily dosing for 14 weeks
57743693|NCT03464968|DRUG|Oxaliplatin,5FU, leucovorin|mFOLFOX
57743694|NCT03464968|DRUG|irinotecan,5FU, leucovorin|mFOLFIRI
57743695|NCT01310387|BEHAVIORAL|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
57743696|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
57743697|NCT02425839|DEVICE|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
57743698|NCT02425839|DEVICE|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
57743699|NCT06626412|DIAGNOSTIC_TEST|Diagnostic Test: 18F-SynVesT-1 PET|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
57743700|NCT06626412|DIAGNOSTIC_TEST|Volumetric MRI|Magnetic resonance imaging of brain volume.
57743701|NCT00328510|DEVICE|GTC frame|
57743702|NCT00328510|DEVICE|Thermoplastic facemask|
58313358|NCT01496742|DRUG|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
57743703|NCT00328510|RADIATION|Stereotactic radiation therapy|
57743704|NCT06429254|OTHER|Experimental group|Life Scale will be administered as pre-tests to the EFT group. After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.
58118098|NCT05043532|PROCEDURE|3 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
58313359|NCT01496742|DRUG|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
58313360|NCT01496742|DRUG|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
58313361|NCT01496742|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
57743705|NCT00778765|DRUG|400 mg Gabapentin Capsules|
57743706|NCT04603352|OTHER|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
57743707|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
58313362|NCT01496742|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
58313363|NCT01496742|DRUG|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
58447797|NCT00128310|DRUG|Gemcitabine|
57743708|NCT03747341|DRUG|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
57743709|NCT03747341|DRUG|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
58118099|NCT02289209|RADIATION|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
58118100|NCT02289209|DRUG|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
58118101|NCT01712412|DRUG|IW-9179|
58447798|NCT03676972|DEVICE|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
58447799|NCT01059734|GENETIC|DNA analysis|
58447800|NCT01059734|GENETIC|RNA analysis|
58447801|NCT01059734|GENETIC|mutation analysis|
58447802|NCT01059734|GENETIC|polymerase chain reaction|
58447803|NCT01059734|GENETIC|polymorphism analysis|
57743710|NCT03747341|DRUG|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
57743711|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
57743712|NCT03747341|DRUG|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
57743713|NCT03747341|DRUG|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
57743714|NCT03930342|BEHAVIORAL|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
58118102|NCT01712412|DRUG|Placebo|
58118103|NCT06081725|BEHAVIORAL|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
58118104|NCT06081725|BEHAVIORAL|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
58313364|NCT04749199|BEHAVIORAL|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
58313365|NCT04749199|BEHAVIORAL|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
58313366|NCT01389778|DRUG|Metformin ER|Metformin ER 1500 mg for 12 weeks
58313367|NCT01389778|DRUG|Metformin|
58313368|NCT04131972|DEVICE|REGENERA|REGENERA breast implant
58313369|NCT05284175|DRUG|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
58313370|NCT03986099|DIAGNOSTIC_TEST|Monitoring virus load|Near point of care
58118105|NCT06081725|BEHAVIORAL|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
58447804|NCT01059734|OTHER|laboratory biomarker analysis|
58447805|NCT01926834|DRUG|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
58447806|NCT01926834|DRUG|placebo|normal saline, 500ml,i.v.,qd, for 7 days
58447807|NCT06276426|OTHER|Soy foods|Soy milk, soy yogurt, tofu, tempeh, soy nuts, edamame, soy protein bar, and soy-based frozen meat substitutes.
58447808|NCT06276426|OTHER|Non-Soy Plant-Based Foods|Pea milk, almond milk yogurt, chickpeas, chickpea chips, lentil chips, non-soy protein bar, and non-soy based frozen meat substitutes.
58447809|NCT05248581|PROCEDURE|Liver transplantation|living donor liver transplantation
58447810|NCT03470480|DEVICE|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
57743715|NCT06716034|OTHER|Personalized Nutrition Plan and Support|The intervention is a virtually-delivered, personalized nutrition plan and support to improve dietary intake of healthy food (fruit, vegetables and whole grains), based on the principles of a Mediterranean-style diet. Components of the intervention include nutrition counselling, menu planning and the provision of groceries, delivered biweekly, face-to-face, by a registered dietitian over 8 weeks, using a virtual platform. The nutrition counselling structure is grounded in evidence-based behaviour change theory for dietary interventions. Youth and parents will co-develop a personalized menu plan. In addition to biweekly nutrition counselling, participants will receive a food pantry basket, and weekly grocery deliveries to support the menu plan.
57743716|NCT02721082|BEHAVIORAL|Opt Out Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
58118106|NCT06081725|BEHAVIORAL|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
58447811|NCT03470480|DEVICE|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
58447812|NCT03470480|BEHAVIORAL|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
58447813|NCT03470480|BEHAVIORAL|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
58447814|NCT03172312|PROCEDURE|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
57743717|NCT02721082|DRUG|Nicotine Replacement Therapy|Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
57743718|NCT02721082|BEHAVIORAL|Opt In Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
58118107|NCT00514293|DRUG|bexarotene|
58118108|NCT00514293|DRUG|capecitabine|
58118109|NCT00514293|DRUG|carboplatin|
58118110|NCT00514293|DRUG|cisplatin|
58118111|NCT00514293|DRUG|docetaxel|
58118112|NCT00514293|DRUG|tretinoin|
58118113|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
58118114|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
58118115|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
58313371|NCT04487548|OTHER|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~1. A brief (\<5 minutes) advice~2. Preoperative smoking cessation video prepared by QuitNow~3. Patients will be provided brochures on smoking cessation~4. A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~5. All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
58313372|NCT03575169|DEVICE|BIS Monitor|Unilateral BIS electrode
58313373|NCT06514859|PROCEDURE|Laparoscopic repair of inguinal hernia|Laparoscopic repair of inguinal hernia
58313374|NCT06514859|PROCEDURE|Open repair of inguinal hernia|Repair of inguinal hernia by open technique-mesh hernioplasty -
58313375|NCT06466239|OTHER|PNF Stretching|PNF was applied to the hamstring muscle, with a 1-day washout period in between.
58313376|NCT06466239|OTHER|Static Stretching|Static stretching was applied to the hamstring muscle, with a 1-day washout period in between.
58313377|NCT03857256|DRUG|CP105F|Natural Health Product
58313378|NCT03857256|DRUG|Placebo|tablet manufactured to mimic the CP105F beta-glucan
58118116|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
58118117|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
58118118|NCT00604656|DRUG|insulin aspart|
58118119|NCT05586971|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
58118120|NCT05586971|DRUG|Allopurinol|Xanthine Oxidase Inhibitor
58313379|NCT01756703|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
58313380|NCT01756703|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
58313381|NCT01756703|DRUG|Placebo|Placebo for 8 weeks
58313382|NCT02305264|DRUG|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
58313383|NCT06552468|DEVICE|AF monitoring by a smartwatch with PPG|The device we used for intervention is a smartwatch (JKwear 1, Chengdu CVhealth Science and Technology Co., Ltd, CN) for collecting watch-recorded-PPG (W-PPG).
58313384|NCT06206486|OTHER|no intervention, observational|This study is observational. No intervention description available.
58313385|NCT01555775|DIETARY_SUPPLEMENT|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
58313386|NCT01555775|DIETARY_SUPPLEMENT|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
58313387|NCT03668210|PROCEDURE|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
58313388|NCT05645991|DIETARY_SUPPLEMENT|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
58118121|NCT05586971|DRUG|Placebo|Matching placebo
57743719|NCT02721082|DRUG|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
57743720|NCT01695564|DEVICE|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
57743721|NCT01695564|DEVICE|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
57743722|NCT04214704|DEVICE|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
57743723|NCT04214704|DEVICE|Conventional lancing device|Conventional lancing device
57743724|NCT06579807|BEHAVIORAL|Exercise training|The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
57743725|NCT03346226|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
57743726|NCT03346226|DRUG|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
57743727|NCT04496180|DEVICE|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
57743728|NCT00668122|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
57743729|NCT00668122|DRUG|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
57743730|NCT05154279|DRUG|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
57743731|NCT04967768|OTHER|Questionnaire about impact of the COVID-19 pandemic on orthopaedic resident training|Answers were collected for the effects of the COVID-19 pandemic on the real-life experiences of orthopaedic residents
57743732|NCT02070055|OTHER|No intervention|
58118122|NCT01625377|DRUG|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
58118123|NCT01625377|DRUG|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
58118124|NCT01625377|DRUG|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
58118125|NCT01625377|DRUG|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
57743733|NCT05962788|DRUG|voclosporin|Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID or 4 capsules (31.6 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
57743734|NCT05624125|OTHER|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
57743735|NCT05624125|OTHER|Placebo|Two 70 ml placebo drinks daily for 4 months.
57743736|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
57743737|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
57743738|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
57743739|NCT02194270|DRUG|Ambroxol hydrochloride - soft pastille|
57743740|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - low dose|
57743741|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - high dose|
57743742|NCT03806270|DRUG|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
57743743|NCT03806270|DRUG|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
57743744|NCT05137132|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
57743745|NCT05137132|DIETARY_SUPPLEMENT|Placebo|MCT oil
57743746|NCT03327987|BIOLOGICAL|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
58118126|NCT01625377|DRUG|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
58118127|NCT01790620|OTHER|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
57957995|NCT05520983|BEHAVIORAL|Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
58118128|NCT01790620|OTHER|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
58447815|NCT02460809|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
58118129|NCT04925206|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
58447816|NCT04030026|DRUG|NAL ER|Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period.
58447817|NCT04030026|DRUG|Placebo|Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
58447818|NCT04914026|OTHER|Biomarker analysis|Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
58447819|NCT02481297|DRUG|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
58447820|NCT02481297|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
58447821|NCT04628780|BIOLOGICAL|PF-07209960|PD-1 targeted IL-15 mutein
58447822|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
58447823|NCT02233634|DRUG|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
58447824|NCT02233634|OTHER|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
58447825|NCT02233634|OTHER|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
58447826|NCT02552030|DEVICE|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
58447827|NCT02552030|DEVICE|iPhone 4s|
58447828|NCT02731495|DIETARY_SUPPLEMENT|EGCG|EGCG (Epigallocatechin -3-gallate)
58118130|NCT02509000|OTHER|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
58118131|NCT03443869|DRUG|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
58447829|NCT02731495|DIETARY_SUPPLEMENT|Placebo (deionized water)|
58447830|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
58447831|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
58447832|NCT06465329|DRUG|REGN7075|IV infusion
58447833|NCT04479332|PROCEDURE|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
58447834|NCT02936388|PROCEDURE|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
58447835|NCT02936388|PROCEDURE|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
58447836|NCT02466282|DEVICE|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
58447837|NCT02466282|DEVICE|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
58118132|NCT03443869|DRUG|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
58447838|NCT05647590|PROCEDURE|Chemotherapy|3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
58447839|NCT05647590|PROCEDURE|Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)|"* RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks ... maintenance"
57743747|NCT02800850|BEHAVIORAL|Bright Light|
57743748|NCT02800850|BEHAVIORAL|Placebo Light|
58118133|NCT03443869|DRUG|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
58118134|NCT03443869|DRUG|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
58118135|NCT03443869|DRUG|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
57743749|NCT00549588|OTHER|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
58118136|NCT03443869|DRUG|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
57743750|NCT00549588|OTHER|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
57743751|NCT00549588|OTHER|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
57743752|NCT00549588|OTHER|Intervention: none (only UV)|
58447840|NCT05647590|PROCEDURE|Maintenance chemotherapy|Maintenance chemotherapy will follow 3-6 weeks after RT.
57743753|NCT02045394|OTHER|Chest X-ray|
57743754|NCT02045394|OTHER|computed tomography of the chest|
57743755|NCT02045394|PROCEDURE|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
58447841|NCT03930602|DRUG|BMS-986165|Participants will receive BMS-986165.
57743756|NCT06732661|PROCEDURE|Preserve pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
57743757|NCT06732661|PROCEDURE|Dissect pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
57743758|NCT05335317|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
57743759|NCT05335317|DRUG|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
57743760|NCT05335317|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
57743761|NCT05335317|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
57743762|NCT05335317|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
58447842|NCT03930602|DRUG|Fluvoxamine|Participants will receive fluvoxamine.
57743763|NCT05335317|DIAGNOSTIC_TEST|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
57743764|NCT05335317|DIAGNOSTIC_TEST|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
57743765|NCT05335317|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
57743766|NCT05335317|OTHER|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
57743767|NCT05335317|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
58118137|NCT00317161|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
57743768|NCT05335317|DIAGNOSTIC_TEST|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
57743769|NCT05335317|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
57743770|NCT05335317|DIAGNOSTIC_TEST|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
57743771|NCT05335317|DIAGNOSTIC_TEST|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
57743772|NCT05335317|DIAGNOSTIC_TEST|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
57743773|NCT06343610|DIETARY_SUPPLEMENT|Active product|Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
57743774|NCT06343610|DIETARY_SUPPLEMENT|Placebo|No active ingredients.
57743775|NCT02392013|OTHER|Home Modification|Removal of home barriers or hazards.
57743776|NCT01911039|BIOLOGICAL|Regulatory T Cells|
57743777|NCT00425048|PROCEDURE|wearing gloves|
57743778|NCT01184287|DRUG|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
57743779|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
58313389|NCT05645991|DIETARY_SUPPLEMENT|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
58313390|NCT02105090|DRUG|Anesthetics, Local|
58447843|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
58447844|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
58447845|NCT06726226|OTHER|Standard care for preterm infants|Standard care for preterm infants according to the institutional protocol
57743780|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
57743781|NCT06580964|BEHAVIORAL|Heat therapy|Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 7d/wk (6 at-home and 1 in-lab).
57743782|NCT06580964|BEHAVIORAL|High-intensity interval training|High-intensity interval training will be performed 3 days per week for 12 weeks.
57743783|NCT03833999|DRUG|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
57743784|NCT03833999|DIAGNOSTIC_TEST|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
57743785|NCT03833999|DRUG|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
57743786|NCT03833999|DRUG|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
57743787|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
57743788|NCT05385120|PROCEDURE|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
58447846|NCT04764513|BIOLOGICAL|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10\^6、 1×10\^7 and 5×10\^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
57743789|NCT06635486|BEHAVIORAL|Adapted cognitive-behavioral (CBT) intervention|The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
57743790|NCT03680755|BEHAVIORAL|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
57743791|NCT06669624|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
57743792|NCT06669624|OTHER|Waitlist with 4-month delay, then ABC|A 4-month waitlist period, after which they will also receive the home-based ABC program (same as Intervention group).
57743793|NCT06700343|DRUG|Ocrelizumab (US)|IV infusion
57743794|NCT06700343|DRUG|Ocrelizumab (EU)|IV infusion
57743795|NCT06700343|DRUG|ABP 692|IV infusion
57743796|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
58447847|NCT01407510|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
57743797|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
57743798|NCT06162767|PROCEDURE|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
57743799|NCT06162767|PROCEDURE|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
57743800|NCT04490486|BIOLOGICAL|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
57743801|NCT04490486|OTHER|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
57743802|NCT06350032|DRUG|preservative-free parenteral treprostinil|Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
57743803|NCT03575325|DRUG|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
57743804|NCT06720948|DEVICE|ION 3D Facet Screw System|Observational study of subjects previously implanted with ION 3D Facet Screw System.
57957996|NCT05520983|OTHER|Strengthening Families|The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
58313391|NCT02105090|DRUG|Sodium Chloride 0.9%|
58313392|NCT04262219|BEHAVIORAL|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
58313393|NCT04605081|DRUG|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
58313394|NCT04605081|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
58118138|NCT04034030|DEVICE|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
58313395|NCT04748718|OTHER|Exercise-based injury prevention program|\~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
58447848|NCT05779020|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
57743805|NCT04659655|PROCEDURE|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
57743806|NCT04994834|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
57743807|NCT05402657|PROCEDURE|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
57743808|NCT05402657|PROCEDURE|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
57743809|NCT02624362|BEHAVIORAL|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
57743810|NCT02624362|BEHAVIORAL|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
57743811|NCT02624362|OTHER|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
57957997|NCT05520983|OTHER|Virtual psycho-educational discussion groups for caregivers and participants|The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
57957998|NCT05520983|OTHER|Maternal Child Health Bureau (MCHB) Care Coordination|MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
57957999|NCT05945953|OTHER|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
57958000|NCT05945953|OTHER|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
57958001|NCT03682497|DRUG|AZD9977|AZD9977 capsules taken orally for 28 days.
57958002|NCT03682497|DRUG|Spironolactone|Spironolactone tablets taken orally for 28 days.
57958003|NCT04079270|OTHER|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
57958004|NCT03298022|BIOLOGICAL|ALTB-168|monoclonal antibody
57958005|NCT04937088|DRUG|ASA|Liquid aspirin formulation
57958006|NCT00467454|DRUG|Naltrexone|daily
57958007|NCT00467454|DRUG|Placebo|daily
57958008|NCT00548496|DRUG|SB-751689|SB-751689
57958009|NCT00548496|OTHER|Placebo|Placebo to match
57958010|NCT00691431|DEVICE|LASIK|
57958011|NCT00823290|DRUG|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
58313396|NCT00872742|BEHAVIORAL|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
58313397|NCT00872742|BEHAVIORAL|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
57743812|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
57743813|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
57743814|NCT06731998|PROCEDURE|Local Anesthesia|For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.
57743815|NCT06731998|PROCEDURE|Laparoscopic Transversus Abdominis Plane block|Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
58447849|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
58447850|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
57743816|NCT02122133|DEVICE|PC 400|
57743817|NCT02635269|OTHER|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
57743818|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
57743819|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
57743820|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
57743821|NCT06135337|DEVICE|Thioderm Elate|Test Device
58447851|NCT00823563|PROCEDURE|30 cc blood draw|
58447852|NCT00823563|PROCEDURE|Intravascular ultrasound (IVUS)|
58447853|NCT00823563|PROCEDURE|Coronary pressure/flow wire testing|
58447854|NCT00823563|PROCEDURE|Coronary pressure/flow testing: Acetycholine challenge|
58447855|NCT00823563|PROCEDURE|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
58447856|NCT00823563|PROCEDURE|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
58447857|NCT05159999|OTHER|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
58447858|NCT05159999|DRUG|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
58447859|NCT02935530|DRUG|s-LMWH|2125KU, subcutaneous injection of 5-10 days
58447860|NCT02935530|DRUG|LMWH|4250KU, subcutaneous injection of 5-10 days
58447861|NCT02935530|DRUG|Argatroban|20mg, injection for 5-10 days
58447862|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
58447863|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
57743822|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
57958012|NCT01965262|DEVICE|Hema-copolymer Lens|contact lens
57958013|NCT01965262|DEVICE|etafilcon A Lens|contact lens
57958014|NCT03303794|DRUG|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
58447864|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
58447865|NCT05172726|DRUG|tapinarof cream, 1%|applied topically once daily
58447866|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire."
58447867|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
58447868|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion."
58447869|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion."
57743823|NCT06723808|OTHER|Leisure-Time Physical Activity and Occupational Physical Activity|This study does not involve a specific intervention but explores the relationship between leisure-time physical activity (LTPA) and occupational physical activity (OPA) in university staff, with a focus on work ability, musculoskeletal disorders, and quality of life.
57743824|NCT01375348|DRUG|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
57743825|NCT04802538|DEVICE|OstoRing®|Participants will use the OstoRing® along with their standard pouching equipment.
57743826|NCT06323928|DRUG|Lu AG09222|Lu AG09222 will be administered using subcutaneous (SC) injection.
57743827|NCT06323928|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered by SC injection.
58118139|NCT06404697|RADIATION|Boost irradiation|High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
58118140|NCT04109027|BEHAVIORAL|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
58118141|NCT04109027|BEHAVIORAL|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
58447870|NCT06166680|OTHER|Orofacial praxis assessment|- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
58447871|NCT03217708|DEVICE|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
58447872|NCT05944679|RADIATION|No Xray|Just one Xray 12 months after the intervention
58447873|NCT05944679|RADIATION|Xray|Xray at 1, 3, 6 and 12 months after intervention
58447874|NCT03178604|OTHER|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
58447875|NCT03178604|OTHER|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
57743828|NCT06732778|OTHER|Pain Neuroscience Education (PNE)|"PNE was planned online for clients 1 week before menstruation in the form of speaking sessions in a presentation format. The training will be conveyed in relation to pain during menstruation. Visual aids, examples and metaphors will be used to improve patient understanding in the training. Ankle sprain picture, speeding bus picture, action potential picture, picture showing membrane resting potential, rusty nail picture, whole body nervous system picture, neuromatrix picture, lion and lion cub picture that helps explain stress responses, curious neighbors picture etc. will be used. The training session is planned to last between 2 and 4 hours.~The distribution of pain neuroscience training topics will be implemented in the order given below, with 10 main headings.~* Pain and the Biopsychosocial Model~* Injury and pain are not equivalent, pain is a brain output rather than an input~* Action potential, normal electrical activity of nerves and conduction~* Biological process of ion chann"
57743829|NCT06732778|OTHER|Control Group (CG)|The control group will not receive any training or practice.
57743830|NCT05949723|DEVICE|Golf simulator device|The golf simulator can accurately predict the flight trajectory and landing point of the ball using high-speed moving object measurement technology, giving the user the impression that they are playing on a real golf course.
57743831|NCT04603534|OTHER|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
57743832|NCT06135103|DRUG|talfirastide|TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
57743833|NCT06135103|DRUG|Placebo|Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
58118142|NCT03811197|BEHAVIORAL|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
58118143|NCT03811197|BEHAVIORAL|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
58118144|NCT03811197|BEHAVIORAL|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
58118145|NCT04113395|OTHER|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
57743834|NCT05183971|OTHER|Proprioceptive Functional Analysis System|Proprioceptive testing and Physical Performance Tests
58118146|NCT05055791|DRUG|SYHX1903|SYHX1903 tablets, orally, qd
58118147|NCT02984839|DEVICE|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
58118148|NCT02272348|OTHER|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
58118149|NCT02272348|OTHER|Usual diabetes management.|
58118150|NCT02139683|DEVICE|HIFU treatment|HIFU treatment in patients with fibroadenoma
58118151|NCT05079854|DRUG|Intraocular Instillation Solution|Intracameral Moxifloxacin 0.5%
58118152|NCT05079854|DRUG|Moxifloxacin Ophthalmic|Topical Moxifloxacin 0.5%
58118153|NCT03509298|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
58118154|NCT03509298|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
57743835|NCT04407390|DIETARY_SUPPLEMENT|Nicotinamide riboside|The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.
57743836|NCT04407390|DIETARY_SUPPLEMENT|Placebo|Placebo
57743837|NCT06580665|PROCEDURE|Cryoablation|Patients undergo cryoablation.
57743838|NCT06580665|DRUG|Serplulimab|Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
57743839|NCT04062357|DRUG|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
57743840|NCT04062357|OTHER|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
57743841|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57743842|NCT06438588|OTHER|Dietary Intervention|Given FMD
57743843|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
57743844|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
57958015|NCT03303794|DRUG|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
57958016|NCT06374823|DRUG|Multiple Electrolyte|Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
57958017|NCT06374823|DRUG|Normal Saline|Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
57958018|NCT03402607|PROCEDURE|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
57958019|NCT03402607|RADIATION|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
57958020|NCT01829256|BEHAVIORAL|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
57743845|NCT06438588|OTHER|Interview|Ancillary studies
57958021|NCT05047757|DIETARY_SUPPLEMENT|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
57958022|NCT05453617|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
57958023|NCT05453617|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
57958024|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|iPACK block + Adductor Canal Block
57958025|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|Erector Spinae Plane Block
57958026|NCT06302218|DRUG|control group|only spinal anesthesia
58118155|NCT02100865|DEVICE|Solar powered oxygen|
58118156|NCT02100865|DEVICE|Oxygen from cylinders|
58118157|NCT06015373|DRUG|supress the night dose of carvedilol|already described
58118158|NCT05432271|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
58118159|NCT05432271|BEHAVIORAL|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
58118160|NCT05432271|BEHAVIORAL|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
58118161|NCT05432271|BEHAVIORAL|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
58118162|NCT05432271|BEHAVIORAL|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
58118163|NCT02668302|COMBINATION_PRODUCT|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
57743846|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
57743847|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
58118164|NCT02668302|OTHER|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
58118165|NCT05333250|DRUG|Modafinil|Modafinil
58118166|NCT05333250|OTHER|Placebo|Placebo
58447876|NCT03642652|BEHAVIORAL|SMS|Text reminders to mobile telephone
58118167|NCT02678910|PROCEDURE|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
58118168|NCT03955692|DEVICE|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
58118169|NCT00260780|BEHAVIORAL|The MISTERS Intervention for Post Jail Release Men|
58118170|NCT02410148|DEVICE|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
58118171|NCT04707274|OTHER|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
58118172|NCT03246698|OTHER|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
58118173|NCT03246698|OTHER|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
58118174|NCT03246698|OTHER|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
57743848|NCT05884840|DIAGNOSTIC_TEST|HELENA|"The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients."
57743849|NCT05054608|OTHER|No intervention|Observational study. No intervention.
57743850|NCT06732570|DEVICE|high intensity laser|the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.
57743851|NCT06732570|OTHER|manual therapy|manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
57743852|NCT06732570|OTHER|exercise therapy|therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
57743853|NCT03785561|OTHER|participation in a health research study|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
57743854|NCT04332042|DRUG|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
57743855|NCT02942108|PROCEDURE|piezo surgery|
57743856|NCT02942108|PROCEDURE|conventional surgery|
57743857|NCT05129319|DRUG|prabotulinumtoxinA|Injection of glabellar rhytids
57743858|NCT00528138|OTHER|Laboratory Test|CRP, white blood cell count, hepatic function tests
57743859|NCT01292928|DEVICE|Stent implantation|Stent implantation during the index procedure.
57743860|NCT03576157|OTHER|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
57743861|NCT04768400|DRUG|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
57958027|NCT00868946|DRUG|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
57958028|NCT02200380|DRUG|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
57958029|NCT02200380|DRUG|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
57958030|NCT04687696|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
58118175|NCT04812509|DRUG|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
58118176|NCT04812509|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
58118177|NCT00654706|DRUG|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
58118178|NCT00654706|DRUG|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
58118179|NCT03741608|BEHAVIORAL|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
58118180|NCT03741608|BEHAVIORAL|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
58118181|NCT00467584|DRUG|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
58118182|NCT00467584|DRUG|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
58118183|NCT00467584|DRUG|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
58118184|NCT01960816|DEVICE|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
58447877|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
58447878|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
58447879|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
58447880|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
58447881|NCT03534102|DRUG|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
57743862|NCT04987879|BEHAVIORAL|Exercise|Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
57958031|NCT04687696|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
57958032|NCT04687696|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
57958033|NCT05997641|DRUG|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
57958034|NCT05997641|DRUG|Placebo|Visually matching 0 mg DF-003 capsules.
57958035|NCT02150590|DRUG|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
57958036|NCT02150590|DRUG|sham oxygen (room air)|
57958037|NCT03127033|OTHER|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
57958038|NCT04523506|BIOLOGICAL|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
57958039|NCT03268915|DIAGNOSTIC_TEST|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
57958040|NCT01256073|DRUG|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
58447882|NCT03534102|BEHAVIORAL|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
58447883|NCT01668849|DIETARY_SUPPLEMENT|Grape extract|Grape extract self-administered by mouth daily for 35 days
58118185|NCT03538756|DEVICE|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
58118186|NCT05112328|DRUG|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
57743863|NCT03404570|DRUG|Dexmecamylamine HCl|Investigational drug
57743864|NCT03404570|OTHER|Placebo|Oral tablet containing no active drug.
58313398|NCT02054780|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
58447884|NCT01668849|DRUG|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
58447885|NCT00002963|DRUG|aminolevulinic acid hydrochloride|
58447886|NCT00002963|PROCEDURE|conventional surgery|
58447887|NCT03360643|DIAGNOSTIC_TEST|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
58447888|NCT03360643|DIAGNOSTIC_TEST|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
57743865|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
57743866|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
57743867|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
57743868|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
58447889|NCT04414163|DRUG|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
58447890|NCT04775563|OTHER|COVID-19 vaccine hesitancy scale in rheumatic diseases|The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
58447891|NCT04775563|OTHER|COVID-19 vaccine hesitancy associated factors|The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
57743869|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
57743870|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
57743871|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
57743872|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
57743873|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
57743874|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
57743875|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
57743876|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
57743877|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
58118187|NCT05112328|DRUG|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
58118188|NCT02874495|BEHAVIORAL|Psychological tests|Related to affective and cognitive dimensions of pain.
58118189|NCT02874495|DEVICE|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
58118190|NCT02874495|BEHAVIORAL|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
58447892|NCT01300312|DRUG|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
58447893|NCT01300312|DRUG|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
58447894|NCT05326711|BEHAVIORAL|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
57743878|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
57743879|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
57743880|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
57743881|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
57743882|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
57743883|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
57743884|NCT06120907|OTHER|Data collection|The data include phenotypic data, treatments administered, response to treatment, Three-dimensional total body images, biopsies and blood plasma.
57743885|NCT05600920|DRUG|Recombinant human interleukin (IL) 7-hyFc|Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI \>=30 kg/m2, in which case adjusted body weight will be used.
58447895|NCT03779698|OTHER|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
57743886|NCT00419263|DRUG|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
58313399|NCT02054780|BEHAVIORAL|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
58447896|NCT03779698|DRUG|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
58447897|NCT05133154|BIOLOGICAL|Blood samples|In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
58447898|NCT01776840|DRUG|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
58447899|NCT01776840|DRUG|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
58447900|NCT01776840|DRUG|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
57743887|NCT00419263|DRUG|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
57743888|NCT00419263|DRUG|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
57743889|NCT02068807|DIETARY_SUPPLEMENT|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
57743890|NCT02068807|DIETARY_SUPPLEMENT|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
58313400|NCT02933814|DRUG|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
58313401|NCT05167071|DRUG|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
58313402|NCT05167071|DRUG|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
58313403|NCT01390506|DRUG|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
58313404|NCT01390506|DRUG|Placebo|0,9% sodium chloride is administered intravenously
58313405|NCT05192642|DRUG|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
58313406|NCT05192642|DRUG|Data on other treatments|Real word data
58447901|NCT01776840|DRUG|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
57743891|NCT05571280|DIETARY_SUPPLEMENT|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
57743892|NCT05571280|BEHAVIORAL|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
57743893|NCT05571280|BEHAVIORAL|Standard intervention|"The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
57743894|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
57743895|NCT06592664|DRUG|LSTA1|LSTA1 given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
57743896|NCT06592664|DRUG|Nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
57743897|NCT06592664|DRUG|Gemcitabine|gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
57743898|NCT06592664|DRUG|Placebo matching LSTA1|Placebo given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
57743899|NCT06592664|DRUG|LSTA1|LSTA1 given as a slow IV push over 1 minute when standard treatment(s) are given
57743900|NCT06592664|DRUG|Placebo matching LSTA1|Placebo given as an IV infusion over 4 hours when standard treatment(s) are given
57743901|NCT05447117|PROCEDURE|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
58447902|NCT06725082|BIOLOGICAL|Recombinant Humanized Type III Collagen Injection|rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
58447903|NCT04079595|DEVICE|Head immobilization mask|Immobilization
58447904|NCT00655629|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
58447905|NCT00655629|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
58447906|NCT05747742|DEVICE|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
58447907|NCT06579950|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
58447908|NCT05168033|OTHER|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
58447909|NCT05168033|OTHER|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
58447910|NCT02618265|PROCEDURE|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
57743902|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
57743903|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
57743904|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
57743905|NCT06733935|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
57743906|NCT06733935|DRUG|Cyclophosphamide|Lymphodepletion
57743907|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
57743908|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
57743909|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
57743910|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
57743911|NCT03091374|DRUG|Somatotropin (Human)|
57743912|NCT03298009|DRUG|Canagliflozin 100mg|2-week intervention
57743913|NCT03298009|DRUG|Placebo oral capsule|2-week intervention
57743914|NCT03298009|RADIATION|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
57743915|NCT00965224|BIOLOGICAL|dendritic cell vaccination (active specific immunotherapy)|
57743916|NCT00226330|DRUG|Tesaglitazar|(0.5 or 1 mg)
57743917|NCT00226330|DRUG|Pioglitazone|(15, 30 or 45 mg)
57743918|NCT05242991|DEVICE|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
58447911|NCT02618265|PROCEDURE|traditional management|aspirin or clopidogrel monotherapy or double treatment for
58447912|NCT02618265|PROCEDURE|website platform management|second prevention based on website platform management
57743919|NCT01219348|BIOLOGICAL|IDO peptide vaccination|Vaccination every second week
58118191|NCT06529263|OTHER|newborn massage|Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
58118192|NCT02265848|OTHER|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
58313407|NCT05853900|DEVICE|ReMMi-D Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
58447913|NCT05341726|BEHAVIORAL|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
58447914|NCT05341726|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
58447915|NCT02219334|DEVICE|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
57743920|NCT04250454|BEHAVIORAL|CONTRACT|"The intervention will consist of four elements:~1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~2. Home Activity Plan (HAP)~3. Home-based Feedback training~4. Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
57743921|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
57743922|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
58447916|NCT00704366|DRUG|AZD0530|oral, tablet, once daily, dose will be variable
58447917|NCT04917484|DRUG|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
58447918|NCT03712787|DRUG|Tilavonemab|solution for IV infusion
58447919|NCT03635749|DRUG|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
58447920|NCT03635749|DRUG|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
58447921|NCT03635749|DRUG|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
58447922|NCT03635749|DRUG|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
58447923|NCT04658004|DRUG|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
57743923|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
57743924|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.
57743925|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)
57743926|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.
57743927|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
58313408|NCT04738383|PROCEDURE|Version 1: Paramedic|Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.
58447924|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism - TAM 24|TEST
58447925|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism|CONTROL
58447926|NCT04323059|DIETARY_SUPPLEMENT|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
58447927|NCT00412893|DRUG|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
58447928|NCT00412893|DRUG|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
57743928|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
57743929|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
58118193|NCT02265848|OTHER|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
58313409|NCT04738383|PROCEDURE|Version 2: Physician-on-call|This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.
58447929|NCT00508326|DRUG|Paclitaxel|Starting dose 150 mg/m\^2 HAI once every 4 weeks
57743930|NCT05965687|PROCEDURE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
57743931|NCT05965687|PROCEDURE|Nasal oxygen|For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
57743932|NCT05965687|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
58118194|NCT06243354|DRUG|Test product: HYP-2090PTSA|"Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest)."
58447930|NCT05990634|DEVICE|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
58447931|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
58447932|NCT04438395|DEVICE|Cardiac ablation via catheter|Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
58447933|NCT01862536|DRUG|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
58447934|NCT01862536|DRUG|placebo|Daily use in double blind study.
58447935|NCT03211494|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
58447936|NCT03211494|OTHER|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
58447937|NCT06019078|DEVICE|SedLine|Continuous 4 channel processed neurological monitor
58447938|NCT03089580|DEVICE|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
58447939|NCT03089580|PROCEDURE|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
57743933|NCT02675387|DEVICE|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
58118195|NCT01801696|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
58118196|NCT01801696|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
58447940|NCT03120130|BIOLOGICAL|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
58447941|NCT06726447|DEVICE|Artificial Intelligence Tool|The intervention in this study consists of the implementation of an artificial intelligence tool for clinical registration during outpatient consultations. This technology facilitates the documentation of interactions in real time, optimizing the workflow of professionals and enabling more patient-centered care.
58447942|NCT03329846|DRUG|BMS-986205|specified dose on specified day
58447943|NCT03329846|BIOLOGICAL|Nivolumab|Specified dose on specified day
58447944|NCT03329846|DRUG|Placebo|Specified dose on specified day
58447945|NCT01809522|PROCEDURE|Posterior reconstruction of the rhabdosphincter|
58447946|NCT02644317|DEVICE|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
58447947|NCT03871426|PROCEDURE|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
58447948|NCT04663503|OTHER|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
58118197|NCT02779816|DEVICE|Pen device|Adaptive pen device
58447949|NCT00234923|DRUG|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
58447950|NCT00234923|DRUG|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
58447951|NCT00790192|DRUG|Lurasidone|Lurasidone 80 mg tablets
57743934|NCT02675387|DRUG|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
57743935|NCT04980118|BEHAVIORAL|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
57743936|NCT04980118|BEHAVIORAL|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
57743937|NCT06023329|DRUG|ropivacaine|will receive SCPB with ropivacaine via regional anesthesia team
57743938|NCT06023329|DRUG|Saline|will receive SCPB with saline via regional anesthesia team
58118198|NCT06252779|DEVICE|Plasma therapy equipment|The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.
58118199|NCT06252779|DEVICE|Fake therapeutic device|False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
57743939|NCT06732141|BEHAVIORAL|Personalized Telephone-Based Psychological Support|"This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components:~1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects.~2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being.~3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change.~4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels."
57743940|NCT06732141|BEHAVIORAL|Standard Care with Weekly Follow-Up Calls|Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
57743941|NCT06724965|BEHAVIORAL|Trans STAIR|Skills Training in Affect and Interpersonal Regulation (STAIR) is a transdiagnostic evidenced-based mental health treatment for individuals who have experienced multiple traumas. STAIR is based in cognitive-behavioral principles and delivered in a flexible manner over 8 group sessions, with demonstrated efficacy for the treatment of PTSD and other mental health symptoms. This trial will adapt and pilot test the STAIR intervention to be culturally appropriate and acceptable for TGD persons, adding content related to TGD health and wellness, coping with minority stress, responding to stigma and microaggressions, social support, and community connectedness, self-compassion, celebrating trans joy, trans advocacy, sexual health and PrEP use.
57743942|NCT06724965|BEHAVIORAL|PrEP Well|"This pilot trial will leverage PrEP Well, a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care)"
57743943|NCT06733103|BEHAVIORAL|Stroke Cognitive Behavioural Therapy|This is the only intervention in this clinical (feasibility) study
57743944|NCT06626490|DEVICE|Prevision Revision hip endoprosthesis stem implantation|"The Prevision hip endoprosthetic stem is a femoral part of a hip joint endoprosthesis. The system provides cementless and cemented variants. Prevision hip stems are modular with a short proximal and longer distal component, or monobloc hip stems. Modular components are coupled via a Prevision specific conical connection with a torque wrench and a tension nut to apply a predefined torsional moment on the connection. The distal component of modular Prevision stems can be combined with locking screws for additional bone fixation.~Both types, the monobloc and the modular, provide a 12/14 taper that serves as a connection for metal or ceramic prosthesis heads. Prevision hip stems are combined at the acetabulum with a cementless or cemented acetabular cup."
57743945|NCT05400330|BIOLOGICAL|LX1001|Gene therapy
57743946|NCT00382057|DRUG|Testosterone|
57743947|NCT00382057|DRUG|Anastrozole|
57743948|NCT00382057|DRUG|Goserelin|
57958041|NCT06239987|BEHAVIORAL|Care-oriented Practical Training|The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
57958042|NCT05820425|OTHER|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
57958043|NCT00898560|DRUG|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
57958044|NCT00898560|DRUG|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
57958045|NCT05843552|OTHER|no intervention|no intervention, this is an observational study
57958046|NCT03741998|DEVICE|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
57958047|NCT01733017|BEHAVIORAL|Sodium reduction|Teaching and skill building to reduce dietary sodium
57958048|NCT01733017|DIETARY_SUPPLEMENT|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
57958049|NCT01733017|DIETARY_SUPPLEMENT|rice bran oil capsules|placebo capsules
57958050|NCT01733017|BEHAVIORAL|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
57958051|NCT03185390|PROCEDURE|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
57958052|NCT05988801|OTHER|Glass ionomer sealant|glass ionomer-based sealant material
57958053|NCT05988801|OTHER|Resin based sealant|resin-based sealant material
57958054|NCT04515732|DRUG|Apremilast Oral Tablet|As in description
58118200|NCT01309919|DEVICE|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
58118201|NCT01309919|OTHER|Diary|Subjects will keep a bleeding diary for three months
58118202|NCT02505100|OTHER|Touching relaxant|
58118203|NCT02505100|OTHER|Hypnoses|
58447952|NCT00790192|DRUG|Lurasidone|Lurasidone 4 40 mg tablets
58447953|NCT00790192|DRUG|Quetiapine XR|Quetiapine XR 600mg
58118204|NCT03931083|DIAGNOSTIC_TEST|Screening for CIN2+/HSIL|The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
58118205|NCT03454633|PROCEDURE|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
58118206|NCT00875719|DEVICE|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
58118207|NCT00875719|DEVICE|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
58118208|NCT04110028|DRUG|Nicotinamide riboside|Nicotinamide riboside in different doses
58118209|NCT04110028|DRUG|Placebo|Placebo
58118210|NCT00188370|PROCEDURE|high frequency ultrasound imaging|
58118211|NCT03449628|DIETARY_SUPPLEMENT|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
58118212|NCT03449628|DIETARY_SUPPLEMENT|PLACEBO|1 capsule, b.i.d. for 12 weeks
57743949|NCT06681909|BEHAVIORAL|UB Campus Veggie Van|The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
57743950|NCT01901068|DEVICE|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
58118213|NCT02153736|BEHAVIORAL|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
58118214|NCT03072836|OTHER|analysing microbiota|16SRNA gene sequencing of feces
57743951|NCT06722482|DEVICE|FDBA|Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
58118215|NCT03742674|OTHER|Follow up|No intervention
58118216|NCT04232397|DRUG|Anlotinib|anlotinib 8mg qd po
58118217|NCT01280981|DRUG|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
58118218|NCT01082107|OTHER|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (\> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
58118219|NCT03490682|OTHER|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
58118220|NCT03090984|DEVICE|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
58118221|NCT03090984|DEVICE|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
58118222|NCT03090984|DEVICE|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
57743952|NCT06722482|DEVICE|CEBX|Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
57743953|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
57743954|NCT01716429|BEHAVIORAL|Vegan diet|Vegan dietary approaches for weight loss
57743955|NCT01716429|BEHAVIORAL|Low calorie diet|Reduced calorie diet for weight loss
57743956|NCT06526299|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57743957|NCT06526299|PROCEDURE|Bone Scan|Undergo bone scan
58118223|NCT05608564|PROCEDURE|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
58118224|NCT05608564|PROCEDURE|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
57743958|NCT06526299|PROCEDURE|Computed Tomography|Undergo SPECT/CT and CT
57743959|NCT06526299|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
57743960|NCT06526299|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57743961|NCT06526299|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT
57743962|NCT06526299|OTHER|Questionnaire Administration|Ancillary studies
57743963|NCT06526299|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58118225|NCT06358352|DIETARY_SUPPLEMENT|Lutein / Zeaxanthin|lutein extract from lutein oral capsules
58118226|NCT06358352|BIOLOGICAL|Platelet rich fibrin|platelet rich fibrin extracted from patient's blood after centrifuging
58447954|NCT00790192|DRUG|Placebo|Matching Placebo to Lurasidone or Quetiapine
58447955|NCT02089594|DRUG|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
57743964|NCT06356220|OTHER|Gluten-Free Diet Education|The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
57743965|NCT06722261|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
57743966|NCT02618967|BIOLOGICAL|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
57743967|NCT02618967|BIOLOGICAL|AMG 570 Matching Placebo|Placebo administered as single dose subcutaneous in healthy volunteers.
57743968|NCT00536133|DRUG|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
58313410|NCT04738383|PROCEDURE|Version 3: Trained instructor|The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
58313411|NCT05411237|DRUG|Pegylated liposomal doxorubicin|PLD 20 mg/m2 on Day 1 of every 21-day cycle
58447956|NCT02089594|DRUG|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
58447957|NCT04416048|DRUG|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
58447958|NCT04416048|OTHER|Standard Of Care (SOC)|Standard of care treatment
58447959|NCT03593057|OTHER|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
58447960|NCT03593057|OTHER|Control group|Advice on self-care and body awareness.
58447961|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
58447962|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
58447963|NCT00746616|DEVICE|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
58458573|NCT06074848|BEHAVIORAL|Motor Training|Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
57743969|NCT00536133|OTHER|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
57743970|NCT06580223|DRUG|Aspirin 100mg|Aspirin, enteric coating of tablets, oral administration
57743971|NCT06580223|DRUG|Rivaroxaban 10mg|Rivaroxaban, tablets, oral administration.
57743972|NCT03805724|OTHER|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
57743973|NCT06502366|DRUG|BDA MDI HFO 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFO
57743974|NCT06502366|DRUG|BDA MDI HFA 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFA
57743975|NCT06502366|DRUG|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
58313412|NCT05411237|DRUG|Paclitaxel|PTX 100 mg/m2 on Day 1 of every 21-day cycle
58313413|NCT01675778|DRUG|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
58313414|NCT05072288|OTHER|Remote activity program|Participant will have to do exercise at home everyday (15min/day)
58313415|NCT01740206|DRUG|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
58313416|NCT01740206|OTHER|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
58313417|NCT03991533|OTHER|multiparametric MRI|preoperative multiparametric MRI
58313418|NCT01840111|BEHAVIORAL|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
58313419|NCT01840111|BEHAVIORAL|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
58313420|NCT06142019|DEVICE|Controlled desaturation (hypoxemia)|Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures
58313421|NCT00795340|DRUG|carboplatin|Given IV
58313422|NCT00795340|DRUG|cediranib maleate|Given orally
57743976|NCT06504615|DRUG|nivolumab + chemotherapy|As prescribed by the treating clinician, as per product label
57743977|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
57743978|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
57743979|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
57743980|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
57743981|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
57743982|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
57743983|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
57743984|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
57743985|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
57743986|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
57743987|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
57743988|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
57743989|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
57743990|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
57743991|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
57743992|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
57743993|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
58313423|NCT00795340|DRUG|paclitaxel|Given IV
57743994|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
58313424|NCT00795340|OTHER|placebo|Given orally
58313425|NCT04802434|BEHAVIORAL|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
58313426|NCT04802434|BEHAVIORAL|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
58313427|NCT02837159|OTHER|mHealth application|Dietary and physical activity recommendations trough a mobile application
58458574|NCT06074848|BEHAVIORAL|Cognitive Training|an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
58313428|NCT05676658|BEHAVIORAL|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
58313429|NCT05676658|BEHAVIORAL|Placebo coherent breathing|Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
58313430|NCT00720759|DRUG|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
57743995|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
57743996|NCT05230173|OTHER|Pragmatic|"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
57743997|NCT06429176|DRUG|SPL84|SPL84 solution for nebulization
57743998|NCT06429176|OTHER|Placebo|Placebo solution for nebulization
57743999|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
57744000|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
57744001|NCT06634030|DRUG|Saline|Normal saline
57744002|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
57744003|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
58118227|NCT02809092|BIOLOGICAL|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
58447964|NCT05911269|OTHER|TiMBRe|"1 \& 2 Music Listening~* Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~  3 \& 4 Music Facilitated Breathing~* The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~  5 \& 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~* Using music as a structured auditory cue for tensing and releasing of muscles.~  7 \& 8 Body Percussion~* The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body."
58447965|NCT05911269|OTHER|Control|Standard of care study staff calls and cancer survivorship resources
58447966|NCT03971565|BIOLOGICAL|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
58447967|NCT04854551|DRUG|Naltrexone|Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
58447968|NCT04854551|OTHER|Placebo|Placebo will be used to control for expectancy effects
58447969|NCT06723444|BEHAVIORAL|Learning and Memory Training|"The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions)."
58447970|NCT06723444|BEHAVIORAL|Placebo Comparator|The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
58447971|NCT01929382|DRUG|interferon gamma 1b|Standard therapy vs dose titration
58447972|NCT04984486|DEVICE|dental implant|"The procedure used to accomplish its intended use is as follows :~* The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~* After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
58447973|NCT00004936|DRUG|iodinated contrast dye|
58447974|NCT00004936|PROCEDURE|computed tomography|
58447975|NCT00004936|PROCEDURE|magnetic resonance imaging|
58447976|NCT00004936|RADIATION|gadopentetate dimeglumine|
57744004|NCT01521676|GENETIC|molecular alteration|research of molecular alteration
57744005|NCT03458572|DEVICE|Seirin Pyonex press needle acupuncture|Acupuncture
57769674|NCT00068874|BEHAVIORAL|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
58118228|NCT02117193|OTHER|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
58118229|NCT02117193|OTHER|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
57744006|NCT06048822|BEHAVIORAL|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
58118230|NCT06364800|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
58447977|NCT00108771|DRUG|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
57744007|NCT05750290|DRUG|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
57744008|NCT06170541|DEVICE|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
57744009|NCT06170541|DEVICE|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
57744010|NCT06475612|OTHER|Death|Mortality group.
57744011|NCT06475612|OTHER|Survival|Survival group.
58313431|NCT00720759|BEHAVIORAL|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
58447978|NCT00108771|DRUG|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
58447979|NCT04661436|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
58447980|NCT03169335|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
58447981|NCT03169335|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
58447982|NCT03169335|DRUG|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
58447983|NCT03169335|DRUG|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
58447984|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
58447985|NCT00561288|DRUG|acetaminophen|2 x 1000 mg doses per day
58447986|NCT00561288|OTHER|cornstarch|2 x 1000 mg cornstarch per day
58447987|NCT00991653|PROCEDURE|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
58447988|NCT04496856|DIETARY_SUPPLEMENT|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
58447989|NCT05729932|DRUG|Inhaled vaporized cannabis|Double-blind cannabis and placebo doses, administered through vaporizer
58447990|NCT05729932|DRUG|Intransal opioid|Double-blind opioid and placebo doses, administered intranasal route
58458575|NCT04470518|OTHER|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
58118231|NCT06364800|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
58118232|NCT06364800|DRUG|targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
58118233|NCT00838877|DRUG|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
57744012|NCT06545097|DRUG|Cebranopadol|Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).
57744013|NCT06545097|DRUG|Cebranopadol|Once daily on Day 2 (with Cebranopadol 400 ug)
57744014|NCT06545097|DRUG|Placebo|Once daily for 2 days
57744015|NCT05501054|DRUG|Ipilimumab|Given by IV (vein)
57744016|NCT05501054|DRUG|Nivolumab|Given by IV (vein)
57744017|NCT05501054|DRUG|Ciforadenant|Given by PO
57744018|NCT04859608|DRUG|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is \> 150 mg/L). Spacing of infusion can be decided every 3 months.
57744019|NCT06720051|PROCEDURE|Intraosseous dexamethasone injection after 3rd molar surgery|In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
57744020|NCT06720051|PROCEDURE|Submucosal dexamethasone injection after 3rd molar surgery|In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
57744021|NCT06733714|DEVICE|Transcranial Alternating Current Stimulation|An alternate eletric current of 1.6mA in theta frequency is applied in the scalp, using two eletrodes (5x5cm). The eletrodes are located aiming for the left dorsolateral prefrontal Cortex area.
57744022|NCT06733714|DEVICE|Digital Cognitive Training|Using a tablet, the participant will do exercises that were designed to stimulate cognitive domains, especially attention and memory. In this case, we use the BrainHQ platform.
57744023|NCT06720545|DEVICE|No HGNS therapy (HGNS-off)|Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
57744024|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
57744025|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
57744026|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
57744027|NCT06639061|DEVICE|Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)|"We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation."
57744028|NCT06639061|DEVICE|Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)|We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
57744029|NCT06265350|DRUG|Cadonilimab|Cadonilimab, 375mg，Q3W， IV
57744030|NCT06265350|DRUG|Bevacizumab|Bevacizumab, 7.5mg/kg，Q3W， IV
57744031|NCT06265350|PROCEDURE|Cryoablation|Patients accepted Cryoablation of pulmanary metastases
57744032|NCT02808624|DRUG|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
57744033|NCT06479161|DRUG|Tranexamic acid|1.95 grams oral
57744034|NCT00032695|DRUG|methionine|
57744035|NCT02635854|OTHER|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
57744036|NCT02635854|OTHER|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
57744037|NCT03849274|COMBINATION_PRODUCT|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
57744038|NCT03849274|DEVICE|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
57744039|NCT06229145|BIOLOGICAL|Pegloticase|IV infusion
57744040|NCT06229145|DRUG|Methotrexate|Oral
57744041|NCT02807896|OTHER||This study is cohort.
57744042|NCT01191164|PROCEDURE|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
57744043|NCT05652270|BEHAVIORAL|Goal Attainment|Development of an attainable goal
57744044|NCT05652270|BEHAVIORAL|Goal Development|"A Systematic process to help patients create SMaRT  goals"
57744045|NCT05652270|BEHAVIORAL|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
57744046|NCT06724900|BIOLOGICAL|KB304|Genetically modified herpes simplex type 1 virus
57744047|NCT06724900|DRUG|0.9% Normal Saline (NS)|Placebo
57744048|NCT05051761|DRUG|Jaktinib|Administered orally.
57744049|NCT05051761|DRUG|placebo|Administered orally.
57744050|NCT06495294|BIOLOGICAL|Whole Blood|2 units of whole blood administered by Ornge AAS
57744051|NCT06495294|BIOLOGICAL|RBC + plasma|2 units of RBC + 2 units of plasma administered by Ornge AAS
57744052|NCT01292239|DRUG|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
58447991|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
57744053|NCT01292239|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
57744054|NCT01292239|DRUG|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
57769675|NCT00068874|BEHAVIORAL|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
58118234|NCT00838877|DRUG|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
58447992|NCT03044366|OTHER|general anesthesia management of preterm infants|general anesthesia management of preterm infants
58447993|NCT03648294|OTHER|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
58447994|NCT01633541|DRUG|AT-101|Patients will receive AT-101 40 mg orally two times a day.
58447995|NCT01633541|DRUG|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
58447996|NCT01633541|DRUG|Cisplatin|Cisplatin 100 mg/m2
58447997|NCT01633541|DRUG|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
58447998|NCT00575965|DRUG|Simvastatin|Oral tablets taken daily
58447999|NCT04583995|BIOLOGICAL|SARS-CoV-2 rS/Matrix M1-Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
58448000|NCT04583995|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
58448001|NCT04583995|BIOLOGICAL|Licensed seasonal influenza vaccine|Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
58448002|NCT06278766|DRUG|ABBV-552|Oral Solution
58448003|NCT03728543|DRUG|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
58448004|NCT02743455|DRUG|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
58448005|NCT02743455|BIOLOGICAL|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
58448006|NCT02743455|BIOLOGICAL|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
58448007|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
58448008|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
58448009|NCT02743455|BIOLOGICAL|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
58448010|NCT02766634|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
58448011|NCT02766634|BIOLOGICAL|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
58448012|NCT05775016|BEHAVIORAL|Exercise|12 week resistance and cardiovascular exercise program
58448013|NCT04034303|GENETIC|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
58448014|NCT01126723|OTHER|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
58448015|NCT01126723|OTHER|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
58448016|NCT05094648|OTHER|high flow nasal therapy|effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
58448017|NCT04339621|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
58448018|NCT01135615|DRUG|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
57769676|NCT05774899|DRUG|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
57769677|NCT05774899|DRUG|Abemaciclib|CDK4/6 inhibitor, tablet taken orally.
57769678|NCT05774899|DRUG|Lenvatinib|Per standard care, capsule taken orally.
57769679|NCT01263106|DRUG|LY2216684|18-mg LY2216684 oral dose
58448019|NCT01135615|DRUG|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
58313432|NCT00720759|DRUG|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
57744055|NCT01292239|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
57744056|NCT00361374|DIETARY_SUPPLEMENT|eicosapentaenoic acid|1 gram/day
57744057|NCT00361374|DIETARY_SUPPLEMENT|docosahexaenoic acid|1 gram/day
57744058|NCT00361374|DRUG|Placebo|980 milligram/day
57744059|NCT02846623|DRUG|Atezolizumab|Given IV
57744060|NCT02846623|OTHER|Laboratory Biomarker Analysis|Correlative studies
57744061|NCT02846623|BIOLOGICAL|Obinutuzumab|Given IV
57744062|NCT02846623|DRUG|Venetoclax|Given PO
57744063|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
57744064|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
57744065|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
57744066|NCT01106833|DRUG|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
57744067|NCT01106833|DRUG|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
57744068|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
57744069|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
57744070|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
57744071|NCT01394393|BEHAVIORAL|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
57744072|NCT01394393|BEHAVIORAL|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
58313433|NCT00720759|BEHAVIORAL|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
58313434|NCT01267032|BEHAVIORAL|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
58448020|NCT03093337|OTHER|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
57744073|NCT01394393|DIETARY_SUPPLEMENT|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
57744074|NCT06732700|OTHER|Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.|INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed
58313435|NCT01267032|BEHAVIORAL|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
58313436|NCT01267032|BEHAVIORAL|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
58448021|NCT01189474|DEVICE|Blephasteam|Eye lid warming goggles
58448022|NCT06540963|DRUG|Tipifarnib|Tablet
57744075|NCT06089577|DRUG|Cangrelor 50 MG|Cangrelor will be administered during PCI
57744076|NCT00944502|DRUG|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
57744077|NCT03390439|DEVICE|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
57744078|NCT03390439|DEVICE|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
57744079|NCT04766684|DEVICE|J-Tip with Xylocaine MPF with placebo cream|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream
57744080|NCT04766684|DRUG|L.M.X.4 cream with J-Tip saline injection|L.M.X.4 cream with J-Tip saline injection
57744081|NCT02411565|DRUG|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
58448023|NCT06540963|DRUG|Naxitamab|IV
58448024|NCT02011100|DIETARY_SUPPLEMENT|Carnosine|
57744082|NCT02411565|DRUG|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
57744083|NCT02411565|OTHER|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
57744084|NCT02411565|OTHER|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
57744085|NCT06487195|BEHAVIORAL|Peer-facilitated, Recovery-based Self-illness-management programme|The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.
57744086|NCT06487195|BEHAVIORAL|Psycho-education group|The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.
57744087|NCT06487195|BEHAVIORAL|Treatment-as-usual only|Participants in the TAU group will receive routine community mental healthcare services.
57744088|NCT00538551|OTHER|Database|Database
57744089|NCT04960111|DEVICE|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
57744090|NCT05773573|DEVICE|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
57744091|NCT05773573|DEVICE|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
57744092|NCT03972111|DRUG|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
57744093|NCT03728972|DRUG|Pembrolizumab|200mg IVPB every 3 weeks
57744094|NCT02920827|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
57744095|NCT02920827|COMBINATION_PRODUCT|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
57744096|NCT06732323|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
57744097|NCT06732323|DRUG|Investigator's Choice Chemotherapy|Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
57744098|NCT01749982|OTHER|Placebo|
57744099|NCT01749982|DRUG|Choline bitartrate|
58448025|NCT03115762|BIOLOGICAL|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
57744100|NCT01749982|DRUG|Betaine|
57744101|NCT01749982|DRUG|Choline bitartrate + Betaine|
58448026|NCT03115762|BIOLOGICAL|ASKB1202|
57744102|NCT02679261|DRUG|Atorvastatin|Oral administration atorvastatin 20 mg per day
58448027|NCT00172211|DRUG|Physioneal|
58448028|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
58448029|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
58448030|NCT03554928|DIAGNOSTIC_TEST|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
58448031|NCT00277550|DRUG|Tegaserod and Placebo|
57744103|NCT02679261|DRUG|Placebo|Oral administration placebo
57744104|NCT04404712|DRUG|[11C]MK-3168|One PET scan involving administration of PET ligand \[11C\]MK-3168
57744105|NCT00515502|DRUG|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
57744106|NCT00515502|DRUG|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
57744107|NCT05223985|DEVICE|Depth Coagulation Electrode|SEEG and thermocoagulation
57744108|NCT05717634|DIAGNOSTIC_TEST|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
57744109|NCT02869087|DEVICE|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
57744110|NCT03647306|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
57744111|NCT03647306|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
57744112|NCT03647306|BEHAVIORAL|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
57769680|NCT01263106|DRUG|Theophylline|200-mg theophylline oral dose
58458576|NCT01616628|BEHAVIORAL|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
57744113|NCT01814969|RADIATION|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
57744114|NCT01814969|RADIATION|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
57744115|NCT01746693|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
57744116|NCT01746693|OTHER|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
57744117|NCT01746693|DEVICE|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
57744118|NCT01746693|OTHER|Pattern electroretinography|inner retinal function
57744119|NCT01746693|OTHER|Fourier domain optical coherence tomography|Blood flow in retina.
57744120|NCT05763628|DEVICE|Control Lens (stenfilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
57744121|NCT05763628|DEVICE|Test Lens (senofilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
57744122|NCT03512652|DEVICE|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
57744123|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
58448032|NCT05947617|DRUG|VIX001|"This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes."
58448033|NCT01559272|DRUG|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
58448034|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
58448035|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
58448036|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
58448037|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
57744124|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
57744125|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
57744126|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
57744127|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
57744128|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
57744129|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
57958055|NCT03242837|BEHAVIORAL|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
58448038|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
58448039|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
58448040|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
57744130|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
57744131|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
57744132|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
57744133|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
57744134|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
57744135|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
57744136|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
57744137|NCT01492075|DRUG|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
57744138|NCT06353321|DIAGNOSTIC_TEST|PET-CT imaging subsystem of the RefleXion X1 System Device|Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners
57958056|NCT03242837|OTHER|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
58118235|NCT01346410|RADIATION|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
58448041|NCT01559272|DRUG|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
58448042|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
58448043|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
58448044|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
58448045|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
58448046|NCT06709898|OTHER|Cognitive job accommodation|Job accommodation focused on the cognitive aspects at work
58448047|NCT02058446|DRUG|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
58448048|NCT06525779|DEVICE|Use of macintosh laryngoscope|The requirement of external laryngeal manipulation recorded in use of macintosh vs mcGrath laryngoscope in double lumen tube insertion
58448049|NCT06525779|DEVICE|Use of mcGarth laryngoscope|Use of mcGarth laryngoscope
58448050|NCT03981679|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
58448051|NCT06725628|DIAGNOSTIC_TEST|Thy_CLNM_multi_omics|Surgery
58448052|NCT06725732|DRUG|Tranexamic Acid (TXA)|To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
58448053|NCT06725732|DRUG|Tranexamic Acid|To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
58448054|NCT02278926|OTHER|Ultrasound|Ultrasound measurements
58448055|NCT02278926|OTHER|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
57744139|NCT06733896|OTHER|trigger point pressure|The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.
57744140|NCT06733896|OTHER|neck exercises|Manual Cervical Traction Technique and others
57744141|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
57744142|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
57744143|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
57744144|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
57744145|NCT06732531|DRUG|BH011|BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
57744146|NCT03457753|DRUG|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
57744147|NCT02251990|DRUG|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
57744148|NCT02251990|DRUG|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
57744149|NCT02792166|PROCEDURE|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
57744150|NCT02792166|PROCEDURE|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
57769681|NCT05245604|DRUG|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
58118236|NCT02320357|DRUG|Treatment by clopidogrel|Peripheral blood will be obtained during the study
57769682|NCT05245604|DRUG|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
58118237|NCT05786807|DRUG|K-CAB|Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
58118238|NCT05488184|DIETARY_SUPPLEMENT|Flavoured Oral Nutritional Supplement (ONS)|Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
58118239|NCT05112809|DEVICE|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
58448056|NCT02938208|DEVICE|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
58448057|NCT03273335|DEVICE|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
58448058|NCT05263414|DEVICE|tVNS|tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
58448059|NCT03571555|BEHAVIORAL|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
58448060|NCT02351765|DRUG|Acelarin|First-in-class nucleotide analogue
58448061|NCT02351765|DRUG|Cisplatin|Platinum-compound chemotherapy drug
58448062|NCT00099138|BEHAVIORAL|Caloric Restriction (CR)|
58448063|NCT00099138|BEHAVIORAL|Exercise|
58448064|NCT02386982|DRUG|HMS5552|
58448065|NCT00679835|DRUG|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
58118240|NCT03577184|DRUG|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
58118241|NCT06545968|BEHAVIORAL|A social media based intervention|WatsApp-based modules to influence retention in care behaviour
58448066|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
58448067|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
58448068|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
58448069|NCT00797849|DEVICE|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
58448070|NCT00797849|DEVICE|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
58448071|NCT02482116|OTHER|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
58448072|NCT02517541|DEVICE|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
58448073|NCT01398371|DRUG|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
58448074|NCT01398371|DRUG|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
58448075|NCT04799249|DRUG|Trilaciclib|Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
58448076|NCT04799249|DRUG|Placebo|Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
58448077|NCT04799249|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
58448078|NCT04799249|DRUG|Carboplatin|Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
58118242|NCT02479828|DRUG|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
58448079|NCT00187252|DEVICE|Atrial Overdrive Pacing|Pacemaker/ ICD implant
58448080|NCT05943886|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
58448081|NCT05943886|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen.
58448082|NCT01459445|DRUG|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
57744151|NCT04072159|BEHAVIORAL|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
57744152|NCT06698887|DRUG|Idecabtagene vicleucel|As per CA089-1043 study protocol
58118243|NCT02479828|DRUG|Ropivacaine|
58118244|NCT02479828|DEVICE|ultrasound|
58118245|NCT02479828|DRUG|Placebo|
58118246|NCT01713712|BEHAVIORAL|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
58118247|NCT00969839|DEVICE|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
58118248|NCT03731481|BEHAVIORAL|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
58118249|NCT03329118|DRUG|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
58118250|NCT00677911|BEHAVIORAL|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
58118251|NCT05238493|DRUG|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
58118252|NCT05238493|DRUG|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
58118253|NCT00784212|DRUG|BGG492|
58118254|NCT00784212|DRUG|BGG492|
58118255|NCT00784212|DRUG|Placebo|
58448083|NCT03362749|OTHER|RFA, MWA, cryo and IRE|local tumor ablation
58448084|NCT02665182|BEHAVIORAL|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
58448085|NCT01361646|DRUG|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
58448086|NCT01748838|DRUG|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
58448087|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430 in capsules
57744153|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
57744154|NCT04754607|OTHER|Low Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
57744155|NCT04754607|OTHER|Sham|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
57744156|NCT05072873|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
57744157|NCT05072873|OTHER|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
57744158|NCT06733220|PROCEDURE|Surgery for strabismus|Patients will undergo surgery to correct strabismus, congenital or acquired
57744159|NCT01953848|DRUG|EC905|Oral
57744160|NCT01059565|DRUG|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
57744161|NCT01059565|DRUG|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
57744162|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
57744163|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
57744164|NCT01744652|DRUG|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
57744165|NCT01744652|DRUG|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
57744166|NCT05773768|DEVICE|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
57744167|NCT06733207|OTHER|Pupil examination|Pupil assessment : bilateral clinical examination of the patient's pupils, assessed in qualitative data : mydriasis, myosis, pupillary light reflex, anisocoria or isochoria.
57744168|NCT00934284|OTHER|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
57744169|NCT00934284|OTHER|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
58118256|NCT01960751|OTHER|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
57744170|NCT05320731|PROCEDURE|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
57744171|NCT05320731|PROCEDURE|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
57744172|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
57744173|NCT06711510|OTHER|Clinical, behavioral and cognitive evaluation|Questionnaries and tests
57744174|NCT06711510|OTHER|blood sampling|blood sampling (56ml max)
57744175|NCT06711510|OTHER|brain MRI|brain MRI (35 to 70 minutes)
57744176|NCT06711510|OTHER|olfactory swab sampling with nasal brush|olfactory swab sampling with nasal brush
57744177|NCT06711510|OTHER|skin punch biopsy|skin punch biopsy (optional intervention)
58118257|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.
58458577|NCT04550858|DRUG|Rebamipide|rebamipide use for ttt of h.pylori infection
57744178|NCT06711510|OTHER|lumbar puncture for CSF sampling|lumbar puncture for CSF sampling (optional intervention)
57744179|NCT06340620|DEVICE|Endoscopic ultrasound examination|Endoscopic ultrasound examination will be performed.
58118258|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic spoon grasper|Hysteroscopic endometrial biopsy performed through the spoon grasper.
58118259|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic alligator grasper|Hysteroscopic endometrial biopsy performed through the alligator grasper.
57744180|NCT06732427|DRUG|fospropofol Disodium for injection|Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)
57744181|NCT06732427|DRUG|Propofol|Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
57744182|NCT04378348|BEHAVIORAL|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
57744183|NCT04378348|BEHAVIORAL|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
57744184|NCT04378348|BEHAVIORAL|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
57744185|NCT05460325|DRUG|Lanadelumab|Lanadelumab subcutaneous injection
57744186|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
57744187|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
57744188|NCT02739282|OTHER|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
57744189|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
57769683|NCT02309177|DRUG|nab-Paclitaxel|
57769684|NCT02309177|DRUG|Nivolumab|
57769685|NCT02309177|DRUG|Gemcitabine|
57769686|NCT02309177|DRUG|Carboplatin|
57958057|NCT02705989|DRUG|BMS-986195|Specified dose on specified day
57958058|NCT02705989|OTHER|Placebo|Specified dose on specified day
57958059|NCT04235556|BEHAVIORAL|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
57958060|NCT03027739|BIOLOGICAL|CART-19|CART-19 cells treated
57958061|NCT04821869|DRUG|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
57958062|NCT04821869|DEVICE|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
57958063|NCT03277495|BEHAVIORAL|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
57958064|NCT04373031|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
57958065|NCT04373031|DRUG|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
57958066|NCT05058833|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
57958067|NCT05058833|DIAGNOSTIC_TEST|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
57958068|NCT05313061|DRUG|MTX|MTX continuation
57958069|NCT01240460|DRUG|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
57958070|NCT01240460|DRUG|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
57958071|NCT04710342|DEVICE|CapBuster|Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
58118260|NCT05368142|DRUG|Nocardia rubra Cell Wall Skeleton|Nocardia rubra cell wall skeleton for external application
58118261|NCT05368142|DRUG|Silver ions dressing|Silver ions dressing for external application
58118262|NCT01697007|BIOLOGICAL|HIVIS DNA vaccine|
58118263|NCT01697007|DEVICE|Zetajet|
58118264|NCT01697007|DEVICE|Derma Vax Electroporation|
58118265|NCT01697007|BIOLOGICAL|Modified Vaccinia Ankara (MVA-CDMR)|
58118266|NCT02688608|DRUG|Pembrolizumab|200 mg IV once every 3 weeks
58118267|NCT06041581|BEHAVIORAL|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
58118268|NCT06041581|BEHAVIORAL|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
58118269|NCT06041581|BEHAVIORAL|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
58118270|NCT06041581|OTHER|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
58118271|NCT02806349|DIETARY_SUPPLEMENT|American Ginseng|herb
58118272|NCT02806349|DIETARY_SUPPLEMENT|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
58118273|NCT02806349|DIETARY_SUPPLEMENT|Control|Fiber matched control for intervention (corn starch and wheat bran)
58118274|NCT00617435|DIETARY_SUPPLEMENT|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
58448088|NCT01748838|DRUG|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
58448089|NCT01748838|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
58448090|NCT01748838|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
58448091|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430
58448092|NCT03166241|DIAGNOSTIC_TEST|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
57958072|NCT02814630|BIOLOGICAL|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
58448093|NCT03166241|DIAGNOSTIC_TEST|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
58448094|NCT03166241|DIAGNOSTIC_TEST|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
58448095|NCT03166241|DIAGNOSTIC_TEST|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
57958073|NCT01382693|BEHAVIORAL|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
57958074|NCT01382693|BEHAVIORAL|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
57958075|NCT06434480|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given."
58448096|NCT03166241|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
57958076|NCT02483312|BIOLOGICAL|IL-12|
57958077|NCT00921700|DRUG|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
57958078|NCT00921700|DRUG|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
57958079|NCT00921700|DRUG|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
57958080|NCT00921700|DRUG|Placebo|Single oral dose of lactose as placebo in gelatine capsules
57958081|NCT04726878|PROCEDURE|Erector spinae plane block|Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
58118275|NCT00617435|DIETARY_SUPPLEMENT|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
58118276|NCT00617435|DIETARY_SUPPLEMENT|control diet|Mixed of different oil
58118277|NCT04559685|COMBINATION_PRODUCT|SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
58118278|NCT04559685|DEVICE|MR-Guided Focused Ultrasound device (MRgFUS)|MR-Guided Focused Ultrasound device (MRgFUS) alone
58118279|NCT03833388|DRUG|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
58118280|NCT03833388|DRUG|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
58118281|NCT00577759|OTHER|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
58118282|NCT00577759|OTHER|Passive Intervention|Provision of tools to help with referrals to community resources
57744190|NCT06418373|BEHAVIORAL|Get Ready with My Heart Program|"In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program."
57744191|NCT06418373|BEHAVIORAL|Conventional intervention|Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
57958082|NCT04726878|PROCEDURE|Sham block|Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
58448097|NCT03166241|DIAGNOSTIC_TEST|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
58448098|NCT03221686|DIETARY_SUPPLEMENT|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
58448099|NCT03221686|DIETARY_SUPPLEMENT|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
58448100|NCT04892082|BEHAVIORAL|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
58448101|NCT04892082|OTHER|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
57744192|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
57744193|NCT06568237|DRUG|Placebo|Matching placebo administered orally
57744194|NCT05630547|DRUG|SAR443820|Tablet by oral administration
57958083|NCT04726878|PROCEDURE|General anesthesia|"Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl."
57958084|NCT04726878|PROCEDURE|Patient-controlled analgesia|All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
57958085|NCT04726878|DRUG|Oxycodone|Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
57958086|NCT04726878|DRUG|paracetamol|intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
57958087|NCT01849172|OTHER|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
58118283|NCT00577759|OTHER|No intervention|No intervention
58118284|NCT00963183|DRUG|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
58118285|NCT00963183|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
58448102|NCT06725641|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
58448103|NCT06725641|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）|Cholinergic agonists
58448104|NCT01727596|OTHER|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
58118286|NCT05295771|PROCEDURE|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
58118287|NCT01477437|OTHER|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
58118288|NCT01033344|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
58118289|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
58118290|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
58118291|NCT06482593|DRUG|Zinc-Oxide Eugenol Sealer|Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
58118292|NCT06482593|DRUG|AH-Plus Epoxy Resin Sealer|Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
58118293|NCT06482593|DRUG|Bio-C Sealer|Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
58118294|NCT05240339|OTHER|Observation of minor phenomena|observation twice a year over 3 years
58118295|NCT04727697|OTHER|Augmented Reality|Patients will receive the preoperative AR experience during their immediately preoperative office visit. The duration of the exposure is approximately 15 minutes.
58118296|NCT04727697|OTHER|Standard of Care preoperative teaching and handouts|At preoperative appointments, patients receive verbal teaching and written handouts about day of surgery instructions and expectations.
58118297|NCT01806233|PROCEDURE|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
58118298|NCT01806233|PROCEDURE|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
57744195|NCT05630547|OTHER|Placebo|Tablet by oral administration
57744196|NCT04945317|OTHER|ROSE (presence of cytotech) & liquid prep|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
58118299|NCT00803842|DRUG|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
58118300|NCT00294424|PROCEDURE|Short waiting time|
58118301|NCT00294424|PROCEDURE|Non-fixed waiting time|
58118302|NCT00638859|DRUG|Telithromycin (HMR3647)|
58118303|NCT04255459|OTHER|Moist Snuff|Moist Snuff product
57744197|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & liquid prep|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
58118304|NCT04255459|OTHER|Camel Snus|Camel Snus product
57744198|NCT04945317|OTHER|ROSE (presence of cytotech) & tissue clot sample|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
57744199|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & tissue clot sample|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
57769687|NCT05183217|BEHAVIORAL|Online Continence promotion program without tailoring|The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
58118305|NCT04255459|OTHER|Cigarettes|Cigarette product
58118306|NCT04255459|OTHER|No tobacco usage|No tobacco usage
58118307|NCT00174499|DRUG|2 mg nicotine gum|2 mg nicotine gum
58118308|NCT00174499|DRUG|4 mg nicotine gum|4 mg nicotine gum
58118309|NCT05200702|DEVICE|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
57744200|NCT06733792|BEHAVIORAL|CBT-based intervention|"* 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use).~* 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use).~* 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use).~* 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan."
57744201|NCT06733792|BEHAVIORAL|Self-help guide|Psychoeducation on cannabis.
57744202|NCT05222282|OTHER|Sexual Health|Prevention of sexual dysfunction
57744203|NCT06383585|DEVICE|oZTEo|An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
58118310|NCT05434208|OTHER|Nurse-led telephonic calls|active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
58118311|NCT05715255|BEHAVIORAL|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
57744204|NCT04106726|DRUG|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
58448105|NCT05066165|GENETIC|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
58448106|NCT05066165|GENETIC|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
57744205|NCT04106726|DRUG|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
57744206|NCT04106726|DRUG|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
57744207|NCT03094260|DEVICE|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
57744208|NCT03094260|DEVICE|Low intensity light therapy|"Treatment with light therapy in low intensity (\<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
57744209|NCT00360438|DRUG|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
57744210|NCT06453265|DRUG|Cebranopadol- 600 ug|"Dose ascending cohorts~- Cebranopadol 600 ug single dose"
57744211|NCT06453265|DRUG|Cebranopadol- 800ug|"Dose ascending cohorts~- Cebraopadol 800 ug single dose"
57744212|NCT06453265|DRUG|Cebranopadol- 1000ug|"Dose ascending cohorts~- Cebranopadol 1000 ug single dose"
57744213|NCT06453265|DRUG|Treatment A:|Cebranopadol, dose determined in Part A
57744214|NCT06453265|DRUG|Treatment B|Oxycodone HCl IR 40 mg
57744215|NCT06453265|DRUG|Treatment C|Placebo
57958088|NCT01849172|OTHER|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
58448107|NCT02801565|DRUG|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
57744216|NCT06453265|DRUG|Qualification|Oxycodone 40mg
57744217|NCT06453265|DRUG|Qualification|Matching Placebo
57744218|NCT04866550|OTHER|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
57958089|NCT02065154|DRUG|Cyclophosphamide|
58448108|NCT06346574|BEHAVIORAL|Experimental|Participants will receive access to health and wellness app and guide
58448109|NCT04950465|OTHER|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste containing 0.454% SnF2.
57744219|NCT04401514|DEVICE|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
57744220|NCT06733636|OTHER|Sudoku Puzzles|Sudoku puzzles of consistent and regular difficulty
58118312|NCT05715255|BEHAVIORAL|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
58118313|NCT01206361|DRUG|XALACOM|Xalacom eye drops
58118314|NCT01206361|DRUG|Duotrav|Duotrav eye drops
58118315|NCT01206361|DRUG|Ganfort|Ganfort eye drops
58118316|NCT02277457|RADIATION|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
58118317|NCT02277457|DRUG|Erlotinib|150 mg once daily
58118318|NCT02277457|DRUG|Crizotinib|250 mg twice daily
58118319|NCT03291977|DRUG|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
58118320|NCT03291977|PROCEDURE|White-light surgery|The surgery will be performed under classical conditions
58448110|NCT04950465|OTHER|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.
58448111|NCT04950465|OTHER|Sensodyne Repair and Protect|Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
57744221|NCT06733636|OTHER|ScentCare (Olfactory Training Device)|ScentCare is a smell training device with eight encapsulated scents housed in separate compartments and is contained using a charcoal filter, which will be dispersed in the base of our device to prevent smell contamination in the user's environment. The outer casing contains an opening that can be manually rotated to line up with the casing on each scent. This is facilitated by a rod in the center of the device, which serves as the axis of rotation. By pressing the capsule, the desired scent is released through a hole in the casing, similar to the mechanism of a pen. The user presses the compartment back downwards into the casing when done. The ScentCare mobile application offers clear instructions for at-home smell training and testing, with features like scent randomization to prevent users from getting accustomed to a specific order. It provides detailed guidance on device use and allows users to schedule sessions and receive daily reminders, ensuring a structured training regimen.
57744222|NCT04674124|BEHAVIORAL|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
57744223|NCT04875481|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
57744224|NCT04875481|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
57744225|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
57744226|NCT04412044|DRUG|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
57958090|NCT02281695|OTHER|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
57958091|NCT01618214|DRUG|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
57958092|NCT04918329|OTHER|Observational study|Non interventional study
57958093|NCT03970902|OTHER|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
57958094|NCT03970902|OTHER|Care As Usual|No intervention Patients receive care as usual from their family physician
57958095|NCT03915223|PROCEDURE|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
57958096|NCT06475144|OTHER|online escape room teaching|here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.
57958097|NCT06475144|OTHER|online video-based teaching|"The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay."
57958098|NCT04324372|DRUG|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
57958099|NCT01910714|BEHAVIORAL|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
57744227|NCT06579599|OTHER|an integrated working group nursing|(1) Establishment of an integrated team in the operating room; (2) Development of a nursing plan; (3) Nursing safety training and reflection in the operating room; (4) Designate a person to manage instruments and equipment in the operating room and establish protocols (5) Nurses should also participate in the development of the patient's individualized surgical plan communicate with the surgeon about the preparation of items needed for surgery to ensure seamless coordination. Assist anesthesiologists and surgeons and oversee the implementation of aseptic procedures.
58118321|NCT02934295|BIOLOGICAL|Determination of Anti-Rubella Antibody, E1|
58118322|NCT02956642|DEVICE|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
58118323|NCT02956642|DEVICE|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
58118324|NCT05333419|DRUG|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
58118325|NCT02780700|DRUG|Nintedanib|
58448112|NCT05184517|DRUG|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
58448113|NCT05184517|DRUG|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
58448114|NCT05864144|DRUG|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
58448115|NCT05864144|DRUG|Cemiplimab|Cemiplimab IV every 21 days.
58448116|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
58448117|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
57744228|NCT05952180|DEVICE|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
57744229|NCT05952180|OTHER|Standard cycloergometer|the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
57958100|NCT01910714|BEHAVIORAL|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
58448118|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
58448119|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
58448120|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
58118326|NCT02780700|DRUG|Capecitabine|
58118327|NCT04995978|DRUG|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
58118328|NCT04995978|DRUG|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
58118329|NCT03107013|DRUG|[14C]-BTD-001|Carbon-14 labeled BTD-001
58118330|NCT03273244|DEVICE|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
58118331|NCT00631865|BIOLOGICAL|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
58118332|NCT02587702|OTHER|β-Palmitate Content|
58118333|NCT02587702|OTHER|Placebo|
58118334|NCT02587702|OTHER|β-Palmitate Content Naturely in Human Milk|
58118335|NCT01981486|DRUG|Placebo Tablets|BID modified-release tablets
58448121|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
58448122|NCT00193817|PROCEDURE|Two field vs Three field lymphadenectomy|
58448123|NCT00587678|DRUG|Simvastatin|40mg each night
58448124|NCT00587678|DRUG|Ezetimibe|10mg daily
58448125|NCT00587678|DRUG|Simvastatin/Ezetimibe|40mg/10mg each night
58448126|NCT00061893|DRUG|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
58448127|NCT00061893|DRUG|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
58448128|NCT00061893|DRUG|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
58118336|NCT01981486|DRUG|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
58118337|NCT01595009|DRUG|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
58118338|NCT00418483|BIOLOGICAL|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
58118339|NCT00418483|BIOLOGICAL|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
58118340|NCT00418483|BIOLOGICAL|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
57744230|NCT04776980|DIAGNOSTIC_TEST|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
57744231|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
58118341|NCT00418483|BIOLOGICAL|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
57744232|NCT03178617|OTHER|Educational Intervention|Attend HIP
57744233|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
57744234|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
58118342|NCT00418483|BIOLOGICAL|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
57744235|NCT04871789|DIAGNOSTIC_TEST|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
57744236|NCT02883738|OTHER|tremor|evaluation of the intensity of the tremor
58118343|NCT00418483|BIOLOGICAL|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
58118344|NCT00418483|BIOLOGICAL|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
58118345|NCT05489185|DRUG|Tranexamic acid|Intravenous or topical administration
58448129|NCT00061893|DRUG|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
57744237|NCT00701038|DEVICE|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
57744238|NCT05193591|OTHER|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
57744239|NCT05323318|OTHER|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
57744240|NCT06732401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57744241|NCT06732401|DRUG|Ceralasertib|Given PO
57744242|NCT06732401|PROCEDURE|Computed Tomography|Undergo CT scan
57744243|NCT06732401|BIOLOGICAL|Durvalumab|Given IV
57744244|NCT06732401|PROCEDURE|Echocardiography|Undergo echocardiography
57744245|NCT01918995|DRUG|Regadenoson|Intravenous (IV)
57958101|NCT02475798|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
57958102|NCT02167932|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
58118346|NCT05489185|OTHER|Physiologic saline|Placebo
58118347|NCT02459704|PROCEDURE|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
58118348|NCT02459704|DEVICE|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
58118349|NCT01617733|DRUG|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
58118350|NCT00977002|OTHER|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
57744246|NCT01918995|DRUG|Placebo|Intravenous (IV)
57744247|NCT03083899|OTHER|Out-patient clinic on demand (patient-initiated)|Free use of any resources in the out-patient clinic
57744248|NCT03083899|OTHER|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
57744249|NCT03258580|DEVICE|Medoc thermal stimulator|Heat pain stimulation for substudy 1
57744250|NCT03258580|DEVICE|Electric shock stimulator|Electric pain stimulation for substudy 1
57744251|NCT03258580|DEVICE|Cold water bath|Cold pain stimulation for substudy 1
57744252|NCT03258580|BEHAVIORAL|Pain assessment performance feedback|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
57744253|NCT05731128|DRUG|Dupilumab|injection solution subcutaneous
57744254|NCT05731128|DRUG|Placebo|injection solution subcutaneous
57744255|NCT04538742|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
57744256|NCT04538742|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
58118351|NCT00977002|OTHER|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
58118352|NCT00003235|DRUG|carboplatin|
58118353|NCT00003235|DRUG|paclitaxel|
58118354|NCT00003235|RADIATION|radiation therapy|
58118355|NCT04371250|OTHER|Survey and Questionnaire|Resilience and Loneliness questionnaires
57744257|NCT04538742|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
57744258|NCT04538742|DRUG|Pertuzumab|Pertuzumab: administered as an IV infusion
57958103|NCT03177772|BEHAVIORAL|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
58118356|NCT04144296|DIAGNOSTIC_TEST|Study procedure|"* Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line"
58118357|NCT02687009|DRUG|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
58448130|NCT00061893|DRUG|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
58448131|NCT00061893|DRUG|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. \[Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.\]
58448132|NCT00061893|DRUG|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
58448133|NCT00061893|PROCEDURE|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
58448134|NCT00061893|RADIATION|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
58448135|NCT00061893|DRUG|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
58448136|NCT00061893|DRUG|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
58448137|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
58448138|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
57958104|NCT04406909|OTHER|Access to training facility|Access to training facility under national regulations for COVID control
57958105|NCT01185405|OTHER|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
58448139|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
58448140|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
57744259|NCT04538742|DRUG|Tucatinib|Tucatinib administered orally (tablet) twice daily
57744260|NCT00907829|DRUG|lidocaine|comparison of the effect of the drug to help improve finger function
57744261|NCT00907829|DEVICE|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
57744262|NCT00713648|DRUG|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
57744263|NCT06523673|RADIATION|Stereotactic Body Radiotherapy|The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
57744264|NCT06523673|DRUG|second-line systemic therapy|a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
57744265|NCT06096493|PROCEDURE|curative surgery for cancer rectum|Curative surgery for cancer rectum.
57744266|NCT06615921|OTHER|No Intervention|This is a non-interventional study.
57958106|NCT04624165|OTHER|Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
57744267|NCT00970138|DRUG|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
57744268|NCT06723262|OTHER|Tonotopic cochlear implant fitting FS4T|Comparison of FS4T and FS4noT
57744269|NCT01761097|DEVICE|Endocuff attachment|Endocuff
57744270|NCT04598724|OTHER|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
58118358|NCT05638152|OTHER|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~* natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~* Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~* Music available to patients~* Comfort Talk communication course for PACU nurses"
58118359|NCT04947579|DRUG|CC-99677|Oral
58118360|NCT04947579|OTHER|Placebo|Oral
58118361|NCT04254523|DEVICE|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
58118362|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
58118363|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
58118364|NCT03947606|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
58448141|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
58118365|NCT02495610|OTHER|Gait analysis and MRI:|"* Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
57744271|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
57744272|NCT00002153|DRUG|A-007|
57744273|NCT02816151|DRUG|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
57744274|NCT02816151|DRUG|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
57744275|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
58448142|NCT01789684|OTHER|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
57744276|NCT05279170|OTHER|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
57744277|NCT01328080|RADIATION|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
57744278|NCT06596642|DRUG|Luspatercept|As per product label
57744279|NCT00775710|DEVICE|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
57744280|NCT04973605|DRUG|BGB-11417|Administered orally daily
57744281|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
57744282|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
58118366|NCT02342444|DRUG|Enoxaparin Sodium Injection 30 mg BID|
58118367|NCT02342444|DRUG|Enoxaparin Sodium Injection 40 mg QD|
58448143|NCT02466984|DRUG|metoclopramide intravenous|Administration route
58448144|NCT06170853|OTHER|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
58448145|NCT04887324|OTHER|no intervention|no intervention
58448146|NCT01054482|DRUG|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
58448147|NCT01054482|OTHER|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
57744283|NCT04889430|DRUG|Iptacopan|Iptacopan 200mg twice daily oral
57744284|NCT03979573|DIAGNOSTIC_TEST|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
58448148|NCT03650088|BEHAVIORAL|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
58448149|NCT04555564|PROCEDURE|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
58448150|NCT00984308|PROCEDURE|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
58118368|NCT06012058|DIAGNOSTIC_TEST|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
58118369|NCT06012058|DIAGNOSTIC_TEST|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
58448151|NCT00557999|OTHER|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
58448152|NCT00002306|DRUG|Fluconazole|
58448153|NCT04120415|BIOLOGICAL|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
58448154|NCT04120415|BIOLOGICAL|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
58448155|NCT04120415|BIOLOGICAL|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
58448156|NCT05959460|OTHER|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
58448157|NCT02737579|PROCEDURE|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
58448158|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
58448159|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
58448160|NCT00286494|DRUG|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
58448161|NCT03679728|BEHAVIORAL|First trimester|Analysis of sensorimotor outcomes
58448162|NCT03679728|BEHAVIORAL|Second trimester|Analysis of sensorimotor outcomes
58448163|NCT02650089|OTHER|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
58448164|NCT02650089|OTHER|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
58448165|NCT02650089|OTHER|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
58448166|NCT04557540|BEHAVIORAL|Lifestyle Therapy|Receive The WORD lifestyle CER weight loss intervention
58448167|NCT04557540|OTHER|Quality-of-Life Assessment|Ancillary studies
58448168|NCT04557540|OTHER|Questionnaire Administration|Ancillary studies
58448169|NCT04557540|OTHER|Short-Term Fasting|Receive Fasting WORD intermittent fasting weight loss intervention
58118370|NCT01115218|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin C
58118371|NCT03907826|DRUG|PD-1 blocking antibody|Toripalimab 240mg, D1, every 3 weeks per cycle
58118372|NCT03907826|DRUG|GP|Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
58118373|NCT03907826|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
58118374|NCT01338844|DIETARY_SUPPLEMENT|Myo-inositol|
58118375|NCT01338844|DIETARY_SUPPLEMENT|D-chito-Inositol|
58118376|NCT04279639|BEHAVIORAL|qigong|Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.
57744285|NCT03979573|DIAGNOSTIC_TEST|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
57744286|NCT03979573|DIAGNOSTIC_TEST|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
57744287|NCT03979573|DIAGNOSTIC_TEST|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
57744288|NCT05109091|DRUG|ATH434 dose level 1|ATH434 taken BID
57958107|NCT03739450|BEHAVIORAL|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
57958108|NCT03739450|BEHAVIORAL|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
58118377|NCT03982849|DRUG|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
58118378|NCT03982849|DRUG|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
58118379|NCT04209920|DEVICE|CAD-CAM milled PMMA crown|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
58118380|NCT04209920|OTHER|Cast metal coping using nickel chromium alloy|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
58118381|NCT00467818|DRUG|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
58118382|NCT00467818|OTHER|Placebo|Same dosage as that of omega 3 fatty acids
58118383|NCT03120156|DEVICE|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
58118384|NCT03120156|DEVICE|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
58448170|NCT04991675|BEHAVIORAL|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
58448171|NCT04991675|BEHAVIORAL|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
58448172|NCT03288571|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
57744289|NCT05109091|DRUG|ATH434 dose level 2|ATH434 taken BID
57744290|NCT05109091|DRUG|Placebo|Placebo taken BID
57744291|NCT03509116|OTHER|Observations|Consultation observations
57744292|NCT03509116|OTHER|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
57744293|NCT05968651|DRUG|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
57744294|NCT05615649|DEVICE|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
57744295|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
57744296|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
58118385|NCT03120156|OTHER|No insoles|control group with no insoles in the shoes
58118386|NCT00330421|DRUG|sorafenib tosylate|Given PO
58118387|NCT00330421|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58118388|NCT00330421|OTHER|laboratory biomarker analysis|Correlative studies
58118389|NCT00330421|OTHER|pharmacological study|Correlative studies
58118390|NCT00330421|PROCEDURE|computed tomography|Correlative studies
58118391|NCT00330421|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
58118392|NCT04984291|DEVICE|Alliance Glenoid|Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
58448173|NCT06530212|PROCEDURE|SGJIB|sleeve gastrectomy with jejunoileal bypass with anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction.
58448174|NCT06530212|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.
58448175|NCT01233063|BEHAVIORAL|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
58448176|NCT04192955|DRUG|Acetyl Salicylate|Tablets
58448177|NCT00022802|DEVICE|Image-guided surgical system|
58448178|NCT04626375|DRUG|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
57958109|NCT00516737|DRUG|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
57958110|NCT00516737|DRUG|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
58448179|NCT04626375|DRUG|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
58448180|NCT02756572|DRUG|Cladribine|Given IV
58448181|NCT02756572|DRUG|Cyclosporine|Given PO
58448182|NCT02756572|DRUG|Cytarabine|Given IV
58448183|NCT02756572|BIOLOGICAL|Filgrastim|Given SC
57958111|NCT02917889|DRUG|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
57958112|NCT02917889|DRUG|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
57958113|NCT02917889|OTHER|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
57958114|NCT02917889|OTHER|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
57958115|NCT02222259|PROCEDURE|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
57958116|NCT04980612|BEHAVIORAL|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
57958117|NCT04980612|BEHAVIORAL|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
57958118|NCT04395794|DIAGNOSTIC_TEST|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
57958119|NCT04395794|OTHER|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
57958120|NCT06299527|OTHER|Exercise Program|Exercise Program In our study, the telerehabilitation program was applied for both synchronous and asynchronous groups, 3 days a week, 1 session per day, for 8 weeks. The exercises were combined individually according to the person's capacity, and the intensity and duration of the exercise will gradually increase according to the patient's tolerance.
57958121|NCT04580381|DRUG|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
58118393|NCT04984291|DEVICE|Identity Stem|Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
58118394|NCT02408666|OTHER|Interview|
58118395|NCT05551377|OTHER|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
58118396|NCT04100499|DEVICE|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
58118397|NCT05736965|DRUG|Selinexor|Selinexor 60mg, PO d3,10,17
58448184|NCT02756572|DRUG|Fludarabine Phosphate|
58448185|NCT02756572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
58448186|NCT02756572|OTHER|Laboratory Biomarker Analysis|Correlative studies
58448187|NCT02756572|DRUG|Melphalan|Given IV
58448188|NCT02756572|DRUG|Mitoxantrone Hydrochloride|Given IV
58448189|NCT02756572|DRUG|Mycophenolate Mofetil|Given PO
58448190|NCT02756572|OTHER|Questionnaire Administration|Ancillary studies
58448191|NCT02756572|DRUG|Sirolimus|Given PO
58448192|NCT02756572|RADIATION|Total-Body Irradiation|Undergo TBI
58118398|NCT05736965|DRUG|Azacitidine|Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
58118399|NCT05736965|DRUG|Venetoclax|Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
58118400|NCT06383559|DRUG|Lenvatinib and Sintilimab|XELOX regimen combined with Sintilimab and Lenvatinib
58118401|NCT01838902|DRUG|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
58118402|NCT01838902|DRUG|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
58118403|NCT01838902|DRUG|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
58118404|NCT01838902|DRUG|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
58118405|NCT00928252|DRUG|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
58118406|NCT04292106|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
58448193|NCT02756572|DRUG|Melphalan Hydrochloride|Given IV
58448194|NCT01120106|DRUG|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
58448195|NCT01120106|DRUG|placebo|saline continuous infusion
58448196|NCT05154110|OTHER|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
58448197|NCT05154110|OTHER|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
58448198|NCT04459377|DRUG|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
58458578|NCT05896228|DRUG|Iberdomide|"Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy"
57744297|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
57744298|NCT01417299|DIETARY_SUPPLEMENT|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
58118407|NCT04292106|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
58118408|NCT03454971|OTHER|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
58118409|NCT03158142|DRUG|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
58118410|NCT02043366|DRUG|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
58118411|NCT02043366|DRUG|Butorphanol|Butorphanol is intravenously administrated
58118412|NCT02043366|DRUG|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
58118413|NCT02043366|DRUG|Remifentanil|Remifentanil is intravenously administrated
58118414|NCT02043366|DRUG|Sufentanil|Sufentanil is intravenously administrated
58118415|NCT01323881|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
58118416|NCT06171698|DEVICE|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
58118417|NCT02833415|DRUG|[U-13C3] glycerol|Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
58118418|NCT02833415|DRUG|Empagliflozin|Active drug
57744299|NCT01417299|DIETARY_SUPPLEMENT|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
57744300|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
57744301|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
58118419|NCT02833415|DRUG|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
58118420|NCT06038357|BEHAVIORAL|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
58448199|NCT04459377|DRUG|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
58448200|NCT04037865|DRUG|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
58448201|NCT00786318|DRUG|ziprasidone|ziprasidone 20mg IM
58448202|NCT00786318|DRUG|Standard therapy|Haldol 5mg/ Ativan 2mg IM
58448203|NCT03741504|PROCEDURE|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
58448204|NCT00260884|BEHAVIORAL|conventional gastrectomy or radical lymph node dissection|
58448205|NCT00592124|DRUG|Tenofovir disoproxil fumarate|300 mg tablet daily
58448206|NCT00592124|DRUG|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
58448207|NCT05607524|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and twice a day
58448208|NCT05607524|DIETARY_SUPPLEMENT|placebo|Eat a capsule for once, and twice a day
58448209|NCT02588235|DRUG|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
58448210|NCT02588235|DRUG|Atorvastatin|atorvastatin (20 mg/day）
58118421|NCT06038357|OTHER|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
58448211|NCT00002164|DRUG|Nelfinavir mesylate|
58448212|NCT01640782|DRUG|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"* Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
58448213|NCT01640782|DRUG|Leucovorin, 5-Fluorouracil|"* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
57744302|NCT06491511|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
57744303|NCT02101229|DRUG|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
57744304|NCT00745745|DEVICE|Device Implantation|ICD lead implantation
58448214|NCT02328248|PROCEDURE|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
58448215|NCT06312735|DEVICE|VR (Reducept)|Reducept is a novel VR intervention that consists of a combination of pain neuroscience education (PNE) and pain management techniques. It includes different psychological therapy modalities (e.g. acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and hypnotherapy) into a single application.
58448216|NCT04538976|DRUG|Sildenafil|Sildenafil in standard dosage
58458579|NCT05896228|DRUG|Carfilzomib|"Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15."
57744305|NCT01092338|DRUG|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
57744306|NCT04063189|DRUG|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
57744307|NCT06733233|DRUG|T-DXd combined with immune checkpoint inhibitor|Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses.
58448217|NCT03444493|OTHER|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
58448218|NCT01262859|DRUG|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
58448219|NCT02558855|OTHER|Thrust Joint Manipulation of the Lumbar Spine|
58448220|NCT02558855|OTHER|Non-thrust Joint Manipulation of the Lumbar Spine|
58448221|NCT05315479|DRUG|N1539|Once daily
58448222|NCT01103765|PROCEDURE|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
58448223|NCT01103765|PROCEDURE|stent deployment without post-dilatation|stent deployment without systematic post dilatation
58448224|NCT06408571|OTHER|etiology|As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
58448225|NCT03067246|DEVICE|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
58448226|NCT03067246|DEVICE|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
58448227|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
58448228|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
58448229|NCT01035671|DRUG|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
58448230|NCT03692039|PROCEDURE|M-pro files in rotating motion|An endodontic file that has controlled memory properties
58448231|NCT03692039|PROCEDURE|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
58448232|NCT05308979|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
58448233|NCT00980356|DRUG|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
58448234|NCT02727907|DRUG|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
58448235|NCT02727907|DRUG|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
57744308|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
57744309|NCT05979909|DRUG|Mitomycin C|Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
57744310|NCT05536349|DRUG|Pirtobrutinib|Given by PO
57744311|NCT05536349|DRUG|Obinutuzumab|Given by (IV) vein
57744312|NCT05536349|DRUG|Venetoclax|Given by PO
57744313|NCT05536349|DRUG|Valacyclovir|Given by PO
57744314|NCT05536349|DRUG|Allopurinol|Given by PO
57744315|NCT03543930|DEVICE|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
57958122|NCT00749996|DEVICE|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
58448236|NCT02727907|DRUG|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
58448237|NCT04713488|BIOLOGICAL|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
58448238|NCT00997282|DRUG|OPC-262 2.5 mg|orally administered once daily for 24 weeks
58448239|NCT00997282|DRUG|OPC-262 5 mg|orally administered once daily for 24 weeks
58448240|NCT00997282|DRUG|Placebo|orally administered once daily for 24 weeks
58448241|NCT04800848|DEVICE|Mask|Physical Fitness is evaluated with the use of a face mask
58448242|NCT05874284|DRUG|Gelofusin|In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
58448243|NCT01597635|DRUG|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
58448244|NCT01597635|DRUG|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
58448245|NCT01597635|DRUG|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
58448246|NCT01597635|DRUG|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
58448247|NCT01597635|DRUG|Placebo (saline)|Administered intravenously to match intervention
58448248|NCT04341714|OTHER|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
58448249|NCT02464618|BEHAVIORAL|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
57744316|NCT06723678|PROCEDURE|Two distally inclined 45-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.
57744317|NCT06723678|PROCEDURE|Two distally inclined 30-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
57744318|NCT03663231|DEVICE|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
57744319|NCT03663231|DEVICE|Placebo|IND/IDE exempt device primarily water
57744320|NCT06031272|DRUG|3BNC117-LS-J|Administered by intravenous (IV) infusion
58448250|NCT02045095|DRUG|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
57744321|NCT06031272|DRUG|10-1074-LS-J|Administered by intravenous (IV) infusion
57744322|NCT06031272|DRUG|Placebo for 3BNC117-LS-J|Administered by intravenous (IV) infusion
57744323|NCT06031272|DRUG|Placebo for 10-1074-LS-J|Administered by intravenous (IV) infusion
57744324|NCT00614666|DRUG|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~* 50 mg BID (n=8) vs placebo capsule BID (n=2)~* 250 mg BID (n=8) vs Placebo capsule BID (n=2)~* 500 mg BID (n=8) vs Placebo capsule BID (n=2)~* 750 mg TID (n=8) vs Placebo capsule TID (n=2)~At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
57744325|NCT05105594|OTHER|survey application|Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
57744326|NCT00785655|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
57744327|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
57744328|NCT03213652|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58448251|NCT04693559|PROCEDURE|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
57744329|NCT03213652|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
57744330|NCT03213652|PROCEDURE|Bone Scan|Undergo a bone scan
57744331|NCT03213652|PROCEDURE|Computed Tomography|Undergo a CT scan
58448252|NCT04693559|PROCEDURE|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
57744332|NCT03213652|DRUG|Ensartinib|Given PO
58448253|NCT04693559|PROCEDURE|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
57744333|NCT03213652|OTHER|Laboratory Biomarker Analysis|Correlative studies
58448254|NCT02041325|DRUG|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
58448255|NCT02041325|DRUG|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
57744334|NCT03213652|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57744335|NCT03213652|OTHER|Pharmacological Study|Correlative studies
57744336|NCT03213652|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
57744337|NCT03213652|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
57744338|NCT03213652|PROCEDURE|X-Ray Imaging|Undergo an x-ray
57744339|NCT06732921|DEVICE|Alertwatch - Recovery Control Tower|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
57744340|NCT06724601|DEVICE|Electrical Impedance Tomography|Electrical Impedance Tomography data and the physiological and clinical parameters will be recorded continuously in three different positions (supine 1, car seat, supine 2) to assess alterations in lung volume and cardiorespiratory events.
57744341|NCT06733493|BEHAVIORAL|integrated psychosocial care|Employment of a psychologist in psychotherapeutic training as a member of the multiprofessional team at the ICU ward for the duration of one year. Tasks: Psychosocial Support for staff, patients and their relatives.
57744342|NCT01563536|DRUG|ABT-267|Tablet
57744343|NCT01563536|DRUG|ABT-450|Tablet
57744344|NCT01563536|DRUG|ABT-333|Tablet
57744345|NCT01563536|DRUG|Ritonavir|Capsule
57744346|NCT01563536|DRUG|Ribavirin|Tablet
57958123|NCT00749996|PROCEDURE|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
57744347|NCT06399614|OTHER|Occupational Therapy-led Hand Therapy Service|Types of interventions provided by the therapist will include splinting, targeted exercises and activities, occupation-based intervention, edema management, scar management; desensitisation, functional tasks completion, and education. All interventions provided are within occupational therapists' scope of practice and are evidence based. Number of treatment sessions will be individualised to the patient and guided by stages of recovery.
57958124|NCT01780831|DRUG|Raltegravir|RAL was given as oral granules for suspension.
57958125|NCT00501813|PROCEDURE|Hepatectomy|irregular Hepatectomy
58118422|NCT00720122|DRUG|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
58448256|NCT03158324|DRUG|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
58448257|NCT04502641|DRUG|Docetaxel|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
58448258|NCT04502641|DRUG|5-fluorouracil|600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.
58448259|NCT04502641|DRUG|Cisplatin|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
58448260|NCT04502641|RADIATION|Intensity Modulated Radiation Therapy|The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.
57744348|NCT06399614|OTHER|Care as usual|Care as usual group: Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services\&#39; protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
57744349|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
57744350|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
57744351|NCT02176551|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
57744352|NCT02176551|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
57744353|NCT06579703|DRUG|Ketorolac|"Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)"
57958126|NCT00501813|PROCEDURE|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
57958127|NCT02416284|OTHER|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
57958128|NCT03911765|BEHAVIORAL|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
57958129|NCT06287320|RADIATION|concurrent or sequential chemoradiotherapy|Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.
57958130|NCT06287320|DRUG|Immunotherapy|anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
57958131|NCT02467530|OTHER|AGE|
58448261|NCT04502641|DRUG|Platinum|100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
58448262|NCT01042925|DRUG|XL147 (SAR245408)|administered orally once daily as tablet(s)
58448263|NCT01042925|BIOLOGICAL|trastuzumab|administered by IV once every 3 weeks
57958132|NCT01052311|DRUG|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
57958133|NCT01052311|DRUG|Placebo|Placebo tablets once daily
58448264|NCT01042925|DRUG|paclitaxel|administered by IV once every week
58448265|NCT02111330|DRUG|PBF-509|
58448266|NCT02111330|DRUG|Placebo|
58448267|NCT03197584|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
58448268|NCT03197584|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
58448269|NCT03197584|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
58448270|NCT03197584|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
58448271|NCT03197584|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
58448272|NCT03197584|DRUG|Fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
58448273|NCT03197584|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
58448274|NCT03197584|DRUG|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
58448275|NCT03197584|DRUG|omega-3 acid ethyl esters|omega-3 acid ethyl esters
58448276|NCT03197584|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
58448277|NCT03197584|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
58448278|NCT03197584|BIOLOGICAL|ALT-803|Recombinant human super agonist IL-15 complex
58448279|NCT03197584|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2 vaccine
58448280|NCT03197584|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
58448281|NCT03197584|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1 vaccine
58448282|NCT03197584|BIOLOGICAL|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
58448283|NCT03197584|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
58448284|NCT03197584|BIOLOGICAL|haNK®|NK-92 \[CD16.158V, ER IL-2\]
58448285|NCT00356681|DRUG|AMG 706 placebo|Blinded placebo
58448286|NCT00356681|DRUG|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
58448287|NCT00356681|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
57744354|NCT06481592|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
57958134|NCT01052311|DRUG|Tredaptive|Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
58448288|NCT00356681|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
58448289|NCT05375448|OTHER|Neural mobilisation|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
58448290|NCT04553900|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
58448291|NCT04393168|COMBINATION_PRODUCT|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
58448292|NCT06106048|OTHER|Closed kinetic chain exercises|"Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
58448293|NCT06106048|OTHER|Abdominal contraction exercises|"Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
58448294|NCT01403155|BIOLOGICAL|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
58448295|NCT01362348|DRUG|pazopanib eye drops|10 mg/mL (1 drop) four times daily
58448296|NCT06188026|DRUG|NNC0194-0499|Once a week for 5 weeks as an injection in dose of 30 mg. The injection will be given under the skin
58448297|NCT06188026|DRUG|ethinylestradiol/levonorgestrel|Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
58448298|NCT03571204|BIOLOGICAL|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
58448299|NCT03571204|BIOLOGICAL|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
58448300|NCT02238119|DRUG|Tiotropium + formoterol combination|
58448301|NCT02238119|DRUG|Tiotropium|
58448302|NCT02238119|DRUG|Formoterol|
58448303|NCT05188664|DRUG|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
57744355|NCT05807074|DRUG|Tranexamic Acid|Applied intraoperatively
57744356|NCT05807074|OTHER|Saline|Applied intraoperatively
57744357|NCT06723834|OTHER|Psychiatric Service Dog|Partnership with a trained service dog for PTSD.
57744358|NCT06723834|BEHAVIORAL|Prolonged Exposure Therapy|12 weeks of Prolonged Exposure once per week.
57744359|NCT00329069|DRUG|atorvastatin (drug)|
57744360|NCT03319940|DRUG|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
57958135|NCT03283800|OTHER|Copper impregnated compression stocking|Copper impregnated compression stocking
57958136|NCT03283800|OTHER|Normal compression stocking|Normal compression stocking without copper
57958137|NCT01730235|OTHER|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
57744361|NCT03319940|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
57958138|NCT00938756|OTHER|diagnostic laboratory biomarker analysis|
57958139|NCT00938756|OTHER|immunoenzyme technique|
57958140|NCT00938756|PROCEDURE|magnetic resonance imaging|
57958141|NCT05033496|DIAGNOSTIC_TEST|Thyroid function test|Thyroid function test
58448304|NCT05188664|DRUG|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
57744362|NCT03319940|DRUG|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
57744363|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
57744364|NCT06191627|DIAGNOSTIC_TEST|Patch testing|Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.
57744365|NCT04050865|DRUG|Dexamethasone, 0.4mg|Ophthalmic Insert
57744366|NCT04050865|DEVICE|Placebo plug with no drug|Ophthalmic Insert
58118423|NCT05322564|OTHER|Standardized opiate prescription|The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
58118424|NCT05639842|OTHER|Pain in competitive athletes with physical disabilities. Techniques for its management, support received and perceived difficulties.|A total of 413 athletes with physical disabilities participated in the study, 157 Spanish athletes and 260 Latin American athletes. The athletes were contacted through different sports federations, Paralympic Committees and sports teams of people with disabilities.For the distribution of the questionnaire, the researcher made an initial telephone contact with the Spanish Paralympic Committee and the Spanish Sports Federation for People with Physical Disabilities, to explain the objectives of the study and ask for their collaboration in the dissemination. Subsequently, the information was officially sent to them by email.
58118425|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
58448305|NCT04534686|BEHAVIORAL|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
58448306|NCT04534686|BEHAVIORAL|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
58448307|NCT05567250|BEHAVIORAL|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
58448308|NCT02038335|DRUG|DMPA|Depot medroxyprogesterone acetate
58448309|NCT02038335|DRUG|NET-EN|Norethisterone enantate
57744367|NCT06043739|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally
57744368|NCT06043739|DRUG|Filgotinib|Film-coated mini-tablets administered orally
57744369|NCT06732882|DRUG|AZD4604|Participants will receive AZD4604 via Genuair/Turbuhaler device.
57744370|NCT06732882|OTHER|Placebo|Participants will receive placebo via Genuair/Turbuhaler device.
57744371|NCT06732882|DEVICE|Genuair|Participants will either receive AZD4604 or placebo via Genuair device.
57744372|NCT06732882|DEVICE|Turbuhaler|Participants will receive either AZD4604 or placebo via Turbuhaler device.
57744373|NCT01753687|OTHER|Ocular scattering of the tear film|
57744374|NCT01753687|OTHER|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
57744375|NCT01753687|OTHER|Measurement of tear film osmolarity|
58448310|NCT02038335|DRUG|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
57744376|NCT06733961|DIAGNOSTIC_TEST|SCUBE-1 and VAP-1|There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
57744377|NCT02472964|BIOLOGICAL|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
57744378|NCT02472964|BIOLOGICAL|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
58448311|NCT02038335|DEVICE|LNG-I|Levonorgestrel subdermal implant
57958142|NCT02554539|PROCEDURE|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
58448312|NCT02038335|DEVICE|ENG-I|Etonogestrel subdermal implant
58448313|NCT02038335|DEVICE|Cu-IUD|Copper IUD
58448314|NCT05878535|DRUG|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
57744379|NCT02472964|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
57744380|NCT02472964|DRUG|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
58118426|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
57744381|NCT06078904|DRUG|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
57744382|NCT06078904|DRUG|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
57744383|NCT06078904|DRUG|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
57744384|NCT06078904|DRUG|Placebo|Placebo, one pill a day, oral intake
57744385|NCT03814733|DRUG|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
57744386|NCT03814733|DRUG|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
57744387|NCT03814733|DRUG|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
58118427|NCT05618119|DRUG|[18F]MC225|\[18F\]MC225 PET scan
58448315|NCT05878535|DRUG|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
58448316|NCT00006591|DRUG|Ritonavir|
58448317|NCT00006591|DRUG|Amprenavir|
58448318|NCT00741975|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
57744388|NCT03814733|DRUG|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
57744389|NCT03814733|DRUG|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
57744390|NCT03814733|DRUG|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
57744391|NCT06476197|DEVICE|SAT-003|Device: SAT-003(Software) Using SAT-003 for 12 weeks
57744392|NCT06721026|OTHER|Continuous intravenous stable isotope amino acid tracer infusion|During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.
57744393|NCT06721026|OTHER|Amino acid infusion|In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.
57744394|NCT06297486|GENETIC|SPK-8011|Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.
57744395|NCT06723873|OTHER|Kinesiology Taping|The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.
57744396|NCT06723873|OTHER|Placebo Kinesio Taping|In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
57744397|NCT05770479|BEHAVIORAL|Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules|ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
58118428|NCT00054483|DRUG|bortezomib|Given IV
58118429|NCT00054483|OTHER|laboratory biomarker analysis|Correlative studies
58118430|NCT00054483|OTHER|pharmacological study|Correlative studies
58118431|NCT00135395|DRUG|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
58118432|NCT00135395|DRUG|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
58118433|NCT01073306|BIOLOGICAL|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
58118434|NCT01073306|OTHER|Placebo|Subcutaneous injection of placebo
58118435|NCT00387998|OTHER|AHRQ staying healthy booklet|educational booklet about prevention
58118436|NCT00387998|OTHER|Risk primer|Know your chances booklet
58448319|NCT00741975|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
58448320|NCT00567450|DRUG|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
58448321|NCT00567450|DRUG|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
58448322|NCT04354662|DRUG|Toripalimab|240mg d1
58448323|NCT04354662|DRUG|Docetaxel|50mg/m2, d1;
58448324|NCT04354662|DRUG|Fluorouracil|2600 mg/m², d1
58448325|NCT04354662|DRUG|Leucovorin|200 mg/m², d1
58448326|NCT04354662|DRUG|Oxaliplatin|85 mg/m², d1
58448327|NCT03800121|BIOLOGICAL|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
58448328|NCT02946034|DRUG|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
58448329|NCT02946034|DRUG|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
58118437|NCT02330120|DRUG|propofol|
58118438|NCT02330120|DRUG|dexmedetomidine|
58118439|NCT05493696|DEVICE|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
58118440|NCT05493696|OTHER|Traditional physical therapy program|applied 3 times/week for 12 weeks
58118441|NCT00569426|DEVICE|NovoFine® needle 6 mm|
58118442|NCT00569426|DEVICE|NovoFine® needle 8 mm|
58118443|NCT03247283|DRUG|BMS-986205|Carbon 14 tagged BMS-986205
58118444|NCT04248374|OTHER|Taste Intensity|Taste intensity with and without sour adaptation
57744398|NCT05770479|OTHER|Treatment As Usual|Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
57744399|NCT01580072|OTHER|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
57958143|NCT03601286|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
57958144|NCT05122234|BIOLOGICAL|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
57958145|NCT05122234|OTHER|Placebo|Normal saline
57958146|NCT05122234|DRUG|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
57958147|NCT03797469|DIETARY_SUPPLEMENT|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
57958148|NCT03797469|DIETARY_SUPPLEMENT|Pyruvate|2 tablets of 1500 mg each will be administered orally.
57958149|NCT03797469|DIETARY_SUPPLEMENT|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
57958150|NCT05459623|OTHER|Manual myofascial release|will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
57958151|NCT05459623|OTHER|Emmett intervention|"will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute."
58118445|NCT01041781|DRUG|carboplatin|Given IV
58118446|NCT01041781|DRUG|celecoxib|Given orally
58118447|NCT01041781|DRUG|gemcitabine hydrochloride|Given IV
58118448|NCT01041781|DRUG|pemetrexed disodium|Given IV
58118449|NCT01041781|OTHER|placebo|Given orally
58118450|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
57744400|NCT01580072|OTHER|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
57958152|NCT03099486|DRUG|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
57958153|NCT03099486|DRUG|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
57958154|NCT03099486|DRUG|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
57958155|NCT00089908|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
57958156|NCT00089908|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
57958157|NCT04900597|OTHER|Elecare Jr|Elecare Jr is a standard pediatric elemental formula
57958158|NCT04900597|OTHER|Nourish|Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
57958159|NCT04900597|OTHER|Real Foods Blends|Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
57958160|NCT01781221|DEVICE|Alpha-Bio's GRAFT Natural Bovine Bone|
57958161|NCT01781221|DEVICE|Bio-Oss xenograft|
58118451|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
58118452|NCT04835103|BEHAVIORAL|CM|Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation
58118453|NCT04835103|BEHAVIORAL|P/T|Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
58118454|NCT01413399|DRUG|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
58118455|NCT04935775|OTHER|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
58118456|NCT04347447|OTHER|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
58118457|NCT00968383|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
58118458|NCT00968383|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
58118459|NCT00968383|DRUG|Statins|Participants will receive statins.
58118460|NCT00968383|DRUG|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
58118461|NCT00968383|PROCEDURE|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
58118462|NCT05909267|DRUG|L-dopa/Carbidopa|Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
58118463|NCT05909267|DRUG|Placebo|Patients and healthy controls will receive one time administration of Placebo.
58118464|NCT01584609|DEVICE|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
58118465|NCT01584609|DEVICE|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
58118466|NCT04473508|DRUG|Local administration of ropivacaine|Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery
58118467|NCT04473508|DRUG|Local administration of placebo (saline solution)|injection of saline solution in addition with conventional anesthesia for spine surgery
58118468|NCT02029209|DRUG|Anlotinib|Anlotinib QD
57958162|NCT02486055|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
58118469|NCT02029209|DRUG|Placebo Capsule|Placebo capsule QD
58118470|NCT05477329|DEVICE|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
58118471|NCT01394458|OTHER|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
58448330|NCT01358825|PROCEDURE|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
58448331|NCT04830579|DRUG|Etoricoxib film-coated tablet 120 mg|Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
58448332|NCT04830579|DRUG|Arcoxia® film-coated tablet 120 mg|Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
58448333|NCT00725049|DEVICE|Dental Implant (Nanotite)|Root form titanium dental implant
58448334|NCT02634333|PROCEDURE|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
58118472|NCT01394458|DRUG|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
58118473|NCT02028000|PROCEDURE|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
58118474|NCT02028000|PROCEDURE|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
58118475|NCT02028000|PROCEDURE|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
58118476|NCT00280436|DRUG|GW679769|
58118477|NCT03306576|DEVICE|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
58118478|NCT03306576|DEVICE|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
58118479|NCT03213756|DEVICE|Isometric exercises using Hand grip and elastic bands|"* Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~* Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
58118480|NCT06042283|BEHAVIORAL|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
58448335|NCT02634333|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
58448336|NCT02634333|PROCEDURE|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
58118481|NCT04464694|DRUG|Ranibizumab|Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3\~7 days before vitrectomy.
58448337|NCT02634333|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
58448338|NCT05993663|BEHAVIORAL|Arts in health group intervention|12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
58458580|NCT05896228|DRUG|Daratumumab|"Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1."
57744401|NCT05509296|DEVICE|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
57744402|NCT05509296|DEVICE|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
57958163|NCT03597932|DEVICE|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
57958164|NCT03237065|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
57958165|NCT03237065|DRUG|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
57958166|NCT05102955|OTHER|Observational questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
57958167|NCT04644809|DRUG|LY3561774|Administered SC.
57958168|NCT04644809|DRUG|Placebo|Administered SC.
57958169|NCT05160259|RADIATION|Radial visualization of the foramen arcuale atlantis|In patients with diagnosed Kimmerle's anomaly, using transcranial Doppler sonography to determine the degree of changes in blood flow in the vertebral arteries
57958170|NCT05787405|OTHER|Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.
57958171|NCT00793650|DRUG|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
57958172|NCT00793650|DRUG|Melphalan|"All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2."
57958173|NCT00793650|PROCEDURE|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
57958174|NCT05747911|OTHER||Groups will not be intervened. Only observational data will be used.
57958175|NCT01090882|DRUG|Bupivocaine|20ml 0.25% at beginning of operation
57958176|NCT01090882|DRUG|0.9% normal saline solution|20ml 0.9% NaCl
57958177|NCT04869085|BEHAVIORAL|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
57958178|NCT00143585|PROCEDURE|intramyocardial delivery of either VEGF165 or placebo|
57958179|NCT02565979|DIETARY_SUPPLEMENT|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
57958180|NCT02565979|DIETARY_SUPPLEMENT|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
57958181|NCT03538509|OTHER|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
58118482|NCT04464694|OTHER|Sham injection|Patients will receive single sham injection 3\~7 days before vitrectomy.
58118483|NCT04464694|PROCEDURE|Pars plana vitrectomy|Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
58118484|NCT02629874|DRUG|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
58118485|NCT02629874|DRUG|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
58118486|NCT02629874|DRUG|Placebo|
57744403|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
57744404|NCT04739813|BIOLOGICAL|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744405|NCT04739813|DRUG|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744406|NCT04739813|DRUG|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744407|NCT04739813|BIOLOGICAL|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744408|NCT04739813|DRUG|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744409|NCT04739813|DRUG|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
57744410|NCT02948569|DRUG|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
57744411|NCT01446081|BEHAVIORAL|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
57744412|NCT05694741|DRUG|AZD0186|Subjects will receive AZD0186 orally.
57744413|NCT05694741|DRUG|Placebo|Subjects will receive placebo orally.
57744414|NCT05566600|BIOLOGICAL|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
57744415|NCT04620278|GENETIC|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
57744416|NCT06695195|DRUG|Cannabidiol (CBD)|25 mg capsule twice daily
57744417|NCT06695195|DRUG|Placebo|25 mg capsule twice daily
57744418|NCT06618547|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
57744419|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
57744420|NCT06348199|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
57744421|NCT06348199|DRUG|Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
57744422|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
57744423|NCT01889433|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
57958182|NCT01657409|DRUG|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
57958183|NCT01657409|DRUG|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
57744424|NCT01889433|DRUG|Pegasys|180 µg subcutaneously, once a week
57744425|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
57744426|NCT02506842|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
57744427|NCT02506842|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
57744428|NCT02506842|DRUG|oxaliplatin|Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
58118487|NCT04774575|BIOLOGICAL|biomarker-guided strategy|Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
57958184|NCT01657409|DRUG|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
57958185|NCT02723123|OTHER|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
57958186|NCT06320483|DEVICE|Vibroacoustic device BARK VibroLUNG|"The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver."
57958187|NCT04513002|DIETARY_SUPPLEMENT|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
57958188|NCT03697187|DRUG|rhC1INH|Recombinant human C1 inhibitor
57958189|NCT00927836|BIOLOGICAL|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
58448339|NCT03079063|BIOLOGICAL|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
57744429|NCT02506842|DRUG|folinic acid|Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
57744430|NCT02506842|DRUG|fluorouracil|Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
57744431|NCT05286827|DRUG|Olaparib|Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
57744432|NCT06416800|DRUG|Digoxin|Oral; Tablet
57744433|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
58448340|NCT03079063|BIOLOGICAL|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
58448341|NCT06270485|PROCEDURE|PEEP|Application of different PEEP-Levels during invasive mechanical ventilation
58448342|NCT04526912|DRUG|VIB7734|Single subcutaneous dose
58448343|NCT04526912|DRUG|Placebo|Intravenous single dose matched to VIB7734.
58448344|NCT04344275|OTHER|-Scapular endurance test|The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
58448345|NCT04344275|OTHER|-Muscle strength test|Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
58448346|NCT03315520|DRUG|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
58448347|NCT00808119|DRUG|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
58448348|NCT02442349|DRUG|AZD9291|Once daily tablet 80 mg
58448349|NCT05367570|BEHAVIORAL|Cross-sectional observational study|The first work package of this project is an explanatory cross-sectional study with no intervention.
58448350|NCT05193162|OTHER|No any intervention|have no any intervention
58448351|NCT02742220|OTHER|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
57744434|NCT06416800|DRUG|Metformin|Oral; Tablet
57744435|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
57744436|NCT06416800|DRUG|Probenecid|Oral; Tablet
57744437|NCT00100685|DRUG|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
57958190|NCT00927836|DRUG|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
57744438|NCT04380402|DRUG|Atorvastatin|Atorvastatin 40 mg tablet
57744439|NCT01791725|DRUG|ELND005|
57744440|NCT01791725|DRUG|Placebo|
57744441|NCT06698250|DRUG|Zanzalintinib|Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
57744442|NCT06698250|DRUG|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
57744443|NCT06698250|DRUG|Tremelimumab|Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
57744444|NCT03663868|DIAGNOSTIC_TEST|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
57744445|NCT04041362|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion plus standard ART
57744446|NCT04041362|OTHER|Antiretroviral Therapy (ART)|Standard ART
57744447|NCT06733376|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.
57744448|NCT06733376|BEHAVIORAL|Prolonged Exposure|Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.
57744449|NCT06733376|BEHAVIORAL|Skills Training for Affective and Interpersonal Regulation|Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.
58118488|NCT04634110|DRUG|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
58448352|NCT02742220|OTHER|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
57744450|NCT05480150|DRUG|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
58118489|NCT06057285|DEVICE|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
58118490|NCT02637076|DRUG|Xyrem|single 3.0 gram dose
58118491|NCT06035783|DEVICE|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
58118492|NCT05489484|DEVICE|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
58118493|NCT02680795|DRUG|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
58118494|NCT03804320|OTHER|Active Surveillance|
58118495|NCT00993616|DRUG|belinostat|Given IV
58118496|NCT00993616|DRUG|carboplatin|Given IV
58118497|NCT00672620|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
58118498|NCT00672620|DRUG|Duloxetine|Duloxetine capsules
57958191|NCT00700271|DRUG|Amlodipine|5 mg or 10 mg tablets.
58448353|NCT02485561|BEHAVIORAL|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
57744451|NCT05480150|DRUG|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
57744452|NCT05480150|DRUG|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
57744453|NCT01458197|DRUG|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
57744454|NCT01458197|DRUG|Placebo|Capsule, qd, 12 weeks
57744455|NCT01458197|DRUG|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
57744456|NCT03328299|DRUG|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
57744457|NCT03328299|DRUG|bupivacaine|20 ml of 0.5 % bupivacaine
57744458|NCT02698124|DRUG|Decitabine|
57958192|NCT00700271|DRUG|Valsartan|160 mg capsules.
57744459|NCT03318523|DRUG|Placebo|Administered as specified in the treatment arm
57744460|NCT03318523|DRUG|BIIB054|Administered as specified in the treatment arm.
57744461|NCT03321396|DEVICE|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
57744462|NCT05496374|DRUG|Placebo|Placebo-matching capsules will be administered orally.
57744463|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
57744464|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
57958193|NCT04082195|OTHER|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
57958194|NCT04082195|OTHER|Uno board game|A popular board game which is not a mobile app.
57958195|NCT03285997|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
57958196|NCT03285997|BIOLOGICAL|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
57958197|NCT03076983|DEVICE|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
57744465|NCT00501254|DRUG|Slow release acetyl salicylic acid|
57744466|NCT00501254|BEHAVIORAL|Antithrombotic effect|
57744467|NCT06141148|DIAGNOSTIC_TEST|sputum analysis|sputum analysis to diagnose tuberculosis
57744468|NCT06141148|DIAGNOSTIC_TEST|lymph node biobsy|to diagnose tuberculous lymphadenitis
57958198|NCT04534660|DEVICE|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
57958199|NCT05325905|DIAGNOSTIC_TEST|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
57958200|NCT00603915|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) day 1 and day 8
57958201|NCT00603915|DRUG|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
57958202|NCT00603915|DRUG|erlotinib|150mg daily (post GC therapy)
57958203|NCT04577443|DRUG|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
57958204|NCT04577443|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
57958205|NCT00643695|BEHAVIORAL|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
57744469|NCT03345498|DRUG|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
57958206|NCT00643695|OTHER|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
57958207|NCT04015154|DEVICE|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
58118499|NCT00672620|DRUG|Placebo|Placebo-matching capsules
58118500|NCT03880279|BIOLOGICAL|TAC01-CD19|Dose-escalating cohorts plus expansion groups
58118501|NCT04811261|DRUG|Intravenous Infusion of UCLSCs|The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
58118502|NCT04106375|BEHAVIORAL|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
58118503|NCT00385541|DRUG|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
58118504|NCT00385541|DRUG|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
58118505|NCT03248856|DRUG|Triamcinolone Acetonide|Intratympanic administration
58118506|NCT01765985|DEVICE|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
58118507|NCT01765985|DEVICE|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
58118508|NCT00326079|DEVICE|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
58118509|NCT03522948|BEHAVIORAL|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
58448354|NCT02485561|BEHAVIORAL|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
58448355|NCT04485949|COMBINATION_PRODUCT|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
58448356|NCT04485949|COMBINATION_PRODUCT|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
58448357|NCT04485949|PROCEDURE|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
58448358|NCT04485949|DRUG|SOC: Temozolomide|Temozolomide administered orally.
58448359|NCT02896283|RADIATION|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
58448360|NCT02896283|RADIATION|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
58448361|NCT02747186|DRUG|Lidocaine|Intraoral maxillary field block
57744470|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
57744471|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
57744472|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
57744473|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
57744474|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
58118510|NCT06484556|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
58118511|NCT06484556|DRUG|NW-301D|TCR-T T cell targeting KRAS G12D mutation
58448362|NCT04110912|OTHER|This is a registry and no interventions are taking place.|
58448363|NCT03852017|BEHAVIORAL|Audio Program|
58448364|NCT03887013|DRUG|Trimetazidine|Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
58448365|NCT00890747|DRUG|sunitinib malate|Given PO
58448366|NCT00890747|OTHER|pharmacological study|Correlative studies
58448367|NCT00890747|OTHER|laboratory biomarker analysis|Correlative studies
58458581|NCT05896228|DRUG|Dexamethasone|"Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15."
57744475|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
57744476|NCT06435286|DRUG|Proflavine Hemisulfate|Approximately 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
57958208|NCT05741255|BEHAVIORAL|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
58448368|NCT03691597|DIAGNOSTIC_TEST|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G"
58448369|NCT02882594|BEHAVIORAL|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
58448370|NCT04080102|OTHER|High Intensity Interval Training|Exercise
58448371|NCT04080102|DIETARY_SUPPLEMENT|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
58448372|NCT04080102|OTHER|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
58448373|NCT01579890|DRUG|Diclofenac|diclofenac topical lotion
58448374|NCT06398938|RADIATION|Interventional Radiotherapy|The patients will undergo four IRT fractions in one week
58448375|NCT03506997|DRUG|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
58448376|NCT00006107|DRUG|Taxotere|
58448377|NCT00006107|PROCEDURE|Surgery|
58448378|NCT00006107|RADIATION|radiation therapy|
57744477|NCT06435286|DEVICE|Artificial Intelligence Mobile High-Resolution Microendoscope|The AI-mHRME will be inserted through the endoscope biopsy channel and gently placed against the mucosa where proflavine was sprayed. The probe will transmit images to the computer/laptop for the clinician to observe any abnormal tissues and save photos of these tissues.
57958209|NCT01724658|DRUG|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
57958210|NCT01724658|DRUG|placebo|placebo orally twice a week with progynova 1 mg oral daily
57958211|NCT02490514|OTHER|No intervention|No intervention was administered in this study.
57958212|NCT01514032|PROCEDURE|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
57958213|NCT01514032|PROCEDURE|Retrograde intrarenal surgery|Retrograde intrarenal surgery
57958214|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
57958215|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
57958216|NCT03648697|BIOLOGICAL|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
57958217|NCT02223572|RADIATION|hip Xray|
57958218|NCT01508728|DEVICE|ORTHOSENS orthosis|with active vibration
57958219|NCT01508728|DEVICE|ORTHOSENS orthosis|with placebo vibration
57958220|NCT00845728|DRUG|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
57958221|NCT00845728|DRUG|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
57958222|NCT00756145|PROCEDURE|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
57958223|NCT00756145|PROCEDURE|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
57958224|NCT00756145|PROCEDURE|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
58118512|NCT02516566|OTHER|PEEP|Mechanical ventilation with PEEP 8 cmH2O
58118513|NCT05312645|DRUG|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
58118514|NCT05312645|OTHER|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
58448379|NCT02591940|PROCEDURE|Surgery or Treatment by Heart Catheter|
58448380|NCT03257124|DRUG|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
58448381|NCT06440941|OTHER|chatbot-based mindfulness-based stress reduction|During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
58458582|NCT05896228|DRUG|Acetaminophen|"Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1."
58118515|NCT04916925|DRUG|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
58118516|NCT04916925|DRUG|Clomid|CLOMID is adrug used for ovulation induction
58448382|NCT06085508|BEHAVIORAL|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
58448383|NCT01922713|OTHER|white maize and a corn oil capsule|\~ 0 ug RAE/d
58448384|NCT01922713|OTHER|orange maize and a corn oil capsule|\~600 ug RAE/d
58448385|NCT01922713|OTHER|white maize and a vitamin A capsule|600 ug RAE/d
58448386|NCT02286921|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
57958225|NCT04437355|DIAGNOSTIC_TEST|Specific provocation test|To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (\<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
57958226|NCT00921232|BEHAVIORAL|Questionnaires|"During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data"
57958227|NCT01476657|DRUG|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
57958228|NCT03881397|BEHAVIORAL|Family Media Use Plan|A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
57958229|NCT03881397|BEHAVIORAL|Media Use Resources Awareness|Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
57958230|NCT00274521|DRUG|Tiotropium|
57958231|NCT02555735|DRUG|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
57958232|NCT06207136|OTHER|Mediterranean-style diet|Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
57958233|NCT04395911|DEVICE|SCD|cytopheretic device
57958234|NCT01339546|OTHER|no intervention|
57958235|NCT01265524|DRUG|CLP|Oral administration
57958236|NCT01265524|DRUG|Placebo|Oral administration
57958237|NCT05119712|DRUG|Terbinafine Tablets|500mg oral terbinafine or placebo daily
57958238|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
57958239|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
57958240|NCT02287974|DRUG|Stem cell infusion|Unique stem cell infusion of the randomized group
57958241|NCT05113836|BIOLOGICAL|Deep nasopharyngeal swab|On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
57958242|NCT05113836|BIOLOGICAL|Blood sample at D1, D3 and D7|"Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total)."
57958243|NCT05603715|DRUG|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
57958244|NCT04732741|DIAGNOSTIC_TEST|Salivary Gamma-synuclein|Gamma-synuclein salivary levels measured using ELISA assay
58118517|NCT01730677|DRUG|Lapatinib|lapatinib 1000mg, once daily
58118518|NCT01730677|DRUG|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
57958245|NCT04732741|DIAGNOSTIC_TEST|Incisional biopsy|"A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region."
57958246|NCT04732741|DIAGNOSTIC_TEST|Conventional visual and tactile examination|Conventional visual and tactile examination using light and mirror
57958247|NCT06187376|DRUG|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
57958248|NCT06187376|DRUG|Placebo|Matching placebo tincture.
57958249|NCT00566930|OTHER|spinal manipulation|Monthly cervical spinal manipulation
57958250|NCT00566930|OTHER|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
57958251|NCT02341092|BEHAVIORAL|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
57958252|NCT03432078|OTHER|Hypnotherapy|Non-pharmacological treatment
58118519|NCT00838474|OTHER|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
58118520|NCT05279014|OTHER|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
58118521|NCT04402554|BEHAVIORAL|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
58118522|NCT00282555|DRUG|S-Tenatoprazole-Na (STU-Na)|
58118523|NCT01557595|DEVICE|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
58118524|NCT04243174|BEHAVIORAL|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
58118525|NCT00533403|DRUG|MK0686|
58118526|NCT01958281|DRUG|SOF|Tablet(s) administered orally once daily
57744478|NCT00999258|DRUG|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
58118527|NCT01958281|DRUG|RBV|200 mg tablet administered orally once daily
58118528|NCT01958281|DRUG|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
58118529|NCT00736320|DRUG|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
57744479|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
57744480|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
57744481|NCT01994954|OTHER|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
57958253|NCT04708275|PROCEDURE|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
57958254|NCT00514865|DRUG|ONO-2333Ms Experimental 2|5-10 mg QD(once a day) for 8 weeks
57958255|NCT00514865|DRUG|Placebo|0 mg QD(once a day) for 8 weeks
57958256|NCT00514865|DRUG|ONO-2333Ms Experimental 1|1-2 mg QD(once a day) for 8 weeks
57958257|NCT02042937|OTHER|Exercise|Exercise to improve gluteus maximus recruitment
57958258|NCT00465595|DRUG|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
57958259|NCT03967548|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
58118530|NCT00736320|RADIATION|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
58118531|NCT05152342|BEHAVIORAL|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
58118532|NCT05152342|BEHAVIORAL|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
58458583|NCT05896228|DRUG|Diphenhydramine|"Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1."
57958260|NCT02027103|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
57958261|NCT02027103|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
57958262|NCT00740350|PROCEDURE|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
57958263|NCT03083340|BEHAVIORAL|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
57958264|NCT03627221|BEHAVIORAL|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
57958265|NCT03607760|DEVICE|ECMO|the patients with severe respiratory failure were supported by ECMO
57958266|NCT03607760|DEVICE|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
58448387|NCT02286921|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
58448388|NCT02286921|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
58448389|NCT06725953|BEHAVIORAL|Social Cognitive Theory-based, Technology-delivered Physical Activity Program|Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
58448390|NCT01362608|DRUG|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
58448391|NCT01362608|DRUG|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
58448392|NCT01521026|BEHAVIORAL|Cognitive Training|12-week compensatory cognitive training in group format
58448393|NCT04260789|DEVICE|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
58448394|NCT06503809|BEHAVIORAL|Ketogenic Diet|Participants will consume a very-low-carbohydrate ketogenic diet for 26 weeks.
58448395|NCT06503809|BEHAVIORAL|Standard Diet|Participants will consume an American Diabetes Association-recommended standard diet for 26 weeks.
58448396|NCT02610582|DRUG|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
58448397|NCT00451971|DRUG|LEFLUNOMIDE|
58448398|NCT05913830|OTHER|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
58448399|NCT06528236|DIAGNOSTIC_TEST|Artificial intelligence model|Using the artificial intelligence model to diagnosis benign, borderline, and malignant ovarian masses.
58448400|NCT01380769|DRUG|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
58448401|NCT01380769|OTHER|Best Supportive Care|best supportive care
58448402|NCT03399630|OTHER|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
58448403|NCT03399630|OTHER|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
58448404|NCT06461338|PROCEDURE|acupuncture|Acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
58448405|NCT06461338|PROCEDURE|Sham acupuncture|Sham acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with sham electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
58448406|NCT02106871|DRUG|Sildenafil|50mg of Sildenafil daily for 4 weeks
58448407|NCT01257516|DRUG|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
57744482|NCT03646799|DRUG|CKD-387|test drug
57744483|NCT03646799|DRUG|D484|reference drug
57744484|NCT06723587|OTHER|Instep weights use|"Players will perform their scheduled training sessions while wearing a 150-gram instep weight. The use of instep weights in the intervention group will be introduced progressively and gradually, increasing both the frequency of sessions and the duration of their use.~During weeks 1-2, instep weights will be used in one training session per week. During weeks 3-5, will be used in two training sessions per week.~And during weeks 6-8, will be used in three training sessions per week.~The duration of instep weight usage within each session will increase by 5% weekly, starting at 40% in Week 1 and reaching 75% by Week 8."
58448408|NCT01257516|DRUG|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
58448409|NCT02332174|DRUG|rufinamide|comparison of different doses, sex and medication conditions
58448410|NCT00273273|PROCEDURE|blood draw|
58448411|NCT05155813|DEVICE|WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.
58448412|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
58448413|NCT01525615|DRUG|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
58448414|NCT01525615|DRUG|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
58448415|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
58448416|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
58448417|NCT01525615|DRUG|placebo to tiotropium+olodaterol|comparator
58448418|NCT00130169|DRUG|E7974|Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
58448419|NCT04526223|OTHER|comprehensive treatment regimen|"1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d"
58458584|NCT05896228|DRUG|Montelukast|"Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D)."
58458585|NCT00434538|DEVICE|BST-DermOn|
58458586|NCT03883256|DEVICE|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
58118533|NCT02519283|BEHAVIORAL|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
57744485|NCT05978921|OTHER|Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
58458587|NCT03883256|DEVICE|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
58118534|NCT02519283|BEHAVIORAL|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up."
58118535|NCT05043233|DRUG|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
57744486|NCT05978921|OTHER|Normal life|Normal life and carry out all the activities they have been doing previously.
57744487|NCT06724068|OTHER|Diabetes，Insulin resistance，Control|This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
57744488|NCT06379919|PROCEDURE|Irrisept Irrigation|Irrisept Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device. Irrisept contains 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United Staes Pharmacopeia (USP). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle.
57744489|NCT06379919|PROCEDURE|Saline Irrigation Solution Delivery|Normal saline is isotonic and the most commonly used wound irrigation solution due to safety (lowest toxicity) and physiologic factors.
57958267|NCT00476879|DRUG|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
57958268|NCT02555943|DRUG|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
57958269|NCT02555943|DRUG|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
57958270|NCT02555943|DRUG|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
57958271|NCT02555943|DRUG|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
57958272|NCT02555943|DRUG|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
57958273|NCT00110565|DEVICE|Pulsed magnetic field pad|
57958274|NCT06268379|PROCEDURE|Surgery|Not an interventional study, it is an observational, longitudinal study.
57958275|NCT05842187|PROCEDURE|Biopsy of tumor tissue for organoid culture|By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
57958276|NCT06170515|DIAGNOSTIC_TEST|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
57958277|NCT06170515|DIAGNOSTIC_TEST|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
57958278|NCT03721666|OTHER|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
57958279|NCT00722150|DRUG|Artesunate|2 mg/kg/day x 7 days
57958280|NCT00722150|DRUG|Artesunate|4 mg/kg/day x 7 days
58458588|NCT04778735|PROCEDURE|Liver Transplantation|Liver Transplantation is performed under spesific conditions to increase the life time of patients with liver diseases.
57958281|NCT00722150|DRUG|Artesunate|6 mg/kg/day x 7 days
57958282|NCT05167942|DEVICE|deep transcranial magnetic stimulation with H1 coil|Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
57958283|NCT05167942|DEVICE|High frequency deep transcranial magnetic stimulation with H1 coil|high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
57958284|NCT05167942|DEVICE|iTBS deep transcranial magnetic stimulation with H1 coil|iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
57958285|NCT04388995|DIAGNOSTIC_TEST|volume expansion|volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
57958286|NCT01857713|DEVICE|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
57958287|NCT04394533|DRUG|Prilocaine (Hyperbaric 2%)|2 ml hyperbaric prilocaine
57958288|NCT04394533|DRUG|Bupivacaine (Hyperbaric 0.5%)|2 ml hyperbaric bupivacaine
58118536|NCT03291457|DRUG|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
58118537|NCT03291457|DRUG|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
58118538|NCT00580853|DRUG|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
58118539|NCT00580853|DRUG|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
58118540|NCT00580853|DRUG|Placebo|Placebo
58118541|NCT01144884|OTHER|Procedure (education and exercise)|education/exercise
58118542|NCT05544747|OTHER|Action Observation Therapy|"following phases will be included in action observation therapy group:~1. upper limb active range of motion (AROM) exercises.~2. reaching movement or object manipulation.~3. upper limb functional tasks."
58118543|NCT05544747|OTHER|Mirror Therapy|"following phases will be included in mirror therapy group:~1. AROM exercises),~2. reaching movement or object manipulation, and~3. functional task practice"
58118544|NCT01704664|DIETARY_SUPPLEMENT|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
58118545|NCT01704664|DRUG|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
58448420|NCT00644150|BEHAVIORAL|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
57958289|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
57958290|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
57958291|NCT00685126|DRUG|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
57958292|NCT00571350|PROCEDURE|tvt-o operation|transvaginal tention free obturator tape
57958293|NCT00571350|PROCEDURE|tvt o operation|transobturator vaginal tape insertion
57958294|NCT05667714|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
57958295|NCT05667714|DRUG|Placebo|Placebo was provided by Sinovac Life Sciences Co. , Ltd.
57958296|NCT02347176|OTHER|Placebo|Subcutaneous injection with placebo
57958297|NCT02347176|BIOLOGICAL|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
57958298|NCT02347176|BIOLOGICAL|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
57958299|NCT02347176|BIOLOGICAL|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
57958300|NCT06033820|DRUG|ZR2-ICE|"* Drug: zanubrutinib Oral Capsule~* Drug: lenalidomide Oral Capsule~* Drug: R-ICE chemotherapy"
57958301|NCT01617330|PROCEDURE|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
57958302|NCT05815303|DRUG|Cadonilimab|10mg/kg iv on day 1, every 21 day
57958303|NCT05815303|DRUG|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
57958304|NCT05815303|DRUG|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
57958305|NCT06369012|DRUG|Mefenamic acid 500 mg|To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
57958306|NCT05749380|DRUG|AmBisome|Reference, dose of 3 mg/kg.
57958307|NCT05749380|DRUG|DKF-5122|Test, dose of 3 mg/kg
57958308|NCT03840655|PROCEDURE|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
57958309|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57958310|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57958311|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57958312|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57958313|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58448421|NCT00644150|DRUG|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
57744490|NCT05847933|DEVICE|rTMS (cTBS 50Hz experiment)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
57744491|NCT05847933|DEVICE|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 0%~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
58448422|NCT00644150|BEHAVIORAL|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
58448423|NCT00836186|RADIATION|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
58448424|NCT00442728|DEVICE|ELECTRICAL STIMULATION|
58448425|NCT04618289|DIETARY_SUPPLEMENT|Vitamin D3-fortified fruit juice supplement|Vitamin D3-fortified fruit juice supplement
58448426|NCT01416402|DRUG|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
58448427|NCT01416402|DRUG|Febuxostat|80 mg once daily orally for 5 weeks
58448428|NCT01416402|DRUG|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
58448429|NCT05060770|GENETIC|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
58448430|NCT02724449|DEVICE|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
58448431|NCT03363516|DIAGNOSTIC_TEST|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
58448432|NCT06304207|COMBINATION_PRODUCT|Onsite Maintenance Exercise Training|Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.
57744492|NCT05847933|DEVICE|rTMS (cTBS 50 Hz active control)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: Right superior frontal cortex~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
57744493|NCT05847933|DEVICE|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics:~* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
57744494|NCT05847933|DEVICE|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 30 minutes, continuously~* Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
57744495|NCT05847933|DEVICE|rTMS (high frequency sham)|"* Frequency: 20 Hz~* Intensity: 10% of MSO~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
57958314|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57958315|NCT05157815|DIETARY_SUPPLEMENT|Soluble Fibre|10g soluble corn fibre to be consumed twice per day
57958316|NCT05157815|DIETARY_SUPPLEMENT|Calorie Matched Control|2g maltodextrin consumed twice per day
57744496|NCT05847933|DEVICE|rTMS (high frequency active control)|"* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: right superior frontal cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
57744497|NCT05847933|DEVICE|rTMS (low frequency active control )|"* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: Right superior frontal cortex of the dominant brain hemisphere~* Duration: 6 minutes~* Timing: Starting 1 minutes before and continuing during the memory task (Online)"
58118546|NCT01704664|DIETARY_SUPPLEMENT|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
58448433|NCT06304207|COMBINATION_PRODUCT|Telehealth Maintenance Exercise|Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
58448434|NCT01109355|OTHER|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
58448435|NCT01109355|OTHER|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
58448436|NCT02518386|OTHER|No intervention|No intervention is planned
58448437|NCT05701020|OTHER|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
57958317|NCT05616936|BIOLOGICAL|injectable platelet rich fibrin|injectable platelet rich fibrin
58448438|NCT00152893|DRUG|chromium nicotinate|
58448439|NCT00152893|DRUG|Placebo|
58448440|NCT00165880|DRUG|E7070|
58448441|NCT01200303|PROCEDURE|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
57958318|NCT04159038|OTHER|Intervention Group|The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.
57958319|NCT04159038|OTHER|Control group|The control group will continue usual WIC care.
57744498|NCT05847933|DEVICE|rTMS ( cTBS 30 Hz active control)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on right superior frontal cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
57744499|NCT05847933|DEVICE|rTMS (cTBS 30 Hz)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
57744500|NCT04278287|RADIATION|Radiotherapy|59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.
57744501|NCT04278287|DRUG|Albumin-Bound Paclitaxel|100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
57744502|NCT04278287|DRUG|Cisplatin|25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
57744503|NCT03042065|DEVICE|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
57744504|NCT03042065|DEVICE|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
57958320|NCT05059496|OTHER|Hamstring stretching with Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
57958321|NCT05059496|OTHER|Hamstring stretching with out Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
57958322|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
58448442|NCT02289313|BEHAVIORAL|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
58448443|NCT05527665|PROCEDURE|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
58448444|NCT06359613|DIETARY_SUPPLEMENT|nutrient rich food product|Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
57744505|NCT02071173|DEVICE|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
57744506|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
57744507|NCT04881201|PROCEDURE|blood sample|blood sample
58448445|NCT06359613|DIETARY_SUPPLEMENT|food product|Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
57744508|NCT02301702|BIOLOGICAL|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
57744509|NCT02301702|BIOLOGICAL|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
57744510|NCT04538326|BEHAVIORAL|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
57744511|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
57744512|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
57744513|NCT06637371|DRUG|AMG 691|Subcutaneous (SC) injection
57744514|NCT06637371|DRUG|Placebo|SC injection
57744515|NCT03954782|DRUG|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
57958323|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
58448446|NCT06309563|DIETARY_SUPPLEMENT|Aminoacid supplementation|Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
58448447|NCT06309563|DIETARY_SUPPLEMENT|Placebo|Low-calorie and low-protein diet + placebo for 2 weeks
58448448|NCT03501225|PROCEDURE|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
58448449|NCT03501225|PROCEDURE|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
58448450|NCT01217762|DEVICE|IRay|Low voltage stereotactic radiotherapy system
57744516|NCT03954782|DRUG|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
57744517|NCT03227354|DEVICE|Vittamed 205|non-invasive Intracranial Pressure measurement
57958324|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
58448451|NCT05782062|DEVICE|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
58448452|NCT05782062|DEVICE|Balloon|Use of balloon for disrupting thrombus.
57744518|NCT05215340|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
57744519|NCT05215340|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
57744520|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
57744521|NCT05594979|DIETARY_SUPPLEMENT|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
57744522|NCT00318357|DEVICE|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
57958325|NCT02488122|OTHER|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
57958326|NCT02488122|OTHER|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
57958327|NCT03354663|DEVICE|TactiCath SE|Ablation to achieve pulmonary vein isolation.
58448453|NCT04715529|DRUG|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
58448454|NCT04715529|DRUG|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
58118547|NCT01704664|DRUG|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
58118548|NCT01292200|BEHAVIORAL|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
57744523|NCT00318357|DEVICE|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
57744524|NCT01297959|DRUG|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
58118549|NCT01292200|BEHAVIORAL|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
58118550|NCT06398782|DEVICE|body composition assessment|body composition of cancer survivors were assessed by Dual-energy X-ray absorptiometry
57744525|NCT01297959|DRUG|Saline solution|Saline solution matched to E-101
57958328|NCT03355508|DEVICE|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
57958329|NCT02716610|DRUG|INH 69 U (low)|inhaled human insulin
57958330|NCT02716610|DRUG|INH 69 U (high)|inhaled human insulin
57744526|NCT02200731|BEHAVIORAL|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
57744527|NCT06732375|BEHAVIORAL|Resilience Reminders|"RR™ includes: 1) CBT; 2) resilience training; 3) mindfulness-based stress reduction; 4) peer support; and 5) family conversations delivered in small virtual groups, with a mentor who facilitates resilience-building conversations prompted from Skill of the Week lessons."
57744528|NCT02968784|DEVICE|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
57744529|NCT05415813|OTHER|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
57744530|NCT05415813|OTHER|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
57744531|NCT00319540|BEHAVIORAL|Control with depression course (CWD)|
57744532|NCT01055821|DRUG|pegylated interferon and ribavirin|48 weeks
57744533|NCT01055821|BIOLOGICAL|TG4040 + SOC|6 injections
57744534|NCT01055821|BIOLOGICAL|TG4040 + SOC|13 injections
57744535|NCT04914611|OTHER|No intervention|No intervention
57744536|NCT05901545|BIOLOGICAL|Panitumumab|Given by IV
57744537|NCT05901545|OTHER|Indium In 111 Panitumumab|Given by IV
57744538|NCT05901545|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
57744539|NCT05901545|PROCEDURE|Computed Tomography|Undergo SPECT/CT
57744540|NCT05901545|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
57744541|NCT05901545|OTHER|Imaging agent|Receive local injection of optical dye
57744542|NCT05901545|PROCEDURE|Intraoperative Imaging|Undergo Intraoperative Imaging
57744543|NCT05901545|PROCEDURE|Near Infrared Imaging|Undergo Near Infrared Imaging
57744544|NCT05901545|PROCEDURE|Electrocardiography|Undergo Electrocardiography
57744545|NCT05901545|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58118551|NCT04212702|DRUG|Hormonal therapy-based treatments|Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only
58118552|NCT00981253|BEHAVIORAL|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
58118553|NCT00981253|BEHAVIORAL|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
58118554|NCT04087668|PROCEDURE|Monitored Anesthesia Care|MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
58118555|NCT04087668|PROCEDURE|General Anesthesia|Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
58118556|NCT04087668|PROCEDURE|Induction Without Neuromuscular Blockade|Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
58118557|NCT03862599|DEVICE|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
58118558|NCT03862599|OTHER|Standard care|Cialis and vacuum pump
58118559|NCT02661126|DRUG|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
58118560|NCT00794261|DRUG|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
58118561|NCT00794261|DRUG|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
58118562|NCT04902274|OTHER|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
58448455|NCT06720857|DIAGNOSTIC_TEST|Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium|Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
57744546|NCT00912548|DRUG|goserelin|"1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
57744547|NCT00912548|DRUG|tamoxifen|"1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
57744548|NCT05292625|BIOLOGICAL|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
58118563|NCT04902274|OTHER|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
58313437|NCT03003117|BEHAVIORAL|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
58448456|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
57744549|NCT05292625|BIOLOGICAL|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
57744550|NCT05292625|OTHER|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
57744551|NCT04526366|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
57958331|NCT02716610|DRUG|INH 139 U|inhaled human insulin
58118564|NCT04902274|OTHER|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
58118565|NCT05074186|DEVICE|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
58118566|NCT03404076|DIAGNOSTIC_TEST|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
58118567|NCT03563950|DRUG|Rifampin|Specified dose on specified days
58118568|NCT03563950|DRUG|BMS-986224|Specified dose on specified days
58118569|NCT04179591|OTHER|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
58118570|NCT04179591|OTHER|Orthesis|Customized arch support insoles
58118571|NCT00264810|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
58118572|NCT00264810|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
58118573|NCT03553784|OTHER|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
58118574|NCT01501799|DRUG|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
58118575|NCT01501799|DRUG|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
58118576|NCT01501799|DRUG|Placebo (Vehicle Gel)|Vehicle Gel
58118577|NCT06544993|DRUG|Meso-botox|Micro-Botox, is a highly diluted Botulinum toxin type A
58448457|NCT02236468|BEHAVIORAL|WASH/malaria behavior change|WASH/malaria behavior change communication
57744552|NCT04526366|DEVICE|Polysomnography|Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
57744553|NCT06733389|OTHER|peripheral waveform collection|The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
57744554|NCT02899780|DEVICE|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
57744555|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
57744556|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
57744557|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
57744558|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
57958332|NCT02716610|DRUG|INH 208 U|inhaled human insulin
57958333|NCT02716610|DRUG|LIS 18 U|subcutaneous insulin lispro
58118578|NCT01632787|OTHER|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
58448458|NCT02236468|DIETARY_SUPPLEMENT|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
58448459|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
58448460|NCT01157247|PROCEDURE|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
58313438|NCT03003117|BEHAVIORAL|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
58313439|NCT03530293|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
57744559|NCT06579326|DIAGNOSTIC_TEST|Photoacoustic imaging|"It could provide three-dimensional ultrasound images of vessels in the target area. It could also provides super-resolution and large-depth photoacoustic images. By effectively extracting photoacoustic spectral features and using spectral feature unmixing algorithm, blood oxygen saturation can be calculated.~."
57744560|NCT02763800|DRUG|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
58448461|NCT04005157|PROCEDURE|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
58448462|NCT04005157|DEVICE|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
58448463|NCT01841723|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57744561|NCT02763800|DRUG|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
58448464|NCT01841723|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
57744562|NCT06701435|DEVICE|Cold Compression|Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.
57744563|NCT06731907|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg IV Infusion.
57744564|NCT06731907|DRUG|Carboplatin|Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
57744565|NCT06731907|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion.
57744566|NCT06731907|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m\^2 IV infusion.
57744567|NCT06731907|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2 IV infusion.
57744568|NCT06731907|BIOLOGICAL|HER3-DXd|HER3-Dxd 5.6mg/kg IV infusion.
57744569|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
57744570|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
57744571|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
57744572|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
57744573|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
57744574|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
57744575|NCT04039399|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
57744576|NCT04039399|PROCEDURE|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
57744577|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
57744578|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
57744579|NCT04914286|DRUG|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
57744580|NCT04914286|DRUG|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
57958334|NCT01117636|DRUG|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
57958335|NCT01117636|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
58313440|NCT03530293|DRUG|Placebo oral capsule|non-active dosage form
58313441|NCT01923558|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
58313442|NCT02049632|PROCEDURE|Omission of axillary clearance|
58313443|NCT00544414|DRUG|cisplatin|
58448465|NCT01841723|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58448466|NCT01841723|PROCEDURE|Computed Tomography|Undergo CT
58448467|NCT01841723|DRUG|Ibrutinib|Given PO
58448468|NCT01841723|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
58448469|NCT02018081|DRUG|Levofloxacin|8 blood sampling by patients between the 48th and 60th
57744581|NCT06177158|BEHAVIORAL|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
57744582|NCT06550986|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
57744583|NCT04766944|OTHER|No intervention|No intervention
57744584|NCT02515279|DRUG|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
58448470|NCT05031793|OTHER|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
58448471|NCT05031793|OTHER|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
58448472|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
58448473|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
58448474|NCT03895333|OTHER|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
58448475|NCT03464747|DEVICE|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
58448476|NCT04148495|DRUG|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
57744585|NCT02515279|DRUG|Ribavirin|1000-1600 mg day orally for 48 weeks.
57744586|NCT00609427|BEHAVIORAL|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
57744587|NCT00609427|BEHAVIORAL|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
57744588|NCT04439292|DRUG|Dabrafenib Mesylate|Given PO
57744589|NCT04439292|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
57744590|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
57958336|NCT01117636|DRUG|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
57958337|NCT00166205|DEVICE|Swedish Adjustable Gastric Band|Long term implantable device.
58313444|NCT00544414|DRUG|docetaxel|
58313445|NCT00544414|DRUG|fluorouracil|
58313446|NCT00544414|DRUG|gemcitabine hydrochloride|
58313447|NCT00544414|DRUG|leucovorin calcium|
58313448|NCT00544414|GENETIC|gene expression analysis|
58313449|NCT00544414|GENETIC|protein expression analysis|
58313450|NCT00544414|OTHER|laboratory biomarker analysis|
58313451|NCT00544414|PROCEDURE|adjuvant therapy|
58313452|NCT00544414|PROCEDURE|biopsy|
58313453|NCT00544414|PROCEDURE|conventional surgery|
58313454|NCT00544414|PROCEDURE|neoadjuvant therapy|
58313455|NCT00544414|PROCEDURE|quality-of-life assessment|
58313456|NCT00544414|RADIATION|radiation therapy|
58313457|NCT00386061|DRUG|rimonabant (SR141716)|
58313458|NCT01484340|DRUG|Nicotine|"The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
58313459|NCT01484340|BEHAVIORAL|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
58313460|NCT03133676|DRUG|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
58313461|NCT03133676|DRUG|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
58313462|NCT03095287|BIOLOGICAL|Alphanate|Bolus IV injection.
58313463|NCT04200300|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
58313464|NCT06062056|OTHER|EHR alert|An EHR alert will be fired if a behavioral health patient is missing a COVID-19 or influenza vaccine.
57744591|NCT04217681|BEHAVIORAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
57744592|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
57744593|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
57744594|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
57744595|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
57744596|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
57744597|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
57744598|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
57744599|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
57744600|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
57744601|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
57744602|NCT04672941|DRUG|Tiotropium bromide plus Olodaterol|Tiotropium bromide plus Olodaterol
57744603|NCT03683069|DRUG|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
57744604|NCT05982457|BEHAVIORAL|virtual reality group|"Before the training, the Descriptive Information Form and the State and Trait Anxiety Inventory as a pre-test will be applied by face interview method. They will study for two hours. After the introduction and information, the lens and pupil distances of the virtual reality Glasses will be adjusted according to each student and students are expected to wear their vision. The application is the same for every student. Students will be introduced through the images projected to the computer simultaneously while in the application. Cervical dilation and effacement application will be monitored using virtual reality glasses. Next, the students will be asked to touch the woman's perineum with their hands to make her image transparent and we ask them to watch the cervix structures again. After the application, Learning Satisfaction and Self-Confidence in Learning Scale and State and Trait Anxiety Inventory will be applied as a post-test."
57744605|NCT06117280|OTHER|Paraxanthine 200 mg|For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
57744606|NCT06117280|OTHER|Paraxanthine 300 mg|For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
57744607|NCT06117280|OTHER|Placebo|The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
57958338|NCT00692211|OTHER|Mailed fecal occult blood tests|Stool blood test
58448477|NCT04148495|DRUG|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
58448478|NCT02191371|DRUG|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
58448479|NCT02191371|DRUG|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
58448480|NCT02952599|DRUG|Edoxaban|Prescribed according to approved label
58448481|NCT03015324|DRUG|Hydroxychloroquine|Hydroxychloroquine
58448482|NCT05301010|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
58448483|NCT05301010|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
58448484|NCT05301010|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
57744608|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
57744609|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
57744610|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
57744611|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
57744612|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
57744613|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
57744614|NCT01460550|PROCEDURE|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
58118579|NCT05911230|DIAGNOSTIC_TEST|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
58118580|NCT00673985|OTHER|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
58118581|NCT00673985|DEVICE|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
58118582|NCT03064542|DRUG|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
58118583|NCT05022836|DIAGNOSTIC_TEST|four-limb blood pressure measurements|Four-limb blood pressures were measured by certificated nurses at admission.
58448485|NCT03863509|BEHAVIORAL|Cigarettes|smokes daily
58448486|NCT03863509|BEHAVIORAL|E-Cigarettes|E-cigarette usage \>/= 5 days/week
58448487|NCT00398658|DRUG|gentamycin and clindamycin|
58448488|NCT03058926|OTHER|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
57744615|NCT01460550|PROCEDURE|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
57744616|NCT06732973|DRUG|JS005|JS005：The drug was administered by a single subcutaneous injection
57744617|NCT03927950|DRUG|escitalopram|escitalopram 10-20mg per day 12 weeks
57744618|NCT03927950|DRUG|bupropion|bupropion 150-300mg per day 6 weeks
57744619|NCT06682520|OTHER|Postpartum NEST-Rural Program (Hospital based service model)|NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
57744620|NCT03673306|OTHER|Clinical outcomes|Clinical outcomes
58118584|NCT02405910|DRUG|Nab-paclitaxel|
57744621|NCT02769286|DRUG|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
58118585|NCT02405910|DRUG|Gemcitabine|
58313465|NCT06062056|BEHAVIORAL|Motivational Interviewing|In response to the alert and using support tools in the EHR, the behavioral health clinician will integrate motivational interviewing into the counseling session to discuss vaccine hesitancy (if it is deemed appropriate based on patient needs and clinical judgment).
58313466|NCT06062056|BEHAVIORAL|Warm hand off to nurse|For patients interested in vaccination following motivational interviewing, the behavioral health clinician will do a warm hand off to a nurse for vaccination
58448489|NCT02954614|BEHAVIORAL|Active play in after school programs (ASP)|"* A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
57744622|NCT06732466|DRUG|Chlorhexidine toothpaste|A toothpaste containing 0.3% chlorhexidine + 3% AmCl
57744623|NCT06732466|DEVICE|Toothbrush|Commercially available adult soft bristle toothbrush
57744624|NCT06732466|DRUG|Placebo toothpaste without chlorhexidine and AmCl|Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.
57744625|NCT01292954|DIETARY_SUPPLEMENT|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
57744626|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
57744627|NCT00587327|DRUG|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
57744628|NCT00587327|DRUG|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
58448490|NCT01176058|DRUG|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
57744629|NCT00587327|DRUG|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
57744630|NCT06706960|DIAGNOSTIC_TEST|measurement of IJV-height|"Protocol 1: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is smaller than CCA throughout the whole respiratory cycle.~Protocol 2: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is completely collapsed throughout the whole respiratory cycle.~Protocol 3: IJV tapering portion is portrayed in a longitudinal view. With a skin marker, the IJV height at the end of expiration is marked and measured at the following two positions:~1. Measurement 1: at the very end of the tapering portion (collapsing point / top of pulsation).~2. Measurement 2: at the beginning of the tapering portion (taper point)."
57744631|NCT04293146|PROCEDURE|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
57744632|NCT04293146|PROCEDURE|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
57744633|NCT06733844|DIETARY_SUPPLEMENT|Weekly iron folic acid supplementations|In the intervention arm, adolescent girls will receive weekly iron and folic acid supplements (WIFAS), nutrition education, and group counseling sessions. WIFAS will be delivered quarterly, with each girl consuming one supplement at the facilitation center and the remaining 12 at home, once a week. The supplements contain 60mg of iron and 2.8mg of folic acid. A quarterly cash transfer of PKR 1,000 will be given to the mother, conditional on the girl's WIFAS consumption and attendance at the quarterly education and counseling sessions. The girl will report her supplement intake at each visit and receive 13 more supplements. The intervention will last 18 months.
57744634|NCT06002165|BEHAVIORAL|Usual Care|"All clinics in North Carolina Perinatal Region IV have access to Severe HTN Bundle resources on the AIM website (https://saferbirth.org/psbs/severe-hypertension-in-pregnancy) and the locally adapted Outpatient HTN Bundle resources on the North Carolina Perinatal Region IV Provider Support Network website (https://www.mombaby.org/outpatient-bundle-for-severe-hypertension/). At baseline, the clinical leadership of all enrolled sites will receive direct communication via email that describes and provides links to the available resources. This will constitute usual care."
57744635|NCT06002165|BEHAVIORAL|ACHIEVE Multi-component Implementation Strategy|The intervention is comprised of four implementation strategies: facilitation/coaching, training, simulation, and delivering educational materials. The ACHIEVE study team, primarily the Nurse Coordinator, will engage teams within each clinic to participate in quality improvement activities utilizing these four strategies. The Nurse Coordinator will train the providers/staff on the O-HTN bundle components, facilitate corresponding office systems and workflow changes, and conduct simulations of patients with severe hypertension so care teams can practice the steps involved in recognizing and responding to episodes of severe hypertension in a timely manner.
57744636|NCT04330638|OTHER|Usual Care|Usual Care
58118586|NCT06158061|DIAGNOSTIC_TEST|tryptase enzyme level|"In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy."
58448491|NCT00904735|DRUG|hydroxyurea|Given orally
58448492|NCT00904735|DRUG|imatinib mesylate|Given orally
57744637|NCT04330638|DRUG|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
57744638|NCT04330638|DRUG|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
57958339|NCT00692211|OTHER|Mailed fecal immunochemical tests|Stool blood test
57958340|NCT03405948|DRUG|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
57958341|NCT03616678|DEVICE|VenTouch System|"The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester."
58118587|NCT03463356|BEHAVIORAL|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
58448493|NCT04022863|DIAGNOSTIC_TEST|TEP|Tumor Educated Platelets
58448494|NCT04022863|DIAGNOSTIC_TEST|ctDNA|circulating tumor DNA
58448495|NCT00358007|DEVICE|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
58448496|NCT00732875|BIOLOGICAL|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
58448497|NCT03477045|DIETARY_SUPPLEMENT|Single dose fish oil|Fish oil consumed within a single high fat test meal
58448498|NCT03477045|DIETARY_SUPPLEMENT|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
58448499|NCT03477045|DIETARY_SUPPLEMENT|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
58448500|NCT03477045|DIETARY_SUPPLEMENT|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
57744639|NCT04330638|DRUG|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
57744640|NCT06574009|BEHAVIORAL|Multimodal pain care|Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
57744641|NCT06574009|DRUG|Medication optimization|Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
57744642|NCT06574009|DEVICE|Buprenorphine rotation|Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
57744643|NCT06574009|OTHER|Opioid tapering|Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
57744644|NCT01536132|DRUG|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
57744645|NCT01536132|DRUG|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
57744646|NCT01643590|BIOLOGICAL|JVS-100 15 mg dose Injection|Intramyocardial Injection
57744647|NCT01643590|BIOLOGICAL|Placebo Injection|Intramyocardial Injection
58448501|NCT02741596|DRUG|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
58448502|NCT02741596|DRUG|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
57744648|NCT01643590|BIOLOGICAL|JVS-100 30 mg dose injection|Intramyocardial Injection
57744649|NCT04436068|DEVICE|Hyperfine MRI scan|Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
58118588|NCT04336956|OTHER|hospitalized children with Covid19|All patients under 18 years hospitalized with a covid19 diagnosis
58448503|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
58448504|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
58448505|NCT06726642|DIAGNOSTIC_TEST|Cell-free DNA analysis|Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).
58448506|NCT00851617|DEVICE|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
58448507|NCT00378781|DRUG|Heparin|Heparin flush solution into CVC once daily.
58448508|NCT00378781|DRUG|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
58448509|NCT04803149|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
57744650|NCT05169515|DRUG|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
57744651|NCT05169515|DRUG|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
57744652|NCT05169515|DRUG|Iberdomide|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
57744653|NCT05169515|DRUG|Golcadomide|Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
57744654|NCT05169515|DRUG|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
57744655|NCT05169515|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
57744656|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
57744657|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
57744658|NCT06579742|DIETARY_SUPPLEMENT|Live Conscious Beyond Collagen|Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
57744659|NCT06579742|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
57744660|NCT06721091|DRUG|VNA-318|"Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel"
57744661|NCT06721091|DRUG|Placebo|"Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)"
57744662|NCT05755308|PROCEDURE|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
57744663|NCT05755308|PROCEDURE|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
57744664|NCT01860703|DRUG|Deferiprone|Ferriprox 500 mg tablets
57744665|NCT01860703|DRUG|deferiprone matching placebo tablets|deferiprone matching placebo tablets
57744666|NCT01860703|DRUG|moxifloxacin|Active control
57744667|NCT01860703|DRUG|placebo|moxifloxacin-matching placebo
57744668|NCT01432548|PROCEDURE|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
57744669|NCT06087341|OTHER|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
57744670|NCT02567084|DEVICE|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
57744671|NCT04733287|OTHER|High Intensity Interval Training of the Knee Extensors|"Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at \~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at \~80% of maximum aerobic power. Recovery of 4 minutes at \~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity."
57744672|NCT04733287|OTHER|Muscle Heat Therapy|Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to \~39C, a similar temperature induced by exercise.
57744673|NCT04733287|OTHER|Muscle Disuse|Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.
57744674|NCT04733287|OTHER|Sham Heat Therapy|Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
57744675|NCT02478411|PROCEDURE|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
57744676|NCT02478411|PROCEDURE|Conventional physiotherapy|30 minutes of conventional physiotherapy
57744677|NCT06732128|OTHER|nature-based virtual reality applications and videos|Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
57744678|NCT06732128|OTHER|nature-based videos|Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
57744679|NCT05737082|DRUG|HCP2201|Take 2 tablets once per period
57744680|NCT05737082|DRUG|RLD2205|Take 2 tablets once per period
57744681|NCT05737082|DRUG|RLD2206|Take 1 tablet once per period
57744682|NCT00626028|DRUG|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
57744683|NCT00626028|DRUG|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
57744684|NCT00626028|DRUG|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
57744685|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
57744686|NCT03598270|DRUG|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
57744687|NCT03598270|DRUG|Carboplatin|Intravenous. Day 1
57958342|NCT03677700|OTHER|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
57744688|NCT03598270|DRUG|Paclitaxel|175 mg/m². Intravenous. Day 1
57744689|NCT03598270|DRUG|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
57744690|NCT03598270|DRUG|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
57744691|NCT03598270|DRUG|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
57744692|NCT03598270|DRUG|Atezolizumab|1200 mg. Intravenous. Day 1
57744693|NCT01938612|DRUG|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
58448510|NCT04803149|DEVICE|Conventional Radiofrequency|Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
57744694|NCT01938612|DRUG|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
57744695|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
57958343|NCT02111993|DEVICE|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
58118589|NCT05159310|PROCEDURE|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
57958344|NCT02111993|DEVICE|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
58118590|NCT01165996|OTHER|flow cytometry|Correlative studies
58118591|NCT01165996|OTHER|DNA methylation analysis|Correlative studies
58118592|NCT01165996|OTHER|cytogenetic analysis|Correlative studies
57744696|NCT05188469|DRUG|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
57744697|NCT05188469|DRUG|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
58118593|NCT01165996|DRUG|decitabine|Given subcutaneously
58118594|NCT01165996|GENETIC|microarray analysis|Correlative studies
57744698|NCT05188469|DRUG|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
57744699|NCT05188469|DRUG|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
57958345|NCT00130403|DRUG|risedronate sodium|
57958346|NCT01509352|PROCEDURE|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
57958347|NCT01509352|PROCEDURE|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
57744700|NCT05188469|DRUG|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
57744701|NCT00254202|DRUG|Iloperidone|
57744702|NCT00254202|DRUG|Ziprasidone|
57744703|NCT00254202|DRUG|Placebo|
57958348|NCT03513003|DEVICE|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
57958349|NCT03513003|BEHAVIORAL|Stop habit|Children stop the use of their pacifier and/or baby bottle
57958350|NCT02889796|DRUG|Filgotinib|200 mg or 100 mg tablet(s) administered orally once daily
57958351|NCT02889796|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
57958352|NCT02889796|DRUG|Adalimumab|40 mg administered via subcutaneous injection once every two weeks
57958353|NCT02889796|DRUG|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
58118595|NCT01165996|GENETIC|gene expression analysis|Correlative studies
58313467|NCT04816344|PROCEDURE|Outpatient Anesthesia|The inclusion criteria were children aged between 2 and 10 years, undergoing outpatient anaesthesia for elective MRI under sedation, and classified as American Society of Anesthesiologists (ASA) grade I-II. The study exclusion criteria were defined as difficult airway, allergies to the study drugs, asthma, severe central nervous system disease (eg, brain tumour, uncontrolled seizures), mental motor retardation, the application of another procedure after MRI sedation, and those whose parents declined to participate in the study.
58313468|NCT01655901|BEHAVIORAL|Active video gaming|
57958354|NCT02889796|DRUG|MTX|Commercially sourced tablet(s) administered orally
57958355|NCT04405011|DRUG|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
57958356|NCT04405011|DRUG|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
57958357|NCT04149067|DRUG|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
57958358|NCT04149067|DRUG|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
57958359|NCT05216965|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
57958360|NCT00541554|DRUG|Abilify (aripiprazole)|
57958361|NCT04971304|DRUG|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
57958362|NCT00401271|DRUG|OPC-67683|
57958363|NCT00401271|DRUG|Rifafour e-275|
57958364|NCT01554280|DEVICE|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
58118596|NCT01165996|OTHER|pharmacological study|Correlative studies
58118597|NCT01165996|GENETIC|polymorphism analysis|Correlative studies
58118598|NCT04556110|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
58313469|NCT01655901|BEHAVIORAL|Passive video gaming|
58313470|NCT01655901|BEHAVIORAL|Resting|
58313471|NCT04926168|OTHER|Delay of TMZ|Delay of TMZ to analyze the current standard of care practice of prescribing TMZ post combination (RT and TMZ).
57744704|NCT02184793|DEVICE|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
57744705|NCT00713440|OTHER|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
57744706|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
57744707|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
57744708|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
58118599|NCT04556110|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
57744709|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
57744710|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
57744711|NCT06723275|OTHER|Standardized assessments, guided tumor biopsy and biobanking|"Standardized assessment of Scores~* Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
57744712|NCT06723275|OTHER|Standardized assessments and biobanking|"* Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
57744713|NCT06733298|DRUG|[ 14C]-labeled RO7269162|Participants will receive one oral dose of \[14C\]-labeled RO7269162.
58448511|NCT02151669|BEHAVIORAL|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
58448512|NCT02464046|DRUG|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
57744714|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
57744715|NCT06577714|DIAGNOSTIC_TEST|Electromechanical wave imaging (EWI)|EWI is a high-frame rate ultrasound technique that images the electromechanical wave corresponding to the propagation of the onset of myocardial contraction in response to electrical activation, namely electromechanical coupling.
57958365|NCT02452580|OTHER|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
58448513|NCT02464046|DRUG|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
58448514|NCT03591718|DRUG|BI 456906|Solution for injection
57958366|NCT03524248|RADIATION|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
57958367|NCT02989792|GENETIC|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
57958368|NCT02989792|OTHER|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
57958369|NCT01146106|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
57958370|NCT05972460|DRUG|IMM2510|IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
58448515|NCT03591718|DRUG|Placebo|solution for injection
58448516|NCT04523857|DRUG|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
57744716|NCT06695897|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
57958371|NCT04864444|DRUG|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
58118600|NCT06482463|BIOLOGICAL|CSF sample|an additional CSF sample of 1 ml is taken from the external ventriculostomy
58448517|NCT04523857|DRUG|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
58448518|NCT04755036|OTHER|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
58118601|NCT01903486|DRUG|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
58448519|NCT04756804|DRUG|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
58448520|NCT04756804|DRUG|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
58448521|NCT05590975|BEHAVIORAL|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
58118602|NCT01809054|DRUG|Arixtra|
58118603|NCT01809054|DEVICE|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
57744717|NCT00095225|DRUG|Avastin (bevacizumab)|
57744718|NCT00095225|DRUG|Tarceva (erlotinib HCl)|
57744719|NCT04185805|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
57958372|NCT04864444|DRUG|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
57958373|NCT00645983|DIETARY_SUPPLEMENT|Chamomile Extract|220 mg - 1100 mg daily
58118604|NCT01809054|DRUG|Aspirin|
58118605|NCT00588393|DRUG|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
57744720|NCT04185805|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
57744721|NCT06280196|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
57744722|NCT06280196|DRUG|EU-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
57744723|NCT06280196|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
57744724|NCT06280196|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
58313472|NCT04926168|OTHER|Standard of Care (SOC) Adjuvant TMZ (no intervention|SOC in Adjuvant Setting no intervention
58313473|NCT05232890|OTHER|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
58313474|NCT05232890|OTHER|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
58313475|NCT00843349|DRUG|Lanthanum Carbonate|Phosphorus binder
58313476|NCT00843349|OTHER|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
58313477|NCT00843349|DRUG|LC Placebo|Placebo for Lanthanum Carbonate
58313478|NCT00843349|OTHER|Ad Libitum Diet|Patients continued to eat their usual diet.
58313479|NCT01498302|OTHER|diagnostic laboratory biomarker analysis|
58313480|NCT01498302|OTHER|flow cytometry|
58313481|NCT04711005|DRUG|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
58313482|NCT04711005|DRUG|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
58313483|NCT01490411|DRUG|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
58313484|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
58313485|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
58313486|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
58313487|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
58313488|NCT03571789|DEVICE|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
58313489|NCT03761316|OTHER|interview regarding goals|interview regarding goals
58313490|NCT03984929|BEHAVIORAL|Conexion Localized|The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.
58313491|NCT03984929|BEHAVIORAL|Conexion Generic|The generic version of Conexion is an online health information resource on diabetes and depression.
58313492|NCT00265434|DRUG|Pulmozyme|
57744725|NCT06280196|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
58118606|NCT02915679|OTHER|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling"
58118607|NCT04593290|DEVICE|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
58118608|NCT06008405|DRUG|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
58118609|NCT01460927|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
58118610|NCT03650400|DRUG|Fevipiprant|Chewable tablet
58118611|NCT03189797|OTHER|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
58118612|NCT02477761|DIETARY_SUPPLEMENT|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
58118613|NCT03951428|DIAGNOSTIC_TEST|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
58448522|NCT02466763|PROCEDURE|Cochlear implant surgery|Surgical placement of a cochlear implant device.
58448523|NCT02195570|OTHER|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
58448524|NCT02195570|BEHAVIORAL|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
58448525|NCT03547310|BEHAVIORAL|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
58448526|NCT04043559|OTHER|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
58448527|NCT04043559|OTHER|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
57744726|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
57744727|NCT06729021|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
57744728|NCT06729021|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
57744729|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
58118614|NCT04224090|DIAGNOSTIC_TEST|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
58118615|NCT02596997|DRUG|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
58118616|NCT01454700|DEVICE|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
57958374|NCT00645983|OTHER|Placebo|1 to 5 capsules daily
57744730|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
57744731|NCT03691116|BEHAVIORAL|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
57744732|NCT03691116|BEHAVIORAL|Treatment as usual|Ordinary psychological assessment and counseling.
57744733|NCT05750459|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
57744734|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
58448528|NCT04800458|BIOLOGICAL|Blood samples|"* Thrombopoietin : 7 ml whole blood.~* Anti-platelet antibodies free : 14 ml whole blood.~* Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
57744735|NCT05274074|BEHAVIORAL|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
57744736|NCT03624465|DEVICE|Levita Magnetic Surgical System|Device for use as a surgical tool.
57744737|NCT04526795|DRUG|Cytarabine|Given IV
57744738|NCT04526795|DRUG|Fludarabine|Given IV
57744739|NCT04526795|DRUG|Pegcrisantaspase|Given IV
57744740|NCT06575140|DEVICE|Associative Peripheral Stimulation (APS) 1.0|Associative peripheral stimulation paired with rehabilitative exercises.
57744741|NCT06575140|DEVICE|Peripheral Neuromuscular Stimulation|Random peripheral stimulation paired with rehabilitative exercises.
57744742|NCT03248102|DIAGNOSTIC_TEST|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
58118617|NCT01454700|OTHER|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
58448529|NCT00217932|DRUG|Divalproex Sodium (Depakote)|
58448530|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
58448531|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
57744743|NCT03048851|DEVICE|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
57744744|NCT03048851|DEVICE|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
57958375|NCT01358656|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith \& Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
58118618|NCT04817592|PROCEDURE|Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure for correction of Myopia
58313493|NCT02506920|DIETARY_SUPPLEMENT|Six different types of fat in a meal in random order|Oral fat tolerance test
58448532|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
58448533|NCT01459588|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
58448534|NCT01459588|DRUG|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
57744745|NCT03048851|DEVICE|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
57744746|NCT03048851|DEVICE|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
57744747|NCT03048851|PROCEDURE|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
57744748|NCT06496490|DRUG|TQB2102 for injection|HER2 dual-antibody-drug Conjugate (ADC).
57744749|NCT06496490|DRUG|TQB2102 for injection combined with Benmelstobart injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
58118619|NCT03971942|BEHAVIORAL|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
58313494|NCT02078258|BEHAVIORAL|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
58448535|NCT02677194|DEVICE|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
58313495|NCT02515474|PROCEDURE|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
58313496|NCT02515474|PROCEDURE|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
58313497|NCT04804137|OTHER|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
58313498|NCT04804137|OTHER|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
58313499|NCT04804137|OTHER|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
58313500|NCT04804137|OTHER|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
58313501|NCT01467752|PROCEDURE|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
58313502|NCT02297126|OTHER|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
58313503|NCT00632294|PROCEDURE|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
58313504|NCT00666770|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
58313505|NCT00666770|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
58313506|NCT00666770|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
58313507|NCT05595226|PROCEDURE|RT3D-TEE-guided mitral valve repair|RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
57744750|NCT06308380|PROCEDURE|Specific protocol of rehabilitation exercise|Specific protocol of rehabilitation exercise
57744751|NCT06308380|PROCEDURE|Short gastrocnemius surgery.|During surgery, a partial release of the gastrocnemius muscle tendon is performed to relieve tension and allow greater range of motion. This procedure is typically performed on an outpatient basis and under local or regional anesthesia, which allows for a quicker recovery compared to more invasive surgeries.
57744752|NCT04611503|DRUG|subretinal injection of rAAV.hPDE6A|"The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg)."
57744753|NCT06732869|BEHAVIORAL|eHealth physical activity coaching intervention|Patients will attend a PR program and in week 5 of PR will receive an eHealth PA coaching intervention until 6 months after end of PR. The PA goals will be prescribed through a phone call and the personalisation of goal prescription will be based on an algorithm considering patient's performance in the previous week, perceived easiness of achieving the previous goal and confidence to change it. If patient does not achieve the goal, reasons, barriers to PA and strategies to overcome them will be identified. Patients will receive a daily notification about their goal achievements, at 6PM every day, giving them the possibility to increase their PA to achieve the goal, if they have not reached it yet. Patients will also receive personalized notifications sent manually by the researcher whenever appropriate. PA goals will be prescribed on a weekly basis.
57744754|NCT06732869|BEHAVIORAL|pulmonary rehabilitation|Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.
57744755|NCT00114010|DRUG|AMA1/Alhydrogel|
57744756|NCT00336674|BIOLOGICAL|Intranasal insulin|440IU Insulin
57744757|NCT00336674|OTHER|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
57744758|NCT00717860|DRUG|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
58118620|NCT03971942|BEHAVIORAL|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
58118621|NCT05719714|DRUG|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
58448536|NCT02677194|OTHER|Control device|Device without any LED exposition
58118622|NCT02266836|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
58118623|NCT03690479|DEVICE|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
58313508|NCT04198168|DRUG|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
58448537|NCT02342223|DEVICE|Voluma|
58448538|NCT04617067|DRUG|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
58448539|NCT04617067|DRUG|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
58448540|NCT05206721|OTHER|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
58448541|NCT04718623|DIAGNOSTIC_TEST|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
58448542|NCT04485559|DRUG|Everolimus|Given PO
58448543|NCT04485559|DRUG|Trametinib|Given PO
58448544|NCT00310089|BIOLOGICAL|filgrastim|
58448545|NCT00310089|BIOLOGICAL|pegfilgrastim|
57744759|NCT00717860|DRUG|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
57744760|NCT05491148|OTHER|work conditions|an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
57744761|NCT01568671|OTHER|Room temperatures|Room temperature of metabolic chamber set between 16C and 31C
57744762|NCT03605095|DRUG|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
57744763|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
58118624|NCT03690479|DEVICE|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
58448546|NCT00310089|DRUG|cediranib maleate|
58448547|NCT00310089|DRUG|cyclophosphamide|
58448548|NCT00310089|DRUG|docetaxel|
58448549|NCT00310089|DRUG|doxorubicin hydrochloride|
58448550|NCT00310089|OTHER|laboratory biomarker analysis|
57744764|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
57744765|NCT01505023|DIETARY_SUPPLEMENT|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
57744766|NCT03260166|DRUG|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
57744767|NCT05008666|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
57744768|NCT05008666|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
57744769|NCT05008666|DRUG|Azacitidine|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
57744770|NCT05008666|DRUG|L-DEP|L-DEP
58118625|NCT04249089|BEHAVIORAL|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
58313509|NCT06366308|PROCEDURE|Transperineal Prostate Biopsy|The investigators plan to retrospectively review data from over 10000 men receiving transperineal prostate biopsy in our center.
58313510|NCT01946867|DEVICE|NBTXR3 activated by IMRT|
58313511|NCT02497066|OTHER|Neuropathic pain cream|Subjects will apply the cream to the painful area.
58313512|NCT02497066|OTHER|Nociceptive pain cream|Subjects will apply the cream to the painful area.
58313513|NCT02497066|OTHER|Mixed pain cream|Subjects will apply the cream to the painful area.
58313514|NCT03742596|DIETARY_SUPPLEMENT|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
58313515|NCT03742596|DRUG|Control|The Placebos will be coded in a specific label by a researcher.
58448551|NCT00310089|PROCEDURE|conventional surgery|
58448552|NCT00310089|PROCEDURE|neoadjuvant therapy|
58448553|NCT05206760|PROCEDURE|Brain biopsy|Biopsy of brain tissue
58448554|NCT00361556|BEHAVIORAL|The Back Book|A book on how to prevent back pain
58448555|NCT00361556|BEHAVIORAL|The Back Guide|A guide for the prevention of back pain.
58448556|NCT00361556|BEHAVIORAL|General health book|A book on general health
58448557|NCT06458543|DRUG|Longidaza|Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
58448558|NCT06458543|DRUG|Metronidazole 500 mg|Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
58448559|NCT06165328|DIAGNOSTIC_TEST|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
58448560|NCT02420704|PROCEDURE|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
58448561|NCT00306553|BIOLOGICAL|CYT004-MelQbG10|
58448562|NCT04039958|DRUG|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
58448563|NCT04039958|DRUG|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
58448564|NCT04039958|DRUG|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
58448565|NCT01366599|DRUG|HEC or MEC|Any HEC or MEC, including aprepitant
58448566|NCT00462306|PROCEDURE|Survey: Berlin questionnaire|Completion of questionnaire
58448567|NCT06726772|BEHAVIORAL|Group Psychotherapy|Group psychotherapy based on Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) elements
58448568|NCT02330055|PROCEDURE|Forty-five degrees elevated upper body position|
58448569|NCT02330055|PROCEDURE|non-elevated upper body position|
57744771|NCT01869010|OTHER|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
58118626|NCT00774358|DRUG|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
58118627|NCT05566665|DIAGNOSTIC_TEST|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
57744772|NCT02524392|OTHER|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
58118628|NCT04457869|DRUG|F520|3mg/kg every 3 weeks
58118629|NCT00446498|DEVICE|CPAP and Non Invasive Ventilation|
58118630|NCT03350048|DIAGNOSTIC_TEST|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
58118631|NCT05268978|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
58118632|NCT01894984|DRUG|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
58118633|NCT01894984|DRUG|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
57744773|NCT03115983|DEVICE|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
57744774|NCT03115983|DEVICE|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
57744775|NCT03115983|PROCEDURE|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
57744776|NCT03115983|PROCEDURE|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
58118634|NCT03788265|DEVICE|Lipogems|harvest and inject micro-fragment adipose tissue
58118635|NCT01939600|OTHER|Starch-free breakfast|Starch-free breakfast alone
58118636|NCT01939600|OTHER|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
58118637|NCT01939600|OTHER|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
58118638|NCT01939600|OTHER|Amioca|Starch-free breakfast plus 56.4g amioca starch
58118639|NCT05287139|OTHER|Quality of Life|Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
58118640|NCT01153061|DEVICE|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
58118641|NCT01153061|DEVICE|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
58118642|NCT04467697|DRUG|SOV2012-F1|Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
58118643|NCT04906603|DEVICE|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
58118644|NCT04463433|BEHAVIORAL|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
57744777|NCT06732388|PROCEDURE|Biopsy|Undergo tissue biopsy
57744778|NCT06732388|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58118645|NCT04463433|BEHAVIORAL|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
58313516|NCT04676204|DRUG|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
57744779|NCT06732388|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
58448570|NCT02330055|DEVICE|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
58448571|NCT02330055|OTHER|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
57744780|NCT06732388|DRUG|Itraconazole|Given PO
57744781|NCT06732388|DRUG|Placebo Administration|Given PO
58448572|NCT02330055|OTHER|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
58448573|NCT02330055|OTHER|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
57744782|NCT06732388|OTHER|Questionnaire Administration|Ancillary studies
57744783|NCT06732388|PROCEDURE|Radiofrequency Ablation|Undergo radiofrequency ablation
57744784|NCT05747196|DEVICE|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
57744785|NCT04014920|DEVICE|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
57744786|NCT04014920|DEVICE|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
58118646|NCT01609660|DIETARY_SUPPLEMENT|Saccharomyces boulardii|100mg daily for seven days prior to surgery
58118647|NCT03522922|DEVICE|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
58118648|NCT03522922|DRUG|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
58118649|NCT00186927|BIOLOGICAL|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
58118650|NCT05029583|OTHER|routine screening|routine screening for advanced NASH
58313517|NCT04676204|DRUG|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
57744787|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
57744788|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
57744789|NCT01421576|DIETARY_SUPPLEMENT|High fat meal|offer high fat-meal in the morning before drug intake.
57744790|NCT00142493|DRUG|Propofol|1.2ug/ml
57744791|NCT00142493|DRUG|Thiopental Sodium|2.0ug/ml
57744792|NCT00142493|DRUG|Dexmedetomidine Hydrochloride|0.5ng/ml
58118651|NCT05029583|OTHER|physician-driven screening|physician-driven screening for advanced NASH
58313518|NCT04676204|DRUG|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
58448574|NCT02330055|OTHER|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
57744793|NCT00142493|DRUG|Midazolam Hydrochloride|60ng/ml
57744794|NCT00142493|DRUG|placebo|intralipid, saline, saline with multi-Vit solution
57744795|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
57744796|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
57744797|NCT05003349|OTHER|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
57744798|NCT05003349|OTHER|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
57744799|NCT05003349|OTHER|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
57744800|NCT05003349|OTHER|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
57744801|NCT05003349|OTHER|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
57744802|NCT05003349|OTHER|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
57744803|NCT02125201|DRUG|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
57744804|NCT06732934|OTHER|exercise (Basic Body Awareness Therapy|"Body Awareness Therapy is a patient-centered physiotherapy approach that also includes mental health, focusing on movement awareness training. This therapy primarily consists of exercises aimed at improving postural disorders, balance, and muscle tension. It aims to help individuals experience and accept bodily responses while increasing coping strategies.~The therapy includes body scanning, integration of sound and movement, stretching exercises, and exercises focusing on body alignment and midline orientation.~Floor exercises: body scanning, stretching, strength accumulation, sound resonance.~Seated exercises: body alignment, trunk rotation, head and neck movements. Standing exercises: support surface perception, midline elevation and lowering, bilateral arm movements, rotation, one-legged balance, voice exercises, and group movements."
57744805|NCT06732934|OTHER|exercise (aerobic exercise)|"The continuous exercise protocol specified by the American College of Sports Medicine (ACSM) will be applied under supervision on a treadmill. The exercise duration will follow ACSM recommendations, starting at 30 minutes in the first week and increasing to 45 minutes by the 12th week.~Exercise intensity will be assessed using the target heart rate method (220 - age). The intensity of aerobic exercise will be set at a moderate level (64-77% HRmax), according to ACSM guidelines.~During exercise, heart rate will be monitored through a heart rate monitoring device. A 5-minute warm-up and a 5-minute cool-down exercise will be performed before and after each session, with an intensity of 50-60% of the maximum heart rate."
57744806|NCT00850473|DIAGNOSTIC_TEST|PET/CT|Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
58448575|NCT05083533|BEHAVIORAL|tele-rehabilitation exercise|"Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Treatment program planned to stretch the muscles of individuals with short hamstring muscle group.~Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions."
58448576|NCT05083533|BEHAVIORAL|Home exercise|All participants received home exercise for 8 weeks. The exercise program includes stretching exercises Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.
58448577|NCT04354376|DRUG|Loop diuretics, thiazides, dihydropyridines|Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
58448578|NCT04354376|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
58448579|NCT05505344|DEVICE|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
58448580|NCT00771888|DRUG|lanreotide|lanreotide
58448581|NCT01822457|DEVICE|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
58448582|NCT05295875|DRUG|ALT-801|Injected subcutaneously (SC)
58448583|NCT05295875|OTHER|Placebo|Injected subcutaneously (SC)
58448584|NCT00893061|DRUG|anastrozole|Given orally
58448585|NCT00893061|DRUG|exemestane|Given orally
57958376|NCT01358656|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
58313519|NCT04676204|DRUG|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
58313520|NCT04676204|DRUG|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
57958377|NCT02368717|DRUG|Mesalazine Enema|
58118652|NCT03133442|DEVICE|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
58313521|NCT04676204|DRUG|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
58313522|NCT03227588|DIAGNOSTIC_TEST|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
58313523|NCT05601336|DRUG|Dapagliflozin 5 MG|SGLT2 inhibitor
58313524|NCT05601336|DRUG|Metformin Hydrochloride 1000 MG|metformin
58313525|NCT05601336|DRUG|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
58313526|NCT01866254|DRUG|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
58313527|NCT01866254|DRUG|Morphine|Injection of 200 mcg of intrathecal morphine
58313528|NCT04054297|BEHAVIORAL|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
58313529|NCT04054297|BEHAVIORAL|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
58313530|NCT02314546|DRUG|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
58313531|NCT02314546|DRUG|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
58313532|NCT02314546|DRUG|saline placebo|Placebo - Control patients will receive intranasal saline.
58313533|NCT05991375|DRUG|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
58313534|NCT05991375|OTHER|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
58313535|NCT05023980|DRUG|Pirtobrutinib|Oral
58313536|NCT05023980|DRUG|Bendamustine|IV
58313537|NCT05023980|DRUG|Rituximab|IV
58313538|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
58313539|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
58313540|NCT01520753|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
58313541|NCT00290225|BEHAVIORAL|Breath Water Sound Course and Traumatic Incident Reduction|
58313542|NCT01949545|DRUG|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
58448586|NCT00893061|DRUG|letrozole|Given orally
58313543|NCT04734613|BEHAVIORAL|Tai Chi exercise|Yang style Tai Chi 16 movements
58313544|NCT04734613|BEHAVIORAL|self management|health education and dietary counseling
58313545|NCT05141773|DEVICE|Computed adenoma detection system (CADe) plus endocuff|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
58313546|NCT05141773|DEVICE|Endocuff|An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
58313547|NCT04222049|DEVICE|Vibro Tactile Gadget|The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
58313548|NCT04938336|BEHAVIORAL|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
58313549|NCT00093522|BIOLOGICAL|autologous tumor cell vaccine|
58313550|NCT00093522|BIOLOGICAL|keyhole limpet hemocyanin|
58313551|NCT00093522|BIOLOGICAL|therapeutic autologous dendritic cells|
58313552|NCT00093522|DRUG|fludarabine phosphate|
58313553|NCT00093522|PROCEDURE|conventional surgery|
58448587|NCT00893061|DRUG|tamoxifen citrate|Given orally
58448588|NCT00918099|PROCEDURE|Avaulta mesh|Insertion of a mesh vs conventional repair
58448589|NCT00918099|PROCEDURE|Anterior repair|Conventional repair
58448590|NCT00664885|OTHER|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
58448591|NCT02497183|DEVICE|ultrasound|A repeat ultrasound exam following oral contrast material consumption
58448592|NCT02497183|OTHER|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
58118653|NCT05716139|PROCEDURE|Natural Cycle|The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
58118654|NCT05716139|PROCEDURE|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
58118655|NCT04748211|PROCEDURE|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
58118656|NCT04748211|PROCEDURE|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
58118657|NCT04509973|DRUG|Dexamethasone|ATC code: H02AB02
58118658|NCT04003870|DEVICE|CASO|Customized arch support orthoses (CASO)
58313554|NCT03103958|DIETARY_SUPPLEMENT|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
57958378|NCT02368717|DRUG|Placebo Enema|
57958379|NCT00223496|DRUG|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
57958380|NCT00726687|DRUG|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
57958381|NCT00726687|DRUG|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
58118659|NCT04003870|DEVICE|HL|Orthotic Heel Lift (HL)
58448593|NCT01534000|PROCEDURE|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
58448594|NCT04108611|PROCEDURE|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
58448595|NCT02361333|BEHAVIORAL|Teaching Intervention|Patients will be taught how to install and use a remote monitor
58448596|NCT05273320|DRUG|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
57958382|NCT05173454|BEHAVIORAL|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
58118660|NCT03867851|DRUG|IBsolvMIR|Study drug IBsolvMIR
58118661|NCT03867851|DRUG|Heparin|Clinical praxis
58118662|NCT04195997|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.
58313555|NCT03103958|DIETARY_SUPPLEMENT|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
58313556|NCT05282784|OTHER|Hyperthermia|"Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week."
58313557|NCT05282784|RADIATION|Radiotherapy|Patients will be treated with radiotherapy 5 times a week.
57958383|NCT02392273|DRUG|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
57958384|NCT02475811|RADIATION|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
58313558|NCT03482024|DRUG|Tirzepatide|Administered SC.
58313559|NCT05397652|DRUG|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
58448597|NCT04138641|DRUG|Cangrelor|Cangrelor intravenous
58448598|NCT02707146|BEHAVIORAL|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
58448599|NCT02707146|OTHER|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
58448600|NCT02707146|DEVICE|iPad|
58448601|NCT00293657|DRUG|Lornoxicam 8 mg|
58448602|NCT00293657|DRUG|Lornoxicam 16 mg|
58448603|NCT00293657|DRUG|Placebo|
57958385|NCT04938258|BEHAVIORAL|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
58118663|NCT04195997|DRUG|Heparin|heparin during left atrial appendage occlusion.
58313560|NCT05397652|DRUG|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
58448604|NCT01951651|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
58448605|NCT01951651|DRUG|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
58448606|NCT01270178|DRUG|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
58448607|NCT06504810|OTHER|light|light level
58448608|NCT02996630|PROCEDURE|Sonography|Fetal Ultrasound exploration
57958386|NCT00000848|DRUG|Indinavir sulfate|
57958387|NCT00000848|DRUG|Saquinavir|
57958388|NCT03458390|DEVICE|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
57958389|NCT00368771|BEHAVIORAL|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
58313561|NCT00025402|BIOLOGICAL|filgrastim|
58118664|NCT06543264|DEVICE|Cryotherapy|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
58118665|NCT05564949|OTHER|CKD|Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
58118666|NCT04081337|DRUG|Tirzepatide|Administered SC
58118667|NCT04081337|DRUG|Placebo|Administered SC
58313562|NCT00025402|BIOLOGICAL|recombinant interferon alfa|
58313563|NCT00025402|DRUG|busulfan|
58313564|NCT00025402|DRUG|cyclophosphamide|
58313565|NCT00025402|DRUG|cytarabine|
58313566|NCT00025402|DRUG|etoposide|
58313567|NCT00025402|DRUG|hydroxyurea|
58313568|NCT00025402|DRUG|idarubicin|
58313569|NCT00025402|PROCEDURE|allogeneic bone marrow transplantation|
58448609|NCT02996630|DEVICE|Magnetic Resonance Imaging|Fetal MRI for brain study
58448610|NCT02996630|OTHER|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
58118668|NCT06530745|PROCEDURE|Hyaluronic acid (HA) injection|2% hyaluronic acid Synocrom Forte (Croma-Pharma GmbH, Leobendorf, Austria) injection
58313570|NCT00025402|PROCEDURE|peripheral blood stem cell transplantation|
58313571|NCT00025402|RADIATION|radiation therapy|
58313572|NCT04777513|PROCEDURE|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
58313573|NCT04777513|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
58313574|NCT04777513|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
58313575|NCT04777513|DEVICE|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
58313576|NCT04777513|DEVICE|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
58313577|NCT00355719|DRUG|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
58313578|NCT00355719|DRUG|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
57744807|NCT05441163|OTHER|APA and nutrition intervention|"- APA intervention: weekly supervised sessions at home with the APA professional combined with unsupervised sessions, alone or with the APA partner, for 8 weeks.~The supervised session will be broken down as follows: warm-up block (approximately 10'), aerobic block (15'), muscle strengthening/resistance block (15') and stretching/relaxation block (10'). The remaining 10' will be used to review the session and the individual sessions. This program can be adapted to the needs and abilities of the patient if necessary.~- Nutritional intervention: dietitian weekly visits at home during 8 weeks with dietetic counseling; decision of oral, enteral and/or parenteral feeding validated by the clinical steering committee according to the Société Francophone de Nutrition Clinique et Métabolisme (SFNCM) guidelines."
57744808|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
57744809|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
57744810|NCT05691478|DRUG|Cisplatin|Given IV
57744811|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
57744812|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
57744813|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57744814|NCT05691478|DRUG|Methotrexate|Given IV
57744815|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
57744816|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
57744817|NCT06235801|DRUG|Gilteritinib|Given by PO
57744818|NCT06235801|DRUG|Momelotinib|Given by PO
57744819|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
57744820|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
57744821|NCT06346899|OTHER|No intervention|This is a non-interventional study.
57744822|NCT03901235|BIOLOGICAL|Mesenchymal Stromal Cells|Suspension of mesenchymal stromal cells for intratissular injection
57744823|NCT04879550|DIAGNOSTIC_TEST|Antithrombin III|Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
58448611|NCT02996630|PROCEDURE|Surgical intervention|Congenital Heart Disease repair
57744824|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
57744825|NCT03278262|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
57744826|NCT05864781|BEHAVIORAL|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
57744827|NCT06733012|DEVICE|Splanchnic nerve block|Catheter based ablation on the right greater splanchnic nerve
57744828|NCT06733012|OTHER|Sham-control procedure|Sham-control ablation procedure
57744829|NCT03740282|DEVICE|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
57958390|NCT00368771|BEHAVIORAL|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
58448612|NCT02996630|PROCEDURE|Brain monitoring|EEG and continuous brain oximetry before surgery.
57744830|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
57744831|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
57958391|NCT00368771|BEHAVIORAL|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
57958392|NCT04760925|DEVICE|CascadeTM, Non-Occlusive Remodeling Net|Temporary assistance device for coil embolization of intracranial aneurysms
57958393|NCT06197828|OTHER|This study is an observational studie which have no intervention|This study is an observational studie which have no intervention
57958394|NCT01568593|DEVICE|T2750|1 drop in each eye 3 to 6 times daily during 84 days
58448613|NCT02996630|PROCEDURE|cord blood sample|Cord blood samples will be taken after birth in both groups.
58448614|NCT00269919|DRUG|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
57744832|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
57744833|NCT06676319|DRUG|Lunsekimig|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
57744834|NCT06676319|DRUG|Short-Acting Beta Agonists (SABA)|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
57744835|NCT06676319|DRUG|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
57744836|NCT06676319|DRUG|Fluticasone/salmeterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
57744837|NCT06676319|DRUG|Budesonide/formoterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
57744838|NCT02982005|DRUG|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
57958395|NCT01568593|DEVICE|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
58313579|NCT00355719|DRUG|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
58118669|NCT06530745|PROCEDURE|Platelet-rich plasma (PRP) injection|PRP from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with iFuge D06 (Neuation Technologies Pvt. Ltd, Gujarat, India) injection
58118670|NCT00004843|PROCEDURE|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
58118671|NCT00004843|OTHER|Observation|Usual care
58118672|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
58118673|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
58118674|NCT00948402|DRUG|Metformin|metformin 1250 mg three times daily
58118675|NCT00948402|DRUG|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
58448615|NCT02609061|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
58448616|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
58448617|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
58448618|NCT03754348|RADIATION|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
58448619|NCT00977626|DRUG|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
58448620|NCT00977626|DRUG|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
58448621|NCT00977626|DRUG|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
58448622|NCT01934491|BEHAVIORAL|Cognitive Training A|
57744839|NCT02982005|DRUG|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
57958396|NCT06539572|PROCEDURE|Cleft lip repair; palatoplasty; alveolar bone grafting|cleft surgical treatment based on Chang Gung Craniofacial Center Protocol for cleft treatment
57744840|NCT03998787|OTHER|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
57744841|NCT03407599|DRUG|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
57744842|NCT03407599|DRUG|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
57958397|NCT05334186|BEHAVIORAL|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
57958398|NCT02138032|BEHAVIORAL|Gains Framed Message|
57958399|NCT02138032|BEHAVIORAL|Loss Framed Message|
58118676|NCT03342703|DIAGNOSTIC_TEST|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
57958400|NCT06221475|DRUG|BAY2927088 coated tablet 10 mg|4 coated tablets (10 mg) per single dose 30 min after a light meal
57958401|NCT06221475|DRUG|[14C]-BAY2927088 solution for infusion|IV infusion 15 min ending at 2 hours oral post-dose
57958402|NCT06221475|DRUG|[14C]-BAY2927088 oral solution|After a light meal
57958403|NCT00037609|DRUG|Capecitabine|1000 mg/m\^2 taken by mouth twice daily.
57958404|NCT00037609|DRUG|Exisulind|125 mg taken by mouth twice daily.
57958405|NCT02274103|BEHAVIORAL|BFST|Family-based skills training.
57958406|NCT01495442|DEVICE|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
57958407|NCT01495442|DEVICE|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
58118677|NCT01890083|BEHAVIORAL|Exercise|
58118678|NCT01890083|BEHAVIORAL|Health Education|
58118679|NCT03654209|DEVICE|Argon Plasma Coagulation|APC will be applied to the perimeter of the resection site
58118680|NCT03654209|DEVICE|Snare Tip Soft Coagulation|STSC will be applied to the perimeter of the resection site
58118681|NCT03215173|BEHAVIORAL|Fit After Baby|Mobile application
58448623|NCT01934491|BEHAVIORAL|Cognitive Training B|
57744843|NCT06732492|DRUG|RD13-02 cell infusion|CAR-T cells
57744844|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
57958408|NCT01314300|DRUG|Lidocaine|Lidocaine 5% plaster
58118682|NCT03215173|BEHAVIORAL|Text4Baby Control Group|Receive free text messages
58118683|NCT04064229|DEVICE|ivWatch Model 400 with SmartTouch Sensor|The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
58313580|NCT06036095|DRUG|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
58448624|NCT06185582|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
58118684|NCT04064229|DEVICE|ivWatch Model 400 with Fiber Optic Sensor|The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
57744845|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
57744846|NCT06431802|OTHER|Conventional intervention|A nursing specialist with extensive clinical and teaching experience will provide on-site course training. The training will cover topics related to pain and pain assessment, such as: pain definition, types, physiological mechanisms, performance, pain assessment tools, and frequency of pain assessment. Interventions will be provided once a week for 4 weeks.
57744847|NCT06431802|BEHAVIORAL|Platform intervention|Using a pre-assigned account to log in to the platform, read the guidance instructions and enter the platform to start training. Basic knowledge of pain and pain assessment can be learnt through the Learning Resources module on the platform, and pain assessment training can be conducted through the Pain Assessment Exercise module. During pain assessment training the platform provides instant feedback based on the participant's exercises. Interventions will be completed in 4 weeks.
57744848|NCT04943874|DEVICE|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
57958409|NCT04253275|GENETIC|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
57744849|NCT04943874|DEVICE|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
57744850|NCT03362333|OTHER|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
57744851|NCT03362333|OTHER|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
57744852|NCT04341701|PROCEDURE|MRI|The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
57958410|NCT04253275|DIAGNOSTIC_TEST|MRI without injection|MRI at inclusion for controls
57958411|NCT05810545|OTHER|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
57958412|NCT01678183|BEHAVIORAL|Monthly Financial Incentive|A cash payment.
57958413|NCT01678183|BEHAVIORAL|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
57958414|NCT01394146|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
57958415|NCT00156312|DRUG|Docetaxel|
57958416|NCT00156312|DRUG|Capecitabine|
57958417|NCT06222151|OTHER|Intervention 1: Mobilization during hospitalization|Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
57958418|NCT06222151|OTHER|Intervention 2: Mobilization the first 4 postoperative weeks|Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
58118685|NCT05900661|DRUG|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
57744853|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
57744854|NCT06513351|BEHAVIORAL|Novel PPH Risk Prediction Model - Comparator Arm B|Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
57744855|NCT01494168|PROCEDURE|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
57744856|NCT06144840|DRUG|Dersimelagon|MT-7117
57744857|NCT06144840|DRUG|Placebo|Placebo
58118686|NCT05900661|DRUG|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
58118687|NCT05900661|DRUG|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
58118688|NCT05717881|DIETARY_SUPPLEMENT|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
58118689|NCT05717881|DIETARY_SUPPLEMENT|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
58118690|NCT04488640|PROCEDURE|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
58118691|NCT02203747|OTHER|Administration of patient self-assessment|
58118692|NCT03491358|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
58448625|NCT04600713|OTHER|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
57744858|NCT06732206|OTHER|Short Solution Focused Approach Program|It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.
57744859|NCT05807451|PROCEDURE|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
57744860|NCT01487811|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
57744861|NCT04856722|PROCEDURE|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
58118693|NCT03491358|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
58118694|NCT06160999|BEHAVIORAL|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
58118695|NCT06160999|BEHAVIORAL|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
58118696|NCT05293028|DRUG|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
57744862|NCT04856722|PROCEDURE|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
58118697|NCT01439100|DRUG|Oxycodone/Naloxone Prolonged Release tablets|
58118698|NCT01439100|DRUG|Placebo|Dummy tablet
58118699|NCT05303922|DIAGNOSTIC_TEST|Dual-energy CT|Dual-energy CT
58118700|NCT05303922|DIAGNOSTIC_TEST|MRI|MRI
58118701|NCT04551885|DRUG|FT516|Experimental Interventional Therapy
58118702|NCT04551885|DRUG|Avelumab|Monoclonal antibody
58118703|NCT04551885|DRUG|Cyclophosphamide|Lympho-conditioning agent
57744863|NCT04856722|PROCEDURE|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
57744864|NCT06678178|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
57744865|NCT06678178|BEHAVIORAL|Warning High Climate Impact Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
57744866|NCT06678178|BEHAVIORAL|Traffic Light Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
58118704|NCT04551885|DRUG|Fludarabine|Lympho-conditioning agent
58118705|NCT04551885|DRUG|IL-2|Biologic response modifier
58118706|NCT04735419|OTHER|No intervention|No intervention
58448626|NCT03202407|DRUG|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
58118707|NCT04527471|DRUG|Ensifentrine Dose 1|Study drug delivered twice daily via pMDI
57744867|NCT06678178|BEHAVIORAL|Climate Grade Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
57744868|NCT06678178|BEHAVIORAL|Numeric Carbon Footprint Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
57744869|NCT02732938|DRUG|PF-04136309|PF-04136309 oral dosing
57744870|NCT02732938|DRUG|Nab-paclitaxel|Nab-paclitaxel IV dosing
57744871|NCT02732938|DRUG|Gemcitabine|Gemcitabine IV dosing
57744872|NCT00454948|BEHAVIORAL|Home-based nutrition sessions and play group exercise|
57744873|NCT00454948|BEHAVIORAL|Group-based nutrition sessions and mail-out activities|
58118708|NCT04527471|DRUG|Placebo pMDI|Placebo delivered twice daily via pMDI
58313581|NCT06036095|DRUG|Propofol|Intravenous maintenance of anesthesia group using propofol
57744874|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
57744875|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
57744876|NCT06714955|DRUG|Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
57744877|NCT06714955|DRUG|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
57744878|NCT06714955|DRUG|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.|Drug: Placebo Administered SC
57744879|NCT06717685|DRUG|Adenosine|Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
57744880|NCT06717685|DRUG|Verapamil Injection|Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.
57744881|NCT03931148|DIAGNOSTIC_TEST|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
57744882|NCT03931148|DIAGNOSTIC_TEST|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
57744883|NCT03931148|DIAGNOSTIC_TEST|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
58313582|NCT01707524|PROCEDURE|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
57744884|NCT03931148|OTHER|Qualitative interview|Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
58118709|NCT00471406|PROCEDURE|Photodynamic Therapy with Verteporfin|
58118710|NCT04679870|DRUG|GB2064|GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
58118711|NCT00717756|DRUG|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
58118712|NCT04701697|DRUG|Recombinant Human Albumin Injection|Participants will receive Recombinant Human Albumin Injection of intravenous infusion
58118713|NCT04701697|DRUG|HumanAlbumin|Participants will receive HumanAlbumin of intravenous infusion
58118714|NCT01123486|DRUG|hydromorphone|hydromorphone 0.02 mg/kg
58313583|NCT03052686|OTHER|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
58118715|NCT00532597|PROCEDURE|On-line hemodiafiltration|
58313584|NCT00691275|DRUG|Ondansetron|
58313585|NCT00691275|DRUG|Saline|
58313586|NCT05258552|PROCEDURE|enema|preoperative enema
58313587|NCT00863122|DRUG|lapatinib|1500 mg lapatinib by mouth per day for 10 days
58313588|NCT03222726|OTHER|exercise group|less than 6000 steps/day or 40,000 steps/week
57744885|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
57744886|NCT02264678|DRUG|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
57744887|NCT02264678|DRUG|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
58118716|NCT00532597|PROCEDURE|Low flux hemodialysis|
58118717|NCT01638702|OTHER|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
58118718|NCT03692676|DEVICE|Spiriva Respimat|soft-mist inhaler
58313589|NCT03366753|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
58313590|NCT03366753|PROCEDURE|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
58313591|NCT03323762|DEVICE|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
57744888|NCT02264678|DRUG|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
58448627|NCT02687464|OTHER|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
58448628|NCT02687464|PROCEDURE|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
58448629|NCT04095182|DRUG|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
58448630|NCT04095182|DRUG|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
58448631|NCT04095182|DRUG|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)
58448632|NCT04095182|DRUG|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
58448633|NCT04095182|DRUG|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
58448634|NCT04095182|DRUG|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
57744889|NCT02264678|DRUG|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
57744890|NCT02264678|DRUG|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
57744891|NCT02264678|DRUG|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
57744892|NCT02264678|DRUG|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).
57958419|NCT06222151|OTHER|Control group|"The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge."
57958420|NCT01726348|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
57958421|NCT02424526|OTHER|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
58448635|NCT03318380|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
58448636|NCT01749878|DRUG|REGN1500|
58448637|NCT01749878|DRUG|placebo|
58448638|NCT03761186|BEHAVIORAL|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
57958422|NCT02424526|DEVICE|Treadmill|
57958423|NCT01768455|DRUG|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
57958424|NCT01768455|DRUG|Glimepiride|Glimepiride 4mg (qd) on Day1
57958425|NCT01931800|BIOLOGICAL|Sampling of blood|
57958426|NCT02229552|OTHER|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
58448639|NCT03761186|BEHAVIORAL|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
58448640|NCT03761186|BEHAVIORAL|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
58448641|NCT00410930|BIOLOGICAL|Subcutaneous immunotherapy - Recombinant birch pollen|
57744893|NCT02264678|DRUG|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
57744894|NCT04830475|DEVICE|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
57744895|NCT04830475|DEVICE|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
57744896|NCT00365443|BIOLOGICAL|V502|
57744897|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
57744898|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
57744899|NCT06732154|DRUG|HRS-5632|HRS-5632 Injection
57744900|NCT06732154|DRUG|Placebo|Sodium chloride injection
57744901|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
57958427|NCT05797324|OTHER|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
57958428|NCT05797324|OTHER|Sham|Sham protocol (white light \<100 lux equivalent).
57958429|NCT00723164|DRUG|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
57958430|NCT00723164|DRUG|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
57958431|NCT02825095|PROCEDURE|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
58118719|NCT05207215|OTHER|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
58118720|NCT01259427|BEHAVIORAL|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
58118721|NCT01259427|BEHAVIORAL|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
58118722|NCT01314742|DRUG|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
57744902|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
57744903|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
57744904|NCT01263808|DRUG|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
57744905|NCT01263808|DRUG|Indacaterol 300 µg|QD via SDDPI
57958432|NCT02825095|PROCEDURE|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
58118723|NCT01314742|OTHER|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
57744906|NCT01263808|DRUG|Indacaterol 600 µg|QD via SDDPI
57744907|NCT01263808|DRUG|Placebo|QD via SDDPI
57744908|NCT01263808|DRUG|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
57744909|NCT06533449|DEVICE|Couplet Care Bassinet|Couplet Care Bassinet
57744910|NCT06533449|DEVICE|Standard Bassinet|Standard Bassinet
57744911|NCT03607929|PROCEDURE|optimal|Physiological Saline Solution
57744912|NCT03607929|PROCEDURE|variability|Other solutions
57744913|NCT05712356|DRUG|LSTA1|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
57744914|NCT05712356|DRUG|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
57744915|NCT05712356|DRUG|Cisplatin|cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
57744916|NCT05712356|DRUG|Gemcitabine|gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
57958433|NCT02825095|PROCEDURE|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
57744917|NCT05712356|DRUG|FOLFOX regimen|"The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)"
57744918|NCT05712356|DRUG|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
57744919|NCT04881006|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
58448642|NCT05346575|BEHAVIORAL|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
58448643|NCT05346575|BEHAVIORAL|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
58118724|NCT04999332|DRUG|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
58118725|NCT02663089|DRUG|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.
58448644|NCT02307058|RADIATION|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
58448645|NCT02307058|RADIATION|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
58118726|NCT02663089|DRUG|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
58448646|NCT04078555|DRUG|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
58448647|NCT04078555|DRUG|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
58448648|NCT02825615|PROCEDURE|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
58448649|NCT03836768|DRUG|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
57744920|NCT04881006|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
57744921|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
57744922|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
57744923|NCT04536272|DRUG|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
57744924|NCT04536272|DRUG|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
57744925|NCT06732167|PROCEDURE|GBR|GBR surgical procedure with simultaneous implant placement including membrane placement
57744926|NCT06732167|PROCEDURE|GBR|GBR surgical procedure with simultaneous implant placement including membrane placement
57744927|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
57744928|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
58118727|NCT02663089|DRUG|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
58118728|NCT01713309|DRUG|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
58313592|NCT06255743|DIAGNOSTIC_TEST|Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies|determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
57744929|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
58118729|NCT02165579|OTHER|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
58448650|NCT05711121|PROCEDURE|Transforaminal epidural steroid injection|Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
58448651|NCT05711121|PROCEDURE|Caudal epidural steroid injection|Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
58448652|NCT05923814|DRUG|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
58448653|NCT02441023|BEHAVIORAL|Nutritional therapy and education|"1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
58448654|NCT02441023|BEHAVIORAL|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
58448655|NCT00172263|PROCEDURE|blood sampling|
58448656|NCT01951560|DRUG|Valproic Acid|By infusion over 1 hour
58448657|NCT01951560|DRUG|Isotonic saline solution|By infusion over 1 hour
58448658|NCT05864417|OTHER|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
58448659|NCT05864417|OTHER|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
58448660|NCT02735668|OTHER|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands)."
58448661|NCT02735668|OTHER|Multimodal Physiotherapy|"The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
58448662|NCT02735668|OTHER|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
58448663|NCT02735668|BEHAVIORAL|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
58448664|NCT02085018|DRUG|Omeprazole|Drug
58448665|NCT02085018|DRUG|Matched placebo|Matched placebo
57744930|NCT03079154|OTHER|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
57744931|NCT03079154|OTHER|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
57744932|NCT04150003|BEHAVIORAL|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
57744933|NCT04150003|OTHER|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
57744934|NCT00610116|DEVICE|Electronic Repositioning|Change of pacing vectors for CRT pacing
58448666|NCT04755608|OTHER|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
58448667|NCT04755608|OTHER|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
58448668|NCT01997424|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
58448669|NCT01997424|DEVICE|FibroScan, Echosens, Paris, France|
58448670|NCT00962637|DRUG|Androxal|12.5 mg once daily
58448671|NCT00962637|DRUG|Androxal|25 mg once daily
58448672|NCT00962637|DRUG|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
58448673|NCT00962637|DRUG|Placebo|1 capsule daily
58448674|NCT02883803|BIOLOGICAL|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
58448675|NCT02883803|BIOLOGICAL|Injection of albumin alone|Injection of albumin alone
58448676|NCT00252070|BEHAVIORAL|Functional Exercise for People with Arthritis (FEPA)|
58448677|NCT05822882|PROCEDURE|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
58448678|NCT05375591|OTHER|Non-Interventional Study|First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
58448679|NCT03457376|DIAGNOSTIC_TEST|Hand Grip Force|Hand Grip Force
57744935|NCT05205330|DRUG|CR6086|oral CR6086, twice a day for 14 days
57744936|NCT05205330|BIOLOGICAL|AGEN2034|AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
57744937|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo"
57744938|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)"
57744939|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)"
57744940|NCT06732245|DRUG|NA-931|"NA-931, an oral, daily~• A quadruple receptor agonist"
57744941|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
57744942|NCT06732245|DRUG|NA-931|"NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
57744943|NCT06732245|DRUG|NA-931 150 mg + no Tirzepatide|NA-931 150 mg + no Tirzepatide
57744944|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
57744945|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
57744946|NCT04554914|BIOLOGICAL|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
57744947|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
57744948|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
57744949|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
57744950|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
57744951|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
57744952|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
57744953|NCT02676375|DRUG|Combination Bupropion + NRTs|
57744954|NCT02676375|OTHER|Extended Treatment|
57744955|NCT02676375|OTHER|Home Visits & Calls|
57744956|NCT02676375|DRUG|Monotherapy|
57744957|NCT04219540|DRUG|XR-B (SUBLOCADETM)|XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.
57958434|NCT02825095|DRUG|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
57744958|NCT04219540|DRUG|XR-NTX|XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
57958435|NCT02825095|PROCEDURE|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
58448680|NCT03457376|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
57744959|NCT01428076|DRUG|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
57744960|NCT02036489|DRUG|Vincristine|
57744961|NCT02036489|DRUG|Daunorubicin|
57744962|NCT02036489|DRUG|Prednisone|
57744963|NCT02036489|DRUG|L-asparaginase|
57744964|NCT02036489|DRUG|Ciclophosphamide|
57744965|NCT02036489|DRUG|Metotrexate|
57744966|NCT02036489|DRUG|ARA-C|
57744967|NCT02036489|DRUG|Hidrocortisone|
57744968|NCT02036489|DRUG|Mercaptopurine|
57744969|NCT02036489|DRUG|VP-16|
57744970|NCT02036489|DRUG|Dexametasone|
57744971|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
57744972|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
57744973|NCT02559336|OTHER|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
57958436|NCT05166304|DRUG|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
57958437|NCT05166304|DRUG|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
57958438|NCT04018911|DEVICE|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
58118730|NCT01411267|DRUG|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
58448681|NCT03457376|DIAGNOSTIC_TEST|Maximal Expiratory Pressure|Maximal Expiratory Pressure
58448682|NCT05413161|BIOLOGICAL|ADL-018|150 mg/mL, Solution for injection in PFS
57744974|NCT02753790|RADIATION|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume \[PTV\] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
57744975|NCT06732479|BEHAVIORAL|Behavioural Skill Training Programme|"BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently"
57744976|NCT05776173|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
57744977|NCT05130970|DRUG|Garadacimab|Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
57744978|NCT05130970|DRUG|Placebo|Participants received a matching placebo IV loading dose, followed by 3 SC doses.
57744979|NCT04496219|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy
57744980|NCT04496219|BIOLOGICAL|BCG Solution|Given by intravesical injection
57744981|NCT04496219|OTHER|Best Practice|Receive standard of care symptom management
57744982|NCT04496219|OTHER|Quality-of-Life Assessment|Ancillary studies
57744983|NCT04496219|OTHER|Questionnaire Administration|Ancillary studies
57744984|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels + fibroblasts|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours.
57744985|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest.
57744986|NCT06733610|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.
57744987|NCT06229002|PROCEDURE|Transcranial alternative current stimulation (tACS) at alpha frequency|Single session of tACS
57744988|NCT06229002|PROCEDURE|Sham stimulation|Single session of tACS sham stimulation
57744989|NCT06368765|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
57744990|NCT06368765|OTHER|Water|Participants will be administered water during one of the study visits
57744991|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
57744992|NCT05905926|DRUG|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
57744993|NCT04253522|BEHAVIORAL|Cognitive training|Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
57744994|NCT03842995|BEHAVIORAL|Genetic Counselor|Standard of Care
57744995|NCT03842995|BEHAVIORAL|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
57744996|NCT05140928|OTHER|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
57744997|NCT05140928|OTHER|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
57744998|NCT06732336|DIAGNOSTIC_TEST|89Zr-trastuzumab|Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.
57744999|NCT05612880|DRUG|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
57745000|NCT06025474|DRUG|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
57745001|NCT06025474|DRUG|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
57745002|NCT06025474|DRUG|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
57745003|NCT06025474|DRUG|Citalopram 20mg|Encapsulated citalopram tablets, once daily
57745004|NCT06025474|DRUG|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
57745005|NCT06025474|DRUG|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
57745006|NCT06025474|DRUG|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
57958439|NCT04018911|DEVICE|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
57745007|NCT06406309|BEHAVIORAL|Power Down manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for children with ADHD). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep during the 2-week intervention phase. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
57745008|NCT02159742|OTHER|Data Collection|
57745009|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
57745010|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
57745011|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
57745012|NCT06684119|DEVICE|Electrical Impedance Tomography positive end-expiratory pressure titration|A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
57745013|NCT05451251|DEVICE|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine lesion
57745014|NCT06395272|DEVICE|SURA|The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.
57745015|NCT05240716|OTHER|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
57745016|NCT03952858|OTHER|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
57745017|NCT03548740|BIOLOGICAL|Human Papillomavirus|women with high-risk Human Papillomavirus or not
57745018|NCT05111561|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
57745019|NCT05111561|DRUG|Binimetinib|Given PO
57745020|NCT05111561|PROCEDURE|Biopsy|Undergo biopsy
57745021|NCT05111561|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57745022|NCT05111561|PROCEDURE|Computed Tomography|Undergo CT
57745023|NCT05111561|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57745024|NCT06171542|DEVICE|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
57745025|NCT04073238|DEVICE|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
57745026|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
57745027|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
57745028|NCT04665635|PROCEDURE|Rectosigmoid resection|Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
57745029|NCT06723366|DRUG|Angong Niuhuang Pill (ANP)|Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
57745030|NCT06723366|OTHER|Control (Standard treatment)|Blank control
57745031|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
57745032|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
57958440|NCT04018911|DEVICE|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
58448683|NCT05413161|BIOLOGICAL|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
58448684|NCT05413161|BIOLOGICAL|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
57745033|NCT05368779|BEHAVIORAL|The internet-based psychosocial intervention|Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
57745034|NCT05807139|OTHER|Placebo|Placebo
57745035|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
57745036|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
57745037|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
57745038|NCT04447170|PROCEDURE|Simple repair or Graham technique|Simple suture with or without omental protective patch
57745039|NCT00109291|DRUG|Placebo|
57745040|NCT00109291|DRUG|peginesatide|
57745041|NCT06723015|DRUG|18F-AV-1451|"Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment.."
57745042|NCT06732063|DEVICE|endodontic retreatment|Re-treatment of previously failed root canal treatments
57745043|NCT01105611|DRUG|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
57745044|NCT01105611|DRUG|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
57745045|NCT02644187|DEVICE|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
57745046|NCT02644187|DEVICE|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
58118731|NCT01411267|DRUG|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age"
58118732|NCT01411267|DRUG|Etoposide|150 mg/m2/day IV on days 1 through 5.
58118733|NCT01411267|DRUG|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
58448685|NCT00571974|DEVICE|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
58448686|NCT00571974|DRUG|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
57745047|NCT02644187|DRUG|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
57745048|NCT00493922|PROCEDURE|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
57745049|NCT00493922|PROCEDURE|Microscopy|Microscopy for diagnosis of malaria
57745050|NCT00493922|PROCEDURE|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
57745051|NCT00059358|DRUG|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
57745052|NCT00059358|DRUG|Ribavirin|Oral tablet taken daily
57745053|NCT00059358|DRUG|Peginterferon alfa-2b|Subcutaneous injection
57745054|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
58118734|NCT01797471|RADIATION|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
58118735|NCT01664689|PROCEDURE|Microcoaxial Phacoemulsification|
58118736|NCT03414866|BEHAVIORAL|EQ-5D-5L QOL questionnaire|Written questionnaire
58118737|NCT03854084|OTHER|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
58118738|NCT03854084|OTHER|Control group|Simulation of the techniques was used in the interventional group
58448687|NCT00571974|PROCEDURE|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
58448688|NCT00952029|BIOLOGICAL|bevacizumab|
58448689|NCT00952029|DRUG|FOLFIRI regimen|
58448690|NCT00952029|DRUG|fluorouracil|
58448691|NCT00952029|DRUG|irinotecan hydrochloride|
58448692|NCT00952029|DRUG|leucovorin calcium|
58448693|NCT00673335|DRUG|letrozole|
58448694|NCT00673335|DRUG|Placebo|
58448695|NCT03730532|OTHER|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
57745055|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
57745056|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
57745057|NCT01239030|DRUG|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
57745058|NCT01239030|DRUG|Placebo|Placebo capsules
57745059|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
57745060|NCT05936567|DRUG|Povorcitinib|oral; tablet
57958441|NCT04018911|DRUG|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
58118739|NCT03577236|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
58118740|NCT06318650|BIOLOGICAL|Demineralized Dentin Matrix|"preparation of Allogenic Demineralized Dentin Matrix: Extracted teeth will be collected from the Departments of oral maxillofacial surgery and periodontics, Cairo university. Cleaning the teeth from any caries, Filings, cement, tartar, soft tissue debris and prosthetic components will be performed using a diamond bur under abundant irrigation with physiological water. Then it will be proceeded to the following steps~1. (Washing with Distilled water ) 2. (Quick Freezing with liquid nitrogen, then Grinding to particle size of 300- 800 μm). 3.(Ultrasonic Cleaning cycles, 1st with Distilled water , 2nd with 5-7% Hydrogen Perioxide then 3rd with Distilled water for at 60-80 o) 4. (Defatting with Chloroform Methanol Solution1:0.5. 5. (Demineralization with0.5N HCL) 6. (Dehydration with Neutral Ethyl Alcohol then Defatting with Chloroform Methanol Solution 1:0.5 for ) 7. (Washing with Normal Saline \& Freeze Drying then Sterilization using Ethylene oxide gas)."
58118741|NCT06318650|BIOLOGICAL|Demineralized freeze-dried bone allograft (DFDBA)|combination allograft, is a particulate bone graft combining 70% mineralized ground cortical with 30% demineralized ground cortical Particle sizing: 250 - 1000um.
58118742|NCT04299854|DRUG|Dinoprostone 10mg|Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
58118743|NCT04299854|DEVICE|single balloon Foley catheter|A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
58448696|NCT03730532|OTHER|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
58448697|NCT01586949|BEHAVIORAL|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
58448698|NCT03351647|BIOLOGICAL|Evaluation of biological predictive factors of clinical response to ustekinumab|The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
58448699|NCT01699230|DIETARY_SUPPLEMENT|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
58448700|NCT04824469|OTHER|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
57745061|NCT05936567|DRUG|Placebo|oral; tablet
58448701|NCT06006195|OTHER|patients with dysphagia symptoms|patients with dysphagia symptoms examined by high resolution impedance manometry
58448702|NCT06006195|OTHER|patients without dysphagia symptoms|patients without dysphagia symptoms examined by high resolution impedance manometry
58448703|NCT01278563|BEHAVIORAL|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
57745062|NCT05530551|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
57958442|NCT01569685|DRUG|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
57958443|NCT01569685|DRUG|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
57958444|NCT04113772|DRUG|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
57958445|NCT04113772|DRUG|Orfadin|Orfadin
57958446|NCT01562548|DRUG|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
57958447|NCT01562548|DRUG|Placebo|no active ingredient
57958448|NCT04758585|PROCEDURE|Arthroscopy|Shoulder Arthroscopy
57958449|NCT00176111|PROCEDURE|peripheral nerve stimulation (procedure)|
57958450|NCT01926483|OTHER|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
57958451|NCT02469090|DRUG|APL-130277|"Use to treat up to 5 OFF episodes per day"
57958452|NCT02469090|DRUG|Placebo|placebo
57958453|NCT01168661|BEHAVIORAL|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) \>= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
58448704|NCT06375213|DIAGNOSTIC_TEST|Plasma tau phosphorylated at Thr217|Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.
57745063|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
57745064|NCT03464812|BEHAVIORAL|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
58313593|NCT01134666|DRUG|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
58448705|NCT06375213|OTHER|Neurocognitive examination|Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.
58448706|NCT03025646|OTHER|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~1. Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~   Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~2. Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
58448707|NCT05957965|DEVICE|Wii fit|Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
58448708|NCT05957965|OTHER|Strengthening, proprioceptive exercises.|"-Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board"
58448709|NCT03214575|DEVICE|Conventional method|
58448710|NCT03214575|PROCEDURE|GPS Method|
58448711|NCT05622565|DIAGNOSTIC_TEST|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
58448712|NCT01912196|DRUG|MSI-195|
58448713|NCT01912196|DRUG|Placebo|
58448714|NCT02373488|OTHER|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
58448715|NCT02373488|OTHER|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
58448716|NCT02373488|OTHER|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
58448717|NCT06390683|OTHER|Rewilding|Yards of the assisted living centers will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
58448718|NCT04051853|DRUG|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
58448719|NCT04051853|OTHER|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
57745065|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
57745066|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
57745067|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
57745068|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
57745069|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
57745070|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
57745071|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
57745072|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
57745073|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
57745074|NCT03939377|OTHER|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
57745075|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
57745076|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
57745077|NCT02063828|DEVICE|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
57745078|NCT02063828|DEVICE|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
57745079|NCT02063828|DEVICE|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
57745080|NCT05596448|PROCEDURE|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
57745081|NCT00001926|DRUG|O15|
58448720|NCT04051853|OTHER|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
57745082|NCT00001926|DEVICE|Cadwell rTMS|
57745083|NCT05554354|DRUG|Binimetinib|Given PO
58448721|NCT00239928|DRUG|pegaptanib sodium|1 drop per dosed eye per protocol.
58448722|NCT03810196|DEVICE|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
57745084|NCT05554354|PROCEDURE|Biopsy|Undergo tumor biopsy
57745085|NCT05554354|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57745086|NCT05554354|PROCEDURE|Bone Scan|Undergo bone scan
57745087|NCT05554354|PROCEDURE|Computed Tomography|Undergo CT scan
57745088|NCT05554354|PROCEDURE|Echocardiography|Undergo ECHO
57958454|NCT01168661|BEHAVIORAL|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
57745089|NCT05554354|DRUG|Fulvestrant|Given IM
57745090|NCT05554354|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57745091|NCT05554354|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57745092|NCT01421433|DRUG|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
57958455|NCT01168661|BEHAVIORAL|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
57958456|NCT00920660|DRUG|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
58448723|NCT01402817|DRUG|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
58448724|NCT00748670|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
57745093|NCT01421433|DRUG|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
57745094|NCT04466748|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
57745095|NCT04466748|DRUG|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
57745096|NCT02668081|PROCEDURE|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
57745097|NCT02668081|PROCEDURE|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
57745098|NCT05390970|PROCEDURE|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
57745099|NCT06733116|OTHER|Delphi method survey|This intervention involves a Delphi method study, where a panel of experts in isokinetic testing will collaborate to reach a consensus on best practices for standardizing the reporting of isokinetic test data. Unlike other clinical studies, this intervention focuses on gathering expert opinions iteratively to establish a unified framework for data reporting, without direct clinical or experimental treatment. The process includes multiple rounds of feedback, refining key elements related to testing protocols, measurement parameters, and result presentation, ensuring broad expertise from various fields such as medicine, rehabilitation, and biomechanics.
57745100|NCT05060016|DRUG|Tarlatamab|Intravenous (IV) infusion
58448725|NCT03004911|DEVICE|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
58118744|NCT06546644|BEHAVIORAL|Structured school-based intervention|A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
58118745|NCT06467422|DEVICE|tTIS on dACC, theta frequency (5 Hz)|"Device: Transcranial electric stimulation device~The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.006 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 6 Hz can be generated in the target area. The experimental group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model."
58118746|NCT06467422|DEVICE|tTIS on dACC, High frequency|The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The sham group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.
58118747|NCT00108420|DRUG|Prazosin|
58118748|NCT03082391|DEVICE|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
58118749|NCT03082391|DEVICE|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
58118750|NCT02691897|DRUG|Melatonin|Melatonin 3mg once daily at bedtime
58118751|NCT02691897|DRUG|Placebo|Placebo 1 tablet once daily at bedtime
58118752|NCT02755480|DEVICE|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
58118753|NCT03378622|OTHER|Anchor|Anchor technique for mesh attachment
58118754|NCT03378622|OTHER|Suture|Suture technique for mesh attachment
58118755|NCT02784925|DEVICE|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
58118756|NCT01147120|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
58118757|NCT01147120|PROCEDURE|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
58118758|NCT04487210|BIOLOGICAL|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
58118759|NCT02729688|DEVICE|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
58118760|NCT02729688|DEVICE|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
58118761|NCT04777630|DIAGNOSTIC_TEST|None, neuroimaging|Observation only to observe differences in neuroimaging
58448726|NCT03004911|DEVICE|Paper booklet|A 64-page booklet with content similar to the mobile application
58448727|NCT03133247|DRUG|SHR-1316|PD-L1
58448728|NCT02445872|DRUG|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
58448729|NCT02445872|DRUG|Palonosetron|
57745101|NCT05471960|OTHER|Natural progression over time|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
57745102|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
57745103|NCT05697848|OTHER|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
57745104|NCT05697848|OTHER|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
57745105|NCT04967417|DRUG|Pemetrexed, Carboplatin, Pembrolizumab|"* Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg"
57745106|NCT04967417|DRUG|Paclitaxel, Carboplatin, Pembrolizumab|"* Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg"
57745107|NCT03351972|DRUG|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
57745108|NCT03351972|OTHER|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
57745109|NCT00201084|BEHAVIORAL|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
57745110|NCT03528070|DRUG|Tranilast|Subjects will be treated with tranilast
58118762|NCT00331630|DRUG|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
58118763|NCT00331630|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
58118764|NCT00471835|PROCEDURE|computed tomography|
58118765|NCT00471835|PROCEDURE|positron emission tomography|
58118766|NCT00471835|RADIATION|stereotactic body radiation therapy|
58118767|NCT00007878|DRUG|bortezomib|Given IV
58118768|NCT00007878|DRUG|fluorouracil|Given IV
58118769|NCT00007878|DRUG|leucovorin calcium|Given IV
58118770|NCT00007878|OTHER|pharmacological study|Correlative studies
58118771|NCT00007878|OTHER|laboratory biomarker analysis|Correlative studies
58118772|NCT00050921|DRUG|somatropin|
58118773|NCT00050921|BIOLOGICAL|Hepatitis A virus, inactivated|
58118774|NCT00050921|DRUG|Keyhole-Limpet Hemocyanin|
58118775|NCT06052371|DEVICE|VerioVue (Enhancements) blood glucose monitoring system|VerioVue meter with expanded haematocrit range
58118776|NCT02133339|DRUG|TRN-157|
58118777|NCT02133339|DRUG|Placebo|
58118778|NCT00608205|DRUG|cisplatin|Given IV
58118779|NCT00608205|DRUG|fluorouracil|Given IV
58118780|NCT00608205|RADIATION|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
58118781|NCT02721797|PROCEDURE|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
58118782|NCT02232074|OTHER|Patient navigation enhanced with legal support|
58118783|NCT00376571|PROCEDURE|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
57958457|NCT00920660|DRUG|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
58118784|NCT02337933|DRUG|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
58118785|NCT02337933|DRUG|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
58118786|NCT04177069|DIETARY_SUPPLEMENT|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
58448730|NCT02445872|DRUG|Dexamethasone|
58448731|NCT00419731|DRUG|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
58448732|NCT00419731|DRUG|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
57745111|NCT04283448|BEHAVIORAL|Dietary Lentil|Participants in the Lentil arm of the study will consume midday meals containing 0.66 cups of lentils seven days per week for 12 weeks.
57745112|NCT04283448|BEHAVIORAL|Control|Participants in the Control arm of the study will consume midday meals containing 0.00 cups of lentils seven days per week for 12 weeks.
58118787|NCT03077997|BEHAVIORAL|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, \& diabetes distress in people with type 2 diabetes mellitus.
58118788|NCT06451809|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
58118789|NCT04740021|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
58118790|NCT04740021|DRUG|Carboplatin|AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
58118791|NCT04740021|DRUG|Etoposide|100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
58118792|NCT05583383|DRUG|camrelizumab|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
58118793|NCT05571709|OTHER|Exercise training|Resistance training of the lower limbs
58118794|NCT05571709|BEHAVIORAL|Questionnaire|Physical activity questionnaire
58118795|NCT05571709|PROCEDURE|Percutaneous muscle biopsy|Muscle biopsy of the vastus lateralis (m. quadriceps)
58118796|NCT05571709|PROCEDURE|Blood sample|Venous blood sample
58118797|NCT02419482|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
58118798|NCT02419482|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
58118799|NCT04104958|GENETIC|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
58118800|NCT04570566|PROCEDURE|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
58118801|NCT01123785|DRUG|INO-8875|eye drops for 14 days in one eye
58118802|NCT01123785|DRUG|Placebo|Matched vehicle-control
58118803|NCT00532519|DRUG|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
58118804|NCT04602104|BIOLOGICAL|low dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58118805|NCT04602104|BIOLOGICAL|medium dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58118806|NCT04602104|BIOLOGICAL|high dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58118807|NCT04602104|BIOLOGICAL|Dosage 1of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58118808|NCT04602104|BIOLOGICAL|Dosage 2 of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58448733|NCT03401775|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
57745113|NCT01229540|GENETIC|genetic analyzer|
57745114|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
57958458|NCT00920660|DRUG|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
57958459|NCT00920660|DRUG|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
58118809|NCT04602104|BIOLOGICAL|No hMSC-derived exosomes|basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
58118810|NCT04381585|DEVICE|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
57745115|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
57745116|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
57745117|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
57745118|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
57745119|NCT00643916|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
57745120|NCT06733532|DIETARY_SUPPLEMENT|Berry Propel Fitness Water|Subject will consume 1 Liter of commercially available Berry Propel Fitness Water at a rate of 250 milliliters per 7.5 minutes
57958460|NCT00920660|DRUG|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
57958461|NCT00920660|DRUG|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
57745121|NCT06733532|DIETARY_SUPPLEMENT|Essentia Hydroboost Raspberry Pomegranate|Subject will consume 1 Liter of commercially available Essentia Hydroboost Raspberry Pomegranate at a rate of 250 milliliters per 7.5 minutes
57958462|NCT03496090|OTHER|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
57958463|NCT03496090|OTHER|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
57958464|NCT00004262|PROCEDURE|conventional surgery|
57958465|NCT00004262|RADIATION|3-dimensional conformal radiation therapy|
57958466|NCT00004262|RADIATION|stereotactic radiosurgery|
57745122|NCT06733532|DIETARY_SUPPLEMENT|Smart Water|Subject will consume 1 Liter of commercially available Smart Water at a rate of 250 milliliters per 7.5 minutes.
57745123|NCT02395042|DRUG|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
57958467|NCT00004262|DRUG|motexafin gadolinium|Given IV
57958468|NCT00004262|PROCEDURE|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
57958469|NCT00004262|PROCEDURE|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
57958470|NCT02684214|BEHAVIORAL|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
57958471|NCT02684214|BEHAVIORAL|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
58118811|NCT04675983|DRUG|Sintilimab|Administered IV
58118812|NCT04675983|DRUG|Ramucirumab|Administered IV
58118813|NCT04675983|DRUG|Cisplatin|Administered IV
58118814|NCT04675983|DRUG|5-fluorouracil|Administered IV
58118815|NCT04675983|DRUG|Oxaliplatin|Administered IV
58118816|NCT04675983|DRUG|Capecitabine|Administered orally
58118817|NCT05521763|BEHAVIORAL|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
58118818|NCT02682290|OTHER|Expectoration and measurement of sputum rheological properties|
57745124|NCT02395042|DRUG|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
58118819|NCT01987622|PROCEDURE|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
58118820|NCT01987622|PROCEDURE|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
58118821|NCT02353065|PROCEDURE|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
58118822|NCT02353065|RADIATION|Bedside x-ray|Portable x-ray of fracture post-reduction
58118823|NCT01674478|DIETARY_SUPPLEMENT|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
58118824|NCT01674478|DIETARY_SUPPLEMENT|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
58313594|NCT01114555|DRUG|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
58313595|NCT00120939|DRUG|Motexafin Gadolinium|
57958472|NCT04433650|DEVICE|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
57958473|NCT00317798|BIOLOGICAL|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
57958474|NCT00317798|DRUG|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
57958475|NCT03534427|OTHER|Jump rope exercise intervention|12-week jump rope exercise program
57958476|NCT03725748|OTHER|irrigation|irrigation the edges of the cs scar before closure
57958477|NCT00643643|DRUG|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
57958478|NCT00643643|DRUG|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
57958479|NCT00643643|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
57958480|NCT00643643|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
57958481|NCT00643643|OTHER|Placebo|Matching placebo oral tablet twice daily for 10 days
57958482|NCT06092073|PROCEDURE|recto-intercostal fascial plane block|Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.
57958483|NCT06092073|DRUG|bupivacaine|bupivacaine 0.25%
57958484|NCT06084377|GENETIC|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
57958485|NCT00326898|OTHER|Laboratory Biomarker Analysis|Correlative studies
57958486|NCT00326898|OTHER|Placebo|Given PO
57958487|NCT00326898|OTHER|Quality-of-Life Assessment|Ancillary studies
57958488|NCT00326898|DRUG|Sorafenib Tosylate|Given PO
57958489|NCT00326898|DRUG|Sunitinib Malate|Given PO
57958490|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
58118825|NCT05720871|DEVICE|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
58118826|NCT05720871|DEVICE|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
58118827|NCT00268502|OTHER|study of socioeconomic and demographic variables|
58118828|NCT00268502|PROCEDURE|fatigue assessment and management|
58118829|NCT00268502|PROCEDURE|management of therapy complications|
58118830|NCT00268502|PROCEDURE|psychosocial assessment and care|
58118831|NCT00268502|PROCEDURE|quality-of-life assessment|
58118832|NCT05912686|DRUG|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
58118833|NCT05912686|DRUG|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
58118834|NCT01833949|PROCEDURE|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
58118835|NCT01833949|PROCEDURE|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
58118836|NCT06210412|BEHAVIORAL|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
58118837|NCT02337179|PROCEDURE|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
58118838|NCT03291509|BEHAVIORAL|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
58118839|NCT03291509|BEHAVIORAL|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
58118840|NCT03291509|BEHAVIORAL|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
58118841|NCT03291509|BEHAVIORAL|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
58118842|NCT03540810|DRUG|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
58118843|NCT03540810|DRUG|Placebo|The patients will receive placebo with their usual treatment
58118844|NCT03709082|DRUG|Palbociclib 75mg|Oral Administration
58118845|NCT03709082|DRUG|Letrozole 2.5mg|Oral Adminstration
58118846|NCT03709082|DRUG|T-DM1|Intravenous Administration
58118847|NCT03709082|DRUG|Palbociclib 100mg|Oral Administration
58118848|NCT03709082|DRUG|Palbociclib 125mg|Oral Administration
57769688|NCT05183217|BEHAVIORAL|Online Continence promotion program with tailoring|"The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention."
58118849|NCT03709082|DRUG|Palbociclib|Oral Administration
58118850|NCT01766778|DRUG|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
58118851|NCT01766778|DRUG|Metformin|Metformin maximum tolerance dose
58118852|NCT06303583|DRUG|paclitaxel|paclitaxel, 50 mg/m2, QW\*5
58118853|NCT06303583|DRUG|carboplatin|area under the curve of2mg/mL/min, QW\*5
57958491|NCT00737867|DRUG|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
57958492|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
58118854|NCT06303583|DRUG|tislelizumab|200mg Q3W, 2cycles
58118855|NCT06303583|RADIATION|radiotherapy|41.4Gy in 23 fractions
58118856|NCT01136226|DRUG|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
58448734|NCT01806142|OTHER|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
58448735|NCT01806142|OTHER|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
58118857|NCT04857307|DRUG|Alprazolam|"* Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points."
58448736|NCT05236608|DRUG|Nivolumab|Administered together with ADG106 via intravenous infusion.
58448737|NCT05236608|DRUG|ADG106|Administered as an intravenous infusion over 90 minutes.
58448738|NCT02893241|DRUG|Cafedrine/theodrenaline|
57745125|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
57745126|NCT04528069|DEVICE|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
57958493|NCT00737867|DRUG|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
57958494|NCT00264875|DRUG|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
57958495|NCT05692037|COMBINATION_PRODUCT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
57958496|NCT02321254|DEVICE|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
57745127|NCT04528069|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
57958497|NCT02321254|BEHAVIORAL|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
57958498|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 500mg|Mitopure containing softgels
57958499|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 1000mg|Mitopure containing softgels
57958500|NCT03464500|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
57958501|NCT03161756|DRUG|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
57958502|NCT03161756|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
57958503|NCT03161756|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
58448739|NCT02893241|DRUG|Ephedrine|
57958504|NCT05373147|BIOLOGICAL|αPD1-MSLN-CAR T cells|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
57958505|NCT00649532|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fasting
57958506|NCT00649532|DRUG|Zofran® Tablets 24 mg|24mg, single dose fasting
57958507|NCT04280900|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
57958508|NCT04280900|BEHAVIORAL|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
57958509|NCT00419328|DRUG|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level"
58118858|NCT02487784|PROCEDURE|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
58448740|NCT00597688|DRUG|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
58448741|NCT00597688|DRUG|Placebo gel|Oral mucosal application of placebo gel
58448742|NCT04477161|DIETARY_SUPPLEMENT|Ketone Ester Elite endurance Nutrition Drink|Subjects will take one bottle four times daily for four weeks
58448743|NCT04477161|OTHER|Stool Sample|Subjects will provide a stool sample at 2 timepoints.
58448744|NCT00638495|DRUG|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
58448745|NCT00638495|DRUG|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
58448746|NCT04886908|OTHER|Data extraction from medical files|Data extraction from medical files
58448747|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
58118859|NCT02487784|PROCEDURE|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
58118860|NCT01812421|OTHER|Hypertension Health Education Protocol (HHEP)|
58118861|NCT04459663|DRUG|Toripalimab injection combine with Axitinib|The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
58118862|NCT02866175|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
58118863|NCT02866175|DRUG|Clopidogrel|Clopidogrel 75 mg once-daily
57958510|NCT00516347|GENETIC|comparative genomic hybridization|
57958511|NCT00516347|GENETIC|genetic linkage analysis|
58448748|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
58448749|NCT04004910|DRUG|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
57745128|NCT03034642|PROCEDURE|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
57745129|NCT00293683|DEVICE|Insorb absorbable skin staple|
57958512|NCT00516347|OTHER|laboratory biomarker analysis|
58118864|NCT02866175|DRUG|Prasugrel|prasugrel 5mg or 10 mg once-daily
58118865|NCT02866175|DRUG|Ticagrelor|ticagrelor 90 mg twice-daily
58448750|NCT05545072|DRUG|Dupilumab|Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
58448751|NCT05545072|DRUG|Placebo|A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
58448752|NCT05545072|DRUG|Intranasal Corticosteroid Sprays (INCS)|All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will be continued throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
58118866|NCT02866175|DRUG|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
58118867|NCT02116283|BEHAVIORAL|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
58448753|NCT00641004|DRUG|Rebamipide and Esomeprazole|"1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
58118868|NCT02116283|OTHER|Smartphone|Participants will use an Android-based smartphone as their own for one month
58118869|NCT05218863|OTHER|No intervention|No intervention
58118870|NCT00097071|DRUG|insulin lispro|
58118871|NCT00097071|DRUG|insulin aspart|
58448754|NCT01304602|DRUG|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
57745130|NCT02799966|DEVICE|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
57745131|NCT01025440|DEVICE|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
57745132|NCT00160680|DRUG|Levocetirizine|"* Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use"
57745133|NCT04701684|DEVICE|Direct to Angio Suite (DTAS) Philips' CBCT triage|Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
57958513|NCT00516347|OTHER|questionnaire administration|
58448755|NCT01304602|DRUG|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
57745134|NCT04701684|PROCEDURE|Conventional CT/MR triage|First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
57745135|NCT00480103|DEVICE|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
57745136|NCT03280121|DEVICE|EsophyX ZR transoral device|TIF
57745137|NCT00526643|DRUG|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
57745138|NCT00526643|DRUG|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
57958514|NCT00516347|PROCEDURE|study of high risk factors|
57958515|NCT00193765|PROCEDURE|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
57958516|NCT00193765|PROCEDURE|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
57958517|NCT00902785|OTHER|no drug|observational no drug
58118872|NCT03908021|DIAGNOSTIC_TEST|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
58118873|NCT05613699|BEHAVIORAL|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
58118874|NCT05613699|BEHAVIORAL|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
58118875|NCT05613699|BEHAVIORAL|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
58118876|NCT00000992|DRUG|Itraconazole|
58118877|NCT00174642|DRUG|Insulin Glargine|One daily injection in the evening. 100 U/ml
58118878|NCT00174642|DRUG|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
58118879|NCT00174642|DRUG|Metformin|At same dosages as the previous treatment
58118880|NCT00174642|DRUG|insulin secretagogue|sulfonylurea or glinide
58118881|NCT00240006|PROCEDURE|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
58118882|NCT06544434|DEVICE|Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)|MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
58118883|NCT06544434|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
58118884|NCT05026983|DRUG|Binimetinib|Given PO
58118885|NCT05026983|DRUG|Encorafenib|Given PO
58448756|NCT01669486|OTHER|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
58448757|NCT03018613|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
57745139|NCT04009369|OTHER|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
57745140|NCT01958632|PROCEDURE|Nerve reconstruction|
57745141|NCT05591027|DRUG|Centella asiatica product|A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
57745142|NCT05591027|DRUG|Placebo|A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
57958518|NCT04760665|BIOLOGICAL|Fecal microbiota transplantation|Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
57958519|NCT04760665|OTHER|Placebo|Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
58118886|NCT05026983|OTHER|Questionnaire Administration|Ancillary studies
58118887|NCT05026515|BEHAVIORAL|Parents|To observe the influence of the parents/caregivers behavior on their child during dental treatment
58118888|NCT05067049|DEVICE|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
58118889|NCT05067049|DEVICE|Unconnected arm|Follow-up visits with the pysicians as usual
58118890|NCT00325403|DRUG|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
58118891|NCT00325403|OTHER|Placebo|Placebo oral tablet twice daily
58118892|NCT00005782|DRUG|Granulocyte colony-stimulating factor|
58118893|NCT00005782|PROCEDURE|Leukapheresis|
58118894|NCT01685970|DRUG|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
57958520|NCT05740228|DEVICE|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
58118895|NCT01685970|DRUG|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
58118896|NCT05248932|DRUG|Norepinephrine bolus|5 microgram bolus therapy
58118897|NCT05248932|DEVICE|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
58118898|NCT05248932|DRUG|Norepinephrine infusion|2.5 microgram/min infusion
58118899|NCT04170699|PROCEDURE|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
58448758|NCT03018613|OTHER|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
57745143|NCT06144866|DRUG|Dabigatran, rivaroxaban, apixaban, edoxaban|For patients who received direct oral anticoagulants (DOAC) before ischemic stroke or intracranial hemorrhage, the DOAC level upon hospital arrival will be measured.
57745144|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Sustain|Sustain improvements during QI collaborative focused on PCC
57745145|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Spread|Implement change package developed during QI Collaborative
58118900|NCT03105609|DEVICE|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
58448759|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
58448760|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
58448761|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
58118901|NCT05399810|OTHER|Computer Application (ICOGNI) Training|Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
58118902|NCT00440596|BEHAVIORAL|Mindfulness based stress reduction|8 weeks group MBSR
58118903|NCT00440596|BEHAVIORAL|Progressive Muscle Relaxation|8 weeks PMR in group format
58118904|NCT04899739|DIAGNOSTIC_TEST|Echoendoscopy|Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
58448762|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
58448763|NCT05038150|DRUG|SGN1|The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
58448764|NCT03633110|BIOLOGICAL|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
58448765|NCT03633110|DRUG|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
58448766|NCT03633110|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
58448767|NCT04924517|BEHAVIORAL|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
58458589|NCT05249023|OTHER|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
57958521|NCT05740228|DEVICE|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
57958522|NCT05740228|DEVICE|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
57958523|NCT05581914|OTHER|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
57958524|NCT05581914|OTHER|Care as Usual|The care as usual the adolescents receives
57958525|NCT03602872|BIOLOGICAL|Human allogeneic mesenchymal bone marrow derived stem cells|Intraarticular administration of 20x10\^6 MSCs
57958526|NCT00194545|BEHAVIORAL|Medication diaries|Caregivers expected to complete medication diaries daily
57958527|NCT03604965|DRUG|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
58118905|NCT05652621|DIETARY_SUPPLEMENT|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
58118906|NCT01957657|DRUG|BI 207127|oral administration
58118907|NCT01957657|DRUG|faldaprevir|oral administration
58118908|NCT01957657|DRUG|BI 207127|oral administration
58118909|NCT01957657|DRUG|BI 207127|oral administration
58118910|NCT01957657|DRUG|BI 207127|oral administration
58118911|NCT01957657|DRUG|faldaprevir|oral administration
58118912|NCT01957657|DRUG|faldaprevir|oral administration
58118913|NCT01957657|DRUG|faldaprevir|oral administration
58118914|NCT02235233|DRUG|Technetium Tc 99M Mebrofenin|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
58118915|NCT04122274|BEHAVIORAL|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
58118916|NCT04122274|BEHAVIORAL|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
58118917|NCT04122274|BEHAVIORAL|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
58118918|NCT03558100|BEHAVIORAL|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
57745146|NCT05253248|DIETARY_SUPPLEMENT|OMIS|This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
57745147|NCT03765866|PROCEDURE|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
57745148|NCT04199949|BEHAVIORAL|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
57745149|NCT02355002|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
57745150|NCT03602170|BEHAVIORAL|High-Intensity Interval Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.
57745151|NCT03602170|BEHAVIORAL|Moderate-Intensity Continuous Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
57745152|NCT01543061|DEVICE|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
57958528|NCT03604965|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
57958529|NCT04064775|BEHAVIORAL|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
57958530|NCT06445868|OTHER|Sedentary behaviour intervention|COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
57958531|NCT02741102|PROCEDURE|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
57958532|NCT04190225|BEHAVIORAL|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
57958533|NCT03343132|BEHAVIORAL|Standard locomotor therapy|Typical clinical therapy.
57958534|NCT01716910|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus NCFM and cellobiose|
57958535|NCT01801956|BEHAVIORAL|physical activity|free membership of a sport club
57958536|NCT01801956|OTHER|Motivational interview|Four motivational interviews by instructors of the local sport club
57958537|NCT01801956|OTHER|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
57958538|NCT01297270|DRUG|BI201335|QD BI 201335
57958539|NCT01297270|DRUG|PegIFN/RBV|
57958540|NCT01297270|DRUG|BI201335|QD (once daily) BI 201335
57958541|NCT01297270|DRUG|Placebo|
57958542|NCT06339528|PROCEDURE|Vojta's Reflex Locomotion|"Reflex locomotion according to Vojta's therapy is a neurorehabilitative concept originally used for diagnostics and treatment of infants who were at risk of non-physiological psychomotor development, especially spastic cerebral palsy. This concept utilizes stimulation of specific zones described by Vojta to evoke global motor and non-motor response.~Trigger zones are specific body zones that are stimulated with pressure during reflex locomotion stimulation. They are pressure stimulated in order to induce reflex response. Variations of stimulation of different trigger zones (spatial summation) causes multiplication of afferent impulses. Sufficiently long stimulation of trigger zones (temporal summation) induces isometric contraction in muscle groups described by Vojta."
57958543|NCT06339528|PROCEDURE|Sham stimulation|Control group received sham stimulation by physicians at zones outside of the pressure zones, specifically 4-5 cm above the patella and on the lateral malleolus.
57958544|NCT00679705|DRUG|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
57958545|NCT00679705|DRUG|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
57745153|NCT01543061|PROCEDURE|No treatment|One month of contact lens wear with no eye drop use
57745154|NCT01543061|DEVICE|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
57745155|NCT06089356|DRUG|zolmitriptanee|zolmitriptane tablet daily
57958546|NCT00679705|DRUG|Placebo|Glucose 5%, IV
57958547|NCT03524261|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
57958548|NCT03524261|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
57958549|NCT02841215|DRUG|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
57958550|NCT02841215|DRUG|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
57958551|NCT01312935|DRUG|PMX-60056|investigational drug
58118919|NCT01081184|BIOLOGICAL|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
58118920|NCT00929357|DRUG|DMARDs or Biologics|
58458590|NCT04189367|DRUG|Traditional Chinese Medicine|"One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks."
58118921|NCT02512913|BEHAVIORAL|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
57745156|NCT06089356|DRUG|topiramate|topiramate once daily
57745157|NCT06089356|DRUG|Valproate|valproate once daily
58118922|NCT02576990|BIOLOGICAL|Pembrolizumab|IV infusion
58118923|NCT05291143|BEHAVIORAL|Short videos on blood pressure monitoring|Short videos on blood pressure monitoring
58118924|NCT05112900|BEHAVIORAL|Text Messaging (TM)|\[see arm/group descriptions\]
58118925|NCT05112900|BEHAVIORAL|Text Messaging + Health Navigation (TM+HN)|\[see arm/group descriptions\]
58118926|NCT01811277|DRUG|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
58118927|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
58118928|NCT01309009|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
58118929|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
58313596|NCT00834184|DRUG|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
58448768|NCT04924517|BEHAVIORAL|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
58448769|NCT06726382|DRUG|Esketamine Nasal Spray|1 x 28 mg dose
58448770|NCT06726382|DRUG|Esketamine 28 mg|1 x 5,6 ml p.o.
57745158|NCT02825082|PROCEDURE|Abdominal emergency surgery|all abdominal emergency surgery procedures
57745159|NCT03871179|DIAGNOSTIC_TEST|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
57745160|NCT05633875|OTHER|MRI|Patients will undergo MRI without contrast agent
58313597|NCT02875457|DRUG|apatinib;etoposide and cisplatin|
58313598|NCT02875457|DRUG|placebo;etoposide and cisplatin|
58313599|NCT00656617|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)
58313600|NCT00656617|DRUG|Cytarabine|1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
58313601|NCT00656617|DRUG|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
58313602|NCT04377867|DRUG|Abatacept Injection [Orencia]|Patients on abatacept to control disease symptoms
58313603|NCT04909723|COMBINATION_PRODUCT|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
58313604|NCT04909723|BIOLOGICAL|NB1000S|A recombinant live biotherapeutic product.
58313605|NCT04909723|DRUG|NB2000P|A botanically derived polysaccharide.
58313606|NCT04909723|DRUG|Placebo|Placebo
58448771|NCT06726382|DRUG|Cobicistat 150 MG|1 x 150 mg tablet
58448772|NCT03976388|DEVICE|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
58448773|NCT03976388|OTHER|Small-Group Discussion|Small group discussion led by a physician.
57745161|NCT01847703|PROCEDURE|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
57745162|NCT01847703|PROCEDURE|Abdominal surgery|Current gold standard
57745163|NCT02002026|PROCEDURE|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
57745164|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
57745165|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
57745166|NCT02215122|DRUG|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
57745167|NCT02215122|DRUG|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
57745168|NCT02215122|DRUG|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
57745169|NCT04909242|DRUG|DZD9008|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
57745170|NCT04909242|DRUG|Placebo|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
57745171|NCT04909242|DRUG|DZD9008|In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
57745172|NCT04909242|DRUG|DZD9008|Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
57745173|NCT03575273|BEHAVIORAL|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
57745174|NCT03575273|BEHAVIORAL|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
58313607|NCT00658528|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
58448774|NCT04254224|PROCEDURE|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
58448775|NCT06725823|PROCEDURE|suprascapular nerve block group|A volume of (10 ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.
57745175|NCT03575273|BEHAVIORAL|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
57745176|NCT03575273|BEHAVIORAL|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
57745177|NCT03575273|PROCEDURE|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
57745178|NCT03575273|DIETARY_SUPPLEMENT|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
57745179|NCT05125770|BIOLOGICAL|New crown vaccine|New Coronavirus vaccine
57745180|NCT01519531|DRUG|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
57745181|NCT01519531|DRUG|VIA-3196|Oral, daily dosing for 14 days
57745182|NCT04133155|DRUG|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
57745183|NCT05977231|PROCEDURE|BT|A program of BT (including exercise and muscle training)
57745184|NCT05977231|PROCEDURE|bPFMT|A bPFMT program at home
57745185|NCT05977231|PROCEDURE|iVES|An iVES program at home
57745186|NCT05977231|PROCEDURE|BT + bPFMT|Combination of BT and bPFMT
57745187|NCT05977231|PROCEDURE|BT + iVES|Combination of BT and iVES
57745188|NCT05977231|PROCEDURE|bPFMT + iVES|Combination of bPFMT and iVES
57958552|NCT03524339|DRUG|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
57958553|NCT03524339|DRUG|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
58313608|NCT00658528|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
58313609|NCT05883111|DIAGNOSTIC_TEST|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
58313610|NCT04502277|DRUG|Fluconazole Powder|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
58448776|NCT06725823|PROCEDURE|shoulder anterior capsular block group|A volume of (10ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.
58448777|NCT02266355|DRUG|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
58448778|NCT03061435|PROCEDURE|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
58448779|NCT03061435|PROCEDURE|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
58448780|NCT00411671|DRUG|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
58448781|NCT01855737|DRUG|Warfarin|Prescribe warfarin to the patients who are needed.
58448782|NCT04974801|DEVICE|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
58448783|NCT04974801|DEVICE|Usual Care|Continued Usual Care routines.
57745189|NCT00290641|BIOLOGICAL|filgrastim|
57745190|NCT00290641|BIOLOGICAL|graft-versus-tumor induction therapy|
57745191|NCT00290641|DRUG|cyclophosphamide|
57745192|NCT00290641|DRUG|cyclosporine|
57745193|NCT00290641|DRUG|fludarabine phosphate|
57745194|NCT00290641|DRUG|mycophenolate mofetil|
57745195|NCT00290641|PROCEDURE|umbilical cord blood transplantation|
57745196|NCT00290641|RADIATION|radiation therapy|
57745197|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
57745198|NCT06576362|PROCEDURE|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
57745199|NCT06733727|DRUG|Letrozole|Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage
57745200|NCT06733727|DRUG|Mifepristone|Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
57745201|NCT00483184|BIOLOGICAL|Veldona,|Very low dose oral natural human interferon alpha lozenges
57745202|NCT01532128|DRUG|rasagiline|1 mg rasagiline (single-dose)
58313611|NCT04023578|DEVICE|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
58313612|NCT05499286|OTHER|Mindfulness Program|Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
57745203|NCT01532128|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
57958554|NCT05872776|DEVICE|Neuromodulation with RR2 device|non-invasive neuromodulation with RR2 device
57958555|NCT05872776|DEVICE|Mock sham neuromodulation with sham RR2 device|Mock sham stimulation with RR2 device
57958556|NCT03824847|DRUG|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
57745204|NCT02801994|DEVICE|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
57745205|NCT02305927|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
57745206|NCT02305927|OTHER|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
57745207|NCT03963674|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
57745208|NCT05668533|DIAGNOSTIC_TEST|Interscalene versus PENG Block|"1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."
57745209|NCT01059175|DEVICE|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
57745210|NCT01059175|DEVICE|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
57745211|NCT00157781|DEVICE|Medtronic AT500|
57745212|NCT05964478|OTHER|Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine|Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
57745213|NCT01338025|DRUG|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
57745214|NCT01338025|DRUG|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
57745215|NCT00611000|DIETARY_SUPPLEMENT|folic acid|
57745216|NCT00611000|GENETIC|DNA methylation analysis|
57745217|NCT00611000|GENETIC|gene expression analysis|
57745218|NCT00611000|GENETIC|microarray analysis|
57745219|NCT00611000|GENETIC|polymorphism analysis|
57745220|NCT00611000|OTHER|laboratory biomarker analysis|
57745221|NCT04740489|BEHAVIORAL|Phase 3 Cardiac rehabilitation|Phase 3 CR is a comprehensive outpatient programme, considered the core rehabilitation phase, in which participants receive structured exercise, health education, risk factor modification and psychological support. Upon discharge from clinically supervised phase 3 CR participants are generally signposted to long-term community-based exercise classes (phase 4). The current study will take place within a core phase 3 CR programme in the UK.
57745222|NCT03549650|DRUG|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
57745223|NCT03549650|DRUG|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
57745224|NCT04760093|DIETARY_SUPPLEMENT|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
57745225|NCT04760093|DIETARY_SUPPLEMENT|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
57745226|NCT05741216|OTHER|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
57745227|NCT05741216|OTHER|Ocular Lubricant|Commercially available ocular lubricant
57745228|NCT05697094|BEHAVIORAL|Meditation to Remove Stress and Create A Proper System in Mind|Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.
57745229|NCT06648772|DRUG|Roflumilast Cream 0.3%|Roflumilast Cream 0.3%
57745230|NCT06648772|DRUG|Vehicle cream|Vehicle cream
57745231|NCT02795273|DRUG|Grass-SPIRE|
57745232|NCT02795273|DRUG|Placebo|
57745233|NCT06164470|BEHAVIORAL|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
57745234|NCT01469533|OTHER|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
58448784|NCT05685342|DRUG|Acetaminophen/Ibuprofen fixed-dose combination|Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
57958557|NCT03824847|DRUG|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
58118930|NCT05830448|BEHAVIORAL|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
58448785|NCT00977171|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
58448786|NCT03766659|DIAGNOSTIC_TEST|MOSE|EUS-FNB with MOSE
58448787|NCT03766659|DIAGNOSTIC_TEST|ROSE|EUS-FNA with ROSE
57745235|NCT01469533|OTHER|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
57745236|NCT00004827|DRUG|docosahexaenoic acid|
57745237|NCT03059108|PROCEDURE|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
57745238|NCT03059108|PROCEDURE|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
57745239|NCT06579508|OTHER|Cycle ergometer|"The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh."
57745240|NCT02425982|PROCEDURE|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
57745241|NCT02425982|PROCEDURE|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
57745242|NCT02672787|BEHAVIORAL|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
57745243|NCT02672787|BEHAVIORAL|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
57745244|NCT02021838|OTHER|Lethality Assessment Program|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services.
57745245|NCT02021838|OTHER|Domestic Violence High Risk Team|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services and a team who monitors the clinical and criminal justice progress.
57745246|NCT01274195|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
58118931|NCT05830448|BEHAVIORAL|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
58448788|NCT02023957|BEHAVIORAL|Interactive computer-assisted screening (iCAS)|
58448789|NCT06467903|DEVICE|SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .|second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
58448790|NCT00004893|BIOLOGICAL|recombinant interleukin-12|
58448791|NCT04415814|PROCEDURE|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
57745247|NCT01355393|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
57745248|NCT01355393|BIOLOGICAL|sargramostim|Given ID
57745249|NCT01355393|DRUG|rintatolimod|Given ID
57745250|NCT04732806|BEHAVIORAL|Mightier video games|Biofeedback video game play in home
57745251|NCT06440148|BIOLOGICAL|SCLEROSTIN|Pathogenesis of mastocytosis bone disease
58448792|NCT04415814|PROCEDURE|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
57745252|NCT02621099|DEVICE|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
57745253|NCT04557072|DRUG|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
57745254|NCT04557072|DRUG|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
58448793|NCT02818972|DEVICE|RelayPro|Endovascular treatment with investigational device.
58448794|NCT06149455|OTHER|Duration of antibiotics|Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
58448795|NCT02362724|DEVICE|Sapphire|silicone hydrogel contact lens
58448796|NCT02362724|DEVICE|Pearl|silicone hydrogel contact lens
57745255|NCT06217367|DRUG|50 mg Diphenhydramine|Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
57745256|NCT06217367|DRUG|10 mg Loratadine|Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
58118932|NCT03689296|OTHER|Questionnaires (Phase 3)|"* CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale"
58448797|NCT03721341|RADIATION|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
58448798|NCT03721341|DRUG|Chemotherapy|Chemotherapy may be given as indicated.
57745257|NCT06217367|DRUG|5 mg Desloratadine|Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
57745258|NCT06217367|OTHER|Placebo (Sugar Pill)|Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
58448799|NCT03721341|DRUG|Immunotherapy|Immunotherapy may be given as indicated.
58448800|NCT03721341|DRUG|Hormones|Hormones may be given as indicated.
58448801|NCT03721341|OTHER|Observation|Observation only is acceptable if this is the standard practice.
58448802|NCT03721341|RADIATION|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
58448803|NCT01965704|DRUG|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
58448804|NCT01965704|DRUG|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
58448805|NCT04005599|DRUG|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
58448806|NCT04005599|DRUG|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
58448807|NCT05676307|BEHAVIORAL|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
58448808|NCT02686385|DRUG|Prednisolone|
58448809|NCT02686385|DRUG|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
58448810|NCT01380795|BIOLOGICAL|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
58448811|NCT06429449|DRUG|Venetoclax|Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
58448812|NCT06429449|DRUG|Azacitidine|An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
57745259|NCT01918735|DRUG|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
57745260|NCT01918735|DRUG|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
57745261|NCT05630183|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
58118933|NCT03689296|OTHER|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
58118934|NCT03689296|OTHER|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
58118935|NCT03907280|DRUG|BI 1265162 (T1)|oral solution
58118936|NCT03907280|DRUG|BI 1265162 (T2)|Solution for inhalation
58448813|NCT06429449|DRUG|Mitoxantrone|Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
58448814|NCT05052190|BEHAVIORAL|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
58448815|NCT05052190|BEHAVIORAL|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
58448816|NCT05052190|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
58118937|NCT03907280|DRUG|BI 1265162 (R)|concentrate for i.v. solution
58118938|NCT03907280|DRUG|BI 1265162 (T3)|Solution for inhalation
58118939|NCT02752256|DRUG|Tissue Plasminogen Activator|
58118940|NCT06527963|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
58118941|NCT02260375|BIOLOGICAL|Mesenchymal Stromal Cells|
58448817|NCT05052190|BEHAVIORAL|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
58448818|NCT05052190|BEHAVIORAL|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
57745262|NCT05630183|DRUG|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
57745263|NCT05630183|DRUG|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
57745264|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
57745265|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
57745266|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
57745267|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
57958558|NCT01902550|DRUG|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
57745268|NCT00520780|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
57745269|NCT00520780|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
57745270|NCT03195192|OTHER|biomarker study|This is a biomarker study
57958559|NCT01902550|DRUG|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
57958560|NCT01902550|DRUG|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
57958561|NCT04847973|OTHER|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
57958562|NCT04847973|DIETARY_SUPPLEMENT|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
58448819|NCT05052190|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
58448820|NCT01582139|DEVICE|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
57958563|NCT05625828|BEHAVIORAL|Cognitive-motor Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of cognitive-motor exercises where participants have to perform two tasks consequently (for example, walking while answering math questions or throwing a ball while reverse walking) and 5 minutes of stretching exercises.
57958564|NCT05625828|BEHAVIORAL|Multifactorial Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of multifactorial exercises that consists of high speed walking, resistance training and balance training in single task condition and 5 minutes of stretching exercises.
58118942|NCT00947063|DRUG|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
58118943|NCT00947063|DRUG|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
57958565|NCT01914562|DRUG|OCA 10 mg|OCA 10 mg tablet oral
57958566|NCT01914562|DRUG|OCA 25 mg|OCA 25 mg tablet oral
58118944|NCT00721058|OTHER|CT-scan|A pre-operative CT-scan will be made
58118945|NCT02660190|DRUG|hexaminoavolunate|
58118946|NCT02660190|PROCEDURE|WL cystoscopy|
58118947|NCT06059170|BEHAVIORAL|LARS score/ EORTC QLQ C30|administering questionnaire
58118948|NCT06157307|DEVICE|Aortic compression|Aortic compression with four different methods on each participants
58118949|NCT01139255|BEHAVIORAL|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
58118950|NCT05170256|DRUG|Trastuzumab|Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
58118951|NCT01982487|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
58118952|NCT01982487|DRUG|IDO1 inhibitor INCB024360|Given PO
58118953|NCT01982487|OTHER|laboratory biomarker analysis|Correlative studies
58118954|NCT01982487|OTHER|pharmacological study|Correlative studies
58118955|NCT01784133|DRUG|omiganan|
58118956|NCT01784133|DRUG|placebo|
58118957|NCT01835145|DRUG|Cabozantinib S-malate|Given PO
58118958|NCT01835145|DRUG|Dacarbazine|Given IV
58118959|NCT01835145|OTHER|Laboratory Biomarker Analysis|Correlative studies
58118960|NCT01835145|DRUG|Temozolomide|Given PO
58118961|NCT03387033|DEVICE|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
58118962|NCT02887209|BEHAVIORAL|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
58118963|NCT03384745|DRUG|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
58118964|NCT03384745|DRUG|Placebo|Placebo contains no active drug.
57745271|NCT04319211|OTHER|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
57745272|NCT04840810|PROCEDURE|In-plane Axis|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
58118965|NCT03384745|DRUG|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
58118966|NCT02470039|DRUG|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
57745273|NCT04840810|PROCEDURE|Out of plane Axis|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
58118967|NCT02470039|DRUG|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
58118968|NCT02470039|DRUG|placebo|Administered once daily
58118969|NCT02581800|OTHER|App group|
58118970|NCT02123927|DRUG|TAK-438|TAK-438 tablets
58118971|NCT02123927|DRUG|Placebo|TAK-438 placebo-matching tablets
58118972|NCT02890823|DRUG|Cholecalciferol|
58118973|NCT00232115|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
58118974|NCT00232115|DRUG|Placebo|Vehicle cream (placebo)
58118975|NCT00221390|DRUG|Ropinirole (+ physical therapy)|
58118976|NCT00221390|DRUG|(vs.) Placebo + physical therapy|
58118977|NCT02732561|DEVICE|Alpha Stim device|cranial electrotherapy stimulation device
58118978|NCT02732561|DEVICE|Sham device|Sham device
58118979|NCT02167464|DRUG|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
58118980|NCT02167464|OTHER|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
58118981|NCT02167464|DRUG|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
58313613|NCT01812187|BEHAVIORAL|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
58118982|NCT05494684|OTHER|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
58118983|NCT01829477|DRUG|TAK-875|TAK-875 50 mg tablets
58118984|NCT01829477|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
58118985|NCT01829477|DRUG|Glimepiride|Glimepiride tablet.
58118986|NCT04253548|BEHAVIORAL|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
58118987|NCT02857881|PROCEDURE|De-epithelization and therapeutic photokeratectomy|
58118988|NCT05100758|DIETARY_SUPPLEMENT|Active Hexoses Correlated Compound|Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
58313614|NCT02258581|DRUG|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
58313615|NCT02258581|DRUG|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
58118989|NCT02688400|DRUG|Diacerein|
58118990|NCT02688400|DRUG|Celecoxib|
58118991|NCT02688400|DRUG|Placebo|
58118992|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fasted state.
58118993|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fed state.
58118994|NCT06302231|BEHAVIORAL|Dietary Approach|Intermittent fasting plus energy restriction without aerobic exercise training.
58118995|NCT06301802|PROCEDURE|CIC|clean intermittent catheterization
58118996|NCT06301802|DRUG|Anticholinergic|antimuscarinic once daily
58118997|NCT03765268|PROCEDURE|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
58118998|NCT03765268|PROCEDURE|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
58118999|NCT01487733|GENETIC|gene expression analysis|
58119000|NCT01487733|GENETIC|in situ hybridization|
58119001|NCT01487733|OTHER|immunohistochemistry staining method|
58119002|NCT01487733|OTHER|laboratory biomarker analysis|
58119003|NCT00143754|PROCEDURE|Hydration|
58119004|NCT03661437|DEVICE|Actigraph|Wear Actiwatch
58119005|NCT03661437|OTHER|Questionnaire Administration|Ancillary studies
58119006|NCT03661437|PROCEDURE|Systematic Light Exposure|Undergo BWL treatment
58119007|NCT03661437|PROCEDURE|Systematic Light Exposure|Receive DWL treatment
58119008|NCT05738109|OTHER|Self-Talk Journals|Participants randomized to the intervention group will receive a physical copy of the 91-day self-talk journal during the baseline meeting. Participants will also be introduced the purpose of the journal and its intended usage (i.e., daily journaling). Intervention participants will not be offered guidance or feedback on the journal after these initial instructions, in order to emulate an ad libitum usage. Control group participants will not receive any contact with the researchers outside of the planned questionnaires and to receive their journal at the three-month timepoint.
58448821|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
58448822|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
58448823|NCT01844453|PROCEDURE|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
57745274|NCT06382012|DRUG|Fosaprepitant 150 mg|Fosaprepitant 150mg IV administered over 15 minutes
57745275|NCT06382012|DRUG|Ondansetron 4 mg|Ondansetron 4mg IV administered over 15 minutes
57745276|NCT05072080|BIOLOGICAL|CHIKV VLP/adjuvant|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
57745277|NCT05072080|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
58119009|NCT05858385|OTHER|Intervention based on key factors identified by the severe RIOM prediction model|Intervention based on key factors identified by the severe RIOM prediction model
58119010|NCT06014684|BEHAVIORAL|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
58119011|NCT02454270|DRUG|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
58119012|NCT02454270|DRUG|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
58119013|NCT02051881|OTHER|Taking intestinal biopsies|
58119014|NCT05468164|DRUG|Selpercatinib|Administered orally
58119015|NCT05468164|DRUG|Omeprazole|Administered orally
58119016|NCT04928651|DRUG|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
58119017|NCT06430879|DEVICE|VICTORY PATCH|Drug- free, non-invasive patch (VICTORY Patch) with haptic vibrotactile trigger technology (VTT)
58119018|NCT06430879|DEVICE|Sham Patch without VTT|Sham Patch without haptic vibrotactile trigger technology (VTT)
58119019|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
58119020|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
58119021|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
58119022|NCT01022788|BEHAVIORAL|Home-based counselling|
58119023|NCT06214897|DIETARY_SUPPLEMENT|C-RUSF (Ready-to-use Supplemental Food with added Choline)|Ready-to-use Supplemental Food with added Choline
58119024|NCT06214897|DIETARY_SUPPLEMENT|S-RUSF (Ready-to-use Supplemental Food without added Choline)|Standard Ready-to-use Supplemental Food
57745278|NCT04279223|PROCEDURE|Laparoscopic cholecystectomy|Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
57745279|NCT01698684|DRUG|Placebo|One dose 15 minutes before attempting intercourse
57745280|NCT01698684|DRUG|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
57745281|NCT01698684|DRUG|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
57958567|NCT05170243|DRUG|9MW1911 Injection|Single dose intravenously on day 1
58313616|NCT02258581|DRUG|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
58313617|NCT05322785|OTHER|Breath collection|Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
58448824|NCT03229109|DEVICE|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
58448825|NCT04861935|DEVICE|ultrasound evaluation|ultrasound evaluation of normal patients and patients who have a sacral dimple
58448826|NCT03652935|BEHAVIORAL|Mindfulness Based Stress Reduction|
58448827|NCT03652935|OTHER|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
57745282|NCT00675389|BEHAVIORAL|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for \~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
57745283|NCT00675389|BEHAVIORAL|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
57745284|NCT04832828|DIAGNOSTIC_TEST|Roth´s Test|Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
57745285|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
57745286|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
57745287|NCT03215732|DIAGNOSTIC_TEST|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
58448828|NCT00127023|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
58448829|NCT02463279|DEVICE|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
58448830|NCT02340065|PROCEDURE|standard colonoscopy|examination of the colon with a conventional colonoscope
58448831|NCT02340065|PROCEDURE|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
58448832|NCT01435213|DRUG|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
58448833|NCT01435213|DRUG|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
58448834|NCT01435213|DRUG|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
58448835|NCT01435213|OTHER|Cold pressor test|30-45 min cold pressor test of the foot
57745288|NCT03527225|OTHER|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
57745289|NCT00413387|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
57745290|NCT00413387|DRUG|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
57745291|NCT04001673|BEHAVIORAL|Pharmacist's intervention|Information about bDMARDs management.
57745292|NCT00289354|DRUG|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
58313618|NCT04139135|DRUG|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
58313619|NCT04139135|DRUG|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
58448836|NCT01435213|DRUG|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
58448837|NCT01435213|DRUG|Placebo|A single dose of placebo (capsules) administered orally
58448838|NCT02397304|OTHER|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
58448839|NCT04712370|PROCEDURE|Conventional caudal block|Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
58448840|NCT04712370|PROCEDURE|Ultrasound-guided caudal block|Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
58448841|NCT04712370|PROCEDURE|Ultrasound guided erector spinae plane Block|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
58448842|NCT05362929|DEVICE|Sciton Halo|Laser treatment
58448843|NCT03997669|OTHER|Collection of pleural effusion|Detection of pleural effusion
58448844|NCT01370265|DRUG|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
58448845|NCT01370265|DRUG|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
58458591|NCT04189367|DRUG|Western medicine|"Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks"
58119025|NCT04020107|OTHER|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
57745293|NCT06578910|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
57745294|NCT06578910|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
57745295|NCT01509222|BEHAVIORAL|Personalized nutrition counseling|
57745296|NCT03872752|BEHAVIORAL|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
57745297|NCT00842140|DRUG|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
58119026|NCT02862639|DEVICE|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
58313620|NCT04213261|BIOLOGICAL|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
57745298|NCT00842140|DRUG|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
57745299|NCT00842140|DRUG|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
57745300|NCT06230289|PROCEDURE|Transabdominal plane block|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
57745301|NCT00189215|DEVICE|cardiac stabilizer instead of cardiopulmonary bypass|
57745302|NCT06191718|DEVICE|Mitral Valve Replacement|Foldax Mitral Valve Replacement
57745303|NCT02320565|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
57745304|NCT02320565|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
57745305|NCT01508429|OTHER|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
57745306|NCT01508429|DRUG|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
57745307|NCT06005805|DIETARY_SUPPLEMENT|Mastic gum|Mastic gum 3g/pack daily for 21 days
57958568|NCT05170243|DRUG|9MW1911 Injection Placebo|Single dose of matching placebo intravenously on day 1
57745308|NCT06005805|BEHAVIORAL|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
57745309|NCT02782169|DRUG|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
57958569|NCT02936141|BEHAVIORAL|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
57745310|NCT02782169|DRUG|Placebo|Matching placebo capsule with excipient to match Pregabalin
57745311|NCT02008890|BIOLOGICAL|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
57745312|NCT02008890|BIOLOGICAL|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
57745313|NCT02008890|BIOLOGICAL|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
57745314|NCT06367192|DEVICE|The adapted Kids in Transition to School Intervention|An intensive, school readiness intervention designed to improve preschoolers' early literacy, numeracy, and self-regulation skills at high risk for academic difficulties. The intervention is delivered virtually over 8 weeks with caregivers and intentionally occurs over the summer when there is a gap in preschool services.
57745315|NCT06367192|DEVICE|Standard school resources|Information about local preschool programs and age appropriate books for children will be provided.
57745316|NCT04443140|DIAGNOSTIC_TEST|PCR, lung ultrasound|PCR for Covid-19
57745317|NCT06647810|DRUG|BI 690517 formulation 1|BI 690517 formulation 1
57745318|NCT06647810|DRUG|BI 690517 formulation 2|BI 690517 formulation 2
57745319|NCT06647810|DRUG|Probenecid|Probenecid
57745320|NCT02181803|DRUG|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
57745321|NCT02181803|DRUG|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
57769689|NCT03361787|BEHAVIORAL|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
57958570|NCT03434405|BEHAVIORAL|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
57958571|NCT03434405|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
57958572|NCT03434405|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
57958573|NCT03878511|DIETARY_SUPPLEMENT|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
57958574|NCT03878511|DIETARY_SUPPLEMENT|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
58119027|NCT02862639|DEVICE|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
57745322|NCT02181803|DRUG|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
57745323|NCT06386757|PROCEDURE|Combined Video Laryngoscopy (VL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.
57745324|NCT06386757|PROCEDURE|Combined Direct Laryngoscopy (DL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation
57745325|NCT05410600|OTHER|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
57745326|NCT00649558|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
57745327|NCT00649558|DRUG|Actos® Tablets 45 mg|45mg, single dose fasting
57745328|NCT03083587|BEHAVIORAL|Normal lifestyle|Normal lifestyle
57745329|NCT03083587|BEHAVIORAL|Exercise|Mild exercise 3 min every half hour
57745330|NCT03083587|PROCEDURE|muscle and fat biopsy|Biopsy under local anesthesia
57745331|NCT03083587|DEVICE|Continuous glucose monitoring|Glucose concentrations during the study period
57745332|NCT03083587|DEVICE|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
58448846|NCT01370265|DRUG|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
58448847|NCT02392806|DEVICE|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
58448848|NCT02392806|DEVICE|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B\&B Bubbler at time of extubation
58458592|NCT03153774|DIAGNOSTIC_TEST|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
57745333|NCT05578963|OTHER|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
57745334|NCT04823377|OTHER|Usual care|Patients receiving systemic anticancer treatment in their last days of life
57745335|NCT04823377|OTHER|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
57745336|NCT03709355|DRUG|Elpida®|Elpida® capsules, 20mg
57745337|NCT03709355|DRUG|Rifampin|Rifampin capsules, 150mg
57745338|NCT03709355|DRUG|Rifabutin|Rifabutin capsules, 150mg
57745339|NCT03709355|DRUG|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
57745340|NCT03709355|DRUG|Omeprazole|Omeprazole Film-coated tablets 20mg
57745341|NCT03709355|DRUG|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
57745342|NCT03709355|DRUG|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
57745343|NCT02616874|DRUG|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
57745344|NCT02616874|DRUG|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
57745345|NCT01372306|DRUG|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
57745346|NCT05460416|DRUG|Acetylsalicylic acid|160mg once a day
57745347|NCT06580795|BEHAVIORAL|Student citizens' assembly|The intervention consists in participating in a deliberative mini-public, a student citizens' assembly whose mission is to to co-create a list of concrete proposals that would improve the access of USPN students to sustainable diets and physical activity
58119028|NCT01787474|DRUG|Cytarabine|Given IV
57745348|NCT03626155|BEHAVIORAL|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
57745349|NCT03626155|BEHAVIORAL|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
57745350|NCT02217930|DRUG|WCK 2349|
57745351|NCT02217930|DRUG|Placebo|
57745352|NCT02217930|DRUG|Moxifloxacin|
57745353|NCT04915573|DIAGNOSTIC_TEST|Specimen|Sputum will be collected in clean disposable containers
57745354|NCT06488378|DRUG|Axatilimab|Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
57745355|NCT06488378|DRUG|Olaparib|Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
57745356|NCT05368662|OTHER|Quality of life and sleep questionnaire|Evaluation of quality of life and quality of sleep by questionnaires
57745357|NCT01146509|DRUG|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
57745358|NCT05970627|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
57745359|NCT05970627|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
57745360|NCT05970627|DRUG|S1|S-1 orally intake as perioperative chemotherapy
58119029|NCT01787474|BIOLOGICAL|Filgrastim|Given SC
58119030|NCT01787474|BIOLOGICAL|Filgrastim-sndz|Given SC
58119031|NCT01787474|DRUG|Fludarabine Phosphate|Given IV
58119032|NCT01787474|OTHER|Laboratory Biomarker Analysis|Correlative studies
57745361|NCT04855422|DIAGNOSTIC_TEST|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
57745362|NCT04855422|DIAGNOSTIC_TEST|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
57745363|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
57745364|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
58448849|NCT06302946|OTHER|neuromuscular stimulation ,mindfulness breathing and traditional physiotherapy program|receive neuromuscular stimulation ,mindfulness breathing and traditional physiotherapy program. The experimental group participants will receive functional electrical stimulation ((Ev-906,4CH Digital TENS/EMS, Taiwan)) that will last 8 consecutive weeks, three sessions per week (24 sessions in total) protocol with Mindful breathing is a mindfulness exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention
57745365|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
57745366|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
57745367|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
57745368|NCT02782338|DRUG|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
57958575|NCT06276803|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.
57958576|NCT06081556|DIAGNOSTIC_TEST|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
57958577|NCT04000685|OTHER|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
58448850|NCT06302946|OTHER|traditional physiotherapy program|participants in the control group perceived the traditional physiotherapy program
57745369|NCT01180855|DRUG|Placebo|Placebo pill nightly for 42 nights.
58119033|NCT01787474|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
58119034|NCT02795104|BEHAVIORAL|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
57958578|NCT04000685|OTHER|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
58119035|NCT02795104|BEHAVIORAL|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
57745370|NCT01180855|DRUG|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
57745371|NCT01180855|OTHER|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
57745372|NCT03683797|OTHER|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
57745373|NCT06122714|DRUG|AZD4144 Part A|Part A: Participants will be administered a single oral dose on Day 1.
57745374|NCT06122714|DRUG|AZD4144 Part B|Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
57745375|NCT06122714|DRUG|Placebo Part A|Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
57745376|NCT06122714|DRUG|Placebo Part B|Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
57745377|NCT00877825|PROCEDURE|dairy food control diet and high- and low- isoflavone soyfood diets|
57745378|NCT01368965|DEVICE|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
57745379|NCT04932122|PROCEDURE|Dorsal wrist ganglion alone (DWG)|Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
57745380|NCT04932122|PROCEDURE|DWG/PIN|Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
57958579|NCT04000685|OTHER|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
57958580|NCT05825508|DEVICE|ankle robot|home ankle robot and video game
58119036|NCT02795104|BEHAVIORAL|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
58119037|NCT02916979|DRUG|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
58119038|NCT02916979|DRUG|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
58313621|NCT05414604|DIAGNOSTIC_TEST|3D spine CT|CT scan of the spine
58313622|NCT05902624|DRUG|Hepatitis B Virus Vaccine(HBV)|Hepatitis B Virus Vaccine(HBV)
57745381|NCT03280173|DRUG|tafamidis|bioavailability study
57745382|NCT00507000|DRUG|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
58119039|NCT02916979|BIOLOGICAL|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
58119040|NCT02916979|DRUG|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
58119041|NCT01506323|BEHAVIORAL|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
58119042|NCT01506323|BEHAVIORAL|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
58119043|NCT01628120|BIOLOGICAL|Epoetin Hospira|Subcutaneous(SC) injection
58119044|NCT00176904|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
58119045|NCT00176904|DRUG|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
58119046|NCT05403411|OTHER|Distance education for nursing students on critical thinking|The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
58119047|NCT05582733|OTHER|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
58119048|NCT05582733|OTHER|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
58448851|NCT03612336|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
57745383|NCT00507000|DRUG|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
57745384|NCT02728557|BEHAVIORAL|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
57745385|NCT02728557|BEHAVIORAL|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
57745386|NCT06732076|BEHAVIORAL|web based education|web based education
57745387|NCT04437940|DIAGNOSTIC_TEST|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
57745388|NCT01866228|OTHER|Consultation Recording|
57745389|NCT01803308|DRUG|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
57745390|NCT01803308|DRUG|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
57745391|NCT01803308|DRUG|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
57745392|NCT03846648|DRUG|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
57745393|NCT01833338|DEVICE|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
57745394|NCT04598867|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
57745395|NCT04598867|DRUG|Placebo|Placebo capsules
57745396|NCT04598867|DRUG|Afobazol|Afobazol 10 mg tabletes
57745397|NCT05309278|BEHAVIORAL|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
57745398|NCT05309278|BEHAVIORAL|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
57745399|NCT02131779|BEHAVIORAL|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
58119049|NCT05598437|DEVICE|Dry eye device|Dry eye analysis
58119050|NCT06271811|PROCEDURE|Flossing band|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
58119051|NCT06271811|OTHER|Conventional physiotherapy|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
58119052|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
57745400|NCT02131779|BEHAVIORAL|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
57745401|NCT02747238|DEVICE|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
57745402|NCT02747238|PROCEDURE|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
57745403|NCT02747238|PROCEDURE|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
57745404|NCT01297231|OTHER|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
57745405|NCT04048824|BEHAVIORAL|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
57745406|NCT04048824|BEHAVIORAL|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
57745407|NCT05387941|DRUG|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
57745408|NCT00326131|DRUG|Oral Taxane|
58119053|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
57745409|NCT02106299|DEVICE|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
57745410|NCT02106299|DEVICE|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
57745411|NCT04262544|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
57745412|NCT04262544|OTHER|Usual Care|Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
57745413|NCT03148223|DEVICE|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
57745414|NCT06580483|OTHER|amalgam restoration|An abutment tooth is restored on a side by amalgam plug
57745415|NCT06580483|OTHER|nano-composite|An abutment tooth is restored on a side by nano-composite
57745416|NCT06360939|RADIATION|SBRT|Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
57745417|NCT06360939|PROCEDURE|CA|CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
57745418|NCT05768698|DIAGNOSTIC_TEST|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
57745419|NCT00476216|DRUG|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
58313623|NCT01443884|DIETARY_SUPPLEMENT|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
58313624|NCT01443884|DIETARY_SUPPLEMENT|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
58313625|NCT06232876|DEVICE|Blinded continuous vital sign monitoring|Continuous blinded vital sign monitoring.
58448852|NCT03612336|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58448853|NCT04924595|BEHAVIORAL|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
58448854|NCT04708093|DEVICE|whole body vibration training|Oscillating platform
57769690|NCT01230606|OTHER|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
57769691|NCT00294216|DRUG|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
58313626|NCT06232876|DEVICE|Unblinded continuous vital sign monitoring|Continuous unblinded vital sign monitoring.
58313627|NCT06112145|OTHER|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
58313628|NCT06091514|DEVICE|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
58313629|NCT06091514|OTHER|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
58313630|NCT00410358|DRUG|Gimatecan|
58313631|NCT02746861|BEHAVIORAL|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
58313632|NCT04925401|BEHAVIORAL|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
57745420|NCT00609687|PROCEDURE|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
58448855|NCT05397769|DRUG|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
58448856|NCT06726486|DIETARY_SUPPLEMENT|Atémpero|A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.
57745421|NCT01368367|OTHER|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
57958581|NCT03096509|OTHER|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
57958582|NCT02936700|BEHAVIORAL|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
57958583|NCT02936700|BEHAVIORAL|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions"
57958584|NCT04880200|DIAGNOSTIC_TEST|POC NAT & Adherence Intervention|The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
57958585|NCT04247425|OTHER|Exercise Counseling|Receive instructional guidance
58448857|NCT06726486|DIETARY_SUPPLEMENT|Control (Standard treatment)|A complete high-protein and high-calorie diet with mixed fibre was administered.
58448858|NCT05514054|DRUG|Imlunestrant|Administered orally.
58448859|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
58448860|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
58448861|NCT05514054|DRUG|Letrozole|Administered per local approved label.
58448862|NCT05514054|DRUG|Exemestane|Administered per local approved label.
58448863|NCT01426958|DRUG|afatinib|standard therapeutic dose
58448864|NCT01426958|DRUG|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
58448865|NCT01426958|DRUG|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
58448866|NCT03596203|DEVICE|TransCutaneous Magnetic Stimulator (TCMS)|TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
58448867|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
58448868|NCT03136016|BEHAVIORAL|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
58448869|NCT03136016|BEHAVIORAL|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
58448870|NCT03136016|BEHAVIORAL|nudging + educational activities|Group 4 will receive both interventions
57958586|NCT04247425|OTHER|Quality-of-Life Assessment|Ancillary studies
57958587|NCT04247425|OTHER|Questionnaire Administration|Ancillary studies
58448871|NCT01559675|DRUG|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
58448872|NCT01559675|DRUG|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
58448873|NCT00051376|DRUG|L-Arginine|
58448874|NCT00402467|DRUG|Rivaroxaban (BAY59-7939)|2.5mg bid
58448875|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|5mg bid
58448876|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|10 mg bid
58448877|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|20mg bid
58448878|NCT00402467|DRUG|Enoxaparine|30mg bid
58448879|NCT00402467|DRUG|Enoxaparine|30mg bid
58448880|NCT02068326|BEHAVIORAL|Mentalization Based Treatment|
57745422|NCT01015157|PROCEDURE|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
57745423|NCT04161508|DRUG|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
58119054|NCT03858881|BEHAVIORAL|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
58119055|NCT03858881|BEHAVIORAL|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
58119056|NCT03858881|BEHAVIORAL|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
58119057|NCT00589095|OTHER|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
58448881|NCT02068326|BEHAVIORAL|Treatment As Usual|Treatment As Usual
58448882|NCT02915042|DRUG|Dexmedetomidine|Analgesic Efficacy
58448883|NCT02915042|DRUG|Placebo|Saline placebo
58448884|NCT04440826|OTHER|Whole Food Meal|Whole foods meal
58448885|NCT04440826|OTHER|Processed Food Meal|Processed food meal
58448886|NCT04440826|OTHER|Gluten-free and lactose-free|Gluten-free and lactose-free food meal
58448887|NCT06495021|PROCEDURE|Lymphatic Pump Osteopathic Manipulative Therapy|OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
58448888|NCT01943812|DRUG|Estradiol and progeterone|Estradiol and progesterone
57745424|NCT04161508|DRUG|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
57745425|NCT03466294|DRUG|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
58448889|NCT01968330|BEHAVIORAL|Go!®to sleep|
58448890|NCT04248127|OTHER|Honey sweetened yogurt|2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
58448891|NCT04248127|OTHER|Sugar sweetened yogurt|sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
58448892|NCT00056979|DRUG|CAMPATH-1H|
58448893|NCT00056979|DRUG|Anti-CD45|
57745426|NCT00676767|DIETARY_SUPPLEMENT|Resistant Starch Type 4|
57745427|NCT00676767|DIETARY_SUPPLEMENT|Dextrose|
57745428|NCT00676767|DIETARY_SUPPLEMENT|Puffed wheat|
57745429|NCT00584727|DEVICE|senofilcon A toric contact lens|contact lens
57745430|NCT00584727|DEVICE|alphafilcon A toric|contact lens
57745431|NCT00584727|DEVICE|etafilcon A sphere|contact lens
58448894|NCT00056979|DRUG|FK506|
58448895|NCT00056979|DRUG|Fludarabine|
58448896|NCT00776971|OTHER|Sugar-sweetened soft drink|500mL as a preload drink
58448897|NCT00776971|OTHER|Aspartame-sweetened soft drink|500mL as a preload drink
58448898|NCT00776971|OTHER|Semi-skimmed milk|500mL as a preload drink
58448899|NCT00776971|OTHER|Water|500mL as a preload drink
58448900|NCT00014079|GENETIC|DNA stability analysis|
58448901|NCT00014079|GENETIC|loss of heterozygosity analysis|
58448902|NCT00014079|GENETIC|microsatellite instability analysis|
58448903|NCT04720521|DIAGNOSTIC_TEST|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
58448904|NCT02432586|BEHAVIORAL|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
58448905|NCT06409910|RADIATION|Radiotherapy|Non-institutional-standard radiotherapy
58448906|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
57745432|NCT02607995|BEHAVIORAL|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
57745433|NCT02753049|BEHAVIORAL|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
57745434|NCT01436825|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
58448907|NCT05939999|OTHER|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
58448908|NCT05939999|OTHER|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
58448909|NCT04633382|COMBINATION_PRODUCT|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
58448910|NCT04053166|DEVICE|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
58448911|NCT04053166|OTHER|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
58448912|NCT04053166|BIOLOGICAL|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
58448913|NCT04053166|OTHER|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
58448914|NCT04053166|OTHER|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
58448915|NCT01854970|DRUG|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
58448916|NCT00930085|OTHER|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
58448917|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
58448918|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
58448919|NCT06415461|BIOLOGICAL|PremierMaxCB®-Platinum (CFL001);|Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
58448920|NCT06363734|DRUG|Osimertinib plus Dalpiciclib|osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
58448921|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1%|
58448922|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
58448923|NCT00016679|DRUG|1-Octanol|
58448924|NCT05161923|PROCEDURE|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
58448925|NCT03842033|BEHAVIORAL|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
58448926|NCT03842033|BEHAVIORAL|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
58448927|NCT03842033|BEHAVIORAL|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
57745435|NCT01426165|DRUG|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
57745436|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
57745437|NCT04917523|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cell), Inactivated|0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
58448928|NCT05072938|DRUG|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
58448929|NCT05072938|DRUG|Axid Capsule 150mg|Nizatidine Monotherapy
58448930|NCT02875379|PROCEDURE|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
58448931|NCT03342417|BIOLOGICAL|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
57745438|NCT03311412|DRUG|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
57958588|NCT04247425|OTHER|Resistance Training|Complete progressive resistance training
57958589|NCT01899235|DEVICE|drug eluting balloon|
57958590|NCT01899235|DEVICE|drug eluting stent|
58448932|NCT03342417|BIOLOGICAL|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
58448933|NCT00852865|DRUG|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4\*109 CFU
58448934|NCT00852865|DRUG|Placebo|1 capsule per day
58448935|NCT03292068|COMBINATION_PRODUCT|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
57745439|NCT03311412|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
57745440|NCT03311412|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
57745441|NCT00107003|DRUG|lapatinib ditosylate|
57745442|NCT00107003|PROCEDURE|Adjuvant therapy|
57745443|NCT00107003|PROCEDURE|Conventional surgery|
58448936|NCT03292068|DIETARY_SUPPLEMENT|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
58448937|NCT03292068|OTHER|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
57745444|NCT00107003|PROCEDURE|Neoadjuvant therapy|
57745445|NCT04808804|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
57745446|NCT04474002|DRUG|4L Klean Prep®|Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
57745447|NCT04474002|DRUG|1L Klean prep® and 2 sachets Picoprep®|Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
57745448|NCT00220298|DRUG|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
57745449|NCT06490107|DRUG|Durvalumab combined with S-1|"The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles"
57745450|NCT02291679|DRUG|Linaclotide|
57745451|NCT02291679|DRUG|Matching Placebo|
57745452|NCT00447980|DRUG|NT-501|High Dose
58448938|NCT05099796|PROCEDURE|Transforaminal epidural steroid injection|
58448939|NCT05099796|PROCEDURE|Caudal epidural steroid injection|
57745453|NCT00447980|DRUG|NT-501|Low Dose
57745454|NCT00950066|DRUG|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
57958591|NCT02811692|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
57745455|NCT00950066|DRUG|Amlodipine|Oral administration of Amlodipine 5mg once a day
57745456|NCT00950066|DRUG|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
57745457|NCT00950066|DRUG|Placebo|Oral administration of a placebo once a day
57745458|NCT04616261|BEHAVIORAL|Training|6 weeks of training
57745459|NCT04616261|DRUG|Formoterol|inhalation of 54 microg formoterol
57745460|NCT04616261|DRUG|Placebo|inhalation of placebo
57745461|NCT01441102|DRUG|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
57745462|NCT00591474|DIETARY_SUPPLEMENT|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
57745463|NCT00591474|DIETARY_SUPPLEMENT|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
57745464|NCT05186870|OTHER|Outcome measures|Observational study
57745465|NCT01602887|DRUG|PD-0332991|isethionate hard capsule, 125 mg, single dose
57745466|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
57745467|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
57745468|NCT01602887|DRUG|PD-0332991|oral solution, 50 mg, single dose
57745469|NCT04244890|DEVICE|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
57745470|NCT01398280|DRUG|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
57745471|NCT01398280|DRUG|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
57745472|NCT05840432|DEVICE|Postoperative hypotension prediction index|Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
57745473|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
57958592|NCT02322060|PROCEDURE|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
57958593|NCT02322060|PROCEDURE|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
57958594|NCT02322060|PROCEDURE|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
57958595|NCT02322060|PROCEDURE|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
57958596|NCT00179582|DRUG|VSL#3|
57958597|NCT05138835|DRUG|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
57958598|NCT05691855|DRUG|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
57745474|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
57745475|NCT01315093|DRUG|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
57745476|NCT01315093|DRUG|no heparin|
57745477|NCT00733538|DRUG|zometa|patients receiving treatment during their follow-up
58448940|NCT04174690|DEVICE|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
58448941|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
58448942|NCT06727461|OTHER|Home-based Feeding EnhancEment in Dementia (Feed@home)|"The FEED@home program is an 8-week initiative led by a speech therapist (ST) and nurse team through teleconsultations and home visits:~* Within 3 days after discharge, a nurse teleconsultation with the family caregiver to assess the patient's mealtime behaviors and provide feeding strategy recommendations and educational materials.~* Two to three home visits by STs during mealtime (depending on the mastery of feeding techniques) to assess swallowing and cognitive feeding issues, providing tailored interventions and proper training of feeding techniques.~* Two teleconsultations by nurses to assess the caregiver's techniques and provide additional training.~* One additional home visit during mealtime by a nurse to assess the caregiver's mastery of the feeding techniques through observation.~* The program lasts 8 weeks, regardless of readmissions, unless the patient converts to tube feeding, moves to a care home, passes away, or withdraws from study."
58448943|NCT01764711|DRUG|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
58448944|NCT03871062|PROCEDURE|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
58448945|NCT03871062|PROCEDURE|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
58448946|NCT03811444|DEVICE|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
58448947|NCT03811444|DEVICE|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
58448948|NCT03811444|DEVICE|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
58448949|NCT05503186|OTHER|Text Message|The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.
58448950|NCT05503186|OTHER|Standard of Care|Information provided by the physician and/or pharmacist.
57745478|NCT05762133|BEHAVIORAL|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of Perinatal Depression (PND) with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
57745479|NCT04920357|DRUG|Vaccination|Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
57745480|NCT04162665|RADIATION|Adaptive short course radiation therapy|Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.
57745481|NCT04162665|DRUG|Standard of care chemotherapy regimen|The recommendations are CAPOX, FOLFOX, or FLT.
57745482|NCT05381155|BEHAVIORAL|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
57958599|NCT04901910|BEHAVIORAL|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
57745483|NCT00487266|OTHER|Acupuncture|Acupuncture of low back and legs.
57745484|NCT05715996|DEVICE|mixed reality guided localization|In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
57745485|NCT05591508|DIETARY_SUPPLEMENT|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
57745486|NCT03258567|BIOLOGICAL|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
57745487|NCT05744648|PROCEDURE|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
57745488|NCT05744648|PROCEDURE|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
57745489|NCT01584765|DRUG|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
57745490|NCT03440931|DIAGNOSTIC_TEST|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
57745491|NCT00935376|BEHAVIORAL|Sleep Education Program|Treatment as usual.
57745492|NCT00935376|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
57745493|NCT00935376|BEHAVIORAL|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
57745494|NCT06524349|DEVICE|3D printed knee extender device|Participants will receive a 3D printed knee extender device with sealed water bottles and an at-home rehabilitation program designed to be used with the 3D printed knee extender device.
57745495|NCT02837627|OTHER|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
57745496|NCT03365024|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
57745497|NCT03365024|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
57745498|NCT03258749|DRUG|Tiotropium|inhaled Tiotropium(18μg, qd)
57745499|NCT03258749|DRUG|Formoterol|inhaled formoterol(4.5μg, bid)
57745500|NCT00208416|PROCEDURE|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
57745501|NCT00208416|PROCEDURE|Conventional surgical technique|A conventional surgical technique used in total hip replacement
57745502|NCT00130533|DRUG|Capecitabine|
57745503|NCT01939548|DRUG|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
57745504|NCT01939548|DRUG|Placebo|Placebo BID until the Week 12 visit
57745505|NCT01939548|DRUG|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
57745506|NCT03853668|BEHAVIORAL|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
57745507|NCT02136940|DRUG|AMA0076|
57745508|NCT02136940|DRUG|Placebo|
57745509|NCT03899753|DEVICE|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
57745510|NCT03899753|DEVICE|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
57745511|NCT05824065|DRUG|OMA102|1 mg
57745512|NCT05824065|DRUG|OMA102|2 mg
57745513|NCT05824065|DRUG|Placebo|OMA102 - Placebo
57745514|NCT03827122|DRUG|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
57745515|NCT01826474|DRUG|PRO045, 0.15 mg/kg/week|Subcutaneous injection
57745516|NCT01826474|DRUG|PRO045, 1.0 mg/kg/week|Subcutaneous injection
57745517|NCT01826474|DRUG|PRO045, 3.0 mg/kg/week|Subcutaneous injection
57745518|NCT01826474|DRUG|PRO045, 6.0 mg/kg/week|Subcutaneous injection
57745519|NCT01826474|DRUG|PRO045, 9.0 mg/kg/week|Subcutaneous injection
57745520|NCT01826474|DRUG|PRO045, selected dose|Subcutaneous injection
57745521|NCT03817996|OTHER|Fluid challenge|250ml of saline in Responders (those who increased \>10% their cardiac output after a passive leg raising maneuver).
57745522|NCT01743079|DRUG|Telbivudine|LdT 600mg QD
57745523|NCT01743079|DRUG|Lamivudine|LAM 100mg QD
57745524|NCT01532115|DRUG|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
57745525|NCT01532115|DRUG|Placebo|single-dose
57745526|NCT01532115|DRUG|moxifloxacin|400 mg moxifloxacin (single-dose)
57745527|NCT04022200|DEVICE|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
57745528|NCT03483987|DRUG|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
57745529|NCT03483987|DRUG|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
57745530|NCT03483987|DRUG|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
58119058|NCT03724006|BEHAVIORAL|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
58119059|NCT04461509|DRUG|18F-PSMA|"Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer"
58119060|NCT00525109|OTHER|No Intervention|No intervention
58448951|NCT02147756|DEVICE|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
57745531|NCT03483987|DRUG|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
57745532|NCT03483987|DRUG|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
57745533|NCT03483987|DRUG|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
57745534|NCT00310232|DRUG|Epoetin Alfa|
58119061|NCT02796027|OTHER|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
58119062|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
58119063|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Placebo|
58448952|NCT02147756|DEVICE|Repair|
58448953|NCT02534415|DRUG|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
58448954|NCT02534415|DRUG|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
58448955|NCT02534415|DRUG|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
58448956|NCT01900795|DRUG|V117957|V117957 4.5 mg suspension taken orally after surgery.
58448957|NCT01900795|DRUG|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
58448958|NCT01900795|DRUG|Placebo|Placebo taken orally after surgery.
58448959|NCT04168229|DEVICE|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
57745535|NCT01384708|DRUG|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
57745536|NCT06097949|DEVICE|AcuPebble SA100|This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.
57745537|NCT00248781|DEVICE|Telecommunications system|
57745538|NCT00248781|DEVICE|attention control|health education
57745539|NCT04275466|PROCEDURE|necrotic cavity lavage|"1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is \>100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is \>38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
57745540|NCT00894231|DRUG|levocetirizine (Xyzal)|5mg po QD
57745541|NCT00894231|DRUG|placebo|sugar tablet
57745542|NCT05718375|DRUG|CU01-1001|CU01-1001
58448960|NCT04168229|DEVICE|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
57745543|NCT05718375|DRUG|Placebo|Placebo
57745544|NCT03860233|DRUG|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
58119064|NCT04847297|PROCEDURE|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
58119065|NCT04847297|PROCEDURE|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
58448961|NCT03294590|OTHER|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
58448962|NCT03294590|OTHER|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
57745545|NCT03860233|DRUG|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
57745546|NCT06184672|OTHER|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
57745547|NCT03496155|BEHAVIORAL|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
57745548|NCT05080946|DRUG|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
57745549|NCT05080946|DRUG|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
57745550|NCT03771976|PROCEDURE|Cesarean section|Risk of cesarean section between the cohorts
57745551|NCT03771976|PROCEDURE|No cesarean section|Vaginal birth rate between the cohorts
57745552|NCT06072534|DRUG|"Mivacurium Chloride"|emergence modified sequence intubation
57745553|NCT00219076|DRUG|aliskiren|
57745554|NCT04437251|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
57745555|NCT05678764|DEVICE|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
57745556|NCT02262533|DRUG|Apixaban|
57745557|NCT02262533|DRUG|Atenolol|
57745558|NCT03907995|BEHAVIORAL|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
57745559|NCT01073423|BEHAVIORAL|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
58448963|NCT01492790|PROCEDURE|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
58448964|NCT01492790|PROCEDURE|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
58448965|NCT02219854|PROCEDURE|Laparoscopic gastrectomy|
58448966|NCT02219854|PROCEDURE|Open gastrectomy|
58448967|NCT03116711|OTHER|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
58448968|NCT03116711|OTHER|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
58448969|NCT03116711|OTHER|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
58448970|NCT03116711|OTHER|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
57745560|NCT01073423|BEHAVIORAL|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
57745561|NCT00222651|DRUG|tenecteplase|
57745562|NCT05904951|DEVICE|INVADER™ PTCA Balloon Dilatation Catheter|INVADER™ PTCA Balloon Dilatation Catheter is a single use, EO sterilized, monorail rapid exchange (RX) coronary angioplasty balloon dilatation catheter. The INVADER™ PTCA has been designed to dilate the stenotic atherosclerotic lesions in coronary arteries or bypass grafts. The INVADER™ PTCA is an interventional, non-surgical device, and considered minimally invasive.
57745563|NCT03583749|DRUG|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
57745564|NCT03583749|DRUG|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
58119066|NCT02368847|DEVICE|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
58119067|NCT02368847|DEVICE|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
58119068|NCT02371798|DRUG|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
58448971|NCT02949726|DRUG|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
58448972|NCT02949726|DEVICE|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
58448973|NCT01398007|PROCEDURE|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
57745565|NCT02863068|DRUG|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
57958600|NCT04901910|BEHAVIORAL|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
57958601|NCT02950220|DRUG|Ibrutinib|Given PO
57958602|NCT02950220|OTHER|Laboratory Biomarker Analysis|Correlative studies
57958603|NCT02950220|BIOLOGICAL|Pembrolizumab|Given IV
57958604|NCT04697407|BIOLOGICAL|Blood sampling|In all groups, 80 ml of blood will be collected. For patients, this will be done during routine cares.
57958605|NCT04697407|BIOLOGICAL|CSF sampling|Only in both patients groups whom will have a CSF sampling in routine care, some CSF will be collected for the study in addition, with a limit of 5 ml for routine care and study.
57958606|NCT04011865|PROCEDURE|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
57958607|NCT02534259|OTHER|Force monitoring of external fixator struts|
58119069|NCT00909727|DRUG|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
58313633|NCT04128553|BEHAVIORAL|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
58313634|NCT02619201|DRUG|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
58313635|NCT02619201|DRUG|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
58313636|NCT03329989|BIOLOGICAL|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
58313637|NCT02598908|DIAGNOSTIC_TEST|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
58313638|NCT02100787|OTHER|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
58313639|NCT03955549|BEHAVIORAL|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
58313640|NCT03955549|BEHAVIORAL|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
58313641|NCT03955549|DRUG|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
58313642|NCT01101178|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
58313643|NCT01101178|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
58313644|NCT05764499|OTHER|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
57745566|NCT02863068|OTHER|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
57745567|NCT00004122|BIOLOGICAL|BCG vaccine|
57745568|NCT00004122|BIOLOGICAL|recombinant interferon alfa|
57958608|NCT04467307|DEVICE|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
57958609|NCT04931992|OTHER|No intervention|Retrospective analysis
58119070|NCT00909727|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
57745569|NCT03364751|OTHER|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
57745570|NCT03364751|OTHER|Cigarette|Patients will continue to smoke cigarettes ad libitum.
57745571|NCT02199028|DRUG|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
57745572|NCT02199028|OTHER|Control|No hyaluronidase administered into insulin infusion set.
58119071|NCT00215982|DRUG|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
58119072|NCT00215982|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
58119073|NCT00215982|DRUG|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
58119074|NCT00455663|BEHAVIORAL|Cognitive Adaptation Training|Environmental supports for all independent living skills
58119075|NCT00455663|BEHAVIORAL|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
58119076|NCT00455663|OTHER|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
58119077|NCT01200056|DRUG|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
58119078|NCT05998213|OTHER|Fecal microbiota transplant|Frozen FMT via duodenal tube (2 times) and enemas (4 times)
58119079|NCT06119607|DEVICE|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
58119080|NCT05605964|DRUG|Relugolix|Relugolix tablet
58119081|NCT05605964|DRUG|Leuprolide Acetate|Leuprolide acetate injection
58119082|NCT01090765|DRUG|TRC105|
58119083|NCT00006156|OTHER|Control|No injection of FSH
58119084|NCT00006156|DRUG|Drug: FSH|FSH Stimulation Test
58119085|NCT05128188|OTHER|No intervention will be given in this study|No intervention will be given in this study
57745573|NCT03339323|OTHER|Exercise|TKA patients do the exercise intervention
57745574|NCT00251862|BEHAVIORAL|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
57958610|NCT06194773|PROCEDURE|Totalfil|Root canal treatment using TotalFil sealer
57745575|NCT00251862|BEHAVIORAL|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
57745576|NCT00251862|BEHAVIORAL|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
57745577|NCT05942911|DRUG|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
57745578|NCT05942911|DRUG|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
57958611|NCT06194773|PROCEDURE|NeoSealer|Root canal treatment using NeoSealer
57958612|NCT06194773|PROCEDURE|AH-Plus sealer|Root canal treatment using AH-Plus sealer
57958613|NCT03958552|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
57958614|NCT02454166|OTHER|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
57958615|NCT02454166|OTHER|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
57958616|NCT06222840|OTHER|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
57958617|NCT06222840|OTHER|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
57958618|NCT06222840|OTHER|Clinical datas analysis|Clinical datas analysis
57958619|NCT06222840|OTHER|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
57958620|NCT05828693|BEHAVIORAL|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
57958621|NCT05828693|BEHAVIORAL|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
57958622|NCT02852512|PROCEDURE|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
57958623|NCT02085434|BEHAVIORAL|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
57958624|NCT01981642|OTHER|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
57958625|NCT01981642|OTHER|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
57958626|NCT04385654|DRUG|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
58119086|NCT01439503|BEHAVIORAL|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
58119087|NCT00793728|PROCEDURE|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
58119088|NCT03643419|PROCEDURE|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
58119089|NCT03643419|DEVICE|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
57745579|NCT05942911|DRUG|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
57745580|NCT05942911|DRUG|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
57745581|NCT03498833|OTHER|Test-retest reliability testing|Set of patient reported outcome measures
58119090|NCT02851290|PROCEDURE|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
58119091|NCT02851290|PROCEDURE|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
58119092|NCT04361019|OTHER|On-Line Survey|A survey has been sent by email to the students of the participating universities
58119093|NCT02725944|DEVICE|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
58313645|NCT04772976|OTHER|Observational study, not applicable|Observational study, not applicable
58448974|NCT04507607|DRUG|Tenofovir Alafenamide 25 MG|TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
58448975|NCT02741635|DEVICE|New Nasal Pillows Mask|Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
58448976|NCT02028533|DRUG|Oxytocin|
58448977|NCT02028533|DRUG|Placebo|
58448978|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
58448979|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
58448980|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
58448981|NCT03769259|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|Participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
57745582|NCT00158665|BIOLOGICAL|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
57745583|NCT01332227|DRUG|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
57745584|NCT01332227|DRUG|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
57745585|NCT01332227|DRUG|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
57745586|NCT01332227|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
57745587|NCT02134587|OTHER|Multifaceted educational intervention|"1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
57745588|NCT03358563|DRUG|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
57745589|NCT03358563|DRUG|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
58119094|NCT03818958|OTHER|blood sampling|blood sampling
58119095|NCT06230120|DEVICE|Spinal Cord Stimulation|"Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)"
58313646|NCT02396667|OTHER|5D ultrasound|Measure the femur length by 5DLB to calculate fetal weight
58119096|NCT06230120|DEVICE|Sham|Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
58119097|NCT03672500|DRUG|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
58119098|NCT03672500|OTHER|Sham injection|Sham injection of the perineum
58119099|NCT01077713|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
58119100|NCT01077713|DRUG|cisplatin|60mg/m2 on day 1 of each 3 week cycle
58119101|NCT01077713|DRUG|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
58119102|NCT01077713|DRUG|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
57745590|NCT03358563|DRUG|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
58119103|NCT01001169|BIOLOGICAL|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
58119104|NCT05269654|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
58119105|NCT05269654|OTHER|Normal Saline|Sham Comparator
58119106|NCT06546371|DEVICE|Spinal cord stimulator|Electrical stimulation of the dorsal horn to reduce chronic pain.
58119107|NCT02445170|PROCEDURE|Amputation|Transmetatarsal or below-knee amputation
58119108|NCT04780503|DIAGNOSTIC_TEST|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
58119109|NCT01161641|DRUG|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
58448982|NCT03769259|BEHAVIORAL|Present-Centered Therapy (PCT)|Participants in PCT will receive will include 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. PCT consists of (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors among military personnel; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions.
58448983|NCT03769259|BEHAVIORAL|Treatment as Usual (TAU)|"All participants will receive the following interventions or procedures, regardless of treatment assignment:~* Suicide risk assessment using the Columbia Suicide Severity Rating Scale~* VA's safety planning intervention, which include Military Crisis Line contact information and lethal means access reduction~* Caring contacts and outreach~* Psychotropic medication, group therapy, substance abuse counseling, and other mental health interventions provided routinely as a part of treatment as usual"
58448984|NCT04593524|DIETARY_SUPPLEMENT|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
58448985|NCT04593524|OTHER|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
57745591|NCT03358563|RADIATION|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
58119110|NCT01161641|DRUG|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
58119111|NCT01161641|DRUG|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
58119112|NCT06545071|BEHAVIORAL|NEAT-O program|NEAT-O's curriculum is designed to interrupt the cycle of negative emotions and opioid use through a multifaceted approach encompassing physiological, psychological, and behavioral strategies. The program includes interactive modules that capture the core therapeutic components of CBT and teach skills to support OUD recovery.
58119113|NCT02310477|DRUG|regorafenib|regorafenib for all groups
58119114|NCT05267808|PROCEDURE|Drug-induced sleep endoscopy|Endoscopy during drug-induced sleep
58119115|NCT02015793|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
58119116|NCT02015793|BIOLOGICAL|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
58119117|NCT04960696|DIAGNOSTIC_TEST|OSDI|Change of OSDI in distance education
58119118|NCT04960696|DIAGNOSTIC_TEST|tear break up time|Change of tear break up time in distance education
58119119|NCT04960696|DIAGNOSTIC_TEST|schirmer|Change of schirmer in distance education
58119120|NCT04643678|DRUG|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
58119121|NCT04643678|OTHER|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
58119122|NCT00414947|DRUG|Vildagliptin (LAF237)|
58119123|NCT03928782|RADIATION|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
58119124|NCT01663909|BEHAVIORAL|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
58119125|NCT01342679|DRUG|dasatinib|100mg QD
58119126|NCT00738556|DEVICE|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
58119127|NCT04296864|DRUG|Dupilumab|monoclonal antibody
58448986|NCT02742831|BEHAVIORAL|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan."
58448987|NCT02742831|OTHER|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
58448988|NCT02028442|BIOLOGICAL|Enadenotucirev|Oncolytic virus
57745592|NCT02766569|DEVICE|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
57745593|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
58448989|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
58448990|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
58448991|NCT05810363|DRUG|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
58448992|NCT05810363|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
58448993|NCT00226057|DRUG|Raptiva|Open Label
58448994|NCT00494585|DRUG|CEP-701|80 mg orally twice a day for 30 days
58448995|NCT01073449|PROCEDURE|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
58448996|NCT05497089|DRUG|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
58448997|NCT05497089|DRUG|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
58448998|NCT04872192|OTHER|transversus thoracic muscle plane block|transversus thoracic muscle plane block by injection of 15 ml of bupivacaine 0.25% on each side combined with general anaesthesia
58448999|NCT04872192|OTHER|general anaesthesia|transversus thoracic muscle plane block by injection of 15 ml of saline on each side combined with general anaesthesia
58449000|NCT00867165|DRUG|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
58449001|NCT00867165|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
58449002|NCT03987477|BEHAVIORAL|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
57745594|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
58449003|NCT03987477|BEHAVIORAL|Waiting list|Waiting list procedure for the control group.
58449004|NCT06725459|DEVICE|Prophylactic ciNPWT|The prophylactic closed incision negative pressure wound therapy (ciNPWT) will be applied to one breast for up to 7 days postoperatively to promote wound healing and prevent complications.
58449005|NCT06725459|OTHER|Standard Adhesive Dressing|The standard adhesive strip dressing will be applied to one breast immediately after surgery. It provides a protective covering for the wound during the initial healing phase and is the standard of care for incision management.
57745595|NCT03317002|DRUG|Placebo|Matching placebo (tablet)
57745596|NCT06234410|RADIATION|Computed tomography coronary angiography (CTCA)|Single CTCA scan prior to kidney transplantation
57745597|NCT03128996|DRUG|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
57745598|NCT03128996|DRUG|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
57745599|NCT01898468|PROCEDURE|Pericostal Closure Technique|
57745600|NCT01898468|PROCEDURE|Intracostal Closure Technique|
57745601|NCT03234205|DEVICE|MRI scan|"MRI standard protocol with addition of:~* a second clinical respiratory belt besides belt usually installed for clinical examination~* a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~* 12 sequences during free respiration are added lasting supplementary 15 minutes~* Use of cardiac antennae usually used for cardiac MRI scans"
58119128|NCT00893542|DRUG|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
58449006|NCT02046707|OTHER|initial evaluation|
58449007|NCT02046707|OTHER|Period of cardiac rehabilitation|
58449008|NCT02046707|OTHER|final evaluation|
58449009|NCT02046707|OTHER|Concentric and eccentric exercise sessions|
58449010|NCT00195949|PROCEDURE|Laparoscopic pyloromyotomy|
58449011|NCT05396053|OTHER|Physical therapy exercises|Three times a week for 12 weeks.
58449012|NCT05396053|OTHER|Mirror therapy|Three times a week for 12 weeks.
58449013|NCT05396053|OTHER|Constraint Induced Movement Therapy|Three times a week for 12 weeks.
58449014|NCT06726707|DEVICE|Diaper with a copper-based product|The device is an incontinence aid and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
58449015|NCT06726707|COMBINATION_PRODUCT|Barrier product with common diaper|The control device (common diaper) is an incontinence aid and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
57745602|NCT05828966|DRUG|human chorionic gonadotropin (hCG)|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
58119129|NCT03629574|PROCEDURE|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
58119130|NCT04455568|DEVICE|use EKG Wisdom bracelet|Non-invasive Wearable Device (use EKG Wisdom bracelet)
58119131|NCT00322309|OTHER|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
58449016|NCT00950846|DRUG|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
58449017|NCT00950846|DRUG|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
58449018|NCT00950846|DRUG|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
58449019|NCT00950846|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
57745603|NCT05828966|DRUG|Magnesium sulfate|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
57745604|NCT00006041|BIOLOGICAL|MUC1-KLH conjugate vaccine|
57745605|NCT00006041|BIOLOGICAL|MUC1-KLH vaccine/QS21|
57745606|NCT00006041|BIOLOGICAL|QS21|
57745607|NCT05232695|DIAGNOSTIC_TEST|metabolically healthy obese|Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
57745608|NCT05191758|DIETARY_SUPPLEMENT|FPP supplement|Participants will take the supplements per randomization
57958627|NCT04385654|DRUG|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
57958628|NCT06266143|DRUG|Y101D|Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
57958629|NCT04740476|DRUG|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
57958630|NCT00909558|BIOLOGICAL|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
57958631|NCT02836067|BEHAVIORAL|Counseling|Smoking cessation counseling
57958632|NCT02836067|OTHER|Smoking Cessation drugs|Medication to aid smoking cessation
57958633|NCT02836067|PROCEDURE|Bronchoscopy|Bronchoscopy
57958634|NCT02836067|PROCEDURE|Blood Draw|Screening and research blood draws
57958635|NCT02836067|BEHAVIORAL|Questionnaires|Behavioral questionnaires
57958636|NCT03847987|DRUG|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
57958637|NCT03847987|DRUG|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
57958638|NCT03847987|DRUG|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
57958639|NCT02448407|BIOLOGICAL|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
57958640|NCT02448407|DRUG|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
57962321|NCT01414257|DRUG|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
57962322|NCT00789529|DEVICE|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
57962323|NCT00789529|DEVICE|ReNu MultiPlus®|soft contact lens disinfecting solution
57962324|NCT04067063|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
57962325|NCT00883337|DRUG|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
57962326|NCT00883337|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
57962327|NCT02318472|DEVICE|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
57962328|NCT02318472|DEVICE|Plaster cast|Lower limb plaster cast
57962329|NCT05397990|BEHAVIORAL|Exercise|12 weeks of moderate intensity exercise, three times a week.
57962330|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
57962331|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
57962332|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
57962333|NCT01131000|OTHER|Normal Saline|Normal Saline, 100 ml, Single-dose
57962334|NCT00291447|BIOLOGICAL|ch806|ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
57962335|NCT06038786|BEHAVIORAL|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
57962336|NCT01823679|DRUG|Capecitabine|Given orally
57962337|NCT06099938|DRUG|sufentanil, ropivacaine|The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
58119132|NCT00322309|DRUG|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
58119133|NCT02099500|PROCEDURE|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
58119134|NCT02099500|OTHER|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
58119135|NCT00519012|DRUG|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
58119136|NCT00519012|DRUG|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
58119137|NCT00711906|DRUG|Cotrimoxazole|Cotrimoxazole
58119138|NCT00711906|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
58119139|NCT04706975|DRUG|difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg administered twice daily
58119140|NCT04706975|DRUG|Placebo|Oral Placebo administered twice daily
58119141|NCT04648059|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
57745609|NCT06224738|BIOLOGICAL|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
57745610|NCT03952832|DRUG|Leflunomide|Given PO
57745611|NCT03952832|OTHER|Quality-of-Life Assessment|Ancillary studies
57745612|NCT03952832|OTHER|Questionnaire Administration|Ancillary studies
57745613|NCT05817448|DIAGNOSTIC_TEST|HIF 1α and LC3B expression and MMP-9 level|"5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression"
57958641|NCT06409312|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports the therapeutic training of people with musculoskeletal conditions. It provides two therapeutic training programs for patients, one for each specific indication. Patients have continuous access to these programs through Akina Cloud, allowing them to independently complete nine training sessions without supervision. A minimum of three sessions per week is recommended, but patients have the option to engage in daily sessions if preferred. These therapy programs are based on current treatment guidelines and supported by relevant scientific research. They include customizable physical exercises tailored to individual needs and difficulty levels. Patients receive audio-visual guidance during these exercise sessions to ensure proper execution. Exercise therapy has demonstrated its ability to reduce pain, improve physical function, and enhance the overall quality of life for patients suffering from back pain and hip osteoarthritis.
57958642|NCT05009719|BIOLOGICAL|Prophylactic Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
57745614|NCT05684081|BEHAVIORAL|Digital payment|The proposed intervention is designed to support the implementation of polio campaigns through digital payments
57745615|NCT04789096|DRUG|Tucatinib|Oral tablet
57745616|NCT04789096|DRUG|Pembrolizumab|Intravenous
57745617|NCT04789096|DRUG|Trastuzumab|Intravenous
57958643|NCT05009719|BIOLOGICAL|Preventive Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
58119142|NCT03868449|OTHER|Question Prompt List|Question prompt list
58119143|NCT03868449|OTHER|3 questions|3 questions from the AskShareKnow model
58119144|NCT01220349|DEVICE|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
57745618|NCT04789096|DRUG|Capecitabine|Oral tablet
57745619|NCT01825213|DEVICE|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
57745620|NCT06580314|DRUG|Olaparib|Given PO
57745621|NCT06580314|BIOLOGICAL|Bevacizumab|Given IV
58119145|NCT00743691|OTHER|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
58119146|NCT03342898|BIOLOGICAL|YF-17D|YF-17D SC injection.
58119147|NCT03342898|BIOLOGICAL|TDV|TDV SC injection.
58119148|NCT03342898|DRUG|Placebo|Normal Saline (0.9% NaCl) SC injection.
58119149|NCT01950988|DEVICE|Manual toothbrush reference|
58119150|NCT01950988|PROCEDURE|Measure of the dental plaque|
58119151|NCT01950988|DEVICE|Manual toothbrush Broscyl®|
58119152|NCT04756609|PROCEDURE|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
58119153|NCT04756609|OTHER|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
58119154|NCT03776903|OTHER|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
58119155|NCT05367856|DRUG|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
58313647|NCT05658068|BEHAVIORAL|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
57745622|NCT06580314|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57745623|NCT06580314|PROCEDURE|Computed Tomography|Undergo CT
57745624|NCT06580314|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57745625|NCT00222534|DRUG|Acetazolamide|
57745626|NCT00222534|DRUG|Placebo|
57745627|NCT00156065|DRUG|Haloperidol|2-8 mg BID
57745628|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
57745629|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
57745630|NCT02615574|BIOLOGICAL|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
57745631|NCT02615574|DRUG|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
57745632|NCT03049410|PROCEDURE|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
57745633|NCT03049410|PROCEDURE|Open Radical Cystectomy|Removal of bladder and adjacent organs
57745634|NCT04888390|BEHAVIORAL|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
57745635|NCT04888390|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
57745636|NCT02479230|BIOLOGICAL|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
57745637|NCT02479230|DRUG|gemcitabine hydrochloride|Given IV
57745638|NCT01710176|DRUG|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
57745639|NCT01710176|DRUG|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
57745640|NCT01710176|DRUG|trabectedin 1.3 mg/m2|
57745641|NCT01710176|DRUG|high-dose ifosfamide 14 g/m2, given in in 14 days|
57745642|NCT01710176|DRUG|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
58313648|NCT02768987|BEHAVIORAL|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
58313649|NCT05413772|OTHER|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
57745643|NCT01710176|DRUG|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
57745644|NCT02211326|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
57745645|NCT02211326|BEHAVIORAL|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
57745646|NCT00831779|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
57745647|NCT00831779|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
57745648|NCT06203106|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
57745649|NCT00860379|DRUG|Selenium1|2 ug/kg
57745650|NCT00860379|DRUG|Selenium2|4 ug/kg
57745651|NCT00860379|DRUG|Placebo|IV saline as placebo
58119156|NCT03636321|PROCEDURE|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
58119157|NCT03993171|DRUG|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
58119158|NCT01915056|OTHER|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
58119159|NCT06452810|DIETARY_SUPPLEMENT|Experimental: Sahajan Golden Glow Balm|Participants will apply the Sahajan Golden Glow Balm twice daily (morning and night) to the periorbital area following the specified instructions.
58119160|NCT05304299|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
57745652|NCT06034548|BEHAVIORAL|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
57958644|NCT04993365|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
58119161|NCT05936879|OTHER|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
58119162|NCT05936879|OTHER|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
58119163|NCT06543147|OTHER|breast cancer and breast self- examination education|The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
58119164|NCT06375590|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid stenosis with the Navitor platform
58119165|NCT03602014|DRUG|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
58119166|NCT03602014|OTHER|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
58119167|NCT03554421|PROCEDURE|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
58119168|NCT04845061|DRUG|Nebivolol Tablets|cardio selective beta-1 blocker
58119169|NCT02637557|DRUG|IW-3718|
58119170|NCT02637557|DRUG|Matching Placebo|
58119171|NCT02637557|DRUG|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
58119172|NCT00442845|DRUG|Atorvastatin (Lipitor)|
58119173|NCT03422146|OTHER|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
57745653|NCT03855449|BEHAVIORAL|eDECIDE Web-based Intervention Group|"Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
57958645|NCT04993365|BIOLOGICAL|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
57958646|NCT03682978|DRUG|Arbaclofen|Arbaclofen tablet.
58119174|NCT03422146|OTHER|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
58119175|NCT03857022|DEVICE|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
58119176|NCT01268176|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU once per month for 3 months
58119177|NCT06332547|OTHER|Restrictive Transfusion Strategy|Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
58119178|NCT06332547|OTHER|Liberal Transfusion Strategy|Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
57745654|NCT06579547|RADIATION|Low Dose Computer Tomography|Participants will undergo MRI scans of their skeletal system, followed by the Intervention of a Low Dose CT scan of the same body region for comparison purposes.
57958647|NCT03682978|DRUG|Placebo|Placebo tablet.
58449020|NCT04203836|DRUG|LEO 152020 Tablet|film-coated tablet
58119179|NCT04169282|DEVICE|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
58119180|NCT04559256|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
58119181|NCT05869097|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
58119182|NCT05869097|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
58119183|NCT06280469|DEVICE|Single-Balloon Enteroscopy|The inflated balloon is supposed to fix the intestine to the endoscope system.Pushing the endoscope deeper into the small bowel with the balloon and enteroscope.
58119184|NCT05269628|DRUG|Cannabidiol (CBD)|Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.
58119185|NCT05269628|DRUG|Tetrahydrocannabinol (THC)|The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.
58119186|NCT05269628|DRUG|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
58119187|NCT05269628|DRUG|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
57958648|NCT04567212|GENETIC|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
57958649|NCT04567212|OTHER|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
58119188|NCT01272557|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
57745655|NCT06732050|DEVICE|nociception guided treatment|For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
57745656|NCT00725452|BIOLOGICAL|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
57769692|NCT04944394|OTHER|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
57958650|NCT01169077|DRUG|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
57958651|NCT01169077|BIOLOGICAL|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
57958652|NCT00716105|OTHER|Standard infant formula|From 3 to 12 months of age. As per standard requirement
57958653|NCT00716105|OTHER|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
57958654|NCT05929690|OTHER|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
57958655|NCT04899297|OTHER|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
57958656|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2 in orange juice|1000 IU dose
57958657|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3 in orange juice|1000 IU
57958658|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2|capsule, 1000 IU
57958659|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3|capsule, 1000 IU
57958660|NCT01778114|OTHER|Placebo|Placebo
58119189|NCT01272557|DRUG|Sorafenib|Sorafenib 400 mg bid (oral) continuously
58119190|NCT00898482|OTHER|This is a non-intervention study for all groups.|This is a non-intervention study.
58119191|NCT00898482|OTHER|study of socioeconomic and demographic variables|Non-intervention study.
58119192|NCT06482970|OTHER|Neuromuscular exercise plus pain neuroscience education|"The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).~Pain neuroscience education will take an active, person-centered approach through their own fear-avoidance beliefs."
57958661|NCT00557219|DRUG|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
57958662|NCT00557219|DRUG|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
57958663|NCT00557219|DRUG|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
58119193|NCT06482970|OTHER|Neuromuscular exercise|The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).
58119194|NCT00783666|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
58119195|NCT00448955|DRUG|ARD-0403|ARD-0403
58119196|NCT03878316|DRUG|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
58119197|NCT06166472|DRUG|AK132|IV infusion, specified dose on specified days.
58119198|NCT03416595|DIETARY_SUPPLEMENT|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
58119199|NCT03416595|DIETARY_SUPPLEMENT|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
58119200|NCT00138359|DRUG|Niclosamide|
58119201|NCT05446727|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine
58449021|NCT06151444|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
57745657|NCT05747222|OTHER|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
57745658|NCT05747222|OTHER|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
57745659|NCT04934423|DEVICE|Direct Current Transcranial Stimulation - tDCS|Active intervention
57745660|NCT04934423|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
57745661|NCT01477125|BEHAVIORAL|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
57745662|NCT06061497|OTHER|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
57745663|NCT06061497|BEHAVIORAL|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
57745664|NCT05756855|BEHAVIORAL|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
57745665|NCT01121068|OTHER|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
57745666|NCT03538470|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool"
57745667|NCT05437458|OTHER|Delirium (exposure)|No interventions.
57745668|NCT06474221|BEHAVIORAL|Electronic Based Psychosocial Intervention (EBPSI)|Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
57745669|NCT02527668|DIETARY_SUPPLEMENT|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
57745670|NCT02527668|DIETARY_SUPPLEMENT|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
57745671|NCT02527668|OTHER|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
57745672|NCT01164995|DRUG|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
57745673|NCT03215836|PROCEDURE|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
57745674|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
57745675|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
57745676|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
58119202|NCT00535509|RADIATION|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
57745677|NCT02549469|DRUG|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
57745678|NCT06732440|BEHAVIORAL|Subthreshold Vestibular Conditioning|The subthreshold vestibular conditioning protocols will be performed while seated on a motion platform in a dark room. A 0.5Hz whole-body tilt conditioning stimulus will be delivered. The stimulus will consist of whole-body sinusoidal motions (similar to those used when measuring tilt perceptual thresholds) delivered at 57.4% of the measured baseline threshold (e.g., 0.574°/s for a 1 °/s threshold); the frequency (0.5Hz) was chosen to match the baseline threshold tasks. The participants and experimenter will be blinded to the nature of the condition and will be informed that while the chair may vibrate or move slightly, the motion will not occur in any particular direction. Music, audiobooks, or podcasts of the subject's choosing will be played to further discourage attention to the conditioning stimulus.
57745679|NCT06732440|BEHAVIORAL|Balance Training|Balance training will consist of progressive exposure to continuous pseudorandom platform perturbations delivered using a 6DoF motion platform. Participants will stand on a MOOG hexapod motion platform and will be secured using a safety harness tethered to the ceiling and a full enclosure of safety rails. Balance training will be progressed by (a) gradually increasing the number of degrees of freedom (e.g., 1DOF to 6DOF) in the perturbation, (b) removing visual cues, (c) narrowing the base of support, and (d) increasing the amplitude, velocity, and/or acceleration of the platform motion. In the event that subject experiences a loss of balance, the level of difficulty will be modified accordingly. Each balance training block will include 5 minutes of perturbations followed by 3 minutes of rest, repeated 5 times for a total of 40 minutes of training.
57769693|NCT04944394|OTHER|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
58119203|NCT00535509|OTHER|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
58119204|NCT00535509|DRUG|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
58119205|NCT00380003|DRUG|EVT 201|
58449022|NCT06151444|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
57745680|NCT06010472|DRUG|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
57745681|NCT04649866|DIAGNOSTIC_TEST|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline"
57745682|NCT05885152|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
57745683|NCT04133233|DRUG|ILT101|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
57745684|NCT04133233|DRUG|Placebos|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
57745685|NCT00586911|DRUG|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
57745686|NCT00586911|DRUG|Identical Placebo|Placebo
57745687|NCT06177665|OTHER|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
57745688|NCT06177665|OTHER|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
57745689|NCT04315168|DEVICE|FRED and FRED JR|Intracranial aneurysm treatment
57745690|NCT03583918|DEVICE|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
57745691|NCT00151307|DEVICE|INVOS cerebral oximeter|
58119206|NCT02935959|DRUG|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
58119207|NCT02935959|DRUG|nebulized Dexmedetomidine|
58449023|NCT03335735|BEHAVIORAL|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
58449024|NCT03335735|BEHAVIORAL|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
57745692|NCT05817851|DRUG|Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)|in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
58449025|NCT02297386|DRUG|[18F] DIHYDRO-TESTOSTERONE|
57745693|NCT05817851|DRUG|standard treatment|no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
57745694|NCT05671562|DIETARY_SUPPLEMENT|Lycopene|Capsule containing lycopene 7mg x 2 daily for 12 weeks
57745695|NCT05671562|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive substance 7mg x 2 daily for 12 weeks
57745696|NCT03035292|DIAGNOSTIC_TEST|Red-reflex assessment|The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
57745697|NCT03035292|DIAGNOSTIC_TEST|Infrared-reflex assessment|The infrared reflex was examined using a modified smart phone camera by a medical student examiner
58119208|NCT02935959|DRUG|nebulized midazolam|
58119209|NCT00727454|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
57745698|NCT04752423|OTHER|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
58119210|NCT00727454|DEVICE|No treatment|No treatment
58119211|NCT06057883|DIETARY_SUPPLEMENT|Probiotic|A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
58119212|NCT02267057|DRUG|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
58119213|NCT02267057|DRUG|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
58119214|NCT02267057|DRUG|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
58119215|NCT02267057|DRUG|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
58449026|NCT02297386|DEVICE|PET scan|
58449027|NCT02297386|DEVICE|MRI|
58449028|NCT02297386|OTHER|Blood draw|
58449029|NCT05630950|DEVICE|Smoking cessation mobile application|Mobile application for smoking cessation.
58449030|NCT05630950|BEHAVIORAL|Written material for smoking cessation|Written material for smoking cessation
58119216|NCT03777137|BEHAVIORAL|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
58119217|NCT06393101|DRUG|BRC-002|BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
58119218|NCT06393101|DRUG|BRC-002 Placebo|Oral solution of mono-, di-, and triglycerides
58119219|NCT02752776|DRUG|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
58119220|NCT00329602|DRUG|Placebo|Matching Placebo
58119221|NCT00329602|DRUG|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
58119222|NCT01499121|DRUG|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop \> grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
58119223|NCT02022813|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
58119224|NCT06541366|OTHER|case-control study|physical examination and Survey Form
58119225|NCT03777475|PROCEDURE|transarterial infusion|transarterial infusion
58119226|NCT03942510|OTHER|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
58119227|NCT00409994|DRUG|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
58119228|NCT03662919|DRUG|Infliximab|Administered as specified in the treatment arm.
58119229|NCT03662919|DRUG|Adalimumab|Administered as specified in the treatment arm.
58119230|NCT00003706|DRUG|pemetrexed disodium|
58119231|NCT02363582|OTHER|formula|An infant formula contains prebiotics and lactoferrin
58119232|NCT01901055|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
58119233|NCT01901055|DEVICE|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
58449031|NCT01218581|DRUG|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
58449032|NCT01706523|DRUG|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
58119234|NCT01901055|BEHAVIORAL|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
58119235|NCT03622502|DRUG|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
58119236|NCT03622502|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
58119237|NCT03622502|DRUG|Normal saline|Normal saline was infused over 10 min before end of the surgery
57958664|NCT04134962|DIAGNOSTIC_TEST|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
57958665|NCT06351995|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
58119238|NCT04217226|DEVICE|Perfusion index derived parameters|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time."
58119239|NCT03238950|OTHER|Porcine model|participants to conduct training on porcine model
58449033|NCT00806910|DRUG|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
58449034|NCT00806910|OTHER|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
58119240|NCT03238950|OTHER|Synthetic model|participants to conduct training on synthetic model
57745699|NCT00868855|DRUG|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
58119241|NCT02353000|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
58119242|NCT02353000|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
58119243|NCT05015556|PROCEDURE|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
58313650|NCT04763512|DIETARY_SUPPLEMENT|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
57745700|NCT00914329|DRUG|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
57745701|NCT00914329|DRUG|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
57745702|NCT00914329|DRUG|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
57745703|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
57745704|NCT00003214|DRUG|carboplatin|
57745705|NCT00003214|DRUG|cisplatin|
57958666|NCT06351995|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
57958667|NCT00562549|DRUG|SLx-2101|
57958668|NCT05042310|DRUG|LY3541860|Administered either IV or SC.
57958669|NCT05042310|DRUG|Placebo|Administered either IV or SC.
57958670|NCT05848154|DIAGNOSTIC_TEST|ctDNA detection|Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
57958671|NCT05066490|OTHER|Endurance exercise|Treadmill training at moderate intensity.
57958672|NCT05066490|OTHER|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
57958673|NCT04485312|BEHAVIORAL|preventive protocol|preventive protocol
57958674|NCT04485312|BEHAVIORAL|chlorhexidine added to the preventive protocol|chlorhexidine varnish added to the preventive protocol
57958675|NCT05725356|OTHER|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
57958676|NCT02002975|DRUG|Pioglitazone|Pioglitazone tablets
57958677|NCT01365559|DRUG|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
57958678|NCT01365559|DRUG|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
57958679|NCT05341271|OTHER|Experimental: digital reminiscence group (DRG)|Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
58119244|NCT03604887|DIAGNOSTIC_TEST|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
57745706|NCT00003214|DRUG|cyclophosphamide|
58119245|NCT03277781|OTHER|Screening|Screening for AAA
58119246|NCT01665053|DEVICE|PROMUS Element Plus|A drug eluting coronary stent system
58119247|NCT01665053|DEVICE|SYNERGY|A drug eluting coronary stent system
58119248|NCT03377556|OTHER|Laboratory Biomarker Analysis|Correlative studies
58119249|NCT03377556|OTHER|Pharmacological Study|Correlative studies
58119250|NCT03377556|DRUG|Talazoparib|Given PO
57745707|NCT00003214|DRUG|doxorubicin hydrochloride|
57745708|NCT00003214|DRUG|in vitro sensitivity-directed chemotherapy|
57745709|NCT00003214|DRUG|paclitaxel|
57745710|NCT03503266|DRUG|[14C] MT-7117|14-C MT-7117
57745711|NCT04210206|OTHER|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
57745712|NCT02955264|DIETARY_SUPPLEMENT|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
57745713|NCT02443948|OTHER|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
57745714|NCT06641180|BIOLOGICAL|High-Dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
57745715|NCT06641180|BIOLOGICAL|Standard-dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
57745716|NCT01896570|PROCEDURE|Catheter ablation of subsequent atrial tachycardia|
57745717|NCT03876834|OTHER|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
58119251|NCT02938494|DRUG|IDP-123 Lotion|Lotion
57745718|NCT00349453|DRUG|Deferiprone (L1)|50-100 mg/kg body weight daily
57745719|NCT00349453|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
57745720|NCT00349453|DRUG|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
57745721|NCT06106386|OTHER|cryotherapy|Cooling of irrigation
57745722|NCT04716179|DIAGNOSTIC_TEST|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
57745723|NCT04716179|DIAGNOSTIC_TEST|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
57745724|NCT04716179|DIAGNOSTIC_TEST|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
57745725|NCT04716179|OTHER|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
57745726|NCT05437133|DEVICE|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
58119252|NCT02938494|DRUG|Tazorac Cream|Cream
58119253|NCT02938494|DRUG|Vehicle Lotion|Lotion
58119254|NCT02938494|DRUG|Vehicle Cream|Cream
58119255|NCT01538342|OTHER|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
58119256|NCT01538342|OTHER|2 biopsies|
58119257|NCT01538342|OTHER|biopsy|1 biopsy ok healthy skin
58119258|NCT02465411|DEVICE|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
58119259|NCT04240483|OTHER|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
58119260|NCT04240483|OTHER|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
58119261|NCT01191021|DRUG|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
58119262|NCT05566093|PROCEDURE|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
57745727|NCT06126354|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
57745728|NCT06126354|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
58119263|NCT05566093|PROCEDURE|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
57745729|NCT06126354|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
57745730|NCT06126354|DRUG|Human Growth Hormone|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
57745731|NCT06126354|DRUG|Dexamethasone Oral|Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
57745732|NCT06126354|OTHER|[6,6-2H2] D-glucose|"Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)"
57745733|NCT06126354|DRUG|20% D-glucose (aq)|"20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)"
57745734|NCT06126354|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)"
57769694|NCT02538770|OTHER|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
58119264|NCT06187922|DRUG|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
58119265|NCT06187922|PROCEDURE|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
58119266|NCT01842451|DRUG|VX-135|
58119267|NCT01842451|DRUG|Daclatasvir|
58119268|NCT00492089|DRUG|bevacizumab|Given IV
58119269|NCT00492089|DRUG|placebo|Given IV
58119270|NCT00492089|PROCEDURE|magnetic resonance imaging|
58119271|NCT00492089|PROCEDURE|quality-of-life assessment|
58119272|NCT04922502|BEHAVIORAL|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
57745735|NCT06126354|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|"Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)"
57745736|NCT06126354|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|"Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)"
57745737|NCT06126354|OTHER|Normal saline|Normal saline (0.9% NaCl, aq), variable rate (as needed)
58119273|NCT04922502|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
58119274|NCT01396941|BEHAVIORAL|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
58119275|NCT04211467|OTHER|No Intervention|There is no intervention for this study
58119276|NCT05065463|DRUG|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
58119277|NCT01460251|DRUG|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
58119278|NCT04184037|BEHAVIORAL|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
58449035|NCT03789240|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
58449036|NCT03789240|DRUG|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
58449037|NCT02016651|BEHAVIORAL|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
58449038|NCT00398697|DRUG|Perifosine|
58119279|NCT03238768|OTHER|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
58119280|NCT03238768|OTHER|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
58449039|NCT00398697|DRUG|Gemcitabine|
58449040|NCT04929678|DEVICE|Braive™ Growth Modulation System (Braive™ GMS)|"The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw."
58449041|NCT01412528|OTHER|Allergen extracts|
58449042|NCT00456404|DRUG|peppermint water|
58449043|NCT05669859|PROCEDURE|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
58449044|NCT06609083|DRUG|THC 30mg|High dose of THC (30 mg)
58449045|NCT06609083|DRUG|THC 5mg|Low dose of THC (5 mg)
58449046|NCT06609083|DRUG|THC 0mg|Placebo dose of THC (0 mg)
57745738|NCT06126354|OTHER|Human albumin|Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
57745739|NCT02475122|OTHER|azygos blood flow measurements by MRI|
57745740|NCT05959993|BEHAVIORAL|Human Care Model Based Nursing Interventions|The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
57745741|NCT05305196|OTHER|Eccentric-focused exercises|"Three eccentric-focused exercises:~1. Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~2. Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~3. Shoulder abductor eccentric contraction in shoulder abduction 90 degree"
58119281|NCT05371301|DRUG|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
58119282|NCT05371301|PROCEDURE|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
58119283|NCT01569828|DRUG|LCZ696A|
58119284|NCT01569828|DRUG|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
57745742|NCT05305196|OTHER|Stretching exercises|"1. Modified sleeper stretch~2. Modified cross-body stretch"
57745743|NCT05305196|OTHER|Hot pack|Hot pack application on shoulder region
57745744|NCT05305196|OTHER|Massage|Massage for upper trapezius
57745745|NCT00057551|BEHAVIORAL|Brief Supportive Psychotherapy|brief supportive psychotherapy
57745746|NCT00057551|BEHAVIORAL|CBASP|psychotherapy developed for chronic depression
57745747|NCT00057551|DRUG|Medication Only|antidepressant medication
57745748|NCT02030015|DRUG|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
57745749|NCT02030015|OTHER|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
57745750|NCT05894434|BEHAVIORAL|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
58449047|NCT06609083|DRUG|Cigarette Full Nicotine|Full nicotine cigarette
57745751|NCT05894434|BEHAVIORAL|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
57745752|NCT04872764|OTHER|duration of hospitalization, mortality rate|duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
58449048|NCT06609083|DRUG|Cigarette Reduced Nicotine|Reduced nicotine cigarette
58449049|NCT02733445|DRUG|dasatinib|
58449050|NCT02733445|DRUG|nilotinib|
58449051|NCT01946217|OTHER|questionnaire administration|Ancillary studies
58449052|NCT05928403|OTHER|total knee prosthesis|Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
58449053|NCT00854230|DRUG|Naltrexone|Naltrexone dose 25-100mg
57958680|NCT05341271|OTHER|Experimental: general reminiscence group (GRG)|"Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences"
57958681|NCT01692301|DRUG|LCZ696|200 mg tablet
58449054|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
58449055|NCT00509470|DRUG|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
58449056|NCT00509470|DEVICE|Amlodipine|
57745753|NCT03331718|DRUG|PGA felt reinforcement|During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.
57745754|NCT05310474|DEVICE|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
57745755|NCT01522417|DRUG|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
57745756|NCT01522417|DRUG|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
57745757|NCT01522417|DRUG|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
57958682|NCT01692301|DRUG|Olmesartan|20 mg and 40 mg capsules
58119285|NCT02002780|BEHAVIORAL|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
58119286|NCT00918671|OTHER|No new specific intervention|No new specific intervention
58119287|NCT01382433|PROCEDURE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
58449057|NCT00183105|BEHAVIORAL|Brief Intervention (adaptation of motivational interviewing)|
58449058|NCT01016600|DRUG|Lenalidomide|
58449059|NCT01016600|DRUG|Azacitidine|
58449060|NCT04851626|OTHER|Hypnotic intervention for persistent pelvic pain.|Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
57745758|NCT06068855|DRUG|BOTOX|Intramuscular Injections
58449061|NCT04851626|OTHER|Control group persistent pelvic pain no intervention.|Control group no hypnotic intervention. Waitlist control.
58449062|NCT06690905|DRUG|Piperacillin-tazobactam administered in a prolonged infusion|For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.
58449063|NCT06690905|DRUG|Piperacillin-tazobactam administered in a standard infusion|For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
58449064|NCT03686904|DRUG|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
58449065|NCT03686904|OTHER|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
58449066|NCT03686904|PROCEDURE|Debridement|Removing dead tissue from infected wound (in clinic)
57745759|NCT06068855|DRUG|Placebo|Intramuscular Injections
57745760|NCT06078462|OTHER|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
57745761|NCT04487093|DRUG|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
57745762|NCT04487093|DRUG|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
57745763|NCT00979836|DRUG|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
57745764|NCT04072510|BEHAVIORAL|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
58119288|NCT01382433|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
57745765|NCT04072510|BEHAVIORAL|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
57745766|NCT05148377|DRUG|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
57745767|NCT05148377|DRUG|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
57745768|NCT06524466|DRUG|Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab|"SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT."
57745769|NCT05850832|DRUG|Esmolol|loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
57745770|NCT05850832|DRUG|Magnesium sulfate|loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
57745771|NCT03253224|DRUG|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
57745772|NCT03253224|DRUG|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
57745773|NCT05656599|DRUG|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
57745774|NCT02184611|DRUG|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
57745775|NCT02184611|DRUG|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
57745776|NCT04964765|DIAGNOSTIC_TEST|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
57745777|NCT04964765|DIAGNOSTIC_TEST|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
57745778|NCT00668954|DIETARY_SUPPLEMENT|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
57745779|NCT00668954|DIETARY_SUPPLEMENT|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
58119289|NCT01382433|BEHAVIORAL|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
58119290|NCT04535609|DRUG|Mavodelpar|Once daily
58119291|NCT04535609|DRUG|Placebo|Once daily
58119292|NCT04318470|DIAGNOSTIC_TEST|mNGS|Metagenomic next generation sequencing for microbial DNA
58313651|NCT04763512|DIETARY_SUPPLEMENT|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
58313652|NCT02312843|BEHAVIORAL|Exercise/Aerobic|
58313653|NCT02312843|BEHAVIORAL|Exercise/Stretching|
58449067|NCT03686904|DRUG|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
58449068|NCT03686904|OTHER|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
58119293|NCT03125083|BIOLOGICAL|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
58119294|NCT03385096|DRUG|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
58119295|NCT03385096|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
58119296|NCT03385096|DRUG|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
58119297|NCT03385096|DRUG|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
58119298|NCT04018144|DIAGNOSTIC_TEST|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
58119299|NCT03392597|BEHAVIORAL|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
58119300|NCT03392597|BEHAVIORAL|Programming-as-Usual|Usual afterschool programming.
58119301|NCT02292238|DRUG|Benfotiamine|"* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
58119302|NCT00977925|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
58119303|NCT00977925|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
58119304|NCT00261729|DRUG|Paroxetine|paroxetine 20 mg
58449069|NCT02493686|DIAGNOSTIC_TEST|audiogram|hearing test
58449070|NCT05682339|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
58449071|NCT05682339|OTHER|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
57745780|NCT02302443|BIOLOGICAL|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
57745781|NCT02302443|BIOLOGICAL|Active comparator|Single dose subcutaneous administration of active comparator
57745782|NCT03837912|BEHAVIORAL|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
57745783|NCT04730622|DIAGNOSTIC_TEST|SARC-F questionnaire|Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
57958683|NCT01692301|DRUG|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
57958684|NCT01692301|DRUG|Olmesartan matching placebo|Olmesartan matching placebo capsule
58119305|NCT00261729|DRUG|Prazosin|Prazosin
58119306|NCT00261729|DRUG|placebo|placebo capsules
58119307|NCT03572933|DRUG|ganaxolone|active drug
58119308|NCT03572933|DRUG|Placebo|inactive
58119309|NCT03152461|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
58119310|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
58119311|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
58119312|NCT00762957|DRUG|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
57958685|NCT01692301|DRUG|amlodipine|amlodipine 2.5 mg or 5 mg tablets
57958686|NCT01692301|DRUG|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
57958687|NCT00663065|DRUG|PAZ-417|
57958688|NCT03557281|DRUG|GSK3036656|GSK3036656 will be administered
57958689|NCT03557281|DRUG|Rifafour e-275|Rifafour e-275 will be administered
57958690|NCT00371878|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (Prevnar)|
58119313|NCT01717014|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
58119314|NCT00770003|DRUG|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
58119315|NCT00770003|DRUG|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
58119316|NCT00258973|PROCEDURE|Carotid Ultrasound performed in office practice|
58119317|NCT01499875|DRUG|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
58449072|NCT05682339|OTHER|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
58119318|NCT02125188|DRUG|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
58119319|NCT02125188|DRUG|saline|saline 100ml ivdrip before surgery
58449073|NCT05682339|OTHER|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
58449074|NCT05432284|DRUG|Placebo|Placebo (ambient air)
58449075|NCT05432284|DRUG|THC|Pure THC vapor
58449076|NCT05432284|DRUG|Beta-Myrcene|Pure beta-myrcene vapor
58449077|NCT01187485|DRUG|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
58449078|NCT01187485|DRUG|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
58449079|NCT01187485|DRUG|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
58449080|NCT06727019|DEVICE|low-level red-light|650-nm low-level red-light
58449081|NCT06727019|DRUG|Atropine (0.01%)|Atropine eye drops at concentration of 0.01%
57745784|NCT04730622|DIAGNOSTIC_TEST|Bone tissue histology|Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
57745785|NCT04730622|DIAGNOSTIC_TEST|Muscle tissue histology|Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
57745786|NCT04730622|DIAGNOSTIC_TEST|Myostatin serum levels|Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
57745787|NCT04730622|DIAGNOSTIC_TEST|Insulin-like growth factor 1 (IGF-1) serum levels|Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
57745788|NCT04730622|OTHER|Frequency food questionnaire|Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
57745789|NCT04730622|OTHER|Gut microbiota profiling|Assessment of gut microbiome composition on stool samples.
57745790|NCT06580457|BEHAVIORAL|Personal Causal Model + Personalized Feedback|Receive a personal causal model of one's personalized causes of substance use/urges, along with a 1-hour, live clinical feedback session to suggest how to apply these insights to one's own recovery.
57745791|NCT00493818|DRUG|GSK690693|
57745792|NCT03719755|PROCEDURE|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
57745793|NCT03719755|PROCEDURE|Normal Saline|Cystoscopic distention media of normal saline
57745794|NCT06579651|DEVICE|Nailfold videocapillaroscopy (NVC)|Nailfold videocapillaroscopy (NVC) is the validated technique to assess SSc microvascular damage and is useful for the early diagnosis and follow-up of SSc micro- angiopathy.
57745795|NCT04960865|OTHER|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
57745796|NCT04960865|OTHER|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
57745797|NCT04960865|OTHER|Rigid Taping|Rigid Taping will be applied.
57745798|NCT01385072|BIOLOGICAL|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
57745799|NCT00002292|DRUG|Pentamidine isethionate|
57745800|NCT01206530|DRUG|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
57745801|NCT01206530|DRUG|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
57958691|NCT01272999|OTHER|No intervention|Non interventional
57958692|NCT04273178|DRUG|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
57958693|NCT04833283|DEVICE|ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)|Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
57958694|NCT04833283|DEVICE|ReOxy Cardio device|Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
57958695|NCT00379860|DRUG|LXR-623|
57958696|NCT02767648|OTHER|proteomic urine analysis|proteomic urine analysis
57958697|NCT05648435|DIAGNOSTIC_TEST|Lithium measures|Measurements of lithium levels in blood and urine
57745802|NCT01206530|DRUG|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
57745803|NCT01206530|DRUG|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
57745804|NCT01206530|DRUG|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
57745805|NCT01206530|DRUG|Bevacizumab|
57745806|NCT06195540|DRUG|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
57745807|NCT06195540|DRUG|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
57745808|NCT03295487|PROCEDURE|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
57745809|NCT03076099|DRUG|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
58449082|NCT04491968|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
58119320|NCT06394323|BEHAVIORAL|Behavioral: My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice), is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
58119321|NCT02776761|BIOLOGICAL|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
58119322|NCT02776761|BIOLOGICAL|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
58119323|NCT02776761|BIOLOGICAL|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
57745810|NCT03076099|OTHER|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
57745811|NCT01922115|DRUG|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
58119324|NCT00716183|BIOLOGICAL|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
58119325|NCT00716183|BIOLOGICAL|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
58119326|NCT00716183|BIOLOGICAL|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
58119327|NCT00716183|DRUG|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
57745812|NCT01922115|DRUG|Placebo|
57745813|NCT00228072|PROCEDURE|Suction-curettage|
57745814|NCT02175355|DRUG|Low dose of Micardis®|
57745815|NCT02175355|DRUG|Medium dose of Micardis®|
57745816|NCT02175355|DRUG|High dose of Micardis®|
58119328|NCT06441981|BEHAVIORAL|Education|Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
58119329|NCT02840383|OTHER|Delayed Intervention|Schools not receiving intervention until two years after implementation.
58119330|NCT02840383|OTHER|Intervention|intervention at the beginning of study.
58119331|NCT03497533|BIOLOGICAL|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
57745817|NCT02175355|DRUG|Hydrochlorothiazide|
57745818|NCT02175355|DRUG|Placebo|
57745819|NCT04481737|BEHAVIORAL|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
57958698|NCT05537805|PROCEDURE|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
58449083|NCT04491968|OTHER|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
58449084|NCT04050618|DEVICE|fanfilcon A test lens|Silicone hydrogel contact lens
58449085|NCT04050618|DEVICE|ocufilcon D control lens|hydrogel contact lens
58449086|NCT04050618|DEVICE|etafilcon A control lens|hydrogel contact lens
58449087|NCT02660853|DIAGNOSTIC_TEST|FEV1|Participants have FEV1 test
58449088|NCT05781074|DRUG|Sintilimab|a PD-1 immune checkpoint inhibitor
57958699|NCT04326608|OTHER|physiotherapy|manual therapy and sef-care exercises
57958700|NCT03711643|PROCEDURE|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
57958701|NCT03711643|DEVICE|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
58119332|NCT04730557|BEHAVIORAL|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
58449089|NCT05781074|DRUG|Lenvatinib|Lenvatinib capsules
58449090|NCT05781074|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
58119333|NCT05611307|DIAGNOSTIC_TEST|Lipid profile|Advanced lipid profile
58119334|NCT05611307|DIAGNOSTIC_TEST|Coronary artery assessment|Coronary artery assessment via CT scans
58119335|NCT05611307|DIAGNOSTIC_TEST|Hormone levels for hypogonadism|Hormone levels for hypogonadism
58119336|NCT03376958|DRUG|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
58119337|NCT00593879|DRUG|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
58449091|NCT02320929|PROCEDURE|Intraoperative flexor tendon sheath irrigation|
58449092|NCT02320929|PROCEDURE|Postoperative flexor tendon sheath irrigation|
58449093|NCT06726148|DRUG|ECI830|Experimental
57745820|NCT04481737|BEHAVIORAL|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
57958702|NCT01158482|PROCEDURE|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
58119338|NCT03850509|DRUG|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
58119339|NCT03850509|DRUG|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
58119340|NCT04659681|DIAGNOSTIC_TEST|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
58449094|NCT06726148|DRUG|ribociclib|Approved medication
58119341|NCT04659681|DIAGNOSTIC_TEST|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
58119342|NCT00545012|DRUG|Levetiracetam|
58119343|NCT05887765|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
58119344|NCT05887765|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
58119345|NCT05887765|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
58449095|NCT06726148|DRUG|fulvestrant|Approved medication
58449096|NCT06727253|DIETARY_SUPPLEMENT|Glycan|The post-operative CD patients will receive an orally administered glycan.
58449097|NCT06726694|DEVICE|class II molar relation correction by advanced molar distalization appliance|correction of class II molar relation by a novel miniscrews distalizer
58449098|NCT04871425|DRUG|Ketamine|IV ketamine
58449099|NCT04871425|DRUG|Fentanyl|IV fentanyl
58449100|NCT03741972|DRUG|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
58449101|NCT02636205|DEVICE|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
58449102|NCT04110782|OTHER|Radium223|55 kBq/ Kg
58449103|NCT04472234|OTHER|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
58449104|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
57745821|NCT01400503|DRUG|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
58119346|NCT04366700|PROCEDURE|Periapical surgery with autograft and collagen membrane|periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
58119347|NCT04366700|PROCEDURE|Periapical surgery with collagen membrane|periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
57745822|NCT02212574|DRUG|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
58119348|NCT04665674|OTHER|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
58119349|NCT02586831|DRUG|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
58119350|NCT02586831|DRUG|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
58119351|NCT02586831|DRUG|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
58119352|NCT02586831|DRUG|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
58119353|NCT02586831|OTHER|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
58119354|NCT02586831|OTHER|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
58119355|NCT02586831|OTHER|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
58119356|NCT02586831|OTHER|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
58119357|NCT03357783|OTHER|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
58119358|NCT06543654|OTHER|Omnichroma|Each participants had two kinds of veneers
58119359|NCT06543654|OTHER|Ceram. X Spectra|Ceram. X Spectra
57745823|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
57745824|NCT02212574|DRUG|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
58119360|NCT01300845|PROCEDURE|Humidification|From randomization, oxygen therapy is humidified
57745825|NCT02212574|DRUG|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
57745826|NCT02212574|DRUG|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
57745827|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
58119361|NCT01300845|PROCEDURE|No Humidification|oxygen therapy is never humidified
58119362|NCT00133718|DRUG|Combined lifestyle intervention and optimisation of pharmacological treatment|"1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care"
58119363|NCT01992107|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
58119364|NCT01992107|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
58119365|NCT01992107|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
58119366|NCT01375881|DRUG|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
58119367|NCT02072356|RADIATION|yttrium Y 90 glass microspheres|Given Interartrial
58119368|NCT02072356|OTHER|laboratory biomarker analysis|Alpha-fetoprotein assay
58119369|NCT02072356|DRUG|TheraSphere|TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
58119370|NCT01165684|DRUG|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
58119371|NCT01165684|DRUG|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
57745828|NCT06185205|DRUG|Accelerated partial breast irradiation|High Dose Rate treatment delivery
57745829|NCT02330133|BEHAVIORAL|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
58119372|NCT01165684|DRUG|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
58119373|NCT01132118|DRUG|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
58119374|NCT00058279|BIOLOGICAL|aldesleukin|
58119375|NCT00058279|BIOLOGICAL|ipilimumab|
58119376|NCT05753657|DRUG|Pioglitazone|hyperinsulinemia and hyperglycemia
58119377|NCT01924871|DRUG|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
58119378|NCT01924871|DRUG|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
57745830|NCT02330133|BEHAVIORAL|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
58119379|NCT02398461|DRUG|rHIgM22|Administered via IV infusion
58119380|NCT02398461|DRUG|Placebo|
58119381|NCT00295854|DRUG|MN-001 BID|Eligible patients received 500 mg MN-001 bid
58119382|NCT00295854|DRUG|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
58119383|NCT00295854|DRUG|Placebo|Eligible patients received placebo
58449105|NCT02316561|RADIATION|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
58449106|NCT06468098|DRUG|IBI363 + chemotherapy|In this group, patients will receive IBI363 and chemotherapy
58449107|NCT06468098|DRUG|IBI363 + Investigator's Choice SOC|In this group, patients will receive IBI363 and Investigator's Choice SOC
57958703|NCT06318910|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
57745831|NCT00989768|DRUG|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
57745832|NCT00989768|DRUG|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
57769695|NCT02538770|OTHER|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
57958704|NCT06318910|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
57958705|NCT03530410|DEVICE|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
58449108|NCT06345625|DIAGNOSTIC_TEST|Cognition|"1. The CatchU® app quantitatively and objectively measures the ability to integrate visual-somatosensory information using reaction time test data.~2. Digit Symbol Substitution test assesses processing speed and attention by requiring individuals to match symbols with corresponding numbers within a specified time frame.~3. Trail Making Test part 1 and 2: assesses cognitive flexibility, visual attention, and task-switching by having individuals connect numbered circles in sequence (part 1) and then alternate between numbers and letters (Part 2).~4. Go/No Go test measures an individual's ability to inhibit a prepotent response (No-Go) and execute a response when required (Go). This test provides insights into executive functioning, particularly inhibitory control."
58449109|NCT06345625|DIAGNOSTIC_TEST|Sensory function|"1. Cervical Sensorimotor control will be measured through a wireless wearable sensor 3D-cervical trainer by Sensamove on the placed on the head of the participant. The 3DCT registers cervical position sense by the Head Repositioning Accuracy test where the subject must relocate the head to the previously memorized (neutral) head position with the eyes closed and the joint position error degrees are registered. Cervical movement sense is examined using 'The Fly'-test where the subject ought to follow a movement pattern displayed on the screen in front of them. The movement of the neck-head unit is there upon tracked by the 3DCT and projected on the screen.~2. Vestibular function will be assessed through 3D-video Head Impulse Testing (vHIT), examining the state of the three semicircular canals by delivering the vestibulo-ocular reflex (vor) gain and vor gain asymmetry.~3. For the assessment of static and dynamic visual acuity, functional Head Impulse Testing (fHIT) will be used."
57958706|NCT03960281|OTHER|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
58449110|NCT06345625|DIAGNOSTIC_TEST|Frailty|Frailty will be assessed using the Fried criteria, comprising 5 categories (each accounting for 1 point if scored positive): Unintentional weight loss (interview), weakness (grip strength with hand-held dynamometer), poor endurance and energy (two statements of the CES-D Depression Scale), slowness (walking speed over 15ft through gait analysis) and low physical activity level (Minnesota Leisure Time Activity questionnaire)(Fried et al., 2001).
57958707|NCT04623450|OTHER|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
57958708|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
57958709|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
57958710|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
57958711|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
57958712|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
57958713|NCT02517775|DIETARY_SUPPLEMENT|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
57958714|NCT02084277|DEVICE|Self-ligating brackets (SLB)|
57958715|NCT02084277|DEVICE|Conventional brackets (CB)|
57958716|NCT03799393|BEHAVIORAL|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
57958717|NCT03799393|BEHAVIORAL|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
57958718|NCT02229071|DRUG|Donafenib(200mg)|Donafenib 200mg,bid,po
57958719|NCT02229071|DRUG|Donafenib(300mg)|Donafenib 300mg,bid,po
58449111|NCT06345625|OTHER|Biomechanical movement analysis|Markers will be placed on the predefined anatomical locations and surface electrodes for electromyography will be applied at the predefined muscle locations following the SENIAM-guidelines. The Microsoft HoloLens 2 is fixated on the participant's head which will, on one hand, provide the cue to the participant for the head movement and on the other hand track eye and head movements. A safety harness is attached to the body and the ceiling of the lab. At the start of the trial, the subject will see a projection by the HoloLens 2 on the real environment moving to the left; right; upward; downward (cue in randomized order) which the participant is ought to follow with eyes and head. First while standing still and second while walking the 10-meter overground walkway at a self-preferred walking speed.
57745833|NCT00989768|DRUG|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
58449112|NCT06345625|OTHER|Screening|"The researcher will visit the possible participants (at their home, community centre, etc.) and after written consent on screening procedure is provided, the tests for eligibility will be performed.~1. Interview: asking about age (years), gender (male/female), medical history and the number of falls in the last 12 months .~2. Timed Up-and-Go (TUG) to check walking ability. TUG is a sensitive and specific measure for identifying risk for falls (Shumway-Cook et al., 2000)."
58449113|NCT06345625|OTHER|Follow up|Participants are followed up for 12 months. They fill in a fall diary and telephone reminders will be performed monthly to encourage participants to complete and return their diaries.
58449114|NCT04803851|DRUG|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
57745834|NCT04648189|DRUG|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
57745835|NCT05350943|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
57745836|NCT05350943|DRUG|Gemcitabine|1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W
57745837|NCT05350943|DRUG|Oxaliplatin|85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W
57745838|NCT05350943|DRUG|Toripalimab|3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W
57745839|NCT05350943|DRUG|Donafenib|0.2mg. P.O, BID, continuously
57745840|NCT03206320|DRUG|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
57745841|NCT03443882|DIETARY_SUPPLEMENT|Astaxanthin|an oral dose form
57745842|NCT06580145|DRUG|L-leucine|"L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally."
57745843|NCT06580145|DRUG|L-lysine|"L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally"
57745844|NCT06643351|OTHER|Standard Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
57745845|NCT06643351|OTHER|Liberalized Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
57745846|NCT05711641|DRUG|Lidocaine 10 MG/ML|Application of 10% topical lidocaine in the external auditory canal of tinnitus patients.
58449115|NCT05682742|DEVICE|Robotic-assisted Surgery|Subjects scheduled to undergo robotic-assisted surgery
58449116|NCT02847559|BIOLOGICAL|Bevacizumab|Given IV
58449117|NCT02847559|PROCEDURE|Electric Field Therapy|Undergo electric field therapy using Optune device
58449118|NCT02847559|DEVICE|NovoTTF-200A Device|Undergo electric field therapy using Optune device
58449119|NCT02847559|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
57745847|NCT05711641|DRUG|Distilled water|Application of distilled water in the external auditory canal of tinnitus patients.
57745848|NCT02646228|OTHER|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
57958720|NCT00724997|BIOLOGICAL|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
57958721|NCT03041285|DRUG|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
58449120|NCT02729441|DRUG|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
58449121|NCT02729441|DRUG|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
58119384|NCT01766674|BEHAVIORAL|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
58119385|NCT03635853|DRUG|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
58119386|NCT05492071|DEVICE|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
58449122|NCT04265807|DEVICE|Active Remote Ischemic Conditioning|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
58449123|NCT04265807|DEVICE|Sham Remote Ischemic Conditioning|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
57958722|NCT03041285|RADIATION|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
58119387|NCT05492071|OTHER|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
58449124|NCT00844376|DRUG|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
58449125|NCT00844376|DRUG|Lipitor|A single dose of 80 mg Lipitor tablet
58449126|NCT04485546|DRUG|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
58449127|NCT00139230|DRUG|Taxotere|
58449128|NCT00139230|DRUG|Cisplatin|
58449129|NCT00139230|DRUG|5-Fluorouracil|
58449130|NCT00139230|DRUG|Leucovorin|
58449131|NCT00139230|DRUG|G-CSF|
58449132|NCT00139230|DRUG|Ciprofloxacin|
58449133|NCT03762031|DRUG|GC4711 30mg|single dose given via a 15 minute intravenous infusion
58449134|NCT03762031|DRUG|GC4711 60mg|single dose given via a 15 minute intravenous infusion
58449135|NCT03762031|DRUG|GC4711 90mg|single dose given via a 15 minute intravenous infusion
57958723|NCT02030743|OTHER|Visual training|6 training sessions with computerised visual attention paradigm
58449136|NCT03762031|DRUG|GC4711 120mg|single dose given via a 15 minute intravenous infusion
58449137|NCT03762031|DRUG|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
58449138|NCT03762031|DRUG|GC4711 75mg|single dose given via a 15 minute intravenous infusion
57958724|NCT05560958|DEVICE|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
58313654|NCT04057092|DIETARY_SUPPLEMENT|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
58313655|NCT02934685|RADIATION|hypofraction|70 Gy in 28 fractions over 5.6 weeks
58313656|NCT02934685|RADIATION|convention|80Gy in 40 fractions over 8 weeks
58313657|NCT02882971|BEHAVIORAL|Pain Assessment|To create an objective observational pain scoring system and validate.
58313658|NCT00362232|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
58313659|NCT00362232|DRUG|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
58313660|NCT00362232|DRUG|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
58313661|NCT00362232|DRUG|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
58313662|NCT02348333|DRUG|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
58449139|NCT03762031|DRUG|GC4711 105mg|single dose given via a 15 minute intravenous infusion
58449140|NCT01108913|DRUG|Bimosiamose|
58449141|NCT01108913|DRUG|Placebo|
58449142|NCT03624842|DRUG|Trappsol (R) Cyclo (TM)|
58449143|NCT06692140|DEVICE|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)|Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
58449144|NCT06692140|DEVICE|PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
58119388|NCT00297271|OTHER|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
58119389|NCT02491788|DRUG|Suvorexant|
58119390|NCT02491788|DRUG|Placebo|
58119391|NCT03982433|BEHAVIORAL|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
57958725|NCT05846776|DEVICE|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
57958726|NCT02772432|BEHAVIORAL|Relaxation Response Resiliency Training for Parents of SPLD|
58119392|NCT03290534|DEVICE|CivaSheet|implanting CivaSheet for localized radiation dose delivery
58119393|NCT06031584|DRUG|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
58119394|NCT03179618|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
58119395|NCT03179618|DRUG|Lipid Regulating Drugs|Mainly including statins
58119396|NCT03179618|DRUG|Coronary Vasodilator|Mainly including nitrates
58119397|NCT03179618|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
58449145|NCT01603589|PROCEDURE|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
58449146|NCT01603589|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
58449147|NCT04034784|DEVICE|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
58449148|NCT04034784|OTHER|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
58449149|NCT02392130|DRUG|Clobetasol propionate 0.05% ointment|
58449150|NCT02392130|DRUG|LEO 130852A gel 1%|
57958727|NCT04856709|PROCEDURE|Abdominal Pectopexy|Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.
57958728|NCT04856709|PROCEDURE|Abdominal Sacral Hysteropexy|Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
57958729|NCT06096558|DIETARY_SUPPLEMENT|Melatonin|5 mg Melatonin in one tablet, 30 minutes before night sleep
58119398|NCT02346201|DRUG|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
58119399|NCT02346201|DRUG|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
58119400|NCT02097121|BIOLOGICAL|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
58119401|NCT05033301|DEVICE|Nurse Ned Clinic|Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
58119402|NCT03437759|BIOLOGICAL|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
58119403|NCT01733719|PROCEDURE|ER plus RFA|
58119404|NCT01733719|PROCEDURE|ER plus APC|2 litres/minute, 70 watts
58119405|NCT00000464|DRUG|amiodarone|
58119406|NCT00000464|DRUG|imipramine|
58119407|NCT00000464|DRUG|mexiletine|
58449151|NCT02392130|DRUG|LEO 130852A placebo gel|
58449152|NCT00366951|PROCEDURE|Foley catheter only|
58449153|NCT00366951|PROCEDURE|Extraamniotic saline infusion|
58449154|NCT00491491|DRUG|ibritumomab tiuxetan|0.4 mCi/kg
58449155|NCT00491491|PROCEDURE|BEAM chemotherapy and autologous stem-cell transplantation|
58449156|NCT04846322|DIAGNOSTIC_TEST|PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)|"1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan."
57745849|NCT01925950|DRUG|orBec|
57745850|NCT01925950|DRUG|Placebo|
58119408|NCT00000464|DRUG|procainamide|
58119409|NCT00000464|DRUG|propafenone|
58119410|NCT00000464|DRUG|quinidine|
58119411|NCT00000464|DRUG|sotalol|
58119412|NCT05694325|OTHER|peripheral blood and bone marrow withdrawal|samples evaluation
58119413|NCT04715607|DIAGNOSTIC_TEST|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
58119414|NCT02304120|OTHER|Proprioceptive postural training|
58449157|NCT00106327|BEHAVIORAL|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
58449158|NCT00106327|BEHAVIORAL|Diet|11 nutrition education sessions
58449159|NCT04566601|DRUG|BI 1358894|Film-coated tablet
58119415|NCT02304120|OTHER|Treadmill training|
57958730|NCT06096558|OTHER|placebo|1 tablet of placebo (starch)
57958731|NCT05474300|OTHER|mechanical ventilation|Pressure controlled ventilation mode on mechanical ventilation
57958732|NCT02577861|PROCEDURE|Biopsy from donor eye|Corneal biopsy from undamaged limbus
57958733|NCT02577861|PROCEDURE|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
57958734|NCT02577861|PROCEDURE|Ophtalmologic examination|"The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
57958735|NCT02577861|PROCEDURE|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
57958736|NCT02577861|PROCEDURE|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
57958737|NCT02577861|PROCEDURE|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
58313663|NCT02348333|DRUG|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
58313664|NCT00802971|DIETARY_SUPPLEMENT|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
58313665|NCT01932385|DRUG|Sorafenib|
58313666|NCT01932385|OTHER|Best Supportive Care|
58313667|NCT04753801|BEHAVIORAL|Thinking, writing and imagination|All participants are asked to take some time to think and write about the respective intervention group's content. In some groups (after the writing exercise (approx. 15min)), participants are also asked to imagine that content or engage in a mindfulness activity or recall task for about 5 minutes.
58313668|NCT03349307|DEVICE|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
58313669|NCT05236530|DRUG|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
57958738|NCT02577861|BEHAVIORAL|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
57958739|NCT02577861|PROCEDURE|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
58313670|NCT05236530|DRUG|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
58313671|NCT05236530|DRUG|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
58313672|NCT05236530|DRUG|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
58313673|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
58313674|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
58313675|NCT05236530|DRUG|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
58313676|NCT05236530|DRUG|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
58313677|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
58313678|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
58313679|NCT03176485|OTHER|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
58119416|NCT02304120|OTHER|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
58119417|NCT06503237|DRUG|Anti-CD19 CART cells will be given IV at split doses.|Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
58119418|NCT02114307|DEVICE|REVITIVE IX|neuromuscular electrical stimulation device
58119419|NCT01319682|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
58119420|NCT01319682|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
58119421|NCT05106933|OTHER|Plain water|Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
58119422|NCT05106933|OTHER|Carborie|carbohydrate drink
58119423|NCT06262698|BEHAVIORAL|Experiment group|The experimental group will receive six weeks of HBM-based training.
58119424|NCT06262698|OTHER|Pre-post test|The TCM Attitude Scale (CACMAS), Medication Health Belief Scale
58119425|NCT00735241|DEVICE|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
58119426|NCT00735241|DRUG|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
58119427|NCT00735241|DRUG|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
58313680|NCT00402935|OTHER|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
58313681|NCT00402935|PROCEDURE|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
58313682|NCT00402935|PROCEDURE|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
57745851|NCT04639128|DEVICE|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
58119428|NCT00735241|DRUG|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
58119429|NCT06144814|DRUG|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
58119430|NCT06144814|DRUG|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
58119431|NCT01350063|DRUG|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
58119432|NCT01350063|DEVICE|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
58119433|NCT01350063|OTHER|No intervention|
58119434|NCT01135771|OTHER|glucose and insulin IV to alter blood glucose|
58119435|NCT00929708|DRUG|AZD3199|Dry powder for inhalation, o.d., 4 weeks
58119436|NCT00929708|DRUG|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
58119437|NCT00929708|DRUG|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
58119438|NCT06099314|DRUG|Fruquintinib+PD-1 inhibitors|Third-line treatment with fruquintinib combined with PD-1 inhibitors. Fruquintinib: 5mg,Oral once daily,2 weeks on/1 week off,Q3W； PD-1 inhibitor：for example, Sintilimab,iv,200mg, Q3W.
58119439|NCT06099314|DRUG|Fruquintinib+TAS-102|Fourth-line treatment with fruquintinib combined with TAS-102 . Fruquintinib: 3-5mg(Depending on the patient's physical condition), Oral once daily,3 weeks on/1 week off,Q4W； TAS-102:orally, 35mg/m2 twice daily (maximum dose 80mg in a single dose) for days 1-5, repeated every 14 days.
58119440|NCT04316858|DRUG|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
58119441|NCT04316858|DIETARY_SUPPLEMENT|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
58119442|NCT04316858|DIETARY_SUPPLEMENT|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
58119443|NCT02030574|DRUG|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
58119444|NCT05544513|DRUG|Ferrous sulfate 3 days week|Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
58119445|NCT05544513|DRUG|Ferrous sulfate daily|Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
58119446|NCT05544513|DRUG|Ferrous sulfate higher concentration|Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
58119447|NCT02498522|DRUG|Metformin|83 patients will continue metformin until end of 1st trimester
58119448|NCT01533168|GENETIC|cytogenetic analysis|
58119449|NCT01533168|GENETIC|nucleic acid sequencing|
58449160|NCT04566601|DRUG|Placebo|Film-coated tablet
57745852|NCT04437784|PROCEDURE|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
57745853|NCT04437784|PROCEDURE|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
58119450|NCT01533168|OTHER|diagnostic laboratory biomarker analysis|
58119451|NCT01533168|OTHER|laboratory biomarker analysis|
58119452|NCT01533168|OTHER|medical chart review|
58119453|NCT04430270|BEHAVIORAL|Survey|Sequential Assignment
58119454|NCT03876574|PROCEDURE|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
58119455|NCT03876574|DRUG|Gemcitabine|Given intra-arterially for 30 minutes
58449161|NCT00241722|DRUG|Alvimopan|
58449162|NCT00241722|DRUG|Placebo|
57745854|NCT04437784|PROCEDURE|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
57745855|NCT02231827|OTHER|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
57745856|NCT03565081|DEVICE|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
57958740|NCT03607864|DEVICE|coral bone graft and xenograft|"ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures."
57958741|NCT02227680|OTHER|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
57958742|NCT02227680|OTHER|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
57958743|NCT04612010|DEVICE|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
57958744|NCT01941407|DRUG|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
57958745|NCT02097147|DRUG|Vilazodone 20 mg|Oral administration, once per day.
57958746|NCT02097147|DRUG|Vilazodone 40 mg|Oral administration, once per day.
58119456|NCT03876574|DRUG|Floxuridine|Given intra-arterially continuously for 14 days
58119457|NCT03876574|DRUG|dexamethasone|Given intra-arterially continuously with 5-FUDR
58119458|NCT03463525|DRUG|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
58119459|NCT03463525|DRUG|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
57745857|NCT00642512|DRUG|dronabinol|10 - 20 mg
58119460|NCT03799601|DRUG|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
58119461|NCT03799601|DRUG|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
58119462|NCT03799601|DRUG|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
58119463|NCT05120011|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
58119464|NCT05120011|DIETARY_SUPPLEMENT|L-leucine|L-leucine
58313683|NCT00402935|PROCEDURE|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
58313684|NCT01687660|OTHER|acupuncture|apply acupuncture to prevent the migraine attack
58119465|NCT05151835|DEVICE|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console \[SGC\], a Patient Side Robot \[PSR\], and a Vision Cart \[VCT\], and is used with an endoscope, Surgical Instruments \[SGI\], and Accessories \[ACC\]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
58119466|NCT01937364|DRUG|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
58119467|NCT01937364|DRUG|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
58119468|NCT00526695|DRUG|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
58119469|NCT00524459|DRUG|docetaxel|
58119470|NCT00524459|DRUG|pegylated liposomal doxorubicin hydrochloride|
58119471|NCT00524459|PROCEDURE|conventional surgery|
58119472|NCT00524459|PROCEDURE|neoadjuvant therapy|
58119473|NCT04572568|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
58119474|NCT02717221|OTHER|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
58119475|NCT04524039|DEVICE|intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.
58119476|NCT04524039|DEVICE|sham intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
58119477|NCT03075137|DEVICE|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
58119478|NCT00672971|OTHER|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
58119479|NCT00672971|OTHER|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
58119480|NCT02494128|OTHER|Education|Education in group leadership
58119481|NCT04253561|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.
58119482|NCT04253561|DRUG|Trastuzumab|600 mg every 3 weeks
58119483|NCT04253561|DRUG|Pertuzumab|420 mg every 3 weeks
58119484|NCT04834245|PROCEDURE|Hydrogel/nano silver-based dressing|compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
58119485|NCT03605706|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
58119486|NCT03605706|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
57745858|NCT00642512|DRUG|ondansetron|8 - 16 mg
57745859|NCT00642512|DRUG|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
57745860|NCT00642512|DRUG|placebo|placebo
57745861|NCT05412641|OTHER|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
58119487|NCT03605706|DRUG|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
58119488|NCT06170580|DIAGNOSTIC_TEST|Conventional duplex|Conventional carotid duplex measurement
58119489|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
58119490|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
58119491|NCT05403021|BEHAVIORAL|GETCare Intervention|This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
58313685|NCT01012050|DEVICE|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
58313686|NCT01012050|OTHER|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
58313687|NCT00067340|DRUG|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
58119492|NCT05799872|BEHAVIORAL|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.
58119493|NCT05799872|BEHAVIORAL|Psychoeducational and Behavioral Therapy (PBT)|The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
58119494|NCT00314171|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
58119495|NCT00314171|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
58119496|NCT05747638|BEHAVIORAL|Revised Children's Manifest Anxiety Scale (RCMAS)|All participants will be invited to complete a paper questionnaire.
58119497|NCT04317625|DIAGNOSTIC_TEST|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
58119498|NCT06215781|PROCEDURE|Fully digital workflow of prosthetic fixed dental crown|The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
58119499|NCT06215781|PROCEDURE|Combined digital and conventional workflows of prosthetic fixed dental crown|The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
58119500|NCT06215781|PROCEDURE|Fully conventional workflow of prosthetic fixed dental crown|The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
58119501|NCT01505465|DRUG|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
58119502|NCT01505465|DRUG|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
58119503|NCT03547947|DEVICE|Medacta Shoulder System|Total Shoulder Arthroplasty
58119504|NCT03872037|PROCEDURE|Selective removal of carious tissue and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
58119505|NCT03872037|PROCEDURE|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
58119506|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin)|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
58119507|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
58119508|NCT01250158|DEVICE|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
58119509|NCT04523805|BEHAVIORAL|Adapted judo programme|"The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~* Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~* Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~* Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~* Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting)."
58119510|NCT03721848|BEHAVIORAL|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
58119511|NCT03721848|BEHAVIORAL|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
58313688|NCT00067340|OTHER|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
57745862|NCT06209879|DRUG|SYSTANE™ Hydration Lubricant Eye Drops|SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
57745863|NCT00803452|DRUG|doxycycline|Oral doxycycline 100mg bid
58119512|NCT03330756|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
58119513|NCT03330756|PROCEDURE|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
58119514|NCT04326842|PROCEDURE|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
58119515|NCT04326842|DEVICE|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
58119516|NCT05737056|OTHER|Management of rheumatoid purpura|Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
58119517|NCT04850638|DRUG|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
58119518|NCT04738279|DEVICE|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
58119519|NCT04738279|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
58119520|NCT04120194|BIOLOGICAL|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
58119521|NCT04120194|BIOLOGICAL|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
58119522|NCT00164320|BEHAVIORAL|TEAM|
58119523|NCT00294723|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
58119524|NCT00294723|DRUG|glimepiride|8 mg capsule
58119525|NCT00294723|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
58119526|NCT00294723|DRUG|placebo|Glimepiride placebo, 8mg capsule
58119527|NCT00294723|DRUG|placebo|Liraglutide placebo, 200 mcl
58119528|NCT00294723|DRUG|placebo|Liraglutide placebo, 300 mcl
58119529|NCT03845179|OTHER|Placebo|Saline infusion
58119530|NCT03845179|OTHER|GIP receptor antagonist|Used for infusion on study days
58119531|NCT03845179|DRUG|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
58119532|NCT03845179|OTHER|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
58119533|NCT05711030|PROCEDURE|Thoracic paravertebral block multiple (3) injections|already described in arm description
58119534|NCT05711030|PROCEDURE|Thoracic paravertebral block single injection|already described in arm description
58119535|NCT00527189|BEHAVIORAL|Balance Exercises|Home based balance exercises based on Otago Exercise programme
58119536|NCT02550756|DRUG|CTNX-4975|
58119537|NCT01530685|DIETARY_SUPPLEMENT|Glycabiane|2 gelule per day for 4 months
58119538|NCT01530685|DIETARY_SUPPLEMENT|placebo|2 gelules per day for 4 months
58119539|NCT01919294|DRUG|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
58119540|NCT01333033|DRUG|Oxaliplatin|Given IV
58119541|NCT01333033|DRUG|Leucovorin Calcium|Given IV
58119542|NCT01333033|DRUG|Fluorouracil|Given IV
58119543|NCT01333033|DRUG|Carboplatin|Given IV
58119544|NCT01333033|DRUG|Paclitaxel|Given IV
58313689|NCT01997580|DRUG|escitalopram|SSRI antidepressant
58119545|NCT01333033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
58119546|NCT01333033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
58119547|NCT01333033|RADIATION|Radiation Therapy|Undergo RT
58119548|NCT01895920|OTHER|Blood sample|
58119549|NCT00854009|DRUG|BLI-489|
58119550|NCT00854009|DRUG|Placebo|
58119551|NCT06545292|DIAGNOSTIC_TEST|Therapeutic drug monitoring with a dried blood spot and microatainer.|Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
58119552|NCT02883790|DIETARY_SUPPLEMENT|Somnage|Melatonin 1mg, Zinc, Magnesium
58119553|NCT02883790|OTHER|Placebo|Placebo
58119554|NCT03895099|DRUG|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
58119555|NCT03895099|DRUG|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
58119556|NCT03895099|DRUG|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
58119557|NCT03895099|DRUG|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
58119558|NCT03895099|DRUG|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
58119559|NCT06369415|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)|"Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour"
58119560|NCT02410252|DEVICE|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
58119561|NCT02466100|BEHAVIORAL|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
58119562|NCT05197712|BIOLOGICAL|25 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
58119563|NCT05197712|BIOLOGICAL|50 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
58119564|NCT06301997|DIETARY_SUPPLEMENT|ZAX.1400.P03|ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
58119565|NCT06301997|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
58119566|NCT02213796|DRUG|Meropenem|
58119567|NCT06032351|OTHER|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
58119568|NCT06032351|OTHER|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
58119569|NCT05140642|OTHER|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
58119570|NCT05140642|OTHER|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
58119571|NCT01094444|OTHER|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
58119572|NCT01897974|OTHER|Survey|Families complete survey to measure medication compliance.
58119573|NCT05763966|OTHER|No intervention|Observational study where participants are followed over time
58119574|NCT00759148|DRUG|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
58119575|NCT00759148|OTHER|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
58119576|NCT03229252|DRUG|Placebo Inhalation Solution|Normal Saline Inhalation Solution
58119577|NCT03229252|DRUG|SPX-101|SPX-101 Inhalation Solution
58119578|NCT06222710|PROCEDURE|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
58119579|NCT06222710|PROCEDURE|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
58449163|NCT03921034|DRUG|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
58449164|NCT03921034|DRUG|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
58119580|NCT02557945|DRUG|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
58119581|NCT02557945|DRUG|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
58119582|NCT06313047|DRUG|Doxorubicin|each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
58119583|NCT03262974|DIAGNOSTIC_TEST|PCR|PCR
58119584|NCT03262974|DIAGNOSTIC_TEST|HPLC-UV|HPLC-UV
58119585|NCT03438448|OTHER|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
58119586|NCT03379077|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
58119587|NCT01026961|DRUG|Phenylephrine HCL|Phenylephrine HCL 10mg
58119588|NCT01026961|DRUG|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
58449165|NCT01839058|OTHER|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
58449166|NCT06344728|DRUG|Brensocatib Oral Solution|Brensocatib solution
58449167|NCT06344728|DRUG|Brensocatib Oral Tablet|Brensocatib tablet
57745864|NCT00803452|DRUG|azithromycin|topical 1% azithromycin daily to eye
57745865|NCT03399422|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
57745866|NCT03399422|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
57745867|NCT02339961|RADIATION|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
57745868|NCT04840550|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
57745869|NCT04840550|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
57958747|NCT02097147|DRUG|Paroxetine 20 mg|Oral administration, once per day.
57745870|NCT01473667|PROCEDURE|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
57958748|NCT02097147|DRUG|Placebo|Oral administration, once per day.
57958749|NCT00455598|DRUG|ISIS 113715|doses of 100 and 200 mg per week
57745871|NCT01473667|PROCEDURE|Local site infiltration|Local site infiltration using 2% lidocaine
57745872|NCT04199858|BEHAVIORAL|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
57745873|NCT04199858|BEHAVIORAL|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
57745874|NCT04199858|BEHAVIORAL|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
57745875|NCT04199858|OTHER|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
57745876|NCT04796441|BIOLOGICAL|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
57745877|NCT03156790|DRUG|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
57958750|NCT06098235|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
57958751|NCT06098235|BEHAVIORAL|ORIENT diet intervention|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
57958752|NCT01039337|OTHER|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
57958753|NCT01039337|OTHER|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
57958754|NCT01039337|OTHER|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
58449168|NCT01086774|OTHER|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
58449169|NCT05356832|DIAGNOSTIC_TEST|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
58449170|NCT02735148|OTHER|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~1. Body Weight Supported Treadmill Training,~2. Conventional Training and~3. Combined Training."
58449171|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
58449172|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
58449173|NCT02583919|DRUG|Placebo|once weekly dosing for 26 weeks
58449174|NCT03953833|BIOLOGICAL|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
58119589|NCT01527448|DRUG|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
57769696|NCT02276391|DRUG|Telmisartan/HCTZ combination|
57769697|NCT02276391|DRUG|Telmisartan|
58449175|NCT04257890|BEHAVIORAL|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
57745878|NCT06172972|BEHAVIORAL|Atraumatic nursing care|Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
57745879|NCT02453685|DRUG|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
57745880|NCT02453685|DRUG|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
57745881|NCT02453685|DRUG|insulin aspart|Injected s.c./subcutaneously once daily.
57745882|NCT02668523|DEVICE|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
57745883|NCT01438502|DRUG|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
57745884|NCT00871052|DRUG|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
57745885|NCT05081453|DEVICE|pavlik harness|The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
57745886|NCT04560491|DIAGNOSTIC_TEST|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
57745887|NCT02400138|OTHER|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
57745888|NCT02400138|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
57745889|NCT04650555|DRUG|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
57745890|NCT06732453|OTHER|Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)|Two one-hour chair-based yoga sessions that will include gentle movements, breathing practices, and meditation, along with home practice.
57745891|NCT01279499|DRUG|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
57745892|NCT01279499|DRUG|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
57745893|NCT01279499|DRUG|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
57745894|NCT01279499|DRUG|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
57745895|NCT00345449|BEHAVIORAL|Decision Aid|
57745896|NCT01342874|DIETARY_SUPPLEMENT|Inositol|inositol exposure in early GDM
57745897|NCT00174525|DRUG|AAB-001|
57745898|NCT05441085|DEVICE|programed intermittent epidural bolus interval 90 (EI90)|programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
57745899|NCT05069090|BEHAVIORAL|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
57745900|NCT05426434|DRUG|Dihydroartemisinin-Piperaquine (DP)|DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
57745901|NCT05426434|DRUG|Sulfadoxine pyrimethamine (SP)|SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
57745902|NCT00253669|OTHER|laboratory biomarker analysis|
57958755|NCT03504878|PROCEDURE|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
57745903|NCT00253669|OTHER|physiologic testing|
57745904|NCT00253669|PROCEDURE|management of therapy complications|
58119590|NCT01482156|DRUG|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
58119591|NCT01236833|DRUG|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
58119592|NCT04416984|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
58119593|NCT04416984|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
58119594|NCT04416984|DRUG|Fludarabine|Chemotherapy for lymphodepletion
58119595|NCT04416984|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
57745905|NCT05938985|DIAGNOSTIC_TEST|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
57745906|NCT03531424|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
57745907|NCT03531424|PROCEDURE|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
57745908|NCT06336616|BEHAVIORAL|Behavior Activation|Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
57745909|NCT06733350|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsy
57745910|NCT06733350|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58119596|NCT04795661|DRUG|Pembrolizumab|Administered intravenous (IV)
58119597|NCT03929939|BEHAVIORAL|Exercise training and healthy eating (overseen by IEEM research team)|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
58119598|NCT02335970|OTHER|Training group|"After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
58119599|NCT05181982|OTHER|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
58119600|NCT04806984|OTHER|Participant outreach|Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
58449176|NCT04257890|OTHER|Education material about IGD|Printed education material introducing IGD will be distributed.
58449177|NCT04257890|OTHER|Education material about CBT|Printed education material introducing CBT will be distributed.
57745911|NCT06733350|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57745912|NCT06733350|OTHER|Patient Observation|Undergo standard AS
57745913|NCT06733350|OTHER|Questionnaire Administration|Ancillary studies
57745914|NCT06733350|DRUG|Therapeutic Testosterone|Given via injection, gel, lotion, or transdermal patch
57745915|NCT03709368|OTHER|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
57769698|NCT02771730|BIOLOGICAL|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
58449178|NCT00750724|DRUG|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
58449179|NCT00750724|DRUG|normal saline,2 ml., intraarticular weekly for 5 weeks|
58449180|NCT05456880|BIOLOGICAL|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
58449181|NCT02322437|OTHER|Home treatment|Patients are treated at home whenever possible and appropriate
58449182|NCT02322437|OTHER|Treatment As Usual|Patients are treated at a mental hospital
58449183|NCT05946941|DRUG|Deucravacitinib|Specified dose on specified days
58449184|NCT05946941|OTHER|Placebo|Specified dose on specified days
58119601|NCT00696709|BIOLOGICAL|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
58119602|NCT00696709|BIOLOGICAL|Comparator: Placebo|Placebo; 4-dose regimen administered \~30 days apart.
58119603|NCT01273610|DRUG|Lapatinib|250 mg tablets
58119604|NCT01273610|DRUG|Trastuzumab|Intravenous injection
58119605|NCT01273610|OTHER|laboratory biomarker analysis|
58119606|NCT01273610|OTHER|pharmacological study|
58119607|NCT04504513|DRUG|Trilaciclib|"Trilaciclib is a highly potent, selective, and reversible cyclin-dependent kinase 4/6 inhibitor administered intravenously prior to chemotherapy for chemotherapy-induced myelosuppression (CIM).~In patients being treated for SCLC, trilaciclib transiently maintains G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thus protecting the cells from damage by cytotoxic chemotherapy (myelopreservation). This can reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions."
58119608|NCT05939661|RADIATION|Radiation|Neoadjuvant radiation therapy : 5Gyx5
58119609|NCT05939661|DRUG|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
58119610|NCT05939661|PROCEDURE|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
58119611|NCT06404593|DIAGNOSTIC_TEST|Blood sampling|Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
58119612|NCT05169164|OTHER|No intervention, observational|No intervention, observational
58119613|NCT01199406|DRUG|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
58119614|NCT06256250|PROCEDURE|pulpectomy treatment will be done using the adaptive xp endo shaper.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
58119615|NCT06256250|PROCEDURE|pulpectomy treatment will be done using FANTA AF baby files.|"the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~* BTF1: #20, taper 04, Yellow~* BTF2: #25, taper 04, Red~* BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown."
58449185|NCT05219682|OTHER|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
57745916|NCT03709368|BEHAVIORAL|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
57769699|NCT02771730|BIOLOGICAL|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
57769700|NCT02771730|OTHER|Placebo Comparator|Oral sucrose capsules
57769701|NCT02771730|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
57769702|NCT04885387|DEVICE|chest CT|chest CT pectus deformities diagnostic
58119616|NCT06256250|PROCEDURE|pulpectomy treatment will be done using hand k files.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
58449186|NCT05768412|PROCEDURE|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
58449187|NCT01201720|PROCEDURE|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
58449188|NCT06176742|OTHER|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
58119617|NCT03726190|PROCEDURE|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
58119618|NCT05065879|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
58119619|NCT03604120|DEVICE|Preoxygenation with high flow therapy by nasal cannula|Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
58119620|NCT03604120|DEVICE|Preoxygenation by standard Facial mask|"* For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation."
58119621|NCT05600374|DEVICE|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
58119622|NCT04495491|OTHER|pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
58119623|NCT04495491|OTHER|plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
58119624|NCT04495491|OTHER|mixing mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
58119625|NCT03091166|DRUG|Dexmedetomidine|
58119626|NCT00106262|DRUG|Velcade (bortezomib)|
58119627|NCT00106262|DRUG|Irinotecan|
58119628|NCT00093964|DRUG|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
58119629|NCT00093964|DRUG|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
58119630|NCT01103557|PROCEDURE|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
58119631|NCT03294512|BEHAVIORAL|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
58119632|NCT04385446|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
58119633|NCT00861783|DRUG|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
58119634|NCT00861783|DRUG|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
58119635|NCT00585351|DRUG|Ranitidine|50 mg single dose injection of Ranitidine
58119636|NCT00585351|DRUG|Placebo|50 mg single dose injection of normal saline (placebo)
58119637|NCT00585351|OTHER|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
58119638|NCT00585351|OTHER|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
58119639|NCT05828550|DIAGNOSTIC_TEST|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
58119640|NCT04522414|OTHER|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
58119641|NCT01968109|BIOLOGICAL|Relatlimab|
58119642|NCT01968109|BIOLOGICAL|Nivolumab|
58119643|NCT01968109|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab
58119644|NCT03267264|DEVICE|BD Nano™ vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~2. subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
58449189|NCT06176742|OTHER|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
58449190|NCT04692675|DIAGNOSTIC_TEST|mpMRI|3T endorectal coil MR imaging of the prostate gland
57745917|NCT03709368|BEHAVIORAL|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
57745918|NCT03709368|BEHAVIORAL|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
57745919|NCT03709368|BEHAVIORAL|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
57745920|NCT03709368|OTHER|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
57745921|NCT02060851|OTHER|standard PN|Group 1: a control group who received standard PN
57745922|NCT02060851|DRUG|Vifor|iron sucrose, 200 μg/kg per day, was given everyday with PN,
57745923|NCT02060851|DRUG|Vifor and EPO|EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
58119645|NCT03267264|DEVICE|NovoFine® vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~2. subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
58119646|NCT03267264|DEVICE|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~2. subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
58119647|NCT03267264|DEVICE|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~2. subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
58119648|NCT03368989|DRUG|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
58119649|NCT02546713|OTHER|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
58119650|NCT02546713|OTHER|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
58449191|NCT00882232|DEVICE|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
58449192|NCT04579341|DIETARY_SUPPLEMENT|probiotics|probiotics administration
57745924|NCT06363929|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
57745925|NCT00037219|DRUG|Anidulafungin, VER002|
57745926|NCT00163579|DRUG|Bryophyllum|
57745927|NCT00163579|OTHER|Placebo|
57745928|NCT05340881|BEHAVIORAL|Bright Light Exposure|Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
57745929|NCT05340881|BEHAVIORAL|Dim Light Exposure|A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
57745930|NCT05340881|OTHER|Cognitive Assessment|Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
58119651|NCT01886456|DEVICE|Laser trabeculoplasty|
58449193|NCT02910466|DRUG|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
58449194|NCT04197349|BIOLOGICAL|ALD1910|Single Dose IV infusion
58449195|NCT04197349|BIOLOGICAL|Sumatriptan|Single dose subcutaneous injection
58449196|NCT04197349|BIOLOGICAL|ALD1910|Single dose subcutaneous injection
58119652|NCT01798745|DRUG|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
58119653|NCT01798745|OTHER|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
58119654|NCT01610258|OTHER|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
58119655|NCT02404597|DEVICE|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
58119656|NCT01641744|BEHAVIORAL|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
58119657|NCT01641744|BEHAVIORAL|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
58119658|NCT04573842|OTHER|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
58119659|NCT00278200|BIOLOGICAL|Inactivated EBV-infected vaccine|
58119660|NCT00457522|BEHAVIORAL|Nurse/community health worker telephone intervention|
58119661|NCT05522608|PROCEDURE|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
58119662|NCT01127009|DRUG|bortezomib|Given IV
58119663|NCT01127009|DRUG|mitoxantrone hydrochloride|Given IV
58119664|NCT01127009|DRUG|etoposide|Given IV
58119665|NCT01127009|DRUG|cytarabine|Given IV
58119666|NCT01127009|OTHER|flow cytometry|Correlative studies
58119667|NCT00048360|DRUG|Extended-release bupropion hydrochloride|
58119668|NCT03761836|DEVICE|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
58119669|NCT06422117|DRUG|HSK16149 20mg-40mg BID|Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
58119670|NCT06422117|DRUG|Placebo|Placebo, oral, 2 capsules twice daily
58119671|NCT00482313|DRUG|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
58119672|NCT00482313|DRUG|Placebo|Sugar pill
58449197|NCT02423057|DRUG|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
57745931|NCT05586568|DRUG|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
57745932|NCT05586568|DRUG|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
57769703|NCT04885387|DEVICE|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
58119673|NCT03613350|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
58119674|NCT02444312|BEHAVIORAL|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
58119675|NCT02444312|BEHAVIORAL|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
58119676|NCT02281409|BIOLOGICAL|Mogamulizumab (KW-0761)|
58119677|NCT02384681|OTHER|Exposure to auditory fatigue|12-hour auditory exposure
58449198|NCT03140397|DIETARY_SUPPLEMENT|Placebo|
58449199|NCT03140397|DIETARY_SUPPLEMENT|6-prenylnaringenin|
58449200|NCT03140397|DIETARY_SUPPLEMENT|8-prenylnaringenin|
58449201|NCT05946603|DRUG|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
58449202|NCT05946603|DEVICE|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
58449203|NCT05946603|PROCEDURE|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
58449204|NCT03623763|DIAGNOSTIC_TEST|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
58449205|NCT02412228|DRUG|Ixazomib|"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
58449206|NCT02412228|DRUG|Cyclophosphamide|"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"
58119678|NCT01573091|PROCEDURE|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
58119679|NCT00425815|DRUG|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
58119680|NCT00425815|OTHER|Placebo|Placebo comparison
58119681|NCT00679783|DRUG|AZD2281|PARP inhibitor Olaparib tablets, oral
58119682|NCT03591549|DRUG|Faslodex|intramuscular injection monthly
58119683|NCT03591549|DRUG|Zoladex|intramuscular injection monthly
58449207|NCT02412228|DRUG|Dexamethasone|"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
58119684|NCT00836927|DRUG|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
58119685|NCT00836927|DRUG|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
58119686|NCT01892774|PROCEDURE|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
58119687|NCT03596996|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
58119688|NCT03596996|DIETARY_SUPPLEMENT|Placebo|Placebo with identical appearance comparison intervention arm
58119689|NCT03425864|PROCEDURE|connective tissue graft|patient will receive immediate implant and connective tissue graft
58449208|NCT01231919|DRUG|Akt inhibitor MK2206|Given PO
58449209|NCT01231919|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
58449210|NCT01231919|OTHER|pharmacological study|Correlative studies
58449211|NCT03764644|BEHAVIORAL|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
58449212|NCT03764644|BEHAVIORAL|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
58449213|NCT05252949|DIETARY_SUPPLEMENT|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
58119690|NCT03425864|DEVICE|immediate implant|patient will receive immediate implant with connective tissue graft.
58119691|NCT03304509|OTHER|Telematic follow-up|Telematic follow-up by using a platform with videoconference
58119692|NCT00598559|DRUG|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
58119693|NCT05671289|DIAGNOSTIC_TEST|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
58119694|NCT01502618|BEHAVIORAL|Focus Group|N/A. Protocol is the focus group
58119695|NCT03788577|DIETARY_SUPPLEMENT|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
58119696|NCT03788577|DIETARY_SUPPLEMENT|Placebo|Placebo
58119697|NCT02607800|DRUG|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
58119698|NCT02607800|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
58119699|NCT01840956|BIOLOGICAL|HAVG|HAVG is implanted into patients' arm.
58119700|NCT04244747|DEVICE|induction of labor by breast stimulation|
57745933|NCT05586568|DRUG|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
57745934|NCT03097705|DIAGNOSTIC_TEST|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
57745935|NCT02115633|DEVICE|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
57745936|NCT02115633|DEVICE|Walkasins OFF|Subjects will be wearing a device that is turned off.
57745937|NCT03167307|DRUG|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
57745938|NCT03167307|DRUG|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
57745939|NCT06079905|OTHER|Nonoperative treatment|Nonoperative treatment
58119701|NCT04244747|DEVICE|induction of labor by catheter balloon|
58449214|NCT05252949|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
58119702|NCT03247296|DRUG|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
58119703|NCT04521959|PROCEDURE|Blood flow restricted and normal aerobic exercise and resistance exercise|Interventions of the same duration and intensity will be applied to two groups.
58119704|NCT03339037|DEVICE|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
58119705|NCT03339037|DEVICE|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
58119706|NCT01871779|OTHER|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
58119707|NCT01871779|OTHER|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
57745940|NCT06079905|OTHER|Operative treatment|Operative treatment
57745941|NCT00744770|DRUG|TMC278|
57745942|NCT05186948|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
58313690|NCT04925635|BEHAVIORAL|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
58449215|NCT01493401|PROCEDURE|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
58449216|NCT00638534|DRUG|Telithromycin (HMR3647)|
58449217|NCT01395901|DRUG|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
57745943|NCT04460118|PROCEDURE|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
57745944|NCT04460118|PROCEDURE|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
57745945|NCT04618874|DIAGNOSTIC_TEST|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
57745946|NCT02254226|DRUG|Salmeterol Diskus low|
57745947|NCT02254226|DRUG|Salmeterol Diskus high|
57745948|NCT02254226|DRUG|Salmeterol MDI low|
57745949|NCT02254226|DRUG|Salmeterol MDI high|
57745950|NCT01926730|OTHER|Restriction diet|Selected food items will be limited in the participants diet
57745951|NCT06732362|OTHER|Different DPN ratings|According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
57745952|NCT02452723|BIOLOGICAL|ISC-hpNSC|
57745953|NCT03909126|BIOLOGICAL|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
57745954|NCT03909126|BIOLOGICAL|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
57745955|NCT04762381|DRUG|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
57745956|NCT04762381|OTHER|Placebo|Saline
57745957|NCT04176627|DEVICE|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
57769704|NCT04190147|OTHER|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
57769705|NCT03707444|DEVICE|Scrambler Therapy Device|Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
57769706|NCT05712161|DEVICE|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
57769707|NCT05962593|OTHER|Telephone call|The patients will be randomized for a postoperative telephone call
58119708|NCT04895410|BIOLOGICAL|Lemzoparlimab|Intravenous (IV) infusion
58119709|NCT04895410|DRUG|Dexamethasone|Oral tablet or IV infusion/injection
58119710|NCT04895410|DRUG|Carfilzomib|IV infusion
58119711|NCT04895410|DRUG|Pomalidomide|Oral capsule
58119712|NCT04895410|BIOLOGICAL|Daratumumab|Subcutaneous (SC) injection
58119713|NCT03843957|OTHER|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
58119714|NCT03843957|OTHER|mPATH-Checkin|The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
58449218|NCT01395901|DRUG|Ondansetron|"Single dose Ondansetron IV:~* 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg;~* 13 years to less than 17 years dose: 4 mg"
57745958|NCT05031364|BEHAVIORAL|Behavioral Interventions for Anxiety in Children with Autism (BIACA)|In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
57745959|NCT05031364|BEHAVIORAL|Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)|Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
57745960|NCT02013622|DRUG|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
57745961|NCT05786248|OTHER|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
57745962|NCT06734026|BEHAVIORAL|Cafe Therapy|Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher. Participants will complete at least 18 sessions of training within the time frame. Participants will run the Café with supervision from a researcher, serving customers prepackaged food and drinks per our protocol, along with guidance and direction from a therapist, once a week. Participants will be responsible for interacting with customers and arranging supplies. On a weekly basis, participants will be asked how they feel (for example tired, stressed, overwhelmed, etc) before and after their session and to rate how well they performed in the café.
57745963|NCT01944865|OTHER|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
57745964|NCT01944865|OTHER|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
57745965|NCT05290831|DEVICE|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
57745966|NCT04431466|DRUG|Ivermectin|SOC plus different dosing regimens of Ivermectin
57745967|NCT04431466|OTHER|Standard of Care|Standard treatment for COVID-19
58119715|NCT03843957|OTHER|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
58449219|NCT01395901|DRUG|Placebo to Ondansetron|
58449220|NCT01395901|DRUG|Placebo to Palonosetron|
57769708|NCT06167629|DIAGNOSTIC_TEST|PET 18F-PSMA|Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.
58119716|NCT03843957|OTHER|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
58119717|NCT01006707|DRUG|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
58449221|NCT03413124|DRUG|MGL-3196 Tablet|MGL-3196 in Tablet form
58449222|NCT03413124|DRUG|MGL-3196 Capsule|MGL-3196 in Capsule form
58449223|NCT03776747|DRUG|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
58449224|NCT03776747|DRUG|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
58449225|NCT03776747|DIAGNOSTIC_TEST|Vitals|
58449226|NCT03776747|DIAGNOSTIC_TEST|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
58449227|NCT03776747|DIAGNOSTIC_TEST|Initial protocol MRI scan|Initial scan to determine placement
58449228|NCT03087513|DRUG|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
58449229|NCT03087513|DRUG|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
58449230|NCT01826656|PROCEDURE|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
58449231|NCT01826656|RADIATION|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
58449232|NCT01826656|RADIATION|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
58449233|NCT01826656|RADIATION|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
58449234|NCT06396819|DRUG|collagen-povidone solution|Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
58449235|NCT03610841|DIAGNOSTIC_TEST|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
58449236|NCT03610841|DIAGNOSTIC_TEST|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
58449237|NCT06437262|DRUG|0.20% CHX gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
58449238|NCT06437262|DRUG|0.20% CHX and Cymenol gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
58449239|NCT06437262|DRUG|0.20% CHX gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
58449240|NCT06437262|DRUG|0.20% CHX and Cymenol gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
58449241|NCT03800238|BEHAVIORAL|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
58449242|NCT03800238|BEHAVIORAL|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
58449243|NCT03066063|DEVICE|iCare|The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.
58449244|NCT03066063|BEHAVIORAL|Amblyopia standard of Care|The amblyopia standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily
58449245|NCT03066063|BEHAVIORAL|CI standard of Care|A dosage-matched CI standard of Care group will be prescribed pencil pushups for 20 minutes per day, five days per week.
58449246|NCT00148148|DRUG|caspofungin|
58449247|NCT00148148|DRUG|liposomal amphotericin B|
58119718|NCT02916173|DRUG|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
58449248|NCT06235567|DRUG|Dextenza 0.4Mg Ophthalmic Insert|This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
58449249|NCT06235567|DRUG|topical prednisolone acetate 1% (PredForte) eye drops|The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
58449250|NCT01125800|DRUG|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
58449251|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
58449252|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
58449253|NCT04222296|DEVICE|Fitting strategy of cohlear implant of hearing aid|To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
58449254|NCT02342964|OTHER|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
58449255|NCT04601012|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
58449256|NCT05078372|DRUG|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
58449257|NCT05078372|DRUG|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
58449258|NCT04780165|DEVICE|Blephademodex|During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
58449259|NCT02401165|OTHER|Blood test|blood test
58449260|NCT05443724|DRUG|CVL-231 30 mg|Oral tablets
57745968|NCT05068817|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
57745969|NCT05068817|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
57745970|NCT05068817|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
57745971|NCT00617578|DEVICE|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
57745972|NCT00617578|DEVICE|ATP One Shot OFF|Standard defibrillation shock delivery
57745973|NCT02291731|DRUG|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
57745974|NCT03556111|PROCEDURE|Sticky bone augmentation|"1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement"
57745975|NCT02744222|BIOLOGICAL|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
57745976|NCT02744222|BIOLOGICAL|Avonex®|30 mcg intramuscularly once a week
57745977|NCT02744222|BIOLOGICAL|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
57745978|NCT02744222|OTHER|Placebo|intramuscularly once a week (0,5 ml)
57745979|NCT03393000|DRUG|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
57745980|NCT03393000|OTHER|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
57745981|NCT02939040|BEHAVIORAL|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
57745982|NCT01926756|PROCEDURE|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
57745983|NCT01926756|PROCEDURE|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
57745984|NCT06262568|OTHER|assess the nurse knowledge and practices.|assess the nurse knowledge and practices.
57745985|NCT06533033|DRUG|Rapid Release Capsules Melatoni|"Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks."
57745986|NCT06533033|DRUG|Triamcinolone Acetonide ointment, Kenacort-A orabase|"Twenty-five will be given topical corticosteroid applied twice to three times daily.~Topical antifungal will be applied three to four times daily. This conventional treatment will be given to the patients for 8 weeks"
57745987|NCT03977519|PROCEDURE|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
58449261|NCT06361758|DRUG|Cadonilimab+Lenvatinib|Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
57745988|NCT03977519|PROCEDURE|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
57745989|NCT05353998|OTHER|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
57745990|NCT05353998|OTHER|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
57769709|NCT05971160|BEHAVIORAL|Financial education videos|Brief videos providing structured information on managing one's money
57769710|NCT05971160|OTHER|Microgrant|$150 stipend
57769711|NCT05971160|BEHAVIORAL|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
57769712|NCT02881008|DRUG|Entecavir|
57769713|NCT02881008|DRUG|Myrcludex B|
57769714|NCT05342103|PROCEDURE|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
57769715|NCT02149602|RADIATION|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
58449262|NCT04359199|RADIATION|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
58449263|NCT04359199|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
58449264|NCT04359199|DRUG|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
58449265|NCT04359199|DRUG|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
58449266|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
58449267|NCT01860833|DRUG|Ibuprofen|time of treatment 14 days
58449268|NCT01860833|DRUG|Celecoxib|time of treatment 14 days
58449269|NCT01860833|DRUG|Diclofenac|time of treatment 14 days
57958756|NCT03504878|PROCEDURE|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
57769716|NCT02451501|DEVICE|AKITA|
57958757|NCT02230631|OTHER|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
58313691|NCT04925635|BEHAVIORAL|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
58313692|NCT02470741|DRUG|Letrozole|
58313693|NCT02470741|OTHER|Placebo|
58313694|NCT02145390|PROCEDURE|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
58449270|NCT03373929|DEVICE|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
58449271|NCT03373929|DEVICE|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
57769717|NCT03221504|OTHER|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
57958758|NCT01573715|DRUG|NIMBEX|
57958759|NCT01573715|DRUG|NIMBEX|
57958760|NCT01573715|OTHER|WITHOUT NIMBEX|
57958761|NCT00292825|DEVICE|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
57958762|NCT00292825|DEVICE|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
57958763|NCT00529256|BEHAVIORAL|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
57958764|NCT02615444|DIETARY_SUPPLEMENT|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
57958765|NCT02615444|DIETARY_SUPPLEMENT|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
57958766|NCT01758250|OTHER|Acoustic Radiation Force Impulse (ARFI)|
57958767|NCT01758250|OTHER|Laser Doppler Flowmetry (LDF)|
58313695|NCT02145390|RADIATION|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
58449272|NCT01381393|DRUG|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
58449273|NCT06538922|BEHAVIORAL|Single Session Family Intervention|A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
58449274|NCT03148366|DRUG|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
57958768|NCT01758250|OTHER|Laser Doppler Perfusion Imaging (LDI)|
57958769|NCT01758250|OTHER|Optical Coherence Tomography (OCT)|
57958770|NCT01758250|OTHER|Orthogonal Polarization Spectral Imaging (OPSI)|
58449275|NCT03148366|DRUG|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
58449276|NCT00811603|DRUG|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
58449277|NCT00047515|DRUG|Alcon Investigational Agent|
57745991|NCT04088019|DRUG|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
57745992|NCT05028725|DEVICE|EsophaCap Sponge|Non-invasive strategy to sample esophageal tissue
57745993|NCT05028725|PROCEDURE|Chromoendoscopy|Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus
57745994|NCT05028725|DEVICE|EsoCAN assay|Biomarker Test
57745995|NCT06059222|DRUG|Romosozumab|Romosozumab 210 mg/2.34 ml from baseline to month 11
57745996|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 12
57745997|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
57958771|NCT01758250|OTHER|Nail fold video capillaroscopy (NVC)|
57958772|NCT06240884|PROCEDURE|Infraspinatus-teres minor interfascial block|After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
58119719|NCT02916173|DRUG|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
58119720|NCT04652570|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
58119721|NCT03954028|PROCEDURE|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
58119722|NCT03602690|DRUG|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
58449278|NCT02166619|DEVICE|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
58119723|NCT00004659|PROCEDURE|irradiation|
58449279|NCT06109064|BIOLOGICAL|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
58449280|NCT06109064|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
58449281|NCT06109064|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
58449282|NCT06109064|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
58119724|NCT00004659|PROCEDURE|radiosurgery|
58119725|NCT04562649|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
58449283|NCT05268510|DRUG|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
57745998|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 6
58119726|NCT04562649|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
58313696|NCT02145390|BEHAVIORAL|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
57745999|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5
57746000|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 5 and month 18
57746001|NCT04357327|DIAGNOSTIC_TEST|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
57746002|NCT04250727|DEVICE|ZYN|30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
57746003|NCT00363519|DRUG|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
58119727|NCT01767597|OTHER|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
58119728|NCT01767597|OTHER|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
58449284|NCT05268510|DRUG|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
58449285|NCT05268510|DRUG|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
57746004|NCT00363519|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
57746005|NCT03298646|DRUG|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
57746006|NCT03298646|DRUG|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
57746007|NCT00877331|BEHAVIORAL|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
57746008|NCT02872701|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
57746009|NCT02872701|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
57958773|NCT06240884|PROCEDURE|interscalene block|The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
58119729|NCT00582309|PROCEDURE|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
58119730|NCT00582309|PROCEDURE|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving \>80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
58119731|NCT00582309|PROCEDURE|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
58119732|NCT04657484|DRUG|Medium dose prednisolone|Same as arm description
58449286|NCT05268510|DRUG|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
58449287|NCT04668768|DRUG|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
58449288|NCT00670904|OTHER|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
58449289|NCT00670904|OTHER|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
58449290|NCT01722019|DEVICE|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
58449291|NCT01722019|DEVICE|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
58449292|NCT04355403|DEVICE|Hyalo Gyn gel in prefilled applicators|One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
57746010|NCT02872701|PROCEDURE|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
57746011|NCT02816138|DRUG|Nicotine|Open-label transdermal nicotine patch
57746012|NCT05591339|BIOLOGICAL|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
57746013|NCT05591339|BIOLOGICAL|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
57746014|NCT00003038|DRUG|doxorubicin hydrochloride|
57746015|NCT00003038|DRUG|suramin|
57746016|NCT01970462|DRUG|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
57746017|NCT01970462|DRUG|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
57746018|NCT01911728|DRUG|MDV3100|Oral
57746019|NCT01911728|DRUG|Pioglitazone|Oral
57746020|NCT01911728|DRUG|Warfarin|Oral
57746021|NCT01911728|DRUG|Omeprazole|Oral
57746022|NCT01911728|DRUG|Midazolam|Oral
57746023|NCT03230227|DRUG|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
57746024|NCT03230227|DRUG|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
57746025|NCT00122226|DRUG|Lopinavir/ritonavir + zidovudine + lamivudine|
57746026|NCT00122226|DRUG|Lopinavir/ritonavir + nevirapine|
57958774|NCT06195722|OTHER|simulation|parenteral drug simulation
57958775|NCT01536054|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
57746027|NCT03508648|DRUG|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
58119733|NCT04657484|DRUG|Low dose prednisolone|Same as arm description
58119734|NCT05325242|DEVICE|Embozene particles|Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
58119735|NCT01118728|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
58119736|NCT02219191|DRUG|puerarin tablet 50 mg|
58119737|NCT02219191|DRUG|Atorvastatin tablet 20 mg|Approval No.: H19990258
58119738|NCT02946957|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
58119739|NCT02946957|BEHAVIORAL|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
58119740|NCT05808556|DEVICE|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
58119741|NCT05808556|DEVICE|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
58119742|NCT01533428|DRUG|Capsaicin 8%|Capsaicin 8% transdermal delivery system
58119743|NCT01533428|DRUG|Placebo|Placebo Patch
58119744|NCT04990830|DRUG|Inhaled Low molecular weight heparin|Application with Soft Mist Inhaler
58119745|NCT04990830|DRUG|Standard Treatment|Control Group
58119746|NCT02521675|BEHAVIORAL|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
58119747|NCT02521675|BEHAVIORAL|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90min after lunch These activities shall not exceed one hour"
58119748|NCT02521675|BEHAVIORAL|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
58119749|NCT02521675|DEVICE|Holter Glycemic Ipro2, Medtronic|
58119750|NCT04902807|BIOLOGICAL|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
58119751|NCT01137305|OTHER|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
58119752|NCT02717975|PROCEDURE|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
58119753|NCT02717975|PROCEDURE|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
58119754|NCT00870909|PROCEDURE|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
58313697|NCT02145390|BEHAVIORAL|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
58313698|NCT03631641|BIOLOGICAL|Nivolumab|Given IV
58313699|NCT01192815|DRUG|erlotinib hydrochloride|Given orally or via gastronomy tube
58313700|NCT01192815|RADIATION|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
57746028|NCT03508648|DRUG|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
57746029|NCT04530448|DRUG|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
57746030|NCT04530448|OTHER|Standard of Care|Standard of Care treatment
57746031|NCT02486484|DRUG|ziv-aflibercept|zaltrap injection
57746032|NCT01746342|DEVICE|Effective continuous positive airway pressure (CPAP)|
57746033|NCT01746342|DEVICE|Sham continuous positive airway pressure (CPAP)|
58313701|NCT01192815|OTHER|pharmacogenomic studies|Optional correlative studies
58119755|NCT00870909|PROCEDURE|sham tDCS|sham condition as delivered by the stimulator
58119756|NCT03999437|DRUG|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
58119757|NCT03999437|DRUG|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
58119758|NCT03999437|DRUG|Vehicle Control|Topical liquid solution
58119759|NCT03712657|COMBINATION_PRODUCT|ERAS|"1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging."
58119760|NCT03557138|BEHAVIORAL|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
58119761|NCT01048333|DRUG|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
58119762|NCT01048333|DRUG|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
58119763|NCT01048333|DRUG|Placebo|Placebo Diskus and Placebo Turbuhaler
58119764|NCT04037566|GENETIC|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
58119765|NCT04037566|DRUG|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
58119766|NCT04037566|DRUG|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
58119767|NCT02398318|DEVICE|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
58119768|NCT02398318|DEVICE|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
58119769|NCT01787825|DEVICE|PillCam SB2 capsule|Capsule Endoscopy system
58119770|NCT01787825|DEVICE|CapsoCam SV-1|Capsule endoscopy
58119771|NCT01127490|DRUG|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
58119772|NCT01127490|PROCEDURE|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
58119773|NCT05760079|DIETARY_SUPPLEMENT|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
58119774|NCT01480531|DRUG|Clevidipine|"Clevidipine administration begins in the ER or ICU~* Clevidipine is again administered post op when blood pressure control is required.~* Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~* Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~* Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~* Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
58119775|NCT02318927|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
58119776|NCT04082975|DRUG|NVP-1203|Oral dose for 7 days
58119777|NCT04082975|DRUG|NVP-1203-R|Oral dose for 7 days
57958776|NCT01536054|DRUG|sirolimus|Given PO
57958777|NCT01536054|OTHER|laboratory biomarker analysis|Correlative studies
57958778|NCT01536054|BIOLOGICAL|sargramostim|Given SC
58119778|NCT04082975|DRUG|NVP-1203 placebo|Oral dose for 7 days
58119779|NCT04082975|DRUG|NVP-1203-R placebo|Oral dose for 7 days
58119780|NCT05502315|DRUG|Cabozantinib|40 mg taken orally
58119781|NCT05502315|DRUG|Nivolumab|480 mg by infusion
58119782|NCT03849781|DEVICE|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
58119783|NCT00880282|BIOLOGICAL|cixutumumab|Given IV
58119784|NCT00880282|DRUG|temsirolimus|Given IV
58119785|NCT00880282|OTHER|pharmacological study|Correlative studies
58119786|NCT00880282|OTHER|laboratory biomarker analysis|Correlative studies
58119787|NCT02051127|OTHER|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
58119788|NCT02210884|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
58119789|NCT04638686|DRUG|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
58119790|NCT04638686|DRUG|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
58119791|NCT00952484|BIOLOGICAL|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
58119792|NCT00952484|BIOLOGICAL|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
58119793|NCT01919268|DEVICE|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
58313702|NCT01192815|OTHER|gene expression analysis|Correlative studies
58449293|NCT05900037|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
58449294|NCT05900037|DEVICE|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
58449295|NCT01469273|DRUG|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
58449296|NCT03853135|DIAGNOSTIC_TEST|measurement of serum endocan|measurement of serum levels of endocan
57958779|NCT04770051|PROCEDURE|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
58449297|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
58449298|NCT06627335|DRUG|TCS|Topical corticosteroid
58449299|NCT03122210|DEVICE|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
57958780|NCT03066427|DRUG|Sunitinib|Sunitinib 50 mg/d
58449300|NCT04121702|PROCEDURE|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
58449301|NCT04157803|DIAGNOSTIC_TEST|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
58449302|NCT00778115|DRUG|Loperamide HCl 2 mg and simethicone 125 mg tablets|
58449303|NCT02447614|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy
58449304|NCT02447614|OTHER|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
58449305|NCT02447614|OTHER|no treatment|just regular follow-up
58449306|NCT00970918|PROCEDURE|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
58449307|NCT00970918|BIOLOGICAL|Blood sample testing for hs-CRP|one time, blood sample taking
58449308|NCT03737136|DRUG|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
58449309|NCT03667157|DRUG|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
58449310|NCT03667157|DRUG|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
58449311|NCT04410718|OTHER|Glycaemic levels|Glycaemic levels during admission for COVID-19
58449312|NCT05915299|DEVICE|OCS Heart|"The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
58449313|NCT06727214|DRUG|Chemotherapy with platine|medical records that patients received neoadjuvant systemic chemotherapy platine based
58449314|NCT00268918|DRUG|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
58449315|NCT00268918|DRUG|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
57746034|NCT03511833|DRUG|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg
57746035|NCT03511833|DRUG|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
58449316|NCT04033744|PROCEDURE|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
57746036|NCT06579131|BEHAVIORAL|sitting position|The participants' seating positions will be assessed, and evaluations will be made based on this.
57746037|NCT01201148|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
57746038|NCT02925611|DRUG|Isoflurane|
57958781|NCT00303914|PROCEDURE|assessment of therapy complications|
58449317|NCT02173106|DRUG|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
58119794|NCT01919268|DEVICE|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
58119795|NCT05396456|PROCEDURE|Muscle Fiber Fragment (MFF) Injections|The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
58119796|NCT05914519|PROCEDURE|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
58119797|NCT05914519|PROCEDURE|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
58119798|NCT04615156|DRUG|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
58119799|NCT05233683|DRUG|Caudal block|Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
58119800|NCT05233683|DRUG|Dorsal penile nerve block plus ring block|"It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective."
58119801|NCT05233683|PROCEDURE|Circumcision with Plastibell|Circumcision with Plastibell
58119802|NCT05233683|PROCEDURE|Conventional Dissection Method|Conventional Dissection Method
58119803|NCT00003520|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
58119804|NCT01614509|PROCEDURE|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
58119805|NCT01614509|PROCEDURE|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
58119806|NCT02957279|DRUG|Antibiotics|In the sepsis group, antibiotics were used when needed.
58119807|NCT06337006|PROCEDURE|Placement of the laryngeal mask airway|Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
58119808|NCT05417048|DIAGNOSTIC_TEST|Blood Sample|Up to 5mL of blood via venipuncture
58119809|NCT03482479|DRUG|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
58119810|NCT03482479|OTHER|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
58119811|NCT00927810|DRUG|Canakinumab|
58119812|NCT02450565|OTHER|Questionnaire|
58119813|NCT03177356|PROCEDURE|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
58119814|NCT03177356|PROCEDURE|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
58119815|NCT01549288|BEHAVIORAL|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
58119816|NCT01549288|OTHER|no dietetic input|continuation of anti-epileptic medication without any dietetic input
58119817|NCT04133181|DEVICE|3D guide|Use of a 3D guide in endodontic surgery
58119818|NCT04133181|DEVICE|Mock guide|Use of a mock guide in endodontic surgery
58119819|NCT01441557|DRUG|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
58119820|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
58119821|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
58119822|NCT05092347|DRUG|REGN5459|Administered by intravenous (IV) infusion
58119823|NCT05092347|DRUG|REGN5458|Administered by intravenous (IV) infusion
57746039|NCT02925611|DRUG|Desflurane|
58119824|NCT02437214|OTHER|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
58119825|NCT05265026|BEHAVIORAL|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at \> 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: \>85% of HRmax).
57746040|NCT05612074|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
57746041|NCT02451527|DRUG|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
57746042|NCT02451527|DRUG|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
57746043|NCT05040009|BEHAVIORAL|integrated foot care program|"1. Regular foot care and examination by an adequately trained professional: -~2. Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~1. Foot ulcers and their consequences~2. Preventative foot self-care behaviors~3. Wearing adequately protective footwear~4. Undergoing regular foot checks~5. Practicing proper foot hygiene~6. Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
57746044|NCT04041960|OTHER|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
57746045|NCT01235390|DIETARY_SUPPLEMENT|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
58119826|NCT00295126|PROCEDURE|cellular therapy : Autologous platelet concentrate (APC)|
57746046|NCT01892059|PROCEDURE|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
57746047|NCT01892059|PROCEDURE|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
57746048|NCT03311373|DRUG|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
57746049|NCT03311373|DRUG|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
57746050|NCT03311373|DRUG|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
57746051|NCT03311373|DRUG|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
57746052|NCT01634126|BEHAVIORAL|1 FIT kit|Patient receives 1 FIT
57746053|NCT01634126|BEHAVIORAL|2 FIT kit|Patient receives 2 FIT kits
57746054|NCT02058615|BEHAVIORAL|Male Spouse Transition Toolkit|
57746055|NCT04080050|DRUG|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
57746056|NCT03676855|PROCEDURE|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
57746057|NCT02245958|OTHER|No Intervention|No treatment (intervention) was administered.
57746058|NCT00623090|BEHAVIORAL|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
57746059|NCT00623090|BEHAVIORAL|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
57746060|NCT00623090|BEHAVIORAL|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
57746061|NCT01831622|DRUG|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
57746062|NCT01831622|DRUG|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
57746063|NCT06152133|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
57746064|NCT05227833|DRUG|Vonoprazan fumarate (Vonaspire)|Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.
57746065|NCT05227833|DRUG|Pantoprazole 40mg|Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.
57746066|NCT05227833|OTHER|Placebo|No Intervention
57746067|NCT06195982|DIETARY_SUPPLEMENT|ketone ester|500 mg/kg of ketone ester administered approximately 1 hour prior to the maximal exercise testing and 250 mg/kg administered approximately 30 minutes prior to submaximal exercise testing
57746068|NCT06195982|DIETARY_SUPPLEMENT|placebo|ketone-free placebo administered approximately 1 hour prior to the maximal exercise testing and ketone-free placebo administered approximately 30 minutes prior to submaximal exercise testing
57746069|NCT05976282|OTHER|Fecal Immunochemical Test|The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.
57746070|NCT05976282|OTHER|Septin9 Test|Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
57746071|NCT01936480|DRUG|Moxifloxacin 400mg once time|
57746072|NCT03031587|OTHER|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
58119827|NCT05611268|DRUG|Pentoxifylline|Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
58119828|NCT02933593|DRUG|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
58119829|NCT02933593|DRUG|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
58119830|NCT02933593|DRUG|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
58449318|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
57746073|NCT03031587|DEVICE|MRI|cardiac MRI
57746074|NCT04227015|DRUG|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
57746075|NCT02539810|DEVICE|Renal artery Angioplasty plus stenting.|renal artery stenting
57746076|NCT02539810|DRUG|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
57746077|NCT06579833|RADIATION|Histotripsy|Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.
57746078|NCT02794376|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|
57746079|NCT02794376|BEHAVIORAL|Waiting Period|
57746080|NCT01918410|DEVICE|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
57746081|NCT01918410|DEVICE|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
57746082|NCT00048464|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
58119831|NCT00521170|DRUG|Levocetirizine|
57746083|NCT04216810|OTHER|muscle strengthening exercises|segmental stabilization exercises
57958782|NCT00303914|PROCEDURE|cognitive assessment|
58119832|NCT00303745|DRUG|capecitabine|
58119833|NCT00303745|DRUG|irinotecan hydrochloride|
58119834|NCT00601484|DRUG|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
58119835|NCT00601484|DRUG|Placebo|placebo IV, single dose
58119836|NCT04834557|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58119837|NCT04834557|DRUG|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58119838|NCT04834557|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
58119839|NCT06543693|OTHER|ultrasound training|PoCUS training
58119840|NCT03674008|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
57746084|NCT04216810|OTHER|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
57746085|NCT03963908|BEHAVIORAL|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
58449319|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
57746086|NCT03963908|BEHAVIORAL|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
57746087|NCT01485042|DRUG|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
57746088|NCT04508595|DIAGNOSTIC_TEST|RestEaze|Wearable band to detect leg movements of sleep
57746089|NCT04846959|DRUG|Risankizumab|Subcutaneous Injection
57746090|NCT04846959|DRUG|Comparator|Subcutaneous or Intravenous Injection
57746091|NCT05741879|BEHAVIORAL|Gamified exercise training|"Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s)."
57746092|NCT05741879|BEHAVIORAL|Standard Care|This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
57746093|NCT02919800|BIOLOGICAL|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
57746094|NCT02919800|OTHER|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
57746095|NCT03722927|DRUG|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
57746096|NCT03722927|DRUG|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
58119841|NCT03674008|DRUG|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
58119842|NCT06380465|OTHER|"The water extract of Biang variety purple sweet potato"|"Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring"
58119843|NCT02896465|OTHER|Oral rehydration solution|
58119844|NCT02896465|OTHER|Zinc|
58119845|NCT02896465|OTHER|Human milk oligosaccharides|
58313703|NCT01192815|RADIATION|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
58313704|NCT01192815|OTHER|biopsy|Optional correlative studies
58313705|NCT01192815|OTHER|pharmacological study|Optional correlative studies
58119846|NCT02896465|OTHER|Breastfeeding|
58119847|NCT05751629|DRUG|Dostarlimab|Dostarlimab was administered.
58119848|NCT05751629|DRUG|Bevacizumab|Bevacizumab was administered.
58119849|NCT05751629|DRUG|Niraparib|Niraparib was administered.
58119850|NCT01977430|DRUG|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
58119851|NCT00850902|OTHER|High Humidity (HH)|High Humidity Level
57746097|NCT02077179|BEHAVIORAL|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
58119852|NCT00850902|OTHER|Moderate Humidity|Moderate Humidity Level
57746098|NCT04547608|OTHER|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
57958783|NCT00303914|PROCEDURE|psychosocial assessment and care|
58313706|NCT01192815|OTHER|laboratory biomarker analysis|Optional correlative studies
58449320|NCT04707495|DEVICE|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
58449321|NCT04707495|DEVICE|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
58449322|NCT06344429|DEVICE|Stellest Lenses|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~A Group：Stellest Lenses spectacle (ST)"
58449323|NCT06344429|COMBINATION_PRODUCT|Stellest Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~B Group：Combined Treatment"
58449324|NCT06344429|DRUG|Single vision Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~C Group：0.05% Atropine with single vision"
58449325|NCT02072265|DEVICE|Infrared thermal images|
58449326|NCT01522326|DRUG|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
58449327|NCT01522326|DRUG|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
58449328|NCT02249936|DRUG|AZD1722|
58449329|NCT02249936|DRUG|Omeprazole|
58449330|NCT01692977|OTHER|neuropsychological assessment|
58449331|NCT04608604|OTHER|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
58449332|NCT04268108|BIOLOGICAL|liquid tumor infiltrating lymphocytes|Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
57746099|NCT00003500|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57746100|NCT02186210|DEVICE|prewarming|recovery slope StO2
57958784|NCT00609479|PROCEDURE|Osteosynthesis|"1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
57958785|NCT00679497|BIOLOGICAL|MVA-B|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
57958786|NCT00679497|BIOLOGICAL|Placebo|-3 immunisations at week 0, 4 and 16
57958787|NCT00852995|BIOLOGICAL|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
57958788|NCT00852995|BIOLOGICAL|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
57958789|NCT04794712|DEVICE|Venous reflux tools (Ultrasound and Photo plethysmography (PPG))|Venous reflux tools Pain assessment tools
57958790|NCT01312597|OTHER|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
57958791|NCT02122237|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
57958792|NCT03236558|PROCEDURE|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
57958793|NCT01031914|DEVICE|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
57958794|NCT00001133|DRUG|Indinavir sulfate|
57958795|NCT00001133|DRUG|Ritonavir|
58119853|NCT03820193|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
58313707|NCT01192815|OTHER|questionnaire administration|Optional ancillary studies
58313708|NCT01192815|OTHER|enzyme-linked immunosorbent assay|Optional correlative studies
58313709|NCT01192815|OTHER|polymorphism analysis|Optional correlative studies
58313710|NCT06469086|OTHER|Clinical data collection|The clinical significance of appendicoliths in the conservative management of acute complicated appendicitis with abscesses.
57746101|NCT03211286|DRUG|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
57746102|NCT03211286|DRUG|Saline Solution|saline solution 100 mL intravenous
57746103|NCT03610087|BEHAVIORAL|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
57746104|NCT03610087|BEHAVIORAL|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
57746105|NCT02316795|PROCEDURE|Sentinel lymph node biopsy|
57746106|NCT02316795|DEVICE|Goggle-based device with light-emitting diodes (LED)|
57746107|NCT02316795|DRUG|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
57746108|NCT04515459|OTHER|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~* 2 OTE will be performed before the surgery,~* 6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
57746109|NCT00885196|DRUG|Placebo|
57746110|NCT00885196|DRUG|AEB071|
57746111|NCT01506895|DRUG|darapladib|Experimental compound 160 mg dose
57746112|NCT01506895|DRUG|placebo|Placebo to match
57746113|NCT04499651|BEHAVIORAL|Navigation|Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
57746114|NCT05853887|BEHAVIORAL|iNUDGE|Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
57746115|NCT03869398|DIETARY_SUPPLEMENT|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
58119854|NCT03820193|DRUG|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
57746116|NCT03869398|DIETARY_SUPPLEMENT|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
57746117|NCT05049408|DIAGNOSTIC_TEST|MMP-1 Enzyme Linked Immunosorbent assay (ELISA)|The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
57746118|NCT05918705|PROCEDURE|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
57746119|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
57746120|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
57746121|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
57746122|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
57746123|NCT01552850|DRUG|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
57746124|NCT02652988|OTHER|Active-tDCS|Active home-based tDCS applied at home.
57746125|NCT02652988|OTHER|Sham-tDCS|Sham home-based tDCS applied at home.
57746126|NCT06100133|DIETARY_SUPPLEMENT|Ketone ester|Up to 100g ketone ester daily for 56 days
57746127|NCT05365893|COMBINATION_PRODUCT|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
57746128|NCT05365893|OTHER|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
57746129|NCT06732713|OTHER|Swiss Ball|Swiss ball exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes , 3 to 4 sessions per week for 8 weeks
57746130|NCT06732713|OTHER|Frenkel exercise|Frenkel exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes, 3 to 4 sessions per week for 8 weeks
58119855|NCT03820193|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
58119856|NCT03820193|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
58119857|NCT03820193|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
58119858|NCT03820193|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
58313711|NCT03957993|OTHER|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
58313712|NCT03957993|OTHER|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
58313713|NCT04224116|DRUG|Tranexamic acid injection|to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
58313714|NCT04224116|DRUG|SSI|Serum Salin isotonic injected
57746131|NCT03633968|PROCEDURE|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
57746132|NCT01474096|OTHER|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
57746133|NCT05728723|DEVICE|Android Application|Android Application for 3 months
57746134|NCT05728723|BEHAVIORAL|Pharmacy education|Pharmacy education in hypertensive patients
57746135|NCT05629702|DRUG|Nabiximols|Oromucosal spray
57746136|NCT05629702|DRUG|Temozolomide|Oral capsule
57746137|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
57746138|NCT02248792|DRUG|Methotrexate|
57746139|NCT06731894|PROCEDURE|Biospecimen Collection|Undergo urine sample collection
57746140|NCT06731894|DRUG|Cannabidiol|Given PO
57746141|NCT06731894|DRUG|Dronabinol|Given PO
57746142|NCT06731894|DRUG|Placebo Administration|Given PO
57746143|NCT06731894|OTHER|Survey Administration|Ancillary studies
57746144|NCT06732219|BEHAVIORAL|Functional Communication Training|Functional Communication Training (FCT) focuses on teaching an appropriate functional communicative response (FCR) to access the reinforcer maintaining severe problem behavior (SPB). This procedure involves selecting an appropriate topography for the FCR (e.g., touching a card, exchanging a picture) and using a backward chaining approach. The training will progress from full physical prompts to partial prompts and eventually to independent, unprompted responses, all within a trial-based format.
57746145|NCT06732219|BEHAVIORAL|Extinction-Correlated Stimuli|A distinct extinction-correlated stimulus (e.g., a laminated picture card) will be used in all treatment sessions where severe problem behavior (SPB) is subject to extinction contingencies. This stimulus will also be present during relapse challenges (described below). The selection of the stimulus will be individualized for each participant to ensure it has no prior association with treatment-related contexts, minimizing the influence of pre-existing learning histories.
57746146|NCT06732219|BEHAVIORAL|Caregiver Fading|"Behavioral Skills Training (BST) will be used to teach caregivers to (1) implement the behavioral intervention package (i.e., differential reinforcement of alternative behavior with extinction) in a controlled setting with confederates and (2) transition into behavioral sessions with the participant while gradually phasing out the clinical therapist.~Caregivers will begin by implementing mastered intervention components alongside the therapist during sessions with the participant, where the therapist will provide in-situ feedback. Once the caregiver demonstrates at least 80% treatment integrity across two consecutive sessions, the therapist will systematically increase their distance by 3 meters each session (maintaining at least 80% integrity) until they are fully removed from the treatment area."
57746147|NCT06732219|BEHAVIORAL|Structured-Probe Schedule Thinning|"Once a clinically significant decrease in severe problem behavior (SPB) is achieved (defined as an 80% reduction from the baseline mean rate), schedule thinning will be implemented. This process involves reducing the density of reinforcement by introducing a multiple schedule with alternating periods where reinforcement for the functional communication response (FCR) is available and unavailable.~Schedule thinning will begin immediately at the terminal schedule, with an 80% reduction in reinforcer density from treatment. Specifically, the FCR will be placed on extinction for 540 seconds and reinforced for 60 seconds during each session. This schedule was selected based on prior analyses of effective reductions in reinforcer density. If the treatment effect remains strong (defined as maintaining at least an 80% reduction in SPB relative to baseline), schedule thinning will proceed at this step until three consecutive sessions show consistent results."
57746148|NCT06732219|BEHAVIORAL|Multiple-Context Generalization Training|In multiple-context training, treatment will be implemented at the terminal schedule (i.e., after completing schedule thinning) in new contexts, including unique locations and with different individuals, distinct from the setting used during the initial treatment phase.
58313715|NCT03950882|DRUG|PXL770|Oral capsule
57746149|NCT03263429|DRUG|Glutaminase Inhibitor CB-839|Given by mouth
57746150|NCT03263429|BIOLOGICAL|Panitumumab|Given by vein
57746151|NCT03263429|DRUG|Irinotecan Hydrochloride (phase I only)|Given by vein
57746152|NCT03263429|OTHER|Laboratory Biomarker Analysis|Correlative studies
57746153|NCT03263429|OTHER|Pharmacological Study|Correlative studies
57746154|NCT03263429|DEVICE|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
57746155|NCT02652481|DEVICE|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~\* May only be used internationally outside the US"
57746156|NCT00236873|DRUG|topiramate|
57769718|NCT03221504|OTHER|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
57769719|NCT03837392|DIAGNOSTIC_TEST|Baseline Assessment (18-26 weeks pregnant)|At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
58313716|NCT03950882|DRUG|Placebo|Oral capsule
58313717|NCT01919853|BEHAVIORAL|Mindfulness-Based Stress Reduction|
58313718|NCT01919853|BEHAVIORAL|Attention Control|
58313719|NCT00719667|OTHER|coronary artery bypass grafting|on pump off pump
58119859|NCT05770258|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
57746157|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
57746158|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
57746159|NCT04944641|BEHAVIORAL|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
57746160|NCT04944641|DRUG|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
57746161|NCT03621644|RADIATION|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
57746162|NCT04445636|DRUG|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
57746163|NCT04445636|DRUG|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
58313720|NCT00989300|DRUG|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
57746164|NCT04955912|OTHER|music medicine|To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
57746165|NCT03510572|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
57746166|NCT03270449|OTHER|Multidisciplinary intervention|10 week multidisciplinary education and exercise
57746167|NCT00293267|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
57746168|NCT00293267|DRUG|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
57746169|NCT06463288|PROCEDURE|Jacobsons Breathing Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
57746170|NCT06463288|PROCEDURE|Pranayama Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
57746171|NCT03860584|DIETARY_SUPPLEMENT|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
57746172|NCT03860584|DIETARY_SUPPLEMENT|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
57746173|NCT05485805|DRUG|Naproxen sodium and caffeine (BAY2880376)|Tablet, oral use, single dose
57746174|NCT05485805|DRUG|Naproxen sodium (Aleve)|Tablet, oral use, single dose
57746175|NCT05485805|DRUG|Caffeine|Tablet, oral use, single dose
57746176|NCT05485805|DRUG|Placebo|Tablet, oral use, single dose
57746177|NCT06733870|PROCEDURE|guided immediate implant surgery|fully guided immediate implant placement and loading
57769720|NCT03837392|BEHAVIORAL|Online Intervention and Phone Coaching Interventions|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
58119860|NCT01876186|DRUG|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
58119861|NCT01876186|DRUG|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
58119862|NCT05277727|DIETARY_SUPPLEMENT|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
58119863|NCT05277727|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily with food (morning and evening).
58119864|NCT00599183|OTHER|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
58119865|NCT03822052|OTHER|Lactated ringers|IV fluid
58313721|NCT00989300|DRUG|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
58313722|NCT00989300|OTHER|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
58313723|NCT04956809|DRUG|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
57746178|NCT06244277|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
57746179|NCT06244277|DRUG|Zolpidem|Zolpidem 10Mg Tab 10mg tablet once daily
57746180|NCT04711915|DRUG|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
57746181|NCT04711915|DRUG|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
57746182|NCT03608930|DEVICE|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
57746183|NCT01760850|OTHER|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
57746184|NCT01760850|OTHER|educational intervention|Engage in an educational information session for diabetes
57746185|NCT01760850|OTHER|questionnaire administration|Ancillary studies
58119866|NCT03822052|OTHER|5% dextrose lactated ringers|IV fluid
58119867|NCT05882474|DEVICE|PaCO2|Level of partial pressure of carbon dioxide
57746186|NCT00002109|DRUG|Thymopentin|
57746187|NCT00002109|DRUG|Stavudine|
57746188|NCT00002109|DRUG|Zidovudine|
57746189|NCT00002109|DRUG|Zalcitabine|
57746190|NCT00002109|DRUG|Didanosine|
57746191|NCT04255628|DIAGNOSTIC_TEST|FDG PET|Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
57746192|NCT01474733|OTHER|educational intervention|series of lectures and workshops on health literacy
57746193|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
58119868|NCT01016652|DEVICE|etafilcon A multifocal contact lens|low-add multifocal contact lens
57746194|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
57746195|NCT03058211|DIAGNOSTIC_TEST|Echocardiography|Standard protocols
58119869|NCT01016652|DEVICE|etafilcon A Contact Lens|standard sphere contact lens
58119870|NCT06504472|DIETARY_SUPPLEMENT|ProstaThrive™ Supplement|Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.
58119871|NCT06504472|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
58119872|NCT05149742|BEHAVIORAL|Cognitive and audiometry evaluation|"For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires"
58313724|NCT04956809|DRUG|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
58313725|NCT04910464|DRUG|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
58313726|NCT04910464|OTHER|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
58313727|NCT00557232|DRUG|bevacizumab|1.25mg/month
58313728|NCT03320811|OTHER|Data record|
57746196|NCT03058211|DIAGNOSTIC_TEST|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
57746197|NCT00446810|DRUG|Benfotiamine|
57746198|NCT00446810|DRUG|Placebo|
57746199|NCT02432872|DRUG|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
57746200|NCT02432872|DRUG|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
57746201|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
57746202|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
57746203|NCT00854633|DRUG|Talactoferrin|Enteral, 150 mg/kg twice per day
57746204|NCT00854633|DRUG|Placebo|Oral, twice per day
57746205|NCT03490513|DRUG|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
57746206|NCT03490513|DRUG|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
57746207|NCT05031702|DIETARY_SUPPLEMENT|Camellia Sinensis leaf extract|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
57746208|NCT05031702|COMBINATION_PRODUCT|Placebo|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
57746209|NCT02658864|DRUG|lafutidine|comparison of different doses, sex and medication conditions
57746210|NCT02219022|OTHER|Control group|
57746211|NCT02219022|OTHER|Experimental group|
57746212|NCT06134349|OTHER|Lithium MR imaging|After obtaining written informed consent and within four weeks of reaching a stable therapeutic serum lithium concentration, lithium MR imaging will be performed using a 7 Tesla MR system (Achieva, Philips Medical Systems, Eindhoven, The Netherlands) with a dual-tuned 7Li/1H volume head coil (RAPID Biomedical GmbH, Rimpar, Germany). Various approaches, including whole-brain, voxel-wise, parcellation, mean, and regions of interest, will be applied to measure lithium concentrations.
57746213|NCT04899050|DRUG|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
57746214|NCT06381089|DEVICE|Robotic Rehabilitation|Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.
57746215|NCT06381089|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.
57746216|NCT02767115|DIETARY_SUPPLEMENT|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
57746217|NCT02767115|OTHER|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
57746218|NCT00911534|DRUG|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
58449333|NCT00811525|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
58449334|NCT05935020|OTHER|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
58449335|NCT05935020|OTHER|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
58119873|NCT03184454|DEVICE|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
57746219|NCT00911534|DRUG|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
57746220|NCT01834755|OTHER|Evaluation of psychological phenotype|
57746221|NCT06576271|DRUG|GSK4527363|GSK4527363 will be administered to participants.
57746222|NCT06576271|DRUG|Placebo matching GSK4527363|Placebo matching GSK4527363 will be administered to participants.
57746223|NCT06576271|DRUG|Belimumab|Belimumab will be administered to participants.
57746224|NCT06194123|OTHER|Crest Daily Whitening Serum|one week's use of Crest Daily Whitening Serum as described on the label.
58119874|NCT01879839|DIETARY_SUPPLEMENT|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
57746225|NCT05449951|OTHER|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
57746226|NCT05449951|OTHER|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
57746227|NCT03256162|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
57746228|NCT03256162|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
57746229|NCT05263752|DEVICE|ERCP with NvisionVLE® Imaging Low Profile System|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
57746230|NCT05786690|OTHER|Interventions|the temporospatial and kinematic gait characteristics
57746231|NCT03982186|DRUG|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
57746232|NCT03982186|DRUG|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
57746233|NCT03982186|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
57746234|NCT03982186|DRUG|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
57746235|NCT03982186|DRUG|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
58449336|NCT05935020|BEHAVIORAL|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
58449337|NCT05096065|DRUG|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
58449338|NCT05096065|DRUG|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
58449339|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
58449340|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
58449341|NCT05096065|DRUG|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
58449342|NCT06568042|DRUG|LY3848575|Administered SC
58449343|NCT06568042|DRUG|Placebo|Administered SC
58449344|NCT01080807|DRUG|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
58449345|NCT01080807|DRUG|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
58449346|NCT06703567|BEHAVIORAL|Standard Policy|Patients will receive information about the GEP test by clinical teams
58449347|NCT06703567|BEHAVIORAL|Standard Policy + GEP Information Film|Patients will receive information about the GEP test by clinical teams and, after consultation with physician, they will be sent a link to view the film regarding OncotypeDX
58449348|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
58449349|NCT06200753|PROCEDURE|Mechanical Thrombectomy|"Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury."
58449350|NCT03400852|DRUG|MNK-1411|MNK-1411 (1 mg/mL suspension) for subcutaneous injection
58449351|NCT03400852|OTHER|Placebo|Placebo suspension for subcutaneous injection
58449352|NCT04809571|OTHER|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
58458665|NCT04608617|DEVICE|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
58119875|NCT04845074|PROCEDURE|TSA-group|Anatomical total shoulder arthroplasty followed by standard rehabilitation.
58449353|NCT06707337|OTHER|Brief Self-compassion Program|Brief Self-compassion Program will be held in a face-to-face hospital environment for the patients with colorectal cancer in the experimental group. This training program has been developed based on the concepts of Mindfulness-Based Compassionate Living and Mindfulness-Based Stress Reduction Programs. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the mindfulness-based model. The training program was created in a certain flow, based on the introduction to a short self-compassion program (1 sessions), the importance of self-compassion and self-care in the cancer experience (1 sessions), a self-compassionate approach to challenging emotions and situations (1 sessions). There are 3 sessions in the program and the frequency of sessions is 3 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 patients with colorectal cancer in the experimental group.
58449354|NCT00970112|PROCEDURE|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
58449355|NCT02487095|DRUG|Topotecan|Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
58449356|NCT02487095|DRUG|VX-970 (M6620)|VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
58449357|NCT04522453|OTHER|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
58449358|NCT04522453|OTHER|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
58449359|NCT06726057|BEHAVIORAL|Imlementation strategies in conjunction with multicomponent hypertension intervention|In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.
58449360|NCT06726057|BEHAVIORAL|Multicomponent hypertension intervention|"The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Establishing hypertension triage counters and care coordinators in primary care facilities for the care of referred patients."
58449361|NCT00488735|BEHAVIORAL|Cognitive-behavioral rehabilitation|
58449362|NCT00488735|BEHAVIORAL|Traditional primary care|
58449363|NCT02924493|OTHER|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
58449364|NCT02598284|OTHER|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
58119876|NCT04845074|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
58449365|NCT02598284|OTHER|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
58449366|NCT05617144|OTHER|Aromatherapy treatment|60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
58119877|NCT03204591|OTHER|No intervention|No intervention
58119878|NCT02660411|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
58119879|NCT02660411|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
58119880|NCT01305083|DRUG|Udenafil|Placebo-control
58449367|NCT03148613|DEVICE|Carbon Monoxide Breath Sensor System (COBSS)|Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
58449368|NCT03148613|DEVICE|Bedfont - Micro+™ Smokerlyzer®|Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
58449369|NCT02050009|DRUG|metformin hydrochloride|Given PO
58449370|NCT02050009|DRUG|carboplatin|Given IV
58449371|NCT02050009|DRUG|paclitaxel|Given IV
58449372|NCT02050009|OTHER|laboratory biomarker analysis|Correlative studies
58449373|NCT02171507|DRUG|Dabigatran etexilate|
58449374|NCT02171507|DRUG|Diclofenac|
58449375|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
57746236|NCT04616287|OTHER|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
57958796|NCT05204966|DIAGNOSTIC_TEST|AI analysis|"1. Bottle feeding filming~   - With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
57958797|NCT01564862|DRUG|vortioxetine (Lu AA21004)|Lu AA21004 capsules
57958798|NCT01564862|DRUG|Duloxetine|Duloxetine capsules
57958799|NCT01564862|DRUG|Placebo|Placebo matching capsules
57958800|NCT06118060|OTHER|Acupressure|In this study, the frequency of acupressure was twice a day (the interval between each acupressure was more than 6 hours, 6:00 to 9:00 in the morning and 1:00 to 4:00 in the afternoon); the acupressure was applied from the first day after surgery for a total of 5 days, that is, each patient received a total of 10 acupressure; the duration was 5 minutes, and the bilateral acupressure required 10 minutes.
57958801|NCT06222125|DRUG|HB0025|HB0025 IV every 2 weeks (q2w)
57958802|NCT00864955|RADIATION|UVA and UVB irradiation|"* 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
57958803|NCT01580488|DRUG|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
57958804|NCT01580488|DRUG|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
58119881|NCT01305083|DRUG|Placebo|Placebo
58449376|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
58449377|NCT02274792|DRUG|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
58449378|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
58449379|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
58449380|NCT02036125|DEVICE|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
58449381|NCT02036125|DRUG|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
58449382|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
58449383|NCT04064749|BEHAVIORAL|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
58449384|NCT04494074|OTHER|External Cooling|External Cooling
58449385|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
58449386|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
58449387|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
57746237|NCT05773976|DEVICE|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil"
57746238|NCT05384626|DRUG|NVL-655|Oral Tablet of NVL-655
57746239|NCT03657433|DIETARY_SUPPLEMENT|Ferrous sulfate 325mg|Oral tablets supplied for home use
57958805|NCT01580488|DRUG|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
57958806|NCT01580488|DRUG|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
57958807|NCT01580488|DRUG|Daivonex® ointment|once daily application, 3 weeks
57958808|NCT01580488|DRUG|Daivonex® ointment vehicle|once daily application, 3 weeks
57958809|NCT01200901|DRUG|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
58119882|NCT00210626|DRUG|PROCRIT|40,000 IU/mL/week for max of 12 weeks
58119883|NCT00210626|DRUG|Placebo|40,000 IU/mL/week for max of 12 weeks
58119884|NCT04732299|OTHER|MRI examination|Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
58119885|NCT03872284|OTHER|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
58119886|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
58119887|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
58119888|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
58119889|NCT00886483|DEVICE|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
58119890|NCT00886483|DEVICE|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
58119891|NCT00778557|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
58119892|NCT04839588|OTHER|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
58119893|NCT02336997|PROCEDURE|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
58119894|NCT02336997|PROCEDURE|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1\*10e6 cells/cm2.
58119895|NCT02336997|PROCEDURE|PLACEBO|Saline will be injected into expanded skin.
58119896|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
58119897|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
58119898|NCT04941222|OTHER|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
58119899|NCT00006129|DRUG|testosterone|
58119900|NCT03393858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
58119901|NCT03393858|BIOLOGICAL|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
58119902|NCT03393858|DEVICE|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
58449388|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
58449389|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
58449390|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
58449391|NCT03659799|DRUG|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
58449392|NCT03659799|DRUG|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
57746240|NCT03657433|DRUG|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
57746241|NCT04501510|DIAGNOSTIC_TEST|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
57769721|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
57769722|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 8 weeks postpartum|The follow-up assessment at 8-weeks postpartum will be completed via phone.
57769723|NCT02695602|PROCEDURE|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
57769724|NCT02695602|PROCEDURE|Submucous Resection with non powered instrument|
58119903|NCT03322462|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
58119904|NCT03322462|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
58119905|NCT02811809|DRUG|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
58119906|NCT02811809|DRUG|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
58119907|NCT06103409|BIOLOGICAL|Implantation of allogeneic MSCs on burn wounds|Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
58449393|NCT03659799|OTHER|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
58449394|NCT03659799|OTHER|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
58449395|NCT00226928|BEHAVIORAL|Supportive-Expressive Group Therapy plus education|
58449396|NCT00226928|BEHAVIORAL|Education|
58449397|NCT01293825|DRUG|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
58449398|NCT06727305|DRUG|Sirolimus 0.5 Mg Oral Tablet|Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
58449399|NCT06727305|DRUG|Sirolimus 1Mg Oral Tablet|Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
58449400|NCT06727305|DRUG|Sirolimus 2 MG Oral Tablet|Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
57746242|NCT02288468|DEVICE|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
58449401|NCT06727305|DRUG|Everolimus 0.5 MG Oral Tablet|Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
58449402|NCT06727305|DRUG|Everolimus 1 MG Oral Tablet|Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
58449403|NCT06727305|DRUG|Everolimus 2 MG Oral Tablet|Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
58449404|NCT06725472|PROCEDURE|Open Heart Surgery|This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.
58449405|NCT04533321|DRUG|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
58449406|NCT01333293|DRUG|injections|subcutaneous injections
58449407|NCT06726525|DEVICE|HPMC+GlicoPro eyedrops|HPMC+GlicoPro eyedrops, artificial tears for dry eye disease
58449408|NCT06726525|DEVICE|Hydroxypropyl-methylcellulose|Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease
58449409|NCT02795117|DRUG|Ivermectin|
58449410|NCT02795117|DRUG|Ivermectin (reference)|
58449411|NCT02795117|DRUG|Placebo|
58449412|NCT00181766|DRUG|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
58449413|NCT00000424|PROCEDURE|Tidal lavage vs. sham lavage of the knee|
57746243|NCT02191072|DRUG|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
57746244|NCT00660842|PROCEDURE|carboplatin|AUC 6 IV day 1 every 21 days
58449414|NCT00673582|DRUG|Rosuvastatin|10 mg/day rosuvastatin
58449415|NCT00673582|DRUG|Placebo|Placebo, 10 mg a day for 96 weeks
58449416|NCT03796065|BEHAVIORAL|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
58449417|NCT04909489|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
58449418|NCT04585204|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test
58449419|NCT04792021|DRUG|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
58449420|NCT01242592|DRUG|Anti-Tuberculosis Treatment|
57746245|NCT00660842|DRUG|paclitaxel|175 mg/m2 IV day 1 every 21 days
57746246|NCT00660842|DRUG|carboplatin|AUC 2 IV every week
58449421|NCT06722872|OTHER|Laughter therapy|Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.
58449422|NCT06727188|DIAGNOSTIC_TEST|Laboratory as cbc crp|Using laboratory and imaging investigations to help in diagnosis and follow up the cases
58449423|NCT01591941|OTHER|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
58449424|NCT05653661|PROCEDURE|Biopsy|Undergo tissue biopsies
58449425|NCT05653661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58119908|NCT03542136|DEVICE|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
58119909|NCT02979379|OTHER|Pain|
58119910|NCT00914433|DRUG|TPI 1100|1 dose only increasing dose
58119911|NCT05271539|DRUG|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
58119912|NCT05271539|DRUG|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
58119913|NCT04571242|DEVICE|DTM Programming|DTM-SCS programming
58119914|NCT04571242|DEVICE|Conventional SCS programming|Conventional SCS programming
58119915|NCT03939169|OTHER|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
58449426|NCT05653661|PROCEDURE|Computed Tomography|Undergo CT scans
58449427|NCT05653661|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
58449428|NCT05653661|DRUG|Nab-paclitaxel/Danburstotug Complex AP160|Given IV
58449429|NCT02485132|OTHER|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
58449430|NCT04320017|DIAGNOSTIC_TEST|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"* 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
58119916|NCT02045628|BEHAVIORAL|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
58119917|NCT02067780|DRUG|Levofloxacin 500mg|One tablet per day for 7days.
58119918|NCT04665076|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
58119919|NCT04665076|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
58119920|NCT04665076|PROCEDURE|Leukapheresis|Leukapheresis
58119921|NCT04041765|DRUG|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
58119922|NCT05742581|OTHER|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
58119923|NCT01107535|BIOLOGICAL|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
58119924|NCT06479304|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
58119925|NCT06479304|DRUG|Prednisone tablet|Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
58119926|NCT01608009|DRUG|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
58119927|NCT04550195|DRUG|BMS-986337|Specified Dose on Specified Days
58119928|NCT04550195|OTHER|BMS-986337 Placebo|Specified Dose on Specified Days
58449431|NCT02637765|BEHAVIORAL|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
58449432|NCT00896298|DRUG|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
58449433|NCT00896298|DRUG|Placebo|Sugar pill
58449434|NCT06375174|PROCEDURE|Thrombectomy|All procedures correspond to standard care and clinical routine
58449435|NCT01649934|BEHAVIORAL|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
57746247|NCT00660842|DRUG|paclitaxel|60mg/m2 IV every week
57746248|NCT00383487|DRUG|Calcitriol|0.5 micrograms/kilogram q weekly
58449436|NCT01649934|BEHAVIORAL|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
58458666|NCT04608617|OTHER|Baseline Effectiveness Cohort|No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
57746249|NCT00383487|DRUG|Naproxen-n-butyl nitrate|400 mg BID, oral
57746250|NCT00808275|DIETARY_SUPPLEMENT|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
57746251|NCT03076970|DRUG|lasmiditan 200 mg|drug including single placebo tablet
57746252|NCT03076970|DRUG|Sumatriptan|drug including single placebo tablet
57746253|NCT03076970|DRUG|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
57746254|NCT05566223|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
58449437|NCT04254666|BEHAVIORAL|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
58449438|NCT04557800|DRUG|DNL151|oral dose(s)
58449439|NCT04557800|DRUG|Placebo|oral dose(s)
58449440|NCT06421038|OTHER|Thyme honey|Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days
58449441|NCT06421038|DRUG|Kenalog|kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)
58449442|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
58449443|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
58449444|NCT06351150|DRUG|Angiotensin II Injection|1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.
58449445|NCT06351150|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection, not containing active ingredients.
58449446|NCT04544358|BEHAVIORAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
58449447|NCT02539901|BEHAVIORAL|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
58449448|NCT02539901|BEHAVIORAL|Free hearing test categorization|Free hearing test categorization evaluation
58449449|NCT02539901|BEHAVIORAL|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
58449450|NCT02539901|BEHAVIORAL|psychomotor infancy development scale|
57746255|NCT05566223|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
57746256|NCT05566223|BIOLOGICAL|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
58449451|NCT02539901|BEHAVIORAL|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
58449452|NCT05089643|DRUG|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
57746257|NCT05566223|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
57746258|NCT05566223|DRUG|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
57746259|NCT05119894|DRUG|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
57746260|NCT05119894|DRUG|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
57746261|NCT05119894|DRUG|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
57746262|NCT05119894|DRUG|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
57746263|NCT05111795|DEVICE|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
57746264|NCT06074705|DRUG|DS-1471a|Intravenous administration on Day 1 of each 28-day cycle
57746265|NCT00273312|DRUG|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
58449453|NCT05089643|DRUG|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
57746266|NCT01641393|DRUG|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
57769725|NCT01454453|DRUG|Patients- dose titration|dose titration (patients) - 4-10 weeks
58449454|NCT05364463|PROCEDURE|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
58449455|NCT01007357|DEVICE|Body MR imaging|Body MR imaging will be performed to optimize sequences
58449456|NCT00530738|DRUG|Lipoplus|i.v. fat emulsion for parenteral nutrition
58449457|NCT00530738|DRUG|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
58449458|NCT02382445|DEVICE|Anesthesia depth monitor|
57746267|NCT01641393|DRUG|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
57746268|NCT02593175|DRUG|Carboplatin|Given IV
57746269|NCT02593175|DRUG|Paclitaxel|Given IV
57746270|NCT02593175|BIOLOGICAL|Panitumumab|Given IV
57746271|NCT01587534|DRUG|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
57746272|NCT02434133|PROCEDURE|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
57746273|NCT04683926|DRUG|Desmetramadol|Analgesic
57746274|NCT02164877|DRUG|pectin|Patients allocated to experiment group will receive 15g pectin each day
57746275|NCT01314274|DRUG|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
57746276|NCT01314274|DRUG|NaCl|10ml of 0.9% NaCl intranasal submucosal
58119929|NCT04550195|BIOLOGICAL|Famotidine|Specified Dose on Specified Days
58119930|NCT06277258|OTHER|Patient Empowerment model|"Session I~* Knowledge about the disease, calories \& diet distribution, physical activities, symptoms of hypoglycemia, Blood Glucose target etc.~* Training on use of glucometer and record keeping Session II~* Evaluation and interpretation of sugar level based on the sugar chart.~* Tuning of diet and exercise if needed.~* Discussion about the challenges faced by the patient during maintenance of sugar level.~Session III \& ongoing~* Tuning of the diet based on calories, evaluation of the understanding~* Assessment of patient satisfaction~* Assessment of patients' knowledge and skill to designate her as Empowered~Assurance and counseling of patient and family will be rendered in each session."
58119931|NCT03031522|RADIATION|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
58449459|NCT02382445|DEVICE|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
58449460|NCT02382445|DRUG|propofol and sevoflurane|
58449461|NCT04014283|DIETARY_SUPPLEMENT|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
58449462|NCT04014283|OTHER|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
58449463|NCT04014283|OTHER|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
58449464|NCT04093713|PROCEDURE|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
57746277|NCT06496178|DRUG|Petosemtamab|MCLA-158
57746278|NCT06496178|DRUG|Investigator's Choice|Cetuximab
57746279|NCT06496178|DRUG|Investigator's Choice|Methotrexate
57746280|NCT06496178|DRUG|Investigator's Choice|Docetaxel
57746281|NCT06359210|BEHAVIORAL|Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
57746282|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
57746283|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
57746284|NCT01981564|BEHAVIORAL|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
58119932|NCT05652920|BIOLOGICAL|Ori-C101|Hepatic arterial infusion
58449465|NCT00876161|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
58449466|NCT00876161|DRUG|Lactose|
58449467|NCT00005961|DRUG|O6-benzylguanine|
57746285|NCT01981564|BEHAVIORAL|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
57746286|NCT01624675|DRUG|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.
57746287|NCT01624675|DRUG|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
57746288|NCT05092321|BEHAVIORAL|Aquatic Occupational Therapy|Group of 4-8 children, paired with a swim buddy. Intervention techniques including discrete teaching, motor shaping, behavioral management, therapeutic relationship and individualized goals.
57769726|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
58119933|NCT03051685|DRUG|DFN-15 Dose 1|
58119934|NCT03051685|DRUG|DFN-15 Dose 2|
58119935|NCT03051685|DRUG|DFN-15 Dose 3|
58449468|NCT00005961|DRUG|carmustine|
58449469|NCT05306587|DRUG|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
58449470|NCT02532608|OTHER|Acute sleep deprivation|Participants will stay awake for 36 hours
58119936|NCT03051685|DRUG|Active Comparator|
58119937|NCT05304637|DEVICE|iTEAR100 treatment|Vibratory energy to the external nasal nerve
58119938|NCT00638170|BIOLOGICAL|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
58119939|NCT00638170|BIOLOGICAL|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
58458667|NCT02600481|PROCEDURE|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
58119940|NCT06483373|DRUG|SPH7854|SPH7854： Orally, 50-3200mg
58119941|NCT06483373|DRUG|Placebo|Placebo：Orally；
58119942|NCT04884659|OTHER|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
58119943|NCT04884659|OTHER|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
58119944|NCT00767117|DRUG|Etravirine; Lopinavir; Ritonavir|
58449471|NCT01409447|DEVICE|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
58449472|NCT01523418|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
58449473|NCT06279455|OTHER|Pelvic Floor Muscle Exercise|A 12-week pelvic floor muscle exercise program was applied to pregnant women.
58449474|NCT03626961|OTHER|readmission|Readmission after 48 hours
57746289|NCT01165775|DEVICE|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
57746290|NCT01677273|DIETARY_SUPPLEMENT|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
58119945|NCT02545998|OTHER|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
58119946|NCT05040685|PROCEDURE|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
58119947|NCT01164423|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
58119948|NCT03503357|OTHER|IFT Testing1|Command List A
58119949|NCT03503357|OTHER|IFT Testing 2|Command List B
58119950|NCT03503357|OTHER|IFT Testing 3|Command List C
58119951|NCT03503357|OTHER|IFT Testing 4|Command List D
58119952|NCT05575960|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents (IPT-A)|Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
58449475|NCT03626961|OTHER|discharge|Discharge
58449476|NCT01463241|BEHAVIORAL|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
57746291|NCT01677273|DIETARY_SUPPLEMENT|Intact casein|30 g protein/supplement, 4 supplements/visit
57746292|NCT01677273|DIETARY_SUPPLEMENT|Intact whey protein|30 g protein/supplement, 4 supplements/visit
57746293|NCT06732518|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
57746294|NCT06732518|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
58119953|NCT04459546|BEHAVIORAL|patient education, training booklet, 3 months tele health|Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
58119954|NCT00904020|DRUG|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
58119955|NCT01170364|DRUG|Sibutramine|1 week of active sibutramine (15mg)
57746295|NCT06732518|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
57746296|NCT06732518|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
57746297|NCT06648642|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues
57746298|NCT06525493|PROCEDURE|Regional Anesthesia|The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
58119956|NCT01170364|DRUG|Placebo|2 weeks of placebo
58119957|NCT05815043|BEHAVIORAL|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
58119958|NCT05815043|DIETARY_SUPPLEMENT|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
58119959|NCT00319956|DRUG|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
58119960|NCT00319956|DRUG|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
58119961|NCT06152627|BEHAVIORAL|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
58119962|NCT06152627|BEHAVIORAL|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
58119963|NCT04703946|OTHER|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~1. Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~2. Association or not of the AG with sex.~3. Association or not of the AG with gestational age.~4. Association or not of the AG with other minor and major malformations."
58119964|NCT02129374|PROCEDURE|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
58119965|NCT04137822|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
57746299|NCT02251327|DEVICE|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
57746300|NCT02803775|DEVICE|CRT Algorithm|Programming based on Electrogram measurement
57746301|NCT06386770|DRUG|Dexmedetomidine Injection [Precedex]|Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
57746302|NCT06386770|DRUG|Bupivacaine Hydrochloride|.Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
57746303|NCT06386770|DRUG|Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
57746304|NCT04834466|BEHAVIORAL|Pain Level experience during orthodontic treatment|A questionnaire was given to patients who have started their orthodontic treatment to assess their pain level experience
58119966|NCT01580761|BEHAVIORAL|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
57746305|NCT01222325|PROCEDURE|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
57746306|NCT04905394|PROCEDURE|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
58119967|NCT01368276|BIOLOGICAL|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
58119968|NCT01368276|DRUG|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
58119969|NCT00730522|DRUG|CPP-109 vigabatrin|tablets, bid for 12 weeks
58119970|NCT00730522|DRUG|Matching Placebo|tablets, bid, 12 weeks
57746307|NCT06429566|DRUG|GB001 recombinant peptide spray low dose group、high dose group|Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
58119971|NCT01910766|DRUG|Coenzyme Q10|no more details
57746308|NCT06429566|DRUG|GB001 recombinant peptide spray placebo|Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
57746309|NCT05808049|OTHER|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
57746310|NCT05808049|OTHER|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
57746311|NCT06096051|PROCEDURE|Use of fixed-dosed 4F-PCC|Determine if fixed-dose 4F-PCC is safe and effective in patients with DOAC-associated ICH when compared to weight-based dosing.
57746312|NCT02848248|DRUG|SGN-CD123A|Intravenous infusion in 3-week cycles
57746313|NCT04952506|DRUG|CKD-349 F1 Tab.|1T Single does
57746314|NCT04952506|DRUG|CKD-349 F2 Tab.|1T Single does
58119972|NCT01910766|DRUG|clomiphene citrate|
58119973|NCT03358459|OTHER|non|non
58119974|NCT05974748|DRUG|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
58449477|NCT00268840|DRUG|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
57746315|NCT04952506|DRUG|D113 Tab.|1T Single does
57769727|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
58449478|NCT00268840|DRUG|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
57746316|NCT01560039|DEVICE|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
58449479|NCT00557635|PROCEDURE|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
57746317|NCT01560039|OTHER|Neurofeedback|EEG neurofeedback based on the primary motor cortex
57746318|NCT01560039|OTHER|Sham neurofeedback|Sham EEG neurofeedback
58119975|NCT05974748|DRUG|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
58119976|NCT05102279|DIETARY_SUPPLEMENT|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
58119977|NCT05678348|DRUG|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
58119978|NCT00425529|DEVICE|Module AOX (attached to Sondalis ISO)|
58119979|NCT02215694|DIETARY_SUPPLEMENT|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
58119980|NCT02215694|DIETARY_SUPPLEMENT|placebo|2g of powder daily without probiotics
58119981|NCT01574989|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
58119982|NCT01574989|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35\^2 electrodes.
58119983|NCT02523911|DRUG|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
58119984|NCT02523911|DRUG|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
58119985|NCT02523911|DRUG|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
58119986|NCT02511236|BEHAVIORAL|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
58449480|NCT03368365|DEVICE|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
58449481|NCT03956550|DRUG|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
58449482|NCT03956550|DRUG|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
58449483|NCT06531486|OTHER|XS-02 capsules|Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.
58458668|NCT02600481|PROCEDURE|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
58458669|NCT04154436|OTHER|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
57746319|NCT04259450|DRUG|14 mg AFM24|14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
58458670|NCT04154436|OTHER|Water (H2o)|Alkaline Solution
57746320|NCT04259450|DRUG|40 mg AFM24|40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
57746321|NCT04259450|DRUG|80 mg AFM24|80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
57746322|NCT04259450|DRUG|160 mg AFM24|160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
57746323|NCT04259450|DRUG|320 mg AFM24|320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
57746324|NCT04259450|DRUG|480 mg AFM24|480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
57746325|NCT04259450|DRUG|720 mg AFM24|720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
58119987|NCT02511236|BEHAVIORAL|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
58119988|NCT02511236|DRUG|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
58119989|NCT03699709|BEHAVIORAL|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
58119990|NCT04576767|OTHER|anaesthetic|different states of consciousness
58119991|NCT00752791|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
58119992|NCT02352337|DRUG|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
58119993|NCT02352337|DRUG|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
58119994|NCT02352337|DRUG|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
58119995|NCT02352337|DRUG|Gemcitabine|Gemcitabine perfusion
58119996|NCT06041464|OTHER|cell culture|isolation of cell culture
58119997|NCT02102165|PROCEDURE|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
58119998|NCT03502642|DEVICE|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
58119999|NCT03502642|PROCEDURE|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
58120000|NCT03502642|DRUG|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
58120001|NCT03502642|DRUG|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
58120002|NCT03502642|DRUG|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
58120003|NCT03246932|BEHAVIORAL|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
58120004|NCT03246932|BEHAVIORAL|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
58120005|NCT03246932|OTHER|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
58120006|NCT00291395|DRUG|PGI2|
58449484|NCT05104307|DEVICE|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
57746326|NCT02937961|BIOLOGICAL|Early SLED|withing 6 to 12 hours
57746327|NCT02937961|BIOLOGICAL|Late SLED|when absolute indications will meet
57746328|NCT02112188|BEHAVIORAL|In-depth Patient Interviews|
57746329|NCT02112188|BEHAVIORAL|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
58120007|NCT01650324|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
58120008|NCT01650324|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
58120009|NCT02696811|DIETARY_SUPPLEMENT|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
58120010|NCT02696811|DIETARY_SUPPLEMENT|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
58120011|NCT03467334|DIETARY_SUPPLEMENT|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
58120012|NCT03467334|DIETARY_SUPPLEMENT|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
58120013|NCT03467334|DRUG|Simethicone 20 MG|Standard treatment for infant colic
58458671|NCT05625321|BEHAVIORAL|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
57769728|NCT05362682|OTHER|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
57769729|NCT02676752|PROCEDURE|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
57769730|NCT02676752|OTHER|Questionnaire Administration|Completion of questionnaires
57769731|NCT02676752|PROCEDURE|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
57769732|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
58120014|NCT00356720|DRUG|Azithromycin|
58120015|NCT03517137|DRUG|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
58120016|NCT03517137|DRUG|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
58120017|NCT03517137|DRUG|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
58120018|NCT03517137|DRUG|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
58120019|NCT03517137|DRUG|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
58120020|NCT03517137|DRUG|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
58120021|NCT03517137|RADIATION|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
58120022|NCT00060957|DRUG|Botulinum toxin type A|
58120023|NCT01709383|DEVICE|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
58120024|NCT01709383|DEVICE|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
58120025|NCT02130466|BIOLOGICAL|Pembrolizumab|IV infusion
58120026|NCT02130466|DRUG|Dabrafenib|oral capsule
58120027|NCT02130466|DRUG|Trametinib|oral tablet
57769733|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
57769734|NCT05226260|BEHAVIORAL|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
58120028|NCT02130466|DRUG|Placebo|IV infusion
58120029|NCT00101543|DEVICE|Electrical Stimulation with Intramuscular Electrodes|
58120030|NCT00101543|PROCEDURE|Body Weight Supported Treadmill Training|
58120031|NCT02003040|DEVICE|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
58120032|NCT00582036|DRUG|Regular Insulin|Use of sliding scale insulin as per Appendix 1
58120033|NCT00582036|DEVICE|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
58120034|NCT03408366|PROCEDURE|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
58120035|NCT03408366|OTHER|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
58458672|NCT05625321|BEHAVIORAL|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
58120036|NCT03408366|OTHER|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
58120037|NCT00915057|DRUG|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
58120038|NCT03104790|BIOLOGICAL|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
58120039|NCT00408733|OTHER|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
58120040|NCT01773512|DRUG|Rosuvastatin|All patients will be using rosuvastatin 40 mg
58120041|NCT00794183|DEVICE|CRT device settings|Comparision of A-V delay settings
58120042|NCT01292109|DRUG|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
58120043|NCT01448135|OTHER|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
58120044|NCT01448135|OTHER|Osmolite 1.2|High protein enteral formula
58120045|NCT03211156|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
58120046|NCT03211156|OTHER|Placebo|Placebo
58120047|NCT06298435|PROCEDURE|Intermittent Positive pressure ventilation|Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
58120048|NCT02322528|DRUG|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
58120049|NCT02099279|DEVICE|echocardiography examination|patients underwent echocardiography examination
58120050|NCT05779150|OTHER|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
58120051|NCT05779150|OTHER|Standard Cream|placebo cream
57746330|NCT02112188|BEHAVIORAL|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
58120052|NCT03673059|DRUG|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
58120053|NCT03673059|OTHER|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
57746331|NCT06440291|PROCEDURE|Cardioneuroablation|Cardioneuroablation procedure performed according to the protocol
57746332|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
58120054|NCT01544166|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants \<2 years of age.
58449485|NCT05357716|DEVICE|HeartWatch|The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
58449486|NCT05357716|DEVICE|Event Recorder|A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
57746333|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
57746334|NCT02937168|DRUG|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
58120055|NCT05105165|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
58449487|NCT05357716|DEVICE|Holter Monitor|A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
57746335|NCT02937168|DRUG|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
57746336|NCT02937168|DRUG|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
57746337|NCT06562361|DRUG|[68Ga]Ga-DOTA-Cys-ATH001|Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
57769735|NCT04227496|DEVICE|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
58120056|NCT04683822|OTHER|Telerehabilitation|Patients will attend telerehabilitation sessions
58120057|NCT02484820|DEVICE|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
58120058|NCT03244020|DRUG|Aspirin 325mg|Aspirin 325 mg by mouth once daily
58120059|NCT03244020|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
58120060|NCT03198013|DRUG|Prednisolone|Specified dose on specified days
58120061|NCT03198013|DRUG|BMS-791826|Specified dose on specified days
58120062|NCT03198013|DRUG|Placebo|Specified dose on specified days
58120063|NCT04579926|OTHER|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
58120064|NCT00198497|DRUG|Placebo|
58120065|NCT00198497|DRUG|Vitrase|Hyaluronidase 55 IU in saline solution
58120066|NCT00198497|DRUG|Vitrase|Hyaluronidase 75 IU in saline solution
58120067|NCT02079792|PROCEDURE|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
58120068|NCT02079792|PROCEDURE|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
58449488|NCT00536237|DRUG|Comparator: niacin / Duration of Treatment: 17 Weeks|
58449489|NCT00536237|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
58449490|NCT00536237|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
58458673|NCT02520726|DRUG|Sertraline|\< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
58458674|NCT02520726|DRUG|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
58120069|NCT03402893|DRUG|ONEXTON Topical Gel|Onexton gel applied once daily to face
58120070|NCT03651115|DIAGNOSTIC_TEST|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
58120071|NCT02559050|OTHER|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
57769736|NCT01597505|DRUG|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
58449491|NCT05771766|OTHER|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
58120072|NCT05945199|DEVICE|tDCS|"* 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group"
58313729|NCT01141816|OTHER|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
57746338|NCT06525324|PROCEDURE|Immediate implant surgery with T-PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
57746339|NCT06525324|PROCEDURE|Immediate implant surgery with PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
57746340|NCT00093834|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
57746341|NCT00093834|DRUG|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
57746342|NCT00093834|DRUG|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
57746343|NCT04950374|OTHER|Moisturizer Body Lotion|The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
57746344|NCT04950374|OTHER|Lip Moisturizer|The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
57746345|NCT01642680|OTHER|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
57746346|NCT01642680|OTHER|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
57746347|NCT01647490|PROCEDURE|Permanent Cardiac Pacemaker Implantation|
57746348|NCT05661955|DRUG|BGB-A445|administered intravenously
57746349|NCT05661955|DRUG|Tislelizumab|administered intravenously
57746350|NCT04357262|OTHER|StreaMD|Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
57746351|NCT00554879|PROCEDURE|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
57746352|NCT00554879|PROCEDURE|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
57746353|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
57746354|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
57746355|NCT01770054|OTHER|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
57746356|NCT01371773|PROCEDURE|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
57746357|NCT04003168|DRUG|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
57746358|NCT04266301|DRUG|Sabatolimab|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
57746359|NCT04266301|DRUG|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
57746360|NCT04266301|DRUG|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
57746361|NCT02436265|DRUG|Dexamethasone|IV dexamethasone
57746362|NCT02436265|DRUG|Ropivacaine|Ropivacaine only
58449492|NCT05771766|OTHER|Postural Drainage|Postural Drainage
58449493|NCT02631980|DRUG|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
58449494|NCT02631980|DRUG|IV placebo|Intravenous 0.9% saline (250 ml)
58120073|NCT05945199|BEHAVIORAL|Assessment of risk behaviours|Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
58120074|NCT05945199|OTHER|Scales|EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
57746363|NCT05944523|PROCEDURE|Erector Spina Plan Block|Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
57746364|NCT04823260|DRUG|Nicotinamide Mononucleotide|Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
57746365|NCT04823260|OTHER|Placebo|Rice flour in white capsule resembling NMN
57746366|NCT00685958|DRUG|enoxaparin (XRP4563)|14 days of treatment
57746367|NCT03407794|OTHER|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
57746368|NCT03407794|OTHER|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
57746369|NCT01636180|DRUG|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
57746370|NCT01636180|DRUG|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
57746371|NCT05875948|DRUG|R2R01|Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
57746372|NCT05875948|DRUG|Terlipressin|"In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin."
57746373|NCT03065868|DRUG|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
57746374|NCT06017219|DIETARY_SUPPLEMENT|spermidine|spermidine
57746375|NCT06338319|BEHAVIORAL|Book-Sharing for Toddlers with Clefts (BOOST)|BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
58120075|NCT01461200|OTHER|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
57746376|NCT00696748|DRUG|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
57746377|NCT00696748|DRUG|Placebo|Placebo 4 mL intramuscular
57746378|NCT02144064|DRUG|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
57746379|NCT04020341|DRUG|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
57746380|NCT04020341|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
57746381|NCT04020341|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
57746382|NCT04020341|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
57746383|NCT00924287|DRUG|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
57746384|NCT00924287|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
57746385|NCT00924287|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
57746386|NCT00924287|DRUG|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
57746387|NCT06580171|OTHER|Walking and Remembering Test|Only Walking and Remembering Test will be applied to the group.
58458675|NCT00530413|DRUG|Phenobarbital|Phenobarbital will be given based on weight range
57746388|NCT02446301|DRUG|Bain®|Nalbuphine HCl 20mg, IM injection
58120076|NCT04081480|DRUG|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
58120077|NCT00630565|BIOLOGICAL|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
58120078|NCT00630565|DRUG|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
58120079|NCT00630565|DRUG|cyclophosphamide|4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
58120080|NCT00630565|DRUG|dexamethasone|20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
58120081|NCT00630565|DRUG|etoposide|300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
58458676|NCT00530413|OTHER|Placebo|Placebo group
58120082|NCT00630565|PROCEDURE|bone marrow transplantation|Day 0 infusion of bone marrow cells
58120083|NCT00630565|PROCEDURE|hematopoietic stem cell transplantation|Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)
58120084|NCT00630565|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
58120085|NCT00630565|RADIATION|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
58120086|NCT05561309|DRUG|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
58120087|NCT04293666|DIETARY_SUPPLEMENT|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
58120088|NCT04293666|DIETARY_SUPPLEMENT|placebo|Maltodextrin, same calorie as kefir, 200ml/day
58120089|NCT05695248|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous bolus injection.
58120090|NCT02641613|PROCEDURE|retroclavicular block|retroclavicular block for forearm or hand surgery
58120091|NCT02641613|PROCEDURE|supraclavicular block|supraclavicular block for forearm or hand surgery
58120092|NCT04867525|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
58120093|NCT06483295|OTHER|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
58120094|NCT05247710|PROCEDURE|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
58120095|NCT02833402|DEVICE|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
58120096|NCT04553575|BIOLOGICAL|serology|biological blood samples withdrawn at 6, 12 and 24 months
58120097|NCT02044172|PROCEDURE|Radical prostatectomy|radical prostatectomy
58120098|NCT02044172|RADIATION|Conformal radiation therapy|Conformal radiation therapy, external beam
58120099|NCT02044172|OTHER|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
58120100|NCT02250560|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
58120101|NCT05913336|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
57746389|NCT02446301|DRUG|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
57746390|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
57746391|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
57746392|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
57746393|NCT00002481|DRUG|cisplatin|
57746394|NCT00002481|DRUG|cyclophosphamide|
57746395|NCT00002481|DRUG|cytarabine|
58120102|NCT06038513|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours
58120103|NCT01577511|BIOLOGICAL|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
58120104|NCT03781297|OTHER|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
58313730|NCT05088265|DEVICE|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
58449495|NCT05217940|DIAGNOSTIC_TEST|Diagnostic tests for anal cancer screening|The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
57746396|NCT00002481|DRUG|dexamethasone|
57746397|NCT00002481|DRUG|etoposide|
57746398|NCT00002481|PROCEDURE|autologous bone marrow transplantation|
57746399|NCT00002481|RADIATION|radiation therapy|
57746400|NCT01981694|DRUG|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
58120105|NCT03781297|OTHER|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
58120106|NCT00427622|OTHER|physiologic testing|
58313731|NCT05096377|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
58120107|NCT05059535|DRUG|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
58120108|NCT05083650|PROCEDURE|Macular hole closure with amniotic membrane with/without internal limiting membrane peeling|Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
58120109|NCT03467477|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
58120110|NCT03467477|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
58120111|NCT00686036|DRUG|vandetanib|300 mg orally, once daily for up to 18 months
58120112|NCT00686036|DRUG|Placebo|
58120113|NCT02710071|DRUG|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
58120114|NCT02710071|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
58313732|NCT04868032|BEHAVIORAL|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
58458677|NCT02166099|PROCEDURE|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
58458678|NCT03531489|DEVICE|AIR-AD|Non-significant risk medical device as decided by institutional review board
58458679|NCT02006316|PROCEDURE|Microsurgical subinguinal varicocelectomy|
58458680|NCT02568735|DRUG|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
57746401|NCT01981694|DRUG|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
57746402|NCT04402866|DRUG|TD-0903|Study Drug to be administered by inhalation
57746403|NCT04402866|DRUG|Placebo|Placebo to be administered by inhalation
57746404|NCT03417167|OTHER|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
57746405|NCT04745611|DIAGNOSTIC_TEST|MRI|3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
57746406|NCT04745611|DIAGNOSTIC_TEST|Neuropsychological assessment|Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
57746407|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Patient|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) \& Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
57746408|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Family|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
57746409|NCT02294890|PROCEDURE|Total knee arthroplasty|
57746410|NCT00030693|BIOLOGICAL|recombinant fowlpox-B7.1 vaccine|Given intratumorally
57746411|NCT00030693|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
57746412|NCT00030693|OTHER|laboratory biomarker analysis|Correlative studies
57746413|NCT00030693|PROCEDURE|quality-of-life assessment|Ancillary studies
57958810|NCT06016426|OTHER|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
58120115|NCT05730140|OTHER|this study did not involve interventions; it only observational study|this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
58120116|NCT06126809|DEVICE|Steep-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
58120117|NCT06126809|DEVICE|Flat-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
58120118|NCT06126809|DEVICE|Sham-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
58120119|NCT00600197|BEHAVIORAL|back school|A kind of educational program for low back pain
58120120|NCT02497677|BEHAVIORAL|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
58120121|NCT02497677|BEHAVIORAL|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
57746414|NCT06514144|DRUG|BGF|budesonide/glycopyrrolate/formoterol fumarate
57746415|NCT00680511|BEHAVIORAL|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
57746416|NCT00680511|BEHAVIORAL|Functional Family Therapy (FFT)|FFT
58449496|NCT00663013|OTHER|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
57746417|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
57746418|NCT06219317|DRUG|Placebo|standard saline solution
57746419|NCT06495619|BEHAVIORAL|treatment-as-usual|life style modification intervention for weight loss
57746420|NCT06495619|BEHAVIORAL|combined TAU and guided self-help|combined TAU and guided self-help for improving eating behaviors
57746421|NCT06495619|BEHAVIORAL|combined TAU, GSH, and biofeedback|combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
57746422|NCT05804773|DIAGNOSTIC_TEST|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
57746423|NCT05253872|OTHER|The MelaCare intervention|"The primary principles applied will be:~* Meta-cognitive strategies and normalization of emotions~* Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~* An educational booklet~* Doctor consultation to ensure correct SSE skills and compliance to the protocol~* 3-5 sessions with a experienced and specially trained melanoma nurse~* Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae."
57746424|NCT01767558|OTHER|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
57746425|NCT06220357|DIAGNOSTIC_TEST|Indocyanine Green|The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
57746426|NCT06205589|BIOLOGICAL|ID93 + GLA-SE vaccine|At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
57746427|NCT06205589|BIOLOGICAL|Placebo vaccine|At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
58449497|NCT04090333|OTHER|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
58449498|NCT00393211|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
57746428|NCT04222101|DIAGNOSTIC_TEST|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
57746429|NCT04688242|OTHER|Anal dilatation per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
57746430|NCT04688242|DRUG|administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
57746431|NCT05189808|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation (non-experimental)
57746432|NCT00981981|DIETARY_SUPPLEMENT|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
57746433|NCT00981981|DIETARY_SUPPLEMENT|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
57746434|NCT00981981|DIETARY_SUPPLEMENT|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
57746435|NCT00981981|DIETARY_SUPPLEMENT|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
57746436|NCT00981981|DIETARY_SUPPLEMENT|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
58449499|NCT00393211|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
57746437|NCT00432731|BIOLOGICAL|VARIVAX®|
57746438|NCT00432731|BIOLOGICAL|M-M-RTM II|
57746439|NCT03565510|DIETARY_SUPPLEMENT|High-Protein Diet|The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
57746440|NCT06369259|DRUG|Defactinib|Given by PO
57746441|NCT06369259|DRUG|Cetuximab|Given by IV
57746442|NCT06369259|DRUG|Avutometinib|Given by PO
57746443|NCT06731920|DIAGNOSTIC_TEST|cervical medial branch block|ultrasound-guided cervical medial branch block with fluoroscopic control and digital subtraction angiography
57746444|NCT05356884|BEHAVIORAL|Diabetes Intervention|A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
58120122|NCT01230151|DEVICE|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
58120123|NCT01230151|DEVICE|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
58120124|NCT01000740|GENETIC|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
57746445|NCT05356884|BEHAVIORAL|Leadership & Life Skills|A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
58120125|NCT01000740|GENETIC|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
58120126|NCT03967249|DRUG|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
58120127|NCT03967249|DRUG|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
58120128|NCT00766207|OTHER|Clinical decision support|multi-faceted decision support
58120129|NCT00766207|OTHER|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
58120130|NCT05033613|OTHER|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
58120131|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
58120132|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
58120133|NCT03381248|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
57746446|NCT02718274|DEVICE|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
57746447|NCT02718274|OTHER|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
57746448|NCT03520764|DIETARY_SUPPLEMENT|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
57746449|NCT03520764|DIETARY_SUPPLEMENT|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
57746450|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
57746451|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
57746452|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
57746453|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
57746454|NCT04668885|DRUG|CPX-351|"Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
58449500|NCT01867736|DEVICE|Passeo-18 Lux DRB|
58449501|NCT01867736|DEVICE|Standard PTA (POBA)|
57746455|NCT04578990|OTHER|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
57769737|NCT01597505|DRUG|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
57769738|NCT01597505|DRUG|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
57769739|NCT01455792|PROCEDURE|Biopsies using image fusion|MRI and soft image fusion guided biopsy
58120134|NCT03381248|OTHER|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
58120135|NCT03381248|OTHER|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
58120136|NCT01270750|DRUG|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
58449502|NCT03359174|DRUG|All-trans retinoic acid|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
58449503|NCT04100382|DEVICE|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
58449504|NCT01001117|DEVICE|LensAR laser surgery|Use of laser for cataract surgery
57769740|NCT01455792|PROCEDURE|Gold standard biopsy|Gold standard TRUS biopsy
58120137|NCT01201746|PROCEDURE|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
58120138|NCT01201746|PROCEDURE|Periodontal therapy|Scaling, root planning and oral hygiene instructions
58120139|NCT00195299|DRUG|Temsirolimus|
58449505|NCT01001117|DEVICE|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
58449506|NCT04311489|DRUG|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
58449507|NCT04311489|DRUG|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
57746456|NCT04578990|OTHER|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
57746457|NCT04578990|OTHER|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
58120140|NCT04203407|BEHAVIORAL|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
58120141|NCT04203407|BEHAVIORAL|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
58449508|NCT03824002|DRUG|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
58449509|NCT03824002|DRUG|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
58449510|NCT03824002|DRUG|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
58449511|NCT03824002|DRUG|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
58449512|NCT03824002|DRUG|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
58449513|NCT04608565|DEVICE|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
58449514|NCT05897034|DRUG|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
58449515|NCT05897034|DRUG|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
58449516|NCT05897034|DRUG|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
58449517|NCT04542954|OTHER|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
58449518|NCT04593758|DRUG|CPI-613 + Hydroxychloroquine|"dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg"
58449519|NCT02484755|DRUG|Gefitinib|See Arm Description
58449520|NCT00349817|BEHAVIORAL|web-based learning, didactic lecture and role-play|
58458681|NCT02568735|DRUG|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
57746458|NCT02346305|DEVICE|Non-invasive ventilation|Home NIV installation
57746459|NCT02436330|BEHAVIORAL|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
57746460|NCT02436330|BEHAVIORAL|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
57746461|NCT06198465|DRUG|adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil|adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
57746462|NCT01416870|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
57746463|NCT01416870|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
57746464|NCT02565043|DEVICE|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
58120142|NCT05647083|OTHER|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
58120143|NCT05728632|DRUG|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
58120144|NCT05728632|DRUG|Placebo|Placebo, capsule, once daily, for 12 months
58120145|NCT01883089|BEHAVIORAL|Motivational Enhancement Therapy|
58120146|NCT05305209|OTHER|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
57746465|NCT00898469|GENETIC|polymorphism analysis|
57746466|NCT06731972|OTHER|Exercises|Classical massage, stretching, functional exercises, electrical modalities, thermal agents, home exercises, etc., plus home exercises.
57746467|NCT06731972|DEVICE|Mobile game|mobile application games (such as Temple Run, Flappy Bird, Angry Birds, etc., or games the patient is already playing) as part of their home exercise program.
58120147|NCT05305209|OTHER|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
58120148|NCT00551564|DRUG|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
58120149|NCT04984018|DRUG|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
58120150|NCT00174733|DRUG|Ciclesonide (XRP1526)|
58120151|NCT04472975|DRUG|Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS|Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
58120152|NCT05476874|PROCEDURE|Open Mini-Laparotomy|A 5-cm paraumbilical skin is made, and the abdominal wall is incised in layers. The distal catheter tip is inserted into the peritoneal cavity in a craniocaudal direction, and the abdominal wound is sutured in layers.
58120153|NCT05476874|PROCEDURE|Abdominal Puncture|An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
57746468|NCT03152383|BEHAVIORAL|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
57746469|NCT03152383|BEHAVIORAL|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
57746470|NCT03152383|BEHAVIORAL|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
58120154|NCT05461820|DRUG|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
58120155|NCT02110771|BEHAVIORAL|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
58120156|NCT02110771|BEHAVIORAL|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
58120157|NCT03828123|BIOLOGICAL|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
58120158|NCT03757455|PROCEDURE|ERAS protocol preoperative actions|"First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
58120159|NCT03757455|PROCEDURE|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
58449521|NCT00604565|DRUG|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
58449522|NCT00604565|OTHER|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
58458682|NCT03885635|PROCEDURE|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
58120160|NCT03757455|PROCEDURE|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
58120161|NCT04072718|RADIATION|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
58120162|NCT01740700|DEVICE|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
58120163|NCT04741035|OTHER|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
58120164|NCT04741035|OTHER|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
58120165|NCT05942612|DRUG|SHR-2001|Subcutaneous injection, single dose
58120166|NCT05942612|DRUG|Placebo|Subcutaneous injection, single dose
58120167|NCT00804609|DRUG|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
58120168|NCT00804609|DRUG|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
58449523|NCT00806988|PROCEDURE|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~1. All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~2. The heart will be arrested with cardioplegia.~3. A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
57746471|NCT03152383|BEHAVIORAL|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
57746472|NCT01186029|DRUG|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
57746473|NCT01196338|BEHAVIORAL|Early weight-bearing and range of motion exercises|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
57746474|NCT01196338|BEHAVIORAL|non-weight bearing, no range of motion|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
57746475|NCT01982240|DRUG|Plecanatide|Plecanatide tablets QD for 12 weeks
57746476|NCT01982240|DRUG|Placebo|Matching placebo tablets QD for 12 weeks
57746477|NCT01982240|DRUG|Bisacodyl|Rescue medication
57746478|NCT05732233|DEVICE|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
57746479|NCT00134550|DRUG|Atorvastatin (10 mg or 80 mg)|
58120169|NCT00193778|PROCEDURE|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
58120170|NCT00193778|OTHER|No Loco-regional treatment|This group will not receive any loco-regional treatment
57746480|NCT06188572|OTHER|Michigan Neuropathy Screening Instrument|A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
57746481|NCT06188572|OTHER|Numeric Pain Scale|"In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain."
57746482|NCT06188572|OTHER|Mandibular Function Disorder Questionnaire|This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
57746483|NCT06188572|OTHER|Fonseca Anamnestic Index|This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
57746484|NCT06188572|OTHER|Ferrans&Powers Quality of Life Index Diabetes Version|This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
57746485|NCT01081093|PROCEDURE|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
57746486|NCT02495051|PROCEDURE|esophageal biopsies|
57746487|NCT06732635|PROCEDURE|Enhanced recovery after surgery (ERAS)|Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
57746488|NCT03130751|BEHAVIORAL|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
57746489|NCT04477928|DIAGNOSTIC_TEST|Sera and whole blood sampling|"* Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
57746490|NCT04477928|DIAGNOSTIC_TEST|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
57746491|NCT01596582|BEHAVIORAL|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
57746492|NCT03661411|DRUG|Aspirin|100mg qd
57746493|NCT03661411|DRUG|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
57746494|NCT03661411|DRUG|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
57746495|NCT05098093|DIETARY_SUPPLEMENT|SBE|Hard-shell capsule
57746496|NCT05098093|DIETARY_SUPPLEMENT|DBE|Hard-shell capsule
58449524|NCT00806988|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
57746497|NCT05098093|DIETARY_SUPPLEMENT|BP|Hard-shell capsule
57746498|NCT04568135|OTHER|survey|survey
57746499|NCT01903850|DEVICE|spray cryotherapy|spray cryotherapy
57746500|NCT01900782|BIOLOGICAL|Intervention A|Prefilled syringe.
58449525|NCT06261593|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
58449526|NCT02279667|DRUG|BIA 2-093|oral suspension 50 mg/mL
57746501|NCT01900782|BIOLOGICAL|Intervention B|Prefilled syringe.
57746502|NCT01900782|BIOLOGICAL|Placebo|Prefilled syringe to match experimental drug and active comparator.
57746503|NCT05451654|DRUG|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
57746504|NCT05451654|DRUG|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
57746505|NCT03496506|DRUG|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
58120171|NCT04025034|PROCEDURE|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
57746506|NCT03496506|DRUG|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
57746507|NCT04454658|DRUG|ABBV-744|Tablet; Oral
57746508|NCT04454658|DRUG|Navitoclax|Tablet; Oral
57746509|NCT04454658|DRUG|Ruxolitinib|Tablet; Oral
57746510|NCT05597254|DIETARY_SUPPLEMENT|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
57746511|NCT05597254|DIETARY_SUPPLEMENT|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
58449527|NCT02279667|DRUG|BIA 2-093|200 mg tablet
58449528|NCT02279667|DRUG|BIA 2-093|800 mg tablet
57746512|NCT05597254|DIETARY_SUPPLEMENT|Placebo|1 capsule daily of placebo supplementation for 8 weeks
57746513|NCT06265077|DRUG|Placebo|Placebo
57746514|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
58120172|NCT01679132|DEVICE|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
57746515|NCT00302796|DRUG|Bioclavid|500 + 125 mg times 3 or 6
58120173|NCT02229006|RADIATION|18F-NaF PET-CT|
58120174|NCT02437799|OTHER|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
58120175|NCT05834790|OTHER|Mobile Augmented Reality (MAR) for oral health education program|MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
58120176|NCT05834790|OTHER|Lecture-based oral health education program|The oral health education program that will be delivered by traditional lecture-based process
58120177|NCT03140592|PROCEDURE|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
58120178|NCT04840407|BEHAVIORAL|SHARP coach intervention|The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
58120179|NCT04661137|DRUG|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
58120180|NCT04661137|DRUG|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
58120181|NCT04661137|DRUG|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
58120182|NCT04661137|DRUG|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
58120183|NCT04661137|DRUG|Pomalidomide|4 mg PO daily for 21 days
58120184|NCT04661137|DRUG|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
58120185|NCT04661137|DRUG|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
58120186|NCT02127047|DRUG|Sitagliptin|
58449529|NCT03930693|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice shot (70mL containing 400mg inorganic nitrate)
57746516|NCT00302796|DRUG|Placebo|
57746517|NCT02207010|BIOLOGICAL|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
58120187|NCT02127047|DRUG|Exercise|
58120188|NCT05747079|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
58120189|NCT05747079|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
58120190|NCT05747079|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
58120191|NCT00313885|DRUG|eplivanserin (SR46349)|oral administration
58120192|NCT00313885|DRUG|placebo|oral administration
58120193|NCT01751412|RADIATION|Proton Radiation|
58120194|NCT05498285|BEHAVIORAL|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
58120195|NCT02294656|DRUG|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
58120196|NCT02294656|DRUG|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
58449530|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
58449531|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules containing 9000 FCC of acid lactase
58449532|NCT01593631|DIETARY_SUPPLEMENT|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
58449533|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
58449534|NCT01593631|DIETARY_SUPPLEMENT|Placebo|Capsules containing di-calcium-phosphate
57746518|NCT05721534|OTHER|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
58449535|NCT00478842|DEVICE|Deep brain stimulation|Deep brain stimulation
58449536|NCT01479868|DRUG|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
58449537|NCT01479868|DRUG|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
58449538|NCT01479868|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
57746519|NCT01087268|OTHER|questionnaire administration|
58120197|NCT02387320|OTHER|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
58120198|NCT02347878|DRUG|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
58449539|NCT02693041|DRUG|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
58449540|NCT02693041|DRUG|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
58449541|NCT05336578|OTHER|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
58449542|NCT04205526|DEVICE|Active rTMS|Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
58449543|NCT04205526|DEVICE|Sham TMS|For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
58449544|NCT00500188|DRUG|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
58449545|NCT06202963|DRUG|Triamcinolone Acetonide|"1. group will receive ultrasound-guided hydrodilatation~2. group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
58449546|NCT02638324|PROCEDURE|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
58449547|NCT02042521|DRUG|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
58449548|NCT02042521|DRUG|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
58449549|NCT00879385|DRUG|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
58449550|NCT00879385|DRUG|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
58120199|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light|A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
58120200|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light|The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
58120201|NCT03616613|DIAGNOSTIC_TEST|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
58120202|NCT03283709|DEVICE|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
58120203|NCT03283709|DEVICE|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
58449551|NCT00005857|BIOLOGICAL|trastuzumab|
58449552|NCT00005857|DRUG|docetaxel|
58449553|NCT04390243|DRUG|Binimetinib|Given PO
58449554|NCT04390243|DRUG|Encorafenib|Given PO
58449555|NCT02656355|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
58449556|NCT02656355|OTHER|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
58449557|NCT05842759|PROCEDURE|Monitoring|Continuous blood pressure monitoring
57746520|NCT01087268|PROCEDURE|gastrointestinal complications management/prevention|
57746521|NCT01087268|PROCEDURE|quality-of-life assessment|
58449558|NCT05842759|PROCEDURE|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
58449559|NCT05842759|PROCEDURE|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
58449560|NCT05842759|PROCEDURE|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
58449561|NCT05842759|PROCEDURE|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
58449562|NCT04863391|DIAGNOSTIC_TEST|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
58449563|NCT00491413|DRUG|epoetin|
57746522|NCT03274869|OTHER|No intervention|No intervention
57746523|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
57746524|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
57746525|NCT01559844|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
57746526|NCT01559844|DRUG|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
57746527|NCT00627484|PROCEDURE|Gastric bypass|NOTE: the surgery is not paid for by the study
57746528|NCT00627484|PROCEDURE|Gastric banding|NOTE: the surgery is not paid for by the study
57746529|NCT00627484|PROCEDURE|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
57958811|NCT05979610|OTHER|Reiki therapy|"Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization."
57958812|NCT02058680|BIOLOGICAL|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
57958813|NCT03260959|BEHAVIORAL|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
57958814|NCT03881150|OTHER|Comprehensive assessment|Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
57958815|NCT03881150|OTHER|Counseling|Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
58120204|NCT04809870|PROCEDURE|surgery|retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
58120205|NCT01783106|DRUG|Ciprofloxacin|experimental
58120206|NCT01783106|DRUG|Doxycycline|experimental
58120207|NCT01783106|DRUG|Hydroxychloroquine|oral
58449564|NCT01964417|DRUG|Colonoscopy after bowel cleansing|
58449565|NCT05687721|DRUG|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
58449566|NCT05687721|DRUG|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
58449567|NCT01153126|BEHAVIORAL|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
58449568|NCT00972335|DRUG|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
58449569|NCT00972335|DRUG|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
58449570|NCT06504316|DEVICE|CRRT filter|The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
58449571|NCT02378688|DRUG|MT-1303|
58449572|NCT02378688|DRUG|Placebo|
58449573|NCT01209351|DRUG|Placebo|placebo
58449574|NCT01209351|DRUG|teduglutide|teduglutide 4 mg
58449575|NCT00605124|OTHER|Knee muscle exercises|Home exercises three times a week, control every three months
58449576|NCT02218645|DRUG|WE 941 OD tablets|
58449577|NCT02218645|DRUG|Brotizolam|
58120208|NCT01783106|DRUG|Budesonide|active comparator
58120209|NCT00399113|DRUG|188Re-PTI-6D2|monoclonal antibody
58120210|NCT05157321|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
58120211|NCT05157321|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
58120212|NCT03845920|COMBINATION_PRODUCT|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
58120213|NCT03571308|DRUG|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
58120214|NCT05738356|COMBINATION_PRODUCT|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
58120215|NCT04999514|BEHAVIORAL|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
58120216|NCT00581620|BIOLOGICAL|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
58313733|NCT04868032|BEHAVIORAL|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
58313734|NCT04616534|PROCEDURE|Biopsy|Undergo biopsy (dose expansion cohort only)
58449578|NCT02364141|OTHER|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
58449579|NCT02364141|OTHER|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
58449580|NCT01729299|DRUG|Exendin (9-39)|
58449581|NCT01729299|DRUG|acyl ghrelin|
58449582|NCT01729299|DRUG|saline|
58449583|NCT03242629|DRUG|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
58449584|NCT03242629|DRUG|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
58449585|NCT05716061|PROCEDURE|Sacral ESPB|Cadaver study
57746530|NCT00627484|BEHAVIORAL|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
57958816|NCT03881150|OTHER|Group education|Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
58449586|NCT03035799|OTHER|Paleolithic diet|Paleolithic diet
57746531|NCT03830593|PROCEDURE|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
57958817|NCT03881150|OTHER|Exercise sessions in hybrid program|"10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate."
58313735|NCT04616534|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58313736|NCT04616534|PROCEDURE|Diagnostic Imaging|Undergo medical imaging scans
58313737|NCT04616534|DRUG|Elimusertib|Given PO
58449587|NCT03035799|OTHER|General Healthful Diet|General Healthful Diet
57958818|NCT03881150|OTHER|Exercise sessions in standard program|"18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate."
57958819|NCT03881150|OTHER|Transition to unsupervised phase|After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
58120217|NCT01417897|DRUG|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
58120218|NCT01417897|DRUG|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
58120219|NCT01417897|DRUG|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
58120220|NCT03510299|DEVICE|Mcgrath|McGrath assisted insertion of LMA flexible
58120221|NCT03510299|DEVICE|Control|Digital manipulation technique of LMA flexible insertion
58120222|NCT03149913|DEVICE|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
58120223|NCT03149913|DEVICE|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
58120224|NCT05170555|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.
58120225|NCT05170555|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
58120226|NCT04215055|DEVICE|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
58120227|NCT00647582|PROCEDURE|adjuvant therapy|
58120228|NCT00647582|PROCEDURE|therapeutic conventional surgery|
58120229|NCT00647582|RADIATION|intraoperative radiation therapy|
58120230|NCT00647582|RADIATION|radiation therapy|
58449588|NCT00483405|BIOLOGICAL|cetuximab|250 mg/m2, intravenously, once per week
58120231|NCT05753774|BIOLOGICAL|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
58120232|NCT05753774|DRUG|Conventional drugs|Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
58120233|NCT04102774|DEVICE|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
58120234|NCT00492206|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
58120235|NCT05646121|DEVICE|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
58120236|NCT04693065|OTHER|ponseti|Standard of care, treatment by ponseti method
58120237|NCT03259581|COMBINATION_PRODUCT|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
58120238|NCT01645800|DRUG|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
58449589|NCT00483405|DRUG|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
58120239|NCT01645800|DRUG|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
58449590|NCT00483405|DRUG|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
58120240|NCT00374413|DEVICE|Artificial disk|Implant
58120241|NCT00374413|DEVICE|Artificial disc|Implant
58120242|NCT02435979|OTHER|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
58120243|NCT02435979|OTHER|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
58120244|NCT01285531|DEVICE|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
58120245|NCT02346968|OTHER|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
58120246|NCT03718455|DEVICE|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
58120247|NCT01656889|BIOLOGICAL|HP-802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
58120248|NCT01656889|BIOLOGICAL|Vehicle|(fibrinogen solution \& thrombin solution without cells)
58449591|NCT03787121|PROCEDURE|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
58449592|NCT05565937|DEVICE|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
58449593|NCT05565937|DEVICE|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
58449594|NCT02222558|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
58449595|NCT01556451|BIOLOGICAL|Zoster Vaccine Live|Zoster vaccine live
58120249|NCT00601354|BEHAVIORAL|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
58120250|NCT00601354|DRUG|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
58120251|NCT00531375|DEVICE|Silicone hydrogel contact lens|
58120252|NCT03734965|DEVICE|AWAKEN INTUBATION|Intubation
58120253|NCT03323554|DEVICE|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
58120254|NCT03323554|DEVICE|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
58120255|NCT06380946|BIOLOGICAL|iPRF|iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
58120256|NCT01032395|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
58120257|NCT01032395|BIOLOGICAL|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
58120258|NCT01032395|BIOLOGICAL|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
58120259|NCT04455659|DEVICE|Trans-cutaneous Electrical Nerve Stimulation|TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
58120260|NCT04455659|PROCEDURE|Conventional physical therapy exercise|physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
58120261|NCT06200896|DEVICE|Self Forming Magnets used to Create A Compression Anastomosis|Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
58120262|NCT02944643|OTHER|Mindfulness and Support Groups|
58120263|NCT04574583|DRUG|SX-682|SX-682 will be given orally at designated dose twice a day every day
58120264|NCT04574583|DRUG|M7824|Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
58449596|NCT05960981|BEHAVIORAL|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
58449597|NCT04480268|DRUG|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~* nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~* cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~* capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~* gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
58449598|NCT00381758|DRUG|Methylphenidate Extended Release Capsules|
57746532|NCT01955954|DEVICE|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
57746533|NCT04803981|OTHER|SpoonfulONE|SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
58120265|NCT04574583|BIOLOGICAL|MVA-BN-CV301|MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
57746534|NCT00809887|DRUG|Micafungin lock therapy|
57746535|NCT06174714|BEHAVIORAL|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
58120266|NCT04574583|BIOLOGICAL|recombinant fowlpox viral (FPV)-CV301|FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
58313738|NCT04616534|DRUG|Gemcitabine|Given IV
57746536|NCT02538731|PROCEDURE|dilation-assisted stone extraction|
58120267|NCT00003942|BIOLOGICAL|RevM10 gene|
58120268|NCT00003942|BIOLOGICAL|RevM10/polAS gene|
58120269|NCT00003942|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58120270|NCT00003942|PROCEDURE|peripheral blood stem cell transplantation|
58120271|NCT00030108|DRUG|ixabepilone|
58120272|NCT03299153|OTHER|barberry juice|
58120273|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 1|SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
58120274|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 2|SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
58313739|NCT00774917|DEVICE|Numen|Numen Co-Cr coronary stent implant
58313740|NCT02423408|DRUG|TNX-201|TNX-201 capsule
58313741|NCT02423408|DRUG|Placebo|Placebo capsule
58120275|NCT02849925|DRUG|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
58120276|NCT04529148|DRUG|Ginkgo biloba dropping pills，best western medicine treatment|oral
58120277|NCT04529148|DRUG|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
58120278|NCT01172600|OTHER|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
58120279|NCT01172600|OTHER|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
58449599|NCT04977284|DEVICE|DS7R, Digitimer, UK|Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
57746537|NCT02538731|DEVICE|Spyglass Guided Laser Lithotrips|
57746538|NCT02131272|DRUG|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
57746539|NCT02131272|DRUG|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
57746540|NCT02131272|BEHAVIORAL|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
57746541|NCT02413580|BIOLOGICAL|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
57746542|NCT00571454|BEHAVIORAL|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
57746543|NCT03546881|PROCEDURE|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
57746544|NCT03546881|PROCEDURE|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
57746545|NCT00006352|BIOLOGICAL|BCG vaccine|
58120280|NCT00567281|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
57746546|NCT00006352|BIOLOGICAL|monoclonal antibody BEC2|
58120281|NCT00567281|DEVICE|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
58120282|NCT05621642|OTHER|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
58120283|NCT05621642|OTHER|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
58313742|NCT00537277|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
58449600|NCT05265208|DRUG|Capecitabine|Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
58449601|NCT05265208|DEVICE|Selective Internal Radiotherapy (SIRT)|During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.
58449602|NCT05265208|PROCEDURE|Surgery|Surgery will be performed according to local practice.
57746547|NCT05562882|DRUG|Daratumumab Injection|intravenous daratumumab administration
57746548|NCT03749564|BEHAVIORAL|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
57958820|NCT04520672|OTHER|Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
57958821|NCT04520672|OTHER|Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
57958822|NCT03934450|DRUG|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
57958823|NCT03934450|DRUG|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
58120284|NCT05621642|OTHER|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
58120285|NCT04480723|OTHER|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
58120286|NCT04480723|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
58120287|NCT06113796|OTHER|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
58120288|NCT02410525|DRUG|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
58120289|NCT02410525|DRUG|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
58120290|NCT02410525|DRUG|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
58120291|NCT00219258|DRUG|Zoledronic acid|
58120292|NCT02832609|OTHER|Supine|measurements after 30 minutes in complete supine position
58120293|NCT04110522|OTHER|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
58120294|NCT02253277|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
58120295|NCT02253277|DRUG|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
58120296|NCT04040010|DIETARY_SUPPLEMENT|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
58449603|NCT05892601|OTHER|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
58449604|NCT04729725|BIOLOGICAL|Anti-TGF-beta Monoclonal Antibody SAR-439459|Given IV
58449605|NCT04729725|BIOLOGICAL|Cemiplimab|Given IV
58449606|NCT00586859|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
58120297|NCT00027469|PROCEDURE|MRI|
58120298|NCT05849610|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
58120299|NCT05849610|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
58120300|NCT05849610|DRUG|Lenalidomide|Lenalidomide will be administered by oral route.
58120301|NCT05849610|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
58120302|NCT05849610|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
58120303|NCT04310410|COMBINATION_PRODUCT|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
58120304|NCT05117892|OTHER|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
58120305|NCT04568447|DEVICE|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
58313743|NCT05991817|PROCEDURE|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
58120306|NCT05038813|DRUG|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
57746549|NCT03749564|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
57746550|NCT03749564|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
58120307|NCT05933096|DIAGNOSTIC_TEST|Contrast-enhanced multispectral optoacoustic tomography|Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
58120308|NCT06192082|PROCEDURE|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
58120309|NCT06192082|PROCEDURE|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
58120310|NCT01508026|DRUG|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
58120311|NCT01508026|DRUG|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
58449607|NCT05282069|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
58449608|NCT05282069|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
58449609|NCT05282069|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
58449610|NCT05282069|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
58449611|NCT05282069|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
58449612|NCT00936702|DRUG|carboplatin|Given IV
58449613|NCT00936702|DRUG|everolimus|Given PO
58449614|NCT00936702|DRUG|paclitaxel|Given IV
58449615|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
58449616|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
58449617|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
58449618|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
58449619|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
58449620|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
58449621|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
58449622|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
57746551|NCT03749564|BEHAVIORAL|Extended SMT|Additional 6 SMT sessions provided
58449623|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
58449624|NCT02296567|OTHER|Control Group|Control group Subjects will no previous anti-VEGF treatment
58449625|NCT03027622|BEHAVIORAL|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
58449626|NCT05152459|DRUG|Tazemetostat|Given PO
58449627|NCT05152459|BIOLOGICAL|Ublituximab|Given IV
58449628|NCT05152459|DRUG|Umbralisib|Given PO
58449629|NCT05620082|DIETARY_SUPPLEMENT|Standard liquid-based oral nutritional supplement|An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
58449630|NCT05620082|DIETARY_SUPPLEMENT|Fortified porridge|Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
58449631|NCT01784731|BEHAVIORAL|Willingness to pay|
58449632|NCT00174902|DRUG|inderal (drug), acetylsalicylic acid (drug)|
58449633|NCT00909506|DRUG|Placebo|"Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day)."
58120312|NCT01508026|DRUG|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
58120313|NCT01508026|DRUG|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
58120314|NCT01508026|DRUG|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
58120315|NCT01508026|DRUG|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
58120316|NCT01508026|DRUG|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
58120317|NCT01508026|DRUG|Placebo|Dose matched placebo, oral administration
58120318|NCT00939445|PROCEDURE|Online HDF|Online HDF
58120319|NCT00939445|PROCEDURE|Short Daily Hemodialysis|Short Daily Hemodialysis
58120320|NCT05634187|DEVICE|Functional endoscopy|Transnasal endoscopy by an ultrathin video endoscope
58120321|NCT05433428|DRUG|Lubricant Eye Drops|Prolonged use of lubricant eye drops pre and post-op.
58120322|NCT05433428|DRUG|Preservative Free|Preservative free eye drops
58120323|NCT05433428|DRUG|Preservative|Eyedrops with preservatives
58120324|NCT01046253|DRUG|Lansoprazole|30 mg Delayed-Release Capsules
58120325|NCT01046253|DRUG|Prevacid®|30 mg Delayed-Release Capsule
58120326|NCT02174939|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
58120327|NCT02174939|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
58120328|NCT02185781|OTHER|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
58120329|NCT02062047|PROCEDURE|FMSRP|FMSRP in a maximum of 24 hours.
58449634|NCT00909506|DRUG|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks."
58449635|NCT00909506|DRUG|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day)."
58449636|NCT00466440|DRUG|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
58120330|NCT02062047|DRUG|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
58449637|NCT00466440|DRUG|placebo|Loading dose, then po QD until unblinding
58449638|NCT00466440|DRUG|docetaxel|75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
58449639|NCT00466440|DRUG|prednisone|5 mg po BID, six 21-day cycles
58120331|NCT02062047|PROCEDURE|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
58120332|NCT02062047|OTHER|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
58120333|NCT05164549|DRUG|Buprenorphine Injectable Product|Investigational Medicinal Product
58120334|NCT05164549|DRUG|Methadone|Standard of Care
58120335|NCT05164549|DRUG|Buprenorphine|Standard of Care
58120336|NCT03486613|OTHER|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
58120337|NCT03486613|OTHER|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
58120338|NCT02034799|BIOLOGICAL|Bioseal Fibrin Sealant|
58120339|NCT02034799|OTHER|Standard of Care (SoC)|
58120340|NCT00192699|DEVICE|Bimetric femoral stem|Cemented Bi-Metric femoral stem
58120341|NCT05378906|DRUG|DRV/COBI FDC|Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
58120342|NCT05378906|DRUG|COBI|Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.
58120343|NCT05378906|DRUG|DRV|Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
58120344|NCT01053273|PROCEDURE|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
58120345|NCT01053273|PROCEDURE|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
58120346|NCT05987046|BEHAVIORAL|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
58120347|NCT02583542|DRUG|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
58313744|NCT03199690|DRUG|Dolutegravir|Antiviral (integrase inhibitor)
58313745|NCT03199690|DRUG|Rifampicin|Antibiotic
58313746|NCT05203653|BEHAVIORAL|Resistance exercise only|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
58313747|NCT05203653|BEHAVIORAL|Resistance exercise plus cool down|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
58313748|NCT04269616|BEHAVIORAL|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
58313749|NCT04269616|BEHAVIORAL|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
58120348|NCT02583542|DRUG|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
58120349|NCT00274209|PROCEDURE|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
58120350|NCT00000819|DRUG|Prednisone|
58120351|NCT03486977|PROCEDURE|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
58120352|NCT02477566|DRUG|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
58449640|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
58449641|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
57746552|NCT01764165|OTHER|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
57746553|NCT01764165|OTHER|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
57746554|NCT01229930|DRUG|carboplatin|
57746555|NCT01229930|DRUG|cediranib maleate|
57746556|NCT01229930|DRUG|paclitaxel|
57746557|NCT01229930|OTHER|laboratory biomarker analysis|
57746558|NCT01229930|OTHER|pharmacological study|
57746559|NCT01229930|PROCEDURE|quality-of-life assessment|
57746560|NCT06580405|DEVICE|KNP-1000 Apheresis System|sFlt-1 is removed from the participants' plasma through treatment.
57746561|NCT04824482|OTHER|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
57746562|NCT04824482|OTHER|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
57746563|NCT00343928|OTHER|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
57746564|NCT00377403|DRUG|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
57746565|NCT00377403|DRUG|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
58120353|NCT02477566|DRUG|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
58120354|NCT02386410|BEHAVIORAL|Group parent training for anxious parents|
58120355|NCT02386410|BEHAVIORAL|Internet delivered parent training for anxious parents|
58120356|NCT04806009|BEHAVIORAL|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
57746566|NCT00377403|DRUG|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
58120357|NCT04806009|BEHAVIORAL|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
58449642|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
58449643|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
57746567|NCT00377403|DRUG|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
57746568|NCT00377403|DRUG|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
57746569|NCT00377403|DRUG|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
57746570|NCT01845740|DRUG|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
57746571|NCT01845740|DRUG|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
57746572|NCT00095706|DRUG|Bevacizumab (drug), Herceptin (drug)|
57746573|NCT03057353|DEVICE|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
57746574|NCT03544892|OTHER|Low carbohydrate diet|60-80 g total carbohydrate per day
57746575|NCT03544892|OTHER|Standard of care diet|\> 150 g total carbohydrate per day
57746576|NCT05314036|OTHER|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
57746577|NCT01763710|DRUG|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
57746578|NCT01763710|DRUG|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
58449644|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
58449645|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
57746579|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
57746580|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
58120358|NCT01126515|PROCEDURE|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
58120359|NCT01126515|PROCEDURE|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
58120360|NCT05155800|DEVICE|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
58120361|NCT00949130|DRUG|NXL103|BID for 7-14 days
58120362|NCT00949130|DRUG|Linezolid|BID for 7-14 days
58120363|NCT04833712|RADIATION|Stereotactic Radioablation|Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
58120364|NCT02964728|DRUG|Botulinum Neurotoxin Type A|topical injection
58120365|NCT02964728|OTHER|Normal saline|topical injection
58120366|NCT01150448|DRUG|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
58120367|NCT01150448|DRUG|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
58449646|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
58120368|NCT04523558|DEVICE|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
58120369|NCT01241942|DEVICE|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
58120370|NCT01241942|OTHER|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
58120371|NCT05710185|DRUG|Deucravacitinib|See arm/group description
58120372|NCT02405507|DIETARY_SUPPLEMENT|wheat bread with wheat germ|
58120373|NCT02405507|DIETARY_SUPPLEMENT|wheat bread without wheat germ|
58449647|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
58120374|NCT03029533|DRUG|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
58120375|NCT03029533|DRUG|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
58120376|NCT05391399|DEVICE|Interlocking detachable coils system|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
58120377|NCT05391399|DEVICE|Interlock Fibered IDC Occlusion System|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
58120378|NCT05180578|OTHER|Goat milk diet|Elimination of cow milk from diet . Goat milk containing diet.
58120379|NCT04538040|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
58449648|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
57746581|NCT00439712|DRUG|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
57746582|NCT00439712|DRUG|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
57746583|NCT01024426|PROCEDURE|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
57746584|NCT01024426|OTHER|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
57746585|NCT03369548|OTHER|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
58449649|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
58449650|NCT01867749|BEHAVIORAL|Group Interpersonal Psychotherapy (IPT-G)|
58449651|NCT01867749|BEHAVIORAL|Coping with Depression (CWD)|
58449652|NCT00900666|DRUG|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
58449653|NCT00900666|DRUG|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
57746586|NCT03369548|OTHER|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
57746587|NCT03369548|DIETARY_SUPPLEMENT|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
57746588|NCT03369548|OTHER|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
58120380|NCT00642538|DRUG|MKC253 Inhalation Powder|Inhalation Powder, prandial
58120381|NCT00642538|DRUG|Technosphere Inhalation Powder|Inhalation Powder, prandial
58120382|NCT00642538|DRUG|subcutaneous injection|10µg Exenatide, prandial
58120383|NCT01204320|PROCEDURE|Paclitaxel-coated Balloon|POBA
57746589|NCT05675657|OTHER|No Block|The patients will receive general anesthesia.
58120384|NCT01204320|DEVICE|Paclitaxel-eluting Stent|Stenting
58120385|NCT00317499|OTHER|Placebo|Placebo
58449654|NCT03958058|DRUG|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
57746590|NCT05675657|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
57746591|NCT05675657|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
57746592|NCT00288483|DRUG|Policosanol|
57746593|NCT05907824|OTHER|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
57746594|NCT05461222|DEVICE|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
57746595|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
58449655|NCT03958058|OTHER|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
58449656|NCT02936817|DEVICE|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
57746596|NCT00234052|BIOLOGICAL|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
57746597|NCT00234052|DRUG|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
57746598|NCT00234052|DRUG|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
57746599|NCT01808950|DRUG|0.06% Resiquimod Gel - A|single 60mg dose
57746600|NCT01808950|DRUG|0.06% Resiquimod Gel - B|single 100mg dose
57958824|NCT03934450|DRUG|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
58120386|NCT00317499|DRUG|Etanercept|Etanercept
58120387|NCT06105281|BEHAVIORAL|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
58449657|NCT02936817|RADIATION|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
58449658|NCT04201665|DRUG|Carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
57746601|NCT01808950|DRUG|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
57746602|NCT00781391|DRUG|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
57746603|NCT00781391|DRUG|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
57746604|NCT00781391|DRUG|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
57746605|NCT00781391|DRUG|placebo warfarin|placebo warfarin
57746606|NCT00781391|DRUG|placebo edoxaban|placebo edoxaban
57958825|NCT03934450|DRUG|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
57958826|NCT03834415|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10\>8 CFU
57958827|NCT03834415|OTHER|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
57958828|NCT00006565|DEVICE|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
57958829|NCT00006565|DEVICE|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
58120388|NCT04295395|DEVICE|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
58120389|NCT05252806|DIAGNOSTIC_TEST|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
58120390|NCT04881955|DRUG|[14C]-Ecopipam|\[14C\]-Ecopipam
58120391|NCT01918878|DRUG|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
58120392|NCT04758650|DRUG|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
58120393|NCT06037200|DEVICE|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
58120394|NCT03004521|DRUG|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
58120395|NCT03004521|DRUG|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
58120396|NCT02391428|PROCEDURE|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
58120397|NCT02391428|DIETARY_SUPPLEMENT|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
58120398|NCT05460442|PROCEDURE|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
58120399|NCT05460442|PROCEDURE|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
58120400|NCT05460442|PROCEDURE|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
58120401|NCT02699580|DEVICE|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
58313750|NCT02668003|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
58313751|NCT05803460|BEHAVIORAL|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
57958830|NCT05722665|OTHER|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
58120402|NCT02699580|PROCEDURE|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
58120403|NCT00995137|BIOLOGICAL|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
58120404|NCT04266691|OTHER|nonIntervention|nonIntervention
58120405|NCT04170179|PROCEDURE|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
58120406|NCT04170179|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58120407|NCT04170179|DRUG|Toripalimab|240mg intravenously every 3 weeks
58120408|NCT05694091|OTHER|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
58120409|NCT03896217|DRUG|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
58120410|NCT05262621|OTHER|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
58313752|NCT05803460|BEHAVIORAL|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
58313753|NCT05803460|BEHAVIORAL|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
58313754|NCT05803460|BEHAVIORAL|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
58313755|NCT05803460|BEHAVIORAL|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
58313756|NCT05803460|BEHAVIORAL|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
57958831|NCT04428424|DRUG|Enbrel|As provided in real world practice
58449659|NCT04201665|DRUG|Oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
57958832|NCT00424827|DRUG|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
57746607|NCT03176420|PROCEDURE|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
57746608|NCT05641558|DRUG|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
57746609|NCT05641558|DRUG|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
57746610|NCT05641558|DRUG|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
57746611|NCT05641558|OTHER|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
57746612|NCT02514629|DRUG|Placebo|
58449660|NCT02947646|DEVICE|BabyGentleStick™ ON|experimental intervention
58449661|NCT02947646|DEVICE|BabyGentleStick™ OFF|active comparator
57746613|NCT02514629|DRUG|Metformin|
58120411|NCT05262621|OTHER|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
58120412|NCT04516525|DEVICE|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
58120413|NCT05426720|OTHER|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
58120414|NCT00491504|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
58120415|NCT00491504|OTHER|Placebo|Placebo: 2 sprays in each nostril
58449662|NCT04233203|DRUG|Insulin Faster Aspart|Currently receiving Faster Aspart during 3 or more months.
58449663|NCT04233203|DEVICE|Insulin pump|Currently receiving CSII therapy during 6 or more months.
58449664|NCT05041283|OTHER|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
57746614|NCT02514629|DRUG|Testosterone Undecanoate|
57746615|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
57746616|NCT00785291|BIOLOGICAL|Bevacizumab|Given IV
57746617|NCT00785291|DRUG|Ixabepilone|Given IV
57746618|NCT00785291|OTHER|Laboratory Biomarker Analysis|Correlative studies
57746619|NCT00785291|DRUG|Nab-paclitaxel|Given IV
57746620|NCT00785291|DRUG|Paclitaxel|Given IV
57746621|NCT00785291|OTHER|Questionnaire Administration|Ancillary studies
57746622|NCT05236686|PROCEDURE|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
57746623|NCT00554918|DRUG|docetaxel|
57746624|NCT00554918|DRUG|prednisolone|
58120416|NCT00043836|DRUG|ALT-711|
58120417|NCT02206204|DRUG|selexipag|
58120418|NCT02206204|DRUG|placebo for selexipag|
58120419|NCT02206204|DRUG|moxifloxacin|
58120420|NCT02206204|DRUG|moxifloxacin-matching placebo|
58120421|NCT05116020|OTHER|Usual chiropractic care|Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
58120422|NCT04209972|DEVICE|Precision Ultra-High-Resolution CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
58120423|NCT04209972|DEVICE|Genesis high-end CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
58313757|NCT01521741|OTHER|Breast Cancer-Related Lymphedema Screening|All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
58449665|NCT05041283|OTHER|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
58449666|NCT00644020|DRUG|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
58449667|NCT02305771|DEVICE|Electroencephalography|
58449668|NCT02305771|DEVICE|MRI|
58449669|NCT03904121|PROCEDURE|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
58449670|NCT01239966|DEVICE|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
58449671|NCT06095219|OTHER|Non- contrast Magnetic Resonance Imaging (MRI) of the hip|Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.
58120424|NCT01346423|BEHAVIORAL|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
58120425|NCT01346423|BEHAVIORAL|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
58120426|NCT05894863|DEVICE|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
58120427|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
58120428|NCT01579474|DRUG|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
58120429|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
58449672|NCT06095219|OTHER|Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent|The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
58449673|NCT01941329|PROCEDURE|Panretinal Photocoagulation (PRP)|
58449674|NCT01941329|DRUG|Intravitreous injection of ranibizumab|
58449675|NCT05460611|DEVICE|Sciton HALO 1470nm Non-ablative laser|Patients will be treated with the 1470nm non-ablative laser.
57746625|NCT00554918|DRUG|zoledronic acid|
57746626|NCT00554918|PROCEDURE|quality-of-life assessment|
57746627|NCT00554918|RADIATION|strontium chloride Sr 89|
57746628|NCT03375983|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
57746629|NCT03927469|OTHER|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
57746630|NCT01760239|BEHAVIORAL|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
57746631|NCT00968682|BIOLOGICAL|trastuzumab|
57746632|NCT00968682|OTHER|laboratory biomarker analysis|
57746633|NCT00968682|PROCEDURE|assessment of therapy complications|
57746634|NCT01789554|OTHER|MLS dispatch for bystander CPR|
57958833|NCT00252707|DRUG|Gefitinib or Docetaxel|
57958834|NCT03038425|DRUG|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
57958835|NCT03038425|DRUG|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
57958836|NCT04090112|DRUG|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
57958837|NCT04090112|DRUG|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
57958838|NCT06410560|OTHER|Training about storytelling and creative writing: 12 hours|Participants in training courses on creative writing and storytelling.
57958839|NCT06410560|OTHER|Training only about theoretical narrative medicine: 4 hours|Participants in training courses on only theoretical narrative medicine.
57958840|NCT03003208|OTHER|Pulmonary rehabilitation|An exercise and education program
57958841|NCT03554915|OTHER|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
57958842|NCT03554915|OTHER|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
57746635|NCT05382312|DRUG|GSK3036656|GSK3036656 will be administered.
57746636|NCT05382312|DRUG|Bedaquiline|Bedaquiline will be administered.
57746637|NCT05382312|DRUG|Delamanid|Delamanid will be administered.
57958843|NCT00512798|DRUG|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2"
57958844|NCT00512798|DRUG|temozolomide|"Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2"
57958845|NCT00512798|OTHER|immunoenzyme technique|Not noted
57958846|NCT00512798|DRUG|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
57958847|NCT00512798|DRUG|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
57958848|NCT00836212|DRUG|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
57746638|NCT05382312|DRUG|RIFAFOUR e-275|RIFAFOUR e-275 will be administered.
57746639|NCT05382312|DRUG|BTZ-043|BTZ-043 will be administered.
57746640|NCT02565914|DRUG|TEZ/IVA|Fixed dose tablet for oral administration.
58120430|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
58449676|NCT03709004|OTHER|Pacifier|Pacifier given to mom.
58449677|NCT03647657|DRUG|177Lu-PP-F11N|Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
58449678|NCT03647657|DRUG|Sacuitril|Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
58449679|NCT02838758|DEVICE|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
58449680|NCT02838758|DRUG|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
57746641|NCT02565914|DRUG|IVA|Tablet for oral administration.
57746642|NCT00477230|DEVICE|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
57746643|NCT00477230|DRUG|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
57746644|NCT00460187|DEVICE|Percutaneous intervention of the carotid artery|
58120431|NCT00992264|BEHAVIORAL|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
57746645|NCT05832450|OTHER|Red cell concentrate transfusion|Perioperative data of patient undergoing elective brain tumor resection with requirements of red cell concentrate transfusion.
57746646|NCT00405626|DRUG|Bellis Perenis ,Arnica montana|
57746647|NCT05089617|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
57746648|NCT04208516|PROCEDURE|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
57746649|NCT04208516|PROCEDURE|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
57746650|NCT04208516|PROCEDURE|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
57746651|NCT04208516|PROCEDURE|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
57746652|NCT04208516|DRUG|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
57746653|NCT04208516|DRUG|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
57746654|NCT04208516|DRUG|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
57746655|NCT04208516|DRUG|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
57746656|NCT04208516|DRUG|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
57746657|NCT04000295|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
57746658|NCT04000295|DRUG|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
57746659|NCT04000295|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
57958849|NCT00836212|DRUG|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
57958850|NCT00099190|DRUG|ARQ 501|
58120432|NCT00992264|BEHAVIORAL|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
58120433|NCT00992264|BEHAVIORAL|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
58120434|NCT00992264|BEHAVIORAL|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
58120435|NCT02809183|DRUG|Placebo|oral suspension
58120436|NCT02809183|DRUG|TRC101|oral suspension
58120437|NCT03847558|DIAGNOSTIC_TEST|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
58120438|NCT05819567|DEVICE|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
58449681|NCT02838758|DRUG|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
58449682|NCT02184923|OTHER|presentation of visual vertical|
58449683|NCT05979337|BEHAVIORAL|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
58120439|NCT00134836|BEHAVIORAL|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
58449684|NCT05979337|BEHAVIORAL|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
57746660|NCT06733168|DEVICE|electrical impedance tomography|"Before initiating recruitment maneuver, all patients were placed on mechanical ventilation set according to the ARDSnetwork strategy for 10 minutes, ensuring SpO2 of 88-95%, PaO2 of 55-80 mmHg, and a mean arterial pressure (MAP) ≥ 65 mmHg.~* PEEP was incrementally increased by 5 cmH2O every minute: from 10 to 15, to 20, and finally to 25 cmH2O, with a maximum pressure limit of 40 cmH2O.~* Following recruitment maneuver at the final PEEP level, the process of identifying the optimal PEEP was initiated.~* Then, PEEP will be set to 20 cmH2O and was gradually decreased by 2 cmH2O every 30 seconds until it reached 6 cmH2O or SpO2 dropped to ≤ 80%.~* Selection of optimal PEEP: The optimal PEEP was defined as the intersection point between the alveolar overdistension and collapse curves as measured by the EIT system."
58120440|NCT00343980|DRUG|rosiglitazone|Tablets, 4 mg once or twice a day.
58120441|NCT00343980|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
58120442|NCT00343980|DRUG|glimepiride|Tablets, 4 mg/day.
58449685|NCT05979337|BEHAVIORAL|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
58449686|NCT06270953|DEVICE|Dozee Pro NX|Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements
58449687|NCT00139048|BEHAVIORAL|Decision Aid|
58449688|NCT02620592|DRUG|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
58449689|NCT02620592|DRUG|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
58449690|NCT03604211|RADIATION|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
58449691|NCT05200715|OTHER|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
58449692|NCT01186302|OTHER|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
57746661|NCT06733168|OTHER|Non-EIT|Patients will have PEEP set using the low FiO2-PEEP table, based on the ARDSnet protocol
57746662|NCT02943057|DRUG|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
57746663|NCT01292876|DEVICE|Extracellular Matrix|Extracellular Matrix
57746664|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
57958851|NCT05992246|DIAGNOSTIC_TEST|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
57958852|NCT02064387|DRUG|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
57958853|NCT02895061|DRUG|Alfacalcidol|Alfacalcidol 1 microgram/capsule
58449693|NCT02114463|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
58449694|NCT02114463|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
58449695|NCT02114463|DRUG|ropivacaine|0.2% ropivacaine
57958854|NCT05797701|DRUG|SAR443820|Tablet by oral administration
57958855|NCT05797701|DRUG|SAR443820|Capsule by oral administration
57958856|NCT02665507|DEVICE|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
57958857|NCT02665507|DEVICE|Sham|Hand held laser that emits no LLLI
57958858|NCT00554125|DRUG|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
58449696|NCT02114463|DRUG|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
57746665|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
57746666|NCT02904408|BEHAVIORAL|psychotherapy|Group psychotherapy
57746667|NCT05002569|BIOLOGICAL|Nivolumab|Specified dose on specified days
57746668|NCT05002569|BIOLOGICAL|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
57746669|NCT02413164|OTHER|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
57746670|NCT03768479|DEVICE|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
57746671|NCT01159054|DRUG|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
57746672|NCT03185481|DRUG|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
57746673|NCT03185481|DRUG|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
57746674|NCT03185481|DRUG|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
57746675|NCT03185481|DRUG|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
57746676|NCT03185481|DRUG|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
58120443|NCT06013709|DEVICE|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
58120444|NCT05065970|DRUG|Felzartamab|anti-CD38+ monoclonal antibody
57746677|NCT03185481|DRUG|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
57746678|NCT03185481|DRUG|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
57746679|NCT03185481|DRUG|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
57746680|NCT06301412|DEVICE|hypothermia|hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
57746681|NCT06130826|PROCEDURE|Biopsy|Undergo tissue biopsy
57746682|NCT06130826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58313758|NCT05662995|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
57746683|NCT06130826|PROCEDURE|Bone Scan|Undergo bone scan
57746684|NCT06130826|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57746685|NCT06130826|DRUG|Immunotherapy|Receive M5A-IL2 ICK SC
57746686|NCT06130826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57746687|NCT06130826|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57746688|NCT06130826|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57746689|NCT01054768|DRUG|alpha-lipoic acid and acetyl-L-carnitine|none to report
57746690|NCT01054768|DRUG|Control|none to report
57746691|NCT00003508|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57746692|NCT00998608|DRUG|risperidone|risperidone 4mg/d
57746693|NCT03102814|BEHAVIORAL|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
57746694|NCT03102814|BEHAVIORAL|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
57746695|NCT05042778|OTHER|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
57746696|NCT03436329|PROCEDURE|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
57746697|NCT03436329|PROCEDURE|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
57746698|NCT03270605|PROCEDURE|Myomectomy|Surgical removal of uterine fibroid
57746699|NCT06579209|DIETARY_SUPPLEMENT|Nicotinamide adenine dinucleotide|Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
57746700|NCT06012734|DRUG|LB-100|IV on day 1 and day 3
57746701|NCT06012734|DRUG|Atezolizumab|IV on day 1
57746702|NCT06723314|PROCEDURE|Vestibular Subperiosteal Tunnel Access vista|CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
57746703|NCT05581550|RADIATION|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
57746704|NCT05581550|RADIATION|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
57746705|NCT00363675|BEHAVIORAL|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
57746706|NCT03611348|DRUG|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
57746707|NCT03611348|DEVICE|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
57746708|NCT05872568|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|The recommended dose range is 360 to 720mg,bid
57746709|NCT05588726|BEHAVIORAL|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
57746710|NCT05588726|BEHAVIORAL|Mindfulness|Once weekly coaching calls with advice on mindfulness
57746711|NCT02938598|BEHAVIORAL|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
57746712|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
57746713|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
57746714|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
58449697|NCT02536027|PROCEDURE|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
57746715|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
57746716|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
57746717|NCT00049374|BIOLOGICAL|oblimersen sodium|
58449698|NCT03686735|OTHER|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
58449699|NCT03686735|OTHER|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
58449700|NCT03686735|OTHER|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
58449701|NCT03686735|OTHER|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
57746718|NCT00049374|DRUG|dexamethasone|
57746719|NCT00049374|DRUG|thalidomide|
57746720|NCT00837174|DRUG|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
57746721|NCT04367350|DIAGNOSTIC_TEST|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
57746722|NCT04367350|DIAGNOSTIC_TEST|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
57746723|NCT00392405|DRUG|3 amps of sodium bicarbonate mixed in one liter of D5W|
57746724|NCT00722891|DEVICE|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
57746725|NCT00722891|DEVICE|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
57746726|NCT01215292|DRUG|Acyline|300 mcg/kg on Day 1
57746727|NCT01215292|DRUG|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
57746728|NCT01215292|DRUG|ketoconazole 400|400 mg PO daily, Days 3-10
57746729|NCT01215292|DRUG|Ketoconazole 800|800 mg PO daily, Day 3-10
57746730|NCT01215292|DRUG|Dutasteride|2.5 mg PO daily, Day 3-10
58120445|NCT05065970|OTHER|Placebo|Placebo comparator
58120446|NCT00421096|DRUG|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
58120447|NCT00421096|PROCEDURE|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
58120448|NCT00421096|DRUG|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
58120449|NCT01492270|PROCEDURE|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
58120450|NCT01492270|PROCEDURE|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
58120451|NCT01492270|PROCEDURE|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
58120452|NCT01492270|PROCEDURE|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
58120453|NCT04482114|RADIATION|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
58120454|NCT02165670|DEVICE|Coronary stenting with CE-marked stent|
58120455|NCT06104696|PROCEDURE|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
58449702|NCT00137514|DRUG|chloroquine|
58449703|NCT00137514|DRUG|amodiaquine|
57746731|NCT01215292|DRUG|Anastrozole|1 mg PO daily, Day 3-10
57746732|NCT01215292|DRUG|Placebo ketoconazole|placebo to mimic ketoconazole
57746733|NCT06444906|DEVICE|Dermacyte Matrix|The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
57746734|NCT06444906|OTHER|Standard of Care (SOC)|SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
57746735|NCT06273644|OTHER|Carbohydrates|Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
57746736|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57958859|NCT02579655|BEHAVIORAL|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
57958860|NCT02579655|BEHAVIORAL|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
57958861|NCT00281879|BIOLOGICAL|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
57958862|NCT00281879|BIOLOGICAL|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
57746737|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
57958863|NCT00281879|DRUG|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
57958864|NCT00281879|DRUG|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
57746738|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
57746739|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
57746740|NCT01811082|DRUG|Coenzyme A|Coenzyme A 400mg per day.
57746741|NCT01811082|DRUG|Pantethine|Pantethine 600mg per day.
57746742|NCT02085148|DRUG|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
57958865|NCT00281879|DRUG|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
57958866|NCT00281879|DRUG|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
58120456|NCT02459054|DEVICE|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
58120457|NCT04138459|OTHER|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork"
58120458|NCT00617110|OTHER|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
58120459|NCT00617110|OTHER|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
58120460|NCT04345978|BEHAVIORAL|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
58120461|NCT03150979|OTHER|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
58120462|NCT03150979|OTHER|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
58120463|NCT00688285|OTHER|automated clinical alerts|automated clinical alerts in the electronic medical record
58120464|NCT00688285|OTHER|provider education|PCP education session on CKD
58449704|NCT03030001|BIOLOGICAL|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
58449705|NCT03072264|BEHAVIORAL|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
58449706|NCT03072264|DRUG|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
58449707|NCT03072264|BEHAVIORAL|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
58449708|NCT01574508|DRUG|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
58449709|NCT01574508|DRUG|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
58449710|NCT02750670|DRUG|Obinutuzumab|Type II anti-CD20 monoclonal antibody
57746743|NCT02085148|DRUG|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
57746744|NCT02085148|DRUG|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
57746745|NCT03974542|BEHAVIORAL|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
57746746|NCT02609217|OTHER|Questionnaires and interviews|
57746747|NCT00075062|PROCEDURE|Flexible Sigmoidoscopy|
57746748|NCT00075062|PROCEDURE|Rectal Biopsy|
57958867|NCT00281879|DRUG|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
57958868|NCT00281879|DRUG|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
57958869|NCT00281879|DRUG|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
57958870|NCT00281879|DRUG|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
57958871|NCT00281879|DRUG|methotrexate|Administered on days +1, +3, and +7.
57958872|NCT00281879|DRUG|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
58313759|NCT02023827|BEHAVIORAL|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
58449711|NCT02750670|DRUG|Gemcitabine|Antineoplastic agent
58449712|NCT02750670|DRUG|Dexamethasone|Corticosteroid
58449713|NCT02750670|DRUG|Cisplatin|Antineoplastic Agent
57746749|NCT00738946|DRUG|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
57746750|NCT05338723|DRUG|Rosuvastatin 20mg|20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
57958873|NCT00281879|DRUG|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
57958874|NCT00281879|DRUG|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
58449714|NCT00775996|DRUG|Clorazepate Dipotassium 15mg Tablets|
58449715|NCT00496080|DEVICE|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
57746751|NCT00997087|DRUG|Flumazenil|Sublingual daily
57958875|NCT00281879|PROCEDURE|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
57958876|NCT00281879|PROCEDURE|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
57958877|NCT00281879|RADIATION|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
57958878|NCT00253630|OTHER|Laboratory Biomarker Analysis|Correlative studies
57958879|NCT00253630|DRUG|Vorinostat|Given PO
57958880|NCT01240642|DRUG|ASA404|
58120465|NCT00003148|BIOLOGICAL|aldesleukin|
58313760|NCT00862589|OTHER|GLP-1 infusion|physiological effect of GLP-1
58313761|NCT02650752|DRUG|Lapatinib in Tandem With Capecitabine|
57746752|NCT02489396|BEHAVIORAL|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal \& breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
57746753|NCT02489396|BEHAVIORAL|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
57746754|NCT02489396|BEHAVIORAL|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
57746755|NCT02489396|BEHAVIORAL|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
57746756|NCT04153227|DIAGNOSTIC_TEST|Bone mineral density (BMD)|Bone mineral density (BMD) is measured by Dual-energy X-ray absorptiometry (DXA). BMD provides a measure of bone mass.
57746757|NCT04153227|DIAGNOSTIC_TEST|Trabecular bone score (TBS)|The Trabecular Bone Score (TBS) is a novel gray-level texture measurement that can be extracted from DXA images. TBS provides a measure of bone quality (bone microarchitecture).
58449716|NCT05072106|DRUG|Lurbinectedin|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
57746758|NCT04153227|DIAGNOSTIC_TEST|Fracture risk Assessment Tool (FRAX)|The Fracture risk Assessment Tool (FRAX) is a fracture risk calculator that estimates an individual's 10-year probability of incurring a hip or other major osteoporotic fracture.
58313762|NCT06522204|DRUG|%5 Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
58313763|NCT05031351|DRUG|Withania somnifera|Nuclear Factor Kappa Beta Inhibitor
58449717|NCT05072106|DRUG|Bosentan|Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
58449718|NCT04189705|DRUG|MCT-SR|Rebamipide 150mg
58449719|NCT04189705|DRUG|Mucosta Tab.|Rebamipide 100mg
57958881|NCT00896311|DRUG|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
58449720|NCT02868411|OTHER|Rectal Swab|
58449721|NCT00614679|DRUG|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
58449722|NCT02927392|DRUG|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
58449723|NCT05932797|OTHER|Multimodal intervention in Long Covid19|The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
58449724|NCT05548517|BEHAVIORAL|Time Restricted Eating (TRE)|9-hour eating window
58449725|NCT05548517|BEHAVIORAL|Calorie Restriction|daily calorie restriction
58449726|NCT01366989|DEVICE|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
57958882|NCT00896311|DRUG|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
58313764|NCT05031351|DRUG|Placebo|Placebo Comparator
58449727|NCT00358930|DRUG|ARQ 501|
58449728|NCT01541046|BIOLOGICAL|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
58449729|NCT01541046|BIOLOGICAL|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
58449730|NCT00814450|DEVICE|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
58449731|NCT04226508|OTHER|Physical exercise|"The patients can choose between three modality of EX:~1. Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~2. Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~3. Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
57746759|NCT05603468|DRUG|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
57746760|NCT05603468|DRUG|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
57746761|NCT05603468|DRUG|Normal saline|Normal saline
57746762|NCT06248619|BIOLOGICAL|Teprotumumab|SC injection
58120466|NCT04586647|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
58120467|NCT01572649|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
58120468|NCT01572649|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
58449732|NCT04210674|OTHER|The traditional medicinal product of Argan spinosa oil|All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
58449733|NCT01820286|BEHAVIORAL|Positive psychology intervention|
58449734|NCT01820286|BEHAVIORAL|Recollection intervention|
58449735|NCT01179581|DRUG|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
58449736|NCT01179581|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
58449737|NCT01179581|DRUG|GLPG0634|multiple dose, capsule, 10 days
58449738|NCT01179581|DRUG|placebo|multiple dose, capsule, 10 days
58449739|NCT02794766|DRUG|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
58449740|NCT02794766|DRUG|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
57746763|NCT06248619|OTHER|Placebo|SC injection
57746764|NCT05829655|DRUG|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
57746765|NCT05829655|DRUG|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
57746766|NCT05829655|DRUG|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
57958883|NCT03431571|PROCEDURE|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
58449741|NCT02794766|DRUG|Placebo|Placebo 1 gum each 12 hours for 10 days
58449742|NCT02135055|OTHER|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
58449743|NCT02135055|DRUG|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
57958884|NCT02342795|OTHER|e-cigarette|
57958885|NCT02342795|OTHER|cigarette substitute|
57958886|NCT06343675|OTHER|There is no intervention|There is no intervention
57958887|NCT01411085|DRUG|Risperidone + Desipramine|
57958888|NCT00033410|DRUG|carboplatin|
58449744|NCT02135055|DRUG|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
58449745|NCT02135055|PROCEDURE|Sedation interruption|Sedation interruption is performed at 8 am every morning.
58449746|NCT00391482|BEHAVIORAL|Peer Mentoring Intervention for HCV-Infected IDUs|
58449747|NCT02354274|RADIATION|Escalated: Inhomogeneous dose plan|
58449748|NCT02354274|RADIATION|Standard: Homogeneous dose plan|
58449749|NCT04379063|OTHER|COVID-19 pandemic|Currently practicing during the COVID-19 pandemic
58449750|NCT04115384|DRUG|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
58449751|NCT02987751|DRUG|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
57746767|NCT05829655|DRUG|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
57958889|NCT00033410|DRUG|paclitaxel|
57958890|NCT00033410|DRUG|tirapazamine|
57746768|NCT05829655|DRUG|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
57746769|NCT05829655|DRUG|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
57746770|NCT00378989|BEHAVIORAL|Consultation at the occupational health services|Consultation at the occupational health services
57746771|NCT06038656|DIETARY_SUPPLEMENT|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
57746772|NCT00345982|DRUG|Serdolect|16 mg, 12 weeks
57746773|NCT00345982|DRUG|placebo|placebo
57746774|NCT02264704|OTHER|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
57746775|NCT02264704|OTHER|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
58449752|NCT02987751|DRUG|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
57746776|NCT01049113|DRUG|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
58449753|NCT04639544|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
58449754|NCT04639544|DIETARY_SUPPLEMENT|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
57746777|NCT02195986|DRUG|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
57746778|NCT02195986|DRUG|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
57746779|NCT02195986|DRUG|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
57746780|NCT00262587|DRUG|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
57746781|NCT00262587|DRUG|Placebo|Inhaled sugar powder in a placebo inhaler
57746782|NCT00141427|DRUG|Pregabalin|
57746783|NCT05237050|OTHER|Sound therapy associated with relaxation|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest."
57746784|NCT05237050|OTHER|Relaxation alone|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session)."
57958891|NCT00033410|RADIATION|radiation therapy|
57958892|NCT04620460|DEVICE|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
57958893|NCT01525004|DRUG|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
57958894|NCT01525004|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
57958895|NCT05779982|PROCEDURE|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
57958896|NCT02797808|DRUG|Sertraline|Impact of sertraline on functional brain connectivity
57958897|NCT02797808|OTHER|No Intervention|Healthy control non-intervention
57958898|NCT02510768|DEVICE|ELAPR002f|Intradermal implant
57958899|NCT02510768|DEVICE|ELAPR002g|Intradermal implant
57958900|NCT02510768|DEVICE|Saline|Intradermal implant
57958901|NCT02482129|DRUG|LME636 60 mg/mL ophthalmic solution|
57958902|NCT02482129|DRUG|Dexamethasone 0.1% ophthalmic solution|
58449755|NCT02498288|DRUG|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
58449756|NCT02498288|DRUG|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
57746785|NCT05497440|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
57746786|NCT03763422|DRUG|Temozolomide|Oral Administration of Temozolomide
57746787|NCT03763422|RADIATION|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
57746788|NCT03763422|PROCEDURE|Surgery|Surgery
57746789|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
57746790|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
57746791|NCT01618864|DEVICE|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
57746792|NCT01346748|DRUG|statin|Sinvastatin 80 mg per day - 21 days versus placebo
57958903|NCT02482129|DRUG|LME636 Vehicle|Inactive ingredients used for masking purposes
57958904|NCT01759758|OTHER|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
58120469|NCT03805828|OTHER|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
57746793|NCT02087631|DRUG|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
57746794|NCT04198805|DIETARY_SUPPLEMENT|Vitamin E [(all-rac)-α-tocopheryl acetate]|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
58449757|NCT02498288|DRUG|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
58449758|NCT02544503|DEVICE|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
57746795|NCT04198805|DIETARY_SUPPLEMENT|Omega-3 fatty acid (DHA EE)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
57746796|NCT04198805|COMBINATION_PRODUCT|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
57746797|NCT04198805|OTHER|Placebo|Matching soybean placebo (3 capsules) of all arms daily for 6 months.
57746798|NCT00975312|DRUG|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
57746799|NCT00975312|DRUG|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
57746800|NCT04739501|PROCEDURE|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
57746801|NCT03951454|BEHAVIORAL|Conexiones|5 Conexiones telephone sessions
58449759|NCT02544503|DEVICE|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
57746802|NCT03951454|BEHAVIORAL|Taking Time|1 Taking Time telephone session
57746803|NCT06580444|DRUG|Brexanolone|The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
57958905|NCT01759758|OTHER|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
57746804|NCT05217342|DRUG|Diuretic therapy|Standard diuretic therapy according to the current guidelines
57746805|NCT03162575|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
57746806|NCT02382198|DRUG|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
57746807|NCT02382198|DRUG|Placebo|
57746808|NCT03355638|DRUG|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
57746809|NCT03355638|DRUG|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
57746810|NCT03355638|DRUG|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
57746811|NCT00769548|DRUG|flutamide|Drug used for TAS.
57746812|NCT00769548|DRUG|goserelin acetate|Drug used for TAS.
57746813|NCT00769548|RADIATION|low-LET photon therapy|radiation therapy
57746814|NCT04674241|DRUG|Dexmedetomidine|Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
57746815|NCT04674241|DRUG|0.9% saline|0.9% saline is administered with the same volume at the same speed as the other group.
57746816|NCT04979559|DEVICE|Mobile health apps|Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
57746817|NCT04979559|OTHER|Standard care|Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
57958906|NCT04659460|DEVICE|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
57746818|NCT02123108|DRUG|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
57746819|NCT02123108|DRUG|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) \< 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
57746820|NCT02123108|DRUG|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
57746821|NCT02123108|DRUG|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
57746822|NCT04818580|PROCEDURE|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
58449760|NCT02544503|DEVICE|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
57746823|NCT01206998|DRUG|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
57746824|NCT01206998|DRUG|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
57746825|NCT02481310|DRUG|Cyclophosphamide|Given IV
57746826|NCT02481310|DRUG|Cytarabine|Given IT or intraventricularly
57746827|NCT02481310|DRUG|Doxorubicin Hydrochloride|Given IV
57746828|NCT02481310|DRUG|Etoposide|Given IV
58120470|NCT06366256|BEHAVIORAL|Traditional ultrasound biofeedback|"Participants use a B-mode ultrasound device to view their tongue movement on a screen. The participant sees the ultrasound image of their tongue moving in sagittal plane on the screen. The speech-language pathologist working with the participant also views participant's tongue movement and provides verbal instruction on how the participant should move their tongue to produce a perceptually correct r sound in simple syllables (CV, VC), as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
58449761|NCT02544503|DEVICE|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
58449762|NCT00068341|BIOLOGICAL|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
58449763|NCT00068341|DRUG|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
57746829|NCT02481310|DRUG|Ixazomib Citrate|Given PO
57746830|NCT02481310|OTHER|Laboratory Biomarker Analysis|Correlative studies
58449764|NCT00068341|DRUG|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
58449765|NCT00068341|BIOLOGICAL|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
58449766|NCT01634776|DIETARY_SUPPLEMENT|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
58449767|NCT01634776|DIETARY_SUPPLEMENT|corn oil|
58449768|NCT00376129|DRUG|Alefacept|15 mg i.m. once weekly for 12 weeks
58449769|NCT05287386|DRUG|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
58449770|NCT02574273|BEHAVIORAL|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
58449771|NCT02574273|OTHER|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
57746831|NCT02481310|DRUG|Methotrexate|Given IT or intraventricularly
57746832|NCT02481310|DRUG|Prednisone|Given PO
57746833|NCT02481310|BIOLOGICAL|Rituximab|Given IV
57746834|NCT02481310|DRUG|Therapeutic Hydrocortisone|Given IT or intraventricularly
57746835|NCT02481310|DRUG|Vincristine Sulfate|Given IV
57746836|NCT02366910|DEVICE|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
57746837|NCT02366910|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
57746838|NCT05524974|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
57746839|NCT05524974|DRUG|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
57746840|NCT05524974|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
57746841|NCT05524974|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
57746842|NCT05524974|DRUG|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
57746843|NCT04862182|DIAGNOSTIC_TEST|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
57746844|NCT02824133|DRUG|AZD4547|80 mg bd (per os)
57746845|NCT05330221|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
57746846|NCT05330221|DRUG|PHARM-PAL2|"All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention."
57746847|NCT02481544|BEHAVIORAL|Gratitude Journaling Plus SOC|
57746848|NCT02481544|BEHAVIORAL|Memorable Events Journaling Plus SOC|
57746849|NCT05016700|DIAGNOSTIC_TEST|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
57746850|NCT02571517|DRUG|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
57746851|NCT02571517|OTHER|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
57746852|NCT00387582|DRUG|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
57746853|NCT00387582|PROCEDURE|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
57746854|NCT01080508|OTHER|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
57746855|NCT01080508|OTHER|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
57746856|NCT06079463|OTHER|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
57746857|NCT03371082|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
57746858|NCT03371082|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
57746859|NCT00474695|DRUG|Lucentis|0.05 mg intravitreal injection
57746860|NCT05560048|DIETARY_SUPPLEMENT|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
57746861|NCT05560048|DIETARY_SUPPLEMENT|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
57746862|NCT02839551|PROCEDURE|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
58449772|NCT02726412|PROCEDURE|Acute vs elective|non-intverention study
58449773|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
58449774|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
57746863|NCT05782764|DRUG|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
57746864|NCT04332796|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
57746865|NCT04332796|DEVICE|ZnO-NPs socks|ZnO-NPs socks was given to patients for 4 weeks
57746866|NCT04332796|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
57746867|NCT01371214|BEHAVIORAL|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
57746868|NCT02191267|RADIATION|[F18]-T807|\[F18\]-T807 PET Scan to measure tau deposition in the brain.
57746869|NCT02191267|RADIATION|[F18]-Florbetapir|\[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
57746870|NCT02191267|DEVICE|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
57746871|NCT02191267|GENETIC|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
57746872|NCT00356954|DRUG|N-acetylcystein|
57746873|NCT00356954|DRUG|ascorbic acid|
57746874|NCT01394900|BEHAVIORAL|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
58449775|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
58449776|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
58449777|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
58449778|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
57746875|NCT01394900|BEHAVIORAL|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
57746876|NCT02398929|DRUG|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
57746877|NCT02398929|DRUG|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
57746878|NCT05542940|OTHER|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
58313765|NCT05664906|DRUG|Chinese Medicine Oral Rinse Formula-I (CMORF-I)|"* Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT."
58449779|NCT03038126|OTHER|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
58449780|NCT03038126|OTHER|Usual care|Standard clinical care
58449781|NCT05414890|DIAGNOSTIC_TEST|CBA-TSA|Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
58449782|NCT06473220|BEHAVIORAL|Narrative nursing|Narrative nursing is an intervention mode of psychological nursing.
58449783|NCT03410524|DRUG|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
58449784|NCT03410524|DRUG|Water|3 mL of water as placebo added to the bowel preparation
58449785|NCT00598936|DEVICE|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
58449786|NCT04494906|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
58449787|NCT04494906|OTHER|Square stepping exercise|Square stepping exercise
58449788|NCT02929030|DEVICE|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
58449789|NCT03029468|BEHAVIORAL|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
58449790|NCT03029468|BEHAVIORAL|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
58449791|NCT03384940|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
58449792|NCT02186574|DRUG|Tenofovir disoproxil|
58313766|NCT05664906|OTHER|Standard Care|• Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
58313767|NCT05664906|OTHER|Placebo|Placebo granules, instruction is the same as CMORF-I.
58313768|NCT03309618|DRUG|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
58449793|NCT02186574|DRUG|Placebo Oral Tablet|
58449794|NCT00165178|DRUG|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
57746879|NCT05273632|DRUG|Oxytocin|trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
57746880|NCT00512512|PROCEDURE|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
57958907|NCT01206205|DRUG|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
58313769|NCT03309618|DRUG|placebo|
58449795|NCT00165178|DRUG|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
58449796|NCT00165178|DRUG|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
58449797|NCT00165178|DRUG|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
58449798|NCT00165178|DRUG|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
58449799|NCT00165178|DRUG|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
58449800|NCT00165178|DRUG|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
58449801|NCT00165178|DRUG|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
58449802|NCT00165178|DRUG|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
58449803|NCT00165178|DRUG|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
58449804|NCT00462007|DRUG|Stalevo|Oral 3-4 daily doses for 6 weeks
57746881|NCT02310529|BEHAVIORAL|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
57746882|NCT03687190|BEHAVIORAL|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
57746883|NCT03687190|DRUG|conventional medicine|participants without Tai chi training still received routine conventional medicine
57746884|NCT03585582|OTHER|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
57746885|NCT04738526|OTHER|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
57746886|NCT04738526|OTHER|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
57746887|NCT04738526|OTHER|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
57746888|NCT03432364|GENETIC|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
57746889|NCT04329754|DEVICE|Cataract surgery|Cataract surgery with implantation of an intraocular lens (IOL)
57746890|NCT00108602|DRUG|acetazolamide|
57746891|NCT03664869|DRUG|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
57746892|NCT03664869|DRUG|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
57746893|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
57746894|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
57746895|NCT05550142|DRUG|Placebo|Saline solution
57746896|NCT01403896|DRUG|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
57746897|NCT01403896|DRUG|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
57746898|NCT02692326|PROCEDURE|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
57746899|NCT03538951|DRUG|10% VDA-1102|200 mg twice-daily for 12 weeks
57746900|NCT03538951|DRUG|20% VDA-1102|200 mg once-daily for 12 weeks
57746901|NCT05288010|COMBINATION_PRODUCT|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
57746902|NCT03204916|BEHAVIORAL|Discussion|Participate in focus group
57746903|NCT03204916|OTHER|Medical Chart Review|Data abstraction and central review
57746904|NCT03204916|OTHER|Questionnaire Administration|Complete questionnaire
58120471|NCT06366256|BEHAVIORAL|Simplified ultrasound biofeedback|"Participants use a B-mode ultrasound device that captures the movement of their tongue and software that transforms the movement of their tongue into gamified objects on a screen. The participant sees a game object (a character) move on the screen towards goals; the movement of the game object represents the movement of the tongue and the goals are representative of tongue movements that correlate with an acoustic percept of accuracy. The speech-language pathologist working with the participant views the movement of the game object and provides verbal instruction on how the participant should move the game character in order to reach the goals when saying simple syllable words (CV, VC) as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
58120472|NCT02261428|DEVICE|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
57746905|NCT01792180|BEHAVIORAL|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
57746906|NCT03742700|BEHAVIORAL|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
57746907|NCT03742700|BEHAVIORAL|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
57958908|NCT04516928|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
58120473|NCT02261428|DEVICE|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
58120474|NCT05816330|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
58120475|NCT05816330|OTHER|Normal Saline|Administered one time via subcutaneous route.
58120476|NCT01998321|OTHER|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production
58120477|NCT01998321|OTHER|conventional technique for TKA|
58120478|NCT03345316|DRUG|FFI-1010|Intravenous single dosing
58120479|NCT00663559|DRUG|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
58120480|NCT05688930|OTHER|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
58120481|NCT05688930|OTHER|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
58449805|NCT01982123|DIAGNOSTIC_TEST|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
58449806|NCT01982123|PROCEDURE|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
58449807|NCT01982123|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
58449808|NCT01982123|DRUG|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
58449809|NCT02564133|DEVICE|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
58449810|NCT02959359|DRUG|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
58449811|NCT02959359|DRUG|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
58449812|NCT02341352|DRUG|fluoride varnish|Sodium fluoride 50mg/ml
58449813|NCT02341352|BIOLOGICAL|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
57746908|NCT03742700|BEHAVIORAL|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
57746909|NCT02566018|PROCEDURE|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
57746910|NCT02566018|PROCEDURE|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
57746911|NCT00916032|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
57746912|NCT05900726|DIAGNOSTIC_TEST|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
57746913|NCT05900726|DIAGNOSTIC_TEST|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
57746914|NCT05900726|OTHER|Bowel diary|A daily diary to assess episodes of faecal incontinence
57746915|NCT05900726|OTHER|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
57746916|NCT05900726|OTHER|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
57746917|NCT05900726|OTHER|FISI|Questionnaire to assess the severity of faecal incontinence
57746918|NCT05900726|OTHER|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
57746919|NCT05900726|OTHER|St Mark's incontinence score|A score of incontinence
57746920|NCT00244296|DRUG|Duloxetine hydrochloride|
57746921|NCT00244296|DRUG|placebo|
57746922|NCT01803074|DRUG|BMS-955176|BMS-955176
57746923|NCT01803074|DRUG|Placebo matching with BMS-955176|Placebo matching with BMS-955176
57746924|NCT01803074|DRUG|Atazanavir|Atazanavir
58120482|NCT03972982|DRUG|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
58120483|NCT03972982|DRUG|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
58120484|NCT03270176|DRUG|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
58120485|NCT03270176|DRUG|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
58120486|NCT05834712|DEVICE|mobile platform or not mobile platform|Intervention using WeChat
58120487|NCT00254111|DEVICE|Ultra Probe Laser System|
58120488|NCT03567720|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
58120489|NCT03567720|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
58120490|NCT03567720|DEVICE|Immunopulse|Device that administers electroporation
58120491|NCT03567720|DRUG|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
58120492|NCT03567720|DRUG|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
58120493|NCT03933657|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
58120494|NCT03256799|DRUG|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
58120495|NCT03318770|DRUG|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
58449814|NCT02341352|DIETARY_SUPPLEMENT|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
58449815|NCT00671034|DRUG|Calaspargase Pegol-mknl|Given IV
58449816|NCT00671034|DRUG|Cyclophosphamide|Given IV
58449817|NCT00671034|DRUG|Cytarabine|Given IV, IT, PO, or SC
58449818|NCT00671034|DRUG|Daunorubicin Hydrochloride|Given IV
58449819|NCT00671034|DRUG|Dexamethasone|Given PO or IV
57746925|NCT01803074|DRUG|Ritonavir|Ritonavir
57746926|NCT01803074|DRUG|Tenofovir|Tenofovir
57746927|NCT01803074|DRUG|Emtricitabine|Emtricitabine
58120496|NCT04675710|PROCEDURE|Conventional Surgery|Undergo surgery
57746928|NCT06497452|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
57746929|NCT01542606|DEVICE|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
57746930|NCT04207827|BEHAVIORAL|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
57746931|NCT04207827|BEHAVIORAL|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
57746932|NCT04207827|OTHER|Usual Care|Usual postnatal care
57746933|NCT06289075|OTHER|Intensive Care Unit (ICU) treatment|ICU treatment
57746934|NCT02934074|OTHER|No intervention|
58120497|NCT04675710|DRUG|Dabrafenib|Given PO
58120498|NCT04675710|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58120499|NCT04675710|BIOLOGICAL|Pembrolizumab|Given IV
58120500|NCT04675710|OTHER|Quality-of-Life Assessment|Ancillary studies
58120501|NCT04675710|DRUG|Trametinib|Given PO
58120502|NCT00780520|DIETARY_SUPPLEMENT|alanine-glutamine infusion|
58120503|NCT00870922|PROCEDURE|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
58120504|NCT02160197|DEVICE|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
58120505|NCT02160197|DEVICE|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
58120506|NCT04876196|OTHER|Selfapy for Bulimia Nervosa|Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
58120507|NCT03304080|DRUG|Anastrozole|1 mg orally daily, day 1 to day 28
57746935|NCT01746004|DRUG|[^14C]-LY2157299|\[\^14C\]-LY2157299 monohydrate administered as oral solution
57746936|NCT06579924|PROCEDURE|Disposable mini-PCNL|Mini-PCNL carried out using disposable scope
57746937|NCT06579924|PROCEDURE|Re-usable mini-PCNL|Mini-PCNL carried out using re-usable scope
57746938|NCT00765596|OTHER|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
58120508|NCT03304080|DRUG|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
58120509|NCT03304080|DRUG|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
58120510|NCT03304080|DRUG|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
58120511|NCT00043706|DRUG|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
58120512|NCT04252469|OTHER|Oral care|oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
57746939|NCT01232608|BEHAVIORAL|Exercise|12 months of exercise training
57746940|NCT05477758|BEHAVIORAL|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
57746941|NCT05477758|OTHER|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
57958909|NCT04516928|OTHER|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
57958910|NCT03544827|DRUG|Atropine|Atropine 0.01% then atropine 0.1%
57958911|NCT03544827|DRUG|Atropine|Atropine 0.1% then atropine 0.01%
57958912|NCT04011280|DRUG|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
58120513|NCT04774081|DEVICE|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
58120514|NCT02553239|DEVICE|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
58120515|NCT03701828|PROCEDURE|Weight loss surgery|All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
58120516|NCT02419677|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
58120517|NCT02419677|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
58120518|NCT06172842|DIAGNOSTIC_TEST|Echocardiography|Multi-modality echocardiography
58120519|NCT04208139|DIAGNOSTIC_TEST|IVUS|IVUS
58120520|NCT00003938|DRUG|liposomal amphotericin B|
58449820|NCT00671034|DRUG|Doxorubicin Hydrochloride|Given IV
58449821|NCT00671034|OTHER|Laboratory Biomarker Analysis|Correlative studies
58449822|NCT00671034|DRUG|Mercaptopurine|Given PO
58449823|NCT00671034|DRUG|Methotrexate|Given IV, IT, or PO
58449824|NCT00671034|DRUG|Pegaspargase|Given IV
57746942|NCT05477758|BEHAVIORAL|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
58120521|NCT05224921|OTHER|Not applicable (cohort study)|This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
58120522|NCT05621486|BIOLOGICAL|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
58120523|NCT05158114|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58120524|NCT04203680|DRUG|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
58120525|NCT04203680|DRUG|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
58120526|NCT01824251|DRUG|NPB-01|
58120527|NCT05493111|DRUG|AR-15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 365 days.
58120528|NCT05493111|DRUG|Vehicle|Topical ocular administration of one drop in both eyes BID for 365 days.
58120529|NCT00635154|BIOLOGICAL|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
58120530|NCT00635154|DRUG|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
58120531|NCT02381821|OTHER|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
58120532|NCT02381821|DRUG|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
58120533|NCT04862390|DEVICE|Continuous glucose monitoring|Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan
58120534|NCT03083483|DEVICE|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
58120535|NCT02097446|DEVICE|Guardix-FL|
57746943|NCT02351219|DRUG|FOLFOXIRI|
57958913|NCT05235035|BEHAVIORAL|Night shift work|Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
58120536|NCT02097446|DEVICE|Interceed|
58120537|NCT01387282|DRUG|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
57746944|NCT04521855|OTHER|Questionnaire|Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
57746945|NCT06362512|BEHAVIORAL|Dual-task training|participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
57746946|NCT06362512|BEHAVIORAL|Single-task training|participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.
57958914|NCT04754451|DRUG|Group L|Attach two lidocaine patches for 12 hours, one above and below the incision site.
58120538|NCT01387282|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
58120539|NCT04190654|DRUG|KW-6356|Single oral dose of KW-6356
58120540|NCT00696358|RADIATION|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
58120541|NCT00696358|RADIATION|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
58120542|NCT05053698|OTHER|Aqueous flare measurement|Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
58449825|NCT00671034|OTHER|Pharmacological Study|Correlative studies
58449826|NCT00671034|DRUG|Prednisone|Given IV or PO
57746947|NCT06362512|BEHAVIORAL|Upper limb strengthening exercise|participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
57746948|NCT03599349|DEVICE|Microfocused ultrasound w/ visualization|
57746949|NCT00010855|BEHAVIORAL|Self-hypnotic relaxation|
57958915|NCT00065728|DRUG|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
57958916|NCT01060059|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
57958917|NCT01060059|DRUG|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
58120543|NCT02460848|OTHER|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
58120544|NCT02460848|OTHER|Outpatient therapeutic program and counseling|
58120545|NCT02304874|OTHER|Phlebotomy|
58120546|NCT06109558|DRUG|LMV-12(HE003)|1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
58120547|NCT04866589|BEHAVIORAL|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
58120548|NCT02020603|DEVICE|epinephrine injection plus soft coagulation using hemostatic forceps|
58120549|NCT02020603|DEVICE|epinephrine injection plus argon plasma coagulation|
58120550|NCT04411459|OTHER|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
58120551|NCT04769466|OTHER|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
58120552|NCT01206842|OTHER|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
58120553|NCT00004143|DRUG|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
57746950|NCT01620866|OTHER|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
57746951|NCT03246282|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
57746952|NCT03246282|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
57746953|NCT03246282|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
57746954|NCT04605796|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
58120554|NCT05311852|DIETARY_SUPPLEMENT|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
58120555|NCT05311852|DIETARY_SUPPLEMENT|Placebo|assumption of a placebo product 2 time/day for 8 weeks
58120556|NCT03027661|DRUG|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
58120557|NCT03027661|DRUG|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
57958918|NCT00705783|DRUG|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
57958919|NCT00705783|DRUG|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
58120558|NCT00246974|DRUG|Gemcitabine|intravenous
58313770|NCT05672563|DRUG|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
58313771|NCT05666024|OTHER||Prospective observational study
58313772|NCT06129214|PROCEDURE|Prepectoral|Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
58313773|NCT06129214|PROCEDURE|Subpectoral|No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
57746955|NCT05906602|DEVICE|Real Ischemic Conditioning|10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.
58313774|NCT01692574|BEHAVIORAL|Behavior Modification for Weight Loss|
58313775|NCT01692574|BEHAVIORAL|Alternative Approach to Weight Loss|
58313776|NCT01692574|BEHAVIORAL|Cognitive-Behavior Therapy for Depression|
58313777|NCT01692574|BEHAVIORAL|Depression Support and Education|
58313778|NCT06013566|DEVICE|SSVEP|Non-invasive, non-interventional SSVEP EEG device
57746956|NCT05906602|DEVICE|Sham Ischemic Conditioning|Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
57746957|NCT01197196|BEHAVIORAL|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
57958920|NCT02948621|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
57958921|NCT05685186|DIAGNOSTIC_TEST|Spirometry|To assess lung function
57958922|NCT05685186|DIAGNOSTIC_TEST|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
58120559|NCT00246974|DRUG|Cisplatin|intravenous
58120560|NCT00246974|DRUG|Gefitinib|oral
58120561|NCT05055921|DEVICE|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|"The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.~Other Names:~* Unpinning Termination Therapy~* Multi-stage therapy~* Multi-stage electrotherapy~* MultiPulse Therapy"
58120562|NCT06546787|OTHER|PSYCHOTHERAPY|IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
58120563|NCT03985592|BEHAVIORAL|Education|Intervention description provided in elaboration on arms of the study.
58120564|NCT01773564|DEVICE|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
58120565|NCT01773564|DEVICE|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
58120566|NCT05234437|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
58120567|NCT05267756|DEVICE|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
58120568|NCT04828161|DRUG|ensovibep|IV on day 1 only.
58120569|NCT04828161|DRUG|Placebo|IV on day 1 only.
58120570|NCT01132456|DEVICE|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
58120571|NCT03640156|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
58120572|NCT03640156|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
58120573|NCT04592354|DIETARY_SUPPLEMENT|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
58120574|NCT04816097|DRUG|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
58120575|NCT00191009|DRUG|atomoxetine hydrochloride|
58120576|NCT00191009|DRUG|placebo|
58120577|NCT06362993|OTHER|Bundling|Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.
58120578|NCT06362993|OTHER|MEGH|Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
58313779|NCT02475369|DRUG|pancrelipase|
57746958|NCT01197196|OTHER|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
57746959|NCT00832273|DEVICE|ELAD®|liver assist system
58120579|NCT03565211|DRUG|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
58313780|NCT00747604|BIOLOGICAL|mecasermin [rDNA origin] injection|As prescribed by the physician.
57746960|NCT00677352|DRUG|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
57746961|NCT00677352|DRUG|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
57746962|NCT01686555|DRUG|ABT-199|Tablet
57746963|NCT01686555|OTHER|Placebo|Tablet
57746964|NCT03098134|BEHAVIORAL|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
58120580|NCT02234297|DRUG|BLZ-100|
58120581|NCT01758302|BEHAVIORAL|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
58120582|NCT01758302|BEHAVIORAL|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
58120583|NCT01758302|OTHER|Cookies|Participants are asked to taste test chocolate chip cookies
58120584|NCT01758302|OTHER|Vegetables|Participants are asked to taste test raw celery or radishes
58120585|NCT01758302|BEHAVIORAL|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
58120586|NCT01011322|DRUG|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
58120587|NCT01011322|DRUG|placebo|placebo
58120588|NCT01880333|OTHER|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
58313781|NCT00091429|DRUG|Ranolazine|
58313782|NCT05755126|BEHAVIORAL|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
58313783|NCT05755126|BEHAVIORAL|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
58313784|NCT02663986|BEHAVIORAL|Organizational Skills Training (OST) Intervention|
57746965|NCT03098134|OTHER|Health Education|Video based health education covering common myths and false believes about dental surgeries
58120589|NCT00434161|DRUG|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
58120590|NCT00434161|DRUG|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
58120591|NCT00434161|DRUG|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
58120592|NCT04782830|DEVICE|Accelerometer|A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
58120593|NCT04782830|DRUG|placebo pill|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
58120594|NCT04782830|DRUG|Midodrine or atomoxetine pill|Either midodrine or atomoxetine at their regular dose.
58120595|NCT01385410|BEHAVIORAL|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
58120596|NCT03495648|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
57746966|NCT04131608|DIAGNOSTIC_TEST|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
58120597|NCT03231839|BEHAVIORAL|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
58120598|NCT03231839|BEHAVIORAL|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
58120599|NCT03231839|BEHAVIORAL|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
58120600|NCT01512381|DEVICE|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
58120601|NCT01512381|DEVICE|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
57746967|NCT01950949|OTHER|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
57746968|NCT03365882|BIOLOGICAL|Cetuximab|Given IV
57746969|NCT03365882|DRUG|Irinotecan Hydrochloride|Given IV
57746970|NCT03365882|OTHER|Laboratory Biomarker Analysis|Correlative studies
57746971|NCT03365882|BIOLOGICAL|Pertuzumab|Given IV
57746972|NCT03365882|BIOLOGICAL|Trastuzumab|Given IV
57746973|NCT03365882|DEVICE|HER-2 testing|Central testing of HER-2 for eligibility
57746974|NCT03878732|DIAGNOSTIC_TEST|Bindex measurement|One time bone density measurement with ultrasound device
58120602|NCT01442909|DRUG|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
58120603|NCT00720850|DRUG|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
58120604|NCT01683617|BEHAVIORAL|Coping skills and relaxation training with new technologies|
58120605|NCT01683617|BEHAVIORAL|Traditional coping skills and relaxation training|
58120606|NCT03731351|PROCEDURE|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
58120607|NCT02736227|DRUG|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
58120608|NCT01101009|DRUG|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
58120609|NCT01101009|DRUG|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
58120610|NCT02627027|DRUG|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
58313785|NCT00056147|DRUG|denufosol tetrasodium (INS37217)|
58313786|NCT02415946|PROCEDURE|Sinus floor augmentation (lateral)|
58313787|NCT02415946|PROCEDURE|Sinus floor augmentation (transcrestal)|
58313788|NCT03185000|DRUG|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
58449827|NCT00671034|RADIATION|Radiation Therapy|Some patients undergo RT
57746975|NCT06485076|OTHER|Early Palliative Care|see previous description
57746976|NCT00370630|DRUG|Avastin (Bevacizumab) and triamcinolone|
57746977|NCT03553004|DRUG|Niraparib Treatment|Niraparib treatment by mouth (oral)
57746978|NCT04205630|DRUG|SYD985|SYD985 powder for concentrate for solution for infusion
57746979|NCT02960100|OTHER|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
57746980|NCT02960100|OTHER|Media Intervention|Receive targeted HPV vaccine narrative-style video
57746981|NCT02960100|OTHER|Survey Administration|Ancillary studies
58120611|NCT02627027|DRUG|CKD-395 0.25/750mg|oral administration
58120612|NCT00992069|DRUG|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
58120613|NCT00992069|DRUG|TMC207|Single oral dose of 400 mg in the morning
58120614|NCT00484523|PROCEDURE|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
58120615|NCT04147754|PROCEDURE|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
58120616|NCT04147754|PROCEDURE|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
58120617|NCT04147754|PROCEDURE|Erector spinae block|Preoperative erector spinae block at physician discretion
58120618|NCT01889511|BEHAVIORAL|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
58120619|NCT03471962|OTHER|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
58120620|NCT02307383|DRUG|Lactitol|
58120621|NCT02307383|DRUG|Lactobacillus|
58120622|NCT00822198|DEVICE|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
58120623|NCT00429923|DRUG|Difluprednate|
57958923|NCT05685186|DIAGNOSTIC_TEST|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
57958924|NCT05685186|DIAGNOSTIC_TEST|CT of the chest|Low radiation to assess structural lung disease
58120624|NCT00429923|DRUG|Difluprednate|
58120625|NCT00429923|DRUG|Placebo|
57958925|NCT05685186|DIAGNOSTIC_TEST|MRI of the chest|To assess lung function and structural lung disease
58120626|NCT02123992|DEVICE|Elevate Apical and Posterior|
58120627|NCT02123992|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
58120628|NCT03294356|OTHER|FT210771|An electronic cigarette
58120629|NCT03294356|OTHER|FT210751|An electronic cigarette
57746982|NCT06461130|OTHER|Study Group|Group of people doing dual tasks during double-leg cycling training.
57746983|NCT06461130|OTHER|Control Group|The group that received only aerobic exercise.
57746984|NCT02377154|DEVICE|Slit lamp|Examination of cornea
57746985|NCT02377154|DEVICE|Autorefractor|Measurement of refraction
57746986|NCT02377154|DEVICE|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
57958926|NCT03124784|DEVICE|RD Disposable Sensors|Noninvasive pulse oximeter sensor
57958927|NCT00246428|BEHAVIORAL|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
58120630|NCT03294356|OTHER|6T30134157764|An electronic cigarette
58120631|NCT03294356|OTHER|G41A7C071|An electronic cigarette
58120632|NCT03294356|OTHER|M011161212|An electronic cigarette
58120633|NCT03294356|OTHER|FT21002|A combustible cigarette
58120634|NCT02006485|DRUG|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
58120635|NCT02006485|DRUG|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
58120636|NCT02006485|DRUG|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
58120637|NCT06177678|DRUG|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
57746987|NCT02377154|DEVICE|Pentacam HR|Measurement of white-to-white distance; Keratometry
57746988|NCT02377154|DEVICE|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
57746989|NCT02377154|DEVICE|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
57746990|NCT00411593|DRUG|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
57746991|NCT00411593|DRUG|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
57746992|NCT03628287|OTHER|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
57746993|NCT03628287|OTHER|Original Care Coordination Program|Original Care Coordination
57958928|NCT02106312|RADIATION|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
57958929|NCT00748579|DRUG|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
58120638|NCT06177678|DRUG|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
58120639|NCT05813782|BEHAVIORAL|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
58120640|NCT02784106|DRUG|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
58313789|NCT01559168|DEVICE|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
58120641|NCT02784106|DRUG|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
58120642|NCT02784106|DRUG|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
58120643|NCT04352413|DRUG|PLM60|Administration: Intravenous infusion
58120644|NCT03167099|PROCEDURE|Full Weight Bearing|full weight bearing after fixation of a distal femur fracture
58120645|NCT02277652|DEVICE|The Miller Laryngoscope|Direct laryngoscopy
58120646|NCT02277652|DEVICE|The Bonfils intubation fibrescope|Optical laryngoscopy
58120647|NCT02277652|DEVICE|The GlideScope Ranger|Videolaryngoscopy
58120648|NCT02277652|DEVICE|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
58120649|NCT01813461|DRUG|14C-labeled prodrug isavuconazonium sulfate|oral
58120650|NCT04497480|BEHAVIORAL|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
58120651|NCT05374863|DEVICE|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
58120652|NCT05374863|DEVICE|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
58120653|NCT05374863|DEVICE|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
58120654|NCT02636127|OTHER|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
58120655|NCT00508586|DRUG|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
58120656|NCT01966042|PROCEDURE|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
58449828|NCT00671034|DRUG|Thioguanine|Given PO
57746994|NCT04235335|BEHAVIORAL|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
58120657|NCT01966042|PROCEDURE|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
57746995|NCT06579001|DRUG|Nasal spray dexmedetomidine|Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment
58120658|NCT01966042|PROCEDURE|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
58120659|NCT01966042|BIOLOGICAL|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
58313790|NCT02631057|DRUG|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
58313791|NCT02631057|DRUG|Warfarin|Warfarin tablet (adjustment by each patients)
58313792|NCT02316925|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning
58313793|NCT02316925|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning
58313794|NCT05115929|PROCEDURE|Decompressive Laparotomy|As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
58449829|NCT00671034|DRUG|Vincristine Sulfate|Given IV
58449830|NCT06527586|DEVICE|soft contact lens|Vision Correction
58449831|NCT00655538|DRUG|Placebo|po daily for 36 weeks
58449832|NCT00655538|DRUG|dalcetrapib|600mg po daily for 36 weeks
58449833|NCT03708718|DRUG|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
58449834|NCT03708718|DRUG|Placebo oral capsule; From August 2020 'no additional treatment'|Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
58120660|NCT04228510|PROCEDURE|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
58120661|NCT05713474|DIAGNOSTIC_TEST|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
58120662|NCT05713474|DIAGNOSTIC_TEST|Conventional EMG|Diagnostic EMG exam with conventional EMG
58120663|NCT04272021|DRUG|Methylphenidate|standard therapy for ADHD
58120664|NCT06053099|OTHER|Plasma ctDNA|"* Plasma ctDNA before surgery (optional)~* Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~* Plasma ctDNA every 6 months~* Plasma ctDNA at relapse"
58120665|NCT06053099|OTHER|FFPE blocks|"* Surgery FFPE blocks~* FFPE blocks at relapse (optional)"
58120666|NCT06084507|DRUG|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
58120667|NCT06084507|DRUG|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
58120668|NCT06483152|OTHER|Metro Transit Pass|A transit pass that enables riders to use the Minneapolis Metro Transit system that will paid for by the study for 6 months
58120669|NCT06483152|OTHER|Standard of Care|The current standard of care for Ryan White eligible clients is to receive two $10 bus cards a month from a case manager
58120670|NCT06464809|OTHER|kinesio taping (KT)|
58120671|NCT00553540|DEVICE|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
58120672|NCT05150509|DIAGNOSTIC_TEST|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
58120673|NCT03044158|DEVICE|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
58120674|NCT03044158|BEHAVIORAL|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
57746996|NCT05131880|OTHER|GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
57746997|NCT05298150|OTHER|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
57746998|NCT05298150|OTHER|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
57746999|NCT02603081|DRUG|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
58120675|NCT03044158|OTHER|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
57747000|NCT00986206|DIAGNOSTIC_TEST|Biomarker LPA and HE4|Non Interventional Trial
58120676|NCT05483322|DRUG|LAM-002A|25mg capsules
58313795|NCT05115929|PROCEDURE|Decompressive Craniectomy|As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
57747001|NCT06370026|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
57747002|NCT00402181|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
58120677|NCT05147454|OTHER|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
58120678|NCT05266456|BIOLOGICAL|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
58120679|NCT05266456|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
58120680|NCT05822518|DIETARY_SUPPLEMENT|Neo-mune powder (otsuka pharmaceutical)|"* Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~* Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
58313796|NCT00084630|DRUG|imatinib mesylate|Given orally
58313797|NCT00084630|OTHER|laboratory biomarker analysis|Correlative studies
57747003|NCT00402181|DRUG|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
57747004|NCT03123965|DRUG|glecaprevir|Glecaprevir will be administered orally.
57747005|NCT03123965|DRUG|pibrentasvir|Pibrentasvir will be administered orally.
58120681|NCT05822518|DRUG|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
58120682|NCT00427986|DRUG|Galactose, intravenous|
58313798|NCT01550926|DRUG|120 mg orlistat|2 X60 mg capsule
58313799|NCT01550926|DRUG|60 mg orlistat|60 mg orlistat
58313800|NCT01550926|DRUG|orlistat experimental dose|experimental
58120683|NCT01215942|DRUG|LY2127399|Administered Subcutaneously
58120684|NCT03051256|DRUG|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
58120685|NCT03051256|DRUG|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
58120686|NCT02334059|DRUG|Ketamine|Ketamine infusion plus placebo infusion of normal saline
58120687|NCT02334059|DRUG|Ketamine plus magnesium|Ketamine plus magnesium infusion
57747006|NCT03497455|DEVICE|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
57747007|NCT03497455|DEVICE|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
58120688|NCT02334059|OTHER|Placebo|2 placebo infusions
57747008|NCT03497455|OTHER|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
57747009|NCT03700138|DRUG|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
57747010|NCT03700138|DRUG|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
57747011|NCT00561210|DIETARY_SUPPLEMENT|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
57747012|NCT00561210|DIETARY_SUPPLEMENT|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
57747013|NCT01146496|DEVICE|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
57747014|NCT01777659|DEVICE|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
58120689|NCT03029520|OTHER|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
58120690|NCT03029520|OTHER|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
58120691|NCT01304446|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
58120692|NCT04753736|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
58120693|NCT02752945|OTHER|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
58120694|NCT02752945|OTHER|Usual care|Usual care afforded by local CAMHS services
58120695|NCT00916890|DRUG|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
58120696|NCT00916890|DRUG|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
58120697|NCT00916890|DRUG|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
58313801|NCT06492213|OTHER|No interventions|It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
57747015|NCT03195868|DEVICE|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
57747016|NCT04979455|OTHER|Core temperature monitoring|Core temperature will be monitored on the day of exercise
57747017|NCT04979455|BEHAVIORAL|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
57747018|NCT04979455|OTHER|Heart rate monitoring|Heart rate will be monitored on the day of exercise
57747019|NCT04979455|OTHER|Urine collection|Urine samples will be collected at baseline and on the day of exercise
57747020|NCT04979455|OTHER|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
57747021|NCT04979455|OTHER|Blood collection|Blood samples will be completed at baseline
57747022|NCT04979455|OTHER|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
57747023|NCT04979455|OTHER|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
57747024|NCT04979455|OTHER|Stool collection|Stool samples will be collected at baseline and on the day of exercise
57958930|NCT00748579|DRUG|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
58120698|NCT00916890|DRUG|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
58120699|NCT01226277|DRUG|GDC-0917|Oral repeating dose
58120700|NCT05263583|DRUG|Sepantronium Bromide|continuous intravenous infusion
58120701|NCT01255371|DRUG|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
57747025|NCT05283967|DIAGNOSTIC_TEST|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
57747026|NCT00002507|DRUG|mitomycin C|
57747027|NCT00002507|DRUG|porfiromycin|
58120702|NCT01255371|DRUG|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
58120703|NCT04272359|DRUG|Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas|"Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety."
58120704|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
58120705|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
58120706|NCT00041574|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
58449835|NCT02922335|BEHAVIORAL|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
57958931|NCT02670642|DRUG|Esomeprazole|Proton pump inhibitor
57958932|NCT05852756|BEHAVIORAL|pecha kucha|pecha kucha training
57747028|NCT00002507|RADIATION|brachytherapy|
57747029|NCT00002507|RADIATION|radiation therapy|
57747030|NCT00844025|BEHAVIORAL|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
57747031|NCT05875519|DRUG|Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)|Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
57747032|NCT04753372|DRUG|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
57747033|NCT04718428|DIAGNOSTIC_TEST|Nail Ultrasonography|The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
58120707|NCT06126796|DIAGNOSTIC_TEST|CxBladder Monitor|CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.
58120708|NCT06126796|DIAGNOSTIC_TEST|Cystoscopy|Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
58120709|NCT05178355|DRUG|KVD824|Active
58120710|NCT05178355|DRUG|Placebo to KVD824|Placebo
58449836|NCT02922335|BEHAVIORAL|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
57747034|NCT03141424|DRUG|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
57747035|NCT01229631|DIETARY_SUPPLEMENT|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
57747036|NCT01229631|DIETARY_SUPPLEMENT|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
57747037|NCT01844284|DEVICE|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
57958933|NCT04138485|BIOLOGICAL|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
57958934|NCT04138485|BIOLOGICAL|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
57958935|NCT04082585|BEHAVIORAL|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
57958936|NCT01738971|OTHER|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
57958937|NCT01738971|OTHER|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
58449837|NCT02857673|BEHAVIORAL|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
57747038|NCT01844284|DEVICE|Absorb™ BVS|Subjects receiving Absorb™ BVS
57747039|NCT06011941|PROCEDURE|Modified laparoscopic transcystic biliary drainage|First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
57747040|NCT04540705|BIOLOGICAL|Nivolumab|Specified dose on specified days
57747041|NCT04540705|DRUG|Axitinib|Specified dose on specified days
58449838|NCT02857673|BEHAVIORAL|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
57747042|NCT04540705|DRUG|Cabozantinib|Specified dose on specified days
57747043|NCT04558255|DIAGNOSTIC_TEST|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
57747044|NCT00994981|DRUG|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
57747045|NCT00994981|DRUG|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
57747046|NCT04977050|DIAGNOSTIC_TEST|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
57747047|NCT05327387|OTHER|model-based electrical brain stimulation|Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
57747048|NCT01579734|DRUG|Tamoxifen|1 tablet, 5 mg / day for 5 years
57747049|NCT01579734|DRUG|Placebo|1 tablet day for 5 years
57747050|NCT00762320|DRUG|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
57747051|NCT05651854|OTHER|pranayama breathing|Bhramari and sheetali pranayama breathing
57747052|NCT03942133|PROCEDURE|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
57958938|NCT04561154|OTHER|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
58120711|NCT04459195|BEHAVIORAL|2 Minute Static Stretching|Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
57747053|NCT03942133|PROCEDURE|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
57747054|NCT00808379|DRUG|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
58313802|NCT00888836|PROCEDURE|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
57747055|NCT00808379|RADIATION|Additional Radiation boost to the primary tumor volume|15-20Gy
57747056|NCT03377543|DRUG|Aspirin|81mg aspirin pill daily at bedtime over a 25 day period
57747057|NCT03377543|DRUG|Placebo|81mg non-active pill that looks like aspirin
57958939|NCT05244850|OTHER|Test|Measurements
57747058|NCT04168554|DEVICE|Telemedicine|Patient is examined using telemedicine
57747059|NCT05924542|BEHAVIORAL|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
58449839|NCT05138029|DRUG|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
58449840|NCT05138029|PROCEDURE|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
58313803|NCT00888836|PROCEDURE|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
57747060|NCT01821261|DEVICE|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
57747061|NCT01821261|DRUG|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
57747062|NCT01821261|DRUG|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
57747063|NCT00445679|DRUG|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
57747064|NCT00445679|DRUG|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
57747065|NCT05552651|DRUG|Envafolimab|300mg,sc,d1,Q3W;
57747066|NCT05552651|DRUG|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
57747067|NCT05552651|DRUG|Carboplatin|AUC=5, iv,D1,Q3W
57747068|NCT04605562|DRUG|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
57747069|NCT04605562|DRUG|Palbociclib|Administered orally
58313804|NCT00888836|BEHAVIORAL|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
58313805|NCT02324153|DRUG|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
58313806|NCT02324153|DRUG|Microcrystalline Cellulose|Placebo Comparator
58313807|NCT02324153|DRUG|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
58313808|NCT05170113|DIETARY_SUPPLEMENT|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
58313809|NCT05170113|DIETARY_SUPPLEMENT|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
58313810|NCT05170113|DIETARY_SUPPLEMENT|Caffeine formulation|Caffeine formulation capsule- I capsule daily
58313811|NCT05170113|DIETARY_SUPPLEMENT|Placebo|Placebo capsule- 1 capsule daily
58313812|NCT01240382|DRUG|3% DE-089 ophthalmic solution|
57747070|NCT04605562|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
57747071|NCT04605562|DRUG|PD-1 blocking antibody|Administered every 3 weeks
57747072|NCT04605562|DRUG|Galunisertib|Administered orally
57958940|NCT00798746|BEHAVIORAL|Telephone Questionnaire|Ten questions regarding symptoms of reflux
58313813|NCT01240382|DRUG|0.1% sodium hyaluronate ophthalmic solution|
58313814|NCT00671060|DRUG|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
58313815|NCT00671060|DRUG|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
58313816|NCT01344928|BEHAVIORAL|HIT exercise intervention|
58313817|NCT01344928|BEHAVIORAL|Aerobic exercise intervention|
58313818|NCT03847493|OTHER|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
58313819|NCT04571489|DRUG|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
58313820|NCT04571489|DRUG|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
58313821|NCT04571489|DRUG|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
58313822|NCT01902667|PROCEDURE|Magnetic Resonance Imaging|
58313823|NCT01152671|DRUG|Placebo|single oral dose
58313824|NCT01152671|DRUG|RO5024048|single oral dose
58313825|NCT04992533|PROCEDURE|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
58120712|NCT04459195|BEHAVIORAL|5 Minute Static Stretching|Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
58120713|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
58120714|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
58120715|NCT01701128|OTHER|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
58120716|NCT03175120|DRUG|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
58120717|NCT03175120|DRUG|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
58120718|NCT05205850|DRUG|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
58313826|NCT04992533|PROCEDURE|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
58449841|NCT05138029|DRUG|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
57747073|NCT03536000|DIAGNOSTIC_TEST|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
57747074|NCT06580418|OTHER|Additional biopsies and blood samples|During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
57747075|NCT03689335|PROCEDURE|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
57747076|NCT03689335|DEVICE|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
57747077|NCT03665610|DRUG|ozanimod|ozanimod
57747078|NCT02453581|DRUG|OZ439|OZ439 Powder for Oral Suspension
57747079|NCT02657031|DRUG|Prochlorperazine|prochlorperazine 10 mg IV
57747080|NCT02657031|DRUG|Ketamine|Ketamine 0.3 mg/kg IV
57958941|NCT05269407|DEVICE|Peripheral perfusion index|"The study aimed to generate a model relating pre-spinal perfusion index to the likelihood and severity of the reduction in blood pressure in the first 20 min after spinal injection.~A correlation between the delta PI and the delta SBP (the difference between the baseline maternal systolic blood pressure and the lowest blood pressure)will be investigated to establish a predictive model to define cut-off values at which perfusion index variation indicated a low risk (no or mild hypotension groups) or a high risk (moderate, severe groups) of reduction in blood pressure.. The incremental change of a measure PI, the ΔPI will be calculated as the absolute change in PI between supine and sitting positions, ΔPI=PIsupine-sitting. The relative change in PI the rPI, will be expressed as the percentage of change in PI, rPI=ΔPI/PIsitting× 100."
57747081|NCT02657031|DRUG|Diphenhydramine|Diphenhydromine 25 mg IV
57747082|NCT02657031|DRUG|Ondansetron|Ondansetron 4 mg IV
58120719|NCT06486597|DIETARY_SUPPLEMENT|Meal|Liquid meal
58120720|NCT06543524|OTHER|Care of premature infants|No intervention was performed
58120721|NCT00296114|PROCEDURE|Serum and DNA Samples|To collect serum and DNA samples from subjects
58313827|NCT03073707|BEHAVIORAL|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
58313828|NCT03679793|PROCEDURE|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
58313829|NCT03679793|PROCEDURE|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
58313830|NCT01395719|OTHER|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
58313831|NCT02608619|RADIATION|F-choline PET Scan|
58313832|NCT02608619|DEVICE|FDG-PET|
58313833|NCT02608619|PROCEDURE|biopsy|
58313834|NCT01510639|BIOLOGICAL|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
58313835|NCT03708224|BIOLOGICAL|Atezolizumab|Given intravenously (IV)
58313836|NCT03708224|BIOLOGICAL|Tocilizumab|Given IV
58313837|NCT03708224|BIOLOGICAL|Tiragolumab|Given IV
58120722|NCT05728047|PROCEDURE|Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam)|The 'Cytocam' is a hand held computer-controlled device, a third generation video-microscope, which enables real time visualisation of the in vivo microcirculation, based upon the principle of incident dark field (IDF) illumination.
58120723|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
58120724|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
58120725|NCT00444795|DRUG|sunitinib malate|Sunitinib : dosing not pre-determined
58120726|NCT00760383|DIETARY_SUPPLEMENT|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
58120727|NCT00760383|DIETARY_SUPPLEMENT|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
58120728|NCT02059993|DEVICE|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
58120729|NCT04223505|DIAGNOSTIC_TEST|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
58449842|NCT05616468|BIOLOGICAL|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
58449843|NCT05616468|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
58449844|NCT05616468|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
58449845|NCT04479826|DEVICE|Advanced hybrid closed loop system|Free living follow-up of meal handelling
57958942|NCT01677715|DIETARY_SUPPLEMENT|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
57958943|NCT01677715|DIETARY_SUPPLEMENT|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
57958944|NCT00023374|DRUG|Rifampin|6mos REZ intermittent
57958945|NCT00023374|DRUG|Pyrazinamide|6mos REZ intermittent
57958946|NCT00023374|DRUG|Ethambutol|6mos REZ intermittent
57958947|NCT00023374|DRUG|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
57958948|NCT00865072|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
57958949|NCT00865072|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
57958950|NCT02312492|OTHER|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
58120730|NCT04223505|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
58120731|NCT01968733|DRUG|Solithromycin|
58120732|NCT01968733|DRUG|Moxifloxacin|
58120733|NCT04247490|DIAGNOSTIC_TEST|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
58313838|NCT00375752|DRUG|Letrozole|2.5 mg.tablet.
58313839|NCT00375752|DRUG|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
58313840|NCT05729958|DIAGNOSTIC_TEST|CT scan|CT scan of the involved ankle
58313841|NCT00914069|DEVICE|RIVS vascular access|Access to peripheral vasculature
58313842|NCT00914069|DEVICE|Conventional vascular access|Vascular access using conventional venous access device
58313843|NCT01010763|DEVICE|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
58313844|NCT03871556|DIAGNOSTIC_TEST|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
58313845|NCT01065012|DRUG|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
58313846|NCT01065012|DRUG|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
58313847|NCT01065012|DRUG|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
57747083|NCT02657031|DRUG|Normal Saline|Normal Saline 500 cc IV Bolus
58120734|NCT06094868|DRUG|Fruquintinib|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
58120735|NCT04342923|OTHER|No intervention|Blood analysis
58120736|NCT01832805|OTHER|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
58120737|NCT03641898|PROCEDURE|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.
58120738|NCT03641898|DIAGNOSTIC_TEST|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
58120739|NCT01059071|DRUG|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
58120740|NCT01059071|DRUG|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
58120741|NCT03940430|DRUG|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
58120742|NCT03940430|DRUG|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
58120743|NCT03141099|OTHER|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
57747084|NCT01719835|DRUG|Cyclophosphamide|750mg/m2 IV every 21 days
58120744|NCT03141099|OTHER|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
58120745|NCT03141099|OTHER|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
58120746|NCT03141099|OTHER|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
58120747|NCT03616834|DRUG|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
57747085|NCT01719835|DRUG|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
57747086|NCT01719835|DRUG|Doxorubicin|50mg/m2 IV every 21 days
57747087|NCT01719835|DRUG|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
57747088|NCT01719835|DRUG|Prednisolone|100mg PO Days 1-5 every 21 days
57747089|NCT01719835|DRUG|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
57747090|NCT01719835|DRUG|Cisplatin|100mg/m2 IV Day 15 every 28 days
57747091|NCT00314314|DRUG|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
57747092|NCT00314314|DRUG|Diluent|Intranasal spray; 8 weeks
57747093|NCT05777798|DEVICE|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
58120748|NCT00346086|DRUG|AIC (Amb a 1 Immunostimulatory Conjugate)|
57747094|NCT01562210|DRUG|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
57747095|NCT01562210|DRUG|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
57747096|NCT01562210|RADIATION|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
58120749|NCT04648475|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
58120750|NCT00000563|DRUG|dexamethasone|
57747097|NCT05600348|DIETARY_SUPPLEMENT|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
57747098|NCT04158050|DRUG|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
57747099|NCT01949779|DEVICE|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
57747100|NCT03861013|BEHAVIORAL|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
58120751|NCT06244303|DRUG|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)|Toothpaste, toothbrush \& mouthwash regime
58120752|NCT06244303|DRUG|manual toothbrush + Colgate dental cream|toothpaste + toothbrush
58120753|NCT01727479|OTHER|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
58120754|NCT01727479|OTHER|Placebo|
58120755|NCT01851070|DRUG|Allogeneic Mesenchymal Precursor Cells|
58120756|NCT01851070|DRUG|Normal Saline|
58120757|NCT00227825|BEHAVIORAL|Motivational interviewing|
58449846|NCT04005261|DIAGNOSTIC_TEST|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
57747101|NCT05019092|DIAGNOSTIC_TEST|Ultrasound examination of lower limb veins|Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
57747102|NCT04684121|DRUG|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
57747103|NCT04684121|DRUG|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
57747104|NCT00526266|BEHAVIORAL|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
58120758|NCT04674098|DEVICE|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
57747105|NCT00526266|BEHAVIORAL|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
57747106|NCT05391854|DIETARY_SUPPLEMENT|Pep2dia|700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner
57747107|NCT05391854|DIETARY_SUPPLEMENT|Placebo|700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
58120759|NCT00450996|DRUG|Topical Steroids|
58120760|NCT02006706|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
58313848|NCT01065012|DRUG|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
57747108|NCT05527379|DEVICE|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
58120761|NCT02006706|DRUG|methotrexate|10 - 25 mg/week
58120762|NCT02006706|DRUG|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
58120763|NCT02634060|DEVICE|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
58120764|NCT02708277|DEVICE|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
58120765|NCT02708277|DEVICE|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
58120766|NCT00888810|DRUG|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
58120767|NCT00888810|DRUG|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
58120768|NCT03586336|DEVICE|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
58120769|NCT03586336|DEVICE|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
58120770|NCT03819686|BEHAVIORAL|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching \~20-minutes of videos from the website)
58313849|NCT01065012|DRUG|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
58313850|NCT01065012|DRUG|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
58313851|NCT01951300|OTHER|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
58313852|NCT03307135|DEVICE|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
58120771|NCT03819686|BEHAVIORAL|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
58120772|NCT04426409|DRUG|tarivid ointment|Vaseline ointment is applied to both noses.
58120773|NCT03265496|PROCEDURE|Clinical exam|Clinical exam is performed before treatment start
58120774|NCT03265496|PROCEDURE|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
58120775|NCT03265496|PROCEDURE|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
58120776|NCT03265496|DRUG|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
58120777|NCT03265496|PROCEDURE|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
58120778|NCT03265496|BIOLOGICAL|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
58120779|NCT00118300|DRUG|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
58120780|NCT00118300|RADIATION|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)\* intracavitary brachytherapy once weekly in weeks 4-8.
58120781|NCT00118300|RADIATION|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
58120782|NCT00962000|OTHER|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
58120783|NCT00962000|OTHER|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
58120784|NCT00141752|DEVICE|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
58120785|NCT06143735|DRUG|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
58120786|NCT00359853|DRUG|Oral norfloxacin|
58120787|NCT00788619|PROCEDURE|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
58120788|NCT00788619|PROCEDURE|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
58120789|NCT02249884|DRUG|Urea Dose A|Urea cream for topical use.
58120790|NCT02249884|DRUG|Urea Dose B|Urea cream for topical use.
57747109|NCT04857931|DRUG|Colchicine|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
58313853|NCT03307135|DEVICE|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
57747110|NCT04857931|DRUG|Placebo|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
57747111|NCT00500942|BEHAVIORAL|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
57747112|NCT00820833|OTHER|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
57747113|NCT00820833|OTHER|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
57747114|NCT00224874|DRUG|Etanercept|Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
57747115|NCT00224874|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
58120791|NCT02249884|DRUG|Urea Dose C|Urea cream for topical use.
58120792|NCT02249884|DRUG|Chamomile Dose A|Chamomile gel for topical use.
58120793|NCT02249884|DRUG|Chamomile Dose B|Chamomile gel for topical use.
58120794|NCT02249884|DRUG|Chamomile Dose C|Chamomile gel for topical use.
58120795|NCT05879328|PROCEDURE|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
58313854|NCT03307135|DEVICE|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
58313855|NCT03767478|DEVICE|Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 6 months at suprathreshold (2 x motor threshold).
58120796|NCT06100237|DRUG|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
58120797|NCT06100237|DRUG|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
58120798|NCT06100237|DRUG|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
58458683|NCT03885635|PROCEDURE|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
57747116|NCT00224874|DRUG|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
57747117|NCT00224874|DRUG|Pentostatin|Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
57747118|NCT01655290|OTHER|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
57747119|NCT00095524|DRUG|Aripiprazole|
57958951|NCT02312492|OTHER|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
57958952|NCT02312492|OTHER|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
57958953|NCT05913414|DRUG|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
57958954|NCT05913414|DRUG|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
57958955|NCT05913414|RADIATION|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
57958956|NCT05932550|DRUG|Maraviroc 300 mg|10 week treatment as add-on therapy to anti-depressants
57958957|NCT01283165|BEHAVIORAL|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
57958958|NCT00181181|DRUG|atorvastatin|Atorvastatin 80 mg daily for 3 months
57958959|NCT00181181|OTHER|placebo|placebo daily
57958960|NCT06548906|DRUG|GZR4 Injection|GZR4 Injection administered sc, once weekly.
57958961|NCT04849780|DEVICE|ACUVUE Oasys 1-Day|TEST
57958962|NCT04849780|DEVICE|Habitual Lens|Subjects' own Habitual Lenses
58120799|NCT06203899|BEHAVIORAL|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
58120800|NCT06203899|BEHAVIORAL|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
58120801|NCT01390883|DRUG|Fondaparinux Sodium|
58120802|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
58120803|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
58120804|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
58120805|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
58120806|NCT04964999|OTHER|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
58120807|NCT03314766|DEVICE|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
58313856|NCT03767478|DEVICE|Sham Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 6 months at suprathreshold (2 x motor threshold).
58313857|NCT01045278|DRUG|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
58313858|NCT00436761|BIOLOGICAL|anti-thymocyte globulin|
58313859|NCT00436761|BIOLOGICAL|graft-versus-tumor induction therapy|
58313860|NCT00436761|BIOLOGICAL|sargramostim|
58313861|NCT00436761|DRUG|busulfan|
58313862|NCT00436761|DRUG|cyclosporine|
58313863|NCT00436761|DRUG|melphalan|
57747120|NCT04367584|OTHER|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
57747121|NCT01345721|BIOLOGICAL|MenACWY-CRM|
58313864|NCT00436761|DRUG|methylprednisolone|
58313865|NCT00436761|OTHER|flow cytometry|
58313866|NCT00436761|OTHER|immunologic technique|
58313867|NCT00436761|OTHER|laboratory biomarker analysis|
58120808|NCT00673491|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
57747122|NCT01471054|DRUG|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
57747123|NCT01471054|DRUG|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
58313868|NCT00436761|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58313869|NCT00436761|PROCEDURE|umbilical cord blood transplantation|
58313870|NCT04686032|OTHER|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
58313871|NCT04686032|OTHER|Early ambulation|Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
57747124|NCT03493048|DRUG|Irinotecan|Irinotecan 130 mg/m²
57747125|NCT03493048|DRUG|Cetuximab|Cetuximab, iv, 500mg/m2
57747126|NCT03493048|DRUG|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
57747127|NCT03493048|DRUG|Oxaliplatin|oxaliplatin 85 mg/m²
57747128|NCT03493048|DRUG|Leucovorin|leucovorin 200 mg/m²
57747129|NCT02651766|PROCEDURE|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
57747130|NCT05454150|DEVICE|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
57747131|NCT05454150|DEVICE|self-expanding valve|Evolut R/Pro, Medtronic©
57747132|NCT01800968|DRUG|Liraglutide|Active Drug
57747133|NCT01800968|DRUG|Placebo|Placebo
58313872|NCT03069664|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
58313873|NCT03069664|DEVICE|Covered Self-expandable Metal Stent|Pancreatic duct stent
58313874|NCT02110251|BEHAVIORAL|Supervised Exercise Therapy|
58313875|NCT01621074|DIETARY_SUPPLEMENT|Sodium bicarbonate|Ergogenic effect
57747134|NCT01832428|OTHER|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
57747135|NCT00955669|BIOLOGICAL|Symptoms and Objective Examination|5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
57747136|NCT04139564|DEVICE|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
57747137|NCT04139564|DEVICE|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
57747138|NCT04058353|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
57747139|NCT04058353|DRUG|IVA|Mono-tablet for oral administration.
57747140|NCT04058353|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
58313876|NCT01621074|DIETARY_SUPPLEMENT|Placebo|Placebo effect
57747141|NCT05380648|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
57747142|NCT04029129|OTHER|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
57747143|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
57747144|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） High Dose|
57747145|NCT01512901|DRUG|Sham|
57747146|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID|Patients receive tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
57747147|NCT06354179|DRUG|LCP-tacrolimus QD + MMF BID|Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. The MMF dose may be decreased at any time during the study according to the investigator's decision.
58313877|NCT00080340|DRUG|TLK286 (Telcyta) HCl for Injection|
58313878|NCT00080340|DRUG|gefitinib (Iressa)|
58313879|NCT05985759|DRUG|N acetyle cystiene|N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
58313880|NCT00998192|BIOLOGICAL|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
58313881|NCT00998192|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
58313882|NCT00998192|DRUG|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
57747148|NCT06354179|DRUG|LCP-tacrolimus QD + MMF QD|Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
57747149|NCT01959451|DRUG|Prasugrel|see Arm description
57747150|NCT01959451|DRUG|Clopidogrel|see arm description
57747151|NCT02642250|DRUG|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
58120809|NCT01033162|BEHAVIORAL|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~* Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~* Reduce patients' negative affect and increase their emotional well being~* Improve patients' sense of social support~* Improve patients' health self-efficacy~* Improve patients' ratings of experience with cancer specialty care services~* Improve patients' health related quality of life (HRQL)~* Improve clinicians' ratings of quality of patient contacts~* Reduce healthcare utilization and costs (obtained via the EMR)"
58120810|NCT04383990|OTHER|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
58120811|NCT00149292|DRUG|LY2140023|
58120812|NCT00149292|DRUG|olanzapine|
58120813|NCT00149292|DRUG|placebo|
58120814|NCT00208156|DRUG|Mifepristone|
58120815|NCT04174924|PROCEDURE|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
58120816|NCT02985151|DEVICE|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
58120817|NCT01336894|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58120818|NCT01336894|RADIATION|iodine I 125|Undergo seed implant radiotherapy
58449847|NCT04157777|OTHER|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
57747152|NCT02642250|DRUG|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
57747153|NCT03001297|BIOLOGICAL|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
57958963|NCT05661773|DEVICE|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
57958964|NCT04775329|DRUG|Rifaximin|Rifaximin 1000mg OM
57958965|NCT01175902|DRUG|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
57958966|NCT01175902|DRUG|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
57958967|NCT04619485|DEVICE|CO2 LASER|5 SESSIONS OF CO2 VAGINAL LASER
57958968|NCT04619485|DEVICE|CO2 SHAM LASER|5 SESSIONS OF CO2 VAGINAL SHAM LASER
57958969|NCT06106854|BEHAVIORAL|Behavioral: SystemCHANGE|six-month SystemCHANGE™ intervention
57958970|NCT06106854|OTHER|Education|Six patient education booklets
57958971|NCT00466648|PROCEDURE|Tissue adhesive|
57958972|NCT01576692|BIOLOGICAL|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once"
57958973|NCT01576692|DRUG|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3"
57958974|NCT01576692|OTHER|Cytokines|"Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC \>2,000/mm\^3"
58120819|NCT01336894|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
58120820|NCT06008600|DEVICE|Kinocardiography|Smartphone (application with seismocardiography)
58120821|NCT04259606|DIETARY_SUPPLEMENT|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
58120822|NCT04259606|OTHER|Calcined magnesia|White, odor, color and flavorless thin powder.
58120823|NCT02587442|DRUG|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
58120824|NCT03265470|DRUG|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
58120825|NCT03265470|DRUG|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
58120826|NCT05236075|DEVICE|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
58120827|NCT01146132|DIETARY_SUPPLEMENT|Conventional diet +/- wine|usual eating habits
58449848|NCT00017511|DRUG|cevimeline hydrochloride|
58449849|NCT03688815|DIAGNOSTIC_TEST|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
58449850|NCT01152528|DEVICE|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
58449851|NCT02426463|DRUG|propofol|
58449852|NCT02426463|DRUG|oxycodone|
58449853|NCT05317065|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
58449854|NCT00300755|DRUG|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
58449855|NCT00993408|DEVICE|ACT-293987 (NS-304)|
58449856|NCT02562716|DRUG|Fluorouracil|Given IV
58449857|NCT02562716|DRUG|Gemcitabine Hydrochloride|Given IV
58449858|NCT02562716|DRUG|Irinotecan Hydrochloride|Given IV
58449859|NCT02562716|DRUG|Oxaliplatin|Given IV
58449860|NCT02562716|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
58449861|NCT02562716|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
58449862|NCT05661279|PROCEDURE|general anesthesia|general anesthesia
58449863|NCT05661279|PROCEDURE|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
57958975|NCT01576692|BIOLOGICAL|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.
57958976|NCT01576692|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
57958977|NCT02490293|DRUG|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
57958978|NCT02490293|DRUG|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
57958979|NCT01908101|DRUG|Eribulin Mesylate|Given IV
57958980|NCT01908101|OTHER|Laboratory Biomarker Analysis|Correlative studies
57958981|NCT02104583|DRUG|Eleclazine|Eleclazine tablets administered orally
57958982|NCT02104583|DRUG|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
57958983|NCT02188316|DEVICE|Jumbo forceps|comparison of different polypectomy devices
57958984|NCT02188316|DEVICE|Hot biopsy forceps|comparison of different polypectomy devices
57958985|NCT04864431|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
57958986|NCT04864431|OTHER|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
57958987|NCT03042715|BEHAVIORAL|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
58120828|NCT01146132|DIETARY_SUPPLEMENT|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
58120829|NCT02320474|DRUG|Aflibercept|
58120830|NCT06545123|BEHAVIORAL|Concurrent exercise training|The experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists
58120831|NCT00656500|BEHAVIORAL|Standard brief advice|Brief general assistance with smoking cessation
58120832|NCT00656500|BEHAVIORAL|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
58449864|NCT05661279|PROCEDURE|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
58449865|NCT01056939|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
58120833|NCT04909632|DIAGNOSTIC_TEST|Liquid chromatography-mass spectrometry (LC-MS) analysis|The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
58120834|NCT03756753|DIAGNOSTIC_TEST|Results available to provider|Results of point of care testing are given to provider
58120835|NCT01133821|DRUG|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
58120836|NCT01133821|DRUG|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
58120837|NCT04782102|BEHAVIORAL|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
58120838|NCT03603756|DRUG|SHR-1210|a novel anti-PD-1 antibody
58120839|NCT03603756|DRUG|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
58120840|NCT03603756|DRUG|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
58120841|NCT03603756|DRUG|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
58120842|NCT03603756|DRUG|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
58120843|NCT00386113|BIOLOGICAL|Fluarix and adjuvanted influenza vaccine|
58120844|NCT05963256|DEVICE|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
58120845|NCT00124020|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
58120846|NCT00124020|DRUG|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
58313883|NCT06252480|DEVICE|tDCS|4 variance of different intensities of tDCS (0.5mA, 1 mA, 1.5mA and 2mA). At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment.
58313884|NCT05624541|DIAGNOSTIC_TEST|Measurements|All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
58449866|NCT01056939|DEVICE|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
58449867|NCT00657982|DRUG|RAD001|10mg BID
58449868|NCT03246789|BEHAVIORAL|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
57747154|NCT03001297|BIOLOGICAL|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
57958988|NCT04589104|BEHAVIORAL|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth"
57958989|NCT03150225|OTHER|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
58120847|NCT01836835|OTHER|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
58120848|NCT01836835|OTHER|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
58120849|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 1472 mcg, single dose
58120850|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 736 mcg, single dose
58120851|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 368 mcg, single dose
58120852|NCT00783406|DRUG|Placebo|Placebo
58120853|NCT05067257|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
58120854|NCT05067257|DRUG|Placebo|Vehicle solution
58120855|NCT05073575|PROCEDURE|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
58120856|NCT05073575|PROCEDURE|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
58120857|NCT01696591|BIOLOGICAL|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
58120858|NCT03885102|BEHAVIORAL|Intradialytic exercise intervention|50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
58120859|NCT03885102|BEHAVIORAL|Usual Care|Usual care with no exercise intervention or health literacy counselling
58120860|NCT01448083|OTHER|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
58120861|NCT01919632|BEHAVIORAL|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
58120862|NCT02311023|OTHER|Intermittent fasting|
58120863|NCT02236130|PROCEDURE|Regional block|Single shot peripheral nerve block
58120864|NCT02236130|PROCEDURE|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
57747155|NCT03001297|BIOLOGICAL|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
57747156|NCT03001297|BIOLOGICAL|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
57747157|NCT03001297|BIOLOGICAL|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
58120865|NCT02236130|DRUG|Local Anesthetic Ropivacaine|0.5% Ropivacaine
58120866|NCT02236130|DRUG|Opioids Morphine|Morphine
57747158|NCT03154801|OTHER|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
57747159|NCT05460494|BEHAVIORAL|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
57747160|NCT06305949|DEVICE|Optimized transcranial Direct Current Stimulation|transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
57747161|NCT06305949|DEVICE|Sham transcranial Direct Current Stimulation|transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
57747162|NCT03406728|OTHER|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
58120867|NCT02236130|DRUG|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
58120868|NCT00910182|PROCEDURE|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
58120869|NCT01319656|BEHAVIORAL|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
58120870|NCT05895253|DEVICE|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
58120871|NCT02725970|OTHER|survey|Cross-sectional survey
58120872|NCT05336084|BEHAVIORAL|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
58120873|NCT02233179|DEVICE|Removable cast walker|Offloading device that can be removed by patients.
58120874|NCT02233179|DEVICE|Irremovable cast walker|Offloading device that cannot be removed by patients.
58120875|NCT03445975|PROCEDURE|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
58120876|NCT04187651|OTHER|platelet rich plasma|platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
58120877|NCT00379457|BIOLOGICAL|dactinomycin|
58120878|NCT00379457|DRUG|carboplatin|
57747163|NCT03406728|OTHER|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
57747164|NCT03406728|DEVICE|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
57747165|NCT04419948|OTHER|White bread|White bread (120g) containing 54 g CHO
58120879|NCT00379457|DRUG|cyclophosphamide|
58120880|NCT00379457|DRUG|doxorubicin hydrochloride|
58120881|NCT00379457|DRUG|etoposide|
58120882|NCT00379457|DRUG|ifosfamide|
58120883|NCT00379457|DRUG|topotecan hydrochloride|
58120884|NCT00379457|DRUG|vincristine sulfate|
58120885|NCT00379457|DRUG|vinorelbine tartrate|
58120886|NCT00379457|PROCEDURE|conventional surgery|
58313885|NCT02136381|BEHAVIORAL|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
58449869|NCT03246789|BEHAVIORAL|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
58449870|NCT03088527|DRUG|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
57747166|NCT04419948|OTHER|Butter|Butter 39 g
57747167|NCT04419948|OTHER|Refined olive oil|Refined olive oil (40 ml).
57747168|NCT04419948|OTHER|EVOO with 250 mg/kg oleocanthal|Extra virgin olive oil containing 250 mg/kg oleocanthal.
57747169|NCT04419948|OTHER|EVOO with 500 mg/kg oleocanthal|Extra virgin olive oil containing 500 mg/kg oleocanthal.
57747170|NCT04419948|OTHER|Ibuprofen|Ibuprofen 400 mg
58120887|NCT00379457|RADIATION|radiation therapy|
58120888|NCT00099528|DRUG|REN-1654|
58449871|NCT01449435|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
57747171|NCT00100451|PROCEDURE|exercise|
57747172|NCT02002403|DRUG|Danazol|
57747173|NCT03104764|DEVICE|Scalpel|Labial frenulum removed by scalpel
57747174|NCT03104764|DEVICE|Er:YAG laser|Labial frenulum removed by Er:YAG laser
57747175|NCT04405518|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
57958990|NCT03150225|DIETARY_SUPPLEMENT|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
57958991|NCT04049045|DRUG|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
57958992|NCT04049045|DRUG|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
57958993|NCT04858165|PROCEDURE|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
57958994|NCT06424093|PROCEDURE|Virtual Reality Technology|To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
57958995|NCT04195321|DRUG|Norepinephrine|infusion will be started after induction of spinal anesthesia
57958996|NCT04195321|DRUG|phenylephrine|infusion will be started after induction of spinal anesthesia
57958997|NCT01309178|DRUG|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
57958998|NCT01309178|DRUG|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
57958999|NCT01784965|DRUG|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
57959000|NCT01784965|DRUG|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
57959001|NCT03732300|OTHER|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
58120889|NCT01638936|DRUG|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
58120890|NCT05236946|RADIATION|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
58120891|NCT05236946|DRUG|Tyrosine kinase inhibitor|TKI
58449872|NCT01366326|DRUG|Methylnaltrexone bromide|Subcutaneous MNTX
58449873|NCT03094117|OTHER|News items with spin|Interpretation of news items with spin
58449874|NCT03094117|OTHER|News items without spin|Interpretation of news items without spin
58449875|NCT01865227|BEHAVIORAL|Group Counseling|
58120892|NCT06124430|OTHER|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
58120893|NCT00913965|DRUG|Atenolol Tablets 100 mg (Cord Laboratories)|
58120894|NCT00913965|DRUG|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
58120895|NCT02518685|DEVICE|TransPyloric Shuttle|
58120896|NCT02518685|DEVICE|Sham procedure|
58120897|NCT02518685|BEHAVIORAL|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
58120898|NCT01375933|BIOLOGICAL|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
58120899|NCT01047345|BIOLOGICAL|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
58120900|NCT01047345|BIOLOGICAL|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
58120901|NCT00274326|DRUG|SR121463B|
58120902|NCT02688894|OTHER|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
58120903|NCT03714100|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
58120904|NCT04529642|DIAGNOSTIC_TEST|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
58120905|NCT03252795|PROCEDURE|uterus transplantation|transplantation of a uterus from a deceased donor
58120906|NCT03083210|DRUG|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
58120907|NCT00795561|PROCEDURE|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
58120908|NCT00795561|PROCEDURE|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
58120909|NCT00401219|DRUG|conjugated estrogens/progestin (MPA)|
58120910|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
58120911|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
58120912|NCT03658135|DRUG|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
58120913|NCT03658135|OTHER|Placebo|Inactive ingredient
58120914|NCT00003213|DRUG|dexamethasone|4 mg Dexamethasone in the morning
57747176|NCT04373538|BEHAVIORAL|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
58120915|NCT00003213|DRUG|granisetron hydrochloride|1 mg Granisetron in the morning
58120916|NCT00003213|DRUG|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
58120917|NCT06384144|OTHER|Expectant Management of First Trimester Miscarriage|Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
58313886|NCT02136381|BEHAVIORAL|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
58120918|NCT06384144|OTHER|Medical Management of First Trimester Miscarriage|Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
58120919|NCT00162604|DRUG|Cefuroxime|
58120920|NCT04641429|BEHAVIORAL|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
58120921|NCT04641429|BEHAVIORAL|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
58120922|NCT03674164|OTHER|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
58120923|NCT01568489|DRUG|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
58120924|NCT00604409|RADIATION|SIRT|Undergo SIRT
58120925|NCT00604409|DRUG|capecitabine|Given PO
58120926|NCT02907112|BEHAVIORAL|Meat reduction|Advice, Motivational material and food products provided to participants
58120927|NCT02720952|DRUG|Infacort®|dry granule formulation of hydrocortisone
58120928|NCT02903056|OTHER|Rett Syndrome|Diagnosis of Rett Syndrome
58120929|NCT02322047|DRUG|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
58120930|NCT02322047|DRUG|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
58120931|NCT02322047|DRUG|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
58120932|NCT02322047|DRUG|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
58120933|NCT05921058|DRUG|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
57747177|NCT06367205|DRUG|Goal-Directed Fluid Therapy (GDFT)|Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
57747178|NCT06367205|DRUG|Regular Fluid Therapy|Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary
57747179|NCT02495025|BEHAVIORAL|Telephone-based developmental screening and care coordination|
57747180|NCT05806229|PROCEDURE|Mid transverse process to pleura block (MTP)|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
57959002|NCT04868084|BEHAVIORAL|Physical literacy in the early years|Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
57959003|NCT05564169|DRUG|Placebo|treatment per os
57959004|NCT05564169|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
58120934|NCT05921058|DRUG|Placebo|NaCl 0,9% infusion
58120935|NCT03289975|OTHER|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
58120936|NCT04963348|OTHER|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
58120937|NCT05896670|DRUG|licaminlimab|ophthalmic suspension 60 mg/mL Subjects will receive licaminlimab eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
58120938|NCT05896670|OTHER|vehicle of OCS-02|inert ophthalmic suspension vehicle of OCS-02 Subjects will receive vehicle eye drops TID for 6 weeks. All subjects will be assigned artificial tears TID for 2 weeks.
58120939|NCT00249548|BEHAVIORAL|Contingency management|
58120940|NCT03544320|DEVICE|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
58120941|NCT03544320|DEVICE|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
58120942|NCT04436692|BEHAVIORAL|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
57959005|NCT05564169|DRUG|Standard of care|Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
58120943|NCT00783796|DEVICE|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
58120944|NCT05031728|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
58120945|NCT05197907|PROCEDURE|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
58120946|NCT05197907|PROCEDURE|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
58120947|NCT01498484|BIOLOGICAL|EBV-specific T cells (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
58120948|NCT01947777|DRUG|IPI-145|25 mg oral capsule
58120949|NCT01947777|DRUG|Rifampin|2x 300 mg oral capsule
58120950|NCT02064426|DRUG|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
58120951|NCT02064426|BIOLOGICAL|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
58120952|NCT06375928|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
58313887|NCT05286346|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
58120953|NCT06375928|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
58120954|NCT06375928|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
58120955|NCT01875575|DIETARY_SUPPLEMENT|Placebo|
58120956|NCT01875575|DIETARY_SUPPLEMENT|Glucose 25g|
58120957|NCT01875575|DIETARY_SUPPLEMENT|Glucose 10g|
58120958|NCT01468051|BIOLOGICAL|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
58120959|NCT01468051|BIOLOGICAL|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
58120960|NCT02184273|DRUG|Magnesium metamizol|
58120961|NCT02184273|DRUG|Placebo|
57747181|NCT05806229|PROCEDURE|Mid transverse process to pleura Sham block|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
57747182|NCT03148470|DEVICE|Sham iTBS|Placebo stimulation for the iTBS group
57747183|NCT03148470|DEVICE|Sham cTBS|Placebo stimulation for the cTBS group
58120962|NCT05096325|DEVICE|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
58120963|NCT03535909|DIAGNOSTIC_TEST|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
58120964|NCT01276782|DRUG|Levothyroxine|It is FDA approved drug for thyroid disease
57747184|NCT03148470|DEVICE|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
57747185|NCT03148470|DEVICE|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
57747186|NCT01172002|DRUG|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
57747187|NCT01172002|DRUG|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
57747188|NCT04239040|PROCEDURE|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
57747189|NCT04239040|BIOLOGICAL|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
58120965|NCT05825300|BEHAVIORAL|Email message|Email message encourages patients to donate blood
58120966|NCT05825300|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
58120967|NCT00501761|BEHAVIORAL|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
57747190|NCT04239040|DRUG|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
57747191|NCT04239040|DRUG|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
58120968|NCT00501761|BEHAVIORAL|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
58120969|NCT00501761|BEHAVIORAL|Suggested Exercise Program|Exercise program performed over 7 days.
58120970|NCT04181450|OTHER|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., \& Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
58120971|NCT05832255|DRUG|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
58120972|NCT04118231|OTHER|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
58313888|NCT05286346|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
58313889|NCT03791320|DIAGNOSTIC_TEST|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
58449876|NCT00207311|DRUG|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
58449877|NCT00207311|BEHAVIORAL|Xenicare Program|Xenicare program for 36 weeks.
57747192|NCT00575926|DRUG|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
57747193|NCT03212157|OTHER|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
58120973|NCT05866146|OTHER|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
58120974|NCT05866146|OTHER|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
58120975|NCT05850351|OTHER|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
58120976|NCT05850351|OTHER|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
58120977|NCT00640978|DRUG|RAD001|30 mg orally weekly for 4 weeks
58120978|NCT00640978|DRUG|Erlotinib|150 mg by mouth daily for 28 Days
58120979|NCT04771000|DRUG|Ambrisentan|Endothelin receptor antagonist
58120980|NCT04771000|DRUG|Placebo|Placebo
58449878|NCT02174991|DRUG|Rho-Kinase Inhibitor (AR-12286)|
58449879|NCT05371925|DRUG|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
58449880|NCT01561235|OTHER|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
58449881|NCT00348985|DRUG|belinostat|
58449882|NCT00348985|DRUG|bortezomib|
58449883|NCT00348985|OTHER|pharmacological study|
58449884|NCT05617781|BEHAVIORAL|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
58449885|NCT06138769|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day
58449886|NCT05210491|OTHER|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
57747194|NCT03212157|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
57747195|NCT03212157|DIAGNOSTIC_TEST|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
57747196|NCT01821742|OTHER|Ultrasound cardiac output measurement|
58449887|NCT05910216|OTHER|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
58449888|NCT05910216|OTHER|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
58449889|NCT01588444|DEVICE|cortical FDBA|cortical mineralized freeze-dried bone allograft
58449890|NCT01588444|DEVICE|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
57747197|NCT03361436|DRUG|Eribulin Mesylate|Given IV
57747198|NCT03361436|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57747199|NCT03361436|OTHER|Laboratory Biomarker Analysis|Correlative studies
57747200|NCT03361436|OTHER|Quality-of-Life Assessment|Ancillary studies
58120981|NCT04759495|DEVICE|Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)|rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
58120982|NCT04759495|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)|FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
58120983|NCT04552704|BIOLOGICAL|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
58449891|NCT04567641|DIETARY_SUPPLEMENT|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
58449892|NCT05817838|BEHAVIORAL|Financial Incentives|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store
57747201|NCT03361436|OTHER|Questionnaire Administration|Ancillary studies
57747202|NCT03361436|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57747203|NCT03786731|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
58120984|NCT04552704|DRUG|Placebo Administration|Given IV
58120985|NCT01348295|OTHER|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
58120986|NCT04017013|PROCEDURE|Epidural Analgesia|"The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
58120987|NCT04017013|DRUG|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
58120988|NCT05855915|DIAGNOSTIC_TEST|Kinesio taping|Kinesotaping will be applied with routine physical therapy
58120989|NCT05855915|DIAGNOSTIC_TEST|Sham taping|Sham taping will be applied with routine physical therapy
58449893|NCT05817838|BEHAVIORAL|Financial Incentives and Multilevel Multicomponent|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing
58120990|NCT00745095|DRUG|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
58120991|NCT02462538|DRUG|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
58120992|NCT02462538|DRUG|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
58120993|NCT04228341|OTHER|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
58120994|NCT04228341|OTHER|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
58120995|NCT04228341|OTHER|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
58120996|NCT04228341|OTHER|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
58449894|NCT05817838|OTHER|School Engagement|For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
58449895|NCT04214340|OTHER|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
57747204|NCT00559650|DRUG|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
57747205|NCT00559650|DRUG|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
57747206|NCT01298999|DRUG|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
57747207|NCT01298999|DRUG|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
57747208|NCT01735890|DRUG|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
57747209|NCT06384417|BEHAVIORAL|Hello for Cancer game|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~The questions used in Hello for Cancer were modified from the original Hello game based on the results of phase 1 of testing this game in cancer populations. The modifications made to the game will be assessed for acceptability during this study."
58458684|NCT05219357|OTHER|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
58120997|NCT04228341|OTHER|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
58120998|NCT04228341|OTHER|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
58120999|NCT04228341|OTHER|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
58121000|NCT04228341|OTHER|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
57747210|NCT06384417|OTHER|Table Topics game|To play Table Topics, players are provided a deck of cards that have a variety of general conversation starter questions. The group takes turns selecting a card and reading it to the group for the group to answer. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
58121001|NCT04164888|DRUG|CIVI 007|hypercholesterolemia agent
58121002|NCT01813656|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
58121003|NCT01813656|DRUG|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
58121004|NCT04043520|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
58121005|NCT04043520|DRUG|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
58121006|NCT04043520|DRUG|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
58121007|NCT04043520|DRUG|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
58121008|NCT01341639|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
58121009|NCT01341639|BIOLOGICAL|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
58121010|NCT01341639|BIOLOGICAL|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
57959006|NCT01492608|DRUG|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
58121011|NCT01341639|BIOLOGICAL|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
58121012|NCT01341639|BIOLOGICAL|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
58121013|NCT05380856|DEVICE|Turning ON the neuromodulator|IPG on
58121014|NCT05380856|DEVICE|Turning OFF the neuromodulator|IPG OFF
58121015|NCT00343850|DRUG|Asacol (mesalamine)|
58121016|NCT06077565|OTHER|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
58449896|NCT03779659|DEVICE|Synapse TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
58449897|NCT03779659|DRUG|Topical anesthetic gel|"The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures.~The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure"
58449898|NCT03631342|OTHER|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
58449899|NCT03631342|OTHER|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
58449900|NCT03631342|OTHER|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
58449901|NCT03631342|OTHER|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
58449902|NCT03631342|OTHER|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
58449903|NCT04502537|DRUG|Roxadustat|Oral
58449904|NCT04502537|DRUG|erythropoietin|injection
58121017|NCT06077565|OTHER|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
58449905|NCT06051669|DEVICE|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
58449906|NCT06051669|DEVICE|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
58449907|NCT05055024|DRUG|Mazindol|Drug: NLS-2
58121018|NCT06077565|OTHER|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
58121019|NCT05283239|OTHER|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
58121020|NCT05101928|DRUG|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
58121021|NCT05101928|DRUG|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
58121022|NCT00650156|BIOLOGICAL|adalimumab|40 mg single sc dose
58121023|NCT00650156|BIOLOGICAL|adalimumab|80 mg single sc dose
58121024|NCT02352883|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58121025|NCT02352883|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy
58121026|NCT02352883|PROCEDURE|Therapeutic Surgical Procedure|Undergo wide local excision
58121027|NCT02352883|RADIATION|Radiation Therapy|Undergo radiation therapy
58121028|NCT02352883|DRUG|Endocrine Therapy|Undergo endocrine therapy
58121029|NCT02352883|OTHER|Quality-of-Life Assessment|Ancillary studies
58121030|NCT02352883|OTHER|Laboratory Biomarker Analysis|Correlative studies
58121031|NCT02352883|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58121032|NCT01640496|DRUG|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
58121033|NCT01640496|OTHER|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
58121034|NCT03537781|BEHAVIORAL|Food labelling versus no food labelling|Food labelling availability and satiety status
58121035|NCT05200858|DEVICE|TENS - high-dose|Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
58121036|NCT05200858|DEVICE|TENS - low-dose|Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
58121037|NCT04914715|DEVICE|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
58449908|NCT00135317|DRUG|darbepoetin alfa|
58449909|NCT02420379|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
58449910|NCT04280055|DRUG|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
57747211|NCT02538185|DEVICE|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
57747212|NCT02538185|DEVICE|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
58121038|NCT04914715|DEVICE|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
58121039|NCT05393947|OTHER|patient education|It is planned to provide education to patients about the side effects of chemotherapy.
58121040|NCT03482713|DRUG|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
58121041|NCT03482713|DRUG|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
58121042|NCT00710203|DEVICE|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
58121043|NCT00710203|PROCEDURE|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
58121044|NCT00710203|PROCEDURE|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
58449911|NCT01235013|DRUG|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
58449912|NCT03109184|BEHAVIORAL|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
58449913|NCT05568628|DEVICE|ultrasound|screening of breast lesions by ultrasonography
58121045|NCT00710203|OTHER|No treatment|A fourth lesion will not be treated and will serve as a control.
58121046|NCT04032873|OTHER|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
58121047|NCT04032873|OTHER|Physician|The monetary cost information is relayed by the patient's physician
58121048|NCT04032873|OTHER|Study Team|The monetary cost information is relayed by a member of the study team
58121049|NCT04032873|OTHER|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
58121050|NCT04032873|OTHER|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
58121051|NCT00219661|PROCEDURE|drainage of subglottic secretions (HiLo Evac tube)|
58449914|NCT00855621|PROCEDURE|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
58449915|NCT00724672|DRUG|etanercept|etanercept 50 mg subcutaneously once weekly
58449916|NCT00724672|DRUG|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
58449917|NCT00724672|DRUG|adalimumab|adalimumab 40 mg subcutaneously biweekly
58449918|NCT03168828|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
58121052|NCT02133755|DRUG|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
58121053|NCT02177955|DRUG|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
58121054|NCT02177955|DRUG|10 mg diazepam|10 mg midazolam 45 minutes before surgery
58121055|NCT04153253|DRUG|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
58121056|NCT04153253|PROCEDURE|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
58121057|NCT02746263|DRUG|IV acetaminophen|
58121058|NCT02746263|DRUG|Oral acetaminophen|
58121059|NCT02746263|DRUG|Morphine|Patient controlled analgesia
58121060|NCT01557647|DRUG|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
58121061|NCT01557647|DRUG|Placebo|placebo inhalation solution
58121062|NCT04145908|PROCEDURE|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
58121063|NCT00000275|DRUG|Flupenthixol|
58121064|NCT04639934|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
58121065|NCT00958581|DRUG|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
58449919|NCT05599737|RADIATION|Integrated boost|Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
58449920|NCT04484870|DRUG|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
58449921|NCT01664182|BIOLOGICAL|Bevacizumab|Given IV
58449922|NCT01664182|DRUG|Pazopanib Hydrochloride|Given PO
58449923|NCT01664182|DRUG|Sorafenib Tosylate|Given PO
58449924|NCT01664182|DRUG|Sunitinib Malate|Given PO
58449925|NCT01664182|BIOLOGICAL|Trebananib|Given IV
58449926|NCT03806621|PROCEDURE|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
58449927|NCT02486016|DRUG|Duragesic reference fentanyl TDS|25 µg/hour
58449928|NCT02486016|DRUG|Apotex generic fentanyl TDS|25 µg/hour
58121066|NCT00958581|DRUG|Normal Saline|Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
58121067|NCT00958581|DRUG|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
58121068|NCT04664842|OTHER|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
58121069|NCT04664842|OTHER|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
58121070|NCT06339593|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
58121071|NCT00976235|DEVICE|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
58121072|NCT00315549|DRUG|Telithromycin|
58121073|NCT00315549|DRUG|Penicillin|
58121074|NCT01388023|DIETARY_SUPPLEMENT|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
58121075|NCT04109911|DIETARY_SUPPLEMENT|Fermented oyster extract|Fermented oyster extract 1,200 mg/day for 12 weeks
58121076|NCT04109911|DIETARY_SUPPLEMENT|Placebo|Placebo
58449929|NCT02486016|DRUG|Mylan generic fentanyl TDS|25 µg/hour
58449930|NCT03337971|DIETARY_SUPPLEMENT|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
58449931|NCT03337971|DIETARY_SUPPLEMENT|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
58449932|NCT03512301|DEVICE|CAMCI|CAMCI battery of computerized tasks
58449933|NCT06456255|DRUG|Sensorcaine with Epinephrine|The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.
58121077|NCT02046291|DRUG|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
58121078|NCT02442479|BEHAVIORAL|resistance training|
58121079|NCT01983020|DRUG|Lidocaine|
58121080|NCT01983020|DRUG|Ketamine|
58121081|NCT01983020|OTHER|Saline|
58121082|NCT04884581|DEVICE|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
58121083|NCT02025114|DRUG|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
58121084|NCT00171496|DRUG|Cyclosporine microemulsion|
58121085|NCT00171496|DRUG|Tacrolimus|
58449934|NCT06456255|OTHER|Sham injection|Punctures without any medication injected onto the septum
58449935|NCT05935332|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
58449936|NCT05935332|OTHER|Placebo|placebo
58449937|NCT04643626|DEVICE|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
58449938|NCT05684458|PROCEDURE|Reiki|Reiki, a non-invasive, free and safe complementary therapy method, is practiced with a series of hand positions held on the patient's body to help balance the life force energy.
57747213|NCT02538185|DEVICE|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
57747214|NCT02538185|DRUG|Vaccin rabique Pasteur®|
57747215|NCT02538185|DRUG|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
57747216|NCT01443819|OTHER|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
57959007|NCT02765074|DRUG|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
57959008|NCT04381390|DIETARY_SUPPLEMENT|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
57959009|NCT04381390|DIETARY_SUPPLEMENT|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
58449939|NCT01130753|DRUG|Erlotinib|Erlotinib 150mg per day for 8 weeks
58449940|NCT01877512|DRUG|Change in daily dosage of Growth Hormone|
58449941|NCT00093210|DRUG|rFIX|
58449942|NCT00093210|DRUG|rFIX-R|
58449943|NCT02921581|RADIATION|FDG-PET guided dose painting|
57747217|NCT01443819|OTHER|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
57959010|NCT00857727|DRUG|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
57959011|NCT00857727|DRUG|Saline|Given by a continuous infusion
57959012|NCT05506761|PROCEDURE|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
58121086|NCT05657093|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
58121087|NCT05657093|COMBINATION_PRODUCT|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
58121088|NCT04915807|DRUG|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
58121089|NCT04915807|DRUG|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
57959013|NCT05506761|PROCEDURE|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
57959014|NCT05411419|PROCEDURE|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
57959015|NCT05969509|OTHER|progressive relaxation exercise|applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
58121090|NCT06460974|OTHER|stress ball|A stress ball was applied to the patients in the during chemotherapy treatment.
58449944|NCT01214005|BEHAVIORAL|smoking abstinence|3 days of biologically-confirmed smoking abstinence
58449945|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
58449946|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
58449947|NCT01910402|DRUG|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
58121091|NCT05895370|BIOLOGICAL|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
58121092|NCT05895370|DRUG|Interleukin-2|500,000IU/m\^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
58121093|NCT03833596|DRUG|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
58121094|NCT03833596|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
58121095|NCT04784117|OTHER|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
58121096|NCT03083249|OTHER|Gardasil|None-data gathering only
58121097|NCT06102629|PROCEDURE|laparoscopy / laparotomy|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
58121098|NCT06102629|OTHER|NO INTERVENTION|".We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
58121099|NCT05091606|PROCEDURE|Perfusion İndex in Patients with Spinal Anesthesia|Comparison of lower and upper extremity perfusion index values
58121100|NCT02534948|BEHAVIORAL|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
58449948|NCT01910402|DRUG|Atazanavir|Atazanavir capsule 300 mg
58449949|NCT01910402|DRUG|Ritonavir|Ritonavir tablet 100 mg
58449950|NCT01910402|DRUG|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
57747218|NCT01443819|OTHER|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
58121101|NCT04409366|OTHER|Conventional Crown Lengthening (CCL)|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days
58121102|NCT04409366|OTHER|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
58121103|NCT03035279|DRUG|SC-006|Intravenous
58121104|NCT03035279|DRUG|ABBV-181|Intravenous
58121105|NCT01741857|BIOLOGICAL|human umbilical cord derived MSC transplantation for SLE|
58121106|NCT00387712|OTHER|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
58121107|NCT00387712|OTHER|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
58449951|NCT03564613|DRUG|DTG|Subjects with DTG exposure during any trimester will be included
57747219|NCT00606775|DRUG|Carvedilol|2.5-5mg/day
57747220|NCT02979938|OTHER|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
58449952|NCT01729286|DEVICE|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
58449953|NCT01729286|OTHER|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
58458685|NCT05219357|DRUG|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
57747221|NCT00994357|DEVICE|Real-time CGM|See previous description.
57747222|NCT00994357|OTHER|Standard care|See text.
57747223|NCT02771743|DRUG|Cisplatin|
57747224|NCT02771743|DRUG|Doxorubicin|
57747225|NCT02771743|DRUG|Etoposide|
57747226|NCT02771743|DRUG|Cyclophosphamide|
57747227|NCT02771743|DRUG|Ifosfamide|
57747228|NCT02771743|DRUG|Carboplatin|
58449954|NCT03062020|DEVICE|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
58449955|NCT03106064|BEHAVIORAL|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
58449956|NCT03106064|OTHER|Usual Care|Usual hospital care
58449957|NCT05745311|DRUG|The KPCXM18 injection|Intravenous infusion
58449958|NCT05745311|DRUG|Placebo|Intravenous infusion
58449959|NCT01053494|PROCEDURE|massage therapy|Undergo massage therapy
58449960|NCT01053494|OTHER|questionnaire administration|Ancillary studies
58449961|NCT01053494|PROCEDURE|quality-of-life assessment|Ancillary studies
58449962|NCT01053494|OTHER|intervention by caregiver|Undergo massage by caregiver
58449963|NCT01053494|PROCEDURE|standard follow-up care|Undergo standard follow-up care
58449964|NCT02151188|DIETARY_SUPPLEMENT|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
58449965|NCT02151188|DEVICE|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
58449966|NCT00441246|DRUG|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
57747229|NCT02771743|PROCEDURE|Tandem HDCT/auto-SCT|
57747230|NCT02771743|RADIATION|Radiotherapy|
57747231|NCT02771743|DRUG|Interleukin-2|
57747232|NCT02771743|DRUG|Isotretinoin|
57747233|NCT02771743|RADIATION|MIBG|
57747234|NCT04931927|BEHAVIORAL|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]
57747235|NCT04931927|BEHAVIORAL|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
57747236|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
57747237|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
57747238|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
57747239|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
58121108|NCT05924256|DRUG|SHR-A1811|SHR-A1811
58449967|NCT03525691|DEVICE|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
58449968|NCT05806320|OTHER|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
58458686|NCT01140841|DRUG|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
57747240|NCT00316082|DRUG|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
57747241|NCT00316082|DRUG|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
57747242|NCT05671874|BEHAVIORAL|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
57747243|NCT05540925|PROCEDURE|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups."
57747244|NCT01676337|OTHER|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
57747245|NCT01507805|DEVICE|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
57747246|NCT01507805|DEVICE|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
58121109|NCT05924256|DRUG|SHR 3680 + leuprolide|SHR 3680 + leuprolide
58121110|NCT05924256|DRUG|SHR-A1921|SHR-A1921
58121111|NCT05924256|DRUG|SHR-A1811|SHR-A1811
58121112|NCT06484309|BEHAVIORAL|Reflexology Group|"* In the 3rd stage of labor, local anesthesia (5 ml lidocaine 2%) will be applied and episiotomy repair will begin.~* Reflexology application will be started at the same time,~* Reflexology application will continue for at least 20-30 minutes during the episiotomy repair until the episiotomy repair is completed,~* Pain will be evaluated with VAS to determine the pain level four times in total: just before suturing, during perineal suturing (internal), during skin suturing and immediately after suturing is completed,~* Approximately 15-20 minutes after the end of the episiotomy repair, a face-to-face interview will be held and the McGill Pain Questionnaire will be filled out."
58121113|NCT06546241|BEHAVIORAL|Celebrandome|This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
58121114|NCT03890250|OTHER|Aerobic exercise|A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
58121115|NCT03890250|OTHER|Neuromuscular electrical stimulation|Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
58121116|NCT02153307|DEVICE|Implantable loop recorders system Reveal ICM LINQ®,|
58121117|NCT00311779|DRUG|Spinosad Creme Rinse|
58121118|NCT01762358|OTHER|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
58449969|NCT05806320|OTHER|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
58449970|NCT00035490|DRUG|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
57747247|NCT01535820|DRUG|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
58121119|NCT01762358|OTHER|Physiotherapy|Twelve times standardized Physiotherapy
58121120|NCT02776007|DEVICE|Libre Flash CGMS|
58449971|NCT00035490|DRUG|placebo|placebo tablet, once daily for one year
58121121|NCT02776007|DEVICE|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
58121122|NCT03845946|BEHAVIORAL|angioedema|electronic tracking book
58121123|NCT04105790|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
58121124|NCT04951050|DEVICE|Rapamycin target eluting stent|Rapamycin target eluting stent
58121125|NCT03212196|PROCEDURE|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
58121126|NCT03212196|PROCEDURE|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
58121127|NCT04764500|OTHER|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
58121128|NCT04764500|OTHER|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
58449972|NCT00035490|DRUG|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
58449973|NCT05076201|BEHAVIORAL|Patients with completed rehab|The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
58449974|NCT01333228|OTHER|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
57747248|NCT01535820|DRUG|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
57959016|NCT02497859|BEHAVIORAL|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
58313890|NCT04159376|DIAGNOSTIC_TEST|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
58313891|NCT04521296|OTHER|Part 1|- DWJ1248 600mg PO (100mg 2 tab, TID)
58313892|NCT04521296|OTHER|Part 2|- DWJ1248 600mg PO (200mg 1 tab, TID)
58449975|NCT02285335|DIETARY_SUPPLEMENT|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
58449976|NCT01952236|BEHAVIORAL|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
58449977|NCT01952236|BEHAVIORAL|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
58449978|NCT02025179|DRUG|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
58449979|NCT02025179|DEVICE|Vibration|Vibration 10 min/day for 12 months
58449980|NCT01395576|DEVICE|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
58449981|NCT03154385|DRUG|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
58449982|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
58449983|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
58449984|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
57747249|NCT00689221|DRUG|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
57959017|NCT02497859|BEHAVIORAL|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
57959018|NCT02497859|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
57959019|NCT02497859|BEHAVIORAL|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
57959020|NCT06263569|PROCEDURE|Total hip arthroplasty|Unilateral primary total hip arthroplasty procedure.
57959021|NCT05337332|DRUG|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
57959022|NCT01666327|DRUG|MT-1303|
57959023|NCT00412750|DRUG|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
58449985|NCT06147999|DEVICE|Biophotonizer - a Biophoton Generator|A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
58449986|NCT06423456|DRUG|Lidocaine IV|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
58449987|NCT06423456|DRUG|Saline|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
58449988|NCT02551341|PROCEDURE|higher PEEP ventilation|
58449989|NCT05701293|PROCEDURE|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
58449990|NCT05029869|DIAGNOSTIC_TEST|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
58458687|NCT01140841|DRUG|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
57747250|NCT00689221|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
58121129|NCT04764500|OTHER|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
58121130|NCT03101943|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
58121131|NCT03101943|OTHER|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
58121132|NCT03101943|OTHER|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
58121133|NCT03902275|OTHER|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
58121134|NCT03902275|OTHER|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
58121135|NCT04955379|DEVICE|EQ103|Ophthalmic Refractometer with a measurement and background channel
58121136|NCT02490423|OTHER|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
58121137|NCT02089490|DEVICE|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
58121138|NCT05645679|DEVICE|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
58449991|NCT00549315|DEVICE|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
58449992|NCT02348593|DRUG|JZP-110|
58449993|NCT02348593|DRUG|Placebo oral tablet|
58449994|NCT06175481|OTHER|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
58449995|NCT04317040|DRUG|Efprezimod alfa|Efprezimod alfa is given on Day 1.
58449996|NCT04317040|DRUG|Placebo|Placebo is given on Day 1.
57747251|NCT00689221|RADIATION|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
57747252|NCT04188977|OTHER|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
57747253|NCT04188977|OTHER|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
58121139|NCT04272775|DRUG|Ixazomib|Ixazomib capsules.
58449997|NCT04188938|OTHER|Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma|
57747254|NCT06497244|PROCEDURE|micro osteo-perforation|the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
57747255|NCT01688466|DRUG|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
57747256|NCT05422417|DEVICE|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
58121140|NCT04272775|DRUG|Lenalidomide|Lenalidomide capsules.
58121141|NCT04272775|DRUG|Dexamethasone|Dexamethasone tablets.
58121142|NCT05865509|OTHER|Escape room|Students were given training on stress response using the escape room method.
58121143|NCT05865509|OTHER|Storytelling|Students were given training on stress response using the storytelling method.
58121144|NCT00841256|BIOLOGICAL|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
58449998|NCT05201508|PROCEDURE|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
58449999|NCT05201508|PROCEDURE|Sutures only|Traditional hiatal closure with non-absorbable sutures.
58450000|NCT02336230|DRUG|remestemcel-L|Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
58450001|NCT01574274|DRUG|SC-PEG|11 doses Intravenously over one hour
58450002|NCT01574274|DRUG|Oncaspar|16 doses Intravenously over one hour
58450003|NCT01186185|DRUG|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
57747257|NCT05422417|DEVICE|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
57747258|NCT05422417|DEVICE|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
57747259|NCT05009303|DEVICE|OneStep Smartphone App and C-Mill Treadmill|OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
57747260|NCT01268748|PROCEDURE|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
58450004|NCT04947696|DIAGNOSTIC_TEST|Blood sampling|Blood sampling preoperatively and sequentially up to 30 days post op
57747261|NCT01268748|PROCEDURE|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
57747262|NCT01698294|OTHER|Clinical Observation|Participants maintain usual diet and undergo clinical observation
57747263|NCT01698294|DIETARY_SUPPLEMENT|Flaxseed|Given PO
57747264|NCT01698294|OTHER|Laboratory Biomarker Analysis|Correlative studies
57747265|NCT01698294|OTHER|Questionnaire Administration|Ancillary studies
57747266|NCT04629703|DRUG|Fostamatinib|Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
58450005|NCT00490269|DRUG|Placebo|
57747267|NCT04629703|DRUG|Placebo|Placebo (twice daily) for 14 days and Standard of Care
57747268|NCT01156948|DRUG|misoprostol|400ug vaginally the day before surgery
57747269|NCT01156948|DRUG|oral misoprostol|400ug misoprostol orally the day before the surgery
57747270|NCT01903538|DEVICE|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
57747271|NCT01903538|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
57747272|NCT01788865|DEVICE|cSEMS(Covered self-expandable dual-layered metal stent) implant|
57747273|NCT00319748|DRUG|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
57747274|NCT04924231|BEHAVIORAL|astigmatism|astigamatism at least 1 month after the cataract surgery
57747275|NCT03945188|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
57747276|NCT03945188|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
57747277|NCT06086327|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
57747278|NCT06578897|DEVICE|3D Metal Tibial and Femoral cones|"* To collect retrospective clinical outcomes and data on revision TKAs using Medacta GMK Revision with 3D metal tibial and femoral cones~* Evaluate the patient reported functionality of the operated knee~* Evaluate the clinical and radiological performance~* Evaluate safety of the cones~* Evaluate survivorship of revisions using tibial and femoral cones"
57747279|NCT04588961|PROCEDURE|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
57747280|NCT04588961|PROCEDURE|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
57747281|NCT03391674|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
57747282|NCT04133727|BEHAVIORAL|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
57747283|NCT04133727|OTHER|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
57747284|NCT06432517|OTHER|Power Bike（Ergoselect 100P）|Changes in the participants' energy balance will be measured through moderate to high intensity exercise. Observation of food intake, body composition, metabolic rate, food assimilation rate.
57747285|NCT02676102|BEHAVIORAL|Control Group|Generic Video about organ donation
57747286|NCT02676102|BEHAVIORAL|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
57747287|NCT02676102|BEHAVIORAL|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
57959024|NCT00412750|DRUG|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
58450006|NCT00490269|DRUG|Dronabinol|
58450007|NCT00502671|DRUG|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
57959025|NCT01179958|BEHAVIORAL|aerobic training|24 weeks of aerobic training, 4X/week
57959026|NCT01179958|BEHAVIORAL|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
58450008|NCT01459484|DRUG|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
58121145|NCT00841256|DRUG|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
58121146|NCT04689477|DEVICE|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
58450009|NCT01459484|OTHER|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
58450010|NCT03371693|DEVICE|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
58450011|NCT03371693|DEVICE|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
58450012|NCT03371693|DEVICE|IVCT|platinum-based intravenous chemotherapy
58450013|NCT03071887|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
58450014|NCT01055561|OTHER|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
58450015|NCT02807207|DRUG|A: pacritinib|Treatment A
58450016|NCT02807207|OTHER|B: Placebo|Treatment B
58450017|NCT02807207|DRUG|C: moxifloxacin|Treatment C
58450018|NCT04832932|BIOLOGICAL|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
58450019|NCT04291573|DEVICE|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
58450020|NCT04291573|DEVICE|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
58450021|NCT00003461|PROCEDURE|surgical procedure|
57747288|NCT05330065|DRUG|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
57747289|NCT03156660|BEHAVIORAL|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps"
57747290|NCT03156660|BEHAVIORAL|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps"
58121147|NCT04453566|OTHER|Online Survey|Online Survey
58121148|NCT05566886|DEVICE|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
58121149|NCT05469282|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701 (Ceragem Master V6)
58450022|NCT00003461|RADIATION|astatine At 211 monoclonal antibody 81C6|
58450023|NCT00199121|DRUG|Zidovudine (drug)|
58450024|NCT02172638|PROCEDURE|Fast-Track Protocol|
58450025|NCT02172638|PROCEDURE|Usual management|
58450026|NCT00354679|BIOLOGICAL|bevacizumab|
58450027|NCT00354679|DRUG|cisplatin|
58450028|NCT00354679|DRUG|irinotecan hydrochloride|
58450029|NCT00354679|GENETIC|proteomic profiling|
58450030|NCT00354679|OTHER|diagnostic laboratory biomarker analysis|
58450031|NCT00354679|OTHER|mass spectrometry|
58450032|NCT00354679|PROCEDURE|adjuvant therapy|
58450033|NCT00354679|PROCEDURE|neoadjuvant therapy|
58450034|NCT00354679|PROCEDURE|therapeutic conventional surgery|
58450035|NCT00354679|RADIATION|radiation therapy|
58450036|NCT02093793|DEVICE|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
58450037|NCT01817023|RADIATION|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
58450038|NCT01817023|DRUG|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
58450039|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
58121150|NCT04530786|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
58121151|NCT02807142|BIOLOGICAL|NC 1 cell therapy|All patients will be treated with NC1
58121152|NCT04168476|OTHER|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
58450040|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
58450041|NCT01579227|DEVICE|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
58450042|NCT01579227|DIETARY_SUPPLEMENT|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
58450043|NCT01579227|DEVICE|Tamoxifen Cream|Tamoxifen cream
57959027|NCT05946473|DIETARY_SUPPLEMENT|Gum base containing xylitol and essencial oils|Participants will be asked to chew 2 pieces of chewing gum containing additives for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
57959028|NCT05946473|DIETARY_SUPPLEMENT|Gum base with no additives|Participants will be asked to chew 2 pieces of pure gum base for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
57959029|NCT00421668|DRUG|Zinc|zinc
57959030|NCT00421668|DRUG|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
57747291|NCT03156660|BEHAVIORAL|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale"
57959031|NCT00421668|DRUG|Placebo|Placebo
57959032|NCT05626530|DRUG|Letermovir|Open label 480 mg given daily for 60 days
57959033|NCT04349423|BEHAVIORAL|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
57959034|NCT04103801|DIETARY_SUPPLEMENT|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
57959035|NCT01659320|DRUG|Minocycline|Minocycline 100 mg twice daily for 8 weeks
57959036|NCT04797832|DRUG|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
57959037|NCT00317525|DEVICE|Spectacle Lenses|
57959038|NCT00364312|BEHAVIORAL|diet and physical activity|
57959039|NCT01148537|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.
57959040|NCT01148537|DRUG|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
57959041|NCT01148537|DRUG|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
57959042|NCT00452699|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
57959043|NCT00452699|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
57959044|NCT00106171|DRUG|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
58450044|NCT01579227|DEVICE|Placebo cream|Placebo cream
58450045|NCT01579227|DIETARY_SUPPLEMENT|placebo capsule|placebo capsule
58450046|NCT05976802|DRUG|High dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
57747292|NCT01067170|DEVICE|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
57959045|NCT01147146|DRUG|propofol, fentanyl, atracurium|general anesthesia
57959046|NCT01147146|DRUG|bupivacaine|spinal anesthesia
57959047|NCT01147146|DRUG|bupivacaine, Midazolam|spinal anesthesia \& sedation
57959048|NCT01503255|BEHAVIORAL|cognitive behavioral group therapy|6 weekly 90-minute group sessions
57959049|NCT01503255|BEHAVIORAL|health education group|6 weekly 90-minute group sessions
57959050|NCT00010361|DRUG|cyclosporine|
57959051|NCT00010361|DRUG|fludarabine|
57959052|NCT00010361|DRUG|mycophenolate mofetil|
57959053|NCT02519166|BIOLOGICAL|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
57959054|NCT00185081|DRUG|Indium labeled IMP-205xm734|
57959055|NCT00149578|DRUG|Gemcitabine Oxaliplatin 5FU and Leucovorin|
57959056|NCT01870401|DEVICE|Lutonix DCB|
57959057|NCT01870401|DEVICE|Uncoated PTA Catheter|
57959058|NCT03700307|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
57959059|NCT06255457|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement of mitral regurgitation
57959060|NCT03628014|OTHER|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities"
57959061|NCT00002278|DRUG|Diclazuril|
57959062|NCT02188030|OTHER|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
58121153|NCT04168476|OTHER|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
58121154|NCT03363581|BEHAVIORAL|Food Preference|Buffet meal to assess food preference
58450047|NCT05976802|DRUG|Low dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
58450048|NCT05976802|DRUG|Matching placebo rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
58450049|NCT06032169|OTHER|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
58450050|NCT01619839|DRUG|NKTR-181|
58450051|NCT01619839|DRUG|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
58450052|NCT04734717|DIAGNOSTIC_TEST|Neurology test|movement examination of patients with covid19 disease
58450053|NCT03941496|DRUG|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay"
58450054|NCT01168726|BEHAVIORAL|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
58121155|NCT01953497|DRUG|URC102|
58121156|NCT01953497|DRUG|Placebo|
58121157|NCT04967313|BEHAVIORAL|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
58313893|NCT01642381|BEHAVIORAL|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
58313894|NCT01642381|BEHAVIORAL|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
57747293|NCT05685459|OTHER|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
57747294|NCT02044991|DRUG|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
57747295|NCT02044991|DRUG|Placebo Injection|A placebo injection
57747296|NCT00109538|DRUG|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
58313895|NCT05395585|PROCEDURE|Manual placental separation|Manual separation of the placenta from uterus
58313896|NCT05751551|OTHER|Personalized, home-based motor-cognitive training|"The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration."
58313897|NCT04732234|PROCEDURE|Superior Hypogastric Plexus Block|Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
58313898|NCT06520163|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
58313899|NCT06520163|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
58313900|NCT06520163|DRUG|PEG-rhG-CSF|Day 6: 6mg
58313901|NCT06520163|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
58313902|NCT06520163|COMBINATION_PRODUCT|CHOP|\[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
58313903|NCT06520163|COMBINATION_PRODUCT|Hyper-CVAD|\[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
58313904|NCT06520163|COMBINATION_PRODUCT|ID-MTX + Ara-C|\[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
58313905|NCT06520163|COMBINATION_PRODUCT|DA-EPOCH|\[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
58313906|NCT06520163|COMBINATION_PRODUCT|GDP|\[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
58313907|NCT06520163|COMBINATION_PRODUCT|GDPE|\[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
58313908|NCT06520163|COMBINATION_PRODUCT|ICE|\[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
58313909|NCT06520163|COMBINATION_PRODUCT|DICE|\[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
58313910|NCT06520163|DRUG|G-CSF|From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
58313911|NCT06307379|OTHER|no intervention|only observational
58450055|NCT01168726|BEHAVIORAL|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
58450056|NCT01168726|BEHAVIORAL|Alcohol Education|Educational information about harms associated with heavy drinking.
58450057|NCT00774293|DRUG|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
58450058|NCT00774293|DRUG|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
57959063|NCT02188030|OTHER|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
58450059|NCT01475435|PROCEDURE|non- surgical periodontal treatment|scaling and root planning
58450060|NCT01475435|PROCEDURE|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
58450061|NCT01521507|DEVICE|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
58450062|NCT01521507|DEVICE|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
58450063|NCT04441411|DEVICE|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
58450064|NCT01626924|DRUG|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
58450065|NCT00626275|DRUG|ADL5859|
58450066|NCT00626275|DRUG|Naproxen|
58450067|NCT00626275|DRUG|Placebo|
58450068|NCT00626275|DRUG|ADL5859|
58450069|NCT00626275|DRUG|Placebo|
58450070|NCT03637777|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
58450071|NCT02079038|DEVICE|Totalis|
58450072|NCT02079038|PROCEDURE|Comparator Surgical Procedure|
58450073|NCT05668910|GENETIC|whole genomic methylation and fragmentation profile analysis of cfDNA|The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
58450074|NCT04504981|BEHAVIORAL|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
58450075|NCT01451489|DRUG|FK506|FK506:0.05-0.1mg/kg/d
58450076|NCT01451489|DRUG|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
58450077|NCT02707068|BEHAVIORAL|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
58450078|NCT02300259|DRUG|LY2623091|Administered orally
58450079|NCT02300259|DRUG|Itraconazole|Administered orally
58450080|NCT02300259|DRUG|Simvastatin|Administered orally
58450081|NCT02300259|DRUG|Tadalafil|Administered orally
58450082|NCT02300259|DRUG|Diltiazem|Administered orally
58450083|NCT05032482|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
58450084|NCT00920855|DRUG|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
58450085|NCT00920855|DRUG|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
58450086|NCT03004729|OTHER|CoMiSS questionnaire|
58450087|NCT06063863|DIAGNOSTIC_TEST|Nurse led screening with Optos ultra-widefield retinal-imaging device|The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
58450088|NCT04249856|DIAGNOSTIC_TEST|Dynamic Spectral Imaging (DYSIS)|Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
58450089|NCT04892264|BIOLOGICAL|Belantamab Mafodotin|Given IV
58450090|NCT04892264|BIOLOGICAL|Daratumumab|Given IV
57747297|NCT00109538|OTHER|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
58450091|NCT04892264|DRUG|Dexamethasone|Given PO
58450092|NCT04892264|DRUG|Lenalidomide|Given PO
58450093|NCT04892264|OTHER|Quality-of-Life Assessment|Ancillary studies
58450094|NCT04892264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58121158|NCT05180006|DRUG|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
58121159|NCT05180006|DRUG|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
58121160|NCT05180006|DRUG|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
58450095|NCT04892264|PROCEDURE|Skeletal Survey X-Ray|Undergo X-ray skeletal survey
58450096|NCT04892264|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo whole body low dose CT
57747298|NCT00530855|DRUG|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
58450097|NCT04892264|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58450098|NCT04892264|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58450099|NCT00915863|PROCEDURE|Billroth-II-type reconstruction|surgical procedure
58450100|NCT00915863|PROCEDURE|Isolated Roux-en-Y type reconstruction|surgical procedure
58450101|NCT06419075|DRUG|Tranexamic acid|The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
58450102|NCT06419075|DRUG|Vasopressin|The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
58450103|NCT06419075|OTHER|NaCl 0.9%|The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
58450104|NCT02227004|DIAGNOSTIC_TEST|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
58450105|NCT05590052|DEVICE|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
58450106|NCT05590052|DEVICE|Thermocautery|achievement of hemostasis using thermocautery
58450107|NCT03483896|OTHER|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
58450108|NCT01115868|DRUG|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
57747299|NCT05134181|DRUG|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
58121161|NCT05180006|DRUG|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
58121162|NCT02789007|OTHER|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
58121163|NCT04366479|BEHAVIORAL|Multistage Fitness Test|Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
58121164|NCT05214742|OTHER|Diagnostic Test|Molecular diagnosis carried out in the context of care
58121165|NCT02655627|OTHER|Internet based exercise training|
58121166|NCT02655627|OTHER|group exercise training|
58121167|NCT02655627|OTHER|Physical activity counselling via a brochure|
58121168|NCT02518230|DEVICE|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
58450109|NCT01115868|DRUG|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
58121169|NCT02518230|DEVICE|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
58121170|NCT05622955|OTHER|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
58121171|NCT03386097|OTHER|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
58121172|NCT00391690|DRUG|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
58121173|NCT01051609|OTHER|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
58121174|NCT01051609|OTHER|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
58450110|NCT01115868|DRUG|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
58450111|NCT01115868|DRUG|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
57747300|NCT03343223|BEHAVIORAL|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
58450112|NCT03601260|DRUG|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
58450113|NCT00346125|BIOLOGICAL|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
57747301|NCT02191553|BEHAVIORAL|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
57747302|NCT02191553|BEHAVIORAL|Loving-kindness meditation|Following Kristin Neff protocol
57747303|NCT02191553|BEHAVIORAL|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
57747304|NCT02191553|BEHAVIORAL|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
57747305|NCT00002258|DRUG|Interleukin-3|
58121175|NCT01051609|BEHAVIORAL|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
58121176|NCT01051609|OTHER|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
58121177|NCT01051609|PROCEDURE|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
58121178|NCT01689480|OTHER|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
58450114|NCT00346125|DRUG|doxorubicin hydrochloride|65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
58450115|NCT00346125|DRUG|ifosfamide|9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
58450116|NCT00346125|DRUG|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
58450117|NCT00346125|PROCEDURE|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
58450118|NCT00346125|RADIATION|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
58450119|NCT01102036|OTHER|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
58450120|NCT01102036|OTHER|Yoghurt without probiotics|Yoghurt without probiotics
58450121|NCT02346175|DRUG|SHR3824|
58450122|NCT02346175|DRUG|Placebo|
58450123|NCT05478642|OTHER|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
58121179|NCT01399723|DRUG|Amoxicillin|Oral 45mg/kg 12 hourly
58121180|NCT01399723|DRUG|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
58121181|NCT00271804|DRUG|bortezomib|
57747306|NCT02579252|BIOLOGICAL|AADvac1|
57747307|NCT02579252|DRUG|Placebo|
57747308|NCT02693275|DEVICE|Quotient® System iPad Test|See arm/group description
57747309|NCT05034523|RADIATION|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
57747310|NCT05189366|BEHAVIORAL|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
57747311|NCT05189366|BEHAVIORAL|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
58121182|NCT03752671|DEVICE|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
58450124|NCT06278792|PROCEDURE|Diuretic protocol|Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result
58450125|NCT06278792|PROCEDURE|Standard of Care|Diuretic therapy at the discretion of the physician
58450126|NCT03241082|DEVICE|ultrasound|validation of portable ultrasound to measure body composition
58450127|NCT04486651|DRUG|Irinotecan Hydrochloride Injection|160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
58450128|NCT04486651|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
57747312|NCT03362567|OTHER|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
57747313|NCT03362567|OTHER|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
57747314|NCT03594565|DRUG|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
57747315|NCT06313580|OTHER|Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
57747316|NCT06313580|OTHER|Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
57959064|NCT04709783|OTHER|3-Step Workout for Life|Participants will receive the 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise training. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
57959065|NCT00047138|BIOLOGICAL|dactinomycin|
57959066|NCT00047138|DRUG|carboplatin|
57959067|NCT00047138|DRUG|cyclophosphamide|
57959068|NCT00047138|DRUG|doxorubicin hydrochloride|
57959069|NCT00047138|DRUG|etoposide|
57959070|NCT00047138|DRUG|vincristine sulfate|
57959071|NCT00047138|PROCEDURE|adjuvant therapy|
57959072|NCT00047138|PROCEDURE|conventional surgery|
57959073|NCT00047138|PROCEDURE|neoadjuvant therapy|
57959074|NCT00047138|RADIATION|radiation therapy|
57959075|NCT00299208|DRUG|Artesunate|
57959076|NCT00299208|DRUG|Azithromycin|
57959077|NCT00299208|DRUG|Quinine|
57959078|NCT03375190|OTHER|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
57959079|NCT03375190|OTHER|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
57959080|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
57959081|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
58450129|NCT04486651|DRUG|Placebo|Administered as IV infusion on Day 1 of each 21-day cycle.
58450130|NCT00671424|DRUG|Hydrochlorothiazide (HCTZ)|
58450131|NCT00671424|DRUG|Remogliflozin etabonate (GSK189075)|
58450132|NCT00671424|DRUG|Furosemide|
58450133|NCT00238979|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
58450134|NCT01677325|DRUG|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
58450135|NCT03138421|DRUG|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
58450136|NCT03138421|DRUG|Placebo|Matching placebo
58450137|NCT02679755|DRUG|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
58450138|NCT02679755|DRUG|Letrozole|2.5 mg/d tablets orally on a continuous regimen
58450139|NCT04230915|OTHER|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
58450140|NCT01864343|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
57959082|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
58121183|NCT03752671|PROCEDURE|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
57747317|NCT03697902|DIAGNOSTIC_TEST|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
57747318|NCT02271256|DEVICE|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
58121184|NCT00993057|DRUG|Insulin|Adjustable insulin infusion scale with loading doses
58121185|NCT06030921|OTHER|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
58450141|NCT00947271|BEHAVIORAL|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health
58450142|NCT00947271|BEHAVIORAL|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
58450143|NCT01787630|DEVICE|Hyaluronic acid|Injection in connection with ultrasound
57747319|NCT06111651|BEHAVIORAL|Parenting Intervention|parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
57747320|NCT02803268|DRUG|MT-8554 low dose|
57747321|NCT02803268|DRUG|MT-8554 middle dose|
58121186|NCT05074082|PROCEDURE|Flap reconstruction|Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
58121187|NCT02289768|DRUG|5-fluorouracil/salicylic acid|
58313912|NCT05226429|BIOLOGICAL|UNAIR Inactivated COVID-19 Vaccine|UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
58313913|NCT05226429|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
58313914|NCT02934646|DEVICE|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
58313915|NCT04320667|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
58313916|NCT04377568|BIOLOGICAL|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
58313917|NCT00117416|PROCEDURE|controlling the MAP|
58313918|NCT05974332|DIAGNOSTIC_TEST|Oncostatin M|Test to diagnosis of Ulcerative colitis
58313919|NCT02456311|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
58313920|NCT03979417|OTHER|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
58121188|NCT02289768|DRUG|Vehicle|
58313921|NCT03184272|PROCEDURE|baseline alert 1|measurement in supine position
58313922|NCT03184272|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
58313923|NCT03184272|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
58313924|NCT03184272|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
58313925|NCT03184272|PROCEDURE|passive leg raising|measurement under passive leg raising
58313926|NCT03184272|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
58313927|NCT03184272|PROCEDURE|baseline in narcosis 2|measurement in supine position
58313928|NCT03184272|PROCEDURE|start capnoperitoneum|measurement in supine position
58313929|NCT03184272|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
58313930|NCT03184272|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
58313931|NCT03184272|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
58313932|NCT03184272|PROCEDURE|baseline|measurement in supine position
58313933|NCT03184272|PROCEDURE|baseline alert 2|measurement in supine position
58313934|NCT03184272|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
58313935|NCT03184272|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
58450144|NCT05246371|DRUG|Propofol, dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
58450145|NCT05246371|DRUG|Desflurane|Patients will receive maintenance of general anesthesia by desflurane.
58450146|NCT04052308|BEHAVIORAL|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
57747322|NCT02803268|DRUG|MT-8554 high dose|
57747323|NCT02803268|DRUG|Placebo|
58121189|NCT00002407|DRUG|Indinavir sulfate|
58121190|NCT00002407|DRUG|Nevirapine|
58121191|NCT00002407|DRUG|Lamivudine|
58121192|NCT00002407|DRUG|Stavudine|
58121193|NCT00002407|DRUG|Didanosine|
58121194|NCT04757415|OTHER|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
58121195|NCT04757415|OTHER|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
58121196|NCT01110681|DEVICE|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
58121197|NCT00982410|BEHAVIORAL|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
58121198|NCT00982410|BEHAVIORAL|educational supportive group|A control condition providing social support and education about pain and/or drug use.
58121199|NCT03842371|OTHER|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
58313936|NCT06214884|BEHAVIORAL|Mindfulness for All|"Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
58450147|NCT04052308|BEHAVIORAL|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
58450148|NCT04052308|BEHAVIORAL|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
58450149|NCT04052308|BEHAVIORAL|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
58450150|NCT04052308|BEHAVIORAL|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
57959083|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
58121200|NCT01680679|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine (TIV)|
58121201|NCT01680679|BIOLOGICAL|Inactivated poliovirus vaccine (IPV), trivalent|
58121202|NCT01485913|OTHER|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
58121203|NCT02848430|DIETARY_SUPPLEMENT|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
58121204|NCT03149588|DRUG|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
58121205|NCT03149588|DRUG|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
58121206|NCT03176225|PROCEDURE|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
58121207|NCT03176225|DEVICE|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
58121208|NCT03176225|DEVICE|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
58121209|NCT02246842|BIOLOGICAL|D-Gam® (human anti-D immunoglobulin)|
58121210|NCT02246842|BIOLOGICAL|Rhophylac® (human anti-D immunoglobulin)|
58121211|NCT03141489|DIETARY_SUPPLEMENT|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
58121212|NCT01188707|DRUG|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
58121213|NCT00035009|DRUG|MK0869, aprepitant|
58121214|NCT00035009|DRUG|Comparator: paroxetine HCL|
58121215|NCT06528717|PROCEDURE|Carotid graft interposition|In patients with extensive atherosclerotic carotid disease, when endarterectomy isn't feasible, replacement of the carotid artery with a graft is needed. Graft interposition can be performed either by end-to-end proximal and distal anastomoses in the undiseased common and internal carotid artery with ligation of the external carotid artery, or by side-to-end proximal anastomosis on the origin of the internal carotid artery and end-to-end distal anastomosis on the internal carotid artery with flow preservation in the external carotid artery.
58121216|NCT03803709|DIETARY_SUPPLEMENT|inulin|inulin given at different dosis from day 3 to day 20
58121217|NCT03803709|DIETARY_SUPPLEMENT|placebo|maltodextrine given at different dosis from day 3 to day 20
58121218|NCT00555009|DRUG|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
58121219|NCT00555009|DRUG|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
58121220|NCT04528095|DRUG|Clozapine|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
58450151|NCT04052308|BEHAVIORAL|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
58450152|NCT03604029|DEVICE|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
58450153|NCT05173909|DEVICE|BIS closed-loop target controlled infusion|BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
58450154|NCT00556894|DRUG|CF101|orally q12h
57747324|NCT02183987|OTHER|Active Knowledge Translation Intervention|"1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (\>3 months) starting dialysis early (eGFR \>10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up."
57747325|NCT04983550|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
57747326|NCT04983550|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
57959084|NCT00985205|DIETARY_SUPPLEMENT|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
57959085|NCT00985205|DIETARY_SUPPLEMENT|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
57959086|NCT01961700|OTHER|Physiotherapy|Physiotherapy treatment
57959087|NCT02500628|DRUG|Metformin|500 mg orally after baseline testing of heart rate
57959088|NCT05240755|DRUG|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
57959089|NCT03270865|DEVICE|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
57959090|NCT03773042|DRUG|HSK3486|For induction and maintenance of sedation.
57959091|NCT03773042|DRUG|Propofol|For induction and maintenance of sedation.
57959092|NCT03250403|DRUG|PRP injection|peri-neural injection of platelet rich plasma
57959093|NCT03250403|OTHER|traditional medical treatment|traditional medical treatment
57959094|NCT05396742|DRUG|Ravulizumab|Solution for infusion or injection, as applicable
57747327|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Bread with Yeast|Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
57747328|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Sourdough Bread|Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
57959095|NCT05396742|DRUG|rHuPH20|Solution for infusion
57959096|NCT02849132|DRUG|Entecavir|oral entecavir 0.5mg daily for 8 years
57959097|NCT02952222|DRUG|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
58121221|NCT04528095|DEVICE|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
58450155|NCT00556894|DRUG|Placebo|orally q12h
58450156|NCT02380287|DRUG|humanized monoclonal antibody against human IL-17|
58450157|NCT04871659|OTHER|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
58450158|NCT00410878|DRUG|OROS Hydromorphone HCI (slow release)|
58458688|NCT05672329|OTHER|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
58121222|NCT04528095|DEVICE|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
58121223|NCT03150251|OTHER|Cereal - oats|Consumption of one cereal in the beginning of each visit
58121224|NCT03150251|OTHER|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
58121225|NCT05984537|DRUG|Bivalirudin|Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.
58313937|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
58121226|NCT05984537|DRUG|standard heparin|Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
58121227|NCT03341273|DRUG|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
58121228|NCT03341273|OTHER|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
58121229|NCT03341273|DEVICE|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
58121230|NCT04690270|DRUG|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
58121231|NCT01877707|OTHER|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
58450159|NCT04041934|DIETARY_SUPPLEMENT|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
57747329|NCT04949659|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
57747330|NCT02367755|DRUG|Propofol|Propofol use during therapeutic hypothermia
57747331|NCT02367755|DRUG|Lorazepam|Lorazepam use during therapeutic hypothermia
57747332|NCT01785303|BEHAVIORAL|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
57747333|NCT01785303|PROCEDURE|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
57747334|NCT06273098|BEHAVIORAL|Bladder Health Education|This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
57747335|NCT05432076|DEVICE|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~* Being extubated~* A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~* Baby dreams of boredom~* Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
57747336|NCT00333164|DRUG|Asprin, Cilostazol|
58121232|NCT04409665|DRUG|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
57747337|NCT06580236|DRUG|B11-FC|Infusion
58121233|NCT04409665|DRUG|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
58121234|NCT01963364|DIETARY_SUPPLEMENT|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
58121235|NCT01963364|DIETARY_SUPPLEMENT|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
58121236|NCT06264947|DEVICE|laser acupuncture|wavelength: 808nm energy: 18j power: 100mw
58121237|NCT06264947|DEVICE|sham laser acupuncture|wavelength: 0nm energy: 0j power: 0mw
57747338|NCT06580236|DRUG|Botulinum neurotoxin type A|Infusion
57747339|NCT06580236|OTHER|Placebo|Infusion
57747340|NCT05965011|OTHER|Exercise training|The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
57747341|NCT04833387|DRUG|PD-1 antibody|Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
57747342|NCT03984799|PROCEDURE|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
57747343|NCT01391221|DRUG|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
57747344|NCT03390205|DIAGNOSTIC_TEST|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
58121238|NCT00026104|DRUG|gemcitabine hydrochloride|Given IV
58121239|NCT00026104|DRUG|paclitaxel|Given IV
58121240|NCT00026104|DRUG|tipifarnib|Given orally
58121241|NCT00026104|RADIATION|radiation therapy|Undergo radiation therapy
58313938|NCT00063453|DIETARY_SUPPLEMENT|Selenium|selenium (200 μg/d L-selenomethionine)
58313939|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E placebo|placebo
58313940|NCT00063453|DIETARY_SUPPLEMENT|Selenium placebo|placebo
58313941|NCT06042517|DEVICE|Ultrasound|The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.
58313942|NCT06042517|DIAGNOSTIC_TEST|OGTT with unlabeled glucose and liver NMR|Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.
58313943|NCT06042517|DIAGNOSTIC_TEST|OGTT with carbon-13 labeled glucose and liver NMR|Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.
58121242|NCT01584661|BEHAVIORAL|Dietary recommendations|
58450160|NCT04676295|BEHAVIORAL|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
58450161|NCT04321044|GENETIC|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
58450162|NCT02849119|PROCEDURE|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
58450163|NCT00074334|BIOLOGICAL|TGFa-PE38 immunotoxin|
58450164|NCT00074334|PROCEDURE|conventional surgery|
58450165|NCT00497757|BIOLOGICAL|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
58450166|NCT01687608|BIOLOGICAL|AskBio009|Single dose IV injection
58450167|NCT00545090|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
58450168|NCT02134860|OTHER|Bed rest|8 days of full bed rest
58450169|NCT02134860|OTHER|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
58450170|NCT02134860|OTHER|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
58450171|NCT02134860|OTHER|Cognitive testing|Daily testing of memory and concentration using standardized tests
58450172|NCT02134860|OTHER|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
58450173|NCT02134860|OTHER|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
58450174|NCT02134860|OTHER|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
57747345|NCT02982694|DRUG|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
57747346|NCT02982694|DRUG|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
57747347|NCT00645164|OTHER|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
58450175|NCT00397384|DRUG|cetuximab|Given IV
58450176|NCT00397384|DRUG|erlotinib hydrochloride|Given PO
58450177|NCT00397384|OTHER|laboratory biomarker analysis|Correlative studies
58450178|NCT02469350|OTHER|Serious game|Rehabilitation with serious game
58450179|NCT05701007|DRUG|abiraterone|mCRPC
58450180|NCT05701007|DRUG|enzalutamide|mCRPC
58450181|NCT05701007|DRUG|docetaxel|mCRPC
58450182|NCT05701007|DRUG|apalutamide|mCRPC
58450183|NCT05701007|DRUG|cabazitaxel|mCRPC
58450184|NCT05701007|DRUG|Radium-223|mCRPC
58450185|NCT05701007|DRUG|Lutetium-177|mCRPC
58450186|NCT05701007|DRUG|degarelix|mCSPC
58450187|NCT05701007|DRUG|goserelin|mCSPC
57747348|NCT00645164|DRUG|Xenaderm|20 mg under Finn chambers
57747349|NCT06060977|DRUG|IMG-007|Intravenous Infusion
57747350|NCT00331643|DRUG|ixabepilone|Given IV
58121243|NCT06371599|BEHAVIORAL|Playing game|Active Distraction Methods
58121244|NCT06371599|BEHAVIORAL|Watching cartoon|Passive Distraction Methods
58121245|NCT03395821|BEHAVIORAL|Conventional training|traditional training according to residency program
58121246|NCT03395821|BEHAVIORAL|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
58121247|NCT00208949|DRUG|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
58121248|NCT00208949|DRUG|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
58121249|NCT03996603|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
58121250|NCT00679523|DRUG|AN2690 Solution, 5.0%|Once daily application for 180 days
58450188|NCT05701007|DRUG|leuprorelin|mCSPC
58450189|NCT05701007|DRUG|triptorelin|mCSPC
58450190|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Resource Energy|Carbohydrate Supplement
58450191|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
58450192|NCT01757314|BEHAVIORAL|ultrasound technique|instruction in the ultrasound technique
58450193|NCT01757314|OTHER|palpation technique|placement of a line via palpation technique
58450194|NCT00918177|DRUG|AP09004|
58450195|NCT00918177|DRUG|Carbidopa/Levodopa, immediate release|
58450196|NCT05098730|BEHAVIORAL|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
58450197|NCT00209352|DRUG|Acyclovir|
58450198|NCT05577923|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
58450199|NCT05577923|DRUG|pyrotinib|Pyrotinib 320mg, PO daily, continuously
58450200|NCT05577923|DRUG|Dalpiciclib|Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
58450201|NCT05577923|DRUG|fulvestrant|Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
58450202|NCT01613677|DRUG|BKM120|
58450203|NCT03391934|DRUG|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
58450204|NCT00652795|DRUG|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
58450205|NCT00652795|DRUG|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
58450206|NCT00335400|DRUG|Anesthetic Dilating Gel|
58121251|NCT00679523|DRUG|AN2690 Solution, 7.5%|Once daily application for 180 days
58121252|NCT00182091|DRUG|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
58121253|NCT00182091|DRUG|Saline|To maintain study-subject blinding, doses were sham adjusted.
58121254|NCT05955352|PROCEDURE|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
58121255|NCT00739856|PROCEDURE|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
58121256|NCT02215174|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
58121257|NCT04810819|DRUG|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
58121258|NCT04810819|DRUG|Placebo|Placebo
58121259|NCT03968471|BEHAVIORAL|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
58121260|NCT00226720|PROCEDURE|Outpatient detoxification program|Outpatient detoxification program
58121261|NCT02841306|DRUG|Ursodeoxycholic Acid|
58121262|NCT00367588|BEHAVIORAL|Low bacterial diet|
58121263|NCT00999609|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
58450207|NCT06223685|DRUG|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
57747351|NCT05840172|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
57747352|NCT05840172|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
58121264|NCT02591784|DRUG|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
58121265|NCT02591784|RADIATION|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
58121266|NCT02929693|DRUG|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
58121267|NCT02929693|DRUG|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
58121268|NCT02929693|DRUG|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
58121269|NCT06546410|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
58121270|NCT03057262|DEVICE|Repositioning splint|Application of repositioning splint in the study group.
58121271|NCT02942303|DRUG|Dysport|
58121272|NCT02942303|PROCEDURE|lateral orbicularis injection|
58121273|NCT02942303|PROCEDURE|Lateral orbicularis + corrugator injection|
58121274|NCT00798551|BEHAVIORAL|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
58121275|NCT05930574|PROCEDURE|Abdominal surgery|surgical interventions by gastrointestinal emergencies, hepatobiliary emergencies and trauma
58313944|NCT06042517|DIAGNOSTIC_TEST|CGM glucose reading|A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
58313945|NCT06042517|DIAGNOSTIC_TEST|HEC - Hyperinsulinemic-Euglycemic-Clamp|A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
58313946|NCT00525356|DEVICE|Medtronic Talent Stent-Graft-System|
58313947|NCT03979313|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
58313948|NCT03979313|DRUG|Placebo|Commercially available 0.9% (w/v) saline
57747353|NCT05840172|DEVICE|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
57747354|NCT04305314|OTHER|PRI (Enhanced Recovery after surgery protocol)|Standard use of Spanish perioperative guidelines (PRI)
57747355|NCT00712868|DRUG|Lactic acid|Once a day
57747356|NCT02327754|DRUG|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
58313949|NCT06486701|BEHAVIORAL|have a sing|Singing
58313950|NCT05222308|OTHER|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
58313951|NCT00392223|DRUG|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
58313952|NCT00392223|DRUG|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
57747357|NCT02327754|DRUG|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
58121276|NCT05812105|OTHER|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
58121277|NCT00625690|OTHER|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
58121278|NCT00625690|PROCEDURE|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
58121279|NCT00625690|PROCEDURE|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
58121280|NCT00625690|PROCEDURE|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
58121281|NCT06484712|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
57747358|NCT00630110|DRUG|docetaxel|docetaxel (75 mg/m2)
57747359|NCT00630110|DRUG|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
57747360|NCT06574815|PROCEDURE|Early implant loading|Patients underwent definitive restoration at 6 weeks after implant surgery (early loading).
57747361|NCT06574815|PROCEDURE|Delayed implant loading|Patients underwent definitive restoration at 6 months after implant surgery (delayed loading).
57747362|NCT06574815|PROCEDURE|GBR using an SIS membrane|An small intestine submucosa (SIS) membrane was used in the guided bone regeneration (GBR) surgery.
57747363|NCT06574815|PROCEDURE|GBR using an Bio-Gide membrane|An Bio-Gide membrane was used in the guided bone regeneration (GBR) surgery.
57747364|NCT00377325|DRUG|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
57747365|NCT00952822|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
57747366|NCT06580977|BEHAVIORAL|cardiovascular training|Cardiovascular training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. The training is performed on a cycle ergometer at 60% of peak power output (Wmax) for 30 min (i.e., 5 min warm-up, 20 min at 60% Wmax, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (max. 55 min) and 5% of intensity (in Watt) every two weeks. If participants report a too low (i.e., Borg scale ≤ 11) or too high (i.e., Borg scale ≥ 16) subjective rate of perceived exertion (RPE; Borg scale 6-20) intensity will be increased or decreased until the target levels are met (i.e., Borg scale 12-15). During training, heart rate, intensity (in Watt) and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
57747367|NCT06580977|BEHAVIORAL|stretching|The stretching training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. Stretching training consists of lying, seated, and standing flexibility exercises (according to the recommendations of the American Parkinson´s Disease Foundation and the Parkinson Society Canada) for 30 min (i.e., 5 min warm-up, 20 min main part, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (i.e., adding additional repetitions and exercises; max. 55 min) every two weeks. Intensity of stretching exercises will be assessed by subjective rate of perceived muscle tension on a visual analog scale (VAS) from 0 to 10 and will be moderate defined as 5 to 7 on the VAS. During training VAS, heart rate, and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
57747368|NCT01420848|OTHER|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
57747369|NCT01420848|OTHER|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
57747370|NCT03531320|DRUG|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
57747371|NCT02115594|DRUG|Fulvestrant|
57747372|NCT02115594|DRUG|Entinostat|
57747373|NCT02115594|DRUG|Placebo|
57747374|NCT03190538|OTHER|No intervention|There will be no specific intervention to these paediatric NASH patient
57747375|NCT03064516|PROCEDURE|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
57747376|NCT03064516|PROCEDURE|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
57747377|NCT05047198|PROCEDURE|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
58121282|NCT02638831|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
58121283|NCT02638831|DRUG|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
57747378|NCT05047198|PROCEDURE|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
57747379|NCT05691257|DRUG|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
58121284|NCT01140074|DRUG|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
58121285|NCT05133128|OTHER|blood samples|blood samples
58121286|NCT02267096|BEHAVIORAL|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
58121287|NCT02267096|BEHAVIORAL|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
58121288|NCT04428671|BIOLOGICAL|Cemiplimab|Given IV
58121289|NCT04428671|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
58121290|NCT04428671|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
58121291|NCT02675543|DEVICE|Vitreous Tamponade with Silicone Oil|
58121292|NCT04843163|BEHAVIORAL|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
58121293|NCT06484101|PROCEDURE|Exercise|3 x 30 seconds of supramaximal exercise
57747380|NCT05691257|DRUG|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
57747381|NCT04679090|OTHER|Exercise Program|Participants will exercise twice a week for twelve weeks total.
57747382|NCT06336668|DIETARY_SUPPLEMENT|Human milk-based HMF|The study subject will be fed human milk fortified with a human-milk-based HMF.
57747383|NCT00009828|DRUG|leucovorin calcium|
57747384|NCT00009828|DRUG|paclitaxel|
58121294|NCT04686136|DRUG|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
58121295|NCT02948322|DEVICE|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
58121296|NCT02948322|DRUG|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
57747385|NCT00009828|DRUG|tegafur-uracil|
57747386|NCT00683644|DRUG|Zinc|Zinc taken once daily
58121297|NCT02948322|PROCEDURE|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
58121298|NCT01621490|BIOLOGICAL|Nivolumab|
58121299|NCT01621490|DRUG|Ipilimumab|
58121300|NCT05666843|BEHAVIORAL|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
58121301|NCT00907842|DEVICE|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
58450208|NCT06223685|DIETARY_SUPPLEMENT|Probiotic|2x1 capsules per day. 12 weeks.
58450209|NCT00675909|DRUG|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
58450210|NCT00675909|DRUG|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
58450211|NCT00675909|DRUG|Oral midazolam|oral midazolam 0.5mg/kg
58450212|NCT04932239|OTHER|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
58450213|NCT01749306|BIOLOGICAL|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
58450214|NCT01749306|OTHER|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
58450215|NCT02607618|DRUG|Iclaprim|Experimental treatment
58450216|NCT02607618|DRUG|Vancomycin|Active comparator
58450217|NCT05727735|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
58450218|NCT05727735|DRUG|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
58450219|NCT04521322|DRUG|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
58450220|NCT04995536|BIOLOGICAL|CpG-STAT3 siRNA CAS3/SS3|Given intratumorally
58450221|NCT04995536|RADIATION|Radiation Therapy|Undergo radiation therapy
58450222|NCT04803695|DIAGNOSTIC_TEST|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
57747387|NCT00683644|DRUG|Placebo oral capsule|Placebo capsules taken once daily
58450223|NCT02851303|DRUG|Morphine|Morphine wean protocol as described in arm description
58450224|NCT02851303|DRUG|Methadone|Methadone wean protocol as described in arm description
58450225|NCT00012103|OTHER|bronchoalveolar lavage|
58121302|NCT01466803|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
58121303|NCT01466803|DRUG|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
58121304|NCT04571723|BEHAVIORAL|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
58121305|NCT04571723|BEHAVIORAL|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
58121306|NCT05209646|DIETARY_SUPPLEMENT|Bee honey|patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
58450226|NCT00012103|OTHER|screening questionnaire administration|
58450227|NCT00012103|OTHER|sputum cytology|
58450228|NCT00012103|PROCEDURE|bronchoscopic and lung imaging studies|
58450229|NCT00012103|PROCEDURE|bronchoscopy|
58450230|NCT00012103|PROCEDURE|computed tomography|
58450231|NCT00012103|PROCEDURE|study of high risk factors|
58450232|NCT04816214|DRUG|Capmatinib|Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).
57747388|NCT04273230|OTHER|Microalbuminuria detection|Detection of microalbumin in urine
57747389|NCT02822222|DRUG|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
57747390|NCT02822222|DRUG|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
57747391|NCT00825266|DRUG|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
58450233|NCT04816214|DRUG|Osimertinib|Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)
58450234|NCT04816214|DRUG|Pemetrexed|Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
58450235|NCT04816214|DRUG|Cisplatin|Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.
58450236|NCT04816214|DRUG|Carboplatin|Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
58450237|NCT02820675|OTHER|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
58450238|NCT02820675|OTHER|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
58121307|NCT06465823|DRUG|Bumetanide|"Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing."
58121308|NCT06465823|DRUG|Placebo|Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
58121309|NCT00035633|DRUG|Entecavir|
58121310|NCT01127542|DRUG|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
58121311|NCT02750761|DRUG|Tedizolid Phosphate (IV)|200 mg/vial powder for injection
58121312|NCT02750761|DRUG|Tedizolid Phosphate (oral suspension)|Powder for oral suspension 20 mg/mL following reconstitution
58121313|NCT01409850|DEVICE|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
58121314|NCT01409850|DEVICE|Soft splint|
58450239|NCT00825188|DRUG|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
57747392|NCT00825266|DRUG|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
58121315|NCT06211426|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
58121316|NCT06211426|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58121317|NCT04954131|BIOLOGICAL|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
58121318|NCT04954131|OTHER|Placebo|Saline solution (0.9%)
58313953|NCT00392223|DRUG|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
58313954|NCT00392223|DRUG|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
58313955|NCT01471626|DEVICE|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
58313956|NCT04491058|DIAGNOSTIC_TEST|SSCT thickness measurement|Thickness measurement with ultrasound
58313957|NCT05558371|OTHER|No intervention.|No intervention administered as part of this study; observational only.
58313958|NCT01772082|BEHAVIORAL|Internet mediated walking program|
58313959|NCT00761319|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
58313960|NCT00761319|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
58313961|NCT00764218|DEVICE|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
58313962|NCT00764218|OTHER|No positive airway pressure treatment|No treatment
58313963|NCT02642900|PROCEDURE|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
58313964|NCT02642900|DRUG|Nystatin 100.000 units|Control group treated with nystatin
58313965|NCT04207671|PROCEDURE|Complete omission of chest tube|No chest tube implacement
58313966|NCT04207671|PROCEDURE|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
58313967|NCT03989544|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
58313968|NCT02684929|DIETARY_SUPPLEMENT|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
58313969|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
58450240|NCT00825188|DRUG|eplerenone|Eplerenone 25-50mg daily x 8 weeks
58450241|NCT00825188|DRUG|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
58450242|NCT00825188|DRUG|amlodipine|amlodipine 5-10mg daily for 8 weeks
57959098|NCT02952222|DRUG|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
58121319|NCT03960320|OTHER|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
58121320|NCT00284297|PROCEDURE|History taken and clinical examination|History is taken and clinical examination is followed
58121321|NCT02033265|PROCEDURE|Brachial plexus block|Ultrasound guided axillary brachial plexus block
58121322|NCT01443806|DRUG|Oseltamivir|75 mg, one time
58121323|NCT04370184|PROCEDURE|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
58121324|NCT06209788|PROCEDURE|experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
58121325|NCT01338428|BEHAVIORAL|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
58121326|NCT01338428|BEHAVIORAL|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
58121327|NCT06379009|OTHER|Training|12 week home-based training program
58121328|NCT03407859|BIOLOGICAL|Sequential Treatment With different CART|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
58458689|NCT05672329|OTHER|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
57959099|NCT02952222|DRUG|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
57959100|NCT00181194|DEVICE|Asthma Control and Communication Instrument|
57959101|NCT04603573|DEVICE|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
57959102|NCT04603573|DEVICE|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
57959103|NCT00152425|DRUG|Certolizumab Pegol (CDP870)|
57959104|NCT01958801|OTHER|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
57959105|NCT01958801|OTHER|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
57959106|NCT02469766|PROCEDURE|SWL|Patients in this arm will undergo SWL
57959107|NCT02469766|PROCEDURE|Semirigid URS|Patients in this arm will undergo semirigid URS
57959108|NCT02469766|PROCEDURE|Flexible URS|Patients in this arm will undergo Flexible URS
57959109|NCT03961087|DRUG|Coenzyme Q10|Coenzyme Q10 will be given twice
57959110|NCT03961087|DRUG|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
57959111|NCT05578742|PROCEDURE|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
57959112|NCT05578742|PROCEDURE|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
57959113|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 1|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 short hairpin (sh)RNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 1 in the dose escalation phase of the study will receive a fixed number of intramuscular (IM) injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 1.2e13 vg/subject."
57959114|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 2|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 2 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 3.6e13 vg/subject."
58121329|NCT02855190|OTHER|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
58121330|NCT04700995|PROCEDURE|NiTi instruments|Root canal filling removal
58121331|NCT01909466|DRUG|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
58121332|NCT04107493|DEVICE|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
58121333|NCT04107493|DEVICE|Mobi|ResMed's variant of POC
58121334|NCT01395953|DRUG|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
58121335|NCT01395953|DRUG|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
58121336|NCT03937466|DEVICE|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
58121337|NCT00000898|DRUG|Ritonavir|
58121338|NCT00000898|DRUG|Nelfinavir mesylate|
57747393|NCT03157518|DIETARY_SUPPLEMENT|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
57747394|NCT03978234|DRUG|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
57747395|NCT04578327|DEVICE|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
57747396|NCT04578327|PROCEDURE|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
57747397|NCT01298960|DRUG|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
57959115|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 3|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject."
57959116|NCT06185673|GENETIC|BB-301: Dose expansion phase 2a|Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
57959117|NCT00891605|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
57747398|NCT04727151|BIOLOGICAL|TAC01-HER2|"TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
57959118|NCT00891605|DRUG|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
58121339|NCT00000898|DRUG|Saquinavir|
58121340|NCT01589536|OTHER|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
57747399|NCT04727151|BIOLOGICAL|TAC01-HER2 plus pembrolizumab|"TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
57747400|NCT05944965|DRUG|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
57747401|NCT05944965|DRUG|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
57747402|NCT05944965|DRUG|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
57959119|NCT00517595|DRUG|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
57959120|NCT04652271|PROCEDURE|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
57959121|NCT01861405|BEHAVIORAL|neuropsychological testing and quality of life assessments|
58121341|NCT02076477|RADIATION|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
58121342|NCT02076477|DRUG|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
58121343|NCT02076477|DRUG|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
58121344|NCT02076477|DRUG|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
58121345|NCT04760067|OTHER|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
58121346|NCT02971046|OTHER|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
58121347|NCT02231190|DRUG|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
58121348|NCT02231190|DRUG|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
58121349|NCT03841097|DRUG|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
58121350|NCT03841097|DRUG|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
58121351|NCT02259712|OTHER|Hypopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
57747403|NCT01241357|DEVICE|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
57747404|NCT01696487|DIETARY_SUPPLEMENT|High oral Fructose challenge (150g per day for 28 days)|
57747405|NCT04380922|OTHER|Periodontal screening|Periodontal data collection (PPD, REC, CAL)
57747406|NCT04512521|DRUG|Mepolizumab|Mepolizumab therapy
57747407|NCT02681913|DRUG|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
57747408|NCT03236298|DEVICE|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
57747409|NCT00846872|DRUG|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
57747410|NCT00846872|DRUG|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
57747411|NCT00846872|DRUG|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
57747412|NCT01758354|OTHER|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
58121352|NCT02259712|BEHAVIORAL|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
58313970|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
58313971|NCT01027949|DRUG|Oral Treprostinil|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
58313972|NCT00828256|PROCEDURE|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
58313973|NCT06026397|DRUG|SK10|Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
58313974|NCT06026397|DRUG|Placebo|Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
57747413|NCT05609084|PROCEDURE|Speech therapy|Patients will connect on an interface to pratice speech therapy
57747414|NCT05609084|PROCEDURE|Speech therapy assessment|Patients will be followed by an speech therapist
57747415|NCT01204801|DEVICE|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
57747416|NCT01204801|DRUG|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
57747417|NCT01190696|PROCEDURE|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
57747418|NCT01190696|DEVICE|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
57747419|NCT00381966|DEVICE|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
57747420|NCT00962195|DIETARY_SUPPLEMENT|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
58121353|NCT02259712|OTHER|Pelvic-perineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
58121354|NCT02259712|OTHER|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
58121355|NCT05050786|DEVICE|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
58121356|NCT05050786|OTHER|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
58121357|NCT06338709|DEVICE|BariClip® Device Treatment|Device Administration (Implantation)
58121358|NCT05134064|DEVICE|total-body PET/CT|PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
58121359|NCT04371978|DRUG|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
58121360|NCT00908752|DRUG|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
58121361|NCT00908752|OTHER|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
58121362|NCT00908752|PROCEDURE|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
58121363|NCT03686709|DIAGNOSTIC_TEST|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
58121364|NCT06543641|DIAGNOSTIC_TEST|Coronary computed tomography angiography|All patients received coronary computed tomography angiography.
57747421|NCT03369717|DRUG|Amoxi Clavulanate|Postoperative antibiotics
57747422|NCT03912844|PROCEDURE|SIRT followed by liver resection or liver transplantation|The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
57747423|NCT06292156|DEVICE|Theta treatment group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks
57747424|NCT06292156|DEVICE|Alpha active control group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks
58121365|NCT06543641|DIAGNOSTIC_TEST|Invasive coronary angiography|According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
58121366|NCT02452645|BEHAVIORAL|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
58313975|NCT04009382|OTHER|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
58313976|NCT04009382|OTHER|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
58313977|NCT00618501|DRUG|cytarabine|
58313978|NCT00618501|DRUG|daunorubicin hydrochloride|
58313979|NCT00618501|DRUG|etoposide|
58313980|NCT00618501|DRUG|imatinib mesylate|
58313981|NCT00618501|DRUG|leucovorin calcium|
58313982|NCT00618501|DRUG|methotrexate|
57747425|NCT06292156|DEVICE|Sham control group|Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).
57747426|NCT02985866|DEVICE|Artificial Pancreas|Use of CTR at home for 3 months
57747427|NCT02985866|OTHER|Sensor Augmented Therapy|Use of personal pump with study CGM \& glucometer at home for 3 months
58313983|NCT00618501|DRUG|prednisolone|
58313984|NCT00618501|DRUG|therapeutic hydrocortisone|
58313985|NCT00618501|DRUG|vincristine sulfate|
58313986|NCT00618501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58313987|NCT03980223|DRUG|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
57747428|NCT02881723|PROCEDURE|Surgery|
57747429|NCT02881723|RADIATION|Radio- chemotherapy|
57747430|NCT03705208|OTHER|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
57747431|NCT00801008|BEHAVIORAL|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
57747432|NCT00654810|BEHAVIORAL|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
58313988|NCT00676884|DRUG|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
58313989|NCT00676884|DRUG|placebo|1.5 mL s.c. b.i.d.
58313990|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
58313991|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
58121367|NCT02452645|BEHAVIORAL|Comparison Group|Written materials, videos, books, and telephone counseling.
57747433|NCT00097331|DRUG|SB683699|
58121368|NCT02375126|PROCEDURE|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
58121369|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
58121370|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
58121371|NCT04583579|DEVICE|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
58121372|NCT04583579|DEVICE|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
58121373|NCT04583579|DEVICE|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
58121374|NCT00886665|DRUG|placebo|placebo, 4 g, powder, oral, 3 times a day
58121375|NCT00886665|DRUG|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
58121376|NCT02677909|DEVICE|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
58121377|NCT00466297|BEHAVIORAL|Face-to-face communication interactions|
58121378|NCT01820871|OTHER|Self-Management Using Smartphone Application for Type2 DM|
57747434|NCT02870140|DEVICE|SUPRAFLEX|Percutaneous Coronary Intervention
57747435|NCT02870140|DEVICE|XIENCE|Percutaneous Coronary Intervention
57747436|NCT02723864|DRUG|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
58121379|NCT01820871|OTHER|self-management using booklet for management type 2 DM|
58121380|NCT06067711|DEVICE|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
58121381|NCT02510716|BEHAVIORAL|SGR|
58121382|NCT02510716|BEHAVIORAL|Support message only|
58121383|NCT03263481|PROCEDURE|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
58121384|NCT03752541|BIOLOGICAL|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
57747437|NCT06202326|DEVICE|renal artery doppler|doppler ultrasound follow up
57747438|NCT03520166|OTHER|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
57747439|NCT03520166|OTHER|No treatment|No treatment
57747440|NCT00180726|PROCEDURE|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
57747441|NCT05941754|DIETARY_SUPPLEMENT|omega-3|supplement in the market
57747442|NCT05941754|DIETARY_SUPPLEMENT|placebo|corn oil
57747443|NCT05769985|OTHER|Caregiver's responses and patient satisfaction|Interaction between caregivers' responses and patient satisfaction about those responses
57747444|NCT05638399|DRUG|Denosumab 60 mg/ml [Prolia]|60 mg subcutaneously per 6 month
57747445|NCT05638399|DRUG|Zoledronate|5mg, intravenous infusion once a year
58121385|NCT00034125|DRUG|LY353381|
58121386|NCT00034125|DRUG|tamoxifen|
58121387|NCT03513497|OTHER|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
58121388|NCT05822596|DEVICE|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
58121389|NCT04256265|DRUG|Risdiplam|Risdiplam will be administered orally once daily
58121390|NCT04263870|DRUG|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
58121391|NCT01099384|BEHAVIORAL|Written self-help materials|Written materials to help adolescents stop tobacco use
58121392|NCT01099384|BEHAVIORAL|Group behavioral counseling|group behavioral counseling (2 day weekend program)
58313992|NCT04745351|DRUG|Remdesivir|Administered as Intravenous (IV) infusion once daily
58121393|NCT06318858|DIETARY_SUPPLEMENT|Iron supplement|Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
58121394|NCT06350721|DEVICE|DizzyVR|Each patient will receive a total of 8 sessions of vestibular rehabilitation with the DizzyVR system. Each session will last for 50 minutes, with a frequency of one session per week. The total duration of the intervention will be 10 weeks, with the initial assessment/T0 taking place in the first week and the final assessment/T2 in the tenth week. Similarly, the total expected participation time for each participant is set at 12 weeks (T3).
58121395|NCT03465371|OTHER|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
58450243|NCT02754531|DEVICE|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
58450244|NCT02754531|OTHER|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
58450245|NCT02976935|OTHER|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
58450246|NCT06192849|DRUG|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
58450247|NCT03594773|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
58450248|NCT03594773|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
58450249|NCT00483691|BEHAVIORAL|Home Visit|Homw visits scheduled weekly for one year.
58450250|NCT02660164|DEVICE|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
58450251|NCT03355846|DRUG|Centella|after meals twice a day for 15 days
58450252|NCT03355846|DRUG|Proctocella|after hygiene treatment for 4 weeks;
58450253|NCT03355846|DRUG|Flavonil® cps|after meals twice a day for 15 days
58450254|NCT03355846|DRUG|Flavonil® Cream|"treatment for 4 weeks;~."
58450255|NCT03355846|DRUG|Rectalgan Mousse|for 4 weeks
58450256|NCT03015636|BEHAVIORAL|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
57747446|NCT05032209|OTHER|follow-up of children with severe asthma in adulthood|follow-up of children with severe asthma in adulthood
58121396|NCT03465371|OTHER|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
58313993|NCT04745351|DRUG|RDV Placebo|Administered as IV saline once daily
58450257|NCT03015636|OTHER|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
58450258|NCT00203164|DRUG|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
58450259|NCT03385148|DRUG|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
58450260|NCT01344902|DRUG|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
58450261|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will complete a virtual reality exercise (i.e., Supernatural) tutorial (YouTube instruction and in-headset gameplay instruction/practice) and will complete a 18-20 minute affect measurement medium intensity virtual reality exercise (i.e., Supernatural) session in the Behavioural Medicine Lab (UVic).
58450262|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will be provided a virtual reality headset (Meta Quest 3 Headset) and subscription to a virtual reality exercise game (i.e., Supernatural) for 10 weeks. Participants will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity (equivalent to 75 minutes of vigorous physical activity) per week in their own home.
57747447|NCT04064151|BEHAVIORAL|My Guide|12-week long health promotion Smartphone application
57747448|NCT05649111|DRUG|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
58313994|NCT04745351|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
58450263|NCT02804126|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
58450264|NCT02804126|PROCEDURE|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
58450265|NCT02804126|DRUG|Bupivacaine|In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
58450266|NCT02804126|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
58450267|NCT02804126|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
58450268|NCT02804126|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
57747449|NCT04946968|DRUG|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
57747450|NCT06213948|DRUG|Mirtazapine 15 MG|"Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)"
57747451|NCT06457555|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|This study is a mixed method research conducted to determine the knowledge levels and experiences of nurses working in adult intensive care units regarding the prevention of pressure sores. In accordance with the purpose of the study, parallel data type in convergent parallel mixed design will be used as the research design. The quantitative phase will be conducted as a descriptive survey, and the qualitative phase will be conducted as a descriptive case study design. In this mixed design, equal priority, parallel timing and combining results during interpretation are planned.
57747452|NCT06560047|PROCEDURE|Catheter ablation|Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
57747453|NCT02522936|DRUG|Biotene oral spray|Biotene oral spray will be provided to participants.
57747454|NCT03928080|DIAGNOSTIC_TEST|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
57747455|NCT02925676|DEVICE|hyposafe H02|hypoglycaemia notification device
57747456|NCT03818282|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
57747457|NCT03833882|DEVICE|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
57747458|NCT03833882|OTHER|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
57747459|NCT05138718|DIAGNOSTIC_TEST|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
57747460|NCT03910413|DIAGNOSTIC_TEST|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
57747461|NCT01093612|PROCEDURE|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
57747462|NCT01093612|RADIATION|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
57747463|NCT01093612|PROCEDURE|Biopsy|Correlative Studies
57747464|NCT01093612|OTHER|Immunohistochemistry staining method|Correlative studies
57747465|NCT01093612|OTHER|laboratory biomarker analysis|Correlative studies
57747466|NCT01093612|GENETIC|mutation analysis|Correlative studies
57747467|NCT05066464|OTHER|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
57747468|NCT04171102|DEVICE|ProFlor Hernia implant|Inguinal hernia repair
57959122|NCT01861405|RADIATION|Standard of Care WBRT or SRS|
57959123|NCT01861405|DEVICE|Functional magnetic resonance imaging|
57959124|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
57959125|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
57959126|NCT00399165|DRUG|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
57959127|NCT00399165|OTHER|placebo sesame oil|placebo sesame oil
57747469|NCT01429129|DRUG|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
57747470|NCT04636970|OTHER|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
57959128|NCT00399165|DRUG|Dutasteride|24.5 mg po once (Day 0)
57959129|NCT00207454|BEHAVIORAL|Social Cognitive Counseling|
57959130|NCT02026609|OTHER|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
57959131|NCT02026609|OTHER|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
57959132|NCT00251537|DRUG|LTB4|
57959133|NCT03140137|DRUG|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
57959134|NCT02468791|DRUG|Rituximab|
57959135|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.003%|
57959136|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.004%|
57959137|NCT03110900|DRUG|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
57959138|NCT03110900|DRUG|Loxapine|loxapine + placebo
57959139|NCT00793481|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
57959140|NCT02537171|DRUG|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
57959141|NCT01459250|DRUG|AGO178C|
57959142|NCT01493336|DRUG|capecitabine RTD|single oral dose
57959143|NCT01493336|DRUG|capecitabine [Xeloda]|single oral dose
57959144|NCT01493336|DRUG|capecitabine [Xeloda]|standard treatment
57959145|NCT05393466|DRUG|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
57959146|NCT01317433|DRUG|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
57959147|NCT01317433|DRUG|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
57747471|NCT00744484|BEHAVIORAL|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
57747472|NCT00744484|BEHAVIORAL|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
58121397|NCT03465371|OTHER|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
58121398|NCT03108365|DEVICE|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
58121399|NCT03108365|DEVICE|Cotton Gauze|Size: 1 x 1 cm
58121400|NCT03109366|BEHAVIORAL|Online patient-provider communication service|
58450269|NCT02804126|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
58450270|NCT02804126|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
58450271|NCT02987465|DRUG|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
58450272|NCT02987465|DRUG|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
57747473|NCT06056375|BEHAVIORAL|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
57747474|NCT05482360|OTHER|PrEP Optimization Interventions|There will be three strategies or bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders and are unknown at this time.
57747475|NCT04406948|DRUG|MGCND00EP1|Patients will take cannabis oil during the study
57959148|NCT01054742|DRUG|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
58121401|NCT02422290|DRUG|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
58121402|NCT05286528|DRUG|Bosutinib|Bosutinib as prescribed in real world
58121403|NCT05286528|DRUG|Imatinib|Imatinib as prescribed in real world
58121404|NCT05286528|DRUG|Nilotinib|Nilotinib as prescribed in real world
58121405|NCT05286528|DRUG|Dasatinib|Dasatinib as prescribed in real world
58121406|NCT05286528|DRUG|Ponatinib|Ponatinib as prescribed in real world
58121407|NCT03182608|DIAGNOSTIC_TEST|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
57747476|NCT04406948|DRUG|Placebo|Patient will take carrier oil during the study
57747477|NCT04406948|DIAGNOSTIC_TEST|ECG|"A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results."
58121408|NCT02958215|DRUG|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
57959149|NCT01054742|DRUG|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
57959150|NCT02630758|BEHAVIORAL|Mindfulness-based Yoga|See study arm description.
57959151|NCT02630758|BEHAVIORAL|Walking Control Condition|See study arm description.
57959152|NCT04529759|OTHER|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
57959153|NCT04529759|OTHER|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
58121409|NCT02958215|OTHER|Placebo|5 ml normal saline will be given before spinal anesthesia
58121410|NCT01414465|DRUG|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
58313995|NCT04932109|OTHER|No intervention|No intervention in this group
58313996|NCT03955315|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
58313997|NCT03955315|PROCEDURE|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
58450273|NCT02987465|DRUG|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
58450274|NCT02987465|DRUG|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
58450275|NCT02987946|DEVICE|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
58450276|NCT02987946|DRUG|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
58450277|NCT02418039|DIETARY_SUPPLEMENT|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
58450278|NCT02418039|DIETARY_SUPPLEMENT|Normal protein|A normal protein diet will be administrated in patients with MHE.
58450279|NCT02935647|DRUG|Diprivan|
58121411|NCT06347497|DRUG|Zonisamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
58121412|NCT06347497|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
58121413|NCT00917033|DEVICE|GlideScope|Orotracheal intubation
58121414|NCT00917033|DEVICE|Macintosh direct laryngoscope|Orotracheal intubation
58121415|NCT00009711|PROCEDURE|management of therapy complications|
58121416|NCT00959959|DRUG|TOK-001|2 capsules (325 mg each), once per day
58121417|NCT00959959|DRUG|TOK-001|4 capsules (325 mg each), once per day
58313998|NCT04184141|DRUG|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
58313999|NCT04184141|DRUG|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
57747478|NCT04406948|DIAGNOSTIC_TEST|EEG|An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
57747479|NCT04406948|DIAGNOSTIC_TEST|Blood and urine collection|safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
57747480|NCT01804920|DIETARY_SUPPLEMENT|D-serine|
57747481|NCT01804920|DIETARY_SUPPLEMENT|Placebo|
57747482|NCT01263951|DRUG|Everolimus|One 5 mg. tablet daily.
57747483|NCT01263951|DRUG|Sorafenib|200 mg. twice daily.
57747484|NCT04375748|DIAGNOSTIC_TEST|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
58314000|NCT04184141|DRUG|Placebo|Placebo candy
58314001|NCT05181072|BEHAVIORAL|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
58314002|NCT05181072|BEHAVIORAL|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
58314003|NCT03747003|OTHER|No intervention is provided|No intervention is provided
58314004|NCT05262101|DRUG|TQB2858 injection|TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
58314005|NCT00712920|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
58314006|NCT00712920|DRUG|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
58314007|NCT00712920|DRUG|Placebo|Placebo
58314008|NCT03815513|OTHER|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
57747485|NCT04375748|DIAGNOSTIC_TEST|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
57959154|NCT03022773|OTHER|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
57959155|NCT00264433|DRUG|ADH -1 (Exherin™)|
57959156|NCT00270530|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
58121418|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), once per day
58121419|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day
58121420|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day with supplement
58121421|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
58314009|NCT04068532|DRUG|Placebo|Administered as specified in the treatment arm.
58314010|NCT04068532|DRUG|BIIB104|Administered as specified in the treatment arm.
58314011|NCT05604313|DEVICE|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
58314012|NCT03749200|OTHER|Obemat2.0 therapy|
58314013|NCT03749200|OTHER|Regular practise in primary care|
58314014|NCT01813175|OTHER|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
58314015|NCT01813175|OTHER|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
58121422|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), once per day
58121423|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
58121424|NCT06087913|DRUG|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
57747486|NCT04835155|PROCEDURE|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
58450280|NCT01636635|OTHER|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
57747487|NCT06286150|PROCEDURE|Surgical robot system|SHURUI Single-port surgical robot system
57747488|NCT02660710|DRUG|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
57747489|NCT01799564|PROCEDURE|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
57747490|NCT00616187|DRUG|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
57747491|NCT00616187|DRUG|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
57747492|NCT00970879|DRUG|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
57747493|NCT00970879|DRUG|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
57747494|NCT01459510|BEHAVIORAL|Play Nicely Program|Multi media educational intervention
57747495|NCT02683850|DIETARY_SUPPLEMENT|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
57747496|NCT02813148|DRUG|Naloxegol|Non-interventional study of drug utilization
57747497|NCT05361226|OTHER|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
57747498|NCT05279781|PROCEDURE|Non surgical root canal treatment|Complete root canal treatment will be performed followed by direct restoration
57747499|NCT05279781|PROCEDURE|Pulpotomy|Full pulpotomy followed by direct restoration
58121425|NCT06087913|DRUG|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
58121426|NCT05312125|PROCEDURE|backward downhill walking|Children in the intervention group will take backward downhill walking program plus to routine physiotherapy.
58121427|NCT05312125|PROCEDURE|routine physiotherapy|Children in one of the groups will take routine physiotherapy programme
58121428|NCT04392089|DEVICE|Masimo, LidCO|"* Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO"
58121429|NCT05658367|PROCEDURE|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
58314016|NCT01813175|OTHER|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
58314017|NCT05567341|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
58314018|NCT05567341|PROCEDURE|Sham-control|A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
58314019|NCT01140906|DRUG|Placebo|capsules, daily, orally
58314020|NCT01140906|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
57747500|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
57747501|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
57747502|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
57747503|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
57747504|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
57747505|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
58314021|NCT01140906|DRUG|Duloxetine|encapsulated capsules, daily, orally
58314022|NCT06410183|OTHER|no intervention|no intervention
58450281|NCT03094741|OTHER|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
58450282|NCT04303481|OTHER|normal diet|Control
57747506|NCT01813474|DRUG|olaparib|tablet oral
57747507|NCT03748290|DRUG|Pregabalin|Pregabalin 75 mg for 12 weeks
57747508|NCT03748290|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
57747509|NCT01841346|PROCEDURE|Procedure: PCI|
57747510|NCT00824226|DIETARY_SUPPLEMENT|magnesium|magnesium 350 mg tablets once a day for 3 weeks
57747511|NCT00144274|DRUG|Ambroxol Lozenge|
57747512|NCT00014638|DRUG|letrozole|
57747513|NCT04085783|PROCEDURE|PRP|Platelet Rich Plasma
57747514|NCT01625351|DRUG|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
57747515|NCT01625351|DRUG|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
57747516|NCT01625351|DRUG|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
57747517|NCT01625351|DRUG|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
57747518|NCT01625351|DRUG|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
57747519|NCT01625351|BIOLOGICAL|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
57747520|NCT01625351|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
57747521|NCT03545867|BEHAVIORAL|Seated control (CON)|Seated rest
57747522|NCT03545867|BEHAVIORAL|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
57747523|NCT03545867|BEHAVIORAL|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
57747524|NCT03545867|BEHAVIORAL|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
57747525|NCT03545867|OTHER|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
57747526|NCT01093118|DRUG|TMI-358|Micro implant monthly x 3
57747527|NCT01093118|DRUG|MMI-467|Micro implant monthly x 3
58121430|NCT05658367|PROCEDURE|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
57747528|NCT01281644|DEVICE|Diode Laser|810 nm diode laser
57747529|NCT02357251|OTHER|Enhanced recovery protocol|
57747530|NCT06526117|DRUG|Hydroxyurea|The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
57747531|NCT04125368|BEHAVIORAL|Health Facility Interventions|"1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
57747532|NCT04125368|BEHAVIORAL|Community Interventions|"1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
57747533|NCT04125368|BEHAVIORAL|Health System Interventions|"1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T."
57747534|NCT02328833|OTHER|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
57747535|NCT00005041|DRUG|tipifarnib|
58121431|NCT05658367|PROCEDURE|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
58121432|NCT02354378|DRUG|Dexmedetomidine|
57747536|NCT01496833|DEVICE|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
57747537|NCT01515748|DRUG|Docetaxel (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
57747538|NCT01515748|DRUG|Oxaliplatin (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
57747539|NCT01515748|DRUG|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
57747540|NCT04102202|DRUG|BOL-DP-o-05|BOL-DP-o-05
57747541|NCT04102202|DRUG|Placebo|Placebo
57747542|NCT04184193|OTHER|Pulmonary Rehabilitation|Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
57959157|NCT01787357|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
57747543|NCT02707354|DEVICE|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
57747544|NCT02154633|BEHAVIORAL|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
57747545|NCT02154633|BEHAVIORAL|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
57747546|NCT06088940|DIETARY_SUPPLEMENT|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
57747547|NCT06088940|OTHER|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
57747548|NCT02889653|DRUG|Any oral antithrombotics (antiplatelets or anticoagulants)|
57747549|NCT03278015|DRUG|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
57747550|NCT03278015|DRUG|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
57747551|NCT03278015|DRUG|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
58121433|NCT02354378|OTHER|Memory Test|
57747552|NCT05534347|BIOLOGICAL|Blood sample|Addtional tube of blood needed for follow up of patients
57747553|NCT05534347|BIOLOGICAL|Joint puncture|Joint puncture if needed according to routine care of the patients
57747554|NCT00225433|DRUG|follitropin beta|Follitropin beta
57747555|NCT00225433|DRUG|ganirelix acetate|Ganirelix acetate
58121434|NCT06154863|DRUG|RAI|Radioactive iodine
58121435|NCT01669109|BEHAVIORAL|Hatha yoga|
58458690|NCT05672329|OTHER|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
57747556|NCT02943408|BEHAVIORAL|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
57747557|NCT02943408|BEHAVIORAL|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
57747558|NCT03653455|BEHAVIORAL|Email reminders|Patients will receive email reminders until their PROs are completed.
57747559|NCT03653455|BEHAVIORAL|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
57747560|NCT03653455|BEHAVIORAL|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
57747561|NCT04164992|DEVICE|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
57747562|NCT01380951|DRUG|telbivudine|telbivudine 600mg/d 96 weeks
57747563|NCT01295450|DRUG|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
57747564|NCT01295450|DRUG|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
57959158|NCT01787357|DRUG|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
58121436|NCT04170166|PROCEDURE|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
58121437|NCT04170166|PROCEDURE|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
58121438|NCT02497781|DRUG|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
58121439|NCT02497781|DRUG|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
58121440|NCT01584336|PROCEDURE|LATG|"1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy."
58121441|NCT00815490|DEVICE|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
58121442|NCT03992287|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
58121443|NCT03992287|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
58121444|NCT05117099|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
58121445|NCT04616417|PROCEDURE|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
58121446|NCT01494688|DRUG|Paclitaxel|Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
58121447|NCT01494688|DRUG|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
58121448|NCT03533946|DRUG|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.
58121449|NCT04810923|PROCEDURE|i-PRF|intra-articular i-PRF injection after arthrocentesis
58121450|NCT04810923|PROCEDURE|Arthrocentesis|Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
58121451|NCT00468741|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
58121452|NCT00468741|BEHAVIORAL|CHESS|informational services of CHESS available to subject
58121453|NCT00468741|BEHAVIORAL|CHESS|CHESS informational services and social support available to subject
58121454|NCT03982966|DIETARY_SUPPLEMENT|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
58121455|NCT05411042|DEVICE|Dance somatosensory game|dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
58450283|NCT04303481|OTHER|weight loss program kit|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
58450284|NCT04303481|OTHER|weight loss program kit with A. muciniphila prebiotics|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
58450285|NCT00258492|BEHAVIORAL|Aerobic exercise|
58121456|NCT02359604|DRUG|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
58121457|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
58121458|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
58121459|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
58121460|NCT01599208|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
58314023|NCT05884580|DEVICE|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
58450286|NCT03607942|DIETARY_SUPPLEMENT|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
58121461|NCT04142346|BEHAVIORAL|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
58121462|NCT00520507|DRUG|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
58121463|NCT00520507|DRUG|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
58121464|NCT01679821|OTHER|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
58314024|NCT02948400|BEHAVIORAL|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
58450287|NCT03607942|DIETARY_SUPPLEMENT|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
58458691|NCT05672329|OTHER|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
58450288|NCT05047861|PROCEDURE|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
57747565|NCT01248832|BEHAVIORAL|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
58450289|NCT05047861|PROCEDURE|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
58450290|NCT03026881|DRUG|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
58450291|NCT03026881|DRUG|Apatinib|Oral
58450292|NCT03026881|DRUG|Paclitaxel|Intravenous injection
58450293|NCT02698826|OTHER|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
58450294|NCT03087136|DIAGNOSTIC_TEST|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
58450295|NCT03087136|DIAGNOSTIC_TEST|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
57747566|NCT01248832|BEHAVIORAL|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
57747567|NCT03509649|PROCEDURE|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
57747568|NCT00240487|DRUG|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
57747569|NCT00240487|OTHER|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
57747570|NCT00137566|DRUG|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
57747571|NCT00137566|OTHER|Placebo|
57747572|NCT00112268|BEHAVIORAL|QuitLink (office support system for quit line referral)|
57747573|NCT06333054|DRUG|Pyrethrum Extract|Treatment with Goldgeist® Forte
57747574|NCT06333054|DEVICE|Silcap Shampoo|Treatment with Silcap Shampoo
57747575|NCT00036881|DIETARY_SUPPLEMENT|zinc sulfate|
57747576|NCT00036881|OTHER|placebo|
58314025|NCT03879330|DEVICE|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
57747577|NCT06057142|BEHAVIORAL|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
57747578|NCT03961789|OTHER|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
57747579|NCT05779202|OTHER|No intervention is planned.|No intervention is planned.
57959159|NCT01787357|DRUG|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
58121465|NCT03267342|BEHAVIORAL|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
58121466|NCT03267342|BEHAVIORAL|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
58121467|NCT03267342|BEHAVIORAL|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
58121468|NCT03267342|BEHAVIORAL|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
58121469|NCT01604681|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
58121470|NCT01604681|DIETARY_SUPPLEMENT|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
58121471|NCT04380220|DIAGNOSTIC_TEST|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
58121472|NCT03516383|DEVICE|PWVi|
58121473|NCT04018261|DRUG|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
58121474|NCT02789033|DRUG|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
58121475|NCT02789033|DRUG|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
58450296|NCT04578951|DEVICE|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
57747580|NCT03999879|DIAGNOSTIC_TEST|Measure of OxPhos upregulation|OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
57747581|NCT03999879|DIAGNOSTIC_TEST|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
57747582|NCT00989248|OTHER|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
58121476|NCT02789033|DRUG|Placebo|placebo
58121477|NCT00338247|DRUG|lapatinib + capecitabine|Experimental
58121478|NCT00523393|DRUG|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
58121479|NCT00523393|DRUG|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
58121480|NCT00290121|DRUG|Olanzapine|
58121481|NCT03348215|OTHER|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
58314026|NCT04013464|DRUG|Escitalopram|Escitalopram 10-20mg/d
58314027|NCT04800627|BIOLOGICAL|Pembrolizumab|Given IV
58314028|NCT04800627|DRUG|Pevonedistat|Given IV
58314029|NCT00227916|BEHAVIORAL|Behavior Therapy|
58450297|NCT02944214|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
57747583|NCT04605848|DIAGNOSTIC_TEST|Infrared themrography|measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
57747584|NCT05943457|DIETARY_SUPPLEMENT|Vitamin K2 or menaquinone-7|Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
57747585|NCT05943457|OTHER|Placebo|Placebo pills will be administered orally once daily for 6 months
57747586|NCT04189718|PROCEDURE|osseodensification protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
57747587|NCT04189718|PROCEDURE|conventional implant site preparation protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
57747588|NCT01489995|DRUG|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
57747589|NCT01489995|DRUG|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
58450298|NCT02944214|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
58121482|NCT04222036|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
58121483|NCT04222036|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
58121484|NCT04222036|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
58121485|NCT03431584|DRUG|infiltration of corticosteroids|infiltration of corticosteroids
58121486|NCT03431584|DRUG|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
58121487|NCT04200508|OTHER|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
58121488|NCT05977621|OTHER|Transrectal ultrasound (TRUS)|Transrectal ultrasound (TRUS) images of the female pelvis
58121489|NCT01290393|OTHER|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
58121490|NCT03970772|DRUG|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
58121491|NCT03970772|OTHER|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
58121492|NCT00650299|DRUG|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
58121493|NCT00650299|DRUG|Xanax XR® Tablets 3 mg|3mg, single dose fed
58121494|NCT05064696|OTHER|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
58121495|NCT05064696|DEVICE|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
58450299|NCT04485897|DEVICE|icare HOME device (Icare Oy, Vanda, Finland)|icare HOME device versus hospital based measurements
58450300|NCT04769570|PROCEDURE|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
58450301|NCT04769570|PROCEDURE|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
58450302|NCT04769570|PROCEDURE|Group Control|consist of the patient group without any procedure.
58450303|NCT01721863|OTHER|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
58450304|NCT05947318|DEVICE|transcranial alternating current stimulation 70 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 70 Hz"
58450305|NCT05947318|BEHAVIORAL|Training|Training of the upper limb with specific kinematic and kinetic tasks plus functional training
58450306|NCT05947318|DEVICE|transcranial alternating current stimulation 7 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 7 Hz"
57747590|NCT01489995|DRUG|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
58121496|NCT02962011|DEVICE|Knotless barbed suture|uterine incision closure
58121497|NCT02962011|DEVICE|polyglactin 910|uterine incision closure
58121498|NCT03229655|PROCEDURE|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
58121499|NCT03356613|OTHER|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
57747591|NCT01489995|DRUG|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
58121500|NCT03356613|OTHER|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
58121501|NCT02084381|DEVICE|MCO-Ci 400|hemodialysis
58121502|NCT02084381|DEVICE|Revaclear 400|hemodialysis
58121503|NCT04787406|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period."
58121504|NCT04897698|DIETARY_SUPPLEMENT|LB001|Probiotics
58121505|NCT04302779|BEHAVIORAL|Solid Model|Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
58450307|NCT05947318|DEVICE|transcranial alternating current stimulation Sham|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The stimulation will be turn on for 30 seconds (at 70 Hz)"
58450308|NCT04870502|DRUG|Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG|In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
58450309|NCT06435377|PROCEDURE|Procedure: Cold EMR + APC|"* Initial submucosal injection of saline solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare~* Biopsy of the resection bed~* Ablation of the defect using argon plasma coagulation (APC)."
58450310|NCT03678311|DEVICE|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.
58450311|NCT03488966|BEHAVIORAL|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
58450312|NCT02753426|DRUG|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
58450313|NCT02753426|DRUG|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
57959160|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
57747592|NCT01489995|DRUG|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
57747593|NCT03198026|DRUG|Ibrutinib|Given PO
57747594|NCT03198026|BIOLOGICAL|Obinutuzumab|Given IV
57747595|NCT03198026|OTHER|Laboratory Biomarker Analysis|Correlative studies
57959161|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
57959162|NCT04457427|DEVICE|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
57959163|NCT04847661|DRUG|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
58450314|NCT02021942|DRUG|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
58450315|NCT03104179|DEVICE|Cytosorb Adsorber|Cytokine adsorption during CPB
57747596|NCT04725344|OTHER|ACTIV'DOS group|ACTIV'DOS group use ACTIV'DOS application (with smartphone) to do the self rehabilitation each day (15 minutes per day) during 6 weeks. There are 7 exercices.
57747597|NCT04725344|OTHER|Usual practise|Control group uses a standard sheet of paper to do the self-rehabilitation (15 minutes per day) during 6 weeks. There are 7 exercises.
57959164|NCT00247754|BEHAVIORAL|Cognitive Behaviour Treatment|
57959165|NCT05491993|DIAGNOSTIC_TEST|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
57959166|NCT00291005|DRUG|ARD6562, Docetaxel|
57959167|NCT04569721|DEVICE|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
58121506|NCT04302779|BEHAVIORAL|Liquid Model|To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
58121507|NCT01081561|DRUG|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
58121508|NCT05412758|DIETARY_SUPPLEMENT|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
58121509|NCT03795103|DEVICE|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
58121510|NCT03795103|OTHER|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
58121511|NCT03795103|OTHER|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
58121512|NCT06545383|OTHER|Dynamic Neuromuscular Stabilization Exercises|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally DNS exercises will be performed in 40-minute sessions, 2 days a week for 6 weeks.
58450316|NCT06009367|PROCEDURE|Fascial Manipulation by Stecco method|Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
57747598|NCT03115892|DRUG|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
57747599|NCT03115892|DRUG|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
57747600|NCT05240105|OTHER|no intervention, purely observational|There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
57747601|NCT06472596|DIAGNOSTIC_TEST|CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha|compare results of investigations in asthmatics and non asthmatics
57747602|NCT05559034|BEHAVIORAL|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
57747603|NCT03589079|GENETIC|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
57747604|NCT06473662|DRUG|Oral insulin|Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
57747605|NCT01616901|PROCEDURE|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
57747606|NCT04262362|PROCEDURE|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
57747607|NCT02781402|PROCEDURE|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
57747608|NCT04292249|OTHER|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP\>20 mg/L a regular CRP-measurement will be performed.
58450317|NCT04965324|OTHER|Anaesthesia Depth|
57747609|NCT02104622|DEVICE|ReWalk Rehabilitation 2.0|
57747610|NCT06577636|PROCEDURE|Propofol anesthesia|EEG-guided infusion of anesthestetics
57747611|NCT02892812|BIOLOGICAL|Pneumococcal conjugate vaccine|
57747612|NCT01769300|BEHAVIORAL|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
58121513|NCT06545383|OTHER|Exercise|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally, the control group will be asked to walk at moderate intensity for 40 minutes, 2 days a week, for 6 weeks.
58121514|NCT03424291|DRUG|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
58121515|NCT00240682|DRUG|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
58121516|NCT01298856|PROCEDURE|hydrotherapy|hydrotherapy and ankle taping and land-based
58121517|NCT03947580|OTHER|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
58450318|NCT02185066|DRUG|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
57747613|NCT01733108|DRUG|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
57747614|NCT01733108|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
57747615|NCT00859079|DRUG|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
57747616|NCT00859079|DRUG|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
58121518|NCT03947580|OTHER|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
58121519|NCT03947580|OTHER|Use of no pad|Description is not needed
57747617|NCT00852631|DRUG|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
57747618|NCT00253968|DRUG|Eplivanserin|oral administration
57747619|NCT00253968|DRUG|placebo|oral administration
57747620|NCT01204827|DEVICE|13C Methacetin Breath Test (BreathID)|
57747621|NCT05199818|DRUG|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
57747622|NCT05199818|DRUG|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
57747623|NCT06448351|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
57747624|NCT06448351|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
57747625|NCT06448351|OTHER|Vaping session|Sample study e-liquids in vaping sessions at research lab with e-cig study device
57747626|NCT06448351|OTHER|Survey Administration|Ancillary studies
57747627|NCT00553930|DRUG|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
57747628|NCT00553930|DRUG|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
57747629|NCT04629482|OTHER|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
57747630|NCT06236750|DEVICE|EPIFIX|EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
58121520|NCT02145975|DRUG|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
57747631|NCT02716389|OTHER|Zebris CMS 70|
57747632|NCT02716389|OTHER|3-D Bulls Eye Spirit Meter|
57747633|NCT02808936|PROCEDURE|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
58121521|NCT02145975|DRUG|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
58121522|NCT03144856|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
57747634|NCT02808936|PROCEDURE|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
57747635|NCT01722968|DRUG|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
57747636|NCT01722968|DRUG|Paclitaxel|80mg/m2 iv weekly
57747637|NCT01218126|DRUG|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
57747638|NCT01218126|DRUG|placebo|placebo comparison with active
57747639|NCT03696017|OTHER|Multi-domain assessment battery|Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
57747640|NCT02062268|BEHAVIORAL|health education & law enforcement|
57747641|NCT04459390|DIAGNOSTIC_TEST|realtime PCR|Detection of SARS-CoV-2 genes by realtime PCR
57747642|NCT03365076|OTHER|Physical activity|Aerobic physical activity as stated in Arm A
57747643|NCT00910923|DRUG|JNJ-38431055|
57747644|NCT02633800|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
57747645|NCT02633800|DRUG|Cetuximab|Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
57747646|NCT02633800|DRUG|Cisplatin|Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
57747647|NCT02633800|DRUG|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
57747648|NCT02633800|DRUG|Placebo|Placebo to match patritumab
57747649|NCT00276471|DEVICE|Implantable pulse generator and electrodes|
57747650|NCT04295005|DRUG|Empagliflozin|film coated tablet
57747651|NCT04295005|DRUG|DPP-4i|film coated tablets, specifically Sitagliptin
57747652|NCT04295005|DRUG|GLP-1-RA|subcutaneous injection or tablet
58121523|NCT05733195|OTHER|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
58121524|NCT04431271|PROCEDURE|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
58121525|NCT00615784|DRUG|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
58121526|NCT04152928|DIAGNOSTIC_TEST|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
58121527|NCT02701478|DRUG|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
58450319|NCT02185066|DRUG|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
58450320|NCT03407417|OTHER|virtual technology - highly tailored|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
58450321|NCT03407417|OTHER|virtual technology - tailored minimally|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Minimally tailored patient reminders will be customized using 4 randomly selected constructs.
58450322|NCT06130241|PROCEDURE|sentinle lymphnode biopsy|intraoperative sentinle lymphnode biopsy
58450323|NCT00330759|BIOLOGICAL|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
58450324|NCT00330759|DRUG|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
58450325|NCT05456789|DEVICE|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
58450326|NCT05456789|OTHER|conventional treatment|conventional treatment of pulmonary embolism
58450327|NCT04085276|DRUG|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
58450328|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
58450329|NCT04085276|DRUG|Placebo|Placebo, i.v., q3w;
57747653|NCT06104033|DEVICE|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
57747654|NCT06104033|DEVICE|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
58121528|NCT00003145|DRUG|Fludarabine Phosphate|Given IV
58121529|NCT00003145|RADIATION|Total-Body Irradiation|Undergo TBI
58121530|NCT00003145|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
58121531|NCT00003145|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
58121532|NCT00003145|DRUG|Cyclosporine|Given PO or IV
58121533|NCT00003145|DRUG|Mycophenolate Mofetil|Given PO or IV
58121534|NCT00003145|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
58121535|NCT00003145|OTHER|Laboratory Biomarker Analysis|Correlative studies
58121536|NCT01474278|DRUG|Placebo|Single dose
58121537|NCT01474278|DRUG|RO5028442|Single dose
58121538|NCT05060627|DRUG|Belantamab mafodotin|"In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
58450330|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
57747655|NCT06456632|OTHER|Intervention Su Jok Therapy|Su Jok Therapy
57747656|NCT05304338|DRUG|Chlorhexidine|Gargling with 10 mL 0.2% Chlorhexidine
57747657|NCT05304338|OTHER|Oil Pulling|In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
58121539|NCT05060627|DRUG|Carfilzomib|"In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
58121540|NCT05060627|DRUG|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
58450331|NCT03945461|OTHER|Chewing gum|xylitol based, peppermint flavored gum
58450332|NCT06144879|PROCEDURE|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
58450333|NCT06144879|PROCEDURE|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
58450334|NCT06144879|PROCEDURE|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
58450335|NCT05115968|PROCEDURE|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
57747658|NCT05304338|OTHER|Distilled Water|Gargling with 10 mL distilled water
58121541|NCT05241236|DEVICE|Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer|Subjects diagnosed by a transperineal fusion or random transperineal or random transrectal prostate biopsy. Laser treatment plan generated by biopsy results +/- MRI is uploaded into the device. In procedure suite, a transperineal anesthetic block is conducted following by Bianco - USPTO PCT/US18/24404. On lithotomy a transrectal ultrasound probe is advanced, the prostate scanned. The images are acquired by fusion device. Co-registration is performed by surgeon delimiting boundaries of prostate. Medical device delivers real-time fusion guidance outlining prostate contours, ablation goals and laser introduce location. Surgeon executes plan or adjust as needed. Surgeon activates laser device, performs ablation monitored by medical device in real-time. The fusion device will deliver great perspective between the ablation areas and critical anatomical landmarks such as: NVB, membranous urethra, etc. Patient is dismissed to the recovery room and discharged afterwards
58121542|NCT01729936|BEHAVIORAL|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
58121543|NCT02893748|DEVICE|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
58121544|NCT02893748|PROCEDURE|Colonoscopy|Screening colonoscopy as per standard of care.
58121545|NCT02893748|DRUG|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
58121546|NCT02952248|DRUG|BI 754091|
58121547|NCT02424981|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
58121548|NCT06191367|OTHER|Aerobic Exercises|Aerobic Exercises
58121549|NCT06191367|DEVICE|Incentive Spirometer Device|is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.
58121550|NCT06191367|OTHER|Traditional Chest Physiotherapy|"1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration."
58121551|NCT00957983|DRUG|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
58121552|NCT02989766|BEHAVIORAL|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
58450336|NCT05854355|OTHER|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
58450337|NCT05189912|DEVICE|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
58450338|NCT05189912|BEHAVIORAL|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
58450339|NCT03707301|OTHER|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
57747659|NCT02250105|DRUG|ARI-3037MO|Lipid lowering
58450340|NCT06271044|OTHER|With radioiodine treatment|Postoperative radioiodine not given
58450341|NCT06271044|PROCEDURE|With postoperative radioiodine treatment|Postoperative radioiodine given
58450342|NCT04787107|DEVICE|Mechanical Chair Massage|Healthcare staff will be placed into either massage or break intervention
58450343|NCT05831592|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound assessment (sensitivity, specificity) in undernutrition in patients
57747660|NCT02250105|DRUG|Placebo|Inactive
57747661|NCT01433354|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
58121553|NCT03287596|DEVICE|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
58450344|NCT02172144|DRUG|BI 1744 CL solution for inhalation|
58450345|NCT02172144|DRUG|Placebo matching BI 1744 CL|
57747662|NCT02774070|RADIATION|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
57747663|NCT02774070|RADIATION|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
57747664|NCT06216522|OTHER|Topical Sesame Oil|5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
57747665|NCT06216522|OTHER|Liquid paraffin oil|5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
57747666|NCT04912648|OTHER|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
58121554|NCT00838318|BEHAVIORAL|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
58121555|NCT01185288|BIOLOGICAL|Adalimumab|Adalimumab in pre-filled syringes
58121556|NCT01185288|DRUG|Methotrexate|Methotrexate capsule
58121557|NCT02327000|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
58121558|NCT02327000|DRUG|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
58450346|NCT02172144|DRUG|Moxifloxacin (Avalox®)|
58450347|NCT00056693|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
58450348|NCT04424667|OTHER|donor milk|pasteurized donor milk
58450349|NCT01606969|DRUG|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
58450350|NCT01606969|DRUG|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
58458692|NCT03900507|PROCEDURE|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
58121559|NCT04053842|DIAGNOSTIC_TEST|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.
58121560|NCT04053842|DRUG|[18F]PSMA-1007 Injection|\[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
58121561|NCT04053842|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
58121562|NCT04053842|DIAGNOSTIC_TEST|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
58121563|NCT00026936|PROCEDURE|Radiotherapy|
58121564|NCT01193608|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
58121565|NCT01193608|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
58121566|NCT01193608|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
58121567|NCT01193608|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
58121568|NCT01193608|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
58121569|NCT01193608|OTHER|Placebo|Placebo, IV
58121570|NCT04291079|BIOLOGICAL|SRK-181|anti-latent TGFβ1 monoclonal antibody
58121571|NCT04291079|BIOLOGICAL|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
58121572|NCT04630197|BEHAVIORAL|e-CBT|The description is provided in the treatment arm description.
58121573|NCT05107440|OTHER|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
58458693|NCT04380506|PROCEDURE|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
58458694|NCT00918385|DRUG|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
57747667|NCT06457633|BEHAVIORAL|Experiential FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) carried out experientially.
57747668|NCT06457633|BEHAVIORAL|Traditional FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.)
57747669|NCT06457633|BEHAVIORAL|Online FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) performed virtually.
57747670|NCT01952496|OTHER|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months.~Arm: Force-measuring platform"
58121574|NCT04001608|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
58121575|NCT04001608|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
58121576|NCT02455700|DEVICE|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
58121577|NCT05791760|BEHAVIORAL|Compassion-focused therapy (CFT) for complex PTSD|The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
58121578|NCT02264951|DIETARY_SUPPLEMENT|Tributyrin|a triglyceride containing three C4-acids
58121579|NCT02264951|DIETARY_SUPPLEMENT|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
58121580|NCT02264951|DIETARY_SUPPLEMENT|Olive oil|a triglyceride containing mostly three oleic acids
58121581|NCT02264951|DIETARY_SUPPLEMENT|Carrot|mainly water and glucose
58121582|NCT03164148|DEVICE|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
58121583|NCT00619632|BEHAVIORAL|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
58121584|NCT00619632|BEHAVIORAL|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
58121585|NCT00619632|BEHAVIORAL|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
58121586|NCT01548872|DRUG|HTK solution|50 ml/kg bolus in 2 minutes
58121587|NCT01548872|DRUG|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
58121588|NCT05505123|DRUG|Sevoflurane|induction and maintenance with sevoflurane for deep sedation
58121589|NCT05505123|DRUG|Propofol|induction and maintenance with propofol for deep sedation
58121590|NCT01400113|DRUG|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
58314030|NCT05922332|DIETARY_SUPPLEMENT|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
58314031|NCT05922332|DIETARY_SUPPLEMENT|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
58121591|NCT01400113|DRUG|Placebo|Placebo Sublingual Tablet, single-dose
58121592|NCT01927757|BIOLOGICAL|Etanercept|Administered by subcutaneous injection
58121593|NCT01927757|DRUG|Methotrexate|Background methotrexate at least 15 mg weekly
58121594|NCT01315145|PROCEDURE|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
58121595|NCT01315145|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
57747671|NCT01437826|DRUG|antioxidants|tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
58121596|NCT01568008|DRUG|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
58121597|NCT03294538|DRUG|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
58121598|NCT03294538|DRUG|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
58121599|NCT03294538|DRUG|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
58121600|NCT02271555|DRUG|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
58121601|NCT02271555|DRUG|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
58121602|NCT02271555|DRUG|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
58121603|NCT05131126|PROCEDURE|Latarjet method|This operation consists of fixing a bone graft
58121604|NCT05131126|OTHER|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
58121605|NCT04755881|OTHER|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
58121606|NCT04561128|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
58121607|NCT04561128|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels
58121608|NCT02027779|BIOLOGICAL|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
58121609|NCT02027779|BIOLOGICAL|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
58450351|NCT04358302|BEHAVIORAL|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
57747672|NCT01437826|DRUG|placebo|placebo had an identical appearance as intervention
58121610|NCT02505854|DIETARY_SUPPLEMENT|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
58121611|NCT02505854|DIETARY_SUPPLEMENT|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
58121612|NCT02505854|DIETARY_SUPPLEMENT|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
57747673|NCT03227679|OTHER|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
57747674|NCT03227679|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
57747675|NCT03227679|DRUG|Bupropion|FDA-approved smoking cessation pharmacotherapy
57747676|NCT03227679|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
58121613|NCT04414215|BEHAVIORAL|Emotional working memory training|Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
58121614|NCT04414215|BEHAVIORAL|Placebo working memory training|Working memory training that does not involve emotional stimuli using an N-back training program
58121615|NCT05053893|DRUG|Roxadustat;Sacubitril Valsartan Sodium Tablets;|Select the appropriate dose according to the patient's situation
58121616|NCT05053893|DRUG|EPO; ACEI / ARB|Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
58121617|NCT03081715|OTHER|PD-1 Knockout T Cells|Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
58121618|NCT01919879|DRUG|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
58121619|NCT01919879|DRUG|Cetuximab|Cetuximab administered intravenously
58121620|NCT03646981|DEVICE|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
58121621|NCT04893148|DRUG|IGlarLixi|Changing to iGlarLixi from insulin glargine
58121622|NCT04893148|DRUG|Dulaglutide|Add dulaglutide to insulin glargine
58121623|NCT00772564|DRUG|Atorvastatin|Oral Atorvastatin
58121624|NCT00003961|BIOLOGICAL|sargramostim|
58121625|NCT02236533|DIETARY_SUPPLEMENT|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
58121626|NCT04511559|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.
58121627|NCT04511559|DIAGNOSTIC_TEST|tissue DNA Methylation Sequencing|Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
58121628|NCT04126057|DEVICE|SightGlass Vision DOT Spectacle Lenses|Subjects randomized to test vs control, left eyes and right eyes
58121629|NCT04125628|BEHAVIORAL|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
58121630|NCT04125628|BEHAVIORAL|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
58121631|NCT04497428|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
58121632|NCT04497428|OTHER|cTBS|continuous theta-burst stimulation
58121633|NCT06241898|DRUG|BB-1709|Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
58121634|NCT01573065|BEHAVIORAL|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
58121635|NCT05881148|OTHER|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
58121636|NCT05881148|OTHER|Standard carbon-free sprinting spiked-shoes|cf
58121637|NCT01433835|DRUG|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
58450352|NCT04380389|DIAGNOSTIC_TEST|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
58121638|NCT01433835|OTHER|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
58121639|NCT05016349|DRUG|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
58121640|NCT05016349|DRUG|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
58121641|NCT05016349|DRUG|Mifepristone|Mifepristone 200mg capsules daily for 28 days
58121642|NCT05016349|DRUG|Cannabidiol|Liquid taken orally for daily for 28 days
58121643|NCT05016349|DRUG|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
58450353|NCT02228317|DEVICE|Telemedicine consultation|Telemedicine consultation done by telephone or video
57959168|NCT05196659|BEHAVIORAL|Integrated comprehensive cardiovascular disease management|"1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   - individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team"
57959169|NCT02790151|BEHAVIORAL|Standard Therapy|Learning and practicing Memory strategies
57959170|NCT02790151|BEHAVIORAL|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
57959171|NCT00887237|DEVICE|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
57959172|NCT00887237|DEVICE|Conventional cardiac resynchronization|Conventional cardiac resynchronization
57959173|NCT05056025|DIETARY_SUPPLEMENT|Postbotics and Vitamins|2 capsule 3 times a day, before meals
58450354|NCT01127243|PROCEDURE|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
57959174|NCT05056025|DIETARY_SUPPLEMENT|Vitamins|2 capsule 3 times a day, before meals
57959175|NCT03048422|DRUG|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
57959176|NCT03048422|DRUG|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
57959177|NCT03048422|DRUG|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
58121644|NCT05016349|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
58121645|NCT05016349|DRUG|Standard therapy|Patients will receive the approved standard therapy tamoxifen
58450355|NCT01127243|PROCEDURE|inpatient LSH|patients discharged home the day after the operation
58450356|NCT02089919|BIOLOGICAL|cancer stem cell vaccine|
58450357|NCT00040170|BIOLOGICAL|MVA-MUC1-IL2|
58450358|NCT06550219|DEVICE|Nasal humidified heated high flow cannula (NHHHC)|Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.
58458695|NCT00918385|DRUG|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
57959178|NCT03048422|DRUG|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
58121646|NCT03337178|BEHAVIORAL|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
58121647|NCT03337178|BEHAVIORAL|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
58121648|NCT05681624|OTHER|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
58121649|NCT05681624|OTHER|Room air|Room air, no mask
58121650|NCT06130956|DIETARY_SUPPLEMENT|Vegan diet|Vegan diet for 2 weeks before surgery
58121651|NCT06130956|DIETARY_SUPPLEMENT|Omnivorous diet|Omnivorous diet for 2 weeks before surgery
58121652|NCT02605109|OTHER|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
58121653|NCT06544551|DRUG|Peginterferon Alfacon-2|Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
58121654|NCT06544551|DRUG|Peginterferon Alfacon-2 placebo|Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
58121655|NCT05503004|BEHAVIORAL|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
58121656|NCT05503004|BEHAVIORAL|Standard care|Standard care before surgery
58121657|NCT05654779|BIOLOGICAL|LCAR-AMDR Cells Product|Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
58121658|NCT06484036|PROCEDURE|periodontal treatment strategy|Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
58121659|NCT01933295|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
58121660|NCT01933295|BEHAVIORAL|Sleep Education|
58121661|NCT01933295|BEHAVIORAL|Sleep Restriction Therapy|
58121662|NCT03267056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
58121663|NCT00743067|DRUG|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
58121664|NCT02507375|DRUG|Erlotinib|Erlotinib will be administered as oral tablets.
58121665|NCT02507375|DRUG|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
58121666|NCT04820608|DEVICE|Cross-linking|Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
58121667|NCT01701284|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
58121668|NCT05263232|OTHER|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
58450359|NCT06550219|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV)|Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.
58121669|NCT02663596|DRUG|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
58121670|NCT03199248|PROCEDURE|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
58450360|NCT06550219|DEVICE|Nasal continuous positive airway pressure NCPAP|Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
58450361|NCT06550219|DEVICE|lung ultrasound|Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
58450362|NCT00410761|DRUG|ZD6474 (Vandetanib)|once daily oral tablet
58121671|NCT01055249|DRUG|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
58121672|NCT01055249|DRUG|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
58121673|NCT03757962|OTHER|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
58121674|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
58121675|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
58121676|NCT01197963|PROCEDURE|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
58450363|NCT02412098|DRUG|Eleclazine|Eleclazine tablets administered orally
58450364|NCT05809609|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
58450365|NCT05809609|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
58458696|NCT01476059|OTHER|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
58121677|NCT01197963|DIETARY_SUPPLEMENT|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
58121678|NCT00765700|DRUG|Topical Ketoprofen 10% Cream|Topical Administration
58121679|NCT00765700|DRUG|Topical Placebo Cream|Topical Administration
58121680|NCT01633827|DRUG|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
58121681|NCT01633827|DRUG|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
58121682|NCT01633827|OTHER|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
58121683|NCT01633827|OTHER|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
58121684|NCT04879420|DRUG|Teriparatide|Teriparatide dispensing claim is used as the reference group.
58121685|NCT04879420|DRUG|Risedronate|Risedronate dispensing claim is used as the exposure group.
57747677|NCT06202833|DEVICE|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
57747678|NCT06202833|DEVICE|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
58121686|NCT00901628|DRUG|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
58121687|NCT00901628|DRUG|morphine sulfate|10mg intraoperative periarticular injection
58314032|NCT02321527|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
58450366|NCT05053659|DRUG|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
58450367|NCT05053659|DRUG|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
58121688|NCT00901628|DRUG|ketorolac|30 mg intraoperative periarticular injection
58121689|NCT00901628|DRUG|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
58121690|NCT00901628|DRUG|cefuroxime|750mg intraoperative periarticular injection
58121691|NCT06227975|DRUG|[14C]-BMS-986368|Specified dose on specified days
58121692|NCT01807871|DRUG|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
58121693|NCT01807871|DRUG|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
58121694|NCT00042497|BIOLOGICAL|autologous dexosomes loaded with tumor-specific peptides|
58314033|NCT02321527|DEVICE|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
58314034|NCT02321527|PROCEDURE|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
58314035|NCT02321527|BEHAVIORAL|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
58450368|NCT04699656|DRUG|Plazomicin Injection|single dose of plazomicin
58458697|NCT01476059|OTHER|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
58458698|NCT03189186|DRUG|Pembrolizumab Injection [Keytruda]|Same as arm description
58121695|NCT04381884|DRUG|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
58121696|NCT05313204|OTHER|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
58121697|NCT00135707|DRUG|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
58121698|NCT00135707|DRUG|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
58121699|NCT01727245|OTHER|Obese|gastric bypass
58121700|NCT01727245|OTHER|Control group|Cholecystectomy and anti-reflux surgery
57959179|NCT00743379|DRUG|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
57959180|NCT02164981|DRUG|sodium nitroprusside|intravenous
57959181|NCT02164981|OTHER|Placebo|Placebo
57959182|NCT03714945|OTHER|No intervention|No intervention is required as this study is observational.
57959183|NCT00733707|BEHAVIORAL|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
57959184|NCT02953535|DRUG|Magicbuvir|1 tablet contains 400 mg sofosbuvir
57959185|NCT02953535|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
57959186|NCT02953535|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
57959187|NCT01233973|OTHER|video decision aid|video
57959188|NCT03926221|BEHAVIORAL|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
57959189|NCT05287009|PROCEDURE|ILM nonpeeling|ILM is not peeled after ERM removal
57959190|NCT05287009|PROCEDURE|ILM peeling|ILM is peeled after ERM removal
57959191|NCT04029519|DEVICE|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
57959192|NCT02542761|DEVICE|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
57959193|NCT02542761|DEVICE|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
57959194|NCT05199259|DIAGNOSTIC_TEST|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
57959195|NCT00336947|DRUG|tegafur-gimeracil-oteracil potassium|
57959196|NCT00336947|DRUG|tegafur-uracil|
57959197|NCT00336947|PROCEDURE|adjuvant therapy|
57959198|NCT06173193|BEHAVIORAL|Multicomponent exercise regimen|"A multicomponent exercise regimen applied is comprised of the step-aerobic and resistance training programs alternating every two weeks. The trainees participate in supervised training sessions 3 times a week for 8 months. Each session will include a 10-minutes warm-up, 30-minutes of effective training part and a 10-minutes period for cooling down.~Step-aerobic: The program includes accelerating and decelerating through forwards and sideways movements with stops and turns to music. The degree of difficulty of movements and steps as well as training intensity will be gradually increased by increasing the height of the step benches.~Resistance training: The participants will undergo a progressive resistance training program. Resistance training will emphasize training of following muscle groups: Quadriceps and hamstrings, hip abductors, adductors and extensors, and calf muscles. In addition to lower limb exercises, trunk and upper body exercises will be applied at intervals."
57959199|NCT06173193|BEHAVIORAL|Standard rehabilitative management|The treatments that will be provided to the members of a reference group represent the standard rehabilitative management for knee OA patients. The home exercises focus on functional exercises maintaining lower extremity flexibility and muscle function. The home exercises are instructed to be carried out three times a week, each work-out lasting 30 minutes.
57959200|NCT00687362|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
57959201|NCT00777569|DRUG|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
57959202|NCT00777569|DRUG|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
57959203|NCT00777569|DRUG|Nicotine Lozenge|4 mg nicotine lozenge
57959204|NCT00488982|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days
57959205|NCT00488982|DRUG|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
57959206|NCT01107431|DIETARY_SUPPLEMENT|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
57959207|NCT01107431|DIETARY_SUPPLEMENT|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
57959208|NCT03098836|DRUG|ARN-509|240 mg orally daily
57747679|NCT05347264|OTHER|gun massager|15 to 20 minutes along with hot pack.
57747680|NCT05347264|OTHER|transverse friction massage|15 to 20 minutes along with hot pack.
57959209|NCT03098836|DRUG|Abiraterone Acetate|1000 mg orally daily
57959210|NCT03098836|DRUG|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
57959211|NCT02944630|BEHAVIORAL|Psychotherapy|Individual psychotherapy
57959212|NCT01127165|DRUG|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.
57959213|NCT01127165|DRUG|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
57959214|NCT02686593|DRUG|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
57959215|NCT04934787|DEVICE|ENMS-BSF assisted gait training|"1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
57959216|NCT02199197|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
57959217|NCT02199197|DRUG|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
57959218|NCT04170517|DIAGNOSTIC_TEST|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
57959219|NCT06437678|DRUG|Liposomal Irinotecan Hydrochloride|Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
58121701|NCT04447274|DRUG|Camrelizumab and Apatinib|Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
58121702|NCT03654456|BIOLOGICAL|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
58121703|NCT03538236|DEVICE|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
58121704|NCT03538236|BEHAVIORAL|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
58121705|NCT03742531|DRUG|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
57959220|NCT05754840|DRUG|MPL-001|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
58121706|NCT02524379|DRUG|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
58121707|NCT00265759|DRUG|anastrozole|Given PO
58121708|NCT00265759|DRUG|exemestane|Given PO
58121709|NCT00265759|DRUG|letrozole|Given PO
58121710|NCT00265759|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
58121711|NCT04459481|DEVICE|bending angle|patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
58121712|NCT01994603|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
58121713|NCT01994603|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
58121714|NCT02326428|DEVICE|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
58121715|NCT02326428|DRUG|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
58121716|NCT01761357|OTHER|answering to questionnaires of quality of live|
58121717|NCT04130256|DEVICE|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
58450369|NCT04868617|DEVICE|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
58450370|NCT06048159|DEVICE|HD-tACS|High definition tACS will be applied during speech therapy.
58450371|NCT06048159|DEVICE|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
58450372|NCT00200330|BEHAVIORAL|Behavioral weight loss treatment|
58450373|NCT00200330|BEHAVIORAL|Behavioral and home environment weight loss treatment|
58121718|NCT05463861|DRUG|Lemborexant|Lemborexant tablet administered orally once daily.
58450374|NCT05072730|DEVICE|Super High Pressure Balloon (OPN NC)|"Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion."
58458699|NCT03189186|PROCEDURE|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
57959221|NCT05754840|DRUG|MPL-005|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
57959222|NCT05754840|DRUG|MPL-009|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
58121719|NCT05463861|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily.
58121720|NCT01630200|DRUG|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
58121721|NCT01630200|DRUG|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
58121722|NCT04468919|BEHAVIORAL|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
58121723|NCT04468919|BEHAVIORAL|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
58121724|NCT04468919|BEHAVIORAL|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
58121725|NCT04468919|BEHAVIORAL|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
58121726|NCT00719784|DEVICE|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
58121727|NCT03019393|OTHER|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
58121728|NCT05973227|DEVICE|use of the TRIDENT system|usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
58121729|NCT02577159|DRUG|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
58121730|NCT03664856|OTHER|interview|The patient will be asked to answer the questions that the interviewer will ask him.
58121731|NCT01698996|PROCEDURE|Packing vs No Packing|
57747681|NCT06481748|OTHER|Batman|"The investigators foresee several teams engaged throughout the day to ensure greater variability, each team will consist of three students for the experimental condition (Batman; pregnant girl, observer) and two students for the control condition (pregnant girl and observer), plus the presence in both cases of a member of the research team. The 'pregnant girl' will be properly prepared and equipped with a sponge prosthesis to simulate pregnancy. In addition, the subject dressed as Batman must be prepared to play the role in a natural and non-invasive manner. During this phase, the student observers collaborating in the study will carefully record the behavior of the passengers in the underground."
58121732|NCT04921033|DIETARY_SUPPLEMENT|EEN (Nestle Modulen®)|35kcal/kg/day for every patient
57959223|NCT05593900|BEHAVIORAL|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
57747682|NCT04369014|DRUG|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
57959224|NCT01965132|DRUG|Biologic or targeted synthetic DMARD|
57959225|NCT05954442|DRUG|Everolimus|Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .
57959226|NCT05954442|DRUG|Investigator's Choice of Chemotherapy|Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
57959227|NCT02806323|OTHER|Yoga practice|
57959228|NCT03428165|OTHER|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
57959229|NCT04001816|OTHER|Orthodontic Brackets|Self ligating and Conventional brackets
57959230|NCT04462952|DRUG|Adavosertib (AZD1775)|Adavosertib taken orally
57959231|NCT02918773|DEVICE|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
57959232|NCT02918773|DEVICE|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
57959233|NCT04091997|DIAGNOSTIC_TEST|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
57959234|NCT02706808|DIETARY_SUPPLEMENT|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
57959235|NCT02706808|DIETARY_SUPPLEMENT|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
57959236|NCT03938805|BEHAVIORAL|Internet-based cognitive behavioral therapy for insomnia|Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
57959237|NCT03938805|OTHER|Control group|Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
57959238|NCT00603759|DRUG|celecoxib|100 mg qid
57959239|NCT00603759|DRUG|placebo|1 cap qid
57959240|NCT05067842|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
57959241|NCT05102643|BIOLOGICAL|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
57959242|NCT05102643|BIOLOGICAL|Matching placebo|Solution for intramuscular injection
57959243|NCT01992783|DIETARY_SUPPLEMENT|Hi-maize resistant starch|13.5 g/day
57959244|NCT01992783|DIETARY_SUPPLEMENT|Maltodextrin|13.5 g/day
57959245|NCT04010500|DEVICE|no mouthguard|Control (not using mouthguard)
58121733|NCT04921033|DRUG|Standart of care|"* Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
58121734|NCT06349720|BEHAVIORAL|respiratory rehabilitation|"Emote respiratory rehabilitation:Patients wear monitoring devices and upload real-time monitoring data such as vital signs through the FREE rehabilitation app installed on their personal phones. Medical staff monitor changes in patients' vital signs in real time through the FREE rehabilitation app on the medical end, and adjust respiratory rehabilitation plans based on their phone or video guidance.~Outpatient respiratory rehabilitation:Traditional outpatient respiratory rehabilitation is based on a group approach, with individualized intensity determined based on baseline assessment results, and is conducted under supervision twice a week for a period of 12 weeks."
58121735|NCT01604421|PROCEDURE|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
58121736|NCT01604421|PROCEDURE|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
58121737|NCT05697809|DRUG|OXU-001|Suprachoroidal sustained release dexamethasone acetate
58121738|NCT05697809|DEVICE|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
58121739|NCT05697809|DRUG|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
58121740|NCT00796510|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
58121741|NCT00796510|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
58121742|NCT04469608|BEHAVIORAL|acupuncture|Traditional Chinese medicine clinical daycare
58121743|NCT02901899|DRUG|Guadecitabine|Given SC
58121744|NCT02901899|OTHER|Laboratory Biomarker Analysis|Correlative studies
58121745|NCT02901899|BIOLOGICAL|Pembrolizumab|Given IV
58121746|NCT00719381|DRUG|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
58121747|NCT02180308|DEVICE|PET/MRI|Simultaneous PET/MRI (3T system)
58121748|NCT01809613|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
58121749|NCT02139514|BEHAVIORAL|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
58121750|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
58121751|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
58121752|NCT01797120|DRUG|Fulvestrant|"Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
58121753|NCT01797120|DRUG|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
58121754|NCT01797120|DRUG|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
58121755|NCT02473978|DEVICE|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
58121756|NCT05177757|OTHER|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
58121757|NCT03243539|PROCEDURE|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
58121758|NCT04043845|DRUG|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
58121759|NCT04043845|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
58121760|NCT05721144|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
58121761|NCT05659550|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
58121762|NCT05699356|OTHER|Non Surgical treatment|Non Surgical
57747683|NCT04369014|DRUG|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
58121763|NCT05699356|PROCEDURE|laparoscopic drilling|Surgical intervension
58121764|NCT05699356|BEHAVIORAL|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
58121765|NCT05699356|PROCEDURE|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
58121766|NCT03301675|OTHER|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
58121767|NCT00194103|BEHAVIORAL|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
58121768|NCT00194103|BEHAVIORAL|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
58121769|NCT05215899|OTHER|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
58121770|NCT05137080|DRUG|Dexamethasone|24mg dexamethasone
58121771|NCT05137080|DRUG|Isotonic saline|Isotonic saline
58121772|NCT05306379|DRUG|Simvastatin|Oral dose 40 mg
58121773|NCT05306379|DRUG|Voclosporin|Oral dose 23.7 mg twice daily
58121774|NCT01817556|DRUG|Stillen Tab.|
58121775|NCT01817556|DRUG|Mucosta Tab.|
58121776|NCT05084742|DEVICE|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
58121777|NCT03761433|DEVICE|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
58450375|NCT05072730|DEVICE|Intravascular lithotripsy (IVL)|"Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion."
58450376|NCT01635595|PROCEDURE|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
58450377|NCT01635595|PROCEDURE|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
58450378|NCT03847935|PROCEDURE|surgery|A1 pulley release of finger
58450379|NCT03847935|PROCEDURE|corticosteroid injections|corticosteroid injection to A1 pulley
58450380|NCT03847935|OTHER|Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
58450381|NCT03847935|OTHER|Modality Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
58314036|NCT04161196|PROCEDURE|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
58314037|NCT04161196|PROCEDURE|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
58121778|NCT04122105|DRUG|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
58121779|NCT06357026|DEVICE|Percutaneous Ventricular Assist System（Phigine Medical）|Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.
58121780|NCT06357026|DEVICE|intra-aortic balloon pump (IABP)|IABP provides intraoperative circulatory support during high-risk PCI.
58121781|NCT03034083|BEHAVIORAL|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
58121782|NCT01752348|OTHER|Endotoxin, US standard reference E.coli|
58121783|NCT02390622|OTHER|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
58121784|NCT03028662|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
58121785|NCT04210895|OTHER|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
58450382|NCT05366634|BIOLOGICAL|MDK-703 or Placebo|Injection
58450383|NCT01387126|DIETARY_SUPPLEMENT|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
58450384|NCT04973072|BEHAVIORAL|One large reward treatment|Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
58458700|NCT03189186|PROCEDURE|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
58121786|NCT04210895|OTHER|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
58121787|NCT00522457|DRUG|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
58121788|NCT05636878|OTHER|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
58121789|NCT01479452|PROCEDURE|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
58121790|NCT01479452|OTHER|Usual care|Non-surgical obesity treatment
58121791|NCT00004376|DRUG|guanfacine|
58121792|NCT04605510|OTHER|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
58121793|NCT06386497|DEVICE|Nocturnal translational vestibular stimulation|Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.
58121794|NCT00003536|DRUG|antineoplaston A10|
58121795|NCT00003536|DRUG|methotrexate|
58121796|NCT00003536|PROCEDURE|alternative product therapy|
58121797|NCT00003536|PROCEDURE|biological therapy|
58121798|NCT00003536|PROCEDURE|biologically based therapies|
58121799|NCT00003536|PROCEDURE|cancer prevention intervention|
58121800|NCT00003536|PROCEDURE|chemotherapy|
58121801|NCT00003536|PROCEDURE|complementary and alternative therapy|
58121802|NCT00003536|PROCEDURE|differentiation therapy|
58121803|NCT05210023|OTHER|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
58121804|NCT05210023|OTHER|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
58121805|NCT03279679|PROCEDURE|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
58121806|NCT03279679|PROCEDURE|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
58121807|NCT03279679|DEVICE|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
58121808|NCT03279679|DRUG|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
58121809|NCT00829413|DRUG|SonoVue®|SonoVue (2.4 mL)
58121810|NCT04936971|DRUG|Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm|Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
58121811|NCT04936971|OTHER|no intervention|Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
58121812|NCT06169098|PROCEDURE|Auricular acupressure on the left ear|Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
58121813|NCT06169098|PROCEDURE|Auricular acupressure on the right ear|Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
58121814|NCT06169098|PROCEDURE|Sham auricular acupressure|Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
58121815|NCT02103088|BEHAVIORAL|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
58121816|NCT00805909|DRUG|NI-0401|5 daily infusions with escalating doses of NI-0401
58121817|NCT05650788|DIAGNOSTIC_TEST|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
58121818|NCT01474226|DIETARY_SUPPLEMENT|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
58458701|NCT03243851|DRUG|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
58458702|NCT03243851|DRUG|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
57747684|NCT00372281|DRUG|Cliavist|Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
57747685|NCT05477082|OTHER|Observational group|Includes blood draws and data collection only
57747686|NCT03175770|PROCEDURE|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
57747687|NCT06329492|BIOLOGICAL|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
57959246|NCT04010500|DEVICE|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
57959247|NCT04010500|DEVICE|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
57959248|NCT00239876|DRUG|FTY720|
57961481|NCT05827029|PROCEDURE|Preopertive drink|"* Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
57961482|NCT00246532|DRUG|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
57961483|NCT00246532|DRUG|Placebo|Patients will receive placebo tablets.
57961484|NCT05864976|DEVICE|Support Vector Machine|Machine learning algorithm
57961485|NCT04668352|DRUG|Dactolisib|TORC1 inhibitor
57961486|NCT04668352|OTHER|Placebo|Placebo
57961487|NCT02926950|DRUG|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
57961488|NCT02926950|DRUG|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
57961489|NCT02926950|DRUG|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
57961490|NCT04840680|OTHER|No Intervention|This is a non-interventional study.
57747688|NCT02361515|RADIATION|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
57747689|NCT02361515|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
57747690|NCT05982769|BEHAVIORAL|Endurance Training 3 times per week|endurance training will be performed from home 3 times per week under the supervision of the research team.
57747691|NCT05982769|BEHAVIORAL|Resistance Exercise|resistance training will be performed from home 2 times per week under the supervision of the research team.
57747692|NCT05982769|BEHAVIORAL|Standard of Care|continue usual activity
57961491|NCT05206526|BEHAVIORAL|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
57961492|NCT05206526|BEHAVIORAL|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
57961493|NCT05816980|RADIATION|Hyperfractionated external beam radiation|40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
57961494|NCT00022529|DRUG|BMS-214662|Given IV
57961495|NCT00022529|BIOLOGICAL|trastuzumab|Given IV
57961496|NCT00022529|OTHER|pharmacological study|Correlative studies
57961497|NCT00608985|DRUG|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
57961498|NCT00608985|DRUG|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
57961499|NCT00608985|DRUG|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
57961500|NCT00608985|DRUG|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
57961501|NCT04665830|DRUG|Evolocumab|treated patients with evolocumab for high cholesterol
57961502|NCT03232476|DEVICE|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
57961503|NCT03183674|DRUG|Oxytocin|Single dose oxytocin 45 minutes before the test
57961504|NCT03183674|OTHER|placebo|saline solution 0,9% spray nasal
57961505|NCT01008280|DRUG|baclofen|baclofen 10 mg tid
57961506|NCT01008280|DRUG|placebo|placebo pill tid
57961507|NCT02381665|DEVICE|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
57961508|NCT02381665|DEVICE|Flexstim IF faked|Patient enrolled will receive a sham device.
58314038|NCT04398472|BEHAVIORAL|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
58314039|NCT01773369|BEHAVIORAL|Early leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
58314040|NCT01773369|BEHAVIORAL|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.
58450385|NCT04973072|BEHAVIORAL|Small wins treatment|The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
58450386|NCT04885335|OTHER|PAS (Pediatric Appendicitis Score) survey|Score ≤ 5: appendicitis unlikely. Score ≥ 6: probable appendicitis. core ≥ 7: very probable appendicitis
58450387|NCT02366312|DRUG|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
58450388|NCT02178761|DEVICE|drug-eluting balloon|angioplasty completed with drug-eluting balloons
58450389|NCT02178761|DEVICE|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
58450390|NCT02178761|DEVICE|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
58450391|NCT02178761|DEVICE|Stent System|stenting with either bare-metal stents or drug-eluting stents
58450392|NCT04640233|BIOLOGICAL|Gam-COVID-Vac|Vaccine for intramuscular injection
58450393|NCT04640233|OTHER|Placebo|Placebo comparator
57959249|NCT01469858|DEVICE|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
58450394|NCT05021770|DRUG|Orelabrutinib|150mg or 200mg orally daily
58450395|NCT05021770|DRUG|Orelabrutinib|RP2D
57747693|NCT04434560|DRUG|Nivolumab|Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
57959250|NCT02349698|BIOLOGICAL|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
58450396|NCT05021770|DRUG|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
58450397|NCT04081779|OTHER|Survivorship Care Plan|Receive patient-generated SCP
58450398|NCT04081779|OTHER|Educational Intervention|Receive telephone-based educational counseling session
58450399|NCT04081779|OTHER|Questionnaire Administration|Ancillary studies
58450400|NCT01390922|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
58450401|NCT03827655|DRUG|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
58450402|NCT03827655|DRUG|TAK-954|TAK-954 intravenous infusion.
58450403|NCT03573323|DRUG|Ixekizumab|Administered SC
57747694|NCT04434560|DRUG|Ipilimumab|Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
57747695|NCT04535947|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
57747696|NCT04535947|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
58450404|NCT03573323|DRUG|Guselkumab|Administered SC
58450405|NCT03573323|DRUG|Placebo|Administered SC
57747697|NCT04843930|DEVICE|AKL-T01|AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
57959251|NCT01060358|PROCEDURE|method (non-surgical) to measure neuromuscular neutral zones|
57959252|NCT00191594|DRUG|Duloxetine Hydrochloride|
57959253|NCT05970263|DRUG|Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.|2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
57961509|NCT05841758|DRUG|Hydroxychloroquine|Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
57961510|NCT05841758|DRUG|Placebo|Placebo during a 12 months double blind placebo-controlled period
57961511|NCT02844114|DRUG|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
57961512|NCT02844114|DRUG|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
57961513|NCT02844114|DRUG|Chemotherapy|iv.30 minutes
57961514|NCT02213601|BEHAVIORAL|Yoga|
57961515|NCT03365466|DRUG|Low dose aspirin|LDA 25mg tid
57961516|NCT03365466|DRUG|Low molecular weight heparin|LMWH 5000u IH qd
57961517|NCT03365466|DRUG|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
57961518|NCT03365466|DRUG|no treatment|Patients who did not receive any treatment.
58450406|NCT05471544|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
58121819|NCT01474226|DIETARY_SUPPLEMENT|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
58121820|NCT01844583|DRUG|Alisertib|Alisertib tablets
58121821|NCT01844583|DRUG|Esomeprazole|Esomeprazole capsules
58121822|NCT01844583|DRUG|Rifampin|Rifampin capsules
58121823|NCT01578174|DRUG|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
57747698|NCT06136390|OTHER|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
57747699|NCT06136390|OTHER|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
57747700|NCT00232492|DRUG|Placebo males|Intravenous saline bolus (Placebo-control) males
57959254|NCT05970263|OTHER|External Comparator|Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
57959255|NCT03546075|DIETARY_SUPPLEMENT|Resveratrol|
57959256|NCT03546075|OTHER|Placebo|
57959257|NCT06392880|OTHER|Floss Band|A floss band will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
57959258|NCT06392880|OTHER|Mulligan Mobilization|Mulligan mobilization will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
57959259|NCT06392880|OTHER|Control|Participants will practice various weight-bearing active ankle motions simultaneously.
57747701|NCT00232492|DRUG|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
57747702|NCT00232492|DRUG|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
57747703|NCT00232492|DRUG|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
57959260|NCT02123485|DEVICE|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
57959261|NCT02123485|DEVICE|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
57959262|NCT04986709|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
57959263|NCT05988151|OTHER|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
57961519|NCT01430442|DRUG|Rimegepant|Rimegepant capsules
57961520|NCT01430442|DRUG|Placebo|Rimegepant placebo-matching capsules
57961521|NCT01430442|DRUG|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
57961522|NCT00002350|BIOLOGICAL|APL 400-003|
57961523|NCT02918019|DRUG|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
57961524|NCT02918019|DRUG|Placebo|Placebo matched with MSTT1041A.
57961525|NCT01306227|DRUG|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
57961526|NCT01306227|DRUG|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
57961527|NCT00144482|DRUG|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
57961528|NCT00144482|DRUG|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
57961529|NCT02585011|DRUG|Ropivacaine|
57961530|NCT02585011|DRUG|Epinephrine|
57961531|NCT02585011|DRUG|Saline|
57961532|NCT05396274|DEVICE|High Flow Nasal Cannula|high flow nasale cannula
57961533|NCT03521505|DRUG|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration
57961534|NCT03521505|DRUG|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration."
57961535|NCT02780882|DRUG|Pasireotide|
57961536|NCT00976066|DRUG|Part A Assessing GSK1521498|"Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
57961537|NCT00976066|DRUG|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
58121824|NCT01578174|DRUG|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
58121825|NCT04165720|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
58121826|NCT03185897|OTHER|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
58121827|NCT04060823|OTHER|Easy Breathing program|Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
58121828|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
58121829|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
58121830|NCT03249181|DRUG|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
58121831|NCT03249181|DRUG|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
58121832|NCT02497833|DIETARY_SUPPLEMENT|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
58121833|NCT02497833|OTHER|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
58121834|NCT01572766|OTHER|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
58121835|NCT05789277|OTHER|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging"
58121836|NCT05789277|OTHER|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
58121837|NCT02010411|DRUG|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
58314041|NCT01773369|BEHAVIORAL|Parent leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
58314042|NCT01555593|DEVICE|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
58314043|NCT01820832|DRUG|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
57747704|NCT00232492|DRUG|Placebo females|Intravenous saline bolus (Placebo-control) females
57747705|NCT00232492|DRUG|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
57747706|NCT00232492|DRUG|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
57959264|NCT01489514|OTHER|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~1. Histamine control purchased from Greer.~2. Saline control purchased from Greer.~3. Standard Peanut Extract purchased from Greer.~4. Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A \& T.~5. Sterile extract prepared from roasted \& blanched but untreated peanuts. This is prepared by North Carolina A \& T.~6. Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A \& T. This is not classified as a drug and is~7. Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~8. Sterile extracts containing peanuts that have been treated with alcalase"
57747707|NCT00232492|DRUG|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
57747708|NCT04308564|DIAGNOSTIC_TEST|Blood test|Blood test for the identification of biomarkers
57747709|NCT02909348|DRUG|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
57959265|NCT06344078|PROCEDURE|sigmoid resection and anastomosis / stoma|intestinal resection and recostruction or creation of stoma
57959266|NCT00085371|DRUG|triapine|Given IV
57959267|NCT05654129|OTHER|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
57959268|NCT05654129|OTHER|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
57959269|NCT02926209|DEVICE|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
57959270|NCT02926209|PROCEDURE|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
57959271|NCT05449600|DEVICE|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
58314044|NCT04800497|PROCEDURE|Hepatic resection|Hepatic resection for HCC
58450407|NCT05471544|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
58450408|NCT00584415|DEVICE|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
58450409|NCT06164665|DRUG|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
58450410|NCT06164665|OTHER|Placebo|100% microcrystalline cellulos
58450411|NCT01167374|RADIATION|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
58450412|NCT04450940|BEHAVIORAL|PACV survey|
58450413|NCT04450940|BEHAVIORAL|Placebo survey|
58450414|NCT03393494|DRUG|Adapalene and Benzoyl Peroxide Topical Gel|Test product
57959272|NCT05449600|DEVICE|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
57959273|NCT05449600|DEVICE|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
57959274|NCT01016639|OTHER|oxaliplatin, capecitabine, radiotherapy|
57959275|NCT01920204|DRUG|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
57959276|NCT03330886|DRUG|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
57959277|NCT01687712|DRUG|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
57959278|NCT01687712|DRUG|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
57959279|NCT04231383|OTHER|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
57959280|NCT02937350|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
57959281|NCT01489527|BIOLOGICAL|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
57959282|NCT01489527|OTHER|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
57959283|NCT02158780|PROCEDURE|Scrotal Orchidopexy|Single incision
57959284|NCT02158780|PROCEDURE|Inguinal Orchidopexy|Double Incision (Standard)
57959285|NCT00006112|DRUG|chemotherapy|
57959286|NCT00006112|DRUG|fluorouracil|
57959287|NCT00006112|DRUG|leucovorin calcium|
57959288|NCT00006112|DRUG|mitomycin C|
57959289|NCT02800200|PROCEDURE|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
57959290|NCT02800200|DEVICE|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
57959291|NCT01819779|DRUG|Exforge tab. 10/160mg|
57959292|NCT01819779|DRUG|Lodivixx tab. 5/160mg|
57959293|NCT00144183|DRUG|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
57959294|NCT00144183|DRUG|Zidovudine (ZCV)|
57959295|NCT00144183|DRUG|3TC|
57959296|NCT02190851|DEVICE|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
57959297|NCT02190851|DEVICE|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
57959298|NCT03178487|DRUG|Upadacitinib|Tablet
57959299|NCT03178487|DRUG|Placebo|Tablet
57959300|NCT04208477|PROCEDURE|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
58314045|NCT06197490|BIOLOGICAL|Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation|Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
57959301|NCT04492683|COMBINATION_PRODUCT|DBV1605|"Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation."
58314046|NCT06197490|DRUG|Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation|Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
58450415|NCT03393494|DRUG|Epiduo Topical Product|RLD product
58450416|NCT03393494|DRUG|Placebo|Placebo gel
58450417|NCT04014062|COMBINATION_PRODUCT|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
58450418|NCT04014062|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
58450419|NCT02611817|DRUG|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
58450420|NCT02611817|DRUG|Placebo|Vedolizumab placebo-matching SC injection.
58450421|NCT02611817|DRUG|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
57959302|NCT04824586|DRUG|Fast-acting human insulin|Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
57959303|NCT02686086|DEVICE|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
57959304|NCT02686086|DEVICE|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
57959305|NCT02686086|DRUG|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
57959306|NCT03453983|DEVICE|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
57959307|NCT04669834|OTHER|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
57959308|NCT04669834|OTHER|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
57959309|NCT02669017|DRUG|ADCT-402|intravenous infusion
57959310|NCT03368651|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
57959311|NCT02901288|DRUG|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
57959312|NCT02901288|DRUG|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
57959313|NCT02901288|DRUG|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
57959314|NCT02901288|DRUG|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
57959315|NCT02901288|DRUG|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
57959316|NCT03927105|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
57959317|NCT03927105|DRUG|cabiralizumab|Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
57959318|NCT02204696|PROCEDURE|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
57959319|NCT01425203|DRUG|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
57959320|NCT01425203|DRUG|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
57959321|NCT01425203|BIOLOGICAL|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
57959322|NCT01425203|DRUG|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
57959323|NCT04953312|BIOLOGICAL|Blood samples|blood
57959324|NCT01637233|DRUG|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
57959325|NCT01637233|DRUG|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
57959326|NCT01637233|DRUG|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
57959327|NCT02859935|BEHAVIORAL|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
57959328|NCT03252483|OTHER|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
57959329|NCT03252483|OTHER|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
57959330|NCT00653822|DRUG|alefacept|IC and SC
57959331|NCT00653822|DRUG|placebo|IV and SC
57959332|NCT00415779|DRUG|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
57959333|NCT00415779|DRUG|zoledronic acid|2 mg IV every 2 weeks
58314047|NCT00789165|DRUG|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
58314048|NCT00789165|DRUG|no therapy|No therapy; this is not a placebo-controlled trial
58450422|NCT00754377|OTHER|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
58450423|NCT02257229|PROCEDURE|Surgical|Surgery only
58450424|NCT02257229|PROCEDURE|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
58450425|NCT02257229|PROCEDURE|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
58450426|NCT00311935|PROCEDURE|method of hernia repair|
58450427|NCT01220167|DRUG|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
58450428|NCT01220167|DRUG|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
58450429|NCT01220167|DRUG|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
58450430|NCT04915443|DEVICE|Periotome|"Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth."
58450431|NCT04915443|DEVICE|Piezotome|"Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL."
58450432|NCT05458206|OTHER|mulligan snag mobilization and diaphragmatic release|"The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement"
57959334|NCT05512533|DEVICE|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
58314049|NCT00193648|DRUG|Rosiglitazone (Avandia)|oral drug administration
58450433|NCT04399395|DRUG|Naltrexone/bupropion|Approved drug for obesity treatment
58450434|NCT04399395|OTHER|Lifestyle|Lifestyle
58450435|NCT03501732|BEHAVIORAL|Values Affirmation|Experimental Group selects two values and describes why they are important
58450436|NCT03501732|BEHAVIORAL|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
58450437|NCT00075621|DRUG|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
57959335|NCT00381771|BEHAVIORAL|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
57959336|NCT06149858|PROCEDURE|hernioplasty|ventral hernia repair with mesh
57959337|NCT02672566|DRUG|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
57959338|NCT02672566|OTHER|Usual care|Patients will all benefit from the usual care
57959339|NCT01736579|DRUG|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
57959340|NCT01635114|DIETARY_SUPPLEMENT|resveratrol|150 mg resVida per day for 12 weeks
57959341|NCT01635114|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
57959342|NCT00940355|BEHAVIORAL|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
57959343|NCT02133989|DRUG|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
57959344|NCT02133989|DRUG|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
57959345|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
57959346|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
57959347|NCT05120310|BEHAVIORAL|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
57959348|NCT03351257|OTHER|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
57959349|NCT04596475|DRUG|glecaprevir/pibrentasvir (GLE/PIB)|The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
58314050|NCT00193648|DRUG|Adalimumab (Humira)|Injection of drug biweekly
58314051|NCT01543854|DRUG|RLX030|Intravenous infusion of RLX030 over 20 hrs
58314052|NCT01543854|DRUG|Placebo|Intravenous infusion of placebo over 20 hours
58314053|NCT00191750|DRUG|Pemetrexed|
58314054|NCT01703468|DRUG|Oxcarbazepine|
58314055|NCT03715647|OTHER|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
58314056|NCT03715647|OTHER|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
58314057|NCT03715647|OTHER|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
58121838|NCT04388891|DEVICE|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
58121839|NCT00810732|DRUG|Open|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
58121840|NCT00810732|DRUG|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
58121841|NCT00810732|DRUG|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
58121842|NCT01455753|OTHER|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
58121843|NCT01455753|OTHER|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
58121844|NCT04656977|OTHER|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
58121845|NCT04656977|OTHER|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
58121846|NCT05783583|DEVICE|Remote Digital Slit Lamp|Slit Lamp Examination
58121847|NCT02453425|OTHER|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
58121848|NCT02453425|OTHER|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
58121849|NCT02453425|OTHER|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
58121850|NCT06341088|PROCEDURE|unilateral suture sacro-hysteropexy|patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.
58121851|NCT06341088|PROCEDURE|bilateral suture sacro-hysteropexy|patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable suture and bilaterally suspended to the anterior longitudinal ligament.
58450438|NCT00075621|DRUG|melphalan|200 mg/kg over 2 days
58121852|NCT05593198|PROCEDURE|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
58121853|NCT05593198|PROCEDURE|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
58121854|NCT04309409|DRUG|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
58121855|NCT05420506|DEVICE|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
58121856|NCT02946164|BEHAVIORAL|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
58121857|NCT01323348|BEHAVIORAL|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~* Measurement of HbA1c in office with immediate feedback~* Measurement of blood pressure with immediate feedback~* Assessment of retinopathy risk with immediate feedback~* Personalized risk assessment reports based on current HbA1c~* Brief assessment of patient understanding of key issues with immediate feedback~* Supplemental diabetes management educational materials (provided at baseline only)~* Feedback to primary care provider~* Email reminder to study participants with email access of individualized risk assessment findings"
58121858|NCT01539109|BEHAVIORAL|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
58121859|NCT01539109|PROCEDURE|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
58314058|NCT01311791|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
58314059|NCT01311791|DRUG|Standard medical therapy|as defined per protocol
58314060|NCT01724268|DRUG|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
58314061|NCT01724268|DRUG|Anti TNF + Meth|
58450439|NCT00075621|PROCEDURE|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
58450440|NCT03515824|BIOLOGICAL|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
58450441|NCT03455738|OTHER|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a \>10% decrease in mean arterial pressure (MAP).
58450442|NCT06024486|DIAGNOSTIC_TEST|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
58450443|NCT02718729|PROCEDURE|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
58450444|NCT05705466|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
58450445|NCT05705466|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
58450446|NCT05705466|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
58450447|NCT03178383|BEHAVIORAL|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
58450448|NCT03178383|BEHAVIORAL|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
58450449|NCT05425329|DIETARY_SUPPLEMENT|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
58450450|NCT05425329|DIETARY_SUPPLEMENT|Placebo treatment|Capsule containing maltodextrin.
58450451|NCT04098809|DEVICE|16 French urinary catheter|16 French urinary catheter
58450452|NCT04098809|DEVICE|20 French urinary catheter|20 French urinary catheter
58450453|NCT05279859|DRUG|ERAS-007|Administered orally
58450454|NCT05279859|DRUG|ERAS-601|Administered orally
58450455|NCT05279859|DRUG|Gilteritinib|Administered orally
58450456|NCT00452790|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
58121860|NCT01539109|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
58450457|NCT00452790|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
58450458|NCT04375917|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
58450459|NCT02741245|DRUG|Ezetimibe 10 mg|
58450460|NCT02741245|DRUG|Rosuvastatin 2.5 mg|
58450461|NCT02741245|DRUG|Placebo for Ezetimibe|
58450462|NCT02741245|DRUG|Placebo for Rosuvastatin|
58450463|NCT01022658|DRUG|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
58450464|NCT04935073|DRUG|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
58450465|NCT04935073|DRUG|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
58450466|NCT02158871|BEHAVIORAL|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
58450467|NCT02158871|BEHAVIORAL|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
58450468|NCT06316349|OTHER|Isolated Resistance Training Program|The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.
57959350|NCT02569762|DIETARY_SUPPLEMENT|Sucralose-Aspartame|Sucralose or aspartame
57959351|NCT02569762|DIETARY_SUPPLEMENT|Aspartame-Sucralose|Aspartame or sucralose
57959352|NCT03299920|OTHER|Standardized instructions|Specific instructions related to peripheral nerve block.
57959353|NCT03299920|OTHER|Conventional instructions|Usual post-operative instructions.
58121861|NCT02123056|DRUG|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
58121862|NCT02123056|DRUG|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
58121863|NCT02486796|BIOLOGICAL|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
58121864|NCT02486796|DRUG|Coenzyme Q10|Preparation of coenzyme Q10
58121865|NCT02486796|DRUG|Melatonin|Preparation of melatonin
58121866|NCT00040872|BIOLOGICAL|filgrastim|
58121867|NCT00040872|BIOLOGICAL|monoclonal antibody 3F8|
58121868|NCT00040872|BIOLOGICAL|sargramostim|
58121869|NCT00040872|DRUG|carboplatin|
58121870|NCT00040872|DRUG|cisplatin|
58121871|NCT00040872|DRUG|cyclophosphamide|
58121872|NCT00040872|DRUG|doxorubicin hydrochloride|
58121873|NCT00040872|DRUG|etoposide|
58121874|NCT00040872|DRUG|isotretinoin|
58121875|NCT00040872|DRUG|thiotepa|
58121876|NCT00040872|DRUG|topotecan hydrochloride|
58121877|NCT00040872|DRUG|vincristine sulfate|
58121878|NCT00040872|PROCEDURE|autologous bone marrow transplantation|
58121879|NCT00040872|PROCEDURE|bone marrow ablation with stem cell support|
58121880|NCT00040872|PROCEDURE|conventional surgery|
58121881|NCT00040872|PROCEDURE|drug resistance inhibition treatment|
58121882|NCT00040872|PROCEDURE|peripheral blood stem cell transplantation|
58121883|NCT00040872|PROCEDURE|syngeneic bone marrow transplantation|
58121884|NCT00040872|RADIATION|radiation therapy|
58121885|NCT06283862|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
58121886|NCT01908114|BEHAVIORAL|Enhanced Community mobilization|
58121887|NCT01908114|BIOLOGICAL|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
58121888|NCT02318498|PROCEDURE|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
58121889|NCT02958956|DRUG|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
58121890|NCT02984436|PROCEDURE|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
58121891|NCT02984436|BEHAVIORAL|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
58121892|NCT00719342|DRUG|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
58121893|NCT00719342|OTHER|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
58121894|NCT00281294|DRUG|Fontolizumab|
58121895|NCT01626859|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
58121896|NCT01626859|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
58121897|NCT01626859|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
58121898|NCT03923595|OTHER|Adherence intervention research|dedicated management
58121899|NCT03513354|OTHER|Soil group|Exercises in soil.
58121900|NCT03513354|OTHER|Pool group|Exercises in pool.
58121901|NCT05259033|DRUG|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
58121902|NCT05259033|DRUG|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
58121903|NCT05253560|DIAGNOSTIC_TEST|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
58121904|NCT04156269|BIOLOGICAL|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
58121905|NCT03305055|DRUG|ketamine|Information included in arm descriptions
58121906|NCT03305055|DRUG|Fentanyl|Information included in arm descriptions
58121907|NCT01618799|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
58121908|NCT01618799|DRUG|Lamotrigine|2 x 25 mg tablet once a day
58121909|NCT02729896|DRUG|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
58121910|NCT02729896|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
58121911|NCT02729896|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
58121912|NCT02729896|DRUG|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
58450469|NCT06316349|OTHER|Neuromuscular electrical stimulation|For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
58121913|NCT01892579|BEHAVIORAL|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
58121914|NCT01892579|OTHER|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
58121915|NCT03873701|DIAGNOSTIC_TEST|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
58450470|NCT02625805|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
58450471|NCT02625805|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
57747710|NCT04791982|BEHAVIORAL|Educational sessions|Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
57747711|NCT01795430|DRUG|etoposide|Given IV
57747712|NCT01795430|DRUG|ifosfamide|Given IV
57747713|NCT01795430|RADIATION|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
57747714|NCT01795430|DRUG|topotecan hydrochloride|Given IV
57747715|NCT01795430|DRUG|busulfan|Given IV
57747716|NCT01795430|DRUG|melphalan|Given IV
57747717|NCT01795430|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
57747718|NCT01795430|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
57747719|NCT01795430|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
57747720|NCT02226913|DRUG|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
57959354|NCT04732507|COMBINATION_PRODUCT|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
57959355|NCT00813423|DRUG|Hydroxychloroquine|Given PO
58450472|NCT02625805|DRUG|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
58450473|NCT02721602|BEHAVIORAL|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
58450474|NCT03641040|DIAGNOSTIC_TEST|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
57959356|NCT00813423|OTHER|Laboratory Biomarker Analysis|Correlative studies
57959357|NCT00813423|OTHER|Pharmacological Study|Correlative studies
58450475|NCT03641040|DIAGNOSTIC_TEST|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
58450476|NCT02137824|PROCEDURE|sinus floor elevation|
57747721|NCT02226913|DRUG|sodium bicarbonate|8.4% sodium bicarbonate
57747722|NCT02226913|DRUG|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
57747723|NCT04052464|OTHER|endometrium biopsy|All patients will have endometrium biopsy.
57747724|NCT04052464|OTHER|endometrium lavage|In some selected cases biopsy is preceded by endometrium lavage.
57747725|NCT04052464|OTHER|repeated endometrium lavage|Endometrium lavage is repeated during the same cycle.
57747726|NCT02953301|DRUG|resminostat|
57747727|NCT02953301|DRUG|Placebo|
57747728|NCT03113474|OTHER|Food palatability|Food palatability is modulated
57747729|NCT04830072|BEHAVIORAL|Brief AWARD advice and active referral to somking cessation services|The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.
58121916|NCT01911585|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
58121917|NCT01924390|DEVICE|Mineralized freeze-dried bone allograft alone|
58121918|NCT01924390|DEVICE|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
58121919|NCT03156166|PROCEDURE|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
58121920|NCT06045481|DRUG|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
58121921|NCT04251611|OTHER|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
58121922|NCT03081767|DIAGNOSTIC_TEST|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
58121923|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
58450477|NCT03544021|BIOLOGICAL|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
58450478|NCT02444949|DRUG|endostar|
58450479|NCT02444949|RADIATION|intensity modulated radiation|
58450480|NCT02444949|DRUG|cisplatin|
58450481|NCT04068246|DRUG|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
58450482|NCT04068246|DRUG|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
58450483|NCT03573141|OTHER|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
58450484|NCT01817426|DRUG|Infliximab|
58450485|NCT01817426|OTHER|Placebo|
57747730|NCT04830072|BEHAVIORAL|Chat-based support through Instant Messaging apps|Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.
57747731|NCT04830072|OTHER|Leaflet|Leaflet on harms of smoking
57747732|NCT04830072|BEHAVIORAL|AR images|AR images of the harms of smoking and the benefit of abstinence.
58121924|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
58121925|NCT00449072|DRUG|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
58450486|NCT03637660|DRUG|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
58450487|NCT00428948|DRUG|Tolvaptan|Tolvaptan was supplied as tablets.
58450488|NCT00428948|DRUG|Placebo|Placebo was supplied as tablets.
58450489|NCT02083692|DRUG|Metformin|
58450490|NCT05753488|DIAGNOSTIC_TEST|graft function|renal transplantation
58450491|NCT05531981|OTHER|detect HPV E7 ctDNA|Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR
58450492|NCT02754921|PROCEDURE|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
58450493|NCT02754921|PROCEDURE|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
58450494|NCT04698603|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
58450495|NCT00024180|DRUG|romidepsin|
58450496|NCT02300363|DRUG|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
58450497|NCT02300363|DRUG|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
58450498|NCT02300363|DRUG|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
58450499|NCT02505659|BEHAVIORAL|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
58450500|NCT00479336|DRUG|OPC-41061 7.5mg|7.5mg, 1 tablet a day
58450501|NCT00479336|DRUG|OPC-41061 placebo|placebo, 1 tablet a day
57747733|NCT06347302|BIOLOGICAL|Blood sampling|Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
57747734|NCT06347302|OTHER|vitreous sampling|Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
57747735|NCT06347302|OTHER|Sub-retinal fluid sampling|Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.
57747736|NCT06347302|OTHER|Retinal tissue sampling|cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
57747737|NCT03603080|DRUG|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
58450502|NCT00479336|DRUG|OPC-41061 15mg|15mg, 1 tablet a day
58450503|NCT00479336|DRUG|OPC-41601 30mg|30mg, 1 tablet a day
58121926|NCT00449072|DRUG|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
58121927|NCT01687309|DRUG|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
58121928|NCT01687309|DRUG|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
58121929|NCT01687309|OTHER|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
58121930|NCT01687309|OTHER|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
58121931|NCT01781065|DEVICE|transcranial direct current stimulation|
58121932|NCT00349505|PROCEDURE|hyper thermic chemo + surgery|
58121933|NCT04330248|DRUG|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
57747738|NCT00550485|DRUG|escitalopram|escitalopram 4 mg
57747739|NCT01799265|DEVICE|Somnetics Transcend Auto|
58121934|NCT04330248|DRUG|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
58121935|NCT02281942|BEHAVIORAL|Yoga|
58121936|NCT02281942|BEHAVIORAL|Education|
57747740|NCT01799265|DEVICE|Respironics REMstar Auto with C-Flex|
57747741|NCT00845663|DRUG|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
57747742|NCT00845663|DRUG|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
57747743|NCT00361140|DRUG|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
57747744|NCT00361140|DRUG|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
58121937|NCT06542159|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.
58121938|NCT06542159|RADIATION|Conventional SBRT|SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
58121939|NCT06205719|DRUG|ciprofol|sedation
58121940|NCT06205719|DRUG|Remazolam|sedation
58121941|NCT06205719|DRUG|Flumazenil|antagonism
58121942|NCT06205719|DRUG|Remifentanil|2ug/kg Remifentanil
58121943|NCT03882164|DIAGNOSTIC_TEST|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
58121944|NCT04954456|DRUG|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
58121945|NCT04807114|DRUG|Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)
58121946|NCT04807114|DRUG|Chemotherapy + Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
58121947|NCT03651674|DEVICE|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
58121948|NCT03651674|DRUG|Drug treatment|Patients only have antipsychotic drugs
58450504|NCT05523544|BEHAVIORAL|schematherapy|psychotherapy
57747745|NCT00107250|DRUG|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
57747746|NCT00107250|DRUG|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
57747747|NCT00107250|DRUG|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
57747748|NCT00107250|DRUG|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
57747749|NCT04365582|DRUG|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
57747750|NCT04365582|DRUG|Hydroxychloroquine|200 mg x 3/day for 10 days
57747751|NCT04365582|DRUG|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
57959358|NCT00813423|DRUG|Sunitinib Malate|Given PO
58121949|NCT01842048|OTHER|Hyperthermia|
58121950|NCT01842048|RADIATION|External-beam radiotherapy|
58121951|NCT05561114|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
58121952|NCT05561114|OTHER|Control|Standard Endoscopic Dilation
58121953|NCT01411995|DRUG|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
58121954|NCT01411995|DRUG|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
58121955|NCT04510701|OTHER|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
58121956|NCT03811379|DRUG|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
58121957|NCT05780437|BIOLOGICAL|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
58121958|NCT05780437|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
58121959|NCT05780437|BIOLOGICAL|Remdesivir|Antiviral agent
58121960|NCT00622908|DRUG|ISV-403|0.6% TID, 5 days
58121961|NCT00622908|DRUG|Vehicle|Vehicle of ISV-403 TID, 5 days
58121962|NCT03841383|DIAGNOSTIC_TEST|Echo stress dipyridamole|Echo stress dipyridamole
58450505|NCT01001247|DRUG|TMC278; Omeprazole|
58121963|NCT03064412|BIOLOGICAL|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
58121964|NCT03064412|BIOLOGICAL|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
58121965|NCT05316675|DRUG|Isotretinoin|isotretinoin 13-cis-retinoic acid), derived from vitamin A
58121966|NCT03158298|OTHER|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
58121967|NCT05392621|BEHAVIORAL|Yoga|A single Hatha yoga session designed to support stress management.
58121968|NCT05392621|BEHAVIORAL|Deep Breathing|A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.
58121969|NCT05392621|BEHAVIORAL|Progressive Muscle Relaxation|A single session of progressive muscle relaxation designed to elicit relaxation.
58121970|NCT05392621|BEHAVIORAL|Quiet sitting|A single session of quiet sitting.
58450506|NCT05322434|OTHER|The Effect Of Online Breastfeeding Counseling Given At The Post-Birth Period On Breastfeeding Behavior|The aim of the study is to investigate breastfeeding behavior and initiation of solid food by giving breastfeeding counseling to women within the framework of the Health Belief Model for 6 months from birth.
58450507|NCT02056795|DEVICE|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
58450508|NCT02056795|DEVICE|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
57747752|NCT03750006|BEHAVIORAL|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
57747753|NCT05890443|BEHAVIORAL|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
57747754|NCT05439902|DRUG|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
57747755|NCT05439902|DRUG|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
57747756|NCT04592445|DEVICE|Satera GSN Ablation|The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
57747757|NCT04592445|DEVICE|Sham Control|The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
57747758|NCT02923804|DIETARY_SUPPLEMENT|Omega-3|3x 1g capsules taken daily for 6 months
57747759|NCT02923804|DIETARY_SUPPLEMENT|Olive oil|3x 1g capsules taken daily for 6 months
57747760|NCT04932629|BIOLOGICAL|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10\*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
57747761|NCT00416182|DRUG|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
57747762|NCT00416182|DRUG|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
58121971|NCT03076177|OTHER|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
58121972|NCT05188521|DRUG|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
58121973|NCT05188521|DRUG|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 12 weeks
58121974|NCT06090656|DRUG|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
58121975|NCT06090656|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
58450509|NCT01505959|DEVICE|CPAP treatment|Usual CPAP treatment
58121976|NCT06244979|OTHER|Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)|100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
58121977|NCT00794079|DIETARY_SUPPLEMENT|omega-3 fatty acids|4 grams per day for 8 weeks
58121978|NCT00794079|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 8 weeks
57747763|NCT04616508|BEHAVIORAL|motor control assessment|Basic science study of control of reaching movements
58121979|NCT04623736|BEHAVIORAL|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
58121980|NCT01107236|DRUG|IW-6118|Single dose
58121981|NCT01107236|DRUG|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
58121982|NCT01107236|DRUG|Naproxen Sodium|Single dose
58121983|NCT03763110|DEVICE|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
58121984|NCT03763110|DRUG|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
58121985|NCT02254148|DRUG|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
58121986|NCT02254148|DRUG|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
58121987|NCT02254148|DRUG|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
58121988|NCT02254148|DRUG|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
58121989|NCT02254148|DRUG|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
58121990|NCT02254148|DRUG|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
58121991|NCT02254148|DRUG|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
58314062|NCT00977145|BIOLOGICAL|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
58314063|NCT00916578|RADIATION|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
57747764|NCT05807243|OTHER|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
57747765|NCT02605629|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
58121992|NCT01339910|DRUG|Fludarabine and Busulfan|"(Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
58121993|NCT01339910|DRUG|Fludarabine and Melphalan|"(Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2"
58121994|NCT01339910|DRUG|Busulfan and Fludarabine|"(Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)"
58121995|NCT01339910|DRUG|Busulfan and Cyclophosphamide|"(Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
57959359|NCT01148277|DRUG|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
58121996|NCT01339910|DRUG|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
58314064|NCT00916578|DRUG|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
58314065|NCT01452256|DRUG|Desflurane|4-6 Vol %
57959360|NCT01148277|DRUG|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
58314066|NCT01452256|DRUG|Propofol|TIVA to achieve BIS value of 40-60
58314067|NCT00961064|DRUG|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
58450510|NCT01505959|DEVICE|CPAP treatment|CPAP treatment with telemedicine system
57747766|NCT02605629|OTHER|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
57747767|NCT04231708|DRUG|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
57747768|NCT04231708|DEVICE|Active rTMS|10Hz rTMS over the left dlPFC
58121997|NCT04972656|DRUG|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
58121998|NCT04972656|DRUG|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
58121999|NCT05869942|DIAGNOSTIC_TEST|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
58122000|NCT05869942|DIAGNOSTIC_TEST|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
58122001|NCT01555619|DEVICE|CRT-D System|Implantation of a CRT-D System
58122002|NCT03043378|BEHAVIORAL|Questionnaires|Participants complete three questionnaires at consultation visit.
58122003|NCT03852199|OTHER|Test protocol for proprioceptive force sense in case group|"* The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~* Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
58122004|NCT02829671|OTHER|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
58122005|NCT03327896|OTHER|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
58450511|NCT01284517|DRUG|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
57747769|NCT04231708|DRUG|Placebo|lactose (inside capsule)
57747770|NCT04231708|DEVICE|Sham rTMS|inactive stimulation over the left dlPFC
57747771|NCT03993548|BEHAVIORAL|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
57747772|NCT03993548|BEHAVIORAL|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
57747773|NCT03993548|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
57747774|NCT03993548|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
58122006|NCT03743428|DRUG|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
58122007|NCT03743428|DRUG|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
58450512|NCT01284517|DRUG|Placebo|Equivalent to Lurasidone dosing
58450513|NCT02114138|PROCEDURE|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
58450514|NCT02114138|DIAGNOSTIC_TEST|urine collection|urine collection will be performed on both the control group and hospitalized participants
58450515|NCT02510001|DRUG|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
58450516|NCT02510001|DRUG|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
58450517|NCT02510001|DRUG|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
57747775|NCT03993548|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
57747776|NCT03993548|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
57747777|NCT03993548|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
57747778|NCT05030948|BEHAVIORAL|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
57747779|NCT01877408|PROCEDURE|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
57747780|NCT01877408|DEVICE|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
57959361|NCT01148277|DRUG|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
57747781|NCT02329054|DRUG|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
57747782|NCT00789087|PROCEDURE|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
57747783|NCT00789087|PROCEDURE|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
57747784|NCT01245010|OTHER|Water|Water and education will be provided
57747785|NCT01245010|OTHER|Education|Education
58314068|NCT02295059|DIETARY_SUPPLEMENT|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
58314069|NCT04782141|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
58450518|NCT02148523|BEHAVIORAL|Comparison to peers|
57747786|NCT05321719|BEHAVIORAL|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
57747787|NCT05321719|BEHAVIORAL|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
57747788|NCT05321719|BEHAVIORAL|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
57747789|NCT05321719|BEHAVIORAL|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
57747790|NCT01263834|DRUG|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
57747791|NCT01263834|DRUG|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
57747792|NCT00104169|DRUG|Epoetin Alfa|
57747793|NCT05182879|DIAGNOSTIC_TEST|Assessement with GERONTOPOLE scale|"The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)"
57747794|NCT03102723|DRUG|Cangrelor|"1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
57747795|NCT04745481|DEVICE|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
57747796|NCT04745481|DEVICE|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
57747797|NCT05933031|DRUG|Tegoprazan 50 mg Triple Therapy|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
57747798|NCT05933031|DRUG|Tegoprazan 100 mg Triple Therapy|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
57747799|NCT05933031|DRUG|Lansoprazole Triple Therapy|Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
58314070|NCT04782141|PROCEDURE|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
58450519|NCT02148523|BEHAVIORAL|Adherence feedback|
58450520|NCT02148523|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
58450521|NCT00659074|DRUG|Ondansetron|ODT, single-dose, fasting
58450522|NCT00659074|DRUG|Zofran|ODT, single-dose, fasting
58450523|NCT05533996|DIAGNOSTIC_TEST|ultrasound|Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
58122008|NCT03430375|DEVICE|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
58122009|NCT03430375|DEVICE|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
58122010|NCT04708795|DRUG|AP701|Preparation of Cannabis flowers (Cannabis flos)
58122011|NCT06009523|DEVICE|Transcranial direct current stimulation|1 stimulation per day during 15 days.
58314071|NCT04782141|PROCEDURE|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
57747800|NCT06246604|DIAGNOSTIC_TEST|Ultrasound screening for lower limbs DVT|Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.
57747801|NCT06246604|DIAGNOSTIC_TEST|Standard-of-care|Ultrasound examination of lower limbs is performed according to clinical risk of DVT
57747802|NCT01826227|PROCEDURE|Positron Emission Tomography|
57959362|NCT02870855|DRUG|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
57959363|NCT04104438|DRUG|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
57959364|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
57959365|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
57959366|NCT04369066|DIAGNOSTIC_TEST|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
57959367|NCT04369066|DIAGNOSTIC_TEST|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
57959368|NCT04740047|DIAGNOSTIC_TEST|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
57959369|NCT01962051|DEVICE|Amplatzer Cardiac Plug|
57959370|NCT03067272|DEVICE|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
57959371|NCT06519019|PROCEDURE|Dental Implant Surgery - Hydrophilic group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
57959372|NCT06519019|PROCEDURE|Dental Implant Surgery - Conventional group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
57959373|NCT01834729|DRUG|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
57747803|NCT01826227|RADIATION|18F-Fluoro-2-deoxy-D-lucose|
57747804|NCT01826227|PROCEDURE|Cytoreductive surgery|
57959374|NCT01834729|OTHER|Placebo|placebo capsule identical to the study drug
58122012|NCT05432843|DRUG|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
58122013|NCT05432843|DRUG|Placebo|Patients receive a treatment with placebo for 8 weeks
58314072|NCT01757548|PROCEDURE|open operation|high ligation of spermatic vein by open operation
57747805|NCT02577666|BEHAVIORAL|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
57747806|NCT02577666|BEHAVIORAL|Housing Only|receives 3 months of project supported rental assistance
57747807|NCT02577666|BEHAVIORAL|Treatment as Usual|receives services as normally offered within the community
57747808|NCT03683147|OTHER|Laboratory Biomarker Analysis|Correlative studies
58122014|NCT02158936|DRUG|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
58122015|NCT02158936|DRUG|Azacitidine|Subcutaneous Injection (IV if local standard)
58122016|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets
58314073|NCT01757548|PROCEDURE|microsurgery|high ligation of spermatic vein by microsurgery
58314074|NCT00747877|DRUG|cyclophosphamide|Given orally
58314075|NCT00747877|DRUG|melphalan|Given IV
58314076|NCT00747877|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
57959375|NCT04204174|DIETARY_SUPPLEMENT|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
57959376|NCT02929264|DRUG|ABX-1431|Capsules, 40 mg, single dose
57959377|NCT02929264|DRUG|Placebo|Capsules, single dose
57959378|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
57959379|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
57959380|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
57959381|NCT01356914|DRUG|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
57959382|NCT01286246|DRUG|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
57959383|NCT01286246|DRUG|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
57959384|NCT05997875|BEHAVIORAL|Educational Materials|"Participants are provided with the Getting Ready: Your Vascular Access Journey video and brochure about hemodialysis vascular access. The video is available for viewing via smartphone or computer. Both the brochure and video were created with input from patients with chronic kidney disease."
57959385|NCT05997875|BEHAVIORAL|Motivational Interviewing|Participants receive coaching with telehealth-based motivational interviewing designed to prepare participants to move forward with vascular access creation. Motivational interviewing will consist of a minimum of 3 and maximum of 8 telehealth sessions with a coach. The coach will use patient-centered communication skills to work though the stages of pre-contemplative, contemplative, preparation, action, and maintenance of an arteriovenous vascular access.
57959386|NCT05997875|BEHAVIORAL|Usual Care|Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
57959387|NCT05997875|OTHER|Patient Lists for Clinicians: System-Level Intervention|Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
57959388|NCT03224273|OTHER|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
57959389|NCT04926272|DRUG|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
57959390|NCT05051007|DRUG|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
57959391|NCT05051007|DRUG|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
57959392|NCT06193512|DEVICE|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
57959393|NCT06193512|PROCEDURE|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
57959394|NCT04690400|OTHER|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
58122017|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets will be supplied
58122018|NCT02417090|DRUG|Insulin|Pregnant women who used insulin to treat gestational diabetes
58122019|NCT02417090|DRUG|Metformin|Pregnant women who used metformin to treat gestational diabetes
58122020|NCT05976971|OTHER|7T MRI|Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
58122021|NCT06544083|DIAGNOSTIC_TEST|Proteomics|Proteomic is performed on all blood samples.
58122022|NCT06358378|DEVICE|Aktiia SA Bracelet|The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
58314077|NCT03854500|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
58314078|NCT03854500|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
58122023|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
58122024|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
58122025|NCT00697775|BIOLOGICAL|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
58122026|NCT05602090|DRUG|4 IU of recombinant GH (Somatotropin )|4 IU of recombinant GH
58122027|NCT00132002|DRUG|vorinostat|Given PO
58122028|NCT00132002|OTHER|laboratory biomarker analysis|Correlative studies
58122029|NCT02899130|DRUG|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
58122030|NCT02899130|DRUG|Placebo|Inactive compound that is similar looking as the intervention
58122031|NCT02863302|OTHER|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
58122032|NCT03303638|BEHAVIORAL|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
58122033|NCT01974895|BIOLOGICAL|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
58122034|NCT01974895|BIOLOGICAL|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
58122035|NCT00866242|BIOLOGICAL|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
58122036|NCT02255513|DRUG|HLD200|
58450524|NCT03173404|PROCEDURE|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
57747809|NCT03683147|BEHAVIORAL|Meditation-Based Stress Reduction Program|Participate in 6-week online program
57747810|NCT03683147|OTHER|Quality-of-Life Assessment|Ancillary studies
57747811|NCT03683147|OTHER|Questionnaire Administration|Ancillary studies
58122037|NCT02255513|DRUG|Placebo|
58122038|NCT02202174|DEVICE|Supraglottic Airway Device|
58122039|NCT00661505|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
58122040|NCT04758936|DRUG|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
58450525|NCT04569292|OTHER|No intervention on patients|No intervention on patients
57747812|NCT03284788|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
57747813|NCT05257772|DEVICE|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
57747814|NCT01057238|OTHER|Intensive Communication System|Regular family meetings once a week, using a standard protocol
57747815|NCT04640532|DRUG|KRT-232|KRT-232, administered by mouth
57747816|NCT04640532|DRUG|TL-895|TL-895, administered by mouth
57747817|NCT02940366|DRUG|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
57747818|NCT02940366|DRUG|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
57747819|NCT02162784|DRUG|Budesonide/Procaterol, 180/10mcg X1|one puff
57747820|NCT02162784|DRUG|Budesonide/procaterol 180/10 mcg X 2|2 puffs
58122041|NCT04758936|DRUG|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
58122042|NCT00365261|DRUG|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
58122043|NCT00365261|DRUG|Placebo|placebo 2 to 3 mg po at bedtime
58122044|NCT06485895|DIAGNOSTIC_TEST|test IGRA|BLOOD SAMPLES
58122045|NCT06485895|DIAGNOSTIC_TEST|TEST QUATIFERON TB Gold Plus|BLOOD SAMPLES
58122046|NCT01841320|OTHER|Integrated methadone and antiretroviral therapy (iMART) clinic|
58122047|NCT03818620|DEVICE|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
58122048|NCT03818620|DEVICE|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
58122049|NCT04277611|PROCEDURE|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
58450526|NCT00539994|DRUG|retapamulin|200mg BID retapamulin 3 days
58450527|NCT00539994|DRUG|Retapamulin|200mg BID retapamulin 5 days
58450528|NCT00539994|DRUG|Placebo|200mg BID placebo 5 days
58450529|NCT04533724|DRUG|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
58450530|NCT03710122|DRUG|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
58122050|NCT03529955|DRUG|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
58122051|NCT03925220|BEHAVIORAL|The SUPPER Project|Substance Use Promoted by Eating family meals Regularly
58122052|NCT03925220|BEHAVIORAL|Improving nutrition and physical activity among youth|A brief intervention focused on improving nutrition and physical activity among youth
58122053|NCT04043013|DEVICE|Mini-Taurus® (Rocky Mountain©) Brackets|
58122054|NCT04043013|DEVICE|Smart Clip® SL3 High Torque (3M Unitek©)|
58122055|NCT04043013|DEVICE|Tip-Edge Plus® (TP Orthodontics©)|
58122056|NCT04043013|DEVICE|Victory® (3M Unitek©)|
58122057|NCT04350567|OTHER|Sleep Deprivation|On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
57747821|NCT02162784|DRUG|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
57747822|NCT04081467|OTHER|Bed rest|10-day of complete bed rest
57747823|NCT03222648|OTHER|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
57747824|NCT03222648|OTHER|Usual Care|Continuation of usual care
57747825|NCT05362890|DEVICE|DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE|The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
57747826|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
57959395|NCT04690400|OTHER|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
57959396|NCT05280678|PROCEDURE|Orthodontic miniscrew insertion in the mandibular buccal shelf|"Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion."
57959397|NCT06501287|DIAGNOSTIC_TEST|Postprandial triglyceride|impact of postprandial triglyceride level on coronary atherosclerosis
57959398|NCT00634491|DRUG|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
57959399|NCT00634491|DRUG|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
57959400|NCT00634491|DRUG|normal salin|1 cc/kg/hr 6 hour before and after angiography
57959401|NCT00378170|DEVICE|intubation of patients undergoing elective surgery|
57959402|NCT05409339|DRUG|Caffeine|150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
57959403|NCT05409339|DRUG|Placebo|Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
57959404|NCT00670592|DRUG|HCD122|
57959405|NCT02406807|OTHER|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
57747827|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
57959406|NCT02406807|OTHER|Sham Spinal lumbar manipulation|Sham manipulation
57959407|NCT04032990|DEVICE|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
58122058|NCT04389879|OTHER|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
58122059|NCT02565420|OTHER|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
58122060|NCT02565420|OTHER|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
58122061|NCT00475020|DRUG|Busulfan|Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days
58122062|NCT00475020|DRUG|Fludarabine|40 mg/m\^2 by vein daily over 1 hour x 4 days
58122063|NCT00475020|DRUG|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
58122064|NCT03881813|DEVICE|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
58122065|NCT06327295|DRUG|ATB1651-102- Cohort 1|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
58122066|NCT06327295|DRUG|ATB1651-102- Cohort 2|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
58122067|NCT06327295|DRUG|ATB1651-102- Cohort 3|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
58122068|NCT06327295|DRUG|ATB1651-102- Cohort 4|Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
58122069|NCT06327295|DRUG|Placebo|participants will receive matching placebo across cohorts 1-4 of the study.
58122070|NCT04076358|BEHAVIORAL|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
58122071|NCT00000654|DRUG|Fialuridine|
58122072|NCT02442856|DEVICE|Thigh Cuff|
58122073|NCT02563522|GENETIC|Engensis (VM202)|gene therapy
58122074|NCT02563522|DRUG|Placebo|Standard of care plus placebo
58122075|NCT06131021|DRUG|Amoxicillin|Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
58122076|NCT06131021|DRUG|Metronidazole|Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
57747828|NCT01484548|BIOLOGICAL|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
57959408|NCT01050400|GENETIC|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
57747829|NCT00050180|DRUG|Midazolam|
57747830|NCT00050180|DRUG|Indinavir|
57747831|NCT00050180|DRUG|Saquinavir|
57747832|NCT04310553|PROCEDURE|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
57959409|NCT04882891|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
57959410|NCT01058343|BIOLOGICAL|IFN-K|3 to 4 IM injections over 3 months
57959411|NCT05979571|OTHER|Mobile health app|Breastfeeding knowledge and promotion information will be delivered through the AmiBreastfeed app platform
57959412|NCT03947814|DRUG|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
57959413|NCT01345331|BEHAVIORAL|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
57959414|NCT04053738|DEVICE|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
57959415|NCT00907400|DRUG|PN400|oral tablet
57959416|NCT00907400|DRUG|Naproxen|oral tablet
57959417|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
57959418|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
57959419|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
57959420|NCT00938314|DRUG|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
57959421|NCT00880815|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
57959422|NCT00880815|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57959423|NCT00880815|DRUG|Bendamustine|Given IV
57959424|NCT00880815|BIOLOGICAL|Filgrastim|Given IV
57959425|NCT00880815|DRUG|Fludarabine|Given IV
57959426|NCT00880815|DRUG|Methotrexate|Given IV
57959427|NCT00880815|BIOLOGICAL|Rituximab|Given IV
57959428|NCT00880815|DRUG|Tacrolimus|Given IV and PO
57959429|NCT05738850|DRUG|ABBV-932|Oral Capsule
57959430|NCT05738850|DRUG|Placebo|Oral Capsule
57959431|NCT01285908|DRUG|Intravenous Norepinephrine Infusion|
57959432|NCT05993637|OTHER|Examination of propriception|application of the tests used in proprioception assessment to patients by a physiotherapist
57959433|NCT06449638|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
57959434|NCT06449638|OTHER|Revita|Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58314079|NCT05020353|DEVICE|OraQuick® HIV Self-Test|OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.
58450531|NCT03710122|OTHER|Placebo|Placebo for Vancomycin
58450532|NCT05492240|OTHER|i-STRONGER|An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
58450533|NCT05492240|OTHER|Usual Care|Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
58450534|NCT01227980|DRUG|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
58450535|NCT01227980|DRUG|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
58450536|NCT05737251|BEHAVIORAL|PoET|PoET consists of two online-sessions, each 3.5 hours within groups of 30 people. The following lessons regarding positive psychology constructs were conducted (including short information on each construct and specific exercises): happiness, hope, humour, optimism, gratitude, self-efficacy, flow, meaningfulness, forgiveness, spirituality and resilience.
58450537|NCT04579640|DIETARY_SUPPLEMENT|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
57747833|NCT03330223|DEVICE|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
57747834|NCT04779970|OTHER|Cessation of ongoing treatment|Cessation of ongoing treatment
57747835|NCT03071055|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection
57747836|NCT00506259|DRUG|dTR Melatonin (NIH CC PDS)|
57959435|NCT06449638|OTHER|Relese|Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
57959436|NCT06449638|OTHER|Cogenex|Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
57959437|NCT06449638|OTHER|Enverse|Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
57959438|NCT06095856|DEVICE|Leaf Gauge|Occlusal device used to locate centric relation of the jaws
57959439|NCT06095856|DEVICE|Lucia Jig|Occlusal device used to locate centric relation of the jaws
57959440|NCT06095856|DEVICE|Kois Deprogrammer|Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
57959441|NCT04673786|BIOLOGICAL|CT-P43|45mg or 90mg dose subcutaneous administration
57959442|NCT04673786|BIOLOGICAL|Stelara|45mg or 90mg dose subcutaneous administration
57959443|NCT04080622|DRUG|Selenium|Selenium 300 µg/day (IV infusion)
57959444|NCT04080622|DRUG|Placebos|NaCl 0,9% (IV infusion)
57747837|NCT00506259|DEVICE|Phototherapy (Bright Light)|
57747838|NCT00506259|DRUG|Melatonin CR|
57959445|NCT00713700|DEVICE|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
57959446|NCT04751162|DEVICE|Actigraphy device (wearable) and mobile application|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
57959447|NCT02797886|OTHER|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
57959448|NCT02797886|OTHER|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
57959449|NCT02797886|OTHER|VOL|The subject initiates and completes the movement without electrical stimulation.
57959450|NCT03105570|PROCEDURE|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
58122077|NCT06131021|OTHER|Placebo|Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
58122078|NCT02354300|DEVICE|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
58122079|NCT00197275|BIOLOGICAL|Hib-MenAC mixed with Tritanrix™-HepB|
58314080|NCT04658355|OTHER|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
58314081|NCT04658355|OTHER|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
58450538|NCT04840082|DIAGNOSTIC_TEST|Nasopharyngeal swab for COVID-19 testing|A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
58450539|NCT06206993|BEHAVIORAL|Resistance training including the Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.
58450540|NCT06206993|BEHAVIORAL|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
58450541|NCT04806074|BEHAVIORAL|Experimental Group|Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
58450542|NCT04806074|BEHAVIORAL|Comparison Group|Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
58450543|NCT01954641|OTHER|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
58450544|NCT01954641|OTHER|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
58450545|NCT05159518|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion
58450546|NCT03392220|PROCEDURE|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
58450547|NCT03392220|PROCEDURE|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
58450548|NCT01123616|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
58450549|NCT01999296|DEVICE|Use of Thunderbeat (TM) in laparoscopic surgery|
58450550|NCT02939586|PROCEDURE|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
58450551|NCT02939586|PROCEDURE|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
58450552|NCT04252131|DRUG|cassia seed tablet|traditional Chinese herbs
58450553|NCT06193642|OTHER|experimental|Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
58450554|NCT02436018|DEVICE|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
58450555|NCT02436018|DEVICE|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
58450556|NCT03009851|BEHAVIORAL|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
58450557|NCT02537717|DEVICE|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
58450558|NCT02537717|DEVICE|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
57747839|NCT02992990|PROCEDURE|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
57747840|NCT05199779|BEHAVIORAL|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
57747841|NCT05199779|BEHAVIORAL|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
57747842|NCT04719091|DEVICE|Lubricity|Oral spray
57747843|NCT03369379|DRUG|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
57747844|NCT03369379|OTHER|Placebo|Placebo pill
57747845|NCT04995679|PROCEDURE|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
57747846|NCT04523896|RADIATION|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
58122080|NCT01223807|OTHER|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
58122081|NCT06201273|BEHAVIORAL|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
58122082|NCT06201273|BEHAVIORAL|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
58450559|NCT00669214|DRUG|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
58450560|NCT00669214|DRUG|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
58450561|NCT02195375|DRUG|Flutiform 500/20 µg BID|
58450562|NCT02195375|DRUG|Flutiform 250/10 µg BID|
57747847|NCT00737555|DRUG|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
57747848|NCT05969574|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
57747849|NCT05969574|DIAGNOSTIC_TEST|Blood test AMH|Measurement of AMH performed on the day of first consultation
57747850|NCT02668224|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
57747851|NCT02668224|OTHER|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
57747852|NCT04220164|OTHER|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
57747853|NCT01313286|DRUG|LY2608204 Reference|Administered orally
57747854|NCT01313286|DRUG|LY2608204 Test|Administered orally.
57959451|NCT03406065|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
57747855|NCT06449040|DRUG|Liposomal amphotericin B (AmBisome®)|Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
58450563|NCT02195375|DRUG|Seretide Accuhaler 50/500 µg BID|
58450564|NCT04603261|DIAGNOSTIC_TEST|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
58450565|NCT01865760|DIETARY_SUPPLEMENT|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
58450566|NCT01865760|DIETARY_SUPPLEMENT|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
57747856|NCT01273233|BIOLOGICAL|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
57747857|NCT01273233|OTHER|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
57747858|NCT02954523|DRUG|Dasatinib|oral every day
57747859|NCT02954523|DRUG|Osimertinib|oral every day
57747860|NCT03228056|DIAGNOSTIC_TEST|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
58122083|NCT01649141|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
58122084|NCT00071552|DRUG|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
58122085|NCT00071552|DRUG|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
58122086|NCT03765073|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
58122087|NCT03765073|BIOLOGICAL|Placebo|Saline control
57747861|NCT00414817|BEHAVIORAL|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
57747862|NCT02880800|DRUG|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
58122088|NCT06374030|PROCEDURE|Endotracheal intubation|All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
58122089|NCT04905342|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
58122090|NCT04905342|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
58122091|NCT02407379|PROCEDURE|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
58122092|NCT02407379|PROCEDURE|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
58122093|NCT02775890|BEHAVIORAL|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (\>85 grams).
58314082|NCT02320175|BEHAVIORAL|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
58314083|NCT01765322|DEVICE|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
58450567|NCT01865760|DRUG|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
58450568|NCT01100320|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
58450569|NCT01100320|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
58450570|NCT03938896|OTHER|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
58450571|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
58450572|NCT03292224|DIAGNOSTIC_TEST|- Microscopic examination and culture of collected specimens|"1. Unstained wet mount with 10%-20% KOH.~2. Wet mounts stained with:~   * Lactophenol cotton blue.~  * India ink~  * Gram stain Culturing on Sabouraud´s dextrose agar ."
57747863|NCT02880800|DRUG|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
57747864|NCT02880800|DRUG|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
57747865|NCT02880800|DRUG|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
57747866|NCT01273948|DRUG|Bavituximab|"1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
57747867|NCT01273948|DRUG|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
57747868|NCT01494337|PROCEDURE|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
58122094|NCT05618171|DIAGNOSTIC_TEST|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
58122095|NCT05571527|BIOLOGICAL|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
58122096|NCT05571527|DRUG|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
58122097|NCT00830674|DRUG|Placebo|single dose IV or SC administration
58122098|NCT00830674|DRUG|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
58122099|NCT05679765|DRUG|Greater Occipital Nerve Block with dexamethasone and lidocaine|Ultrasound guided Greater occipital nerve block on the side of headache
58122100|NCT05679765|DRUG|Greater Occipital Nerve Block with 0.9% saline|Ultrasound guided Greater occipital nerve block on the side of headache
58122101|NCT01127581|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
58122102|NCT01127581|DRUG|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
58122103|NCT00349063|DEVICE|soft contact lens|
58122104|NCT00349063|DRUG|Soft contact lens multipurpose disinfection regimen|
58122105|NCT05343156|DRUG|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
58122106|NCT00279448|DRUG|exemestane|On tablet of 25 mg per day during 5 years
57747869|NCT01494337|PROCEDURE|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
58122107|NCT00279448|DRUG|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
58122108|NCT05811156|BEHAVIORAL|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
58122109|NCT01176448|DEVICE|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
58122110|NCT01176448|DEVICE|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
58122111|NCT01105650|DRUG|Fludarabine|Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
58122112|NCT01105650|DRUG|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
58122113|NCT01105650|DRUG|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
58122114|NCT01105650|BIOLOGICAL|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.
58122115|NCT01105650|DRUG|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
57747870|NCT02330718|OTHER|No intervention|
57747871|NCT02219048|DRUG|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
57747872|NCT02219048|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
57747873|NCT05433870|OTHER|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
58122116|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
58122117|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
58122118|NCT01105650|DRUG|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
58122119|NCT01490281|BEHAVIORAL|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
58122120|NCT01490281|BEHAVIORAL|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
58122121|NCT01524042|PROCEDURE|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
58122122|NCT02456909|DEVICE|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
58122123|NCT02456909|DEVICE|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
58122124|NCT02456909|DRUG|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
58122125|NCT00347503|DRUG|ketorolac 0.4%, bromfenac 0.09%|
58122126|NCT03420066|OTHER|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
58122127|NCT01997554|OTHER|Blood sample|An extra blood sample of 10 ml is collected
58314084|NCT02422654|DRUG|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
58314085|NCT05944796|OTHER|Diathermy|The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
58314086|NCT05944796|OTHER|Placebo|The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
58122128|NCT04736264|OTHER|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
58122129|NCT04736264|OTHER|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
58122130|NCT04736264|OTHER|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
58122131|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
58122132|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
58122133|NCT04317573|DEVICE|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
58122134|NCT03316937|PROCEDURE|Types of scalers|Scaling
58122135|NCT05116228|DRUG|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
57747874|NCT00000126|PROCEDURE|Surgery|
57747875|NCT00678314|DRUG|Ropivacaine 0.2%|10 ml
57747876|NCT00678314|DRUG|Ropivacaine 0.75%|3 ml
58122136|NCT05116228|DRUG|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
58122137|NCT05709509|DRUG|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
58122138|NCT05709509|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
58314087|NCT03816046|DRUG|botulinum toxin A|injection in hair bearing area of armpits
57747877|NCT00678314|DRUG|Normal saline|10 ml
57747878|NCT02454101|PROCEDURE|cord milking|milking of the cord 5 times toward the neonate
57747879|NCT02454101|PROCEDURE|delayed cord clamping|delay clamping of the cord for 120 seconds
57747880|NCT03810625|DRUG|D-0502|D-0502 oral tablets
57747881|NCT01805492|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
57747882|NCT04911790|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
57747883|NCT05564013|DEVICE|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
57747884|NCT04851483|DRUG|BAY2328065|Solid Form, Oral administration.
57747885|NCT04851483|DRUG|Placebo|Matching placebo of BAY2328065.
57747886|NCT01316510|DIETARY_SUPPLEMENT|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
57747887|NCT01316510|OTHER|Placebo|Dilute Nutramigen formula
57747888|NCT04846452|DRUG|Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin|Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
57747889|NCT04846452|DRUG|Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin|Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
57747890|NCT04434989|RADIATION|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
57747891|NCT04434989|PROCEDURE|radiofrequency ablation|RFA for perivascular HCC
57747892|NCT02149251|GENETIC|Pre-genetic diagnosis|
57959452|NCT03406065|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
57959453|NCT04146610|DRUG|an antibody drug conjugate|Multiple dose grouping
58122139|NCT05709509|OTHER|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
58122140|NCT05163509|COMBINATION_PRODUCT|Unity-based MR-Linac guided Radiotherapy|The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
58122141|NCT00161278|DRUG|Carboplatin|
58122142|NCT00161278|DRUG|Paclitaxel|
58122143|NCT00161278|PROCEDURE|Gene expression profiling (analysis) of tumor samples|
58122144|NCT02354586|DRUG|Niraparib|
58122145|NCT06412393|DIETARY_SUPPLEMENT|Black tomato extract powder|take 2 packets per day for 8 weeks
58122146|NCT06412393|DIETARY_SUPPLEMENT|Placebo powder|take 2 packets per day for 8 weeks
58314088|NCT04646629|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
58450573|NCT00475748|PROCEDURE|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
58122147|NCT05775757|RADIATION|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
57747893|NCT06472466|BEHAVIORAL|Sleep/eating virtual reality self-help exposure-based intervention|"Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties."
57747894|NCT06472466|BEHAVIORAL|Sleep/eating self-help written materials.|Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
57747895|NCT01324271|DEVICE|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
57747896|NCT04901650|DIAGNOSTIC_TEST|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
57747897|NCT00698490|BIOLOGICAL|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
57747898|NCT00698490|BIOLOGICAL|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
57747899|NCT03602651|OTHER|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
57747900|NCT00279201|DRUG|Insulin glargine|Subcutaneous injection daily
57747901|NCT00279201|DRUG|Lispro Low Mix|Subcutaneous injection twice daily.
57747902|NCT00279201|DRUG|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
57959454|NCT03652142|OTHER|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
58122148|NCT05520281|BEHAVIORAL|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
58122149|NCT05140161|DEVICE|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
58314089|NCT04646629|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
58450574|NCT03579706|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
57747903|NCT00279201|DRUG|Lispro|Lispro subcutaneous injection 3 times daily.
57747904|NCT04014764|OTHER|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
57747905|NCT06099067|DRUG|Canagliflozin|Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
57747906|NCT06099067|DRUG|DPP4 inhibitor|DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
57747907|NCT06099067|DRUG|Liraglutide|Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
57747908|NCT06099067|DRUG|Saxagliptin|Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
57747909|NCT06099067|DRUG|2nd generation Sulfonylurea|2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
57747910|NCT04114734|BEHAVIORAL|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
57747911|NCT00259532|PROCEDURE|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
57747912|NCT02368808|BEHAVIORAL|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
57747913|NCT02535104|DRUG|Ranpirnase|Topical application by subject
57959455|NCT03652142|DRUG|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
58122150|NCT00597233|DRUG|insulin aspart|
58122151|NCT00597233|DRUG|soluble human insulin|
58122152|NCT00597233|DRUG|insulin NPH|
58122153|NCT04429451|BIOLOGICAL|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
58314090|NCT01759914|DRUG|Potent topical steroid|
58314091|NCT01759914|DRUG|Superpotent topical steroid|
58314092|NCT04023708|DRUG|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
58122154|NCT01673009|DRUG|Gleevec|Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
58122155|NCT01095003|DRUG|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
58122156|NCT01095003|DRUG|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
58122157|NCT03504852|DRUG|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
58122158|NCT05977257|DEVICE|VitaFlow® Transcatheter Aortic Valve Replacement System|This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
58122159|NCT06096623|BEHAVIORAL|Weekly Survey|Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
58122160|NCT04052867|DRUG|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
58122161|NCT04052867|DRUG|Normal saline|An equivalent volume of normal saline is given
58122162|NCT03519256|BIOLOGICAL|Nivolumab|Specified dose on specified days
58122163|NCT03519256|BIOLOGICAL|BCG|Specified dose on specified days
58122164|NCT03519256|DRUG|BMS-986205|Specified dose on specified days
58122165|NCT03246230|BIOLOGICAL|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
58122166|NCT03246230|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
58122167|NCT01821625|DRUG|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
58122168|NCT04082962|DRUG|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
58122169|NCT04543136|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
58122170|NCT04543136|DEVICE|New intermittent Variant 1 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
58122171|NCT04543136|DEVICE|New intermittent Variant 2 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
58314093|NCT02030873|OTHER|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
58314094|NCT02141555|DRUG|Vaginal Misoprostol|Misoprostol inserted into vagina
58314095|NCT02141555|DRUG|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
58122172|NCT04787757|PROCEDURE|Percutaneous cardiac procedure|Collection and analysis of intraprocedural information to provide artificial intelligence algorithms
58450575|NCT03579706|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
57747914|NCT02535104|DRUG|Vehicle|Vehicle control
58122173|NCT03966170|DRUG|Citicoline|Citicoline as neuroprotector
58122174|NCT03966170|DRUG|Placebo oral tablet|placebo drug
58122175|NCT02494726|OTHER|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
58122176|NCT00017563|DRUG|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
58450576|NCT02817126|PROCEDURE|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
58450577|NCT02817126|PROCEDURE|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
57747915|NCT03175302|BEHAVIORAL|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
57747916|NCT02166424|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
57747917|NCT02166424|DIETARY_SUPPLEMENT|Olive oil|
58122177|NCT00017563|DRUG|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
58122178|NCT00017563|PROCEDURE|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
58122179|NCT03580343|DRUG|tofacitinib|tofacitinib extended release, 11mg, daily, oral
58122180|NCT02485496|DEVICE|Endovascular abdominal repair|
58122181|NCT00698685|DRUG|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
58314096|NCT03300765|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
58314097|NCT03300765|RADIATION|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
58314098|NCT00966433|PROCEDURE|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
58314099|NCT00966433|DEVICE|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
58122182|NCT00698685|BIOLOGICAL|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
58122183|NCT00698685|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
58122184|NCT04936997|BIOLOGICAL|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
58122185|NCT03784261|DRUG|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
58122186|NCT03784261|DRUG|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
58122187|NCT03784261|DRUG|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
58122188|NCT01657539|DIETARY_SUPPLEMENT|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
58122189|NCT01657539|DIETARY_SUPPLEMENT|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
58122190|NCT02015091|BIOLOGICAL|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
58122191|NCT01800565|OTHER|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
58122192|NCT01800565|OTHER|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
58122193|NCT00922779|DRUG|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
58450578|NCT04161742|DEVICE|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
58450579|NCT01216683|BIOLOGICAL|rituximab|Given IV
57959456|NCT03979274|DRUG|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
57959457|NCT03979274|DRUG|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
57959458|NCT02090400|DRUG|Bazedoxifene|20 mg Oral daily for 12 months
57959459|NCT02090400|DRUG|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
57959460|NCT01034995|DRUG|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
58122194|NCT00922779|DRUG|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
58122195|NCT01164943|PROCEDURE|Stimulation with human FSH|Human FSH
57959461|NCT01034995|DRUG|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
57959462|NCT01034995|DRUG|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
57959463|NCT05490420|OTHER|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
57959464|NCT02693587|DRUG|Misodel and Angusta|
58122196|NCT01164943|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
58122197|NCT00885690|DRUG|Sertindole|Sertindole 16-24 mg once daily
58122198|NCT00885690|DRUG|Olanzapine|Olanzapine 10-20 mg
58122199|NCT00228904|PROCEDURE|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
58122200|NCT00228904|PROCEDURE|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
58122201|NCT00409890|DRUG|Hyoscine Butyl Bromide|
58122202|NCT05166993|DEVICE|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
58122203|NCT02367495|DEVICE|PCB|PCB with Citrate-based excipient
58122204|NCT06192251|BEHAVIORAL|Lifestyle Medicine|Education and support for lifestyle modification to improve health conditions
58122205|NCT01174056|DRUG|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
58122206|NCT01174056|DRUG|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
58122207|NCT01174056|DRUG|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
58122208|NCT01174056|DRUG|Pioglitazone|PPAR-gamma agonist
58122209|NCT02856256|DIETARY_SUPPLEMENT|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
58122210|NCT00624156|BEHAVIORAL|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
58122211|NCT00624156|BEHAVIORAL|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
58450580|NCT01216683|DRUG|Bendamustin|Given IV
58450581|NCT01216683|DRUG|bortezomib|Given IV
58450582|NCT01216683|DRUG|lenalidomide|Given orally
58450583|NCT02493036|DRUG|SYN-010|
58450584|NCT01560286|BIOLOGICAL|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
58450585|NCT02739399|DRUG|Phenylephrine|Intravenous administration
58122212|NCT00364403|BEHAVIORAL|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
58122213|NCT00364403|BEHAVIORAL|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
58122214|NCT05435222|BEHAVIORAL|Male-specific psychotherapeutic program (MSPP)|The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
58122215|NCT05435222|BEHAVIORAL|Cognitive beahvioral therapy (CBT)|This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.
58122216|NCT04956549|BEHAVIORAL|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
58122217|NCT04956549|BEHAVIORAL|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
58122218|NCT01134653|OTHER|Jump Stretch|distraction with early mobilization
58122219|NCT00953979|DRUG|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
58122220|NCT02192905|BEHAVIORAL|Diabetes Prevention Program Lifestyle Intervention|
58122221|NCT02739542|DRUG|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
58122222|NCT02739542|DRUG|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
58122223|NCT06469879|DRUG|TQB2450+Anlotinib|"TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week."
58122224|NCT06469879|DRUG|TQB2450 placebo + Anlotinib placebo|No drug substance is contained
58122225|NCT01503723|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
58122226|NCT00929409|DRUG|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
58122227|NCT00929409|DRUG|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
58122228|NCT06398769|DEVICE|SecuFix UM|All surgeries were performed using Secufix UM.
58122229|NCT06398769|DEVICE|VCare UM|All surgeries were performed using VCare UM.
58122230|NCT00003096|GENETIC|DNA ploidy analysis|
58122231|NCT00003096|GENETIC|comparative genomic hybridization|
58314100|NCT00966433|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
58450586|NCT03032263|DEVICE|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
58450587|NCT03032263|DEVICE|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
58450588|NCT03149172|DEVICE|Equimatrix®|Ridge preservation bone grafting after tooth extraction
58450589|NCT03149172|DEVICE|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
58450590|NCT03149172|DEVICE|Endobon®|Ridge preservation bone grafting after tooth extraction
58122232|NCT00003096|GENETIC|cytogenetic analysis|
58122233|NCT00003096|GENETIC|fluorescence in situ hybridization|
58122234|NCT03711955|OTHER|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
58122235|NCT01384695|DRUG|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
58122236|NCT01384695|DRUG|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
58314101|NCT04660045|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
58314102|NCT06298149|BEHAVIORAL|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
58450591|NCT02867735|DRUG|LKA651|Interventional
58450592|NCT02867735|OTHER|Sham Comparator|
58450593|NCT00202007|DRUG|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
58450594|NCT00202007|DRUG|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
58450595|NCT05332847|DEVICE|POC-US|Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
57747918|NCT04897984|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
57747919|NCT01417689|OTHER|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
57747920|NCT00998179|DEVICE|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
58122237|NCT01693783|BIOLOGICAL|Ipilimumab|Given IV
58122238|NCT01693783|OTHER|Laboratory Biomarker Analysis|Correlative studies
58122239|NCT02224456|DRUG|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
58122240|NCT02925273|OTHER|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand"
58122241|NCT02925273|OTHER|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
58122242|NCT00800059|RADIATION|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
58122243|NCT02775968|DRUG|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
58122244|NCT03405285|DEVICE|Connected Catheter|The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
58122245|NCT05166330|DRUG|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
58122246|NCT05166330|DRUG|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
58122247|NCT00165399|DRUG|Docetaxel|Given intravenously on day 2 of four three-week cycles
58314103|NCT01384877|DRUG|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
58314104|NCT01384877|DRUG|Placebo (D5W)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
58450596|NCT05242393|OTHER|No intervention is planned|No intervention is planned
58314105|NCT01225302|DRUG|Linifanib|Low dose linifanib (once a day)
58314106|NCT01225302|DRUG|Linifanib|High dose linifanib (once a day)
58314107|NCT01225302|DRUG|Carboplatin|Given on Day 1 of every 21-day cycle
57747921|NCT00998179|DEVICE|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
57747922|NCT02401581|OTHER|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
57747923|NCT02639260|DRUG|N-acetyl D-mannosamine|dose escalation
57747924|NCT02258139|DEVICE|B&L Investigational Contact Lens|The lens used in this study will be supplied by the Sponsor. All subjects will wear a -3.00D lens.
57747925|NCT01121042|DRUG|Ondansetron|8mg per day oral capsule
57747926|NCT01121042|DRUG|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
58314108|NCT01225302|DRUG|Paclitaxel|Given on Day 1 of every 21-day cycle
58314109|NCT02397525|DRUG|LIPO-202|
58314110|NCT01053832|DEVICE|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
58314111|NCT00014014|DRUG|Lamivudine/Zidovudine|
57747927|NCT03502655|OTHER|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
57747928|NCT03502655|OTHER|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
57747929|NCT03502655|OTHER|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
57747930|NCT03502655|OTHER|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
58314112|NCT03738696|DRUG|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
58314113|NCT03738696|DRUG|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
58450597|NCT01799226|OTHER|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
58450598|NCT01799226|OTHER|Triclosan|this intervention will use Colgate Total which contains triclosan
58122248|NCT00165399|DRUG|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
58122249|NCT00165399|DRUG|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
58122250|NCT00165399|DRUG|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
58122251|NCT01691859|DRUG|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
58122252|NCT01989507|DRUG|Nicotine|
58122253|NCT01989507|BEHAVIORAL|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
58122254|NCT01364870|DEVICE|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
58122255|NCT01364870|DEVICE|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
58122256|NCT03987152|DRUG|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
58122257|NCT02051803|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
58122258|NCT02051803|BEHAVIORAL|Health Education (HE)|
58122259|NCT01508936|DRUG|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
58122260|NCT01508936|DRUG|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
58122261|NCT03295643|DEVICE|Mobile smoking cessation program and CO breath sensor device|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
58122262|NCT02989142|BEHAVIORAL|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
58122263|NCT00506753|BEHAVIORAL|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
58122264|NCT00506753|BEHAVIORAL|RT/SU|Relaxation Training followed by Treatment as Usual
58122265|NCT03581474|DEVICE|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
58122266|NCT00290056|DRUG|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
58122267|NCT02240758|PROCEDURE|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
58122268|NCT00002174|DRUG|Thalidomide|
58122269|NCT00766584|OTHER|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
58314114|NCT05684107|PROCEDURE|IPACK block|the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
58314115|NCT05684107|PROCEDURE|adductor canal block|"the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn"
58122270|NCT05152641|DRUG|BGE-117, 4mg|BGE-117, 4mg Capsules
58122271|NCT05152641|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous Sulfate, 325mg Tablets
58122272|NCT05152641|OTHER|Matching Placebo|Matching Placebo to BGE-117 Capsules
58122273|NCT05152641|DRUG|BGE-117, 12mg|BGE-117, 12mg Capsules
58122274|NCT05775913|DEVICE|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
58122275|NCT02625948|DRUG|Tranexamic Acid|
58122276|NCT04223050|DRUG|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
58122277|NCT03496870|DRUG|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
58122278|NCT03496870|DRUG|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
58122279|NCT04604665|OTHER|High frequency postural change|"Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs."
58122280|NCT04604665|OTHER|Conventional care|Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
58122281|NCT03955679|GENETIC|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
58122282|NCT05830006|PROCEDURE|Microfat grafting|Microfat grafting in cleft lip nasal deformities
58122283|NCT03583333|DRUG|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
58122284|NCT03583333|DRUG|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
58122285|NCT03583333|DRUG|Linezolid|Open-label 600 mg Linezolid
58122286|NCT05731713|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
58122287|NCT02314377|DRUG|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
58122288|NCT01555320|DRUG|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
58122289|NCT01555320|DRUG|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
58122290|NCT06544668|OTHER|Breast cancer patients with bone metastasis|This study is an observational study
58122291|NCT06544668|OTHER|Breast cancer patients without bone metastasis|This study is an observational study
58122292|NCT04023279|OTHER|TENS|100 Hz and 100 usec for 20 minutes
58122293|NCT04023279|OTHER|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
58122294|NCT05191446|BEHAVIORAL|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
58122295|NCT05191446|OTHER|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
57747931|NCT02470546|DRUG|Metformin|Metformin 1000mg twice a day
57747932|NCT02470546|DRUG|Placebo|Placebo 1000mg twice a day
57747933|NCT06097754|DIETARY_SUPPLEMENT|Ketone ester|"Ketone ester: A total of 300g ketone ester supplementation will be provided in one of the 72h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
57747934|NCT06097754|DIETARY_SUPPLEMENT|Placebo|"Placebo: Water, 5% sucralose (w/w), octaacetate (1 mM)~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
57747935|NCT05961358|PROCEDURE|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
58122296|NCT01946347|OTHER|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
58122297|NCT01946347|OTHER|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
58122298|NCT02676154|DRUG|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
57747936|NCT05961358|PROCEDURE|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
57747937|NCT02347020|BEHAVIORAL|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
58314116|NCT05684107|PROCEDURE|sciatic nerve block|patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
58314117|NCT03795948|OTHER|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
58314118|NCT06443827|DRUG|Amantadine Sulfate|intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
58314119|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
58314120|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
58314121|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
58314122|NCT02455193|BEHAVIORAL|Exercise|
58314123|NCT02455193|BEHAVIORAL|Diet|
58314124|NCT05880888|BIOLOGICAL|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
57959465|NCT05088707|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
58314125|NCT04422886|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
58314126|NCT04422886|BEHAVIORAL|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
58314127|NCT04422886|DEVICE|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
57959466|NCT05088707|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
57959467|NCT02975843|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
57959468|NCT06367296|OTHER|Prolonged resistance exercise training|"Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm."
57961538|NCT00976066|DRUG|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
57961539|NCT03239717|OTHER|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
57961540|NCT03239717|OTHER|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
57961541|NCT01972230|DRUG|Sevoflurane|
57961542|NCT01972230|DRUG|Diprivan + Remifentanil TCI|
57961543|NCT00758745|DEVICE|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
57961544|NCT00758745|DEVICE|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
57961545|NCT03959280|OTHER|Tailored intervention|"* The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions."
58314128|NCT04016974|DRUG|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
58314129|NCT04016974|DRUG|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
57747938|NCT02347020|BEHAVIORAL|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
57747939|NCT02347020|BEHAVIORAL|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
57959469|NCT02028195|OTHER|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
57959470|NCT05841095|DRUG|ISA104|SLP vaccine
57959471|NCT05841095|DRUG|Placebo|Saline solution (0.9% NaCl)
57959472|NCT00413361|DRUG|versus hydroxychloroquine|versus hydroxychloroquine
57959473|NCT00432978|DRUG|Bosentan administration|
57959474|NCT02867761|DRUG|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
57959475|NCT02867761|DRUG|Placebo|27.5/15.6 mcg placebo
57959476|NCT00388908|BEHAVIORAL|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
57959477|NCT00388908|OTHER|Usual Care|
57959478|NCT01844895|DRUG|Abatacept|
57959479|NCT01890421|DRUG|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
57959480|NCT05006885|DRUG|ALT-801|Injected subcutaneously (SC)
57959481|NCT05006885|OTHER|Placebo|Injected subcutaneously (SC)
57959482|NCT03317756|OTHER|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
57959483|NCT03317756|OTHER|Patient Control|Patients will receive an attention control
57959484|NCT03923569|DIAGNOSTIC_TEST|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
57959485|NCT03923569|DIAGNOSTIC_TEST|blood sample|blood sample for genetic testing of the Apolipoprotein E
57959486|NCT03923569|DIAGNOSTIC_TEST|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
57959487|NCT03923569|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
57959488|NCT06033235|DIAGNOSTIC_TEST|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
57959489|NCT01843218|OTHER|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
57959490|NCT03865693|DEVICE|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
57959491|NCT02692209|DEVICE|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
57959492|NCT02692209|DEVICE|FFDM Alone|FFDM Alone Images
57959493|NCT00294307|BEHAVIORAL|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];
57961546|NCT03959280|OTHER|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
57961547|NCT04776590|DRUG|Tislelizumab|neoadjuvant immunotherapy
57961548|NCT01700933|OTHER|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
57961549|NCT01700933|OTHER|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
57961550|NCT01726751|DEVICE|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
57961551|NCT01726751|DEVICE|Spinal cord nerve stimulation|
57747940|NCT02347020|BEHAVIORAL|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
57959494|NCT00294307|BEHAVIORAL|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.
57959495|NCT00294307|BEHAVIORAL|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
57959496|NCT06484790|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
57959497|NCT06484790|DRUG|NW-301D|TCR-T T cell targeting KRAS G12D mutation
57959498|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
57961552|NCT04316585|DRUG|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
57961553|NCT04316585|DRUG|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
57961554|NCT01445678|DRUG|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
57961555|NCT01445678|DRUG|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
57961556|NCT05244681|OTHER|Semi-structured interview|Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
57961557|NCT02945631|RADIATION|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
57961558|NCT02945631|RADIATION|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
57961559|NCT02824744|DEVICE|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
57961560|NCT02824744|DEVICE|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
57961561|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about acceptance
57961562|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about refusal
57961563|NCT00030342|BIOLOGICAL|recombinant interferon alfa|
57961564|NCT00030342|BIOLOGICAL|sargramostim|
57961565|NCT00030342|BIOLOGICAL|therapeutic autologous lymphocytes|
57961566|NCT00030342|DRUG|fluorouracil|
57961567|NCT05389878|OTHER|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
57961568|NCT05040308|OTHER|Integrating PrEP delivery|Integration of PrEP delivery services in NSP and MAT programs
57961569|NCT05438316|DRUG|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
57961570|NCT05438316|DRUG|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
57961571|NCT05593887|PROCEDURE|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
57961572|NCT05593887|PROCEDURE|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
57961573|NCT05593887|PROCEDURE|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
57961574|NCT04951258|OTHER|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
57961575|NCT04951258|OTHER|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
57961576|NCT01392820|DRUG|TC-5214|Tablet, Oral, twice daily
57961577|NCT01392820|DRUG|Placebo|Tablet, Oral, twice daily
57961578|NCT05531669|BEHAVIORAL|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
57961579|NCT05531669|BEHAVIORAL|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
57961580|NCT05357300|DEVICE|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
57961581|NCT01871454|RADIATION|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
57961582|NCT01871454|DRUG|Pentoxifylline|pentoxifylline
58450599|NCT02472574|DEVICE|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
58450600|NCT02472574|DRUG|rt-PA|Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
58450601|NCT02311114|OTHER|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
58450602|NCT02311114|OTHER|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
58450603|NCT02311114|OTHER|Survey|Surveys with participants will be conducted using validated survey tools.
57747941|NCT01175915|OTHER|Western therapy|"1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~3. No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
57959499|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
57959500|NCT00955630|DRUG|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
57959501|NCT00955630|DRUG|ranibizumab|prn injections of ranibizumab throughout the study
57959502|NCT03335332|BEHAVIORAL|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
57959503|NCT03335332|BEHAVIORAL|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
57959504|NCT03678402|DEVICE|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
57959505|NCT01325428|DRUG|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
57959506|NCT01325428|DRUG|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
57959507|NCT05853614|BEHAVIORAL|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
57959508|NCT04977180|DRUG|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
57959509|NCT05151055|DIETARY_SUPPLEMENT|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
57959510|NCT05151055|DIETARY_SUPPLEMENT|Placebo|starch
57961583|NCT05462431|BEHAVIORAL|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
57961584|NCT04123899|DRUG|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
57961585|NCT04123899|DRUG|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
57961586|NCT01463098|DRUG|E2006 1.0 mg|E2006 1.0 mg capsule.
57961587|NCT01463098|DRUG|E2006 2.5 mg|E2006 2.5 mg capsule.
57961588|NCT01463098|DRUG|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
57961589|NCT01463098|DRUG|E2006 10.0 mg|E2006 10.0 mg capsule.
57961590|NCT01463098|DRUG|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
57961591|NCT01463098|DRUG|E2006 50.0 mg|E2006 50.0 mg capsule.
57961592|NCT01463098|DRUG|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
57961593|NCT01463098|DRUG|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
57961594|NCT01463098|DRUG|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
57961595|NCT01463098|DRUG|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
58122299|NCT06297889|BEHAVIORAL|core strength training 1-6weeks|Behaviour: core strength training intervention for 1-6 weeks. Experimental: The experimental group performed core strength training during weeks 1-3. Subjects were first provided with basic information, familiarised with the content of the first phase of core strength training and watched a core strength video to understand its importance. The initial intervention was designed to ensure that subjects were proficient in core strength training, including warm-up and stretching patterns. During weeks 4-6, subjects will be supervised and assisted and a test will be organised at the end of week 6. Variables related to physical fitness and skills were recorded to assess whether core strength training improved physical fitness and skills.
58122300|NCT06297889|BEHAVIORAL|core strength training 7-12weeks|"Behaviour: core strength training intervention #7-12 weeks#.~Experimental: Weeks 7-9 were the experimental group:~Continued to warm up before each training session. The training content will increase in difficulty during this phase, and the supervisor should explain the training content and watch videos of the movements prior to training and prepare the training equipment in advance to protect the athlete from injury. Weeks 10-12: This is an advanced stage, requiring equipment and difficult movements to complete, please supervisors to arrange personnel to do a good job of protection to ensure that the subjects can complete the training tasks. A test will be conducted the day after Week 12 to measure the athlete's physical fitness and skills."
58122301|NCT01326403|DRUG|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
58122302|NCT02568384|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
58122303|NCT05628675|OTHER|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
58122304|NCT05435001|DEVICE|Holter ECG Monitoring|Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
58122305|NCT02385526|DEVICE|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
58122306|NCT01025856|OTHER|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
58122307|NCT01025856|OTHER|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
58122308|NCT01025856|OTHER|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
58122309|NCT01025856|OTHER|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
58122310|NCT01791283|PROCEDURE|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
58122311|NCT06203275|DRUG|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
58122312|NCT06203275|DRUG|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
58122313|NCT03617484|DRUG|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
58122314|NCT03617484|DRUG|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
58122315|NCT04155164|DRUG|Metformin|Participants will receive Metformin at 1000mg for 12 months.
58122316|NCT04155164|DRUG|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
58122317|NCT06483659|DRUG|Oxytocin|Intravenous Oxytocin infusion
58122318|NCT06483659|DRUG|Placebo|0.9% Saline
58122319|NCT04132661|DRUG|Bisacodyl 5 milligram|one single dose
58450604|NCT04055779|OTHER|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
58122320|NCT04132661|DRUG|Placebo oral tablet|one single dose
58122321|NCT03650582|DRUG|Glucagon|Intranasal glucagon
58122322|NCT03650582|DRUG|Placebo|Intranasal placebo
58450605|NCT04055779|OTHER|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
57747942|NCT01175915|OTHER|Reduning Injection|"1. Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~2. Reduning Injection, 0.5\~15ml, depending on patient's condition, IV per day, or according to the instruction;~3. Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
57959511|NCT02090712|PROCEDURE|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
58314130|NCT03852511|BIOLOGICAL|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
58314131|NCT01235221|DRUG|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
58314132|NCT01730313|DRUG|Pyridoxine|
58314133|NCT01730313|DRUG|Sodium Valproate|
58314134|NCT01730313|DRUG|Phenytoin|
58314135|NCT01730313|DRUG|Placebo|
58314136|NCT00090532|DRUG|AG-013,958|
58314137|NCT02773225|DRUG|Eltrombopag|"* CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
58314138|NCT02773225|DRUG|Placebo (for Eltrombopag)|"* CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --\> dose escalation~* 12 month after start of eltrombopag --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
58314139|NCT01994031|DRUG|Paclitaxel liposome injection|
58314140|NCT01994031|DRUG|Paclitaxel injection|
58314141|NCT01883167|DRUG|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
58314142|NCT01883167|DRUG|Febuxostat 40 mg|Febuxostat 40 mg qd
58314143|NCT01883167|DRUG|placebo|placebo qd
58314144|NCT04146701|OTHER|Blood draw|venous blood withdraw (ca. 40ml)
58314145|NCT03913962|OTHER|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
58314146|NCT05849857|DRUG|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
58314147|NCT03290768|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
58314148|NCT03290768|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
58314149|NCT03290768|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
58314150|NCT02314013|DRUG|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
58314151|NCT02634177|GENETIC|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
58314152|NCT02634177|OTHER|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
58314153|NCT03920800|OTHER|Data extraction from medical files|Data extraction from medical files
58314154|NCT03920800|BIOLOGICAL|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
58314155|NCT00375661|DRUG|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
58314156|NCT02629978|PROCEDURE|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
58314157|NCT04923451|DEVICE|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
58314158|NCT04923451|DEVICE|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
58314159|NCT00624208|DRUG|droperidol and saline|droperidol 20 mcg.kg-1 and saline
58314160|NCT00624208|DRUG|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
58314161|NCT00624208|DRUG|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
58314162|NCT00624208|DRUG|saline and saline|saline and saline
58314163|NCT04326374|DRUG|TransCon hGH|Once weekly subcutaneous injection
58314164|NCT04326374|DRUG|daily hGH|Once daily subcutaneous injection
58314165|NCT00254085|DRUG|Insulin Aspart|
58314166|NCT01552486|OTHER|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
58314167|NCT01552486|OTHER|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
58450606|NCT00703924|DRUG|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
58450607|NCT00703924|DRUG|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
58450608|NCT02722226|OTHER|Simulation|High fidelity simulation based sedation learning program
57959512|NCT05552911|PROCEDURE|Pretreatment strategies before drug balloon therapy|Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
57959513|NCT05552911|PROCEDURE|Different types of in-stent restenosis were treated with drug-coated balloons|A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
57959514|NCT02268058|DRUG|Acetaminophen|routine administration of medication for a 72 hour period
57959515|NCT02268058|DRUG|Ibuprofen|routine administration of medication for a 72 hour period
57959516|NCT04218253|DIETARY_SUPPLEMENT|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
57959517|NCT04218253|BEHAVIORAL|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
57959518|NCT02971670|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
57959519|NCT02474082|BIOLOGICAL|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
57959520|NCT02474082|DRUG|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
57959521|NCT06364085|DEVICE|Neuromodulation programming|"Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up."
57959522|NCT02979665|DRUG|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
57959523|NCT03378908|BEHAVIORAL|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
57959524|NCT04890210|DIETARY_SUPPLEMENT|Early Diet Group|Initiation of clear fluid diet 1 hour after esophageal variceal ligation
57959525|NCT04890210|DIETARY_SUPPLEMENT|Late Diet Group|Initiation of clear fluid diet 6 hours after esophageal variceal ligation
57959526|NCT01112046|PROCEDURE|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
57959527|NCT01112046|PROCEDURE|Laparoscopic resection|Surgical treatment performed under general anesthesia
57959528|NCT04930055|BIOLOGICAL|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
57959529|NCT01119248|OTHER|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
57959530|NCT02387580|DRUG|OZ439 + TPGS|
57959531|NCT02387580|DRUG|OZ439 Prototype 1|
57959532|NCT02387580|DRUG|OZ439 Prototype 3|
57959533|NCT02387580|DRUG|PQP|
57959534|NCT02260843|OTHER|Generic Fitness|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
57959535|NCT02260843|OTHER|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
57959536|NCT01394939|BIOLOGICAL|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
57959537|NCT01394939|DRUG|Irinotecan|180 mg/m2 IV every 2 weeks.
57959538|NCT02535533|DRUG|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
57959539|NCT02535533|DRUG|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
57959540|NCT02535533|DRUG|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
57959541|NCT02535533|DRUG|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
58122323|NCT01543100|OTHER|blood and bone marrow samples|"Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
58314168|NCT00710658|BEHAVIORAL|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
58450609|NCT02722226|DEVICE|Airway management|Workshop on using airway management and oxygenation devices.
58450610|NCT02722226|BEHAVIORAL|Crisis resource management|Learning crisis resource management principles
58450611|NCT00681889|DRUG|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
58450612|NCT03771651|DRUG|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
58450613|NCT03647826|BEHAVIORAL|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
57747943|NCT01175915|OTHER|Reduning Injection plus western therapy|"1. General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~2. Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~3. Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
57959542|NCT02535533|DRUG|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
57959543|NCT02365168|OTHER|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
58450614|NCT00135889|DRUG|Femoral perineural infusion|
57747944|NCT06415357|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.
57959544|NCT02365168|OTHER|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
57959545|NCT02365168|OTHER|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
57959546|NCT02365168|OTHER|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
57959547|NCT00083083|DRUG|carboplatin|
57959548|NCT00083083|DRUG|cisplatin|
57959549|NCT00083083|DRUG|docetaxel|
57959550|NCT00083083|DRUG|etoposide|
57959551|NCT00083083|DRUG|paclitaxel|
57959552|NCT00083083|DRUG|vinblastine sulfate|
57959553|NCT00083083|DRUG|vinorelbine tartrate|
57959554|NCT00083083|GENETIC|gene expression analysis|
57959555|NCT00083083|PROCEDURE|positron emission tomography|
57959556|NCT00083083|RADIATION|fludeoxyglucose F 18|
57959557|NCT00083083|RADIATION|radiation therapy|
57959558|NCT00782457|PROCEDURE|RECTAL CANCER RESECTION|
57959559|NCT05804708|DRUG|GH001|GH001 is administered via inhalation
57959560|NCT01446419|DEVICE|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
57959561|NCT01446419|DEVICE|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
57959562|NCT01849770|DRUG|Mexiletine|
57959563|NCT01849770|DRUG|Placebo|
57959564|NCT00847366|DRUG|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
57959565|NCT00847366|DRUG|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
57959566|NCT00847366|DRUG|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
57961596|NCT01463098|DRUG|E2006 Matched Placebo|E2006-matched placebo capsule.
57961597|NCT03404011|OTHER|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
57961598|NCT03404011|DEVICE|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
57961599|NCT01791608|DIETARY_SUPPLEMENT|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
57961600|NCT01791608|DIETARY_SUPPLEMENT|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
57961601|NCT01791608|DIETARY_SUPPLEMENT|Milk without fortification without zinc|Milk without fortification
57961602|NCT03754309|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
57961603|NCT03754309|DRUG|Placebo|Matched placebo
57961604|NCT03445078|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
57961605|NCT03445078|DIETARY_SUPPLEMENT|ordinary corn powder|ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
58450615|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
58450616|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
58122324|NCT02934750|BEHAVIORAL|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~1. Breathe in through your nose (as if you are smelling something) for about 2 seconds.~2. Pucker your lips like you're getting ready to blow out candles on a birthday cake.~3. Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~4. Repeat."
58122325|NCT02984306|DIETARY_SUPPLEMENT|Cherry powder|
58122326|NCT02984306|DIETARY_SUPPLEMENT|Placebo|
58122327|NCT03389386|DIAGNOSTIC_TEST|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
58122328|NCT03389386|OTHER|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
58122329|NCT03389386|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
58122330|NCT01197313|OTHER|Home-based exercise|
58122331|NCT00322400|DRUG|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
58122332|NCT00322400|DRUG|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
58122333|NCT00322400|DRUG|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
58314169|NCT00988338|BIOLOGICAL|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
58450617|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
58450618|NCT03292380|OTHER|No intervention was included|
58450619|NCT01236521|DRUG|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
58450620|NCT01236521|BEHAVIORAL|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
58450621|NCT02471014|DRUG|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
58450622|NCT02471014|OTHER|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
57747945|NCT06415357|BEHAVIORAL|Motivational Text Messaging (MTM)|Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.
57747946|NCT06415357|BEHAVIORAL|Standard ART Counseling|All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
57747947|NCT06370988|DEVICE|iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
57747948|NCT06370988|DEVICE|Sham iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
57747949|NCT04766762|PROCEDURE|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
57959567|NCT05222217|DEVICE|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
57959568|NCT00870064|PROCEDURE|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
57959569|NCT00870064|PROCEDURE|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
58450623|NCT02471014|OTHER|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
58450624|NCT02194595|DRUG|Basal insulin and exenatide|
58122334|NCT04805684|DEVICE|LUS Twelve area|Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
58122335|NCT04805684|DEVICE|LUS Fourteen area|Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
58122336|NCT00231868|DRUG|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
58122337|NCT00231868|PROCEDURE|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
58122338|NCT00231868|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
58122339|NCT03997747|OTHER|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
58450625|NCT02194595|DRUG|Basal insulin only|
58450626|NCT02194595|DRUG|Basal insulin and bolus insulin|
57747950|NCT04766762|PROCEDURE|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
57747951|NCT00828984|DRUG|macrogol 3350-based oral osmotic laxative|Given PO
57747952|NCT00828984|OTHER|Placebo|Given PO
57747953|NCT00828984|OTHER|Laboratory Biomarker Analysis|Correlative studies
57959570|NCT03721094|OTHER|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
57959571|NCT00662103|BEHAVIORAL|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
58122340|NCT01055964|DRUG|Tacrolimus|
58122341|NCT05299268|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
58122342|NCT05299268|BEHAVIORAL|No pain (Isotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
58122343|NCT02022007|DRUG|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
58122344|NCT02022007|DRUG|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
58122345|NCT02022007|DRUG|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
58122346|NCT06227065|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
58450627|NCT04373226|BEHAVIORAL|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
58450628|NCT05853822|OTHER|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
58450629|NCT05853822|OTHER|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
58450630|NCT06097065|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Grouping based on detected oral glucose tolerance test results without any other intervention.
57747954|NCT00202202|PROCEDURE|consultation format|
57747955|NCT01417507|PROCEDURE|cognitive assessment|Undergo neurocognitive assessment
57747956|NCT01417507|PROCEDURE|magnetic resonance imaging|Undergo MRI
57747957|NCT01417507|OTHER|laboratory biomarker analysis|Correlative studies
57747958|NCT01417507|OTHER|questionnaire administration|Ancillary studies
57747959|NCT01417507|PROCEDURE|quality-of-life assessment|Ancillary studies
57747960|NCT05873608|OTHER|Educational video|Testing an educational video
57747961|NCT05873608|OTHER|Interview|Participate in interview
57747962|NCT05873608|OTHER|Observation|Undergo observation
57959572|NCT00662103|OTHER|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health \& Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
57959573|NCT00662103|OTHER|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
57959574|NCT00662103|OTHER|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
58122347|NCT06227065|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
58122348|NCT06227065|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
58122349|NCT06227065|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
58122350|NCT01104519|DRUG|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
58122351|NCT01104519|DRUG|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
58450631|NCT05307354|OTHER|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
57747963|NCT02980055|PROCEDURE|collagen matrix|Surgical procedure for root coverage using collagen matrix
57959575|NCT00662103|PROCEDURE|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
57959576|NCT00662103|PROCEDURE|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
57959577|NCT00662103|PROCEDURE|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
57959578|NCT00662103|PROCEDURE|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
58450632|NCT05307354|OTHER|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
57959579|NCT06400888|OTHER|needle-free subcutaneous injector for Mecbl|needle-free subcutaneous injector for Mecbl
57959580|NCT06400888|OTHER|intramuscular injection of Mecbl|intramuscular injection of Mecbl
57959581|NCT00868283|DRUG|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
57959582|NCT00868283|DRUG|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
57959583|NCT00595712|PROCEDURE|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
57959584|NCT00595712|PROCEDURE|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
57959585|NCT05700903|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH)|8 weeks of GnRH agonist
58122352|NCT02033525|DRUG|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
57959586|NCT05700903|DRUG|Androgen receptor (AR) inhibitor|2 weeks of AR Inhibitor
57959587|NCT05700903|DRUG|Placebo|Placebo tablet and injection
57959588|NCT01482364|DEVICE|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
57959589|NCT01482364|DEVICE|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
57959590|NCT05815589|OTHER|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
57959591|NCT05588570|BEHAVIORAL|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
58122353|NCT02033525|OTHER|Rehabilitation|Standard rehabilitation program
58122354|NCT03632174|OTHER|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
58122355|NCT03632174|OTHER|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
58122356|NCT03631524|DEVICE|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
58122357|NCT04044430|DRUG|Binimetinib|Given PO
58122358|NCT04044430|DRUG|Encorafenib|Given PO
58122359|NCT04044430|BIOLOGICAL|Nivolumab|Given IV
58122360|NCT04044430|OTHER|Questionnaire Administration|Ancillary studies
58122361|NCT04670913|DRUG|Camrelizumab|A human anti-PD-1 monoclonal antibody
58122362|NCT04670913|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
57747964|NCT02980055|PROCEDURE|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
58122363|NCT00999869|DRUG|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
58450633|NCT03862183|OTHER|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
57747965|NCT01124760|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
57747966|NCT01124760|DRUG|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
57747967|NCT01124760|DRUG|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
57747968|NCT02923843|OTHER|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
57747969|NCT02331862|DRUG|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
57747970|NCT01107860|DEVICE|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
57747971|NCT01107860|DEVICE|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
57747972|NCT02257268|BEHAVIORAL|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
57959592|NCT06303934|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
58122364|NCT00999869|DRUG|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
58122365|NCT04049331|DRUG|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
58122366|NCT04049331|OTHER|placebo|first two doses four weeks apart; following three more doses every ten weeks.
58122367|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
58122368|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
58122369|NCT00645489|BEHAVIORAL|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
58122370|NCT00645489|OTHER|wait list|Wait list
58122371|NCT04871737|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
58122372|NCT01604213|DRUG|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
57747973|NCT05753150|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
57747974|NCT05753150|DRUG|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
58122373|NCT01604213|DRUG|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
58122374|NCT04546607|OTHER|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
58122375|NCT01684410|BIOLOGICAL|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
58122376|NCT01684410|BIOLOGICAL|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
58122377|NCT01684410|BIOLOGICAL|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
58122378|NCT05496075|DRUG|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
58122379|NCT05496075|DRUG|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
58122380|NCT04236765|OTHER|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
58122381|NCT00788190|PROCEDURE|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
58122382|NCT00788190|OTHER|Conservative Management|Conservative management of Distal Radius Fractures
58122383|NCT02867904|DRUG|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
58122384|NCT02867904|DRUG|Marcaine (4ml 0.5%, injection)|Control
58122385|NCT00163384|DRUG|Ciclesonide|
58122386|NCT05783479|DRUG|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
58122387|NCT05783479|DRUG|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
58122388|NCT05751070|OTHER|Bowen Technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Bowen treatment will be 15 to 20 Bowen moves with 2 mins gap between each set for total of 20 mins."
58122389|NCT05751070|OTHER|Graston technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Graston treatment will be by using lubricant on the skin then a stainless steel instrument to relax the fascia and muscles. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute for total of 20 mins."
58122390|NCT03093454|DRUG|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
58122391|NCT03734237|BIOLOGICAL|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
58122392|NCT03734237|BIOLOGICAL|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
58122393|NCT03734237|BIOLOGICAL|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
58122394|NCT01398579|PROCEDURE|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
58122395|NCT00257296|OTHER|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
58122396|NCT00257296|OTHER|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
58122397|NCT01948505|DRUG|Intravenous acetaminophen|
58122398|NCT01948505|DRUG|Placebo for IV acetaminophen|
58122399|NCT01455558|DRUG|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
58122400|NCT03316313|DIAGNOSTIC_TEST|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
58314170|NCT02484521|DEVICE|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
58450634|NCT04402424|DIAGNOSTIC_TEST|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
58450635|NCT03062514|DEVICE|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
58450636|NCT02472717|DRUG|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
58450637|NCT02472717|OTHER|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
58450638|NCT05880966|BEHAVIORAL|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
57747975|NCT05753150|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
57747976|NCT05801211|PROCEDURE|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
58122401|NCT05549284|DRUG|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
58122402|NCT05265195|OTHER|Mixed Methods study|Mixed Methods study
58122403|NCT05289622|DEVICE|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
58122404|NCT01009398|OTHER|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
58122405|NCT04954950|OTHER|no intervention|no intervention
58122406|NCT05575375|BEHAVIORAL|Values Affirmation + Usual Care|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. The participant's study medication monitoring devices will be labeled with the participants' most important core value(s). Participants will also continue with their usual care.
58122407|NCT05575375|OTHER|Usual Care|Participants will be asked to continue with their usual care (e.g., cardiac rehabilitation, ongoing medical management)
58122408|NCT04812106|OTHER|No Intervention|No Intervention
58122409|NCT00006166|PROCEDURE|Transjugular intrahepatic portasystemic shunts (TIPS)|
58122410|NCT00006166|PROCEDURE|Total paracentecis (TP)|
58122411|NCT04621409|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
58122412|NCT04621409|BIOLOGICAL|Placebo|IV infusion of saline, approximately 5 hours
58122413|NCT01968798|DRUG|Aspirin|100mg enteric-coated aspirin, taken daily
58122414|NCT01968798|DRUG|Placebo|100mg enteric-coated placebo, taken daily
58122415|NCT01189825|BEHAVIORAL|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
58122416|NCT03376594|DRUG|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
58122417|NCT03376594|DRUG|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
58122418|NCT06424847|BEHAVIORAL|Lifestyle intervention (physical activity and diet)|"The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet."
58314171|NCT02484521|OTHER|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~1. GAF- Global assessment of functioning~2. PANSS- Positive and negative syndrome scale~3. SANS- Scale for the Assessment of Negative Symptoms~4. The Calgary Depression Scale for schizophrenia~5. Demographic Questionnaire~6. Hamilton Anxiety scale"
58314172|NCT02199574|DRUG|EXPAREL|133 mg EXPAREL in 10 mL.
58450639|NCT00837200|DRUG|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
58450640|NCT01178268|DEVICE|XIENCE V EECSS|Patients who will receive this stent.
58450641|NCT01178268|DEVICE|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
57959593|NCT06303934|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
58450642|NCT00842556|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
57747977|NCT00500877|BEHAVIORAL|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
57959594|NCT06303934|DEVICE|Persistent Nasogastric Tube Feeding|After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
58122419|NCT06424847|BEHAVIORAL|Lifestyle (physical activity and diet) and Sleep intervention|"Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits."
58122420|NCT06424847|BEHAVIORAL|Health education intervention|Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
58122421|NCT03400306|DRUG|Veliparib, capsule|capsule; 50 mg or 100 mg
58122422|NCT03400306|DRUG|Veliparib, tablet|tablet; 400 mg
58122423|NCT03400306|DRUG|Carboplatin|Intravenous
58122424|NCT03400306|DRUG|Paclitaxel|Intravenous
58122425|NCT01482624|DEVICE|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
58122426|NCT01482624|PROCEDURE|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
58122427|NCT00265304|DRUG|Ketoprofen|
58122428|NCT00729859|DRUG|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
58122429|NCT00729859|DRUG|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
58122430|NCT00729859|DRUG|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
58122431|NCT00657956|DEVICE|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
58450643|NCT00842556|DRUG|Glimepiride|Tablets, Oral, 4 mg, Single Dose
58450644|NCT00842556|DRUG|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
58450645|NCT06166381|DRUG|Parenteral Antibacterial Agents|Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
58450646|NCT06166381|DRUG|Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft|in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
57747978|NCT00745810|OTHER|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
57747979|NCT00241527|DRUG|Esomeprazole|
57747980|NCT04582474|OTHER|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
57747981|NCT04467554|DEVICE|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
57747982|NCT04215042|DRUG|sodium chloride infusion|
58122432|NCT05006937|PROCEDURE|Dusting|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
57747983|NCT04858958|DRUG|Furmonertinib 160mg|randomized to 160mg QD
57747984|NCT04858958|DRUG|Furmonertinib 240mg|randomized to 240mg QD
58122433|NCT05006937|PROCEDURE|Basket extraction|Basket extraction is when a small wire basket is used to remove stone fragments.
58450647|NCT01635231|OTHER|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
58450648|NCT04723017|OTHER|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
58450649|NCT04723017|OTHER|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
57747985|NCT04278625|DRUG|Acetaminophen|IV acetaminophen given as part of standard of care.
57747986|NCT01207102|DRUG|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
58122434|NCT04262596|OTHER|Interactive Consulting System|Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
58122435|NCT04262596|OTHER|A traditional patient decision aid brochure|Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
58314173|NCT05517590|DRUG|Tranexamic acid|1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
58314174|NCT05517590|DRUG|Saline|100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
58314175|NCT02957552|BIOLOGICAL|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
57747987|NCT01207102|DRUG|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
57747988|NCT03093831|DRUG|Ibrutinib|560mg administered orally once daily.
57747989|NCT03701984|DRUG|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
57747990|NCT03701984|DRUG|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
58450650|NCT02686918|OTHER|Advanced Practice Nurse consultation|
58450651|NCT02168907|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
58122436|NCT06483607|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
58122437|NCT06483607|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
58122438|NCT01927536|DEVICE|White LED Flashlight|white light setting
58122439|NCT01927536|DEVICE|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
58122440|NCT02275923|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
58122441|NCT05625256|DEVICE|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
58122442|NCT01843283|BEHAVIORAL|Daily Enhancement Meaningful Activity (DEMA)|
58122443|NCT01843283|BEHAVIORAL|Information Support (IS)|
58122444|NCT01054599|DRUG|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
58122445|NCT01054599|OTHER|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
58122446|NCT01054599|DRUG|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
58122447|NCT04185558|DEVICE|ActiGraft|Whole Blood Clot (WBC) gel
58122448|NCT04185558|DEVICE|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
58122449|NCT04954014|DRUG|Bevacizumab|Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
57747991|NCT03701984|DRUG|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
57747992|NCT00886340|BEHAVIORAL|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
58122450|NCT04954014|DRUG|BAT|Patients will receive best available treatment for COVID-19.
58122451|NCT02197533|OTHER|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
58122452|NCT00521456|DRUG|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
58450652|NCT02168907|DRUG|bendamustine hydrochloride|Given IV
58450653|NCT02168907|BIOLOGICAL|rituximab|Given IV
58450654|NCT02168907|OTHER|laboratory biomarker analysis|Correlative studies
57747993|NCT00886340|BEHAVIORAL|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
58122453|NCT04395365|DRUG|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
58122454|NCT04395365|DRUG|Placebo oral tablet|Placebo
58122455|NCT00046709|DRUG|Smoked Marijuana|
58122456|NCT05073653|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
58122457|NCT05073653|DIAGNOSTIC_TEST|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
58450655|NCT01773486|DRUG|Hesperidin|Citrus polyphenol, hesperidin
58450656|NCT01773486|DRUG|Placebo|Placebo matching hesperidin
57747994|NCT03376581|PROCEDURE|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
57747995|NCT01423630|DIETARY_SUPPLEMENT|Probiotics and fruit fibre|probiotics and fruit fibre
57747996|NCT01834885|DRUG|QVA149|QVA149 via inhaler twice a day
57747997|NCT01834885|DRUG|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
57747998|NCT02311530|DRUG|Felodipine|Extended Release Tablets, 10mg
58122458|NCT04538963|DEVICE|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
58122459|NCT00815451|DIETARY_SUPPLEMENT|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
58122460|NCT00815451|DIETARY_SUPPLEMENT|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
58122461|NCT01325675|BEHAVIORAL|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
58122462|NCT04258670|OTHER|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)
58122463|NCT03996486|DRUG|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
58122464|NCT00544765|DRUG|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
58122465|NCT00544765|DRUG|NX|Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
58122466|NCT01689259|DRUG|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
58122467|NCT01689259|DRUG|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
58122468|NCT01689259|DRUG|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
58122469|NCT01689259|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
58122470|NCT00049036|BIOLOGICAL|rituximab|Given IV
58122471|NCT00049036|DRUG|etoposide|Given IV
58122472|NCT00049036|DRUG|doxorubicin hydrochloride|Given IV
58122473|NCT00049036|DRUG|vincristine sulfate|Given IV
58122474|NCT00049036|DRUG|prednisone|Given orally
58122475|NCT00049036|DRUG|cyclophosphamide|Given IV
58122476|NCT00049036|OTHER|laboratory biomarker analysis|Correlative studies
58122477|NCT03680170|BEHAVIORAL|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
58122478|NCT03680170|BEHAVIORAL|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
58122479|NCT00152165|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
58122480|NCT04523649|DEVICE|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
58122481|NCT05918523|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
58450657|NCT02747810|DEVICE|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
58122482|NCT01768728|PROCEDURE|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
58122483|NCT01768728|PROCEDURE|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
57959595|NCT01221428|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
58122484|NCT03777670|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
57959596|NCT03264430|DRUG|Ketamine|an antagonist of the NMDA receptor
58122485|NCT01027442|DEVICE|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
58122486|NCT01027442|DEVICE|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
57747999|NCT02311530|DRUG|Felodipine (Plendil®)|
58122487|NCT01027442|DEVICE|Dental Implants|Dental implants placed via conventional free-hand method
58314176|NCT00091858|DRUG|Darbepoetin Alfa|6.75 mcg/kg Q4W
57959597|NCT03264430|DRUG|bupivacaine|local anaesthetic
58122488|NCT06544837|DIAGNOSTIC_TEST|Window of Implantation|Determine the subject's window of implantation through testing and adjust the embryo implantation time
58122489|NCT02201498|PROCEDURE|Pulpotomies with Formocresol/OZE and Biodentine|
58122490|NCT04891588|DRUG|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
58122491|NCT00017784|DRUG|Valganciclovir|
58314177|NCT00091858|DRUG|Placebo|Placebo Q4W
58122492|NCT00897897|DEVICE|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
58122493|NCT03248479|DRUG|Magrolimab|Administered intravenously
58122494|NCT03248479|DRUG|Azacitidine|Administered according to region-specific drug labeling either subcutaneously or intravenously
58122495|NCT04713696|OTHER|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
58122496|NCT04713696|OTHER|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
58122497|NCT05819008|DIAGNOSTIC_TEST|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995)."
58122498|NCT04852536|DEVICE|Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS|5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.
58122499|NCT05342350|OTHER|GALAD Score|GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)
58122500|NCT05698381|DIETARY_SUPPLEMENT|Liquid vinegar|2 tablespoons consumed twice daily with meals
58122501|NCT05698381|DIETARY_SUPPLEMENT|Vinegar pill|2 pills consumed upon waking
58122502|NCT01519609|DRUG|bowel prep before endoscopy|bowel prep before colonoscopy
58122503|NCT02564913|OTHER|clinical evaluation|
58450658|NCT02478463|DRUG|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
58450659|NCT02478463|DRUG|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
57748000|NCT02553525|PROCEDURE|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
57959598|NCT04560088|BEHAVIORAL|Mindfulness|Mindfulness-based mobile health intervention.
57959599|NCT04560088|BEHAVIORAL|Breathing|Breathing mobile health intervention.
57959600|NCT05522166|OTHER|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
58122504|NCT06075654|OTHER|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
58122505|NCT04055363|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
58122506|NCT01820377|BEHAVIORAL|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
58122507|NCT05655936|BEHAVIORAL|Heart Health Doula Intervention Program|The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
58122508|NCT05655936|BEHAVIORAL|Usual Care|Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
58122509|NCT04481971|DRUG|Prednisolone|Tablets
58122510|NCT04481971|DRUG|lactose in capsules gelatin|Tablets
58450660|NCT05974930|DEVICE|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
58122511|NCT05518942|BEHAVIORAL|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
58122512|NCT04790305|DRUG|Huaier Granule|The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
58122513|NCT02229890|DRUG|alteplase|
58122514|NCT01489722|DRUG|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
58122515|NCT01566409|DRUG|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
58122516|NCT01566409|OTHER|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
58122517|NCT04489407|DEVICE|Remote Photoplethysmography (rPPG) vital sign acquisition|Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
58122518|NCT04840979|DRUG|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
58122519|NCT04840979|DRUG|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
58122520|NCT01781039|DEVICE|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (\> 50% of the time), and 100 persons reporting little difficulty HIN (\< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
58122521|NCT05572411|OTHER|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
58122522|NCT03845933|PROCEDURE|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
58122523|NCT00138385|BIOLOGICAL|FluMist|
58122524|NCT00138385|BIOLOGICAL|Fluzone|
58122525|NCT00362986|DRUG|sunscreen|
58122526|NCT00362986|OTHER|placebo|
58122527|NCT05067348|DRUG|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
58122528|NCT00894907|OTHER|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI \>12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP\>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP\>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP\>65mmHg (MAP: Mean Arterial Pressure); IAPP \>60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
57748001|NCT02553525|PROCEDURE|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
57748002|NCT01850979|DRUG|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
57748003|NCT01850979|DRUG|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
57748004|NCT04913844|OTHER|Physical performance tests and observational assessments|There will be no interventions. Physical performance tests and observational assessments will be conducted.
57959601|NCT01564615|DEVICE|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
58122529|NCT00894907|OTHER|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP \>65mmHg;IAPP \>60mmHg"
58122530|NCT04511390|DEVICE|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
58122531|NCT03864588|DRUG|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
58450661|NCT02248805|DRUG|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
58450662|NCT02908126|DRUG|Oxytocin|Oxytocin drug
58450663|NCT00290173|DRUG|efficacy of oral ritodrine in maintaining uterine quiescence|
58450664|NCT00158717|DRUG|Hepsera|
58122532|NCT01058421|PROCEDURE|intensive physical therapy|four week course of daily intensive physical therapy
58122533|NCT01058421|PROCEDURE|control group|four weeks of routine physical therapy
58122534|NCT04025619|DEVICE|tape|Sports tape
58122535|NCT04560764|DEVICE|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
58122536|NCT04560764|DEVICE|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
58122537|NCT04560764|DEVICE|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
58122538|NCT04560764|OTHER|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
58122539|NCT02872649|DRUG|Dabigatran|
58122540|NCT02872649|DRUG|Phenprocoumon|
58122541|NCT03321058|BEHAVIORAL|Assessment|Assessment of patients' medication organisation and comprehension of generics
58122542|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
58122543|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
58122544|NCT03154658|DRUG|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
58122545|NCT02295709|PROCEDURE|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
58122546|NCT02295709|PROCEDURE|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
58122547|NCT02295709|DRUG|Dexamethasone|One of the most efficient steroids
58122548|NCT02295709|DEVICE|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
58122549|NCT02295709|RADIATION|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
57748005|NCT02918110|DRUG|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
57748006|NCT04802941|DEVICE|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
57748007|NCT04802941|DRUG|General practice|General practice
58122550|NCT05906082|BEHAVIORAL|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
58122551|NCT05906082|BEHAVIORAL|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
57748008|NCT04320628|DEVICE|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
57748009|NCT04320628|OTHER|NSS|NSS
57748010|NCT02821403|DEVICE|clear lens with regular coating|
57748011|NCT02821403|DEVICE|regular coating lens with yellow tint|
57748012|NCT02821403|DEVICE|clear lens with blue-light blocking coating|
57748013|NCT01691833|DIETARY_SUPPLEMENT|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
58122552|NCT04837053|OTHER|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
58122553|NCT04837053|OTHER|Routine care|Care as usual within the included study sites.
58122554|NCT04524299|RADIATION|chest radiation(IMRT)|Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
58314178|NCT03352284|DEVICE|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
58122555|NCT04524299|DRUG|Concurrent chemotherapy twice a week|"During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy"
58122556|NCT04524299|DRUG|Concurrent chemotherapy once a week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
58122557|NCT00002175|DRUG|Dinitrochlorobenzene|
58122558|NCT04879810|PROCEDURE|Sigmoidoscopy and biopsy, blood work|Flexible tube up lower colon, blood draws, quality of life questionnaires
58122559|NCT02471066|DEVICE|rTMS|"* Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
58122560|NCT06546189|DIETARY_SUPPLEMENT|OMNi BiOTiC® 41167|"The product OMNi BiOTiC® 41167 contains lactobacillus strains"
58122561|NCT06546189|OTHER|Placebo|Placebo
58122562|NCT04127409|OTHER|Control Chicken-meat|
58122563|NCT04127409|OTHER|Control Eggs|
58122564|NCT04127409|OTHER|Omega-3-PUFA Enriched Chicken-meat|
58122565|NCT04127409|OTHER|Omega-3PUFA Enriched Eggs|
58122566|NCT06413537|DRUG|SPG601|synthetic small molecule
58314179|NCT00724776|BIOLOGICAL|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
58450665|NCT04609631|BEHAVIORAL|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
58450666|NCT04609631|BEHAVIORAL|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
57748014|NCT01691833|DIETARY_SUPPLEMENT|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
57748015|NCT02219126|OTHER|Dietary intervention|
57748016|NCT04508439|DRUG|Enoxaparin|Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
57748017|NCT02279043|BEHAVIORAL|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
57959602|NCT01564615|DEVICE|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
57959603|NCT01954693|DRUG|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
57959604|NCT01954693|DRUG|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
57959605|NCT00035880|DRUG|ABX-CBL|
57959606|NCT01936545|DRUG|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
57959607|NCT01936545|DRUG|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
57959608|NCT00511355|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
57959609|NCT00511355|DRUG|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
57959610|NCT01934283|DEVICE|urine folly catheter|
57959611|NCT01745146|BEHAVIORAL|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
57959612|NCT01745146|BEHAVIORAL|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
57959613|NCT01384578|DRUG|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
57959614|NCT01384578|DRUG|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
57959615|NCT02070042|DRUG|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
57959616|NCT02070042|DRUG|Placebo|Placebo capsules (olive oil) twice a day
57959617|NCT02876887|DRUG|Cocoa|
57959618|NCT02876887|DRUG|Placebo|
57959619|NCT05344456|DEVICE|Change in the device PVC algorithm to ''Off''|PVC algorithm change from Atrial Pace mode to Off
57959620|NCT05244265|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).
57959621|NCT05244265|BEHAVIORAL|Treatment as usual (TAU)|Different interventions and support in outpatient and other services.
57959622|NCT00913029|DEVICE|iStent|iStent
57959623|NCT00913029|DRUG|latanoprost/timolol|Combination latanoprost/timolol
57959624|NCT05558956|DRUG|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
58122567|NCT06413537|DRUG|Placebo|Placebo
58122568|NCT06163703|BEHAVIORAL|Family Life Skills Triple P|The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
58122569|NCT02328781|DEVICE|Drug-eluting stent|
58122570|NCT00004776|DRUG|topiramate|
58122571|NCT06412497|DRUG|Rituximab|For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.
58122572|NCT06412497|DRUG|Rabbit ATG|Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.
58122573|NCT06412497|DRUG|Cyclophosphamide|"Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines."
58122574|NCT06412497|DRUG|Fludarabine|For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.
58122575|NCT06412497|RADIATION|Total Body Irradiation|"For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.~Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus."
58122576|NCT06412497|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines.
58122577|NCT06412497|DRUG|Post-Transplant G-CSF|Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.
58122578|NCT06412497|DRUG|Tacrolimus|Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
58122579|NCT06412497|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
58122580|NCT03493100|DIETARY_SUPPLEMENT|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
58122581|NCT03493100|OTHER|Usual care|The control group will receive treatment according to usual care.
58122582|NCT03752593|OTHER|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
58122583|NCT04095299|RADIATION|50.4 Gy to the tumor and elective volume|Standard radiotherapy
58122584|NCT04095299|RADIATION|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
58122585|NCT04095299|DRUG|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
58122586|NCT04501471|BEHAVIORAL|SAAF-T|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
58122587|NCT04501471|BEHAVIORAL|Fuel for Families|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
58314180|NCT04909762|OTHER|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
58314181|NCT06397482|DIETARY_SUPPLEMENT|Encapsulated Calcium Butyrate|Contains at minimum 35% butyric acid
58122588|NCT03145532|OTHER|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
58122589|NCT01253720|BEHAVIORAL|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
58122590|NCT02272868|BIOLOGICAL|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
58122591|NCT02272868|DRUG|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
58122592|NCT02272868|DRUG|rifaximin+omeprazole+miralax|
58122593|NCT02052609|DRUG|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
58122594|NCT02052609|DRUG|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
58122595|NCT00424489|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
58122596|NCT00424489|DRUG|Cyclophosphamide|
58122597|NCT00424489|DRUG|ATG (rabbit)|
58122598|NCT00424489|DRUG|Mesna|
58122599|NCT00424489|DRUG|Methylprednisolone|
58122600|NCT00424489|DRUG|G-CSF|
57959625|NCT04094220|PROCEDURE|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
58122601|NCT01000896|DRUG|AZD0530|film coated tablet, PO, daily
58122602|NCT01000896|DRUG|Carboplatin|intravenous, 3 weeks
58122603|NCT01000896|DRUG|paclitaxel|intravenous, 3 weeks
58122604|NCT00090038|DRUG|rituximab|Dose, schedule,and duration specified in protocol
58122605|NCT01073995|DRUG|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
58122606|NCT02584140|BEHAVIORAL|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
58122607|NCT02584140|BEHAVIORAL|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
58122608|NCT02584140|DRUG|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
58122609|NCT00156949|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
58122610|NCT04469738|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
58122611|NCT04469738|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
58122612|NCT02127996|DRUG|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
58122613|NCT02127996|DRUG|placebo|Normal saline
58450667|NCT02139072|DEVICE|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
58450668|NCT02139072|PROCEDURE|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
58450669|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
58122614|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
58122615|NCT01369277|DRUG|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
58122616|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
58122617|NCT04665505|BEHAVIORAL|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
58122618|NCT04665505|BEHAVIORAL|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
58122619|NCT03775681|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
58122620|NCT03775681|OTHER|Interview|Ancillary studies
58122621|NCT03775681|DEVICE|Laryngeal Mask Airway|Wear LMA
58122622|NCT00234429|DRUG|Gefitinib, raltitrexed|
58122623|NCT00519337|DRUG|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
58122624|NCT00519337|DRUG|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
58122625|NCT00003399|DRUG|carmustine|
58122626|NCT00003399|DRUG|cisplatin|
58122627|NCT00003399|DRUG|cyclophosphamide|
58122628|NCT00003399|DRUG|dexamethasone|
58122629|NCT00003399|DRUG|etoposide|
58122630|NCT00003399|DRUG|melphalan|
58122631|NCT00003399|DRUG|paclitaxel|
58122632|NCT00003399|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
58122633|NCT01005836|BEHAVIORAL|Cognitive behavioral therapy for youth anxiety|
58122634|NCT01005836|OTHER|Usual clinic care|
58122635|NCT01005836|BEHAVIORAL|Cognitive behavioral treatment for youth depression|
58122636|NCT04689074|OTHER|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
58122637|NCT04689074|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
58122638|NCT04689074|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
58122639|NCT01495377|DRUG|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
58122640|NCT01495377|DRUG|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
58450670|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
58450671|NCT01412164|DEVICE|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
58450672|NCT01587144|DRUG|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
58450673|NCT01587144|DRUG|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
58450674|NCT01587144|RADIATION|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
58450675|NCT01587144|DRUG|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
57748018|NCT02279043|BEHAVIORAL|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
57748019|NCT05721131|DEVICE|NC° Thermometer (Gen 3)|The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
57748020|NCT05759416|DRUG|Melatonin2%gel|Intra-pocket application of 2% Melatonin gel
58450676|NCT03703544|OTHER|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
58450677|NCT03703544|OTHER|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
58450678|NCT05441631|DRUG|Insulin|"* Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)"
58450679|NCT05441631|DRUG|Subcutaneous Insulin|"* Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine"
58450680|NCT03870295|DIAGNOSTIC_TEST|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
58450681|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration|After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
57748021|NCT05759416|DRUG|PLACEBO|placebo intra-pocket application
58450682|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration|After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
58450683|NCT03004365|DRUG|C16G2 Varnish|Antimicrobial Peptide
58450684|NCT03004365|DRUG|Placebo Varnish|Placebo
58450685|NCT06101706|BEHAVIORAL|Fatigue assessment|FACIT-F questionnaire and Visual Analog Scale for fatigue
58450686|NCT06101706|BEHAVIORAL|Quality of life assessment|PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
58450687|NCT06101706|OTHER|Assess severity of psoriatic arthritis|DAPSA score
58450688|NCT06101706|OTHER|Assess severity of cutaneous psoriasis|PASI score
58450689|NCT03697642|PROCEDURE|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
58450690|NCT03697642|PROCEDURE|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
57748022|NCT04777045|DRUG|Diltiazem Hydrochloride|"Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm."
57748023|NCT04777045|DRUG|Placebo|Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
57748024|NCT05461781|PROCEDURE|distal radial artery|primary percutaneous coronary intervention via distal radial aretry
57748025|NCT05461781|PROCEDURE|proximal radial aretry|primary percutaneous coronary intervention via proximal radial aretry
57748026|NCT01381796|DRUG|NP101|comparison of NP101 with minor patch modifications
57748027|NCT01381796|DRUG|sumatriptan succinate|tablet, 100 mg
58122641|NCT01495377|DRUG|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
58122642|NCT01495377|DEVICE|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
58122643|NCT00767507|DRUG|cangrelor|
58122644|NCT00767507|OTHER|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
58122645|NCT01904578|OTHER|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
58122646|NCT01904578|OTHER|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
58122647|NCT04000321|OTHER|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
58122648|NCT04000321|OTHER|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
58122649|NCT01523899|DEVICE|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
58122650|NCT01523899|DIAGNOSTIC_TEST|Standard culture|
58122651|NCT03104322|OTHER|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
58122652|NCT03104322|OTHER|usual care|usual care
58122653|NCT00708422|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
58122654|NCT00708422|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
58122655|NCT04363125|DIAGNOSTIC_TEST|Pathology result|Pathology result of rectal biopsy
58122656|NCT02507206|DRUG|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
58122657|NCT02507206|DRUG|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
58122658|NCT05008289|DEVICE|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
58122659|NCT05008289|DEVICE|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
58122660|NCT03830645|BIOLOGICAL|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
58314182|NCT01741870|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
57748028|NCT02173548|DRUG|Anakinra|
58314183|NCT01741870|OTHER|Treatment as usual|routine care
58314184|NCT00125918|DRUG|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
58450691|NCT04308941|DIAGNOSTIC_TEST|Intraocular pressure|The intraocular pressure will be measured using one of three devices
58450692|NCT00202761|BEHAVIORAL|PIH|Intensified training
57748029|NCT02173548|DRUG|Placebo|
57748030|NCT01673906|DRUG|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
57959626|NCT03750266|OTHER|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
57959627|NCT04884048|DIAGNOSTIC_TEST|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
57959628|NCT00691483|DRUG|placebo|placebo tablet taken orally twice daily for 12 weeks
57748031|NCT02248298|DRUG|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
58122661|NCT01691248|DRUG|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
58122662|NCT01691248|DRUG|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
58122663|NCT04813250|OTHER|ventilation mode setting|Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
58122664|NCT02031848|OTHER|Diet Intervention|
58122665|NCT02031848|OTHER|Assessments and Diet Intake|
58122666|NCT00209118|DRUG|paroxetine|
58122667|NCT04750005|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
57748032|NCT02248298|DRUG|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
58122668|NCT04750005|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
58122669|NCT04750005|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
58122670|NCT04750005|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
58122671|NCT01021436|DRUG|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
58122672|NCT04308681|OTHER|BMS-986278 Placebo|Specified Dose on Specified Days
58122673|NCT04308681|DRUG|BMS-986278|Specified Dose on Specified Days
58122674|NCT01937390|DRUG|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
58450693|NCT05206175|OTHER|Affect Treatment Program for Methamphetamine Use Disorder|Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
57959629|NCT00691483|DRUG|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
58122675|NCT01937390|DRUG|Indacterol 300 µg|inhalation powder
58122676|NCT01937390|DRUG|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
58122677|NCT01937390|DRUG|Indacterol 150 µg|inhalation powder
58314185|NCT00125918|DRUG|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
58122678|NCT00731159|BIOLOGICAL|sperm capacitation|sperm capacitation measured at Bar Ilan University
58122679|NCT00731159|OTHER|biologic|sperm synthesis of G-actine to F-actine
58450694|NCT05577338|BEHAVIORAL|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
58450695|NCT05577338|BEHAVIORAL|health education|disease-related health knowledge
58122680|NCT00731159|OTHER|sperm capacitation|sperm synthesis of G-actine to F-actine
58122681|NCT03665181|OTHER|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
58122682|NCT00855283|DRUG|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
58122683|NCT00855283|DRUG|IN NEO|40 mg Neostigmine via intranasal administration
58122684|NCT00855283|DRUG|IN NEO|60 mg Neostigmine via intranasal administration
58314186|NCT00125918|DRUG|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
58314187|NCT00125918|DRUG|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
58314188|NCT00125918|DRUG|placebo|placebo tablet taken by mouth once a day for 16 weeks
58314189|NCT03755817|DEVICE|SCENAR application|Active SCENAR application on the painful area
58314190|NCT03755817|DEVICE|SCENAR application with the device off|Placebo SCENAR application on the painful area
58450696|NCT05010096|DRUG|Copanlisib|Given IV
58450697|NCT05010096|DRUG|Elimusertib|Given PO
58450698|NCT02338544|DRUG|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
58122685|NCT00855283|DRUG|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
58122686|NCT00855283|DRUG|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
58122687|NCT01110265|BEHAVIORAL|attention training|
58122688|NCT01110265|BEHAVIORAL|placebo training|
58122689|NCT01412138|OTHER|genetic analysis|"1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
58122690|NCT03476720|DEVICE|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
58122691|NCT04641936|OTHER|No intervention required|No intervention required
58122692|NCT05033223|OTHER|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
58122693|NCT03383393|DRUG|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
58122694|NCT01606306|DRUG|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
58122695|NCT01606306|DRUG|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
58122696|NCT01606306|DRUG|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
58122697|NCT01623622|DRUG|HC-58|once or more / week
58122698|NCT01623622|DRUG|Placebo|once or more / week
58122699|NCT06015633|OTHER|No intervention|Observational only
58122700|NCT05670054|DRUG|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
58122701|NCT03341507|DEVICE|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
58122702|NCT03341507|DEVICE|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
58122703|NCT03829098|OTHER|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
58122704|NCT03089528|DEVICE|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
58122705|NCT03089528|DEVICE|laringoscope|the trachea will be intubated with a laringoscope
58122706|NCT03049683|OTHER|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
58122707|NCT05226910|DEVICE|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
58122708|NCT05226910|DEVICE|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
58122709|NCT05070156|BIOLOGICAL|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
58122710|NCT05070156|BIOLOGICAL|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
58122711|NCT05070156|BIOLOGICAL|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
58122712|NCT00996190|DRUG|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
58122713|NCT00757913|DIETARY_SUPPLEMENT|n-3 enriched nutrition|
58122714|NCT01579409|OTHER|PNNS guidelines|Application of PNNS guidelines
58122715|NCT02320942|OTHER|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
58122716|NCT02741492|PROCEDURE|Transversus Abdominis Plane Block|Continuous Nerve Block
58122717|NCT02741492|PROCEDURE|Sham Block|Continuous Sham Catheter
58122718|NCT02970643|DRUG|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
58122719|NCT02970643|DRUG|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
58122720|NCT06143059|DRUG|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
58122721|NCT06143059|DRUG|Saline|Saline is administered as the placebo
58122722|NCT02942966|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
58122723|NCT04152629|DRUG|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
57748033|NCT02248298|DRUG|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
57748034|NCT05988996|BEHAVIORAL|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
57748035|NCT01319266|DRUG|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
57748036|NCT03577587|DIETARY_SUPPLEMENT|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
57748037|NCT03577587|DIETARY_SUPPLEMENT|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
57748038|NCT03831659|OTHER|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
57748039|NCT02813070|DRUG|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
57748040|NCT05667220|DRUG|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
58122724|NCT04152629|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
58122725|NCT02511509|DEVICE|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
58122726|NCT02511509|DEVICE|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
58122727|NCT02229240|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
58122728|NCT02229240|DRUG|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
58314191|NCT05634291|OTHER|Standard of care|Standard of care as prescribed by healthcare provider.
58314192|NCT05634291|DEVICE|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
58122729|NCT00981305|DRUG|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
58314193|NCT02433717|DRUG|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
57748041|NCT05667220|DRUG|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
57959630|NCT02112370|DRUG|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
57959631|NCT02112370|OTHER|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
58122730|NCT00981305|DRUG|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
58122731|NCT05847582|BEHAVIORAL|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
58314194|NCT04451083|DRUG|FOY-305|Multiple-dose of FOY-305 will be administered orally at 4 times/day.
58314195|NCT03803696|BEHAVIORAL|Enhanced Standard Care|"* Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material"
58314196|NCT03803696|BEHAVIORAL|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~- 3 Monthly visits with trained study nurse practitioners~* Referral to specialist if~* Psychological etiology~* Sexual Trauma~* Relationship Discord~* Concern for Malignancy or anatomic scarring requiring surgery"
58314197|NCT05300386|DRUG|Escitalopram|We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
58314198|NCT00464685|DRUG|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
58314199|NCT00464685|DRUG|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
58314200|NCT00464685|PROCEDURE|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
58450699|NCT03187119|BEHAVIORAL|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
57959632|NCT00328770|DRUG|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
57959633|NCT02415738|PROCEDURE|Prone positioning|
58122732|NCT05847582|BEHAVIORAL|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
57748042|NCT06458205|COMBINATION_PRODUCT|Multi-component intervention for smokers|"1. Community-based spirometry pulmonary function tests and result interpretations and health education;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for smokers whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to smokers with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients or asthma patients;~7. To actively include smokers whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than11.1mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \<18.5;~9. Pay-for-population mechanism for medical practitioners."
57748043|NCT00838955|DRUG|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
57748044|NCT02073799|PROCEDURE|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
57748045|NCT04893486|DRUG|PTX-022|QTORIN 3.9 % Sirolimus Topical Gel
57748046|NCT04893486|DRUG|Vehicle comparator|Vehicle comparator topical gel
57748047|NCT06072378|BEHAVIORAL|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
57748048|NCT04052204|DRUG|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
58450700|NCT03187119|BEHAVIORAL|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
57748049|NCT04052204|DRUG|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
58450701|NCT06385119|DRUG|Plixorafenib|Oral Tablet
58450702|NCT06385119|DRUG|Cobicistat|Oral Tablet
58450703|NCT06139341|DRUG|BI 765845|BI 765845
58450704|NCT06139341|DRUG|Placebo|Placebo
58450705|NCT03700801|DRUG|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
58450706|NCT03700801|DRUG|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
58450707|NCT03361293|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
57748050|NCT04052204|DRUG|talazoparib|poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
58450708|NCT03361293|BEHAVIORAL|Cognitive training|BrainHQ Computerized cognitive training
58450709|NCT03361293|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
58450710|NCT02241148|DRUG|Acetaminophen 500mg|500 mg, tablets every 8 hours
58450711|NCT02241148|DEVICE|Kinesio taping|Taping will be changed every week.
58450712|NCT03170700|BEHAVIORAL|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
57748051|NCT04052204|DRUG|enzalutamide|androgen receptor inhibitor
57748052|NCT06579521|OTHER|Alcohol|A standard dose of alcohol will be administered (volume calculated with regard to age, sex assigned at birth, height, and weight) in the form of vodka and combined with mixer at a 1:4 ratio to reach a target breath alcohol concentration of .08%.
57748053|NCT06579339|OTHER|xylitol chewing gum|Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
57748054|NCT00910442|DIETARY_SUPPLEMENT|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
57748055|NCT03737838|DEVICE|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
57748056|NCT01826864|BIOLOGICAL|sargramostim|Given SC
57748057|NCT01826864|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
57748058|NCT01826864|OTHER|laboratory biomarker analysis|Correlative studies
57959634|NCT01764074|BEHAVIORAL|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
57959635|NCT00711100|OTHER|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
58450713|NCT03170700|BEHAVIORAL|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
58450714|NCT03550612|DIAGNOSTIC_TEST|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
58122733|NCT05847582|BEHAVIORAL|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
58450715|NCT03550612|DIAGNOSTIC_TEST|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
58450716|NCT00506870|DEVICE|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
58450717|NCT00506870|DEVICE|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
58450718|NCT02783196|DRUG|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
58450719|NCT02783196|DRUG|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
58450720|NCT01224119|DEVICE|Amplex|225 micrograms of B2A per cc of ceramic granules
58450721|NCT01224119|PROCEDURE|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
58450722|NCT02256566|BEHAVIORAL|emotional memory training exercise|
58450723|NCT02256566|BEHAVIORAL|memory training exercise|
58450724|NCT02055287|DRUG|LY03004|
58450725|NCT00706446|DRUG|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
58450726|NCT00706446|DRUG|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
58450727|NCT00706446|DRUG|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
57748059|NCT01826864|OTHER|hypertonic saline|Given SC
58122734|NCT05898178|OTHER|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
58122735|NCT04971057|OTHER|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
57748060|NCT05955703|BEHAVIORAL|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
57748061|NCT02281799|DRUG|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
57748062|NCT01704313|PROCEDURE|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
58122736|NCT02520115|DRUG|Dexamethasone|Given PO
57748063|NCT01704313|PROCEDURE|Continuous|Continuous suturing technique used for the anastomosis
58122737|NCT02520115|OTHER|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
58450728|NCT00706446|DRUG|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
58450729|NCT00706446|DRUG|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
58450730|NCT00426920|DRUG|Insulin|
58450731|NCT04404231|RADIATION|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
57748064|NCT04270214|DRUG|Dysport Injectable Product|Dysport injections optimized using kinematics
58450732|NCT04404231|OTHER|No Infrared treatment|This is sham treatment. No light is actually given.
58450733|NCT00191334|DRUG|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
58450734|NCT00191334|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
57748065|NCT06099301|BEHAVIORAL|Brief advice of a list of mobile apps|The mobile apps in the list should: (1) focus primarily on anxiety/depression/stress, (2) be available for free download; (3) be available in English or Chinese; and (4) have a user star rating in the app store.
57748066|NCT02200913|OTHER|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
57748067|NCT02200913|OTHER|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
57748068|NCT04207346|DEVICE|TMS 1 hz|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
57748069|NCT04207346|DEVICE|Sham TMS|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
57748070|NCT03961620|DEVICE|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
57748071|NCT03004794|OTHER|medical records review|
57748072|NCT04567108|BEHAVIORAL|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
57748073|NCT04567108|BEHAVIORAL|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
57748074|NCT04567108|BEHAVIORAL|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
57748075|NCT04567108|BEHAVIORAL|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
57748076|NCT05674396|RADIATION|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
57748077|NCT05674396|RADIATION|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
57748078|NCT00142727|DRUG|Methadone|
57748079|NCT00142727|DRUG|Full opioid agonist|
57748080|NCT00142727|DRUG|Partial opioid agonist|
57748081|NCT00142727|DRUG|Opioid antagonist|
57748082|NCT04394390|DIETARY_SUPPLEMENT|vitamin d|vitamin D levels
57748083|NCT02471092|OTHER|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
57748084|NCT03609567|OTHER|Aromatherapy|Aromatherapy using essential oils
57748085|NCT03609567|OTHER|Placebo|Aromatherapy using odorless placebo oil
57748086|NCT00434382|DRUG|Sevoflurane|
57748087|NCT00434382|DRUG|Isoflurane|
57748088|NCT00434382|DRUG|Desflurane|
57748089|NCT00434382|DRUG|Propofol|
57748090|NCT00434382|DRUG|Fentanyl|
57748091|NCT00434382|DRUG|Sufentanil|
57748092|NCT00434382|DRUG|Alfentanil|
57748093|NCT00434382|DRUG|Remifentanil|
57748094|NCT00434382|DEVICE|Midlatency auditory evoked potentials|
57748095|NCT03733405|BEHAVIORAL|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
57748096|NCT03733405|BEHAVIORAL|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
57748097|NCT04118348|BEHAVIORAL|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
57748098|NCT04118348|BEHAVIORAL|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
57748099|NCT01631084|OTHER|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
58122738|NCT02520115|DRUG|Valproic Acid|Given PO
57748100|NCT01631084|OTHER|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
57748101|NCT05895032|OTHER|Exercise|12-week exercise intervention
57748102|NCT05895032|OTHER|Usual Care|usual care
57748103|NCT04941040|DRUG|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h"
57748104|NCT04941040|DRUG|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
57748105|NCT06579612|OTHER|Personalized follow-up and support|After a pulmonary rehabilitation program, an interview with a professional will enable the professional to identify the barriersand enablers of physical activity engagement, and to identify (with the patient) a plan for maintaining a physical activities adapted in daily life. Adapted solutions will then be proposed.
57748106|NCT02047045|PROCEDURE|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
57748107|NCT02047045|DRUG|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
57748108|NCT02592382|DIETARY_SUPPLEMENT|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
57748109|NCT04685902|DEVICE|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
57748110|NCT06263621|BEHAVIORAL|"Intervention Standard"|"The two cafes will offer entrees in two sizes, a smaller and larger size. In the intervention cafe, the smaller size will be labeled Standard during the intervention period, and Small during all other times. In the control cafe, the smaller size will always be labeled Small. The larger size will always be labeled Large for both cafes during the duration of the study."
57748111|NCT03151005|DRUG|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
57748112|NCT03151005|DRUG|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
57748113|NCT04962425|DRUG|Trastuzumab|Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
57748114|NCT00710138|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
57748115|NCT05602636|DRUG|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
57748116|NCT02606903|DRUG|BI 695501 prefilled syringe|
57748117|NCT02606903|DRUG|BI 695501 autoinjector|
57748118|NCT01592370|BIOLOGICAL|Nivolumab|Administered by intravenous (IV) infusion
57748119|NCT01592370|BIOLOGICAL|Ipilimumab|Administered by IV infusion
57748120|NCT01592370|BIOLOGICAL|Lirilumab|Administered by IV infusion
57748121|NCT01592370|BIOLOGICAL|Daratumumab|Administered by IV infusion
57748122|NCT01592370|DRUG|Pomalidomide|Administered PO
57748123|NCT01592370|DRUG|Dexamethasone|Administered PO and by IV infusion
57748124|NCT02115880|BEHAVIORAL|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
57748125|NCT00033358|DRUG|medroxyprogesterone|Given intramuscularly
57748126|NCT00033358|DRUG|ethinyl estradiol|Given orally
57748127|NCT00033358|DRUG|norgestrel|Given orally
57748128|NCT00033358|OTHER|laboratory biomarker analysis|Correlative studies
57748129|NCT04304664|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
57748130|NCT04230044|DRUG|Perampanel|Perampanel tablets.
57748131|NCT01785680|OTHER|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC\>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
57748132|NCT01785680|OTHER|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
57748133|NCT02077166|DRUG|Ibrutinib|
57748134|NCT02077166|DRUG|Lenalidomide|
57748135|NCT02077166|DRUG|Rituximab|
57748136|NCT02863679|DRUG|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
57959636|NCT00711100|OTHER|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
57959637|NCT00711100|OTHER|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
58450735|NCT04612166|BEHAVIORAL|Medication Action Plan and Patient Empowerment (MAP-PE )|"Intervention patients (after consenting) will meet with a study health coach for an in-person meeting where the health coach will review the pharmacists Medication Action Plan (MAP) for deprescription of high-risk medication. The MAP will have previously been approved by both the patient and the patient's primary care physician. If the patient is on more than one high risk medication, the medication that puts them at the highest risk will be deprescribed first and only one medication will be decreased at a time. During this initial meeting, the health coach will use motivational interviewing and distribute materials to empower and support the patient in the reduction of the medication as outlined on their MAP. The health coach will then follow up with the patient on a schedule determined~by the type and dosage of medication being reduced. Follow ups will decrease in frequency over time (starting with at least once a week). The patients will be followed for up to 12 months."
58450736|NCT04549545|DEVICE|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
58450737|NCT04549545|DEVICE|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
58450738|NCT03654794|BIOLOGICAL|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
58450739|NCT00010036|DRUG|carboplatin|
58450740|NCT00010036|DRUG|irinotecan hydrochloride|
58450741|NCT00010036|RADIATION|radiation therapy|
58450742|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
58450743|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
58450744|NCT00685165|DRUG|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
58450745|NCT00685165|DRUG|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
58450746|NCT03083366|DEVICE|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
58450747|NCT06483724|PROCEDURE|cervical tourniquet|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-An assistant slides a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix 4-The bladder peritoneum is isolated from the uterus 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
58450748|NCT06483724|PROCEDURE|uterine artery ligation|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-The bladder peritoneum is isolated from the uterus 4-The uterine vessels were ligated in continuity at the level of the utero-vesical fold on each side 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
58450749|NCT00808093|DRUG|GSK256073|GSK256073 100 mg study drug
58450750|NCT02869633|DRUG|Ibrutinib|Given by mouth
58450751|NCT02869633|OTHER|Laboratory Biomarker Analysis|Correlative studies
58450752|NCT03074708|OTHER|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
58450753|NCT03552497|DIAGNOSTIC_TEST|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
58450754|NCT06062979|DRUG|rilpivirine/cabotegravir|WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
58450755|NCT03360903|DRUG|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline"
58450756|NCT03360903|DRUG|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate"
58450757|NCT04149249|OTHER|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
58450758|NCT04149249|OTHER|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
58450759|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
57748137|NCT05327881|DIAGNOSTIC_TEST|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
57748138|NCT04274673|DEVICE|measuring cotinine level|Measuring of the cotinine levels
57748139|NCT04209075|DIETARY_SUPPLEMENT|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
57748140|NCT04209075|DRUG|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
57748141|NCT04209075|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
57748142|NCT04833764|DRUG|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
57748143|NCT06265545|DRUG|Ivosidenib,Venetoclax,gilteritinib,Selinexor|if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
57748144|NCT01492023|BEHAVIORAL|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
57748145|NCT01846793|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
57748146|NCT03716609|DIETARY_SUPPLEMENT|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
57748147|NCT03716609|OTHER|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
57748148|NCT03716609|OTHER|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
57748149|NCT01437748|DRUG|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
57748150|NCT01437748|DRUG|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
57748151|NCT01951625|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
57748152|NCT01951625|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
57748153|NCT01951625|DRUG|Placebo|
57748154|NCT02118129|BEHAVIORAL|an educational video|
57748155|NCT02118129|OTHER|wait listed|
57748156|NCT02245932|DIETARY_SUPPLEMENT|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
57748157|NCT02245932|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplementation (two doses per day)
57748158|NCT04120233|DRUG|Placebo|Matched placebo administered orally
57748159|NCT04120233|DRUG|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
57748160|NCT04120233|DRUG|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
57748161|NCT04120233|DRUG|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
57748162|NCT04120233|DRUG|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
57748163|NCT04120233|DRUG|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
57748164|NCT00500903|DRUG|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
57748165|NCT04455789|PROCEDURE|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
57748166|NCT01189279|DRUG|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
57748167|NCT01189279|DRUG|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
57748168|NCT01189279|DRUG|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
58314201|NCT02479490|DRUG|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
57748169|NCT03548298|PROCEDURE|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
57748170|NCT02341001|OTHER|Daily text message of support|
57748171|NCT04570436|DRUG|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
57748172|NCT04570436|DRUG|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
57748173|NCT04570436|DRUG|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
57748174|NCT04570436|DRUG|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
57748175|NCT04570436|OTHER|placebo|participants will receive an oral dose of placebo
57748176|NCT00479245|OTHER|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
57748177|NCT00042679|DRUG|Gemcitabine|
57748178|NCT00042679|DRUG|Carboplatin|
57748179|NCT00042679|DRUG|LY900003|
57748180|NCT04719689|OTHER|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
57748181|NCT04719689|OTHER|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
57748182|NCT05445648|DRUG|Tislelizumab Injection|After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
57748183|NCT05445648|PROCEDURE|Transurethral resection of bladder tumor|After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.
57748184|NCT05445648|RADIATION|Adjuvant radiotherapy|On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
57748185|NCT02559752|OTHER|NIH Toolbox Cognitive Battery|"* For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
57748186|NCT04159480|DEVICE|Experimental - Cogito Companion|Cogito Companion
57748187|NCT04159480|BEHAVIORAL|Active Control|Use of MyCAP
57748188|NCT04852016|BEHAVIORAL|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
57748189|NCT04852016|BEHAVIORAL|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
57748190|NCT00969475|DEVICE|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
57748191|NCT00818961|BIOLOGICAL|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
58122739|NCT02761096|DEVICE|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
58122740|NCT02761096|OTHER|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
58122741|NCT05285280|DIAGNOSTIC_TEST|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
58122742|NCT03997266|DRUG|Ampicillin|Intravenous ampicillin
58122743|NCT03997266|DRUG|Gentamycin|Intravenous gentamycin
58122744|NCT03997266|DRUG|Normal saline|Intravenous normal saline
58122745|NCT01576588|DRUG|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
58122746|NCT01576588|DRUG|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
58122747|NCT04352374|OTHER|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
58122748|NCT04352374|DEVICE|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
58314202|NCT05696600|PROCEDURE|Scaling and root planing and open flap debridement|"Scaling and root planing involves removal of plaque and calculus.~Open Flap debridement involves reflection of full thickness mucoperiosteal flap, thorough debridement of the surgical site and approximation and suturing of the flap at the original position."
57748192|NCT00818961|BIOLOGICAL|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
57748193|NCT00818961|BIOLOGICAL|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
57748194|NCT00818961|DRUG|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
57748195|NCT00818961|DRUG|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
58314203|NCT02402062|DRUG|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
57748196|NCT00818961|DRUG|fludarabine phosphate|For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
58122749|NCT02529059|DRUG|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
58450760|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
57748197|NCT00818961|DRUG|methotrexate|5 mg/m2 administered on days +1, +3 and +6
57748198|NCT00818961|DRUG|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
57748199|NCT00818961|PROCEDURE|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
58314204|NCT04832737|BEHAVIORAL|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
58314205|NCT01352039|BIOLOGICAL|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
58314206|NCT01352039|BIOLOGICAL|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
58450761|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
57748200|NCT03412682|DRUG|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
57748201|NCT03412682|DRUG|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
57748202|NCT03412682|DRUG|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
57748203|NCT03439774|DEVICE|Topcon CT-800|tonometer
57748204|NCT03439774|DEVICE|Topcon TRK-2P|tonometer, pachymeter
57748205|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
57748206|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
57748207|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
57748208|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
57748209|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
58122750|NCT00153283|DRUG|Gabapentin|
58122751|NCT06307028|BEHAVIORAL|SISTA-P Intervention|This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
58314207|NCT06521242|OTHER|Patient Education|The intervention group was given 120 minutes of training.
58314208|NCT00898937|GENETIC|microarray analysis|tumor specimen will be assessed by microarray analysis
58314209|NCT00898937|PROCEDURE|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
58314210|NCT01478646|OTHER|conventional breathing therapy|duration: 60 minutes.
58450762|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
58450763|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
58450764|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
58450765|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
58314211|NCT01478646|OTHER|reflectory breathing therapy|duration: 60 minutes.
57748210|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
57748211|NCT06029309|DRUG|Zanubrutinib|"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1."
57748212|NCT06029309|DRUG|Tafasitamab|"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15"
57748213|NCT00693251|PROCEDURE|Crush technique|Crush technique
57748214|NCT00693251|PROCEDURE|provisional T stenting|Provisional T stenting
57748215|NCT02630134|OTHER|These patients receive the Baeta device and take it home|
57748216|NCT00291148|DRUG|paroxetine|
58122752|NCT05707299|PROCEDURE|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
58450766|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
58450767|NCT04543773|DEVICE|rTMS|rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
58450768|NCT00566423|OTHER|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
57748217|NCT00291148|DRUG|pregabalin|
57748218|NCT00276640|DRUG|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
57748219|NCT00276640|DRUG|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
58314212|NCT01563783|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
58314213|NCT01563783|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
58450769|NCT00003663|BIOLOGICAL|rituximab|
58450770|NCT00003663|DRUG|dexamethasone|
57748220|NCT00276640|RADIATION|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
57748221|NCT03900702|BEHAVIORAL|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
57748222|NCT04787601|OTHER|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
57748223|NCT04787601|OTHER|Classic Training|Classic match preparation training
57748224|NCT00262275|DRUG|Aspirin, Clopidogrel|
58314214|NCT01563783|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
58314215|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
58314216|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
58450771|NCT05532358|DRUG|anle138b (TEV-56286)|Anle138b (TEV-56286) as perpetrator
57748225|NCT02568748|BIOLOGICAL|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
57748226|NCT02568748|PROCEDURE|TACE|Trans-arterial chemoembolization
57748227|NCT02401568|DEVICE|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
57748228|NCT02401568|PROCEDURE|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
57959638|NCT00711100|OTHER|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
58122753|NCT05400265|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
58122754|NCT05400265|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
58314217|NCT01219608|DIETARY_SUPPLEMENT|Enteral Nutrition|Ordinary Enteral Nutrition
58314218|NCT02950389|DEVICE|PMMA filter|
58450772|NCT05532358|DRUG|Fluvoxamine 100 mg QD for 5 days|Anle138b (TEV-56286) as victim
58450773|NCT04714164|BEHAVIORAL|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
58450774|NCT02938195|RADIATION|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
58450775|NCT02938195|PROCEDURE|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
58450776|NCT05065905|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
58122755|NCT00002719|BIOLOGICAL|filgrastim|
58122756|NCT00002719|DRUG|amsacrine|
58122757|NCT00002719|DRUG|carmustine|
58122758|NCT00002719|DRUG|cytarabine|
58122759|NCT00002719|DRUG|etoposide|
58122760|NCT00002719|DRUG|idarubicin|
58122761|NCT00002719|DRUG|mitoxantrone hydrochloride|
58122762|NCT00002719|PROCEDURE|peripheral blood stem cell transplantation|
58122763|NCT01297010|DRUG|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
58122764|NCT01297010|DRUG|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
58122765|NCT04450303|BEHAVIORAL|Telehealth CBT|The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
58122766|NCT01576978|BEHAVIORAL|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
58122767|NCT00873951|OTHER|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
58122768|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
58122769|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
58122770|NCT00873951|DIETARY_SUPPLEMENT|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
58122771|NCT04373577|PROCEDURE|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
58122772|NCT04373577|PROCEDURE|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
58122773|NCT06547138|DEVICE|Prophylactic mesh|Prevention of incisional hernia after a prophylactic mesh in high-risk patients
58122774|NCT00140257|DRUG|Escitalopram|
58122775|NCT03739190|DEVICE|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
58122776|NCT01234636|DIETARY_SUPPLEMENT|Placebo oil|Placebo oil of 4g/day
58122777|NCT01891513|BEHAVIORAL|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
58122778|NCT01891513|DRUG|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
58122779|NCT01891513|DRUG|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
58122780|NCT01891513|DRUG|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
58122781|NCT01075763|DRUG|Interferon beta-1a|Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
58122782|NCT01075763|DRUG|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
58122783|NCT03341065|DEVICE|exoskeleton type robot|
58122784|NCT03341065|DEVICE|end-effector type robot|
57959639|NCT00711100|OTHER|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
58122785|NCT05037149|DRUG|STP707|STP707 Powder for Injection
58122786|NCT00462982|DRUG|sunitinib malate|
58122787|NCT00046423|DRUG|ABI-007|
58122788|NCT02200900|OTHER|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
58122789|NCT02200900|OTHER|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
58314219|NCT02950389|DEVICE|HFR17 filter|
57748229|NCT02081573|BEHAVIORAL|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
57748230|NCT02695030|DEVICE|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
57748231|NCT03044483|OTHER|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
57748232|NCT02798510|RADIATION|Concurrent Chemoradiotherapy|
57748233|NCT02798510|DRUG|capecitabine|
57748234|NCT02798510|DRUG|gemcitabine|
57748235|NCT03872921|DRUG|norUrsodeoxycholic Acid|oral treatment
57748236|NCT03382782|BEHAVIORAL|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
57748237|NCT03382782|BEHAVIORAL|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI \& Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
58122790|NCT02200900|OTHER|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
58122791|NCT02200900|OTHER|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
58122792|NCT04601584|BIOLOGICAL|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
58122793|NCT04601584|BIOLOGICAL|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
58122794|NCT04601584|BIOLOGICAL|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
58122795|NCT04601584|BIOLOGICAL|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
57748238|NCT03382782|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
57748239|NCT02633137|DRUG|Lenalidomide|
57748240|NCT02633137|DRUG|R-CHOP|"* Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
57748241|NCT02633137|DRUG|high-dose cytarabine (HIDAC)|
57959640|NCT05926726|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
57959641|NCT02447848|DRUG|sufentanil sublingual 30 mcg tablet|
58122796|NCT04601584|BIOLOGICAL|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
58122797|NCT04601584|BIOLOGICAL|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
58122798|NCT04102020|DRUG|Venetoclax|Tablet: Oral
58122799|NCT04102020|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
58122800|NCT04102020|DRUG|Azacitidine|Oral Tablet
58122801|NCT01485536|DRUG|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
58122802|NCT04921280|BEHAVIORAL|Internet based Cognitive Behavioural Therapy|"The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures."
58122803|NCT05285020|OTHER|Alter G|"It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions)."
58122804|NCT05285020|OTHER|Parallel bars and Scale|It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
58122805|NCT05285020|OTHER|Standard rehabilitation protocol|It is the hospital's standard protocol for that injuries once a day for two weeks.
57748242|NCT04173455|DRUG|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
58122806|NCT00743197|DRUG|Aspirin|Aspirin 81 mg daily
58122807|NCT00743197|DRUG|Lisinopril|Lisinopril 10 mg every night
58122808|NCT00743197|DRUG|Simvastatin|Simvastatin 20 mg every night
58122809|NCT00743197|DRUG|Lovaza|Lovaza 1 gram daily
58122810|NCT00743197|BEHAVIORAL|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
58122811|NCT00160771|BEHAVIORAL|Joint Motion Analysis|Joint motion will be recorded for analysis.
58122812|NCT01400282|DEVICE|High frequency spinal cord stimulation|
58122813|NCT04143113|OTHER|Decision Aid|Shared decision making tool
58450777|NCT00662207|DEVICE|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
58450778|NCT00662207|PROCEDURE|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
58450779|NCT04067934|BEHAVIORAL|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
58450780|NCT01468740|DRUG|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
58450781|NCT01468740|DRUG|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
58450782|NCT01468740|DRUG|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
58450783|NCT01468740|DRUG|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
58450784|NCT01468740|DRUG|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
58122814|NCT03462940|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
58122815|NCT00860028|DRUG|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
58122816|NCT00860028|DRUG|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
58122817|NCT00185419|DRUG|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
58122818|NCT00185419|DRUG|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
58122819|NCT05408286|BEHAVIORAL|administration of questionnaires|administration of questionnaires
57748243|NCT04813627|PROCEDURE|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every three months
57748244|NCT00922285|OTHER|psychosocial support for caregiver|6 weekly 60 minute sessions
57748245|NCT00922285|OTHER|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
57748246|NCT00922285|PROCEDURE|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
57748247|NCT00922285|PROCEDURE|stress management therapy|6 weekly 60 minute sessions
58122820|NCT02294071|DRUG|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
58122821|NCT02294071|DRUG|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
58122822|NCT00494104|DIETARY_SUPPLEMENT|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
58122823|NCT05056181|OTHER|Physical Activity|Physical activity
58122824|NCT05079009|DEVICE|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
58122825|NCT01104662|DRUG|Vancomycin|
58122826|NCT01104662|DRUG|Daptomycin|
58122827|NCT01104662|DRUG|Semi-Synthetic Penicillin|
58122828|NCT04892459|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
58314220|NCT02950389|DEVICE|F7 filter|
58122829|NCT04892459|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
58122830|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
58122831|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
58122832|NCT04314739|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
58122833|NCT04314739|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
58122834|NCT01635985|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
58122835|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
58122836|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
58122837|NCT01635985|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
58122838|NCT01635985|DRUG|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
58122839|NCT01635985|DRUG|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
58122840|NCT00102362|BEHAVIORAL|Behavior Therapy|
58122841|NCT00306748|DRUG|MD-1100 Acetate|
58122842|NCT04886375|PROCEDURE|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
58122843|NCT04886375|PROCEDURE|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
58122844|NCT00704418|DRUG|Bromfenac|sterile ophthalmic solution
58122845|NCT00704418|DRUG|Placebo|sterile ophthalmic solution
58122846|NCT00680875|BEHAVIORAL|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
58122847|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
58450785|NCT01468740|DRUG|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
57748248|NCT01760096|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
58122848|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seeds|4.1 grams (1½ teaspoons/\~0.15ounces) of pumpkin seeds
58122849|NCT00996736|DRUG|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
58122850|NCT00996736|DRUG|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
58122851|NCT04525807|DIAGNOSTIC_TEST|Multi-omics|Use multi-omics to analyze
58122852|NCT01336829|DRUG|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
58122853|NCT01336829|DRUG|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
58122854|NCT01336829|DRUG|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
58122855|NCT01336829|DRUG|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
58122856|NCT00319111|DRUG|bosentan|"Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)"
58122857|NCT00863525|DRUG|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
58122858|NCT00863525|DRUG|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
58122859|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
58122860|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
58122861|NCT06161402|BEHAVIORAL|Elastic band-based progressive resistance training (EB-PRT)|EB-PRT will be implemented during week 1-14. The EB-PRT comprises a 4-week training phase, 6-week consolidation phase and a 4-week maintenance phase.
58122862|NCT01334788|OTHER|sleep deprivation|Sleep restriction
58122863|NCT01334788|OTHER|Normal sleep|These are subjects who are randomized to sleep normally.
58122864|NCT00672854|DRUG|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
58314221|NCT00498303|BIOLOGICAL|trivalent split influenza vaccine|
58314222|NCT01683526|PROCEDURE|Direct laryngoscopy|
57748249|NCT01760096|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
57748250|NCT01760096|DRUG|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
57748251|NCT03713554|PROCEDURE|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
58450786|NCT01468740|DRUG|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
58450787|NCT01468740|DRUG|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
58450788|NCT01468740|DRUG|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
57748252|NCT04473131|OTHER|No intervention|Only blood samples will be taken from participants for this study
57748253|NCT04550988|OTHER|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
57748254|NCT03584932|BEHAVIORAL|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
57748255|NCT02432105|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
57748256|NCT02432105|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
57748257|NCT01936025|DRUG|Dextromethorphan|
57748258|NCT01936025|DRUG|Sitagliptin|
57748259|NCT01936025|DRUG|Placebo|
57748260|NCT03973008|RADIATION|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
58314223|NCT01683526|DEVICE|Video laryngoscopy (Glidescope)|
58314224|NCT00390689|DRUG|Pramipexole 0.125 mg tablet|
58314225|NCT00390689|DRUG|Pramipexole 0.5 mg tablet|
58314226|NCT02373527|OTHER|No Fasting prior to catheterization|No restriction for oral intake
58314227|NCT00511719|DRUG|Technosphere Insulin|48U
58314228|NCT00511719|DRUG|Actrapid|24IU
58314229|NCT01009567|DRUG|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
58314230|NCT01009567|DRUG|Control|Receive human albumin 20% infusion
58314231|NCT05257616|OTHER|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
58314232|NCT05257616|OTHER|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
58314233|NCT00420745|BIOLOGICAL|Rotarix™|Two-dose oral vaccination.
58314234|NCT00420745|BIOLOGICAL|Placebo|Two-dose oral administration
58314235|NCT05240690|BIOLOGICAL|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
58314236|NCT00052338|DRUG|gemcitabine hydrochloride|Given IV
58314237|NCT00052338|DRUG|carboplatin|Given IV
58314238|NCT00052338|DRUG|bortezomib|Given IV
58314239|NCT00052338|OTHER|laboratory biomarker analysis|Correlative studies
58314240|NCT01586325|DRUG|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
58314241|NCT01586325|DRUG|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
58314242|NCT01586325|DRUG|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
58314243|NCT01586325|DRUG|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
58450789|NCT00871871|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
58450790|NCT00871871|DRUG|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
58450791|NCT00871871|DRUG|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
58314244|NCT05145972|OTHER|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
58314245|NCT02556749|DIETARY_SUPPLEMENT|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
58314246|NCT02556749|DIETARY_SUPPLEMENT|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
58314247|NCT02587936|OTHER|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
58450792|NCT00871871|DRUG|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
58450793|NCT01544426|PROCEDURE|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
57748261|NCT03973008|DRUG|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
57748262|NCT05748912|PROCEDURE|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
58122865|NCT00672854|DRUG|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
58122866|NCT02010047|DEVICE|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
58122867|NCT06179966|OTHER|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
58122868|NCT06179966|OTHER|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
58314248|NCT05686941|OTHER|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
58314249|NCT05686941|OTHER|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
58314250|NCT01284543|DEVICE|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
58314251|NCT01284543|DEVICE|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
58314252|NCT00485823|DRUG|Olanzapine Hydrochloride|
58314253|NCT00485823|PROCEDURE|Weight Management Program|
58314254|NCT02019355|DRUG|5-fluorouracil 5% cream|
58314255|NCT02019355|DRUG|Calcipotriol 0.005% ointment|
58314256|NCT02019355|DRUG|Vaseline|
58314257|NCT02661308|DEVICE|Litebook|
58314258|NCT00218413|BIOLOGICAL|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
58314259|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
58314260|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182
58314261|NCT00218413|BIOLOGICAL|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
58450794|NCT01544426|PROCEDURE|Office hysteroscopy|Office hysteroscopy
58450795|NCT05651100|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
58450796|NCT04494035|DEVICE|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
58450797|NCT04452019|DEVICE|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
58450798|NCT04452019|DEVICE|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
58450799|NCT06306209|OTHER|Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management|All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.
57748263|NCT05759195|DIAGNOSTIC_TEST|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
57748264|NCT01249248|DEVICE|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
57748265|NCT02792465|DRUG|CFI-402257|
57748266|NCT02792465|DRUG|Fulvestrant|
57748267|NCT00976599|DRUG|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
57748268|NCT00976599|DRUG|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
57748269|NCT05776030|DEVICE|Single Speed Ergonomic Wheelchair|"Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2"
57748270|NCT05776030|DEVICE|Multi-Speed Ergonomic Wheelchair|The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
57748271|NCT02455648|PROCEDURE|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
57748272|NCT02455648|PROCEDURE|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
57748273|NCT05989217|DEVICE|Occlusal Splint|Occlusion Splint
58122869|NCT04544371|DEVICE|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
58122870|NCT04544371|PROCEDURE|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
58122871|NCT04360421|DRUG|Liposomal bupivacaine|"Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia."
58122872|NCT04414501|BEHAVIORAL|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
58122873|NCT01142037|DIETARY_SUPPLEMENT|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
58122874|NCT01596647|DRUG|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
58122875|NCT01596647|DRUG|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
57748274|NCT05989217|RADIATION|Laser Therapy|Laser Therapy
58122876|NCT01596647|DRUG|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
58122877|NCT01596647|DRUG|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
58122878|NCT01596647|DRUG|TKI258|dovitinib, 5 days on / 2 days off dose schedule
58122879|NCT05329636|BIOLOGICAL|Fecal Microbial Transplant (FMT)|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
58122880|NCT05329636|OTHER|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
58122881|NCT05329636|BIOLOGICAL|Auto Fecal Microbial Transplant (FMT) via enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
58122882|NCT00023283|DRUG|Buprenorphine|"1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
58314262|NCT00218413|BIOLOGICAL|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
58314263|NCT06412822|OTHER|Blood sampling|Blood sampling
57748275|NCT00026273|DRUG|FOLFIRI regimen|
57748276|NCT00026273|DRUG|fluorouracil|
57748277|NCT00026273|DRUG|irinotecan hydrochloride|
57748278|NCT00026273|DRUG|leucovorin calcium|
57748279|NCT03059901|OTHER|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
57748280|NCT00135005|DRUG|AMN107, STI571|
57748281|NCT00252655|DRUG|Rapamune and Prograf|
57748282|NCT00379132|DRUG|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
58314264|NCT06412822|OTHER|Urine sampling|Urine sampling
57748283|NCT03960905|OTHER|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
57748284|NCT03208023|PROCEDURE|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
57748285|NCT03208023|OTHER|No intervention|No intervention
58122883|NCT02780557|BEHAVIORAL|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
58122884|NCT02780557|BEHAVIORAL|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
58122885|NCT04552613|DRUG|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
58122886|NCT04552613|DRUG|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
58122887|NCT01475474|DEVICE|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
58122888|NCT01682174|OTHER|Control Drink|
58122889|NCT01682174|OTHER|Experimental Drink|
58122890|NCT02941809|BEHAVIORAL|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
58122891|NCT00407849|DRUG|triamcinolone acetonide|Intravitreal injection
58122892|NCT04371484|OTHER|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
58122893|NCT02823899|BIOLOGICAL|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
58122894|NCT02823899|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
58122895|NCT00000695|DRUG|Interferon beta-1b|
58122896|NCT00000695|DRUG|Zidovudine|
58122897|NCT05742633|OTHER|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
58122898|NCT05742633|OTHER|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
58122899|NCT01829464|DRUG|Placebo|TAK-875 placebo-matching tablets
58122900|NCT01829464|DRUG|TAK-875|TAK-875 tablets
58122901|NCT01829464|DRUG|TAK-875|TAK-875 tablets
58122902|NCT05809674|DEVICE|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
58122903|NCT05254366|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
58450800|NCT06270914|BEHAVIORAL|Inclusive Positive Behavior Interventions and Supports|The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
58122904|NCT04065893|PROCEDURE|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
58122905|NCT04065893|DRUG|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
58122906|NCT06101836|OTHER|Training intervention|Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
58122907|NCT05434403|DEVICE|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
58122908|NCT05434403|DEVICE|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
58314265|NCT06156566|DRUG|Tecovirimat Oral Capsule|600 mg, twice daily, 14 days.
58314266|NCT06156566|DRUG|Placebo|3 capsules, twice daily, 14 days.
58314267|NCT00829556|DEVICE|Integuseal|
58450801|NCT05229484|OTHER|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
58450802|NCT00178568|BEHAVIORAL|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
58450803|NCT00001114|DRUG|Interferon alfa-2b|
58450804|NCT00001114|DRUG|Didanosine|
58122909|NCT02980848|OTHER|Screening digital mammography|Screening with digital mammography alone
58122910|NCT02980848|OTHER|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
58450805|NCT05862909|OTHER|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
58450806|NCT05862909|OTHER|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
57748286|NCT04097457|BEHAVIORAL|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
57748287|NCT05347979|DRUG|Dabigatran Etexilate|Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
57748288|NCT05347979|DRUG|Relacorilant|Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
57748289|NCT05888506|DIETARY_SUPPLEMENT|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
57748290|NCT05888506|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
57748291|NCT06338982|PROCEDURE|Interoperative wisdom tooth removal in conjunction with BSSO|The objective of the present randomized controlled trial is to assess the fracture pattern, condylar segment positioning, frequency of complications, and PROMs following BSSO with or without impacted mandibular third molars. this is illustrated by the fact that the test group had their wisdom teeth removed in connection with the sagittal split of the mandible (the BSSO surgery). Subsequently, all outcome measures are compared with the control group, who had their wisdom teeth removed 6 months prior their BSSO surgery.
57748292|NCT03113643|DRUG|Azacitidine|Chemotherapy
57748293|NCT03113643|DRUG|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
57748294|NCT03113643|DRUG|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
58122911|NCT02980848|OTHER|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
58450807|NCT03464409|OTHER|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
57748295|NCT04791761|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
58122912|NCT02980848|OTHER|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
58122913|NCT02980848|OTHER|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
58122914|NCT02007148|DRUG|capecitabine|twice a day
58122915|NCT02007148|DRUG|Docetaxel|cycles repeated every 3 weeks
58122916|NCT03097042|PROCEDURE|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
57748296|NCT04791761|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
58122917|NCT03097042|PROCEDURE|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
58122918|NCT02837978|DRUG|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
58122919|NCT02837978|DRUG|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
58122920|NCT04767074|OTHER|Non-pharmacological Cough control Therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations."
58122921|NCT06203314|OTHER|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
57748297|NCT04791761|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
58122922|NCT06138535|DEVICE|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
58122923|NCT04976959|DRUG|High Fiber supplement|The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
58122924|NCT00006259|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
58122925|NCT03892759|OTHER|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
58122926|NCT05892211|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
58122927|NCT05892211|DIAGNOSTIC_TEST|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
58122928|NCT05892211|GENETIC|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
58122929|NCT05892211|DIAGNOSTIC_TEST|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
58122930|NCT05892211|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
58122931|NCT03439163|DEVICE|MRI scan|All participants underwent the MRI scan
58122932|NCT02669680|DRUG|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
58122933|NCT02669680|OTHER|Standard therapy|
58122934|NCT05662553|PROCEDURE|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
58122935|NCT05662553|PROCEDURE|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
58450808|NCT03464409|OTHER|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
58450809|NCT03464409|OTHER|SF-36|A health-related quality of life (QoL) self-reported survey.
57748298|NCT04791761|OTHER|Opioid disposal pouch|Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
57748299|NCT04791761|OTHER|Opioid disposal education|An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
57748300|NCT00857207|BEHAVIORAL|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
57748301|NCT02813837|BIOLOGICAL|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
57748302|NCT01531166|DRUG|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
57748303|NCT03994068|DIAGNOSTIC_TEST|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
57748304|NCT01402141|DIETARY_SUPPLEMENT|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
58122936|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
58450810|NCT02657889|DRUG|niraparib|
58450811|NCT02657889|BIOLOGICAL|pembrolizumab|
58450812|NCT00574717|PROCEDURE|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
58450813|NCT02719613|DRUG|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
57748305|NCT01402141|DIETARY_SUPPLEMENT|Placebo|Placebo(35g/day) for 12 weeks
57748306|NCT00540124|DRUG|Tadalafil|5 mg once a day
58122937|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
58122938|NCT00390312|DRUG|Intranasal Placebo|Intranasal placebo
58122939|NCT00390312|DRUG|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
58122940|NCT00390312|DRUG|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
58122941|NCT00390312|DRUG|Intravenous morphine|Intravenous morphine 7.5 mg
58122942|NCT00390312|DRUG|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
58122943|NCT00390312|DRUG|Oral placebo|Oral placebo
58122944|NCT00390312|DRUG|Intravenous placebo|Intravenous placebo
58122945|NCT02730715|DRUG|Basiliximab|Periodic blood collection to monitor Treg cells
58122946|NCT02730715|DRUG|Thymoglobulin|Periodic blood collection to monitor Treg cells
58122947|NCT01003886|DRUG|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
58122948|NCT01803152|BIOLOGICAL|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
58122949|NCT01803152|BIOLOGICAL|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
58450814|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
58450815|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
58122950|NCT01803152|DRUG|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
58122951|NCT01803152|DRUG|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
57748307|NCT00540124|DRUG|Placebo|once a day
57748308|NCT00540124|DRUG|Tamsulosin|0.2 mg once a day
57748309|NCT05311202|BEHAVIORAL|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
57748310|NCT05311202|BEHAVIORAL|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
58122952|NCT01803152|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
58122953|NCT06482307|DIAGNOSTIC_TEST|[18F]-olaparib PET scan|The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
58122954|NCT03592875|BEHAVIORAL|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
58122955|NCT00135213|BEHAVIORAL|training in smoking cessation|
58122956|NCT02940743|BEHAVIORAL|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
58122957|NCT02940743|BEHAVIORAL|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
58122958|NCT02940743|BEHAVIORAL|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
58122959|NCT01182233|RADIATION|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
58122960|NCT05561413|BEHAVIORAL|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
58122961|NCT05561413|BEHAVIORAL|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
58122962|NCT04620174|OTHER|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
58122963|NCT04620174|OTHER|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
58450816|NCT02719613|DRUG|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
58122964|NCT05892978|OTHER|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
58122965|NCT03656796|OTHER|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
58122966|NCT03656796|OTHER|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
58122967|NCT02194309|DRUG|Telmisartan low|
58122968|NCT02194309|DRUG|Telmisartan high|
58122969|NCT02194309|DRUG|amlodipine|
58122970|NCT04498923|DRUG|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
58122971|NCT03932266|DRUG|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
58122972|NCT03932266|DRUG|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
58122973|NCT03932266|DRUG|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
58122974|NCT03932266|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
58122975|NCT06265935|BEHAVIORAL|Experimental Group|It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
58122976|NCT01143025|DRUG|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
58122977|NCT01143025|DRUG|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
58122978|NCT01143025|DRUG|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
58122979|NCT06138379|OTHER|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
58122980|NCT06138379|OTHER|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
58122981|NCT02042391|DRUG|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
58122982|NCT02042391|DRUG|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
58122983|NCT02042391|DRUG|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
58122984|NCT02042391|DRUG|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
58450817|NCT02719613|DRUG|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
58122985|NCT00252551|PROCEDURE|Osteosynthesis|
58122986|NCT00252551|PROCEDURE|Simple surgery|Surgery without device
58122987|NCT03036579|DEVICE|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
58122988|NCT00332293|DRUG|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
58122989|NCT00332293|DRUG|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
58122990|NCT00684333|DEVICE|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
58122991|NCT04509609|OTHER|Exon 3 truncating mutation|Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
58122992|NCT04509609|OTHER|Any other mutation in SGBC gene|Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
58122993|NCT03246295|OTHER|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
58122994|NCT01270048|DRUG|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
58122995|NCT01270048|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
58122996|NCT06057519|DRUG|Optimised dose rifampicin|Optimized dose of rifampicin
58450818|NCT02719613|DRUG|Pomalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
58314268|NCT05531253|OTHER|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
58314269|NCT01899092|DRUG|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
58450819|NCT02719613|DRUG|Nivolumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
57748311|NCT05311202|BEHAVIORAL|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
57748312|NCT05311202|BEHAVIORAL|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
57748313|NCT05311202|BEHAVIORAL|Control group|Reading a book related to cognitive function \& exercise for 40 minutes
57748314|NCT04530890|DIAGNOSTIC_TEST|Blood samples|Only blood samples at different times of treatment
57748315|NCT05786716|DRUG|Trastuzumab|An initial loading dose of 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.
57748316|NCT05786716|DRUG|Pertuzumab|An initial loading dose of 14 mg/kg administered intravenously every 21 days followed thereafter by a maintenance dose of 7 mg/kg.
57748317|NCT04584905|DIETARY_SUPPLEMENT|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
57959642|NCT03372031|BEHAVIORAL|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
57959643|NCT03372031|BEHAVIORAL|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
57959644|NCT04538794|DRUG|CDX-0159|Administered intravenously
57959645|NCT04538794|DRUG|Normal Saline|Administered intravenously
57959646|NCT03470493|DIAGNOSTIC_TEST|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
57959647|NCT03824665|DRUG|Nalbuphine Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline"
57959648|NCT03824665|DRUG|Fentanyl Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline"
57959649|NCT03824665|DRUG|Control Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline."
57959650|NCT02018627|DRUG|Xeris glucagon|The subject is given an injection of xeris glucagon
57959651|NCT02018627|DRUG|Lilly glucagon|The subject is given an injection of lilly glucagon
57959652|NCT00435968|DRUG|CVT E002 (Cold-fX)|
57959653|NCT01934088|DRUG|Propofol|
57959654|NCT01934088|DRUG|Midazolam|
57959655|NCT01934088|DRUG|Fentanyl|
57959656|NCT01558661|DRUG|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
57959657|NCT03195907|OTHER|Pulmonary physiotherapy|
57959658|NCT02230280|OTHER|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
57959659|NCT06471270|DIAGNOSTIC_TEST|histologic evaluation|histologic evaluation
57959660|NCT06471270|DIAGNOSTIC_TEST|biochemical analysis|IL-6, IL-8 and sCD44
57959661|NCT06471270|DIAGNOSTIC_TEST|clinical examination|clinical examination
58122997|NCT06057519|DRUG|Standard dose rifampicin|Standard dose rifampicin
58314270|NCT03552406|BIOLOGICAL|ISU104|Intravenous Infusion for 1 hour.
58122998|NCT04359095|DRUG|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
58122999|NCT04359095|DRUG|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
58123000|NCT04359095|DRUG|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
58123001|NCT04359095|OTHER|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
58123002|NCT03834675|DIAGNOSTIC_TEST|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
58123003|NCT04595136|DRUG|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
58123004|NCT04595136|DRUG|normal saline|0.9% NS via nebulization
58123005|NCT03092908|DIETARY_SUPPLEMENT|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
58123006|NCT03092908|DIETARY_SUPPLEMENT|placebo (water)|Administer 5 ml placebo (water) three times a day.
58123007|NCT02686840|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
58123008|NCT02686840|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
58123009|NCT00268346|DRUG|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
58123010|NCT03468036|OTHER|none, does not apply|none: does not apply
58123011|NCT00002637|BIOLOGICAL|aldesleukin|
58123012|NCT00002637|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
58123013|NCT00002637|BIOLOGICAL|recombinant interferon gamma|
58123014|NCT05095064|DRUG|Onivyde® + 5-FULV|Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
58123015|NCT03987438|BEHAVIORAL|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
58314271|NCT03552406|DRUG|Cetuximab|Intravenous Infusion for 1 hour (2 hours at initial dose)
58314272|NCT00687700|DRUG|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
58314273|NCT00687700|DRUG|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
58123016|NCT04485052|DRUG|IBI188|anti-CD47 Monoclonal antibody
58123017|NCT04485052|DRUG|Azacitidine|Demethylation drugs
58123018|NCT04485052|DRUG|Decitabine|Demethylation drugs
58123019|NCT03422926|BEHAVIORAL|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
58123020|NCT02879721|DRUG|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
58123021|NCT02879721|DRUG|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
58123022|NCT01537484|PROCEDURE|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
58123023|NCT06125613|BEHAVIORAL|Experimental|"In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total."
58123024|NCT02508961|BEHAVIORAL|Exercise|web-based physio exercise programme
58123025|NCT03262298|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
58123026|NCT00546390|DEVICE|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
58123027|NCT03666637|PROCEDURE|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
58123028|NCT01142843|DRUG|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
58123029|NCT04299997|OTHER|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
58123030|NCT02767193|BIOLOGICAL|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
58123031|NCT02767193|BIOLOGICAL|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
58123032|NCT02767193|BIOLOGICAL|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
58123033|NCT02767193|BIOLOGICAL|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
58123034|NCT05370521|DRUG|Tildacerfont|Oral tablet formulation taken once daily.
58123035|NCT05370521|DRUG|Placebo|Non-active dosage form taken once daily.
58123036|NCT03089398|PROCEDURE|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
58123037|NCT03089398|DEVICE|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
58123038|NCT03089398|DEVICE|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
58123039|NCT01497236|DIETARY_SUPPLEMENT|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
58314274|NCT00687700|DRUG|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
58314275|NCT00687700|DRUG|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
58314276|NCT01367691|DEVICE|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
58450820|NCT02610686|DRUG|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
58450821|NCT02917135|DEVICE|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
58450822|NCT06173583|DIAGNOSTIC_TEST|Detection/screening|Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
58450823|NCT03461107|OTHER|No intervention|
58450824|NCT01061970|DRUG|Fispemifene|once daily for 4 weeks
58450825|NCT02037139|OTHER|Screening|Standard care screening
58450826|NCT02037139|OTHER|Brochure|Participants are given an illustrated educational brochure
58450827|NCT02037139|BEHAVIORAL|Education|Participants undergo a in-person educational intervention
58450828|NCT04838535|DIAGNOSTIC_TEST|Raman spectrum|The wavelength of the follicular fluids were scaned by Raman spectrum
58450829|NCT05788055|DIAGNOSTIC_TEST|Stool Analysis|Stool Analysis to detect H.Pylori Antigen in Stool
58450830|NCT01388569|OTHER|flow cytometry|
58450831|NCT01388569|OTHER|immunologic technique|
58450832|NCT01388569|OTHER|laboratory biomarker analysis|
58450833|NCT06198387|RADIATION|hormone and RT|The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).
58450834|NCT06198387|DRUG|ADT combined with abiraterone|The patients will receive a two-year course of ADT combined with abiraterone.
58450835|NCT02316418|DEVICE|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
58123040|NCT05317156|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
58123041|NCT03162666|DEVICE|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
58123042|NCT01999309|DRUG|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
58123043|NCT01999309|DRUG|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
58123044|NCT05072301|BEHAVIORAL|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
58123045|NCT05072301|BEHAVIORAL|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
58123046|NCT03181438|PROCEDURE|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
58123047|NCT03181438|PROCEDURE|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
58123048|NCT03767777|DEVICE|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
58123049|NCT04959695|BEHAVIORAL|PE Coach|PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
58123050|NCT04959695|BEHAVIORAL|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
58123051|NCT01333241|BEHAVIORAL|Lifestyle behavior interventon grop|
58123052|NCT01333241|OTHER|Placebo Comparator: Control group|
58123053|NCT00658320|DRUG|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
58123054|NCT00658320|DRUG|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
58123055|NCT00658320|DRUG|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
58123056|NCT00658320|DRUG|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
58123057|NCT00658320|DRUG|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
58123058|NCT06014632|OTHER|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
58123059|NCT06014632|OTHER|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
58123060|NCT01352650|DRUG|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
58123061|NCT01352650|DRUG|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
57959662|NCT01816243|DRUG|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
58123062|NCT05810766|OTHER|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
58123063|NCT05810766|OTHER|conventional physical therapy|Hot pack for 15 minutes
58123064|NCT00232336|DRUG|quetiapine|
58123065|NCT03405207|DRUG|Vitamin D3 50000 UNT Oral Capsule|Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
58123066|NCT03405207|DRUG|Placebo oral capsule|identical as active drug providing by pharmaceutical company unless it is placebo
58123067|NCT00380471|DEVICE|Bath PUVA|
58123068|NCT00564525|DRUG|Amitriptyline|Medication taken for 4 weeks
58123069|NCT00564525|DRUG|Placebo|Medication taken for 4 weeks
58123070|NCT05187026|OTHER|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
58123071|NCT00365612|DRUG|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
58123072|NCT01290939|BIOLOGICAL|bevacizumab|
58123073|NCT01290939|DRUG|lomustine|
58123074|NCT01290939|GENETIC|DNA methylation analysis|
58123075|NCT01290939|OTHER|laboratory biomarker analysis|
58123076|NCT01290939|PROCEDURE|cognitive assessment|
58123077|NCT01290939|PROCEDURE|quality-of-life assessment|
58123078|NCT02331537|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
58123079|NCT06078254|DEVICE|ULTRASOUND|Ultrasound and CT chest for all patients
58123080|NCT03356587|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
58123081|NCT05487833|BIOLOGICAL|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
58123082|NCT05487833|OTHER|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
58123083|NCT06408909|BEHAVIORAL|Clinical Pharmacist Intervention Group|Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
58123084|NCT01325207|RADIATION|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
58123085|NCT02918162|DRUG|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
58123086|NCT02918162|DRUG|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
58123087|NCT05700591|DRUG|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
58123088|NCT05700591|DRUG|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
58123089|NCT02914795|OTHER|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
58123090|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
58123091|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
58123092|NCT02765321|BEHAVIORAL|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
58123093|NCT02046421|DRUG|mifepristone|Given PO
58123094|NCT02046421|DRUG|carboplatin|Given IV
58123095|NCT02046421|DRUG|gemcitabine hydrochloride|Given IV
58123096|NCT02046421|OTHER|laboratory biomarker analysis|Correlative studies
58123097|NCT02046421|OTHER|pharmacological study|Correlative studies
58123098|NCT03688230|DRUG|abituzumab|1000 mg IV
58123099|NCT03688230|COMBINATION_PRODUCT|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
58123100|NCT04262830|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
58123101|NCT04262830|DIAGNOSTIC_TEST|Echocardiography|Echocardiography, heart ultrasound, will be performed in conjunction with cardiac MRI.
58123102|NCT04262830|DIAGNOSTIC_TEST|Electrocardiogram|Measuring conduction abnormalities
58123103|NCT02725307|DEVICE|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
58123104|NCT00035087|DRUG|epothilone b|
58123105|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
58123106|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
57959663|NCT01816243|DRUG|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
58123107|NCT02339909|BEHAVIORAL|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
58123108|NCT02339909|BEHAVIORAL|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
58123109|NCT02339909|BEHAVIORAL|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
58123110|NCT04337996|DIAGNOSTIC_TEST|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
58123111|NCT03916653|PROCEDURE|osseous resection using piezoelectric device in surgical crown lengthening|In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
58123112|NCT03916653|PROCEDURE|Osseous resection using conventional rotary instruments in surgical crown lengthening|For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
58314277|NCT02868944|DRUG|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
58123113|NCT04258241|PROCEDURE|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
58123114|NCT04258241|PROCEDURE|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
58123115|NCT04258241|DEVICE|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
58123116|NCT04258241|DRUG|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
58123117|NCT04258241|DRUG|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
58123118|NCT00249275|DEVICE|spectacles|
58123119|NCT00194740|DRUG|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
58123120|NCT00194740|DRUG|Vinorelbine|27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
58123121|NCT00194740|DRUG|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
58123122|NCT06101654|DEVICE|Pulse oximeter|Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
58123123|NCT04121806|OTHER|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
58123124|NCT00513968|GENETIC|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
57959664|NCT01084070|OTHER|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
57959665|NCT01084070|OTHER|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
57959666|NCT01088074|DEVICE|Histoacryl Tissue Adhesive|
57959667|NCT01088074|DEVICE|Dermabond|
57959668|NCT01088074|DEVICE|Staples|
57959669|NCT01088074|DEVICE|Monocryl 4-0|
57959670|NCT01097863|DEVICE|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
57959671|NCT01097863|DEVICE|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
57959672|NCT01097863|DEVICE|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
57959673|NCT03064139|BEHAVIORAL|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
57959674|NCT03064139|BEHAVIORAL|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
57959675|NCT00853697|OTHER|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
57959676|NCT03424447|PROCEDURE|efferent limb stimulation|
57959677|NCT00640471|BIOLOGICAL|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
57959678|NCT00640471|DRUG|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
58123125|NCT00513968|DRUG|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
58123126|NCT02324465|DEVICE|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
57959679|NCT04033835|OTHER|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
57959680|NCT04033835|OTHER|Treatment as usual|Treatment as usual
57959681|NCT03116646|DIAGNOSTIC_TEST|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
57959682|NCT04163445|DEVICE|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
58123127|NCT02324465|DEVICE|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
58123128|NCT05637281|DRUG|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
58123129|NCT05637281|OTHER|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
58123130|NCT02687204|DRUG|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
58123131|NCT02687204|DRUG|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
58123132|NCT01886274|DEVICE|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
58123133|NCT02785913|OTHER|Laboratory Biomarker Analysis|Correlative studies
58123134|NCT02785913|DRUG|Taselisib|Given PO
58123135|NCT01917409|DEVICE|conventional laryngoscopy|the device is to assist nasotracheal intubation
58123136|NCT01917409|DEVICE|video-stylet|the device is to guide the nasotracheal tube into trachea
58123137|NCT06202157|OTHER|LMB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
58123138|NCT06202157|OTHER|DHB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
58123139|NCT06145178|BIOLOGICAL|SPYVAC01|Novel vaccine SPYVLP01
58123140|NCT02573909|DRUG|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
58123141|NCT02573909|DRUG|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
58123142|NCT01386346|DRUG|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
58123143|NCT01386346|DRUG|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
58123144|NCT01386346|DRUG|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
58123145|NCT01386346|DRUG|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
58123146|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
58123147|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
58123148|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
58123149|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
58123150|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
58123151|NCT03401905|PROCEDURE|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
58123152|NCT03401905|PROCEDURE|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
58123153|NCT05412732|OTHER|prospective biomedical research study|A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
58123154|NCT02806232|DRUG|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
58123155|NCT02806232|DRUG|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
58123156|NCT02806232|DRUG|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
58123157|NCT02895529|DRUG|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
58123158|NCT02895529|DRUG|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
58123159|NCT00406757|DRUG|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
58123160|NCT00406757|DRUG|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
58123161|NCT00406757|DRUG|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
58123162|NCT00406757|DRUG|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
58123163|NCT00258622|DRUG|NS1209|
58123164|NCT00258622|DRUG|Lidocaine|
58123165|NCT02190461|PROCEDURE|Early Respiratory Rehabilitation Program|
58123166|NCT02190461|PROCEDURE|Conventional Respiratory Rehabilitation Program|
58123167|NCT05361278|OTHER|Chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
58123168|NCT05361278|OTHER|Activated chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
58123169|NCT05361278|OTHER|Chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the gel after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
58123170|NCT05361278|OTHER|Activated chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
58123171|NCT05361278|OTHER|Sodium hypochlorite solution|"* Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
58123172|NCT04843670|PROCEDURE|duodenopancreatectomy|resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
58123173|NCT01479881|DRUG|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
58123174|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
58123175|NCT01479881|DRUG|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
58123176|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
58123177|NCT01884025|BEHAVIORAL|Get Moving and Get Well|Walking Class
58123178|NCT01884025|BEHAVIORAL|Health and Humor Class|Class about the role of humor in health
58123179|NCT00352495|DRUG|carboplatin|
58123180|NCT00352495|DRUG|vinblastine sulfate|
58123181|NCT00922532|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
58123182|NCT00922532|DRUG|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
58123183|NCT05796609|OTHER|Driving under the influence of alcohol|"Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
58314278|NCT02868944|DRUG|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
58314279|NCT01303484|DIETARY_SUPPLEMENT|Bi2muno® GOS|5.5g/day for 10 weeks
58314280|NCT01303484|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily for 10 weeks
57959683|NCT04163445|DEVICE|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
57959684|NCT04743947|OTHER|No intervention; observational study|no intervention
57959685|NCT01353742|DRUG|Lamivudine|100mg tablet
57959686|NCT01353742|DRUG|Adefovir dipivoxil|10mg tablet
57959687|NCT01353742|DRUG|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
57959688|NCT03754244|DRUG|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
58123184|NCT05796609|OTHER|Driving under the influence of a placebo|"Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
58123185|NCT04207281|DIETARY_SUPPLEMENT|Raw Honey|Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
58123186|NCT04207281|DIETARY_SUPPLEMENT|Comparator|Honey comparator(1.5 tablespoons) administered for 7 days
58123187|NCT04645095|DEVICE|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
58123188|NCT04645095|DEVICE|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
57959689|NCT02467933|OTHER|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
58123189|NCT02748226|PROCEDURE|endovascular treatment|endovascular treatment
58123190|NCT01911975|DRUG|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
58123191|NCT01911975|DRUG|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
58123192|NCT02137083|DRUG|Docetaxel|75mg/m2 D2 every 21 days
58123193|NCT02137083|DRUG|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
58123194|NCT03958890|DRUG|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
58123195|NCT03958890|DRUG|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
58123196|NCT03915938|DRUG|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
58123197|NCT03915938|DRUG|Placebo|Administered in an identical way than ketamine.
58123198|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
58123199|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
58123200|NCT03308448|DRUG|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
58123201|NCT02396381|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
58450836|NCT06457061|OTHER|Survey Study|"Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers."
58450837|NCT06423469|DEVICE|Noninvasive ICP monitoring|The brain4care system is a FDA approved noninvasive device for surrogate intracranial pressure monitoring. Serial monitoring sessions were performed in included patients. Information recorded was for study purposes only and did not affect any therapy planned for the attending teams.
58123202|NCT02396381|OTHER|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
58450838|NCT06000748|DRUG|MAP-Target Algorithm|This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
58123203|NCT00902083|DRUG|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
58123204|NCT00902083|PROCEDURE|surgery|remove tumor surgery
58123205|NCT00902083|DRUG|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
57748318|NCT03786029|DRUG|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
57959690|NCT02467933|OTHER|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
57959691|NCT02467933|OTHER|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
58123206|NCT00902083|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
58123207|NCT04620109|DRUG|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
58123208|NCT04620109|DRUG|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
58314281|NCT02357459|DRUG|FX006|Single 5 mL IA injection
58314282|NCT02357459|DRUG|Placebo|Single 5 mL IA injection
58314283|NCT02357459|DRUG|TCA IR 40|Single 1 mL IA injection
58314284|NCT03318562|DRUG|eFT508|200 mg eFT508 dosed BID for 3 week cycles
58314285|NCT02549118|DRUG|Tenoxicam|
58450839|NCT06444035|DRUG|HA35 injection|HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
58123209|NCT01235052|RADIATION|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
58123210|NCT04867395|BEHAVIORAL|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
58123211|NCT05289765|OTHER|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
58123212|NCT05289765|OTHER|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
58123213|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
58123214|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
58123215|NCT00358384|DRUG|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
58123216|NCT00358384|DRUG|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
58123217|NCT00358384|DRUG|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
58123218|NCT00358384|DRUG|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
58123219|NCT01412541|PROCEDURE|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
58123220|NCT01412541|DEVICE|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
58123221|NCT04480203|OTHER|Stressproffen cognitive based stress management|The participants will download an app (Stressproffen 2A) with cognitive based stress management.
58123222|NCT04480203|OTHER|Stressproffen mindfulness based intervention|The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
58123223|NCT04480203|OTHER|Control|The participants will receive no app. (They will be able to download it after the end of the 3 year study).
57748319|NCT03786029|DRUG|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
57748320|NCT03786029|DRUG|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
58123224|NCT00586521|DRUG|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
58123225|NCT04812587|BEHAVIORAL|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
58314286|NCT02549118|DRUG|Pethidine|
58314287|NCT03636633|OTHER|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
58314288|NCT03636633|OTHER|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
58314289|NCT00753519|DEVICE|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
58314290|NCT00753519|DEVICE|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
58314291|NCT02369653|DRUG|Apixaban|
58314292|NCT02369653|OTHER|No systemic anticoagulant prophylaxis|
58314293|NCT06516120|BEHAVIORAL|RGS-app|Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
57748321|NCT00210795|DRUG|epoetin alfa|
58314294|NCT01566370|DRUG|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
58314295|NCT01566370|DRUG|Placebo|placebo
58450840|NCT04950361|OTHER|talocalcaneal coalition|patients with talocalcaneal coalition
58450841|NCT03309748|PROCEDURE|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
58123226|NCT03887195|OTHER|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
58123227|NCT00347542|DRUG|Vitamin D|
58123228|NCT00721409|DRUG|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
58123229|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
58123230|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
58123231|NCT02047266|PROCEDURE|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
58123232|NCT02047266|PROCEDURE|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time\>250seconds).
58123233|NCT02047266|PROCEDURE|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time\>450seconds).
58123234|NCT02047266|DEVICE|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
58123235|NCT02047266|DEVICE|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
58314296|NCT01787838|OTHER|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
58314297|NCT02646163|DRUG|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
58314298|NCT03328065|OTHER|Interviews|Semi-directed interviews, recorded and transcribed for analysis
58314299|NCT03328065|OTHER|Questionnaires|economic and psycho-social questionnaires
57748322|NCT01454206|BEHAVIORAL|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
57748323|NCT02132364|OTHER|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
57748324|NCT05226455|DRUG|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
57748325|NCT03469323|DRUG|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
58123236|NCT04226911|BEHAVIORAL|S&SEs|"S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned."
58123237|NCT04226911|BEHAVIORAL|Sugar|"Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products."
58123238|NCT00000882|DRUG|Indinavir sulfate|
58123239|NCT00000882|DRUG|Delavirdine mesylate|
58123240|NCT00000882|DRUG|Lamivudine|
58123241|NCT00000882|DRUG|Stavudine|
58123242|NCT00000882|DRUG|Zidovudine|
58123243|NCT06441552|OTHER|non-interventional|non-interventional
58123244|NCT00125359|DRUG|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
58123245|NCT05004428|OTHER|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
58123246|NCT05899790|OTHER|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
58123247|NCT05042635|DRUG|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
58123248|NCT05042635|DRUG|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
58123249|NCT06382116|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
58123250|NCT06382116|DRUG|Pemetrexed+Cisplatin or Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
58123251|NCT03177603|DRUG|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
58123252|NCT03758365|DRUG|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123253|NCT03758365|DRUG|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123254|NCT03758365|DRUG|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123255|NCT03758365|DRUG|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123256|NCT03758365|DRUG|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
57748326|NCT03469323|DRUG|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
57959692|NCT02911532|PROCEDURE|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
57959693|NCT03899662|OTHER|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
57959694|NCT03899662|OTHER|Physical Training|Physical training included aerobic, strength, flexibility and balance.
58123257|NCT03758365|DRUG|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123258|NCT03758365|DRUG|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
58123259|NCT01547195|PROCEDURE|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
58123260|NCT01547195|PROCEDURE|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
58123261|NCT02703610|DRUG|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
58123262|NCT02703610|DRUG|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
58123263|NCT01523964|OTHER|Testing with EIM|
58123264|NCT03567109|OTHER|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
58123265|NCT05402449|OTHER|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
58123266|NCT05402449|DIETARY_SUPPLEMENT|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
57748327|NCT01732068|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
57748328|NCT01732068|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
57748329|NCT01732068|DRUG|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
57959695|NCT03232515|COMBINATION_PRODUCT|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
58123267|NCT04744740|DEVICE|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
58123268|NCT05127993|DEVICE|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
58123269|NCT05049044|OTHER|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
58123270|NCT00119613|DRUG|placebo|placebo
58123271|NCT00119613|DRUG|darbepoetin alfa|darbepoetin alfa
58123272|NCT03361423|DEVICE|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
58123273|NCT03361423|DEVICE|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
58123274|NCT03543956|BEHAVIORAL|Questionnaire|Questionnaire
58123275|NCT00675649|BIOLOGICAL|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
58123276|NCT00675649|BIOLOGICAL|placebo|placebo sc injection every 4 weeks from week 0 to week 20
58123277|NCT02081521|BEHAVIORAL|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
58123278|NCT05559268|DRUG|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
58123279|NCT05559268|DRUG|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
58123280|NCT00198029|DEVICE|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
58123281|NCT02315898|DRUG|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
58123282|NCT05531266|OTHER|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10\^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
58123283|NCT05531266|OTHER|glucocorticoids|Participants were treated with glucocorticoids only.
58123284|NCT02992171|BEHAVIORAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
58123285|NCT02864758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
58123286|NCT02864758|DRUG|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
58123287|NCT02864758|DRUG|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
58123288|NCT03953170|DRUG|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
58123289|NCT03953170|DRUG|Placebo|Placebo
58123290|NCT04480463|DRUG|SCD411|IVT (intravitreal) injection
58123291|NCT04480463|DRUG|Aflibercept|IVT injection
58123292|NCT02579096|DRUG|allopurinol capsule, 100-800 mg by mouth once daily|Patients will be up-titrated up to the dose required to reach target uric acid levels.
58123293|NCT02579096|DRUG|febuxostat tablet 40-120 mg by mouth once daily|Patients will be up-titrated to the dose required to reach target uric acid levels.
58123294|NCT02579096|DRUG|Placebo, vehicle control (febuxostat-shaped)|Placebo tablets resembling febuxostat will be given with allopurinol.
58123295|NCT02579096|DRUG|Placebo, vehicle control (allopurinol-shaped)|Placebo capsules resembling allopurinol will be given with febuxostat.
58123296|NCT03147196|DRUG|Bicalutamide|Given PO
58123297|NCT03147196|OTHER|Laboratory Biomarker Analysis|Correlative studies
58123298|NCT03147196|OTHER|Questionnaire Administration|Ancillary studies
58123299|NCT03147196|DRUG|Raloxifene Hydrochloride|Given PO
58123300|NCT02651636|DRUG|myo-inositol,alpha-lipoic acid and folic acid|
58123301|NCT06000423|DRUG|Tranexamic acid|1300mg TXA taken three times per day for five days
58123302|NCT06000423|OTHER|Placebo|Placebo pills taken three times daily for five days.
58123303|NCT01491620|DEVICE|532 nm KTP laser|Laser treatment sessions on the neck and/or chest
58123304|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
58123305|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
58123306|NCT04306900|COMBINATION_PRODUCT|TTX-030 and mFOLFOX6|Dose and schedule per protocol
58123307|NCT04306900|COMBINATION_PRODUCT|TTX-030 and budigalimab|Dose and schedule per protocol
58123308|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
58123309|NCT04306900|COMBINATION_PRODUCT|TTX-030 and pembrolizumab|Dose and schedule per protocol
58123310|NCT04306900|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
58123311|NCT04306900|COMBINATION_PRODUCT|Budigalimab and mFOLFOX6|Dose and schedule per protocol
58123312|NCT06081751|BEHAVIORAL|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
58314300|NCT05944432|DEVICE|FreeStyle Libre 3 Continuous Glucose Monitoring System.|Subjects will be randomised to use the FreeStyle Libre 3 system
57959696|NCT00180310|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
57748330|NCT02396654|OTHER|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
57748331|NCT01687257|DRUG|SOF|SOF 400 mg tablet administered orally once daily
57959697|NCT00180310|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
57959698|NCT02674438|OTHER|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
57959699|NCT02216461|DRUG|Low dose of BIBW 2948 BS for oral inhalation|
57959700|NCT02216461|DRUG|Medium dose of BIBW 2948 BS for oral inhalation|
57959701|NCT02216461|DRUG|High dose of BIBW 2948 BS for oral inhalation|
57959702|NCT02216461|DRUG|Placebo|
57959703|NCT03060070|DRUG|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
57959704|NCT03060070|DRUG|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
57959705|NCT03060070|DRUG|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
57959706|NCT00272038|DRUG|Tarceva|150mg QD
57959707|NCT03406221|BEHAVIORAL|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
57959708|NCT03406221|OTHER|Control Condition|Standard of care
57959709|NCT06093061|COMBINATION_PRODUCT|CCRT with Maintenance Tislelizumab and Metronomic Capecitabine|"CCRT: Radiotherapy will be delivered once daily, for 5 days per week, over 6 to 7 weeks. During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).~Maintenance: Tislelizumab 200mg, day 1 per 3-week cycle, intravenous (IV) infusion and capecitabine 650 mg/m2, days 1-21 per 3-week cycle, bidaily, oral, for a total of 12 months (17 cycles)."
57959710|NCT00312910|DRUG|Probiotics-Bio-plus|
57959711|NCT06195020|OTHER|Metaverse|"The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months."
57959712|NCT06195020|OTHER|Polyclinic information|This group will be informed only at the outpatient clinic. The intervention will last 3 months.
57959713|NCT04756037|DRUG|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
57959714|NCT03444285|OTHER|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
57959715|NCT03444285|OTHER|Hot Pack|20 minutes of hot-pack on both hamstring
57959716|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
57959717|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
57959718|NCT00848354|BIOLOGICAL|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
57959719|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
57959720|NCT00848354|DRUG|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
57959721|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
57959722|NCT00848354|DRUG|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
58123313|NCT06081751|BEHAVIORAL|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
58123314|NCT04326777|PROCEDURE|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
58123315|NCT06433453|DRUG|Indomethacin 50 MG|The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
58123316|NCT06433453|PROCEDURE|Transvaginal ultrasound scans|Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
58123317|NCT06433453|DIAGNOSTIC_TEST|Finger prick blood test|Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
58123318|NCT06433453|DIAGNOSTIC_TEST|Urine test|Early morning urine tests to assay reproductive hormones
58123319|NCT03869749|BEHAVIORAL|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
58123320|NCT03869749|BEHAVIORAL|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
58123321|NCT00778947|PROCEDURE|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
58123322|NCT00778947|PROCEDURE|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
58123323|NCT03139968|DEVICE|(sham) radiation absorbing drape (RADPAD®)|
58123324|NCT02772536|OTHER|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
58123325|NCT01484821|DEVICE|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
58123326|NCT02563509|BIOLOGICAL|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
57748332|NCT01687257|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
57959723|NCT02937714|OTHER|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
57959724|NCT01261156|DRUG|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
57959725|NCT01261156|DRUG|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
57959726|NCT04564586|BEHAVIORAL|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
57959727|NCT05465356|OTHER|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
57959728|NCT05465356|OTHER|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
57959729|NCT00781456|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
57959730|NCT00781456|DRUG|Placebo|1 tablet daily to match experimental arm
57959731|NCT04074928|BIOLOGICAL|QIVc|Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.
57959732|NCT04074928|BIOLOGICAL|Comparator QIV|Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
57959733|NCT05419089|PROCEDURE|Robotic surgery|Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
57959734|NCT02499068|DEVICE|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
57959735|NCT05246137|BIOLOGICAL|COVID-19 Vaccine 40 ug/dose|Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
58123327|NCT03845309|BEHAVIORAL|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
58123328|NCT00536926|DEVICE|Home spirometry with data transfer via cell phone|home spirometry recording
58123329|NCT00536926|DEVICE|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
58123330|NCT00536926|DEVICE|Home spirometer w/o BT|Standard home spirometry
58123331|NCT04050488|DRUG|Zinc Sulfate|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
58123332|NCT04050488|DRUG|Placebos|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
58123333|NCT03112057|DIAGNOSTIC_TEST|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
58123334|NCT02210351|DEVICE|MRI test|
58123335|NCT01621464|DEVICE|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
58123336|NCT05840809|DRUG|First line tuberculosis treatment|This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
58123337|NCT00748293|OTHER|Low-residue diet|Commercialized (not yet marketed)low-residue diet
58123338|NCT00098709|DEVICE|Fetal pulse oximeter|
58123339|NCT02939274|DRUG|Verteporfin|
57748333|NCT02235350|OTHER|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
58123340|NCT02939274|DEVICE|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
58123341|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
58123342|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
58123343|NCT06094556|DRUG|SHR-1826|dose is calculated based on the subjects' baseline weight.
58123344|NCT03951948|OTHER|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
58123345|NCT03196024|BEHAVIORAL|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
58123346|NCT03196024|BEHAVIORAL|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
58123347|NCT05056142|PROCEDURE|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
58123348|NCT05056142|PROCEDURE|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
58314301|NCT05944432|DEVICE|Self monitoring of blood glucose|Subjects will be randomised to continue with their current glucose monitoring system
58314302|NCT01642368|OTHER|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
58314303|NCT00739232|DRUG|HSD-016|
58314304|NCT00739232|OTHER|placebo|
58314305|NCT06040320|DRUG|Polatuzumab vedotin|Given at 1.8 mg/kg
58314306|NCT06040320|DRUG|Rituximab|Given at 375 mg/m\^2
58314307|NCT06040320|DRUG|CHP|Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
58123349|NCT06314321|OTHER|Baduanjin exercise|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
58123350|NCT04253431|DEVICE|Droplet lancing device (HTL-Strefa S.A.)|
58123351|NCT04253431|DEVICE|Microlet 2 lancing device (Bayer)|
57748334|NCT02235350|OTHER|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
57748335|NCT03263884|DEVICE|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
58123352|NCT04253431|DEVICE|OneTouch Delicia lancing device (LifeScan)|
58123353|NCT04253431|DEVICE|ReliOn lancing device (ReliOn)|
58123354|NCT04253431|DEVICE|Accu-Chek Softclix lancing device (Roche)|
58123355|NCT04253431|DEVICE|BGStar lancing device (Sanofi Aventis)|
58123356|NCT04253431|DEVICE|Ultra-Fine 33G lancets (BD)|
58123357|NCT04253431|DEVICE|Droplet 33G lancets (HTL-Strefa S.A.)|
58123358|NCT04253431|DEVICE|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
58450842|NCT03309748|DEVICE|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
58450843|NCT01695135|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
58450844|NCT01695135|DRUG|Placebo|Placebo (4 tablets) taken orally once daily
58450845|NCT01695135|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
58450846|NCT02720341|DEVICE|ARMin|single sessions of about one hour each
57748336|NCT03263884|DEVICE|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
58450847|NCT03469648|PROCEDURE|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
58450848|NCT03835299|BEHAVIORAL|Fear Intervention|Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
58450849|NCT01473732|DRUG|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
57748337|NCT04373876|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|Patients implanted with a totally subcutaneous defibrillator system
58450850|NCT01473732|DRUG|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
57748338|NCT04465019|DEVICE|Exoskeleton Rehabilitation|The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
57959736|NCT03917602|PROCEDURE|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
57959737|NCT05798260|DIAGNOSTIC_TEST|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
57959738|NCT03800654|BEHAVIORAL|Mindful Action for Pain|MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.
57959739|NCT03800654|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
57959740|NCT05079607|OTHER|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
57959741|NCT05079607|OTHER|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
57959742|NCT02098564|OTHER|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
57959743|NCT02098564|OTHER|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
57959744|NCT00288093|RADIATION|3-Dimensional Conformal Radiation Therapy|
57959745|NCT00288093|DRUG|Triapine|
57959746|NCT05300516|PROCEDURE|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
58123359|NCT04253431|DEVICE|HaemoFine 33G lancets (HTL-Strefa S.A.)|
58123360|NCT04253431|DEVICE|Softclix 28 G lancets (Roche)|
58123361|NCT04253431|DEVICE|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
58123362|NCT04253431|DEVICE|GlucoJect Dual S lancing device (Menarini)|
58123363|NCT04253431|DEVICE|Microlet 28G lancets (Bayer)|
58123364|NCT04253431|DEVICE|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
58123365|NCT03936400|BEHAVIORAL|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
58123366|NCT05492591|DRUG|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
58123367|NCT05492591|DRUG|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
58123368|NCT05492591|DRUG|Valacyclovir|Valacyclovir is a positive control drug.
58123369|NCT05441202|DEVICE|transdermal therapy|transdermal therapy with Chinese medicine
58123370|NCT05448677|DRUG|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
58123371|NCT05448677|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
58123372|NCT05448677|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
58123373|NCT03354247|BEHAVIORAL|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
58123374|NCT05371522|RADIATION|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain \[18F\]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
58123375|NCT01946165|DRUG|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
58123376|NCT01946165|DRUG|Prednisone|5 mg by mouth once daily for each 28 day cycle.
58123377|NCT01946165|DRUG|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
58123378|NCT01946165|DRUG|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
58123379|NCT01922349|DRUG|BI 113608|Medium dose (Multiple dosing)
58123380|NCT01922349|DRUG|Placebo|Placebo (Multiple dosing)
58123381|NCT01922349|DRUG|BI 113608|Low dose (Multiple dosing)
58123382|NCT01922349|DRUG|Placebo|Placebo (Single dosing)
58123383|NCT01922349|DRUG|BI 113608|High dose (Single dosing)
58123384|NCT01922349|DRUG|BI 113608|Medium dose (Single dosing)
58123385|NCT01922349|DRUG|BI 113608|Low dose (Single dosing)
58123386|NCT01922349|DRUG|BI 113608|High dose (Multiple dosing)
58123387|NCT04407819|RADIATION|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
58123388|NCT00002387|DRUG|Indinavir sulfate|
58123389|NCT00002387|DRUG|Efavirenz|
58123390|NCT00002965|BIOLOGICAL|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
58123391|NCT05743218|OTHER|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
58123392|NCT04646174|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
58123393|NCT04646174|BEHAVIORAL|American Lung Association self-management strategies for smoking cessation|Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
58123394|NCT05164809|DEVICE|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
58123395|NCT01945632|DEVICE|conventional gracey curettes|
58123396|NCT01945632|DEVICE|Vertically oscillating ultrasonic device|
58123397|NCT01945632|DEVICE|piezoelectric ultrasonic scraper|
58123398|NCT02492490|OTHER|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
58123399|NCT02492490|DRUG|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
58123400|NCT00368966|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
58123401|NCT00368966|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|
58123402|NCT00334490|DRUG|Sildenafil|12.5 mg Sildenafil once with optional second dose
58123403|NCT00334490|DRUG|Sildenafil|12.5 mg orally once with optional second dose
58123404|NCT00334490|DRUG|Placebo|Oral Placebo in 5 mls distilled water
58123405|NCT06344000|OTHER|inapplicable|inapplicable
58123406|NCT01790022|DRUG|Methylprednisolone|
58123407|NCT01447264|PROCEDURE|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
58123408|NCT01447264|PROCEDURE|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
58123409|NCT01353300|GENETIC|DNA analysis|
58123410|NCT01353300|GENETIC|cytogenetic analysis|
58123411|NCT01353300|GENETIC|gene expression analysis|
58450851|NCT01473732|DRUG|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
58450852|NCT04012580|BEHAVIORAL|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
58450853|NCT01744249|DRUG|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
58450854|NCT01744249|DRUG|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
58450855|NCT01744249|DRUG|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
58450856|NCT02664662|OTHER|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
58450857|NCT06436534|DRUG|Ganciclovir Oral Capsule|2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
58450858|NCT06436534|DRUG|Ganciclovir Simulant Oral Capsule|2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
58450859|NCT06436534|DRUG|Mometasone Nasal|From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
57748339|NCT01605929|PROCEDURE|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
58123412|NCT01353300|GENETIC|gene rearrangement analysis|
58123413|NCT01353300|GENETIC|mutation analysis|
58450860|NCT06117436|DRUG|Cilostazol|Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
58450861|NCT06117436|DRUG|Selenium|Selenium 200 mcg oral tablet once daily
58450862|NCT05177614|DIETARY_SUPPLEMENT|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
58450863|NCT05177614|DIETARY_SUPPLEMENT|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
58123414|NCT01353300|GENETIC|polymerase chain reaction|
58123415|NCT01353300|GENETIC|polymorphism analysis|
58123416|NCT01353300|OTHER|laboratory biomarker analysis|
58123417|NCT01353300|OTHER|medical chart review|
58123418|NCT01083875|DRUG|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
58123419|NCT01083875|DRUG|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
58123420|NCT00646945|DRUG|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
58123421|NCT00646945|DRUG|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
58123422|NCT02992405|BEHAVIORAL|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
58123423|NCT02992405|BEHAVIORAL|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
58123424|NCT01440530|BEHAVIORAL|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
58314308|NCT01658410|DRUG|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
58314309|NCT01658410|DRUG|NaCl|NaCl, Route: intracoronary
58450864|NCT05177614|DIETARY_SUPPLEMENT|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
58450865|NCT00068614|BIOLOGICAL|HER-2/neu peptide vaccine|
58450866|NCT04258930|OTHER|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
58450867|NCT04258930|DEVICE|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
58450868|NCT04258930|DEVICE|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
58314310|NCT00872547|DEVICE|DePuy ASR™ Hip System|Resurfacing system
58123425|NCT01440530|OTHER|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
58123426|NCT05190263|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
58123427|NCT02623829|DRUG|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
58123428|NCT02623829|DRUG|Saline|1ml of normal saline will be administered
58123429|NCT02470195|BEHAVIORAL|workshop|workshop for procedural simulation for education in difficult airway situation
58123430|NCT02301247|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
58123431|NCT02301247|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
58123432|NCT06543576|BIOLOGICAL|Bevacizumab|Given IV
58123433|NCT06543576|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57748340|NCT05855330|DRUG|Arginine Hydrochloride|Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
57748341|NCT06211660|BEHAVIORAL|AI-based AR training system|Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
57748342|NCT06211660|BEHAVIORAL|Hand scanner and Video training|Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
57748343|NCT01091155|DEVICE|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
58123434|NCT06543576|RADIATION|Brachytherapy|Undergo brachytherapy
58123435|NCT06543576|DRUG|Cisplatin|Given IV
58123436|NCT06543576|RADIATION|External Beam Radiation Therapy|Undergo EBRT
58123437|NCT06543576|DRUG|Paclitaxel|Given IV
58123438|NCT06543576|BIOLOGICAL|Pembrolizumab|Given IV
58123439|NCT06543576|OTHER|Questionnaire Administration|Ancillary study
58123440|NCT03825484|DRUG|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
58314311|NCT00872547|DEVICE|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
58450869|NCT06333379|OTHER|Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF|Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.
57748344|NCT04962555|PROCEDURE|Meniscus Suture|Patients with knee joint meniscus injury undergoing meniscus suture
57748345|NCT04962555|PROCEDURE|Partial meniscus resection|Patients with knee joint meniscus injury undergoing partial meniscus resection
57748346|NCT04962555|PROCEDURE|Subtotal meniscus resection|Patients with knee joint meniscus injury undergoing subtotal meniscus resection
57748347|NCT04962555|PROCEDURE|Complete meniscectomy|Patients with knee joint meniscus injury undergoing complete meniscectomy
57748348|NCT04134156|PROCEDURE|sleeve gastrectomy|5-port sleeve gastrectomy
57748349|NCT04134156|PROCEDURE|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
58123441|NCT00455052|DRUG|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
58123442|NCT04452578|PROCEDURE|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
58123443|NCT05462288|DEVICE|Entia Liberty|Home monitoring blood analyser
58123444|NCT05690568|OTHER|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
58123445|NCT03392974|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
58123446|NCT03718338|PROCEDURE|Evaluation|Undergo clinical evaluations
58123447|NCT03718338|OTHER|Quality-of-Life Assessment|Ancillary studies
58123448|NCT03872999|OTHER|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
58123449|NCT03317613|DRUG|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
58123450|NCT06231758|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
58123451|NCT06231758|DRUG|Metformin|Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
58123452|NCT00314691|GENETIC|Blood samples|
58314312|NCT00527995|DRUG|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
58123453|NCT00310258|BEHAVIORAL|Drug use prevention intervention|
58123454|NCT00215462|DRUG|Vinorelbine|
58123455|NCT02228174|DEVICE|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
58123456|NCT05485909|OTHER|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
58123457|NCT05485909|DRUG|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
58123458|NCT03110666|BIOLOGICAL|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
58123459|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Treat)|Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.
58123460|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Placebo)|Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.
58123461|NCT04910490|OTHER|No interventions - retrospective data collection|No new/additional patients will be enrolled within this project.
58123462|NCT01438723|DRUG|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
58123463|NCT01438723|DRUG|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
58123464|NCT01654380|DRUG|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
58123465|NCT01654380|OTHER|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
58123466|NCT01941095|DRUG|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123467|NCT01941095|DRUG|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123468|NCT01941095|DRUG|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123469|NCT01941095|DRUG|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123470|NCT01941095|DRUG|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123471|NCT01941095|DRUG|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
58123472|NCT01941095|DRUG|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
58450870|NCT06144463|DIAGNOSTIC_TEST|lung ultrasound-guided fluid resuscitation|For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion
58450871|NCT01018277|OTHER|Mobilization (walking)|25 meters twice
58450872|NCT05064371|DRUG|Eptinezumab|Concentrate for solution for IV infusion
57748350|NCT01372657|OTHER|biometry calculation|
57748351|NCT03592511|DIETARY_SUPPLEMENT|WGPF-burger|Volunteers consumed a WGPF-burger daily
57959747|NCT03777683|DIETARY_SUPPLEMENT|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
58123473|NCT03262181|OTHER|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
57748352|NCT03592511|DIETARY_SUPPLEMENT|Control-burger|Volunteers consumed a Control-burger daily
58123474|NCT03262181|OTHER|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
58123475|NCT00006443|DRUG|Indinavir sulfate|
58123476|NCT00006443|DRUG|Nelfinavir mesylate|
58123477|NCT00006443|DRUG|Lamivudine|
58123478|NCT00006443|DRUG|Stavudine|
58123479|NCT00203307|DRUG|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
58123480|NCT00203307|DRUG|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
58123481|NCT05063461|DEVICE|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
58123482|NCT05063461|PROCEDURE|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
58123483|NCT04685421|DRUG|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
58123484|NCT03673826|DRUG|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
58123485|NCT03673826|DRUG|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
58123486|NCT03673826|DRUG|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
58123487|NCT00775697|DRUG|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
58123488|NCT00775697|DRUG|Montelukast|montelukast 4 mg day for 4 weeks
58123489|NCT01243554|BEHAVIORAL|Exercise|Exercise training at the hospital
58123490|NCT04534283|DRUG|Abemaciclib|Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
58123491|NCT04534283|DRUG|LY3214996|Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
58123492|NCT00279721|PROCEDURE|IMRT|
58123493|NCT00619385|DRUG|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
58123494|NCT05690685|DEVICE|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period."
58123495|NCT03749265|OTHER|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
58123496|NCT03879213|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
58123497|NCT03879213|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
58123498|NCT04302948|OTHER|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
58123499|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
58123500|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
58123501|NCT04642456|DIAGNOSTIC_TEST|MRI spine/pelvis|We will be capturing 3D Magnetic Resonance (MR) images of the subject lying supine with extended knees, using a T1 weighted spine-echo (SE) sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weighted images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
58450873|NCT01861626|DRUG|V0057 - A mg|Single oral administration
58450874|NCT01861626|DRUG|Isotretinoin|Single oral administration
58123502|NCT04642456|DIAGNOSTIC_TEST|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
58123503|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
58123504|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
58123505|NCT04576546|DIETARY_SUPPLEMENT|D-chiro-inositol|Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
58123506|NCT04576546|DIETARY_SUPPLEMENT|Myo-inositol|Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
58123507|NCT01775215|RADIATION|Cardiac I123-MIBG Scintigraphy|
58123508|NCT01775215|OTHER|Cardiac MRI|
58123509|NCT01775215|OTHER|Stress and rest Echocardiogram|
58123510|NCT01775215|OTHER|High Sensitivity Troponin I|
58123511|NCT01775215|OTHER|Brain Natriuretic Peptide|
58123512|NCT03713138|DIETARY_SUPPLEMENT|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
58314313|NCT06492915|DRUG|Chiauranib|Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
57748353|NCT05698446|PROCEDURE|Modified Broström + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
58314314|NCT06492915|DRUG|Albumin-paclitaxel Injection|Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
58314315|NCT06492915|DRUG|Gemcitabine Injection|Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
58314316|NCT05241951|OTHER|Structured hand-off|Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams
58314317|NCT05241951|OTHER|Medication reconciliation during transitional period|Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)
57748354|NCT05698446|PROCEDURE|Anatomic reconstruction operation|Anatomic reconstruction operation
58123513|NCT02397070|PROCEDURE|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
57748355|NCT02026089|BIOLOGICAL|Varicella vaccine|Varivax 0.5ml subcutaneous injection
57748356|NCT04069000|BEHAVIORAL|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
58123514|NCT02397070|DEVICE|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
58123515|NCT01636856|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
58123516|NCT01636856|BEHAVIORAL|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
58123517|NCT02426619|DEVICE|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
58123518|NCT02426619|DEVICE|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
58123519|NCT05337956|PROCEDURE|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
57748357|NCT04069000|BEHAVIORAL|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
57748358|NCT02354664|OTHER|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
57748359|NCT02354664|OTHER|Spirometry|Upright forced vital capacity (FVC)
58123520|NCT02709356|DIETARY_SUPPLEMENT|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
58123521|NCT02709356|DIETARY_SUPPLEMENT|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
58123522|NCT02463513|DIETARY_SUPPLEMENT|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
58123523|NCT02463513|DIETARY_SUPPLEMENT|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
58123524|NCT02463513|DIETARY_SUPPLEMENT|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
58123525|NCT03352427|DRUG|Dasatinib|60 mg/m2 orally twice daily
57748360|NCT02354664|OTHER|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
57748361|NCT02354664|OTHER|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
58123526|NCT03352427|DRUG|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
58123527|NCT02106065|BEHAVIORAL|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
58123528|NCT02106065|OTHER|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
58123529|NCT06458790|BEHAVIORAL|AARC|This intervention will adapt an already-existing evidence-based Centering Parenting program addressing topics that are specific to African American families. There will be 9 90 min sessions via zoom and in person. Group education topics include (parenting goals, infant feeding and sleep, self-care). Participants will complete surveys and interviews at various times to evaluate the program. The survey topics will include: parent stress, parent confidence and thoughts about the intervention. Surveys will be completed independently by participants online via redcap at a time that is convenient to them; if requested, the coordinator may complete the survey with the participant directly by phone /zoom. Interviews will be completed with a coordinator via zoom/phone.
58123530|NCT04933513|BEHAVIORAL|pre DBS patients responding to the DBS-PS scale|we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
58123531|NCT05344183|DEVICE|Low-level laser|A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
58123532|NCT06444074|BEHAVIORAL|Patient Activation through Conversations (PACT) Program|Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
58123533|NCT06444074|BEHAVIORAL|Usual Care|Routine Chronic Disease care
58123534|NCT05859165|DIETARY_SUPPLEMENT|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
58123535|NCT05859165|DIETARY_SUPPLEMENT|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
58123536|NCT02506647|DRUG|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
58123537|NCT02506647|DRUG|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
58123538|NCT02112240|OTHER|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
58123539|NCT02112240|DRUG|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
58123540|NCT02112240|OTHER|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
58123541|NCT02112240|PROCEDURE|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
58123542|NCT02112240|RADIATION|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
58123543|NCT04930081|BEHAVIORAL|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
58123544|NCT04702620|DEVICE|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
58123545|NCT05854654|DIAGNOSTIC_TEST|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
58123546|NCT01773148|DEVICE|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
58123547|NCT05782790|BEHAVIORAL|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
58314318|NCT05241951|OTHER|Transitional medication monitoring|Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery
58314319|NCT05241951|OTHER|Teleconsultation|Ad hoc consultation to provide additional clarification to SNF clinical teams
58314320|NCT04226157|DEVICE|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
58314321|NCT04226157|OTHER|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
58314322|NCT01189266|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
57748362|NCT02354664|OTHER|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
58123548|NCT05782790|BEHAVIORAL|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
58123549|NCT03168074|DRUG|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
58123550|NCT00013351|PROCEDURE|Prevention of Falls|
58123551|NCT00993187|DRUG|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
58123552|NCT00993187|DRUG|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
58123553|NCT00993187|DRUG|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
57748363|NCT02354664|OTHER|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
58123554|NCT00993187|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
58123555|NCT05677607|DIAGNOSTIC_TEST|Magnetic resonance imaging|Imaging diagnostics mainly based on Magnetic resonance imaging.
57748364|NCT01919242|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
58123556|NCT05673668|DEVICE|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
58123557|NCT00493571|DRUG|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
58123558|NCT02789306|PROCEDURE|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
58123559|NCT03339349|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
58123560|NCT04190290|OTHER|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
58123561|NCT04190290|DIAGNOSTIC_TEST|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
58123562|NCT05663281|DIAGNOSTIC_TEST|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
58123563|NCT00006381|BIOLOGICAL|trastuzumab|
58123564|NCT00006381|DRUG|celecoxib|
58123565|NCT06364605|DEVICE|Rehabilitation with the iReach novel multisensory medical device|From the results of Phases 1,2 and 3, in Phase 4 a medical device for spatial and sensorimotor rehabilitation in infants aged 3 to 36 months will be tested and developed.
58123566|NCT02199509|DRUG|Levetiracetam|Anticonvulsant
57748365|NCT03067038|DEVICE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
57748366|NCT03067038|DEVICE|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
58123567|NCT05825053|BEHAVIORAL|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
58123568|NCT05825053|BEHAVIORAL|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
57748367|NCT06374446|OTHER|Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.
58123569|NCT05154721|DEVICE|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
58314323|NCT01189266|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
58314324|NCT01189266|OTHER|Laboratory Biomarker Analysis|Correlative studies
58314325|NCT01189266|DRUG|Vorinostat|Given PO
58314326|NCT00219609|DRUG|UK-390,957|
58123570|NCT05154721|DEVICE|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
58123571|NCT00980603|DRUG|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
58123572|NCT00980603|DRUG|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
58314327|NCT02305979|DRUG|Loratadine|
58314328|NCT04005872|DRUG|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
57748368|NCT06374446|OTHER|Virtual Reality Combined with Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
57748369|NCT06374446|OTHER|Virtual Reality|Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
57748370|NCT06374446|OTHER|Control Group|This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
57748371|NCT03776955|DRUG|Carvedilol|Oral tablet
57748372|NCT01592331|DRUG|Placebo|Single oral dose
57748373|NCT01592331|DRUG|RO5508887|Single oral dose
57748374|NCT00011505|DRUG|G-CSF|
57748375|NCT00011505|PROCEDURE|Leukapheresis|
57748376|NCT03948048|DEVICE|ECMO|ECMO is used to intervene septic shock and refractory septic shock
57748377|NCT03249155|BEHAVIORAL|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
57748378|NCT03249155|BEHAVIORAL|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
57748379|NCT03263754|BEHAVIORAL|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
57748380|NCT03263754|BEHAVIORAL|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
57748381|NCT04184726|BEHAVIORAL|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
57748382|NCT00166296|DRUG|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
57748383|NCT00166296|DRUG|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
57748384|NCT01561001|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
57748385|NCT05902832|BEHAVIORAL|EmotiPlay|EmotiPlay is a computer-based intervention program, designed to enhance emotion recognition (ER) by addressing multiple modalities of emotional cues (facial expressions, tone of voice, body language),
57748386|NCT00310219|PROCEDURE|computed tomography|
57748387|NCT00310219|PROCEDURE|positron emission tomography|
57748388|NCT04584164|DEVICE|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
57748389|NCT01422408|DRUG|Fluocinonide Cream|Given topically
57748390|NCT01422408|PROCEDURE|Management of Therapy Complications|Receive fluocinonide cream
58123573|NCT00980603|DRUG|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
58123574|NCT04947956|DRUG|Camrelizumab|The camrelizumab-based treatment will be determined by the investigator.
57748391|NCT01422408|OTHER|Questionnaire Administration|Ancillary studies
57748392|NCT06280703|DRUG|LY3938577|Administered Intravenously (IV)
58123575|NCT01282996|OTHER|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
58123576|NCT06232083|RADIATION|PLDR+Cardunizumab|Application of PLDR external irradiation combined with Cardunizumab in recurrent cervical cancer
58123577|NCT04054024|DRUG|Erenumab|140 mg Erenumab
58123578|NCT04054024|DRUG|Placebos|Saline
57748393|NCT06280703|DRUG|Placebo|Administered Intravenously (IV)
57748394|NCT06280703|DRUG|Insulin Degludec|Administered Intravenously (IV)
57748395|NCT06280703|DRUG|Insulin Lispro|Administered Intravenously (IV)
57748396|NCT05017922|PROCEDURE|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
57748397|NCT06185257|DEVICE|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
58123579|NCT01519583|BEHAVIORAL|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
58314329|NCT04005872|DRUG|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
57748398|NCT04341506|DEVICE|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
57748399|NCT01812655|DEVICE|Virtual Reality|
57748400|NCT01812655|OTHER|Passive Distraction|
57748401|NCT06490250|OTHER|Inspiratory Muscle Training|The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day
58123580|NCT01519583|BEHAVIORAL|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
58123581|NCT01519583|BEHAVIORAL|Control Group|Maintain usual physical activity, and return for follow-up measures.
58123582|NCT05478993|DRUG|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
57748402|NCT06490250|OTHER|Baduanjin Exercise|The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
58123583|NCT02026414|DIETARY_SUPPLEMENT|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
58123584|NCT02026414|OTHER|Exercise|
58123585|NCT04943809|DEVICE|POD 26P AY FT|Routine cataract surgery
58123586|NCT04943809|DEVICE|POD 26P AY F|Routine cataract surgery
58123587|NCT01103037|DRUG|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
58123588|NCT01103037|DRUG|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
58123589|NCT00311818|DRUG|Insulin glargine|
58450875|NCT01909999|PROCEDURE|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
58450876|NCT01909999|PROCEDURE|Clinical parameters evaluation|"The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
58123590|NCT02093689|DRUG|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
58123591|NCT02093689|DRUG|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
57748403|NCT00303862|DRUG|cediranib maleate|Given orally
57748404|NCT00303862|OTHER|laboratory biomarker analysis|Correlative studies
58450877|NCT01909999|PROCEDURE|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
57748405|NCT04565171|DRUG|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
57748406|NCT02935491|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
57748407|NCT00175825|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
57748408|NCT00175825|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
57748409|NCT00914004|DRUG|Desipramine HCl 50 mg Tablets Cord Laboratories|
57748410|NCT00914004|DRUG|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
57748411|NCT02297568|DRUG|Calciferol|Comparison 25OHD levels between calciferol and placebo
57748412|NCT02297568|DRUG|placebo|
58123592|NCT02093689|DRUG|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
57748413|NCT05989100|BEHAVIORAL|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
58123593|NCT04956419|DRUG|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
57748414|NCT05989100|BEHAVIORAL|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
57748415|NCT05989100|BEHAVIORAL|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
57748416|NCT03023592|DRUG|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
57748417|NCT06462911|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
57748418|NCT01337895|OTHER|Low dairy|No more than 1 serving per day
57748419|NCT01337895|OTHER|High dairy|4 or more servings per day
57748420|NCT05892068|DRUG|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
57748421|NCT03544346|OTHER|Exploratory brain and general health assessment|Exploratory brain and general health assessment
58123594|NCT04956419|DRUG|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
58123595|NCT02673164|BIOLOGICAL|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
58123596|NCT02849821|OTHER|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
58123597|NCT02849821|OTHER|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
58123598|NCT01874951|DRUG|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
58123599|NCT01874951|DRUG|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
58314330|NCT00815529|DEVICE|Acupuncture, Pak-sham needle|25\*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
57748422|NCT00487409|PROCEDURE|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
57748423|NCT00487409|PROCEDURE|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
57748424|NCT05090709|OTHER|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
57748425|NCT05090709|OTHER|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
57748426|NCT03076255|PROCEDURE|Computed Tomography|Undergo CT simulation
57748427|NCT03076255|DEVICE|Medical Device|Given thermoplastic mask
57748428|NCT03076255|DEVICE|Medical Device|Given MID
57748429|NCT03076255|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT imaging
57748430|NCT01843374|DRUG|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
57748431|NCT01843374|DRUG|Placebo|Placebo is to be administered as an IV solution, followed by observation.
57748432|NCT05617690|DRUG|Cyclopol|Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h
57748433|NCT05617690|DRUG|Propofol|Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
57748434|NCT03489304|DRUG|Zaleplon|non-benzodiazepine hypnotic agent
57748435|NCT00056251|PROCEDURE|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
57748436|NCT04953390|DEVICE|Phonak Audeo hearing aid|Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3
57748437|NCT04953390|DEVICE|Phonak hearing aid with multiple directionality settings, adjustable via a mobile app|Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
57959748|NCT03777683|OTHER|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
57959749|NCT06156085|DRUG|Vonoprazan and Amoxicillin|vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days
57959750|NCT06156085|DRUG|Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole|lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
58123600|NCT04662892|DRUG|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
57748438|NCT03355417|OTHER|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
57748439|NCT00746590|DRUG|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
58123601|NCT01492062|DEVICE|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
58314331|NCT02637596|PROCEDURE|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
57748440|NCT06577623|BEHAVIORAL|MINDful TIME|Group-based psychoeducational mindfulness-based intervention.
58314332|NCT05242211|OTHER|exercise test|Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
57748441|NCT05005780|DEVICE|Negative peak triggered 100 Hz triplet burst TMS|MagVenture MagPro X100: Ipsilesional negative peak triggered 100 Hz triplet burst TMS.
57748442|NCT05005780|DEVICE|1 Hz rTMS|MagVenture MagPro X100: Contralesional 1 Hz rTMS.
57748443|NCT00033696|BIOLOGICAL|filgrastim|
57748444|NCT00033696|DRUG|carboplatin|
57748445|NCT00033696|DRUG|etoposide|
57748446|NCT00033696|DRUG|paclitaxel|
57748447|NCT00033696|DRUG|topotecan hydrochloride|
57748448|NCT00033696|RADIATION|radiation therapy|
58314333|NCT02715453|OTHER|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge"
57748449|NCT04844580|DRUG|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
57748450|NCT04844580|DRUG|Placebo|Aviptadil Placebo will be used for this arm.
57748451|NCT00990080|BIOLOGICAL|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
57748452|NCT05979753|OTHER|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
57748453|NCT01718327|DRUG|Sunitinib|sunitinib dose :37.5mg/day
57748454|NCT06295770|DRUG|Obinutuzumab|Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
57748455|NCT03357874|DRUG|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
57748456|NCT03357874|DRUG|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
57748457|NCT05038384|OTHER|Survey Administration|Complete survey
57748458|NCT03819140|DRUG|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
57748459|NCT04517396|OTHER|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
57748460|NCT04517396|OTHER|Placebo|The control intervention will be a placebo, for 10 days.
57748461|NCT04517396|OTHER|Usual care|All participants will otherwise receive usual medical care
57748462|NCT00815295|DRUG|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
57748463|NCT00815295|DRUG|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
57748464|NCT00572195|DEVICE|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
58314334|NCT00677638|DEVICE|Ventor Embracer|Implantation of Ventor Embracer
57748465|NCT03595579|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks.
57748466|NCT03595579|DRUG|Bupropion|Bupropion taken twice daily for 6 weeks.
57959751|NCT03662425|DRUG|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
57959752|NCT03662425|DRUG|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
57959753|NCT00651092|PROCEDURE|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
57959754|NCT00651092|PROCEDURE|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
58123602|NCT04642352|DRUG|superior laryngeal nerve block|A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
57748467|NCT06215014|OTHER|Isometric handgrip training|Participants will train three days per week at home for 1 month using a reliable and validated digital handgrip dynamometer (DynX, MD System, Inc., Westerville, USA) in a seated position. The isometric handgrip training protocol will consist of four sets (2 for each hand) of two-min sustained contractions starting at 30% of maximum voluntary contraction (MVC) interspersed by 1-min resting periods (a total of 12-min). All training sessions will be remotely supervised via Zoom or phone call by a research team member to ensure compliance with the exercise prescription. Before each training session, MVCs will be re-assessed over three repetitions, each separated by 30-s, to ensure an accurate exercise prescription. The highest value will be used to determine the target intensity of the session
57748468|NCT06240325|BEHAVIORAL|SPP|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
57748469|NCT06240325|BEHAVIORAL|Sleep Psychoeducation|Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
57748470|NCT01911377|DRUG|Botulinum Toxin Type A|
57748471|NCT01911377|DRUG|Normal Saline for Injection|
57748472|NCT01235403|DRUG|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
58123603|NCT02520557|OTHER|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
58123604|NCT03919201|OTHER|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
58123605|NCT03919201|OTHER|No exercise intervention group|Control group: no exercise intervention
57748473|NCT05681806|DIETARY_SUPPLEMENT|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
58123606|NCT03672110|DRUG|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
58123607|NCT00372788|DRUG|AZD6244|oral vial
57748474|NCT05681806|DIETARY_SUPPLEMENT|Creatine Monohydrate|5g creatine monohydrate
57748475|NCT03191487|OTHER|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
57748476|NCT03191487|OTHER|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
57748477|NCT00176579|PROCEDURE|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
57748478|NCT01652144|DRUG|AT7519M|
57748479|NCT00428090|DRUG|Rosiglitazone|XR (extended release) oral tablets
57748480|NCT02858050|DEVICE|Portal-724 MEMs Cap|
57748481|NCT02686580|BIOLOGICAL|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
57748482|NCT04969484|OTHER|Telehealth visit|ImPACTT Telehealth visit with the PC provider
57748483|NCT02130310|BIOLOGICAL|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
57959755|NCT04700176|DRUG|Daratumumab|During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
57959756|NCT04700176|DRUG|Pomalidomide|Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
58123608|NCT00372788|DRUG|Pemetrexed|oral
58123609|NCT03211559|OTHER|Exercise|clinical pilates on mat
58123610|NCT04588259|DRUG|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
58123611|NCT04588259|DRUG|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
58123612|NCT04588259|DRUG|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
58123613|NCT05252481|DEVICE|Active tDCS|Eight sessions of transcranial current direct stimulation
58123614|NCT05252481|DEVICE|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
57748484|NCT02130310|OTHER|Placebo injection|Normal saline injected at each centimeter of ulcer bed
57748485|NCT01489579|BEHAVIORAL|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
57748486|NCT01489579|BEHAVIORAL|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
57748487|NCT03964597|DIAGNOSTIC_TEST|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
57748488|NCT06578988|PROCEDURE|Mammography Images|Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
57748489|NCT06146491|DRUG|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
57748490|NCT00047801|DRUG|TLK286 in combination with docetaxel|
57748491|NCT02697851|DRUG|Microgynon 30®|
58123615|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
58123616|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
58123617|NCT02058056|RADIATION|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
58123618|NCT00216398|DRUG|Lanreotide (Autogel formulation)|
58123619|NCT05414474|OTHER|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
58123620|NCT05414474|OTHER|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
58123621|NCT05414474|OTHER|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
58123622|NCT05414474|OTHER|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
58123623|NCT05414474|OTHER|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
58123624|NCT05414474|OTHER|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
58123625|NCT05731427|DIAGNOSTIC_TEST|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
57748492|NCT02697851|DRUG|Evotaz®|
57748493|NCT06296576|PROCEDURE|arterial ultrasound scan|An arterial ultrasound scan of the lower limbs with pulsed Doppler analysis of arterial flow spectra over the abdominal aorta, dorsal artery of the foot and lateral plantar artery, bilaterally
57748494|NCT01951638|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
57748495|NCT01951638|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
57748496|NCT01951638|DRUG|Placebo|
57748497|NCT05450315|BEHAVIORAL|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
57748498|NCT05450315|BEHAVIORAL|Canadian Physical Activity Guidelines|
57748499|NCT00770107|DRUG|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
57748500|NCT00770107|DRUG|Placebo|Placebo, once daily, for a duration of 4 weeks
57748501|NCT03326505|BIOLOGICAL|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
57748502|NCT03326505|OTHER|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
58123626|NCT05731427|DRUG|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
57748503|NCT02324218|OTHER|Data collection|Data extraction from CPRD database of UK.
57959757|NCT04700176|DRUG|All-trans retinoic acid|ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
57959758|NCT04700176|DRUG|Dexamethasone|Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
57959759|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
57959760|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
57748504|NCT06166693|DEVICE|"MINDLiNG Digital Mental Health Intervention"|The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
57748505|NCT03789682|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
57748506|NCT06346379|BEHAVIORAL|Baduanjin exercise|Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
57748507|NCT03315143|DRUG|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
57748508|NCT03315143|DRUG|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
57748509|NCT01921296|DRUG|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
57748510|NCT01248273|BIOLOGICAL|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
57748511|NCT04883307|BEHAVIORAL|Coaching|Professional development coaching based on a curriculum of positive psychology principles and coaching principles.
58314335|NCT01772862|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
58450878|NCT01909999|PROCEDURE|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
58450879|NCT01909999|PROCEDURE|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
58450880|NCT01909999|DRUG|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
58450881|NCT00721448|DRUG|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
58450882|NCT00721448|DRUG|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
58450883|NCT03645733|PROCEDURE|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
58450884|NCT00585117|PROCEDURE|PET-imaging with CuATSM|imaging with CuATSM
58450885|NCT00585117|PROCEDURE|PET Imaging|Imaging with CuATSM
58450886|NCT00585117|PROCEDURE|PET CuATSM|Imaging with CuATSM
57748512|NCT04883307|BEHAVIORAL|Wellness resources|Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
57748513|NCT04553341|DEVICE|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
57748514|NCT06378892|DRUG|Lorlatinib|Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
58314336|NCT00672802|DRUG|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
58314337|NCT03680027|DIETARY_SUPPLEMENT|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
58450887|NCT00585117|PROCEDURE|PET imaging|imaging with CuATSM
58450888|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
58450889|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
58450890|NCT03155724|DEVICE|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
58450891|NCT03528226|BEHAVIORAL|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
58450892|NCT03528226|BEHAVIORAL|Normal life procedure|No supervised exercise training during the 4 month period.
57748515|NCT06225167|BEHAVIORAL|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
57748516|NCT06185933|DRUG|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
57748517|NCT06185933|DRUG|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
57748518|NCT03221621|PROCEDURE|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
57748519|NCT03221621|DRUG|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
57748520|NCT05563103|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
57748521|NCT05563103|OTHER|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
57748522|NCT05563103|OTHER|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
57748523|NCT05563103|OTHER|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
57748524|NCT06567678|DRUG|Colchicine 0.5 MG oral tablet twice daily|Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU and Aspirin reaction unit test assay, followed by a subsequent repeat test 2-week after a 2-week, colchicine 0.5mg oral tablet twice-daily
57748525|NCT04360525|OTHER|Reasons|Causes of sigmoid volvulus
57748526|NCT05349825|DIAGNOSTIC_TEST|Genetic analysis and Losartan plazma level measurement|20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
57748527|NCT01356355|DRUG|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
57748528|NCT01356355|DRUG|Placebo|One capsule twice a day daily till ureteral stent in situ
57748529|NCT01356355|DRUG|Tolterodine|One capsule twice a day daily till ureteral stent in situ
57748530|NCT04311606|DRUG|Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
57748531|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
57748532|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) alone|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
57748533|NCT03495011|DIAGNOSTIC_TEST|Breast MRI|Quantitative, multiparametric breast MRI
58123627|NCT03963570|BEHAVIORAL|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
58314338|NCT03997877|OTHER|Physical activity|Increase physical activity Balanced diet
58314339|NCT00379405|DRUG|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
57748534|NCT03495011|OTHER|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
57748535|NCT06113601|OTHER|There is no intervention.|There is no intervention in the study.
57748536|NCT05632510|DIAGNOSTIC_TEST|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
57748537|NCT05339048|GENETIC|Genetic risk variants|Exposure: Genetic predisposition to complex diseases.
57748538|NCT05339048|OTHER|Diet|Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.
57748539|NCT05339048|BEHAVIORAL|Physical activity|Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.
57748540|NCT05339048|OTHER|Socio-economic conditions|Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
57748541|NCT02240095|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
57748542|NCT02240095|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
57748543|NCT02240095|BEHAVIORAL|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
57748544|NCT02415426|BEHAVIORAL|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek \& Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html).
57748545|NCT06199258|DIAGNOSTIC_TEST|pulmonary function test|pulmonary function testing
57748546|NCT06052241|DRUG|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
57748547|NCT01936857|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
57748548|NCT01936857|DRUG|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
57748549|NCT01944631|DEVICE|Placebo|Nasal spray saline
57748550|NCT01944631|DEVICE|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
57748551|NCT02203474|DRUG|Tiotropium HFA BAI 5 mcg|
57748552|NCT02203474|DRUG|Tiotropium 18 mcg Capsule|
57748553|NCT02203474|DRUG|Placebo|Placebo
57748554|NCT01538732|DRUG|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
57748555|NCT02652741|DRUG|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
57748556|NCT03764332|DEVICE|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
57748557|NCT04303949|OTHER|Behavioral:|Facilitating couples reduce anxiety, depression and grief through e-book education.
57748558|NCT01578148|PROCEDURE|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~1. Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~2. Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~3. Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~4. Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
57748559|NCT01578148|PROCEDURE|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~1. TENS stimulation (45 minutes):~   • Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~2. Other modalities of PT per the therapist's choice:~   * Infrared treatment on the pain areas (about 15 minutes)~  * Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~  * Exercise and training:~     * Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~    * Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~  * Hot/cold pack to the pain area for about 15 minutes"
57748560|NCT03797521|DRUG|SXC-2023|SXC-2023 oral capsules
58314340|NCT00742937|DIETARY_SUPPLEMENT|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
57748561|NCT03797521|DRUG|Placebo|Matching Placebo oral capsules
57748562|NCT01299948|DRUG|Prednisolone|5 mg prednisolone orally per day
57748563|NCT00003780|BIOLOGICAL|tumor infiltrating lymphocyte therapy|
57748564|NCT00003780|DRUG|gemcitabine hydrochloride|
57748565|NCT03494166|BEHAVIORAL|Start with SMSH+TIPC|See arm/group descriptions
57748566|NCT03494166|BEHAVIORAL|Start with SMSH alone|See arm/group descriptions
57748567|NCT02055131|DRUG|aspirin|
57748568|NCT06270654|PROCEDURE|Erector spinae plane block|"After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side."
57748569|NCT06270654|PROCEDURE|Skin infiltration LA|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
57748570|NCT02047500|DRUG|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
57748571|NCT02047500|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
57748572|NCT02047500|DRUG|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
57748573|NCT06492824|BEHAVIORAL|Enjoyable Activities Condition|Participants complete an introduction video about the intervention. They will then take a pre-intervention survey, after which they will choose five enjoyable activities from a large list. Daily text message reminders will be sent to BA participants in the morning to remind them to do their enjoyable activities for the day, as well as a link to a checklist where they will report how frequently they have completed any of their five activities from the previous day (example text message in documentation). At the end of the month, they will complete a follow-up survey consisting of the same measures from the pre-intervention survey.
57748574|NCT06492824|BEHAVIORAL|Healthy Activities Condition|They will take a pre-intervention survey and choose five enjoyable activities from the same list; however, active control participants will not explicitly be asked to complete these activities for the intervention. Participants in the active control condition will be promoted to complete tasks such as drinking more water, going to bed early, brushing their teeth, showering or bathing for that day, and eating well balanced meals. Daily text reminders will be sent about these healthy living activities in the morning. In that same message, they will receive a link to a checklist where they will report about their completed healthy living activities for the previous day (example text message in documentation). At the end of the month, they will also complete a follow-up survey consisting of the same measures from the pre-intervention survey.
57748575|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
57748576|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
57748577|NCT00754338|DRUG|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
57748578|NCT04717726|DIETARY_SUPPLEMENT|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
57748579|NCT04717726|DIETARY_SUPPLEMENT|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
58123628|NCT03963570|BEHAVIORAL|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
58123629|NCT04752436|BEHAVIORAL|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
58123630|NCT04861545|OTHER|Soy|"Isolated soy protein food sources are foods that include isolated soy protein in different forms and matrix (e.g. soy beverage and meat analogue).~Non-isolated soy protein food sources of soy protein are foods made with soy (e.g. Tofu, tempeh, edamame)."
58123631|NCT00535106|DEVICE|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
58123632|NCT00535106|DEVICE|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
58123633|NCT00535106|OTHER|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
57748580|NCT04717726|BEHAVIORAL|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
57748581|NCT04717726|DIETARY_SUPPLEMENT|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
57748582|NCT00335218|DRUG|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
57748583|NCT00335218|DRUG|Placebo|1 tablet daily
57748584|NCT03364322|OTHER|Observation|Observation
57748585|NCT04823429|BEHAVIORAL|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
57748586|NCT04823429|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
57748587|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
57748588|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
57748589|NCT01276925|DEVICE|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
57748590|NCT01276925|PROCEDURE|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
57748591|NCT01276925|DRUG|Saline|Isotonic. 10 ml for the femoral nerve.
57748592|NCT01276925|PROCEDURE|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
57748593|NCT01276925|DRUG|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
57748594|NCT05590780|OTHER|Clinical Attachment level|1-year
57748595|NCT05741684|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
57748596|NCT05741684|BEHAVIORAL|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
57748597|NCT04021810|DEVICE|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
57748598|NCT04021810|DEVICE|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
57748599|NCT01127867|DIETARY_SUPPLEMENT|dietary intervention|dietary intervention
57748600|NCT00441701|DRUG|Navarixin 1 mg|Navarixin 1 mg capsules
57748601|NCT00441701|DRUG|Navarixin 10 mg|Navarixin 10 mg capsules
57748602|NCT00441701|DRUG|Placebo to match navarixin|Placebo to navarixin capsules
57748603|NCT00441701|DRUG|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
57748604|NCT05242328|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
57748605|NCT05242328|PROCEDURE|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
57748606|NCT03540654|OTHER|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
57748607|NCT03244072|DRUG|Moxifloxacin|Intracameral injection
57748608|NCT03244072|DRUG|Placebo|intracameral injection
57748609|NCT05201573|OTHER|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
57748610|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
57748611|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
57748612|NCT00753792|DRUG|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
57748613|NCT03501433|DIETARY_SUPPLEMENT|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
57748614|NCT03501433|DIETARY_SUPPLEMENT|Placebo|2x/day for 7 days
57748615|NCT05241704|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
57748616|NCT05241704|PROCEDURE|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
58123634|NCT04168541|OTHER|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
58123635|NCT02483637|DEVICE|RejuvenAir|Device: RejuvenAir
58123636|NCT04514393|DRUG|Methotrexate|Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
58123637|NCT04514393|DRUG|Ibrutinib|Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
58123638|NCT04514393|DRUG|Temozolomide|Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
58123639|NCT04383756|BIOLOGICAL|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
58123640|NCT04383756|BIOLOGICAL|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
58123641|NCT02976298|OTHER|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
58123642|NCT02220907|DRUG|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
57748617|NCT00286845|DRUG|Standard Chemotherapy|physician determined
58123643|NCT01183000|PROCEDURE|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
58123644|NCT05409911|DRUG|S-217622|Tablet for oral administration
58123645|NCT02506166|DEVICE|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
58123646|NCT03466957|OTHER|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
57748618|NCT01696981|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
57748619|NCT01696981|PROCEDURE|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
57748620|NCT00419822|PROCEDURE|Acupuncture|6 Acupuncture visits
57959761|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is \>5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is \<5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
57959762|NCT06211231|BEHAVIORAL|Digitally delivered mindfulness- and acceptance-based psychological intervention|MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
57959763|NCT00612638|DRUG|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
58123647|NCT02707536|PROCEDURE|Socket grafting with PRF|Extraction with socket grafting using PRF.
58123648|NCT02707536|PROCEDURE|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
58123649|NCT06546293|OTHER|core stabilization exercises|The program consists of lumbo-pelvic/core strength and stability exercises. The program will be implemented individually under the supervision of a physiotherapist twice a week for 12 weeks.
58314341|NCT00742937|DIETARY_SUPPLEMENT|Placebo|second capsule with vitamin E, eight days after delivery.
58314342|NCT01278368|PROCEDURE|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
58314343|NCT01278368|PROCEDURE|Pancreatic resection|Pancreatic resection
57748621|NCT00419822|PROCEDURE|Sham Acupuncture|6 Acupuncture visits with sham procedure
57748622|NCT00419822|OTHER|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
57748623|NCT05276466|DIAGNOSTIC_TEST|Polymerase Chain Reaction and Next-Generation DNA Sequencing|"The qPCR Rapid Screening Panel is a quantitative real-time PCR test for bacteria and fungi.~Next-Generation DNA Sequencing is the Comprehensive Sequencing test will detect virtually all microbial organisms and fungal pathogens that may be present in patient specimens."
57959764|NCT01450033|BEHAVIORAL|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
57959765|NCT01450033|BEHAVIORAL|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
57959766|NCT00781716|DEVICE|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
58123650|NCT06546293|OTHER|daily physical activity program|The program consists of a daily physical activity program established and monitored for participation through weekly exercise tracking chart. The program will be implemented through weekly physiotherapist's control of the exercise tracking chart for 12 weeks.
58123651|NCT06450002|OTHER|physical therapy|Tens and Hot packs for 20 minutes, ultrasound for 5 minutes on the back and back exercise in form of bridging exercise and core stability exercise
58314344|NCT03839641|OTHER|High fat meal|60% fat meal
58314345|NCT03839641|OTHER|Low fat meal|20% fat meal
58450893|NCT06500637|DRUG|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
57748624|NCT01864239|OTHER|Medicines Advice Service|"The intervention consists of:~1. Telephone consultations with a pharmacist~2. Follow-up tailored written information~3. A medicine reminder chart"
57748625|NCT03980444|DEVICE|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
57748626|NCT03980444|PROCEDURE|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
57748627|NCT02034708|DRUG|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
57748628|NCT02034708|DRUG|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
57748629|NCT05190250|DIAGNOSTIC_TEST|Pipelle biopsy|Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
57748630|NCT00023153|DRUG|Adefovir Dipivoxil|
57748631|NCT03530930|DRUG|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
57748632|NCT01708330|DRUG|Lidocaine|2% Lidocaine gel
57748633|NCT01708330|DRUG|Placebo gel|odorless, colorless gel will be used as a placebo
57748634|NCT05308732|DRUG|Copaiba|A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
58123652|NCT01903577|OTHER|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
58123653|NCT01903577|OTHER|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
57748635|NCT06029101|PROCEDURE|posterior fossa craniectomy with or without duraplasty|craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
57748636|NCT02815462|OTHER|FAMFACESG|- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
58123654|NCT00809042|DRUG|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
58123655|NCT00809042|DRUG|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
58123656|NCT00809042|DRUG|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
58314346|NCT05125445|PROCEDURE|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
57748637|NCT02815462|OTHER|Control|- Usual hospital Care
57748638|NCT02815462|OTHER|FAMFACESG|- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
57748639|NCT02815462|OTHER|FAMFACESG|"* For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator."
57748640|NCT02815462|OTHER|FAMFACESG|- For low risk patients, PNs will continue usual hospital care.
57748641|NCT01792479|DRUG|BIND-014|
57748642|NCT01379872|OTHER|Non-Interventional Study|This is a non-interventional study
57748643|NCT00689026|DRUG|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
57748644|NCT00689026|OTHER|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
57748645|NCT03089437|BEHAVIORAL|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
57748646|NCT03089437|BEHAVIORAL|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
57748647|NCT03811964|OTHER|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
57748648|NCT05276830|DRUG|BXCL501|Sublingual film containing 40 Micrograms BXCL501
57748649|NCT05276830|DRUG|BXCL501|Sublingual film containing 60 Micrograms BXCL501
57748650|NCT05276830|DRUG|Placebo film|Matching Sublingual Placebo film
57748651|NCT04987762|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
57959767|NCT02631330|OTHER|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
57959768|NCT03039842|DRUG|Dextromethorphan|
57959769|NCT03039842|DRUG|Memantine|
57959770|NCT03039842|DRUG|dextromethorphan+memantine|
57959771|NCT03039842|DRUG|placebo+valproate|
58123657|NCT00809042|DRUG|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
58123658|NCT03866850|BEHAVIORAL|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
58123659|NCT03686358|PROCEDURE|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~* Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~* Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~* Identification of prognostic factors"
58123660|NCT03473782|OTHER|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
58123661|NCT03473782|OTHER|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
58123662|NCT00752323|DRUG|aminolevulinic acid|Given orally
58123663|NCT00752323|PROCEDURE|Surgical Resection|Surgical resection - 6 biopsies from 3 fluorescent regions
58123664|NCT02028936|OTHER|Grape juice R@isol|
58123665|NCT02028936|OTHER|Commercially-available grape juice|
57748652|NCT03531047|PROCEDURE|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
57748653|NCT01139307|OTHER|cell culture procedure|
57748654|NCT01139307|OTHER|laboratory biomarker analysis|
57748655|NCT06016452|DRUG|Chlorophyllin|Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
57748656|NCT00306982|BIOLOGICAL|Fluarix|
57748657|NCT00511875|DRUG|doxycycline monohydrate|50mg once daily for 24 months
57748658|NCT00511875|DRUG|placebo|placebo taken once daily for 24 months
57748659|NCT00487617|PROCEDURE|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
58123666|NCT01989065|BEHAVIORAL|Lifestyle counseling|see arm description
58123667|NCT01989065|BEHAVIORAL|Text Messaging|See Arm Description
58314347|NCT05125445|PROCEDURE|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
57748660|NCT04814082|DEVICE|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
57748661|NCT04814082|DEVICE|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
57748662|NCT04886882|OTHER|placebo comparator|solution containing 0.9 % sodium chlorine
57748663|NCT04886882|OTHER|sham comparator|vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
57748664|NCT04886882|OTHER|Experimental drug 1|A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
57748665|NCT04886882|OTHER|Experimental drug 2|A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
58314348|NCT02633774|DRUG|Propafenone|AAD(antiarrhythmic drug)
58314349|NCT02633774|DRUG|Apixaban|anti-coagulation
58314350|NCT04834596|OTHER|retrospectives analysis on hepatic scanner|hepatic scanner will be analysed by two radiologist and by the software
58314351|NCT02425085|PROCEDURE|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
57748666|NCT04886882|DRUG|Centella asiatica|A cream containing Centella asiatica
57748667|NCT00799643|DRUG|Salsalate|Salsalate 3.5 g/d orally, divided dosing
57748668|NCT00799643|DRUG|Salsalate Placebo|
57748669|NCT04011774|OTHER|PLANI-REV|Cognitive remediation program.
57748670|NCT04011774|OTHER|RELAXATION|Stimulation with no cognitive remediation.
57748671|NCT04893655|DRUG|Dobutamine Hydrochloride|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
57959772|NCT00791271|DRUG|Decitabine|Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
57959773|NCT00791271|DRUG|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
57959774|NCT06311474|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a dyadic therapy that focuses on enhancing the parent-child relationship and improving child behavior through positive parenting and limit setting skills. All PCIT sessions are delivered remotely via Zoom once per week for up to 20 weeks. Session length is about 1 hour. There are two distinct phases of PCIT, the Child Directed Interaction and the Parent Directed Interaction. Each phase begins with a Teach session, where parents learn about the skills they will practice during that portion of PCIT, and is followed by Coach sessions, in which the PCIT therapist provides direct feedback and live coaching on the use of the skills. An additional component is Daily Play practice. Parents are instructed to spend five minutes per day playing with their child, during which they practice skills learned during sessions. Adaptations have been made to the standard approach to increase suitability for the TSC population.
57959775|NCT02461992|DRUG|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
57959776|NCT05571787|DRUG|HMPL-523|700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
57748672|NCT05242640|OTHER|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
57748673|NCT05242640|OTHER|Exercise|Participants will complete a moderate-intensity walking program
57748674|NCT05242640|OTHER|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
57748675|NCT01459861|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
57748676|NCT01459861|PROCEDURE|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
57748677|NCT05458648|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
57748678|NCT01774513|DEVICE|Procore-Needle|
57748679|NCT02119910|BEHAVIORAL|Technology Supported Manual|
57748680|NCT03985891|DRUG|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
57748681|NCT03985891|DRUG|Chemotherapy|Folfox
57748682|NCT00703690|DRUG|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
57748683|NCT00703690|DRUG|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
57748684|NCT00703690|DRUG|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
57748685|NCT06149793|DRUG|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
57748686|NCT06149793|OTHER|Placebo Control|Placebo Control
57748687|NCT00349479|BEHAVIORAL|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
58314352|NCT02425085|PROCEDURE|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
58314353|NCT02138383|DRUG|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
57748688|NCT02495480|DEVICE|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
57748689|NCT01033357|DEVICE|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
57748690|NCT01033357|DEVICE|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
57748691|NCT05904665|DIAGNOSTIC_TEST|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
57748692|NCT05052086|DIAGNOSTIC_TEST|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
57748693|NCT04763057|DRUG|NeoPUTTY MTA|NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
57748694|NCT04763057|DRUG|calcium hydroxide|Calcium hydroxide the gold standard for IPT
57748695|NCT02610738|BEHAVIORAL|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
57748696|NCT00329329|DRUG|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
57959777|NCT05571787|DRUG|Rabeprazole|40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
57959778|NCT00001193|PROCEDURE|high dose melphalan and autologous bone marrow transplantation|
57748697|NCT01961336|DRUG|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
57748698|NCT04779138|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
57959779|NCT02682901|DRUG|Cycloset|Cycloset 1.6 -3.2 mg/day
57959780|NCT02682901|DRUG|Placebo|Non-active placebo for cycloset
57959781|NCT02200185|DRUG|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~* SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
57959782|NCT02200185|DRUG|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
57959783|NCT02200185|DRUG|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
57959784|NCT06159595|DEVICE|Intracranial electrodes|Surgically-implanted intracranial electrodes.
57959785|NCT05583266|DRUG|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
57959786|NCT05583266|DRUG|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
57959787|NCT00993811|DEVICE|Shang Ring circumcision|novel device for adult male circumcision
57959788|NCT05847998|DEVICE|Standardized measurement of capillary refill time by second generation DICART prototype|"Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax"
58123668|NCT05197946|DIAGNOSTIC_TEST|MRI|Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
58123669|NCT00555256|DRUG|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
58123670|NCT02720003|DEVICE|LTX DCB|Treatment with a drug-coated balloon
58123671|NCT00108732|DRUG|Bicalutamide|Given orally
58123672|NCT00108732|DRUG|Goserelin Acetate|Given SC
58314354|NCT02138383|DRUG|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
58314355|NCT02138383|DRUG|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
57748699|NCT06118268|DEVICE|iTBS (Active)|"The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands)."
57748700|NCT06118268|DEVICE|iTBS (Sham)|DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
57748701|NCT00569582|DRUG|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
57748702|NCT02311205|PROCEDURE|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
57748703|NCT02311205|DRUG|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
57748704|NCT00885092|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
57959789|NCT05847998|DIAGNOSTIC_TEST|Clinical measurement of capillary refill time|"Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements."
57959790|NCT01316172|BEHAVIORAL|5 Cs|education on consultation
57959791|NCT02207933|PROCEDURE|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
57959792|NCT02207933|PROCEDURE|Gait training|Gait training only for 3 times a week for 6 weeks.
57959793|NCT05946408|OTHER|Supervised antenatal exercises|"Supervised antenatal exercises along with education twice a week. Protocol consists of warm up (10 min), Aerobic training (20 mins, 60-75% of max. HR), Strength training (25 minutes), followed by a cool down of 15 minutes.~The Interventions to be provided for a period of 12 weeks."
57959794|NCT05946408|OTHER|Antenatal Education|Antenatal education at 12th week of pregnancy. Which consists of education on Posture in pregnancy, Role of pelvic floor muscles, Labor and breathing and relaxation techniques.
57959795|NCT02981875|OTHER|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
58123673|NCT00108732|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
58123674|NCT00108732|BIOLOGICAL|Recombinant Vaccinia-TRICOM Vaccine|Given SC
58123675|NCT00108732|BIOLOGICAL|Sargramostim|Given SC
58314356|NCT01937299|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
58314357|NCT01937299|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
58314358|NCT01937299|DRUG|Travoprost 0.004% ophthalmic solution|
58314359|NCT03811938|PROCEDURE|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
58314360|NCT03811938|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
58314361|NCT03335176|BEHAVIORAL|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
58314362|NCT05753800|DEVICE|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
58314363|NCT00873652|BIOLOGICAL|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
58314364|NCT03088059|DRUG|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
58314365|NCT03088059|DRUG|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
58314366|NCT03088059|DRUG|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
58314367|NCT03088059|DRUG|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
58314368|NCT03088059|DRUG|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
58123676|NCT00865709|DRUG|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
58123677|NCT00865709|DRUG|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
58123678|NCT01627873|DRUG|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
58123679|NCT01627873|DRUG|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
58314369|NCT03088059|DRUG|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
58314370|NCT03088059|DRUG|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
58314371|NCT03452787|OTHER|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
58314372|NCT01163617|DEVICE|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
58314373|NCT01163617|DEVICE|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
58450894|NCT00183131|BEHAVIORAL|Brief Personalized Feedback|
58450895|NCT05113446|DIAGNOSTIC_TEST|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
58450896|NCT06129279|OTHER|EFT group|"Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed."
58450897|NCT04796363|PROCEDURE|Erector Spinae Plane Block with Bubivacaine|Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
57748705|NCT00885092|DEVICE|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
57748706|NCT00885092|DEVICE|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
57748707|NCT00885092|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
57748708|NCT03284034|DEVICE|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
58450898|NCT04796363|PROCEDURE|Standard General Anaesthesia|Standard General Anaesthesia without ESPB
58450899|NCT05201404|DRUG|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
58450900|NCT05201404|DRUG|Placebo|Control arm
58450901|NCT04480840|DRUG|PLN-74809|PLN-74809
58450902|NCT04480840|DRUG|Placebo|Placebo
58450903|NCT02003534|DRUG|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
57748709|NCT03284034|DRUG|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
57748710|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in single sitting|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
57959796|NCT02981875|OTHER|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
57959797|NCT04086550|DEVICE|LIQOSEAL|Adjunctive bioresorbable patch
57959798|NCT04086550|DEVICE|DuraSeal, Adherus|synthetic absorbable sealants
57959799|NCT05273827|DRUG|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
57959800|NCT05273827|DRUG|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
57959801|NCT06485154|DRUG|TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir|Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
57959802|NCT01078831|OTHER|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
57959803|NCT06395727|DRUG|Fentanyl|traditional fentanyl dose
57959804|NCT06395727|DRUG|Lidocain|lidocaine nebuliser and lidocaine spray targeting difficult swallowing
57959805|NCT03655964|DRUG|Olmesartan|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
57959806|NCT03655964|DRUG|Nebivolol|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
58123680|NCT03513393|DRUG|velpatasvir|Test 1
58123681|NCT03513393|DRUG|velpatasvir|Test 2
58123682|NCT03513393|DRUG|velpatasvir|Reference
58123683|NCT01332409|DRUG|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
58123684|NCT06338397|OTHER|SCANN|Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
58123685|NCT05569148|COMBINATION_PRODUCT|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
58123686|NCT01769209|DRUG|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
58123687|NCT01769209|DRUG|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
58123688|NCT01769209|DRUG|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
58123689|NCT01769209|DRUG|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
58123690|NCT01769209|DRUG|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
58123691|NCT01769209|DRUG|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
58123692|NCT01769209|DRUG|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
58123693|NCT04493450|OTHER|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
58123694|NCT03349671|PROCEDURE|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
58123695|NCT03403764|OTHER|Wellness Intention|
58123696|NCT04653220|OTHER|Control 1|25g glucose dissolve in 250ml of water
58123697|NCT04653220|OTHER|Control 2|25g glucose dissolve in 250ml of water
58123698|NCT04653220|OTHER|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
58123699|NCT04653220|OTHER|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
58123700|NCT04653220|OTHER|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
58123701|NCT04653220|OTHER|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
58123702|NCT04653220|OTHER|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
58123703|NCT04653220|OTHER|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
58123704|NCT05814081|PROCEDURE|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
58123705|NCT02134522|DEVICE|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
58314374|NCT01163617|DEVICE|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
58450904|NCT05246774|BIOLOGICAL|Biological sample collection|"The following biological samples will be collected on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* fecal sample~* urinary sample~* blood sample (22 ml at each occasion)"
58450905|NCT05246774|OTHER|Questionnaires|"The following questionnaires will be filled by the patients on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* CTCAE Radiation Adverse Event Questionnaire~* Lower Urinary Tract Disorders Questionnaire (IPSS Score)~* Quality of Life Questionnaire (FACT-P)~* Physical Activity Questionnaire (IPAQ)"
58123706|NCT01943071|BEHAVIORAL|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
58123707|NCT05646680|PROCEDURE|two step adnexectomy|instead of standard resection of salpinx and ovary, they are now separately excised
58123708|NCT04582266|DRUG|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
58123709|NCT00103675|PROCEDURE|Acupuncture|
58450906|NCT00387296|DEVICE|functional microarray|functional microarray application
58123710|NCT04566159|BEHAVIORAL|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
58123711|NCT04566159|OTHER|Standard Care|Standard tobacco treatment care offered by the inpatient care
58123712|NCT05002907|OTHER|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
58123713|NCT05002907|OTHER|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
58123714|NCT05002907|OTHER|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
57748711|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in two sittings|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
57748712|NCT02396745|DEVICE|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
58450907|NCT02335307|GENETIC|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
57748713|NCT00602056|OTHER|Redesigned immunization card|A low cost nad simplified redesigned immunization card
57748714|NCT00602056|OTHER|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
57748715|NCT00602056|OTHER|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
57748716|NCT01615874|DRUG|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
57959807|NCT03655964|OTHER|No antihypertensive treatment|Patients will be left without treatment
57959808|NCT01149265|BEHAVIORAL|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
57959809|NCT01149265|BEHAVIORAL|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
57959810|NCT02211274|OTHER|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
57959811|NCT04660162|DEVICE|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
57959812|NCT04660162|OTHER|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
57959813|NCT00428532|DRUG|Licorice root extract or Pomegranate juice|
57959814|NCT05505266|OTHER|observational|observational
57959815|NCT04904289|OTHER|All intervention of real world|We analyzed all data we can obtain from our databases
57959816|NCT02627820|DRUG|Isis 420915/GSK 299872|Open label study in comparison to historic control.
57959817|NCT04720326|DRUG|Tacrolimus Pill|Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
57959818|NCT04720326|DRUG|Tacrolimus capsule|Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
57959819|NCT00987363|OTHER|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
57959820|NCT04173429|DRUG|Nadroparin calcium, warfarin|Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
57959821|NCT00962832|DRUG|Placebo|Placebo was supplied as a sterile liquid solution.
57959822|NCT00962832|DRUG|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
57959823|NCT01098071|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
57959824|NCT00006366|DRUG|fluorouracil|
57959825|NCT00006366|DRUG|irinotecan hydrochloride|
57959826|NCT00006366|PROCEDURE|conventional surgery|
57959827|NCT00006366|RADIATION|radiation therapy|
57959828|NCT03439150|DIAGNOSTIC_TEST|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
57959829|NCT02687399|OTHER|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
57959830|NCT02687399|BIOLOGICAL|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
57959831|NCT03891589|BEHAVIORAL|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
58314375|NCT01163617|DEVICE|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
57748717|NCT01615874|DRUG|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
57748718|NCT01615874|DRUG|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
57748719|NCT01615874|DRUG|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
57748720|NCT01615874|DRUG|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
57748721|NCT01615874|DRUG|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
57748722|NCT01615874|DRUG|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
57748723|NCT05872373|BEHAVIORAL|Snakebite prevention and first aid|The study will offer a communication strategy to develop an effective narrative by using a mix-media campaign, where IEC materials would be chiefly localized.
57748724|NCT01102244|DRUG|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
57748725|NCT01102244|DRUG|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
57748726|NCT04266379|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
57748727|NCT04266379|DEVICE|Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring|Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
57748728|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
57748729|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment.
57748730|NCT01179204|PROCEDURE|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
57748731|NCT02275065|DRUG|Bictegravir|Bictegravir tablet(s) administered orally once daily
57748732|NCT02275065|DRUG|Placebo|Placebo to match bictegravir administered orally once daily
57748733|NCT00833560|DRUG|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
57748734|NCT00833560|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
57748735|NCT00833560|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
57748736|NCT02865720|DRUG|CINRYZE 500 U|IV infusion administered twice weekly
57748737|NCT02865720|DRUG|CINRYZE 1000 U|IV infusion administered twice weekly
57748738|NCT00000657|DRUG|Zidovudine|
58314376|NCT05917340|DRUG|High dose rifampicin (25mg/kg)|Given for 2 months
58314377|NCT05917340|DRUG|Moxifloxacin 400mg|Given for 2 months
58314378|NCT05917340|DRUG|Aspirin 150 mg|Given for 2 months
58314379|NCT05917340|DRUG|Isoniazid|Given for 6 months
57748739|NCT00000657|DRUG|Didanosine|
57748740|NCT05506748|OTHER|pantients undergoing pancreaticoduodenectomy|The study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.
57748741|NCT01499082|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
57748742|NCT01499082|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
57748743|NCT03192605|OTHER|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
57748744|NCT03192605|OTHER|Placebo|Placebo - matched for calories and fiber
57748745|NCT04781738|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
57748746|NCT01032733|BEHAVIORAL|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
57748747|NCT01032733|OTHER|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
57748748|NCT01186445|DRUG|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
57748749|NCT01186445|DRUG|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
58314380|NCT05917340|DRUG|Pyrazinamide|Given for 6 months
58314381|NCT05917340|DRUG|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
58314382|NCT05917340|DRUG|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
58314383|NCT05917340|DRUG|HRZE|2 months
58314384|NCT05917340|DRUG|HRE|7-10 months as per TB program guidelines
58123715|NCT05002907|OTHER|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
58123716|NCT05002907|OTHER|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
58123717|NCT05002907|OTHER|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
57748750|NCT00566579|PROCEDURE|Cryotherapy|Double freezing technique
57748751|NCT00204295|DRUG|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
57748752|NCT03386201|DRUG|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
58123718|NCT05002907|OTHER|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
58123719|NCT03363295|DRUG|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
58123720|NCT04811768|PROCEDURE|Maxillary sinus augmentation|The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
58123721|NCT00528281|DRUG|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
58123722|NCT00528281|DRUG|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
58123723|NCT06546813|OTHER|scales and questionnaire administration|evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
58123724|NCT01432171|DRUG|Lacosamide|Given PO
58123725|NCT01432171|OTHER|Placebo|Given PO
58123726|NCT01428505|RADIATION|[18F]PBR111|radioligand to assess binding to TSPO
58123727|NCT00952783|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
58123728|NCT05050409|BEHAVIORAL|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
58123729|NCT05050409|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
58314385|NCT02177994|DRUG|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
58314386|NCT03772873|PROCEDURE|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
58314387|NCT02428400|BIOLOGICAL|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
58314388|NCT02428400|BIOLOGICAL|Placebo|Placebo: adenovirus reference material (ARM) buffer
58314389|NCT02990052|PROCEDURE|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
58314390|NCT02990052|PROCEDURE|Conservative treatment|Closed reduction \& casting of distal radius fracture
58314391|NCT05448638|PROCEDURE|the combination of transversus thoracic muscle plane and pectoral nerves blocks|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
58450908|NCT02335307|OTHER|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
58450909|NCT02335307|OTHER|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
57748753|NCT06121154|DIAGNOSTIC_TEST|SARC-F questionnaire|"The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia."
57748754|NCT06121154|DIAGNOSTIC_TEST|Gait speed|Low gait speed was defined as walking below than 0.8 meters per second.
57748755|NCT06121154|DIAGNOSTIC_TEST|The chair rise test|the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
57748756|NCT06121154|DIAGNOSTIC_TEST|Grip strength|Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
57748757|NCT06121154|DIAGNOSTIC_TEST|Visual analog scale|The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
57748758|NCT03371940|BEHAVIORAL|Program ACTIVE Exercise|Please see the Exercise arm description above.
57748759|NCT03371940|BEHAVIORAL|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
57748760|NCT03371940|BEHAVIORAL|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
57748761|NCT03371940|BEHAVIORAL|Usual Care - No intervention|Please see the Usual Care arm description above.
57748762|NCT01693068|DRUG|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
57748763|NCT01693068|DRUG|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
57748764|NCT05938257|PROCEDURE|TMJ discopexy|Arthroscopic versus open TMJ discopexy
57748765|NCT04747730|OTHER|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
57748766|NCT00386503|DRUG|Artesunate + Amodiaquine|
57748767|NCT04928105|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
57748768|NCT01257841|DRUG|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
57748769|NCT01257841|BEHAVIORAL|Fasting|Complete fasting, save for water and multivitamin, for four days.
57748770|NCT01231529|DRUG|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
57748771|NCT04445480|PROCEDURE|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
57748772|NCT04445480|OTHER|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
58450910|NCT00507013|DEVICE|QuickClose device|
58450911|NCT05156788|DRUG|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
58450912|NCT05071170|BEHAVIORAL|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
58450913|NCT04893434|DRUG|Gadobutrol|Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
57748773|NCT06579560|DIAGNOSTIC_TEST|Audiovestibular assessment in Patients with Fibromyalgia|Audiovestibular assessment in Patients with Fibromyalgia
57748774|NCT01407081|BEHAVIORAL|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
57748775|NCT00149305|OTHER|Genetic analyses|
57748776|NCT00149305|OTHER|Genetic analyses|
57748777|NCT05935917|DRUG|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
57748778|NCT02029079|DIETARY_SUPPLEMENT|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
57748779|NCT00208143|DRUG|Quetiapine|
57748780|NCT00208143|DRUG|Risperidone|
58314392|NCT05448638|PROCEDURE|the pectoral nerves block only|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
58450914|NCT04893434|DIAGNOSTIC_TEST|MRI|All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations. For SA1, subjects will undergo a single research DCE-MRI exam. Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
57961606|NCT00529074|DEVICE|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
58314393|NCT00678457|DRUG|Ondansetron|ondansetron (4 μg/kg b.i.d.)
58450915|NCT04038541|DIETARY_SUPPLEMENT|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
58314394|NCT00678457|DRUG|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
58314395|NCT00678457|DRUG|Placebo|placebo
58314396|NCT05531955|DRUG|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
58314397|NCT05531955|OTHER|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
58314398|NCT02062697|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
58314399|NCT02062697|PROCEDURE|Liquid-PAP smear|
57748781|NCT03475082|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (\>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
57748782|NCT02054767|DRUG|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
57748783|NCT00003125|BIOLOGICAL|ALVAC-CEA vaccine|
57748784|NCT00003125|BIOLOGICAL|aldesleukin|
57748785|NCT00003125|BIOLOGICAL|sargramostim|
57748786|NCT00003125|BIOLOGICAL|vaccinia-CEA vaccine|
57748787|NCT03323333|BEHAVIORAL|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
57748788|NCT02433743|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
57748789|NCT04843033|DRUG|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
57748790|NCT02075879|BEHAVIORAL|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
57748791|NCT02075879|OTHER|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
57748792|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
57748793|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
57748794|NCT03581812|DIETARY_SUPPLEMENT|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
58123730|NCT05050409|OTHER|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
57748795|NCT04028284|DEVICE|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
58123731|NCT06206395|DEVICE|Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging|"2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment."
58123732|NCT03992196|DRUG|Rotigotine 1 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).
57748796|NCT04028284|OTHER|US-guided epidural|traditional thoracic epidural procedure
57748797|NCT04722445|DIAGNOSTIC_TEST|Early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation (NMES)|NMES will be applied to the quadriceps muscle to generate muscle contraction. Ultrasound measurement of the quadriceps thickness will be provided during contraction and rest, and the shortening of the quadriceps muscle will be measured. A second measurement using Shear-wave elastography measurement will also be undertaken. The measures will be undertaken at day 1 of neuromuscular blockers liberation (if any) as well as at day 3 and day 7 for the patients that will still be received mechanical ventilation at that time.
58123733|NCT03992196|DRUG|Rotigotine 2 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).
58123734|NCT03992196|DRUG|Rotigotine 3 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
58314400|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain Russian BCG-I|"* Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
57748798|NCT06057376|OTHER|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
57748799|NCT06057376|OTHER|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
57748800|NCT02322008|BIOLOGICAL|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
57748801|NCT04342351|DRUG|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
57748802|NCT04342351|DRUG|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
58314401|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain TICE|"* Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
58314402|NCT00089388|DRUG|cilengitide|Given IV
58314403|NCT04002986|GENETIC|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
58314404|NCT03889132|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
57748803|NCT04342351|OTHER|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
57748804|NCT04342351|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
57748805|NCT04777864|BEHAVIORAL|Decision Aid|In addition to usual care, participants (parents and adolescents) receive the newly developed decision aid prior to their clinic visit(s). Clinicians receive a summary to review and use to help facilitate the decision making process.
57748806|NCT04354987|DRUG|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
57748807|NCT04354987|DRUG|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
57748808|NCT06140108|DRUG|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 3 months.
57748809|NCT06140108|DRUG|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 3 months.
57748810|NCT02883062|DRUG|Atezolizumab|Given IV
57748811|NCT02883062|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57748812|NCT02883062|DRUG|Carboplatin|Given IV
57748813|NCT02883062|PROCEDURE|Lumpectomy|Undergo lumpectomy
57748814|NCT02883062|PROCEDURE|Mastectomy|Undergo mastectomy
57748815|NCT02883062|DRUG|Paclitaxel|Given IV
57748816|NCT00700921|DRUG|Lovastatin|40mg po once daily
57748817|NCT00700921|DRUG|Placebo|One capsule, once daily
57748818|NCT01435811|BIOLOGICAL|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
57748819|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation"
57748820|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App"
57748821|NCT02240433|DRUG|LY2157299|LY2157299 administered orally
57748822|NCT02240433|DRUG|Sorafenib|Sorafenib administered orally
57748823|NCT02151266|BEHAVIORAL|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
57748824|NCT02151266|BEHAVIORAL|Exercise Only|
57748825|NCT02151266|BEHAVIORAL|Stretching and Flexibility|
58314405|NCT03515408|DEVICE|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
58314406|NCT01925417|BIOLOGICAL|RBX2660 (microbiota suspension)|
57748826|NCT04731454|OTHER|Control Diet (CD)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
57748827|NCT04731454|OTHER|Healthy Nordic Diet (ND)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
57748828|NCT01278134|DRUG|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
57748829|NCT01278134|DRUG|RO5024048|1000 mg bid orally, up to 24 weeks
57748830|NCT01278134|DRUG|danoprevir|100 mg bid orally, up to 24 weeks
57748831|NCT01278134|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
57748832|NCT01278134|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
57748833|NCT01278134|DRUG|ritonavir|100 mg bid orally, up to 24 weeks
57748834|NCT02961023|OTHER|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
57748835|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
57748836|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
57748837|NCT02382068|DRUG|Dexamethasone|Given via intratympanic injection
57748838|NCT02382068|OTHER|Placebo|Given via intratympanic injection
57748839|NCT02382068|DRUG|Cisplatin|"Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum"
57748840|NCT03673254|DEVICE|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
57748841|NCT00115115|DRUG|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
57748842|NCT06221579|OTHER|No intervention, interviews with MCI patients as part of the development phase|No intervention, interviews with MCI patients as part of the development phase
57748843|NCT05719441|BIOLOGICAL|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
58450916|NCT04038541|DIETARY_SUPPLEMENT|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
58450917|NCT02611726|OTHER|Acupuncture|Acupuncture
57748844|NCT05719441|BIOLOGICAL|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
57748845|NCT05719441|OTHER|Placebo|Sodium Chloride for Injection USP, 0.9%
57748846|NCT05719441|DRUG|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
57748847|NCT06580847|BEHAVIORAL|Group Singing|12 week choir program consisting of 1.5 hours of in-person instruction per week.
57748848|NCT06580847|BEHAVIORAL|Audiobook Club|12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
57748849|NCT00523159|DRUG|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
57748850|NCT00523159|DRUG|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
57748851|NCT05763069|OTHER|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
57748852|NCT03434938|BEHAVIORAL|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
57748853|NCT01989026|BIOLOGICAL|BCG|
57748854|NCT05159622|BEHAVIORAL|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety \& affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
57748855|NCT01835392|PROCEDURE|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
57748856|NCT01835392|OTHER|Control|Sham placement of blood pressure cuff without inflation
57748857|NCT00736645|DIETARY_SUPPLEMENT|selenomethionine|Given orally
57748858|NCT00736645|DRUG|finasteride|Given orally
57748859|NCT00736645|OTHER|placebo|Given orally
57748860|NCT06220955|OTHER|centric relation registration|centric relation registration using conventional and digital methods
57748861|NCT06220955|OTHER|maximum intercuspation registration|maximum intercuspation registration
57748862|NCT05264025|DRUG|Fexofenadine|tablet
58314407|NCT04226443|DRUG|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
57748863|NCT05264025|DRUG|Placebo|tablet
57748864|NCT01552954|BEHAVIORAL|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
57748865|NCT05435781|DRUG|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
57748866|NCT05435781|DRUG|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
57748867|NCT06338657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57748868|NCT06338657|PROCEDURE|Computed Tomography|Undergo CT scan
57748869|NCT06338657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57748870|NCT06338657|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
57748871|NCT06338657|PROCEDURE|Tumor Resection|Undergo surgical resection
57748872|NCT04983381|OTHER|Multimedia education video|The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
57748873|NCT03919136|DEVICE|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
57748874|NCT05788757|DEVICE|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
57748875|NCT06157242|DRUG|Xeruborbactam Oral Prodrug|Experimental
57748876|NCT06157242|DRUG|Ceftibuten|Experimental
58450918|NCT04260646|DEVICE|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
57748877|NCT01530217|DRUG|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
57748878|NCT02276222|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
57748879|NCT02276222|DRUG|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
57748880|NCT04529668|DRUG|vitamin D supplementation|vitamin D supplementation
57748881|NCT04529668|DRUG|usual therapy for nasal polyposis|steroids ( systemic and local )
57748882|NCT06579027|DEVICE|SPEED Training|Children will use ride-on toys controlled using their affected arm to navigate through their environment and complete playful theme-based challenges. Children will use their affected UE during navigation to start and stop the toy, move steadily forward and backward, turn to the right and left, perform 180° and 360° turns to either side, and avoid obstacles. Children will complete object-based UE tasks requiring gross and fine motor control at intermediate stops during navigation. Navigational tasks will be progressed by increasing complexity of paths (straight to slalom paths needing more directional changes), spaces (wide to narrow spaces), and precision (obstacle courses and mazes requiring skillful navigation, motor planning, and route finding). Object-based tasks will be progressed in terms of force requirements (small to large forces), range of motion (near to far reaches), precision (manipulation of large to small objects), and speed of movements (slow to fast).
57748883|NCT06579027|BEHAVIORAL|CRAFT Training|Children will engage in predominantly seated activities based on conventional occupational therapy to promote unimanual and bimanual UE function. Training sessions will be based on playful child-friendly themes (e.g., dinosaurs, space exploration, aquatic theme, etc.) and all training activities will incorporate the session theme. Activities will involve practice of functional gross and fine motor UE movement patterns that children typically use during daily life. Training will emphasize the use of the affected UE in different roles (i.e., stabilizer, mobilizer, and active and passive assist) during warm-up, building, and art-craft activities. The training will be progressed in terms of forces needed, range of motion, precision, and movement speed.
57748884|NCT04451122|OTHER|cleansing the eyelid margins|using eyelid cleaning wipes to cleansing the eyelid margins
57748885|NCT05085119|PROCEDURE|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
57748886|NCT03570684|DEVICE|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
57748887|NCT06489561|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
57748888|NCT02230202|OTHER|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
57748889|NCT02230202|OTHER|single blood draw|single blood draw of approximately 45 mL.
57748890|NCT03521596|OTHER|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
57748891|NCT02736695|DRUG|F-18 AV 1451|Tau binding agent
57748892|NCT01185626|OTHER|SCP care|
57748893|NCT03767166|DEVICE|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
57748894|NCT01394354|DRUG|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
57748895|NCT01394354|DRUG|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
57959832|NCT03891589|DIETARY_SUPPLEMENT|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
58450919|NCT04260646|DEVICE|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
58450920|NCT03487991|BEHAVIORAL|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
57748896|NCT01394354|DRUG|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
57748897|NCT01394354|DRUG|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
57748898|NCT00633464|DRUG|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
58450921|NCT05831358|OTHER|Multiple Myeloma M-Protein Analysis|Participants will be screened with a blood test for monoclonal protein analysis
57748899|NCT00633464|DRUG|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
57748900|NCT05542043|OTHER|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
57748901|NCT01621126|DEVICE|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
57748902|NCT02558582|BEHAVIORAL|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
57748903|NCT02558582|BEHAVIORAL|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
57748904|NCT05582564|OTHER|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
57748905|NCT02525965|PROCEDURE|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin \>1cm
57748906|NCT02525965|PROCEDURE|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin \<1cm
57748907|NCT04741308|BEHAVIORAL|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
57748908|NCT03838926|DRUG|Trichostatin A|Intravenous Infusion
57748909|NCT02414048|DRUG|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
57748910|NCT06164925|DIAGNOSTIC_TEST|Nutrition screening and assessment|"The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength."
57748911|NCT05777330|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
58123735|NCT06046027|DEVICE|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
58123736|NCT05159635|DEVICE|Active Living programme and wearable technical aids|attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
58123737|NCT05159635|DEVICE|Wearable technical aids|apply wearable technical aids for 8 weeks.
58123738|NCT05602922|COMBINATION_PRODUCT|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
57748912|NCT05777330|DIAGNOSTIC_TEST|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
57748913|NCT05777330|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in first-degree relatives at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
57748914|NCT03948191|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
57748915|NCT03948191|DRUG|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
57748916|NCT04025151|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
57748917|NCT04025151|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
57748918|NCT04025151|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
57748919|NCT04025151|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
57748920|NCT04025151|BEHAVIORAL|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
57748921|NCT04025151|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
57748922|NCT03640702|OTHER|Protocol change|To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
57748923|NCT05920980|DRUG|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
57748924|NCT05920980|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
57748925|NCT04576468|PROCEDURE|Open flap debridement|Surgical intevention
57748926|NCT04576468|PROCEDURE|perforated membrane|surgical intervention
57748927|NCT04576468|PROCEDURE|leucocyte - platelet rich fibrin|surgical intervention
57748928|NCT05724979|OTHER|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
57748929|NCT01993225|DRUG|Androxal 12.5 mg/25 mg|
57748930|NCT01993225|DRUG|Placebo Capsules|
57748931|NCT01993225|DRUG|AndroGel 1.62%|
57748932|NCT01993225|DRUG|Placebo Gel|
57748933|NCT04896268|DEVICE|Radiofrequency|Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
57748934|NCT04896268|DEVICE|Arterial ligation then recto-anal repair with Doppler|"The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return."
57748935|NCT03697109|DRUG|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
57748936|NCT03697109|OTHER|Placebo|Placebo matched to study drug
57748937|NCT01501708|DRUG|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
57748938|NCT05088070|DRUG|SPH 3348|2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
57748939|NCT05088070|DRUG|SPH 3348|1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
57748940|NCT05088070|DRUG|SPH 3348|2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
57748941|NCT05088070|DRUG|SPH 3348|4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
57748942|NCT05088070|DRUG|SPH 3348|6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
57748943|NCT05088070|DRUG|SPH 3348|8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
57748944|NCT03839264|DIAGNOSTIC_TEST|Graft stenosis and thrombosis|
57748945|NCT00906841|DRUG|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
57748946|NCT06102265|PROCEDURE|sterilization|the use of sterilization methods and the reuse of gowns
57748947|NCT02468401|PROCEDURE|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
57748948|NCT04475549|DRUG|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
57748949|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
57748950|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 10|Subjects will consume 10 grams of fructan
57748951|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
57748952|NCT00988403|DIETARY_SUPPLEMENT|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
57748953|NCT02036203|DEVICE|SCu300A IUB|Spherical copper contraceptive
57748954|NCT02036203|DEVICE|TCu380A IUD|T-shaped copper IUD
57748955|NCT05639790|COMBINATION_PRODUCT|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
57748956|NCT05639790|OTHER|Health Counselling|Health Counselling from a licensed mental health counselor
57748957|NCT02462707|DRUG|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
57748958|NCT05860127|BEHAVIORAL|Referral for Cognitive Stimulation Therapy|Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
57748959|NCT05860127|OTHER|No change to Standard of Care|Participants will not receive referral from a physician. They will continue with standard of care at their site.
57748960|NCT01858467|DEVICE|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
57748961|NCT01858467|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
57748962|NCT03661138|DRUG|Upadacitinib|Upadacitinib is administered orally.
57748963|NCT03661138|DRUG|Placebo for upadacitinib|Placebo is administered orally.
57748964|NCT03661138|DRUG|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
57748965|NCT03977090|DRUG|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
57748966|NCT03977090|DRUG|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
57748967|NCT05525273|DRUG|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
57748968|NCT00268294|DEVICE|Cardiac Resynchronization Therapy|
58450922|NCT05831358|OTHER|Multiple Myeloma Knowledge Questionnaires|Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
57748969|NCT03731689|DRUG|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
57748970|NCT03731689|DRUG|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
57748971|NCT01637779|BEHAVIORAL|Fact sheet|fact sheet about pain management during immunization
57748972|NCT01082094|BIOLOGICAL|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
57748973|NCT02502201|OTHER|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
57748974|NCT02502201|OTHER|six-minute walk study outdoors|Performance of a six-minute walk test.
57748975|NCT00644397|DEVICE|95-degree Angled Blade Plate|
57748976|NCT00644397|DEVICE|4.5mm Condylar Locking Plate|
57748977|NCT02084459|BEHAVIORAL|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
57748978|NCT03235505|DRUG|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
57748979|NCT03235505|DRUG|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
57748980|NCT03235505|BEHAVIORAL|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
57748981|NCT02622165|BEHAVIORAL|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
57748982|NCT01610427|PROCEDURE|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
57748983|NCT00510094|BEHAVIORAL|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
58123739|NCT05602922|OTHER|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
58450923|NCT01000623|DRUG|venlafaxine|Given orally
58450924|NCT01000623|DRUG|placebo|Given orally
58450925|NCT01000623|PROCEDURE|hypnotherapy|Practice hypnosis
58450926|NCT01000623|PROCEDURE|mind-body intervention procedure|Practice focused attention
57748984|NCT00510094|BEHAVIORAL|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
57748985|NCT01477853|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally daily
57748986|NCT01477853|DRUG|Atorvastatin|Atorvastatin 80 mg tablet orally daily
57748987|NCT01477853|OTHER|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
57748988|NCT01477853|OTHER|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
57748989|NCT01477853|DRUG|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
57748990|NCT01477853|DRUG|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
57748991|NCT01477853|DRUG|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
57748992|NCT01477853|DRUG|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
58450927|NCT04378270|DEVICE|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
58450928|NCT00732823|DEVICE|Placebo - No device worn|
58450929|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
58450930|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
58450931|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
57748993|NCT05431075|DRUG|Amoxicillin|Included in quadruple eradication medication.
57748994|NCT05431075|DRUG|Tetracycline tid|Included in quadruple eradication medication.
57748995|NCT05431075|DRUG|Tetracycline qid|Included in quadruple eradication medication.
57748996|NCT05431075|DRUG|Bismuth Potassium Citrate|Included in quadruple eradication medication.
57748997|NCT05431075|DRUG|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
57748998|NCT05431075|DRUG|Esomeprazole 20mg|Included in quadruple eradication medication.
57748999|NCT03377023|DRUG|Nivolumab|Intravenous nivolumab every 2 weeks.
57749000|NCT03377023|DRUG|Ipilimumab|Intravenous ipilimumab every 6 weeks.
57749001|NCT03377023|DRUG|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
57749002|NCT02934152|DRUG|H pylori eradication|H pylori eradication
57749003|NCT02934152|OTHER|H pylori eradication timing|Early or late eradication
58450932|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
58450933|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
58450934|NCT03018899|PROCEDURE|paravertebral block|Ultrasound guided two-segment paravertebral block
58450935|NCT03018899|PROCEDURE|epidural anesthesia|thoracic epidural anesthesia
58450936|NCT05622604|BEHAVIORAL|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
57749004|NCT04414449|OTHER|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
57749005|NCT01549431|DRUG|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"
57749006|NCT01549431|DRUG|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"
57749007|NCT01549431|DRUG|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
57749008|NCT00491803|DRUG|Sildenafil|sildenafil 20 mg orally
57749009|NCT00491803|DRUG|Sildenafil|sildenafil 40 mg orally
57749010|NCT06078605|OTHER|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
57749011|NCT06078605|OTHER|Placebo|Placebo
57749012|NCT04678466|BIOLOGICAL|flotetuzumab|CD123 x CD3 bispecific DART® antibody
57749013|NCT05698238|DRUG|CA9hu-1|Humanized monoclonal antibody to human carbonic anhydrase IX
57749014|NCT04275700|PROCEDURE|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
57959833|NCT03302754|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
58450937|NCT05622604|BEHAVIORAL|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
57749015|NCT02414269|GENETIC|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
57749016|NCT02414269|DRUG|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
57749017|NCT02414269|DRUG|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
57749018|NCT06313801|DRUG|Docetaxel|Docetaxel 50 mg/m2 intravenously on day 1
57749019|NCT06313801|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 on Day 1
57749020|NCT06313801|DRUG|Calcium folinate|200 mg/m2 2-hour intravenous infusion on day 1
58450938|NCT06461663|DEVICE|Breast Cancer Locator Guided Breast Conserving Surgery|Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
57749021|NCT06313801|DRUG|Fluorouracil|2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
57749022|NCT06313801|PROCEDURE|Diagnostic laparoscopy|Access to the abdominal cavity by Hassen (3 trocars). Carboxyperitoneum - 12 mm of water column - stable pressure maintenance throughout the operation. Revision. Photo recording of 4 quadrants of the abdominal cavity from the paraumbilical port. The evaluation of the PCI index. The evaluation of other distant dissemination. Standard peritoneal lavage of 300 ml Sol. NaCl 0.9 % (37 ºС), with the exposure of 3-5 minutes (with Trendelenburg and Fowler position alternately) and the lavage aspiration, the transfer of the lavage for the cytological examination. Biopsy of perioneal lessions if needed.The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
57959834|NCT01913392|PROCEDURE|laparoscopic sleeve gastrectomy|
58123740|NCT03551249|DEVICE|Focused ultrasound (FUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
58314408|NCT04226443|DRUG|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
58314409|NCT03781271|DEVICE|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
58314410|NCT00634504|DRUG|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
58314411|NCT00634504|DRUG|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
58314412|NCT04571203|BIOLOGICAL|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
58314413|NCT00204789|DRUG|Difluoromethylornithine|
58314414|NCT05156008|OTHER|Ultrasound-guided vascular access|Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
58314415|NCT00317369|DRUG|OPC-6535(Tetomilast)|
58314416|NCT00797563|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
58314417|NCT01450735|DEVICE|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
58314418|NCT04465422|BEHAVIORAL|Occupational therapy based on the MOHO theory|"We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model."
58314419|NCT04465422|BEHAVIORAL|Occupational therapy|The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
58314420|NCT01782092|OTHER|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
57749023|NCT06313801|COMBINATION_PRODUCT|dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).|Diagnostic laparoscopy described earlier and PIPAC session. The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml. The rate of administration is 30 ml per minute. The maximum pressure in the injector system is 250 PSI. After the spray stage, the exposure is 30 minutes while maintaining the declared intraperitoneal pressure. After the exposure stage, only gas is removed from the abdominal cavity. The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
57749024|NCT05448300|DEVICE|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
57749025|NCT06296836|DRUG|Metformin|Continuation of home metformin
57749026|NCT01290406|DRUG|BEZ235|
57749027|NCT01274182|BIOLOGICAL|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
57749028|NCT01274182|BIOLOGICAL|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
57749029|NCT01274182|BIOLOGICAL|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
57749030|NCT01391520|DRUG|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
57749031|NCT01391520|DRUG|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
57749032|NCT00796250|BIOLOGICAL|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
57749033|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
57749034|NCT00796250|DRUG|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
57749035|NCT00796250|DRUG|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
57749036|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
57749037|NCT00796250|BIOLOGICAL|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
57749038|NCT01764087|DRUG|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
57749039|NCT02269566|DRUG|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
57749040|NCT02269566|DRUG|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
57749041|NCT04040751|BEHAVIORAL|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
57749042|NCT04040751|BEHAVIORAL|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
57749043|NCT00508430|DRUG|ASP8825|oral
57749044|NCT00508430|DRUG|Placebo|oral
57749045|NCT05046054|DEVICE|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
57749046|NCT05046054|DEVICE|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
57749047|NCT05167266|BEHAVIORAL|Psychoeducation|Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
57749048|NCT06405503|OTHER|NO INTERVENTION|NO INTERVENTION - OBSERVATIONAL ONLY
57959835|NCT02576743|DEVICE|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
57959836|NCT01380457|DRUG|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
57959837|NCT01380457|DRUG|Marinol|Capsules, 10 mg, single-dose, fasting conditions
58314421|NCT06420739|DIAGNOSTIC_TEST|Gastric Ultrasound|Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.
58314422|NCT01582451|DRUG|LY2605541|
58314423|NCT01582451|DRUG|Insulin glargine|
57749049|NCT03851796|BEHAVIORAL|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
57749050|NCT03851796|BEHAVIORAL|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
57749051|NCT02219984|DRUG|Anticoagulants|
57749052|NCT01457911|DRUG|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
57749053|NCT01457911|DRUG|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
57749054|NCT05895136|DRUG|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
57749055|NCT05895136|DRUG|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
57749056|NCT05895136|DRUG|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
58123741|NCT02462824|BEHAVIORAL|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
58123742|NCT05409677|OTHER|This was a retrospective study with no intervention other than normal treatment|This was a retrospective study with no intervention other than normal treatment
57749057|NCT03953235|BIOLOGICAL|GRT-C903|a shared neoantigen cancer vaccine prime
57749058|NCT03953235|BIOLOGICAL|GRT-R904|a shared neoantigen cancer vaccine boost
57749059|NCT03953235|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
58450939|NCT06268652|OTHER|Organoid-guided personalized treatment|After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
58450940|NCT06268652|DRUG|Gemcitabine|1000mg/m2，IV, days 1, 8, q3w
57749060|NCT03953235|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
57749061|NCT00111670|DRUG|DPP-IV Inhibitor|Escalating doses po bid or qd
57749062|NCT00111670|DRUG|Placebo|po bid or qd
57749063|NCT06525194|BEHAVIORAL|Education|"An Interprofessional Education Program Based on the ARCS-V Motivation Model on the Theme of Chronic Disease Management and Patient Safety"
57749064|NCT00466882|DEVICE|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
57749065|NCT02200796|OTHER|Control Meal|High carbohydrate meal
57749066|NCT02200796|OTHER|Low Protein Meal|Omelet with 15 g of protein
58450941|NCT06268652|DRUG|Capecitabine|1000mg/m² , PO, bid, days1-14, q3w
58450942|NCT06268652|DRUG|Vinorelbine|25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
58450943|NCT06268652|DRUG|Eribulin|1.4mg/m², IV, days 1 and 8, q3w
57749067|NCT02200796|OTHER|Moderate Protein Meal|Omelet with 30 g of protein
57749068|NCT02200796|OTHER|High Protein Meal|Omelet with 45 g of protein
57749069|NCT05303779|OTHER|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
57749070|NCT05303779|DRUG|Medication and eye glasses|medication and eye glasses used post strabismus surgery
57749071|NCT04118244|DIAGNOSTIC_TEST|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
57749072|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
57749073|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
57749074|NCT01741519|DRUG|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
57749075|NCT01741519|DRUG|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
57749076|NCT06393621|DIETARY_SUPPLEMENT|KEFPEP®|Twice daily (one pack before breakfast and the other before dinner)
57749077|NCT06393621|OTHER|Placebo|Twice daily (one pack before breakfast and the other before dinner)
58123743|NCT00306345|BEHAVIORAL|Outreach|
58123744|NCT01977092|BEHAVIORAL|Motivational interviewing case management|
58123745|NCT01977092|BEHAVIORAL|Resource referrals|
58123746|NCT01171066|DEVICE|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
57749078|NCT00705133|DRUG|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
57749079|NCT03105674|DRUG|Multi-drug local anesthetics (Combination)|"1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
57749080|NCT03105674|DRUG|Standard local anesthetics (Combination)|Marcaine and Lidocaine
57749081|NCT02964416|DRUG|Injection Tramadol|
58123747|NCT01096927|DRUG|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
58123748|NCT03967002|PROCEDURE|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors."
58123749|NCT05092490|PROCEDURE|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
58123750|NCT05092490|PROCEDURE|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
58123751|NCT05059756|DEVICE|PTNS|PTNS and PFR
58123752|NCT05059756|DEVICE|Sham PTNS|Sham PTNS and PFR
58123753|NCT00116935|DRUG|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
58123754|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
58123755|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
58123756|NCT01136538|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
58123757|NCT06126081|DEVICE|LBBP+GDMT|LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
58123758|NCT06126081|DRUG|GDMT|GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
58123759|NCT03475927|OTHER|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
58123760|NCT01046123|RADIATION|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
58123761|NCT00454974|DEVICE|Wearable artificial kidney|
58123762|NCT02203565|DRUG|Dakin's solution|Applied topically
57749082|NCT02964416|OTHER|placebo|0.9% Normal saline in 10 ml syringe
57749083|NCT01552590|DRUG|Tolvaptan|
58123763|NCT02203565|RADIATION|radiation therapy|Undergo radiation therapy
57749084|NCT01552590|DRUG|Placebo|
57749085|NCT00243880|DRUG|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
57749086|NCT06150651|OTHER|CAR T-cell therapy|1x10\^6 cells/kg CD-19 CAR-T cells
57749087|NCT01340469|BIOLOGICAL|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
57749088|NCT01551732|BEHAVIORAL|ACT|10 session manualized cognitive behavioral anger control therapy
57749089|NCT01551732|BEHAVIORAL|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
57749090|NCT01738984|BEHAVIORAL|MomZing Web Program|Online web platform that is accessed via a television connected to internet
57749091|NCT01738984|BEHAVIORAL|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
58123764|NCT02203565|OTHER|questionnaire administration|Ancillary studies
58123765|NCT02203565|OTHER|laboratory biomarker analysis|Optional correlative studies
58123766|NCT05428852|OTHER|Laboratory Biomarker Analysis|Correlative Studies
57749092|NCT04051268|BIOLOGICAL|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
57749093|NCT04051268|BIOLOGICAL|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
57749094|NCT04051268|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Active Comparator
57749095|NCT01990846|DRUG|Flufirvitide 3|
57749096|NCT01990846|DRUG|Placebo for Flufirvitide-3|
57749097|NCT02709005|DRUG|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
57749098|NCT02709005|OTHER|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
58123767|NCT05428852|OTHER|Neurocognitive Assessment|NRG-CC
57749099|NCT06169514|OTHER|No intervention|No intervention
58123768|NCT05428852|OTHER|Questionnaire Administration|Ancillary studies
58123769|NCT05428852|DEVICE|Fitbit|Fitbit Activity Tracking
58123770|NCT05428852|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
58123771|NCT00422656|DRUG|Perifosine|
58123772|NCT01363037|DRUG|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
58123773|NCT01363037|DRUG|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
58123774|NCT01363037|OTHER|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
58123775|NCT01363037|DRUG|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
58123776|NCT02745977|OTHER|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
58123777|NCT06027840|DRUG|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
57749100|NCT04855032|BEHAVIORAL|Reactive Perturbations|A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.
58123778|NCT06027840|BEHAVIORAL|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
58123779|NCT06027840|BEHAVIORAL|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
58123780|NCT00001090|BIOLOGICAL|APL 400-047|
57749101|NCT04855032|BEHAVIORAL|Proactive Perturbations|A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
57749102|NCT06578975|DIAGNOSTIC_TEST|HT-ENDO-MOS-A13|Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
58123781|NCT00001090|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
58123782|NCT00001090|DRUG|Sargramostim|
58123783|NCT01274416|BEHAVIORAL|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
58123784|NCT01274416|BEHAVIORAL|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
58123785|NCT03269110|DIAGNOSTIC_TEST|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
58123786|NCT04059601|DIAGNOSTIC_TEST|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
58123787|NCT04059601|DIAGNOSTIC_TEST|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
58123788|NCT04725084|OTHER|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
58123789|NCT04725084|OTHER|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
58123790|NCT04725084|OTHER|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
58123791|NCT05150236|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.
58123792|NCT05150236|DRUG|Ipilimumab|Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.
58123793|NCT05150236|DRUG|Nivolumab|Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
58123794|NCT01631864|DRUG|LCZ696|LCZ696 was provided as 400 mg tablets.
58123795|NCT01631864|DRUG|amlodipine|amlodipine was provided as 5 mg tablets.
58123796|NCT01631864|DRUG|Placebo|Matching placebo to LCZ696 and amlodipine.
58123797|NCT00635778|DRUG|dalotuzumab|Administered as an IV infusion over one to two hours
58123798|NCT00282256|DRUG|tacrolimus modified release (MR)|Oral
58123799|NCT00282256|DRUG|tacrolimus|Oral
58123800|NCT01063530|DEVICE|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
58123801|NCT01063530|DEVICE|DIstilled water|Application of distilled water in cervical lesions
58123802|NCT03713268|DEVICE|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
58123803|NCT00309075|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
58123804|NCT05777538|OTHER|hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days.
58123805|NCT05777538|OTHER|foot exercises|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each.
58123806|NCT03828045|DRUG|Apremilast|Apremilast
58123807|NCT05133895|DRUG|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
58123808|NCT05750628|DRUG|INE963|oral INE963
58123809|NCT05750628|DRUG|KAE609 (Cipargamin)|oral KAE609 (Cipargamin)
58123810|NCT05750628|DRUG|SoC (Coartem)|SoC (Coartem)
58123811|NCT05750628|DRUG|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
58123812|NCT03849599|BIOLOGICAL|PRV-300|Treatment
58123813|NCT03849599|BIOLOGICAL|Placebo|Control
58123814|NCT00001052|BIOLOGICAL|Aluminum hydroxide|
58123815|NCT00001052|BIOLOGICAL|QS-21|
58123816|NCT00001052|BIOLOGICAL|rgp120/HIV-1MN|
58123817|NCT04094870|DRUG|Sertraline|daily SSRI (Sertraline 25mg)
58123818|NCT04094870|BEHAVIORAL|Interpersonal therapy|11 sessions over a 24-week period
58123819|NCT00814099|BEHAVIORAL|Team approach to sedation management|"The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance"
58123820|NCT00814099|BEHAVIORAL|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
58123821|NCT04025788|DEVICE|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
58123822|NCT01575678|DRUG|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
58123823|NCT01575678|DRUG|Lactose|blinded capsule 1/day, oral use, for 4 weeks
57749103|NCT06578975|OTHER|Normal diagnosis|Standard diagnosis for endocrine hypertension
58314424|NCT01207960|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
57749104|NCT04124926|DRUG|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
57749105|NCT04124926|DRUG|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
57749106|NCT03105414|DEVICE|Mechanical ventilation|Mechanical ventilation
58123824|NCT03312062|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
58123825|NCT03821220|BEHAVIORAL|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
58123826|NCT03821220|BEHAVIORAL|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
58123827|NCT03821220|BEHAVIORAL|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
58123828|NCT05388682|DEVICE|Percutaneous transluminal pulmonary angioplasty|Percutaneous transluminal pulmonary angioplasty
58123829|NCT05219227|OTHER|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~1. Static abdominal exercises:~2. Dynamic abdominal exercises:~   * Hip shrugging exercise from crook lying position:~  * Lateral flexion of the trunk from crook lying position:~  * Antero-posterior flexion of the trunk from crook lying position:"
58123830|NCT04121390|BEHAVIORAL|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
58123831|NCT00003696|DRUG|carboplatin|
58123832|NCT00003696|DRUG|cyclophosphamide|
58123833|NCT00003696|DRUG|doxorubicin hydrochloride|
58123834|NCT00003696|DRUG|etoposide|
58123835|NCT00003696|DRUG|paclitaxel|
58123836|NCT01929109|DRUG|LY2409021|Administered orally
58123837|NCT04017936|DRUG|Anakinra|Active Treatment
58123838|NCT02933866|DRUG|DSXS topical|topical treatment
58123839|NCT02933866|DRUG|Vehicle topical|topical treatment
58123840|NCT03560609|DEVICE|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
58123841|NCT03560609|DEVICE|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
58123842|NCT03560609|DEVICE|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
58123843|NCT03560609|DEVICE|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
58123844|NCT03560609|DEVICE|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
58123845|NCT03387098|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
58123846|NCT03387098|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
58123847|NCT03387098|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
58123848|NCT03387098|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
58123849|NCT03387098|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
58123850|NCT03387098|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
58123851|NCT03387098|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
58123852|NCT03387098|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
58123853|NCT03387098|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
58123854|NCT03387098|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
57749107|NCT01666951|DRUG|LCP-Tacro tablets|Tacrolimus
58123855|NCT03387098|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
58123856|NCT03387098|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
58123857|NCT03387098|DRUG|lovaza|Omega-3-acid ethyl esters
57749108|NCT01666951|DRUG|Prograf|Tacrolimus
57749109|NCT05001724|BIOLOGICAL|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
57749110|NCT05001724|DRUG|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
58123858|NCT03387098|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
58123859|NCT03387098|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
58314425|NCT02787304|DRUG|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
57749111|NCT05001724|DRUG|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
57749112|NCT02744833|DRUG|GMI-1271|
57749113|NCT02744833|DRUG|Enoxaparin Sodium (Lovenox®)|
58123860|NCT00751946|BEHAVIORAL|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
58314426|NCT02787304|DRUG|Placebo|Matching placebo
58314427|NCT04103008|DIAGNOSTIC_TEST|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
58314428|NCT04132713|DRUG|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
57749114|NCT04238364|DRUG|EI-1071|EI-1071 Tablet(s)
57749115|NCT04238364|DRUG|Placebo|Matching Placebo Tablet(s)
57749116|NCT04232514|DRUG|HEC74647|Administered HEC74647 200 mg orally once daily in fed state
57749117|NCT04232514|DRUG|HEC110114|Administered HEC110114 800 mg orally once daily in fed state
57749118|NCT02618616|DRUG|ZPL-3893787|
57749119|NCT02618616|DRUG|Placebo|
58123861|NCT00751946|BEHAVIORAL|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
58123862|NCT04022499|BEHAVIORAL|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
58123863|NCT04022499|BEHAVIORAL|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
58123864|NCT00113490|BIOLOGICAL|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
58123865|NCT00113490|BIOLOGICAL|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
58123866|NCT01626820|BIOLOGICAL|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
58123867|NCT04175496|OTHER|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
58123868|NCT04175496|OTHER|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
58123869|NCT04175496|OTHER|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
58123870|NCT04175496|OTHER|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
58123871|NCT04175496|OTHER|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
58123872|NCT05411809|DRUG|drug adjuvant therapy|The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
58123873|NCT00404274|DRUG|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
57749120|NCT04648540|DRUG|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
58123874|NCT00404274|DRUG|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
57749121|NCT04648540|DRUG|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
58123875|NCT04287881|GENETIC|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
58123876|NCT05259111|OTHER|Home hospital|Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
58123877|NCT03978884|DRUG|Losartan 50Mg Tab|Take 1 tab daily
58123878|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
57749122|NCT03515928|OTHER|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
57749123|NCT03515928|DIAGNOSTIC_TEST|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
57749124|NCT05365321|DRUG|WP1122|Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
57749125|NCT02469948|DRUG|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
57749126|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
58123879|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
58123880|NCT03978884|DRUG|Amlodipine 5mg|Take 1 tablet daily
58123881|NCT01799590|DRUG|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
58123882|NCT05563909|OTHER|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
58123883|NCT05563909|OTHER|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
58123884|NCT05563909|OTHER|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
58123885|NCT02873390|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
58123886|NCT04241159|BIOLOGICAL|Allogeneic Young Plasma|"The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks."
58123887|NCT01536223|DRUG|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
58123888|NCT01536223|DRUG|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
58123889|NCT06542965|OTHER|Non-Interventional Research|Non-Interventional Research
58123890|NCT00433381|BIOLOGICAL|Bevacizumab|Given IV
58123891|NCT00433381|DRUG|Irinotecan Hydrochloride|Given IV
58123892|NCT00433381|DRUG|Temozolomide|Given orally
58123893|NCT06016465|DRUG|Dexamethasone Oral|Two 4mg pills
58123894|NCT06016465|DRUG|Placebo|2 placebo pills
58123895|NCT02586766|BEHAVIORAL|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
58123896|NCT03432195|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
58123897|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
58123898|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
58123899|NCT04582721|OTHER|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~* 1) CON-SCS with Subcutaneous stimulation~* 2) HF-SCS~* 3) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
58123900|NCT05899166|OTHER|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
58123901|NCT05899166|OTHER|Standard diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
58123902|NCT05263219|PROCEDURE|dTACE-HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination."
58123903|NCT05263219|PROCEDURE|HAIC|"HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles."
58123904|NCT05263219|DRUG|dTACE-HAIC protocol|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h."
58123905|NCT05263219|DRUG|HAIC protocol|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
58123906|NCT05487456|OTHER|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
58123907|NCT05487456|OTHER|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
58123908|NCT05487456|OTHER|CIG|Ad libitum use of subject's own preferred brand of cigarettes
58123909|NCT05487456|OTHER|Smoking Abstinence|Abstention from cigarette smoking
58123910|NCT03182257|DRUG|ONO-7579|ONO-7579 Tablets
58123911|NCT04714619|DRUG|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
58123912|NCT05795491|DEVICE|Blue Light Emitting Diode Therapy|Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
58123913|NCT05795491|DRUG|Azole Antifungal|Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
58123914|NCT05865054|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
58123915|NCT05258656|BEHAVIORAL|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
58123916|NCT05258656|BEHAVIORAL|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
58123917|NCT04373759|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
58123918|NCT04373759|OTHER|Modified Rankin score|"0 - no symptoms at all~1. - no significant disability despite symptoms; able to carry out all usual duties and activities~2. - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. - Moderate disability; requiring some help, but able to walk without assistance~4. - Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. - Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. - Dead"
58123919|NCT04544176|OTHER|Observational|There will be no interventions in this study, it is purely observational using data already collected.
58123920|NCT03800069|DEVICE|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
58123921|NCT04059796|DEVICE|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
58123922|NCT04059796|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
58123923|NCT02565095|PROCEDURE|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
58123924|NCT00368277|DRUG|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
58123925|NCT00368277|DRUG|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
58123926|NCT00368277|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
58123927|NCT00368277|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
57749127|NCT00683826|OTHER|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
58123928|NCT05427097|DEVICE|Helical® patches|Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
58123929|NCT04872907|DEVICE|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
58123930|NCT04872907|DEVICE|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
58123931|NCT04872907|DRUG|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
58123932|NCT00275002|DRUG|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
58123933|NCT00275002|DRUG|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
58314429|NCT04098835|BEHAVIORAL|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
57959838|NCT05730465|BEHAVIORAL|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
57959839|NCT03477864|BIOLOGICAL|Ipilimumab|Given via intraprostatic injection
57959840|NCT03477864|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
57959841|NCT03477864|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
57959842|NCT03477864|BIOLOGICAL|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
58123934|NCT04319484|DRUG|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
58123935|NCT04319484|DRUG|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
58123936|NCT00662129|BIOLOGICAL|bevacizumab|
58123937|NCT00662129|DRUG|gemcitabine hydrochloride|
58123938|NCT00662129|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
58123939|NCT04471935|DEVICE|At home Speech Hero therapy app|Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
58123940|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose
58123941|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
58123942|NCT01056874|DRUG|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
58123943|NCT03803566|OTHER|Pegboard practice|Practice of the grooved pegboard test
58123944|NCT03803566|OTHER|Force control practice|Practice performing steady muscle contractions
58123945|NCT02018146|OTHER|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
58123946|NCT02018146|OTHER|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
58123947|NCT02546908|OTHER|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
58123948|NCT01229085|DRUG|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
58123949|NCT04842110|DEVICE|Experimental: eonTM FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
58123950|NCT02189083|DRUG|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
58123951|NCT00698906|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
58123952|NCT00698906|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
58123953|NCT01834053|BIOLOGICAL|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
58123954|NCT05720572|DRUG|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
58123955|NCT05720572|DRUG|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
58123956|NCT04897828|DEVICE|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
58123957|NCT00299156|DRUG|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
58123958|NCT00140517|DRUG|sulphadoxine-pyrimethamine|
58314430|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
57749128|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
58123959|NCT00140517|DRUG|chloroquine|
58123960|NCT06288282|OTHER|No Intervention|No intervention will be used.
58123961|NCT02852564|DRUG|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
58314431|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
58314432|NCT06036472|PROCEDURE|Standard periodontal therapy (steps 1 & 2)|participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
58314433|NCT06036472|PROCEDURE|supragingival debridement with anesthesia (step 1)|periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
58123962|NCT06348836|OTHER|Exercise|Description of exercises are noted in the arms/groups descriptions
58123963|NCT04559607|DRUG|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
58123964|NCT04559607|DEVICE|TACE|TACE if necessary
58123965|NCT04559607|DRUG|Apatinib|Apatinib: 250m, po, QD
58123966|NCT04842487|DRUG|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
57749129|NCT02659761|DRUG|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
57749130|NCT03442712|OTHER|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
58123967|NCT02750306|DRUG|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
58123968|NCT02750306|DRUG|Placebo|Placebo to suvorexant
58123969|NCT01362933|PROCEDURE|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
58123970|NCT04165681|OTHER|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
58123971|NCT03567213|DEVICE|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
58123972|NCT02763722|OTHER|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
58123973|NCT02320279|DEVICE|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
58450944|NCT04864249|DEVICE|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
58450945|NCT04864249|OTHER|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
57749131|NCT03442712|OTHER|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
57749132|NCT05563194|DEVICE|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
57749133|NCT05563194|DEVICE|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
58123974|NCT00200122|DEVICE|Spinal Cord Stimulation|
58123975|NCT04569500|OTHER|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
58123976|NCT04191564|PROCEDURE|low perfusion state|reduce SAP below 100 mmHg
58123977|NCT04191564|PROCEDURE|normal perfusion state|maintain SAP above 100 mmHg
58123978|NCT01717898|DRUG|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
58123979|NCT01717898|DRUG|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
58123980|NCT01717898|DRUG|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
58123981|NCT01977261|PROCEDURE|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
58123982|NCT01977261|PROCEDURE|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
58123983|NCT00928837|DIETARY_SUPPLEMENT|Flavocoxid 500 mg|flavonoid mixture
58123984|NCT00928837|DRUG|Naproxen|non-steroidal anti-inflammatory drug
58123985|NCT00928837|OTHER|Placebo|Placebo
58123986|NCT00928837|OTHER|flavocoxid 250 mg|Medical food product
58123987|NCT04177264|PROCEDURE|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
58123988|NCT04177264|PROCEDURE|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
58450946|NCT00394199|DRUG|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
58450947|NCT00394199|DRUG|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
58450948|NCT00394199|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
58123989|NCT04177264|PROCEDURE|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
58123990|NCT04177264|PROCEDURE|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
58123991|NCT04177264|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
58450949|NCT05294315|PROCEDURE|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
57749134|NCT05563194|DEVICE|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
57749135|NCT06048510|DIAGNOSTIC_TEST|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
57749136|NCT03897257|DRUG|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
57959843|NCT06101615|OTHER|IASTM (FAT)|Group-A participants would receive Facial Abrasion Technique (FAT) with an Instrument, FAT-Tool. Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm), to avoid possible confounding circadian effects. The FAT group will receive 2 min application on the quadriceps and hamstring muscles with a FAT-tool Pro Large model, which consists of a handle and 20cm treatment surface. The muscles will be treated in a pre-stretched position, meaning a knee flexion in a supine position for the quadriceps muscle and a hip flexion and knee extension in a side-lying position for the hamstring muscles.
57959844|NCT06101615|OTHER|Foam Rolling|Group-B participants would receive Foam Rolling (FR). Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm) to avoid possible confounding circadian effects. The Foam Roller group will receive 2x1 min of FR on the quadriceps and the hamstrings on the dominant leg with the opposite leg crossed over the dominant one. During each minute the muscle will be rolled out 4-5 times, with a break of 30s in between sets. They will be instructed to utilize short, kneading like movements in one direction and a quick motion in the other direction. A grid foam roller will be utilized with a length of 33cm, diameter of 14 cm and with a hard hollow core, wrapped in ethylene vinyl acetate foam.
57959845|NCT02841371|RADIATION|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
57959846|NCT02025387|BEHAVIORAL|Physical activity feedback|
57959847|NCT02025387|BEHAVIORAL|Usual care except physical activity measurement|
57959848|NCT02516748|BEHAVIORAL|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
57959849|NCT05416853|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
57959850|NCT01789814|DRUG|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
57959851|NCT01789814|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
57959852|NCT06459245|BEHAVIORAL|Resistance training|Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.
57959853|NCT02122978|BEHAVIORAL|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
57959854|NCT02122978|BEHAVIORAL|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
57959855|NCT02122978|BEHAVIORAL|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
57959856|NCT01227902|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
57959857|NCT02191943|DEVICE|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
58123992|NCT04177264|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
58123993|NCT00801190|OTHER|HES (130/0.4)|33 ml/kg i.v. during surgery
58123994|NCT00801190|OTHER|Ringer's Lactate|33 ml/kg i.v.
58123995|NCT04709159|OTHER|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
58123996|NCT05958290|OTHER|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
58123997|NCT01189864|DRUG|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
58123998|NCT01189864|DRUG|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
58123999|NCT01189864|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
58124000|NCT01065103|PROCEDURE|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
57749137|NCT03897257|DRUG|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
57749138|NCT03897257|DRUG|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
57749139|NCT03897257|DRUG|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).
58124001|NCT02678195|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
58124002|NCT02678195|DRUG|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
58124003|NCT00882622|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
58124004|NCT00882622|PROCEDURE|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
58124005|NCT06545084|PROCEDURE|Leukocyte and Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin (L-PRF) is a collection of growth factors rich in proinflammatory cells that promote healing after dental surgery. A L-PRF clot is obtained by collecting blood from the subject, similar to a phlebotomist drawing blood via venipuncture. The blood samples are spun in a centrifuge using the recommended settings by the manufacture(1). The resultant product has separated the red blood cells from the L-PRF clot which is placed back into the subject to promote healing of the surgical site.
58124006|NCT00245713|DRUG|levetiracetam|
58450950|NCT05294315|PROCEDURE|Single level erector spinae block|erector spinae block at 4th transverse process
57749140|NCT03897257|DRUG|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
57749141|NCT03833297|DRUG|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
57749142|NCT00388310|PROCEDURE|Culture|Culture
57749143|NCT02510430|BEHAVIORAL|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
57749144|NCT02510430|BEHAVIORAL|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
57749145|NCT02510430|BEHAVIORAL|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
57749146|NCT02526654|DIAGNOSTIC_TEST|Heidelberg Edge Perimeter|HEP measures peripheral vision
57749147|NCT02526654|DIAGNOSTIC_TEST|Octopus Visual Field|OVF measures peripheral vision
57749148|NCT02526654|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
58124007|NCT04161144|DRUG|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
58124008|NCT04161144|DRUG|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
57959858|NCT02191943|DEVICE|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
57959859|NCT00003345|DRUG|cisplatin|
57959860|NCT00003345|DRUG|irinotecan hydrochloride|
57959861|NCT00044577|DRUG|abacavir/lamivudine|
57959862|NCT00044577|DRUG|abacavir|
57959863|NCT00044577|DRUG|lamivudine|
57959864|NCT00044577|DRUG|tenofovir|
57959865|NCT05386329|BEHAVIORAL|Mindset: Therapist-guided smartphone-delivered CBT|All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
57959866|NCT02491255|DEVICE|Lotus Valve System|Device: Lotus Valve System
57959867|NCT03575858|DEVICE|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
57959868|NCT03575858|DEVICE|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
57959869|NCT01120496|DRUG|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
57959870|NCT01120496|DRUG|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
58124009|NCT02224391|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
58124010|NCT02224391|OTHER|Laboratory Biomarker Analysis|Correlative studies
58124011|NCT02224391|DRUG|Nicotine Patch|Given via transdermal patch
58124012|NCT02224391|OTHER|Questionnaire Administration|Ancillary studies
58124013|NCT02224391|OTHER|Sham Intervention|Undergo sham training
58124014|NCT06167538|OTHER|Decannulation|From the 1st of September 2021, the investigators started to perform decannulation earlier after admission to the Department of Brain Injury. Before attempting to decannulate a patient, several factors were considered and assessed by the patient's treating team: patient's level of consciousness, hemodynamical stability, need for and frequency of salivary aspiration, cough strength and respiration frequency. Patients could not be under treatment for pneumonia and simultaneously have respiratory instability at the time of decannulation.
58124015|NCT02848599|DRUG|morphine|
58124016|NCT02848599|DRUG|levobupivacaine|
58124017|NCT00780026|DRUG|insulin|bolus or infusion 80 to 110 mg/dl
58124018|NCT02848703|DEVICE|Magnetic Resonance Imaging (MRI)|
58124019|NCT02848703|DEVICE|phosphorus-31 Magnetic Resonance Spectroscopy|
58124020|NCT02848703|DEVICE|sodium-23 MRI|
58124021|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
58124022|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
58124023|NCT00678067|DIETARY_SUPPLEMENT|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
58124024|NCT00678067|OTHER|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
58124025|NCT02611024|DRUG|Lurbinectedin|lurbinectedin (PM01183) 4 mg vials
58124026|NCT02611024|DRUG|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
58124027|NCT04039542|OTHER|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
58124028|NCT02920164|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
58124029|NCT02920164|DEVICE|Placebo acupuncture|Placebo acupuncture with placebo needles
58124030|NCT04712656|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea.
58124031|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia With Tragus Pressure|Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
58124032|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia Without Tragus Pressure|Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
58124033|NCT03763500|OTHER|Internet-based education|A six-step Internet-based patient education.
58124034|NCT01703507|DRUG|Ipilimumab|Given IV
58124035|NCT01703507|RADIATION|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
58124036|NCT01703507|RADIATION|Stereotactic Radiosurgery (SRS)|Undergo SRS
58314434|NCT06251947|DRUG|Efbemalenograstim Alfa|Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
58450951|NCT04348266|DEVICE|Radiofrequency ablation (RFA)|Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
58450952|NCT02424617|DRUG|erlotinib|erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
58124037|NCT03435198|DIAGNOSTIC_TEST|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
58124038|NCT03528408|DRUG|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
58124039|NCT03528408|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
58124040|NCT00681720|DRUG|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
58124041|NCT00681720|DRUG|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
58124042|NCT05260645|BEHAVIORAL|Back School|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
58124043|NCT04172389|PROCEDURE|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
58124044|NCT02012309|BIOLOGICAL|PCV-13|
58124045|NCT02012309|BIOLOGICAL|PPSV-23|
58124046|NCT04126356|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
58124047|NCT02162758|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules
58124048|NCT02162758|DRUG|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
58124049|NCT05588284|DEVICE|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
58124050|NCT05588284|OTHER|anticoagulation alone|a medicine for anticoagulation therapy
58124051|NCT02371525|BEHAVIORAL|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
58124052|NCT04291066|DRUG|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
58124053|NCT00720798|DRUG|Tocilizumab|For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
58124054|NCT00720798|DRUG|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
58124055|NCT00720798|DRUG|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
58124056|NCT00720798|DRUG|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
58124057|NCT03912207|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
58124058|NCT03912207|OTHER|Saline placebo|Saline is a routinely used placebo.
58124059|NCT02243956|OTHER|Flavanol rich food product|polyphenol rich test product
58124060|NCT00284102|PROCEDURE|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
58124061|NCT04644133|OTHER|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
58124062|NCT04644133|OTHER|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
57749149|NCT00677833|DRUG|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
57959871|NCT05089500|OTHER|Endoscopic injection sclerotherapy|Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
58124063|NCT04998409|DEVICE|Monofocal lens|not applicable as patients are already implanted with the monofocal lens
58124064|NCT04873583|DRUG|Methylprednisolone|At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose)
58124065|NCT04873583|DRUG|Prednisolone|"Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)"
58124066|NCT01609764|BEHAVIORAL|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
58124067|NCT01499914|BIOLOGICAL|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
58124068|NCT00663221|DIETARY_SUPPLEMENT|Anthocyans, Calcium and Vitamin D|
58124069|NCT00663221|DIETARY_SUPPLEMENT|placebo|
58124070|NCT01699581|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
58124071|NCT05100745|DEVICE|Therapeutic Device|This device delivers ultrasound energy to the targeted area of the lower limb.
58124072|NCT04536259|BEHAVIORAL|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
58124073|NCT04536259|BEHAVIORAL|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
58314435|NCT05617365|COMBINATION_PRODUCT|Osteopathic Manipulative Therapy and Exercise Therapy|"At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head."
57749150|NCT00677833|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
57749151|NCT04492527|BEHAVIORAL|Telehealth coaching sessions|Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
57959872|NCT05089500|OTHER|Endoscopic Band Ligation|Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
58124074|NCT04536259|BEHAVIORAL|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
58124075|NCT03208426|DRUG|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
58124076|NCT03208426|DRUG|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
58124077|NCT03208426|DRUG|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
58124078|NCT03208426|DRUG|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
58124079|NCT03208426|DRUG|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
58124080|NCT03208426|DRUG|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
58124081|NCT03208426|DRUG|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
58124082|NCT03208426|DRUG|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
58124083|NCT01545635|DRUG|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
58124084|NCT01545635|DRUG|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
58124085|NCT03491436|DEVICE|iHealth Align|remote monitor glucometer
57749152|NCT03827057|BEHAVIORAL|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
57749153|NCT03827057|BEHAVIORAL|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
57749154|NCT00378352|DRUG|Epoetin alfa|Randomized
58124086|NCT04403048|PROCEDURE|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
58124087|NCT04403048|PROCEDURE|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
58124088|NCT00600795|OTHER|CSF collection|CSF collection at time of VPS insertion
57749155|NCT02904876|RADIATION|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
57749156|NCT03918863|OTHER|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
57749157|NCT03918863|OTHER|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
57749158|NCT03977675|DRUG|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
58124089|NCT01434342|DRUG|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
58124090|NCT00625807|BEHAVIORAL|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
58124091|NCT00625807|BEHAVIORAL|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
58124092|NCT04000009|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
58124093|NCT00358826|DRUG|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
58124094|NCT00358826|DRUG|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
58124095|NCT02419352|DRUG|Sugammadex|
58124096|NCT02419352|DRUG|Neostigmine/atropine|
58124097|NCT06528665|DRUG|ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults|"ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned."
58124098|NCT03147170|DIAGNOSTIC_TEST|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
58124099|NCT02768298|DRUG|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
58124100|NCT02768298|DRUG|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
58124101|NCT02768298|DRUG|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
58124102|NCT02768298|DRUG|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
58124103|NCT06004609|DEVICE|Low-level laser therapy (LLLT)|Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
58124104|NCT06004609|OTHER|Conventional physical therapy|Conventional physical therapy will be applied three time each week, for 12 weeks
58124105|NCT00720486|BEHAVIORAL|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
58124106|NCT00720486|BEHAVIORAL|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
58124107|NCT05760664|OTHER|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
58124108|NCT05760664|OTHER|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
58124109|NCT05760664|OTHER|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
58124110|NCT06437080|DRUG|Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg|01 tablet daily for 03 months, This is assigned to Group A.
58124111|NCT06437080|DRUG|Ferric Carboxymaltose|03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
58124112|NCT05725746|DIAGNOSTIC_TEST|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
58124113|NCT02547857|OTHER|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
58124114|NCT05591196|DEVICE|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
58124115|NCT05591196|OTHER|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
58124116|NCT00040378|DRUG|alphatocopherol|400 IU daily
58124117|NCT00040378|DRUG|Selenium|200mcg daily
58124118|NCT00040378|DRUG|Placebo replacement for vitamin E|1 placebo pill daily
57749159|NCT05194904|DRUG|Dexmedetomidine|This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children
58314436|NCT01762787|DRUG|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
57749160|NCT02096328|DRUG|POL7080|Intravenous infusion
58124119|NCT00040378|DRUG|Placebo replacement for Selenium|1 placebo pill daily
58124120|NCT01073436|OTHER|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
58124121|NCT00275483|DEVICE|Vital-band (R)|
58124122|NCT03401710|DRUG|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
58124123|NCT04932356|OTHER|Therapeutic education by phone|The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.
58124124|NCT04932356|OTHER|Therapeutical education traditional|The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
58124125|NCT02512354|OTHER|Sample of a fragment of fetal tissue|
58124126|NCT02512354|OTHER|Parent's blood samples|
58124127|NCT00028353|DRUG|GTX-006 (Acapodene)|
57749161|NCT03493243|OTHER|Questionnaires|2-hour clinical observation
57749162|NCT03466086|DEVICE|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
57749163|NCT03466086|DEVICE|Control Eye Drops|Systane® BALANCE eye drops
57749164|NCT00995072|DRUG|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
57749165|NCT00995072|DRUG|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
57749166|NCT03865602|BEHAVIORAL|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
57749167|NCT03865602|BEHAVIORAL|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
57749168|NCT05207514|DRUG|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
58124128|NCT04581005|BEHAVIORAL|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
58124129|NCT04965571|GENETIC|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
57749169|NCT05207514|DRUG|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
57749170|NCT05207514|DRUG|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
58124130|NCT06328283|OTHER|measure of Glutamine synthetase and BCLFAF1|compare Glutamine synthetase and BCLFAF1 in cases and controls
58314437|NCT01762787|DRUG|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
58314438|NCT01762787|DRUG|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
58314439|NCT01762787|DRUG|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
57749171|NCT05207514|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
57749172|NCT04206189|DIETARY_SUPPLEMENT|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
57749173|NCT00780858|DRUG|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
57749174|NCT02712034|BEHAVIORAL|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
58124131|NCT03615937|BEHAVIORAL|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
58314440|NCT01762787|DRUG|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
58314441|NCT01273961|DEVICE|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
58314442|NCT02339636|OTHER|PDUS examination|
58314443|NCT00649688|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
58314444|NCT00649688|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
58314445|NCT03582683|BEHAVIORAL|Chronic Pain Self-Management Program (CPSMP)|Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
58450953|NCT02424617|DRUG|bemcentinib|Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
58450954|NCT02532517|DEVICE|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
58124132|NCT03615937|BEHAVIORAL|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
57749175|NCT02712034|OTHER|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
57749176|NCT03959462|DEVICE|real anodal transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
57749177|NCT03959462|DEVICE|sham transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
57749178|NCT04548063|OTHER|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
57749179|NCT04548063|OTHER|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
57749180|NCT04548063|OTHER|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
57749181|NCT00406133|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
57749182|NCT05638633|DRUG|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
57749183|NCT05638633|DRUG|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
57749184|NCT05638633|DRUG|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
57749185|NCT05638633|DRUG|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
57749186|NCT03232983|DRUG|LY900014 (SC)|Administered SC
57749187|NCT03232983|DRUG|LY900014 (IV)|Administered IV
57749188|NCT01649232|DEVICE|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
58124133|NCT03615937|BEHAVIORAL|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
58124134|NCT03615937|OTHER|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
58124135|NCT03615937|OTHER|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
58124136|NCT00535522|DRUG|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
58124137|NCT00535522|DRUG|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
57749189|NCT01409148|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
57749190|NCT00534131|PROCEDURE|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
57959873|NCT05146570|DIAGNOSTIC_TEST|D-lactate test|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
57749191|NCT00534131|PROCEDURE|APPEAR Procedure|Perineal incision to reach the distal rectum
57749192|NCT00534131|PROCEDURE|Proctectomy|standard rectal excision which does not preserve the anal canal
57749193|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
57749194|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Posterior TAP Block|
57749195|NCT01429480|DRUG|Patient controlled analgesia|
57749196|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
57749197|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
57749198|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
57749199|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
57749200|NCT04141527|PROCEDURE|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
57749201|NCT04716348|PROCEDURE|muscle energy technique|muscle energy technique for suboccipital muscles
57749202|NCT00082173|DRUG|Moxifloxacin|400mg daily for 8 weeks
57749203|NCT01406626|BEHAVIORAL|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
57749204|NCT05804045|DRUG|Pimicotinib(ABSK021)|capsule
57749205|NCT05804045|DRUG|Placebo|capsule
57749206|NCT02384759|DRUG|aflibercept|
57749207|NCT02384759|DRUG|LV5FU2|
57749208|NCT01040260|OTHER|Counseling|Smoking cessation counseling
57749209|NCT01040260|BEHAVIORAL|Contingency management|Use of tangible rewards for abstinence from smoking
57749210|NCT01040260|DRUG|Nicotine patches|Nicotine patches
57749211|NCT02778100|DRUG|Nasal Glucagon|Administered intranasally.
57749212|NCT02778100|DRUG|Oxymetazoline|Administered intranasally.
57749213|NCT02690974|DRUG|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
57749214|NCT03534973|OTHER|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
57749215|NCT03534973|OTHER|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
58124138|NCT01296932|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
58450955|NCT02912715|DEVICE|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
58450956|NCT00821808|DEVICE|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
57749216|NCT01971723|OTHER|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (\>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
57749217|NCT01971723|OTHER|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
57749218|NCT00671931|DRUG|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
57749219|NCT00671931|DRUG|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
57749220|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
57749221|NCT00671931|DRUG|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
58124139|NCT02159105|DEVICE|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
58124140|NCT03218592|DRUG|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
58124141|NCT03218592|DRUG|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
57749222|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
57749223|NCT06309108|OTHER|Education Booklet|The education group was given training with a education booklet
57749224|NCT06309108|OTHER|Augmented Reality Group|The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
57749225|NCT05165342|DEVICE|Rexon-eye|a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
57749226|NCT05514912|DRUG|Cisplatin|Given IV
57749227|NCT05514912|DRUG|Gemcitabine Hydrochloride|Given IV
57749228|NCT05514912|DRUG|Infigratinib Phosphate|Given PO
57749229|NCT05514912|DRUG|Nab-paclitaxel|Given IV
57749230|NCT03356379|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
57749231|NCT02089256|DRUG|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
57749232|NCT04620291|BIOLOGICAL|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
57749233|NCT01569438|DRUG|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
57749234|NCT01569438|DRUG|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
58124142|NCT03218592|DRUG|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
58124143|NCT02943525|PROCEDURE|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
58124144|NCT01775033|OTHER|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
58314446|NCT01710423|BEHAVIORAL|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
58314447|NCT04342169|DRUG|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
58314448|NCT04342169|DRUG|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
58314449|NCT02873663|PROCEDURE|Plasma and head hair collection|Plasma and head hair collection
57749235|NCT04483310|BEHAVIORAL|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
57749236|NCT04483310|BEHAVIORAL|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
57749237|NCT06579287|DRUG|SHJ002|Topical ophthalmic
57749238|NCT06579287|DRUG|Atropine|Topical ophthalmic
57749239|NCT05590455|DRUG|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
57749240|NCT04563221|DEVICE|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
58124145|NCT02472392|DRUG|Rabbit anti-thymocyte globulin|Active treatment
58124146|NCT02472392|DRUG|Busulfan|comparitor
58124147|NCT02472392|DRUG|Melphalan|comparitor
58314450|NCT04639882|BEHAVIORAL|Personalized normative feedback|Information presenting perceived and actual drinking norms.
58314451|NCT04649424|DEVICE|CanSwab|New nasopharyngeal swab design.
58314452|NCT02747927|DRUG|Placebo|TDV placebo-matching SC injection.
58314453|NCT02747927|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
58450957|NCT00821808|DEVICE|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
58450958|NCT02917785|DEVICE|Karman curettage|
57749241|NCT00140504|OTHER|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
57749242|NCT00053989|BIOLOGICAL|anti-thymocyte globulin|iv
57749243|NCT00053989|BIOLOGICAL|graft-versus-tumor induction therapy|iv
57749244|NCT00053989|BIOLOGICAL|sargramostim|iv
57749245|NCT00053989|BIOLOGICAL|therapeutic allogeneic lymphocytes|iv
57749246|NCT00053989|DRUG|cyclophosphamide|injection
57749247|NCT00053989|DRUG|fludarabine phosphate|iv
57749248|NCT00053989|DRUG|methylprednisolone|oral
57749249|NCT00053989|DRUG|mycophenolate mofetil|oral
57749250|NCT00053989|DRUG|tacrolimus|oral
57749251|NCT00053989|PROCEDURE|allogeneic bone marrow transplantation|iv
57749252|NCT00053989|PROCEDURE|peripheral blood stem cell transplantation|iv
57749253|NCT00053989|PROCEDURE|umbilical cord blood transplantation|iv
57749254|NCT02316964|DRUG|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
57749255|NCT02316964|BIOLOGICAL|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
57749256|NCT02316964|BIOLOGICAL|aldesleukin|Given SC
57749257|NCT02316964|OTHER|laboratory biomarker analysis|Correlative studies
57749258|NCT01256411|DRUG|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
57749259|NCT01256411|DRUG|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
58124148|NCT02472392|DRUG|Fludarabine|comparitor
58124149|NCT02472392|DRUG|Cyclophosphamide|comparitor
58124150|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
58124151|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
58124152|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
57749260|NCT01256411|DRUG|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
57749261|NCT00032279|DRUG|Visilizumab|
57749262|NCT05117138|BIOLOGICAL|AMT-116 CAR-T cells|"1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled."
57749263|NCT05117138|BIOLOGICAL|AMT-253 CAR-T cells|"1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum)."
58450959|NCT01980095|DRUG|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
58124153|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
58450960|NCT01980095|DRUG|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
57749264|NCT00373399|DRUG|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
57749265|NCT00373399|DRUG|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
57749266|NCT00373399|DRUG|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
57749267|NCT00568048|BIOLOGICAL|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
57749268|NCT00568048|DRUG|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
57749269|NCT03813446|DEVICE|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
57749270|NCT05956288|DEVICE|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
57749271|NCT02545777|DRUG|diclofenac sodium enteric-coated|
57749272|NCT02545777|DRUG|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
57749273|NCT02545777|DRUG|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
57749274|NCT02545777|DRUG|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
57749275|NCT03044964|DRUG|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
57749276|NCT03044964|DRUG|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
57749277|NCT03369275|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
58124154|NCT03170648|DEVICE|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
57749278|NCT03369275|OTHER|Placebo|Placebo, with excipients, will be administered intravenously.
57749279|NCT01034267|DRUG|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
57749280|NCT02541890|BEHAVIORAL|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
58124155|NCT03708913|DEVICE|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
58124156|NCT00907309|BEHAVIORAL|iMET|Participants will receive the iMET intervention
58124157|NCT00907309|BEHAVIORAL|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
58124158|NCT02241603|BEHAVIORAL|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
58124159|NCT01478620|DRUG|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
58450961|NCT01975363|DIETARY_SUPPLEMENT|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
58450962|NCT01975363|OTHER|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
58450963|NCT01975363|OTHER|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
57749281|NCT03424434|OTHER|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
57749282|NCT03326531|OTHER|Not applicable for this study|Not applicable for this study
57749283|NCT01362439|DRUG|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
57749284|NCT03536546|BEHAVIORAL|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
57749285|NCT03536546|BEHAVIORAL|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
57749286|NCT05569746|DRUG|INM004|Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
57749287|NCT05569746|OTHER|SoC|Standard of care
57749288|NCT04498130|BEHAVIORAL|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
57749289|NCT04498130|BEHAVIORAL|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
57749290|NCT04549363|DRUG|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
57749291|NCT06385743|OTHER|Neuromuscular Training-based Exercise Program|Neuromuscular training has been accepted as an effective treatment modality to improve the neurophysiological states of the joints for coordinated work. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility). All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
57749292|NCT06385743|OTHER|''Thrower's Ten'' Exercise Program|"''Thrower's Ten'' Exercise Program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added. All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks."
57749293|NCT01503632|BEHAVIORAL|Behavioral Intervention|Receive intervention program
58450964|NCT01975363|OTHER|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
58450965|NCT02229188|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
58450966|NCT02229188|BEHAVIORAL|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
57749294|NCT01503632|BEHAVIORAL|Compliance Monitoring|Correlative studies
57749295|NCT01503632|OTHER|Laboratory Biomarker Analysis|Correlative studies
57749296|NCT01503632|DRUG|Mercaptopurine|Given orally
58124160|NCT02201251|DRUG|Topiramate|Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
58124161|NCT02201251|DRUG|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
58124162|NCT03561506|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
58314454|NCT04132219|BEHAVIORAL|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
58450967|NCT02229188|BEHAVIORAL|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
58450968|NCT05523336|OTHER|observation|observation and prospective data collection
57749297|NCT01503632|OTHER|Questionnaire Administration|Ancillary studies
57749298|NCT01503632|PROCEDURE|Standard Follow-Up Care|Receive usual standard of care
57749299|NCT05351255|DEVICE|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
57749300|NCT03389542|PROCEDURE|Surgery|Early mitral valve repair
57749301|NCT03389542|OTHER|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
57749302|NCT03066050|OTHER|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
57749303|NCT03066050|OTHER|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
57749304|NCT03066050|OTHER|CABG|Participants underwent coronary artery bypass grafting
57749305|NCT00895986|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
57749306|NCT00895986|BEHAVIORAL|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
57749307|NCT02525848|DRUG|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
57749308|NCT02525848|DRUG|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
58450969|NCT05759897|DRUG|HRS-7535|HRS-7535
57749309|NCT02525848|DRUG|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
57749310|NCT02884297|DRUG|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
58124163|NCT03561506|DRUG|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
57749311|NCT03856710|DEVICE|self-gripping mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
57749312|NCT03856710|DEVICE|Stapled mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
57749313|NCT01046539|DRUG|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
57749314|NCT01046539|DRUG|Placebo|0 mg
57749315|NCT00005057|BIOLOGICAL|adenovirus RSV-TK|
57749316|NCT00005057|DRUG|ganciclovir|
57749317|NCT02281669|DRUG|Pentostam|Intralesional injection of Pentostam
57749318|NCT01816750|DEVICE|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
57749319|NCT02142933|OTHER|vagino-perineal swab|
57749320|NCT02107209|PROCEDURE|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
57749321|NCT03943784|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
57749322|NCT03943784|DRUG|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
57749323|NCT02804568|DRUG|ALKS 3831|Oral capsule, daily administration
57749324|NCT02807636|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
57749325|NCT02807636|DRUG|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
58124164|NCT02537756|BEHAVIORAL|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
58124165|NCT01961908|DRUG|Proellex|
58450970|NCT05759897|DRUG|Placebo|Placebo
58450971|NCT04560933|PROCEDURE|Blood sample collection|Blood sample collection
58450972|NCT05570266|DIAGNOSTIC_TEST|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
58450973|NCT01620229|DRUG|brentuximab vedotin|Given IV
58450974|NCT01620229|OTHER|laboratory biomarker analysis|Correlative studies
58450975|NCT01620229|OTHER|pharmacological study|Correlative studies
58450976|NCT00302341|DRUG|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
58124166|NCT05411770|DEVICE|Thoracic kyphosis and lumbar lordosis angle assessment|Thoracic kyphosis and lumbar lordosis angle assessment was performed with the reliable Baseline Bubble Inclinometer®.
58124167|NCT05411770|DEVICE|Temporomandibular range of motion|TMJ range of motion, maximum mouth opening amount (MAAM), right and left lateral movements of the mandible (laterotrusion), anterior movement of the mandible (protrusion), and backward movement of the mandible (retrusion) were measured with a millimetric ruler, while the adolescent was seated on a chair.
58124168|NCT05411770|DEVICE|Measuring the cervical joint range of motion|Cervical joint flexion, extension, lateral flexion and rotation ranges of motion were measured with a universal goniometer while the adolescent was sitting in a chair.
58124169|NCT05411770|DEVICE|Craniovertebral angle measurement|Head posture of the adolescent was evaluated by craniovertebral angle (CVA) method. Adolescents sat on a chair with back support in an upright position and turned sideways to the worker. The pivot point was accepted as the seventh cervical vertebra, and the angle between the head (tragus) and the horizontal plane was measured with a goniometer and recorded in degrees.
58124170|NCT05411770|DEVICE|Tragus-to-wall distance measurement|Tragus-to-wall distance was measured using a tape measure and recorded in cm.
58124171|NCT05411770|DEVICE|Scoliosis angle assessment|Scoliosis angle assessment was done with a scoliometer.
58124172|NCT00000909|DRUG|Aldesleukin|
58124173|NCT02762097|PROCEDURE|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
58124174|NCT02762097|PROCEDURE|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
58124175|NCT02762097|DRUG|normal saline|Normal saline would be injected into uterine cavity to delineate defects
58124176|NCT00966225|DIETARY_SUPPLEMENT|LIP-01|comparison of different dosages of natural health product
58314455|NCT05237375|OTHER|The MIDWIZE model|"So-called MIDWIZE ambassadors are planned to be appointed to lead the clinical implementation of the quality improvement components.~Initial training workshops will be held with the ambassadors on practical aspects of the chosen components and how to explain their benefits to the units' staff. Training will also be provided on how to enhance interdisciplinary teamwork and coordinate quality improvements. The workshops will be held onsite at Naguru hospital and online via the project's MIDWIZE virtual platform. The ambassadors will themselves hold training workshops to support midwives and other healthcare providers at the clinics during the implementation of the quality improvements components. The virtual MIDWIZE platform will contain videos, posters, presentations, and other training material that the ambassadors can utilise to enhance the units' capacity and engage their colleagues."
58450977|NCT00302341|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
58450978|NCT06262386|DRUG|Cisplatin based chemottherapy|adjuvant therapy for high risk patient
57749326|NCT02807636|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
57749327|NCT02807636|OTHER|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
57749328|NCT02807636|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
57749329|NCT03157609|DEVICE|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
57749330|NCT03651167|OTHER|Survey|Participants will complete a survey online
58124177|NCT05538884|PROCEDURE|Intertransverse process block|The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
58124178|NCT04122222|BIOLOGICAL|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
58124179|NCT01645306|DRUG|Revacept|single intravenous injection
58124180|NCT01645306|DRUG|Placebo|single intravenous injection
58314456|NCT02620280|DRUG|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
58450979|NCT03353844|BEHAVIORAL|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
57749331|NCT06182306|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
57749332|NCT03129854|DEVICE|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
57749333|NCT05534022|DEVICE|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
58124181|NCT00696449|DRUG|Adapalene|All Subjects will treat the face once daily in the evening.
58450980|NCT02621307|DIETARY_SUPPLEMENT|Salba|
57749334|NCT03223974|DEVICE|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for \>30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
57749335|NCT03223974|DEVICE|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
57749336|NCT00553696|DRUG|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
58450981|NCT02621307|DIETARY_SUPPLEMENT|Flax|
58450982|NCT02621307|DIETARY_SUPPLEMENT|Control|
58450983|NCT05128201|RADIATION|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
57749337|NCT00553696|DRUG|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
57749338|NCT00553696|DRUG|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
58124182|NCT00696449|BEHAVIORAL|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
58124183|NCT00696449|BEHAVIORAL|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
58124184|NCT00696449|BEHAVIORAL|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
58124185|NCT00696449|BEHAVIORAL|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
58124186|NCT00738673|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
58314457|NCT02620280|DRUG|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
58314458|NCT02620280|DRUG|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
57749339|NCT02718703|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
57749340|NCT00877643|OTHER|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
57749341|NCT00877643|OTHER|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
58124187|NCT01024933|BEHAVIORAL|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
58314459|NCT02620280|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
57749342|NCT05039372|BEHAVIORAL|TRAINING AND CONSULTANCY|TRAINING AND CONSULTANCY
58124188|NCT01024933|BEHAVIORAL|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
58124189|NCT01338636|DRUG|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
58124190|NCT03106090|OTHER|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
58124191|NCT03801161|BIOLOGICAL|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP \>5 mg/L in infants within 24 hours of immunization.
58124192|NCT02040766|DRUG|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
58124193|NCT02040766|DRUG|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
58450984|NCT06284850|DRUG|Empagliflozin10Mg Tab|TB JARDIANCE 10MG
57749343|NCT03449810|PROCEDURE|DSE plus MET group A|"The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles."
58124194|NCT02040766|DRUG|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
58314460|NCT02620280|DRUG|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
58314461|NCT04547751|OTHER|targeted high-resolution mass spectrometry|"difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry"
58314462|NCT00254371|PROCEDURE|Androgen Replacement|
58450985|NCT03212118|BEHAVIORAL|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
58450986|NCT03212118|BEHAVIORAL|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
57749344|NCT03449810|PROCEDURE|DSE alone group B|The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.
58124195|NCT02040766|DRUG|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
58124196|NCT02040766|DRUG|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
58124197|NCT04484337|DRUG|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
58124198|NCT04484337|DRUG|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
58124199|NCT04484337|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
58124200|NCT04484337|DRUG|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
58124201|NCT04484337|DRUG|Topical steroid|Steroid will be available for topical application
58124202|NCT04484337|DRUG|Placebo creams/gels|Placebo creams/gels will be available for topical application
58124203|NCT04484337|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
58124204|NCT01665170|DRUG|Passiflora incarnata|3 x 1 tablet per day for 3 days
58124205|NCT01665170|DRUG|Placebo|3 x 1 ablet per day for 3 days
57749345|NCT03449810|PROCEDURE|Standard Physiotherapy treatment group C|In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
57749346|NCT05047367|BEHAVIORAL|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
57749347|NCT04028986|DRUG|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
57749348|NCT03934736|DRUG|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
57749349|NCT06248918|BEHAVIORAL|WATSOCPAP|Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
57749350|NCT04162769|DRUG|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
57749351|NCT04162769|DRUG|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
58124206|NCT04502342|COMBINATION_PRODUCT|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
58314463|NCT02090881|OTHER|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
58450987|NCT03212118|BEHAVIORAL|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
57749352|NCT04162769|DRUG|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
57749353|NCT03590756|OTHER|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
57749354|NCT00338884|DRUG|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
58124207|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
58124208|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
58124209|NCT05938790|OTHER|Continuous Fetal Monitoring|Fetal doppler used to monitor fetal heart rate in triage
58124210|NCT05938790|OTHER|Point of Care Handheld Ultrasound|Point of Care Handheld Ultrasound
58124211|NCT00878995|DRUG|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
58124212|NCT00878995|DRUG|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
58450988|NCT00431626|DRUG|Dutasteride (Avodart)|
58124213|NCT00526578|BEHAVIORAL|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
58124214|NCT02736500|DRUG|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
58450989|NCT00431626|DRUG|Placebo|Placebo before and after treatment of TURP
58450990|NCT01216813|OTHER|informational intervention|
58450991|NCT01216813|PROCEDURE|assessment of therapy complications|
58450992|NCT01216813|PROCEDURE|psychosocial assessment and care|
57749355|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation two days a week
57749356|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation three days a week
57749357|NCT00036998|PROCEDURE|conventional surgery|
57749358|NCT00036998|PROCEDURE|neoadjuvant therapy|
58124215|NCT02736500|DRUG|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
58314464|NCT06034184|OTHER|Virtual Reality|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
58314465|NCT02204189|DRUG|TongFuSan|TongFuSan 1g
58314466|NCT03789877|OTHER|Physical Activity|Participate in home-based walking program
58314467|NCT03789877|OTHER|Questionnaire Administration|Ancillary studies
58314468|NCT03789877|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
58450993|NCT03225235|RADIATION|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
58450994|NCT02241564|OTHER|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
58450995|NCT02241564|DRUG|Switch from calcineurin inhibitor to an mTOR inhibitor|
58450996|NCT05717816|DEVICE|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
58450997|NCT05206149|DRUG|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
58450998|NCT05206149|DRUG|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
58450999|NCT05546775|DIAGNOSTIC_TEST|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~* To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~* To assess the growth parameters in patients with CGD."
58451000|NCT00051493|DRUG|ALIMTA|
58451001|NCT00051493|DRUG|Carboplatin|
57749359|NCT00036998|PROCEDURE|thermal ablation therapy|
57749360|NCT06348784|DIAGNOSTIC_TEST|Assesment of Different NEoplasias in the adenexa model|The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites
57749361|NCT06348784|DIAGNOSTIC_TEST|Risk of malignancy index|The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level
57749362|NCT06348784|DIAGNOSTIC_TEST|Histopathologic examination|Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy
57749363|NCT01686789|DRUG|Pegylated interferon alpha-2a|
57749364|NCT04086420|BEHAVIORAL|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
57749365|NCT04086420|BEHAVIORAL|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
57749366|NCT00002426|DRUG|Adefovir dipivoxil|
57749367|NCT02784483|DRUG|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
57749368|NCT02565290|DIETARY_SUPPLEMENT|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
58124216|NCT04963426|BEHAVIORAL|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
58314469|NCT03789877|PROCEDURE|Sham Intervention|Undergo sham rTMS
58314470|NCT01868672|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
58314471|NCT05173311|BEHAVIORAL|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
58314472|NCT06193135|DRUG|Corifolitropin Alfa|Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.
58314473|NCT06193135|DRUG|Folitropin Beta|Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
58314474|NCT01066377|DIETARY_SUPPLEMENT|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
58314475|NCT02511717|OTHER|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
58314476|NCT02511717|OTHER|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
58314477|NCT02664688|OTHER|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
58314478|NCT02664688|OTHER|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
58314479|NCT03821597|PROCEDURE|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
58314480|NCT03821597|PROCEDURE|No sequential compression.|No sequential compression devices are applied.
58451002|NCT05639231|BEHAVIORAL|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~* Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~* Customizable diary to document mobility goals, results, difficulties and needs.~* Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing).~* iPad 10.2'' with videos of the exercises.~HCPs (physicians \& nursing staff):~* E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation.~* Oral presentation on the intervention.~* Checklist to remind HCPs to address mobility.~ENVIRONMENT:~* Posters in the wards about mobility and other topics of interest to older adults.~* Walking itineraries in the wards."
58451003|NCT01900158|DRUG|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
58451004|NCT06528158|OTHER|sibling group|"The group will be based on a systemic model and led by two child psychiatrists trained in family and multi-family therapy, who will not subsequently be involved in the data analysis. It will consist of 4 sessions of 1h30, spread over a period of 2 months, with a maximum of 8 participants per session. The first 3 sessions will be spaced 15 days apart, and the last session will take place 3 weeks apart from the third session.~The characteristics of the group (frequency, duration, number of sessions and participants) were built on data from the literature as well as on clinical feedback from a first pilot group conducted in January and February 2024 on the Toulouse pediatric unit by the two therapists who will lead the groups during the study."
58451005|NCT01128049|BEHAVIORAL|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
58451006|NCT01128049|PROCEDURE|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
58451007|NCT01128049|DRUG|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
58451008|NCT03008161|DRUG|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
58451009|NCT03008161|DRUG|Placebo|Placebo
58451010|NCT05083429|DRUG|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
58451011|NCT05083429|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference
58451012|NCT01751009|DIETARY_SUPPLEMENT|Vitamin A supplements|Sprinkles with Vitamin A
58451013|NCT01751009|DIETARY_SUPPLEMENT|Sprinkles without Vitamin A|Active comparator
58451014|NCT01648634|DRUG|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
57749369|NCT02565290|DIETARY_SUPPLEMENT|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
57749370|NCT06111222|DEVICE|HECATE|The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
57749371|NCT04064879|OTHER|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
57749372|NCT05760001|OTHER|Assigned Interventions|"Financial well-being interventions:~• Tax preparation; access to public benefits; financial counseling and microgrants~Place-based interventions:~• Vacant lot greening; abandoned house remediation; trash cleanup; tree planting"
57749373|NCT03455374|DEVICE|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
57749374|NCT04688424|DEVICE|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
58451015|NCT01648634|DRUG|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
57749375|NCT04688424|OTHER|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
57749376|NCT05586152|DRUG|INV-102|INV-102 Ophthalmic Solution
57749377|NCT05586152|DRUG|Vehicle|Vehicle Ophthalmic Solution
57749378|NCT03249051|OTHER|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
57749379|NCT05674760|DEVICE|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
57749380|NCT05674760|OTHER|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
57749381|NCT05858697|OTHER|Declining participation in the Aarhus intervention|Each year a fraction of the children invited into the Aarhus intervention decline to participated.
57749382|NCT05858697|BEHAVIORAL|Participation in the Aarhus intervention|A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
57749383|NCT00981084|DRUG|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
57749384|NCT01104610|DEVICE|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
57749385|NCT02386995|DEVICE|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
57749386|NCT02386995|DEVICE|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
57749387|NCT03213275|OTHER|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
57749388|NCT04285450|DIETARY_SUPPLEMENT|Vitamin K|1mg
57749389|NCT04285450|OTHER|Placebo|Lactose
57749390|NCT01694732|DRUG|Varenicline|
57749391|NCT01694732|DRUG|placebo|
57749392|NCT05794438|BEHAVIORAL|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
57749393|NCT05794438|BEHAVIORAL|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
57749394|NCT01685138|DRUG|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
57749395|NCT00137930|BIOLOGICAL|Live attenuated rotavirus vaccine|
57749396|NCT02908373|OTHER|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
57749397|NCT04766268|OTHER|Prostate artery embolization|Prostate artery embolization (PAE) is a safe and effective minimally invasive interventional radiology procedure in which intraprostatic vessels are embolized to shrink the size of the prostate gland. LUTS is mainly categorized into irritative, obstructive, and mixed types. This has a variable impact on patients' quality of life by interfering with sleep, activities of daily living, anxiety, mobility, leisure, and effect on sexual activities. This trial aims to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
57749398|NCT02138630|DIETARY_SUPPLEMENT|Capsaicin|
57749399|NCT02138630|DIETARY_SUPPLEMENT|Placebo|Sugar capsule
58451016|NCT05845086|BEHAVIORAL|Preoperative patient education|In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
58451017|NCT04097366|DIAGNOSTIC_TEST|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
57749400|NCT05877300|COMBINATION_PRODUCT|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
57749401|NCT04995185|RADIATION|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
57749402|NCT03371875|BEHAVIORAL|Automated transition care reminders|The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
57749403|NCT05556720|BIOLOGICAL|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
57749404|NCT05556720|BIOLOGICAL|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
57749405|NCT03220243|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
58124217|NCT04963426|OTHER|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
57749406|NCT01389830|BEHAVIORAL|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
57749407|NCT04102579|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
57749408|NCT04102579|DRUG|Placebo|non-active dosage form
57749409|NCT02514018|BIOLOGICAL|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
57749410|NCT04166253|DRUG|Vitamin D|Alfacalcidol oral tablets once daily
57749411|NCT05620212|BEHAVIORAL|Recovery College participation|Recovery College participation in any way (visitors, course/retreat participants, volunteers, employees).
57749412|NCT03103243|BEHAVIORAL|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
58124218|NCT04699422|PROCEDURE|Serratus anterior plane block|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
58451018|NCT04097366|DIAGNOSTIC_TEST|CESM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
58451019|NCT04097366|DIAGNOSTIC_TEST|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
57749413|NCT04263597|DRUG|2'-fucosyllactose|2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
57749414|NCT00908167|DRUG|Sorafenib|Please see detailed description.
57749415|NCT00908167|DRUG|Cytarabine|Please see Detailed Description.
58451020|NCT02374151|DEVICE|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
57749416|NCT00908167|DRUG|Clofarabine|Please see Detailed Description.
58451021|NCT06005181|BEHAVIORAL|Music listening|Daily music listening
57749417|NCT02853890|OTHER|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
58451022|NCT06005181|BEHAVIORAL|Piano training|Daily piano practice
58451023|NCT02304523|DRUG|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
57749418|NCT03201016|DIAGNOSTIC_TEST|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
57749419|NCT01111357|BIOLOGICAL|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
57749420|NCT04337099|DRUG|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
58124219|NCT04699422|DRUG|PCIA with Piritramide|A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
58124220|NCT00266409|DRUG|Niravam|
58124221|NCT00266409|DRUG|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
58451024|NCT02304523|DRUG|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
58124222|NCT01368003|DRUG|STA9090|200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
58124223|NCT01368003|DRUG|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
57749421|NCT06324266|DRUG|Cyclophosphamide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
58124224|NCT03232203|DRUG|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
58124225|NCT02098993|DRUG|Unfractionated heparin|
58124226|NCT05911607|PROCEDURE|Low power laser|Phototherapy for extraction sockets using two different lasers.
58124227|NCT04148222|OTHER|No intervention|There is no intervention for this study
58124228|NCT01893138|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
58124229|NCT01893138|BIOLOGICAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
58124230|NCT02660242|DRUG|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
58124231|NCT02660242|OTHER|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
58124232|NCT02660242|OTHER|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
58124233|NCT00314938|DRUG|PHA-794428|
58124234|NCT05805475|OTHER|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
58124235|NCT05805475|OTHER|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
58124236|NCT01351142|OTHER|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
58124237|NCT06543966|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
58124238|NCT06543966|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds
58124239|NCT00981786|DRUG|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
58124240|NCT00981786|DRUG|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
58124241|NCT01973114|DRUG|Latanoprost|
58124242|NCT01973114|OTHER|Placebo|
58124243|NCT01904500|DRUG|Pre-operative cefazolin|
58314481|NCT05930288|BEHAVIORAL|Walking exercise|The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
57749422|NCT06324266|DRUG|Lenalidomide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
58124244|NCT03086356|DRUG|Dabigatran etexilate|Days 1-4 and Day 8-11
58124245|NCT03086356|DRUG|Idarucizumab|Day 11
58124246|NCT01721525|DRUG|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects \> 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
58124247|NCT06094374|BEHAVIORAL|observation of physical activity behavior|"An observational study will be conducted to gather data on multiple levels aiming to identify diverse digital phenotypes related to PA behavior among community-dwelling older adults.~A hybrid approach will be employed, combining both cross-sectional and longitudinal data collection methods. The overall aim is to employ data analysis to identify patterns of PA - behavior (referred to as phenotypes) and to pinpoint prognostic factors that affect PA outcomes.~This integrated strategy will be complemented by four distinct measurement approaches, ensuring a comprehensive assessment of the research objectives. These measurement approaches include:self-reporting, clinical, ecological momentary and time series assessment."
58124248|NCT06436196|DEVICE|Video Laryngoscope|Use of Video laryngoscope to secure airway
58124249|NCT06436196|DEVICE|Direct laryngoscope|Macintosh or Miller's laryngoscopes used to secure paediatric airways
58124250|NCT00521248|DRUG|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
58124251|NCT00521248|DRUG|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
58124252|NCT00816959|DRUG|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
58124253|NCT00816959|DRUG|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
58314482|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
57749423|NCT01050816|PROCEDURE|Chondron(autologous chondrocyte) Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
58124254|NCT04844177|OTHER|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
58124255|NCT00045448|DRUG|alvocidib|
58124256|NCT00045448|DRUG|docetaxel|
58124257|NCT03366909|BEHAVIORAL|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
58124258|NCT03366909|BEHAVIORAL|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
58124259|NCT01439893|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
58124260|NCT01439893|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
58124261|NCT04857619|OTHER|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
58124262|NCT04458077|BEHAVIORAL|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
58124263|NCT00858000|OTHER|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
58124264|NCT00005842|BIOLOGICAL|trastuzumab|
58124265|NCT00005842|DRUG|tipifarnib|
58451025|NCT02304523|DRUG|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
58451026|NCT01992588|DRUG|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
58451027|NCT01992588|DRUG|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
58451028|NCT03846050|BEHAVIORAL|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
58451029|NCT03846050|BEHAVIORAL|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
58124266|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
58124267|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
58451030|NCT01754974|BIOLOGICAL|Peginterferon Lambda-1a|
57749424|NCT02674893|DRUG|Liraglutide|
57749425|NCT02674893|OTHER|Observation alone|
57749426|NCT03780348|DIAGNOSTIC_TEST|New Method|A 'new' WHZ tool will be used to assess children.
57749427|NCT03780348|DIAGNOSTIC_TEST|Existing Method|'Existing' WHZ tools will be used to assess children
58451031|NCT01754974|DRUG|Ribavirin|
58451032|NCT01754974|BIOLOGICAL|Peginterferon alfa-2a|
58451033|NCT02959593|DEVICE|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
58451034|NCT01219309|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|3 capsules bid orally
58451035|NCT01219309|DIETARY_SUPPLEMENT|Placebo (olive oil)|3 capsules bid orally
58451036|NCT03599791|DRUG|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
58451037|NCT03599791|DRUG|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
58451038|NCT03599791|DRUG|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
57749428|NCT03982602|OTHER|Ketogenic diet|Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
58124268|NCT00782509|DRUG|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
58124269|NCT05443243|PROCEDURE|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
58124270|NCT05683509|PROCEDURE|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
58124271|NCT05683509|PROCEDURE|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
58124272|NCT01106183|DIETARY_SUPPLEMENT|transfer factor|capsules, 2 per day by mouth for 7 weeks.
58124273|NCT01106183|DIETARY_SUPPLEMENT|Placebo|cornstarch, 2 capsules per day by mouth.
58124274|NCT04757259|DRUG|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams \[mg\] twice daily \[BID\]).
58314483|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract Placebo|Cocoa extract placebo
57749429|NCT01914835|BEHAVIORAL|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
58124275|NCT03301909|DEVICE|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
58124276|NCT03301909|DRUG|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
58124277|NCT02178709|DRUG|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
58124278|NCT03696381|OTHER|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
58124279|NCT03696381|OTHER|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
58124280|NCT01620177|DRUG|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
58124281|NCT01620177|DRUG|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
58124282|NCT03305029|DRUG|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
58124283|NCT03824626|DIAGNOSTIC_TEST|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
58124284|NCT03530956|DEVICE|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
58124285|NCT04120428|OTHER|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
58451039|NCT02734693|DRUG|dasotraline 4mg|dasotraline 4mg/day
58451040|NCT02734693|OTHER|Placebo|placebo/day
58451041|NCT00820469|DRUG|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
58451042|NCT00820469|DRUG|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
58451043|NCT01507688|BEHAVIORAL|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
57749430|NCT04474743|OTHER|No intervention - cross-sectional observational only|No intervention - cross-sectional observational only
58124286|NCT01310049|DRUG|LEO 32731|"* Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days"
58314484|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
58451044|NCT04499937|BEHAVIORAL|Streak incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
58451045|NCT04499937|BEHAVIORAL|Loss-based incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
58451046|NCT04499937|BEHAVIORAL|Flat-fee control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
57749431|NCT01169675|DRUG|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
57749432|NCT01169675|DRUG|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
57749433|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
57749434|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
57749435|NCT01169675|DRUG|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
57749436|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
57749437|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
58124287|NCT04547946|DRUG|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
58124288|NCT04578470|DRUG|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
58124289|NCT04578470|DRUG|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
58124290|NCT04663126|DRUG|Tc-99m tilmanocept|IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
58124291|NCT02986009|BEHAVIORAL|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
58124292|NCT02986009|BEHAVIORAL|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
58124293|NCT02079948|DRUG|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression."
58124294|NCT02079948|DRUG|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression"
58124295|NCT02079948|PROCEDURE|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
58124296|NCT02079948|PROCEDURE|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
58124297|NCT05567380|OTHER|Observation|Observation of Rheumatoid arthritis disease response to JAK inhibitors and TNF inhibitors after definite timepoints from the initialization of treatment in comparison to the current standard of care of therapy with conventional DMARDs.
58124298|NCT01076803|DRUG|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
58124299|NCT01540175|OTHER|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
58124300|NCT01521559|PROCEDURE|Macular Laser Photocoagulation|
57749438|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
57749439|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
57749440|NCT01169675|DRUG|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
57749441|NCT01169675|DRUG|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
57749442|NCT01169675|DRUG|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
58124301|NCT01521559|DRUG|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
58124302|NCT03029663|PROCEDURE|Transurethral resection of the bladder tumour|
58124303|NCT03231254|DEVICE|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
58124304|NCT06409962|OTHER|Technological combination|The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
57749443|NCT00433303|BEHAVIORAL|Correlation between early delivery and coital activity|
57749444|NCT01196455|DRUG|Capecitabine and Mitomycin C|"* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~* Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
57749445|NCT02713802|DRUG|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
57749446|NCT02713802|DRUG|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
57749447|NCT04730050|DRUG|TT-01025-CL|Oral tablet
57749448|NCT02645981|DRUG|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
57749449|NCT02645981|DRUG|Sorafenib|Control
57749450|NCT04879914|DIETARY_SUPPLEMENT|Butyrate|3 cps/die 300 mg/cps
58124305|NCT03562806|DIAGNOSTIC_TEST|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
58124306|NCT01254409|BIOLOGICAL|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
58124307|NCT01254409|OTHER|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
58124308|NCT05520424|DIETARY_SUPPLEMENT|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
58124309|NCT03194035|BIOLOGICAL|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
58124310|NCT06048900|DEVICE|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
58124311|NCT05753384|DRUG|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
57749451|NCT04879914|DIETARY_SUPPLEMENT|Placebo|3 cps/die 300 mg/cps
57749452|NCT02108379|DEVICE|Rhinix Nasal Filters|
58124312|NCT05355597|DRUG|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
58124313|NCT05355597|DRUG|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
58124314|NCT03534986|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
58124315|NCT03534986|DEVICE|Hill-Rom The Vest|High-frequency chest wall oscillation vest
58124316|NCT03534986|DEVICE|Respirtech inCourage|High-frequency chest wall oscillation vest
58124317|NCT03534986|DEVICE|Electromed SmartVest|High-frequency chest wall oscillation vest
58124318|NCT00153088|DRUG|Telmisartan capsule 40 mg|
57749453|NCT03094780|BEHAVIORAL|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
58124319|NCT00153088|DRUG|Placebo|
58124320|NCT00153088|DRUG|Telmisartan capsule 80 mg|
58124321|NCT00505609|BEHAVIORAL|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
58124322|NCT04632823|COMBINATION_PRODUCT|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
58124323|NCT06047145|DIETARY_SUPPLEMENT|soy isoflavones|1 capsule daily for 84 days
58314485|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
58314486|NCT01021189|DRUG|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
57749454|NCT03094780|OTHER|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
57749455|NCT02966756|DRUG|Venetoclax|Tablet; Oral
57749456|NCT00796692|DRUG|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
57749457|NCT00796692|DRUG|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
57749458|NCT00404365|OTHER|counseling intervention|
57749459|NCT00404365|OTHER|screening questionnaire administration|
57749460|NCT00404365|OTHER|study of socioeconomic and demographic variables|
57749461|NCT00404365|PROCEDURE|psychosocial assessment and care|
58124324|NCT06047145|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 84 days
58124325|NCT02619123|OTHER|Tailored screening according to breast density|Different interval of mammography screening according to breast density
58124326|NCT02619123|OTHER|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
58124327|NCT00721877|DRUG|resveratrol|Given orally
58124328|NCT00721877|OTHER|pharmacological study|Correlative studies
58124329|NCT00721877|OTHER|laboratory biomarker analysis|Correlative studies
58124330|NCT02072564|OTHER|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
58124331|NCT00298870|DRUG|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
58124332|NCT00298870|DRUG|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
58124333|NCT02496026|DEVICE|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
58124334|NCT02496026|DEVICE|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
58314487|NCT01021189|DRUG|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
58314488|NCT01801540|DIETARY_SUPPLEMENT|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
58314489|NCT02137798|DEVICE|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
57749462|NCT06578936|OTHER|abdominal massage andwarm application|Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
58124335|NCT01823003|RADIATION|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall \> 1 cm, tumour size \< 2 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
58124336|NCT01823003|RADIATION|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall \> 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
58124337|NCT01823003|RADIATION|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
57749463|NCT01717781|PROCEDURE|Thunderbeat technology|
57749464|NCT01717781|PROCEDURE|Standard bipolar electrosurgery|
57749465|NCT02328885|DRUG|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
58124338|NCT01823003|RADIATION|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
58124339|NCT04790851|BIOLOGICAL|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
58451047|NCT04499937|BEHAVIORAL|Flat-Fitbit control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
58451048|NCT03287999|DIAGNOSTIC_TEST|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
58451049|NCT03287999|DIAGNOSTIC_TEST|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
58451050|NCT00210782|DRUG|topiramate, phenytoin|
58451051|NCT06502496|BEHAVIORAL|art-therapy|Over the 6 sessions, different artistic techniques will be explored, depending on the artist leading the workshop: stencil, graffiti, spray paint, collage, oil pastel, calligraphy and acrylic doodling. A collective work may also be proposed.
57749466|NCT03602417|DEVICE|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
57749467|NCT03602417|DEVICE|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
57749468|NCT03894852|DIAGNOSTIC_TEST|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
57749469|NCT03854968|OTHER|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
57749470|NCT03633942|DEVICE|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
57749471|NCT04285008|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
57749472|NCT04932876|BIOLOGICAL|SARS - COV 2 VACCINE|Vaccination for SARS - COV 2
57749473|NCT02976441|RADIATION|Radiation therapy|
58124340|NCT04790851|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
58124341|NCT04790851|BIOLOGICAL|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
58124342|NCT05474625|DEVICE|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
58314490|NCT06097832|BIOLOGICAL|NXC-201 CAR-T|NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
58314491|NCT02172547|DRUG|Spiriva|
58314492|NCT06053944|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine.
58314493|NCT02475148|DRUG|JNJ 54175446|
58314494|NCT02475148|DRUG|Placebo|
58314495|NCT02475148|OTHER|High fat/high Calorie Breakfast|
58451052|NCT06502496|BEHAVIORAL|relaxation|relaxation sessions with the referent psychologist
57749474|NCT02976441|DRUG|Temozolomide|
57749475|NCT02976441|PROCEDURE|Stem cell collection|
57749476|NCT02976441|PROCEDURE|Stem cell infusion|
57749477|NCT03880838|BEHAVIORAL|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
58124343|NCT05474625|DEVICE|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
58124344|NCT05474625|DEVICE|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
58124345|NCT05474625|OTHER|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
58124346|NCT02574052|BEHAVIORAL|participants' food choices|just recorded the participants' food choices in the school cafeteria
58124347|NCT02574052|BEHAVIORAL|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
58124348|NCT02574052|BEHAVIORAL|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
58124349|NCT00099736|DRUG|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
58124350|NCT00099736|DRUG|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
58124351|NCT00099736|DRUG|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
58124352|NCT04474938|DRUG|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
58124353|NCT04474938|DRUG|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
58124354|NCT04474938|DRUG|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
58124355|NCT02318121|PROCEDURE|Amniotomy first|rupture of membranes to augment labor
58124356|NCT02318121|PROCEDURE|Oxytocin first|Administration of oxytocin to augment labor
58124357|NCT02318121|PROCEDURE|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
58124358|NCT02318121|DRUG|Oxytocin|
58124359|NCT01776281|BEHAVIORAL|Kangaroo Mother Care|
58124360|NCT01776281|BEHAVIORAL|Standard Care|
58124361|NCT04535908|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
58124362|NCT03629158|BEHAVIORAL|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
58124363|NCT06193278|DEVICE|Neuromodulation|Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
58124364|NCT02204371|DRUG|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
58124365|NCT02204371|DRUG|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
58124366|NCT05128409|DRUG|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
58124367|NCT05128409|DRUG|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
58314496|NCT04759547|DEVICE|handheld ultrasound-assisted technique|Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
58314497|NCT04759547|OTHER|conventional palpation-guided technique|The interspinous space is detected by palpation
58314498|NCT04490460|DIETARY_SUPPLEMENT|WBF-0031|Medical food formulation WBF-0031
58314499|NCT03764124|DIAGNOSTIC_TEST|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
58124368|NCT01891292|DRUG|Enalapril|0.25-0.35 mg/kg/day
58124369|NCT01891292|DRUG|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
58124370|NCT01199757|DRUG|Fluticasone furoate|cohort of patients receiving fluticasone furate
58124371|NCT01199757|DRUG|mometasone furoate|cohort receiving mometasone furoate
58124372|NCT01199757|DRUG|fluticasone propionate|cohort of patients on fluticasone propionate
58124373|NCT00584766|PROCEDURE|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
58124374|NCT05346549|BEHAVIORAL|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
58124375|NCT05346549|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
58124376|NCT01747850|BEHAVIORAL|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
57749478|NCT03880838|BEHAVIORAL|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
57749479|NCT03880838|BEHAVIORAL|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
57749480|NCT03880838|BEHAVIORAL|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
57749481|NCT04573465|BEHAVIORAL|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
57749482|NCT04573465|BEHAVIORAL|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
57749483|NCT04573465|BEHAVIORAL|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
57749484|NCT00305799|PROCEDURE|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
57749485|NCT02154984|BEHAVIORAL|behavioral dietary intervention|Follow tRD
57749486|NCT02154984|BEHAVIORAL|telephone-based intervention|Receive coaching calls
57749487|NCT02154984|OTHER|laboratory biomarker analysis|Correlative studies
57749488|NCT06013254|DIETARY_SUPPLEMENT|sour liquid|applying lemon juice
57749489|NCT04996615|OTHER|no intervention|no intervention
57749490|NCT00241579|DRUG|Smoked Cannabis|
57749491|NCT00587964|RADIATION|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
57749492|NCT04385368|DRUG|Durvalumab + SoC chemotherapy|Experimental Treatment
58124377|NCT01747850|DRUG|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
57749493|NCT04385368|OTHER|Placebo + SoC chemotherapy|Placebo Comparator
57749494|NCT05790538|PROCEDURE|Assessment of Therapy Complications|Complete clinic assessments
57749495|NCT05790538|OTHER|Electronic Health Record Review|Medical records are reviewed
57749496|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear SmartSocks
57749497|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
57749498|NCT05790538|OTHER|Survey Administration|Complete survey
57749499|NCT04525495|DRUG|Dopamine|Dopamine treatment
57749500|NCT04135157|PROCEDURE|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
57749501|NCT04135157|PROCEDURE|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
57749502|NCT04135157|OTHER|Control|Only general anesthesia will be performed.
57749503|NCT04216030|OTHER|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
58124378|NCT01747850|DRUG|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
58124379|NCT03233620|OTHER|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
58124380|NCT02275364|DEVICE|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
58124381|NCT02275364|DEVICE|Placebo strip|Placebo strip
58124382|NCT02275364|OTHER|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
58124383|NCT02359890|DEVICE|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
58124384|NCT03222141|DEVICE|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
58124385|NCT02503579|BEHAVIORAL|physical training|physical activity program, 30 minutes
58124386|NCT04516148|DRUG|Cefazolin|Dosing per hospital policy
58124387|NCT04516148|DRUG|Clindamycin|Dosing per hospital policy
58124388|NCT04196465|DRUG|IMC-001|IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys
58451053|NCT02768493|DRUG|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
57749504|NCT04216030|OTHER|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
57749505|NCT04499807|OTHER|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
57749506|NCT04496726|OTHER|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
57749507|NCT02182973|DIETARY_SUPPLEMENT|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
57749508|NCT02120508|DEVICE|rTMS|To test the efficacy of this specific setting.
57749509|NCT04032665|DIAGNOSTIC_TEST|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
57959874|NCT05146570|DIAGNOSTIC_TEST|Standard diagnostic tests|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
57959875|NCT04545346|OTHER|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
57959876|NCT04336995|DIAGNOSTIC_TEST|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
57959877|NCT02986230|OTHER|CP-CDS|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
57959878|NCT03789227|PROCEDURE|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
58124389|NCT05525195|PROCEDURE|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
58124390|NCT05067088|OTHER|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
58124391|NCT05657548|RADIATION|spine and pelvis radiography|X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
58124392|NCT05665582|OTHER|Family program|A 4-day psychoeducational family program.
58314500|NCT03931070|DRUG|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
57749510|NCT02922348|DRUG|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
57749511|NCT02922348|DRUG|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
57749512|NCT06239155|DRUG|AST-3424|liquid formulation for Intravenous infusion
57749513|NCT02417818|DEVICE|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
57749514|NCT02417818|DEVICE|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
57749515|NCT04899882|OTHER|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
57749516|NCT04853680|DEVICE|Anti-adhesion barrier (Collarbarrier)|Collagen derived anti-adhesion barrier
57749517|NCT02112981|DEVICE|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
57749518|NCT02112981|DEVICE|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
57749519|NCT01753921|OTHER|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
57749520|NCT01753921|OTHER|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
57749521|NCT01753921|DEVICE|MRI|MRI study of the brain will be performed at t=3months.
57749522|NCT04020848|OTHER|Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.|Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
57749523|NCT04020848|OTHER|The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire|Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
57749524|NCT05177458|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.
57749525|NCT05177458|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
57749526|NCT00816881|DEVICE|flutter mucus clearance device|five minutes every session, four sessions per day
57749527|NCT03153579|DRUG|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
57749528|NCT03153579|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
57749529|NCT03238300|DRUG|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
57749530|NCT03238300|DRUG|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
57749531|NCT05843916|DRUG|Recombinant human alpha galactosidase A (agalsidase beta)|All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks
57749532|NCT05843916|DRUG|Recombinant human alpha-galactosidase A (agalsidase beta)|All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
57749533|NCT04701151|DRUG|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
57749534|NCT05597657|OTHER|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
57749535|NCT02163733|DRUG|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
57749536|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
57749537|NCT02163733|OTHER|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
57749538|NCT02163733|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
57749539|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
57749540|NCT01973660|DRUG|Lapatinib|
57749541|NCT01973660|DRUG|Trastuzumab|
57959879|NCT06391138|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
58451054|NCT02768493|DRUG|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
58314501|NCT03931070|DRUG|Placebo - Cap|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
58314502|NCT02721069|DRUG|NRL-1|
57749542|NCT01973660|DRUG|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
57749543|NCT01973660|DRUG|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
58451055|NCT00900055|GENETIC|microarray analysis|
57749544|NCT02203240|OTHER|Cocoa|
57749545|NCT02203240|OTHER|Placebo|
57749546|NCT03289234|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
57749547|NCT01472198|DRUG|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
57749548|NCT01472198|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
57749549|NCT01472198|DRUG|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
57749550|NCT04233476|DRUG|99mTc-3PRGD2 injection|A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
57749551|NCT04202380|DRUG|Azithromycin|Patients will receive Azithromycin orally 1000 mg
57749552|NCT04202380|DRUG|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
57749553|NCT04202380|DRUG|Azithromycin|Azithromycin 500 mg orally once
57749554|NCT04202380|DRUG|Azithromycin|Azithromycin 250 mg orally daily for 4 days
57749555|NCT01466985|DRUG|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
57749556|NCT01466985|DRUG|Placebo|Placebo tablets once daily for 7 days.
57749557|NCT04602533|DRUG|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
57749558|NCT04602533|DRUG|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
58451056|NCT00900055|GENETIC|polyacrylamide gel electrophoresis|
58451057|NCT00900055|GENETIC|polymerase chain reaction|
58451058|NCT00900055|GENETIC|protein expression analysis|
57749559|NCT00005600|PROCEDURE|management of therapy complications|
57749560|NCT00733603|OTHER|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
57749561|NCT00733603|OTHER|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
58314503|NCT04108390|OTHER|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
58314504|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 7g|Xylitol 7g in 300mL tap water
58451059|NCT00900055|GENETIC|reverse transcriptase-polymerase chain reaction|
57749562|NCT05919693|DRUG|EYE103|EYE103 is a humanized antibody formulated for IVT administration
57749563|NCT05684406|GENETIC|Genotyping|Genotyping by Real Time PCR
57749564|NCT05019248|BIOLOGICAL|Most recent vaccine to seasonal influenza|Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
57749565|NCT05738187|PROCEDURE|local cryotherapy treatment|cryotherapy
57749566|NCT02362048|DRUG|ACP-196|
57749567|NCT02362048|DRUG|ACP-196 in combination with pembrolizumab|
57749568|NCT02471651|DRUG|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
57749569|NCT02471651|DRUG|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
57749570|NCT00063050|BEHAVIORAL|Physical activity and nutrition intervention|
57749571|NCT05204225|OTHER|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
57749572|NCT05204225|OTHER|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
58451060|NCT00900055|GENETIC|western blotting|
58451061|NCT00900055|OTHER|chromatography|
58451062|NCT00900055|OTHER|high performance liquid chromatography|
58451063|NCT00900055|OTHER|immunoenzyme technique|
58451064|NCT03157375|DEVICE|Intraocular Lens Implantation|
58451065|NCT00415285|DRUG|Docetaxel|
58451066|NCT00415285|DRUG|Capecitabine|
58451067|NCT00415285|DRUG|Docetaxel/Capecitabine|
58451068|NCT01230463|DRUG|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
58451069|NCT01230463|DRUG|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
57749573|NCT01723722|DRUG|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
57749574|NCT01723722|DRUG|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
58314505|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 10g|Erythritol 10g in 300mL tap water
58451070|NCT02435004|DEVICE|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
58451071|NCT04186767|DIETARY_SUPPLEMENT|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
58451072|NCT05802589|PROCEDURE|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
58451073|NCT05802589|PROCEDURE|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
58451074|NCT05802589|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
58451075|NCT06371105|OTHER|10-week water-based aerobic training|The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
58451076|NCT01855412|OTHER|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
58451077|NCT01835821|DEVICE|prosthetic crowns|prosthetic crowns
58451078|NCT03471312|DRUG|Magnesium|magnesium therapy
58451079|NCT01662323|BEHAVIORAL|GP's treating HF according the dutch guidelines|
58451080|NCT01657175|OTHER|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
58451081|NCT01253291|DRUG|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
58451082|NCT02869399|DIETARY_SUPPLEMENT|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
58451083|NCT05598281|DRUG|AMG 510|Oral tablet
58451084|NCT05598281|DRUG|Digoxin|Oral tablet
57749575|NCT00522301|DRUG|sorafenib tosylate|
57749576|NCT00522301|OTHER|immunoenzyme technique|
57749577|NCT00522301|OTHER|immunohistochemistry staining method|
57749578|NCT00522301|OTHER|laboratory biomarker analysis|
57749579|NCT00522301|OTHER|pharmacological study|
57749580|NCT02096523|OTHER|Blood collection for platelet protein samples|
57749581|NCT03350568|OTHER|Total dietary NEAC assessed at baseline|
57749582|NCT01096992|DRUG|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
57749583|NCT01096992|DRUG|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
57749584|NCT01096992|DRUG|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
57959880|NCT04646759|DRUG|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
57959881|NCT04646759|DRUG|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
57959882|NCT00113542|DRUG|Tetrathiomolybdate (TM)|
58314506|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 17g|Xylitol 17g in 300mL tap water
58314507|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 35g|Xylitol 35g in 300mL tap water
58314508|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 25g|Erythritol 25g in 300mL tap water
58314509|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 50g|Erythritol 50g in 300mL tap water
58314510|NCT00025779|DRUG|methylphenidate|
58314511|NCT00025779|DRUG|guanfacine|
57749585|NCT03918746|BEHAVIORAL|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
58451085|NCT06110013|DEVICE|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
58451086|NCT00752193|OTHER|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
58451087|NCT00752193|OTHER|Placebo|Placebo in combination with antibiotic therapy
58451088|NCT04325893|DRUG|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
58451089|NCT04325893|DRUG|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
58451090|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
58451091|NCT02081157|DEVICE|GalaFlex Mesh|
58451092|NCT02864589|BEHAVIORAL|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
58451093|NCT02864589|BEHAVIORAL|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
57749586|NCT04043923|DRUG|Norketotifen|Oral capsule
57749587|NCT04043923|DRUG|Placebo|Oral capsule
57749588|NCT06184828|BIOLOGICAL|Whole blood transfusion|The transfusion of whole blood units
57749589|NCT06184828|BIOLOGICAL|Blood components transfusion|The transfusion of blood components units rather than whole blood
58314512|NCT03001102|DEVICE|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
57749590|NCT02159131|DRUG|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
57749591|NCT02159131|DRUG|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
57749592|NCT02159131|DRUG|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
57749593|NCT05279625|DEVICE|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
57749594|NCT03132428|DRUG|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
57749595|NCT03840590|DEVICE|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
57749596|NCT03840590|DEVICE|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
57749597|NCT04432701|BEHAVIORAL|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
58314513|NCT03001102|DEVICE|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
58314514|NCT03001102|DEVICE|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
58314515|NCT04302597|PROCEDURE|Staples|Skin closure using surgical stapler.
58314516|NCT04302597|PROCEDURE|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
58314517|NCT03804619|DEVICE|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
58314518|NCT00432822|DRUG|tetrahydrobiopterin (BH4)|
57749598|NCT01123382|DEVICE|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
57749599|NCT01123382|OTHER|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
57749600|NCT04225988|DRUG|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
57749601|NCT04225988|DRUG|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
57749602|NCT02984657|PROCEDURE|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
57749603|NCT02984657|PROCEDURE|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
58124393|NCT02578732|DRUG|FOLFOXA|"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."
58124394|NCT02637193|DRUG|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
58124395|NCT02637193|DRUG|Moxifloxacin|400 mg single dose moxifloxacin
58124396|NCT02637193|DRUG|Drug - placebo|Placebo administered for 16 days
58124397|NCT04356521|PROCEDURE|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
58124398|NCT04356521|PROCEDURE|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
57749604|NCT02671032|DEVICE|Nucleus CI532 cochlear implant|
57749605|NCT01252823|DEVICE|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
57749606|NCT03327766|DIAGNOSTIC_TEST|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
57749607|NCT03202706|PROCEDURE|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
57749608|NCT05089838|BIOLOGICAL|CMV-TCR-T cells|Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
57749609|NCT00412100|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
57749610|NCT05973448|OTHER|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
57749611|NCT05973448|OTHER|Control Lighting Condition|Standard night light plugged into wall socket
57749612|NCT00504426|DRUG|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
57749613|NCT02077348|DRUG|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
57749614|NCT02077348|DRUG|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
57749615|NCT05055102|OTHER|Data collection|demographics co-morbidities risk factors operative, hospital and vascular follow-up data
57749616|NCT00020553|PROCEDURE|psychosocial assessment and care|
57749617|NCT02191696|DEVICE|IMED-4 recording|
57749618|NCT00538590|DEVICE|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
57749619|NCT00538590|DRUG|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
57749620|NCT05288426|OTHER|No intervention|This is an observational study, with no intervention.
57749621|NCT04444167|BIOLOGICAL|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
57749622|NCT04444167|DRUG|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
57749623|NCT03656705|BIOLOGICAL|CCCR-NK92 cells|CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
57749624|NCT06397131|COMBINATION_PRODUCT|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.
57749625|NCT06020222|DEVICE|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
57749626|NCT06020222|OTHER|education|Provide preventive CIPN education leaflets
57749627|NCT02555540|BIOLOGICAL|Boostrix|Randomised assignment
57749628|NCT02555540|BIOLOGICAL|Placebo (Saline)|Randomised assignment
57749629|NCT06489873|DIETARY_SUPPLEMENT|Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)|Each participant will be assigned to t a LZF supplement daily for six months
57749630|NCT06489873|DIETARY_SUPPLEMENT|Placebo Comparator|Each participant will be assigned to take a placebo supplement daily for six months
57749631|NCT02421484|BIOLOGICAL|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
57749632|NCT01118533|DEVICE|metal reusable blades MacIntosh|laryngoscope blades
57749633|NCT01118533|DEVICE|Single use plastic blades HEINE XP®|laryngoscope blades
57749634|NCT04669730|OTHER|usual care|Routine care
57749635|NCT04669730|BEHAVIORAL|Walk|Walk 30mins
57749636|NCT04669730|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
57749637|NCT04669730|BEHAVIORAL|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
57749638|NCT04900129|COMBINATION_PRODUCT|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
57749639|NCT05394662|DEVICE|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
57749640|NCT05225623|BEHAVIORAL|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
57749641|NCT05225623|BEHAVIORAL|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
57749642|NCT05550116|OTHER|Giomer|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
57749643|NCT05550116|OTHER|Two composite resin sealants|Unfilled composite resin sealants
57749644|NCT01825681|BEHAVIORAL|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
57749645|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
57749646|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
57749647|NCT00255931|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
57749648|NCT00255931|BEHAVIORAL|Attention Placebo|Untrained relaxation
58124399|NCT00926744|BEHAVIORAL|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
58451094|NCT06152510|OTHER|Virtual Reality Rehabilitation System|In a single session to evaluate postural control, both children with ASD and typically developing peers will participate in an activity utilizing the Virtual Reality Rehabilitation System (VRRS) in conjunction with a stabilometric balance platform. During the assessment task, participants will stand on the balance platform with their eyes open, focusing on a fixed point displayed on the VRRS screen for a duration of one minute. This process will be repeated three times for each participant. The combined use of VRRS and the stabilometric balance platform aims to provide a comprehensive evaluation of postural control abilities in both groups, allowing for the observation and measurement of potential differences in stability and balance performance between children with ASD and their neurotypical counterparts.
57749649|NCT06162650|RADIATION|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
57749650|NCT06162650|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
57959883|NCT02983682|DRUG|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
58124400|NCT06325878|GENETIC|Genome-wide association study|Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP
57749651|NCT03640351|DRUG|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
58124401|NCT04212039|DRUG|Saline Solution|0.5 ml/kg saline
57749652|NCT03640351|DRUG|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
57749653|NCT03640351|DRUG|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
57749654|NCT03297515|DIETARY_SUPPLEMENT|Madeos|Arm 1: Omega 3
57749655|NCT03297515|DIETARY_SUPPLEMENT|Placebo|Arm 2 : Placebo
57749656|NCT05841979|BEHAVIORAL|Moodlifters|Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta \& Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.
57749657|NCT05841979|BEHAVIORAL|Physical Activity|Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan \& Karlamangla, 2014; Strasser \& Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).
57749658|NCT05841979|BEHAVIORAL|Nature Experiences|Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.
58124402|NCT04212039|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
58124403|NCT04603963|DEVICE|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
58451095|NCT03553758|DRUG|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
58124404|NCT00944970|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
58124405|NCT00944970|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
58124406|NCT05498246|PROCEDURE|laparoscopic partial nephrectomy|Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
58124407|NCT01001065|PROCEDURE|Vascular ultrasound|RI ist predictive for arteriosclerosis
58124408|NCT00221507|BEHAVIORAL|Reminder-Recall-Outreach|
58124409|NCT00221507|BEHAVIORAL|Case Management|
58124410|NCT00221507|BEHAVIORAL|Patient Navigator|
58314519|NCT06031285|DRUG|Sintilimab|Perioperative Sinitilimab, bevacizumab biosimilar and TACE-HAIC
58451096|NCT03202342|OTHER|Water|Water, 300 ml, at room temperature
58451097|NCT03202342|OTHER|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
57749659|NCT05168891|PROCEDURE|Surgical therapy|Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
57749660|NCT05168891|PROCEDURE|Non-surgical therapy of peri-implantitis|Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
57749661|NCT00875004|BIOLOGICAL|epoetin beta|
57749662|NCT00875004|DRUG|systemic chemotherapy|
57749663|NCT00875004|PROCEDURE|quality-of-life assessment|
58314520|NCT04208230|DEVICE|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
58314521|NCT00214721|DRUG|Experimental Peritoneal Dialysis Solution|
58314522|NCT00596492|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
58451098|NCT03202342|OTHER|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
58451099|NCT03202342|OTHER|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
58451100|NCT03202342|OTHER|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
58451101|NCT01365286|DRUG|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
58451102|NCT01365286|DRUG|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
58451103|NCT00759161|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
58451104|NCT00759161|DRUG|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
58451105|NCT04437485|BEHAVIORAL|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
58451106|NCT04437485|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
57749664|NCT02110901|DRUG|PRT-201|
57749665|NCT02110901|DRUG|Placebo|
57749666|NCT04016948|DEVICE|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
57749667|NCT04016948|DEVICE|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
57749668|NCT02178748|BIOLOGICAL|MVA85A|Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
57749669|NCT06580613|OTHER|New model of Hypertension Management|Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
57749670|NCT06580613|OTHER|Control|Hypertension Management as usual
57749671|NCT05821738|DRUG|Avapritinib|administered orally
57749672|NCT02671448|BEHAVIORAL|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
57749673|NCT02671448|BEHAVIORAL|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
57959884|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
57959885|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
57959886|NCT04365465|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
57959887|NCT04365465|DEVICE|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
58314523|NCT00596492|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
58314524|NCT00962598|DRUG|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
58314525|NCT00962598|DIETARY_SUPPLEMENT|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
58314526|NCT03750565|DRUG|TD-1473 - Dose A|oral capsule/tablet, QD
57749674|NCT02671448|BEHAVIORAL|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
57749675|NCT02802800|OTHER|Plyometric training|Plyometric exercises
57749676|NCT04991467|BEHAVIORAL|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
57749677|NCT04991467|BEHAVIORAL|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
58124411|NCT01711021|DRUG|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
58124412|NCT01711021|DRUG|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
58124413|NCT05174611|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
58124414|NCT05174611|OTHER|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
58124415|NCT02744183|BEHAVIORAL|Exercise|Moderate intensity exercise
58124416|NCT02744183|BEHAVIORAL|Breakfast|Breakfast consumption
58124417|NCT02744183|BEHAVIORAL|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
58124418|NCT06117488|DEVICE|endoscopy|gastro duodenal endoscoe
58124419|NCT00002583|DRUG|cisplatin|50 mg/m2 IV
58124420|NCT00002583|DRUG|vinorelbine ditartrate|25 mg/m2 IV
58124421|NCT01016509|DRUG|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.
58124422|NCT01016509|DRUG|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
58124423|NCT02113306|DEVICE|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
58124424|NCT02113306|DEVICE|sham stimulation|electrodes will be put upside down
58124425|NCT02207309|DRUG|Pazopanib|
58124426|NCT02207309|DRUG|Placebo (for Pazopanib)|
58314527|NCT03750565|DRUG|TD-1473 - Dose B|oral capsule/tablet, QD
57749678|NCT04991467|BEHAVIORAL|CARE Program|Participant will take part in 12 week CARE program.
58314528|NCT03750565|DRUG|TD-1473 - Dose C|oral capsule/tablet, QD
57749679|NCT04991467|BEHAVIORAL|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
57749680|NCT04991467|BEHAVIORAL|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
57749681|NCT03468556|DRUG|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
57749682|NCT03468556|DRUG|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
57749683|NCT05502705|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
57749684|NCT05502705|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
57749685|NCT02548767|OTHER|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
57749686|NCT02548767|OTHER|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
57749687|NCT02548767|OTHER|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
57749688|NCT02548767|OTHER|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
57749689|NCT05686005|DRUG|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
57749690|NCT05686005|DRUG|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
57749691|NCT01129388|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
58124427|NCT01093937|DRUG|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
58124428|NCT03965312|DEVICE|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
58124429|NCT03965312|DEVICE|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
58124430|NCT03965312|DEVICE|Patient monitor|Temperature will be measured using a commercially available patient monitor.
58451107|NCT04437485|DRUG|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
58451108|NCT04437485|OTHER|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
58451109|NCT00143910|OTHER|observation|
58451110|NCT04258878|PROCEDURE|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
58451111|NCT03218384|DRUG|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
58451112|NCT03218384|DRUG|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
57749692|NCT01129388|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
57749693|NCT01129388|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
58124431|NCT00487344|PROCEDURE|Non-Personalized Meal Planning|
58124432|NCT00487344|PROCEDURE|Personalized Meal Planning and Dietetic Consultation|
58124433|NCT06456307|BEHAVIORAL|Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)|The intervention includes systematic screening for PMAD symptoms using PHQ-2 and GAD-2, non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) and in-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to PM+
58124434|NCT00662766|DIETARY_SUPPLEMENT|black currant seed press residue|Black currant seed press residue, baked into bread
58314529|NCT03750565|DRUG|Placebo|oral capsule/tablet, QD
58314530|NCT03965364|DEVICE|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
58314531|NCT01544231|BIOLOGICAL|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
58314532|NCT02515786|OTHER|oxygen humidification|humidification for oxygen delivered by nasal catheter
58124435|NCT00662766|DIETARY_SUPPLEMENT|Bread without black currant seed press residues|Same bread but without seeds
58124436|NCT00662766|DIETARY_SUPPLEMENT|Baseline data|No supplement was administered.
58124437|NCT01872143|DEVICE|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
58124438|NCT05528458|DRUG|Osimertinib 80Mg Tab|Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
58124439|NCT03820713|PROCEDURE|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
58314533|NCT05317351|DEVICE|Standard Colonoscopy|Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
58314534|NCT05317351|DEVICE|Artificial Intelligence Aided Colonoscopy (GI Genius™)|Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
58314535|NCT05317351|DEVICE|Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
58314536|NCT05370118|BEHAVIORAL|Telerehabilitation physical activity behavioral (TPAB) intervention|The intervention includes the behavior change techniques of self-monitoring of behavior, action planning, graded tasks, restructuring the physical and social environment, problem-solving, and prompts/cues.
58314537|NCT02993367|DRUG|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
58124440|NCT03820713|PROCEDURE|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
58124441|NCT02238223|DRUG|Alesion®|
57749694|NCT01533493|DRUG|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
57749695|NCT01533493|DRUG|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
57749696|NCT01533493|DRUG|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
57749697|NCT06486532|BEHAVIORAL|HeartBeet Clinic|16 weeks of group based lifestyle medicine coaching covering the six pillars of lifestyle medicine. The six pillars of lifestyle medicine include regular physical activity; a whole-food plant-based diet; restorative sleep; limiting substance use (e.g., tobacco and alcohol use); having meaningful social connections; and stress management. Groups will be led by clinician or health coach expert.
57749698|NCT06486532|BEHAVIORAL|Self-paced education|Self-paced course and workbook with no contact with study clinician or health coach expert
57749699|NCT03676179|PROCEDURE|patella denervation|patella denervation
57749700|NCT03676179|PROCEDURE|patella non-denervation|patella non-denervation
57749701|NCT05101629|DRUG|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
57749702|NCT05101629|DRUG|Lenvatinib Capsules|Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
57749703|NCT01778348|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
57749704|NCT01778348|DEVICE|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
57749705|NCT02139722|BEHAVIORAL|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
57749706|NCT00975845|OTHER|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
57749707|NCT03401684|BEHAVIORAL|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
57749708|NCT04997954|DRUG|MediCabilis CBD oil|"The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~* Cannabis sativa L. dry extract~* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~* 50 mg of Cannabidiol (CBD+CBDA)~* Less than 2 mg tetrahydrocannabinol (THC)~* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut"
57749709|NCT05586594|DIAGNOSTIC_TEST|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
57749710|NCT06174311|BEHAVIORAL|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
57749711|NCT00696410|DRUG|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
57749712|NCT06136975|DEVICE|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
57749713|NCT02489955|DRUG|Amikacin|
58124442|NCT03812081|DEVICE|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
58124443|NCT03812081|DEVICE|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
57749714|NCT02489955|DRUG|Tobramycin|
57749715|NCT02489955|DRUG|Colomycin|
57749716|NCT05195073|BIOLOGICAL|Laparoscopy|3 D laparoscopy
58124444|NCT02324998|DRUG|Olaparib|PARP Inhibitor
58124445|NCT02324998|DRUG|Degarelix|Gonadotrophin releasing hormone blocker
58124446|NCT02631928|DRUG|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
58124447|NCT02631928|DRUG|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
58314538|NCT02993367|DRUG|Placebo Butylphthalide Soft Capsules|
57749717|NCT05350241|OTHER|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
58124448|NCT02270879|PROCEDURE|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
57749718|NCT05350241|OTHER|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
57749719|NCT00035529|DRUG|Placebo|Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
58451113|NCT03218384|DEVICE|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
58451114|NCT04918706|GENETIC|Allogeneic MSC|These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
58451115|NCT04918706|DRUG|Placebo|The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
58451116|NCT04050059|DRUG|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
58451117|NCT04050059|DRUG|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
58451118|NCT02750852|PROCEDURE|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
58451119|NCT00003815|BIOLOGICAL|bleomycin sulfate|
58451120|NCT00003815|DRUG|carmustine|
58451121|NCT00003815|DRUG|cyclophosphamide|
58451122|NCT00003815|DRUG|cytarabine|
58451123|NCT00003815|DRUG|doxorubicin hydrochloride|
57749720|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.
58124449|NCT06015048|DRUG|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
58124450|NCT06015048|DRUG|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
58124451|NCT05803915|DRUG|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
58124452|NCT01290263|DRUG|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
58124453|NCT01290263|DRUG|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
58124454|NCT01595503|PROCEDURE|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
58124455|NCT01595503|PROCEDURE|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
58314539|NCT06158945|DIAGNOSTIC_TEST|urinary endothelin 1|assesment of endothelin 1 in urinary sample
58314540|NCT03638466|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
58314541|NCT03638466|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
58451124|NCT00003815|DRUG|etoposide|
58451125|NCT00003815|DRUG|melphalan|
58451126|NCT00003815|DRUG|prednisolone|
58451127|NCT00003815|DRUG|vincristine sulfate|
58451128|NCT00003815|PROCEDURE|autologous bone marrow transplantation|
58451129|NCT00003815|RADIATION|radiation therapy|
58451130|NCT05757648|DRUG|Non-buffered Anesthetic|non-buffered LA, 2% lidocaine with epinephrine 1:100,000
58451131|NCT05757648|DRUG|Buffered Anesthetic|A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
58451132|NCT05757648|DEVICE|Onset|"The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge."
58451133|NCT06451627|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .
58451134|NCT06451627|DRUG|saline|Saline will be infused at a speed of 0.3mg / kg / h during surgery .
58451135|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
57749721|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.
58124456|NCT00992407|DRUG|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
58124457|NCT00992407|DRUG|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
58451136|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
58451137|NCT01453140|DRUG|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
58451138|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
57749722|NCT03086330|DRUG|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
57749723|NCT03086330|DRUG|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
57749724|NCT04614233|DIETARY_SUPPLEMENT|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
57749725|NCT04614233|DRUG|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
57749726|NCT04462861|DEVICE|Central venous access device (CVAD) Snuggie Securement Device|Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
57749727|NCT04639674|DRUG|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
57749728|NCT03233243|DRUG|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
57749729|NCT05166044|BIOLOGICAL|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
57749730|NCT01523054|DRUG|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
57749731|NCT01523054|DRUG|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
57749732|NCT04746573|DEVICE|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
57749733|NCT02434094|BEHAVIORAL|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
57749734|NCT03343197|DRUG|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
57749735|NCT03343197|DRUG|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
57749736|NCT04143841|DEVICE|Viveye OMNS treatment|The Viveye OMNS treatment ( \~30 min) will be applied once, during the treatment visit only
58124458|NCT05612438|DEVICE|RADIX 2 Stent|RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis \> 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.
58124459|NCT01066052|DRUG|r-hGH|Subcutaneous administration.
58314542|NCT03638466|BEHAVIORAL|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
58314543|NCT03638466|DRUG|SPN-810|Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score
58124460|NCT03199157|DRUG|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
58124461|NCT01530815|DRUG|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
58314544|NCT03638466|DRUG|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
58314545|NCT01202591|DRUG|AZD4547|Tablet oral twice daily
58314546|NCT01202591|DRUG|Exemestane|Tablet oral once daily
58314547|NCT01202591|DRUG|Placebo|Tablet oral twice daily
58314548|NCT01202591|DRUG|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
58314549|NCT06412003|BEHAVIORAL|Home-based balance training|This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
58451139|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
58451140|NCT01453140|DRUG|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
58124462|NCT02370407|DEVICE|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
58124463|NCT02370407|DEVICE|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
58124464|NCT01373775|OTHER|Patient charts reviewing|Reviewing chart and identifying risk factors
58124465|NCT06412133|BEHAVIORAL|photography|This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
58124466|NCT00482547|DEVICE|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
58124467|NCT00482547|DEVICE|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
58124468|NCT05295758|BEHAVIORAL|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
58451141|NCT01082250|DRUG|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
58451142|NCT06166940|OTHER|ROTEM Guided Management|ROTEM guided management of hemostasis after CPB
58451143|NCT05923840|DIAGNOSTIC_TEST|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
58451144|NCT05923840|DIAGNOSTIC_TEST|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
58451145|NCT05923840|DIAGNOSTIC_TEST|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
58451146|NCT00684996|DRUG|etaracizumab|Given IV
58451147|NCT00684996|BIOLOGICAL|bevacizumab|Given IV
58451148|NCT03746327|DRUG|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
58451149|NCT02956343|DEVICE|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
58451150|NCT00590187|DRUG|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
58451151|NCT00590187|DRUG|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
58451152|NCT00590187|DRUG|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
58451153|NCT00590187|DRUG|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
58451154|NCT00590187|DRUG|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
58451155|NCT00590187|DRUG|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
58451156|NCT00590187|DRUG|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
58124469|NCT05966064|DRUG|Denosumab 120 Mg/1.7 Ml Inj|Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
58124470|NCT05966064|DRUG|Placebo|placebo randomized at baseline and after 3 months
58124471|NCT00719290|PROCEDURE|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
58314550|NCT03493971|PROCEDURE|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
58451157|NCT00590187|DRUG|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
58451158|NCT00590187|DRUG|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
58451159|NCT00209859|DRUG|Methotrexate|
58451160|NCT00209859|DRUG|Intraarticular betamethasone|
58451161|NCT00209859|DRUG|Cyclosporine/placebo-cyclosporine|
58124472|NCT00719290|PROCEDURE|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
58314551|NCT03493971|PROCEDURE|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
58451162|NCT03101566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV
58451163|NCT03101566|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV
58451164|NCT03101566|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV
57749737|NCT04143841|DEVICE|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( \~30 min) will be applied once, during the treatment visit only
57749738|NCT05050201|DEVICE|Sleepio|Digital CBT application for insomnia
58124473|NCT03643666|DRUG|dexamethasone|before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
58124474|NCT03643666|DRUG|magnesium sulphate|patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
58124475|NCT03643666|DRUG|Placebo (saline)|before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
58451165|NCT03101566|DRUG|Nivolumab|Nivolumab 360 mg or 240 mg IV
58451166|NCT00226824|DRUG|galantamine|
58451167|NCT05258136|DRUG|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
57749739|NCT02683564|DRUG|BOW015|monoclonal antibody against TNF-alpha
57749740|NCT02683564|DRUG|Remicade|monoclonal antibody against TNF-alpha
57749741|NCT06380218|BEHAVIORAL|Nutrional and physical activity program|Nutritional prevention and physical activity workshops associated with a substitution of saturated and/or trans fatty acids by cis-unsaturated acids via the consumption of Primevère margarine to influence lifestyle habits, quality of life and improvement of the lipid profile of women with cardiovascular risk
57749742|NCT04631263|DEVICE|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
57749743|NCT05724355|DRUG|Dalpiciclib Isetionate Tablets, Camrelizumab|Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
57749744|NCT05548101|PROCEDURE|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
57749745|NCT00895401|DIETARY_SUPPLEMENT|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
57749746|NCT00895401|OTHER|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
57749747|NCT00446381|DRUG|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
57749748|NCT00446381|DRUG|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
57749749|NCT00892112|DRUG|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
57749750|NCT00892112|DRUG|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
57749751|NCT03703466|DRUG|Abemaciclib|Administered orally.
57749752|NCT05061316|DIETARY_SUPPLEMENT|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
57749753|NCT00696384|DRUG|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
58124476|NCT02326077|OTHER|Ultrasound|Monitoring of the mechanism of labor
58124477|NCT02326077|OTHER|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
58124478|NCT02326077|OTHER|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
58124479|NCT01760603|PROCEDURE|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
58314552|NCT04308135|DIAGNOSTIC_TEST|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
58451168|NCT01028417|DEVICE|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
57749754|NCT00696384|DRUG|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
57749755|NCT00696384|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
57749756|NCT03030222|DRUG|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
57749757|NCT03030222|DRUG|Placebo Oral Tablet|Empagliflozin matching placebo
57749758|NCT01530230|DRUG|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
57749759|NCT04918784|DEVICE|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
57749760|NCT04918784|DEVICE|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
57749761|NCT05307848|OTHER|No intervention|No intervention
58124480|NCT00395798|DEVICE|Soft or stiff cervical collar(device), neck school(behavior)|
58124481|NCT00843609|DEVICE|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
58124482|NCT05485675|BEHAVIORAL|Stand & Move at Work|Web-based platform only.
58124483|NCT05485675|BEHAVIORAL|Stand & Move at Work+|Web-based platform and support from an expert facilitator
58124484|NCT03879356|DRUG|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
57749762|NCT02026323|OTHER|acupuncture|acupuncture
57749763|NCT01132326|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
57749764|NCT05854225|DRUG|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
58451169|NCT05882812|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
58451170|NCT05882812|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
57749765|NCT06150365|BIOLOGICAL|KSX01-TCRT cell therapy|Patient autologous T cell therapy
57749766|NCT05148325|DRUG|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
57749767|NCT01621698|PROCEDURE|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
57749768|NCT01621698|PROCEDURE|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
57749769|NCT00254033|DRUG|Dextroamphetamine|
57749770|NCT00254033|DRUG|Methylphenidate|
57749771|NCT00468221|DRUG|Ozone Exposure|Low dose ozone exposure in chamber
57749772|NCT01176487|OTHER|questionnaire administration|
57749773|NCT01176487|PROCEDURE|quality-of-life assessment|
57749774|NCT01176487|RADIATION|3-dimensional conformal radiation therapy|
57749775|NCT01176487|RADIATION|palliative radiation therapy|
58451171|NCT05882812|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
57749776|NCT01176487|RADIATION|whole-brain radiation therapy|
58451172|NCT03433963|DIETARY_SUPPLEMENT|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
58451173|NCT03433963|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
58451174|NCT01867762|DRUG|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
58451175|NCT01867762|DRUG|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
58451176|NCT03159559|DRUG|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
57749777|NCT05361655|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
57749778|NCT05361655|DRUG|Aromatase inhibitor|Aromatase inhibitor therapy
57749779|NCT05806749|COMBINATION_PRODUCT|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
57749780|NCT03116048|OTHER|Chronic pain evaluation|Chronic pain assessment with study questionnaire
57749781|NCT02428322|DIETARY_SUPPLEMENT|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
57749782|NCT02428322|DIETARY_SUPPLEMENT|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
57749783|NCT04415450|BEHAVIORAL|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
57749784|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Energy|Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine
57749785|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Sleep|Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine
57749786|NCT06524674|DIETARY_SUPPLEMENT|Energy Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine
57749787|NCT06524674|OTHER|Sleep Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
57749788|NCT00530595|DRUG|candesartan or valsartan or losartan|
57749789|NCT00331747|DRUG|Glatiramer acetate|
57749790|NCT02678130|DEVICE|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
57749791|NCT02678130|DEVICE|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
58451177|NCT06301451|DEVICE|General dietary guidance and hydrogen water prepared by portable hydrogen rich water machine|The trial group drink the hydrogen water prepared by the experimental equipment on the basis of receiving general dietary guidance.
58451178|NCT00351754|DRUG|Isovue|
58451179|NCT04807686|DEVICE|Auditory simulation|Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.
58451180|NCT05200065|PROCEDURE|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
57749792|NCT06579729|BEHAVIORAL|Dietary intervention for low free sugars|After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.
57749793|NCT03676426|OTHER|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
57749794|NCT03676426|OTHER|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
57749795|NCT00787657|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
57749796|NCT01494428|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
58124485|NCT06074471|PROCEDURE|ultrasound guided supraclavicular brachial plexus block|"Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))"
58124486|NCT05640310|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
58124487|NCT05387265|DRUG|CX-904|CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
58124488|NCT01569152|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
58124489|NCT01569152|DRUG|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
58124490|NCT01569152|DRUG|Methotrexate|MTX dosed at the stable dose receive upon study entry
58124491|NCT00855556|GENETIC|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~1. Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~2. Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~3. No fasting, activity or medication restrictions are required prior to or following blood collection.~4. Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
58124492|NCT05013671|OTHER|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
58124493|NCT05013671|OTHER|balance|compare the balance of residents with BPPV with residents without BPPV
58124494|NCT01316653|BEHAVIORAL|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
58124495|NCT01316653|BEHAVIORAL|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
58124496|NCT04016636|OTHER|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
57749797|NCT01494428|DEVICE|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
58124497|NCT02703077|PROCEDURE|Spyglass|Endoscopic direct view of the bile ducts
58124498|NCT02703077|PROCEDURE|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
58124499|NCT02703077|PROCEDURE|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
58124500|NCT02703077|PROCEDURE|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
57749798|NCT04183270|OTHER|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
57749799|NCT00976352|DRUG|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
57749800|NCT00976352|OTHER|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
57749801|NCT06109792|PROCEDURE|implant supported mandibular overdenture|In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
57959888|NCT04365465|OTHER|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
58124501|NCT02277769|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
58124502|NCT02277769|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
58124503|NCT00506909|DRUG|Oxytocin|20 IU BID or 40 IU BID
58124504|NCT00506909|DRUG|Placebo|20 IU BID or 40 IU BID
58124505|NCT05345132|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
58124506|NCT05345132|DRUG|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
58124507|NCT05961800|BEHAVIORAL|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
58124508|NCT05961800|BEHAVIORAL|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
58124509|NCT05961800|BEHAVIORAL|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
58124510|NCT00648323|DRUG|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
58124511|NCT04113343|DRUG|Remimazolam|Remimazolam via oral administration
58124512|NCT04113343|OTHER|Alcohol|Alcohol
58124513|NCT05156242|DEVICE|Active-tDCS priming MCE|tDCS is used to enhance cortical excitability before motor control exercises.
58124514|NCT05156242|DEVICE|Sham-tDCS priming MCE|tDCS will be set at 0 mA for 20 minutes before motor control exercise.
58124515|NCT05156242|DEVICE|NMES priming MCE|NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.
58124516|NCT05156242|OTHER|Conventional physical therapy|Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
58124517|NCT06130358|OTHER|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
58124518|NCT06130358|OTHER|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
58124519|NCT00676000|PROCEDURE|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
58124520|NCT00676000|PROCEDURE|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
58124521|NCT05137756|OTHER|no intervention|no intervention
57749802|NCT02201914|DRUG|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
57749803|NCT02201914|DRUG|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
57749804|NCT02201914|DRUG|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
57749805|NCT01514214|DEVICE|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
57749806|NCT01514214|DEVICE|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
58124522|NCT01059500|DEVICE|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP \>5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP\>20% consider empiric anticoagulation with heparin if no contraindications.
58124523|NCT06054932|DRUG|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
58124524|NCT06054932|DRUG|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
58124525|NCT00431262|DRUG|antabuse (disulfiram)|
58124526|NCT04251065|DRUG|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade \> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
58124527|NCT00001765|DEVICE|Nexell Isolex with T-cell Depletion|
58124528|NCT00001765|DEVICE|Baxter isolex 300i|
58124529|NCT00612326|PROCEDURE|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
58124530|NCT04669665|DRUG|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
58124531|NCT04669665|DRUG|Placebo|Intranasal placebo
58124532|NCT04669665|OTHER|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
58124533|NCT04669665|DEVICE|Intranasal device|Device to deliver intranasal solution
58124534|NCT01908127|BEHAVIORAL|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
58124535|NCT01908127|BEHAVIORAL|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
58124536|NCT01908127|DRUG|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
58124537|NCT01908127|PROCEDURE|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
58124538|NCT03788499|OTHER|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
58124539|NCT00629616|DRUG|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
58124540|NCT00629616|DRUG|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
58124541|NCT01662466|DRUG|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
58124542|NCT01662466|DIETARY_SUPPLEMENT|DHEA|DHEA 25mg tid
58124543|NCT01662466|DRUG|Placebo|Carrier cream without added testosterone in the identical type of pump
58124544|NCT00858195|DRUG|Indomethacin 75mg Extended-Release Capsules, Sandoz|
58124545|NCT00858195|DRUG|Indocin 75mg SR Capsules|
58124546|NCT05767723|DRUG|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
58124547|NCT05767723|DRUG|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
58124548|NCT00055783|BIOLOGICAL|apolizumab|
58124549|NCT01096290|DRUG|lubiprostone|24mcg BID, capsule, oral 30days
58124550|NCT01096290|DRUG|Matched placebo|Twice daily for 30days, oral
58124551|NCT05339009|BIOLOGICAL|BioADM determination in plasma|BioADM determination in plasma
58124552|NCT02343120|DRUG|Zanubrutinib|Oral administration by capsule
57749807|NCT06240585|OTHER|presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume|presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
58124553|NCT03891056|PROCEDURE|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
58124554|NCT02796235|OTHER|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
57749808|NCT03638895|DEVICE|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
57749809|NCT03638895|BEHAVIORAL|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
57749810|NCT06466850|BIOLOGICAL|Exosome|intra-articular injection is suggested for two times: day 1and day 90
58124555|NCT05664256|OTHER|Build capacity of canteen|"The investigators will conduct 1 day orientation training to the school nurse, principal and canteen managers of the facilities.~Different sessions on basic nutrition concept, healthy eating, healthy cooking practices including purchasing and serving will be conducted.~The investigators will develop training manuals: training curriculum, facilitators guide, and participants guide, aligning with policy contents."
58124556|NCT05664256|OTHER|Information, Education and Communication materials|Posters showing healthy plate model will be displayed on the canteen walls. The fact sheet on healthy eating will be distributed to all the public facilities and make it available at the entrance/ gate of the canteen.
58124557|NCT05664256|OTHER|Monitoring visit|A monitoring team from each municipality will be formed. The monitoring plan will be prepared with the team. At least one monitoring visit from the municipality government with onsite feedback will be done.
58124558|NCT03138070|DRUG|BYL719|BYL719 400 mg daily by mouth continue for 14 days
58124559|NCT06041256|COMBINATION_PRODUCT|AURN001|Corneal Endothelial Cells and Y27632
57749811|NCT01161979|DRUG|Zonisamide|Zonisamide capsules 100 mg
58124560|NCT01531205|DRUG|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
58124561|NCT01531205|DRUG|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m\^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
58124562|NCT01531205|DRUG|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
58124563|NCT01531205|DRUG|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
58124564|NCT01531205|DRUG|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m\^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
58124565|NCT04191239|DEVICE|GE ventilator with two different modes|GE ventilator with two different modes
58124566|NCT05029323|DIAGNOSTIC_TEST|Fast HUTT|Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
58124567|NCT05029323|DIAGNOSTIC_TEST|Conventional HUTT|Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
58124568|NCT05366764|DRUG|SAR443765|solution for injection
58124569|NCT05366764|DRUG|Placebo|solution for injection
58124570|NCT05366764|DRUG|Salbutamol or levosalbutamol|metered dose inhaler
58124571|NCT02928848|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
58124572|NCT04883736|DRUG|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
58124573|NCT04883736|DRUG|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
58124574|NCT04883736|DRUG|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
58124575|NCT00913107|DRUG|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days."
58124576|NCT00913107|DRUG|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days."
58124577|NCT00109109|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
58124578|NCT05557565|DRUG|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
58124579|NCT04366609|DRUG|Methylphenidate|Treatment with methylphenidate through dose escalation
58124580|NCT03504111|PROCEDURE|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
58124581|NCT03504111|PROCEDURE|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
58124582|NCT04356859|DRUG|Albumin Human|Addition of albumin during acute resuscitation following burn injury
58124583|NCT00879242|DRUG|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
58124584|NCT05273619|DRUG|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
58124585|NCT05273619|DRUG|Placebo|4 tablets twice a day
58124586|NCT03979248|DRUG|BMS-986165|Specified dose on specified days.
58124587|NCT03979248|DRUG|Rabeprazole|Specified dose on specified days.
58124588|NCT05361122|DIETARY_SUPPLEMENT|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).
58124589|NCT05361122|DIETARY_SUPPLEMENT|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
58124590|NCT00479622|DRUG|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
58124591|NCT04238520|BEHAVIORAL|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
58124592|NCT04238520|BEHAVIORAL|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
58124593|NCT04384172|DEVICE|Tibial e-stim|For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
58124594|NCT04384172|DEVICE|Genital e-stim|For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
58124595|NCT00436358|OTHER|Not applicable: none|Please refer to the detailed description section
58124596|NCT03967236|OTHER|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
58124597|NCT04627376|OTHER|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
58124598|NCT00942461|PROCEDURE|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
58124599|NCT00942461|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
58124600|NCT01409044|OTHER|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
58124601|NCT01878370|OTHER|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
58124602|NCT01878370|OTHER|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
58124603|NCT00764309|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
58124604|NCT05638503|OTHER|Left ventricular hypertrophy|Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
58124605|NCT05638503|OTHER|Left ventricular non-hypertrophy|Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
58124606|NCT01349439|DRUG|Propranolol|1mg per Kg (participant weight)
58451181|NCT05200065|PROCEDURE|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
58451182|NCT03160339|BIOLOGICAL|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
57749812|NCT01161979|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
57749813|NCT01269996|DRUG|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
58124607|NCT01349439|DRUG|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
58451183|NCT03160339|BIOLOGICAL|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
58451184|NCT02383875|BEHAVIORAL|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
58451185|NCT04528641|BIOLOGICAL|GRAd-COV2|Single intramuscular administration.
58451186|NCT06268535|DRUG|Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023|Disproportionality analysis studying the association between cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.
58451187|NCT00883961|OTHER|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
58124608|NCT05682495|DRUG|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
58124609|NCT05682495|DRUG|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
58124610|NCT05682495|DRUG|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
58124611|NCT05682495|DRUG|ARM D|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
58124612|NCT05682495|DRUG|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
58124613|NCT05682495|DRUG|ARM F|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
58124614|NCT00379548|BEHAVIORAL|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
58124615|NCT02623959|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
58124616|NCT02623959|DRUG|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
58124617|NCT02623959|DRUG|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
58124618|NCT02623959|OTHER|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
58124619|NCT02623959|DRUG|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
58124620|NCT02623959|BEHAVIORAL|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
58124621|NCT04697966|BEHAVIORAL|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
58124622|NCT04697966|BEHAVIORAL|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
58124623|NCT01298570|DRUG|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
58124624|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
58124625|NCT01298570|DRUG|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
58124626|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
58124627|NCT05608356|BIOLOGICAL|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
58124628|NCT05608356|DRUG|Sham Injection|Sham injection as a placebo injection
58124629|NCT01138683|PROCEDURE|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
58124630|NCT01138683|DRUG|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
58124631|NCT00383890|DRUG|Dexmedetomidine HCL Injection|
58451188|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
58451189|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
58451190|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
58451191|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
58451192|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
58124632|NCT00383890|DRUG|Placebo|
58124633|NCT05468229|DRUG|Dorzagliatin|single oral dose of dorzagliatin 50 mg
58124634|NCT05468229|DRUG|Placebo|Matching placebo
58124635|NCT03587207|BIOLOGICAL|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
58124636|NCT03587207|BIOLOGICAL|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group
58124637|NCT03587207|BIOLOGICAL|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
58124638|NCT02949323|OTHER|urinary stone|patients of group one have urinary stones
58124639|NCT03770923|DRUG|Rupatadine|Rupatadine 10 mg daily
58124640|NCT03770923|DRUG|Montelukast|Montelukast 10 mg daily
58124641|NCT01392898|DRUG|liraglutide|liraglutide 1.8 mg q.d.
58124642|NCT01392898|DRUG|Insulin|insulin dosed according titration scheme
58124643|NCT00002252|DRUG|Octreotide|
58124644|NCT02801877|BEHAVIORAL|IntelliCare|
58124645|NCT02801877|BEHAVIORAL|Hub App with the Recommender System|
58451193|NCT01594320|BIOLOGICAL|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 \& Day 21
58451194|NCT02620982|DEVICE|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
58451195|NCT05499377|DEVICE|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
57749814|NCT01269996|DRUG|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
57749815|NCT02001766|BEHAVIORAL|Exercise training|
57749816|NCT02241122|PROCEDURE|prostate biopsy|
57749817|NCT04839965|BIOLOGICAL|Ampion|Ampion administered via intravenous infusion
57749818|NCT04839965|OTHER|Saline|Placebo administered via intravenous infusion
57749819|NCT00238433|BIOLOGICAL|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC\> 1500 for 2 consecutive days.
57749820|NCT00238433|DRUG|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
57749821|NCT00238433|DRUG|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
58124646|NCT02801877|BEHAVIORAL|Coaching|
58124647|NCT03832465|DRUG|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
58124648|NCT03832465|DRUG|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
58124649|NCT03202758|DRUG|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
58124650|NCT01953666|OTHER|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
58124651|NCT01953666|OTHER|Self - Training at home|Only instructions for a self - training at home
58124652|NCT04582396|PROCEDURE|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
58124653|NCT04582396|PROCEDURE|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
58124654|NCT04582396|BEHAVIORAL|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
58124655|NCT03258359|BIOLOGICAL|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
58124656|NCT00100165|DRUG|Placebo|Placebo by mouth twice a day for 4 weeks
58124657|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
58124658|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 75 mg|3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
58124659|NCT04401566|OTHER|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
58124660|NCT04401566|OTHER|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
58451196|NCT00580723|OTHER|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
58451197|NCT04145882|PROCEDURE|additional osteotomies|varisation osteotomy, supination osteotomy or both
58451198|NCT04688359|BEHAVIORAL|Guided Self Determination|Nurse lead intervention in primary care
58451199|NCT05712070|BEHAVIORAL|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
58451200|NCT05712070|BEHAVIORAL|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
58451201|NCT01156714|BEHAVIORAL|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
58451202|NCT01156714|BEHAVIORAL|Memory training with computerized memory program|memory testing and training on computer program
58451203|NCT01156714|BEHAVIORAL|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
58451204|NCT00966511|PROCEDURE|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
58451205|NCT01787461|DIETARY_SUPPLEMENT|Imedeen|Two tablets per day for 6 months
58451206|NCT01787461|DIETARY_SUPPLEMENT|Placebo|Two tablets per day for 6 months
58451207|NCT02354235|DRUG|Teneligliptin|
58451208|NCT02354235|DRUG|Canagliflozin|
58451209|NCT02354235|DRUG|Placebo|
58451210|NCT00463255|BEHAVIORAL|diet|
58451211|NCT04709042|PROCEDURE|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
58451212|NCT04709042|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
58451213|NCT01011673|DRUG|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
58451214|NCT01011673|DRUG|Ketorolac|ketorolac 30mg IVSS
58451215|NCT05435664|BEHAVIORAL|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
58124661|NCT04401566|OTHER|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
58124662|NCT03335371|DRUG|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
58451216|NCT02282280|DRUG|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
58451217|NCT02582645|PROCEDURE|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
58451218|NCT02582645|PROCEDURE|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
58451219|NCT03380897|OTHER|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
58451220|NCT03380897|OTHER|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
58451221|NCT04140396|DRUG|Saline infusion|Normal saline infusion at 10mL/hour
58451222|NCT04140396|DRUG|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
58451223|NCT01425034|OTHER|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
57749822|NCT00238433|DRUG|thiotepa|250 mg/m2/day/iv on days -3 and -2
57749823|NCT00238433|PROCEDURE|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
58451224|NCT01425034|OTHER|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
58451225|NCT05189470|PROCEDURE|Inforatio technique|Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
58451226|NCT05189470|OTHER|Usual care of the respective outpatient clinics|Usual care of the DFUs includes local wound care and offloading treatment.
58451227|NCT04073186|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
58124663|NCT03335371|DRUG|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
58124664|NCT03335371|DRUG|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
58124665|NCT03707873|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
58124666|NCT00602030|DRUG|Entinostat|Entinostat tablets on Days 1 and 15 of a 28-day cycle.
58124667|NCT00602030|DRUG|Placebo|Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
58124668|NCT00602030|DRUG|Erlotinib|Erlotinib 150 mg tablets once daily.
58124669|NCT03943251|DRUG|HEC113995PA•H2O tablet|2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
58124670|NCT03943251|DRUG|Placebo tablet|2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
58124671|NCT05915052|PROCEDURE|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
58124672|NCT05915052|PROCEDURE|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
58124673|NCT05755425|DEVICE|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
58124674|NCT05755425|DEVICE|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
58124675|NCT04164953|PROCEDURE|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
58124676|NCT06358183|OTHER|No intervention|no intervention used
58124677|NCT04554654|DIAGNOSTIC_TEST|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
58124678|NCT04464044|DEVICE|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
58124679|NCT00531206|DRUG|Tipranavir|
58124680|NCT00531206|DRUG|Ritonavir|low dose
58124681|NCT01346852|DRUG|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
58124682|NCT06233253|OTHER|Best Practice|Receive usual care
58124683|NCT06233253|OTHER|Medical Chart Review|Ancillary studies
58124684|NCT06233253|BEHAVIORAL|Online Mindfulness Meditation|Receive an online mindfulness intervention
58124685|NCT06233253|OTHER|Survey Administration|Ancillary studies
58124686|NCT06312683|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
58124687|NCT01816477|DEVICE|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
58451228|NCT03636217|OTHER|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
58451229|NCT03636217|OTHER|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
58124688|NCT01816477|DRUG|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
58124689|NCT06388980|OTHER|Validated questionnaires and ad hoc questions|validated questionnaires and open questions online through the institution's intranet anonymous
58124690|NCT02347670|BEHAVIORAL|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
58451230|NCT03636217|OTHER|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
58451231|NCT02289677|DEVICE|ATMOS Scope|Video-laryngoscopy 1
58451232|NCT02289677|DEVICE|COOPDECH|Video-laryngoscopy-1
58451233|NCT02289677|DEVICE|AirTraq|Optical-laryngoscopy
58124691|NCT02347670|BEHAVIORAL|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
58124692|NCT00655642|DRUG|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
58124693|NCT00655642|DRUG|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
58124694|NCT00655642|DRUG|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
58124695|NCT00655642|DRUG|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
58124696|NCT02309749|OTHER|CAP|
58124697|NCT02799602|DRUG|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
58124698|NCT02799602|DRUG|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
58124699|NCT02799602|DRUG|Docetaxel|As prescribed by the treating physician.
58124700|NCT02799602|DRUG|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
58124701|NCT00670956|DRUG|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
58124702|NCT00670956|DRUG|Placebo|PLACEBO: IM x 2 doses 24 hours apart
58124703|NCT00536575|DRUG|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
58451234|NCT05266417|DRUG|INS-GSH|Intranasal INS-GSH Twice Daily
58451235|NCT05266417|DRUG|Matched Placebos|Intranasal Matched Placebos Twice Daily
58451236|NCT03064646|OTHER|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
58451237|NCT00251459|DRUG|rhuFab V2 (ranibizumab)|
58451238|NCT04528160|OTHER|Pain neuroscience education and exercise|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
58451239|NCT04528160|OTHER|Usual Care|Usual care delivered at primary care for older adults with pain.
58451240|NCT01276262|DRUG|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
58451241|NCT01276262|DRUG|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
58124704|NCT00536575|DRUG|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
58124705|NCT04488575|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbe
58451242|NCT01276262|DRUG|Placebo|Oral tablets BID, repeated doses for 21 days
58451243|NCT01395732|DRUG|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
58451244|NCT02181114|BEHAVIORAL|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
58451245|NCT02545608|DEVICE|Restylane Vital|
58451246|NCT06097026|PROCEDURE|Alveolar recruitment maneuver|Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.
58451247|NCT06097026|DRUG|Nitric Oxide|Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
58451248|NCT02907762|DEVICE|Endovascular aneurysm repair EVAR|
58124706|NCT04488575|DRUG|Placebo|Placebo oral capsule
58451249|NCT05315492|BEHAVIORAL|Community Care Consortium (CCC)|The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
58124707|NCT02382666|DRUG|Rolapitant|
58124708|NCT00198081|DRUG|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
58124709|NCT00198081|DRUG|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
58124710|NCT02105376|DEVICE|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
58124711|NCT05132413|DRUG|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
58124712|NCT05132413|DRUG|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
58124713|NCT05132413|DRUG|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
58124714|NCT00836836|OTHER|Modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
58124715|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)"
58124716|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient & soy protein supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)"
58451250|NCT02688244|PROCEDURE|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
58124717|NCT02975089|DIETARY_SUPPLEMENT|Nutrition education on balanced diet & food supplement|"1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)"
58124718|NCT03870997|BEHAVIORAL|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
58124719|NCT03870997|BEHAVIORAL|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
58124720|NCT01141725|DRUG|bendamustine hydrochloride|Given IV
58124721|NCT01141725|DRUG|idarubicin|Given IV
58124722|NCT04792528|OTHER|Computerized cognitive training.|COGMED RM program (Pearson Inc., UK)
58124723|NCT04792528|OTHER|Generalized brain training / Active control|Solitaire
58124724|NCT02672553|DEVICE|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
58124725|NCT02672553|DEVICE|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
58124726|NCT04217278|DRUG|Vyxeos|Vyxeos administered by intravenous infusion
58124727|NCT04217278|DRUG|Fludarabine|Fludarabine administered by intravenous infusion
58124728|NCT04217278|DRUG|Busulphan|Busulphan administered by intravenous infusion
58124729|NCT04217278|DRUG|Thiotepa|Thiotepa administered by intravenous infusion
58124730|NCT04217278|DRUG|Cytarabine|Cytarabine administered by intravenous infusion
58124731|NCT00046813|DRUG|Nicotine patch|
58124732|NCT00940056|PROCEDURE|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
58451251|NCT02688244|PROCEDURE|No irrigation|Suction only, using suction device
58451252|NCT05247086|DEVICE|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
58451253|NCT03725631|DIAGNOSTIC_TEST|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
57749824|NCT00238433|PROCEDURE|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
57749825|NCT05305287|DRUG|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
57749826|NCT05305287|OTHER|Placebo|Placebo for pioglitazone
57749827|NCT05853679|DEVICE|Lumoral Treatment|The device will be used 5 to 7 times per week according to the manufacturer's instructions.
57749828|NCT05853679|OTHER|Standard oral hygiene instructions according to the Finnish Dental Association|Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
58124733|NCT00940056|DRUG|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
58451254|NCT00150267|DRUG|Xalacom|
58451255|NCT04538638|PROCEDURE|Mesenteric sparing ileocolic resection|Mesentery left in situ
58451256|NCT04538638|PROCEDURE|Central mesenterectomy ileocolic resection|Mesentery is taken up to the level of the ileocolic trunk
58451257|NCT04105049|OTHER|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
57749829|NCT02332720|DRUG|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
57749830|NCT02332720|DRUG|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
57749831|NCT02332720|DRUG|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
58124734|NCT01349556|DRUG|Tretinoin|tretinoin 0.025% cream
58124735|NCT05611749|DRUG|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
58124736|NCT05611749|OTHER|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
58124737|NCT05654909|PROCEDURE|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
58124738|NCT06322927|OTHER|Patient Interview|Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
58124739|NCT02337465|DEVICE|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
58124740|NCT02337465|RADIATION|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
58124741|NCT02946099|PROCEDURE|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
58124742|NCT02946099|PROCEDURE|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
58124743|NCT03565549|BEHAVIORAL|Mnemonic|A mnemonic used as a memory aid
58124744|NCT03565549|BEHAVIORAL|CCHR rule|A list of the CCHR items
58451258|NCT04618003|BEHAVIORAL|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
58451259|NCT03485066|BEHAVIORAL|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
58124745|NCT04068142|OTHER|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
58124746|NCT01493765|OTHER|Simulator training with expert scoring|Residents will be trained using surgical simulation
58124747|NCT00133770|DRUG|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
58124748|NCT03532009|DRUG|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
58124749|NCT03532009|DRUG|Placebo|Oral use for approximately 3 months
58124750|NCT04924309|OTHER|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
57749832|NCT02332720|DRUG|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
57749833|NCT02332720|DRUG|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
57749834|NCT02332720|DRUG|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
57749835|NCT03124979|DEVICE|LNCS DBI Sensor|Noninvasive Measurement of SpO2
57749836|NCT02414542|DEVICE|MINIMA stem|
57749837|NCT00900068|OTHER|immunoenzyme technique|
57749838|NCT00900068|OTHER|laboratory biomarker analysis|
58124751|NCT01173809|DRUG|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
58124752|NCT01173809|DRUG|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
58124753|NCT03065309|DRUG|Remifentanil|bolus dose
58451260|NCT02870283|DRUG|Lithium|
58124754|NCT01000753|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58124755|NCT02405195|PROCEDURE|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
58124756|NCT05431868|OTHER|AT LISA tri 839MP (Carl Zeiss Meditec AG)|This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
58451261|NCT02870283|DRUG|Valproic Acid|
58124757|NCT00450307|BIOLOGICAL|monoclonal antibody 3F8|
58451262|NCT02870283|DRUG|Carbamazepine|
58451263|NCT01101035|DRUG|Febuxostat|Febuxostat tablets
58451264|NCT01101035|DRUG|Allopurinol|Allopurinol tablets
58451265|NCT04113317|DRUG|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
58124758|NCT00450307|BIOLOGICAL|sargramostim|
58451266|NCT06173414|OTHER|No intervention measures|No intervention measures
58451267|NCT01485159|PROCEDURE|Spirometry|assessment of lung function by spirometry
57749839|NCT00900068|OTHER|medical chart review|
57749840|NCT06412627|PROCEDURE|4°C frozen normal saline gauze|Soak two 4x4 gauze pads in 15 ml of normal saline, refrigerate at 4°C, and then apply in the oral cavity for 15 minutes before removal.
57749841|NCT00135369|DRUG|stavudine extended-release, lamivudine, efavirenz|
57749842|NCT00439205|DEVICE|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
57749843|NCT00439205|DEVICE|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
57749844|NCT01171326|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
57749845|NCT00269035|DRUG|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
57749846|NCT00269035|DRUG|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
57749847|NCT02126501|OTHER|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
57749848|NCT03338894|BEHAVIORAL|Yoga|1 Hour yoga class
57749849|NCT05676580|PROCEDURE|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
57749850|NCT05676580|OTHER|abstention|No surgery
57749851|NCT06073730|PROCEDURE|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
57749852|NCT06073730|PROCEDURE|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
57749853|NCT03119324|DEVICE|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
57749854|NCT03119324|DEVICE|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
58451268|NCT03324243|DRUG|Crenolanib|66.7 mg/m2 three times a day (TID)
58451269|NCT03324243|DRUG|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
58451270|NCT03324243|DRUG|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
58451271|NCT00988884|BIOLOGICAL|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
58451272|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
58124759|NCT00376220|DRUG|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
58124760|NCT00376220|OTHER|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
58124761|NCT06460714|OTHER|Shock wave therapy, stretching and orthosis|Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
58124762|NCT06460714|OTHER|Stretching, strengthening and orthosis|In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
58124763|NCT03879200|OTHER|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
58124764|NCT04375254|OTHER|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
58124765|NCT00274703|DRUG|mepolizumab|
57749855|NCT03119324|DRUG|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
58124766|NCT04447638|PROCEDURE|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
58124767|NCT03203148|DIAGNOSTIC_TEST|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
58124768|NCT01652365|BEHAVIORAL|RDT Training and Subsidy Offered|
58124769|NCT01652365|BEHAVIORAL|Information/Education Campaign|
58314553|NCT04308135|DIAGNOSTIC_TEST|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
58314554|NCT04308135|DIAGNOSTIC_TEST|lab investigations|Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
58314555|NCT04308135|DIAGNOSTIC_TEST|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
57749856|NCT01829438|BEHAVIORAL|Listening to fast music|
57749857|NCT01829438|BEHAVIORAL|Listening to preferred music|
57749858|NCT01829438|BEHAVIORAL|Listening to slow music|
57749859|NCT03037450|PROCEDURE|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
57749860|NCT03905330|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
57749861|NCT03905330|OTHER|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
58124770|NCT04238767|DRUG|Dolutegravir|Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
58124771|NCT03457909|DEVICE|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
58124772|NCT04809181|DRUG|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
58124773|NCT04419337|DRUG|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
58124774|NCT04442906|DRUG|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
58124775|NCT04442906|DRUG|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
57749862|NCT04584229|OTHER|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
58124776|NCT04442906|DRUG|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
58124777|NCT03231670|PROCEDURE|Blood sampling|5ml blood will be taken in addition to standard sampling
58124778|NCT00963157|DRUG|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
58124779|NCT00963157|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
58124780|NCT04655599|DRUG|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
58124781|NCT04655599|DRUG|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
58124782|NCT00989261|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
58124783|NCT04303338|PROCEDURE|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
58124784|NCT03272256|DRUG|IM156|Sequential 3+3 design.
58124785|NCT02222766|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
58124786|NCT02222766|BEHAVIORAL|Control|Minimal attention control- 9 weekly mailed information on general child development
58124787|NCT00522613|BEHAVIORAL|Recovery Group Project|Recovery Group Workbook \& Group Sessions
58124788|NCT00006075|DRUG|Chlorhexidine gluconate|
58124789|NCT03478059|BEHAVIORAL|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
58124790|NCT05745298|DEVICE|Xcite Clinical Station|The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
58124791|NCT01251926|DRUG|EZN-2208|
58124792|NCT01251926|DRUG|Bevacizumab|
58124793|NCT02140450|DRUG|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
58451273|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
58451274|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
58451275|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
58451276|NCT01528930|DRUG|Amikacin|500 mg, once daily for 2 years
57749863|NCT01514448|DRUG|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
58124794|NCT02140450|DRUG|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
58124795|NCT02140450|DRUG|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
58124796|NCT02140450|DRUG|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
58124797|NCT02140450|DRUG|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
58124798|NCT00878254|BIOLOGICAL|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
58124799|NCT00878254|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.
58124800|NCT00878254|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
58124801|NCT00878254|DRUG|Cytarabine|Cytarabine 2 grams/m\^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.
58124802|NCT00878254|DRUG|Doxorubicin|Doxorubicin 45 mg/m\^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.
58124803|NCT00878254|DRUG|Etoposide|Etoposide 60 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
58124804|NCT00878254|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
58124805|NCT00878254|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3 per study protocol.
58124806|NCT00878254|DRUG|Mesna|Mesna 360 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
58124807|NCT00878254|DRUG|Methotrexate|Methotrexate 1,200 mg/m\^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
58124808|NCT00878254|DRUG|Vincristine|Vincristine 1.5 mg/m\^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
58124809|NCT01904786|DRUG|Melatonin|
58451277|NCT03868033|DRUG|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
58451278|NCT03868033|DRUG|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
58451279|NCT06393075|BEHAVIORAL|combined care guidance|Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
58451280|NCT06393075|BEHAVIORAL|general care guidance|general care guidance
58451281|NCT02023307|DEVICE|V-Loc Suture|
57749864|NCT00945464|OTHER|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
57749865|NCT02239393|BIOLOGICAL|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
58124810|NCT01904786|DRUG|placebo|
57749866|NCT00365391|BIOLOGICAL|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
57749867|NCT00365391|DRUG|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
57749868|NCT06059105|DEVICE|Immediate Implant Surgery|Inverted Co-Axis 12º Southern Implants
58124811|NCT01496040|DRUG|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
58314556|NCT04308135|DIAGNOSTIC_TEST|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
58314557|NCT04308135|DIAGNOSTIC_TEST|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test."
57749869|NCT06059105|DEVICE|Immediate Implant Surgery|Internal Conical (Deep Tapered Conical) South Implants
57749870|NCT00814294|DRUG|placebo|placebo capsule,0 units, quater in die (QID) for 18 weeks
57749871|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
57749872|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
57749873|NCT01766622|DRUG|[18F]-CP18|7mCi, IV (in the vein) at baseline
57749874|NCT01766622|PROCEDURE|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third \[18F\]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
57749875|NCT05388500|DRUG|Paclitaxel + Trastuzumab|"Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
57749876|NCT05388500|DRUG|Trastuzumab|"Regarding neoadjuvant treatment :~- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
57749877|NCT01024608|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
57749878|NCT01024608|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
57749879|NCT04489043|OTHER|Exercise and healthy lifestyle recommendations|In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
58124812|NCT03338361|BEHAVIORAL|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
58124813|NCT03338361|BEHAVIORAL|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
58124814|NCT03338361|BEHAVIORAL|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
58124815|NCT03338361|BEHAVIORAL|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
58124816|NCT04963465|DIAGNOSTIC_TEST|Ferning on microscopy|Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
58124817|NCT03960697|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
58314558|NCT04308135|DIAGNOSTIC_TEST|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
58314559|NCT04308135|DIAGNOSTIC_TEST|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
58314560|NCT04308135|DIAGNOSTIC_TEST|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
58314561|NCT04308135|OTHER|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
58124818|NCT04983121|DRUG|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
57749880|NCT01002872|DRUG|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
58124819|NCT02380846|OTHER|White rice|Control - white rice
58124820|NCT02380846|OTHER|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
58124821|NCT02380846|OTHER|Rice with fish|Treatment 2 - steamed white rice with steamed fish
58124822|NCT02380846|OTHER|Rice with egg white|Treatment 3 - steamed white rice with egg white
58124823|NCT02380846|OTHER|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
58124824|NCT04566835|OTHER|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
57749881|NCT01002872|DRUG|placebo|Initial dose of placebo will be 1 pill three times a day
57749882|NCT01876316|DRUG|Moxifloxacin|single oral administration of 400mg of moxifloxacin
58124825|NCT04566835|BEHAVIORAL|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
57749883|NCT01876316|DRUG|Placebo|single oral administration of 400mg of placebo
58314562|NCT04308135|OTHER|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
58314563|NCT04308135|OTHER|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
58314564|NCT02254824|DRUG|Xuezhikang|Xuezhikang
58314565|NCT02254824|DRUG|Atorvastatin|Atorvastatin
58314566|NCT02254824|BEHAVIORAL|Lifestyle modification|Lifestyle modification
58314567|NCT04270955|PROCEDURE|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
58314568|NCT04270955|PROCEDURE|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
58314569|NCT00315367|DRUG|Donepezil HCI (drug)|
58314570|NCT00765076|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
58314571|NCT00765076|BIOLOGICAL|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
58314572|NCT02251639|BEHAVIORAL|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
58314573|NCT02251639|DEVICE|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
58314574|NCT02251639|PROCEDURE|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
58451282|NCT06206460|OTHER|Online Assessment|"Online Assessment which consists of:~* Sociodemographic data (life changes, medical and gynaecological history)~* German PMS symptom diary retrospectively for last menstrual cycle~* Quality of Life Inventory (SF-12)~* Expectancy of relief"
57749884|NCT02329548|OTHER|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
57749885|NCT03404310|DIETARY_SUPPLEMENT|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
57749886|NCT03404310|OTHER|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
57749887|NCT04721925|BEHAVIORAL|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
57749888|NCT01304030|BEHAVIORAL|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
58124826|NCT03697421|OTHER|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
58124827|NCT03697421|OTHER|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
58124828|NCT02101632|DIETARY_SUPPLEMENT|Bee Venom Ointment|2 weeks
58124829|NCT02101632|OTHER|Vaseline Ointment|2 weeks
58124830|NCT03197402|DIETARY_SUPPLEMENT|Leucine-enriched protein gel delivery system|Leucine enriched
58124831|NCT03197402|DIETARY_SUPPLEMENT|Milk protein gel delivery system|Non-leucine enriched
58124832|NCT02368613|DRUG|DW-3102|
58451283|NCT04801758|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
57749889|NCT01304030|BEHAVIORAL|Residency Training as usual|Residents will receive their typical didactic and clinical education
57959889|NCT06549374|OTHER|blood sampling|"After informing eligible patients (or their trusted support person, relative/guardian/curator where applicable) and in the absence of any opposition, they are included in the research.~Blood samples from an arterial catheter already in place will be taken every day from D1 to D7, then every 72 hours until discharge from intensive care, or until D28. For each of these samples, a maximum volume of 4 ml will be collected in a heparinized tube. Samples will not be taken if the hemoglobin level is below 7g/dl. For patients undergoing controlled surgery, the D1 sample will be taken as soon as possible after induction of anaesthesia.~Patients will be monitored until discharge from intensive care, or until D28 at the latest. Apart from the blood samples included in this study, all other examinations will be carried out as part of routine management. Data will be collected exclusively from medical records."
57959890|NCT01679210|BEHAVIORAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
57959891|NCT03109171|OTHER|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
57959892|NCT00846014|DRUG|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
57959893|NCT05148975|DIAGNOSTIC_TEST|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
57959894|NCT03353857|DRUG|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
57959895|NCT03353857|DRUG|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
57959896|NCT03353857|DRUG|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
57959897|NCT03353857|DRUG|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
57959898|NCT03353857|DRUG|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
57959899|NCT03353857|DRUG|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
57959900|NCT03353857|DRUG|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
57959901|NCT01031446|DRUG|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
57959902|NCT01031446|DRUG|everolimus|Taken daily by mouth.
57959903|NCT01031446|DRUG|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
57959904|NCT01031446|OTHER|laboratory biomarker analysis|Blood collection
58124833|NCT04357275|OTHER|ICU treatment|ICU treatment according to standard of care
58124834|NCT03464136|BIOLOGICAL|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
58124835|NCT03464136|BIOLOGICAL|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
58124836|NCT03464136|BIOLOGICAL|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
58124837|NCT03464136|BIOLOGICAL|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
58124838|NCT03464136|BIOLOGICAL|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
58124839|NCT02627911|DEVICE|Diabeloop System|Insulin delivery
58124840|NCT02627911|DEVICE|Continuous Glucose Monitoring|
58124841|NCT02627911|DEVICE|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
58124842|NCT02627911|DIETARY_SUPPLEMENT|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
58124843|NCT03182179|DRUG|Ondansetron 4 MG|Ondansetron is taken orally BD
58124844|NCT03182179|DRUG|Placebo|Placebo is taken orally BD
58124845|NCT02531932|DRUG|Carboplatin|Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
58124846|NCT02531932|DRUG|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
58451284|NCT02483780|BEHAVIORAL|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
57749890|NCT00826306|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
57749891|NCT05773118|DEVICE|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
57749892|NCT05773118|DEVICE|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
57749893|NCT05773118|DEVICE|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
57749894|NCT01313702|DRUG|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
58124847|NCT03674710|PROCEDURE|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58124848|NCT03674710|PROCEDURE|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58314575|NCT04069858|DRUG|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
58451285|NCT00503269|PROCEDURE|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
58451286|NCT00503269|PROCEDURE|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
58451287|NCT04220346|OTHER|Tablet group|Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
58451288|NCT04400058|BIOLOGICAL|Octagam 10%|Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
58451289|NCT04400058|OTHER|Saline Solution|Placebo
57749895|NCT01313702|DRUG|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
57749896|NCT01313702|DRUG|usual care|the drugs used in clinical practice, defined by physician
57749897|NCT04710082|PROCEDURE|Photorefractive keratectomy (PRK)|Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
57749898|NCT02885987|DEVICE|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
57959905|NCT06312072|OTHER|No intervention; observational study|No intervention; observational study
57959906|NCT01568814|DRUG|Low volume PEG|low volume polyethylene glycol 2 liter one time
57959907|NCT01568814|DRUG|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
57959908|NCT06008990|DRUG|Buprenorphine|Pregnant mother must be taking Buprenorphine
57959909|NCT06008990|DIAGNOSTIC_TEST|Maternal Brain MRI|Maternal Brain MRI obtained between 24-32 week gestation
57959910|NCT06008990|OTHER|Blood Samples|During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
57959911|NCT06008990|BEHAVIORAL|Questionnaires|Participants will answer questionnaires about their medical history, pregnancy, and substance use.
57959912|NCT06537115|BEHAVIORAL|exercise|progressive resistance exercise
57959913|NCT06537115|DIETARY_SUPPLEMENT|whey protein powder|The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
57959914|NCT06537115|DRUG|Eldecalcitol|Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
57959915|NCT03548051|PROCEDURE|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
57959916|NCT03548051|DRUG|Saline|250 ml of saline delivered by retention enema
57959917|NCT01675960|DRUG|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
57959918|NCT01675960|DRUG|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
57959919|NCT02956993|DRUG|vonapanitase|
57959920|NCT02956993|DRUG|Placebo|
57959921|NCT04377737|DIAGNOSTIC_TEST|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
58124849|NCT03674710|PROCEDURE|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58124850|NCT03674710|PROCEDURE|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58124851|NCT03674710|PROCEDURE|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58124852|NCT03674710|PROCEDURE|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
58124853|NCT05320263|PROCEDURE|Contact aspiration Thrombectomy|"The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature."
58124854|NCT05320263|PROCEDURE|Stent retriever thrombectomy|The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
58124855|NCT06484946|OTHER|aquatic occupational therapy|Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
58314576|NCT02513875|DIETARY_SUPPLEMENT|vitamin D|60,000 IU per week for 8 weeks
58314577|NCT02513875|DIETARY_SUPPLEMENT|Placebo|placebo +diet and lifestyle
58451290|NCT01582620|PROCEDURE|Telestroke|remote videoconference consultations
58451291|NCT02124213|DRUG|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
58451292|NCT02124213|DRUG|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
58451293|NCT02124213|DRUG|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
57749899|NCT04502576|DEVICE|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
57749900|NCT05079074|DIAGNOSTIC_TEST|ctDNA testing|ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
57749901|NCT05559502|DEVICE|HFNO group|HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.
57749902|NCT05559502|DEVICE|ET group|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
57749903|NCT06579898|OTHER|Progressive resistance exercise training|A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.
57749904|NCT04169308|DRUG|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
57749905|NCT05488132|DRUG|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
57749906|NCT04749732|BEHAVIORAL|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
57749907|NCT04749732|BEHAVIORAL|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
57749908|NCT04749732|BEHAVIORAL|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
57749909|NCT03645759|BEHAVIORAL|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
58124856|NCT05705713|RADIATION|chest computed tomography (CT)|Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
58124857|NCT01911494|BEHAVIORAL|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
58124858|NCT01911494|DEVICE|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
58124859|NCT01911494|DRUG|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
58124860|NCT01911494|DRUG|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
58124861|NCT03336541|DRUG|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
58124862|NCT03336541|DRUG|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
58124863|NCT02879279|DEVICE|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
58124864|NCT02879279|OTHER|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
58124865|NCT05936749|GENETIC|Pre-implantation genetic testing|
58124866|NCT03916952|DIAGNOSTIC_TEST|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
58124867|NCT02889185|DEVICE|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
58124868|NCT00158119|BEHAVIORAL|InVEST (Increased Velocity Exercise Specific to Task)|
58124869|NCT04042532|DEVICE|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
58124870|NCT04695405|GENETIC|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
58124871|NCT00215319|DEVICE|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
58124872|NCT00277745|DEVICE|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
58124873|NCT03492359|DEVICE|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
58124874|NCT03492359|DEVICE|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
58124875|NCT03492359|DEVICE|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
58124876|NCT02247479|DRUG|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
58124877|NCT02247479|OTHER|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
58124878|NCT03562442|BEHAVIORAL|Smoking cessation|Smoking cessation with or without professional / medical support
58124879|NCT03082274|DIAGNOSTIC_TEST|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
58124880|NCT03082274|DIAGNOSTIC_TEST|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
58124881|NCT05256628|OTHER|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
58124882|NCT05256628|OTHER|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
58451294|NCT05417737|OTHER|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
58124883|NCT00446732|DEVICE|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
58124884|NCT00439075|PROCEDURE|CPAP|
58124885|NCT00439075|DRUG|standard treatment|
58124886|NCT00964626|DRUG|cisplatin|
58124887|NCT00964626|DRUG|paclitaxel|
58124888|NCT06546215|DRUG|Digoxin|Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
58124889|NCT00139321|DEVICE|Force platform and electromyography|
58124890|NCT06046664|DIAGNOSTIC_TEST|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
58124891|NCT01978678|DRUG|Pulmicort|ACQ and FeNO
58124892|NCT04807842|DEVICE|vaginal gel|The placebo gel is a non-buffered gel. The active device is an acidic gel.
58124893|NCT01699607|DRUG|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
58124894|NCT05925790|DIAGNOSTIC_TEST|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described \[Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527\].
58124895|NCT05925790|DIAGNOSTIC_TEST|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
58124896|NCT06044181|PROCEDURE|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
58124897|NCT05130892|DRUG|Colchicine|1 tablet (0.5mg) / time, once a day
57749910|NCT03645759|OTHER|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
57749911|NCT04128644|BEHAVIORAL|Thoughts & health|12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
58124898|NCT05130892|DRUG|Tranilast|1 capsule (0.1g) / time, 3 times a day
58124899|NCT05130892|DRUG|Oridonin|2 tablets (0.5g) / time, 3 times a day;
58124900|NCT02287168|PROCEDURE|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
58124901|NCT02287168|PROCEDURE|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
58124902|NCT02287168|PROCEDURE|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
57749912|NCT04128644|OTHER|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
58124903|NCT02141100|DRUG|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
58124904|NCT05749627|DRUG|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
57749913|NCT00558311|DRUG|Clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h
57749914|NCT00558311|DRUG|Placebo|Placebo administered by continuous infusion matching clazosentan administration
57749915|NCT00136955|DRUG|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
57749916|NCT00099892|DRUG|vildagliptin|
57749917|NCT05374226|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
58124905|NCT05749627|DRUG|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
58124906|NCT03972566|DRUG|INOMAX|INOMAX + PBM
58124907|NCT06496919|DRUG|Recombinant Mutant Human Tumor Necrosis Factor|The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
58124908|NCT04721756|DRUG|18F-LY3546117 Injection|370 megabecquerel (MBq) intravenous injection
58124909|NCT04721756|PROCEDURE|PET Scan|positron emission tomography (PET) scan
58124910|NCT01564433|PROCEDURE|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
58124911|NCT01564433|PROCEDURE|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
58124912|NCT05803018|DRUG|BL-B01D1|Administration by intravenous infusion
58124913|NCT05292742|DRUG|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
58124914|NCT05292742|DRUG|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
58124915|NCT02773836|OTHER|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
58124916|NCT00930865|DRUG|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
58124917|NCT00930865|DRUG|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
58124918|NCT05718609|DRUG|Rabeprazole|proton-pump inhibitor (PPI)
58124919|NCT05718609|DRUG|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
58124920|NCT05718609|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
58124921|NCT05718609|DRUG|Furazolidone|Antibiotic for H. pylori eradication
58124922|NCT05718609|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
58124923|NCT03202225|DEVICE|constrained polyethylene|constrained polyethylene insert
58124924|NCT03706638|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
58124925|NCT05042856|PROCEDURE|PanOptix IOL implantation|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
58124926|NCT03630666|DRUG|IADT|Patient will receive one injection of IADT at randomization
58124927|NCT03630666|COMBINATION_PRODUCT|IADT + radiotherapy|Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
58124928|NCT01361126|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
58124929|NCT03286582|DRUG|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
58124930|NCT03286582|DRUG|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
58124931|NCT03890185|COMBINATION_PRODUCT|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
58124932|NCT03890185|DRUG|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
58124933|NCT03340168|OTHER|Bisphenol-S|Oral and dermal exposure in volunteers
58124934|NCT06141096|DRUG|MB07133|Evaluate the effectiveness and safety of different doses of MB07133
58124935|NCT05103722|OTHER|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
58124936|NCT05533346|BEHAVIORAL|with WISE (Walking Instruction based on Self-Efficacy)|Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
58124937|NCT05533346|BEHAVIORAL|without WISE (Walking Instruction based on Self-Efficacy)|The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
58124938|NCT06441435|DIETARY_SUPPLEMENT|Low protein diet with AC-134|Low protein diet combined with AC-134 Dosage: 2 capsules,three times/day
58124939|NCT06441435|OTHER|Standard treatment|Low protein diet
58124940|NCT03917771|OTHER|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
58124941|NCT03917771|OTHER|Usual follow-up|Usual follow-up carried out in GO consultation
58124942|NCT06088771|BIOLOGICAL|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
58124943|NCT06088771|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
58124944|NCT06284525|DEVICE|Ankle resistance and biofeedback|An ankle exoskeleton will provide stance phase resistance and a plantar pressure biofeedback system will encourage late stance push-off.
58124945|NCT00218179|OTHER|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
58124946|NCT00514137|DRUG|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
58124947|NCT06322407|PROCEDURE|Stellate Ganglion Block (SGB)|All SGB procedures will be performed by the same experienced physicians. Patients will be positioned in a supine position with the neck slightly hyperextended and receive a SGB procedure using the B-ultrasound visualization technique (Aurora A5 Ultrasound, Risco Tech Co., Ltd.). 1% lidocaine 5mL (Shanxi Jinxin Shuanghe Pharm Co., Ltd.) will be injected below the prevertebral fascia on the surface of longus colli muscle
58124948|NCT06322407|DRUG|standardized drug treatment|Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
58124949|NCT03627936|DRUG|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
58124950|NCT03627936|DRUG|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
58124951|NCT03942523|BEHAVIORAL|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
58124952|NCT06526962|DEVICE|5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser|Outpatient hysteroscopic polypectomy
58124953|NCT03862248|DRUG|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
58124954|NCT03862248|DRUG|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
58124955|NCT03862248|DRUG|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
58124956|NCT02583620|GENETIC|blood sample|A blood test is realized on the subject
58124957|NCT03060005|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
58124958|NCT03060005|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
58124959|NCT06132646|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
58124960|NCT05640453|DRUG|Pregabalin|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
58124961|NCT05640453|DRUG|Dexmedetomidine|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
58124962|NCT06381063|DRUG|pain management|o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
58124963|NCT06381063|DRUG|ketoprofen|Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
58124964|NCT06381063|DRUG|PLacebo|Placebo twice a day, during 48 h after surgery, intravenous administration
58124965|NCT06403865|DRUG|Cabotegravir, Rilpivirine Drug Combination|Treatment switch to CAB+RPV LA
58314578|NCT03629301|BEHAVIORAL|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
58451295|NCT06156280|DRUG|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
57749918|NCT06145243|OTHER|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
57749919|NCT06145243|OTHER|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
58124966|NCT05802966|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
58124967|NCT01195259|DRUG|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
58124968|NCT00812253|DRUG|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
58124969|NCT00812253|DRUG|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
58124970|NCT05017584|DRUG|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
58124971|NCT04078451|PROCEDURE|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
58124972|NCT04800653|PROCEDURE|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
58124973|NCT02285127|PROCEDURE|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
58124974|NCT04901000|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
58451296|NCT06156280|DRUG|Placebo injection|Placebo comparator
58451297|NCT00295542|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
58124975|NCT04029675|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
58124976|NCT04281680|DRUG|Pasireotide 0.9 MG/ML|900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
58124977|NCT01686841|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
58124978|NCT05147051|DRUG|Meglumine Sodium Succinate|500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
58124979|NCT05147051|DRUG|Placebo|Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
58124980|NCT03012477|DRUG|Cisplatin|chemotherapy
58124981|NCT03012477|DRUG|AZD1775|Wee1 tyrosine kinase inhibitor
58124982|NCT05867355|PROCEDURE|surgical fixation|compare implant removal rates between surgical fixation techniques.
58124983|NCT00423956|PROCEDURE|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
58124984|NCT04390828|BEHAVIORAL|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
58124985|NCT03783208|DRUG|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
58124986|NCT03783208|OTHER|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
58124987|NCT00914888|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
58124988|NCT00914888|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
58124989|NCT00914888|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
58124990|NCT00914888|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
58124991|NCT00177593|BEHAVIORAL|behavioral weight loss|
58124992|NCT04597086|OTHER|Best Practice|Receive standard of care
58124993|NCT04597086|PROCEDURE|Bright White Light Therapy|Receive BWLT
58124994|NCT04597086|OTHER|Survey Administration|Ancillary studies
58124995|NCT03997448|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
58124996|NCT03997448|DRUG|Abemaciclib|Abemiciclib 150mg PO
58124997|NCT05722600|OTHER|Grape juice|Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
58124998|NCT05722600|OTHER|Placebo drink|Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
58124999|NCT00011297|DRUG|gabapentin (Neurontin)|
58125000|NCT00011297|DRUG|lorazepam (Ativan)|
58125001|NCT05730686|PROCEDURE|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
58125002|NCT05045209|OTHER|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
58125003|NCT01415466|DRUG|Cresto|tablet, 20mg
58125004|NCT01415466|DRUG|Olmetec|tablet, 40mg
58125005|NCT01415466|DRUG|Cresto, Olmetec|tablet, 20mg and 40mg
58125006|NCT00280267|DRUG|Testosterone gel|
58125007|NCT04371809|OTHER|DNA methylome|Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
58125008|NCT00769106|BIOLOGICAL|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
58125009|NCT01617577|DRUG|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
58125010|NCT01617577|DRUG|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
58125011|NCT03882320|PROCEDURE|Patient Controlled Analgesia (PCA)|Patient Controlled Analgesia (PCA)
58125012|NCT06263322|BEHAVIORAL|Actionable remotely generated health data|Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
58125013|NCT06263322|BEHAVIORAL|Non-Actionable remotely generated health data|Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
58125014|NCT03769480|OTHER|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
58125015|NCT04790084|OTHER|no intervention|no intervention
58125016|NCT00617461|DRUG|GEn 1200mg/day|1200mg/day gabapentin enacarbil
58125017|NCT00617461|DRUG|GEn 3600mg/day|3600mg/day gabapentin enacarbil
58125018|NCT05131906|DEVICE|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
58125019|NCT04296357|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
58125020|NCT04296357|OTHER|Physical development and General Health|Physical development and General health examination
58125021|NCT04296357|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
58125022|NCT02234609|DEVICE|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
58125023|NCT03629925|DRUG|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
57749920|NCT06145243|OTHER|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
57749921|NCT03949166|OTHER|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
58125024|NCT03629925|DRUG|Gemcitabine|1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
58125025|NCT03629925|DRUG|Cisplatin|75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
58125026|NCT03629925|DRUG|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
58125027|NCT03629925|DRUG|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
58314579|NCT03629301|OTHER|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
57749922|NCT00746122|PROCEDURE|Open repair|Standard treatment of emergency open surgery
58125028|NCT00810368|DRUG|Carnosine|500mg Carnosine x2 daily
58125029|NCT00810368|DRUG|Placebo|Microcrystalline cellulose placebo tablets x2 daily
58125030|NCT04456361|BIOLOGICAL|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
57749923|NCT00746122|PROCEDURE|EVAR|Emergency endovascular aneurysm repair
58125031|NCT01002690|DRUG|Etoricoxib|90 mg/day orally for 10-13 days
58125032|NCT03321565|OTHER|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
58125033|NCT04130789|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
57749924|NCT01811212|DRUG|Cabozantinib S-malate|Given PO
57749925|NCT01811212|OTHER|Laboratory Biomarker Analysis|Correlative studies
57749926|NCT01919203|DRUG|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
57749927|NCT02448251|DRUG|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
57749928|NCT02120027|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
57749929|NCT02120027|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
58125034|NCT04130789|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
58125035|NCT00145938|DRUG|sildenafil|
58125036|NCT00006052|DRUG|imatinib mesylate|
58125037|NCT03842943|DRUG|Pembrolizumab|Preoperative infusions
58125038|NCT03842943|DRUG|Talimogene Laherparepvec|Preoperative intralesional injection
58125039|NCT05960864|DRUG|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
58125040|NCT04604184|DRUG|BI 764198|BI 764198
58314580|NCT03550209|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
58125041|NCT04604184|DRUG|Placebo|Placebo
58314581|NCT03550209|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
58314582|NCT02820415|OTHER|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
58125042|NCT06157086|OTHER|ofatumumab|There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
58125043|NCT02991547|OTHER|Observational|
58125044|NCT06378619|DIAGNOSTIC_TEST|Tapping Test|For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
58125045|NCT06378619|DIAGNOSTIC_TEST|Archimedes Spiral|For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.
58125046|NCT01030965|DRUG|GSK573719 125mcg|125mcg once-daily
58125047|NCT01030965|DRUG|GSK573719 250mcg|250mcg once-daily
58125048|NCT01030965|DRUG|GSK573719 500mcg|500mcg once-daily
58125049|NCT01030965|DRUG|Placebo|once-daily
58125050|NCT03576391|BEHAVIORAL|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
58125051|NCT03576391|BEHAVIORAL|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
58125052|NCT03576391|BEHAVIORAL|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
58125053|NCT03576391|BEHAVIORAL|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
58125054|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
58125055|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
58125056|NCT05813587|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
58125057|NCT05813587|OTHER|Normal saline|Normal saline
58125058|NCT03281499|OTHER|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
58125059|NCT00806156|DRUG|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
58125060|NCT00806156|DRUG|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
58125061|NCT04491409|OTHER|Best Practice|Undergo standard of care
58125062|NCT04491409|OTHER|Medical Chart Review|Medical charts reviewed
58125063|NCT04626999|PROCEDURE|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
58125064|NCT04626999|PROCEDURE|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
58314583|NCT01184911|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
58125065|NCT03192774|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
58125066|NCT06021977|DRUG|Zanubrutinib|Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
58125067|NCT02419690|BEHAVIORAL|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
58125068|NCT04041609|DRUG|LYR-210|A single administration of LYR-210 depot
58125069|NCT04041609|OTHER|Sham comparator|Sham comparator
58125070|NCT05305274|OTHER|screening|This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
58125071|NCT03778866|OTHER|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
58125072|NCT01060592|DEVICE|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
58125073|NCT02259751|DRUG|KUC 7483 CL|
58125074|NCT02259751|DRUG|Placebo|
58125075|NCT05348109|OTHER|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
58125076|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
58125077|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
58314584|NCT05424120|PROCEDURE|Manual aspiration|One option from standard of care
58314585|NCT05424120|PROCEDURE|Wall suction|One option from standard of care
58314586|NCT05424120|PROCEDURE|Vacuum bottle drainage|One option from standard of care
58314587|NCT00382616|DRUG|Phosphatidylserine-Omega3|
58314588|NCT00903201|DRUG|SB656933|20 mg
58314589|NCT00903201|DRUG|SB656933|50mg
58314590|NCT00903201|DRUG|Placebo|placebo
58451298|NCT00295542|PROCEDURE|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
57749930|NCT06472401|OTHER|Integrated Learning Support System|"Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session"
57749931|NCT06472401|OTHER|Standard Learning Model|"Students will receive standard simulation preparation consisting of:~- Expository and dialogued theoretical class."
57749932|NCT06268158|BEHAVIORAL|Eye patch|The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
57749933|NCT01977300|DRUG|Valproate|serum level of 50 to 125 ug/L
57749934|NCT01977300|DRUG|Lithium|serum levels of 0.6 to 1.2 mmol/L
57749935|NCT01977300|DRUG|Risperidone|1 to 6 mg/day
58451299|NCT00295542|DRUG|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
57749936|NCT01977300|DRUG|Olanzapine|5 to 25 mg/day
57749937|NCT01977300|OTHER|Placebo|manufactured to mimic risperidone and olanzapine
57749938|NCT05307380|DIAGNOSTIC_TEST|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
57749939|NCT04573621|PROCEDURE|Pelvic drain|A pelvic drain is placed
57749940|NCT04573621|OTHER|No pelvic drain is placed|A pelvic drain is not placed
57749941|NCT02038894|DRUG|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
57749942|NCT02038894|DRUG|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
58314591|NCT03260400|DEVICE|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
58451300|NCT00295542|DRUG|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
57749943|NCT02038894|DRUG|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
57749944|NCT02038894|DRUG|Propofol|
57749945|NCT01143688|DRUG|albuterol|
57749946|NCT01143688|DRUG|placebo inhaler|
58125078|NCT05451459|OTHER|12-week FMS Intervention|4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
58125079|NCT05451459|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
57749947|NCT01143688|PROCEDURE|placebo acupuncture|
58451301|NCT00295542|DRUG|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
57749948|NCT03715205|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
58451302|NCT00295542|DRUG|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
58451303|NCT00295542|PROCEDURE|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
58451304|NCT05627635|BIOLOGICAL|Balstilimab|Given IV
57749949|NCT01722942|PROCEDURE|ICD implantation|ventricular ICD implantation
57749950|NCT01722942|DRUG|amiodarone hydrochloride|amiodarone prescription
57749951|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
57749952|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
57749953|NCT04841941|DEVICE|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
58125080|NCT04759508|DIETARY_SUPPLEMENT|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
58125081|NCT04759508|DIETARY_SUPPLEMENT|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
58125082|NCT02090608|DRUG|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
58125083|NCT06011577|DRUG|REL-1017|REL-1017 tablet
58125084|NCT06011577|DRUG|Placebo|Placebo tablet
58314592|NCT02252263|DRUG|Elotuzumab|
58451305|NCT05627635|BIOLOGICAL|Bevacizumab|Given IV
58451306|NCT05627635|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
58451307|NCT05627635|BIOLOGICAL|Botensilimab|Given IV
58451308|NCT05627635|PROCEDURE|Computed Tomography|Undergo a CT scan
58451309|NCT05627635|DRUG|Fluorouracil|Given IV
58314593|NCT02252263|DRUG|Lirilumab|
58314594|NCT02252263|DRUG|Urelumab|
58451310|NCT05627635|DRUG|Leucovorin Calcium|Given IV
58451311|NCT05627635|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58451312|NCT05627635|DRUG|Oxaliplatin|Given IV
58451313|NCT05627635|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
58451314|NCT05627635|PROCEDURE|X-Ray Imaging|Undergo an x-ray
58125085|NCT05202704|PROCEDURE|Procedure/Surgery: Experimental: Hidden conditioning + Positive Expectation|Patients will be submitted to quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectations about the treatment by means of a workshop. Immediately after the first session of manipulative therapy, participants will be submitted again to the QST but now the heat pain threshold of the hidden conditioning group will be surreptitiously downgraded (the intense noxious stimulus will be downgraded to the moderate stimulus - individually obtained during the QST) as a mean to conditioning patients to believe that spinal manipulative therapy promoted pain relief. Patients will be invited to report the pain intensity perceived just after the QST (second test - conditioning procedure). The objective of questioning the pain intensity after the conditioning test is a procedure check to ensure that the conditioning procedure worked.
58125086|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Positive Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate whether the positive instructions will show any effect.
58125087|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Neutral Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce neutral expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate/confirm the effect of neutral instructions.
58125088|NCT05202704|PROCEDURE|Spinal Manipulative Therapy|All the groups recruited in the study will receive five sessions of Spinal Manipulative Therapy. The intervention will be performed with the patient in the supine position. The clinician-researcher will passively lean over the patient to the side to be manipulated and ask the patient to place their hands behind their head. The researcher will then passively rotate the patient on the side to be manipulated and perform a posterior and inferior thrust on the opposite anterosuperior spine. The patients will receive 4 maneuvers (twice towards right side and twice towards left side).
58125089|NCT02815878|BEHAVIORAL|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
58125090|NCT00001337|DRUG|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
58125091|NCT00001337|BIOLOGICAL|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
58125092|NCT01368523|DRUG|nilotinib|
58125093|NCT03086772|BEHAVIORAL|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
58125094|NCT03086772|BEHAVIORAL|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
58125095|NCT01286038|DRUG|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
58451315|NCT04862065|DEVICE|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57959922|NCT01315262|DRUG|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
58451316|NCT02518971|DRUG|Tamsulosin|0.4 mg daily
58451317|NCT02518971|DRUG|Placebo|one capsule daily
58451318|NCT03997526|DEVICE|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
57749954|NCT01975896|BEHAVIORAL|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
57959923|NCT05348655|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease
57959924|NCT05348655|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
57749955|NCT04697277|DRUG|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
57749956|NCT04512066|DRUG|RO6889450|Participants will receive oral RO6889450 QD.
57959925|NCT02178488|DRUG|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
57959926|NCT02178488|OTHER|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
57959927|NCT01477931|DRUG|Bupropion extended release|300mg once a daily, PO, 8weeks
57959928|NCT03814980|BEHAVIORAL|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
58451319|NCT06023940|DIETARY_SUPPLEMENT|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
57749957|NCT04512066|DRUG|Placebo|Participants will receive oral placebo QD.
57749958|NCT04512066|DRUG|Risperidone|Participants will receive oral risperidone QD.
57749959|NCT01059630|DRUG|Obinutuzumab|IV infusion.
57749960|NCT01059630|DRUG|Bendamustine|IV infusion.
57749961|NCT06341725|OTHER|malignant lymph nodes|observational study
57749962|NCT05780489|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
58451320|NCT00624273|DRUG|Sildenafil therapy|oral use
58451321|NCT00998465|OTHER|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
58451322|NCT00998465|OTHER|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
58451323|NCT00998465|OTHER|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
58451324|NCT00998465|RADIATION|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
58451325|NCT00998465|RADIATION|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
58451326|NCT00998465|RADIATION|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
58451327|NCT00998465|OTHER|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
58451328|NCT00998465|OTHER|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
58451329|NCT00998465|DIETARY_SUPPLEMENT|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
58451330|NCT01740713|DRUG|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
58451331|NCT01740713|DRUG|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
58451332|NCT01740713|DRUG|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
58451333|NCT01802008|PROCEDURE|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
58451334|NCT01802008|PROCEDURE|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
57749963|NCT06276270|DEVICE|Mucopad HA|The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
57749964|NCT01367509|DRUG|Methylnaltrexone (MNTX)|
57749965|NCT04870710|DEVICE|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
57749966|NCT04663022|OTHER|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
57749967|NCT01755442|OTHER|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
57959929|NCT03814980|DEVICE|application on a computer tablet|a computer tablet
58125096|NCT01836848|PROCEDURE|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
58451335|NCT01963195|DRUG|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
58451336|NCT02348125|DRUG|Mitochondrial Cocktail|
58451337|NCT00894140|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
57749968|NCT01755442|DRUG|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
57749969|NCT01463722|OTHER|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
57749970|NCT03825783|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
57749971|NCT00724152|BEHAVIORAL|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
57749972|NCT00724152|BEHAVIORAL|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
57749973|NCT03630822|BEHAVIORAL|Psychiatric Advanced Directive|The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
57749974|NCT03630822|BEHAVIORAL|Standard care|standardized maintenance with the patient
58451338|NCT03530943|BEHAVIORAL|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
58451339|NCT03530943|BEHAVIORAL|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
58451340|NCT00583336|DEVICE|ShuntCheck|Thermal dilution test for CSF flow
58451341|NCT02662972|DRUG|Botulinum Toxin Type A|
58451342|NCT02690350|DRUG|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
57749975|NCT02891057|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
57749976|NCT03391609|DRUG|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
57749977|NCT03391609|DRUG|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
57749978|NCT01763879|OTHER|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
57749979|NCT01763879|OTHER|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
57749980|NCT06033248|DIAGNOSTIC_TEST|urine sample|urine sample will be collected
57749981|NCT03546517|OTHER|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
57749982|NCT03546517|OTHER|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
57749983|NCT03349801|OTHER|No intervention|According to clinical practice.
57749984|NCT03295890|PROCEDURE|Dry Needing|Dry Needling
57749985|NCT01907191|DRUG|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy
57749986|NCT01907191|DRUG|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
57749987|NCT00258258|DRUG|paricalcitol|
57749988|NCT00258258|DRUG|zoledronic acid|
57749989|NCT04794231|OTHER|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)
58451343|NCT04619615|OTHER|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
58451344|NCT04619615|OTHER|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
57749990|NCT04794231|OTHER|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
58451345|NCT06073613|DIAGNOSTIC_TEST|oral health status|"* CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,...) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions"
58451346|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
57749991|NCT05925933|OTHER|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
57749992|NCT06364657|DIAGNOSTIC_TEST|Eye Exam|"* Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface"
57749993|NCT01510431|DRUG|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
57749994|NCT05021510|OTHER|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
57749995|NCT05021510|OTHER|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
57959930|NCT03602287|DRUG|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
57749996|NCT01185067|DRUG|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
57749997|NCT04182100|DRUG|P1101|P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
57749998|NCT04182100|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
57749999|NCT04182100|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
57750000|NCT03941275|DIAGNOSTIC_TEST|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
58125097|NCT04659915|DRUG|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
58125098|NCT04659915|DRUG|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
58125099|NCT03875157|BIOLOGICAL|IBI318|0.3 mg intravenous infusion, C1D1 and afterwards Q2W
58451347|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
58451348|NCT04208308|DIETARY_SUPPLEMENT|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
58451349|NCT04208308|DIETARY_SUPPLEMENT|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
57750001|NCT03065270|OTHER|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
57750002|NCT03065270|OTHER|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
57750003|NCT02456402|DEVICE|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
57750004|NCT02456402|DEVICE|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
58125100|NCT03875157|BIOLOGICAL|IBI318|1 mg intravenous infusion, C1D1 and afterwards Q2W
58125101|NCT03875157|BIOLOGICAL|IBI318|3 mg intravenous infusion, C1D1 and afterwards Q2W
58125102|NCT03875157|BIOLOGICAL|IBI318|10 mg intravenous infusion, C1D1 and afterwards Q2W
58125103|NCT03875157|BIOLOGICAL|IBI318|30 mg intravenous infusion, C1D1 and afterwards Q2W
58125104|NCT03875157|BIOLOGICAL|IBI318|100 mg intravenous infusion, C1D1 and afterwards Q2W
58125105|NCT03875157|BIOLOGICAL|IBI318|300 mg intravenous infusion, C1D1 and afterwards Q2W
57750005|NCT01180348|DRUG|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
57750006|NCT01180348|DRUG|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
57750007|NCT02080468|DRUG|lomitapide|20 mg
57750008|NCT02080468|DRUG|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
57959931|NCT03602287|DRUG|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
57959932|NCT06095765|DRUG|Colchicine 0.5 MG Oral Tablet|Oral intake of 0.5 mg colchicine once daily
58125106|NCT03875157|BIOLOGICAL|IBI318|600 mg intravenous infusion, C1D1 and afterwards Q2W
58125107|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
57959933|NCT06095765|DRUG|Placebo|Oral intake of matching placebo once daily
57959934|NCT01521273|OTHER|Bean varieties|10 x 50 g/ arm
58125108|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
58125109|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion Q3W
58125110|NCT03554096|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
58125111|NCT01345032|OTHER|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
57750009|NCT02899325|DRUG|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
57750010|NCT02150018|OTHER|non invasive ventilation|
57750011|NCT02115555|BEHAVIORAL|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
57750012|NCT02115555|BEHAVIORAL|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
58125112|NCT01345032|OTHER|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
58125113|NCT03363074|DEVICE|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
58125114|NCT03363074|DEVICE|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
58451350|NCT03291483|OTHER|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
58451351|NCT03291483|OTHER|plyometric training|Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
58451352|NCT02738749|DEVICE|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
58451353|NCT05561023|DRUG|Hawthorn red pigment|"For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme"
58451354|NCT02586870|DEVICE|Intravascular Ultrasound|
57750013|NCT02115555|BEHAVIORAL|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
57750014|NCT03996850|PROCEDURE|Computed Tomography|Undergo SPECT/CT
57750015|NCT03996850|OTHER|Questionnaire Administration|Ancillary studies
57750016|NCT03996850|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
57750017|NCT03996850|RADIATION|Technetium Tc-99m Sestamibi|Given IV
58451355|NCT02781675|OTHER|Dietary Intervention|3 wk dietary intervention with prescribed menus and \~50% foods provided.
58451356|NCT05077930|BIOLOGICAL|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
58451357|NCT05077930|DRUG|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
58451358|NCT05983471|DRUG|ME-015 (Suplatast Tosilate)|Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)
58451359|NCT05983471|OTHER|Identical placebo|Without active component
58451360|NCT00001917|DRUG|O15|
58451361|NCT00001917|DRUG|[F-18] FP-TZTP|
58451362|NCT00869466|BEHAVIORAL|behavioral dietary intervention|
58451363|NCT00869466|BEHAVIORAL|exercise intervention|
58451364|NCT00869466|OTHER|counseling intervention|
57750018|NCT03428425|DRUG|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
57750019|NCT04196426|BEHAVIORAL|Nutrition education intervention about osteoporosis and calcium|The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
57750020|NCT03610295|PROCEDURE|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
57750021|NCT03610295|PROCEDURE|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
57750022|NCT01037855|OTHER|Non-intervention observational study|Non-intervention observational study
57750023|NCT02297022|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
57750024|NCT00671203|PROCEDURE|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
58451365|NCT00869466|OTHER|educational intervention|
58451366|NCT00869466|OTHER|laboratory biomarker analysis|
58451367|NCT00869466|OTHER|questionnaire administration|
58451368|NCT00869466|PROCEDURE|quality-of-life assessment|
58451369|NCT00869466|PROCEDURE|support group therapy|
58125115|NCT05719870|BEHAVIORAL|Educational training|The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
58125116|NCT01912105|DEVICE|Airway medix closed suction system|
58125117|NCT01912105|DEVICE|standard closed suctioning systems|
58125118|NCT02476526|DRUG|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
58125119|NCT02476526|DRUG|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
58125120|NCT02476526|DRUG|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
58125121|NCT02476526|PROCEDURE|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
58125122|NCT05925153|OTHER|No intervention|No intervention
58125123|NCT00027807|BIOLOGICAL|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
58451370|NCT03955614|OTHER|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
58451371|NCT03955614|OTHER|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
58451372|NCT03955614|OTHER|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
58451373|NCT02756338|DEVICE|BioMonitor 2 Insertable Cardiac Monitor|
58451374|NCT00086047|BEHAVIORAL|Coping Skills Training|8 weekly sessions of behavioral treatment
58451375|NCT00086047|BEHAVIORAL|Education|8 weekly sessions of fibromyalgia education
58451376|NCT06725771|DRUG|Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline|Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
58451377|NCT06725771|DRUG|Sertraline Hydrochloride Tablets|Sertraline are given to patients simultaneously
58451378|NCT05628142|RADIATION|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
58451379|NCT03240887|BEHAVIORAL|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
58451380|NCT03067428|DIETARY_SUPPLEMENT|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
58125124|NCT00027807|BIOLOGICAL|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
58451381|NCT03067428|DIETARY_SUPPLEMENT|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
58451382|NCT06375070|PROCEDURE|PFO closure|PFO closure
58451383|NCT06375070|DRUG|anticoagulant|rivaroxaban
58451384|NCT01051687|DRUG|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
58451385|NCT00531258|DEVICE|rTMS|Bilateral rTMS
58451386|NCT00531258|DEVICE|Sham rTMS|sham rTMS
58451387|NCT02225093|DRUG|Caffeine|Oral
58451388|NCT02225093|DRUG|Dextromethorphan|Oral /.L
58451389|NCT02225093|DRUG|Enzalutamide|Oral
58451390|NCT02225093|DRUG|Enzalutamide Placebo to Match (PTM)|Oral
58125125|NCT00027807|BIOLOGICAL|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
58125126|NCT00428415|DRUG|Tesofensine|
58125127|NCT02590861|PROCEDURE|Dental implant|All participants will receive the same intervention, this is a single group study.
58125128|NCT01202006|OTHER|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
58125129|NCT05694468|OTHER|Psychomotor Relaxation|Psychomotor relaxation sessions.
58125130|NCT03144687|DRUG|Itacitinib|Itacitinib self-administered orally once daily .
58125131|NCT03144687|DRUG|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
57750025|NCT06256133|PROCEDURE|Enhanced Recovery After Surgery protocol|Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
57750026|NCT05795101|DRUG|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
57750027|NCT05795101|DRUG|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
58125132|NCT03123822|DEVICE|Glasses|Glasses traditionally prescribed for refractive error
57750028|NCT05539092|OTHER|changing angle of bed|Before the cardiac catheterization procedure: patients' demographic characteristics and health relevant data will be collected on the first day of admission. the researcher will change angle of bed from 15° to 45°.
57750029|NCT05382182|DRUG|androgen deprivation therapy|outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
57750030|NCT05382182|RADIATION|external beam radiotherapy|outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
57750031|NCT06579066|DRUG|Probiotic Blend Capsule|Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
57750032|NCT06579066|DRUG|Activated Charcoal|Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
57750033|NCT01866943|DRUG|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
57750034|NCT01866943|DRUG|Normal Saline Solution|
57750035|NCT04496102|DEVICE|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
57750036|NCT03451734|DRUG|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
57750037|NCT03451734|DRUG|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
57750038|NCT03451734|DRUG|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
57750039|NCT02529826|PROCEDURE|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
58125133|NCT05391009|DIAGNOSTIC_TEST|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
58451391|NCT00000526|DRUG|encainide|
57750040|NCT06311279|PROCEDURE|Anterior resection of Rectal cancer|Anterior resection of cancer rectum and type of anastomosis (End to end or side to end)
57750041|NCT01654432|OTHER|Paravertebral Blocks (PVB)|
57750042|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
57750043|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
57750044|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
57750045|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
57750046|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
57750047|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
57750048|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
57750049|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
57750050|NCT02879812|OTHER|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
57750051|NCT02879812|OTHER|Educational Video for Staff|Dialysis facility staff will watch a \~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
57750052|NCT02879812|OTHER|Educational Video for Patients|Dialysis facilities will receive a \~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
58314595|NCT03396562|OTHER|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
58451392|NCT00000526|DRUG|flecainide|
58451393|NCT00000526|DRUG|moricizine|
58451394|NCT02601404|DEVICE|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
58451395|NCT03633851|DEVICE|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
58451396|NCT03633851|OTHER|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
58451397|NCT00836589|DEVICE|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
58451398|NCT05336786|DRUG|Perflutren Lipid Microspheres|Given IV
58125134|NCT05391009|DIAGNOSTIC_TEST|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
58125135|NCT00991848|DRUG|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
58125136|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
58125137|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
58125138|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
58451399|NCT05336786|PROCEDURE|Ultrasound|Undergo ultrasound
58451400|NCT05402670|OTHER||
58451401|NCT06089278|DRUG|300mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
58451402|NCT06089278|DRUG|600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
58451403|NCT06089278|DRUG|TQH2722 injection matching placebo|Placebo without active substance.
58451404|NCT04540965|DRUG|Telaglenastat|Glutaminase inhibitor
58451405|NCT04540965|DRUG|Famotidine|Histamine-H2 Receptor Antagonist
58451406|NCT04540965|DRUG|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
58451407|NCT01683708|DIETARY_SUPPLEMENT|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
58451408|NCT05549011|OTHER|PENG Block|PENG block for analgesic purposes performed before hip surgery
58451409|NCT05549011|OTHER|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
58451410|NCT05549011|DIAGNOSTIC_TEST|Numeric Rating Scale|Self-reported pain intensity score between 0-10
58451411|NCT05549011|DIAGNOSTIC_TEST|Angle of sitting|Measurement of sitting angle in degrees with a protractor
58451412|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
57959935|NCT06208020|OTHER|Functional near-infrared spectroscopy (fNIRS) detection|fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
58451413|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
57959936|NCT00142701|BEHAVIORAL|diet|
57959937|NCT00142701|BEHAVIORAL|physical activity|
57959938|NCT00142701|BEHAVIORAL|stress management|
57959939|NCT00142701|BEHAVIORAL|smoking cessation|
57959940|NCT00394459|DEVICE|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
57959941|NCT00394459|DEVICE|Perifix Standard|Perifix Standard
57959942|NCT00394459|DEVICE|Perifix New|Perifix New
57959943|NCT02247193|DRUG|Botulinum Toxin Type A|Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
57959944|NCT02247193|DRUG|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
57959945|NCT02344888|DRUG|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
58125139|NCT01930461|BIOLOGICAL|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
58125140|NCT02457858|DRUG|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
58314596|NCT05848063|OTHER|Global hip muscles strengthening exercises|Strengthening exercises will be given to all hip muscles
58451414|NCT00756366|OTHER|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
58451415|NCT02826343|DRUG|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
58451416|NCT02826343|DRUG|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
58451417|NCT02826343|DRUG|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
58451418|NCT00700440|DRUG|C225 (cetuximab)|one week before and then weekly during radiotherapy
58451419|NCT03591926|DRUG|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
58451420|NCT02784795|DRUG|LY3039478|Administered orally
58451421|NCT02784795|DRUG|Taladegib|Administered orally
58451422|NCT02784795|DRUG|Abemaciclib|Administered orally
58451423|NCT02784795|DRUG|Cisplatin|Administered IV
58451424|NCT02784795|DRUG|Gemcitabine|Administered IV
58451425|NCT02784795|DRUG|Carboplatin|Administered IV
58451426|NCT02784795|DRUG|LY3023414|Administered orally
57750053|NCT02879812|OTHER|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
57750054|NCT02879812|OTHER|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
58125141|NCT03873480|PROCEDURE|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
58125142|NCT05875688|OTHER|Cementation Technique A|"* Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration."
58125143|NCT05875688|OTHER|Cementation Technique B|"* Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place."
58451427|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
58451428|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
58451429|NCT02030522|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
58451430|NCT00567853|DEVICE|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
58451431|NCT04796597|DEVICE|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
58451432|NCT05864222|OTHER|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
57750055|NCT02879812|OTHER|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
57750056|NCT04042155|DRUG|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
57750057|NCT03940820|BIOLOGICAL|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
57750058|NCT00232830|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
57750059|NCT00232830|DEVICE|bare-metal stent|any bare-metal stent brand
57750060|NCT02314624|BEHAVIORAL|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
57750061|NCT02314624|BEHAVIORAL|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
57750062|NCT03230773|DEVICE|Defibrillator model|Comparison of the performance of different public access defibrillators
57750063|NCT01224301|BEHAVIORAL|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
57750064|NCT01224301|BEHAVIORAL|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
57750065|NCT00134290|DRUG|metformin|
57750066|NCT00134290|BEHAVIORAL|"standard diet advice"|
57750067|NCT00134290|BEHAVIORAL|"personal diet advice"|
57750068|NCT06580873|DRUG|DOVATO|HIV-1 medication
57959946|NCT02344888|DRUG|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
57959947|NCT06264115|PROCEDURE|Laparoscopic Cholecystectomy|Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
58125144|NCT05875688|OTHER|Cementation Technique C|"* The utilisation of an appropriate quantity of cement.~* The mitigation of cement waste.~* Prolonged retention of dental crowns."
58125145|NCT02177084|DEVICE|PTNS|
58125146|NCT04509479|PROCEDURE|Valve replacement|Description of valve replacements
58125147|NCT00195598|DRUG|VENLAFAXINE|
58125148|NCT00195598|DRUG|Paroxetine|
58125149|NCT05764122|DRUG|BIIB131|Administered as specified in the treatment arm.
58125150|NCT05764122|DRUG|Placebo|Administered as specified in the treatment arm.
58125151|NCT01966081|OTHER|Blood sample|
57750069|NCT02185625|DEVICE|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
57750070|NCT05189951|OTHER|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
57750071|NCT05189951|OTHER|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
58125152|NCT01966081|OTHER|tissue samples from abdominal subcutaneous adipose|
58125153|NCT03574155|BEHAVIORAL|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
58125154|NCT05113056|DEVICE|Acutus Medical Pulsed Field Ablation System|All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
58125155|NCT05330507|OTHER|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
57750072|NCT05189951|OTHER|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
58125156|NCT03602768|BEHAVIORAL|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
58125157|NCT03602768|BEHAVIORAL|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
58125158|NCT03602768|BEHAVIORAL|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
58125159|NCT03680963|PROCEDURE|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
58125160|NCT03680963|PROCEDURE|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
58125161|NCT05702177|DRUG|Daridorexant 25 mg|A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
58125162|NCT05702177|DRUG|Daridorexant 50 mg|A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
58125163|NCT05702177|DRUG|Placebo|A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
58125164|NCT04682002|OTHER|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
58125165|NCT04682002|OTHER|Usual care|Administration of routine care based on international guidelines
58125166|NCT04682002|OTHER|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
58451433|NCT01966523|BEHAVIORAL|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
58451434|NCT01966523|OTHER|Control|
57750073|NCT06291610|BEHAVIORAL|Clinical trial decision support intervention|"1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention."
58125167|NCT04682002|OTHER|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
58125168|NCT04682002|OTHER|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
58125169|NCT04682002|OTHER|Coaching|There will be five personalized coaching sessions during the pregnancy.
58125170|NCT06298656|OTHER|No intervention|It is an observational study.
58125171|NCT01347788|DRUG|cabozantinib|Cabozantinib PO QD
58125172|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
58125173|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
58125174|NCT06243211|PROCEDURE|DMED|Decompression of spinal cord with stabilization - posterior approach.
58125175|NCT06243211|PROCEDURE|ANGI|Implantation of nerve tissue following decompression ans stabilization.
58125176|NCT05241821|PROCEDURE|Mechanical thrombectomy|Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
58125177|NCT05241821|DRUG|Thrombolytic Agent|Drug aimed to dissolve thrombus affecting the cerebral circulation
58125178|NCT05259306|DEVICE|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
58125179|NCT02470507|OTHER|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
57750074|NCT01261702|DRUG|Placebo|Normal saline IV
57750075|NCT01261702|DRUG|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
57750076|NCT00147940|PROCEDURE|Acoustic rhinometry (procedure)|
57750077|NCT05049759|BEHAVIORAL|Confident, Active and Happy Youth|The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
57750078|NCT05323539|OTHER|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
57750079|NCT02036957|PROCEDURE|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
58451435|NCT02982564|BEHAVIORAL|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
58451436|NCT02982564|BEHAVIORAL|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
58451437|NCT02577692|OTHER|Oxygen|breathing oxygen
57750080|NCT02036957|PROCEDURE|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
57959948|NCT03278132|BIOLOGICAL|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
57959949|NCT00495651|DRUG|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
57959950|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
57959951|NCT00495651|DRUG|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
57959952|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
57959953|NCT05269290|DRUG|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
57959954|NCT05269290|DRUG|Placebo|Placebo will be administered once a day on top of standard therapy.
58125180|NCT04872322|DRUG|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
58125181|NCT04872322|DRUG|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
58125182|NCT04872322|DRUG|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
58125183|NCT04872322|DRUG|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
58125184|NCT04872322|PROCEDURE|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
58451438|NCT02577692|OTHER|Ambient|breathing ambient air
58451439|NCT05068258|PROCEDURE|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
58451440|NCT03833869|PROCEDURE|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
58451441|NCT05839171|BEHAVIORAL|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
58451442|NCT06499493|OTHER|Myofascial induction in gastrocnemius muscle|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
58451443|NCT00002092|DRUG|Cimetidine|
58451444|NCT04985721|DRUG|Pamiparib|40 mg orally twice a day
58451445|NCT04985721|DRUG|Tislelizumab|200 mg IV every 21 days
58451446|NCT00867516|BIOLOGICAL|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
58451447|NCT00867516|BIOLOGICAL|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
58451448|NCT06527118|OTHER|ACTIVITIES TO LEARN SELF CARE SKILLS|This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
58451449|NCT01681160|OTHER|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
58451450|NCT01681160|OTHER|conventional therapy|patients receive ordinary treatment for diabetic foot
58451451|NCT04681105|DRUG|Acetaminophen|Given PO
58451452|NCT04681105|DRUG|Dexamethasone|Given IV
58451453|NCT04681105|DRUG|Diphenhydramine|Given IV or PO
58451454|NCT04681105|BIOLOGICAL|Flotetuzumab|Given IV
58451455|NCT04681105|DRUG|Ibuprofen|Given PO
58451456|NCT04681105|DRUG|Ranitidine|Given IV
58451457|NCT03920254|DRUG|TD-1473 Dose A|See Arm description
58451458|NCT03920254|DRUG|TD-1473 Dose B|See Arm description
58451459|NCT03920254|DRUG|TD-1473 Dose C|See Arm description
58125185|NCT01769378|DRUG|Placebo|Administered SQ
58125186|NCT01769378|DRUG|Dulaglutide|Administered SQ
58125187|NCT01769378|DRUG|Glimepiride|Administered PO
58451460|NCT05775770|DRUG|Insulin|insulin therapy
58451461|NCT00741052|DRUG|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
58451462|NCT00741052|DRUG|Azithromycin|1 gm Azithromycin single dose
58125188|NCT05969470|DEVICE|Internal fixation with short intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
58125189|NCT05969470|DEVICE|Internal fixation with long intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
58125190|NCT01630980|OTHER|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
58451463|NCT03391661|BEHAVIORAL|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
58451464|NCT03391661|BEHAVIORAL|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
58451465|NCT04392817|BEHAVIORAL|Arabic Articulatory Error Remediation software program|A speech therapy computerized intervention
58451466|NCT02420093|DEVICE|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
58451467|NCT00003505|DRUG|antineoplaston A10|
58451468|NCT00003505|DRUG|antineoplaston AS2-1|
58451469|NCT00003505|PROCEDURE|alternative product therapy|
58451470|NCT00003505|PROCEDURE|biological therapy|
58451471|NCT00003505|PROCEDURE|biologically based therapies|
58451472|NCT00003505|PROCEDURE|cancer prevention intervention|
58451473|NCT00003505|PROCEDURE|complementary and alternative therapy|
58451474|NCT00003505|PROCEDURE|differentiation therapy|
58451475|NCT05184530|DRUG|Evolocumab 140 MG/ML|140 mg per two weeks, subcutaneous injection
58451476|NCT00407186|DRUG|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
58451477|NCT00407186|RADIATION|radiotherapy|45 Gy in 25 fracions (5 days/week)
58451478|NCT00407186|DRUG|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
57750081|NCT03383770|PROCEDURE|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
57750082|NCT03383770|PROCEDURE|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
57750083|NCT02265302|DRUG|BIIL 284 oral solution|
57959955|NCT00612443|BEHAVIORAL|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
58125191|NCT05382923|BEHAVIORAL|Bright Light|3 consecutive days of 1 hour bright light
58451479|NCT02239159|OTHER|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
58451480|NCT02777775|PROCEDURE|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~* The skin area will be cleaned~* The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~* Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~* A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
58451481|NCT00498459|BEHAVIORAL|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
58451482|NCT01721161|BIOLOGICAL|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
58451483|NCT01721161|DRUG|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
58451484|NCT03333707|BEHAVIORAL|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
58451485|NCT02848222|DEVICE|Bruder Moist Heat Compress|
58451486|NCT02848222|OTHER|Washcloth|
58451487|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/rilpivirine|
58451488|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/efavirenz|
58451489|NCT04958499|BEHAVIORAL|Bio-healthy Park|Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
58451490|NCT00880698|BIOLOGICAL|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose
58451491|NCT00880698|BIOLOGICAL|Placebo|2 mL solution
58451492|NCT03041948|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
58125192|NCT05382923|BEHAVIORAL|Bright Light + Exercise + Melatonin|3 consecutive days of bright light, exercise, and melatonin
58451493|NCT03041948|PROCEDURE|Caudal-epidural nerve block|See arm description
58451494|NCT03041948|DRUG|Acetaminophen|See arm description
57750084|NCT02265302|DRUG|BIIL 284 wetability improved formulation (WIF) tablets|
57750085|NCT02265302|DRUG|Placebo|
57750086|NCT01836705|DRUG|SAR302503 (TG101348)|"Pharmaceutical form:capsule~Route of administration: oral"
57750087|NCT01836705|DRUG|Placebo SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
58125193|NCT05382923|BEHAVIORAL|Control|3 consecutive days of dim red light + light stretching + placbo
58451495|NCT03041948|DRUG|Sevoflurane|See arm description
58451496|NCT03041948|DRUG|Remifentanil|See arm description
58451497|NCT03041948|DRUG|Propofol|See arm description
57750088|NCT01836705|DRUG|Panolosetron|"Pharmaceutical form:solution~Route of administration: intravenous"
58125194|NCT04574882|OTHER|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
58125195|NCT01672190|OTHER|Yoga Therapy Program|
58125196|NCT02994056|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
58125197|NCT02994056|DRUG|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
58451498|NCT03041948|DRUG|Morphine|See arm description
58451499|NCT03041948|DRUG|Ondansetron|See arm description
57750089|NCT04450602|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
57750090|NCT04450602|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
58125198|NCT05981625|OTHER|Giomer varnish containing surface pre-reacted glass fillers|"Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity"
58125199|NCT06342921|DRUG|15 mg ADC189|Use only once during the whole study.
58125200|NCT06342921|DRUG|45 mg ADC189|Use only once during the whole study.
58125201|NCT06342921|DRUG|Placebo|Use only once during the whole study.
58125202|NCT00819247|DRUG|Degarelix|Given as a subcutaneous injection.
58125203|NCT01673958|OTHER|Exercise|Comparison between stair descending and stair ascending training
58125204|NCT06428708|DIAGNOSTIC_TEST|[18F] PSMA-1007 PET/CT|\[18F\] PSMA-1007 PET/CT scan
58125205|NCT00160212|DRUG|Daglutril|
58451500|NCT03041948|DRUG|Dexamethasone|See arm description
58451501|NCT03041948|DRUG|Ketorolac|See arm description
58451502|NCT06129643|DRUG|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
58451503|NCT06129643|DEVICE|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
58451504|NCT06129643|COMBINATION_PRODUCT|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
58451505|NCT01952886|DRUG|Granisetron|
58451506|NCT01952886|DRUG|Ondansetron|
58451507|NCT02931019|PROCEDURE|Intubation|
58451508|NCT05109780|DEVICE|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
58451509|NCT04318769|BEHAVIORAL|AFFIRM|AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
57750091|NCT04450602|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
58125206|NCT03244774|DRUG|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
58125207|NCT03244774|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
58125208|NCT02427607|DRUG|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
58125209|NCT03977584|DRUG|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
58125210|NCT03977584|DRUG|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
58125211|NCT03977584|OTHER|[^18F]GTP1|IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
58125212|NCT05095909|DEVICE|Cryo-compression|Programmable intermittent compression with integrated cryo-therapy.
58125213|NCT05095909|OTHER|Cryo-therapy|Subjects are fitted with gel ice packs and wraps.
58125214|NCT00803959|OTHER|Office evaluation|Office evaluation
58125215|NCT00803959|OTHER|UDS|Urodynamics
58125216|NCT00509964|DRUG|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
58125217|NCT00509964|DRUG|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
57750092|NCT04450602|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
57750093|NCT04450602|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
57750094|NCT04450602|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57750095|NCT04450602|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
57750096|NCT04450602|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
57750097|NCT01137474|DRUG|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
57750098|NCT01137474|DRUG|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
57750099|NCT06412653|DRUG|Zinc Acetate Dihydrate|In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
58125218|NCT03698526|DEVICE|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
58125219|NCT00970281|DRUG|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
58125220|NCT00970281|DRUG|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
58125221|NCT01473966|DIETARY_SUPPLEMENT|coffee|patients will receive a cup of coffee at room temperature orally twice daily
58125222|NCT01473966|DIETARY_SUPPLEMENT|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
58125223|NCT00805298|DRUG|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
58125224|NCT00805298|DRUG|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
58125225|NCT00805298|DRUG|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
58125226|NCT00805298|DRUG|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
58125227|NCT02779309|PROCEDURE|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
58125228|NCT06249399|OTHER|Aerobic Exercise|Aerobic Exercise training will be provided three days a week, 45 minutes a day, for 12 weeks. Patients will be subjected to submaximal aerobic exercise with rhythmic movements without equipment via video conference accompanied by a physiotherapist.
58125229|NCT06249399|BEHAVIORAL|Behavioral Treatment Program|Behavioral Treatment Program will be completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.
58125230|NCT00889590|DRUG|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
58451510|NCT05852080|BEHAVIORAL|multilevel system intervention based on information platform|"1. Standardized templates of medical record~2. Continuous medical quality control and feedback system: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the percentage of stroke of undetermined cause.~3. Team collaboration based on video conferencing: hospitals will receive corresponding suggestions for their improvement from experts online.~4. Enhanced feedback incentives"
58451511|NCT05897008|BIOLOGICAL|CMAB007|for subcutaneous injection only
58451512|NCT05897008|BIOLOGICAL|Xolair|for subcutaneous injection only
58451513|NCT00957879|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
58451514|NCT00957879|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
57750100|NCT06579664|DEVICE|iTBS|Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.
57750101|NCT06579664|DEVICE|sham iTBS|Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.
58451515|NCT06466694|BEHAVIORAL|Modified Dialectical Behavioural Therapy|The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. To evaluate through a patient lens content of the Dialectical Behavior Therapy (DBT) through the lens of an Indigenous Knowledge Carrier (Elder)
58451516|NCT05557344|DRUG|Acetaminophen IV|An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
58451517|NCT05557344|DRUG|Acetaminophen|A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
58451518|NCT00067184|DEVICE|Toitu 320/325|Fetal monitor
58451519|NCT05456737|OTHER|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
58451520|NCT01290757|DRUG|Dabigatran etexilate|150 mg Capsugel (T)
58451521|NCT01290757|DRUG|Dabigatran etexilate|150 mg Qualicaps (R)
58451522|NCT04983277|OTHER|no intervention|no intervention
58451523|NCT01078441|DRUG|liposomal doxorubicin|Given IV
58451524|NCT01078441|DRUG|bortezomib|Given subcutaneously.
58451525|NCT01078441|DRUG|dexamethasone|Given orally
57750102|NCT01175525|DRUG|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
57750103|NCT01175525|DRUG|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
57961607|NCT04536883|PROCEDURE|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
58451526|NCT01078441|DRUG|cyclophosphamide|Given IV
58451527|NCT00141674|PROCEDURE|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
58451528|NCT00497445|PROCEDURE|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
58451529|NCT00497445|PROCEDURE|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
58451530|NCT01775774|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
58451531|NCT01569841|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
58451532|NCT01569841|DRUG|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
58451533|NCT01494792|DEVICE|In Vitro Diagnositc aid for diagnosis|
58451534|NCT03415204|OTHER|acupuncture|acupuncture for post operative pain
57750104|NCT01168193|OTHER|No intervention|
57750105|NCT04759690|BEHAVIORAL|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
58451535|NCT00556998|DRUG|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
58451536|NCT03493295|DRUG|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
57750106|NCT04759690|BEHAVIORAL|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
57750107|NCT01984684|DRUG|delafloxacin|
57750108|NCT01984684|DRUG|vancomycin|
57750109|NCT01984684|DRUG|aztreonam|
57750110|NCT01954355|DRUG|LDE225|400, 600 and 800 mg OD
57750111|NCT01954355|DRUG|Paclitaxel|80 mg/m2 (days 1, 8, 15)
57750112|NCT06535841|BIOLOGICAL|MTX-474|MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
57750113|NCT06535841|OTHER|Placebo|Matching Placebo - Normal Saline
57750114|NCT06495671|DEVICE|Magnetically enhanced diffusion|Iron nanoparticle (intra-arterial) + External magnet workstation
58125231|NCT03122002|DRUG|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
58125232|NCT03122002|DIAGNOSTIC_TEST|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
58125233|NCT03122002|OTHER|Intravascular therapy|Intravascular therapy including thrombectomy
58125234|NCT03122002|OTHER|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
58125235|NCT03122002|OTHER|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
58125236|NCT00570271|OTHER|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
58125237|NCT00570271|OTHER|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
58125238|NCT00570271|OTHER|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
58125239|NCT00570271|OTHER|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
58125240|NCT00570271|OTHER|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
58125241|NCT00570271|OTHER|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
58125242|NCT02122081|RADIATION|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
58125243|NCT02122081|DRUG|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
57750115|NCT03017079|DIETARY_SUPPLEMENT|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
57750116|NCT03017079|OTHER|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
58451537|NCT00991991|GENETIC|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
57750117|NCT01030861|DRUG|Teplizumab|intravenous infusions
57750118|NCT01030861|DRUG|Placebo infusion|Placebo for Teplizumab
57750119|NCT04465357|DRUG|Erenumab-Aooe 140 MG/ML [Aimovig]|140 mg/mL administered subcutaneously
57750120|NCT01440426|PROCEDURE|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
57750121|NCT01440426|DEVICE|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
57750122|NCT04928820|PROCEDURE|Computed Tomography|Undergo PET/CT
57750123|NCT04928820|OTHER|Gallium Ga 68 Gozetotide|Given IV
57750124|NCT04928820|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57750125|NCT03371810|BEHAVIORAL|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
57750126|NCT03371810|BEHAVIORAL|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
57750127|NCT03508843|BEHAVIORAL|interactive virtual presence|installing the car seat with advice via interactive virtual presence
58125244|NCT02122081|BIOLOGICAL|anti-thymocyte globulin|
58125245|NCT02122081|DRUG|tacrolimus|Given IV or PO
58125246|NCT02122081|DRUG|methotrexate|Given IV
58125247|NCT02122081|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
58125248|NCT02122081|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
58125249|NCT02122081|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
58125250|NCT02122081|OTHER|laboratory biomarker analysis|Correlative studies
58125251|NCT02072759|DIETARY_SUPPLEMENT|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)"
58125252|NCT02072759|DIETARY_SUPPLEMENT|Placebo|
58125253|NCT06261970|BEHAVIORAL|Connect|Community level enhancements
58451538|NCT00991991|GENETIC|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
58451539|NCT00991991|GENETIC|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
58451540|NCT00991991|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
58451541|NCT00991991|OTHER|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
58451542|NCT00952458|DEVICE|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
58451543|NCT00420862|PROCEDURE|Spiral Computed Tomography|
57750128|NCT04127838|BEHAVIORAL|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
57750129|NCT05400343|PROCEDURE|Standard care (control group)|"Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment."
57750130|NCT05400343|PROCEDURE|US-guided ﬂuid management (active group)|Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.
57750131|NCT05400343|OTHER|Standard ICU Care|All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
57750132|NCT02586025|DRUG|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
57961608|NCT05665270|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
58125254|NCT06483945|DEVICE|Dexcom CGM G6/G6 Pro/G7|Dexcom CGM G6/G6 Pro/G7 device
57750133|NCT02586025|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
57750134|NCT02586025|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
57750135|NCT02586025|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
57750136|NCT02586025|DRUG|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
57750137|NCT02586025|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
57750138|NCT03642925|DIETARY_SUPPLEMENT|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
57750139|NCT00566683|DRUG|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
57750140|NCT00566683|DRUG|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
57750141|NCT04335045|DRUG|Placebo|1\~8 Placebo capsule(s) corresponding to each PH100 dose
58451544|NCT05373446|DRUG|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
58451545|NCT05373446|DRUG|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
58451546|NCT05373446|DRUG|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
58451547|NCT05508022|BEHAVIORAL|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
57750142|NCT04335045|DRUG|PH100 100mg|1 x 100 mg PH100 oral capsule
57961609|NCT05665270|DRUG|Prednisolone Acetate 1%|"Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen."
58451548|NCT00108862|OTHER|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
58451549|NCT00108862|OTHER|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
58451550|NCT02186275|DRUG|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"* Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
58451551|NCT02186275|DRUG|Vitamin D3 800 UI/day then 800 UI/day|"* Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
58451552|NCT01726894|DEVICE|Irreversible Electroporation|
58451553|NCT00458380|PROCEDURE|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
58451554|NCT00305435|DRUG|Romiplostim (AMG-531)|Romiplostim (AMG-531)
58451555|NCT02372578|DRUG|ASP3662|oral
58451556|NCT02372578|DRUG|pregabalin|oral
58451557|NCT02372578|DRUG|ASP3662 placebo|oral
58451558|NCT02372578|DRUG|pregabalin placebo|oral
58451559|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
57750143|NCT04335045|DRUG|PH100 200mg|1 x 200 mg PH100 oral capsule
57750144|NCT04335045|DRUG|PH100 400mg|2 x 200 mg PH100 oral capsules
57750145|NCT04335045|DRUG|PH100 800mg|4 x 200 mg PH100 oral capsules
57750146|NCT04335045|DRUG|PH100 1200mg|6 x 200 mg PH100 oral capsules
57750147|NCT04335045|DRUG|PH100 1600mg|8 x 200 mg PH100 oral capsules
57750148|NCT03940599|DEVICE|step counter|Fitbit
58451560|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
58451561|NCT01717872|DEVICE|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
58451562|NCT04581226|DIAGNOSTIC_TEST|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
58451563|NCT01172626|DRUG|valproate sodium|oral administration,15-30mg/kg,daily
58451564|NCT01172626|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
58451565|NCT01172626|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
58451566|NCT05092672|BEHAVIORAL|Exercise|Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
58451567|NCT01064934|PROCEDURE|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
57750149|NCT03940599|DEVICE|weight scale|BodyTrace weight scale
57750150|NCT03940599|DEVICE|step counter with screen covered|Fitbit with screen covered
57750151|NCT01353222|BIOLOGICAL|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
57750152|NCT01353222|OTHER|Standard of Care|Observation only until documentation of disease recurrence.
57750153|NCT02621580|DEVICE|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
57750154|NCT03613311|DIAGNOSTIC_TEST|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
57961610|NCT04555122|BEHAVIORAL|Social Distancing Advertisements|Participants will receive 3 types of advertisements to increase social distancing/staying at home.
58125255|NCT03830528|DRUG|KW-6356 Low Dose|KW-6356 will be administered as single doses.
58125256|NCT03830528|DRUG|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
58125257|NCT03830528|DRUG|KW-6356 High Dose|KW-6356 will be administered as single doses.
58451568|NCT01064934|OTHER|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
58125258|NCT03830528|DRUG|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
58125259|NCT03830528|DRUG|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
58125260|NCT03830528|DRUG|Placebo|All study cohorts (except Part C) are placebo controlled.
58125261|NCT03169959|DRUG|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
58125262|NCT03169959|DRUG|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
58125263|NCT03169959|DRUG|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
58125264|NCT03169959|DRUG|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
58125265|NCT03169959|DRUG|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
58125266|NCT03169959|DRUG|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
58125267|NCT04529070|BEHAVIORAL|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
58125268|NCT04529070|BEHAVIORAL|standard of care|standard of care
58125269|NCT01269970|OTHER|18-FDG-PET-CT|
58125270|NCT05329805|BEHAVIORAL|job crafting intervention|the participated nurses will receive session about job crafting followed by activity related to job crafting
58125271|NCT02928913|OTHER|No intervention|
58451569|NCT01683539|BEHAVIORAL|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
57959956|NCT00612443|BEHAVIORAL|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
57959957|NCT00855114|DRUG|everolimus|5 mg/day x 7 days by mouth
58125272|NCT05140096|DRUG|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
58125273|NCT05140096|DRUG|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
57959958|NCT00855114|PROCEDURE|therapeutic conventional surgery|Definitive excision of breast cancer tissue
58125274|NCT05140096|DRUG|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
58451570|NCT01683539|BEHAVIORAL|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
58451571|NCT06527326|DIETARY_SUPPLEMENT|Live Combined Bifidobacterium|the Bifidobacterium genus supplement
57959959|NCT00887393|OTHER|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (\< 15% of total kcaloric intake)
57959960|NCT00887393|OTHER|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
57959961|NCT04799587|OTHER|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
58125275|NCT04471207|DEVICE|Therapist Guided Prolonged Exposure with BioWare Device|"Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
57750155|NCT05941130|DRUG|Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory"
57750156|NCT05941130|DRUG|Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory"
57750157|NCT02440633|DRUG|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
57750158|NCT01118364|OTHER|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
57750159|NCT01118364|OTHER|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
57750160|NCT02827006|PROCEDURE|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
57750161|NCT05087082|OTHER|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
57750162|NCT01269879|DEVICE|Flexi-Bar vibration device only|daily vibration training 10min twice
57750163|NCT01269879|DEVICE|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group"
58451572|NCT06527326|DIETARY_SUPPLEMENT|Placebo|Placebo
57750164|NCT01844752|DRUG|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
57750165|NCT01844752|DRUG|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
57750166|NCT01844752|DRUG|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
57750167|NCT03458884|OTHER|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
57750168|NCT00236301|DRUG|CLIMASTON (drug)|CLIMASTON(drug)
57750169|NCT00236301|DRUG|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
57750170|NCT00236301|DRUG|placebo|placebo
57959962|NCT04799587|OTHER|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
58125276|NCT04471207|DEVICE|Record Only Prolonged Exposure with BioWare Device|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
57959963|NCT05460039|OTHER|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
57959964|NCT03175549|DRUG|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
58125277|NCT02921477|DRUG|bosutinib|
58125278|NCT02842697|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
58451573|NCT01105208|DRUG|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
58451574|NCT01105208|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
58451575|NCT02911974|DEVICE|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
58451576|NCT02911974|DEVICE|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
58451577|NCT05084430|DRUG|M032|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
57750171|NCT02879266|BIOLOGICAL|TetraVax-DV TV005|Contains 10\^3 plaque-forming units (PFUs) of rDEN1Δ30, 10\^4 PFUs of rDEN2/4Δ30(ME), 10\^3 PFUs of rDEN3Δ30/31-7164, and 10\^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
57750172|NCT02879266|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
57750173|NCT06451120|DRUG|Platelet-Rich Plasma (PRP) Injections|Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection
57750174|NCT06451120|DEVICE|Centrifuge|The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.
57750175|NCT03977558|BEHAVIORAL|Intervention group|Isocaloric diet including \~50g canola oil
57959965|NCT03175549|DRUG|Placebo|Identical placebo pills taken orally for 14 days
57959966|NCT01441752|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
57959967|NCT01441752|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
58451578|NCT05084430|DRUG|Pembrolizumab|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
58451579|NCT00003279|BIOLOGICAL|BCG vaccine|
58451580|NCT00003279|BIOLOGICAL|monoclonal antibody BEC2|
58451581|NCT01713959|DEVICE|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
58451582|NCT01713959|DEVICE|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
58451583|NCT02792231|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
58451584|NCT02792231|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
58451585|NCT02792231|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
58451586|NCT02792231|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
58451587|NCT02646631|OTHER|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
57750176|NCT03977558|BEHAVIORAL|Control group|ESC/EAS Guidelines for the management of dyslipidemias
57750177|NCT06323733|OTHER|Exercise Intervention|The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
57750178|NCT05917639|DEVICE|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
57750179|NCT05917639|DEVICE|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
57750180|NCT05917639|DEVICE|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
57750181|NCT05909514|BEHAVIORAL|PelvicSense(R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
57750182|NCT01615328|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
57750183|NCT01615328|DEVICE|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
57750184|NCT04010071|DRUG|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
57750185|NCT02348450|DRUG|Irinotecan|40mg
57750186|NCT02348450|DRUG|Etoposide|5ml：0.1g
57750187|NCT02348450|DRUG|Cisplatin|6ml：30mg
57750188|NCT01806987|BEHAVIORAL|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
57750189|NCT00330174|DRUG|Acamprosate|2 333mg tablets three times daily
57750190|NCT05802368|OTHER|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
57750191|NCT05802368|OTHER|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
58451588|NCT02646631|BEHAVIORAL|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
57750192|NCT04679181|OTHER|Telemedecine|telemedical consultation
57750193|NCT04151225|DRUG|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
58451589|NCT02646631|BEHAVIORAL|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
58451590|NCT02646631|OTHER|Educational Materials|Printed educational materials on the management of epilepsy
58451591|NCT00005952|BIOLOGICAL|filgrastim|
58451592|NCT00005952|DRUG|temozolomide|
58451593|NCT00005952|PROCEDURE|peripheral blood stem cell transplantation|
58451594|NCT05424016|DRUG|Propranolol|120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
58451595|NCT05424016|OTHER|follow-up|routine follow-up (neurosurgical consultation and an MRI every six months)
57750194|NCT04151225|DRUG|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
58125279|NCT02842697|PROCEDURE|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
58125280|NCT02842697|PROCEDURE|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
57750195|NCT05346003|PROCEDURE|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
57750196|NCT01410474|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
57750197|NCT03016767|PROCEDURE|Manual oral stimulation protocol|
57750198|NCT02657616|DRUG|vitamin-k-antagonists|
57750199|NCT02657616|DRUG|Novel oral anticoagulants|
57750200|NCT00760149|DRUG|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
57750201|NCT03523468|PROCEDURE|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
57750202|NCT03523468|PROCEDURE|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
57750203|NCT04888091|PROCEDURE|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
57750204|NCT04888091|PROCEDURE|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
57750205|NCT00413270|DRUG|nilotinib|
57750206|NCT01094925|DRUG|lactose|Single oral dose
57959968|NCT02307370|DEVICE|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
57959969|NCT01785134|PROCEDURE|Omentectomy|
57959970|NCT01785134|PROCEDURE|Gastric bypass operation|
57959971|NCT03152682|DIETARY_SUPPLEMENT|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
57750207|NCT01094925|DRUG|Gabapentin 300mg|Single oral dose of 300mg gabapentin
57959972|NCT03152682|OTHER|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
57959973|NCT00581295|DEVICE|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
57959974|NCT02001376|OTHER|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
57959975|NCT02001376|OTHER|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
57959976|NCT02001376|OTHER|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
58125281|NCT03653195|OTHER|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
58125282|NCT05629949|DRUG|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
57750208|NCT01094925|DRUG|Gabapentin 600mg|Single oral dose of 600mg gabapentin
57750209|NCT05009342|DEVICE|below-knee soft resin cast|Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
57750210|NCT05009342|DEVICE|Below-knee rigid resin cast|Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
57750211|NCT05154383|BIOLOGICAL|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
57750212|NCT05154383|BIOLOGICAL|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
57750213|NCT00686140|DRUG|celecoxib|400mg/day, twice a day, 12 weeks
57750214|NCT00686140|DRUG|Placebo|twice a day, 12 weeks
57750215|NCT05471648|DRUG|420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
57750216|NCT05471648|DRUG|Perjeta (EU origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
57750217|NCT05471648|DRUG|Perjeta (US origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
57750218|NCT02204995|PROCEDURE|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
57750219|NCT02204995|PROCEDURE|Trapeziectomy|Trapeziectomy
57959977|NCT02872623|RADIATION|Enterography-MRI without enteroclysis|
57959978|NCT02872623|RADIATION|enteroCT with enteroclysis|
57959979|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
57959980|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
58125283|NCT05629949|DRUG|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
58125284|NCT05629949|DRUG|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
58125285|NCT04716738|DIAGNOSTIC_TEST|Blood analyses and coprological|We will take a blood and stool sample
57750220|NCT02615964|RADIATION|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
57750221|NCT01011621|DRUG|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
57750222|NCT01011621|DRUG|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
57750223|NCT01314040|OTHER|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
57750224|NCT01314040|OTHER|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
57750225|NCT01314040|OTHER|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
57750226|NCT01314040|OTHER|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
58125286|NCT00503620|DRUG|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
58314597|NCT05848063|OTHER|Hip abductors strengthening exercises|Strengthening exercises will be given to hip abductor muscles
58451596|NCT03883581|DRUG|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
58451597|NCT00704938|BIOLOGICAL|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
58451598|NCT00704938|BIOLOGICAL|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.
58451599|NCT00704938|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
58451600|NCT00704938|BIOLOGICAL|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
58451601|NCT00704938|DRUG|cyclophosphamide|60mg/kg/day (Days-7,-6)
57750227|NCT03917667|DIAGNOSTIC_TEST|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
57750228|NCT03956472|PROCEDURE|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
57750229|NCT03956472|DEVICE|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
57750230|NCT03956472|OTHER|Fake Osteopathic protocol|Placebo intervention
58125287|NCT03714295|OTHER|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
58314598|NCT05000762|DIETARY_SUPPLEMENT|Zinc|Zinc gluconate 30 mg/day orally
58451602|NCT00704938|DRUG|fludarabine phosphate|25mg/m\^2 (Days -5, -4, -3, -2, and -1)
58451603|NCT05094726|RADIATION|photobiomodulation|Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.
58451604|NCT05094726|OTHER|placebo intervention by photobiomodulation device|placebo intervention while the photobiomodulation device is on the off mode
58451605|NCT03501472|BEHAVIORAL|text-only PWL|
58451606|NCT03501472|BEHAVIORAL|low-emot PWL|
58451607|NCT03501472|BEHAVIORAL|high-emot PWL|
57750231|NCT03956472|OTHER|PEEP-Sham|PEEP 0 cmH2O (hidden)
57959981|NCT01405261|DRUG|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
57959982|NCT01405261|DRUG|oral placebo|Subjects will be randomised to receive a single dose of placebo.
57959983|NCT06377826|OTHER|aerobic exercises|group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
58314599|NCT01895842|DRUG|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
58314600|NCT03056924|BIOLOGICAL|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
58314601|NCT03056924|BIOLOGICAL|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
58451608|NCT03501472|BEHAVIORAL|immed posttest|
58451609|NCT03501472|BEHAVIORAL|delay posttest|
58451610|NCT02727218|PROCEDURE|Chest tube removal|chest tube removal post thoracoscopic surgery
58451611|NCT03217955|BEHAVIORAL|CBT-SA|Info has been included in arm description
58451612|NCT03217955|BEHAVIORAL|Standard Treatment|Info has been included in arm description
57750232|NCT01572779|DEVICE|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
57750233|NCT01572779|DEVICE|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
57750234|NCT01963325|DRUG|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
57750235|NCT06048770|BIOLOGICAL|RBI-4000|RBI-4000 intramuscular injection.
57750236|NCT06048770|BIOLOGICAL|RabAvert|RabAvert intramuscular injection.
57750237|NCT03121157|BEHAVIORAL|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
57750238|NCT02954354|DRUG|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
57750239|NCT02954354|DRUG|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
57750240|NCT02954354|DRUG|Oseltamivir|75 mg capsules taken orally
57750241|NCT02954354|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
57750242|NCT06418555|BEHAVIORAL|A home rehabilitation program centered on exercise|Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
57750243|NCT05282797|DRUG|ANEB-001|Experimental Treatment
57750244|NCT05282797|DRUG|Placebo|Placebo comparator
57750245|NCT05596305|BEHAVIORAL|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
58451613|NCT04374461|DRUG|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
57750246|NCT05576584|DRUG|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
57750247|NCT05576584|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
57750248|NCT02426788|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
57750249|NCT03294330|DRUG|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
57750250|NCT00817180|OTHER|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
57750251|NCT00817180|OTHER|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
57750252|NCT00627380|BEHAVIORAL|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
57750253|NCT00627380|OTHER|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
57750254|NCT02255357|DRUG|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
57750255|NCT02255357|DRUG|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
57750256|NCT04417998|DRUG|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
57750257|NCT04417998|DRUG|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
58451614|NCT04374461|OTHER|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
57750258|NCT04417998|DEVICE|Siemens E7 Reconstruction Tool|Software to correct for motion
57750259|NCT00077064|DRUG|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
57750260|NCT00708240|DRUG|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
57750261|NCT04826601|OTHER|essential oils|A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
57750262|NCT04617002|DRUG|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
57750263|NCT05064852|DRUG|Surufatinib|The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.
57750264|NCT02520167|BEHAVIORAL|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
57750265|NCT03286374|BEHAVIORAL|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~1. Four weeks with an institutional stay at Muritunet (BL)~2. Follow-up;~   1. Eight weeks, telephone contact between therapist at Muritunet and the participant.~  2. 16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~  3. 28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~  4. 40 weeks, telephone contact between therapist at Muritunet and the participant.~  5. 52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
57750266|NCT06282679|DRUG|Botulinum Toxin Type A Injection [Botox]|you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
57750267|NCT01187979|BEHAVIORAL|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
57750268|NCT01187979|BEHAVIORAL|Life skills curriculum|Standard department of education lifeskills curriculum
57750269|NCT01430260|DRUG|Ciclesonide|200 ㎍ once daily
57750270|NCT01430260|DRUG|Levocetirizine|5mg once daily
57750271|NCT01430260|DRUG|Ciclesonide & Levocetirizine|"* Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily"
57750272|NCT04419090|OTHER|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
58451615|NCT01061359|DRUG|Epirubicin: Observational Study|Observational: Chemotherapy
57750273|NCT04621110|DRUG|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
57750274|NCT04621110|DRUG|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
57750275|NCT04621110|DRUG|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
58451616|NCT03351517|DRUG|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
58451617|NCT03351517|DRUG|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
57750276|NCT04621110|DRUG|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
57750277|NCT04861857|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement
57959984|NCT06377826|OTHER|resistance training|this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
57959985|NCT06377826|DRUG|medication|This group will be just on medication and no exercise will be given to this group
57959986|NCT01487759|DIETARY_SUPPLEMENT|Oligofructose enriched inulin|
58451618|NCT06061822|DIAGNOSTIC_TEST|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
58451619|NCT01592071|OTHER|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
58451620|NCT04590807|DEVICE|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
58451621|NCT04590807|DEVICE|Anterior vertebral body tethering|Vertebral screws and cable
58451622|NCT04851912|OTHER|Winterlight Apps|Longitudinal speech recordings
57750278|NCT04861857|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement
57750279|NCT03450902|COMBINATION_PRODUCT|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
57750280|NCT03450902|COMBINATION_PRODUCT|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
57750281|NCT03450902|COMBINATION_PRODUCT|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
57750282|NCT03450902|OTHER|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
57750283|NCT03298451|DRUG|Durvalumab|Durvalumab IV (intravenous infusion).
57750284|NCT03298451|DRUG|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
57750285|NCT03298451|DRUG|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
57750286|NCT03298451|DRUG|Sorafenib|Sorafenib, as per standard of care
58314602|NCT03056924|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
58451623|NCT03530397|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
57750287|NCT03298451|DRUG|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
57750288|NCT03298451|DRUG|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
57750289|NCT03182335|OTHER|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
57750290|NCT05437081|BEHAVIORAL|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
57750291|NCT05608850|OTHER|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
57750292|NCT05608850|OTHER|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
57750293|NCT00541450|DRUG|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
57750294|NCT00541450|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
57750295|NCT00541450|DRUG|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
58451624|NCT03530397|DRUG|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
57750296|NCT00541450|DRUG|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
57750297|NCT00541450|DRUG|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
58314603|NCT01481467|BEHAVIORAL|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
57959987|NCT01487759|DIETARY_SUPPLEMENT|Maltodextrin|
58314604|NCT05138562|DRUG|Placebo Comparator: Placebo|4 x placebo capsules, QD
58314605|NCT05138562|DRUG|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
58314606|NCT05138562|DRUG|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
58314607|NCT05138562|DRUG|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
58314608|NCT04817878|COMBINATION_PRODUCT|Developmental assessment|Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
58451625|NCT03530397|DRUG|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
58451626|NCT03530397|BIOLOGICAL|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
58125288|NCT05713591|BEHAVIORAL|Transition care model|The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
58125289|NCT00559156|DIETARY_SUPPLEMENT|arginine/omega-3 fatty acids/nucleotides oral supplement|
58125290|NCT00559156|DRUG|cisplatin|
58125291|NCT00559156|PROCEDURE|adjuvant therapy|
58125292|NCT00559156|RADIATION|radiation therapy|
58125293|NCT02771665|OTHER|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
58125294|NCT02745951|OTHER|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
58125295|NCT02745951|OTHER|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
58125296|NCT05641597|OTHER|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
58125297|NCT05641597|OTHER|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
58125298|NCT05641597|OTHER|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
58125299|NCT05641597|OTHER|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
58125300|NCT02380183|DEVICE|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
58125301|NCT05047406|DIETARY_SUPPLEMENT|Bacillus clausii Probiotic liquid|mini bottles for oral administration containing 2 million spores of Bacillus clausii
58314609|NCT02064062|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
58314610|NCT05743907|DRUG|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
58314611|NCT05743907|DRUG|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
58314612|NCT01336270|OTHER|biological collection|to collect some human cell samples in melanoma
58314613|NCT03772223|DRUG|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
58314614|NCT03772223|DRUG|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
58314615|NCT03772223|DRUG|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
58314616|NCT05486169|PROCEDURE|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
58314617|NCT00165074|DRUG|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
58314618|NCT02896166|OTHER|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
58314619|NCT01416571|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
58314620|NCT03613870|DEVICE|PermeaDerm|Wound treatment with PermeaDerm
58314621|NCT03613870|DEVICE|Mepilex Ag|Wound treatment with Mepilex Ag
58314622|NCT00255177|DRUG|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
58314623|NCT00255177|DRUG|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
58314624|NCT04778878|DEVICE|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
58314625|NCT05486273|OTHER|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
58314626|NCT05486273|OTHER|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
58314627|NCT03210532|DRUG|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
58314628|NCT03210532|DRUG|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
58451627|NCT03530397|DRUG|Paclitaxel or Nab-Paclitaxel|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
58451628|NCT05134558|RADIATION|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
58125302|NCT04911959|DRUG|Lenvatinib|Lenvatinib is taken orally.
58125303|NCT04911959|PROCEDURE|TACE|TACE treatment once.
58125304|NCT06001632|DIETARY_SUPPLEMENT|krill oil (SuperbaBoostTM)|4 g/day of Krill oil supplements (LC n-3 PUFAs) (1g capsule containing 191mg EPA, 94mg DHA and 78mg choline).
58314629|NCT03210532|DRUG|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
58314630|NCT04885608|OTHER|PReGe|There will be two weekly sessions of 45 minutes, outdoors in outdoor fitness parks. The components of balance, gait, resistance, strength and elasticity will be worked on and breathing exercises will be performed. The sessions will be guided and dosed by physiotherapists, considering the level of perception of effort. Indications will be given to carry out other sessions of 60 to 120 minutes of therapeutic walking (minimum speed of 4 km/hour) during the week, to complete the 150-300 minutes per week of physical activity recommended by the WHO.
58314631|NCT00370708|PROCEDURE|Oral Intake following admittance to the postpartum ward|
58314632|NCT06387017|DIAGNOSTIC_TEST|blood sampling|blood collection
58314633|NCT06387017|DIAGNOSTIC_TEST|stool collection|stool collection
58125305|NCT06001632|DIETARY_SUPPLEMENT|4g/day of mixed vegetable oil|vegetable oil capsules (mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
58125306|NCT04400526|BEHAVIORAL|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
58125307|NCT04400526|BEHAVIORAL|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
58451629|NCT03781661|OTHER|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
58451630|NCT01603303|BEHAVIORAL|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
57750298|NCT00541450|DRUG|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
58451631|NCT01603303|OTHER|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
58451632|NCT01603303|OTHER|Luvena|Use vaginally 2 or 3 times a week.
57750299|NCT05263466|DIAGNOSTIC_TEST|PET-MRI|For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
57750300|NCT05263466|PROCEDURE|Brain tumour biopsy|All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
57750301|NCT04355351|OTHER|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
58451633|NCT01603303|OTHER|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
58451634|NCT01603303|OTHER|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
57750302|NCT04355351|OTHER|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
57750303|NCT04073602|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
57750304|NCT00464815|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
57750305|NCT00464815|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose
57750306|NCT03081390|OTHER|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
57959988|NCT03849131|BIOLOGICAL|Biological collection|"Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.~It will include:~* DNA samples collection~* RNA samples collection~* Blood sample collection"
57959989|NCT01065688|PROCEDURE|Roux-en Y reconstruction|surgical procedure
58125308|NCT04400526|BEHAVIORAL|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
58451635|NCT01603303|BEHAVIORAL|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
58451636|NCT01603303|BEHAVIORAL|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
57959990|NCT01065688|PROCEDURE|Billroth-I reconstruction|surgical procedure
58125309|NCT01759290|DEVICE|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
58314634|NCT06387017|RADIATION|low dose CT scan|low dose CT scan evaluation
58451637|NCT04669808|DRUG|STP705|Dry powder for intra-and peri-lesional injection.
58451638|NCT01618669|DRUG|Regadenoson|Administered as an intravenous (IV) bolus
58451639|NCT01618669|PROCEDURE|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
58451640|NCT02921659|DIETARY_SUPPLEMENT|Niagen™|nicotinamide riboside chloride, 250mg capsules
58451641|NCT02921659|DIETARY_SUPPLEMENT|Placebo|silicified microcrystalline cellulose, vegetarian capsule
58451642|NCT00003425|BIOLOGICAL|filgrastim|
58451643|NCT00003425|DRUG|amifostine trihydrate|
58451644|NCT00003425|DRUG|cyclophosphamide|
58451645|NCT00003425|DRUG|melphalan|
58451646|NCT00003425|PROCEDURE|peripheral blood stem cell transplantation|
58125310|NCT01190969|DIETARY_SUPPLEMENT|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
58125311|NCT03781700|DRUG|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
58125312|NCT03781700|DRUG|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
58125313|NCT04784195|BEHAVIORAL|Observation|Verification of morfology and functionality of neck muscles
57750307|NCT03081390|OTHER|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
57750308|NCT03081390|OTHER|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
57750309|NCT01181726|DRUG|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
58125314|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
58125315|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
58125316|NCT02381977|OTHER|No intervention|
58125317|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
58125318|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
58125319|NCT05042141|DIETARY_SUPPLEMENT|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
58125320|NCT05042141|DIETARY_SUPPLEMENT|Placebo oral capsule|Placebo
58125321|NCT00454636|DRUG|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
58125322|NCT00454636|DRUG|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
58451647|NCT01555372|DEVICE|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
57750310|NCT01181726|DRUG|Activella®|1 mg/0.5 mg Tablets
57750311|NCT00994838|OTHER|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
57750312|NCT05035472|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
58125323|NCT00454636|DRUG|Epirubicin|50 mg/m2/day, IV, every 3 weeks
57750313|NCT05035472|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
57750314|NCT01479387|DRUG|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
57750315|NCT00466635|DRUG|GT267-004 (tolevamer potassium sodium)|
57750316|NCT02640378|OTHER|NO intervention|This study was a cross-sectional study. It had no intervention.
57750317|NCT00993655|DRUG|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
57750318|NCT00993655|DRUG|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
57750319|NCT00993655|DRUG|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
57750320|NCT02470130|BEHAVIORAL|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
57750321|NCT00311038|DRUG|ONO-1101|
57750322|NCT03731754|PROCEDURE|Traditional Closure|Primary closure discontinuously the perineal wound of APR
57750323|NCT03731754|PROCEDURE|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
57750324|NCT00500864|DRUG|Magnesium Sulfate 2 grams|
58125324|NCT00454636|DRUG|Cisplatin|60 mg/m2/day, IV, every 3 weeks
58125325|NCT00454636|DRUG|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
58125326|NCT00454636|DRUG|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
58125327|NCT00454636|DRUG|Docetaxel|60 mg/m2/day, IV, every 3 weeks
58125328|NCT00454636|DRUG|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
58125329|NCT00922974|RADIATION|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
58125330|NCT00922974|RADIATION|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
58314635|NCT03813108|BIOLOGICAL|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
58125331|NCT06303999|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58125332|NCT06303999|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58125333|NCT04800588|DIAGNOSTIC_TEST|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
58125334|NCT01091025|OTHER|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
58125335|NCT00365352|DRUG|XP13512 600MG|XP13512 600MG ONCE DAILY
58125336|NCT00365352|DRUG|XP13512 1200MG|XP13512 1200MG ONCE DAILY
58125337|NCT00365352|DRUG|PLACEBO|PLACEBO ONCE DAILY
58125338|NCT03741413|OTHER|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
58125339|NCT03741413|OTHER|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
58125340|NCT03741413|OTHER|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
58125341|NCT00846625|DRUG|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
58125342|NCT00846625|DRUG|ranibizumab|Intravitreal injection, 0.5 mg
58125343|NCT02070744|DRUG|VX-661|Tablet, oral use
58125344|NCT02070744|DRUG|Ivacaftor|Film coated tablet, oral use
58125345|NCT02070744|DRUG|Placebo matched to VX-661|Tablet, oral use
58125346|NCT02070744|DRUG|Placebo matched to Ivacaftor|Film coated tablet, oral use
58125347|NCT02978326|DRUG|SAGE-217 15/20 mg Oral Solution|SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
58125348|NCT02978326|DRUG|Placebo|SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
58125349|NCT02978326|DRUG|SAGE 217 30 mg Capsules|SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
58125350|NCT03481309|DEVICE|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
58125351|NCT03481309|DEVICE|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
58125352|NCT03481309|DEVICE|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
58125353|NCT02494713|DRUG|Degarelix|Subcutaneous injection, once/month for 4 months
58125354|NCT02494713|DRUG|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
57750325|NCT01063101|OTHER|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
58125355|NCT02494713|DRUG|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
58125356|NCT02494713|DRUG|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
58125357|NCT02494713|DRUG|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
58125358|NCT01648010|DEVICE|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
58125359|NCT01648010|DEVICE|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
58125360|NCT05793736|DEVICE|Biofeedback training|The intervention lasts 5 weeks, twice a week, each session lasts 45 minutes in which HRV (Heart Rate Variability) is detected, through plethysmographic sensors placed on the finger or earlobe during assigned tasks. During tasks that involve progressively more complex phases, they allow the person to receive immediate feedback on the video screen.
58125361|NCT05793736|DRUG|Treatment as usual|The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
58125362|NCT01506830|PROCEDURE|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
58125363|NCT01506830|PROCEDURE|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
58125364|NCT00381537|DRUG|phenobarbitone|
58125365|NCT00381537|DRUG|carbamazepine|
58314636|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
57750326|NCT01063101|OTHER|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
57750327|NCT04430751|BEHAVIORAL|Medical QiGong training|"The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization."
57750328|NCT03664505|DEVICE|Compression garment (manual)|Garment based on manual measurement
58314637|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
58314638|NCT03813108|BIOLOGICAL|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
58314639|NCT03813108|DRUG|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
58451648|NCT01555372|DEVICE|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
58451649|NCT06409065|BEHAVIORAL|Meditation Program|Meditation and discussion sessions will be audio recorded
57750329|NCT03664505|DEVICE|Compression garment (scan)|Garment based on scan measurement
57750330|NCT02425332|DEVICE|Lokomat gait trainer|
57750331|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
58314640|NCT05534542|OTHER|exercıse|ıntradıalıtıc core stabılızatıon
58314641|NCT04173949|DRUG|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
58451650|NCT00327106|DRUG|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
58451651|NCT00327106|DRUG|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
58451652|NCT04079426|OTHER|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
57750332|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
57750333|NCT03133026|DEVICE|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
57750334|NCT00941993|DEVICE|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
57750335|NCT02507648|DRUG|Oseltamivir|1 tablet contains 75 mg oseltamivir
57750336|NCT02507648|DRUG|Tamiflu®|1 tablet contains 75 mg oseltamivir
57750337|NCT03281148|DEVICE|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
57750338|NCT03281148|DEVICE|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
57750339|NCT06319417|DIETARY_SUPPLEMENT|HT treatment|Total consumption of 60 mg/day of HT
58314642|NCT03873584|OTHER|Fatigue|Iron deficiency anemia with fatigue symptoms
58314643|NCT04763967|DEVICE|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
58314644|NCT04763967|DEVICE|Standard of Care|Current Standard of Care for pediatric patients
57750340|NCT06319417|DIETARY_SUPPLEMENT|Placebo treatment|Consumption of placebo treatment of 4 caramels/day
57959991|NCT05639972|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
57959992|NCT05639972|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
57959993|NCT06045338|BEHAVIORAL|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
57959994|NCT04093531|DRUG|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
58314645|NCT05980546|DRUG|Bupivacaine Injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
58451653|NCT03111836|BEHAVIORAL|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
57750341|NCT05443165|BEHAVIORAL|The effectiveness of the online decision support system developed for symptom self-management|"The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area."
57750342|NCT05443165|BEHAVIORAL|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
57750343|NCT02306759|DRUG|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
57750344|NCT02306759|DRUG|Placebo|Normal saline 50ml, administered over 15 minutes
57750345|NCT01843192|DEVICE|Endocutter|
57750346|NCT01271348|DRUG|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
57750347|NCT01271348|DRUG|placebo|Placebo tablet, q.d.
57750348|NCT01665664|OTHER|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
57750349|NCT04072094|PROCEDURE|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
57750350|NCT04072094|PROCEDURE|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
57750351|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
57750352|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
58451654|NCT03111836|BEHAVIORAL|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
58451655|NCT03111836|BEHAVIORAL|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
57750353|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
57750354|NCT00654901|BIOLOGICAL|Infanrix Hexa™|0.5 mL, Intramuscular
57750355|NCT04238026|PROCEDURE|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
58451656|NCT05437523|OTHER|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
57750356|NCT03177668|DRUG|YS110|Intravenous administration
57750357|NCT00324584|DEVICE|Telemonitoring of glucose values using GlucoNet device|
57750358|NCT04575168|DIAGNOSTIC_TEST|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
57750359|NCT05521854|BEHAVIORAL|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
57750360|NCT05521854|BEHAVIORAL|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
57750361|NCT06156423|OTHER|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
58314646|NCT05980546|DRUG|Dexamethasone injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
58314647|NCT05980546|DRUG|Fentanyl|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
57750362|NCT06156423|OTHER|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
57750363|NCT05933759|BEHAVIORAL|Telemedical coaching|Individual telemedical coaching delivered by a nutritional consultant
57750364|NCT05933759|BEHAVIORAL|Low-Insulin-Method|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
58451657|NCT05437523|OTHER|Standard of care without constipation action plan|Standard of care without constipation action plan
57750365|NCT05902962|DRUG|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
58314648|NCT05980546|DRUG|Mepivacaine|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
58314649|NCT02908347|DRUG|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
58314650|NCT02908347|DRUG|Placebo|hard gelatine capsules without active ingredient
57750366|NCT03462732|DEVICE|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
57750367|NCT03462732|DEVICE|Nelaton catheter|plus nelaton catheter
57750368|NCT04272580|DRUG|Control group|No preload was given before spinal anesthesia.
57750369|NCT04272580|DRUG|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
57750370|NCT04272580|DRUG|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
57750371|NCT04272580|DRUG|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
57750372|NCT06525948|DRUG|rhTPO|rhTPO
57750373|NCT06525948|DRUG|Cyclosporin A|cyclosporine A
57750374|NCT03695302|BEHAVIORAL|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
57750375|NCT02428465|BEHAVIORAL|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
57750376|NCT03802864|DRUG|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
58125366|NCT06095258|DRUG|Traditional Chinese medicine treatment|About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
58451658|NCT05665894|DEVICE|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
58451659|NCT04899622|BEHAVIORAL|MBSR|Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
58451660|NCT04899622|BEHAVIORAL|Exercise|"Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises."
57750377|NCT03802864|DRUG|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
57750378|NCT00156793|PROCEDURE|AI-700 contrast-enhanced echocardiography|
57750379|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
57750380|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
57750381|NCT03634124|BIOLOGICAL|Blood test|Additional blood test of 4,5 ml of venous blood
57750382|NCT03634124|OTHER|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
57750383|NCT04367857|OTHER|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
58125367|NCT06095258|DRUG|Western medicine treatment|Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
57750384|NCT04367857|BEHAVIORAL|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
58125368|NCT01964664|BEHAVIORAL|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
58125369|NCT01964664|BEHAVIORAL|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
58125370|NCT00502775|DRUG|fluticasone furoate, fexofenadine|
58125371|NCT04125654|DEVICE|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
58125372|NCT05250414|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
58125373|NCT04516850|GENETIC|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
58125374|NCT04516850|GENETIC|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
58125375|NCT05606393|OTHER|virtual reality speech training|virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software
58125376|NCT05606393|OTHER|traditional speech therapy|traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
58125377|NCT04586621|DEVICE|Atoldys/ Lexilens - SHAM|Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
58125378|NCT04586621|DEVICE|SHAM- Atoldys/ Lexilens|SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
58125379|NCT00933751|DEVICE|Central vein catheterization|Blood samplings from IVC catheter
58451661|NCT04899622|BEHAVIORAL|Online Self-Management Guide|Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
58125380|NCT01934296|DEVICE|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
58125381|NCT03085173|BIOLOGICAL|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
58125382|NCT05997056|DRUG|nab-sirolimus|Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion
58125383|NCT02490488|DRUG|Masitinib|
58125384|NCT02490488|DRUG|Gemcitabine|
58125385|NCT02490488|DRUG|Placebo|
58125386|NCT04801966|DRUG|Trametinib|2 mg per day, continuous
58125387|NCT04801966|DRUG|Cobimetinib|60 mg/day for 21 days of a 28 day cycle
58125388|NCT04801966|DRUG|Binimetinib|45 mg/twice a day, continuous
58125389|NCT04801966|DRUG|Alpelisib|300 mg/day, continuous
58125390|NCT04801966|DRUG|Vemurafenib|960 mg/twice per day, continuous
58125391|NCT04801966|DRUG|Dabrafenib|150 mg/twicce per day, continuous
58125392|NCT04801966|DRUG|Encorafenib|450 mg/day, continuous
58125393|NCT04801966|DRUG|Palbociclib|125 mg/day, day 1-21 of a 28 day cycle
58125394|NCT04801966|DRUG|Olaparib|300 mg/twice per day, continuous
58125395|NCT04801966|DRUG|Ribociclib|600 mg/day, on day 1 -21 of a 28 day cycle
58125396|NCT04801966|DRUG|Abemaciclib|150 mg twice/day, continuous
58125397|NCT04801966|DRUG|Talazoparib|1 mg/day, on day 1 -28 of each 28 day cycle
58125398|NCT04801966|DRUG|Nivolumab|240 mg IV once every 2 weeks
58125399|NCT04801966|DRUG|Atezolizumab|1200 mg IV on Day 1 of a 21 day cycle
58314651|NCT04456127|PROCEDURE|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
58314652|NCT01490710|OTHER|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient...)
58125400|NCT04801966|DRUG|Pembrolizumab|200 mg IV on day 1 of a 21 day cycle
58125401|NCT03473314|DRUG|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
58125402|NCT04323670|DEVICE|"Selectra 3D guiding catheter"|His lead measurements
58125403|NCT03415906|COMBINATION_PRODUCT|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
58125404|NCT03415906|DRUG|valsartan|Angiotensin receptor inhibition alone
58125405|NCT01788956|DEVICE|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
58125406|NCT01788956|DEVICE|Co-Oximeter|
58125407|NCT05528016|PROCEDURE|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
58125408|NCT00669864|DRUG|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
58125409|NCT00669864|DRUG|metformin|Tablets, 1000 - 2000 mg daily
58125410|NCT03876613|BEHAVIORAL|Different music types|the type of music that reduces anxiety best and most effectively.
58125411|NCT01623128|BEHAVIORAL|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
58125412|NCT03236857|DRUG|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
58125413|NCT03236857|DRUG|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
58125414|NCT01766921|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
58125415|NCT04560881|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
58125416|NCT04560881|BIOLOGICAL|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
58125417|NCT01659567|DRUG|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
58125418|NCT01659567|DRUG|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
58125419|NCT00408902|DRUG|tandutinib|Given orally, 500 mg bid daily
58125420|NCT00408902|OTHER|laboratory biomarker analysis|Correlative studies
58125421|NCT00442806|DRUG|Injection of ADRC's|ADRC's are injected
58125422|NCT00442806|OTHER|Injection of Placebo|Placebo is injected
58125423|NCT02740608|DEVICE|OrganOx metra|Normothermic Machine Liver Perfusion
57750385|NCT03758963|DEVICE|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
57750386|NCT06243705|DEVICE|Robot-Pet|The robot-pet makes sounds like a real cat and responds to touch and petting
57750387|NCT06243705|DEVICE|Virtual Reality Glasses|VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
58125424|NCT03146091|OTHER|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
58125425|NCT03146091|OTHER|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
58125426|NCT04646057|DEVICE|DuraSorb®|Monofilament Surgical Mesh
58125427|NCT00352157|BEHAVIORAL|Revival Soy Dietary Supplement|
58125428|NCT00212095|DRUG|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
58125429|NCT03166982|PROCEDURE|transvaginal approach|
58125430|NCT03166982|PROCEDURE|laparoscopic approach|
58125431|NCT01153984|DRUG|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
58125432|NCT00233857|PROCEDURE|Auricular acupuncture|
58314653|NCT01490710|OTHER|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
58451662|NCT05491408|DEVICE|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure \[4,5\].
58451663|NCT03178435|OTHER|Measures to prevent AKI among critically ill patients|"1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary"
58451664|NCT02398240|DRUG|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
58451665|NCT02398240|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
58451666|NCT02398240|DRUG|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
57750388|NCT04557930|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
58125433|NCT05993338|DIAGNOSTIC_TEST|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
58125434|NCT04439656|DIAGNOSTIC_TEST|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
58314654|NCT06228339|DRUG|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
58314655|NCT06228339|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (Reference Drug)
58314656|NCT00004855|DRUG|Lopinavir/Ritonavir|
58314657|NCT00004855|DRUG|Abacavir sulfate|
58314658|NCT00004855|DRUG|Nevirapine|
58314659|NCT00004855|DRUG|Lamivudine|
58314660|NCT00004855|DRUG|Stavudine|
58451667|NCT02398240|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
58125435|NCT05153122|DEVICE|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
58125436|NCT02523456|BEHAVIORAL|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
58125437|NCT02523456|BEHAVIORAL|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
58125438|NCT02873988|OTHER|bronchial epithelial cell culture|
58125439|NCT00001776|DEVICE|Cadwell Rapid Rate Magnetic Stimulator|
58125440|NCT05123937|OTHER|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
58125441|NCT05123937|OTHER|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
58125442|NCT06132035|DRUG|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
58125443|NCT06132035|DRUG|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
58125444|NCT06132035|DRUG|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
58125445|NCT05530356|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
58125446|NCT05530356|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
58125447|NCT05530356|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
58125448|NCT05530356|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
57750389|NCT02006082|DEVICE|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
57750390|NCT06545981|OTHER|Lumbar puncture and administration of medication|Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
57750391|NCT03210155|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
57750392|NCT03210155|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
58125449|NCT05530356|RADIATION|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
58125450|NCT02686216|DRUG|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
58125451|NCT02962128|DIETARY_SUPPLEMENT|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high \[10% energy\] LA-containing diet for 12 weeks.
58125452|NCT02962128|DIETARY_SUPPLEMENT|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low \[2.5% energy\] LA-containing diet for 12 weeks.
58125453|NCT00892398|DRUG|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
58125454|NCT00892398|PROCEDURE|standard care|standard post-operative care after trabeculectomy with mitomycin C
58451668|NCT04674007|OTHER|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
58451669|NCT02316080|OTHER|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
58451670|NCT02316080|OTHER|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
58451671|NCT00028847|DRUG|cytarabine|
58125455|NCT02845258|PROCEDURE|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
58125456|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
57750393|NCT02840357|OTHER|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
57750394|NCT02840357|OTHER|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
57750395|NCT04523987|DRUG|Ciprofloxacin|Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
57750396|NCT01194570|DRUG|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
57750397|NCT01194570|OTHER|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
57750398|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
57750399|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
57750400|NCT05120089|OTHER|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
57750401|NCT01236079|BEHAVIORAL|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
57750402|NCT01345630|DRUG|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
57750403|NCT01345630|DRUG|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
57750404|NCT01345630|DRUG|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
57750405|NCT01345630|DRUG|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
57750406|NCT01345630|DRUG|placebo for maraviroc|placebo for maraviroc
57750407|NCT04499573|DRUG|CD19/CD22 CAR-T|"The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg"
57750408|NCT05543850|DEVICE|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
57750409|NCT05543850|DEVICE|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
57750410|NCT05673226|OTHER|Surface disinfection with Organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
57750411|NCT06082245|PROCEDURE|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~* patients received general anesthesia"
57750412|NCT06082245|PROCEDURE|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~* patients received general anesthesia"
57750413|NCT06082245|PROCEDURE|Lidocaine injection|"* patients received general anesthesia~* the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
57750414|NCT05210855|DIAGNOSTIC_TEST|CT scan|Scan with classic dose followed by ultra-low dose
57750415|NCT02256215|DRUG|Vitamin D|
58125457|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
58314661|NCT05018780|OTHER|Muscle Energy Technique|"Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
58125458|NCT06036511|DRUG|Ketamine Hydrochloride|"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."
58125459|NCT03047226|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
58125460|NCT06121453|BEHAVIORAL|Multicomponent Adherence Intervention|multi-part intervention to reduce barriers to medication use
58125461|NCT04072588|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
58125462|NCT02142244|PROCEDURE|Near infra red sentinel node biopsy|Explicated in the protocol arm
58125463|NCT02142244|DRUG|Indocyanine green|Explicated in the protocol arm
58451672|NCT00028847|DRUG|imatinib mesylate|
58451673|NCT01242917|DRUG|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
58451674|NCT01242917|DRUG|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
58451675|NCT01242917|DRUG|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
58451676|NCT06330740|OTHER|Clinical Decision Support|Upon ordering antibiotics the provider will be prompted to utilize an indication-based order set which guides the clinician to the appropriate empiric antibiotic choice.
58451677|NCT00254137|DRUG|capecitabine|
58451678|NCT00254137|DRUG|irinotecan|
58451679|NCT00254137|DRUG|oxaliplatin|
58451680|NCT00254137|DRUG|cetuximab|
58451681|NCT05586919|PROCEDURE|Direct Puncture Repair / Ethanol|Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
58451682|NCT05586919|PROCEDURE|Direct Puncture Repair / Polidocanol|Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
57750416|NCT05004987|DRUG|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
57750417|NCT05004987|DRUG|Placebo|Daily dose of placebo will mimic that of ESC.
58451683|NCT00800566|DRUG|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
58451684|NCT04948047|DIAGNOSTIC_TEST|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
58451685|NCT04948047|DIAGNOSTIC_TEST|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
58451686|NCT06362096|DRUG|Trastuzumab+pyrotinib+taxene|Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes
58451687|NCT02490449|DRUG|Dexlansoprazole MR|Administration of drug after or before diet
57750418|NCT05182567|DRUG|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
57750419|NCT05182567|DRUG|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
57750420|NCT05182567|DRUG|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
57750421|NCT05182567|DRUG|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
58451688|NCT04934566|OTHER|ECMO flow|Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
58451689|NCT02029911|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
58451690|NCT03997461|DEVICE|BPro|BPro and Oscar 2 comparison for 24 hours
58451691|NCT04339816|DRUG|Azithromycin|orally or into nasogastric tube for 5 days
58451692|NCT04339816|DRUG|Hydroxychloroquine|orally or into nasogastric tube for 5 days
58451693|NCT04339816|DRUG|Placebo|orally or into nasogastric tube for 5 days
58451694|NCT03715803|DEVICE|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
58451695|NCT03715803|DEVICE|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
58451696|NCT05513339|DEVICE|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
58451697|NCT03679065|DRUG|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
58451698|NCT03679065|DRUG|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
57750422|NCT02044185|DRUG|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
57750423|NCT00800839|DRUG|Busulfan|Starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
57750424|NCT00800839|DRUG|Fludarabine|Dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
57750425|NCT00800839|DRUG|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
57750426|NCT03362450|OTHER|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
58125464|NCT02142244|DEVICE|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
58125465|NCT01170442|DRUG|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
58125466|NCT01170442|DRUG|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
58125467|NCT01170442|DRUG|Placebo|placebo orally, daily for six months
58125468|NCT01921426|DRUG|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
58125469|NCT03472729|OTHER|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
58125470|NCT03020121|PROCEDURE|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
58125471|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
58125472|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
58125473|NCT03054103|DRUG|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
58125474|NCT04502875|DRUG|PRP|Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
58125475|NCT04502875|DRUG|PPP|PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
58125476|NCT06120127|RADIATION|SBRT|postoperative SBRT of liver lesions
58125477|NCT06120127|DRUG|Chemotherapy|XELOX/FOLFOX/FOLFIRI
58125478|NCT06120127|DRUG|PD-1 antibody|Sintilimab (200mg d1，q3w)
58125479|NCT06146257|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
58451699|NCT03679065|DRUG|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
58125480|NCT02268669|OTHER|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
58451700|NCT04410094|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
58125481|NCT01024738|DRUG|Fluoride|Brush half mouth twice daily for four days.
58125482|NCT01024738|DRUG|Triclosan, fluoride|Brush twice daily
58125483|NCT01024738|DRUG|Chlorhexidine Gluconate|Rinse mouth twice a day
58125484|NCT03050593|DIAGNOSTIC_TEST|MRI scan, Echo scan|
58125485|NCT01925755|OTHER|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
58125486|NCT03806036|DRUG|Vitamin D|300.000 I.U single dose of VIT D IM injection
58451701|NCT04410094|DRUG|Itraconazole|Itraconazole capsules will be administered orally.
57750427|NCT05280418|BIOLOGICAL|Tezepelumab|Monoclonal antibody designed for the treatment asthma.
57750428|NCT05280418|BIOLOGICAL|Placebo|Matched placebo.
58125487|NCT03806036|DRUG|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
58125488|NCT04723602|BIOLOGICAL|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
58125489|NCT04723602|BIOLOGICAL|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
58125490|NCT01909622|DIETARY_SUPPLEMENT|Vitamin D|
58125491|NCT01909622|DIETARY_SUPPLEMENT|No vitamin D|
58125492|NCT04956666|DRUG|Lyophilized S95014|"Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015."
58125493|NCT00261157|DEVICE|InTouch Telerounding Robot|
58125494|NCT02593851|DRUG|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
58125495|NCT02593851|DRUG|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
58125496|NCT01725945|BEHAVIORAL|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
58125497|NCT01827722|DRUG|Ozurdex|Intravitreal injection of Ozurdex
58125498|NCT01827722|DRUG|Ranibizumab|Intravitreal Injection of Ranibizumab
58125499|NCT01827722|DRUG|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
58451702|NCT04410094|DRUG|Rifampin|Rifampin capsules will be administered orally.
58451703|NCT05520632|DIAGNOSTIC_TEST|Brainstem Auditory Evoked Potentials|Performing Brainstem Auditory Evoked Potentials under sedation
58451704|NCT02146794|DEVICE|Renal denervation|Renal denervation
58451705|NCT03469466|DIAGNOSTIC_TEST|bedside ultrasound|bedside ultrasound imaging of the lungs
58125500|NCT00359086|DRUG|MGCD0103|MGCD0103 given orally three times per week
58125501|NCT00704795|OTHER|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
58125502|NCT00704795|OTHER|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
58125503|NCT03466190|PROCEDURE|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
58125504|NCT03466190|PROCEDURE|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
58125505|NCT04154748|DEVICE|Argon Plasma Coagulation 90W power|
58125506|NCT04154748|DEVICE|Argon Plasma Coagulation 60W power|
58125507|NCT04154748|DRUG|Omeprazole 120 mg|
58125508|NCT04154748|DRUG|Omeprazole 40 mg|
58125509|NCT01226056|DRUG|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
58125510|NCT02297009|PROCEDURE|Buccal swab|Buccal swabs will be taken from the volunteers
58125511|NCT01989520|DRUG|Phase IIb formulation|Single oral dose 45mg AZD5069
58125512|NCT01989520|DRUG|Putative phase III formulation|Single oral dose 45mg AZD5069
58125513|NCT01989520|DRUG|Slow dissolution variant 1|Single oral dose 45mg AZD5069
58125514|NCT01989520|DRUG|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
58125515|NCT01989520|DRUG|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
58125516|NCT01055223|DRUG|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
58125517|NCT01055223|DRUG|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
58125518|NCT01055223|DRUG|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
58125519|NCT03560375|BEHAVIORAL|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
57750429|NCT05408806|OTHER|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
57750430|NCT00003617|DRUG|chlorambucil|
58125520|NCT03560375|BEHAVIORAL|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
58125521|NCT03560375|DRUG|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
58125522|NCT04322175|DRUG|Meloxicam|Meloxicam Eye Drops
57750431|NCT00003617|DRUG|clarithromycin|
57750432|NCT00003617|DRUG|omeprazole|
57750433|NCT00003617|DRUG|tinidazole|
58125523|NCT05115032|DEVICE|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
58125524|NCT05115032|BEHAVIORAL|At-home rehabilitation exercises|6 weeks of daily rehabilitation exercises involving nodding and shaking of the head
58125525|NCT05251493|DRUG|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
58125526|NCT05251493|DRUG|Iron sucrose|iron sucrose 100 mg/mL
58125527|NCT00004109|DRUG|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
58125528|NCT00004109|RADIATION|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
58451706|NCT05771649|BEHAVIORAL|Mindfulness-based intervention|A mindfulness instructor will guide focused attention meditations that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
58125529|NCT02034331|DRUG|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
58125530|NCT02034331|DRUG|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
58125531|NCT02034331|DRUG|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
58125532|NCT02034331|OTHER|Heat application|For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
58125533|NCT00634907|GENETIC|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
58125534|NCT00634907|OTHER|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
58125535|NCT02718495|DRUG|PTI-428|
58125536|NCT02718495|DRUG|Placebo|
58125537|NCT05424926|OTHER|collection of clinical parameters and blood sample|"* A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
58125538|NCT02149303|DRUG|Dabigatran 75 mg|PO BID
58125539|NCT02149303|DRUG|Dabigatran 150 mg|PO BID
58125540|NCT02433665|DRUG|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
58125541|NCT02433665|DEVICE|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
58125542|NCT05276284|COMBINATION_PRODUCT|Atezolizumab, 6-mercaptopurine, 6-thioguanine|Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
58125543|NCT03923036|DRUG|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
58125544|NCT02520271|BEHAVIORAL|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
58125545|NCT02520271|BEHAVIORAL|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
58451707|NCT05771649|BEHAVIORAL|Physical exercise|An instructor will guide to running with mental association strategies that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
58451708|NCT00547651|DRUG|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
58451709|NCT00547651|DRUG|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
58451710|NCT04924816|PROCEDURE|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
58125546|NCT05790174|BEHAVIORAL|"ROS chubby and healthy - a multidisciplinary family-based weight-loss treatment program"|"The weight-loss treatment program ROS is family-based and delivered by a multidisciplinary team of physicians, nurses, dieticians, and psychologists. The treatment is based on an individualized tailored plan made together with the family. The plan consists of dietary changes, more physical activity, regular weight checks, and motivational conversations. The program includes options of cooking classes, group session with a psychologist and participation in structured physical activity called ROS sports twice a week. Follow up visits are scheduled every 2-3 months at the different health care professionals."
58125547|NCT03382366|DIAGNOSTIC_TEST|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
58125548|NCT03937063|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
58125549|NCT02841774|DRUG|Pravastatin|40mg daily (Weeks 2 - 14)
58125550|NCT02841774|DRUG|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
58125551|NCT01153048|OTHER|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
58125552|NCT03494595|PROCEDURE|Pediatric Liver transplantation|Pediatric Liver transplantation
58125553|NCT06461208|DRUG|Encapsulated FMT|Encapsulated Faecal Microbiota Transplant
58125554|NCT06461208|OTHER|Placebo|The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
58125555|NCT04319666|DEVICE|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
58125556|NCT01984242|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
58125557|NCT01984242|DRUG|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
58125558|NCT01984242|DRUG|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
58125559|NCT00551005|DRUG|celecoxib|
58125560|NCT00551005|DRUG|etoposide|
58125561|NCT00551005|OTHER|immunoenzyme technique|
58125562|NCT00551005|OTHER|laboratory biomarker analysis|
58125563|NCT03559387|DRUG|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
58125564|NCT03559387|DRUG|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
58125565|NCT03820583|PROCEDURE|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
58125566|NCT04483700|DRUG|Filgotinib|Tablets administered orally once daily
58125567|NCT04483700|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
58125568|NCT04832113|OTHER|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
58125569|NCT04832113|OTHER|conventional management|Dietary and hydratation advices according to the recommendations
58125570|NCT00016926|DRUG|capecitabine|
58125571|NCT00343759|DRUG|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
58125572|NCT02975271|DRUG|Serlopitant|
58125573|NCT02975271|DRUG|Placebo|Matching placebo
58125574|NCT05102175|OTHER|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
58125575|NCT00202449|DRUG|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
58125576|NCT00202449|DRUG|paroxetine|20 mg taken at 10a for duration of the study
58125577|NCT00202449|DRUG|Placebo|Placebo
58125578|NCT06454006|DEVICE|Placebo PBMT-sMF|Placebo, without therapeutic dose.
58451711|NCT05926934|DEVICE|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
58125579|NCT06454006|DEVICE|Active PBMT-sMF|Active with a dose of 31.50 J per site.
58314662|NCT05018780|OTHER|Sacral Manipulation|"* To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
57750434|NCT01484639|OTHER|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
57750435|NCT01484639|OTHER|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
57959995|NCT00584194|BIOLOGICAL|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to \< 1:40.
57959996|NCT00314600|DEVICE|above and below elbow cast|
57959997|NCT00640328|DRUG|Ofatumumab 100|100mg
57959998|NCT00640328|DRUG|Ofatumumab 300|300mg
57959999|NCT00640328|DRUG|Ofatumumab 700|700mg
57960000|NCT00640328|DRUG|Placebo|matching placebo
57960001|NCT04161131|BEHAVIORAL|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
57960002|NCT00006089|OTHER|Laboratory Biomarker Analysis|Correlative studies
57960003|NCT00006089|BIOLOGICAL|Trastuzumab|Given IV
57960004|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
57960005|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
57960006|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
57960007|NCT03861676|RADIATION|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
57960008|NCT03861676|DRUG|(18F)DCFPyL|18F-DCFPyl PET/CT scan
57960009|NCT00163787|BEHAVIORAL|outcome measures and self report|
57960010|NCT03413020|DRUG|esomeprazole|proton pump inhibitor
57960011|NCT03413020|DRUG|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
57960012|NCT03413020|DRUG|amoxicillin|antibiotic for H. pylori eradication
57960013|NCT03413020|DRUG|clarithromycin|antibiotic for H. pylori eradication
57960014|NCT03413020|DRUG|metronidazole|antibiotic for H. pylori eradication
57960015|NCT03413020|DRUG|levofloxacin|antibiotic for H. pylori eradication
57960016|NCT06394687|DIETARY_SUPPLEMENT|Milk Protein Concentrate|Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.
57960017|NCT06394687|DIETARY_SUPPLEMENT|Micellar Casein Isolate|Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.
57960018|NCT00465959|DRUG|trospium chloride inhalation powder (TrIP)|
57960019|NCT00465959|DRUG|Placebo|
57960020|NCT02799069|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
57960021|NCT02799069|DRUG|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
57960022|NCT02799069|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
57960023|NCT06212245|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg
57960024|NCT03448588|DIAGNOSTIC_TEST|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
57960025|NCT01428817|DRUG|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
57960026|NCT01428817|DRUG|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
57960027|NCT01428817|DRUG|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
58125580|NCT06098846|DIETARY_SUPPLEMENT|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
58125581|NCT06098846|DIETARY_SUPPLEMENT|Placebo transdermal patch|Application of a placebo transdermal patch
58125582|NCT01054508|DRUG|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
58125583|NCT04962685|OTHER|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
58125584|NCT00417690|DRUG|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
58125585|NCT00417690|DRUG|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
58125586|NCT05412498|BEHAVIORAL|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
58125587|NCT05412498|BEHAVIORAL|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
58125588|NCT01819636|OTHER|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
58125589|NCT00315874|DRUG|Buprenorphine transdermal delivery system|
58125590|NCT02551289|OTHER|Gluten free diet|Patients will follow a gluten free diet
58125591|NCT01152203|DRUG|Bendamustine|Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
58125592|NCT01152203|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
58125593|NCT06496737|BEHAVIORAL|Moderate-Intensity Interval Training (MIIT)|Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches, three times a week for 12 weeks
58125594|NCT06496737|BEHAVIORAL|High-Intensity Interval Training (HIIT)|High-Intensity Interval Training (HIIT) is developed by university badminton coaches, three times a week for 12 weeks
58125595|NCT05249907|OTHER|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
58125596|NCT00698100|BIOLOGICAL|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
57960028|NCT01428817|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
57750436|NCT05925374|BEHAVIORAL|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
57960029|NCT01428817|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
57960030|NCT02751840|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine capsule before RMR measurement
57960031|NCT02751840|DIETARY_SUPPLEMENT|Placebo|Placebo capsule (starch) before RMR measurement
57960032|NCT02751840|OTHER|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
57960033|NCT02751840|OTHER|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
57960034|NCT01411748|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
57960035|NCT01411748|DRUG|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
57960036|NCT01816581|DRUG|Targin|
57960037|NCT01816581|DRUG|Oxynorm|
57960038|NCT01816581|DRUG|Morphine|
57960039|NCT00003580|DRUG|amifostine trihydrate|
57960040|NCT00003580|DRUG|cisplatin|
57960041|NCT00003580|RADIATION|radiation therapy|
57960042|NCT00554203|DRUG|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
57960043|NCT01780025|BEHAVIORAL|Auditory evoked potentials and audiometry|
57960044|NCT01780025|BEHAVIORAL|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
57960045|NCT03686397|DRUG|SVT-15652|1 vial twice daily
57960046|NCT03686397|DRUG|Placebo|1 vial twice daily
57960047|NCT02822066|PROCEDURE|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
57960048|NCT03640039|PROCEDURE|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
57960049|NCT04741724|DEVICE|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
57960050|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
57960051|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
57960052|NCT03023943|OTHER|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
57960053|NCT05105178|OTHER|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
57960054|NCT05105178|OTHER|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
58125597|NCT00698100|BIOLOGICAL|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
58125598|NCT04255719|PROCEDURE|DBS|Unilateral DBS for treatment of patients with PD
58125599|NCT02032368|PROCEDURE|transarterial chemoembolization (TACE)|
58125600|NCT01157390|OTHER|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage \& frequency: Fed as need Duration: at least 3 months
58125601|NCT01157390|OTHER|Breast feeding|Breast feeding
58125602|NCT02259556|BIOLOGICAL|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
58125603|NCT01095510|BIOLOGICAL|CINRYZE|
58125604|NCT03767192|DEVICE|Active Stimulation|SPG stimulation and standard of care
58125605|NCT03767192|DEVICE|Sham Stimulation|Sham SPG stimulation and standard of care
58125606|NCT05152719|BEHAVIORAL|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
58125607|NCT02920411|OTHER|Pediatopic Treatment Cream|Applied twice a day minimum.
58125608|NCT02920411|OTHER|Pediatopic Body lotion|Applied at libitum.
58125609|NCT02353130|DRUG|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
58125610|NCT00927147|RADIATION|BNCT|Boronophenylalanine infusion followed by neutron irradiation
58125611|NCT00927147|DRUG|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
58125612|NCT02401542|DRUG|Vofatamab|
58125613|NCT02401542|DRUG|Docetaxel|
58125614|NCT02401542|DRUG|Placebo|
58125615|NCT02029937|DRUG|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
58125616|NCT01683175|DRUG|Erlotinib|
58451712|NCT05926934|DEVICE|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
58451713|NCT05926934|DEVICE|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
57750437|NCT00403624|DRUG|OXALIPLATIN|
57750438|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
58125617|NCT01683175|DRUG|cis-platinum|
57750439|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
57750440|NCT00698594|BIOLOGICAL|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
58125618|NCT01683175|DRUG|Vinorelbine|
58125619|NCT02120053|DEVICE|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
58125620|NCT02120053|DEVICE|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
58125621|NCT02161965|DRUG|Rivaroxaban|20mg or 15mg
58125622|NCT02161965|DRUG|Fluindione|
58125623|NCT02161965|DRUG|Warfarin|
58125624|NCT00003908|DRUG|carboplatin|
58125625|NCT00003908|DRUG|docetaxel|
58125626|NCT04308577|OTHER|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
58125627|NCT00750659|DRUG|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
58125628|NCT05984056|BEHAVIORAL|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
57750441|NCT00765843|DEVICE|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
57750442|NCT06020092|PROCEDURE|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
58125629|NCT03990675|PROCEDURE|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
58125630|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
58125631|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
58125632|NCT06262711|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).
58125633|NCT06262711|DIETARY_SUPPLEMENT|Placebo|Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
58451714|NCT02205671|BEHAVIORAL|Building Better Caregivers Small-group Workshop|
58125634|NCT03235778|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
58125635|NCT03235778|DRUG|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
58125636|NCT05870553|DRUG|CTP0301-A|Bowel Preparation
58125637|NCT05870553|DRUG|CTP0301-B|Bowel Preparation
58125638|NCT05870553|DRUG|Cool prep|Bowel Preparation
58125639|NCT05111821|PROCEDURE|Magnetic Resonance Imaging (MRI)|Quantification of iron will be performed through Magnetic Resonance Imaging
58125640|NCT05111821|DRUG|Deferiprone treatment|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
58125641|NCT01191320|DRUG|Placebo|Placebo capsule 1x daily for 3 months
58125642|NCT01191320|DRUG|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
58125643|NCT05635149|RADIATION|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
58125644|NCT05596708|DRUG|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
58125645|NCT02639949|BEHAVIORAL|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
58125646|NCT02639949|BEHAVIORAL|Standard Care|
58125647|NCT01829009|OTHER|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
58125648|NCT05914103|PROCEDURE|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
58125649|NCT01550588|DEVICE|Device closure|PFO Amplatzer device closure
58125650|NCT01550588|DRUG|Standard medical treatment|Standard Medical management using anti-coagulant therapy
58125651|NCT04117165|DIAGNOSTIC_TEST|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
58125652|NCT04117165|DRUG|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
58125653|NCT02492399|PROCEDURE|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
58125654|NCT02492399|PROCEDURE|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
58125655|NCT05867160|OTHER|ASM as adjunctive therapy|ASM approved as adjunctive therapy
58125656|NCT05091788|DEVICE|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
58451715|NCT01775371|DEVICE|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
58451716|NCT01775371|OTHER|Usual Care|Usual opioid analgesia determined by the provider
58125657|NCT00858910|OTHER|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
58125658|NCT00858910|OTHER|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home."
58125659|NCT03799263|PROCEDURE|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
58125660|NCT04740385|DIAGNOSTIC_TEST|Lung auscultation|auscultation of air entry through chest wal
58125661|NCT04740385|DEVICE|Fiberoptic bronchoscopy|Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
58125662|NCT04740385|DEVICE|Lung Ultrasound|real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
58125663|NCT01255475|DRUG|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
58125664|NCT01255475|DRUG|Placebo|Patients will receive placebo
58314663|NCT02925468|DEVICE|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
58314664|NCT01355965|BIOLOGICAL|Autologous T cells|
58451717|NCT05191693|PROCEDURE|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
58125665|NCT00950157|OTHER|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
58125666|NCT04232462|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
58125667|NCT00821210|DEVICE|Sham CPAP|CPAP with pressure of 3cm H2O
58125668|NCT00821210|DEVICE|CPAP of optimal pressure|CPAP of optimal pressure
58125669|NCT02877056|PROCEDURE|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
58125670|NCT01180595|DEVICE|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
58125671|NCT01180595|DEVICE|Trabecular Metal Monoblock Tibial Total Knee Component|
58125672|NCT03863678|OTHER|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
58125673|NCT03863678|OTHER|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
58125674|NCT05722067|OTHER|calcium ionophore|The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
58125675|NCT00988923|OTHER|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
58125676|NCT00988923|OTHER|No intervention|the intervention tool was switched in off, only bolus was activated
57960055|NCT05381246|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
58125677|NCT02521207|DRUG|Ibuprofen|
58125678|NCT03594123|DRUG|Brexpiprazole|2 or 3 mg tablet
58125679|NCT03594123|DRUG|Brexpiprazole|0.5 to 3 mg tablet
58125680|NCT05034731|DEVICE|Remote Fitting|Processors will be programmed using remote fitting application.
58125681|NCT05034731|DEVICE|In-Office Fitting|Processors will be programmed using standard Target CI application.
58125682|NCT06217172|DEVICE|RHEUPP App|RHEUPP App; Monthly RAPID3 response; General recommendations for managing Flare through App and Social Monitor for appropriate orientation; 3 month consultation by telehealth.
58125683|NCT06217172|OTHER|Usual Follow-up|Usual Care in Rheumatoid Arthritis Ambulatory Service
58125684|NCT03679377|DEVICE|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
58125685|NCT01034319|BEHAVIORAL|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
58125686|NCT01034319|BEHAVIORAL|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
58125687|NCT04898062|DEVICE|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
58125688|NCT01029353|PROCEDURE|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
58125689|NCT01029353|PROCEDURE|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
58125690|NCT05852847|DRUG|Baricitinib 2 MG [Olumiant]|Oral baricitinib was given at a dose of 2 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
58125691|NCT05852847|DRUG|Danazol|Danazol was given at a dose of 200 mg bid for 6 months
58125692|NCT00678392|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
58125693|NCT00678392|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
58125694|NCT03284775|DEVICE|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
58125695|NCT01932034|DEVICE|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
58314665|NCT00879216|DRUG|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
58314666|NCT00879216|DRUG|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
58125696|NCT05959785|PROCEDURE|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
58125697|NCT05959785|PROCEDURE|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
58125698|NCT05969197|OTHER|Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
58125699|NCT05969197|OTHER|Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
58125700|NCT05069636|OTHER|Lymphatic OMM|Patients receive lymphatic myofascial release and thoracic pump techniques.
58125701|NCT05069636|OTHER|Light Touch|Patients receive a series of light touch techniques.
58125702|NCT01136642|DRUG|Nicotrol|
58125703|NCT02551445|BEHAVIORAL|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
58125704|NCT02068482|DRUG|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
58125705|NCT02336737|DEVICE|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
58125706|NCT02336737|DRUG|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
58125707|NCT02336737|DRUG|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
58125708|NCT06272409|DRUG|DEP114|DEP114 oral solution
58125709|NCT06272409|DRUG|Desloratadine 0.5 MG/ML|Desloratadine oral solution
57750443|NCT06020092|PROCEDURE|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
57960056|NCT05381246|OTHER|Reiki|In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
58125710|NCT02237183|DRUG|Iloprost|Given via inhalation
58125711|NCT02237183|OTHER|Placebo Administration|Given via inhalation
58125712|NCT02237183|OTHER|Quality-of-Life Assessment|Ancillary studies
58125713|NCT02237183|OTHER|Questionnaire Administration|Ancillary studies
58125714|NCT04726202|OTHER|Standard procedure|Coding of cases follows the standard procedures established at the hospital
58125715|NCT04726202|OTHER|precoding|"Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report."
58125716|NCT04344418|DEVICE|Nurse-performed Focused cardiac ultrasound (FoCUS)|A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
58125717|NCT04344418|OTHER|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
58125718|NCT01303562|OTHER|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
58125719|NCT02283775|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
57750444|NCT00762450|DRUG|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
57750445|NCT00762450|DRUG|fluoride|Rinse 3 times daily with assigned toothpaste slurry
57960057|NCT05043467|DRUG|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
57750446|NCT00762450|DRUG|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
58125720|NCT02283775|DRUG|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
58125721|NCT02283775|DRUG|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
58125722|NCT03445195|DRUG|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
58125723|NCT03445195|DRUG|Placebo|Matching 1g IV solution.
58125724|NCT03445195|DRUG|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
58125725|NCT02974114|DRUG|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
58125726|NCT02974114|DRUG|Paracetamol|Test product containing 500 mg paracetamol
58125727|NCT02974114|OTHER|Placebo|Placebo to match paracetamol 665mg sustained release tablets
58125728|NCT00128557|DIETARY_SUPPLEMENT|vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)|Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
58125729|NCT04126681|DRUG|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
58125730|NCT04126681|DRUG|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
58125731|NCT04126681|DRUG|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
58125732|NCT04126681|DRUG|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
58125733|NCT05147077|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group."
58125734|NCT00674180|BEHAVIORAL|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
58125735|NCT00674180|BEHAVIORAL|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
58125736|NCT00674180|BEHAVIORAL|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
58125737|NCT01399164|OTHER|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
58125738|NCT01038570|DRUG|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
58125739|NCT01038570|DRUG|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
58125740|NCT02624570|DRUG|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
58125741|NCT01583777|DRUG|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
58125742|NCT04502069|DRUG|Opaganib|500 mg Q12 hours orally
58125743|NCT05415566|COMBINATION_PRODUCT|toy nebulizer and toy mask|The treatment was administered using therapeutic play.
57960058|NCT04358679|OTHER|Conventional Treatment|"Conventional Treatment:~* Deep breathing: 10-15 reps, twice a day (BD)~* Assisted coughing 10-15 reps, BD~* range of motion (ROM)+ stretching 10 reps, BD~* Tilt table standing"
58125744|NCT03186066|DEVICE|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
58125745|NCT03186066|PROCEDURE|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
58125746|NCT03070249|BEHAVIORAL|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
58125747|NCT03520673|DIAGNOSTIC_TEST|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
58125748|NCT03947515|PROCEDURE|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
58125749|NCT03947515|OTHER|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
58125750|NCT03947515|OTHER|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
58125751|NCT02844153|OTHER|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
58125752|NCT02096419|DRUG|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
58125753|NCT05868109|DRUG|inhaled nitric oxide (iNO)|In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
58125754|NCT05868109|DRUG|Sham|In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
58125755|NCT01628081|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
58125756|NCT01628081|DIETARY_SUPPLEMENT|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
58125757|NCT03665909|OTHER|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
58125758|NCT05105373|BEHAVIORAL|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~1. Poor parental bonding and child attachment;~2. Harsh parenting~3. Inequitable socialisation by gender~4. Parental conflict."
58125759|NCT02518113|DRUG|LY3039478|Administered orally
58125760|NCT02518113|DRUG|Dexamethasone|Administered orally
58451718|NCT02346045|PROCEDURE|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
58451719|NCT03479086|DRUG|Topiramate|200mg/day 100mg b.i.d
58125761|NCT02518113|DRUG|Placebo|Administered orally
58125762|NCT04782726|OTHER|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
58125763|NCT04782726|OTHER|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
58125764|NCT02200965|OTHER|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
58125765|NCT03777033|DRUG|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
58451720|NCT03479086|DRUG|Naltrexone|50mg/day
58451721|NCT05377853|BEHAVIORAL|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
57750447|NCT04060875|DEVICE|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
58125766|NCT05510648|OTHER|high-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
58125767|NCT05510648|OTHER|sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
58451722|NCT04001348|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451723|NCT04001348|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451724|NCT04001348|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451725|NCT04001348|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451726|NCT04001348|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
57960059|NCT04358679|OTHER|Upper Limb ergometer training|Conventional Treatment + upper limb (UL) ergometry exercise UL ergometry exercise 15 to 20 mints , 2 times ,five days per week for 6 weeks.
57960060|NCT05489978|BEHAVIORAL|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~1. Para-social contact~   * Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~  * Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~2. Participatory learning techniques~   * Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~  * Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~3. Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
57960061|NCT01212185|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
57960062|NCT01212185|OTHER|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
57960063|NCT00316563|DRUG|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
57960064|NCT00316563|OTHER|Placebo|
57960065|NCT01515774|DRUG|Mirapex ER|Change Requip or Mirapex to Mirapex ER
57960066|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
57960067|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
57960068|NCT00528762|BEHAVIORAL|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
57960069|NCT03187665|DEVICE|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
57960070|NCT03187665|DEVICE|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
57960071|NCT03025958|DRUG|Nimotuzumab|Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.
57960072|NCT03025958|RADIATION|Radiation|Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
58125768|NCT02035709|DRUG|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
58125769|NCT03601663|BEHAVIORAL|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
58125770|NCT03601663|BEHAVIORAL|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
58125771|NCT03601663|BEHAVIORAL|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
58451727|NCT04001348|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451728|NCT04001348|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451729|NCT04001348|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451730|NCT04001348|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
57960073|NCT04124146|RADIATION|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
57960074|NCT02518009|OTHER|Genetic men treated with estrogen|Observational during estrogen treatment
57960075|NCT02518009|OTHER|Genetic women treated with androgen|Observational during androgen treatment
57960076|NCT03034395|PROCEDURE|Wide Local Excision|Surgery
57960077|NCT02618304|DRUG|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
57960078|NCT01870154|BEHAVIORAL|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
57960079|NCT00042380|DRUG|Novasoy|
57960080|NCT01096563|DRUG|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
57960081|NCT01096563|DRUG|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
57960082|NCT00028990|DRUG|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
57960083|NCT00028990|DRUG|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
57960084|NCT05838391|RADIATION|Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery|Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
57960085|NCT05838391|DRUG|Mitomycin-C|As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
57960086|NCT05838391|DRUG|5-Fluorouracil|As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
57960087|NCT05838391|DRUG|Capecitabine|As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
58125772|NCT05838066|DRUG|KN026|IV infusion
58125773|NCT05838066|DRUG|HB1801|IV infusion
58125774|NCT05838066|DRUG|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
58125775|NCT05838066|DRUG|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
58125776|NCT05838066|DRUG|Docetaxel|75 mg/m\^2, D1 Q3W, IV infusion
58125777|NCT02957656|BIOLOGICAL|H7N9 pLAIV|10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
58125778|NCT02957656|BIOLOGICAL|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
58125779|NCT02957656|BIOLOGICAL|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
58125780|NCT05713409|DIAGNOSTIC_TEST|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
58125781|NCT01198236|DRUG|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1\*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells\> 0.5\*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
58125782|NCT03526965|OTHER|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
58125783|NCT03526965|DRUG|Usual care|Intervention included pain medications and exercise movements for neck.
58125784|NCT00944697|DRUG|Oxycodone Naloxone|Oxycodone Naloxone tablets
58125785|NCT00944697|DRUG|Placebo tablets|Placebo Oxycodone Naloxone tablets
58125786|NCT03263299|DRUG|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
58125787|NCT03263299|DRUG|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
58125788|NCT03263299|DRUG|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
58125789|NCT01840189|OTHER|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
58125790|NCT01840189|OTHER|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
58125791|NCT02313103|DRUG|lofexidine HCl|400 micrograms
58125792|NCT06071013|DRUG|Nintedanib, gefitinib, erlotinib, afatinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
58125793|NCT00386464|DEVICE|noninvasive positive pressure ventilation|
58125794|NCT03130764|DRUG|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
58125795|NCT03130764|DRUG|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
58125796|NCT03791749|OTHER|Breastfeeding Support|12-minute simple technique
58125797|NCT05395000|BEHAVIORAL|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
58125798|NCT05395000|BEHAVIORAL|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
58125799|NCT05395000|BEHAVIORAL|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
58125800|NCT00263107|PROCEDURE|telerounding versus bedside rounding|
58125801|NCT04552574|DIETARY_SUPPLEMENT|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
58125802|NCT00289601|DRUG|eptifibatide|
58125803|NCT02324972|DRUG|AQX-1125|Synthetic SHIP1 activator
58125804|NCT02324972|DRUG|Placebo|
58125805|NCT06396520|OTHER|No intervention, observational|No intervention, observational
58125806|NCT05927285|DIAGNOSTIC_TEST|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
58125807|NCT05927285|OTHER|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
58125808|NCT00012714|BEHAVIORAL|Case management services|
58125809|NCT05198804|DRUG|ZN-c3|ZN-c3 will be administered.
58125810|NCT05198804|DRUG|Niraparib|Niraparib will be administered.
58451731|NCT04001348|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58125811|NCT02448771|DRUG|Palbociclib|
57960088|NCT01999283|OTHER|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
57960089|NCT01999283|OTHER|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
57960090|NCT01573273|DRUG|Oxytocin|intranasal administration, 40 IUs
57960091|NCT01573273|DRUG|Saline|intranasal administration, 40 IUs
58125812|NCT02448771|DRUG|Bazedoxifene|
58125813|NCT01627275|BIOLOGICAL|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
58125814|NCT05405998|OTHER|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~1. before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~2. after the installation of the pump following the above mentioned hospitalization."
58125815|NCT02276313|DEVICE|Passeo-18 Lux|Endovascular Therapy
58125816|NCT01431924|DRUG|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
58125817|NCT01431924|DRUG|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
58125818|NCT02560350|OTHER|no intervention|no intervention
58125819|NCT01224132|DRUG|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
58125820|NCT00154414|DRUG|liraglutide|
58125821|NCT04393506|DRUG|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
58451732|NCT04001348|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
57750448|NCT03706118|OTHER|Magnetic resonance imaging|At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
57750449|NCT00981890|DRUG|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
57750450|NCT03587246|DIAGNOSTIC_TEST|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
57750451|NCT00389883|DRUG|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
57750452|NCT06222515|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
57750453|NCT03470779|OTHER|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
57960092|NCT00005648|DRUG|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
58125822|NCT04393506|DRUG|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
58125823|NCT04393506|PROCEDURE|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
58125824|NCT04393506|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
58125825|NCT02437149|BEHAVIORAL|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
58125826|NCT02437149|BEHAVIORAL|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
58125827|NCT02437149|BEHAVIORAL|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
58125828|NCT05823090|DEVICE|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
58125829|NCT04297280|DRUG|Sintilimab|a PD-1 immune check inhibitor
58125830|NCT04297280|COMBINATION_PRODUCT|TACE|TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
58125831|NCT01890915|OTHER|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
58125832|NCT03785236|RADIATION|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
58125833|NCT05053165|DRUG|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
58125834|NCT05053165|DRUG|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
58125835|NCT05053165|DRUG|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
58125836|NCT01820039|OTHER|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
57750454|NCT03470779|OTHER|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
57750455|NCT01032655|DRUG|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid"
58125837|NCT02986763|BIOLOGICAL|Questionnaire, blood, urine, hair and dust samplings|
58125838|NCT02540356|BIOLOGICAL|BAX69 Single-Route Arm|Intraperitoneal (IP) only
58125839|NCT02540356|BIOLOGICAL|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
58125840|NCT05376046|BIOLOGICAL|Erythrocytic parameters and thrombin generation assay measurement|Erythrocytic parameters and thrombin generation assay measurement
57750456|NCT05340959|DEVICE|Devices: Osstell®, Periotest® and AnyCheck®.|"1. Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~2. Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~3. AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
58451733|NCT04001348|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451734|NCT04001348|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451735|NCT04001348|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
57750457|NCT05805995|PROCEDURE|vertebral derotation|"* Incentive spirometer (Mediciser): Used for breathing exercises.~* Cycle ergometer ( Mijnhardt , St. Paul, MN): Used for lower limb exercise."
57750458|NCT04475432|DRUG|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
57750459|NCT04475432|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
57750460|NCT00447148|PROCEDURE|3-dimensional coronary angiography|3-dimensional coronary angiography
57750461|NCT01939704|OTHER|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
57750462|NCT01939704|OTHER|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
57750463|NCT01256853|DRUG|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
57750464|NCT04905615|OTHER|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
57750465|NCT05899842|DRUG|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
57750466|NCT00542880|DRUG|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
57750467|NCT00542880|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
57750468|NCT03078088|DRUG|Tham|alkalinizer
57750469|NCT03078088|DRUG|Saline|Placebo
57750470|NCT01945151|OTHER|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
57960093|NCT00005648|DRUG|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
57960094|NCT03885128|DEVICE|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
57960095|NCT03885128|DEVICE|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
57960096|NCT00809770|BEHAVIORAL|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
57960097|NCT00809770|BEHAVIORAL|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
57960098|NCT05901818|DRUG|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
57960099|NCT03583190|OTHER|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
57750471|NCT00032474|DRUG|Ginkgo biloba extract|
57750472|NCT05947929|OTHER|Aerobic excise|the treadmill exercises three times a week for 12 weeks) based on the Following protocol: Intensity exercise: determined by karvonen formula: Exercise heart rate = \[(A-B) × desired intensity\] + B \[A represents maximum heart rate (220-age) and B for resting heart rate (average of three measurements)\]. The desired intensity will be at 50- 70%. Heart rate was measured by pulse-meter to detect pulse rate before exercise (Resting HR)\].
57750473|NCT05947929|OTHER|acupuncture|the acupuncture needles will be inserted through the adhesive pads. The acupuncture needles used in the study are 40 mm in length and 0.30 mm in diameter and manufactured by Suzhou Hwato Medical Instruments Co. Ltd (Suzhou, China). The following acupoints will be used: DU20 (Baihui), ST36 (Zusanli), ST37 (Shangjuxu), SP6 (Sanyinjiao), ST25 (Tianshu), and LR3 (Taichong).
57960100|NCT03583190|OTHER|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
57750474|NCT03458455|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
57750475|NCT03458455|RADIATION|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
57750476|NCT03458455|DRUG|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
57750477|NCT00137540|DEVICE|RF ablation|
57750478|NCT00137540|DRUG|anti-arrhythmic drug therapy|
58125841|NCT04906577|OTHER|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
58125842|NCT04906577|OTHER|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
58125843|NCT04500522|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
57750479|NCT00762944|DEVICE|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
57750480|NCT00643058|BIOLOGICAL|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
57750481|NCT03260868|DRUG|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
57750482|NCT03260868|DRUG|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
57750483|NCT01996579|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
57960101|NCT03583190|OTHER|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
57960102|NCT03583190|OTHER|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
57960103|NCT03583190|OTHER|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
58125844|NCT04500522|DRUG|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
58125845|NCT00532337|DRUG|ONO-5334|Placebo - 24/mos.
58125846|NCT00532337|DRUG|ONO-5334|100mg QD /24 months
58125847|NCT00532337|DRUG|ONO-5334|50mg BID /24 mos.
58314667|NCT01116531|DRUG|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
57960104|NCT00004900|BIOLOGICAL|filgrastim|
57960105|NCT00004900|DRUG|anastrozole|
58125848|NCT00532337|DRUG|ONO-5334|300mg QD /24 mos.
58314668|NCT01116531|DRUG|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
58314669|NCT01116531|DRUG|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
58314670|NCT00167791|DRUG|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
58314671|NCT04155645|DRUG|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
58314672|NCT04155645|DRUG|Placebo|Randomized subjects will receive SC dose of placebo injection.
57960106|NCT00004900|DRUG|carboplatin|
57960107|NCT00004900|DRUG|cisplatin|
57960108|NCT00004900|DRUG|cyclophosphamide|
57960109|NCT00004900|DRUG|etoposide|
57960110|NCT00004900|DRUG|thiotepa|
58125849|NCT00532337|DRUG|ONO-5334|Alendronate 70mg once weekly / 24 mos
58125850|NCT01690442|BEHAVIORAL|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
57750484|NCT01996579|OTHER|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
58125851|NCT01690442|BEHAVIORAL|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
58125852|NCT01209052|DRUG|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
58125853|NCT01209052|OTHER|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
58125854|NCT06496087|DIETARY_SUPPLEMENT|DEPREXIL|The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
57750485|NCT01531452|DRUG|Oxaliplatin|130mg/m2 d1,repeated q21d
57750486|NCT01531452|DRUG|s1|80mg/m2/d, d1-14,repeated q21d
57750487|NCT01633879|BEHAVIORAL|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
57750488|NCT01633879|BEHAVIORAL|health and success parent and school|Parenting education and school intervention
57750489|NCT04511455|DRUG|Cabozantinib|Cabozantinib 60 mg/day peroral
57750490|NCT02270151|DEVICE|MyDiagnostick|Diagnostick strategy with MyDiagnostick
57750491|NCT03063294|OTHER|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
57750492|NCT03063294|OTHER|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
57750493|NCT04099043|DEVICE|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
57750494|NCT03114826|GENETIC|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
57750495|NCT03399032|DRUG|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
57750496|NCT01825668|OTHER|Plant Sterols|
57750497|NCT01825668|OTHER|High cholesterol|
57750498|NCT01825668|OTHER|Placebo|
57750499|NCT00822133|DRUG|lidocaine|lidocaine 5%
57750500|NCT00822133|DRUG|ketamine|ketamine cream
57750501|NCT00822133|DRUG|non-active drug cream|will be put on the skin
57750502|NCT05085626|DRUG|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
57750503|NCT05085626|DRUG|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
57750504|NCT04110002|BEHAVIORAL|Injury Prevention Program|
57750505|NCT01487317|DRUG|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped
57750506|NCT01487317|DRUG|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
57750507|NCT02030782|OTHER|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
58125855|NCT04078048|DIETARY_SUPPLEMENT|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
57750508|NCT02030782|OTHER|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
57750509|NCT03051971|DEVICE|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
57750510|NCT03051971|DEVICE|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
57750511|NCT00637208|PROCEDURE|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
57750512|NCT00637286|DRUG|Zolmitriptan|5mg Nasal Spray
57750513|NCT00526630|DRUG|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
57750514|NCT00526630|DRUG|Placebo|Participants will be given placebo instead of active MPD.
57750515|NCT00003796|DRUG|irofulven|
57750516|NCT05554068|DRUG|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
57750517|NCT00919074|PROCEDURE|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
57750518|NCT00919074|PROCEDURE|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
57960111|NCT00004900|PROCEDURE|peripheral blood stem cell transplantation|
57960112|NCT00004900|RADIATION|radiation therapy|
58125856|NCT04111770|DEVICE|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
58125857|NCT04111770|DEVICE|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
58314673|NCT02619188|OTHER|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
58125858|NCT02619799|DRUG|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
57750519|NCT04040660|DRUG|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
57750520|NCT05011994|BEHAVIORAL|Maintenance intervention|"The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity"
57750521|NCT03384173|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
57750522|NCT05311800|OTHER|Physical activity|Comparison of HIIT mode (running vs cycling)
57750523|NCT01273025|DIETARY_SUPPLEMENT|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
57750524|NCT01342705|PROCEDURE|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
57750525|NCT02450266|DEVICE|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
57750526|NCT02450266|DEVICE|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
57750527|NCT03313518|DEVICE|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
57750528|NCT03313518|DEVICE|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
58125859|NCT02619799|DRUG|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
58125860|NCT06308874|DRUG|Amg dose administration group|Orally, Amg tablet single administration
58125861|NCT06308874|DRUG|Amg dose administration group- Placebo|Orally, Placebo Amg tablet single administration
58125862|NCT06308874|DRUG|Bmg dose administration group|Orally, Bmg tablet single administration
58125863|NCT06308874|DRUG|Bmg dose administration group- Placebo|Orally, Placebo Bmg tablet single administration
58314674|NCT02619188|OTHER|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
58451736|NCT04001348|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
57750529|NCT01547897|DRUG|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
58125864|NCT05876195|BIOLOGICAL|Keyhole-Limpet Hemocyanin|Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)
58125865|NCT05876195|DRUG|Saline|Placebo intervention.
58314675|NCT02619188|OTHER|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
58314676|NCT02619188|OTHER|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
58314677|NCT04055870|PROCEDURE|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
58314678|NCT02802228|DRUG|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
58314679|NCT02802228|DRUG|Placebo|matched placebo delivered as infusion and oral capsule
58314680|NCT00294658|PROCEDURE|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
58314681|NCT00294658|DRUG|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
57750530|NCT00868465|DRUG|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
57750531|NCT00868465|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
57750532|NCT06347094|OTHER|Personalized Dietary Plan|Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet
57750533|NCT06347094|DIETARY_SUPPLEMENT|Oral (Poly)phenol Challenge Test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
57750534|NCT06347094|OTHER|General Dietary Advice|Prescription of balanced dietary plans
57750535|NCT00428467|PROCEDURE|LV Apex Compression|
57750536|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
58314682|NCT00026130|DRUG|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
58314683|NCT00026130|DRUG|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
57750537|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
57750538|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
57750539|NCT00178425|PROCEDURE|Serial blood sampling as described in protocol|
57750540|NCT00178425|PROCEDURE|Estimation of Creatinine Clearance at regular intervals|
57750541|NCT02508467|DRUG|Fisogatinib (BLU-554)|
57750542|NCT01223157|BIOLOGICAL|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
57750543|NCT03143725|DRUG|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
57750544|NCT00279669|PROCEDURE|Ultrasound examination|contact ultrasound examination
57750545|NCT01417429|DRUG|Galantamine|8mg/a day or placebo
58451737|NCT04001348|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
58451738|NCT01933308|OTHER|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
58451739|NCT01933308|OTHER|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
57750546|NCT01417429|DRUG|IV Nicotine|1.0 mg/70 kg of nicotine against saline
57750547|NCT02001194|BEHAVIORAL|Individual Incentives|
57750548|NCT02001194|BEHAVIORAL|Team Incentives|
57750549|NCT02001194|BEHAVIORAL|Individual plus Team Incentives|
57750550|NCT03685591|DRUG|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
57750551|NCT03685591|DRUG|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
57750552|NCT06088524|OTHER|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
57750553|NCT04334226|OTHER|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
57750554|NCT05980182|BEHAVIORAL|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
57750555|NCT06258018|DRUG|Temodal|given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
57750556|NCT06258018|DRUG|Niraparib|given orally in continous
57750557|NCT00707265|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
57750558|NCT00707265|DEVICE|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
57750559|NCT01797679|OTHER|Strength Training|
57750560|NCT01797679|OTHER|Aerobic Exercise|
57750561|NCT03026790|OTHER|Medication management|Individualized management of medications for pain
58125866|NCT05876195|DRUG|Montanide ISA 51 VG|Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant
57750562|NCT03026790|OTHER|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
57750563|NCT03026790|DRUG|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
57750564|NCT06208748|DRUG|Bezuclastinib in combination with sunitinib|Bezuclastinib in combination with sunitinib (sutent)
58125867|NCT05876195|DRUG|Alhydrogel|Alhydrogel is a vaccine adjuvant
58125868|NCT03048162|DRUG|sodium chloride|500 ml of 0.9% isotonic sodium chloride
58125869|NCT03048162|DRUG|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
58125870|NCT03048162|DRUG|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
57750565|NCT02365519|BIOLOGICAL|LME636 ophthalmic solution|
58125871|NCT04908566|DRUG|PD-1 antibody combined with FOLFIRINOX regimen|Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
58451740|NCT01933308|OTHER|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
58451741|NCT00965666|DRUG|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
58451742|NCT01425801|DRUG|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
57750566|NCT02365519|BIOLOGICAL|LME636 Vehicle|Inactive ingredients used as a placebo comparator
57750567|NCT03655795|BIOLOGICAL|Bronchial basal cells|Autologous transplantation of bronchial basal cells
57750568|NCT05696210|OTHER|Transfusion rate of red blood cells|Transfusion rate of red blood cells greater than 7
57750569|NCT03319537|DRUG|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
58451743|NCT01425801|DRUG|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
58451744|NCT01425801|DRUG|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
58451745|NCT01425801|DRUG|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
57750570|NCT03319537|DRUG|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
57750571|NCT03248375|RADIATION|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
57750572|NCT01418274|DRUG|danoprevir|oral doses of danoprevir
57960113|NCT05707923|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
57960114|NCT01047774|DIETARY_SUPPLEMENT|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
57960115|NCT01047774|DIETARY_SUPPLEMENT|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
57960116|NCT05677074|DIETARY_SUPPLEMENT|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
57960117|NCT05677074|DIETARY_SUPPLEMENT|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
58125872|NCT04908566|DRUG|PD-1 antibody combined with SOX program|"Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles."
58125873|NCT05132309|COMBINATION_PRODUCT|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
58125874|NCT00392639|PROCEDURE|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
58451746|NCT01425801|DRUG|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
58451747|NCT01425801|DRUG|Salbutamol placebo|Pressurized inhalation, once-daily
58451748|NCT01425801|DRUG|LAS100977 placebo|Dry powder inhalation, once-daily
58451749|NCT06410898|DEVICE|Punch Biopsy 5mm|Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
58451750|NCT01272232|DRUG|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
58451751|NCT01272232|DRUG|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
58125875|NCT03774238|OTHER|FMD analysis|Blood sample and vascular exploration.
58125876|NCT03868137|DRUG|Ibuprofen|3 doses of Ibuprofen 800 mg
57750573|NCT01418274|DRUG|escitalopram|oral doses of escitalopram
57750574|NCT01418274|DRUG|ritonavir|oral doses of ritonavir
57750575|NCT04241094|BEHAVIORAL|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
58125877|NCT03868137|DRUG|Placebos|Placebo
58125878|NCT01456182|DRUG|AFX-2|Dose level 1
58125879|NCT01456182|DRUG|AFX-2|Dose level 2
58125880|NCT01456182|DRUG|AFX-2|Dose level 3
58125881|NCT01456182|DRUG|AFX-2|Dose level 4
58125882|NCT01456182|DRUG|AFX-2|Dose level 5
58314684|NCT00026130|RADIATION|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
58125883|NCT06257108|OTHER|Class II Cavity Restorations|The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
58125884|NCT02248077|DEVICE|AutoloGel|
57750576|NCT04023864|DIETARY_SUPPLEMENT|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
57750577|NCT04023864|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
57750578|NCT00112879|DRUG|arsenic trioxide|
57750579|NCT00112879|DRUG|ascorbic acid|
57750580|NCT00112879|DRUG|dexamethasone|
57750581|NCT00112879|DRUG|thalidomide|
57750582|NCT00112879|PROCEDURE|anti-cytokine therapy|
57750583|NCT00112879|PROCEDURE|antiangiogenesis therapy|
57750584|NCT00112879|PROCEDURE|biological therapy|
57750585|NCT00112879|PROCEDURE|chemotherapy|
57750586|NCT00112879|PROCEDURE|drug resistance inhibition|
57750587|NCT00112879|PROCEDURE|growth factor antagonist therapy|
57960118|NCT05677074|DIETARY_SUPPLEMENT|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
57960119|NCT05428150|DRUG|Esbriet 267 MG Oral Capsule|Reference Formulation
57960120|NCT05428150|DRUG|EXCL-100, 600 MG Oral Tablet|Test Formulation
57960121|NCT04735094|DIAGNOSTIC_TEST|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
57960122|NCT03047980|DRUG|Sirolimus|Low dose oral sirolimus
57960123|NCT03771742|PROCEDURE|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
57960124|NCT03771742|PROCEDURE|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
57960125|NCT03483480|PROCEDURE|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
57960126|NCT03483480|PROCEDURE|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
57960127|NCT03527563|BEHAVIORAL|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
57960128|NCT06420973|DRUG|RC48+carboplatin±bevacizumab|RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
57960129|NCT06413862|DRUG|Ciprofol|The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).
57960130|NCT06413862|DRUG|Propofol|The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
57960131|NCT03874377|BEHAVIORAL|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
58125885|NCT02248077|OTHER|Usual and Customary Care (UCC)|
58125886|NCT01521442|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
58125887|NCT01521442|BEHAVIORAL|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
58125888|NCT00966953|DRUG|Fluoride|Brush twice daily
58125889|NCT00966953|DRUG|Triclosan/Fluoride toothpaste|Brush twice daily
58125890|NCT00966953|DRUG|Fluoride|Brush twice daily
58125891|NCT00966953|DRUG|Fluoride|Brush twice daily
57750588|NCT00112879|PROCEDURE|non-specific immune-modulator therapy|
57750589|NCT01782443|DRUG|Ziv-aflibercept|
57750590|NCT01201057|DRUG|0.5% SPL7013 Gel|Vaginal gel
57750591|NCT01201057|DRUG|1.0% SPL7013 Gel|Vaginal gel
57750592|NCT01201057|DRUG|3.0% SPL7013 Gel|Vaginal gel
57750593|NCT01201057|OTHER|Placebo Gel|Vaginal gel
57750594|NCT02244255|DRUG|FLOMAX® capsules|
57750595|NCT02244255|DRUG|Ascending doses of HYTRIN® capsules|
57750596|NCT05183022|DEVICE|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
57750597|NCT01550198|DEVICE|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
57750598|NCT06132555|OTHER|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
57750599|NCT06132555|OTHER|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
57750600|NCT06132555|OTHER|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
57750601|NCT03033654|OTHER|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
57750602|NCT04791501|DEVICE|Mechanical ventilation|Ventilatory support
57750603|NCT00203359|DRUG|etanercept given by perispinal administration|
57750604|NCT06246786|DRUG|Cyclosporin A|Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
57750605|NCT01385345|DRUG|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
57750606|NCT01357616|DRUG|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
57750607|NCT01357616|DRUG|Brinzolamide 1% ophthalmic suspension|
58451752|NCT01272232|DRUG|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
58451753|NCT04645446|DRUG|Pro-ocular gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
57750608|NCT01357616|DRUG|Timolol 0.5% ophthalmic solution|
57750609|NCT00611858|DRUG|Cetuximab|
57750610|NCT00611858|DRUG|5-Fluorouracil|
57750611|NCT00611858|RADIATION|Radiation|
57750612|NCT02375295|DRUG|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
57750613|NCT02978755|DRUG|GM102|GM102 escalating doses (phase1)
57750614|NCT02978755|DRUG|GM102 escalating doses|GM102 escalating doses combined with paclitaxel and carboplatin
57750615|NCT02978755|DRUG|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
57750616|NCT01445652|DEVICE|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
57960132|NCT03874377|BEHAVIORAL|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
57960133|NCT03605680|DRUG|Centanafadine SR|100 mg, BID, oral tablets
57750617|NCT01445652|OTHER|Spectacles|Spectacles per current prescription
57750618|NCT04365595|OTHER|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
57750619|NCT02145221|OTHER|Music Therapy|
57750620|NCT03084666|DEVICE|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
57750621|NCT05128643|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
57750622|NCT02009670|DIETARY_SUPPLEMENT|13C inulin|Oral 13C inulin
57750623|NCT02009670|OTHER|Placebo|Oral maltodextrin
57750624|NCT06517667|DRUG|Icross tear substitute|Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
57750625|NCT06517667|DRUG|Hyabak tear substitute|Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
57960134|NCT03605680|OTHER|Placebo|BID, oral tablet.
57960135|NCT03605680|DRUG|Centanafadine SR|200 mg, BID, oral tablets
58125892|NCT00966953|OTHER|antibacterial plant extract|Brush twice daily
58314685|NCT02471443|PROCEDURE|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
57750626|NCT03824379|DIETARY_SUPPLEMENT|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
57750627|NCT03824379|DRUG|Antidiabetic|insulin or oral hypoglycemics
57750628|NCT00004339|DRUG|tetrathiomolybdate|
57750629|NCT00004339|DRUG|trientine|
57960136|NCT05506059|DIAGNOSTIC_TEST|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
57960137|NCT00302965|DRUG|Frozen Plasma|
57960138|NCT00184678|DRUG|somatropin|
58451754|NCT04645446|DRUG|Placebo gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
58451755|NCT05649007|DEVICE|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
58125893|NCT02369809|DRUG|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
58125894|NCT01963039|DEVICE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
58125895|NCT01963039|PROCEDURE|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
58125896|NCT02114697|DRUG|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
58125897|NCT02114697|BEHAVIORAL|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
58125898|NCT05445128|BIOLOGICAL|MGTA-145|MGTA-145 will be administered as an IV infusion
58125899|NCT05445128|DRUG|Plerixafor|240 µg/kg administered subcutaneously
58125900|NCT04634448|PROCEDURE|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
58125901|NCT04634448|DIAGNOSTIC_TEST|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
58125902|NCT01945138|DEVICE|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
58125903|NCT01580878|DRUG|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
58125904|NCT01580878|DRUG|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
57750630|NCT01342224|BIOLOGICAL|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
57750631|NCT02889133|DRUG|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
57750632|NCT02889133|DRUG|Saline|Salt water IV - 500 mL, one pint normal saline.
57750633|NCT02889133|PROCEDURE|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
57750634|NCT02889133|PROCEDURE|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
57750635|NCT02178605|PROCEDURE|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
57750636|NCT05522725|OTHER|Single-use wipes installed at the bedside|
58125905|NCT01580878|DRUG|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
58125906|NCT00747188|BEHAVIORAL|PBL|
58125907|NCT04438057|BIOLOGICAL|CCP|Randomized open label study to receive 2:1 CCP to standard of care
58125908|NCT01144663|BIOLOGICAL|Nimenrix™|4- or 3-dose intramuscular injection
58125909|NCT01144663|BIOLOGICAL|Menjugate®|3-dose intramuscular injection
58125910|NCT01144663|BIOLOGICAL|NeisVac-CTM|3-dose intramuscular injection
58125911|NCT01144663|BIOLOGICAL|Infanrix™ hexa|4-dose intramuscular injection
58125912|NCT01144663|BIOLOGICAL|Synflorix™|4-dose intramuscular injection
58125913|NCT01004172|DRUG|carboplatin|
58125914|NCT01004172|DRUG|bevacizumab|
58125915|NCT01004172|DRUG|herceptin|
58125916|NCT03841032|DRUG|Coppertone, BAY1183345|Lotion, for 4 weeks
58125917|NCT06547580|OTHER|Group-based PFMT|Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.
58125918|NCT06547580|OTHER|Individualized PFMT|Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
58125919|NCT01789320|DRUG|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
58125920|NCT04173936|BEHAVIORAL|tai chi|12-week community-based tai chi program
58125921|NCT04437342|OTHER|PHQ-9 (Patient Health Questionnaire) Depression Scale|9 question questionnaire for assessment of depression
58125922|NCT04437342|OTHER|GAD-7 (General Anxiety Disorder) scale|7 question questionnaire for assessment of General Anxiety Disorder
58125923|NCT04437342|OTHER|38 questions questionnaire|38 questions questionnaire
58125924|NCT04437342|OTHER|EPDS (Edinburgh Postnatal Depression Scale)|10 questions scale for detection of postpartum depression
58125925|NCT02697409|BEHAVIORAL|Education Against Tobacco intervention|
58125926|NCT05951569|DEVICE|Community-Derived Open-Source Automated Insulin Delivery Loop System|The Loop System consists of an insulin pump and a Dexcom CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
58125927|NCT03528668|DEVICE|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
58125928|NCT04568681|DEVICE|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
58125929|NCT01107002|PROCEDURE|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
58125930|NCT05265182|PROCEDURE|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
58125931|NCT02954679|OTHER|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
58125932|NCT00757601|DRUG|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
58125933|NCT00757601|DRUG|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
58125934|NCT02388178|DRUG|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
58125935|NCT02388178|DRUG|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
58125936|NCT02388178|DRUG|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
58125937|NCT00349947|BEHAVIORAL|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
58125938|NCT05822401|BEHAVIORAL|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
58125939|NCT05822401|BEHAVIORAL|Usual care (control)|Will continue their work as usual
58125940|NCT01328275|DRUG|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
58125941|NCT01775020|DIETARY_SUPPLEMENT|L-arginine|
58125942|NCT04242771|BEHAVIORAL|Mindfulness|Subjects practice mindfulness before bedtime
58125943|NCT04809246|OTHER|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
58125944|NCT01608581|OTHER|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
58125945|NCT01827007|OTHER|Volume expansion with gelofusine|
57750637|NCT01930357|BIOLOGICAL|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
57750638|NCT01930357|BIOLOGICAL|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
57750639|NCT01104740|OTHER|Biological sample collection|Blood (serum) sample collection
58125946|NCT01779622|OTHER|Mixed meal|Ingestion of mixed meal
58125947|NCT01124851|DRUG|ABT-652|See arm description for details
58125948|NCT01124851|DRUG|Placebo|See arm description for details
58125949|NCT00605449|DRUG|GSK376501|
58125950|NCT02756312|OTHER|IV Anesthesia|The patients will receive intravenous anesthesia
58125951|NCT02756312|OTHER|IH anesthesia|The patients will receive inhalation anesthesia
58125952|NCT05749133|BIOLOGICAL|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based."
58125953|NCT00510510|DRUG|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
58125954|NCT00510510|DRUG|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
57750640|NCT04202939|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
58125955|NCT00510510|DRUG|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
58125956|NCT03129919|DEVICE|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
58125957|NCT03129919|DEVICE|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
58125958|NCT02282436|OTHER|No specific intervention for this study|No specific intervention for this study
58125959|NCT04865107|BIOLOGICAL|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
58125960|NCT04865107|BIOLOGICAL|Placebo|PlasmaLyte A and 5% Human Albumin
58125961|NCT00760058|DEVICE|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
58125962|NCT00760058|DEVICE|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
58125963|NCT00760058|DEVICE|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
58125964|NCT03540056|DIAGNOSTIC_TEST|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
58125965|NCT05431881|PROCEDURE|Binaural beat|Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.
58125966|NCT05431881|PROCEDURE|Silent|Apply a wave file which is created in silence.
58125967|NCT00561730|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
58125968|NCT06355245|DIAGNOSTIC_TEST|Blood sampling|Collection of blood samples
58125969|NCT03558308|BEHAVIORAL|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
58125970|NCT03558308|OTHER|Sham computerized gaming|Sham training with generally stimulating computer-games
58125971|NCT01637038|OTHER|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
58125972|NCT04040920|DEVICE|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
58125973|NCT04040920|OTHER|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
58125974|NCT03413631|BEHAVIORAL|Prenatal mentalization intervention|
58125975|NCT03413631|OTHER|Prenatal obstetric treatment as usual|
58125976|NCT02444403|BEHAVIORAL|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
58125977|NCT03726463|PROCEDURE|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
58314686|NCT04459338|BIOLOGICAL|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
58125978|NCT02841709|DRUG|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
58125979|NCT02841709|DRUG|Placebo|Capsules for oral administration matching the ACT-541468 capsules
58125980|NCT04819971|DRUG|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
58125981|NCT04819971|DRUG|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
58125982|NCT04819971|DRUG|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
58125983|NCT04819971|DRUG|S1|S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
58125984|NCT04819971|DRUG|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
58314687|NCT04459338|OTHER|Saline|Placebo comparator
57750641|NCT02080780|DRUG|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
58314688|NCT04706377|DIETARY_SUPPLEMENT|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
58314689|NCT04706377|OTHER|Placebo|Placebo tablet
58314690|NCT00352118|BIOLOGICAL|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
58314691|NCT00352118|BIOLOGICAL|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
58314692|NCT00352118|DRUG|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
58314693|NCT00352118|DRUG|docetaxel|Intravenous over 1 hour on day 1.
58314694|NCT00352118|DRUG|fluorouracil|Intravenous continuously on days 1-4.
58314695|NCT00352118|PROCEDURE|conventional surgery|As appropriate, neck dissection.
58314696|NCT00352118|RADIATION|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
58314697|NCT01865851|DEVICE|Classic Face Mask and NuMask|
58314698|NCT00455871|DRUG|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
58314699|NCT00455871|DRUG|Lucentis|Lucentis intravitreal injection
58125985|NCT03556371|DRUG|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
58125986|NCT03556371|DRUG|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
58125987|NCT02001558|DRUG|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
58125988|NCT02001558|OTHER|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
58125989|NCT06404411|OTHER|Assigned interventions|Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.
58125990|NCT06404411|OTHER|conventional rehabilitation|Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
58125991|NCT05559203|BEHAVIORAL|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care (https://dancesingcare.uk/) and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
58125992|NCT03847376|DRUG|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter \[mL\] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
58125993|NCT06484959|OTHER|Assigned Interventions|Assigned Interventions
58125994|NCT03151239|DIETARY_SUPPLEMENT|NMN supplement|Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
58125995|NCT03151239|OTHER|Placebo|Intervention will last at least 8 weeks in the form of two capsules.
58125996|NCT02366221|OTHER|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
58314700|NCT00107497|RADIATION|Radiation therapy|
57750642|NCT02080780|DRUG|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
57750643|NCT02098980|DIETARY_SUPPLEMENT|Vitamin D|
57750644|NCT06275152|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
57750645|NCT06275152|DEVICE|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
57750646|NCT04686786|DRUG|CVL-865|Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
57750647|NCT04334473|PROCEDURE|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
57960139|NCT04717674|DRUG|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|\[18F\]FPIA radiotracer administration
58314701|NCT02805738|DRUG|CKD-390|CKD-390 1 Tablet (48 weeks)
58314702|NCT02805738|DRUG|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
58314703|NCT01549574|DRUG|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
57750648|NCT04334473|DIAGNOSTIC_TEST|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
57750649|NCT01619202|BEHAVIORAL|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
57750650|NCT03616184|DRUG|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
57750651|NCT00777374|DRUG|Patch|epicutaneous application of allergen patch
57750652|NCT00777374|DRUG|Placebo patch|epicutanoeus application of a placebo patch
57960140|NCT04717674|PROCEDURE|PET/CT|PET/CT scan
58125997|NCT02366221|OTHER|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
58125998|NCT02153398|DRUG|D961H sachet 10 mg|
58125999|NCT02153398|DRUG|D961H capsule 10mg|
58126000|NCT02153398|DRUG|D961H capsule 20 mg|
58126001|NCT05362448|DEVICE|Frequency|First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
58126002|NCT04975399|DRUG|CC-92328|CC-92328
58126003|NCT06105983|DRUG|Sisunatovir|Single Dose
58126004|NCT06105983|DRUG|Rabeprazole 40 mg|Tablets once daily for 7 days
58126005|NCT06105983|DRUG|Sisunatovir suspension|Tablets once daily for 7 days
58126006|NCT06105983|DRUG|Rabeprazole 20 mg|Tablets once daily for 7 days
58126007|NCT02192099|DRUG|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
58126008|NCT02156648|OTHER|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
58126009|NCT04170881|OTHER|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
57750653|NCT04218448|OTHER|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
57750654|NCT01602406|DRUG|LJM716|LJM716
57750655|NCT01602406|DRUG|Trastuzumab|Trastuzumab
57750656|NCT05613738|DRUG|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
57750657|NCT05613738|DRUG|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
57750658|NCT05613738|DRUG|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
57750659|NCT00990717|BIOLOGICAL|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2"
57750660|NCT03233802|BEHAVIORAL|Individualized Assess & Treatment (IATP)|See previous description
57750661|NCT03233802|BEHAVIORAL|Packaged Cognitive-Behavioral (PCBT)|See previous description
57750662|NCT03233802|BEHAVIORAL|Case Management (CaseM)|See previous description
57750663|NCT06490757|DRUG|Baricitinib|An ancillary study will be performed in a subgroup of 12 patients to assess the variation of the results of PET-CT with 18FDG from baseline to 3 months. The variation of tumor features assessed by PET-CT with 18FDG after three months of treatment, will be assessed. The median value of the SUV max and tumor to non-tumor ratio of the SUV max value for each HCA lesion between the PET CT with 18FDG performed at baseline and after 3 months of treatment will be assessed.
57750664|NCT04679402|OTHER|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
57750665|NCT02342886|DRUG|Moxifloxacin|Oral
57750666|NCT02342886|DRUG|PA-824|Oral
57750667|NCT02342886|DRUG|Pyrazinamide|Oral
57750668|NCT02342886|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
57750669|NCT02342886|DRUG|HR (rifampicin plus isoniazid combination tablets)|Oral
58126010|NCT02586103|DEVICE|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
58126011|NCT05327166|OTHER|ED-LINC|The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
58126012|NCT02374918|DEVICE|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
58126013|NCT02374918|DEVICE|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
58126014|NCT02374918|DEVICE|HC wavelength-1 bright light|30 minutes of light exposure
58126015|NCT02374918|DEVICE|HC wavelength-2 bright light|30 minutes of light exposure
58126016|NCT01056549|DRUG|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
58126017|NCT00508170|BEHAVIORAL|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
58126018|NCT01729130|PROCEDURE|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
58126019|NCT06237075|DEVICE|transcranial direct current stimulation|2-milliamp stimulation for 5\~15 min
58314704|NCT01549574|DRUG|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
58126020|NCT06424899|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
58314705|NCT02856217|PROCEDURE|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
57750670|NCT05399680|DEVICE|S.M.A.R.T. RADIANZ™ Vascular Stent System|The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
57750671|NCT05399680|DEVICE|BRITE TIP RADIANZ™ Guiding Sheath|BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
57750672|NCT05399680|DEVICE|SABERX RADIANZ™ PTA Balloon Catheter|SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
57750673|NCT06217757|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
57750674|NCT06217757|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
57750675|NCT06217757|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
57750676|NCT06217757|DRUG|Sugemalimab|Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
57750677|NCT06217757|DRUG|Olaparib|Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
57750678|NCT04444037|DEVICE|OCT-guided PCI|using optical coherence tomography imaging to help PCI procedure
57750679|NCT03751631|DRUG|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
57750680|NCT03751631|DRUG|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
57750681|NCT03751631|DRUG|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
57750682|NCT03509974|DEVICE|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
57750683|NCT03778879|DRUG|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
57750684|NCT05864664|PROCEDURE|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed"
57750685|NCT05174663|OTHER|Almond-enriched diet - 1.5 oz|Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
57750686|NCT05174663|OTHER|Almond-enriched diet - 2.5 oz|Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
57750687|NCT05174663|OTHER|Control snack|Participants will receive a control snack daily for 16 weeks.
57750688|NCT04487067|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
58126021|NCT06424899|RADIATION|radical chemoradiotherapy|The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
58126022|NCT06424899|DRUG|Platinum based chemotherapy|Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
58314706|NCT02856217|PROCEDURE|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
58314707|NCT04262349|BEHAVIORAL|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
57750689|NCT04487067|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
57750690|NCT00010179|DRUG|lurtotecan liposome|
57750691|NCT02264522|OTHER|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
57750692|NCT02264522|OTHER|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
57750693|NCT02264522|OTHER|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
57750694|NCT02264522|OTHER|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
57750695|NCT02748187|OTHER|CBASP|Interpersonal psychotherapy for chronic depression
57750696|NCT01826240|BEHAVIORAL|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
57750697|NCT04609267|DIAGNOSTIC_TEST|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
58126023|NCT00084084|DRUG|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
58126024|NCT00000619|PROCEDURE|catheterization, Swan-Ganz|
58126025|NCT02743702|OTHER|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~* supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~* lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~* sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~* diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~* in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~* exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
58126026|NCT02743702|OTHER|USUAL THERAPIES|
58126027|NCT02281578|BEHAVIORAL|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
58126028|NCT02281578|BEHAVIORAL|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
58126029|NCT02553369|OTHER|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
58126030|NCT00216437|DRUG|Capecitabine (Xeloda)|
58126031|NCT04365751|PROCEDURE|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
58126032|NCT02030184|DRUG|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
58126033|NCT04464135|OTHER|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
58126034|NCT04464135|OTHER|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
58126035|NCT05658887|DRUG|Gabapentin|One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure
58126036|NCT05658887|DRUG|Gabapentin Placebo|Gabapentin Placebo
58126037|NCT04322071|OTHER|Interview|Qualitative interviews only
58126038|NCT01454466|PROCEDURE|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
58126039|NCT04496635|OTHER|Implementation of a bundle of care|
57750698|NCT05541016|PROCEDURE|Biospecimen Collection|Undergo blood and saliva specimen collection for NavDx testing
58126040|NCT01471483|BEHAVIORAL|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
58126041|NCT01471483|OTHER|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
58126042|NCT03190746|DIAGNOSTIC_TEST|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
58126043|NCT04164771|OTHER|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
57750699|NCT05541016|DRUG|Cisplatin|Given IV
58314708|NCT00230516|DRUG|Nexium|
58314709|NCT00230516|DRUG|Prevacid|
58314710|NCT00674726|OTHER|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
57750700|NCT05541016|PROCEDURE|Computed Tomography|Undergo CT scan
57750701|NCT05541016|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
57750702|NCT05541016|DRUG|Docetaxel|Given IV
57750703|NCT05541016|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
57750704|NCT05541016|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57750705|NCT05541016|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57750706|NCT05541016|PROCEDURE|Modified Barium Swallow Study|Undergo MBSS
57750707|NCT05541016|OTHER|Observation|Undergo observation
57750708|NCT05541016|PROCEDURE|Positron Emission Tomography|Undergo PET scan
57750709|NCT05541016|OTHER|Quality-of-Life Assessment|Ancillary studies
57750710|NCT05541016|OTHER|Questionnaire|Ancillary studies
58314711|NCT02564341|BEHAVIORAL|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
58314712|NCT02564341|BEHAVIORAL|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
58314713|NCT02564341|BEHAVIORAL|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
57750711|NCT01293058|DRUG|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
57750712|NCT01293058|DRUG|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
57750713|NCT04517864|DRUG|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
57750714|NCT04517864|DRUG|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
57750715|NCT00444691|DEVICE|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
57750716|NCT02007005|DRUG|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
57750717|NCT03118024|DRUG|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
57750718|NCT03118024|DRUG|Catecholamines|catecholamine restrictive anesthesia protocol
57750719|NCT02445040|DEVICE|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
57750720|NCT02172625|DIETARY_SUPPLEMENT|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
57960141|NCT05855265|DEVICE|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
57960142|NCT03705715|DRUG|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|\[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
57960143|NCT03705715|OTHER|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
57960144|NCT03612986|DIETARY_SUPPLEMENT|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
57960145|NCT03612986|DIETARY_SUPPLEMENT|Placebo|Placebo comparator. No chemical effect expected
57750721|NCT02172625|OTHER|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
57750722|NCT03323619|PROCEDURE|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
57750723|NCT04793919|DRUG|Mylotarg|See the protocol
57750724|NCT04793919|DRUG|Arsenic Trioxide|See the protocol
57750725|NCT04793919|DRUG|All-trans retinoic acid|See the protocol
57750726|NCT05679011|OTHER|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
57750727|NCT06083025|DEVICE|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
58314714|NCT04578938|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
57750728|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation On
57960146|NCT06103032|PROCEDURE|Breast Conserving Surgery|Patients undergoing breast conserving surgery
57960147|NCT06103032|PROCEDURE|Mastectomy|Patients undergoing mastectomy
58126044|NCT01396681|DRUG|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4\~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
58126045|NCT01644890|DRUG|NK105|IV, Weekly
58126046|NCT01644890|DRUG|Paclitaxel|IV, Weekly
57750729|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation Off
58126047|NCT02831569|DRUG|Loxoprofen sodium|
58126048|NCT02831569|DRUG|Methocarbamol|
58126049|NCT05123625|PROCEDURE|Reduce surgical procedures|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
58126050|NCT06158321|DEVICE|M1 or DLPFC sham stimulation|Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.
57750730|NCT00045305|DRUG|Cyclosporine|Immunosuppressant
57750731|NCT00045305|DRUG|Methotrexate|Antimetabolite
57750732|NCT00045305|DRUG|Photopheresis|Psoralens
58126051|NCT06158321|DEVICE|M1 rTMS|The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.
58126052|NCT06158321|DEVICE|DLPFC rTMS|The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
58126053|NCT04677062|DRUG|GV-328|Patients with GV-328 treatment
58126054|NCT04277533|DIAGNOSTIC_TEST|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
58126055|NCT00058292|BIOLOGICAL|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
57750733|NCT00045305|DRUG|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
57750734|NCT00045305|DRUG|Pentostatin|Purine analogue
57750735|NCT00045305|PROCEDURE|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
58126056|NCT00058292|BIOLOGICAL|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
58126057|NCT00058292|DRUG|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
58126058|NCT00058292|DRUG|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
58126059|NCT00058292|DRUG|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
58126060|NCT00058292|DRUG|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
58126061|NCT00058292|PROCEDURE|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
57750736|NCT00045305|PROCEDURE|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
57750737|NCT00045305|RADIATION|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
57750738|NCT00279292|PROCEDURE|Celiac Plexus Neurolysis|
57750739|NCT01238055|DRUG|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks"
57750740|NCT01238055|DRUG|Docetaxel only|Docetaxel 60 mg/m2 iv
57960148|NCT01225679|DEVICE|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
58126062|NCT00058292|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
58126063|NCT01915732|DRUG|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
57750741|NCT04167605|OTHER|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
57750742|NCT04167605|OTHER|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
57750743|NCT01189968|DRUG|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
58126064|NCT01915732|DRUG|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
58126065|NCT03874130|DRUG|Scopolamine|IV Scopolamine
57750744|NCT04818294|DEVICE|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
57750745|NCT02057874|DEVICE|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
57750746|NCT02057874|DRUG|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
58126066|NCT02596334|DRUG|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
58126067|NCT02596334|DRUG|dolutegravir|
58451756|NCT05716074|OTHER|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
58451757|NCT05716074|OTHER|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
58451758|NCT06313164|DIETARY_SUPPLEMENT|enhanced glutathione|L-glutathione (in combination with tannin, low molecular weight chitosan and polyethylene glycol)
58451759|NCT06313164|OTHER|placebo comparator|placebo group
58451760|NCT04874935|DRUG|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
58451761|NCT04874935|DRUG|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
58451762|NCT00931931|BIOLOGICAL|HSV1716|
58451763|NCT05672290|OTHER|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
57750747|NCT00047476|DRUG|dexmethylphenidate(d-mph)|
57750748|NCT05455905|DIAGNOSTIC_TEST|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
57750749|NCT05455905|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
57750750|NCT05455905|DIAGNOSTIC_TEST|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
58451764|NCT05672290|OTHER|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
58451765|NCT00825201|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
58451766|NCT00825201|OTHER|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
58126068|NCT04987164|DIETARY_SUPPLEMENT|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
58126069|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA fingerstick point of care assay|Xpert® HBV DNA point of care assay from finger-stick whole blood
58126070|NCT04289428|DIAGNOSTIC_TEST|Point of Care ALT|Point of Care ALT from finger-stick whole blood
58451767|NCT00825201|OTHER|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
58126071|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA point of care assay from dried blood spot|Xpert® HBV DNA point of care assay from dried blood spot
58126072|NCT05592509|DIETARY_SUPPLEMENT|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
58126073|NCT00178581|DRUG|Glutamine|
58126074|NCT05884853|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
58126075|NCT04282538|DEVICE|Active rTMS|4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
58126076|NCT04282538|DEVICE|Sham rTMS|4-week (5 days per week) sham rTMS
58451768|NCT00825201|OTHER|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
57750751|NCT05455905|DIAGNOSTIC_TEST|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
57750752|NCT04123067|DRUG|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
57750753|NCT04123067|DRUG|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
57750754|NCT01931280|BEHAVIORAL|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
57750755|NCT05508230|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
57750756|NCT00811343|BIOLOGICAL|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
57750757|NCT00784394|DRUG|diindolylmethane|Given PO
57750758|NCT00784394|OTHER|placebo|Given PO
57750759|NCT00784394|OTHER|pharmacological study|Correlative studies
57750760|NCT00784394|OTHER|laboratory biomarker analysis|Correlative studies
57750761|NCT00784394|OTHER|quality-of-life assessment|Ancillary studies
57750762|NCT05065489|OTHER|No intervention|No intervention
58314715|NCT04578938|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
57750763|NCT00972348|OTHER|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
57750764|NCT00972348|OTHER|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
57750765|NCT02578979|DEVICE|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
57750766|NCT02578979|DEVICE|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
57750767|NCT06442618|OTHER|Extracorporeal Shockwave Treatment (Group A)|Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol
57750768|NCT06442618|OTHER|Nutraceutical Supplementation (Group B)|Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.
57750769|NCT06442618|OTHER|Combined Treatment (Group C)|Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
57750770|NCT05084417|OTHER|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
57750771|NCT02213562|DIETARY_SUPPLEMENT|200 mg of chrysanthemum flower oil|
57750772|NCT02213562|DIETARY_SUPPLEMENT|300 mg of chrysanthemum flower oil|
57750773|NCT02213562|DIETARY_SUPPLEMENT|400 mg of chrysanthemum flower oil|
57750774|NCT05934968|OTHER|Mad Dog cooking class series|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
57750775|NCT05211388|PROCEDURE|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
57960149|NCT03729492|DIAGNOSTIC_TEST|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
58314716|NCT04578938|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
58314717|NCT04556175|BEHAVIORAL|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
58314718|NCT04556175|BEHAVIORAL|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
58451769|NCT00825201|OTHER|laboratory biomarker analysis|Correlative studies
57750776|NCT05211388|PROCEDURE|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
57750777|NCT03368820|OTHER|No intervention|Treatment left at the discretion of the participant
57750778|NCT05070247|DRUG|TAK-500|TAK-500 intravenous infusion.
57750779|NCT05070247|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
58126077|NCT04282538|DEVICE|Active tDCS|4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
58126078|NCT04282538|DEVICE|Sham tDCS|4-week (5 days per week) sham tDCS
57750780|NCT05838807|DEVICE|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
57750781|NCT05838807|DEVICE|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
57750782|NCT05838807|DEVICE|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
57750783|NCT05838807|DEVICE|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
57750784|NCT05100290|DIAGNOSTIC_TEST|Hyperventilation Provocation Test (HPTest)|"During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate."
57750785|NCT03901196|DIAGNOSTIC_TEST|Elemental analysis|LIBS multi elemental analysis of the specimen
57750786|NCT05461976|BEHAVIORAL|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
57750787|NCT00652158|DRUG|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
58451770|NCT00154570|DEVICE|EGG, 24 hour esophageal pH monitor|
58451771|NCT00775099|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
57750788|NCT01922492|PROCEDURE|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
57960150|NCT04714541|DRUG|Ketamine Hcl 50Mg/Ml Inj|Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
57960151|NCT00903929|DRUG|Eltrombopag|dose escalation
57960152|NCT02558374|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
57960153|NCT02558374|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
57960154|NCT02558374|OTHER|Placebo|1 drop QD, AM, OU
57960155|NCT01106846|DRUG|Group A: Saline Group|Saline continuous infusion
58314719|NCT03638791|BEHAVIORAL|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
58314720|NCT00630292|OTHER|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
58314721|NCT05409391|DEVICE|Insulin Titration System|A noval insulin titration system, which is based on deep learning
58314722|NCT05955066|DRUG|Baricitinib 4 MG|1 capsule (4mg) daily for 24 weeks
58314723|NCT05955066|DRUG|Placebo|1 capsule daily
58314724|NCT05743972|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
58314725|NCT05743972|DIAGNOSTIC_TEST|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
58451772|NCT00775099|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
58451773|NCT00469703|DRUG|Thalidomide|
58451774|NCT06060795|DIAGNOSTIC_TEST|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
58451775|NCT04816084|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|"Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age,~* known risk-factor for Covid-19~* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays"
57750789|NCT01922492|DRUG|Oral anti-diabetic drugs|"* Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
58451776|NCT05888675|DRUG|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
58451777|NCT01521130|DRUG|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
58451778|NCT04724408|DEVICE|VieScope|see above
58451779|NCT04724408|DEVICE|Conventional|see above
57750790|NCT06509126|DRUG|Panitumumab|Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
57750791|NCT06509126|DRUG|Irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
57750792|NCT06509126|DRUG|5-fluorouracil|Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
57750793|NCT06509126|DRUG|L-folinic acid|Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
57750794|NCT05842226|OTHER|Micro-teaching enriched with standard patient|The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
57750795|NCT05589870|OTHER|Multi-drug analysis of polypharmacy treatment|Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
57750796|NCT03300791|OTHER|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
57750797|NCT05886400|OTHER|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
57750798|NCT05886400|OTHER|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
57750799|NCT00453986|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
57750800|NCT00453986|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose
57750801|NCT00453986|BIOLOGICAL|Fluarix™|One intramuscular dose
57750802|NCT06181864|OTHER|NAO intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. the children are guided by the voice of the robot Nao. The robot guides them in carrying out practical and relaxation activities. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
58451780|NCT00615017|DRUG|AZD9773 (CytoFab)|intravenous infusions
57960156|NCT01106846|DRUG|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
58126079|NCT04282538|OTHER|Walking training|4-week (5 days per week) walking training
58126080|NCT04282538|OTHER|Cognition training|4-week (5 days per week) cognition training
58126081|NCT01215448|DIETARY_SUPPLEMENT|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
58126082|NCT01242280|DEVICE|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
58126083|NCT01242280|DEVICE|Tamponade|Sengstaken-Blakemore tube
58314726|NCT04561791|DEVICE|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
58314727|NCT03079830|DRUG|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
58451781|NCT00615017|OTHER|Placebo|Placebo
58451782|NCT05381363|DRUG|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
57750803|NCT06181864|OTHER|Traditional intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. The children are guided by the instructions of the operator who guides them in carrying out practical and relaxation activities. Consequently, the operator will provide feedback, to return information to the subject regarding the accuracy of the response.
57750804|NCT04837300|OTHER|Resisted Sprint Traininig|The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
57750805|NCT00742638|DRUG|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
57750806|NCT00742638|DRUG|Sodium valproate|Sodium valproate tablet 200 mg
57750807|NCT04511754|BEHAVIORAL|Experiential Psychotherapy Skill Training|The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
57750808|NCT04511754|BEHAVIORAL|Standard Psychotherapy Skill Training|Standard didactic training with research support, examples, and opportunities to ask questions.
57750809|NCT03623087|DRUG|Cisplatin|SIMPLE
57750810|NCT03623087|DRUG|Gemcitabine|SIMPLE
58126084|NCT06214377|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.
58126085|NCT06214377|DEVICE|Sham Transcranial Direct Current Stimulation|The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
58126086|NCT06214377|DRUG|Dopaminergic medication|After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
58126087|NCT06455826|DRUG|VP-001|A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
58126088|NCT06364722|OTHER|Acupuncture treatment|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
58451783|NCT05381363|OTHER|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
58126089|NCT06364722|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
58314728|NCT03079830|DRUG|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
58451784|NCT05774639|DRUG|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
58451785|NCT05774639|DRUG|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
58451786|NCT02995980|DEVICE|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
58451787|NCT02995980|DEVICE|digital mammography|routine digital mammography
58451788|NCT00006474|DRUG|O6-benzylguanine|
58451789|NCT00006474|DRUG|temozolomide|
57750811|NCT03623087|DRUG|Etoposide (VP-16)|SIMPLE
57750812|NCT03623087|DEVICE|Ifosfamide|SIMPLE
57750813|NCT03623087|DRUG|Dexamethasone|SIMPLE
57750814|NCT03623087|DRUG|L-asparaginase|SIMPLE
57750815|NCT02635048|PROCEDURE|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
57750816|NCT02635048|PROCEDURE|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
57750817|NCT01064297|DRUG|Lamotrigine monotherapy|Lamotrigine monotherapy
57750818|NCT01064297|DRUG|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
57750819|NCT01064297|DRUG|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
57750820|NCT01134146|RADIATION|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
57750821|NCT04769726|DIETARY_SUPPLEMENT|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
57750822|NCT04848428|BEHAVIORAL|Online mindfulness-based cognitive therapy|The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
58314729|NCT02318264|DEVICE|Kinesio Tape|Elastic tape placed over the skin
58451790|NCT00006474|PROCEDURE|conventional surgery|
58451791|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
58451792|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
58451793|NCT01410513|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
58451794|NCT05311735|PROCEDURE|Freeze-Dried Bone Allograft control|Bone grafting to prevent alveolar ridge collapse after tooth removal
58451795|NCT05311735|PROCEDURE|Mineralized Dentin Graft|Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
58451796|NCT05311735|PROCEDURE|Partial-Demineralized Dentin Graft|Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
58451797|NCT03609996|DEVICE|Panretinal Photocoagulation|Laser treatment for PDR
57750823|NCT04848428|BEHAVIORAL|Online standardized education|One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
57750824|NCT04035057|OTHER|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
57750825|NCT04035057|OTHER|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
57750826|NCT03055143|DRUG|SPARC-08-038|2 mg/ml intravenous infusion
57750827|NCT03055143|DRUG|Ref-08-038|2 mg/ml intravenous infusion
57750828|NCT04814836|PROCEDURE|Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)|35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
57750829|NCT04814836|PROCEDURE|Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)|35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
58451798|NCT03609996|DRUG|Lucentis|Intraviteral injection
58451799|NCT02043938|DEVICE|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
58451800|NCT05760859|OTHER|Initial cue|"Symptom volunteered by the patient"
58451801|NCT02650765|OTHER|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
58451802|NCT06194214|DRUG|Pirtobrutinib|Administered Orally.
58451803|NCT06194214|DRUG|Digoxin|Administered Orally.
58451804|NCT03951272|DEVICE|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
58451805|NCT00021749|DRUG|Oblimerson sodium, G3139|
58451806|NCT00027170|DEVICE|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
58451807|NCT01122602|DRUG|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
58451808|NCT01122602|DRUG|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
57750830|NCT04814836|PROCEDURE|Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)|the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.
58314730|NCT05366686|BEHAVIORAL|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
58314731|NCT05622149|BEHAVIORAL|Diet Only|Food tracking based on macronutrient goals.
58314732|NCT05622149|BEHAVIORAL|Training Only|Subjects completed 16 weeks of supervised resistance training
58314733|NCT05622149|BEHAVIORAL|Diet plus Training|Food tracking plus resistance training.
58314734|NCT01454752|DRUG|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
58451809|NCT01122602|DRUG|Placebo|Two placebo tablets
58451810|NCT03300557|DRUG|Exemestane|Given PO
58451811|NCT03300557|OTHER|Laboratory Biomarker Analysis|Correlative studies
58451812|NCT03300557|OTHER|Pharmacokinetic Study|Correlative studies
58451813|NCT03300557|OTHER|Questionnaire Administration|Ancillary studies
58451814|NCT01685567|DEVICE|MICHI NPS+f|Cerebral protection with carotid flow reversal
58451815|NCT02103491|DIETARY_SUPPLEMENT|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
58451816|NCT02103491|DIETARY_SUPPLEMENT|Placebo administration|
58451817|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
58451818|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
58451819|NCT00330603|PROCEDURE|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
58451820|NCT00182039|DRUG|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
58451821|NCT00182039|DRUG|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
58451822|NCT03919539|DIAGNOSTIC_TEST|5hmc testing|NGS
58451823|NCT06216067|DEVICE|CALLISTO eye|Cataract toric lens placement tool
58451824|NCT06216067|DEVICE|Wavetec AnalyzOR|Cataract toric lens placement tool
58451825|NCT01125982|DRUG|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
58451826|NCT01125982|DRUG|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
58451827|NCT04623788|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with contrast
58451828|NCT04820244|OTHER|No intervention|No intervention
58451829|NCT03354117|DRUG|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
58451830|NCT05718856|DRUG|TPO-RAs|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.
57750831|NCT04814836|PROCEDURE|Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).|The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
57750832|NCT04814836|PROCEDURE|Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)|Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
58451831|NCT05718856|DRUG|TPO-RAs combining anti-CD 20 monoclonal antibody|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater."
58451832|NCT00354380|DRUG|Methylene blue|
58451833|NCT00354380|DRUG|Artesunate|
57750833|NCT03713528|DRUG|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
57750834|NCT04816513|DRUG|Ustekinumab|Ustekinumab will be administered as SC injection.
57750835|NCT01588626|DRUG|AZD6140|tablet
57750836|NCT05816070|DRUG|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
57750837|NCT05816070|DRUG|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
57750838|NCT03240731|BIOLOGICAL|bone marrow transplant|haploidentical bone marrow transplant
57750839|NCT04879290|OTHER|FiO2 0.5|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 0.5 (50%)
58126090|NCT05221580|DRUG|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
58126091|NCT06266377|OTHER|Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder|"The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0)."
58126092|NCT06266377|OTHER|Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder|A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
58126093|NCT01608295|DRUG|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
58126094|NCT01608295|DRUG|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
58126095|NCT00287118|DRUG|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
58126096|NCT04112485|PROCEDURE|Microdiscectomy|
58126097|NCT00758849|DRUG|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
58126098|NCT00758849|DRUG|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
58126099|NCT00341354|BEHAVIORAL|Prolonged Mechanical Ventilation|
58126100|NCT00029679|DRUG|Gingko biloba|
58126101|NCT00029679|DRUG|Borage oil|
58126102|NCT05815381|OTHER|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
58126103|NCT01805609|BEHAVIORAL|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
58126104|NCT01805609|BEHAVIORAL|questionnaires|
58126105|NCT04173013|BIOLOGICAL|Uromune|2 sprays of solution once daily for a total of 3 months.
58451834|NCT00354380|DRUG|Amodiaquine|
58451835|NCT03512171|DRUG|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
58451836|NCT03512171|DRUG|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
58451837|NCT03512171|DIAGNOSTIC_TEST|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
58451838|NCT03512171|DIAGNOSTIC_TEST|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
58451839|NCT02696265|PROCEDURE|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
58451840|NCT02696265|PROCEDURE|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
58451841|NCT03113032|OTHER|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
58451842|NCT03113032|OTHER|Normal pre-surgical care|Routine pre-surgical care
58451843|NCT04183374|OTHER|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
57750840|NCT04879290|OTHER|FiO2 1|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 1 (100%)
57750841|NCT06294496|PROCEDURE|CEA/CAS|carotid endarterectomy (CEA) and carotid artery stenting (CAS)
57750842|NCT06084858|OTHER|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
58451844|NCT04410172|DIAGNOSTIC_TEST|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
58451845|NCT03982641|PROCEDURE|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
58451846|NCT03854838|DRUG|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
58451847|NCT03854838|RADIATION|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
58451848|NCT03076762|DRUG|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
58451849|NCT05579977|DRUG|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
58451850|NCT05579977|OTHER|Placebo|No drug
58451851|NCT05579977|DRUG|Rybelsus|Oral Semaglutide
58451852|NCT01722539|DRUG|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
58451853|NCT01722539|DRUG|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
58451854|NCT01722539|DRUG|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
58451855|NCT01722539|DRUG|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
58451856|NCT01336933|DRUG|prednisone|Given PO
58451857|NCT01336933|DRUG|cyclophosphamide|Given IV
58451858|NCT01336933|DRUG|etoposide|Given PO or IV
58451859|NCT01336933|DRUG|Vincristine|Given IV
58451860|NCT01336933|DRUG|pralatrexate|Given IV
58451861|NCT01336933|OTHER|laboratory biomarker analysis|Correlative studies
58451862|NCT01336933|GENETIC|comparative genomic hybridization|Correlative studies
58451863|NCT01336933|GENETIC|gene expression analysis|Correlative studies
58451864|NCT01336933|GENETIC|nucleic acid sequencing|Correlative studies
58451865|NCT01336933|GENETIC|mutation analysis|Correlative studies
58451866|NCT01336933|OTHER|immunohistochemistry staining method|Correlative studies
58451867|NCT01336933|GENETIC|microarray analysis|Correlative studies
57750843|NCT00567190|DRUG|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
58314735|NCT01454752|OTHER|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
58314736|NCT04388423|OTHER|simulated puncture training|The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
58451868|NCT01336933|GENETIC|RNA analysis|Correlative studies
58451869|NCT04035252|DIAGNOSTIC_TEST|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
58451870|NCT00329368|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
58451871|NCT00329368|BIOLOGICAL|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
58451872|NCT00329368|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
58451873|NCT00329368|DRUG|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
57750844|NCT00567190|DRUG|Placebo|Placebo (matching pertuzumab) was administered intravenously.
58314737|NCT04388423|OTHER|traditional bedside teaching|The residents are trained by traditional bedside teaching
58314738|NCT06085144|DRUG|Galcanezumab|Receiving either 120mg or 300mg injections.
58451874|NCT00329368|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
58451875|NCT01239069|DRUG|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
58451876|NCT01239069|DRUG|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
58451877|NCT01239069|OTHER|Placebo|DE-110 ophthalmic suspension vehicle;QID
58451878|NCT01527968|DRUG|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
58451879|NCT01527968|DRUG|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
58451880|NCT01527968|DRUG|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
58451881|NCT04282252|DRUG|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
58451882|NCT00996463|PROCEDURE|Electro-thermo-coagulation|Electro-thermo-coagulation
58451883|NCT00996463|DRUG|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
58451884|NCT00996463|DRUG|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
58126106|NCT04941664|DRUG|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
58451885|NCT05057481|DRUG|Mycophenolate Mofetil 500mg|MMF 2gram/day orally for 12 weeks
58451886|NCT05057481|DRUG|Rituximab|375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
58451887|NCT06332066|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
58451888|NCT06270069|OTHER|Excercise-based therapy|An individual 60-min motor training sessions twice a week for eight-week outpatient program, that included exercises aimed at improving postural control, strengthening and stabilizing the back muscles, and stretching
58451889|NCT06096649|OTHER|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Instructions: Apply to the entire face twice daily - morning and evening
58451890|NCT06096649|OTHER|Topical Vehicle|Instructions: Apply to the entire face twice daily - morning and evening
58451891|NCT00304174|BEHAVIORAL|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
58451892|NCT03703778|PROCEDURE|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
58126107|NCT03797755|RADIATION|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
58451893|NCT03703778|DRUG|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
58451894|NCT03703778|DRUG|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
58451895|NCT04791436|DIAGNOSTIC_TEST|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
58451896|NCT04791436|DIAGNOSTIC_TEST|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
58451897|NCT04272346|BEHAVIORAL|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
58451898|NCT04272346|BEHAVIORAL|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
58126108|NCT00981604|PROCEDURE|SILS|Single Incision Laparoscopic Cholecystectomy
58314739|NCT00038662|DRUG|Atrasentan|
58314740|NCT00864071|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
58126109|NCT00981604|PROCEDURE|Standard Laparoscopic Cholecystectomy|4 port technique
58126110|NCT03820921|DIAGNOSTIC_TEST|EUS-FNB|"EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA)."
58126111|NCT03820921|OTHER|Immunohistochemistry|IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
58314741|NCT00864071|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
57750845|NCT00567190|DRUG|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
57750846|NCT00567190|DRUG|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
57750847|NCT00303199|DRUG|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
57750848|NCT01162681|DRUG|A-623|High dose given subcutaneously once a week for up to 52 weeks
57750849|NCT01162681|DRUG|A-623|Low dose given subcutaneously once a week for up to 52 weeks
57750850|NCT01162681|DRUG|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
57750851|NCT01162681|OTHER|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
57750852|NCT04723823|OTHER|Motor or sensory imagery with fMRI|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
57750853|NCT03536286|BEHAVIORAL|Encouragement|Households will be visited and encouraged to enroll in Asili
57750854|NCT00990639|DRUG|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
57750855|NCT02758353|DRUG|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
57750856|NCT02320292|OTHER|Quality-of-Life Assessment|Ancillary studies
57750857|NCT02320292|BIOLOGICAL|Rituximab|Given IV
57750858|NCT02320292|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
57750859|NCT06454032|BEHAVIORAL|Fitness walking|Fitness walking for 12 weeks.
57750860|NCT06454032|BEHAVIORAL|Maintained lifestyle|Maintained their normal lifestyle, without exercise intervention.
57750861|NCT00644631|DRUG|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
57750862|NCT00644631|DRUG|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
57750863|NCT04274920|OTHER|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
57750864|NCT04274920|OTHER|Light cured calcium hydroxide|Light cured calcium hydroxide
57960157|NCT02524353|OTHER|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
57960158|NCT03186235|OTHER|Flow cytometry|Isolation of T regulatory cells from blood
57960159|NCT05321979|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
57960160|NCT00324285|DRUG|Amylase resistant starch added ORS|
58126112|NCT04868526|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
58126113|NCT04448665|DIAGNOSTIC_TEST|microbiological investigation|a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
58314742|NCT00002129|DRUG|Vesnarinone|
58314743|NCT02679846|OTHER|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
57750865|NCT06174584|DRUG|Hypertonic saline|Hypertonic saline
57750866|NCT06174584|OTHER|Cow Milk|Cow Milk
57750867|NCT05228899|DRUG|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
57750868|NCT05228899|OTHER|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
57750869|NCT05164575|BEHAVIORAL|progressive resistance exercise|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
57750870|NCT05164575|BEHAVIORAL|self-management strategies|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
57750871|NCT00430248|DRUG|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
57750872|NCT00430248|DRUG|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
57750873|NCT00430248|DRUG|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
57750874|NCT02487810|BEHAVIORAL|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
57750875|NCT02487810|BEHAVIORAL|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
58126114|NCT02933775|GENETIC|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
58126115|NCT02933775|DRUG|Fludarabine|30 mg/m\^2/day×4 days
58126116|NCT02933775|DRUG|Cyclophosphamide|500 mg/m\^2/day×2 days
58126117|NCT01150747|DRUG|ceftriaxone|250mg IM once
58126118|NCT01150747|DRUG|Azithromycin|1 gm once
58126119|NCT06299137|PROCEDURE|Serratus Anterior Plane Block|Patients who undergo randomization to the intervention arm will undergo the Serratus Anterior Plane Block.
58126120|NCT06299137|DRUG|Ropivacaine injection|For the Serratus Anterior Plane Block, Ropivacaine will be used as the anesthetic.
58126121|NCT00706745|DIETARY_SUPPLEMENT|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
58451899|NCT04272346|BEHAVIORAL|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
58451900|NCT00395356|BEHAVIORAL|calorie controlled diet|
57750876|NCT04492579|OTHER|Gentle-UHT donor human milk supplementation|Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born \>36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
58126122|NCT00706745|DIETARY_SUPPLEMENT|placebo|identical placebo capsules.
58126123|NCT06456372|BEHAVIORAL|Digital Health Intervention Group|Our digital health intervention (DHI) uses Patient-Centered Digital Healthcare Technologies (PC-DHT) to promote co-regulation (child/parent), capture patient data, support efficient healthcare delivery, enhance patient engagement, and facilitate shared decision-making, thereby improving access to timely and targeted mental health intervention for children at great risk for poor outcomes. This system will integrate treatment across multiple points of care and will enable health care providers and caregivers to share reliable and targeted information that will facilitate collaborative decision-making (e.g., making decisions about changing or titrating medications/dosages or shifting behavioral therapy and educational intervention targets) and improve patient experiences and outcomes.
58126124|NCT04749602|DRUG|Nivolumab|40 mg of the nivolumab will be used intrapleurally (once).
58126125|NCT01376128|DRUG|Paroxetine|
58126126|NCT01690936|DIETARY_SUPPLEMENT|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
57750877|NCT04425005|OTHER|Home-based exercise|Home-based exercise training, supervised by videoconference.
57750878|NCT02609165|DRUG|rhNGF 180 µg/ml eye drops solution|eye drops
57750879|NCT02609165|DRUG|vehicle eye drops|placebo
57750880|NCT02709668|DIETARY_SUPPLEMENT|Enlyte|gel cap of reduced B vitamins
57750881|NCT02709668|OTHER|placebo|identical to Enlyte
57750882|NCT02483897|DRUG|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
57750883|NCT02483897|DRUG|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
57960161|NCT04161833|DIETARY_SUPPLEMENT|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
58314744|NCT02862509|DRUG|Budesonide nasal instillation|
58314745|NCT02862509|DRUG|Normal saline nasal instillation|
58451901|NCT06217848|DRUG|Saxenda|Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
58451902|NCT05890768|DRUG|Lumateperone|FDA approved antipsychotic drug
58451903|NCT05890768|DRUG|Risperidone|FDA approved antipsychotic drug
58451904|NCT05691894|DRUG|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
58451905|NCT05691894|DRUG|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
58451906|NCT03445884|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
58451907|NCT03973359|BEHAVIORAL|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
58451908|NCT01914263|BIOLOGICAL|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
58451909|NCT00844012|DRUG|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
58451910|NCT00844012|DRUG|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
58451911|NCT00999544|DRUG|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
58451912|NCT00999544|DRUG|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
58451913|NCT00999544|DRUG|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
58451914|NCT00999544|DRUG|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
58451915|NCT00999544|DRUG|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
58451916|NCT00999544|DRUG|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
58451917|NCT00999544|DRUG|Oxycodone 0mg, IN|Oxycodone 0mg, IN
57750884|NCT06181110|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
57750885|NCT05673239|DRUG|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
57750886|NCT03382964|BIOLOGICAL|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
57750887|NCT00558064|DRUG|telmisartan+amlodipine|
57750888|NCT00558064|DRUG|amlodipine|
57750889|NCT03788538|DRUG|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
58451918|NCT00999544|DRUG|Oxycodone 15mg, IN|Oxycodone 15mg, IN
58451919|NCT00999544|DRUG|Oxycodone 30mg, IN|Oxycodone 30mg, IN
58451920|NCT06033066|BEHAVIORAL|Financial Incentives|Small financial incentive or prize incentive
58451921|NCT06033066|BEHAVIORAL|Message|Message inviting participant to enroll
58451922|NCT02897648|DRUG|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
58451923|NCT02581306|OTHER|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
58451924|NCT03592316|OTHER|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
58451925|NCT01978496|DRUG|Placebo|matching placebo
58451926|NCT01978496|DRUG|Eletriptan 20 mg|20mg oral
58451927|NCT01978496|DRUG|Eletriptan 40 mg|40mg oral
58451928|NCT01978496|DRUG|Eletriptan 80 mg|80mg oral
58451929|NCT03488836|PROCEDURE|reciproc|rotary reciprocating protocol
58451930|NCT03488836|PROCEDURE|race rotary|race rotary group protocol
58451931|NCT01550536|BEHAVIORAL|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
58451932|NCT06124365|OTHER|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
58126127|NCT04709848|OTHER|None - standard of care|Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
58126128|NCT02090439|DRUG|Silodosin|
58126129|NCT04826588|DRUG|Methylprednisolone sodium succinate 10 mg/kg intravenously|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
58126130|NCT04826588|BIOLOGICAL|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
58126131|NCT00295958|BIOLOGICAL|LMB-2 immunotoxin|
58126132|NCT00295958|BIOLOGICAL|MART-1 antigen|
58126133|NCT00295958|BIOLOGICAL|gp100 antigen|
58126134|NCT00295958|BIOLOGICAL|incomplete Freund's adjuvant|
58126135|NCT05118295|DEVICE|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
58126136|NCT03499938|DEVICE|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
58126137|NCT05582499|DRUG|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
58126138|NCT05582499|DRUG|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
58126139|NCT05582499|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
58126140|NCT05582499|DRUG|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
58126141|NCT05582499|DRUG|Camrelizumab|an anti-programmed death-1 (PD1) antibody
58126142|NCT05582499|DRUG|SHR-A1921|Trophoblast cell-surface antigen 2 (TROP2) ADC
58126143|NCT05582499|DRUG|Pertuzumab|Pertuzumab
58126144|NCT05582499|DRUG|Trastuzumab|Trastuzumab
58126145|NCT05582499|DRUG|Goserelin|goserelin
57750890|NCT01000168|OTHER|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
58126146|NCT05582499|DRUG|Letrozole|letrozole
58451933|NCT06124365|OTHER|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
58126147|NCT05582499|DRUG|Nab paclitaxel|Albumin paclitaxel
57750891|NCT03505281|BIOLOGICAL|Blood samples|"Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)"
57750892|NCT03639701|DRUG|Thymidine|Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
57750893|NCT05012800|BIOLOGICAL|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
58126148|NCT05582499|DRUG|Carboplatin|Carboplatin
58126149|NCT05582499|DRUG|Epirubicin|Epirubicin
57750894|NCT06580535|OTHER|blood sample|Blood sample taking from patient for tissue culture
58126150|NCT05582499|DRUG|Cyclophosphamide|Cyclophosphamide
58126151|NCT05582499|DRUG|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
58126152|NCT05582499|DRUG|Apatinib|tyrosine kinase inhibitors
58126153|NCT05582499|DRUG|Famitinib|tyrosine kinase inhibitors
58126154|NCT02649283|DEVICE|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
58126155|NCT02649283|PROCEDURE|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
58126156|NCT06395857|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
58126157|NCT04704609|OTHER|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
58126158|NCT01072942|DRUG|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
58126159|NCT01072942|DRUG|Placebo|Placebo TID for 10 days
58126160|NCT00336310|DRUG|Repaglinide|
58126161|NCT02824900|DEVICE|Vibration stimuli to neck muscles|
58126162|NCT02824900|DEVICE|Vibration stimuli to hand|
58126163|NCT02824900|BEHAVIORAL|conventional physiotherapy|
58126164|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
58126165|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
58126166|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
58126167|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
58314746|NCT04920669|PROCEDURE|erector spinae block with bupivacaine|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
58314747|NCT04920669|PROCEDURE|erector spinae block with bupivacaine + dexmedetomidine|Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
58314748|NCT03945890|OTHER||
58451934|NCT01759420|DRUG|Ondansetron|4mg of intravenous ondansetron
58126168|NCT02407444|OTHER|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
58126169|NCT02407444|OTHER|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
58126170|NCT00427492|DRUG|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
58126171|NCT00427492|DRUG|Placebo|
58126172|NCT04963088|DRUG|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
58126173|NCT04963088|DRUG|Anlotinib|oral administration daily d1-d14, q3w;
58126174|NCT04963088|DRUG|Oxaliplatin|30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
58126175|NCT04963088|DRUG|Capecitabine|1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
58126176|NCT02236338|PROCEDURE|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
58126177|NCT02236338|DEVICE|ClosureFAST radiofrequency catheter|
58126178|NCT02236338|DEVICE|EVLT 980nm diode laser system|
58314749|NCT02918344|OTHER|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
57750895|NCT02119260|DRUG|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
57750896|NCT02119260|DRUG|GSK2798745 suspension|Aqueous suspension of GSK2798745 (\>=0.5 mg)
57750897|NCT02119260|DRUG|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)
57960162|NCT06151171|DIETARY_SUPPLEMENT|CoQ10|"Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day."
57960163|NCT01049763|DRUG|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
57960164|NCT02677155|RADIATION|Radiotherapy|Radiotherapy 8 Gy single dose
57960165|NCT02677155|BIOLOGICAL|Rituximab|Intranodal injection 5 mg
57960166|NCT02677155|BIOLOGICAL|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
57960167|NCT02677155|BIOLOGICAL|GM-CSF|Subcutaneous injection of 50 ug
57960168|NCT02677155|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
57960169|NCT03636243|BIOLOGICAL|Vascularly biological assessment|22.5 ml of blood will be collected at day -15, month 3 and month 12.
57960170|NCT03636243|BIOLOGICAL|Analysis of vasomotor endothelial function|Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
57960171|NCT03636243|BIOLOGICAL|Analysis of arterial compliance|Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12
57960172|NCT03636243|BIOLOGICAL|Exploration of microcirculation|The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
57960173|NCT03636243|BIOLOGICAL|Venous Doppler Ultrasound|aneurysm screening at day -15, month 3 and month 12
57960174|NCT03636243|BIOLOGICAL|Arterial pressure measurement|measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
57960175|NCT03636243|BIOLOGICAL|Intima-Media Thickness measurement|Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
58126179|NCT02514174|DRUG|Afatinib|afatinib starting at 30 mg daily dose
58126180|NCT03858257|DEVICE|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
58126181|NCT03858257|DEVICE|Standard oxygenation|Supplemental oxygen through a facemask.
58314750|NCT02918344|PROCEDURE|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
58314751|NCT00205166|PROCEDURE|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
58314752|NCT00205166|DRUG|Caffeine|Caffeine 400 mg po
58314753|NCT00205166|DRUG|Caffeine|Caffeine 200 mg po
58451935|NCT03929107|BIOLOGICAL|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
58451936|NCT02774980|BEHAVIORAL|Recurrent depression|
58126182|NCT03849313|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
58126183|NCT02073630|OTHER|active cerebellar stimulation|
58126184|NCT02073630|OTHER|sham cerebellar stimulation|
58126185|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
58451937|NCT01185015|DRUG|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
57750898|NCT02119260|DRUG|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
57750899|NCT02119260|DRUG|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
57750900|NCT02119260|DRUG|Placebo capsule|Matching white opaque placebo blend filled capsule
57750901|NCT00281710|DRUG|Methylprednisolone|
57750902|NCT02278068|DEVICE|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
57750903|NCT01925833|PROCEDURE|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
57750904|NCT01925833|PROCEDURE|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
57750905|NCT05580848|PROCEDURE|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
57750906|NCT00743769|DRUG|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
57750907|NCT00743769|OTHER|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
57750908|NCT00815282|OTHER|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
57750909|NCT00502255|DEVICE|Health Buddy system|Patients are followed on distance by the Health Buddy system.
57750910|NCT00502255|DEVICE|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
57750911|NCT00768820|DRUG|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
58451938|NCT02098746|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
57750912|NCT00960180|DRUG|MR1817|
57750913|NCT00960180|DRUG|Placebo|
57750914|NCT00022412|DIETARY_SUPPLEMENT|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
57750915|NCT00022412|PROCEDURE|conventional surgery|Procedure: Prostatectomy for prostate cancer
57750916|NCT04356833|DRUG|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|Patients in the cohort 1 rt-PA group will receive the first dose as soon as possible after registration. 10mg rt-PA in 5mL diluent will be administered by nebulisation every 6 hours for 14 days, resulting in a total daily dose of 40mg.
58126186|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
58126187|NCT03516747|DIAGNOSTIC_TEST|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
58126188|NCT03516747|DIAGNOSTIC_TEST|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
58126189|NCT02295397|OTHER|food|food provocation, skin testing, blood sampling
58126190|NCT06455020|PROCEDURE|Catheter ablation|Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission
58451939|NCT02893709|DRUG|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
58451940|NCT01155336|DRUG|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
58451941|NCT01155336|DRUG|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
57750917|NCT04356833|DRUG|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV will receive 60mg daily over three doses for 14 days
57750918|NCT04356833|DRUG|nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients will receive 60mg daily for over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
57960176|NCT03636243|BIOLOGICAL|Exploration of neuropathy|non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
57960177|NCT03636243|BEHAVIORAL|level of physical activity|pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
57960178|NCT03636243|OTHER|thoracic scanner|non-injected thoracic scanner visit at month 3
57960179|NCT01464476|DRUG|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
58126191|NCT06455020|PROCEDURE|Stepped-care strategies|Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
58126192|NCT00948675|DRUG|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
58451942|NCT00748345|DRUG|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
58451943|NCT05770817|OTHER|N/A: SKyRoCKeT is an observational study|None; this is an observational study
58451944|NCT03818750|DEVICE|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
58451945|NCT03818750|BEHAVIORAL|Alcohol Use Disorders Identification Test|Questionnaire
58451946|NCT00763646|DRUG|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
58451947|NCT03714724|DIAGNOSTIC_TEST|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
58451948|NCT00869752|BIOLOGICAL|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
58451949|NCT00869752|DRUG|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
58451950|NCT00869752|DRUG|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
58451951|NCT05927766|DEVICE|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
58451952|NCT02041481|DRUG|MEK inhibitor MEK162|Given PO
58451953|NCT02041481|DRUG|leucovorin calcium|Given IV
58451954|NCT02041481|DRUG|fluorouracil|Given IV
58451955|NCT02041481|DRUG|oxaliplatin|Given IV
58451956|NCT02041481|OTHER|pharmacological study|Correlative studies
58451957|NCT02041481|OTHER|Laboratory Biomarker Analysis|Correlative Studies
58451958|NCT05378321|DIAGNOSTIC_TEST|Non-invasive diagnostic testing|Non-invasive diagnostic testing consists of the use of the FibroScan device and the calculation of non-invasive blood-based scores for the diagnosis of NAFLD
58451959|NCT04036981|DRUG|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
58451960|NCT00425646|BIOLOGICAL|bevacizumab|
58451961|NCT00425646|DRUG|imatinib mesylate|
58451962|NCT06376578|BEHAVIORAL|Exercise intervention|Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
58451963|NCT06376578|BEHAVIORAL|Polar A380 wristwatch physical activity tracker|The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
58451964|NCT05191394|DIAGNOSTIC_TEST|Evolution of antibodies titre|For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.
57960180|NCT01464476|DRUG|Placebo|Dose-matched placebo. Once daily, oral administration
57960181|NCT02743832|PROCEDURE|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
57960182|NCT02743832|PROCEDURE|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
57960183|NCT04139876|PROCEDURE|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
58126193|NCT00948675|DRUG|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
58126194|NCT00948675|DRUG|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
58126195|NCT00948675|BIOLOGICAL|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
58126196|NCT00508560|BEHAVIORAL|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
58126197|NCT00508560|BEHAVIORAL|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
58126198|NCT02556242|OTHER|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
58126199|NCT02556242|OTHER|Generalised Indoor residual spraying|IRS is carried out as normally practiced
58126200|NCT02898649|DEVICE|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
58126201|NCT01241461|DRUG|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
58126202|NCT06110039|OTHER|Cervicothoracic Junction Mobilization|The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.
58126203|NCT06110039|OTHER|Upper Thoracic Spine Manipulation:|The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
58126204|NCT00006864|BIOLOGICAL|aldesleukin|
58126205|NCT00154024|DRUG|atorvastatin|
58126206|NCT00154024|DRUG|irbesartan|
58126207|NCT01520051|DRUG|Mepolizumab|3 monthly intravenous infusions of 750 mg
58126208|NCT01520051|DRUG|Placebo|3 monthly intravenous infusions with saline
58126209|NCT03752788|BEHAVIORAL|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
58126210|NCT03752788|BEHAVIORAL|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
58126211|NCT06373575|PROCEDURE|Lung and inferior vena cava ultrasound guidance|The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.
58126212|NCT06373575|PROCEDURE|Conventional protocol guidance|Fluid removal using conventional protocol including blood pressure and physical examination
58126213|NCT02983448|DEVICE|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
58126214|NCT03287050|DRUG|Pembrolizumab|200 mg IV q 21 days
58126215|NCT03287050|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
58126216|NCT05338060|OTHER|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
58126217|NCT05802680|DEVICE|Transcranial photobiomodulation|Administration of Sham or 1064 (+/- 50) nanometers tPBM
58126218|NCT05802680|DEVICE|Sham transcranial photobiomodulation|Sham treatment
58126219|NCT05722509|PROCEDURE|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
58126220|NCT05722509|PROCEDURE|"Only Exodontia Group"|Third molar exodontia without associated surgery.
58126221|NCT00802802|DRUG|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
58126222|NCT00802802|DRUG|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
58126223|NCT00244322|DRUG|LY450139 dihydrate|
58126224|NCT00244322|DRUG|placebo|
58126225|NCT02185612|BEHAVIORAL|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
58126226|NCT04639596|BEHAVIORAL|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
58126227|NCT02046928|DRUG|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
58126228|NCT02207231|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
58126229|NCT02207231|DRUG|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
58126230|NCT02207231|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
58126231|NCT02207231|DRUG|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
58126232|NCT06274606|OTHER|Exercise Group|Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
58126233|NCT02154529|DRUG|Tesevatinib|
58126234|NCT02154529|DRUG|Trastuzumab|
58126235|NCT03287700|OTHER|No intervention|No intervention will be administered to any group in this observational study.
58126236|NCT03069274|BEHAVIORAL|Intervention|General nutritional recommendations, change drinking habits
57750919|NCT06430840|BEHAVIORAL|CostCOM (Cost Communication, Financial navigation and counseling)|"Patients will receive two 1-hour, phone or video sessions with a remote financial counselor, each session will cover each of these 3 components of CostCOM.~Out-of-pocket cost communication (OOPC): A review of insurance benefits and education of the patient-specific OOPC for anticipated treatment regimen if any (i.e., medication). The OOPC is provided as a total estimate and will be updated at 3-month session in case of changes in treatment or insurance.~Financial navigation: Real-time professional guidance to identify financial assistance programs (e.g., co-pay, living expenses) that alleviate costs of care and discuss information to improve insurance coverage.~Financial counseling: To address the range of patients' financial concerns and enroll patients in financial assistance programs."
57750920|NCT06430840|BEHAVIORAL|Provision of local and national resources to address financial and social needs|Patients will be provided with a comprehensive list of local resources (in patients' preferred language) in Orange County that can help with food insecurity, ir transportation, as well as contact information for national non-profit organization where patients can self-refer for financial navigation (e.g., Patient Advocate Foundation (PAF)
57750921|NCT06430840|BEHAVIORAL|Financial Education|Patient will receive online and paper educational materials on topics such as health insurance and health insurance literacy, navigating hospitals' price estimator tool.
58126237|NCT03069274|BEHAVIORAL|General nutritional recommendations|Only general nutritional recommendations were given
58126238|NCT01669395|OTHER|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
58126239|NCT01669395|OTHER|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
58126240|NCT04232150|DRUG|single-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
58126241|NCT04232150|DRUG|Double-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
58126242|NCT04232150|PROCEDURE|spinal anesthesia with no sedation.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
58126243|NCT04835948|DRUG|single dose of Anti-thymocyte globulin|Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
58126244|NCT02280629|DRUG|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
58126245|NCT02280629|DRUG|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
58126246|NCT02280629|DRUG|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
58126247|NCT01784042|DRUG|Placebo|placebo
58126248|NCT01784042|DRUG|Lovaza|
58126249|NCT01784042|OTHER|Dietary energy restriction|
58126250|NCT04195165|BEHAVIORAL|SIT|For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.
57960184|NCT04139876|PROCEDURE|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
57960185|NCT02079987|BEHAVIORAL|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
57960186|NCT02079987|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
57960187|NCT02972164|BEHAVIORAL|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
57960188|NCT01972893|DRUG|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
57960189|NCT01972893|DRUG|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
57960190|NCT05170711|PROCEDURE|hypotensive anesthesia|hypotensive anesthesia
57960191|NCT05170711|PROCEDURE|normotensive anesthesia|normotensive anesthesia group
57960192|NCT06437873|PROCEDURE|Total Thyroidectomy (TT)|TT:Surgical removal of the entire thyroid gland.
57960193|NCT06437873|RADIATION|Radioactive iodine treatment(RAIT)|RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
57960194|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
57960195|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens2|TEST
57960196|NCT03534700|PROCEDURE|parasacral flap reconstruction|parasacral flap reconstruction
57960197|NCT03534700|PROCEDURE|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
57960198|NCT02343471|DIETARY_SUPPLEMENT|20 g whey protein|
57960199|NCT01035905|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57960200|NCT01035905|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
57960201|NCT01357369|PROCEDURE|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
57960202|NCT02510287|DRUG|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
57960203|NCT02510287|DRUG|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
57960204|NCT02510287|DRUG|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
57960205|NCT02510287|DRUG|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
57960206|NCT02510287|DRUG|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
57960207|NCT02499432|BEHAVIORAL|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
57960208|NCT01916265|DRUG|Glucagon|
57960209|NCT04099303|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
57960210|NCT04099303|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
57960211|NCT04099303|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
57960212|NCT04099303|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
57960213|NCT06372132|PROCEDURE|G-POEM|Gastric Per-Oral Endoscopic Pyloromyotomy
57960214|NCT02085603|DRUG|Saracatinib|
57960215|NCT02085603|DRUG|Placebo|
57960216|NCT04451915|OTHER|late management strategy|late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
57960217|NCT04451915|OTHER|early management strategy|early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
57960218|NCT01827033|BEHAVIORAL|meditation training|
58126251|NCT04195165|BEHAVIORAL|ACTIVE|For the ACTIVE+EX condition, the subject will be asked to take \>10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.
58126252|NCT04195165|BEHAVIORAL|EX|The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
58126253|NCT02764008|DRUG|Bupivacaine|20 ml %0,25 bupivacaine
58126254|NCT02764008|DEVICE|Ultrasound|
58126255|NCT04154709|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
58126256|NCT05172375|BEHAVIORAL|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
58126257|NCT06386783|DRUG|Dexmedetomidine Injection [Precedex]|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
58126258|NCT06386783|DRUG|Fentanyl HCl|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
58126259|NCT02473809|DRUG|Liraglutide|Once daily
58126260|NCT02473809|DRUG|Placebo|Once daily
58126261|NCT04414956|DIAGNOSTIC_TEST|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
58126262|NCT04414956|DIAGNOSTIC_TEST|AFP|AFP will be tested using serum sample every 6 months.
58126263|NCT04414956|DIAGNOSTIC_TEST|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
58126264|NCT04414956|DIAGNOSTIC_TEST|Sonography|Sonography will be tested by experts every 6 months.
58126265|NCT04414956|DIAGNOSTIC_TEST|CT|Contrast-enhanced CT will be tested annually.
57750922|NCT06430840|OTHER|Usual care|Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.
57750923|NCT06430840|OTHER|Screening for financial and social needs|Patients will be screened for financial hardship and health-related social risks.
57750924|NCT04392505|DRUG|Durvalumab Injection|Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
57750925|NCT01559454|DRUG|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
57750926|NCT01559454|DRUG|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
57750927|NCT03568266|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
57750928|NCT06200103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57750929|NCT06200103|PROCEDURE|Bone Scan|Undergo bone scan
57750930|NCT06200103|OTHER|Clinical Observation|Undergo active monitoring
57960219|NCT06163612|BEHAVIORAL|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
57960220|NCT06163612|BEHAVIORAL|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
57960221|NCT06163612|OTHER|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
57960222|NCT06163612|BEHAVIORAL|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
57750931|NCT06200103|PROCEDURE|Computed Tomography|Undergo SPECT/CT or PET/CT
57960223|NCT00969449|DRUG|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
57960224|NCT00969449|DRUG|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
57960225|NCT04065529|COMBINATION_PRODUCT|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
57960226|NCT04065529|COMBINATION_PRODUCT|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
58126266|NCT03385473|GENETIC|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
57750932|NCT06200103|OTHER|Gallium Ga 68 Gozetotide|Given IV
57750933|NCT06200103|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
58126267|NCT03385473|DIAGNOSTIC_TEST|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
58126268|NCT00628823|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten containing foods removed from diet
57750934|NCT06200103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57750935|NCT06200103|OTHER|Questionnaire Administration|Ancillary studies
57750936|NCT06200103|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
58126269|NCT03810430|BEHAVIORAL|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
58126270|NCT06288061|DEVICE|Non-invasive Neuromodulation|"This intervention group will receive neuromodulation treatment two days a week for a total of six sessions.~The patient is placed in the supine position with a cushion under the knees. The physiotherapist will be positioned behind the patient's head on the side to be treated. The technique will be applied on both anterolateral sides of the neck, where the Phrenic nerve passes in front of the anterior Scalene, between the Subclavian arteries and veins. Neuromodulation will be applied with a Pointer Excel II. It will be applied with negative polarity, at a frequency of 2 Hertz (HZ) and with a current intensity varying between 0 and 45 milliamperes (mA). The intensity shall be increased progressively until the patient's diaphragmatic contraction can be observed without pain. The technique shall be applied on each side for a total of 8 minutes, divided into intervals of 10 seconds of stimulation and 20 seconds of rest."
58126271|NCT06288061|OTHER|Cervico-dorsal Massage|"This intervention group will receive manual therapy two days a week for a total of six sessions.~The patient shall be placed prone position with a cushion under his or her feet. This group will receive manual therapy on the entire posterior cervical and dorsal region, the area between the occipital bone, the shoulders and the scapulae. The massage will be carried out with a little oil or cream for about 20 minutes."
58126272|NCT01003132|OTHER|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
58126273|NCT02966379|DEVICE|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point"
58126274|NCT04808089|OTHER|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
58126275|NCT04808089|OTHER|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
58126276|NCT00861445|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
58126277|NCT00861445|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
58126278|NCT05638425|RADIATION|Radiotherapy combined with PD-1 inhibitors|Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
58126279|NCT05213936|DEVICE|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
57960227|NCT03485833|DIAGNOSTIC_TEST|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
57960228|NCT01908660|DRUG|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
57960229|NCT02579980|PROCEDURE|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
57960230|NCT02579980|PROCEDURE|Surgery|Standard of care procedure for sarcoma patients
57960231|NCT02645175|DIETARY_SUPPLEMENT|TW1025|20ml, 3 times per day (daily dose: 60 ml)
57960232|NCT02645175|DIETARY_SUPPLEMENT|Placebo|20ml, 3 times per day (daily dose: 60 ml)
57960233|NCT03505229|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
57960234|NCT05121532|DIAGNOSTIC_TEST|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
57960235|NCT03649399|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
57960236|NCT01373983|DRUG|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
57960237|NCT04880577|DRUG|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
57960238|NCT04880577|DRUG|Placebo|Placebo arm
57960239|NCT01826747|DRUG|crinone (progesterone 8%, vaginal application)|
57960240|NCT05066243|OTHER|questionnaire|this study is to develop a questionnaire for vulval conditions
57960241|NCT02691780|DRUG|Sorafenib|
57960242|NCT01520571|PROCEDURE|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
57960243|NCT01520571|PROCEDURE|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
57960244|NCT03959722|DIETARY_SUPPLEMENT|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
57960245|NCT03959722|DIETARY_SUPPLEMENT|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
58126280|NCT05213936|DEVICE|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
58126281|NCT01645384|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
58126282|NCT06545747|RADIATION|DCE-MRI based split-course hypo-RT|Tumor delineation will be based on DCE-MRI and CT. MRI help define the tumor boundary. Different radiation doses will be delivered based on the Ktrans value of the tumor area on DCE-MRI.
58126283|NCT06545747|RADIATION|CT based split-course hypo-RT|Tumor delineation will be based on CT. The total dose for both the first and boost courses of hypo-RT to the tumor area will be constant.
58126284|NCT06545747|DRUG|Concurrent chemotherapy|Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.
58126285|NCT06545747|DRUG|Consolidative immunotherapy|Consolidative PD-1/PD-L1 inhibitors
58126286|NCT00538343|DRUG|berubicin hydrochloride (RTA 744)|
58126287|NCT02215577|PROCEDURE|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
58126288|NCT02215577|PROCEDURE|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
58126289|NCT00680121|DRUG|Benfotiamine|Benfotiamine 600 mg
58126290|NCT00680121|DRUG|Placebo|Placebo
58126291|NCT05072340|BEHAVIORAL|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
58126292|NCT05382221|OTHER|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
58126293|NCT05382221|OTHER|Standard Care|one offer of cessation treatment annually
58126294|NCT02456532|DRUG|placebo|six months of nightly placebo
58126295|NCT02456532|DRUG|Zolpidem CR|six months of nightly zolpidem
58126296|NCT02456532|DRUG|Eszopiclone|
58126297|NCT00004381|DRUG|tin mesoporphyrin|
58126298|NCT04076501|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
58126299|NCT04076501|PROCEDURE|Sham room air|Room air applied via mask
58126300|NCT06189378|OTHER|Inclusion of patient-provided pictures into blood pressure diaries|Patient-provided pictures with positive meaning were included into blood pressure diaries
58126301|NCT06189378|OTHER|Conventional blood pressure diary|Conventional blood pressure diary
58126302|NCT06546267|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT for Prostate cancer will be evaluated
58126303|NCT06546267|RADIATION|Intensity Modulated Radiotherapy|Patients treated with IMRT for Prostate cancer will be evaluated
58126304|NCT06546267|RADIATION|Stereotactic Body Radiotherapy|Patients treated with SBRT for Prostate cancer will be evaluated
58126305|NCT05342857|DRUG|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T\&E criteria in Taiwan local consensus
58126306|NCT05071807|DRUG|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
58126307|NCT05071807|OTHER|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
58126308|NCT01752257|DRUG|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
58126309|NCT01619826|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
58126310|NCT01619826|BEHAVIORAL|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
58126311|NCT02933281|BIOLOGICAL|MTBVAC|Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU
58126312|NCT02933281|BIOLOGICAL|BCG|BCG 5 x 10\^5 CFU
58126313|NCT05052138|OTHER|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
58126314|NCT01600495|OTHER|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
58126315|NCT05271474|DEVICE|ANNE ONE Platform|ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
58126316|NCT01697020|DRUG|Mercaptopurine 20mg/ml oral suspension|50mg
58126317|NCT01697020|DRUG|Mercaptopurine 50mg tablet|50mg
58126318|NCT05698368|BEHAVIORAL|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
58126319|NCT05698368|OTHER|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
58126320|NCT05894161|OTHER|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day."
57750937|NCT05334498|OTHER|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
58126321|NCT01817348|PROCEDURE|Lidocaine group|"* Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
58126322|NCT01817348|OTHER|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
58126323|NCT03918798|DRUG|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
58126324|NCT03918798|DRUG|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
58126325|NCT05759975|DEVICE|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
58126326|NCT05759975|DEVICE|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
58126327|NCT01502566|BEHAVIORAL|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
58126328|NCT05493007|PROCEDURE|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
58126329|NCT05493007|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
58126330|NCT00978900|DIETARY_SUPPLEMENT|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
58126331|NCT00978900|DIETARY_SUPPLEMENT|Water|
58126332|NCT04114669|BEHAVIORAL|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
58126333|NCT04114669|BEHAVIORAL|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
58451965|NCT01576432|BEHAVIORAL|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
58451966|NCT00100789|DRUG|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
58451967|NCT00100789|DRUG|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
58451968|NCT01774799|BEHAVIORAL|Advance care planning intervention|
58451969|NCT01774799|OTHER|Control group|
58451970|NCT01708512|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
57750938|NCT05334498|OTHER|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
57750939|NCT01786928|OTHER|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
57750940|NCT02629991|DRUG|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
57750941|NCT02629991|OTHER|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
58126334|NCT05863546|OTHER|Traditional treatment|The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
58126335|NCT05863546|DEVICE|Therapeutic ultrasound|US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
58126336|NCT00237549|PROCEDURE|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
58126337|NCT01860248|DRUG|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
58126338|NCT01860248|DRUG|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
58126339|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
58126340|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
58126341|NCT04812756|BEHAVIORAL|Step-2-It - text messaging program|participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
58126342|NCT03730103|OTHER|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
58126343|NCT02128048|DEVICE|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
58126344|NCT04053790|DRUG|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
58126345|NCT04053790|OTHER|placebo|a tablet of placebo every 12 hours given by mouth
58126346|NCT05381623|PROCEDURE|Simplified suture-less approach|Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.
57750942|NCT04063774|DIAGNOSTIC_TEST|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
57750943|NCT05000567|OTHER|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
57750944|NCT02450331|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
58126347|NCT05381623|PROCEDURE|Application of hemostatic sponges and compressive sutures|Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
58126348|NCT03408626|DRUG|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
58126349|NCT03408626|DEVICE|conventional rotary|traditional rotary method
58126350|NCT03167671|DEVICE|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
58126351|NCT03167671|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
58126352|NCT04465942|DRUG|(chemo)immunotherapy|Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
57960246|NCT04925895|OTHER|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
57960247|NCT04925895|OTHER|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
57960248|NCT04925895|OTHER|Cryotherapy|application of cold pack on knee joint for 10 minutes
58126353|NCT01835678|DRUG|Linagliptin|orally 5 mg/d for 4 weeks
58126354|NCT01835678|DRUG|Placebo|orally once a day for 4 weeks
58126355|NCT02004704|DRUG|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
58126356|NCT01195714|DRUG|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
58126357|NCT00665041|DRUG|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
57750945|NCT00618254|DRUG|Granisetron|
58126358|NCT03239132|BEHAVIORAL|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
58126359|NCT03239132|BEHAVIORAL|Meditation educational materials|Meditation educational materials
58126360|NCT03197064|DRUG|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
58126361|NCT01346332|DEVICE|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
58126362|NCT05564832|DRUG|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
58126363|NCT01265784|DRUG|TP-434|
58126364|NCT01265784|DRUG|Ertapenem|
58126365|NCT01265784|DRUG|Placebo|Administered IV to maintain the blind.
58126366|NCT04799158|DRUG|Vonoprazan|Orally via capsules
58126367|NCT04799158|DRUG|Placebo|Orally via capsules
58126368|NCT05549856|PROCEDURE|Wet suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). Before puncturing the lesion, flush the needle with 5ml saline, then use a 10 ml syringe in order to replacing the column of air with fluid. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
58126369|NCT05549856|PROCEDURE|Dry suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). The stylet is removed and a 10 ml air-filled pre-vacuum syringe is attached. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
57750946|NCT05949970|PROCEDURE|Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.
58314754|NCT01608594|DRUG|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
57750947|NCT03948750|PROCEDURE|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
57750948|NCT06495788|DEVICE|High-intensity laser therapy (HILT)|"* Pulsed high-intensity laser therapy (HILT) will be applied 3 sessions per week for 8 weeks with pulsed emission (1064 nm), very high peak power (3 kW), a short duration (120-150 ms), and low frequency (10-40 Hz).The probe is fixed vertically at 90° to the most painful points while the patients sit on a chair and wear safety eyewear.~* Conventional treatment ( 3 days per week for 8 weeks).: in the form of~* Hot pad: It will be used over the temporomandibular joint (TMJ) for 5 minutes at the beginning of each session.~* Ultrasound therapy (US): it will be applied over the TMJ with pulsed intensity of 1.0 W/cm2 at a 1MHz frequency for 5 min/session.~* TENS: one electrode is placed over the TMJ and the other just above the mandibular angle. it will be applied with a low frequency of 50 HZ, tolerable intensity for 15 minutes.~* Exercise therapy: anterior, medial and lateral glide of the mandible. Each glide will be done 10-15 repetitions, 5-6 times in a session, 10 minutes as a total."
58314755|NCT01608594|DRUG|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
58314756|NCT00409825|DRUG|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
57750949|NCT06495788|DEVICE|placebo high-intensity laser therapy|The same treatment procedure will be applied in the placebo group as in the experimental group, but the laser device is turned off during applications, in addition to the conventional treatment in the form of hot pad, US, TENS, and exercise therapy.
57750950|NCT05654896|DRUG|Ceftriaxone Sodium|Antibiotic will be administered prophylactically for TACE
58126370|NCT00168883|DRUG|Carboplatin|
58126371|NCT00168883|DRUG|Paclitaxel|
58126372|NCT00168883|DRUG|Vinorelbine|
58314757|NCT00409825|PROCEDURE|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
57750951|NCT00814424|DEVICE|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
57750952|NCT00814424|DEVICE|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
57750953|NCT04649502|COMBINATION_PRODUCT|Metformin|Metformin in combination with doxycycline
57750954|NCT01235546|DRUG|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
58126373|NCT00565305|BEHAVIORAL|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
58126374|NCT00565305|RADIATION|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
58126375|NCT01644500|DRUG|Dulaglutide|Administered SC
58126376|NCT01644500|DRUG|Glimepiride|Administered orally
58126377|NCT01644500|DRUG|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
58126378|NCT01644500|DRUG|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
58126379|NCT02009800|BIOLOGICAL|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
58126380|NCT02788461|RADIATION|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
58126381|NCT02788461|RADIATION|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
58126382|NCT03652701|OTHER|Hair Up|Herbal topical
58451971|NCT01535807|DEVICE|CorMatrix extra cellular matrix (ECM)|"* Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
57750955|NCT01235546|DRUG|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
57750956|NCT04237506|BEHAVIORAL|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
57750957|NCT06495203|DRUG|anti-VEGF treatment|Follow clinical practice/administration
57750958|NCT02937272|DRUG|LY3200882|Administered orally
57750959|NCT02937272|DRUG|LY3300054|Administered intravenously
58126383|NCT03652701|OTHER|Placebo|Placebo
58126384|NCT00332761|DRUG|Caduet|
58126385|NCT05231642|OTHER|Nutritional Interventional|Individualised postprandial glucose and vascular risk responses
57750960|NCT02937272|DRUG|Gemcitabine|Administered intravenously
57750961|NCT02937272|DRUG|nab-Paclitaxel|Administered intravenously
57750962|NCT02937272|DRUG|Cisplatin|Administered intravenously
57750963|NCT02937272|RADIATION|Intensity Modulated Radiotherapy|
57750964|NCT04503525|OTHER|Nutritional assessment|Nutritional assessment in COVID patients
58126386|NCT05169762|OTHER|standard treatment|starndard treatment for transgender women
58126387|NCT05896631|OTHER|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
58126388|NCT05896631|OTHER|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
58126389|NCT05936099|BEHAVIORAL|E-cigarette & Tobacco Use Treatment Intervention|The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
58126390|NCT01938118|BEHAVIORAL|Obesity Prevention Group|
58126391|NCT01938118|BEHAVIORAL|Injury Prevention Group|
58126392|NCT01106963|PROCEDURE|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
58126393|NCT04825938|DRUG|Toripalimab , Carboplatin, Nab-paclitaxel|Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
58126394|NCT04353908|PROCEDURE|Rehabilitation|The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks
58126395|NCT04353908|PROCEDURE|Collagen Injection|With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
58126396|NCT00821392|DRUG|Febuxostat|
58126397|NCT05413603|PROCEDURE|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
58126398|NCT05413603|PROCEDURE|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
58126399|NCT02717247|DEVICE|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
58126400|NCT02717247|DEVICE|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
58126401|NCT01900236|BEHAVIORAL|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
58451972|NCT01043211|DRUG|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
57750965|NCT01016080|DRUG|glutathione|250 mg capsules, twice daily, orally
57750966|NCT01016080|DRUG|placebo|250 mg capsules, twice daily, orally
57750967|NCT03721575|PROCEDURE|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
57750968|NCT03721575|PROCEDURE|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
57750969|NCT02408575|DEVICE|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
57750970|NCT02408575|DEVICE|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
57960249|NCT04925895|OTHER|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
57960250|NCT01407783|BEHAVIORAL|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
57960251|NCT00689949|DIETARY_SUPPLEMENT|folic acid|0.4 mg of folic acid per day
57960252|NCT03881995|DRUG|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
57960253|NCT03881995|DRUG|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
57960254|NCT06541054|OTHER|WARM SOCKS|One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
57960255|NCT06322875|PROCEDURE|Recombinant type III humanized collagen solution for injection|Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
57960256|NCT06322875|OTHER|SkinCeuticals recombinant humanized collagen (RHC) serum|Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face
57960257|NCT06322875|OTHER|Regular face cream smear|Subjects received Regular face cream smear application on the whole face
57960258|NCT02235532|OTHER|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
57960259|NCT02235532|OTHER|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
58126402|NCT05585996|BIOLOGICAL|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
58126403|NCT06485024|DEVICE|Modeling Resin|it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
57960260|NCT01418976|BEHAVIORAL|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
57960261|NCT05687084|DEVICE|Uterine manipulator use|The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
57960262|NCT06220734|PROCEDURE|transurethral resection of the prostate|transurethral resection of the prostate for indicated patients then US was done for early detection of fluid accumulation in the lungs
57960263|NCT00294112|DRUG|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
57960264|NCT00294112|DRUG|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
58126404|NCT01742975|DEVICE|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
58126405|NCT00618163|DRUG|Meloxicam|
58126406|NCT00006250|DRUG|chlorambucil|
58126407|NCT00006250|DRUG|dexamethasone|
58126408|NCT00006250|DRUG|fludarabine phosphate|
58126409|NCT00006250|DRUG|mitoxantrone hydrochloride|
58126410|NCT03744260|DIAGNOSTIC_TEST|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
58126411|NCT05448144|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
58126412|NCT06412562|DIAGNOSTIC_TEST|The Maudsley 3-item Visual Analogue Scale (M3VAS)|Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
58126413|NCT00991588|PROCEDURE|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
58126414|NCT02572310|DEVICE|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
58126415|NCT02127606|DEVICE|Vibration with tilt-table standing|
58126416|NCT03411005|DIETARY_SUPPLEMENT|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
58126417|NCT05473676|DEVICE|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
58126418|NCT01621425|OTHER|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
58126419|NCT01621425|OTHER|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
58126420|NCT01621425|OTHER|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
58126421|NCT04076176|DIETARY_SUPPLEMENT|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
58126422|NCT04076176|DIETARY_SUPPLEMENT|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
58126423|NCT05909475|DIETARY_SUPPLEMENT|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
58126424|NCT05909475|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
58126425|NCT03383744|DIETARY_SUPPLEMENT|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
58126426|NCT01625156|OTHER|Laboratory Biomarker Analysis|Correlative studies
58126427|NCT01625156|OTHER|Pharmacological Study|Correlative studies
58126428|NCT01625156|DRUG|Temsirolimus|Given IV
58126429|NCT01625156|DRUG|Tivantinib|Given PO
58126430|NCT03104738|OTHER|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
58126431|NCT03558477|DRUG|YYD601 1|YYD601 1
58126432|NCT03558477|DRUG|YYD601 2|YYD601 2
58126433|NCT03558477|DRUG|YYD601 3|YYD601 3
58126434|NCT03558477|DRUG|Nexium|Nexium
58126435|NCT05180864|PROCEDURE|Gastrectomy|Open or minimally invasive (sub)total gastrectomy
58126436|NCT04654104|OTHER|check immune check points|we will evaluate the expression of immune check points
58126437|NCT00065858|DRUG|BufferGel|
58126438|NCT00469625|DRUG|paricalcitol (initial dose 1 mcg orally per day)|
58126439|NCT05495542|OTHER|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects \[5\]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered \[6\]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory \[7\]
58126440|NCT03186911|BEHAVIORAL|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
58126441|NCT03459937|BEHAVIORAL|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
58126442|NCT03459937|BEHAVIORAL|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
58126443|NCT00967642|DRUG|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
58126444|NCT04750187|OTHER|Hypo-pressive abdominal exercise intervention|An 8-week hypo-pressive abdominal exercise program
58126445|NCT06456203|DIAGNOSTIC_TEST|AI|Artificial intelligence triage and reporting system
58126446|NCT02576509|DRUG|Nivolumab|Specified Dose on Specified Days
58126447|NCT02576509|DRUG|Sorafenib|Specified Dose on Specified Days
58126448|NCT05307861|DEVICE|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
58126449|NCT05307861|DEVICE|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
58126450|NCT02608853|OTHER|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
58126451|NCT00096395|DRUG|gemcitabine hydrochloride|Given IV
58126452|NCT00096395|DRUG|sorafenib tosylate|Given orally
58126453|NCT00096395|OTHER|laboratory biomarker analysis|Correlative studies
58126454|NCT05589675|OTHER|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
58126455|NCT05589675|OTHER|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
58126456|NCT00777829|DRUG|zolpidem|Participants will receive one dose of 10 mg before each nap.
58126457|NCT00777829|DRUG|Placebo|Participants will receive a dose of placebo before each nap.
58126458|NCT01570465|OTHER|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
58126459|NCT01017783|BEHAVIORAL|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
58126460|NCT01017783|BEHAVIORAL|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
58126461|NCT01017783|BEHAVIORAL|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
58126462|NCT02995070|PROCEDURE|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
58126463|NCT02995070|DEVICE|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
58126464|NCT02995070|DEVICE|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
58126465|NCT00472290|DRUG|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
58126466|NCT05240209|OTHER|The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.|Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
58126467|NCT04112251|DIETARY_SUPPLEMENT|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
58126468|NCT03365323|OTHER|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
58126469|NCT03365323|OTHER|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
58126470|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
58126471|NCT00990613|DRUG|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
58126472|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
58126473|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
58126474|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
57960265|NCT02438709|DRUG|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
57960266|NCT04420598|DRUG|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowe"
57960267|NCT03657251|GENETIC|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
57960268|NCT04539730|DRUG|Liposomal bupivacaine|266 mg or 20 ml Liposomal Bupivacaine injectable solution
57960269|NCT04539730|PROCEDURE|Drug: SoC Ropivacaine|0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
57960270|NCT05500625|PROCEDURE|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
57960271|NCT05500625|PROCEDURE|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
57960272|NCT03995615|PROCEDURE|scaling and root planing|"* After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
57960273|NCT01387893|BEHAVIORAL|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
57960274|NCT00006121|DRUG|oxaliplatin|
57960275|NCT01902966|DRUG|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
57960276|NCT01902966|BEHAVIORAL|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
57960277|NCT01902966|BEHAVIORAL|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
57960278|NCT01902966|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
57960279|NCT06062862|DEVICE|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
57960280|NCT06062862|DEVICE|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
57960281|NCT00023387|DRUG|Rifapentine|
57960282|NCT00023387|DRUG|25-desacetyl Rifapentine|
57960283|NCT00023387|DRUG|Isoniazid|
57960284|NCT04453293|BIOLOGICAL|BCG (Tokyo 172) vaccine|Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
57960285|NCT04453293|DRUG|Placebo|Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
57960286|NCT05628220|OTHER|physiotherapy|rehabilitation through using session of virtual reality desensitization
57960287|NCT00825565|DRUG|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
57960288|NCT02005757|DRUG|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
57960289|NCT02005757|DRUG|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
58126475|NCT05351164|DRUG|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
58126476|NCT04531228|PROCEDURE|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
57960290|NCT05086471|DEVICE|NaviCam SB|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
58126477|NCT02192736|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
58126478|NCT03828942|DRUG|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
57960291|NCT05086471|DEVICE|PillCam SB3|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
57960292|NCT04654208|DRUG|palbociclib|patients on palbociclib combination treatment
57960293|NCT02073773|DRUG|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
57960294|NCT02073773|OTHER|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
57960295|NCT01515787|DRUG|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
57960296|NCT01515787|OTHER|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
57960297|NCT01515787|PROCEDURE|surgery|low anterior resection with total mesorectal excision
57960298|NCT01515787|PROCEDURE|magnetic resonance imaging or endorectal ultrasound|
57960299|NCT04955392|OTHER|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~1. Inhibition of the suboccipital muscles.~2. Parietal Lift.~3. Sutherland Technique of Sphenobasilar Synchondrosis.~4. Compression technique of the fourth ventricle (CV4)."
57960300|NCT04955392|OTHER|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
57960301|NCT02531646|RADIATION|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
57960302|NCT00393575|BEHAVIORAL|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
57960303|NCT02326558|PROCEDURE|laparoscopic microwave ablation-assisted enucleation|
57960304|NCT02326558|PROCEDURE|conventional laparoscopic partial nephrectomy|
57960305|NCT05551832|DRUG|Arm I (Placebo),|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
57960306|NCT05551832|DRUG|Arm II (ESMESOL)|SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
57960307|NCT06267833|BEHAVIORAL|exercise|In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
58126479|NCT00004096|DRUG|carboplatin|
58126480|NCT00004096|DRUG|vinorelbine ditartrate|
58126481|NCT00337571|DRUG|Aripiprazole|Tablets, Oral, once daily, 8 weeks
58126482|NCT00337571|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
58126483|NCT00946257|DRUG|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
58126484|NCT06401083|DRUG|Caffeine citrate|20 mg/kg caffeine-citrate before the planned extubation.
58126485|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
58126486|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
58126487|NCT00958243|BIOLOGICAL|Placebo|Placebo
58126488|NCT04305964|DEVICE|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
58126489|NCT04305964|DIAGNOSTIC_TEST|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
58126490|NCT00857636|BEHAVIORAL|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
58126491|NCT01714570|DRUG|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
58126492|NCT01714570|DRUG|Imipenem|0.5g q6h, 5-10 days
58126493|NCT01906541|GENETIC|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
58126494|NCT01870661|DEVICE|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
58126495|NCT01870661|DEVICE|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
58126496|NCT03428594|BIOLOGICAL|CKD-11101|
58126497|NCT03428594|BIOLOGICAL|NESP|
58126498|NCT06073249|OTHER|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
58126499|NCT06073249|OTHER|Tibial Nerve Stimulation|The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
58126500|NCT04073147|DRUG|Venetoclax|Venetoclax per os
57750971|NCT04967235|OTHER|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
57960308|NCT04124588|DEVICE|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
57960309|NCT04124588|DEVICE|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
57960310|NCT06538883|DRUG|Sedation with Ciprofol|During the drug administration period, ciprofol were IV infused at loading doses of 0.1 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
57960311|NCT06538883|DRUG|Sedation with Propofol|During the drug administration period, propofol were IV infused at loading doses of 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Propofol were then immediately administered at an initial maintenance dose of 1.5 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
57960312|NCT03594890|BIOLOGICAL|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
57960313|NCT03594890|BIOLOGICAL|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
57960314|NCT03594890|BIOLOGICAL|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
57960315|NCT03594890|BIOLOGICAL|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
57960316|NCT04066075|BEHAVIORAL|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
57960317|NCT00705939|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
57960318|NCT03640871|DEVICE|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
57960319|NCT02543528|DEVICE|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
58126501|NCT04073147|DRUG|Obinutuzumab|ObintuzumabIV
58126502|NCT00093990|DRUG|Tipifarnib;Zarnestra; R115777|
58126503|NCT05435508|OTHER|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
58126504|NCT05435508|OTHER|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
58126505|NCT00216502|DRUG|galantamine hydrobromide|
58126506|NCT01238848|DRUG|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
58126507|NCT01238848|DRUG|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
58126508|NCT04613830|DRUG|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
58126509|NCT04613830|DRUG|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
58126510|NCT00429806|DRUG|DHEA|DHEA
58126511|NCT00429806|DRUG|Placebo|Placebo
58126512|NCT02253979|DEVICE|Standard double lumen tube|Endotracheal left side double lumen tube
58126513|NCT02253979|DEVICE|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
58126514|NCT01818856|DRUG|Ritonavir withdrawal, atazanavir 200 mg/12h|
58126515|NCT01818856|DRUG|Telaprevir interactions|
58126516|NCT05182632|BEHAVIORAL|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
58126517|NCT01032369|OTHER|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
58126518|NCT01032369|OTHER|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
58126519|NCT04438005|DRUG|ICP-022|ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
58126520|NCT01415778|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
58126521|NCT01415778|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
58126522|NCT00625911|DRUG|morphine|intravenous patient controlled analgesia, standard protocol
58126523|NCT00625911|DRUG|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
58126524|NCT03196999|BEHAVIORAL|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
58126525|NCT03196999|BEHAVIORAL|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
58126526|NCT03196999|BEHAVIORAL|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
57960320|NCT02543528|DEVICE|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
57960321|NCT02543528|DEVICE|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
57960322|NCT02543528|DEVICE|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
57960323|NCT02543528|DEVICE|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
57960324|NCT05048875|DRUG|JNJ-64281802 (sentinel high dose)|Group 1a, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
57960325|NCT05048875|DRUG|JNJ-64281802 (remaining high dose)|Group 1b, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
57960326|NCT05048875|DRUG|JNJ-64281802 (medium/low dose)|Group 2, JNJ-64281802 (low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days) AND JNJ-64281802 (medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days)
58126527|NCT01855724|DRUG|Gemcitabine-Pazopanib|
58126528|NCT02857842|DRUG|Prednisolone|
58126529|NCT00193609|DRUG|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
58126530|NCT00193609|DRUG|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
58126531|NCT02684552|DEVICE|Non invasive ventilation|Training on treadmill with Non invasive ventilation
58126532|NCT02684552|DEVICE|Oxygen|Training on treadmill with oxygen
58126533|NCT00664781|DRUG|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
58126534|NCT00664781|GENETIC|protein expression analysis|
58126535|NCT00664781|GENETIC|western blotting|
58126536|NCT00664781|OTHER|immunohistochemistry staining method|
58126537|NCT00664781|OTHER|liquid chromatography|
58126538|NCT00664781|OTHER|mass spectrometry|
58126539|NCT00664781|OTHER|pharmacological study|
58126540|NCT04059211|DIAGNOSTIC_TEST|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
58126541|NCT04549064|DIAGNOSTIC_TEST|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
58126542|NCT04021537|DEVICE|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
58126543|NCT02959905|BIOLOGICAL|TSA-CTL|Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
58126544|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
58126545|NCT02959905|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.
58451973|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
58451974|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
58451975|NCT03890588|OTHER|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
58451976|NCT05415358|OTHER|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of pembrolizumab discontinuation.
58451977|NCT00076414|DRUG|Acetylcholine|
58451978|NCT00076414|DRUG|L-NMMA|
58451979|NCT06157866|OTHER|Electroacupuncture|During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. A low-amplitude, sub-sensory electrical current will be activated by the acupuncturist.
58451980|NCT06157866|BEHAVIORAL|Cognitive Training|Cognitive training with a pain specialist.
58451981|NCT06157866|BEHAVIORAL|Education Training|Education training with a pain specialist.
58451982|NCT04410185|BEHAVIORAL|Meditation|Meditation sessions will take place over 12 weekly sessions of 1.5 hours
58451983|NCT02544568|OTHER|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
57960327|NCT05048875|DRUG|JNJ-64281802 (daily dosing regimen X)|Group 3, JNJ-64281802 (800-mg twice per day loading dose for 2 days/250-mg maintenance dose for 21 days)
57960328|NCT05048875|DRUG|JNJ-64281802 (weekly dosing regimen Y1)|Group 4, JNJ-64281802 (450-mg twice per day loading dose for 2 days/1200-mg maintenance dose weekly \[3 doses over 15 days\])
57960329|NCT05048875|DRUG|JNJ-64281802 (weekly dosing regimen Z2)|Group 5, JNJ-64281802 (250-mg twice per day loading dose for 2 days/500-mg maintenance dose weekly \[3 doses over 15 days\])
57960330|NCT05048875|DRUG|Placebo|No therapeutic effect, used as a control in testing new drugs
57960331|NCT00870753|BEHAVIORAL|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
57960332|NCT05485948|DRUG|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
57960333|NCT00826124|PROCEDURE|Epidural steroid injection|Injection based solely on history and physical exam
57960334|NCT00826124|PROCEDURE|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
57960335|NCT00826124|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
57960336|NCT04868812|DEVICE|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
57960337|NCT01171456|DRUG|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
57960338|NCT01171456|DRUG|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
57960339|NCT04469478|OTHER|Survey and interview|Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
57960340|NCT05174000|DRUG|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
57960341|NCT05174000|DRUG|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
57960342|NCT03215966|COMBINATION_PRODUCT|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
57960343|NCT03215966|DRUG|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
57960344|NCT03215966|DRUG|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
57960345|NCT05185609|OTHER|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
57960346|NCT05185609|OTHER|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
57960347|NCT00003955|BIOLOGICAL|dactinomycin|
57960348|NCT00003955|BIOLOGICAL|filgrastim|
57960349|NCT00003955|BIOLOGICAL|pegfilgrastim|
57960350|NCT00003955|BIOLOGICAL|sargramostim|
57960351|NCT00003955|DRUG|cyclophosphamide|
57960352|NCT00003955|DRUG|irinotecan hydrochloride|
57960353|NCT00003955|DRUG|vincristine sulfate|
57960354|NCT00003955|RADIATION|radiation therapy|
57960355|NCT03695068|BEHAVIORAL|RISE Intervention|Described in Arms description.
58126546|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
58126547|NCT01723995|RADIATION|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
58126548|NCT03818048|DRUG|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
58126549|NCT03818048|DRUG|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
58126550|NCT05159609|DEVICE|Closed loop auditory stimulus|50ms of low volume pink noise delivered during slow wave sleep
58126551|NCT05653596|BEHAVIORAL|Virtual reality-based cognitive intervention|This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
58126552|NCT05023213|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
58126553|NCT02815852|OTHER|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women \<40 years the typical imaging presentation pattern of malignancies observed in women\> 40 years are confirmed.
58126554|NCT05854758|OTHER|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
58126555|NCT05854758|OTHER|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
58126556|NCT05129579|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
58451984|NCT06376630|DRUG|Esmolol Hcl 10Mg/Ml Inj|"the loading dose of 500 mkg/kg for 1 minute, followed by the initial rate of 50 mkg/kg/min. Individual titration depending on the desired hemodynamical effect (to the heart rate of 60 bpm or to the maximum tolerated dose maintaining stable hemodynamics) every 5-15 minutes (the maximum allowed rate of administration is 300 mkg/kg/min) for 6 hours.~Thereafter patients in both treatment arms - the IV esmolol arm and the placebo arm, will be administered oral β-adrenergic blockers, if decided so by the treating physician and unless contraindicated."
57750972|NCT04967235|OTHER|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
57750973|NCT05666453|BIOLOGICAL|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
57750974|NCT05666453|OTHER|No intervention|None of investigational drugs are administered to patients.
57750975|NCT03881306|DRUG|D-TACE|D-TACE with CalliSpheres-Oxaliplatin
57750976|NCT02063334|DIETARY_SUPPLEMENT|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
57750977|NCT02063334|DIETARY_SUPPLEMENT|Placebo|
57750978|NCT05025969|OTHER|Glioma data collection|Glioma data collection
57750979|NCT05025969|OTHER|Brain metastasis data collection|Brain metastasis data collection
57750980|NCT00936442|DRUG|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
57750981|NCT00936442|OTHER|Educational materials|Reception of educational material on regular basis.
57750982|NCT03968432|BEHAVIORAL|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS\&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
57960356|NCT03616938|PROCEDURE|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
57960357|NCT06419140|DRUG|Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation|Motivational counseling to perform nutritional, psychological, and exercise inventions
58126557|NCT05129579|OTHER|no intervention|No intervention will be made in the control group.
58126558|NCT05263648|OTHER|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
58126559|NCT04776551|PROCEDURE|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
58126560|NCT02260557|DRUG|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
58126561|NCT02260557|DRUG|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
58126562|NCT06542081|BEHAVIORAL|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
58451985|NCT00488488|DRUG|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
58451986|NCT05147376|DRUG|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
58451987|NCT05147376|DRUG|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
57750983|NCT03968432|BEHAVIORAL|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
57750984|NCT04834791|DRUG|Letrozole 2.5mg|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
57750985|NCT04834791|DRUG|Gonadotropin|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
58126563|NCT00930488|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
58126564|NCT04931667|DRUG|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
58126565|NCT06121206|OTHER|Altitude-like hypoxia (12% O2)|Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
58126566|NCT06121206|OTHER|Normoxia (20% O2)|Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
58314758|NCT06519630|DEVICE|Rehabotics Physiotherapy|The intervention will be consisted of sessions for participants in the intervention group which includes a repetition of each of the four Sollerman AR Games named, Wallet, Key, Jar, Screwdriver and one repetition of Balloon Pop. Participants will interact with the AR Box and Block Test (BBT) and the serious games under controlled conditions. A clinician will be present throughout the whole session providing help if participants encounter any difficulties. Following the games, the clinician will initiate a stretching program using the Active Exoskeletal Aid, performing 3 sets of 10 repetitions on the finger flexors of the patient's hand. Each rehabilitation session will last 30 minutes and will be conducted three times a week. Similarly, the traditional physiotherapy training program will be prescribed for the control group and will be consisted of sessions lasting 30 minutes per day, three days per week. Both programs duration will be five weeks.
58314759|NCT06519630|OTHER|Traditional Physiotherapy|Similarly, the hand functional training program prescribed for the control group consisted of sessions lasting 30 minutes per day, three days per week. Both programs lasted for five weeks and were designed by two clinical experts.
58451988|NCT04138992|DRUG|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
58451989|NCT04138992|DRUG|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
58451990|NCT04138992|DRUG|Docetaxel|used in neoadjuvant chemotherapy
58451991|NCT04138992|RADIATION|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
58451992|NCT03833726|PROCEDURE|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
58451993|NCT03833726|PROCEDURE|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
58451994|NCT02405156|DRUG|Letrozole|
58451995|NCT02405156|DRUG|Placebo|
58451996|NCT02405156|DRUG|Misoprostol|
58451997|NCT01678378|BEHAVIORAL|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
58451998|NCT02071966|DRUG|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
58451999|NCT02071966|DRUG|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
57750986|NCT03887338|OTHER|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
57750987|NCT03344679|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
57750988|NCT03344679|DRUG|Adenosine 12mg|Adenosine 12 mg for PECS block
58126567|NCT06121206|BEHAVIORAL|Cognitive training|The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
58126568|NCT06121206|BEHAVIORAL|Sham training|Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
58126569|NCT04359238|BEHAVIORAL|Individualized excercise|The participants in the intervention group carry out regularly endurance and strength exercises.
58452000|NCT03010527|DRUG|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
58452001|NCT03010527|OTHER|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
58452002|NCT04762732|DEVICE|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
58452003|NCT04762732|DEVICE|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
57750989|NCT03344679|DRUG|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
57750990|NCT04681118|BIOLOGICAL|NurOwn (MSC-NTF cells)|Intrathecal administration
57750991|NCT03580889|DRUG|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
57750992|NCT03580889|DRUG|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
57750993|NCT03580889|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
57750994|NCT00207584|DRUG|Doxycycline treatment|
57750995|NCT01144026|BIOLOGICAL|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
57750996|NCT01144026|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
58452004|NCT01165983|DRUG|Placebo|0mg tablet, taken orally for 12 weeks daily
58126570|NCT04552509|RADIATION|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
58126571|NCT01079637|PROCEDURE|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
58126572|NCT01079637|PROCEDURE|Cast treatment|Cast treatment
58126573|NCT00000359|BEHAVIORAL|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
58452005|NCT01165983|DRUG|Aliskiren|150mg tablet, taken orally for 12 weeks daily
58452006|NCT02953600|DIETARY_SUPPLEMENT|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
58452007|NCT02953600|OTHER|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
57750997|NCT05499390|DRUG|AK112|Subjects receive AK112 intravenously.
57750998|NCT05499390|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
57750999|NCT03300947|DRUG|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
57751000|NCT03300947|DRUG|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
57751001|NCT03300947|DRUG|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
57751002|NCT02380625|DRUG|Azithromycin|Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
57751003|NCT02380625|DRUG|Sunitinib and Erlotinib|Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days
57751004|NCT02380625|DRUG|Atorvastatin and Irbesartan|Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.
57751005|NCT02380625|OTHER|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
57751006|NCT04799626|DRUG|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
57751007|NCT05505877|DRUG|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
57751008|NCT03012464|OTHER|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
58452008|NCT02953600|DIETARY_SUPPLEMENT|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
58452009|NCT06000124|OTHER|Plyometric exercises|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
58452010|NCT06000124|OTHER|Regulation Exercises Program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
58452011|NCT06106113|DRUG|GST-HG171 Tablets|150mg GST-HG171 Tablets
58452012|NCT03077542|PROCEDURE|haploidentical stem cell transplant|haploidentical stem cell transplant
58452013|NCT03077542|DRUG|Sirolimus|conditioning regimen
58452014|NCT03077542|DRUG|Alemtuzumab|conditioning regimen
58452015|NCT03077542|DRUG|Pentostatin|conditioning regimen
58452016|NCT03077542|DRUG|Cyclophosphamide|conditioning regimen
58452017|NCT03077542|DRUG|Hydroxyurea|conditioning regimen
58452018|NCT03077542|DRUG|Filgrastim|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
58452019|NCT02041507|OTHER|Air insufflation method.|Air insufflation colonoscopy.
58452020|NCT02041507|OTHER|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
58452021|NCT02041507|OTHER|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
58452022|NCT02214641|BEHAVIORAL|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
58452023|NCT02214641|BEHAVIORAL|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
58452024|NCT04648319|DRUG|BMS-936558|BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
58452025|NCT02526602|PROCEDURE|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
58452026|NCT02526602|PROCEDURE|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
58452027|NCT01271725|DRUG|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
58452028|NCT01271725|DRUG|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
58452029|NCT01271725|DRUG|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
58452030|NCT03214861|OTHER|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
58452031|NCT03518294|BEHAVIORAL|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
58452032|NCT00020917|BIOLOGICAL|cetuximab|
58452033|NCT00020917|DRUG|fluorouracil|
58452034|NCT00020917|DRUG|irinotecan hydrochloride|
58452035|NCT00020917|DRUG|leucovorin calcium|
57751009|NCT05897567|OTHER|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
57751010|NCT05897567|OTHER|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
57751011|NCT05897567|OTHER|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
58452036|NCT02019732|OTHER|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
58452037|NCT04531761|BEHAVIORAL|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
58452038|NCT00694655|BIOLOGICAL|Yellow Fever Vaccine|Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
58452039|NCT03666871|BIOLOGICAL|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
58452040|NCT03666871|BIOLOGICAL|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
58452041|NCT03247257|PROCEDURE|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
58126574|NCT00000359|BEHAVIORAL|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
58452042|NCT03247257|PROCEDURE|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
58452043|NCT02553057|DEVICE|mechanical ventilation|
58126575|NCT00000359|BEHAVIORAL|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
58126576|NCT00000359|BEHAVIORAL|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
58126577|NCT00000359|BEHAVIORAL|ShamManeuver|Passive movement of the head
58126578|NCT03295721|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
58126579|NCT03295721|DRUG|Saline Placebo|Saline placebo by instillation
58126580|NCT03295721|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
58126581|NCT03295721|DEVICE|Luer-lock applicator|Applicator for instillation
58126582|NCT03295721|DEVICE|Vial access device|Device for withdrawal of drug product
58126583|NCT03598439|BIOLOGICAL|Standard IIV4|Standard inactivated influenza vaccine
58126584|NCT03598439|BIOLOGICAL|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
58126585|NCT03598439|BIOLOGICAL|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
58126586|NCT02296580|DEVICE|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
58452044|NCT05137964|DIAGNOSTIC_TEST|Vitamin D|Serum Biochemical routine lab workup and gynaecological ultra sound AFC
58452045|NCT00613496|DRUG|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
58452046|NCT00613496|DRUG|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
57751012|NCT02898779|DRUG|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
57751013|NCT04675450|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
57751014|NCT04675450|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
58126587|NCT05128357|OTHER|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
58126588|NCT04428567|BEHAVIORAL|Dual-Task Treadmill exercise + Cognitive Training|The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
58126589|NCT03942965|DEVICE|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
58126590|NCT04826796|BEHAVIORAL|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
58314760|NCT06055387|BEHAVIORAL|Frailty intervention measures|"Providing specialized guidance:~* Physical Function and Fall History:~  * Prioritizing home safety for those with physical impairments.~ * Arranging rehab consultations when necessary.~* Nutrition:~  * Assessing diets and offering education.~ * Pre-treatment nutritionist assessments.~ * Monitoring weight, intervening if \>5-10% loss, or \>10% loss.~* Social Support:~  * Evaluating the needs of those without family support.~ * Referring to social services and introducing care resources.~* Cognition:~  * Detecting cognitive issues, addressing reversible causes.~ * Assessing decision-making and medication self-administration.~ * Refer to specialists when needed.~* Polypharmacy and Comorbidity:~  * Collecting medication data, ensuring adherence.~ * Noting chronic illnesses.~ * Collaborating with specialists or pharmacists for complex cases.~* Psychological:~  * Providing weekly support for psychological concerns.~ * Refer to specialists for assessments and treatment options."
58314761|NCT03091439|DRUG|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
58452047|NCT05301517|DRUG|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
57751015|NCT00915031|DEVICE|UroCool|Hypothermia Endorectal Device
57751016|NCT00512148|DEVICE|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
57751017|NCT04154202|OTHER|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
58126591|NCT00322478|BEHAVIORAL|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
58452048|NCT05301517|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
58452049|NCT03331900|DRUG|COR388|Administered as oral capsule
58452050|NCT03331900|DRUG|Placebo|Administered as oral capsule
58452051|NCT01929226|BIOLOGICAL|ETI-204|Monoclonal Antibody
58452052|NCT01929226|OTHER|Placebo|Placebo for ETI-204
58452053|NCT01798966|DEVICE|SENSIMED Triggerfish|
58452054|NCT05662098|DRUG|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
58452055|NCT01315171|DIETARY_SUPPLEMENT|Medium chain triglycerides|4 tablespoons/day for 2 weeks
57751018|NCT05771909|OTHER|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
58126592|NCT00322478|BEHAVIORAL|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
58452056|NCT04266808|DEVICE|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
58452057|NCT04266808|BEHAVIORAL|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
58452058|NCT00112632|DRUG|imatinib mesylate|
58452059|NCT00112632|PROCEDURE|conventional surgery|
58452060|NCT00112632|PROCEDURE|neoadjuvant therapy|
58452061|NCT05113511|DRUG|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
58452062|NCT05113511|DRUG|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
58452063|NCT04676620|PROCEDURE|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
57751019|NCT05771909|OTHER|Control|"The Control Group does not receive the NeurodigitX application."
57751020|NCT05599009|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
57751021|NCT05599009|PROCEDURE|sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
57751022|NCT01216930|OTHER|Observation|Observation
57751023|NCT03280134|PROCEDURE|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
57751024|NCT01220700|OTHER|Triclosane|Triclosane coated suture material
57751025|NCT01220700|OTHER|Control|Ordinary suture material
57751026|NCT01981733|DEVICE|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
58126593|NCT00322478|BEHAVIORAL|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
58126594|NCT04026126|BEHAVIORAL|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
58452064|NCT04175730|DEVICE|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
58452065|NCT04175730|DEVICE|Ultrasound|A single subsequent ultrasound guided prostate biopsy
58452066|NCT05374239|OTHER|Multi-component implementation intervention|The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
58452067|NCT02884024|OTHER|no intervention|there is no intervention in this study
58452068|NCT03560336|DRUG|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
58452069|NCT03168620|PROCEDURE|Restoration|
58452070|NCT01745367|DRUG|Tivozanib Hydrochloride|
57751027|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 150:500 EE EU|
57751028|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 500:200 EE EU|
57751029|NCT02763514|DIETARY_SUPPLEMENT|3 g Placebo|
57751030|NCT00004070|BIOLOGICAL|IL-12|
57751031|NCT03144414|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy
58126595|NCT03041766|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
58126596|NCT03041766|DRUG|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
58452071|NCT01745367|DRUG|paclitaxel|
58452072|NCT01745367|DRUG|Placebo|
58452073|NCT01111695|DEVICE|ApisSept|honey and ionic silver based dressing
58452074|NCT00239733|DRUG|Anti-D|30-minute infusion administered in an outpatient setting
58452075|NCT03847844|BIOLOGICAL|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
58452076|NCT03847844|OTHER|Placebo|Normal saline
58452077|NCT00893958|DRUG|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
58452078|NCT00726648|DRUG|CDP323|50mg capsules, 100mg bid for 4 weeks
58452079|NCT00726648|DRUG|CDP323|250mg capsules, 500mg bid for 4 weeks
57751032|NCT06469710|DEVICE|leukapheresis|Leukapheresis employs the density differential between leukocytes and other blood components to selectively separate leukocytes and return all other components of the blood to the patient. It can process multiple blood volumes in the body circulation, thereby enabling the concentration of nucleated cells to be significantly increased. The procedure is performed while maintaining no significant change in the patient's circulating blood volume, and it is a routine clinical procedure that is well tolerated and safe. CTC can be greatly enriched in a concentrated sample of leukocytes because it has a similar density to that of leukocytes and other nucleated cells. The density of CTCs is similar to that of nucleated cells, such as leukocytes, which enables their enrichment in single leukocyte concentrate samples.
58126597|NCT01894711|DRUG|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
58126598|NCT06121466|DRUG|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
58126599|NCT02304432|DRUG|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
58126600|NCT02304432|DRUG|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
58314762|NCT03091439|DRUG|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
58452080|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg bid for 4 weeks
58452081|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg daily for 4 weeks
58452082|NCT00726648|DRUG|Placebo|placebo capsules for 4 weeks
58452083|NCT06065618|OTHER|Without intervention|Without intervention
58452084|NCT02714569|DRUG|LY3202328|Administered orally
57751033|NCT02993445|OTHER|Alternate Nostril Breathing|
57751034|NCT02993445|DEVICE|Foot Reflexology|
57751035|NCT05706766|BEHAVIORAL|PARE|Aerobic and resistance exercise program via Zoom platform.
57751036|NCT05706766|BEHAVIORAL|Waitlist Control Group|Normal Activities.
57751037|NCT05482048|OTHER|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
57751038|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
57751039|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
57751040|NCT01326858|DRUG|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
57960358|NCT02788864|DRUG|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
57960359|NCT02788864|DRUG|Placebo|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
57960360|NCT00521846|DEVICE|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
57960361|NCT06241612|RADIATION|Individualized Elective Neck Irradiation|Individualized Elective Neck Irradiation
57960362|NCT03718143|DRUG|Combination AZD1775 with AraC|AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
57960363|NCT03718143|DRUG|AZD1775 only|AZD1775 days 1-5 \& 8-12
57960364|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
57960365|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
57960366|NCT01281462|DRUG|Doripenem|500 mg doripenem IV q8h;
58126601|NCT02304432|DRUG|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
58126602|NCT01456611|DRUG|Diclofenac|Diclofenac Sodium Gel 1%
58126603|NCT01456611|DRUG|Placebo|Placebo Topical Gel
58126604|NCT01714648|DRUG|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
58314763|NCT03290651|DIETARY_SUPPLEMENT|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
58314764|NCT03290651|DIETARY_SUPPLEMENT|Placebo|Participants will take the probiotic or placebo daily for 90 days.
58314765|NCT01577914|DRUG|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
58314766|NCT01577914|DRUG|Carvedilol|12.5mg tablet once a day
58314767|NCT02059239|DRUG|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
58314768|NCT02059239|DRUG|Carmustine|300 mg/m2 on Day -6
58452085|NCT02714569|DRUG|Placebo|Administered orally
58452086|NCT02714569|DRUG|Atorvastatin|Administered orally
58452087|NCT02714569|DRUG|Simvastatin|Administered orally
58126605|NCT05151406|OTHER|educational program|The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
58126606|NCT05010603|GENETIC|Blood Draw|Collection of blood samples for genetic testing
57751041|NCT04437238|OTHER|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
57751042|NCT04437238|OTHER|Control - Usual care|Participants allocated to the control condition will receive care as usual.
57751043|NCT06108375|OTHER|music therapy|music played live by a music therapist
57751044|NCT06108375|OTHER|recording|a recording of the same music played by the music therapist
57960367|NCT01281462|DRUG|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
57960368|NCT05134272|DEVICE|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
57960369|NCT05134272|BEHAVIORAL|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
57960370|NCT05134272|BEHAVIORAL|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
57960371|NCT00502216|DRUG|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
57960372|NCT00502216|DRUG|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
58126607|NCT05010603|OTHER|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
58126608|NCT05265325|DRUG|AND017 capsules TIW|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
58126609|NCT05265325|DRUG|AND017 capsules QW|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
57751045|NCT05523414|BEHAVIORAL|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
57751046|NCT06579495|OTHER|Peer involvement in Two player mode(peer involvement) in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
57960373|NCT01583621|DIETARY_SUPPLEMENT|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
57960374|NCT02200315|OTHER|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
57960375|NCT00038350|BEHAVIORAL|Lingual Strengthening|8 week lingual strengthening exercise protocol
57960376|NCT03979092|BEHAVIORAL|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
57960377|NCT03979092|BEHAVIORAL|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
57960378|NCT00184145|OTHER|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
58126610|NCT05265325|DRUG|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
58126611|NCT02927847|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
58126612|NCT02927847|DRUG|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
58126613|NCT02927847|BEHAVIORAL|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
58126614|NCT02927847|BEHAVIORAL|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
58126615|NCT00138905|DEVICE|UMTS mobile basestation radiation|
58126616|NCT01578707|DRUG|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
58126617|NCT01578707|DRUG|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
58126618|NCT03682042|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
58126619|NCT00958256|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
58126620|NCT00958256|DRUG|Rituximab|375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
58126621|NCT00958256|DRUG|Cyclophosphamide|300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
58126622|NCT00958256|DRUG|Mesna|600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
57751047|NCT06579495|OTHER|Single player mode in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
58126623|NCT00958256|DRUG|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
58126624|NCT03309449|DEVICE|Syringe and needle|Intramuscular administration of simulated naloxone
57751048|NCT06579495|OTHER|Children did not engage in any Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
58126625|NCT03309449|DEVICE|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
58126626|NCT03309449|DEVICE|Nasal spray|Nasal spray administration of simulated naloxone
57751049|NCT04398212|DIAGNOSTIC_TEST|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
57751050|NCT01774747|DRUG|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
57751051|NCT01774747|DRUG|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
57751052|NCT02745665|OTHER|flow mediated dilation (endothelial function)|
57751053|NCT02745665|OTHER|ABPI|
57751054|NCT02745665|OTHER|Pulse wave velocity and augmentation index|
57751055|NCT02745665|OTHER|blood pressure|
57751056|NCT02745665|OTHER|ramp test|
57751057|NCT04620187|DRUG|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
57751058|NCT04620187|RADIATION|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
57751059|NCT04620187|DRUG|Standard of Care Chemotherapy|Intravenous injection
57751060|NCT05651776|OTHER|Physical Therapy, Exercise|Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
57751061|NCT04775914|PROCEDURE|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
58126627|NCT01867242|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
58126628|NCT01867242|OTHER|Snus|Winterchill or Robust flavors
58126629|NCT01483508|OTHER|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]
58126630|NCT01483508|OTHER|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]
58126631|NCT01483508|OTHER|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
58314769|NCT02059239|DRUG|Etoposide|100 mg/m2 on days -5 to -2
58314770|NCT02059239|DRUG|Melphalan|140mg/m2 on Day -1
58314771|NCT02059239|DRUG|Cytarabine|200 mg/m2 on days -5 to -2
58126632|NCT01601509|DRUG|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
58126633|NCT01601509|DRUG|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
58126634|NCT04433390|DRUG|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
58126635|NCT04433390|DRUG|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
58126636|NCT02270788|DRUG|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
58126637|NCT02270788|DRUG|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
58126638|NCT02270788|DRUG|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
58314772|NCT02059239|DRUG|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
58314773|NCT02059239|BIOLOGICAL|Autologous Stem Cell Transplantation|
58314774|NCT02059239|BIOLOGICAL|Allogeneic Stem Cell Transplantation|
58314775|NCT02059239|DRUG|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
58314776|NCT02169232|DEVICE|Videolaryngoscope|
58314777|NCT02169232|DEVICE|Fiberoptic|
57751062|NCT04775914|PROCEDURE|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
57751063|NCT04245280|DRUG|Ropivacaine 0.5% Injectable Solution|ropivacaine 0.5% with epinephrine 2.5 mcg/ml
57751064|NCT04245280|DRUG|Saline Solution|normal saline solution (NaCl 0.9%)
58314778|NCT05706701|OTHER|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
58314779|NCT05706701|OTHER|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
58314780|NCT05706701|OTHER|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
58314781|NCT05706701|OTHER|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
58314782|NCT00608920|OTHER|Single Photon Emission Computed Tomography (SPECT)|
58314783|NCT03834090|DEVICE|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
58314784|NCT03834090|OTHER|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
58314785|NCT00521495|DEVICE|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
58314786|NCT00521495|DEVICE|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
58314787|NCT00521495|DEVICE|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
57751065|NCT02561494|DRUG|Nefopam|
57751066|NCT02561494|DRUG|Saline|
57751067|NCT03214367|DRUG|LY900014|Administered SC
57751068|NCT03214367|DRUG|Insulin Lispro|Administered SC
57751069|NCT03214367|DRUG|Insulin Glargine|Administered SC
57751070|NCT03214367|DRUG|Insulin Degludec|Administered SC
57751071|NCT01896882|OTHER|Sodium restriction|
57751072|NCT03325244|OTHER|EEG monitor|sleep patterns will be monitored using EEG monitor
57751073|NCT03325244|OTHER|FitBit|activity levels will be monitored
57751074|NCT05340855|BEHAVIORAL|Wiidookaage'win Facebook Group|A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
57751075|NCT02753855|DRUG|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
57751076|NCT03008967|OTHER|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
57751077|NCT05291780|RADIATION|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
57751078|NCT06579820|COMBINATION_PRODUCT|tubular bandage|The experimental group consisted of the group in which a tubular bandage was applied over the PIC, which was routinely applied.
57751079|NCT01047592|DRUG|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
57751080|NCT01047592|DRUG|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
57751081|NCT01047592|DRUG|placebo|placebo,oral, for 12 weeks
57751082|NCT00173901|DRUG|ceftazidime|
57751083|NCT06049264|OTHER|Thoracic spine manual traction with mobilization protocol.|The therapist will perform one 30-second bout of grade I or II central posterior-anterior mobilization at the T3 spinous process as described by Maitland et al. After the 30-second bout, the therapist proceeded to T4 and performed the same technique. This process was continued sequentially in a caudal direction to T8, for an overall intervention time of approximately 3 minutes. In addition to mobilization, thoracic spine traction will be also given in sitting position.
57751084|NCT06049264|OTHER|Thoracic manipulation protocol|To perform the manipulation, the stabilizing hand will be placed at the level immediately caudal to the restricted segment using a ''pistol grip''. Once the pre manipulative position will be achieved the patient will be instructed to take a deep inhalation and exhale. During the exhalation the treating clinician performed a high velocity, small amplitude thrust in a direction to facilitate relative closing or opening of the respective facet joint as indicated by the segmental examination.
58458703|NCT03321357|DIAGNOSTIC_TEST|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
57751085|NCT05258786|BEHAVIORAL|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"1. Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~2. The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~3. A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~4. Finally, the provider will turn the screen again from the patient and repeat the first stage."
57751086|NCT04636489|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
57751087|NCT04636489|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
57751088|NCT06200844|BIOLOGICAL|ROTAVAC 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.
57751089|NCT06200844|OTHER|Placebo|Placebo is administered as three doses 4 weeks apart
57751090|NCT04021303|DIETARY_SUPPLEMENT|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
57751091|NCT04021303|DIETARY_SUPPLEMENT|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
57960379|NCT00184145|OTHER|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
57751092|NCT00244790|BEHAVIORAL|Diet|crossover low vs high protein diet before and after weight loss
57751093|NCT02276885|RADIATION|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
57751094|NCT02276885|RADIATION|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
57751095|NCT05306041|DRUG|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
57751096|NCT05306041|DRUG|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
57751097|NCT05306041|DRUG|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
57751098|NCT00002587|DRUG|paclitaxel|
57960380|NCT02963532|OTHER|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
57960381|NCT05012293|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
57960382|NCT05012293|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
57960383|NCT03992937|DRUG|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
58126639|NCT03038113|DRUG|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
58126640|NCT03038113|DRUG|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
58126641|NCT03038113|DRUG|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
58126642|NCT05362435|BEHAVIORAL|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
58126643|NCT01138072|DRUG|GSK2248761|200mg once daily
58126644|NCT01138072|DRUG|Simvastatin|20 mg Simvastatin single dose
58126645|NCT01138072|DRUG|Atorvastatin|20 mg atorvastatin single dose
58126646|NCT01138072|DRUG|Rosuvastatin|10 mg rosuvastatin single dose
58126647|NCT04682041|DIETARY_SUPPLEMENT|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
58126648|NCT04682041|OTHER|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
58126649|NCT06130020|BEHAVIORAL|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
58126650|NCT06130020|BEHAVIORAL|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
58126651|NCT06130020|BEHAVIORAL|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
58452088|NCT04262726|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
58126652|NCT00718159|DRUG|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
58126653|NCT04788680|OTHER|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
58126654|NCT04788680|OTHER|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
58126655|NCT04788680|OTHER|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
58452089|NCT04262726|BEHAVIORAL|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
58452090|NCT03121508|BEHAVIORAL|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
57751099|NCT00002587|DRUG|topotecan hydrochloride|
57751100|NCT03111056|BEHAVIORAL|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
57751101|NCT02068495|DRUG|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
58126656|NCT04788680|OTHER|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
58126657|NCT01173770|DRUG|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
58126658|NCT01173770|DRUG|ADC3680B|ADC3680B or Placebo for 7 days
58126659|NCT01173770|DRUG|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
58126660|NCT00738166|OTHER|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
58126661|NCT00738166|OTHER|Diet (organic or conventional)|organic or conventional diet
58126662|NCT00617526|DRUG|RDEA806 400 mg|
58126663|NCT00617526|DRUG|Placebo|Placebo
58126664|NCT00617526|DRUG|RDEA806 1000 mg|
58126665|NCT00617526|DRUG|RDEA806 600 mg|
58126666|NCT00617526|DRUG|RDEA806 800 mg|
58126667|NCT02931474|DRUG|Tesamorelin|Growth Hormone-Releasing
58452091|NCT04758702|BIOLOGICAL|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
57751102|NCT05047055|DRUG|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
57751103|NCT05047055|DRUG|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
57751104|NCT05047055|DRUG|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
57751105|NCT05047055|DRUG|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
57751106|NCT05047055|DRUG|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
58126668|NCT02931474|OTHER|Placebo|
58126669|NCT05496140|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
58314788|NCT06045260|DRUG|177Lu-DOTATOC|Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
58314789|NCT04685954|DEVICE|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
58314790|NCT04685954|DEVICE|Filtek Ultimate Universal|Incremental restorative composite
58314791|NCT06525519|DRUG|ATLG|5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
57751107|NCT00733980|DRUG|GSK561679|GSK561679
57960384|NCT03992937|DEVICE|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
58126670|NCT02837965|DRUG|treatment with topical superpotent corticosteroid therapy|
58126671|NCT02837965|DRUG|treatment with systemic therapy (methotrexate)|
58314792|NCT06525519|DRUG|ATLG|7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
58314793|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
58458704|NCT01343394|BIOLOGICAL|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
58458705|NCT03274284|COMBINATION_PRODUCT|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
57751108|NCT00733980|OTHER|Placebo|Placebo
57751109|NCT03660579|OTHER|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
57751110|NCT03660579|OTHER|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
57960385|NCT03988335|DRUG|RIST4721|RIST4721 oral solution
57960386|NCT03988335|DRUG|Placebo|Placebo oral solution
58126672|NCT02837965|DRUG|treatment systemic therapy (prednisone)|
58126673|NCT02837965|DRUG|treatment with systemic therapy (prednisone)|
58126674|NCT02837965|DRUG|treatment with systemic therapy (doxycycline)|
58126675|NCT05720663|OTHER|Standard of care|Participants will receive the standard of care for their condition
58126676|NCT03871608|OTHER|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
58126677|NCT03871608|OTHER|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
58126678|NCT04591626|DRUG|Dulaglutide|Administered SC
58126679|NCT04591626|DRUG|Placebo|Administered SC
58126680|NCT04591626|DRUG|Insulin Glargine|Administered SC
58126681|NCT00417274|DRUG|Quinacrine|100 mg daily
58126682|NCT00922597|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
58314794|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
58314795|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
58314796|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
58314797|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
58314798|NCT03098979|DRUG|Placebo|Orally once daily for 20 weeks
58314799|NCT03773588|DEVICE|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
58126683|NCT03747822|PROCEDURE|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
58126684|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C1|Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
58314800|NCT03773588|DEVICE|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
58314801|NCT05532878|DRUG|Apixaban|Apixaban 2.5 mg daily
58314802|NCT02104687|PROCEDURE|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
58314803|NCT02104687|PROCEDURE|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
57751111|NCT03660579|OTHER|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
57751112|NCT03660579|OTHER|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
57751113|NCT01071564|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
57960387|NCT05528627|OTHER|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
57960388|NCT05248438|BEHAVIORAL|Questionnaire|Questionnaire
57751114|NCT01071564|OTHER|Laboratory Biomarker Analysis|Correlative studies
57960389|NCT05512741|OTHER|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
57960390|NCT04429620|DIAGNOSTIC_TEST|Immunfluorescence|Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
57960391|NCT02435849|BIOLOGICAL|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
57960392|NCT04193917|DIAGNOSTIC_TEST|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
57960393|NCT05689411|DEVICE|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
57960394|NCT05765539|DEVICE|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~* One examination with the US machine by the midwife focused on 4 targets ;~* One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~* One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
57960395|NCT05506449|DEVICE|Impella CP®|"Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm."
57960396|NCT05506449|OTHER|Standard of Care|This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
57960397|NCT05832294|DEVICE|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
58314804|NCT01115270|OTHER|Non-invasive measures|assessment of cerebrovascular fluid movement
57751115|NCT01071564|OTHER|Pharmacogenomic Study|Correlative studies
57751116|NCT01071564|OTHER|Pharmacological Study|Correlative studies
57751117|NCT01071564|DRUG|Vismodegib|Given PO
57751118|NCT03381755|DRUG|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
57751119|NCT03381755|DRUG|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
57751120|NCT05858138|OTHER|Jing-Si Herbal Tea|patient will receive twice in a day for 24 weeks
57751121|NCT05858138|OTHER|Placebo Jing-Si Herbal Tea|Placebo Jing-Si Herbal Tea
57751122|NCT04497792|DRUG|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
57751123|NCT04497792|DRUG|hypoglycemic therapy|hypoglycemic therapy.
57751124|NCT00180635|DRUG|Aminoguanidine|500mg
57751125|NCT00180635|DRUG|Placebos|2ml
57751126|NCT06054659|DEVICE|Real Time Continuous Glucose Monitoring (rt-CGM)|Participants randomized to rt-CGM will have CGM placed prior to hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will CGM devices but subjects may use their own glucometer for FBG testing as needed including for CGM calibration.
58126685|NCT05447338|PROCEDURE|Maitland C2|Maitland central posterior-anterior passive joint mobilization at C2: The patient will lie prone, the therapist behind the patient's head, with both thumbs will apply a central force on the spinous process of C2. The duration of the application will be up to five applications of 10 to 30 seconds in duration, depending on clinical judgment.
57751127|NCT06054659|OTHER|Fingerstick blood glucose (FBG) monitoring|Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
57751128|NCT06054659|BEHAVIORAL|Diabetes Education|Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
57751129|NCT01256567|BIOLOGICAL|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
57751130|NCT01256567|DRUG|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
57751131|NCT00835848|DRUG|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
57751132|NCT00835848|DRUG|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
57751133|NCT03651648|DEVICE|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
57751134|NCT03651648|DEVICE|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
57751135|NCT03684148|OTHER|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
57751136|NCT03631446|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
57751137|NCT02220894|BIOLOGICAL|pembrolizumab|
57751138|NCT02220894|DRUG|carboplatin|
58314805|NCT04452669|DRUG|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
57751139|NCT02220894|DRUG|paclitaxel|
57751140|NCT02220894|DRUG|pemetrexed|
57751141|NCT00800969|PROCEDURE|FDG-PET-CT|Radiologic standard procedure
57751142|NCT06134830|DRUG|RAI|Radioactive iodine
57751143|NCT02832206|PROCEDURE|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
57751144|NCT05176275|DIAGNOSTIC_TEST|68Ga-NOTA-RP25|The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
57751145|NCT04569630|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
57751146|NCT02731248|OTHER|Prospective screening study|Prospective screening study in newborns
57751147|NCT00353587|DRUG|MBX-102|MBX-102 200 mg once daily for 16 weeks
57751148|NCT00353587|DRUG|MBX-102|MBX-102 400 mg once daily for 16 weeks
57751149|NCT00353587|DRUG|MBX-102|MBX-102 600 mg once daily for 16 weeks
57751150|NCT00353587|DRUG|Placebo|MBX-102 Placebo once daily for 16 weeks
57751151|NCT00353587|DRUG|Actos|Actos 30 mg once daily for 16 weeks
57751152|NCT00763958|DRUG|Placebo|Placebo to match buprenorphine administered for 3 months
57751153|NCT00763958|DRUG|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
57751154|NCT00002155|DRUG|Indinavir sulfate|
57751155|NCT00002155|DRUG|Lamivudine|
57751156|NCT00002155|DRUG|Zidovudine|
57751157|NCT06111209|DRUG|Testosterone cypionate|weekly by intramuscular injection
57751158|NCT06111209|DRUG|Placebo|weekly by intramuscular injection
57751159|NCT00778128|DRUG|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
57751160|NCT00778128|DRUG|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
57751161|NCT06395610|DRUG|CHF6001 DPI|Single dose of CHF6001
58126686|NCT05447338|PROCEDURE|SNAG C1|Sustained natural apophyseal slippage (SNAG) will be applied e.g. in the case of wanting to improve the left rotation. The therapist performs a sustained anterior glide to the C1 transverse process on the left. The participant will be seated, simultaneously rotating their head to the left while holding the SNAG. The glide of C1 will be maintained by the therapist until the participant's head returns to the neutral starting position. The same will be done, but in the opposite direction to improve the right rotation.
58314806|NCT05529433|PROCEDURE|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
58314807|NCT05529433|PROCEDURE|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
58314808|NCT05529433|PROCEDURE|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
58452092|NCT04758702|BIOLOGICAL|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
58452093|NCT04758702|DEVICE|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
58452094|NCT06396234|DEVICE|Safe VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
58452095|NCT06396234|PROCEDURE|Endotracheal intubation using video laryngoscope|Endotracheal intubation (size 7.0 mm) using video laryngoscope
58452096|NCT06396234|DEVICE|SaCo VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
58452097|NCT00587158|DRUG|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
58452098|NCT00587158|OTHER|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
57751162|NCT06395610|DRUG|Erythromycin|Repeated doses of oral Erythromycin
57751163|NCT01451879|DRUG|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
57751164|NCT01451879|DRUG|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
57751165|NCT01405625|OTHER|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
57751166|NCT01405625|OTHER|AAAAI standard of care written action plan|
57751167|NCT01429636|BEHAVIORAL|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
57751168|NCT01429636|BEHAVIORAL|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
57751169|NCT01528384|DRUG|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
58314809|NCT06080126|OTHER|Control: per usual practice|160 patients were included as per usual practice.
58314810|NCT06080126|OTHER|Intervention MAF|160 patients were included with MAF intervention.
58314811|NCT05244096|OTHER|No intervention|Observational study
58314812|NCT01451073|BIOLOGICAL|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
58314813|NCT05762575|OTHER|knotting methods|The volunteers in experimental group study new knotting technology.
58314814|NCT00001011|DRUG|Zidovudine|
58314815|NCT05320042|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
57751170|NCT04031144|PROCEDURE|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
57751171|NCT03006770|BIOLOGICAL|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
57751172|NCT03006770|BIOLOGICAL|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
58314816|NCT05320042|DEVICE|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
58452099|NCT01522716|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
58452100|NCT05743803|OTHER|Sensititization campaign on preoperative fasting rules|"* Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~* Reminder display in surgical wards and consults.~* Individualized fasting cards for patients.~* Short message service reminder on pre-operative fasting rules for patients.~* Medical fasting prescription with clear fasting times."
58452101|NCT02610777|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
57751173|NCT03987841|BEHAVIORAL|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
57751174|NCT03381768|BIOLOGICAL|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
57751175|NCT03381768|BIOLOGICAL|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
57751176|NCT00145015|BEHAVIORAL|Increased dietary intake of salmon or cod|
57751177|NCT00653458|DRUG|Ondansetron|ODT, 8 mg, single-dose, fed conditions
57751178|NCT00653458|DRUG|Zofran|ODT, 8 mg, single-dose, under fed conditions
57751179|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
57751180|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
57751181|NCT00002974|DRUG|carboplatin|
57751182|NCT00002974|DRUG|etoposide|
57751183|NCT00002974|DRUG|ifosfamide|
57751184|NCT00002974|PROCEDURE|hyperthermia treatment|
57751185|NCT04079348|DEVICE|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
57751186|NCT04079348|OTHER|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
57751187|NCT00766233|OTHER|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
57751188|NCT02116348|DRUG|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
57751189|NCT02388802|PROCEDURE|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
57751190|NCT02388802|PROCEDURE|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
57751191|NCT02388802|PROCEDURE|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
58314817|NCT02969278|PROCEDURE|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
58314818|NCT02969278|PROCEDURE|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
58452102|NCT02610777|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
58452103|NCT00106314|DRUG|Dehydroepiandrosterone [DHEA]|
58452104|NCT05617508|OTHER|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
58452105|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
57751192|NCT02388802|DRUG|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
57751193|NCT02388802|PROCEDURE|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
57751194|NCT02388802|PROCEDURE|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
57751195|NCT03278938|DRUG|bupropion|FDA approved drug for treating depression
57751196|NCT03278938|DRUG|citalopram|FDA approved treatment for depression
57751197|NCT05488626|DEVICE|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
57751198|NCT05488626|DEVICE|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
57751199|NCT05488626|DRUG|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
57751200|NCT05488626|DRUG|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
57751201|NCT02680548|DRUG|0.9% saline|
57751202|NCT02680548|DRUG|0.25% bupivacaine hydrochloride injectable suspension USP|
57751203|NCT02680548|DRUG|4mg/cc methylprednisolone acetate injectable suspension USP|
57751204|NCT03014674|BIOLOGICAL|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
58314819|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
58314820|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
58314821|NCT03386227|OTHER|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
57751205|NCT03014674|BIOLOGICAL|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
58126687|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C2|The therapist rotates the head to the right side until the final sensation of the movement is noted, either due to pain or muscular tension. From this position, the therapist asks the patient to rotate the head to the left side while offering resistance with both hands in the opposite direction, in such a way as to generate an isometric contraction of the rotator muscles of the head to the left. The therapist then asks the patient to hold the position for 6 seconds. Subsequently, the therapist with the finger in the transverse process of C1, pushes it in the postero-anterior direction and simultaneously (with the contratome hand) rotates the patient's head to the right. The technique is repeated until the ROM improves, always taking into account the patient's tolerance.
58314822|NCT06403800|OTHER|No intervention|No intervention
57751206|NCT03014674|DEVICE|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
57751207|NCT03014674|DEVICE|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
58314823|NCT01242319|BEHAVIORAL|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
58314824|NCT01385644|OTHER|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
58314825|NCT06231524|OTHER|Analyse pathologic slides|HE-stained whole slide images were used for the validation of the PSN-AI model.
58452106|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
58314826|NCT04092075|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
58452107|NCT00329888|PROCEDURE|Endoscopic papillary balloon dilatation|
58452108|NCT00329888|PROCEDURE|Endoscopic sphincterotomy|
57751208|NCT03574064|OTHER|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
57751209|NCT03574064|OTHER|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
57751210|NCT03574064|OTHER|GLP-2+GIP|GLP-2+GIP injection.
57751211|NCT03574064|OTHER|Placebo|Placebo injection.
57751212|NCT00268827|DRUG|Kaletra soft-gel capsules switched to Kaletra tablets|
57751213|NCT00268827|DEVICE|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
57751214|NCT03670667|OTHER|Non-Interventional|Non-Interventional
57960398|NCT05832294|DEVICE|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
57960399|NCT05315466|PROCEDURE|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
57960400|NCT05315466|PROCEDURE|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
57960401|NCT01381783|PROCEDURE|Phacoemulsification|Phacoemulsification under topical anesthesia
58314827|NCT04092075|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
58452109|NCT00510159|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
58452110|NCT00510159|DRUG|Praziquantel|
58452111|NCT04701333|DRUG|Cabergoline 1 MG|Dopamine agonist
58452112|NCT04701333|DRUG|Placebo|Placebo
58452113|NCT00166829|DRUG|sirolimus, tacrolimus, mycophenolate mofetil|
57751215|NCT03670667|OTHER|Non-Interventional|Non-Interventional
57751216|NCT03670667|OTHER|Non-Interventional|Non-Interventional
57751217|NCT00755040|DRUG|cyclosporine ophthalmic emulsion|Given as eye drops
57751218|NCT00755040|OTHER|placebo|Given as eye drops
57960402|NCT03551743|COMBINATION_PRODUCT|PRT064445/Edoxaban|
58314828|NCT00006039|BIOLOGICAL|pegylated interferon alfa|
58314829|NCT00091819|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
58452114|NCT00555880|DRUG|Midodrine hydrochloride|one dose, 10-30mg, given orally
58452115|NCT00555880|DRUG|Placebo|Placebo
58452116|NCT02535143|OTHER|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
58452117|NCT02535143|DRUG|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
58452118|NCT02535143|OTHER|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
57751219|NCT04137692|OTHER|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
57751220|NCT05874765|DIAGNOSTIC_TEST|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5)|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5) , will be used to diagnose and classify the Tics among all included patients
57751221|NCT06165783|OTHER|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
57751222|NCT03840603|DIAGNOSTIC_TEST|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
58314830|NCT00091819|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
58452119|NCT02535143|DIETARY_SUPPLEMENT|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
57751223|NCT02963974|DEVICE|Cochlear implant|Implantation
57751224|NCT04917133|BEHAVIORAL|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
58452120|NCT00436995|DRUG|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
58452121|NCT00487357|BEHAVIORAL|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
58452122|NCT04627155|DRUG|LY03003|Rotigotine,extended-release microspheres
58452123|NCT00985465|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
57751225|NCT04917133|OTHER|Control|classic 4-week rehabilitation program (standard care)
57751226|NCT00778479|DEVICE|Sepraspray|Max. 10g of Sepraspray
58452124|NCT00872599|DRUG|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
57751227|NCT04232683|DRUG|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
57751228|NCT04232683|DRUG|Placebo oral tablet|Placebo pill given preoperatively
57751229|NCT03834233|DRUG|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
57751230|NCT00260143|DRUG|Testosterone enanthate|
57960403|NCT03551743|COMBINATION_PRODUCT|Placebo/Edoxaban|
57960404|NCT03551743|DRUG|Placebo|
58314831|NCT01089179|DRUG|Metformin|
58452125|NCT00872599|DRUG|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
58452126|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 6 hours|catheter placement for 6 hours beginning in the morning at around 8 a.m.
58452127|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 12 hours|catheter placement for 12 hours in the evening at around 8 p.m.
57751231|NCT00260143|DRUG|Placebo|
57751232|NCT06122740|OTHER|Turkish Validity and Reliability of The MAM-36 Scale|The aim of this study is to adapt the Manual Ability Measure-36 (MAM-36) scale to Turkish society and to make its validity and reliability in Turkish.
57751233|NCT05043051|DEVICE|Vagal stimulation|Vagal stimulation
57751234|NCT05043051|DEVICE|Sham stimulation|Sham vagal stimulation
57751235|NCT00083057|DRUG|gefitinib|
57751236|NCT00083057|DRUG|paclitaxel|
57751237|NCT00083057|RADIATION|radiation therapy|
57751238|NCT03393195|BEHAVIORAL|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
57751239|NCT03393195|BEHAVIORAL|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
57751240|NCT04878835|BIOLOGICAL|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
57960405|NCT03643874|DRUG|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
57960406|NCT03643874|DRUG|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
57960407|NCT06233370|BEHAVIORAL|Moderate intensity walking exercise|For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
57751241|NCT00227617|BIOLOGICAL|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
57960408|NCT00130832|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
58314832|NCT01775098|DRUG|allopurinol|No arms will not be change as the study as been closed.
58314833|NCT05490082|DRUG|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
58452128|NCT01303939|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
58452129|NCT02059226|BEHAVIORAL|cognitive behavioural therapy|Internet-based CBT
58452130|NCT02059226|OTHER|Internet-based resource page|Static webpage
57751242|NCT00227617|DRUG|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
58452131|NCT02507388|DRUG|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
58452132|NCT02507388|DRUG|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
58452133|NCT05912764|OTHER|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
57751243|NCT00227617|DRUG|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
57751244|NCT00227617|DRUG|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
57751245|NCT00680927|OTHER|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
57751246|NCT01091948|DEVICE|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
57751247|NCT01091948|DEVICE|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
57751248|NCT02497287|DRUG|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.
57751249|NCT02497287|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
57751250|NCT02497287|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
57751251|NCT02497287|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
57751252|NCT02497287|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
57751253|NCT03074227|OTHER|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
57751254|NCT03074227|OTHER|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
57751255|NCT00002611|BIOLOGICAL|dactinomycin|
57751256|NCT00002611|BIOLOGICAL|filgrastim|
57751257|NCT00002611|DRUG|cyclophosphamide|
57751258|NCT00002611|DRUG|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
57751259|NCT00002611|DRUG|etoposide|
57751260|NCT00002611|DRUG|vincristine sulfate|
57751261|NCT00002611|PROCEDURE|conventional surgery|
57751262|NCT00002611|RADIATION|radiation therapy|
57751263|NCT04026165|DRUG|SEL|Tablet administered orally once daily
57751264|NCT04026165|DRUG|Placebo|Tablet administered orally once daily
57751265|NCT05040555|COMBINATION_PRODUCT|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
57751266|NCT05011474|BIOLOGICAL|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
57751267|NCT00522626|DEVICE|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
57751268|NCT05076630|OTHER|Air pollutants|Particulate matter and gaseous pollutants
57751269|NCT05979831|DRUG|DS-2325a|Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses
57751270|NCT05979831|OTHER|Placebo|Main Phase: IV infusion followed by SC doses
57960409|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
57960410|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
58314834|NCT01492959|DRUG|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
57751271|NCT03087565|PROCEDURE|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
57751272|NCT03087565|PROCEDURE|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing."
57751273|NCT01440400|PROCEDURE|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
57751274|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
57751275|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
57751276|NCT02128464|PROCEDURE|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
57751277|NCT02128464|PROCEDURE|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
57751278|NCT03625401|DRUG|AD-35 60mg group|AD-35 60mg QD
57751279|NCT03625401|DRUG|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
57751280|NCT01814748|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
57751281|NCT01814748|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
57751282|NCT01814748|DRUG|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
57751283|NCT06223412|BEHAVIORAL|video-based climate change program|The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.
57751284|NCT05590208|PROCEDURE|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
57751285|NCT04274452|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
57751286|NCT04274452|OTHER|Placebo|Intravenous infusion of placebo
57751287|NCT00789815|DEVICE|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3\~12 mg/kg/hour) to maintain BIS around 65\~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
57751288|NCT00789815|DRUG|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S\* 2\~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S\* 2\~3 or if intolerance of procedure. Alfentanil as study arm.~\*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
57751289|NCT04450537|BEHAVIORAL|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
57751290|NCT02563496|DRUG|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
57751291|NCT02563496|DRUG|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
57751292|NCT03433989|DIAGNOSTIC_TEST|telephone interview|questionnaire PDEQ et IES-R
57751293|NCT06579053|DRUG|Spironolactone Tablets (Test)|Take one test tablet each period
57751294|NCT06579053|DRUG|Spironolactone Tablets (Reference)|Take one reference tablet each period
57751295|NCT00212992|PROCEDURE|fixed versus escalating biphasic defibrillation|
57960411|NCT02851173|DEVICE|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
57960412|NCT02851173|DEVICE|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
58314835|NCT02290184|BEHAVIORAL|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
58314836|NCT02290184|BEHAVIORAL|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
58314837|NCT01686893|DEVICE|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
57751296|NCT01825629|OTHER|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
58452134|NCT02673918|OTHER|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
58452135|NCT00002781|DRUG|boronophenylalanine-fructose complex|
58452136|NCT00818792|DEVICE|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
58452137|NCT02726620|PROCEDURE|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
58452138|NCT02726620|PROCEDURE|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
58452139|NCT02726620|PROCEDURE|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
58452140|NCT02726620|PROCEDURE|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
58452141|NCT02726620|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
58452142|NCT02726620|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
58452143|NCT02726620|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
58452144|NCT02726620|DEVICE|Pager system|The mobile pager system through which alerts can be sent
58452145|NCT02726620|PROCEDURE|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
58452146|NCT02726620|PROCEDURE|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
58452147|NCT02726620|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
58452148|NCT02726620|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
58452149|NCT02726620|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
58452150|NCT02726620|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
58452151|NCT02726620|DRUG|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
58452152|NCT02726620|DRUG|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
58452153|NCT02726620|DRUG|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
57751297|NCT01825629|OTHER|Placebo|
57751298|NCT02336243|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
57751299|NCT02336243|DIETARY_SUPPLEMENT|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
58314838|NCT01686893|DEVICE|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
58452154|NCT02726620|DRUG|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
58452155|NCT02726620|DRUG|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
58452156|NCT02726620|DRUG|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
58452157|NCT02726620|DRUG|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
58452158|NCT02726620|DRUG|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
58452159|NCT02726620|DRUG|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
58452160|NCT02726620|DRUG|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
58452161|NCT02726620|DRUG|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
58452162|NCT02726620|DRUG|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
58452163|NCT02726620|DRUG|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
58452164|NCT02726620|DRUG|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
58452165|NCT02726620|DRUG|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
58452166|NCT02726620|DRUG|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
57751300|NCT06328764|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
57751301|NCT00066482|BIOLOGICAL|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
57751302|NCT00066482|BIOLOGICAL|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC \> 5,000/uL
57751303|NCT00066482|DRUG|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
57751304|NCT00066482|DRUG|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
57751305|NCT00066482|DRUG|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
57751306|NCT00066482|PROCEDURE|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
57751307|NCT00066482|BIOLOGICAL|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
57751308|NCT04152902|OTHER|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
57751309|NCT04152902|OTHER|Quality of life|SF-36 Questionnaire
57751310|NCT02773550|DRUG|Bortezomib|Low dose of bortezomib
57751311|NCT02773550|DRUG|Melphalan|
57751312|NCT02773550|DRUG|Prednisone|
58314839|NCT00104689|DRUG|capecitabine|
58452167|NCT02726620|DRUG|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
58452168|NCT02726620|DRUG|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
58452169|NCT02726620|DRUG|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
58452170|NCT02726620|DRUG|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
58452171|NCT02726620|DRUG|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
57751313|NCT01474213|DRUG|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
57751314|NCT01474213|DRUG|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
57751315|NCT00009802|DIETARY_SUPPLEMENT|calcitriol|
57751316|NCT00009802|DRUG|paclitaxel|
57751317|NCT00335452|DRUG|Clopidogrel|oral administration
57751318|NCT00335452|DRUG|acetylsalicyclic acid (ASA)|oral administration
57751319|NCT05072457|DEVICE|Roger On microphone|Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids
57751320|NCT05072457|DEVICE|Roger Select microphone|Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
57751321|NCT04050774|DEVICE|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
57751322|NCT02252419|DRUG|Dexamethasone|Dexamethasone will be administered.
57751323|NCT02252419|DRUG|Paracetamol|Paracetamol will be administered.
57751324|NCT03983187|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
57751325|NCT01053195|BEHAVIORAL|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
57751326|NCT05676632|OTHER|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
58314840|NCT00104689|DRUG|oxaliplatin|
58314841|NCT06098183|OTHER|Whey Protein Isolate|Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving
58314842|NCT06098183|OTHER|Non-caloric Placebo water|Non-caloric placebo
58314843|NCT03437967|DEVICE|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
58452172|NCT02726620|DRUG|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
58452173|NCT02726620|DRUG|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
58452174|NCT02726620|DRUG|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
58452175|NCT02726620|DRUG|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
58452176|NCT02726620|DRUG|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
58452177|NCT02726620|DRUG|Procaine|Local anesthetic used for central neuraxial anesthesia.
58452178|NCT02726620|DRUG|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
58452179|NCT02726620|DRUG|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
58452180|NCT02726620|DRUG|Articaine|Local anesthetic used for central neuraxial anesthesia.
58452181|NCT01226225|BEHAVIORAL|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
57751327|NCT02221167|OTHER|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
58452182|NCT01226225|BEHAVIORAL|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
57751328|NCT04656379|PROCEDURE|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
57751329|NCT02623322|DRUG|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
57751330|NCT02623322|DRUG|Placebo|Placebo will be administered as a single dose by IV administration.
57751331|NCT01328301|OTHER|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
57751332|NCT01328301|OTHER|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
57751333|NCT04894201|RADIATION|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
57751334|NCT01887080|OTHER|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
57751335|NCT01887080|DEVICE|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
57751336|NCT01887080|OTHER|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
57751337|NCT00590902|DRUG|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
57751338|NCT01012232|DRUG|20 mL ropivacaine 5 mg/mL|
57751339|NCT01012232|DRUG|10 mL ropivacaine 10 mg/mL|
57751340|NCT03209323|DEVICE|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
57751341|NCT03209323|DEVICE|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
57751342|NCT03209323|DEVICE|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
57751343|NCT03209323|DEVICE|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
57751344|NCT05171751|DRUG|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
57751345|NCT03163355|OTHER|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
57751346|NCT05016154|BEHAVIORAL|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
57751347|NCT05016154|BEHAVIORAL|SilverCloud guided|Group of participants make use of the SilverCloud guided app
57751348|NCT05016154|BEHAVIORAL|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
57751349|NCT05016154|BEHAVIORAL|Mood Flow|Group of participants make use of the Mood Flow app
57751350|NCT06580379|PROCEDURE|Spine surgery|Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
57751351|NCT00417352|DEVICE|Brace|
57751352|NCT00417352|DEVICE|Added mass|
57751353|NCT05030779|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
57751354|NCT05099926|BEHAVIORAL|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
57751355|NCT05627102|OTHER|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
57751356|NCT05627102|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
57751357|NCT01578811|DRUG|Placebo|Dosage
57751358|NCT01578811|DRUG|SK-MS10|Dosage
57751359|NCT01578811|DRUG|SK-MS10|Dosage
57751360|NCT01783418|BEHAVIORAL|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
57751361|NCT04111003|PROCEDURE|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
58126688|NCT05447338|PROCEDURE|Myofascial inductions; Suboccipital induction|The therapist places his hands under the patient's head in such a way that he can palpate the spinous processes of the cervical vertebrae with his fingers. Next, slowly bring your fingers up until they contact the occipital condyles. At this time he should gently move his fingers downward, thus finding the space between the condyles and the spinous process of the axis. Next, flexing the metacarpophalangeal joints to 90°, slowly elevate the skull. The therapist's hands should remain together and the base of the skull should rest on their palms. The therapist should apply pressure with the index, middle and ring fingers of each hand. This pressure should be maintained for a few minutes until a release of the fascia is noted. In the last phase of the technique, the therapist, without releasing the pressure, opens his hands and slowly brings his head back.
58126689|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 1|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought
58126690|NCT05447338|PROCEDURE|Myofascial inductions; Horizontal induction of the TMJ.|The therapist places the middle fingers of both hands on the lingual aspect of the lower molar teeth and then gently presses towards the table. This pressure must be maintained for a minimum of 90 to 120 seconds. Afterwards, the therapist, very attentive to the changes in the direction of the fascial restriction, follows the release movement.
58126691|NCT05447338|PROCEDURE|Myofascial inductions; Posterior elongation of the cervical fascia in the supine position|Position of the patient, lying on the stretcher in the supine position. Therapist position: Sitting at the head of the table. Technique: With one of his hands, the therapist supports the patient's head on the occipital area and slowly brings it to flexo-elevation. With the other hand, he contacts the mass of the paravertebral muscles, placing the thumb on one side of the spine and the proximal interphalangeal joint of the index finger in flexion on the other. While one hand holds the head position, the other performs a downward vertical slide. The maneuver is repeated between 3 and 7 times in a slow and progressive manner.
58126692|NCT05447338|PROCEDURE|Myofascial induction; Angle of the scapula|Position of the patient, supine position, with the arm resting along the trunk. Position of the therapist, standing or sitting at the head of the table. The therapist places one of his hands under the shoulder blade, embracing the lower angle with the fingertips and bringing it slightly cranially. This maneuver frees access to the superior angle of the scapula, which makes it easier for the index and middle fingers of the other hand to contact the insertion of the angle. More sustained pressure is applied to this point, while the hand placed on the scapula moves in the direction of release.
58452183|NCT01116401|DRUG|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
58452184|NCT00896766|GENETIC|loss of heterozygosity analysis|
58452185|NCT00896766|GENETIC|microarray analysis|
57751362|NCT04111003|PROCEDURE|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
57751363|NCT04111003|PROCEDURE|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
57751364|NCT02080429|PROCEDURE|Passive Descent|
57751365|NCT02080429|PROCEDURE|Pushing|
57751366|NCT03019926|BIOLOGICAL|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
57751367|NCT00455975|DRUG|Bevacizumab|Bevacizumab
58452186|NCT00896766|GENETIC|polymorphism analysis|
58452187|NCT00896766|GENETIC|tumor replication error analysis|
57751368|NCT00694005|PROCEDURE|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
58452188|NCT04797039|PROCEDURE|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
58452189|NCT03823183|BEHAVIORAL|Cognitive training|Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
57751369|NCT00694005|PROCEDURE|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
57751370|NCT00292435|DRUG|Read vine leaf extract (AS 195)|
57751371|NCT05072925|OTHER|Tobacco products|Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
57751372|NCT05050149|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
57751373|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, low dose
57751374|NCT00785408|DRUG|placebo|subcutaneous, twice daily, low dose
57751375|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, middle dose
57751376|NCT00785408|DRUG|placebo|subcutaneous, twice daily, middle dose
57751377|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, high dose
57751378|NCT00785408|DRUG|placebo|subcutaneous, twice daily, high dose
57751379|NCT05711979|BEHAVIORAL|AARC|There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
58126693|NCT05447338|PROCEDURE|Myofascial induction sternocleidomastoid muscles|Objective, release the myofascial restrictions of the fascia of the SCM muscle. Position of the patient, supine position with the head near the upper edge of the stretcher. Therapist position. sitting at the head of the stretcher. Technique: The therapist, with one hand placed on the occipital region, gently rotates the patient's head. The other hand places it on the mass of the SCM muscle with the thumb at the point of insertion on the mastoid process. While one hand applies the rotational movement and a slight extension of the head, the other performs a transverse slide over the zone of restriction in the SCM muscle. A longitudinal sliding movement of the SCM muscle can be made between the thumb and forefinger of the executing hand.
58452190|NCT03823183|BEHAVIORAL|Physical training|Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
57960413|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
57960414|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
57960415|NCT03825965|DRUG|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
57751380|NCT02080975|OTHER|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
57960416|NCT03825965|DRUG|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
57960417|NCT03070158|BEHAVIORAL|Attachment Promotion|"Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up."
58314844|NCT05267717|OTHER|Non-interventional study, all patients being tested with AG Pregnolia System to assess the values of the Cervical Stiffness|Non-interventional study,
58314845|NCT02722967|DRUG|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
58314846|NCT00779337|BIOLOGICAL|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
57960418|NCT01877083|DRUG|Lenvatinib|Starting dose of 24 mg orally, once per day
57960419|NCT06182488|OTHER|ERAS protocols|ERAS protocols for emergency abdominal surgery
57960420|NCT06182488|OTHER|Conventional protocols|Conventional protocols for emergency abdominal surgery
57960421|NCT00046774|DRUG|MRA 003 US|
58314847|NCT04971655|OTHER|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
58314848|NCT05683821|BEHAVIORAL|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~* SmokefreeTXT (if ready to set a quit date in the next 14 days)~* Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~* Daily Challenges (if not ready to quit, but willing to make some changes)"
58314849|NCT05683821|DRUG|Nicotine replacement therapy sampling|"Participants may request:~* Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~* Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
58314850|NCT05683821|COMBINATION_PRODUCT|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
58314851|NCT05683821|COMBINATION_PRODUCT|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
58314852|NCT05683821|COMBINATION_PRODUCT|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
58314853|NCT05683821|BEHAVIORAL|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
58314854|NCT02753881|DRUG|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
58314855|NCT02753881|DRUG|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
58314856|NCT00489242|PROCEDURE|Procedure / Percutaneous angioplasty|
57751381|NCT04790058|OTHER|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements \[troponin and NT-proBNP\] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
57751382|NCT05200130|OTHER|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
57751383|NCT05200130|OTHER|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
57751384|NCT05200130|OTHER|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
57751385|NCT05452655|BEHAVIORAL|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
57751386|NCT05452655|BEHAVIORAL|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
57751387|NCT06286605|PROCEDURE|A-oss and autogenous bone|Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.
57751388|NCT06286605|PROCEDURE|A-oss an LCR-A|Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
57751389|NCT02604290|DEVICE|Kinesio Taping method|"The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
57751390|NCT02604290|DEVICE|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
57751391|NCT01254123|DRUG|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
57751392|NCT01254123|DRUG|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
57751393|NCT02771444|DEVICE|Tomo Assessment|A four-view tomosynthesis examination
57751394|NCT03222193|DEVICE|TRP|3 months of TRP tongue retraining
57751395|NCT03084926|DRUG|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
57751396|NCT02672254|RADIATION|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
57751397|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
57751398|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
57751399|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
57751400|NCT05907382|DRUG|Placebo in Cohorts 1 to 5|oral once
57751401|NCT05907382|DRUG|Placebo in 2 Cohorts|oral once
58452191|NCT03823183|BEHAVIORAL|Cognitive control|Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
57751402|NCT05159089|BEHAVIORAL|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
57751403|NCT05159089|BEHAVIORAL|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
57751404|NCT00173108|BEHAVIORAL|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
57751405|NCT04274894|DRUG|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
57751406|NCT01543243|DEVICE|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
57751407|NCT01543243|DEVICE|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
57751408|NCT00452387|DRUG|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
57751409|NCT00452387|DRUG|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
57751410|NCT00452387|DRUG|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
57751411|NCT00346021|BEHAVIORAL|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
57751412|NCT04838990|OTHER|EDSS|Neurological Exam - EDSS (Expanded Disability Status Scale)
57751413|NCT04838990|OTHER|Discussion of symptoms, Patient reported outcome (MSIS)|Patients will be asked about their wellbeing
58126694|NCT05447338|PROCEDURE|Myofascial induction of pectoralis major and minor|Objective, release the fascia of the pectoralis major and minor muscle. Position of the patient, supine position, with the arm abducted to about 120 degrees. Position of the therapist, standing next to the patient, at head height. Technique: with his cranial hand, the therapist holds the patient's arm, and with the caudal hand, placed in a prone position, contacts the space between pectoralis major and ribs. This contact is made with the fingertips. The pressure should be maintained for about 5 minutes. As the release occurs, both of the therapist's hands must adjust to the direction of the changes. When detecting the restriction in the pectoralis minor, the penetration should be deepened with the hand, sliding it over the ribs. Contact and restraints with the pectoralis minor and major are often particularly painful, forcing the therapist to apply controlled force.
58452192|NCT03823183|BEHAVIORAL|Physical control|Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
58452193|NCT04929535|DRUG|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
58452194|NCT01685775|PROCEDURE|Transvaginal/transumbilical|
58452195|NCT01685775|PROCEDURE|Needlescopic with 3 trocars|
58452196|NCT00005992|BIOLOGICAL|PSA prostate cancer vaccine|
58452197|NCT00005992|BIOLOGICAL|therapeutic autologous dendritic cells|
58452198|NCT02677935|OTHER|Community education programs|
58126695|NCT05447338|PROCEDURE|Myofascial induction; upper trapezius|Objective, release the myofascial restrictions of the upper trapezius. Position of the patient, supine, with the elbow flexed and the hand resting on the abdomen, and the arm in a slight abduction. Therapist position, sitting at the head of the table. Technique: The therapist places his hand on the patient's shoulder so that he can grasp the fibers of the upper trapezius between the index, middle, and ring fingers above and the thumb below. Subsequently, he exerts gentle and sustained pressure overcoming three restraining barriers.
58126696|NCT05447338|PROCEDURE|Myofascial induction, of the fascia of the subscapularis muscle|Position of the patient, supine, with the arm raised about 90-160 degrees, depending on the degree of movement restriction. Therapist position, standing at the head of the table. Phase A With his cranial hand, the therapist holds the patient's arm and performs very gentle traction. The palm of the caudal hand, thumb up, is placed on the outer edge of the scapula, as close as possible to the glenohumeral joint. A slight traction is performed with both hands in opposite directions, subsequently following the direction of release. Phase B, The thumb of the caudal hand slightly invades the space between the inner aspect of the scapula and the thorax. The rest of the application is performed as in phase A. Phase C, the therapist places his caudal hand in a prone position and slowly penetrates the aforementioned space with the tips of the fingers. sustained for a time ranging between 90 seconds and 5 minutes, following the release stages.
58126697|NCT05447338|PROCEDURE|Intraoral myofascial induction of the masseter|Position of the patient, supine position, on the stretcher without the pillow. Position of the therapist, sitting at the head of the table. Technique: The therapist, with the index of his hand, contacts the masseter just below the zygomatic arch and inside the mouth. To ensure proper contact on the masseter, the patient is asked to attempt to close the mouth. Once the muscle is correctly located, the patient should immediately relax the masseter. Next, the therapist compresses the masseter between his index finger and thumb. You have to wait long enough for the release to occur. Sometimes both hands are used by placing the forefinger of the other hand on the outer surface.
58126698|NCT05447338|PROCEDURE|Deep myofascial induction of the external pterygoid|"Objective, release the myofascial restrictions and recover the functional coordination of the external pterygoid muscles.~Position of the patient, supine position, on the stretcher without the pillow. Therapist position, sitting at the head of the table. Technique: The therapist palpates the temporomandibular joint with the index or middle finger of one hand. With the index finger of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs."
58126699|NCT05447338|PROCEDURE|Intraoral mifascial induction of the internal pterygoid|Objective, release the restrictions of the internal pterygoid fascia. Position of the patient, supine position on the stretcher. Therapist position, sitting laterally at the head of the stretcher and looking at the patient. Technique: Therapist palpates the TMJ with the index or middle finger of one hand. With the index of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs. You have to wait three consecutive releases.
58126700|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 2|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought.
58126701|NCT04700449|DRUG|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
58126702|NCT04700449|DRUG|Double-Blind Placebo|Placebo capsule oral administration
58126703|NCT04700449|DRUG|Open-label CBP-307|0.2 mg capsule oral administration
58126704|NCT04700449|DRUG|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
58126705|NCT05760703|DRUG|STSG-0002 Injection|Intravenous infusion
58126706|NCT02806921|DEVICE|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
58126707|NCT02274298|BEHAVIORAL|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
58126708|NCT06236737|OTHER|Sensorimotor Exercise|The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.
58126709|NCT06236737|OTHER|Yoga Exercise|A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
58126710|NCT01151813|DRUG|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
58126711|NCT01151813|DRUG|Placebo|Placebo
58126712|NCT05905848|DRUG|administering RASI (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
58126713|NCT05905848|DRUG|administering CCB (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
58126714|NCT01420783|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
58126715|NCT01938950|OTHER|Aerobic Exercise|
58126716|NCT01938950|OTHER|Resistance Exercise|
58126717|NCT01938950|OTHER|Aerobic and Resistance Exercise|
58126718|NCT00418470|PROCEDURE|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
58126719|NCT00418470|PROCEDURE|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
58126720|NCT04384549|BIOLOGICAL|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
58126721|NCT04384549|OTHER|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
58126722|NCT01031537|BIOLOGICAL|FSME-IMMUN 0.5ml Baxter|Vaccine
58126723|NCT01968382|DRUG|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
58126724|NCT01968382|DRUG|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
58126725|NCT04617665|OTHER|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
58126726|NCT04617665|OTHER|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
58126727|NCT06087874|DIETARY_SUPPLEMENT|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
58126728|NCT06087874|DIETARY_SUPPLEMENT|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
58126729|NCT03392571|DRUG|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
58126730|NCT01263158|OTHER|Expectancy of standard oxytocin treatment|
58126731|NCT01252069|DRUG|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
58126732|NCT01252069|DRUG|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
58126733|NCT02258256|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
58126734|NCT01450709|DIETARY_SUPPLEMENT|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
58126735|NCT02309099|DEVICE|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
58126736|NCT06244654|DEVICE|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones|After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
58126737|NCT06244654|OTHER|No VR|After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
58126738|NCT03510364|BEHAVIORAL|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
58126739|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
58126740|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
58126741|NCT00617448|PROCEDURE|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
58126742|NCT00617448|PROCEDURE|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
58126743|NCT06325579|DEVICE|Immersive Virtual Reality for Dysphagia Treatment|Patients wore a VR headset while undergoing their rehabilitation session
58126744|NCT06220292|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58126745|NCT06220292|DEVICE|Intermittent Oral-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
58126746|NCT06220292|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
58126747|NCT02470559|BIOLOGICAL|Aldesleukin|Given SC
58126748|NCT02470559|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV and IP
58126749|NCT02470559|OTHER|Laboratory Biomarker Analysis|Correlative studies
58126750|NCT02470559|BIOLOGICAL|Sargramostim|Given SC
58126751|NCT04622709|DRUG|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
58126752|NCT02632877|DRUG|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
58126753|NCT02632877|DRUG|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
58126754|NCT05310565|PROCEDURE|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
58126755|NCT02132247|DRUG|Diclofenac hydroxyethylpyrrolidine|
58452199|NCT01347528|BEHAVIORAL|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
58452200|NCT04936061|DEVICE|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
58126756|NCT03665649|PROCEDURE|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
58452201|NCT04936061|DEVICE|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
58452202|NCT04911894|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
58452203|NCT03195816|BEHAVIORAL|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
58126757|NCT03423888|DEVICE|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
58452204|NCT02299726|DRUG|Spironolactone|
58452205|NCT02299726|OTHER|Placebo|Matching placebo
58452206|NCT01088334|OTHER|screening|CT-Chest/abdomen and mammography in women
58452207|NCT00263874|DRUG|UK-500,001|
58452208|NCT04470635|DIAGNOSTIC_TEST|ELISA|Saliva sample collection
58126758|NCT01267266|DRUG|saracatinib|Given orally
58126759|NCT01267266|OTHER|hydrocortisone/placebo|Given orally
58126760|NCT06266988|DRUG|Sacubitril and Valsartan Tablets 97mg/103mg|Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
58126761|NCT06266988|DRUG|Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)|Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
58126762|NCT00486083|DRUG|Atomoxetine Hydrochloride|
58126763|NCT00486083|DRUG|Methylphenidate Hydrochloride|
58126764|NCT03923764|DIETARY_SUPPLEMENT|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
58126765|NCT03923764|OTHER|Habitual Diet|Patients continue their usual diet
58126766|NCT03066453|DRUG|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
58126767|NCT03066453|DRUG|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
58126768|NCT06114407|DRUG|Baricitinib 2mg|Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
58126769|NCT06114407|DRUG|Tofacitinib 5 mg|Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
58126770|NCT02449707|PROCEDURE|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
57751414|NCT06449131|DRUG|Platelet-Rich Plasma and Fibrin Glue|"Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution."
57751415|NCT00642187|DRUG|budesonide|
57751416|NCT00642187|DRUG|Placebo|
57751417|NCT05605054|BEHAVIORAL|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
57751418|NCT05605054|BEHAVIORAL|Self-study|Self-studying of programmatic information and list of service referrals
57751419|NCT06008574|OTHER|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
57751420|NCT06008574|OTHER|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
57751421|NCT06008574|OTHER|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
57751422|NCT05031546|DRUG|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
57751423|NCT05717556|PROCEDURE|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
57751424|NCT01265355|DIETARY_SUPPLEMENT|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
57751425|NCT01265355|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 1 gm daily
57751426|NCT04392466|OTHER|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
57751427|NCT01410058|DIETARY_SUPPLEMENT|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
57751428|NCT01410058|DRUG|Efavirenz 600mg|Efavirenz 600mg based regimen
57751429|NCT01410058|DRUG|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
57751430|NCT04394364|DEVICE|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
58126771|NCT02449707|DEVICE|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
58126772|NCT02449707|DEVICE|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
58126773|NCT02449707|DEVICE|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
58126774|NCT02449707|DEVICE|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
58452209|NCT02232217|BEHAVIORAL|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
58452210|NCT02232217|OTHER|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
57751431|NCT02579954|BEHAVIORAL|Rehabilitation|
57751432|NCT05596175|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
57751433|NCT05493774|OTHER|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
58126775|NCT02449707|PROCEDURE|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
58126776|NCT02449707|PROCEDURE|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
58126777|NCT01365650|DRUG|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
58126778|NCT01365650|DRUG|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
58126779|NCT01365650|DRUG|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
58126780|NCT01346085|DRUG|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
58126781|NCT00776503|DRUG|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
58126782|NCT02907996|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
58126783|NCT01575054|BIOLOGICAL|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
58126784|NCT01575054|DRUG|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
58126785|NCT01282359|OTHER|Clinical practice group|Clinical practice group will not receive any specific education
58126786|NCT01282359|OTHER|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
58126787|NCT01282359|OTHER|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
58126788|NCT04659538|DEVICE|CAPTIS Embolic Protection device|The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
58126789|NCT02585700|BIOLOGICAL|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
58126790|NCT02585700|OTHER|Placebo|0.5 mL of phosphate buffered saline
58126791|NCT02714309|DIETARY_SUPPLEMENT|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
58126792|NCT02714309|OTHER|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
58126793|NCT02714309|OTHER|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
58126794|NCT02714309|OTHER|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
58126795|NCT04480398|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
58126796|NCT04071600|DRUG|Neuropeptide Y|Intranasal
58126797|NCT04071600|OTHER|Placebo|intranasal
58126798|NCT05889338|DRUG|adalimumab and methotrexate|Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
58126799|NCT05848986|OTHER|Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
58126800|NCT05186571|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
58452211|NCT05625659|DIAGNOSTIC_TEST|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
57751434|NCT05493774|OTHER|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
57751435|NCT01896869|DRUG|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
57751436|NCT01896869|BIOLOGICAL|Vaccine|5x10\^8 cells administered in 6 intradermal injections
58126801|NCT05656742|DIETARY_SUPPLEMENT|Vitamin D|oral vitamin D3
58126802|NCT05991739|BEHAVIORAL|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
58126803|NCT02375009|PROCEDURE|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
58126804|NCT01098721|DRUG|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
58126805|NCT03728842|OTHER|Blood collection for laboratory studies|Peripheral whole blood will be collected
58126806|NCT03728842|OTHER|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
58126807|NCT01624220|RADIATION|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
58126808|NCT01624220|RADIATION|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
58126809|NCT01624220|PROCEDURE|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
58126810|NCT01624220|BEHAVIORAL|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
58126811|NCT04245826|OTHER|Change in LCSBs Intake|Effect of changing LCSBs intake
58126812|NCT04245826|OTHER|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
58126813|NCT06126393|DIAGNOSTIC_TEST|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
58126814|NCT06411366|GENETIC|Follistatin plasmid|Follistatin-344 plasmid
58126815|NCT01232270|DRUG|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
58126816|NCT02612636|OTHER|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
58126817|NCT02612636|OTHER|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
58452212|NCT01290614|OTHER|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
58452213|NCT01290614|OTHER|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
58452214|NCT02474563|DRUG|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
58452215|NCT02474563|DRUG|Melphalan|Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.
58452216|NCT02474563|DRUG|Prednisone|Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
58452217|NCT06263374|BEHAVIORAL|Motor imagery of the jaw|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the experimental group, which involves practicing motor imagery in addition to a self-rehabilitation program and physiotherapy. Patients will be guided to visualize three sets of jaw movements three times a day. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers as the study is multicentric.
58452218|NCT06263374|BEHAVIORAL|Control task (Sudoku or Crossword puzzle)|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the control group, which involves practicing a control task (completion of Sudoku or crossword puzzles) in addition to a self-rehabilitation program and physiotherapy. Patients will be instructed to engage in the task for approximately 10 minutes per day, equivalent to the duration of motor imagery practice in the group 1. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers, as the study is multicentric.
57751437|NCT01896869|DRUG|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
58126818|NCT03732846|DRUG|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
58126819|NCT01681030|BIOLOGICAL|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
58126820|NCT01681030|BIOLOGICAL|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
58126821|NCT01681030|OTHER|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
58126822|NCT05357157|OTHER|Electroacupuncture|Subjects will be administered electroacupuncture as described in the electroacupuncture group description
58126823|NCT05357157|DIETARY_SUPPLEMENT|Nutrition|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
58126824|NCT05357157|DIETARY_SUPPLEMENT|Dietary supplement|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
58126825|NCT05777213|BIOLOGICAL|Secretome|The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
58126826|NCT04111744|OTHER|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
58126827|NCT04111744|OTHER|Optimal medical therapy|Standard medication for stable CAD
58126828|NCT00683020|BEHAVIORAL|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
58126829|NCT02309827|DRUG|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
58126830|NCT01802879|DRUG|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
58126831|NCT00000775|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
58126832|NCT04394754|DEVICE|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
58126833|NCT04394754|OTHER|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
58126834|NCT04394754|OTHER|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
58126835|NCT05557786|DEVICE|Transcranial Alternating Current Stimulation|Cerebellar Transcranial Alternating Current Stimulation（tACS）
58126836|NCT04596956|DRUG|sodium bicarbonate Ringer injection|Used in surgery
58126837|NCT04596956|DRUG|Lactated Ringer's solution|Used in surgery
57751438|NCT02218827|DRUG|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
57751439|NCT02360319|DRUG|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
58126838|NCT01210729|DEVICE|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
57751440|NCT02360319|DRUG|aripiprazole long acting injectable formulation|
58126839|NCT03759821|BEHAVIORAL|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
58126840|NCT03759821|BEHAVIORAL|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
58126841|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
58452219|NCT01168349|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
57751441|NCT03220490|BEHAVIORAL|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
57751442|NCT03220490|BEHAVIORAL|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
58126842|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
58126843|NCT04614961|OTHER|Lifestyle therapy - individual|Individual therapy
58126844|NCT04614961|OTHER|Lifestyle therapy - group|Group therapy
58126845|NCT04614961|OTHER|Medical therapy|Medical therapy
58452220|NCT05404087|DEVICE|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
58452221|NCT02403999|OTHER|Test shampoo|Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
57751443|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
58126846|NCT04614961|PROCEDURE|Bariatric surgery|Surgical and endoscopic therapy
58126847|NCT00638365|BIOLOGICAL|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
58126848|NCT00638365|OTHER|Placebo|Placebo single-dose administered intravenously
58126849|NCT00261196|DRUG|Collagenase|Anterior shoulder capsule injection
58452222|NCT02403999|OTHER|Test bath foam|Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
57751444|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
58126850|NCT01226797|DRUG|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
58126851|NCT01226797|DRUG|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
58126852|NCT03703063|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
58126853|NCT03703063|DRUG|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
58126854|NCT03703063|DRUG|Onivyde|Administered by intravenous infusion over 90 minutes.
58126855|NCT03703063|DRUG|Leucovorin|Administered by intravenous infusion over 30 minutes.
58126856|NCT03703063|DRUG|5-fu|Administered by intravenous infusion over 46 hours.
57751445|NCT00498979|BIOLOGICAL|recombinant interferon alfa-2b|recombinant interferon alfa-2b
58126857|NCT01684969|DRUG|Haloperidol|0.5 mg iv x one dose
58126858|NCT01684969|DRUG|Placebo|0.5 mg iv , one dose
58452223|NCT02403999|OTHER|Test head to toe wash|Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
58452224|NCT04449627|OTHER|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
58452225|NCT03360435|DIETARY_SUPPLEMENT|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
58452226|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
57751446|NCT00498979|DRUG|cisplatin|recombinant interferon alfa-2b
57751447|NCT00498979|DRUG|sodium stibogluconate|sodium stibogluconate
58126859|NCT05764044|DRUG|cisplatin, gemcitabine|Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.
58126860|NCT05764044|OTHER|Follow-up|Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
58126861|NCT04167566|COMBINATION_PRODUCT|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
58126862|NCT02947009|BEHAVIORAL|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
58126863|NCT03561948|PROCEDURE|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
58126864|NCT03561948|PROCEDURE|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
58126865|NCT00464750|DEVICE|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
58126866|NCT04765709|COMBINATION_PRODUCT|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
58452227|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
58452228|NCT04184830|DEVICE|non-invasive brain stimulation|
58452229|NCT03940729|DRUG|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
57960422|NCT05650983|BEHAVIORAL|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
58126867|NCT04765709|COMBINATION_PRODUCT|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
58126868|NCT04765709|BIOLOGICAL|durvalumab|Consolidation treatment with durvalumab
58126869|NCT01684358|DEVICE|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
58126870|NCT04730505|DEVICE|MyHOPE™ for Multiple Myeloma|The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.
58452230|NCT03579940|DRUG|Lasmiditan|Administered orally.
58452231|NCT03579940|DRUG|Placebo|Administered orally.
57751448|NCT00498979|DRUG|dacarbazine|dacarbazine
57751449|NCT00498979|DRUG|vinblastine|vinblastine
57751450|NCT02479568|DIETARY_SUPPLEMENT|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
57751451|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
57751452|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
57751453|NCT02159248|DRUG|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
58126871|NCT04730505|DEVICE|MyHope HCP Portal|Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
58126872|NCT01424722|DEVICE|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
58126873|NCT01725425|OTHER|Control|The control is designed to determine average mood.
58126874|NCT01725425|OTHER|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
58126875|NCT01725425|OTHER|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
58126876|NCT01725425|OTHER|Mixed Portions|The purpose is to determine if a change in mood will occur.
58126877|NCT02583204|DEVICE|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
57751454|NCT02608866|RADIATION|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
57751455|NCT02608866|RADIATION|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
58126878|NCT02583204|OTHER|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
58126879|NCT05964634|DIAGNOSTIC_TEST|OCT imaging|Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy.
58126880|NCT06181825|BEHAVIORAL|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
58452232|NCT04171531|DRUG|Botox® injection|Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
57751456|NCT05478980|DIETARY_SUPPLEMENT|Night Time Tea|Night-time Tea
57751457|NCT05478980|DIETARY_SUPPLEMENT|Control Tea|Feel New Tea
57751458|NCT01974167|DRUG|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
57751459|NCT01974167|DRUG|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
58126881|NCT06336863|DIAGNOSTIC_TEST|Allosure and TruGraf|Precision medicine will be employed to withdraw immunosuppression in kidney transplant recipients.
58126882|NCT06336863|OTHER|Immunosuppression Taper|An immunosuppression taper will be employed over a 12-month period for those that are deemed immune quiescent.
58126883|NCT00655577|BEHAVIORAL|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
58126884|NCT02467621|DRUG|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
58126885|NCT02467621|OTHER|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
57751460|NCT01922076|DRUG|Adavosertib|Given PO
57751461|NCT01922076|OTHER|Laboratory Biomarker Analysis|Correlative studies
57751462|NCT01922076|OTHER|Pharmacological Study|Correlative studies
57751463|NCT01922076|RADIATION|Radiation Therapy|Undergo radiation therapy
57751464|NCT00598026|OTHER|Tele- follow-up|Remote transmission to the implantation centre every 3 months
57751465|NCT00598026|OTHER|Conventional follow-up|Visits at the implantation centre every 3 months
57751466|NCT04349280|DRUG|Bintrafusp alfa|Participants will receive bintrafusp alfa.
57751467|NCT04107922|DIETARY_SUPPLEMENT|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
57751468|NCT04107922|OTHER|Placebo|Patients will take placebo
58126886|NCT02178826|DEVICE|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
58126887|NCT02178826|DEVICE|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
58126888|NCT03106584|DIETARY_SUPPLEMENT|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
58126889|NCT03106584|DIETARY_SUPPLEMENT|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
58126890|NCT05861726|BEHAVIORAL|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 \& 70% maximum heart rate
58126891|NCT05861726|OTHER|None (control group)|None (the control group)
58126892|NCT05873894|DEVICE|EEG|EEG recordings and analysis. Sensory evoked potentials analysis Motor evoked potentials studies
57751469|NCT03293576|BEHAVIORAL|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
57751470|NCT02695355|DRUG|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
57751471|NCT02465840|PROCEDURE|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
58126893|NCT06324136|DIAGNOSTIC_TEST|Implementation of the diagnostic algorithm|Patients will be selected based on specific clinical criteria and referred to the tertiary center for genetic testing. All selected patients will undergo genetic testing by whole-exome sequencing (WES), followed by in silico analysis for an extended panel of genes associated with kidney diseases. The results of genetic testing will be evaluated by a multidisciplinary team of experts to establish conclusive diagnosis.
58126894|NCT00868309|BIOLOGICAL|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
58452233|NCT04171531|DEVICE|Mid-urethral sling|"Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate."
58452234|NCT00218504|DRUG|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
58452235|NCT02181309|DRUG|Meloxicam, low dose|
58452236|NCT02181309|DRUG|Meloxicam, medium dose|
58452237|NCT02181309|DRUG|Meloxicam, high dose|
58452238|NCT02892526|OTHER|Abdominoplasty with exeresis of cutaneous tissue|
58452239|NCT02892526|OTHER|Collection of cutaneous tissue|
58452240|NCT04006093|DRUG|Apixaban Oral|one Tablet 5mg
58452241|NCT01593124|DRUG|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
58452242|NCT01593124|OTHER|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
58452243|NCT01593124|DRUG|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
57751472|NCT02465840|PROCEDURE|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
57751473|NCT02465840|OTHER|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
57751474|NCT04954599|DRUG|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
57751475|NCT04954599|DRUG|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
58452244|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
58452245|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
58452246|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
58452247|NCT00651339|DRUG|botox|botox injection
57751476|NCT04954599|DRUG|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
58126895|NCT00868309|BIOLOGICAL|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
58126896|NCT01208064|DRUG|pazopanib hydrochloride|
58126897|NCT01208064|OTHER|laboratory biomarker analysis|
58126898|NCT01208064|OTHER|pharmacogenomic studies|
58126899|NCT01208064|OTHER|pharmacological study|
58126900|NCT01208064|PROCEDURE|quality-of-life assessment|
58126901|NCT04363983|BIOLOGICAL|Blood sampling|"Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells."
58126902|NCT04363983|PROCEDURE|Liver biopsy|"An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.~This biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.~This biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed."
58126903|NCT04363983|BIOLOGICAL|Stool collect|"Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Analysis will be performed for microbiota and metabolism analysis."
58126904|NCT04725149|OTHER|500 ml base solution|Color, taste, aroma, and calorie matched water base
58126905|NCT04725149|OTHER|500 ml containing 30 ml tart cherry concentrate diluted with water and base solution|Montmorency cherry concentrate
58126906|NCT04725149|OTHER|500 ml containing 60 ml tart cherry concentrate diluted with water only|Montmorency cherry concentrate
58126907|NCT02334371|RADIATION|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
58126908|NCT02161874|DEVICE|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
58126909|NCT02161874|DEVICE|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
58126910|NCT01591707|BEHAVIORAL|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
57751477|NCT05100186|DRUG|Dexamethasone 0.4 MG [Dextenza]|Dextenza
58126911|NCT00278694|DRUG|Oxaliplatin|
58126912|NCT00278694|DRUG|Chemoradiation|
58126913|NCT00278694|DRUG|5-FU|
58126914|NCT00278694|RADIATION|Preoperative chemoradiation|
58452248|NCT05217160|DRUG|KeraStat® Gel with Morphine application|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes."
57751478|NCT02403180|DEVICE|DACP MF|Nelfilcon A multifocal contact lenses
58126915|NCT00278694|PROCEDURE|Pelvic surgery|
58126916|NCT00278694|DRUG|Neoadjuvant oxaliplatin|
58126917|NCT04716660|OTHER|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
58126918|NCT05744609|OTHER|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
58126919|NCT04007133|OTHER|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
57751479|NCT02403180|DEVICE|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
57751480|NCT05862922|DEVICE|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
57751481|NCT01291498|DEVICE|High Intensity Focused Ultrasound|One or two HIFU sessions
57751482|NCT04788901|OTHER|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
58126920|NCT02398877|OTHER|stress|
58126921|NCT02226328|DRUG|Propofol sedation|
58126922|NCT02226328|DRUG|Midazolam and Fentanyl sedation|
58126923|NCT05418348|DRUG|GTX-104|new formulation of nimodipine injection for IV infusion
58126924|NCT05418348|DRUG|Nimodipine Capsules|Nimodipine capsules (reference formulation)
58126925|NCT01232673|PROCEDURE|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
58126926|NCT03825458|OTHER|Blood sampling|Blood sampling at each clinical follow-up visit.
58126927|NCT01258491|DRUG|Nicotinic Acids|
58126928|NCT05565820|OTHER|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
58126929|NCT05565820|DRUG|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
58126930|NCT03344367|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
58126931|NCT03935269|DEVICE|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
58126932|NCT03935269|PROCEDURE|Stress management therapy|Undergo Cereset research office intervention
58126933|NCT03935269|OTHER|Questionnaire administration|Ancillary studies
58126934|NCT03935269|OTHER|Quality of Life Assessment|Ancillary studies
58126935|NCT01957488|DEVICE|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
58126936|NCT01957488|DEVICE|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
58126937|NCT01957488|DEVICE|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
58126938|NCT00967538|DRUG|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
58126939|NCT05664464|DRUG|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
58126940|NCT05664464|DRUG|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
58126941|NCT05664464|DRUG|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
58126942|NCT05664464|DRUG|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
58126943|NCT05664464|RADIATION|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
58126944|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 NODAGA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
58126945|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
58126946|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTATATE PET/CT|All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
58126947|NCT04027764|DRUG|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
58126948|NCT01264952|PROCEDURE|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
58126949|NCT04862078|DIAGNOSTIC_TEST|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
58126950|NCT04862078|DIAGNOSTIC_TEST|Usual care|standard follow-up according to the institutional practice
58126951|NCT06159062|DRUG|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
58126952|NCT06159062|DRUG|Placebo|Placebo do not consist any active ingredients.
58126953|NCT01443065|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
58126954|NCT01443065|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
58126955|NCT01443065|DRUG|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
58126956|NCT01443065|DRUG|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
58126957|NCT01443065|DRUG|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
58126958|NCT06547190|BEHAVIORAL|High AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The High AGEs diet was cooked for example by baking and grilling.
58126959|NCT06547190|BEHAVIORAL|Low AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The low AGEs diet was cooked for example by steaming and boiling.
58126960|NCT03996512|OTHER|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
58126961|NCT02629549|DRUG|OTL38|Infusion of OTL38 prior to surgery
58126962|NCT03997370|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58126963|NCT03997370|DRUG|Carboplatin|Given IV
58126964|NCT03997370|DRUG|Iohexol|Given IV
58126965|NCT02896088|OTHER|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
58126966|NCT03736109|GENETIC|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
58126967|NCT01211548|OTHER|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
58126968|NCT02932254|DRUG|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
58126969|NCT02932254|DRUG|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
58126970|NCT06345248|PROCEDURE|US-TAP|regional block team under ultrasound guidance
58126971|NCT06345248|PROCEDURE|LAPTAP|performed TAP block under direct visualization with the laparoscope
58126972|NCT02625831|OTHER|Biological analysis|"Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies"
58126973|NCT01379781|BEHAVIORAL|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
58126974|NCT00661999|BIOLOGICAL|darbepoetin alfa|Given by injection
58126975|NCT00661999|DIETARY_SUPPLEMENT|ferrous sulfate|Given by mouth
58126976|NCT00661999|DRUG|sodium ferric gluconate complex in sucrose|Given by IV
58126977|NCT00661999|OTHER|placebo|Given by mouth
58126978|NCT02493244|OTHER|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
58126979|NCT05560464|DRUG|VX-548|Tablets for oral administration.
58126980|NCT04886115|OTHER|Neuromuscular evaluation|"Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump"
58126981|NCT04886115|OTHER|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
58126982|NCT04886115|OTHER|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
58126983|NCT04886115|OTHER|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
58126984|NCT04886115|OTHER|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
58126985|NCT00018447|DRUG|PTH 1-34|
58126986|NCT00018447|DRUG|MFPSR-fluoride|
57751483|NCT03434327|OTHER|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
57751484|NCT03434327|OTHER|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
58126987|NCT06496269|OTHER|No intervention|No intervention
58126988|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP|"1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0"
58126989|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP; MVA ME-TRAP|"1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)"
58126990|NCT00682084|PROCEDURE|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
57751485|NCT00147680|DRUG|Paclitaxel, Carboplatin|
58126991|NCT00356798|BIOLOGICAL|an inactivated whole virion H5N1 vaccine, adjuvanted|
58126992|NCT00954967|BEHAVIORAL|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
58126993|NCT05458609|DRUG|Lemborexant 10 mg|10 mg of Lemborexant
57751486|NCT06188793|DEVICE|Virtual reality-directed BGBT|Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
58126994|NCT05458609|DRUG|Naltrexone|50 mg of Naltrexone
58126995|NCT05583812|DRUG|FB2001 for inhalation|FB2001 once or twice daily inhalation
58126996|NCT05583812|DRUG|FB2001 for inhalation placebo|FB2001 placebo once or twice daily inhalation
58126997|NCT05476575|OTHER|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
58126998|NCT02319928|PROCEDURE|Colonoscopy|
58126999|NCT02805803|OTHER|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
58127000|NCT01697722|DRUG|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
58127001|NCT01697722|DRUG|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
58127002|NCT03195985|OTHER|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
58127003|NCT03195985|OTHER|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
58127004|NCT05282654|BEHAVIORAL|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
58127005|NCT02602184|DRUG|AR/101|
58127006|NCT02602184|DRUG|Placebo|
58127007|NCT05936944|OTHER|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
58127008|NCT06206356|DEVICE|PNS Injectrode F1|The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
58127009|NCT05372081|OTHER|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
58127010|NCT02478307|OTHER|Cognitive Therapy|
58127011|NCT02478307|OTHER|Mindfulness Meditation|
58127012|NCT02478307|OTHER|Mindfulness-Based Cognitive Therapy|
58127013|NCT00718679|DRUG|IVN201|Intralymphativ injection of the study drug
58127014|NCT00718679|DRUG|Placebo|
58127015|NCT06217809|BEHAVIORAL|The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.|The intervention is gender-specific, youth-co-led, and targets minorities through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to sexual health and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
58452249|NCT05217160|DRUG|KeraStat® Gel application|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes."
58452250|NCT04926649|PROCEDURE|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
58127016|NCT04868448|BIOLOGICAL|Covid-19 vaccines|Observation of individuals who received one or more doses of covid-19 vaccines.
58127017|NCT01220206|DRUG|Placebo|2 placebo capsules daily
58127018|NCT01220206|DRUG|One POMx capsule daily|One POMx capsule, one placebo capsule daily
58127019|NCT01220206|DRUG|2 POMx Capsules|2 POMx Capsules daily
58127020|NCT03031054|PROCEDURE|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
58127021|NCT03031054|PROCEDURE|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
58127022|NCT04219202|RADIATION|Proton radiation|Therapeutic radiation Treatment with Protons
58127023|NCT04219202|RADIATION|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
58127024|NCT00846378|PROCEDURE|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
58127025|NCT00846378|PROCEDURE|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
58127026|NCT05898568|DEVICE|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
58127027|NCT05898568|BEHAVIORAL|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
58452251|NCT01378988|DRUG|Dexmedetomidine|For sedation according to protocol
57751487|NCT05452928|DRUG|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
57751488|NCT05452928|DRUG|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
57960423|NCT04682080|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
57960424|NCT03382847|COMBINATION_PRODUCT|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
57960425|NCT01110200|DRUG|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
57960426|NCT01110200|DRUG|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
57960427|NCT03529773|BIOLOGICAL|Formulation A|RSV vaccine
57960428|NCT03529773|BIOLOGICAL|Formulation B|RSV vaccine
57960429|NCT03529773|BIOLOGICAL|Placebo|Placebo
57960430|NCT04764760|DEVICE|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
57960431|NCT01134965|DRUG|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
57960432|NCT01134965|DRUG|Digoxin|Digoxin 0.5 mg as single dose
57960433|NCT06536738|PROCEDURE|esophageal repair|The surgery confirmed a secondary esophageal fistula following the anterior cervical surgery. The procedure involved trimming the esophageal tissue around the fistula and repairing the fistula.
57960434|NCT01727895|DIETARY_SUPPLEMENT|Beta-glucan (Glucan #300®)|
57960435|NCT04917211|PROCEDURE|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
57960436|NCT03954600|DRUG|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
57960437|NCT03954600|DRUG|Placebos (125 mg)|Placebo, 125 mg oral capsules
57960438|NCT03414580|PROCEDURE|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
57960439|NCT01951469|DRUG|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
57960440|NCT01951469|DRUG|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
57960441|NCT03105687|BEHAVIORAL|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
57960442|NCT03506295|DEVICE|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
57960443|NCT03506295|DEVICE|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
57960444|NCT06144983|DRUG|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
57960445|NCT06144983|DRUG|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
57960446|NCT02611154|DRUG|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
57960447|NCT04132791|OTHER|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
57960448|NCT04132791|OTHER|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
57960449|NCT05327465|OTHER|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
57960450|NCT05327465|OTHER|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
57960451|NCT02129946|OTHER|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
58127028|NCT00235456|PROCEDURE|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
58127029|NCT00235456|PROCEDURE|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
58127030|NCT05364827|DIAGNOSTIC_TEST|CTCA|CTCA performed in intervention arm patients prior to CTO PCI
58127031|NCT05480722|OTHER|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
58127032|NCT05480722|OTHER|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
58127033|NCT01048320|DRUG|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
58127034|NCT01048320|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
58127035|NCT01048320|DRUG|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
58127036|NCT05893056|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
58127037|NCT05893056|DRUG|Tislelizumab|a PD-1 immune check inhibitor
58127038|NCT05893056|DRUG|Lenvatinib|Lenvatinib capsules
58127039|NCT02582970|DRUG|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
58127040|NCT02582970|DRUG|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
58452252|NCT00479713|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
58452253|NCT00479713|DRUG|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
58452254|NCT00479713|DRUG|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
58452255|NCT00479713|DRUG|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
58452256|NCT00402168|DRUG|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
58127041|NCT02582970|DRUG|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
58127042|NCT02582970|DRUG|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
58127043|NCT02658084|DRUG|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
58127044|NCT02658084|DRUG|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
58127045|NCT01271439|DRUG|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
58127046|NCT03891719|PROCEDURE|Unilateral cleft lip rhinoplasty|"* Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
58127047|NCT02974153|BIOLOGICAL|ALD403 (Eptinezumab)|
58127048|NCT02974153|BIOLOGICAL|Placebo|
58127049|NCT04172298|OTHER|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
58127050|NCT04172298|OTHER|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
58127051|NCT04172298|OTHER|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
58127052|NCT01607775|DEVICE|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
58452257|NCT00402168|DRUG|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
58452258|NCT00402168|DRUG|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
58452259|NCT00795704|DRUG|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
58452260|NCT00795704|DRUG|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
58452261|NCT01276639|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
58452262|NCT01276639|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
58127053|NCT01607775|DEVICE|PMMA-cage|The in-house produced cervical cage will be implanted
58127054|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
58127055|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
58127056|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
58127057|NCT05631626|DRUG|Placebo|Placebo
58127058|NCT04024956|DEVICE|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
58127059|NCT05354414|DEVICE|Virtual reality|Administered as specified in the treatment arm.
58127060|NCT05354414|PROCEDURE|Standard of Care|Administered as specified in the treatment arm.
58127061|NCT03416764|DEVICE|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
58127062|NCT02715947|DRUG|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
58127063|NCT06261853|RADIATION|3D-CBCT|CBCT provides a three-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. CBCT radiation doses are typically in the range of 60 microSv.
58127064|NCT06261853|RADIATION|2D-OPG|An OPG provides a two-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. OPG radiation doses are typically in the range of 20 microSv.
58127065|NCT02724683|DEVICE|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
58127066|NCT02724683|BEHAVIORAL|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
58127067|NCT02724683|BEHAVIORAL|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
58127068|NCT02724683|DEVICE|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
58127069|NCT02724683|OTHER|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
58127070|NCT05744973|OTHER|No intervention|This is an observational study
58127071|NCT03066999|PROCEDURE|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
58127072|NCT03066999|DEVICE|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
58127073|NCT04713059|GENETIC|FGFR2|Mutation of FGFR2
58127074|NCT05585957|DIAGNOSTIC_TEST|INTERLEUKIN 6|role of interleukin 6 in the diagnosis of neonatal sepsis in comparison with the routine diagnostic markers of neonatal sepsis
58127075|NCT06290180|BEHAVIORAL|First Face for Mental Heatlh|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
58127076|NCT01158365|DRUG|LACTIC ACID (Dermacid)|Route of administration: local
58452263|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
58452264|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
58127077|NCT01158365|DRUG|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
58127078|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
58127079|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
58127080|NCT05456607|BEHAVIORAL|Mood Monitoring|The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
58127081|NCT06286969|PROCEDURE|acupuncture|The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.
58127082|NCT03882047|DRUG|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
58127083|NCT03882047|DRUG|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
58127084|NCT03882047|DRUG|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
58127085|NCT03882047|DRUG|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
58127086|NCT00997581|DRUG|apremilast|apremilast 20 mg taken twice daily by mouth
58127087|NCT00997581|DRUG|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
58127088|NCT00046865|PROCEDURE|acupressure therapy|
58127089|NCT00046865|PROCEDURE|management of therapy complications|
58127090|NCT00046865|PROCEDURE|nausea and vomiting therapy|
58127091|NCT05116995|DRUG|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
58127092|NCT05116995|DRUG|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
58127093|NCT01437865|DRUG|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
58127094|NCT03775395|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
58127095|NCT03775395|DRUG|Sorafenib|400mg BID daily oral dosing
58127096|NCT03775395|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
58127097|NCT04971096|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
58127098|NCT04971096|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
58127099|NCT04971096|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose.
58127100|NCT00088062|DRUG|STA-5326|
58127101|NCT04478019|DRUG|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
58127102|NCT05511597|BEHAVIORAL|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
58127103|NCT05511597|BEHAVIORAL|Complex task practice|Overground gait flexibility training with added cognitive tasks
58127104|NCT05511597|BEHAVIORAL|Static balance exercise|Mindfulness and breathing combined with static balance exercises
58127105|NCT04884893|DRUG|Nitrous Oxide|50% nitrous oxide
58127106|NCT01208012|DRUG|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
58127107|NCT02116712|DRUG|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
58127108|NCT01113268|OTHER|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
58127109|NCT05137678|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
58127110|NCT02473211|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
57751489|NCT05980208|DRUG|Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
57751490|NCT06580366|DRUG|Sennosid A+B|Bowel Preparation
58127111|NCT02473211|DRUG|Daclatasvir|Daclatasvir 60mg tablet administered once daily
58127112|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
58127113|NCT02527096|DRUG|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
58127114|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
58127115|NCT02068040|DIETARY_SUPPLEMENT|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
58127116|NCT05333523|RADIATION|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~1. Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~2. Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~3. Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
58127117|NCT05333523|RADIATION|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
58127118|NCT05481307|DRUG|RLD2202|Take it once a day per period
57751491|NCT06580366|DRUG|Sodium Picosulfate/Magnesium Oxide/Citric Acid|Bowel Preparation
57751492|NCT01410955|DIETARY_SUPPLEMENT|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
58127119|NCT05481307|DRUG|RLD2203|Take it once a day per period
58127120|NCT04182971|OTHER|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
58127121|NCT04182971|OTHER|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
58127122|NCT04182971|OTHER|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
57751493|NCT01410955|DIETARY_SUPPLEMENT|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
57751494|NCT04023240|DRUG|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
57751495|NCT04023240|PROCEDURE|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
57751496|NCT04023240|PROCEDURE|Positron Emission Tomography (PET) scan|PET images will be acquired.
58127123|NCT04585321|DRUG|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
58127124|NCT04585321|DRUG|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
58127125|NCT05857839|OTHER|Myofascial release|Patients will get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks
58127126|NCT05857839|OTHER|pelvic Support belt|The support belt will be worn for less than two to three hours at a time and it will be used 4 times a week
58127127|NCT05668481|BEHAVIORAL|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
58127128|NCT06211985|DIAGNOSTIC_TEST|Copeptin level measurement|Throughout the study period, a total of 202 eligible patients were admitted to the hospital. Twenty-four patients were excluded due to lack of consent from their families, and an additional 103 patients were excluded based on the predefined exclusion criteria. In the control group, 72 individuals without chronic or acute diseases were initially eligible, but 46 of them were excluded due to lack of consent from their families. The study included patients who met the inclusion criteria and whose families provided consent, and it concluded upon reaching a total of 25 patients for each group. Additional blood samples were collected from each child within every group to assess copeptin levels, in conjunction with routine tests
58127129|NCT04638166|OTHER|Mineral water|Drinking mineral water for 12 weeks
58127130|NCT04638166|OTHER|Plain water|Drinking plain water for 12 weeks
58127131|NCT04267666|DEVICE|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
58127132|NCT04267666|OTHER|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
58127133|NCT00066131|PROCEDURE|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
58127134|NCT00066131|PROCEDURE|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
58127135|NCT01246375|DEVICE|Dual energy X-ray absorptiometry|Device which measures bone density
58127136|NCT02369042|DEVICE|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
58127137|NCT03231956|DEVICE|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
58127138|NCT00060866|DRUG|Propranolol|
58127139|NCT04396028|OTHER|data collection|retrospective data collection
58127140|NCT03002649|DRUG|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
58127141|NCT02779036|PROCEDURE|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
58127142|NCT02779036|PROCEDURE|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
58127143|NCT01015430|DRUG|Placebo (for RO4917523 ascending doses)|Placebo daily po
58127144|NCT01015430|DRUG|Placebo (for RO4917523 fixed dose)|Placebo daily po
58127145|NCT01015430|DRUG|RO4917523|RO4917523 ascending doses daily po
58127146|NCT01015430|DRUG|RO4917523|RO4917523 fixed dose daily po
58127147|NCT05012345|PROCEDURE|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
58127148|NCT05501691|OTHER|Placebo|Laser Simulation
58127149|NCT05501691|RADIATION|445 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 445 nm Diode Laser Wavelength
58127150|NCT05501691|RADIATION|660 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 660 nm Diode Laser Wavelength
57751497|NCT00975910|DRUG|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
57751498|NCT00975910|DRUG|saline|Saline arm: infused at the same rate as lidocaine
57960452|NCT04283695|DRUG|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
58127151|NCT05501691|RADIATION|970 nm Diode Laser Wavelength|The Axial Surface of Class V Cavity will be Irradiated Using a 970 nm Diode Laser Wavelength
58127152|NCT06545149|DIETARY_SUPPLEMENT|BioNutri AR-1,|intervention with fermented and nutritionally balanced food twice a day
58127153|NCT01226069|DRUG|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
58127154|NCT01226069|DRUG|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
58127155|NCT01226069|OTHER|No application|No application
58127156|NCT02521441|BIOLOGICAL|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
58127157|NCT02521441|BIOLOGICAL|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
58127158|NCT05412407|OTHER|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
58127159|NCT03010748|DEVICE|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
58127160|NCT06028009|PROCEDURE|Injection of platelet-rich plasma|Injection of autologous platelet-rich plasma into anterior vaginal wall
58127161|NCT06028009|PROCEDURE|Injection of saline|Injection of sterile normal saline into anterior vaginal wall
58127162|NCT00110968|DRUG|Itopride hydrochloride|
58127163|NCT05865197|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
58127164|NCT03818945|DRUG|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
58127165|NCT03818945|DRUG|Sodium fluoride varnish|5% sodium fluoride \[22,600 ppm F-\]
58127166|NCT01000337|DRUG|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
58127167|NCT01000337|DRUG|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
58127168|NCT01923077|DRUG|Simvastatin|usual care with Simvastatin
58127169|NCT01923077|DRUG|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
58127170|NCT02045121|DEVICE|Indwelling Pleural Catheter|
58127171|NCT02045121|PROCEDURE|Talc Pleurodesis|
58127172|NCT06136052|OTHER|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
58127173|NCT05445297|DRUG|Pharmacological cardioversion with Amiodarone|"Patients in this group will receive intravenous amiodarone according to the following scheme:~1. administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~2. if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached."
58127174|NCT05445297|DRUG|Pharmacological cardioversion with Refralon|"Patients in this group will receive intravenous refralon according to the following scheme:~1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
58127175|NCT04026464|DRUG|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
58452265|NCT05362968|DRUG|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
58452266|NCT04538937|OTHER|no intervention|no intervention
58452267|NCT01508169|DEVICE|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
58452268|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
58452269|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
58127176|NCT04026464|DRUG|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
58127177|NCT01513148|DEVICE|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
58127178|NCT05471674|DRUG|Nivolumab|3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
58127179|NCT05471674|PROCEDURE|Hepatectomy|Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
58127180|NCT05337709|OTHER|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
58127181|NCT04997694|PROCEDURE|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
58127182|NCT03020602|OTHER|Laboratory Biomarker Analysis|Correlative studies
58127183|NCT03020602|OTHER|Pharmacological Study|Correlative studies
58127184|NCT03020602|DRUG|Ubidecarenone Injectable Nanosuspension|Given IV
58127185|NCT00633282|BEHAVIORAL|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
58127186|NCT00633282|DRUG|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
58127187|NCT00633282|DRUG|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
58127188|NCT05014308|PROCEDURE|Piezoelectric Alveolar Decortication, fibrotomy|
58127189|NCT01743157|DRUG|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
58127190|NCT03876561|PROCEDURE|Pelvic floor prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
58127191|NCT03396133|DIAGNOSTIC_TEST|Snap|screen, transmission, and analysis ECG automated
58452270|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
58452271|NCT01620086|DEVICE|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
58452272|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
57751499|NCT05239130|DEVICE|Auralya|Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
57751500|NCT02785341|OTHER|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
57751501|NCT02785341|OTHER|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
57751502|NCT02785341|OTHER|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
57751503|NCT00438880|DRUG|Agatolimod Sodium|Given IV
58127192|NCT03025607|DEVICE|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
58127193|NCT00493272|DRUG|Fibrinogen|Fibrinogen behandling
58127194|NCT00322491|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
58127195|NCT04619810|OTHER|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
58127196|NCT04148313|OTHER|No Intervention|There is no intervention for this study.
58127197|NCT01661270|DRUG|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
58127198|NCT01661270|DRUG|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
58127199|NCT00079807|DRUG|Alpha-Lipoic Acid|
58452273|NCT05661786|OTHER|Observation|Monitor every 6 months
58452274|NCT05661786|OTHER|Antiviral treatment|Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
58452275|NCT03087695|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
58452276|NCT06117865|BEHAVIORAL|Module 1|Module 1: Introduction to IBS by a gastroenterologist.
58452277|NCT06117865|BEHAVIORAL|Module 2|Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.
58127200|NCT02952495|BEHAVIORAL|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
58127201|NCT02532764|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
58127202|NCT02532764|DRUG|Placebo|Normal Saline
58127203|NCT05616208|BIOLOGICAL|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
58127204|NCT04856345|OTHER|Walking with music with synchronisation|Walking with music than one can synch to
58127205|NCT04856345|OTHER|Walking with music without synchronisation|Walking with music than one cannot synch to
58127206|NCT04856345|OTHER|walking without music|Walking without music
58127207|NCT02564263|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
58127208|NCT02564263|DRUG|paclitaxel|80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
58127209|NCT02564263|DRUG|docetaxel|75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle
58127210|NCT02564263|DRUG|irinotecan|180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
58127211|NCT02586259|DRUG|budesonide MMX®|
58127212|NCT02016300|DEVICE|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
58127213|NCT02016300|DEVICE|Non-Bracing|Microfracture performed with no post-operative unloader bracing
58127214|NCT03519828|OTHER|No intervention has been conducted|It is an observational study, and no intervention has been conducted
58127215|NCT01808664|BEHAVIORAL|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
58127216|NCT01808664|BEHAVIORAL|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
58127217|NCT06111911|DIAGNOSTIC_TEST|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
58127218|NCT04292561|DRUG|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
57751504|NCT00438880|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
57751505|NCT00438880|OTHER|Laboratory Biomarker Analysis|Correlative study
58127219|NCT04292561|DRUG|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
58127220|NCT04503330|PROCEDURE|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
58127221|NCT05422547|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
58127222|NCT01367275|DRUG|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
58127223|NCT01367275|DRUG|Irinotecan|180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
58127224|NCT05634109|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
58127225|NCT01186588|DRUG|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
58127226|NCT05861648|DRUG|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
58127227|NCT05861648|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement: Placebo
57751506|NCT00438880|PROCEDURE|Radionuclide Imaging|Undergo imaging scans
57751507|NCT00438880|BIOLOGICAL|Rituximab|Given IV
57751508|NCT00438880|PROCEDURE|Single Photon Emission Computed Tomography|Undergo imaging scans
57751509|NCT00438880|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
57751510|NCT00652782|DRUG|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
57751511|NCT00652782|DRUG|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
57960453|NCT04356183|OTHER|SWET: Supervised Weight loss and Exercise Training|Weight loss will occur via a dietitian-led intervention targeting weight loss over 16 weeks, with weekly weigh-ins and group support sessions. Exercise training will consist of three times per week of an interval-based aerobic program plus twice-weekly resistance training. Both weight loss and exercise training will be supervised to maximize safety and adherence.
57960454|NCT04356183|OTHER|CHAT: Counseling Health As Treatment|Control Arm over 16 weeks.
58127228|NCT05505812|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
58452278|NCT06117865|BEHAVIORAL|Module 3|Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.
58127229|NCT01247259|DRUG|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
58127230|NCT04849988|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
58127231|NCT04849988|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
58127232|NCT02288832|OTHER|-self-collected vaginal samples|
58127233|NCT02288832|DRUG|zithromax|
58127234|NCT02288832|OTHER|usual practices|
58127235|NCT03922438|PROCEDURE|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
58127236|NCT05815069|DIAGNOSTIC_TEST|[18F]AlF-NOTA-pentixather PET/CT|The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
58127237|NCT04240938|PROCEDURE|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
58127238|NCT01180244|DEVICE|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
58127239|NCT01180244|DEVICE|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
58127240|NCT02578550|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
57751512|NCT05093049|DEVICE|Renuvion APR System|The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
58127241|NCT02578550|DRUG|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
58127242|NCT02578550|DRUG|Darunavir|A single tablet containing darunavir 800 mg will be administered.
58127243|NCT02578550|DRUG|Cobicistat|A single table containing cobistat 150 mg will be administered.
58127244|NCT05639634|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
58127245|NCT05639634|OTHER|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
58127246|NCT05639634|DIETARY_SUPPLEMENT|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
58127247|NCT01088126|PROCEDURE|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
58127248|NCT03361371|DEVICE|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
58127249|NCT03361371|DEVICE|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
58127250|NCT00143819|DRUG|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
58452279|NCT06117865|BEHAVIORAL|Module 4|Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).
58452280|NCT06117865|BEHAVIORAL|Module 5|Module 5: Intervention: The low FODMAP diet.
58127251|NCT00143819|DRUG|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
58127252|NCT00859664|OTHER|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
58127253|NCT04635423|BIOLOGICAL|V503|9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
57751513|NCT05093049|PROCEDURE|Gynecomastia Correction Surgery|Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
58127254|NCT04635423|OTHER|Placebo|0.9% sodium chloride (NaCL)
58452281|NCT02855034|OTHER|Blood samples|Blood samples for dosage: copeptin and protein S100B
58452282|NCT01492205|DRUG|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
58452283|NCT01671033|BEHAVIORAL|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
58127255|NCT02737215|DEVICE|CPAP|patients will receive CPAP therapy with Auto-CPAP
58127256|NCT04567342|OTHER|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
58127257|NCT04567342|OTHER|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
58127258|NCT04567342|OTHER|No personal contact attempt|No personal contact attempts will be made.
58127259|NCT04567342|OTHER|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
58127260|NCT03193866|DRUG|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
58127261|NCT05585658|BIOLOGICAL|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
58127262|NCT01540032|BEHAVIORAL|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
58127263|NCT01540032|BEHAVIORAL|Normal diet|Patients will eat their usual diet.
58314857|NCT02538991|DEVICE|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
58452284|NCT01671033|BEHAVIORAL|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
58452285|NCT03242694|DIAGNOSTIC_TEST|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
57751514|NCT00579280|DRUG|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
57751515|NCT00579280|DRUG|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
57751516|NCT00579280|DRUG|placebo|placebo
57751517|NCT01089374|RADIATION|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
57751518|NCT02054806|BIOLOGICAL|Pembrolizumab|IV infusion
57751519|NCT01090570|DRUG|PLX3397|Once-daily oral capsules
57751520|NCT00140205|DRUG|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
57751521|NCT05606757|DRUG|BOTOX Dose A|Injection; intramuscular
57751522|NCT05606757|DRUG|Placebo for BOTOX|Placebo
57751523|NCT05606757|DRUG|BOTOX Dose B|Injection; intramuscular
58127264|NCT03444038|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
58127265|NCT01790165|DRUG|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
58127266|NCT05275400|DRUG|Insulin Efsitora Alfa|Administered SC
58127267|NCT05275400|DRUG|Insulin Degludec|Administered SC
58127268|NCT05666349|DRUG|Niraparib|100 mg, 200 mg, or 300mg oral niraparib once daily.
58127269|NCT05666349|RADIATION|Re-irradiation (re-RT)|Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.
58127270|NCT05817799|DRUG|L-Carnitine 500Mg thrice daily|L-Carnitine 500mg oral thrice daily
58127271|NCT05817799|DRUG|1g L-Carnitine IV three times a week|1g IV L-Carnitine three times a week
58127272|NCT02285140|DRUG|Cefazolin|administration as outlined
58127273|NCT02285140|DRUG|Vancomycin|administration as outlined
58127274|NCT00623103|DRUG|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
58127275|NCT00623103|DRUG|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
58127276|NCT05089123|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
58127277|NCT05089123|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
58452286|NCT03242694|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
58452287|NCT03852134|PROCEDURE|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
58127278|NCT05177627|OTHER|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~* educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~* drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~* classroom lessons on philosophies and theories on communication and trust~* small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
58127279|NCT05177627|OTHER|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
58127280|NCT05177627|OTHER|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~* attendance of clinical internship~* analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
58127281|NCT03015090|DRUG|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
58127282|NCT00972881|BIOLOGICAL|cetuximab|
58127283|NCT00972881|DRUG|capecitabine|
58127284|NCT00972881|DRUG|irinotecan hydrochloride|
58127285|NCT00972881|PROCEDURE|neoadjuvant therapy|
58127286|NCT00972881|PROCEDURE|therapeutic conventional surgery|
58127287|NCT00972881|RADIATION|radiation therapy|
58127288|NCT02495324|DRUG|Placebo|2 weeks of placebo PO daily
58127289|NCT02495324|DRUG|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
58127290|NCT02495324|DRUG|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
58127291|NCT02495324|DRUG|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
58127292|NCT06495814|DRUG|1/bag of Jinlida granules, 3 times/day, taken with hot water.|All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.
58127293|NCT01952249|DRUG|Demcizumab|administered intravenously
58127294|NCT01952249|DRUG|Taxol|administered intravenously
58127295|NCT06007391|DRUG|Nicotinamide|nicotinamide 3g per day
58127296|NCT01712880|PROCEDURE|open debridement with modular exchange|
58127297|NCT01712880|PROCEDURE|one stage exchange|
58127298|NCT04471675|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
58127299|NCT02770950|DRUG|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
58127300|NCT02770950|DRUG|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
58127301|NCT02770950|DRUG|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
58127302|NCT02623088|OTHER|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
58127303|NCT05296915|DEVICE|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
58127304|NCT05296915|DEVICE|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
57751524|NCT05606757|DRUG|BOTOX Dose C|Injection; intramuscular
57751525|NCT00520858|OTHER|Resistance Exercise (RE)|
58127305|NCT05296915|BEHAVIORAL|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
58127306|NCT03231475|DRUG|SPH1188-11|qd.po
58127307|NCT02716129|DRUG|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
58127308|NCT02716129|DRUG|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
58127309|NCT04905433|BEHAVIORAL|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
58127310|NCT04905433|BEHAVIORAL|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
58127311|NCT06438874|OTHER|Exercise Test|Exercise capacity will be measured as peak oxygen consumption (peakVO2) using an incremental exercise test on a cycle ergometer with an open-circuit spirometry system (TrueOne, Parvo Medics, Sandy, UT) to analyze expired gases. Exercise testing will follow the American College of Sports Medicine and American Heart Association guidelines. The investigators will use a graded protocol, starting with a warm-up at 0 watts for 5 minutes, followed by 15 watt increments every 2 minutes until volitional fatigue.
58127312|NCT02172248|DRUG|BI 10773|
58127313|NCT02172248|DRUG|Metformin|
58127314|NCT04518774|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
58127315|NCT03346564|BEHAVIORAL|Ritual training program|Ritual training program including education and demonstration
58127316|NCT03346564|BEHAVIORAL|Routine care|
58127317|NCT00101608|DRUG|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
58127318|NCT01801670|PROCEDURE|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
58127319|NCT01801670|PROCEDURE|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
58127320|NCT04687163|DRUG|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
58127321|NCT04687163|DRUG|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
58127322|NCT04687163|DRUG|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
58127323|NCT01501942|DRUG|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
58127324|NCT01501942|DRUG|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
58127325|NCT04822870|PROCEDURE|quadratus lumborum block|Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
58127326|NCT04822870|PROCEDURE|iliohypogastric/ilioinguinal nerve block|Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
58127327|NCT04822870|PROCEDURE|epidural analgesia|Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
58127328|NCT03901014|OTHER|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
58127329|NCT03901014|OTHER|Very low carbohydrate diet|Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
58127330|NCT02252562|DEVICE|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
58127331|NCT01245790|DRUG|fostamatinib|Oral tablets, single dose
58127332|NCT06123507|BEHAVIORAL|Student practitioner perspective-taking intervention|This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
58127333|NCT05626595|BEHAVIORAL|Project Group - PRO-ECO Project|The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.
58127334|NCT05626595|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
58127335|NCT04908826|PROCEDURE|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
58127336|NCT00797108|DRUG|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
58127337|NCT00797108|DRUG|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
58127338|NCT00797108|DRUG|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
58127339|NCT00211159|DRUG|EPAX 1050TG|
58127340|NCT04259840|OTHER|Observation|Soft tissue implant measurements
58127341|NCT05451836|OTHER|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
58127342|NCT05451836|OTHER|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
58127343|NCT05586425|BEHAVIORAL|Emotion Regulation Skills + Treatment as Usual|ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.
58127344|NCT05586425|BEHAVIORAL|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
58452288|NCT03852134|PROCEDURE|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
58452289|NCT02864121|OTHER|all patients included in IDAHO study|
58452290|NCT05254106|DEVICE|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
58452291|NCT02116881|PROCEDURE|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
58452292|NCT05889715|OTHER|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
58452293|NCT04353245|OTHER|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
58452294|NCT05951946|DRUG|BR3006-1|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
58452295|NCT05951946|DRUG|BR3006-2|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
57751526|NCT00520858|OTHER|Aerobic Exercise (AE)|
57751527|NCT00520858|OTHER|Resistance and Aerobic Exercise (RAE)|
57751528|NCT01312870|DIETARY_SUPPLEMENT|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
57751529|NCT01312870|OTHER|standard hospital diet|standard hospital diet
57751530|NCT01830114|BEHAVIORAL|Web app|The Checkup and Choices web application
57751531|NCT05996666|DEVICE|Liver-cancer early detection test|Blood collection and liver-cancer early detection test
58127345|NCT00062283|DRUG|L-alanosine|
58127346|NCT02398188|DRUG|LIPO-202|
58127347|NCT02398188|DRUG|Placebo|
58127348|NCT04089709|BEHAVIORAL|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
58127349|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
58127350|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
58127351|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
58127352|NCT05291078|DEVICE|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
58127353|NCT01890382|DIETARY_SUPPLEMENT|Whey protein|30 g in total; twice a day (morning and evening)
58127354|NCT01890382|DIETARY_SUPPLEMENT|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
58127355|NCT01890382|DIETARY_SUPPLEMENT|leucine supplementation|7.5 g/d in total; three times per day
58127356|NCT01890382|DIETARY_SUPPLEMENT|soy protein|30 g in total; twice a day
58127357|NCT01890382|DIETARY_SUPPLEMENT|creatine|6.0 g in total; twice a day
58127358|NCT01890382|DIETARY_SUPPLEMENT|placebo|
58452296|NCT05951946|DRUG|BR3006-3|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
58452297|NCT04370158|OTHER|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
58452298|NCT02535325|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
58127359|NCT01916148|DRUG|18F-DOPA|18F-DOPA is a PET scan radiotracer.
58127360|NCT02624843|DRUG|Benzyl Alcohol Lotion 5%|White topical lotion
58127361|NCT02624843|DRUG|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
58452299|NCT02535325|DRUG|Cisplatin|Given IV
58452300|NCT02535325|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58452301|NCT02535325|DRUG|Methoxyamine|Given PO
58452302|NCT02535325|DRUG|Methoxyamine Hydrochloride|Given PO
58452303|NCT02535325|DRUG|Pemetrexed|Given IV
58127362|NCT02624843|DRUG|Placebo|White topical lotion
58127363|NCT03467568|DIETARY_SUPPLEMENT|Sodium Chloride|300mg sodium chloride will be provided in a capsule
58127364|NCT03467568|OTHER|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
58127365|NCT03467568|DIETARY_SUPPLEMENT|Water|Twice during the morning a drink of 150ml of water will be consumed
58127366|NCT03467568|BIOLOGICAL|No water consumed|No water will be consumed during the monring
58127367|NCT02704351|PROCEDURE|Surgery|Sugammadex to reverse neuromuscular blockade
58127368|NCT00998699|DRUG|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
58127369|NCT00998699|DRUG|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
58452304|NCT02535325|DRUG|Pemetrexed Disodium|Given IV
58452305|NCT03382990|DEVICE|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
58452306|NCT03214107|OTHER|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
58452307|NCT03214107|OTHER|Snack|Full snack or Distributed snack
58452308|NCT01633788|DRUG|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
58452309|NCT01633788|DRUG|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
58452310|NCT01633788|DRUG|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
58452311|NCT01633788|DRUG|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
58452312|NCT05676502|DEVICE|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
58452313|NCT06206538|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58127370|NCT01200472|DRUG|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
58127371|NCT01200472|DRUG|Placebo|Placebo capsules identical to apremilast
58452314|NCT06206538|BEHAVIORAL|Rehabilitation therapy|"he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
58452315|NCT02744365|OTHER|Observational|"All women of the biobank have provided:~1. blood samples (plasma, serum and Buffy-coat)~2. urine samples~3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~4. mean arterial blood pressure~5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
58452316|NCT00027625|DRUG|gefitinib|
58452317|NCT00027625|DRUG|temozolomide|
58452318|NCT02471235|BEHAVIORAL|Physiotherapy|Pulmonary rehabilitation
58452319|NCT05659823|DRUG|Bupivacaine-fentanyl-morphine elective group|Guideline recommended analgesia in elective caesarian section.
58452320|NCT05659823|DRUG|Bupivacaine-fentanyl elective group|Current analgesia in elective caesarian section.
57751532|NCT06580522|OTHER|Prone Position Group|After the children in the prone position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were prone positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
57960455|NCT04702646|DRUG|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
58127372|NCT00602329|BIOLOGICAL|bevacizumab|Given IV
58127373|NCT00602329|DRUG|fluorouracil|Given IV
58127374|NCT00602329|DRUG|leucovorin calcium|Given IV
58127375|NCT00602329|DRUG|oxaliplatin|Given IV
58127376|NCT01834963|DRUG|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
58452321|NCT05659823|DRUG|Bupivacaine-fentanyl emergency group|Current analgesia in emergency caesarian section.
58127377|NCT01834963|DRUG|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
58127378|NCT04815902|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
58127379|NCT04815902|DRUG|Losartan|12.5 mg oral Losartan taken for 30 days total.
58127380|NCT04815902|DRUG|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
58127381|NCT04815902|DRUG|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
57751533|NCT06580522|OTHER|Supine Position Group|After the children in the supine position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were supine positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
57751534|NCT05695781|DRUG|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
58127382|NCT01586858|OTHER|Observational|Observational study of subjects previously enrolled in the RAVE trial
58452322|NCT04821258|DIETARY_SUPPLEMENT|MICODIGEST 2.0 supplement|MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes
58452323|NCT04821258|DIETARY_SUPPLEMENT|Placebo supplement|Placebo
58452324|NCT03612778|BEHAVIORAL|Plant-based diet|Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
58452325|NCT03612778|BEHAVIORAL|Mediterranean diet|Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
58452326|NCT01673828|DRUG|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
58452327|NCT01673828|DRUG|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
58452328|NCT03314701|DEVICE|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
58452329|NCT03314701|DEVICE|Airway Pressure Release Ventilation (APRV)|"* high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second"
58452330|NCT02333357|BEHAVIORAL|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
58452331|NCT02333357|BEHAVIORAL|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
58452332|NCT03482531|OTHER|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
58452333|NCT05543902|BEHAVIORAL|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
58127383|NCT01202747|DEVICE|LipiFlow System|In-office treatment for meibomian gland dysfunction
58127384|NCT00585780|DRUG|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
58127385|NCT00585780|DRUG|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
58452334|NCT02857608|DRUG|Lymphoseek|
58452335|NCT01145846|DRUG|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
58458706|NCT00447226|DRUG|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
57751535|NCT05695781|DRUG|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
57751536|NCT00999466|DRUG|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
57751537|NCT00999466|DRUG|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
57751538|NCT00372008|DRUG|Testosterone|
57751539|NCT03069092|BEHAVIORAL|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
57960456|NCT04702646|PROCEDURE|Colonoscopy|colonoscopy will be performed to every patient included in the study
58127386|NCT04128007|DRUG|Roflumilast foam 0.3%|experimental
58127387|NCT04128007|DRUG|Vehicle foam|experimental
58127388|NCT06250595|OTHER|Collection of clinical and laboratory data from EHR.|Observational sutdy
58127389|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
58127390|NCT00147381|DRUG|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
58127391|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
58127392|NCT01512043|BEHAVIORAL|Breathing control|Practice of device guided breathing control twice a day for four weeks.
58127393|NCT01785836|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
57751540|NCT03069092|BEHAVIORAL|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
57751541|NCT03069092|BEHAVIORAL|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
57751542|NCT00006018|DRUG|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
57751543|NCT00006018|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
58127394|NCT01785836|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
58127395|NCT01785836|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
58127396|NCT01785836|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
58458707|NCT00195936|DRUG|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
57751544|NCT01085838|DRUG|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
57751545|NCT05929469|BEHAVIORAL|App|Participants will receive an mHealth program.
58127397|NCT00560235|DRUG|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
58127398|NCT02048865|DRUG|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
57751546|NCT05929469|BEHAVIORAL|Fully Automated Kick-Off|As an orientation to the study, participants will receive a fully automated kick-off session.
58127399|NCT02048865|DRUG|Placebo drug|placebo drug 2.5mg BID for 6 months
58127400|NCT03056274|DRUG|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
58127401|NCT03056274|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
58127402|NCT04572100|OTHER|Transoral Robotic Surgery (TORS) or Radiotherapy|Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
58127403|NCT04572100|OTHER|Chemotherapy and Low-Dose Radiotherapy|Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
58127404|NCT04572100|OTHER|Chemotherapy and High-Dose Radiotherapy|Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
58127405|NCT04572100|DRUG|Paclitaxel|This drug will be combined with carboplatin during induction therapy for 9 weeks.
58127406|NCT04572100|DRUG|Carboplatin|This drug will be combined with paclitaxel during induction therapy for 9 weeks.
57751547|NCT05929469|BEHAVIORAL|Human-Enhanced Kick-Off|As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.
57751548|NCT05929469|BEHAVIORAL|Check-In|Participants will receive a check-in with a study interventionist.
57751549|NCT05929469|BEHAVIORAL|Counseling|Participants will receive counseling from a study interventionist.
57751550|NCT00440869|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg po bid
57751551|NCT00440869|DIETARY_SUPPLEMENT|placebo|bid oral dosing
57751552|NCT05260996|OTHER|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
57751553|NCT00209924|DRUG|Gaboxadol|
57751554|NCT00977665|DRUG|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
57751555|NCT00977665|DRUG|placebo|placebo tablet for 48 weeks
58127407|NCT02222428|DRUG|BI 1744 CL/BI 54903 XX FDC|
58127408|NCT02222428|DRUG|BI 54903 XX|
58127409|NCT02222428|DRUG|BI 1744 CL|
58127410|NCT02314338|OTHER|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
58458708|NCT01479101|OTHER|MammaPrint 70-gene expression profile|
57751556|NCT05024851|OTHER|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
58127411|NCT04438356|COMBINATION_PRODUCT|M-Health|The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
58127412|NCT05450770|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
58127413|NCT05390346|BEHAVIORAL|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
58127414|NCT03500848|DRUG|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
58452336|NCT03563820|BEHAVIORAL|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
58452337|NCT01496235|DIETARY_SUPPLEMENT|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
58452338|NCT01496235|DIETARY_SUPPLEMENT|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
58452339|NCT04006951|OTHER|Biological collection|"Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)"
58452340|NCT03583853|DEVICE|real time PCR|real time PCR will be used for determination of expression of autophagy genes
58452341|NCT01769963|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
58452342|NCT05931926|DEVICE|Fluispotter®|The Fluispotter® has been developed for automated extraction, collection and storage of up to 20 dried venous dried blood spot samples of 3-10 μl over the course of up to 20 hours. The system is attached to the patient through a multilumen microcatheter inserted into a peripheral vein in the arm. The Fluispotter will be inserted in both healthy subjects and patients with adrenal insufficiency.
58452343|NCT02510625|PROCEDURE|Anatomic Glenoid Reconstruction|Distal tibia bone graft
58452344|NCT02510625|PROCEDURE|Arthroscopic bankart Repair|Arthroscopic bankart Repair
58452345|NCT06007183|BIOLOGICAL|CHIKV VLP vaccine booster|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
57751557|NCT02037048|DRUG|oxaliplatin|Given IV
57751558|NCT02037048|DRUG|leucovorin calcium|Given IV
57751559|NCT02037048|DRUG|fluorouracil|Given IV
57751560|NCT02037048|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
57751561|NCT02037048|RADIATION|radiation therapy|Undergo radiation therapy
57751562|NCT02037048|DRUG|carboplatin|Given IV
57751563|NCT02037048|DRUG|paclitaxel|Given IV
57751564|NCT05751512|DRUG|MRG003|Administered intravenously
57751565|NCT05751512|DRUG|Cetuximab injection|Administered intravenously
57751566|NCT05751512|DRUG|Methotrexate Injection|Administered intravenously
57960457|NCT00927771|DRUG|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
57960458|NCT00927771|DRUG|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
57960459|NCT06074874|OTHER|Intestinal tissue analysis|Intestinal tissue analysis
57960460|NCT04754100|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
57960461|NCT01073566|DEVICE|Finesse|Finesse Insulin Delivery Patch
57960462|NCT01073566|DEVICE|Pen/Syringe (Usual injection device)|Pen/Syringe
57960463|NCT04872114|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
57751567|NCT00929162|DRUG|ZD4054 Zibotentan|10 mg oral tablets once daily
57751568|NCT00929162|DRUG|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
57751569|NCT00929162|DRUG|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
57751570|NCT00929162|DRUG|Placebo|matching placebo for ZD4054 10 mg
57751571|NCT03758976|DIAGNOSTIC_TEST|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
57751572|NCT01127282|DRUG|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
57751573|NCT01127282|DRUG|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
57960464|NCT02281019|PROCEDURE|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
58127415|NCT03500848|DRUG|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
58127416|NCT03500848|DRUG|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
58127417|NCT03500848|DRUG|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
58127418|NCT05717699|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
58127419|NCT04669210|DRUG|Ruxolitinib|Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.
58127420|NCT04669210|DRUG|Tacrolimus|Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100
58127421|NCT04669210|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 30 mg/kg from day +5 to +35
58127422|NCT01694485|BIOLOGICAL|Abrilumab|Administered by subcutaneous injection.
58127423|NCT01694485|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
58127424|NCT05097872|OTHER|Diet|Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
58127425|NCT06544304|DEVICE|PMMA|PMMA 30%
58127426|NCT02184728|DEVICE|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
58127427|NCT02041702|DIAGNOSTIC_TEST|Non-Diagnostic Cardiac MRI scan|
58127428|NCT03333226|PROCEDURE|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
58127429|NCT03919942|OTHER|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
58127430|NCT03919942|OTHER|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
58127431|NCT03919942|OTHER|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
58127432|NCT05241535|DRUG|MT-7117|oral
58127433|NCT05241535|DRUG|moxifloxacin|oral
58127434|NCT05241535|DRUG|Placebo|oral
58127435|NCT04897802|DRUG|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
58127436|NCT04897802|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
58127437|NCT03129477|PROCEDURE|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
58127438|NCT02968888|OTHER|Strength training|
58127439|NCT02968888|DIETARY_SUPPLEMENT|Milk 1%|
58127440|NCT02968888|DIETARY_SUPPLEMENT|Whey protein concentrate 80|
58127441|NCT02968888|DIETARY_SUPPLEMENT|Native whey|
58127442|NCT01968252|OTHER|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
58127443|NCT00148564|DRUG|olanzapine|treatment with either Olanzapine or Ziprasidone
58127444|NCT00148564|DRUG|Ziprasidone|treatment with either Olanzapine or Ziprasidone
58127445|NCT05209945|PROCEDURE|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
58127446|NCT01924130|OTHER|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
58127447|NCT01924130|BEHAVIORAL|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
58127448|NCT01924130|BEHAVIORAL|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
58127449|NCT01924130|BEHAVIORAL|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
58127450|NCT02206659|DRUG|Telmisartan|
58127451|NCT02206659|DRUG|Placebo|
58127452|NCT05963100|BIOLOGICAL|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
58127453|NCT00425737|BIOLOGICAL|Rotarix|
58127454|NCT05583071|DRUG|Tafasitamab|IV
58127455|NCT05583071|DRUG|Lenalidomide|Oral
58127456|NCT05583071|DRUG|Rituximab|IV
58127457|NCT05583071|DRUG|Methotrexate|IV
58127458|NCT00988624|DRUG|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
58127459|NCT00988624|DRUG|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
58127460|NCT00988624|DRUG|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
58127461|NCT00988624|DRUG|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
58127462|NCT00988624|DRUG|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
58127463|NCT05911373|OTHER|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
58127464|NCT05911373|OTHER|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
58127465|NCT05562310|DRUG|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
58127466|NCT00409019|DRUG|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
58127467|NCT00409019|DRUG|Adefovir|
58127468|NCT00409019|DRUG|Tenofovir|
58127469|NCT00676871|DRUG|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
58127470|NCT00676871|DRUG|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
58127471|NCT00676871|DRUG|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
58127472|NCT00676871|DRUG|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
57751574|NCT05699330|DEVICE|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
58127473|NCT00676871|DRUG|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
58127474|NCT00676871|DRUG|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
57751575|NCT04806295|OTHER|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
58127475|NCT00676871|DRUG|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
58127476|NCT00071136|DRUG|pemetrexed|
58127477|NCT00071136|DRUG|gemcitabine|
58127478|NCT05713500|OTHER|TCI|Temperament and character inventory
58127479|NCT05713500|OTHER|BPI|Brief Pain Inventory
58127480|NCT05713500|OTHER|CPAQ-8|Chronic Pain Acceptance Questionnaire-8
58127481|NCT05713500|OTHER|SF-MPQ|short-form McGill Pain Questionnaire
58127482|NCT05713500|OTHER|King's Parkinson's Disease Pain Scale (KPPS)|King's Parkinson's Disease Pain Scale
57751576|NCT02701985|DRUG|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
57751577|NCT02701985|DRUG|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
58127483|NCT05713500|OTHER|Hospital Anxiety and Depression scale (HAD) questionary|Hospital Anxiety and Depression scale
58127484|NCT05713500|OTHER|PCS|Pain Catastrophism Scale
58127485|NCT05713500|OTHER|ORT|Opioid Risk Tool
58458709|NCT01479101|OTHER|BluePrint 80 gene expression profile|
57751578|NCT03488368|OTHER|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
57751579|NCT01511822|DRUG|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
58127486|NCT05713500|OTHER|Social Support Questionnaire (SSQ6)|Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)
58127487|NCT05713500|OTHER|IPQ-R|Illness Perception Questionnaire Revised
58127488|NCT05713500|OTHER|WCC-R|Ways of Coping Checklist Revised
58127489|NCT00465686|DEVICE|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
58127490|NCT00465686|DEVICE|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
58127491|NCT00514254|OTHER|questionnaire administration|
58127492|NCT00514254|OTHER|study of socioeconomic and demographic variables|
58127493|NCT00514254|PROCEDURE|evaluation of cancer risk factors|
58127494|NCT02188797|BEHAVIORAL|Group MI risk reduction program|
58127495|NCT02276677|DRUG|Oxytocin|Single dose, intranasal
58127496|NCT02276677|DRUG|Placebo|Single dose, intranasal
58127497|NCT04971551|DRUG|Jaktinib Hydrochloride Tablets|Oral on an empty stomach
58127498|NCT00926406|DRUG|lead chelation therapy|Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
58127499|NCT03202836|DRUG|progesterone|vaginal utrogestan
58127500|NCT03202836|DRUG|Tocolytics|tocolysis for 48 hours
58127501|NCT03202836|DRUG|Steroids|antenatal corticosteroids for 48 hours
58127502|NCT06056388|DEVICE|Straumann BLX implant|Implant system with a deep fixture thread depth.
58127503|NCT06056388|DEVICE|Straumann BLT implant|Implant system with a regular fixture thread depth.
58127504|NCT00653536|DEVICE|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
58127505|NCT01469546|DRUG|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST \[Response Evaluation Criteria In Solid Tumors\] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
58127506|NCT02148302|DEVICE|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
58127507|NCT03150836|DRUG|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
58127508|NCT03150836|DRUG|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
58127509|NCT03150836|RADIATION|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
58127510|NCT05272358|OTHER|NETSARC network|MDTB and/or surgery in NETSARC network
58127511|NCT02129023|DEVICE|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
58127512|NCT00394056|DRUG|Vestipitant|NK1 receptor antagonist
58127513|NCT00394056|DRUG|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
58127514|NCT00394056|OTHER|Placebo|Placebo
58127515|NCT02497456|BEHAVIORAL|Follow-up counselling|
58127516|NCT06170268|OTHER|Routine Care Documentation|Routine Care Documentation
58127517|NCT05278806|OTHER|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
58127518|NCT05278806|OTHER|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
58127519|NCT00648518|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
58127520|NCT00648518|DRUG|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
58127521|NCT01513551|BIOLOGICAL|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
58127522|NCT01513551|BIOLOGICAL|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
58127523|NCT01513551|BIOLOGICAL|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
58127524|NCT04278469|DRUG|Chemotherapy Drugs, Cancer|Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
58127525|NCT03318692|PROCEDURE|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
58127526|NCT03318692|PROCEDURE|CT|CT of operated area is performed within 7 days of surgery
58127527|NCT02832856|BEHAVIORAL|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
58127528|NCT02832856|BEHAVIORAL|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
57751580|NCT01511822|DRUG|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
58127529|NCT02744352|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
58127530|NCT02744352|DRUG|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
58127531|NCT03735446|DRUG|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
58127532|NCT03735446|DRUG|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
58127533|NCT03735446|DRUG|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
57751581|NCT01511822|DRUG|placebo|
57751582|NCT02673398|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
57751583|NCT02673398|OTHER|Laboratory Biomarker Analysis|Correlative studies
57751584|NCT02673398|DRUG|Neratinib|Given PO
57751585|NCT02673398|OTHER|Pharmacological Study|Correlative studies
58127534|NCT03735446|DRUG|Cytarabine|Standard chemotherapy (anti-metabolite)
58127535|NCT04051970|DRUG|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
58127536|NCT00082563|DRUG|Azithromycin/Chloroquine|
58127537|NCT00082563|DRUG|Chloroquine|
58127538|NCT04826510|DRUG|Perospirone hydrochloride tablets|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
58127539|NCT04826510|DRUG|Lithium carbonate + perospirone hydrochloride|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
58452346|NCT06007183|BIOLOGICAL|Placebo booster|Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
57751586|NCT05592054|PROCEDURE|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
57751587|NCT05592054|PROCEDURE|Standard guide catheter|MT procedure with standard guide catheter
57751588|NCT02335073|OTHER|Venous blood|
57751589|NCT02616887|RADIATION|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
57751590|NCT03619460|PROCEDURE|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
57751591|NCT03619460|PROCEDURE|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
57751592|NCT01349920|DRUG|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
57751593|NCT03651050|BEHAVIORAL|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
57751594|NCT03651050|BEHAVIORAL|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
58314858|NCT02538991|DEVICE|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
57751595|NCT02470494|DEVICE|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
57751596|NCT03963154|BIOLOGICAL|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
57751597|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
57751598|NCT01534325|DEVICE|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
58127540|NCT04826510|DRUG|Lithium Carbonate Pill|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
58127541|NCT01868841|DRUG|AdreView|10 millicurie of AdreView (123I-mIBG)
58127542|NCT01868841|OTHER|Single Photon Emission Computed Tomography|
58314859|NCT00053326|DRUG|fenretinide|Given orally
58127543|NCT00689013|OTHER|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
58314860|NCT00053326|OTHER|pharmacological study|Optional correlative studies
58452347|NCT00359996|BEHAVIORAL|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
58452348|NCT00359996|OTHER|No additional educational sessions|
58452349|NCT02343393|DRUG|Hydralazine|
58452350|NCT02343393|DRUG|Isosorbide Dinitrate|
58452351|NCT03326778|PROCEDURE|AVR and CABG|Combined AVR with CABG
58314861|NCT03972540|BEHAVIORAL|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
58452352|NCT01858792|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
58314862|NCT02335944|DRUG|Capmatinib|"In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
58314863|NCT02335944|DRUG|Nazartinib|"In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
58314864|NCT03806816|DIETARY_SUPPLEMENT|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
58314865|NCT03806816|OTHER|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
58314866|NCT00305526|DEVICE|Contak Renewal (CRT-D)|
58314867|NCT02424695|DRUG|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
58314868|NCT02424695|DRUG|Placebo|
58314869|NCT01720966|PROCEDURE|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
58314870|NCT05269329|DRUG|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
58314871|NCT05269329|DRUG|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
58314872|NCT05269329|DRUG|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
58314873|NCT05269329|DRUG|Placebo|1, 2, or 4 tablets twice a day
58314874|NCT03520530|DEVICE|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
58314875|NCT01214278|DRUG|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
58314876|NCT01214278|DRUG|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
58314877|NCT01214278|DRUG|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
58314878|NCT01214278|DRUG|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
58314879|NCT03733236|DEVICE|ISS Active Stimulation|ISS SPG stimulation and standard of care
58314880|NCT05266768|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
58314881|NCT01813279|OTHER|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
58314882|NCT01836120|DRUG|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
58314883|NCT01836120|DRUG|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
58314884|NCT03348995|DEVICE|Bridge-Enhanced ACL Restoration (BEAR)|In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
58314885|NCT03548779|BEHAVIORAL|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
58314886|NCT03548779|DIAGNOSTIC_TEST|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
58452353|NCT01858792|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
58452354|NCT01858792|OTHER|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
58452355|NCT02489071|BEHAVIORAL|Brain Training Program|
58452356|NCT02489071|BEHAVIORAL|Brain Health Program|
58452357|NCT05876507|BEHAVIORAL|Progressive relaxation exercise|Progressive relaxation exercises will take 25-30 minutes of patients daily.
58452358|NCT05482828|DRUG|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
58452359|NCT05482828|DRUG|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
58452360|NCT00043043|DRUG|celecoxib|
58452361|NCT01881516|DEVICE|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
58452362|NCT01881516|DEVICE|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
58452363|NCT01599000|DRUG|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
58127544|NCT00689013|OTHER|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
58127545|NCT00689013|OTHER|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
58127546|NCT04450745|BEHAVIORAL|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
58127547|NCT04450745|BEHAVIORAL|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
58127548|NCT05647486|OTHER|30-day postoperative outcome|The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
58127549|NCT01849042|DRUG|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
58127550|NCT01849042|DRUG|donepezil|
58127551|NCT02745002|DEVICE|navigated bronchoscopy|
58127552|NCT01141465|DRUG|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
58127553|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
58127554|NCT01141465|DRUG|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
58127555|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
58127556|NCT01141465|DRUG|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
58127557|NCT01141465|DRUG|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
58452364|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
58452365|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
58452366|NCT00390767|BIOLOGICAL|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
58452367|NCT01432405|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
57960465|NCT02281019|DEVICE|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
57960466|NCT01019447|OTHER|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
58127558|NCT03294863|DEVICE|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
58127559|NCT03294863|OTHER|Standard of Care|Without the embrace Scar Therapy Device
58127560|NCT00181922|DRUG|ziprasidone (Geodon)|
58127561|NCT05817916|PROCEDURE|ESP block|ESP block: ultrasound guided erector spina plane block
58127562|NCT05817916|PROCEDURE|LP block|LP block: ultrasound guided lumbar plexus block
58127563|NCT02688556|DRUG|cyclosporine|
58127564|NCT02688556|DRUG|vehicle of OTX-101|
58127565|NCT05437965|DRUG|glucocorticoid and immunosuppressants|This study will include patients with isolated coronary arteritis, whose condition could not be controlled by current clinical treatment. After Multiple Disciplinary Team consultation, these patients may be given glucocorticoid and immunosuppressants.
58127566|NCT00207337|DEVICE|Exhale Drug-Eluting Stent|
58127567|NCT04351009|PROCEDURE|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
58127568|NCT00919308|OTHER|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
58127569|NCT00005939|RADIATION|brachytherapy|
58127570|NCT00005939|RADIATION|phosphorus P32|
58127571|NCT00725439|DRUG|Talarozole|Oral Dose 1.0 mg once daily
57960467|NCT01019447|OTHER|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
57960468|NCT00763139|DRUG|Pioglitazone|45 mg by mouth once a day for 8 weeks
57960469|NCT00763139|DRUG|Placebo|By mouth once a day for 8 weeks
57960470|NCT03884582|DEVICE|Cova Monitoring System 3|Healthy Volunteers
57960471|NCT05355142|BEHAVIORAL|PM+|"1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
57751599|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
57751600|NCT04284345|PROCEDURE|Saline Pd/Pa|"Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement."
57751601|NCT05085587|DRUG|Test|2 inhalations of Test and Reference product in each study period
58127572|NCT01205607|DEVICE|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
58127573|NCT01205607|DEVICE|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
58127574|NCT01787136|DRUG|Dextromethorphan|added on therapy
57751602|NCT05085587|DRUG|Reference|2 inhalations of Test and Reference product in each study period
57751603|NCT05969457|DRUG|Naropeine|Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
58127575|NCT03702621|DRUG|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
58127576|NCT03702621|DRUG|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
58127577|NCT05529511|OTHER|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
58127578|NCT05529511|OTHER|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
58127579|NCT01695109|DRUG|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
58127580|NCT01695109|DRUG|Placebo|0.9% NaCl, 0.2 ml
58452368|NCT01432405|DRUG|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
58452369|NCT02524171|BEHAVIORAL|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
58452370|NCT04632771|OTHER|N/A (observational study)|N/A (observational study)
57751604|NCT05969457|OTHER|questionnaires|Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4
57751605|NCT05969457|OTHER|Placebo|Injection of 20 mL of NaCl
57751606|NCT02552628|DEVICE|"Medtronic, Activa® PC on"|
57751607|NCT02552628|DEVICE|"Medtronic, Activa® PC off"|
57751608|NCT02679040|PROCEDURE|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
57751609|NCT02679040|DRUG|Chemotherapy|Chemotherapy treatment
57751610|NCT02679040|RADIATION|Radiation therapy|Radiation therapy
57751611|NCT05735574|OTHER|IPG infections|Infected IPGs
57751612|NCT00545961|DRUG|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
57751613|NCT00545961|DRUG|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
57751614|NCT02340741|PROCEDURE|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
58127581|NCT06496763|DEVICE|Vision-700|OCT machines used for diagnostic purposes
58452371|NCT04657874|OTHER|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
57751615|NCT02340741|PROCEDURE|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
57751616|NCT02340741|PROCEDURE|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
57751617|NCT01155154|DRUG|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
58127582|NCT05832463|DIETARY_SUPPLEMENT|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
58452372|NCT04657874|OTHER|Placebo|Oral tablet without the active principle
57751618|NCT01155154|DRUG|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
58127583|NCT05832463|DIETARY_SUPPLEMENT|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
58127584|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
58127585|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
58127586|NCT05228314|OTHER|Squalene based adjuvant|Squalene based adjuvant
58127587|NCT05228314|OTHER|CpG/alum adjuvant|CpG/alum adjuvant
58127588|NCT03961464|DRUG|d-cycloserine|Single dose
58127589|NCT03961464|DRUG|Placebo|Single dose
58452373|NCT04011657|OTHER|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
58452374|NCT04335617|DRUG|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
58452375|NCT04335617|OTHER|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
57751619|NCT01155154|DRUG|placebo|Two placebo capsules every 6 hours for 7 days
57751620|NCT05857787|DEVICE|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
57751621|NCT05857787|DEVICE|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
58127590|NCT01179919|DRUG|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
58127591|NCT04465188|PROCEDURE|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
58127592|NCT05754047|DIAGNOSTIC_TEST|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
58127593|NCT02447900|DEVICE|BioXmark|
58127594|NCT00039611|DRUG|FOLFOX regimen|
58127595|NCT00039611|DRUG|fluorouracil|
57751622|NCT02612987|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|
57751623|NCT02073695|PROCEDURE|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
57751624|NCT02073695|DEVICE|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
58127596|NCT00039611|DRUG|leucovorin calcium|
58452376|NCT02864563|PROCEDURE|Blood sampling|"* Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
58452377|NCT04995575|PROCEDURE|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
58452378|NCT00643968|DRUG|EFV+TDF|
58452379|NCT00643968|DRUG|EFV+3TC+TDF|
58452380|NCT00972101|RADIATION|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
58452381|NCT00972101|DRUG|Melphalan|140 mg/m\^2 by vein over 30 minutes as a single dose on Day -8
58452382|NCT00972101|DRUG|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
58452383|NCT00972101|DRUG|Fludarabine|40 mg/m\^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
57751625|NCT02073695|OTHER|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
57751626|NCT02073695|OTHER|Functional outcome forms filled in|
57751627|NCT02073695|OTHER|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
57751628|NCT02073695|OTHER|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
57960472|NCT06301178|DRUG|Cholecalciferol|Vitamin D has various critical regulatory roles, including inflammatory control, cellular proliferation and differentiation, and wound healing regulation.
58127597|NCT00039611|DRUG|oxaliplatin|
58127598|NCT04958980|BEHAVIORAL|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
58127599|NCT04349605|BEHAVIORAL|Meditation|Meditation involves guided breathing and mindfulness training.
58127600|NCT04349605|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
58127601|NCT00322933|PROCEDURE|renal replacement therapy (intermittent or continuous)|
58452384|NCT00972101|DRUG|Rituximab|"Regimen 1:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
58452385|NCT00972101|DRUG|Etoposide|60 mg/m\^2 by vein over 1-2 hours as a single dose on Day -3.
58452386|NCT00972101|DRUG|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
57751629|NCT03850652|DIETARY_SUPPLEMENT|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
57751630|NCT03850652|DIETARY_SUPPLEMENT|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
57751631|NCT03394521|OTHER|Routine clinical practice|This is an observational study
57751632|NCT06119984|BEHAVIORAL|Community mobilization|The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
57751633|NCT01969110|DIETARY_SUPPLEMENT|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
57751634|NCT01393782|DRUG|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
57751635|NCT02660723|OTHER|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
57751636|NCT05025657|BEHAVIORAL|ALLY|ALLY is a universal, school-based prevention program that takes place during the school day with individual students over 6 weeks.
57751637|NCT04613908|DEVICE|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
57751638|NCT04613908|OTHER|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance."
57751639|NCT04613908|OTHER|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
57751640|NCT05808738|BEHAVIORAL|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
57751641|NCT00559299|DRUG|GSK163090|
57751642|NCT03281473|OTHER|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
57751643|NCT03281473|OTHER|Strategy 2|PEEP titration according to chest wall elastance measurement
57751644|NCT01089231|DIETARY_SUPPLEMENT|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
57751645|NCT01089231|DIETARY_SUPPLEMENT|Placebo (corn oil)|corn oil (6 capsules per day)
57751646|NCT04000152|DIAGNOSTIC_TEST|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
57751647|NCT04000152|OTHER|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
57751648|NCT05152732|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
57751649|NCT04920864|DEVICE|rTMS|Repetitive transcranial magnetic stimulation
57751650|NCT00778583|DRUG|Nitrofurantoin 100 mg capsules|
57751651|NCT03513757|DRUG|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
57751652|NCT03513757|DRUG|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
57751653|NCT03513757|DRUG|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
57751654|NCT03513757|DRUG|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
57751655|NCT03513757|DRUG|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
57751656|NCT03513757|DRUG|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
57751657|NCT05307770|DIETARY_SUPPLEMENT|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
57751658|NCT05307770|DIETARY_SUPPLEMENT|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
57751659|NCT05180708|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% rapamycin anhydrous gel
58127602|NCT03319420|DRUG|LO2A eye drops|Sodium hyaluronate
57751660|NCT05180708|DRUG|Vehicle|Matching vehicle (QTORIN anyhydrous gel)
57751661|NCT02418247|DRUG|I131|
58127603|NCT03319420|DRUG|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
57751662|NCT02418247|DRUG|I123|
57751663|NCT02944084|DIETARY_SUPPLEMENT|Rice bran extract|
57751664|NCT02944084|DIETARY_SUPPLEMENT|Porridge in water|
57751665|NCT02944084|DIETARY_SUPPLEMENT|Porridge in milk|
57751666|NCT05504226|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
57751667|NCT05504226|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
58452387|NCT00972101|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
58452388|NCT00972101|DRUG|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
58452389|NCT00972101|PROCEDURE|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
58452390|NCT00972101|DRUG|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is \> 2.5 x 10e\^9/L.
58452391|NCT00972101|PROCEDURE|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e\^5 T cells/kg on Day 14+.
57751668|NCT04160325|DIETARY_SUPPLEMENT|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
57751669|NCT04160325|DRUG|azathioprine|azathioprine
57751670|NCT04160325|OTHER|normal diet|normal diet
57751671|NCT04563468|PROCEDURE|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
58452392|NCT04221724|OTHER|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
58452393|NCT01165541|DRUG|Mirtazapine|mirtazapine (7.5-45mg)
58452394|NCT01165541|DRUG|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
57751672|NCT04563468|PROCEDURE|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
57751673|NCT02647606|PROCEDURE|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
58127604|NCT02991625|OTHER|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
58127605|NCT02991625|OTHER|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
58127606|NCT02991625|OTHER|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
58127607|NCT03082781|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
58127608|NCT03082781|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
58452395|NCT01749969|DRUG|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
58452396|NCT01749969|DRUG|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
58452397|NCT01749969|DRUG|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
58452398|NCT02339311|OTHER|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
58452399|NCT03558919|DRUG|Mirabegron 25mg|
57751674|NCT02647606|DEVICE|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
57751675|NCT02647606|DEVICE|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
57751676|NCT02647606|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
57751677|NCT03504163|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
57751678|NCT03504163|DRUG|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
57751679|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
57751680|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
57751681|NCT01787448|DRUG|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
57751682|NCT01787448|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
57751683|NCT05670379|COMBINATION_PRODUCT|Exenatide Implant|Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
57751684|NCT05670379|DRUG|Bydureon BCise (exenatide extended release)|glucagon-like peptide-1 (GLP-1) receptor agonist
57751685|NCT05670379|DRUG|Semaglutide, 1.0 mg/mL|glucagon-like peptide-1 (GLP-1) receptor agonist
57751686|NCT04989127|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
57751687|NCT04989127|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
57751688|NCT04989127|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
57751689|NCT04989127|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
57751690|NCT04989127|DRUG|Analgesic|Analgesics are prescribed for the patients.
58452400|NCT03558919|DRUG|Solifenacin Succinate 5 MG|
58452401|NCT04644211|DRUG|Ruxolitinib|Pill taken by mouth.
58452402|NCT03264365|BEHAVIORAL|Intervention|"Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed"
58452403|NCT05154084|BEHAVIORAL|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
58452404|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
58452405|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
58452406|NCT00603330|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
57751691|NCT04989127|DRUG|Antibiotic|Patients with penicillin allergy
57751692|NCT04610931|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
57960473|NCT02956382|DRUG|Ibrutinib|Ibrutinib is dispensed as a capsule.
57960474|NCT02956382|DRUG|Venetoclax|Venetoclax is dispensed as a tablet.
57960475|NCT04354350|DRUG|Ramipril|Ramipril dispensing claim is used as the reference
58452407|NCT03145311|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|
57960476|NCT04354350|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
58127609|NCT05512000|BEHAVIORAL|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
58452408|NCT05626101|DRUG|BCG|Intravsical induction and maintenance BCG injections.
58452409|NCT05626101|DRUG|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
58452410|NCT01793623|OTHER|atrial tissue|retrieval of discarded atrial tissue
58452411|NCT00481702|DRUG|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
58452412|NCT00481702|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
58452413|NCT00481702|DRUG|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
58452414|NCT06473415|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography using the Sleep-Profiler device
58452415|NCT05887921|PROCEDURE|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
58452416|NCT05724992|GENETIC|Saliva swab testing|41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
58452417|NCT06184607|OTHER|Distance from contact point to attachment level|A periodontal probe will be used to measure distance between contact point to attachment level in maxillary central incisors
58452418|NCT04839016|DRUG|SHR-1314|SHR-1314
58452419|NCT04839016|DRUG|Placebo|Placebo
58452420|NCT00004092|BIOLOGICAL|filgrastim|Given IV or subcutaneously
58452421|NCT00004092|DRUG|carboplatin|Given IV
58452422|NCT00004092|DRUG|cyclophosphamide|Given IV
58452423|NCT00004092|DRUG|doxorubicin hydrochloride|Given IV
58452424|NCT00004092|DRUG|paclitaxel|Given IV
58452425|NCT00004092|DRUG|thiotepa|Given IV
58452426|NCT00004092|PROCEDURE|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
58452427|NCT01966822|DRUG|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
58452428|NCT01966822|DRUG|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
57751693|NCT04610931|BEHAVIORAL|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
57751694|NCT03432923|DRUG|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
57751695|NCT03432923|DRUG|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
57751696|NCT03189784|OTHER|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
57751697|NCT04992351|PROCEDURE|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
57751698|NCT01972529|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
57751699|NCT01972529|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
57751700|NCT01972529|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
57751701|NCT01972529|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
57751702|NCT05700084|DRUG|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
57751703|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
57960477|NCT03290495|DRUG|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
57960478|NCT03290495|DRUG|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
57960479|NCT04852120|OTHER|No intervention|Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
57751704|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
57960480|NCT05162482|BIOLOGICAL|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
57960481|NCT05162482|BIOLOGICAL|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
57960482|NCT05162482|BIOLOGICAL|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
57960483|NCT03868683|OTHER|Glucose Reference 1|30 g of glucose dissolved in 250 ml of water
57960484|NCT03868683|OTHER|Glucose Reference 2|30 g of glucose dissolved in 250 ml of water
57960485|NCT03868683|OTHER|Glucose reference 3|30 g of glucose dissolved in 250 ml of water
57960486|NCT03868683|OTHER|Sucrose|30 g of Sucrose dissolved in 250 ml of water
57960487|NCT03868683|OTHER|Regular Bake beans in tomato sauce|Bake beans in tomato sauce containing 14 g of sugar
57960488|NCT03868683|OTHER|Bake beans in tomato sauce, reduced sugar|Bake beans in tomato sauce containing 12.2 g of sugar
57960489|NCT03868683|OTHER|Bake beans in tomato sauce, low GI|Bake beans in tomato sauce containing 7.2 g of sugar
57960490|NCT03305107|OTHER|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
57960491|NCT03305107|OTHER|Exercise and Water|High intensity interval exercise Water
57960492|NCT03305107|OTHER|Sitting and Chocolate Milk|Sitting Chocolate Milk
57960493|NCT03305107|OTHER|Sitting and Water|Sitting Water
57960494|NCT00986700|DIETARY_SUPPLEMENT|late night meal|Three different kinds of late night meal each for 2 days.
57960495|NCT05847894|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
57960496|NCT05847894|DIAGNOSTIC_TEST|Pulmonary Examination|Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
57960497|NCT02296398|DRUG|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
57960498|NCT05241080|OTHER|Survey|It is a survey based on questionnaire
57960499|NCT04989101|DRUG|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
57960500|NCT04378608|DRUG|OBV/PTV/r) ± ribavirin (RBV)|
57960501|NCT04916405|OTHER|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
57960502|NCT04201925|PROCEDURE|upper blepharoplasty|excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
58127610|NCT05512000|BEHAVIORAL|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
58127611|NCT05512000|BEHAVIORAL|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
58127612|NCT05512000|BEHAVIORAL|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
58127613|NCT05512000|BEHAVIORAL|No teaching control|The words in this set are not taught, only assessed.
58127614|NCT04351178|BEHAVIORAL|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
58127615|NCT04351178|BEHAVIORAL|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
58452429|NCT04648813|DRUG|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
58452430|NCT04648813|DRUG|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
58452431|NCT06054100|DRUG|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
58452432|NCT05003466|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|"2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose.~Administer as an intramuscular injection into the lateral deltoid of the upper arm."
58452433|NCT05003466|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
58452434|NCT00880620|DRUG|Placebo|Placebo
58452435|NCT00880620|DRUG|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
57751705|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
57751706|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
57751707|NCT05700084|DRUG|Capecitabine|1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
57751708|NCT05700084|DRUG|Utidelone Capsule (Part 3)|Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.
57960503|NCT01720537|BIOLOGICAL|PF-05335810 Dose A|Single SC Injection
57960504|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Subcutaneous Injection(s)
57960505|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
57960506|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Intravenous Infusion
57960507|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
57960508|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Subcutaneous Injection(s)
57960509|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Intravenous Infusion
57960510|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Subcutaneous Injection(s)
57960511|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
57960512|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Intravenous Infusion
57960513|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
57960514|NCT01720537|BIOLOGICAL|PF-04950615|Single Subcutaneous Injection(s)
57960515|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Subcutaneous Injection(s)
57960516|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
57960517|NCT01720537|BIOLOGICAL|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
57960518|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Intravenous Infusion
57960519|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
57960520|NCT01594021|DRUG|Gelatin 500 mL|intravenous administration
57960521|NCT01594021|DRUG|Gelatin 50 mL|intravenous administration
57960522|NCT02712515|PROCEDURE|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
58452436|NCT00880620|DRUG|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
58452437|NCT00880620|DRUG|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
58452438|NCT00880620|DRUG|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
58452439|NCT02401347|DRUG|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
58452440|NCT02682147|DRUG|Hypoxia administration study group|scan completed after 5 minutes of breathing in hypoxic air
58452441|NCT02682147|DRUG|Hyperoxia administration study group|scan completed after up to 15 minutes of breathing in hyperoxic air
58452442|NCT02682147|DRUG|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
58452443|NCT00257699|DRUG|Metronidazole placebo|
57751709|NCT03172702|DRUG|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
57751710|NCT00162695|DRUG|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
57751711|NCT02844699|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
57751712|NCT02844699|DRUG|Placebo|5% infusion solution of dextrose (glucose)
57751713|NCT03484598|DEVICE|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
57751714|NCT03440749|OTHER|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
57751715|NCT05189626|OTHER|Muscle energy technique|Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
57751716|NCT05189626|OTHER|Kaltonborn mobilizations|Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
57751717|NCT06296095|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
57751718|NCT02836223|DEVICE|Interdental cleaning device|Water Flosser
57751719|NCT02836223|DEVICE|Manual Tooth brush|Control
57751720|NCT01881139|BEHAVIORAL|exercise training|
57751721|NCT00409682|BIOLOGICAL|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
57751722|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
57751723|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
57751724|NCT06384248|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
57751725|NCT01494584|DRUG|ezogabine/retigabine|ezogabine dose escalation
57751726|NCT02877511|DRUG|BAY987517|Applied liberally to the skin (Formulation: Y73-161
58127616|NCT01045590|DRUG|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
57751727|NCT02877511|DRUG|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
57751728|NCT00441090|DRUG|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
57751729|NCT00441090|DRUG|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
58452444|NCT00257699|DRUG|ciprofloxacin placebo|
58452445|NCT00257699|DRUG|ciprofloxacin|500 mg bid po
57751730|NCT05782257|DIETARY_SUPPLEMENT|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
57751731|NCT05782257|OTHER|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
57751732|NCT03804710|DRUG|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
57751733|NCT03804710|DRUG|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
58452446|NCT00257699|DRUG|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
58452447|NCT04117204|OTHER|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
57751734|NCT03804710|OTHER|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
57751735|NCT05011968|DIETARY_SUPPLEMENT|Lettuce with not biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
58452448|NCT04818619|DIAGNOSTIC_TEST|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
58452449|NCT02199366|PROCEDURE|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
58452450|NCT00175513|DRUG|Valacyclovir (Valtrex)|
58452451|NCT05100615|PROCEDURE|surgery|applying the graft inside bony defect after surgery
57751736|NCT05011968|DIETARY_SUPPLEMENT|Lettuce biofortificated with Iodine|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
58127617|NCT01045590|DRUG|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
58127618|NCT05368623|DIAGNOSTIC_TEST|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
58452452|NCT03536585|DEVICE|Vulvovaginal treatment|"* Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
57960523|NCT02712515|DEVICE|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
57960524|NCT02712515|DEVICE|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
58452453|NCT03536585|DEVICE|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
58452454|NCT00584012|DRUG|Lovastatin|Given PO
57751737|NCT05952635|PROCEDURE|Tip bendable suction ureteral access sheath|Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
57751738|NCT04803110|PROCEDURE|Dental implant placement after tooth extraction|Immediate implant placement after partial or complete tooth extraction.
57960525|NCT00362011|BEHAVIORAL|Salba diet|
57751739|NCT03166943|PROCEDURE|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:"
57751740|NCT03166943|PROCEDURE|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities."
57751741|NCT01872533|OTHER|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at \~ 15% O2 (ca. 2400 m elevation).
57751742|NCT05597501|BEHAVIORAL|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy
57751743|NCT00276692|DRUG|irinotecan hydrochloride|
57751744|NCT04322123|DRUG|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
57751745|NCT04322123|DRUG|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
57751746|NCT04130568|DIAGNOSTIC_TEST|INO survey|Garvin's Learning organisation tool
57751747|NCT01113502|DRUG|Eltrombopag|Oral formulation taken daily
57751748|NCT04667312|DRUG|Durvalumab|Durvalumab
57751749|NCT06571448|DRUG|SR750 tablet|SR750 high dose BID orally for 6 weeks
57751750|NCT06571448|DRUG|SR750 tablet|SR750 low dose BID orally for 6 weeks
57960526|NCT05055193|DRUG|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
57960527|NCT00345670|BIOLOGICAL|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
57960528|NCT00345670|BIOLOGICAL|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
57960529|NCT00345670|BIOLOGICAL|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
57960530|NCT05877482|OTHER|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
57960531|NCT05877482|OTHER|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
57960532|NCT04769011|DIAGNOSTIC_TEST|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
57960533|NCT04769011|DIAGNOSTIC_TEST|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
57960534|NCT04769011|DIAGNOSTIC_TEST|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
58127619|NCT05368623|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
58127620|NCT05368623|DRUG|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
58127621|NCT04324008|DEVICE|Constic|Flowable resin composite
58127622|NCT04324008|DEVICE|G-ænial Universal Flo|Flowable resin composite
58127623|NCT04324008|DEVICE|Tetric N-Flow (self-etch)|Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
58127624|NCT04324008|DEVICE|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Tetric N-Bond Universal, etch\&rinse mode)
58127625|NCT04390854|BIOLOGICAL|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
58127626|NCT04390854|BIOLOGICAL|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
58127627|NCT03868709|DRUG|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
58452455|NCT00584012|DRUG|Docetaxel|Given IV
58452456|NCT04457765|DRUG|Povidone-Iodine (PVP-I)|1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
58452457|NCT01854359|DRUG|Idebenone|
57751751|NCT06571448|DRUG|Placebo|Placebo
57751752|NCT03070496|BIOLOGICAL|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
57751753|NCT03070496|PROCEDURE|ECG|ECG will be performed at 6 months after myocardial infarction
57751754|NCT03070496|DEVICE|MRI|MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
57751755|NCT03070496|OTHER|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
57751756|NCT03399643|DRUG|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
57751757|NCT04042857|DEVICE|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
57751758|NCT05114655|OTHER|Herbaceous Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
57751759|NCT05114655|OTHER|Citrus Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
57751760|NCT05114655|OTHER|Inert Oil|Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
57751761|NCT00444808|DRUG|Intranasal calcitonin|
57960535|NCT04769011|DIAGNOSTIC_TEST|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
57960536|NCT00244023|DRUG|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
57960537|NCT00244023|DRUG|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
57960538|NCT00244023|OTHER|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
57960539|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (8 mg/m^2)|
57960540|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2)|
57960541|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
57960542|NCT01302808|COMBINATION_PRODUCT|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
58127628|NCT03868709|DRUG|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
58127629|NCT06124196|DEVICE|wearable technology|Three wearable devices
58127630|NCT05346055|BEHAVIORAL|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
58452458|NCT03667755|PROCEDURE|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
58452459|NCT05668832|DIETARY_SUPPLEMENT|UVB-exposed button mushrooms|Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
58452460|NCT05792813|DRUG|LGYY|LGYY = Linggui Yangyuan paste
58452461|NCT05792813|DRUG|LGYY mimetic|LGYY = Linggui Yangyuan paste
57751762|NCT04584034|DRUG|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
57751763|NCT04584034|DRUG|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
57751764|NCT04851548|PROCEDURE|hyaluronic acid|after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
57751765|NCT04115111|DRUG|Durvalumab|Durvalumab in monotherapy as second line treatment
57751766|NCT03883815|OTHER|Active Video Games Therapy|"Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills."
57751767|NCT03726255|PROCEDURE|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
57751768|NCT03346811|DRUG|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
58127631|NCT02788422|OTHER|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
57751769|NCT05389579|DEVICE|electric blanket|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
57751770|NCT01078857|OTHER|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
58127632|NCT02788422|OTHER|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
57751771|NCT03802123|DRUG|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
57751772|NCT04110405|BEHAVIORAL|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
57751773|NCT04110405|BEHAVIORAL|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
57751774|NCT05256108|DRUG|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
57751775|NCT05256108|DRUG|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
57751776|NCT05256108|DRUG|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
57751777|NCT05256108|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
57751778|NCT05256108|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
58127633|NCT06340464|OTHER|GNRI, PNI, MNA|Nutrition scoring systems
58127634|NCT02535507|DRUG|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
58452462|NCT05792813|DRUG|WZYZ|WZYZ= Wuzi Yanzong oral solution
58452463|NCT05792813|DRUG|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
58127635|NCT02066675|DRUG|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
58452464|NCT04889508|BEHAVIORAL|Socio-emotional mental training|Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
58127636|NCT04195295|PROCEDURE|Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane|"* In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane"
58127637|NCT04195295|PROCEDURE|Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material|Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.
58127638|NCT04195295|PROCEDURE|Open flap debridement procedure in intrabony defects.|full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
58314887|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
57751779|NCT06219564|PROCEDURE|Peripartum total abdominal hysterectomy (p-TAH)|"Peripartum total abdominal hysterectomy (cesarean hysterectomy) refers to a surgical procedure in which a woman undergoes both a cesarean section (C-section) and a hysterectomy simultaneously.~Placenta Accreta, Increta, or Percreta: These are conditions where the placenta attaches too deeply to the uterine wall. In cases of severe attachment, it may be difficult to remove the placenta without causing excessive bleeding, and a hysterectomy may be required.~Cesarean hysterectomy is a major surgical procedure involving significant medical expertise and coordination among healthcare professionals, including obstetricians and surgeons. The decision to perform a cesarean hysterectomy is usually made in emergency situations to address life-threatening complications."
57751780|NCT06219564|PROCEDURE|Cesarean Section (C/S)|"A cesarean section (C/S) involves making an incision in the abdominal wall and uterus to deliver a baby when a vaginal delivery is not feasible or safe.~Total placenta previa refers to a condition where the placenta completely covers the opening of the cervix in the uterus. This condition can pose significant risks during pregnancy and childbirth, and it often necessitates a planned cesarean section (C/S) for delivery."
57751781|NCT06219564|OTHER|Neonatal mortality|"Neonatal mortality refers to the death of a newborn within the first 28 days of life. This period is divided into early neonatal mortality, which covers the first seven days of life, and late neonatal mortality, which extends from the eighth to the 28th day. Neonatal mortality is a critical measure of the health and well-being of infants and is often used to assess a population's overall health and healthcare systems.~To reduce neonatal mortality, efforts are made to improve maternal healthcare, access to prenatal care, skilled attendance during childbirth, and the availability of neonatal healthcare services. Tracking and addressing factors contributing to neonatal mortality are crucial for improving the chances of survival of newborns and overall health outcomes."
57751782|NCT03868865|BEHAVIORAL|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
57751783|NCT05604924|OTHER|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
57751784|NCT00243542|DRUG|ACZONE Gel, 5%|
57751785|NCT00243542|DRUG|Vehicle|
57751786|NCT00282893|PROCEDURE|transluminal ballooning|
57751787|NCT00282893|OTHER|currently existing therapies for the treatment of vasospasm|
57751788|NCT03659448|DRUG|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
57751789|NCT04123678|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
57751790|NCT05675046|DEVICE|Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
57960543|NCT04993378|DEVICE|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
58127639|NCT06428448|COMBINATION_PRODUCT|REMEDY Spectrum IM Spacer Nail|"The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.~The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools."
58127640|NCT00431548|DRUG|100% O2|
58127641|NCT04978025|DRUG|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
58127642|NCT04978025|DRUG|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
58127643|NCT03455166|DIAGNOSTIC_TEST|Serum Markers|Serum Markers
58127644|NCT02850068|DEVICE|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
58127645|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
58127646|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
58127647|NCT00818623|DRUG|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
58127648|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
58127649|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
58127650|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
58127651|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
58127652|NCT00818623|DRUG|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
58127653|NCT01082653|BIOLOGICAL|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
58127654|NCT00311961|DRUG|Intravenous prednisolone|
58452465|NCT04889508|BEHAVIORAL|Mindfulness-based mental training|Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
58127655|NCT00311961|DRUG|Oral prednisolone|
58127656|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
58127657|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
57751791|NCT02313857|BIOLOGICAL|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
58127658|NCT05101174|BEHAVIORAL|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
58127659|NCT05101174|BEHAVIORAL|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
58127660|NCT01734772|DRUG|dabigatran etexilate|multiple doses of dabigatran
58127661|NCT01734772|DRUG|dabigatran etexilate|medium dose dabigatran
57751792|NCT03295318|BIOLOGICAL|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
58127662|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
58127663|NCT01734772|DRUG|ticagrelor|multiple doses of ticagrelor
58127664|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
58127665|NCT01734772|DRUG|dabigatran etexilate|single dose of dabigatran
58452466|NCT00940940|BIOLOGICAL|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
58452467|NCT00940940|BIOLOGICAL|Placebo vaccine|0.65 mL subcutaneous
58452468|NCT04332107|DRUG|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
58452469|NCT04332107|DRUG|Placebos|Participants will be shipped a dose of matching placebo
58127666|NCT02309125|PROCEDURE|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
58127667|NCT02309125|PROCEDURE|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
58314888|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
58314889|NCT01528085|DRUG|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
58314890|NCT00437762|DRUG|Botulinum Toxin A Injection|Botulinum Toxin A Injection
58452470|NCT05122728|OTHER|Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment|"Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)"
58452471|NCT05259735|COMBINATION_PRODUCT|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
58452472|NCT05259735|OTHER|Comparator|In this arm usual management of T2DM without any clinical guideline
58452473|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
58452474|NCT01370902|DRUG|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
57751793|NCT03295318|BIOLOGICAL|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
57751794|NCT03295318|BIOLOGICAL|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
57751795|NCT00255957|DRUG|HES administration|
57960544|NCT04466800|OTHER|Intervention group_rehabilitation program|"Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate."
57960545|NCT02349178|DRUG|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
57960546|NCT02349178|DRUG|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
57960547|NCT02349178|DRUG|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
57960548|NCT01515657|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
57960549|NCT01515657|DRUG|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
57960550|NCT01515657|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
58314891|NCT00437762|DRUG|Placebo injection|Placebo Injection
58314892|NCT02094365|DRUG|ALS-008176|
58314893|NCT02094365|DRUG|vehicle|
58314894|NCT01513590|DRUG|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
58314895|NCT06099275|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
58314896|NCT03823157|BEHAVIORAL|Tai Chi|mind-body exercise
58314897|NCT06133257|PROCEDURE|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
58314898|NCT06133257|PROCEDURE|standard fluid management|standard fluid management
58314899|NCT05926492|DRUG|Surufatinib plus chemotherapy|"Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
58452475|NCT01370902|DRUG|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
58452476|NCT01370902|DRUG|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
57751796|NCT00255957|DRUG|Hydroxy Ethyl Starch administration to stroke patients|
57751797|NCT05841355|OTHER|Educate|Education sessions
57751798|NCT05841355|OTHER|Empower|Empowerment sessions
57751799|NCT04237805|DRUG|SAF-189s|20mg，40mg，80mg，120mg，160mg，210mg，once daily
57751800|NCT06335264|DEVICE|Watch HOP|A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)
57751801|NCT02921529|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
57751802|NCT02921529|OTHER|false stimulation|Electrodes were attached to specific acupoints without electric current
58127668|NCT05135442|DRUG|Bortezomib Injection|Bortezomib should be administered immediately after each plasma exchange, and the interval between the next plasma exchange is\> 24h. Plasma exchange continued until the patient's platelet count was \>100×109/L for 2 consecutive days, and then changed to once every other day for a total of two times and then stopped.
58127669|NCT02498548|BEHAVIORAL|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
58127670|NCT03353909|DEVICE|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
58127671|NCT02439008|PROCEDURE|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~* Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
58127672|NCT02439008|PROCEDURE|Blood samples collection during radiotherapy|"* Sample T1: within 15 minutes after the administration of the first fraction,~* Sample T2: within 15 minutes after the administration of the second fraction,~* Sample T3: within 15 minutes after the administration of the third fraction"
58127673|NCT02439008|PROCEDURE|Blood samples collection after radiotherapy|"* Sample T4: one week after the end of the radiotherapy,~* Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
58127674|NCT02439008|RADIATION|Radiotherapy|
58127675|NCT01029938|PROCEDURE|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
58127676|NCT01029938|PROCEDURE|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
58127677|NCT04117607|OTHER|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
58127678|NCT04117607|DRUG|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
58127679|NCT04117607|DRUG|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
58127680|NCT01986036|DIETARY_SUPPLEMENT|Protein|Milk-Protein
58127681|NCT01986036|DIETARY_SUPPLEMENT|Calcium|Soluble calcium powder.
58127682|NCT01986036|DIETARY_SUPPLEMENT|Porridge-based breakfast.|Oats and water.
58127683|NCT03137563|OTHER|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
58127684|NCT04960488|PROCEDURE|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
58127685|NCT05420051|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.
57751803|NCT05692622|OTHER|Whole-body exercise and respiratory exercise|The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
58314900|NCT05926492|DRUG|Chemotherapy|"1) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
58314901|NCT00247286|BEHAVIORAL|weighted vaginal cones|
58314902|NCT00247286|BEHAVIORAL|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
58314903|NCT01273259|DRUG|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
57960551|NCT06037330|DRUG|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.
58314904|NCT01273259|DRUG|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
58452477|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
58452478|NCT01370902|DRUG|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
58127686|NCT05420051|BEHAVIORAL|Motivational Interviewing|The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
58127687|NCT02791100|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
58127688|NCT02220465|BEHAVIORAL|PA+ Smoking Cessation (LMPA)|
58127689|NCT02220465|BEHAVIORAL|Standard Care Smoking Counseling (SCC)|
58127690|NCT01624766|BIOLOGICAL|Anakinra|Given SC
58127691|NCT01624766|BIOLOGICAL|Denosumab|Given SC
58127692|NCT01624766|DRUG|Everolimus|Given PO
58127693|NCT05544448|OTHER|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
58127694|NCT02594462|DRUG|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
58127695|NCT04025879|BIOLOGICAL|Nivolumab|Specified dose on specified days
58127696|NCT04025879|DRUG|Carboplatin|Specified dose on specified days
58127697|NCT04025879|DRUG|Cisplatin|Specified dose on specified days
58127698|NCT04025879|DRUG|Paclitaxel|Specified dose on specified days
58127699|NCT04025879|DRUG|Pemetrexed|Specified dose on specified days
58127700|NCT04025879|DRUG|Placebo|Specified dose on specified days
58127701|NCT04025879|DRUG|Docetaxel|Specified dose on specified days
58127702|NCT06135532|PROCEDURE|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
58127703|NCT03236766|OTHER|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
58127704|NCT05631366|BEHAVIORAL|Alcohol Avoidance Training|Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
58452479|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years"
58452480|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years"
58452481|NCT03194906|DRUG|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
58452482|NCT03194906|OTHER|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
58452483|NCT03194906|OTHER|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
58127705|NCT00136201|DRUG|tigecycline|
58452484|NCT00757237|DRUG|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
58127706|NCT05608161|DIAGNOSTIC_TEST|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
58127707|NCT04876378|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58127708|NCT04876378|OTHER|Questionnaire Administration|Complete questionnaires
58314905|NCT04993846|DIAGNOSTIC_TEST|Dental plaque sampling|Dental plaque sampling
58314906|NCT04993846|DIAGNOSTIC_TEST|qPCR|qPCR
58314907|NCT03236792|DRUG|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
58314908|NCT03236792|DRUG|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
58314909|NCT03236792|DRUG|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
58127709|NCT05411536|OTHER|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order."
58127710|NCT01261884|BEHAVIORAL|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
58127711|NCT01261884|BEHAVIORAL|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
58127712|NCT02545946|DEVICE|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I\&D
58127713|NCT02545946|OTHER|traditional I&D with or without packing|abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
58452485|NCT00757237|DRUG|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
58452486|NCT05829954|OTHER|questionnaire|All questionnaire were obtained via online survey system.
57960552|NCT06037330|DRUG|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
57960553|NCT02544932|DRUG|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
57960554|NCT02544932|DRUG|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
57960555|NCT02544932|DRUG|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
57960556|NCT03340610|DRUG|Alflibercept|Intravitreal Injection
57960557|NCT02575287|DEVICE|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
57960558|NCT02575287|DEVICE|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
57960559|NCT02575287|DEVICE|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
57960560|NCT00280761|DRUG|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
57960561|NCT00280761|DRUG|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
57960562|NCT00280761|PROCEDURE|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
57960563|NCT00280761|RADIATION|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
57960564|NCT04187885|BEHAVIORAL|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
57960565|NCT03552341|OTHER|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
57960566|NCT02105454|DRUG|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
57960567|NCT02105454|DRUG|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
58127714|NCT03619031|OTHER|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
58452487|NCT04630665|OTHER|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
58452488|NCT01796717|DRUG|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
58452489|NCT01796717|DRUG|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
57751804|NCT03826290|OTHER|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
58127715|NCT03619031|OTHER|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
58127716|NCT03619031|OTHER|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
58127717|NCT02474264|OTHER|Endothelial function assessment|reactive hyperemia index
58127718|NCT02474264|OTHER|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
58127719|NCT02474264|OTHER|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
58314910|NCT01408693|PROCEDURE|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
58314911|NCT01408693|PROCEDURE|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
58452490|NCT03969095|BEHAVIORAL|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
58452491|NCT05289843|OTHER|Rosmarinus Officinallis|Root canal Irrigants
57751805|NCT02999828|BIOLOGICAL|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
57751806|NCT03014765|OTHER|EDOP|no intervention
57751807|NCT02982525|DIETARY_SUPPLEMENT|No Mussels|Habitual diet only
57751808|NCT02982525|DIETARY_SUPPLEMENT|One mussel portion|1 x 75g mussel portions provided per week
57751809|NCT02982525|DIETARY_SUPPLEMENT|Two mussel portions|2 x 75g mussel portions provided per week
57751810|NCT02982525|DIETARY_SUPPLEMENT|Three mussel portions|3 x 75g mussel portions provided per week
57751811|NCT02430402|OTHER|Rehabilitation in warm climate|
57751812|NCT04296487|OTHER|autologous chondrocytes|autologous chondrocytes implantation (ACI)
57751813|NCT03663686|DRUG|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
57751814|NCT02674217|PROCEDURE|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
57960568|NCT02105454|DRUG|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
57751815|NCT04692402|DEVICE|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
57751816|NCT00790283|DEVICE|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
57751817|NCT02782702|DRUG|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
57751818|NCT00002568|DRUG|cisplatin|
57751819|NCT00002568|DRUG|paclitaxel|
57751820|NCT00002568|PROCEDURE|conventional surgery|
57960569|NCT06152822|DRUG|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
57960570|NCT00996099|DEVICE|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
57960571|NCT00996099|OTHER|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
58127720|NCT04172870|DIAGNOSTIC_TEST|Molecular analysis|RT- PCR
58127721|NCT04556214|PROCEDURE|Liver Transplant|Liver Transplant
58127722|NCT01556009|DRUG|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
58127723|NCT01556009|DRUG|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
58127724|NCT03951337|DRUG|64Cu-ATSM|64 Cu-ATSM PET/CT scan
58127725|NCT04796909|BEHAVIORAL|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
58314912|NCT00862992|DRUG|Cariprazine 3 mg|
58314913|NCT00862992|DRUG|Cariprazine 6 mg|
58314914|NCT00862992|DRUG|Cariprazine 12.5 mg|
58314915|NCT02026141|DRUG|Dexmedetomidine|
58314916|NCT02026141|DRUG|Normal Saline Placebo|
58314917|NCT04518085|BEHAVIORAL|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
58127726|NCT04796909|BEHAVIORAL|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
58127727|NCT01552096|DRUG|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
58127728|NCT00073294|BEHAVIORAL|diet|
58127729|NCT03030196|DRUG|Denosumab|NaCl 0.9% injection is used as placebo
58127730|NCT02898623|OTHER|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
58127731|NCT00000804|DRUG|Indinavir sulfate|
58127732|NCT05380635|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
58127733|NCT03654196|DRUG|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
58127734|NCT03654196|DRUG|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
58127735|NCT05375175|OTHER|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
58127736|NCT05375175|OTHER|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
58127737|NCT01279525|DEVICE|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
58127738|NCT01373970|DRUG|Placebo|Placebo, one tablet daily for 12 weeks
58127739|NCT01373970|DRUG|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
58127740|NCT00929539|DRUG|JTT-130|Tablets
58127741|NCT00929539|DRUG|JTT-130 Placebo|Tablets
58127742|NCT01383525|DEVICE|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
58127743|NCT02679677|DEVICE|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
58127744|NCT03683407|OTHER|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
58127745|NCT00436007|BIOLOGICAL|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
58127746|NCT00436007|BIOLOGICAL|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
58127747|NCT00436007|BIOLOGICAL|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
58127748|NCT00436007|BIOLOGICAL|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
58127749|NCT00436007|BIOLOGICAL|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
58127750|NCT04330937|DIETARY_SUPPLEMENT|dietetics|90 days of consumption
58127751|NCT02438878|BEHAVIORAL|Baby Behavior|
58127752|NCT06485401|DRUG|ADC189|45 mg per tablet, oral administration, single dose.
58127753|NCT04201171|DEVICE|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
58127754|NCT00046267|DRUG|Niacin|
58314918|NCT04518085|BEHAVIORAL|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
58314919|NCT04518085|BEHAVIORAL|Mindfulness session|Single session mindfulness session delivered by audio file
58314920|NCT04518085|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
58314921|NCT05927688|BEHAVIORAL|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
57751821|NCT02089230|DRUG|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
57960572|NCT02511652|DEVICE|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
57960573|NCT02511652|DEVICE|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
58127755|NCT01375322|DRUG|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
58127756|NCT01375322|DRUG|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
58314922|NCT02653846|PROCEDURE|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
58127757|NCT01722981|PROCEDURE|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
58127758|NCT03259100|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
58127759|NCT02674334|DEVICE|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
58127760|NCT02674334|DEVICE|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
58127761|NCT02483975|DRUG|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
58127762|NCT02483975|DRUG|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
58127763|NCT02483975|DRUG|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
58127764|NCT02483975|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
58127765|NCT02329652|DEVICE|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
58127766|NCT05530109|OTHER|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
58127767|NCT03260764|DEVICE|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
58127768|NCT03260764|DEVICE|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
58127769|NCT03260764|DEVICE|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
58127770|NCT03260764|DEVICE|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
58127771|NCT00263809|DEVICE|Pathogen Reduction Technology|
58127772|NCT04882293|DRUG|Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose|1 tablet once a day, 20 mg /160 mg, Orally
58127773|NCT04882293|DRUG|Atorvastatin (Lipitor ®)|1 tablet once a day, 20 mg, Orally
58127774|NCT00821834|DRUG|clopidogrel (SR25990)|"Form: tablets~Route: oral"
58127775|NCT00821834|DRUG|ticlopidine|"Form: tablets~Route: oral"
58452492|NCT00967317|DRUG|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
57960574|NCT02511652|PROCEDURE|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
58127776|NCT00821834|DRUG|Placebo|"Form: tablets~Route: oral"
58127777|NCT02333370|DRUG|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
58127778|NCT02333370|DRUG|Letrozole|25mg
58127779|NCT02333370|DRUG|Tamoxifen|20 mg
58127780|NCT02333370|DRUG|Fulvestrant|500 mg
58127781|NCT02333370|DRUG|goserelin|
58127782|NCT05190510|OTHER|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
58127783|NCT05190510|PROCEDURE|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
58127784|NCT05190510|OTHER|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
58127785|NCT01567956|DRUG|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
58127786|NCT01567956|DRUG|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
58452493|NCT00967317|DRUG|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
58452494|NCT02304744|OTHER|Observational study, no intervention.|Observational study, no intervention.
57960575|NCT02012478|BEHAVIORAL|MI- informed SMS program|
58127787|NCT06497387|BIOLOGICAL|PRG-1801|PRG-1801 (BCMA-targeting CAR-T Cells)
58127788|NCT03565809|OTHER|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
58127789|NCT04555928|OTHER|No intervention|This is a prospective cohort (survey) study. It has no intervention.
58127790|NCT02602379|OTHER|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
58127791|NCT04627506|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
58127792|NCT00684671|BIOLOGICAL|Twinrix|Intramuscular injection, single dose in left deltoid.
58127793|NCT00684671|BIOLOGICAL|Engerix-B|Intramuscular injection, single dose in left deltoid.
58127794|NCT00684671|BIOLOGICAL|Havrix|Intramuscular injection, single dose in right deltoid.
58127795|NCT00684671|BIOLOGICAL|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
58127796|NCT00684671|BIOLOGICAL|Vaqta|Intramuscular injection, single dose in right deltoid.
58127797|NCT04260503|OTHER|Monitoring of the gut-microbiome and ultrasound elasticity.|The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
58127798|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome before and after operation.
58127799|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome along with the disease progress.
58127800|NCT04260503|OTHER|Monitoring of the gut-microbiome.|The investigator will investigate the alteration of gut-microbiome according to the normal development.
58127801|NCT04118478|BEHAVIORAL|multi-component phased training program|The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
58127802|NCT01968265|DRUG|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
58127803|NCT01968265|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
58127804|NCT04820868|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
58127805|NCT01856088|DEVICE|Inspiron Stent|stent implantation
58127806|NCT01856088|DEVICE|Biomatrix Flex Stent|stent implantation
58127807|NCT00356200|DRUG|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
58127808|NCT00356200|DRUG|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
58127809|NCT01187862|DRUG|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
58127810|NCT02879019|OTHER|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
58127811|NCT02879019|OTHER|Walking training group|Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
58127812|NCT04091126|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as intravenous infusion.
58127813|NCT04091126|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
58127814|NCT04091126|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
58127815|NCT04091126|DRUG|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
58127816|NCT04333706|DRUG|Capecitabine|Capecitabine 1000 mg BID
57751822|NCT01514526|DRUG|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
58127817|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg or 200 mg plus Capecitabine|Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
58127818|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg plus Capecitabine|Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
58127819|NCT00323947|DRUG|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
58127820|NCT03737955|DRUG|Gemtuzumab Ozogamicin|Receive IV
58127821|NCT03737955|OTHER|Quality-of-Life Assessment|Ancillary studies
58314923|NCT02653846|PROCEDURE|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
58314924|NCT04444869|DRUG|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
58452495|NCT03015766|OTHER|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
57751823|NCT00825422|DRUG|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
57751824|NCT03915639|PROCEDURE|Peri-incisional injection|The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
57751825|NCT00289887|DRUG|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
57751826|NCT00289887|DRUG|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
57751827|NCT00424125|BEHAVIORAL|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
57751828|NCT00424125|BEHAVIORAL|Control|Usual care.
57751829|NCT02845401|OTHER|Stop NA therapy|Cases will stop antiviral therapy
57751830|NCT00708916|DRUG|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
57751831|NCT06141330|DIETARY_SUPPLEMENT|D Max Drops|Vitamin D
57751832|NCT06141330|DRUG|Azithromycin 250 milligram Oral Capsule|Anti Biotic
57751833|NCT06141330|DRUG|Adapalene|Retinoid
57751834|NCT06022835|OTHER|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
58452496|NCT03015766|OTHER|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
58452497|NCT02768766|DRUG|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
58452498|NCT02768766|DRUG|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
57751835|NCT00551798|PROCEDURE|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
57751836|NCT03658564|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
57751837|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
57751838|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
57751839|NCT03329287|BEHAVIORAL|SCBT|SCBT, one hour per session.
57751840|NCT03329287|DRUG|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
57751841|NCT03329287|BEHAVIORAL|Psychological Placebo|Supportive and relaxation therapy, one our per session.
57751842|NCT00549757|DRUG|Aliskiren|Aliskiren 150 mg film-coated tablets
57751843|NCT00549757|DRUG|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
57751844|NCT06231238|BEHAVIORAL|Balance Acceptance and Commitment Therapy|Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.
58452499|NCT02768766|DRUG|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
57751845|NCT04001179|OTHER|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
57751846|NCT01325285|DEVICE|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
57751847|NCT02764710|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
57751848|NCT01726881|DEVICE|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel."
57751849|NCT01726881|DEVICE|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
57751850|NCT01726881|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
57960576|NCT02990442|DEVICE|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
57960577|NCT00756873|DRUG|Administration of placebo|Placebo qd orally day 0-14
57960578|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
57751851|NCT05470114|DRUG|LEO 138559|LEO 138559 is an antibody given by subcutaneous injection.
57751852|NCT05470114|DRUG|Dupixent®|Dupixent® is an antibody given by subcutaneous injection.
58127822|NCT00530010|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
58127823|NCT05779449|DIETARY_SUPPLEMENT|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~1. packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~   From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~2. capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
58127824|NCT05779449|DIETARY_SUPPLEMENT|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
58127825|NCT05779449|PROCEDURE|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
58127826|NCT05779449|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
58127827|NCT05624164|PROCEDURE|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
58127828|NCT01599338|DRUG|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
58127829|NCT03316729|DRUG|DS-9231|DS-9231 in saline solution for intravenous infusion
57751853|NCT03766022|DEVICE|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
57751854|NCT02726802|OTHER|physical therapy vs. primary care interventions|Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
57751855|NCT02447822|DRUG|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
57751856|NCT06064084|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test 50g
57751857|NCT06064084|OTHER|Intravenous isoglycaemic glucose clamp|Intravenous isoglycaemic glucose clamp
57751858|NCT06064084|OTHER|Liquid Mixed meal test|Liquid Mixed meal test 520 kcal
57751859|NCT01291979|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
57751860|NCT01291979|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
57751861|NCT05273125|BEHAVIORAL|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
57751862|NCT05217238|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the rocuronium injection
57751863|NCT04602312|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
57751864|NCT04805060|DRUG|TQB2858 injection|TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
57751865|NCT01733732|OTHER|SYSTANE® BALANCE Lubricant Eye Drops|
57751866|NCT01733732|OTHER|SYSTANE® Gel|
57751867|NCT03758170|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
57751868|NCT00314548|DRUG|PGE1 (prostacyclin)|alprostadil nebulization
57751869|NCT00314548|DRUG|normal saline|nebulize for 30 mins
57751870|NCT02737800|PROCEDURE|endometrioma aspiration|Transvaginal ultrasound guided aspiration
57751871|NCT02737800|DRUG|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
57751872|NCT02737800|PROCEDURE|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
57751873|NCT03509740|DRUG|tramadol|100 mg tramadol in 100 ml saline with slow infusion
57751874|NCT03509740|DRUG|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
58127830|NCT03316729|DRUG|Placebo|Placebo is matching saline solution for intravenous infusion
57751875|NCT01520818|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
57751876|NCT01520818|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
57751877|NCT01520818|DRUG|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
57960579|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
57960580|NCT03177083|DRUG|peginterferon beta-1a|SC every 2 weeks
58127831|NCT00925314|BIOLOGICAL|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
58127832|NCT01166568|DEVICE|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
58127833|NCT00789425|DIETARY_SUPPLEMENT|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
57960581|NCT03177083|DRUG|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
58127834|NCT00789425|DIETARY_SUPPLEMENT|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
58127835|NCT04051242|DEVICE|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
58127836|NCT06145815|PROCEDURE|Arthroscopic rotator cuff repair|Patients underwent an arthroscopic repair for rotator cuff lesions
58127837|NCT02495558|OTHER|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
58127838|NCT01737671|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
58127839|NCT01737671|DRUG|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
58127840|NCT01737671|DRUG|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
58127841|NCT06316609|OTHER|Gestational Exposure to Emerging Contaminants (ECs)|Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
58127842|NCT02000856|DIETARY_SUPPLEMENT|Beetroot juice|
58452500|NCT02768766|DRUG|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
57960582|NCT03177083|DRUG|interferon beta-1b|Per SMPC
57960583|NCT01641614|PROCEDURE|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
57960584|NCT01641614|PROCEDURE|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
57960585|NCT01978093|BIOLOGICAL|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
58127843|NCT00891475|PROCEDURE|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
58127844|NCT00891475|PROCEDURE|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
58127845|NCT00891475|DRUG|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
58127846|NCT00219297|DRUG|Patupilone|
58127847|NCT05060900|PROCEDURE|Ligament Reconstruction with Allograft Ligament|Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
58127848|NCT02217865|BEHAVIORAL|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
58127849|NCT02217865|BEHAVIORAL|Questionnaire|Questionnaire completion asking general health and demographic questions.
58127850|NCT02217865|BEHAVIORAL|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
58127851|NCT02217865|BEHAVIORAL|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
58127852|NCT03715270|DEVICE|Image surgical area|Image surgical area
58452501|NCT02768766|DRUG|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
58127853|NCT02467036|BEHAVIORAL|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
58127854|NCT05240677|PROCEDURE|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
58127855|NCT02053532|PROCEDURE|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
57751878|NCT05333354|OTHER|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
57751879|NCT01247402|DEVICE|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
58127856|NCT03437083|DRUG|Eribulin mesylate|intravenous infusion
58127857|NCT03129269|PROCEDURE|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
58127858|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months.
58127859|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
58127860|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months
58127861|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
58127862|NCT01767064|OTHER|Posted commitment letter|
58127863|NCT04894513|OTHER|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
58127864|NCT04894513|OTHER|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
58127865|NCT04690777|PROCEDURE|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
58127866|NCT04690777|PROCEDURE|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
57751880|NCT01247402|DEVICE|standard balloon angioplasty|standard balloon angioplasty
57751881|NCT05257330|DIAGNOSTIC_TEST|CSF Examination|Lumbar puncture for CSF Examination
57751882|NCT04704518|DRUG|Sodium Hyaluronate Ophthalmic 0.4%|Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
57751883|NCT04704518|DRUG|Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%|Topical ophthalmic administration of one drop of Thealoz® Duo QID.
57751884|NCT05773560|DEVICE|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
57751885|NCT06509256|DRUG|Tranexamic acid injection|work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
57751886|NCT06346314|OTHER|Scapular retraction exercise|Participant lies prone with hands superior to the head on a treatment plinth and lifts their elbows 10 repetitions for three sets with 30 seconds of rest between each set.
57751887|NCT00198484|DRUG|Vitrase|
58127867|NCT04312906|OTHER|no intervention|No intervention
58127868|NCT01774474|DRUG|Bromfenac|
58127869|NCT01774474|DRUG|Dexamethasone|
58127870|NCT01774474|DRUG|Bevacizumab|
58127871|NCT01774474|DRUG|Triamcinolone Acetonide|
58127872|NCT05743920|BEHAVIORAL|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
58127873|NCT03738332|DEVICE|Low-Level Laser|Low-level laser therapy
57751888|NCT03155789|PROCEDURE|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion"
57751889|NCT06451900|DRUG|Fenofibrate|full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
57751890|NCT06451900|OTHER|placebo|ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
58127874|NCT01550211|DEVICE|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
58127875|NCT01093209|DEVICE|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
58127876|NCT00120900|DRUG|GW406381|
58127877|NCT00295178|DRUG|Daptomycin|
58127878|NCT00295178|DRUG|Vancomycin|
58127879|NCT03508713|DRUG|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
58127880|NCT02728037|PROCEDURE|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
58127881|NCT02728037|PROCEDURE|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
58127882|NCT02728037|DRUG|lidocaine|
58127883|NCT02728037|DRUG|magnesium sulfate, bicarbonate, dextrose.|
58127884|NCT00159965|DRUG|sertraline|flexible dose sertraline
57751891|NCT02459730|PROCEDURE|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
58127885|NCT00159965|DRUG|placebo|flexible dose placebo
58127886|NCT01611090|DRUG|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
58127887|NCT01611090|DRUG|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
58127888|NCT01611090|DRUG|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
58127889|NCT01611090|DRUG|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
58127890|NCT03978403|DRUG|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
58127891|NCT03978403|DRUG|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
58127892|NCT03978403|DRUG|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
58127893|NCT03978403|DRUG|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose
58127894|NCT06062771|DEVICE|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
58314925|NCT04719559|DEVICE|Laser-assisted drug delivery|All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion \& BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
58314926|NCT00833326|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
58314927|NCT00833326|DRUG|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
58314928|NCT00833326|DRUG|Prophylactic growth factors; subcutaneous|standard of care
58314929|NCT01337934|DRUG|Lactated Ringer|Lactated Ringer
57751892|NCT02459730|PROCEDURE|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
57751893|NCT02027402|PROCEDURE|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
58127895|NCT06062771|DEVICE|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
58127896|NCT00663871|DIETARY_SUPPLEMENT|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
58127897|NCT00663871|DIETARY_SUPPLEMENT|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
58127898|NCT02580630|BEHAVIORAL|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
58314930|NCT01337934|DRUG|Albumin|Albumin 4%
58314931|NCT00888745|DRUG|placebo|Intravenous and subcutaneous ascending dose
58314932|NCT00888745|DRUG|PRO283698|Intravenous and subcutaneous ascending dose
58127899|NCT02580630|OTHER|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
58127900|NCT02580630|DRUG|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
58127901|NCT02580630|DRUG|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
58127902|NCT00002899|PROCEDURE|adjuvant therapy|
58127903|NCT00002899|RADIATION|radiation therapy|
58127904|NCT00002899|RADIATION|stereotactic radiosurgery|
57960586|NCT01978093|BIOLOGICAL|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
58127905|NCT03717064|DRUG|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
58127906|NCT03717064|DRUG|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
58127907|NCT01493479|DRUG|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
58127908|NCT01493479|DRUG|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial."
58127909|NCT03199729|OTHER|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
58127910|NCT03199729|OTHER|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
58127911|NCT03199729|OTHER|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
58127912|NCT03213210|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
58127913|NCT02187042|OTHER|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
58127914|NCT02187042|OTHER|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
58127915|NCT03094910|DIAGNOSTIC_TEST|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
58127916|NCT03094910|DIAGNOSTIC_TEST|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
58127917|NCT03094910|DIAGNOSTIC_TEST|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
58314933|NCT04017962|DRUG|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
58314934|NCT04017962|OTHER|blood draw|Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
58314935|NCT01987115|PROCEDURE|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
57960587|NCT01978093|BIOLOGICAL|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
57960588|NCT01978093|BIOLOGICAL|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
57960589|NCT01978093|BIOLOGICAL|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
58127918|NCT03094910|DIAGNOSTIC_TEST|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
58314936|NCT01987115|PROCEDURE|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
58127919|NCT03094910|DIAGNOSTIC_TEST|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
58127920|NCT03094910|DIAGNOSTIC_TEST|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
58127921|NCT05803746|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
58127922|NCT06394102|OTHER|The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.|A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
58127923|NCT05108623|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
58127924|NCT05108623|DRUG|Approved ICIs|Nivolumab and pembrolizumab
58127925|NCT04360811|DIAGNOSTIC_TEST|COVID 19 diagnostic test by PCR|"1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis"
58127926|NCT06464328|BEHAVIORAL|Tai Chi Combined with Music Therapy Intervention|Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for twelve weeks
58127927|NCT06464328|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for twelve weeks
58127928|NCT06464328|BEHAVIORAL|Tai Chi intervention only|Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice; twice a week for twelve weeks
58127929|NCT03856970|DRUG|Microgestin®|30 μg/1500 μg tablets for oral administration
58127930|NCT03856970|DRUG|Levothyroxine|600 μg tablets for oral administration
57751894|NCT03169803|DEVICE|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
57751895|NCT05665933|BEHAVIORAL|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
57751896|NCT03595332|OTHER|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
58127931|NCT03856970|DRUG|Glyburide|5 mg tablets for oral administration
58127932|NCT03856970|DRUG|Digoxin|0.25 mg tablets for oral administration
58127933|NCT03856970|DRUG|IW-3718|500-mg film-coated tablets for oral administration
58127934|NCT02060006|DRUG|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
58127935|NCT00148915|DRUG|ibandronate|
58127936|NCT00148915|DRUG|Placebo|matching placebo
58127937|NCT03493126|DRUG|Estradiol|17β-estradiol vaginal cream
58127938|NCT03493126|OTHER|Placebo|Compounded placebo cream
58127939|NCT05456074|OTHER|Data collection|Retrospective data collection
58314937|NCT04043026|DRUG|Statin|Any statin therapy
57751897|NCT02611739|DEVICE|Medi-Port|Treatment
57751898|NCT02611739|DEVICE|Medi-Port|Control
57751899|NCT01949311|DRUG|Dupilumab|
57751900|NCT00404664|BEHAVIORAL|influenza vaccine, reminders letters, raffle prize|
57751901|NCT03791580|BEHAVIORAL|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
58314938|NCT02453048|BIOLOGICAL|BPZE1|Intranasal live, attenuated vaccine
58314939|NCT02453048|OTHER|Placebo|Diluent
58314940|NCT05273359|DRUG|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
58127940|NCT03093909|DRUG|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
58127941|NCT02427685|DEVICE|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
58127942|NCT01204580|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
58127943|NCT04015232|COMBINATION_PRODUCT|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
58127944|NCT04015232|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
58127945|NCT03883607|DRUG|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
58127946|NCT03883607|DRUG|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
58127947|NCT05991661|DRUG|XKH001 Injection|100mg/ml，1ml/vial
58127948|NCT05991661|DRUG|XKH001 Placebo Injection|1ml/vial
58127949|NCT03034226|OTHER|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
58127950|NCT06014411|OTHER|Time to bathing (delayed)|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
58127951|NCT06014411|OTHER|Time to bathing (early)|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
58127952|NCT02837822|DEVICE|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
58127953|NCT02837822|PROCEDURE|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
58127954|NCT01493908|DRUG|High price|Acetaminophen label as high price
58127955|NCT01493908|DRUG|Low price|Acetaminophen label as low price
58127956|NCT01493908|DRUG|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
58127957|NCT01493908|DRUG|No price|acetaminophen. No price - price issue not introduced to participants.
58127958|NCT01493908|DRUG|Free of charge|Acetaminophen. participants aware the product is free of charge
58127959|NCT03712722|OTHER|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
58127960|NCT04047095|DIETARY_SUPPLEMENT|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
58127961|NCT04047095|DIETARY_SUPPLEMENT|Normal daily meal|Normal daily meal (75-80 g protein)
58127962|NCT02815969|OTHER|vena punction|vena punction and urine collection
58127963|NCT05984771|DIETARY_SUPPLEMENT|Epineuron|Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)
58127964|NCT05984771|OTHER|Placebo group|Usual care
58127965|NCT00091598|DRUG|Ambrisentan|
57960590|NCT01978093|BIOLOGICAL|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
58127966|NCT03378700|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
58314941|NCT05273359|OTHER|Benralizumab placebo|15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
57960591|NCT00004001|DRUG|docetaxel|
57960592|NCT00004001|DRUG|estramustine|
58127967|NCT03378700|OTHER|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
58127968|NCT03209570|OTHER|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
58127969|NCT03209570|OTHER|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
58127970|NCT00824265|DRUG|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
58127971|NCT00824265|DRUG|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
58127972|NCT02363790|PROCEDURE|LVHR PFC|Information included in arm description
58127973|NCT02363790|PROCEDURE|Bridging LVHR|Information included in arm description
58127974|NCT06056479|PROCEDURE|external oblique intercostal block|20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
58314942|NCT05273359|OTHER|Comparison (control) group; no intervention|15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
58314943|NCT04479072|DRUG|Aspirin 81 mg|Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
58314944|NCT04479072|DRUG|Placebo|Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
57960593|NCT00004001|DRUG|mitoxantrone|
57960594|NCT00004001|DRUG|prednisone|
58314945|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
58127975|NCT03676803|OTHER|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
58127976|NCT03676803|OTHER|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
58127977|NCT01802502|DRUG|Rifampicin intravenous|
58127978|NCT01802502|DRUG|Oral rifampicin|
58127979|NCT03991156|DEVICE|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
58127980|NCT03991156|OTHER|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
58127981|NCT03991156|OTHER|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
58127982|NCT00079170|DIETARY_SUPPLEMENT|garlic|
58127983|NCT00079170|DRUG|docetaxel|
58127984|NCT01798069|BEHAVIORAL|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
58127985|NCT01798069|BEHAVIORAL|reading medical publication workshops|
58127986|NCT04194866|OTHER|receiving operation during the day or at night|120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
58127987|NCT04714658|OTHER|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~1. st group collective workshop : allow the patient to better understand autoimmune~2. nd workshop : fatigue and techniques that enable its best management.~3. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
58127988|NCT00265733|DRUG|capecitabine|
58127989|NCT00265733|DRUG|paclitaxel poliglumex|
58127990|NCT03803865|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
58127991|NCT03803865|BEHAVIORAL|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
58127992|NCT06149936|DEVICE|excimer light|Excimer laser using high-dose monochromatic UV radiation
58127993|NCT02554864|DRUG|lidocaine|Local anesthetic
58127994|NCT02554864|DRUG|ropivacaine|Local anesthetic
58127995|NCT04043065|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
58127996|NCT04043065|OTHER|Placebo|Saline
58127997|NCT01955590|BEHAVIORAL|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
57960595|NCT01352806|PROCEDURE|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
58127998|NCT01955590|BEHAVIORAL|EMDR|8-12 sessions of manualized EMDR
58127999|NCT01955590|BEHAVIORAL|Treatment as usual|8-12 sessions of treatment of usual
58128000|NCT02697903|DIETARY_SUPPLEMENT|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
58128001|NCT02697903|DIETARY_SUPPLEMENT|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
58128002|NCT00459888|DEVICE|PolarCath Peripheral Dilatation System (Boston Scientific)|
58128003|NCT00444145|DRUG|Prevacid|30 mg bid for 3 months
58314946|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
58314947|NCT03385538|DRUG|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
58314948|NCT00970554|OTHER|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
57960596|NCT00225511|DRUG|Effexor XR|
57960597|NCT00225511|DRUG|Milnacipran|
57960598|NCT04656873|PROCEDURE|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
58128004|NCT00444145|PROCEDURE|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
58128005|NCT02184130|OTHER|transcranial magnetic stimulation and motion stimuli|
58128006|NCT03956264|DEVICE|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
58128007|NCT03956264|DRUG|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
58128008|NCT05293990|RADIATION|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
58128009|NCT06364670|PROCEDURE|acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
58128010|NCT00495326|DRUG|Nevirapine based therapy|"* Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
58128011|NCT00495326|DRUG|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
58128012|NCT00495326|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"* Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase."
57751902|NCT03791580|BEHAVIORAL|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
58128013|NCT04581538|DEVICE|Intervention of parallel arm 2|"This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care."
58128014|NCT04581538|DEVICE|Intervention of parallel arm 3|"Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed."
58128015|NCT06193395|OTHER|Questionnaire|No intervention, only clinical testing of questionnaire
57751903|NCT04051164|OTHER|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
58128016|NCT01143857|DRUG|Varenicline|Varenicline 2.0 mg/day or Placebo
58128017|NCT00692653|BEHAVIORAL|P4|Tailored online decision support system for prostate cancer treatment decision making
58128018|NCT02756325|DEVICE|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
58128019|NCT06367309|PROCEDURE|Extended totally extraperitoneal repair|The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.
58128020|NCT06367309|PROCEDURE|Intraperitoneal onlay mesh|Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
58128021|NCT04919421|DRUG|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
58128022|NCT04919421|DEVICE|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
58128023|NCT04162626|OTHER|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
58128024|NCT04162626|OTHER|Treatment as usual|Follow up at the Child health center according to national regulations
58314949|NCT00970554|OTHER|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
57751904|NCT04051164|OTHER|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
57751905|NCT02925910|DEVICE|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
57751906|NCT02703350|DRUG|LY900014|Administered subcutaneously (SC)
58128025|NCT00719966|DRUG|anastrozole|Patients receive aromatase inhibition therapy.
58128026|NCT00719966|DRUG|exemestane|Patients receive aromatase inhibition therapy.
58314950|NCT02543840|OTHER|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
58314951|NCT02543840|OTHER|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
58314952|NCT03640819|PROCEDURE|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
58452502|NCT02768766|DRUG|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
57751907|NCT02703350|DRUG|Insulin Lispro|Administered SC
57751908|NCT01826812|OTHER|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
57751909|NCT01826812|OTHER|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
57751910|NCT02863484|OTHER|surgery|pealing of the outer layer of the cavernous sinus
57751911|NCT04873648|BEHAVIORAL|caloric reduced -intermitted fasting diet|obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
57751912|NCT04873648|BEHAVIORAL|Daily calorie restriction|obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
57751913|NCT04873648|BEHAVIORAL|Control group|obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
57751914|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
57751915|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
57751916|NCT05541055|DEVICE|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
57751917|NCT05541055|OTHER|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
58452503|NCT01494948|OTHER|allergen challenge|nasal challenges with antigen to which they are sensitive to
58452504|NCT01825187|DEVICE|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
58452505|NCT01825187|DEVICE|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
57751918|NCT04137848|PROCEDURE|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
57751919|NCT04137848|PROCEDURE|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
57751920|NCT06578884|DEVICE|877PTY|IOL implantation with 6-month follow-up period Monocular UDVA/CDVA Manifest Refraction (SPH, CYL, SEQ) Optical Biometry, Keratometry (K1, K2, AXL, ACD) IOL axis orientation determination Visual function questionnaire Glistening evaluation Tonometry Slit-Lamp examination Fundus visualization
57751921|NCT03288610|DIAGNOSTIC_TEST|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
57751922|NCT05180292|DRUG|Carvedilol 12.5 MG|Carvedilol 12.5 mg
57960599|NCT04656873|OTHER|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
58128027|NCT00719966|DRUG|letrozole|Patients receive aromatase inhibition therapy.
58128028|NCT00719966|PROCEDURE|assessment of therapy complications|Endothelial function is measured
58128029|NCT05507619|OTHER|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
58128030|NCT05507619|OTHER|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
57751923|NCT05130879|BEHAVIORAL|BRAW|"Sessions~1. Happiness and positivity Understanding strengths and resilience and positive attitude~2. Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~3. Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~4. Emotion regulation Preventing and managing conflict Emotion regulation abilities~5. Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~6. Problem solving Problem-solving work-life problems Work-life balance Bringing it together"
57751924|NCT03255824|DRUG|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
57751925|NCT03255824|DRUG|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
58128031|NCT06365723|BEHAVIORAL|Green Walk|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Green' urban environment.
58128032|NCT06365723|BEHAVIORAL|Gray Walk|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated 'Gray' urban environment.
58128033|NCT06233266|DRUG|Ticagrelor-Test product|Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
58128034|NCT06233266|DRUG|Ticagrelor-Reference product|Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
58128035|NCT05318651|DEVICE|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
58128036|NCT02044783|BEHAVIORAL|Behavioral Counseling|
58128037|NCT01871467|DRUG|Sargramostim|
58128038|NCT04595981|DRUG|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
58128039|NCT05376566|DRUG|Hydrochloric Acid (2 M)|Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
58128040|NCT05376566|DRUG|Normal saline|Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
57751926|NCT05204810|OTHER|Anticoagulation strategy|For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant
57751927|NCT05204810|OTHER|Blood sampling|During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
58128041|NCT05065645|DRUG|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
58128042|NCT05065645|DRUG|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
58128043|NCT02769208|DEVICE|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
58128044|NCT02141256|DIETARY_SUPPLEMENT|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
58128045|NCT04786652|DEVICE|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
58128046|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
58128047|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
58314953|NCT06059144|DRUG|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
58314954|NCT05252338|BIOLOGICAL|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
57751928|NCT05204810|OTHER|Scanning of hemodialyzer with micro-computed tomography|After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
57751929|NCT00134979|DRUG|Formoterol|
57751930|NCT02219893|DRUG|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
58128048|NCT00337077|DRUG|eribulin mesylate|Given IV
58128049|NCT00744809|DRUG|TMC278; Moxifloxacin; Efavirenz|
58314955|NCT05264532|OTHER|Informational Intervention|Receive information-graphic video
58128050|NCT06158269|DRUG|DVRd|The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
58128051|NCT06482489|DEVICE|Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).|Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.
58128052|NCT06003920|BEHAVIORAL|Process group|The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
58128053|NCT01456481|DRUG|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
58128054|NCT01456481|DRUG|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
58128055|NCT05936710|DEVICE|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
57960600|NCT04656873|OTHER|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
57960601|NCT03847610|DRUG|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
57960602|NCT03847610|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
57960603|NCT05707091|OTHER|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
57960604|NCT05707091|PROCEDURE|Conventional therapy|Group B treated with ems and exercises
58128056|NCT05936710|DEVICE|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
58128057|NCT06224400|DRUG|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
58128058|NCT06224400|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
58128059|NCT06224400|DRUG|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
58128060|NCT06224400|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
57960605|NCT04549701|OTHER|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
57960606|NCT04549701|OTHER|Standard of care|Standard of care will be provided.
58128061|NCT02642666|BEHAVIORAL|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
58128062|NCT03314025|DRUG|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
57751931|NCT05374902|OTHER|Providing procedural informational animation video|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
57751932|NCT05374902|DEVICE|Buzzy|Buzzy® was placed on the injection site and it was turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
57751933|NCT05374902|COMBINATION_PRODUCT|Multiple interventions|Watching procedural informational animation video prior to venipuncture, and Buzzy application during venipuncture
57960607|NCT05840081|OTHER|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
57960608|NCT03188952|DIAGNOSTIC_TEST|International Caries Classification and Management System|Caries assessment and management system
57960609|NCT00005783|DRUG|Recombinant-methionyl human stem cell factor|
57960610|NCT03987854|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
57960611|NCT03838679|DIAGNOSTIC_TEST|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
57960612|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
57960613|NCT03838679|DIAGNOSTIC_TEST|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
58128063|NCT03314025|DRUG|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
58128064|NCT03314025|DEVICE|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
58128065|NCT00417209|DRUG|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
58128066|NCT00417209|DRUG|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
58128067|NCT00417209|DRUG|Capecitabine|administered orally from Day 1 to Day 14 q3w
58128068|NCT00963209|DRUG|tamoxifen citrate|
58128069|NCT00963209|OTHER|laboratory biomarker analysis|
58128070|NCT00963209|OTHER|pharmacological study|
58128071|NCT00000391|DRUG|Peptide T|
58128072|NCT02659722|DEVICE|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
58128073|NCT03409601|OTHER|100% Portion Size|Meal portion size at baseline
58128074|NCT03409601|OTHER|125% Portion Size|Meal portion size 125% of baseline
58128075|NCT03409601|OTHER|150% Portion Size|Meal portion size 150% of baseline
58128076|NCT03409601|OTHER|175% Portion Size|Meal portion size 175% of baseline
57960614|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
58128077|NCT01992055|BEHAVIORAL|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
58128078|NCT01992055|BEHAVIORAL|Education & relaxation training|The Education \& Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
58128079|NCT04806308|BEHAVIORAL|Otolaryngology stretching micro-breaks (OSMB)|Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
58128080|NCT01986582|DRUG|Oxymetazoline|Intranasal application
58128081|NCT01986582|OTHER|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
58128082|NCT01986582|OTHER|Placebo (lactose powder)|Intranasal application
58128083|NCT04168346|DRUG|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
58128084|NCT04168346|DRUG|Placebos|NaCl 0.9% infusion
58128085|NCT05231109|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
58128086|NCT06159270|OTHER|Blood sample|Venuous blood sampling
58128087|NCT04853459|PROCEDURE|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
58128088|NCT04228952|COMBINATION_PRODUCT|Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK|American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
58128089|NCT02776709|PROCEDURE|ERCP with cholangioscopy|
58128090|NCT06330870|PROCEDURE|WGS/TME evaluation|WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
57751934|NCT01258634|DRUG|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
57751935|NCT01258634|DRUG|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
57751936|NCT01258634|DRUG|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
58128091|NCT06176287|PROCEDURE|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
58128092|NCT06176287|PROCEDURE|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
58128093|NCT06495658|DIETARY_SUPPLEMENT|Prebiotic|Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
58128094|NCT02698800|DEVICE|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
58128095|NCT02698800|DEVICE|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
58128096|NCT00050856|DRUG|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
58128097|NCT03080649|DEVICE|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
58314956|NCT05264532|OTHER|Informational Intervention|Receive family letter
58128098|NCT03080649|DEVICE|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
58128099|NCT06029036|DRUG|Darolutamide+ADT|"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"
58128100|NCT02218164|DRUG|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
58128101|NCT02218164|DRUG|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
58128102|NCT02218164|DRUG|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
58128103|NCT05522270|PROCEDURE|revitalization by concentrated growth factor|modified platelet concentrate
58128104|NCT05898204|OTHER|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
58128105|NCT05898204|OTHER|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
58128106|NCT06426056|RADIATION|radiotherapy|Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
58128107|NCT06426056|DRUG|Nab paclitaxel|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
58128108|NCT06426056|DRUG|Cisplatin|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
58128109|NCT05530681|DIAGNOSTIC_TEST|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
58128110|NCT05530681|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
58128111|NCT00163449|DRUG|Ciclesonide|Efficacy and Safety of Ciclesonide
58128112|NCT00163449|DRUG|Placebo|Placebo
58128113|NCT05123456|PROCEDURE|Radiography|Comparative X-ray of the single knee at 30 ° flexion.
58128114|NCT01907009|DRUG|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
58128115|NCT01907009|DRUG|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
57960615|NCT03838679|DIAGNOSTIC_TEST|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
58128116|NCT05946148|DRUG|Empagliflozin|Empagliflozin 10mg daily, as add-on to previous treatment regimen.
57960616|NCT03838679|DIAGNOSTIC_TEST|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
57960617|NCT03838679|DIAGNOSTIC_TEST|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
58128117|NCT05946148|DRUG|Dulaglutide|Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
58128118|NCT05946148|DRUG|Control Rx|Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
58128119|NCT04815642|RADIATION|radiotherapy|Hypofractionated radiotherapy concomitantly with weekly boost
58128120|NCT02627742|DEVICE|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
58128121|NCT01880073|DEVICE|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
58128122|NCT02401282|BEHAVIORAL|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
58128123|NCT02401282|BEHAVIORAL|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
58128124|NCT04229849|DRUG|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
58128125|NCT04229849|DRUG|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
58314957|NCT05264532|OTHER|Survey Administration|Ancillary studies
58314958|NCT01222299|DRUG|bepotastine besilate nasal product - low dose|sterile nasal product
58128126|NCT00102908|DRUG|Zoledronate|Zoledronate infusion
58128127|NCT00102908|DRUG|Zoledronate placebo|Zoledronate placebo infusion
58128128|NCT00000880|DRUG|Cyclosporine|
58128129|NCT05836077|OTHER|Education with pecha kucha method|Education with pecha kucha method
58128130|NCT02297451|PROCEDURE|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
58128131|NCT02463149|BEHAVIORAL|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
58128132|NCT03256968|DRUG|Ataluren|ataluren
58128133|NCT04462263|DRUG|HTL0014242|Solid suspension capsule
58128134|NCT01617954|DEVICE|MammaPrint|All subjects
58128135|NCT02449876|OTHER|Neuroscience Education|"The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
58128136|NCT03194581|DEVICE|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
57960618|NCT03838679|DIAGNOSTIC_TEST|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
57960619|NCT05196945|DRUG|vonoprazan fumarate + amoxicillin|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
58128137|NCT03660839|DRUG|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
58128138|NCT03660839|DRUG|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
58128139|NCT02159716|BIOLOGICAL|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
58128140|NCT04216043|DIETARY_SUPPLEMENT|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
58128141|NCT04216043|DIETARY_SUPPLEMENT|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
58128142|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
58128143|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
58128144|NCT04533607|BEHAVIORAL|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
58128145|NCT00185523|PROCEDURE|Allogeneic hematopoietic cell transplantation|
58128146|NCT00650936|DEVICE|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
58128147|NCT02103738|OTHER|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
58128148|NCT01505257|BEHAVIORAL|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
58128149|NCT01131858|DRUG|Vigantol|Vigantol 4000IU/day
58128150|NCT01131858|DRUG|Placebo|Placebo
58128151|NCT05770752|PROCEDURE|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
58128152|NCT05875818|DIAGNOSTIC_TEST|In-clinic Rehabilitation|Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
57960620|NCT05196945|DRUG|Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate|Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
57960621|NCT05181527|DRUG|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
57960622|NCT05181527|DRUG|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
57960623|NCT05181527|DRUG|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
58128153|NCT05875818|DIAGNOSTIC_TEST|Tele-rehabilitation|Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
58128154|NCT04782609|DRUG|Icapamespib|to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.
58128155|NCT02517801|DIETARY_SUPPLEMENT|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
58128156|NCT02517801|DIETARY_SUPPLEMENT|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
58128157|NCT04790448|DRUG|Cetuximab|Route of administration: Intravenous
58128158|NCT04790448|DRUG|Irinotecan|Route of administration: Intravenous
58128159|NCT04790448|DRUG|Vemurafenib|Route of administration: Oral
58128160|NCT00576901|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
58128161|NCT00576901|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
58128162|NCT00576901|DRUG|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
58314959|NCT01222299|DRUG|bepotastine besilate nasal product - medium dose|sterile nasal product
58314960|NCT01222299|DRUG|bepotastine besilate nasal product - high dose|sterile nasal product
58128163|NCT05003648|DRUG|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
58128164|NCT05003648|DRUG|Placebo|Matching placebo
58452506|NCT01825187|OTHER|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
58452507|NCT05262257|DRUG|Metformin|Take it regularly for 12 weeks
58452508|NCT05262257|DRUG|Dapagliflozin|Take it regularly for 12 weeks
57751937|NCT01258634|DRUG|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000"
57960624|NCT04711707|OTHER|Community navigator|All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.
57960625|NCT04711707|OTHER|Self-Navigation|The control group will receive an electronic or paper copy of community resources that address the identified social needs.
57960626|NCT06367881|DRUG|Alveofact|Intratracheal High-dose Alveofact versus Low-dose Alveofact with or without Budesonide
57960627|NCT06367881|DRUG|Budesonide|Budesonide
57960628|NCT03368261|OTHER|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
57960629|NCT05060588|DRUG|Sacubitril/Valsartan 49/51mg/Tab|patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
57960630|NCT05060588|DRUG|Valsartan 80mg/Tab|Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
57960631|NCT03650192|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
57960632|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,"
58128165|NCT03254251|BEHAVIORAL|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
58128166|NCT01989728|PROCEDURE|psychiatric examination and feedback|
58452509|NCT05262257|BEHAVIORAL|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
58452510|NCT00738335|DRUG|erlotinib hydrochloride|
58452511|NCT00738335|OTHER|immunoenzyme technique|
57751938|NCT01258634|DRUG|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
57751939|NCT01258634|DRUG|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
58128167|NCT03057249|OTHER|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
58128168|NCT00950872|DEVICE|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
58128169|NCT00000941|DRUG|Pravastatin sodium|
58452512|NCT00738335|OTHER|laboratory biomarker analysis|
58452513|NCT00738335|OTHER|liquid chromatography|
58452514|NCT00738335|OTHER|mass spectrometry|
58452515|NCT00738335|OTHER|pharmacological study|
58452516|NCT00738335|RADIATION|stereotactic radiosurgery|
58452517|NCT00799266|DRUG|Zoledronic acid|intravenous infusion
58452518|NCT00799266|DRUG|Placebo|intravenous infusion
58452519|NCT03103126|BEHAVIORAL|Combined resistance exercise and walking|Combined resistance exercise and walking
58452520|NCT00569140|DRUG|E10030|Intravitreal injection
58452521|NCT03865082|DRUG|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
58452522|NCT03865082|DRUG|Nivolumab|Specified dose on specified days.
58452523|NCT03865082|DRUG|Ipilimumab|Specified dose on specified days.
58452524|NCT00316537|DRUG|ATG002 (study drug)|
58128170|NCT00000941|DRUG|Simvastatin|
58128171|NCT00000941|DRUG|Atorvastatin calcium|
58128172|NCT00000941|DRUG|Ritonavir|
58128173|NCT00000941|DRUG|Nelfinavir mesylate|
58128174|NCT00000941|DRUG|Saquinavir|
58128175|NCT03788525|BEHAVIORAL|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
58128176|NCT03788525|BEHAVIORAL|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
58128177|NCT04814745|DRUG|intrathecal infusion|morphine 150 mcg will be used by intrathecal administration
58128178|NCT04814745|DRUG|Intravenous Infusion|tramadol administration
58314961|NCT01222299|DRUG|placebo comparator nasal product|sterile nasal product
58452525|NCT00623324|DRUG|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
58452526|NCT00623324|DRUG|Placebo|Placebo tablets to match the number of active tablets
57751940|NCT01258634|DRUG|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
57960633|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike"
57960634|NCT05183503|DIAGNOSTIC_TEST|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
57960635|NCT01348646|BEHAVIORAL|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
57960636|NCT05498688|DIETARY_SUPPLEMENT|Low carbohydrate|Participants will have a low carbohydrate meal
57960637|NCT03803644|DRUG|CC-92480|Part 1 dose escalation
57960638|NCT03803644|DRUG|CC-92480|CC-92480
57960639|NCT02481973|OTHER|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
57960640|NCT01028807|OTHER|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
57960641|NCT01028807|OTHER|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
57960642|NCT00751868|DRUG|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
57960643|NCT03049904|BEHAVIORAL|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
58128179|NCT04814745|DRUG|Ropivacaine injection|bilateral transversus abdominis plane block by using ropivacaine 80 mg
58128180|NCT02531984|DRUG|Azithromycin|
58128181|NCT01627366|OTHER|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
58314962|NCT01821313|OTHER|Moderate exercise|
58314963|NCT01821313|OTHER|High Intensity Interval Exercise|
58314964|NCT01260129|DRUG|Silodosin|Silodosin 8 mg orally, once daily after morning meal
58314965|NCT01260129|DRUG|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
58314966|NCT04179630|BIOLOGICAL|Aldafermin (NGM282)|Single 3 mg dose
58314967|NCT02478333|DRUG|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
58314968|NCT02478333|DRUG|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
58314969|NCT02478333|DRUG|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
58452527|NCT04689516|DEVICE|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
58128182|NCT04818242|DEVICE|Dexcom G6 CGM with GTS|CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to \< 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) \> 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
58128183|NCT04818242|DIAGNOSTIC_TEST|POC Blood Glucose Test + Blinded CGM|Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between \<80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
58452528|NCT00392392|DRUG|nab-paclitaxel|ABI-007
58452529|NCT00392392|DRUG|Bevacizumab|Bevacizumab
58452530|NCT00392392|DRUG|Trastuzumab|Trastuzumab
58452531|NCT04509791|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
58452532|NCT03626792|OTHER|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
58452533|NCT03626792|OTHER|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
58452534|NCT02399709|DRUG|simvastatin|
58452535|NCT02399709|DRUG|Placebo|
58452536|NCT03617952|BEHAVIORAL|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
58452537|NCT00548600|PROCEDURE|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
58452538|NCT00548600|RADIATION|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
58452539|NCT00250341|DRUG|QVAR|480 mcg
58452540|NCT00250341|DRUG|Advair|250/50 mcg
58452541|NCT00250341|DRUG|Servent Diskus|50 mcg
58452542|NCT06288048|PROCEDURE|Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|"Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization"
58452543|NCT06288048|PROCEDURE|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
58452544|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
58452545|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
58452546|NCT05753839|OTHER|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
58452547|NCT05631561|DEVICE|Endovascular denervation System (Generator and Catheter )|All patients receive endovascular denervation (EDN) treatment
58452548|NCT00148759|DRUG|LPV/r|LPV/r 800/200 mg once daily
58452549|NCT05982990|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
58452550|NCT05982990|DRUG|ADVAIR DISKUS® 250/50|2 inhalations in one study period
58452551|NCT00858026|OTHER|Breastmilk|Exclusively breastfed babies
58452552|NCT00858026|OTHER|Standard milk|Weaning babies fed with the standard formula
58452553|NCT00858026|OTHER|Fermented milk|Weaning babies fed with the fermented formula
58452554|NCT04506541|OTHER|Kangaroo Care|Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
58452555|NCT06002217|DRUG|Levobupivacaine|Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml
58452556|NCT06002217|OTHER|Placebo Tap block|Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
58128184|NCT02403752|BEHAVIORAL|Paired PLIE Program|Integrative exercise as described above
58314970|NCT02478333|OTHER|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
57751941|NCT01258634|DRUG|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
57751942|NCT01258634|DRUG|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
58452557|NCT01338818|DRUG|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
58452558|NCT05170451|DRUG|CBD|Topical CBD 50 mg/ml applied in 1mL amounts twice daily
58452559|NCT05170451|OTHER|Control|Topical shea butter applied in 1mL amounts twice daily
58452560|NCT03790722|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
58452561|NCT03790722|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
58452562|NCT04440878|BEHAVIORAL|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
58452563|NCT04440878|BEHAVIORAL|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
58452564|NCT03231852|OTHER|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
58452565|NCT00700596|DRUG|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
58452566|NCT00700596|DRUG|Placebo|Control or Placebo SA (30 % ethanolic solution)
58452567|NCT00961155|DRUG|cyklezonid|160 mcg once daily
58452568|NCT00961155|DRUG|montelukast sodium|5 or 10 mg according to age once daily
58452569|NCT00961155|DRUG|placebo|fluticasone placebo twice daily, montelukast placebo once daily
58452570|NCT00961155|DRUG|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
58452571|NCT04582786|DRUG|Morphine|Repeated bolus according to pain score
58452572|NCT04582786|DRUG|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
58452573|NCT04582786|DRUG|STR-324|Infusion of solution for intravenous administration
58452574|NCT03857100|OTHER|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
58452575|NCT02185703|DEVICE|Chordate System S020 in treatment mode|
57751943|NCT05181852|DRUG|IP2015, dose 1|Active
57751944|NCT05181852|DRUG|IP2015, dose 2|Active
57751945|NCT05181852|DRUG|Placebo|Placebo
57751946|NCT05181852|DRUG|Pregabalin|Comparator
57960644|NCT01479712|PROCEDURE|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
57960645|NCT05332483|DRUG|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
57960646|NCT04963257|DRUG|sertraline fluvoxamine|the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
58128185|NCT03309956|DEVICE|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
58452576|NCT02185703|DEVICE|Chordate System S020 in placebo mode|
58452577|NCT02859714|OTHER|screening data|
58452578|NCT00205335|DEVICE|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
58452579|NCT00205335|DEVICE|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
58452580|NCT02186613|BEHAVIORAL|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
58452581|NCT00732212|DEVICE|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
57751947|NCT02732379|PROCEDURE|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
57751948|NCT02732379|PROCEDURE|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
57751949|NCT02732379|PROCEDURE|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
57751950|NCT02732379|PROCEDURE|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
57751951|NCT03786861|PROCEDURE|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
57751952|NCT03786861|PROCEDURE|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
57751953|NCT01490502|DRUG|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
57751954|NCT06459648|OTHER|Headache record|The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.
57751955|NCT06459648|OTHER|Scales|Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.
57751956|NCT06459648|DRUG|Monoclonal antibody anti-CGRP|Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab
57751957|NCT05753787|OTHER|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
57751958|NCT04519086|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI \>30
57960647|NCT04963257|DRUG|sertraline|The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
57960648|NCT01367522|DRUG|SC Methylnaltrexone (MNTX)|
57960649|NCT04728685|PROCEDURE|Mechanical Traction|Mechanical Traction will be applied to the lumbar region using a traction unit.
57960650|NCT02559466|DEVICE|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
58452582|NCT00732212|OTHER|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
58452583|NCT00358397|DRUG|Clostridium novyi-NT spores|
57751959|NCT04519086|PROCEDURE|Laparoscopic appendectomy|All patients with BMI \>30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
57751960|NCT00932776|DEVICE|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
57751961|NCT00932776|DEVICE|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
57751962|NCT01151800|OTHER|Using IVR to maintain ACS patients on best practice guidelines|
57751963|NCT03813238|DRUG|TEV-50717|Dosage ranging from 6 mg to 48 mg.
57751964|NCT03813238|DRUG|Placebo|Dosage ranging from 6 mg to 48 mg.
57751965|NCT04389450|BIOLOGICAL|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
57751966|NCT04389450|BIOLOGICAL|Placebo|Placebo solution for injection
57751967|NCT00783731|DRUG|Low dose midazolam|
57751968|NCT02601989|DRUG|Tadalafil|
57751969|NCT02601989|DRUG|Placebo|Per oral intake of placebo for six weeks
57960651|NCT02559466|DEVICE|Positon Emission Tomography (PET) - Discovery 710®|Class IB
57960652|NCT01514682|DRUG|Anti-inflammatory Combination Therapy|"1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
58452584|NCT01253642|PROCEDURE|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
58452585|NCT01253642|DRUG|Docetaxel|Given IV
58452586|NCT01253642|OTHER|Laboratory Biomarker Analysis|Correlative studies
57751970|NCT04431193|DRUG|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
57751971|NCT06272422|PROCEDURE|hip arthroplasty|resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
57751972|NCT03346603|OTHER|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
57751973|NCT03351855|BIOLOGICAL|HPV-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
57751974|NCT04710745|DIAGNOSTIC_TEST|Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.|Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
57751975|NCT04710745|DIAGNOSTIC_TEST|Echocardiography|"ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index"
57751976|NCT04710745|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives an ECG Holter for a 7-day monitoring.
57751977|NCT04710745|DIAGNOSTIC_TEST|Standardized Mini-Mental Status Exam (SMMSE)|A screening test for evaluating cognitive performance of patients done in the clinician's office.
57751978|NCT03099993|OTHER|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
57751979|NCT04852874|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
57751980|NCT02650050|RADIATION|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
57751981|NCT04864574|OTHER|Garden installation|"Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis."
57751982|NCT06070155|OTHER|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
57751983|NCT02572557|DEVICE|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
58452587|NCT01253642|DRUG|Phenelzine Sulfate|Given PO
58452588|NCT00644696|DRUG|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
58452589|NCT03244917|BEHAVIORAL|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
58452590|NCT03195283|OTHER|Meal service|The type of meal service in the hospital (usual care)
58452591|NCT04183114|BIOLOGICAL|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
58452592|NCT04183114|BIOLOGICAL|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
58452593|NCT04406896|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
58452594|NCT05062005|DRUG|Induction Chemotherapy|Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
58452595|NCT05062005|DRUG|Concurrent Chemotherapy|Cisplatin 100 mg/m², Q3w.
57751984|NCT02572557|DRUG|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
57751985|NCT03087344|DEVICE|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
57751986|NCT03087344|DEVICE|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
57751987|NCT03087344|DEVICE|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
57751988|NCT03126825|DEVICE|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
57751989|NCT03126825|DEVICE|CP910/CP920|The approved CP910 or CP920 Sound Processor.
57751990|NCT05132608|OTHER|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
58452596|NCT05062005|RADIATION|Definitive Radiotherapy|For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
58452597|NCT05084313|OTHER|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
58452598|NCT05084313|OTHER|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
57751991|NCT05096819|OTHER|App|Use of an App to measure 6MWT distance
57751992|NCT04858698|DEVICE|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
57751993|NCT00652223|BIOLOGICAL|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
57751994|NCT06562894|DRUG|SYHX1901|Administered orally, once daily (QD)
57751995|NCT06562894|DRUG|Placebo|Administered orally, once daily (QD)
57751996|NCT05428605|OTHER|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
57751997|NCT00614081|DEVICE|Contrast-enhanced dynamic MRI|
58452599|NCT05084313|OTHER|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
58452600|NCT05380063|DRUG|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
58452601|NCT05380063|DRUG|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
58452602|NCT02356445|OTHER|Cytotoxic drug|Observe patients versus treatment type
58452603|NCT02354534|DRUG|Artesunate Suppositories|
58452604|NCT01788917|DIETARY_SUPPLEMENT|Linseed oil|Dietary supplement: 10 mL linseed oil per day
58452605|NCT02179411|OTHER|tilt test|
58452606|NCT03726957|BEHAVIORAL|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
58452607|NCT03393234|RADIATION|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
58452608|NCT03522792|OTHER|Neurotensin|Intravenous infusion of neurotensin
58452609|NCT03522792|OTHER|Saline|Intravenous infusion of saline
58452610|NCT03522792|OTHER|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
58452611|NCT03522792|OTHER|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
57751998|NCT04332523|DRUG|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
57751999|NCT05682911|DRUG|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
57752000|NCT05682911|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
58128186|NCT03309956|DEVICE|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
58452612|NCT01623479|DRUG|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
58452613|NCT00430716|DRUG|Sildenafil citrate|oral, 20 mg, tid
58452614|NCT00430716|DRUG|Sildenafil citrate|oral 1 mg, tid
58452615|NCT00430716|DRUG|Sildenafil citrate|oral 5 mg, tid
58452616|NCT00430716|DRUG|Sildenafil citrate|oral 20 mg, tid
57752001|NCT03577067|PROCEDURE|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
57752002|NCT03205228|DRUG|Omeprazole|A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
57752003|NCT03205228|BEHAVIORAL|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
57752004|NCT03205228|DRUG|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
57752005|NCT04670133|DIETARY_SUPPLEMENT|Inulin|Supplementation with a prebiotic, specifically inulin.
57752006|NCT04670133|DIETARY_SUPPLEMENT|Maltodextrin|Supplementation with maltodextrin (placebo)
57752007|NCT01670981|BIOLOGICAL|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
57752008|NCT01670981|OTHER|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
57752009|NCT05387824|DEVICE|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
57752010|NCT05387824|DEVICE|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
58452617|NCT02637583|DRUG|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
58452618|NCT02637583|DRUG|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
58452619|NCT03187132|DEVICE|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
58452620|NCT03187132|DEVICE|Active Control|An active control TENS unit used to reduce acute localized pain.
58452621|NCT03058692|BIOLOGICAL|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
58452622|NCT03058692|OTHER|Placebo|Placebo is saline injection
57752011|NCT05387824|BEHAVIORAL|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
57752012|NCT00596843|BEHAVIORAL|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
57752013|NCT00596843|BEHAVIORAL|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
57752014|NCT03799068|OTHER|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
57752015|NCT03799068|OTHER|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
57752016|NCT05339932|OTHER|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
58452623|NCT03058692|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
58452624|NCT05994508|OTHER|Pickleball program|The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
58452625|NCT05291793|DRUG|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
58452626|NCT05291793|DRUG|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
58452627|NCT05291793|DRUG|Saline|2ml sterile saline administered intraarticularly
58452628|NCT00406601|DRUG|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
58452629|NCT04811040|DRUG|Oral Lenacapavir|Tablets administered without regard to food
58452630|NCT04811040|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
58452631|NCT04811040|DRUG|Teropavimab|Administered intravenously
58452632|NCT04811040|DRUG|Zinlirvimab|Administered intravenously
58452633|NCT04327102|BEHAVIORAL|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
58452634|NCT00689312|DRUG|Enfalyte|Each patient will receive one 250 ml dose.
58452635|NCT00689312|DRUG|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
58452636|NCT00689312|DRUG|Pedialyte|Each patient will receive one 250 ml dose.
58452637|NCT00228358|DRUG|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
57752017|NCT01648270|DRUG|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
57752018|NCT06076720|DEVICE|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
57752019|NCT01638325|DRUG|Insulin Lispro|Administered SC
57752020|NCT01638325|DRUG|BC106 insulin lispro|Administered SC
57752021|NCT04604002|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
57752022|NCT04604002|DEVICE|Color Fundus Photography|Non-contact white light photography
57752023|NCT04604002|DEVICE|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
57752024|NCT00338598|DRUG|Glycine|Glycine, 0.8 gr per kg given in two daily doses
57752025|NCT00338598|DRUG|placebo|
57752026|NCT03376815|DIAGNOSTIC_TEST|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
57752027|NCT01751555|DRUG|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
57752028|NCT03577639|OTHER||
58452638|NCT00228358|DRUG|cyclophosphamide|Given IV
58452639|NCT00228358|BIOLOGICAL|denileukin diftitox|Given IV
58452640|NCT00228358|OTHER|flow cytometry|Intracellular cytokine staining (correlative study)
58452641|NCT00228358|OTHER|immunoenzyme technique|ELIspot assay (correlative study)
58452642|NCT01735266|OTHER|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
58452643|NCT01735266|OTHER|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
57752029|NCT04252742|DRUG|Erenumab|140 mg, 2 consecutive injections of 70 mg
57752030|NCT04252742|DRUG|Placebo|2 consecutive injections
57752031|NCT05203484|DEVICE|Multielecotrde Mapping|Multielectrode Mapping with Pentaray/Octaray
57752032|NCT05203484|DEVICE|Point-by-point mapping|Point-by-point mapping with QDot
57752033|NCT05936931|BEHAVIORAL|Changes in CRC screening awareness and intentions|Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
57752034|NCT04201457|DRUG|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
57752035|NCT04201457|DRUG|Trametinib|Tablet; Powder for Oral Solution
57752036|NCT04201457|DRUG|Hydroxychloroquine|Tablet
57752037|NCT05899686|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
57752038|NCT01822587|DRUG|Propranolol, 40 mg|
57752039|NCT01822587|DRUG|Propranolol, 80 mg|
57752040|NCT01822587|DRUG|Placebo|
58452644|NCT01518556|DRUG|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
58452645|NCT03649074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
58452646|NCT05048316|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
57752041|NCT03496519|DRUG|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
57752042|NCT03496519|DRUG|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
57752043|NCT02355028|DRUG|LHA510 ophthalmic suspension|
57752044|NCT02355028|DRUG|LHA510 vehicle|Inactive ingredients used as a placebo comparator
57752045|NCT02355028|DRUG|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
57752046|NCT04866615|DIAGNOSTIC_TEST|Optvue OCT|Optical coherence tomography
58128187|NCT03050632|BEHAVIORAL|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
57752047|NCT04284449|OTHER|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment \& supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
57752048|NCT03367039|PROCEDURE|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
57752049|NCT03367039|PROCEDURE|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
57752050|NCT03087955|DRUG|Acoziborole (SCYX-7158)|
57752051|NCT01281202|DRUG|Vigabatrin|Tablets
57752052|NCT01281202|DRUG|Matching Placebo|Tablets
57752053|NCT01899313|BEHAVIORAL|CBT- based SMS text messaging intervention|
57752054|NCT01899313|BEHAVIORAL|CBT group therapy|
57752055|NCT00863252|DRUG|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
57752056|NCT00863252|DRUG|angiotensin blockade|Continuation of angiotensin blockade
57752057|NCT00554008|PROCEDURE|laparoscopic appendectomy|appendix removal via scope
57752058|NCT00554008|PROCEDURE|open appendectomy|open operation for removal of appendix
57752059|NCT05997264|BIOLOGICAL|AV7909 Full Dose (0.5 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
57960653|NCT01514682|DRUG|Placebo|Non-medication pills; To be taken in morning and evening intervals.
57960654|NCT03158870|PROCEDURE|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
57752060|NCT05997264|BIOLOGICAL|AV7909 Half Dose (0.25 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
57752061|NCT03913598|OTHER|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
57752062|NCT06425549|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
57752063|NCT06425549|DRUG|ustekinumab|Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
57752064|NCT06425549|DRUG|placebo|Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
57752065|NCT02423681|DEVICE|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
57752066|NCT02423681|DEVICE|Without ThermoSmart|ThermoSmart is switched off
57752067|NCT01122082|BEHAVIORAL|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
57752068|NCT03062722|PROCEDURE|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
57752069|NCT04668196|DEVICE|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
57752070|NCT04668196|DEVICE|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
57752071|NCT04668196|DEVICE|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
57752072|NCT03792854|OTHER|EORTC QLQ C30|standardized questionaire
57752073|NCT03792854|OTHER|EORTC QLQ CR29|standardized questionaire
57752074|NCT04220177|DEVICE|SETA LATECBA Stent Grafts|ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
57752075|NCT00617981|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
57752076|NCT00617981|DRUG|5% Dextrose Solution|Single 30 minute intravenous infusion
57752077|NCT04049630|DRUG|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
57752078|NCT04049630|DRUG|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
57752079|NCT04049630|DRUG|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
57752080|NCT04049630|DRUG|Placebo|5 tablets of placebo will be administrated to the participants.
57752081|NCT06252103|DRUG|Ferrous Gluconate 300 MG|iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
57752082|NCT06252103|DRUG|ferrous gluconate with lactoferrin|Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
57752083|NCT01901107|DRUG|Kiklin capsules|oral
57752084|NCT03664466|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin capsules 12 mg twice daily
57752085|NCT03664466|OTHER|Placebo|placebo capsules twice daily
57752086|NCT03086304|DEVICE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
57752087|NCT03086304|DEVICE|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
57752088|NCT04131569|DIAGNOSTIC_TEST|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
57752089|NCT05139875|DRUG|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
57752090|NCT05139875|DRUG|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
58128188|NCT03050632|BEHAVIORAL|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
57752091|NCT05439798|DRUG|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
57752092|NCT05439798|DRUG|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
57752093|NCT05439798|DRUG|Dexamethasone|Dexamethasone
57752094|NCT02943850|BIOLOGICAL|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
57752095|NCT02943850|DEVICE|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
57752096|NCT00251095|DRUG|Taxol|
57752097|NCT00251095|DRUG|TOCOSOL Paclitaxel|100 mg/m2/week
57752098|NCT00486421|BIOLOGICAL|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
57752099|NCT00486421|DRUG|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
57752100|NCT03031964|DEVICE|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
57752101|NCT00877279|DEVICE|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
57752102|NCT00877279|DEVICE|Belotero Soft|Dermal Filler
57752103|NCT06369779|DEVICE|TM Fill in combination with TM Flow|The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
57752104|NCT00117676|DRUG|TDF|300 mg tablet administered orally once daily
57752105|NCT00117676|DRUG|ADV|10 mg tablet administered orally once daily
57752106|NCT00117676|DRUG|TDF placebo|Tablet administered orally once daily
57752107|NCT00117676|DRUG|ADV placebo|Tablet administered orally once daily
58128189|NCT03325530|BEHAVIORAL|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
57752108|NCT00117676|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
57752109|NCT03925701|DRUG|Vildagliptin|vildagliptin twice daily
57752110|NCT03925701|DRUG|vildagliptin\metformin|vildagliptin\\metformin twice daily
57752111|NCT04924283|BEHAVIORAL|Tetris and Assessments|Participants will complete assessments on their phone to rate cravings for alcohol. Participants will complete a visual cognitive interference task (i.e., play Tetris on their phone) after endorsing a alcohol craving, and then re-rate craving after the task.
57752112|NCT04924283|OTHER|Assessment Only|Participants will complete assessments on their phone to rate cravings for alcohol.
57752113|NCT03388567|OTHER|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
57752114|NCT06022757|DRUG|XNW5004|XNW5004 an EZH2 inhibitor, BID, administered in continuous
57752115|NCT06022757|DRUG|KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection|KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
57752116|NCT00282022|DRUG|laromustine|
57752117|NCT06435104|OTHER|neoadjuvant chemotherapy|The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
57752118|NCT06435104|OTHER|aromatherapy|Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
57752119|NCT01833143|DRUG|Bortezomib|
57752120|NCT01833143|DRUG|Acyclovir|
57752121|NCT04370925|PROCEDURE|Radical colectomy|Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
57752122|NCT04370925|PROCEDURE|HIPEC|HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.
58128190|NCT01135641|DRUG|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
58128191|NCT01135641|DRUG|Ciclosporine|
58128192|NCT01135641|DRUG|Corticosteroids|
57752123|NCT04370925|DRUG|Systemic chemotherapy|"Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable."
57752124|NCT03426202|DRUG|Modafinil Oral Tablet|modafinil 200mg
57752125|NCT03426202|DRUG|Placebo Oral Tablet|placebo 200mg
57752126|NCT02580708|DRUG|Rociletinib|
57752127|NCT02580708|DRUG|Trametinib|
57752128|NCT05584852|OTHER||no intervention
57752129|NCT04547010|DIETARY_SUPPLEMENT|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
57752130|NCT03204955|DRUG|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
57752131|NCT03204955|DRUG|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
57752132|NCT03204955|DRUG|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
57752133|NCT00242372|DRUG|Tesaglitazar 0.5|
57752134|NCT00242372|DRUG|Insulin at least 30 units/day|
58452647|NCT01495286|DEVICE|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
57752135|NCT03872479|DRUG|EDIT-101|Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
57752136|NCT06324929|BEHAVIORAL|Survey|Participants complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control.
57752137|NCT05407454|OTHER|Questionnaire|The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.
57752138|NCT04547374|OTHER|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
57752139|NCT04749589|DIAGNOSTIC_TEST|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
57752140|NCT00114179|DRUG|capecitabine|Given orally
57752141|NCT00114179|RADIATION|radiation therapy|Undergo radiotherapy
57752142|NCT00114179|BIOLOGICAL|bevacizumab|Given IV
57752143|NCT00114179|PROCEDURE|therapeutic conventional surgery|Undergo surgery
57752144|NCT00114179|DRUG|gemcitabine hydrochloride|Given IV
57752145|NCT01155752|DRUG|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
57752146|NCT01155752|DRUG|placebo|identical placebo
58452648|NCT02417883|DRUG|Furosemide|Evaluate urinary excretion rate fo furosemide
58452649|NCT00352001|DRUG|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
58452650|NCT00352001|DRUG|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
58452651|NCT02936635|DRUG|tirasemtiv|Oral
57752147|NCT00980070|DEVICE|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
58452652|NCT04548466|DEVICE|PEP bottle|
58452653|NCT03152695|DEVICE|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
58452654|NCT03073421|OTHER|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
58452655|NCT00187863|BEHAVIORAL|pain perception|pain perception
58452656|NCT02366351|DRUG|SHR3824|Once daily, 12 weeks
57752148|NCT00980070|DEVICE|Lumbar Puncture Device|Lumbar Puncture positioner
57752149|NCT00980070|OTHER|Standard of Care|Lumbar Puncture positioner
57752150|NCT01865955|PROCEDURE|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
57752151|NCT01865955|DEVICE|The spinal needle|
57960655|NCT00215605|DRUG|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
57960656|NCT01977781|DRUG|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
58452657|NCT02366351|DRUG|Placebo|Once daily, 12 weeks
58452658|NCT02643459|BEHAVIORAL|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
58452659|NCT01682733|DRUG|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
58452660|NCT01682733|DEVICE|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
58452661|NCT03188107|OTHER|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
57752152|NCT05768685|BEHAVIORAL|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
57752153|NCT03657498|PROCEDURE|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
57752154|NCT03657498|PROCEDURE|Standard orthodontic treatment|treatment with standard orthodontic procedures
57752155|NCT02529150|BEHAVIORAL|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
57752156|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
57752157|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
57752158|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
57752159|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
57752160|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
57752161|NCT03139422|DRUG|Tranexamic Acid 500 MG|oral tablets
57752162|NCT03139422|DRUG|Calcium Dobesilate|oral tablets
57752163|NCT04803448|BEHAVIORAL|Benefit statement|"The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in \>30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis."
57752164|NCT04803448|BEHAVIORAL|Risk Statement|"The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis."
57752165|NCT04803448|BEHAVIORAL|Privacy Statement|"The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
57752166|NCT04803448|BEHAVIORAL|Benefit + Privacy|"The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
57752167|NCT04803448|BEHAVIORAL|Risk + Privacy|"The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
57752168|NCT05364775|OTHER|Focus group|Focus group
57752169|NCT02548455|DEVICE|Quartet 1457Q LV Lead|
57752170|NCT04586725|OTHER|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
57752171|NCT04586725|OTHER|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
57752172|NCT00824096|PROCEDURE|Bronchoscopy|The patients in our ICU intubated for \> 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1\~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3\~4 days even with CLV \<24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
57752173|NCT03247790|DRUG|Lasmiditan|Administered orally
57752174|NCT01620567|OTHER|avocado|1 avocado/day for 6 months
57752175|NCT01620567|OTHER|potato or chickpea|1 cup potatoes or chickpeas/day for 6 months
57752176|NCT05877950|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
57752177|NCT05877950|OTHER|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
57752178|NCT00249106|BIOLOGICAL|ADVAX|
57752179|NCT06471634|BEHAVIORAL|CBTi|A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
57752180|NCT06471634|OTHER|Control - usual care|Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
57960657|NCT01977781|DRUG|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
57752181|NCT06471634|BEHAVIORAL|Sedentary behaviour reduction|Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
57752182|NCT02969525|OTHER|Placebo|
57752183|NCT02969525|DRUG|Bimekizumab|Bimekizumab in different dosage regimens.
57752184|NCT04257266|DEVICE|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
57752185|NCT05385458|BEHAVIORAL|ACT Intervention|Acceptance and Commitment Therapy
57752186|NCT05385458|OTHER|Usual Care|Usual Care Services
57752187|NCT00665574|OTHER|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
57752188|NCT01862705|OTHER|Thoracic spine manipulation|TSM thrust or non-thrust
57752189|NCT00387673|BEHAVIORAL|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
57752190|NCT03995108|DRUG|Mavorixafor|Mavorixafor provided as 100 mg capsules.
57752191|NCT03995108|DRUG|Placebo|Placebo matching to mavorixafor capsules
57752192|NCT04657744|DRUG|Sphingomod|1 capsule contains 0.5 mg Fingolimod
57752193|NCT04657744|DRUG|Gilenya|1 capsule contains 0.5 mg Fingolimod
57752194|NCT06413836|DEVICE|aPDT|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC THERAPY/EC, Sao Carlos, Brazil) will be used to shine light at a wavelength of 660nm, 100 mW (miliWatts) and irradiation time of 3 min. CaOH (calcium hydroxide) paste will be applied at the root canals canals as a long-term dressing for endodontic treatment..
57752195|NCT06413836|PROCEDURE|Endodontic treatment|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC, THERAPY/EC, Sao Carlos, Brazil) will be used with an aluminium foil at the tip of the equipment to block light and use during 3 min as study group. CaOH (calcium hydroxide) will be applied at the root canals as a long-term dressing for endodontic treatment.
57752196|NCT02070484|BIOLOGICAL|NuCel|
57752197|NCT02070484|BIOLOGICAL|Demineralized Bone Matrix|
57752198|NCT03944525|DEVICE|High flow nasal cannula|Oxygen-therapy via HFNC
57752199|NCT03944525|DEVICE|Continuous positive airway pressure|Non-invasive CPAP ventilation
57752200|NCT00005810|BIOLOGICAL|filgrastim|
57752201|NCT00005810|DRUG|carboplatin|
57752202|NCT00005810|DRUG|docetaxel|
57752203|NCT00005810|DRUG|estramustine phosphate sodium|
58452662|NCT05438719|DEVICE|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
58452663|NCT03639363|DRUG|4% chlorhexidine gluconate soap-like solution|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
57752204|NCT00881179|DRUG|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
57752205|NCT00881179|DRUG|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
57752206|NCT06350890|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
57752207|NCT06350890|DRUG|Placebo|Matching placebo administered orally BID as four capsules
57752208|NCT06185998|DEVICE|low pressure tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
57752209|NCT06185998|DEVICE|plated balloon tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
57752210|NCT04296695|DRUG|B/F/TAF|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
57752211|NCT04296695|DRUG|TDF/3TC/EFV|TDF/3TC/EFV
57752212|NCT05592795|OTHER|Whether ERCP or EST is carried out|This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.
57752213|NCT02465281|OTHER|Device: 3T scanner with MRI-compatible robot|
57752214|NCT00772590|DRUG|Raltegravir|Tablets, 400mg, twice daily
57752215|NCT00772590|DRUG|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
57752216|NCT00772590|OTHER|raltegravir placebo|One tablet, twice daily
57752217|NCT00772590|OTHER|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
57752218|NCT00772590|DRUG|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
57752219|NCT01573936|OTHER|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
57752220|NCT06472817|OTHER|Non-Interventional Study|Non-interventional study
57752221|NCT02526043|PROCEDURE|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
57752222|NCT02526043|PROCEDURE|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
57752223|NCT02974790|PROCEDURE|Echocardiography|Two-dimensional imaging echocardiography
57752224|NCT01888393|DRUG|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
57752225|NCT03275025|DRUG|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
57752226|NCT03275025|DRUG|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
57752227|NCT03275025|DRUG|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
57752228|NCT03275025|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
57752229|NCT05834114|OTHER|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
57752230|NCT05834114|OTHER|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
57752231|NCT06200454|DEVICE|neuromuscular ultrasound of cranial nerves|neuromuscular ultrasound of cranial nerves.
58452664|NCT03639363|OTHER|standard soap|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
57752232|NCT04959058|DEVICE|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
57752233|NCT05519280|BEHAVIORAL|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
57752234|NCT00000822|DRUG|Ritonavir|
57752235|NCT00000822|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
57752236|NCT00000822|DRUG|Stavudine|
57752237|NCT00000822|DRUG|Didanosine|
57752238|NCT01982149|GENETIC|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
57752239|NCT01982149|GENETIC|Group 2|Correlate gene expression data from nasal and bronchial epithelium
57752240|NCT01982149|GENETIC|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
57752241|NCT03979196|OTHER|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
57752242|NCT03979196|OTHER|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
58458710|NCT01476423|DRUG|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
57752243|NCT01177423|PROCEDURE|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
57752244|NCT04211922|DRUG|Alkotinib Capsules|Alkotinib 400mg QD
57752245|NCT00801801|DRUG|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
57752246|NCT01735201|DRUG|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
57752247|NCT01735201|DRUG|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
57752248|NCT01735201|DRUG|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
57752249|NCT01735201|DRUG|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
57752250|NCT06423755|OTHER|Swimming programme|A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.
57752251|NCT06423755|OTHER|Standard Physiotherapy care|Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
57752252|NCT05056779|DRUG|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
57752253|NCT05056779|DRUG|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
57752254|NCT03716310|DIAGNOSTIC_TEST|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
57752255|NCT06072703|DEVICE|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
57752256|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System|
57752257|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System.|
57752258|NCT01323530|DRUG|Eribulin mesylate|Intravenous (IV) bolus or infusion.
57752259|NCT01323530|DRUG|Capecitabine|Oral film-coated tablets.
57752260|NCT02283281|DRUG|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
57752261|NCT02283281|DRUG|Dummy oromucosal|drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
57752262|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
57752263|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
57752264|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
57752265|NCT03814798|BIOLOGICAL|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
57752266|NCT01060202|DRUG|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
57752267|NCT02334566|BEHAVIORAL|NET TX|Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
57752268|NCT05831111|BIOLOGICAL|mRNA-1195.1|Sterile liquid for injection
57752269|NCT05831111|BIOLOGICAL|mRNA-1195.2|Sterile liquid for injection
57752270|NCT05831111|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
57752271|NCT05831111|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
57752272|NCT06511336|DRUG|Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt|children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
57752273|NCT00654719|DIETARY_SUPPLEMENT|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
57752274|NCT00654719|DIETARY_SUPPLEMENT|Placebo|Nutritional supplementation containing only 12 kcal/day
57752275|NCT05523622|DEVICE|Tono-Vera tonometer|The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
57752276|NCT05523622|DEVICE|Goldman Applanation Tonometry|This is the current gold standard for measuring eye pressure.
57752277|NCT05968001|DRUG|Obinutuzumab|obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
57752278|NCT02274389|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
57752279|NCT05712694|DRUG|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
57752280|NCT05712694|OTHER|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
57752281|NCT02265614|GENETIC|PGS|
57752282|NCT03251625|DRUG|Probiotic Formula Capsule|
57752283|NCT00734630|DRUG|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
57752284|NCT00734630|DRUG|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
57752285|NCT05030831|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
57752286|NCT04887025|BIOLOGICAL|RGV004|a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
57752287|NCT01232010|DRUG|Mirodenafil|50mg Single Oral Dose of
57752288|NCT01199484|OTHER|Cow's milk|
57752289|NCT01267292|DRUG|Buspirone|\[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]
57752290|NCT01267292|DRUG|Placebo for Buspirone|\[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]
57752291|NCT01267292|DRUG|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
57752292|NCT01267292|DRUG|Placebo for Methylphenidate|\[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
57752293|NCT04026529|OTHER|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope."
57752294|NCT03403348|DRUG|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
57752295|NCT03403348|DRUG|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
58452665|NCT05724407|OTHER|Diagnostic assistance tool|"Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months."
58452666|NCT01771978|DRUG|Placebo|Received 250 ml of a 5% dextrose solution as placebo
57752296|NCT02355743|DRUG|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
57752297|NCT03426384|BEHAVIORAL|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
57752298|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
57752299|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
57752300|NCT02557841|DEVICE|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
57752301|NCT01946542|DRUG|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
58128193|NCT06200701|BEHAVIORAL|Job Crafting program|The training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
58128194|NCT03823300|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
58128195|NCT03823300|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
58128196|NCT03823300|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
58452667|NCT01771978|DRUG|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
58452668|NCT01771978|DRUG|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
58452669|NCT01771978|DRUG|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~* bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~* 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
58452670|NCT04163029|PROCEDURE|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
58452671|NCT02028481|PROCEDURE|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
58452672|NCT02385851|DRUG|CHS-1701|
58452673|NCT02385851|DRUG|Pegfilgrastim|
58452674|NCT04945759|DEVICE|Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon|Evaluation and treatment will be done with the Cybex humac device.
58452675|NCT01946139|PROCEDURE|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
58452676|NCT01946139|OTHER|laboratory biomarker analysis|Correlative studies
58452677|NCT01946139|OTHER|questionnaire administration|Ancillary studies
58452678|NCT01946139|PROCEDURE|quality-of-life assessment|Ancillary studies
58452679|NCT06420089|DRUG|Senza5 CART5|The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
58452680|NCT03075618|BEHAVIORAL|Questionnaires|Questionnaires
58452681|NCT04581486|OTHER|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
58452682|NCT04581486|OTHER|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
58452683|NCT00549640|DRUG|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
58452684|NCT00549640|DRUG|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
58452685|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
58452686|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
58128197|NCT05369871|DEVICE|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
58128198|NCT05369871|DEVICE|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
58128199|NCT05111470|OTHER|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
58452687|NCT02936674|DEVICE|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
58452688|NCT02936674|DEVICE|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
58452689|NCT03370042|PROCEDURE|semilunar coronally positioned flap with free gingival graft|
58452690|NCT03370042|PROCEDURE|semilunar coronally positioned flap alone|
58452691|NCT03594682|OTHER|Intervention/treatment|"experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd"
58452692|NCT05502913|DRUG|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
58452693|NCT05502913|OTHER|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
58452694|NCT02996149|PROCEDURE|Endoscopic lung volume reduction coil treatment|
58452695|NCT04045327|DRUG|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
58452696|NCT04045327|DRUG|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
58452697|NCT03962179|DEVICE|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
57752302|NCT01946542|OTHER|placebo|
57752303|NCT03848403|BIOLOGICAL|Ixekizumab|Administered SC
58452698|NCT04071197|DEVICE|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
58452699|NCT04071197|DEVICE|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
58452700|NCT01544920|BIOLOGICAL|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
58452701|NCT01544920|DRUG|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
58452702|NCT01544920|DRUG|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
58452703|NCT05219331|PROCEDURE|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
58452704|NCT04347863|OTHER|Group swallowing disorder diet preparation program|This program included food properties, select food, type of cooking, using thickener and tasting
58452705|NCT06134219|OTHER|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
58452706|NCT06134219|OTHER|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
58452707|NCT05354908|OTHER|scientific and academic productivity|Number and quartile of scientific products generated by the group
58452708|NCT05051579|DRUG|LY3502970|Administered orally
58128200|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
58452709|NCT05051579|DRUG|Placebo|Administered orally
57752304|NCT04589533|OTHER|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
57752305|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
57752306|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
57752307|NCT02009202|DRUG|polyethylene glycol|
58128201|NCT00977106|DRUG|placebo|single iv infusion
58128202|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
57752308|NCT02009202|DRUG|picosulphate|
57752309|NCT05115448|OTHER|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
57752310|NCT02132845|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
57752311|NCT02132845|DRUG|targeted therapy|Receive target-directed therapy
57752312|NCT02132845|PROCEDURE|therapeutic procedure|Receive standard of care therapy
57752313|NCT02132845|OTHER|laboratory biomarker analysis|Correlative studies
57960658|NCT05726344|DRUG|Lactulose|4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
57960659|NCT05726344|DRUG|Polyethylene Glycol 3350|4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
58128203|NCT03421860|DRUG|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
58128204|NCT03421860|DRUG|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
58128205|NCT03421860|DRUG|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
58452710|NCT00490464|DRUG|Nicardipine and Nipride|
58452711|NCT00974753|DRUG|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
58452712|NCT00974753|OTHER|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
58452713|NCT03946748|DRUG|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
58452714|NCT02836652|DEVICE|HeartMate II (HMII)|Left Ventricular Assist Device
58452715|NCT02836652|DRUG|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
58452716|NCT02836652|DRUG|acetylsalicylic acid (ASA) therapy|(81mg/day)
58452717|NCT02098330|DRUG|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
58452718|NCT02098330|DRUG|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
58452719|NCT02459119|DRUG|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
58452720|NCT02848963|DRUG|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
58458711|NCT00702468|DRUG|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
58128206|NCT03421860|DRUG|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
58128207|NCT02761980|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
58128208|NCT02761980|DRUG|Ibuprofen 250 mg|Ibuprofen 250 mg
58128209|NCT02761980|DRUG|Acetaminophen 500 mg|1 APAP 500 mg caplet
58128210|NCT02761980|DRUG|Placebo|Placebo tablet
58128211|NCT05897580|BEHAVIORAL|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
58128212|NCT05897580|BEHAVIORAL|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
58128213|NCT06291688|BEHAVIORAL|Mobile healthcare education game|Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.
58452721|NCT04388683|DRUG|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
58452722|NCT02018341|OTHER|homeopathic remedy in 30C potency|
58452723|NCT02018341|OTHER|Placebo|
58452724|NCT05399563|OTHER||
58452725|NCT00350571|BEHAVIORAL|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
58452726|NCT00350571|BEHAVIORAL|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
57752314|NCT01559948|BEHAVIORAL|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
57752315|NCT01559948|DEVICE|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
57752316|NCT02708979|OTHER|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
57752317|NCT02708979|OTHER|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
57752318|NCT05810168|OTHER|Dietary modifications|TDA and low FODMAP diet
57752319|NCT00892502|DRUG|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
57752320|NCT00892502|DRUG|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
57752321|NCT00765232|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
57752322|NCT00765232|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
57752323|NCT03479697|DEVICE|HIRREM|Technology
57752324|NCT03479697|OTHER|Continued Current Care|Continue their current clinical care.
57752325|NCT05417880|DRUG|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
57752326|NCT05417880|DRUG|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
57752327|NCT05417880|DRUG|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
57752328|NCT03547843|BEHAVIORAL|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
57752329|NCT03547843|BEHAVIORAL|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
57752330|NCT03547843|OTHER|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
58452727|NCT00350571|BEHAVIORAL|standard care follow up|routine counselor phone calls and letters
58452728|NCT01454596|BIOLOGICAL|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
58452729|NCT01454596|DRUG|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
58452730|NCT01454596|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
58452731|NCT01454596|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
58452732|NCT01429493|RADIATION|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
58452733|NCT01429493|RADIATION|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
58452734|NCT01429493|RADIATION|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
58452735|NCT03169166|DRUG|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
58452736|NCT00128895|DRUG|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
58452737|NCT06027203|PROCEDURE|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
58452738|NCT04376216|DRUG|Prednisone|60 mg with dose tapering over 2 months
58452739|NCT01594931|DRUG|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
58452740|NCT00088140|DRUG|IDN-6556|
58452741|NCT00088140|DRUG|Placebo|
58452742|NCT03018444|DRUG|Atorvastatin|Atorvastatin tablet
58452743|NCT03018444|OTHER|Placebo|Placebo tablet
58452744|NCT02750774|BEHAVIORAL|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
58452745|NCT02750774|OTHER|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
58452746|NCT05915845|OTHER|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
58452747|NCT05915845|OTHER|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
58452748|NCT03923894|DIETARY_SUPPLEMENT|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
57752331|NCT01690091|DRUG|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
58452749|NCT03923894|DIETARY_SUPPLEMENT|Placebo|Placebo 2.07 g/day for 8 weeks.
58452750|NCT04387513|PROCEDURE|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
58452751|NCT05355064|DRUG|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
58452752|NCT04765514|OTHER|Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)|Temozolomide or Radiotherapy
58452753|NCT04765514|COMBINATION_PRODUCT|Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.|Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
58452754|NCT00481819|DRUG|FK506MR|oral
57752332|NCT01690091|DRUG|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
57960660|NCT04595214|OTHER|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
58452755|NCT00481819|DRUG|Prograf|oral
58452756|NCT00481819|DRUG|Mycophenolate Mofetil|oral
58452757|NCT00481819|DRUG|Methylprednisolone|oral
58452758|NCT00481819|DRUG|Prednisolone|oral
58452759|NCT05551858|DRUG|Proglumide|(CAS: 6620-60-6.)
58452760|NCT05551858|DRUG|Placebo|Avicel fiber filled capsule taken by mouth three times daily
58458712|NCT00702468|DRUG|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
58314971|NCT03769493|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
58314972|NCT05729321|COMBINATION_PRODUCT|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
58314973|NCT04238741|OTHER|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
57960661|NCT04196868|DRUG|Metformin treatment|1500 mg once a day, per os, during six months
58314974|NCT04319224|DRUG|Vopratelimab|Specified dose on specified days
58314975|NCT04319224|DRUG|Ipilimumab|Specified dose on specified days
58314976|NCT04319224|DRUG|Nivolumab|Specified dose on specified days
58314977|NCT05745168|DIAGNOSTIC_TEST|OraQuick|The intervention is based on respondent-driven sampling approach. Each selected seed from hotspots and on social networks is provided with two types of coupons for HIVST kit at partner pharmacy: electronic coupons (e-coupons) consisting of a pictured unique anonymous QR code and identifier and the address of pharmacies; paper coupons consisting of similar information to e-coupon. The seeds will then distribute coupons to their networks physically, via social media, and smart phone applications. Each recruited participant will bring the coupon to be scanned at the pharmacies to receive a free access HIVST kit. There, trained community worker will do the study visit including information/consent, e-CRF filling and providing link to send the test results. These recruited individuals will be considered as wave 1 and will each receive 10 additional coupons to recruit new members in the networks. The next round of individuals recruited and enrolled will be considered as wave 2, and so on.
58314978|NCT00966576|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
58314979|NCT05557214|BEHAVIORAL|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
58314980|NCT00457353|DRUG|Bacillus Clausii|For 5 days
58314981|NCT00457353|OTHER|Oral rehydration therapy|For 5 days
58314982|NCT03808766|OTHER|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
58314983|NCT02480296|DRUG|MYK-461|
58314984|NCT02480296|DRUG|Placebo|Placebo comparator
58314985|NCT00359476|DRUG|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
58314986|NCT00152048|DRUG|Eflornithine hydrochloride|
58314987|NCT06425016|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG)|Bariatric Surgery
58314988|NCT06425016|PROCEDURE|Robotic Sleeve Gastrectomy (RSG)|Bariatric Surgery
58314989|NCT04640116|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
58314990|NCT04640116|PROCEDURE|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
58314991|NCT02478827|BEHAVIORAL|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
58314992|NCT02182804|DEVICE|Olympus|narrow band imaging with magnification
58314993|NCT02182804|DEVICE|Cellvizio|probe-based confocal laser endomicroscopy
58314994|NCT00506675|DEVICE|Patching|42 hours per week of patching
58314995|NCT00506675|DRUG|Atropine|daily atropine (1%)
58314996|NCT00506675|DEVICE|Patching|two hours of daily patching for 4 weeks, then no treatment
58314997|NCT00506675|DRUG|Atropine|once weekly atropine for 4 weeks, then no treatment
57960662|NCT04196868|OTHER|Placebo|per os, during six months
57960663|NCT04196868|DRUG|Methotrexate treatment|per os
57752333|NCT02239380|DRUG|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
57752334|NCT05019664|DEVICE|Affixus Natural Nail System|Intramedullary nailing designed for fixation and stabilization of fractures or osteotomies of the humerus. Nails are comprised of proximal and antegrade/retrograde.
57752335|NCT00217646|DRUG|Sorafenib Tosylate|Given orally
57752336|NCT06550336|DRUG|Chidamide|20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
57752337|NCT05596643|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
57752338|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
57752339|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
57752340|NCT05596643|DIAGNOSTIC_TEST|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
57752341|NCT05596643|DIAGNOSTIC_TEST|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
57752342|NCT05596643|DIAGNOSTIC_TEST|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
57752343|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to standing|clinical test to detect sympathetic dysfunction
57752344|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
57752345|NCT05596643|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
57752346|NCT05596643|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
57752347|NCT05596643|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
57752348|NCT05596643|OTHER|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
57752349|NCT05596643|OTHER|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
57752350|NCT01086748|DRUG|Risperidone|Administered orally.
57752351|NCT01086748|DRUG|Placebo|Administered orally.
57752352|NCT01086748|DRUG|LY2140023|Administered orally.
57752353|NCT01941732|DRUG|Sildenafil|
58128214|NCT06291688|BEHAVIORAL|Mobile healthcare education application|Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
57752354|NCT02834156|OTHER|LP in a seated position then LP in a lying position|
57752355|NCT02834156|OTHER|LP in a lying position then LP in a seated position|
57752356|NCT04889001|OTHER|Simulation enhanced HBB training|Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
58314998|NCT02998853|OTHER|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
57752357|NCT04667299|DRUG|Rabeprazole|20mg bid
57752358|NCT04667299|DRUG|Bismuth potassium citrate|0.6g bid
58314999|NCT02222467|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
57752359|NCT04667299|DRUG|Metronidazole|0.4g qid
57752360|NCT04667299|DRUG|Amoxicillin|1g bid
57752361|NCT02563457|OTHER|periodontal manual treatment|periodontal manual treatment
57752362|NCT02563457|OTHER|no periodontal manual treatment|blood sampling
57752363|NCT03372122|DRUG|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
57752364|NCT03372122|COMBINATION_PRODUCT|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
57752365|NCT01172769|BIOLOGICAL|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
57752366|NCT06579482|DRUG|Aesculus hippocastanum, and associations|combination product
57752367|NCT03061565|DRUG|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
57752368|NCT03061565|DRUG|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
57752369|NCT03077191|OTHER|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
57752370|NCT03500614|BEHAVIORAL|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
57752371|NCT03500614|BEHAVIORAL|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
57752372|NCT06370364|OTHER|Nurses' Practice of Safe Blood Transfusion|Nurses' Practice of Safe Blood Transfusion
57752373|NCT04167501|OTHER|biological sample analysis|HPV Prevalence analysis
57752374|NCT03166150|OTHER|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
57752375|NCT03166150|OTHER|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
57752376|NCT03578003|OTHER|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
57752377|NCT06308679|DRUG|Empagliflozin 10 mg tablets|Empagliflozin 10 mg tablets (test drug)
57752378|NCT06308679|DRUG|JARDIANCE®|Empagliflozin 10 mg tablets (reference drug)
57752379|NCT03958084|DIAGNOSTIC_TEST|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
57752380|NCT04381520|OTHER|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
57752381|NCT04381520|DRUG|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
58315000|NCT04799990|DRUG|Risankizumab|Subcutaneous Injection
58452761|NCT02931032|PROCEDURE|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
58452762|NCT00580736|DEVICE|Optical Clearing|Optical Clearing
58452763|NCT00878956|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
57752382|NCT02693938|DEVICE|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
57752383|NCT02693938|DEVICE|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
57752384|NCT00041730|BIOLOGICAL|Id-KLH|
57752385|NCT05321680|OTHER|Treatment withdrawal|Tapering or suspension of antidementia drugs
57752386|NCT05288660|DRUG|ALXN1210|All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
57752387|NCT05288660|DRUG|Placebo|All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
57752388|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
57752389|NCT04156165|OTHER|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
57752390|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Control|Lighter life VLCD products
57752391|NCT04156165|OTHER|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
57752392|NCT01791920|DRUG|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
57752393|NCT01791920|DRUG|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
57752394|NCT05950334|DRUG|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
57752395|NCT05950334|DRUG|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
57752396|NCT05950334|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
57752397|NCT05950334|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
57752398|NCT05950334|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
57752399|NCT01448564|OTHER|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
57752400|NCT01448564|OTHER|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
57752401|NCT04805255|RADIATION|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
57752402|NCT06180304|OTHER|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
57752403|NCT05204589|BIOLOGICAL|Aerosolized Ad5-nCoV|Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
57752404|NCT05204589|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine|Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
58315001|NCT04799990|BIOLOGICAL|Comparator 1|Subcutaneous or Intravenous Injection
58315002|NCT04799990|DRUG|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
58458713|NCT03814707|DRUG|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
57752405|NCT00003260|DRUG|FOLFIRI regimen|
58315003|NCT02313714|DEVICE|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
57752406|NCT00003260|DRUG|FOLFOX regimen|
57752407|NCT00003260|DRUG|fluorouracil|
57752408|NCT00003260|DRUG|irinotecan hydrochloride|
58315004|NCT02313714|DEVICE|Sham|very low electric muscular stimulation
58315005|NCT05679986|OTHER|no intervention|no intervention
58315006|NCT01269294|DRUG|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
58315007|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
58315008|NCT01269294|DRUG|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
58315009|NCT01269294|DRUG|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
58315010|NCT01269294|DRUG|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
58315011|NCT01269294|DRUG|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
58315012|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
58315013|NCT02609490|DRUG|Azilsartan tablets|20mg/tablet
58315014|NCT02609490|DRUG|Azilsartan placebo tablets|placebo tablet
58315015|NCT02609490|DRUG|Olmesartan medoxomil tablets|20mg/tablet
58315016|NCT02609490|DRUG|olmesartan medoxomil placebo tablets|placebo tablet
58315017|NCT02839317|BIOLOGICAL|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
58315018|NCT00651846|DRUG|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
58315019|NCT00651846|DRUG|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
58315020|NCT06458270|BEHAVIORAL|Salt warning label|A salt warning label will feature on the restaurant menu next to menu items that are high in salt (\>3g, more than 50% of guideline daily amount \[GDA\] in the UK).
58315021|NCT06078982|DRUG|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
58315022|NCT06078982|DRUG|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
58315023|NCT02991521|PROCEDURE|Fast exam|Positional change before Fast exam
58315024|NCT00808925|OTHER|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
58315025|NCT03197636|DRUG|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
58315026|NCT04017377|DRUG|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
58315027|NCT05066984|OTHER|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
58315028|NCT02640560|OTHER|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
58315029|NCT02640560|OTHER|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
58315030|NCT04933565|DRUG|ORG-129|ORG-129 oral capsules
58315031|NCT04933565|DRUG|Placebo|Placebo oral capsules
58315032|NCT01184872|DRUG|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
58315033|NCT01184872|DRUG|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
58458714|NCT03814707|BIOLOGICAL|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
57752409|NCT00003260|DRUG|leucovorin calcium|
57752410|NCT00003260|DRUG|oxaliplatin|
57752411|NCT04702633|OTHER|Results obtained by biopsy and MRI results.|Results obtained by biopsy and MRI results.
57752412|NCT04702633|OTHER|Clinical data|Clinical data
57752413|NCT01982435|DRUG|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
57752414|NCT01982435|DRUG|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
58315034|NCT04192682|DRUG|Anlotinib Hydrochloride|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
58315035|NCT04884568|DEVICE|Exufiber|Wound dressed with Exufiber for up to 21 days.
58315036|NCT00942851|DRUG|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
58315037|NCT00942851|DRUG|placebo|topical treatment NOT containing AH-8
58315038|NCT03736720|DRUG|Fluorouracil|Given IV
57752415|NCT03574597|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
58452764|NCT00878956|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
58452765|NCT00521287|OTHER|Immune profiling and DC vaccine|"1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression."
58452766|NCT01012986|OTHER|Assessment of reading skills|
58452767|NCT02108249|DEVICE|Annex™ Adjacent Level System|
58452768|NCT03915171|DIAGNOSTIC_TEST|Next generation sequencing|NGS can provide genetic and MSI test for patients
58452769|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
57752416|NCT03574597|DRUG|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
57752417|NCT02507518|PROCEDURE|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
58128215|NCT06367569|DIAGNOSTIC_TEST|Screening for trilateral retinoblastoma with MRI|The diagnostic accuracy of the screening program, baseline screening with MRI followed by follow-up of suspicious pineal glands in heritable retinoblastoma patients.
58315039|NCT03736720|DRUG|Leucovorin|Given IV
58315040|NCT03736720|DRUG|Liposomal Irinotecan|Given IV
58315041|NCT03736720|PROCEDURE|Quality-of-Life Assessment|Correlative studies
58315042|NCT03136575|BEHAVIORAL|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
58315043|NCT03136575|BEHAVIORAL|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
58315044|NCT05107037|DRUG|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
58315045|NCT03530696|DRUG|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
58315046|NCT03530696|DRUG|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
58315047|NCT05218876|OTHER|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
58315048|NCT05218876|OTHER|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
58315049|NCT05859230|DIETARY_SUPPLEMENT|Experimental: The probiotic drink study group|The 100 ml volume of milk drink containing 10 billion Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded by study team members and subjects. The milk drink bottles are coded by the manufacturing company.
58315050|NCT05859230|DIETARY_SUPPLEMENT|Placebo Comparator: The placebo drink study group|The 100 ml volume of milk drink without containing Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded to study team members and subjects. The milk drink bottles are coded by the manufacturing company.
58315051|NCT04742218|DRUG|K-877|K-877 Tablet
58315052|NCT00761878|PROCEDURE|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
58315053|NCT03861039|DRUG|Tirzepatide|Administered SC
58315054|NCT03861039|DRUG|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
58315055|NCT01781247|BEHAVIORAL|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
58315056|NCT01781247|BEHAVIORAL|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
58315057|NCT02585206|BEHAVIORAL|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
58315058|NCT02585206|BEHAVIORAL|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
58315059|NCT02585206|BEHAVIORAL|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
58452770|NCT01250366|DRUG|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
58452771|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
58452772|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
58452773|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
58452774|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
58452775|NCT01250366|DRUG|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
57752418|NCT01974115|DEVICE|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
57752419|NCT03169218|OTHER|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
58452776|NCT01250366|DRUG|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
58452777|NCT01250366|DRUG|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
58452778|NCT05220878|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
58452779|NCT05220878|BIOLOGICAL|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
58452780|NCT02501252|PROCEDURE|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
57752420|NCT03169218|OTHER|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
57752421|NCT05995028|BIOLOGICAL|Universal CD7-specific CAR gene-engineered T cells|Infusion of 4SCAR7U T cells
57752422|NCT05453825|BIOLOGICAL|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
57752423|NCT05453825|BIOLOGICAL|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
57752424|NCT05453825|BIOLOGICAL|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
57752425|NCT05660200|DIETARY_SUPPLEMENT|IBSA Iron ODF|IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
57752426|NCT05660200|DIETARY_SUPPLEMENT|SiderAL® FORTE|Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
57752427|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
57752428|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
57752429|NCT02232308|DRUG|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
57752430|NCT02232308|DRUG|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
57752431|NCT02232308|DRUG|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
57752432|NCT00168038|BIOLOGICAL|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
57752433|NCT00361439|DRUG|Mometasone|2 puffs in each nostril once daily of nasal spray
57752434|NCT00361439|DRUG|Placebo|2 puffs in each nostril once daily of nasal spray
57752435|NCT00772785|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
57752436|NCT03617744|PROCEDURE|Sleeve gastrectomy|Open sleeve gastrectomy
57752437|NCT01017354|DRUG|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
57752438|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|60000 vitamin D3 orally and once per month
57752439|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
57752440|NCT01966003|DRUG|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
57752441|NCT01966003|DRUG|Paclitaxel|Administered 200 mg/m² IV Q3W
57752442|NCT01966003|DRUG|ABP 215|Administered 15 mg/kg Q3W by IV infusion
57752443|NCT01966003|DRUG|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
57752444|NCT04895865|BEHAVIORAL|RPE-based load and repetition number selection|Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
58452781|NCT01384734|DRUG|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
58452782|NCT01384734|DRUG|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
58452783|NCT01384734|DRUG|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
58452784|NCT01384734|DRUG|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
57752445|NCT04895865|BEHAVIORAL|Predetermined load and number of repetitions|Trainees predetermine the load and perform ten repetitions per set and exercise
57752446|NCT02170025|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
57752447|NCT02170025|DRUG|Placebo|Participants received matching placebo tid.
57752448|NCT04536246|PROCEDURE|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
57752449|NCT04536246|PROCEDURE|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
57752450|NCT03365154|DEVICE|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
57752451|NCT03365154|DEVICE|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
57752452|NCT03823781|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo.
57752453|NCT03823781|DRUG|Normal saline|The study intervention is an intravenous infusion of milrinone or placebo.
57752454|NCT04608175|OTHER|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
57752455|NCT01066325|BEHAVIORAL|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
57752456|NCT01066325|OTHER|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
57752457|NCT01408355|DRUG|PF-06273588|Intravenous, 50 microgram, single dose
57752458|NCT01408355|DRUG|PF-06273588|Oral solution, 50 microgram, single dose
57752459|NCT06168812|DRUG|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
57752460|NCT01939873|BEHAVIORAL|KRISTELLER|
57752461|NCT01839006|PROCEDURE|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
57752462|NCT05134766|OTHER|Observation only|Based on type of SOC applied and the type of CAM products by subject's own decison
57752463|NCT00246116|PROCEDURE|Functional Imaging of Treatment Effects|PET \& VQ Scans
57752464|NCT00511017|DRUG|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
57752465|NCT03967431|OTHER|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
57752466|NCT06069050|PROCEDURE|sequential adolesent left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
57752467|NCT05095805|BEHAVIORAL|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
57752468|NCT05095805|BEHAVIORAL|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
57752469|NCT01756950|BIOLOGICAL|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
57752470|NCT01756950|BIOLOGICAL|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
57752471|NCT01756950|BIOLOGICAL|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
57752472|NCT01756950|BIOLOGICAL|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
57752473|NCT01756950|BIOLOGICAL|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
57752474|NCT01756950|BIOLOGICAL|Placebo|administered as a single 2-hour intravenous infusion
57752475|NCT06083870|DRUG|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
57752476|NCT05711537|DEVICE|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
57752477|NCT03339479|DIAGNOSTIC_TEST|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
57752478|NCT03339479|DIAGNOSTIC_TEST|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
57752479|NCT03339479|DIAGNOSTIC_TEST|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
57752480|NCT06566326|DRUG|Propofol and ketamine|Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
57960664|NCT05688943|PROCEDURE|Spinal Anesthesia|Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
58128216|NCT02922868|DEVICE|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
57752481|NCT06566326|DEVICE|Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool|Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
57752482|NCT00072761|PROCEDURE|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
57752483|NCT03767179|DIAGNOSTIC_TEST|study|procalcitonin, sedimentation, CRP, leukocyte identification
57752484|NCT01245465|OTHER|Profermin|Medical Food (food for special medical purposes)
57752485|NCT04684225|OTHER|Hand Therapy via Telerehabilitation|Hand Therapy via Telerehabilitation
57752486|NCT04684225|OTHER|Hand Therapy via home-exercises|Hand Therapy via home-exercises
57752487|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus Placebo|15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
58452785|NCT01384734|DRUG|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
58452786|NCT01384734|DRUG|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
57752488|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus iron Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
57752489|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus zinc Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
57752490|NCT02846090|DRUG|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
57752491|NCT03322280|PROCEDURE|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
57752492|NCT03322280|PROCEDURE|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
57752493|NCT02231177|DRUG|BI 1744 CL|
57752494|NCT02231177|DRUG|BI 1744 CL/Tiotropium FDC|
57752495|NCT02231177|DRUG|Tiotropium|
57752496|NCT01509781|PROCEDURE|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
57752497|NCT01509781|PROCEDURE|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
57752498|NCT03409666|DEVICE|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
57752499|NCT03409666|DEVICE|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
57752500|NCT00954148|PROCEDURE|PET/CT|5 visits with PET/CT as only testing
57752501|NCT00954148|PROCEDURE|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
57752502|NCT04700501|OTHER|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
57752503|NCT05205902|OTHER|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
57752504|NCT05205902|OTHER|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
57752505|NCT00990964|DEVICE|Attain Success Lead|Attain Success Lead
57752506|NCT02157779|BEHAVIORAL|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
57752507|NCT02157779|BEHAVIORAL|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
57752508|NCT01965405|DRUG|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
58452787|NCT01384734|DRUG|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
57752509|NCT01965405|BEHAVIORAL|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
57752510|NCT01965405|BEHAVIORAL|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
58452788|NCT01384734|DRUG|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
58452789|NCT05659771|BEHAVIORAL|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
57752511|NCT01965405|BEHAVIORAL|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
57752512|NCT01965405|BEHAVIORAL|No additional treatment|No additional treatment will be given.
58452790|NCT02257034|OTHER|Taichi|
57752513|NCT01965405|BEHAVIORAL|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
57752514|NCT01965405|BEHAVIORAL|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
57752515|NCT04827485|OTHER|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
57752516|NCT04827485|OTHER|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
57752517|NCT01756352|DRUG|18F-FET|Radiotracer, surrogate marker for protein synthesis
57752518|NCT05684627|DIETARY_SUPPLEMENT|Fast mimicking diet group|Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.
57752519|NCT05684627|PROCEDURE|Normal diet group|Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
57752520|NCT01414621|OTHER|atrial tissue sample|atrial tissue sample from CABG patient
57752521|NCT03613805|DEVICE|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
57752522|NCT03613805|DEVICE|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
57752523|NCT00877084|OTHER|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
57752524|NCT00877084|OTHER|Usual care|usual care according to clinical pathway for COPD, No training
57752525|NCT04604080|OTHER|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
57752526|NCT02493296|OTHER|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
57752527|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and human counseling|
57752528|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and computer counseling|
57752529|NCT00200304|BEHAVIORAL|Internet weight loss program with SlimFast|
57752530|NCT04000568|OTHER|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
57752531|NCT04119895|OTHER|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
57752532|NCT04119895|OTHER|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
57752533|NCT02592538|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
57752534|NCT02592538|DRUG|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
57752535|NCT02592538|DEVICE|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
57752536|NCT02475252|PROCEDURE|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
57752537|NCT01534026|DRUG|Aspirin|Current dose
57752538|NCT01534026|OTHER|withdrawal of aspirin|Stopping current dose of aspirin
57752539|NCT00604032|DRUG|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
57752540|NCT02969720|DIETARY_SUPPLEMENT|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
57752541|NCT02969720|DIETARY_SUPPLEMENT|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
57752542|NCT05982184|OTHER|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
57752543|NCT04211064|DIAGNOSTIC_TEST|Ultrasonographic measurement of optic nerve sheath diameter|Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
57752544|NCT04211064|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
57752545|NCT04211064|PROCEDURE|Moderate neuromuscular block|Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
57752546|NCT00853164|BEHAVIORAL|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
58128217|NCT02922868|DEVICE|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
58452791|NCT02257034|OTHER|Dance|
58452792|NCT00716963|DRUG|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
58452793|NCT00716963|DRUG|budesonide 400 mcg|budesonide 400 mcg
58452794|NCT00716963|OTHER|Placebo|Placebo
58452795|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
58452796|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
58452797|NCT04283071|DEVICE|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
58452798|NCT02870998|OTHER|Active learning|1-day continuing education activity consisting of a lecture on patient education.
58452799|NCT02870998|OTHER|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
58452800|NCT06472492|BEHAVIORAL|Adjuvant yoga intervention|The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
58452801|NCT05498168|GENETIC|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
58452802|NCT05152758|DEVICE|PARx|Prescription Physical Activity Programming Application
58452803|NCT01363700|DRUG|DE-114 ophthalmic solution|
58452804|NCT01363700|DRUG|Placebo ophthalmic solution|
58452805|NCT01363700|DRUG|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
58452806|NCT03741686|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)
58452807|NCT03741686|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
57752547|NCT00853164|BEHAVIORAL|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
57752548|NCT00853164|BEHAVIORAL|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
57752549|NCT01560325|DRUG|CKD-516 inj.|CKD-516: 3.3\~13mg/m2/day
57752550|NCT05098054|DRUG|Soticlestat|Soticlestat tablets.
57752551|NCT03419364|DRUG|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
57752552|NCT06433531|DRUG|TQH2929 Injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
58128218|NCT00321542|OTHER|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
58128219|NCT04101149|OTHER|No intervention|No intervention.
58128220|NCT03441581|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
58128221|NCT01328730|DEVICE|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
58128222|NCT01328730|DEVICE|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
58452808|NCT00717249|DEVICE|galyifilcon A control lens|Marketed daily wear contact lens
58452809|NCT00717249|DEVICE|galyfilcon A with a silver additive|Investigational daily wear contact lens
58452810|NCT02568514|DEVICE|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
58452811|NCT05663021|DIAGNOSTIC_TEST|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
58452812|NCT04354792|DIAGNOSTIC_TEST|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
58452813|NCT03022396|BIOLOGICAL|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
58452814|NCT03022396|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
58458715|NCT05075746|DEVICE|enVista Toric|enVista Toric IOL
57752553|NCT02899494|OTHER|Antenatal classes|
57752554|NCT02899494|OTHER|Physical and psychic preparation|
57752555|NCT03211364|OTHER|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
57752556|NCT03211364|OTHER|Scapular mobilization|
57752557|NCT02701010|BEHAVIORAL|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
57752558|NCT02701010|BEHAVIORAL|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
57752559|NCT02701010|BEHAVIORAL|Leaflet|"The patients who were given only educational leaflet were included in this group."
57752560|NCT02701010|BEHAVIORAL|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
57752561|NCT04732091|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
57752562|NCT04697264|DIAGNOSTIC_TEST|Blood and tissue sample collection from patients with endometrial cancer|Blood and tissue sample collection from patients undergoing surgery for endometrial cancer and blood sample collection only from patients undergoing chemotherapy for endometrial cancer
57752563|NCT03866941|BEHAVIORAL|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
57752564|NCT02599415|DEVICE|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
57752565|NCT03418116|DEVICE|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
57752566|NCT01995487|DEVICE|BioNIR|drug-eluting stent
57752567|NCT01995487|DEVICE|Resolute|drug-eluting stent
57752568|NCT05727410|DRUG|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
57752569|NCT01878929|DRUG|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
57752570|NCT03861910|DIETARY_SUPPLEMENT|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
57752571|NCT06186141|DRUG|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
57752572|NCT06186141|DRUG|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
57752573|NCT01559233|DEVICE|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
57752574|NCT01751126|DRUG|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
58128223|NCT03342495|OTHER|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
58128224|NCT03342495|OTHER|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
58128225|NCT06162923|BEHAVIORAL|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
57752575|NCT01751126|DRUG|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
57752576|NCT02929433|OTHER|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
57752577|NCT05294796|COMBINATION_PRODUCT|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
57752578|NCT05294796|COMBINATION_PRODUCT|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
57752579|NCT04188379|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
57752580|NCT04188379|OTHER|Placebo|Intravenous infusion of placebo
57752581|NCT01964326|DRUG|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
57752582|NCT04382105|OTHER|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
57752583|NCT02694705|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
57752584|NCT02694705|DEVICE|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
57752585|NCT02694705|DEVICE|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
58315060|NCT02585206|BEHAVIORAL|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
57752586|NCT04843787|DRUG|SLV213|SLV213 oral capsule (200mg) BID
57752587|NCT04843787|DRUG|SLV213|SLV213 oral capsule (400mg) BID
57752588|NCT04843787|DRUG|SLV213|SLV213 oral capsule (800mg) QD
57752589|NCT04843787|DRUG|Placebo|Placebo oral capsule (200mg) BID
57752590|NCT04843787|DRUG|Placebo|Placebo oral capsule (400mg) BID
57752591|NCT04843787|DRUG|Placebo|Placebo oral capsule (800mg) QD
57752592|NCT03224182|DRUG|Qapzola|Qapzola administered by the intravesical route.
57752593|NCT03224182|DRUG|Placebo|Qapzole-matching placebo administered by the intravesical route.
57752594|NCT03768258|DRUG|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
57752595|NCT01367028|DRUG|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
57752596|NCT01367028|DRUG|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
57752597|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
57752598|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
57752599|NCT01270269|BEHAVIORAL|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
57752600|NCT01270269|BEHAVIORAL|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
57752601|NCT03769779|DIETARY_SUPPLEMENT|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
57752602|NCT03769779|DIETARY_SUPPLEMENT|Safflower Oil|Safflower Oil
57752603|NCT00673309|PROCEDURE|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
57752604|NCT00673309|DRUG|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
57752605|NCT00673309|DRUG|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
57752606|NCT00673309|DRUG|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
58128226|NCT06162923|BEHAVIORAL|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
58315061|NCT02585206|BEHAVIORAL|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
58315062|NCT06102551|BEHAVIORAL|Recurrence after surgery|Recurrence after repair was the main outcome
57752607|NCT00673309|DRUG|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
57752608|NCT00673309|DRUG|Insulin Low Dose|Insulin administered IV until 95% wound healing
57752609|NCT00673309|DRUG|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
57752610|NCT00673309|DRUG|Itraconazole|Itraconazole administered until 95% wound healing
57752611|NCT00673309|DRUG|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
57752612|NCT00673309|DRUG|Oxandrolone and Propranolol|Oxandrolone and Propranolol
57752613|NCT00673309|DRUG|Placebo or Control|Administration of Placebo or Control until 95% wound healing
57752614|NCT03511911|DIAGNOSTIC_TEST|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
57752615|NCT03511911|DIAGNOSTIC_TEST|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
57752616|NCT00717639|PROCEDURE|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
57752617|NCT05736341|DRUG|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
57752618|NCT05736341|DRUG|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
57752619|NCT00209573|DRUG|fospropofol disodium|
57752620|NCT01876290|DRUG|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
57752621|NCT01876290|DRUG|Placebo|Placebo
57752622|NCT03493230|BIOLOGICAL|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
58315063|NCT00959751|DRUG|NXN-188|200 mg capsules, 600 mg, PRN
58315064|NCT00959751|DRUG|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
58315065|NCT04075149|DRUG|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
58315066|NCT02638532|PROCEDURE|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
57752623|NCT04467385|OTHER|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~* Coconut ShootersVR - 5 min/day~* Ninja flipVR - 5 min/day.~* Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~* Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~* Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~* Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~* Conventional exercises include:~  * passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
57752624|NCT04467385|OTHER|VR training + conventional therapy|"After the baseline assessment,~* The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~* Coconut ShootersVR - 8 min/day~* Ninja flipVR - 8 min/day~* Conventional Therapy - 20 min per day~  * Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
57752625|NCT04995848|OTHER|Telepalliation|Telepalliation platform Telepal.dk
57752626|NCT00529490|DRUG|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
58452815|NCT03826719|BIOLOGICAL|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
57752627|NCT00529490|DRUG|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
57752628|NCT00316173|DRUG|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
57752629|NCT00316173|DRUG|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
57752630|NCT06525766|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57752631|NCT06525766|PROCEDURE|Bone Scan|Undergo bone scan
57752632|NCT06525766|DRUG|Capecitabine|Given PO
57752633|NCT06525766|PROCEDURE|Computed Tomography|Undergo CT
57752634|NCT06525766|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57752635|NCT06525766|OTHER|Questionnaire Administration|Ancillary studies
57752636|NCT04526535|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
57752637|NCT04050241|DEVICE|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
57752638|NCT04050241|DEVICE|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
57752639|NCT00648128|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
57752640|NCT00648128|DRUG|Clarithromycin|single-dose 500 mg immediate-release oral dose'
57752641|NCT02062359|BIOLOGICAL|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
57752642|NCT02062359|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
57752643|NCT02062359|DRUG|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
57752644|NCT02062359|DRUG|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
57752645|NCT03027648|PROCEDURE|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
57752646|NCT01116492|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
57752647|NCT01116492|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
57752648|NCT05374564|DRUG|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
57752649|NCT03346720|OTHER|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
57752650|NCT03346720|OTHER|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
58315067|NCT02159638|DEVICE|Guardian Enlite sensor|Sensor insertion
58315068|NCT02159638|DEVICE|Dexcom G4 platinum sensor|Sensor insertion
58452816|NCT03826719|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains(trivalent)
58452817|NCT04215536|DRUG|Empagliflozin|Empagliflozin dispensing claim is exposure
58452818|NCT04215536|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
58452819|NCT00472901|DRUG|Afamelanotide (CUV1647)|16mg implant
57752651|NCT02464813|DRUG|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
57752652|NCT02464813|DRUG|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
57752653|NCT02464813|DRUG|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
57752654|NCT03570398|OTHER|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
57752655|NCT03570398|OTHER|abdominal ultrasound|abdominal ultrasound
57752656|NCT03297203|BEHAVIORAL|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
57752657|NCT04493931|DRUG|Gepotidacin|Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
57752658|NCT04493931|DRUG|Cimetidine|Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
57752659|NCT04493931|DRUG|Rifampicin|Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
57752660|NCT04493931|DRUG|Midazolam|Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
57752661|NCT04493931|DRUG|Digoxin|Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
57752662|NCT04493931|OTHER|Placebo matching to gepotidacin|Placebo matching to gepotidacin tablets will be administered orally.
57752663|NCT01613638|OTHER|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
57752664|NCT00265980|DRUG|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
57752665|NCT00265980|DRUG|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
57752666|NCT02745821|DEVICE|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
57752667|NCT03637543|DRUG|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
57752668|NCT01266850|BIOLOGICAL|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
57752669|NCT01266850|BIOLOGICAL|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
57752670|NCT04757987|OTHER|Pain|As above
57752671|NCT06332079|PROCEDURE|166Holmium TARE|166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.
58452820|NCT03112265|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
57752672|NCT06332079|DRUG|Cetuximab|Target agent
57752673|NCT06332079|DRUG|Panitumumab|Target agent
58128227|NCT01434966|OTHER|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
57752674|NCT06332079|DRUG|5-Fluorouracil|Chemotherapy
57752675|NCT06332079|DRUG|Bevacizumab|Target agent
57752676|NCT06332079|DRUG|Capecitabine|Chemotherapy
57752677|NCT00000279|DRUG|Clonidine|
57752678|NCT05382260|OTHER|Listening to music|After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
57752679|NCT02685644|PROCEDURE|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
57752680|NCT03682835|DIETARY_SUPPLEMENT|FDGard|capsule containing peppermint oil and caraway oil
57752681|NCT03682835|OTHER|Placebo|Placebo capsule containing cellulose
57752682|NCT05849779|DRUG|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
57752683|NCT05849779|DRUG|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
57752684|NCT05738993|DRUG|BCD-178|A single intravenous (IV) infusion at a dose of 420 mg
57752685|NCT05738993|DRUG|Perjeta|A single intravenous (IV) infusion at a dose of 420 mg
57752686|NCT03921814|DEVICE|Treatment with IPL device|Exposure of body parts to the IPL device
58452821|NCT03112265|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
58452822|NCT03112265|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
58452823|NCT02763644|DRUG|LFG316 active drug|LFG316
58452824|NCT02763644|OTHER|Standard of care treatment|SoC (site specific)
58452825|NCT01529073|DRUG|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
58452826|NCT04879693|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
58452827|NCT00052585|DRUG|irinotecan hydrochloride|Given IV
58452828|NCT00052585|DRUG|gefitinib|Given orally
58452829|NCT00052585|DRUG|leucovorin calcium|Given IV
58452830|NCT00052585|DRUG|fluorouracil|Given IV
58452831|NCT04429191|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
58452832|NCT01379716|OTHER|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
58452833|NCT00096421|BEHAVIORAL|Tight control of blood glucose levels|
57752687|NCT02432989|BEHAVIORAL|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
57752688|NCT03026023|DRUG|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
57752689|NCT03474302|BEHAVIORAL|Physical Activity|Aerobic, strength training, balance, flexibility
57752690|NCT03474302|OTHER|Successful Aging|Healthy aging education
57752691|NCT06344390|DRUG|Pentoxifylline|Take pentoxifylline 0.4 g twice daily
57752692|NCT04717414|DRUG|ACE-536|Subcutaneous Injection
57752693|NCT04717414|OTHER|Placebo|Subcutaneous Injection
57752694|NCT04279314|DRUG|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
57752695|NCT01351298|DRUG|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
57752696|NCT01351298|DRUG|0.05% xylometazoline hydrochloride|Decongestant
58452834|NCT00096421|BEHAVIORAL|Conventional control of glucose levels|
58452835|NCT03228771|DRUG|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
58452836|NCT03228771|DRUG|ATV gel|Atorvastatin loaded in methyl cellulose gel
58452837|NCT06049329|DRUG|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
58452838|NCT06049329|DRUG|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
58452839|NCT02169986|BEHAVIORAL|electronic reminders|
58452840|NCT00230646|BEHAVIORAL|Exercise counseling|
58452841|NCT00134303|DRUG|Metformin|Metformin is used.
58452842|NCT06109363|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I intervention will be provided to participants once their districts are exposed.
58452843|NCT02614729|OTHER|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
58452844|NCT02614729|OTHER|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
58452845|NCT02614729|OTHER|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
57752697|NCT01351298|DRUG|Isotonic normal saline|Placebo
57752698|NCT01742377|PROCEDURE|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
57752699|NCT01742377|PROCEDURE|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
57752700|NCT01742377|PROCEDURE|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
57752701|NCT02083016|DEVICE|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
58452846|NCT02614729|OTHER|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
57752702|NCT02083016|DEVICE|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
57752703|NCT04750967|DRUG|Lidocaine 1% Injectable Solution|Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
57752704|NCT04750967|DRUG|Amitriptyline|Amitriptyline 25 mg daily
57752705|NCT01160848|DRUG|Area cleaned with saline water and occluded with Tegaderm|
57752706|NCT01160848|DRUG|Area cleaned with saline water|
57752707|NCT01160848|DRUG|Area cleaned with Ethyl alcohol solution|
57752708|NCT01160848|DRUG|Visonac left on the skin for 24 hours in facial area one|
57752709|NCT01160848|DRUG|Visonac wiped off after one hour|
57752710|NCT01160848|DRUG|Visonac left on the skin 24 hours in facial area two|
57752711|NCT04076410|DEVICE|Z1 lens|CE marked device
57752712|NCT04076410|DEVICE|Experimental Lens 1|CE marked device
57752713|NCT04076410|DEVICE|Experimental Lens 2|CE marked device
57752714|NCT04076410|DEVICE|Experimental Lens 3|CE marked device
57752715|NCT04076410|DEVICE|Experimental Lens 4|CE marked device
57752716|NCT05429970|BEHAVIORAL|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
57752717|NCT05429970|BEHAVIORAL|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
57752718|NCT05429970|DRUG|Propranolol|Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
57752719|NCT05429970|DRUG|Etodolac|Etodolac 400 mg PO BID (for 21 consecutive days)
57752720|NCT05959343|BEHAVIORAL|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
57752721|NCT02017054|OTHER|Cath|No intervention - registry
57752722|NCT01185444|PROCEDURE|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
57752723|NCT01185444|PROCEDURE|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
57752724|NCT02492854|DEVICE|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
57752725|NCT02492854|OTHER|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
57752726|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
57752727|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
57752728|NCT01989143|DRUG|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
58452847|NCT05487521|DRUG|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
58452848|NCT06307418|OTHER|Carer eSupport|Internet-based support
58452849|NCT05266612|DRUG|VG2025|"1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15"
57752729|NCT01989143|DRUG|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
57752730|NCT01989143|DRUG|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
57752731|NCT01989143|DRUG|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
58452850|NCT05266612|DRUG|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
58452851|NCT03006380|DRUG|oxytocin|Ecbolic used to reduce blood loss
58452852|NCT01028105|OTHER|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
58452853|NCT03584165|GENETIC|BIIB111|Administered as specified in the treatment arm.
58452854|NCT03584165|GENETIC|BIIB112|Administered as specified in the treatment arm.
57752732|NCT01989143|DRUG|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
57752733|NCT01989143|DRUG|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
57752734|NCT00001507|DRUG|Monoclonal Antibody 3A1|
57752735|NCT00001507|DRUG|Monoclonal Antibody 95-5-49|
57752736|NCT00001507|DRUG|Monoclonal Antibody 95-6-22|
57752737|NCT00001507|DEVICE|Baxter Isolex 3001 Stem Cell Selection System|
57752738|NCT00001507|DEVICE|Ceprate SC|
57752739|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
58452855|NCT06434883|BEHAVIORAL|Anxiety/Depression Program|Participants will complete the Headspace Anxiety/Depression Program, which is a 21 day program based on CBT, combined with mindfulness. The program is trans-diagnostic in nature (i.e. addresses both anxiety and depression symptoms).
58452856|NCT06434883|OTHER|Waitlist|Participants will continue their regular routines for an 21 day period and will not be assigned to an intervention.
58452857|NCT00116012|DRUG|rNAPc2|
57752740|NCT02139098|DRUG|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
57752741|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
57752742|NCT02139098|DRUG|Placebo|Placebo
57752743|NCT05001360|DRUG|XBI-302 + Nivolumab|After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
57752744|NCT04334265|DRUG|Anluohuaxian|6g each time, twice a day
57752745|NCT02298361|OTHER|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
57752746|NCT06453655|BEHAVIORAL|Nursing Process|In the first step of the nursing process, nursing diagnoses NANDA-I and nursing outcomes (NOC) appropriate to the needs of the individual were selected. Immediately afterwards, the baseline measurements of NOCs were made. In the second stage, nursing interventions were determined in line with the selected diagnoses and started to be implemented. Instructions for the implementation of the selected NICs were reminded by phone 3 days before the procedure appointment and compliance with colonoscopy preparation instructions was monitored. In the third stage, after measurement of the NOCs were performed on the day of the procedure. In addition, the BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form and the stages of the nursing process were completed.
57752747|NCT05742828|BEHAVIORAL|Virtual Seating Coach|Power wheelchair intervention
57752748|NCT03846102|DRUG|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
57752749|NCT03846102|DRUG|Placebo|Sodium Chloride 0,9% for injection/infusion.
57752750|NCT03846102|DRUG|Acetaminophen|Acetaminophen 500 milligram tablet
57752751|NCT03846102|DRUG|Morphine|Morphine 1 mg/ml solution for infusion.
58315069|NCT02859298|DEVICE|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
58452858|NCT00887549|DRUG|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
57752752|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
57752753|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
57752754|NCT00002892|BIOLOGICAL|recombinant interferon alfa|
57752755|NCT01844271|DEVICE|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
57752756|NCT02658630|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
58315070|NCT02738502|DRUG|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
58452859|NCT00887549|DRUG|cisplatin|Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
58452860|NCT04955457|OTHER|Healthy women active teachers|The neuropsychological testing data, psychometric measure, demographic, clinical and lifestyle information and blood samples were collected at similar time points. This group not received any intervention.
57752757|NCT02606279|DRUG|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
57752758|NCT02606279|OTHER|Placebo|
58315071|NCT00919672|DEVICE|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
58452861|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
58452862|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
58452863|NCT05343858|DIETARY_SUPPLEMENT|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
58452864|NCT06289933|DRUG|BR3005|One tablet administered alone, Once a day
58452865|NCT06289933|DRUG|BR3005-1|One tablet administered alone, Once a day
58452866|NCT06289933|DRUG|BR3005-2|One tablet administered alone, Once a day
58452867|NCT03275740|DRUG|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
58452868|NCT03275740|DRUG|Placebo intravenous healthy participant|Placebo comparator
58452869|NCT03275740|DRUG|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
58452870|NCT03275740|DRUG|Placebo subcutaneous healthy participant|placebo comparator
58452871|NCT03275740|DRUG|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
58452872|NCT00619515|OTHER|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
58452873|NCT00619515|PROCEDURE|implanted fiducial-based imaging|Undergo fiducial placement imaging
58452874|NCT00619515|RADIATION|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
58452875|NCT02986126|BEHAVIORAL|Resiliency Class|See Arm Description
57752759|NCT04791280|PROCEDURE|Faeces collection|"* faeces collection at inclusion~* follow-up visit 6 months after inclusion"
57752760|NCT03021356|DEVICE|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
57752761|NCT04181970|OTHER|Quality assessment|There is no intervention on study subjects. A tumor review will be performed by expert centers.
57752762|NCT00290862|DEVICE|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
58315072|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and calcium sulfate|
58315073|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and xenograft|
58315074|NCT01170650|DRUG|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
58452876|NCT02986126|OTHER|Resource for Services (RS)|See Resource for Services (RS) Description
58452877|NCT00540072|DRUG|daptomycin|
58452878|NCT02180581|DIETARY_SUPPLEMENT|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months
58452879|NCT02180581|DIETARY_SUPPLEMENT|Placebo|Placebo for 6 months
58452880|NCT01434173|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
58452881|NCT01434173|DRUG|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
58452882|NCT05460455|DRUG|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
58452883|NCT03914417|DRUG|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
58452884|NCT00002503|RADIATION|strontium chloride Sr 89|
58452885|NCT00874146|GENETIC|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
58452886|NCT02928315|DRUG|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
58452887|NCT02928315|OTHER|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
58452888|NCT05289115|DEVICE|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
58452889|NCT05289115|DEVICE|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
58452890|NCT03053947|DRUG|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
58452891|NCT03049761|DEVICE|Water Flosser|Power interdental cleaner
58452892|NCT03049761|DEVICE|String Floss|Mechanical interdental cleaner
58452893|NCT03049761|DEVICE|Manual Toothbrush|ADA standard soft bristle toothbrush
58452894|NCT00375271|PROCEDURE|perioperative hemodynamic optimization protocol|
58452895|NCT02551068|OTHER|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
57752763|NCT05446324|DRUG|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
57752764|NCT03893721|DIAGNOSTIC_TEST|arsenic exposure|analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
57752765|NCT01705496|RADIATION|[124I]FIAU|This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
57752766|NCT00406003|DRUG|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
57752767|NCT01774864|DRUG|DA-8159 (Udenafil)|
57752768|NCT01774864|DRUG|Placebo|
57752769|NCT05391750|BIOLOGICAL|Tocilizumab|Given IV
57752770|NCT05391750|DRUG|Venetoclax|Given PO
57752771|NCT04439643|DEVICE|vascuCAP|time to event and phenotype classification model
57752772|NCT02591134|OTHER|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
57752773|NCT02591134|OTHER|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
57752774|NCT02184754|PROCEDURE|Magnetic endoscope imaging (MEI)|
57752775|NCT01525316|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
57752776|NCT01525316|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
58452896|NCT02551068|OTHER|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
58452897|NCT05596136|DIAGNOSTIC_TEST|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
58452898|NCT00954993|DRUG|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
58452899|NCT02535455|BEHAVIORAL|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
58452900|NCT04932928|DEVICE|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
58452901|NCT04932928|DEVICE|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
58452902|NCT01059409|PROCEDURE|Meniscal Allograft|Meniscal Allograft
58315075|NCT01170650|DRUG|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
58452903|NCT02760966|OTHER|Alcohol 70º|
58452904|NCT02760966|OTHER|Soap|
58452905|NCT01759797|BIOLOGICAL|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
57752777|NCT06579274|DRUG|Parecoxib|Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
58315076|NCT01170650|DRUG|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
58315077|NCT01170650|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
58315078|NCT04632121|DRUG|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
58452906|NCT04301466|DRUG|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
57752778|NCT06579274|DRUG|Placebo|Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
57752779|NCT05145387|BEHAVIORAL|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
57752780|NCT03984370|DRUG|ZP4207|Abdominal SC administration
58315079|NCT03667287|PROCEDURE|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
58315080|NCT02362022|DRUG|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
58315081|NCT02754453|BEHAVIORAL|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
58315082|NCT06329167|DRUG|Daphnetin|150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
57752781|NCT03984370|OTHER|Placebo (saline)|Abdominal SC administration
57752782|NCT01259050|DRUG|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
57752783|NCT00415610|DRUG|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
57752784|NCT06326827|DEVICE|In'Oss™ (MBCP® Putty)|Use of In'Oss™ (MBCP® Putty) in surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia.
57752785|NCT01250990|DRUG|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
57752786|NCT01250990|OTHER|Placebo|Placebo
58452907|NCT04301466|DRUG|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
58452908|NCT00154297|DRUG|Everolimus (RAD001)|
58452909|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
58452910|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
58452911|NCT00423839|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
58452912|NCT05022459|DRUG|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
58452913|NCT05022459|DRUG|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
57752787|NCT06011772|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
57752788|NCT06011772|DRUG|Leucovorin|Given IV
57752789|NCT06011772|DRUG|Oxaliplatin|Given IV
58452914|NCT02058953|PROCEDURE|Craniotomy scheduled|Resection of affected brain tissue
57752790|NCT06011772|DRUG|Fluorouracil|Given IV
57752791|NCT06011772|BIOLOGICAL|Bevacizumab|Given IV
57752792|NCT06011772|DRUG|Irinotecan|Given IV
57752793|NCT06011772|BIOLOGICAL|Cetuximab|Given IV
57752794|NCT06011772|PROCEDURE|Metastasectomy|Undergo metastasectomy
57752795|NCT06011772|PROCEDURE|Biospecimen collection|Undergo collection of blood samples
57752796|NCT06011772|PROCEDURE|Computed Tomography|Undergo CT
57752797|NCT06011772|BIOLOGICAL|Panitumumbab|Given IV
57752798|NCT06576882|DRUG|Vonoprazan|Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
57752799|NCT06576882|DRUG|Amoxicillin|Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
57752800|NCT06576882|DRUG|Clarithromycin|Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
57752801|NCT02987075|OTHER|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
57752802|NCT02987075|OTHER|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
57752803|NCT03702842|DEVICE|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
57752804|NCT03702842|OTHER|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
57752805|NCT03757221|COMBINATION_PRODUCT|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
58452915|NCT02058953|PROCEDURE|Collection for non-craniotomy|CSF, Blood, biopsy
58452916|NCT03469063|DIETARY_SUPPLEMENT|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
58452917|NCT01316874|DRUG|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
58452918|NCT04340635|OTHER||Without intervention
58452919|NCT01014130|RADIATION|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
58452920|NCT01014130|RADIATION|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
58452921|NCT03371472|DEVICE|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
58452922|NCT06378034|DIETARY_SUPPLEMENT|Lactium|300 mg per day, taken 30 min to 60 min before bedtime
58452923|NCT06378034|DIETARY_SUPPLEMENT|Placebo|300 mg per day, taken 30 min to 60 min before bedtime
58458716|NCT05075746|DEVICE|enVista non-Toric (spherical)|enVista non-Toric (spherical) IOL
57752806|NCT06218225|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
57752807|NCT06218225|DIETARY_SUPPLEMENT|Placebo|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
57752808|NCT05602051|DEVICE|virtual reality device|mindfulness combined with virtual reality
58128228|NCT01434966|OTHER|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
58128229|NCT01434966|OTHER|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
58452924|NCT06050746|OTHER|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
58452925|NCT00257426|DRUG|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
58452926|NCT01935635|BIOLOGICAL|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
58452927|NCT03266133|BEHAVIORAL|Sleep Education for Pregnancy|Sleep education specific to pregnancy
58452928|NCT04524858|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
58452929|NCT01517932|DRUG|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
58452930|NCT01517932|DRUG|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
58452931|NCT05268640|PROCEDURE|Double-level cervical cerclage|two cervical sutures + regimen of antibiotics + indomethacin + progesterone
57752809|NCT04027348|DRUG|Dexamethasone|Given IV
57752810|NCT04027348|DRUG|Metoclopramide|Given IV
57752811|NCT04027348|DRUG|Octreotide|Given IV
57752812|NCT00855062|DRUG|minocycline|100 mg capsule every 12 hours by mouth
57752813|NCT00855062|DRUG|minocycline placebo capsule|1 capsule every 12 hours by mouth
57752814|NCT03924479|DEVICE|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
57752815|NCT00400907|OTHER|clinical observation|
57752816|NCT00400907|PROCEDURE|management of therapy complications|
57752817|NCT06236867|OTHER|KaleidoscopeGroup|The group consists of 34 people. Pain level was measured during 3 dialysis sessions.In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
57752818|NCT06236867|OTHER|Ice Application Group|The group consists of 34 people. Pain level was measured during 3 dialysis sessions. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point)
57752819|NCT06236867|OTHER|Control Group|The group consists of 34 people. Pain level will be measured during 3 dialysis sessions. In the control group, the vital signs of the patients before AVF cannulation will be recorded.
58452932|NCT05268640|PROCEDURE|Single-level cervical cerclage|single cervical suture + regimen of antibiotics + indomethacin + progesterone
57752820|NCT01074398|GENETIC|gene expression analysis|
57752821|NCT01074398|GENETIC|polymorphism analysis|
57752822|NCT01074398|GENETIC|protein expression analysis|
57752823|NCT01074398|OTHER|immunohistochemistry staining method|
57752824|NCT01074398|OTHER|laboratory biomarker analysis|
57752825|NCT03062462|DRUG|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
57752826|NCT03062462|DRUG|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
57752827|NCT02379182|BEHAVIORAL|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
58128230|NCT00497796|DRUG|maribavir|100mg twice a day for 14 weeks.
58128231|NCT00497796|DRUG|ganciclovir|1000mg three times per day for 14 weeks.
58452933|NCT00381004|DRUG|Cyclophosphamide|Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
58452934|NCT00381004|DRUG|Fludarabine|Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
58452935|NCT00381004|DRUG|Sargramostim|Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10
57752828|NCT02379182|DEVICE|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
57752829|NCT02379182|DEVICE|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
57752830|NCT01519492|DRUG|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
57752831|NCT05308550|DIAGNOSTIC_TEST|rapid RT-LAMP test to detect SARS-COV-2 RNA|rapid RT-LAMP test to detect SARS-COV-2 RNA
57752832|NCT04398537|DEVICE|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
57752833|NCT04398537|DEVICE|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
57752834|NCT04457557|OTHER|Reduced concentration of local anesthetic (ropivacaine)|Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
57752835|NCT04457557|OTHER|Usual concentration of local anesthetic (ropivacaine)|0.5% ropivacaine 15ml
57752836|NCT03958838|BEHAVIORAL|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
57752837|NCT03154489|OTHER|acenocoumarol|medication review with follow-up in acenocoumarol treatment
57752838|NCT03154489|OTHER|control|group
57752839|NCT00995982|BIOLOGICAL|VRC-FLUDNA056-00VP|
57752840|NCT05473754|BEHAVIORAL|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
57752841|NCT01620905|PROCEDURE|Manipulation|Single level cervical spine joint manipulation
57752842|NCT01458470|DRUG|Memantine|oral tablet, 1 BID, 24 weeks
57752843|NCT01458470|OTHER|Placebo|oral tablet, 1 BID, 24 weeks
57752844|NCT02803554|OTHER|Plasma|Blood plasma from donors aged 25 years or younger
57752845|NCT06452056|DEVICE|Rapid Antigen Screening Test|A point-of-care Rapid Antigen Screening Test (RAST) using a lateral flow immunoassay platform with our partner, BioMedomics Inc. The BioMedomics RAST is a lateral flow immunoassay that detects the nucleocapsid protein (NP) antigen of SARS-CoV-2 using a double antibody sandwich assay. The test cassette contains one detection line (T) fixed with anti-SARS-CoV-2 NP antibody and one quality control line (C) fixed with control antibody. When the test sample is treated with lysis buffer and added to the sample well of the test cassette, the fluid will move forward along the test strip via capillary action. If the sample contains NP antigen at levels higher than the limit of detection, the antigen will bind to the NP capture antibody as well as the immobilized detection antibody on the membrane forming a red T line, indicating a positive result. A positive signal at C line provides assurance that the fluid containing the sample material has moved laterally in an appropriate fashion.
57752846|NCT06214845|PROCEDURE|Red blood cell EXchange (REX)|A single automated REX will be performed, as soon as possible after randomization.
57752847|NCT04147039|BEHAVIORAL|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
57752848|NCT02273830|DRUG|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
58128232|NCT00427128|DRUG|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
58452936|NCT00381004|DRUG|Rituximab|Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
57752849|NCT06532318|BIOLOGICAL|Platelet rich plasma|Freshly prepared autologus platelet rich plasma
57752850|NCT06532318|DRUG|Pfizer Depo-medrol|Methylprednisolone acetate 20mg/ml injection
57752851|NCT06352372|DEVICE|noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)|The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
58128233|NCT00427128|DRUG|placebo|Week 13-36.
58315083|NCT06329167|DRUG|Aescuven|150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
58315084|NCT05112978|DIAGNOSTIC_TEST|MRI|MRI genu non contrast
58315085|NCT03341520|DRUG|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
58452937|NCT03494920|OTHER|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
57752852|NCT03376867|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
57752853|NCT00900874|DRUG|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
57752854|NCT00900874|DRUG|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
57752855|NCT03151681|DRUG|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
57752856|NCT02296554|PROCEDURE|SLAP Repair|SLAP repair for SLAP tear
57752857|NCT02296554|PROCEDURE|Biceps Tenodesis|Biceps tenodesis for SLAP tear
57752858|NCT04928963|DIETARY_SUPPLEMENT|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
57752859|NCT05666219|DRUG|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
57752860|NCT04481295|OTHER|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
57752861|NCT04481295|OTHER|Low SpO2|Low SpO2
57752862|NCT02926248|DRUG|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
57752863|NCT02926248|OTHER|Placebo|
57752864|NCT06371131|PROCEDURE|Right -stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
57752865|NCT04744857|COMBINATION_PRODUCT|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
57752866|NCT00063284|DEVICE|Magstim Rapid Magnetic Stimulator|
57752867|NCT04876222|PROCEDURE|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
58452938|NCT03494920|OTHER|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
58452939|NCT04533386|BEHAVIORAL|Multi-component intervention strategy|Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
57752868|NCT01100554|DEVICE|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
57752869|NCT03431402|DRUG|Hyperbaric oxygen|- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
57752870|NCT06579976|OTHER|No intervention|This is an observational study, no intervention will be implemented.
57752871|NCT00489333|DRUG|ProAlgaZyme|
57752872|NCT05602649|DRUG|Cannabis|Cannabis will be orally ingested
57752873|NCT05602649|DRUG|Placebo|Placebo will be orally ingested
57752874|NCT01952184|DEVICE|CBSvit HS device|closed vitrification with closed storage
57752875|NCT01952184|DEVICE|Cryotop SC device|open vitrification with closed storage
57752876|NCT04358003|DEVICE|Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)|"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician."
57752877|NCT05815654|DEVICE|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
57752878|NCT03323879|RADIATION|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
57752879|NCT06574802|PROCEDURE|ERL + air polishing|Er:YAG laser (ERL) plus sub-gingival air polishing treatment
57752880|NCT06574802|PROCEDURE|ERL|ERL treatment
57752881|NCT05970965|PROCEDURE|Biological sampling|- Saliva and blood sampling
58452940|NCT01774201|OTHER|Breathing exercises|Breathing exercises with positive expiratory pressure.
58452941|NCT01329237|OTHER|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
58315086|NCT03341520|RADIATION|Low dose radiation Therapy (LDRT)|2 x 2 Gy
58458717|NCT03622008|DRUG|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
58458718|NCT03622008|OTHER|Placebo|Placebo IV
58458719|NCT05366023|BEHAVIORAL|BUD1|10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
57752882|NCT05557331|DEVICE|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
57752883|NCT04979975|OTHER|Placebo|PBO- placebo matching to UB-621
57752884|NCT04979975|BIOLOGICAL|UB-621 low-dose|fully human anti-HSV mAb
57752885|NCT04979975|BIOLOGICAL|UB-621 high-dose|fully human anti-HSV mAb
57752886|NCT05871710|OTHER|Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale|The Tele-Pulmonary Rehabilitation Acceptance Scale is a measuring tool that assesses the level of acceptance towards telerehabilitation programs among healthcare providers and patients in the field of pulmonary rehabilitation. It is used to evaluate the attitudes, beliefs, and perceptions of potential users towards telerehabilitation, which is a form of healthcare delivery that utilizes telecommunication technology to provide remote rehabilitation services to patients. The scale is intended to provide a standardized data collection tool that can be used to measure the level of acceptance of telerehabilitation programs among different groups of potential users. This scale will be translated into Turkish by a researcher who has an advanced level of knowledge in English and whose native language is Turkish.
57752887|NCT05871710|OTHER|Scale Evaluation Form|The healthcare providers and the patients will be asked about their opinions on the scale's construction, usefulness, and scope using a 100 mm visual analog scale.
57752888|NCT05598801|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
57752889|NCT02697279|PROCEDURE|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.
57752890|NCT02697279|PROCEDURE|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
57752891|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
57752892|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
57752893|NCT00002402|BIOLOGICAL|Aluminum hydroxide|
57752894|NCT00608010|PROCEDURE|Vitrification|Embryos were vitrified according to a previously described technique
57752895|NCT00608010|PROCEDURE|Slow freezing|Embryos were frozen with slow freezing technique
57752896|NCT01649830|RADIATION|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
57752897|NCT01649830|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
57752898|NCT00328432|DRUG|celecoxib 400 mg bid|
58452942|NCT02423655|OTHER|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
57752899|NCT02945384|BEHAVIORAL|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
57752900|NCT02435368|DRUG|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
57752901|NCT05543291|BEHAVIORAL|renal function|levels of eGFR
57752902|NCT04999878|DRUG|Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
57752903|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
57752904|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
57752905|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
57752906|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
57752907|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
57752908|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
57752909|NCT01444157|OTHER|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
57752910|NCT05549401|DRUG|CKD-348(4) F1|QD, PQ
57752911|NCT05549401|DRUG|CKD-348(4) F2|QD, PQ
57752912|NCT05549401|DRUG|CKD-828, D097, D337|QD, PQ
57752913|NCT05618548|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
58458720|NCT05366023|BEHAVIORAL|BUD2|10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
58458721|NCT05366023|BEHAVIORAL|TDD1|10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
58128234|NCT04940455|OTHER|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
57752914|NCT03050502|DEVICE|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
57752915|NCT03050502|OTHER|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
57752916|NCT04923113|DIAGNOSTIC_TEST|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
57752917|NCT04923113|DRUG|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
57752918|NCT05228548|OTHER|Perioperative blood transfusion|Perioperative blood transfusion
57752919|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
57752920|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
57752921|NCT03308825|BIOLOGICAL|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
57752922|NCT00005801|BIOLOGICAL|therapeutic allogeneic lymphocytes|
57752923|NCT00005801|PROCEDURE|peripheral blood stem cell transplantation|
57752924|NCT00005801|RADIATION|radiation therapy|
57752925|NCT02781948|DEVICE|Optical Coherence Tomography|
57752926|NCT03349164|DIAGNOSTIC_TEST|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
57752927|NCT00983086|DRUG|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
57752928|NCT04789265|OTHER|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
57752929|NCT00306033|DRUG|Intravenous ImmuneGlobulin|
57752930|NCT04811430|DEVICE|Randomized Traditional|Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients
57752931|NCT04811430|DEVICE|Cue(TM) Needle Tracking Technology|Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
57752932|NCT06437379|BEHAVIORAL|Infection control|To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.
57752933|NCT05741580|PROCEDURE|Evolution of symptoms|percentage of patients with improvement in their symptoms
57752934|NCT00627848|DRUG|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
57752935|NCT05122390|OTHER|Contraction Coper|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.
57752936|NCT05122390|OTHER|Contraction Coper Plus|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
57752937|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression|In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
57752938|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + lateral skin incision|Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
57752939|NCT02662725|DRUG|IPILIMUMAB|
57752940|NCT02662725|RADIATION|Stereotactic radiosurgery|
58128235|NCT01725451|DRUG|Testosterone|Administered topically to axillae
58315087|NCT01348243|DRUG|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
58315088|NCT01348243|DRUG|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
58458722|NCT05366023|BEHAVIORAL|TDD2|10 hours of top-down driven computerized cognitive training designed to improve executive function
58458723|NCT05366023|BEHAVIORAL|CSA10|10 hours of computerized games
57752941|NCT00816465|DIETARY_SUPPLEMENT|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
57752942|NCT00816465|OTHER|Placebo|PO Placebo pill
57752943|NCT04035213|BEHAVIORAL|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
57752944|NCT05372770|DEVICE|Flourish Vaginal Care system|Flourish includes Restore® vaginal moisturizing gel, a Class II medical device cleared by the FDA, in addition to two other kit components
57752945|NCT03642041|BEHAVIORAL|smoking|smoking behavior
57752946|NCT03968757|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
57752947|NCT03350334|DRUG|Duloxetine|Peri-operative Duloxetine administration
57752948|NCT03350334|DRUG|placebo|Placebo administration
57752949|NCT03182699|DIAGNOSTIC_TEST|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
57752950|NCT03182699|DIAGNOSTIC_TEST|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
58128236|NCT01725451|OTHER|Deodorant Spray|Administered topically to axillae
58128237|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
58128238|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
58128239|NCT01569451|DRUG|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
58128240|NCT01569451|DRUG|Glatiramer Acetate|20 mg injected subcutaneously daily
58128241|NCT01569451|OTHER|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
58128242|NCT03699267|OTHER|US-guided Bilateral TAP block|
58128243|NCT00855842|DEVICE|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
58128244|NCT04079907|DIETARY_SUPPLEMENT|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
57752951|NCT03182699|DIAGNOSTIC_TEST|Laboratory tests|drawing blood from dialysis machine
57752952|NCT03182699|DIAGNOSTIC_TEST|Body composition monitoring|Measurement with BCM (Fresenius) machine
57752953|NCT03182699|DIAGNOSTIC_TEST|lung ultrasound|ultrasound
57752954|NCT06276933|DRUG|Camrelizumab + chemotherapy+Thalidomide|"Camrelizumab + chemotherapy+Thalidomide Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: Thalidomide Thalidomide 100mg，po qd； Other Name: Thalidomide~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
57752955|NCT06276933|DRUG|Camrelizumab + chemotherapy+placebo|"Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: placebo 100mg placebo 100mg，po qd；~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
57752956|NCT00969384|BEHAVIORAL|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
57752957|NCT05151068|BEHAVIORAL|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
58128245|NCT04079907|DIETARY_SUPPLEMENT|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
58128246|NCT02847806|BIOLOGICAL|Estradiol (Insulin sensitivity)|
58128247|NCT02847806|BIOLOGICAL|Testosterone (Insulin sensitivity)|
58458724|NCT05366023|BEHAVIORAL|CSA20|20 hours of computerized games
57752958|NCT05151068|BEHAVIORAL|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
57752959|NCT03045406|DRUG|Apixaban|Tablets
57752960|NCT03045406|DRUG|Dalteparin|Injections
57752961|NCT02256670|BEHAVIORAL|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
57752962|NCT02216773|PROCEDURE|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
57752963|NCT02216773|PROCEDURE|Portal vein embolization (PVE)|
58128248|NCT04670432|DRUG|Hydroxyethylrutoside|500 mg film-coated tablet
58128249|NCT01385033|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
58458725|NCT05366023|BEHAVIORAL|CSA30|30 hours of computerized games
58458726|NCT05366023|BEHAVIORAL|CSA40|40 hours of computerized games
57752964|NCT01505387|DIETARY_SUPPLEMENT|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
57752965|NCT01505387|DIETARY_SUPPLEMENT|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
57752966|NCT04179721|BEHAVIORAL|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
57752967|NCT04179721|BEHAVIORAL|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
57752968|NCT04632602|OTHER|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
57752969|NCT04413292|DIAGNOSTIC_TEST|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
57752970|NCT06292988|PROCEDURE|Total Thyroidectomy|Total thyroidectomy
57752971|NCT06580288|DRUG|Finerenone|10mg or 20mg
57752972|NCT06580288|DRUG|Placebo|10mg or 20mg
58452943|NCT02423655|OTHER|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
58452944|NCT00931034|BEHAVIORAL|South Beach Diet with South Beach Diet Products|
58452945|NCT00931034|BEHAVIORAL|American Diabetes Association Diabetes Meal Plan|
58452946|NCT03843086|DEVICE|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
58452947|NCT01067274|DRUG|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
57752973|NCT01865708|DRUG|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
57752974|NCT06221202|OTHER|Stories in the Moment Dance Program - Online|Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.
57752975|NCT04618666|PROCEDURE|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
57752976|NCT04419844|PROCEDURE|Tar with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
57752977|NCT04671979|DIAGNOSTIC_TEST|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
57752978|NCT02723942|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
57752979|NCT00004549|PROCEDURE|Magnetic resonance imaging|
58452948|NCT01067274|DRUG|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
58452949|NCT01067274|DRUG|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
58452950|NCT04143685|DRUG|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
58452951|NCT04143685|DRUG|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
58452952|NCT03200834|PROCEDURE|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
58452953|NCT03200834|PROCEDURE|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
58452954|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
58452955|NCT02430090|DRUG|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
57752980|NCT03440684|OTHER|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
57752981|NCT05152173|BIOLOGICAL|EN3835|Participant will receive a maximum dose of up to1.8mg of EN3835 injection
57752982|NCT05152173|OTHER|Placebo|Participant will receive a maximum dose of up to1.8mg of Placebo injection
57752983|NCT04756557|OTHER|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P\&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
57752984|NCT04756557|OTHER|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P\&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
57752985|NCT01980407|DRUG|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
58452956|NCT02430090|DRUG|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
57752986|NCT02080871|DEVICE|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
57752987|NCT02770781|OTHER|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
57752988|NCT05565729|DRUG|LY3471851|Administered SC.
57752989|NCT05565729|DRUG|Placebo|Administered SC.
57752990|NCT05565729|DRUG|Levocetirizine|Administered orally.
57752991|NCT05934812|DRUG|Oxytocin nasal spray|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
57752992|NCT05934812|DRUG|Placebo|Placebo liquid nasal spray administered twice-daily
57752993|NCT00758238|OTHER|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
57752994|NCT04484974|OTHER|Pecan snack|Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.
57752995|NCT04484974|OTHER|Tortilla chip snack|Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
57752996|NCT00578955|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
57752997|NCT00578955|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
58452957|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
58452958|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
58452959|NCT06403462|PROCEDURE|transversalis fascial plane block|ultrasound guidance transversalis fascial plane block after iliac bone graft
58452960|NCT06403462|PROCEDURE|transversus abdominis plane block|ultrasound guidance lateral transversus abdominis plane block after iliac bone graft
58452961|NCT00631358|DRUG|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
58452962|NCT00631358|OTHER|No treatment|Healthy normal control group receiving no treatment
58452963|NCT01748097|DRUG|sodium bicarbonate 4.2%|
58452964|NCT00363532|DRUG|infusion of calcitonin gene related peptide (CGRP)|
58452965|NCT05045261|DRUG|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
58452966|NCT05045261|DRUG|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
58452967|NCT01929590|DRUG|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
58452968|NCT01929590|DRUG|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
58452969|NCT01929590|DRUG|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
58452970|NCT00599066|DEVICE|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
58452971|NCT06392724|GENETIC|GEN6050X intravenous injection|GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.
58452972|NCT01841905|OTHER|Observational Study|Observational Study
58452973|NCT01779232|DRUG|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
57752998|NCT00578955|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
57752999|NCT03020225|DIETARY_SUPPLEMENT|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
57753000|NCT03020225|DIETARY_SUPPLEMENT|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
57753001|NCT03020225|DIETARY_SUPPLEMENT|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
57753002|NCT04835818|DIAGNOSTIC_TEST|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
57753003|NCT01938651|PROCEDURE|high field strength magnetic resonance imaging|Undergo 7T MRI
57753004|NCT01938651|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo 31P MRS
57753005|NCT01938651|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
57753006|NCT01938651|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
57753007|NCT01938651|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
57753008|NCT01948635|DEVICE|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
57753009|NCT01948635|DEVICE|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
57753010|NCT05900284|DRUG|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
57753011|NCT05900284|DRUG|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
57753012|NCT05900284|DRUG|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
57753013|NCT02241941|DRUG|Daptomycin|
57753014|NCT01383265|PROCEDURE|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
57753015|NCT01383265|PROCEDURE|Water method|Control method will use plain water with water method for screening colonoscopy
57753016|NCT04834310|DRUG|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
57753017|NCT04834310|DRUG|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
57753018|NCT04834310|OTHER|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
57753019|NCT04523155|DIETARY_SUPPLEMENT|Medically tailored meals|10 meals per week for 3 months
57753020|NCT01529125|DRUG|zidovudine, lamivudine, nevirapine|
58452974|NCT01779232|DRUG|placebo|administered daily like the active comparator
57753021|NCT04386525|DIETARY_SUPPLEMENT|Omega-3 fish oil|soft gels,1000gm, 84% of DHA and EPA
57753022|NCT03457519|DEVICE|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
57753023|NCT06580431|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
57753024|NCT02992587|OTHER|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
58452975|NCT03196804|DRUG|LC28-0126|LC28-0126
58452976|NCT03196804|DRUG|Placebo|Placebo
58452977|NCT03375034|DRUG|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
57753025|NCT01274052|OTHER|Meal test|Liquid meal test
57753026|NCT03829124|DRUG|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
57753027|NCT03829124|DRUG|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
57753028|NCT04180644|OTHER|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
57753029|NCT00018135|DRUG|calcium acetate|
57753030|NCT00018135|DRUG|aluminum hydroxide|
57753031|NCT00018135|DRUG|Sevelamer|
57753032|NCT05423925|PROCEDURE|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
57753033|NCT05423925|PROCEDURE|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
57753034|NCT00079001|DRUG|zoledronic acid|Given IV
57753035|NCT00079001|OTHER|placebo|Given IV
57753036|NCT00079001|DRUG|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
57753037|NCT00079001|DRUG|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
57753038|NCT00079001|DIETARY_SUPPLEMENT|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
57753039|NCT00079001|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
57753040|NCT04299880|DRUG|Napabucasin|Oral
57753041|NCT04299880|DRUG|Nab-paclitaxel|Intravenous
57753042|NCT04299880|DRUG|Gemcitabine|Intravenous
57753043|NCT04299880|DRUG|Nivolumab|Intravenous
57753044|NCT04299880|DRUG|Paclitaxel|Intravenous
57753045|NCT04299880|DRUG|Irinotecan|Intravenous
57753046|NCT04299880|DRUG|Leucovorin|Intravenous
57753047|NCT04299880|DRUG|5Fluorouracil|Intravenous
57753048|NCT04299880|DRUG|Bevacizumab|Intravenous
57753049|NCT04376554|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days
57753050|NCT04376554|DRUG|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
58452978|NCT03375034|DRUG|NDMC60mg|Oral administration of three NDMC 20mg capsules
58452979|NCT03375034|DRUG|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
57753051|NCT03390868|BEHAVIORAL|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
57753052|NCT02178566|DRUG|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
57753053|NCT06457828|PROCEDURE|Non-corticosteroid injection|no infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
57753054|NCT06457828|DRUG|Corticosteroid injection|infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
57753055|NCT04806828|OTHER|Preoperative classification|Score of inguinal hernia
57753056|NCT03403868|DIAGNOSTIC_TEST|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
57753057|NCT02536365|BEHAVIORAL|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
57753058|NCT02536365|BEHAVIORAL|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
57753059|NCT02070068|DEVICE|PINPOINT System|
57753060|NCT03224013|PROCEDURE|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
57753061|NCT03791164|BEHAVIORAL|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
57753062|NCT03791164|BEHAVIORAL|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
57753063|NCT03116984|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
58452980|NCT03375034|DRUG|Placebo|Oral administration of three Placebo capsules
58452981|NCT03556163|PROCEDURE|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
58452982|NCT03556163|PROCEDURE|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
58452983|NCT05977400|DRUG|Ampicillin|Intravenous Ampicillin
57753064|NCT03116984|RADIATION|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
57753065|NCT04387630|DRUG|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
57753066|NCT04387630|DRUG|Placebo oral tablet|Simethicone 60 mg three times daily.
57753067|NCT01572389|BEHAVIORAL|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
57753068|NCT01572389|BEHAVIORAL|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
57753069|NCT04510675|DEVICE|Test Article|Omeza Collagen Matrix
57753070|NCT04510675|OTHER|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
57753071|NCT05320055|PROCEDURE|robotic repair|robotic assisted retromuscular hernia repair
57753072|NCT02216266|DRUG|Physostigmine|
57753073|NCT02216266|OTHER|Sodium Chloride solution|
58452984|NCT05977400|DRUG|Gentamicin|Intravenous Gentamicin
57753074|NCT01257776|DRUG|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
57753075|NCT04227574|OTHER|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
57753076|NCT04227574|OTHER|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
58452985|NCT05977400|DRUG|Placebo|Intravenous Normal Saline
58452986|NCT00062179|DRUG|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
57753077|NCT06070402|DEVICE|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
57753078|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
58452987|NCT00062179|DRUG|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
58452988|NCT00062179|DRUG|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
58452989|NCT00062179|OTHER|Placebo|placebo 3-7 days before first dose of chemotherapy
57753079|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
58452990|NCT02585362|BEHAVIORAL|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
58452991|NCT02585362|BEHAVIORAL|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
58452992|NCT02585362|DIETARY_SUPPLEMENT|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
58452993|NCT02576639|DRUG|CNP520|
58452994|NCT02576639|DRUG|Placebo|Matching placebo to CNP520 was supplied in capsules.
58452995|NCT01514019|DRUG|Acebutolol|Acebutolol
57753080|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
57753081|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
57753082|NCT01010425|DRUG|Placebo|Placebo, s.c., single-dose
57753083|NCT01010425|DRUG|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
57753084|NCT03248765|OTHER|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
58452996|NCT01514019|DRUG|Placebo|Placebo capsule(Capsules filled up with lactose)
58452997|NCT00878163|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58452998|NCT00878163|DRUG|Erlotinib Hydrochloride|Given PO
58452999|NCT00878163|DRUG|Gemcitabine Hydrochloride|Given IV
58453000|NCT00878163|DRUG|Vismodegib|Given PO
58453001|NCT04395807|DEVICE|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
58453002|NCT04395807|DEVICE|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
58453003|NCT02905266|BIOLOGICAL|Nivolumab|-Specified dose on specified days
58453004|NCT02905266|BIOLOGICAL|Ipilimumab|-Specified dose on specified days
58453005|NCT05385666|OTHER|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
57753085|NCT03305523|DEVICE|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
57753086|NCT02059967|DRUG|Paclitaxel|Given IV
57753087|NCT02059967|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
57753088|NCT02059967|DRUG|carboplatin|Given IV
57753089|NCT05008783|DRUG|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
57753090|NCT05008783|DRUG|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
57753091|NCT05080062|BEHAVIORAL|Requirements and functional Schedule|An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
57753092|NCT05080062|BEHAVIORAL|No intervention|a pain rehabilitation-program
57753093|NCT02460692|DRUG|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
57753094|NCT02460692|DRUG|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
57753095|NCT02460692|DRUG|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
57753096|NCT03537079|OTHER|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
58453006|NCT02602886|BEHAVIORAL|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
57753097|NCT05296499|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
57753098|NCT05296499|DIAGNOSTIC_TEST|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
57753099|NCT05296499|OTHER|6 minute walk test|6MWT
57753100|NCT05296499|DIAGNOSTIC_TEST|Blood tests|FBC, U\&E, LFTS
57753101|NCT05296499|OTHER|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
57753102|NCT05296499|OTHER|Repeat baseline assessments|repeat baseline
57753103|NCT05296499|DIAGNOSTIC_TEST|MR venogram|MRI scan of venous system
57753104|NCT04596202|BEHAVIORAL|Supine position|After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
57753105|NCT04596202|BEHAVIORAL|Prone position|After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
57753106|NCT04596202|BEHAVIORAL|Lateral position|After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
57753107|NCT02026180|DEVICE|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
57753108|NCT00026143|BIOLOGICAL|recombinant interleukin-12|Given IV
57753109|NCT00026143|BIOLOGICAL|recombinant interferon alfa|Given SC
57753110|NCT00026143|OTHER|laboratory biomarker analysis|Correlative studies
58128250|NCT01977469|BEHAVIORAL|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
57753111|NCT05415800|BEHAVIORAL|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
57753112|NCT01648348|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
57753113|NCT01648348|BIOLOGICAL|Bevacizumab|Given IV
57753114|NCT01648348|OTHER|Laboratory Biomarker Analysis|Correlative studies
57753115|NCT01648348|OTHER|Pharmacological Study|Correlative studies
57753116|NCT01648348|OTHER|Quality-of-Life Assessment|Ancillary studies
57753117|NCT03535064|OTHER|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
58453007|NCT05527041|DEVICE|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~* Gaze coordinates~* Pupil sizes~* Accelerometer data~* Gyroscopic data~* Rotation data~* Blink data"
57753118|NCT03687567|PROCEDURE|Preimplantation genetic diagnosis|
57753119|NCT01701986|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
57753120|NCT01701986|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic BMT or PBSCT
57753121|NCT01701986|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57753122|NCT01701986|DRUG|Busulfan|Given IV
57753123|NCT01701986|DRUG|Clofarabine|Given IV
57753124|NCT01701986|DRUG|Gemcitabine Hydrochloride|Given IV
57753125|NCT01701986|DRUG|Mycophenolate Mofetil|Given IV then PO
57753126|NCT01701986|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
58453008|NCT02579213|OTHER|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
57753127|NCT01701986|OTHER|Pharmacological Study|Correlative studies
57753128|NCT01701986|BIOLOGICAL|Rituximab|Given IV
57753129|NCT01701986|DRUG|Tacrolimus|Given IV then PO
57753130|NCT02573402|DEVICE|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
58453009|NCT04675333|DRUG|evorpacept|IV Q3W
58453010|NCT04675333|DRUG|pembrolizumab|IV Q3W
58453011|NCT04675333|DRUG|Cisplatin/Carboplatin; 5FU|IV Q3W
58453012|NCT04781166|BEHAVIORAL|Calm program|7 online modules designed to teach cognitive behavioral skills
58458727|NCT03422835|PROCEDURE|R-TME|Conventional Robotic Total Mesentery Excision
57753131|NCT02573402|DEVICE|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
57753132|NCT05087381|DRUG|FluvoxaMINE Maleate 50 MG|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
57753133|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Bromhexine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
58458728|NCT03422835|PROCEDURE|R-TaTME|Robotic Transanal Total Mesentery Excision
58458729|NCT00204035|BEHAVIORAL|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
57753134|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Cyproheptadine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
57753135|NCT05087381|DRUG|Niclosamide Pill|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
57753136|NCT05087381|COMBINATION_PRODUCT|Niclosamide, Bromhexine|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
57753137|NCT03704155|DRUG|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
57753138|NCT03704155|OTHER|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
57753139|NCT03577860|DRUG|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
58453013|NCT03232996|OTHER|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
58453014|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 1 tablet of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
58453015|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 2 tablets of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
58453016|NCT03369418|DEVICE|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
58453017|NCT03369418|DEVICE|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
58453018|NCT01051674|OTHER|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
58453019|NCT02668497|DRUG|Botulinum Toxin Type A|
58453020|NCT01694381|DRUG|M5|single point mutant of serine protease prourokinase
57753140|NCT03577860|DRUG|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
57753141|NCT04351503|OTHER|Study A|Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
57753142|NCT04351503|OTHER|Study B|Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
57753143|NCT04351503|OTHER|Study C|Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.
57753144|NCT04351503|OTHER|Study D|"Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting)."
57753145|NCT01732848|DRUG|BMS-986094/INX-08189|
57753146|NCT01732848|DRUG|Placebo matching BMS-986094/INX-08189|
57753147|NCT03202381|DRUG|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
57753148|NCT00667472|DRUG|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
57753149|NCT00667472|DEVICE|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
57753150|NCT03532802|DRUG|Metoprolol Succinate|"1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week."
57753151|NCT03532802|DRUG|Placebo oral capsule|"1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week"
58453021|NCT01694381|DRUG|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
58453022|NCT03449966|DEVICE|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
58453023|NCT03449966|DEVICE|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
58453024|NCT01611038|DIETARY_SUPPLEMENT|Methylselenocysteine|Methylselenocysteine capsule given daily
58453025|NCT01611038|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given daily
58453026|NCT05737914|PROCEDURE|Endoscopic thoracic T3 sympathectomy|Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
57753152|NCT00677235|DEVICE|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
57753153|NCT00677235|PROCEDURE|PTA|Treatment of stenoses with PTA only
57753154|NCT02565563|OTHER|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
57753155|NCT02565563|DEVICE|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
57753156|NCT03852043|BEHAVIORAL|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
57753157|NCT03852043|BEHAVIORAL|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
57753158|NCT02138045|DRUG|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
57753159|NCT02138045|DRUG|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
57753160|NCT02915848|DEVICE|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
57753161|NCT05840861|DRUG|Vortioxetine|All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
57753162|NCT05840861|DRUG|Quetiapine|All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
57753163|NCT00543595|DRUG|MK0916|
57753164|NCT02159599|DRUG|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
57753165|NCT02159599|DRUG|Lamivudine|Lamivudine (300mg) : QD
57753166|NCT02159599|DRUG|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
57753167|NCT03420781|DRUG|Placebo|Placebo injected twice daily
57753168|NCT03420781|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily
57753169|NCT04088370|OTHER|Blood Draw|Blood Draw Only
57753170|NCT01574768|PROCEDURE|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
57753171|NCT01965210|OTHER|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
58453027|NCT05737914|PROCEDURE|ThoracicT3 radiofrequency ablation|radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
58453028|NCT01493193|OTHER|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
58453029|NCT01493193|OTHER|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
58453030|NCT01493193|OTHER|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
58453031|NCT03567031|PROCEDURE|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
58453032|NCT04604041|DIAGNOSTIC_TEST|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
57753172|NCT01965210|OTHER|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
57753173|NCT01965210|OTHER|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
57753174|NCT01965210|OTHER|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
57753175|NCT01965210|OTHER|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
57753176|NCT01965210|OTHER|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
57753177|NCT06103825|DRUG|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
57753178|NCT06103825|DRUG|Placebo|Placebo :QD，PO，Day 1-Day 84
57753179|NCT02612064|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
58453033|NCT06265181|BEHAVIORAL|Diabetes coaching|Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.
57753180|NCT02612064|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
57753181|NCT03688061|BIOLOGICAL|ChAd3-hliNSmut|Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV
57753182|NCT03688061|BIOLOGICAL|MVA-hliNSmut|Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
57753183|NCT02013492|DRUG|propranolol hydrochloride|Given PO
57753184|NCT02013492|OTHER|Correlative Studies|"Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
57753185|NCT00663325|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
57753186|NCT01800773|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
57753187|NCT01800773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
57753188|NCT05421338|DRUG|BI 456906 (C-14)|BI 456906 (C-14)
57753189|NCT05786222|BEHAVIORAL|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator \[a trained CSH employee\] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
58453034|NCT02066766|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
58453035|NCT00395655|DRUG|Hydralazine and magnesium valproate administration|
58453036|NCT00395655|PROCEDURE|Core-needle biopsy of the breast|
58453037|NCT01163526|PROCEDURE|CT perfusion|
58458730|NCT05924061|OTHER|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
57753190|NCT05399745|OTHER|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
57753191|NCT02719990|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
57753192|NCT00948298|DRUG|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
57753193|NCT00948298|DRUG|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
57753194|NCT00000605|DRUG|hormone replacement therapy|
57753195|NCT00000605|DRUG|estrogens|
57753196|NCT00000605|DRUG|medroxyprogesterone|
57753197|NCT05995314|DIETARY_SUPPLEMENT|PLACEBO|3 mg/kg of cellulose (0 mg/kg of caffeine)
57753198|NCT05995314|DIETARY_SUPPLEMENT|3 mg/kg of caffeine|Ingestion of 3 mg/kg of body mass of caffeine
57753199|NCT05995314|DIETARY_SUPPLEMENT|6 mg/kg of caffeine|Ingestion of 6 mg/kg of body mass of caffeine
57753200|NCT05295966|OTHER|Cognitive therapy|Cognitive therapy
57753201|NCT05295966|BEHAVIORAL|Physiocognitive Integration|Physiocognitive Integration
58458731|NCT01342913|DRUG|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
58458732|NCT01342913|DRUG|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
58458733|NCT05903508|OTHER|Functional task training and functional therapy program|Functional task training group this will receive walking and no walking activities
57753202|NCT01843543|OTHER|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
57753203|NCT05887505|OTHER|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
57753204|NCT05887505|OTHER|Placebo|Oral supplementation of placebo in 3 consecutive days.
57753205|NCT05030402|PROCEDURE|Maitland|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
57753206|NCT05030402|PROCEDURE|Tens, exercise, SW|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
57753207|NCT05030402|PROCEDURE|Conventional physiotherapy|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
57753208|NCT04849286|DRUG|HTL0016878|Oral solution
57753209|NCT03128424|DEVICE|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
57753210|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except friday|
57753211|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except thursday and friday|
57753212|NCT02489786|DRUG|patients take 0.125 mg of digoxin daily|
57753213|NCT02489786|DRUG|digoxin dose is calculated using Jusko-Koup method and given daily|
57753214|NCT02681848|DRUG|Varenicline|Smoking cessation medication
57753215|NCT02681848|DRUG|Nicotine replacement therapy|
57753216|NCT02787707|DRUG|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
57753217|NCT02787707|DRUG|lactose|2.7 grams Lactose every 8 hour
57753218|NCT04209478|DRUG|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
58453038|NCT03524482|BEHAVIORAL|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
57753219|NCT01904864|DRUG|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
57753220|NCT01904864|DRUG|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
57753221|NCT00560612|DRUG|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
57753222|NCT00560612|DRUG|Placebo|Placebo: same as paroxetine (active comparator)
57753223|NCT00992667|DRUG|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
57753224|NCT05179967|DEVICE|WeFlow-JAAA Stent Graft System|WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.
57753225|NCT04069325|DRUG|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
57753226|NCT04069325|DRUG|placebo|pills, 6g twice daily (BID), oral, 12 weeks
57753227|NCT04069325|DRUG|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
57753228|NCT04107831|OTHER|Pulmonary rehabilitation|Pre-post test design
57753229|NCT02077764|PROCEDURE|OCT and coronary angiography|
57753230|NCT02077764|PROCEDURE|Right heart cat.|
57753231|NCT02077764|RADIATION|PET|
57753232|NCT02077764|PROCEDURE|Echocardiography|
57753233|NCT02077764|PROCEDURE|exercise test|
57753234|NCT02077764|OTHER|blood samples|
57753235|NCT05775588|PROCEDURE|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
57753236|NCT01005342|OTHER|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
57753237|NCT01005342|OTHER|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
57753238|NCT01005342|OTHER|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
57753239|NCT01005342|OTHER|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
57753240|NCT01005342|OTHER|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
57753241|NCT01005342|OTHER|Control|No fiber was added to control meal (250 g black-currant beverage)
57753242|NCT05797064|PROCEDURE|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
57753243|NCT04471155|PROCEDURE|Holep|laser enucleation of the gland versus open enucleation
57753244|NCT00742092|DRUG|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
57753245|NCT00742092|DRUG|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
57753246|NCT05362565|BIOLOGICAL|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
57753247|NCT04186013|DRUG|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
57753248|NCT04186013|RADIATION|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
57753249|NCT02546934|DRUG|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
57753250|NCT02546934|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
57753251|NCT05374954|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
57753252|NCT05374954|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
57753253|NCT01869790|OTHER|Different fat types|Saturated, monounsaturated fats
57753254|NCT02686034|DEVICE|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
57753255|NCT02686034|DEVICE|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
57753256|NCT01953393|OTHER|Low-dose TNF-alpha|
57753257|NCT04845048|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
57753258|NCT04225533|DRUG|SP16|All patients will receive a single dose of SP16
57753259|NCT02908308|PROCEDURE|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
57753260|NCT02908308|PROCEDURE|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
57753261|NCT02858141|OTHER|Data collection|
57753262|NCT03839342|DRUG|Binimetinib|MEK inhibitor, 45mg oral tablet
57753263|NCT03839342|DRUG|Encorafenib|BRAF inhibitor, 450mg oral capsule
57753264|NCT00644202|BEHAVIORAL|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
57753265|NCT00644202|BEHAVIORAL|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
58458734|NCT05903508|OTHER|Functional therapy program Group|Functional therapy program Group this will receive goal directed training
57753266|NCT00644202|BEHAVIORAL|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
57753267|NCT06176599|DRUG|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
58458735|NCT05607667|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
58458736|NCT04042220|DRUG|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
57753268|NCT06176599|DRUG|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
57753269|NCT06395181|BEHAVIORAL|Whole Food Plant-Based Diet|A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
57753270|NCT01730885|OTHER|Comparison of different Blood Glucose Meters|
58458737|NCT06527014|PROCEDURE|Pulse Radiofrequency to the suprascapular nerve|Pulse radiofrequency ablation to the Suprascapular nerve
57753271|NCT00546780|DRUG|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
57753272|NCT00546780|DRUG|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
57753273|NCT01103310|DRUG|BAY94-9392|
57753274|NCT03546894|DRUG|Brigatinib|Brigatinib tablets.
57753275|NCT03546894|DRUG|Alectinib|Alectinib capsules.
57753276|NCT03546894|DRUG|Ceritinib|Ceritinib capsules.
57753277|NCT03546894|DRUG|Lorlatinib|Lorlatinib capsules.
57753278|NCT03546894|DRUG|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
57753279|NCT04734548|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
57753280|NCT04734548|OTHER|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
57753281|NCT06510582|DRUG|Bevacizumab 2 mg/kg|Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
58453039|NCT03524482|BEHAVIORAL|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
58453040|NCT03782233|DRUG|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
58453041|NCT03782233|DRUG|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
58453042|NCT04442542|OTHER|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
58453043|NCT04442542|OTHER|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
58453044|NCT01601535|DRUG|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
58453045|NCT01601535|DRUG|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
58453046|NCT01601535|DRUG|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
58453047|NCT02913482|DRUG|Risdiplam|Risdiplam will be administered orally.
57753282|NCT06510582|DRUG|Bevacizumab 4 mg/kg|Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
57753283|NCT05278780|OTHER|Screening for eligibility|Asynchronous screening
57753284|NCT04108000|BEHAVIORAL|SPIRIT-Dementia|"The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care."
57753285|NCT04108000|BEHAVIORAL|Usual Care|As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
57753286|NCT05018884|PROCEDURE|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
57753287|NCT02137525|DRUG|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
57753288|NCT02137525|DRUG|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
57753289|NCT02137525|DRUG|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
57753290|NCT02137525|DRUG|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
57753291|NCT02137525|DRUG|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
57753292|NCT02137525|DRUG|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
57753293|NCT01947465|BIOLOGICAL|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
57753294|NCT03535142|PROCEDURE|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
57753295|NCT06524011|BIOLOGICAL|Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone|Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
57753296|NCT00509834|DRUG|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
57753297|NCT00509834|DRUG|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
57753298|NCT00509834|DRUG|Placebo|Placebo
57753299|NCT05267392|DRUG|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
57753300|NCT05267392|OTHER|standard of care RT/RCT|standard of care RT/RCT
57753301|NCT01373762|BEHAVIORAL|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
57753302|NCT03388749|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
57753303|NCT00683709|BEHAVIORAL|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
57753304|NCT00683709|BEHAVIORAL|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
58453048|NCT05597774|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
58453049|NCT05597774|OTHER|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
58453050|NCT05597774|OTHER|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
57753305|NCT03115294|DRUG|Theophylline|iv injection
57753306|NCT03115294|PROCEDURE|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
57753307|NCT03115294|DEVICE|Videorecording|Myocardial movement videorecording
57753308|NCT03286751|DRUG|LY900014|Administered SC
57753309|NCT03286751|DRUG|Insulin Lispro|Administered SC
57753310|NCT05322148|DRUG|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
57753311|NCT05514002|BIOLOGICAL|Fluzone Quadrivalent|Intramuscular
57753312|NCT05514002|BIOLOGICAL|Flublok Quadrivalent|Intramuscular
57753313|NCT04477187|DEVICE|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
57753314|NCT02701127|DRUG|Oral niacinamide, 1 gram daily|
57753315|NCT02701127|DRUG|Oral niacinamide, 3 gram daily|
57753316|NCT02701127|DRUG|Placebo|
57753317|NCT05139667|DRUG|Corticosteroid Topical|topical tacrolimus and corticosteroids
57753318|NCT03610464|DRUG|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
57753319|NCT05760157|OTHER|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
57753320|NCT02370433|DRUG|Intravenous Neostigmine and Glycopyrrolate|
57753321|NCT02370433|DRUG|Transdermal Neostigmine and Glycopyrrolate|
57753322|NCT00597948|BEHAVIORAL|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
57753323|NCT03396029|BEHAVIORAL|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
57753324|NCT03396029|BEHAVIORAL|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
57753325|NCT02233933|OTHER|Hemospray|hemospray is used after argon coagulation to stop bleeding
57753326|NCT06085274|PROCEDURE|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
57753327|NCT02244905|BEHAVIORAL|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
57753328|NCT02244905|OTHER|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
57753329|NCT01019044|PROCEDURE|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
57753330|NCT02044848|DRUG|Secukinumab|
57753331|NCT02044848|DRUG|Placebo|Placebo
57753332|NCT05734963|GENETIC|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
57753333|NCT02259738|DRUG|Human Urinary Kallidinogenase|
57753334|NCT02259738|DRUG|Shuxuening injection|
57753335|NCT03357263|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
57753336|NCT03357263|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
57753337|NCT03497650|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
57753338|NCT03497650|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
57753339|NCT02381522|OTHER|Remote Ischemic Pre-conditioning|
57753340|NCT02381522|OTHER|Sham RIPC|
57753341|NCT03479021|DIAGNOSTIC_TEST|Welch-Allyn Spot Vision Screener|photograph of the eye
57753342|NCT04535674|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
57753343|NCT00799292|DRUG|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
57753344|NCT02021175|BEHAVIORAL|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
57753345|NCT02021175|OTHER|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
57753346|NCT00386022|DRUG|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
57753347|NCT00386022|DRUG|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
57753348|NCT00386022|DRUG|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
57753349|NCT03151980|PROCEDURE|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
57960665|NCT05688943|PROCEDURE|General Anesthesia|General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
58453051|NCT03356275|BEHAVIORAL|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
57753350|NCT03151980|OTHER|Untreated skin and sun exposure|Skin that will not receive Hamam.
57753351|NCT01868295|BEHAVIORAL|Sleeping with denture|Sleeping with denture at night
57753352|NCT02048072|DRUG|Gilenya|Autonomic testing during first dose administration of Gilenya.
57753353|NCT00969501|DRUG|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
57753354|NCT00752843|DRUG|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
57753355|NCT02822625|DRUG|QUTENZA®|
57753356|NCT02822625|OTHER|hypnotic message|
57753357|NCT02822625|OTHER|music therapy|
57960666|NCT05010356|DRUG|Insulin|Hyperinsulinemic euglycemic clamp
57960667|NCT01609842|OTHER|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
57753358|NCT05892315|PROCEDURE|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
58453052|NCT00411749|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
58453053|NCT00411749|BIOLOGICAL|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
58453054|NCT02147743|BEHAVIORAL|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
58453055|NCT02147743|BEHAVIORAL|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
58453056|NCT03259555|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
58453057|NCT03259555|DRUG|Placebo|Administered orally daily for 3 weeks.
58453058|NCT04520607|DRUG|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
58453059|NCT04520607|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
58453060|NCT03406273|RADIATION|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
58453061|NCT03406273|RADIATION|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
58453062|NCT04125043|DIAGNOSTIC_TEST|Direct ophthalmoscope|Red reflex test
58453063|NCT03881111|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
58453064|NCT03881111|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
58453065|NCT03881111|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
58453066|NCT03881111|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
57960668|NCT01932957|PROCEDURE|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
58453067|NCT00930891|DRUG|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
58453068|NCT00930891|DRUG|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
58453069|NCT00930891|DRUG|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
58453070|NCT02341235|BEHAVIORAL|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
58453071|NCT02341235|BEHAVIORAL|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
58453072|NCT05768100|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
58453073|NCT05768100|DIETARY_SUPPLEMENT|Placebo|Isovolumic placebo
58453074|NCT03479229|DEVICE|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm\^2
57753359|NCT05892315|PROCEDURE|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
57753360|NCT00490282|RADIATION|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
57753361|NCT00490282|RADIATION|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
57753362|NCT05416957|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
57960669|NCT01932957|PROCEDURE|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
57960670|NCT00703638|DRUG|cisplatin|Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
57960671|NCT00703638|DRUG|pemetrexed disodium|Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
57960672|NCT00703638|DRUG|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
57960673|NCT04492280|DRUG|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
58453075|NCT03479229|DEVICE|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
58453076|NCT05090735|PROCEDURE|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
58453077|NCT05090735|PROCEDURE|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
57753363|NCT04047043|DIAGNOSTIC_TEST|serum taurine|blood sample for serum taurine level
57753364|NCT03072940|OTHER|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
57753365|NCT01593202|BEHAVIORAL|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
57753366|NCT01593202|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
57753367|NCT00320775|DRUG|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
57753368|NCT00381069|BEHAVIORAL|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
57753369|NCT04821479|BIOLOGICAL|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
57753370|NCT05756972|DRUG|PM8002|IV infusion
58453078|NCT05144100|PROCEDURE|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
58453079|NCT05144100|RADIATION|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
58453080|NCT05144100|DRUG|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
58453081|NCT02140515|DRUG|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
58453082|NCT02140515|DRUG|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
58453083|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
58453084|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
58453085|NCT01913951|DRUG|vosaroxin|Given IV over 10 minutes on Day 1 and 4
58453086|NCT01913951|DRUG|Azacitidine|Given SC or IV over 15 minutes on days 1-7
58453087|NCT03850366|DRUG|Bortezomib|GVHD prophylaxis
58453088|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
58453089|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
58453090|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
58453091|NCT02260934|DRUG|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
58453092|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
57753371|NCT05756972|DRUG|Placebo|IV infusion
57753372|NCT05756972|DRUG|Carboplatin|IV infusion
57753373|NCT05756972|DRUG|Pemetrexed|IV infusion
58128251|NCT01977469|BEHAVIORAL|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
58453093|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
58453094|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
58453095|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
58453096|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
58453097|NCT02260934|DRUG|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
58453098|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
58453099|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
58453100|NCT02260934|BIOLOGICAL|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
57753374|NCT04253327|OTHER|questionnaire|"Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email.."
57753375|NCT05245578|DRUG|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
57753376|NCT05245578|DRUG|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
57753377|NCT02304276|RADIATION|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
57753378|NCT02304276|RADIATION|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
57753379|NCT01348750|OTHER|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
57753380|NCT02623010|DRUG|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
57753381|NCT04605978|DRUG|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
57753382|NCT04605978|DRUG|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
57753383|NCT00432757|DRUG|Ketotifen with a Contact Lens (generic name not yet established)|
58453101|NCT05067517|DRUG|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
57753384|NCT00593567|DRUG|gentamicin-collagen sponge|Inserted daily into open ulcer
57753385|NCT00593567|DRUG|Levofloxacin|750mg oral levofloxacin daily
57753386|NCT03764839|BEHAVIORAL|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
57753387|NCT04226222|DIAGNOSTIC_TEST|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
57753388|NCT06115330|DEVICE|Press Needle Acupuncture|Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
58453102|NCT05067517|DRUG|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
58453103|NCT02635607|DRUG|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
58453104|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
58453105|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.
58453106|NCT02635607|DRUG|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
57753389|NCT01314989|DRUG|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
57753390|NCT01314989|DRUG|Sugar pill|liquid placebo
57753391|NCT01815788|DEVICE|Use of a personal sound amplifying device = TeoFirst|
57753392|NCT04482543|DRUG|Methotrexate|Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
57753393|NCT00939484|OTHER|Pharmacological Study|Correlative studies
57753394|NCT00939484|DRUG|Vismodegib|Given PO
57753395|NCT05968222|OTHER|Vibration exercise|Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
57753396|NCT02526355|BEHAVIORAL|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
57753397|NCT04236193|DIAGNOSTIC_TEST|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
57753398|NCT00770926|BEHAVIORAL|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
57753399|NCT02582346|PROCEDURE|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
57753400|NCT03083314|PROCEDURE|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
57753401|NCT03083314|PROCEDURE|COMPLETE AXILLARY DISSECTION (ALND)|
57753402|NCT00964834|DRUG|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
58453107|NCT02635607|DRUG|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
58453108|NCT03917797|BIOLOGICAL|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
58453109|NCT03917797|DRUG|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
57753403|NCT00964834|DRUG|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
57753404|NCT00964834|DRUG|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
57753405|NCT00034255|DRUG|INGAP Peptide|
57753406|NCT02621957|DRUG|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
57753407|NCT02621957|DRUG|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
57753408|NCT06081764|OTHER|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
57753409|NCT04356326|DRUG|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
57753410|NCT04356326|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
57753411|NCT02579876|DRUG|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
57753412|NCT02579876|DRUG|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
57753413|NCT05101525|PROCEDURE|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
57753414|NCT04988802|DIETARY_SUPPLEMENT|Prenatal Nutrients Solgar|Patients will take dietary supplement Prenatal Nutrients from Solgar
57753415|NCT04988802|OTHER|Placebo|Placebo capsules based on starch.
57753416|NCT06457074|DRUG|Finerenone Oral Tablet|Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
57753417|NCT06457074|DRUG|Spironolactone Oral Tablet|Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
57753418|NCT04792697|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
57753419|NCT04792697|OTHER|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
58315089|NCT01603160|BEHAVIORAL|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
57753420|NCT04792697|BEHAVIORAL|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
57753421|NCT04792697|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
57753422|NCT01445925|PROCEDURE|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
57753423|NCT01445925|PROCEDURE|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
57753424|NCT01445925|DRUG|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
57753425|NCT03011723|BEHAVIORAL|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
57753426|NCT01798394|DRUG|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
57753427|NCT01798394|OTHER|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
57753428|NCT04434807|PROCEDURE|Minimally invasive hematoma evacuation|Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
58315090|NCT03062371|BEHAVIORAL|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
57753429|NCT04174248|OTHER|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
57753430|NCT00791206|PROCEDURE|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
57753431|NCT00791206|PROCEDURE|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
57753432|NCT05559957|BEHAVIORAL|observation of delivery and neonatal outcomes|MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
57753433|NCT02093325|DRUG|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
57753434|NCT02093325|DRUG|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
57753435|NCT00122642|PROCEDURE|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
57753436|NCT00122642|DRUG|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
57753437|NCT06491251|PROCEDURE|Bilateral Subinguinal microscopic varicocelectomy|Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
57753438|NCT01217008|BIOLOGICAL|GRNOPC1|One injection of 2 million GRNOPC1 cells.
57753439|NCT04196218|OTHER|Driving simulator|Computer simulated driving assessment
57753440|NCT05964608|BEHAVIORAL|Behavioral Therapy|"Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
57753441|NCT02331381|DEVICE|Magnetic resonance imaging|
58453110|NCT03917797|DRUG|Placebo|MSC infusion vehicle
58453111|NCT00354146|DRUG|tipifarnib (R115777)|
58453112|NCT01368250|PROCEDURE|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
58453113|NCT04742907|DRUG|TU-100|Treatment with investigational product
58453114|NCT04742907|DRUG|Placebo|Treatment with placebo product
58453115|NCT01034514|DEVICE|Real-time Position Management system|Standard of Care
58453116|NCT01034514|DEVICE|Discovery ST multislice PET/CT scanner|Standard of Care
57753442|NCT03238898|DRUG|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
57753443|NCT03238898|OTHER|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
57753444|NCT02953938|BIOLOGICAL|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
57753445|NCT02953938|RADIATION|Grid&Direct short pulse laser photocoagulation|Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
57753446|NCT02641392|DRUG|GED-0301|Mongersen
57753447|NCT02641392|OTHER|Placebo|Placebo
58315091|NCT03456934|OTHER|Modified infant formula|Test formula with lower protein content than standard formula
58315092|NCT03456934|OTHER|Standard infant formula|Standard infant formula
58453117|NCT01034514|DEVICE|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
58453118|NCT01034514|DEVICE|Pinnacle3 treatment planning system|Standard of Care
58453119|NCT01034514|DEVICE|SKYLight nuclear camera|Standard of Care
58453120|NCT01034514|DRUG|DTPA|1 mCi; inhalation
58453121|NCT01034514|DRUG|TECHNETIUM TC 99M MAA|3 mCi; iv
58453122|NCT05944406|OTHER|Educational training of ER Nurses|educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
58453123|NCT03226002|DEVICE|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
58453124|NCT02919761|DRUG|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
58453125|NCT02919761|DRUG|Placebo|Matching placebo 1 mL for subcutaneous injection
58453126|NCT03863288|PROCEDURE|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
57753448|NCT03005509|OTHER|TQIM checklist|"The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
57753449|NCT01287130|DRUG|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
57753450|NCT01287130|DRUG|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
57753451|NCT00832767|PROCEDURE|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
57753452|NCT00832767|PROCEDURE|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
57753453|NCT04994496|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
57753454|NCT04994496|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
57753455|NCT05226182|OTHER|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
57753456|NCT05753722|BIOLOGICAL|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
57753457|NCT05753722|BIOLOGICAL|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
57753458|NCT02924896|DIETARY_SUPPLEMENT|Palm olein|60g of palm olein will be given in a milkshake at breakfast
57753459|NCT02924896|DIETARY_SUPPLEMENT|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
57753460|NCT02924896|DIETARY_SUPPLEMENT|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
57753461|NCT01820559|DRUG|Placebo|Tablets
57753462|NCT01820559|DRUG|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
57753463|NCT01820559|DRUG|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
57753464|NCT04290351|PROCEDURE|band ligation|"Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
57753465|NCT04290351|DRUG|oral 450 mg diosmin+50 mg hesperidin|"450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
58453127|NCT03863288|DRUG|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
57753466|NCT05202925|OTHER|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
57753467|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
57753468|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
57753469|NCT00716092|DRUG|Sitagliptin|100 mg once daily for 28 days
57753470|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
57753471|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
57753472|NCT00716092|DRUG|Linagliptin|5mg once daily for 28 days
57753473|NCT03295513|OTHER|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
57960674|NCT06458933|BEHAVIORAL|Sage|Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).
58453128|NCT03863288|DRUG|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
58453129|NCT03863288|DRUG|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
58453130|NCT03863288|DRUG|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
58453131|NCT03863288|DRUG|Placebo|Placebo intranasal spray liquid administration
57753474|NCT03295513|OTHER|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
57753475|NCT02043691|DEVICE|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
57753476|NCT02043691|DEVICE|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
57753477|NCT02043691|DEVICE|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
57753478|NCT01455935|DRUG|Anti-platelets and statin|
57753479|NCT01455935|DRUG|alteplase|"Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours"
57753480|NCT01455935|PROCEDURE|intra arterial intervention|"1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)"
57753481|NCT03945539|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
57753482|NCT03945539|DRUG|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
57753483|NCT04309045|BEHAVIORAL|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
58453132|NCT04393493|DRUG|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
58453133|NCT04393493|DRUG|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
58453134|NCT04393493|DRUG|Spironolactone|One 50 mg pill administrated every 24 hours in group B
58453135|NCT05011812|DRUG|PBI-0451 Dose 1|Dose level 1 of PBI-0451
57753484|NCT04309045|BEHAVIORAL|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
57753485|NCT04309045|OTHER|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
57753486|NCT03395405|DRUG|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
57753487|NCT03395405|OTHER|Placebo|One tablet twice daily with food for 56 consecutive doses
58315093|NCT02025608|DRUG|Pramipexole|
58315094|NCT02025608|DRUG|Placebo|
58315095|NCT01998360|PROCEDURE|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
58315096|NCT01998360|PROCEDURE|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
58315097|NCT02295137|PROCEDURE|Using pre-procedural CTA to guide advanced EVAR procedure|
58315098|NCT03186352|PROCEDURE|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
58453136|NCT05011812|DRUG|PBI-0451 Dose 2|Dose level 2 of PBI-0451
58453137|NCT05011812|DRUG|PBI-0451 Dose 3|Dose level 3 of PBI-0451
58453138|NCT05011812|DRUG|PBI-0451 Dose 4|Dose level 4 of PBI-0451
58453139|NCT05011812|DRUG|Ritonavir|Ritonavir will be co-administered with the study drug in Treatments J and K
58453140|NCT05011812|DRUG|Midazolam|Midazolam will be co-administered with the study drug in Treatment L
58453141|NCT05011812|DRUG|Placebo|Placebo to match
58453142|NCT05011812|DRUG|PBI-0451|Dose level of PBI-0451 with a projected exposure
58453143|NCT05011812|DRUG|PBI-0451 Dose 5|Dose level 5 of PBI-0451
58453144|NCT03627871|BEHAVIORAL|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
58453145|NCT03627871|BEHAVIORAL|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
58453146|NCT03627871|BEHAVIORAL|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
58453147|NCT03627871|BEHAVIORAL|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
57753488|NCT00606190|PROCEDURE|Retrograde brain perfusion|observational
57753489|NCT00606190|PROCEDURE|Antegrade brain perfusion|observational
57753490|NCT04013100|DIAGNOSTIC_TEST|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
57753491|NCT06495931|DRUG|HRS-1780 tablets|HRS-1780 tablets, three times
57753492|NCT06495931|DRUG|HR20033 tablets|HR20033 tablets, nine times
57753493|NCT06495931|DRUG|HRS-7535 tablets|HRS-7535 tablets ，three times or nine times
58453148|NCT03627871|BEHAVIORAL|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
58453149|NCT03654183|DIAGNOSTIC_TEST|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
58453150|NCT00449124|DRUG|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
58453151|NCT00449124|BIOLOGICAL|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
58453152|NCT01839435|PROCEDURE|outpatient surgery|
57753494|NCT01644734|DRUG|Spiriva HandiHaler|
57753495|NCT00464646|DRUG|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
57753496|NCT00464646|DRUG|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
57753497|NCT00464646|DRUG|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
57753498|NCT00464646|DRUG|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
57753499|NCT00464646|DRUG|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
57753500|NCT02651935|DEVICE|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
57753501|NCT01210430|DRUG|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
57753502|NCT01210430|DRUG|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
57753503|NCT01210430|DRUG|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
57753504|NCT03262610|DRUG|Setmelanotide|daily subcutaneous injection
57753505|NCT05158296|DRUG|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
57753506|NCT05158296|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
57753507|NCT03611244|DEVICE|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
57753508|NCT00123032|BEHAVIORAL|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
57753509|NCT00123032|PROCEDURE|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
57753510|NCT06463444|DRUG|HAIC + Tislelizumab +lenvatinib|"All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later."
57753511|NCT04132843|DRUG|Gadobenate Dimeglumine|Given IV
57753512|NCT04132843|DRUG|Gadobutrol|Given IV
57753513|NCT04132843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58453153|NCT02398305|DEVICE|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
58453154|NCT02398305|DEVICE|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
58453155|NCT05787665|OTHER|phone call at 3 months|patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
58453156|NCT03395899|DRUG|Atezolizumab|PD-L1 antibody
58453157|NCT03395899|DRUG|Cobimetinib|Highly selective small-molecule inhibitor of MEK1 and MEK2
58453158|NCT03395899|DRUG|Ipatasertib|Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
58453159|NCT03395899|DRUG|Bevacizumab|Highly specific humanized monoclonal antibody that targets VEGF
58453160|NCT05448339|COMBINATION_PRODUCT|PVHA or TACE|PVHA or TACE
58453161|NCT01433016|DRUG|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
58453162|NCT01696370|DRUG|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
58453163|NCT01696370|OTHER|Placebo capsule|one capsule three times per day for 3 months
57753514|NCT03917784|DRUG|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
57753515|NCT03917784|DRUG|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
57753516|NCT00583986|DRUG|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
57753517|NCT02007434|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
57753518|NCT02007434|DRUG|Placebo|Phosphate buffered saline placebo for injection
57753519|NCT02007434|OTHER|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
57753520|NCT02007434|DRUG|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
57753521|NCT02007434|DRUG|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
58453164|NCT02210000|DRUG|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
58453165|NCT02210000|DRUG|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
58453166|NCT00235586|PROCEDURE|10 vit. D deficient subjects take vit. D for 3 months.|
58453167|NCT02960516|DEVICE|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
58453168|NCT05839574|DRUG|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
58453169|NCT05839574|DRUG|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
58453170|NCT01402401|DRUG|AUY922|
58453171|NCT01402401|DRUG|Trastuzumab|
57753522|NCT02007434|DRUG|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
57753523|NCT02007434|OTHER|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
57753524|NCT04638998|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|MRSI is a non invasive imaging technique used to detect neuroinflammation.
57753525|NCT04638998|PROCEDURE|Blood draw|Blood will be drawn to assess systemic inflammation in Gulf War verterans.
58453172|NCT04670341|OTHER|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
58453173|NCT04670341|OTHER|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
58453174|NCT01307436|BIOLOGICAL|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
58453175|NCT01307436|BIOLOGICAL|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
58453176|NCT03833739|DEVICE|Fixed appliance|
57753526|NCT02320422|BEHAVIORAL|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
57753527|NCT00873418|BEHAVIORAL|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
57753528|NCT01258192|DRUG|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
58128252|NCT01977469|BEHAVIORAL|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
58128253|NCT05704556|DRUG|VX-548|Tablets for oral administration.
58453177|NCT04057066|BEHAVIORAL|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
58453178|NCT04057066|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
58453179|NCT01676987|DRUG|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
58453180|NCT01676987|DRUG|Budesonide|Delivered dry powder inhaler for 12 weeks.
58453181|NCT04730765|PROCEDURE|left elective colectomy (Surgical Experimental Group)|Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.
58453182|NCT04730765|DRUG|antibiotic therapy (medical Control Group)|Antibiotic treatement for 10 days by oral or intravenous administration
57753529|NCT03088592|DEVICE|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
57753530|NCT03735264|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
57753531|NCT02919722|BEHAVIORAL|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
57753532|NCT06579352|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)|Umbilical cord-derived mesenchymal stem cells administered intravenously.
57753533|NCT03209141|DIAGNOSTIC_TEST|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
57961611|NCT04696588|OTHER|Complex set of kinesiotherapy of cervical spine and delicate massage|"Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~1. Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~2. Massage of cervical interspinales muscles performed by therapist 3 minutes.~3. Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~4. Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes."
58453183|NCT03476148|DEVICE|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
58453184|NCT03476148|OTHER|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
58453185|NCT06256588|DRUG|Dostarlimab|Dostarlimab will be administered as an intravenous (IV) infusion
58453186|NCT06256588|DRUG|Placebo|Placebo will be administered as an IV infusion
58453187|NCT00421057|BEHAVIORAL|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
58453188|NCT00421057|BEHAVIORAL|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
58453189|NCT06063694|DEVICE|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
58453190|NCT05153577|OTHER|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
58453191|NCT05153577|OTHER|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
58453192|NCT03820882|DEVICE|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
58453193|NCT03820882|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
58453194|NCT03899298|BIOLOGICAL|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
58453195|NCT06059235|OTHER|pharmaceutical care|"consultation with a pharmacist performing advanced pharmaceutical care : Package of clinical pharmacy activities including :~Medication history (during assessment consultation) Medication review and consultation with the geriatrician Therapeutic education (during results consultation) Shared decision (at results consultation) One-week follow-up call + usual care"
58453196|NCT03527472|DRUG|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
58453197|NCT03527472|DRUG|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
58453198|NCT05510089|DRUG|Etoposide|D1\~D2: 75mg/m\^2
58453199|NCT05510089|DRUG|Cytarabine|D1\~D2: 300mg/m\^2, q12h
58453200|NCT05510089|DRUG|PEG-rhG-CSF|D6: 6mg
58453201|NCT04589871|OTHER|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
58453202|NCT04589871|OTHER|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
57753534|NCT04240184|OTHER|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
57753535|NCT03688984|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
57753536|NCT04166825|DIAGNOSTIC_TEST|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
57753537|NCT01176721|DEVICE|t-VNS verum|Active stimulation of the left auricle by t-VNS
57753538|NCT01176721|DEVICE|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
57753539|NCT05670483|DEVICE|Use Of APRV mode of Ventilation|"Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~1. P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~2. T high at 4-6 seconds~3. P low at 0~4. T low at 0.5 to 0.8 seconds.~5. ATC (automatic tube compensation) on.~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
57753540|NCT05670483|DEVICE|Use of conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode|"Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~1. Tidal Volume 6-8 ml/kg predicted body weight~2. Respiratory rate (RR) 14 /min~3. Positive end expiratory pressure (PEEP)= 5 cmH2o~4. Pressure Support (PS) = 10 cmH2o~5. Inspiratory time 1.4 Sec~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of mechanical ventilation will be done by switching the ventilation to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
57753541|NCT03233568|DIAGNOSTIC_TEST|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
57753542|NCT04413630|OTHER|family workshop|The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
57753543|NCT02456766|DEVICE|FibroTouch|
57753544|NCT02456766|PROCEDURE|Liver Biopsy|
57753545|NCT05907434|DIAGNOSTIC_TEST|Nephrocheck (AKI score)|Early biomarker of AKI
57753546|NCT05284864|PROCEDURE|Stoma closure|Stoma closure after rectal surgery
57753547|NCT01355588|DRUG|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
57753548|NCT01355588|DRUG|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
57753549|NCT01355588|DRUG|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
57753550|NCT01355588|DRUG|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
57753551|NCT06508047|DEVICE|Informed Vital Core App|Informed Vital Core App will be initiated by the study staff to take a measurement, which takes 60 seconds to calculate and report a breathing rate value.
57961612|NCT01100944|DRUG|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
57961613|NCT00948870|DRUG|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
58453203|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) Online|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of an online family dyadic skills training and in-person core behavioral weight loss sessions.
58128254|NCT03650777|OTHER|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
58315099|NCT06228976|BEHAVIORAL|Mindfulness-based, smoking cessation focused text messages.|Participants will receive mindfulness-based, smoking cessation focused text messages everyday for 12 weeks.
58453204|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) In-Person|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of in-person family dyadic skills training and core behavioral weight loss sessions.
58453205|NCT03782519|OTHER|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
58315100|NCT06228976|BEHAVIORAL|Educational messages|Text messages focus on the health risks of smoking and secondhand smoking, once everyday for 12 weeks.
58315101|NCT06228976|BEHAVIORAL|Control messages|Text messages focus on the general healthy lifestyle, once everyday for 12 weeks.
57753552|NCT06481033|BEHAVIORAL|Real Time fMRI Neurofeedback|The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
57753553|NCT00266825|DRUG|DHA|600 mg DHA
57753554|NCT00266825|OTHER|Placebo capsule|Placebo capsule
57753555|NCT02436811|BEHAVIORAL|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
57753556|NCT02436811|BEHAVIORAL|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
57753557|NCT02436811|BEHAVIORAL|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
57753558|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
57753559|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
57753560|NCT06171334|DEVICE|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
57753561|NCT06293209|DEVICE|3M cold pack|3M cold pack
57753562|NCT06293209|DEVICE|Perskindol cold spray|Perskindol cold spray
57753563|NCT06293209|DEVICE|Placebo|Placebo
57753564|NCT03909984|DEVICE|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
57753565|NCT01561859|BEHAVIORAL|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
57753566|NCT01561859|BEHAVIORAL|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
57753567|NCT02167763|DEVICE|VeraCept Intrauterine Copper Contraceptive|
57753568|NCT02167763|DEVICE|TCu380 IUD|
57753569|NCT06384950|BEHAVIORAL|ChatGPT|Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
57753570|NCT06384950|BEHAVIORAL|patient education with traditional methods.|Patients receive standard traditional education procedures.
57753571|NCT03039595|OTHER|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
57753572|NCT03721640|OTHER|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
57753573|NCT01921816|DEVICE|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
57753574|NCT02063230|DRUG|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
57753575|NCT02063230|DRUG|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
58453206|NCT03782519|OTHER|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
57753576|NCT04433234|DRUG|DS-5141b|Administered via subcutaneous injection once weekly
57753577|NCT05341258|DIAGNOSTIC_TEST|EtCO2|EtCO2
57753578|NCT05341258|DIAGNOSTIC_TEST|PaCO2|PaCO2
57753579|NCT06341608|BEHAVIORAL|Telehealth for opioid use disorder treatment delivery|A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests
58453207|NCT00360412|DRUG|E2007|
58453208|NCT03471247|DEVICE|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
57753580|NCT02510144|DRUG|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
57753581|NCT02510144|DRUG|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
57753582|NCT04493216|DRUG|GSK3640254|GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
57753583|NCT04493216|DRUG|ABC/3TC|ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
57753584|NCT04493216|DRUG|FTC/TAF|FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
57753585|NCT04493216|DRUG|Dolutegravir|Dolutegravir was available as a 50 mg tablet to be administered via oral route.
57753586|NCT04493216|DRUG|Placebo|Placebo matching GSK3640254 was administered in the form of tablets via oral route.
57753587|NCT01003457|OTHER|ultrasonography|transvaginal ultrasonography of bladder wall thickness
57753588|NCT04620967|DRUG|Insulin aspart|Insulin aspart (Iasp) in insulin pump
57753589|NCT04620967|DRUG|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
57753590|NCT01054261|DRUG|avanafil|200 mg avanafil tablet QD
57753591|NCT01762150|DRUG|Sorafenib|Sorafenib 400mg BID by oral until progressed;
57753592|NCT01762150|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
57753593|NCT01762150|DRUG|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
57753594|NCT01855217|DRUG|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
57753595|NCT01855217|DRUG|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
57753596|NCT01855217|DRUG|Placebo|0,9% NaCl
57753597|NCT01292551|DRUG|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
57753598|NCT01292551|DRUG|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
57753599|NCT01828580|DEVICE|active laparoscope positioner (AutoLap)|
58453209|NCT03471247|OTHER|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
57753600|NCT01525602|DRUG|PLX3397|PLX3397 tablets, 200mg
58453210|NCT00055835|DRUG|carboplatin|\*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
58453211|NCT00055835|DRUG|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
57753601|NCT01525602|DRUG|Paclitaxel|Paclitaxel IV
57961614|NCT02995616|DEVICE|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
58453212|NCT00055835|DRUG|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 \& 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
58453213|NCT00055835|DRUG|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
58453214|NCT00055835|PROCEDURE|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
58453215|NCT00055835|RADIATION|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
58453216|NCT01029184|OTHER|commercialized complete cereals|complete cereals suitable for the weaning period
57753602|NCT00005791|DRUG|cisplatin|
57753603|NCT00005791|DRUG|fluorouracil|
57753604|NCT00005791|DRUG|irinotecan hydrochloride|
57753605|NCT01737957|DEVICE|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
57753606|NCT01737957|DEVICE|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
57753607|NCT02013310|DRUG|HT-0712|
57753608|NCT02013310|DRUG|Placebo|
57753609|NCT01197508|DRUG|TC-5214|Twice daily for 8 weeks.
57753610|NCT01197508|DRUG|Placebo|Twice daily for 8 weeks.
57753611|NCT03291743|DEVICE|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
57753612|NCT02088151|DEVICE|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
57753613|NCT02532556|DEVICE|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
57753614|NCT03879746|DRUG|Tamsulosin|drug will be used in treatment of premature ejaculation
57753615|NCT03879746|DRUG|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
57753616|NCT03879746|OTHER|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
57753617|NCT01566331|DEVICE|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
57753618|NCT02770651|DEVICE|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
57753619|NCT02770651|DEVICE|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
57753620|NCT02365675|DEVICE|Cotton gauze with petrolatum|
57753621|NCT02365675|DEVICE|Cellulose acetate with petrolatum|
57753622|NCT02365675|DEVICE|Nanocrystalline silver (Acticoat)|
57753623|NCT02365675|DEVICE|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
57753624|NCT01373931|DRUG|LY2216684|Administered orally
57753625|NCT01373931|DRUG|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
58453217|NCT01029184|OTHER|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
58453218|NCT01768507|DIETARY_SUPPLEMENT|Resveratrol|5 g (10 capsules) as single oral dose on day 1
57753626|NCT01373931|DRUG|Placebo|Administered orally
58453219|NCT03854058|DIAGNOSTIC_TEST|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
58453220|NCT02816697|OTHER|CEASE|"* Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
58453221|NCT02816697|OTHER|Usual Care Tobacco Treatment Services|
58453222|NCT03650491|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
58453223|NCT03073239|GENETIC|ALS patients genetic characterization|Genetic findings in ALS patients
58453224|NCT03073239|OTHER|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
58453225|NCT00670280|BEHAVIORAL|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
58453226|NCT00670280|BEHAVIORAL|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
58453227|NCT00670280|BEHAVIORAL|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
58453228|NCT04452630|OTHER|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
58453229|NCT01135134|DRUG|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
58453230|NCT01135134|DRUG|Placebo|"MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
58453231|NCT01527123|DRUG|GSK2585823|CLDM1%/BPO3%
58453232|NCT03458312|BEHAVIORAL|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
58453233|NCT02724098|DRUG|Dexmedetomidine|
58453234|NCT05898217|OTHER|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
58453235|NCT05898217|OTHER|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
58453236|NCT05898217|OTHER|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
58453237|NCT05898217|OTHER|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
57961615|NCT02995616|DEVICE|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
58453238|NCT02541812|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
58453239|NCT05339022|OTHER|Best Practice|Receive standard of care
58453240|NCT05339022|OTHER|Exercise Intervention|Undergo exercise intervention
58453241|NCT05339022|PROCEDURE|Physical Therapy|Undergo physical therapy
58453242|NCT05339022|OTHER|Quality-of-Life Assessment|Ancillary studies
58453243|NCT05339022|OTHER|Questionnaire Administration|Ancillary studies
58453244|NCT05339022|PROCEDURE|Relaxation Therapy|Undergo progressive muscles relaxation exercises
58453245|NCT05583123|DEVICE|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
58453246|NCT05583123|DEVICE|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
58453247|NCT03071263|DRUG|Patiromer|2 packets/day starting dose, administered orally
58453248|NCT03071263|DRUG|Placebo|2 packets/day starting dose, administered orally
58453249|NCT03071263|DRUG|Spironolactone|25 mg tablet/day starting dose, administered orally
58453250|NCT04641845|OTHER|Cork inlay wedge|
58453251|NCT00016497|PROCEDURE|bilateral myringotomy|
58453252|NCT00016497|PROCEDURE|bilateral myringotomy and tubes|
57753627|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
57753628|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
57961616|NCT02995616|DEVICE|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
57961617|NCT02361216|DRUG|Ingenol Mebutate|
58453253|NCT00016497|PROCEDURE|adenoidectomy|
58453254|NCT01111708|PROCEDURE|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
58453255|NCT06155422|DRUG|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
58453256|NCT00325715|DRUG|AGN 201904|
57753629|NCT02260453|OTHER|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
57753630|NCT02260453|OTHER|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
57753631|NCT02218879|DRUG|Tecfidera|Oral Tecfidera 240 mg bid
57753632|NCT03298230|BEHAVIORAL|REmotely SuPervised Exercise Training|As described in the Arms section.
57753633|NCT03298230|BEHAVIORAL|Supervised Exercise Training|As described in the Arms section.
57753634|NCT03190551|OTHER|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
58453257|NCT00325715|DRUG|esomeprazole|
58453258|NCT02336607|DRUG|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
58453259|NCT02336607|DRUG|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
58453260|NCT02336607|DRUG|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
58453261|NCT02336607|DRUG|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
58453262|NCT00363844|DRUG|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
58453263|NCT02961959|PROCEDURE|Surgery|Arthrodesis of SI-joints, Physiotherapy
58453264|NCT02961959|OTHER|Non-surgery|Physiotherapy
58453265|NCT05711043|DEVICE|Endoscopic sutured gastroplasty with endomina|"Subjects in the intervention group will be treated with an ESG with the endomina ® and TAPES devices (Endo Tools Therapeutics S.A.), both CE-marked for endoscopic gastroplasty. The endomina is a device that can be attached to an endoscope and allows remote actuation of the device during a peroral intervention. Thanks to a therapeutic channel that can be angled perpendicularly to the axis of vision of the endoscope, it allows the possibilities of making transoral full thickness tissue apposition and performing, via a transoral route, large plications with tight serosa to serosa apposition in the stomach. This suturing will be done from the incisura to the upper body of the stomach, along the great curvature with TAPES, a single use needle preloaded with suture.~In addition to the endomina device, any other required endoscopic accessories can be used during the procedure (e.g., grasping forceps, loop cutter)."
57960675|NCT06458933|BEHAVIORAL|Supportive Individual Psychotherapy|Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
57753635|NCT03190551|OTHER|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
57753636|NCT06097676|DRUG|Placebo|Placebo
57753637|NCT06097676|DRUG|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
57753638|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
57753639|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
57753640|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
57961618|NCT02361216|OTHER|Vehicle|Vehicle gel
57961619|NCT01889979|DRUG|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
57961620|NCT01889979|DRUG|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
57961621|NCT04248738|BEHAVIORAL|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
57961622|NCT00142883|DRUG|Pregabalin|pregabalin compared to placebo
57961623|NCT00142883|DRUG|placebo|sugar pill compared to pregabalin
57961624|NCT02236455|BEHAVIORAL|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
57961625|NCT02236455|BEHAVIORAL|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
57961626|NCT02236455|BEHAVIORAL|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
57753641|NCT04715516|BEHAVIORAL|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
57753642|NCT04715516|BEHAVIORAL|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
57753643|NCT05435924|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
57753644|NCT02031367|DRUG|Triamcinolone Acetonide|Corticosteroid arm
57753645|NCT02031367|OTHER|Platelet Rich Plasma|Platelet Rich Plasma
57753646|NCT05749848|DRUG|[¹⁴C]-LY3372689|Administered orally.
57753647|NCT02913664|DRUG|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
57753648|NCT02913664|BEHAVIORAL|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
57753649|NCT02913664|OTHER|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
57753650|NCT02913664|BEHAVIORAL|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
57753651|NCT03754179|DRUG|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
57753652|NCT03754179|DRUG|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
57753653|NCT03754179|DRUG|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
57753654|NCT04074421|DRUG|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
57753655|NCT04074421|DRUG|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
57753656|NCT04074421|DRUG|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
57753657|NCT04590534|DRUG|Chromax|Treatment of BPH by Chromax for 3 Months
57753658|NCT04590534|DRUG|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
57753659|NCT04590534|OTHER|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
57753660|NCT01756911|DEVICE|MFM|Implantation of the MFM
57753661|NCT05388721|OTHER|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
57753662|NCT03197012|DRUG|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
57753663|NCT03197012|DRUG|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
57753664|NCT04983563|DEVICE|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
57753665|NCT02636270|DRUG|Increlex|Treat PAPP-A2 deficient patients with Increlex
57960676|NCT02001233|BIOLOGICAL|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
58453266|NCT03626259|DRUG|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
58453267|NCT03626259|DRUG|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
58458738|NCT02212808|OTHER|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
57960677|NCT00490568|DRUG|Rosiglitazone XR|Experimental drug
57753666|NCT04021017|DRUG|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
57753667|NCT03460028|BEHAVIORAL|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
57753668|NCT04876079|OTHER|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
57753669|NCT04876079|DEVICE|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
57753670|NCT04876079|OTHER|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
57753671|NCT04876079|DRUG|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
57753672|NCT04162093|PROCEDURE|uretero ileal anastomosis in single trough|
57753673|NCT06370910|OTHER|Low-Level Laser Therapy|The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.
58453268|NCT03959163|DIAGNOSTIC_TEST|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
58453269|NCT00362648|BIOLOGICAL|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
58453270|NCT00362648|BIOLOGICAL|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
58453271|NCT02572323|DRUG|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
57753674|NCT04088201|DEVICE|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
57753675|NCT01592903|GENETIC|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"* Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality."
57753676|NCT00116844|DRUG|Valaciclovir|Valtrex 1g once daily
57753677|NCT00116844|DRUG|Placebo|placebo
57753678|NCT03879408|DRUG|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
57960678|NCT04819737|PROCEDURE|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
58315102|NCT06470581|DRUG|Botulinum toxin A|Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
58453272|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
58453273|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
58453274|NCT03653858|DEVICE|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
58453275|NCT00988598|DRUG|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
58453276|NCT00988598|DRUG|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
58453277|NCT04190914|OTHER|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
58453278|NCT00429559|DRUG|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
57753679|NCT03879408|DRUG|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
57753680|NCT03879408|DRUG|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
57753681|NCT03879408|DRUG|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
57753682|NCT03879408|DRUG|Placebo tablet|Single dose of four placebo tablets
57753683|NCT02417779|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
57753684|NCT02417779|DEVICE|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
57753685|NCT05255432|OTHER|nil intervention|Users observation using medical device on manakin, different scenarios per group
57753686|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
57753687|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
57753688|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
57753689|NCT04780373|OTHER|data collection|clinical data collection
57753690|NCT00739375|PROCEDURE|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
57753691|NCT02055157|DRUG|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
57753692|NCT00002558|BIOLOGICAL|filgrastim|
57753693|NCT00002558|DRUG|carboplatin|
57753694|NCT00002558|DRUG|etoposide|
58315103|NCT03998631|PROCEDURE|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
58315104|NCT03998631|PROCEDURE|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
57753695|NCT00002558|DRUG|ifosfamide|
57753696|NCT00002558|DRUG|paclitaxel|
57753697|NCT00002558|PROCEDURE|peripheral blood stem cell transplantation|
57753698|NCT03649230|DRUG|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
57753699|NCT03920228|DRUG|PTX-022|PTX-022 QTORIN
57753700|NCT03920228|DRUG|Placebo|Placebo topical
57753701|NCT04417686|PROCEDURE|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
57753702|NCT04799379|DRUG|microporous polysaccharide hemospheres (MPH) agent in rectal surgery|Use of microporous polysaccharide hemospheres (MPH) agent in patients after rectal surgery to avoid pelvic collections and the use of any drain
57753703|NCT00956566|BEHAVIORAL|dietary intervention|dietary counseling, group teaching
57753704|NCT04706702|BEHAVIORAL|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
57753705|NCT05518656|BEHAVIORAL|Experimental intervention|Daily lessons received by email to be completed the same day
57753706|NCT05518656|BEHAVIORAL|Comparison intervention|Daily lessons receive by email to be completed the same day
57753707|NCT04352478|DIAGNOSTIC_TEST|Histopathological result|Incidental gallbladder cancer and other pathology
57753708|NCT05527366|OTHER|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
57753709|NCT05527366|OTHER|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
57753710|NCT03252080|BEHAVIORAL|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
57753711|NCT03252080|BEHAVIORAL|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
57753712|NCT02472210|DRUG|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
57753713|NCT00867438|PROCEDURE|Sigmoidoscopy|
57753714|NCT06387290|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.
57753715|NCT06387290|BEHAVIORAL|Patient-Centered Chronic Pain Management Visits|Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).
58453279|NCT00429559|DRUG|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
57753716|NCT03058341|DRUG|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
57753717|NCT03058341|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
57753718|NCT04023071|DRUG|FT516|Experimental Interventional Therapy
57753719|NCT04023071|DRUG|Rituximab|Monoclonal Antibody
57753720|NCT04023071|DRUG|Obinutuzumab|Monoclonal Antibody
57753721|NCT04023071|DRUG|Cyclophosphamide|Conditioning agent
57753722|NCT04023071|DRUG|Fludarabine|Conditioning agent
57753723|NCT04023071|DRUG|IL-2|Biologic response modifier
57753724|NCT04023071|DRUG|Bendamustine|Conditioning agent
57753725|NCT02484157|DEVICE|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
57753726|NCT02484157|DEVICE|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
57753727|NCT05801731|OTHER|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
57753728|NCT05801731|OTHER|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
58453280|NCT02753803|DRUG|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
58453281|NCT02753803|DRUG|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
58453282|NCT02753803|DRUG|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
58453283|NCT02753803|DRUG|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
58453284|NCT02753803|DRUG|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
58453285|NCT02753803|DRUG|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
57753729|NCT04858919|DIAGNOSTIC_TEST|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
57753730|NCT04858919|DIAGNOSTIC_TEST|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
57753731|NCT04858919|DIAGNOSTIC_TEST|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
58453286|NCT02414308|DRUG|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
58453287|NCT00247403|DRUG|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
57960679|NCT04819737|OTHER|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
58315105|NCT02353780|DRUG|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
58315106|NCT02353780|DRUG|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
58453288|NCT05694039|DEVICE|Hearing Aids|The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
58453289|NCT00644046|BEHAVIORAL|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
58453290|NCT00890825|DRUG|AZD6244|oral capsules, 75mg twice daily
58453291|NCT00890825|DRUG|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
58453292|NCT00890825|DRUG|Placebo|placebo
58453293|NCT02252146|DRUG|IMO-8400|MO-8400 given subcutaneously twice weekly
58453294|NCT04529967|OTHER|no interventions|it is a observational study, do not have interventions.
58453295|NCT04033367|DRUG|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58453296|NCT04033367|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58453297|NCT03036410|DEVICE|standard telephone setting|without streaming function
58453298|NCT03036410|DEVICE|DECT|cordless telephone (streaming to both hearing devices)
57753732|NCT02543658|DRUG|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
57753733|NCT02543658|COMBINATION_PRODUCT|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
57753734|NCT05655676|DRUG|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
57753735|NCT00061802|DRUG|risperidone, quetiapine|
57753736|NCT02486289|DRUG|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
57753737|NCT02486289|DRUG|Placebo|NBMI Placebo
57753738|NCT02741401|OTHER|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
57753739|NCT02741401|OTHER|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
57753740|NCT03353064|OTHER|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
57753741|NCT03353064|OTHER|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
57753742|NCT02130934|PROCEDURE|Cardiac 3D MRI|
57753743|NCT02133599|DRUG|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
57753744|NCT00715650|BEHAVIORAL|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
57753745|NCT00715650|BEHAVIORAL|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
57753746|NCT06131580|DRUG|Intervention/Treatment|"Drug: osilodrostat~- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."
57753747|NCT01355458|DRUG|CD07805/47 gel|applied topically once daily
57753748|NCT01355458|DRUG|Placebo|applied topically once daily
57753749|NCT02192970|DRUG|Bevacizumab|
57753750|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
57753751|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
57753752|NCT02522858|DRUG|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
57753753|NCT02522858|DRUG|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
58128255|NCT04985422|BEHAVIORAL|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
58453299|NCT03036410|DEVICE|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
58453300|NCT03036410|DEVICE|DuoPhone|streaming function, which provides the speech signal to both ears
58453301|NCT01458639|DRUG|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
57753754|NCT02522858|DRUG|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
57753755|NCT00184548|DRUG|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
57960680|NCT04680611|OTHER|no study intervention. Patients receive standard clinical care|no intervention. observational study
58315107|NCT02353780|DRUG|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
58315108|NCT02179619|DEVICE|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
57753756|NCT00184548|DRUG|placebo|placebo
57753757|NCT04479436|DRUG|Patritumab Deruxtecan|U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
57753758|NCT02489032|BEHAVIORAL|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
57960681|NCT00359775|BEHAVIORAL|Coping Skills Training|6 session behavioral program
57960682|NCT03733392|DEVICE|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
57753759|NCT02489032|OTHER|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
57753760|NCT04562961|OTHER|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
57753761|NCT06118034|DRUG|Colchicine 0.5 MG|Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
57753762|NCT06118034|DRUG|Placebo|Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
57753763|NCT04752449|BEHAVIORAL|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
57753764|NCT00192309|BIOLOGICAL|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
57753765|NCT00192309|BIOLOGICAL|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
57753766|NCT00192309|BIOLOGICAL|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
58128256|NCT04985422|BEHAVIORAL|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
58128257|NCT00437242|DRUG|Odiparcil|
58453302|NCT01458639|DRUG|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
58128258|NCT00418184|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
58128259|NCT00418184|OTHER|Colored cellulose tainted with fishy odor|as arm 1
58453303|NCT06024070|OTHER|Rigid Tape|"The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips"
58453304|NCT03576326|BEHAVIORAL|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
58453305|NCT02735967|OTHER|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
58128260|NCT02969837|DRUG|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
58453306|NCT02735967|DEVICE|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
58453307|NCT02987725|BEHAVIORAL|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
58453308|NCT02987725|BEHAVIORAL|Attention Control|A 30-minute historical story read by a research clinician.
58453309|NCT05258604|PROCEDURE|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
58128261|NCT02969837|DRUG|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
58128262|NCT02969837|DRUG|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
57753767|NCT06020690|DEVICE|bioabsorbable steroid-releasing stent|The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
57753768|NCT05138445|BEHAVIORAL|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
57753769|NCT05138445|BEHAVIORAL|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
57753770|NCT05580666|DRUG|Azithromycin Oral Tablet|Antimicrobial therapy
57753771|NCT05580666|DRUG|Placebo oral tablet|Inert ingredients
57753772|NCT02090634|BEHAVIORAL|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
58453310|NCT05258604|PROCEDURE|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
57753773|NCT02090634|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
57753774|NCT02174432|DRUG|nalbuphine HCl ER|nalbuphine HCl ER BID for up to 50 weeks
57753775|NCT02234544|DRUG|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
57753776|NCT02234544|DRUG|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
57753777|NCT02234544|OTHER|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
57753778|NCT04230421|DEVICE|The Monsenso system with feedback|See description under intervention
57753779|NCT04230421|DEVICE|The Monsenso system without feedback|See description under intervention
57753780|NCT04230421|DEVICE|CAG Bipola and mood monitoring only|See description under intervention
57753781|NCT05740202|DRUG|SHR-7367|The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.
58453311|NCT00483470|BIOLOGICAL|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
57753782|NCT00804401|DRUG|Naproxen Tablets, 500 mg|
57753783|NCT03471169|DRUG|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
57753784|NCT03471169|DRUG|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
58453312|NCT00483470|BIOLOGICAL|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
57753785|NCT02837640|DRUG|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
58453313|NCT00760955|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
57753786|NCT05001438|PROCEDURE|Hidro|Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
57753787|NCT05001438|PROCEDURE|MUA|Movilization under anesthesia
57753788|NCT04999982|OTHER|Screening|Parent-report screening for remediable, unmet social needs.
57753789|NCT04999982|OTHER|Resource Packet|"Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted."
57753790|NCT04999982|OTHER|Resource Navigation|Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.
57753791|NCT04999982|OTHER|Care as usual|Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
58453314|NCT00760955|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
58453315|NCT00760955|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
57753792|NCT03067454|PROCEDURE|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
57753793|NCT03067454|PROCEDURE|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
58453316|NCT00760955|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
58453317|NCT00988078|DRUG|Placebo|Capsule (without biologic action) administered three times a day for six months
58453318|NCT00988078|DRUG|Metformin|Metformin 500mg three times a day for six months
58453319|NCT03868254|DEVICE|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
58453320|NCT03868254|PROCEDURE|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
57753794|NCT04436315|DEVICE|Motor-cognitive training device|Motor-cognitive training device
57753795|NCT04436315|OTHER|Active control condition|Physical activity program
57753796|NCT02428296|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
57753797|NCT01209065|DRUG|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
57753798|NCT01209065|DRUG|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
57753799|NCT01209065|DRUG|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
57753800|NCT06075420|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
57753801|NCT06380699|DRUG|QHRD106 Injection|PEG-tissue kallikrein-1
57753802|NCT06380699|DRUG|Human Urinary Kallidinogenase|tissue kallikrein-1
57753803|NCT06380699|DRUG|placebo|placebo
57753804|NCT05328687|DIAGNOSTIC_TEST|Shear wave elastography|or measuring the muscle stiffness, we use a linear 9 MHz ultrasound probe (9L) and the Logic E9 scanner, both from GE Healthcare (Chalfont St Giles, UK). All measurements are performed with the probe parallel to the muscle fibers. We will measure the stiffness of the trapezius muscle in the middle botulinum toxin A injection side (G1) according to the PREEMPT protocol. All data are saved as images by the observer and subsequently analyzed by a blinded observer.
57753805|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
57753806|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
57753807|NCT00136786|DRUG|Memantine|
57753808|NCT06150703|DRUG|Ovulation induction with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
57753809|NCT06150703|DRUG|Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
57753810|NCT02710279|BEHAVIORAL|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
57753811|NCT02710279|DEVICE|smartphone|
57753812|NCT05118633|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
57753813|NCT05118633|BEHAVIORAL|Reminder bracelet and journaling app control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
57753814|NCT04670900|PROCEDURE|Tension band wiring or plate fixation|Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
57753815|NCT04670900|PROCEDURE|Active non-operative treatment with optional plaster cast|Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
57960683|NCT03592095|DEVICE|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
57960684|NCT03592095|DEVICE|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
58128263|NCT02969837|DRUG|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
58128264|NCT05309421|DRUG|EVX-01|Investigational drug given in combination with standard of care
58128265|NCT05309421|DRUG|Pembrolizumab 25 MG/ML|Standard of care
57753816|NCT03219385|DEVICE|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
57753817|NCT01188109|DRUG|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
57753818|NCT01188109|DRUG|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
57753819|NCT01161368|DRUG|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle."
57753820|NCT06118723|PROCEDURE|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
57753821|NCT06118723|PROCEDURE|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
57753822|NCT06413251|OTHER|Boxing Training|The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.
57753823|NCT06413251|OTHER|Control flexibility|The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
57753824|NCT04965350|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
57753825|NCT00939874|DRUG|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
57753826|NCT01278355|DEVICE|Ear acupuncture|Ear acupuncture
57753827|NCT05604625|DEVICE|Van-Beek activator and a headgear|12 patients will receive Van-Beek activator and a headgear
57753828|NCT05604625|DEVICE|Andresen activator|12 patients will receive Andresen activator.
57753829|NCT00316810|DRUG|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
57753830|NCT00316810|DRUG|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
57753831|NCT03274635|BEHAVIORAL|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
57753832|NCT04591028|DRUG|Indocyanine green|A one time injection of IDC prior to the day of scheduled surgery.
57753833|NCT06358625|OTHER|Pre-treatment biopsy|"A breast biopsy is performed just before the clip is placed in the tumour and additional blood samples are performed."
57753834|NCT01920282|DRUG|Nebivolol|
57753835|NCT01920282|OTHER|Lifestyle Modification|
57753836|NCT01920282|OTHER|Nebivolol plus Lifestyle Modification|
57960685|NCT05320900|DIAGNOSTIC_TEST|Chest auscultation|Chest auscultation data
58453321|NCT03435185|PROCEDURE|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
57960686|NCT00915343|DRUG|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
57753837|NCT04885556|DEVICE|Tampon-like device for absorption of sexual fluids|Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
57753838|NCT01299090|DEVICE|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
57753839|NCT05096156|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
57753840|NCT02161302|DEVICE|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
57753841|NCT02161302|DEVICE|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
57753842|NCT04010240|OTHER|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
57753843|NCT00953264|BEHAVIORAL|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
57753844|NCT02064543|OTHER|GAITRite|mobility test assessing gait parameters
57753845|NCT02064543|OTHER|ADPM|mobility test assessing gait parameters
57753846|NCT00177060|DRUG|hydromorphone|
57753847|NCT00035074|DRUG|Methotrexate|
57753848|NCT05650164|DRUG|avelumab|as provided in real world practice
57753849|NCT05650164|DRUG|axitinib|as provided in real world practice
57753850|NCT04182711|DEVICE|Device|Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
57960687|NCT00915343|DRUG|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
57961627|NCT02236455|BEHAVIORAL|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
57753851|NCT05465057|BEHAVIORAL|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
57753852|NCT05465057|BEHAVIORAL|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
57753853|NCT04419402|DRUG|Lu-PSMA|"Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles."
57753854|NCT04419402|DRUG|Enzalutamide|160 mg (four 40 mg capsules) daily.
57753855|NCT03889626|DRUG|Apatinib|Apatinib: 500mg qd po, q4w
57753856|NCT03889626|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
57753857|NCT00118716|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
57753858|NCT00118716|DRUG|Fluticasone Propionate|Fluticasone Propionate
57753859|NCT05277675|DRUG|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
57753860|NCT05277675|PROCEDURE|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
57753861|NCT05176470|DRUG|Cyclophosphamide|Given IV
57753862|NCT05176470|DRUG|Fludarabine|Given IV
57753863|NCT05176470|BIOLOGICAL|Lifileucel|Given by IV infusion
57753864|NCT05176470|BIOLOGICAL|Pembrolizumab|Given IV
57753865|NCT05176470|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57753866|NCT01938248|DRUG|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
57753867|NCT01938248|DRUG|aspirin|aspirin 81 mg once daily
57753868|NCT03603210|DEVICE|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
57753869|NCT04259086|DRUG|DaxibotulinumtoxinA for injection|Intramuscular injection
57753870|NCT04204200|DIETARY_SUPPLEMENT|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
57753871|NCT04204200|DIETARY_SUPPLEMENT|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
57753872|NCT04204200|DIETARY_SUPPLEMENT|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
57753873|NCT01452633|DRUG|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
57753874|NCT01452633|DRUG|Saline will be injected at the study port site prior to incision|Injection will precede incision
57753875|NCT01452633|DRUG|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
57960688|NCT04608695|PROCEDURE|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
57960689|NCT01938144|DRUG|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
57960690|NCT01938144|DRUG|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
57960691|NCT01938144|DRUG|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
57960692|NCT00487539|BIOLOGICAL|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
57960693|NCT00487539|BIOLOGICAL|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.
57753876|NCT01452633|DRUG|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
57753877|NCT03205657|PROCEDURE|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
57753878|NCT01183663|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
57753879|NCT01183663|DRUG|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
57753880|NCT01183663|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
57753881|NCT01183663|DRUG|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
57753882|NCT01183663|DRUG|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
57753883|NCT01183663|DRUG|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
57753884|NCT01183663|DRUG|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
57753885|NCT01183663|DRUG|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
57753886|NCT01557387|OTHER|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
57753887|NCT03011632|DRUG|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
57753888|NCT03011632|DRUG|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
57753889|NCT00678743|DRUG|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
57753890|NCT01040858|BEHAVIORAL|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
57753891|NCT01040858|OTHER|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
57753892|NCT03994302|DRUG|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
57753893|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
57753894|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
57753895|NCT06579456|OTHER|Surgical Training Intervention|Validation of a Formaldehyde-Free embalmed cadavers for recreate with more precision the experience of learning surgical endoscopy
57753896|NCT06579456|OTHER|Positive Control|training in models that emulate the rigidity, structure, dimensions, and haptic feedback of the anatomical structures to be treated.
57753897|NCT06579456|OTHER|Negative Control|Training proceeded in the rigid described skills acquisition platform, adding suture training using a perforable MMA-type woven fabric
57753898|NCT00155389|DRUG|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
57753899|NCT04167241|DIAGNOSTIC_TEST|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
57753900|NCT00464802|DRUG|MOA-728|
57753901|NCT02519101|DEVICE|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
57753902|NCT02238379|DRUG|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
57753903|NCT02238379|OTHER|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
57753904|NCT02701712|RADIATION|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
57753905|NCT03820856|PROCEDURE|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
57753906|NCT03820856|PROCEDURE|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
57753907|NCT03649620|DIETARY_SUPPLEMENT|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
57753908|NCT03649620|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
57960694|NCT00487539|BIOLOGICAL|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.
57960695|NCT00487539|BIOLOGICAL|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.
57960696|NCT00487539|BIOLOGICAL|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
57960697|NCT01088035|DRUG|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
57960698|NCT03772626|DEVICE|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
57960699|NCT00001570|DRUG|PSC 833|
58315109|NCT02179619|DEVICE|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
58453322|NCT03435185|PROCEDURE|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
57960700|NCT00001570|DRUG|vinblastine|
57960701|NCT04565678|DRUG|Mitapivat tablets|Oral tablets
57960702|NCT04565678|DRUG|Mitapivat coated granules|Oral coated granules
57753909|NCT01857882|OTHER|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
57753910|NCT01871831|DEVICE|6 blood glucose monitoring systems for self-testing|
57753911|NCT00621543|DEVICE|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
57753912|NCT06199557|DRUG|Hydroxyurea, Hydroxycarbamide|Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
57753913|NCT06199557|DRUG|Valproic acid|Valproic acid (VPA) has been used clinically as an anticonvulsant and mood-stabilizing drug. During the last two decades, VPA has been described as a histone deacetylase (HDAC) inhibitor and gained increased interest for use in cancer therapy. VPA is administered orally with available routine measurements of serum levels and has a low toxicity profile.
57753914|NCT06199557|DRUG|6-Mercaptopurine (6-MP)|In 1953, 6-MP was an approved antileukemic agent resulting in remissions in children with acute lymphocytic leukemia (ALL). After adding 6-MP to methotrexate and prednisolone in the treatment regimen, the one-year mean survival of children with ALL was increased from 29% to 50%. 6-MP, even about 70 years after its discovery, remains the standard maintenance therapy once the children are in complete remission.
57753915|NCT04285255|DRUG|Fentanyl|opioids anaesthesia
57753916|NCT04285255|DRUG|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
57753917|NCT04285255|DRUG|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
57753918|NCT04285255|PROCEDURE|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
57753919|NCT04285255|DRUG|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
57753920|NCT01631630|DRUG|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
57753921|NCT01631630|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
57753922|NCT02624544|DRUG|esomeprazole|esomex 40 mg twice daily
57753923|NCT02624544|DRUG|desonide|topical corticosteroid desonid 0,1% b.i.d
57753924|NCT02792361|PROCEDURE|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
57753925|NCT03584620|OTHER|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
57753926|NCT03584620|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
57753927|NCT00484003|DRUG|Pimecrolimus cream 1%|
57753928|NCT02333214|OTHER|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
57753929|NCT02333214|OTHER|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
57753930|NCT04549610|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
57753931|NCT04549610|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
57753932|NCT05987033|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
57753933|NCT05796856|DEVICE|repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)|crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.
57753934|NCT01674374|OTHER|placebo|Given PO
57753935|NCT01674374|PROCEDURE|quality-of-life assessment|Ancillary studies
57753936|NCT01674374|OTHER|questionnaire administration|Ancillary studies
57753937|NCT01674374|DRUG|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
57753938|NCT02650219|GENETIC|genetic analyses|
57753939|NCT02946918|DRUG|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
57753940|NCT03891121|DEVICE|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
57753941|NCT03891121|DRUG|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
57753942|NCT06016530|BEHAVIORAL|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
57753943|NCT06016530|DRUG|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
57753944|NCT06519279|DEVICE|Opals|Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
57753945|NCT02802163|DRUG|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
57753946|NCT02802163|DRUG|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
57753947|NCT02802163|DRUG|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
57753948|NCT02802163|DRUG|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
57753949|NCT04209946|PROCEDURE|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
57753950|NCT04209946|PROCEDURE|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
57753951|NCT00307749|DRUG|Placebo|once daily for 24 weeks
57753952|NCT00307749|DRUG|MCC-257|20mg, once daily for 24 weeks
57753953|NCT00307749|DRUG|MCC-257|40mg, once daily for 24 weeks
57753954|NCT00307749|DRUG|MCC-257|80mg, once daily for 24 weeks
57753955|NCT00898040|GENETIC|polymorphism analysis|
57753956|NCT04108455|OTHER|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
57753957|NCT03406546|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
57960703|NCT01394081|OTHER|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
58128266|NCT02907203|DEVICE|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
57753958|NCT03406546|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
57753959|NCT03406546|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
57753960|NCT01699022|DRUG|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
57753961|NCT00024492|DRUG|Liposome Encapsulated Mitoxantrone (LEM)|
57753962|NCT00000881|DRUG|Cidofovir|
57753963|NCT00000881|DRUG|Probenecid|
57753964|NCT00394355|DRUG|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
57753965|NCT00394355|DRUG|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
57753966|NCT00394355|DRUG|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
57753967|NCT00394355|DRUG|montelukast|10 mg given once daily in the evening by mouth for 1 year.
57753968|NCT06267885|PROCEDURE|Cannulated screws vs wagner's technique|Fixation of fracture neck of femur by cannulated screws or wagner's technique
57753969|NCT03764072|DRUG|VX-150|Capsules for oral administration.
57960704|NCT01394081|OTHER|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
57960705|NCT03786549|OTHER|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients"
57753970|NCT03764072|DRUG|Placebo|Capsules for oral administration.
57753971|NCT01579604|PROCEDURE|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
57753972|NCT00530062|DRUG|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
57753973|NCT00530062|DRUG|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
57753974|NCT03525548|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
57753975|NCT03525548|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
57753976|NCT03525548|DRUG|IVA|Participants received IVA orally once daily in the evening.
57753977|NCT03525548|DRUG|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
57753978|NCT03525548|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
57753979|NCT06181721|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
57753980|NCT05751122|OTHER|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
57753981|NCT05751122|OTHER|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
57753982|NCT04540874|DRUG|BI 894416|BI 894416
57753983|NCT04540874|DRUG|Placebo|Placebo
57753984|NCT03716284|PROCEDURE|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
57753985|NCT00883506|DRUG|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
57753986|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fasting conditions.|
57753987|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fed conditions.|
57753988|NCT00480701|DRUG|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
57960706|NCT03501030|BEHAVIORAL|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
58128267|NCT00699504|DRUG|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
57753989|NCT03159520|BEHAVIORAL|Advice sheet|Advice on management of post orthodontic pain
57753990|NCT01719822|DEVICE|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
57753991|NCT04248647|BEHAVIORAL|Multimodal prehabilitation|"This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist."
57753992|NCT03477279|BEHAVIORAL|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
57960707|NCT04118816|DIAGNOSTIC_TEST|Polysomnography|overnight polysomnography recording at least six hours
58128268|NCT00699504|DRUG|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
57960708|NCT04118816|DIAGNOSTIC_TEST|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
57960709|NCT04118816|OTHER|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
57960710|NCT00754910|DRUG|porfimer sodium|Given IV
57960711|NCT00754910|PROCEDURE|bronchoscopy|Patients undergo bronchoscopy
57960712|NCT02137954|DRUG|Lidocaine|
57960713|NCT02137954|DRUG|Placebo|
58128269|NCT00699504|DRUG|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
58128270|NCT00699504|DRUG|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
58128271|NCT00699504|DRUG|placebo|placebo IV and oral
58128272|NCT04432948|OTHER|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
58128273|NCT04432948|OTHER|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
57753993|NCT04227743|DEVICE|cryobiopsy|. The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
57753994|NCT04035967|OTHER|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
57753995|NCT00103766|DRUG|Alteplase|
57753996|NCT01786902|DRUG|DA-3002|
57753997|NCT01459432|OTHER|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
57753998|NCT05347758|DRUG|HRS-7535|Drug: HRS-7535
57753999|NCT05347758|DRUG|Placebo|Drug: Placebo
57754000|NCT03018964|PROCEDURE|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
57754001|NCT03018964|PROCEDURE|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
57754002|NCT06202560|DRUG|Tofacitinib 5 MG|Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
57754003|NCT06439355|BIOLOGICAL|Fasting blood test|metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
57754004|NCT06439355|OTHER|Subject interview|socio-demographic data, medical and family history, treatment taken
57754005|NCT06439355|OTHER|Motor assessment|MDS-UPDRS scale PART III
57754006|NCT06439355|OTHER|Neurocognitive assessment|MoCA and MMSE scales
57754007|NCT06439355|OTHER|Nutritional assessment|anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
57754008|NCT06439355|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
58453323|NCT06342817|BEHAVIORAL|online mindfulness based meditation program|Participants in the intervention group will attend 8 weekly online meetings lasting approximately 60 minutes each (generally structured in an initial 10 minutes for questions about the practices, 15-20 minutes of exposition on the central theme of the meeting, 5-10 minutes for class practice, 10-15 minutes for post-practice inquiry, 5 minutes for explanation of the week's informal practice and audios for daily practice). Audio in mp3 of the practice carried out at each meeting will be provided to maintain daily individual practice during the week. An online questionnaire related to weekly practices will also be left at the beginning of each meeting.
58453324|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
57754009|NCT02146313|DRUG|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
57754010|NCT02114151|DRUG|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
57754011|NCT02114151|DRUG|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
57754012|NCT03988075|OTHER|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
57754013|NCT03988075|OTHER|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
57960714|NCT00767897|DRUG|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
58128274|NCT04432948|OTHER|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
58453325|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
58453326|NCT00934635|OTHER|PET Scan|PET Scan
57754014|NCT02124265|DRUG|CeraLyte 90|"1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used."
57960715|NCT05075538|BIOLOGICAL|Spikevax|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
57960716|NCT05075538|BIOLOGICAL|Comirnaty|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
58453327|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
58453328|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
58453329|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
58453330|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
58453331|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
58453332|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
58453333|NCT04012541|PROCEDURE|active dental procedure|scaling and root planing
58453334|NCT04012541|DRUG|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
57754015|NCT03931681|DRUG|OKI-179|OKI-179 single agent
57754016|NCT03056482|DRUG|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
57754017|NCT03056482|DRUG|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
57754018|NCT03056482|DRUG|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
57754019|NCT00415792|DRUG|Arvekap, Pregnyl|
57754020|NCT05687955|OTHER|Hip Exercise Program|The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
57754021|NCT01747564|DRUG|YM178 (mirabegron)|oral
57754022|NCT02390531|DRUG|Bevacizumab|Varying dosages in 10µl
57754023|NCT04504656|OTHER|observation of postoperative leak, stenosis, mortality|detect complications in both groups
57754024|NCT00421720|DRUG|Sufentanil|
57754025|NCT00421720|DRUG|Remifentanil|
57754026|NCT04395573|DEVICE|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
57754027|NCT04395573|DEVICE|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
57754028|NCT00214305|BEHAVIORAL|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
57754029|NCT00214305|BEHAVIORAL|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
58128275|NCT02534493|DEVICE|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
58128276|NCT03510559|DRUG|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
58128277|NCT03510559|DRUG|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
58453335|NCT04012541|RADIATION|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
57960717|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
57960718|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
57960719|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
58128278|NCT02428699|OTHER|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
58128279|NCT02428699|OTHER|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
58128280|NCT03206710|OTHER|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
58128281|NCT00197951|DRUG|Treatment of psychiatric symptoms associated to alcoholism|
58453336|NCT02894671|OTHER|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
57754030|NCT02657317|BEHAVIORAL|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
57754031|NCT02657317|OTHER|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
57754032|NCT00668902|DRUG|[13C]Pantoprazole|\[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
57754033|NCT06356025|DRUG|botulinum toxin type A|Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter
57754034|NCT06356025|DRUG|Sodium Chloride 0.9% Inj|Placebo: physiological serum 3mL injection in the upper esophageal sphincter
57754035|NCT02259179|DRUG|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
57754036|NCT02259179|DRUG|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
57754037|NCT03769402|DRUG|Citric acid|Citric acid ph1, 50% concentration solution
57754038|NCT03769402|DRUG|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
57960720|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
57960721|NCT05075538|BIOLOGICAL|Comirnaty Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
57754039|NCT04637334|PROCEDURE|Superior vena cava reconstruction|Endovascular therapy with percutaneous transluminal angioplasty (PTA) and, in recent years, with stenting of the SVC, has been performed with increasing frequency. An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because long-term durability of this treatment method remains to be assessed.
57754040|NCT00854282|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
57754041|NCT02388503|DIETARY_SUPPLEMENT|no added fruit extract|
57754042|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
57754043|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
57754044|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
57754045|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
57754046|NCT02660801|PROCEDURE|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
57754047|NCT02660801|PROCEDURE|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
57754048|NCT02243280|DRUG|ABT-493|Tablet
57754049|NCT02243280|DRUG|ABT-530|Tablet
57754050|NCT04810117|DIAGNOSTIC_TEST|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
57754051|NCT05766917|BEHAVIORAL|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
57754052|NCT06006988|COMBINATION_PRODUCT|myoton pro|MyotonPRO is a mobile, removable handheld myotonometer. This tool is noninvasive and provides a quantitative assessment of a muscle's viscoelastic properties. These properties are characterized by various parameters such as hardness, tone and elasticity. The probe of MyotonPRO delivers a short (15 ms), low intensity (0.58 N) mechanical impact/impact on the skin on the muscle. The response of the touch then generates a recorded signal and an internal software program generates an acceleration graph. Measurements of various viscoelastic muscle properties such as stiffness, tone and elasticity are then extracted from this graph.
57754053|NCT04028349|DRUG|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
57754054|NCT00580814|DRUG|Experimental: methylphenidate treatment|subjects received mehtylphenidate treatment for 12 months
58128282|NCT01025037|DEVICE|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
58128283|NCT02090829|DRUG|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
57754055|NCT01925664|BEHAVIORAL|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
57754056|NCT03627884|DRUG|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
57754057|NCT03627884|DRUG|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
57754058|NCT05810246|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
57754059|NCT05842902|BEHAVIORAL|mPRISM|PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
57754060|NCT03912454|OTHER|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
57754061|NCT02317926|DRUG|Levothyroxine|
57754062|NCT02317926|DRUG|Levothyroxine Plus Liothyronine|
57754063|NCT02317926|DRUG|Desiccated Thyroid Extract|
57754064|NCT02272725|DRUG|Ibuprofen|Ibuprofen
57754065|NCT02272725|DRUG|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
57754066|NCT01738620|BEHAVIORAL|psychological counseling|
57754067|NCT01738620|BEHAVIORAL|prevention of sleep disorders in ICU|
57754068|NCT00059644|DRUG|Ecraprost in lipid emulsion|
57754069|NCT04578444|DRUG|Zanidatamab|Administered intravenously
57754070|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
57754071|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
57754072|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
57754073|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
57960722|NCT05075538|BIOLOGICAL|Spikevax Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
58453337|NCT06262789|OTHER|"Return-to-work after cancer consultation"|"The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation."
58453338|NCT02289495|DRUG|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
58453339|NCT02289495|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
58453340|NCT02289495|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
58453341|NCT01467544|OTHER|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
58453342|NCT05626166|DRUG|Placebo|placebo tablets twice daily
58453343|NCT05626166|DRUG|Diosmin|diosmin 600 mg twice daily
58453344|NCT04394923|PROCEDURE|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
58453345|NCT04394923|PROCEDURE|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
58453346|NCT00451256|DRUG|AVI-5126|
58453347|NCT02232022|DEVICE|Reveal LINQ Insertable Cardiac Monitor|
58453348|NCT02124733|PROCEDURE|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
58453349|NCT05182788|DIETARY_SUPPLEMENT|Placebo pressed candy|consume 2 tablets per day for 8 weeks
58453350|NCT05182788|DIETARY_SUPPLEMENT|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
58453351|NCT05648266|DRUG|Continous SAPB (Ropivacain)|postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
58453352|NCT05648266|OTHER|institutional standard of care pain medication protocol|institutional standard of care pain medication protocol
58453353|NCT03864939|DRUG|dHAM|A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
58453354|NCT03864939|DRUG|No dHAM|A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
58453355|NCT04636281|OTHER|Active and passive static stretching exercises|Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
58453356|NCT00314639|DRUG|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
58453357|NCT00890734|DRUG|CYT003-QbG10|subcutaneous injection
57754074|NCT05535049|PROCEDURE|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
58453358|NCT00890734|DRUG|Placebo|subcutaneous injection
58453359|NCT02477124|DEVICE|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
58453360|NCT02477124|OTHER|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
58453361|NCT04890379|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
58453362|NCT04890379|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
58453363|NCT03880292|PROCEDURE|Document intraoperative Maneuvers|Monitoring procedure during surgery
58453364|NCT03242486|DEVICE|toric intraocular lens|
58453365|NCT03010319|DEVICE|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
58453366|NCT03010319|DEVICE|Secondary Dressings|Dressings to ensure moist wound environment
58453367|NCT03010319|DEVICE|Offloading device|Offloading device to decrease pressure to wound area
57754075|NCT01146314|BEHAVIORAL|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
57960723|NCT03875144|PROCEDURE|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
57960724|NCT03875144|DRUG|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
57960725|NCT03875144|DRUG|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
57960726|NCT03408795|PROCEDURE|Laparoscopic distal gastrectomy|Longitudinal testing of The Japanese Operative Rating Scale for Laparoscopic Distal Gastrectomy
57960727|NCT06425575|BIOLOGICAL|Amniotic suspension allograft|the amniotic suspension allograft consists of fresh amniotic fluid into which micronized amniotic membrane has been added as a suspension.
57960728|NCT04870879|PROCEDURE|Liver Transplant|Liver Transplant from cadaveric donors
57754076|NCT03808779|PROCEDURE|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
57754077|NCT03808779|PROCEDURE|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
57754078|NCT03178279|OTHER|Physical Health Plan|Use of a Physical Health Plan by service users
57754079|NCT02533869|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
57754080|NCT02533869|PROCEDURE|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
57754081|NCT02386657|OTHER|Satisfaction|Satisfaction questionnaire to be filled in
57754082|NCT02386657|OTHER|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
58453368|NCT05416866|PROCEDURE|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
57754083|NCT02386657|OTHER|Pain management|Validated pain scale questionnaire to be filled in
57754084|NCT02855307|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
57754085|NCT02855307|DEVICE|Insulin pump|Patient's insulin pump will be used to infuse insulin.
57754086|NCT02855307|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
57754087|NCT02855307|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
57754088|NCT02855307|OTHER|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
57754089|NCT01922050|DRUG|LEO 43204 Formulation 1|
57754090|NCT01922050|DRUG|LEO 43204 Formulation 2|
57754091|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose X|
57754092|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose Y|
57754093|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose XX|
57754094|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose YY|
57754095|NCT01922050|DRUG|Placebo Formulation 1|
57754096|NCT01922050|DRUG|Placebo Formulation 2|
57754097|NCT05795413|PROCEDURE|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
57754098|NCT05795413|DRUG|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
57754099|NCT05807113|OTHER|Atopi intensive care BNO 3731|Crem twice daily
57754100|NCT05807113|OTHER|Benchmark product|Crem twice daily
57754101|NCT05519384|DRUG|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
57754102|NCT03357614|DRUG|Sulopenem|Antibiotic therapy for complicated UTI
58458739|NCT02212808|OTHER|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
57754103|NCT03357614|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
57754104|NCT03357614|DRUG|Ertapenem|Antibiotic therapy for complicated UTI
57754105|NCT03357614|DRUG|Ciprofloxacin|Antibiotic therapy for complicated UTI
57754106|NCT03357614|DRUG|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
57754107|NCT01629914|BEHAVIORAL|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
57754108|NCT04646655|DRUG|Enoxaparin|subcutaneous injections
57754109|NCT02052310|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
57754110|NCT02052310|DRUG|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
57754111|NCT05362981|OTHER|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
57754112|NCT03309839|OTHER|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
57754113|NCT00656604|GENETIC|proteomic profiling|at the time of each procedure.
57754114|NCT00656604|PROCEDURE|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
57754115|NCT00656604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
57754116|NCT00656604|PROCEDURE|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
57754117|NCT00656604|PROCEDURE|magnetic resonance spectroscopy|Prior to initiation of treatment
57754118|NCT01287611|PROCEDURE|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
57754119|NCT01287611|PROCEDURE|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
57754120|NCT06328530|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
57754121|NCT06328530|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
57754122|NCT04813380|OTHER|Sublingual immunotherapy|Sublingual immunotherapy give to allergic rhinitis patients for treatment
58453369|NCT05416866|PROCEDURE|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
58453370|NCT05416866|PROCEDURE|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
58453371|NCT04306614|PROCEDURE|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
58453372|NCT00002868|BIOLOGICAL|filgrastim|
57754123|NCT02274454|DRUG|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
57754124|NCT02274454|DRUG|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
57754125|NCT04767867|OTHER|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
57754126|NCT04859582|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
57754127|NCT04859582|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
57754128|NCT04859582|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
57754129|NCT04859582|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
57754130|NCT04859582|DRUG|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
57754131|NCT04859582|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
58453373|NCT00002868|BIOLOGICAL|recombinant interferon alfa|
58453374|NCT00002868|DRUG|busulfan|
58453375|NCT00002868|DRUG|cytarabine|
58453376|NCT00002868|DRUG|etoposide|
57754132|NCT02964676|PROCEDURE|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
57754133|NCT02964676|PROCEDURE|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
57754134|NCT05323461|BIOLOGICAL|SCTV01C|intramuscular injection
57754135|NCT05323461|BIOLOGICAL|SCTV01E|intramuscular injection
58453377|NCT00002868|DRUG|hydroxyurea|
57754136|NCT05323461|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
57754137|NCT05323461|BIOLOGICAL|Comirnaty|intramuscular injection
58453378|NCT00002868|DRUG|idarubicin|
58453379|NCT00002868|PROCEDURE|peripheral blood stem cell transplantation|
58458740|NCT06160232|DRUG|Psilocybin (high dose)|Psilocybin-assisted therapy
58458741|NCT06160232|DRUG|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
57754138|NCT03547401|DEVICE|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
57960729|NCT04870879|DRUG|Chemotherapy|Chemotherapy
57754139|NCT03547401|DEVICE|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
57754140|NCT01959425|OTHER|Off OAT Group (Test)|Discontinuation of OAT Therapy
57754141|NCT01959425|OTHER|On OAT Group (Control)|Continuation of OAT Therapy
57754142|NCT02344043|DEVICE|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
57754143|NCT00336739|DRUG|cinacalcet|
57754144|NCT06497218|DIAGNOSTIC_TEST|Blinklab diagnostic device|Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
57754145|NCT02449668|DEVICE|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
57754146|NCT02449668|DEVICE|Sham Acupuncture|
57754147|NCT03498638|BEHAVIORAL|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
57754148|NCT03498638|OTHER|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
57754149|NCT05241964|BIOLOGICAL|PRP|4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
58453380|NCT02494960|BEHAVIORAL|The brief smoking cessation AWARD model|"* Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
58453381|NCT02494960|BEHAVIORAL|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
58453382|NCT03049917|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
58453383|NCT03830359|OTHER|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
57754150|NCT03043079|DIAGNOSTIC_TEST|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
57754151|NCT00410033|DRUG|soluble human insulin|
57754152|NCT00410033|DRUG|isophane human insulin|
57754153|NCT00410033|DRUG|insulin aspart|
57754154|NCT02975570|DRUG|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
57754155|NCT02975570|DRUG|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
57754156|NCT02975570|DRUG|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
57754157|NCT02975570|DRUG|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
58453384|NCT00515151|DRUG|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
58458742|NCT03409614|DRUG|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
58458743|NCT03409614|DRUG|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
57754158|NCT02975570|DRUG|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
57754159|NCT05044013|OTHER|Full access to JomPrEP app|All participants will receive the JomPrEP app with access to all of its features which include: customizable page (using avatars and pseudonyms); visual dashboard (track and visualize progress); HIV testing plan (create plan for HIV testing, order self-testing kits, testing site locator); PrEP Care Plan (PrEPxpress, automated reminders for follow-up care, labs, delivery); chat function and discussion forum; tailored messages and reminders; assessment center (weekly assessment on adherence to PrEP, HIV risk, mood); knowledge center (resources on HIV testing and PrEP); Mental health support (screen for P/SUD, counseling feedback, referral to support services); Integration of provider locator (provides users with a GPS enabled map for PrEP and mental health support providers in Malaysia) and Gamification (offers extrinsic motivation by rewarding points/milestones for doing activities within the app). Participants can also contact the RA using the chat function for support.
57754160|NCT05044013|OTHER|inactivated JomPrEP app|Only information and resources for PrEP services will be available along with access to risk assessment tools.
57754161|NCT06579079|OTHER|Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy.
57754162|NCT06579079|OTHER|Waitlist Control - Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy. Participating schools receiving this treatment will wait one year before developing an implementation strategy for testing.
57754163|NCT05413980|OTHER|Moxifloxacin hydrochloride ophthalmic solution|Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
57754164|NCT02437656|DRUG|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
57754165|NCT03205371|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
57754166|NCT03205371|BIOLOGICAL|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
58453385|NCT00515151|DRUG|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
58453386|NCT03167333|DRUG|platelet rich plasma|The amount of PPR was about 4-5 cc
57754167|NCT03205371|BIOLOGICAL|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
57754168|NCT03205371|BIOLOGICAL|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
57754169|NCT03205371|BIOLOGICAL|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
57754170|NCT04699955|BEHAVIORAL|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
57754171|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
57754172|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
57754173|NCT02344446|OTHER|Skilled Therapy|Active physical therapy treatment
57754174|NCT05208684|OTHER|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
58128284|NCT02090829|OTHER|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
57754175|NCT06384586|DIETARY_SUPPLEMENT|Placebo shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
57754176|NCT06384586|DIETARY_SUPPLEMENT|Functional energy shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
57754177|NCT01094132|DEVICE|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
57754178|NCT01631890|PROCEDURE|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
57754179|NCT01631890|PROCEDURE|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
57754180|NCT03375502|DRUG|Varicella Vaccine|The subject will receive investigational product or comparator.
57754181|NCT03476629|OTHER|Physical activity|Effects of different physical activity programs
58128285|NCT05036603|OTHER|chest physiotherapy|diffferent chest physiotherapy methods
58128286|NCT04566809|OTHER|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
58128287|NCT04566809|OTHER|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
58128288|NCT04107870|BEHAVIORAL|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
57754182|NCT03784040|DRUG|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
57754183|NCT03784040|DRUG|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
57754184|NCT03784040|DRUG|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
57754185|NCT05405959|DEVICE|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
57754186|NCT05405959|DEVICE|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
57754187|NCT03337646|DRUG|Lisdexamfetamine Dimesylate|Medication to treat ADHD
57754188|NCT05809206|OTHER|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
57754189|NCT05809206|OTHER|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
57754190|NCT05809206|OTHER|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
57754191|NCT05809206|DEVICE|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
57754192|NCT00604526|RADIATION|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months."
57754193|NCT04272502|DRUG|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
57754194|NCT01353781|DRUG|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
58453387|NCT03167333|DRUG|Hyaluronic acid|HA was 2.5cc
58453388|NCT05730296|DEVICE|TMS|10 rTMS sessions combined with cognitive training
57754195|NCT03724487|BEHAVIORAL|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
57754196|NCT03724487|BEHAVIORAL|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
57754197|NCT05782049|OTHER|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
57754198|NCT05782049|OTHER|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
58453389|NCT05730296|DEVICE|TMS|10 rTMS sessions
57754199|NCT05782049|OTHER|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
57960730|NCT04732182|DEVICE|BrightGo cognitive training|Training on the BrightGo experimental device in the home
58453390|NCT05730296|DEVICE|TMS|10 sham coils sessions without cognitive training
58453391|NCT04984967|DEVICE|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
58453392|NCT04984967|OTHER|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
57754200|NCT05648162|DEVICE|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
57754201|NCT05648162|DEVICE|Acupuncture|Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
57754202|NCT05648162|DEVICE|tDCS|tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
57754203|NCT05648162|DEVICE|sham tDCS|tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
57754204|NCT05648162|OTHER|NDT-Bobath Rehabilitation|NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
57754205|NCT04643925|DRUG|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
57754206|NCT00699439|OTHER|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
57754207|NCT03613675|DEVICE|Video games|"The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
57754208|NCT00724581|DRUG|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
57754209|NCT00116896|DRUG|OSI-7904L|
57754210|NCT00116896|DRUG|Cisplatin|
57754211|NCT01280838|BEHAVIORAL|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
57754212|NCT01280838|BEHAVIORAL|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
57754213|NCT00695630|DRUG|Flumazenil|2 mL, 0.2 mg SM
57754214|NCT00695630|DRUG|Placebo|2 mL sterile saline SM
57754215|NCT00742079|DRUG|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
57754216|NCT00742079|BEHAVIORAL|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
57754217|NCT06298851|OTHER|Neural Mobilization Group (NMG)|"Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion."
57960731|NCT04732182|DRUG|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
57960732|NCT00992316|DRUG|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
57960733|NCT05984238|DEVICE|ReCET|Investigational product.
57960734|NCT05984238|DRUG|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
57960735|NCT05984238|OTHER|Sham procedure|The sham control for the ReCET procedure.
57960736|NCT01052584|DRUG|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
57960737|NCT01052584|DRUG|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
57960738|NCT01052584|DRUG|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
58453393|NCT03065322|OTHER|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
58453394|NCT05699850|OTHER|ARTIFICIAL INTELLIGENCE (AI)|ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINE
57754218|NCT06298851|OTHER|Dynamic Stretching Group (DSG)|Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.
57754219|NCT06298851|OTHER|Static Stretching Group (SSG)|"Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally."
57754220|NCT02228070|DEVICE|strabismus video goggles|
57754221|NCT00620750|DRUG|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
58453395|NCT05101434|DIAGNOSTIC_TEST|Periodontal Probing|with the help Michigan probe, periodontal pocket measurement was done.
58453396|NCT05931757|DRUG|Olverembatinib|Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
58128289|NCT04107870|BEHAVIORAL|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
58453397|NCT01718457|DEVICE|Endobarrier|
58453398|NCT00659113|DRUG|cisplatin|
58453399|NCT00659113|DRUG|tegafur-gimeracil-oteracil potassium|
58453400|NCT00659113|OTHER|cytology specimen collection procedure|
57754222|NCT03774901|DRUG|Avelumab|intravenous 10 mg/kg every 2 weeks
57960739|NCT05292105|DEVICE|NC Xperience|Coronary dilatation balloon catheter (non compliant)
57960740|NCT06228222|PROCEDURE|renal biopsy|"Renal biopsy will be performed for all patients fulfilling the American College of Rheumatology (ACR) criteria to confirm the diagnosis of lupus nephritis (LN) and to classify the glomerular disease by the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 histopathological classification system"
57960741|NCT01664780|DEVICE|ARFI imaging|
58128290|NCT03825809|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
58128291|NCT03825809|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
58128292|NCT03825809|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
58128293|NCT03825809|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
58128294|NCT03825809|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
58128295|NCT03825809|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
58128296|NCT06165900|DRUG|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
58128297|NCT06165900|DRUG|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
58453401|NCT00659113|PROCEDURE|endoscopic biopsy|
58453402|NCT01931423|BEHAVIORAL|Placental cord drainage|
58453403|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
58453404|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)|Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
58453405|NCT04535635|OTHER|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
58453406|NCT04535635|OTHER|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
58453407|NCT04467086|DRUG|Propranolol Hydrochloride|"Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min."
58453408|NCT02758717|DRUG|Brentuximab Vedotin|Given IV
58453409|NCT02758717|BIOLOGICAL|Nivolumab|Given IV
58453410|NCT04365712|DEVICE|Piezoelectric tool|
58453411|NCT04365712|DEVICE|Oscillating Saw|
58458744|NCT03409614|OTHER|Chemotherapy|Platinum-based doublet chemotherapy Part 1
58458745|NCT03409614|DRUG|Placebo|Matching placebo Part 2
57754223|NCT02267005|DIETARY_SUPPLEMENT|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
57754224|NCT02267005|DIETARY_SUPPLEMENT|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
57754225|NCT05009108|DIAGNOSTIC_TEST|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
57754226|NCT03741101|DRUG|Trametinib|treatment
57754227|NCT04284527|OTHER|Observational study|a reliability - validity study
57754228|NCT04793906|OTHER|Iron supplement with a lunch meal containing beef|Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
57754229|NCT04793906|OTHER|Iron supplement with a lunch meal containing plant-based alternative|Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
57754230|NCT01714804|DEVICE|Accell Evo3 Prospective Use|
57754231|NCT05840484|OTHER|Active Surveillance|Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
57754232|NCT06218758|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
57754233|NCT05993845|OTHER|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video \& audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data \& other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- \& postoperative Standard axial hip x-rays pre- \& postoperative Western Ontario \& McMaster Universities Osteoarthritis Index \& Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
57754234|NCT01690884|DRUG|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
57754235|NCT04979039|OTHER|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
57754236|NCT03076268|BEHAVIORAL|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
57754237|NCT05047874|BEHAVIORAL|systemic methylprednisolone|short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
57754238|NCT04536090|DRUG|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
57754239|NCT06304350|DRUG|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
57754240|NCT06491771|DEVICE|TargetCool|The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
57754241|NCT01903421|DRUG|Spinal anesthesia group: bupivacaine 10-15mg|
57754242|NCT01903421|DRUG|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
57754243|NCT01903421|GENETIC|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
57754244|NCT01903421|OTHER|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
58453412|NCT04891016|DRUG|FLOT combined with toripalimab|Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
57754245|NCT01903421|BEHAVIORAL|Montreal Cognitive Assessment (MOCA) and MMSE|
57754246|NCT01637103|BEHAVIORAL|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
57754247|NCT01637103|BEHAVIORAL|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
58453413|NCT02166892|OTHER|Specially designed plates|
58453414|NCT03669614|DRUG|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
58453415|NCT03669614|DRUG|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
58453416|NCT06106126|DRUG|GST-HG171 Tablets|150mg GST-HG171 100mg Tablets and ritonavir
58453417|NCT02428101|GENETIC|polymorphism analysis|
58453418|NCT02088450|DRUG|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
58453419|NCT05806437|DIETARY_SUPPLEMENT|sideremil vita cp|assunzione per 30 giorni dell'integratore
57754248|NCT01302431|OTHER|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
57754249|NCT02565238|DEVICE|BioMonitor 2|Implantation of BioMonitor 2
57754250|NCT01856530|DRUG|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
57754251|NCT01856530|DRUG|Placebo|Matched placebo nasal spray
57754252|NCT01479998|OTHER|standard care|standard care plus nicotine replacement therapy
57754253|NCT01479998|OTHER|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
57754254|NCT03775200|DRUG|Psilocybin|Dose-finding
57754255|NCT00651053|DEVICE|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
57754256|NCT01873430|DRUG|Melatonin|
57754257|NCT05032001|DRUG|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
57754258|NCT00295022|DRUG|Placebo|"* Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use"
57754259|NCT00295022|DRUG|Montelukast|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use"
57754260|NCT00295022|DRUG|Levocetirizine|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use"
57754261|NCT01169714|DRUG|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
57754262|NCT01169714|DRUG|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
57754263|NCT01169714|DRUG|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
57754264|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
57754265|NCT01169714|DRUG|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
57754266|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
57754267|NCT01494844|DEVICE|Respiratory monitor patient interface.|Wear each interface for 20 minutes
57754268|NCT06148220|RADIATION|[18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
57754269|NCT04716699|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor samples
57754270|NCT04716699|DRUG|Lidocaine|Given IV
57754271|NCT04716699|PROCEDURE|Resection|Undergo surgical resection per standard of care
58453420|NCT00648635|BEHAVIORAL|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
57754272|NCT01552564|PROCEDURE|Index of microvascular resistance|
57754273|NCT01552564|OTHER|Cardiac magnetic resonance|
57754274|NCT01552564|OTHER|Blood markers|
57754275|NCT04602130|OTHER|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
57960742|NCT03937583|DRUG|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
58453421|NCT02539771|OTHER|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
57754276|NCT04602130|OTHER|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
57754277|NCT04602130|OTHER|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
57754278|NCT04602130|OTHER|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
57754279|NCT04699435|OTHER|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
57754280|NCT04699435|OTHER|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
57754281|NCT04699435|OTHER|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
57754282|NCT04658641|DEVICE|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
57754283|NCT04336735|OTHER|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
57754284|NCT01431001|DEVICE|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
57754285|NCT02395861|OTHER|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
57754286|NCT00863655|DRUG|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
57754287|NCT00863655|DRUG|Exemestane|Exemestane 25 mg orally daily.
57754288|NCT00863655|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
57754289|NCT05471037|PROCEDURE|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
57754290|NCT05471037|PROCEDURE|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
57754291|NCT00188955|DRUG|sirolimus|
57754292|NCT02915094|DRUG|Anakinra|
57754293|NCT02831257|DRUG|AZD2014|
57754294|NCT05771779|BIOLOGICAL|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
57754295|NCT05771779|BIOLOGICAL|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
57754296|NCT05771779|BIOLOGICAL|Measles and Rubella (MR)|Live attenuated vaccine
57754297|NCT02287584|DRUG|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
57754298|NCT02287584|DRUG|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
57754299|NCT02287584|DRUG|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
57754300|NCT02287584|DRUG|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
57754301|NCT02287584|DRUG|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
57754302|NCT03164980|DRUG|Trabectidin (Yondelis)|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
57754303|NCT04377932|GENETIC|AGAR T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2 DL2: 1x10\^8/m2 DL3: 3x10\^8/m2 DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
57754304|NCT06518421|BEHAVIORAL|Neuropsychological assessments|"* Pain questionnaires such as Numerical Pain Rating Scale is one of the most widely used multidimensional pain scales to assesses a person's pain based on the words they use to describe their pain.~* Battery of Cognitive questionnaires = The cognitive test battery was designed to assess key cognitive abilities including attention, concentration, verbal learning and memory, verbal fluency, working memory and executive function as well as global cognitive functioning and fear and anxiety~* Mnemonic Simulation Test and Rey Auditory Verbal Learning Test are the neuropsychological assessments designed to evaluate recognition and verbal memory, respectively. Both tasks have been shown to be very sensitive to hippocampal engagement and damage.~* Memory-recall interview is an interview for the interviewees to recall the event from different perspectives, such as from the preadmission date, 2-week post- and 6-month post-surgical date. This supports the memory retrieval process."
57754305|NCT06518421|DIAGNOSTIC_TEST|MR Imaging|Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels. MRI scanners create images of the body using a large magnet and radio waves.
57754306|NCT00876538|DRUG|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
57754307|NCT00876538|DRUG|Placebo Control|Placebo Control 2 capsules once day with the noon meal
57754308|NCT04534257|DEVICE|SELUTION Sirolimus DCB|Suitable lesions will be treated with SELUTION Sirolimus DCB
57754309|NCT05897476|OTHER|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
57754310|NCT03916432|DEVICE|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
57754311|NCT01507636|OTHER|Occupational Therapy|Occupational therapy using a special arm function training.
57754312|NCT01507636|OTHER|Physical therapy|Physical therapy for arm force training.
57754313|NCT06096701|DEVICE|Blood pressure cuff|The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
57754314|NCT05440370|DEVICE|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
57754315|NCT05440370|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
57754316|NCT01742364|DEVICE|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
57754317|NCT01742364|DEVICE|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
57754318|NCT06239870|DRUG|Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy|Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
57754319|NCT01711762|DRUG|GDC-0973|Single oral dose of \[14C\]-GDC-0973
57754320|NCT01595893|DRUG|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
57754321|NCT01595893|DRUG|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
57754322|NCT03776825|DEVICE|Permacol Paste|Permacol Paste Injection
57754323|NCT03171779|OTHER|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
57960743|NCT01378312|BIOLOGICAL|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
57754324|NCT06229132|BEHAVIORAL|LGBTQ-affirmative CBT for transgender individuals|The intervention addresses unique stressors encountered by transgender individuals due to discrimination and lack of adequate and affirming healthcare resources.
57754325|NCT04044222|BIOLOGICAL|Sintilimab|IV
57754326|NCT04044222|DRUG|Carboplatin|IV
57754327|NCT04044222|DRUG|Etoposide|IV
57754328|NCT04044222|DRUG|Ifosfamide|IV
57754329|NCT04044222|DRUG|Placebo|IV
57754330|NCT04044222|DRUG|Carboplatin|IV
57754331|NCT04044222|DRUG|Etoposide|IV
57754332|NCT04044222|DRUG|Ifosfamide|IV
57754333|NCT01078480|PROCEDURE|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
57754334|NCT01078480|PROCEDURE|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
57754335|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
57754336|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
57754337|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
57754338|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
57754339|NCT03340402|RADIATION|Accelerated Partial Breast Irradiation|Proton radiation
57754340|NCT03340402|DEVICE|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
57754341|NCT05988021|DRUG|CCX168|Administered orally.
57754342|NCT03917368|OTHER|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
57754343|NCT03581084|DRUG|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
57754344|NCT04126408|DEVICE|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
58458746|NCT03324776|DRUG|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
57754345|NCT05900856|OTHER|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
57754346|NCT05900856|DEVICE|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
57754347|NCT04177680|DRUG|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
57960744|NCT01378312|BIOLOGICAL|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
57960745|NCT05493943|DEVICE|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
57960746|NCT05493943|OTHER|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
57960747|NCT02973737|DRUG|pyrotinib|400 mg once daily
57960748|NCT02973737|DRUG|placebo|400 mg once daily
57754348|NCT04177680|DRUG|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
57754349|NCT04824079|DRUG|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
57754350|NCT00141739|DRUG|Etanercept|"Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
57754351|NCT05848479|OTHER|Abdominal bracing|they will perform 3 times/week of static abdominal contraction for six weeks.
57754352|NCT05848479|OTHER|clamshell exercise|Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
57960749|NCT02973737|DRUG|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
57960750|NCT04979507|OTHER|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
57754353|NCT03970239|DRUG|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
57754354|NCT03970239|DRUG|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
57754355|NCT00263718|DRUG|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
57754356|NCT04560166|DRUG|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"* Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
57754357|NCT03974659|COMBINATION_PRODUCT|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
57754358|NCT03026218|OTHER|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
57754359|NCT03026218|OTHER|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
57754360|NCT05541562|DIAGNOSTIC_TEST|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
57754361|NCT04860947|DIAGNOSTIC_TEST|Brain MRI|"* Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection."
57754362|NCT04860947|DIAGNOSTIC_TEST|Spinal Cord MRI|Sagittal T2 Sagittal T1 with Gadolinium injection
57754363|NCT04860947|DIAGNOSTIC_TEST|Retinal imaging|spectral-domain high definition optical coherence tomography
57754364|NCT03051503|DRUG|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
57754365|NCT03051503|DEVICE|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
57754366|NCT02640248|DEVICE|Cuff ETT|
57960751|NCT01112098|BEHAVIORAL|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
57960752|NCT03441178|DEVICE|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
57960753|NCT01926782|DRUG|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
57960754|NCT01926782|DRUG|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
58453422|NCT05833529|BEHAVIORAL|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
58453423|NCT05833529|OTHER|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
58458747|NCT03777943|PROCEDURE|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
57960755|NCT01926782|DRUG|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
57754367|NCT05282043|OTHER|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
57754368|NCT04857203|DIAGNOSTIC_TEST|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
58453424|NCT05833529|BEHAVIORAL|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
58453425|NCT02366195|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
57754369|NCT05987306|BEHAVIORAL|Weight loss plus self-compassion|A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
57754370|NCT01473693|OTHER|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
57754371|NCT01473693|OTHER|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
57754372|NCT01497522|DRUG|Vildagliptin|vildagliptin 50 mg twice daily
57754373|NCT01497522|DRUG|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
57754374|NCT03980925|DRUG|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
57754375|NCT03980925|DRUG|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
57754376|NCT03980925|DRUG|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
57754377|NCT05403164|PROCEDURE|Modified Widman flap|"1. Administration of anaesthesia~2. First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~3. Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~4. Second incision (sulcular incision)~5. Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~6. Root surface debridement~7. Flap adaptation, complete coverage interdentally and suturing."
57960756|NCT04421625|DIAGNOSTIC_TEST|Diagnostic test for SARS-Cov2 for patients and health staff|"Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)"
58458748|NCT06162988|DRUG|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
57754378|NCT05403164|PROCEDURE|Gingivectomy|"1. Administration of anaesthesia~2. Marking the base of the sulcus with pocket marker tweezer.~3. First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~4. Second incision (interdental) to free the tissue which is used for analysis later.~5. Debriding the area and applying periodontal pack."
57754379|NCT00142779|DRUG|Fluoxetine|
57754380|NCT05827952|BEHAVIORAL|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
57754381|NCT02475785|DEVICE|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
57754382|NCT02475785|DEVICE|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
57754383|NCT05078151|DIAGNOSTIC_TEST|Whole-Body Diffusion Weighted MRI|MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
57754384|NCT03083938|PROCEDURE|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
57754385|NCT01221948|DEVICE|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
57754386|NCT00006364|DRUG|omacetaxine mepesuccinate|Given IV or SC
57754387|NCT00006364|OTHER|pharmacological study|Correlative studies
57754388|NCT00006364|OTHER|laboratory biomarker analysis|Correlative studies
57754389|NCT05460923|OTHER|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
57754390|NCT05460923|OTHER|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
57754391|NCT01857401|OTHER|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
57754392|NCT00309530|DRUG|5-fluorouracil, levamisol, interferon|
57754393|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
57754394|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
57754395|NCT05688748|OTHER|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
57754396|NCT01551199|BEHAVIORAL|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
57754397|NCT02142647|BEHAVIORAL|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
57754398|NCT02142647|BEHAVIORAL|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
57754399|NCT02826200|DRUG|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
57754400|NCT02826200|OTHER|Standard of care|Standard of care
57754401|NCT05378243|DEVICE|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
57754402|NCT05378243|BEHAVIORAL|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
57754403|NCT03496662|DRUG|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
57754404|NCT03496662|DRUG|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
57754405|NCT03496662|DRUG|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
57754406|NCT03496662|DRUG|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
57754407|NCT03496662|PROCEDURE|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
57754408|NCT03496662|PROCEDURE|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
57754409|NCT01886911|OTHER|Attention Training Intervention Game|
57754410|NCT01886911|OTHER|Prosocial Training Intervention Game|
57754411|NCT01886911|OTHER|Control for Attention Intervention|
57754412|NCT01886911|OTHER|Control for Prosocial Intervention|
57754413|NCT03766256|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
57754414|NCT04049318|OTHER|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
57754415|NCT01210833|DEVICE|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
57754416|NCT03829163|DEVICE|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
57754417|NCT03829163|DEVICE|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
57754418|NCT02295839|BEHAVIORAL|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
57754419|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
57754420|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
57754421|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
57754422|NCT04864002|OTHER|No intervention. only observational cross sectional study|No intervention done. only observational cross sectional study
57754423|NCT01938833|DRUG|Romidepsin|
57754424|NCT01938833|DRUG|Abraxane|
57754425|NCT05059379|RADIATION|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
57754426|NCT05059379|RADIATION|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
57754427|NCT01184365|BEHAVIORAL|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
57754428|NCT01184365|BEHAVIORAL|Energy Management Program|The goal of the EnMP-2 is to control for group effects
57754429|NCT00946439|DEVICE|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
57754430|NCT05847179|DRUG|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
57754431|NCT02617225|BEHAVIORAL|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
57960757|NCT04314440|BEHAVIORAL|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
57960758|NCT00907101|DRUG|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
57960759|NCT06005961|BEHAVIORAL|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
57960760|NCT04788043|DRUG|Magrolimab|45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
57960761|NCT04788043|DRUG|Pembrolizumab|200 mg IV infusion
57960762|NCT04788043|PROCEDURE|PET/CT|Scan
57960763|NCT05743465|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
57960764|NCT00019409|DRUG|asparaginase|
57960765|NCT00019409|DRUG|cyclophosphamide|
57960766|NCT00019409|DRUG|cytarabine|
57960767|NCT00019409|DRUG|daunorubicin hydrochloride|
57960768|NCT00019409|DRUG|mercaptopurine|
57960769|NCT00019409|DRUG|methotrexate|
57960770|NCT00019409|DRUG|prednisone|
57960771|NCT00019409|DRUG|therapeutic hydrocortisone|
57960772|NCT00019409|DRUG|vincristine sulfate|
57960773|NCT00019409|RADIATION|radiation therapy|
57960774|NCT03216356|BEHAVIORAL|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
57960775|NCT03216356|BEHAVIORAL|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
57960776|NCT03216356|DRUG|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
57960777|NCT03216356|DRUG|Placebo|polyethylene glycol 3350 powder
57960778|NCT03216356|DRUG|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
57960779|NCT06010966|DEVICE|rTMS|intermittent theta-burst stimulation (iTBS)
57754432|NCT02617225|BEHAVIORAL|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
57754433|NCT02614495|DRUG|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
57754434|NCT05079022|DRUG|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
57754435|NCT02335190|PROCEDURE|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
57754436|NCT02335190|PROCEDURE|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
57754437|NCT02335190|DRUG|Lidocaine|
57754438|NCT04065100|DIAGNOSTIC_TEST|Sebum test|Measuring sebum in newborn
57754439|NCT02775955|DRUG|RX0041|Active
57754440|NCT03680625|DEVICE|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
57754441|NCT03680625|DEVICE|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
57754442|NCT04617132|BEHAVIORAL|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
57754443|NCT00089141|DRUG|mycophenolate mofetil|Given orally
57754444|NCT00089141|DRUG|placebo|Given orally
57960780|NCT05697458|OTHER|computerized tomography scanning|In all patients the investigators will perform CT for determination of iliac arteries calcifications
58453426|NCT04941495|OTHER|conventional physiotherapy|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying."
58453427|NCT04941495|OTHER|Cervical proprioceptive training|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted."
58453428|NCT03498807|DEVICE|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
58453429|NCT03498807|DEVICE|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
58453430|NCT00617175|DEVICE|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
58453431|NCT00617175|DEVICE|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
58453432|NCT04640649|OTHER|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
57960781|NCT05268926|DRUG|Dapagliflozin 10Mg Tab|dapagliflozin 10 mg/d or matched placebo
57960782|NCT05268926|DRUG|Placebo|Placebo
58453433|NCT04295317|DRUG|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
58453434|NCT04295317|DRUG|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
58453435|NCT00434681|DRUG|paracetamol 4.8% paediatric oral suspension|
58453436|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
57754445|NCT02292017|DEVICE|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
57754446|NCT03721120|DIAGNOSTIC_TEST|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
57754447|NCT03446014|DEVICE|Fitbit Sub-Study|
57754448|NCT03656601|DIAGNOSTIC_TEST|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
57754449|NCT03533426|PROCEDURE|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
57754450|NCT03533426|PROCEDURE|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
57754451|NCT06285513|DIAGNOSTIC_TEST|Cardiac ultrasound|Cardiac ultrasound : determination of impairment of cardiac function by echocardiographic analysis (at V1, V3 and V4), Glycocheck : automatic analysis of sublingual microcirculation, Indirect calorimetry : determining the increase in energy expenditure in patients with septic shock
57754452|NCT05772975|BIOLOGICAL|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
58128298|NCT01134081|BIOLOGICAL|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
57754453|NCT05772975|BIOLOGICAL|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
57754454|NCT04984707|DRUG|KX0826|AR antagonist
57754455|NCT04984707|OTHER|Placebo|Placebo of KX-826
57754456|NCT05635578|BEHAVIORAL|sleep|reiki
57754457|NCT02598986|DIETARY_SUPPLEMENT|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
57754458|NCT03310073|BIOLOGICAL|bOPV|Batch Number: 2042015
58128299|NCT01134081|PROCEDURE|Free Gingival Graft|Harvested tissue from palate
58128300|NCT04988386|DRUG|Acoramidis (AG10)|Acoramidis (AG10) twice daily
58128301|NCT02613923|BEHAVIORAL|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
58128302|NCT02613923|BEHAVIORAL|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
58128303|NCT02613923|PROCEDURE|Blood Draw|blood sample measured for stress and sleep markers
58128304|NCT02613923|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
58128305|NCT02613923|OTHER|Insomnia Severity Index (ISI)|
58128306|NCT02613923|OTHER|SF-12 quality of life survey|
58128307|NCT00636896|DRUG|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
58128308|NCT00636896|DRUG|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
58128309|NCT03491449|PROCEDURE|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
58128310|NCT03491449|PROCEDURE|Group B|Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
58128311|NCT03106870|DRUG|Insulin Mixtard|"Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
57754459|NCT03310073|BIOLOGICAL|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
57754460|NCT03310073|BIOLOGICAL|IPV|The vaccine shall be given intramuscularly.
57754461|NCT05852132|PROCEDURE|pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
57754462|NCT05852132|PROCEDURE|Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
57754463|NCT05852132|PROCEDURE|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
57754464|NCT05521425|DEVICE|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
57754465|NCT06356194|DRUG|Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
58315110|NCT04042792|OTHER|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
57754466|NCT06356194|DRUG|Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
57754467|NCT04390984|DRUG|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
57754468|NCT06579170|BEHAVIORAL|Cyanobacteria exposure during water contact|Cyanobacteria levels in beach water among participants who report water contact in the beach survey
57754469|NCT05095272|BIOLOGICAL|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
57754470|NCT02522143|BEHAVIORAL|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
57754471|NCT02522143|BEHAVIORAL|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
57754472|NCT02300857|BEHAVIORAL|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
57754473|NCT02300857|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
57754474|NCT02300857|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
57754475|NCT00312793|DEVICE|stimulation of the quadriceps muscle with Myospare|
57754476|NCT00490256|PROCEDURE|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
57754477|NCT03579329|PROCEDURE|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
57754478|NCT01265602|DRUG|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
57754479|NCT01265602|DRUG|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
57754480|NCT01265602|DRUG|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
57754481|NCT00831064|PROCEDURE|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
57754482|NCT01060553|OTHER|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
57754483|NCT03619590|OTHER|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
57754484|NCT01412801|BIOLOGICAL|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
57754485|NCT03043001|DRUG|Memantine|All the subjects will receive add-on memantine for 12 week
57754486|NCT03500055|PROCEDURE|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
57754487|NCT02642198|DEVICE|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
57754488|NCT03495388|DRUG|Oxycodone|Post-op pain management medication
57754489|NCT00308256|BEHAVIORAL|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
57754490|NCT01239667|OTHER|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
57754491|NCT01635608|DRUG|Acetaminophen|administration of 500 mg paracetamol
58453437|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
57754492|NCT01635608|DRUG|Talinolol|administration of 50 mg talinolol
57754493|NCT01635608|DRUG|Amoxicillin|administration of 500 mg amoxicillin
57754494|NCT01635608|OTHER|non-caloric water|administration of 240 ml water
57754495|NCT01635608|OTHER|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
57754496|NCT03612648|RADIATION|Three Fraction Accelerated Partial Breast Irradiation|"* TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
57754497|NCT03612648|PROCEDURE|Partial mastectomy|-Standard of Care
58453438|NCT05923879|DRUG|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
58453439|NCT03523884|OTHER|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
57754498|NCT04044456|BEHAVIORAL|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
57754499|NCT04044456|BEHAVIORAL|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
58453440|NCT03523884|OTHER|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
57754500|NCT04044456|BEHAVIORAL|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
57754501|NCT04044456|BEHAVIORAL|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
57754502|NCT04492358|DRUG|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
57754503|NCT04492358|DRUG|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
57754504|NCT04492358|DRUG|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
57754505|NCT00455585|DRUG|nevirapine, stavudine, lamivudine|
57754506|NCT04030858|BEHAVIORAL|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
57754507|NCT03444233|OTHER|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
58453441|NCT04179006|DIETARY_SUPPLEMENT|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
57754508|NCT03740308|DEVICE|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
57754509|NCT03740308|DEVICE|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
57754510|NCT02352597|DRUG|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
57754511|NCT02352597|DRUG|estradiol valerate|2mg from cycle day 7 to day 11
57754512|NCT02352597|DRUG|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
57754513|NCT04224324|PROCEDURE|Tonsillectomy and Adeniodectomy|pediatric patients undergoing tonsillectomy and adenoidectomy
58128312|NCT03106870|DRUG|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
58128313|NCT05928780|DRUG|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
58128314|NCT05928780|DRUG|A2:SG|SG 10mg/kg d1, 8
58128315|NCT05928780|DRUG|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
58128316|NCT05928780|DRUG|B2:SG|SG 10mg/kg， d1, 8
57754514|NCT03933475|DEVICE|Virtual reality game|Use of virtual reality games on television screens
57754515|NCT00834106|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
58128317|NCT05928780|DRUG|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
58128318|NCT05928780|DRUG|C2:SG|SG 10mg/kg d1, 8
58128319|NCT05928780|DRUG|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
58128320|NCT05928780|DRUG|D2:SG|SG 10mg/kg d1, 8
58128321|NCT00430079|DRUG|etanidazole|Given IV
58128322|NCT00430079|PROCEDURE|conventional surgery|Undergo surgery
58128323|NCT00430079|OTHER|pharmacological study|Correlative studies
58453442|NCT00911248|DRUG|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
58453443|NCT05914948|DEVICE|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
57754516|NCT00834106|BIOLOGICAL|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
57754517|NCT05830994|PROCEDURE|G-POEM|An Endoscopic submucosal tunnel is formed and extended to the first part of the duodenum, followed by a pyloromyotomy, beginning approximately two centimetres proximal to the pylorus and ending in the first part of duodenum.
57754518|NCT05830994|PROCEDURE|Sham|Endoscopy is performed and tissue samples are collected from fundus and antrum as part of the Sham procedure
57754519|NCT04012684|DEVICE|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
57754520|NCT04012684|DEVICE|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
57754521|NCT05777148|DEVICE|super high-flux hemodialysis|Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)
57754522|NCT05777148|DEVICE|postdilution online hemodiafiltration|hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
58128324|NCT00430079|OTHER|laboratory biomarker analysis|Correlative studies
58128325|NCT00899964|BEHAVIORAL|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
58453444|NCT00154440|DRUG|proton pump inhibitor|
57754523|NCT01222169|DRUG|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
57754524|NCT00929825|DEVICE|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
57754525|NCT00929825|PROCEDURE|TENS|transcutaneous electrical stimulation
57754526|NCT05063708|DEVICE|Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|In the present study, VitalStim equipment will be used (VitalStim Therapy; Chattanooga Group, Chattanooga, TN, USA). Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation.
57754527|NCT05063708|DEVICE|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation. The training was given according to the manual of the manufacturer, the VitalStim certification course (http://www.vitalstim.com).
57754528|NCT06193265|PROCEDURE|Discectomy|Discectomy is total or more often partial intervertebral disc surgical removal
57754529|NCT05867654|DRUG|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
57754530|NCT05867654|DRUG|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
57754531|NCT05867654|DRUG|Levofloxacin 750mg QID|Oral antibiotic used based on indication
57754532|NCT05613790|DEVICE|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
57754533|NCT05613790|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
58128326|NCT00348010|DRUG|Tramadol HCl ER|
58128327|NCT04659109|DRUG|glenzocimab|IV administration as a sterile product
58128328|NCT04659109|DRUG|Placebo|IV administration
58128329|NCT00543478|DRUG|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
58128330|NCT00543478|DRUG|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
57754534|NCT05375474|DRUG|Oral anticoagulation therapy|Vitamin-K antagonists (warfarin)
57754535|NCT05375474|DRUG|Single antiplatelet therapy|Aspirin
57754536|NCT02230956|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
57754537|NCT02230956|DRUG|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
57754538|NCT00096694|DEVICE|Levonorgestrel-releasing intrauterine device (IUD)|
57754539|NCT03852563|DRUG|BAY207543 (Bepanthol)|Product is applied to one hemiface.
58128331|NCT04608643|DIAGNOSTIC_TEST|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
58128332|NCT00309972|DRUG|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
58128333|NCT00309972|DRUG|Experimental arm (CON):|concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
58315111|NCT04265001|DRUG|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
57754540|NCT03852563|OTHER|Semisolid vaseline|Product is applied to one hemiface.
57754541|NCT02785640|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
57754542|NCT01665703|PROCEDURE|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
58315112|NCT03088397|BEHAVIORAL|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
58315113|NCT03088397|BEHAVIORAL|Website|Patient directed to website with information on various contraceptive methods.
58453445|NCT00154440|DRUG|clarithromycin|
58453446|NCT00154440|DRUG|amoxicillin|
58453447|NCT00154440|DRUG|metronidazole|
58453448|NCT00154440|PROCEDURE|radiation therapy|
58453449|NCT00409539|DRUG|Placebo|Placebo, 2 week duration.
58453450|NCT00409539|DRUG|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
58453451|NCT00409539|DRUG|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
58453452|NCT02507323|DRUG|ticagrelor|A platelet aggregation inhibitor
57754543|NCT02613819|RADIATION|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
57754544|NCT05323617|DRUG|Romiplostim|Administered as a subcutaneous injection.
57754545|NCT05323617|DRUG|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
57754546|NCT05323617|DRUG|Cyclosporine A|Administered orally.
57754547|NCT05861128|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
57754548|NCT01728519|DRUG|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
57754549|NCT01728519|DRUG|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
57754550|NCT01728519|DRUG|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
57754551|NCT01728519|DRUG|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
57754552|NCT03266770|DEVICE|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
57754553|NCT00000986|DRUG|Zidovudine|
57754554|NCT00000986|DRUG|Aldesleukin|
57754555|NCT04433364|OTHER|biological samples, questionnaires and interviews|"Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth."
57754556|NCT05749055|DRUG|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
57754557|NCT05749055|DRUG|Placebo|Placebo
57754558|NCT03248258|OTHER|Qualitative Interview or Focus group discussions|"The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial)."
57754559|NCT01127646|DRUG|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
57754560|NCT01127646|DRUG|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
57754561|NCT01127646|DRUG|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
57754562|NCT05024669|COMBINATION_PRODUCT|Gluma desensitiser|Gluma desensitiser was used before restoration.
57754563|NCT05024669|COMBINATION_PRODUCT|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
57754564|NCT05024669|COMBINATION_PRODUCT|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
57754565|NCT02801539|DEVICE|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
57754566|NCT02801539|DEVICE|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
57754567|NCT01779726|RADIATION|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
57754568|NCT01779726|RADIATION|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
57754569|NCT02255032|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
57754570|NCT02255032|DRUG|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
57754571|NCT05505630|DRUG|Ketamine|A single dose of IV ketamine will be administered.
57754572|NCT05505630|DRUG|Midazolam|A single dose of IV midazolam will be administered
57754573|NCT05505630|DRUG|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
57754574|NCT05505630|DRUG|Saline|A single dose of IV saline will be administered
57754575|NCT03638206|BIOLOGICAL|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
57754576|NCT02932046|DIETARY_SUPPLEMENT|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
57754577|NCT01928420|DRUG|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
57754578|NCT01928420|DRUG|Placebo|Subjects with Alzheimer's Disease placebo comparator
57754579|NCT05700500|PROCEDURE|shockwave therapy, barbotage and infiltration|ultrasound guided interventions
57754580|NCT01738880|DRUG|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
57754581|NCT01738880|DRUG|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
57754582|NCT05414539|OTHER|OptiCogs Online|A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
57754583|NCT02274857|PROCEDURE|Standard PVI Ablation|Standard PVI procedure without FIRMap.
57754584|NCT02274857|PROCEDURE|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
57754585|NCT05324969|BEHAVIORAL|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
57754586|NCT05324969|OTHER|healthy education|9 health education emails will be sent to participating parents in the control group
57754587|NCT00303056|DRUG|HOE140 Icatibant|
57754588|NCT04468269|OTHER|Task oriented balance training with sensory integration group|"Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk"
57754589|NCT04468269|OTHER|Task oriented balance training without sensory integration group|"Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk"
57754590|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
58128334|NCT05997407|BEHAVIORAL|Organic Conceptions mindset management program|"Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group."
58128335|NCT01586741|PROCEDURE|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
58453453|NCT02507323|DRUG|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
58453454|NCT02507323|DRUG|Placebo|placebo
58453455|NCT02926989|DRUG|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
57754591|NCT00822081|DRUG|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
57754592|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
57754593|NCT00822081|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
57754594|NCT05692505|DIAGNOSTIC_TEST|QuadQuik|Invitro diagnostic device
57754595|NCT05318924|DRUG|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
57754596|NCT05318924|OTHER|Placebo|Participants will receive a saline infusion as the placebo control condition.
57754597|NCT00529750|DRUG|IRBESARTAN|Tablets
57754598|NCT00529750|DRUG|Atenolol|Tablets
57754599|NCT02583425|DRUG|DFN-11 Injection|
57754600|NCT00992680|DEVICE|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
57754601|NCT06347510|DIAGNOSTIC_TEST|Suppression of tumorigenicity 2 (ST2)|Suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 (IL-1) receptor family. The ligand and soluble versions are its two isoforms. It was first isolated in 1989. It was found to function as an IL-33 ligand in 2005. The IL-33-ST2L ligand complex\&#39;s creation offers protection against heart fibrosis and hypertrophy. The formation of this complex is inhibited by soluble ST2, which removes the cardioprotective effect. Unlike NT pro BNP, it is unaffected by age, body mass index, creatinine, hemoglobin, and albumin levels, according to studies performed on individuals. with heart failure.
58453456|NCT02926989|DRUG|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
57754602|NCT04437433|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
57754603|NCT03664479|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
57754604|NCT06491836|DIETARY_SUPPLEMENT|oligoantigenic diet|Oligoantigenic diet that will cover recommended daily allowance (RDA) of macronutrients and micronutrients according patients' ages according to our available sources of food in our culture and the diet consists typically of meat (e.g. chicken and lamb), carbohydrate sources (e.g., potatoes and rice), fruits (e.g., bananas, pears and apples), vegetables (e.g., cucumbers, carrot, lettuce, cauliflower, turnips, cabbage and broccoli)
57754605|NCT06491836|OTHER|Food regimen without food restrictions.|Food regimen that will cover recommended daily allowance (RDA) for macronutrients and micronutrients according patients' ages without any food restriction
57754606|NCT05166941|BEHAVIORAL|creative drama|In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
57754607|NCT02521662|DRUG|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
57754608|NCT02521662|DEVICE|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
57754609|NCT02521662|DRUG|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
57754610|NCT02521662|BEHAVIORAL|Behavioural support|Withdrawal-oriented behavioural support
58453457|NCT06233188|PROCEDURE|orthogantic surgery|surgery that correcting the maxilla and mandible related with each other
58453458|NCT00730977|DRUG|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
58453459|NCT00003239|BIOLOGICAL|Recombinant Interferon Alfa|Daily by subcutaneous injection.
57754611|NCT03859258|DEVICE|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
57754612|NCT03521726|DRUG|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
57754613|NCT03521726|DRUG|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
57754614|NCT02521402|BIOLOGICAL|Biovance|decellularized, dehydrated human amniotic membrane
57754615|NCT00552084|DRUG|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
58453460|NCT00003239|DRUG|Cytarabine|Daily by subcutaneous injection.
57754616|NCT00552084|DRUG|Placebo|Placebo supplements will be taken daily for 24 weeks.
57754617|NCT03360708|OTHER|Laboratory Biomarker Analysis|Correlative studies
57754618|NCT03360708|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
57754619|NCT03340480|DRUG|NVP-1402|Oral
57754620|NCT03138096|BIOLOGICAL|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
57960783|NCT03622827|COMBINATION_PRODUCT|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~* Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
57960784|NCT03443154|DIAGNOSTIC_TEST|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
58453461|NCT00003239|DRUG|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
57754621|NCT03138096|OTHER|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
57754622|NCT00664937|DRUG|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
57754623|NCT00664937|DRUG|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
57754624|NCT02722512|BIOLOGICAL|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
57754625|NCT02722512|PROCEDURE|Tumor Resection|Clinically-indicated removal of the tumor
57754626|NCT02722512|RADIATION|Radiation|Focal Radiation Therapy
57754627|NCT01566175|DEVICE|Neovac coronary sinus reducer|reducer
57754628|NCT06414486|DIETARY_SUPPLEMENT|Dietary supplement group|One tablet per day for 3 weeks consumed for subjects randomized in the Dietary supplementation group. This will lead to an intake of 200mg per day of Red Panax Ginseng (corresponding to 22.4mg of ginsenosides and 20.2mg of rare ginsenosides).
57754629|NCT06414486|OTHER|Placebo group|One tablet per day consumed for 3 weeks for subjects randomized in the Control group. The product is composed of rice flour (50mg) and brown sugar (150mg).
57754630|NCT00031486|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
57754631|NCT00031486|DRUG|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
57754632|NCT00850889|DEVICE|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
57754633|NCT00850889|DEVICE|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
57754634|NCT03523312|RADIATION|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
57754635|NCT03523312|DRUG|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
57754636|NCT00733499|DEVICE|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
57754637|NCT00733499|DEVICE|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
57960785|NCT04476238|DIETARY_SUPPLEMENT|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
57754638|NCT05758831|DRUG|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
57754639|NCT05758831|DRUG|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
57754640|NCT04371146|DRUG|Methylphenidate|35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
57754641|NCT04371146|DRUG|Reboxetine|8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
57754642|NCT04371146|DRUG|Placebos|A placebo pill is administered once using a randomized placebo-controlled between subject's design
57754643|NCT02003079|BEHAVIORAL|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
57754644|NCT04762693|DEVICE|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
57754645|NCT02474290|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
57754646|NCT04653402|DEVICE|Hydrocelectomy surgery|The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
57754647|NCT05970822|DRUG|BC3402|Escalating of BC3402 will be administered IV(intravenous)
57754648|NCT05970822|DRUG|Azacitidine|Azacitidine will be administered daily
57754649|NCT02357030|DRUG|Methyl-P plus GWI Nutrient Formula|"Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily"
57754650|NCT00451165|PROCEDURE|laparoscopic colorectal surgery|laparoscopic colorectal surgery
57754651|NCT04251884|PROCEDURE|Local anesthetic (ropivacaine)|Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
57960786|NCT04476238|OTHER|Placebo|250 ml water taken by mouth
57754652|NCT04421482|OTHER|Standard room temperature (RTS) feeding of milk/formula|Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions: standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
57754653|NCT04421482|OTHER|Cold temperature (CS, at 4-9°C) of milk/formula|Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions, standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
57754654|NCT03738202|BEHAVIORAL|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan"
57754655|NCT06100419|PROCEDURE|serratus posterior superior intercostal plane block|With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
57754656|NCT05994209|DEVICE|quitSTART Mobile Application|Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
57754657|NCT05994209|BEHAVIORAL|Chatbot Feature in quitSTART Mobile Application|In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
57754658|NCT03311282|DEVICE|infants bottles|"* angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat"
57754659|NCT03311282|DEVICE|Infants Bottles|"* large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat"
58453462|NCT00938678|DRUG|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
58453463|NCT00938678|DRUG|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
57754660|NCT03311282|DEVICE|Infants Bottles|"* teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat"
57754661|NCT01093144|DEVICE|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
57754662|NCT06090916|OTHER|Best Practice|Receive standard nutrition care
57754663|NCT06090916|OTHER|Dietary Intervention|Participate in weekly support sessions with diet prescription
57754664|NCT06090916|OTHER|Medical Chart Review|Ancillary studies
57754665|NCT06090916|OTHER|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
57960787|NCT02432768|DRUG|Triheptanoin|Anaplerotic dietary oil
57960788|NCT02432768|OTHER|Placebo oil|Safflower oil
57960789|NCT03726645|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation
57960790|NCT00288080|DRUG|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
58315114|NCT03088397|BEHAVIORAL|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
58315115|NCT00083915|DRUG|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
58315116|NCT00083915|DRUG|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
58315117|NCT00083915|DRUG|Adriamycin|20mg/m2 continuous infusion -3 and -2.
58315118|NCT00083915|DRUG|Etoposide|80mg/m2 continuous infusion -3 and -2.
58315119|NCT00083915|DRUG|Melphalan|200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
58315120|NCT00083915|DRUG|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).
58315121|NCT00083915|DRUG|Dexamethasone|40 mg po days 1 - 4 (4 days)
58315122|NCT03526705|DEVICE|NB-UVB|Phototherapy
58315123|NCT04582526|BEHAVIORAL|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
58315124|NCT03037242|PROCEDURE|Transtibial pullout technique|Evaluating radographs
58315125|NCT00382356|DRUG|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
58453464|NCT05009277|DEVICE|Device|LINDA thermal device
58453465|NCT02975050|OTHER|Location|
58453466|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
58453467|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
58453468|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
58453469|NCT01112397|DRUG|AZD1480|continuous daily oral capsule
58453470|NCT01730521|BEHAVIORAL|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
58453471|NCT02783365|BEHAVIORAL|Photo-elicitation and online group support|See above information.
58453472|NCT05432713|DRUG|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
57754666|NCT06090916|OTHER|Nutritional Assessment|Undergo malnutrition screening
57754667|NCT06090916|OTHER|Questionnaire Administration|Ancillary studies
57754668|NCT00921063|DRUG|PD 0332334|250 mg capsule, BID for 4 weeks
58453473|NCT05432713|DRUG|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
58453474|NCT02962167|BIOLOGICAL|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
58453475|NCT02962167|BIOLOGICAL|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
58453476|NCT03324802|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
58453477|NCT03324802|OTHER|Quality-of-Life Assessment|Ancillary studies
58453478|NCT03324802|RADIATION|Radiation Therapy|hypofractionated radiation therapy
58453479|NCT02182934|DRUG|Ginsana|
58453480|NCT02182934|DRUG|Placebo|
57754669|NCT00921063|DRUG|PD 0332334|100 mg capsule, BID for 4 weeks
57754670|NCT00921063|DRUG|placebo|0 mg capsule, BID for 4 weeks
57960791|NCT00288080|DRUG|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
57960792|NCT00288080|DRUG|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
57960793|NCT00288080|DRUG|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
58315126|NCT01869374|DEVICE|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
58315127|NCT01869374|BIOLOGICAL|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
58315128|NCT03246945|BEHAVIORAL|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
58453481|NCT06015386|OTHER|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
58315129|NCT02952417|OTHER|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
58453482|NCT06015386|OTHER|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
58453483|NCT03923257|DRUG|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
58453484|NCT03923257|PROCEDURE|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
57754671|NCT00921063|DRUG|Alprazolam extended release|1 mg capsule, BID for 4 weeks
57754672|NCT04123925|DRUG|Nivolumab|Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
57754673|NCT05063214|DIAGNOSTIC_TEST|Muscle ultrasound evaluation|Muscle ultrasound evaluation will be performed in patients admitted with COVID-19 requiring invasive mechanical ventilation. The measurements of thickness and thickening fraction will occur for diaphragm, abdominal - rectus abdominis, internal oblique, external oblique and transverse abdomen - and parasternal intercostal muscles. Serial measurements of the thickness and echogenicity of the quadriceps femoris muscle will also be performed.
58128336|NCT04913896|DRUG|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
58453485|NCT02685306|BIOLOGICAL|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
58453486|NCT02685306|DRUG|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
58453487|NCT06136364|BIOLOGICAL|CAR-T|CAR-T immunotherapy targeting CD7+
58453488|NCT00724178|DIETARY_SUPPLEMENT|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
58453489|NCT03840863|DIETARY_SUPPLEMENT|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
58453490|NCT00961181|DEVICE|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
57754674|NCT04280653|DEVICE|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
57754675|NCT03672838|BEHAVIORAL|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
57754676|NCT01065350|DRUG|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
58453491|NCT02246595|BIOLOGICAL|CaCP29|
58453492|NCT02246595|BIOLOGICAL|Placebo|
58453493|NCT02254473|OTHER|Wedge Insert|
58453494|NCT02254473|OTHER|Flat Insert|
58453495|NCT04738981|DRUG|UC-MSC|UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
58453496|NCT04738981|DRUG|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
57754677|NCT01065350|DRUG|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
57754678|NCT02676401|DRUG|MT-3995 Low|
57754679|NCT02676401|DRUG|MT-3995 Middle|
57754680|NCT02676401|DRUG|MT-3995 High|
57754681|NCT03681574|DRUG|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
58315130|NCT03518684|DRUG|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
58453497|NCT00003464|DRUG|temozolomide|
58453498|NCT00003464|RADIATION|radiation therapy|
58315131|NCT01570764|DRUG|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
58453499|NCT05835765|DEVICE|Dynamic Elastometric Body in Preterm Newborns|The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
58453500|NCT05289063|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
58453501|NCT05289063|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
58453502|NCT05289063|OTHER|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
58453503|NCT03585478|DRUG|Latiglutenase|Latiglutenase administered orally (daily)
57754682|NCT03681574|DRUG|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
57754683|NCT03681574|DRUG|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
57754684|NCT03125005|DEVICE|Rainbow Universal Pulse Oximeter Sensor|
57754685|NCT05745142|DRUG|Sunitinib|as provided in real world practice
57754686|NCT01837160|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
57754687|NCT01837160|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
57754688|NCT01837160|PROCEDURE|Echocardiogram|Echocardiography.
57754689|NCT01837160|RADIATION|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
57754690|NCT01837160|PROCEDURE|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
57754691|NCT01757834|DEVICE|SWUS Elastography|
57754692|NCT04978714|PROCEDURE|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
57754693|NCT03859882|OTHER|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
57754694|NCT06206967|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
57754695|NCT06206967|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
58315132|NCT01570764|DRUG|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
58453504|NCT03585478|OTHER|Placebo|Placebo administered orally (daily)
58453505|NCT06081543|DIETARY_SUPPLEMENT|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
57754696|NCT00259064|DRUG|Gefitinib|
57754697|NCT00259064|OTHER|Placebo|
58453506|NCT06081543|DIETARY_SUPPLEMENT|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
58453507|NCT03318588|PROCEDURE|Vitrectomy|Pars plana vitrectomy
58453508|NCT02513121|OTHER|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
58453509|NCT06094322|OTHER|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
58453510|NCT03796637|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
58453511|NCT05269160|DRUG|Dermaprazole 1%|Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
58453512|NCT05269160|DRUG|Dermaprazole 2%|Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
58453513|NCT06032910|DEVICE|Surgical mesh|Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.
58453514|NCT02619474|OTHER|Whiteboard|"1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
58453515|NCT04104386|OTHER|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
58453516|NCT02552914|DEVICE|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
58453517|NCT01606709|DRUG|GnRH agonist|GnRH agonist 1mg one dose
58453518|NCT01606709|DRUG|hCG|5,000 IU one dose
58453519|NCT00498914|DRUG|YM155|Continuous IV infusion
58453520|NCT00040443|DRUG|CX516|
58453521|NCT00040443|DRUG|Placebo|
58453522|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
58453523|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
58453524|NCT03476135|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
58453525|NCT00941317|DEVICE|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
58453526|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
58453527|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
58453528|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
57754698|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with sublingual sprayable microemulsion.|Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.
58453529|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
57754699|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with oil droplets|Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.
57754700|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with capsules|Participants received capsules of vitamin D3 4000 IU daily for 30 days.
57754701|NCT02856113|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets.
57754702|NCT02856113|DRUG|Placebo|Alogliptin placebo-matching tablets.
57754703|NCT00091247|DRUG|tetracycline hydrochloride|
57754704|NCT00091247|OTHER|placebo|
57754705|NCT03419416|OTHER|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
57754706|NCT03569384|COMBINATION_PRODUCT|Tele Rehab|The intervention group will obtain telerehabilitation
58453530|NCT05703750|PROCEDURE|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
58453531|NCT05279287|OTHER|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
58453532|NCT04725253|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide, 1,5 gr per day for 7 days.
57754707|NCT03347916|DRUG|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
57754708|NCT03347916|DRUG|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
58453533|NCT04725253|OTHER|Placebo tablets|Placebo tablets, 1 per day for 7 days.
57754709|NCT05125575|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the Test (T) product was administered orally with 240 mL of water.
57754710|NCT05125575|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets|One tablet of the Reference (R) product was administered orally with 240 mL of water.
57754711|NCT02288754|DIAGNOSTIC_TEST|Blood test|No intervention except to collect blood for diagnostic test development
57754712|NCT03648112|DIETARY_SUPPLEMENT|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
57754713|NCT03648112|DIETARY_SUPPLEMENT|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
57754714|NCT03648112|DIETARY_SUPPLEMENT|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
57754715|NCT03648112|DIETARY_SUPPLEMENT|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
57754716|NCT03648112|DIETARY_SUPPLEMENT|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
57754717|NCT05634044|DEVICE|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
57754718|NCT02656810|DRUG|Teriparatide|Single subcutaneous injection
57754719|NCT05836948|DRUG|SHR-9839|Weekly fixed dose injection of SHR-9839
57754720|NCT03144895|PROCEDURE|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
57754721|NCT03092284|BIOLOGICAL|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
57754722|NCT03092284|BIOLOGICAL|Placebo|Saline
57754723|NCT05865743|DRUG|SDD|"The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose."
57754724|NCT03785574|OTHER|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
57754725|NCT03785574|DRUG|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
57754726|NCT00973661|BEHAVIORAL|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
57960794|NCT00288080|RADIATION|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
58128337|NCT05282888|OTHER|blood sample|in order to develop a diagnostic assay using an innovative technology by imaging flow cytometry to identify red blood cell morphological anomalies in the diagnosis flowchart of anemia.
57754727|NCT03187990|DRUG|[68Ga]PSMA-11|PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.
57754728|NCT03187990|DRUG|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
57960795|NCT00288080|DRUG|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
57754729|NCT03685838|OTHER|Compression Stockings|Class II above knee compression stockings
57960796|NCT01487512|DRUG|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
57754730|NCT01720290|DRUG|repaglinide|Dose individually adjusted
57754731|NCT01720290|DRUG|metformin|Dose individually adjusted
57754732|NCT01720290|DRUG|metformin|Dose at 1000 mg/day
57754733|NCT01746095|DRUG|Vancomycin hydrochloride inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
57754734|NCT01746095|DRUG|Placebo inhalation powder|
57960797|NCT01487512|DRUG|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
58315133|NCT03426904|DRUG|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
58315134|NCT03426904|DRUG|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
58453534|NCT02339753|DRUG|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
58453535|NCT02394535|DRUG|Capecitabine|Given PO
58453536|NCT02394535|OTHER|Laboratory Biomarker Analysis|Correlative studies
58453537|NCT02394535|DRUG|Nab-paclitaxel|Given IV
57754735|NCT03042455|DEVICE|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
57754736|NCT03042455|DEVICE|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
57754737|NCT03042455|OTHER|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
57754738|NCT00986076|DRUG|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
57754739|NCT00986076|DRUG|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
57754740|NCT03662932|OTHER|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
57754741|NCT04209816|DIAGNOSTIC_TEST|Lipoprotein kinetics|Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
57754742|NCT00141154|DRUG|Celecoxib|
57754743|NCT00141154|DRUG|Placebo|
57754744|NCT00141154|DRUG|Loxoprofen|
57754745|NCT01007656|DIETARY_SUPPLEMENT|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
57754746|NCT00541918|DRUG|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
57754747|NCT00541918|DRUG|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
57754748|NCT03107078|DRUG|Glucocorticoids|Intravenous Glucocorticoids (GCs)
57754749|NCT03178786|BEHAVIORAL|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
57754750|NCT04384263|BEHAVIORAL|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
57754751|NCT05797831|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
57754752|NCT05797831|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
57754753|NCT00003006|GENETIC|reverse transcriptase-polymerase chain reaction|
57754754|NCT00003006|OTHER|immunohistochemistry staining method|
57754755|NCT05639179|BIOLOGICAL|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
57754756|NCT00002420|DRUG|Emivirine|
57754757|NCT00002420|DRUG|Hydroxyurea|
57754758|NCT00002420|DRUG|Delavirdine mesylate|
57754759|NCT00002420|DRUG|Stavudine|
57754760|NCT00002420|DRUG|Didanosine|
57754761|NCT04113954|DRUG|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
57754762|NCT04113954|DRUG|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
58453538|NCT02394535|OTHER|Questionnaire Administration|Ancillary studies
57754763|NCT05982938|DRUG|Danicopan|Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
57754764|NCT04506957|DEVICE|Pulse CO-Oximetry Hemoglobin measurement transcutaneous|this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
57754765|NCT04082884|BEHAVIORAL|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
57754766|NCT02623855|BEHAVIORAL|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
58453539|NCT02394535|RADIATION|Radiation Therapy|Undergo radiation therapy
58453540|NCT04001413|DRUG|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
58453541|NCT04001413|DRUG|Durvalumab|Durvalumab is an investigational drug in this study.
57754767|NCT02623855|BEHAVIORAL|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
57754768|NCT02623855|DEVICE|Pedometry|Participants will record their daily pedometry.
57754769|NCT02623855|BEHAVIORAL|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
57754770|NCT04343586|DEVICE|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
57754771|NCT00845884|DRUG|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"* Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
57754772|NCT01291784|BIOLOGICAL|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
57754773|NCT00827541|DRUG|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
57754774|NCT06107595|BEHAVIORAL|Placebo|Participant take 1 dose placebo (odor or pill) on post-op day 0 (POD 0) and 3 placebo dose from POD 2 to POD 17
57754775|NCT01265199|DRUG|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
57754776|NCT06443502|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
57754777|NCT06443502|DRUG|Concomitant Antibiotic Therapy|Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
58128338|NCT04014322|OTHER|E-cigarette|"All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)"
58128339|NCT05903326|OTHER|Dexmedetomidine|this was an observational study only based on a change of practice
58128340|NCT03427970|BEHAVIORAL|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
58315135|NCT01474343|GENETIC|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
57754778|NCT05947214|OTHER|Myofascial Decompression Therapy|Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
57754779|NCT05947214|OTHER|positional Release Therapy|Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
57754780|NCT04386434|BEHAVIORAL|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
57754781|NCT03427684|RADIATION|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction \>2Gy .
57754782|NCT03427684|DRUG|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
57754783|NCT00228605|DRUG|OraVescent Fentanyl|
57754784|NCT02753309|DRUG|Sirolimus|
57754785|NCT04558190|DRUG|Intralipid, 20% Intravenous Emulsion|Lipid infusion
57754786|NCT04558190|DIETARY_SUPPLEMENT|MitoQ|Oral administration of MitoQ capsules
57754787|NCT04558190|DRUG|Salbutamol|Beta2-agonist infusion
57754788|NCT01556126|DEVICE|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
57754789|NCT03606356|DRUG|Onabotulinum toxin A|Cranial Subcutaneous Injections
58315136|NCT05051163|DRUG|Ceftriaxone Sodium|7 days of once daily dosing
58315137|NCT05051163|DRUG|Ampicillin|7 days of 6 hourly dosing
58315138|NCT05051163|DRUG|Gentamicin|7 days of once daily dosing
58315139|NCT00481039|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
58453542|NCT03367728|DRUG|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
57754790|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
57754791|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
57754792|NCT04508608|DIAGNOSTIC_TEST|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
57754793|NCT04508608|DIAGNOSTIC_TEST|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
57754794|NCT02498834|BEHAVIORAL|Educational Video and Question Prompt List|Educational Video and Question Prompt List
57754795|NCT04036461|DRUG|CC-99712|CC-99712
57754796|NCT04036461|DRUG|BMS-986405|BMS-986405
57754797|NCT02813187|BIOLOGICAL|cellular and tissue based therapy|
57754798|NCT02813187|PROCEDURE|debridement|
57754799|NCT02813187|PROCEDURE|advanced wound therapy|
58128341|NCT03427970|BEHAVIORAL|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
58128342|NCT05945641|BEHAVIORAL|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,
58128343|NCT05945641|BEHAVIORAL|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
58128344|NCT04159909|DEVICE|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
58128345|NCT04159909|DEVICE|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
58128346|NCT04770623|DRUG|Docetaxel|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
57754800|NCT02813187|DIETARY_SUPPLEMENT|Nutritional screening|
57754801|NCT04022967|DRUG|dolutegravir|One daily tablet (50mg) during 96 weeks
57754802|NCT04022967|DRUG|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
57754803|NCT04022967|DRUG|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
57754804|NCT04022967|DRUG|Lamivudine|One daily tablet (300mg) during 96 weeks
57754805|NCT01048814|OTHER|ChemoFx|Chemoresponse Marker Assay
57754806|NCT01891448|OTHER|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
57754807|NCT01891448|OTHER|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
57754808|NCT05711862|DRUG|SUVO|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
57754809|NCT05711862|DRUG|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
57754810|NCT05531279|DRUG|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
57754811|NCT02940574|DRUG|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
57754812|NCT02940574|OTHER|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
57754813|NCT02393287|OTHER|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
57754814|NCT03716375|DRUG|Intrapleural Medications|urokinase
57754815|NCT03019874|DIETARY_SUPPLEMENT|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
57754816|NCT04707625|DRUG|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
57754817|NCT00501189|BIOLOGICAL|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
57754818|NCT05780294|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
57754819|NCT05780294|DRUG|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
57754820|NCT05780294|DRUG|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
57754821|NCT05780294|DRUG|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
57754822|NCT00845338|DRUG|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
57754823|NCT02742298|DEVICE|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
57754824|NCT02742298|OTHER|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
57754825|NCT03017417|OTHER|Exercise Intervention|Various exercise tests
57754826|NCT03017417|OTHER|standard of care|standard treatment
57754827|NCT03462615|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
57754828|NCT05435274|DRUG|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
57754829|NCT02168530|DRUG|placebo|matching placebo administered daily orally
57754830|NCT02168530|DRUG|vismodegib|vismodegib 150 mg administered daily orally
57754831|NCT04846088|OTHER|Product A|A 4mg nicotine pouch product
57754832|NCT04846088|OTHER|Product B|A 7mg nicotine pouch product
57754833|NCT04846088|OTHER|Product C|A 7mg nicotine pouch product
57754834|NCT04846088|OTHER|Product D|A 7mg nicotine pouch product
57754835|NCT04846088|OTHER|Product E|A 7mg nicotine pouch product
57754836|NCT04846088|OTHER|Product F|A 7mg nicotine pouch product
57754837|NCT04846088|OTHER|Product G|A 7mg nicotine pouch product
57754838|NCT04846088|OTHER|Product H|A 7mg nicotine pouch product
57754839|NCT04846088|OTHER|Product I|A 7mg nicotine pouch product
57754840|NCT05306366|DRUG|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
57754841|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
57754842|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
57754843|NCT00792896|BEHAVIORAL|family conference|family conference
57754844|NCT01691625|OTHER|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
57754845|NCT01691625|OTHER|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
57754846|NCT01174420|DEVICE|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
57754847|NCT01174420|DRUG|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
57754848|NCT02862379|BEHAVIORAL|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
57960798|NCT01487512|DRUG|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
57754849|NCT02280239|DRUG|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
57754850|NCT02280239|DRUG|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
57754851|NCT03953963|DEVICE|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
57754852|NCT03168568|DRUG|Valsartan/Sacubitril or placebo|tablet (double dummy)
57754853|NCT03168568|DRUG|Valsartan or placebo|tablet (double dummy)
57754854|NCT06362980|DRUG|BPI-1178|200 or 300 mg, oral, QD
58128347|NCT04770623|DRUG|Irinotecan|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
58128348|NCT01305070|DEVICE|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
58128349|NCT01305070|DEVICE|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
57754855|NCT06362980|DRUG|Osimertinib|80mg, oral, QD
57754856|NCT00089089|DRUG|decitabine|Given IV
57754857|NCT00089089|OTHER|pharmacological study|Correlative studies
57754858|NCT00089089|OTHER|laboratory biomarker analysis|Correlative studies
57754859|NCT02880592|OTHER|Affinity Allograft|fresh hypothermically stored human amniotic membrane
57754860|NCT02880592|OTHER|Standard of care|offloading, debridement, infection management using appropriate dressings
57754861|NCT03438695|PROCEDURE|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
57754862|NCT03817892|OTHER|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
57754863|NCT03817892|OTHER|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
57754864|NCT03076476|DEVICE|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
57754865|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
57754866|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
57754867|NCT00521703|DRUG|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
57754868|NCT00521703|DRUG|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
57754869|NCT02976142|PROCEDURE|neoadjuvant chemoimmunotherapy|
57754870|NCT02740049|DRUG|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
57754871|NCT01444859|DIETARY_SUPPLEMENT|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
57754872|NCT01444859|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 10 weeks
57754873|NCT01120249|DRUG|everolimus|Given orally
57960799|NCT01487512|DRUG|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
57960800|NCT01175798|DRUG|Cholecalciferol|50,000 IU PO weekly x 6 weeks
58128350|NCT01104207|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
58128351|NCT01104207|DEVICE|placebo rTMS|placebo rTMS
58128352|NCT03409757|DRUG|Velphoro|4 weeks
57754874|NCT01120249|OTHER|placebo|Given orally
57754875|NCT06329726|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
57754876|NCT00766675|DRUG|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
57754877|NCT00766675|DRUG|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
57754878|NCT03257332|PROCEDURE|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
57960801|NCT01246791|DRUG|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
58128353|NCT03409757|OTHER|saliva collection|2 samples
58128354|NCT03409757|OTHER|Supragingival biofilm collection|2 samples
58128355|NCT03409757|OTHER|stool collection|2 samples
58128356|NCT03409757|OTHER|blood collection|2 samples
58128357|NCT04088838|OTHER|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
58315140|NCT02685930|BEHAVIORAL|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
57754879|NCT05897255|DEVICE|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
58453543|NCT03367728|DRUG|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
58453544|NCT03378817|PROCEDURE|HOPE|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
58453545|NCT03378817|OTHER|Conventional cold storage|No intervention
58453546|NCT06426953|OTHER|No intervention|No intervention
58453547|NCT04946890|DRUG|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
58453548|NCT02736201|DEVICE|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
58453549|NCT02736201|OTHER|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
58453550|NCT00000346|BEHAVIORAL|counseling|
58453551|NCT03847766|BEHAVIORAL|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
58453552|NCT03847766|BEHAVIORAL|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
58453553|NCT01957878|BIOLOGICAL|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
58453554|NCT01957878|BIOLOGICAL|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
57754880|NCT01226901|DRUG|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
57754881|NCT05396989|OTHER|No intervention|No intervention
57754882|NCT01984697|BIOLOGICAL|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
57754883|NCT06201130|DIAGNOSTIC_TEST|Suctioning of artificial airway|Collection of tracheal aspirates in either the PICU or NICU will occur. We will instill 1 mL of normal saline, then perform bag ventilation, and then suction out aspirate. Suctioning is routinely performed for tracheostomy and endotracheal tube hygiene - for instance, it is performed on tracheostomies by caregivers at home. The aspirates that will be collected will be clinically indicated and otherwise would be discarded. If the patients weren't enrolled in this research, the aspirates would have been collected anyways.
57754884|NCT00669786|DRUG|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
58453555|NCT03101254|DRUG|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
58453556|NCT03101254|DRUG|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
58453557|NCT03101254|DRUG|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
58453558|NCT03491826|BIOLOGICAL|rupture of membrane|
58453559|NCT00657644|DRUG|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
57754885|NCT04791072|OTHER|Exercise|Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
57754886|NCT00256503|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
57754887|NCT03469284|OTHER|Best Practice|Given standard of care therapy
57754888|NCT03469284|DRUG|Methylene Blue|Given lower dose PO
57754889|NCT03469284|DRUG|Methylene Blue|Given medium dose PO
57754890|NCT03469284|DRUG|Methylene Blue|Given higher dose PO
57754891|NCT03258216|DIAGNOSTIC_TEST|panendoscopy|panendoscopy
57754892|NCT03258216|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
58453560|NCT06142539|RADIATION|CT Radiation Doses|Obtaining Low CT Radiation Doses by Adjusting Dose Levels
58453561|NCT06427408|OTHER|Non applicable|Placental transcriptomic analysis
58453562|NCT00828971|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
58453563|NCT00828971|DRUG|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
58453564|NCT02864693|DEVICE|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
58453565|NCT02864693|DEVICE|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
58453566|NCT01094678|DEVICE|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
58453567|NCT00443417|DRUG|SK-PC-B70M|dosage, frequency
58453568|NCT02096016|PROCEDURE|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
58453569|NCT01916382|DRUG|Nitisinone|drug
57754893|NCT06579586|BEHAVIORAL|Survey study|The Parent's State and Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index-3 (AS-3), and Pain Catastrophising Scale for Parents (PPS-PPS) were completed one day before the operation to measure anxiety level.
57754894|NCT00253344|DRUG|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
57754895|NCT00253344|DRUG|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
57754896|NCT04646239|DIAGNOSTIC_TEST|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
57754897|NCT04646239|DIAGNOSTIC_TEST|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
57754898|NCT01900600|OTHER|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
57754899|NCT01900600|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
57754900|NCT05438654|DIAGNOSTIC_TEST|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
57754901|NCT02660814|OTHER|Non-surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
57754902|NCT02660814|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
57754903|NCT00989092|BIOLOGICAL|darbepoetin alfa|Administered subcutaneously.
57754904|NCT03075384|PROCEDURE|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
57754905|NCT06018792|DIAGNOSTIC_TEST|Molecular Culture|PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
57961628|NCT02339493|OTHER|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
58453570|NCT06008392|GENETIC|Pan-genomic Testing|Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).
58453571|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
57754906|NCT06139757|DEVICE|Oura ring|Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
57754907|NCT04569110|OTHER|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
57754908|NCT05373355|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
57754909|NCT04975269|DRUG|Acetazolamide|Target dose: 500 mg / day
57754910|NCT04975269|DRUG|Placebo|Placebo
57754911|NCT03760536|BEHAVIORAL|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
57754912|NCT00045708|DRUG|ixabepilone|Given IV
57754913|NCT00045708|OTHER|pharmacological study|Correlative studies
57754914|NCT00045708|DRUG|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
57754915|NCT03123146|BEHAVIORAL|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
57754916|NCT02833688|DRUG|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
57961629|NCT02491164|OTHER|BAC TWO|BAC TWO administration
57961630|NCT02491164|DEVICE|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
57961631|NCT06344845|DIAGNOSTIC_TEST|18F-PBB3 PET/CT scan|Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
57754917|NCT02833688|DRUG|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
57754918|NCT00710606|DRUG|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
57754919|NCT00710606|DRUG|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
57754920|NCT00681304|OTHER|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
57754921|NCT04606277|OTHER|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
57754922|NCT01359670|DRUG|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
57754923|NCT01359670|DRUG|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
57754924|NCT01180543|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
57754925|NCT01180543|DEVICE|Placebo Patch|same as active patch
57754926|NCT01572025|DRUG|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
57754927|NCT01572025|DRUG|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
57754928|NCT06078579|DIAGNOSTIC_TEST|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
57754929|NCT03170011|BEHAVIORAL|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
57754930|NCT05605210|DEVICE|Electric stimulation|Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
57754931|NCT01965938|DEVICE|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
57754932|NCT01965938|DEVICE|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
58128358|NCT06229925|DEVICE|Experimental Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.
58453572|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
57754933|NCT04653441|BEHAVIORAL|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
57754934|NCT02093767|DIETARY_SUPPLEMENT|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
57754935|NCT03301012|OTHER|Recovery support as usual|same as arm
57754936|NCT03301012|OTHER|Smartphone assisted relapse prevention|same as arm
57754937|NCT02721576|DRUG|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
57754938|NCT03790761|BEHAVIORAL|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
57754939|NCT02942602|DRUG|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
57754940|NCT02942602|DRUG|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
57754941|NCT02942602|DRUG|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
57754942|NCT02942602|DRUG|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
57754943|NCT02942602|BEHAVIORAL|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
58128359|NCT06229925|DEVICE|Sham Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
58128360|NCT04188821|PROCEDURE|breast drain removal|"Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care."
58453573|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
58453574|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
57754944|NCT05272332|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound upon fasting, after 4 hours, and after nasogastric aspiration, to estimate gastric volume
57754945|NCT06259383|DRUG|Ivermectin|3-day 1 daily dose of 400 μg/kg oral ivermectin
57754946|NCT03781921|OTHER|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
57754947|NCT05672979|DRUG|Brolucizumab Injection [Beovu]|brolucizumab 6mg intravitreal injection
57754948|NCT01385358|PROCEDURE|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
57754949|NCT01385358|PROCEDURE|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
57754950|NCT01075932|DIETARY_SUPPLEMENT|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
57754951|NCT01075932|DIETARY_SUPPLEMENT|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
57754952|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|50μg/dose
57754953|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent High dose|100μg/dose
57754954|NCT05547243|DRUG|Placebo|Saline solution
57754955|NCT05574725|DEVICE|Smartphone|review of the smartphone video on patients phone by general neurologist and epileptogist each separately with comment on onquality of video using videoquality scale(10), semiology, seizure diagnosis
57754956|NCT02319226|OTHER|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
58128361|NCT05241184|DIAGNOSTIC_TEST|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
58128362|NCT02888171|DRUG|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
57754957|NCT06065566|DIETARY_SUPPLEMENT|L-alanyl-L-glutamine dipeptide|"1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention."
57754958|NCT06065566|OTHER|Placebo|"1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention."
58128363|NCT02888171|DRUG|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
58128364|NCT05531409|BEHAVIORAL|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
58128365|NCT01161667|DRUG|naratriptan hydrochloride|2.5 mg tablet
58128366|NCT03767088|DEVICE|WB-EMS|whole body electromyostimulation
58128367|NCT03767088|OTHER|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
58453575|NCT00764361|DRUG|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
58453576|NCT00764361|DRUG|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
58453577|NCT00031473|DRUG|Virazole (Ribavirin) Inhalation Solution|
58453578|NCT06262308|BEHAVIORAL|Psychological intervention along Cognitive Behavioural Therapy principles|Women who have PPROM will be offered a series of 6 sessions with a Clinical Psychologist
57754959|NCT04670692|OTHER|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
57754960|NCT04670692|OTHER|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
57754961|NCT03373526|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
57754962|NCT03373526|OTHER|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
57754963|NCT03684122|BIOLOGICAL|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
57754964|NCT02577055|PROCEDURE|myomectomy|Surgical ablation of all fibroids
57754965|NCT02577055|PROCEDURE|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of \>500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
57754966|NCT05147948|BEHAVIORAL|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
57754967|NCT00002488|DRUG|cisplatin|
57754968|NCT00002488|DRUG|cyclophosphamide|
57754969|NCT00002488|DRUG|etoposide|
57754970|NCT01361425|DRUG|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
57754971|NCT01361425|DRUG|placebo|placebo 500mg 8/8h, orally
57754972|NCT02073825|BEHAVIORAL|Web Brief Intervention (WBI)|4-session WBI
57754973|NCT02454192|BEHAVIORAL|CHAMPS|
57754974|NCT02028026|DRUG|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
57754975|NCT02028026|DRUG|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
57754976|NCT03160989|OTHER|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
57754977|NCT05232864|DRUG|Secukinumab|300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
58128368|NCT03811080|DRUG|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
58128369|NCT03811080|DRUG|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
58128370|NCT03811080|DRUG|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
58128371|NCT02083315|DRUG|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
58128372|NCT02083315|DRUG|TRV130 3 mg|TRV130 3 mg IV x 1 dose
58128373|NCT02083315|DRUG|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
58128374|NCT02083315|DRUG|Morphine 10 mg|Morphine 10 mg IV x 1 dose
58128375|NCT02083315|DRUG|Placebo|Dextrose 5% in water IV x 1 dose
58128376|NCT00449150|DRUG|Cetrorelix 78 mg + 78 mg|
58128377|NCT00449150|DRUG|Cetrorelix 78 mg + 52 mg|
58128378|NCT00449150|DRUG|Placebo|
58128379|NCT05153265|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
58128380|NCT03501680|DRUG|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
58128381|NCT03501680|DEVICE|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
58128382|NCT01806090|DRUG|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
57754978|NCT04065503|BIOLOGICAL|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
57754979|NCT04292782|PROCEDURE|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
57754980|NCT04292782|PROCEDURE|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
57754981|NCT06391710|DRUG|HRS9531|subcutaneous
57754982|NCT06391710|DRUG|Placebo|subcutaneous
57754983|NCT00691938|DRUG|LBH589|
57754984|NCT00691938|DRUG|Decitabine|
57754985|NCT02805426|DRUG|Tranexamic Acid|
57754986|NCT02805426|DRUG|Placebo|
57754987|NCT02805426|DRUG|Misoprostol|
57754988|NCT02123602|OTHER|core stabilization|
57754989|NCT02123602|OTHER|lower extremity training only|
57754990|NCT02623465|DRUG|Insulin Lispro|Administered subcutaneously (SC)
57754991|NCT03359070|DRUG|Dapaconazole|Application of 1 gram on the lesion.
57754992|NCT03359070|DRUG|Miconazole Nitrate|Application of 1 gram on the lesion.
57754993|NCT05994144|OTHER|VIDEO OBSERVED THERAPY|Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
58128383|NCT01806090|OTHER|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
57754994|NCT02635802|DRUG|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
57754995|NCT02635802|DRUG|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
58128384|NCT06441396|OTHER|Telerehabilitation|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. The individuals in this group were made to do the exercises together online via the WhatsApp program. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The main program consists of 15 calisthenic exercises involving the lower extremity, upper extremity and trunk large muscle groups. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The number of repetitions of each exercise started with 10 and was increased by 5 repetitions every two weeks until it reached 20 repetitions.
58128385|NCT06441396|OTHER|Video-based rehabilitation (VTR)|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. Participants were asked to exercise by watching these videos. In addition, these individuals were interviewed once a week to check the progress of the exercise program. Video images were sent to the intervention group for informational purposes, and the individuals in this group were made to do the exercises together online via the WhatsApp program.
58128386|NCT02490709|PROCEDURE|Local excision|Local excision for rectal cancer with good response
57754996|NCT02635802|DRUG|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
57754997|NCT02635802|DRUG|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
57754998|NCT04176380|BIOLOGICAL|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
57754999|NCT05570643|DRUG|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
57755000|NCT05570643|DRUG|Placebo|Injection of NaCl 0.9%.
57755001|NCT02253355|DEVICE|Deep Brain Stimulation|
57755002|NCT01677143|DRUG|Bupivacaine 5mg/ml|5 ml in trocar area
57755003|NCT00156143|PROCEDURE|Blood sample|
58128387|NCT01759199|PROCEDURE|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
58128388|NCT02885337|OTHER|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
58453579|NCT05230628|DEVICE|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
58453580|NCT05230628|DEVICE|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
57755004|NCT00156143|PROCEDURE|Radiography|
57755005|NCT06454617|OTHER|Phantom|The patients will be simultaneously scanned with a QCT phantom
57755006|NCT01669798|DRUG|BIBF 1120|PO 200mg BID
57755007|NCT06405399|OTHER|Educational intervention. observation guide|An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).
57755008|NCT01207570|PROCEDURE|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
57960802|NCT04726371|BEHAVIORAL|Generic Best Practices|GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy.
57755009|NCT01207570|PROCEDURE|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
57755010|NCT02422602|DRUG|Xarelto|Taking conventional charge
57755011|NCT02422602|OTHER|Experimental: Personalized information intervention|
57755012|NCT04309916|DRUG|Tegoprazan|Tegoprazan 50mg tablet
57755013|NCT04309916|DRUG|Esomeprazole|Esomeprazole 40mg tablet
57755014|NCT04204369|OTHER|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~* An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~* A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
57755015|NCT04663451|RADIATION|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
57755016|NCT04930692|DIAGNOSTIC_TEST|Contrast-enhanced CT lymphography with the periareolar injection of iopamidol|"Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator."
57755017|NCT05029258|PROCEDURE|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
57755018|NCT05029258|DIAGNOSTIC_TEST|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
58128389|NCT02885337|OTHER|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
58128390|NCT02327195|DRUG|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
58453581|NCT06122623|OTHER|Health Education|As previously mentioned, the intervention for this study will be a gaming education program that will be conducted once with each participant. Implementation of the program will occur at different times. Each performance will include a maximum of 60 participants who will be divided into small groups within the same room. Seven to 10 participants will comprise a small group, and each group will have one facilitator. The facilitator will be either a member of the research team or a Health lecturer who will be recruited and trained by the Japanese and Indonesian research teams.
58453582|NCT02318563|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
58453583|NCT02318563|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol
58453584|NCT04924985|OTHER|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
58453585|NCT04924985|OTHER|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
58453586|NCT05616923|DRUG|Trametinib|Topical cream containing 0.1 mg/g trametinib
57755019|NCT05129943|DEVICE|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
57755020|NCT05129943|DEVICE|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
58128391|NCT02327195|DRUG|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
58128392|NCT05216536|OTHER|No intervention|No intervention
58128393|NCT05586061|DRUG|Disitamab vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
58128394|NCT05586061|DRUG|Tislelizumab|Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
58128395|NCT05586061|DRUG|S1|S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
58128396|NCT00868400|DIETARY_SUPPLEMENT|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
58128397|NCT00868400|DIETARY_SUPPLEMENT|flavored water|will be given in doses equal to those of high-carbohydrate beverage
58128398|NCT03215108|DEVICE|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
58128399|NCT05086523|DEVICE|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
58458749|NCT04607486|DIAGNOSTIC_TEST|3DfUS and IPSA of leg muscles|"1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
58458750|NCT00061659|DRUG|ABT-510 - Thrombospondin-1 mimetic|
57755021|NCT05224258|DEVICE|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
58453587|NCT02136966|OTHER|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
58453588|NCT01365728|PROCEDURE|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
58453589|NCT03254199|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
58453590|NCT03254199|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
58453591|NCT00596986|DRUG|Duloxetine|Duloxetine 30mg up to 120mg per day.
58453592|NCT00596986|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
58453593|NCT06346834|BIOLOGICAL|sIPV|One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
58453594|NCT06400914|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear.
58453595|NCT06400914|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear.
58453596|NCT06474078|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
58453597|NCT06273150|OTHER|Positive genetic test for pathological expansion in ATN1|Positive genetic test for pathological expansion in ATN1
58453598|NCT02537249|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
58453599|NCT02537249|DRUG|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
58453600|NCT00102765|DRUG|fluticasone propionate/salmeterol powder|
58453601|NCT00102765|DRUG|fluticasone propionate powder|
58453602|NCT00485017|DRUG|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
58453603|NCT00485017|DRUG|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
58453604|NCT02966808|BEHAVIORAL|cognitive and behavioural questionnaires|
58453605|NCT02763839|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
57755022|NCT05493592|BIOLOGICAL|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
58453606|NCT02763839|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
58453607|NCT02763839|DRUG|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
57755023|NCT00709462|BIOLOGICAL|CDX1307|
57755024|NCT02355067|BEHAVIORAL|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
58453608|NCT02599363|DRUG|Ribociclib (LEE011)|
58453609|NCT02599363|DRUG|Paclitaxel|
58453610|NCT04075344|OTHER|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
58453611|NCT03992352|DIAGNOSTIC_TEST|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
58453612|NCT05402514|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with subacromial shoulder pain consist of two daily distributed and progressively adaptable exercises there are delivered through the app as videos with subtitles. Patient education is provided 2-3 times per week as short lessons in the app with a quiz following the text to ensure that the information is properly understood by the patients. An individual physical therapist is assigned to each patient with compulsory telephone or video consultations at the start of the treatment, at 6 weeks and at 3 months. An asynchronous chat function with the physical therapist is available during the treatment period as well as a peer support chat.
58453613|NCT04537793|DRUG|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
58453614|NCT04537793|DRUG|IVA|Granules for oral administration.
58453615|NCT01693549|DRUG|Cabazitaxel|
58453616|NCT05661344|DRUG|BI 1015550|BI 1015550
58458751|NCT00689390|BIOLOGICAL|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
58128400|NCT05086523|DEVICE|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
58128401|NCT01432977|DRUG|paracetamol /droperidol|
58128402|NCT01432977|DRUG|paracetamol / ondansetron|
58128403|NCT01649622|DRUG|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
58128404|NCT00214279|DRUG|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
58128405|NCT03125200|DRUG|ADCT-502|Intravenous Infusion
58315141|NCT06069362|OTHER|Manual physiotherapy and neurodynamic exercises|"* Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability."
57755025|NCT02355067|BEHAVIORAL|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
57755026|NCT03835325|DIETARY_SUPPLEMENT|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
57755027|NCT00367965|DRUG|Eszopiclone|eszopiclone 3 mg
57755028|NCT00367965|DRUG|placebo|placebo tablet
57755029|NCT04547725|OTHER|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
57755030|NCT03203655|BEHAVIORAL|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
57755031|NCT03203655|BEHAVIORAL|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
57755032|NCT02330432|BIOLOGICAL|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
57755033|NCT02330432|OTHER|Best standard care|Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
57755034|NCT05129267|OTHER|Group B|Scaling and Root debridement + iPRF
57755035|NCT05129267|OTHER|Group C|Scaling and Root debridement + iPRF together with vitamin C
57755036|NCT00948974|BEHAVIORAL|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
57755037|NCT00948974|BEHAVIORAL|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
57960803|NCT04726371|BEHAVIORAL|Tailored Best Practices|TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization.
58128406|NCT06242756|PROCEDURE|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
58128407|NCT02534779|OTHER|Placebo Vaginal Insert|Placebo insert
58128408|NCT02854280|BIOLOGICAL|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
58128409|NCT02854280|BIOLOGICAL|Isolated contractions of the quadriceps|Until exhaustion
58315142|NCT05635617|PROCEDURE|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
58315143|NCT02898467|OTHER|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
58315144|NCT02898467|OTHER|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
58315145|NCT05053867|DRUG|tranexamic acid|Inhaled
58128410|NCT02567968|DRUG|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
58128411|NCT02567968|DRUG|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
58315146|NCT05053867|OTHER|Usual Care|Standard of Care
58315147|NCT02193295|BEHAVIORAL|Caloric Restriction|Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
58315148|NCT00706797|DRUG|etanercept (EnbrelTM)|
58453617|NCT03586713|DIAGNOSTIC_TEST|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
57755038|NCT04978155|DIAGNOSTIC_TEST|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
57755039|NCT00421434|DRUG|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
57755040|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
57755041|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
57755042|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
57755043|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
57755044|NCT03794622|OTHER|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
57755045|NCT03794622|OTHER|intramedullary nail fixation|intramedullary nail fixation only
57755046|NCT01058304|OTHER|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
57755047|NCT01058304|OTHER|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
57755048|NCT00980317|PROCEDURE|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
57755049|NCT00551252|DRUG|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
57755050|NCT02227875|DRUG|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
57755051|NCT02227875|DRUG|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
57755052|NCT01972633|PROCEDURE|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
58453618|NCT01207258|BEHAVIORAL|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
57755053|NCT01972633|PROCEDURE|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
57755054|NCT04258956|DRUG|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
57755055|NCT02749357|DEVICE|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
57755056|NCT02749357|DEVICE|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
57755057|NCT02003352|PROCEDURE|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
58315149|NCT00706797|DRUG|methotrexate|
58315150|NCT02799524|OTHER|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
58315151|NCT06190028|DEVICE|Iridium A Gel|IRIDIUM® A gel is a sterile, preservative free ophthalmic gel, containing Carbopol, amino acids, Echinacea and Aloe extract. IRIDIUM® A gel is indicated for the protection of the eye surface particularly at night, even in the presence of changes in histological continuity and blepharitic conditions, including those of an iatrogenic nature, following the use of hypotonic eye drops and of the preservatives contained therein.
58453619|NCT05612308|OTHER|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
57755058|NCT00261495|DRUG|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
57755059|NCT00261495|DRUG|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
57755060|NCT00808574|BEHAVIORAL|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
57755061|NCT06434948|DRUG|Omega-3 Ethyl Esters 4 g|4 grams = 4 capsules, once daily
57755062|NCT06434948|DRUG|Omega-3 Ethyl Esters 2 g|2 grams = 2 capsules, once daily
57755063|NCT00325364|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
57755064|NCT00325364|DRUG|Injectable insulin|patient specific dose, injectable, before meals, 24 months
57755065|NCT00404495|DRUG|Irinotecan|Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
57755066|NCT00404495|DRUG|Temozolomide|Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
57755067|NCT03045848|DEVICE|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
57755068|NCT03279835|OTHER|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
57755069|NCT03279835|OTHER|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
57755070|NCT02094443|DRUG|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
57755071|NCT02094443|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
57755072|NCT00218881|PROCEDURE|HIV educational video|
57755073|NCT03684486|BEHAVIORAL|rehabilitation by effort|
58453620|NCT01794000|DRUG|Prasugrel|Administered orally
58453621|NCT01794000|DRUG|Placebo|Administered orally
58453622|NCT01204177|DRUG|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
57755074|NCT00003092|DRUG|paclitaxel|
57755075|NCT02571270|OTHER|Combined aerobic and resistance physical training program|
57755076|NCT00676182|OTHER|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
57755077|NCT06144424|DRUG|Oral EP262|Once daily
58453623|NCT05555875|BEHAVIORAL|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
58453624|NCT03669367|DRUG|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
57755078|NCT06144424|DRUG|Placebo|Once Daily
57755079|NCT02961530|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
57755080|NCT02961530|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
57755081|NCT04193839|OTHER|Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)|Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
57755082|NCT05584891|PROCEDURE|mastoidectomy and mastoid oblitration|Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
57755083|NCT04997707|DRUG|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
57755084|NCT04997707|DRUG|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
57755085|NCT04997707|DIAGNOSTIC_TEST|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
57755086|NCT04882774|DRUG|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
57755087|NCT00019539|DRUG|bevacizumab|
58453625|NCT03669367|DRUG|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
58453626|NCT03189537|DRUG|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
58453627|NCT03189537|DRUG|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
58453628|NCT01182155|PROCEDURE|Exhaled Breath Sampling|Standard of care
57755088|NCT00019539|DRUG|thalidomide|
57755089|NCT04418635|DIETARY_SUPPLEMENT|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
57755090|NCT01518855|DRUG|Nifedipine (Adalat, BAYA1040)|
57755091|NCT01518855|DRUG|Amlodipine (Norvasc)|
58453629|NCT00176774|DRUG|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
58453630|NCT00176774|DRUG|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
58453631|NCT00176774|DRUG|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
58453632|NCT00176774|DRUG|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
58453633|NCT01906333|OTHER|Exercise|
58453634|NCT01906333|OTHER|Glucose|
58453635|NCT01906333|OTHER|Fasted|
58453636|NCT01473290|DIETARY_SUPPLEMENT|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
58453637|NCT01473290|OTHER|placebo|Given PO
58453638|NCT02602093|PROCEDURE|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
58453639|NCT02602093|PROCEDURE|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
58453640|NCT04337424|DIAGNOSTIC_TEST|Sampling salivary|Collection of 1 to 2 ml of saliva
58453641|NCT00082498|DRUG|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
58453642|NCT00082498|DRUG|Placebo|Patients in Group 1 will receive placebo.
58453643|NCT05772819|DIAGNOSTIC_TEST|exercise MRI|All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
58453644|NCT02109640|DRUG|Targinact|Post-operative analgesia
58453645|NCT02109640|DRUG|Oxycodone|Postoperative analgesia
58453646|NCT02109640|PROCEDURE|Laparoscopic segmental colectomy|
58453647|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
58453648|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
57755092|NCT01518855|DRUG|Diovan|
57755093|NCT03831321|DRUG|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
57755094|NCT03831321|DEVICE|Cystoscopy|Diagnostic cystoscopy
57755095|NCT03831321|DRUG|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
57755096|NCT00435279|DRUG|Eszopiclone|Eszopiclone 3 mg
57755097|NCT00435279|DRUG|Placebo|Placebo
57755098|NCT00435279|DRUG|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
57755099|NCT03358056|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
58453649|NCT06344403|DRUG|analgesic|Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.
58453650|NCT06344403|BEHAVIORAL|Tender point infiltration|Lidocaine mixed with diprospan injected into tender points.
58128412|NCT06004102|OTHER|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
58453651|NCT04665271|BEHAVIORAL|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
58453652|NCT06392958|OTHER|Traditional Chinese Medicine exercises - Baduanjin|According to the four steps of the cross-theoretical model, the behavior stage (pre-intention stage, intention stage, preparation stage, action stage and maintenance stage) and the family empowerment (clarify the problem, express the emotion, formulate the plan, implement the plan, and evaluate the effect). Combined with the characteristics of elderly patients after PCI, the cardiac rehabilitation management plan was designed focusing on the timing of cardiac rehabilitation, the way of health guidance, safety and compliance management.
58453653|NCT02506712|DEVICE|SmartDrive assisting device|oxygen consumption
58453654|NCT02506712|DEVICE|Standard manuel wheelchair|oxygen consumption
58453655|NCT01841879|BEHAVIORAL|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
58453656|NCT01841879|BEHAVIORAL|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
58453657|NCT02428192|BIOLOGICAL|Ipilimumab|Given IV
58453658|NCT02428192|OTHER|Laboratory Biomarker Analysis|Correlative studies
58453659|NCT02428192|BIOLOGICAL|Nivolumab|Given IV
58453660|NCT01262807|OTHER|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
58453661|NCT05187819|DIAGNOSTIC_TEST|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
58453662|NCT04550637|DRUG|Oral apixaban|apixaban (5 mg bid) is given until 12 weeks after surgery
58453663|NCT00424944|BIOLOGICAL|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
58453664|NCT00424944|BIOLOGICAL|GMZ2 malaria vaccine|100 micrograms of GMZ2
58453665|NCT00424944|BIOLOGICAL|Verorab vaccine|Anti-rabies vaccine
58453666|NCT04194268|RADIATION|Carbon Ion|12 x 4 Gy (RBE)
58128413|NCT03164603|DRUG|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
58128414|NCT04860492|DIETARY_SUPPLEMENT|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
58128415|NCT05293353|OTHER|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
58128416|NCT01624519|PROCEDURE|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
58128417|NCT02946385|BIOLOGICAL|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
58128418|NCT02946385|BIOLOGICAL|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
58453667|NCT02677168|DEVICE|cNEP|continuous negative external pressure
58453668|NCT01191723|DRUG|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
58453669|NCT01191723|DRUG|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
58453670|NCT01191723|DRUG|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
58453671|NCT01191723|DRUG|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
58453672|NCT03564717|OTHER|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
58453673|NCT01896024|BEHAVIORAL|Psychiatric Management|
58453674|NCT01896024|BEHAVIORAL|Motive-oriented therapeutic relationship/Plan Analysis|
58453675|NCT01860287|DRUG|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
58453676|NCT01860287|DRUG|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
58453677|NCT01860287|DRUG|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
58453678|NCT01576289|OTHER|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
58128419|NCT00658398|BEHAVIORAL|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
58453679|NCT04593108|DEVICE|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
58453680|NCT04593108|DRUG|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
58453681|NCT00550953|DRUG|telmisartan+amlodipine|
58453682|NCT00550953|DRUG|telmisartan|
58453683|NCT05006235|DRUG|Epinephrine Inhalation Solution|
57755100|NCT03403322|OTHER|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
57755101|NCT03403322|OTHER|Without taping|Children performed functional activities without tape
57755102|NCT02605564|OTHER|Gluten Free Diet|Gluten Free Diet
57755103|NCT02605564|OTHER|Placebo|Placebo No intervention, standard T1DM diet
57755104|NCT06320886|DIAGNOSTIC_TEST|Diagnostic Test|Use both ultrasonography and Computed tomography scan to diagnose the causes of Acute Abdominal Pain in Adults.
57755105|NCT02481284|DEVICE|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
57755106|NCT03362359|DRUG|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
57755107|NCT04896632|DRUG|INE 963|Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
57755108|NCT04896632|OTHER|Placebo|Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
57755109|NCT04031482|OTHER|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts"
58453684|NCT05006235|DRUG|Salbutamol|
57755110|NCT01875185|DRUG|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
57755111|NCT02551523|DRUG|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
57755112|NCT02551523|DRUG|Standard of care combinational antiretroviral therapy|
57755113|NCT01713725|BIOLOGICAL|Omalizumab|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
57755114|NCT01713725|BIOLOGICAL|Placebo|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
58453685|NCT05006235|DRUG|Saline Inhalants|
57755115|NCT01330602|BEHAVIORAL|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy"
57755116|NCT04550325|BIOLOGICAL|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
57755117|NCT00571961|DRUG|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
57755118|NCT00571961|DRUG|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
57755119|NCT00571961|OTHER|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
57755120|NCT00628797|RADIATION|UVA1|intraindividual half body irradiation
57755121|NCT00628797|OTHER|UVA1|60 J/cm2 at least 36 tx
57755122|NCT05655754|DRUG|Methohexital|anesthesia during ECT
57755123|NCT05655754|DRUG|Ketofol|anesthesia during ECT
58315152|NCT04769297|DRUG|Sublingual Micro-Dose Ketamine|daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
58315153|NCT06184282|DRUG|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
58458752|NCT00689390|BIOLOGICAL|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
58458753|NCT00689390|BIOLOGICAL|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
57755124|NCT01389193|DRUG|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
57755125|NCT01389193|DRUG|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
57755126|NCT00002864|DRUG|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
57755127|NCT00002864|DRUG|tamoxifen citrate|20 mg PO for 5 years
57755128|NCT01650493|DEVICE|Clinpro 5000|Dentrifice containing 950ppm fluoride
57755129|NCT01650493|DEVICE|MI Paste Plus|Dentrifice containing 950ppm fluoride
57755130|NCT01650493|DEVICE|Tom's of Maine|Dentrifice that is fluoride free
58315154|NCT06184282|DRUG|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
58315155|NCT02131688|DRUG|Mitoxantrone Hydrochloride Liposome|
58315156|NCT06108921|DRUG|Xylitol Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
58315157|NCT06108921|DRUG|Salt Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
57755131|NCT01387555|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
57755132|NCT01387555|OTHER|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
57755133|NCT02707692|BIOLOGICAL|Fluarix|Intramuscular injection with Fluarix® .
57755134|NCT02707692|BIOLOGICAL|Pneumovax|Intramuscular injection with Pneumovax.
57960804|NCT01069497|OTHER|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
58453686|NCT04662008|BEHAVIORAL|Tele-coaching|This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
58453687|NCT04662008|BEHAVIORAL|Website|This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
58453688|NCT03306667|DRUG|FYU-981|Oral single dosing
58453689|NCT03832348|DEVICE|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
58453690|NCT01934257|OTHER|Marketed milk-based lactose-containing infant formula|
58453691|NCT01934257|OTHER|Marketed milk-based lactose-free infant formula|
58453692|NCT01934257|OTHER|Marketed soy-based lactose-free infant formula|
58453693|NCT04062110|DEVICE|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
58453694|NCT02360826|DRUG|Pravastatin|
58453695|NCT02360826|DRUG|Simvastatin|
58453696|NCT03487731|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
58453697|NCT03487731|DRUG|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
58453698|NCT01495208|DRUG|Aflibercept|intravitreal aflibercept injection 2mg
58453699|NCT00622037|DRUG|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
58453700|NCT00622037|DRUG|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
58453701|NCT00720590|DRUG|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
58453702|NCT00720590|DRUG|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
58453703|NCT00720590|DRUG|Placebo|Daily dose of placebo for 4 weeks
58453704|NCT04073121|DEVICE|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
58453705|NCT01667289|RADIATION|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
58453706|NCT01667289|DRUG|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
58453707|NCT04468581|BEHAVIORAL|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
58453708|NCT02911870|DRUG|SNAC|Oral administration
58453709|NCT02911870|DRUG|Placebo|Oral administration
57960805|NCT02163018|DRUG|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
57960806|NCT02163018|DRUG|Placebo|Subcutaneous administration of increasing doses of placebo
57960807|NCT00066079|PROCEDURE|massage|
58453710|NCT02911870|DRUG|Moxifloxacin|Oral administration
58453711|NCT02163824|DRUG|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
58453712|NCT02163824|DRUG|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
57755135|NCT02707692|OTHER|Placebo|Intramuscular injection with sterile saline (placebo).
57755136|NCT04513613|DEVICE|Procedure/Surgery: Robotic-PVI|Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
57960808|NCT00066079|BEHAVIORAL|relaxation|
57960809|NCT01523379|DRUG|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
57960810|NCT01523379|DRUG|Placebo|NaCl i.v. two times a day, two days in an row
57960811|NCT04195828|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
58453713|NCT02163824|DRUG|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
58453714|NCT02163824|DRUG|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
58453715|NCT03767621|OTHER|Indication of revascularization|Device: iFR/FFR
57755137|NCT03761303|DEVICE|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude\> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
57755138|NCT03761303|DEVICE|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
57755139|NCT03019510|BEHAVIORAL|No exercise|No exercise will be done on the day of the study night to be tested
57755140|NCT03019510|BEHAVIORAL|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
57755141|NCT03019510|BEHAVIORAL|Evening exercise|Evening exercise will be done on the day of the study night to be tested
57755142|NCT01111838|DRUG|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
57755143|NCT00605202|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
58453716|NCT06061939|OTHER|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
57755144|NCT00605202|DIETARY_SUPPLEMENT|Licorice|Licorice candy 32 grams a day for 14 days.
58453717|NCT03385655|DRUG|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
58453718|NCT03385655|DRUG|Savolitinib|600mg once daily, orally.
58453719|NCT03385655|DRUG|Darolutamide|600mg twice daily, orally.
58453720|NCT03385655|DRUG|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
58453721|NCT03385655|DRUG|Ipatasertib|400mg daily 3 weeks on, 1 week off
58453722|NCT03385655|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
57755145|NCT01218880|DRUG|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
57755146|NCT01218880|DRUG|M2ES 15mg|M2ES Dosage：15mg/m2
57755147|NCT01218880|DRUG|M2ES 30mg|M2ES Dosage：30mg/m2
57755148|NCT01218880|DRUG|M2ES 45mg|M2ES Dosage：45mg/m2
57755149|NCT05215067|DRUG|AK104|IV infusion,Specified dose on specified days
57755150|NCT05215067|DRUG|Docetaxel|IV infusion,Specified dose on specified days
57755151|NCT02165332|DRUG|Part 1: SAD RO7033877|Single dose
57755152|NCT02165332|DRUG|Part 1: SAD placebo|Single dose
57755153|NCT02165332|DRUG|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
57755154|NCT02165332|DRUG|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
57755155|NCT02165332|DRUG|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
57755156|NCT02165332|DRUG|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
57755157|NCT04260230|DEVICE|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
57755158|NCT02776332|PROCEDURE|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
57755159|NCT02390934|RADIATION|Radium 223|
57755160|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
57755161|NCT02347657|DRUG|Ivacaftor|Tablet, oral use
58453723|NCT03385655|DRUG|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
58453724|NCT01271556|DRUG|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
57755162|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
57755163|NCT02347657|DRUG|Ivacaftor placebo|Tablet, oral use
58453725|NCT01271556|PROCEDURE|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
58453726|NCT01271556|OTHER|Placebo|placebo, inhalatory (MDI) once
58453727|NCT00371592|DRUG|Acyclovir|800 mg tablet taken orally twice daily
58453728|NCT00371592|DRUG|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
58453729|NCT03129867|DRUG|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
58453730|NCT04830930|DRUG|CKD-381|single-dose, oral administration of CKD-381 1 tablet
58453731|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
58453732|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
58453733|NCT04766463|DRUG|Placebo|Saline Solution
58453734|NCT04766463|DRUG|Morphine|Morphine
58453735|NCT04168658|COMBINATION_PRODUCT|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
58458754|NCT00689390|DRUG|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
58453736|NCT04168658|BEHAVIORAL|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
58453737|NCT04344808|DEVICE|Dynamic navigation system|The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
58453738|NCT04344808|DEVICE|Freehand implant placement|Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
58453739|NCT04474678|OTHER|"My Logbook! - I know my way around!"|"Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment."
58453740|NCT04234620|DRUG|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
58453741|NCT01180465|DRUG|LIPO-102|LIPO-102 High dose
58453742|NCT01180465|DRUG|LIPO-102 Low|LIPO-102 Low dose
58453743|NCT01180465|DRUG|LIPO-102, Placebo|Placebo
58453744|NCT04908085|BEHAVIORAL|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
58453745|NCT05245201|OTHER|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
58453746|NCT05245201|OTHER|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
58453747|NCT02898363|OTHER|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
58453748|NCT03813888|OTHER|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
58453749|NCT03813888|OTHER|Usual Activity group|Usual after school activities at home.
58453750|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
58453751|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
58453752|NCT01766453|BEHAVIORAL|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
58453753|NCT01766453|BEHAVIORAL|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
58453754|NCT06079333|DRUG|dabrafenib/trametinib|braf/mek-inhibition
58453755|NCT04333368|BIOLOGICAL|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
58453756|NCT04333368|OTHER|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
58453757|NCT03635463|DEVICE|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
58453758|NCT03635463|DEVICE|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
57755164|NCT00375154|DEVICE|Noninvasive Positive-Pressure Ventilation (NPPV)|
58453759|NCT06368258|DIETARY_SUPPLEMENT|Red yeast rice|Red yeast rice 160 mg (total monacolins 2.8 mg)
58453760|NCT06368258|OTHER|Placebo|Placebo
58453761|NCT02401685|OTHER|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
58453762|NCT02401685|PROCEDURE|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
58453763|NCT02730728|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
58453764|NCT02730728|DRUG|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
58453765|NCT02730728|DRUG|5ml bolus of 0.5% ropivicaine|Local anesthetic
58453766|NCT05694455|DIAGNOSTIC_TEST|Starling Stroke Volume (Starling SV)- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an Starling SV device to look at Stroke Volume change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
58453767|NCT05694455|DIAGNOSTIC_TEST|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging performed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
57755165|NCT00352482|DRUG|Sildenafil (50 mg)|
57755166|NCT03264651|DRUG|enobosarm|Oral combination therapy of enobosarm and anastrozole
57755167|NCT00169559|DRUG|GW590735|1µg to 20µg daily doses of GW590735
57755168|NCT00169559|DRUG|fenofibrate|Marketed Drug
57755169|NCT05097846|DRUG|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
57755170|NCT05097846|DRUG|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
57755171|NCT05097846|DRUG|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
57755172|NCT05097846|DRUG|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
57755173|NCT00736307|PROCEDURE|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
57755174|NCT03117595|DRUG|Bupivacaine-fentanyl|Dosages as previously written
57755175|NCT03117595|DRUG|Bupivacaine-fentanyl morphine|Dosage as previously written
57755176|NCT04077619|BEHAVIORAL|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
57755177|NCT04077619|BEHAVIORAL|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
57755178|NCT05838261|PROCEDURE|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
57755179|NCT01646593|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
57755180|NCT01942681|DRUG|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
57755181|NCT04209725|DRUG|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
57755182|NCT04209725|DRUG|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
57755183|NCT06427655|DEVICE|SALAD intubation|SALAD suction during intubation
57755184|NCT01171092|DRUG|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
57755185|NCT00615732|PROCEDURE|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
57755186|NCT00615732|PROCEDURE|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
57755187|NCT01576822|OTHER|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
57755188|NCT02384564|DEVICE|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
57755189|NCT02384564|DEVICE|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
57755190|NCT02462525|DRUG|ABBV-838|Varying doses of ABBV-838
57755191|NCT02462525|DRUG|Pomalidomide|Administered orally per the label.
57755192|NCT02462525|DRUG|Dexamethasone|Administered orally per the label.
57755193|NCT01760421|DRUG|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
57755194|NCT01061333|DRUG|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
57755195|NCT01061333|DRUG|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
57755196|NCT01061333|DRUG|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
57755197|NCT01061333|DRUG|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
57755198|NCT03320616|DRUG|EYP001a|Oral EYP001a capsules - 100 mg strength
57960812|NCT04195828|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
57960813|NCT04195828|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
58453768|NCT05694455|DIAGNOSTIC_TEST|Venous Excess Ultrasound Scoring (VExUS)|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the Inferior Vena Cava diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
57755199|NCT06265272|DRUG|Injection of a gadolinium contrast agen|"All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;"
57755200|NCT06265272|DRUG|Radiotracer Injection|"All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan"
57755201|NCT06265272|DIAGNOSTIC_TEST|Imaging|PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
57755202|NCT05961852|DEVICE|Angioplasty|Angioplasty with cutting and drug-coated balloon
57755203|NCT02659787|DRUG|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
57755204|NCT02659787|DRUG|Placebo|Placebo
57755205|NCT00335582|DRUG|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
57755206|NCT03138174|DEVICE|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
57755207|NCT05713201|PROCEDURE|Percutaneous Coronary Intervention|Treatment of coronary stenoses with a drug-eluting stent or balloon
58315158|NCT04249024|DEVICE|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
58453769|NCT05694455|OTHER|Urine Collection|The urine assay is collected passively from the patient will be ran through a Dimethylmethylene blue (DMMB assay)- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
58453770|NCT05004831|DRUG|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
58453771|NCT06543901|PROCEDURE|Submuscular plating|the patient was fixed with a submuscular plate
57755208|NCT05135416|PROCEDURE|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
57755209|NCT05135416|PROCEDURE|Control group|control of consciousness listening to bowel sounds assessment of pain
57755210|NCT02817035|DEVICE|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
57755211|NCT02608398|OTHER|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
57755212|NCT04635579|DEVICE|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
57755213|NCT03559101|OTHER|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
57755214|NCT03559101|OTHER|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
57960814|NCT04195828|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
58315159|NCT04249024|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
58315160|NCT04249024|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
58315161|NCT01979900|DRUG|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
58453772|NCT06543901|PROCEDURE|Traction and casting|the patient was placed on a traction with a thomas splint and then was casted with a hip spica
58458755|NCT00689390|OTHER|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
58458756|NCT04127721|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
57755215|NCT03559101|OTHER|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
57755216|NCT03559101|OTHER|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
57755217|NCT03559101|OTHER|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
57755218|NCT00791843|DRUG|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
57755219|NCT02389257|DEVICE|MINIMAG / MEG|
57755220|NCT02389257|DEVICE|MINIMAG / ECG|
57755221|NCT02131870|DIETARY_SUPPLEMENT|L plantarum DSM 9843 or placebo|
57755222|NCT01722760|PROCEDURE|measurements|
57755223|NCT00414739|DRUG|Benzalkonium chloride|
57755224|NCT06155708|DIETARY_SUPPLEMENT|Ketone|- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
57755225|NCT06155708|DIETARY_SUPPLEMENT|Water|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
57755226|NCT06170164|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
57755227|NCT03471663|DRUG|D-0502|oral tablets
57755228|NCT03471663|DRUG|palbociclib|standard dose of palbociclib
57755229|NCT00004902|DRUG|tocladesine|
57755230|NCT04577677|DEVICE|brain stimulation|tDCS and peripheral nerve stimulation
57755231|NCT04647032|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
57755232|NCT05194306|DRUG|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
57755233|NCT03720938|OTHER|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
58315162|NCT01979900|DRUG|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
58458757|NCT04127721|DRUG|Busulfan|Given IV
58458758|NCT04127721|DRUG|Fludarabine|Given IV
58458759|NCT04127721|DRUG|Itacitinib|Given PO
57755234|NCT01288274|OTHER|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
57755235|NCT04737902|PROCEDURE|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
57755236|NCT02438943|OTHER|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
57755237|NCT02438943|OTHER|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
57755238|NCT02662062|DRUG|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
57755239|NCT02662062|DRUG|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
57755240|NCT02662062|RADIATION|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
57755241|NCT04393298|DRUG|ginisortamab|Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
57755242|NCT04393298|DRUG|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
57755243|NCT04393298|DRUG|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
57960815|NCT02570633|OTHER|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
58315163|NCT01658839|DRUG|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
58458760|NCT04127721|DRUG|Methotrexate|Given IV
58458761|NCT04127721|DRUG|Tacrolimus|Given IV and PO
58458762|NCT02694744|DRUG|patiromer|8.4 g/day starting dose, administered orally
57755244|NCT05747963|DEVICE|software-delivered CBT-I|The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
57755245|NCT05747963|OTHER|online PE|Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
57755246|NCT01944202|BEHAVIORAL|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
57755247|NCT00220974|BEHAVIORAL|Internet-based tailored advice on cardiovascular risk|
57755248|NCT02681614|DEVICE|Uronav guided biopsy|"All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.~Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum."
57755249|NCT02681614|DEVICE|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
57755250|NCT01870193|DIETARY_SUPPLEMENT|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
57755251|NCT06423040|OTHER|Social Media Chatbot on Physical Activity Education|a social media chatbot was used to provide a continuous and real-time multimedia health education program on physical activity for the older adults, as well as supportive messages and feedbacks.
57755252|NCT03945838|OTHER|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
57755253|NCT03888664|DRUG|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
57755254|NCT01122381|DRUG|ethosuximide|ethosuximide (ESX)
57755255|NCT01122381|OTHER|placebo comparator|placebo
57755256|NCT00432081|DRUG|indomethacin|
57755257|NCT02681302|DRUG|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
57755258|NCT02681302|DRUG|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
57755259|NCT05545982|PROCEDURE|Video laryngoscope with Miller approach|Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
57755260|NCT00810836|DRUG|BG00012|oral
57755261|NCT00810836|DRUG|BG00012|Oral
57755262|NCT00810836|DRUG|placebo|oral placebo
57755263|NCT05957926|PROCEDURE|hyaluronic acid added to hydroxyapetite|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
57755264|NCT05957926|PROCEDURE|Hydroxyapatite alone|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
57755265|NCT04309084|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
57755266|NCT01622010|BEHAVIORAL|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
57960816|NCT02570633|OTHER|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
58458763|NCT06091696|OTHER|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
58458764|NCT06091696|OTHER|Aerobic exercises|Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).
57755267|NCT01622010|OTHER|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
58453773|NCT01735448|OTHER|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
57755268|NCT01622010|DEVICE|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
57755269|NCT01083654|BEHAVIORAL|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
57755270|NCT01083654|BEHAVIORAL|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
57755271|NCT05100043|BIOLOGICAL|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
57755272|NCT04692792|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
57755273|NCT04692792|DIETARY_SUPPLEMENT|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
57755274|NCT06496217|DRUG|MBX 2109|Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)
57755275|NCT06496217|DRUG|MBX 2109|Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)
57755276|NCT06496217|DRUG|MBX 2109|Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis
57755277|NCT06496217|DRUG|MBX 2109|Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
57755278|NCT00153998|DRUG|Cetuximab|
57755279|NCT00153998|PROCEDURE|Liver resection|
57755280|NCT00153998|DRUG|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
57755281|NCT00153998|DRUG|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
57755282|NCT03917004|DRUG|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
57755283|NCT04152265|PROCEDURE|colonoscopy|colonoscopy
57755284|NCT04152265|OTHER|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
57755285|NCT04152265|OTHER|demographic data collections|completing the demographic questionnaire
57755286|NCT04152265|OTHER|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
57755287|NCT04152265|PROCEDURE|Collecte the biological samples|blood and faeces collections
57755288|NCT01558310|DRUG|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
57755289|NCT01558310|DRUG|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
57755290|NCT03551275|BIOLOGICAL|BCD-132|Dose Escalation Study
58128420|NCT02899390|BEHAVIORAL|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
58315164|NCT00565461|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
57755291|NCT01383889|OTHER|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
57755292|NCT00917163|DEVICE|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
57755293|NCT00917163|DEVICE|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
58315165|NCT03746509|DEVICE|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
58315166|NCT03746509|DEVICE|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
58315167|NCT04140110|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
58315168|NCT05404100|PROCEDURE|Aortic valve replacement|SAVR or TAVR
58453774|NCT01735448|OTHER|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
57755294|NCT02417103|DRUG|GLP-1 (Liraglutide)|GLP-1 Analogon
57755295|NCT02417103|DRUG|Placebo|Placebo
57755296|NCT03975699|OTHER|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
57755297|NCT04454398|BIOLOGICAL|COVI-GUARD|COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein
57755298|NCT04454398|OTHER|Standard of Care|Standard of Care as determined by the Investigator
57755299|NCT04454398|DRUG|Placebo|Diluent
57755300|NCT04773795|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
57755301|NCT04654988|DRUG|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
57755302|NCT04654988|DRUG|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
57755303|NCT04654988|DRUG|Placebo Prednisone|Placebo Prednisone
57755304|NCT04654988|DRUG|Placebo Azathioprine|Placebo Azathioprine
57755305|NCT05100264|OTHER|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
57755306|NCT05100264|OTHER|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
57755307|NCT03154502|DIAGNOSTIC_TEST|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
57755308|NCT00626730|PROCEDURE|adjuvant therapy|
57755309|NCT00626730|RADIATION|radiation therapy|
57755310|NCT02091479|DRUG|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
57755311|NCT02091479|DRUG|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
57755312|NCT04436666|DEVICE|motivational video production through virtual reality glasses|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
57755313|NCT04436666|OTHER|Ice Application|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
58315169|NCT05694650|BEHAVIORAL|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
57755314|NCT01128803|PROCEDURE|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration \> 2mm
57755315|NCT01245946|PROCEDURE|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
57755316|NCT01245946|DRUG|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
57755317|NCT05616364|DRUG|Dexmedetomidine injection|Dexmedetomidine intravenous
57755318|NCT05616364|DRUG|Tramadol|Tramadol intravenous
57960817|NCT05493020|OTHER|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
58453775|NCT01735448|OTHER|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
58453776|NCT05011227|DRUG|Camrelizumab|2 cycles Camrelizumab before endoscopic surgery and one year after
58453777|NCT05011227|DRUG|Chemotherapy|2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
58453778|NCT05011227|PROCEDURE|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
58453779|NCT04839939|OTHER|Conventional physical therapy|Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
58453780|NCT04839939|OTHER|Ankle Foot Orthosis|Solid prescribed AFO with a wearing schedule of 6-12 hours per day
58453781|NCT04839939|OTHER|Combination Taping|Combination between elastic and inelastic taping
58453782|NCT04390126|OTHER|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
58453783|NCT04390126|OTHER|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
58453784|NCT04406766|DEVICE|Connected nutrition pump system|"For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution."
58453785|NCT06028997|BEHAVIORAL|Behavioral and Sleep Hygiene Education with Mindfulness Intervention|Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
58453786|NCT02329470|PROCEDURE|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
58453787|NCT01225614|DEVICE|Bilevel pressure ventilator|Nocturnal home ventilation
58453788|NCT03250637|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
58453789|NCT01879683|DRUG|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
58453790|NCT03143530|PROCEDURE|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
58453791|NCT03143530|DRUG|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
58453792|NCT03143530|DRUG|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
58453793|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
57960818|NCT03355183|OTHER|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
57755319|NCT04777812|DIAGNOSTIC_TEST|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
57755320|NCT04000841|BEHAVIORAL|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~* Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~* User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~* Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~* User-customized reminders to do specific meditations and display personally selected images or messages."
57755321|NCT03626779|OTHER|Prf|Take 10cc blood from patient and gain prf blug
58453794|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
58453795|NCT06518044|DRUG|N Acetyl L Cysteine|For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
58453796|NCT04445142|PROCEDURE|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
58453797|NCT00731419|DEVICE|SEMS|Comparing plastic and metal stents
58128421|NCT00582400|DRUG|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
58128422|NCT03288766|PROCEDURE|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
58453798|NCT01751984|DRUG|ETC-1002|Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
58453799|NCT01751984|DRUG|Placebo|Placebo once daily for 8 weeks
58453800|NCT00001716|DRUG|Nitric Oxide|
58453801|NCT00001716|DRUG|Nitroglycerin|
58453802|NCT02202239|DRUG|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
58453803|NCT02202239|DRUG|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
58453804|NCT02202239|DRUG|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
58453805|NCT02202239|DRUG|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
58453806|NCT02202239|DRUG|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
58453807|NCT02202239|DRUG|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
58453808|NCT02202239|DRUG|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
58453809|NCT02202239|DRUG|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
58128423|NCT02837757|OTHER|Biological samples|blood and tumor tissue samples
58128424|NCT06344338|DEVICE|tDCS stimulation|In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation
57960819|NCT05269394|DRUG|E2814|Administered intravenously in a blinded fashion
58128425|NCT06344338|DEVICE|TDCS sham-stimulation|TDCS sham-stimulation
57960820|NCT05269394|DRUG|Lecanemab|Administered intravenously
58128426|NCT04415125|DIAGNOSTIC_TEST|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
58128427|NCT00028665|BIOLOGICAL|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
58453810|NCT04421170|BEHAVIORAL|smartphone app for smoking cessation|Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
58453811|NCT01335139|BIOLOGICAL|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
58453812|NCT01335139|BIOLOGICAL|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
58453813|NCT01335139|OTHER|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
58453814|NCT03011788|DRUG|Golytely Oral Solution|Bowel purge prior to,colonoscopy
58453815|NCT05406011|DIETARY_SUPPLEMENT|Pelleted sour cherry (anthocyanin) containing chewing gum usage.|Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).
58453816|NCT05406011|DIETARY_SUPPLEMENT|Pelleted chewing gum for stimulated saliva sampling.|Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.
58453817|NCT05406011|PROCEDURE|Scaling|Scaling after a 1-week control period without chewing the sour cherry gum.
58128428|NCT00028665|BIOLOGICAL|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
58128429|NCT00028665|DRUG|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
57755322|NCT03834103|BEHAVIORAL|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
57755323|NCT01870362|DRUG|Probiotic (Inersan)|
57755324|NCT01870362|DRUG|Placebo|
57755325|NCT01981525|DRUG|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
57960821|NCT05269394|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
58128430|NCT00028665|DRUG|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
58128431|NCT00028665|DRUG|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
58128432|NCT00028665|DRUG|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
58128433|NCT00028665|PROCEDURE|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
58128434|NCT00028665|PROCEDURE|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
58128435|NCT00028665|RADIATION|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
58128436|NCT05895552|DRUG|RTA 901|Administered as specified in the treatment arm.
58128437|NCT05895552|DRUG|RTA 901-Matching Placebo|Administered as specified in the treatment arm.
58128438|NCT00006470|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
58128439|NCT00006470|BIOLOGICAL|monoclonal antibody 3H1 anti-idiotype vaccine|
58128440|NCT00006470|RADIATION|radiation therapy|
58128441|NCT04297228|BEHAVIORAL|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
58128442|NCT04909437|DIETARY_SUPPLEMENT|Mycobiotic|2 sachet/day, 21 days, oral
58128443|NCT04909437|DIETARY_SUPPLEMENT|Placebo|2 sachet/day, 21 days, oral
58128444|NCT03679741|DEVICE|CONTROL Lens|Acuvue OASYS
58128445|NCT03679741|DEVICE|TEST Lens|senofilcon A
58315170|NCT05694650|BEHAVIORAL|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
58453818|NCT04585425|BEHAVIORAL|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
58315171|NCT02632318|DEVICE|Light|30 minutes of dawn simulation
58315172|NCT04828499|PROCEDURE|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
58315173|NCT04828499|PROCEDURE|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
58453819|NCT04585425|BEHAVIORAL|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
58453820|NCT00006326|DRUG|Indinavir sulfate|
57755326|NCT03430193|OTHER|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
57755327|NCT03430193|OTHER|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
57755328|NCT04960605|PROCEDURE|Dental implants|Treatment of the toothless regions with dental implants
57755329|NCT00967382|DRUG|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
58128446|NCT00826774|BEHAVIORAL|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
58128447|NCT00826774|BEHAVIORAL|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
58128448|NCT00826774|BEHAVIORAL|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
58128449|NCT04442776|BEHAVIORAL|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
58453821|NCT00006326|DRUG|Ritonavir|
58453822|NCT00006326|DRUG|Delavirdine mesylate|
57755330|NCT03013023|BEHAVIORAL|BS|NNS, FT, positional support, and oral sucrose feeding
57755331|NCT03013023|BEHAVIORAL|Routine care|Routine NICU care
57755332|NCT03013023|BEHAVIORAL|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
57755333|NCT03013023|BEHAVIORAL|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
57755334|NCT05632835|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..
57755335|NCT05632835|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
57755336|NCT00524914|DRUG|apomorphine|Acute apomorphine subcutaneous 3 mg
57755337|NCT00524914|DRUG|placebo|placebo subcutaneous
57755338|NCT01670448|PROCEDURE|PECBLOCK under echoguidance|Performance of block under echography
57755339|NCT04235907|OTHER|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
57755340|NCT04235907|OTHER|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
57755341|NCT04922151|DRUG|601|intravitreal recombinant humanized anti-VEGF monoclonal antibody
58453823|NCT04325334|BEHAVIORAL|Running volume increase|"Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the 10% rule advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run."
57755342|NCT04922151|DRUG|Ranibizumab|intravitreal recombinant humanized anti-VEGF monoclonal antibody
57755343|NCT03717090|OTHER|No intervention|Sample collection study Sample collection and collection of laboratory values
57755344|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
58315174|NCT01971177|DEVICE|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
58453824|NCT01392131|DIETARY_SUPPLEMENT|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
58453825|NCT01392131|OTHER|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
57755345|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
57755346|NCT05725252|DRUG|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
57755347|NCT05725252|DRUG|NVP-2203-R|administration of active comparator
57755348|NCT04350710|OTHER|PEEP trial|Measurement of Recruitment-to-Inflation Ratio
57755349|NCT01080222|DRUG|telaprevir|tablet, 1125-mg, twice daily
57755350|NCT01080222|DRUG|VX-222|capsule, 100-mg, twice daily
57755351|NCT01080222|DRUG|ribavirin|tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
57755352|NCT01080222|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
57755353|NCT01080222|DRUG|VX-222|capsule, 400-mg, twice daily
57755354|NCT05009524|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
57755355|NCT05009524|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
57755356|NCT06150781|DRUG|erenumab-aooe|Dose and treatment duration will be advised by the HCP
57755357|NCT01949870|DRUG|Cisplatin|day1 and day8 at each cycle
57755358|NCT01949870|DRUG|Gemcitabine|day1 and day8 at each cycle
57755359|NCT01949870|DRUG|Selumetinib|25mg/day, 50mg/day and 75mg/day
57755360|NCT01807806|BEHAVIORAL|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
57755361|NCT03223532|DEVICE|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
57755362|NCT03223532|DEVICE|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
57755363|NCT03645902|DIAGNOSTIC_TEST|Magnetic resonance imaging|
57755364|NCT02427789|OTHER|Physical Exercise|physical exercise
57755365|NCT00908401|OTHER|Breastmilk|Breastmilk: 0.2 ml
57755366|NCT00908401|OTHER|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
57755367|NCT01153139|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
57755368|NCT03811184|DIAGNOSTIC_TEST|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
57755369|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Single intravenous injection of CB2679d/Dalcinonacog alfa
57755370|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
57755371|NCT04372628|DRUG|Lopinavir/Ritonavir 400 mg/100 mg|Lopinavir/Ritonavir tablets
57755372|NCT04372628|OTHER|Placebo|Unmatched placebo
58453826|NCT05162183|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference group.
58453827|NCT05162183|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
58453828|NCT04281615|OTHER|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
58453829|NCT02601157|DRUG|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
58453830|NCT02601157|DRUG|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
58453831|NCT02960386|OTHER|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
58453832|NCT05202678|DEVICE|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
58453833|NCT01104896|DRUG|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
58453834|NCT01104896|DRUG|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
58453835|NCT06006650|DRUG|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
57755373|NCT03040284|DEVICE|Echodia® hand-held equipment (ELIOS)|
57755374|NCT01984580|DRUG|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
57755375|NCT03782311|BEHAVIORAL|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
57755376|NCT06500494|DRUG|Vinorelbine Tartrate Oral|The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.
57755377|NCT05873374|BIOLOGICAL|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
58128450|NCT05608512|OTHER|interview|The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
58128451|NCT04000503|BEHAVIORAL|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
58453836|NCT04435483|DRUG|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
58453837|NCT04435483|DRUG|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
58453838|NCT04435483|DRUG|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
58453839|NCT00611689|DRUG|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in \< 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
57755378|NCT05873374|OTHER|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
57755379|NCT00452686|BIOLOGICAL|Boostrix|
57755380|NCT00452686|BIOLOGICAL|Chinese DT vaccine|
57755381|NCT03681210|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
57755382|NCT00779779|BIOLOGICAL|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
57755383|NCT02440347|DEVICE|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
57755384|NCT02440347|DEVICE|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
57755385|NCT01654601|DRUG|DWCZP|Multiple dose
57755386|NCT01654601|DRUG|Clozaril|multiple-dose
57755387|NCT02264184|DRUG|Tamsulosin|
57755388|NCT02264184|DRUG|Paroxetine|
58453840|NCT01546558|DRUG|Metformin|Metformin 1000 mg bid on Days 1-10
58453841|NCT01546558|DRUG|Ranolazine|Ranolazine 500 mg bid on Days 6-10
58453842|NCT02802839|DEVICE|Virtual Reality|
57755389|NCT04224064|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
57755390|NCT03075579|DRUG|Medication Other|medication of atomoxetine
57755391|NCT03075579|DEVICE|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
57755392|NCT05732441|DRUG|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
57755393|NCT02977559|DEVICE|Laryngeal Tube Suction Disposable|Device for ventilation
57755394|NCT02977559|DEVICE|Laryngeal Mask Airway AuraGain|Ventilation device
57755395|NCT00053495|BIOLOGICAL|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
57755396|NCT00053495|BIOLOGICAL|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
57755397|NCT00982930|DRUG|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
58453843|NCT05005663|OTHER|surgical management of incisional hernia|surgical repair of the incisional hernia
57755398|NCT03179644|OTHER|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
57755399|NCT02685722|BIOLOGICAL|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
57755400|NCT02685722|OTHER|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
57755401|NCT02082925|OTHER|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
57755402|NCT01395108|DRUG|Nemonoxacin|oral once daily
57755403|NCT03652779|DRUG|Tecarfarin 10mg|Tecarfarin 10mg tablets
57755404|NCT03652779|DRUG|Tecarfarin 20mg|two tecarfarin 10mg tablets
57755405|NCT03652779|DRUG|Tecarfarin 30mg|three tecarfarin 10mg tablets
57755406|NCT03652779|DRUG|Tecarfarin 40mg|four tecarfarin 10mg tablets
57755407|NCT02179502|DRUG|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
57755408|NCT02179502|DRUG|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
57755409|NCT02179502|DRUG|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
57755410|NCT02179502|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
57755411|NCT01682213|DRUG|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
57755412|NCT01356680|DRUG|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
57755413|NCT01356680|DRUG|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
57755414|NCT01356680|RADIATION|30Gy IF-RT (Involved-Field Radiotherapy)|
57755415|NCT01356680|RADIATION|30Gy IN-RT (Involved-Node Radiotherapy)|
57755416|NCT00150579|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
57755417|NCT06397599|OTHER|denture adhesive|use of adhesive for completely edentulous
57755418|NCT00812279|OTHER|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
57755419|NCT00812279|OTHER|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
57755420|NCT00812279|OTHER|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
57755421|NCT03595930|DRUG|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
57755422|NCT06004414|BEHAVIORAL|App-based Cognitive Behavioral Therapy (CBT)|SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
57755423|NCT06004414|BEHAVIORAL|Psychotherapy|Psychotherapy with a licensed clinician in the school-based health center.
57755424|NCT04426643|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
57755425|NCT04426643|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
57755426|NCT03513406|DRUG|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
58128452|NCT02134756|DRUG|NutraStem Active|
57755427|NCT03513406|DRUG|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
57755428|NCT03513406|DRUG|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
57755429|NCT06099457|BEHAVIORAL|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
57755430|NCT02415179|DRUG|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
57755431|NCT02415179|DRUG|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
57755432|NCT03620630|DEVICE|myCOPD|myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
58453844|NCT05120427|DIETARY_SUPPLEMENT|Lipid based nutrient Supplements (LNS):|LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
58453845|NCT05120427|DEVICE|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
58453846|NCT04118465|PROCEDURE|external cephalic version|external cephalic version
58453847|NCT01187940|BEHAVIORAL|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
58453848|NCT05054140|DRUG|IMU-838|IMU-838 tablets
58453849|NCT05054140|DRUG|Placebo matching IMU-838|Placebo matching IMU-838 tablets
58453850|NCT01819155|BIOLOGICAL|Adjuvanted seasonal trivalent inactivated influenza vaccine|
58453851|NCT01819155|BIOLOGICAL|Seasonal trivalent inactivated influenza vaccine|
58453852|NCT01819155|BIOLOGICAL|Saline (bacteriostatic 0.9% sodium chloride for injection)|
58453853|NCT01546857|DRUG|Placebo|Normal Saline
57755433|NCT02097979|BEHAVIORAL|Glaucoma Educational Intervention|
57755434|NCT04241458|DRUG|BI 703621|BI 703621
57755435|NCT04241458|DRUG|Placebo|Placebo
57755436|NCT04241458|DRUG|Midazolam|Midazolam
57755437|NCT03344224|DIAGNOSTIC_TEST|laboratory test|laboratory test
58453854|NCT01546857|DRUG|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
58453855|NCT01908686|BEHAVIORAL|Pivotal Response Training|Behavioral intervention for autism
57755438|NCT01705743|DRUG|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
58453856|NCT05184192|DRUG|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
58453857|NCT05184192|DRUG|Placebo|lactose monohydrate NF
58453858|NCT06076148|DEVICE|Virtual reality games|three individual games (physical, cognitive and relaxation) and two multiplayer games will be tested.
57755439|NCT01705743|DRUG|Sevoflurane|100% oxygen+ Sevoflurane
57755440|NCT03487536|OTHER|Nutritional assessment|BMI and cholesterol levels evaluation
57755441|NCT01344668|OTHER|Enhanced Diabetes Education|Provide enhanced diabetes education
58453859|NCT03070080|PROCEDURE|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
58453860|NCT03070080|PROCEDURE|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
58453861|NCT00665665|DRUG|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
58453862|NCT00665665|DRUG|placebo|Placebo for s.c. injection
58453863|NCT00665665|DRUG|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
57755442|NCT01344668|OTHER|Standard Diabetes Education|Provide Standard Diabetes Education
57755443|NCT00454571|DRUG|pazopanib hydrochloride|Given PO
57755444|NCT00454571|DRUG|leuprolide acetate|
57755445|NCT00454571|DRUG|goserelin acetate|
57755446|NCT04040309|BIOLOGICAL|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
57755447|NCT04040309|DRUG|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
57755448|NCT03118921|DEVICE|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
57755449|NCT06243185|DRUG|Dalpiciclib plus letrozole|Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
58128453|NCT02134756|DRUG|NutraStem Placebo|
58128454|NCT00958178|DRUG|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
58453864|NCT00665665|DRUG|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
58453865|NCT00665665|DRUG|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
58453866|NCT03430778|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
58453867|NCT03430778|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
58453868|NCT02631551|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
57755450|NCT06350929|OTHER|Cardiac output monitoring by the Starling™ SV Sebac®|"During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected."
57755451|NCT05965830|DEVICE|Diaphragm ultrasound|A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
57755452|NCT04158414|DIAGNOSTIC_TEST|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
58453869|NCT02631551|DRUG|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
58453870|NCT02631551|DRUG|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
58453871|NCT02631551|DRUG|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
58453872|NCT00421681|BEHAVIORAL|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
58453873|NCT03471273|PROCEDURE|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
58453874|NCT04099966|DRUG|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
58453875|NCT03043885|DEVICE|FDBA|Graft material used to graft extraction socket
58453876|NCT03043885|DEVICE|PRF|Autologous blood product used to graft extraction socket
58453877|NCT03043885|PROCEDURE|Blood Clot|Surgical treatment of extraction socket without addition of graft material
58453878|NCT04867551|DRUG|KDT-3594|oral administration, dose titration
58453879|NCT03200119|BEHAVIORAL|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
58453880|NCT03373149|DRUG|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
58453881|NCT03373149|DRUG|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
58453882|NCT01794988|BEHAVIORAL|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
58453883|NCT01794988|BEHAVIORAL|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
58453884|NCT01794988|BEHAVIORAL|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
58453885|NCT01794988|BEHAVIORAL|NO TIVR|Control - no intervention
58453886|NCT01553903|DRUG|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
58453887|NCT01553903|DRUG|Exemestane|Exemestane 25mg/day during 5 years
58128455|NCT00439790|PROCEDURE|Microneurography|Microneurography
58453888|NCT01553903|DRUG|Anastrozole|Anastrozole 1 mg/day during 5 years,
58453889|NCT01553903|DRUG|Letrozole|Letrozole 2.5 mg/day during 5 years,
58453890|NCT05013424|DRUG|OnabotulinumtoxinA|Intramuscular Injection
58453891|NCT03621657|DRUG|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
58453892|NCT03621657|DRUG|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
58453893|NCT03621657|DRUG|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
58453894|NCT05724745|DIAGNOSTIC_TEST|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
58453895|NCT05724745|DIAGNOSTIC_TEST|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
57755453|NCT05882110|PROCEDURE|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
57755454|NCT03773458|DEVICE|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
58128456|NCT03256110|BEHAVIORAL|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
58453896|NCT05724745|DRUG|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
57755455|NCT02710448|DRUG|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
57755456|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
57755457|NCT05003102|DRUG|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
57755458|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
57755459|NCT05081869|OTHER|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
57755460|NCT05081869|OTHER|Education Program|There will be video training on the subject for both groups.
57755461|NCT02461095|OTHER|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
57755462|NCT02461095|OTHER|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
58128457|NCT05889871|DRUG|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
58453897|NCT05724745|DIAGNOSTIC_TEST|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
57755463|NCT02347644|BEHAVIORAL|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action"
57755464|NCT04545996|OTHER|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
57755465|NCT04545996|OTHER|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
57755466|NCT05701514|PROCEDURE|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
57755467|NCT00257140|DRUG|levofloxacin|
57755468|NCT01875380|DRUG|Regorafenib|
57755469|NCT02958592|OTHER|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
58128458|NCT03296475|PROCEDURE|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
58128459|NCT00308529|DRUG|irinotecan|
58128460|NCT00308529|DRUG|carboplatin|
57960822|NCT05493319|OTHER|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
57960823|NCT04082000|DRUG|BOL-DP-o-04|BOL-DP-o-04
58128461|NCT00308529|DRUG|bevacizumab|
58128462|NCT00308529|PROCEDURE|Radiation Therapy|
58453898|NCT05706948|OTHER|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
58453899|NCT05706948|OTHER|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
58453900|NCT04592588|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
58453901|NCT04592588|BEHAVIORAL|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
57755470|NCT03637244|BEHAVIORAL|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
57755471|NCT04247659|DRUG|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
57755472|NCT02459262|BIOLOGICAL|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
57755473|NCT03066401|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
57755474|NCT04909580|BEHAVIORAL|Decision coaching with a patient decision aid|Decision coaching guided by the Ottawa Decision Support Framework
57755475|NCT00002947|RADIATION|indium In 111 pentetreotide|
57755476|NCT04088721|BIOLOGICAL|AD17002|LTh(αK) as immunomodulator
57755477|NCT04088721|OTHER|Formulation Buffer|Formulation buffer
57755478|NCT04184323|DRUG|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
57755479|NCT04184323|DRUG|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
57755480|NCT05008952|OTHER|High-fat shake|All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
57755481|NCT02546830|DEVICE|FreeO2 v2.2 active|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
57755482|NCT02546830|DEVICE|FreeO2 v2.2 with manual oxygenation|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
58453902|NCT03965013|DRUG|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
58453903|NCT03965013|DRUG|Placebo|A single dose of placebo given in Part 1
58453904|NCT03965013|DRUG|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
57755483|NCT02914132|DEVICE|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
57755484|NCT04159974|DRUG|Durvalumab 50 MG/ML|IV Infusion
57755485|NCT04159974|DRUG|Tremelimumab|IV Infusion, Combination with Durvalumab
57755486|NCT03979170|PROCEDURE|Lung tumor resection|lung tumor resection
57755487|NCT02022579|PROCEDURE|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
57755488|NCT05177445|COMBINATION_PRODUCT|Phototherapy|"Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention."
57755489|NCT05177445|COMBINATION_PRODUCT|OT+Corticosteroids|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
57755490|NCT05960825|COMBINATION_PRODUCT|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
57755491|NCT01230255|PROCEDURE|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
57755492|NCT00005584|BIOLOGICAL|bleomycin sulfate|
57755493|NCT00005584|DRUG|ABVD regimen|
58453905|NCT02385747|PROCEDURE|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
58453906|NCT02624440|DRUG|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
58453907|NCT02624440|DRUG|Clarithromycin|P.o. clarithromycin 250 mg twice daily
58453908|NCT02624440|DRUG|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
58453909|NCT02624440|DRUG|Observation|Observation without prophylactic antibiotic
58453910|NCT02884648|DRUG|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
58453911|NCT02719496|DRUG|IBEROGAST|
57755494|NCT00005584|DRUG|BEACOPP regimen|
57755495|NCT00005584|DRUG|epirubicin hydrochloride|
57755496|NCT00005584|DRUG|prednisone|
57755497|NCT00005584|DRUG|vinblastine sulfate|
57755498|NCT00005584|RADIATION|radiation therapy|
57755499|NCT03785067|DRUG|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
57755500|NCT03785067|DRUG|Placebo oral capsule|1 capsule taken orally once daily for 36 months
57960824|NCT04082000|DRUG|Placebo|Placebo
58453912|NCT03255135|DEVICE|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
57755501|NCT02129101|DRUG|Azacitidine|Given SC or IV
57755502|NCT02129101|DRUG|Decitabine|Given IV
57755503|NCT02129101|OTHER|Laboratory Biomarker Analysis|Correlative studies
57755504|NCT02129101|OTHER|Quality-of-Life Assessment|Ancillary studies
57755505|NCT02129101|DRUG|Sonidegib|Given PO
57755506|NCT03659422|OTHER|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
57755507|NCT00041782|DRUG|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
57755508|NCT00815867|DRUG|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
57755509|NCT03502863|DEVICE|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
57755510|NCT03502863|OTHER|Manual Refraction|Manual refraction and ETDRS chart
57755511|NCT05094531|OTHER|Primary prevention programm|This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).
58453913|NCT04934501|DIAGNOSTIC_TEST|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
58453914|NCT04934501|DIAGNOSTIC_TEST|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
58453915|NCT03015168|RADIATION|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
57755512|NCT00640627|DRUG|Celecoxib|200 mg oral capsule once daily for 6 weeks
57755513|NCT00640627|DRUG|Placebo|Matched oral placebo for 6 weeks
57755514|NCT00514683|DRUG|low dose BIBF1120 once daily|low dose BIBF1120 once daily
57755515|NCT00514683|DRUG|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
57755516|NCT00514683|DRUG|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
57755517|NCT00514683|DRUG|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
57755518|NCT00514683|DRUG|placebo|placebo
57755519|NCT04424862|DRUG|Prednisone, ciclosporin and mycophenolate mofetil|Multitarget Therapy
57755520|NCT04424862|DRUG|Ponticelli Regimen|Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
57755521|NCT01666808|DRUG|FACBC|FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
58128463|NCT00543309|DRUG|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
57755522|NCT01666808|RADIATION|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
57755523|NCT06041984|DRUG|Glycopyrrolate|Intravenous injection of glycopyrrolate 0.2mg
57755524|NCT06041984|OTHER|Placebo|Intravenous injection of saline 1ml
57755525|NCT04863625|BEHAVIORAL|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
57755526|NCT01636999|DRUG|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
58128464|NCT00543309|DRUG|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
58128465|NCT00543309|DRUG|placebo|Placebo bolus on CPB, then placebo infusion
58128466|NCT04637997|DEVICE|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
57755527|NCT02891720|DEVICE|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
57755528|NCT05461703|BEHAVIORAL|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
57755529|NCT04606784|BIOLOGICAL|Ampion|Ampion, nebulized for inhalation
57755530|NCT04606784|OTHER|Standard of Care|Standard of Care
58128467|NCT04637997|DEVICE|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
58128468|NCT03561883|DRUG|IW-3718|oral tablet
58128469|NCT03561883|DRUG|placebo|oral tablet
58128470|NCT03561883|DRUG|Standard-dose PPIs QD|background therapy
57755531|NCT00908492|BEHAVIORAL|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
57755532|NCT00908492|BEHAVIORAL|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
57755533|NCT00995501|DRUG|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
57755534|NCT00995501|DRUG|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
57755535|NCT00995501|DRUG|anesthesia management|Light anesthesia to maintain BIS about 55
57755536|NCT00995501|OTHER|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
57755537|NCT00995501|OTHER|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
57755538|NCT00995501|OTHER|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
57755539|NCT03191695|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
57755540|NCT03671174|DRUG|Prednisone|10mg once daily orally
57755541|NCT03671174|DRUG|Hydroxychloroquine|100mg to 200mg twice daily orally
57755542|NCT03671174|DRUG|Aspirin|50mg once daily orally
57755543|NCT03671174|DRUG|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
57755544|NCT05421455|DRUG|Group A|treat participants with biologics
57755545|NCT05421455|PROCEDURE|Group B|treat participants with surgery
57755546|NCT04959890|GENETIC|Strimvelis|This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
57755547|NCT01375270|PROCEDURE|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
57755548|NCT01375270|PROCEDURE|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
57755549|NCT05682092|DIETARY_SUPPLEMENT|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
57755550|NCT05682092|DIETARY_SUPPLEMENT|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
57755551|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
57755552|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
57755553|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
57755554|NCT01343602|BEHAVIORAL|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
57755555|NCT01343602|OTHER|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
57755556|NCT03046615|DEVICE|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
57755557|NCT03046615|DEVICE|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
57755558|NCT05016583|OTHER|Paula Method|12 weeks of Paula Method of Exercises
57755559|NCT03022201|DRUG|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
57755560|NCT03022201|DRUG|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
57755561|NCT03022201|DRUG|Placebo domperidone|
57755562|NCT03022201|DRUG|Placebo DA-9701|
57755563|NCT01330433|DEVICE|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing \>10kg will receive 2-4ml of CoSeal"
57755564|NCT01573806|DRUG|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
57755565|NCT01573806|DRUG|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
58453916|NCT05851196|OTHER|Proprioceptive training|A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
58453917|NCT02426515|DEVICE|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
58453918|NCT00128739|DRUG|Budesonide|
58453919|NCT02856048|DRUG|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
58453920|NCT03568240|DIAGNOSTIC_TEST|Patients suffering from Sleep apnea|PSG test
58453921|NCT00186225|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
58453922|NCT00740207|DRUG|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
58453923|NCT00740207|DRUG|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
58453924|NCT01509235|PROCEDURE|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
57755566|NCT03882879|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
57960825|NCT04450485|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
58453925|NCT01437280|BIOLOGICAL|CGTG-102|"VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
58453926|NCT05229185|DEVICE|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
58453927|NCT05014672|DRUG|Setanaxib|Oral tablets, 400mg per tablet
58453928|NCT05014672|DRUG|Placebo|Oral tablets
58453929|NCT02631096|DRUG|ARB-001467|An IV infusion of ARB-001467
58453930|NCT02631096|OTHER|Placebo|An IV infusion of placebo
58453931|NCT04034823|BIOLOGICAL|KN035|KN035 5 mg/kg s.c. Q3W
58453932|NCT04034823|BIOLOGICAL|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
58453933|NCT04034823|DRUG|Docetaxel|100 mg/m2 Q3W IV
58453934|NCT00721396|BIOLOGICAL|rMenB+OMV NZ|
58453935|NCT00721396|BIOLOGICAL|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
58453936|NCT00721396|BIOLOGICAL|Pneumococcal vaccine|
58453937|NCT03974386|DEVICE|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
58128471|NCT00401778|DRUG|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
58128472|NCT05607914|PROCEDURE|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
58128473|NCT05607914|PROCEDURE|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
58453938|NCT02843906|PROCEDURE|Lombar Punction|cerebrospinal fluid testing at screening and M36
58453939|NCT02843906|RADIATION|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
58453940|NCT02843906|RADIATION|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
58453941|NCT02843906|OTHER|Psychiatric tests|
58453942|NCT02843906|OTHER|Neuropsychological Tests|done at screening, M12, M24 and M36
58453943|NCT02843906|GENETIC|Apolipoprotein (ApoE) detection|ApoE detection done at screening
58453944|NCT00754585|DEVICE|Logic Back Grahl Duo Back Model DB11-01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
58453945|NCT05222828|DRUG|Carbocaine Injectable Product|One injection per patient
57755567|NCT03882879|BEHAVIORAL|Pre-Intervention Study Visit|At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
57755568|NCT03882879|BEHAVIORAL|Bimonthly Online Survey|All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
57755569|NCT03882879|BEHAVIORAL|6-month Study Visit|All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
57755570|NCT03882879|BEHAVIORAL|12-month Study Visit|At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
57755571|NCT03243422|OTHER|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
57755572|NCT03243422|OTHER|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
57755573|NCT05562479|BIOLOGICAL|Sars Cov 2 infection|Donors recovered from Sars Cov 2 Infection
57755574|NCT05562479|BIOLOGICAL|Sars Cov 2 vaccination|Egg Donors vaccinated
57755575|NCT00969397|DRUG|Topical Antiangiogenic|Topical Antiangiogenic
57755576|NCT00969397|DEVICE|Pulsed Dye Laser|Pulsed Dye Laser
57755577|NCT04470245|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI)|Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
57755578|NCT01313143|DRUG|AOP200704|Comparison of AOP200704 with Esmolol
57755579|NCT01313143|DRUG|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
57755580|NCT03988166|PROCEDURE|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
57755581|NCT03988166|DEVICE|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
58315175|NCT01971177|PROCEDURE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
58453946|NCT02807623|DRUG|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
58453947|NCT02807623|BEHAVIORAL|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
58453948|NCT02807623|DRUG|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
57755582|NCT01370525|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
57755583|NCT01767168|OTHER|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
57755584|NCT00679328|DEVICE|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
57755585|NCT00240292|DRUG|Rosuvastatin|
58453949|NCT04082234|BEHAVIORAL|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
58453950|NCT04082234|OTHER|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
57755586|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
57755587|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
57755588|NCT04636372|DEVICE|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
57755589|NCT04636372|OTHER|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
57755590|NCT03333798|BEHAVIORAL|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~* The Cognitive-Behavioral model~* Tackling traumatic events~* Cognitive reprocessing~* Relaxation techniques~* Prevention of revictimization~* Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
57755591|NCT03333798|BEHAVIORAL|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
57755592|NCT06040190|DRUG|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
58453951|NCT06027866|DEVICE|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
57755593|NCT06040190|DRUG|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
57755594|NCT06040190|DIETARY_SUPPLEMENT|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
57755595|NCT06040190|OTHER|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
57755596|NCT06040190|RADIATION|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
58128474|NCT05733247|OTHER|Copenhagen adductor exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
58128475|NCT05733247|OTHER|The adduction and abduction partner exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
58128476|NCT03832179|DRUG|Bevacizumab|Bevacizumab
58128477|NCT03832179|DRUG|Ranibizumab|Ranibizumab
58128478|NCT03832179|DRUG|Aflibercept|Aflibercept
58128479|NCT03832179|DRUG|Ozurdex|Ozurdex
57755597|NCT00941798|DRUG|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
58128480|NCT05584475|BEHAVIORAL|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
57755598|NCT00941798|DRUG|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
57755599|NCT01537302|DEVICE|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
57755600|NCT05508503|DIAGNOSTIC_TEST|Test of methylated NTMT1 and MAP3K14-AS1|A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
57755601|NCT05508503|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test（optional）
57755602|NCT01870388|DRUG|Baricitinib|Administered orally
57755603|NCT00337272|DRUG|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
57755604|NCT00337272|DRUG|Ramelteon|8 mgs daily for days 1-28 of treatment period
57755605|NCT06129864|DRUG|volrustomig|volrustomig
57755606|NCT03113292|OTHER|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
57755607|NCT03113292|OTHER|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
57755608|NCT02701894|DIETARY_SUPPLEMENT|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
57755609|NCT04701463|DIETARY_SUPPLEMENT|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate|2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
57755610|NCT04701463|COMBINATION_PRODUCT|Placebo|Isocaloric formula
57755611|NCT03895554|PROCEDURE|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
57755612|NCT01048892|BIOLOGICAL|Seneca Valley virus-001|
57755613|NCT01048892|DRUG|cyclophosphamide|
58128481|NCT03937453|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
57755614|NCT01048892|OTHER|laboratory biomarker analysis|
57755615|NCT01048892|OTHER|pharmacological study|
57755616|NCT06037460|DRUG|Tocilizumab treatment|"* 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24"
57755617|NCT06037460|OTHER|questionnaires|HAQ, SF-36, FACIT-Fatigue score
57755618|NCT06037460|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
57755619|NCT06037460|PROCEDURE|18FDG PET scan|PETVAS calculation (to be performed between W0 and W8) (optional).
57755620|NCT06246500|OTHER|No intervention|No intervention
57755621|NCT01701414|DRUG|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
57755622|NCT01701414|DRUG|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
57755623|NCT06225102|BEHAVIORAL|Kegel Exercise|"* Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
57755624|NCT03817138|OTHER|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
57755625|NCT05727722|BIOLOGICAL|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
57755626|NCT04285658|PROCEDURE|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
57755627|NCT04285658|PROCEDURE|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
58128482|NCT05608421|BEHAVIORAL|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
57755628|NCT04285658|PROCEDURE|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
57755629|NCT04109014|OTHER|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
57755630|NCT04176939|BIOLOGICAL|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
57755631|NCT01906671|DRUG|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
57755632|NCT01906671|DRUG|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
57755633|NCT02626832|OTHER|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
58453952|NCT01156480|DRUG|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
57755634|NCT01591382|DRUG|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
57755635|NCT01591382|DRUG|Placebo|Patients who received ketamine-matching placebo were given saline infusions
57755636|NCT01591382|DRUG|Hydromorphone PCA|Intravenous hydromorphone PCA
57755637|NCT00433901|BEHAVIORAL|Targeted parental instruction for positive lifestyle change with follow-up calls.|
57755638|NCT04581525|DEVICE|transcranial direct current stimulation|
57755639|NCT05015816|DIAGNOSTIC_TEST|Total body photography|3 monthly TBP imaging
57755640|NCT05369715|OTHER|Exercise|Aerobic exercise
57755641|NCT00314925|DRUG|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
57755642|NCT03468959|BEHAVIORAL|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
57755643|NCT06398483|PROCEDURE|surgical fixation of acute bony mallet finger|"surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire"
57755644|NCT01132625|DRUG|AUY922|
57755645|NCT03949790|PROCEDURE|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
57755646|NCT03949790|PROCEDURE|Intercostal nerve block|Intercostal nerve block
57755647|NCT03871088|DIETARY_SUPPLEMENT|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
57755648|NCT00331344|DRUG|mitoxantrone hydrochloride|Given IV
57755649|NCT00331344|DRUG|ixabepilone|Given IV
57755650|NCT00331344|DRUG|prednisone|Given orally
57755651|NCT02754102|OTHER|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
57755652|NCT00991341|BIOLOGICAL|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
57755653|NCT00991341|BIOLOGICAL|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
57755654|NCT03467932|DRUG|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
57755655|NCT03467932|DRUG|Placebo oral capsule|Placebo provided QHS, BID, TID
58128483|NCT05608421|BEHAVIORAL|1MoreStepControl|This is an equal attention control group.
58128484|NCT03577509|DRUG|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
57755656|NCT03467932|DRUG|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
57755657|NCT00846105|OTHER|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
57755658|NCT05254548|DRUG|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
57755659|NCT05254548|DRUG|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
57755660|NCT05254548|DRUG|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
57755661|NCT05254548|DRUG|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
57755662|NCT03329898|PROCEDURE|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
58453953|NCT01156480|DRUG|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
58453954|NCT01654926|PROCEDURE|blood ultrafiltration|
58453955|NCT02843269|BEHAVIORAL|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
58453956|NCT05720910|OTHER|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
57755663|NCT03329898|DEVICE|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
57755664|NCT03329898|DRUG|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
57755665|NCT03329898|DRUG|dydrogesterone Tablets|oral dydrogesterone Tablets
57755666|NCT01606527|DRUG|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
57960826|NCT05713643|PROCEDURE|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
57960827|NCT05713643|PROCEDURE|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
57961632|NCT01913080|OTHER|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
58453957|NCT00945282|DRUG|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
58453958|NCT00945282|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
58453959|NCT00945282|DRUG|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
58453960|NCT00945282|DRUG|Placebo|Placebo is a capsule with no drug in it.
58453961|NCT00945282|DRUG|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
58453962|NCT05938621|BEHAVIORAL|behavioral therapy and education|Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
57755667|NCT01463956|DRUG|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
57755668|NCT01463956|BIOLOGICAL|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
57755669|NCT01463956|DRUG|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
57755670|NCT01635257|OTHER|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
57755671|NCT06525844|PROCEDURE|regenerative endodontic therapy using I-PRF|Blood will be taken from medial cubital vein
57755672|NCT06525844|PROCEDURE|blood clot|Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
58128485|NCT04108325|DRUG|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
58128486|NCT02036372|DRUG|Liraglutide|
58453963|NCT00928902|DRUG|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
57755673|NCT00661739|DRUG|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
57755674|NCT04934579|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
57755675|NCT04934579|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
57755676|NCT04934579|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
57755677|NCT01489943|DRUG|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
57755678|NCT01489943|DRUG|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
57755679|NCT01489943|DRUG|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
57755680|NCT01489943|DRUG|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
57755681|NCT01489943|DRUG|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
57755682|NCT05028426|PROCEDURE|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
57755683|NCT04859634|DEVICE|Taking an ultra-widefield fundus image|The participant only needs to take an ultra-widefield fundus image as usual.
57755684|NCT06526221|DIAGNOSTIC_TEST|Urine isoniazid testing (IsoScreen test)|Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for \>48 hours (two or more missed doses).
57755685|NCT04812366|DRUG|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
57755686|NCT04812366|DRUG|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
57755687|NCT04812366|DRUG|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
57755688|NCT04812366|DRUG|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
58128487|NCT02036372|DRUG|Insulin bolus|
58128488|NCT02036372|DRUG|GIK infusion|continuous infusion
58128489|NCT04541719|DRUG|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
58128490|NCT04541719|DRUG|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
58128491|NCT01208480|DRUG|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
58128492|NCT04299178|DEVICE|X-PLO2R POC|Portable Oxygen Concentrator (POC)
58128493|NCT03307239|OTHER|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
58128494|NCT03307239|OTHER|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
58128495|NCT02551497|DRUG|CNV1014802|
57755689|NCT04812366|DRUG|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
57755690|NCT04812366|DRUG|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
57755691|NCT00379522|DRUG|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
57755692|NCT00379522|DRUG|Saline placebo|Placebo for arginine vasopressin
57755693|NCT05225064|BEHAVIORAL|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
57755694|NCT05225064|DEVICE|Mask|Individuals are given cloth masks
57755695|NCT05225064|BEHAVIORAL|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
57755696|NCT05225064|BEHAVIORAL|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
57755697|NCT05225064|BEHAVIORAL|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
58128496|NCT03164395|PROCEDURE|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
58453964|NCT00928902|BIOLOGICAL|melanoma vaccine|six melanoma vaccines given over a 6-week period
58453965|NCT04365621|OTHER|we enrolled ultra-high risk of psychosis (UHR) patient to describe|there is no intervention because we study only the prevalence of patients meeting UHR criteria
58453966|NCT06526416|OTHER|Anterior segment optical coherence tomography|Imaging of the anterior segment of the eye using optical coherence tomography
57755698|NCT01321554|DRUG|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
57755699|NCT01321554|DRUG|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
57755700|NCT01321554|DRUG|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
57755701|NCT04318184|PROCEDURE|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
57755702|NCT06491472|DRUG|Ivonescimab|20mg/kg,IV,d1,Q3W
57755703|NCT06491472|DRUG|Gemcitabine|1000mg/m2, IV, d1/8, Q3W
57755704|NCT06491472|DRUG|Nab paclitaxel|125mg/m2, IV, d1/8, Q3W
57755705|NCT06491472|RADIATION|SBRT|5Gy \*5 F
57960828|NCT05713643|PROCEDURE|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
58128497|NCT03164395|PROCEDURE|External Cardioversion|External Cardioversion per institutional protocol
58453967|NCT00872235|DRUG|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
57755706|NCT05741957|BEHAVIORAL|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
57755707|NCT05741957|BEHAVIORAL|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
58128498|NCT05075564|DRUG|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
58128499|NCT05075564|DRUG|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
58453968|NCT05331560|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
58453969|NCT02347397|DEVICE|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem
58453970|NCT02347397|DEVICE|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
58453971|NCT03767946|DIAGNOSTIC_TEST|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
58453972|NCT03412396|DRUG|Apalutamide|Given PO
58453973|NCT03412396|OTHER|Quality-of-Life Assessment|Ancillary studies
57755708|NCT05741957|OTHER|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
58453974|NCT03412396|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
57755709|NCT01291914|DRUG|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
57755710|NCT01291914|DRUG|Placebo 1 (Carrier)|Single intra-articular injection
57755711|NCT01291914|DRUG|Placebo 2 (Diluent)|Single intra-articular injection
57755712|NCT05161299|PROCEDURE|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
57755713|NCT01426971|DRUG|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
57755714|NCT01426971|DRUG|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
57755715|NCT02764034|DEVICE|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
57755716|NCT06196450|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.
57755717|NCT06196450|DIETARY_SUPPLEMENT|Microcrystalline maltose|Microcrystalline maltose as placebo
57755718|NCT06184711|DEVICE|Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
57755719|NCT06184711|DEVICE|Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
57755720|NCT06184711|DEVICE|Transcranial Magnetic Stimulation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
57755721|NCT01115257|PROCEDURE|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
57755722|NCT01115257|PROCEDURE|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
57755723|NCT05797103|DEVICE|A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands|Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
57755724|NCT03320018|DRUG|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
57755725|NCT03320018|DRUG|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
57755726|NCT03320018|OTHER|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
57755727|NCT03320018|OTHER|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
57755728|NCT00223626|DRUG|Topiramate|the maximum topiramate test dose is 200 mg/d.
57755729|NCT04136886|DRUG|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
57960829|NCT05534932|DEVICE|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
58128500|NCT06357338|OTHER|no intervention|No intervention
58453975|NCT04277559|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
57755730|NCT04136886|RADIATION|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
57755731|NCT06492980|PROCEDURE|triple-branched stent graft|a triple-branched stent graft for aortic arch repairement during surgery
57755732|NCT03390387|DRUG|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
57960830|NCT02956668|OTHER|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
57960831|NCT02956668|OTHER|Blindsight Training alone|The patient undergo visual rehabilitation
58128501|NCT00605748|PROCEDURE|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
58128502|NCT00605748|PROCEDURE|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
58128503|NCT00842842|PROCEDURE|tack fixation of mesh|tack fixation of mesh
58128504|NCT00842842|PROCEDURE|glue fixation of mesh|glue fixation of mesh
57755733|NCT03390387|DRUG|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
57755734|NCT03390387|DRUG|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
57755735|NCT03390387|DRUG|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
57755736|NCT03390387|DRUG|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
57755737|NCT03390387|DRUG|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
57755738|NCT03390387|DRUG|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
57755739|NCT03390387|DRUG|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
57755740|NCT03390387|DRUG|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
57755741|NCT03390387|DRUG|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
57755742|NCT03407690|OTHER|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
57755743|NCT05775055|OTHER|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
57755744|NCT04815044|OTHER|Pregnancy|Experiences from being pregnant when having a history of eating disorder
57755745|NCT04815044|OTHER|Post-Partum|Experiences from the post-partum period when having a history of eating disorder
57755746|NCT03245138|PROCEDURE|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
57755747|NCT03245138|PROCEDURE|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
57755748|NCT00118898|DRUG|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
57755749|NCT00118898|DRUG|Atazanavir|300 mg tablet taken orally daily
57755750|NCT00118898|DRUG|Efavirenz|600 mg tablet taken orally daily
57755751|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
57960832|NCT02542475|DEVICE|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
57960833|NCT04750551|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
57960834|NCT04750551|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
57960835|NCT04152096|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
57960836|NCT04152096|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
57960837|NCT03225300|RADIATION|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
57960838|NCT03665285|DRUG|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
57960839|NCT03665402|DRUG|Isoniazid|One of the first line anti-tubercolosis drug
57960840|NCT01787916|DRUG|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
57960841|NCT01787916|DRUG|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
57960842|NCT03046355|PROCEDURE|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
57960843|NCT03046355|PROCEDURE|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
58128505|NCT00487227|DRUG|caffeine|
58128506|NCT00487227|DRUG|Placebo|
58315176|NCT00851591|DRUG|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
57755752|NCT00118898|DRUG|Ritonavir|100 mg tablet taken orally daily
57755753|NCT00118898|DRUG|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
57755754|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
57755755|NCT02654990|DRUG|Panobinostat Capsules|20 mg, 10 mg or 15 mg (for dose reductions only)
57755756|NCT02654990|DRUG|Bortezomib Injection|1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.
57755757|NCT02654990|DRUG|Dexamethasone tablets|Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
57755758|NCT00914277|DRUG|SAR407899|Oral administration
57755759|NCT00914277|DRUG|Placebo|Oral administration
57755760|NCT00914277|DRUG|Sildenafil|Oral administration
57755761|NCT01896401|DEVICE|InSeal's Vascular Closure Device|
57755762|NCT01568268|DRUG|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
57755763|NCT01568268|DRUG|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
57755764|NCT02346019|PROCEDURE|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
57755765|NCT00152464|DRUG|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
57960844|NCT00191451|DRUG|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
57960845|NCT00191451|DRUG|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
57960846|NCT00191451|DRUG|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
57960847|NCT00176280|DRUG|Leukine|
57960848|NCT00176280|DRUG|Dexamethasone|
58128507|NCT02295956|BEHAVIORAL|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
57755766|NCT00152464|DRUG|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
57960849|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the Turin group|Fracture classification annotations provided by the Turin group: fracture vs non-fracture, and, if fracture, the Arbeitsgemeinschaft für Osteosynthesefragen (AO, in English, Association for the Study of Internal Fixation)/Orthopedic Trauma Association (OTA) classification.
57960850|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the AO expert surgeon group|Fracture classification annotations provided by the AO expert surgeon group: fracture vs non-fracture, and, if fracture, the AO/OTA classification.
57960851|NCT02948803|BEHAVIORAL|smartphone based intervention with Active Coach app|
58128508|NCT02295956|OTHER|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
58128509|NCT02295956|OTHER|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
58128510|NCT02295956|BEHAVIORAL|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
58128511|NCT02295956|OTHER|Booklet|Exercise instructional booklet given to all participants describing all exercises.
58315177|NCT00851591|DRUG|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
58315178|NCT04615000|DIAGNOSTIC_TEST|SARS-CoV-2 serological assessment (IgG)|Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
57755767|NCT03907319|DEVICE|SIS System|Software technology for visualization of anatomical structures in the brain
57755768|NCT05182645|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
57755769|NCT05182645|BEHAVIORAL|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
57755770|NCT03079310|DEVICE|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
57755771|NCT06491849|OTHER|Peri-implant Condition Evaluation|This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
58315179|NCT04683575|DRUG|Selenium Yeast|oral medication
58315180|NCT04683575|DRUG|Placebo|oral medication
58315181|NCT01446705|OTHER|Active Health Information Exchange|Patients selected to share data between the VA \& external healthcare agencies.
58315182|NCT01446705|OTHER|Non-Active Health Information exchange|Patients not selecting to share data
58453976|NCT04277559|OTHER|Classical music|Patients will listen to classical music through headphones before surgery.
58315183|NCT02120404|DRUG|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
58453977|NCT04277559|OTHER|No music|Patients will not listen to music.
57755772|NCT03152084|DRUG|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
57755773|NCT04372836|PROCEDURE|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
57755774|NCT04911309|OTHER|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
57755775|NCT04911309|OTHER|standard therapy / treatment|12 weeks standard therapy / treatment
57755776|NCT00489710|DRUG|talabostat mesylate|
57755777|NCT00489710|BIOLOGICAL|enzyme inhibitor therapy|
57755778|NCT00489710|DIAGNOSTIC_TEST|flow cytometry|
57755779|NCT00489710|DIAGNOSTIC_TEST|laboratory biomarker analysis|
57755780|NCT00489710|BIOLOGICAL|non-specific immune-modulator therapy|
57755781|NCT02221401|DRUG|Linagliptin/Metformin FDC|
57755782|NCT02221401|DRUG|Linagliptin|
57755783|NCT02221401|DRUG|Metformin|
57755784|NCT05818150|DEVICE|Embosphere Microspheres|Embolic Agent: Embosphere Microspheres
58315184|NCT00439621|BIOLOGICAL|RP 01|Active immunotherapy
58315185|NCT00639509|BIOLOGICAL|cixutumumab|Given IV
57755785|NCT05818150|DRUG|Corticosteroid injection|Corticosteroid injection
57755786|NCT03040713|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose
57755787|NCT03040713|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
57755788|NCT01077544|DRUG|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
57755789|NCT00115141|DRUG|Resiquimod|
57755790|NCT01154569|DRUG|Azithromycin|500 mg single dose
57755791|NCT01819246|PROCEDURE|Aphersis Treatment Arm|
57755792|NCT01819246|OTHER|Control Arm|
57755793|NCT02448940|DIETARY_SUPPLEMENT|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
57755794|NCT02448940|DIETARY_SUPPLEMENT|lactose|2 capsule a day containing lactose
57755795|NCT00262795|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
57755796|NCT00262795|DRUG|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
57755797|NCT02859402|DRUG|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
57755798|NCT02859402|DRUG|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
57755799|NCT02445313|DEVICE|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
57755800|NCT00221910|PROCEDURE|Ultrasound|
57755801|NCT06318325|DIAGNOSTIC_TEST|examination|examination of tendon, muscle joints and injuries
57755802|NCT04325438|OTHER|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~1. Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~2. Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
57755803|NCT04304352|DRUG|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
57755804|NCT04304352|DRUG|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
57755805|NCT04304352|DRUG|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
57755806|NCT02331602|DRUG|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
57755807|NCT02331602|DRUG|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
57755808|NCT02341508|BIOLOGICAL|0.5 mg/kg Lpathomab|
58315186|NCT00639509|PROCEDURE|computed tomography|Undergo contrast-enhanced computed tomography
58315187|NCT00639509|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
58315188|NCT06462677|DIAGNOSTIC_TEST|Babesia NAT|Blood donors will be tested with Babesia NAT
58453978|NCT01423968|BIOLOGICAL|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
58453979|NCT01423968|OTHER|saline|
58453980|NCT00571155|DRUG|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
58453981|NCT04469972|OTHER|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
58453982|NCT01623115|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
57755809|NCT02341508|BIOLOGICAL|1.0 mg/kg Lpathomab|
58128512|NCT02234466|DRUG|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
58453983|NCT01623115|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
58453984|NCT01623115|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
58453985|NCT05703321|BEHAVIORAL|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
58453986|NCT05430958|DRUG|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
58453987|NCT05430958|DRUG|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
58453988|NCT05430958|DEVICE|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
58453989|NCT01119469|BEHAVIORAL|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
58453990|NCT03515525|DIAGNOSTIC_TEST|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
58453991|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
58453992|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
58453993|NCT01474941|DRUG|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
58453994|NCT05851833|BEHAVIORAL|Early Mobilization|The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
58128513|NCT02234466|DRUG|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
58128514|NCT02234466|OTHER|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
58128515|NCT04598243|DIETARY_SUPPLEMENT|Smart Energy System|A nutritional /herbal combination
58453995|NCT00997958|DRUG|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
58453996|NCT02310412|BIOLOGICAL|INTERCEPT treated platelets|
58453997|NCT03117816|DRUG|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
58453998|NCT03117816|OTHER|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
58453999|NCT04493996|BEHAVIORAL|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
57755810|NCT02341508|BIOLOGICAL|3.0 mg/kg Lpathomab|
57755811|NCT02341508|BIOLOGICAL|10 mg/kg Lpathomab|
57755812|NCT02341508|BIOLOGICAL|20 mg/kg Lpathomab|
57755813|NCT02341508|OTHER|Saline solution for intravenous infusion|
58454000|NCT03572452|BEHAVIORAL|McKenzie Method|Treatment according to the Mechanical Diagnosis and Therapy Approach
57755814|NCT03953339|PROCEDURE|Release or no release of the suprascapular nerve|
58454001|NCT03572452|BEHAVIORAL|Advice to saty active|Physiotherapy councelling advicing to stay normally active
58454002|NCT04729075|OTHER|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
58454003|NCT01149317|PROCEDURE|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
58454004|NCT00296816|DRUG|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
58454005|NCT00296816|DRUG|Docetaxel (Taxotere®)|75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
58454006|NCT00296816|DRUG|Oxaliplatin (Eloxatin®)|85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
58454007|NCT01936675|OTHER|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
58454008|NCT01169948|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
57755815|NCT02803125|BEHAVIORAL|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
57960852|NCT00737451|BEHAVIORAL|blood sampling|blood sampling 10ml from the study subjects
57960853|NCT02105415|DRUG|Ketamine / Propofol Admixture|
58128516|NCT03151018|DEVICE|Resolute Onyx|
58128517|NCT04483583|DRUG|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
58128518|NCT04483583|DRUG|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
58128519|NCT06304389|OTHER|electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration|Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
57755816|NCT02803125|BEHAVIORAL|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
57755817|NCT02475603|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
57755818|NCT02945332|BEHAVIORAL|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
57755819|NCT02945332|BEHAVIORAL|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
57755820|NCT02945332|DEVICE|Fitbit Flex|
57755821|NCT02708225|BEHAVIORAL|medical clown|a medical clown will assist the child during the performance of pulmonary function test
57755822|NCT04423822|OTHER|stress test|endurance capacity
57755823|NCT02138266|DEVICE|Topcon Specular Microscope SP-1P|
57755824|NCT02138266|DEVICE|Konan Specular Microscope CELLCHEK XL|
57755825|NCT06168292|PROCEDURE|ID-RFA and Radiotherapy|The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
58454009|NCT00687180|DRUG|Treatment with mycophenolat mofetil|
58454010|NCT00687180|DRUG|Treatment with azathioprin|
58454011|NCT03904212|PROCEDURE|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
58454012|NCT03904212|PROCEDURE|saline|injection with saline
58454013|NCT00771199|DRUG|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
58454014|NCT03560310|DRUG|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
58454015|NCT03560310|DRUG|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
58454016|NCT06522789|PROCEDURE|corneal cross-linking procedure|Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
58454017|NCT05980728|OTHER|No Intervention|No Intervention
58454018|NCT06317753|BEHAVIORAL|Aerobic Exercise|Participants allocated to the Aerobic condition will be following a 4 month-intervention aerobic exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
57755826|NCT01493505|DRUG|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
57755827|NCT01493505|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
57755828|NCT01493505|DRUG|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
57755829|NCT01493505|DRUG|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
57755830|NCT02512523|DRUG|Teneligliptin|
57755831|NCT02512523|DRUG|Sitagliptin|
57960854|NCT02105415|DRUG|Etomidate|
57960855|NCT01357486|DRUG|sorafenib|patients receiving sorafenib 400 mg - twice a day
57960856|NCT01357486|DRUG|Pravastatin|patients receiving pravastatin 40 mg - once a day
58315189|NCT04546763|DEVICE|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
58454019|NCT06317753|BEHAVIORAL|Agility-Cognitive Exercise|Participants allocated to the Agility-Cognitive condition will be following a 4 month-intervention agility-cognitive exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
58454020|NCT06317753|BEHAVIORAL|Stretching/relaxation|Participants allocated to the stretching control condition will be following a 4 month-intervention protocol of 1 weekly session with a 50 minutes duration
58454021|NCT02431988|PROCEDURE|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
58454022|NCT02431988|DRUG|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
58454023|NCT02431988|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
57755832|NCT04595721|BEHAVIORAL|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
57755833|NCT04595721|BEHAVIORAL|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
58454024|NCT02431988|BIOLOGICAL|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg"
58454025|NCT03192826|DRUG|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
58454026|NCT03192826|DRUG|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
58454027|NCT03192826|DRUG|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
58454028|NCT02324283|DRUG|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
58454029|NCT02324283|DRUG|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
58454030|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
58454031|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
58454032|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
58454033|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
58454034|NCT01739036|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
58454035|NCT03857919|DEVICE|TearCare|The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.
58454036|NCT03857919|DEVICE|LipiFlow|The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
58454037|NCT04154046|PROCEDURE|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
58454038|NCT00496015|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
57755834|NCT01298505|DRUG|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
57755835|NCT01298505|DRUG|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
57755836|NCT01298505|DRUG|placebo|placebo given twice daily for 7 days
57755837|NCT03943966|DIAGNOSTIC_TEST|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
57755838|NCT06130046|BIOLOGICAL|MR-proADM dosage|Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
57755839|NCT04186780|OTHER|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
57755840|NCT04945148|DRUG|Metformin|Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
57755841|NCT04945148|RADIATION|Radiation IMRT|2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
57755842|NCT04945148|DRUG|Temozolomide|75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
57755843|NCT00269802|DRUG|OROS methylphenidate HCl|
57755844|NCT00269802|DRUG|Ritalin|
57960857|NCT01357486|DRUG|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
57960858|NCT01357486|OTHER|patients receiving best supportive care|palliative management
58315190|NCT04546763|DEVICE|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
58454039|NCT00496015|BIOLOGICAL|Infanrix hexa.|1 intramuscular injection.
58454040|NCT00496015|BIOLOGICAL|Meningococcal vaccine GSK134612.|1 intramuscular injection.
58454041|NCT00496015|DRUG|Paracetamol.|Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
58454042|NCT04551118|DEVICE|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
57755845|NCT00269802|DRUG|Placebo|
58315191|NCT01018979|DRUG|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
58315192|NCT01018979|DRUG|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
57755846|NCT06200337|PROCEDURE|Fine needle acupuncture|All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
58315193|NCT03579667|BEHAVIORAL|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
57755847|NCT05332457|DRUG|Reduced dosage of beta-blocker|"Phase I:~1. CPET performed at trough BB concentration: participants will undergo CPET at least 30 hours after last beta-blocker usage.~2. CPET performed at peak BB concentration : participants will undergo CPET at 3 hours after last beta-blocker usage.~Phase II:~BB dosage will be reduced."
58128520|NCT06304389|OTHER|transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration|Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
58315194|NCT00080054|DRUG|Motexafin Gadolinium Injection|
58315195|NCT06518226|RADIATION|Ultrahypofractionated MRgRT in 2 fractions|2x12 Gy with boost to GTV up to 13.5 Gy
58315196|NCT06518226|RADIATION|Standard of care: MRgRT in 5 fractions|5x7.25 Gy
58315197|NCT01026935|DEVICE|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
58315198|NCT02246777|DEVICE|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
58315199|NCT00323219|DRUG|Cefazolin and Moxifloxacin|See Detailed Description.
58315200|NCT06557681|DEVICE|Virtual Reality-Treadmill Training Group (VTT)|The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.
58315201|NCT06557681|OTHER|Conventional Therapy Group (CT)|The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
58315202|NCT01267578|BIOLOGICAL|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
58315203|NCT02804893|PROCEDURE|VATS|Thorax thoracoscopic surgery (lobectomy)
58315204|NCT02804893|PROCEDURE|RATS|Thorax robotic surgery (lobectomy)
58315205|NCT06033378|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
58315206|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315207|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315208|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
57755848|NCT01016301|OTHER|Pharmacist service|Medication Review, medication report
58315209|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315210|NCT03634423|BEHAVIORAL|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315211|NCT03634423|BEHAVIORAL|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315212|NCT03634423|BEHAVIORAL|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315213|NCT03634423|BEHAVIORAL|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315214|NCT03634423|BEHAVIORAL|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315215|NCT03634423|BEHAVIORAL|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315216|NCT03634423|BEHAVIORAL|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
58315217|NCT03634423|BEHAVIORAL|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
57755849|NCT06415448|DRUG|Donidalorsen|Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
57755850|NCT00246233|DRUG|methylphenidate|
58128521|NCT03270007|DRUG|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
58128522|NCT02026453|OTHER|Pharmacist obtains admission medication history|
58128523|NCT02026453|OTHER|Pharmacy technician obtains admission medication history|
58454043|NCT04551118|DEVICE|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
57755851|NCT04721379|BEHAVIORAL|Meditation|"1. Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~2. Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
57755852|NCT00929084|OTHER|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
57755853|NCT03445065|DEVICE|Eversense XL CGM System|The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
57755854|NCT03445065|DEVICE|Usual SMBG or FGM device used by participants|Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
57755855|NCT01738750|OTHER|Cost Information Included|
57755856|NCT03967769|DEVICE|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
57755857|NCT03294889|RADIATION|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~* 19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~* 17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
57755858|NCT00674622|DRUG|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
57755859|NCT00674622|PROCEDURE|Placebo|Saline/lidocaine
57755860|NCT01487044|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
57755861|NCT05104528|DEVICE|OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3|Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
57769741|NCT04219618|DEVICE|Off-Pump|After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
58315218|NCT06277375|BEHAVIORAL|Massage|The application starts from the neck with small circular strokes with the thumbs. Surface strokes are performed with the palm of the hand from the base of the skull towards the sacral region. Then rhythmic strokes are repeated from the sacrum along the entire spine towards the skull.The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
58315219|NCT00968162|DRUG|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
58315220|NCT03860155|BIOLOGICAL|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
58315221|NCT04508816|DRUG|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
57755862|NCT05104528|DEVICE|Fujifilm Sonosite M-Turbo C Ultrasound system|A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
58128524|NCT05404035|BEHAVIORAL|Family Connections for relatives of people with eating disorders and personality disorders|"The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment."
58128525|NCT05404035|BEHAVIORAL|Optimized Treatment As Usual|"Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs."
58128526|NCT05201690|DRUG|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
58454044|NCT04551118|DEVICE|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
57755863|NCT01970605|PROCEDURE|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
57755864|NCT02525614|DEVICE|Triathlon Standard Keel|Implantation of Knee Prosthesis
57755865|NCT02525614|DEVICE|Triathlon Short Keel|Implantation of Knee Prosthesis
58128527|NCT05201690|DRUG|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
58315222|NCT05392400|DEVICE|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
58315223|NCT05392400|OTHER|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
58315224|NCT05293795|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
58315225|NCT05293795|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
58315226|NCT06514131|PROCEDURE|Pre-moistened wipes|Patients receiving the experimental treatment will have perineal hygiene performed with the pre-moistened wipes without water
58315227|NCT03335527|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
58454045|NCT00001002|DRUG|Zidovudine|
58454046|NCT00001002|DRUG|Foscarnet sodium|
58454047|NCT04561895|GENETIC|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
58454048|NCT03287817|BIOLOGICAL|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).
57755866|NCT05673629|DRUG|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
57755867|NCT05673629|DRUG|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
57755868|NCT00571701|DRUG|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
57755869|NCT00571701|DRUG|placebo|similar appearing capsules containing inert ingredients
58315228|NCT03335527|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
58315229|NCT01065441|BIOLOGICAL|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10\^7 cells
58315230|NCT01065441|PROCEDURE|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
58315231|NCT01065441|BIOLOGICAL|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10\^7 cells
58315232|NCT01065441|BIOLOGICAL|AlloStim|intravenous AlloStim-TM at doses between 1 x 10\^7 to 1 x 10\^9 cells
58315233|NCT01065441|BIOLOGICAL|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
58315234|NCT01065441|BIOLOGICAL|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10\^7 cells.
58315235|NCT01065441|BIOLOGICAL|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
58315236|NCT02101151|DIETARY_SUPPLEMENT|Vitamin D3(cholecalciferol)|
58315237|NCT05304325|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
58315238|NCT05304325|OTHER|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
58315239|NCT05304325|OTHER|Blood pressure|Systolic and diastolic blood pressure will be measured.
58315240|NCT05304325|OTHER|Anthropometric measurements|Body weight, height and waist circumference will be measured.
58315241|NCT05304325|OTHER|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
58315242|NCT05304325|OTHER|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
58315243|NCT05304325|OTHER|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
58315244|NCT05304325|PROCEDURE|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
58315245|NCT02707497|DRUG|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
58315246|NCT02707497|DRUG|Placebo|The control group will not use any platelet-increased drugs.
58315247|NCT03595397|DRUG|Bupivacaine|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
58315248|NCT03595397|DRUG|Magnesium Sulfate|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
58315249|NCT03595397|DRUG|Fentanyl|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
58315250|NCT03595397|PROCEDURE|Thoracic epidural|All patients will receive mid-thoracic epidural analgesia
58315251|NCT05429996|OTHER|Skin Biopsy|Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril
58315252|NCT01314729|DEVICE|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
58315253|NCT01314729|DEVICE|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
58315254|NCT03749161|DEVICE|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
58315255|NCT03749161|DEVICE|Monofocal IOL|Lentis L-313, monofocal IOL
58315256|NCT02054156|DRUG|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
58315257|NCT02054156|DRUG|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
58315258|NCT02054156|DRUG|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
58315259|NCT02025075|DRUG|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
58315260|NCT00557466|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
57755870|NCT06064864|DRUG|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
57755871|NCT04509895|PROCEDURE|Lateral extensile approach in calcaneal fractures fixation|The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.
57755872|NCT04509895|PROCEDURE|Minimally invasive sinus tarsi approach in calcaneal fractures fixation|An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
57755873|NCT03256825|DIAGNOSTIC_TEST|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
57755874|NCT03256825|OTHER|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration"
57755875|NCT00783380|BIOLOGICAL|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
57755876|NCT00783380|BIOLOGICAL|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
57755877|NCT04957862|PROCEDURE|Robotic Assisted Evacuation|On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
57755878|NCT05767684|BIOLOGICAL|Dendritic Cell Vaccine|Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
57755879|NCT05767684|DRUG|Lenvatinib|Lenvatinib 10mg/day on day 43-77
57755880|NCT05767684|DRUG|Nivolumab|Nivolumab 3mg/kg on day 43, 57 and 71.
57755881|NCT05105802|BEHAVIORAL|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
57755882|NCT05105802|BEHAVIORAL|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
57755883|NCT05180266|OTHER|Therapeutic Touch|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
57755884|NCT05180266|OTHER|Music Listening Group|Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again
58128528|NCT05201690|DRUG|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
58315261|NCT00557466|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
58315262|NCT00557466|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
58315263|NCT00557466|DRUG|placebo to formoterol|Placebo AEROLIZER® device
58315264|NCT00557466|DRUG|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
58315265|NCT02585765|DRUG|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
58315266|NCT02585765|DRUG|Placebo|8 weeks of daily placebo capsules.
57755885|NCT05180266|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
57755886|NCT00169000|DRUG|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
57755887|NCT00169000|DRUG|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
57755888|NCT03402516|DEVICE|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
57755889|NCT03402516|DEVICE|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
57755890|NCT00895700|BEHAVIORAL|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
57755891|NCT02350712|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
58454049|NCT01513408|OTHER|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
58454050|NCT00990106|DRUG|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
57755892|NCT02350712|DRUG|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
57755893|NCT02350712|DRUG|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
58454051|NCT00990106|DRUG|placebo|placebo
58454052|NCT01467505|DRUG|Telaprevir|Tablet
58454053|NCT01467505|DRUG|Ribavirin|Tablet
57755894|NCT02350712|DRUG|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
57755895|NCT01068808|PROCEDURE|skin prick test|skin prick test to aeroallergen
57755896|NCT05160324|PROCEDURE|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
57755897|NCT05160324|PROCEDURE|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
58454054|NCT01467505|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
57755898|NCT02281448|DRUG|BIA 2-093|
57755899|NCT02281448|DRUG|Contraceptives, Oral, Combined|
57755900|NCT05284825|RADIATION|12 Gy in 6 daily fractions|12 Gy in 6 daily fractions
57755901|NCT00539279|BEHAVIORAL|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
57755902|NCT00539279|BEHAVIORAL|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
57755903|NCT05140330|BEHAVIORAL|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
57755904|NCT05140330|BEHAVIORAL|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
58315267|NCT02668068|PROCEDURE|large volume whole-lung lavage (WLL)|Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
58315268|NCT02668068|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
57755905|NCT03645967|DEVICE|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
57755906|NCT04156490|OTHER|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
57755907|NCT02073461|DRUG|CD1579 2.5%|
57755908|NCT02073461|DRUG|CD1579 5%|
58315269|NCT03477175|DRUG|E7080|Oral Administration.
58315270|NCT03477175|DRUG|Comparator Drug|Per parent study.
58315271|NCT03477175|DRUG|Comparator Drug: Sorafenib|Per parent study.
58315272|NCT01518062|DRUG|somatropin|4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
58315273|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
57755909|NCT02073461|DRUG|Vehicle|
57755910|NCT04293263|COMBINATION_PRODUCT|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
57755911|NCT04059757|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
57755912|NCT02644590|DRUG|Melatonin|Detailed in arm description
57755913|NCT03381261|DRUG|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
57755914|NCT02503267|OTHER|none intervention|
57755915|NCT04849130|PROCEDURE|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
57755916|NCT04849130|PROCEDURE|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
57755917|NCT06023875|DRUG|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
57755918|NCT06023875|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
57755919|NCT06023875|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
57755920|NCT05224375|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
57755921|NCT01487980|PROCEDURE|Cord clamping|Early vs Delayed
57755922|NCT04150991|OTHER|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
57755923|NCT04150991|OTHER|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
57755924|NCT05032365|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
57755925|NCT05032365|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
57755926|NCT01062503|DRUG|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
57755927|NCT00109044|DRUG|Escitalopram|
57755928|NCT04322604|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
57755929|NCT04322604|OTHER|Placebo|Placebo
57755930|NCT00426608|DRUG|metyrapone|Metyrapone will be available as 250 mg dose capsule.
57755931|NCT00426608|DRUG|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
57755932|NCT00426608|DRUG|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
57755933|NCT00426608|DRUG|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
58315274|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
58454055|NCT01467505|DRUG|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
57755934|NCT01456299|DRUG|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
57755935|NCT01456299|DRUG|Control|The control group, which received an infusion of normal saline
57755936|NCT01456299|DRUG|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
57755937|NCT04177225|PROCEDURE|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
57755938|NCT04177225|OTHER|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
57755939|NCT03945864|DEVICE|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
57755940|NCT03945864|DEVICE|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
57755941|NCT01360541|PROCEDURE|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
57755942|NCT01360541|OTHER|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
57755943|NCT06524063|DRUG|Survivin-loaded dendritic cell injection|The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
57755944|NCT05168579|BEHAVIORAL|Deliberate practice|As above
57755945|NCT04956328|DRUG|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
57755946|NCT04956328|DRUG|UDCA|UDCA：continue prestudy dose
57755947|NCT04956328|DRUG|Placebo|Placebo
57755948|NCT00872040|OTHER|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
57755949|NCT02865070|DEVICE|Skin Sensor|Wireless vitals monitor
57755950|NCT00005855|DRUG|carmustine|
57755951|NCT00005855|DRUG|efaproxiral|
57755952|NCT05384028|OTHER|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
57755953|NCT05384028|OTHER|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
57755954|NCT03078816|DEVICE|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755955|NCT03078816|DEVICE|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755956|NCT03078816|DEVICE|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755957|NCT03078816|DEVICE|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
58315275|NCT01518062|DRUG|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
58315276|NCT00229801|RADIATION|MRI|
58458593|NCT05754294|DIAGNOSTIC_TEST|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
57755958|NCT03078816|DEVICE|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
58315277|NCT04747340|BEHAVIORAL|Training for Awareness Resilience and Action (TARA)|See arm-description
58315278|NCT04747340|OTHER|Standard treatment|See arm-description
58315279|NCT02967575|DEVICE|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible"
58315280|NCT00006126|DRUG|busulfan|
58315281|NCT00006126|DRUG|cyclophosphamide|
57755959|NCT03078816|DEVICE|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755960|NCT03078816|DEVICE|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755961|NCT03078816|DEVICE|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755962|NCT03078816|DEVICE|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
57755963|NCT04333420|DRUG|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
57755964|NCT04333420|DRUG|BSC|Phase II study part: BSC
57755965|NCT04333420|DRUG|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
57755966|NCT04333420|DRUG|Placebo + SOC|Phase III study part: Placebo + SOC
57755967|NCT03668587|OTHER|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
57755968|NCT00190502|DRUG|Polyclonal anti-T-cell antibodies|
57755969|NCT00794638|DRUG|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
58315282|NCT00006126|DRUG|etoposide|
58315283|NCT00006126|DRUG|fludarabine phosphate|
58315284|NCT00006126|PROCEDURE|peripheral blood stem cell transplantation|
58315285|NCT00006126|RADIATION|radiation therapy|
58315286|NCT03625024|BEHAVIORAL|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
57755970|NCT00794638|DRUG|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
57755971|NCT01222195|DRUG|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
57755972|NCT01222195|DRUG|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
58454056|NCT01658748|DEVICE|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
58458594|NCT03905096|DRUG|BI 425809|Film coated tablet
57755973|NCT02930473|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
57755974|NCT02930473|DRUG|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
57755975|NCT04068350|OTHER|Pain questionnaire|Pain questionnaire, 3 months after surgery
57755976|NCT00213655|BIOLOGICAL|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
57755977|NCT03839654|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
57755978|NCT01843998|DRUG|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
57755979|NCT03404492|OTHER|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
58128529|NCT06348693|OTHER|cell isolation from tumor biopsies and biomarker investigation|cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
58128530|NCT02747745|BEHAVIORAL|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
58128531|NCT05366959|OTHER|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
57755980|NCT04236258|DRUG|NIFEdipine ER|Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
57755981|NCT04236258|DRUG|Enalapril|Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
58128532|NCT05366959|OTHER|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
58315287|NCT06480630|DRUG|Basiliximab|Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
57755982|NCT01747590|DRUG|Zolpidem|
57755983|NCT01747590|DRUG|Alprazolam|
57755984|NCT01747590|DRUG|Caffeine|
57755985|NCT01747590|OTHER|Placebo|
57755986|NCT06349148|DIETARY_SUPPLEMENT|enteral immunonutrition|Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).
57755987|NCT06349148|DIETARY_SUPPLEMENT|standard oral enteral nutrition|Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).
57755988|NCT05795530|PROCEDURE|cochlear implantation|surgery for bilateral hearing loss
57755989|NCT03075059|BEHAVIORAL|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
58458595|NCT03905096|DRUG|Donepezil|Film coated tablet
57755990|NCT00844857|DRUG|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
57755991|NCT00844857|DRUG|Placebo|Orally, once daily in the evening for 8 weeks.
57755992|NCT03991117|BEHAVIORAL|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
57755993|NCT05383664|OTHER|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
57755994|NCT01320332|DRUG|ASP3291|Oral tablets
57755995|NCT01320332|DRUG|Placebo|Oral tablets
57755996|NCT00107055|DRUG|REN-1654|
57755997|NCT05826925|OTHER|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
57755998|NCT00790452|DRUG|Aspirin|325 mg daily by mouth
57755999|NCT00790452|DRUG|Placebo|Tablet daily by mouth
57756000|NCT04462666|DRUG|Huzhang granule|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
57756001|NCT04462666|DRUG|Etoricoxib|take one capsule per day in the morning, at approximately 30 minutes after the meal.
57756002|NCT04462666|DRUG|Huzhang granule Placebo|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
57756003|NCT04462666|DRUG|Etoricoxib Placebo|take one capsule per day in the morning, at approximately 30 minutes after the meal.
57756004|NCT02015494|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine delivered IM
57756005|NCT06526364|OTHER|All participants will be asked to provide data and samples for collection and analysis.|"During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC)."
58128533|NCT05366959|OTHER|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
58128534|NCT05366959|OTHER|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
58128535|NCT01526538|DRUG|d-cycloserine|50 mg d-cycloserine
58128536|NCT01526538|DRUG|sugar pill|placebo
58315288|NCT05052905|DEVICE|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
58315289|NCT04363476|OTHER|SHRED Osteoarthritis program|Combined exercise and education intervention
57756006|NCT03790995|PROCEDURE|Robot assisted laparoscopic prostatectomy|
57756007|NCT01443221|DRUG|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
57756008|NCT01443221|DRUG|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
57756009|NCT05855369|DEVICE|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
57756010|NCT05855369|OTHER|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
58128537|NCT00796900|DRUG|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
57756011|NCT05855369|OTHER|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
57756012|NCT04414579|DRUG|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
57756013|NCT02537639|DEVICE|Transesophageal echocardiography simulator|
57756014|NCT04807465|DEVICE|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
57756015|NCT04807465|DEVICE|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
57756016|NCT04807465|DEVICE|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
57756017|NCT00779389|DRUG|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
57756018|NCT00779389|DRUG|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
57756019|NCT00779389|DRUG|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
57756020|NCT00779389|DRUG|Placebo|Placebo for 14-21 days.
57756021|NCT00779389|DRUG|Erlotinib|Erlotinib 150 mg for 14-21 days.
57756022|NCT02513069|OTHER|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
57756023|NCT02513069|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
57756024|NCT02513069|BEHAVIORAL|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
57756025|NCT02513069|OTHER|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
57756026|NCT02513069|OTHER|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
57756027|NCT02513069|OTHER|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
57756028|NCT02513069|OTHER|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
57756029|NCT03281122|DRUG|Placebo|Specified dose on specified days
57756030|NCT03281122|DRUG|BMS-986224|Specified dose on specified days
57756031|NCT00676286|PROCEDURE|3T MR Imaging|3TR Imaging
57756032|NCT00676286|PROCEDURE|C-Choline PET Scanning|C-Choline PET Scanning
57756033|NCT00676286|PROCEDURE|Gene Rearrangement|Gene Rearrangement
57756034|NCT04340310|DIAGNOSTIC_TEST|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
57756035|NCT02560870|DRUG|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
57756036|NCT02560870|DRUG|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
57756037|NCT03414801|OTHER|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
58315290|NCT00891813|DRUG|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
58458596|NCT03600272|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
58458597|NCT03600272|PROCEDURE|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
57756038|NCT03372330|DRUG|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
57756039|NCT03372330|DRUG|Standard care for sepsis|The standard care for the patient with sepsis.
57756040|NCT05861362|RADIATION|Curative radiotherapy|Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist
57756041|NCT05861362|BEHAVIORAL|5:2 intermittent fasting|Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
57756042|NCT00947661|DRUG|SPARC0912|Eye drops, once daily, 12 weeks
57756043|NCT00947661|DRUG|Reference0912|Eye drops, once daily, 12 weeks
57756044|NCT03504098|BEHAVIORAL|nutrition consult|Post-lung cancer operation diet pattern
58315291|NCT03004040|BIOLOGICAL|Flu Vaccine|
58315292|NCT01981083|DIETARY_SUPPLEMENT|Egg albumin-based protein supplement|
58454057|NCT01658748|DEVICE|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
58454058|NCT02371824|OTHER|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
57756045|NCT03848702|DEVICE|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
57756046|NCT02007642|PROCEDURE|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
57756047|NCT01855854|DRUG|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
57756048|NCT00209807|DRUG|escitalopram|escitalopram 10 mg/d for 6 weeks
57756049|NCT00209807|DRUG|Reboxetine|Reboxetine 8 mg/d for 6 weeks
57756050|NCT00209807|OTHER|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
57756051|NCT05582304|DEVICE|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
57756052|NCT05582304|DEVICE|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
57756053|NCT02605226|PROCEDURE|Cryoablation therapy|Cryoablation therapy
57756054|NCT02605226|RADIATION|External beam radiation therapy|External beam radiation therapy
57756055|NCT02605226|DRUG|bicalutamide|bicalutamide
58315293|NCT01981083|DIETARY_SUPPLEMENT|Renal-specific oral supplement|
58315294|NCT00883727|DRUG|Stem cell|IV infusion of stem cells
58315295|NCT00883727|DRUG|Plasmalyte A|IV infusion
58454059|NCT00295191|PROCEDURE|high-flux membrane|high-flux dialyser
58454060|NCT00295191|PROCEDURE|low-flux membrane|low-flux dialyser
58454061|NCT00295191|PROCEDURE|conventional dialysate|conventional dialysate
58454062|NCT00295191|PROCEDURE|ultrapure dialysate|ultrapure dialysate
58454063|NCT02456155|PROCEDURE|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
58454064|NCT02456155|PROCEDURE|placing nasal jejunal tube endoscopically|
58454065|NCT00293917|DRUG|Tacrolimus Cream|
58454066|NCT03326804|DEVICE|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
58454067|NCT04426318|BEHAVIORAL|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
58454068|NCT04524416|DEVICE|Minimally invasive glaucoma surgery (MIGS)|MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
58454069|NCT05921435|DRUG|CKD-341, D958|A single dose of 1tablet under fasting condition
57756056|NCT02605226|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
57756057|NCT02158884|DEVICE|IDEO brace|All participants will receive the IDEO brace.
57756058|NCT03793725|DRUG|SHR1210|Anti-PD-1 Antibody
57756059|NCT03793725|DRUG|Apatinib|Anti-angiogenic drugs
57756060|NCT01398670|BIOLOGICAL|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
57756061|NCT01398670|BIOLOGICAL|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
57756062|NCT02486601|DRUG|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
58315296|NCT04525196|OTHER|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
57756063|NCT02486601|DRUG|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
57756064|NCT05667467|PROCEDURE|Care Bundle Implementation|"In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses."
58454070|NCT04934371|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
58454071|NCT04934371|DEVICE|Sham TDCS|Sham control will be administered to the same area as active TDCS
58454072|NCT00495729|DRUG|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
58454073|NCT00495729|DRUG|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
58454074|NCT00495729|DRUG|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
58454075|NCT04353128|DRUG|Melatonin 2mg|2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
58454076|NCT04353128|DRUG|Placebo oral tablet|Identically looking placebo tablets P.O. before bedtime for 12 weeks
58454077|NCT00153036|DRUG|rt-PA 0.9 mg/kg verum or placebo Intravenous|
58454078|NCT04092153|DEVICE|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
58454079|NCT03767647|BEHAVIORAL|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
58454080|NCT02980471|DEVICE|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
58454081|NCT01175863|DEVICE|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
58454082|NCT01175863|DEVICE|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
58454083|NCT01777074|OTHER|Data collection|Questionnaire, Vaccination book
58454084|NCT03746626|BEHAVIORAL|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
58454085|NCT00809263|DRUG|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
58454086|NCT02447965|DRUG|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
58454087|NCT02447965|DRUG|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
58454088|NCT03111563|OTHER|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
58454089|NCT03729648|BEHAVIORAL|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
57756065|NCT02780232|BEHAVIORAL|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~1. What is 'CUIDA TU ÁNIMO': Description and definition of the program~2. Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~3. How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~4. Forums.~5. Blog.~6. Appointment (Chat or Phone call).~7. Contact."
58128538|NCT00796900|DRUG|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
58315297|NCT05374278|DRUG|[18F]RP-115 PET/MRI or PET/CT and MRI|An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
58315298|NCT05001048|DRUG|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
58315299|NCT05001048|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
58454090|NCT00075712|DRUG|carboplatin|
58454091|NCT00075712|DRUG|paclitaxel|
58454092|NCT00075712|PROCEDURE|adjuvant therapy|
58454093|NCT00075712|PROCEDURE|conventional surgery|
58454094|NCT00075712|PROCEDURE|neoadjuvant therapy|
58454095|NCT01544725|DRUG|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
58458598|NCT00976131|DRUG|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
58458599|NCT00976131|OTHER|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
58458600|NCT00976131|DRUG|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
57756066|NCT03951038|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
57756067|NCT03951038|PROCEDURE|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
57756068|NCT04092725|DRUG|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
57756069|NCT04092725|DRUG|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
57756070|NCT05752799|DRUG|Opioid Free Anaesthesia|"* 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
57756071|NCT05752799|DRUG|Opioid based anesthesia|"* 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
57756072|NCT06259422|DRUG|Iohexol|Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
57756073|NCT06259422|DIAGNOSTIC_TEST|125I-iothalamate and 131I-hippuran|Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
57756074|NCT04961008|OTHER|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
57756075|NCT04961008|OTHER|Routine physiotherapy|Routine pulmonary physiotherapy
57756076|NCT02543255|DRUG|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
57756077|NCT02543255|DRUG|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
57756078|NCT02543255|DRUG|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
57756079|NCT02037438|OTHER|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
57756080|NCT02037438|OTHER|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
57756081|NCT01851174|DRUG|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion
57756082|NCT01851174|DRUG|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
57756083|NCT01301391|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
57769742|NCT04219618|DEVICE|On-Pump|A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
57769743|NCT00119262|DRUG|doxorubicin hydrochloride|Given IV
58128539|NCT02287532|DEVICE|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
58128540|NCT04418141|DRUG|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
58315300|NCT05001048|OTHER|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
58315301|NCT05001048|OTHER|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
58315302|NCT00640289|DRUG|Fibrogammin P|Prophylaxis treatment
58315303|NCT01883674|OTHER|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
58315304|NCT00750269|RADIATION|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
58315305|NCT00750269|RADIATION|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
58315306|NCT00750269|RADIATION|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
58315307|NCT00750269|RADIATION|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
57756084|NCT05606016|BEHAVIORAL|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
57756085|NCT05606016|BEHAVIORAL|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
57756086|NCT05606016|BEHAVIORAL|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
57756087|NCT04949958|OTHER|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
57756088|NCT04949958|OTHER|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
57756089|NCT04949958|OTHER|Control|General advice to be active
57756090|NCT04859725|DEVICE|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
57756091|NCT03582774|OTHER|Best Practice|Undergo standard of care
57756092|NCT03582774|PROCEDURE|Computed Tomography|Undergo PET/CT
57756093|NCT03582774|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
57756094|NCT03582774|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57756095|NCT02513108|PROCEDURE|same day discharge|same day discharge after PCI for stable CAD
57769744|NCT00119262|DRUG|cyclophosphamide|Given IV
58128541|NCT02465658|OTHER|Medical records were reviewed.|retrospective study
58454096|NCT01544725|DRUG|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
57960859|NCT04141709|RADIATION|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~* Scheme A 3\*10 Gy (once a day, 2-3 days a week)~* Scheme B 25\*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3\*10 Gy or 25\*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
57960860|NCT00739414|DRUG|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
57960861|NCT04830670|PROCEDURE|sinus floor elevation with lateral approach|sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
57960862|NCT05210179|BIOLOGICAL|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
58128542|NCT03102580|OTHER|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
58128543|NCT00238069|DEVICE|CPAP machine as a result of sleep study|
58128544|NCT01925313|DRUG|CJ-30044|20.51mg a day,PO,QD
58128545|NCT01925313|DRUG|TALION TAB. 10mg|10mg a day,PO,BID
58315308|NCT00750269|RADIATION|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
58315309|NCT00750269|RADIATION|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
58128546|NCT01051193|DRUG|Oxcarbazepine|
58128547|NCT01783171|DRUG|Akt Inhibitor MK2206|Given PO
58315310|NCT00750269|RADIATION|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
58315311|NCT00750269|RADIATION|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
58315312|NCT00750269|RADIATION|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
58454097|NCT03882892|DRUG|Ezetimibe|Ezetimibe 10 mg tablets
58454098|NCT03882892|DRUG|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
58454099|NCT03882892|DRUG|Placebo|Placebo tablets matched to ezetimibe
58454100|NCT02055898|DRUG|Sodium Oxybate|
58454101|NCT02055898|OTHER|placebo (fresh potable water)|
58454102|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
58454103|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
58454104|NCT04690140|PROCEDURE|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
58454105|NCT04690140|PROCEDURE|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
58454106|NCT04021095|DEVICE|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
58454107|NCT00276510|DRUG|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
58454108|NCT00276510|OTHER|Placebo|1 tablet twice a day, oral route, during 5 years.
58454109|NCT03932877|OTHER|MMP-14 and s-ENG levels|Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
58454110|NCT01618032|OTHER|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
58454111|NCT01618032|OTHER|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
58454112|NCT01618032|OTHER|placebo|Manual contact during a period of time similar of teh other interventions
58454113|NCT00556907|RADIATION|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
58454114|NCT00556907|DEVICE|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
58454115|NCT00992758|BIOLOGICAL|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
58454116|NCT01107951|DRUG|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)"
58454117|NCT02828761|DEVICE|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
58128548|NCT01783171|DRUG|Dinaciclib|Given IV
58315313|NCT05000827|DEVICE|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
58315314|NCT05000827|OTHER|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
58315315|NCT06157437|DEVICE|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
58454118|NCT02828761|PROCEDURE|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
58454119|NCT03065777|DEVICE|ONE ENDO|single file rotary system
58454120|NCT03065777|DEVICE|F6 SKYTaper|single file rotary system
58454121|NCT03065777|DEVICE|ProTaper Universal|multi-file rotary system
58454122|NCT05505448|DRUG|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
57756096|NCT05765279|DRUG|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
58315316|NCT03665324|OTHER|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
57756097|NCT05765279|DRUG|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
58128549|NCT01783171|OTHER|Laboratory Biomarker Analysis|Correlative studies
58128550|NCT01783171|OTHER|Pharmacological Study|Correlative studies
58128551|NCT02070237|DRUG|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
58315317|NCT02702544|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
58315318|NCT02702544|DEVICE|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
58315319|NCT03035019|BEHAVIORAL|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
58454123|NCT05505448|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
58454124|NCT01476007|DRUG|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
58454125|NCT01476007|DRUG|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
58454126|NCT03104296|DIAGNOSTIC_TEST|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
58454127|NCT06156371|OTHER|lymphatic drainage massage|"Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated."
58454128|NCT06156371|OTHER|classic massage|The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.
58315320|NCT04562909|DEVICE|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
58315321|NCT00607893|DEVICE|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
58315322|NCT00607893|DEVICE|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
58315323|NCT02712853|OTHER|Saliva collection|Collection of saliva via swab for miRNA processing
58315324|NCT02712853|OTHER|Vineland Adaptive Behavior Scale-II Assessment|
58315325|NCT03661775|DRUG|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
58315326|NCT02826213|DEVICE|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
58315327|NCT02826213|DEVICE|Waves perfusion device|Renal Perfusion with Waves perfusion device
58315328|NCT01763229|PROCEDURE|transthoracic echocardiography|
58315329|NCT04075448|OTHER|Control|100 grams breakfast cereal
58315330|NCT04075448|OTHER|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
58315331|NCT00960427|DRUG|systemic chemotherapy|
58315332|NCT00960427|GENETIC|RNA analysis|
58315333|NCT00960427|GENETIC|gene expression analysis|
58315334|NCT00960427|GENETIC|reverse transcriptase-polymerase chain reaction|
58315335|NCT00960427|OTHER|immunohistochemistry staining method|
58315336|NCT00960427|OTHER|laboratory biomarker analysis|
58315337|NCT00960427|PROCEDURE|endoscopic biopsy|
58315338|NCT00960427|PROCEDURE|neoadjuvant therapy|
58315339|NCT00960427|PROCEDURE|sigmoidoscopy|
58315340|NCT00960427|RADIATION|radiation therapy|
58315341|NCT03517982|DRUG|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
58315342|NCT06461754|OTHER|Sonographic evaluation of diaphragm and lung|While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
58315343|NCT02190201|DEVICE|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
58458601|NCT00976131|DRUG|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
58315344|NCT02190201|DEVICE|Direct laryngoscope|A kind of traditional laryngoscopes
58315345|NCT00757653|DEVICE|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
58315346|NCT00757653|DEVICE|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
58315347|NCT00757653|DEVICE|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
58315348|NCT04573270|BIOLOGICAL|PrimePro|Intravenous Injection
58315349|NCT04573270|OTHER|Placebo|Intravenous Injection
57756098|NCT05765279|DRUG|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
57756099|NCT05765279|DRUG|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
57756100|NCT01806584|BIOLOGICAL|SRM003|One time implant (3 SRM003 pieces) on surgery day.
57756101|NCT01806584|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
57756102|NCT06469749|BEHAVIORAL|Theory-based and peer-led intervention on Instagram|"A pilot randomized controlled trial of the 12-weeks social media intervention for non-medical use of prescription opioids (NMUPO) among young adults will be developed upon the formative research (Aim 1) grounded in the information-motivation-behavioral-skills (IMB) model. Intervention will be delivered by peer leaders, who are well-trained recovery coaches, via private groups on Instagram. Intervention contents will be tailored to psychosocial factors contributing to NMUPO.~Intervention components. Incorporating Instagram functions, the intervention is planned to include four intervention modules: (1) NMUPO knowledge module, (2) self-care module, (3) virtual goal setting/monitoring module, (4) peer support module. Intervention will be delivered by peer leaders (assisted by clinical psychology trainees a) via private groups operated by their Instagram accounts. The process will be overseen by certificated experts in clinical psychology and addiction treatment."
57756103|NCT03065296|BEHAVIORAL|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
57756104|NCT03065296|OTHER|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
57756105|NCT03041779|DRUG|Diclofenac Sodium 50Mg Suppository|
57756106|NCT03041779|DRUG|Paracetamol 500Mg Suppository|
57756107|NCT00639730|DIETARY_SUPPLEMENT|modified Atkins diet|High fat, low carbohydrate diet
57756108|NCT00420199|DRUG|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
57756109|NCT00420199|DRUG|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
57756110|NCT06128733|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
57756111|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
57756112|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
57756113|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
57756114|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
57756115|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
57756116|NCT06128733|BIOLOGICAL|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
57756117|NCT06128733|BIOLOGICAL|MenABCYW conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
57756118|NCT02524041|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
57756119|NCT02524041|OTHER|blood specimen|blood specimen
57756120|NCT04189354|DEVICE|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
58454129|NCT05971550|OTHER|Absence of antibiotic treatment|Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
58454130|NCT05971550|DRUG|Ceftriaxone|Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
57756121|NCT00533104|PROCEDURE|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
57756122|NCT00533104|PROCEDURE|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
57756123|NCT02979639|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
57756124|NCT03221725|PROCEDURE|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
57756125|NCT01624948|DRUG|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
57756126|NCT01624948|DRUG|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
57756127|NCT03921125|DEVICE|Massimo for Pleth variability index|To assess fluid response
57756128|NCT03261284|DIAGNOSTIC_TEST|D-dimer-guided adjustment stratege|D-dimer-guided adjustment stratege
57756129|NCT03261284|DIAGNOSTIC_TEST|Thepeautic-heparin therapy|0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
57769745|NCT00119262|BIOLOGICAL|bevacizumab|Given IV
57756130|NCT01737346|DRUG|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
57756131|NCT00002180|DRUG|Tenofovir|
57756132|NCT00290602|DRUG|Methylprednisolone sodium succinate|
57756133|NCT04093674|PROCEDURE|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
57756134|NCT04111757|DEVICE|Technolas® TENEO 317 Model 2|LASIK eye surgery
57756135|NCT00264420|DRUG|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
57756136|NCT06286085|OTHER|Lung function tests|Pulmonary function tests
57756137|NCT04295954|OTHER|Yoga Intervention|"It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards."
57756138|NCT04602884|DIAGNOSTIC_TEST|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
57756139|NCT02065765|BIOLOGICAL|Ramucirumab|Administered intravenously (IV)
57960863|NCT05210179|BIOLOGICAL|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
57756140|NCT00056225|DRUG|Folate|
57756141|NCT00056225|DRUG|Vitamin B6|
57756142|NCT00056225|DRUG|Vitamin B12|
57756143|NCT01600664|BEHAVIORAL|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
57756144|NCT01600664|BEHAVIORAL|Convertible PC|Participants will be using the convertible PC without the interactive computer game
57756145|NCT02127086|OTHER|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
57756146|NCT01873170|DRUG|levonorgestrel exposure|
57756147|NCT01873170|DRUG|DMPA exposure|
57756148|NCT01873170|DRUG|etonogestrel exposure|
57756149|NCT01873170|DEVICE|IUD insertion|
57756150|NCT01873170|DEVICE|subdermal contraceptive implant insertion|
57756151|NCT04939545|DRUG|Ropivacain|"Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
57756152|NCT04939545|DRUG|NaCl 0.9%|"Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
57756153|NCT06525818|OTHER|Tube weaning therapy intervention|Participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in individual virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Therapies intervention group participants are already receiving or who begin to receive during the study period will not be stopped during this intervention. The Speech Therapist and Occupational Therapist will be utilized as needed for the child's individualized care plan. They will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.
57769746|NCT00119262|DRUG|paclitaxel|Given IV
57769747|NCT00119262|BIOLOGICAL|filgrastim|Given SC
57769748|NCT00119262|BIOLOGICAL|pegfilgrastim|Given SC
57769749|NCT00119262|RADIATION|radiation therapy|Undergo radiation therapy
57769750|NCT00119262|DRUG|tamoxifen citrate|Given orally
57769751|NCT00119262|DRUG|aromatase inhibition therapy|Receive aromatase inhibition therapy
57769752|NCT02215733|DRUG|ARB|other than telmisartan
57769753|NCT02215733|DRUG|ACEI|
57960864|NCT00488891|DRUG|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
57960865|NCT00488891|DRUG|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
58315350|NCT00733798|DRUG|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
58315351|NCT03157089|DRUG|Afatinib|Film-coated tablet
58315352|NCT03157089|DRUG|pembrolizumab|Solution for infusion
57756154|NCT06525818|OTHER|Feeding Group|All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
57756155|NCT06448338|BEHAVIORAL|MyDiaMate|MyDiaMate program
57756156|NCT05484388|DEVICE|SN2|Investigational device absorption level Normal
57756157|NCT05484388|DEVICE|SP3|Investigational device absorption level Plus
57756158|NCT05771701|DEVICE|Pain pressure threshold measurement|"Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis)."
57756159|NCT00114608|DEVICE|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
57756160|NCT03965156|PROCEDURE|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
57756161|NCT03965156|PROCEDURE|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
57756162|NCT03200106|DEVICE|Alfapump|Alfapump implant
57756163|NCT05127525|DRUG|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
57756164|NCT05127525|DRUG|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
57756165|NCT04955834|DRUG|Insulin degludec injection|long-acting insulin
57756166|NCT04955834|DRUG|Tresiba®|long-acting insulin
57756167|NCT04885933|DIAGNOSTIC_TEST|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
57756168|NCT03379194|BEHAVIORAL|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
57756169|NCT04537468|OTHER|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
57756170|NCT04537468|OTHER|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
57756171|NCT04537468|OTHER|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
57769754|NCT02215733|DRUG|Beta-blockers|
57769755|NCT02215733|DRUG|Diuretics|
57769756|NCT02215733|DRUG|Telmisartan|
57960866|NCT00273377|OTHER|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
57756172|NCT00656279|BEHAVIORAL|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
57756173|NCT01406522|DRUG|Oral tacrine|Tacrine, 160 mg per day, four times daily
57756174|NCT01406522|DRUG|Oral placebo|Microcrystalline cellulose
57756175|NCT03292848|DRUG|Brexpiprazole|Tablet
57756176|NCT02839343|RADIATION|radiation therapy|
57756177|NCT02839343|PROCEDURE|surgery|
57756178|NCT02839343|DRUG|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
57756179|NCT02839343|DRUG|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
57756180|NCT02187913|DIETARY_SUPPLEMENT|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
58454131|NCT06107140|OTHER|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
57756181|NCT04440839|OTHER|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
57756182|NCT04876040|DEVICE|SSO2 Downstream System|60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
57756183|NCT04876040|PROCEDURE|PCI + Impella|Standard of Care Intervention
57756184|NCT04504331|DRUG|Infigratinib|Oral dose
57756185|NCT04504331|DRUG|Tamoxifen|Oral Dose
57756186|NCT04504331|DRUG|Omnipaque 350|IV contrast agent
57756187|NCT04504331|DRUG|Iopamidol|IV contrast agent
57756188|NCT04504331|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
57756189|NCT01968525|BIOLOGICAL|pre-oxygen|3 min of preoxygenation before anesthesia induction.
57756190|NCT04424784|BIOLOGICAL|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
57756191|NCT00824980|DRUG|IP10.C8|IP10.C8 Gel 1%
57756192|NCT01542957|BEHAVIORAL|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
57756193|NCT01542957|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
57756194|NCT00003578|DRUG|CHOP regimen|
57756195|NCT00003578|DRUG|carmustine|
57756196|NCT00003578|DRUG|cyclophosphamide|
57756197|NCT00003578|DRUG|cytarabine|
57756198|NCT00003578|DRUG|doxorubicin hydrochloride|
57756199|NCT00003578|DRUG|etoposide|
57756200|NCT00003578|DRUG|melphalan|
57756201|NCT00003578|DRUG|prednisone|
57756202|NCT00003578|DRUG|vincristine sulfate|
57756203|NCT00003578|PROCEDURE|autologous bone marrow transplantation|
57756204|NCT00003578|PROCEDURE|peripheral blood stem cell transplantation|
57756205|NCT03831243|RADIATION|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
57756206|NCT03831243|RADIATION|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
57756207|NCT04709172|DRUG|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
57756208|NCT02573922|DRUG|oxycodone-naloxone|
57756209|NCT02573922|DRUG|Oxycodone|
57756210|NCT03265106|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
57756211|NCT02158117|DRUG|nasal naloxone|one puff in one nostril with the subject is lying down
57756212|NCT01331057|OTHER|NEEL test|An assessment for children in French with items extracted from the NEEL test
57756213|NCT01331057|OTHER|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
57756214|NCT01331057|OTHER|Interview|For parents of children include in the study: A semi -structured interview
57756215|NCT01119898|DRUG|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
57756216|NCT01119898|DRUG|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
57960867|NCT00273377|OTHER|Supplemental oxygen (80% vs. 30%)|
57960868|NCT00273377|DRUG|Dexamethasone|4 mg
57960869|NCT00273377|DRUG|Placebo|placebo
58315353|NCT01110941|DRUG|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
58315354|NCT03318172|DEVICE|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
58454132|NCT06317571|BEHAVIORAL|fertility support education|In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
58454133|NCT06042959|OTHER|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
58454134|NCT04058041|PROCEDURE|Neural Mobilization|neural exercise Will be performed in the patients
58454135|NCT04058041|PROCEDURE|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
58454136|NCT04058041|PROCEDURE|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
58454137|NCT00408850|DRUG|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
58454138|NCT00408850|DRUG|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
58454139|NCT03564652|DIETARY_SUPPLEMENT|Balanced energy-protein (BEP)|Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
58454140|NCT03564652|DRUG|Azithromycin|A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
58454141|NCT04969029|DRUG|Tirelizumab|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
58454142|NCT00232063|DRUG|ciclosporin|
58454143|NCT00230126|DRUG|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
58454144|NCT00374439|BEHAVIORAL|Cognitive-behavioral|Cognitive-behavioral approach
58454145|NCT00374439|BEHAVIORAL|Interpersonal Therapy|Interpersonal therapy approach
58454146|NCT04143867|DEVICE|Nolix Device|For temporary management of SUI
57756217|NCT05788302|BEHAVIORAL|Prolonged Exposure|- Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
58315355|NCT04199520|COMBINATION_PRODUCT|surgery combined with systemic therapy|surgery combined with systemic therapy
58454147|NCT05695807|DEVICE|Carboxytherapy|Device generating CO2 gas
58454148|NCT01038141|PROCEDURE|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
58454149|NCT06212297|GENETIC|LX101|Subretinal administration of LX101 to the contralateral, previously uninjected eye
58454150|NCT04377217|OTHER|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
58454151|NCT01606072|DRUG|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
58454152|NCT01067677|DRUG|Metaclopramide|0.5 mg/kg for rescue after PONV
58454153|NCT01067677|DRUG|Ondansetron|0.1 mg/kg (max 4 mg0
58454154|NCT01067677|DRUG|diphenhydramine|0.25 mg/kg (max 25 mg)
58454155|NCT01067677|DRUG|Saline|equal volume (5 ml)as experimental rescue medications
58454156|NCT03279029|BIOLOGICAL|blood samples|blood samples
58454157|NCT03279029|BIOLOGICAL|biopsy|biopsy of aortic valve
58454158|NCT05418296|DEVICE|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
58454159|NCT04154475|DIETARY_SUPPLEMENT|yogurt diet|500 g yogurt/day
58454160|NCT04154475|DIETARY_SUPPLEMENT|dairy diet|500 g non-yogurt dairy products
58454161|NCT04154475|DIETARY_SUPPLEMENT|standard diet|500 g soya-yogurt
58454162|NCT04787224|OTHER|immediate implant with vestibular socket therapy|A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
58458602|NCT01161186|DRUG|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
58458603|NCT05480683|DIAGNOSTIC_TEST|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
57756218|NCT04453423|DRUG|Anlotinib + Pemetrexed+Carboplatin|"Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle"
57756219|NCT04453423|DRUG|Pemetrexed|500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
57756220|NCT04453423|DRUG|Anlotinib + Pemetrexed|"Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)"
57756221|NCT04453423|DRUG|Anlotinib|12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
57756222|NCT06256289|DRUG|Canagliflozin 100mg Tab|Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
57756223|NCT06256289|DRUG|Metformin Hydrochloride|Metformin 1000mg twice daily
57756224|NCT01355601|OTHER|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
57756225|NCT01355601|OTHER|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
57756226|NCT02710292|DEVICE|Delefilcon A contact lenses|
57756227|NCT02710292|DEVICE|Narafilcon A contact lenses|
57756228|NCT00736489|DRUG|AZD3199|Dry powder for inhalation, single dose
57756229|NCT00736489|DRUG|Formoterol|Dry powder for inhalation, single dose
58315356|NCT04199520|OTHER|systemic therapy|systemic therapy
58458604|NCT04014335|DRUG|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
57756230|NCT00736489|DRUG|Placebo|Dry powder for inhalation, single dose
57756231|NCT05601401|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
57756232|NCT05100225|BIOLOGICAL|PTP-001|Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
57756233|NCT05100225|OTHER|Placebo control|The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
57756234|NCT00003979|DRUG|CHS 828|
57756235|NCT02026856|DRUG|sodium selenite pentahydrate|
57756236|NCT02026856|OTHER|placebo - continuous saline NaCl 50 ml|
57756237|NCT03034343|BEHAVIORAL|Mindfulness|
57756238|NCT03654781|DRUG|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
57756239|NCT03654781|PROCEDURE|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
57756240|NCT02487498|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
57756241|NCT02487498|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
57756242|NCT02487498|DRUG|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
57756243|NCT02487498|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
57756244|NCT03895164|BEHAVIORAL|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
57756245|NCT03895164|BEHAVIORAL|Standard NE|Standard nutrition education package from primary health care
57756246|NCT06484569|OTHER|Control|The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.
57756247|NCT06484569|OTHER|exercise and cranio sacral therapy|Posture exercises Stretching exercises Strengthening Exercises In addition, deep tissue massage will be applied to increase blood circulation and cranio-sacral therapy will be applied to increase cerebrospinal fluid circulation.
57756248|NCT01493687|DRUG|CD5024|CD5024 1% Cream, once daily
57756249|NCT01493687|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
57756250|NCT02877030|OTHER|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
57756251|NCT05488275|PROCEDURE|Surgery|MPFL reconstruction
57756252|NCT01674309|DRUG|FOLFORINOX|INTRAVENOUS administration
57756253|NCT03738839|DEVICE|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
57756254|NCT03738839|PROCEDURE|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
57756255|NCT03738839|PROCEDURE|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
57756256|NCT01059643|DRUG|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
57756257|NCT01059643|DRUG|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
57756258|NCT04034108|PROCEDURE|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
57756259|NCT06303076|DRUG|Tizanidine Hcl 4Mg Tab|"Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response."
57756260|NCT06303076|DRUG|Zolpidem Tartrate 10 mg|"nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose."
57756261|NCT01758835|OTHER|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
57756262|NCT01758835|OTHER|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
57756263|NCT01758835|OTHER|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
58454163|NCT05041231|DEVICE|Photobiomodulation therapy (PBT)|"Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm)."
58454164|NCT05041231|DEVICE|Sham Photobiomodulation therapy (Sham PBT)|Similar to active PBT, however, the device will not provide the active electromagnetic waves)
57756264|NCT04452292|OTHER|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
58454165|NCT02451917|DRUG|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
58454166|NCT02451917|DRUG|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
58454167|NCT01050634|DRUG|Aromasin (exemestane)|25mg oral tablet, daily, for \>1yr
58454168|NCT03678701|DIETARY_SUPPLEMENT|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
57756265|NCT04452292|OTHER|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
57756266|NCT03865966|OTHER||No intervention
57756267|NCT04916600|DEVICE|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
57756268|NCT02032160|BIOLOGICAL|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
57756269|NCT02032160|BIOLOGICAL|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
57756270|NCT00785317|DRUG|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
58315357|NCT00662337|DRUG|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
58315358|NCT00963235|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
58454169|NCT00317993|DRUG|ezetimibe|
58454170|NCT00317993|DRUG|simvastatin|
58454171|NCT00317993|DRUG|ezetimibe plus simvastatin|
58454172|NCT04453865|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
58454173|NCT04453865|OTHER|Online Resources and Referrals|Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
58454174|NCT03960216|PROCEDURE|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
58454175|NCT03960216|PROCEDURE|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
58454176|NCT01176032|DRUG|Aliskiren|Aliskiren 300 mg film coated tablets
58454177|NCT01176032|DRUG|Losartan|Losartan 100 mg tablets
57756271|NCT02262546|DRUG|Pramipexole extended-release (ER) tablets|
58454178|NCT01176032|DRUG|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
58454179|NCT01176032|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
57756272|NCT02262546|DRUG|Pramipexole immediate-release (IR) tablets|
57756273|NCT02262546|DRUG|Moxifloxacin|
57756274|NCT02262546|DRUG|Pramipexole Placebo|
57756275|NCT02262546|DRUG|Moxifloxacin Placebo|
57756276|NCT03002064|DRUG|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
57756277|NCT03002064|DRUG|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
57756278|NCT03002064|DRUG|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
57756279|NCT04469881|BEHAVIORAL|VR|"Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
57756280|NCT00580658|DEVICE|Medtronic Activa Gpi|Activa Therapy, Gpi
57756281|NCT06341621|DRUG|3-year abemaciclib without chemo|aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
57756282|NCT06341621|DRUG|treatment of physician's choice|treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
57756283|NCT03532308|DRUG|Fermented Soy|Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
57756284|NCT03532308|OTHER|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
57756285|NCT02395133|DRUG|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
58454180|NCT03780335|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
57756286|NCT02395133|DRUG|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
57756287|NCT02238925|DRUG|CPX-351|
57756288|NCT01299519|BEHAVIORAL|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
57961633|NCT04230863|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
57756289|NCT01299519|BEHAVIORAL|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
57756290|NCT02296190|DRUG|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
57756291|NCT02296190|DRUG|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
57756292|NCT01472874|DRUG|Once a day Trientine|Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
57756293|NCT03019354|DEVICE|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
57756294|NCT03019354|DEVICE|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
57756295|NCT03848598|DIAGNOSTIC_TEST|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
57756296|NCT03262740|DRUG|BMS-986195|Oral administration of specified dose on specified days
57756297|NCT03262740|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
57756298|NCT04839263|PROCEDURE|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op"
57756299|NCT02733809|DRUG|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
57756300|NCT01079559|DEVICE|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
57756301|NCT01079559|DEVICE|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
57756302|NCT03105284|PROCEDURE|Liposuction|Fat harvest by liposuction (Colemans method)
57756303|NCT05174481|OTHER|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
57756304|NCT01597830|OTHER|Mobility shoe|flat, specialized shoe
57756305|NCT01597830|OTHER|control shoe|control shoe
57756306|NCT01693692|DRUG|TD-9855 Group 1|
57756307|NCT01693692|DRUG|TD-9855 Group 2|
57756308|NCT01693692|DRUG|Placebo|
57756309|NCT04536311|PROCEDURE|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
57756310|NCT02878928|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
57756311|NCT05145725|BEHAVIORAL|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
58454181|NCT01662167|DRUG|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
58454182|NCT01662167|DRUG|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
58454183|NCT04916574|OTHER|Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum|Concentration of active substance on nasal mucosal surface in time
58454184|NCT02788344|OTHER|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
57756312|NCT01893385|DRUG|Vitamin D (drug)|
57756313|NCT01727063|PROCEDURE|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
57756314|NCT01834508|DRUG|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
57756315|NCT01686880|DEVICE|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
57961634|NCT02796378|DRUG|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
58454185|NCT03535974|DIETARY_SUPPLEMENT|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
58454186|NCT03535974|DIETARY_SUPPLEMENT|Placebo|Placebo administration for 6 weeks bid
57756316|NCT02223039|BIOLOGICAL|AbGn-168H|AbGn-168H monoclonal antibody
57756317|NCT02223039|BIOLOGICAL|Placebo|Placebo of AbGn-168H
57756318|NCT05081492|BIOLOGICAL|Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody|Given IT
57756319|NCT00586599|OTHER|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
57756320|NCT00432874|PROCEDURE|wound hydration method|Anterior vs lateral wound hydration
57756321|NCT04111068|DEVICE|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
57756322|NCT04111068|DEVICE|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
57756323|NCT06363825|DRUG|camrelizumab|"TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge."
57961635|NCT02796378|DRUG|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
57961636|NCT02796378|DRUG|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
57961637|NCT03198208|DRUG|Fentanyl dose administration|
57961638|NCT02861040|OTHER|Laboratory Biomarker Analysis|Correlative studies
57961639|NCT02861040|OTHER|Pharmacological Study|Correlative studies
57961640|NCT02861040|DRUG|Vincristine Sulfate Liposome|Given IV
57961641|NCT02861040|DRUG|Volasertib|Given IV
57961642|NCT05507866|OTHER|CSNEI|CSNEI is a policy intervention designed to address childhood obesity by modifying lunch and breakfast meal/menu items, changing the school cafeteria environments, and making changes to purchasing and procurement practices.
57961643|NCT01716572|DRUG|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
57961644|NCT01716572|PROCEDURE|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
57961645|NCT06000293|OTHER|Oral health education|Anticipatory Guidance (AG) provided to the primary caregivers-infant pairs in the intervention group
57961646|NCT04971005|DRUG|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
57961647|NCT04971005|DRUG|Ocrelizumab|600 mg every 6 months continuously
57756324|NCT04447430|DEVICE|bright light|treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
57756325|NCT04447430|DEVICE|dim red light|treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
58315359|NCT00963235|PROCEDURE|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
58454187|NCT01003847|DRUG|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
58454188|NCT01102088|RADIATION|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
58454189|NCT03006146|DRUG|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
58454190|NCT02710656|DEVICE|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
58454191|NCT02710656|DEVICE|Standard PTA|Percutaneous angioplasty performed with a standard balloon
58454192|NCT01400698|DRUG|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
58454193|NCT01400698|DRUG|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
57756326|NCT01916005|DEVICE|18F-FDG PET/CT|
57756327|NCT03610763|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
57756328|NCT03610763|BEHAVIORAL|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
57756329|NCT00034957|DRUG|Investigational drug|
57756330|NCT02236065|PROCEDURE|Umbilical cord blood therapy|
57756331|NCT02236065|BIOLOGICAL|Filgrastim|
57756332|NCT01690130|DEVICE|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
57961648|NCT04971005|DRUG|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
58454194|NCT01400698|OTHER|Observation only|Subjects were only observed.
58454195|NCT03550378|DRUG|MEDI0382|Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
58454196|NCT03550378|DRUG|Placebo|Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
57961649|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
57961650|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg single dose
57961651|NCT01244880|OTHER|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
58454197|NCT05196607|OTHER|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
58454198|NCT02060435|OTHER|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
57961652|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg tablet single dose
57961653|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
57961654|NCT01244880|OTHER|Placebo|Placebo tablet single dose
57961655|NCT01244880|OTHER|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
57961656|NCT01244880|OTHER|Placebo|Placebo tablet single dose
57961657|NCT02639897|OTHER|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
58454199|NCT05384340|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|On the first day, an acute test will be carried out with beet juice rich in nitrate, in which two units of juice will be provided, totaling 140 ml (800 mg of nitrate) for each protocol. That is, each participant will receive 2 units of juice bottles. From the second to the seventh day, participants will receive 6 units of vials of the juice corresponding to the first intervention on the first visit to the laboratory and will drink one vial a day for a week. Of the 8 units (100%), six bottles (75%) will be provided for the participants to take home. On the seventh day of the intervention, the participants will return to the laboratory for the consumption of the seventh and last bottle of juice. Between one protocol and another, a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
58454200|NCT02763423|PROCEDURE|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
58454201|NCT01454791|DRUG|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
58454202|NCT01454791|OTHER|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
58454203|NCT02632292|DEVICE|Absorb GT1|Bioresorbable vascular scaffold
58454204|NCT02632292|DEVICE|Promus|Everolimus-eluting stent
58454205|NCT01338337|DRUG|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
58454206|NCT05627271|OTHER|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
57756333|NCT01690130|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
58454207|NCT05627271|OTHER|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
58454208|NCT05627271|OTHER|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
57756334|NCT05448898|DRUG|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
57756335|NCT05448898|OTHER|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
57756336|NCT02569710|DRUG|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
57960870|NCT05430100|OTHER|The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
57961658|NCT02198807|DRUG|Fosmidomycin-Piperaquine|
58454209|NCT04508166|DRUG|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
58454210|NCT04508166|DRUG|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
58454211|NCT04508166|DRUG|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
57756337|NCT02569710|DRUG|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
57756338|NCT02569710|DRUG|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
57756339|NCT04391946|BEHAVIORAL|Data registry|Collection of clinical data, treatment regimens and survival data
57756340|NCT01768832|BEHAVIORAL|Treadmill|
57756341|NCT01768832|BEHAVIORAL|Tango|
57756342|NCT01768832|BEHAVIORAL|Stretching|
57756343|NCT03403426|DEVICE|Wingman Crossing Catheter|Endovascular CTO crossing
57756344|NCT05213195|DRUG|NKG2D CAR-NK|NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
57756345|NCT02607982|DRUG|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
57756346|NCT02607982|DRUG|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
57756347|NCT02607982|RADIATION|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
57961659|NCT05355350|DRUG|Piperacillin / Tazobactam Injection|4.5 grams QID
57756348|NCT06327464|DIETARY_SUPPLEMENT|Exogenous ketones|Consumption of a single exogenous ketone supplement with breakfast
57756349|NCT06143696|DRUG|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
57756350|NCT06143696|DRUG|Femoston|Oral administration, 1 pill each time, once a day
57756351|NCT01678131|DRUG|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
57756352|NCT01678131|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
57756353|NCT01678131|BIOLOGICAL|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
57961660|NCT05355350|DRUG|Meropenem|1 gram TID
57961661|NCT03628170|OTHER|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
57961662|NCT03628170|OTHER|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
57961663|NCT04431115|OTHER|Interviews|Interviews for stakeholders
57961664|NCT05167773|DEVICE|tonometer|A subject undergoes intraocular pressure measurement with tonometer
57961665|NCT06434831|DEVICE|Medical device for SNM: Interstim II, Interstim micro|ANI will be used during the SNM (2 hours)
57961666|NCT01394705|DEVICE|BodyMedia|Accelerometer
57961667|NCT04019132|DIAGNOSTIC_TEST|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
57961668|NCT03138876|DEVICE|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
57961669|NCT03138876|DRUG|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
57756354|NCT01678131|PROCEDURE|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
57756355|NCT01678131|DRUG|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
57756356|NCT01678131|PROCEDURE|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
57756357|NCT06254898|BEHAVIORAL|Child life standard of care|Standard preparation and support provided to the participant by a Certified Child Life Specialist.
57960871|NCT05430100|OTHER|The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
57756358|NCT06254898|BEHAVIORAL|Child life standard of care + incentives provided with conditional agreement.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.
57756359|NCT06254898|BEHAVIORAL|Child life standard of care + incentive provided unconditionally.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
57756360|NCT04078737|DRUG|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
57756361|NCT04078737|DRUG|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
57756362|NCT00194688|DRUG|H. pylori treatment|
57756363|NCT03489590|DRUG|PFP|"* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
57756364|NCT03996057|DRUG|Methenamine Hippurate 1000 MG|Discussed in arm/group description
57756365|NCT03996057|DRUG|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
57756366|NCT03996057|DIETARY_SUPPLEMENT|D-mannose|Powder or tablet, depending on what patient is already using.
57756367|NCT00985725|DRUG|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
57756368|NCT00985725|DRUG|Matching placebo|oral, once daily
57756369|NCT01530672|DEVICE|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
57756370|NCT02020122|DRUG|Duloxetine|duloxetine 60mg
57756371|NCT02020122|DRUG|Pregabalin|pregabalin 150mg
57756372|NCT02020122|DRUG|Placebo|non active placebo
57756373|NCT02310555|PROCEDURE|Gastric bypass|
57756374|NCT02310555|PROCEDURE|Modified gastric bypass.|
58128552|NCT06495983|DEVICE|dynamic microdialysis sampling|Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
57756375|NCT02310555|PROCEDURE|Slevee Gastrectomy|
57756376|NCT05485792|DIAGNOSTIC_TEST|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
57756377|NCT04842578|OTHER|Cross- Section of CT Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
57756378|NCT04842578|OTHER|3D simulation Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
57756379|NCT00084370|DRUG|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
57756380|NCT00084370|PROCEDURE|oophorectomy|
57756381|NCT02706860|DRUG|Atorvastatin|
57756382|NCT03455322|DRUG|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
57756383|NCT01241149|PROCEDURE|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
57756384|NCT02914925|DEVICE|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
57756385|NCT01928966|OTHER|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
57756386|NCT06575569|BEHAVIORAL|high-intensity interval training|Patients had no adverse events after 2 weeks of adaptive exercise training and voluntarily continued participants, intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times. Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and health education materials pushed by cardiovascular nurses.
57756387|NCT06575569|BEHAVIORAL|Moderate-intensity continuous training|Using routine postoperative care and follow-up, establish WeChat group as contact for postoperative follow-up, no adverse events after 2 weeks of adaptive exercise training and voluntary participants, patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve). Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and pushed health education materials by cardiovascular nurses.
58454212|NCT04508166|BEHAVIORAL|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
57756388|NCT06069583|BEHAVIORAL|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
57756389|NCT06429605|DRUG|duloxetine|In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
57756390|NCT00453011|DEVICE|posterior chamber intraocular lens|
57756391|NCT00453011|DEVICE|anterior chamber intraocular lens|
57756392|NCT00286793|DRUG|AT-101|Oral
57756393|NCT03356730|DRUG|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
57756394|NCT03356730|OTHER|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
57756395|NCT00387894|DRUG|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
57756396|NCT05035368|DRUG|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
58454213|NCT03933813|OTHER|Iron Sucrose|Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
58458605|NCT04467073|BEHAVIORAL|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
57756397|NCT05035368|OTHER|Placebo|Placebo is administered with the same schedule of Ladarixin.
57756398|NCT01555788|DEVICE|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
57756399|NCT02368106|RADIATION|Radiation Therapy|targeted radiation treatment
57756400|NCT02824302|OTHER|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
57756401|NCT05794802|DIETARY_SUPPLEMENT|BHB supplement|Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)
57756402|NCT05794802|OTHER|Placebo solution|80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
57756403|NCT06203886|DEVICE|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
57756404|NCT03054038|DRUG|Afatinib|Given by mouth
57756405|NCT03054038|BIOLOGICAL|Necitumumab|Given IV
57756406|NCT03054038|OTHER|Laboratory Biomarker Analysis|Correlative studies
57756407|NCT05939921|DRUG|Metformin|T2DM patients will be provided with metformin in a specified dose
57756408|NCT01166516|DEVICE|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
57756409|NCT05399225|DIAGNOSTIC_TEST|Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio and procalcitonin in sepsis
57756410|NCT02447289|DRUG|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
57756411|NCT02447289|DRUG|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
57756412|NCT02447289|DRUG|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
57756413|NCT02447289|DRUG|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
57756414|NCT06196216|RADIATION|MSCT|Enhanced CT chest
57756415|NCT00615264|DRUG|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
57756416|NCT00615264|DRUG|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
57756417|NCT03221855|DRUG|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
57756418|NCT03221855|DRUG|Placebo|Capsules 10mg orally each 8 hours for 7 days.
57756419|NCT04626739|DRUG|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
57756420|NCT04626739|DRUG|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
57756421|NCT04626739|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
57756422|NCT04626739|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
57756423|NCT04626739|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
57756424|NCT05398302|PROCEDURE|Image Guided Biopsy|Undergo image-guided biopsy
57756425|NCT03466424|RADIATION|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
57756426|NCT01376323|DRUG|GSK256073 1mg|GSK256073 1mg capsule
57756427|NCT01376323|DRUG|GSK256073 5mg|GSK256073 5mg capsule
57756428|NCT01376323|DRUG|GSK256073 10mg|GSK256073 10mg capsule
57756429|NCT01376323|DRUG|GSK256073 25mg|GSK256073 25mg capsule
57756430|NCT01376323|DRUG|Placebo|placebo capsule
57756431|NCT01376323|DRUG|Sitagliptin 100mg|Sitagliptin 100mg capsule
57756432|NCT01915576|DRUG|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
57756433|NCT01915576|DRUG|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
57756434|NCT01915576|DRUG|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
57960872|NCT05430100|OTHER|The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
57960873|NCT03429192|PROCEDURE|Surgery|Surgeries plus dissection of lymph nodes
57756435|NCT02043028|DEVICE|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
57756436|NCT02043028|DEVICE|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
57756437|NCT03060655|BIOLOGICAL|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
57756438|NCT03060655|BIOLOGICAL|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
57756439|NCT00212498|PROCEDURE|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
57756440|NCT01956422|DEVICE|Continuous Positive Airway Pressure(CPAP)|
57756441|NCT01956422|DEVICE|Venturi Mask FiO2 40%|
57756442|NCT03321825|DEVICE|Belotero® Volume Lidocaine|Mode of application: subdermal injection
57756443|NCT02202746|DRUG|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
57756444|NCT06624748|BEHAVIORAL|emotional and physical support to the pregnant woman provided by attendant|The companion will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, taking a warm shower, etc.), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
57756445|NCT00674570|DRUG|Hydrocortisone|25 mg/oral one hour prior to extinction task
57756446|NCT00674570|DRUG|D-Cycloserine|50 mg/oral one hour prior to extinction task
57756447|NCT00674570|DRUG|Placebo|One hour prior to extinction task
57756448|NCT02782390|OTHER|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).
57756449|NCT02782390|OTHER|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
57756450|NCT03015506|OTHER|Bread|
57756451|NCT03375281|PROCEDURE|RFA|thermal ablation using radiofrequency for HCC
57756452|NCT00161590|DRUG|CHOP and alemtuzumab|
57756453|NCT01906684|DRUG|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
57756454|NCT00817557|DRUG|Loteprednol|Anti-inflammatory
57756455|NCT00817557|OTHER|Rewetter|
57756456|NCT05219266|DRUG|midostaurin|Patients receive midostaurin
57756457|NCT04748081|PROCEDURE|hepatectomy|hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
57756458|NCT04247282|DRUG|M7824|M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).
57756459|NCT04247282|DRUG|N803|N-803 (15 mcg/kg, subcutaneously) will be given on day 1 to patients enrolled in arm 3.
57756460|NCT04247282|BIOLOGICAL|TriAd vaccine|TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3
57756461|NCT03607357|DEVICE|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
57756462|NCT03607357|DEVICE|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
57756463|NCT05026125|DRUG|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
57756464|NCT05026125|DRUG|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
57756465|NCT02101086|OTHER|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
57756466|NCT03260582|OTHER|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
57756467|NCT01342458|OTHER|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
57756468|NCT05261893|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
57756469|NCT05261893|OTHER|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
57960874|NCT01109784|DRUG|prasugrel|prasugrel 10 mg/day
58128553|NCT03228095|DIAGNOSTIC_TEST|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
58315360|NCT02880423|PROCEDURE|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
57960875|NCT01109784|DRUG|clopidogrel|clopidogrel per os 150mg/day
58128554|NCT03228095|DIAGNOSTIC_TEST|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
57756470|NCT00085202|BIOLOGICAL|filgrastim|Given subcutaneously
58315361|NCT02880423|PROCEDURE|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
57756471|NCT00085202|DRUG|cisplatin|Given IV
57756472|NCT00085202|DRUG|cyclophosphamide|Given IV
57756473|NCT00085202|DRUG|vincristine|Given IV
57756474|NCT00085202|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
57756475|NCT00085202|RADIATION|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
57756476|NCT00855010|DRUG|pioglitazone|pioglitazone 45 mg daily
57756477|NCT00855010|DRUG|placebo|one daily
57756478|NCT03039439|PROCEDURE|Biospecimen Collection|Previously collected tumor tissue and blood samples
57756479|NCT03039439|OTHER|Laboratory Biomarker Analysis|Correlative studies
57756480|NCT03948984|BEHAVIORAL|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
57756481|NCT01368848|DRUG|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W -\> Bevacizumab Q3W until progression"
57756482|NCT01368848|DRUG|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
57756483|NCT01368848|DRUG|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
57756484|NCT06254534|DIAGNOSTIC_TEST|optic nerve ultrasonography|The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
57756485|NCT04983108|OTHER|No Intervention|No intervention. This is an observational Study
57756486|NCT01194895|OTHER|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
57756487|NCT01194895|OTHER|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
57756488|NCT05956704|DEVICE|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
57756489|NCT05956704|DEVICE|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
57756490|NCT01874457|BIOLOGICAL|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
57756491|NCT04075825|BIOLOGICAL|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
57756492|NCT05252819|DIAGNOSTIC_TEST|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
57756493|NCT05850039|OTHER|Sampling|Sample collection: a small fragment of atrial wall will be collected
57756494|NCT01946022|DRUG|randomization between the two GnRH analogues (agonist and antagonist)|
57756495|NCT01422525|PROCEDURE|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
57756496|NCT01546259|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
57756497|NCT01756664|OTHER|Sunscreen|
57756498|NCT01756664|OTHER|Vaseline|
57756499|NCT02849275|OTHER|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
57756500|NCT02849275|OTHER|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
57756501|NCT01208948|DRUG|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
57756502|NCT01953614|OTHER|Chiropractic adjustment|
57961670|NCT03138876|PROCEDURE|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
57756503|NCT01953614|OTHER|Sham adjustment|
57756504|NCT04894526|OTHER|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
57756505|NCT04894526|OTHER|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
57756506|NCT03464279|BEHAVIORAL|Nudge using Behavioral Economic Interventions|
57756507|NCT03464279|BEHAVIORAL|Standard Practices to Reduce Health System Antibiotic Prescription|
57756508|NCT02385994|DEVICE|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
57756509|NCT05728255|DIAGNOSTIC_TEST|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
57756510|NCT06221423|DRUG|Fruquintinib Combined With TAS-102|Fruquintinib Combined With TAS-102
57756511|NCT04786379|PROCEDURE|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
57756512|NCT04786379|PROCEDURE|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
57961671|NCT00428597|DRUG|sunitinib malate|"* sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
57961672|NCT00428597|DRUG|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
57961673|NCT02448732|DRUG|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
57961674|NCT04823949|DEVICE|Home blood pressure monitoring|See arm description
57961675|NCT04460235|DRUG|Prevenar13 Pneumo-23|Vaccination according national guidelines
57756513|NCT03705195|DRUG|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
57756514|NCT03540511|DIAGNOSTIC_TEST|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
57756515|NCT01860469|PROCEDURE|vancomycin-soaked mesh|
57756516|NCT01860469|PROCEDURE|plain mesh|
57756517|NCT00462280|DRUG|lovastatin|Given PO
57756518|NCT00462280|OTHER|placebo|Given PO
57756519|NCT00462280|PROCEDURE|biopsy|Correlative studies
57756520|NCT00462280|PROCEDURE|laboratory biomarker analysis|Correlative studies
57756521|NCT01303081|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
57756522|NCT01303081|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
57756523|NCT01303081|BEHAVIORAL|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
57756524|NCT01303081|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
57756525|NCT01303081|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
57756526|NCT04378192|DEVICE|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
57756527|NCT04378192|DEVICE|face mask|use of face mask before intubation of a morbidly obese patient
57756528|NCT05722470|BEHAVIORAL|eating disorders|Assessment of eating disorders among adolescents
57756529|NCT03348072|PROCEDURE|Cardiac surgery|Cardiac surgery
57756530|NCT01382329|BIOLOGICAL|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
57756531|NCT00006825|BIOLOGICAL|trastuzumab|
57756532|NCT00006825|DRUG|pegylated liposomal doxorubicin hydrochloride|
57756533|NCT03013088|DEVICE|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
57756534|NCT06187740|RADIATION|thoracic radiotherapy|"Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy."
57756535|NCT06373484|BEHAVIORAL|Behavioral Parent Training|Two 15-session multi-component cognitive-behavioral group treatments for children with disruptive behavior and their parents (i.e., one program for children aged 6-8 years and their parents and another for children aged 9-12 years and their parents. The programs have a child and parent group that are implemented concurrently).
57756536|NCT02847299|DEVICE|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
57756537|NCT00895622|RADIATION|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
57756538|NCT00895622|RADIATION|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
57756539|NCT01424930|DRUG|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
58128555|NCT03228095|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
57756540|NCT01424930|DRUG|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
57756541|NCT03675932|OTHER|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
57756542|NCT03600584|PROCEDURE|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
57756543|NCT03600584|PROCEDURE|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
58128556|NCT03228095|PROCEDURE|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
57756544|NCT01837004|BEHAVIORAL|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
57756545|NCT02573025|DRUG|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
57756546|NCT02573025|DRUG|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
57756547|NCT04060602|BEHAVIORAL|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
57756548|NCT04060602|BEHAVIORAL|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
57756549|NCT06443619|PROCEDURE|unilateral USG-deep SAPB with glucose|patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
57756550|NCT06443619|PROCEDURE|unilateral USG-deep SAPB without glucose|will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
57756551|NCT04344639|OTHER|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
57756552|NCT00508261|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection
57756553|NCT00508261|BIOLOGICAL|Infanrix™ hexa|Single dose intramuscular injection
57756554|NCT00508261|BIOLOGICAL|Meningitec™|Single dose intramuscular injection
57756555|NCT05807581|OTHER|physical activity|treadmill running 3 times weekly
57756556|NCT05807581|OTHER|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
57756557|NCT00732186|BIOLOGICAL|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
57756558|NCT02411838|OTHER|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI\>28 will follow a regimen of fasting for three days per week."
57756559|NCT00325325|DRUG|everolimus and tacrolimus|
57756560|NCT00249743|DEVICE|FallSaver (formerly called NOCwatch)|
57756561|NCT04104451|DRUG|Corlicyte|expanded umbilical cord lining mesenchymal stem cells
57756562|NCT05863130|DRUG|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
57756563|NCT05863130|DRUG|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
57756564|NCT01933022|DRUG|Eligard|Subcutaneous Injection
57756565|NCT05363969|DEVICE|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
57756566|NCT03877458|OTHER|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
57756567|NCT03877458|OTHER|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
57756568|NCT03877458|OTHER|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
57756569|NCT04765735|DEVICE|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
57756570|NCT01741376|DRUG|Progesterone|Progesterone 200 mg twice daily
57756571|NCT01741376|DRUG|Placebo|
57756572|NCT05884463|DRUG|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
58315362|NCT05948306|OTHER|Critical Patient-Centered Skin Care Protocol|"A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added."
57756573|NCT05884463|DRUG|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
57756574|NCT04069598|DIAGNOSTIC_TEST|Statin intolerance test|Statin intolerance test
57756575|NCT05403190|DEVICE|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
57756576|NCT00775814|DRUG|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
57756577|NCT00775814|DRUG|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
58128557|NCT03228095|PROCEDURE|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
58128558|NCT03228095|DIAGNOSTIC_TEST|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
57756578|NCT06569875|DEVICE|iCARE|iCARE is an internet-based cognitive behavioral therapy program designed for women experiencing symptoms of postpartum depression, including anxiety, irritability, and sadness. The program offers digital therapy through an online platform tailored to mothers with mild to moderate postpartum depression. The program consists of 7 modules, each with its own theme, incorporating cognitive behavioral therapy, a well-established therapeutic approach for depression. The content includes text, images, audio files, and short films, supplemented with small tasks to provide knowledge and tools to understand and manage one's situation. The treatment course is self-directed, allowing participants to engage with the content at their own pace and at times that are most convenient for them
57756579|NCT00962247|DEVICE|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
57756580|NCT05801575|DRUG|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
57756581|NCT05850468|DRUG|fentanyl infusion after general anesthesia and erector spinea block|intraoperative opioid infusion in active comparative group
57756582|NCT05850468|DRUG|lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block|intraoperative non opioid infusion in experimental group
57756583|NCT00465933|DRUG|AIDA|
57756584|NCT00167830|BEHAVIORAL|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
57756585|NCT00167830|BEHAVIORAL|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
57756586|NCT00167830|BEHAVIORAL|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
57756587|NCT05476835|COMBINATION_PRODUCT|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
57756588|NCT06446505|OTHER|Deep Brain Stimulation Decision Aid|An online decision support tool that provides education about deep brain stimulation and the alternatives, and includes value clarification exercise.
57756589|NCT06212648|DRUG|SPC1001 High|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756590|NCT06212648|DRUG|SPC1001 Mid1|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756591|NCT06212648|DRUG|SPC1001 Mid2|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756592|NCT06212648|DRUG|SPC1001 Low|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756593|NCT06212648|DRUG|SPC3001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756594|NCT06212648|DRUG|SPC4001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
57756595|NCT06212648|DRUG|SPC4002|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
58128559|NCT03228095|PROCEDURE|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
58128560|NCT03228095|DIAGNOSTIC_TEST|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
57756596|NCT06212648|DRUG|Placebo|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
58454214|NCT05932108|BEHAVIORAL|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
58454215|NCT05932108|OTHER|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
57756597|NCT01580839|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
58128561|NCT01418157|DRUG|Acetazolamide|125 mg twice daily until 4380 meters altitude
58128562|NCT01418157|DRUG|Placebo|Twice daily
58128563|NCT04276038|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
57756598|NCT01580839|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
57756599|NCT04059692|OTHER|Cervical manipulation intervention|Cervical manipulative technique
58454216|NCT05777044|BEHAVIORAL|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
58454217|NCT03520985|DRUG|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
58454218|NCT03520985|DRUG|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients \> 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
58454219|NCT03228108|DRUG|Ciprofloxacin|see study arms.
58454220|NCT03228108|DRUG|Trimethoprim/Sulfamethoxazole|see study arms.
58454221|NCT03228108|DRUG|Fosfomycin|see study arms.
58454222|NCT03228108|DRUG|Pivmecillinam/augmentin|see study arms.
58454223|NCT00443144|DRUG|recombinant human growth hormone|
58454224|NCT03236441|DEVICE|RIPC|Remote ischemic preconditioning
58454225|NCT03236441|DEVICE|Sham-RIPC|Control
58454226|NCT03901144|DRUG|2% urea/20% glycerol cream|Moisturizing cream for topical application
58454227|NCT03901144|DRUG|Miniderm® 20% cream|Moisturizing cream for topical application
58454228|NCT03901144|DRUG|Diprobase® cream|Emollient cream for topical application
58454229|NCT06383832|DRUG|Dapagliflozin|Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
58454230|NCT02183857|DEVICE|Ultrasound|
57756600|NCT04059692|OTHER|Placebo intervention|Sham intervention
57756601|NCT03073564|DIAGNOSTIC_TEST|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
57756602|NCT03073564|DIAGNOSTIC_TEST|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
57756603|NCT05836870|OTHER|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
57756604|NCT05836870|BEHAVIORAL|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
57756605|NCT03562065|BIOLOGICAL|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
57756606|NCT02203708|OTHER|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
58315363|NCT02034006|DRUG|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
58315364|NCT06280651|OTHER|dietary preferences and their implications for oral health in children with Autism Spectrum Disorder|This study design typically does not involve interventions. Instead, it observes and analyzes existing conditions or behaviors-in this case, dietary preferences and their implications for oral health in children with Autism Spectrum Disorder (ASD)-without the researchers applying any specific treatment or experimental condition to the participants. The aim is to identify correlations or patterns at a specific point in time, rather than to assess the effects of an intervention.
58454231|NCT02183857|OTHER|Landmark|
58315365|NCT02166112|PROCEDURE|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
58315366|NCT03247309|BIOLOGICAL|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
58454232|NCT04718207|DEVICE|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
58454233|NCT03318835|DRUG|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
58454234|NCT03318835|DRUG|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
58454235|NCT01467011|DRUG|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
58454236|NCT02692937|PROCEDURE|Neurolysis|
58454237|NCT02692937|OTHER|Traditional neck-specific exercise program|
58454238|NCT06413485|BEHAVIORAL|Level of recreational water contact activities|We will examine a graded classification of this exposure based on individuals' minimum level of water contact: 1) no water contact; 2) minimal contact; 3) body immersion; 4) swallowed water. Minimal contact is defined as water contact that does not result in body immersion (e.g., wading below one's waist, boating, fishing). Body immersion is defined as entering the water above one's waist (e.g., swimming, surfing, snorkelling), and swallowing water as ingestion of any amount of water.
57756607|NCT03888339|PROCEDURE|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
57756608|NCT03888339|PROCEDURE|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
57756609|NCT03123848|DRUG|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
57756610|NCT00429663|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
57756611|NCT00429663|DEVICE|locking periarticular plate|Standard of care device for femur fractures
57756612|NCT00021814|DRUG|Doxazosin|
57756613|NCT00021814|DRUG|Finasteride|
57756614|NCT00021814|DRUG|Doxazosin placebo|
57756615|NCT00021814|DRUG|Finasteride placebo|
57756616|NCT04149925|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
57756617|NCT04149925|DEVICE|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
57756618|NCT01133158|DRUG|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
57756619|NCT00263328|DRUG|Tacrolimus|Standard of care
57756620|NCT00263328|DRUG|CP-690,550|CP-690,550 5 mg BID
57756621|NCT00263328|DRUG|CP-690,550|CP-690,550 10 mg BID
58315367|NCT03247309|DIAGNOSTIC_TEST|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
58454239|NCT04084717|DRUG|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
58454240|NCT03222700|PROCEDURE|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
58454241|NCT02663011|OTHER|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
58454242|NCT04215926|OTHER|No intervention; cross-sectional study|No intervention; cross-sectional study
58454243|NCT05467241|BEHAVIORAL|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
57756622|NCT00256958|PROCEDURE|total knee replacement|
57756623|NCT02768610|DRUG|Dexmedetomidine|
57756624|NCT02768610|DRUG|Normal Saline|
57756625|NCT02561286|BEHAVIORAL|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
57756626|NCT02561286|BEHAVIORAL|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
58315368|NCT05238662|PROCEDURE|pedicle screw fixation on one side and intervertebral cage on the other sided|pedicle screw fixation on one side and intervertebral cage on the other sided
57756627|NCT00019058|DRUG|chemotherapy|
57756628|NCT00019058|DRUG|hydroxyurea|
57756629|NCT00019058|DRUG|pentoxifylline|
57756630|NCT00019058|RADIATION|radiation therapy|
58315369|NCT05238662|PROCEDURE|pedicle screw fixation and interbody cage on the same side|pedicle screw fixation and interbody cage on the same side
58315370|NCT00169832|DRUG|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
57756631|NCT02994914|OTHER|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
57756632|NCT00823784|PROCEDURE|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
57756633|NCT00823784|PROCEDURE|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
57756634|NCT01242748|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
57756635|NCT01242748|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
57756636|NCT02920697|DRUG|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
57756637|NCT01590290|OTHER|financial compensation|financial monetary reimbursement
57756638|NCT00304512|DRUG|migalastat HCl|
57756639|NCT02756754|DEVICE|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
57756640|NCT05042089|OTHER|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
57756641|NCT06151535|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
57756642|NCT02933801|DRUG|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
57756643|NCT02933801|OTHER|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
57756644|NCT03952702|PROCEDURE|Myopic overcorrection|Myopic overcorrection
58128564|NCT02658604|OTHER|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
58128565|NCT00949299|DRUG|buprenorphine|intradermal injection
58128566|NCT05515952|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
58128567|NCT05515952|DEVICE|Transcranial Magnetic Stimulation (Sham)|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used.
58128568|NCT03230851|DRUG|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
58128569|NCT03230851|DRUG|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
58128570|NCT03230851|DRUG|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
57756645|NCT04665648|DRUG|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
57756646|NCT04665648|DRUG|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
57756647|NCT00958763|BEHAVIORAL|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
57756648|NCT00958763|BEHAVIORAL|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
57756649|NCT00958763|OTHER|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
57756650|NCT02010632|DRUG|Generic clopidogrel product Apolets®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
57756651|NCT02010632|DRUG|Original clopidogrel product Plavix®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
57756652|NCT01865916|DRUG|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
57756653|NCT01865916|DRUG|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
57756654|NCT00685945|DRUG|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
57756655|NCT00685945|DRUG|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
57756656|NCT00685945|DRUG|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
57756657|NCT00685945|DRUG|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
57756658|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
57756659|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule at recommended dose orally.
57756660|NCT05782543|PROCEDURE|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
57756661|NCT04963205|DEVICE|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
57756662|NCT04963205|OTHER|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
57756663|NCT02887430|OTHER|foot reflexology therapy|standard care and foot reflexology
57756664|NCT05526586|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
57756665|NCT05526586|OTHER|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
58454244|NCT03462108|BIOLOGICAL|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
58454245|NCT03462108|OTHER|Placebo|Placebo contains 30% sucrose in DMEM
57756666|NCT05526586|OTHER|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
57756667|NCT05526586|OTHER|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
57756668|NCT05526586|OTHER|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
57756669|NCT04886479|OTHER|Control|No lens
57756670|NCT04886479|DEVICE|Test Lens|Low Dk HEMA contact lens worn for 3 hours
57756671|NCT00687570|DIETARY_SUPPLEMENT|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery
57756672|NCT00687570|DRUG|Laxabon®|Laxabon® 4 litres starting the day before surgery
57756673|NCT02163590|OTHER|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
57756674|NCT02163590|OTHER|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
57756675|NCT02163590|OTHER|Placebo|Intervention that mimics the experimental procedures
57756676|NCT01381419|DRUG|GSK1144814|Single dose.
57756677|NCT01381419|DRUG|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
57756678|NCT01381419|DRUG|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
58454246|NCT01490775|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
57756679|NCT03285048|BEHAVIORAL|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
57756680|NCT02789475|DRUG|Amlodipine|Amlodipine administration
57756681|NCT02789475|DRUG|Rosuvastatin|Rosuvastatin administration
58454247|NCT01490775|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
58454248|NCT01156220|DRUG|Furosemide|Injection, 40 mg, single dose over 5 min
58454249|NCT01156220|DRUG|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
57756682|NCT01746043|DRUG|Armodafinil|150 mg by mouth once a day for 6 weeks.
57756683|NCT01746043|OTHER|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
57756684|NCT01746043|DRUG|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
57756685|NCT01746043|BEHAVIORAL|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
57756686|NCT05067569|BEHAVIORAL|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
57756687|NCT05067569|BEHAVIORAL|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
57756688|NCT06185010|OTHER|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
57756689|NCT06185010|OTHER|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
57756690|NCT06185010|OTHER|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
57756691|NCT06185010|OTHER|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
57756692|NCT06185010|OTHER|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
57756693|NCT02160314|DEVICE|pessary|disposable, single-use pessary
57756694|NCT02160314|DEVICE|Absorbent pad|
57756695|NCT02417584|DEVICE|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
57756696|NCT02036645|BIOLOGICAL|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
58315371|NCT03245606|PROCEDURE|Liver biopsy|Measurement of liver fibrosis
58315372|NCT03245606|DEVICE|Abdominal MRI|Measurement of liver fibrosis
58315373|NCT03245606|DEVICE|Transient elastography|Measurement of liver fibrosis
58315374|NCT04841889|DIAGNOSTIC_TEST|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
58315375|NCT03739892|BEHAVIORAL|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
57756697|NCT02036645|BIOLOGICAL|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
57756698|NCT02036645|BIOLOGICAL|IV Placebo|Placebo for IV injection
57756699|NCT02036645|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
57756700|NCT00777907|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
57756701|NCT00777907|DEVICE|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
57756702|NCT00420992|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
57756703|NCT00420992|DRUG|Placebo|capsules, bid
58315376|NCT02902575|PROCEDURE|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
58315377|NCT04555447|DIETARY_SUPPLEMENT|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
58315378|NCT04555447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
58315379|NCT04319705|DRUG|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
57756704|NCT03571958|BEHAVIORAL|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
57756705|NCT06214286|DEVICE|Shockwave|Shockwave therapy
57756706|NCT06214286|OTHER|Kinesio taping|Kinesio taping application
57756707|NCT06214286|OTHER|conventional physical therapy|conventional physical therapy
57756708|NCT05312567|DRUG|FP-101|daily oral tablet administration (b.i.d.)
57756709|NCT03591367|DIAGNOSTIC_TEST|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
57756710|NCT03591367|DIAGNOSTIC_TEST|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
57756711|NCT05244603|BEHAVIORAL|Ideal binary mask|Speech in noise processed by ideal binary mask to reduce background noise
57756712|NCT01160874|OTHER|Polysomnography|Sleep study monitoring
57756713|NCT01160874|OTHER|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
57756714|NCT01160874|BEHAVIORAL|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
57756715|NCT01160874|OTHER|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
57756716|NCT04436263|BEHAVIORAL|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
57756717|NCT04436263|BEHAVIORAL|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
57756718|NCT04506255|DEVICE|Silicone tape|Medical grade tape with silicone adhesive
57756719|NCT01957917|OTHER|NAC (Nutritional Assessment and Counseling)|
57756720|NCT01957917|OTHER|Cash Transfer|
57756721|NCT01957917|OTHER|Food Assistance|
57756722|NCT06096480|PROCEDURE|gabapentin + bilateral spine erector block|preoperative, ultrasound-guided, bilateral ESP block (administration of a local anesthetic mixture of ropivacaine 0.375% and lidocaine 1%) and a 100mg dose of oral gabapentin 4 nights daily before surgery and 2 weeks postoperatively.
57756723|NCT02584725|DRUG|Tranexamic Acid|Comparison of 3 different doses of the drug
57756724|NCT03484455|DEVICE|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
57756725|NCT03484455|DEVICE|Static cold storage|Static cold storage (standard of care)
58454250|NCT02991638|DRUG|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
57756726|NCT02719379|BIOLOGICAL|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
57756727|NCT02804087|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
57756728|NCT02804087|OTHER|Sham Implantation|Sham Implantation
57756729|NCT01802684|BIOLOGICAL|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
57960876|NCT06501755|DEVICE|transcranial alternating current stimulation (tACS)|Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
58454251|NCT00017602|BIOLOGICAL|oblimersen sodium|
57756730|NCT02115867|DIETARY_SUPPLEMENT|Probiotic|Symprove probiotic
57756731|NCT04936854|DRUG|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
57756732|NCT04936854|DRUG|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
57756733|NCT04384016|BIOLOGICAL|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
57756734|NCT03360630|BIOLOGICAL|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
57756735|NCT03360630|BIOLOGICAL|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
58454252|NCT00017602|DRUG|dexamethasone|
58454253|NCT03880058|DRUG|SLI-F06|Active treatment
58454254|NCT03880058|DRUG|Formulation buffer|Placebo treatment
57756736|NCT05753865|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
57756737|NCT05753865|DRUG|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m\^2
57756738|NCT01237795|OTHER|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
58454255|NCT03061357|BEHAVIORAL|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
57756739|NCT00887276|DRUG|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
57756740|NCT00887276|DRUG|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
57756741|NCT03401892|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
57756742|NCT03401892|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
57756743|NCT03401892|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
57756744|NCT01970787|DEVICE|Radiofrequency Ablation (RFA) using the HALO Ablation System|
57756745|NCT02799615|DRUG|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
57756746|NCT04678921|DRUG|TJ210001|human anti-C5aR monoclonal antibody
57756747|NCT04954313|DRUG|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
57756748|NCT04954313|OTHER|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
57756749|NCT04954313|OTHER|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).
57756750|NCT05356598|OTHER|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
57756751|NCT05356598|OTHER|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
57756752|NCT05356598|OTHER|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
57756753|NCT01974700|DRUG|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
57756754|NCT01038388|DRUG|Bortezomib|1.3mg/m² given IV or subcutaneously
57756755|NCT01038388|DRUG|Lenalidomide|25 mg given PO
57756756|NCT01038388|DRUG|Dexamethasone|20 mg given PO
57756757|NCT01038388|DRUG|Vorinostat|100, 200, or 300 mg given PO
57756758|NCT06273943|DRUG|Cabotegravir Tablets, for oral use.|Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
57756759|NCT06273943|DRUG|Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.|Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
57756760|NCT06273943|DRUG|Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use|"* Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
57756761|NCT06273943|PROCEDURE|Rectal Biopsies|"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
57756762|NCT02491190|BEHAVIORAL|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
57960877|NCT00049673|DRUG|prednisone|Given orally
57960878|NCT00049673|DRUG|thalidomide|Given orally
58315380|NCT04319705|DRUG|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
58315381|NCT05888519|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
57960879|NCT05392491|OTHER|No intervention|No intervention. It is an observational study
57960880|NCT00028912|DRUG|bortezomib|
57960881|NCT00028912|DRUG|carboplatin|
57960882|NCT01850056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|
57960883|NCT01850056|DEVICE|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
57960884|NCT03639714|BIOLOGICAL|GRT-C901|a patient-specific neoantigen cancer vaccine prime
57960885|NCT03639714|BIOLOGICAL|GRT-R902|a patient-specific neoantigen cancer vaccine boost
57960886|NCT03639714|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
57960887|NCT03639714|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
58128571|NCT03230851|DRUG|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
58315382|NCT05888519|OTHER|FID123301 ocular lubricant|Investigational ocular lubricant
58315383|NCT05888519|OTHER|FID122505 ocular lubricant|Comparator ocular lubricant
57756763|NCT03881098|PROCEDURE|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
57756764|NCT03881098|PROCEDURE|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
57756765|NCT03881098|PROCEDURE|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
57756766|NCT00180479|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
57756767|NCT00180479|DEVICE|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
57756768|NCT05130125|DRUG|rFSH|rFSH or HP-hMG or rFSH and HP-hMG
57756769|NCT01924611|PROCEDURE|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
57756770|NCT01924611|PROCEDURE|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
57756771|NCT05593302|BEHAVIORAL|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
57756772|NCT05878119|DRUG|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
57756773|NCT05878119|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
57756774|NCT05878119|OTHER|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
57756775|NCT05878119|OTHER|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
57756776|NCT04193501|DRUG|Melatonin 3 mg|Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
57756777|NCT04193501|OTHER|Placebo|Similar looking placebo
57756778|NCT03019146|OTHER|HIIT|
57756779|NCT03019146|OTHER|HOLD|
57756780|NCT03019146|OTHER|HUG|
57756781|NCT01718002|BEHAVIORAL|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
57756782|NCT00498563|PROCEDURE|altitude exposure in hypobaric chamber|
57756783|NCT00110890|DRUG|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
57756784|NCT00110890|OTHER|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
58454256|NCT01827150|DRUG|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
58454257|NCT05823402|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
57756785|NCT02547870|DRUG|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
57756786|NCT02547870|DRUG|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
57756787|NCT02547870|DRUG|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
57756788|NCT01037842|DRUG|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
57756789|NCT01037842|DRUG|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
58454258|NCT04591938|DEVICE|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
57756790|NCT01468298|OTHER|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
57756791|NCT01468298|OTHER|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
57756792|NCT03486028|OTHER|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
57756793|NCT03486028|OTHER|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
57756794|NCT01618474|DRUG|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
57756795|NCT01618474|DRUG|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
57756796|NCT03448445|OTHER|Usual care setting|usual care settings without any intervention
57756797|NCT01073904|DRUG|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
57756798|NCT01073904|DRUG|Postinor 2|Single dose of 1.5 mg tablet
57756799|NCT01302470|PROCEDURE|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
57756800|NCT01302470|PROCEDURE|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
57756801|NCT00000431|DRUG|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
57756802|NCT00003132|DRUG|bryostatin 1|
57756803|NCT00003132|DRUG|cisplatin|
57756804|NCT00022230|BIOLOGICAL|aldesleukin|
57756805|NCT00022230|BIOLOGICAL|filgrastim|
57756806|NCT00022230|BIOLOGICAL|sargramostim|
57756807|NCT00022230|BIOLOGICAL|therapeutic autologous lymphocytes|
57756808|NCT00022230|DRUG|cyclophosphamide|
57756809|NCT00022230|DRUG|doxorubicin hydrochloride|
57756810|NCT00022230|DRUG|paclitaxel|
57756811|NCT02238002|PROCEDURE|cataract surgery|The patients of both groups underwent cataract surgery
57756812|NCT04425902|DRUG|GSK3640254 200 mg|GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
57756813|NCT04425902|DRUG|Caffeine 200 mg|Caffeine will be available as oral tablets at unit dose strength of 200 mg.
58128572|NCT03230851|DRUG|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
58128573|NCT03230851|DRUG|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
58128574|NCT03230851|DRUG|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
57756814|NCT04425902|DRUG|Metoprolol 100 mg|Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
58128575|NCT02270736|DRUG|NT 201 Placebo|NT 201 placebo matching injection.
57756815|NCT04425902|DRUG|Montelukast 10 mg|Montelukast will be available as oral tablets at unit dose strength of 10 mg.
57756816|NCT04425902|DRUG|Flurbiprofen 100 mg|Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
57756817|NCT04425902|DRUG|Omeprazole 40 mg|Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
57756818|NCT04425902|DRUG|Midazolam 5 mg (2.5 mL)|Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
57756819|NCT04425902|DRUG|Digoxin 0.25 mg|Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
57756820|NCT04425902|DRUG|Pravastatin 40 mg|Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
57756821|NCT02141763|DRUG|UCB4940 40 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
58128576|NCT02270736|DRUG|NT 201|NT 201 injection.
58128577|NCT01291303|PROCEDURE|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
58128578|NCT01291303|PROCEDURE|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
58128579|NCT02348268|OTHER|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
57756822|NCT02141763|DRUG|UCB4940 80 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
57756823|NCT02141763|DRUG|UCB4940 160 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
57756824|NCT02141763|DRUG|UCB4940 240 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
57756825|NCT02141763|DRUG|UCB4940 320 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
57756826|NCT02141763|DRUG|UCB4940 560 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
57756827|NCT02141763|OTHER|Placebo|"* Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous"
57756828|NCT01037439|DEVICE|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
57756829|NCT02342522|DEVICE|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
57756830|NCT02342522|DEVICE|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
57756831|NCT06222216|OTHER|Chilled Needle|Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
57756832|NCT06222216|OTHER|Control Group|SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.
58454259|NCT00628030|BEHAVIORAL|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
58454260|NCT00628030|OTHER|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
58454261|NCT02102789|DRUG|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
58454262|NCT02102789|DRUG|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
58454263|NCT02203695|DRUG|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
58454264|NCT02203695|RADIATION|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
58315384|NCT02472405|DEVICE|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
58315385|NCT02472405|DEVICE|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
58454265|NCT01065038|DRUG|Anagrelide|
58454266|NCT01065038|DRUG|Hydroxyurea|
57756833|NCT00065585|PROCEDURE|Accupuncture|
57756834|NCT05493072|OTHER|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
57756835|NCT04345159|OTHER|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
57756836|NCT05962710|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
57756837|NCT02464800|PROCEDURE|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
57756838|NCT02901626|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~1. Nulliparous 65 mm, 32 mm~2. Multiparous 70 mm, 32 mm~3. Alternative 70 mm, 35 mm"
57756839|NCT04906525|BEHAVIORAL|Resistance training|Participants will undergo 6 weeks of supervised resistance training
58315386|NCT02641054|DRUG|CVXL-0107|
58315387|NCT02641054|DRUG|Placebo|
58315388|NCT02641054|DRUG|Levodopa|
58315389|NCT00002846|BIOLOGICAL|aldesleukin|
58315390|NCT00002846|PROCEDURE|conventional surgery|
57756840|NCT04906525|OTHER|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
57756841|NCT02149784|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
57756842|NCT01104194|DIETARY_SUPPLEMENT|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
57756843|NCT01104194|DIETARY_SUPPLEMENT|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
57756844|NCT02000414|DRUG|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
57756845|NCT00163995|DRUG|urotensin II|
57756846|NCT00459238|OTHER|counseling intervention|subjects will receive telephone based counseling
57756847|NCT00459238|OTHER|educational intervention|subjects will received telephone based education
57756848|NCT00496405|DRUG|bevacizumab|
57756849|NCT05462535|DRUG|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
57756850|NCT03522805|DEVICE|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
57756851|NCT00894673|BIOLOGICAL|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
57756852|NCT00894673|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
57756853|NCT00959543|OTHER|MRI|MRI and clinical investigation
57756854|NCT02807428|DRUG|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
57756855|NCT02807428|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
57756856|NCT04524598|DEVICE|Limbix Spark|The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
57756857|NCT04524598|OTHER|Psychoeducation|The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
57756858|NCT02430467|BEHAVIORAL|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
57756859|NCT02430467|BEHAVIORAL|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
57756860|NCT00856674|BIOLOGICAL|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
57756861|NCT04574830|OTHER|No Intervention|No Intervention
57756862|NCT01291147|DRUG|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
57756863|NCT01291147|DRUG|0.9% Saline|0.9% saline continous infusion for 48 hours
57756864|NCT03588793|OTHER|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
57756865|NCT01368146|DEVICE|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
57756866|NCT01368146|DEVICE|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
57756867|NCT01368146|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
57756868|NCT02237508|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
57756869|NCT02237508|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
57756870|NCT02237508|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
57756871|NCT02237508|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
57756872|NCT00893399|DRUG|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
57756873|NCT00893399|DRUG|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
57756874|NCT04040257|BEHAVIORAL|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
57756875|NCT04719039|BEHAVIORAL|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
57756876|NCT03830190|OTHER|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
57756877|NCT05068869|OTHER|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
57756878|NCT05068869|OTHER|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
57756879|NCT03089125|BEHAVIORAL|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness"
57756880|NCT03089125|OTHER|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
57756881|NCT02462902|DRUG|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
57756882|NCT02462902|DRUG|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
57756883|NCT05356754|DEVICE|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
57756884|NCT04892784|DEVICE|Press tack needle acupuncture|Pyonex press tack needle sized 0.20x1.2mm
57756885|NCT06113510|RADIATION|Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography|18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.
57756886|NCT01696331|BEHAVIORAL|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
57756887|NCT05582005|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children 3 year old and younger, scheduled for elective MRI, that are not intubated or require higher oxygen support and with no parents/guardians refusal will be placed on an electrocardiogram during post-anesthesia recovery. The NIPE monitor will be connected to the patients monitor in the PACU. Values will be recorded from the time of patient awaking until the patient meets the discharge criteria from PACU not before 1 hour.
57756888|NCT04601558|BEHAVIORAL|The letters with the Cochrane abstracts in the form of blog-shots|"The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
57756889|NCT04601558|BEHAVIORAL|The letters with remainder on cardiovascular risk factors|"The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
57756890|NCT01755143|OTHER|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
57756891|NCT01755143|DEVICE|Pacemaker System|
57756892|NCT03090867|OTHER|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
57756893|NCT03090867|OTHER|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
57756894|NCT03362463|OTHER|Non-Interventional Study|Non-Interventional Study
57756895|NCT03262857|DRUG|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
58128580|NCT02348268|OTHER|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
58315391|NCT05759910|DIETARY_SUPPLEMENT|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
58315392|NCT05759910|DIETARY_SUPPLEMENT|Placebo|Participants will take placebo capsules during 3 months
58315393|NCT00485836|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
58315394|NCT00485836|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
58315395|NCT00485836|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
58454267|NCT03258307|OTHER|Preoperative level|Blood sample
58454268|NCT00005674|DRUG|Creatine|
58454269|NCT01204749|DRUG|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
58454270|NCT01204749|DRUG|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
58454271|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
57756896|NCT05174793|OTHER|dehydration and rehydration|dehydration and rehydration
57756897|NCT00227526|BEHAVIORAL|Prehabilitation|
57756898|NCT00273702|DRUG|N-Acetyl Cysteine|
57756899|NCT00503022|DRUG|ACZ885|
57756900|NCT02484001|DRUG|ESL 800 mg|one (1) tablet of 800 mg (QD).
57756901|NCT02484001|DRUG|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
57756902|NCT02484001|DRUG|ESL 1600 mg|two (2) tablets of 800 mg (QD).
57756903|NCT02484001|DRUG|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
57756904|NCT00582257|BEHAVIORAL|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
57756905|NCT01931735|PROCEDURE|Randomized Meniscectomy|Arthroscopic meniscectomy
57756906|NCT01931735|PROCEDURE|Randomized Lavage|Arthroscopic Lavage
57756907|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
57756908|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
57756909|NCT06067633|OTHER|Triple-Masked|Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant
57756910|NCT06067633|OTHER|Usual Procedures|Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
57756911|NCT05197361|DIAGNOSTIC_TEST|Invasive coronary physiology|Estimation of guide-wire coronary physiology parameters
57756912|NCT03764449|DRUG|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
57756913|NCT03764449|DRUG|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
57756914|NCT03047928|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
57756915|NCT03047928|BIOLOGICAL|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
57756916|NCT05461261|DRUG|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
57756917|NCT05461261|DRUG|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
57756918|NCT05461261|DRUG|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
57756919|NCT02393872|BEHAVIORAL|Feel4Diabetes-intervention|Community-based intervention.
57756920|NCT03718689|DEVICE|Laser etching|Acid etching
57756921|NCT00004670|PROCEDURE|pallidotomy|
57756922|NCT06081595|DRUG|Fluzoparib|Fluzoparib 100mg bid
57756923|NCT06081595|DRUG|Apatinib|Apatinib 375mg qd
57756924|NCT00292175|PROCEDURE|Narrow Band Imaging|
57756925|NCT00292175|PROCEDURE|colonoscopy|
57756926|NCT01341002|PROCEDURE|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
57756927|NCT01341002|PROCEDURE|Transfusion|transfusion based on guidelines
57756928|NCT05435755|BIOLOGICAL|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
57756929|NCT05435755|BIOLOGICAL|placebo (saline)|2 times placebo (normal saline) injections as control group
57756930|NCT00583622|DRUG|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
57756931|NCT00583622|DRUG|Carboplatin|333 mg/m\^2 by vein over 2 hours for 3 Days
57756932|NCT00583622|DRUG|Docetaxel|300 mg/m\^2 by vein over 2 hours for 1 Day
57756933|NCT00583622|DRUG|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
57756934|NCT00583622|DRUG|Melphalan|50 mg/m\^2 by vein over 15 minutes for 3 Days
57756935|NCT00583622|PROCEDURE|Stem Cell Transplant|"* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
57756936|NCT03607188|DRUG|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
57756937|NCT03285425|OTHER|Natural history|Parent interview
57756938|NCT03681418|PROCEDURE|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
57756939|NCT01170416|OTHER|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
57756940|NCT04194203|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
57756941|NCT04194203|DRUG|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
57756942|NCT04194203|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
57756943|NCT04194203|DRUG|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
57756944|NCT04194203|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
57756945|NCT04194203|DRUG|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
57756946|NCT02571374|DIETARY_SUPPLEMENT|symbiotic group|this group received sachets of symbiotic
57756947|NCT02571374|DIETARY_SUPPLEMENT|placebo group|this group received placebo
57756948|NCT00828308|DRUG|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
57756949|NCT00828308|PROCEDURE|Prostatectomy|Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
57756950|NCT04958330|PROCEDURE|lateral prostate capsule sparing|When resect the bladder and prostate, the lateral prostate capsule will be preserved.
57756951|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
57756952|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
57756953|NCT06182566|PROCEDURE|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
57756954|NCT06182566|PROCEDURE|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
57756955|NCT04029701|DRUG|Ruyizhenbao Pill|Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
57756956|NCT04029701|DRUG|Placebo of Ruyizhenbao Pill|Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
57756957|NCT00110370|DRUG|Lispro Mixture Therapy|
57756958|NCT00110370|DRUG|Glargine Basal-Bolus Therapy|
57756959|NCT03261128|OTHER|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
57756960|NCT00687999|DRUG|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
57756961|NCT03536910|OTHER|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
57756962|NCT01548430|DRUG|TTP4000|
57756963|NCT01548430|DRUG|Placebo|
57756964|NCT01795365|OTHER|Active surveillance|
57756965|NCT00813852|BEHAVIORAL|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
57756966|NCT06619691|OTHER|Fine motor skills|Only intervention
58128581|NCT02348268|DEVICE|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
58454272|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
58454273|NCT00236353|DRUG|risperidone|
58454274|NCT03345251|DEVICE|Hydrotubation|
57756967|NCT04433884|DEVICE|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
57756968|NCT05672212|DEVICE|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
57756969|NCT05672212|DEVICE|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
57756970|NCT05672212|DRUG|Sufentanil|Sufentanil
57756971|NCT02617875|OTHER|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
57756972|NCT02617875|OTHER|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
57756973|NCT00508404|DRUG|Panitumumab|Administered by intravenous infusion
57756974|NCT00508404|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
57756975|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
57756976|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
57756977|NCT00437645|DRUG|Valsartan 160 mg capsules|
57756978|NCT00437645|DRUG|Amlodipine 5 mg capsules|
57756979|NCT00437645|DRUG|placebo|capsules
57756980|NCT04366063|BIOLOGICAL|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
57756981|NCT04366063|BIOLOGICAL|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
57756982|NCT05576532|DRUG|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
58128582|NCT05801263|DIAGNOSTIC_TEST|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
58128583|NCT02647983|DRUG|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
57756983|NCT03800732|OTHER|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
57756984|NCT03800732|OTHER|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
57756985|NCT03800732|OTHER|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
57756986|NCT01286441|DRUG|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
57756987|NCT01286441|DRUG|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
57756988|NCT01286441|DRUG|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
57756989|NCT01286441|DRUG|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
57756990|NCT02500459|DRUG|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
57756991|NCT02500459|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
57756992|NCT03034616|DEVICE|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
57756993|NCT03516643|OTHER|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
57756994|NCT04377230|PROCEDURE|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
57756995|NCT04377230|PROCEDURE|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
57756996|NCT01057784|PROCEDURE|Bariatric surgery.|Bariatric Surgery
57756997|NCT03322098|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
57756998|NCT03322098|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
57756999|NCT00112580|BIOLOGICAL|ipilimumab|
57757000|NCT05321355|DEVICE|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
57757001|NCT04164654|BEHAVIORAL|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
58128584|NCT04901325|DRUG|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
57757002|NCT02312856|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
57757003|NCT06162143|DEVICE|Gelsectan®|Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
58128585|NCT00989352|DRUG|Methotrexate|3g/m² i.v. max. 9 times
58128586|NCT00989352|DRUG|Lomustine|110 mg/m² p.o., max. 3 times
58128587|NCT00989352|DRUG|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
58128588|NCT00989352|DRUG|Rituximab|375 mg/m² i.v., max. 10 times
58128589|NCT00577460|DRUG|Pramipexole|Pramipexole ER 0.375 -4.5 mg
58128590|NCT00577460|DRUG|Placebo|Placebo tablets identical to Pramipexole ER tablets
58128591|NCT01755858|DRUG|Bendavia|
58128592|NCT01755858|DRUG|Placebo|
58454275|NCT00920751|PROCEDURE|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
58128593|NCT04002388|BEHAVIORAL|activity monitor group|will receive a FitBit and will be asked to wear this for one year
58128594|NCT04002388|BEHAVIORAL|usual care group|will NOT receive a FitBit
58454276|NCT00920751|PROCEDURE|Air insufflation|Conventional air insufflation colonoscopy
58454277|NCT01475877|DRUG|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
57757004|NCT02799784|DRUG|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
57757005|NCT02799784|DRUG|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
57757006|NCT02799784|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
57757007|NCT04437420|DRUG|injection of BEP 800|injection of BEP 800
57757008|NCT04437420|OTHER|Control|no injection of BEP 800
57757009|NCT05181514|OTHER|20% Intralipid|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
57757010|NCT05181514|OTHER|Normal Saline|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
57757011|NCT04108130|OTHER|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
57757012|NCT04108130|PROCEDURE|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
57757013|NCT04108130|OTHER|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
58128595|NCT04787302|DRUG|CVL-231|Cohort 1: 30mg dose of CVL-231
58128596|NCT04787302|DRUG|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
58458606|NCT01277744|PROCEDURE|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
57757014|NCT04108130|PROCEDURE|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
57757015|NCT04108130|BEHAVIORAL|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
57757016|NCT04781361|DRUG|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
57757017|NCT04781361|DRUG|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L"
57757018|NCT00321048|DEVICE|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
57757019|NCT06626373|OTHER|Elderberry Juice|Participants will consume elderberry juice 1-week.
57757020|NCT06626373|OTHER|Placebo Beverage|Participants will consume placebo beverage twice/day for 1-week.
57757021|NCT05083195|OTHER|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
57757022|NCT05083195|OTHER|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
57757023|NCT01337557|DRUG|Bepotastine|1.5% bid
57757024|NCT04904822|PROCEDURE|Vaginal bisection|Uterine bisection vaginally by scalpel 24
57960888|NCT04427631|DEVICE|Bone conduction headphones|Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
57960889|NCT06267027|BEHAVIORAL|Exercise|The aim of exercise therapy is to stretch and strengthen the wrist extensor and flexor muscles. All study groups were given a home exercise program including stretching and eccentric strengthening exercises. The patient was instructed to start with stretching, and the patient was informed to stretch for 30s by flexing the wrist with the other hand while the shoulder was flexed 90 degrees, the elbow was in extension and the forearm was pronated. When stretching exercises could be performed painlessly, the patient was instructed to move on to strengthening exercises. Eccentric strengthening exercises for wrist extensors and flexors were explained with a support under the forearm and each patient was given a written program supported with visuals. It was emphasized that the exercises should be performed within the pain limit and patients were told to stop if they had severe pain. The exercise program was told to be performed 2 times a day, in 3 sets, 10 repetitions.
58128597|NCT04787302|DRUG|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
58458607|NCT01277744|DRUG|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
58458608|NCT00297388|DRUG|Risperidone, long-acting injectable|
58458609|NCT00561652|BEHAVIORAL|Education & Exercise|Education \& Exercise
57757025|NCT04904822|PROCEDURE|Abdominal bisection|Uterine bisection by endokinfe
57757026|NCT05810493|OTHER|Observation|Follow-up of disease, therapeutics and evolution
57757027|NCT03268239|DEVICE|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~* 3D T1 GRE after injection (Gradient-Recalled Echo)~* 3D T1 TSE before injection (Turbo Spin Echo)~* 3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
57757028|NCT04913064|OTHER|Questionnaire Administration|Ancillary studies
57757029|NCT04913064|DRUG|White Button Mushroom Extract|Given PO
57757030|NCT06409221|OTHER|Non-interventional study, Observational only|Observational study only, there are no planned interventions.
57757031|NCT02390726|BIOLOGICAL|Fecal Microbiota Transplant|
57757032|NCT02390726|BIOLOGICAL|Placebo|
57757033|NCT02153138|DEVICE|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~1. The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~2. The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
57757034|NCT02153138|DEVICE|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
57757035|NCT02153138|DEVICE|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
57757036|NCT06625034|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57757037|NCT06625034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57757038|NCT06625034|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
57757039|NCT06625034|PROCEDURE|Positron Emission Tomography|Undergo PET
57757040|NCT06625034|OTHER|Questionnaire Administration|Ancillary studies
58128598|NCT04832230|OTHER|Hearing test|"The hearing test is composed of several examinations:~* pure tone audiogram~* otoscopy~* tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
58128599|NCT04832230|OTHER|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
58128600|NCT04832230|OTHER|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
57757041|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive human-driven treatment planning
57757042|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive RapidPlan treatment planning
57757043|NCT01445808|BEHAVIORAL|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
57757044|NCT01445808|BEHAVIORAL|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
57757045|NCT01445808|OTHER|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
57757046|NCT04242693|BEHAVIORAL|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
57757047|NCT06460558|OTHER|Type 1 diabetes with insulin infusion system|No intervention
57757048|NCT02765919|RADIATION|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
58128601|NCT04832230|OTHER|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
58128602|NCT04832230|OTHER|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
58128603|NCT04832230|OTHER|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
58128604|NCT04832230|OTHER|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
57757049|NCT02765919|RADIATION|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
58128605|NCT04832230|BIOLOGICAL|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
58458610|NCT00561652|PROCEDURE|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education \& Exercise)
58458611|NCT01460966|PROCEDURE|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
58458612|NCT01460966|PROCEDURE|Thrombus aspiration catheter|Thrombus aspiration catheter only
58458613|NCT04068701|OTHER|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
57757050|NCT01126827|BEHAVIORAL|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
57757051|NCT02295514|BIOLOGICAL|PTP1B dosage|PTP1B sampled and dosed during sepsis
57757052|NCT03181802|DRUG|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
57757053|NCT03181802|DRUG|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
57757054|NCT02260076|DRUG|PEG 400|
57757055|NCT02260076|DRUG|Placebo|
57757056|NCT03483974|DIAGNOSTIC_TEST|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
57757057|NCT04814654|BEHAVIORAL|CHALO! 2.0|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
57757058|NCT04814654|BEHAVIORAL|Attention-matched control (AMC)|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
57757059|NCT04814654|BEHAVIORAL|Digital coupon only (DCO)|"The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers."
57757060|NCT02633930|DRUG|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
57757061|NCT02633930|DRUG|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
57757062|NCT02633930|DRUG|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
57757063|NCT02633930|DRUG|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
57757064|NCT02633930|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
57757065|NCT01621880|DRUG|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
57757066|NCT01621880|DRUG|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
57757067|NCT00431184|DRUG|Pentazocine|see arms description
57757068|NCT00431184|DRUG|Lorazepam|see arms description
57757069|NCT00652938|BIOLOGICAL|HPV Vaccine (GSK580299) Cervarix TM|IM administration
57757070|NCT00652938|BIOLOGICAL|Engerix B|IM administration
57757071|NCT02487472|OTHER|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
57757072|NCT01599390|OTHER|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
57757073|NCT02323087|DEVICE|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
57757074|NCT02323087|DEVICE|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
57757075|NCT05271058|OTHER|Control group|23 eyes that didn't receive any intraoperative steroids
57757076|NCT05271058|DRUG|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
58458614|NCT01021735|DRUG|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
57757077|NCT05271058|DRUG|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
57757078|NCT03928028|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
57757079|NCT03928028|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
57757080|NCT03278535|DIAGNOSTIC_TEST|CAREN-based gait analysis|subjects only walk at CAREN at different speed
57757081|NCT04000867|DEVICE|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
57757082|NCT01224925|PROCEDURE|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
57757083|NCT01224925|PROCEDURE|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
57757084|NCT05598242|BIOLOGICAL|Amniotic membrane extract eye drops (AMEED)|Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
57757085|NCT02404389|DRUG|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
57757086|NCT02404389|DRUG|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
57757087|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
57757088|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
57757089|NCT04378322|BEHAVIORAL|Nutrition education tool|Participants will be asked to review nutrition education materials online.
58458615|NCT01021735|DRUG|Rituximab|1g x2 by IV infusion repeated every 5 months or more
57757090|NCT01330316|DRUG|BI 201335|BI 201335 for 24 weeks
57757091|NCT01330316|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
57757092|NCT05578950|DRUG|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
57757093|NCT05578950|DRUG|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
57757094|NCT03662074|DRUG|Gemcitabine|Given IV
57757095|NCT03662074|BIOLOGICAL|Nivolumab|Given IV
57757096|NCT00204984|DRUG|oral hydralazine and intravenous nesiritide|vasodilators
57757097|NCT01055730|OTHER|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
57757098|NCT00449280|DRUG|Sorafenib|400mg BID (200 mg twice daily)
57757099|NCT00449280|DRUG|Rapamycin|30mg once weekly
57757100|NCT00449280|DRUG|Rapamycin|3mg once daily
57757101|NCT03088709|DRUG|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
57757102|NCT03088709|DRUG|Tacrolimus|IV medication given for prevention of graft versus host disease.
57757103|NCT03088709|DRUG|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
57757104|NCT03088709|OTHER|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
57757105|NCT00246987|DRUG|Muraglitazar|
58458616|NCT04176198|DRUG|Nusivertib|Oral PIM Inhibitor
57757106|NCT04010630|DRUG|Sodium bicarbonate infusion|"Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion."
58458617|NCT04176198|DRUG|Ruxolitinib|Oral JAK inhibitor
57757107|NCT05769738|DRUG|Furosemide|40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
57757108|NCT05769738|DRUG|Normal saline|4ml of normal saline to be nebulized 3 times daily for 3 days
57757109|NCT03550833|BEHAVIORAL|Questionnaire|Questionnaire
57757110|NCT03550833|BIOLOGICAL|blood sample|7 ml whole blood for Peripheral blood
57757111|NCT02516722|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
58458618|NCT04176198|DRUG|Momelotinib|Oral JAK inhibitor
58458619|NCT05260671|DRUG|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
57757112|NCT02127372|DRUG|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~* Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~* Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~* Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~* Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~* Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~* Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
57757113|NCT02127372|DRUG|Docetaxel|
57757114|NCT02127372|DRUG|Cisplatin|
57757115|NCT01435655|DRUG|tafamidis|tafamidis meglumine 20 mg QD
57757116|NCT05904470|DRUG|Bemnifosbuvir|550 mg administered orally once a day (QD) for 8 weeks
57757117|NCT05904470|DRUG|Ruzasvir|180 mg administered orally once a day (QD) for 8 weeks
57757118|NCT05078060|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
57757119|NCT05078060|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
57757120|NCT06320301|DRUG|Adebrelimab + GEMOX + TKI|"Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated."
57757121|NCT01969019|DRUG|methylprednisolone, prednisone|
57757122|NCT00806234|DRUG|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
57757123|NCT00806234|DRUG|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
57757124|NCT00806234|DRUG|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
57757125|NCT01886001|DRUG|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
57757126|NCT01886001|DRUG|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
57757127|NCT01886001|DRUG|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
57757128|NCT01886001|OTHER|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
57757129|NCT00936832|DRUG|FOLFIRI regimen|
57757130|NCT00936832|DRUG|fluorouracil|
57757131|NCT00936832|DRUG|irinotecan hydrochloride|
57757132|NCT00936832|DRUG|leucovorin calcium|
57757133|NCT00936832|DRUG|sunitinib malate|
57757134|NCT00936832|OTHER|laboratory biomarker analysis|
57757135|NCT00936832|OTHER|pharmacogenomic studies|
57757136|NCT00936832|OTHER|pharmacological study|
57757137|NCT01916655|BEHAVIORAL|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
57757138|NCT01916655|BEHAVIORAL|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
57757139|NCT01916655|BEHAVIORAL|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
57757140|NCT03375476|DIAGNOSTIC_TEST|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
57757141|NCT03375476|DIAGNOSTIC_TEST|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
57757142|NCT03375476|DIAGNOSTIC_TEST|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
57757143|NCT01368900|DEVICE|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
57757144|NCT06068231|DEVICE|Temporary Crown|Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.
58454278|NCT05195229|DEVICE|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
57757145|NCT06068231|DEVICE|Permanent Crown|Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.
57757146|NCT01521962|DRUG|Alogliptin|Alogliptin tablets
57757147|NCT01521962|DRUG|Insulin|Insulin injection
57757148|NCT02081950|BIOLOGICAL|Enoxaparin sodium|comparison of 2 different administration of drug
57757149|NCT04828564|DRUG|Ribavirin Capsules|Ribavirin 200 mg capsules
57757150|NCT04828564|DRUG|Favipiravir|Favipiravir 200 mg tablets
57757151|NCT06389201|DRUG|HCQ|HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
57757152|NCT06389201|OTHER|Placebo|Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.
57757153|NCT00622011|DRUG|Risperidone and Zotepine for delirium|try risperidone or zotepine in the treatment of delirium
57757154|NCT00915135|DRUG|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
57757155|NCT03621202|DEVICE|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
57757156|NCT00016692|DRUG|Z-100|
57757157|NCT00584935|DRUG|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
57757158|NCT05672602|DIAGNOSTIC_TEST|Measurement of ncRNAs and cytokines|Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
57757159|NCT05147610|DIAGNOSTIC_TEST|Intraocular pression|"First, measurement of the eye pressure by air-puff tonometry and estimation of the pachymetries with the TONOREF III.~Secondly, measurement of the eye pressure by GAT. Thirdly, measurement of the eye pressure by Icare 200."
57757160|NCT04735744|OTHER|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
57757161|NCT00551070|OTHER|Laboratory Biomarker Analysis|Correlative studies
57757162|NCT00551070|OTHER|Pharmacological Study|Correlative studies
57757163|NCT00551070|DRUG|Selumetinib|Given PO
57757164|NCT00551070|DRUG|Selumetinib Sulfate|Given PO
57757165|NCT00846638|BEHAVIORAL|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
57757166|NCT00846638|BEHAVIORAL|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
57757167|NCT04769323|DEVICE|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
57757168|NCT04769323|OTHER|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
57757169|NCT04504201|OTHER|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
57757170|NCT01718743|DRUG|Ixazomib Citrate|Given PO
57757171|NCT01718743|DRUG|Lenalidomide|Given PO
57757172|NCT01718743|OTHER|Questionnaire Administration|Ancillary studies
57757173|NCT00005954|DRUG|temozolomide|
57757174|NCT01919359|DIETARY_SUPPLEMENT|Multizyme Cellular Vitality Cyruta Plus SHEP|
57757175|NCT00082732|BEHAVIORAL|behavioral dietary intervention|
57757176|NCT00082732|DIETARY_SUPPLEMENT|dietary intervention|
57757177|NCT00082732|PROCEDURE|therapeutic dietary intervention|
57757178|NCT02864225|DEVICE|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
57757179|NCT02864225|DEVICE|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
57757180|NCT02864225|DEVICE|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
57757181|NCT00302783|BEHAVIORAL|Multi-Source Feedback: including self-assessment & coaching|
57757182|NCT01538472|DRUG|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
57757183|NCT01538472|DRUG|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
57757184|NCT01538472|DRUG|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
57757185|NCT01538472|DRUG|BCNU|300 mg/m2 by vein on Day -6.
57757186|NCT01538472|DRUG|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
57757187|NCT01538472|DRUG|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
57757188|NCT01538472|DRUG|Melphalan|140 mg/m2 by vein on Day -1.
57757189|NCT01538472|PROCEDURE|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
57757190|NCT01538472|DRUG|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
57757191|NCT05602545|OTHER|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
57757192|NCT06063798|OTHER|General anesthesia for laryngotracheal surgery|Patients undergoing general anesthesia and mechanical ventilation.
57757193|NCT06063798|OTHER|Mechanical ventilation by FCV|Mechanical ventilation is assured by Flow-controlled ventilation mode.
57757194|NCT06063798|OTHER|Mechanical ventilation by HFJV|Mechanical ventilation is assured by High frequency jet ventilation mode.
57757195|NCT01718028|OTHER|Propylene glycol 0.6% ocular emulsion|
57757196|NCT01718028|OTHER|Sodium chloride 0.9% saline solution|
57757197|NCT02249455|DEVICE|Acapella|Treatment time for 20 min twice daily
57757198|NCT02249455|OTHER|ELTGOL|ELTGOL technique 20 min twice daily
57757199|NCT02249455|OTHER|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
57757200|NCT02461810|DEVICE|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
57757201|NCT02461810|PROCEDURE|Balloon Kyphoplasty|
57757202|NCT00423384|DRUG|Placebo|Placebo
57757203|NCT00423384|DRUG|Ibandronate|I.v.
57757204|NCT06116565|BIOLOGICAL|CM310|CM310, subcutaneous injection
57757205|NCT03114280|DRUG|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
57757206|NCT03114280|OTHER|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
57757207|NCT01170338|DRUG|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
57757208|NCT01170338|DRUG|control|this is the placebo that will help us maintain a blinded study
57757209|NCT03287739|BEHAVIORAL|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
57757210|NCT00066430|PROCEDURE|infrared photocoagulation therapy|
57757211|NCT00066430|DEVICE|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
57757212|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
57757213|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
57757214|NCT04520802|DIAGNOSTIC_TEST|18F-DPA-714 PET/CT neuroimaging|"* Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response"
57757215|NCT00330915|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
57757216|NCT01694784|BEHAVIORAL|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
57757217|NCT01694784|BEHAVIORAL|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
57757218|NCT01694784|BEHAVIORAL|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
57757219|NCT01694784|BEHAVIORAL|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
57757220|NCT02427711|DEVICE|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
57757221|NCT01105026|DEVICE|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
57757222|NCT04696913|DIAGNOSTIC_TEST|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
57757223|NCT04696913|DIAGNOSTIC_TEST|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
57757224|NCT03978325|OTHER|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
57757225|NCT03978325|OTHER|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
57757226|NCT01512771|OTHER|CPAP|6 weeks of CPAP
57757227|NCT05971914|PROCEDURE|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
58454279|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
58454280|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
57757228|NCT06474897|OTHER|Ozone therapy|Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
57757229|NCT06474897|OTHER|Mulligan Mobilization|Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
57757230|NCT03168295|DRUG|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
57757231|NCT03168295|DRUG|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
58454281|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
57757232|NCT01199926|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
57757233|NCT01199926|DRUG|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
57757234|NCT02837354|OTHER|No intervention|
57757235|NCT00965926|DRUG|YM178|oral
57757236|NCT00570674|DRUG|Abraxane|
57757237|NCT00570674|DRUG|Erbitux|
57757238|NCT00570674|DRUG|Carboplatin|
57757239|NCT00570674|RADIATION|Intensity Modulated Radiation Therapy|
57757240|NCT06156722|PROCEDURE|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
57757241|NCT06156722|PROCEDURE|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
57757242|NCT00946296|DRUG|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
57757243|NCT05660590|OTHER|complex decongestive physiotherapy with low pressure compression bandage|both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
57757244|NCT05660590|OTHER|complex decongestive physiotherapy with high pressure compression bandage|complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
58454282|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
58454283|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
58454284|NCT02724358|PROCEDURE|TACE|iodized oil (5ml) + Pirarubicin (20mg)
58454285|NCT02724358|DRUG|Rg3|20mg, BID, maintained though Month 12.
58454286|NCT02724358|OTHER|TACE + Rg3|
58454287|NCT02724358|PROCEDURE|protective therapy|standard liver protective therapy
57757245|NCT04131270|BEHAVIORAL|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
57757246|NCT04131270|BEHAVIORAL|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
57757247|NCT05604716|OTHER|observational study|observational study
57757248|NCT00187330|DRUG|Intravenous N-acetylcysteine|
57757249|NCT01584180|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
57757250|NCT01584180|DEVICE|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
57757251|NCT03590340|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
57757252|NCT03590340|OTHER|Normal saline|Normal saline is 0.9% sodium chloride
57757253|NCT03590340|BIOLOGICAL|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
57757254|NCT02634788|DRUG|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
57757255|NCT02634788|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
57757256|NCT02859610|OTHER|research on interactions between portal hypertension and microparticles|
57757257|NCT02228395|DRUG|PF-04958242|Administered as specified in treatment arm
57757258|NCT02228395|DRUG|Placebo|Administered as specified in treatment arm
57757259|NCT06020625|GENETIC|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size \>50 genes, if \<40 ng material available."
57757260|NCT00463827|DRUG|Atorvastatin|
57757261|NCT00463827|DRUG|atorvastatin|atorvastatin 40mg
57757262|NCT00463827|DRUG|matched placebo|Matched placebo
57757263|NCT03502486|OTHER|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
57757264|NCT03502486|OTHER|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
58128606|NCT05624931|BEHAVIORAL|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
57757265|NCT03502486|OTHER|Reading|20 minutes of seated reading
57757266|NCT02103621|BEHAVIORAL|Unified Protocol (UP)|
57757267|NCT02103621|BEHAVIORAL|Taper and Monitoring (TAP-M)|
58454288|NCT04324671|DEVICE|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP\*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
57757268|NCT03546348|OTHER|no intervention|only measurement of the carrying angle
57757269|NCT00674089|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A 50,000 IU
57757270|NCT00674089|DIETARY_SUPPLEMENT|Placebo|Vitamin A Placebo
58454289|NCT00763386|DEVICE|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
58454290|NCT00763386|DEVICE|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
58454291|NCT04140968|DRUG|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
58458620|NCT06235866|OTHER|Pulmonary rehabilitation|According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
57757271|NCT05440513|DEVICE|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
57757272|NCT01337674|DRUG|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
57757273|NCT01337674|DRUG|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
57757274|NCT01337674|DRUG|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
57757275|NCT01337674|DRUG|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
57757276|NCT05272891|OTHER|experimental group|audio book app
57757277|NCT04617184|OTHER|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
57757278|NCT02978443|DRUG|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
57757279|NCT02978443|DRUG|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
57757280|NCT02249819|DEVICE|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
57757281|NCT01018225|DRUG|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
57757282|NCT01018225|DRUG|Placebo|Placebo pill, once a day, for six weeks
57757283|NCT02405260|DRUG|TTP399 400 mg|once daily
57757284|NCT02405260|DRUG|TTP399 800 mg|once daily
57757285|NCT02405260|DRUG|Sitagliptin 100 mg|once daily
57757286|NCT02405260|DRUG|Placebo|once daily
57757287|NCT05573503|OTHER|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
57757288|NCT02725125|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
57757289|NCT00002832|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
57757290|NCT00002832|DRUG|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
57757291|NCT00002832|DRUG|Decitabine|IV for 6 hours every 12 hr for 5 days.
57757292|NCT00002832|PROCEDURE|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
58128607|NCT05624931|OTHER|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
58454292|NCT03153696|BEHAVIORAL|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
58454293|NCT00495768|BEHAVIORAL|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
57757293|NCT00002832|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
57757294|NCT06274684|DEVICE|Use of Virtual Reality Assistance during prostate biopsies|Patient will be equipped with VR headset providing a immersive experience during prostate biopsies
57757295|NCT04045444|OTHER|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
57757296|NCT04045444|OTHER|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
58128608|NCT04085770|DRUG|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
57757297|NCT00499863|DRUG|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
57757298|NCT00499863|DRUG|Placebo|Placebo patch
57757299|NCT02081625|DRUG|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
57757300|NCT01370512|DRUG|Droxidopa|100 mg tablets by mouth three times a day
57757301|NCT01370512|DRUG|Pyridostigmine|60 mg tablets by mouth three times a day
57757302|NCT01370512|OTHER|Placebo|Looks exactly like the study drug but contains no active ingredients
57757303|NCT02243241|DRUG|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.
57757304|NCT02243241|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
57757305|NCT02243241|DRUG|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
57757306|NCT02243241|DRUG|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
57757307|NCT01575353|DEVICE|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
57757308|NCT01575353|DEVICE|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
57757309|NCT02514421|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
57757310|NCT02514421|DRUG|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
58454294|NCT00184223|BEHAVIORAL|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
58454295|NCT00184223|OTHER|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
58454296|NCT02344654|DRUG|Indocyanine green|
58454297|NCT02344654|DEVICE|Near-infrared illumination|To see the fluorescence from indocyanine green
58454298|NCT02344654|DRUG|Urografin|
57757311|NCT02514421|DRUG|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
57757312|NCT02472652|DRUG|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
57757313|NCT03687801|BEHAVIORAL|Online hearing support|The intervention group will follow an online hearing support for five weeks
57757314|NCT03687801|BEHAVIORAL|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
57757315|NCT02073097|DRUG|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
57757316|NCT02073097|BIOLOGICAL|Rituximab|Given IV (375mg/m\^2)
57757317|NCT02073097|DRUG|Cyclophosphamide|Given IV (750mg/m\^2)
57757318|NCT02073097|DRUG|Doxorubicin hydrochloride|Given IV (50mg/m\^2)
57757319|NCT02073097|DRUG|Vincristine sulfate|Given IV (1.4mg/m\^2)
57757320|NCT02073097|DRUG|Prednisone|Given PO (100mg)
57757321|NCT02073097|DRUG|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
57757322|NCT02073097|DRUG|Acyclovir|PO (400mg)
57757323|NCT03652974|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
57757324|NCT03652974|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
58454299|NCT02344654|RADIATION|X-ray|
57757325|NCT03652974|DRUG|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
58128609|NCT06484218|PROCEDURE|conventional endodontic treatment|The conventional access cavity was prepared under the microscope through the incisal edge as this approach facilitates straight-line access. A high-speed contra-angle handpiece, associated with a long surgical bur 010 (Meisinger, CO, USA), was used until the dentin was exposed, which is in general 3 to 4 millimeters from the incisal edge. Then, the ultrasonic tip ED5 (woodpecker-DTE, Guilin, China) was marked with a stopper according to the calcification level viewed on the preoperative CBCT and then used gently at the stopper level until the canal was found.
57757326|NCT03652974|DRUG|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
57757327|NCT01778556|BIOLOGICAL|Metreleptin|Recombinant analog of the human hormone, leptin
57757328|NCT00370721|DRUG|bevacizumab|
57757329|NCT03534310|DRUG|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
57757330|NCT03534310|OTHER|lifestyle modification|
57757331|NCT03534310|OTHER|sleeve gastrectomy|
58454300|NCT01691794|DRUG|Atazanavir|
58454301|NCT01691794|DRUG|Ritonavir|
58454302|NCT02304939|PROCEDURE|changeover|
58454303|NCT02304939|DEVICE|use of automatic infusion pump|
57757332|NCT05608304|BEHAVIORAL|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
57757333|NCT05608304|BEHAVIORAL|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
58454304|NCT02304939|BEHAVIORAL|datas collection|
58454305|NCT03684174|DEVICE|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
58454306|NCT01487135|DRUG|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
58454307|NCT01487135|DRUG|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
58454308|NCT01487135|DRUG|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
58454309|NCT02277600|DRUG|BMS-663068|BMS-663068
58454310|NCT02277600|DRUG|Darunavir|Darunavir
58454311|NCT02277600|DRUG|Cobicistat|Cobicistat
58454312|NCT01733875|DRUG|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
58454313|NCT01733875|DRUG|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
58454314|NCT01733875|DRUG|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
58454315|NCT01733875|DRUG|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
58454316|NCT01733875|DRUG|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
58454317|NCT01733875|DRUG|Placebo|A single dose of placebo will be administered orally once a day.
58128610|NCT06484218|PROCEDURE|Guided endodontic treatment|In all cases, digital and clinical protocols were followed according to the method reported by Zehnder et al. and Connert et al. The guide was replaced, and the access cavity precisely drilled using the EG6 drill, mounted on a low-speed contra-angle handpiece. With every 3 mm of progression, the cavity was rinsed, and the head of the bur was cleaned until reaching the canal. The irrigation was done to avoid overheating the dentine and the accumulation of dentine debris
58454318|NCT01733875|DRUG|CC-220|CC-220 4 mg will be administered orally once a day
58454319|NCT01733875|DRUG|CC-220|CC-220 6 mg will be administered orally once a day
58454320|NCT01733875|DRUG|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
58454321|NCT02684773|PROCEDURE|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
58454322|NCT02684773|PROCEDURE|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
58454323|NCT04827264|DIAGNOSTIC_TEST|Safe Return to Play Following ACL Reconstruction Checklist|"All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports"
58454324|NCT02197117|DEVICE|Remote ischemic conditioning|
58454325|NCT02197117|DEVICE|Control|
58454326|NCT01269866|DRUG|Cymbalta|Cymbalta 60 to 120 mg PO QD
58454327|NCT01380223|DRUG|placebo|I.V. infusion of placebo for 8 hr
58454328|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
58454329|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
58454330|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
58454331|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
58454332|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
58454333|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
58454334|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
58454335|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
58454336|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
58454337|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
58454338|NCT00872963|BIOLOGICAL|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
58454339|NCT03264274|DRUG|Aflibercept|Antiangiogenic
58454340|NCT03264274|PROCEDURE|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
58454341|NCT01064115|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
58128611|NCT06382519|DRUG|Thalidomide|thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
58128612|NCT01574248|DRUG|icatibant|Subcutaneous at time 0 and 6 hours
58128613|NCT01574248|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
58128614|NCT02655237|DRUG|Relugolix|Relugolix tablets
58128615|NCT02655237|DRUG|Relugolix Placebo|Relugolix placebo-matching tablets
58128616|NCT02655237|DRUG|Leuprorelin|Leuprorelin injection
58454342|NCT06524128|DEVICE|Dreeft wheels (EPPUR company)|The braking system (Dreeft wheels) is installed directly on the participant's wheelchair, by a trained occupational therapist. The Dreeft wheels are supplied for a period of 1 month.
58454343|NCT04361370|DRUG|Olaparib-Pembrolizumab-Bevacizumab|"* Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
58454344|NCT05022186|DRUG|Cannabidiol Oil|Patients will use it with specific instructions and they will be monitored at least one time in a month
58454345|NCT05022186|DRUG|Homotaurine|Patients will use it with specific instructions and they will be monitored at least one time in a month
58454346|NCT00219063|DRUG|aliskiren|
58454347|NCT03055117|BEHAVIORAL|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
58454348|NCT03055117|BEHAVIORAL|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
58454349|NCT03055117|BEHAVIORAL|Home exercise|Supervised home exercise
58454350|NCT04649814|OTHER|Questionnaire|Questionnaire for all, interview for part of the respondents.
58454351|NCT03642977|DIAGNOSTIC_TEST|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
58454352|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
58454353|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
58454354|NCT03155126|OTHER|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
58454355|NCT01307384|DEVICE|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
58454356|NCT00380055|BEHAVIORAL|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
57757334|NCT05608304|BEHAVIORAL|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
57757335|NCT03122561|DRUG|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
57757336|NCT03122561|DRUG|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
57757337|NCT03122561|DRUG|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
57757338|NCT03217448|DRUG|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
57757339|NCT03217448|DRUG|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
57757340|NCT00628901|PROCEDURE|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
57757341|NCT00628901|DEVICE|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
57757342|NCT00628901|DEVICE|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
57757343|NCT05873725|DRUG|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
57757344|NCT00548730|PROCEDURE|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
57757345|NCT01804101|OTHER|Laboratory Biomarker Analysis|Correlative studies
57757346|NCT01804101|DRUG|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
57757347|NCT02402088|BEHAVIORAL|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
57757348|NCT02402088|BEHAVIORAL|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
57757349|NCT02402088|BEHAVIORAL|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
57757350|NCT01668082|PROCEDURE|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
57757351|NCT00406224|DRUG|breathing 100% oxygen|
57757352|NCT03402256|BEHAVIORAL|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
57757353|NCT06491199|OTHER|Home blood pressure telemonitoring program and clinician monitoring|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Clinician monitoring includes OBIM physicians reviewing transmitted BP data and contacting patients to adjust antihypertensive medication regimens."
57757354|NCT01544998|DRUG|Nesiritide|10 ug/kg
57757355|NCT01544998|DRUG|Tadalafil|5 mg
58454357|NCT00380055|BEHAVIORAL|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
57757356|NCT01544998|DRUG|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
57757357|NCT01544998|DRUG|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
57757358|NCT04807985|DEVICE|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
58454358|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-01|1 capsule after breakfast once a day
58454359|NCT05952232|DIETARY_SUPPLEMENT|MK-GH-04|1 capsule after breakfast once a day
58454360|NCT05952232|DIETARY_SUPPLEMENT|TSH-GH-03|1 capsule after breakfast once a day
58454361|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-02|1 capsule after breakfast once a day
58454362|NCT04002076|BEHAVIORAL|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
58128617|NCT02655237|DRUG|Leuprorelin Placebo|Leuprorelin placebo-matching injections
58454363|NCT04002076|BEHAVIORAL|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
58454364|NCT01033539|OTHER|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
57757359|NCT04874402|PROCEDURE|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
57757360|NCT04874402|PROCEDURE|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
57757361|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 500mg per day(once a day)
57757362|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
57757363|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
57757364|NCT01499225|DRUG|INSADOL[Zea mays L. extract] 35mg Tab|"\[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day"
57757365|NCT01499225|DRUG|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
57757366|NCT01499225|DRUG|Placebo|Placebo
57757367|NCT01695824|DEVICE|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
57757368|NCT01695824|PROCEDURE|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
58128618|NCT01581957|OTHER|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
58128619|NCT01581957|OTHER|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
58128620|NCT01102465|DRUG|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
58128621|NCT02608502|BIOLOGICAL|RSV-F Vaccine|
58128622|NCT02608502|BIOLOGICAL|Phosphate Buffer Placebo|
58128623|NCT00414401|BEHAVIORAL|Clinical Reminder|
58128624|NCT00421005|DRUG|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
58128625|NCT04854148|OTHER|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
58315396|NCT05666973|PROCEDURE|Open Mesh Hernioplasty|"* Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture"
58315397|NCT03810443|DIAGNOSTIC_TEST|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
58315398|NCT03169439|PROCEDURE|Irreversible electroporation|minimal invasive ablative technique for tumors
58315399|NCT01555814|DRUG|Amisulpride|4-week open label amisulpride treatment
58315400|NCT00187434|DEVICE|Infant Flow System|
58315401|NCT00187434|DEVICE|Bubble CPAP|
58315402|NCT03555929|DRUG|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
58315403|NCT03555929|DRUG|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
58454365|NCT04218617|DEVICE|Diagnostic MRI|Diagnostic MRI
57757369|NCT01695824|DRUG|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
57757370|NCT03389568|BEHAVIORAL|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
57757371|NCT01793025|BIOLOGICAL|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
57757372|NCT06198023|BEHAVIORAL|Educational|The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.
57757373|NCT06198023|BEHAVIORAL|Interactive|The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
57757374|NCT04056884|BEHAVIORAL|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
57757375|NCT00603577|DRUG|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
57757376|NCT00603577|DRUG|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
57757377|NCT00520390|DRUG|EZN-2208|
57757378|NCT01082562|DRUG|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
57757379|NCT01082562|DRUG|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
57757380|NCT00897130|DRUG|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
58315404|NCT02022917|DRUG|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
57961676|NCT05514964|BEHAVIORAL|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
58315405|NCT02059109|PROCEDURE|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
58315406|NCT03170713|DRUG|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
58315407|NCT03170713|DRUG|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
58315408|NCT03170713|OTHER|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
58315409|NCT01997658|DRUG|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
58315410|NCT01997658|DRUG|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
58315411|NCT02910232|DEVICE|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
58315412|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
58315413|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
58315414|NCT04780399|DRUG|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
58315415|NCT05948488|OTHER|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
58315416|NCT02202252|PROCEDURE|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
58315417|NCT02202252|PROCEDURE|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
58315418|NCT02202252|PROCEDURE|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
57961677|NCT02288338|DRUG|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
57961678|NCT02288338|DRUG|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57757381|NCT04957017|BEHAVIORAL|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
57757382|NCT02624739|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
57757383|NCT01992679|BEHAVIORAL|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
57757384|NCT01945749|DRUG|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
57757385|NCT01945749|DRUG|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
57757386|NCT01945749|OTHER|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
57757387|NCT01204268|PROCEDURE|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
57960890|NCT06267027|DEVICE|Kinesiotaping|Area where the tape would be applied was clean and dry. If there is excessive hair in the application area, patients were asked to shave this area. It was explained that cream and similar substances should not be used. Muscle inhibition technique and fascia correction technique were used as the application technique. An X strip of approximately 25 cm and a Y strip of 10 cm in length are prepared as long as the distance between the lateral epicondyle and the wrist. The short arms of the X strip are adhered to the dorsal side of the hand without stretching and the crossed part of the strip is placed on the wrist with maximal stretching. The long arms of the X strip are adhered along the extensor carpi ulnaris and extensor carpi radialis to the lateral epicondyle without stretching. The Y strip was applied using the fascia correction method. The tails of the Y band were applied using an oscillating motion. The taping procedure was applied 2 times a week for 3 weeks for a total of 6 times.
57960891|NCT06267027|DEVICE|High intensity laser therapy|The elbow area was marked and then the epicondylitis protocol was selected. The epicondylitis protocol consists of 3 phases. Phase 1 and 2 consist of analgesic treatment and phase 3 consists of anti-inflammatory treatment. In phase 1 and phase 2 treatment protocol, 8 W was applied to a circular area with a radius of 1.0 cm for 3 min. In Phase 3 protocol, a dose of 80 J/cm2 at 8 W power was applied and the patient's treatment was completed.
58315419|NCT05230901|OTHER|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
57757388|NCT01204268|PROCEDURE|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
57757389|NCT02417064|DRUG|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
57757390|NCT02417064|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
57757391|NCT02417064|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
57757392|NCT02417064|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
57757393|NCT02417064|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
57757394|NCT02417064|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
57757395|NCT05550415|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
57757396|NCT05550415|DRUG|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
57757397|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
57757398|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
57757399|NCT00284063|PROCEDURE|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
57757400|NCT03017430|DRUG|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
57757401|NCT03017430|DRUG|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
57757402|NCT03017430|DRUG|Doxylamin|
57757403|NCT03017430|DRUG|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
57757404|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
57757405|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
57757406|NCT02834702|DEVICE|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
57757407|NCT02834702|DEVICE|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
58454366|NCT04218617|DEVICE|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
58454367|NCT04218617|OTHER|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
58454368|NCT04218617|OTHER|QOL assessment|QOL assessment
58454369|NCT04218617|OTHER|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
58454370|NCT04218617|RADIATION|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
57757408|NCT01760889|DRUG|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once-daily for 4 weeks; then,~* 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~* if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
57757409|NCT01760889|DRUG|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once daily for 1 week; then~* 120 mg capsule once-daily for 1 week, then,~* 140 mg capsule once-daily for 2 weeks, then~* 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~* if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
57757410|NCT01760889|DRUG|Placebo|One capsule a day for 26 weeks
57757411|NCT01126138|DRUG|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
57757412|NCT01126138|DRUG|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
57757413|NCT01480947|DRUG|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
57960892|NCT05714683|DRUG|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
57960893|NCT03709381|DRUG|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
58454371|NCT04218617|RADIATION|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
58454372|NCT05774301|BEHAVIORAL|simulation-based training|the training will include a theoretical \& practical parts
58454373|NCT02568761|PROCEDURE|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
58454374|NCT02568761|OTHER|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
58454375|NCT01167803|DRUG|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
58454376|NCT01167803|DRUG|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
58454377|NCT00905450|DRUG|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
58454378|NCT00905450|DRUG|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
58454379|NCT02984488|PROCEDURE|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
58454380|NCT02984488|PROCEDURE|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
58454381|NCT04130607|OTHER|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
58454382|NCT05772624|DRUG|low dose nivolumab in combination with AVD|Nivolumab as an standard dose of 40mg in combination with AVD.
58454383|NCT02539641|RADIATION|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
58454384|NCT02539641|OTHER|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
58454385|NCT02271698|DRUG|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
57757414|NCT04751201|BEHAVIORAL|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
57757415|NCT02967614|DRUG|[A]|One eye drop(about 40ul) / Day1 \~ Day8 / BID
57757416|NCT02967614|DRUG|[B]|One eye drop(about 40ul) / Day1 \~ Day92 / BID
58454386|NCT02271698|OTHER|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
58454387|NCT06379165|DRUG|Meloxicam Nanocrystal Injection|30 mg (1 mL), once daily, by intravenous infusion
58454388|NCT06379165|DRUG|Placebo|1 mL Placebo, once daily, by intravenous infusion
57757417|NCT02967614|DRUG|[A]+[B](1)|One eye drop(about 40ul) / Day9 \~ Day100 / BID
57757418|NCT02967614|DRUG|[A]+[B](2)|One eye drop(about 40ul) / Day93 \~ Day100 / BID
57757419|NCT01452997|DRUG|NSAI treatment|Ibuprofen 5% gel
57757420|NCT01452997|DRUG|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
57757421|NCT05596890|DRUG|Paclitaxel-albumin|260mg/m2, ivdrip, d1
57757422|NCT05596890|DRUG|Cisplatin|60mg/m2, ivdrip, d1
57757423|NCT05596890|DRUG|Carboplatin|AUC=4-6, ivdrip, d1
57757424|NCT05596890|DRUG|Tislelizumab|200mg, ivdrip, d1
57757425|NCT05596890|RADIATION|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
57757426|NCT05596890|PROCEDURE|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
57757427|NCT03390699|DIAGNOSTIC_TEST|Microbial profile|microbiological testing
57757428|NCT04552743|DRUG|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
57757429|NCT04552743|DRUG|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
57757430|NCT01292070|BIOLOGICAL|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm."
57757431|NCT01292070|BIOLOGICAL|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
57757432|NCT01292070|BIOLOGICAL|Positive Control - Histamine Prick|1.0 mg/mL
57757433|NCT01292070|BIOLOGICAL|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
57757434|NCT03184584|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
57757435|NCT05038280|BEHAVIORAL|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
57757436|NCT03036384|DRUG|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
57757437|NCT03036384|DRUG|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
57757438|NCT03036384|DRUG|Sufentanil|2.5µg sufentanyl
57757439|NCT03036384|DRUG|Morphine|100 µg Morphine
57960894|NCT03709381|DRUG|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
58315420|NCT05230901|DRUG|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
58315421|NCT05230901|DRUG|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
58454389|NCT01960140|DRUG|Baricitinib|Administered orally
58454390|NCT01960140|DRUG|Simvastatin|Administered orally
58454391|NCT04107714|BEHAVIORAL|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure."
58454392|NCT05757986|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
58454393|NCT02995356|OTHER|Collecting cervical liquid and sera samples|
58454394|NCT02484066|DEVICE|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
58454395|NCT02484066|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
57757440|NCT02613104|OTHER|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
57757441|NCT02613104|OTHER|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
57757442|NCT02613104|OTHER|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
57757443|NCT02613104|OTHER|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
57757444|NCT03566303|DRUG|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
57757445|NCT03566303|DRUG|Warfarin|Warfarin
57757446|NCT03907163|DRUG|Dronabinol|Capsules containing 5 mg Dronabinol
57757447|NCT03907163|OTHER|Placebo|capsules identical in appearance to dronabinol
57757448|NCT05674630|DEVICE|Magic Touch drug eluting balloon based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
57757449|NCT05674630|DEVICE|Drug-eluting stent-based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
57757450|NCT05797922|DRUG|DWP16001|DWP16001 0.3mg
57757451|NCT01641263|BEHAVIORAL|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
57757452|NCT01641263|BEHAVIORAL|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
58315422|NCT03873532|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
57757453|NCT03174314|BEHAVIORAL|Standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
57757454|NCT03174314|DEVICE|VIS4ION System|"When in Assistive Mode, participants will navigate campus while receiving navigation assistance (acquiring data and simultaneously providing assistance/audio feedback). When in Passive Mode, participants will navigate campus wearing the backpack without receiving navigation assistant."
57757455|NCT01683760|DRUG|Fluconazole|Prophylactic fluconazole administration in VLBW infants
57960895|NCT03943212|OTHER|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
57960896|NCT03943212|OTHER|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
57961679|NCT02288338|DRUG|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
58315423|NCT03873532|DRUG|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
58315424|NCT04221971|DRUG|chemotherapy combined with NK cells infusion|chemotherapy combined with NK cells infusion
57961680|NCT02288338|DRUG|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
58315425|NCT01701310|DRUG|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
58315426|NCT01701310|DRUG|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
58454396|NCT02484066|DEVICE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
57757456|NCT06492798|DRUG|umbilical cord mesenchymal stem cell|intravenous infusion of umbilical cord mesenchymal stem cell
57757457|NCT00048672|DRUG|Gleevec|Starting dose of 400 mg orally daily.
57757458|NCT00377286|DIETARY_SUPPLEMENT|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
57757459|NCT00377286|OTHER|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
57757460|NCT05977426|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
57757461|NCT04947163|DEVICE|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
57757462|NCT04947163|DEVICE|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
57757463|NCT05403099|OTHER|Hyaluronic acid|immediate placement of dental implant after topical application of hyaluronic acid on implant surface
57757464|NCT05403099|OTHER|conventional implant placement|immediate placement of dental implant without application of hyaluronic acid on implant surface
57757465|NCT04990869|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
57757466|NCT04990869|DIETARY_SUPPLEMENT|Placebo|Placebo
57757467|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
57757468|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
57960897|NCT01317589|DRUG|fentanyl|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
57961681|NCT02288338|DRUG|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57757469|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
57757470|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
57757471|NCT03646032|BEHAVIORAL|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
57757472|NCT03646032|BEHAVIORAL|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
57757473|NCT01003925|BEHAVIORAL|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
57757474|NCT01003925|BEHAVIORAL|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
57757475|NCT01638247|DRUG|Tamoxifen|25 mg daily.
57757476|NCT01638247|DRUG|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
57757477|NCT01638247|DRUG|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
57757478|NCT03859414|DRUG|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
57757479|NCT03859414|DRUG|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
57757480|NCT03859414|DRUG|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
57757481|NCT03859414|DRUG|Placebo|CHF 5993 placebo pMDI
57757482|NCT00408148|DRUG|Placebo|Undistinguishable placebo tablets
57757483|NCT00408148|DRUG|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
57757484|NCT00662857|DRUG|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
57757485|NCT00662857|DRUG|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
57757486|NCT00662857|DRUG|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
57757487|NCT02905383|OTHER|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
57757488|NCT01498432|DRUG|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
57757489|NCT01498432|DRUG|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
57757490|NCT02767063|DRUG|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
57757491|NCT02767063|DRUG|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
57757492|NCT06053034|DEVICE|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
57757493|NCT05659225|DEVICE|Electronic Stethoscope|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.
57757494|NCT05659225|OTHER|Standard treatment according to GINA(2019)|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
57757495|NCT01568099|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
57757496|NCT01568099|OTHER|Control|Untreated control
57757497|NCT04062448|DRUG|Ibrutinib|Ibrutinib 420 mg will be administered orally.
57757498|NCT04062448|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered intravenously.
57757499|NCT01656330|DRUG|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
57757500|NCT01656330|DRUG|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
57757501|NCT01656330|DRUG|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
57757502|NCT01656330|DRUG|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
57757503|NCT01656330|OTHER|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
57757504|NCT03203109|BEHAVIORAL|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
57757505|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
57757506|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
57757507|NCT02124343|OTHER|Interval Exercise|
57757508|NCT03675152|OTHER|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
57757509|NCT03675152|OTHER|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
57757510|NCT03675152|OTHER|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
57757511|NCT02317393|OTHER|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
57757512|NCT02317393|OTHER|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
57757513|NCT04317508|DRUG|Topicale GelPatch (Benzocaine 18%)|Intervention group
57757514|NCT04317508|DRUG|Benzocaine oral gel 20%|control group
57961682|NCT02288338|DRUG|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
58454397|NCT02579200|DEVICE|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.
57757515|NCT01612325|DEVICE|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
57757516|NCT04636658|OTHER|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
57757517|NCT04636658|OTHER|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
57757518|NCT05351996|DEVICE|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
57757519|NCT05351996|DEVICE|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
57757520|NCT05351996|OTHER|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
57961683|NCT02288338|DRUG|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
58454398|NCT02579200|DEVICE|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
58454399|NCT02947386|OTHER|Laboratory Biomarker Analysis|Correlative studies
58454400|NCT02947386|BIOLOGICAL|Nimotuzumab|Given IV
58454401|NCT02947386|BIOLOGICAL|Nivolumab|Given IV
58454402|NCT03008694|DEVICE|PET/CT|pet/ct is used as radiotherapy simulation
58454403|NCT00395746|DRUG|sulfonylurea|SU agent
58454404|NCT00395746|DRUG|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
58454405|NCT00395746|DRUG|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
58454406|NCT03689023|OTHER|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
58454407|NCT02845817|OTHER|Qualitative research|Semi-structured interviews
58315427|NCT05581563|PROCEDURE|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
58454408|NCT05223270|OTHER|wound dressing under the NIMV mask|wound dressing under the NIMV mask
58454409|NCT03563066|DRUG|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.
57757521|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
57757522|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
57961684|NCT02288338|DRUG|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
57961685|NCT02288338|DRUG|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
58315428|NCT04814446|BIOLOGICAL|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
58315429|NCT05636943|BEHAVIORAL|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
58315430|NCT05636943|BEHAVIORAL|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
58315431|NCT02349438|DEVICE|senofilcon A|A soft spherical contact lens
58315432|NCT02349438|DEVICE|lotrafilcon B|
58315433|NCT00002302|DRUG|Epoetin alfa|
58454410|NCT03563066|DRUG|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
58454411|NCT03003052|PROCEDURE|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
58454412|NCT04907981|DIAGNOSTIC_TEST|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
58454413|NCT04954508|DIAGNOSTIC_TEST|The hug-up test|It is a new physical test used to detect supraspinatus tear
58454414|NCT04954508|DIAGNOSTIC_TEST|EC test|It is a traditional physical test used to detect supraspinatus tear
58454415|NCT04954508|DIAGNOSTIC_TEST|FC test|It is a traditional physical test used to detect supraspinatus tear
58454416|NCT04954508|DIAGNOSTIC_TEST|Neer impingement sign|It is a traditional physical test used to detect supraspinatus tear
58454417|NCT04954508|DIAGNOSTIC_TEST|Hawkins-Kennedy impingement sign|It is a traditional physical test used to detect supraspinatus tear
58454418|NCT04954508|DIAGNOSTIC_TEST|diagnostic arthroscopy|The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (\>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
58454419|NCT04236102|DIAGNOSTIC_TEST|Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples|Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
58454420|NCT05347836|DIAGNOSTIC_TEST|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
58454421|NCT05624476|DIAGNOSTIC_TEST|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
58454422|NCT04811066|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period."
58454423|NCT00688259|BEHAVIORAL|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
58454424|NCT00688259|BEHAVIORAL|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
58454425|NCT00314743|DRUG|Ondansetron|
58454426|NCT00314743|DRUG|Dexamethasone|
58454427|NCT00314743|DRUG|Aprepitant|
58454428|NCT00472459|PROCEDURE|Photodynamic therapy with Metvix 160 mg/g cream|
58454429|NCT03326388|DRUG|Selumetinib|Selumetinib Intermittent Dosing
58454430|NCT00905463|PROCEDURE|Lung transplantation|Lung transplantation
58454431|NCT02604446|DRUG|Tapentadol|
58454432|NCT02604446|DRUG|Oxycodone|
58454433|NCT02604446|DRUG|Placebo|
58454434|NCT02604446|DRUG|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
58454435|NCT03710746|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
58454436|NCT03710746|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
58454437|NCT04369313|PROCEDURE|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
58454438|NCT04369313|PROCEDURE|early cord clamping|umbilical cord clamping within 15 seconds after birth
58454439|NCT00215358|DRUG|Formoterol Fumarate|
58315434|NCT02064244|OTHER|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
58315435|NCT01160614|DRUG|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
58315436|NCT06478290|COMBINATION_PRODUCT|curcumin, omega-3, and vitamin D (COD)|Combination of curcumin, omega-3, and vitamin D supplements (COD). Acumin™Turmeric Complex/Dr. D's Ultra BioTurmeric: 500 mg/day (oral, 2 tablets taken by mouth), Vitamin D: 2500 IU/day (oral, 1 tablet taken by mouth), Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
58315437|NCT04548245|DEVICE|EEG|EEG
58315438|NCT03837847|BEHAVIORAL|Health Coaching Calls|Participants in this group will receive 12 weekly health coaching calls
58315439|NCT03837847|BEHAVIORAL|Control|Participants in this group will receive 6 educational guides
58315440|NCT02880618|DEVICE|Barostim Neo™ System|
58315441|NCT05612321|DEVICE|Vacuum application|vacuum-assisted delivery
58315442|NCT06515782|OTHER|Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.|"In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD."
58315443|NCT00267540|BEHAVIORAL|cholecalciferol (D3) (vitamin)|
58315444|NCT00675350|DRUG|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
58315445|NCT01860989|DRUG|KAE609|KAE609 75mg single dose
58454440|NCT04748666|BEHAVIORAL|Problem Solving Training|Problem Solving Training (PST) is a metacognitive strategy training approach, grounded in self-management theory, that teaches a simple, systematic method for evaluating problems, generating and selecting solutions, developing specific goals and action plans, and evaluating and revising plans as needed.
58454441|NCT00264199|DRUG|GLP-1|iv. by weight (1.0 pmol/kg/min )
58454442|NCT00264199|DRUG|placebo|same rate of infusion as GLP-1
58454443|NCT04581265|DRUG|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
58454444|NCT00005608|DRUG|leucovorin calcium|
58454445|NCT00005608|DRUG|tegafur-uracil|
58454446|NCT05356416|OTHER|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
58454447|NCT05356416|OTHER|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
58454448|NCT02338635|DRUG|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
58454449|NCT00194805|BEHAVIORAL|Telehealth for Diabetes Self Management|
58454450|NCT00194805|OTHER|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
57961686|NCT02288338|DRUG|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
57757523|NCT04737564|BEHAVIORAL|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
57757524|NCT02708875|OTHER|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
57757525|NCT02708875|OTHER|Glucose Challenge|Glucose drink (50g glucose)
57757526|NCT01346319|DRUG|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
57757527|NCT01346319|DRUG|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
57757528|NCT01487278|DRUG|misprostol|600 mcg misoprostol oral
57757529|NCT01487278|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
57757530|NCT04073264|PROCEDURE|monofilament|In the intervention group,monofilament absorbable suture,will be used.
57757531|NCT04175795|BEHAVIORAL|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
57757532|NCT04539821|OTHER|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
57757533|NCT00111748|DRUG|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
57757534|NCT06526403|DEVICE|Zero-fluoroscopy ASD closure|Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
57757535|NCT00003835|DRUG|leucovorin calcium|Given IV
57757536|NCT00003835|DRUG|fluorouracil|Given IV
58454451|NCT02314663|DEVICE|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
58454452|NCT01982734|DIETARY_SUPPLEMENT|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
58454453|NCT02374164|DRUG|Febuxostat XR|Febuxostat XR capsules
58454454|NCT04019353|GENETIC|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
58454455|NCT00773162|DRUG|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
57757537|NCT00003835|DRUG|irinotecan hydrochloride|Given IV
58454456|NCT00773162|DRUG|Sugar Pill|Sugar pill to match seroquel
57757538|NCT00003835|OTHER|laboratory biomarker analysis|Correlative studies
57757539|NCT00834808|DRUG|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
57757540|NCT00265135|DRUG|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
57757541|NCT02877602|DEVICE|MRI|
57757542|NCT02877602|DEVICE|Transient Elastography|
57757543|NCT03002610|OTHER|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
57757544|NCT03002610|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
57757545|NCT03002610|OTHER|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
57757546|NCT01489189|OTHER|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
57757547|NCT01489189|DRUG|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
57757548|NCT01489189|OTHER|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
57757549|NCT04367558|PROCEDURE|Minimally invasive, in-office, RF reduction of the affected area|Usage of RF needle to treat one or more of the affected areas
57757550|NCT04987125|BEHAVIORAL|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
57757551|NCT04987125|BEHAVIORAL|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
57757552|NCT01089322|DRUG|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
57757553|NCT02235246|DRUG|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
57757554|NCT02235246|DRUG|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
57757555|NCT04191629|COMBINATION_PRODUCT|EO1404|
57757556|NCT04191629|PROCEDURE|Endothelial brushing or Descemet stripping|
57757557|NCT03627039|DRUG|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
57757558|NCT03627039|DRUG|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
57757559|NCT02200263|DIETARY_SUPPLEMENT|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
57757560|NCT02200263|DIETARY_SUPPLEMENT|Placebo|two softgels once-daily with a meal
58454457|NCT01095432|PROCEDURE|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
57757561|NCT01040702|DRUG|methylphenidate|a single doses of 10-20 mg in each one of two visits
57757562|NCT01040702|DIETARY_SUPPLEMENT|sweetener pill|a capsule containing a sweetener pill
57757563|NCT02331797|DEVICE|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
57757564|NCT02331797|DEVICE|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
57757565|NCT04551092|DEVICE|NEVR|a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
57757566|NCT03406819|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
58315446|NCT01860989|DRUG|KAE609|KAE609 150mg single dose
58315447|NCT01860989|DRUG|KAE609|KAE609 225mg single dose
58315448|NCT01860989|DRUG|KAE609|KAE609 300mg single dose
58454458|NCT04703088|DRUG|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
57757567|NCT03406819|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
57757568|NCT03406819|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
57757569|NCT00904514|GENETIC|gene expression analysis|
57757570|NCT00904514|GENETIC|microarray analysis|
57757571|NCT00904514|GENETIC|mutation analysis|
57757572|NCT00904514|GENETIC|polymerase chain reaction|
57757573|NCT00904514|OTHER|flow cytometry|
57757574|NCT00904514|OTHER|immunoenzyme technique|
58315449|NCT06209242|PROCEDURE|Percutaneous pinning|Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol
58315450|NCT06209242|PROCEDURE|Cast immobilization|Using sugar tong slab and then replace to short arm casting within 1 week
57757575|NCT00904514|OTHER|laboratory biomarker analysis|
57757576|NCT00886639|OTHER|6MWT with oxygen|2 liter per minute as continuous-flow
57757577|NCT00886639|OTHER|6MWT with medical air|2 liters as continuous-flow
57757578|NCT03147235|BEHAVIORAL|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
57757579|NCT02098187|DRUG|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
57757580|NCT02098187|DRUG|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
57757581|NCT02098187|DRUG|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
57757582|NCT02098187|DRUG|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
57757583|NCT02098187|DEVICE|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
57757584|NCT02098187|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
58315451|NCT00720278|DRUG|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
57757585|NCT05120115|OTHER|Weight belt|Wearing belt around waist with various weights attached.
57757586|NCT04049747|PROCEDURE|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]
57757587|NCT04049747|PROCEDURE|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
57757588|NCT04049747|PROCEDURE|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
57757589|NCT04049747|PROCEDURE|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
57757590|NCT00992953|BEHAVIORAL|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
57757591|NCT00992953|BEHAVIORAL|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
57757592|NCT03152955|DRUG|Ketamine|Ketamine will be applied in patient-controlled analgesia.
57757593|NCT03152955|OTHER|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
57757594|NCT03152955|DRUG|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
57757595|NCT03152955|DRUG|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
57757596|NCT06624319|DRUG|Dexmedetomidine as adjuvent to bupvacaine in tap block|The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block
57757597|NCT06457425|DRUG|Flonoltinib 50mg|Flonoltinib 50mg
57757598|NCT06457425|DRUG|Flonoltinib 100mg|Flonoltinib 100mg
58128626|NCT04550949|DRUG|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
58128627|NCT04550949|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
57757599|NCT06457425|DRUG|Ruxolitinib|For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
58128628|NCT04289545|DIETARY_SUPPLEMENT|Functional bread|Postprandial effects of bread containing galactomannan
57757600|NCT04969237|DIAGNOSTIC_TEST|Vitamine D in blood samples|vitamine D values
57757601|NCT01330810|DRUG|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
57757602|NCT05203120|RADIATION|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
57757603|NCT02207725|BIOLOGICAL|Andexanet|
57757604|NCT02207725|OTHER|Placebo|
57757605|NCT04531566|DIETARY_SUPPLEMENT|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
57757606|NCT04531566|DIETARY_SUPPLEMENT|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
57757607|NCT05477732|DIETARY_SUPPLEMENT|Bifidobacterium longum OLP-01|Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
57757608|NCT05477732|OTHER|Placebo|Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
57757609|NCT02766621|BIOLOGICAL|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
57757610|NCT02766621|DRUG|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
57757611|NCT03605433|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
57757612|NCT06340074|BEHAVIORAL|HELM|HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.
57961687|NCT02288338|DRUG|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961688|NCT02288338|DRUG|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961689|NCT02288338|DRUG|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961690|NCT02288338|DRUG|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
57961691|NCT02288338|DRUG|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961692|NCT02288338|DRUG|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961693|NCT02288338|DRUG|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
57961694|NCT02288338|DRUG|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
57961695|NCT01708460|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
57961696|NCT05172739|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
57757613|NCT06340074|BEHAVIORAL|Implementation Attention Control (IAC)|Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
57757614|NCT04903171|OTHER|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
57757615|NCT02755064|DRUG|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
57757616|NCT02755064|DRUG|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
57757617|NCT02755064|DRUG|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
57757618|NCT02755064|DRUG|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
57757619|NCT02755064|DRUG|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
57757620|NCT03594539|OTHER|Withholding standard phosphate binder|In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
57757621|NCT04185714|OTHER|Kinesiotaping|Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.
57757622|NCT04185714|OTHER|Placebo taping|sham taping
58128629|NCT03076021|DRUG|Isotretinoin|Drug interaction study
58315452|NCT00720278|DRUG|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
58315453|NCT00720278|DRUG|Placebo|0 mcg Placebo daily
58454459|NCT04703088|DRUG|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
58454460|NCT06465940|DEVICE|Total hip arthroplasty|Replacement of hip joint
58454461|NCT00443040|DRUG|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
58454462|NCT00443040|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
57757623|NCT02153801|PROCEDURE|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
58454463|NCT06271434|DIETARY_SUPPLEMENT|THYROX (Atlantic krill oil|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
58454464|NCT06271434|DIETARY_SUPPLEMENT|Placebo|The control capsules will be made of olive oil of equal size and color.
58454465|NCT03923790|BEHAVIORAL|Educational Packet|The patient will receive an educational packet.
58454466|NCT03923790|BEHAVIORAL|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
57757624|NCT00004408|DRUG|poloxamer 188|
57757625|NCT05086016|DEVICE|Catheterized Stenting|Catheterized stenting of vascular narrowings.
57757626|NCT03716921|OTHER|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
57757627|NCT05924178|BEHAVIORAL|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
57757628|NCT05924178|BEHAVIORAL|routine treatment|The control group receives conventional treatment preoperative.
58128630|NCT03076021|DRUG|dextromethorphan|Drug interaction study
58128631|NCT04238156|OTHER|Hypopressive abdominal exercises|Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
58128632|NCT00965653|DRUG|folic acid|\>/= 5 mg po weekly
58128633|NCT00965653|DRUG|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
58128634|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
58454467|NCT03923790|BEHAVIORAL|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
57757629|NCT03818789|BEHAVIORAL|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
57757630|NCT03818789|BEHAVIORAL|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
57757631|NCT02579564|DRUG|Gemcitabine|
57757632|NCT02579564|DRUG|Vinorelbine|
57757633|NCT02579564|DRUG|Paclitaxel|
57757634|NCT02579564|DRUG|Pemetrexed|
57757635|NCT02579564|DRUG|Oncorine|
57757636|NCT02579564|DRUG|Endostar|
57757637|NCT02579564|DRUG|Cisplatin|
57757638|NCT01553318|DRUG|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
57757639|NCT01553318|DRUG|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
57757640|NCT02019628|DIETARY_SUPPLEMENT|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
57757641|NCT01457781|COMBINATION_PRODUCT|Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
57757642|NCT01457781|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS Device|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula
57757643|NCT01457781|COMBINATION_PRODUCT|Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
57757644|NCT02561169|DRUG|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
57757645|NCT02561169|OTHER|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
57757646|NCT01321541|DRUG|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
57757647|NCT01321541|DRUG|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
57757648|NCT02699879|DRUG|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
57757649|NCT00627900|DEVICE|bare metal stent|implantation of a bare metal stent
57757650|NCT00627900|DEVICE|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
58454468|NCT03923790|BEHAVIORAL|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
57757651|NCT00942617|DRUG|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
57757652|NCT01719107|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
57757653|NCT01719107|DIETARY_SUPPLEMENT|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
57757654|NCT01137188|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
57757655|NCT02403882|BEHAVIORAL|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
58128635|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
58128636|NCT04132856|OTHER|Psychosocial Navigator|Services of psychosocial navigator
58128637|NCT04132856|OTHER|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
58128638|NCT02863575|DRUG|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
57757656|NCT02403882|BEHAVIORAL|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
57757657|NCT02403882|BEHAVIORAL|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
57757658|NCT02403882|BEHAVIORAL|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
57757659|NCT02403882|BEHAVIORAL|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
57757660|NCT04416893|DIAGNOSTIC_TEST|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
57757661|NCT04416893|DIAGNOSTIC_TEST|Sars-Cov2 serology|A microsample of blood will be taken for serology
57757662|NCT00186316|BIOLOGICAL|Idiotype-pulsed allogeneic dendritic cells|
57757663|NCT01980238|DEVICE|cannula ileostomy|
57757664|NCT01980238|DEVICE|loop ileostomy|
57757665|NCT01980238|DEVICE|LAR|
57757666|NCT03331484|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
57757667|NCT03331484|DRUG|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
57757668|NCT03520400|BEHAVIORAL|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
57757669|NCT02480595|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
57757670|NCT06208085|DIETARY_SUPPLEMENT|Avocado|Intervention arm
57757671|NCT02098213|OTHER|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
57757672|NCT02098213|OTHER|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
57757673|NCT03586583|DEVICE|FBP|Old processing
57757674|NCT03586583|DEVICE|ISR|New processing
57757675|NCT02857530|DRUG|rhTPO|rhTPO
57757676|NCT02857530|DRUG|placebo|without rhTPO
57757677|NCT03006484|OTHER|No intervention|No intervention will be needed.
57757678|NCT04457830|DRUG|F520|3mg/kg every 3 weeks
57757679|NCT02594748|BEHAVIORAL|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
57757680|NCT02594748|BEHAVIORAL|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
58128639|NCT02863575|DRUG|Ibuprofen|Ibuprofen capsule
57757681|NCT02568631|OTHER|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
58128640|NCT02863575|DRUG|Placebo|Placebo treatment
58454469|NCT03923790|DIAGNOSTIC_TEST|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
57757682|NCT02568631|OTHER|control video game|The patients will play 6 sessions of one hour with the control video game
57757683|NCT02716948|OTHER|Laboratory Biomarker Analysis|Correlative studies
58128641|NCT05561400|DEVICE|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
58128642|NCT05561400|OTHER|Placebo|sham tDCS to the right cerebellum
57757684|NCT02716948|BIOLOGICAL|Nivolumab|Given IV
57757685|NCT02716948|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
57757686|NCT06162832|COMBINATION_PRODUCT|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
57757687|NCT06162832|COMBINATION_PRODUCT|Allograft and Saline solution|This will be used as the control group
57757688|NCT04782557|DIAGNOSTIC_TEST|EUS-guided portal vein and hepatic vein aspiration|EUS-guided portal vein and hepatic vein aspiration
57757689|NCT05823246|DRUG|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
57757690|NCT04426864|OTHER|Supervised Aerobic Plus Stretching Exercises|An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
58128643|NCT05478226|OTHER|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
58128644|NCT02015000|PROCEDURE|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
58454470|NCT05255575|DRUG|Ertapenem|Patients will receive ertapenem therapy.
57757691|NCT04426864|OTHER|Supervised Resistance Plus Stretching Exercises Group|According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.
57757692|NCT04426864|OTHER|Home-based Stretching Exercises Group|Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
57757693|NCT03269240|BEHAVIORAL|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
57757694|NCT03269240|OTHER|Onsite training|Participants are training at their health facilities
57757695|NCT03269240|OTHER|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
57757696|NCT04607655|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
57757697|NCT04607655|DRUG|Placebo|Placebo is administered as inhalation once a day
57757698|NCT01771393|DEVICE|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
57757699|NCT01771393|DEVICE|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
57757700|NCT05379257|COMBINATION_PRODUCT|Random dosage and time of furosemide|Random dosage and time of furosemide, using a designated app
57757701|NCT00426725|DEVICE|EasyLabour|According to the trial protocol
57757702|NCT01009879|DRUG|Etanercept|Etanercept 50 mg SQ qweek
57757703|NCT02198495|DRUG|Supplementation of ferric carboxymaltose|
57757704|NCT02198495|DRUG|Supplementation of iron sucrose|
57757705|NCT06255392|DRUG|Fluzoparib|Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
58128645|NCT04590443|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
58128646|NCT01830569|BEHAVIORAL|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
58454471|NCT04914065|OTHER|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~1. Inspiratory muscles: diaphragm~2. Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~1. Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~2. Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
58454472|NCT00106847|DRUG|Infliximab|
58454473|NCT00184795|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
58454474|NCT00184795|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
58454475|NCT00184795|DRUG|placebo|Placebo tablets for 24 weeks
58454476|NCT04438694|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
57757706|NCT06255392|DRUG|Apatinib Mesylate|Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
57757707|NCT06255392|DRUG|Capecitabine tablets|Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
57757708|NCT06255392|DRUG|Vinorelbine Tartrate Oral|For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
57757709|NCT06255392|DRUG|Eribulin mesylate injection|Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
57757710|NCT06255392|DRUG|Gemcitabine Hydrochloride|Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
57757711|NCT06255392|DRUG|Paclitaxel-albumin|Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
57757712|NCT03348579|OTHER|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
57757713|NCT03348579|OTHER|Targeted experience feedback|"Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi"
57757714|NCT03435575|DEVICE|Boosth|Boosth activity tracker which measures steps
58128647|NCT01830569|OTHER|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
58128648|NCT01861366|OTHER|A one year multifaceted implementation strategy|
58454477|NCT04438694|DRUG|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
58454478|NCT00639470|OTHER|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
58454479|NCT00429949|DRUG|Dasatinib|
58454480|NCT03760991|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
58454481|NCT05937763|OTHER|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
58454482|NCT02264158|DRUG|Telmisartan high|
58454483|NCT02264158|DRUG|Telmisartan low|
58454484|NCT02264158|DRUG|Lacidipine high|
58454485|NCT02264158|DRUG|Lacidipine low|
58454486|NCT02264158|DRUG|Placebo|
58454487|NCT04737278|DRUG|Cunermuspir|"Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide"
58454488|NCT04737278|OTHER|Placebo|same non-medical ingredients and encapsulation as Intervention 1
58454489|NCT02356913|DRUG|Nicotine gum|
58454490|NCT02654548|OTHER|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
58454491|NCT02776111|OTHER|Blood Sample|A one time blood sample will be provided.
58454492|NCT04137913|BEHAVIORAL|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
58454493|NCT00043719|DRUG|Nitroglycerin ointment|
58128649|NCT01861366|OTHER|A three hour lecture about the guidelines|
58454494|NCT00043719|DRUG|Calcium supplement with vitamin D|
58454495|NCT05238766|BEHAVIORAL|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
58454496|NCT01693029|DRUG|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
58454497|NCT01693029|DRUG|US-licensed epoetin alfa|Solution for subcutaneous injection.
58454498|NCT02803736|DEVICE|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
58454499|NCT03897959|DEVICE|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
58454500|NCT02302365|DEVICE|Spectra Optia® Apheresis System|White Blood Cell Depletion
58454501|NCT02813889|DEVICE|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
58454502|NCT05288647|PROCEDURE|TMJ injection|four sodium hyaluronate injections in superior TMJ space
58454503|NCT01806220|PROCEDURE|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
58454504|NCT01806220|PROCEDURE|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
58454505|NCT00007592|DRUG|Chlorthalidone|
58454506|NCT00007592|DRUG|Furosemide|
58454507|NCT05927844|DRUG|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
58454508|NCT05927844|DRUG|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
58454509|NCT02210728|DRUG|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
58454510|NCT02210728|BEHAVIORAL|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
58454511|NCT05072392|DEVICE|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
58454512|NCT01638663|DRUG|Tolvaptan|15 mg pr day for 1 day
58454513|NCT01638663|DRUG|Placebo|1 tablet Unikalk 1 pr day for 1 day
58454514|NCT00356044|PROCEDURE|Coronary angioplasty|
58454515|NCT05077800|DRUG|FOLFIRNINOX|Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
58454516|NCT05077800|DRUG|Losartan|Taken Orally
58454517|NCT05077800|DRUG|9-ING-41|Administered by intravenous infusion
58454518|NCT02531217|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
58454519|NCT04513548|DRUG|Ligelizumab|One injection every four weeks
57757715|NCT04572178|BEHAVIORAL|Cash payment and brief behavioral counseling|"The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again."
57757716|NCT04890535|DRUG|TBAJ-587|oral suspension
57757717|NCT04890535|DRUG|Placebo|matching placebo oral suspension for TBAJ-587
57757718|NCT00664898|DRUG|bortezomib|Escalating intravenous repeating dose
57757719|NCT00664898|DRUG|SGN-40|Escalating intravenous repeating dose
57757720|NCT01392300|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
57757721|NCT01392300|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
57757722|NCT01662063|DRUG|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
57757723|NCT00051168|DRUG|Travatan|Travoprost (0.004%) 1 drop each eye once daily
57757724|NCT06368986|DRUG|VH4011499|VH4011499 administered in fasted or fed conditions.
57757725|NCT05809661|BEHAVIORAL|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
57757726|NCT03163914|DRUG|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
57757727|NCT03163914|DRUG|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
57757728|NCT03163914|DRUG|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
57757729|NCT03163914|DRUG|Saline|saline infusion will apply till the end of the surgery
57757730|NCT03655925|DIAGNOSTIC_TEST|plasmatic HLA-G|plasmatic HLA-G by blood sample
57757731|NCT00129922|DRUG|paclitaxel|
57757732|NCT00129922|DRUG|Fluorouracil|
57757733|NCT00129922|DRUG|Epirubicin|
58454520|NCT04513548|DRUG|Placebo|One injection every four weeks
58454521|NCT00006252|DRUG|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
57757734|NCT00129922|DRUG|Cyclophosphamide|
58454522|NCT00006252|DRUG|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
58454523|NCT00006252|BIOLOGICAL|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
57757735|NCT05739669|DEVICE|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
58454524|NCT00006252|DRUG|G-CSF|5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5
58454525|NCT00006252|BIOLOGICAL|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
58454526|NCT01246427|DRUG|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
57757736|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
57757737|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
57757738|NCT05950425|OTHER|Aspiration training|"Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge."
57757739|NCT00278070|DRUG|vinorelbine oral formulation|Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
58454527|NCT01246427|DRUG|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
58454528|NCT02952885|DRUG|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
57757740|NCT01033214|DEVICE|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
57757741|NCT04840277|DEVICE|Remote hearing aid adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
57757742|NCT05777967|BIOLOGICAL|human autologous synovial stem cells|A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
57757743|NCT00001599|DRUG|Thalidomide|
58454529|NCT00796666|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
58454530|NCT00796666|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
57757744|NCT02615236|DEVICE|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
57757745|NCT02615236|PROCEDURE|Clinical diagnosis|diagnosis of OASIS clinically
57757746|NCT03552302|BEHAVIORAL|Yoga|"1. Yoga stretch warm-up exercise for 15 minutes.~2. Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~3. Great rest for 15 minutes"
57757747|NCT01910623|OTHER|Health Related Quality of Life (HRQOL) measures|
57757748|NCT02609646|DRUG|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
57757749|NCT02609646|DRUG|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
57757750|NCT02609646|DRUG|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
57757751|NCT02609646|DRUG|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
57757752|NCT01744886|PROCEDURE|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
57757753|NCT04970199|DEVICE|laser application on acupoints|laser acupuncture
57757754|NCT06165406|PROCEDURE|Distal radial access|Distal radial access for coronary procedures
57757755|NCT05225688|BEHAVIORAL|Bike exertion test|maximal exercise test
58454531|NCT01919528|PROCEDURE|ultrasound|catheterization of the axillary vein under ultrasound guidance
58454532|NCT02525653|DRUG|albumin-bound paclitaxel|
58454533|NCT02525653|DRUG|gemcitabine|
58454534|NCT01441843|DRUG|Lorazepam|Once 1mg \<75kg body weight, 1.5mg 75kg and \>75kg body weight, IV, before surgery
58454535|NCT01441843|DRUG|NaCl 0.9% (Sodium Chloride)|Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
58454536|NCT06468956|DRUG|SHR-1819|SHR-1819 injection
58454537|NCT06468956|DRUG|Placebo|placebo
58454538|NCT02181465|BIOLOGICAL|G17DT|
58454539|NCT04862325|OTHER|Multimodal Prehabilitation|"1. High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~2. Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~3. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
58454540|NCT02517034|OTHER|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
58454541|NCT02517034|OTHER|Quality-of-Life Assessment|Ancillary studies
58454542|NCT02517034|OTHER|Questionnaire Administration|Ancillary studies
57757756|NCT00365586|DRUG|Ketoprofen Topical Patch , 20%|
57757757|NCT01937039|PROCEDURE|Sample collection|Blood, tissue, urine, and other samples may be collected
57757758|NCT02427659|BEHAVIORAL|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
57757759|NCT02427659|BEHAVIORAL|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
58454543|NCT02517034|OTHER|Survey Administration|Ancillary studies
58454544|NCT03898726|BIOLOGICAL|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
58454545|NCT00483613|BEHAVIORAL|Cognitive-behavioral therapy of Meichenbaum|
58454546|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
58454547|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
58454548|NCT01725490|DRUG|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
58454549|NCT04152226|DRUG|J. Lividum|Investigational Product
58454550|NCT01177007|DEVICE|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
58454551|NCT02828735|DEVICE|respiration assessment|Respiration Breathing Exercise
58128650|NCT04842058|OTHER|Mobilisation procedure|A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.
58454552|NCT01579435|DEVICE|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
58454553|NCT01176734|DEVICE|tVNS-Device|Active treatment with the t-VNS device.
58454554|NCT04899843|DIETARY_SUPPLEMENT|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
58454555|NCT04899843|DIETARY_SUPPLEMENT|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
58454556|NCT05055544|DRUG|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
57757760|NCT02427659|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
57757761|NCT02432469|BEHAVIORAL|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
57757762|NCT03202043|OTHER|High dose vegetable juice|High dose (13 fl oz) vegetable juice
57757763|NCT03202043|OTHER|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
57757764|NCT03202043|OTHER|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
57757765|NCT03202043|OTHER|Control bottled water|Control (12 fl oz) bottled water
57757766|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
57757767|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
57757768|NCT00058422|BIOLOGICAL|darbepoetin alfa|
57757769|NCT00058422|BIOLOGICAL|filgrastim|
58454557|NCT05055544|DRUG|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
58454558|NCT00013520|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
58454559|NCT00013520|DRUG|Atazanavir|
58454560|NCT00013520|DRUG|Lamivudine/Zidovudine|
58454561|NCT00013520|DRUG|Abacavir sulfate|
58454562|NCT00013520|DRUG|Efavirenz|
58454563|NCT00013520|DRUG|Nevirapine|
58454564|NCT00013520|DRUG|Lamivudine|
58454565|NCT00013520|DRUG|Stavudine|
58454566|NCT00013520|DRUG|Zidovudine|
58454567|NCT00013520|DRUG|Didanosine|
58454568|NCT01876355|DRUG|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
58454569|NCT01876355|DRUG|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
57757770|NCT00058422|BIOLOGICAL|rituximab|
57757771|NCT00058422|DRUG|cyclophosphamide|
58454570|NCT03115944|DEVICE|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
58454571|NCT02609958|DRUG|Varlitinib|"varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID"
58454572|NCT03980249|DRUG|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
58454573|NCT04933071|BEHAVIORAL|Podcast|A list of podcasts that are specified for each rotation
58454574|NCT03190395|PROCEDURE|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
58454575|NCT03190395|PROCEDURE|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
58454576|NCT05175092|PROCEDURE|Living Donor Liver Transplantation|The LDLT will be performed by the UW Division of Transplantation in accordance with the standard of care for this operation.
57757772|NCT00058422|DRUG|doxorubicin hydrochloride|
57757773|NCT00058422|DRUG|prednisone|
57757774|NCT00058422|DRUG|vincristine sulfate|
57757775|NCT00058422|RADIATION|indium In 111 ibritumomab tiuxetan|
57757776|NCT00058422|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
57757777|NCT02693821|DRUG|Gabapentin|gabapentin 300 mg per day, orally during 30 days
57757778|NCT02693821|DRUG|Placebo|Placebo 300 mg per day, orally during 30 days
57757779|NCT03366922|DIETARY_SUPPLEMENT|Artemisia Annua, Moringa oleifera|As described above
57757780|NCT04438863|DIAGNOSTIC_TEST|home spirometry|portable hand-held spirometer to collect and store daily spirometric data (including FVC, FEV1, forced expiratory flow after 25 to 75% of vital capacity has been expelled, and peak flow).
57757781|NCT02603822|DIETARY_SUPPLEMENT|12C mannitol|12C mannitol 100 mg
58128651|NCT00143156|DRUG|pregabalin|
57757782|NCT02603822|DRUG|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
57757783|NCT02603822|DIETARY_SUPPLEMENT|13C mannitol|13C mannitol 100 mg
57757784|NCT02603822|DIETARY_SUPPLEMENT|Lactulose|lactulose 1 g
57757785|NCT03167684|DEVICE|Oral appliance therapy|Fitted oral appliance
57757786|NCT04365517|DRUG|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
57757787|NCT05444062|BEHAVIORAL|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
57757788|NCT05817266|DEVICE|Field-cycling imaging (FCI)|FCI scan
57757789|NCT05597722|BEHAVIORAL|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
57757790|NCT05597722|DRUG|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
57757791|NCT02398968|DIETARY_SUPPLEMENT|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
57757792|NCT01423682|BEHAVIORAL|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
57757793|NCT04148014|BEHAVIORAL|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
57757794|NCT01786330|DEVICE|Procare abdominal binder|
57757795|NCT01786330|OTHER|Standard of Care|
57757796|NCT05199623|DRUG|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
57757797|NCT05199623|BEHAVIORAL|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
57757798|NCT04012515|DEVICE|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
57757799|NCT03527355|BIOLOGICAL|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
58128652|NCT05439824|BIOLOGICAL|SYS6006 20 μg|SARS-CoV-2 mRNA Vaccine
58128653|NCT05439824|BIOLOGICAL|SYS6006 30 μg|SARS-CoV-2 mRNA Vaccine
57757800|NCT03527355|BIOLOGICAL|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
57757801|NCT03527355|OTHER|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
57757802|NCT04137354|OTHER|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
57757803|NCT04137354|OTHER|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
57757804|NCT04137354|OTHER|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
57757805|NCT04137354|OTHER|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
58128654|NCT05439824|BIOLOGICAL|Placebo|Placebo
58128655|NCT00344552|DRUG|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
58128656|NCT00950807|DRUG|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
58128657|NCT00950807|DRUG|Placebo|Inactive/ excipients only
58128658|NCT00950807|DRUG|GSK573179|GSK573179 investigational drug
58128659|NCT05084781|PROCEDURE|Coblation Debridement (FLOW90)|bipolar radiofrequency energy
58454577|NCT04836585|OTHER|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~1. Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~2. PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~3. Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
58454578|NCT04803266|RADIATION|Internal mammary node irradiation|Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
58454579|NCT04803266|RADIATION|No internal mammary node irradiation|Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
58454580|NCT01460108|DEVICE|AeriSeal System|20 mL
58454581|NCT03687788|BEHAVIORAL|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
58454582|NCT04130321|DIETARY_SUPPLEMENT|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
58454583|NCT04130321|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo daily during 12 weeks
58454584|NCT03321084|OTHER|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
58454585|NCT03321084|OTHER|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
58454586|NCT04982939|DRUG|Sintilimab|Sintilimab, 200mg IV d1 Q3W
58454587|NCT04982939|DRUG|S-1|S-1, 40-60mg BID d1-14 Q3W
58454588|NCT04982939|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
58454589|NCT05553795|PROCEDURE|Early removal of chest drain|Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.
58454590|NCT05553795|PROCEDURE|Chest drain|The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
58454591|NCT02907424|DIETARY_SUPPLEMENT|2 months of treatment|standard 2 months of treatment
58454592|NCT01885221|BEHAVIORAL|Multimedia Support Intervention|
58454593|NCT03324490|PROCEDURE|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected."
58454594|NCT03324490|PROCEDURE|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure."
58454595|NCT03324490|DRUG|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
58454596|NCT03324490|DRUG|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
58454597|NCT03324490|DRUG|Fentanyl|Neuro-axially injected
58454598|NCT03324490|DRUG|Dexmedetomidine|Neuro-axially injected
58454599|NCT02907151|OTHER|Survey|Complete a survey prior to the consultation and a questionnaire after
58454600|NCT02762695|OTHER|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
58454601|NCT02762695|OTHER|Usual Care|Usual Care at Primary Health Care Center
58454602|NCT03706443|OTHER|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
58454603|NCT03706443|OTHER|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
58454604|NCT05714826|OTHER|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
58454605|NCT05714826|OTHER|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
58128660|NCT00756288|PROCEDURE|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
58128661|NCT00756288|PROCEDURE|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
57757806|NCT04770363|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
57757807|NCT01546961|DRUG|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
57757808|NCT03099330|DRUG|TQ-B3139|TQ-B3139 p.o. qd
57757809|NCT02582138|OTHER|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~* a daily total energy intake of 25-30 kcal/kg body weight;~* an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
57757810|NCT02582138|OTHER|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
57757811|NCT04570917|BEHAVIORAL|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
57757812|NCT04570917|BEHAVIORAL|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
57757813|NCT01570530|PROCEDURE|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
57757814|NCT01570530|PROCEDURE|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
58128662|NCT01111110|DEVICE|anti-static then static|Albuterol using static chambers
58128663|NCT01111110|DEVICE|Static then anti-static chamber|albuterol with Static then anti-static chambers
58128664|NCT03836209|DRUG|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
58128665|NCT03836209|DRUG|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
58128666|NCT03836209|DRUG|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
58128667|NCT03836209|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
58454606|NCT04879056|DIAGNOSTIC_TEST|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
58454607|NCT00997919|DRUG|MABT5102A|single SC dose
58454608|NCT00997919|DRUG|MABT5102A|single IV dose
58454609|NCT02038153|OTHER|Laboratory Biomarker Analysis|Correlative studies
58454610|NCT02038153|DRUG|Lenalidomide|Given PO
58454611|NCT03649217|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
58454612|NCT02343146|BEHAVIORAL|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
58454613|NCT00286585|DRUG|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
58454614|NCT00286585|DRUG|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
58454615|NCT01545726|DRUG|QAW039|QAW039 was supplied as capsules for oral administration.
58454616|NCT01545726|DRUG|Placebo|Placebo was supplied as capsules for oral administration.
58454617|NCT01260714|DRUG|Azacitidine|Given SC
57757815|NCT06176001|OTHER|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
57757816|NCT05794048|BIOLOGICAL|Hepatocellular carcinoma|Tumor and liver biopsy
57757817|NCT05794048|BIOLOGICAL|Pancreatic adenocarcinoma|Tumor and pancreatic biopsy
57757818|NCT05794048|BIOLOGICAL|Pancreatic neuroendocrine tumor|Tumor and pancreatic biopsy
57757819|NCT06378853|OTHER|no intervention|no intervention
57757820|NCT04080752|DRUG|JNJ-61393215|JNJ-61393215 will be administrated orally.
57757821|NCT04080752|DRUG|Placebo|Matching placebo will be administered orally.
57757822|NCT02144922|DRUG|Pitavastatin|statin
57757823|NCT02144922|OTHER|Control|Life style modification alone
57757824|NCT03261102|BIOLOGICAL|Adalimumab|
57757825|NCT03895411|DRUG|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
57757826|NCT03895411|DRUG|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
57757827|NCT03895411|DRUG|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
57757828|NCT05976204|PROCEDURE|ToF primary repair|ToF primary repair for patients with ToF
57757829|NCT04710927|DEVICE|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
57757830|NCT04710927|DEVICE|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
57757831|NCT04710927|DEVICE|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
57757832|NCT05644223|DRUG|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
57757833|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
57757834|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+CaCO3|
57757835|NCT05541302|DEVICE|TMS|Transcranial Magnetic Stimulation
57757836|NCT04115007|RADIATION|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
57757837|NCT04115007|DRUG|Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
57757838|NCT03576768|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
57757839|NCT03576768|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
57757840|NCT03576768|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
58128668|NCT01042366|BIOLOGICAL|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
57757841|NCT03576768|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
57757842|NCT00895882|DRUG|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
57757843|NCT00895882|DRUG|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
57757844|NCT00895882|DRUG|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
57757845|NCT00895882|DRUG|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
57757846|NCT00895882|DRUG|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
57757847|NCT04615130|OTHER|Rehabilitation|Rehabilitation, exercise training
57757848|NCT00489385|DRUG|Albinterferon|
57757849|NCT00489385|DRUG|Ribavirin|
58454618|NCT01260714|DRUG|Etoposide|Given IV
57757850|NCT00489385|DRUG|Albuferon|
57757851|NCT03408275|OTHER|None - observational|None - observational
57757852|NCT00378001|DRUG|FSH-IBSA|
57757853|NCT00378001|DRUG|GONAL-F|
57757854|NCT00521144|DRUG|obatoclax mesylate|Given IV
58128669|NCT00724568|DRUG|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
58454619|NCT01260714|OTHER|Laboratory Biomarker Analysis|Correlative studies
58454620|NCT01260714|DRUG|Mitoxantrone Hydrochloride|Given IV
58454621|NCT00117637|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
58454622|NCT00117637|DRUG|Interferon|Interferon
58454623|NCT01847963|DRUG|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
58454624|NCT01847963|DRUG|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
57757855|NCT00521144|DRUG|topotecan hydrochloride|Given IV
57757856|NCT00521144|OTHER|laboratory biomarker analysis|Correlative studies
57757857|NCT03464487|DIETARY_SUPPLEMENT|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
57757858|NCT03886259|OTHER|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
57757859|NCT03886259|OTHER|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
57757860|NCT01712100|DRUG|Irbesartan|
57757861|NCT01712100|DRUG|Avapro|
57757862|NCT02293772|OTHER|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
57757863|NCT02293772|OTHER|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
57757864|NCT02293772|OTHER|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
57757865|NCT05648825|DEVICE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
57757866|NCT00071721|DRUG|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
57757867|NCT00071721|DRUG|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
57757868|NCT01407211|DIETARY_SUPPLEMENT|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
57757869|NCT06170775|OTHER|Pulp therapy|Pulp capping material
57757870|NCT06170775|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
57757871|NCT06170775|OTHER|MTA|MTA
57757872|NCT03608280|PROCEDURE|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
57757873|NCT03608280|PROCEDURE|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
57757874|NCT00944047|DRUG|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
57757875|NCT00944047|DRUG|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
57757876|NCT00944047|DRUG|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
57757877|NCT00944047|DRUG|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
57757878|NCT00944047|BIOLOGICAL|Growth Factor Support|"* All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
57757879|NCT00944047|PROCEDURE|Surgery|"* After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
57757880|NCT03110341|DRUG|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
57757881|NCT03110341|DRUG|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
57757882|NCT00081302|BIOLOGICAL|cetuximab|
57757883|NCT00081302|DRUG|carboplatin|
57757884|NCT00081302|DRUG|paclitaxel|
57757885|NCT00081302|RADIATION|radiation therapy|
57757886|NCT00105235|DRUG|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
57757887|NCT00105235|DRUG|Cyclosporine|Oral immunosuppressant
57757888|NCT00105235|DRUG|Mycophenolate mofetil|Oral immunosuppressant
57757889|NCT00105235|DRUG|Tacrolimus|Oral immunosuppressant
57757890|NCT00105235|PROCEDURE|Liver transplant|Occurs at study entry
58454625|NCT05661812|DIAGNOSTIC_TEST|Quationnaires and symptom registration|Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
58454626|NCT05661812|DIAGNOSTIC_TEST|PNIF and spirometry|To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
57757891|NCT00105235|PROCEDURE|Immunosuppression withdrawal|Beginning no earlier than Year 1
57757892|NCT02656576|PROCEDURE|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
57757893|NCT02656576|PROCEDURE|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
57757894|NCT05850780|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain."
57757895|NCT05850780|DRUG|MTA|Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
57757896|NCT03117348|OTHER|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
57757897|NCT05378984|OTHER|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
57757898|NCT05378984|OTHER|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
57757899|NCT01770210|DRUG|Patients on atorvastatin treatment|Statins Therapy
57757900|NCT03753295|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
57757901|NCT05411432|DRUG|68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans
57757902|NCT01224158|DEVICE|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
57757903|NCT01224158|DEVICE|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
57757904|NCT02173054|OTHER|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
57757905|NCT02173054|OTHER|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
57757906|NCT02173054|OTHER|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
57757907|NCT06361901|DEVICE|Zenicog;language rehabilitation program|This program is an AI-based computerized cognitive and language training program.
57757908|NCT06361901|PROCEDURE|Conventional language rehabilitation|Conventional language rahabilitation therapy will apply for all participants with speech impairement
57757909|NCT02500329|DRUG|Gemigliptin|Gemigliptin for 4 weeks
57757910|NCT02500329|DRUG|Acarbose|Acarbose for 4 weeks
57757911|NCT00740961|BEHAVIORAL|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
57757912|NCT00740961|DRUG|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
57757913|NCT00740961|OTHER|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
58128670|NCT00724568|DRUG|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
57757914|NCT00740961|OTHER|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
57757915|NCT00740961|OTHER|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
57757916|NCT00740961|PROCEDURE|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
57757917|NCT00740961|PROCEDURE|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
57757918|NCT00800202|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
57757919|NCT00800202|DRUG|carboplatin|AUC6 iv every 3 weeks for 6 cycles
57757920|NCT00800202|DRUG|erlotinib [Tarceva]|150mg/day po
57757921|NCT00800202|DRUG|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
57757922|NCT06524999|BEHAVIORAL|Progressive muscle relaxation|This intervention consists of two parts. The first part gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are relaxation exercises accompanied. Both the briefing and the intervention lasted 30 minutes for each patient.
57757923|NCT04460144|DIAGNOSTIC_TEST|Mass spectrometry|Proteomic analysis
58454627|NCT05661812|DIAGNOSTIC_TEST|SPT, spesific IgE, pBAT and NPT|To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
58454628|NCT04034706|OTHER|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
58454629|NCT04034706|OTHER|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
58454630|NCT04034706|OTHER|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
58454631|NCT04034706|PROCEDURE|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
58454632|NCT04034706|OTHER|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
58454633|NCT04734886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 + vitamin D|1 \* 10\^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
58454634|NCT04734886|DIETARY_SUPPLEMENT|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
57757924|NCT01055925|DEVICE|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
58454635|NCT03074565|DEVICE|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
58454636|NCT03074565|DEVICE|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
57757925|NCT01055925|DEVICE|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
57757926|NCT04543006|DIAGNOSTIC_TEST|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
57757927|NCT02310022|DRUG|Drug Omega 3|4 g (4 capsules) once a day, administered with food
58128671|NCT00724568|DRUG|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
58128672|NCT00724568|DRUG|Doxil|Patients will be treated with Doxil on day 4.
58454637|NCT01418430|DRUG|CHOP-daclizumab|
58128673|NCT01451853|DRUG|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
58454638|NCT00318084|DRUG|Esomeprazole|
58454639|NCT00318084|PROCEDURE|Ambulatory 24-hour esophageal pH-monitoring|
57757928|NCT02310022|DRUG|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
57757929|NCT02273284|DEVICE|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
57757930|NCT06325748|BIOLOGICAL|SENTI-202|"SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in 3 weekly doses (Days 0, 7, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles."
57757931|NCT00704301|DRUG|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
58128674|NCT01451853|DRUG|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
58454640|NCT01962441|DRUG|SOF|400 mg tablet administered orally once daily
58454641|NCT01962441|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58454642|NCT01962441|DRUG|Peg-IFN|180 µg administered via subcutaneous injection once weekly
57757932|NCT00704301|DRUG|Placebo|Placebo, 2 times a day
58454643|NCT05734599|DEVICE|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
58454644|NCT05719649|DIETARY_SUPPLEMENT|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
58454645|NCT05719649|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
58454646|NCT00120016|BEHAVIORAL|dietary counseling|telephone counseling
58454647|NCT01046981|PROCEDURE|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
58454648|NCT01046981|PROCEDURE|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
57757933|NCT05367063|DRUG|Canagliflozin 100mg or Sitagliptin 100mg|70 eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
57757934|NCT04932499|OTHER|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
57757935|NCT04932499|OTHER|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
57757936|NCT01875354|DIETARY_SUPPLEMENT|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
57757937|NCT01875354|DIETARY_SUPPLEMENT|Placebo and Low Fat Eating Plan|
57757938|NCT00264979|PROCEDURE|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
57757939|NCT00264979|PROCEDURE|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
57757940|NCT04810221|OTHER|Controlled desaturation study|Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
57757941|NCT00809692|PROCEDURE|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
57757942|NCT00809692|PROCEDURE|new technique for histamine response|laser Dopper technique and genotyping
57757943|NCT05706090|DRUG|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
57757944|NCT05706090|PROCEDURE|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
57757945|NCT04532723|DEVICE|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
57757946|NCT01936701|PROCEDURE|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
57757947|NCT02489110|BEHAVIORAL|Webnovela|
57757948|NCT02489110|BEHAVIORAL|Information|
57757949|NCT01249469|OTHER|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
57960898|NCT01317589|DRUG|methadone|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
58454649|NCT04960969|OTHER|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
58454650|NCT01698385|OTHER|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
58454651|NCT04273334|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
58454652|NCT04044469|BEHAVIORAL|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
58454653|NCT04044469|BEHAVIORAL|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
57757950|NCT01905644|PROCEDURE|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
57960899|NCT02447315|DRUG|Pilocarpine|oral
58454654|NCT04044469|BEHAVIORAL|Control group|This group receives no further information after watching the videotaped doctor's report.
57757951|NCT05930197|DRUG|Bismuth subsalicylate|BSS is a commonly used, widely available, OTC medication for a variety of gastrointestinal GI symptoms. It is available in the generic form, but also under the more commonly known brands: Bismatrol; Diotame; Geri-Pectate; Kao-Tin; Peptic Relief; Pepto-Bismol; Pink Bismuth and Stomach Relief. It received approval by the US Food and Drug Administration (FDA) in 1939.
57757952|NCT05490121|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
57757953|NCT05842655|PROCEDURE|The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth|A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
57757954|NCT05535543|PROCEDURE|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
57757955|NCT06624514|BEHAVIORAL|Training Group|Implicit approach bias is the behavioral action tendency to be faster to approach rather than avoid cues for a stimulus category. The Approach-Avoidance Task (AAT)is a computerized program in which participants make approach or avoidance movements in response to an irrelevant feature of an image presented on a computer screen (e.g., push when in portrait, pull when in landscape). The intervention in this study is a treatment version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).
58454655|NCT02104453|PROCEDURE|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
57757956|NCT06624514|BEHAVIORAL|Sham Training Group|A sham-training control condition
57757957|NCT00682643|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray
57757958|NCT00682643|DRUG|vehicle placebo nasal spray|placebo
58454656|NCT05448040|PROCEDURE|Socket preservation|Tooth extraction and preservation with a biomaterial
58454657|NCT00667888|RADIATION|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
58454658|NCT00667888|RADIATION|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
58454659|NCT05715164|DEVICE|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
58454660|NCT05715164|DRUG|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
58454661|NCT05715164|OTHER|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
58454662|NCT06361563|DRUG|Nivolumab|As per product label
58454663|NCT03494270|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
58454664|NCT03494270|DRUG|Monorova|Rosuvastatin 20mg
58454665|NCT01274481|DRUG|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
57757959|NCT00466102|DRUG|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
57757960|NCT00466102|DRUG|Placebo|2 tablets are taken once daily during study therapy
57757961|NCT00004884|DRUG|cisplatin|
57757962|NCT00004884|DRUG|docetaxel|
57757963|NCT00004884|DRUG|gemcitabine hydrochloride|
57757964|NCT00859651|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
57757965|NCT00859651|DRUG|Placebo capsule|Matching placebo capsules
57757966|NCT04899245|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
57757967|NCT00524199|DRUG|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
57757968|NCT00524199|OTHER|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
57757969|NCT00605514|DRUG|VRC-EBODNA023-00-VP|
57757970|NCT00605514|DRUG|VRC-MARDNA025-00-VP|
58454666|NCT05035758|OTHER|Transcendental Meditation|"In the beginning, the patients from group B will receive an introductory lecture about transcendental meditation (TM) which includes general information, the procedure itself and other techniques of relaxation and personal development.~In this first session the method is learned by practice, in the following 3 meetings additional instructions are given about the correct practice of the TM technique; TM is practiced twice a day for 20 minutes. The method is easy to learn and effortless. To guarantee the right performance of TM by the patients, there will be two group meetings per week and one individual personal meeting with the TM teacher.After discharge from the rehabilitation program (after 4 weeks) there will be meetings offered according to the patients need. This will then be arranged individually."
58454667|NCT05035758|OTHER|Yoga|"In addition to the standard rehabilitation exercise training, the patients in this group will receive a 20-minute workshop where they learn how to do the yoga exercise. The initial yoga workshop will be held by Dr. Gilda Wüst who is a yoga expert with a lot of experience based in St. Radegund.~After this, yoga sessions will be included (additionally to the regular/standard exercise) into their daily timetable. Two yoga sessions will be done every day, one in the morning (6:30-6:50) and one in the evening (16:30-16:50) and will last for about 20 minutes."
58454668|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
58454669|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
58454670|NCT05580822|DRUG|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
58454671|NCT05580822|DRUG|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
58454672|NCT01288755|DRUG|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
58454673|NCT01288755|DRUG|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
58454674|NCT05345353|BEHAVIORAL|Fat For Fight (FFF), The Aarhus Protocol|A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
58454675|NCT05345353|BEHAVIORAL|The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol|A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
58454676|NCT01212562|PROCEDURE|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
58454677|NCT00001118|DRUG|Enfuvirtide|
58454678|NCT02374749|BEHAVIORAL|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
58454679|NCT02374749|BEHAVIORAL|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
58454680|NCT05272371|COMBINATION_PRODUCT|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
58454681|NCT02719171|DRUG|risankizumab|Risankizumab administered by SC injection
58454682|NCT02719171|DRUG|placebo for risankizumab|Placebo for risankizumab administered by SC injection
58454683|NCT05751746|DRUG|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
58454684|NCT05448495|OTHER|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
58454685|NCT05448495|OTHER|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane
57757971|NCT06432933|OTHER|No preventive oxygen therapy (2L)|Participants will not receive preventive oxygen 2L during the first postoperative night after bariatric surgery.
58454686|NCT03866655|DEVICE|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
58454687|NCT02736058|DEVICE|Trans- abdominal sonography|
58454688|NCT02736058|DEVICE|Trans-vaginal sonography|
58454689|NCT02736058|PROCEDURE|post-operative pathological specimen examination|
57757972|NCT06432933|OTHER|Preventive oxygen therapy (2L) standard care|Participants will receive preventive oxygen 2L during the first postoperative night after bariatric surgery, standard care.
57757973|NCT02789683|OTHER|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
58454690|NCT05940194|BIOLOGICAL|COVIVAC vaccine|For prevention Covid-19
57757974|NCT02789683|OTHER|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
57757975|NCT02789683|OTHER|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
57960900|NCT02447315|DRUG|Placebo|oral
57960901|NCT00699517|DRUG|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
57960902|NCT00699517|DRUG|Placebo|I.V. infusion followed by administration of cisplatin
57757976|NCT05668169|OTHER|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
57757977|NCT02316769|PROCEDURE|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
57757978|NCT02316769|PROCEDURE|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
57757979|NCT03988634|DRUG|sacubitril/valsartan|Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
57757980|NCT03988634|DRUG|valsartan|Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
58128675|NCT01451853|DRUG|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
58128676|NCT01451853|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
58454691|NCT00276263|DRUG|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
58454692|NCT00114816|DRUG|capecitabine|
58454693|NCT00114816|DRUG|docetaxel|
58454694|NCT03827135|OTHER|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
58454695|NCT03827135|OTHER|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
58454696|NCT01949935|DRUG|Mupirocin|
58454697|NCT02461381|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
58454698|NCT04562181|OTHER|Bispectral index and qCON/qNOX monitoring|This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
57757981|NCT03988634|DRUG|sacubitril/valsartan matching placebo|Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
57757982|NCT03988634|DRUG|valsartan matching placebo|Valsartan matching placebo was available as tablet form to be taken orally, twice daily
57757983|NCT05401643|OTHER|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
57757984|NCT04887792|DRUG|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
57757985|NCT04887792|DRUG|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
58128677|NCT00526968|DRUG|EVT 101|8 mg capsule, single oral dose
58128678|NCT00526968|DRUG|EVT 101|15 mg capsule, single oral dose
58128679|NCT00526968|DRUG|placebo|Placebo capsule, single oral dose
58454699|NCT04325971|OTHER|Neuroimaging|MR, EEG recordings
58454700|NCT04585282|BEHAVIORAL|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
58128680|NCT03703713|DRUG|Sodium chloride|Treatment with Sodium chloride
58454701|NCT04585282|BEHAVIORAL|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
58454702|NCT00744926|DRUG|placebo|sc, once weekly
58454703|NCT00744926|DRUG|taspoglutide|10mg sc, once weekly
58454704|NCT00744926|DRUG|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
58128681|NCT04360031|DRUG|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
58128682|NCT06486246|PROCEDURE|Adductor canal block|Injection of the local anesthetic prior to the surgery, either in the the adductor canal or in the genicular nerves by the anesthesiologist under ultrasound guidance.
58128683|NCT00067236|DRUG|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
58128684|NCT00067236|DRUG|Placebo tablet|placebo tablet, twice a day for 90 days
57757986|NCT02260401|OTHER|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
57757987|NCT00473070|DRUG|Tobradex AF|
57757988|NCT00449241|DEVICE|Acupuncture|
57757989|NCT00202774|DRUG|(capecitabine, oxaliplatin, 5-fluorouracil)|
57757990|NCT03540355|DRUG|Cipros 20 association|oral, once a day
57757991|NCT03540355|DRUG|Crestor 20 mg|Oral, once a day
57757992|NCT04085302|DEVICE|Digital Behaviour Change Intervention|14 days
57757993|NCT06391684|BEHAVIORAL|Social/non social; predictable vs unpredictable|Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
57757994|NCT03771430|BEHAVIORAL|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results"
57757995|NCT03771430|PROCEDURE|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
57757996|NCT06624527|OTHER|Psychoeducation based on Cognitive Behavioral Therapy|A psycho-educational application based on Cognitive Behavior Therapy consisting of a total of 8 sessions prepared by the researcher.
57757997|NCT05647525|DIAGNOSTIC_TEST|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
57757998|NCT00853502|DRUG|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
58454705|NCT01843036|OTHER|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
58454706|NCT01244841|PROCEDURE|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
58454707|NCT00523757|DRUG|Spironolactone|
58454708|NCT00523757|DRUG|Placebo|
58454709|NCT01983228|BEHAVIORAL|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
58454710|NCT00292942|DRUG|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
58454711|NCT00292942|DRUG|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
58454712|NCT00002009|DRUG|Sargramostim|
57757999|NCT03291886|DRUG|Entinostat|Given PO
57758000|NCT03291886|DRUG|Entinostat(Placebo)|Given PO
57758001|NCT03291886|DRUG|Exemestane|Given PO
58454713|NCT02669342|DEVICE|Radiance™ Clear Sharklet® Silicone Foley Catheter|
58454714|NCT02669342|DEVICE|Silicone Foley Catheter|
58454715|NCT01574586|DEVICE|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
58454716|NCT04499495|OTHER|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
57758002|NCT02424084|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
57758003|NCT04953364|BEHAVIORAL|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
57758004|NCT04953364|BEHAVIORAL|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
57758005|NCT01898702|BEHAVIORAL|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
57758006|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE)|"Spinal stabilization exercises (SSE) including bridging, planks and tummy tuck-in will be performed. Each participant received a total 7 session thrice a week sessions in two weeks, . Each session had lasted for 30-40 minutes. Spinal stabilization exercises were repeated 5-15 times depending on the endurance of patients.~Home exercise plan will also be given e.g. postural care, precautions in lifting and carrying weights etc."
58454717|NCT02334930|OTHER|Biopsy|
58454718|NCT03188146|DRUG|Ursodeoxycholic Acid|Standard care of PBC patients
58454719|NCT01203735|DRUG|Valproic acid|800mg per day for entire period of RT
58454720|NCT06172686|DRUG|Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).|The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
57758007|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|In experimental group in addition SSE group interventions, participants will receive the latissimus dorsi stretching (LDS). Each participant received a total 7 session thrice a week sessions in two weeks. Each session had lasted for 30-40 minutes. each stretch of latissimus dorsi was of 20-30 seconds with 10-20 repetitions in each session.
57758008|NCT04676425|DRUG|MK-8189|Administered at a dose of 4 mg via oral tablet
57758009|NCT04968691|OTHER|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
57758010|NCT04968691|OTHER|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
57758011|NCT02835339|DRUG|Magnesium sulfate 4g loading dose, 1g/hr infusion|
57758012|NCT02835339|DRUG|Magnesium sulfate 6g loading dose, 2g/hr infusion|
57758013|NCT06343311|BIOLOGICAL|EB103|EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
57758014|NCT03716817|DEVICE|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
57758015|NCT02661100|DRUG|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
57758016|NCT02661100|BIOLOGICAL|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
57758017|NCT02661100|BIOLOGICAL|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
57758018|NCT05178121|BEHAVIORAL|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
57758019|NCT01208298|DEVICE|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
57758020|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
57758021|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
57758022|NCT06154343|DRUG|GQ1005|an antibody drug conjugate
57758023|NCT06037590|COMBINATION_PRODUCT|Levodopa Cyclops™|Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
57758024|NCT06037590|COMBINATION_PRODUCT|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
57758025|NCT01109823|DRUG|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
57758026|NCT01987817|BIOLOGICAL|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
57758027|NCT01987817|BIOLOGICAL|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
57758028|NCT00817999|DIETARY_SUPPLEMENT|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
57758029|NCT00817999|DRUG|Clopidogrel 75 mg/day|
57758030|NCT00817999|DRUG|Clopidogrel 300 mg|
57758031|NCT06286124|PROCEDURE|Hybrid Surgery|Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
57960903|NCT05785312|DEVICE|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
57960904|NCT05785312|OTHER|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
57960905|NCT02364128|BEHAVIORAL|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
57960906|NCT06133283|BEHAVIORAL|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
57960907|NCT06133283|BEHAVIORAL|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
57960908|NCT06133283|BEHAVIORAL|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
57960909|NCT01535573|DRUG|Citalopram|20 mg once per day for 9 weeks
57960910|NCT01535573|DRUG|Citalopram|40 mg per day for 9 weeks
57960911|NCT01535573|DRUG|Placebo|0 mg per day for 9 weeks
57960912|NCT01002807|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
57960913|NCT01002807|DRUG|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
57960914|NCT01002807|DRUG|Glucophage|Tablets, Oral, 1000 mg, Single Dose
57960915|NCT03961282|OTHER|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
57960916|NCT03961282|OTHER|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
57758032|NCT00779974|OTHER|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
57758033|NCT00403897|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
57758034|NCT05392023|OTHER|Relaxation Exercises and Scapular Stabilization exercise program|Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
57758035|NCT05392023|OTHER|Relaxation Exercises of cervico- scapular region|Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
57758036|NCT04411602|DRUG|SARS-CoV-2 plasma|To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
57758037|NCT01105923|OTHER|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
57758038|NCT02228954|PROCEDURE|Molecular imaging|
57758039|NCT01114204|DRUG|Ferumoxytol|IV Ferumoxytol
57758040|NCT01114204|DRUG|Iron Sucrose|IV Iron Sucrose
57758041|NCT05416255|DIAGNOSTIC_TEST|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
57758042|NCT00962351|PROCEDURE|Total Hip Replacement|
57758043|NCT02569437|DRUG|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
57758044|NCT02569437|DRUG|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
57758045|NCT02569437|DRUG|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
58454721|NCT06172686|DRUG|Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
57758046|NCT02569437|DRUG|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
57758047|NCT02569437|DRUG|sugar pill|placebo pill to match doxycycline
57758048|NCT04406480|GENETIC|CGH-array and exome sequencing|A blood sample will be used for CGH-array and exome sequencing
57758049|NCT01933451|OTHER|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
57758050|NCT03270514|DRUG|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
58454722|NCT02383381|PROCEDURE|lateral rectus recession|typical surgery for correcting intermittent exotropia
57758051|NCT03270514|DRUG|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
57758052|NCT04729894|OTHER|Medication Lockbox|Participants will receive a medication lockbox to store medications in their home.
57758053|NCT04729894|BEHAVIORAL|Education|Participants will receive information on safe medication storage practices.
57758054|NCT04773158|BEHAVIORAL|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
58128685|NCT04668339|BIOLOGICAL|ARCT-021 single dose priming|ARCT-021 higher dose (one dose) + placebo (one dose)
57758055|NCT00740558|PROCEDURE|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
58128686|NCT04668339|BIOLOGICAL|ARCT-021 two lower dose priming|ARCT-021 lower dose (two doses, Day 0 and Day 28)
58128687|NCT04668339|BIOLOGICAL|ARCT-021 two higher dose priming|ARCT-021 higher dose (two doses, Day 0 and Day 28)
57758056|NCT00740558|PROCEDURE|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
57758057|NCT04660422|OTHER|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
57758058|NCT04660422|OTHER|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
57758059|NCT04660422|OTHER|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
58128688|NCT04668339|BIOLOGICAL|Placebo (two doses), priming|Placebo (two doses, Day 0 and Day 28)
58128689|NCT04668339|BIOLOGICAL|Randomized booster|ARCT-021 (single dose) OR placebo, booster
58128690|NCT04668339|BIOLOGICAL|Placebo booster|Placebo (single dose)
57758060|NCT04660422|OTHER|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
57758061|NCT01074606|DEVICE|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
57758062|NCT04978974|BEHAVIORAL|Stress Management Program|Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
58454723|NCT02832934|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
58454724|NCT02832934|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
58454725|NCT00269308|PROCEDURE|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
57758063|NCT06342180|DIAGNOSTIC_TEST|Serum uric acid level|An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
57758064|NCT01279343|DEVICE|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
57758065|NCT05943769|PROCEDURE|Apical microsurgery|inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.
57758066|NCT04999644|DRUG|Full Nicotine Cigarettes|A full nicotine tobacco cigarette that will be smoked by participants
57758067|NCT04999644|DRUG|Reduced Nicotine Cigarettes|A reduced nicotine tobacco cigarette that will be smoked by participants
57758068|NCT04999644|BEHAVIORAL|Average Nicotine Expectancy|"Participant instructed the cigarette is the same level of nicotine as your usual brand."
57758069|NCT04999644|BEHAVIORAL|Very Low Nicotine Expectancy|"Participant instructed the cigarette is a very low level of nicotine compared to your usual brand."
57758070|NCT04106232|OTHER|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
57758071|NCT06056609|OTHER|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
57758072|NCT03642938|BEHAVIORAL|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
57758073|NCT03642938|BEHAVIORAL|Control|The Control group will perform 30 minutes of quiet rest.
57758074|NCT00485225|DRUG|EN3270|Transdermal Therapeutic System
57758075|NCT04539314|DRUG|Bupivacain|We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
57758076|NCT04539314|DRUG|Dexmedetomidine o.5 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
57758077|NCT04539314|DRUG|Dexmedetomidine 1 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
57758078|NCT02231866|BIOLOGICAL|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
57758079|NCT02231866|BIOLOGICAL|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
57758080|NCT04098406|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
57758081|NCT04098406|DRUG|Placebo|Placebo was liquid with identical color and taste
57758082|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
57758083|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
57758084|NCT03337932|DRUG|Controls without a history of lyme disease.|No intervention.
57758085|NCT03587142|DRUG|Buspirone|Buspirone tablet
57758086|NCT03587142|DRUG|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
57758087|NCT01892345|DRUG|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
57758088|NCT01892345|DRUG|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
57758089|NCT02953743|DRUG|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
58128691|NCT04858100|PROCEDURE|Surgical excision of the lesion|"The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case."
58128692|NCT04858100|OTHER|Wait and see approach|"The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression."
58128693|NCT04189848|DRUG|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
58128694|NCT04189848|DRUG|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
58128695|NCT04276870|BIOLOGICAL|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
58128696|NCT02519413|DRUG|dimethyl fumarate|delayed release capsules
58128697|NCT00098488|DRUG|tanespimycin|Given IV
58454726|NCT00269308|PROCEDURE|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
58454727|NCT00269308|BEHAVIORAL|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
58454728|NCT02394314|DRUG|MEDI0382|MEDI0382 administered subcutaneously
58454729|NCT02394314|DRUG|Placebo|Placebo administered subcutaneously
58454730|NCT05355103|OTHER|Educational tool about epidural analgesia|See arm description
58454731|NCT02036047|DEVICE|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
58454732|NCT02036047|DEVICE|Regular polypectomy snare (Snare Master, SD-210U-10)|
57758090|NCT00108238|DRUG|Estradiol followed by progesterone|
57758091|NCT00108238|DRUG|Raloxifene|
57758092|NCT04392063|DRUG|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
58128698|NCT00098488|BIOLOGICAL|rituximab|Given IV
58128699|NCT03659409|BEHAVIORAL|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
57758093|NCT03306901|PROCEDURE|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
57758094|NCT03306901|DRUG|5-fluorouracil|3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
57758095|NCT03306901|DRUG|Cisplatin|45\~60mg intravenously over 1 hour on day 1
57758096|NCT03306901|RADIATION|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
57758097|NCT03884114|OTHER|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
58128700|NCT03659409|BEHAVIORAL|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
58128701|NCT02240407|GENETIC|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10\^13 vg per TA muscle (range of 7.64 x 10\^11 vg/gm to 4.6 x 10\^11 vg/gm based on TA weight).
58454733|NCT03264859|DIAGNOSTIC_TEST|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
58454734|NCT04864639|OTHER|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
58454735|NCT04539600|DRUG|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
58454736|NCT03901131|DRUG|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
58454737|NCT01655758|DRUG|0.5% timolol|
58454738|NCT01655758|DRUG|timolol-dorzolamide fixed combination|
58454739|NCT01655758|DRUG|Latanoprost|
58454740|NCT01655758|DRUG|Travoprost|
58454741|NCT01655758|DRUG|Bimatoprost|
57758098|NCT03884114|OTHER|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
57758099|NCT03884114|OTHER|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
58128702|NCT02240407|DRUG|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
58128703|NCT02240407|OTHER|saline|Same volume as rAAV9-DES-hGAA injection will be used.
58128704|NCT02240407|DRUG|Rituxan|Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
57758100|NCT03753451|PROCEDURE|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
57758101|NCT05516225|DRUG|PBCLN-003|Human Milk Oligosaccharide Concentrate
57758102|NCT02800967|DIETARY_SUPPLEMENT|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
57758103|NCT02800967|DIETARY_SUPPLEMENT|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
57758104|NCT02800967|DIETARY_SUPPLEMENT|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
57758105|NCT06441747|DRUG|Durvalumab|Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
57758106|NCT06441747|DRUG|Olaparib|Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
57758107|NCT04192084|PROCEDURE|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
57758108|NCT00659490|DRUG|AZD1940|800ug oral administration
57758109|NCT00659490|DRUG|Naproxen|500mg oral administration
57758110|NCT00659490|DRUG|Placebo|Placebo given pre-surgery
57758111|NCT06246448|PROCEDURE|Robotic-assisted radical cholecystectomy|Procedure will be performed robotic-assisted
57758112|NCT06246448|PROCEDURE|Open radical cholecystectomy|Procedure will be open
57758113|NCT04194567|OTHER|Black Ragi|Pancakes made out of the dark ragi
57758114|NCT04194567|OTHER|White Ragi|Pancakes made out of the white ragi
57758115|NCT06057207|DIAGNOSTIC_TEST|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
57758116|NCT06057207|DIAGNOSTIC_TEST|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
57758117|NCT06057207|OTHER|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.
57758118|NCT06057207|OTHER|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic dehiscence, wound/local infection, postoperative bleeding, reoperation and systemic complications: sepsis, pneumonia, uroinfection, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure. Length of ICU and overall hospital stay with final outcome after discharge from hospital will be documented.
57758119|NCT03367507|BEHAVIORAL|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
57758120|NCT03909178|PROCEDURE|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
58128705|NCT02240407|DRUG|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
58128706|NCT02240407|DRUG|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
58128707|NCT02240407|DRUG|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
58454742|NCT06264726|OTHER|HealtheRx|CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support.
58454743|NCT02884388|PROCEDURE|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
58454744|NCT02884388|PROCEDURE|general anesthesia|Patients in this group were assigned to receive general anesthesia.
58454745|NCT01780116|BEHAVIORAL|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
58454746|NCT04972786|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
58454747|NCT05546151|DRUG|BMS-986322|Specified dose on specified days
58454748|NCT05546151|OTHER|Placebo for BMS-986322|Specified dose on specified days
58454749|NCT01001975|DRUG|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
58454750|NCT01001975|DRUG|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
58454751|NCT01001975|DRUG|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
58454752|NCT04816474|BEHAVIORAL|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
58454753|NCT04247230|DRUG|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
58454754|NCT04247230|OTHER|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
58454755|NCT04247230|DRUG|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
58128708|NCT02240407|DRUG|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
58454756|NCT03098641|PROCEDURE|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
58454757|NCT02426333|OTHER|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
58454758|NCT03584750|OTHER|Floating|Floating in specialized tank with full floatation and sensory deprivation.
58454759|NCT03584750|OTHER|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
58454760|NCT04930523|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
58454761|NCT04930523|OTHER|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
58454762|NCT03671941|DRUG|D578|D578 Tab.1T single oral administration under fasting condition
58454763|NCT03671941|DRUG|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
57758121|NCT03909178|PROCEDURE|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
57758122|NCT04294992|DRUG|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
57758123|NCT01718093|DRUG|Sitagliptin|up to 50 mg twice a day
57758124|NCT01718093|DRUG|Metformin|up to 1000 mg twice a day
57758125|NCT01718093|DRUG|Sitagliptin + Metformin|up to 50/1000 mg twice a day
57758126|NCT05731089|PROCEDURE|Phacoemulsification with IVI of aflibercept|IVI was either before or after cataract surgery
57758127|NCT06038955|BEHAVIORAL|Virtual reality Based Cognitive Remediation|The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
57758128|NCT06038955|BEHAVIORAL|Virtual reality control training|The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
57758129|NCT00746096|DRUG|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
57758130|NCT00746096|DRUG|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
57758131|NCT04654039|OTHER|Other: Non intervention|Non intervention
58454764|NCT06217107|BEHAVIORAL|Micro-learning content|This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
57758132|NCT00131339|BEHAVIORAL|Cognitive behavioral therapy|
57758133|NCT00131339|DRUG|D-cycloserine|
57758134|NCT00847405|DRUG|Sumatriptan Succinate|100 mg Tablets
57758135|NCT00847405|DRUG|Imitrex®|100 mg Tablet
57758136|NCT04484025|DRUG|Ebselen|Glutathione peroxidase mimetic
57758137|NCT04484025|DRUG|Placebo|Matching placebo containing excipients
57758138|NCT02986607|DRUG|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
57758139|NCT01715974|DRUG|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
57758140|NCT01715974|DRUG|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
57758141|NCT01875939|DRUG|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
57758142|NCT01875939|DRUG|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
57758143|NCT05631184|BEHAVIORAL|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
57758144|NCT05631184|BEHAVIORAL|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
57758145|NCT06580015|PROCEDURE|Computed Tomography|Undergo PET-CT
57758146|NCT06580015|OTHER|Flotufolastat F-18 Gallium|Given IV
57758147|NCT06580015|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
57758148|NCT06580015|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
57758149|NCT03135665|DEVICE|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
57758150|NCT05593757|DRUG|Quinidine|Oral quinidine
57758151|NCT05593757|DRUG|Verapamil|Oral verapamil
57758152|NCT03295903|DIETARY_SUPPLEMENT|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
57758153|NCT03112941|PROCEDURE|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
57758154|NCT03112941|OTHER|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
57758155|NCT03852238|OTHER|Blood test and self-administrated questionnaires|
57758156|NCT02329184|DRUG|MYK-461|
57758157|NCT05292534|DEVICE|hearing aid amplification|Hearing aid will be fit to prescribed participant hearing loss.
57758158|NCT05292534|DEVICE|hearing aid amplification with an added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
57758159|NCT02106585|DRUG|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
58454765|NCT06217107|BEHAVIORAL|Health360x app|The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
58454766|NCT06217107|BEHAVIORAL|Culturally congruent coaching|The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
57960917|NCT00556660|DRUG|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
57960918|NCT00017862|DRUG|SCH55700|
57960919|NCT01762280|DRUG|Famitinib Malate Capsule|
58454767|NCT01332123|DEVICE|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
58454768|NCT00549692|DRUG|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
58454769|NCT03546621|DRUG|Myrcludex B|2 mg, once daily, subcutaneously
58454770|NCT03546621|DRUG|Myrcludex-B|5 mg, once daily, subcutaneously
58454771|NCT03546621|DRUG|Myrcludex-B|10 mg, once daily, subcutaneously
58454772|NCT03546621|DRUG|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
58454773|NCT04360746|OTHER|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
57758160|NCT03156322|DRUG|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
57758161|NCT03156322|DRUG|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
57758162|NCT03156322|DRUG|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
57960920|NCT02357498|PROCEDURE|transsphenoidal surgery|
57960921|NCT06107075|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
57960922|NCT06107075|DIETARY_SUPPLEMENT|Placebo|around 40g pea protein powder not containing phospholipids
57960923|NCT05838638|BEHAVIORAL|eSSET-CINV|Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
58128709|NCT05701683|DRUG|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
58128710|NCT04558554|OTHER|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
57758163|NCT04413591|BEHAVIORAL|Community based combination HIV prevention package|The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
57758164|NCT05556174|OTHER|periodic lung recruitment maneuvers|lung recruitment maneuvers repeated every 30 minutes
57758165|NCT01446484|BIOLOGICAL|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
57758166|NCT01446484|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
58128711|NCT03734185|OTHER|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
57758167|NCT01446484|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
57758168|NCT01446484|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
57758169|NCT01446484|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
57758170|NCT01446484|DRUG|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
57758171|NCT01446484|DRUG|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
57758172|NCT01446484|PROCEDURE|Kidney transplantation|Living related kidney transplantation
57758173|NCT06484270|OTHER|Simulation based safety mobilization program|"Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured."
57758174|NCT01533701|OTHER|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
58128712|NCT01567930|DRUG|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
58454774|NCT04360746|OTHER|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
58454775|NCT04228263|DRUG|Hydroxychloroquine|400mg
58454776|NCT04228263|DRUG|Folic Acid|5 mg
58454777|NCT04228263|DRUG|Low-dose aspirin|75 mg
58454778|NCT04903782|DIAGNOSTIC_TEST|Family-based whole genome sequencing|"1. Germline whole-genome family-based sequencing and variant identification.~2. Multidisciplinary Meeting case discussion.~3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling.~4. Psychosocial study to analyse the impact of germline sequencing on families."
58454779|NCT00024336|DRUG|tamoxifen citrate|
58454780|NCT00024336|RADIATION|radiation therapy|
58454781|NCT05103826|DRUG|SHR6390、Famitinib|SHR6390, oral;Famitinib, oral.
57758175|NCT04392778|BIOLOGICAL|MSC Treatment|"Protocol length: 1 week~Doses:~1. Application: 3 million cells/kg IV-------------------------------------------------0 day~2. Application: 3 million cells/kg IV ------------------------------------------------3rd day~3. Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
57758176|NCT04392778|BIOLOGICAL|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
57758177|NCT03108157|PROCEDURE|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
58454782|NCT03007966|PROCEDURE|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
58454783|NCT03007966|PROCEDURE|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
57758178|NCT00181571|DRUG|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
57758179|NCT00181571|DRUG|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
58128713|NCT01517256|BEHAVIORAL|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
58128714|NCT01517256|OTHER|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
57758180|NCT01450748|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
57758181|NCT01450748|DRUG|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
57758182|NCT04426396|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, CT-FFR computed by coronary CT angiography
57758183|NCT00258999|DEVICE|Skin Cholesterol Testing|
58128715|NCT00717457|DRUG|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
58128716|NCT00717457|DRUG|taspoglutide|10mg once weekly
58128717|NCT00717457|DRUG|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
58454784|NCT03007966|DRUG|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
58454785|NCT03007966|DRUG|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
58454786|NCT03007966|DRUG|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
58454787|NCT03145740|OTHER|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
58454788|NCT03145740|OTHER|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
58454789|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
58454790|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
57758184|NCT02955030|BIOLOGICAL|NSV0001|sublingual
57758185|NCT02955030|BIOLOGICAL|"Influenza HA vaccine Biken HA"|subcutaneous
57758186|NCT02955030|BIOLOGICAL|Placebo|sublingual
57758187|NCT01848379|PROCEDURE|ADT+FD|
57758188|NCT01848379|PROCEDURE|FD|
57758189|NCT04462315|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
57758190|NCT04462315|DEVICE|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
57758191|NCT06001502|DEVICE|Virtual Reality distraction therapy|The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
57758192|NCT03319784|DRUG|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
57758193|NCT03319784|DRUG|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
57758194|NCT00118781|DRUG|iseganan hydrochloride|
57758195|NCT02301351|OTHER|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
57758196|NCT02301351|OTHER|Text Warning Label|All packs provided will include standard text warning labels
57758197|NCT00061763|DRUG|Deferasirox|
57758198|NCT01750879|DRUG|Peanut Flour|Peanut Flour
57758199|NCT01750879|DRUG|Oat Flour|Oat Flour
58454791|NCT00286442|DRUG|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
57758200|NCT06229834|PROCEDURE|Chiropractic Care|The chiropractic care protocol can be personalized to the patient's clinical needs and follows the scope of chiropractic care practice in the Commonwealth of Massachusetts and the State of Connecticut. Components of the chiropractic intervention include: posture correction / spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation (i.e. chiropractic adjustment) / mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports.
57758201|NCT06229834|BEHAVIORAL|Headache Health Education|Material to be covered will focus on pre-defined migraine specific topics including materials we have previously used in a popular Osher Clinical Center patient education program called the Migraine Toolkit. Sessions will be delivered by trained research assistants and will utilize publicly available short videos followed by scripted discussions with the participant. Participants will be allowed to continue usual care throughout the study.
57758202|NCT04149990|DRUG|Valsartan+ sacubitril|Treatment with Entresto(valsartan+sacubitril)
57758203|NCT04149990|DRUG|Placebo Oral Tablet|Matching placebo treatment
57758204|NCT05217095|DEVICE|Convergence Dialyzer|The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
57758205|NCT05634239|BEHAVIORAL|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
57758206|NCT02044627|DRUG|[14C-ETC-1002]|
57758207|NCT05873543|OTHER|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|"The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms."
57758208|NCT00946335|DRUG|veliparib|Given PO
57758209|NCT00946335|DRUG|temozolomide|Given PO
57758210|NCT00946335|OTHER|pharmacological study|Correlative studies
58454792|NCT04148534|DRUG|Rocroniom, Non Depolarizing Muscle Relaxant|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
58454793|NCT02072863|DRUG|Oprozomib|Study subjects will receive oprozomib administered orally.
57758211|NCT00946335|OTHER|laboratory biomarker analysis|Correlative studies
57758212|NCT00286117|DRUG|Anastrozole|oral
57758213|NCT00286117|DRUG|Tamoxifen|oral
57758214|NCT05809713|OTHER|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
57758215|NCT05809713|OTHER|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
58128718|NCT00476606|DRUG|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
58128719|NCT00476606|DRUG|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
58128720|NCT00476606|DRUG|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
58454794|NCT02072863|DRUG|Melphalan|Study subjects will receive melphalan 9 mg/m2.
58454795|NCT02072863|DRUG|Prednisone|Study subjects will receive prednisone 60 mg/m2.
58454796|NCT04872361|PROCEDURE|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
58454797|NCT04872361|PROCEDURE|High PEEP|PEEP of 10 cm H2O will be applied
57758216|NCT03091686|BEHAVIORAL|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
57758217|NCT03091686|BEHAVIORAL|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
57758218|NCT00446069|DRUG|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
57758219|NCT01908465|DRUG|Ebastine|
57758220|NCT01908465|DRUG|Placebo|
57758221|NCT00666432|OTHER|This is an observational study model that is family based|This is an observational study model that is family based
57758222|NCT03224221|DRUG|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
58128721|NCT00763022|DRUG|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
58454798|NCT04872361|PROCEDURE|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
58454799|NCT04872361|DEVICE|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
58454800|NCT04984239|BEHAVIORAL|Acceptance and Commitment Therapy for aphasia|The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
58454801|NCT02255916|OTHER|Music|live sound-bed music intervention
58454802|NCT01138423|DRUG|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
58454803|NCT01138423|DRUG|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
58454804|NCT01138423|DRUG|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
58454805|NCT01138423|DRUG|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
58454806|NCT01138423|DRUG|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
58454807|NCT02572544|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
58454808|NCT00139074|DRUG|Quetiapine fumarate|oral variable dose
58454809|NCT00139074|DRUG|sodium valproate|oral
58454810|NCT01753622|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
58454811|NCT03530826|OTHER|No intervention|No Intervention
57758223|NCT03224221|DRUG|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
57758224|NCT05514080|OTHER|Insulin closed-loop|41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
57758225|NCT01106053|DRUG|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
58128722|NCT00763022|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
58128723|NCT00763022|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
58128724|NCT03552757|DRUG|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
58128725|NCT03552757|DRUG|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
58454812|NCT02433886|PROCEDURE|Gamma Ventral Capsulotomy|
58454813|NCT03705052|OTHER|Questionnaire|Patients and caregivers were asked to complete a questionnaire
58454814|NCT02729220|OTHER|Bronchoscopy|Sampling of airways
57758226|NCT03899168|OTHER|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
57758227|NCT03899168|OTHER|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
57758228|NCT03899168|OTHER|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
57758229|NCT02946840|DEVICE|FNA with 25 G Beacon needle|
57758230|NCT05322525|DRUG|ON101 Cream|"Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day"
57758231|NCT00724464|BIOLOGICAL|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
57758232|NCT00724464|DRUG|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
57758233|NCT04751422|OTHER|Electronic Health Record Review|Medical data is collected
58454815|NCT05488639|OTHER|Registration of football exposure and occurrence of injuries and illnesses only|"Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
58454816|NCT03038321|DRUG|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
58454817|NCT03038321|DRUG|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
58454818|NCT03038321|DRUG|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
58454819|NCT01484210|DRUG|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
58454820|NCT01724866|DRUG|SPI-2012|SPI-2012 SC injection.
58454821|NCT01724866|DRUG|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
58454822|NCT01724866|DRUG|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
58454823|NCT01724866|DRUG|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
58454824|NCT05869435|DEVICE|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
58454825|NCT04852861|DIAGNOSTIC_TEST|immunogenicity after first and second dose|Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
58454826|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
57758234|NCT03299686|DRUG|CJM112|300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
57758235|NCT03299686|OTHER|Placebo to CJM112|Placebo to match CJM112 + standard of care treatment
57758236|NCT06468033|BIOLOGICAL|Ropeginterferon alfa-2b|"Pre-filled Syringe.~Dosage: up to 500mcg"
58454827|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
58454828|NCT02727829|DEVICE|pefusion index measurement|perfusion index measurement using massimo radical 7 device
58454829|NCT00367939|DRUG|valsartan + amlodipine|
58454830|NCT02972203|BEHAVIORAL|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
58454831|NCT02972203|BEHAVIORAL|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
57758237|NCT06468033|OTHER|Placebo|Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
57758238|NCT06510725|DEVICE|Mutitarget tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
57758239|NCT06510725|DEVICE|Single-target tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
57758240|NCT06510725|DEVICE|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
57758241|NCT01780935|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
57758242|NCT01572064|PROCEDURE|Blood sample|1 fasted blood sample taken for metabolomics
57758243|NCT01572064|OTHER|MRI Scan|1 single visit for MRI and MRS
57758244|NCT00595504|DRUG|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
57758245|NCT00595504|DRUG|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
57758246|NCT03243162|BEHAVIORAL|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
57758247|NCT03243162|OTHER|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
57758248|NCT00170833|DRUG|Everolimus|
57758249|NCT02076984|PROCEDURE|Laparoscopic incisional or ventral hernia repair|
57758250|NCT01691521|DRUG|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
57758251|NCT01691521|DRUG|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
57758252|NCT01691521|DRUG|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
57758253|NCT01691521|DRUG|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
57758254|NCT00626366|RADIATION|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
57758255|NCT00626366|DRUG|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
57758256|NCT00626366|DRUG|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
57758257|NCT00582946|DEVICE|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
57758258|NCT01988272|DEVICE|SPECT/CT imaging|Patients will undergo scanning on the above system.
57758259|NCT04151784|OTHER|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
58128726|NCT03552757|DRUG|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
58454832|NCT00803283|DRUG|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
58454833|NCT00803283|DRUG|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
58454834|NCT00216671|DRUG|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
57758260|NCT04151784|OTHER|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
57758261|NCT04465279|DEVICE|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
57758262|NCT04368650|DRUG|BMP-2|lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.
57758263|NCT04368650|PROCEDURE|PRF|For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
58128727|NCT03552757|DRUG|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
57758264|NCT04246983|DIAGNOSTIC_TEST|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
58128728|NCT03500484|DRUG|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
58454835|NCT00216671|DRUG|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
58454836|NCT05237648|OTHER|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
58454837|NCT05237648|OTHER|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
58454838|NCT04072913|OTHER|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
58454839|NCT01536717|DRUG|Articaine hydrochloride 2% solution|"* 4 ml/h periosteal wound infusion~* duration of 72 h"
58454840|NCT01536717|DRUG|Sodium Chloride|Placebo Sodium chloride 0,9%
58454841|NCT04472949|DRUG|Durvalumab|Durvalumab: 1500 mg iv
58454842|NCT04472949|DRUG|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
58454843|NCT04472949|DRUG|etoposide|Etoposide: 100 mg/m2 iv
58454844|NCT04472949|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
58454845|NCT04314908|PROCEDURE|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
58454846|NCT04314908|PROCEDURE|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
58454847|NCT04314908|PROCEDURE|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
57758265|NCT00194051|PROCEDURE|gastric bypass surgery|
57758266|NCT01729884|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
58454848|NCT04314908|PROCEDURE|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
58454849|NCT02223780|OTHER|early palliative care|the patients will benefit from an early palliative care consultation
58454850|NCT05195567|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
57758267|NCT06066281|BEHAVIORAL|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
57758268|NCT05718843|DRUG|BI 425809|BI 425809
57769757|NCT01411722|DEVICE|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
58128729|NCT02317237|PROCEDURE|Local anesthesia|Conscious sedation
58128730|NCT01282151|DRUG|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
58128731|NCT01282151|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
58454851|NCT05195567|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
57758269|NCT04444635|PROCEDURE|Serratus Anterior Plan Block+ Fentanyl infusion|"After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion"
57758270|NCT04444635|DRUG|Fentanyl|Continuous fentanyl infusion throughout the surgical procedure.
57758271|NCT05448170|DRUG|Linerixibat|open label investigational product
57758272|NCT06225856|DRUG|YY201|Oral administration under fasting state.
57758273|NCT00591201|DRUG|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
57758274|NCT00591201|DRUG|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
57758275|NCT01934803|DIETARY_SUPPLEMENT|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
57758276|NCT01934803|DIETARY_SUPPLEMENT|Placebo|
57758277|NCT01536041|DRUG|ONO-6950|200 mg QD, single dose
57758278|NCT01536041|DRUG|ONO-6950|20 mg QD, single dose
57758279|NCT01536041|DRUG|Montelukast|10 mg Montelukast, QD single dose
57758280|NCT01536041|DRUG|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
57758281|NCT01847170|BIOLOGICAL|Fecal Microbial Transplantation|
58128732|NCT05765565|DEVICE|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
57758282|NCT02565719|DRUG|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
57758283|NCT02565719|DRUG|Pegasys|immunotherapy
57758284|NCT02565719|DRUG|Viread|HBV RT polymerase inhibitor
57758285|NCT02565719|DRUG|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
57758286|NCT02174887|DRUG|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
57758287|NCT01564368|PROCEDURE|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
57758288|NCT05924399|BEHAVIORAL|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
57758289|NCT02985762|DRUG|EXPAREL|
58128733|NCT05765565|DEVICE|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
58128734|NCT04057053|DRUG|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
58128735|NCT03913000|DRUG|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
58128736|NCT06115005|BIOLOGICAL|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
58128737|NCT04449484|DRUG|MEDI1341|Intravenous infusion over 60 minutes
57758290|NCT00525525|DRUG|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
57758291|NCT00525525|DRUG|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
57758292|NCT00525525|DRUG|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
57758293|NCT02609321|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
58128738|NCT04449484|OTHER|Placebo|Intravenous infusion over 60 minutes
58128739|NCT01634906|DRUG|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
57758294|NCT02609321|PROCEDURE|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
57758295|NCT03719794|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
57758296|NCT03719794|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement once daily for 12 weeks
57758297|NCT05968014|PROCEDURE|PENG vs FICB|pericapsular nerve group block versus fascia iliaca compartment block
57758298|NCT01036308|DIETARY_SUPPLEMENT|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
57758299|NCT01036308|DIETARY_SUPPLEMENT|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
58128740|NCT05588856|OTHER|In depth Interview|In depth Interviews
58128741|NCT05328713|DIAGNOSTIC_TEST|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
57758300|NCT03975764|DIAGNOSTIC_TEST|Collection of fecal sample|Analysis of fecal microbiome
57758301|NCT01379976|DRUG|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
57758302|NCT01379976|DRUG|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
57758303|NCT03298282|OTHER|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
57758304|NCT03298282|OTHER|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
57758305|NCT03298282|OTHER|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
57758306|NCT03778034|OTHER|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
58454852|NCT03480152|BIOLOGICAL|National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine|Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
58454853|NCT03531671|DEVICE|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
58454854|NCT02372526|OTHER|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
58454855|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
58454856|NCT02372526|OTHER|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
58454857|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
58454858|NCT03735836|OTHER|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
58454859|NCT01573546|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression \> 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
58454860|NCT01573546|BEHAVIORAL|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
58454861|NCT01573546|OTHER|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
57758307|NCT03778034|OTHER|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
58128742|NCT00442910|DRUG|3% SPL7013 Gel (VivaGel)|3% vaginal gel
58128743|NCT00442910|DRUG|Placebo Gel|Placebo for SPL7013 gel
57758308|NCT04000620|PROCEDURE|surgery|treatment intent surgery
57758309|NCT04000620|PROCEDURE|punture|diagnostic punture
57758310|NCT04433962|OTHER|Exercise training|
58128744|NCT00442910|DRUG|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
58128745|NCT05883410|OTHER|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
58128746|NCT05883410|OTHER|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
57758311|NCT02201056|DRUG|TAK-935|TAK-935 oral solution
57758312|NCT02201056|DRUG|Placebo|TAK-935 placebo-matching oral solution
57758313|NCT02484170|DRUG|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
57758314|NCT02484170|DRUG|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
57758315|NCT01191840|DRUG|Vancomycin|Duration
57758316|NCT01191840|DRUG|Vancomycin|Duration
57758317|NCT01210521|DRUG|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
57758318|NCT00758459|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
57758319|NCT00758459|DRUG|Placebo|Dosing to match AZD1236
57758320|NCT01226511|DRUG|Duloxetine|Administered orally
57758321|NCT01226511|DRUG|Placebo|Administered orally
57758322|NCT02380222|OTHER|Interview|Single interview lasting approximately one hour
57758323|NCT02434289|DIETARY_SUPPLEMENT|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
57758324|NCT02434289|OTHER|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
57758325|NCT02346396|DEVICE|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
57758326|NCT01091402|PROCEDURE|autologous serum skin test, serum IL-18|
58454862|NCT05646134|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
58454863|NCT05646134|DEVICE|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
57758327|NCT06487598|DRUG|inj insulin to one group|One group- only inj insulin for 3 months.
57758328|NCT06487598|DRUG|Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day|second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
57758329|NCT02268695|DRUG|Cisplatin|
57758330|NCT02268695|DRUG|5-Fluorouracile|
57758331|NCT02268695|DRUG|Docetaxel|
57758332|NCT02268695|DRUG|Cetuximab|
57758333|NCT02268695|DRUG|granulocyte colony-stimulating factor (G-CSF)|
58454864|NCT03546946|BEHAVIORAL|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
58454865|NCT03546946|BEHAVIORAL|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
58454866|NCT02121379|BEHAVIORAL|pulmonary rehabilitation|
58454867|NCT00867230|DRUG|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
58454868|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
58454869|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
57758334|NCT01986881|DRUG|Ertugliflozin|Oral, once daily, for up to approximately 6 years
57758335|NCT01986881|DRUG|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
57758336|NCT01986881|DRUG|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
57758337|NCT06520943|OTHER|blood gas analysis|"1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)"
57758338|NCT03354364|DIETARY_SUPPLEMENT|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
57758339|NCT03354364|DIETARY_SUPPLEMENT|Control|Snacks without added fiber.
57758340|NCT04896333|OTHER|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
57758341|NCT03559088|OTHER|Migraine App|Smart phone app used to report migraine burden to the EHR.
57758342|NCT02416492|BIOLOGICAL|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
57758343|NCT02416492|PROCEDURE|Sham Control|Sham Surgery
57758344|NCT06451822|DEVICE|mIntense L+AS|The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
57758345|NCT05343416|PROCEDURE|Open abdomen procedure|All patients underwent to open abdomen procedure
57758346|NCT04074200|PROCEDURE|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
57769758|NCT05929508|OTHER|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
58454870|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
58454871|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
58128747|NCT05883410|OTHER|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
58128748|NCT03694990|OTHER|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
58454872|NCT05281666|DEVICE|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
58454873|NCT05281666|DEVICE|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
58454874|NCT05686785|DIAGNOSTIC_TEST|Transient elastography|Transient elastography measures liver stiffness in kPa
58454875|NCT06079385|OTHER|Acupuncture treatment|Acupuncture treatment with needles
58454876|NCT00202514|DRUG|divalproex sodium extended release|
58454877|NCT01406301|DRUG|fondaparinux|fondaparinux
58454878|NCT02949609|OTHER|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
58454879|NCT02949609|OTHER|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
58454880|NCT05046223|PROCEDURE|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
58454881|NCT05046223|PROCEDURE|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
58454882|NCT00942565|DRUG|tramadol/acetaminophen|
57758347|NCT04074200|PROCEDURE|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
58454883|NCT00942565|DRUG|acetaminophen|
58454884|NCT02775188|DEVICE|interACTION|
57758348|NCT04074200|DEVICE|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
57758349|NCT00743561|DEVICE|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
57758350|NCT00743561|DEVICE|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
57758351|NCT05756231|BEHAVIORAL|SIHT-16|a pencil-paper assessment tool.
57758352|NCT03338621|DRUG|Pretomanid|200 mg tablets
57758353|NCT03338621|DRUG|Bedaquiline|100 mg tablets
57758354|NCT03338621|DRUG|Moxifloxacin|400 mg tablets
57758355|NCT03338621|DRUG|Pyrazinamide|500 mg tablets
58128749|NCT02746952|BIOLOGICAL|UCART19|
58454885|NCT02775188|OTHER|Standard of Care Physical Therapy|
58454886|NCT03689582|DRUG|68Ga-PSMA|"Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
58128750|NCT01575509|OTHER|Berry product|Sugar infused dried lingonberry
58128751|NCT01575509|OTHER|Bread product|Brown bread
58128752|NCT01575509|OTHER|Bread product|Whole grain bread
58128753|NCT01575509|OTHER|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
58454887|NCT02723812|BIOLOGICAL|GCFLU® Influenza vaccine (Split virion, Inactivated)|
58454888|NCT05932277|DRUG|BMS-986419|Specified dose on specified days
58454889|NCT05932277|DRUG|Caffeine|Specified dose on specified days
58454890|NCT05932277|DRUG|Bupropion|Specified dose on specified days
58454891|NCT05932277|DRUG|Flurbiprofen|Specified dose on specified days
58454892|NCT05932277|DRUG|Omeprazole|Specified dose on specified days
58454893|NCT05932277|DRUG|Midazolam|Specified dose on specified days
58454894|NCT05932277|DRUG|Fexofenadine|Specified dose on specified days
58454895|NCT01300728|DRUG|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
57758356|NCT03338621|DRUG|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
57758357|NCT03338621|DRUG|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
57758358|NCT04772222|DRUG|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
57758359|NCT04772222|DRUG|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
57758360|NCT01834105|DRUG|Liuwei Dihuang Pills|
57758361|NCT04766086|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
58454896|NCT01300728|OTHER|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
58454897|NCT05608746|OTHER|Physical Exercise|Home-based individualized training, consisting of unsupervised aerobic exercise and resistance exercise, with moderate intensity. The pt. receives an exercise manual and exercise videos online, through an APP.
57758362|NCT04766086|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
57758363|NCT04766086|BIOLOGICAL|Placebo|Saline control
57758364|NCT03371641|BEHAVIORAL|ASQ parental questionnaire|ASQ parental questionnaire
57758365|NCT03371641|BEHAVIORAL|Development scales|WPPSI - IV and NEPSY development scales
57758366|NCT03371641|BEHAVIORAL|Scale of Conners|Scale of Conners
57758367|NCT03371641|BEHAVIORAL|SCQ Questionnaire|SCQ questionnaire
57758368|NCT03371641|PROCEDURE|Blood sample (mother)|Blood sample (mother) before delivery
57758369|NCT03371641|PROCEDURE|Cord blood sample|Cord blood sample after delivery
57758370|NCT03371641|PROCEDURE|Placenta sample|Placenta sample
57758371|NCT02382718|BIOLOGICAL|FAST fish mCyp c 1|Subcutaneous immunotherapy
57758372|NCT02382718|BIOLOGICAL|Placebo|Subcutaneous immunotherapy
58128754|NCT01575509|OTHER|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
58454898|NCT05608746|OTHER|Pelvic Floor exercise|Patients will be assessed by a physiotherapist and instructed in a pelvic floor exercise program, accessed through the APP. Furthermore, the pt. is provided with general information about pelvic floor anatomy and muscle function.
58454899|NCT05608746|OTHER|Sexual counseling|Patients will be provided with 1 video-consultation with a clinical sexologist, during the prehabilitation period. The patients will be instructed in strategies to improve postoperative communication regarding, sex, realistic expectations, erectile dysfunction and the use of aids.
57758373|NCT05274932|OTHER|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
57758374|NCT03956290|BEHAVIORAL|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
57758375|NCT03538483|DRUG|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
57758376|NCT03538483|DRUG|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
57758377|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
57758378|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
57758379|NCT01677702|DIETARY_SUPPLEMENT|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
57758380|NCT02168764|DEVICE|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
57758381|NCT04665154|DRUG|MAS825|single dose i.v. and s.c.
57758382|NCT04665154|DRUG|Placebo|single dose i.v. and s.c.
57758383|NCT03339284|DRUG|Dexamethasone sodium phosphate|Dexamethasone injection
58128755|NCT01856153|DIETARY_SUPPLEMENT|Before meal|
58128756|NCT01856153|DIETARY_SUPPLEMENT|With Meal|
57758384|NCT03339284|DRUG|Ropivacaine Hydrocloride|Ropivacaine injection
57758385|NCT03339284|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
57758386|NCT04728308|DRUG|Bupivacain|Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
57758387|NCT03361995|DEVICE|Cooling Procedure using the ZOLL Thermogard XP3 IVTM System|Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
57758388|NCT03361995|DEVICE|PCI|Standard of Care for PCI
57758389|NCT04157101|BEHAVIORAL|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
57769759|NCT04702880|BIOLOGICAL|BMS-986012|Specified dose on specified days
57769760|NCT04702880|DRUG|Carboplatin|Specified dose on specified days
58128757|NCT01856153|DIETARY_SUPPLEMENT|After meal|
58128758|NCT00421174|DRUG|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
58128759|NCT00421174|DRUG|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
58454900|NCT05608746|DIETARY_SUPPLEMENT|Nutritional supplement|Patients are systematically screened for malnutrition to assess the nutritional status. Patients are given recommendations with dietary advice online, through the APP. If the patient is at nutritional risk, the patient is provided with a nutritional supplement.
58454901|NCT05608746|OTHER|Stress management|Patients are systematically screened for anxiety and depression. If patients are at risk of anxiety or depression, they are referred to a consultation with a nurse, who will provide information and strategies to handle the uncertainties they may experience.
58454902|NCT05608746|OTHER|Standard pre-surgical preparation and pt. information.|One week preoperatively the usual regime for the presurgical preparation and information will be followed.
58454903|NCT01849601|DEVICE|percutaneous transluminal angioplasty balloon catheter|
57758390|NCT04157101|BEHAVIORAL|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
58128760|NCT01089699|BEHAVIORAL|online support group|online support group
58128761|NCT01089699|BEHAVIORAL|online support group|online support group
58128762|NCT01089699|BEHAVIORAL|home study support materials|self-study materials
58454904|NCT05754853|DRUG|MRG002|Administrated intravenously
58454905|NCT05754853|DRUG|Docetaxel Injection|Administrated intravenously
58454906|NCT05754853|DRUG|Paclitaxel Injection|Administrated intravenously
58454907|NCT05754853|DRUG|Gemcitabine Hydrochloride for Injection|Administrated intravenously
58454908|NCT05754853|DRUG|Pemetrexed Disodium Injection|Administrated intravenously
58454909|NCT01778790|DEVICE|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
58454910|NCT03841110|DRUG|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
58454911|NCT03841110|DRUG|Nivolumab|Immune Checkpoint Inhibitor
58454912|NCT03841110|DRUG|Pembrolizumab|Immune Checkpoint Inhibitor
58454913|NCT03841110|DRUG|Atezolizumab|Immune Checkpoint Inhibitor
58454914|NCT03841110|DRUG|Cyclophosphamide|Lympho-conditioning agent
58454915|NCT03841110|DRUG|Fludarabine|Lympho-conditioning agent
58454916|NCT03841110|DRUG|IL-2|Biologic response modifier
58454917|NCT01311882|DRUG|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
58454918|NCT01311882|DRUG|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
58454919|NCT01311882|DRUG|Zopiclone|1 x 7.5 mg Zopiclone tablet
58454920|NCT01311882|DRUG|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
58454921|NCT01311882|DRUG|Matching Placebo for MK-4305|Matching Placebo for MK-4305
58454922|NCT02106000|DEVICE|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
58454923|NCT05003479|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
58454924|NCT05003479|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
58454925|NCT00925262|BEHAVIORAL|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
58454926|NCT00925262|BEHAVIORAL|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
58454927|NCT00925262|BEHAVIORAL|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
58454928|NCT03795116|DEVICE|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
58454929|NCT03795116|DEVICE|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
58454930|NCT01630915|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
58454931|NCT02939365|DRUG|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
58454932|NCT04757207|OTHER|survey|International Physical Activity Questionnaire (short form)
58454933|NCT04585724|DRUG|Abemaciclib|Given PO
58454934|NCT04585724|DRUG|Palbociclib|Given PO
58454935|NCT04585724|OTHER|Quality-of-Life Assessment|Ancillary studies
58454936|NCT04585724|DRUG|Ribociclib|Given PO
58454937|NCT05189548|BIOLOGICAL|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
57758391|NCT04984057|DRUG|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
57758392|NCT04984057|DRUG|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
57758393|NCT04318158|DRUG|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
57758394|NCT04318158|DRUG|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
57758395|NCT04318158|DRUG|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
57758396|NCT04531163|DRUG|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
57758397|NCT02886806|OTHER|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
57758398|NCT02886806|OTHER|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
57758399|NCT04382924|DRUG|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
57758400|NCT03361748|BIOLOGICAL|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
57758401|NCT01241383|DRUG|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
57758402|NCT02609880|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
57758403|NCT02609880|BEHAVIORAL|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
57758404|NCT06019689|BEHAVIORAL|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
57758405|NCT06345976|OTHER|questionnaire|On-line self-questionnaire, in the form of an 18-question form, the link to which is sent by e-mail to patients with albinism who have agreed to take part in the study.
57758406|NCT05794633|OTHER|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
57758407|NCT05794633|OTHER|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
57758408|NCT04606095|DIAGNOSTIC_TEST|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
57758409|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
58128763|NCT06434285|OTHER|Questionnaire development|Cognitive interviewing group will be run to inform questionnaire development.
58454938|NCT05850949|DIETARY_SUPPLEMENT|Konjac Grain|Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
57758410|NCT04606095|DEVICE|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
58454939|NCT03210207|PROCEDURE|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
58454940|NCT00004858|BIOLOGICAL|B43-genistein immunoconjugate|
57758411|NCT04606095|DEVICE|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
57758412|NCT05287555|OTHER|Telemonitoring Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, SpO2 sensor and modems.
57758413|NCT05287555|OTHER|Standard Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, and modems
57758414|NCT04975022|DRUG|N11005|oral insulin N11005, 300IU, p.o.
57758415|NCT04975022|DRUG|Novolin R|reference preparation Novolin R, 0.1 IU/Kg, i.h.
58454941|NCT06039553|PROCEDURE|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
58454942|NCT05016466|OTHER|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
58454943|NCT05016466|OTHER|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
58454944|NCT01421017|RADIATION|Radiation|
58454945|NCT01421017|DRUG|Imiquimod|
58454946|NCT01421017|DRUG|Cyclophosphamide|
58454947|NCT00737776|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58454948|NCT01548274|DRUG|Sarpogrelate|Sarpogrelate 300mg/day
58454949|NCT06261177|DEVICE|Functional Electrical Stimulation (FES)|45 mins per day for the duration of 4 weeks (20 sessions).
58454950|NCT06261177|DEVICE|Sham FES|Sham FES
58454951|NCT02483806|PROCEDURE|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0-\>5-\>10, 0-\>10-\>5, 5-\>10-\>0, 5-\>0-\>10, 10-\>5-\>0, 10-\>0-\>5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
58454952|NCT04507243|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
58454953|NCT04507243|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
58454954|NCT01046565|DRUG|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
58454955|NCT01046565|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
58454956|NCT06164574|OTHER|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
58454957|NCT06071949|DRUG|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
58454958|NCT06071949|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
58454959|NCT03308916|DIAGNOSTIC_TEST|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
58454960|NCT03308916|DIAGNOSTIC_TEST|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
58454961|NCT03308916|DIAGNOSTIC_TEST|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
58454962|NCT03308916|DIAGNOSTIC_TEST|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
58454963|NCT03308916|DIAGNOSTIC_TEST|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
58454964|NCT03308916|DIAGNOSTIC_TEST|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
58454965|NCT03308916|DIAGNOSTIC_TEST|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
58454966|NCT02625792|DRUG|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
58454967|NCT01349517|PROCEDURE|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
58454968|NCT01349517|PROCEDURE|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
58454969|NCT01349517|PROCEDURE|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
58454970|NCT01349517|PROCEDURE|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
58454971|NCT01169129|OTHER|surgery|resection of brain metastases
58454972|NCT01169129|RADIATION|radiosurgery|radiosurgery to brain metastases
58454973|NCT04804683|GENETIC|Genetic dissection of Fibromuscular Dysplasia|Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
58454974|NCT04804683|OTHER|Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia|Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
58454975|NCT01247324|DRUG|Interferon beta-1a|
58454976|NCT01247324|DRUG|Ocrelizumab-matching placebo|
58454977|NCT01247324|DRUG|Ocrelizumab|
58454978|NCT01247324|DRUG|Interferon beta-1a-matching placebo|
58454979|NCT03243617|OTHER|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
58454980|NCT03243617|OTHER|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
57758416|NCT01291537|DRUG|Duodopa|
57758417|NCT01291537|DRUG|best médical treatment|
57758418|NCT05842512|DRUG|ADI-PEG20|Treatment for NASH
57758419|NCT05842512|OTHER|Placebo|Treatment for NASH
57758420|NCT06300255|BEHAVIORAL|H.O.O.V.E.S. Healing Intensives|"H.O.O.V.E.S. is a private, donor-supported charity dedicated to providing fully-funded, \[4\]-day, non-clinical healing intensives for veterans, their families and caregivers, and first responders across the nation who are seeking recovery from service-connected stress. 1~References~1. Home. HOOVES for Vets. Accessed January 24, 2024. https://www.hooves.us/."
57758421|NCT06384612|BEHAVIORAL|use of pocket cards|Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes
57758422|NCT02094014|BEHAVIORAL|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
57758423|NCT02094014|BEHAVIORAL|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
57758424|NCT02094014|BEHAVIORAL|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
57758425|NCT03520595|DRUG|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
57758426|NCT03520595|DRUG|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
57758427|NCT03520595|DRUG|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
57758428|NCT04416698|BEHAVIORAL|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
57758429|NCT04416698|BEHAVIORAL|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
57758430|NCT00238030|DRUG|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
57758431|NCT00238030|DRUG|iv thryoxine|thyroxine 2 mcg/kg iv
57758432|NCT00045435|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
57758433|NCT00045435|DRUG|fludarabine phosphate|Given IV
57758434|NCT00045435|RADIATION|total-body irradiation|Undergo TBI
57758435|NCT00045435|DRUG|cyclosporine|Given PO
57758436|NCT00045435|DRUG|mycophenolate mofetil|Given PO
58454981|NCT00651781|DRUG|Bortezomib|2 times per week of Velcade administration.
57758437|NCT00045435|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
57758438|NCT05325255|OTHER|Myofascial release of subscapularis|It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
57758439|NCT05325255|OTHER|Maitland mobilization|It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
57758440|NCT05325255|OTHER|Stretching exercises|It is the technique use to increase flexibility and range of motion of short and hypomobile structures
57758441|NCT05325255|OTHER|Cold pack|It is the application of cold to provide analgesic effects
57758442|NCT02252432|DRUG|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
57758443|NCT02252432|DRUG|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
57758444|NCT02252432|DRUG|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
58454982|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D|
58454983|NCT01121796|OTHER|Water or milk|
57758445|NCT02028559|DEVICE|Propulse 1|Move kidney stones with Propulse 1 device.
57758446|NCT01912924|DEVICE|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
57758447|NCT00820274|PROCEDURE|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
57758448|NCT04410068|DEVICE|WARMTAC|Randomization to one of the arms previous to surgery.
58454984|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D enriched milk|
57758449|NCT04410068|DEVICE|3M Bair Hugger|Randomization to one of the arms previous to surgery.
57758450|NCT02897479|DRUG|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
57758451|NCT06320626|OTHER|Emicizumab - PK-guided dose reduction|PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
57758452|NCT06320626|OTHER|Emicizumab - Dosis continuation group|Continue on their current dose regimen
57758453|NCT06320626|OTHER|Emicizumab - Dose adjustment group|Adjusted in dosing regimen according to local protocol
57758454|NCT04860518|DRUG|IFN beta-1a|Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
57758455|NCT04860518|DRUG|Dexamethasone|Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
57758456|NCT01436201|DRUG|Digoxin|Administered orally
57758457|NCT01436201|BIOLOGICAL|Dulaglutide|Administered as subcutaneous injection
57769761|NCT04702880|DRUG|Etoposide|Specified dose on specified days
57769762|NCT04702880|BIOLOGICAL|Nivolumab|Specified dose on specified days
58454985|NCT06202222|OTHER|rehabilitation|The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
58454986|NCT01712126|DRUG|Irbesartan and Hydrochlorothiazide|
58454987|NCT01712126|DRUG|Avalide|
58454988|NCT01480960|OTHER|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
58454989|NCT02741622|BEHAVIORAL|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
58454990|NCT02741622|BEHAVIORAL|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
58454991|NCT02967146|DEVICE|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
58454992|NCT00086866|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
58454993|NCT00086866|BIOLOGICAL|SB-AS02B adjuvant|
58454994|NCT00086866|BIOLOGICAL|SB-AS15 adjuvant|
58454995|NCT00333021|DRUG|Fondaparinux sodium|
58454996|NCT00333021|DRUG|GSK576428|
58454997|NCT06034288|DRUG|Xeomin 100 UNT Injection|intravesical injection
58454998|NCT06034288|DRUG|Botox 100 UNT Injection|intravesical injection
58454999|NCT03890068|DRUG|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
58455000|NCT04400188|DRUG|Fluzoparib|Given PO
58455001|NCT04400188|DRUG|temozolomide|Given PO
58455002|NCT04400188|BIOLOGICAL|SHR-1316|Given injection
58455003|NCT02994563|DEVICE|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
57758458|NCT04948450|BEHAVIORAL|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
57758459|NCT04948450|BEHAVIORAL|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
57758460|NCT04948450|BEHAVIORAL|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
57769763|NCT00278382|DRUG|sorafenib tosylate|Given orally
57769764|NCT00278382|OTHER|laboratory biomarker analysis|Correlative studies
58455004|NCT03245125|BEHAVIORAL|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
58455005|NCT00271375|BEHAVIORAL|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
58455006|NCT00271375|BEHAVIORAL|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
58455007|NCT00271375|BEHAVIORAL|Control|Control group usual care
58455008|NCT01057849|DRUG|risperidone|3-6 mg per day
58455009|NCT01057849|DRUG|olanzapine|5-20 mg per day
58455010|NCT01057849|DRUG|Aripiprazole|10-30 mg per day
58455011|NCT03490825|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
58455012|NCT03490825|DIETARY_SUPPLEMENT|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
58455013|NCT03490825|OTHER|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
58455014|NCT03490825|OTHER|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
58455015|NCT01889875|DRUG|"ALK Grazax 75,000 SQ-T Phleum pratense"|
58455016|NCT01889875|DRUG|"ALK AluTard 225 Phleum pratense"|
58455017|NCT05625984|DEVICE|Fascigel|The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
58455018|NCT03201588|DIETARY_SUPPLEMENT|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
58455019|NCT00809016|RADIATION|3-dimensional conformal radiation therapy|
58455020|NCT00809016|RADIATION|fludeoxyglucose F 18|
58455021|NCT00809016|RADIATION|intensity-modulated radiation therapy|
58455022|NCT03422029|DRUG|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
58455023|NCT06189326|PROCEDURE|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
57758461|NCT04948450|OTHER|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 7.5 %."
57758462|NCT02392325|BIOLOGICAL|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)
57758463|NCT02392325|BIOLOGICAL|Placebo|Administered subcutaneously in 0.5 mL
57758464|NCT02392325|BIOLOGICAL|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
57758465|NCT05771337|DIAGNOSTIC_TEST|blood sample|blood sample
57758466|NCT01713543|OTHER|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
57758467|NCT03472222|BEHAVIORAL|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
57758468|NCT03517592|OTHER|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
57758469|NCT03517592|OTHER|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
57758470|NCT03670225|DEVICE|Invia Motion Endure|NPWT Invia Motion Endure
57758471|NCT00000280|DRUG|Nimodipine|
57758472|NCT01106443|PROCEDURE|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
57758473|NCT01106443|PROCEDURE|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
57758474|NCT01106443|PROCEDURE|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
57758475|NCT01106443|PROCEDURE|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
57758476|NCT06108401|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
57758477|NCT06108401|DIETARY_SUPPLEMENT|Cow milk-based infant formula|Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
57758478|NCT05547425|DEVICE|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
57758479|NCT05547425|DEVICE|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
58455024|NCT06189326|PROCEDURE|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
58455025|NCT05298202|BIOLOGICAL|Capsaicin|application of capsaicin gel from shoulder to wrist and mid thigh to ankle
57758480|NCT05547425|DEVICE|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
57758481|NCT05547425|DEVICE|Raw images|No editing is performed on images.
57758482|NCT04070625|OTHER|Communication book group|Communication book
57758483|NCT04070625|OTHER|Control group|Simple speech therapy
57758484|NCT03324893|DIAGNOSTIC_TEST|[F-18]-FCH PET/MRI|Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
57758485|NCT01737099|DIETARY_SUPPLEMENT|DHA-O|
57758486|NCT01737099|DIETARY_SUPPLEMENT|Fish oil|
57758487|NCT01737099|DIETARY_SUPPLEMENT|Placebo|
57758488|NCT06626113|DRUG|ascorbic acid|ascorbic acid
57758489|NCT02130284|DEVICE|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
57758490|NCT02348684|RADIATION|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
57758491|NCT00384059|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
57758492|NCT00384059|BIOLOGICAL|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
58455026|NCT05298202|BIOLOGICAL|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
57758493|NCT00384059|BIOLOGICAL|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
57758494|NCT00384059|BIOLOGICAL|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
57758495|NCT00384059|BIOLOGICAL|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
57758496|NCT06248398|PROCEDURE|Surgery with RobOtol®|Patient having cochlear implantation surgery with RobOtol®.
57758497|NCT06248398|PROCEDURE|Conventional manual surgery|Patient having conventional manual cochlear implantation surgery
57758498|NCT03175627|DEVICE|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
57758499|NCT03175627|DEVICE|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
57758500|NCT05782725|OTHER|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
57769765|NCT03344822|DIAGNOSTIC_TEST|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
58455027|NCT05298202|OTHER|Exercise|treadmill walking 3.5 mph at 5% grade
58455028|NCT05298202|OTHER|Hot environment|38°C, 60% relative humidity
58455029|NCT05131425|BEHAVIORAL|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
58455030|NCT05131425|OTHER|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
58455031|NCT00466063|DRUG|Deferasirox|
58455032|NCT05199051|COMBINATION_PRODUCT|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
58455033|NCT06136780|OTHER|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
58455034|NCT03304561|OTHER|Traditional rehabilitation|traditional ACL rehabilitation program
58455035|NCT03304561|OTHER|Cross-over training|Cross-over training addition to the traditional rehabilidation
58455036|NCT04912778|OTHER|Filling in an online survey|Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
58455037|NCT06275555|DRUG|bivalirudin|bivalirudin as an anticoagulant
58455038|NCT06275555|DRUG|unfractionated heparin|unfractionated heparin as an anticoagulant
58455039|NCT06374953|DIAGNOSTIC_TEST|Ultrasound-based viscoelastic hemostasis analysis|Adding recombinant tissue plasminogen activator (rtPA) and/or Tranexamic acid （TXA）to blood in vitro, and fibrinolysis capacity is assessed using ultrasound-guided viscoelastic coagulation testing.
58455040|NCT06179576|BEHAVIORAL|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
58455041|NCT04256824|DRUG|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
58455042|NCT04256824|DRUG|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
58455043|NCT06264739|DRUG|esp Dexmedetomidine (dekstomid)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
58455044|NCT06264739|DRUG|esp remifentanyl (ultiva)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
58455045|NCT06290596|DRUG|Vasopressin|Hemostatic drug.
57758501|NCT05035914|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
57758502|NCT00622843|BIOLOGICAL|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
57758503|NCT00622843|BIOLOGICAL|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
57769766|NCT03344822|DIAGNOSTIC_TEST|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
57769767|NCT04676126|DIETARY_SUPPLEMENT|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
58455046|NCT06290596|DRUG|Tranexamic acid|Hemostatic drug.
58455047|NCT06290596|OTHER|Saline|Placebo
58455048|NCT04364828|GENETIC|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
58455049|NCT04364828|GENETIC|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
58455050|NCT04364828|GENETIC|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
58455051|NCT02954107|OTHER|MRI|
58455052|NCT02954107|OTHER|24h-EEG + video|
58455053|NCT02954107|OTHER|Neuropsychological tests|
58455054|NCT02519608|DRUG|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
58455055|NCT02519608|DRUG|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
58455056|NCT02519608|DRUG|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
58455057|NCT03366181|DEVICE|internal cardioverter defibrillator implant (ICD)|to implant ICD in failing heart subjects with reduced left ventricle ejection fraction (LVEF \< 35%).
58455058|NCT03366181|PROCEDURE|percutaneous catheter ablation|to perform catheter ablation in patients with heart failure and reduced left ventricle ejection fraction (LVEF \< 35%).
58455059|NCT06366178|DEVICE|BONFIX system|"The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide."
58455060|NCT00688584|BEHAVIORAL|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
58455061|NCT00688584|BEHAVIORAL|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
58455062|NCT00614380|DRUG|telmisartan/amlodipine 40/5 mg fixed combination|
58455063|NCT00614380|DRUG|telmisartan/amlodipine 80/5 mg fixed combination|
57758504|NCT00681616|DEVICE|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
57758505|NCT00681616|DEVICE|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
57758506|NCT00681616|DEVICE|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
57758507|NCT01019538|OTHER|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
57758508|NCT06043986|DEVICE|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
57758509|NCT00538928|OTHER|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
57758510|NCT03874065|OTHER|Medical Chart Review|Collection of data from participant's medical chart
58455064|NCT00367250|DRUG|Cetuximab|weekly i.v.
58455065|NCT00367250|DRUG|Trastuzumab|weekly i.v.
58455066|NCT06491602|DIAGNOSTIC_TEST|renal biobsy|analsis of renal biobsy and decide grade of renal affection
58455067|NCT06322563|DRUG|LTC004+regorafenib|LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
58455068|NCT00423657|DRUG|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
58455069|NCT00423657|DRUG|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
58455070|NCT00423657|DRUG|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
58455071|NCT06524687|DRUG|Imvotamab|Administered intravenously
58455072|NCT03367858|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
58455073|NCT03367858|BEHAVIORAL|Brief Adolescent Mindfulness (BAM)|Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
58455074|NCT05007522|DRUG|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
58455075|NCT05007522|DRUG|Placebo|Matching placebo tablet
58455076|NCT05541146|COMBINATION_PRODUCT|Intraperitoneal chemotherapy|Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
57758511|NCT00087958|DRUG|XRP9881|
57758512|NCT00524225|DRUG|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
57758513|NCT06262061|DRUG|Propranolol|20mg oral propranolol BID x 14 days
57758514|NCT06262061|DRUG|Placebo|Placebo pill orally BID x 14 days
57758515|NCT03253484|RADIATION|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
57758516|NCT02317939|OTHER|instruction|online instruction tutorials at followup visits
57758517|NCT02317939|OTHER|standard baseline instruction|self-guidance at followup visits
57758518|NCT02843256|DEVICE|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
57758519|NCT06100510|DRUG|Aspirin 325mg|Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
57758520|NCT01147484|DRUG|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
57758521|NCT02277743|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
57758522|NCT02277743|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
57758523|NCT04904770|DEVICE|Scoop stretcher|Already included in arm/group description
57758524|NCT04904770|DEVICE|Vacuum mattress|Already included in arm/group description
57758525|NCT06178861|DEVICE|Group wearing a radiotherapy bra|Group wearing a radiotherapy bra
57758526|NCT03220399|DRUG|NVP-1603-1 (P)|1capsule, single oral dosing
57758527|NCT03220399|DRUG|NVP-1603-2 (T)|1tablet, single oral dosing
57758528|NCT03220399|DRUG|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
57758529|NCT03381404|DRUG|[14C] MT-8554|14-C MT-8554
57758530|NCT00871689|BIOLOGICAL|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
57758531|NCT00871689|DRUG|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
57758532|NCT00871689|DRUG|fludarabine phosphate|25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
57758533|NCT00871689|PROCEDURE|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
57758534|NCT00871689|RADIATION|total-body irradiation|administered on days -5 through -2; 330 cGy daily
57758535|NCT01203670|DIETARY_SUPPLEMENT|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
57758536|NCT01963338|DEVICE|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
57758537|NCT01963338|DEVICE|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
57758538|NCT01963338|DRUG|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
57758539|NCT03786952|BEHAVIORAL|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
57758540|NCT03786952|BEHAVIORAL|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
57758541|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
57758542|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
57758543|NCT03786952|BEHAVIORAL|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
57758544|NCT03786952|BEHAVIORAL|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
57758545|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
57769768|NCT04676126|DRUG|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
57769769|NCT04676126|OTHER|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
58455077|NCT02576223|DRUG|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
58455078|NCT02576223|DRUG|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
58455079|NCT02576223|DRUG|PCA-pump|"PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes."
58455080|NCT05682755|DRUG|Chidamide|initial time：platelet count ≥50×10\^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10\^9/L-increased by 5 mg 20×10\^9/L≤ platelet count \<50×10\^9/L-remains unchanged platelet count \<50×10\^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
58455081|NCT02988778|DRUG|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
58455082|NCT02988778|DRUG|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
58455083|NCT00080665|DRUG|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
58455084|NCT00080665|DRUG|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
58455085|NCT01480622|DRUG|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
58455086|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
58455087|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
58455088|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
58455089|NCT04694690|OTHER|Self adhesive resin cement|Self adhesive resin cement
58455090|NCT04694690|OTHER|Resin cement|Resin Cement system used after surface treatment
58455091|NCT00804466|DEVICE|OncoE6|HPV oncoprotein assay
58455092|NCT00804466|DEVICE|EVA System|low-cost colposcope
58455093|NCT05532865|OTHER|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
58455094|NCT05532865|OTHER|Stool samples|A stool sample for collection of digestive microbiota at inclusion
58455095|NCT05532865|OTHER|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
57758546|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
57758547|NCT00117156|DRUG|Fludarabine|
57758548|NCT00117156|DRUG|Rituximab|
57758549|NCT04242433|DRUG|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
57758550|NCT00003163|BIOLOGICAL|filgrastim|
58455096|NCT05532865|OTHER|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
58455097|NCT05532865|OTHER|Skin biopsies|At inclusion and 18 months
57758551|NCT00003163|BIOLOGICAL|sargramostim|
57758552|NCT00003163|DRUG|cyclophosphamide|
57758553|NCT00003163|DRUG|melphalan|
57758554|NCT00003163|PROCEDURE|autologous bone marrow transplantation|
57758555|NCT00003163|PROCEDURE|peripheral blood stem cell transplantation|
57758556|NCT00003163|RADIATION|radiation therapy|
57758557|NCT03420924|DEVICE|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
57758558|NCT03420924|DEVICE|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
57758559|NCT05354843|DRUG|ET0038|ET0038 for oral administration
57758560|NCT06065878|PROCEDURE|IPACK + Genicular Nerve Block|IPACK and Genicular Nerve block were applied with the same total volume of local anesthetic as the control group.
58455098|NCT02719821|BEHAVIORAL|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
58455099|NCT05733858|DEVICE|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
58455100|NCT05733858|DEVICE|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
58455101|NCT05733858|DEVICE|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
58455102|NCT05733858|BEHAVIORAL|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
58455103|NCT01792700|DRUG|esomeprazole|
58455104|NCT01792700|DRUG|tripotassium dicitrate bismuthate|
58455105|NCT01792700|DRUG|metronidazole|
58455106|NCT01792700|DRUG|tetracycline|
58455107|NCT01792700|DRUG|moxifloxacin|
58455108|NCT01792700|DRUG|amoxicillin|
58455109|NCT03498950|OTHER|laser therapy|laser irradiation on the taste papillae
57758561|NCT02755597|DRUG|Venetoclax|Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
57758562|NCT02755597|DRUG|Bortezomib|Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.
57758563|NCT02755597|DRUG|Dexamethasone|Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
57769770|NCT00642629|DRUG|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
57769771|NCT00642629|DRUG|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
57960924|NCT05812989|BEHAVIORAL|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
58455110|NCT04562454|OTHER|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
58455111|NCT00348439|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
58455112|NCT00348439|DRUG|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
58455113|NCT04951830|DIAGNOSTIC_TEST|MRI|MRI of TMJ
58455114|NCT05117736|DRUG|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
58455115|NCT05117736|DRUG|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
58455116|NCT02534545|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
58455117|NCT02534545|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
58455118|NCT02408588|OTHER|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
58455119|NCT00569712|DRUG|budesonide/formoterol fumarate dihydrate inhalation aerosol|
58455120|NCT00569712|GENETIC|DNA methylation analysis|
58455121|NCT00569712|GENETIC|comparative genomic hybridization|
58455122|NCT00569712|GENETIC|microarray analysis|
58455123|NCT00569712|OTHER|bronchoalveolar lavage|
58455124|NCT00569712|OTHER|immunoenzyme technique|
58455125|NCT00569712|OTHER|laboratory biomarker analysis|
58455126|NCT00569712|PROCEDURE|bronchoscopy|
58455127|NCT01173016|DRUG|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
58455128|NCT00876616|DRUG|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
58455129|NCT00876616|DRUG|Cyclophosphamide|CTX 0.75g/m2 BSA
58455130|NCT06472674|OTHER|No intervention|No intervention
58455131|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
58455132|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
58455133|NCT04067323|DIETARY_SUPPLEMENT|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
58455134|NCT04067323|DIETARY_SUPPLEMENT|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
58455135|NCT05929521|OTHER|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
58455136|NCT04552769|DRUG|Abemaciclib|200 mg orally
58455137|NCT03011281|DRUG|Tofacitinib|
58455138|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
58455139|NCT04837937|BEHAVIORAL|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
58455140|NCT04837937|BEHAVIORAL|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
57758564|NCT02755597|DRUG|Placebo for venetoclax|Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
57758565|NCT04302376|DIAGNOSTIC_TEST|Cather-related thrombosis ultrasonography|Doppler and compression ultrasound to detect catheter-related thrombosis
57758566|NCT01970852|OTHER|Standard tablet computer|No special enhancements or links to personal health information.
57758567|NCT01970852|OTHER|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
57758568|NCT00048230|DRUG|bortezomib|
57758569|NCT06014138|DRUG|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
57758570|NCT06014138|DRUG|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
57758571|NCT00047775|DRUG|BiDil|
57758572|NCT04012060|PROCEDURE|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
57758573|NCT04012060|PROCEDURE|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
57758574|NCT00983632|PROCEDURE|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
57758575|NCT00983632|DEVICE|selective vagus nerve stimulation|electrical vagus stimulation
57758576|NCT06624579|PROCEDURE|confocal endomicroscopy|The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
57758577|NCT02730182|OTHER|altitude exposure|altitude exposure
57758578|NCT04341961|OTHER|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
57758579|NCT01437163|DEVICE|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
57758580|NCT01437163|DEVICE|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
57758581|NCT03625986|OTHER|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
58455141|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
58455142|NCT03779542|PROCEDURE|cataract surgery|phacoemulsification and intraocular lens implantation
58455143|NCT03656029|DRUG|Cannabis|Participants will smoke as much of the cigarette as they wish
58455144|NCT03656029|DRUG|Placebo|Participants will smoke a placebo cigarette
58455145|NCT01092728|DRUG|Dasatinib|100 mg daily.
58455146|NCT01092728|PROCEDURE|Surgical Resection|Complete surgical resection of tumor(s).
58455147|NCT00034775|DRUG|risperidone|
58455148|NCT02320006|OTHER|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
58455149|NCT05655663|OTHER|Vascular investigation|Measure of of carotid stiffness
58455150|NCT04974255|OTHER|Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples|Examination of pathology specimen and laboratory measuring
58455151|NCT02469623|DEVICE|Dipole Density Mapping with AcQMap followed by ablation|
58455152|NCT05057663|DRUG|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
58455153|NCT01801566|PROCEDURE|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
57758582|NCT03625986|OTHER|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
57758583|NCT04980664|OTHER|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
57758584|NCT05680337|DEVICE|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
57758585|NCT05064787|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
57758586|NCT01410370|RADIATION|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
58455154|NCT06528951|OTHER|Control Phase ( 6Weeks)|The participants will perform a control phase of six weeks of resistance training using the same volume for the upper (160 repetitions) and lower limbs (230 repetitions), with relative intensities ranging from 40% to 70% of 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 5-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 5-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 6-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 5-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
58455155|NCT06528951|OTHER|15% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 15% (upper limbs - 184 repetitions; lower limbs - 268 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 4-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 3-8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
58455156|NCT06528951|OTHER|30% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
58455157|NCT06528951|OTHER|One group that performed 15% more volume and increased to 30% (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed a 15% volume will now increase more by 15% and perform 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
58455158|NCT06528951|OTHER|One group that performed 30% more volume and increased to 45% (10 Weeks).|The participants will perform 10 weeks of resistance training. The group that performed a 30% volume will now increase more by 15% and perform 45% (upper limbs - 232 repetitions; lower limbs - 334 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 2-3 sets of 8 repetitions in the sit-to-stand exercise, v) 2-3 sets of 8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
58455159|NCT06528951|OTHER|Control group ( 29 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
58455160|NCT03431441|DEVICE|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
58455161|NCT02230566|DRUG|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
58455162|NCT02230566|OTHER|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
58455163|NCT05740488|DRUG|Apalutamide|240mg, po, qd
58455164|NCT05740488|DRUG|89Sr|100\~150MBq(based on weight), iv, q90d
58455165|NCT05740488|DRUG|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
58455166|NCT00557921|DRUG|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
57758587|NCT01410370|DRUG|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
57758588|NCT05416905|DEVICE|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
57758589|NCT05416905|DEVICE|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
57758590|NCT04461327|BEHAVIORAL|Painful stimulations of major depressive patients|"All three pain mechanisms will be tested in one session lasting 1h approximately.~The mechanisms are tested in the following order:~1. Aδ and C threshold~2. Wind-up~3. CPM~(more details in detailed description)"
57758591|NCT04461327|BIOLOGICAL|Blood sample|The blood test is made between 2 and 24 hours before the experimental procedure. The biological collection is made to measure medications' concentration if the patient takes antiepileptics and/or lithium, and to measure complete blood count (CBC).
57758592|NCT04461327|DIAGNOSTIC_TEST|Clinical assessment|"A clinical assessment will be made by a trained researcher.~(more details in detailed description)"
57758593|NCT04461327|BEHAVIORAL|Social touch|Stroking
57758594|NCT01557322|BIOLOGICAL|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
58128764|NCT03914313|DEVICE|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
58128765|NCT04289636|BEHAVIORAL|Behavioral weight loss program|Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
58128766|NCT04289636|BEHAVIORAL|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
58128767|NCT04289636|BEHAVIORAL|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
58128768|NCT00175019|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
58128769|NCT00175019|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
58128770|NCT00175019|DRUG|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
58455167|NCT00557921|DRUG|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
58455168|NCT02977000|DRUG|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
58455169|NCT04958369|DEVICE|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
58455170|NCT04958369|DEVICE|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
58455171|NCT04230317|DIAGNOSTIC_TEST|Chest CT|Low dose CT taken with three different protocols
58455172|NCT01665469|DIETARY_SUPPLEMENT|Tomato extracted lycopene|
57758595|NCT01557322|DRUG|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
57758596|NCT00462137|PROCEDURE|Sleep Studies|
57758597|NCT02980926|DRUG|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
57758598|NCT02980926|DRUG|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
57758599|NCT01971164|DRUG|JTZ-951|Subjects will receive JTZ-951 or Placebo
57758600|NCT01971164|DRUG|Placebo|
57758601|NCT05144932|DEVICE|Stroke Alarm|The patients are in this clinical trial instructed to use the device continuously for 1 month.
58128771|NCT00499642|DRUG|Lecozotan SR|
58128772|NCT00499642|DRUG|Moxifloxacin|
58128773|NCT02557607|DEVICE|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
57758602|NCT03430141|OTHER|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
58128774|NCT03655106|DEVICE|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
58128775|NCT03655106|DEVICE|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
58128776|NCT02384616|OTHER|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
58128777|NCT05524688|DIETARY_SUPPLEMENT|Beta-glucan|2, 250 mg capsules of beta-glucan per day
58128778|NCT05524688|DIETARY_SUPPLEMENT|Placebo|2, 250 mg capsules of cellulose
58455173|NCT01665469|DIETARY_SUPPLEMENT|Placebo|
58455174|NCT01918124|RADIATION|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
58455175|NCT01918124|DRUG|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
58455176|NCT01918124|DRUG|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
58455177|NCT01918124|DRUG|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
58455178|NCT03142529|DRUG|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
58455179|NCT05048173|PROCEDURE|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
58455180|NCT05048173|PROCEDURE|Lymphadenectomy|Conventional lymphadenectomy
57758603|NCT05234359|DIAGNOSTIC_TEST|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
57758604|NCT05234359|DIAGNOSTIC_TEST|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
57758605|NCT03880630|OTHER|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
57758606|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
57758607|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
57758608|NCT01455207|BEHAVIORAL|Neuropsychological testing|assessment of memory, executive functions and ataxia
57758609|NCT01455207|BIOLOGICAL|blood draw|hepatic markers, red blood markers and vitamin markers
57758610|NCT01455207|GENETIC|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
57758611|NCT01455207|OTHER|Brain imaging examination|MRI, DTI and PET examinations
57758612|NCT06171230|OTHER|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
57758613|NCT06171230|OTHER|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
57758614|NCT00638235|DEVICE|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
57758615|NCT00638235|DEVICE|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
57758616|NCT00638235|DEVICE|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
57758617|NCT00638235|DEVICE|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
57758618|NCT00638235|DEVICE|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
57758619|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
57758620|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
57758621|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
57758622|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
57758623|NCT03280771|COMBINATION_PRODUCT|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
57758624|NCT03280771|COMBINATION_PRODUCT|Control group soap|A colourful, translucent bar or soap with the toy alongside it
57758625|NCT04849221|OTHER|Tympanometry measurement in both ears|Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE
57758626|NCT04849221|OTHER|Collection of clinical and paraclinical data|"Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria..."
58455181|NCT02528825|DRUG|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
57758627|NCT04849221|OTHER|Intracranial pressure reading (ICP)|a single measure
57758628|NCT00963911|OTHER|Geriatric screening tests|"The G-8 consists of eight items: patient age (\>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment."
57769772|NCT03562546|OTHER|Strength From Within|A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
57769773|NCT05112211|DRUG|Doxycycline Hyclate|patients administrated with doxycycline tablets 100mg orally per day
58455182|NCT00088530|DRUG|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
58455183|NCT00088530|DRUG|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
58455184|NCT02832544|DRUG|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
57758629|NCT00963911|OTHER|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
57758630|NCT04417387|OTHER|Observational|
57758631|NCT02468635|OTHER|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
57758632|NCT02468635|OTHER|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
57758633|NCT06483425|GENETIC|Sequencing of DNA, RNA, and Proteins|Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
57758634|NCT03526601|DIAGNOSTIC_TEST|NT-proBNP, echocardiography|screening
57758635|NCT01704625|PROCEDURE|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
57758636|NCT01704625|PROCEDURE|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
57758637|NCT01520402|DRUG|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
57758638|NCT06232720|DEVICE|Q300 QART Medical|The Q300TM Imaging system includes a Quantitative Phase Microscope. Q300TM uses a low intensity coherent light source, in a uniquely configured interferometer, which measures light delay as it passes different locations across the sperm cell. The amount
57758639|NCT01827826|BEHAVIORAL|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
57758640|NCT03897062|DRUG|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
57758641|NCT03897062|OTHER|placebo|Placebo controlled double blind suvorexant vs placebo
57758642|NCT05601934|OTHER|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
57758643|NCT01042028|DRUG|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
57758644|NCT01042028|DRUG|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
58128779|NCT06078163|OTHER|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
58128780|NCT06078163|OTHER|rehabilitation|rehabilitation protocol lasting 20 sessions.
58128781|NCT00577668|DRUG|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
58128782|NCT00576381|DRUG|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
58455185|NCT02832544|DRUG|Vitamin K antagonists (VKA)|
58455186|NCT04632888|OTHER|Telephone support for breastfeeding follow-up|The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
58455187|NCT05256680|OTHER|Gardening Activities|"In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home."
58455188|NCT01936714|PROCEDURE|cataract surgery|
57758645|NCT03841656|PROCEDURE|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
58455189|NCT04683835|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
57758646|NCT02476955|DRUG|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
57758647|NCT02476955|DRUG|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
57758648|NCT02476955|DRUG|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
57758649|NCT01618084|DEVICE|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
57758650|NCT05166525|OTHER|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
57758651|NCT01706302|OTHER|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
57758652|NCT03080116|DRUG|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
57758653|NCT03080116|DRUG|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
57758654|NCT03080116|OTHER|Placebo|4 tablets, per OS
58455190|NCT03936608|DEVICE|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
58455191|NCT03936608|DEVICE|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
58455192|NCT06011408|OTHER|TDtect|Collecting video data on abnormal movement
58455193|NCT05299398|DRUG|Trazodone|Trazodone capsule once daily
58455194|NCT05299398|DRUG|Placebo|Placebo capsule once daily
57758655|NCT00612534|DRUG|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
57758656|NCT00612534|DRUG|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
57758657|NCT00612534|DRUG|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
57758658|NCT00612534|DRUG|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
57758659|NCT00797979|DEVICE|Skull Grip bone fixation|Skull Grip bone fixation
57758660|NCT00797979|DEVICE|sutures|Standard skull bon flap fixation, sutures
57758661|NCT01842113|DRUG|Rifaximin|Rifaximin 550mg by mouth twice a day
57758662|NCT01842113|DRUG|Lactulose|Lactulose 30ml by mouth three times a day
57758663|NCT01842113|DRUG|Lactulose Placebo|Lactulose Placebo 30ml three times a day
57758664|NCT01842113|DRUG|Rifaximin Placebo|Rifaximin Placebo twice a day
57758665|NCT02541825|DEVICE|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
57758666|NCT02541825|DEVICE|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
57758667|NCT00943306|DRUG|lomitapide|5-60 mg po every day
57758668|NCT04606537|DRUG|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
57758669|NCT04606537|DRUG|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
57758670|NCT04606537|DRUG|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
58455195|NCT05555966|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
58455196|NCT01875159|DRUG|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
58455197|NCT06268054|DRUG|DEH113|Tablets
58455198|NCT06268054|DRUG|Placebo Comparator|Tablets
58455199|NCT00524277|BIOLOGICAL|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
58455200|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
58455201|NCT00524277|BIOLOGICAL|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
58455202|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
57758671|NCT03760770|PROCEDURE|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
57758672|NCT01830088|BEHAVIORAL|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
57758673|NCT01830088|BEHAVIORAL|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
57758674|NCT02222480|DRUG|Fimasartan|
57758675|NCT02222480|DRUG|Hydrochlorothiazide|
57758676|NCT02222480|DRUG|Placebo|
57758677|NCT01551602|DRUG|AK159|transdermal administration of teriparatide acetate
57758678|NCT01551602|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
57758679|NCT01551602|DRUG|Placebo|Multiple administration of placebo AK159
57758680|NCT06496191|BIOLOGICAL|FMT|- Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4
57758681|NCT06496191|OTHER|SMT|Baclofen + AUD counselling
57758682|NCT06496191|OTHER|Placebo|Placebo identical to the FMT arm.
57758683|NCT04623073|PROCEDURE|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
57758684|NCT06403579|DEVICE|virtula reality goggles|no intervention
57758685|NCT01265901|DRUG|Sunitinib|As per label.
57758686|NCT01265901|BIOLOGICAL|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
57758687|NCT01265901|DRUG|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
57758688|NCT01265901|DRUG|IMA901|Intradermal vaccinations with IMA901 vaccine.
57758689|NCT01974037|DIETARY_SUPPLEMENT|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
57758690|NCT01974037|DIETARY_SUPPLEMENT|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
57758691|NCT01439061|DEVICE|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
57758692|NCT01521884|OTHER|SC anti-TNF|SC anti-TNF
57758693|NCT03299764|DEVICE|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
58128783|NCT05145283|DRUG|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
58128784|NCT05145283|DRUG|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
57758694|NCT03299764|DEVICE|Standard non-invasive ventilation|Standard non-invasive ventilation
57758695|NCT05870202|OTHER|screening tool|The screening tool identifies areas of treatment burden in patients with type 2 diabetes. The tool is in the form of a brief questionnaire that the patient completes prior to a clinical appointment. The patient's responses to the questionnaire are then included in the discussion with the patient's primary care clinician during the clinical visit.
57758696|NCT04131790|BEHAVIORAL|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
57758697|NCT04131790|BEHAVIORAL|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
57758698|NCT02323646|DRUG|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
57758699|NCT02323646|DRUG|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
57758700|NCT04288635|BIOLOGICAL|Whole blood samples|Whole blood samples at admission, from day one to three after admission
57758701|NCT04363099|OTHER|observational|observational management of outpatients COVID 19
57758702|NCT05319106|OTHER|stem cell preparation combined with silver ion dressing|The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
57758703|NCT05319106|PROCEDURE|silver ion dressing|fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
57758704|NCT03021668|DEVICE|Prevena Peel & Place Dressing|Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
57758705|NCT03021668|OTHER|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
57758706|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
57758707|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
58455203|NCT05579015|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
58455204|NCT05579015|OTHER|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
58455205|NCT05277376|DRUG|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
58455206|NCT01732744|OTHER|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
58455207|NCT01732744|OTHER|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
58455208|NCT01732744|OTHER|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
58455209|NCT01732744|OTHER|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
58455210|NCT02986711|BEHAVIORAL|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
58455211|NCT02986711|BEHAVIORAL|Control|Only survey questions about smoking status
58455212|NCT05697783|DRUG|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
58455213|NCT00226590|DRUG|Gemcitabine|Induction Chemotherapy.
58455214|NCT00226590|DRUG|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
58455215|NCT00226590|DRUG|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
58455216|NCT00226590|PROCEDURE|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
58455217|NCT02120066|PROCEDURE|Vitrectomy for submacular hemorrhage|
58455218|NCT02120066|DRUG|subretinal injection of tissue-plasminogen activator|
58455219|NCT03549975|DRUG|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
58455220|NCT02306681|OTHER|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
57758708|NCT04591990|DRUG|Administration of AVP|Administration of AVP
57758709|NCT04591990|DRUG|Administration of placebo AVP|Administration of placebo AVP
57758710|NCT04591990|DRUG|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
57758711|NCT04591990|DRUG|Administration of hydrocortisone|Administration of hydrocortisone
57758712|NCT01124721|BEHAVIORAL|Cognitive training|Cognitive computerized training for several days per week.
57758713|NCT01124721|BEHAVIORAL|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
57758714|NCT03823222|DIETARY_SUPPLEMENT|Duckweed protein|20 grams isolated protein
57758715|NCT03823222|DIETARY_SUPPLEMENT|Whey protein|20 grams isolated protein
57758716|NCT01370681|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001|
57758717|NCT01370681|DRUG|Period I : CJ30001, Period II : HKB0701 and SLM0807|
57758718|NCT02020239|OTHER|Exercise|
57758719|NCT02699502|OTHER|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
57758720|NCT05719948|PROCEDURE|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
57758721|NCT06445790|BEHAVIORAL|Cognitive Behavior Therapy for Chronic Pelvic Pain-CBT-cp|CBT-cp will be administered weekly sessions for 12 weeks.
57758722|NCT05395988|DEVICE|Digital hand washing instructions|Tablet displaying animated hand washing instructions
57758723|NCT05395988|DEVICE|Digital hand washing reward|Tablet displaying animated hand washing instructions and animated animals as reward
57758724|NCT00714376|DRUG|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
57758725|NCT01007864|DRUG|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
57758726|NCT01007864|DRUG|pramipexole or ropinirole|continuation of pre-study treatment regimen
57758727|NCT02736825|DEVICE|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
57758728|NCT02736825|DEVICE|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
57758729|NCT02462954|DEVICE|ContraGel|
57758730|NCT02462954|DEVICE|HEC Universal Placebo gel|
57758731|NCT00402480|DRUG|Hydroxyurea|
57758732|NCT05654792|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
57758733|NCT05357014|DIAGNOSTIC_TEST|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
57758734|NCT02498353|RADIATION|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
57758735|NCT02498353|RADIATION|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
57758736|NCT02498353|PROCEDURE|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
57758737|NCT00153959|BEHAVIORAL|acute psychiatric day care|
58128785|NCT02635100|OTHER|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
58128786|NCT02596503|DRUG|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
58128787|NCT02596503|DRUG|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
58128788|NCT02596503|OTHER|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
58455221|NCT01096836|OTHER|macronutrient and energy manipulation|
57758738|NCT03074214|PROCEDURE|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
57758739|NCT05662384|OTHER|No intervention is planned|Observational study, no intervention
57758740|NCT06509451|DRUG|Giomer pit and fissure sealant without etching|S-PRG filler containig pit and fissure sealant without etching step
57758741|NCT06509451|DRUG|Giomer pit and fissure sealant with etching|S-PRG filler containig pit and fissure sealant with etching step
57758742|NCT02136433|DEVICE|Tablet - self exercise|
57758743|NCT02136433|OTHER|GRASP self exercise|
57758744|NCT04182854|DRUG|Furosemid hydrochlorothiazide|furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
57758745|NCT06135311|DEVICE|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
58455222|NCT03056677|DIETARY_SUPPLEMENT|Control|200mls water will be given prior to a mixed carbohydrate meal
58455223|NCT03056677|DIETARY_SUPPLEMENT|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
58455224|NCT03056677|DIETARY_SUPPLEMENT|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
58455225|NCT06339151|DRUG|Dexamethasone before surgery|Dexamethasone 0.15 mg/kg IV before surgery
58455226|NCT06339151|DRUG|Dexamethasone before and 12 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 12 hours post operation
57758746|NCT06135311|DEVICE|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
57758747|NCT00215540|DRUG|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
57758748|NCT00215540|DRUG|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
57758749|NCT00215540|DRUG|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
57758750|NCT01817374|DIAGNOSTIC_TEST|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
57758751|NCT03745222|DRUG|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
57758752|NCT03745222|DRUG|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
57758753|NCT03745222|OTHER|Placebo|Placebo
57758754|NCT03883516|OTHER|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
57758755|NCT03883516|OTHER|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
57758756|NCT03883516|OTHER|No Pre-briefing|no instruction of the study participants prior to the simulation training
58455227|NCT06339151|DRUG|Dexamethasone before and 24 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 24 hours post operation
58455228|NCT04612725|BIOLOGICAL|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
58455229|NCT04612725|BIOLOGICAL|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
58455230|NCT04456634|DRUG|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
58455231|NCT04456634|OTHER|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
58455232|NCT02155634|DRUG|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
58455233|NCT03990896|DRUG|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
58455234|NCT04076540|DRUG|AZD4041|Administration by Oral syringe
58455235|NCT04076540|DRUG|Placebo|Administration by Oral syringe
58455236|NCT06394986|PROCEDURE|Hemodialysis session|Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
58455237|NCT03284606|DEVICE|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
58455238|NCT03284606|PROCEDURE|Common rehabilitation|Common rehabilitation for hemiplegic patients
58455239|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
58455240|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
57758757|NCT05301504|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
58455241|NCT04811742|OTHER|bathing|immerson bathing and showering
58455242|NCT04967976|PROCEDURE|TiLoop Bra mesh in expander-implant breast reconstrution|The tissue expander is inserted with TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral.
58455243|NCT04967976|PROCEDURE|sub-pectoral expander-implant breast reconstruction|The tissue expander is inserted without TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
57758758|NCT05011643|OTHER|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
57758759|NCT03737786|OTHER|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
57758760|NCT04931641|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
57758761|NCT04931641|OTHER|Maltodextrin|Maltodextrin (placebo)
58455244|NCT00416624|DRUG|darbepoetin alfa|
58455245|NCT00416624|DRUG|epoetin alfa|
57758762|NCT04931641|DIETARY_SUPPLEMENT|Ferrous fumarate|50 mg iron as ferrous fumarate
57758763|NCT01768208|DRUG|Saxagliptin|
57758764|NCT01250535|DRUG|Warfarin|10 mg, po, single dose on day 7
57758765|NCT01250535|DRUG|Placebo|po, once a day, days 1 through 14
57758766|NCT01250535|DRUG|Lovastatin|40 mg, po, once a day, days 1 through 14
57758767|NCT00312702|BIOLOGICAL|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
57758768|NCT02361125|DRUG|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
57758769|NCT02361125|BEHAVIORAL|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
57758770|NCT01424475|GENETIC|Healthy|Healthy Volunteers
57758771|NCT01424475|GENETIC|PKD Patients|PKS Patients
57758772|NCT06084559|OTHER|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
57758773|NCT06084559|OTHER|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
58455246|NCT00416624|PROCEDURE|fatigue assessment and management|
58455247|NCT00416624|PROCEDURE|quality-of-life assessment|
58455248|NCT05979948|DRUG|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
58455249|NCT05979948|DRUG|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
58455250|NCT05979948|DRUG|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
58455251|NCT02291146|BEHAVIORAL|LA Sprouts intervention|see arm 1 description
57758774|NCT03364855|OTHER|Star excursion balance test|Star excursion balance test,
57758775|NCT03364855|OTHER|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
57758776|NCT03364855|OTHER|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
57758777|NCT05517200|DIAGNOSTIC_TEST|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
57758778|NCT00409695|DRUG|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
57758779|NCT00409695|DRUG|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
57758780|NCT05673408|DEVICE|Philips IntelliVue X3 Patient Monitor|All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
57758781|NCT04332510|OTHER|Intact formula|600 ml of infant formula with intact protein
57758782|NCT04332510|OTHER|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
57758783|NCT04332510|OTHER|High protein formula|600 ml of infant formula with high protein level
57758784|NCT04332510|OTHER|Human breast milk|600 ml of breast milk, safe for human consumption
57758785|NCT00252434|BEHAVIORAL|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
57758786|NCT05490264|BIOLOGICAL|[68Ga]Ga-NOTA-SNA002|\[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
57758787|NCT03143114|PROCEDURE|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
57758788|NCT06458920|BEHAVIORAL|Social regulation|Participants will regulate emotion with the help of a friend
57758789|NCT06458920|BEHAVIORAL|Cognitive regulation|Participants will regulate emotion on their own
57758790|NCT01673763|DEVICE|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
57758791|NCT01518946|DRUG|Midodrine HCl|dose at the subject's current dose level
57758792|NCT01518946|DRUG|Placebo|single dose of matching placebo
57758793|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
57758794|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
57758795|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
57758796|NCT05518383|DRUG|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
57758797|NCT06437197|PROCEDURE|Pulpotomy|Removal of the coronal pulp chamber in an adult teeth
57758798|NCT03269994|DRUG|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
57758799|NCT03269994|DRUG|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
57758800|NCT05300971|OTHER|Heat therapy|36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
57758801|NCT05300971|OTHER|Thermoneutral water immersion|36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature \>0.2°C, and 12 weeks of follow-up.
57758802|NCT05703984|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
57758803|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
57758804|NCT05703984|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
57758805|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
57758806|NCT00176163|BEHAVIORAL|Operant behavioral treatment; Drug: THC|
57758807|NCT04829825|DIAGNOSTIC_TEST|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
57758808|NCT05937425|OTHER|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
57758809|NCT02904616|DEVICE|mobile spectrofluorimeter|
57758810|NCT02573480|BEHAVIORAL|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
57758811|NCT06186206|BEHAVIORAL|Social media interventions for vaccine uptake|"Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates."
57758812|NCT03573661|DEVICE|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
57758813|NCT01569659|DRUG|Lurasidone|80 mg/day for up to 30 weeks
57758814|NCT01569659|DRUG|Lurasidone|Up to 240 mg/day for up to 30 weeks
57758815|NCT02318043|DRUG|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
57758816|NCT05107960|DRUG|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
57758817|NCT02535364|BIOLOGICAL|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
57758818|NCT01861457|OTHER|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
57758819|NCT01861457|OTHER|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
57758820|NCT03904030|OTHER|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
57758821|NCT05446610|OTHER|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
57758822|NCT03732118|DEVICE|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
57758823|NCT02335008|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
57758824|NCT02335008|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
57758825|NCT04007458|BEHAVIORAL|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
57758826|NCT04007458|BEHAVIORAL|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
57758827|NCT03833635|OTHER|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
57758828|NCT03833635|OTHER|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
57758829|NCT05127148|OTHER|Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.|Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
57758830|NCT02150720|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
57758831|NCT02150720|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
57758832|NCT02150720|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
57758833|NCT01337986|DRUG|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
58455252|NCT05418322|BEHAVIORAL|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
58455253|NCT00646646|DRUG|propofol|sedative
58455254|NCT00646646|DRUG|dexmedetomidine|Sedative
58455255|NCT00646646|DRUG|Midazolam|sedative
58455256|NCT00646646|DRUG|saline placebo|saline placebo
57758834|NCT01337986|DRUG|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
57758835|NCT05358678|DIAGNOSTIC_TEST|cs niche group|"A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness."
57758836|NCT01633125|OTHER|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
57758837|NCT01058317|DRUG|Propranolol|Propranolol 2mg/kg divided twice daily
57758838|NCT02008591|PROCEDURE|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
57758839|NCT03943589|DRUG|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
57758840|NCT02106130|DRUG|Rebamipide|oral administration, 3 times/day
57758841|NCT02106130|DRUG|Mosapride citrate|oral administration, 3 times/day
57758842|NCT02613221|DRUG|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
57758843|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0008%|
57758844|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.001%|
57758845|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0012%|
57758846|NCT00637130|DRUG|TRAVATAN|
57758847|NCT00637130|OTHER|Vehicle|
57758848|NCT05445154|DRUG|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
57758849|NCT05505474|DEVICE|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
57758850|NCT06003465|DRUG|LY3437943|Administered SC
57758851|NCT06003465|DEVICE|Test|Used to administer LY3437943 SC
57758852|NCT06003465|DEVICE|Reference|Used to administer LY3437943 SC
57758853|NCT03633929|OTHER|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
57758854|NCT03782090|DEVICE|Endobronchial intubation|"1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
57758855|NCT02496338|OTHER|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
57758856|NCT05276167|DEVICE|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
57758857|NCT00708435|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
57758858|NCT00708435|BIOLOGICAL|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
57758859|NCT04547088|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
57758860|NCT04547088|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
57758861|NCT01991821|DRUG|APD421|
57758862|NCT01991821|DRUG|Placebo|
57758863|NCT05903222|OTHER|Non-Interventional|This study is a non-interventional study of all patients previously enrolled in the PALACS trial
57758864|NCT00402571|DRUG|acetaminophen|
57758865|NCT01755702|DRUG|Placebo|Placebo
57758866|NCT01755702|DRUG|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
57758867|NCT01755702|DRUG|ibuprofen marketed formulation|ibuprofen marketed formulation
57758868|NCT01755702|DRUG|Paracetamol marketed formulation|Paracetamol marketed formulation
57758869|NCT03009682|DRUG|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
57758870|NCT06325423|COMBINATION_PRODUCT|neoadjuvant chemotherapy|platinum-based chemotherapy before radical cystectomy or bladder preservation
57758871|NCT03707639|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
57758872|NCT03707639|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
57758873|NCT02914808|OTHER|Patients will undergo a lower limb MRI and blood tests|
57758874|NCT04209413|PROCEDURE|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
57758875|NCT04446897|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
57758876|NCT04446897|OTHER|standard treatment|standard treatment according to clinical protocols
57758877|NCT00493077|DRUG|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
57758878|NCT05365243|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
57758879|NCT01127880|DRUG|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
57758880|NCT01127880|DRUG|Placebo|.9% Normal Saline as a placebo
57758881|NCT01478009|DIETARY_SUPPLEMENT|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
57758882|NCT01478009|DIETARY_SUPPLEMENT|Placebo|Placebo (3.0g/day) for 12 weeks
57758883|NCT02259504|OTHER|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
57758884|NCT02259504|OTHER|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
57758885|NCT01105702|DRUG|Temozolomide|
57758886|NCT01105702|DRUG|Bevacizumab|
57758887|NCT01105702|DRUG|Lithium Carbonate|
57758888|NCT01105702|RADIATION|Radiation|
57758889|NCT02601534|BEHAVIORAL|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
57758890|NCT02601534|BEHAVIORAL|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
57758891|NCT04128293|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
57758892|NCT04128293|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
57758893|NCT02307201|DRUG|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
57758894|NCT00530803|DRUG|EMLA Cream|60 minutes x1
57758895|NCT00530803|COMBINATION_PRODUCT|Synera Patch|20 minutes x1
57758896|NCT03962244|DEVICE|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
58128789|NCT04641559|OTHER|Personalized nutrition group|"A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI."
58455257|NCT04164134|OTHER|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
57758897|NCT03962244|DEVICE|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
57758898|NCT04612946|BEHAVIORAL|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
57758899|NCT04612946|BEHAVIORAL|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
57758900|NCT04190628|DRUG|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
57758901|NCT04190628|DRUG|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
57758902|NCT02020525|PROCEDURE|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
57758903|NCT02020525|PROCEDURE|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
57758904|NCT02124889|BEHAVIORAL|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
57758905|NCT00000844|DRUG|Interferon alfa-n3|
57758906|NCT00000844|DRUG|Interferon alfa-n1|
57758907|NCT01432496|DRUG|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
57758908|NCT01432496|DRUG|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
57758909|NCT03326960|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
57758910|NCT03326960|DRUG|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
57758911|NCT03326960|DRUG|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
57758912|NCT01925625|BIOLOGICAL|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
57758913|NCT04581421|OTHER|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
57758914|NCT04581421|OTHER|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
57758915|NCT05993702|DRUG|regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
57758916|NCT05993702|DRUG|fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; or Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
57758917|NCT04449848|OTHER|Sitting after intra tympanic injection|Sitting after intra tympanic injection
57758918|NCT00524030|DRUG|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
57758919|NCT00524030|DRUG|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
58128790|NCT04641559|OTHER|Personalized Plan group|Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
58455258|NCT05549817|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
58455259|NCT05549817|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
58455260|NCT04809012|BIOLOGICAL|STI-3031|STI-3031 is an anti-PD-L1 antibody
58455261|NCT03089021|OTHER|mulligan mobilization|mobilization with movement for spinous process or facet joint.
58455262|NCT03089021|OTHER|maitland mobilization|posterioanterior of spinous process or facet joint.
58455263|NCT03291938|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
58455264|NCT03291938|OTHER|Pharmacodynamic Study|Correlative studies
58455265|NCT03291938|OTHER|Pharmacokinetic Study|Correlative studies
58455266|NCT05976516|DIAGNOSTIC_TEST|CXCL2/CXCL8|Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
58455267|NCT06401369|PROCEDURE|Lingual brackets|These brackets will be used on the lingual surfaces of the upper and lower teeth.
57758920|NCT01965379|OTHER|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
57758921|NCT01965379|OTHER|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
57758922|NCT05041153|DRUG|Lenvatinib|Given by PO
57758923|NCT05041153|BIOLOGICAL|Pembrolizumab|Given by IV
57758924|NCT04186845|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
57758925|NCT03749122|PROCEDURE|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
57758926|NCT01677364|DRUG|Oxytocin|Arm - Induction of labour
57758927|NCT00829335|PROCEDURE|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
57758928|NCT03761537|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
57758929|NCT03761537|OTHER|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
57769774|NCT06319768|DRUG|Pentoxifylline|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
58455268|NCT06401369|PROCEDURE|Buccal brackets|These brackets will be used on the vestibular surfaces of the upper and lower teeth.
57758930|NCT02769234|PROCEDURE|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
57758931|NCT02769234|PROCEDURE|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
57758932|NCT05558865|BEHAVIORAL|somnovia|Participants receive access to the digital health application somnovia
58455269|NCT00154856|BEHAVIORAL|Detect the variation of limb lengthening|
58455270|NCT03947710|OTHER|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
58455271|NCT03947710|OTHER|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
57758933|NCT05509725|DRUG|Probiotic formulation|Participants will be asked to take 2 doses daily
57758934|NCT05509725|DRUG|Placebo|Participants will be asked to take 2 doses daily
57758935|NCT03171480|DRUG|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
57758936|NCT03171480|DRUG|Placebo|The pharmacy has compounded an identical appearing placebo
57758937|NCT04963374|OTHER|risk evolution scale|Padua score、Caprini score、Prime score
57758938|NCT06191809|PROCEDURE|Controlled Ovarian Stimulation Protocol|"Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos."
57758939|NCT02595216|DEVICE|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
57758940|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
57758941|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
57758942|NCT01712009|DRUG|Naproxen|
57758943|NCT01712009|DRUG|Loratadine|
57758944|NCT01712009|BIOLOGICAL|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
57758945|NCT01712009|DRUG|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
57758946|NCT02991482|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
57758947|NCT02991482|DRUG|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
57758948|NCT02991482|DRUG|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
57758949|NCT01645748|DRUG|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
57758950|NCT01645748|DRUG|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
57758951|NCT01645748|DRUG|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
57960925|NCT05812989|BEHAVIORAL|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
58455272|NCT03947710|OTHER|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
57758952|NCT03665844|DEVICE|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
57758953|NCT03665844|DEVICE|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
57758954|NCT02380443|BIOLOGICAL|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
57758955|NCT02380443|PROCEDURE|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
57758956|NCT01900262|OTHER|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
57758957|NCT01900262|OTHER|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
57758958|NCT01900262|OTHER|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
57758959|NCT02515565|DRUG|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
57758960|NCT02515565|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
57758961|NCT03519750|DRUG|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
57758962|NCT01787097|DRUG|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
57758963|NCT01787097|DRUG|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
57758964|NCT01787097|DRUG|Formoterol 24ug|Turbuhaler
57758965|NCT01787097|DRUG|BUD total dose 800ug|Turbuhaler
57758966|NCT05276232|DRUG|Cannabis(THC) inhaled|Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
57758967|NCT05279456|BIOLOGICAL|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
57758968|NCT03651102|DRUG|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
57758969|NCT00642837|DRUG|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
57758970|NCT00642837|DRUG|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
57758971|NCT00642837|DRUG|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
57758972|NCT00642837|DRUG|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
57758973|NCT00642837|DRUG|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
57758974|NCT00642837|DRUG|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
57758975|NCT00642837|DRUG|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
57758976|NCT00642837|DRUG|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
57758977|NCT00642837|DRUG|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
57758978|NCT00642837|DRUG|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
58455273|NCT01894607|PROCEDURE|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
57758979|NCT01969422|PROCEDURE|observation|intervention is the contact with online question answering serice ad subseudd
58128791|NCT04641559|OTHER|Control group|The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
58128792|NCT04574193|DEVICE|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
57758980|NCT03122119|DRUG|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
57758981|NCT00177203|BEHAVIORAL|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
57758982|NCT05751174|OTHER|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
57758983|NCT05542810|COMBINATION_PRODUCT|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
57758984|NCT03515382|DRUG|GLPG1690|A single oral dose of GLPG1690.
58455274|NCT01894607|DRUG|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
57758985|NCT03515382|DRUG|Itraconazole|A single oral dose of itraconazole.
57758986|NCT03515382|DRUG|Voriconazole|A single oral dose of voriconazole.
57758987|NCT00998907|DEVICE|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
57758988|NCT00998907|DEVICE|PDS II|polyglactin 910 suture material for abdominal wall closure
57758989|NCT05780814|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
57758990|NCT05780814|BEHAVIORAL|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
57758991|NCT00998400|BEHAVIORAL|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
57758992|NCT05476055|GENETIC|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
57758993|NCT06072222|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
57758994|NCT06072222|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
57758995|NCT06072222|DEVICE|ventilator|ventilator
57758996|NCT04077957|DRUG|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
57758997|NCT04077957|DRUG|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
57758998|NCT04077957|DRUG|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
57758999|NCT04077957|DRUG|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
57759000|NCT04077957|DRUG|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
57759001|NCT04077957|DRUG|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
57759002|NCT00003884|DRUG|zoledronic acid|
57759003|NCT00003884|PROCEDURE|quality-of-life assessment|
57759004|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
57759005|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
58455275|NCT01894607|BEHAVIORAL|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
57759006|NCT03447080|OTHER|Ricebran soybean milk|White Bread with rice bran soybean milk
57759007|NCT03447080|OTHER|Soybean milk|White Bread with soybean milk
57759008|NCT00159705|DRUG|pregabalin|
58455276|NCT03395483|OTHER|Haemodynamic monitoring|see Group description
58455277|NCT02090426|OTHER|Link2Care|
58455278|NCT01788566|DRUG|Necitumumab|Administered IV
58455279|NCT01788566|DRUG|Gemcitabine|Administered IV
58455280|NCT01788566|DRUG|Cisplatin|Administered IV
58455281|NCT01068522|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
57759009|NCT02614443|OTHER|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
57759010|NCT02614443|OTHER|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
57759011|NCT02614443|OTHER|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
57759012|NCT05497713|OTHER|Mindsets|The primary objective of this trial is to determine whether mindsets sustain the feasibility of taking cold showers over a 3-month period.
57960926|NCT05112783|DEVICE|Henan Tuoren Endotracheal Tube|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
57960927|NCT05112783|DEVICE|Smiths Portex Tracheal Tubes|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
58128793|NCT04574193|OTHER|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
58455282|NCT01068522|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
57759013|NCT05375123|DEVICE|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
57759014|NCT02493400|OTHER|No intervention in the follow up study.|
57759015|NCT00242528|DRUG|Zoledronic acid|
57759016|NCT05388058|DRUG|Cannabidiol|Applied topically
57759017|NCT05388058|DRUG|Placebo Administration|Applied topically
57759018|NCT05388058|OTHER|Quality-of-Life Assessment|Ancillary studies
57759019|NCT05388058|OTHER|Questionnaire Administration|Ancillary studies
57759020|NCT03760601|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
57759021|NCT06379191|BEHAVIORAL|Nutrition intervention model based on WeChat applets|"We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group."
57759022|NCT02907814|DEVICE|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
57759023|NCT02907814|OTHER|Eye Exam|This is a brief, non-contact ocular exam.
57759024|NCT03060798|DRUG|Desflurane|general anesthesia using desflurane.
57759025|NCT03060798|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
57759026|NCT01696448|DIETARY_SUPPLEMENT|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
57759027|NCT01696448|OTHER|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
57759028|NCT00006002|DRUG|dexamethasone|
57759029|NCT00006002|DRUG|semaxanib|
57759030|NCT05227755|DIETARY_SUPPLEMENT|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
57759031|NCT05227755|DIETARY_SUPPLEMENT|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
57759032|NCT00483834|DRUG|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
57759033|NCT00483834|DRUG|Irinotecan|200mg/m\^2, IV, day 1 each cycle
57759034|NCT00483834|DRUG|Capecitabine|1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
57759035|NCT06447350|BEHAVIORAL|Induced hypocrisy|Induced hypocrisy task
57759036|NCT06447350|BEHAVIORAL|social identity mapping|Social identity mapping task
57759037|NCT06447350|BEHAVIORAL|Motivational modeling|Motivational modeling task
57759038|NCT06447350|BEHAVIORAL|motivational interviewing|motivational interviewing
57759039|NCT03727009|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
57759040|NCT00695786|DRUG|Lenalidomide|Given PO
58455283|NCT01250106|DIETARY_SUPPLEMENT|Lactobacillus reuteri|twice daily
58455284|NCT03016572|BEHAVIORAL|Standard of Care|Follow-Up Calls, Questionnaires
57759041|NCT00695786|BIOLOGICAL|Rituximab|Given IV
57759042|NCT04458623|DIAGNOSTIC_TEST|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
57759043|NCT04496999|DRUG|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
57759044|NCT04496999|DRUG|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
57759045|NCT04274270|DRUG|Endostar|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
57759046|NCT03631225|DIAGNOSTIC_TEST|Vectra|Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
57759047|NCT02178059|DRUG|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
57759048|NCT02178059|DRUG|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
57759049|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: fortified spread|Provision of fortified spread
57759050|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
57759051|NCT05073042|BEHAVIORAL|Morning exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.
57759052|NCT05073042|BEHAVIORAL|Evening exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
57759053|NCT05073042|BEHAVIORAL|Time of choice exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
57759054|NCT04760522|GENETIC|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
57759055|NCT01013610|DRUG|LNK-754|Escalating dose
57759056|NCT01013610|DRUG|Placebo|Escalating dose
57759057|NCT04732052|DEVICE|Transcranial Direct Current Stimulation|non-invasive brain stimulator
57759058|NCT03215901|BEHAVIORAL|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
57759059|NCT03215901|BEHAVIORAL|Active Control Video|Video on another topic.
57759060|NCT01064908|DEVICE|OxyMask|Novel vortex oxygen delivery mask
57759061|NCT00375362|DRUG|Nitroderm patch|
57759062|NCT01522534|DRUG|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
57759063|NCT01522534|DRUG|Morphine|Morphine alone with a placebo nerve block
57759064|NCT01373632|DEVICE|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
57759065|NCT01373632|DEVICE|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
57759066|NCT01976065|DRUG|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
57759067|NCT01976065|OTHER|Standard Treatment|Standard Treatment no use of study drug
57759068|NCT01238640|DRUG|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
57759069|NCT01238640|DRUG|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
57759070|NCT01238640|DRUG|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
57759071|NCT01724645|DIETARY_SUPPLEMENT|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
57759072|NCT01724645|DIETARY_SUPPLEMENT|Control group|"Told to  eat as usal diets."
57759073|NCT02465502|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
57759074|NCT03234153|DRUG|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
57759075|NCT03234153|DRUG|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
57759076|NCT03996408|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
57759077|NCT03996408|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
57759078|NCT00317889|PROCEDURE|Bone preparation technique: compaction|
57759079|NCT00317889|PROCEDURE|Bone preparation technique: broaching|
57759080|NCT05154123|DRUG|Drug: AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered."
57759081|NCT05154123|DRUG|AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)"
57759082|NCT02707458|DRUG|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
57759083|NCT03391765|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
57759084|NCT03391765|DRUG|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
57759085|NCT04770064|DRUG|High-dose/short-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
57759086|NCT04770064|DRUG|Low-dose/sustained-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
57759087|NCT04770064|OTHER|Oral placebo capsule|Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
57759088|NCT06184243|BEHAVIORAL|Parent Training|Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
57759089|NCT06184243|BEHAVIORAL|Video Modeling|The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
57759090|NCT01299155|DEVICE|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
57759091|NCT01299155|DEVICE|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
57759092|NCT05386667|DRUG|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
57759093|NCT05386667|OTHER|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
57759094|NCT05386667|OTHER|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
57759095|NCT05386667|PROCEDURE|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
57759096|NCT04461743|OTHER|No intervention|No intervention, regular therapy
57759097|NCT05982665|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 300 ml/min.
57759098|NCT05982665|OTHER|Placebo|Ambient air, flow rate 300 ml/min.
57759099|NCT02415699|DRUG|Fluorouracil|
57759100|NCT02415699|DRUG|Oxaliplatin|
57759101|NCT02415699|DRUG|Leucovorin|
57759102|NCT02415699|BIOLOGICAL|DC-CIK|
57759103|NCT02240108|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
57759104|NCT02240108|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
57759105|NCT05404425|PROCEDURE|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
57759106|NCT05404425|PROCEDURE|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
57759107|NCT02668016|DRUG|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
57759108|NCT02668016|OTHER|Placebo|Placebo tablets taken orally once daily for one month
57759109|NCT02206490|DRUG|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
57759110|NCT02206490|DRUG|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
57759111|NCT02857426|DRUG|Nivolumab|
57759112|NCT03916744|DRUG|Giredestrant|Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
57759113|NCT03916744|PROCEDURE|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
57759114|NCT01646190|DIETARY_SUPPLEMENT|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
57759115|NCT01646190|PROCEDURE|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
57759116|NCT01646190|BEHAVIORAL|Fasting state after midnight|No preoperative glucose load
57759117|NCT01646190|BEHAVIORAL|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
57759118|NCT01646190|BEHAVIORAL|urinary catheter removal|at POD 1
57759119|NCT01646190|BEHAVIORAL|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
57759120|NCT01646190|BEHAVIORAL|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
57759121|NCT01646190|BEHAVIORAL|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), \>4h out of bed on POD1, \>6h on POD2, complete at POD3
58455285|NCT03016572|BEHAVIORAL|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
58455286|NCT03016572|BEHAVIORAL|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
58455287|NCT02462148|DRUG|Dexamethasone|Used in nerve block mixture
58455288|NCT02462148|DRUG|Bupivacaine|Used in nerve block mixture
58455289|NCT02462148|DRUG|Epinephrine|Used in nerve block mixture
57759122|NCT01646190|OTHER|Preanesthetic medication|Preanesthetic oral medication before surgery
57759123|NCT04491812|OTHER|Kinesio Tape|Elastic Kinesiology Tape
57759124|NCT04491812|OTHER|Physical therapy program|designed physical therapy program
57759125|NCT05810207|PROCEDURE|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
57759126|NCT04119453|DRUG|Rivoceranib|Film-coated tablets
57759127|NCT01271569|DRUG|Fospropofol disodium|Fospropofol disodium： 0.5g
57759128|NCT02596126|DRUG|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
57759129|NCT02596126|DRUG|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
57759130|NCT00622180|DEVICE|NBUVB|NBUVB hand foot box
57759131|NCT00622180|DEVICE|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
57759132|NCT01939886|DRUG|Mefloquine - Artesunate|
57759133|NCT01939886|DRUG|Artemether-lumefantrine combination|
57759134|NCT02034825|OTHER|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
57759135|NCT03674554|PROCEDURE|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
57759136|NCT03674554|PROCEDURE|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
57759137|NCT03161457|BIOLOGICAL|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
57759138|NCT03161457|BIOLOGICAL|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
57759139|NCT02450630|BEHAVIORAL|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
57759140|NCT05305014|DIAGNOSTIC_TEST|blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)|Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
57759141|NCT04336748|DRUG|Hydroxychloroquine|low dose (200mg) Hydroxychloroquine once daily for 4 weeks
57759142|NCT04336748|DRUG|Placebo|Placebo
57759143|NCT05210829|DIAGNOSTIC_TEST|stationary and trait anxiety scale|survey
57759144|NCT00714922|PROCEDURE|PRK|Laser refractive surgery
57759145|NCT00714922|PROCEDURE|SBK|Laser refractive surgery
58455290|NCT02462148|PROCEDURE|Saphenous Peripheral Nerve Block|Peripheral nerve block.
57759146|NCT00593125|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
57759147|NCT04829721|OTHER|Educational Intervention with video|Women randomized to an educational video workshop group.
57759148|NCT01605760|DRUG|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
58455291|NCT01233596|DEVICE|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
58455292|NCT00760682|PROCEDURE|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
58455293|NCT04064658|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
57759149|NCT00168545|BIOLOGICAL|Measles vaccine|
57759150|NCT01919970|OTHER|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
57759151|NCT01919970|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
57759152|NCT03454165|COMBINATION_PRODUCT|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
57759153|NCT03454165|COMBINATION_PRODUCT|Ibrutinib|A novel BTK inhibitor.
57759154|NCT01468441|DRUG|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
57759155|NCT01468441|DRUG|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
58455294|NCT04064658|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
57759156|NCT02597465|DRUG|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
58455295|NCT04064658|PROCEDURE|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
57759157|NCT02597465|DRUG|Reference1507|Investigators choice including chemotherapy or supportive therapy
57759158|NCT03737084|BEHAVIORAL|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
57759159|NCT05885659|OTHER|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
58128794|NCT03709862|DIAGNOSTIC_TEST|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
58128795|NCT04021069|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
58455296|NCT04496739|BEHAVIORAL|Cancer Educational Materials|Receive educational materials about breast cancer risk and chemoprevention via RealRisk
58455297|NCT04496739|OTHER|Decision Aid|Given patient-centered decision support via an action plan
58455298|NCT04496739|OTHER|Decision Aid|Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
58455299|NCT04496739|OTHER|Interview|Participate in audio-recorded interview via telephone or video conference
58455300|NCT04496739|OTHER|Questionnaire Administration|Ancillary studies
58455301|NCT02152826|DEVICE|Potassium oxalate|Professional application
57759160|NCT05885659|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
57759161|NCT05885659|BEHAVIORAL|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
57759162|NCT00133757|DRUG|Bupropion SR|
57759163|NCT03364348|DRUG|Utomilumab|Given IV
57759164|NCT03364348|DRUG|Trastuzumab|Given IV
57759165|NCT03364348|DRUG|Ado-Trastuzumab Emtansine|Given IV
57759166|NCT04032535|DRUG|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
57759167|NCT05966402|OTHER|Virtual Reality|Immersion in Virtual Reality
57759168|NCT02723058|BEHAVIORAL|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
57759169|NCT03119727|DEVICE|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
57759170|NCT05865613|DEVICE|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
57759171|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
57759172|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
57759173|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, \<= 4 mg, Once daily, 7 days
57759174|NCT00836602|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
58128796|NCT03958032|OTHER|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
58455302|NCT03952013|OTHER|To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure|All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
57759175|NCT01888211|DIETARY_SUPPLEMENT|Omega 3 fatty acid supplementation|2 grams Omacor daily
57759176|NCT01888211|DIETARY_SUPPLEMENT|Olive Oil|2 grams olive oil daily
57759177|NCT00838799|DRUG|RGH-896|45 mg TID, capsules, 14 weeks.
57759178|NCT00838799|DRUG|RGH-896|30 mg TID, capsules, 14 weeks.
58128797|NCT01315249|DRUG|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
57759179|NCT00838799|DRUG|RGH-896|15 mg TID, capsules, 14 weeks.
57759180|NCT00838799|DRUG|pregabalin|100 mg, TID, capsules, 14 weeks.
58128798|NCT01315249|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
58455303|NCT04268082|DEVICE|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
57759181|NCT00838799|DRUG|placebo|TID, capsules, 14 weeks.
57759182|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
57759183|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
57759184|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
57759185|NCT00642902|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
57759186|NCT01807650|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
57759187|NCT01807650|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
58128799|NCT01315249|DRUG|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
58455304|NCT04268082|OTHER|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
58455305|NCT04098523|DIAGNOSTIC_TEST|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
58455306|NCT01917747|BEHAVIORAL|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
58455307|NCT01917747|BEHAVIORAL|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
58455308|NCT03748966|DRUG|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
58455309|NCT06239740|PROCEDURE|Electroacupuncture group|The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.
58455310|NCT06239740|PROCEDURE|Sham acupuncture|participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
58455311|NCT06443372|OTHER|Clinical periodontal measurements, GCF sampling|"Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
58455312|NCT03693521|DEVICE|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
58455313|NCT03693521|OTHER|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
58455314|NCT00141102|DRUG|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
58455315|NCT00141102|DRUG|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
58455316|NCT02840708|DRUG|Sargramostim|
58455317|NCT03991845|DRUG|Vit D|Vit D supplementation was done
58455318|NCT04844736|PROCEDURE|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
58455319|NCT00900510|PROCEDURE|Incision and drainage|
58455320|NCT00900510|DRUG|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
58455321|NCT00900510|DRUG|Placebo|
58455322|NCT00833040|DRUG|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
58455323|NCT00420576|DRUG|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
58455324|NCT00314730|DEVICE|handheld Personal Digital Assistant (PDA)|
58455325|NCT02122679|DRUG|Tranexamic Acid|
58455326|NCT02122679|DRUG|placebo|
58128800|NCT01315249|DRUG|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
58455327|NCT03402802|DRUG|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
58455328|NCT00730158|DRUG|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
58455329|NCT00730158|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
58455330|NCT00730158|DRUG|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
58455331|NCT01915160|BEHAVIORAL|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
58455332|NCT01915160|BEHAVIORAL|TF-CBT|Treatment as usual.
57759188|NCT06071065|BEHAVIORAL|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
57759189|NCT04473690|BIOLOGICAL|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
57759190|NCT04473690|BIOLOGICAL|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
57759191|NCT04473690|BIOLOGICAL|Placebo|Buffered saline solution
57759192|NCT00571766|DRUG|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
57759193|NCT00571766|DRUG|Placebo|Placebo 2 g twice a day for 14 weeks
57759194|NCT01253863|OTHER|exploration|exploration of wound for determining damaged tissue
57759195|NCT04362163|DEVICE|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
57759196|NCT02452086|DEVICE|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
57759197|NCT02452086|PROCEDURE|Placebo|LLLT with zero intensity
57759198|NCT01331460|BEHAVIORAL|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
57759199|NCT01331460|OTHER|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
57759200|NCT01856712|DRUG|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
57759201|NCT00677443|DRUG|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
57759202|NCT00677443|DRUG|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
57759203|NCT04361344|BIOLOGICAL|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
57759204|NCT04069130|DRUG|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
57759205|NCT03156933|OTHER|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
57759206|NCT00385411|DRUG|valproate microgranules|20 to 30 mg/kg/day
57759207|NCT01840553|DRUG|oral sodium phosphate tablets|
57759208|NCT01840553|DRUG|polyethylene glycol|
57759209|NCT00097643|BEHAVIORAL|exercise|
57759210|NCT00097643|BEHAVIORAL|health promotion|
57759211|NCT02691182|DRUG|SPN-810|
57759212|NCT00070135|BIOLOGICAL|filgrastim|Given SC
57759213|NCT00070135|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
57759214|NCT00070135|DRUG|busulfan|Given IV
57759215|NCT00070135|DRUG|fludarabine phosphate|Given IV
57759216|NCT00070135|DRUG|methotrexate|Given IV
57759217|NCT00070135|DRUG|tacrolimus|Given PO or IV
57759218|NCT00070135|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
57759219|NCT00237939|DRUG|Aripiprazole|
57759220|NCT05343338|DRUG|Sivelestat sodium|After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
57759221|NCT02426723|DRUG|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
57759222|NCT02426723|DRUG|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
57759223|NCT02826967|PROCEDURE|Colonic Irrigation|
57759224|NCT00916461|DRUG|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
57759225|NCT00916461|DRUG|Placebo|Placebo + treatment as usual.
57759226|NCT04894734|DEVICE|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
57759227|NCT04894734|DEVICE|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
57759228|NCT02621346|BEHAVIORAL|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
57759229|NCT02621346|BEHAVIORAL|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
57759230|NCT02621346|BEHAVIORAL|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
57759231|NCT05096208|BIOLOGICAL|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
57759232|NCT05096208|BIOLOGICAL|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
57759233|NCT05096208|BIOLOGICAL|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
57759234|NCT05096208|BIOLOGICAL|Placebo|Placebo
57759235|NCT05064826|OTHER|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
57759236|NCT01184599|DRUG|aliskiren|150 mg/day p.o.
57759237|NCT01253525|BIOLOGICAL|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
57759238|NCT01253525|DRUG|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
57759239|NCT01209637|BEHAVIORAL|exercise training|exercise training min. 4 times a day for at least 30 min
57759240|NCT01209637|BEHAVIORAL|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
57759241|NCT01440686|DRUG|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
57759242|NCT01440686|DRUG|Placebo|Tablets, oral administrations
57759243|NCT06127576|DEVICE|paraboloid geometry double and triple dental abutment-implant|"The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made."
57759244|NCT03746054|COMBINATION_PRODUCT|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
57759245|NCT03746054|COMBINATION_PRODUCT|usual clinical practice|usual clinical practice in each center
57759246|NCT06521164|DEVICE|Haermonics Pure system|pericardial flushing with Haermonics Pure system
57759247|NCT01936896|DRUG|Alpha 1-Antitrypsin|
57759248|NCT02030730|BEHAVIORAL|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
57759249|NCT01041014|BEHAVIORAL|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
57759250|NCT03954743|BIOLOGICAL|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
57759251|NCT03954743|BIOLOGICAL|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
57759252|NCT05908214|OTHER|wide pulse high frequency neuromuscular electrical stimulation training|Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
57759253|NCT04444648|COMBINATION_PRODUCT|No intervention|No intervention
57759254|NCT00691808|DRUG|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
57759255|NCT00691808|DRUG|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
57759256|NCT00691808|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
57759257|NCT04043962|BEHAVIORAL|Web-based CBT (Web-MAP)|see arm description
57759258|NCT05306093|DIETARY_SUPPLEMENT|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
57759259|NCT05306093|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
57759260|NCT03437395|DEVICE|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
57759261|NCT03437395|RADIATION|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
57759262|NCT02084537|PROCEDURE|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
57759263|NCT02084537|PROCEDURE|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
57759264|NCT04580563|DRUG|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
57759265|NCT04580563|DRUG|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
57759266|NCT04603976|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
57759267|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
57759268|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
57759269|NCT03921190|PROCEDURE|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
57759270|NCT04210414|OTHER|Embryo transfer|Transfer of only one embryo
57759271|NCT00027924|DRUG|busulfan|
57759272|NCT00027924|DRUG|cyclosporine|
57759273|NCT00027924|DRUG|fludarabine phosphate|
57759274|NCT00027924|DRUG|methotrexate|
57759275|NCT00027924|PROCEDURE|peripheral blood stem cell transplantation|
57759276|NCT00514943|DRUG|BIBW 2992|experimental drug taken once daily orally
57759277|NCT00514943|DRUG|Cetuximab|active comparator administered weekly intravenously
57759278|NCT03725839|DEVICE|F&P Interface|F\&P Interface to be used for OSA therapy
57759279|NCT04709601|DRUG|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
57759280|NCT02643576|BEHAVIORAL|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
58455333|NCT05754723|BEHAVIORAL|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
58455334|NCT02798393|OTHER|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
57759281|NCT02643576|BEHAVIORAL|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
57759282|NCT02643576|BEHAVIORAL|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
57759283|NCT02767583|DEVICE|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
57759284|NCT02401464|DRUG|TAK-536 Tablet|TAK-536 10 mg tablet
57759285|NCT02401464|DRUG|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
57759286|NCT02401464|DRUG|TAK-536 Ganule Formulation|TAK-536 granule formulation
57759287|NCT06624696|DRUG|Penehyclidine hydrochloride|The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
57759288|NCT06624696|DRUG|Normal Saline|The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
57759289|NCT04396002|DIAGNOSTIC_TEST|Life Space Questionnaire|This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
57759290|NCT04396002|DIAGNOSTIC_TEST|Low Luminance Questionnaire|This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
58455335|NCT02798393|OTHER|Sham|
57759291|NCT04396002|DIAGNOSTIC_TEST|Contrast sensitivity under dim illumination|Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
57759292|NCT04396002|DIAGNOSTIC_TEST|Visual field under dim illumination (MAIA)|Sensitivity in the central visual area will be assessed under dim illumination
57759293|NCT04396002|DIAGNOSTIC_TEST|Macular Pigment Optical Density (MPOD)|Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
57759294|NCT04396002|DIAGNOSTIC_TEST|Dark Adaptation|After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
57759295|NCT00294099|BIOLOGICAL|Aluminum hydroxide|Aluminum hydroxide adjuvant.
57759296|NCT00294099|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
57759297|NCT04235790|DEVICE|Eye Tracking Device|Eye tracking glasses
57759298|NCT00187915|DRUG|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
57759299|NCT00187915|DRUG|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
57759300|NCT04876794|DEVICE|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
57759301|NCT02243644|DRUG|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
57759302|NCT02243644|DRUG|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
57759303|NCT04073810|DIAGNOSTIC_TEST|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
57759304|NCT04073810|DIAGNOSTIC_TEST|Coronary CT angiography|CTCA at baseline and 2 years
57759305|NCT04073810|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
57759306|NCT00106132|DRUG|Triamcinolone Acetonide|
58455336|NCT05353322|BEHAVIORAL|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
58455337|NCT05353322|BEHAVIORAL|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
58455338|NCT05353322|BEHAVIORAL|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
58455339|NCT05787340|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation.
57759307|NCT01438125|OTHER|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
57759308|NCT01438125|OTHER|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
57759309|NCT01322789|BIOLOGICAL|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
57759310|NCT05600049|DEVICE|Prototypes (815-v1 001) to (815-v1 050)|"Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
57759311|NCT05600049|DEVICE|Prototype (815-v1 051) to (815-v1 100)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
57759312|NCT05600049|DEVICE|Prototypes (815-v1 101) to (815-v1 150)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
57759313|NCT05600049|DEVICE|Prototypes (815-v1 151) to (815-v1 200)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
57759314|NCT05254639|DRUG|DONEPEZIL|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
57759315|NCT05254639|DRUG|PLACEBO|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
57759316|NCT00861601|DRUG|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
57759317|NCT00861601|DRUG|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
57759318|NCT01839422|BEHAVIORAL|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
57759319|NCT01839422|OTHER|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
57759320|NCT03057743|DEVICE|Positron emission tomography (PET/CT) imaging|
57759321|NCT03057743|DEVICE|radiotracer [18F]ISO-1|
57759322|NCT04197648|DEVICE|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
57759323|NCT02716337|DIETARY_SUPPLEMENT|Addition of human milk fortifiers according to human milk analysis|
57759324|NCT05259787|DRUG|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
57759325|NCT05259787|DRUG|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
57759326|NCT00291759|DRUG|Tamoxifen|
57759327|NCT00291759|DRUG|Anastrozole|
57759328|NCT05976425|DEVICE|ModPG3 Investigational Device|"* Connex Vital Sign Monitor with ModPG3~* Laptop~* Data Collection Software~* USB cable~* Power strip~* Welch Allyn FlexiPort Disposable Blood Pressure Cuffs"
57759329|NCT05976425|DEVICE|Invasive Reference Equipment|"* Surveyor S12/S19~* Hill-Rom ICU Medical data collection cable DIR 60119852~* Hill-Rom Edwards data collection cable DIR 60119853"
58455340|NCT02899936|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
57759330|NCT02041689|BEHAVIORAL|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
57759331|NCT02041689|BEHAVIORAL|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
57759332|NCT02041689|BEHAVIORAL|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
57759333|NCT05965063|DIETARY_SUPPLEMENT|Bifidobacterium M-16V|Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.
57759334|NCT05965063|OTHER|allergy food avoidance|strict avoidance of the specific allergenic food
57759335|NCT05655026|DEVICE|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
57759336|NCT03266614|BEHAVIORAL|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
57759337|NCT06255015|DEVICE|Breastfeeding toolkit card|The card is delivered at 24 weeks and is also referred to in the 32 and 36 week antenatal meetings. It will also be referred to in the first 24 hours post-partum and in home visits.
57759338|NCT00768430|DRUG|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
57759339|NCT00768430|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
57759340|NCT04243070|DIAGNOSTIC_TEST|3-channel Holter ECG recording|3-channel Holter ECG recording for patients undergoing an EPS
57759341|NCT04243070|DIAGNOSTIC_TEST|12-channel Holter ECG recording|12-channel Holter ECG recording for patients undergoing a routine follow-up
57759342|NCT01609816|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
57759343|NCT01533363|PROCEDURE|Stapled hemorrhoidopexy|
57759344|NCT01533363|PROCEDURE|Milligan Morgan|
57759345|NCT01720732|BEHAVIORAL|Lifeline NET|Short Version of Narrative Exposure Therapy
57759346|NCT01909414|BIOLOGICAL|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
57759347|NCT01909414|BIOLOGICAL|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.
57759348|NCT01909414|BIOLOGICAL|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
57759349|NCT01909414|BIOLOGICAL|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
57759350|NCT05927025|PROCEDURE|Hand K-files|It is used for cleaning and shaping root canals.
58455341|NCT02899936|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
57759351|NCT02768454|DRUG|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
57759352|NCT05297890|DRUG|Lorlatinib|Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
58455342|NCT05157295|DRUG|OnabotulinumtoxinA|100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
57759353|NCT03249506|DRUG|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
58455343|NCT01412177|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
58455344|NCT01412177|DRUG|Placebo|Single intratympanic injection of placebo
57759354|NCT03249506|DRUG|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
57759355|NCT03249506|DRUG|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
57759356|NCT03249506|DRUG|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
58455345|NCT05817565|DEVICE|Ultrasound (Phyaction 190 I); with a frequency of 3 MHz was used|Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position.
58455346|NCT01758809|PROCEDURE|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
58455347|NCT01758809|PROCEDURE|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
58455348|NCT02754570|DRUG|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
57759357|NCT03249506|DRUG|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
57759358|NCT03249506|DRUG|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
57759359|NCT03249506|DRUG|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
57759360|NCT03249506|DRUG|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
57759361|NCT03021577|DEVICE|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
57759362|NCT03021577|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
57759363|NCT03021577|PROCEDURE|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
57759364|NCT05917301|RADIATION|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
57759365|NCT01396317|DRUG|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
57759366|NCT02092558|DRUG|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
57759367|NCT02092558|DRUG|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
57759368|NCT04567511|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
57759369|NCT04576364|DRUG|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
57759370|NCT04576364|DRUG|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
57759371|NCT01665339|OTHER|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
57759372|NCT01665339|OTHER|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
57759373|NCT05458375|DRUG|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
57759374|NCT06374940|PROCEDURE|Manipulator-assisted Abdominal Hysterectomy|Manipulator-assisted Abdominal Hysterectomy
57759375|NCT02871960|PROCEDURE|Robotic and Laparoscopic Colectomy|
57759376|NCT03265054|BIOLOGICAL|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
58455349|NCT03066869|DRUG|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
57759377|NCT01704469|PROCEDURE|The local anesthetic injection|
57759378|NCT00782496|DEVICE|Education + new meter|Diabetes education and a new meter with basic features
58455350|NCT05167435|OTHER|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
58455351|NCT05167435|OTHER|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
57759379|NCT00782496|DEVICE|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
57759380|NCT03417947|DIETARY_SUPPLEMENT|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
57759381|NCT03417947|DIETARY_SUPPLEMENT|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
57759382|NCT03552133|DEVICE|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
57759383|NCT06260735|DEVICE|Trans-spinal electrical stimulation|Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).
57759384|NCT06260735|DEVICE|Electrical muscle activation|Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.
57759385|NCT06260735|OTHER|Treadmill walking|Stepping on a treadmill with individually preferred speed.
57759386|NCT02936050|PROCEDURE|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
57759387|NCT00962143|DEVICE|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
57759388|NCT00962143|PROCEDURE|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
57759389|NCT06259643|OTHER|Power wheelchair soccer|Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
57759390|NCT03517423|DRUG|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
57759391|NCT02056860|PROCEDURE|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
57759392|NCT02056860|PROCEDURE|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
57759393|NCT02056860|PROCEDURE|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
57759394|NCT02056860|PROCEDURE|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
57759395|NCT02056860|PROCEDURE|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
58455352|NCT03153514|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
58455353|NCT05899439|OTHER|blood draw|a peripheral blood draw
58455354|NCT01059097|PROCEDURE|Pancreaticoduodenectomy|
58455355|NCT02579460|OTHER|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
58455356|NCT01679496|OTHER|Food items|Food items with different fatty acid composition
58455357|NCT02522247|PROCEDURE|UPP|surgery with cold steel in general anesthesia
58455358|NCT00694616|DEVICE|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
57759396|NCT04182763|OTHER|CoA-Z|People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
57759397|NCT04182763|OTHER|Placebo|The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
57759398|NCT05916976|DIAGNOSTIC_TEST|cardiac MRI|Multiparametric MRI of the heart
58455359|NCT00694616|DEVICE|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
58455360|NCT03188159|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
58455361|NCT05450367|OTHER|Data collection|Data collection
58455362|NCT06073808|DEVICE|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
58455363|NCT06073808|DEVICE|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
58455364|NCT00877136|DEVICE|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
58455365|NCT00697931|BIOLOGICAL|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
58455366|NCT00697931|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
58455367|NCT01647165|DRUG|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
57759399|NCT01191203|DRUG|Copper IUD|Copper IUD (CuT360)
57759400|NCT01191203|DRUG|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
57759401|NCT02676596|DRUG|K-312 10 mg QD|
57759402|NCT02676596|DRUG|K-312 25 mg QD|
57759403|NCT02676596|DRUG|K-312 50 mg QD|
57759404|NCT02676596|DRUG|K-312 100 mg QD|
57759405|NCT02676596|DRUG|K-312 200 mg QD|
57759406|NCT02676596|DRUG|K-312 400 mg QD|
57759407|NCT02676596|OTHER|Placebo|
57759408|NCT02947438|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
57759409|NCT02947438|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
57759410|NCT01194284|DRUG|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
57759411|NCT02104492|OTHER|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
57759412|NCT02104492|OTHER|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
57759413|NCT01217424|OTHER|questionnaire administration|
57759414|NCT01217424|PROCEDURE|aromatherapy and essential oils|
57759415|NCT01217424|PROCEDURE|management of therapy complications|
57759416|NCT01217424|PROCEDURE|massage therapy|
57759417|NCT01217424|PROCEDURE|psychosocial assessment and care|
57759418|NCT01217424|PROCEDURE|reflexology procedure|
57759419|NCT04138836|DRUG|BBT-877|BBT-877 oral capsule.
57759420|NCT04138836|DRUG|Midazolam|Midazolam oral syrup.
57759421|NCT04138836|DRUG|Itraconazole|Itraconazole oral capsule.
57759422|NCT04138836|DRUG|Esomeprazole|Esomeprazole oral capsule.
57759423|NCT01563848|PROCEDURE|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
57759424|NCT01563848|PROCEDURE|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
57759425|NCT01563848|PROCEDURE|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
57759426|NCT00889057|DRUG|sorafenib|400 mg bid until progression or inacceptable toxicity
57759427|NCT02470858|DRUG|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
57759428|NCT02470858|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
57759429|NCT02470858|DRUG|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
57759430|NCT01546467|BEHAVIORAL|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
57759431|NCT03988582|BIOLOGICAL|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
57759432|NCT06296823|BEHAVIORAL|Simulated jetlag protocol|16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
57759433|NCT05760807|DRUG|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
57759434|NCT02643862|DRUG|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
57759435|NCT02643862|DRUG|Placebo|Placebo
57759436|NCT04038528|BEHAVIORAL|telemonitoring of T2DM|"Baseline record of:~* Weight~* Height~* BMI~* Abdominal circumference~* Winsor Index~* ECG~* Retinography~* Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~* Blood sugar (two measurements per week).~* Body weight (weekly)~* Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
58455368|NCT01647165|DRUG|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
58455369|NCT01647165|DRUG|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
57759437|NCT00634816|RADIATION|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
57759438|NCT04441281|PROCEDURE|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
58455370|NCT04983966|DRUG|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
57759439|NCT00448890|DRUG|GSK729327|Tablets
58455371|NCT04983966|DRUG|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
58455372|NCT02292108|BEHAVIORAL|dietetic counselling|
58455373|NCT02292108|BEHAVIORAL|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
58455374|NCT02103309|DEVICE|Nelfilcon A contact lenses|
58455375|NCT02103309|DEVICE|Etafilcon A contact lenses|
58455376|NCT03633344|DRUG|Carbowhite|
58455377|NCT03633344|DRUG|Carbowhite placebo|
58455378|NCT03421522|OTHER|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
58455379|NCT03788174|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
58455380|NCT03788174|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
58455381|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
58455382|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
58455383|NCT02981368|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
58455384|NCT02981368|DIAGNOSTIC_TEST|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
58455385|NCT00904813|RADIATION|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
58455386|NCT00904813|RADIATION|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
58455387|NCT03274908|OTHER|regular medical treatment|regular medical treatment
58455388|NCT02454023|DEVICE|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
57759440|NCT00448890|DRUG|Placebo|GSK729327 Matching placebo - Tablets
57759441|NCT03404102|DEVICE|Cu-IUD|Copper Intra-uterine device used as contraceptive method
57759442|NCT05285462|BEHAVIORAL|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
57759443|NCT05285462|BEHAVIORAL|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
57759444|NCT05133050|DRUG|Ramipril|We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
57960928|NCT01789970|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
57960929|NCT01789970|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
57960930|NCT00150592|DRUG|SPD503 (Guanfacine HCl)|
58455389|NCT02454023|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
58455390|NCT02967653|DRUG|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
58455391|NCT06035731|OTHER|SOCIO-AESTHETICS care|SOCIO-AESTHETICS well being care performed by qualify person
57960931|NCT00150592|DRUG|Placebo|
57960932|NCT00293579|DRUG|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
57960933|NCT03726684|DEVICE|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
57960934|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|20 minutes exposure
57960935|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|40 minutes exposure
57960936|NCT04609189|DRUG|Pearlium/EffectiCal|Oral administration of Pearlium/EffectiCal.
57960937|NCT04609189|DRUG|Calcium carbonate/vitamin D3|Oral administration of Calcium Carbonate/Vitamin D3
57960938|NCT04192578|DEVICE|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
57759445|NCT05912140|OTHER|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
57759446|NCT02943941|OTHER|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
57759447|NCT01772784|OTHER|Phenolic acids|Phenolic acids
57759448|NCT01438788|OTHER|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
57759449|NCT06383780|DRUG|GP combined with Tislelizumab|Gemcitabine combined with cisplatin regimen combined with Tislelizumab
57759450|NCT06383780|DRUG|TPC combined with Tislelizumab|cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
57759451|NCT00756522|OTHER|There is no intervention. Study is observational.|There is no intervention. Study is observational.
57759452|NCT06212908|OTHER|Basic Periodontal Therapy|All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
57759453|NCT00968435|OTHER|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
58455392|NCT03540108|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
58455393|NCT03540108|DIETARY_SUPPLEMENT|Placebo Comparator: Maltodextrin|Please see intervention description above.
58455394|NCT06185517|DIAGNOSTIC_TEST|Questionnaire translation and validation|Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
58455395|NCT02567981|DIETARY_SUPPLEMENT|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
58455396|NCT02567981|DIETARY_SUPPLEMENT|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
58455397|NCT02567981|DIETARY_SUPPLEMENT|Ferrous sulphate|"Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
58455398|NCT02567981|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
57759454|NCT03661502|DEVICE|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
58128801|NCT04751110|OTHER|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
58455399|NCT04178798|DRUG|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
58455400|NCT04763395|OTHER|No intervention|No intervention
58455401|NCT00955214|DEVICE|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
58128802|NCT06485219|DRUG|11.2 mg/m2 Purinostat Mesylate|Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
58455402|NCT05417750|DRUG|TIL therapy|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
57759455|NCT03661502|DEVICE|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
57759456|NCT03895489|DEVICE|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
57759457|NCT03895489|DEVICE|Stryker|Stryker Triathlon Total Knee prosthesis
57759458|NCT03895489|DEVICE|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
57759459|NCT01494870|PROCEDURE|PCI|urgent PCI on admission
57759460|NCT04732208|DIAGNOSTIC_TEST|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
57759461|NCT04987632|DRUG|Letrozole|Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.
57759462|NCT04987632|DEVICE|acupuncture|Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.
57759463|NCT04987632|OTHER|Governor vessel moxibustion|It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation
57759464|NCT02931201|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
57759465|NCT03150498|DRUG|BTD-001|BTD-001 in fed vs fasted state
57759466|NCT00061516|DRUG|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
57759467|NCT00061516|DRUG|AZOPT (brinzolamide)|brinzolamide suspension, 1%
57759468|NCT02564302|DEVICE|MUSE Headband|MUSE Headband will help patients with mindfulness.
58455403|NCT02875535|BEHAVIORAL|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
58455404|NCT04731285|DIAGNOSTIC_TEST|Pressure wire fractional flow reserve|Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
58455405|NCT04731285|DIAGNOSTIC_TEST|CFD-based RuiXin-FFR|"CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour"
58455406|NCT05237349|DRUG|Envafolimab|300mg,sc,d1,Q3W
58455407|NCT05237349|DRUG|Oxaliplatin|130mg/m2, iv,d1,Q3W
58455408|NCT05237349|DRUG|S1|40mg/m2, op,bid,d1-14,Q3W
58455409|NCT03624673|PROCEDURE|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
58455410|NCT03624673|PROCEDURE|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
57759469|NCT04923555|BEHAVIORAL|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
57759470|NCT04923555|BEHAVIORAL|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
57759471|NCT04923555|BEHAVIORAL|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
57759472|NCT02799472|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
57759473|NCT02799472|DRUG|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
57759474|NCT02799472|DRUG|MTX|Capsule, tablet or liquid administered orally or as SC injection.
57759475|NCT02799472|DRUG|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
57759476|NCT04238312|DEVICE|RESPeRATE™|Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
57759477|NCT04238312|BEHAVIORAL|Tell, Show and Do technique|Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
57759478|NCT04409067|DIAGNOSTIC_TEST|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
57759479|NCT03384264|OTHER|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
57759480|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
57759481|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
57759482|NCT02960399|BIOLOGICAL|Zostavax®|Zostavax® immunization
57759483|NCT03074812|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
57759484|NCT06424730|OTHER|Feasibility Interview|One audio-recorded interview with the participants lasting about 30-minutes
57759485|NCT06424730|BEHAVIORAL|Team Based Equity Conscious Telemedicine Hypertension Intervention|Will provide blood pressure monitor connected to a telehealth application. Patients will be asked to measure home blood pressure once daily. Will intensify medications as needed based on blood pressure measurement. Trained nurses or pharmacists will provide 4 self-management telephone calls (up to 30 minutes per call) to patients to address hypertension knowledge, medication adherence, healthy eating, physical activity, weight management, stress management, tobacco and alcohol use, and sleep apnea (with referrals if needed). Will support needs relevant in blood pressure control using locally available resources via community health worker and social workers.
57759486|NCT06424730|BEHAVIORAL|Usual Care|Usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
57759487|NCT03092375|DRUG|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
57759488|NCT03092375|DRUG|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
57759489|NCT02848482|DEVICE|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
57759490|NCT02848482|PROCEDURE|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
58128803|NCT06485219|DRUG|15 mg/m2 Purinostat Mesylate|Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
58128804|NCT02361047|BEHAVIORAL|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
58128805|NCT01089647|DRUG|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
58128806|NCT01089647|DRUG|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
58128807|NCT00600925|DRUG|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
57759491|NCT02848482|DRUG|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
57759492|NCT01460498|DRUG|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
57759493|NCT01460498|DRUG|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
57759494|NCT01460498|DRUG|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
57759495|NCT01995539|BEHAVIORAL|therapy regimen|Subjects will be recommend changes in therapy regimens.
57759496|NCT06625671|DRUG|DB-2304|DB-2304
57759497|NCT06625671|DRUG|Placebo|Placebo
57759498|NCT02016404|OTHER|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
57759499|NCT02016404|OTHER|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
57759500|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
57759501|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
57759502|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
58128808|NCT05903365|OTHER|Blood sampling|Additional blood samples at J100, M6, M12, M24
58128809|NCT00592098|DRUG|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
58128810|NCT00592098|DRUG|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
57759503|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
57759504|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
57759505|NCT03131960|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
57759506|NCT03131960|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
57759507|NCT02413060|OTHER|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
57759508|NCT02413060|BEHAVIORAL|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
58455411|NCT05225129|OTHER|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
57759509|NCT00137943|BEHAVIORAL|Full Parent communication intervention|
57759510|NCT00137943|BEHAVIORAL|Brief Parent Communication Intervention|
57759511|NCT00137943|BEHAVIORAL|Control Parent Intervention|
57759512|NCT00402194|DRUG|Losartan|Tablet, 100mg, once per day for 3 months
57759513|NCT02119143|DIETARY_SUPPLEMENT|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
57759514|NCT02119143|DIETARY_SUPPLEMENT|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
58455412|NCT01205100|BEHAVIORAL|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
58455413|NCT01205100|DRUG|Placebo|
58455414|NCT02416843|OTHER|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
58455415|NCT00217425|BIOLOGICAL|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
58455416|NCT00217425|DRUG|cyclophosphamide|IV infusion per institutional guidelines.
58455417|NCT00217425|DRUG|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
58455418|NCT00217425|DRUG|prednisone|Prednisone is taken orally.
58455419|NCT00217425|DRUG|vincristine|IV push using extravasation precautions.
58455420|NCT01622959|PROCEDURE|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
58455421|NCT05697198|DIAGNOSTIC_TEST|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
58455422|NCT01813916|OTHER|proteomic analysis|
58455423|NCT00357630|DRUG|gemcitabine hydrochloride|
58455424|NCT00357630|PROCEDURE|quality-of-life assessment|
58455425|NCT01392547|DRUG|vatreptacog alfa (activated)|1-3 doses per bleeding episode
58455426|NCT01392547|DRUG|eptacog alfa (activated)|1-3 doses per bleeding episode
58455427|NCT03382886|DRUG|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
58455428|NCT03382886|DRUG|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
58455429|NCT05569239|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1.
58455430|NCT05569239|BIOLOGICAL|Saline Solution|One single administration intramuscularly at Day 1.
58455431|NCT02867267|DRUG|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
58455432|NCT02867267|OTHER|Placebo|Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
58455433|NCT05759507|PROCEDURE|abdominal surgery|
57759515|NCT02802501|DRUG|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
57759516|NCT02802501|DRUG|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
57759517|NCT02802501|DRUG|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
58455434|NCT06104085|DIAGNOSTIC_TEST|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
58455435|NCT00951366|OTHER|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
58455436|NCT03096340|DRUG|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
58455437|NCT01239511|DRUG|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
57759518|NCT02802501|DRUG|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
57759519|NCT02802501|DRUG|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
57759520|NCT02802501|DRUG|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
57759521|NCT02802501|DRUG|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
57759522|NCT04369001|BEHAVIORAL|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
57759523|NCT04369001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
57759524|NCT03917940|DIETARY_SUPPLEMENT|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
57759525|NCT03917940|DRUG|Glimepiride|glimepiride 2 mg or 3 mg per day oral
57759526|NCT00106184|DRUG|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
57759527|NCT00106184|DRUG|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
57759528|NCT01490125|DRUG|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
57759529|NCT01490125|DRUG|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
57759530|NCT01490125|DRUG|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
57759531|NCT01490125|DRUG|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
57759532|NCT01490125|DRUG|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
57759533|NCT04009590|OTHER|Educational Intervention|Read educational booklet
57759534|NCT04009590|OTHER|Questionnaire Administration|Ancillary studies
57759535|NCT04009590|BEHAVIORAL|Smoking Cessation Intervention|Utilize Quit4Health
57759536|NCT04846023|DEVICE|aEEG via vEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
57759537|NCT04837859|DRUG|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
57759538|NCT01661556|DRUG|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
57759539|NCT01661556|DRUG|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
57759540|NCT05249062|DEVICE|SHAPES app|Participants will be asked to use the app and connected devices daily for 3 months.
57759541|NCT00298922|DRUG|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
57759542|NCT00298922|DRUG|Placebo|tablet orally thrice weekly for 24 weeks
57759543|NCT00978484|BEHAVIORAL|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
57759544|NCT00978484|BEHAVIORAL|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
57759545|NCT00459342|DRUG|dasatinib|Given orally
58455438|NCT00830544|DRUG|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
58455439|NCT00830544|DRUG|Chemotherapy|Neoadjuvant chemotherapy
57759546|NCT05108649|OTHER|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
57759547|NCT05108649|OTHER|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
57759548|NCT02277990|DEVICE|TYRX™ Absorbable Antibacterial Envelope|
58455440|NCT00830544|DRUG|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
57759549|NCT00516464|DRUG|Lucentis (ranibizumab)|
57759550|NCT01439607|OTHER|Bone marrow and blood sampling|Bone marrow and blood sampling
57759551|NCT01465607|BEHAVIORAL|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
57759552|NCT01465607|BEHAVIORAL|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
57759553|NCT01815528|DRUG|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10"
57759554|NCT02850822|DRUG|Demethylation drug|Demethylation drug,such as Decitabine
57759555|NCT02850822|DRUG|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
57759556|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with uncoated balloon|
57759557|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with Paclitaxel balloon|
57759558|NCT03260530|OTHER|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
57759559|NCT03260530|OTHER|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
57759560|NCT01448694|OTHER|No treatment|No treatment, only collecting observational data.
57759561|NCT04202926|DEVICE|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
57759562|NCT04202926|DEVICE|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
57759563|NCT02093455|DIETARY_SUPPLEMENT|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
57759564|NCT02093455|DIETARY_SUPPLEMENT|Placebo|
58128811|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
58455441|NCT01776658|DRUG|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
57759565|NCT03185559|DEVICE|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
58455442|NCT01776658|DRUG|Placebo|Ocular topical administration of placebo for 10 consecutive days
58455443|NCT00100035|PROCEDURE|Polarity therapy|
58455444|NCT02448277|DEVICE|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
58455445|NCT02448277|DEVICE|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
58455446|NCT02448277|DEVICE|Glidescope|the device is to assist the nasotracheal tube into trachea
58455447|NCT00870181|BIOLOGICAL|ADV-TK/GCV|gene therapy
58455448|NCT00870181|PROCEDURE|Surgery|
58455449|NCT00870181|DRUG|systemic chemotherapy|
57759566|NCT03185559|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
57759567|NCT01264380|DRUG|RO5185426|Single oral dose, fasted
58455450|NCT05742477|DRUG|Antibiotic|role of antibiotics in treatment of neonatal sepsis
58455451|NCT03636581|BEHAVIORAL|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
58455452|NCT05572866|OTHER|COVID-19 pandemic|To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
58455453|NCT00377793|DRUG|Levitra (Vardenafil, BAY38-9456)|
58455454|NCT00377793|DRUG|Placebo|
57759568|NCT01264380|DRUG|RO5185426|Single oral dose, with high fat meal
57759569|NCT01264380|DRUG|RO5185426|Continuous administration, orally twice daily
57759570|NCT05285384|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
57759571|NCT02209012|DRUG|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
57759572|NCT02209012|DRUG|Topical Solution Vehicle|Vehicle PDT given in CP0108
57759573|NCT02209012|DEVICE|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
57759574|NCT00327184|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
57759575|NCT00327184|BIOLOGICAL|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
57759576|NCT00327184|BIOLOGICAL|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
57759577|NCT00327184|BIOLOGICAL|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
57759578|NCT01928316|DRUG|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
57759579|NCT01928316|DRUG|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
58128812|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
58455455|NCT06020898|DRUG|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
58455456|NCT06020898|DRUG|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
58455457|NCT00681629|DRUG|Quetiapine XR|400-800 mg, oral, bid
58455458|NCT00681629|OTHER|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
58455459|NCT00895284|PROCEDURE|Robotic hysterectomy|Robotic hysterectomy.
58455460|NCT00895284|PROCEDURE|Standard Hysterectomy|Standard hysterectomy.
58455461|NCT00160186|DRUG|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
58455462|NCT00160186|DRUG|Placebo|Placebo
58455463|NCT02972060|DRUG|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
58455464|NCT02972060|DRUG|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
58455465|NCT04248699|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
58455466|NCT03951077|DRUG|Elagolix|Capsule administered orally
58455467|NCT03951077|DRUG|Placebo|Capsule administered orally
58455468|NCT01971541|BEHAVIORAL|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
58455469|NCT01971541|BEHAVIORAL|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
58455470|NCT05762497|OTHER|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
58455471|NCT05229393|OTHER|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
58455472|NCT05229393|OTHER|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
58455473|NCT05229393|OTHER|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
58455474|NCT01377584|BEHAVIORAL|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
58455475|NCT01377584|BEHAVIORAL|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
58455476|NCT01377584|DEVICE|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
58128813|NCT01584921|DRUG|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
58455477|NCT01377584|OTHER|No intervention|No intervention will be received.
57759580|NCT02678325|OTHER|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
58128814|NCT01163760|DEVICE|etafilcon A|daily disposable contact lens
58128815|NCT01163760|DEVICE|ocufilcon D|daily disposable contact lens
57759581|NCT02678325|OTHER|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
57759582|NCT00461292|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection \> Week 12; injections into detrusor
57759583|NCT00461292|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
57759584|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection \> 12 weeks; injections into detrusor
57759585|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
57759586|NCT04798443|PROCEDURE|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
57759587|NCT04798443|PROCEDURE|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
57759588|NCT04604301|DEVICE|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
57759589|NCT00008021|BIOLOGICAL|filgrastim|
57759590|NCT00008021|BIOLOGICAL|monoclonal antibody Lym-1|
57759591|NCT00008021|DRUG|cyclosporine|
57759592|NCT00008021|DRUG|paclitaxel|
57759593|NCT00008021|PROCEDURE|peripheral blood stem cell transplantation|
57759594|NCT00008021|RADIATION|indium In 111 monoclonal antibody Lym-1|
57759595|NCT00008021|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
57759596|NCT01092481|DRUG|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
57759597|NCT04305002|DRUG|Exenatide|Injections, 2 mg once weekly for 18 months
57759598|NCT04305002|DRUG|Placebo|Injections, once weekly for 18 months
57759599|NCT00161070|DRUG|anticoagulation|
58455478|NCT02719548|DEVICE|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield"
57759600|NCT00161070|DRUG|aspirin and dipyridamole|
57759601|NCT00161070|DRUG|aspirin alone|
57759602|NCT04680325|DIETARY_SUPPLEMENT|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
57759603|NCT03952221|DEVICE|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
57759604|NCT03952221|DEVICE|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
57759605|NCT03952221|DEVICE|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
57759606|NCT03952221|DEVICE|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
57759607|NCT05946980|OTHER|Multi-component hand hygiene intervention in primary health care facilities|"Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination."
57759608|NCT04834700|OTHER|online group|In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
57759609|NCT06245122|DRUG|CS23546|Tablets administered orally.
57759610|NCT01262326|OTHER|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
57759611|NCT00235599|PROCEDURE|IGFBP-3 Stimulation Test|
57759612|NCT05373797|BEHAVIORAL|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
57759613|NCT02575898|OTHER|First Session|Creative Practice and Positive Re-enforcement
57759614|NCT02575898|OTHER|Second Session|Disease Related
57759615|NCT02575898|BEHAVIORAL|Third through Sixth Sessions|Life Review and Legacy
57759616|NCT00336141|DRUG|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
58455479|NCT02719548|DEVICE|Modified PF breast shield - Soft edge oval - Hard oval|"1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield"
58455480|NCT02719548|DEVICE|Hard oval - Soft edge oval - Modified PF breast shield|"1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield"
58455481|NCT03133611|OTHER|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
57759617|NCT03207139|DRUG|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
57759618|NCT04808375|OTHER||
57759619|NCT05581680|OTHER|dental impressions|dental impressions
57759620|NCT05581680|OTHER|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
57759621|NCT05581680|OTHER|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
57759622|NCT05581680|OTHER|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
58455482|NCT03133611|OTHER|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
57759623|NCT01568346|OTHER|MRI|Breast MRI
57759624|NCT04508452|DRUG|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
57759625|NCT01175889|DEVICE|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
57759626|NCT02768662|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
57759627|NCT05434845|OTHER|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
57759628|NCT05492825|OTHER|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
58455483|NCT05125159|PROCEDURE|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
58455484|NCT00000928|BEHAVIORAL|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
58455485|NCT05258240|OTHER|Virtual Reality|Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
58455486|NCT05258240|OTHER|Conventional Physical Therapy|Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
58455487|NCT05892614|DRUG|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
58455488|NCT05892614|DRUG|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
58455489|NCT05892614|DRUG|Placebo|IV infusion over approximately 60 minutes every 4 weeks
58455490|NCT04864171|DEVICE|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
58455491|NCT05546034|DIAGNOSTIC_TEST|Standard nutrition screening tools to be compared with routine blood tests|None other than completion of questionnaires one of which would be done in routine practice
58455492|NCT04498078|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate (20 g per day)
58455493|NCT01020786|DRUG|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
58455494|NCT01020786|DRUG|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
58455495|NCT00677404|BIOLOGICAL|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
58455496|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
58455497|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
58455498|NCT00003619|BIOLOGICAL|filgrastim|
58455499|NCT00003619|DIETARY_SUPPLEMENT|vitamin E|
58455500|NCT00003619|DRUG|busulfan|
58455501|NCT00003619|DRUG|cytarabine|
58455502|NCT00003619|DRUG|etoposide|
58455503|NCT00003619|DRUG|fludarabine phosphate|
58455504|NCT00003619|DRUG|isotretinoin|
58455505|NCT00003619|DRUG|topotecan hydrochloride|
58455506|NCT00003619|PROCEDURE|bone marrow ablation with stem cell support|
58455507|NCT00003619|PROCEDURE|peripheral blood stem cell transplantation|
58455508|NCT01980329|DRUG|Maraviroc|
58455509|NCT05642585|DRUG|MY008211A tablets|Single oral
58455510|NCT05642585|DRUG|Placebo|Single oral
58455511|NCT01180335|DRUG|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
58455512|NCT01180335|DRUG|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
57759629|NCT05492825|OTHER|Physical Therapy|The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
57759630|NCT05492825|OTHER|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
57759631|NCT01555190|DRUG|myo-inositol 1500 gr|
57759632|NCT01555190|DRUG|myo-inositol 2000 gr + folic acid 200 mcg|
57759633|NCT00745706|DEVICE|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
57759634|NCT04382703|BEHAVIORAL|Self-Affirmation Exercise|"The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will .........................................~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me"
57759635|NCT04382703|BEHAVIORAL|Control|Given a questionnaire minus the self affirming exercise
57759636|NCT00361959|DRUG|Tiotropium bromide 18mcg|
57759637|NCT00361959|DRUG|Fluticasone propionate/ salmeterol combination 50/500mcg|
57759638|NCT04768842|DRUG|LY3209590|Administered SC.
57759639|NCT04665024|PROCEDURE|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
57759640|NCT04665024|PROCEDURE|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
57759641|NCT06038435|BEHAVIORAL|Cognitive Orientation Approach|Cognitive training will be given for the selected occupation
57759642|NCT06038435|BEHAVIORAL|Ayres Sensory Integration Therapy|Sensory integration therapy will be applied.
57759643|NCT00001579|DRUG|5-Fluorouracil|
57759644|NCT00001579|DRUG|Ethynyluracil|
57759645|NCT00001579|DRUG|Leucovorin|
57759646|NCT01657266|DRUG|PRO-155|Pre-medication (before surgery) and maintenance treatment.
57759647|NCT01657266|DRUG|Nevanac|Pre-medication (before surgery) and maintenance treatment.
57759648|NCT00482820|BEHAVIORAL|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
57759649|NCT02345525|BEHAVIORAL|mCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
57759650|NCT02345525|BEHAVIORAL|hCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
58455513|NCT05330013|DRUG|Dapagliflozin|Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).
57759651|NCT05540314|PROCEDURE|robotic bariatric surgery|robotic bariatric surgery
57759652|NCT05555992|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
57759653|NCT00771225|PROCEDURE|fascial repair|surgery to treat genital prolapse with fascia repair
58455514|NCT05330013|DEVICE|MRI scan|For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).
58455515|NCT05330013|DEVICE|CMR imaging|Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
58455516|NCT00259714|DRUG|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
58455517|NCT00259714|DRUG|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
57759654|NCT00771225|PROCEDURE|mesh repair|surgery to genital prolapse with mesh
57759655|NCT00425425|BIOLOGICAL|cetuximab|
57759656|NCT00425425|DRUG|fluorouracil|
57759657|NCT00425425|DRUG|oxaliplatin|
57759658|NCT00425425|PROCEDURE|conventional surgery|
57759659|NCT00425425|PROCEDURE|neoadjuvant therapy|
57759660|NCT00425425|RADIATION|radiation therapy|
57759661|NCT00079911|DRUG|valacyclovir hydrochloride|valacyclovir hydrochloride
57759662|NCT01319799|OTHER|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
57759663|NCT02079064|DRUG|Desflurane|Inhalational anesthetic
58455518|NCT06218563|OTHER|vibration-induced illusion of movement|Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
58455519|NCT03976258|DRUG|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
58455520|NCT03976258|DRUG|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
58455521|NCT03976258|DRUG|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
58455522|NCT03976258|DRUG|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
58455523|NCT04959396|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
58455524|NCT04945083|OTHER|Experimental Nutritional Pudding|High Calorie, High Protein pudding
58455525|NCT03164811|PROCEDURE|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
57759664|NCT02079064|DRUG|Propofol|Intravenous anesthetic that can be given by continuous infusion
57759665|NCT03077984|COMBINATION_PRODUCT|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
57759666|NCT06100315|DRUG|Nalbuphine|bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
57759667|NCT01725269|DRUG|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
58128816|NCT03744416|OTHER|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
58455526|NCT03164811|OTHER|Controlled|standard fluid treatment by an anesthesiologist
57759668|NCT03340584|OTHER|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
57759669|NCT03340584|OTHER|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
57759670|NCT00212381|DRUG|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
57759671|NCT00212381|DIETARY_SUPPLEMENT|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
57759672|NCT02014818|DEVICE|CoCr-EES|
57759673|NCT01500330|PROCEDURE|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
57759674|NCT01500330|PROCEDURE|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
57759675|NCT03666884|DRUG|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
57759676|NCT03666884|BIOLOGICAL|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
57759677|NCT03425448|DRUG|Heparin|Heparin hemodialysis catheter lock solution
57759678|NCT03425448|DEVICE|Neutrolin|Neutrolin hemodialysis catheter lock
58455527|NCT03787186|DRUG|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
58455528|NCT03787186|DRUG|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1690
57759679|NCT02247336|BEHAVIORAL|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
57759680|NCT06624540|BEHAVIORAL|This is a pre- and post- quasi-experimental study.|We will use new equipment and implement EBP (VAP management) for patients by trained nurses (Study 2) and check the outcome of the patients. We will compare our study 1 findings for this study as historical data.
57759681|NCT06624540|BEHAVIORAL|Education with EBP|"Study 2: Nurse's EBP training ( VAP management), 2 hours lecture and 3 hours skill training for total 4 times in 1 month.~Study 3: Introduce new equipment necessary for EBP implementation for VAP management, and EBP-trained nurses implementation for VAP management."
58128817|NCT06009913|OTHER|online teaching|teaching of subject was done using online system only
58455529|NCT03787186|DRUG|[14C]-GLPG1690 capsules|single oral dose of \[14C\]-GLPG1690
58455530|NCT01863459|DRUG|Lisdexamfetamine Dimesylate|
58455531|NCT01863459|DRUG|placebo|
58455532|NCT02375035|DEVICE|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
58455533|NCT01422161|DRUG|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
58455534|NCT01422161|DRUG|Placebo|The control group will receive a placebo injection.
58455535|NCT00151385|PROCEDURE|single blood draw|
58455536|NCT04722523|DRUG|Cisplatin|Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8
58455537|NCT04722523|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 2, 5, and 8
58455538|NCT04722523|DRUG|Docetaxel|Docetaxel 75mg/m2 on weeks 2, 5, and 8
58455539|NCT04722523|DRUG|Cetuximab|Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10
58455540|NCT04722523|DRUG|Cemiplimab|Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37
58455541|NCT04722523|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
58455542|NCT04722523|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of \>0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines \[2\]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
58455543|NCT04722523|DRUG|Paclitaxel|If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
58455544|NCT00601497|DEVICE|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
58455545|NCT00155493|PROCEDURE|obtain surgical specimen for analysis|
57759682|NCT03994458|BEHAVIORAL|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
57759683|NCT03994458|BEHAVIORAL|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
58128818|NCT06009913|OTHER|In class teaching|subjects were explained in normal class room
58128819|NCT03487055|BIOLOGICAL|TK006|Subcutaneous injection in the upper arm
58128820|NCT03614377|DIAGNOSTIC_TEST|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
58128821|NCT05707000|OTHER|group A concentric muscle training|"One set of each of the following exercises will completed during each session:~* leg press,~* knee flexion,~* knee extension,~* Quad drills For each set, 12 repetitions will be performed at a resistance load of 60% of the one-repetition maximum (1RM) for that exercise. The exercises will be performed 2 times a week for 6 weeks."
58455546|NCT05470335|PROCEDURE|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
58455547|NCT03267550|DEVICE|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
58455548|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
58455549|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
58455550|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
58455551|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
58455552|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
58455553|NCT02859259|DRUG|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
58455554|NCT02859259|DRUG|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
58455555|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
58455556|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
58455557|NCT00629044|BIOLOGICAL|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
58455558|NCT01207375|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
58455559|NCT01207375|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
58455560|NCT05942144|OTHER|Exercise-snacks program|"Subjects in the exercise-snacks group will perform 4 exercise-snacks sessions per working day for 4 weeks. These sessions will consist of 80 one-to-one walks to be completed as quickly as possible. They will also receive information about their attitudes to physical activity."
58455561|NCT04434417|DEVICE|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
58455562|NCT02752880|DRUG|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
57759684|NCT05788835|PROCEDURE|DEB-TACE and HAIC|Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
57759685|NCT05788835|PROCEDURE|DEB-TACE|Drug-eluting bead transarterial chemoembolization
57759686|NCT03503825|DRUG|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
57759687|NCT06525402|OTHER|Sodium Bicarbonate Group (Usual care)|In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.
57759688|NCT06525402|OTHER|Saline Group|The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.
57759689|NCT06525402|OTHER|Black Mulberry Syrup Group|The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.
57759690|NCT01887470|DRUG|Full dose preparation|
57759691|NCT01887470|DRUG|Split dose preparation|
57759692|NCT01390714|DRUG|E3710|"Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
57759693|NCT01390714|DRUG|E3710|"Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
57759694|NCT04189263|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
57759695|NCT04189263|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
57759696|NCT01146301|DRUG|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
57759697|NCT02291523|BIOLOGICAL|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
57759698|NCT02552290|OTHER|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
57759699|NCT02552290|OTHER|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
58128822|NCT05707000|OTHER|Group B fascilitatory kinesiotaping|Kinesiotaping is applied on the anterior thigh (quadriceps) region starting at 1/5 of the distance between anterosuperior iliac spine (ASIS) and tibia tuberosity. The tape is applied with 20% tension of the tape. The tape was tensioned from proximal region of mid quadriceps down to tibia tuberosity and, once it reached the knee, the tape was divided in the middle allowing it to circle the joint
58455563|NCT02752880|DRUG|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
57759700|NCT02552290|OTHER|No intervention|Wait
58455564|NCT03658122|BEHAVIORAL|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
57759701|NCT05586464|DRUG|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
58128823|NCT04982146|DRUG|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
57759702|NCT05586464|DRUG|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
57759703|NCT03573908|DRUG|Linaclotide|Oral capsule
57759704|NCT03573908|DRUG|Placebo|Matching placebo oral capsule
57759705|NCT02731625|OTHER|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
57759706|NCT02731625|OTHER|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
57759707|NCT04247997|PROCEDURE|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
57759708|NCT03842410|DEVICE|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
57759709|NCT03896009|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
57759710|NCT03896009|DRUG|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
57759711|NCT03896009|DRUG|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
57759712|NCT03896009|DRUG|Placebo|Placebo taken once upon onset of a qualifying migraine.
57759713|NCT04307433|BEHAVIORAL|Storytelling narrative videos on tablets|The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
57759714|NCT00586170|DEVICE|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
57759715|NCT00586170|DEVICE|Placebo Device|10 hours of treatment per day for up to 24 weeks
57759716|NCT00586170|PROCEDURE|Surgery|Open Reduction and Internal Fixation of the nonunion site
57759717|NCT00671905|PROCEDURE|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
57759718|NCT00671905|PROCEDURE|PV isolation|Circumferential PV isolation
57759719|NCT02080104|DRUG|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
57759720|NCT00336843|DRUG|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
57759721|NCT02819102|DRUG|BCX7353 and probes|
57759722|NCT05297474|OTHER|MRI|No intervention was performed in this study.
57759723|NCT03803891|PROCEDURE|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
57759724|NCT04609202|BEHAVIORAL|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
57759725|NCT04609202|OTHER|Usual care|Usual care provided by doctors
57759726|NCT06244810|DEVICE|Lingual retainer from Fiber|lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
57759727|NCT06244810|DEVICE|Lingual retainer from metal|lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
57759728|NCT06244810|DEVICE|Traditional retianer from braided|lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
57759729|NCT05400512|BEHAVIORAL|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
57759730|NCT05400512|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
57759731|NCT05400512|DEVICE|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
57759732|NCT03361891|BEHAVIORAL|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
57759733|NCT03582605|DRUG|Amoxicillin|see previous descriptions
57759734|NCT03582605|DRUG|Placebo oral capsule|see previous descriptions
57759735|NCT05252845|BIOLOGICAL|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
57759736|NCT05252845|DRUG|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
57759737|NCT05252845|DRUG|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
57759738|NCT03875625|PROCEDURE|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
57759739|NCT03875625|BEHAVIORAL|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
57759740|NCT03875625|BEHAVIORAL|Conventional care (control)|receive routine care
57759741|NCT00122564|BIOLOGICAL|HIV-1 gp 160|
57759742|NCT00122564|BIOLOGICAL|DC-Chol|
57759743|NCT06303154|DEVICE|Mobiderm Intimate Bra group|At the conclusion of the surgical operation, MOBIDERM Intimate bra will be placed on the patient by the medical team. It will be recommended for the patients to wear MOBIDERM Intimate Bra during day and night for 3 weeks after the surgery, and as much time as the patients tolerate the device during the rest of the study, until 6 months after radiotherapy
57759744|NCT02540694|DEVICE|Endosonography|
57759745|NCT04173767|DEVICE|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated \& humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
57759746|NCT06096545|PROCEDURE|Axillary sentinal lymph node biopsy|"For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively."
57960939|NCT00935558|BIOLOGICAL|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
57960940|NCT00935558|DRUG|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
58128824|NCT04982146|DRUG|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
57759747|NCT04916964|OTHER|Test and exercise home-based program|"Eight home-based physiotherapy sessions will occur in two months, once a week, to activate the preserved implicit memory (PIM). The recommendations are to train three weeks with the same exercise program, three times a week (one time coached by the attributed physiotherapist and two times coached by a natural or family caregiver). After three weeks, the participants can choose if they want to keep the same exercises or change all or some of these, in testing other tasks. Every training session will be planned to last 45 minutes. During each training session, the participant will note on his/her own Training booklet each task performed. The Training booklet will be used to plane, organize, and remember details for the next training session."
57759748|NCT02727686|OTHER|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
57759749|NCT03460457|DRUG|TQB2450|Pharmacokinetics/Dynamics Study
57759750|NCT03076944|DRUG|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
58455565|NCT05963620|OTHER|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
58455566|NCT03062735|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
57759751|NCT03076944|DRUG|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
57759752|NCT02536638|OTHER|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
57759753|NCT05716230|OTHER|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
57759754|NCT02301156|DRUG|Ublituximab|Administered as an IV infusion
57759755|NCT02301156|DRUG|Ibrutinib|Administered orally
57759756|NCT02333760|GENETIC|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
57759757|NCT04131530|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
57759758|NCT01626222|DRUG|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
57759759|NCT01626222|DRUG|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
57759760|NCT04212364|BEHAVIORAL|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
57759761|NCT04212364|DRUG|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
57759762|NCT03017326|DRUG|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
57759763|NCT03017326|DRUG|Doxorubicin|Arms C, D and E used in combination
58455567|NCT03062735|OTHER|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
58455568|NCT05487222|DEVICE|ICON|hemodynamics variability in response to different fluid regiemens
58455569|NCT00389844|BEHAVIORAL|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
58455570|NCT00389844|BEHAVIORAL|Plus component (motivation) of the Exercise Plus Program|Motivation only
58455571|NCT00389844|BEHAVIORAL|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
58455572|NCT05072158|OTHER|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
58455573|NCT05172609|BEHAVIORAL|Exposure Based Implementation Strategy (EBIS)|EBIS will include psychoeducation, assessment/hierarchy building. guided practice, and guidance for application to clinical practice.
58128825|NCT03118466|DRUG|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
58128826|NCT03118466|DRUG|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
58128827|NCT03118466|DRUG|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
58128828|NCT03118466|DRUG|Mitoxantrone|It interfere with cell reproduction
58128829|NCT02606500|DRUG|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years."
58455574|NCT05172609|BEHAVIORAL|Implementation as Usual (IAU)|IAU will consist of standard didactic training and ongoing consultation activities for enrolled clinicians
58455575|NCT02643108|PROCEDURE|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
58455576|NCT01324817|DEVICE|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
58455577|NCT01324817|DEVICE|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
58455578|NCT03499184|DIETARY_SUPPLEMENT|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
58455579|NCT03499184|DIETARY_SUPPLEMENT|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
58455580|NCT03499184|DRUG|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
58455581|NCT03499184|DRUG|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
58455582|NCT05183945|DEVICE|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
58455583|NCT05183945|DEVICE|Coil|A coil which is used for preoperative localization of lung nodules.
58455584|NCT05932615|DEVICE|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
58455585|NCT05932615|DEVICE|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
58455586|NCT03685955|BIOLOGICAL|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
57759764|NCT03017326|DRUG|Carboplatin|Arms C and D used in combination
57759765|NCT03017326|DRUG|5Fluorouracil|Arm C used alone
58128830|NCT03328793|BEHAVIORAL|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
58128831|NCT03328793|BEHAVIORAL|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
58128832|NCT03328793|BEHAVIORAL|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
58455587|NCT04435444|OTHER|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
57759766|NCT03017326|DRUG|Vincristine|Arms C and D used in combination
57759767|NCT03017326|DRUG|Etoposide|Arm D used in combination
58128833|NCT03328793|OTHER|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
58128834|NCT03328793|OTHER|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
58128835|NCT03328793|OTHER|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
58455588|NCT04435444|OTHER|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
58455589|NCT00690729|BEHAVIORAL|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
58455590|NCT00690729|BEHAVIORAL|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
58455591|NCT04023526|DRUG|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
58455592|NCT04023526|DRUG|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
58455593|NCT03943615|DRUG|Voxelotor|
57759768|NCT03017326|DRUG|Irinotecan|Arm D used in combination
57759769|NCT03017326|DRUG|Gemcitabine|Arm F used in combination
57759770|NCT03017326|DRUG|Oxaliplatin|Arm F used in combination
58128836|NCT01604044|DRUG|Meropur 150 a day|one subcutaneous injection a day
58128837|NCT01604044|DRUG|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
58128838|NCT03682952|DRUG|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
58128839|NCT03682952|DRUG|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
58128840|NCT06440655|DEVICE|Platelet rich plasma|Subjects were treated by Platelet rich plasma in each side of head (Left or right)
58455594|NCT03174353|DRUG|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
58455595|NCT03056417|BEHAVIORAL|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
58455596|NCT00960063|DRUG|Temozolomide|
58455597|NCT00960063|DRUG|Vincristine|
58455598|NCT00960063|DRUG|Ifosfamide|
58455599|NCT00960063|DRUG|Irinotecan|
58455600|NCT00960063|BIOLOGICAL|Robatumumab|
58455601|NCT00960063|DRUG|Doxorubicin|
58455602|NCT00960063|DRUG|Cyclophosphamide|
58455603|NCT00960063|DRUG|Etoposide|
58455604|NCT01715168|DRUG|DOXIL/CAELYX|
58455605|NCT01715168|DRUG|ATI-0918|
58455606|NCT04257201|OTHER|Yellow Oyster -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
58455607|NCT04257201|OTHER|Yellow Oyster -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
58455608|NCT04257201|OTHER|White button -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
58455609|NCT04257201|OTHER|White button -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
58455610|NCT04257201|OTHER|Control|Participants will consume the standardized test day salad only
58128841|NCT06440655|DEVICE|Platelet rich fibrin|Subjects were treated by Platelet rich fibrin in each side of head (Left or right)
58455611|NCT05058807|OTHER|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
58455612|NCT05058807|OTHER|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
57759771|NCT03017326|DRUG|Sorafenib|Arm used in combination
58128842|NCT02800798|OTHER|Preeclampsia positive|
58128843|NCT02603952|DRUG|Oseltamivir|75 mg capsules orally BID from Day 1 to Day 5.
58128844|NCT02603952|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
58455613|NCT04744961|OTHER|SCAR-Q survey|Telephone survey
57759772|NCT04836221|BEHAVIORAL|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
57759773|NCT00259922|DRUG|Placebo|Placebo
57759774|NCT00259922|DRUG|Alvimopan|0.5 mg QD
57759775|NCT00259922|DRUG|Alviompan|0.5 mg BID
57759776|NCT00369538|DRUG|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
57759777|NCT00369538|DRUG|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
58128845|NCT02603952|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
58128846|NCT04809675|DEVICE|Hard occlusal splint|Use of a hard occlusal splint at times they considered helpful.
58455614|NCT01683799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
58455615|NCT00953667|DRUG|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
58455616|NCT04376307|PROCEDURE|minimal flow anesthesia|Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
58455617|NCT02749539|DEVICE|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
57759778|NCT05786729|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
57759779|NCT05786729|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
57759780|NCT05358925|OTHER|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 4-10 minutes long, for a total of \~72 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: symptoms, basic factors about BPD, the naturalistic long term course of BPD, prevalence of BPD and its common comorbid disorders, key principles for recovery, available psychotherapeutic treatment options for BPD, common factors amongst treatments, medications, the interpersonal hypersensitivity model of BPD, and a review of the top 10 tips."
57759781|NCT05358925|OTHER|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from the first two time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
57759782|NCT05358925|OTHER|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, coping, self-compassion and self-care, stress and anxiety, depression, and healthy sleep habits.
57759783|NCT05083143|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
57759784|NCT00903786|DRUG|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
57759785|NCT02504125|DRUG|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
57759786|NCT02504125|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
58455618|NCT02749539|PROCEDURE|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
57759787|NCT06449092|DIAGNOSTIC_TEST|Lipid profile|carotid intima media thickness
57759788|NCT04199260|DEVICE|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
57759789|NCT02421562|PROCEDURE|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
57759790|NCT04437095|OTHER|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
57759791|NCT02712125|DRUG|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
57759792|NCT02712125|DRUG|Placebo|placebo vaginal tablets once daily until delivery
57759793|NCT04918225|RADIATION|Magnetic Resonance Imaging|"Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities"
58128847|NCT04809675|DEVICE|Flexible customized mouthguard|Use of a flexible customized mouthguard at times they considered helpful.
57759794|NCT04918225|DIAGNOSTIC_TEST|Neurological examination|Global disability will be scored using the Expanded Disability Status Scale score
57759795|NCT04918225|DIAGNOSTIC_TEST|Multiple Sclerosis Functional Composite|"* Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test"
58128848|NCT04375293|OTHER|Microbiome swabs|Swabs for analysis of microbiome
58128849|NCT05237596|DRUG|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
58128850|NCT00628160|DRUG|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
58128851|NCT00628160|DRUG|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
58128852|NCT01506947|DRUG|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
58128853|NCT01506947|DRUG|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
58455619|NCT03347123|DRUG|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
58455620|NCT03347123|DRUG|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
58455621|NCT03347123|DRUG|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
57759796|NCT04918225|DIAGNOSTIC_TEST|Physiotherapist examination|"* American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale"
57759797|NCT02809898|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
57759798|NCT04196998|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
57759799|NCT04196998|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
57759800|NCT04196998|DRUG|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
57759801|NCT00079508|DRUG|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
57759802|NCT00002763|BIOLOGICAL|recombinant interferon alfa|
57759803|NCT04074590|DRUG|LYS006|capsule for oral use
57759804|NCT04074590|DRUG|Placebo|capsule for oral use
57759805|NCT02810093|OTHER|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
57759806|NCT05319249|BIOLOGICAL|NK cells|NK cells will be given as a single intravenous infusion.
57759807|NCT05319249|DRUG|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
57759808|NCT06363422|PROCEDURE|Epicanthoplasty|Patients with unsatisfied blepharoplasty underwent epicanthoplasty in our center
57759809|NCT04802343|DRUG|BAY1817080|Oral, tablet.
57759810|NCT04802343|DRUG|Placebo|Oral, tablet.
57759811|NCT01463280|DRUG|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
57759812|NCT03245385|DRUG|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
57759813|NCT06197906|DEVICE|Device implant|subcutaneous device implanting
57759814|NCT02600884|BEHAVIORAL|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
57759815|NCT02600884|BEHAVIORAL|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
57759816|NCT05199363|OTHER|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
57759817|NCT05199363|OTHER|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
58455622|NCT03347123|DRUG|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
58455623|NCT02960217|DRUG|UX007|liquid for oral (PO) administration
58455624|NCT02960217|DRUG|Placebo|liquid safflower oil for PO administration
57759818|NCT05199363|OTHER|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
57759819|NCT05239325|BEHAVIORAL|World Cancer Day Walk|Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
57759820|NCT06016010|DRUG|USL|500mg of Achyranthis Radix Extract
57759821|NCT06016010|DRUG|USL Placebo|USL Placebo
57759822|NCT00005993|DRUG|aldesleukin|
57759823|NCT00005993|DRUG|filgrastim|
57759824|NCT00005993|DRUG|recombinant human stem cell factor|
57759825|NCT00005993|PROCEDURE|peripheral blood stem cell transplantation|
57759826|NCT02916602|DRUG|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
57759827|NCT02916602|DRUG|HCP0605|amlodipine, Losartan FDC
58455625|NCT05220085|DRUG|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
58455626|NCT02675907|DRUG|N1539|
58455627|NCT02675907|DRUG|Intravenous Placebo|
58455628|NCT00035789|DRUG|Entecavir|
58455629|NCT05003037|DRUG|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
58455630|NCT05030181|OTHER|kinesiotaping and exercise|kinesiotaping group, ''I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
58455631|NCT05030181|OTHER|exercise|exercise
57759828|NCT04618601|DRUG|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
57759829|NCT03919812|DIETARY_SUPPLEMENT|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
57759830|NCT00228696|OTHER|none, screening only|Screening protocol with no intervention
57759831|NCT02985983|DRUG|Brodalumab|Administered Brodalumab by subcutaneous (SC) injection until week 66.
58455632|NCT04309110|DEVICE|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
58455633|NCT03803189|BEHAVIORAL|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
58455634|NCT01372059|OTHER|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
58455635|NCT01372059|OTHER|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
58455636|NCT01372059|OTHER|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
58455637|NCT02644759|BIOLOGICAL|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
58455638|NCT03495830|PROCEDURE|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
57759832|NCT02985983|DRUG|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
57759833|NCT04797091|OTHER|Retrospective data collection|Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
57759834|NCT05322070|DRUG|Fluocinolone Acetonide Intravitreal Implant 0.18 mg|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
57759835|NCT04816019|BIOLOGICAL|ChAdOx1 nCov-19|A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
57759836|NCT04178057|BIOLOGICAL|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
57759837|NCT04178057|BIOLOGICAL|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
57759838|NCT04178057|BIOLOGICAL|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
57759839|NCT04178057|BIOLOGICAL|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
57759840|NCT05278689|OTHER|No intervention|No intervention
57759841|NCT04327141|BEHAVIORAL|P-IF|Protein pacing and intermittent fasting
57759842|NCT04327141|BEHAVIORAL|HH|Heart Healthy
57759843|NCT03124199|DRUG|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
57759844|NCT03960632|DIAGNOSTIC_TEST|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
57759845|NCT03852849|BEHAVIORAL|Personal involved intervention strategies|Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
57759846|NCT03852849|DRUG|The dosage of 400mg EFV|The dosage of 400mg EFV will be used in the antiviral therapy.
58455639|NCT00503750|DRUG|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
58455640|NCT00503750|DRUG|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
58455641|NCT00503750|DRUG|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
58455642|NCT01227798|DRUG|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
58455643|NCT01227798|DRUG|Placebo|Normal Saline
58455644|NCT02748863|DRUG|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
58455645|NCT02748863|DRUG|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
58455646|NCT02748863|DRUG|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
58455647|NCT00752050|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
58455648|NCT00752050|DRUG|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
58455649|NCT00884546|DRUG|BMS-833923|Capsule, Oral, Once daily, 6 months
58455650|NCT00884546|DRUG|Lenalidomide|Capsule, Oral, Once daily, 6 months
58455651|NCT00884546|DRUG|Dexamethasone|Capsule, Oral, Once a week, 6 months
58455652|NCT00884546|DRUG|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
58455653|NCT02068924|OTHER|Slow freezing versus vitrification|
58455654|NCT02946281|BEHAVIORAL|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
57759847|NCT00262717|DEVICE|HIV drug resistance tests based upon genotype testing|
57759848|NCT06339060|COMBINATION_PRODUCT|Experimental: Arm 1 Organ preservation|"Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy"
57759849|NCT06339060|COMBINATION_PRODUCT|Active Comparator: Arm 2 Surgery|"Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week."
57759850|NCT06203184|OTHER|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
57759851|NCT05587244|DEVICE|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
57759852|NCT02228967|BEHAVIORAL|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
58455655|NCT06440421|BEHAVIORAL|MTL Labels|The MTL label developed by the United Kingdom (UK) Food Standards Agency (FSA) includes per serving size information and grades each nutrient i.e., energy, sugar, fat, saturated fat, and sodium separately based on recommended thresholds. Green signifies a healthy amount of that nutrient; red signifies an unhealthy amount, and amber signifies that the nutrient levels fall between healthy and unhealthy amounts. Additionally, the label also shows how much of a person's daily allowance for a particular nutrient is met by consuming one serving of the product. Lastly, MTL includes the absolute values of each nutrient per serving of a product and the percentage of an adult's daily reference intake that is met by consuming a serving of this product. These will be displayed on all food and beverage products shown on this version of Bahrain e-Mart.
58455656|NCT00551759|DRUG|5-Fluorouracil|given IV
58455657|NCT00551759|DRUG|Oxaliplatin|given IV
58455658|NCT00551759|DRUG|Cetuximab|given IV
58455659|NCT00551759|DRUG|Docetaxel|given IV
58455660|NCT00551759|PROCEDURE|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
58455661|NCT00551759|RADIATION|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
58455662|NCT01599156|PROCEDURE|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
58455663|NCT03282058|DEVICE|Silastic Stent|The silastic stent is a splint made of silicone.
57759853|NCT06140901|DIAGNOSTIC_TEST|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
57759854|NCT06273111|DRUG|5% simvastatin ointment|5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
57759855|NCT02417532|DEVICE|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
57759856|NCT05290844|OTHER|cricoid pressure|cricoid force in pediatric patients
57759857|NCT01807156|DRUG|Tivozanib|Oral medication given daily. No placebo.
57759858|NCT00245102|DRUG|sorafenib tosylate|Given orally
57759859|NCT01544959|DRUG|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
58455664|NCT04750291|DRUG|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
58455665|NCT04750291|OTHER|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
58455666|NCT00802516|DIETARY_SUPPLEMENT|stanol ester|enriched margarine
58455667|NCT00802516|DIETARY_SUPPLEMENT|sterol ester|enriched margarine
58455668|NCT00802516|DIETARY_SUPPLEMENT|No intervention|placebo margarine
58455669|NCT05822934|DRUG|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
58455670|NCT03357107|PROCEDURE|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
58455671|NCT03495466|PROCEDURE|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
58455672|NCT06136429|PROCEDURE|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
58455673|NCT05665010|OTHER|Genetic susceptibility|Genetic susceptibility increases the risk of ovarian injury
58455674|NCT04088006|DEVICE|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
58455675|NCT01999452|BEHAVIORAL|Paleolithic diet|
58455676|NCT01999452|BEHAVIORAL|Diabetes diet|
58455677|NCT04519736|DEVICE|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
57759860|NCT01544959|DRUG|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
57759861|NCT03725540|DEVICE|I-gel|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
57759862|NCT03725540|DEVICE|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
57759863|NCT05699421|OTHER|screening programme|CMV screening during the first trimester of pregnancy and neonatal
57759864|NCT06382714|OTHER|For the intervention group, a museum visit with virtual reality glasses will be applied.|Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
57759865|NCT01491139|DRUG|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
57759866|NCT01491139|DRUG|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
57759867|NCT01491139|RADIATION|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
57759868|NCT03183102|DIETARY_SUPPLEMENT|Flaxseed|2 months of dietary flaxseed supplementation
57759869|NCT00953537|DRUG|capecitabine|
57759870|NCT00953537|OTHER|laboratory biomarker analysis|
57759871|NCT00953537|OTHER|pharmacological study|
57759872|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
58455678|NCT04338282|DRUG|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
58455679|NCT02589054|OTHER|Monitoring|
57759873|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
58455680|NCT02485691|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
58455681|NCT02485691|DRUG|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
58455682|NCT02485691|DRUG|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
58455683|NCT02485691|DRUG|prednisone|Pharmaceutical form: tablet Route of administration: oral
58455684|NCT05256485|BEHAVIORAL|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
58455685|NCT01379183|DRUG|Erythromycin|200 mg suspension
58455686|NCT01379183|DRUG|Placebo|200 mg suspension
58455687|NCT01379183|PROCEDURE|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
58455688|NCT01379183|OTHER|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
58455689|NCT04049487|OTHER|Exercise|Both groups will participate in group exercise as previously described
58455690|NCT04292535|DRUG|Placebo into the intranasal mucosa|6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
58455691|NCT04292535|DRUG|20 IU NovoLog Insulin aspart into the intranasal mucosa|5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58128854|NCT03033420|DEVICE|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
58455692|NCT04292535|DRUG|40 IU NovoLog Insulin aspart into the intranasal mucosa|4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58455693|NCT04292535|DRUG|60 IU NovoLog Insulin aspart into the intranasal mucosa|3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58455694|NCT04292535|DRUG|80 IU NovoLog Insulin aspart into the intranasal mucosa|2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58455695|NCT04292535|DRUG|100 IU NovoLog Insulin aspart into the intranasal mucosa|1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58455696|NCT04292535|DRUG|120 IU NovoLog Insulin aspart into the intranasal mucosa|6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
58455697|NCT02054585|OTHER|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
58455698|NCT02054585|OTHER|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
58455699|NCT01332994|DRUG|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
58455700|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
58455701|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
58455702|NCT02091817|DRUG|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
58455703|NCT02091817|DRUG|Placebo|Placebo will be given to control group and experimental group as well.
58455704|NCT00391300|PROCEDURE|bioelectric field imaging|
58455705|NCT00391300|PROCEDURE|biopsy|
58455706|NCT00391300|PROCEDURE|histopathologic examination|
58455707|NCT02790996|DRUG|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
58455708|NCT02222610|DRUG|0.5 mg ranibizumab|
58455709|NCT02222610|PROCEDURE|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
58455710|NCT04608721|OTHER|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
58455711|NCT00004249|BIOLOGICAL|QS21|
58455712|NCT00004249|BIOLOGICAL|keyhole limpet hemocyanin|
58455713|NCT00004249|DRUG|polysialic acid|
58455714|NCT00646685|PROCEDURE|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
58455715|NCT00646685|PROCEDURE|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
58455716|NCT00956917|DEVICE|Akern USA EFG|Impedance measurement device
58455717|NCT00956917|DEVICE|RJL Impedance analyzer|Impedance analyzer
58455718|NCT05161416|BEHAVIORAL|Bubble Blowing|Active Distraction Methods
58455719|NCT05161416|BEHAVIORAL|Cartoon Watching|Passive Distraction Methods
58455720|NCT05852067|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
58455721|NCT05852067|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
58455722|NCT05940116|DRUG|HS-20117|"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"
58455723|NCT02885688|DIETARY_SUPPLEMENT|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
58455724|NCT02885688|PROCEDURE|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
57759874|NCT06103214|OTHER|acute normovolemic hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
57759875|NCT06103214|OTHER|acute hypervolemic hemodilution (AHH)|The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
57759876|NCT04563650|BIOLOGICAL|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
57759877|NCT05185778|BIOLOGICAL|stool examination, blood sample collected|"Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:~* Saline and iodine wet mount.~* Formalin-ethyl acetate sedimentation method.~* Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.~  * Collection of peripheral blood samples for Automated CBC and blood indices evaluation.~ * Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction)."
57759878|NCT06194084|OTHER|Two-sequence of durian pulp doses (100 g and 200 g)|Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
57759879|NCT01315730|DEVICE|Tactile Stimulation|See Arms
57759880|NCT03615781|PROCEDURE|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
57759881|NCT03615781|PROCEDURE|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
57759882|NCT03615781|DRUG|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
57759883|NCT03615781|DRUG|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
57759884|NCT04577807|BIOLOGICAL|Lerapolturev|Lerapolturev administered via direct lesion injection
57759885|NCT04577807|BIOLOGICAL|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
57759886|NCT04387864|DEVICE|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
57759887|NCT00880308|DRUG|LDE225|
58455725|NCT04528914|OTHER|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
58455726|NCT03571126|DRUG|Olanzapine|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
58455727|NCT03571126|DRUG|Placebos|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
58455728|NCT02638766|DRUG|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
57759888|NCT06395155|DRUG|DHP2306R1|100mg per capsule, BID
57759889|NCT06395155|DRUG|DHP2306R2|75mg per Tab, BID
57759890|NCT06452953|DRUG|suanzaoren decoction|The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver
57759891|NCT06452953|DRUG|Eszopiclone 1 mg|Eszopiclone is used in the treatment of various types of insomnia.
57759892|NCT01310309|DEVICE|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
57759893|NCT00326586|DRUG|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
57759894|NCT02950857|DRUG|EPEG|(Pegylated erythropoeitin)
57759895|NCT00693576|DRUG|simvastatin|20 mg simvastatin daily
57759896|NCT03912493|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
57759897|NCT03912493|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
57759898|NCT03571737|DRUG|Ibuprofen|Ibuprofen tablet
57759899|NCT03571737|DRUG|Lidocaine Patch 4%|Lidocaine patch
57759900|NCT03333915|DRUG|Pamiparib|Pamiparib is provided as oral capsules
57759901|NCT06625619|OTHER|Non-Interventional Study|Non-interventional study
57759902|NCT01808625|OTHER|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
58128855|NCT02439398|BIOLOGICAL|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
58128856|NCT02439398|OTHER|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
58128857|NCT03331042|DRUG|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
58455729|NCT05620316|DRUG|BOTOX® Injection|100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
58455730|NCT05620316|OTHER|Prick skin|patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.
58455731|NCT00301626|BEHAVIORAL|smoking reduction intervention (including NRT)|
58455732|NCT03620266|DIETARY_SUPPLEMENT|Bilberry|The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
58455733|NCT03620266|DIETARY_SUPPLEMENT|Placebo|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
58455734|NCT03620266|DIETARY_SUPPLEMENT|Bioprocessed oat bran|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
58455735|NCT03620266|DIETARY_SUPPLEMENT|Combination bilberry/oats|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
58455736|NCT02539004|OTHER|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
58455737|NCT01859923|DRUG|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
58455738|NCT01859923|DRUG|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
58455739|NCT01859923|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
58455740|NCT01361555|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
58455741|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
58455742|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
58455743|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
58455744|NCT05449184|PROCEDURE|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
58455745|NCT05449184|PROCEDURE|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
58455746|NCT05490862|BEHAVIORAL|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
58455747|NCT05490862|BEHAVIORAL|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
58455748|NCT03641937|DEVICE|INVSENSOR00011|INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
58455749|NCT04868955|OTHER|Oral screen training|Oral screen training (IQoro®) during 13 weeks.
58455750|NCT01815944|DRUG|0.75% Ropivacaine|
58455751|NCT01815944|DRUG|Normal saline|
58128858|NCT03331042|DRUG|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
58128859|NCT03331042|DRUG|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
58128860|NCT03331042|DRUG|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
58128861|NCT05143671|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
57759903|NCT06282315|DRUG|Pre-screening Phase|"The entire school population will be invited to participate in the study. The purpose of this phase is to confirm participant eligibility for enrolment in the study based on the inclusion and exclusion criteria. Given the context in which the clinical trial is being conducted, in many instances, group meetings with the parents/guardians of potential participants in the community or at school might be necessary as part of the informed consent process. This consent process may be performed up to three months before the start of the screening visit activities.~Participants and parents/guardians of subjects will be asked to confirm in writing their agreement to participate in the trial before any study-specific procedure is conducted. In addition, written assent will be sought for participants over 12 years of age."
57759904|NCT06282315|DRUG|Screenig Phase|"The purpose of the screening visit is to confirm subject eligibility for enrolment in the study based on the inclusion/exclusion criteria. Screening visits in a particular school can be performed between 14 and 7 days before the intervention (Day 0).~To continue with the screening activities, participants must have signed written consent from their parent or legal guardian, and in the case of participants aged 12 years or older, they must also have a signed assent form before any specific study procedure is performed.If the consent/assent process has not been finalized during the pre-screening phase, this can be completed during the screening visit, but always before any trial procedure.~All participants who consent to participate in the trial will be given a Participant Screening Number, which will be assigned sequentially as the informed and assent forms are signed."
57759905|NCT06282315|DRUG|Randomization|Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.
58128862|NCT05143671|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
58128863|NCT05143671|PROCEDURE|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
58455752|NCT01815944|DRUG|Dextrose 5%|
58455753|NCT01769313|DEVICE|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
58455754|NCT01769313|DEVICE|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
58455755|NCT03507036|DEVICE|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
58455756|NCT06353594|DEVICE|Primary PCI|Coronary percutaneous revascularization
58455757|NCT00064285|DRUG|alvocidib|
58455758|NCT00064285|DRUG|imatinib mesylate|
58455759|NCT01742195|PROCEDURE|Oral EBUS insertion|
58455760|NCT01742195|PROCEDURE|Nasal EBUS insertion|
58455761|NCT06424444|DRUG|Reproxalap ophthalmic solution (0.25%)|Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks
58455762|NCT06424444|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
58455763|NCT04024943|DEVICE|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
58455764|NCT00486369|DRUG|Oral salmon calcitonin|
58455765|NCT02649140|DIETARY_SUPPLEMENT|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
58455766|NCT05459467|OTHER|Exercise|12 weeks high intensity exercise programme
58128864|NCT05143671|PROCEDURE|Carotid artery stenting|Carotid artery stenting.
58455767|NCT01599975|DRUG|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
58455768|NCT01599975|DRUG|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
58455769|NCT01599975|DRUG|Matched placebo|2 tablets of matched placebo daily by mouth
58455770|NCT00769886|DRUG|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
58455771|NCT00769886|DRUG|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
58455772|NCT00769886|DRUG|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
58455773|NCT00769886|DRUG|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
58455774|NCT02102035|PROCEDURE|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
58455775|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
58455776|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|
58455777|NCT05042700|DRUG|Melatonin|Enema with 25 mg melatonin
58455778|NCT05042700|DRUG|Placebo|Enema without melatonin
58455779|NCT05627973|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
58455780|NCT04356495|DIETARY_SUPPLEMENT|Vitamins|2 tablets daily from the first day (day 0) to day 9
58455781|NCT04356495|DRUG|Telmisartan|1 tablet daily from the first day (day 0) to day 9
58455782|NCT04356495|DRUG|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
58455783|NCT04356495|DRUG|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
57759906|NCT06282315|DRUG|Baseline Effectiveness Cohort|"Before the administration of the study drug at school, participants selected for the Effectiveness Cohort will perform an additional study visit during which they will provide the study team with a stool sample for STH analysis. A dried blood spot (DBS) sample will also be taken to test for S. stercoralis.~Sampling of the baseline effectiveness cohort will be conducted within 7 days before the start of the school study intervention. In addition to the delivery of the stool/blood sample, participants from the effectiveness cohort will be evaluated for scabies by designated study personnel following the IACs simplified criteria."
57759907|NCT06282315|DRUG|Day 0 Trial Intervention|"Within seven days after the first sample for the baseline effectiveness cohort is collected, the school's mass administration of the allocated drug will take place. All participants included in the list of eligible subjects from a particular randomized school will receive a single dose of the medication administered to their school (FDC or ALB). Before the administration, participants will be asked about any medical condition that has arisen since the last study visit, in which case information will be documented as a concomitant disease.~In case a participant vomits within one hour after the study drug intake (during the study physician observation period), the participant will continue participating in the trial and may still participate in the effectiveness cohort. If they are chosen for the day 21 or month 11 effectiveness cohort, an additional sensitivity analysis will be performed without including these participants, considered as Intervention Fail."
57759908|NCT06282315|DRUG|Active Surveillance (study visit Day 1, Day 2 and Day 7)|Active safety surveillance will be performed at school during the trial intervention on day 0 until day 7 post-intervention. The assessment will include recording of all AEs and SAEs presented by study participants from the intake of the study drugs, and for two additional days (Day 1 and Day 2 study visits). During active surveillance, participants will be visited by a study physician at school during the study intervention, on day one and day two, and they will be questioned about any potential AE or change in a pre-existing condition. In addition, a final safety visit will be conducted to all participants at Day 7 to collect data on any potential AE occurred between day 2 and the end of the surveillance period and to perform a follow up of any AE ongoing after Day 2 visit.
57759909|NCT06282315|DRUG|Passive Surveillance|Passive surveillance will be carried out by monitoring AEs in health facilities near the schools involved in the study for six days after the intervention until Day 7 (end of the safety surveillance period). Although AE will be actively monitored during the scheduled study visits, this passive surveillance will allow for the identification of AEs and potential SAEs that might occur and remained underreported in case the participant does not attend school during the active safety surveillance period.
58455784|NCT03102554|GENETIC|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
58455785|NCT03827408|DRUG|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
58455786|NCT03827408|DRUG|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
58455787|NCT03827408|DRUG|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
58455788|NCT03992079|PROCEDURE|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
58455789|NCT01775644|DRUG|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
58455790|NCT02800616|OTHER|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
58455791|NCT02800616|BEHAVIORAL|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
58455792|NCT01353404|DRUG|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
58455793|NCT01353404|DRUG|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
58455794|NCT01353404|DRUG|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
58455795|NCT01353404|DRUG|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
58455796|NCT01353404|DRUG|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
58455797|NCT01353404|DRUG|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
58455798|NCT04735874|OTHER|Evaluate vascular disease risk factors in children with Down Syndrome|We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw \[lipid panel with subfractions (NMR), insulin, glucose, and CRP\].
58455799|NCT04735874|OTHER|Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome|We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
57759910|NCT06282315|DRUG|Post-Treatment Effectiveness Evaluation|"Post-treatment effectiveness evaluation will be performed by measuring the prevalence of STH at two time points: 21 days after the intervention (± 7 days) and 11 months after intervention (± 28 days). Additionally, the reduction in S. stercoralis seroprevalence will be evaluated 11 months after the intervention.~These participants will be tested for STH by Kato-Katz at the two post-treatment time points (day 21 and month 11) and for S. stercoralis by NIE ELISA at 11 months. The diagnostic test will be the same as in the intervention of Baseline Effectiveness Cohort.~As part of the genetic monitoring pilot study and the microbiome analysis, the same samples will be collected as described in the intervection of Baseline Effectiveness Cohort."
57759911|NCT01423786|DIETARY_SUPPLEMENT|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
58455800|NCT02653326|DEVICE|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
57759912|NCT01859793|DRUG|sitagliptin|100 mg pill, administered once/day orally
57759913|NCT01859793|DRUG|Placebo|Matching placebo in appearance given once/day orally
58455801|NCT02653326|PROCEDURE|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
58455802|NCT02653326|BEHAVIORAL|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
57759914|NCT04274959|OTHER|ceramic onlay with shoulder preparation design.|ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,
57759915|NCT04274959|OTHER|,ceramic onlay with butt joint preparation design|ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
57759916|NCT04782934|DEVICE|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
57759917|NCT05750186|OTHER|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
57759918|NCT01416233|PROCEDURE|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
57759919|NCT00838682|DRUG|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
58455803|NCT02653326|OTHER|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
58455804|NCT02653326|DRUG|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
58455805|NCT04970875|OTHER|Questionnaire|QoL questionnaire
58455806|NCT01137032|DRUG|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
58455807|NCT01307319|DRUG|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
58455808|NCT01307319|DRUG|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
57759920|NCT00838682|DRUG|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
57759921|NCT01021592|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
57759922|NCT01498822|DRUG|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
57759923|NCT01498822|DRUG|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
57759924|NCT02823821|OTHER|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
57759925|NCT02823821|OTHER|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
57759926|NCT02143037|BEHAVIORAL|prize contingency management for attending treatment|
57759927|NCT02143037|BEHAVIORAL|usual care|
57759928|NCT05048849|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
57759929|NCT06247202|OTHER|Smart Phone Education (mhealth)|Nutrition and Health Education module delivered through m-health approach (smart phones)
57759930|NCT06247202|OTHER|Paper Education (conventional)|Nutrition and Health Education module delivered through conventional approach (paper)
57759931|NCT00509236|DRUG|Sitagliptin|25 mg (one 25-mg tablet) once daily
57759932|NCT00509236|DRUG|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
57759933|NCT02524301|DRUG|Positron Emission Tomography using [11C]diprenorphine|PET using \[11C\]diprenorphine
57759934|NCT01300325|OTHER|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
57759935|NCT04671901|DRUG|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
57759936|NCT05538962|DIAGNOSTIC_TEST|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
57759937|NCT02579798|DEVICE|PEEP (positive end-expiratory pressure)|
57759938|NCT05981664|DEVICE|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
57759939|NCT04947254|DRUG|Abiraterone Acetate|Given PO
57759940|NCT04947254|DRUG|Antiandrogen Therapy|Given ADT
57759941|NCT04947254|DRUG|Apalutamide|Given PO
57759942|NCT04947254|PROCEDURE|Biopsy|Undergo biopsy
57759943|NCT04947254|DRUG|Niraparib|Given PO
57759944|NCT04947254|DRUG|Prednisone|Given PO
57759945|NCT04947254|RADIATION|Radiation Therapy|Undergo radiation therapy
57759946|NCT05886725|OTHER|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
57759947|NCT02073916|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
57759948|NCT02073916|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
57759949|NCT02073916|DRUG|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
57759950|NCT05878392|OTHER|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
57759951|NCT00658437|DRUG|CY-503|solution for subcutaneous injection, 350 ng twice weekly
57759952|NCT05363319|DRUG|Cemiplimab|solution for injection via intravenous (IV) infusion
57759953|NCT05363319|DRUG|Platinum-based chemotherapy|IV administration
57759954|NCT06473844|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg once daily from recruitment to hospital discharge
57759955|NCT06473844|DRUG|Placebo|Placebo single tablet once daily from recruitment to hospital discharge
57759956|NCT01889186|DRUG|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
57759957|NCT01889186|DRUG|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
57759958|NCT03390777|PROCEDURE|surgery|surgery without the use of prgf
57759959|NCT03390777|DEVICE|PRGF after surgery|surgery and application of PRGF
57759960|NCT00000192|DRUG|Lamotrigine|
57759961|NCT00314561|DRUG|Pioglitazone, Rosiglitazone|
57759962|NCT00738101|DRUG|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
57759963|NCT02645084|OTHER|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
57759964|NCT05530590|OTHER|Training to Serve (TTS) in person training|Participants receive in person training.
57759965|NCT05530590|OTHER|Training to Serve online training (eTTS)|Participants receive online training.
57759966|NCT02835872|OTHER|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
57759967|NCT03490214|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
57759968|NCT05877443|PROCEDURE|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
57759969|NCT05877443|PROCEDURE|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
57759970|NCT05877443|PROCEDURE|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
57759971|NCT05712902|DRUG|DZD9008|Daily dose of DZD9008
57759972|NCT02872948|GENETIC|Diagnostic|
57759973|NCT00001785|DRUG|Recombinant human interferon beta-1a|
57759974|NCT04659395|OTHER|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
57759975|NCT01453348|BIOLOGICAL|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
57759976|NCT01453348|BIOLOGICAL|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
57759977|NCT01453348|BIOLOGICAL|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
57759978|NCT01453348|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
57759979|NCT06437093|OTHER|TEACHING RELACTATION TECHNIQUES|"In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally."
58458621|NCT04541407|DRUG|Temozolomide plus Osimertinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
57759980|NCT02816190|PROCEDURE|prone position|
57759981|NCT05134402|DIAGNOSTIC_TEST|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
57759982|NCT05485363|DIAGNOSTIC_TEST|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
57759983|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
57759984|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
57759985|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
57759986|NCT04418934|DEVICE|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
57759987|NCT03350100|DIETARY_SUPPLEMENT|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
57759988|NCT01465828|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
57759989|NCT01465828|DRUG|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
57759990|NCT01960595|PROCEDURE|IV fentanyl PCA|
57759991|NCT01960595|PROCEDURE|local bupivacaine infiltration and post-OP IV fentanyl PCA|
57759992|NCT01960595|PROCEDURE|Nerve Blocks and post-OP IV fentanyl PCA|
57759993|NCT05124093|PROCEDURE|Apnoeic oxygenation|"After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%."
57759994|NCT02564679|PROCEDURE|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
57759995|NCT02564679|BEHAVIORAL|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
57759996|NCT03994042|DEVICE|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
57759997|NCT05002205|OTHER|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
57759998|NCT05002205|OTHER|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
57759999|NCT05002205|OTHER|ECG|During two study visits, the presence of arrhythmia will be explored.
57760000|NCT05002205|OTHER|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
57760001|NCT05002205|OTHER|Vital parameters|blood pressure, pulse, weight
57760002|NCT06610981|DEVICE|Laser acupuncture|Laser acupuncture will be used in this study with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks
57760003|NCT06610981|OTHER|traditional physical therapy|exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks
57760004|NCT06610981|DEVICE|Sham laser acupuncture|Participants will receive laser acupuncture while the device is turned off.
57760005|NCT03042962|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
57760006|NCT03042962|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
57760007|NCT05977894|OTHER|Reduced Environmental Stimulation Therapy|"During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation."
58455809|NCT04906122|OTHER|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling.|The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group. The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
58455810|NCT05362123|OTHER|non interventional|Online google form questioner
58455811|NCT02611180|PROCEDURE|Skin punch biopsy|
58455812|NCT02611180|PROCEDURE|Peripheral blood draw|
57760008|NCT05470478|DEVICE|Mobile neural decoding platform (mobile iBCI)|An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
57760009|NCT02223884|DRUG|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
57760010|NCT02223884|DRUG|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
57760011|NCT00676130|DRUG|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
58455813|NCT02742961|OTHER|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
57760012|NCT00676130|DRUG|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
57760013|NCT03156634|OTHER|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
57760014|NCT03156634|OTHER|WebMD|WebMD is an internet based health information source.
57760015|NCT03737201|OTHER|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
57760016|NCT03737201|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
57760017|NCT03737201|OTHER|Control|without any cavity disinfectant
57760018|NCT01308606|DRUG|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
57760019|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
57760020|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
57760021|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
57760022|NCT01308606|DRUG|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
58455814|NCT00416208|DRUG|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
58455815|NCT04968158|DRUG|Etoricoxib 90 mg / Tramadol 50 mg|One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
57760023|NCT01789697|OTHER|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
57760024|NCT04885270|DRUG|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
57760025|NCT05921305|DRUG|MTX|MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
57760026|NCT05921305|DRUG|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
57760027|NCT02486679|DRUG|Prostin (PGE2) tablets|
57760028|NCT02486679|DEVICE|Foley catheter|
57760029|NCT05265455|DIETARY_SUPPLEMENT|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
57760030|NCT05265455|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
57760031|NCT00116272|DRUG|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
57760032|NCT05819996|BEHAVIORAL|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
57760033|NCT03135535|DEVICE|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
57760034|NCT01373450|DRUG|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
57760035|NCT01373450|DRUG|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
57760036|NCT01373450|DRUG|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
57760037|NCT01373450|DRUG|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
57760038|NCT01373450|DRUG|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
58455816|NCT04968158|DRUG|Acetaminophen 325 mg / Tramadol 37.5 mg|One tablet, every 8 hours of 325 mg/ 37.5 m
58455817|NCT02416999|DRUG|Ultra-low dose Bevacizumab|
57760039|NCT05994391|DIETARY_SUPPLEMENT|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin"
57760040|NCT05994391|DIETARY_SUPPLEMENT|Placeo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose"
57760041|NCT00926510|BEHAVIORAL|Language toolkit|Simple toolkit of interactive things to stimulate language.
57760042|NCT00926510|BEHAVIORAL|Safety counseling|Smoke detector and general safety counseling
57760043|NCT01741454|DRUG|Tamsulosin|0.4 mg by mouth once per day.
57760044|NCT01741454|DRUG|Tolterodine ER|4 mg by mouth once a day.
57760045|NCT02074046|BIOLOGICAL|cancer stem cell vaccine|
57760046|NCT01288339|DRUG|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
58128865|NCT04085666|DRUG|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
58455818|NCT02416999|DRUG|Temozolomide|
58455819|NCT05515835|DEVICE|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
58455820|NCT02222571|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
58455821|NCT02222571|BEHAVIORAL|Supervision for Safety|group-based safety intervention for parents
58455822|NCT05927038|OTHER|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
58455823|NCT05927038|OTHER|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
58455824|NCT03675503|OTHER|Fall Prevention Decision Support|Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
58455825|NCT02053012|DEVICE|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
58455826|NCT02464436|DRUG|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
58455827|NCT02302768|DIETARY_SUPPLEMENT|Selenomethionine|
58455828|NCT02302768|OTHER|Placebo|
58455829|NCT03273673|OTHER|Biofeedback Intervention|Visual and Tactile Biofeedback
58455830|NCT03125226|DEVICE|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
58455831|NCT01145742|BEHAVIORAL|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
58455832|NCT05955846|PROCEDURE|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
58128866|NCT04085666|OTHER|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
58455833|NCT05955846|DEVICE|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
58455834|NCT03515577|PROCEDURE|Computed Tomography|Undergo PET/CT
58455835|NCT03515577|DRUG|Fluciclovine F18|Given fluciclovine F18
58455836|NCT03515577|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
58455837|NCT03515577|OTHER|Laboratory Biomarker Analysis|Correlative studies
58455838|NCT03515577|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58455839|NCT01814527|DIETARY_SUPPLEMENT|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
58455840|NCT01814527|DRUG|Placebo|5 capsules that are identical to the treatment.
58455841|NCT00153296|DRUG|Carbamazepine|
58455842|NCT00451672|DRUG|bromocriptine|
58455843|NCT02454738|RADIATION|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
58455844|NCT00972192|BEHAVIORAL|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
58455845|NCT00972192|BEHAVIORAL|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
58455846|NCT01290523|DEVICE|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
58455847|NCT03918616|DRUG|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
58455848|NCT04393415|COMBINATION_PRODUCT|stem cells|giving stem cells to patients with covid - 19
58128867|NCT03323125|OTHER|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
58455849|NCT00878241|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
58455850|NCT03018236|DRUG|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
58455851|NCT03018236|DRUG|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
58128868|NCT04091347|BEHAVIORAL|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
58128869|NCT04281992|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
58128870|NCT03582332|DRUG|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
58128871|NCT03582332|DRUG|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
58128872|NCT03582332|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
58128873|NCT03582332|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
58128874|NCT00597194|PROCEDURE|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
58455852|NCT03018236|DRUG|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
58455853|NCT03018236|DRUG|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
58455854|NCT03708107|DEVICE|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
58455855|NCT03708107|OTHER|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
58455856|NCT00025597|DRUG|carboplatin|
58455857|NCT00025597|DRUG|cyclophosphamide|
58455858|NCT00025597|DRUG|doxorubicin hydrochloride|
58455859|NCT00025597|DRUG|etoposide|
58455860|NCT00025597|DRUG|vincristine sulfate|
58455861|NCT00025597|PROCEDURE|conventional surgery|
58455862|NCT02337868|BIOLOGICAL|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
58455863|NCT02337868|OTHER|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
58455864|NCT01263964|PROCEDURE|coronary angiogram|coronary angiogram
58455865|NCT05930652|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
57760047|NCT01288339|DRUG|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
57760048|NCT00114361|DRUG|Ribavirin|1200 mg a day, 48 weeks
58455866|NCT04675385|DRUG|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
58455867|NCT02016976|DRUG|EMLA Analgesic Cream|
58455868|NCT02016976|DRUG|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
58455869|NCT05917912|DRUG|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
58455870|NCT05917912|DRUG|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
58455871|NCT05997446|DEVICE|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
58455872|NCT05107895|BEHAVIORAL|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
58455873|NCT01832077|DEVICE|90 D|rural doctors exam eye fundus by 90 D
58455874|NCT01832077|DEVICE|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
58455875|NCT01141712|PROCEDURE|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
58455876|NCT01141712|DRUG|BCNU|Participants will receive BCNU 300 mg/m\^2 Day -6
58455877|NCT01141712|DRUG|Etoposide|Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
58455878|NCT01141712|DRUG|Cytarabine|Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
58455879|NCT01141712|DRUG|Melphalan|Participants will receive Melphalan 140 mg/m\^2 Day -1
57760049|NCT00114361|DRUG|Peginterferon alpha 2a|180 µg per week, 48 weeks
57760050|NCT02627508|DRUG|Pregnenolone|orally administered Pregnenolone capsules
57760051|NCT02627508|DRUG|Placebo|orally administered placebo capsules
57760052|NCT00832195|DEVICE|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
57760053|NCT00832195|DEVICE|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
57760054|NCT05791448|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57760055|NCT05791448|PROCEDURE|Computed Tomography|Undergo CT scan
58455880|NCT01934959|DRUG|Bifico|
57760056|NCT05791448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57760057|NCT05791448|DRUG|RNA Transcription Modulator AU-409|Given PO
57760058|NCT01575743|BEHAVIORAL|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
57760059|NCT02145325|DRUG|Expanded Tregs|
58128875|NCT03665103|OTHER|Laser-assisted ICSI|Laser opening of the zona pellucida.
58128876|NCT01582607|DRUG|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
58455881|NCT01792310|DRUG|LAM561|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
58455882|NCT01619371|DEVICE|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
58455883|NCT05297877|OTHER|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
58455884|NCT05297877|OTHER|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
58455885|NCT02914639|DRUG|SF0166 Topical Ophthalmic Solution|
58455886|NCT02970981|BIOLOGICAL|Nivolumab|
58455887|NCT02970981|BIOLOGICAL|Ipilimumab|
58455888|NCT04217382|OTHER|patient with melanoma pre transplantation|survival time without melanoma recurrence
58455889|NCT05783206|DRUG|MIR 19 ®|"MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs."
57760060|NCT06578715|BEHAVIORAL|Emotional Freedom Technique|EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
57760061|NCT01022086|PROCEDURE|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
57760062|NCT01022086|BIOLOGICAL|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
57760063|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
58455890|NCT05783206|COMBINATION_PRODUCT|Standard therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
58455891|NCT01169025|DRUG|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
58455892|NCT01169025|DRUG|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
58455893|NCT00472225|DRUG|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
58455894|NCT01742273|DRUG|Vitamin K1|Vitamin K1 to slow vascular calcification
58455895|NCT02107833|DRUG|OPRX-106|
58455896|NCT02376634|BEHAVIORAL|Hypnosis|Patients will be taught self-hypnosis.
58455897|NCT06014346|OTHER|Psychological strategy|"* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* then realization accompanied by a training of these exercises"
57760064|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
57760065|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
57760066|NCT00372801|DRUG|Ibuprofen|
57760067|NCT01296022|DEVICE|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
57760068|NCT01296022|DEVICE|Implantation of transvenous ICD|Implantation of transvenous ICD
57760069|NCT01488708|DRUG|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
57760070|NCT01488708|DRUG|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
57760071|NCT03237273|OTHER|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
57760072|NCT01481155|PROCEDURE|ablative CO2 laser therapy|CO2 laser therapy
57760073|NCT01481155|PROCEDURE|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
58128877|NCT01582607|DRUG|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
58455898|NCT06014346|OTHER|Physiological strategy|- ingesting a salty snack
58455899|NCT00626444|DRUG|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
58455900|NCT00985673|BIOLOGICAL|GSK2340274A|Two intramuscular injections
58455901|NCT00985673|BIOLOGICAL|GSK2340273A|Two intramuscular injections
58455902|NCT00985673|BIOLOGICAL|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
58455903|NCT00985673|BIOLOGICAL|Saline placebo|Single intramuscular injection
58455904|NCT01302717|DEVICE|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
57760074|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
57760075|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
57760076|NCT04256356|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
57760077|NCT04256356|OTHER|Breastfeeding infants|reference group
57760078|NCT00865943|DRUG|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
57760079|NCT00865943|DRUG|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
57760080|NCT02294136|BEHAVIORAL|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
57760081|NCT02294136|BEHAVIORAL|Educational Control|Attention Control
57760082|NCT05756608|DIAGNOSTIC_TEST|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
57760083|NCT06352359|DRUG|ONC-841|ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
57760084|NCT02217280|DRUG|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
57760085|NCT04555096|DRUG|GC4419|180 Minute IV Infusion
57760086|NCT04555096|DRUG|Placebo|180 Minute IV Infusion
57760087|NCT02102880|GENETIC|the polymerase chain reaction (PCR)|
57760088|NCT00705302|BEHAVIORAL|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
57760089|NCT00705302|BEHAVIORAL|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
57760090|NCT00876915|DRUG|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
57760091|NCT00643123|DRUG|Allopurinol|300-600 mg/day over a 6 week period
57760092|NCT00643123|OTHER|Placebo|Inactive substance
57760093|NCT03013946|BEHAVIORAL|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
57760094|NCT04495439|DEVICE|Augmentation with the ISS Study System|Augmentation with the ISS Study System
57760095|NCT04495439|OTHER|Augmentation with PMMA|Augmentation with PMMA (standard)
57760096|NCT00377780|DRUG|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
58128878|NCT01582607|DRUG|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
58128879|NCT01582607|DRUG|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
57760097|NCT01368445|DRUG|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM \& PM)
58128880|NCT01582607|DRUG|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
58128881|NCT01582607|DRUG|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
58128882|NCT03392298|DRUG|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
58128883|NCT06196684|PROCEDURE|Mitral allograft implantation|Tricuspid valve replacement with mitral valve allograft
58128884|NCT00802451|DRUG|Mesalamine|
58128885|NCT05449977|DIAGNOSTIC_TEST|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
58455905|NCT01302717|DEVICE|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
57760098|NCT01368445|DRUG|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
57760099|NCT01368445|DRUG|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
57760100|NCT03034499|PROCEDURE|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
57760101|NCT03034499|PROCEDURE|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
57760102|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
57760103|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
57760104|NCT00959101|DRUG|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
57760105|NCT00959101|DRUG|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
57760106|NCT05716984|DRUG|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
57760107|NCT05716984|DRUG|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
57760108|NCT02212444|DEVICE|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
57760109|NCT02212444|DEVICE|Off -the-shelf triplanar orthoses|
57760110|NCT01201811|DRUG|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
58128886|NCT05140447|OTHER|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
58455906|NCT03301883|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
57760111|NCT03728608|DEVICE|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
57760112|NCT03728608|DEVICE|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
57760113|NCT05629663|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
57760114|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
58128887|NCT05769530|DRUG|Nalbuphine，dexmedetomidine|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
58128888|NCT00002047|DRUG|Zidovudine|
57760115|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
57760116|NCT05917977|BEHAVIORAL|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
57760117|NCT05917977|OTHER|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
57760118|NCT03076541|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
58128889|NCT01230580|DRUG|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
58128890|NCT01230580|DRUG|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
58128891|NCT01933607|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
58455907|NCT03301883|DRUG|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
57760119|NCT04141735|DIAGNOSTIC_TEST|ultrasound|no intervention
57760120|NCT04269239|BEHAVIORAL|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
57760121|NCT04269239|BEHAVIORAL|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
57760122|NCT05114525|BEHAVIORAL|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
57760123|NCT06153043|OTHER|Women patients with classical congenital adrenal hyperplasia|The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
57760124|NCT02653638|OTHER|Control|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
57760125|NCT02653638|DRUG|Indomethacin|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
57760126|NCT06307184|PROCEDURE|Natural proliferative phase frozen embryo transfer|When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
57760127|NCT06472336|PROCEDURE|Intracranial stenting|Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.
57760128|NCT06472336|PROCEDURE|Continuation of conventional endovascular therapy (EVT)|Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
57760129|NCT05868915|BIOLOGICAL|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
57760130|NCT05362552|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
57760131|NCT02546414|OTHER|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
57760132|NCT04104750|OTHER|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
57760133|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
57760134|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
57760135|NCT02525003|OTHER|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
57760136|NCT01121302|DRUG|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
57760137|NCT01121302|DRUG|Placebo|
57760138|NCT03730285|DEVICE|Telemedicine|Installation of videotelephone with broadband in patient's home
57760139|NCT02981901|OTHER|Patient with ovarian epithelial cancer|
57760140|NCT05275439|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
57760141|NCT03542526|DEVICE|electrogradiogram|12 lead ecg ambulatory blood prussre
57760142|NCT03542526|DEVICE|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
58128892|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
58128893|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
57760143|NCT00006048|DRUG|cisplatin|
57760144|NCT00006048|DRUG|gefitinib|
58128894|NCT06012903|OTHER|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
57760145|NCT00006048|DRUG|gemcitabine hydrochloride|
57760146|NCT02391636|DRUG|Carbetocin|at delivery of anterior shoulder
57760147|NCT02391636|DRUG|Oxytocin|at delivery of anterior shoulder
57760148|NCT03756584|DEVICE|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
57760149|NCT02878174|PROCEDURE|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
57760150|NCT02630095|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
57760151|NCT02630095|DEVICE|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
57760152|NCT05685992|OTHER|no intervention|no intervention
57760153|NCT01988948|OTHER|Various biological sampling|
57760154|NCT04095260|OTHER|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
57760155|NCT06539351|OTHER|Skin biopsy|4mm skin punch biopsy
57760156|NCT00892125|DRUG|paliperidone ER; Carbamazepine|
57760157|NCT03237858|DEVICE|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
57760158|NCT03237858|DEVICE|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
58128895|NCT06012903|OTHER|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
58128896|NCT06012903|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
57760159|NCT06328582|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing."
57760160|NCT06328582|PROCEDURE|Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture|"Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral)."
57760161|NCT00674466|DRUG|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
57760162|NCT00674466|DRUG|Placebo|twice-a-week
57760163|NCT00961025|DRUG|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
57760164|NCT00961025|DRUG|Placebo|placebo
57760165|NCT04286126|DEVICE|Active bilateral DMPFC|Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).
57760166|NCT04286126|DEVICE|Active right-sided OFC|Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
57760167|NCT01555164|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
57760168|NCT01555164|DRUG|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
57760169|NCT01555164|DRUG|Metformin|Metformin tablet(s) administered orally once daily
57760170|NCT01555164|DRUG|Placebo to match metformin|Placebo to match metformin for the duration of the study
57760171|NCT01555164|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
57760172|NCT01555164|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
57760173|NCT04524078|OTHER|intensive integrated intervention care program|intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
57760174|NCT00509548|DRUG|TG100801|Eye drop, twice a day, 30 days.
57760175|NCT00632957|DIETARY_SUPPLEMENT|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
57760176|NCT00632957|DIETARY_SUPPLEMENT|Placebo|corn/soybean oil capsules 1g/three times daily
57760177|NCT05698134|DIAGNOSTIC_TEST|ROTEM|ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.
57760178|NCT05698134|OTHER|Standard of care|Standard of care
57760179|NCT06013943|DRUG|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
57760180|NCT00464451|DRUG|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
57760181|NCT00464451|DRUG|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
57760182|NCT01394874|BEHAVIORAL|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
58455908|NCT03301883|DRUG|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
57760183|NCT03580590|DRUG|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
57760184|NCT03580590|DRUG|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
57760185|NCT03580590|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
57760186|NCT00927056|PROCEDURE|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
57760187|NCT03266822|OTHER|No intervention|Observational study
57760188|NCT04671238|DEVICE|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
57760189|NCT06262165|OTHER|Patients with Anorexia Nervosa|Patients with Anorexia Nervosa hospitalized for malnutrition
57760190|NCT01154478|OTHER|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
57760191|NCT01154478|OTHER|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
57760192|NCT01154478|OTHER|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
58455909|NCT03301883|DRUG|MTX|Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
58455910|NCT05569902|DEVICE|active tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
57760193|NCT01154478|OTHER|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
57760194|NCT06228521|OTHER|Liquid nitrogen sprayed|Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.
57760195|NCT06228521|OTHER|980nm diode laser applied|980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
57760196|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
57760197|NCT03749577|DIETARY_SUPPLEMENT|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
57760198|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
57760199|NCT03749577|DIETARY_SUPPLEMENT|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
57760200|NCT03198286|OTHER|Informational Intervention|Receive treatment summary and survivor care plan
57760201|NCT02998814|OTHER|acid-etch|acid-etch
57760202|NCT02998814|OTHER|self-etch adhesive|Self etch (7th generation ) bonding agent
57760203|NCT02998814|OTHER|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
57760204|NCT02998814|OTHER|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
57760205|NCT05384925|OTHER|comparison|abdominal surgery as a risk factor for diverticulosis
58455911|NCT05569902|DEVICE|sham tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
58455912|NCT00285896|DRUG|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
58455913|NCT00285896|DRUG|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
58455914|NCT03361085|PROCEDURE|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
58455915|NCT01512134|DEVICE|Deep Brain Stimulation Device|Deep brain stimulation surgery
57760206|NCT02437825|DRUG|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
57760207|NCT02437825|OTHER|placebo|placebo ( saline) act as comperator in this study.
57760208|NCT04731155|DRUG|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
57760209|NCT04731155|DRUG|standard medications|standard medications was giving to subjects according guidelines
57760210|NCT03816995|DEVICE|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
57760211|NCT03816995|DEVICE|Alexis O Wound Protector|wound retraction
57760212|NCT05226858|DIAGNOSTIC_TEST|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
57760213|NCT02422719|DRUG|Radotinib|Radotinib 400mg bid
58455916|NCT06350188|OTHER|experimental|15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month
58455917|NCT06350188|OTHER|traditional|15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
58455918|NCT04294121|OTHER|Food marketing on product packaging|Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
58455919|NCT00637065|DRUG|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
57760214|NCT01301274|DRUG|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
57760215|NCT01301274|DRUG|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
57760216|NCT02013336|DRUG|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|chemotherapy
57760217|NCT03300570|DRUG|Dolcanatide|Given PO
57760218|NCT03300570|OTHER|Laboratory Biomarker Analysis|Correlative studies
57760219|NCT03300570|OTHER|Placebo Administration|Given PO
57760220|NCT03300570|OTHER|Questionnaire Administration|Ancillary studies
57760221|NCT04211415|DRUG|DS-2741a|Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
57760222|NCT04211415|DRUG|Placebo|Single, subcutaneous injection administered weekly for 4 weeks
57760223|NCT00158340|BEHAVIORAL|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
57760224|NCT00158340|BEHAVIORAL|Usual clinical care|Control group participants receive treatment as usual.
57760225|NCT01758484|OTHER|palliative care|Undergo supportive care intervention
57760226|NCT01758484|OTHER|questionnaire administration|Ancillary studies
57760227|NCT01758484|PROCEDURE|quality-of-life assessment|Ancillary studies
57760228|NCT01840384|DIETARY_SUPPLEMENT|Multi-micronutrients|
57760229|NCT01840384|DIETARY_SUPPLEMENT|Maltodextrin and Lactose|
57760230|NCT03499522|OTHER|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\]."
57760231|NCT04307459|OTHER|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
58455920|NCT00637065|DRUG|Placebo|Placebo tables - identical to active drug but without the active ingredient -
58128897|NCT06012903|OTHER|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
58128898|NCT06012903|OTHER|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
58455921|NCT04206735|OTHER|Interprofessional Education (IPE)|We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.
58455922|NCT04206735|OTHER|Usual care|Usual care of patients hospitalized with severe COPD exacerbation
58455923|NCT00170508|BIOLOGICAL|Fluzone®|
58455924|NCT00003316|DRUG|gemcitabine hydrochloride|
58455925|NCT02005016|BEHAVIORAL|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
58455926|NCT00791388|DRUG|Placebo|oral capsule, 2x/day for 14 days
58455927|NCT00791388|DRUG|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
58455928|NCT00791388|DRUG|PG-760564|oral capsule, 100mg, 2x/day for 14 days
58455929|NCT00791388|DRUG|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
58455930|NCT00791388|DRUG|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
58455931|NCT00405080|DRUG|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
58455932|NCT00405080|DRUG|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
58455933|NCT02738814|DRUG|propofol|When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
58455934|NCT01599663|OTHER|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
58455935|NCT02304900|OTHER|white implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
58455936|NCT02304900|OTHER|yellow implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
57760232|NCT03790670|DRUG|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
58128899|NCT00218309|DRUG|Hydromorphone|
58455937|NCT03568981|RADIATION|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
58455938|NCT03568981|RADIATION|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
58455939|NCT05507307|BEHAVIORAL|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
58455940|NCT03714178|DEVICE|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
58455941|NCT00632216|DRUG|Risedronate Sodium|
58455942|NCT05020509|PROCEDURE|medial branch block|lumbar medial branch block
58455943|NCT06086821|DIAGNOSTIC_TEST|Periodontal Re-Evaluation|Recording of the periodontal charting
58455944|NCT02307708|DEVICE|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
58455945|NCT02307708|OTHER|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
58455946|NCT03947177|BEHAVIORAL|GMIT|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
58455947|NCT03947177|BEHAVIORAL|GMIT+|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
58455948|NCT00471692|DRUG|Ropivicaine|
58455949|NCT05677893|DRUG|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
58455950|NCT05677893|OTHER|Placebo|Normal saline
58128900|NCT05543148|OTHER|Questionnaire|Evaluate hearing loss and communication and conversation disabilities
58128901|NCT01147952|BEHAVIORAL|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
57760233|NCT05670925|DRUG|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
57760234|NCT05683717|DRUG|TT-01488 Tablets|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
57760235|NCT04345458|DRUG|prefilled liquid etanercept(Yisaipu)|
57760236|NCT04345458|DRUG|lyophilized etanercept powder(Yisaipu)|
57760237|NCT04803578|OTHER|Conventional physiotherapy|The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
58128902|NCT01400425|DRUG|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
58455951|NCT01231958|BEHAVIORAL|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
58455952|NCT03980015|OTHER|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
58455953|NCT04048486|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
58455954|NCT04048486|OTHER|Physical development and General Health|Physical development and General health examination
58455955|NCT04048486|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
58455956|NCT01990521|PROCEDURE|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
58455957|NCT01990521|DEVICE|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
57760238|NCT03287414|DRUG|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
58128903|NCT03814343|DRUG|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
58128904|NCT03814343|DRUG|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
57760239|NCT03287414|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
57760240|NCT03287414|DRUG|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
57760241|NCT01329354|BIOLOGICAL|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
57760242|NCT02085681|OTHER|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
57760243|NCT02085681|OTHER|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
57760244|NCT00161239|DRUG|Doxil, Methotrexate, L-Asparaginase, Prednisone|
57760245|NCT02628132|DRUG|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
57760246|NCT02628132|DRUG|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
58128905|NCT03490721|OTHER|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
58128906|NCT01911195|DRUG|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
57760247|NCT02677025|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
57760248|NCT02677025|BEHAVIORAL|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
57760249|NCT05163613|OTHER|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
57760250|NCT05163613|OTHER|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
58455958|NCT00793195|DRUG|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
57760251|NCT00570024|PROCEDURE|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
57760252|NCT00570024|PROCEDURE|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
57760253|NCT05199610|DRUG|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
57760254|NCT06249763|DIETARY_SUPPLEMENT|High gluten diet|Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
57760255|NCT06249763|DIETARY_SUPPLEMENT|Gluten free diet|Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
57760256|NCT03122054|PROCEDURE|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
57760257|NCT04230057|DIETARY_SUPPLEMENT|Antitumor B|Single dose 2400 mg
57760258|NCT00496002|DRUG|Clevudine|
57760259|NCT00496002|DRUG|Adefovir|
57760260|NCT02891343|OTHER|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
58128907|NCT01911195|OTHER|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
58128908|NCT04578743|DEVICE|Graded Exercise Therapy: ClearPlay(TM)|ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
58128909|NCT02305758|DRUG|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
58128910|NCT02305758|DRUG|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
57760261|NCT01015976|PROCEDURE|bariatric surgery|Roux en Y bariatric surgery
57760262|NCT01015976|OTHER|control|No surgery
58128911|NCT02305758|DRUG|Modified FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
58128912|NCT02305758|DRUG|FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
58128913|NCT02305758|DRUG|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
57760263|NCT06625073|DRUG|Empagliflozin|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
57760264|NCT06625073|DRUG|Placebo|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
57760265|NCT06347484|BEHAVIORAL|EHR-informed Recruitment Method of Contact|The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR
57760266|NCT06347484|BEHAVIORAL|Educational Text-Messages and Connection to Cardiovascular Research Opportunities|All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
57760267|NCT01802437|DRUG|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
57760268|NCT01802437|BEHAVIORAL|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
57760269|NCT01802437|BEHAVIORAL|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
57760270|NCT01949103|DRUG|TD-1607|
58455959|NCT00793195|DRUG|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
58455960|NCT00361881|DRUG|ME-609|Cream, dose 5 times daily during 5 days.
58455961|NCT00361881|DRUG|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
58455962|NCT00361881|DRUG|Vehicle|Dose 5 times daily for 5 days
58455963|NCT01845935|DEVICE|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
58455964|NCT06527170|PROCEDURE|Sleeve gastrectomy|Each patient undergoes bariatric surgery. Each patient is diagnosed before surgery for erectile dysfunction. Similar tests are done 1 year after
58455965|NCT00420485|DRUG|gimatecan|
57760271|NCT01949103|DRUG|Placebo|
58455966|NCT05887986|OTHER|hand-held fan airflow stimulation|"Outcome dyspnea measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the dyspnea level will be evaluated.~Outcome comfort measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the comfort level of the patients will be evaluated."
58455967|NCT04900012|PROCEDURE|Distal pancreatectomy|We are going to collect all cases
58455968|NCT05106881|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
58455969|NCT01746303|DIETARY_SUPPLEMENT|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
58455970|NCT01746303|DIETARY_SUPPLEMENT|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
58455971|NCT01746303|OTHER|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
58455972|NCT01746303|OTHER|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
57760272|NCT06484829|DRUG|Purinostat Mesylate 3mg/m2|3 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
57760273|NCT06484829|DRUG|Purinostat Mesylate 4 mg/m2|4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
57760274|NCT06484829|DRUG|Purinostat Mesylate 6 mg/m2|6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
57760275|NCT06484829|DRUG|Purinostat Mesylate 8.4 mg/m2|8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
58128914|NCT02305758|DRUG|Fluorouracil infusion|2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
58128915|NCT05460065|DRUG|single E4 30 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
58455973|NCT00857285|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
58455974|NCT00857285|DRUG|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
58455975|NCT05272618|DIAGNOSTIC_TEST|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
57760276|NCT05944055|BIOLOGICAL|Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?|Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
57760277|NCT05652348|OTHER|Establishment of organoid cultures and in vitro sensitivity testing|Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.
57760278|NCT04693676|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
57760279|NCT01542060|DRUG|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
57760280|NCT06231823|OTHER|Extraction|Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
57760281|NCT00901888|DRUG|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
57760282|NCT00901888|DRUG|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
57760283|NCT04754672|BEHAVIORAL|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
57760284|NCT04754672|BEHAVIORAL|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
57760285|NCT04137614|PROCEDURE|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
57760286|NCT04137614|PROCEDURE|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
57760287|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
58128916|NCT05460065|DRUG|single E4 100 mg|Administration of a single i.v. infusion of E4 100 mg (n=6)
58128917|NCT05460065|DRUG|multiple E4 100 mg|Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
58128918|NCT05460065|DRUG|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
58128919|NCT01531465|OTHER|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
58128920|NCT01531465|OTHER|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
58128921|NCT02425579|DRUG|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
58128922|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
58128923|NCT02425579|DRUG|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
58455976|NCT00798616|DRUG|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
58455977|NCT00798616|DRUG|placebo|oral or IV placebo
57760288|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
57760289|NCT06427122|BEHAVIORAL|EMD Protocol for Urge|During the EMD-U sessions, the patient is asked to focus on the spot on his/her skin where the urge to scratch is highest. The patient is asked to rate the level of urge to scratch this spot on a 10-point scale and to imagine that they scratch this spot as they would like. At the same time eye movements are offered for 30 seconds. This procedure is repeated until the level of urge to scratch has become nihil. This procedure is repeated for all other skin parts where the patient experiences an urge to scratch, until there are no skin parts left. As a homework assignment straight after the first session, the patient is instructed and encouraged to practice the same intervention at home. The two EMD-U sessions and two phone calls, take place in the first three weeks of the study. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home.
58128924|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
58455978|NCT02305030|DRUG|BIA 9-1067|
58455979|NCT02305030|DRUG|Warfarin|
58455980|NCT02961608|DRUG|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
57760290|NCT06427122|OTHER|Care as Usual|Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
57760291|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
57760292|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
57760293|NCT02313909|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
57760294|NCT02313909|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
57760295|NCT02313909|OTHER|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
57760296|NCT02313909|OTHER|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
57760297|NCT04575363|OTHER|Blood sample|Blood sample
58455981|NCT05565287|COMBINATION_PRODUCT|ultra early physiotherapy intervention|"* NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
58455982|NCT05101447|DRUG|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
58455983|NCT04721678|BEHAVIORAL|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
58455984|NCT00597402|DRUG|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
58455985|NCT00597402|DRUG|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
58455986|NCT00597402|RADIATION|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
58455987|NCT00597402|DRUG|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
58455988|NCT01972581|OTHER|Reaction Time Training|
58455989|NCT06543667|BIOLOGICAL|Limbal Stem Cell Derived Exosomes Eye Drop|Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
57760298|NCT04839029|PROCEDURE|Bipolar En bloc TURBT|patients subjected to Bipolar resection of bladder tumor by Collins loop
57760299|NCT04839029|PROCEDURE|Monopolar En bloc TURBT|patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
57760300|NCT03590600|DRUG|BTZ-043|Powder and solvent for oral suspension
57760301|NCT03590600|DRUG|Placebo|Matching placebo: powder and solvent for oral suspension
57760302|NCT02296632|BEHAVIORAL|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
57760303|NCT05164302|PROCEDURE|Auricular acupuncture|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
57760304|NCT03482505|DEVICE|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
57760305|NCT01905930|DEVICE|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
57760306|NCT01905930|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
57760307|NCT02809144|PROCEDURE|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
57760308|NCT04976803|OTHER|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
57760309|NCT02740322|PROCEDURE|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
57760310|NCT02740322|PROCEDURE|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
57760311|NCT02740322|DEVICE|Audiogram|A standard audiogram will be administered by an audiologist.
57760312|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
57760313|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
57760314|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
57760315|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
57760316|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
57760317|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
57760318|NCT01592162|DRUG|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
57760319|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
58455990|NCT06112483|BEHAVIORAL|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn \& Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
58455991|NCT01809821|BEHAVIORAL|Online Sleep Education|
58455992|NCT01489319|DRUG|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
58455993|NCT01489319|DRUG|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
58455994|NCT02921672|OTHER|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
58455995|NCT01248195|DRUG|Amisulpride open label|4-week open label amisulpride treatment
58455996|NCT01248195|DRUG|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
57760320|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
57760321|NCT05917704|OTHER|Guitar then physical therapy|See arm/group descriptions
58455997|NCT01248195|DRUG|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
58455998|NCT01248195|DRUG|12-week clozapine open-label treatment|12-week clozapine open-label treatment
58455999|NCT01248195|BEHAVIORAL|Psychosocial intervention|Psychosocial intervention
58456000|NCT01030029|DEVICE|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
58456001|NCT01030029|DEVICE|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
57760322|NCT05917704|OTHER|Physical therapy then guitar|See arm/group descriptions
57760323|NCT03626090|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
57760324|NCT03324438|BEHAVIORAL|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
57760325|NCT03324438|BEHAVIORAL|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
57760326|NCT03324438|BEHAVIORAL|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
58456002|NCT04959747|OTHER|acupuncture|"Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
58456003|NCT00064363|DRUG|talampanel|
57760327|NCT03113123|DRUG|PrEP with Truvada®|"Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
57760328|NCT05115344|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
57760329|NCT05115344|DRUG|flonoltinib 50mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
57760330|NCT05115344|DRUG|flonoltinib 100mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
57760331|NCT05115344|DRUG|flonoltinib 150mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
57760332|NCT05115344|DRUG|flonoltinib 225mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
57760333|NCT05115344|DRUG|flonoltinib 325mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
57760334|NCT05094167|OTHER|V9|one times a day during the whole treatment
57760335|NCT05094167|OTHER|placebo|placebo
57760336|NCT04219852|OTHER|data collection|data collection
57760337|NCT05539703|OTHER|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
57760338|NCT01445405|DRUG|Bortezomib (Velcade, PS-341)|
57760339|NCT01445405|DRUG|Cetuximab|
57760340|NCT01445405|DRUG|Cisplatin|
57760341|NCT01445405|PROCEDURE|Radiation Therapy|
57760342|NCT04036071|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
57760343|NCT03976466|DEVICE|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
57760344|NCT03976466|PROCEDURE|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
57760345|NCT06223503|BEHAVIORAL|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
57760346|NCT06054230|DEVICE|Genomic Sequencer|Genomic Sequencing Device
57760347|NCT01680393|DEVICE|Sequential compression device|a sequential compression device will be applied to the legs
57760348|NCT01680393|OTHER|TED stockings|TED stockings will be applied to the patients legs during surgery
58456004|NCT05259345|PROCEDURE|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
57760349|NCT05248321|DRUG|Tranexamic Acid Powder|2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
57760350|NCT00855595|DRUG|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
57760351|NCT00855595|DRUG|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
57760352|NCT00855595|DRUG|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
57760353|NCT00379119|OTHER|diagnostic laboratory biomarker analysis|
57760354|NCT00379119|OTHER|flow cytometry|
57760355|NCT00379119|OTHER|physiologic testing|
57760356|NCT00379119|PROCEDURE|computed tomography|
57760357|NCT02816086|OTHER|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
57760358|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 1|1 x 10\^7 Inf.U MVA-BN-WEV vaccine
57760359|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 2|1 x 10\^8 Inf.U MVA-BN-WEV vaccine
57760360|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 3|2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
57760361|NCT00615381|DRUG|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
57760362|NCT00953134|DIETARY_SUPPLEMENT|Ferrous fumarate (iron)|60 mg of ferrous fumarate
57760363|NCT00953134|DIETARY_SUPPLEMENT|folic acid|400 mcg folic acid
57760364|NCT01852058|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
57760365|NCT04508179|DRUG|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
57760366|NCT04508179|DRUG|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
57760367|NCT04508179|DRUG|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
57760368|NCT04508179|DRUG|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
57760369|NCT04508179|DRUG|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
57760370|NCT05374044|DIAGNOSTIC_TEST|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
57760371|NCT05886322|DIAGNOSTIC_TEST|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
57760372|NCT05886322|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
57760373|NCT05886322|DIAGNOSTIC_TEST|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
57760374|NCT05838001|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
57760375|NCT05838001|PROCEDURE|marker clip localization|Positioning marker clip in the center of the breast lesion
57760376|NCT01461382|OTHER|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
58456005|NCT05259345|PROCEDURE|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
58456006|NCT05259345|PROCEDURE|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
58456007|NCT01645072|OTHER|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI \>55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
58456008|NCT01645072|OTHER|Control group|The ongoing anti epileptic drug treatment will be continued without change.
58456009|NCT06352541|DRUG|PRO-232|Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
58456010|NCT06352541|OTHER|Placebo|Sodium Chloride 0.9%
58456011|NCT02168114|OTHER|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
58456012|NCT02168114|PROCEDURE|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
58456013|NCT04510649|DRUG|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
58456014|NCT04510649|DRUG|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
57760377|NCT01461382|OTHER|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
57760378|NCT03502616|DRUG|Tofacitinib|Oral administration twice per day
58456015|NCT06115616|BEHAVIORAL|Morning exercise|Exercise before noon in the morning
58456016|NCT06115616|BEHAVIORAL|Afternoon exercise|Exercise in the late after noon
58456017|NCT00389948|DRUG|Lanzoprazole|
58456018|NCT04014179|DIAGNOSTIC_TEST|Xpert HCV Viral Load Fingerstick|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.
58456019|NCT04014179|DIAGNOSTIC_TEST|Aptima HCV Quant DX Assay|"The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.~The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment."
57760379|NCT04498325|DRUG|NT-I7|Supplied by study
57760380|NCT04498325|DRUG|Placebo|Supplied by study
58456020|NCT04357535|DRUG|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
58456021|NCT02634385|PROCEDURE|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
58456022|NCT02634385|PROCEDURE|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
58456023|NCT05028192|OTHER|no intervention|no intervention
58456024|NCT02641847|DRUG|docetaxel|
58456025|NCT02641847|DRUG|doxorubicin or epirubicin|
58456026|NCT02641847|DRUG|cyclophosphamide|
58456027|NCT02641847|DRUG|gemcitabine|
58456028|NCT02641847|DRUG|cisplatin|
58456029|NCT04921566|DRUG|Torasemide tablet 10 mg|Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.
58456030|NCT04921566|DRUG|Toradiur® tablet 10 mg|Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
58456031|NCT03728465|BIOLOGICAL|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
57760381|NCT04498325|PROCEDURE|Blood for research purposes|Prior to injection (Day 0), Day 7, and Day 14
57760382|NCT04498325|PROCEDURE|Blood for pharmacokinetic samples|-Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
57760383|NCT04498325|PROCEDURE|Nasopharyngeal, oropharyngeal, or saliva swab|-Prior to study treatment, Day 4(optional), Day 7, and Day 14
57760384|NCT04498325|PROCEDURE|Blood for anti-drug antibody (ADA)|Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
57760385|NCT04176341|OTHER|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
57760386|NCT04513522|BIOLOGICAL|Nivolumab|Specified dose on specified days
57760387|NCT04513522|BIOLOGICAL|Ipilimumab|Specified dose on specified days
57760388|NCT04379193|BEHAVIORAL|Neuroproprioceptive facilitation and inhibition physical therapy|All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).
57760389|NCT00017940|GENETIC|Human Nerve Growth Factor|
57760390|NCT05565807|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
57760391|NCT03115333|DIAGNOSTIC_TEST|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
57760392|NCT04773210|DEVICE|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
57760393|NCT04773210|DEVICE|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
57760394|NCT03810534|BEHAVIORAL|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
57760395|NCT04794426|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
57760396|NCT04794426|DEVICE|Hall Technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
57760397|NCT06426017|OTHER|High Protein Low Calorie Dietary Intervention|High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
57760398|NCT03052114|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
57760399|NCT02622204|PROCEDURE|Corrective osteotomy|corrective osteotomy for varus alignment
57760400|NCT03873818|BIOLOGICAL|Ipilimumab|Given IV
57760401|NCT03873818|BIOLOGICAL|Pembrolizumab|Given IV
57760402|NCT06194409|DIAGNOSTIC_TEST|Echocardiography, Urine analysis , blood culture|All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography
57760403|NCT03389152|DEVICE|Elastography|liver stiffness measurements by shear wave-based elastography
57760404|NCT01529008|DRUG|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
57760405|NCT01529008|DRUG|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
57760406|NCT04271943|BEHAVIORAL|Computer Based Exercises|For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises
58456032|NCT03728465|BIOLOGICAL|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
58456033|NCT00527735|DRUG|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
58456034|NCT00527735|DRUG|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
57760407|NCT04271943|DIETARY_SUPPLEMENT|Aerobic Exercises|For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
57760408|NCT05742425|DRUG|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
57760409|NCT01769170|DRUG|Brincidofovir|
57760410|NCT01769170|OTHER|Placebo|
57760411|NCT06342986|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
57760412|NCT06342986|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
57760413|NCT06342986|DRUG|CY|CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
57760414|NCT04905277|DRUG|Atenolol 50 MG|50 mg Atenolol daily
57760415|NCT04905277|DRUG|Placebo|one placebo daily
57760416|NCT02323984|OTHER|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
57760417|NCT02628392|DRUG|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
57760418|NCT02628392|DRUG|Sitagliptin|capsules
57760419|NCT02628392|DRUG|placebo|matching DS-8500a tablets and sitagliptin capsules
57760420|NCT03263832|DIAGNOSTIC_TEST|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
57760421|NCT06624891|OTHER|perioperative fluid responsiveness with the Pleth variability index|Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.
57760422|NCT06624891|OTHER|perioperative fluid responsiveness with delta PP|fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
57760423|NCT02512679|DRUG|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
57760424|NCT02512679|DRUG|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
58456035|NCT00527735|DRUG|Paclitaxel|175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
57760425|NCT02512679|DRUG|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
57760426|NCT02512679|DRUG|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
57760427|NCT01163643|DRUG|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
57760428|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
57760429|NCT01163643|DRUG|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
57760430|NCT01163643|DRUG|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
57760431|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
57760432|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
57760433|NCT02309112|OTHER|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
57760434|NCT01190046|BEHAVIORAL|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
57760435|NCT00954954|DEVICE|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
58456036|NCT00527735|DRUG|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
57760436|NCT00954954|DEVICE|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
57760437|NCT03809364|BEHAVIORAL|START Together|Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
57760438|NCT05964855|DEVICE|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
57760439|NCT05964855|DEVICE|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
57760440|NCT05964855|DEVICE|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
57760441|NCT05964855|DEVICE|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
57760442|NCT05964855|DEVICE|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
57760443|NCT04360850|BEHAVIORAL|online survey|A brief survey for therapists to fill out
57760444|NCT05316584|BEHAVIORAL|Remote monitoring|See prior description of the intervention.
57760445|NCT01480596|BIOLOGICAL|Belimumab|10mg/kg IV infusion
57760446|NCT01480596|OTHER|Placebo|placebo IV infusion
58456037|NCT04702412|OTHER|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
57760447|NCT00148226|BEHAVIORAL|Decision Aid|
57760448|NCT00035035|DRUG|GEMZAR|
57760449|NCT00035035|DRUG|ALIMTA|
57760450|NCT06624761|DEVICE|ShotBlocker|A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
57760451|NCT01814059|DRUG|sirolimus|
57760452|NCT00134602|BEHAVIORAL|Needs assessment followed by tailored intervention|
57760453|NCT04792125|BEHAVIORAL|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
57760454|NCT04792125|BEHAVIORAL|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
58456038|NCT06440473|DRUG|Roflumilast|Roflumilast 0.3% cream
58456039|NCT06440473|OTHER|Vehicle (Roflumilast 0.3% vehicle cream)|Vehicle (Roflumilast 0.3% vehicle cream)
57760455|NCT04792125|BEHAVIORAL|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
57760456|NCT05893680|OTHER|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
57760457|NCT05893680|OTHER|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
57760458|NCT05893680|DRUG|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
57760459|NCT05893680|OTHER|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
57760460|NCT01152775|OTHER|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
57760461|NCT01152775|OTHER|No Media|This group will not be exposed to multimedia
58456040|NCT03358277|DRUG|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
58456041|NCT00225901|DRUG|Recombinant human hepatocyte growth factor|
57760462|NCT03258424|DRUG|PTI-428|PTI-428 or placebo will be given QD for 14 days.
57760463|NCT03258424|DRUG|Placebo|PTI-428 or placebo will be given QD for 14 days.
57760464|NCT04309825|PROCEDURE|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
57760465|NCT06624774|OTHER|Prehabilitation|The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
58456042|NCT05918796|DRUG|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
58456043|NCT05918796|DRUG|Dexamethasone|dexamethasone
58456044|NCT00963391|OTHER|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
58456045|NCT04291612|OTHER|Physical exam|Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
58456046|NCT05221411|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
58456047|NCT05221411|DRUG|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
57760466|NCT05616741|DEVICE|Cerebri biofeedback|Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
57760467|NCT05616741|OTHER|Cerebri headache diary|Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
57760468|NCT00844909|DRUG|CNTO 136|
57760469|NCT04402437|PROCEDURE|LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
58456048|NCT02316730|DRUG|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
58456049|NCT02316730|DRUG|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
58456050|NCT02863614|DRUG|Ibuprofen 600 mg|
58456051|NCT02863614|DRUG|Lorazepam 1 mg|
58456052|NCT02863614|DRUG|Placebo|
58456053|NCT04666285|OTHER|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
58456054|NCT01885156|DRUG|Naftin 1% Cream|Topically applied once a day
58456055|NCT01885156|DRUG|Placebo Cream|Topically applied once a day
58456056|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
58456057|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
58456058|NCT03824041|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
58456059|NCT04503746|DRUG|ALH-L1005 600mg/day|ALH-L1005 300mg 2 tablet and placebo 2 tablet
58456060|NCT04503746|DRUG|ALH-L1005 1,200mg/day|ALH-L1005 300mg 4 tablet
58456061|NCT04503746|DRUG|Placebo|Placebo 4 tablet
58456062|NCT04019899|DIETARY_SUPPLEMENT|control group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
58456063|NCT04019899|DIETARY_SUPPLEMENT|study group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
58456064|NCT06372626|BIOLOGICAL|ZG005|"ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage."
58456065|NCT06372626|DRUG|Etoposide|IV infusion
58456066|NCT06372626|DRUG|Cisplatin|IV infusion
58456067|NCT06372626|DRUG|Placebo|0.9% Sodium Chloride Injection
58456068|NCT01747512|DRUG|C-PERT|Patients with thyroid and Head and Neck cancer
58456069|NCT01747512|DRUG|G-PERT|Patients with thyroid and Head and Neck cancer
58456070|NCT05583487|OTHER|Nurse-led progressive mobility protocol|The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.
58456071|NCT05583487|OTHER|Standard of Care|For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
58456072|NCT04616755|OTHER|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
58456073|NCT02789059|OTHER|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
58456074|NCT04147689|DEVICE|DESIRIAL® PLUS|"DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study."
58456075|NCT06227871|PROCEDURE|Exploratory laparotomy|Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
58456076|NCT04400357|PROCEDURE|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
58456077|NCT04400357|PROCEDURE|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
58456078|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
58456079|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
58456080|NCT03614117|DIETARY_SUPPLEMENT|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
58456081|NCT06056492|BEHAVIORAL|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
58456082|NCT02314052|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
58456083|NCT00343265|DRUG|Vaginal progesterone gel|Vaginal gel once daily
58456084|NCT00343265|DRUG|Placebo gel|once daily
58456085|NCT00507169|DRUG|SVT-40776|
58456086|NCT02798250|OTHER|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
58456087|NCT02798250|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
58456088|NCT02798250|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
58456089|NCT02798250|DEVICE|Dexcom G4 Platinum glucose sensor|
58456090|NCT02798250|DEVICE|Accu Chek Combo insulin pump|
58456091|NCT06360822|BEHAVIORAL|ED-LCS|This is a lung cancer educational intervention for patients in the emergency department.
58456092|NCT05904561|RADIATION|low level laser therapy|"comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest"
58456093|NCT00072007|BIOLOGICAL|filgrastim|filgrastim
58456094|NCT00072007|BIOLOGICAL|rituximab|rituximab
58456095|NCT00072007|DRUG|CHOP regimen|CHOP regimen
58456096|NCT00072007|DRUG|cladribine|cladribine
58456097|NCT00072007|DRUG|cyclophosphamide|cyclophosphamide
58456098|NCT00072007|DRUG|doxorubicin hydrochloride|doxorubicin hydrochloride
58456099|NCT00072007|DRUG|prednisone|prednisone
58456100|NCT00072007|DRUG|vincristine sulfate|vincristine sulfate
58456101|NCT01664910|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
58456102|NCT01664910|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
58456103|NCT01664910|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
58456104|NCT01664910|DRUG|Bendamustine Hydrochloride|Given IV
58456105|NCT01664910|DRUG|Fludarabine Phosphate|Given IV
58456106|NCT01664910|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
58456107|NCT01664910|DRUG|Methotrexate|Given IV
58456108|NCT01664910|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
58456109|NCT01664910|BIOLOGICAL|Rituximab|Given IV
58456110|NCT01664910|DRUG|Tacrolimus|Given IV or PO
58456111|NCT01773317|OTHER|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
58456112|NCT01773317|OTHER|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
58456113|NCT00210717|DRUG|paliperidone palmitate|
58456114|NCT03894488|DIAGNOSTIC_TEST|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
58456115|NCT02028923|DRUG|Morphine gel|Topical
58456116|NCT02028923|OTHER|Neutral gel|Topical
58456117|NCT02584179|DEVICE|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
58456118|NCT06236971|BEHAVIORAL|MRI scanning first at supine position and then turn into lateral position|Magnetic resonance imaging was used to scan the upper airway of sedated subjects, first at supine position and then turn into lateral position.
58456119|NCT03798613|DEVICE|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
58456120|NCT03798613|DEVICE|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
58456121|NCT05005481|OTHER|NIL intervention|NIL intervention will be performed on patients.
58456122|NCT06002269|COMBINATION_PRODUCT|Dietary and Exercise Intervention|Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
58456123|NCT02626585|PROCEDURE|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
57760470|NCT04402437|PROCEDURE|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
57760471|NCT03439189|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
57760472|NCT03439189|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
57760473|NCT03439189|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
57760474|NCT05915962|PROCEDURE|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
57760475|NCT00944723|DIETARY_SUPPLEMENT|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
57760476|NCT00944723|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement with zinc
58456124|NCT04274816|DRUG|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
57760477|NCT00944723|DIETARY_SUPPLEMENT|Non-fortified bread|Daily consumption of non-fortified bread
58456125|NCT04235517|OTHER|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
58456126|NCT06276998|DRUG|LNK01001|Capsule; Oral
58456127|NCT06276998|DRUG|Placebo|Capsule; Oral
58456128|NCT05853341|DRUG|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
57760478|NCT00944723|DIETARY_SUPPLEMENT|Placebo supplement|Daily intake of placebo supplement
57760479|NCT02729181|DEVICE|DRX9000|
57760480|NCT06089122|BIOLOGICAL|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
57760481|NCT03205540|PROCEDURE|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
57760482|NCT03205540|PROCEDURE|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
57760483|NCT02714855|DRUG|Apixaban|
57760484|NCT00615186|DRUG|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
57760485|NCT00615186|DRUG|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
57760486|NCT03340948|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
57760487|NCT03509532|DEVICE|PCI|PCI
57760488|NCT03312153|DRUG|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
57760489|NCT03312153|DRUG|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
57760490|NCT04092465|PROCEDURE|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
57760491|NCT03688152|DRUG|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
58456129|NCT05853341|DRUG|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
58456130|NCT04107246|DEVICE|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
58456131|NCT04792736|DIAGNOSTIC_TEST|Blood lactate level|Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
58456132|NCT01548027|PROCEDURE|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
58456133|NCT01548027|PROCEDURE|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months
58456134|NCT01548027|OTHER|No intervention|No intervention
58456135|NCT06387823|DRUG|Sivelestat sodium|Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
58456136|NCT06387823|DRUG|Dexamethasone|Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)
58456137|NCT06387823|DRUG|Sivelestat sodium placebo|Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
57760492|NCT03688152|DRUG|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
57760493|NCT02731664|BIOLOGICAL|GLP-1|Intravenous infusion of GLP-1
57760494|NCT02731664|BIOLOGICAL|Intravenous saline|Control
57760495|NCT02012062|DRUG|TPF neoadjuvant chemotherapy|
57760496|NCT02012062|DRUG|Concurrent chemotherapy with cisplatin during radiotherapy|
57760497|NCT02012062|DRUG|Concurrent nimotuzumab during radiotherapy|
57760498|NCT02012062|RADIATION|Radical radiotherapy|
58456138|NCT06387823|DRUG|Dexamethasone placebo|Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
58456139|NCT02703298|DRUG|TRX-818 capsules|
58456140|NCT05822557|OTHER|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
58456141|NCT03481335|OTHER|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
58456142|NCT03295435|OTHER|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural \& Prosthetic units present Group C: No natural units present"
58456143|NCT02388581|DRUG|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
58456144|NCT05369663|DEVICE|mask use|face mask use
58456145|NCT02313259|OTHER|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
58456146|NCT02313259|BEHAVIORAL|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
58456147|NCT03408197|DEVICE|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
58456148|NCT03408197|DEVICE|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
58456149|NCT06018844|OTHER|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
58456150|NCT01745926|DEVICE|MECHANICAL CHEST COMPRESSION|
58456151|NCT03309566|DRUG|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
58456152|NCT04674891|OTHER|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
57760499|NCT00839345|DRUG|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
57760500|NCT03158363|OTHER|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
57760501|NCT03993509|DEVICE|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
57760502|NCT00871650|OTHER|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
57760503|NCT00871650|OTHER|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
57760504|NCT00871650|OTHER|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
57760505|NCT04585659|OTHER|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
57760506|NCT00145457|PROCEDURE|Blood sample|
57760507|NCT00145457|PROCEDURE|Radiography|
57760508|NCT05265663|RADIATION|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
57760509|NCT02636257|PROCEDURE|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
57760510|NCT02636257|PROCEDURE|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
58456153|NCT04674891|OTHER|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
58456154|NCT00633971|OTHER|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
58456155|NCT04664153|DRUG|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
58456156|NCT04664153|DRUG|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
58456157|NCT00181363|DEVICE|Mamma board|use of mamma board during radiotherapy
58456158|NCT04957797|PROCEDURE|round tunnel|reamed with round tunnel
58456159|NCT04957797|PROCEDURE|flat tunnel|reamed with flat tunnel
58456160|NCT01317758|DRUG|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
58456161|NCT01317758|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
58456162|NCT01317758|BIOLOGICAL|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
58456163|NCT05936112|OTHER|Fecal calprotectin dosage|Dosing calprotectin in infants' feces + questionnaire/interview with parents
58456164|NCT05936112|OTHER|Questionnaire and interview with parents|Dosing calprotectin in infants' feces + questionnaire/interview with parents
58456165|NCT06347198|DRUG|Fruquintinib|Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
58456166|NCT06347198|DRUG|Sintilimab|Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
58456167|NCT06347198|DRUG|Inulin|Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
58456168|NCT04716426|DRUG|Tetracycline hydrochloride 3%|Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
57760511|NCT01599923|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
58456169|NCT04716426|DRUG|Placebo|Formulation composed of FDA approved inactive ingredients.
58456170|NCT01774032|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
58456171|NCT00809900|DIETARY_SUPPLEMENT|Experimental|Administration of of 480 mL cranberry juice
58456172|NCT04101071|OTHER|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
58456173|NCT04101071|OTHER|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
58456174|NCT01239849|DRUG|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100\~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130\~159 mg/dl is 20 mg, 160\~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol"
58456175|NCT01166841|PROCEDURE|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
58456176|NCT04800250|PROCEDURE|Treatment of gingival recessions|Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
58456177|NCT05283551|DRUG|Famciclovir|Famciclovir (500mg BD)
58456178|NCT02110563|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
58456179|NCT01844388|DRUG|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
58456180|NCT01844388|DRUG|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
57760512|NCT04269915|BIOLOGICAL|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
57760513|NCT00231907|BIOLOGICAL|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
57760514|NCT00231907|BIOLOGICAL|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
57760515|NCT01578863|OTHER|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
57760516|NCT03213990|OTHER|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
57760517|NCT03213990|OTHER|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
57760518|NCT02107794|OTHER|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
57760519|NCT03929562|BEHAVIORAL|Brief advice|One 10-minute brief advice session
57760520|NCT03929562|BEHAVIORAL|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
57760521|NCT01099514|DRUG|Nilotinib|D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
57760522|NCT03663764|DRUG|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
57760523|NCT03663764|RADIATION|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
57760524|NCT03663764|DRUG|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
57760525|NCT06111339|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
57760526|NCT06111339|OTHER|Saline Solution|The placebo will be a 0.9% saline solution administered over 40 minutes.
57760527|NCT01822938|OTHER|incentive program for physical activity|
57760528|NCT01960725|BIOLOGICAL|RV5 (Pentavalent Rotavirus Vaccine)|
57760529|NCT01975155|OTHER|food questionnaire|
57760530|NCT01975155|OTHER|Urinary mycotoxin test|
57760531|NCT03319511|OTHER|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
57760532|NCT03319511|OTHER|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
57760533|NCT05347901|DIAGNOSTIC_TEST|Echocardiography, Genomics NGS sequencing|The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
57760534|NCT01036022|DRUG|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
57760535|NCT00234650|PROCEDURE|Colonoscopy|
57760536|NCT02949921|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
57760537|NCT03536364|BEHAVIORAL|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
57760538|NCT03536364|BEHAVIORAL|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
57760539|NCT03536364|BEHAVIORAL|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
57760540|NCT05149092|DIETARY_SUPPLEMENT|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
57760541|NCT05149092|DIETARY_SUPPLEMENT|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
57760542|NCT02125448|DEVICE|MRI and PET-CT|
57760543|NCT00221143|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
57760544|NCT04334239|OTHER|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
57760545|NCT00160420|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 months
57760546|NCT00175344|PROCEDURE|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
57760547|NCT06625424|OTHER|Short Sprint Interval Training with passive recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc. Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
57760548|NCT06625424|OTHER|Short Sprint Interval Training with Active Recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which the Subjects will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
57760549|NCT02162680|DRUG|1% lidocaine|
57760550|NCT02162680|DRUG|bacteriostatic normal saline (BNS)|
57760551|NCT04557839|OTHER|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
57760552|NCT04557839|OTHER|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~* eyes open firm surfaces~* Eyes open soft surfaces~* Eyes closed firm surfaces~* Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~* These exercise will perform with turning the head side to side ad up and down~* Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
58456181|NCT00815217|PROCEDURE|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
58456182|NCT00815217|OTHER|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
57760553|NCT01257464|DRUG|Sitagliptin|100mg po one dose
57760554|NCT01257464|DRUG|Placebo|Sugar pill po one dose
57760555|NCT02799186|PROCEDURE|blood sample for genetic analysis|
57760556|NCT05282290|DRUG|Antihypertensive drugs (no restriction on the type of drugs)|"The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening."
57760557|NCT02564783|OTHER|No intervention|No intervention
57760558|NCT01336985|DRUG|Irinotecan|
57760559|NCT01336985|PROCEDURE|Chemoembolization|
57760560|NCT01336985|DEVICE|Drug-Eluting Beads|
57760561|NCT01336985|PROCEDURE|Biopsy|
57760562|NCT00697190|DEVICE|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
57760563|NCT00697190|DEVICE|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
57760564|NCT00005625|DRUG|trabectedin|
57760565|NCT01471132|DRUG|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
57760566|NCT01471132|DRUG|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
57760567|NCT03304002|OTHER|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
57760568|NCT01933035|OTHER|Immune Thrombocytopenics|Full blood count with extended platelet parameters
57760569|NCT01933035|OTHER|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
57760570|NCT01933035|OTHER|Control Population|Full blood count with extended platelet parameters
57760571|NCT05747339|BIOLOGICAL|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
57760572|NCT06625970|DRUG|Darolutamide|Pharmaceutical form: 300 mg tablets Administration route: oral (PO) Posology: 600 mg twice daily (BID)
58456183|NCT05342558|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcgs|Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
58456184|NCT05342558|DRUG|Umeclidinium/Vilanterol 62.5/25 mcgs|Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
58456185|NCT02932137|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
58456186|NCT04404868|OTHER|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
57760573|NCT06625970|RADIATION|Stereotactic Body RadioTherapy (SBRT)|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~At study entry, each investigational site will be asked to choose one regimen (normo-fractionation or moderate hypo-fractionation) which will be applied for all patients included by the investigational site in the study.~SBRT, experimental treatment, will be used as a boost in Arms C \& D. The placement of 3 to 4 fiducial markers for stereotactic boost is mandatory.~SBRT will be applied only on Prostate: 2 times 10 Gy delivered to the prostate with a gap of one week between each SBRT fraction."
57760574|NCT06625970|DRUG|ADT (Standard of Care)|"Androgen Deprivation Therapy (ADT)~The ADT treatment will be chosen at the investigator's discretion, and will be administered according to local standard procedures for up to 2 years.~Patients who may have received ADT prior joining the study should have started the ADT treatment within a maximum of 6 weeks before randomization. Otherwise ADT will be started on Day 1 (or 14 days at the latest after the randomization)."
57760575|NCT06625970|RADIATION|radiotherapy|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~Arm A and Arm B:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46-54 Gy and prostate 78 Gy (39 fractions over 8 weeks).~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions; prostate 60 Gy delivered concomitantly in 20 fractions over 4 weeks.~Arm C and Arm D:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46 Gy in 23 fractions over 4.5 weeks.~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions over 4 weeks."
57760576|NCT00378443|DRUG|prednisone + Inhibace/Cozaar|
57760577|NCT00378443|DRUG|Inhibace/Cozaar|
57760578|NCT00076960|DRUG|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
57760579|NCT06029894|DIETARY_SUPPLEMENT|Citicoline Supplement|Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
57760580|NCT06029894|OTHER|Placebo|Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
57760581|NCT04034394|OTHER|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
57760582|NCT04034394|OTHER|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
57760583|NCT05613114|DRUG|Dalfampridine 10 MG|The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
57760584|NCT05613114|DRUG|Placebo|Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
57760585|NCT05613114|BEHAVIORAL|Physiotherapy|Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
57760586|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
57760587|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
57760588|NCT00800280|DRUG|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
57760589|NCT02357004|DRUG|Carvedilol|CR 40 mg daily in addition to normal BP medications
57760590|NCT02357004|DRUG|Chlorthalidone|12.5 mg daily in addition to normal BP medications
57760591|NCT03113084|BIOLOGICAL|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
57760592|NCT03113084|BIOLOGICAL|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
58458622|NCT04541407|DRUG|Temozolomide plus Lorlatinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
57760593|NCT04410289|PROCEDURE|Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
57760594|NCT04410289|PROCEDURE|Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
57760595|NCT03893201|OTHER|Questionnaires|Questionnaires to assess quality of life
57760596|NCT03983122|PROCEDURE|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
57760597|NCT03629652|OTHER|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
57760598|NCT03629652|OTHER|Conventional Rehabilitation|The body is in the supine position without lowered head
57760599|NCT05673876|DRUG|GDC-8264|GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
57760600|NCT04597710|GENETIC|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
57760601|NCT03874845|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
57760602|NCT03874845|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
57760603|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine low dose|50μg/dose
57760604|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine high dose|100μg/dose
57760605|NCT04587128|DRUG|Panitumumab|Epidermal growth factor receptor inhibitor, anti-neoplastic
57760606|NCT04587128|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor, anti-neoplastic
57760607|NCT04587128|DRUG|Irinotecan|anti-neoplastic, chemotherapy drug
57760608|NCT04587128|DRUG|FOLFIRI Protocol|folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab
57760609|NCT04587128|DRUG|Bevacizumab|Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)
57760610|NCT03083535|PROCEDURE|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
57760611|NCT03083535|PROCEDURE|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
57760612|NCT03083535|PROCEDURE|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
57760613|NCT00046501|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
57760614|NCT00046501|DRUG|Humulin N|
57760615|NCT00046501|DRUG|Humulin L|
57760616|NCT00046501|DRUG|Lispro|
57760617|NCT00195026|DEVICE|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
57760618|NCT00738686|DEVICE|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
57760619|NCT02246335|DEVICE|Cemented total hip arthroplasty|
57760620|NCT02246335|DEVICE|Cemented hemiarthroplasty|
57760621|NCT01622244|OTHER|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
57760622|NCT01622244|OTHER|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
57760623|NCT01622244|BEHAVIORAL|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
57760624|NCT05239988|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
57760625|NCT05313386|DRUG|BXCL501|BXCL501 is given in a film form
57760626|NCT05313386|DRUG|Placebo film|Placebo is given in a film form
57760627|NCT03033459|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
57760628|NCT03033459|BEHAVIORAL|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
58456187|NCT06260566|DRUG|N-Acetylcysteine|"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."
58456188|NCT05588349|OTHER|Dry needling|Dry needling + stretching exercise
58456189|NCT05588349|OTHER|Stretching exercise|Stretching exercise only
58456190|NCT03416855|DRUG|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
58456191|NCT02702466|OTHER|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
58456192|NCT03430791|DRUG|Nivolumab 240 mg IV|Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
58456193|NCT03430791|DRUG|Nivolumab 3 mg/kg|Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
58456194|NCT03430791|DRUG|Ipilimumab 1 mg/kg|Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
58456195|NCT03430791|DEVICE|NovoTTF200A (Optune)|A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
58456196|NCT02724332|DRUG|Rapamycin|2mg,po,bid
58456197|NCT02162550|DRUG|Bydureon|once weekly injection
57760629|NCT05856214|BEHAVIORAL|Couple-Based Violence Prevention education(CBVPE)|Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
58456198|NCT02162550|DRUG|placebo|once weekly injection
58456199|NCT02461654|OTHER|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
58456200|NCT01842802|DEVICE|Diode Laser|Diode Laser for treatment of subcutaneous fat
58456201|NCT01842802|DEVICE|YAG laser|YAG laser for treatment of subcutaneous fat
58456202|NCT05439044|OTHER|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
58456203|NCT02216708|OTHER|Rapid dehydration|
58456204|NCT02216708|OTHER|Slow rehydration|
58456205|NCT03255902|BEHAVIORAL|Parenting classes|Parenting Classes:The Incredible Years curriculum
58456206|NCT05308992|DEVICE|HydroGlyde Condom|The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
58456207|NCT01836588|PROCEDURE|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
58456208|NCT00675402|OTHER|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
58456209|NCT04696263|DEVICE|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
58456210|NCT04696263|DEVICE|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
58456211|NCT04080180|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
57760630|NCT06434792|DRUG|Bronpass Tab.|Twice daily for 12 weeks
57760631|NCT06434792|OTHER|Placebo|Twice daily for 12 weeks
57760632|NCT00710632|OTHER|laboratory biomarker analysis|
57760633|NCT00710632|OTHER|physiologic testing|
57760634|NCT00710632|OTHER|questionnaire administration|
58128925|NCT05428722|BEHAVIORAL|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
58128926|NCT00593281|DRUG|Hylenex|Add Hylenex to SC injection of Morphine
58128927|NCT05011500|RADIATION|Radiotherapy with Closed Mask|Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.
58456212|NCT04080180|BEHAVIORAL|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
58456213|NCT02229058|DRUG|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
58456214|NCT02229058|DRUG|S-1|40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.
58456215|NCT01562080|DIETARY_SUPPLEMENT|Armolipid Plus|one tablet per day during 12 weeks
58456216|NCT01562080|DIETARY_SUPPLEMENT|placebo|one tablet per day during 12 weeks
58456217|NCT04428346|BEHAVIORAL|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
58456218|NCT03453905|DIAGNOSTIC_TEST|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
58456219|NCT03453905|OTHER|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
58456220|NCT00138749|DRUG|SS-RBX|
58456221|NCT06133322|BEHAVIORAL|Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
58456222|NCT05716555|DEVICE|Deep brain stimulation|Electrical stimulation of lateral habenula
58456223|NCT05361369|DRUG|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
58456224|NCT04782063|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
58456225|NCT02205996|DRUG|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
58456226|NCT02205996|DEVICE|Euglycaemic Hypoglycaemic Insulin clamp|
58456227|NCT06360146|OTHER|Early mobilisation|Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
58456228|NCT02591810|PROCEDURE|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
58456229|NCT02591810|PROCEDURE|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
58456230|NCT02591810|PROCEDURE|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
58456231|NCT01017185|DRUG|HF10|
58456232|NCT00881738|DRUG|Clarithromycin 250 mg Tablets (Geneva, USA)|
58456233|NCT00881738|DRUG|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
57760635|NCT00710632|PROCEDURE|management of therapy complications|
57760636|NCT00735501|DRUG|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
57760637|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
57760638|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
57760639|NCT00000379|DRUG|Fluoxetine|
57760640|NCT00000379|BEHAVIORAL|EMDR|
58128928|NCT05011500|RADIATION|Radiotherapy with Open Mask and Surface Scanning|Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
57760641|NCT03540875|DEVICE|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
57760642|NCT03540875|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
57760643|NCT03540875|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
57760644|NCT05762848|DEVICE|Mobile Phone Head Circumference App|Measurement of Head circumference of Babies/Infants with a mobile phone application.
57760645|NCT03262558|OTHER|No intervention|Patients will undergo standard clinical routine practice in this indication
57760646|NCT01487876|BIOLOGICAL|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
57760647|NCT01487876|OTHER|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
57760648|NCT04822844|OTHER|Lavender Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
57760649|NCT04822844|OTHER|Ginger Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
57760650|NCT02666287|DRUG|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
57760651|NCT02666287|DRUG|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
57760652|NCT02666287|DRUG|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
57760653|NCT02666287|DRUG|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
57760654|NCT02666287|DRUG|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
57760655|NCT02087436|DEVICE|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
57760656|NCT02087436|DEVICE|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
57760657|NCT06009601|DIAGNOSTIC_TEST|Pectus Study Form|"Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives."
57760658|NCT06009601|DIAGNOSTIC_TEST|Adams Test|Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
57760659|NCT06009601|DIAGNOSTIC_TEST|Scoliosis Graphy|"ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs."
57760660|NCT06009601|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes."
58128929|NCT05011500|RADIATION|Radiotherapy with No Mask|Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
58128930|NCT04126811|DRUG|Apatinib Mesylate, Pirarubicin, Ifosfamide|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
57760661|NCT02042079|PROCEDURE|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
57760662|NCT04975633|DEVICE|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
57760663|NCT03140501|DEVICE|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
57760664|NCT03547492|BEHAVIORAL|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
58456234|NCT02408133|OTHER|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
58456235|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
58456236|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
58456237|NCT04997499|BEHAVIORAL|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
58456238|NCT04711785|BEHAVIORAL|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
58456239|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures|All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
58456240|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures|All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding...
58456241|NCT04326920|DRUG|Sargramostim|Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
58456242|NCT04326920|OTHER|Control|Standard of care
58456243|NCT01808859|DEVICE|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
58456244|NCT03082248|OTHER|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
58456245|NCT03082248|PROCEDURE|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
58456246|NCT01903460|DRUG|LUM001|
58456247|NCT01903460|DRUG|Placebo|
57760665|NCT03547492|BEHAVIORAL|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
57760666|NCT03547492|BEHAVIORAL|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
58128931|NCT04126811|DRUG|Apatinib Mesylate|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
58456248|NCT03450863|DRUG|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
58456249|NCT04658329|DRUG|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
58456250|NCT01865266|DRUG|Ulinaststin for injection|
58456251|NCT01865266|DRUG|placebo|
58456252|NCT00983307|DRUG|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
57760667|NCT03547492|BEHAVIORAL|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
57760668|NCT03547492|BEHAVIORAL|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
57760669|NCT03547492|BEHAVIORAL|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
57760670|NCT02503683|DRUG|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
57760671|NCT02503683|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
57760672|NCT03692338|BEHAVIORAL|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
57760673|NCT05968768|DRUG|Naxitamab|Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
57760674|NCT06267456|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
57760675|NCT06267456|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
57760676|NCT06267456|DIAGNOSTIC_TEST|Upper Quarter Y Balance Test|The Upper Extremity Y Balance Test was created using three rulers placed on the ground in the medial, inferolateral, and superolateral directions. The rulers in the superolateral and inferolateral directions were positioned at a 90° angle to each other, while the ruler in the medial direction was placed at a 135° angle with respect to these two directions. In this test, both arms started in a push-up position with shoulder-width apart. The athlete was then instructed to touch, using their non-dominant hand, the maximum reachable point in the medial, inferolateral, and superolateral directions.
57760677|NCT01885728|DIETARY_SUPPLEMENT|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
57760678|NCT03761082|OTHER|NA(observation study)|NA(observation study)
57760679|NCT03315130|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
57760680|NCT03315130|DRUG|Placebo|Daily subcutaneous (SC) injection
57760681|NCT06161311|DEVICE|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
57760682|NCT03842839|DRUG|Tiotropium Inhalation Powder [Spiriva] 0.018mg|Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
57760683|NCT03842839|DRUG|Salbutamol sulphate aerosol (Ventolin) 0.01mg|As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
58456253|NCT00983307|RADIATION|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
58456254|NCT02512549|OTHER|Pulmonary Rehabilitation|
57760684|NCT06407076|OTHER|Interviews|Following the design of the questionnaire, using open-ended questions based on the availability, accessibility, acceptability and quality (AAAQ) framework, qualitative semi-structured personal interviews were used to collect the data. In this way it was possible to collect information in a more detailed way. The subjects included in the study had to answer the questions posed by the main researcher, responding with open or closed answers, through a questionnaire created for this purpose.
57760685|NCT06624553|DEVICE|FreeStyle Libre 2, flash glucose monitoring|"Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit."
58456255|NCT04350281|DRUG|Interferon Beta-1B|Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
58456256|NCT04350281|DRUG|Hydroxychloroquine|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
58456257|NCT03122041|DRUG|Sitagliptin|
58456258|NCT03122041|BEHAVIORAL|Lifestyle intervention|
58456259|NCT06236100|BEHAVIORAL|Strengthening Families Program + Family Advocate|This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.
57760686|NCT04709432|PROCEDURE|ECMO|ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
57760687|NCT04945421|DRUG|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
57760688|NCT04945421|DRUG|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
57760689|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
57760690|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
57760691|NCT03566459|OTHER|CBOC offering Tele-MOUD to Veterans|CBOC offering medications for opioid use disorder (MOUD) using telemedicine
57760692|NCT03566459|OTHER|CBOC not offering Tele-MOUD to Veterans|CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
57760693|NCT05302505|OTHER|simulation-based training|Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
57760694|NCT01475695|DRUG|14C GSK2251052|1500 mg iv dose GSK2251052
57760695|NCT02098018|BEHAVIORAL|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
57760696|NCT02098018|BEHAVIORAL|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
57760697|NCT04598035|DIAGNOSTIC_TEST|Diagnostic Tests|"1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain"
57760698|NCT02939300|DRUG|Nivolumab|"* Melanoma:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
57760699|NCT02939300|DRUG|Ipilimumab|"* Non-small Cell Lung Cancer / Head and Neck Cancer:~  - Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  - Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
57760700|NCT04323982|PROCEDURE|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
57760701|NCT04323982|PROCEDURE|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
57760702|NCT02788630|BEHAVIORAL|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
57760703|NCT01539876|PROCEDURE|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
57760704|NCT04490564|DIAGNOSTIC_TEST|PD-L1 Kit|Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples
57760705|NCT05889884|DEVICE|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
57760706|NCT05341986|OTHER|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
57760707|NCT06101251|BEHAVIORAL|Driving Tips|Each week participants will receive a safe driving tip for one of the four behaviors via text message.
57760708|NCT06101251|BEHAVIORAL|Standard Feedback|Each week participants will receive a text message showing their overall driving score (out of 100) and subscores for distraction, hard braking, fast acceleration, and speeding (all running averages). The scoreboard will indicate whether their scores have gone up, down, or stayed the same. The message will include a link to a dashboard.
58128932|NCT04126811|DRUG|Pirarubicin, Ifosfamide|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
58128933|NCT02171533|DRUG|dabigatran|
58456260|NCT06236100|BEHAVIORAL|Strengthening Families Program|This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
58456261|NCT03805802|OTHER|active product|Once daily consumption over the period of the study
58456262|NCT03805802|OTHER|reference product|Once daily consumption over the period of the study
58456263|NCT02221869|DRUG|Xyrem|
58456264|NCT06447558|BEHAVIORAL|palatal stimulation with a finger in premature infants|Oral administration of breast milk droplets, palatal stimulation with a finger in premature infants
58456265|NCT05212558|OTHER|Placebo respiratory muscle training|Unloaded respiratory muscle training plus conventional respiratory exercises
58456266|NCT05212558|OTHER|Inspiratory muscle training|Inspiratory muscle training plus conventional respiratory exercises
58456267|NCT05212558|OTHER|Combined inspiratory and expiratory muscle training|Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
58456268|NCT00447720|BEHAVIORAL|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
58456269|NCT04945187|OTHER|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
58456270|NCT04122326|BEHAVIORAL|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
58456271|NCT03902691|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
58456272|NCT03902691|DRUG|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
58456273|NCT04081922|PROCEDURE|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
58456274|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
58456275|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
58456276|NCT03381521|DEVICE|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
58456277|NCT03381521|DRUG|Normal saline|The normal saline was used for injection solution
58456278|NCT00373581|DRUG|Vigabatrin|
58456279|NCT00373581|DRUG|Cocaine|
58456280|NCT05774535|OTHER|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~* informed consent;~* personal data and medical records;~* registration of medical therapy and post-procedural pharmacological protocol~* surgical check;~* supra-aortic trunks EchocolorDoppler;~* pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~* surgical checks;~* registration of drug therapy;~* recording of all adverse events that occurred during hospitalization~* supra-aortic trunks EchocolorDoppler and cIMT measurement;~* blood sampling."
58456281|NCT06237959|DIETARY_SUPPLEMENT|Keranat™|300 mg/capsule(proso millet and wheat extract 600 mg/day)
58456282|NCT06237959|DIETARY_SUPPLEMENT|placebo|300 mg/capsule(600 mg/day as placebo)
58456283|NCT03845127|DEVICE|Revivent TC Ventricular Enhancement System|Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
58456284|NCT03845127|DRUG|GDMT|Guideline Directed Medical Therapy
58456285|NCT04563377|BIOLOGICAL|ChAdOx1.HTI and MVA.HTI|ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu
58456286|NCT05204446|BEHAVIORAL|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
58456287|NCT05204446|BEHAVIORAL|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
58128934|NCT02171533|DRUG|Verapamil|
58128935|NCT02171533|DRUG|Verapamil ER|
58456288|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
58456289|NCT01373463|DRUG|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
58456290|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
57760709|NCT06101251|BEHAVIORAL|Assigned Focus Area Feedback|Each week feedback will focus the participant's attention on the driving behavior with the greatest opportunity for improvement based on their baseline driving behavior. Participants will be assigned a goal for the week of a score 5 points (3 points in the case of Driver Focus) better than their baseline for that area. If they meet the goal, they will be given a new goal 5 points higher; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be assigned a new behavior to focus on.
57760710|NCT06101251|BEHAVIORAL|Study Dashboard (Standard)|By clicking the link in the feedback text, they will be able to view a weekly dashboard that provides detailed information about their baseline, best, last, and average scores for each of the four behaviors, plus descriptions of the four behaviors.
58456291|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
58456292|NCT01373463|DRUG|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
58456293|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
57760711|NCT06101251|BEHAVIORAL|Study Dashboard (focused)|Same as standard study dashboard, except participants will see at the top of the dashboard how well they are doing relative to their weekly goals.
57760712|NCT06101251|BEHAVIORAL|UBI-like Behavioral Incentive|At the end of the 12-week intervention period, their overall driving score will be translated into a $0-$100 reward amount. For example, a participant with an overall driving score of 84 at the end of the intervention period would receive $84 in compensation.
57760713|NCT06101251|BEHAVIORAL|Sef-Chosen Focus Area Feedback|Participants will be asked to select which driving behavior they want to focus on improving, and to set a goal for the week that is above their baseline score. If they meet the goal, they will be asked to set a new, higher goal; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be asked if they want to focus on a new behavior.
57760714|NCT05962983|BEHAVIORAL|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
57760715|NCT01632943|DEVICE|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
57760716|NCT01702441|DRUG|Subcutaneous AKB-9778|
57760717|NCT01786486|DEVICE|Amplatzer Cardiac Plug|
57760718|NCT00382824|DIETARY_SUPPLEMENT|Coenzyme Q10|active drug
57760719|NCT00382824|OTHER|Placebo|Placebo
58456294|NCT01373463|PROCEDURE|Lobectomy|Surgery
58456295|NCT01373463|PROCEDURE|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
58456296|NCT00922623|DEVICE|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
58456297|NCT00804700|BEHAVIORAL|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
58456298|NCT00823251|DEVICE|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
58456299|NCT06477159|DRUG|Pancrelipase Capsules|Treatment with Pancreatic Enzyme Replacement Therapy
57760720|NCT02993887|BEHAVIORAL|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
57760721|NCT02993887|BEHAVIORAL|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
57760722|NCT00881491|DRUG|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
57760723|NCT00881491|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
58456300|NCT05797012|OTHER|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
57760724|NCT00881491|DRUG|Mineral Trioxide Aggregate|standard material providing an apical barrier
57760725|NCT00185640|DRUG|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
57760726|NCT00185640|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
57760727|NCT00185640|DRUG|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
58456301|NCT06249685|DEVICE|Bilateral hearing devices|Three week trial while wearing bilateral hearing devices.
57760728|NCT00185640|DRUG|Filgrastim|"* Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
58458623|NCT03588663|DEVICE|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
57760729|NCT00185640|RADIATION|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
57760730|NCT03911427|OTHER|Active oat beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
57760731|NCT03911427|OTHER|Control rice beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
57760732|NCT00328614|DRUG|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
57760733|NCT00328614|DRUG|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
57760734|NCT00328614|DRUG|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
57760735|NCT00328614|DEVICE|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
57760736|NCT00816933|PROCEDURE|appendectomy|appendectomy according to the number of trocar
57760737|NCT06475001|DRUG|VER-01|"Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil."
57760738|NCT06475001|DRUG|Placebo|Comparator without active ingredient
57760739|NCT04469647|DIAGNOSTIC_TEST|Serology Test|"Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test."
57760740|NCT01092403|DRUG|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
57760741|NCT01092403|DRUG|Placebo|Placebo once daily by inhalation
57760742|NCT01830595|DRUG|Recombinant Lactoferrin|
57760743|NCT01830595|DRUG|Placebo|
57760744|NCT05837208|OTHER|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
57760745|NCT02332343|OTHER|No intervention - Natural history study|
57760746|NCT04588935|DRUG|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
57760747|NCT03585296|DRUG|ATI-502|Topical Solution
57760748|NCT00774384|BIOLOGICAL|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
57760749|NCT00004410|DRUG|tauroursodeoxycholic acid|
57760750|NCT00246337|DRUG|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
57760751|NCT00246337|DRUG|MK0974|MK0974 25 mg; one orally-administered dose
57760752|NCT00246337|DRUG|MK0974|MK0974 50 mg; one orally-administered dose
57760753|NCT00246337|DRUG|MK0974|MK0974 100 mg; one orally-administered dose
57760754|NCT00246337|DRUG|MK0974|MK0974 200 mg; one orally-administered dose
57760755|NCT00246337|DRUG|MK0974|MK0974 300 mg; one orally-administered dose
57760756|NCT00246337|DRUG|MK0974|MK0974 400 mg; one orally-administered dose
57760757|NCT00246337|DRUG|MK0974|MK0974 600 mg; one orally-administered dose
57760758|NCT00246337|DRUG|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
57760759|NCT03324880|BIOLOGICAL|rhPTH (1-84)|rhPTH (1-84) SC injection.
57760760|NCT03324880|BIOLOGICAL|Placebo|Placebo QD SC injection.
57760761|NCT04045093|DRUG|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
57760762|NCT04045093|DRUG|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
57760763|NCT02890537|DRUG|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
57760764|NCT02890537|DRUG|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
57760765|NCT03518125|BIOLOGICAL|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
57760766|NCT03518125|BIOLOGICAL|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
57760767|NCT03518125|DRUG|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
57760768|NCT02320643|DEVICE|Seratom® PA mesh|Partially absorbable mesh
57760769|NCT05862467|BEHAVIORAL|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
58456302|NCT05089799|BEHAVIORAL|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~1. welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~2. providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~3. providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~4. providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~5. Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
58456303|NCT01089686|PROCEDURE|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
58456304|NCT01089686|PROCEDURE|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
58456305|NCT03775798|DRUG|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
58456306|NCT04688658|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
58456307|NCT04688658|DRUG|Duvelisib|Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
58456308|NCT01911611|DRUG|RO6870868|Single ascending doses
58456309|NCT01911611|DRUG|placebo|Single ascending doses
58456310|NCT03116516|DRUG|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
58456311|NCT03116516|DRUG|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
58456312|NCT01210716|DEVICE|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
58456313|NCT04486235|BEHAVIORAL|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
58456314|NCT05515731|BIOLOGICAL|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
58456315|NCT05416216|BEHAVIORAL|WELL|The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
58456316|NCT05640440|DIAGNOSTIC_TEST|Executive function testing|Assessment of executive function subdivision
58456317|NCT01622621|PROCEDURE|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
58456318|NCT01622621|RADIATION|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
58456319|NCT02764463|DEVICE|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
58456320|NCT02075112|DRUG|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
58456321|NCT02075112|RADIATION|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
58456322|NCT02075112|DRUG|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
58456323|NCT02498301|DRUG|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
58456324|NCT02498301|DRUG|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
58456325|NCT06055179|DRUG|Xiao Chai Hu Tang (XCHT)|XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
58456326|NCT06055179|DRUG|Placebo|Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
57760770|NCT02848261|BEHAVIORAL|Developmental Demands|Education and training related to use of CGM in this age group
57760771|NCT02848261|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
57760772|NCT02848261|BEHAVIORAL|Remote Monitoring|Education and training on the use of remote monitoring
57760773|NCT02848261|BEHAVIORAL|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
58128936|NCT04648358|DRUG|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
57760774|NCT02848261|BEHAVIORAL|No intervention|No intervention - serves as the control group
57760775|NCT00172354|DRUG|Hydrocortisone|
57760776|NCT00487058|DRUG|Gimatecan|
57760777|NCT00203060|DRUG|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
57760778|NCT00203060|DRUG|placebo|tablet, once daily, 58 weeks
57760779|NCT03577158|DEVICE|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
57760780|NCT03577158|DEVICE|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
57760781|NCT03577158|DEVICE|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
57760782|NCT03035890|RADIATION|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
57760783|NCT03035890|DRUG|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
57760784|NCT00180128|DRUG|all-trans retinoid acid|
57760785|NCT00180128|DRUG|idarubicin|
57760786|NCT00180128|DRUG|mitoxantrone|
58456327|NCT06055179|DRUG|Irinotecan regimen|"Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks."
58456328|NCT06055179|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
58456329|NCT01485094|DRUG|GRT6010|Oral solution given once daily.
58456330|NCT01485094|DRUG|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
58456331|NCT01485094|DRUG|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
58456332|NCT00532662|DRUG|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
58456333|NCT04427319|DIETARY_SUPPLEMENT|β-alanine|7 days of consumption
58456334|NCT04427319|DIETARY_SUPPLEMENT|wheat semolina|7 days of consumption
57760787|NCT00180128|DRUG|daunorubicin|
57760788|NCT00180128|DRUG|cytarabine|
57760789|NCT00087360|OTHER|counseling intervention|
57760790|NCT00087360|OTHER|physiologic testing|
57760791|NCT00087360|PROCEDURE|evaluation of cancer risk factors|
57760792|NCT00339690|OTHER|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
57760793|NCT01208740|DRUG|Metformin|500 mg three times daily
57760794|NCT01208740|DRUG|Placebo|1 pill three times daily
57760795|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
57760796|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
57760797|NCT04141631|DRUG|EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"
57760798|NCT05087914|DRUG|Carbidopa-Levodopa (100mg/25mg):|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
57760799|NCT05087914|DRUG|Naproxen|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
57760800|NCT03474549|DEVICE|Tigertriever revascularization device|Mechanical Thrombectomy
57760801|NCT00981851|DRUG|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
57760802|NCT00981851|DRUG|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
57760803|NCT02483286|BEHAVIORAL|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
57760804|NCT02483286|BEHAVIORAL|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
57760805|NCT02483286|BEHAVIORAL|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
57760806|NCT03395808|DRUG|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
57760807|NCT02028832|PROCEDURE|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
57760808|NCT02028832|PROCEDURE|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
57760809|NCT01395823|DIETARY_SUPPLEMENT|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
57760810|NCT01395823|OTHER|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
57760811|NCT00990340|DEVICE|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
57760812|NCT00990340|PROCEDURE|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
57760813|NCT06205732|OTHER|Immunotherapy, targeted therapy.|Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
57760814|NCT03177122|DRUG|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
58456335|NCT04024891|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
58456336|NCT04024891|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
57760815|NCT03551314|OTHER|Nasal Intermittent Positive Pressure|"- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
57760816|NCT03551314|OTHER|Continuous Positive Airway Pressure|"- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
57760817|NCT01247428|DEVICE|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
57760818|NCT00118092|DRUG|tanespimycin|Given IV
57760819|NCT00118092|OTHER|laboratory biomarker analysis|Correlative studies
57760820|NCT06058390|DRUG|Bepirovirsen|Bepirovirsen will be administered.
58456337|NCT06159452|DRUG|SAR153191-P3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
58456338|NCT06159452|DRUG|SAR153191-P2 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
58456339|NCT06159452|DRUG|SAR153191-C1F3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
58456340|NCT02737007|DRUG|[14C]-GSK3191607|\[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
58456341|NCT00079040|DRUG|cisplatin|Given IV
57760821|NCT05553639|BIOLOGICAL|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
58456342|NCT00079040|DRUG|etoposide|Given IV
58456343|NCT00079040|BIOLOGICAL|bevacizumab|Given IV
58456344|NCT00079040|OTHER|laboratory biomarker analysis|Correlative studies
57760822|NCT00993239|DRUG|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
57760823|NCT01056588|BEHAVIORAL|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
58456345|NCT03799796|BEHAVIORAL|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
58456346|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
58456347|NCT01682408|DRUG|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
58456348|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
58456349|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
58456350|NCT01682408|DRUG|Ranitidine|150 mg ranitidine
58456351|NCT04443634|PROCEDURE|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
58456352|NCT04443634|PROCEDURE|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
58456353|NCT04443634|PROCEDURE|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
58456354|NCT04443634|DRUG|Bupivacaine 20 ml|20ml bupivacaine 0.5%
58456355|NCT04443634|DRUG|Bupivacaine 30ml|30ml bupivacaine 0.5%
58456356|NCT04443634|DRUG|Bupivacaine 10ml|10ml bupivacaine 0.5%
58456357|NCT01364584|DRUG|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
58456358|NCT01364584|DRUG|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
58456359|NCT03016312|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
58456360|NCT03016312|DRUG|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
58456361|NCT06125834|DRUG|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
58456362|NCT01072188|DEVICE|Arginine/Calcium Carbonate|One time treatment
58456363|NCT01072188|DEVICE|Nupro - Fluoride Free|Brush twice daily
57760824|NCT01056588|BEHAVIORAL|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
57760825|NCT02178644|DRUG|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
57760826|NCT04338854|PROCEDURE|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
57760827|NCT00691132|DRUG|phenethyl isothiocyanate|Given orally
57760828|NCT00691132|OTHER|placebo|Given orally
57760829|NCT01403025|DRUG|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
57760830|NCT01494155|DRUG|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
58456364|NCT02812836|DEVICE|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
58456365|NCT06349694|OTHER|Transcutaneous MPN stimulation (T-MPNS)|Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
58456366|NCT06349694|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
58456367|NCT06349694|OTHER|BT (Control group)|Conventional bladder training
58456368|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
58456369|NCT02201524|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
58456370|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
58456371|NCT02201524|OTHER|Placebo|Subjects will receive placebo for 4 weeks
57760831|NCT01494155|DRUG|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
57760832|NCT01494155|RADIATION|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
57760833|NCT02583438|DRUG|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
57760834|NCT05222464|OTHER|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
57760835|NCT04067401|BEHAVIORAL|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
57760836|NCT04067401|BEHAVIORAL|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
57760837|NCT02560662|BEHAVIORAL|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
57760838|NCT01667913|OTHER|6 minutes walking test|
57760839|NCT00122590|DRUG|nelfinavir|
57760840|NCT00122590|DRUG|lopinavir/r|
57760841|NCT00122590|DRUG|indinavir|
57760842|NCT00122590|DRUG|ritonavir|
57760843|NCT02259517|DRUG|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
57760844|NCT02259517|DRUG|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
57760845|NCT02544464|DRUG|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
58456372|NCT02528708|DRUG|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
58456373|NCT02528708|DRUG|Placebo|0.9% saline solution
57760846|NCT02544464|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
57760847|NCT02293395|DRUG|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
58456374|NCT00310011|DRUG|cisplatin|
58456375|NCT00310011|DRUG|gemcitabine hydrochloride|
58456376|NCT00310011|DRUG|paclitaxel|
58456377|NCT00310011|PROCEDURE|conventional surgery|
58456378|NCT03538418|OTHER|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
58456379|NCT05646498|PROCEDURE|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
58456380|NCT05646498|DEVICE|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
58456381|NCT04243694|BEHAVIORAL|Mindfulness training|Participants of the intervention group will receive 6-weeks of mindfulness training.
58456382|NCT02047955|DEVICE|Shoulder Arthroplasty|"Data will be collected for commercially available Sponsor devices. These systems treat both the humeral and glenoid side of the shoulder joint. The following products will be included in the study in the geographies where they are commercially available.~* Aequalis Ascend Flex Convertible Shoulder System~* Pyrocarbon Humeral Head (used with Aequalis Ascend Flex)~* Simpliciti Shoulder Prosthesis~* Aequalis Reversed Fracture Prosthesis~* Aequalis PerFORM Glenoid~* Aequalis PerFORM+ Glenoid~* Aequalis PerFORM Reversed Glenoid~Devices previously included, but discontinued under clinical investigation plan (CIP) version 4.0:~* Aequalis Resurfacing Head~* Aequalis Ascend Anatomic Shoulder System~* Aequalis IM Humeral Nail - Short and Long~* ORTHOLOC™ SPS (Shoulder Plating System)~* Aequalis Reversed II Shoulder System~* Aequalis Adjustable Reversed Prosthesis~* Aequalis Flex Revive Shoulder System"
58456383|NCT00752700|OTHER|Conventional resistance training|Conventional resistance training program (CRT)
58456384|NCT00752700|OTHER|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
58456385|NCT02818868|DRUG|apixisaban|
58456386|NCT02182323|DRUG|BI 201335 NA|
57760848|NCT02293395|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
58456387|NCT02182323|DRUG|Placebo solution|
57760849|NCT02293395|DRUG|Clopidogrel|Clopidogrel 75 mg once daily orally.
57760850|NCT02293395|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily orally.
58456388|NCT02179008|DRUG|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
58456389|NCT02179008|DRUG|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
58456390|NCT02179008|DRUG|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
58456391|NCT02179008|DRUG|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
58456392|NCT02179008|DRUG|DE-117 High Dose ophthalmic solution|High Dose DE-117
58456393|NCT02179008|DRUG|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
58456394|NCT00629226|BIOLOGICAL|cetuximab|Given IV
58456395|NCT00629226|DRUG|bortezomib|Given IV
58456396|NCT00629226|DRUG|cisplatin|Given IV
58456397|NCT00629226|RADIATION|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
58456398|NCT02997501|PROCEDURE|T790M+ Testing|The patient will need to have T790M+ testing
58456399|NCT02997501|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
58456400|NCT02997501|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
58456401|NCT02997501|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
58456402|NCT02997501|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
58456403|NCT02997501|PROCEDURE|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
58456404|NCT00896714|DEVICE|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
58456405|NCT04139655|DRUG|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
58128937|NCT04648358|DRUG|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
58456406|NCT04139655|DRUG|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
58456407|NCT03572179|DEVICE|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
58456408|NCT06451302|DRUG|cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide|The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
58128938|NCT04696419|OTHER|Different intensities of contact to dogs|Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
58456409|NCT05024435|DEVICE|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
58456410|NCT03063463|PROCEDURE|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
57760851|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally|coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine
58128939|NCT04123210|DIETARY_SUPPLEMENT|Vitamin A supplement|
58456411|NCT03063463|PROCEDURE|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
58456412|NCT00215111|BEHAVIORAL|Low carbohydrate, reduced glycemic load, and a control diet|
58456413|NCT04781010|DEVICE|MRI|MRI pattern in children with Leukodystrophy
57760852|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously|coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
57760853|NCT04445857|OTHER|Normal Saline (NS)|coadministration of normal saline and a single-shot hyperbaric bupivacaine
57760854|NCT03748511|OTHER|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
57760855|NCT05647863|OTHER|Functional Cognitive and Sensory Treatment (F-CaST)|F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
57760856|NCT00722501|DRUG|ERB-257|
57760857|NCT00722501|OTHER|placebo|
58128940|NCT04123210|DIETARY_SUPPLEMENT|Placebo|
58128941|NCT01479439|DRUG|Losartan|Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months
58128942|NCT00013546|DRUG|TMTDS|
58128943|NCT03311646|OTHER|Normal nicotine content cigarettes (NNC, Baseline)|Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
58128944|NCT03311646|OTHER|Very low nicotine content (VLNC)|Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
58456414|NCT05513326|OTHER|Exercises and education|"Exercises: 3 training sessions per week that will last for 30 minutes. Sessions will start with 5 minutes of activation (walking on a treadmill or cycling). Then, participants will be asked to complete 5 exercises targeting lower limb strengthening (time: 18 minutes) followed by 2 exercises designed to improve balance and 3 stretching exercises for the lower limb (time: 7 minutes).~Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions."
58456415|NCT05513326|OTHER|Education alone|Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions.
58456416|NCT04085549|DEVICE|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
58456417|NCT04085549|OTHER|Reference Cream|Commercial refence cream not containing berry and plant oils.
58456418|NCT05644314|DEVICE|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
58456419|NCT02767271|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
58456420|NCT03694405|BIOLOGICAL|MenACWY-CRM|Booster vaccination with MenACWY-CRM
58456421|NCT03694405|BIOLOGICAL|MenACWY-DT|Booster vaccination with MenACWY-DT
58456422|NCT03694405|BIOLOGICAL|MenACWY-TT|Booster vaccination with MenACWY-TT
58456423|NCT05605626|OTHER|the better retaining of skills|identify which teaching program has the better retaining of skills
58456424|NCT04614896|DIAGNOSTIC_TEST|Transoral ultrasound of tongue tumors|A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
58456425|NCT00962208|DEVICE|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
58456426|NCT00962208|DEVICE|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
57760858|NCT05614414|PROCEDURE|tracheal intubation by Videolaryngoscope|The investigators performed laryngoscopy using a McGrath video-laryngoscope with a number 4 blade.
58128945|NCT05627427|DRUG|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
58128946|NCT05627427|DRUG|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
58456427|NCT04043117|OTHER|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
58456428|NCT04043117|OTHER|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
58456429|NCT01879917|DRUG|Liraglutide|
58456430|NCT01879917|DRUG|Placebo|Saline
58456431|NCT02253615|OTHER|Machines exercises|Resistance training in pneumatic machines.
58456432|NCT02253615|OTHER|Elastic exercises|Resistance training with elastic tubes.
58456433|NCT00414856|DRUG|AFQ056|
58456434|NCT03685630|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection"
58456435|NCT05863897|BEHAVIORAL|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
58456436|NCT00683111|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
58456437|NCT00683111|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
58456438|NCT00499681|DRUG|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
58456439|NCT00499681|DRUG|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
58456440|NCT00499681|OTHER|placebo|Given once daily for 2 weeks
58456441|NCT00879021|DRUG|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
58456442|NCT00879021|DRUG|matching placebo|150 mg by mouth ,twice a day for 49 weeks
58456443|NCT04197830|PROCEDURE|Thrombectomy for stroke|Patients who have had thrombectomy for acute stroke.
58456444|NCT02196961|DRUG|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
58456445|NCT02178995|DRUG|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
58456446|NCT05853146|DEVICE|Oxitone 1000M|World's First FDA-cleared Wrist-Sensor Pulse Oximetry Monitor
58456447|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
58456448|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
58456449|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
58456450|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
58456451|NCT03967145|BEHAVIORAL|Determining quality of life|Quality of Life
58456452|NCT04092686|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
58456453|NCT04092686|DRUG|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
58456454|NCT04092686|DRUG|Placebo|Placebo tablet dosed once daily
58458624|NCT03588663|OTHER|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
57760859|NCT05614414|PROCEDURE|tracheal intubation by direct laryngoscope|The investigators performed laryngoscopy using either a Macintosh laryngoscope using a number 4 blade.
57760860|NCT03762343|DRUG|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
57760861|NCT03762343|DRUG|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
57760862|NCT02355613|RADIATION|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
57760863|NCT02355613|RADIATION|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
57760864|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline
57760865|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
57760866|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
57760867|NCT01782872|PROCEDURE|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
57760868|NCT00511979|DRUG|Technosphere Insulin|
57760869|NCT00511979|DRUG|Technosphere insulin|
57760870|NCT00511979|DRUG|Technosphere insulin|
57760871|NCT00511979|DRUG|Regular human insulin|
57760872|NCT01965782|DRUG|[^14C]-LY3023703|Administered orally
57760873|NCT04728178|OTHER|Crystalloid solution|Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
57760874|NCT04728178|OTHER|Colloid solution|Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
57760875|NCT02126683|DRUG|Hydroxychloroquine|
57760876|NCT03458767|BEHAVIORAL|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
57760877|NCT03062202|BEHAVIORAL|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
57760878|NCT04763811|OTHER|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
57760879|NCT04763811|OTHER|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
57760880|NCT01511796|OTHER|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
58128947|NCT05814458|DEVICE|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
58456455|NCT03179566|BEHAVIORAL|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
58458625|NCT03588663|OTHER|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
57760881|NCT04897425|DEVICE|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
57760882|NCT00270361|DRUG|nesiritide|
57760883|NCT00270361|DRUG|usual long term cardiac medications|
57760884|NCT00270361|DRUG|nesiritide|
57760885|NCT04934722|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
57760886|NCT04934722|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
57760887|NCT04934722|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
57760888|NCT04934722|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
57760889|NCT01222143|DRUG|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
57760890|NCT01222143|DRUG|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10."
57760891|NCT01038115|PROCEDURE|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
57760892|NCT00805090|DRUG|Sporanox|200 mg
57760893|NCT00805090|DRUG|Diclofenac Sodium|37.5 mg
57760894|NCT03188120|DRUG|Spiriva Respimat|Drug
57760895|NCT02796430|OTHER|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
57760896|NCT02796430|OTHER|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
57760897|NCT02913066|OTHER|S-1 concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.
57760898|NCT02913066|OTHER|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
57760899|NCT02923739|BIOLOGICAL|Bevacizumab|Given IV
58456456|NCT03179566|BEHAVIORAL|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
58456457|NCT04498715|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
58456458|NCT04498715|DRUG|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
57760900|NCT02923739|BIOLOGICAL|Emactuzumab|Given IV
57760901|NCT02923739|OTHER|Laboratory Biomarker Analysis|Correlative studies
57760902|NCT02923739|DRUG|Paclitaxel|Given IV
57760903|NCT02923739|OTHER|Pharmacological Study|Correlative studies
57760904|NCT00735111|OTHER|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
57760905|NCT04774523|PROCEDURE|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~1. Standard AV programming: perform echo for AoVTI assessment.~2. Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~3. AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
57760906|NCT04774523|PROCEDURE|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
57760907|NCT04774523|PROCEDURE|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
57760908|NCT04774523|OTHER|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
57760909|NCT02243202|DRUG|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
57760910|NCT02243202|DRUG|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
57760911|NCT02243202|DRUG|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
57760912|NCT02243202|DRUG|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
57760913|NCT03732625|DRUG|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
57760914|NCT02669095|DEVICE|Investigational Contact Lenses (Test)|
57760915|NCT02669095|DEVICE|Marketed Contact Lenses (Control)|
57760916|NCT05412888|DIETARY_SUPPLEMENT|CoQ10 supplementation|Young men training endurance running will be supplemented with CoQ10
57760917|NCT05412888|PROCEDURE|Ischemic preconditioning training|Young men training endurance running will undergo IPC training
57760918|NCT05412888|DIETARY_SUPPLEMENT|IPC training combined with CoQ10 supplementation|Young men training endurance running will undergo IPC training combined with CoQ10 supplementation
57760919|NCT05412888|DIETARY_SUPPLEMENT|Sham IPC combined with placebo|Young men training endurance running will undergo sham IPC training combined with placebo supplementation
57760920|NCT05664932|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
57760921|NCT05664932|BIOLOGICAL|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
57760922|NCT04655885|BEHAVIORAL|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
57760923|NCT04655885|BEHAVIORAL|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
57760924|NCT06446076|BEHAVIORAL|Gamification (Gain/Loss framing)|"Participants will take part in a 6-week game-based program designed to help them reach their daily step goals. They are encouraged to maintain their daily step counts to achieve their daily step target over the 6-week intervention period. The gamification design incorporates two theoretically effective behavioral economics principles, Fresh Start and Loss Aversion. All participants start from the Silver rank (middle rank), and their rank changes based on each final point of the week. The ranks are set from top to bottom as Platinum, Gold, Silver, Bronze, and Blue. In loss framing, if the daily step target is 6000 steps, maintaining 70 points for achieving 6000 steps on day 1, and a deduction of 10 points for not achieving it. In gain framing, achieving 6000 steps on day 1 results in an addition of 10 points, with no increase for not achieving it. After one week, ranks increase if the points at midnight on Sunday are 40 or above, and decrease if below this threshold."
57760925|NCT06446076|BEHAVIORAL|Social support|Participants in this group are asked to designate a family member or friend to provide social support. This supporter is encouraged to check the participant's progress and provide support during the interventional period. The supporter will also receive weekly emails throughout the period, informing them about the participant's daily step counts, achievement status, points, levels, and other relevant information.
57760926|NCT04358172|OTHER|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
58128948|NCT05814458|DEVICE|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
58128949|NCT00389636|DEVICE|TheraGauze|TheraGauze
58128950|NCT00389636|DRUG|Regranex|Regranex + TheraGauze
58128951|NCT03803410|PROCEDURE|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
58128952|NCT03488342|PROCEDURE|Repair for primary inguinal hernia|Repair for primary inguinal hernia
58128953|NCT01179048|DRUG|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
58128954|NCT01179048|DRUG|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
57760927|NCT04129814|PROCEDURE|Non surgical periodontal therapy|single session full-mouth scaling and root planing
58128955|NCT01658943|DRUG|Akt Inhibitor MK2206|Given PO
58128956|NCT01658943|DRUG|Fluorouracil|Given IV
58128957|NCT01658943|DRUG|Oxaliplatin|Given IV
57760928|NCT01945905|OTHER|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
57760929|NCT01945905|OTHER|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
57760930|NCT00751764|DRUG|Moxidectin|
57760931|NCT01550484|DRUG|18F-AV-133|222 MBq (6 mCi)
57760932|NCT04203043|DRUG|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
57760933|NCT04203043|OTHER|Placebo|Placebo
57760934|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
58128958|NCT01658943|DRUG|Selumetinib|Given PO
58128959|NCT01292161|DRUG|Silymarin|Tab 210 mg, 630 mg, daily, six months.
58128960|NCT00723554|DRUG|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
58128961|NCT00723554|DRUG|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
58128962|NCT00802100|DRUG|Olanzapine|Daily tablets of 10 to 30 mg
58128963|NCT00802100|DRUG|Perphenazine|Daily tablets of 8 to 24 mg
57760935|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
57760936|NCT02675478|DRUG|AC220|
57760937|NCT04842214|BEHAVIORAL|Oncological Rehabilitation|Multidimensional rehabilitation
57760938|NCT01715610|DRUG|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
57760939|NCT01715610|DRUG|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
57760940|NCT01715610|DRUG|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
57760941|NCT06311084|OTHER|Imaginator 2.0|Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
57760942|NCT01105286|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
57760943|NCT03010839|PROCEDURE|Modified Remote Ischemic Preconditioning|mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
57760944|NCT03010839|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
57760945|NCT06626152|DRUG|Apo-levocarb|As above.
57760946|NCT04741516|DRUG|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
57760947|NCT00224770|DRUG|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
57760948|NCT00224770|PROCEDURE|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
57760949|NCT02572947|DRUG|Dolutegravir|
57760950|NCT05591248|DEVICE|VRR|Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
58128964|NCT00802100|DRUG|Aripiprazole|Daily tablets of 10 to 30 mg
58128965|NCT00802100|DRUG|Metformin|Daily tablets of 850 to 2550 mg
57760951|NCT00347516|PROCEDURE|IOL calculation formula|
57760952|NCT00717314|DRUG|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
57760953|NCT00717314|DRUG|CNI (50%)|50% reduction from BL
57760954|NCT00717314|DRUG|CNI (≥75%)|≥75% reduction from BL
57760955|NCT01682993|OTHER|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
57760956|NCT01682993|OTHER|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
57760957|NCT03010462|DEVICE|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
57760958|NCT03010462|DEVICE|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
57760959|NCT04359771|DEVICE|Yellow micro-pulse laser|applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
57760960|NCT04359771|DEVICE|Diode micro-pulse laser|applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
57760961|NCT06365307|COMBINATION_PRODUCT|"Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)"|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
57760962|NCT06365307|OTHER|Synthetic osteoplastic material based on β-TCP or bone autograft|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
57760963|NCT00327002|DRUG|LY518674|
57760964|NCT01196208|DRUG|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
57760965|NCT02974881|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
57760966|NCT00949715|DEVICE|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
57760967|NCT00949715|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
57760968|NCT05709990|DRUG|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
58128966|NCT00802100|DRUG|Simvastatin|Daily tablets of 20 to 40 mg
58128967|NCT00802100|DRUG|Benztropine|Daily tablets of 1 to 2 mg
58128968|NCT03931863|DRUG|Ondansetron 4mg|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
57760969|NCT05709990|DRUG|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
57760970|NCT05709990|BEHAVIORAL|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
57760971|NCT00979823|OTHER|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
57760972|NCT00979823|OTHER|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
57760973|NCT05474521|DEVICE|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
57760974|NCT04308902|OTHER|VLBW|Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
57760975|NCT04308902|OTHER|Term-born Comparison|Children born \>=37 weeks gestation and weighing more than 2500g
57760976|NCT03494569|DRUG|Fludarabine|Given IV
57760977|NCT03494569|OTHER|Laboratory Biomarker Analysis|Correlative studies
57760978|NCT03494569|DRUG|Melphalan|Given as per City of Hope Standard Operating Procedure
57760979|NCT03494569|RADIATION|Total Marrow Irradiation|Undergo TMLI
57760980|NCT04961866|DIETARY_SUPPLEMENT|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
57760981|NCT04961866|DIETARY_SUPPLEMENT|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
57760982|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
57760983|NCT03145766|BIOLOGICAL|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
57760984|NCT03145766|BIOLOGICAL|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
57760985|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
57760986|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
57760987|NCT03145766|BIOLOGICAL|Human Rabies Immunoglobulins (HRIG)|Commercialized formulation of HRIG
57760988|NCT02929355|OTHER|carotid assesment by duplex ultrasonography|
57760989|NCT04946929|DRUG|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
57760990|NCT04946929|DRUG|Low molecular weight heparin|half amount low molecular weight heparin
57760991|NCT01802255|DRUG|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
57760992|NCT01802255|DRUG|Midazolam|Intravenous sedation.
58456459|NCT04498715|DEVICE|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
57760993|NCT00052676|DRUG|patent blue V dye|
57760994|NCT00052676|PROCEDURE|radionuclide imaging|
57760995|NCT00052676|PROCEDURE|sentinel lymph node biopsy|
57760996|NCT00052676|RADIATION|technetium Tc 99m sulfur colloid|
57760997|NCT00148382|DRUG|ATL-962|
57760998|NCT03129048|BEHAVIORAL|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
57760999|NCT05211271|DEVICE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
57761000|NCT00985985|DRUG|Nicotine|2 mg or 4 mg nicotine lozenge
57761001|NCT00985985|DRUG|Placebo|placebo lozenge
57761002|NCT00953303|DRUG|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
57761003|NCT00953303|DRUG|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
57761004|NCT05186337|BEHAVIORAL|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
57761005|NCT04105335|DRUG|MTL-CEBPA|Intravenous administration
57761006|NCT04105335|DRUG|Pembrolizumab|Intravenous administration
57761007|NCT04900350|DRUG|AK117|Subjects receive AK117 intravenously.
57761008|NCT04900350|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
57761009|NCT01683162|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
57761010|NCT01683162|DRUG|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
57761011|NCT01683162|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
57761012|NCT02965222|DEVICE|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
57761013|NCT06274814|PROCEDURE|U/S guided Type 2 Pectoral Nerve Block|20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles
57761014|NCT06274814|PROCEDURE|U/S guided RIB combined with the sub-serratus plane block (RISS)|he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
57761015|NCT06142825|OTHER|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
57761016|NCT01673893|DEVICE|ClearWay™ Rx catheter|
57761017|NCT06623396|BIOLOGICAL|M28z1XXPD1DNR CAR|Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
57761018|NCT04766632|DEVICE|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
57761019|NCT03862287|DRUG|Lidocaine|See arm description.
57761020|NCT03862287|DRUG|Bupivacaine Hcl 0.5% Inj_#2|See arm description.
57761021|NCT05674591|BEHAVIORAL|Cognitive Processing Therapy (CPT)|The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
58128969|NCT03931863|DRUG|Ondansetron 8mg|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
58128970|NCT03931863|DRUG|100ml normal saline 0.9 percent|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
58128971|NCT01837862|DRUG|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
58128972|NCT01837862|DRUG|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients \< 12kg: 0.05 mg/kg; for patient \> 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
58456460|NCT00851357|DRUG|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
58456461|NCT00851357|BEHAVIORAL|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
58456462|NCT00851357|DRUG|Placebo|Placebo nicotine patch
57761022|NCT03757143|DRUG|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
57761023|NCT03757143|DRUG|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
57761024|NCT03757143|DEVICE|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
57761025|NCT03757143|DEVICE|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
57761026|NCT03830203|DRUG|BAT1806|8 mg/kg
57761027|NCT03830203|DRUG|Actemra(EU-licensed)|8 mg/kg
57761028|NCT05608096|DEVICE|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
57761029|NCT03839732|DIAGNOSTIC_TEST|Score of abdominal aorta calcifications|Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
57761030|NCT00732602|OTHER|GIP-infusion|
57761031|NCT00732602|OTHER|Sodium-chloride|
57761032|NCT00732602|OTHER|GLP-2 infusion|
58128973|NCT01837862|DRUG|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
58128974|NCT01837862|DRUG|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
58456463|NCT00851357|OTHER|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
58456464|NCT01320358|DRUG|ECMPS-IEM|ECMPS-IEM
58456465|NCT06139549|OTHER|Gross motor development group session|Group session for gross motor development
58456466|NCT00917930|BEHAVIORAL|physical training|intensive cardiac rehabilitation program
58456467|NCT04247217|RADIATION|HDR salvage brachytherapy|In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.
58456468|NCT02428777|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
58456469|NCT02428777|DRUG|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
58456470|NCT02428777|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
58456471|NCT03074071|BEHAVIORAL|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
58456472|NCT02010268|OTHER|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
58456473|NCT03976765|OTHER|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
58456474|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
58456475|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
58456476|NCT02111447|DRUG|Propofol|Propofol infusion with nasal oxygen
58456477|NCT02111447|DRUG|Propofol|Propofol infusion with an LMA
58456478|NCT02111447|DRUG|Sevoflurane|Sevoflurane with an LMA
58456479|NCT02111447|DRUG|Isoflurane|Isoflurane with an LMA
58128975|NCT01837862|DRUG|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
58128976|NCT01837862|DRUG|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
58128977|NCT03172780|DRUG|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
58128978|NCT03172780|DRUG|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
58128979|NCT03172780|DRUG|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
58128980|NCT01110447|DRUG|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
58128981|NCT01110447|OTHER|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
58128982|NCT05805553|DRUG|Propranolol|2mg/kg/day in 3-4 dividd doses
58128983|NCT05805553|DRUG|Nandrolone Decanoate|1mg/kg weekly
58128984|NCT03886090|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
58456480|NCT03306966|DEVICE|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
58456481|NCT03310723|DEVICE|Face Mask preoxygenation|Standard face mask preoxygenation.
58456482|NCT03310723|DEVICE|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
58456483|NCT01212861|DEVICE|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
58456484|NCT02095470|DEVICE|video laryngoscope|newly developed innovatory device
58456485|NCT02095470|DEVICE|traditional laryngoscope|traditional way for intubation
58456486|NCT02320916|PROCEDURE|23Gauge|Arterial puncture will be made using a 23Gauge needle
58456487|NCT02320916|PROCEDURE|25Gauge|Arterial puncture will be made using a 25Gauge needle
58456488|NCT05329844|DRUG|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
58456489|NCT03078322|DRUG|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58456490|NCT03078322|DRUG|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58456491|NCT06462053|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
58456492|NCT06462053|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg d1 q3w
58456493|NCT06462053|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
58456494|NCT06462053|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
58456495|NCT06462053|DRUG|Capecitabine|Xeloda
58456496|NCT02949349|DRUG|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
58456497|NCT02949349|DRUG|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
58456498|NCT02949349|DRUG|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
58456499|NCT02003326|OTHER|Inflammatory markers|
58128985|NCT03886090|BEHAVIORAL|rest|Seated rest following motor skill practice
58128986|NCT03886090|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
58128987|NCT04666909|DIAGNOSTIC_TEST|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP \> 135 mm Hg or DBP \> 85 mmHg (based on the average of 3 BP readings); or average SBP \> 130 mm Hg or DBP \> 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
58456500|NCT03571139|DEVICE|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
58456501|NCT00425724|DRUG|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
58456502|NCT00746070|OTHER|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
58456503|NCT01425502|BEHAVIORAL|DQIP Intervention|"The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives"
58456504|NCT04412577|DRUG|TQB3473|TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
58456505|NCT05043350|DRUG|Loratadine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
58456506|NCT05043350|DRUG|Famotidine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
58456507|NCT00227721|DRUG|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
58456508|NCT00227721|DRUG|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
58456509|NCT03268785|DIAGNOSTIC_TEST|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
58456510|NCT03287921|DRUG|mono bronchodilatation|within indication according to current GOLD recommendation
58456511|NCT03287921|DRUG|dual bronchodilatation|within indication according to current GOLD recommendation
58456512|NCT00037167|DEVICE|Exercise poles|
58456513|NCT02898454|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
58456514|NCT02898454|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
58456515|NCT02898454|DRUG|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension~Route of administration: Intranasal"
58128988|NCT05921890|DRUG|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
58128989|NCT04360993|RADIATION|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
58456516|NCT02539797|DEVICE|tDCS|comparing anodal, cathodal, and sham tDCS
58456517|NCT00791063|OTHER|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
58456518|NCT04831645|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
58456519|NCT04831645|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
58456520|NCT02530346|DRUG|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
58456521|NCT02530346|DRUG|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
58456522|NCT06063174|BEHAVIORAL|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
58456523|NCT06063174|BEHAVIORAL|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
58456524|NCT06063174|BEHAVIORAL|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
58456525|NCT06063174|BEHAVIORAL|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
58456526|NCT06063174|BEHAVIORAL|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
58456527|NCT06063174|BEHAVIORAL|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
58456528|NCT04508881|DEVICE|Ahmed Glaucoma Valve|To compare the prevalence of postoperative hypotony between the 2 arms
58456529|NCT02123134|DRUG|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
57761033|NCT05999084|DRUG|Anti-amyloid Monoclonal Antibodies (mAbs)|Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
57761034|NCT05999084|COMBINATION_PRODUCT|Standard of Care|The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
57761035|NCT01546792|BEHAVIORAL|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
57761036|NCT05318469|DRUG|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
57761037|NCT05318469|DRUG|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
57761038|NCT02282397|DEVICE|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
57761039|NCT01957501|OTHER|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
57761040|NCT01959347|PROCEDURE|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
58456530|NCT02123134|DRUG|Placebo|Phosphate buffered saline placebo for injection
58456531|NCT00492245|PROCEDURE|PTK with mitomycin in Adenoviral Opacities|
58456532|NCT05313035|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
58456533|NCT05313035|BIOLOGICAL|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
57761041|NCT01959347|OTHER|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
57761042|NCT02269514|OTHER|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
58456534|NCT00860808|DRUG|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
57761043|NCT02269514|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
57761044|NCT02269514|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
57761045|NCT02269514|OTHER|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
58456535|NCT01739166|OTHER|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
58456536|NCT03850860|OTHER|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
57761046|NCT02269514|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
57761047|NCT03767270|BIOLOGICAL|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
58128990|NCT02315690|DRUG|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
58456537|NCT01442480|DIETARY_SUPPLEMENT|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
58456538|NCT01442480|DIETARY_SUPPLEMENT|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
58458626|NCT03588663|OTHER|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
58458627|NCT00049023|RADIATION|90Y-DOTA-tyr3-OCTREOTIDE|
58458628|NCT04905550|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
57761048|NCT03767270|OTHER|Placebo|5% dextrose in water
57761049|NCT05671640|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
57761050|NCT00229957|BEHAVIORAL|Occupational therapy|
57761051|NCT00229957|BEHAVIORAL|Physiotherapy|
57761052|NCT00229957|BEHAVIORAL|Self-management|
57761053|NCT02552238|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
57761054|NCT01227603|DRUG|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
57761055|NCT01227603|DRUG|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
57761056|NCT01227603|DRUG|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
57761057|NCT00830622|OTHER|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
57761058|NCT01257711|PROCEDURE|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
57761059|NCT03161366|BIOLOGICAL|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
57761060|NCT01120158|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
57761061|NCT01120158|DRUG|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
57761062|NCT05124106|DIAGNOSTIC_TEST|Raman Spectrometry|Bladder tumor is examined with Raman spectrometry during endoscopy
57761063|NCT00849004|OTHER|silicone gel|silicone gel
57761064|NCT00849004|OTHER|silicone sheet|silicone sheet
57761065|NCT00849004|OTHER|paper tape|paper tape
57761066|NCT03034018|DRUG|suvorexant|10-20 mg taken at bedtime for four weeks
57761067|NCT03034018|DRUG|placebo|placebo taken at bedtime for four weeks
57761068|NCT02530814|OTHER|Blood Collection|Onetime blood collection.
57761069|NCT01874314|DRUG|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
57761070|NCT01874314|OTHER|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
57761071|NCT01874314|DRUG|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
57761072|NCT00027001|BEHAVIORAL|Aerobic and Resistance Exercises|
57761073|NCT00027001|BEHAVIORAL|Qigong|
57761074|NCT03877965|DRUG|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
57761075|NCT01618890|PROCEDURE|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
57761076|NCT00231673|DRUG|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
57761077|NCT02891538|DRUG|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*
57761078|NCT05250622|OTHER|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
57761079|NCT05250622|OTHER|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
57761080|NCT00235092|DEVICE|Cypher Sirolimus-Eluting Stent|
57761081|NCT00235092|DEVICE|Taxus Paclitaxel-Eluting Stent|
57761082|NCT00661661|DRUG|CP-690,550|5 mg BID up to 10 mg BID until launch
57761083|NCT01076283|DRUG|Baclofen|Baclofen 10mg t.i.d.
57761084|NCT01076283|DRUG|Cyproheptadine|'active' placebo
57761085|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
58458629|NCT04905550|RADIATION|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
58458630|NCT06135961|DEVICE|eCTG monitoring with the NFMS|Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
58458631|NCT02690181|BIOLOGICAL|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
57761086|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
57761087|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
57761088|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
57761089|NCT03585101|DRUG|Elbasvir/grazoprevir|Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
57761090|NCT00650195|DRUG|Metolazone Tablets 10 mg|10mg, single dose fasting
57761091|NCT00650195|DRUG|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
58458632|NCT05139043|DRUG|Dexamethasone|Given IV and PO
57761092|NCT04667975|DRUG|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
57761093|NCT01889173|DRUG|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
57761094|NCT01889173|DRUG|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
57761095|NCT01889173|DRUG|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
58458633|NCT03590652|DRUG|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
57761096|NCT01889173|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
57761097|NCT03473223|BIOLOGICAL|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration
57761098|NCT03473223|OTHER|Placebo|25% albumin solution diluted to 4.4%
57761099|NCT00816179|PROCEDURE|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
57761100|NCT01581723|DEVICE|Monopolar diathermy|monopolar diathermy
57761101|NCT01581723|DEVICE|Bipolar diathermy|bipolar diathermy
57761102|NCT01664520|DRUG|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
57761103|NCT06300138|DRUG|Itraconazole|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months
57761104|NCT06300138|DEVICE|Infrared thermotherapy apparatus|infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
57761105|NCT06300138|OTHER|Itraconazole and Infrared thermotherapy apparatus|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
57761106|NCT03226964|DEVICE|high flow nasal oxygen|humidified high flow nasal oxygen
57761107|NCT06075797|BEHAVIORAL|PediQUEST ResPOND|"PPC teams will have access to feedback reports and the PQ-ResPOND checklist (standardized framework to diagnosis and treatment of recurrent pain behaviors in children with severe neurologic impairment).~Integration of the PPC team into care will be achieved through (i) initial consultation (goals: identify treatment goals, and address recurrent pain), and (ii) follow-up: the team will contact or visit the family in response to feedback reports or for treatment monitoring purposes."
57761108|NCT04665011|DEVICE|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
57761109|NCT04665011|DEVICE|Caretaker|non-invasive blood pressure monitor
57761110|NCT03489096|DEVICE|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
57761111|NCT03389139|DEVICE|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
57761112|NCT03389139|DEVICE|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
57761113|NCT05426564|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
58128991|NCT02315690|PROCEDURE|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
58128992|NCT02846948|OTHER|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
58458634|NCT03590652|DRUG|Pomalidomide|4mg days PO 1-21/28 days
58458635|NCT03590652|DRUG|Dexamethasone|"40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg"
58458636|NCT03590652|DRUG|Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)|1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
57761114|NCT05628805|DEVICE|iTBS|intermittent theta burst stimulation with TMS
57761115|NCT01722162|DRUG|Bevacizumab|
57761116|NCT01722162|DRUG|Capecitabine|
57761117|NCT01722162|DRUG|Levocetirizine|
57761118|NCT03394443|BEHAVIORAL|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~* As a first step, it will be a vertical analysis of the thematization of each interview~* Then, in a second step, a transversal analysis between the contents of the different interviews."
57761119|NCT05588609|DRUG|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
57761120|NCT05588609|DRUG|Enzalutamide Pill|second-generation androgen receptor antagonist
57761121|NCT05588609|DRUG|Abiraterone acetate tablets|androgen synthesis inhibitor
58458637|NCT04059510|PROCEDURE|rectovaginal swab|Self taken rectal and vaginal swab
58458638|NCT04059510|PROCEDURE|pregnancy test|Urine pregnancy test
58458639|NCT04059510|PROCEDURE|Menstrual cup|Menstrual cup vaginal fluid collection
58458640|NCT04059510|PROCEDURE|Blood test|Venous blood sample
58458641|NCT04059510|OTHER|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
57761122|NCT05588609|BIOLOGICAL|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
57761123|NCT04391465|OTHER|Electrophysiological Pacing|Assess the MCA CBF velocity response at different paced heart rates.
57761124|NCT00232960|PROCEDURE|Radiotherapy 50 Gy|
57761125|NCT01495884|DRUG|non-pegylated liposomal doxorubicon (Myocet™)|
57761126|NCT01495884|DRUG|Lapatinib (Tyverb™)|
57761127|NCT04713267|DEVICE|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
57761128|NCT01027975|PROCEDURE|laparoscopic Nissen/laparoscopic Thal|
57761129|NCT02227316|DRUG|IV Ibuprofen|Uterine fibroid embolization
57761130|NCT02227316|DRUG|IV Acetaminophen|Uterine fibroid embolization
57761131|NCT02227316|DRUG|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
57761132|NCT03575338|PROCEDURE|Open Scarf Osteotomy|Open Scarf Osteotomy
57761133|NCT03575338|PROCEDURE|Minimally invasive scarf Osteotomy|Minimally invasive scarf Osteotomy
58128993|NCT05043636|DEVICE|Vagus|Cardiovascular autonomic neuropathy (Vagus) both resting heart rate variability and cardiovascular reflex tests The examination consists of 4 measures, all aimed at measuring heart rate. Measurements are taken for 5 minutes rest, change of position from lying to standing position, during deep breathing and by Valsalva (by breathing in a mouthpiece with a 40 mmHg resistance).
57761134|NCT00070811|PROCEDURE|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
58128994|NCT05043636|DEVICE|HeartsTrends|• Cardiovascular autonomic neuropathy (HeartTrends®) measurers 60-minutes heart rate variability via a chest belt electrode (a Holter monitor) and an external data acquisition device.
58128995|NCT05043636|DEVICE|Sudoscan|Peripheral small-fiber sympathetic function (Sudoscan), measuring sudomotor function by electrochemical skin conductance in hands and feet
58128996|NCT05043636|DEVICE|UllMeter|• Pressure pain sensitivity of the chest bone is recorded (with a device which has the size and shape as a pen)during rest as a measure for sympathetic autonomic activity of the brain (UllMeter®) (www.stressmeter.org)
58128997|NCT05043636|DEVICE|DPN-check|Nerve conduction velocity and amplitude of the Sural nerves by DPN-check
58128998|NCT05043636|DEVICE|Rolltemp|Cold and warm sense of foot and lower leg
58128999|NCT05043636|DEVICE|Dexcom G6 Device|"Insertion of continuous glucose monitor ( The Dexcom G6 Device)~After 10 days in the study the patient will return the glucose monitor and diary by prepaid mail.~Glycemic variability and hypoglycemia duration will be calculated from CGM data. Glycemic variability will be assessed by standard deviation (SD) and Coefficient of Variance (CV). We define normo-glycemic range as sensor glucose between 4.0 and 10.0 mmol/L. Hypoglycemia will be defined in two ranges as SG ≤3.9 mmol/L or SG ≤3.0 mmol/L). An episode of hypoglycemia will be defined as at least 15 minutes with SG below 3.9 mmol/L or 3.0 mmol/L, respectively. CGM recordings with less than 72 hours of data will be excluded from analysis."
58129000|NCT04175951|DEVICE|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
58129001|NCT02426957|BEHAVIORAL|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
57761135|NCT03790332|DRUG|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
57761136|NCT00003084|DRUG|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
58129002|NCT02236507|DEVICE|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
57761137|NCT00003084|DRUG|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
57761138|NCT00003084|DRUG|Etoposide|Oral etoposide twice daily on days 1-14.
57761139|NCT00003084|DRUG|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
57761140|NCT00003084|DRUG|Paclitaxel|IV over 1 hour on day 2.
57761141|NCT00003084|DRUG|Vinblastine|IV on days 8, 22, and 36.
57761142|NCT00069784|DRUG|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
57761143|NCT00069784|DRUG|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
57761144|NCT00069784|DRUG|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
58129003|NCT00951288|DIETARY_SUPPLEMENT|Saffron|Saffron 20 mg/day supplementation
58129004|NCT00951288|DIETARY_SUPPLEMENT|Placebo|Placebo
58129005|NCT06001125|DRUG|Methotrexate|Methotrexate 20 mg PO weekly
57761145|NCT00069784|DEVICE|reusable pen device for insulin injection|
58458642|NCT00786383|BIOLOGICAL|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
57761146|NCT00621608|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
57761147|NCT00621608|PROCEDURE|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
57761148|NCT01164462|BIOLOGICAL|blood test: rapid finger-stick blood specimen test|
57761149|NCT01164462|BIOLOGICAL|blood test: conventional test|
57761150|NCT02467517|DRUG|Ketamine|
57761151|NCT02467517|DRUG|Magnesium Sulfate|
57761152|NCT02467517|DRUG|placebo : sodium chloride|
57761153|NCT03677011|DIAGNOSTIC_TEST|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
57761154|NCT04836858|BIOLOGICAL|CMK389|Active
57761155|NCT04836858|BIOLOGICAL|Placebo|Placebo Comparator
58456539|NCT06453408|PROCEDURE|Punción seca con aguja retráctil|"The placebo dry needling protocol will be performed in the same position, with identical antiseptic measures and the same number of simulated incisions as the real dry needling protocol, using DONGBANG AcuPrime® 0.30 x 30mm blunt-tipped placebo needles with a retractable handle. These needles simulate the sensation of needle contact without penetrating the skin. The therapist will hold the needle and guide tube, pressing the tube against the skin and simulating needle manipulation. Changes in pressure direction will mimic the real technique. The protocol will end with compression using an alcohol swab and an upper trapezius stretch.~Participants in both groups will receive the same information about the sensations of the dry needling procedure. At the beginning, they will be informed that they may or may not feel the needle insertion. They will also be told that the physiotherapist will manually manipulate the needle multiple times during the procedure."
58456540|NCT06453408|PROCEDURE|Punción seca con aguja normativa.|To perform the actual SP, patients shall be asked to lie prone with arms close to the body. The dry needling shall be performed with a 0,30 × 30 mm DN needle (APS Regular Agupunt) with a guide tube. The therapist shall first clean the area with alcohol. The trapezius muscle is then firmly grasped with a clamp between the thumb and index finger, so that the needle is directed deep into the index finger until the tip of the needle is felt to be approaching (33). This procedure involves an approximate insertion of the needle to a depth of 30 mm and ensures the intramuscular penetration necessary for dry needling. Puncture of the PGM shall be performed using the Hong technique (34), performing up to 12 inlets and outlets, at a frequency of 1 Hz. When the needle is withdrawn, the area is firmly compressed with cotton wool for 60 seconds. Finally, the upper trapezius muscle is stretched, following the technique originally described by Simons (35).
57761156|NCT04483154|DEVICE|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
57761157|NCT00103961|BEHAVIORAL|Questionnaire|A behavioral questionnaire will occur at Week 8
57761158|NCT05596084|PROCEDURE|maxillary sinus augmentation and implant placement|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
57761159|NCT05596084|PROCEDURE|Maxillary sinus augmentation with bovine bone graft|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
57761160|NCT03642860|DRUG|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
57761161|NCT03642860|DRUG|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
57761162|NCT06499623|DIAGNOSTIC_TEST|Blood test|Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
57761163|NCT06499623|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement
58129006|NCT03061409|DIETARY_SUPPLEMENT|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
58129007|NCT03061409|DIETARY_SUPPLEMENT|Placebo|served as placebo
58129008|NCT02983708|BIOLOGICAL|Peripheral blood mononuclear cells (mPBMC)|
58129009|NCT02983708|DRUG|G-CSF|
58129010|NCT02983708|DRUG|Placebo|
58456541|NCT01316016|DIETARY_SUPPLEMENT|Rose hip|40 g of rose hip powder daily for 6 weeks.
58456542|NCT04897217|DRUG|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
58456543|NCT04897217|DRUG|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
58456544|NCT03876717|DRUG|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
58456545|NCT03876717|DRUG|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
58456546|NCT00471055|DRUG|"0.0125% Capsaicin gel CAPSIKA gel"|
58456547|NCT00471055|DRUG|Placebo|Placebo
58456548|NCT03691909|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
57761164|NCT06499623|OTHER|Nutritional Risk Assessment Questionnaire|Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
57761165|NCT03711630|BEHAVIORAL|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
57761166|NCT04740619|PROCEDURE|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
57761167|NCT00006422|PROCEDURE|current standard of care treatments|
57761168|NCT01450722|PROCEDURE|bypass surgery, stent placement|bypass surgery, stent placement
57761169|NCT01450722|PROCEDURE|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
57761170|NCT05467579|DEVICE|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
57761171|NCT02542644|DEVICE|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
57761172|NCT04215016|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
57761173|NCT04858802|DEVICE|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
57761174|NCT04858802|PROCEDURE|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
57761175|NCT04146246|DIAGNOSTIC_TEST|G6PD assay|A test for G6PD deficiency.
57761176|NCT04806646|DRUG|Sonidegib|TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
57761177|NCT04981691|BIOLOGICAL|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
57761178|NCT01058538|DRUG|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
57761179|NCT01800201|BEHAVIORAL|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
57761180|NCT04069780|PROCEDURE|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
57761181|NCT04069780|PROCEDURE|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
57761182|NCT04069780|PROCEDURE|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
58129011|NCT02192346|DRUG|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
58129012|NCT02192346|DRUG|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
58129013|NCT02192346|DRUG|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
58456549|NCT03558542|OTHER|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
58458643|NCT00786383|BIOLOGICAL|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
58458644|NCT00786383|BIOLOGICAL|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
57761183|NCT04002804|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
57761184|NCT01819025|BEHAVIORAL|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
57761185|NCT01819025|BEHAVIORAL|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
57761186|NCT05566808|OTHER|Autologous Costal Cartilage Graft|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
57761187|NCT05566808|OTHER|Costal Cartilage Allograft.|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
57761188|NCT03319082|COMBINATION_PRODUCT|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
57761189|NCT05176977|BEHAVIORAL|Peer Support-Whole Health Coaching|Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
57761190|NCT03138733|DRUG|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
57761191|NCT03138733|DRUG|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
57761192|NCT04879199|DIAGNOSTIC_TEST|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
57761193|NCT04879199|DIAGNOSTIC_TEST|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
57761194|NCT06621966|OTHER|Olive Oil Topical Oil|The IVG will receive standard PI prevention care along with a topical application of olive oil for 7 consecutive days. PI point prevalence and baseline risk assessments will be performed prior to the intervention. Post-intervention assessments will be conducted from days 3 to 8. Descriptive statistics and paired sample t-tests will be utilized for data analysis.
57761195|NCT00947726|DRUG|CeraVe|Using OTC cream on foot twice daily for two weeks.
57761196|NCT01231139|DRUG|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
57761197|NCT01231139|DRUG|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
57761198|NCT05770830|DEVICE|Esophageal temperature|Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
57761199|NCT05770830|DEVICE|Skin core temperature|Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
57761200|NCT03837808|DRUG|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
57761201|NCT03837808|DRUG|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
57761202|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) according to Expiratory Flow Limitation|Positive End expiratory pressure will be set according to the positive end-expiratory pressure able to revert the expiratory flow limitation.
57761203|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) not according to Expiratory Flow Limitation|Positive End expiratory pressure will be set not according to the positive end-expiratory pressure able to revert the expiratory flow limitation but to a standard level of 4 cmH2O.
57761204|NCT06492161|DEVICE|Physical activity measure|After surgery, patients patients will be fitted with GT3X ActiGraph's activity monitor to capture and record continuous physical activity.
57761205|NCT00146601|DRUG|Fulvestrant|
57761206|NCT05375955|DRUG|PF-07038124 ointment 0.01%|Atopic Dermatitis and Plaque Psoriasis
57761207|NCT05375955|DRUG|Vehicle ointment|Atopic Dermatitis and Plaque Psoriasis
57761208|NCT05375955|DRUG|PF-07038124 ointment 0.03%|Atopic Dermatitis and Plaque Psoriasis
57761209|NCT05375955|DRUG|PF-07038124 ointment 0.06%|PF-07038124 ointment 0.06% (Plaque Psoriasis only)
57761210|NCT05254444|BEHAVIORAL|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
57761211|NCT05254444|BEHAVIORAL|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
57761212|NCT06210906|OTHER|Assessment of gastric volume|Gastric volume is assessed using ultrasound.
57761213|NCT04366726|COMBINATION_PRODUCT|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
57761214|NCT06448325|OTHER|Hip arthroplasty|Surgical treatment of the hip after osteoporosis fracture. The focus of the study is the prediction of further fractures (and therefore further surgical procedures) after the first one.
57761215|NCT05842785|DRUG|Phase I dose escalation|The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
58458645|NCT00786383|BIOLOGICAL|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
58456550|NCT06202495|DEVICE|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
57761216|NCT05842785|DRUG|Phase II-HNSCC|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
57761217|NCT05842785|DRUG|Phase II-Advanced melanoma|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
57761218|NCT05842785|DRUG|Phase II-solid tumors or lymphomas|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
57761219|NCT05787613|DRUG|HLX26|Anti-LAG-3 monoclonal Antibody Injection
57761220|NCT05787613|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
57761221|NCT05787613|DRUG|Chemotherapy drug|non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
57761222|NCT05787613|DRUG|Placebo|placebo
57761223|NCT05958498|COMBINATION_PRODUCT|injectable platelet rich fibrin and microosteoperforation|i-PRF which second product of blood versus mops which is surgical procedure
57761224|NCT06439056|DRUG|NEX-22A, a prolonged release formulation of liraglutide|NEX-22A, a prolonged release formulation of liraglutide
57761225|NCT04422613|DIAGNOSTIC_TEST|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
57761226|NCT03819582|DEVICE|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
57761227|NCT02295566|DRUG|Nitric Oxide|Not required
57761228|NCT02295566|DRUG|Control|Not required
57761229|NCT01005303|DRUG|Placebo|1 Tablet Daily
57761230|NCT01005303|DRUG|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
57761231|NCT04465825|BEHAVIORAL|HITT: intermittent high intensity exercise|Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
57761232|NCT00993824|DRUG|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
57761233|NCT00993824|DRUG|placebo|
57761234|NCT05941325|DRUG|fruquintinib|VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
57761235|NCT05941325|DRUG|Envafolimab|anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
57761236|NCT04112225|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
57761237|NCT03070717|PROCEDURE|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
58456551|NCT06202495|OTHER|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
58456552|NCT00269672|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
58456553|NCT06436118|BEHAVIORAL|RELAX® glasses|Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use.
58456554|NCT05052034|OTHER|Music|Through headphones, the patients would listen to different types of music during the intervention.
58456555|NCT05979740|DRUG|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection \[2.0 mg/kg, Q2W, iv\] and Toripalimab injection \[3mg/kg, Q2W, iv\] for 1\~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
57761238|NCT03557086|BEHAVIORAL|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
57761239|NCT03557086|OTHER|Verbal Narrative|Verbal description of end of life care options
57761240|NCT06624787|DEVICE|Rapid Diagnostic Test|The Liverpool School of Tropical Medicine (LSTM) in collaboration with Global Access Diagnostics (GADx) have achieved the development of the first RDT to detect CCHF viral antigens with a sensitivity and specificity that exceeds the minimum recommendation in the WHO target product profile (TPP)of \>80% and \>90% for sensitivity and specificity respectively for minimal performance in pre-clinical studies. The RDT is not only faster providing a test result within 20 minutes, but is also substantially cheaper than RT-PCR, and simpler to perform. A predicted price per test of around $5, whereas the current price of the RT-PCR test ranges from $1,000 to $1,200 for 96 reactions. The RDT does not require refrigeration or require specialist personnel to undertake, and the only additional apparatus needed is a stopwatch to monitor running time.
57761241|NCT04850404|PROCEDURE|abdominal nerve block|All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
57761242|NCT04384822|BEHAVIORAL|Tai Chi Group|Mind-body exercise intervention
57761243|NCT04384822|BEHAVIORAL|CBT-I Group|First-line clinically recommended non-pharmacological treatment of insomnia
57761244|NCT01689584|GENETIC|salivary kit|The saliva samples will be made of selected related (DNA).
57761245|NCT01834443|DEVICE|Direct current galvanic vestibular stimulation|
57761246|NCT02302131|OTHER|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
57761247|NCT06339580|DEVICE|Volume-targeted non-invasive ventilation|A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
57761248|NCT03501329|COMBINATION_PRODUCT|Biological,Psychological and Social support|
57761249|NCT02234063|OTHER|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
57761250|NCT00959062|DRUG|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
57761251|NCT00959062|DRUG|placebo|Preparation visually identical to clonidine.
57761252|NCT01406704|DRUG|Rosiglitazone|Rosiglitazone (8 mg/day)
57761253|NCT01406704|DRUG|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
57761254|NCT01406704|DRUG|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
57761255|NCT01785563|DEVICE|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
57761256|NCT05705999|DEVICE|transcranial magnetic stimulation|The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session
57761257|NCT01927679|DRUG|Vitamin E|
57761258|NCT01927679|DRUG|Eucerin|Control
57761259|NCT04191109|OTHER|Observational study|This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
57761260|NCT05548439|BIOLOGICAL|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
57761261|NCT02458001|BEHAVIORAL|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
57761262|NCT01648621|BEHAVIORAL|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
57761263|NCT01648621|BEHAVIORAL|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
57761264|NCT01648621|BEHAVIORAL|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
57761265|NCT01648621|BEHAVIORAL|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
57761266|NCT01648621|BEHAVIORAL|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness \[MRC\] Class 4 \& 5 or modified MRC \[mMRC\] 3 \& 4) f. frequent ED visits (\> 2) in last 12 months~5. 12 weeks of clinical stability with no ED visits."
57761267|NCT01648621|BEHAVIORAL|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
58456556|NCT06217939|DRUG|Early hydrocortisone|"For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
58456557|NCT06217939|DRUG|Normal saline placebo|"For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
58458646|NCT00786383|BIOLOGICAL|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
57761268|NCT01648621|BEHAVIORAL|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
57761269|NCT01648621|BEHAVIORAL|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
57761270|NCT01648621|BEHAVIORAL|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate."
57761271|NCT01648621|BEHAVIORAL|Smoking cessation|Referral to a smoking cessation program (as applicable)
57761272|NCT01648621|BEHAVIORAL|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
57761273|NCT01648621|BEHAVIORAL|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
57761274|NCT04280523|DRUG|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
57761275|NCT05240430|DRUG|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
57761276|NCT05914402|PROCEDURE|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
57761277|NCT05083325|DRUG|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
57761278|NCT05083325|DRUG|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
57761279|NCT02456701|BIOLOGICAL|KTN3379|IV every 2 weeks
57761280|NCT02456701|DRUG|vemurafenib|960 mg po bid
57761281|NCT05061537|BIOLOGICAL|PF-07263689|Genetically engineered oncolytic vaccinia virus
57761282|NCT05061537|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
57761283|NCT02681575|BEHAVIORAL|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
57761284|NCT02536014|DRUG|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
57761285|NCT02536014|DRUG|Saline|Saline infusion during the same time period
57761286|NCT06510530|DIETARY_SUPPLEMENT|Astragalus|Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
57761287|NCT06510530|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
57761288|NCT03042598|DEVICE|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
57761289|NCT02481375|DIETARY_SUPPLEMENT|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
57761290|NCT02481375|DIETARY_SUPPLEMENT|Iron|12-wk supplementation of iron
57761291|NCT02481375|DIETARY_SUPPLEMENT|Placebo|12-wk supplementation of placebo
57761292|NCT05067439|DRUG|Abrocitinib|200 mg once daily (QD)
57761293|NCT05067439|DRUG|Omeprazole|single doses of 10 mg
57761294|NCT05067439|DRUG|Caffeine|single dose of 100 mg
57761295|NCT05067439|DRUG|Efavirenz|single doses of 50 mg
57761296|NCT03056625|OTHER|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
57761297|NCT03056625|OTHER|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
57761298|NCT05140291|OTHER|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
57761299|NCT05140291|OTHER|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
57761300|NCT00250913|BEHAVIORAL|Telephone-based physical activity counseling program|
57761301|NCT06253949|PROCEDURE|ligation of inferior mesenteric artery in colorectal cancer|This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
58129014|NCT02192346|DRUG|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
58129015|NCT02192346|DRUG|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
58129016|NCT02192346|DRUG|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
57761302|NCT05796180|BEHAVIORAL|Behavioral: sexual health counseling based on the BETTER model|"The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
57761303|NCT04228640|OTHER|NMN|Investigational Product
57761304|NCT04228640|OTHER|Placebo|Starch Powder
57761305|NCT04269018|BEHAVIORAL|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
57761306|NCT04269018|BEHAVIORAL|General health messages|Daily text related with general health message
57761307|NCT01908322|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
57761308|NCT01483937|DEVICE|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
57761309|NCT01483937|OTHER|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
57761310|NCT00909428|DRUG|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
57761311|NCT06138249|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D
58129017|NCT02192346|DRUG|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
58456558|NCT06217939|DRUG|Open-label hydrocortisone|An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
57761312|NCT05617001|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
57761313|NCT04011579|OTHER|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
57761314|NCT01023243|OTHER|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
57761315|NCT01023243|OTHER|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
57761316|NCT06063122|DEVICE|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
57761317|NCT02661802|OTHER|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
57761318|NCT00978965|GENETIC|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
57761319|NCT02425748|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
57761320|NCT02425748|BIOLOGICAL|γδ T Cell|γδ T cells will be used against non small lung tumor.
58129018|NCT02192346|DRUG|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
58129019|NCT02192346|DRUG|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
58129020|NCT02972398|DRUG|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
57761321|NCT02425748|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
57761322|NCT02320747|OTHER|Tai Chi|
57761323|NCT03221088|DRUG|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
58456559|NCT05563129|OTHER|First aid lessons|The school children will have first aid training
58456560|NCT00788307|BIOLOGICAL|Ad5-CMV-NIS|
58456561|NCT00788307|DRUG|liothyronine sodium|
58456562|NCT00788307|GENETIC|reverse transcriptase-polymerase chain reaction|
58456563|NCT00788307|OTHER|laboratory biomarker analysis|
58456564|NCT00788307|RADIATION|iodine I 131|
58456565|NCT00006053|DRUG|imatinib mesylate|
57761324|NCT03221088|DRUG|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
57761325|NCT03322371|DEVICE|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
57761326|NCT06386003|DRUG|Psilocybin|Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
57761327|NCT05931627|PROCEDURE|Patients undergoing ACL reconstruction with or without a tourniquet|Patients undergoing ACL reconstruction with or without a tourniquet
57761328|NCT05545891|DRUG|Placebo|A drug that contains no medicine
57761329|NCT05545891|DRUG|Aripiprazole|Atypical antipsychotic medication
58129021|NCT02972398|DRUG|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
57761330|NCT03271476|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
57761331|NCT02995850|DRUG|CRS+HIPEC|"1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
57761332|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
58456566|NCT05224115|OTHER|[11C]CHDI-00485180-R|Mutant huntingtin aggregate binding PET radioligand.
58456567|NCT05224115|OTHER|[11C]CHDI-00485626|Mutant huntingtin aggregate binding PET radioligand.
58456568|NCT03944928|OTHER|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
58456569|NCT03543761|DEVICE|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
58456570|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
58456571|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
58456572|NCT00723307|DRUG|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
58456573|NCT00723307|DRUG|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
58456574|NCT01420861|DRUG|GTx-758|two GTx 758 tablets per day
58456575|NCT03938935|PROCEDURE|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
58456576|NCT04204265|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose in a 5-mL glass syringe.
58456577|NCT00649844|DRUG|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
58456578|NCT00649844|DRUG|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
58456579|NCT02964221|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
57761333|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
57761334|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
57761335|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
57761336|NCT00618696|BIOLOGICAL|anti-CD45 monoclonal antibody AHN-12|150 mg/m\^2 cold antibody at Day 0
57761337|NCT00618696|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m\^2
57761338|NCT04503096|DEVICE|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
57761339|NCT01984801|DRUG|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
57761340|NCT01984801|DRUG|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
57761341|NCT01984801|DRUG|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
58456580|NCT02208102|PROCEDURE|Radio-frequency catheter ablation|
58456581|NCT06256172|DEVICE|Medlink|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
58456582|NCT05655884|OTHER|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
57761342|NCT01984801|OTHER|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
57761343|NCT01984801|OTHER|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
57761344|NCT01984801|OTHER|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
57761345|NCT01984801|OTHER|Patch only|Only patch will be applied
57761346|NCT05564741|DRUG|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
57761347|NCT01228422|BIOLOGICAL|Interferon alpha 2a|3MUI
57761348|NCT05313750|DRUG|anti-infective therapy sitafloxacin|anti-infective therapy
57761349|NCT05313750|DRUG|anti-infective therapy levofloxacin|anti-infective therapy
57761350|NCT01897831|DRUG|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
57761351|NCT04302831|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
57761352|NCT04302831|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
57761353|NCT04302831|BEHAVIORAL|Flexibility training|stretches to improve flexibility
57761354|NCT04302831|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
57761355|NCT04302831|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
57761356|NCT03960229|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
57761357|NCT03960229|OTHER|Gradient-Density Centrifugation|sperm selection of IVF treatment
57761358|NCT03020563|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine
57761359|NCT03020563|DRUG|Bupivacaine|Bupivacaine
57761360|NCT00518635|DRUG|Nutropin|Nutropin 0.1 mg/day self-administered once a day
57761361|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
57761362|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
57761363|NCT00578721|DRUG|Aspirin|325 mg taken daily with an arginine-restricted diet
57761364|NCT04425018|DRUG|Paclitaxel|Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
57761365|NCT04425018|DRUG|Pertuzumab|Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
57761366|NCT04425018|DRUG|Margetuximab|Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
57761367|NCT04425018|DRUG|Trastuzumab|Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
57761368|NCT03427554|DRUG|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
57761369|NCT03427554|DRUG|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
57761370|NCT03427554|DRUG|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
57761371|NCT01108393|DRUG|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
57761372|NCT01108393|DRUG|Placebo|Placebo
57761373|NCT01960075|DRUG|Fosphenytoin|
57761374|NCT01960075|DRUG|Levetiracetam|
57761375|NCT01960075|DRUG|Valproic acid|
57761376|NCT00004062|DRUG|azacitidine|
57761377|NCT00004062|DRUG|liothyronine sodium|
57761378|NCT00004062|RADIATION|iodine I 131|
57761379|NCT01829984|OTHER|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
57761380|NCT01829984|OTHER|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
57761381|NCT04990284|DRUG|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
57761382|NCT04990284|DRUG|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
57761383|NCT04863989|PROCEDURE|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
57761384|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
57761385|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
57761386|NCT04444284|OTHER|Placebo|Single dose administered intranasally on Day 1
57761387|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
57761388|NCT04499716|PROCEDURE|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
57761389|NCT04499716|PROCEDURE|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
57761390|NCT04499716|PROCEDURE|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
57761391|NCT04499716|PROCEDURE|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
57761392|NCT04499716|PROCEDURE|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
57761393|NCT04499716|PROCEDURE|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
57761394|NCT04581148|DIAGNOSTIC_TEST|Blood test antibodies against SARS-CoV-2|Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
57761395|NCT04658823|DRUG|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
57761396|NCT04658823|DRUG|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
57761397|NCT05050578|DEVICE|Lehfilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
57761398|NCT05050578|DEVICE|Senofilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
57761399|NCT05050578|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
57761400|NCT06626022|DEVICE|MRI|Standard prostate mpMRI.
58456583|NCT05655884|OTHER|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
58456584|NCT03180385|DEVICE|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
58456585|NCT03180385|DEVICE|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
58456586|NCT04368260|DEVICE|Control swab|FDA-cleared nasopharyngeal swab
58456587|NCT04368260|DEVICE|Prototype swab|Injection molded polypropylene flocked nylon nasopharyngeal swab
57761401|NCT06626022|DEVICE|ExactVu|microUltrasound
57761402|NCT01743794|DRUG|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
57761403|NCT01743794|DRUG|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
57761404|NCT00156806|PROCEDURE|Aloe barbadensis topical application in a moisturizing cream vehicle.|
57761405|NCT04148339|OTHER|No Intervention|There is no intervention for this study.
58456588|NCT02982902|BIOLOGICAL|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
58456589|NCT03110471|BEHAVIORAL|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
58456590|NCT03110471|BEHAVIORAL|usual care|usual care
58456591|NCT00213863|DEVICE|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
58456592|NCT03770312|DRUG|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
58456593|NCT03770312|DRUG|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
57761406|NCT04687735|OTHER|Intervention after nerve block|Brachial plexus block + Physical therapy
57761407|NCT00978354|DRUG|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
57761408|NCT00978354|DRUG|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
57761409|NCT00577018|DRUG|Prucalopride|4 mg o.d.
57761410|NCT00577018|DRUG|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
57761411|NCT00577018|OTHER|Placebo|o.d.
57761412|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
57761413|NCT00768508|DRUG|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
57761414|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
57761415|NCT00768508|OTHER|Placebo + Cognitive Behavioral Therapy|Placebo comparator
57761416|NCT04555902|BEHAVIORAL|Postcard|The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
57761417|NCT04555902|BEHAVIORAL|Small Gift|Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
57761418|NCT04555902|BEHAVIORAL|Loss Frame and Fear Appeals|The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
57761419|NCT03186482|DRUG|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
57761420|NCT03186482|DRUG|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
57761421|NCT03186482|DRUG|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
58456594|NCT04565626|OTHER|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
58456595|NCT02915666|DRUG|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
58456596|NCT02915666|DRUG|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
58456597|NCT02915666|DRUG|Trametinib|trametinib 2 mg PO daily for 8-week cycles
58456598|NCT05979844|DRUG|3,4-methylenedioxymethamphetamine (MDMA)|2 MDMA sessions; PTSD+ Veteran partner only
57761422|NCT00581373|OTHER|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
57761423|NCT00295763|DRUG|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
57761424|NCT05391932|BEHAVIORAL|MINDGAPS|Utilize wearable sensor technology to provide simple, precise measures of gaze and postural stability, as well as remote monitoring of patient adherence to vestibular exercises during a 6-week training period. Additionally, NIH Toolbox data will be used to display patient status compared to normative values and to indicate progress over time relative to measurement error.
57761425|NCT03561337|DIETARY_SUPPLEMENT|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
57761426|NCT03561337|DIETARY_SUPPLEMENT|CARBOHDYRATE|CHO before and after training
57761427|NCT05233202|DRUG|Levosimendan|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
57761428|NCT05233202|DRUG|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
57761429|NCT00017056|DRUG|ixabepilone|
57761430|NCT04075617|DEVICE|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
57761431|NCT04075617|OTHER|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
57761432|NCT01053260|BEHAVIORAL|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
57761433|NCT01053260|BEHAVIORAL|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
57761434|NCT02189902|DIETARY_SUPPLEMENT|4000 IU/d D3 over 12 weeks|
57761435|NCT02189902|DIETARY_SUPPLEMENT|7000 IU/d D3 over 12 weeks|
57761436|NCT03697525|DEVICE|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
57761437|NCT01641796|DRUG|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
57761438|NCT01489644|DRUG|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
57761439|NCT01489644|DRUG|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
57761440|NCT01489644|DRUG|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
57761441|NCT04013412|DIETARY_SUPPLEMENT|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
57761442|NCT06425848|DEVICE|Observational|We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
58129022|NCT01969357|DRUG|Placebo|Tablets(n=4),once daily for 84 days
58456599|NCT05979844|BEHAVIORAL|Brief Cognitive Behavioral Conjoint Therapy (bCBCT)|8 bCBCT sessions; sessions 1-3 massed ; sessions 4-5 massed; Both partners
58456600|NCT05936008|BEHAVIORAL|Exercise MICT|Standard of care, exercise recommendations for people with stroke
58456601|NCT05936008|BEHAVIORAL|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
57761443|NCT02544828|DRUG|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
57761444|NCT02544828|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
57761445|NCT00784433|DIETARY_SUPPLEMENT|alcohol|150 cc
57761446|NCT04573725|DRUG|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
57761447|NCT04573725|DRUG|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
57761448|NCT03217435|PROCEDURE|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
57761449|NCT03217435|PROCEDURE|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
57761450|NCT03217435|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
57761451|NCT03217435|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
58129023|NCT01969357|DRUG|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
58129024|NCT01969357|DRUG|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
58456602|NCT04415203|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)|Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
57761452|NCT03519243|BIOLOGICAL|BCD-131|subcutaneously monthly
57761453|NCT03519243|BIOLOGICAL|Mircera|subcutaneously monthly
57761454|NCT05739383|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Subcutaneous injection in pre-filled syringe.
57761455|NCT05739383|DRUG|Placebo in 1.5ml|Matching placebo in 1.5ml solution for injection
57761456|NCT06525363|DRUG|Chitosan|chitosan nanoparticles 1%w/w will be formulated in form of spray for oral application twice daily
57761457|NCT01674348|DRUG|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
57761458|NCT01674348|DRUG|Placebo|Placebo
57761459|NCT00755222|BIOLOGICAL|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
57761460|NCT00755222|BIOLOGICAL|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
57761461|NCT03114371|DRUG|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
57761462|NCT03114371|DRUG|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
57761463|NCT03114371|DRUG|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
57761464|NCT00925405|PROCEDURE|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
57761465|NCT00925405|PROCEDURE|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
57761466|NCT03754205|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
57761467|NCT02290002|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
57761468|NCT02290002|OTHER|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
57761469|NCT00547287|DRUG|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
57761470|NCT00547287|DRUG|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
57761471|NCT02874651|DRUG|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
57761472|NCT02874651|DRUG|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
57761473|NCT02492555|OTHER|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
58129025|NCT01969357|DRUG|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
58129026|NCT01969357|DRUG|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
57761474|NCT02492555|OTHER|OD|A screening of FC and DA on demand (OD)
57761475|NCT06623968|PROCEDURE|Dental implants|Long-term follow-up study on singel-tooth implants
57761476|NCT02932592|DEVICE|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
57761477|NCT04489693|BEHAVIORAL|Ambulatory Care Coordinator Team (ACCT)|See arm description
57761478|NCT04489693|BEHAVIORAL|Comprehensive Care Physician Program (CCP)|see arm description
58129027|NCT00938210|PROCEDURE|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
58129028|NCT04316312|DEVICE|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
58129029|NCT00043381|DRUG|decitabine (5-aza-2'deoxycytidine)|
57761479|NCT04489693|BEHAVIORAL|Comprehensive Care Community & Culture Program (C4P)|see arm description
57761480|NCT05046496|DIAGNOSTIC_TEST|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
57761481|NCT05839223|OTHER|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
57761482|NCT01846000|PROCEDURE|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
58129030|NCT01718938|DRUG|velusetrag dose 1|
58129031|NCT01718938|DRUG|velusetrag dose 2|
58129032|NCT01718938|DRUG|velusetrag dose 3|
58129033|NCT01718938|DRUG|placebo|
58129034|NCT00331890|DRUG|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
58129035|NCT00331890|DRUG|Placebo|As active drug
57761483|NCT03710525|OTHER|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
57761484|NCT03710525|OTHER|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
57761485|NCT01567332|DEVICE|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
57761486|NCT01567332|DEVICE|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
57761487|NCT05525936|DIAGNOSTIC_TEST|Echocardiography and central venous pressure|To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
57761488|NCT01756521|DRUG|Moxifloxacin|
57761489|NCT01238224|DRUG|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
57761490|NCT00575497|PROCEDURE|More frequent hemodialysis|Six Day per week short daily hemodialysis
57761491|NCT00575497|PROCEDURE|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
57761492|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other day short daily hemodialysis
57761493|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other night hemodialysis
57761494|NCT00575497|PROCEDURE|More frequent hemodialysis|5 days per week short daily hemodialysis
57761495|NCT00575497|PROCEDURE|More frequent hemodialysis|5 nights per week hemodialysis
57761496|NCT00575497|PROCEDURE|Conventional Hemodialysis|3 days per week short daily hemodialysis
57761497|NCT02850432|PROCEDURE|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
57761498|NCT02850432|OTHER|Conservative treatment|rehabilitation with medical therapy
57761499|NCT01515462|GENETIC|OTL-103|OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
57761500|NCT05389111|OTHER|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
57761501|NCT05389111|OTHER|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
57761502|NCT02623114|DRUG|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
57761503|NCT02623114|DRUG|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
57761504|NCT00819364|BEHAVIORAL|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
57761505|NCT00819364|BEHAVIORAL|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
57761506|NCT02317055|OTHER|imaging|
57761507|NCT04141449|OTHER|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
57761508|NCT04141449|OTHER|Enhanced care|Provider education and limited patient counseling.
57761509|NCT02789384|OTHER|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
57761510|NCT00939601|BEHAVIORAL|Motivational Enhancement Therapy|
57761511|NCT00939601|BEHAVIORAL|Educational Counseling|
57761512|NCT00239564|DRUG|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
57761513|NCT00239564|DRUG|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
57761514|NCT00239564|DRUG|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
57761515|NCT00239564|DRUG|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
57761516|NCT00239564|DRUG|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
57761517|NCT01452646|OTHER|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
57761518|NCT02563002|DRUG|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
57761519|NCT02563002|DRUG|FOLFIRI|Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
57761520|NCT02563002|BIOLOGICAL|Pembrolizumab|IV infusion
57761521|NCT02563002|BIOLOGICAL|Bevacizumab|IV infusion
57761522|NCT02563002|BIOLOGICAL|Cetuximab|IV infusion
57761523|NCT01677221|DEVICE|Acleara Acne Treatment System|
57761524|NCT06284863|DIETARY_SUPPLEMENT|Natritional Education Program In Hemodialysis Patients|Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
57761525|NCT04761276|DEVICE|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
57761526|NCT05537480|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device will be worn by participants during several periods.
57761527|NCT03911453|DRUG|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
57761528|NCT03850080|DRUG|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
57761529|NCT05432908|BEHAVIORAL|Orofacial exercises and oropharyngeal functions|Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
57761530|NCT06214858|DRUG|SHEN211 tablets|SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
58129036|NCT06130735|BEHAVIORAL|Cognitive Computerized Training|Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
58129037|NCT05121233|DRUG|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
58129038|NCT05121233|DRUG|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
58129039|NCT04022148|BIOLOGICAL|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
58456603|NCT04415203|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)|Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
58456604|NCT01300234|DRUG|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
58456605|NCT01300234|DRUG|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
57761531|NCT06214858|DRUG|SHEN211 placebo tablets|placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
57761532|NCT02393521|DEVICE|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
57761533|NCT06315296|BEHAVIORAL|Behavioral Dietary Intervention|Follow a time-restricted diet
57761534|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive interactive positive reinforcement messages
57761535|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
57761536|NCT06315296|BEHAVIORAL|Dietary Counseling and Surveillance|Receive counseling calls
57761537|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
57761538|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57761539|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
57761540|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
57761541|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
57761542|NCT06315296|OTHER|Interview|Ancillary studies
57761543|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
57761544|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
57761545|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive text messages about healthy eating habits and food suggestions
57761546|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58456606|NCT00877240|BEHAVIORAL|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
58456607|NCT03958175|OTHER|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
58456608|NCT04335643|BEHAVIORAL|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
58129040|NCT02256085|DEVICE|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
58456609|NCT03300401|DRUG|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
58456610|NCT03300401|DRUG|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
58456611|NCT03300401|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
58456612|NCT03300401|DEVICE|Positron Emission Tomography|Undergo PET/CT
58129041|NCT02256085|DEVICE|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
58456613|NCT03300401|DEVICE|Computed Tomography|Undergo CT scan
58456614|NCT03300401|BIOLOGICAL|Yttrium-90 (90Y)|Given IV
58456615|NCT03009786|OTHER|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
58456616|NCT02005367|BEHAVIORAL|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
58456617|NCT02005367|BEHAVIORAL|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
58456618|NCT05353595|DIETARY_SUPPLEMENT|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
58456619|NCT05353595|BEHAVIORAL|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
58456620|NCT04759235|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Anatomical (T2W) and functional MRI (DWI) at a 3.0T Siemens or Philips scanner Three MRI scan series (before, during, after nCRT) Measurements: change in apparent diffusion coefficient (ADC)
58456621|NCT04759235|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT)|PET-CT scan at diagnosis and 4-6 weeks after nCRT before operation Measurements: change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value)，MTV（Metabolic tumor volume）
58456622|NCT04759235|DIAGNOSTIC_TEST|Blood and urine metabolic biomarker|Blood and urine specimens are collected before radiotherapy, the third week of radiotherapy, and at the end of radiotherapy.
58456623|NCT06075979|OTHER|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
58456624|NCT06075979|OTHER|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
58456625|NCT03609086|OTHER|Melatonin analysis|Measurement of 6-hydroxymelatonin
58456626|NCT00526292|BIOLOGICAL|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
58456627|NCT00526292|DRUG|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
58456628|NCT00526292|DRUG|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
58456629|NCT00170872|DRUG|Lumiracoxib|
58456630|NCT00273338|DRUG|calcitriol|
58456631|NCT00273338|DRUG|docetaxel|
58456632|NCT04479085|OTHER|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
58456633|NCT02495701|PROCEDURE|Hip arthroscopic surgery|Hip arthroscopic surgery
58456634|NCT05809921|DRUG|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
58456635|NCT05809921|DRUG|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
58456636|NCT01414894|OTHER|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
58456637|NCT01414894|OTHER|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
58456638|NCT04699890|OTHER|Blood sampling, questionnaires and specific exams|Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
58456639|NCT03050801|DEVICE|rTMS|Altering the connectivity of trans-synaptic pathways
58456640|NCT02744092|DRUG|Rivaroxaban|Anticoagulation therapy.
57761547|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
57761548|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
57761549|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
57761550|NCT06315296|OTHER|Interview|Ancillary studies
58456641|NCT02744092|DRUG|Apixaban|Anticoagulation therapy.
58456642|NCT02744092|DRUG|Edoxaban|Anticoagulation therapy.
58456643|NCT02744092|DRUG|Dabigatran|Anticoagulation therapy.
58456644|NCT02744092|DRUG|Warfarin|Anticoagulation therapy.
57761551|NCT04325113|DRUG|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
57761552|NCT04492319|DRUG|Control Test|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
58456645|NCT02744092|DRUG|Dalteparin|Anticoagulation therapy.
58456646|NCT02744092|DRUG|Enoxaparin|Anticoagulation therapy.
58456647|NCT02744092|DRUG|Fondaparinux|Anticoagulation therapy.
57761553|NCT04492319|DRUG|Neostigmine|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml neostigmine 500 μg in each side .
57761554|NCT04167995|DRUG|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
57761555|NCT01105013|DRUG|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
57761556|NCT06622785|BEHAVIORAL|Physical activity|Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
57761557|NCT06622785|BEHAVIORAL|Exercise Benefits|Data were collected using a Exercise Benefits/Barriers Scale .
57761558|NCT05279222|OTHER|Gait adaptability training|All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
57761559|NCT02531763|BEHAVIORAL|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
57761560|NCT01287884|OTHER|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
57761561|NCT03327584|PROCEDURE|Arthrocentesis|Athrocentesis
57761562|NCT03030937|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
57761563|NCT03030937|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC.
57761564|NCT04601441|DRUG|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
57761565|NCT03733561|DRUG|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
58456648|NCT03477734|DEVICE|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
57761566|NCT03733561|DRUG|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
57761567|NCT03249610|BEHAVIORAL|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
57761568|NCT01606696|BEHAVIORAL|HIIT|Higher intensity interval training.
57761569|NCT01606696|BEHAVIORAL|Standard intensity non-interval training|Standard intensity non-interval training.
57761570|NCT06537011|DRUG|AK112|"1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery."
57761571|NCT04144803|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
57761572|NCT04774133|DIAGNOSTIC_TEST|Blood sample|Pazients will undergo to blood samples at predefined times
57761573|NCT03116464|BEHAVIORAL|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
57761574|NCT06019195|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
58456649|NCT02859246|DRUG|Mucinex®|Mucinex®
58456650|NCT04290039|DRUG|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
57761575|NCT06626256|BIOLOGICAL|Aldesleukin|Given SC
57761576|NCT06626256|PROCEDURE|Biopsy|Undergo biopsy
57761577|NCT06626256|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57761578|NCT06626256|PROCEDURE|Computed Tomography|Undergo CT
57761579|NCT06626256|DRUG|Cyclophosphamide|Given IV
57761580|NCT06626256|PROCEDURE|Excisional Biopsy|Undergo excisional biopsy
57761581|NCT06626256|DRUG|Fludarabine|Given IV
57761582|NCT06626256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57761583|NCT06626256|PROCEDURE|Standard Treatment|Receive standard of care therapy
57761584|NCT06626256|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given STIL101 for injection IV
57761585|NCT05773014|PROCEDURE|Speculum Exams|Same as arm
57761586|NCT05773014|PROCEDURE|Digital Exams|Same as arm
57761587|NCT05686772|DRUG|Dopamine partial agonists|Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)
57761588|NCT05686772|OTHER|Psychiatric comorbidities|Mainly substance use disorders and personality disorders
57761589|NCT05686772|OTHER|Sex|Biological sex at birth
57761590|NCT05686772|OTHER|Gender|Current gender identity
57761591|NCT05686772|OTHER|Socioeconomic status|Including main source of income, employment status, homelessness
57761592|NCT05686772|OTHER|Gambling history|History of gambling (i.e., recreational or problematic) prior to admission in the clinics
57761593|NCT00548132|DEVICE|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
57761594|NCT00970216|DRUG|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
57761595|NCT01756261|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
57761596|NCT04095143|DIAGNOSTIC_TEST|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
57761597|NCT04095143|DIAGNOSTIC_TEST|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
57761598|NCT04095143|DIAGNOSTIC_TEST|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
57761599|NCT04095143|DIAGNOSTIC_TEST|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
57761600|NCT04095143|DIAGNOSTIC_TEST|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
57761601|NCT04095143|DIAGNOSTIC_TEST|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
58456651|NCT04290039|DRUG|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
58456652|NCT02213835|OTHER|Specific Carbohydrate diet (SCD)|
58456653|NCT04629755|BEHAVIORAL|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
58456654|NCT05408962|OTHER|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
58456655|NCT06314334|DRUG|Sintilimab+Pegaspargase|"1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;"
58456656|NCT06314334|DRUG|P-GemOx|"1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip"
58456657|NCT06314334|DRUG|GELAD|"1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip."
58456658|NCT06314334|RADIATION|IMRT|Intensity modulated radiotherapy (50-56Gy)
58456659|NCT02113917|BIOLOGICAL|Identification of biological markers|
58456660|NCT06201260|OTHER|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
58456661|NCT06201260|OTHER|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
58456662|NCT04694235|DIETARY_SUPPLEMENT|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
58456663|NCT01360671|DRUG|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
58456664|NCT04610047|DRUG|Norketotifen|Oral capsule
58456665|NCT04610047|DRUG|Placebo|Oral capsule
58456666|NCT05723224|PROCEDURE|elective endoscopic gallbladder treatment|Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
58456667|NCT01071057|DRUG|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
57761602|NCT04095143|DIAGNOSTIC_TEST|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
57761603|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
57761604|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
57761605|NCT04538365|DRUG|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
57761606|NCT04538365|DRUG|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
57761607|NCT00278538|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
57761608|NCT01710163|DRUG|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
57761609|NCT01710163|DRUG|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
57761610|NCT00651235|DRUG|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
57761611|NCT00651235|DRUG|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
57761612|NCT05582694|BIOLOGICAL|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
57761613|NCT03254160|DRUG|DNS-3379|DNS-3379
57761614|NCT03254160|DRUG|Placebo|Placebo
57761615|NCT03354650|DIAGNOSTIC_TEST|blood culture|blood culture to determine causative organisms of neonatal sepsis
57761616|NCT01042509|DRUG|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
57761617|NCT00601003|DRUG|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
57761618|NCT00601003|DRUG|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
57761619|NCT00601003|DRUG|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
57761620|NCT06095557|DEVICE|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
57761621|NCT03966053|DRUG|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
57761622|NCT02283489|DRUG|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
57761623|NCT02283489|DRUG|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
57761624|NCT02283489|DRUG|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
57761625|NCT00265330|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
57761626|NCT01073670|DRUG|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
57761627|NCT01073670|DRUG|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
57761628|NCT01073670|DRUG|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
58129042|NCT02256085|DEVICE|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
57761629|NCT04952584|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
57761630|NCT01106430|DRUG|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
57761631|NCT01106430|DRUG|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
57761632|NCT05287308|DRUG|doxorubicin|doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
57761633|NCT05287308|DRUG|epirubicin|epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
57761634|NCT05287308|DRUG|pirarubicin|pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
57761635|NCT05287308|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
57761636|NCT05287308|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
58456668|NCT01071057|DRUG|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
57761637|NCT05287308|DRUG|paclitaxel|paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
57761638|NCT05287308|DRUG|docetaxel|docetaxel 80\~100mg/m2, i.v., d1, q3w.
57761639|NCT04711356|DRUG|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
57761640|NCT04266639|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
57761641|NCT04266639|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
58129043|NCT02457013|DEVICE|HFNC|Hygh flow nasal canula HFNC
58129044|NCT02457013|DEVICE|nCPAP|nasal nCPAP
58129045|NCT04895111|DIAGNOSTIC_TEST|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
58129046|NCT04491149|DEVICE|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
58129047|NCT05310370|GENETIC|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
58129048|NCT04316273|OTHER|colonic surgery|resection of duplicated colon
58129049|NCT04035642|RADIATION|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
58456669|NCT05772741|OTHER|Biological sample collection|Collection of biological samples
58456670|NCT00737646|BEHAVIORAL|Usual care|No intervention will be conducted in this arm of the study.
57761642|NCT04860817|BIOLOGICAL|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~1. Dose level one: 0.6×10\^7 cells/kg;~2. Dose level two: 1×10\^7 cells/kg;~3. Dose level three: 1.5×10\^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m\^2×6d, Cyclophosphamide 300 mg/m\^2×6d or Cyclophosphamide 600 mg/m\^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
57761643|NCT01583101|OTHER|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
57761644|NCT01583101|OTHER|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
57761645|NCT02628002|DEVICE|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
58129050|NCT04035642|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
58456671|NCT00737646|BEHAVIORAL|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
57761646|NCT02628002|DEVICE|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
57761647|NCT05929443|OTHER|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
57761648|NCT03694314|DIETARY_SUPPLEMENT|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
57761649|NCT03694314|DIETARY_SUPPLEMENT|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
58129051|NCT04035642|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
58129052|NCT04035642|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
58129053|NCT01491009|DRUG|Remifentanil|IV infusion
58129054|NCT01491009|DRUG|Midazolam|IV infusion
58456672|NCT00737646|BEHAVIORAL|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
58456673|NCT00450970|DRUG|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
58456674|NCT03826121|DIETARY_SUPPLEMENT|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
58456675|NCT03826121|DIETARY_SUPPLEMENT|placebo|placebo for 12 weeks.
58456676|NCT00085163|DRUG|celecoxib|
58456677|NCT00085163|DRUG|fluorouracil|
58456678|NCT00085163|DRUG|leucovorin calcium|
58456679|NCT00085163|PROCEDURE|adjuvant therapy|
58456680|NCT03028298|DRUG|Low dose sildenafil citrate|
58456681|NCT03028298|DRUG|High dose sildenafil citrate|
58456682|NCT01121146|DEVICE|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
58456683|NCT01096316|BEHAVIORAL|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
58456684|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
58456685|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
58456686|NCT00973752|DRUG|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
58456687|NCT00973752|DRUG|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
58456688|NCT00973752|DRUG|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
58456689|NCT00973752|DRUG|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
58456690|NCT00973752|DRUG|Cytarabine|Intrathecally during Induction and CNS therapy
58456691|NCT00973752|DRUG|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
57761650|NCT05982301|DRUG|Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU|The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
57761651|NCT00146614|DRUG|Sirolimus|
57761652|NCT00146614|DRUG|Tacrolimus|
57761653|NCT00146614|DRUG|Methotrexate|
57761654|NCT00146614|PROCEDURE|Stem Cell Transplantation|
57761655|NCT03682705|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
57761656|NCT03682705|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
57761657|NCT03682705|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
57761658|NCT03682705|DRUG|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
57761659|NCT05412810|OTHER|oxygen|oxygen exposure of more than 50% for 1.5 hours
57761660|NCT02352441|OTHER|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
57761661|NCT02081235|PROCEDURE|surgery for congenital heart disease|surgery for congenital heart disease
57761662|NCT03685396|BIOLOGICAL|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
57761663|NCT03685396|DRUG|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
57761664|NCT01100255|DRUG|Ketamine infusion|0.5mg/kg IV over 40 minutes
57761665|NCT01100255|OTHER|Saline|saline infusion
57761666|NCT00886067|DRUG|AZD1446|Solution, oral, single dose
57761667|NCT00886067|RADIATION|2-[18F]-F-A85380|iv, single dose
57761668|NCT00076791|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
57761669|NCT00076791|DRUG|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
57761670|NCT00803621|OTHER|Toxoplasma PCR assay|Toxoplasma PCR assay
57761671|NCT05217186|DIAGNOSTIC_TEST|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
57761672|NCT02701335|DEVICE|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
57761673|NCT02701335|DEVICE|Gloreha device|Robotic assisted passive mobilization.
57761674|NCT02701335|DEVICE|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
58456692|NCT00973752|DRUG|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
58456693|NCT00973752|DRUG|Clofarabine|Intravenously during Consolidation 1 Therapy
57761675|NCT04871035|DEVICE|Immunoadsorption|1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
57761676|NCT04871035|DEVICE|Plasma Exchange|1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
57761677|NCT04889235|PROCEDURE|Major liver resection|All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
57761678|NCT02635074|DRUG|Cytarabine|Given IV
57761679|NCT02635074|DRUG|Ibrutinib|Given PO
57761680|NCT02635074|DRUG|Idarubicin|Given IV
57761681|NCT05300802|DRUG|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
57761682|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
57761683|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
57761684|NCT06431438|DRUG|TQA3810|TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
57761685|NCT06214078|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
57761686|NCT06214078|OTHER|placebo|The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
57761687|NCT01450202|OTHER|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
57761688|NCT01450202|OTHER|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
58456694|NCT00973752|DRUG|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
57761689|NCT02634840|PROCEDURE|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
57761690|NCT01379027|BEHAVIORAL|Pure self-help Internet CBT for depression|Internet, CBT, Depression
57761691|NCT01379027|BEHAVIORAL|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
57761692|NCT01379027|BEHAVIORAL|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
57761693|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
57761694|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
57761695|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
57761696|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
57761697|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
57761698|NCT06624982|OTHER|observational study|Observational study; alveolar ridge preservation
57761699|NCT00723099|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
57761700|NCT00723099|DRUG|Cyclophosphamide|Given IV
57761701|NCT00723099|DRUG|Cyclosporine|Given IV
57761702|NCT00723099|DRUG|Fludarabine Phosphate|Given IV
57761703|NCT00723099|OTHER|Laboratory Biomarker Analysis|Correlative studies
57761704|NCT00723099|DRUG|Mycophenolate Mofetil|Given IV or PO
57761705|NCT00723099|RADIATION|Total-Body Irradiation|Undergo TBI
57761706|NCT00723099|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
57761707|NCT00884754|DEVICE|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
58456695|NCT04458506|PROCEDURE|Maxillary expansion|Correction of the unilateral posterior cross bite in children
57761708|NCT05464381|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
58456696|NCT06084832|BIOLOGICAL|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
58456697|NCT05254665|DRUG|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
58456698|NCT02519023|DRUG|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
57761709|NCT05464381|DRUG|Placebo|Placebo
57761710|NCT00762632|DRUG|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
57761711|NCT00762632|DRUG|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
57761712|NCT04130139|OTHER|oocyte pick up simulator|oocyte pick up simulation
57761713|NCT01896284|DRUG|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
57761714|NCT03493763|DIAGNOSTIC_TEST|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
57761715|NCT00421213|DRUG|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
57761716|NCT00977756|DRUG|Raltegravir (RAL)|400 mg twice daily (BID)
57761717|NCT00977756|DRUG|Atazanavir (ATV)|300 mg daily
57761718|NCT00977756|DRUG|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
57761719|NCT00977756|DRUG|Tenofovir (TDF)|300 mg daily
57761720|NCT00977756|DRUG|Etravirine (ETV)|200 mg BID
57761721|NCT00977756|DRUG|Darunavir (DRV)|Dosing by weight
57761722|NCT00977756|DRUG|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
57761723|NCT00977756|DRUG|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
57761724|NCT01960530|DRUG|Hydrocortisone granules|Multi-particulate granules
57761725|NCT01960530|DRUG|Hydrocortisone Tablet|Standard hydrocortisone tablets
57761726|NCT01960530|DRUG|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
57761727|NCT01960530|OTHER|Dexamethasone|Challenge agent
57761728|NCT02507778|DEVICE|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
58456699|NCT02519023|DRUG|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
57761729|NCT01357330|DRUG|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
57761730|NCT01357330|DRUG|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
57761731|NCT06550349|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
57761732|NCT00650143|DRUG|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
57761733|NCT00650143|DRUG|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
57761734|NCT00650143|DRUG|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
57761735|NCT00650143|DRUG|Gelatin|One capsule p.o. per day for 28 days
58456700|NCT02519023|DEVICE|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
57761736|NCT01583686|DRUG|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
57761737|NCT01583686|BIOLOGICAL|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
57761738|NCT01583686|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
57761739|NCT01583686|DRUG|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
57761740|NCT03928145|DRUG|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
57761741|NCT03928145|DRUG|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
57761742|NCT03928145|DRUG|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
57761743|NCT03928145|DRUG|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
57761744|NCT04846764|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure"
57761745|NCT04143984|DRUG|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
57761746|NCT04143984|RADIATION|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
57761747|NCT04143984|DRUG|Camrelizumab|An anti-PD-1 antibody.
57761748|NCT04567264|DEVICE|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
57761749|NCT02857439|OTHER|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
57761750|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
57761751|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
57761752|NCT01492686|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
57761753|NCT01492686|DRUG|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
57761754|NCT01492686|DRUG|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
57761755|NCT02974816|DEVICE|Glooko's mobile application|Standard of care and Remote monitoring
57761756|NCT00286208|DRUG|Mifepristone, misoprostol|
57761757|NCT01667367|DRUG|RG1662|Single oral dose
57761758|NCT01667367|DRUG|placebo|Single oral dose
57761759|NCT02975635|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
57761760|NCT03804775|DIAGNOSTIC_TEST|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
57761761|NCT05153460|DEVICE|Telemetry and manual monitoring vs Contactless monitoring devices|"All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
57761762|NCT00519701|DRUG|hydroxyurea|
57761763|NCT04570241|BEHAVIORAL|Malaria toolkit|Knowledge, attitude, and practice on malaria
57761764|NCT05806944|DEVICE|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
57761765|NCT05806944|DEVICE|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
57761766|NCT03379623|OTHER|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
58456701|NCT02519023|DRUG|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
58456702|NCT02519023|DRUG|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
58456703|NCT02519023|DRUG|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
58456704|NCT02519023|DRUG|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
57761767|NCT03842592|DIAGNOSTIC_TEST|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
57960941|NCT04828408|PROCEDURE|Bariatric surgery|Patients with a body mass index (BMI) ˃35, age interval of 18-65, and ASA score II-III undergoing laparoscopic bariatric surgery were included in the study. Patients with neuromuscular, cardiopulmonary, and cerebrovascular diseases, phrenic nerve damage or diaphragm paralysis, those who have undergone thoracic surgery, who could not communicate, who did not want to participate in the study, who used alcohol, those who needed postoperative intensive care, those who had surgical complications during surgery, and those who were switched to open surgery were not included in the study.
58456705|NCT06502665|OTHER|Women having had second ovulation induction after failed oocyte pick-up|IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes
58456706|NCT06555185|OTHER|Potentiation warm-up protocol|The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.
58456707|NCT06555185|OTHER|Usual warm-up protocol|The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
58456708|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
58456709|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Audio-track.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
58456710|NCT05478941|BEHAVIORAL|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
58456711|NCT02584946|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
58456712|NCT01811888|BEHAVIORAL|Quantitative sensory testing (QST)|
58456713|NCT02536898|OTHER|Fracture Liaison Service|
58456714|NCT02536898|OTHER|Current treatment|
58456715|NCT00361192|PROCEDURE|biopsy of temporal artery|
58456716|NCT06340022|OTHER|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.
58456717|NCT06340022|OTHER|Face Image Scale (FIS) scoring system|Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.
58456718|NCT06340022|OTHER|Visual Analogue Scale (VAS)|In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.
58456719|NCT06340022|OTHER|pulse rate|Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
58456720|NCT00333008|DRUG|Doxil|
58456721|NCT00333008|DRUG|Cyclophosphamide|
58456722|NCT00333008|DRUG|Vincristine|
58456723|NCT00333008|DRUG|Prednisone|
58456724|NCT00333008|DRUG|Rituximab|
58456725|NCT00333008|DRUG|Pegfilgrastim|
58456726|NCT03999515|DRUG|Abiraterone Acetate|Given PO
58456727|NCT03999515|DRUG|Enzalutamide|Given PO
58456728|NCT03999515|DRUG|Erdafitinib|Given PO
58456729|NCT04598022|OTHER|cross-sectional observation|observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester
58456730|NCT04598022|OTHER|cross-sectional follow-up observation|follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
57761768|NCT05680454|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
57761769|NCT05680454|BIOLOGICAL|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
58456731|NCT00889135|DRUG|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
57761770|NCT02832622|DEVICE|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
58456732|NCT03651037|BEHAVIORAL|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
58456733|NCT02793726|PROCEDURE|NMR|NMR
57960942|NCT01898065|DRUG|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
57761771|NCT02832622|DEVICE|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
58456734|NCT05800223|DRUG|Almonertinib|The dosage is 110 mg/day (2 tablets/day) orally once a day
58456735|NCT05800223|RADIATION|SBRT|SRT, 27Gy-40Gy/3-5f
58456736|NCT03652012|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
58456737|NCT04722874|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
58456738|NCT04722874|DEVICE|RLRL|RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
58456739|NCT02008123|DRUG|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
58456740|NCT02640638|BEHAVIORAL|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
58456741|NCT06304116|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
58456742|NCT06304116|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58456743|NCT06304116|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58456744|NCT01192997|BIOLOGICAL|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
58456745|NCT01192997|BIOLOGICAL|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
58456746|NCT02161796|DRUG|FG-4592|Oral
58456747|NCT02161796|DRUG|Placebo|Oral
58456748|NCT01687361|DIETARY_SUPPLEMENT|branched-chain amino acids (BCAA) supplementation|
58456749|NCT01687361|DRUG|PLACEBO|
57761772|NCT05760976|DRUG|Cisatracurium|Advanced intravenous injection of cisatracurium before the succinylcholine injection
58456750|NCT02526277|DEVICE|MMF07 Foot Massager|
58456751|NCT02526277|DEVICE|Heat Therapy|
58456752|NCT05339360|PROCEDURE|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
57761773|NCT00302432|BEHAVIORAL|Behavior therapy, cigarette holders, Flowers Menthol|
57761774|NCT01852331|DRUG|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
57761775|NCT01852331|DRUG|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
58456753|NCT01451723|DRUG|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
58456754|NCT01451723|OTHER|Placebo|Matching placebo capsules
58456755|NCT02475538|DEVICE|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
58456756|NCT02475538|DEVICE|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
58456757|NCT04363203|DRUG|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.
58456758|NCT04363203|DRUG|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
58456759|NCT04363203|DRUG|Placebo oral tablet|Placebo in pill packs identical to study drugs
57761776|NCT05175599|OTHER|Water Birth|The water birth group will use a tub of a water to labor and give birth.
57960943|NCT01507272|DRUG|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
58456760|NCT00981097|GENETIC|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
58456761|NCT00981097|OTHER|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
58456762|NCT00008008|BIOLOGICAL|filgrastim|
58456763|NCT00008008|BIOLOGICAL|sargramostim|
58456764|NCT00008008|DRUG|cyclophosphamide|
58456765|NCT00008008|DRUG|thiotepa|
58456766|NCT00008008|PROCEDURE|autologous bone marrow transplantation|
58456767|NCT00008008|PROCEDURE|bone marrow ablation with stem cell support|
58456768|NCT00008008|PROCEDURE|peripheral blood stem cell transplantation|
58456769|NCT00504088|PROCEDURE|Bypass|
58456770|NCT00504088|PROCEDURE|Silverhawk Plaque Excision|
58456771|NCT05581017|PROCEDURE|Preoperative biliary drainage|Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
58456772|NCT03973216|BEHAVIORAL|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
58456773|NCT01831167|OTHER|dynamic light|
58456774|NCT02872116|DRUG|Nivolumab|Specified dose on specified days
58456775|NCT02872116|DRUG|Ipilimumab|Specified dose on specified days
57761777|NCT02592330|PROCEDURE|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
58456776|NCT02872116|DRUG|Oxaliplatin|Specified dose on specified days
58456777|NCT02872116|DRUG|Capecitabine|Specified dose on specified days
57761778|NCT02592330|BIOLOGICAL|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
57761779|NCT02592330|PROCEDURE|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
58456778|NCT02872116|DRUG|Leucovorin|Specified dose on specified days
58456779|NCT02872116|DRUG|Fluorouracil|Specified dose on specified days
58456780|NCT02107066|BEHAVIORAL|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
58456781|NCT05299476|DRUG|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
58456782|NCT03634085|DRUG|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
58456783|NCT01799707|BEHAVIORAL|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
58456784|NCT01799707|BEHAVIORAL|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
58456785|NCT04992117|OTHER|NO INTERVENTION|NO INTERVENTION
58458647|NCT03554382|OTHER|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
58458648|NCT04179097|DIAGNOSTIC_TEST|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
57761780|NCT01437150|DEVICE|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
57761781|NCT01437150|PROCEDURE|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
57761782|NCT00385892|DEVICE|Abdominal binder|
57960944|NCT01507272|DRUG|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
57960945|NCT01507272|DRUG|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
57960946|NCT01507272|DRUG|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
57960947|NCT00699907|DRUG|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
57960948|NCT01975168|DEVICE|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
57960949|NCT01353703|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
58129055|NCT02116049|BEHAVIORAL|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
58456786|NCT05238389|DEVICE|AI-based upper limb robotic therapy|"Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years)."
58456787|NCT03418155|DRUG|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
58456788|NCT03418155|DRUG|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
58456789|NCT03844399|DEVICE|Ablation|The medical device will passively record image data during the standard care ablation
58456790|NCT03844399|DEVICE|Biopsy|The medical device will passively record image data during the standard care biopsy
58456791|NCT03881839|OTHER|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
58456792|NCT03360266|COMBINATION_PRODUCT|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
58456793|NCT03360266|COMBINATION_PRODUCT|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
58456794|NCT03360266|DRUG|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
58456795|NCT04044768|GENETIC|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
58456796|NCT02579668|OTHER|Language Therapy|
58456797|NCT06083649|BEHAVIORAL|The AI-assisted tool used in this study was called Dental Monitoring (DM).|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
57761783|NCT03040921|PROCEDURE|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
58456798|NCT06036277|OTHER|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
58456799|NCT06036277|OTHER|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
58456800|NCT00702858|DRUG|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
58456801|NCT00702858|DRUG|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
58456802|NCT02602535|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
58456803|NCT02602535|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
58456804|NCT00004164|BIOLOGICAL|filgrastim|
58456805|NCT00004164|DRUG|cisplatin|
57761784|NCT04142502|DRUG|Propofol|Propofol as a sedation drug
57761785|NCT04142502|DRUG|Dexmedetomidin|Dexmedetomidine as a sedation drug
57761786|NCT04021186|OTHER|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
58456806|NCT00004164|DRUG|docetaxel|
58456807|NCT00004164|DRUG|fluorouracil|
58456808|NCT00004164|DRUG|leucovorin calcium|
57761787|NCT06155305|PROCEDURE|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
57761788|NCT05762835|BEHAVIORAL|Virtual family-centered rounds (FCR)|"Parents will be given the option to join FCR virtually or in-person; this intervention is changing the behavior of how providers deliver healthcare and how parents engage in their child's care.~The NICU team members will use a computer with a speaker and pan-tilt-zoom camera, mounted on a stand with wheels to launch telehealth connections using the secure application called ExtendedCare. From within this telehealth connection, a NICU team member will send an electronic message (e.g. via text or email) to the subscribed parent(s) and wait for the parent to join the visit to establish a secure videoconference. The message to the parent includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. FCR will then proceed in usual fashion with the NICU team members and - if in attendance - parent(s)."
57761789|NCT00649363|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
57761790|NCT00649363|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
58456809|NCT00004164|RADIATION|radiation therapy|
58456810|NCT06021639|DIETARY_SUPPLEMENT|The last 24 hours will consume low fiber food.|White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
58456811|NCT03148535|DRUG|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
58456812|NCT03148535|DRUG|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
58456813|NCT02486575|OTHER|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
58456814|NCT02486575|OTHER|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
58456815|NCT02906423|OTHER|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
58456816|NCT01217944|DRUG|Ranibizumab|0.5 mg ranibizumab intravitreal injection
58456817|NCT01217944|DRUG|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
58456818|NCT01217944|DRUG|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
58456819|NCT01217944|DRUG|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
57761791|NCT00405457|DRUG|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
57761792|NCT02587026|OTHER|Blood sample collection|
58456820|NCT00467740|DRUG|BI 1744 CL|
58456821|NCT03573934|OTHER|GLP-2|GLP-2
58456822|NCT03573934|OTHER|GIP|GIP
58456823|NCT03573934|OTHER|GLP-2+GIP|GLP-2+GIP
58456824|NCT03573934|OTHER|Placebo|Placebo
58456825|NCT01285817|DRUG|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
58456826|NCT04925349|DIAGNOSTIC_TEST|Blood sample collection|blood sample collection
58456827|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
58456828|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 of a 21-day cycle.
58456829|NCT02868554|DEVICE|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
58456830|NCT02868554|DEVICE|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
58456831|NCT03298802|DRUG|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
58456832|NCT03298802|DRUG|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
58456833|NCT01173601|DRUG|LY2216684|
58456834|NCT01173601|DRUG|Placebo|
58456835|NCT01173601|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
57761793|NCT02587026|OTHER|Tumor tissue sample collection|
57761794|NCT01933880|DRUG|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
57761795|NCT01933880|OTHER|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
57761796|NCT03569696|BIOLOGICAL|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
57960950|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
57960951|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
57960952|NCT06095739|COMBINATION_PRODUCT|DA-OTC-002|"The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject"
57960953|NCT00353418|DRUG|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
57960954|NCT00353418|DRUG|Ribavirin|800 mg orally daily for 48 weeks
57960955|NCT00353418|DRUG|Ribavirin|1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
57960956|NCT02979431|BIOLOGICAL|ALX-0171 3.0 mg/kg|
57960957|NCT02979431|BIOLOGICAL|ALX-0171 6.0 mg/kg|
57960958|NCT02979431|BIOLOGICAL|ALX-0171 9.0 mg/kg|
57960959|NCT02979431|OTHER|Placebo|
57960960|NCT01056250|PROCEDURE|SILS cholangiography|intraoperative
57960961|NCT04732286|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
58456836|NCT01631435|OTHER|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
57761797|NCT02981381|DEVICE|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
57761798|NCT02981381|DEVICE|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
57761799|NCT02981381|DEVICE|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
57761800|NCT03712735|DRUG|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
57761801|NCT04450186|OTHER|EEG/fMRI neurofeedback|EEG/fMRI neurofeedback
57761802|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Holmium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser
57761803|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Thulium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
57761804|NCT05807659|DRUG|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
57761805|NCT02929225|DRUG|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
57761806|NCT02929225|OTHER|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
57761807|NCT02785874|DRUG|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
57761808|NCT03008525|BIOLOGICAL|subcutaneous and visceral adipose tissue biopsies|Subcutaneous and visceral adipose tissue biopsies during operation
57761809|NCT03008525|BIOLOGICAL|blood samples analysis|"Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin."
57761810|NCT05360030|DRUG|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
57761811|NCT05360030|DRUG|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
57761812|NCT05360030|DRUG|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
57761813|NCT05360030|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
57761814|NCT05360030|DEVICE|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
57761815|NCT05360030|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
57761816|NCT03068325|OTHER|TF-EAT|
57761817|NCT00353613|BEHAVIORAL|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
57761818|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 1|
57761819|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 2|
58129056|NCT02116049|BEHAVIORAL|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
58129057|NCT01625026|DRUG|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
58456837|NCT01631435|DEVICE|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
57761820|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 3|
57761821|NCT01980615|DRUG|Inhaled GFF (PT003)|
58456838|NCT02195908|OTHER|single point Neiguan(PC6) plus antiemetic drug|
58456839|NCT02195908|OTHER|single point Zhongwan(CV12) plus antiemetic drug|
58456840|NCT02195908|OTHER|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
58456841|NCT02195908|DRUG|only antiemetic drug|
57761822|NCT01980615|DRUG|Inhaled Symbicort Dose 1|
57761823|NCT01980615|DRUG|Inhaled Symbicort Dose 2|
57761824|NCT00780650|DRUG|Atomoxetine|80 mg oral dose, once per day for 6 weeks
57761825|NCT00780650|DRUG|Placebo|80 mg dose once per day for 6 weeks
57761826|NCT05296395|OTHER|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
57761827|NCT05296395|OTHER|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
57761828|NCT00668135|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
57761829|NCT00668135|DRUG|Placebo|Matching placebo
57761830|NCT02565901|DRUG|Carboplatin|Given IV
57761831|NCT02565901|DRUG|Docetaxel|Given IV
57761832|NCT02565901|OTHER|Laboratory Biomarker Analysis|Correlative studies
57761833|NCT02565901|DRUG|Sirolimus|Given PO
57761834|NCT00002760|DRUG|ketoconazole|400 mg PO tid for as long as treatment is effective
57761835|NCT00002760|DRUG|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
57761836|NCT00002760|OTHER|Withdrawal of antiandrogen therapy|no drugs given
57761837|NCT02366897|DEVICE|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
57761838|NCT04140253|BEHAVIORAL|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
57761839|NCT01776021|OTHER|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
57761840|NCT01776021|OTHER|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
57761841|NCT04532658|BEHAVIORAL|Coaching program|"* Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement"
57761842|NCT00883038|OTHER|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
57761843|NCT00883038|OTHER|low-fat vegetarian diet|The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
57761844|NCT02100150|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
57761845|NCT02100150|DRUG|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
57761846|NCT03021486|DRUG|Chlorpromazine|Given IV
57761847|NCT03021486|DRUG|Haloperidol|Given IV
57761848|NCT03021486|OTHER|Quality-of-Life Assessment|Ancillary studies
57761849|NCT03021486|OTHER|Questionnaire Administration|Ancillary studies
57761850|NCT05356390|OTHER|Stabilization exercises|"Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
57761851|NCT05356390|OTHER|Muscle energy techniques|"Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
57761852|NCT05839353|OTHER|SBAR training by serious game|SBAR training by serious game
57761853|NCT02304965|BEHAVIORAL|Daily physical activity|A combination of walking (\> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
57761854|NCT02421666|BEHAVIORAL|PNMI|Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
57761855|NCT01711957|PROCEDURE|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
57761856|NCT03798600|DRUG|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
57761857|NCT04096612|PROCEDURE|Orbital decompression combined with MPT|Orbital decompression combined with MPT
57761858|NCT05030896|OTHER|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
57761859|NCT00236171|DRUG|Protopic, Advantan|
57761860|NCT00236171|PROCEDURE|Blood and Urine Test|
57761861|NCT00236171|PROCEDURE|coherence tomography|
57761862|NCT02401074|BIOLOGICAL|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
57960962|NCT04732286|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
57960963|NCT00002778|BIOLOGICAL|sargramostim|
57960964|NCT00002778|BIOLOGICAL|therapeutic allogeneic lymphocytes|
57960965|NCT00002778|PROCEDURE|allogeneic bone marrow transplantation|
57960966|NCT00002778|PROCEDURE|in vitro-treated bone marrow transplantation|
57761863|NCT00717821|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
57761864|NCT00717821|DRUG|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
57761865|NCT00717821|DRUG|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
57761866|NCT05811039|DEVICE|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
57761867|NCT02378740|DRUG|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
57761868|NCT02378740|DRUG|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
57761869|NCT03072238|DRUG|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
58456842|NCT02828371|DEVICE|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
58456843|NCT02828371|OTHER|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
58456844|NCT03253042|OTHER|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
57761870|NCT03072238|DRUG|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
57761871|NCT03072238|DRUG|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
57761872|NCT03072238|DRUG|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
57761873|NCT00904891|BEHAVIORAL|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
57761874|NCT00904891|BEHAVIORAL|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
57761875|NCT02307591|DRUG|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
57960967|NCT02117765|DRUG|Ustekinumab|
57960968|NCT00809107|DRUG|HCG|5000IU
58129058|NCT01625026|DRUG|Placebo|Placebo to obeticholic acid
58129059|NCT02230397|OTHER|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
58456845|NCT03253042|OTHER|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
58456846|NCT03282461|DRUG|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
58456847|NCT05148364|BEHAVIORAL|interview|"A spiritual consultant and a psychologist will interview the participants about their experiences of chronic low back pain, how they interpret their pain experience and how they cope with the persistent pain. Each participant will be interviewed individually.~Questions related to the following three aspects will be asked:~1. Attributes: describe the changes in your personality, mood, and general happiness you have observed after you starting having chronic low back pain.~2. Pain resilience: How would you describe this persisting pain experience? How do you arrange your daily activity? What do you do to deal with this persistent pain?~3. Spirituality: As a person with chronic low back pain, how do you interpret this pain experience? Do you seek connections with higher powers (such as powers from religion) when you are desperate because of pain? Since the pain is chronic and persistent, it might not go away, how would you define your life?"
58129060|NCT02230397|OTHER|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
58129061|NCT00002027|DRUG|Diclazuril|
57761876|NCT02307591|DRUG|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day"
58456848|NCT05241379|DEVICE|Amber UI System|The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
58456849|NCT01009658|DIETARY_SUPPLEMENT|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
58456850|NCT01009658|DIETARY_SUPPLEMENT|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
58456851|NCT04977440|DIETARY_SUPPLEMENT|Whey protein|"Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given"
58456852|NCT06020157|OTHER|Simple Suture Technique|The half of the full arch flap will be closed by the simple suture technique.
58456853|NCT06020157|OTHER|Continuous Suture Technique|The half of the full arch flap will be closed by the continuous suture technique.
58456854|NCT00182169|DRUG|Human recombinant growth hormone|
58456855|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
58456856|NCT03389022|DRUG|Saline|Intravenous injection given pre-incisional in the operating room.
58456857|NCT03389022|DRUG|Ketamine|0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
58456858|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.
57761877|NCT02869919|OTHER|AKI|Vitamin D levels
57761878|NCT05428514|OTHER|Maternity Housing|Receives a bed in the maternity home, wrap-around services, etc.
57761879|NCT01163890|BEHAVIORAL|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
57761880|NCT01163890|BEHAVIORAL|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
57761881|NCT06419244|DIAGNOSTIC_TEST|Myosteatosis|Determination of myosteatosis by imaging
57761882|NCT01598298|DRUG|duloxetine hydrochloride|Given PO
57761883|NCT01598298|OTHER|placebo|Given PO
57761884|NCT01398423|DRUG|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
57761885|NCT01398423|DRUG|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
57761886|NCT04504643|OTHER|Technology-assisted circuit training|Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
57761887|NCT04504643|OTHER|Conventional circuit training|Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
57761888|NCT04504643|OTHER|Nordic walking|Classic nordic walking 3 times a week for one hour during 8 weeks
57761889|NCT01003522|OTHER|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
58129062|NCT04714268|PROCEDURE|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
58456859|NCT03389022|DRUG|Ketamine|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
58456860|NCT00138593|DRUG|vildagliptin|
58456861|NCT00887302|PROCEDURE|Gastric Band|Places a band over the upper portion of the stomach.
58456862|NCT00887302|PROCEDURE|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
58456863|NCT00887302|PROCEDURE|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
58456864|NCT02478008|DEVICE|CardiAQ TMVI System (Transapical DS)|
57761890|NCT01003522|OTHER|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
58129063|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
58129064|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
58456865|NCT04344223|DEVICE|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
58456866|NCT04344223|DEVICE|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
58456867|NCT05361616|DEVICE|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
58458649|NCT02093884|OTHER|Text Messaging Intervention|
58458650|NCT02093884|OTHER|Standard Referral|
57761891|NCT01003522|PROCEDURE|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
57761892|NCT01003522|PROCEDURE|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
57761893|NCT01003522|OTHER|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
57761894|NCT01003522|OTHER|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
58456868|NCT03022877|DRUG|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
57761895|NCT01003522|OTHER|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
57761896|NCT01896635|BIOLOGICAL|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
57761897|NCT01896635|OTHER|Placebo infusion|Placebo infusion not containing any donor microbial material
57761898|NCT01925027|DEVICE|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
57761899|NCT04983758|OTHER|Oral Rehabilitation with dental implants|Patients have been treated with oral dental implants supporting fixed dental prostheses
57761900|NCT02541032|PROCEDURE|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
57761901|NCT02541032|PROCEDURE|Standard dental treatment|Supragingival mechanical scaling and polishing.
57761902|NCT02541032|DRUG|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
57761903|NCT02532179|BIOLOGICAL|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
57761904|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
57761905|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
57761906|NCT01112228|PROCEDURE|Bariatric surgery|Bariatric surgery: Gastric bypass, Sleeve gastrectomy, or Gastric banding
57761907|NCT00909480|DRUG|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
57761908|NCT00909480|DRUG|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
57761909|NCT02098408|BEHAVIORAL|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
58456869|NCT05865626|OTHER|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
58456870|NCT04107662|DEVICE|Tbit system|Suspected traumatic brain injury with head CT
58456871|NCT04684264|OTHER|Heart Failure Prevention Clinic|Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
57761910|NCT02098408|BEHAVIORAL|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
57761911|NCT04566302|DEVICE|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
57761912|NCT04959630|BEHAVIORAL|Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)|Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
57761913|NCT05550363|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
57761914|NCT05550363|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
57761915|NCT06359236|OTHER|BI'KILO Intervention|"The study consists of three stages: preparation phase, implementation phase and follow-up phase. During the preparation phase, participants' weight and body fat ratio will be calculated using a body analysis scale, and their height, waist and hip circumference will be measured.~The implementation phase will last six weeks and consists of six modules, each lasting one week. The skills and practices aimed to be acquired in each module will be required to be applied in the following practice modules.~At the end of the implementation phase, participants' weight, waist and hip circumferences will be measured again.~The final phase, called the follow-up phase, will last four weeks. During this phase, participants will continue to keep a self-monitoring record of their eating and physical exercise, complete a hunger scale, and application card notifications will continue to be displayed."
57761916|NCT05502614|DEVICE|Neuromodulation|Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
57761917|NCT00267410|BEHAVIORAL|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
57761918|NCT03659604|BEHAVIORAL|'SmartLife' with tailored feedback|'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
57761919|NCT03659604|BEHAVIORAL|'SmartLife' without tailored feedback|'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
57761920|NCT03659604|BEHAVIORAL|No game|Passive control: School classes will be asked to continue their daily life as usual.
57761921|NCT01913106|DRUG|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
57761922|NCT01087996|BIOLOGICAL|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
57761923|NCT01087996|BIOLOGICAL|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
57761924|NCT06251986|OTHER|ofatumumab|This is an observational study, there is no treatment allocation.
57761925|NCT04045730|DRUG|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
57761926|NCT06065384|OTHER|experimental group: intensive motor training|Intervention group: receive an extra 12 hours of motor training each week (distributed over the week) for 10 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
57761927|NCT06065384|OTHER|usual care|usual rehabilitation
57761928|NCT01949233|DRUG|Irbesartan 150-300mg capsules daily for 6 months|
57761929|NCT01949233|DRUG|Doxycycline 100-200mg capsules daily for 6 months|
57761930|NCT01949233|DRUG|Doxycycline placebo capsules daily for 6 months|
57761931|NCT01949233|DRUG|Irbesartan placebo capsules daily for 6 months|
57761932|NCT00954226|DRUG|Erlotinib Hydrochloride|Given PO
58456872|NCT06112574|BEHAVIORAL|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
58458651|NCT03332459|DRUG|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
57761933|NCT00954226|OTHER|Laboratory Biomarker Analysis|Correlative studies
57761934|NCT05741099|BIOLOGICAL|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
57761935|NCT05741099|OTHER|Comparator|Patients in comparator group will receive placebo treatment
57761936|NCT03841955|DEVICE|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
57761937|NCT03841955|DEVICE|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
57761938|NCT03997513|BEHAVIORAL|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
57761939|NCT03857568|DRUG|SHR0410|drug will be dosed repeatedly
57761940|NCT03857568|DRUG|Placebo|Placebo will be dosed repeatedly
57761941|NCT00886028|DRUG|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
57761942|NCT00886028|DRUG|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
57761943|NCT02491021|OTHER|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
57761944|NCT01551004|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
57761945|NCT01551004|OTHER|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
57761946|NCT05999786|BEHAVIORAL|early rehabiliation swallowing program|not receiving early rehabilitation swallowing program from before and after surgery
57761947|NCT05999786|BEHAVIORAL|not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
57761948|NCT06197555|OTHER|Sodium Monofluorophosphate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
57761949|NCT06197555|OTHER|Stannous Fluoride|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
57761950|NCT06197555|OTHER|Nano-Hydroxyapatite|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
57761951|NCT06197555|OTHER|8% Arginine & Calcium Carbonate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
57761952|NCT06619782|OTHER|Practice Facilitation|Practice facilitation (PF) is a supplemental support to increase competence and and adoption of the National Institute of Mental Health (NIMH) youth suicide prevention. pathway in primary care. Practices will receive 6 months of PF which involves clinic- and provider- level data review and adoption data for the 5 components of the prevention pathway, clinical coaching around implementing the different components , logistical coaching in identifying multilevel contextual barriers to implementation and strategies to overcome them
57761953|NCT06619782|OTHER|Training in National Institute of Mental Health Youth Suicide Prevention Pathway|Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
57761954|NCT05995301|DRUG|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
57761955|NCT05995301|DRUG|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
57761956|NCT03857230|DRUG|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
58129065|NCT06076681|DRUG|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
57761957|NCT03857230|DRUG|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
57761958|NCT01397994|DRUG|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
57761959|NCT01397994|DRUG|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
57761960|NCT05448547|RADIATION|Radiotherapy or surgery|see arm/ group description
57761961|NCT05448547|OTHER|initial observation|see arm/ group description
57761962|NCT05448547|DRUG|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
57761963|NCT01303120|DRUG|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
58456873|NCT01027715|OTHER|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
57761964|NCT01303120|DRUG|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
57761965|NCT01303120|DRUG|Patient-controlled analgesia|Patient controlled analgesia with morphine
57761966|NCT05438186|DRUG|Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
57761967|NCT03962296|DRUG|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
57761968|NCT03962296|DRUG|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
57761969|NCT03962296|DRUG|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
57761970|NCT03680664|DEVICE|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
57761971|NCT03680664|OTHER|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
57761972|NCT03680664|BEHAVIORAL|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
57761973|NCT03915184|BIOLOGICAL|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
57761974|NCT00749125|DRUG|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
57761975|NCT02655601|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
57761976|NCT02655601|RADIATION|Radiation Therapy|RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
57761977|NCT02655601|DRUG|Temozolomide|Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
57761978|NCT00595270|BIOLOGICAL|IC51|
57761979|NCT01203930|DRUG|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
57761980|NCT01203930|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
57761981|NCT02710305|DRUG|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
57761982|NCT02710305|DRUG|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
57761983|NCT03831984|DRUG|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
57761984|NCT03831984|DRUG|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
57761985|NCT01040390|DRUG|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
57761986|NCT01824615|DRUG|Sunitinib|37.5mg everyday from D1-D28
57761987|NCT05971901|DIAGNOSTIC_TEST|BV|The use of the BV test, ordered at the discretion of the treating physician
58129066|NCT06076681|DRUG|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
58456874|NCT05327179|OTHER|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
57761988|NCT02378558|DEVICE|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
58456875|NCT05327179|OTHER|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
57761989|NCT06212466|DEVICE|CardioFlux|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.
57761990|NCT03264885|OTHER|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
57761991|NCT03326310|DRUG|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
57761992|NCT03326310|DRUG|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
57761993|NCT03114917|OTHER|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
57761994|NCT05156502|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
57761995|NCT05156502|DEVICE|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
57761996|NCT04598854|DEVICE|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
57761997|NCT04598854|DEVICE|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
57761998|NCT04358276|OTHER|Computer-Assisted Intervention|Complete online course
57761999|NCT04358276|DEVICE|Dermatoscope|Receive dermatoscope
57762000|NCT04358276|OTHER|Educational Intervention|Receive study packet
57762001|NCT04358276|OTHER|Educational Intervention (Physician)|Receive physician directed letter and educational package
57762002|NCT04358276|OTHER|Questionnaire Administration|Ancillary studies
57762003|NCT04358276|OTHER|Text Message|Receive text messages
57762004|NCT01821417|DEVICE|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
57762005|NCT01821417|DEVICE|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
57762006|NCT00910403|PROCEDURE|LASIK|Excimer Laser Ablation using LASIK
57762007|NCT04465461|PROCEDURE|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
57762008|NCT04465461|DEVICE|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
57960969|NCT04606459|DEVICE|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
57762009|NCT00594191|DRUG|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
57960970|NCT04606459|OTHER|Optimal medical therapy|Guideline-directed medical therapy
58458652|NCT03332459|DRUG|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
57762010|NCT00594191|DRUG|Placebo|Placebo with the same characteristics of the drug and at the same dose
57762011|NCT00407199|DRUG|quetiapine|
57762012|NCT00288301|BEHAVIORAL|Weight loss intervention|weight loss intervention
57762013|NCT03998683|DRUG|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
57960971|NCT03187769|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
57960972|NCT03187769|DRUG|Olanzapine|Daily oral dosing
57762014|NCT03998683|DRUG|Placebo|Placebo will be administered as SC injection.
57762015|NCT05205317|DRUG|Metformin Hydrochloride Sustained-release Tablets|drug
57762016|NCT05205317|PROCEDURE|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
57762017|NCT05889806|OTHER|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
57762018|NCT03390530|DRUG|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
57762019|NCT03390530|DRUG|Placebo|Placebo
57762020|NCT01417052|DRUG|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
57762021|NCT01417052|DRUG|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
57762022|NCT01417052|DRUG|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
57762023|NCT01417052|DRUG|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
57762024|NCT01417052|DRUG|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
57762025|NCT01417052|DRUG|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
57762026|NCT01417052|DRUG|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
57762027|NCT01417052|DRUG|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
57762028|NCT01417052|DRUG|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
57762029|NCT01417052|DRUG|Placebo|Matching placebo dosing in capsule form
57762030|NCT02612480|DRUG|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
57762031|NCT02612480|DRUG|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
57762032|NCT02612480|DRUG|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
57762033|NCT02612480|DRUG|Placebo|7 day treatment with placebo
57762034|NCT03485677|DRUG|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
57762035|NCT03485677|DRUG|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
57762036|NCT02110745|DRUG|Sevofluorane|Comparison of different induction drugs and techniques
57762037|NCT02110745|DRUG|Propofol|Comparison of different induction drugs and techniques
57762038|NCT01630720|DIETARY_SUPPLEMENT|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
57960973|NCT00911989|DEVICE|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
57762039|NCT00242281|DRUG|APC-111 MP Tablet, 775 mg|
57762040|NCT01547988|OTHER|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
57762041|NCT04959487|OTHER|Food support|1. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
57762042|NCT04959487|OTHER|Nutritional Counseling and education|2. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
57762043|NCT00344604|BEHAVIORAL|Role of psychosocial and quality of life parameters prior to and following LASIK.|
57762044|NCT00602914|DEVICE|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
57762045|NCT00602914|DEVICE|MicronJet|MicronJet, Intradermal Injection
57762046|NCT04062123|DRUG|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
57762047|NCT04062123|DRUG|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
57762048|NCT04062123|DRUG|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
57762049|NCT04062123|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
57762050|NCT04062123|DRUG|Placebo|Crystalloid IV solution will be infused, with no active drug.
57762051|NCT06129240|COMBINATION_PRODUCT|LIQ861|trepostinil inhalation powder
57762052|NCT05555160|DEVICE|PICC|Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
57762053|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection once a week, 0.1/cm2
57762054|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection twice a week, 0.1/cm2
57762055|NCT05159323|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging|A novel diffusion-based magnetic resonance imaging method
57762056|NCT00082394|DRUG|Trizivir|
57762057|NCT00082394|DRUG|atazanavir|
57762058|NCT00082394|DRUG|Combivir|
57762059|NCT06614049|BEHAVIORAL|Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications|Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
57762060|NCT00641914|DRUG|budesonide|
57762061|NCT00641914|DRUG|Placebo|
57762062|NCT03771014|OTHER|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
57762063|NCT04299516|PROCEDURE|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
57762064|NCT04299516|PROCEDURE|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
57762065|NCT05166538|DRUG|Ticagrelor|direct-acting oral P2Y12-receptor antagonist
57762066|NCT05166538|DRUG|Clopidogrel|platelet aggregation inhibitor
57762067|NCT02856425|DRUG|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
57762068|NCT02856425|DRUG|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
57762069|NCT04370054|BIOLOGICAL|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
57762070|NCT02104362|RADIATION|exclusive single-fraction irradiation|
57762071|NCT02276924|DEVICE|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
57762072|NCT00617695|DRUG|Zolmitriptan|5mg nasal spray
57762073|NCT00617695|DRUG|Placebo|
57762074|NCT05006677|DRUG|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
57762075|NCT05006677|DRUG|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
57762076|NCT05006677|DRUG|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
57762077|NCT05006677|OTHER|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
57762078|NCT03263221|PROCEDURE|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
57762079|NCT03484676|DEVICE|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
57762080|NCT05640414|OTHER|Weekly Family Food Packages|Families receive weekly family food packages for 6 months
57762081|NCT05640414|BEHAVIORAL|Family Health Group Sessions|Families with children aged 6-17 years attend 6 monthly group sessions with cooking demonstrations
57762082|NCT01874145|DRUG|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
57762083|NCT01874145|DRUG|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
57762084|NCT00432250|PROCEDURE|Cervical length ultrasound|
57762085|NCT03160287|BEHAVIORAL|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
57762086|NCT01728792|BIOLOGICAL|TDV|TDV IM or SC injection
57762087|NCT01519388|OTHER|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
57762088|NCT01519388|DEVICE|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
57762089|NCT03207906|DRUG|VBP-926|Topical VBP-926 solution
57762090|NCT01101360|DEVICE|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
57762091|NCT01101360|DEVICE|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
57762092|NCT01101360|DEVICE|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
57762093|NCT02944656|DRUG|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
57960974|NCT04674631|OTHER|The effect of neuropathic pain on quality of life, depression and sleep quality|The effect of neuropathic pain on quality of life, depression and sleep quality
57960975|NCT03839459|DRUG|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
57960976|NCT03506542|DEVICE|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
57960977|NCT03506542|PROCEDURE|Phacotrabeculectomy|Trabeculectomy with cataract extraction
57960978|NCT03506542|DRUG|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
57960979|NCT03665142|OTHER|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
57762094|NCT02944656|DRUG|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
57762095|NCT00253201|DRUG|galantamine hydrobromide|
57762096|NCT02347514|BEHAVIORAL|Diabetes group visit|
57762097|NCT00221286|DRUG|pegylated interferon alfa-2a|
57762098|NCT00221286|DRUG|tenofovir DF / emtricitabine combination therapy|
57762099|NCT00221286|DRUG|pegIFN / TDF / FTC combination therapy|
57762100|NCT02440984|PROCEDURE|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
57762101|NCT01623648|OTHER|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
57762102|NCT01623648|OTHER|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
57762103|NCT01623648|OTHER|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
57762104|NCT00003137|DRUG|irinotecan hydrochloride|
57762105|NCT01364597|DRUG|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
57762106|NCT04191447|DRUG|Flamboyant 200/12|Flamboyant 200/12 capsule
57762107|NCT04191447|DRUG|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
57762108|NCT04191447|OTHER|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
57762109|NCT04191447|OTHER|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
57762110|NCT00402701|BEHAVIORAL|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
57762111|NCT06626438|OTHER|Treatable traits model of care|Embedded multidisciplinary clinic with treatable traits model of care.
57762112|NCT00864708|DEVICE|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
57762113|NCT00154206|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
57762114|NCT06181032|DRUG|Adebrelimab|Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;
57762115|NCT06181032|DRUG|Apatinib|Apatinib: 250 mg, po, QD, Q3W;
57762116|NCT06181032|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;
57762117|NCT06181032|DRUG|Cisplatin|Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
57762118|NCT02607371|OTHER|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
57762119|NCT02607371|OTHER|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
57762120|NCT02607371|OTHER|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
57762121|NCT02607371|OTHER|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
57762122|NCT02607371|OTHER|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
57762123|NCT02466646|DRUG|Klorhex® Gel, rinse and spray|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
57762124|NCT02466646|PROCEDURE|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
57762125|NCT02466646|PROCEDURE|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
57762126|NCT04018248|DRUG|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
57762127|NCT04018248|DRUG|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
57762128|NCT04077255|DRUG|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
57762129|NCT04061226|DEVICE|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
57762130|NCT01339286|DRUG|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
57762131|NCT00170222|DRUG|doxycycline|
57762132|NCT02753348|OTHER|Echocardiography|
57762133|NCT02753348|OTHER|Blood analysis from umbilical cord blood|
57762134|NCT02753348|OTHER|ECG|
57762135|NCT02753348|OTHER|Measurement of oxygen saturation|
57762136|NCT00113932|PROCEDURE|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin\* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, \& every 2 weeks until HB \>12 gm/dl\*\*\*; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount \<30,000/μl
57762137|NCT05907486|DRUG|N-acetyl-cysteine|8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45
57762138|NCT05907486|DRUG|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
57762139|NCT05907486|DRUG|Cytarabine|2g/m2, day -8, intravenously
57762140|NCT05907486|DRUG|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
57762141|NCT01576367|BIOLOGICAL|ACZ885|
57762142|NCT05933265|DRUG|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
57762143|NCT06281353|DRUG|Curcumin Oral Capsule|Curcumin oral capsule in nano-sized particle.
57762144|NCT06281353|DRUG|Trichloroacetic acid|TCA 90%
57762145|NCT06281353|PROCEDURE|Blood sample collection|HIV and CD4+ 4th generation.
57762146|NCT06281353|PROCEDURE|Cotton swab|Cotton swab for collecting sample from AGW lesions.
57762147|NCT06319703|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) Videos|Text message-delivered video-based DSMES intervention.
57762148|NCT06319703|BEHAVIORAL|Community Health Worker Support (CHW)|Assess participants' SDOH barriers to Type 2 diabetes care and link them to available resources in the community.
57762149|NCT00727324|DRUG|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
57762150|NCT04083716|DRUG|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
57762151|NCT04083716|DRUG|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
57762152|NCT03120689|OTHER|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
57762153|NCT03120689|OTHER|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
57762154|NCT03120689|OTHER|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
57762155|NCT03120689|OTHER|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
57762156|NCT03007654|DEVICE|Mediclore|apply medical device fully around intrauterine surgery area
57762157|NCT03007654|DEVICE|Adept|apply medical device fully around intrauterine surgery area
57762158|NCT05922839|DRUG|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
57762159|NCT00765310|DIETARY_SUPPLEMENT|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
57762160|NCT00765310|DIETARY_SUPPLEMENT|Placebo|two capsules once daily in morning on empty stomach
57762161|NCT01768546|BEHAVIORAL|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
57762162|NCT01768546|BEHAVIORAL|Interactive tracking and problem solving web portal|
57762163|NCT05340751|DIAGNOSTIC_TEST|Blood drawn|Hemoglobin and Hematocrit Levels
57762164|NCT04835714|DRUG|BI 1701963|BI 1701963
57762165|NCT04835714|DRUG|BI 3011441|BI 3011441
57762166|NCT01438463|BIOLOGICAL|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
57762167|NCT01438463|BIOLOGICAL|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
57762168|NCT01438463|BIOLOGICAL|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
57762169|NCT01438463|BIOLOGICAL|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
57762170|NCT01438463|BIOLOGICAL|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
57960980|NCT03665142|OTHER|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
58456876|NCT01256268|DRUG|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
58456877|NCT01256268|DRUG|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
58456878|NCT01256268|DRUG|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
58456879|NCT01388517|DRUG|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
58456880|NCT01388517|DRUG|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
58456881|NCT01388517|DRUG|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
58456882|NCT04955171|DRUG|BEOVU intravitreal injection|BEOVU intravitreal injection
58456883|NCT03908333|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
58456884|NCT03908333|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
58456885|NCT03908333|DRUG|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
58456886|NCT03908333|DRUG|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
58456887|NCT04403412|PROCEDURE|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
58456888|NCT04403412|PROCEDURE|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
58456889|NCT04403412|PROCEDURE|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
58456890|NCT06187259|DEVICE|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
58456891|NCT06187259|DEVICE|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
57762171|NCT03391960|DEVICE|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
57762172|NCT05232032|DRUG|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
57762173|NCT05232032|DEVICE|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
57762174|NCT05882201|PROCEDURE|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
57762175|NCT05882201|PROCEDURE|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
57762176|NCT05882201|PROCEDURE|General care|using ordinary technique
58456892|NCT00925834|BEHAVIORAL|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
58456893|NCT01790594|BIOLOGICAL|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
58456894|NCT01790594|DRUG|methylprednisolone|
58456895|NCT01790594|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|
58456896|NCT01790594|DRUG|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
57762177|NCT05590988|OTHER|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
57762178|NCT05590988|OTHER|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
58456897|NCT01790594|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
58456898|NCT03360123|DRUG|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
58456899|NCT03360123|DRUG|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
57762179|NCT02475135|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
57762180|NCT02475135|DRUG|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
58456900|NCT05318261|PROCEDURE|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
58456901|NCT05036174|DRUG|Diphenhydramine 5%|Diphenhydramine 5% ointment
58456902|NCT05036174|DRUG|Placebo|Placebo matched to diphenhydramine 5% ointment
58456903|NCT01378559|OTHER|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
58456904|NCT05238077|PROCEDURE|Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy|Patients will have different kinds of light shined on different areas
58456905|NCT05376384|DIAGNOSTIC_TEST|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
58456906|NCT05376384|PROCEDURE|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
58456907|NCT00660192|DRUG|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
57762181|NCT02475135|DRUG|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
57762182|NCT02475135|DRUG|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
57762183|NCT02475135|DRUG|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
57762184|NCT02475135|OTHER|High-fat Breakfast|High-fat breakfast will be administered.
57762185|NCT02475135|OTHER|Standardized Regular Breakfast|Standardized regular breakfast will administered.
58456908|NCT00660192|OTHER|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
58456909|NCT00556075|DRUG|Proellex 25 mg|1 capsule daily for 4 months
58456910|NCT00556075|DRUG|Placebo|1 capsule daily for 4 months
58456911|NCT00556075|DRUG|Proellex 50 mg|2 capsules daily for 4 months
58456912|NCT05664321|OTHER|Observational, case-control study|obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].
58456913|NCT05754216|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
58456914|NCT06185465|DEVICE|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
57762186|NCT04500496|DRUG|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
57762187|NCT04500496|DRUG|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
57762188|NCT01731743|DEVICE|AT LISA tri 839MP|
57762189|NCT00286000|DRUG|Administration of high dose simplified folfiri|
57762190|NCT00156858|DRUG|intravenous busulfan|
57762191|NCT00517309|BIOLOGICAL|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
57762192|NCT00517309|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
57762193|NCT05155995|DRUG|HCP2001|Take it once per period.
57762194|NCT05155995|DRUG|RLD2007|Take it once per period.
57762195|NCT05155995|DRUG|RLD2008|Take it once per period.
57762196|NCT05155995|DRUG|RLD2102|Take it once per period.
57762197|NCT01457235|OTHER|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
57762198|NCT04943263|OTHER|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
57762199|NCT05256095|BEHAVIORAL|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
58456915|NCT06185465|DEVICE|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
58456916|NCT03965975|DEVICE|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
58456917|NCT03965975|DEVICE|S-There|"Second intervention (assigned to the All participants arm)."
58456918|NCT04507022|DRUG|Estradiol Valerate|2mg three times daily
58456919|NCT04507022|DRUG|Progesterone|100 mg daily intramuscular
58456920|NCT04507022|DRUG|Aromatase inhibitor|2.5 mg twice daily for 5 days
58456921|NCT03041571|BEHAVIORAL|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
58456922|NCT03041571|BEHAVIORAL|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
58456923|NCT01129622|DRUG|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
58456924|NCT01410890|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
58456925|NCT00837915|DRUG|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
58456926|NCT00790426|DRUG|TKI258|
58456927|NCT05987358|DRUG|TQB3454 tablets|TQB3454 is a selective IDH1 mutant enzyme inhibitor.
58456928|NCT05987358|DRUG|TQB3454 tablets matching placebo|Placebo tablets without active substance.
58456929|NCT02787395|PROCEDURE|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
58456930|NCT06001346|BEHAVIORAL|ActiveCBT|Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
58456931|NCT06001346|BEHAVIORAL|CalmCBT|Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
58456932|NCT02754973|BEHAVIORAL|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
58456933|NCT02754973|BEHAVIORAL|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
57960981|NCT01119456|BIOLOGICAL|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
58456934|NCT03836625|OTHER|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
58456935|NCT04948853|BEHAVIORAL|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
58456936|NCT05313789|DEVICE|Analgesia Nociception Index (ANI)|Monitorization of Analgesia Nociception Index in Intensive Care Patients
58456937|NCT01389882|PROCEDURE|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
58456938|NCT00860730|DEVICE|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
58456939|NCT05313113|BEHAVIORAL|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
57762200|NCT00954733|OTHER|Arterial blood draw|One arterial blood draw
57762201|NCT01117701|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
57762202|NCT05782010|DEVICE|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
57762203|NCT01141023|DRUG|DaTscan|
57762204|NCT00061113|DRUG|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
57762205|NCT00061113|DRUG|fluoxetine|20mg, QD x 16 weeks
57762206|NCT00061113|DRUG|placebo + CBT|single fixed morning dose X 16 weeks
57762207|NCT00957606|PROCEDURE|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
57762208|NCT00255346|DRUG|Dasatinib (BMS-354825)|70 mg orally twice daily
57762209|NCT02459158|DRUG|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
57960982|NCT01119456|BIOLOGICAL|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
57960983|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
57960984|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
57960985|NCT01119456|BIOLOGICAL|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
58456940|NCT00301795|BIOLOGICAL|oblimersen sodium|Given IV
58456941|NCT00301795|BIOLOGICAL|rituximab|Given IV
58456942|NCT00301795|OTHER|laboratory biomarker analysis|Correlative studies
57960986|NCT01119456|BIOLOGICAL|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
57960987|NCT01119456|BIOLOGICAL|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
57960988|NCT01119456|BIOLOGICAL|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
58458653|NCT03912012|DRUG|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
57762210|NCT02459158|DRUG|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
57762211|NCT05958160|OTHER|Modified Atkins diet|The modified Atkins diet is a less restrictive version of the ketogenic diet
57762212|NCT05958160|DRUG|Topiramate|Topiramate is an anti-seizure medication
57762213|NCT04568954|DIAGNOSTIC_TEST|Truenat TB platform/TB assays|"Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life."
57762214|NCT01637701|PROCEDURE|PkEP|Plasmakinetic enucleation of the prostate
57762215|NCT01637701|PROCEDURE|B-TURP|Bipolar transurethral resection of the prostate
57762216|NCT00457639|DRUG|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
57762217|NCT00283920|DRUG|[(11)C] PBR28|
57762218|NCT03204058|DRUG|Placebos|Oral prophylaxis followed by placement of placebo gel
57762219|NCT03204058|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
57762220|NCT03204058|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
57762221|NCT04146896|DRUG|NYX-2925 50 mg|NYX-2925 administered orally
57762222|NCT04146896|DRUG|Placebo|Placebo administered orally
57762223|NCT05923229|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
57762224|NCT05923229|OTHER|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
57960989|NCT05261620|DIETARY_SUPPLEMENT|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity \[DPPH (2,2-diphenyl-1-picrylhydrazyl) test\] and phenolic profiles \[HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis\] will be performed for wine selection for the clinical trial.
57960990|NCT06282120|DRUG|Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy|The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
57960991|NCT04797845|OTHER|teleconsultation|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
57960992|NCT00883714|OTHER|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
57960993|NCT00883714|OTHER|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
57762225|NCT03489057|BEHAVIORAL|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
57762226|NCT03489057|BEHAVIORAL|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
57762227|NCT02239497|PROCEDURE|Femoral block by ultrasound and neurostimulation|
57762228|NCT02239497|DRUG|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
58129067|NCT06076681|DRUG|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
58456943|NCT01329302|PROCEDURE|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
58456944|NCT05242029|DRUG|Placebo|Participants will receive placebo in a clinical setting.
58456945|NCT05242029|DRUG|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
58456946|NCT06391099|OTHER|Best Practice|Undergo standard of care diet
58456947|NCT06391099|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
58456948|NCT06391099|PROCEDURE|Computed Tomography|Under CT
58456949|NCT06391099|OTHER|Dietary Intervention|Undergo ketogenic diet
58456950|NCT06391099|OTHER|Educational Activity|Receive coaching support
58456951|NCT06391099|OTHER|Glucose Measurement|Undergo blood glucose testing
58456952|NCT06391099|OTHER|Ketone Measurement|Undergo ketone measurement
58456953|NCT06391099|OTHER|Questionnaire Administration|Ancillary studies
58456954|NCT06461988|DRUG|Talquetamab|"Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3a: 60 mcg/kg C1D5a: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13"
58456955|NCT06461988|DRUG|Talquetamab and Lenalidomide|Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)
58456956|NCT05878834|DIETARY_SUPPLEMENT|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
58456957|NCT05878834|DIETARY_SUPPLEMENT|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
58456958|NCT00322881|DRUG|Paclitaxel|
58456959|NCT00322881|DRUG|Carboplatin|
58456960|NCT05973734|BIOLOGICAL|Infusion of recipient T regulatory cell|Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
58129068|NCT02910609|DEVICE|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
58456961|NCT05973734|BIOLOGICAL|Infusion of concomitant Donor Derived Vertebral Bone Marrow|The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
58456962|NCT04053257|OTHER|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
58456963|NCT02376764|PROCEDURE|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
58456964|NCT00778778|DRUG|cefprozil 500mg tablets|
58456965|NCT03369821|DIAGNOSTIC_TEST|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
58456966|NCT03369821|OTHER|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
58129069|NCT05906810|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
58129070|NCT00971893|DRUG|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
57762229|NCT06465277|DIAGNOSTIC_TEST|Dobutamine stress CMR|"Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team."
57762230|NCT06465277|DIAGNOSTIC_TEST|Cardiac biomarker sample|blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
57762231|NCT04529265|DRUG|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia and 1mg/kg MB at the end of surgery
57762232|NCT04529265|DRUG|Placebo|Equal volume of normal saline after induction of anesthesia and at the end of surgery
57762233|NCT01167686|DIETARY_SUPPLEMENT|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
57762234|NCT02596763|DRUG|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
57762235|NCT03978910|OTHER|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
58456967|NCT01390896|DRUG|Fondaparinux Sodium|
57762236|NCT03041844|DEVICE|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)
58456968|NCT06037915|DEVICE|low flow oxygen with nasopharyngeal tube|low flow oxygen with nasopharyngeal tube
58456969|NCT06037915|DEVICE|high flow oxygen with OptiflowTM Nasal High Flow|high flow oxygen with OptiflowTM Nasal High Flow
57762237|NCT03041844|DEVICE|Sham Applicator|Sham ultrasound applicator
57762238|NCT06611683|PROCEDURE|Inspiratory muscle training|A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.
57762239|NCT06611683|PROCEDURE|Routine care|Subjects received routine care without intervention.
57762240|NCT02442843|DEVICE|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
57762241|NCT02442843|DEVICE|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
57762242|NCT04535622|BEHAVIORAL|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
57762243|NCT00002635|BIOLOGICAL|filgrastim|
57762244|NCT00002635|DRUG|aminocamptothecin|
57762245|NCT06470074|DEVICE|Transcranial electrical stimulation|Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
57762246|NCT05578625|OTHER|plasma circulation DNA methylation sequencing|10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
57762247|NCT00804492|BEHAVIORAL|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
57762248|NCT05995080|OTHER|clorhexidine gluconate bathing|daily skin cleansing with chlorhexidine gluconate
57762249|NCT04645784|OTHER|Supporting Student-Athletes Mental Wellness|The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
57762250|NCT03123289|DRUG|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
57960994|NCT05813509|DEVICE|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
57960995|NCT03294018|OTHER|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
57960996|NCT01780883|DRUG|melatonin|
57960997|NCT01780883|DRUG|Placebo|Placebo tablets of Circadin®
58456970|NCT02549547|BEHAVIORAL|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~* Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~* Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~* Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
58456971|NCT00953602|OTHER|Genetically modified potato|Genetically modified potato
58456972|NCT05513352|DEVICE|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
57762251|NCT03123289|DRUG|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
57762252|NCT04959474|OTHER|Best Practice|Given standard dietary recommendations
57762253|NCT04959474|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
57762254|NCT04959474|PROCEDURE|Resection|Undergo surgical resection
57762255|NCT04959474|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
57762256|NCT04959474|OTHER|Dietary Intervention|Undergo a caloric restriction diet
57762257|NCT04959474|OTHER|Questionnaire Administration|Ancillary studies
57762258|NCT04959474|OTHER|Quality-of-Life Assessment|Ancillary studies
57762259|NCT01602081|DEVICE|reinforce soft tissue|reinforce soft tissue
57762260|NCT03018002|OTHER|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
57762261|NCT03775226|DEVICE|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
57762262|NCT00660335|DRUG|RG1068 (synthetic human secretin)|Single-dose, IV infusion
57762263|NCT04452448|DEVICE|LASIK|All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
57762264|NCT00501878|DRUG|2.5% or 10% phenylephrine|
58129071|NCT05197166|OTHER|Acute Clinical Settings|Acute clinical settings, like hospitals, where students are exposed to normal daily shift activities, involving prolonged walking and standing positions.
58129072|NCT00253032|DEVICE|PRIMA|
58456973|NCT05513352|DEVICE|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
58456974|NCT05513352|DEVICE|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
58456975|NCT01582815|DRUG|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
58456976|NCT01582815|DRUG|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
58456977|NCT02444429|DRUG|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
58456978|NCT02444429|OTHER|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
58456979|NCT02444429|OTHER|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
58456980|NCT04955717|OTHER|Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert|Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
57762265|NCT01659892|DRUG|Montelukast|5 mg Chewable Tablet
57960998|NCT01848535|DIETARY_SUPPLEMENT|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
58456981|NCT03137992|DRUG|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
57762266|NCT01659892|DRUG|Singulair|5 mg Chewable Tablet
57960999|NCT01848535|DIETARY_SUPPLEMENT|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
57961000|NCT05771298|DEVICE|532nm KTP|one to three treatment sessions
57961001|NCT05771298|DEVICE|585nm PDL|one to three treatment sessions
57961002|NCT01665118|DEVICE|Trusculpt (Radio Frequency) Device|
57961003|NCT03563937|DRUG|Phenprocoumon|Follow the physician's prescription.
57961004|NCT03563937|DRUG|Apixaban|2.5 mg or 5 mg, twice daily
57961005|NCT03563937|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
57961006|NCT03563937|DRUG|Edoxaban|30 mg or 60 mg, once daily
57762267|NCT00433615|DRUG|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
57762268|NCT00433615|DRUG|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
57762269|NCT06056921|BIOLOGICAL|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
57762270|NCT00927355|DRUG|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
57762271|NCT00927355|DRUG|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
57762272|NCT00145301|DRUG|Lumiracoxib|
57762273|NCT06494969|DEVICE|Intraocular pressure measurement|Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
57762274|NCT04735016|DEVICE|DiamondTemp™ Ablation System|A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
57762275|NCT05845775|PROCEDURE|Percutaneous dilatational tracheostomy|The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy
57762276|NCT05845775|DEVICE|Bronchoscopy|Fiberoptic bronchoscopy
57762277|NCT05845775|DEVICE|ultrasonography|ultrasonography
57762278|NCT05845775|DIAGNOSTIC_TEST|Bronchoscopy application|Fiberoptic bronchoscopy application
57762279|NCT05845775|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination
57762280|NCT00228293|DEVICE|investigational monitor/defibrillator with CPR feedback|
57762281|NCT03448159|DRUG|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
57762282|NCT03448159|OTHER|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
57762283|NCT03448159|BEHAVIORAL|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
57762284|NCT06488820|DEVICE|Catheter ablation using pulsed-field ablation (PFA) system|PFA will be used to isolate the pulmonary veins and additional left atrial structure as needed
57762285|NCT02696564|DRUG|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
57762286|NCT02696564|DRUG|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
57762287|NCT04748042|DRUG|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
57762288|NCT04748042|DRUG|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
57762289|NCT04748042|RADIATION|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
57762290|NCT04748042|BIOLOGICAL|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
57762291|NCT04748042|DRUG|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
57762292|NCT01985620|BEHAVIORAL|Educational intervention|
57762293|NCT00058201|DRUG|fluorouracil|Given IV
57762294|NCT00058201|DRUG|gemcitabine hydrochloride|Given IV
57762295|NCT00058201|DRUG|leucovorin calcium|Given IV
57762296|NCT00058201|OTHER|clinical observation|No intervention
57762297|NCT04557826|DEVICE|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
57762298|NCT04436458|DRUG|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
57762299|NCT04436458|DRUG|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
57762300|NCT00171639|DRUG|zoledronic acid|
57762301|NCT02705781|DEVICE|smARTrack Feeding Tube System|
57762302|NCT05346848|DRUG|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
57762303|NCT05346848|DRUG|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
57762304|NCT01672853|BIOLOGICAL|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
57762305|NCT01672853|BIOLOGICAL|Placebo|Subcutaneous injections weekly for a total of 96 injections
57762306|NCT04912674|DEVICE|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
57762307|NCT01705535|BEHAVIORAL|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
57762308|NCT01705535|OTHER|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
57762309|NCT01705535|BEHAVIORAL|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
57762310|NCT06263088|OTHER|EQUITY GI|"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
57762311|NCT06000319|BIOLOGICAL|Natural Matrix Protein (NMP) Fibers|human bone allograft
57762312|NCT06000319|PROCEDURE|Lumbar interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
57762313|NCT06000319|PROCEDURE|Cervical interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
57762314|NCT02739347|DEVICE|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
57762315|NCT02739347|DEVICE|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
58456982|NCT03137992|DRUG|Test Product (tiotropium bromide inhalation powder)|Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
57762316|NCT03666936|OTHER|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
57762317|NCT03634618|OTHER|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
57762318|NCT03634618|OTHER|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
57762319|NCT04805749|OTHER|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~4. Cranial osteopathy techniques to address the vagus parasympathetic nerves."
57762320|NCT00210327|DRUG|Bortezomib (drug)|
57762321|NCT06153602|DRUG|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.08 ml intrathecal
57762322|NCT06153602|DRUG|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
57762323|NCT01633801|DEVICE|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
57762324|NCT01633801|DEVICE|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
57762325|NCT01750762|DRUG|Lenalidomide|
57762326|NCT05542290|PROCEDURE|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
57961007|NCT00667615|DRUG|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
57961008|NCT04057625|DEVICE|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
57961009|NCT01571115|BEHAVIORAL|Physical Exercise|
58129073|NCT01434836|OTHER|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
58456983|NCT03137992|DRUG|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
58456984|NCT05936489|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
58456985|NCT05936489|DRUG|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
58456986|NCT02055326|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
58456987|NCT02055326|BEHAVIORAL|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
57762327|NCT05542290|PROCEDURE|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
58456988|NCT02055326|BEHAVIORAL|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
57762328|NCT04121884|BEHAVIORAL|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
57762329|NCT04737109|DRUG|Ipatasertib|Ipatasertib
57762330|NCT04737109|DRUG|Darolutamide|Darolutamide
57762331|NCT04737109|DRUG|Androgen Deprivation Therapy|ADT per institutional standards
57762332|NCT03779178|DRUG|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
57762333|NCT03779178|DRUG|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
57762334|NCT03351738|DRUG|MEDI5884|Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
57762335|NCT03351738|DRUG|Placebo|Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
57762336|NCT01481545|RADIATION|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
57762337|NCT01481545|DRUG|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
57762338|NCT01481545|DRUG|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
57762339|NCT01481545|DRUG|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
58129074|NCT01434836|OTHER|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
58456989|NCT06352580|OTHER|Survey|26 survey questions were administered face to face to parents, which they could answer in a short time.
58456990|NCT02721875|DRUG|Volasertib|
58456991|NCT02721875|DRUG|Volasertib|
58456992|NCT02721875|DRUG|Azacitidine|
58456993|NCT01105910|OTHER|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
58129075|NCT01245166|DRUG|Acarbose|Acarbose 50 mg, per orem, thrice daily
58456994|NCT01105910|OTHER|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
58456995|NCT03749759|PROCEDURE|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
58456996|NCT04018053|DRUG|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
57762340|NCT01481545|DRUG|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
57762341|NCT01481545|DRUG|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
57762342|NCT03549884|PROCEDURE|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
57762343|NCT03549884|PROCEDURE|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
57762344|NCT03767725|BIOLOGICAL|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
58129076|NCT01245166|DRUG|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
58129077|NCT05389410|DEVICE|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
58129078|NCT05389410|DEVICE|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
58129079|NCT06495762|OTHER|e-health assesment|This study is purely observational and does not forsee any intervention but only observational assesment of parents' wellbeing
58129080|NCT05394168|BIOLOGICAL|HLX53|There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.
58456997|NCT04018053|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
58456998|NCT02051452|DRUG|Methylphenidate|
58456999|NCT02051452|OTHER|Saline|
58457000|NCT02870777|COMBINATION_PRODUCT|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
58457001|NCT03892616|DRUG|BI 1358894 (B)|Tablet formulation 2 (TF2a), fed
58457002|NCT03892616|DRUG|BI 1358894 (C)|Tablet formulation 2 (TF2a), fasted
58457003|NCT03892616|DRUG|BI 1358894 (D)|Tablet formulation 2 (TF2b), fed
57762345|NCT05256030|OTHER|Speed-based relearning training|Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
57762346|NCT05256030|OTHER|Neurodevelopmental Therapy|Neurodevelopmental Therapy
57762347|NCT03853460|PROCEDURE|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
57762348|NCT03853460|PROCEDURE|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
57762349|NCT02124148|DRUG|Prexasertib|Administered IV
57762350|NCT02124148|DRUG|Cisplatin|Administered IV
57762351|NCT02124148|DRUG|Cetuximab|Administered IV
57762352|NCT02124148|DRUG|G-CSF|Administered SC
57762353|NCT02124148|DRUG|Pemetrexed|Administered IV
57762354|NCT02124148|DRUG|Fluorouracil|Administered IV
57762355|NCT02124148|DRUG|LY3023414|Administered PO
57762356|NCT02124148|DRUG|Leucovorin|Administered IV
57762357|NCT03761498|OTHER|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
57762358|NCT05965843|OTHER|underling disease|"Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19."
57762359|NCT02541214|DEVICE|Trial Nasal Mask|
57762360|NCT05537558|DRUG|Antidepressant|Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
57762361|NCT03386032|DRUG|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
57762362|NCT03386032|DRUG|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
57762363|NCT03386032|OTHER|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
57762364|NCT00544063|DRUG|irinotecan hydrochloride|
57762365|NCT00544063|DRUG|oxaliplatin|
57762366|NCT02484079|PROCEDURE|Polypectomy|
57762367|NCT05207930|DEVICE|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
57762368|NCT05207930|DEVICE|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
57762369|NCT05164874|DEVICE|Mobile Mammography Unit|The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
57762370|NCT04854005|PROCEDURE|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
57762371|NCT03456037|OTHER|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
57762372|NCT00718822|OTHER|oxygen concentration in the culture atmosphere|
57762373|NCT03857503|DIAGNOSTIC_TEST|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures."
57762374|NCT01255592|DRUG|AZD5069|Oral dose bid
58129081|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
58129082|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
58129083|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
57762375|NCT01255592|DRUG|Placebo|Oral dose bid
57762376|NCT02420743|PROCEDURE|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
57762377|NCT02420743|PROCEDURE|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
57762378|NCT02743923|DRUG|carboplatin|AUC 6
57762379|NCT02743923|DRUG|paclitaxel|200mg/m2
57762380|NCT02743923|DRUG|Bevacizumab|15 mg/kg
57762381|NCT02743923|DRUG|Pemetrexed|500 mg/m2
57762382|NCT02743923|DRUG|cisplatin|75 mg/m2
58129084|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
58129085|NCT02563756|PROCEDURE|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
58457004|NCT03892616|DRUG|BI 1358894 (E)|Tablet formulation 2 (TF2b), fasted
58457005|NCT03892616|DRUG|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
58457006|NCT02349633|DRUG|PF-06747775|
58457007|NCT02349633|DRUG|Palbociclib|
58457008|NCT02349633|DRUG|Avelumab|
58457009|NCT04736914|DRUG|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
58457010|NCT01862289|OTHER|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
58457011|NCT03707353|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
58457012|NCT06116734|DRUG|Grastofil®|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
58457013|NCT06116734|DRUG|Lapelga|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
58457014|NCT01917383|DRUG|Trabodenoson|Ophthalmic eye drop
58457015|NCT01917383|DRUG|Latanoprost|Ophthalmic eye drop
58457016|NCT01917383|DRUG|Timolol|Ophthalmic eye drop
58457017|NCT02138890|DEVICE|APS|Intra-articular Injection
57762383|NCT05003050|OTHER|Meditation|Holistic natural therapy
57762384|NCT05003050|OTHER|Pranic Healing|Energy therapy
57762385|NCT01423214|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
57762386|NCT01423214|PROCEDURE|Laparoscopic surgery|Conventional laparoscopic procedures
57762387|NCT01053377|DRUG|Tamiflu (verum)|
57762388|NCT01053377|DRUG|Tamiflu placebo|
57762389|NCT00502034|DRUG|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
57762390|NCT00502034|DRUG|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
58457018|NCT02138890|DEVICE|Saline|Intra-articular injection
58457019|NCT01091675|DRUG|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
58457020|NCT06238440|OTHER|Splint and taping methods|"In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape"
58457021|NCT03107260|OTHER|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
57762391|NCT03763916|PROCEDURE|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
57762392|NCT03763916|PROCEDURE|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter
57762393|NCT03763916|PROCEDURE|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
57762394|NCT02000830|DRUG|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
57762395|NCT02000830|DRUG|Placebo|Matching placebo administered by IM injection
57762396|NCT01271998|DRUG|TR-701 FA|200 mg, oral, once daily for 3 days.
57762397|NCT01407588|PROCEDURE|Magnetic navigation|Ablation with use of the magnetic navigation system
57961697|NCT05172739|DRUG|Opioid-free Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
57961698|NCT04970251|DRUG|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
58458654|NCT03912012|DEVICE|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
58458655|NCT03912012|DEVICE|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
58458656|NCT03912012|BIOLOGICAL|Blood sampling|37 mL of blood sample will be performed at Day 1
57762398|NCT01407588|PROCEDURE|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
57762399|NCT05791890|DRUG|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
57762400|NCT01993459|DRUG|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
57762401|NCT01993459|DRUG|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
57762402|NCT00257959|DRUG|amiodarone beta blocker sotalol|
57762403|NCT06625008|OTHER|3D-printed model|The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
57762404|NCT04821128|OTHER|Radiologic and pathological review.|"We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis."
57762405|NCT05019833|DEVICE|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
57762406|NCT03766841|BEHAVIORAL|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
57762407|NCT04598906|BEHAVIORAL|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
57762408|NCT04598906|BEHAVIORAL|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
57762409|NCT05848921|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
57762410|NCT05848921|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
57762411|NCT02205216|DEVICE|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
57762412|NCT02205216|DEVICE|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
57762413|NCT02205216|BEHAVIORAL|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
57762414|NCT06450717|DEVICE|Khymeia VRRS|VRRS is an electronic device for remote rehabilitation of cognitive (e.g., memory, attention, spatial perception, logical-mathematical skills, language, executive functions...) and motor (gross and fine motor skills) functions. It can be used in on-line and off-line mode at home, and the exercises are chosen by the therapist according to the patient's specific difficulties and needs from a cognitive and motor library.
57762415|NCT03819725|DEVICE|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
57762416|NCT04843722|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
57961699|NCT01839864|BEHAVIORAL|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
57961700|NCT02905175|PROCEDURE|blood sample|
57961701|NCT02905175|PROCEDURE|synovial tissue|synoviocytes from synovial tissue
58129086|NCT02563756|PROCEDURE|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
58457022|NCT05452889|DIAGNOSTIC_TEST|18F-FGLN PET Imaging|PET/CT Imaging: The duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An arterial line will be placed in the radial artery for arterial blood sampling and this will be performed by an experienced anesthesiologist. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Blood Sampling: For the PET scan, the amount of blood will not be more than 43 arterial samples and a blood volume loss of no more than 60 ml (4-5 tablespoonfuls). Participants will be retained in the PET facility following the PET scan to evaluate for bleeding from the arterial puncture site and/or to promote urination to increase elimination of the radiotracer.
58458657|NCT03912012|BIOLOGICAL|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
58458658|NCT03912012|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
57762417|NCT05301270|DIAGNOSTIC_TEST|EMG Evaluation|Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
57762418|NCT01119430|DRUG|DU125530|20mg/twice a day
57762419|NCT01119430|DRUG|Placebo|Similar pill as active comparator twice a day
57762420|NCT03950180|OTHER|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
57762421|NCT06437236|DRUG|ondansetron|"Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
57762422|NCT06437236|DRUG|granisetron|"Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
57762423|NCT04414280|DEVICE|Medtronic MiniMed 670G|The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
57762424|NCT04414280|DEVICE|Medtronic MiniMed 780G|The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.
58457023|NCT05452889|DRUG|(18F)FPGLU|\[F-18\]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
57762425|NCT04414280|DEVICE|Tandem Control-IQ|The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
57762426|NCT00206557|DRUG|Raloxifene|
57762427|NCT00206557|DRUG|Estradiol/dyhydroprogestrone|
57762428|NCT01770301|DRUG|Paclitaxel|
57762429|NCT01770301|DRUG|Bevacizumab|
57762430|NCT06065813|DRUG|Toripalimab|200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
57762431|NCT06065813|RADIATION|Conventional segmental radiotherapy|the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
57762432|NCT06065813|OTHER|opreation|The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab
57762433|NCT05286944|OTHER|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
58457024|NCT02326038|DRUG|Methylphenidate|single oral administration of 20 mg tablet
57762434|NCT02543190|BEHAVIORAL|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
57762435|NCT01899456|DEVICE|Catheter-based renal denervation|
57762436|NCT04822350|DRUG|Avelumab|As provided in real world practice
57762437|NCT06149546|DIETARY_SUPPLEMENT|Control|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Four scheduled appointments with a dietitian"
57762438|NCT06149546|DIETARY_SUPPLEMENT|Intervention|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Seven scheduled appointments with a dietitian~* Six scheduled appointments with a physiotherapist"
57762439|NCT04772846|DRUG|Oral tablet|Oral 250mg chloroquine tablets
58457025|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
57762440|NCT04772846|DRUG|Placebo|Oral placebo tablets
58457026|NCT02677298|DRUG|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
58457027|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
58457028|NCT06411717|DEVICE|Microstructure lens A|Subjects randomized to Trial Group A will be required to wear microstructural lens A (microstructural design type with low defocus ratio) for 12 months
58457029|NCT06411717|DEVICE|Microstructure lens B|Subjects randomized to Trial B will be required to wear microstructural lens B (high defocus ratio microstructural design type) for 12 months
58457030|NCT06411717|OTHER|Control group|Subjects randomized to the control group will be required to wear aspherical single-light lenses for 12 months
58457031|NCT05123534|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.
58457032|NCT04699565|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Evaluate the predictive value of myocardial viability measured with cardiac magnetic resonance for the identification of LV REM 6 months after STEMI
58457033|NCT01344915|PROCEDURE|Locked knee brace|
58457034|NCT01344915|PROCEDURE|Locked knee brace|
58457035|NCT02159066|DRUG|LGX818|Combination of LGX818 and MEK162 (Part I)
58457036|NCT02159066|DRUG|MEK162|Combination of LGX818 and MEK162 (Part I)
58457037|NCT02159066|DRUG|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
58457038|NCT02159066|DRUG|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
58457039|NCT02159066|DRUG|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
58457040|NCT02159066|DRUG|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
58457041|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) lecture|OHEM via lecture will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
58457042|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) exhibition|OHEM via exhibition will be delivered to the mothers who will be instructed to teach their children.
58457043|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) demonstration|OHEM via demonstration will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
58457044|NCT00048412|DRUG|FLUDARABINE|
58457045|NCT00048412|DRUG|CAMPATH 1H|
58457046|NCT00048412|DRUG|FK50|
58457047|NCT00048412|PROCEDURE|Stem Cell Collection and Infusion|
58457048|NCT05279352|DRUG|FBR-002|Administration on D1 and D3
58457049|NCT05279352|DRUG|Placebo|Administration on D1 and D3
58457050|NCT04950244|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
58457051|NCT01259141|DRUG|Moxifloxacin|0.4 Qd for 7days
58457052|NCT01259141|DRUG|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
58457053|NCT00468026|DEVICE|ProstaPlant Stent|
58457054|NCT00359463|DRUG|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
58457055|NCT05361824|DRUG|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
58457056|NCT05361824|DRUG|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
58457057|NCT03753685|DRUG|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
57961010|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center);~Camrelizumab at a fixed dose of 200mg, administered via intravenous drip, with each infusion lasting no less than 30 min and no more than 60 min. Administered on day 1 of every 2-week cycle (d1, q2w).~Each treatment cycle is 14 days, and all drugs are administered on day 1."
58457058|NCT06148207|RADIATION|[18F]BF3-BPA Injection for PET Imaging|Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
58457059|NCT04055675|DIAGNOSTIC_TEST|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
58457060|NCT02525471|DRUG|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
58457061|NCT03410628|DEVICE|gammaCore|Non-invasive vagal nerve stimulator
58457062|NCT02232035|DRUG|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
58457063|NCT04622111|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
58457064|NCT04622111|DRUG|Placebo|matching placebo tablet
58457065|NCT04622111|DRUG|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
58457066|NCT02016196|DRUG|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~--------------------------------------------------------------------------------"
58457067|NCT02016196|DRUG|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
58457068|NCT03788057|OTHER|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
58457069|NCT05150184|OTHER|Non-interventional|observational study, thus no different arm/groups
58457070|NCT00883363|PROCEDURE|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
57762441|NCT01139463|DRUG|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
57762442|NCT02671201|OTHER|Education|Different methods in education of emergency ultrasound
57762443|NCT03715400|BEHAVIORAL|Positive Virtual Reality Training|Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
57762444|NCT02478346|DRUG|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
57762445|NCT03723343|DRUG|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
57762446|NCT03723343|DRUG|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
57762447|NCT01388348|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
57762448|NCT00825097|PROCEDURE|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
57762449|NCT00825097|DRUG|Botulinum toxin injection|Botulinum toxin type A
57762450|NCT02994602|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
57762451|NCT06298565|BIOLOGICAL|efgartigimod|efgartigimod
57762452|NCT03833128|DRUG|Low Dose REN001|Oral
57762453|NCT03833128|DRUG|High Dose REN001|Oral
57762454|NCT05076149|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
57762455|NCT05076149|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
57762456|NCT05076149|DRUG|IVA|Tablet for oral administration.
57762457|NCT05076149|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
57762458|NCT05076149|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
57762459|NCT05076149|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
57762460|NCT03575533|DIAGNOSTIC_TEST|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
57762461|NCT00632281|RADIATION|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
57762462|NCT04479033|OTHER|Multidisciplinary collaborative model of community care management|An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
57762463|NCT05466539|DRUG|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
57762464|NCT05466539|DRUG|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
58457071|NCT04649112|GENETIC|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
58457072|NCT03473236|DRUG|GB002|Inhaled GB002
58457073|NCT03473236|DEVICE|Generic Dry Powder Inhaler|dry powder inhaler used for inhalation of active drug or placebo
58457074|NCT03473236|DRUG|Placebo|Inhaled placebo
58457075|NCT00115505|OTHER|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
57762465|NCT06139068|OTHER|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.
57762466|NCT06139068|OTHER|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
57762467|NCT06134921|DEVICE|transcranial direct current stimulation (Active)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down."
57762468|NCT06134921|DEVICE|transcranial alternating current stimulation (active)|Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.
57762469|NCT06134921|DEVICE|transcranial electrical stimulation (sham)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes."
57762470|NCT06134921|OTHER|Conventional physical therapy program|A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
57762471|NCT02202434|DEVICE|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
57762472|NCT02202434|DEVICE|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
57762473|NCT02202434|DEVICE|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
57762474|NCT00525135|DRUG|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
57762475|NCT04092179|DRUG|Enasidenib|Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.
57762476|NCT04092179|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
57762477|NCT01953003|DRUG|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
57762478|NCT01953003|DRUG|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
57762479|NCT06625814|DRUG|Levothyroxine|single oral dose
57762480|NCT06625814|DRUG|Enlicitide Decanoate|single oral dose
57762481|NCT00992537|DRUG|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
57762482|NCT00992537|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
57762483|NCT00992537|DRUG|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
57762484|NCT00297193|PROCEDURE|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
57762485|NCT01516775|OTHER|clear fluid ingestion|drinking of clear fluid in preoperative period
57762486|NCT01737684|DRUG|Vibegron|50 mg tablet, oral
57762487|NCT01335516|OTHER|Glypressin (terlipressin)|Study drug (without placebo)
57762488|NCT01282801|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
57762489|NCT01282801|DRUG|Effexor® XR|150 mg Extended-Release Capsule
57762490|NCT01920048|PROCEDURE|Percutaneous Coronary Intervention|
57762491|NCT01920048|DRUG|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
57762492|NCT01920048|DEVICE|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
57762493|NCT03468933|DRUG|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
57762494|NCT03468933|PROCEDURE|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
57762495|NCT01755624|DEVICE|NovoTTF-100A device|
57762496|NCT01755624|OTHER|Best Standard of Care|
57762497|NCT02070705|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
57762498|NCT02070705|DRUG|Ferumoxytol|Given IV
57762499|NCT05348967|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement with D-chiro-inositol and alpha-lactalbumin
57762500|NCT01784692|DIETARY_SUPPLEMENT|Immulina|
57762501|NCT03604822|PROCEDURE|Music therapy|ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
57762502|NCT04637464|OTHER|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
57762503|NCT01986101|DRUG|Placebo|Placebo comparator
57762504|NCT01986101|DRUG|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
57762505|NCT01986101|DRUG|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
57762506|NCT02713711|RADIATION|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
57762507|NCT02713711|PROCEDURE|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
57762508|NCT02713711|PROCEDURE|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
57762509|NCT04262765|DRUG|Ramipril, Amlodipine and Atorvastatin|compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
57762510|NCT03387202|PROCEDURE|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
57762511|NCT03387202|DIAGNOSTIC_TEST|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
57762512|NCT05802186|PROCEDURE|Computed Tomography|Undergo CT
57762513|NCT05802186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57762514|NCT05802186|PROCEDURE|Positron Emission Tomography|Undergo PET
58129087|NCT04991779|DIAGNOSTIC_TEST|AI-assisted cEEG detection tool|"This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association."
57762515|NCT05802186|OTHER|Quality-of-Life Assessment|Ancillary studies
57762516|NCT05802186|OTHER|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
57762517|NCT05802186|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57762518|NCT05802186|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
57762519|NCT03578614|OTHER|Physical Activity|"3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used."
57762520|NCT00280657|DRUG|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
57762521|NCT00280657|DRUG|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
57762522|NCT00280657|DRUG|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
57762523|NCT03708640|OTHER|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
57762524|NCT03708640|OTHER|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
57762525|NCT03708640|OTHER|Physical Activity Counseling|Group receives baseline counseling on physical activity
57762526|NCT05158101|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57762527|NCT05568524|OTHER|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
57762528|NCT05568524|OTHER|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
57762529|NCT05016726|DEVICE|Intravascular Lithotripsy|Intravascular Lithotripsy and/or Rotational Atherectomy and/or Orbital Atherectomy to the target vessel prior to placing a coronary stent.
57762530|NCT05043701|DRUG|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
57762531|NCT00903734|DRUG|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
57762532|NCT02978001|OTHER|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
57762533|NCT05781139|DIAGNOSTIC_TEST|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
57762534|NCT06215690|DIAGNOSTIC_TEST|Ultrasound measurements|"Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth"
57762535|NCT03263689|DRUG|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
57762536|NCT02457416|OTHER|Peanut|Treatment with peanut in increasing doses until a maintenance dose
57762537|NCT02224963|BEHAVIORAL|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
57762538|NCT02224963|BEHAVIORAL|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
57762539|NCT05098106|DIAGNOSTIC_TEST|Bronchoscopy, blood sampling; testing.|BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
57762540|NCT05291182|DRUG|SY-4835|WEE1 inhibitor
57762541|NCT03120754|PROCEDURE|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
57762542|NCT03120754|PROCEDURE|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
58457076|NCT00115505|OTHER|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
57762543|NCT02000739|GENETIC|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
57762544|NCT00001060|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
57762545|NCT03323580|OTHER|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
57762546|NCT03323580|OTHER|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
57762547|NCT05159401|PROCEDURE|prevention of respiratory failure|Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
57762548|NCT00002802|DRUG|carboplatin|
57762549|NCT00002802|DRUG|cisplatin|
58457077|NCT03239834|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
58457078|NCT02963454|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
57762550|NCT00002802|DRUG|cyclophosphamide|
57762551|NCT00002802|DRUG|dacarbazine|
57762552|NCT00002802|DRUG|doxorubicin hydrochloride|
57762553|NCT00002802|DRUG|etoposide|
57762554|NCT00002802|DRUG|ifosfamide|
57762555|NCT00002802|DRUG|melphalan|
57762556|NCT00002802|DRUG|mesna|
57762557|NCT00002802|DRUG|vincristine sulfate|
57762558|NCT00002802|DRUG|vindesine|
57762559|NCT00002802|PROCEDURE|autologous bone marrow transplantation|
58457079|NCT02963454|DRUG|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
58457080|NCT02963454|DRUG|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
57762560|NCT00002802|PROCEDURE|conventional surgery|
57762561|NCT00002802|RADIATION|low-LET cobalt-60 gamma ray therapy|
58457081|NCT03865446|DRUG|Dacomitinib|anti-cancer agent
57762562|NCT00002802|RADIATION|low-LET electron therapy|
57762563|NCT00002802|RADIATION|low-LET photon therapy|
57762564|NCT00002802|RADIATION|radioisotope therapy|
57762565|NCT06439940|DIAGNOSTIC_TEST|Blood sample extraction|We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
57762566|NCT02629835|OTHER|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
57762567|NCT02629835|OTHER|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
57762568|NCT02150200|OTHER|shorter hospitalization stay|
57762569|NCT02150200|OTHER|questionnaires|
57762570|NCT00005837|DRUG|oxaliplatin|
57762571|NCT02729935|DRUG|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
57762572|NCT02729935|DRUG|Placebo|An equal volume of saline
57762573|NCT00906048|DRUG|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight \> 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
57762574|NCT03389360|DIAGNOSTIC_TEST|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
57762575|NCT03771196|OTHER|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
57762576|NCT03771196|OTHER|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
57762577|NCT03866668|DRUG|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
57762578|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
57762579|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
58457082|NCT02268149|DRUG|BIIL 284 BS|
58457083|NCT02268149|DRUG|Prednisone|
58457084|NCT02268149|DRUG|Placebo|
58457085|NCT06515587|DIAGNOSTIC_TEST|Lewis genotype detection reagent|By evaluating the results of the Lewis gene test combined with the CA19-9 test, different subtypes of pancreatic cancer patients were differentiated to evaluate the prognosis
57762580|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
57762581|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
57762582|NCT02138643|PROCEDURE|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
57762583|NCT02138643|PROCEDURE|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
57762584|NCT02244164|DRUG|Incretinomimetics|
57762585|NCT02244164|DRUG|DPP-4 inhibitors|
57762586|NCT05044325|DRUG|GSK3884464|GSK3884464 will be administered
57762587|NCT05044325|DRUG|Placebo|Placebo to match GSK3884464 will be administered.
57762588|NCT00529321|BIOLOGICAL|MVA-HCV (Immunotherapy)|MVA-HCV
57762589|NCT00709059|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
57762590|NCT00709059|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks
57762591|NCT05152134|BEHAVIORAL|Empowered Relief On-Demand|Tailored interactive digital health treatment for chronic pain
57762592|NCT05152134|BEHAVIORAL|Health Education|The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
57762593|NCT00147901|DRUG|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
57762594|NCT05900622|OTHER|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
58129088|NCT05438797|DRUG|Adoptive TIL-TCM transfer therapy|Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
58129089|NCT05990478|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Participants will have pre- and post-treatment CEM of the affected breast
58129090|NCT05990478|DIAGNOSTIC_TEST|Breast MRI|Pre- and post-NAT breast MRI will be performed for all participants
58457086|NCT05706779|DRUG|Encorafenib Oral Capsule + Cetuximab|Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
58457087|NCT01222845|DRUG|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
58457088|NCT03522298|DRUG|Paxalisib (GDC-0084)|Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
58457089|NCT01132807|BIOLOGICAL|Bleomycin Sulfate|Given IV
58457090|NCT01132807|DRUG|Doxorubicin Hydrochloride|Given IV
58457091|NCT01132807|DRUG|Procarbazine Hydrochloride|Given PO
58457092|NCT01132807|DRUG|Vinblastine Sulfate|Given IV
58457093|NCT01132807|DRUG|Dacarbazine|Given IV
58457094|NCT01132807|DRUG|Cyclophosphamide|Given IV
58457095|NCT01132807|DRUG|Etoposide phosphate|Given IV
58457096|NCT01132807|DRUG|prednisone|Given PO
58457097|NCT01132807|DRUG|Radiation Therapy|Undergo radiation therapy
57762595|NCT05900622|OTHER|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
57762596|NCT04642963|RADIATION|Cardiac Radiosurgery|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
57762597|NCT00722384|DRUG|bevasiranib|
57762598|NCT00722384|DRUG|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
57762599|NCT00873236|BIOLOGICAL|bevacizumab|Given IV
57762600|NCT00873236|BIOLOGICAL|recombinant interferon alpha-2a|Given SC
57762601|NCT05936606|DRUG|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
57762602|NCT05936606|DRUG|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
57762603|NCT01986361|DRUG|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
57762604|NCT01986361|DRUG|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
57762605|NCT00890175|DRUG|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
57762606|NCT00890175|DRUG|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
57762607|NCT06175793|BEHAVIORAL|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
57961011|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center); Each treatment cycle is 14 days, and all drugs are administered on day 1."
57961012|NCT03622099|DRUG|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
57961013|NCT03279003|DEVICE|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
57961014|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem \& Delta-TT cup with a polyethylene insert
57961015|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert
57961016|NCT03093038|DEVICE|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
57961017|NCT05495893|DRUG|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
57961018|NCT05495893|DRUG|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
57961019|NCT05066256|DIAGNOSTIC_TEST|Left ventricular diastolic function|Transthoracic echocardiography Mitral E/e'
57961020|NCT05066256|DIAGNOSTIC_TEST|Inferior vena cava variation|Inferior vena cava variation from ultrasound
57961021|NCT06431061|DEVICE|Lens A (omafilcon B)|15 minutes of daily wear.
57961022|NCT06431061|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
57961023|NCT03847142|OTHER|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
57961024|NCT03847142|OTHER|Outpatient primary care|Usual care delivered through the outpatient primary care setting
57961025|NCT03550066|BEHAVIORAL|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
57961026|NCT03550066|BEHAVIORAL|No affirmation|A health message alone
57961027|NCT02848196|RADIATION|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
57762608|NCT03076372|DRUG|MM-310|MM-310
57762609|NCT04976114|PROCEDURE|Story book with information about surgery techniques|Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
57762610|NCT04976114|PROCEDURE|Video with information about surgery techniques|Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
57762611|NCT04976114|PROCEDURE|Story book and Video with information about surgery techniques|Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
57762612|NCT03763955|BEHAVIORAL|MIRT|"4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)"
57762613|NCT01179360|OTHER|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
57762614|NCT03620838|DRUG|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
57762615|NCT04585438|DRUG|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
57762616|NCT03303469|DRUG|FMISO|FMISO PET/CT imaging at baseline
57762617|NCT03303469|DRUG|FMISO|FMISO PET/CT post TACE
57762618|NCT03303469|DRUG|FMISO|FMISO PET/CT post SBRT
57762619|NCT02875405|PROCEDURE|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
57762620|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt + Vitamin D|cheese \& yogurt with added 420 IU cholecalciferol
57762621|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt|Cheese \& yogurt without added vitamin D
57762622|NCT05841238|DRUG|LY3502970|Administered orally.
57762623|NCT05798039|BEHAVIORAL|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
57762624|NCT03397680|DIAGNOSTIC_TEST|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
57762625|NCT04402463|OTHER|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
57762626|NCT04402463|OTHER|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
57762627|NCT02820363|DEVICE|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids."
57762628|NCT02820363|PROCEDURE|SOC treatment|surgical repair of tibial fracture
57762629|NCT02385734|OTHER|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
57961028|NCT00798226|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
58457098|NCT01132807|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
58457099|NCT01132807|PROCEDURE|computed tomography|Undergo FDG PET/CT
57961029|NCT00798226|DIETARY_SUPPLEMENT|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
57762630|NCT02385734|PROCEDURE|Coronally Advanced Flap|Periodontal plastic surgery technique
57762631|NCT00497640|PROCEDURE|Artificial Neural Network|Use of a predicted optimal CPAP
57762632|NCT01529281|DIETARY_SUPPLEMENT|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.
57762633|NCT01529281|DIETARY_SUPPLEMENT|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
57961030|NCT00538720|DRUG|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
58457100|NCT01132807|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
57961031|NCT00538720|DEVICE|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
57961032|NCT00000896|DRUG|Indinavir sulfate|
57961033|NCT00000896|DRUG|Lamivudine/Zidovudine|
57961034|NCT00000896|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
57961035|NCT00000896|DRUG|Interleukin-12|
57961036|NCT00000896|DRUG|Nevirapine|
57961037|NCT00000896|DRUG|Stavudine|
57961038|NCT00000896|DRUG|Sargramostim|
58129091|NCT00464165|DRUG|rimonabant|
58457101|NCT05218369|DRUG|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
58457102|NCT00267215|DRUG|Lumiracoxib|
58457103|NCT03921827|DEVICE|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
58457104|NCT03147846|PROCEDURE|delayed cord clamping|delay of cord clamping for 60 seconds
58457105|NCT03147846|PROCEDURE|cord milking|active cord milking 5 times
58457106|NCT03910504|DRUG|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.
58457107|NCT03910504|DRUG|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
57762634|NCT05094401|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
57762635|NCT04534634|COMBINATION_PRODUCT|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m\^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10\^7/kg, intravenously infusion."
57762636|NCT03859401|DEVICE|EnMPC (Ensemble Model Predictive Control) AP Controller|This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
57762637|NCT03859401|DEVICE|rMPC (Naïve Model Predictive Control) AP Controller|This AP controller does not have the ability to anticipate exercise activity.
57762638|NCT03704584|DRUG|Treatment Group: Corticosteroid injection|Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.
57762639|NCT03704584|DRUG|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
57762640|NCT03704584|DRUG|Treatment Group: Lidocaine|Subjects will receive an injection of lidocaine (1% lidocaine HCl).
57762641|NCT05813067|DIETARY_SUPPLEMENT|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
57762642|NCT05813067|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
57762643|NCT05582551|OTHER|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
57762644|NCT04045821|DRUG|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
57762645|NCT04045821|DRUG|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
57762646|NCT04045821|PROCEDURE|dilation and curettage|all participants will undergo routine D\&C procedure
57762647|NCT01352585|DRUG|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
57762648|NCT05996328|OTHER|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
57762649|NCT05996328|OTHER|Study -defined standard of care|study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
57961039|NCT00271323|DRUG|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
57961040|NCT00271323|RADIATION|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
57961041|NCT04219150|DEVICE|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
58457108|NCT03416140|OTHER|Therapeutic Exercise|30 minutes per day of therapeutic exercise
58457109|NCT04712955|OTHER|Bloodflow restricted exercise|Low-intensity bloodflow restricted resistance exercise is conducted as traditional knee extension exercise with a load corresponding to 30% of 1 repetition maximum (RM), with concurrent partial occlusion of the circulation by means of inflatable pneumatic cuffs wrapped around the proximal part of the thighs. Cuffs are inflated to a pressure corresponding to 50% of the arterial occlusion pressure, which only compromises venous but not arterial blood flow.
58457110|NCT01488045|DRUG|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
58457111|NCT01488045|DRUG|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
57762650|NCT03145571|PROCEDURE|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
57762651|NCT04264793|BEHAVIORAL|Behavioral Lifestyle Intervention|In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
58129092|NCT00747175|DRUG|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
58458659|NCT03912012|RADIATION|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
57762652|NCT04264793|BEHAVIORAL|Usual Care|Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
57762653|NCT01954368|DRUG|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
57762654|NCT01954368|DRUG|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
57762655|NCT05751031|DRUG|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
57762656|NCT03653507|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
57762657|NCT03653507|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
57762658|NCT03653507|DRUG|capecitabine|Capecitabine will be administered orally twice daily (bid).
57762659|NCT03653507|DRUG|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
57762660|NCT00285493|DRUG|Antibiotics|
57762661|NCT05493423|DEVICE|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
57762662|NCT00087542|DRUG|ACP-103|
57762663|NCT03881280|BEHAVIORAL|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~* Fill in a registration questionnaire, which will tailor recommendations.~* Receive information and video content recommendations.~* Set goals related to their child's lifestyle and tracking progress.~* Earn points by watching the contents.~* Invite children to play a serious game.~* Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
57762664|NCT01478074|DRUG|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC \> 1000
57762665|NCT01478074|DRUG|Cytarabine|2 g/m2 daily from day -6 through -2
57762666|NCT01478074|DRUG|Fludarabine|30 mg/m2 daily from day -6 through -2
57762667|NCT01478074|BIOLOGICAL|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg
57762668|NCT01478074|BIOLOGICAL|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
57762669|NCT05075187|DIAGNOSTIC_TEST|Genetic Screening|Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
57961042|NCT04219150|DRUG|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
57762670|NCT04859660|DRUG|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
57762671|NCT04859660|DRUG|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
57961043|NCT04948398|DRUG|Guselkumab|Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
57961044|NCT05381064|DEVICE|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
57961045|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 5mg, with additional doses of 2.5mg as necessary
57961046|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 10mg, with additional doses of 2.5mg as necessary
57961047|NCT00527579|DRUG|[F-18]FBR|
57961048|NCT06438172|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
57961049|NCT06438172|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
57961050|NCT06438172|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
57961051|NCT06438172|DRUG|HPP2002-1|Placebo drug. Take it once daily for 8 weeks orally.
57961052|NCT02501278|BIOLOGICAL|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~* VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~* INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
57961053|NCT02501278|RADIATION|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
57961054|NCT02501278|DRUG|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
57961055|NCT06093139|DIETARY_SUPPLEMENT|Probiotic capsule|probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules
57961056|NCT06093139|DIETARY_SUPPLEMENT|Placebo|placebo consisted of the same capsules filled with potato starch
57961057|NCT04188184|DRUG|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
57762672|NCT03611504|DEVICE|Hemospray®|Hemospray® application
57762673|NCT05673590|DRUG|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
57762674|NCT05673590|DRUG|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
57762675|NCT05135546|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
57762676|NCT05135546|DRUG|Placebo|6 ml of 0.9% solution of NaCl for inhalation
57762677|NCT04804995|OTHER|There is no intervention.|No intervention.
57762678|NCT02002884|DRUG|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
57762679|NCT02002884|DRUG|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
57762680|NCT02002884|DRUG|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
57762681|NCT04935814|DRUG|Vasopressin, Arginine|Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
57762682|NCT00048880|DRUG|HeFi-1 Monoclonal Antibody|
57762683|NCT02497898|BIOLOGICAL|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
57762684|NCT03690830|OTHER|metabolomics analysis|collect blood samples and endometrial cells
58129093|NCT00747175|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
57762685|NCT00412048|PROCEDURE|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
57762686|NCT01581840|DRUG|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
57762687|NCT01581840|DRUG|Panitumumab|3 or 6 mg/kg (according to dose level)
57762688|NCT02801669|DRUG|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
57762689|NCT02801669|DRUG|placebo|Placebo orally administered once daily.
57762690|NCT03933111|DIAGNOSTIC_TEST|local sound velocity measurement|All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
57762691|NCT02932059|BEHAVIORAL|Metamemory|Metamemory evaluation using a sentence construction strategy
57762692|NCT03784690|OTHER|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
57961058|NCT04188184|DRUG|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
57961059|NCT05350826|OTHER|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
57961060|NCT01090401|DEVICE|Linox smart S DX|ICD lead
57961061|NCT04329195|DRUG|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
57961062|NCT04329195|DRUG|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
57961063|NCT00207467|BEHAVIORAL|Patient-delivered partner treatment|
57961064|NCT00207467|BEHAVIORAL|Booklet-enhanced partner referral|
57961065|NCT01662895|DRUG|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
57961066|NCT01662895|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
57961067|NCT02472132|DEVICE|POC US|Use of point of care ultrasound in insertion of CVC
57961068|NCT04446364|OTHER|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
57762693|NCT03784690|OTHER|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
57762694|NCT03036059|DRUG|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
57762695|NCT04748016|OTHER|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
57762696|NCT04748016|OTHER|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
57762697|NCT03440502|PROCEDURE|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
57762698|NCT04302623|BEHAVIORAL|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
57762699|NCT02269371|OTHER|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
57762700|NCT02269371|OTHER|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
57762701|NCT05034848|PROCEDURE|Assessment of BMD by DXA and HRpQCT|"* DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples"
57762702|NCT04551599|DRUG|Danicopan|A single dose of danicopan (200 milligrams) will be administered orally.
57762703|NCT01320943|DRUG|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
57762704|NCT01320943|OTHER|Stop TDF|Participants will stop TDF therapy
57762705|NCT05529160|DEVICE|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
57762706|NCT00430053|GENETIC|gene rearrangement analysis|
57762707|NCT00430053|GENETIC|polymerase chain reaction|
57762708|NCT00430053|GENETIC|proteomic profiling|
57762709|NCT00430053|OTHER|flow cytometry|
57762710|NCT00430053|OTHER|immunohistochemistry staining method|
57762711|NCT00430053|PROCEDURE|biopsy|
57762712|NCT05799326|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
58457112|NCT01488045|DRUG|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
58457113|NCT02093507|OTHER|parents manipulation|parents perform manipulation the child foot to correct the deformity
57762713|NCT05799326|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.
57762714|NCT03192644|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
57762715|NCT03192644|PROCEDURE|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
57762716|NCT03192644|DRUG|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
57762717|NCT03192644|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
57762718|NCT00374660|DRUG|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
57762719|NCT00374660|DRUG|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
57762720|NCT05732792|OTHER|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
57762721|NCT04962399|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
57762722|NCT02717169|DEVICE|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
57762723|NCT03572660|BIOLOGICAL|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
57762724|NCT06129253|OTHER|Urine Sample Collection|When urine is collected as a sample in either CSS or LS, first flow urine samples will be collected
57762725|NCT06129253|OTHER|Self-collected Vaginal Swab|Self-collected Vaginal Swab will be collected by the participant under the supervision of a trained nurse or other health care worker.
57762726|NCT06129253|OTHER|Blood Samples|If funding permits, a blood sample may be collected from participants in LS once during the follow-up period. If blood sample collection was not feasible during a visit, two additional attempts may be made to collect blood samples from LS participants during the subsequent follow-up visits.
57762727|NCT04837872|OTHER|Multimodal Physical Therapy (MPT)|Individualized physical therapy and static progressive splint (flexion with or without extension splint).
57762728|NCT02335151|DRUG|Desflurane|Apply desflurane as anesthetic
57762729|NCT01177514|DRUG|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
57762730|NCT01177514|DRUG|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
57762731|NCT00182962|BEHAVIORAL|Geriatric Resources for Assessment & Care of Elders (GRACE)|
57762732|NCT05537402|DRUG|Atezolizumab and bevacizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
57762733|NCT05537402|RADIATION|transarterial chemoembolization (TACE) or transarterial radioembolization (TARE|TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
57762734|NCT05235620|OTHER|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
57762735|NCT03146039|RADIATION|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
58457114|NCT05086497|DIAGNOSTIC_TEST|Whole Brain Spectroscopy Imaging Array Mapping Layout|All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
58457115|NCT00859547|BIOLOGICAL|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
58457116|NCT03090308|OTHER|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for \> 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
58457117|NCT03093896|DIETARY_SUPPLEMENT|snack mix|commercial cereal mix with bits of beef jerky and coconut
58457118|NCT03093896|DIETARY_SUPPLEMENT|almonds, 1.5 oz|almonds, 1.5 oz/day
58457119|NCT03093896|DIETARY_SUPPLEMENT|almonds, 3 oz|almonds, 3.0 oz/day
57762736|NCT01273428|DRUG|HP011-101|
57762737|NCT01273428|DEVICE|HP-828-101|
57762738|NCT01273428|OTHER|Standard Care|
57762739|NCT03082716|DRUG|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
57762740|NCT03082716|DRUG|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
57762741|NCT06539975|DRUG|Evening Primrose Oil 1000 MG|Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
57762742|NCT06183814|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
57762743|NCT04667364|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
57762744|NCT02261584|DEVICE|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
57762745|NCT02261584|DEVICE|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
57762746|NCT00910455|DRUG|SRX246|single oral dose of SRX246 capsule
57762747|NCT00910455|DRUG|Placebo|Single oral dose of placebo capsule
57961069|NCT04446364|OTHER|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
57961070|NCT05409547|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
57961071|NCT06148558|OTHER|Sunscreen Moisturizer|A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
57961072|NCT06148558|OTHER|Gentle Cleansing Lotion|A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
57961073|NCT06148558|OTHER|Facial Moisturizer|A provided facial moisturizer (Goodier) was used 1x daily (PM).
57961074|NCT05143073|BEHAVIORAL|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
57762748|NCT04378023|DRUG|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
57762749|NCT04378023|PROCEDURE|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
57762750|NCT05381298|PROCEDURE|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
57762751|NCT05381298|PROCEDURE|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
57762752|NCT05688735|OTHER|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
57762753|NCT05688735|OTHER|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
57762754|NCT05481216|OTHER|COVID-19|Diagnosed with COVID-19 infection
57762755|NCT05481216|OTHER|HIV-1 infection|Diagnosed with HIV-1 infection
57762756|NCT04902222|DRUG|Morphine|Administration of 0.1 mg/kg (IBW) intravenous morphine
57762757|NCT04187391|DEVICE|Active tDCS|Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
57762758|NCT04187391|DEVICE|Placebo tDCS|Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
57762759|NCT04187391|BEHAVIORAL|Language training|patients receive language training
57762760|NCT04187391|BEHAVIORAL|Unstructured cognitive training|patients receive unstructured cognitive training.
57762761|NCT01165073|DIETARY_SUPPLEMENT|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
57762762|NCT01165073|DIETARY_SUPPLEMENT|Normal oral intake & supplementation if necessary|Enteral nutrition
57762763|NCT06624709|DRUG|Iron Supplement|The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
57762764|NCT00305383|DRUG|Viramidine|
57762765|NCT00305383|DRUG|Peginterferon alfa-2b|
57762766|NCT03844022|DIAGNOSTIC_TEST|MRI|magnetic resonance imaging
57762767|NCT03264963|OTHER|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
57762768|NCT03264963|OTHER|Control|Recording of sleep environment 2 nights per week for 12 weeks
57762769|NCT04285632|OTHER|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
57762770|NCT01949688|BIOLOGICAL|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
58129094|NCT05975970|DEVICE|MyoTrain AR|MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.
57762771|NCT06510452|DRUG|2000 mg of Cefazolin|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
57762772|NCT06510452|DRUG|500 mg of Metronidazole IV|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
57762773|NCT06510452|DRUG|NACL 0.9% 100 ml|receive 100 ml NACL0.9% without any antibiotics in it.
57762774|NCT02013388|DRUG|N91115|Given PO daily for 14 days
57762775|NCT02013388|DRUG|Placebo|Given PO daily for 14 days
57762776|NCT02013388|DRUG|N91115|Given PO only on Day 1
57762777|NCT02013388|DRUG|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
57762778|NCT03587298|PROCEDURE|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
57762779|NCT05137379|BEHAVIORAL|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
57762780|NCT02889666|DRUG|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762781|NCT02889666|DRUG|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762782|NCT02889666|DRUG|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762783|NCT02889666|DRUG|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762784|NCT02889666|DRUG|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762785|NCT02889666|DRUG|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
57762786|NCT02889666|DRUG|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
58457120|NCT01557426|OTHER|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
57762787|NCT02889666|DRUG|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
57762788|NCT06040034|DRUG|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
57762789|NCT06318442|DRUG|Semaglutide Oral Product|Oral semaglutide 3mg once uptitrated to twice daily
57762790|NCT06318442|DRUG|Metformin Oral Tablet|Metformin modified release tablets 500mg once daily uptitrated to twice daily).
57762791|NCT06318442|DRUG|Placebo|Placebo tablets
57762792|NCT04966143|BIOLOGICAL|LY011|Targeting CLDN 18.2 Car-T injection
57762793|NCT02464683|DIETARY_SUPPLEMENT|VitaminD|200 International Units (oral dose) daily of 60 days
57762794|NCT03021135|PROCEDURE|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
57762795|NCT03021135|PROCEDURE|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
57762796|NCT05514262|OTHER|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
57762797|NCT05514262|DEVICE|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
57762798|NCT01644201|DIETARY_SUPPLEMENT|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
57762799|NCT01644201|DIETARY_SUPPLEMENT|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
57762800|NCT00390195|DRUG|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
58129095|NCT05975970|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
58129096|NCT03312257|COMBINATION_PRODUCT|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
58129097|NCT05300984|OTHER|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
58129098|NCT05300984|OTHER|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
58457121|NCT02604381|DIETARY_SUPPLEMENT|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
57762801|NCT00390195|DRUG|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
57762802|NCT03794375|OTHER|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
57762803|NCT03794375|OTHER|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
57762804|NCT04845464|OTHER|Cognitive Assessment (not diagnostic)|Sleep quality and cognition will be assessed in young adults
57762805|NCT03583645|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
57762806|NCT03583645|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
57762807|NCT02282410|DRUG|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
57762808|NCT00892489|DRUG|ER OROS Paliperidone|
57762809|NCT06449716|OTHER|12-week progressive power-oriented resistance exercise program|2x/week, 35-45 min sessions, on leg press machine
57762810|NCT05058209|DRUG|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
58129099|NCT05300984|OTHER|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
58129100|NCT04099888|DRUG|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
58129101|NCT04099888|DRUG|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
58457122|NCT02604381|OTHER|Placebo|
58457123|NCT00647296|DRUG|Placebo|Placebo: 2 tablets taken orally twice daily
58457124|NCT00647296|DRUG|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
58129102|NCT00032162|DRUG|carboplatin|AUC 6 q4w
58129103|NCT00032162|DRUG|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
58129104|NCT05518435|OTHER|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
58129105|NCT00920140|DRUG|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
58129106|NCT00920140|DRUG|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
58129107|NCT04986228|OTHER|Digital aftercare|The intervention group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge. These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.
58457125|NCT00647296|DRUG|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
58457126|NCT00647296|DRUG|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
58457127|NCT05275816|OTHER|Comparing the appropriateness of our practice and the usability of the AUC through comparing the actual management provided at our institution with that recommended by the AUC.|"The AUC application for carpal tunnel syndrome management requires four patients' variables to generate appropriateness ratings for six different treatment options. Each procedure is rated as appropriate, maybe appropriate, or rarely appropriate. The six procedures include splint, steroid injection, carpal tunnel release, oral steroids or Ketoprofen phonophoresis, investigation of alternative diagnoses, and further investigation using an electro-diagnostic study.~To judge the usability of the AUC for the management of carpal tunnel syndrome, the required parameters of each patient were collected and entered into the AUC application by two independent authors to generate the appropriateness rating of the provided treatment for each patient. Afterwards, the agreement between the AUC recommendations and the actual treatment that was provided at our institution was assessed."
58457128|NCT00822614|DRUG|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
58457129|NCT00822614|DRUG|Opioid|Current optimized BTP treatment
57762811|NCT05058209|DRUG|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
57762812|NCT06324019|OTHER|putting on an examination gown|During the gynecological examination, the patient in the experimental group will be made to wear an examination gown, while the patient in the control group will use the routine practice of the hospital. In this way, with the gynecological examination clothing to be developed, the body privacy of the patients will be protected during the examination. In addition, women will feel less anxiety during gynecological examination and important steps will be taken in maintaining women\&#39;s health by ensuring regular gynecological examination.
57762813|NCT05779306|DEVICE|IOL Master 700|Biometry using the IOL Master 700
57762814|NCT05779306|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
57762815|NCT05779306|DEVICE|MS-39|Corneal Topography using the MS-39
57762816|NCT05779306|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
57762817|NCT05779306|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
57762818|NCT05779306|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
57762819|NCT00002396|DRUG|Tenofovir disoproxil fumarate|
57762820|NCT02364180|DIAGNOSTIC_TEST|Electromyography (EMG)|
57762821|NCT01996358|DRUG|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
57762822|NCT01996358|DRUG|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
57762823|NCT01996358|DRUG|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
57762824|NCT04006925|DRUG|Sodium Oxybate|"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
57762825|NCT04006925|OTHER|Placebo|Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
57762826|NCT02206217|DEVICE|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
57762827|NCT01923805|DEVICE|Vitagel|Vitagel
57762828|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
57762829|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
57762830|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
57762831|NCT02556151|PROCEDURE|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
57762832|NCT04131478|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
58457130|NCT00364585|DEVICE|GreenLight Model 120 Laser System|
58457131|NCT00898963|GENETIC|gene expression analysis|
57762833|NCT02935049|PROCEDURE|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
57762834|NCT01918696|BEHAVIORAL|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
57762835|NCT01918696|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
57762836|NCT01918696|BEHAVIORAL|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
57762837|NCT02173730|DRUG|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
57762838|NCT02173730|DRUG|Pantoprazole|Pantoprazole tablet 40 mg
57762839|NCT02415348|DEVICE|Fibroscan|
57762840|NCT02110732|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|
57762841|NCT00235924|DRUG|soy isoflavone|
57762842|NCT03600675|OTHER|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
58457132|NCT00898963|GENETIC|microarray analysis|
58457133|NCT00898963|GENETIC|polymorphism analysis|
58457134|NCT00898963|OTHER|diagnostic laboratory biomarker analysis|
58457135|NCT00898963|OTHER|immunohistochemistry staining method|
58457136|NCT00898963|OTHER|immunologic technique|
58457137|NCT02728180|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
58457138|NCT02728180|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
58457139|NCT05103007|PROCEDURE|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
57762843|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
57762844|NCT06618105|DRUG|Test Placebo|Matching Placebo of T inhalation aerosol
57762845|NCT06618105|DRUG|Reference Placebo|Matching Placebo of R inhalation aerosol
57762846|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
57762847|NCT02121678|OTHER|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
57762848|NCT02121678|OTHER|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
57762849|NCT05089435|DEVICE|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
57762850|NCT04787510|DRUG|low molecular weight Heparin as standard of care treatment|STANDARD OF CARE
57762851|NCT03012061|DRUG|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
57762852|NCT03012061|DRUG|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
57762853|NCT03012061|DRUG|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
57762854|NCT03012061|DRUG|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
57762855|NCT06147518|DRUG|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
57762856|NCT06147518|DRUG|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%
57762857|NCT06147518|DRUG|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%
57762858|NCT06023602|DRUG|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
57762859|NCT06023602|DRUG|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
57762860|NCT02949401|BEHAVIORAL|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
57762861|NCT01871558|DRUG|Vildagliptin|50 mg b.i.d
57762862|NCT01871558|DRUG|Metformin|metformin is to be kept unchanged
57762863|NCT01871558|DRUG|sulfonylurea (SU)|
57762864|NCT01871558|DRUG|Basal Insulin|
57762865|NCT00401635|DRUG|liposomal doxorubicin|
57762866|NCT00401635|DRUG|carboplatin|
57762867|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
57762868|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
58457140|NCT05103007|PROCEDURE|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
58457141|NCT03292835|DEVICE|LeiProtect®|Filmogenic dressing gel
58458660|NCT01746368|OTHER|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
57762869|NCT01799460|DRUG|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
57762870|NCT01799460|DRUG|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
57762871|NCT05224635|PROCEDURE|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
57762872|NCT00818363|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
57762873|NCT00818363|DRUG|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
57762874|NCT01845974|DEVICE|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
57762875|NCT01845974|DEVICE|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
57762876|NCT03873220|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
58129108|NCT04986228|OTHER|TAU|The control group will receive the regular follow-up consultations in the clinic (treatment-as-usual, TAU). This includes at least one consultation with the case-leading therapist from the previous inpatient stay about 6 weeks after discharge. The assessment consisting of questionnaires at multiple time points about different topics is the same as in the intervention group.
58129109|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
57762877|NCT03873220|DEVICE|Sleep Monitor|Remote Sensor
57762878|NCT03873220|DEVICE|Polysomnography|Sleep Monitor
57762879|NCT03873220|DEVICE|Videography|Thermal Camera
58457142|NCT01600885|DRUG|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
57762880|NCT00637819|DRUG|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
57762881|NCT04639193|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
57762882|NCT04639193|DRUG|Eszopiclone|Eszopiclone tablet (encapsulated)
57762883|NCT04639193|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
57762884|NCT04639193|DRUG|Venlafaxine|Venlafaxine capsule
57762885|NCT01359267|DRUG|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
57762886|NCT05398380|OTHER|Liver transplantation|Liver transplantation
57762887|NCT00385554|DRUG|UC-781 carbomer gel, 0.1% and 0.25%|
58457143|NCT01600885|DRUG|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
57762888|NCT03292601|DEVICE|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
57762889|NCT03292601|OTHER|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
57762890|NCT01942902|DEVICE|Continuous Glucose Monitoring System|
57762891|NCT01995448|BIOLOGICAL|Blood test|Residue of blood further to NFS.
58129110|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
57762892|NCT01454635|DRUG|Sertraline|dosage,frequency and duration
57762893|NCT01407354|DEVICE|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
57762894|NCT01407354|OTHER|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
57762895|NCT02780830|DRUG|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
57762896|NCT02780830|DRUG|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
57762897|NCT05643599|DIETARY_SUPPLEMENT|Mad Honey|mad honey (80 mg/kg); (n:6)
57762898|NCT05643599|DIETARY_SUPPLEMENT|Normal Honey|normal honey (80 mg/kg),(n:6)
57762899|NCT05643599|DIETARY_SUPPLEMENT|Control|Control
57762900|NCT05767528|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
57762901|NCT04227080|DRUG|BH4|oral administration of 20 mg/kg KUVAN (BH4)
57762902|NCT05103163|OTHER|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
57762903|NCT02815995|DRUG|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
57762904|NCT02815995|DRUG|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
58129111|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
58129112|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
58129113|NCT03929367|DRUG|Oxytocin|Single IV administration of oxytocin
58129114|NCT05360316|DEVICE|ESWT|extracorporeal shock wave therapy
58129115|NCT01562496|BEHAVIORAL|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
57762905|NCT06192147|DIETARY_SUPPLEMENT|protein restricted diet combined with vitamin D intervention|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
57762906|NCT04963894|OTHER|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
57762907|NCT04963894|OTHER|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
57762908|NCT04389502|DEVICE|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
57762909|NCT04389502|OTHER|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
57762910|NCT06030401|DEVICE|Transthoracic Ultrasound|Sonar of The Chest
57762911|NCT04048863|DEVICE|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
57762912|NCT04048863|DEVICE|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
57762913|NCT00673062|DRUG|SCH 900538|(4X50mg Capsules)
57762914|NCT00673062|DRUG|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
57762915|NCT00673062|DRUG|Placebo Capsules|Placebo
57762916|NCT04614883|DEVICE|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
57762917|NCT04614883|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
57762918|NCT03918070|DEVICE|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC \& the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
57762919|NCT03233061|DIAGNOSTIC_TEST|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
57762920|NCT06524076|PROCEDURE|Partial Pulpotomy|After removing caries high-speed handpiece with water coolant using a round diamond bur. Once there is an exposure, the bur is changed with another sterile one with which the superficially inflamed pulp tissue will be gently removed to a depth of 1-3 mm beneath the pinpoint pulp exposure that occurred at the end of caries removal. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
57762921|NCT06524076|PROCEDURE|Complete pulpotomy|After removing caries with a large round bur, the access cavity will be opened. Excavation of inflamed coronal pulp tissues will be done using a sharp excavator. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
57762922|NCT00508352|PROCEDURE|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
57762923|NCT03109821|OTHER|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
57762924|NCT03036501|DRUG|[^14C]-Risdiplam|\[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.
57762925|NCT00744094|DIETARY_SUPPLEMENT|protein drink|250 ml protein hydrolysate solution
57762926|NCT00744094|BEHAVIORAL|Resistance training|12 weeks resistance training, 3 days per week
57762927|NCT06089252|DRUG|walnut extract|Four times a day over a 10-day period
58129116|NCT03712553|BEHAVIORAL|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
57762928|NCT04121481|DIETARY_SUPPLEMENT|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
57762929|NCT04121481|DIETARY_SUPPLEMENT|Broad Spectrum Safety|Benefits in Sports Nutrition
57762930|NCT03592225|BEHAVIORAL|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
57762931|NCT05095363|BEHAVIORAL|PCplanner|A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
57762932|NCT05956548|PROCEDURE|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
57762933|NCT01653080|PROCEDURE|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
57762934|NCT00258180|BIOLOGICAL|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
57762935|NCT00258180|DRUG|cyclophosphamide|Administered IV over 1 hour on days 1-4
57762936|NCT05298098|DRUG|Hypertonic Saline Solution|Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.
57762937|NCT05298098|DRUG|Placebo|Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
57762938|NCT03166475|PROCEDURE|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
57762939|NCT02991144|GENETIC|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
57762940|NCT02991144|DRUG|Reactive Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
57762941|NCT02991144|DRUG|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
57762942|NCT05684913|PROCEDURE|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
57762943|NCT05684913|PROCEDURE|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
57762944|NCT04879459|OTHER|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
57762945|NCT06540001|DEVICE|Automated visual acuity|The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
57762946|NCT05694403|OTHER|Survey|Questionnaire
57762947|NCT01781390|OTHER|Placebo|Matching placebo solution for infusion.
57762948|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
57762949|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
57762950|NCT01320930|BEHAVIORAL|Pulmonary rehabilitation|
57762951|NCT01320930|BEHAVIORAL|conventional care|
57762952|NCT02529475|DRUG|Gadoteric acid|Comparison with patients with Meniere's disease
57762953|NCT05338918|OTHER|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
57762954|NCT05338918|OTHER|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
57762955|NCT01978366|DRUG|HT-100|May be administered in either fed or fasted state
57762956|NCT01759654|BIOLOGICAL|AdimFlu-V|
57961075|NCT05143073|BEHAVIORAL|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
57961076|NCT05813197|BEHAVIORAL|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
58129117|NCT03712553|BEHAVIORAL|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
57961077|NCT05813197|BEHAVIORAL|Usual services|Usual services
57961078|NCT01178658|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
58129118|NCT03712553|BEHAVIORAL|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
58129119|NCT03712553|BEHAVIORAL|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
58457144|NCT03955835|DEVICE|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
58457145|NCT01057953|GENETIC|Blood drawn|Blood drawn for patient
58457146|NCT04418778|BEHAVIORAL|BEAR|Building Empowerment and Resilience Therapy group
57762957|NCT06625294|PROCEDURE|Task -oriented training with bilateral functional task training exercises|"Task oriented training approach with BFTT will consists of different tasks including:~Hand Movements:~1. Fold a small cloth towel with both hands with initially putting the towel flat on the table and gradually folding it into a large towel roll.~2. Put a small amount of putty on patient's table and instruct to roll it with the help of rolling pin moving it back and forth using both the hands.~3. Place a jar with a removable lid on the table and instruct the patient to remove lid from the jar completely by holding the jar with either hand and remove the lid with the alternate hand.~4. Pouring water: Pour water from jug while holding the jug in unaffected hand to cup/glass that is held in affected hand and activity can be done the other way round as well.~5. Pour water from one hard plastic cup to another while alternatively involving both the hands (we must not allow deformation of the cup)~6. Plunging action with coffee maker against water resistance:Fill the coffee maker with water."
57762958|NCT06625294|PROCEDURE|Task Oriented Training with CIMT|"• Hand Movements:~1. Sitting at a table (Wrist Extension): Affected forearm resting on table. Place cylindrical object in palm of patient's hand. Patient asked to move the hand towards the forearm (dorsiflexion) by extending the wrist - no elbow flexion allowed.~2. Sitting at a table (Radial Deviation of Wrist): Therapist should place forearm with ulnar side on table in mid-pronation / supination position. Thumb in line with forearm and wrist in extension. Fingers around cylindrical object. Patient is asked to lift hand off table. No wrist flexion or extension.~Advanced Hand Activities:~1. Have the patient reach forward to pick up the top of a pen with their affected hand, bring the affected arm back to their side and put the pen cap down in front of them.~2. Place (beans), in a teacup an arm's length away on the affected side. Place another teacup an arm's length away on the intact side. Have the patient pick up one beans with their affected hand and place the beans in the cup on the"
57762959|NCT01491074|DRUG|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
57762960|NCT01491074|DRUG|NaCl 0.9% 100 ml|Placebo
57762961|NCT02684201|DEVICE|Boston Scientific Stimulator Lead|A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
57762962|NCT01671839|DEVICE|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
57762963|NCT04498195|BEHAVIORAL|increased exercise and physical activity|Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
57762964|NCT00079638|DRUG|Niacin|
57762965|NCT00079638|DRUG|Atorvastatin|
57762966|NCT00079638|DRUG|Simvastatin|
57762967|NCT00079638|DRUG|Ezetimibe|
57762968|NCT00079638|DRUG|Rosuvastatin|
57762969|NCT05296291|DEVICE|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
58457147|NCT05514769|PROCEDURE|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
58457148|NCT04706962|DRUG|TH1902|Intravenous infusion
58457149|NCT04123522|PROCEDURE|anterior approach|anterior approach
57762970|NCT05296291|DEVICE|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
57762971|NCT05296291|DEVICE|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
58457150|NCT04123522|PROCEDURE|posterior appraoch|posteiror appraoch
58457151|NCT04757493|DRUG|Prucalopride 2mg|Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
58457152|NCT01475591|BEHAVIORAL|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
57762972|NCT05084222|DRUG|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
57762973|NCT05084222|DRUG|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
57762974|NCT05084222|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
57762975|NCT01074892|DRUG|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
58457153|NCT02063204|DRUG|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
58457154|NCT05806463|BEHAVIORAL|Mother's Time|Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
58457155|NCT02919228|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
58457156|NCT02383563|DRUG|metformin extended release|
57762976|NCT01074892|DRUG|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
57762977|NCT01074892|DEVICE|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
57762978|NCT00219440|OTHER|Actos plus standard diet|Actos plus standard diet
57961079|NCT04934761|PROCEDURE|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV\< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV \<10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV\<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
57762979|NCT00219440|OTHER|Actos plus structured diet|Actos plus structured diet
57762980|NCT00219440|OTHER|Metformin plus standard diet|Metformin plus standard diet
57762981|NCT05536778|OTHER|Realization of the 3 tests|The participants will have to perform the isokinetic evaluation during one session and the two functional tests during another session. Those sessions will be separated by 14 days.
57762982|NCT03044522|OTHER|Opioid Education|
57762983|NCT06386263|DRUG|Trastuzumab deruxtecan|This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.
57762984|NCT03117725|DRUG|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
57762985|NCT03117725|DRUG|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
57762986|NCT06321458|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
57762987|NCT06321458|BEHAVIORAL|Usual care|Usual care
57762988|NCT01295723|RADIATION|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
57762989|NCT01295723|RADIATION|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
57762990|NCT06480214|PROCEDURE|endoscopic spine surgery|we would administer the endoscopic spine surgery to patients with Lumbar spinal stenosis and Lumbar disc herniation.
57762991|NCT03396484|DRUG|Methyldopa|Tablet for oral dosing
57762992|NCT03396484|DRUG|Placebo|Tablet for oral dosing
57762993|NCT02034253|DRUG|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
57762994|NCT00817375|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
57762995|NCT00817375|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
57762996|NCT05157074|BEHAVIORAL|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
57762997|NCT01614639|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
57762998|NCT03736343|DRUG|Alcohol|Participants will complete two drinking sessions.
57762999|NCT01694602|BIOLOGICAL|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
57763000|NCT06116201|OTHER|Estradiol|Estradiol
57763001|NCT06116201|OTHER|Estradiol and Anti-Androgen|Estradiol and Anti-Androgen
57763002|NCT06116201|OTHER|No intervention|No intervention
57763003|NCT05425251|DIAGNOSTIC_TEST|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
57763004|NCT03482856|BEHAVIORAL|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
57961080|NCT04934761|PROCEDURE|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
57961081|NCT06268691|OTHER|Insecticide Coating INESFLY|The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
57763005|NCT03482856|BEHAVIORAL|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
57763006|NCT02060591|DRUG|Exparel|
57763007|NCT02060591|DRUG|Marcaine|
57763008|NCT01615354|DRUG|Aleglitazar|Multiple oral doses
57763009|NCT01615354|DRUG|Microgynon®|Multiple oral doses
57763010|NCT01615354|DRUG|Placebo|Multiple oral doses
57763011|NCT02585596|DRUG|YH23537 1000mg/day|YH23537 500mg 2 tab
57763012|NCT02585596|DRUG|YH23537 2000mg/day|YH23537 500mg 4 tab
57763013|NCT02585596|DRUG|YH23537 3000mg/day|YH23537 500mg 6 tab
57763014|NCT02585596|DRUG|placebo|YH23537 500mg tab placebo
57763015|NCT06287996|OTHER|footbath and actigraphy|Receive warm water foot bath for 4 weeks, 1 hour before going to bed every night (7-9PM), temperature 42℃ for 20 minutes, water depth 10cm above the ankle joint and wearing an actigraphy for 4 weeks
57763016|NCT06287996|DEVICE|actigraphy|Wearing an actigraphy for 4 weeks
57763017|NCT02555462|DEVICE|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
57763018|NCT02635165|DEVICE|Thoracic osteosyntheses with Stracos|
57763019|NCT02293746|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
57763020|NCT00600379|DEVICE|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
57763021|NCT03713021|DEVICE|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
57763022|NCT05023135|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
57763023|NCT00487734|RADIATION|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
57763024|NCT00487734|DRUG|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
57961082|NCT06277388|DEVICE|Impedance cardiography|The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).
57961083|NCT00772668|DRUG|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
58129120|NCT01532622|DIETARY_SUPPLEMENT|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
57763025|NCT05582096|DRUG|LY3457263|Administered SC.
57763026|NCT05582096|DRUG|Tirzepatide|Administered SC.
57763027|NCT05582096|DRUG|Placebo|Administered SC.
57763028|NCT04079530|DRUG|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
58129121|NCT01532622|OTHER|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
57763029|NCT04079530|DRUG|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
57763030|NCT04079530|DRUG|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
57763031|NCT04222062|DRUG|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
57763032|NCT01201603|DIETARY_SUPPLEMENT|orange juice|250ml of orange juice or a sugars matched orange drink
57763033|NCT01031901|DRUG|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
57763034|NCT01031901|DRUG|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
57763035|NCT01031901|DRUG|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
57763036|NCT01021774|PROCEDURE|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
57763037|NCT02675790|DRUG|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
57763038|NCT02675790|DRUG|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
57763039|NCT05116449|BEHAVIORAL|Quality of life questionnaires|Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
57763040|NCT05634967|OTHER|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
57763041|NCT06456099|DRUG|Ultrasound-guided corticosteroid injection|Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
57961084|NCT00772668|DRUG|Bortezomib|Administered intravenously per protocol.
57961085|NCT00772668|DRUG|Cyclophosphamide|Administered intravenously per protocol.
57961086|NCT00772668|DRUG|Prednisone|Administered orally (PO) per protocol.
57961087|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
57961088|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
57961089|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
57961090|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
57961091|NCT01393197|OTHER|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
57763042|NCT06456099|BEHAVIORAL|Home exercise program|"Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog)."
57763043|NCT06456099|BEHAVIORAL|Patient information leaflet|"In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice."
57763044|NCT04795310|DEVICE|Pulsed dye laser|"PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment."
57763045|NCT05649345|DRUG|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
57763046|NCT03281824|BIOLOGICAL|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
57763047|NCT02833441|BEHAVIORAL|Peer Support|
58457157|NCT06110663|DRUG|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
57763048|NCT06564636|DEVICE|CATALYSTEM|CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
57763049|NCT02813746|DIETARY_SUPPLEMENT|Fitness program|
57763050|NCT02813746|BEHAVIORAL|Stop smoking|
57763051|NCT02813746|PROCEDURE|Endometrial fluid collection|
57763052|NCT05093387|DRUG|Carboplatin|Given IV
57763053|NCT05093387|BIOLOGICAL|Pembrolizumab|Given IV
57763054|NCT05093387|GENETIC|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
57763055|NCT03245255|DRUG|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
57763056|NCT04699916|OTHER|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
57763057|NCT00576732|DRUG|Placebo|Oral solution qd or bid for 6 weeks
57763058|NCT00576732|DRUG|Risperidone high dose|Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
57763059|NCT00576732|DRUG|Risperidone low dose|Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
57763060|NCT03999268|BEHAVIORAL|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
57763061|NCT03999268|BEHAVIORAL|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
57763062|NCT02452684|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
57763063|NCT02696902|DRUG|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
57961092|NCT05354986|OTHER|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
57763064|NCT02696902|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
57763065|NCT01235572|PROCEDURE|standard follow-up care|Undergo early discharge and standard outpatient care
57763066|NCT01235572|OTHER|medical chart review|Undergo early discharge and standard outpatient care
57763067|NCT01235572|PROCEDURE|quality-of-life assessment|Ancillary studies
57763068|NCT02080182|DRUG|Acetylcysteine|
57763069|NCT02080182|DRUG|placebo acetylcysteine|
57763070|NCT05022095|OTHER|Questionnaires|Diverse questionnaires have to be filled in.
57763071|NCT01460160|DRUG|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
57763072|NCT06625827|DRUG|Digoxin|Oral administration
57763073|NCT06625827|DRUG|Nemtabrutinib|Oral administration
57763074|NCT05978505|DRUG|Reboxetine 4 MG Oral Tablet|7 nightly doses (4mg) to commence after surgery.
57763075|NCT05978505|DRUG|Placebo|7 nightly doses to commence after surgery.
57763076|NCT05011123|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
57763077|NCT05011123|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
57763078|NCT05299021|PROCEDURE|Double-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
57763079|NCT05299021|PROCEDURE|Single-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
57763080|NCT03790943|DIAGNOSTIC_TEST|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
57763081|NCT04006561|RADIATION|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
57763082|NCT04860960|DRUG|Hydroxypropyl-beta-cyclodextrin|Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
57763083|NCT04860960|DRUG|Placebo|0.5N saline provided every 2 weeks intravenously
57763084|NCT06230068|OTHER|Expressive writing|See description under arm/group description.
57763085|NCT04919902|PROCEDURE|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
57961093|NCT05354986|OTHER|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
57763086|NCT04472377|DEVICE|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
57763087|NCT03051022|DRUG|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
57763088|NCT03051022|DRUG|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
57763089|NCT04636346|BEHAVIORAL|Acceptance and Commitment Therapy|Seven group sessions
57763090|NCT04636346|OTHER|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
57763091|NCT04116749|OTHER|Water|Drink water freely until 2 hours before anesthesia.
57763092|NCT00186498|DRUG|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
57763093|NCT00186498|DRUG|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
57763094|NCT01364922|DRUG|hydrocodone/acetaminophen extended release|
57763095|NCT01364922|DRUG|Placebo|
57763096|NCT05999708|DRUG|GSK4381406|GSK4381406 will be administered.
57763097|NCT05999708|DRUG|Placebo|Placebo will be administered.
57763098|NCT05999708|DRUG|Indomethacin|Indomethacin will be administered.
57763099|NCT05929235|DRUG|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
57763100|NCT06283446|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
57763101|NCT06283446|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
57763102|NCT00766454|GENETIC|DNA analysis|
57763103|NCT00766454|GENETIC|mutation analysis|
57763104|NCT00766454|GENETIC|polymorphism analysis|
57763105|NCT00766454|OTHER|laboratory biomarker analysis|
57763106|NCT00766454|OTHER|medical chart review|
57763107|NCT00766454|OTHER|questionnaire administration|
57763108|NCT00766454|PROCEDURE|evaluation of cancer risk factors|
57763109|NCT04508556|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
57763110|NCT04508556|DIAGNOSTIC_TEST|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
57763111|NCT04508556|DIAGNOSTIC_TEST|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
57961094|NCT03570112|DRUG|SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg|sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
58457158|NCT06110663|DRUG|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
57763112|NCT01081041|DRUG|Cetuximab|Administered intravenously
57763113|NCT01081041|DRUG|Cisplatin|Administered intravenously
57763114|NCT01081041|DRUG|Carboplatin|Administered intravenously
57763115|NCT01081041|DRUG|5-Fluorouracil|Administered intravenously
57763116|NCT04501289|DRUG|Low dose magnesium sulphate|Participants in this arm will receive 4g of 20% intravenous (I.V.) MgSO4 (Magphate®) given over 10 minutes, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 administered intramuscularly 4 hourly for 24 hours, for participants with severe preeclampsia and for 24 hours post delivery or post last seizure episode, whichever occurs last, for cohorts with eclampsia.
57763117|NCT04501289|DRUG|Pritchard regimen|Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
57763118|NCT04338425|BEHAVIORAL|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
57763119|NCT04338425|BEHAVIORAL|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
57763120|NCT06315140|OTHER|Nutrition|The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.
57763121|NCT00000157|DRUG|Aspirin|
57763122|NCT06061432|PROCEDURE|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
57961095|NCT03308396|DRUG|Guadecitabine|Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2
57961096|NCT03308396|DRUG|Durvalumab|Day 8 Durvalumab (1500 mg IV)
57961097|NCT02301403|DRUG|Nicotine patch|8 weeks of nicotine patch
57961098|NCT02301403|BEHAVIORAL|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
57961099|NCT02301403|DRUG|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
57763123|NCT01386996|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
57763124|NCT01386996|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
57961100|NCT02301403|DRUG|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
57961101|NCT02301403|BEHAVIORAL|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
57961102|NCT02301403|BEHAVIORAL|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
57961103|NCT02301403|BEHAVIORAL|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
57961104|NCT01692548|OTHER|Neurofeedback|
57961105|NCT04831333|OTHER||
57961106|NCT04036409|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
57961107|NCT04036409|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
57961108|NCT04894656|DIAGNOSTIC_TEST|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
57763125|NCT03863522|PROCEDURE|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
57763126|NCT03863522|DEVICE|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
57763127|NCT00844116|DEVICE|spirometry|Conventional and telematic spirometry
57763128|NCT04703296|BEHAVIORAL|MBAT course|"The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete."
57763129|NCT03450655|OTHER|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
57763130|NCT00405639|DRUG|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
57763131|NCT00405639|DRUG|Placebo|Normal saline will be used for placebo.
57763132|NCT04623320|DIAGNOSTIC_TEST|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
57763133|NCT04623320|DIAGNOSTIC_TEST|13C glucose breath test|13C glucose breath test to compare with the golden standard
57763134|NCT00067990|DRUG|Losartan 100mg|To be started within three months of transplant and continued for five years.
57763135|NCT00067990|DRUG|Placebo|No treatment with continued follow-up for five years.
57763136|NCT06291155|DRUG|SGLT2 inhibitor|All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
57763137|NCT03443713|DEVICE|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
57763138|NCT06624423|OTHER|corn silk tea|Corn Silk Tea
57763139|NCT04425343|GENETIC|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
57763140|NCT04547439|DRUG|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
57763141|NCT04547439|OTHER|Placebo|Placebo will be given nightly for 8 weeks
57763142|NCT02648984|OTHER|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
57763143|NCT02412501|DEVICE|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
57763144|NCT01233583|DRUG|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
57763145|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
57763146|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
58129122|NCT04330807|OTHER|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
57763147|NCT01885260|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
57763148|NCT02671383|DRUG|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
57763149|NCT02671383|DRUG|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
57763150|NCT00325221|DEVICE|HM on|Home Monitoring activated after implantation
57763151|NCT00325221|DEVICE|HM Off|Home Monitoring activated 9 months after implantation
57763152|NCT00550550|DRUG|Placebo|Placebo sublingual tablet, once daily
57763153|NCT00550550|BIOLOGICAL|SCH 697243|Grass sublingual tablet, once daily
57763154|NCT00550550|DRUG|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
57763155|NCT00550550|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
57763156|NCT00550550|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
57763157|NCT00550550|DRUG|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
57763158|NCT00550550|DRUG|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
57763159|NCT00550550|DRUG|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
57763160|NCT00550550|DRUG|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
57763161|NCT04152343|DEVICE|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions \>2cm
57763162|NCT06261684|DRUG|Intralesional Acyclovir|Intralesional Acyclovir in plantar warts
57763163|NCT06261684|DEVICE|Cryotherapy|Cryotherapy of plantar warts
57763164|NCT01382602|BIOLOGICAL|AMDC-USR|AMDC-USR Treatment
57763165|NCT01382602|BIOLOGICAL|Placebo|Placebo treatment
57763166|NCT05578586|DRUG|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
57763167|NCT05829980|PROCEDURE|Laser assisted in-situ keratomileusis|Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
57763168|NCT05829980|PROCEDURE|Photorefractive keratectomy|Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
57763169|NCT00555022|DRUG|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
57763170|NCT00555022|DRUG|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
58457159|NCT02714192|OTHER|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
57763171|NCT00555022|DRUG|Placebo|Subjects will receive placebo.
57961109|NCT02678858|BEHAVIORAL|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
57961110|NCT02678858|BEHAVIORAL|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
58457160|NCT03844555|DRUG|Elafibranor|120mg oral single dose
57763172|NCT00980005|BIOLOGICAL|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
57763173|NCT00980005|BIOLOGICAL|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
58457161|NCT02760615|DRUG|Caffeine|Caffeine tablets
57763174|NCT06625658|DEVICE|clear aligner group|aligner group change aligner every10 day
57763175|NCT03645135|OTHER|Goal elicitation|Patients will be asked to list 2 goals for their visit
57763176|NCT04617548|COMBINATION_PRODUCT|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
57763177|NCT00462670|DRUG|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
57763178|NCT01268202|DRUG|Pravastatin|Pravastatin 40mg/day during 12 months
57763179|NCT05650723|DRUG|Zanubrutinib Pill|320 mg once per day by mouth
57763180|NCT05650723|DRUG|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
57763181|NCT05650723|DRUG|Obinutuzumab Injection|1000 mg IV given every 28 days
57763182|NCT04459286|DRUG|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
58457162|NCT02760615|DRUG|Losartan|Losartan tablets
58457163|NCT02760615|DRUG|Omeprazole|Omeprazole capsules
58457164|NCT02760615|DRUG|Dextromethorphan|Dextromethorphan capsules
58457165|NCT02760615|DRUG|Midazolam|Midazolam syrup
58457166|NCT02760615|DRUG|Vedolizumab|Vedolizumab solution for IV infusion
58457167|NCT06171958|DRUG|Iodine-containing Contrast Media|Patients will receive or not receive ICM depending on their medical need.
57763183|NCT04459286|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
57763184|NCT00001015|DRUG|Ribavirin|
58129123|NCT04330807|OTHER|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
57763185|NCT03154281|DRUG|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
57763186|NCT03154281|DRUG|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
57763187|NCT05434117|BEHAVIORAL|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
57763188|NCT05434117|BEHAVIORAL|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
57763189|NCT04175301|DRUG|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
57763190|NCT04175301|DRUG|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
57763191|NCT02962856|DRUG|BAY987517|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
57763192|NCT02962856|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
57763193|NCT06120517|COMBINATION_PRODUCT|emg- biofeedback|EMG activity shows the electrical activity measured during striated muscle contraction. The electrical activity of the muscle is in microvolts (1 volt = 1,000,000μV). Biofeedback units usually produce audio or visual feedback depending on the amount of electrical activity. Recording the bio-electrical activity of the muscle is a practical indicator of its contractility.
57763194|NCT05177406|OTHER|Aimovig|patients newly initiating Aimovig therapy
58129124|NCT04058223|DEVICE|Hemorrhoidopexy|stapled hemorrhoidopexy
58129125|NCT04219501|OTHER|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
58129126|NCT00622609|DRUG|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
57763195|NCT00012038|DRUG|irofulven|
57763196|NCT03894150|DRUG|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
58129127|NCT00622609|DRUG|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
58129128|NCT01462565|DRUG|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
58129129|NCT01462565|DRUG|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
58129130|NCT03670238|DEVICE|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
58129131|NCT03670238|DEVICE|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
58129132|NCT00361322|DRUG|clindamycin phosphate|
58129133|NCT00361322|DRUG|salicylic acid|
58457168|NCT01706172|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
58457169|NCT01706172|OTHER|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
58457170|NCT02611973|OTHER|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
58457171|NCT02611973|OTHER|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
58457172|NCT02611973|OTHER|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
58457173|NCT02611973|DRUG|Hydroxyurea treatment (HU)|HU maintenance
58457174|NCT01863381|DEVICE|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
57763197|NCT06382038|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
57763198|NCT00477061|DRUG|Morphine|
57763199|NCT02320032|DRUG|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
57763200|NCT06625164|OTHER|exercise|core stabilization exercises
57763201|NCT01749072|DRUG|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
57763202|NCT01749072|DRUG|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
57763203|NCT05118230|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
57763204|NCT03118284|OTHER|urine collection|
57763205|NCT03118284|OTHER|Blood collection|
57763206|NCT03118284|BEHAVIORAL|NRS|
57763207|NCT05335109|DRUG|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
57763208|NCT05335109|DRUG|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
57763209|NCT05091853|DEVICE|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
57763210|NCT00214825|DRUG|eplerenone|50 mg daily for 6 weeks with placebo
57961111|NCT06370455|PROCEDURE|comparison of septal advancement flap effect on nasal tip in primary rhinoplasty to columellar strut technique|All patients will be operated on under general anesthesia through an open rhinoplasty then will undergo 2 different procedures according to each group.
57961112|NCT06247891|PROCEDURE|ECS Group|Patients underwent endoscopic and endocytoscopic evaluations.
57961113|NCT05956106|DIETARY_SUPPLEMENT|Black Mulberry Fruit Powder|Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
57763211|NCT00214825|DRUG|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
57763212|NCT03610737|DEVICE|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
57763213|NCT03610737|OTHER|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
57763214|NCT04942301|DRUG|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
57763215|NCT04942301|DEVICE|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
57763216|NCT04942301|COMBINATION_PRODUCT|combination therapy|Combination therapy with chemotherapy drugs was used
57763217|NCT03628963|DEVICE|Concerto+|a user-centered, multifunctional and personalized eHealth platform
57763218|NCT04398446|DRUG|Hemp-based CBD|3x Daily dosing for 12 weeks
57763219|NCT04398446|OTHER|Placebo oral tablet|3x Daily dosing for 12 weeks
57763220|NCT01218945|PROCEDURE|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
57763221|NCT02623816|DRUG|Optimal Dosing of Omeprazole|Omeprazole 20 mg
57763222|NCT04999358|BEHAVIORAL|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
57763223|NCT04999358|BEHAVIORAL|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
57763224|NCT01121198|DRUG|ASP1941|oral
57763225|NCT01121198|DRUG|placebo|oral
57763226|NCT02390856|DEVICE|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
57763227|NCT02390856|DEVICE|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
57763228|NCT05732532|DRUG|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
57961114|NCT01662583|OTHER|Text Message|
57961115|NCT01662583|OTHER|Written reminder|
57961116|NCT04481776|OTHER|Breakfast consumption|Standardised breakfast consumption across seven days
57961117|NCT04481776|OTHER|Breakfast omission|No breakfast consumed across seven days
57961118|NCT05195697|OTHER|Observational study of different treatments and time to treatment|Different treatment based on the clinical decision
57961119|NCT04451629|BEHAVIORAL|pelvıc base exercıse, core exercise|Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
57763229|NCT05732532|DRUG|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
57763230|NCT05732532|DRUG|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
57763231|NCT05732532|DRUG|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
57763232|NCT05732532|PROCEDURE|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
57763233|NCT05116176|DEVICE|Implantable cardioverter-defibrillators|500 patients age \>65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
57763234|NCT01337414|BEHAVIORAL|VMS diary booklet|
57763235|NCT01337414|BEHAVIORAL|Standard of Care|
57763236|NCT01140334|BEHAVIORAL|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
57763237|NCT01140334|BEHAVIORAL|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
57763238|NCT01377480|DRUG|Posaconazole|POS 40 mg/mL oral suspension
57763239|NCT01377480|DRUG|Placebo for posaconazole|Placebo oral suspension
57763240|NCT01377480|DRUG|Benznidazole|BNZ 100 mg oral tablet
57763241|NCT02765022|DEVICE|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
57763242|NCT02765022|PROCEDURE|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
57763243|NCT04489420|BIOLOGICAL|CYNK001-IV|Planned Starting dose dor IV 1.2x10\^9 cells/dose
57763244|NCT04489420|BIOLOGICAL|CYNK001-IT|Planned starting dose for IT 200 x10\^6 +/- 50 x10\^6 cells dose
57763245|NCT06100302|OTHER|no-intervention|no-intervention
57763246|NCT00345319|BIOLOGICAL|rabies vaccine|Administration of PCECV according to ESSEN regimen
57763247|NCT02889601|OTHER|Psycho-behavioural assessment|DAPHNE Scale
57763248|NCT00656318|OTHER|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
57763249|NCT04754139|OTHER|WeChat mobile mini-application|Sexual health education and the role of PrEP
57763250|NCT00885963|DRUG|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
57763251|NCT04005027|OTHER|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
57763252|NCT00591864|DEVICE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
57763253|NCT05492526|DEVICE|Ki Monitor without feedback|Physical activity Monitor - No feedback
57763254|NCT05492526|DEVICE|Ki monitor with contextualised data feedback|Physical activity monitor and feedback
57763255|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in cases group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
57763256|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in control group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
57763257|NCT01645826|DRUG|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
57763258|NCT01645826|DRUG|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
57763259|NCT03844243|DRUG|NGF|Intramuscular injection
57763260|NCT03844243|DRUG|Isotonic-saline|Intramuscular injection
57763261|NCT03982043|BEHAVIORAL|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
57763262|NCT03718962|DEVICE|Surrounding needling+ phototherapy|Surrounding needling+ phototherapy
57763263|NCT03718962|DEVICE|phototherapy|phototherapy
57763264|NCT03312608|DIAGNOSTIC_TEST|Navigated transcranial magnetic stimulation|
57763265|NCT04328402|DIAGNOSTIC_TEST|Polysomnography|Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
58129134|NCT03784456|DIETARY_SUPPLEMENT|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
57763266|NCT02733783|DEVICE|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
57763267|NCT00099099|BEHAVIORAL|Caloric Restriction (CR)|
57763268|NCT01043016|PROCEDURE|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
57763269|NCT00058019|DRUG|ixabepilone|Given IV
57763270|NCT02061696|DEVICE|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
57763271|NCT02061696|PROCEDURE|Standard Manual Compression|Closure procedure by Manual Compression
57763272|NCT03913208|PROCEDURE|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
57763273|NCT03913208|PROCEDURE|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
57763274|NCT02454829|OTHER|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
57763275|NCT05556317|BEHAVIORAL|Resistive exercise|advices and resistive exercise
57763276|NCT04636554|OTHER|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
57763277|NCT05764343|OTHER|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
57763278|NCT05414318|DEVICE|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
57763279|NCT04815317|OTHER|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
57961120|NCT06391697|DEVICE|eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System|"The Magnetic Bead Tracking System is an investigational device that consists of pairs of magnetic beads, and a set of magnetic field sensors that measure and track the length of muscles and the speed at which they move in real-time. When the beads are implanted in muscle in the residual limb of an amputee, the muscle length signal is communicated to an investigational, robotic ankle-foot prosthesis.~The e-OPRA is an investigational implant system that lets a lower leg prosthesis attach securely to the remaining tibia bone. The e-OPRA device has been designed so that it can be implanted with an electrode set that consists of an electrical connector and electrodes to allow it to be used with both a neuro-mechanical (powered) prosthesis system, in addition to the standard prosthesis.~The operation to implant these devices will represent a modification of the surgical technique currently employed for standard below knee amputation."
57961121|NCT04057339|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
57961122|NCT04057339|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
57763280|NCT04815317|OTHER|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
57763281|NCT04815317|OTHER|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
57763282|NCT04815317|OTHER|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
57763283|NCT05171413|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
57763284|NCT03919786|PROCEDURE|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
57961123|NCT04947488|DIETARY_SUPPLEMENT|Bioarginina C|Dietary supplement vials
57961124|NCT03099889|BEHAVIORAL|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
57961125|NCT05261269|DRUG|DAN-222|Administered IV every week to subjects
57961126|NCT05261269|DRUG|Niraparib|Administered orally once daily
57961127|NCT05069987|OTHER|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax \& Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
57763285|NCT04369638|DEVICE|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
57763286|NCT04369638|DEVICE|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
57763287|NCT06202027|DRUG|FGF23-related hypophosphataemic rickets and osteomalacia|FGF23-related hypophosphataemic rickets and osteomalacia
57763288|NCT02920775|OTHER|Non-interventional study - retrospective database review|
57763289|NCT03541772|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
57763290|NCT03541772|DIETARY_SUPPLEMENT|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
57763291|NCT00730379|DRUG|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
57763292|NCT01285284|OTHER|Music|A previously defined list of songs will be administered by headphones to these patients.
57763293|NCT01285284|OTHER|No music|No music will be administered by the headphones connected to the MP3 device.
57763294|NCT02558270|DRUG|Dapagliflozin|
57763295|NCT02558270|DRUG|Placebo|
57961128|NCT03201185|DRUG|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
57961129|NCT00513032|DRUG|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
57763296|NCT01175148|DRUG|Atorvastatin calcium (Lipitor)|40 mg PO daily
57763297|NCT03352843|DRUG|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
57763298|NCT03962725|DRUG|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
57763299|NCT03962725|DRUG|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
57763300|NCT05566639|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
57763301|NCT05566639|BIOLOGICAL|Licensed quadrivalent inactivated seasonal influenza vaccine|Sterile suspension for injection.
57763302|NCT00510458|DEVICE|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
57763303|NCT01212536|DEVICE|Airtraq laryngoscopy|laryngoscopy and intubation
57763304|NCT05102422|DRUG|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
57763305|NCT05102422|DRUG|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
57763306|NCT05351476|BEHAVIORAL|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
57961130|NCT06202300|OTHER|Inflammation burden|Coronary artery disease patients undergone multimodality imaging with different level inflammation burden
57763307|NCT05351476|BEHAVIORAL|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
57763308|NCT03620721|BEHAVIORAL|mindfulness|8-week mindfulness based group intervention
57763309|NCT05012475|BEHAVIORAL|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
57763310|NCT03873194|OTHER|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
57961131|NCT03671031|PROCEDURE|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
57961132|NCT03671031|PROCEDURE|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
57961133|NCT04304027|OTHER|Tailored exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
57961134|NCT04304027|OTHER|Standard exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at \>70% heart rate reserve followed by 2 minutes working rest
57961135|NCT04871529|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57961136|NCT04871529|DRUG|Avelumab|Given IV
57961137|NCT04871529|DRUG|Gemcitabine Hydrochloride|Given IV
57961138|NCT04871529|DRUG|Carboplatin|Given IV
57961139|NCT02865382|PROCEDURE|white light was used for colonoscopy withdrawal|
57961140|NCT02865382|PROCEDURE|OE mode was used for colonoscopy withdrawal|
57763311|NCT03873194|OTHER|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
57763312|NCT02640443|DRUG|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
57763313|NCT05518292|OTHER|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
57763314|NCT05518292|OTHER|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
57763315|NCT05923580|BEHAVIORAL|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
57763316|NCT05174923|BEHAVIORAL|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
57763317|NCT05174923|BEHAVIORAL|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
57763318|NCT05174923|BEHAVIORAL|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
57763319|NCT05889923|DEVICE|With EDU|using the EDU to perform the procedure
57763320|NCT06444022|BIOLOGICAL|Human amniotic epithelial stem cells（hAESCs）|Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)
57763321|NCT06444022|BIOLOGICAL|placebo (cell preservation solution)|Same dose placebo (cell preservation solution) injections as control group
57763322|NCT02948881|DRUG|ibandronate|
57763323|NCT01526590|DRUG|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
57763324|NCT04157998|DRUG|normal saline|intrvenous administration of 10ml normal saline preoperative
57763325|NCT04157998|DRUG|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
57763326|NCT06576687|OTHER|Physical Rehabilitation|Exercises include (1) single-limb hops to stabilization, (2) hop to stabilization and reach, (3) unanticipated hop to stabilization, (4) single-limb stance activities, and (5) continuous choice-reaction hopping.
57763327|NCT00347997|DEVICE|217z Laser|LASIK correction of myopia and myopic astigmatism
57763328|NCT02749851|DEVICE|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
57763329|NCT02749851|DEVICE|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
57763330|NCT03760263|DRUG|Tacrolimus|Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
57763331|NCT06539507|DRUG|BCX17725|BCX17725 for injection
57763332|NCT06539507|DRUG|Placebo|Placebo for injection
57763333|NCT05477277|DIAGNOSTIC_TEST|MAsS|Add MAsS to standard of care MRI scan
57961141|NCT05097807|BEHAVIORAL|smartphone related behaviors|Participants are required to watch specific contents on their own smartphones.
57961142|NCT03783520|DEVICE|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
57961143|NCT03783520|OTHER|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
57961144|NCT00993031|DRUG|Lopinavir/ritonavir|LPV 200mg/r 50mg
57961145|NCT00993031|DRUG|Efavirenz|600mg
57961146|NCT00993031|DRUG|Zidovudine|Zidovudine 300 mg
57961147|NCT00993031|DRUG|Lamivudine|Lamivudine 150 mg
57961148|NCT00209339|DEVICE|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
57961149|NCT04505228|DRUG|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
57961150|NCT04505228|DRUG|Atropine Sulfate|The basic treatment for heart disease
57961151|NCT02834637|DRUG|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
57961152|NCT02834637|DRUG|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
57961153|NCT00586573|DRUG|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
57763334|NCT02322541|OTHER|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
57763335|NCT04699357|DRUG|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
57763336|NCT00161395|BEHAVIORAL|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
57763337|NCT00161395|BEHAVIORAL|Preconception advice|Preconception advice for diet and frequency of intercourse.
57763338|NCT01488565|DRUG|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
57763339|NCT01860443|OTHER|Telepsychiatry collaborative program|"The intervention includes:~* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~* Online supervision in a web platform by specialists~* Telephone monitoring"
57763340|NCT01860443|OTHER|Usual care|"* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
57763341|NCT00213564|DRUG|response to infliximab associated with methotrexate|
57763342|NCT00566176|DEVICE|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
57763343|NCT00405405|DRUG|Cisplatin|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
57763344|NCT00405405|DRUG|Docetaxel|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
57961154|NCT01550497|OTHER|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
57763345|NCT00405405|DRUG|Bevacizumab|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
58457175|NCT01863381|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
58457176|NCT02497924|DRUG|GBT440|GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
58457177|NCT01677689|DRUG|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
57763346|NCT00405405|DRUG|Erlotinib|"* Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
57763347|NCT00405405|RADIATION|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
57763348|NCT06625385|DEVICE|3M™ V.A.C.® Peel and Place Dressing|Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
57763349|NCT03322826|PROCEDURE|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
57763350|NCT03322826|PROCEDURE|lymphadenectomy|Routine lymph nodes dissection in lung cancer
57763351|NCT05737433|DRUG|[14C]-rencofilstat 225mg|radio-labelled 225mg oral dose of rencofilstat
57763352|NCT02816034|BEHAVIORAL|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
57763353|NCT02816034|BEHAVIORAL|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
57763354|NCT02010801|PROCEDURE|irreversible electroporation|
57763355|NCT02010801|DEVICE|nanoknife AngioDynamics US Ltd|
57763356|NCT01641926|BIOLOGICAL|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
57763357|NCT01641926|BIOLOGICAL|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
57763358|NCT06623214|DEVICE|nebulyft|Micro Radiofrequency Skin Treatment Device(nebulyft)
57763359|NCT04244851|OTHER|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
57763360|NCT06444295|BEHAVIORAL|Activity scheduling|"Participants will engage in activity scheduling in the app (i.e., Activities module). On the first day of using the app, users will create a list of valued/important and avoided activities (e.g., spending time with friends, going to the gym), and then have the option to add alcohol protective behavioral strategies (e.g., adding ice to drinks, alternating alcoholic and nonalcoholic beverages) to activities that the user identifies as being likely to involve drinking. On subsequent days, users will be encouraged to complete at least one activity from their list."
57961155|NCT02462473|DRUG|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
57961156|NCT02462473|DRUG|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
57961157|NCT02462473|DRUG|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
57961158|NCT02462473|DRUG|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
58457178|NCT01677689|DRUG|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
58457179|NCT01650558|DRUG|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
58457180|NCT01650558|DRUG|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
57763361|NCT06444295|BEHAVIORAL|Cognitive restructuring|"Participants will engage in cognitive restructuring in the app (i.e., Thoughts activities). Users first go through an activity involving the identification of maladaptive cognitions and create a list of their maladaptive cognitions. On subsequent days, they engage in a guided in-app activity involving cognitive restructuring of maladaptive cognitions from their list."
57763362|NCT06444295|BEHAVIORAL|Coaching calls|Participants will receive 10-20 minute weekly coaching calls during the app use period (4 total, including coaching provided in the enrollment call). All coaching calls will, at minimum, include a check-in, troubleshooting of technical issues, check-in about experience with symptom self-monitoring, and offers of referrals. Coaching calls in conditions involving activity scheduling will involve assistance with the Activities module. Coaching calls in conditions involving cognitive restructuring will involve assistance with the Thoughts module.
57763363|NCT06444295|BEHAVIORAL|Non-core intervention components|"All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues"
57763364|NCT05967780|OTHER|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
57763365|NCT05967780|OTHER|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
57763366|NCT05967780|OTHER|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
57763367|NCT04570813|OTHER|Artistic activies|12 workshops of artictic activities during 12 weeks
57763368|NCT06625983|OTHER|CRC decision tool|CRC decision tool included in the primary care bundle questionnaire
57763369|NCT04172805|DRUG|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
57763370|NCT00813137|DRUG|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
57763371|NCT03279055|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
57763372|NCT05413525|PROCEDURE|ultrasound-guided manual vacuum aspiration (USG- MVA)|USG-MVA was carried out as an outpatient day procedure. Women was given a 400μg oral misoprostol tablet 2-3 hours before the procedure. All patients will be given 500mg naproxen orally an hour before the procedure. During the USG-MVA, all the women were placed in the lithotomy position and aseptically dressed. Speculum was performed to visualize the cervix with PCB performed. USG-MVA was performed using a 60ml charged syringe with a flexible curetteattached to it. Transabdominal USG during MVA was performed. During the procedure, local lidocaine gelwas applied to the cervical canal and over the end of the MVA catheter tip during the insertion.The USG-MVA was stopped as soon as USG confirmed that the uterine cavity was empty, defined as a thin endometrial lining with no evidence of retained products of conception.
57961159|NCT02462473|DRUG|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
57961160|NCT02037659|PROCEDURE|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
57961161|NCT04397094|DRUG|Theracal LC|pulpotomy
57961162|NCT04397094|DRUG|Formocresol|Pulpotomy
57961163|NCT03589404|DEVICE|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
57961164|NCT05537714|BEHAVIORAL|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
58457181|NCT05315349|OTHER|Complete ophthalmological check-up|Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)
57763373|NCT02688465|DRUG|Apomorphine|
58457182|NCT05315349|BIOLOGICAL|Blood sampling|Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
57961165|NCT02085499|OTHER|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.~NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
58457183|NCT04513756|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
58129135|NCT03784456|DIETARY_SUPPLEMENT|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
58457184|NCT02372877|DEVICE|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
58457185|NCT01261988|DEVICE|VIPER|Comparison of ostomy systems
58457186|NCT01261988|DEVICE|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
58457187|NCT00130858|DRUG|Topotecan|
58457188|NCT00130858|DRUG|Carboplatin|
58457189|NCT01329263|OTHER|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
58457190|NCT03470688|BIOLOGICAL|Originator|Originator anti-TNF agents
58457191|NCT03470688|BIOLOGICAL|Biosimilar|Biosimilar anti-TNF agents
58457192|NCT05445895|DRUG|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
58457193|NCT05445895|DRUG|Plavix 75mg|Plavix 75mg will be added to Aspirin 100mg
57763374|NCT05720013|DIETARY_SUPPLEMENT|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
57763375|NCT05720013|DIETARY_SUPPLEMENT|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
57763376|NCT01181505|DRUG|Tolterodine|
57763377|NCT01548937|DRUG|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
57763378|NCT04139980|OTHER|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
57763379|NCT03520465|DEVICE|DynaMesh®-CICAT longitudinal measure 10x35 cm|
57763380|NCT03098940|DRUG|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
57763381|NCT01861886|DEVICE|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
57763382|NCT00100932|DRUG|E7389 28 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
57763383|NCT00100932|DRUG|E7389 21 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
58129136|NCT05108038|DRUG|CKD-382, D860, D027|QD, PO for 7days
58457194|NCT04895449|BIOLOGICAL|MVA-SARS-2-ST|i.m. vaccine administration
58457195|NCT04310111|PROCEDURE|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
58457196|NCT00446979|DRUG|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
58457197|NCT00446979|DRUG|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
58457198|NCT03630796|DRUG|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
58457199|NCT03630796|DRUG|TIVA|Total intravenous anesthesia
58457200|NCT04752267|PROCEDURE|Computed Tomography|Undergo PET/CT
58457201|NCT04752267|DRUG|18F-FMAU|Given IV
58457202|NCT04752267|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
58457203|NCT04752267|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58457204|NCT02040649|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
58457205|NCT02040649|OTHER|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
58457206|NCT00354016|BIOLOGICAL|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
57763384|NCT03541044|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
57763385|NCT03541044|DRUG|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
57763386|NCT00297115|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
57763387|NCT00297115|DRUG|Placebo|once daily
57763388|NCT02813356|DRUG|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
57763389|NCT02813356|DRUG|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
58457207|NCT00516113|DRUG|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
57763390|NCT00243828|DEVICE|Total Face Mask|
57763391|NCT00722579|DEVICE|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
57763392|NCT02875275|OTHER|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
57763393|NCT02875275|OTHER|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
57763394|NCT02875275|OTHER|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
57763395|NCT02875275|OTHER|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
57763396|NCT03968003|DIETARY_SUPPLEMENT|Inulin|Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
57763397|NCT06439641|OTHER|Ulcerative colitis Disease Activity Index|QUESTIONNAIRE - Score between 0 to 12, the higher is the worse
57763398|NCT03305874|OTHER|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
57763399|NCT02024672|OTHER|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
57763400|NCT00166725|DRUG|Octreotide LAR|
57763401|NCT00344812|DRUG|LAAM. buprenorphine and methadone|
57763402|NCT06319846|DRUG|Tirofiban|Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
58457208|NCT05925777|DEVICE|THEAL (Mectronic, Bergamo)|laser therapy high intensity
57763403|NCT06319846|DRUG|Placebo|Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
57763404|NCT02465996|DEVICE|pCLE examination|All FD patients received pCLE examination.
57763405|NCT02465996|DRUG|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
57763406|NCT04354766|OTHER|Blood sample|This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
58457209|NCT04477408|OTHER|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
57763407|NCT00542048|DRUG|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
58457210|NCT00914186|DRUG|TS022|Lotion
57763408|NCT01650519|DRUG|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
57763409|NCT01650519|DRUG|IV ketorolac|30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds
58457211|NCT00914186|DRUG|Vehicle|Lotion
58457212|NCT06285487|BEHAVIORAL|Group Program|Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
58457213|NCT01232868|BIOLOGICAL|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
57763410|NCT03421496|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
57763411|NCT03421496|DRUG|Placebo|Matching oral solution
57763412|NCT03421496|DRUG|Vigabatrin|Powder suspension
57763413|NCT02160171|DEVICE|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
57763414|NCT06616844|DEVICE|InnovaMatrix® AC|SOC plus weekly application of the study device
57763415|NCT02063100|DRUG|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
57763416|NCT02063100|DRUG|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
57763417|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
57763418|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
57763419|NCT02063100|DRUG|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
57763420|NCT03347175|PROCEDURE|Volume controlled ventilation|Volume controlled ventilation mode
57763421|NCT03347175|PROCEDURE|Pressure controlled ventilation|Pressure controlled ventilation
57763422|NCT03347175|PROCEDURE|CPAP mode|CPAP mode only
57763423|NCT06028035|DIETARY_SUPPLEMENT|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
57763424|NCT06433310|DIETARY_SUPPLEMENT|L-Phenylalanine 500 mg Veg Capsule product|500 mg Veg Capsule product
57763425|NCT04707404|PROCEDURE|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
58129137|NCT00243932|DRUG|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
57763426|NCT05086250|DRUG|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
57763427|NCT05086250|DRUG|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
57763428|NCT05086250|DRUG|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
57763429|NCT05086250|DRUG|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
57763430|NCT00787319|OTHER|no intervention|Outpatients with age-related macular degeneration (AMD)
57763431|NCT02584348|DEVICE|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
57763432|NCT02263001|OTHER|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
57763433|NCT02263001|OTHER|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
57763434|NCT01433523|DRUG|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
57763435|NCT01433523|DRUG|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
57763436|NCT01433523|DRUG|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
58457214|NCT04312308|OTHER|Sample collection|"1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
57763437|NCT05636462|OTHER|Global postural re-education program|"Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks."
57763438|NCT05636462|OTHER|Conventional Physical Therapy|Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
57763439|NCT05019274|OTHER|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
57763440|NCT05019274|OTHER|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
57763441|NCT02481492|DEVICE|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
57763442|NCT02481492|DEVICE|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
57763443|NCT00351637|DRUG|Sublingual Methadone|
57763444|NCT02281396|BIOLOGICAL|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
57763445|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
58129138|NCT00243932|DRUG|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
57763446|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
57763447|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
57763448|NCT01153269|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
57763449|NCT04788953|DRUG|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
58129139|NCT01249664|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
58129140|NCT01249664|PROCEDURE|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
57763450|NCT04788953|DRUG|Placebo|Control subjects will receive placebo tablets for oral use.
57763451|NCT02821819|OTHER|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
58129141|NCT03778905|OTHER|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
58129142|NCT04469153|OTHER|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
58129143|NCT02402166|DRUG|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
57763452|NCT02821819|DRUG|Gonadotrophins|Urinary FSH 150-225 IU/d
57763453|NCT02821819|DRUG|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
57763454|NCT02821819|DRUG|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
57763455|NCT00101127|BIOLOGICAL|filgrastim|
57763456|NCT00101127|BIOLOGICAL|pegfilgrastim|
57763457|NCT00101127|DRUG|docetaxel|
57763458|NCT00101127|DRUG|gemcitabine hydrochloride|
57763459|NCT06070584|PROCEDURE|aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
57763460|NCT03432884|DRUG|BGB-3111|Subjects will receive BGB-3111
57763461|NCT03432884|DRUG|Placebo|Subjects will receive Placebo
57763462|NCT03432884|DRUG|Moxifloxacin|Subjects will receive Moxifloxicin
57763463|NCT02167217|DRUG|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
57763464|NCT01595412|PROCEDURE|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
57763465|NCT01595412|PROCEDURE|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
57763466|NCT05492773|DEVICE|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
57763467|NCT05492773|DEVICE|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
57763468|NCT05720585|OTHER|Intervention of mobile health application|According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
57763469|NCT03946800|BIOLOGICAL|MEDI1191|Subjects will receive MEDI1191 (at least twice)
57763470|NCT03946800|BIOLOGICAL|Durvalumab|Subject will receive durvalumab every 4 weeks
57763471|NCT00449098|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
57763472|NCT00449098|DRUG|Trabeculectomy with MMC|Trabeculectomy with MMC
57763473|NCT03584503|OTHER|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
57961166|NCT02085499|OTHER|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.~S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
57763474|NCT00535743|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
57763475|NCT00535743|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
57763476|NCT00535743|DRUG|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
57763477|NCT04230655|DIETARY_SUPPLEMENT|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
57763478|NCT04230655|BEHAVIORAL|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
57763479|NCT04230655|DEVICE|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
57763480|NCT02935348|RADIATION|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
57763481|NCT02221102|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
57763482|NCT02221102|DRUG|edoxaban|orally active direct factor Xa inhibitor
57763483|NCT02221102|DRUG|placebo|
57763484|NCT02801188|DRUG|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
57763485|NCT02801188|DRUG|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
57763486|NCT03701295|DRUG|Azacitidine|Given IV or SC
57763487|NCT03701295|DRUG|Pinometostat|Given IV
57763488|NCT01336634|DRUG|Dabrafenib|Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
57763489|NCT01336634|DRUG|Trametinib|Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
57763490|NCT02736968|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
57763491|NCT02736968|OTHER|Placebo|Placebo
57961167|NCT01617837|DEVICE|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
57961168|NCT01617837|OTHER|Placebo band|Comparison between groups 0-48 hours postoperatively
57961169|NCT01789450|PROCEDURE|Section of Periareolar Dermis in Breast Reduction.|
57763492|NCT05195619|BIOLOGICAL|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
57763493|NCT05195619|DRUG|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
57763494|NCT03755635|COMBINATION_PRODUCT|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
57763495|NCT05445544|OTHER|Observational studies, The diagnosis was preeclampsia|Observational studies, The diagnosis was preeclampsia
57763496|NCT05904223|DIAGNOSTIC_TEST|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
57763497|NCT06453122|OTHER|Oral care|The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
57763498|NCT03288090|OTHER|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
57763499|NCT03288090|OTHER|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
57763500|NCT03288090|OTHER|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
57763501|NCT03148236|DRUG|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
57763502|NCT03148236|OTHER|Placebo|50mL infused over 30 minutes
57763503|NCT01695733|BIOLOGICAL|trivalent influenza vaccine|
57763504|NCT05806502|DIAGNOSTIC_TEST|Nω-hydroxy-nor-arginine|Arginase inhibitor
57763505|NCT02375282|PROCEDURE|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
57763506|NCT00584402|DRUG|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
57763507|NCT03465020|OTHER|Observation|Safety and efficacy outcomes of patients on different treatments
57763508|NCT05465512|OTHER|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
57763509|NCT01145807|DRUG|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
58457215|NCT01503008|DEVICE|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
58458661|NCT01746368|OTHER|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
57763510|NCT01145807|DRUG|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
57763511|NCT01145807|DRUG|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
57961170|NCT04145401|DEVICE|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
58129144|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
58129145|NCT01309945|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
58129146|NCT01309945|DRUG|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
58129147|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
57763512|NCT01837329|DRUG|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
58129148|NCT01309945|DRUG|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
57763513|NCT06625866|BEHAVIORAL|Feedback and information|"The healthcare professionals in the intervention arm will be exposed to feedback and information behavioral strategies. Namely, interns, residents, obstetricians/gynecologists, and nurses will receive written feedback about the episiotomy rates in the hospital each month during the study period. Moreover, at least two academic sessions will be designed to outline the indications, surgical technique, complications, and surgical ethics for the procedure (i.e., episiotomy). Likewise, each session will also include a patient testimonial about their experience during delivery and their follow-up when an episiotomy was performed.~The feedback intervention will be provided for 2 months, and the feedback intervention + the information intervention will be provided for 2 additional months."
57763514|NCT00291902|DRUG|SB-681323|
57763515|NCT06001983|OTHER|imaginary resisted exercises|"1. Imagination of squeezing a Sponge ball 15 reps~2. Imagination of Finger Exerciser 15 reps~3. Imagination of Theraband 15 reps~4. Imagination of pressing Rubber ball 15 reps~5. Imagination of pressing Hard object 15 reps"
57763516|NCT06001983|OTHER|physical resisted exercises|"1. Resisted exercise of Squeezing a Sponge ball 15 reps~2. Resisted exercise of Finger Exerciser 15 reps~3. Resisted exercise of pulling theraband 15 reps~4. Resisted exercise of pressing Rubber ball 15 reps~5. Resisted exercise of pressing Hard object 15 reps"
57763517|NCT02531178|BIOLOGICAL|ABBV-257|subcutaneous injection
57763518|NCT02531178|BIOLOGICAL|Placebo|Placebo for ABBV-257
57763519|NCT00113282|DRUG|Interleukin-2 (IL-2)|
57763520|NCT04484714|BEHAVIORAL|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
57763521|NCT03559218|DEVICE|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
57763522|NCT03559218|OTHER|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
57763523|NCT02477280|DRUG|Methylphenidate|Cross-over
57763524|NCT02477280|DRUG|Placebo|Medikinet
58129149|NCT01179490|DRUG|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
58457216|NCT01503008|DRUG|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
58457217|NCT01379417|DIETARY_SUPPLEMENT|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
58457218|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
57763525|NCT01835262|DRUG|Morphine|Morphine: 0.1 mg /kg given as IVP
57763526|NCT01835262|DRUG|Ketamine|Ketamine:0.3 mg/given as IVP
57763527|NCT03626532|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
57763528|NCT03626532|BEHAVIORAL|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
57763529|NCT02446795|DRUG|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
57763530|NCT02446795|DRUG|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
57763531|NCT02446795|DRUG|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
57763532|NCT00793156|DRUG|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
58129150|NCT01179490|DRUG|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
58129151|NCT04611698|DEVICE|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
58129152|NCT01335477|DRUG|placebo|placebo matching BIBF 1120 BID
57763533|NCT00793156|DRUG|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
57763534|NCT00793156|OTHER|Placebo|Placebo daily dose
57763535|NCT02326350|DRUG|Aspirin 75mg|Active treatment
58129153|NCT01335477|DRUG|BIBF 1120|BIBF 1120 BID (twice daily)
58129154|NCT06346548|OTHER|oral photography|The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner
57763536|NCT02326350|DRUG|Lactose powder|Placebo
57763537|NCT06293300|DRUG|BoNT A|Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
57763538|NCT03944044|OTHER|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
57763539|NCT00001125|BIOLOGICAL|Varicella Virus Vaccine (Live)|
57763540|NCT02649062|BIOLOGICAL|NGM282|
57763541|NCT02649062|OTHER|Placebo|
57763542|NCT00000664|DRUG|Interleukin-2, Polyethylene Glycolated|
57763543|NCT00000664|DRUG|Zidovudine|
57763544|NCT04539457|BEHAVIORAL|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
57763545|NCT04539457|BEHAVIORAL|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
57763546|NCT02352363|DRUG|CVT-301|
57763547|NCT02352363|OTHER|Observational cohort|
57763548|NCT05493384|OTHER|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
57763549|NCT03987425|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
57763550|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
57763551|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
58457219|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
57763552|NCT01542021|DRUG|androgen deprivation therapy|
57763553|NCT01226563|DEVICE|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
57763554|NCT01226563|DEVICE|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
57763555|NCT04040881|BEHAVIORAL|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
57763556|NCT04985006|BEHAVIORAL|running at moderate intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.
57763557|NCT04985006|BEHAVIORAL|running at high intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
57763558|NCT03861858|BEHAVIORAL|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
57763559|NCT03990584|PROCEDURE|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
57763560|NCT03990584|PROCEDURE|conventional needle irrigation|conventional needle irrigation
58457220|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
58129155|NCT02386033|DRUG|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
58457221|NCT00404651|BIOLOGICAL|DTaP-HBV-IPV vaccine|0.5 mL, IM
58457222|NCT04041583|DEVICE|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis \[2\]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion \[2\].
57763561|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
57763562|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
57763563|NCT05968040|PROCEDURE|Inferior vena cava diameter measurement by ultrasonography|The diameter of the inferior vena cava will be measured at 2 cm close to the entrance of the right atrium. Ultrasound images will be taken at the end of inspiration (Dmax) and at the end expiration (Dmin) to calculate the inferior vena cava dispensability index (dIVC), and will be recorded before and after fluid challenge test of 5 ml/kg crystalloid within 15 min. The IVC distensibility index (IVC-DI) will be calculated using the formula: IVC-DI = IVCmax - IVCmin/ IVCmin. The indices will be expressed as a percentage.
57763564|NCT05968040|PROCEDURE|difference between peak velocities of carotid artery by ultrasound|"Carotid ultrasound images will be obtained from the left CCA in both short-axis and long-axis views by experienced sonographers. The patient will be in supine position, with the head rotated slightly to the right. A broadband linear array transducer 12-4 MHz and the short-axis view will be used for orientation and identification of the CCA. Next, in the long-axis view, Peak Waveform Doppler signals will be acquired by placing a 0.5 mm calliper at the center of the vessel and parallel to the vessel walls, approximately 2 cm proximal from the carotid bifurcation. Insonation-angles between the ultrasound beam and blood flow will be maintained.~ΔVpeakCCA = (MaxCDPV-MinCDPV)+(MaxCDPV+MinCDPV)x100"
57763565|NCT05968040|PROCEDURE|cardiac output be transthoracic echocardiography|"CO will be recorded as baseline measure and after fluid administration. If CO increased more than 15%, it will be considered fluid responder. Increase in cardiac output = (cardiac output after first fluid challenge - cardiac output before)/cardiac output before) X 100.~TTE will be used to measure LTOT and VTI x HR."
57763566|NCT02162303|DRUG|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
57763567|NCT02162303|DRUG|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
57763568|NCT05497427|DEVICE|BrainCheck Assessment|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
57763569|NCT03513601|DRUG|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
57763570|NCT03513601|DRUG|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
57763571|NCT00955786|DRUG|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
57763572|NCT00094328|DRUG|Bicalutamide|oral
57763573|NCT00094328|DRUG|Anastrozole|oral
57763574|NCT04028310|OTHER|Phonological|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
57763575|NCT04028310|OTHER|Visual-attention|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
57763576|NCT04524143|OTHER|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
57763577|NCT04524143|OTHER|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
57763578|NCT05290246|BEHAVIORAL|Time restricted eating|Limiting daily eating time to an 8 hour window
57763579|NCT05290246|BEHAVIORAL|Caloric reduction|Cut caloric intake by 15%
57763580|NCT06248840|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
58458662|NCT04802330|OTHER|Questionnaire|Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
57763581|NCT06248840|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
57763582|NCT06082921|BEHAVIORAL|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
57763583|NCT06082921|BEHAVIORAL|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
57763584|NCT05842213|BIOLOGICAL|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
57763585|NCT05842213|BIOLOGICAL|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
57763586|NCT03381001|PROCEDURE|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
57763587|NCT03381001|PROCEDURE|embryo transfer with no culture|embryos will be transfer with no culture after thaw
57763588|NCT04573543|DIAGNOSTIC_TEST|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
58457223|NCT03144739|OTHER|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
57763589|NCT04573543|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
57763590|NCT04573543|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
57763591|NCT04573543|DIAGNOSTIC_TEST|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
57763592|NCT06344234|DIAGNOSTIC_TEST|End-inspiratory Maneuvers|Airway pressure, flow, and esophageal pressure will be continuously recorded in all patients using a dedicated pneumotachograph and pressure transducer: all signals will be acquired and stored. Once a stable ventilation pattern is observed NIV will be administered by setting ventilator in invasive-pressure support ventilation. PEEP and PS-level will by kept constant while expiratory trigger will be adjusted to optimize patient-ventilatory synchrony. Immediately after, sudden end-inspiratory and end-expiratory occlusion maneuvers will be performed to measure plateau pressure and end-expiratory airway occlusion pressure (ΔPocc), respectively. Invasive PSV will be used only to perform the occlusion maneuvers, subsequently, PSV will be delivered in non-invasive PSV mode. Patient's blood-gas parameters and vital signs will be collected, including discomfort assessment. During the occlusion maneuvers, diaphragm ultrasound will be performed, and images will be recorded.
57763593|NCT05915390|DIETARY_SUPPLEMENT|walnuts|walnuts will provide 15% of the total energy
57763594|NCT05915390|DIETARY_SUPPLEMENT|Habitual diet|continue with habitual diet and abstain from walnuts
57763595|NCT00861614|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
57763596|NCT00861614|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
57763597|NCT00415584|DRUG|Cinacalcet HCl|
57763598|NCT03350126|DRUG|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
57763599|NCT03350126|DRUG|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
57763600|NCT06103084|DIETARY_SUPPLEMENT|Bahgina|Bahgina, a locally produced cereal based food, will be provided at 200g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
57763601|NCT06103084|DIETARY_SUPPLEMENT|SQLNS|Small quantity lipid based nutrient supplement (SQ-LNS) will be provided at 20g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
57763602|NCT02286167|OTHER|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
57763603|NCT01838408|OTHER|Ez2go Complete|EZ2Go Complete
57763604|NCT01838408|OTHER|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
57763605|NCT01958840|BEHAVIORAL|Behavioral Activation for Depression Treatment|
57763606|NCT01958840|BEHAVIORAL|Supportive Counseling|
58129156|NCT02386033|DRUG|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
58129157|NCT04686253|OTHER|not appliable|not appliable
58129158|NCT02541526|DRUG|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
58129159|NCT02541526|DRUG|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
58457224|NCT03144739|OTHER|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
57763607|NCT03183388|BEHAVIORAL|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
57763608|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
57763609|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
57763610|NCT04775121|OTHER|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
57763611|NCT05494827|OTHER|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
57763612|NCT05494827|OTHER|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
57763613|NCT05494827|OTHER|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
57763614|NCT05420922|DRUG|Lenvatinib Oral Product|Lenvatinib or Sorafenib
57763615|NCT05420922|DRUG|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
57763616|NCT05420922|PROCEDURE|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
57763617|NCT05214313|BEHAVIORAL|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~* 10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~* Active phase: (25 min)~* 5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~* 20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~* 10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
57763618|NCT03078153|BEHAVIORAL|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
57763619|NCT03078153|BEHAVIORAL|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
57763620|NCT05287425|DRUG|Gentamicin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
57763621|NCT05287425|DRUG|Ciprofloxacin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
57763622|NCT05287425|DRUG|Povidone Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
57763623|NCT05287425|DRUG|Povidone and Benzalkonium Chloride Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
57763624|NCT06310902|DIAGNOSTIC_TEST|Single-cell Sequencing Analysis|Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
57763625|NCT02448667|DIETARY_SUPPLEMENT|FAXE Kondi|Sucrose and glucose containing softdrink
58129160|NCT02896361|DEVICE|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
57763626|NCT02448667|DIETARY_SUPPLEMENT|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
57763627|NCT00426426|BEHAVIORAL|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
57763628|NCT00426426|BEHAVIORAL|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
57763629|NCT00426426|BEHAVIORAL|Waiting list|
57763630|NCT03510624|DRUG|Rebaudioside A|Rebaudioside A 3g
57763631|NCT03510624|DRUG|Placebo|Empty capsules
57763632|NCT06013501|BEHAVIORAL|puppet show|puppet show to the child before and during subcutaneous application
57763633|NCT03626441|DIETARY_SUPPLEMENT|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
57763634|NCT03626441|DIETARY_SUPPLEMENT|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
57763635|NCT01350505|BEHAVIORAL|White light exposure|\~200 lux of broad spectrum white light
57763636|NCT01350505|BEHAVIORAL|Dim white light exposure|\~28 lux of broad spectrum white light
57763637|NCT01350505|BEHAVIORAL|Very dim white light exposure|\<0.5 lux of broad spectrum white light
57763638|NCT01350505|BEHAVIORAL|Dim orange light exposure|\~28 lux of orange light
57763639|NCT00628914|DRUG|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
57763640|NCT00628914|DRUG|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
57763641|NCT00628914|DRUG|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
57763642|NCT04372225|OTHER|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
57763643|NCT05012371|DRUG|Cabozantinib|Given PO
57763644|NCT05012371|DRUG|Everolimus|Given PO
57763645|NCT05012371|DRUG|Lenvatinib|Given PO
57763646|NCT05012371|OTHER|Questionnaire Administration|Ancillary studies
57763647|NCT05345379|OTHER|Single intervention|Single intervention at the day of fixed orthodontic appliance bonding
57763648|NCT03324464|BEHAVIORAL|Central Executive Training: Working Memory|Computerized working memory training
57763649|NCT03324464|BEHAVIORAL|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
57763650|NCT01642602|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
57763651|NCT02463201|BEHAVIORAL|Weight loss|
57763652|NCT01950065|DEVICE|iovera|
57763653|NCT01028261|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
57763654|NCT04585893|DRUG|Rituximab|375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
57763655|NCT04585893|DRUG|Etoposide|Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
57763656|NCT02914314|DRUG|perampanel|oral suspension.
57763657|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
57763658|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
57763659|NCT03166371|DIETARY_SUPPLEMENT|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
57763660|NCT03166371|OTHER|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
57763661|NCT01741116|DRUG|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
57763662|NCT00015821|DRUG|thalidomide|Given PO
57763663|NCT00015821|OTHER|laboratory biomarker analysis|Correlative studies
57763664|NCT03668262|DRUG|Cis-atracurium|Different concentration of cis-atracurium
57763665|NCT00003511|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57763666|NCT02206295|DRUG|selexipag|
57763667|NCT04601363|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
57763668|NCT04100122|PROCEDURE|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
57763669|NCT00525772|DRUG|ciclesonide|low dose- 50ug and 200ug
57763670|NCT00525772|DRUG|ciclesonide|high dose- 100ug and 400ug
57763671|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
57763672|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
57763673|NCT04263103|OTHER|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
57763674|NCT00171873|DRUG|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
57763675|NCT00171873|DRUG|Placebo|Sodium chloride intramuscularly every 28 days
57763676|NCT06010901|DRUG|TQB2618 injection|TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
57763677|NCT06010901|DRUG|Penpulimab injection|Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
57763678|NCT06010901|DRUG|Anlotinib hydrochloride capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
57763679|NCT00358137|BEHAVIORAL|Aerobic Conditioning Program|
57763680|NCT00358137|BEHAVIORAL|Strength Training Program|
57763681|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
57763682|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
57763683|NCT04754256|BEHAVIORAL|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
57961171|NCT05898958|PROCEDURE|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
58457225|NCT05998122|OTHER|nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
57763684|NCT05923086|DRUG|ORE001|Administration before major meal
57763685|NCT05923086|DRUG|Placebo|Administration before major meal
57763686|NCT04866121|PROCEDURE|Acupuncture|A standardized acupuncture protocol will be administered
57763687|NCT00086541|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
57763688|NCT04407013|OTHER|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
57763689|NCT04407013|OTHER|Control group with usual care|Control group will receive usual care (symptom monitoring only)
57763690|NCT02698540|OTHER|Nutritional Supplement|High calorie, high protein peptide based
57763691|NCT06626035|DRUG|Methadone based ERAS|Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision \[pre-CPB in CS\] and 0.05 mg at the end of surgery \[after CPB in CS\]) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
57763692|NCT06626035|DRUG|SOC non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
57763693|NCT03365986|DIAGNOSTIC_TEST|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
57763694|NCT01316770|DRUG|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
57763695|NCT01316770|DRUG|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
57763696|NCT02871830|BEHAVIORAL|Physical Activity|15 mins physical activity per day within the school setting.
57763697|NCT03059407|BEHAVIORAL|Dog therapy only|Canine assisted therapy only during echocardiogram
57763698|NCT03059407|BEHAVIORAL|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
58457226|NCT02146417|PROCEDURE|Low pressure pneumoperitoneum|
58457227|NCT02146417|PROCEDURE|Normal pressure pneumoperitoneum (12 mmHg)|
57763699|NCT03059407|BEHAVIORAL|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
57763700|NCT05778721|OTHER|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
57763701|NCT04079868|BEHAVIORAL|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
57763702|NCT02450721|OTHER|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
57763703|NCT02922894|PROCEDURE|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
57763704|NCT02922894|PROCEDURE|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
57763705|NCT02922894|DRUG|Trazodone|100mg before bedtime
57763706|NCT02922894|DRUG|Placebo|One placebo pill before-bedtime
57763707|NCT02922894|PROCEDURE|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
57763708|NCT01073800|DRUG|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
57763709|NCT01073800|DRUG|placebo|placebo
57763710|NCT02630524|BEHAVIORAL|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
57763711|NCT06151990|OTHER|lipid profile|Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting
57763712|NCT02093039|DEVICE|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
57763713|NCT01304121|DEVICE|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
57763714|NCT02496767|DRUG|Tirasemtiv|
58457228|NCT02146417|PROCEDURE|Deep neuromuscular block|
58457229|NCT04875013|DEVICE|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
58457230|NCT02172963|BIOLOGICAL|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
58457231|NCT01944007|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
58457232|NCT00054392|DRUG|carboplatin|
58457233|NCT00054392|DRUG|gemcitabine hydrochloride|
58457234|NCT00054392|DRUG|paclitaxel|
58457235|NCT03215017|DEVICE|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
58457236|NCT03215017|DRUG|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
58457237|NCT04903561|DEVICE|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
58457238|NCT02575755|DRUG|Azithromycin plus piperaquine phosphate|
57763715|NCT02496767|DRUG|Placebo tablets|
57763716|NCT03155932|DRUG|APD334|APD334 active treatment for 24 weeks.
57763717|NCT02112760|OTHER|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
57763718|NCT06624605|OTHER|Large Language Model-generated Plain Language Summary of Ophthalmology notes|Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
57763719|NCT05364684|DRUG|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
57763720|NCT04775238|OTHER|Silver nanoparticles|AgNPs (19±5 nm)
57763721|NCT04775238|OTHER|Copper nanoparticles|CuNPs (150-350 nm)
57763722|NCT04698317|PROCEDURE|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
57763723|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
57763724|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
57763725|NCT02357290|DRUG|Open-label Treatment with N-Acetylcysteine|
57763726|NCT00873665|OTHER|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
57763727|NCT00873665|OTHER|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
57763728|NCT04387981|DRUG|[14C]-orvepitant|Oral solution of \[14C\]-orvepitant
57763729|NCT02648971|PROCEDURE|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
57763730|NCT02648971|PROCEDURE|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
57763731|NCT02757482|OTHER|training|
58457239|NCT02575755|DRUG|Sulfadoxine-pyrimethamine|
58457240|NCT04842708|DIAGNOSTIC_TEST|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
58457241|NCT01179321|OTHER|Early referral to Dietitian for assessment and nutrition support|
58457242|NCT00965081|DRUG|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
58457243|NCT00965081|DRUG|Placebo|QD po at the same time each day for 12 weeks
58457244|NCT05925946|DIETARY_SUPPLEMENT|CURE-DM|"1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
58457245|NCT05841368|DIAGNOSTIC_TEST|CAM-ICU|Delirium in adult patients will be screened according to CAM-ICU
58457246|NCT05841368|DIAGNOSTIC_TEST|pCAM-ICU|Delirium in adult patients will be screened according to pCAM-ICU
58457247|NCT05470387|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
58457248|NCT05470387|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
58457249|NCT02204930|DRUG|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
58457250|NCT00602212|BEHAVIORAL|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
58457251|NCT00602212|BEHAVIORAL|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
58457252|NCT02313220|DRUG|Dapagliflozin|Oral use
58457253|NCT02313220|DRUG|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
58457254|NCT02313220|DRUG|Placebo|Oral and Subcutaneous use.
58457255|NCT01893801|DRUG|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
58457256|NCT01893801|DRUG|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
58457257|NCT01893801|DRUG|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
58457258|NCT04283305|OTHER|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
58457259|NCT04283305|OTHER|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
58457260|NCT06419985|DRUG|80mg Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 80mg
57763732|NCT06120673|DRUG|Obinutuzumab|"Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion."
57763733|NCT06120673|DRUG|Oral prednisolone and cyclophosphamide|"Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight"
57763734|NCT05585138|OTHER|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
57763735|NCT05585138|OTHER|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
57763736|NCT00621712|DEVICE|GamCath® central venous catheter|choice of catheter type
57763737|NCT00621712|DEVICE|GamCath Dolphin® Protect central venous catheter|choice of catheter type
58457261|NCT06419985|DRUG|160mg Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 160mg
58457262|NCT06419985|DRUG|Administration of Ketamine HCl Prolonged Release - 240mg|Administration of Ketamine HCl Prolonged Release - 240mg
58457263|NCT01719796|PROCEDURE|Regional analgesia infusion|
58457264|NCT01799096|DIETARY_SUPPLEMENT|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
58457265|NCT01799096|DIETARY_SUPPLEMENT|Aspartame|Intensely sweetened soft drink (no energy content)
58457266|NCT03707795|DRUG|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
58457267|NCT04960449|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
58457268|NCT00687401|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
58457269|NCT02922725|DRUG|5-hydroxytryptophan and Creatine|
58457270|NCT02922725|OTHER|Placebo control|
58457271|NCT02785185|DRUG|IDP-122 Vehicle Lotion|Vehicle
58457272|NCT02785185|DRUG|IDP-122 Vehicle Cream|Vehicle
58457273|NCT02785185|DRUG|IDP-122 Lotion|Lotion
58457274|NCT02785185|DRUG|Ultravate Cream|Cream
58457275|NCT05870514|DRUG|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
58457276|NCT05870514|DRUG|Propofol|Propofol
58457277|NCT00004380|DRUG|relaxin|
58457278|NCT02451059|BEHAVIORAL|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
57763738|NCT04331535|DIAGNOSTIC_TEST|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
57763739|NCT04916119|DRUG|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
57763740|NCT01681108|BEHAVIORAL|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
57763741|NCT01147692|BIOLOGICAL|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
57763742|NCT00004011|DRUG|carboplatin|
57763743|NCT00004011|DRUG|paclitaxel|
57763744|NCT00004011|PROCEDURE|conventional surgery|
57763745|NCT02920203|GENETIC|Heart and spleen tissue|genetic sequencing
57763746|NCT01994356|BEHAVIORAL|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
57763747|NCT01994356|BEHAVIORAL|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
57763748|NCT01774071|DRUG|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan."
57763749|NCT01774071|DRUG|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
57763750|NCT03007784|DEVICE|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
57763751|NCT02166450|DRUG|Nystatin|100 000 IU every 6 h as a suspension
57763752|NCT06188520|DRUG|AZD8421|CDK2 inhibitor
57763753|NCT06188520|DRUG|Camizestrant|SERD
57763754|NCT06188520|DRUG|Ribociclib|CDK4/6 inhibitor
57763755|NCT06188520|DRUG|Palbociclib|CDK4/6 inhibitor
57763756|NCT06188520|DRUG|Abemaciclib|CDK4/6 inhibitor
57763757|NCT06190262|BEHAVIORAL|The intervention is community based group psychoeducation|The intervention is community based group psychoeducation
57763758|NCT04183634|DRUG|Rotigotine TTS (Test)|Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
57763759|NCT04183634|DRUG|Neupro (Reference)|Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
58129161|NCT02472288|DEVICE|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
58457279|NCT02451059|BEHAVIORAL|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
58457280|NCT02451059|BEHAVIORAL|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
57763760|NCT02722343|DRUG|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
57763761|NCT02722343|DRUG|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
58457281|NCT01411826|BEHAVIORAL|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
57763762|NCT00206193|DRUG|mifepristone|
57763763|NCT00206193|DRUG|misoprostol|
57763764|NCT00206193|DRUG|sulprostone|
57763765|NCT02837562|OTHER|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
57763766|NCT03644901|PROCEDURE|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
57763767|NCT00560664|PROCEDURE|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
57763768|NCT00560664|PROCEDURE|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
57763769|NCT02244801|DRUG|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
57763770|NCT00002443|DRUG|Indinavir sulfate|
57763771|NCT00002443|DRUG|Zidovudine|
57763772|NCT02574000|OTHER|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
57763773|NCT02574000|OTHER|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
57763774|NCT06388811|OTHER|Early Osteoarthritis Questionnaire|Self administered questionnaire
57763775|NCT02826122|DEVICE|Pai APP|Prescription: Target 100 PAI Points per week
57763776|NCT02826122|DEVICE|FitBit APP|Prescription: Target daily 10.000 steps
57763777|NCT03570983|DRUG|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
57763778|NCT03570983|DRUG|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
57763779|NCT03570983|DRUG|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
57763780|NCT03570983|DRUG|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
57763781|NCT03570983|DRUG|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
57763782|NCT01338012|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
57763783|NCT03244462|DRUG|BAY1834845|Single oral dose (IR \[immediate release\] tablets)
57763784|NCT03244462|DRUG|BAY1834845|I.v. infusion of \[13C6\]-labeled BAY1834845
57763785|NCT03244462|DRUG|Methotrexate|Single dose of commercially available MTX
57763786|NCT04933201|OTHER|Music|Perioperative musical intervention
57763787|NCT04933201|OTHER|Routine perioperative treatment|Routine perioperative treatment
57763788|NCT05643820|DRUG|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
58457282|NCT01411826|BEHAVIORAL|Information Only|Information from CDC website on colon cancer screening.
58457283|NCT00941941|PROCEDURE|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
57763789|NCT05643820|DRUG|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
57763790|NCT04845724|OTHER|Standard Diet|
57763791|NCT04845724|OTHER|Modified Diet|
57763792|NCT06516627|BEHAVIORAL|Positive Labels|"Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best)."
57763793|NCT06516627|BEHAVIORAL|Spectrum Labels|"All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best)."
57763794|NCT06516627|BEHAVIORAL|FDA High In Labels|Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.
57763795|NCT06516627|BEHAVIORAL|FDA Traffic Light Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red."
57763796|NCT04786314|OTHER|Hot Water Application|Pregnant women will apply hot water to their legs before going to sleep for a week.
57763797|NCT04786314|OTHER|Cold Water Application|Pregnant women will apply cold water to their legs before going to sleep for a week.
57763798|NCT01862796|BEHAVIORAL|Underfeeding diet|Heart healthy diet with 35% reduced calories
57763799|NCT01862796|BEHAVIORAL|Weight maintaining diet|Heart healthy weight-maintaining diet
57763800|NCT02853461|OTHER|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
57763801|NCT02853461|OTHER|Microbiological analysis|Plating the sonicates on agar plates.
57763802|NCT05677932|DEVICE|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
57763803|NCT05677932|DEVICE|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
57763804|NCT03885466|BEHAVIORAL|Nordic Walking exercise|Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
57763805|NCT00039325|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
57763806|NCT04599101|DEVICE|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
57763807|NCT04599101|DEVICE|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
58457284|NCT00941941|PROCEDURE|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
57763808|NCT03424590|DEVICE|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
57763809|NCT03480217|BEHAVIORAL|Multifaceted Implementation Strategy|"Key components include:~* educational presentations to primary care providers at grand rounds~* patient information materials on ABPM and HBPM~* training registered nurses to assist providers with teaching patients to conduct HBPM~* information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~* a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~* periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~* an accessible, culturally-adapted and locally tailored ABPM service"
57763810|NCT04399356|DRUG|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
57763811|NCT04399356|DRUG|Placebo|The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
57763812|NCT04399356|OTHER|Telehealth monitoring|In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
57763813|NCT03400501|DRUG|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
57763814|NCT03400501|DRUG|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
57763815|NCT06624631|OTHER|Delivery strategy A|Delivery of PDMC at the primary admitting facility
57763816|NCT06624631|OTHER|Delivery strategy B|Referral to the closest peripheral facility for dispensing of PDMC two weeks post discharge
57763817|NCT02390739|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
57763818|NCT02390739|DRUG|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
57763819|NCT02390739|DRUG|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
57763820|NCT02390739|BIOLOGICAL|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
57763821|NCT00695747|PROCEDURE|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
57763822|NCT01611584|DRUG|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
57763823|NCT04550663|DRUG|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
57763824|NCT05720234|DRUG|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
57763825|NCT02118662|OTHER|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
57763826|NCT02118662|OTHER|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
57763827|NCT02118662|OTHER|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
57763828|NCT02118662|OTHER|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
58457285|NCT03140514|DRUG|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
58457286|NCT01689142|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
58457287|NCT01689142|DRUG|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
58457288|NCT00433641|DRUG|sibutramine|placebo
57763829|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
57763830|NCT02178410|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
57763831|NCT02178410|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
58457289|NCT00433641|DRUG|sibutramine|oral 15 mg sibutramine once per day
57763832|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
57763833|NCT04138342|DRUG|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
57763834|NCT04138342|DRUG|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
57763835|NCT01872910|DRUG|Placebo|Administered orally
57763836|NCT01872910|DRUG|LY3023703|Administered orally
57763837|NCT01872910|DRUG|Celecoxib|Administered orally
57763838|NCT05461690|DRUG|Niraparib|200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
57763839|NCT00150774|DRUG|Levetiracetam|
57763840|NCT03324984|DRUG|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
58457290|NCT00433641|DRUG|sibutramine|oral sibutramine 10 mg once per day
58457291|NCT05670522|DEVICE|Transcranial direct current stimulation|"Transcranial direct-current stimulation (tDCS), over the motor cortex, is a potential therapy option for motor control deficits in children with CP. The application of tDCS involves positioning 2 rubber electrodes sheathed in saline-soaked pads onto the scalp, held in place by a rubber strap. Low-intensity, direct-current, of 1 to 2 mA, is delivered to cortical areas from the device.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
58457292|NCT05670522|DEVICE|Virtual reality|"Virtual reality rehabilitation is an emerging therapy for motor rehabilitation of children with CP. The therapy is provided through a computer-simulated environment where they interact with real-world-like objects and events through sight, sound, and touch. The Wii Remote was used as the interactive interface, and standard computer/television screens were used as the display hardware. Therefore, VR therapy was of the non-immersive type.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
58457293|NCT02933788|DRUG|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
57763841|NCT03324984|DRUG|0.75% bupivacaine|Bupivacaine is used on label
57763842|NCT03548805|PROCEDURE|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
57763843|NCT03548805|PROCEDURE|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
57763844|NCT01213108|BEHAVIORAL|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
57763845|NCT01213108|BEHAVIORAL|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
57763846|NCT01342822|DEVICE|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
57763847|NCT00142922|BEHAVIORAL|Breaking Down Barriers|completed
57763848|NCT02105805|BEHAVIORAL|Dietetic group sessions|Group sessions to improve dietary adherence
57763849|NCT02078505|BEHAVIORAL|diet|Carbohydrate poor diet
57763850|NCT04838418|PROCEDURE|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
57763851|NCT03066843|DRUG|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
57763852|NCT03066843|DEVICE|Blue light therapy|Subjects will be exposed to blue light
57763853|NCT02753205|DRUG|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
57763854|NCT02753205|DRUG|normal saline|infusion of normal saline
57763855|NCT05280769|OTHER|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
57763856|NCT05280769|OTHER|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
57763857|NCT05280769|OTHER|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
57763858|NCT05280769|OTHER|Smokeless tobacco|Participant's typical brand of smokeless tobacco
57763859|NCT05297643|DEVICE|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
57763860|NCT05297643|OTHER|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
57763861|NCT00920023|DRUG|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
57763862|NCT04875832|BEHAVIORAL|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
57763863|NCT05851599|OTHER|SKF7® Labisia pumila standardized extract|Botanical extract of Labisia pumila (Kacip Fatimah)
57763864|NCT01538108|DEVICE|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
57763865|NCT01538108|PROCEDURE|Plain Balloon angioplasty (PBA)|PBA
57763866|NCT05932056|BEHAVIORAL|Miles de Manos (Thousands of Hands)|Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
57763867|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine 0.25% and magnesium sulfate|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus 3.75 ml NS and 125 mg MgSO4 (1.25ml)."
57763868|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine and dememdetomidine|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg."
57763869|NCT01054573|DRUG|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
57763870|NCT01054573|DRUG|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
57763871|NCT01054573|DRUG|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
57763872|NCT05563363|OTHER|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
57763873|NCT05563363|OTHER|standard inpatient treatment|Inpatient treatment on addiction ward
57763874|NCT06050902|DEVICE|Subclavian venipuncture for catheter placement using the needle-steering device|"1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture."
57763875|NCT00002901|DRUG|docetaxel|
57763876|NCT06568341|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Outcome Expectations For Yoga (OEY) Scale
57763877|NCT05483933|DRUG|Pegylated Liposomal Doxorubicin + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
57763878|NCT05483933|DRUG|Mirvetuximab + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
57763879|NCT02720822|DRUG|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
57763880|NCT02720822|DRUG|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
57763881|NCT02720822|DRUG|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
57763882|NCT02720822|DRUG|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
57763883|NCT02720822|DEVICE|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
57763884|NCT01326273|PROCEDURE|Lymphopheresis|Lymphopheresis
57763885|NCT01326273|PROCEDURE|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
57763886|NCT01326273|PROCEDURE|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
57763887|NCT01326273|PROCEDURE|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
57763888|NCT02237235|DRUG|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
58457294|NCT02933788|DRUG|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
58457295|NCT01686334|BIOLOGICAL|DC vaccine|Autologous WT1 mRNA-electroporated DCs
58457296|NCT02619760|DRUG|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
58457297|NCT02619760|DRUG|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
57763889|NCT02237235|DRUG|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
57763890|NCT01712555|PROCEDURE|autologous fat grafting with PRP to anophthalmic orbits|
57763891|NCT05740410|DEVICE|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
58129162|NCT02472288|DEVICE|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
58129163|NCT02681965|BEHAVIORAL|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
57763892|NCT02567825|DEVICE|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
57763893|NCT02567825|DRUG|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
57763894|NCT02567825|DRUG|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
57763895|NCT04280822|DRUG|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"
57763896|NCT03434002|OTHER|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
57763897|NCT03434002|OTHER|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
57763898|NCT01536184|BEHAVIORAL|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
57763899|NCT05529745|OTHER|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
57763900|NCT03032354|DRUG|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
57763901|NCT03032354|OTHER|Placebo, (Placebo group)|Placebo during 6 months
57763902|NCT02437474|BEHAVIORAL|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
57763903|NCT02437474|BEHAVIORAL|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
57763904|NCT02437474|BEHAVIORAL|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
57763905|NCT00210262|BEHAVIORAL|Feedback and Education|
57763906|NCT03880084|OTHER|Observation|To systematically assess the onset of delirium, quantify the level of agitation/sedation, estimate the grade of pain and survey the level of dyspnea in patients undergoing non invasive mechanical ventilation
57763907|NCT03393702|DRUG|Gabapentin|"1. Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~2. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
57763908|NCT03393702|DRUG|Placebo|"1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day."
57763909|NCT00226512|DRUG|Campath-1H /ATG|
57763910|NCT02444663|RADIATION|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
57763911|NCT02444663|RADIATION|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
57763912|NCT02444663|RADIATION|Device Valgus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763913|NCT02444663|RADIATION|Device Valgus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
58129164|NCT03148574|DRUG|Misoprostol|intrauterine tablets
58129165|NCT03148574|DRUG|Oxytocin|intravenous
58457298|NCT05404243|DRUG|phenolization|In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
58457299|NCT05404243|PROCEDURE|Conventional surgery|In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
58457300|NCT04440267|DRUG|vincristine|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457301|NCT04440267|DRUG|daunorubicin|acute lymphoblastic leukemia (ALL) -based chemotherapy
57763914|NCT02444663|RADIATION|Device Valgus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763915|NCT02444663|RADIATION|Device Valgus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763916|NCT02444663|RADIATION|Device Varus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763917|NCT02444663|RADIATION|Device Varus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763918|NCT02444663|RADIATION|Device Varus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763919|NCT02444663|RADIATION|Device Varus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
57763920|NCT00898014|GENETIC|fluorescence in situ hybridization|
57763921|NCT00898014|OTHER|immunologic technique|
57763922|NCT00898014|OTHER|laboratory biomarker analysis|
57763923|NCT03176238|DRUG|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
57763924|NCT03176238|DRUG|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
57763925|NCT06362902|PROCEDURE|Laparoscopic right hemicolectomy with transrectal specimen extraction|Laparoscopic right hemicolectomy with transrectal specimen extraction
58457302|NCT04440267|DRUG|cyclophosphamide|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457303|NCT04440267|DRUG|L-Asparaginase|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457304|NCT04440267|DRUG|prednisone|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457305|NCT04440267|DRUG|mercaptopurine|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457306|NCT04440267|DRUG|methotrexate|acute lymphoblastic leukemia (ALL) -based chemotherapy
57763926|NCT04616014|DRUG|ORMD-0801 QD|16 mg, QD, two capsules, 8 mg each.
57763927|NCT00006008|DRUG|arsenic trioxide|
57763928|NCT05857111|DEVICE|Celbrea|The test with the CELBREA® device will be added to the routine screening according to the protocols of the health facility.
57763929|NCT04477421|PROCEDURE|FS-SMILE|Femtosecond small incision lenticule extraction
57763930|NCT04477421|PROCEDURE|S-LASIK|Femtosecond laser Insitu keratomileusis
57763931|NCT03673462|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
57763932|NCT03673462|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
57763933|NCT03673462|BIOLOGICAL|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
57763934|NCT03673462|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58457307|NCT04440267|DRUG|dexamethasone|acute lymphoblastic leukemia (ALL) -based chemotherapy
58457308|NCT04440267|DRUG|Tyrosine kinase inhibitor|acute lymphoblastic leukemia (ALL) -based chemotherapy
57763935|NCT03673462|BIOLOGICAL|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
57763936|NCT03673462|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
57763937|NCT03673462|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
57763938|NCT03673462|BIOLOGICAL|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
57763939|NCT05151497|OTHER|Experimental group:Halliwick + Método Watsu|Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
57763940|NCT05151497|OTHER|Control group:Halliwick|Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
57763941|NCT00671008|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
57763942|NCT00671008|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
57763943|NCT02938923|DRUG|Testosterone|Topical testosterone gel 1%
57763944|NCT02938923|DRUG|Placebo gel|Inactive skin gel
57763945|NCT02938923|BEHAVIORAL|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
58457309|NCT03683173|BEHAVIORAL|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
58457310|NCT03467347|DRUG|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
58457311|NCT04103359|OTHER|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
58457312|NCT02028377|PROCEDURE|PET/MRI|PET/MRI
58457313|NCT00120926|DRUG|Parenteral Nutrition|
58457314|NCT04713280|PROCEDURE|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
58457315|NCT01320475|DRUG|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
58457316|NCT01320475|DRUG|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
57763946|NCT02938923|BEHAVIORAL|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
57763947|NCT02938923|BEHAVIORAL|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
57763948|NCT05007145|DRUG|PD-1 inhibitor|PD-1 Inhibitor 200mg D1 Q3W
57763949|NCT05007145|DRUG|Albumin-Bound Paclitaxel|125 mg/m\^2 D1/D8 Q3W
57763950|NCT05007145|DRUG|Cisplatin|75 mg/m\^2 D1 Q3W
57763951|NCT05007145|RADIATION|Radiation|40Gy/2.0Gy
57763952|NCT04667013|DRUG|Tetramethylpyrazine nitrone (TBN) tablet / Placebo|Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
57763953|NCT03412968|PROCEDURE|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
57763954|NCT03412968|PROCEDURE|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
57763955|NCT00964457|DRUG|cetuximab|cetuximab 500mg per meter square every second week
57763956|NCT05555888|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
57763957|NCT05555888|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
57763958|NCT05555888|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
57763959|NCT05555888|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
57763960|NCT01600222|DRUG|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
57763961|NCT02759185|DRUG|High THC cannabis|Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
57763962|NCT02759185|DRUG|High CBD cannabis|Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
57763963|NCT02759185|DRUG|THC/CBD cannabis|Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
57763964|NCT02759185|DRUG|Placebo cannabis|Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
57763965|NCT01059032|OTHER|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
57763966|NCT02480816|DIETARY_SUPPLEMENT|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
57763967|NCT00238732|DRUG|Bazedoxifene/Conjugated Estrogen|
57763968|NCT05302557|OTHER|Ileostomy stimulation|Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
57763969|NCT00949884|DRUG|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
57763970|NCT00949884|DRUG|Placebo|placebo oral tablets once daily for two weeks
57763971|NCT00949884|DRUG|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
57763972|NCT03221101|DEVICE|Home ventilator|
57763973|NCT03992534|COMBINATION_PRODUCT|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
57763974|NCT04670237|DEVICE|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
57763975|NCT04705064|DIAGNOSTIC_TEST|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
57763976|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
57763977|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
57763978|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
57763979|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
57763980|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
57763981|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
57763982|NCT04052191|BIOLOGICAL|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
57763983|NCT04802096|OTHER|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
57763984|NCT04802096|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
57763985|NCT04236921|DRUG|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
58457317|NCT05968677|DIETARY_SUPPLEMENT|FSMP|Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
57763986|NCT04236921|DRUG|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
57763987|NCT04219098|PROCEDURE|Butterfly IQ|10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
57763988|NCT04219098|OTHER|Standard of Care|The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
57763989|NCT04797182|DRUG|avatrombopag|avatrombopag,60 mg/d,po
57763990|NCT02013596|OTHER|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
57763991|NCT02013596|OTHER|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
57763992|NCT03821337|DEVICE|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
57763993|NCT03821337|DEVICE|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
57763994|NCT04496869|OTHER|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
57763995|NCT00113360|DRUG|RAD001|Starting dose of 5 or 10 mg by mouth daily.
57763996|NCT00113360|DRUG|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
57763997|NCT00925821|PROCEDURE|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
57763998|NCT00925821|DRUG|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
57763999|NCT02428244|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
57764000|NCT02428244|BEHAVIORAL|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
57764001|NCT06264544|DIETARY_SUPPLEMENT|zinc, selenium, and L-tyrosine in SEPP1|zinc, selenium, and L-tyrosine in SEPP1 polymorphism
57764002|NCT06264544|OTHER|Placebo|placebo comparator in SEPP1 polymorphism group
57764003|NCT01726855|PROCEDURE|vascularized finger dorsal fascial flap|
57764004|NCT03812861|OTHER|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
58457318|NCT05968677|OTHER|Nutritional counseling|Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
58457319|NCT04052490|OTHER|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
58457320|NCT00028483|DRUG|cBR96-doxorubicin immunoconjugate|
57764005|NCT00893347|BEHAVIORAL|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
57764006|NCT00893347|BEHAVIORAL|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
57764007|NCT01555801|DEVICE|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
57764008|NCT01555801|DEVICE|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
57764009|NCT03227016|DRUG|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
57764010|NCT03227016|DRUG|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
57764011|NCT06309238|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication
57764012|NCT06309238|PROCEDURE|Bariatric surgery|Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
57764013|NCT00621816|DRUG|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
57764014|NCT00621816|DRUG|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
57764015|NCT05925634|BEHAVIORAL|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
57764016|NCT05925634|BEHAVIORAL|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
57764017|NCT03009721|DRUG|Other: Not applicable-observational study|
57764018|NCT01862952|OTHER|starting of anti-epileptic drug treatment|
58457321|NCT00028483|DRUG|docetaxel|
58457322|NCT02033434|DRUG|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
57764019|NCT01857622|DRUG|DU-176b 15mg|oral DU-176b 15mg once daily
57764020|NCT01857622|DRUG|DU-176b 30mg|oral DU-176b 30mg once daily
57764021|NCT01857622|DRUG|DU-176b 60mg|oral DU-176b 60mg once daily
57764022|NCT04785664|OTHER|Community-based pro-Active Monitoring Program|The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
57764023|NCT03017157|OTHER|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
57764024|NCT03017157|OTHER|Blood test|Blood test to determine thyroid function
57764025|NCT00189592|DEVICE|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
57764026|NCT00189592|PROCEDURE|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
57764027|NCT04618263|DRUG|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
57764028|NCT00328640|DRUG|Optimal treatment|
57764029|NCT01272960|DEVICE|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
57764030|NCT01272960|DEVICE|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
57764031|NCT02306122|BEHAVIORAL|Pharmacist calls patient unless physician cancels call|
57764032|NCT02306122|BEHAVIORAL|Patient nonadherence information sent to physician|
57764033|NCT02306122|BEHAVIORAL|Pharmacist calls patient if physician requests call|
57764034|NCT02306122|BEHAVIORAL|Doctor receives information and may be allowed certain actions|
57764035|NCT04895189|OTHER|No intervention|There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.
57764036|NCT00003086|BIOLOGICAL|filgrastim|
57764037|NCT00003086|DRUG|CAF regimen|
57764038|NCT00003086|DRUG|carboplatin|
57764039|NCT00003086|DRUG|cisplatin|
57764040|NCT00003086|DRUG|cyclophosphamide|
57764041|NCT00003086|DRUG|doxorubicin hydrochloride|
57764042|NCT00003086|DRUG|fluorouracil|
58457323|NCT03324373|DRUG|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
57764043|NCT00003086|DRUG|ifosfamide|
57764044|NCT00003086|DRUG|melphalan|
57764045|NCT00003086|DRUG|paclitaxel|
57764046|NCT00003086|DRUG|thiotepa|
57764047|NCT00003086|PROCEDURE|peripheral blood stem cell transplantation|
57764048|NCT00003086|RADIATION|samarium Sm 153 lexidronam pentasodium|
57764049|NCT03565068|DRUG|MK-8189|MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
57764050|NCT03565068|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
57764051|NCT03565068|DRUG|Background AAP Therapy|Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
57764052|NCT06155383|DRUG|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
57764053|NCT06155383|DRUG|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
57764054|NCT06155383|DRUG|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
57764055|NCT06155383|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
57764056|NCT00644462|DEVICE|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
57764057|NCT02956434|BEHAVIORAL|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
57764058|NCT04615182|DEVICE|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
57764059|NCT06626100|BEHAVIORAL|Exercise-themed game|The intervention includes three parts: quiz questions on knowledge on and benefits of exercise; monitored step count using smartphone tracker; whatsapp reminders on the benefits of exercise.
57764060|NCT06626100|BEHAVIORAL|Diet-themed game|The intervention includes two parts: quiz questions on knowledge on and benefits of healthy diet; whatsapp reminders on the benefits of healthy diet.
57764061|NCT05266963|DRUG|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
57764062|NCT05266963|DRUG|Placebo|Placebo
57764063|NCT04704154|DRUG|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
57764064|NCT04704154|DRUG|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
57764065|NCT04207840|COMBINATION_PRODUCT|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
57764066|NCT04207840|COMBINATION_PRODUCT|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
57764067|NCT04207840|COMBINATION_PRODUCT|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
57764068|NCT00699140|BIOLOGICAL|IGIV3I Grifols|Immune Globulin Intravenous (Human)
57764069|NCT01378910|DRUG|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
57764070|NCT04706533|DIAGNOSTIC_TEST|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
57764071|NCT02654210|OTHER|No Intervention|No Intervention
57764072|NCT05696314|DIAGNOSTIC_TEST|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
57764073|NCT05696314|DIAGNOSTIC_TEST|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
57764074|NCT02118480|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
58129166|NCT01765530|DEVICE|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
57764075|NCT02118480|OTHER|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
57764076|NCT06546319|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
57764077|NCT03266848|DIAGNOSTIC_TEST|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
57764078|NCT02993939|PROCEDURE|Interscalene block|Ultrasound guided single shot block above the clavicle
57764079|NCT02993939|PROCEDURE|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
57764080|NCT04146649|PROCEDURE|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
57764081|NCT06434714|DEVICE|Auricular percutaneous nerve field stimulator|Percutaneous nerve field stimulator device placed on the ear for 5 days
57764082|NCT06434714|DEVICE|Sham auricular percutaneous nerve field stimulator|Non-functioning percutaneous nerve field stimulator device placed on the ear for 5 days
57764083|NCT04310917|OTHER|blood lipoprotein (a) test|research specific blood sample
57764084|NCT05130814|DEVICE|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
57764085|NCT05130814|PROCEDURE|cleansing|cleaning of the wound area with saline or ringer's lactate
57764086|NCT05130814|COMBINATION_PRODUCT|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
57764087|NCT05130814|DRUG|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
57764088|NCT05130814|PROCEDURE|topical treatment|topical treatment indicated for that stage of the lesion
57764089|NCT05130814|PROCEDURE|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
57764090|NCT05088889|DRUG|Nivolumab|Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
57764091|NCT05088889|DRUG|ipilimumab|Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
57764092|NCT05088889|RADIATION|Stereotactic body radiation therapy|Three fractions of 8 Gy, treated on alternate days
57764093|NCT05088889|RADIATION|Low dose irradiation|a single fraction of 2Gy will be given to the metastatic lesions at first progression
57764094|NCT02836158|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
57764095|NCT06624384|DRUG|Group 1 drug|Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
57764096|NCT06624384|DRUG|Group 2: Drug and placebo|Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
57764097|NCT06624384|DRUG|Group 3: Drug and palcebo|Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
57764098|NCT00227864|BEHAVIORAL|Behavior Therapy|
57764099|NCT00227864|OTHER|Treatment as Usual|
57764100|NCT02843802|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
57764101|NCT02843802|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
57764102|NCT00153387|BEHAVIORAL|Women's health|
57764103|NCT05437354|OTHER|survey|Oncology medical staff should respond to a survey
58457324|NCT03324373|DRUG|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
57764104|NCT05892666|OTHER|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
57764105|NCT05892666|OTHER|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
57764106|NCT05892666|OTHER|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
58129167|NCT01079442|OTHER|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
58457325|NCT03324373|PROCEDURE|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
58457326|NCT03285802|DRUG|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
58457327|NCT03285802|DRUG|Everolimus|Everolimus 10mg daily q 28 days
57764107|NCT02955472|DRUG|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
57764108|NCT02955472|DRUG|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
57764109|NCT01373216|DRUG|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
57764110|NCT01547026|BEHAVIORAL|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
57764111|NCT02778126|DRUG|[¹⁴C]Prexasertib|Administered IV Infusion
57764112|NCT02778126|DRUG|Prexasertib|Administered IV Infusion
57764113|NCT02291484|DEVICE|Cardiac CT scan|CT-guided management
57764114|NCT04078360|BEHAVIORAL|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~1. Self awareness messages~2. Self reflection messages~3. Motivational messages~4. Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~5. Health education messages~6. Personalized feedback and information~7. Help-seeking resources~8. Goal setting messages"
57764115|NCT04078360|BEHAVIORAL|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
57764116|NCT04078360|BEHAVIORAL|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
57764117|NCT02343003|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
57764118|NCT02343003|DRUG|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
57764119|NCT03040882|OTHER|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
57764120|NCT03040882|OTHER|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
57764121|NCT03299790|OTHER|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
57764122|NCT03299790|OTHER|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
57764123|NCT03355430|PROCEDURE|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
57764124|NCT03355430|PROCEDURE|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
57764125|NCT01525134|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
57764126|NCT01525134|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
57764127|NCT03463915|DRUG|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
57764128|NCT03463915|DRUG|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
57764129|NCT02210793|PROCEDURE|transepithelial PRK|
57764130|NCT02210793|PROCEDURE|LASIK|
57764131|NCT02986490|BIOLOGICAL|Blood sample|Blood sample
57764132|NCT03609346|DEVICE|PCI|The placement of 1 or more stents in the diseased coronary artery lesion(s).
57764133|NCT00118261|BIOLOGICAL|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
57764134|NCT00118261|DRUG|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
57764135|NCT00118261|DRUG|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
57764136|NCT00118261|DRUG|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
57764137|NCT00118261|DRUG|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
58129168|NCT01079442|OTHER|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
58129169|NCT03541564|DRUG|BMS-986165|Specified dose on specified days
57764138|NCT06189404|DRUG|Tigulixostat|300 mg oral dose
57764139|NCT06189404|DRUG|Theophylline|400 mg oral dose
57764140|NCT01369134|DEVICE|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
58129170|NCT03541564|DRUG|Moxifloxacin|Specified dose on specified days
58129171|NCT03541564|OTHER|Placebo|Specified dose on specified days
58129172|NCT03505853|DRUG|Givosiran|single dose of givosiran by subcutaneous (sc) injection
58129173|NCT03505853|DRUG|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
58129174|NCT03544138|DEVICE|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
58129175|NCT02878109|DEVICE|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
57764141|NCT05425511|BEHAVIORAL|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
57764142|NCT00840255|BEHAVIORAL|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
57764143|NCT00840255|OTHER|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
57764144|NCT00030420|DRUG|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
57764145|NCT00030420|DRUG|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
57764146|NCT05970302|DRUG|Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine|Use the above medications on a regular basis.
57764147|NCT02294630|DRUG|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
57764148|NCT04895514|PROCEDURE|Gamma-irradiated corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
57764149|NCT05763784|DEVICE|Tightrope|Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
57764150|NCT06326255|BEHAVIORAL|laughter yoga|each class, including warm-up exercises, laughter yoga exercises, breathing and a relaxation session and sharing
57764151|NCT01421095|DRUG|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
57764152|NCT04033263|OTHER|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764153|NCT04033263|OTHER|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764154|NCT04033263|OTHER|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764155|NCT04033263|OTHER|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764156|NCT04033263|OTHER|Mouth rinse 5|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764157|NCT04033263|OTHER|Mouth rinse 6|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764158|NCT04033263|OTHER|Mouth rinse 7|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764159|NCT04033263|OTHER|Mouth rinse 8|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764160|NCT04033263|OTHER|Mouth rinse 9|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
57764161|NCT01592149|OTHER|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
57764162|NCT01833312|DEVICE|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
57764163|NCT01833312|DRUG|Buspirone|anti-shivering treatment
57764164|NCT01833312|DRUG|Pethidine|anti-shivering treatment
57764165|NCT03114202|OTHER|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
57764166|NCT03114202|OTHER|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
57764167|NCT04241692|DEVICE|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
58457328|NCT05180695|DRUG|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
58457329|NCT05180695|DRUG|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
58457330|NCT05620095|DEVICE|drug-coated balloon|To evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.
57764168|NCT04241692|DEVICE|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
57764169|NCT01897701|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
57764170|NCT01897701|BIOLOGICAL|Adjuvant 1|
57764171|NCT01897701|BIOLOGICAL|Placebo|
57764172|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
57764173|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
57764174|NCT04042116|DRUG|Lucitanib|"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
57764175|NCT04042116|DRUG|Nivolumab|IV nivolumab 480 mg will be administered once every 4 weeks.
57764176|NCT02430701|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
57764177|NCT02430701|DEVICE|NanoKnife|
57764178|NCT03884504|DEVICE|Ventricular Assist Device System|Ventricular Assist Device System
57764179|NCT00553501|BIOLOGICAL|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV
57764180|NCT00553501|BIOLOGICAL|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV
57764181|NCT04005534|DRUG|Standard group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
57764182|NCT04005534|DRUG|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
57764183|NCT01678014|PROCEDURE|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
58129176|NCT02878109|DEVICE|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
58457331|NCT03416088|BEHAVIORAL|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
58457332|NCT03416088|BEHAVIORAL|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
57764184|NCT01678014|PROCEDURE|Capsulotomy|
57764185|NCT06613529|OTHER|online mindfulness training|"Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning."
57764186|NCT01602757|DRUG|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
57764187|NCT00212901|DRUG|High dose ACE-I vs ARB|
57764188|NCT00635765|DRUG|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
57764189|NCT06284317|DRUG|Adjuvant durvalumab|Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
57764190|NCT00799695|BEHAVIORAL|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
57764191|NCT04072341|DRUG|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
57764192|NCT04072341|OTHER|Control Period|In the control period they will only follow standard treatment for their comorbidities.
58129177|NCT04518176|PROCEDURE|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
58129178|NCT04518176|DRUG|Oxytocin|20 units by slow intravenous drip injection
57764193|NCT01933971|DRUG|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
57764194|NCT01933971|DRUG|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
57764195|NCT02139657|BIOLOGICAL|RIG-C|
57764196|NCT02955121|OTHER|Prescriber Access to Genetic Information|
57764197|NCT00063102|DRUG|ABT-751|
57764198|NCT04197011|DEVICE|prosthetic device|Individuals with TFA will use a combination of prosthetic devices.
57764199|NCT05324930|DEVICE|Piscean collagen dressing|Piscean collagen dressing
57764200|NCT05324930|DEVICE|Saline infused dressing|Saline infused dressing
57764201|NCT05960370|OTHER|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
57764202|NCT04195880|OTHER|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
57764203|NCT06481852|DRUG|MTT with antibiotic preconditioning + fiber supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
57764204|NCT06481852|DRUG|MTT with antibiotic preconditioning + placebo supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
57764205|NCT06481852|OTHER|MTT with placebo + placebo supplementation.|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
57764206|NCT05869682|PROCEDURE|Bright White Light Therapy|Wear AYOpro BWL therapy
57764207|NCT05869682|DRUG|Combination Drug Therapy|Receive SOC ADT combination therapy
57764208|NCT05869682|OTHER|Electronic Health Record Review|Ancillary studies
57764209|NCT05869682|OTHER|Quality-of-Life Assessment|Ancillary studies
57764210|NCT05869682|OTHER|Questionnaire Administration|Ancillary studies
57764211|NCT02276066|DIAGNOSTIC_TEST|GFR by Iohexol|Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
57764212|NCT02276066|DIAGNOSTIC_TEST|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
57764213|NCT02276066|DIAGNOSTIC_TEST|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
57764214|NCT05515614|DIETARY_SUPPLEMENT|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
57764215|NCT05515614|DIETARY_SUPPLEMENT|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
57764216|NCT03743896|DRUG|Transdermal Glucosamine Cream|
57764217|NCT06285669|OTHER|kinesiotaping application|kinesiotaping application
57764218|NCT04821635|DEVICE|Rower assisted by electrostimulation (FES-ROW)|"1. Pre-inclusion visit~2. Inclusion visit~3. Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~   Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~4. Interim assessment visit at Month 3 (M3)~5. Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~   Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~6. Final assessment visit at Month 6 (M6)~7. End of clinical research visit, 3 months after the end of training (Month 9, M9)"
57764219|NCT02235363|PROCEDURE|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
57764220|NCT00710372|BIOLOGICAL|CYT006-AngQb|s.c. injection
57764221|NCT01001949|DIETARY_SUPPLEMENT|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
57764222|NCT01001949|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
57764223|NCT06122220|PROCEDURE|ONSD+AF|Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
57764224|NCT04651400|DRUG|Antithrombin III|Antithrombin III
57764225|NCT03219008|DRUG|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
57764226|NCT03219008|COMBINATION_PRODUCT|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
57764227|NCT03219008|DRUG|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
57764228|NCT03219008|COMBINATION_PRODUCT|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
57764229|NCT03219008|DRUG|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
57764230|NCT03219008|DRUG|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
57764231|NCT03219008|COMBINATION_PRODUCT|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
57764232|NCT03219008|COMBINATION_PRODUCT|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
57764233|NCT03219008|DRUG|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
57764234|NCT03219008|COMBINATION_PRODUCT|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
57764235|NCT03219008|DRUG|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
57764236|NCT03219008|COMBINATION_PRODUCT|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
57764237|NCT03219008|OTHER|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
57764238|NCT06160739|DRUG|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug
57764239|NCT02294539|DRUG|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
57764240|NCT02294539|DRUG|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
57764241|NCT02294539|DRUG|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
57764242|NCT02294539|DRUG|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
57764243|NCT05916092|DEVICE|TransLoc 3D|TransLoc 3D SI Joint Fusion System
57764244|NCT01655602|PROCEDURE|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
57764245|NCT01655602|PROCEDURE|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
57764246|NCT01655602|PROCEDURE|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
57764247|NCT02923102|DIETARY_SUPPLEMENT|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
57764248|NCT02923102|DIETARY_SUPPLEMENT|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
57764249|NCT02880007|RADIATION|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
57764250|NCT02880007|RADIATION|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
57764251|NCT02880007|DRUG|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
58457333|NCT03416088|BEHAVIORAL|Body motion|Exercise or body postural changes
58457334|NCT02620969|OTHER|Blood and dialysate sampling|Blood and dialysate sampling
57764252|NCT03485911|DRUG|BCX7353 capsules|BCX7353 oral capsules administered once daily
57764253|NCT03485911|DRUG|Placebo oral capsule|Matching oral capsules administered once daily
57764254|NCT05127798|OTHER|Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.|Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
58457335|NCT01919944|DRUG|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
57764255|NCT05713006|DRUG|Alectinib Oral Product|Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
57764256|NCT03620422|OTHER|Mannitol|Mannitol-Induced Cough Challenge
57764257|NCT03620422|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
57764258|NCT03620422|OTHER|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
57764259|NCT06495541|DRUG|Pyrotinib|Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
57764260|NCT01656928|BEHAVIORAL|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
57764261|NCT01420432|BIOLOGICAL|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
57764262|NCT05675852|OTHER|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
57764263|NCT03654339|PROCEDURE|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
57764264|NCT04860414|BIOLOGICAL|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
57764265|NCT04860414|OTHER|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
57764266|NCT04860414|OTHER|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
57764267|NCT04860414|OTHER|Objective taste tests|Recording of gustatory evoked potentials
57764268|NCT00500240|DRUG|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
57764269|NCT00500240|DRUG|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
57764270|NCT02002182|BIOLOGICAL|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
57764271|NCT03436966|DEVICE|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
57764272|NCT05233943|DEVICE|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
57764273|NCT01412190|DEVICE|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
57764274|NCT01412190|OTHER|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
57764275|NCT06107764|DEVICE|intermittant theta burst stimulation (iTBS)|iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.
57764276|NCT06107764|DEVICE|continuous theta burst stimulation (cTBS)|cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses
57764277|NCT06107764|DEVICE|sham rTMS|sham rTMS does not deliver a significant change in magnetic field strength
58457336|NCT01919944|DRUG|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
58457337|NCT03790111|DRUG|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
57764278|NCT02459821|OTHER|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
57764279|NCT02459821|OTHER|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
57764280|NCT04321967|DRUG|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
57764281|NCT04321967|DRUG|Dermabond|Topical skin adhesive
57764282|NCT01431040|OTHER|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
57764283|NCT01431040|OTHER|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
57764284|NCT05344261|PROCEDURE|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
57764285|NCT05344261|PROCEDURE|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
57764286|NCT05344261|PROCEDURE|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
57764287|NCT03091647|BEHAVIORAL|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
57764288|NCT03091647|BEHAVIORAL|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
57764289|NCT05529758|BEHAVIORAL|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
57764290|NCT06112223|DRUG|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
57764291|NCT06112223|DRUG|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
57764292|NCT04158180|DIAGNOSTIC_TEST|Questionnaire|A battery of questionnaires will be propose to the participants
57764293|NCT04686162|OTHER|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
57764294|NCT03399162|BEHAVIORAL|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
57764295|NCT03399162|BEHAVIORAL|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
57764296|NCT03852966|BEHAVIORAL|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
57764297|NCT03749447|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules
57764298|NCT01086865|DRUG|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
57764299|NCT03214081|DRUG|Vonoprazan|Vonoprazan tablets
57764300|NCT06363058|OTHER|ES Cycling Training|Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks
57764301|NCT02183935|DEVICE|Duodena-jejunal liner|
57764302|NCT03635489|DRUG|Paclitaxel|175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
57764303|NCT03635489|DRUG|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
57764304|NCT03635489|DRUG|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
57764305|NCT03635489|DRUG|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
57764306|NCT06342089|OTHER|Type I diabetes milletus|the exposure is type I diabetes milletus
57764307|NCT06062459|OTHER|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
57764308|NCT06062459|OTHER|Balance Training|Balance training exercises on to enhance proprioception and stability
57764309|NCT06062459|OTHER|Control Group|Participants received hot pack and stretching exercise
57764310|NCT02062866|PROCEDURE|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
57764311|NCT02062866|PROCEDURE|Second Intent|The wound will not be sutured, and allowed to heal on its own.
57764312|NCT00658138|DEVICE|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
57764313|NCT00658138|DEVICE|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
57764314|NCT05485610|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
57764315|NCT05485610|OTHER|Placebo|NMN-free placebo capsules for 3 months
57764316|NCT02913976|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
57764317|NCT02913976|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
57764318|NCT04632901|DIAGNOSTIC_TEST|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
57764319|NCT04632901|DIAGNOSTIC_TEST|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
57764320|NCT05603832|DRUG|F14|625 mg intra-articular sustained-release celecoxib
57764321|NCT05603832|DRUG|0.25 % Bupivacaine HCl|Local anesthetic
57764322|NCT05603832|DRUG|Acetaminophen|Analgesic
57764323|NCT05603832|DRUG|Methocarbamol|Muscle relaxant
57764324|NCT02867514|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
57764325|NCT01356316|BIOLOGICAL|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
57764326|NCT00032890|DRUG|glucosamine|
57764327|NCT00032890|DRUG|chondroitin sulfate|
57764328|NCT00032890|DRUG|glucosamine and chondroitin sulfate combined|
57764329|NCT00032890|DRUG|celecoxib|
57764330|NCT03311763|BEHAVIORAL|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
57764331|NCT03311763|BEHAVIORAL|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
57764332|NCT04664725|DRUG|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
57764333|NCT00003640|BIOLOGICAL|filgrastim|
57764334|NCT00003640|DRUG|cisplatin|
57764335|NCT00003640|DRUG|doxorubicin hydrochloride|
57764336|NCT00003640|DRUG|methotrexate|
57764337|NCT00003640|DRUG|vinblastine sulfate|
57764338|NCT00003640|PROCEDURE|surgical procedure|
57764339|NCT00003640|RADIATION|radiation therapy|
57764340|NCT00084214|DRUG|STA-4783|
57764341|NCT00084214|DRUG|Paclitaxel|
57764342|NCT01417611|PROCEDURE|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
57764343|NCT04693936|COMBINATION_PRODUCT|Nutraceutical Combination Plan|"Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment."
57764344|NCT03253016|DIAGNOSTIC_TEST|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
57764345|NCT06112730|OTHER|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
57764346|NCT06112730|OTHER|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
57764347|NCT00001790|DRUG|FK463|
57764348|NCT04951674|OTHER|High fiber diet|30 grams of fiber per day
57764349|NCT04951674|OTHER|Control diet|No diet education and change in diet
57764350|NCT04707196|DRUG|Abemaciclib|Administered orally
57764351|NCT04707196|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
57764352|NCT04707196|DRUG|Fulvestrant|Administered intramuscularly
57764353|NCT00053001|BIOLOGICAL|epoetin alfa|
57764354|NCT00053001|DRUG|thalidomide|
57764355|NCT02410993|PROCEDURE|CABG surgery|
57764356|NCT04944355|OTHER|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
57764357|NCT03328000|RADIATION|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
57764358|NCT05363657|PROCEDURE|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
57764359|NCT05363657|PROCEDURE|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
57764360|NCT05363657|PROCEDURE|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
57764361|NCT05363657|DIAGNOSTIC_TEST|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
57764362|NCT05377970|OTHER|Thinkific Prehabilitation Exercise Program|Prehabilitation exercise program through the Thinkific platform
57764363|NCT02848716|PROCEDURE|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
57764364|NCT02848716|RADIATION|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
57764365|NCT02848716|RADIATION|chemoradiation|
57764366|NCT02006875|DEVICE|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
57764367|NCT03960671|DRUG|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
57764368|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
57764369|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
57764370|NCT03077464|BEHAVIORAL|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
57764371|NCT00026858|BEHAVIORAL|collaboration|
57764372|NCT01336621|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
57764373|NCT04755270|DEVICE|VR Glasses|techniques of hypnofertility and VR glasses
57764374|NCT00438620|BEHAVIORAL|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
57764375|NCT03757234|DRUG|Omadacycline|po tablets
57764376|NCT03757234|DRUG|Levofloxacin|iv solution/po tablets
58129179|NCT02822781|OTHER|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
58129180|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
58129181|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
57764377|NCT03757234|DRUG|Omadacycline|iv solution
58129182|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
58129183|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
58129184|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
58129185|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
58129186|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
58129187|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
58129188|NCT03619252|BIOLOGICAL|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
58129189|NCT03619252|DRUG|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
58129190|NCT05948748|PROCEDURE|foot surgery|minimally invasive osteoarticular foot surgery
58129191|NCT03805464|OTHER|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
57764378|NCT06175585|OTHER|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
57764379|NCT06175585|OTHER|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
57764380|NCT04943042|DRUG|Avatrombopag|According to prescription
57764381|NCT02260128|OTHER|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
57764382|NCT02459223|DIETARY_SUPPLEMENT|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
57764383|NCT02459223|DIETARY_SUPPLEMENT|Khichadi|Khichadi.
57764384|NCT02938169|BEHAVIORAL|exercise|"* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)"
57764385|NCT01105806|BEHAVIORAL|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
57764386|NCT01105806|BEHAVIORAL|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
57764387|NCT03139396|PROCEDURE|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
57764388|NCT02924324|DEVICE|propofol|
57764389|NCT02924324|DRUG|ropivacaine|
57764390|NCT02924324|BEHAVIORAL|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
57764391|NCT02924324|BEHAVIORAL|Post-procedural quality of life (QOL)|
57764392|NCT03134014|DIETARY_SUPPLEMENT|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
57764393|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
57764394|NCT01370005|DRUG|BI 10773|BI 10773 high dose once daily
57764395|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
57764396|NCT01370005|DRUG|BI 10773|BI 10773 low dose once daily
57764397|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
57764398|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
57764399|NCT00308932|DRUG|HFA FP MDI|
57764400|NCT01148862|DEVICE|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
57764401|NCT00150384|DRUG|Amlodipine/Atorvastatin|
57764402|NCT00633919|BIOLOGICAL|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
57764403|NCT00633919|BIOLOGICAL|Placebo|Sublingual immunotherapy once daily for 2 years
57764404|NCT00633919|DRUG|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
57764405|NCT00633919|DRUG|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
57764406|NCT00633919|DRUG|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
57764407|NCT00633919|DRUG|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
57764408|NCT00633919|DRUG|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
57764409|NCT05074355|DRUG|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
57764410|NCT05074355|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
57764411|NCT01921881|OTHER|St John's wort|
57764412|NCT02473458|DRUG|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules"
57764413|NCT02473458|DRUG|Placebo|
57764414|NCT05549765|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
57764415|NCT05549765|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
57764416|NCT01862822|OTHER|upright position|
58129192|NCT06143865|OTHER|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
57764417|NCT05845476|OTHER|Patient SOGI Self-Report|"EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record."
57764418|NCT05845476|OTHER|SOGI Resource for Clinical Care Education (SORCE)|SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
57764419|NCT05845476|OTHER|Cancer Center Care Environment|At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
57764420|NCT05830435|BEHAVIORAL|Trier social stress test|TSST-VR-friendly: The assistant behind the desk asks the participant to prepare a small talk on their favourite holiday within 5 minutes. Then the participant is asked to tell about his holiday for 5 minutes. Then the participant is asked to do a simple math task: adding the number 5 to 0 for 5 minutes. The research assistant gives friendly gestures and verbal encouragements. TSST-VR-neutral: The assistant asks the participant to prepare a speech for a job interview in the upcoming 5 minutes. Then the participant is asked to deliver the speech for 5 minutes in front of two panelists and camera. Then the participant is asked to do a math task, subtracting the number 13 from 1022 for 5 minutes. During the performance the two panellist have neutral gestures and give neutral verbal instructions. TSST-VR unfriendly: The procedure of the TSST-VR unfriendly is the same as the neutral TSST-VR, with the addition that the two panellist give unfriendly gestures such as tapping on the table.
57764421|NCT02440802|GENETIC|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
57764422|NCT06310499|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
57764423|NCT04061590|DRUG|Cisplatin|Given IV
57764424|NCT04061590|BIOLOGICAL|Pembrolizumab|Given IV
57764425|NCT04061590|DRUG|Pemetrexed|Given IV
57764426|NCT04061590|DRUG|Pemetrexed Disodium|Given IV
57764427|NCT04061590|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
57764428|NCT04194996|PROCEDURE|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
57764429|NCT05399095|BEHAVIORAL|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
57764430|NCT05399095|BEHAVIORAL|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
57764431|NCT03499015|PROCEDURE|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
57764432|NCT00871884|BEHAVIORAL|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
57764433|NCT00871884|BEHAVIORAL|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
57764434|NCT00871884|BEHAVIORAL|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
57764435|NCT01287520|DRUG|LY2090314|Administered intravenously
57764436|NCT01287520|DRUG|pemetrexed|Administered intravenously
57764437|NCT01287520|DRUG|Carboplatin|Administered intravenously
57764438|NCT01287520|OTHER|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
57764439|NCT03798002|OTHER|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
57764440|NCT03798002|OTHER|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
57764441|NCT04891796|OTHER|No intervention|No intervention
57764442|NCT05288725|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
57764443|NCT05288725|DRUG|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
57764444|NCT05288725|DEVICE|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
57764445|NCT00958022|DRUG|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
57764446|NCT06625125|BEHAVIORAL|Mindfulness-based intervention|"The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
57764447|NCT06625125|BEHAVIORAL|Progressive muscle relaxation|"he progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
57764448|NCT05301062|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
57764449|NCT05997121|DEVICE|Transforaminal lumbar interbody fusion|Transforaminal Lumbar Interbody Fusion indicates a surgical approach in the lumbar spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height. Screws and rods are also added to maintain the level secure while the bones fuse together.
57764450|NCT02130453|DRUG|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
57764451|NCT01866163|DRUG|LEO 90100|
57764452|NCT01866163|DRUG|Vehicle|
57764453|NCT00546325|DRUG|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
57764454|NCT00546325|DRUG|Placebo|Matching placebo tablets. Once daily before breakfast
57764455|NCT03971708|DRUG|Lidocaine|Local anesthetic
57764456|NCT03971708|DRUG|Ropivacaine|Local anesthetic
57764457|NCT05354063|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
57764458|NCT05354063|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
57764459|NCT05354063|DRUG|Placebo|Placebo IM on day 0 and day 21.
57764460|NCT03347747|OTHER|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
57764461|NCT02734680|RADIATION|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
57764462|NCT02734680|RADIATION|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
57764463|NCT02734680|DRUG|S-1|Taking S-1 orally after radiation
57764464|NCT03545347|DRUG|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.
57764465|NCT03545347|DIETARY_SUPPLEMENT|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
57764466|NCT03545347|OTHER|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
57764467|NCT03545347|DRUG|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
58129193|NCT03287609|DRUG|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
58129194|NCT03287609|DRUG|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
58129195|NCT01060670|DEVICE|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
58129196|NCT01060670|OTHER|Conventional Wound Therapy|Conventional Wound Therapy
58129197|NCT01881321|BEHAVIORAL|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
58129198|NCT05712330|OTHER|non invasive ventilation samples|machine samples for bacterial culture will be performed
57764468|NCT05984316|OTHER|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
57764469|NCT02673710|OTHER|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
57764470|NCT03354325|BEHAVIORAL|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
57764471|NCT03354325|BEHAVIORAL|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
57764472|NCT04255342|DEVICE|Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery|At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
57764473|NCT01279330|OTHER|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
57764474|NCT01279330|OTHER|Control|No intervention (Patients receive by mail the materials needed for stool samples).
57764475|NCT06365645|BEHAVIORAL|M.Bapp|Please see experimental group description.
57764476|NCT06365645|BEHAVIORAL|App-based parenting education|Please see active comparator group description.
57764477|NCT02294825|PROCEDURE|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
57764478|NCT06624592|DRUG|Sevoflurane|Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
57764479|NCT06624592|DRUG|Isoflurane|Subjects will receive standard of care anesthesia Isoflurane
57764480|NCT02601716|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
57764481|NCT02601716|BIOLOGICAL|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
57764482|NCT02601716|BIOLOGICAL|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
57764483|NCT00008463|DRUG|Ribavirin|
57764484|NCT00008463|DRUG|Interferon alfa-2a|
57764485|NCT00008463|DRUG|Peginterferon alfa-2a|
57764486|NCT03437590|DRUG|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
57764487|NCT03437590|DRUG|[18F]-JNJ-64413739|\[18F\]-JNJ-64413739 fluid for injection administered intravenously.
57764488|NCT04122391|OTHER|sound level volume|Noise level during cardiac arrest
57764489|NCT00987064|DEVICE|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
57764490|NCT00987064|DEVICE|Placebo TLA|TLA treatment with disabled filtration function
57764491|NCT04525547|DRUG|Nintedanib|Nintedanib
57764492|NCT03529448|DRUG|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
57764493|NCT03529448|DRUG|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
57764494|NCT03529448|RADIATION|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
57764495|NCT05715359|PROCEDURE|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
57764496|NCT02760056|DRUG|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
57764497|NCT02760056|DRUG|Placebo|Patient will receive a matching placebo to take twice daily for one week.
58129199|NCT05712330|OTHER|patient samples|Patient samples for sputum culture
57764498|NCT06445075|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
57764499|NCT06445075|DRUG|Placebo|Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo will be administered every 4 weeks by intravenous (IV) infusion.
57764500|NCT06445075|DRUG|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide will be administered every week by subcutaneous injection.
57764501|NCT06445075|DRUG|Tirzepatide|Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide will be administered every week by subcutaneous injection.
57764502|NCT05590546|OTHER|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
57764503|NCT04534114|DRUG|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
57764504|NCT04534114|DRUG|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
57764505|NCT01861522|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
57764506|NCT01861522|DRUG|Placebo|Two Placebo tablets will be taken orally twice a day
57764507|NCT03768765|PROCEDURE|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
57764508|NCT03325543|OTHER|Verbal instruction and Vaginal palpation|The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
57764509|NCT05440383|DRUG|KLH-2109|Oral administration
57764510|NCT05440383|DRUG|Leuprorelin|Subcutaneous administration
57764511|NCT01543412|DRUG|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
57764512|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
57764513|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
57764514|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
57764515|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
57764516|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
57764517|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
57764518|NCT05447624|PROCEDURE|Radiofrequency ablation of genicular nerves|The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
57764519|NCT02152228|DRUG|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
57764520|NCT05502419|PROCEDURE|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
57764521|NCT05502419|PROCEDURE|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
57764522|NCT04494438|DRUG|Rituximab|
58129200|NCT05712330|OTHER|parent questionnaire|parent questionnaire
57764523|NCT04728334|DRUG|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
57764524|NCT00770432|DRUG|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
57764525|NCT00770432|OTHER|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
57764526|NCT04947371|DRUG|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
57764527|NCT03781830|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
57764528|NCT02825134|DEVICE|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
57764529|NCT02825134|DEVICE|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
57764530|NCT04918368|BEHAVIORAL|Behavioral scales were used|Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
58129201|NCT01345019|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
58129202|NCT01345019|DRUG|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
58129203|NCT01345019|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
58129204|NCT01345019|DRUG|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
58129205|NCT01345019|DRUG|Denosumab (for the open-label treatment phase)|Administered by subcutaneous injection once every 4 weeks.
57764531|NCT01266694|DRUG|Colchicines|oral form, 1 mg, once a day during 14 days
57764532|NCT01266694|DRUG|Placebo|oral form, placebo
57764533|NCT04631705|BIOLOGICAL|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
57764534|NCT04631705|BIOLOGICAL|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
57764535|NCT04631705|DRUG|Placebo|Inhalation of DZIF-10c diluent as placebo
57764536|NCT04631705|DRUG|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
57764537|NCT04618822|BEHAVIORAL|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
57764538|NCT04618822|BEHAVIORAL|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
57764539|NCT04618822|BEHAVIORAL|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
57764540|NCT02558361|DRUG|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. \[30mg po BID after initial titration\]
57764541|NCT03971838|BEHAVIORAL|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
57764542|NCT03290612|DIETARY_SUPPLEMENT|Vitamin C|1.5g Ascorbic Acid
57764543|NCT03290612|OTHER|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
57764544|NCT05867719|OTHER|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
57764545|NCT00486135|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
57764546|NCT00486135|DRUG|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
57764547|NCT03704532|PROCEDURE|Operative treatment|Open surgical repair of tendon rupture
57764548|NCT03704532|PROCEDURE|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
57764549|NCT01595243|BEHAVIORAL|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
57764550|NCT05728567|OTHER|whether the participants had T2DM|whether the participants had T2DM
57764551|NCT05779553|DIAGNOSTIC_TEST|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
57764552|NCT03640546|BEHAVIORAL|Within My Reach/ Within Our Reach|Relationship education workshops
57764553|NCT04367038|OTHER|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
57764554|NCT01276561|PROCEDURE|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
57764555|NCT01276561|PROCEDURE|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
58129206|NCT04495049|DEVICE|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
58129207|NCT04823299|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation ablation
58129208|NCT04823299|PROCEDURE|Radiofrequency catheter ablation +EPS guided trigger and substrate ablation|RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
58129209|NCT01535326|PROCEDURE|air insufflation|insufflate air during the insertion of colonoscopy
57764556|NCT03880695|DRUG|Anlotinib+ Liposomal Doxorubicin|Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
57764557|NCT05458258|DEVICE|Bioelectrical Impedence Analysis Device|A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.
57764558|NCT05458258|OTHER|6 Minute Walk Test|Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.
57764559|NCT05458258|DIAGNOSTIC_TEST|Computed Tomography Scans to Measure Skeletal Muscular Index|Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).
57764560|NCT05458258|DIAGNOSTIC_TEST|Blood Test/Blood Draw|Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.
57764561|NCT05458258|OTHER|Hand Grip Strength Test|Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.
57764562|NCT00723437|DRUG|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
57764563|NCT02873819|DRUG|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
57764564|NCT02873819|DRUG|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
57764565|NCT02873819|DRUG|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
57764566|NCT02873819|DRUG|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
57764567|NCT02873819|DRUG|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
57764568|NCT06100055|DEVICE|Rectal Irrigation|"Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation."
57764569|NCT04942808|RADIATION|Periapical radiographs|Periapical radiographs on reevaluation
57764570|NCT03715712|OTHER|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure \> 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion
57764571|NCT03715712|OTHER|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
57764572|NCT03579264|BEHAVIORAL|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
57764573|NCT02571322|DEVICE|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
57764574|NCT02571322|OTHER|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
57764575|NCT06625541|DRUG|AJ302-IM|7 cohorts (7 dose levels) of participants are planned to be dosed.
57764576|NCT06625541|DRUG|Placebo|Matching placebo
57764577|NCT02337517|OTHER|Laboratory Biomarker Analysis|Correlative studies
57764578|NCT02337517|DRUG|Vismodegib|Given PO
57764579|NCT03392207|BIOLOGICAL|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
57764580|NCT01202487|DRUG|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
57764581|NCT00888901|DRUG|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
57764582|NCT00888901|DRUG|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
57764583|NCT02696122|PROCEDURE|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
57764584|NCT02696122|PROCEDURE|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
57764585|NCT03996044|OTHER|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
57764586|NCT03996044|OTHER|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
57764587|NCT03996044|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
57764588|NCT03996044|BIOLOGICAL|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
57764589|NCT01164228|DRUG|Gemcitabine|Given IV
57764590|NCT01164228|DRUG|Sunitinib|Given PO
57764591|NCT02204579|DRUG|NPSP795|
57764592|NCT00664638|DEVICE|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
57764593|NCT04960553|DEVICE|Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
57764594|NCT01218529|DRUG|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
57764595|NCT03332641|DIETARY_SUPPLEMENT|Citron peel extract|Citron peel extract for 12 weeks
57764596|NCT03332641|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
57764597|NCT02225379|DEVICE|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
57764598|NCT02665702|DRUG|NVB|25mg/m2 ，D1，8
57764599|NCT02665702|DRUG|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
57764600|NCT02665702|DRUG|Endostar|15mg/d，d1-d7 civ
57764601|NCT05496972|BEHAVIORAL|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
57764602|NCT00310895|DRUG|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
57764603|NCT05563792|BEHAVIORAL|Options for Pain Management using Non-medication Strategies|The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
57764604|NCT04179981|DEVICE|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
57764605|NCT04179981|OTHER|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
57764606|NCT05647551|DRUG|BOTOX®/VISTABEL®|Facial Injection
57764607|NCT05647551|DEVICE|Juvéderm® VOLBELLA® with Lidocaine|Facial Injection
57764608|NCT05647551|DEVICE|Juvéderm® VOLIFT® with Lidocaine|Facial Injection
57764609|NCT05647551|DEVICE|Juvéderm® VOLUMA® with Lidocaine|Facial Injection
58129210|NCT01535326|PROCEDURE|water immersion|infuse water during insertion, aspirate water during withdrawal
58129211|NCT01535326|PROCEDURE|water exchange|infuse and remove water during insertion phase of colonoscopy
58457338|NCT01216202|RADIATION|Preoperative radiotherapy|"Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes."
58457339|NCT03630835|OTHER|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
58457340|NCT01612975|DRUG|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
58457341|NCT01612975|DRUG|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
58457342|NCT01103167|BEHAVIORAL|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
57764610|NCT02057003|DRUG|DAA against HCV|
57764611|NCT06624683|DEVICE|Intelligent footbath basin|before night sleep, takes 30 mins, starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
57764612|NCT00363610|DRUG|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
57764613|NCT01313546|OTHER|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
57764614|NCT03485014|DRUG|Exparel|EXPAREL 4 mg/kg
57764615|NCT02070900|DEVICE|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
57764616|NCT02070900|OTHER|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
57764617|NCT03848364|BEHAVIORAL|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
57764618|NCT06333834|DRUG|Traditional scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)
58129212|NCT04453748|OTHER|Complex diagnostic panel|Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
58457343|NCT04471350|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
58457344|NCT04835844|DEVICE|CARTO|Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
58457345|NCT04835844|DEVICE|RHYTHMIA|Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
57764619|NCT06333834|DRUG|Serial dose of scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
57764620|NCT00735865|PROCEDURE|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin \& tarsal/inferior fornix conjunctiva obtained \& plated according to protocol
57764621|NCT00735865|PROCEDURE|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin \& conjunctiva/inferior fornix of BOTH eyes"
57764622|NCT00735865|PROCEDURE|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
57764623|NCT00735865|OTHER|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
57764624|NCT03131635|BEHAVIORAL|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
57764625|NCT03296709|DEVICE|PPC z|Installation of a preformed pediatric zircona crown
57764626|NCT03296709|DEVICE|PPC m|Installation of a preformed pediatric metal crown
57764627|NCT03928002|OTHER|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
57764628|NCT03928002|PROCEDURE|Cardiac catheterization|pulmonary vascular resistance calculation ;
58457346|NCT01091064|OTHER|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
58457347|NCT03170726|DRUG|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
58457348|NCT03170726|DRUG|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
58457349|NCT03170726|OTHER|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
58457350|NCT03783507|BEHAVIORAL|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
58457351|NCT03783507|BEHAVIORAL|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
58457352|NCT03783507|BEHAVIORAL|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
58457353|NCT03783507|BEHAVIORAL|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
58457354|NCT00248495|DRUG|cisplatin|Given IV
58457355|NCT00248495|DRUG|pemetrexed disodium|Given IV
57764629|NCT05975502|OTHER|Epidemiological study|Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
57764630|NCT05512429|OTHER|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
57764631|NCT03595501|DEVICE|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
58457356|NCT00248495|PROCEDURE|adjuvant therapy|Metastasis prevention/control
58457357|NCT00248495|PROCEDURE|conventional surgery|Undergoing tissue removal
58457358|NCT00248495|PROCEDURE|neoadjuvant therapy|Tumor Reduction
58457359|NCT06052228|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
57764632|NCT03595501|DEVICE|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
57764633|NCT05619874|BEHAVIORAL|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
57764634|NCT05619874|BEHAVIORAL|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
57764635|NCT04281433|OTHER|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
57764636|NCT00118625|BIOLOGICAL|Tree MATA MPL|
57764637|NCT01754883|DRUG|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
57764638|NCT05613101|PROCEDURE|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
57764639|NCT05613101|PROCEDURE|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
57764640|NCT00750100|DRUG|human chorionic gonadotropin|hCG 200IU in the late follicular phase
57764641|NCT00750100|DRUG|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
57764642|NCT02961114|PROCEDURE|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
57764643|NCT02961114|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
57764644|NCT02961114|BIOLOGICAL|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
57764645|NCT02597907|DRUG|aprepitant|aprepitant 80 mg is given to all patients before surgery
57764646|NCT02597907|DRUG|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
57764647|NCT02597907|DRUG|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
57764648|NCT04844437|DIAGNOSTIC_TEST|Transperineal ultrasound|The fetal head station is evaluated by transperineal ultrasonography in valsalva.
57764649|NCT03931447|BIOLOGICAL|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
57764650|NCT03931447|BIOLOGICAL|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
57764651|NCT04396041|DEVICE|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
57764652|NCT04396041|DEVICE|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
57764653|NCT04396041|DEVICE|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
57764654|NCT00638196|DRUG|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
57764655|NCT01449240|OTHER|No treatment|
57764656|NCT02180438|DRUG|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
57764657|NCT06333210|BIOLOGICAL|anti-TRBV9 monoclonal antibody infusions|infusions
57764658|NCT06333210|OTHER|Placebo infusions|infusions
57764659|NCT06333210|DRUG|Adalimumab subcutaneous injection|subcutaneous injection
57764660|NCT06333210|OTHER|Placebo subcutaneous injection|subcutaneous injection
57961172|NCT05898958|PROCEDURE|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
57961173|NCT01338415|DRUG|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
58129213|NCT02351726|DEVICE|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
57764661|NCT01298921|DRUG|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
57764662|NCT01298921|DRUG|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
57764663|NCT01656837|BEHAVIORAL|Comprehensive Community Treatment|
57764664|NCT01656837|BEHAVIORAL|MST-BSF|
57764665|NCT00615862|OTHER|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
57764666|NCT05767775|OTHER|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
57764667|NCT03395249|DRUG|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
57764668|NCT03395249|DRUG|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
57764669|NCT03395249|DRUG|Orapenem®|Tebipenem pivoxil granules
57764670|NCT00792103|DRUG|NP101|NP101 study patch 4 hour application
57764671|NCT05386563|PROCEDURE|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
57764672|NCT05386563|PROCEDURE|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
57764673|NCT01683240|DEVICE|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
57764674|NCT03187015|DRUG|Entinostat|HDAC (histone deacetylase inhibitor)
57764675|NCT03187015|DRUG|Midazolam|benzodiazepine central nervous system (CNS) depressant
57764676|NCT01629680|DRUG|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
57764677|NCT01629680|DRUG|Placebo|coated tablets identical in number and appearance as the study drug
57764678|NCT01849900|OTHER|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
57764679|NCT01849900|BEHAVIORAL|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
57764680|NCT00337662|DRUG|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
57764681|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, for 10 weeks.
57764682|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, 10 weeks
57961174|NCT04407559|OTHER|Serological analyses to be lead on a pre-existing biobank|"3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~* WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~* Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~* Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime."
57961175|NCT03403205|DRUG|ALXN1840|ALXN1840 administered orally in 15 mg tablets
57764683|NCT05507658|DRUG|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles."
57764684|NCT05893199|DEVICE|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
57764685|NCT05893199|OTHER|Usual care|usual follow-up in primary care both arms
57764686|NCT04834778|DRUG|HC-5404-FU|HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
57764687|NCT02053545|DRUG|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
57764688|NCT05726682|DRUG|SAR445419|Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
57764689|NCT01395654|DRUG|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
57764690|NCT02057601|DRUG|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
57764691|NCT02150837|OTHER|5 & 2 & 2 Plan|Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, \>72g protein, \>100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
57764692|NCT02150837|OTHER|4 & 2 & 1 Plan|Medifast has developed the 4 \& 2 \& 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 \& 2 \& 1 Plan consists of 4 Medifast meal replacements, 2 Lean \& Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, \>72g protein, \>100g carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
57764693|NCT00790114|DRUG|AZD7325|Oral, day 1-12
57764694|NCT00790114|DRUG|Midazolam|single dose, twice during treatment
57764695|NCT00790114|DRUG|Caffeine|single dose, twice during treatment
57764696|NCT00352898|BIOLOGICAL|MeMuRu-OKA (study vac)|
57764697|NCT00352898|BIOLOGICAL|MMR, Varicella vacc (control)|
57764698|NCT04195529|GENETIC|presence of genetic variants|identification of the presence of genetic variants
57764699|NCT04649827|OTHER|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
57764700|NCT01500564|DEVICE|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
57764701|NCT01500564|DEVICE|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
57764702|NCT01979731|OTHER|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
57764703|NCT01979731|OTHER|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
57764704|NCT03601455|BIOLOGICAL|Durvalumab|Given IV
57764705|NCT03601455|RADIATION|External Beam Radiation Therapy|Undergo EBRT
57764706|NCT03601455|BIOLOGICAL|Tremelimumab|Given IV
57764707|NCT03748017|DIETARY_SUPPLEMENT|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
57764708|NCT03748017|DIETARY_SUPPLEMENT|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
57764709|NCT05398146|BEHAVIORAL|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
57764710|NCT05398146|BEHAVIORAL|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
57764711|NCT05398146|BEHAVIORAL|listening to music|Children were allowed to listen to music with headphones during dressing changes.
57764712|NCT05398146|OTHER|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
57764713|NCT02798211|DRUG|Secukinumab 300 mg|150 mg x 2 s.c. injection
57764714|NCT02798211|DRUG|Secukinumab 150 mg|150 mg s.c. injection
57764715|NCT02798211|OTHER|Placebo|Placebo
57764716|NCT06235658|BEHAVIORAL|Gentle Yoga|Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
57764717|NCT02508532|DRUG|Avapritinib|avapritinib tablets
57764718|NCT06624865|OTHER|Blood and stool sampling|Blood and stool sampling
57764719|NCT05239910|DRUG|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
57764720|NCT02336919|BEHAVIORAL|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
57764721|NCT02473861|OTHER|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
57764722|NCT00021034|DRUG|chemotherapy|
57764723|NCT00021034|DRUG|taurolidine|
57764724|NCT00509418|DIETARY_SUPPLEMENT|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
57764725|NCT00509418|OTHER|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
57764726|NCT02401373|BIOLOGICAL|Ad5-EBOV|intramuscular injection
57764727|NCT06617104|OTHER|no intervention|no intervention
57764728|NCT01199159|DRUG|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
57764729|NCT01199159|DRUG|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
57764730|NCT06396754|OTHER|AI-analysis on diagnostic and surgical specimens|The analysis will report a list of AI-based biomarkers to assess the tumour-immune spatial microenvironment as well as final spatial immune-ecology prognostic (SIPA) reports for every patient.
57764731|NCT05453747|OTHER|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
57764732|NCT05453747|OTHER|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
57764733|NCT05029024|OTHER|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
57764734|NCT05029024|OTHER|control group|standard care alone
57764735|NCT04704453|DRUG|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
57764736|NCT04704453|DRUG|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
57764737|NCT05003388|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
57764738|NCT04665622|OTHER|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
57764739|NCT05910086|OTHER|collection of data from the medical record|"collection of data from the medical record:~1. During epidural space puncture = cerebrospinal fluid (CSF) reflux, presence of glucose / strip, saline injection, intrathecal catheter insertion, intrathecal levobupivacaine and sufentanil injection, catheter insertion time, number of punctures, function of the person performing the procedure.~2. Analgesia and hemodynamics during labor, blood pressure, pulse rate, amount of local anesthetic used, whether emergency cesarean section was performed~3. Demographic data (age, weight, height, body mass index (BMI))~4. Post-partum monitoring of decubitus or orthostatic headaches, intensity, any other associated clinical signs~5. Analgesics used and their efficacy~6. The use of one or more blood patches, with the volume injected and their efficacy~7. Identification of the breach during epidural analgesia or after delivery~8. Call the patient at 1 week to reassess the episode and its consequences."
57764740|NCT05217043|OTHER|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
57764741|NCT02460263|DEVICE|Tablo Hemodialysis System|
57764742|NCT04998162|PROCEDURE|SVF injection|Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
57764743|NCT02415777|DRUG|Ursodeoxycholic acid, thiamine, riboflavin|
57764744|NCT01583244|DRUG|No Intervention (subjects were previously treated with Orencia®)|No Intervention
57764745|NCT01215357|DRUG|Ecopipam|50mg tablets
57764746|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
57764747|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Experimental|
57764748|NCT04890795|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
57764749|NCT01342692|DRUG|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
57764750|NCT01342692|DRUG|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
57764751|NCT01342692|DRUG|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
57764752|NCT01342692|DRUG|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
57764753|NCT04041050|DRUG|Navitoclax|Tablet; Oral
57764754|NCT04041050|DRUG|Ruxolitinib|Tablet; Oral
57764755|NCT04041050|DRUG|Celecoxib|Capsule; Oral
57764756|NCT00460720|OTHER|Observational treatment compliance survey|Observational treatment compliance survey
57764757|NCT06624566|OTHER|Experimental: Implementation of an intensive therapeutic group exercise program in the neurorehabilitation process|"The variables will be measured prior to group assignment The age and sex variables and the satisfaction survey will be measured at the beginning of the program, the other variables at 20 sessions, at 40 sessions, at 60 sessions and/or at hospital discharge. Before the patient starts the program, he/she is classified in group A -patients who have seated trunk control for at least 2 minutes (with supervision) and no standing control (Item 3.3, Berg scale)- or in group B -patients who have standing trunk control for 2 minutes (with supervision) (Item 2.3 on the Berg scale)-. There is a maximum of 4 patients per group with 1 physiotherapist per group.~The difference with respect to the usual treatment of the neurorehabilitation service of the HMS is that in the EINTER program, strength and endurance exercises will be implemented in addition to the usual care plan. The sessions in the EINTER program will be carried out in groups of 4 people with similar functional capacities."
57764758|NCT02235467|BEHAVIORAL|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
57764759|NCT05496621|OTHER|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
57764760|NCT01069081|DRUG|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
57764761|NCT01069081|DRUG|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
57764762|NCT01069081|DRUG|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
57764763|NCT06029556|OTHER|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
57764764|NCT06029556|OTHER|Ergometry in Bed|Ankle pumps (5\*2), knee extension (5\*2), breathing exercises with elbow flexion and extension(5\*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
57764765|NCT04714801|DRUG|adipose derived mesenchymal stromal cells|Intravenous infusion of cells
57764766|NCT04714801|DRUG|Saline|Intravenous infusion of saline
57764767|NCT00640237|DIETARY_SUPPLEMENT|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
57764768|NCT02760329|PROCEDURE|Blood draw|Biomarkers analyses
58129214|NCT05048303|PROCEDURE|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
58129215|NCT01411332|RADIATION|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
58129216|NCT01411332|RADIATION|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
58129217|NCT05003011|DEVICE|Cardiospire|Non-invasive hemodynamic monitoring
58129218|NCT00004193|DRUG|ISIS 2503|
58129219|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
58129220|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluzone)|
58129221|NCT02706236|DRUG|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
58129222|NCT02706236|DRUG|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
58457360|NCT04781335|DRUG|Dexycu|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
58457361|NCT04781335|DRUG|Standard of Care post operative eye drops (steroid, antibiotic, NSAID)|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
58457362|NCT04692623|DRUG|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
58457363|NCT04692623|DRUG|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
58457364|NCT03998540|DIAGNOSTIC_TEST|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
58457365|NCT03998540|OTHER|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
58457366|NCT03998540|OTHER|Mass Spectometry|samples previously used for western blotting will be subjected to mass spectrometry analysis
58457367|NCT03998540|OTHER|RNA seq|analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
58457368|NCT01419795|DRUG|lenalidomide|Given PO
58457369|NCT01419795|BIOLOGICAL|rituximab|Given IV
58457370|NCT01419795|OTHER|pharmacological study|Correlative studies
58457371|NCT01419795|OTHER|laboratory biomarker analysis|Correlative studies
58129223|NCT04366336|PROCEDURE|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
58457372|NCT03571230|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
58457373|NCT03571230|DRUG|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
58457374|NCT03571230|DRUG|one proton pump inhibitor(PPI)|All the patients need this drug.
58457375|NCT03571230|DRUG|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
58457376|NCT03571230|DRUG|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
58457377|NCT03658005|OTHER|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).
58457378|NCT03383861|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
58129224|NCT04366336|PROCEDURE|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
58129225|NCT04878146|PROCEDURE|Sacro-spinous fixation|Uterine cervix will be attached to the sacro-spinous ligament
58129226|NCT04878146|PROCEDURE|Subtotal hysterectomy|Done on both arms
58129227|NCT04878146|PROCEDURE|Sacrocolpopexy|Uterine cervix is attached to sacral promontory with two synthetic meshes
58129228|NCT01706926|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
58129229|NCT01706926|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
58129230|NCT01706926|BIOLOGICAL|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
58457379|NCT03564288|DRUG|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
58457380|NCT03059316|COMBINATION_PRODUCT|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
58457381|NCT03059316|DRUG|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
57764769|NCT02760329|PROCEDURE|Urine|Biomarker analyses
57764770|NCT02760329|PROCEDURE|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
57764771|NCT02760329|PROCEDURE|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
58129231|NCT01706926|OTHER|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
58129232|NCT01371409|OTHER|continuous theta burst stimulation|80% active motor threshold, 600 pulses
58129233|NCT06343168|OTHER|prevalence of frailty|determine the prevalence of frailty
57764772|NCT04887948|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
57764773|NCT04887948|BIOLOGICAL|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
57764774|NCT04887948|OTHER|Saline|Normal saline for injection
57764775|NCT04791202|DRUG|Dextrose|See arm descriptions
57764776|NCT04791202|DRUG|Methylprednisolone Acetate 40 MG/ML|See arm descriptions
57764777|NCT05046522|DRUG|Palmitoylethanolamide sold as Levagen +|Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
57764778|NCT05046522|DRUG|Placebo comparator - maltodextrin and microcrystalline cellulose mix|Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
57764779|NCT03492736|DIETARY_SUPPLEMENT|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
57764780|NCT03492736|OTHER|Placebo|30 days placebo taken nightly 1 hour before bed
57764781|NCT05542563|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
57764782|NCT02254408|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
57764783|NCT02254408|DRUG|Placebo|Tablets administered orally or via nasogastric tube
57764784|NCT05714605|BEHAVIORAL|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
57764785|NCT00854516|PROCEDURE|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
57764786|NCT02761655|BEHAVIORAL|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
57764787|NCT01455025|DRUG|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
57764788|NCT01964521|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
57764789|NCT03320798|OTHER|Data record|
57764790|NCT02775422|BIOLOGICAL|Serological Test s for the Virus Chicken Pox Virus|
57764791|NCT06056622|OTHER|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
57764792|NCT06056622|OTHER|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
57764793|NCT03317223|DRUG|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
57764794|NCT03402880|BIOLOGICAL|Pembrolizumab|Given IV
57764795|NCT03402880|DRUG|Epacadostat|Given PO
57764796|NCT03402880|OTHER|Laboratory Biomarker Analysis|Correlative studies
57764797|NCT03454425|DEVICE|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
57764798|NCT03454425|DEVICE|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
57764799|NCT00975052|DRUG|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
57764800|NCT00975052|DRUG|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
57764801|NCT00975052|DRUG|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
57764802|NCT00975052|DRUG|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
57961176|NCT03403205|DRUG|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
57961177|NCT06042933|OTHER|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
57961178|NCT06042933|OTHER|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
57764803|NCT05646199|DRUG|Metformin|Participants will receive metformin
57764804|NCT05646199|DRUG|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
58457382|NCT03059316|DRUG|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
57764805|NCT03833180|DRUG|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
57764806|NCT02304016|BEHAVIORAL|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
57764807|NCT00365560|DRUG|tiotropium|
57764808|NCT00365560|DRUG|placebo|
57764809|NCT06155578|DRUG|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
57764810|NCT06155578|DRUG|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
57764811|NCT02489266|BIOLOGICAL|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
57764812|NCT02489266|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
57764813|NCT02489266|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
57764814|NCT02489266|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
58457383|NCT02458716|PROCEDURE|Robotic Assisted Radical Prostatectomy|Undergo RARP
58457384|NCT02458716|PROCEDURE|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
58457385|NCT02458716|OTHER|Laboratory Biomarker Analysis|Correlative studies
58457386|NCT02458716|OTHER|Quality-of-Life Assessment|Ancillary studies
57764815|NCT01316341|DRUG|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
57764816|NCT01316341|DRUG|Placebo|patient to receive two placebos
57764817|NCT01316341|DRUG|Placebo|patient to receive two placebos
57764818|NCT01316341|DRUG|Placebo|patient to receive two placebos
57764819|NCT01316341|DRUG|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
57764820|NCT05347966|OTHER|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
57961179|NCT03756038|DRUG|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
57764821|NCT04284839|DRUG|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
57764822|NCT04284839|DRUG|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
57764823|NCT06227962|DIAGNOSTIC_TEST|Neuropsychological assesment|Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test
57764824|NCT06227962|DIAGNOSTIC_TEST|Psychosocial functioning and quality of life (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)
57764825|NCT06227962|DIAGNOSTIC_TEST|Parental psychosocial functioning (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
57764826|NCT05810051|BEHAVIORAL|Cardiac rehabilitation|"The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training."
57961180|NCT03756038|DRUG|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
57961181|NCT03473431|DRUG|Ketamine|single infusion of 0.5 mg / kg ketamine
57961182|NCT03473431|OTHER|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
57961183|NCT00928538|OTHER|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
57961184|NCT03598166|DIAGNOSTIC_TEST|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
57961185|NCT02381119|BEHAVIORAL|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
57961186|NCT02381119|BEHAVIORAL|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
57961187|NCT05399459|DRUG|Rimegepant 25 MG|Single dose of 25 mg orally disintegrating tablet of rimegepant
57961188|NCT05399459|DRUG|Rimegepant 75 MG|Single dose of 75 mg orally disintegrating tablet of rimegepant
57961189|NCT05399459|DRUG|Placebo|Matching placebo tablet
57961190|NCT00383045|DRUG|Buprenorphine/Subutex|
57961191|NCT00383045|DRUG|Naltrexone|
57764827|NCT04330365|BEHAVIORAL|Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm|Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
57764828|NCT04740203|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
57764829|NCT02812472|OTHER|Treadmill training with functional electrical stimulation|
57764830|NCT02812472|OTHER|Treadmill training without functional electrical stimulation|
57764831|NCT01457105|DEVICE|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
57764832|NCT03324659|BEHAVIORAL|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
57764833|NCT03324659|BEHAVIORAL|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
57764834|NCT05667779|DRUG|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
57764835|NCT05667779|OTHER|Placebo|A placebo comparator will be administered at all dose levels.
57764836|NCT01654081|DRUG|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
57764837|NCT01068314|OTHER|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
57764838|NCT04199312|DEVICE|The ZELTIQ System|The MMS device will be used to perform the treatments.
57764839|NCT04307706|BEHAVIORAL|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
57764840|NCT04903457|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
57764841|NCT04903457|BEHAVIORAL|Motor learning|Sequential finger tapping task training is applied to stroke patients.
57764842|NCT01975220|DRUG|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
57764843|NCT01975220|DRUG|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
57764844|NCT01975220|DRUG|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
57764845|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
57764846|NCT01975220|DRUG|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
58457387|NCT02458716|DRUG|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
57764847|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
57764848|NCT00110253|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
57764849|NCT01615575|PROCEDURE|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
57764850|NCT01615575|PROCEDURE|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
57764851|NCT05670002|DIETARY_SUPPLEMENT|Milk supplement|Children will take the milk supplement for a period of 6 months. During the intervention, anthropometry data, Zinc Protoporphyrin levels, dietary intake, any illness will be recorded.
57764852|NCT02213328|DRUG|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
57764853|NCT03383562|PROCEDURE|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
57764854|NCT03104647|OTHER|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
57764855|NCT03629860|PROCEDURE|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
57764856|NCT06527664|DEVICE|custom-made acetabular implant|custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
57961192|NCT00383045|PROCEDURE|Drug counseling|
57961193|NCT01188083|DIETARY_SUPPLEMENT|Fructose Drink|Fructose Based beverage 8 oz
57961194|NCT01188083|DIETARY_SUPPLEMENT|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
57961195|NCT00713583|DRUG|levodopa|800mg levodopa and 200mg carbidopa per day
57961196|NCT00713583|DRUG|Placebo|Placebo
58129234|NCT02014181|DIETARY_SUPPLEMENT|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
58129235|NCT04637438|OTHER|Fecal Microbiota Transplantation|FMT via colonoscopy
58457388|NCT00591682|DRUG|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
58457389|NCT03775460|DRUG|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
58457390|NCT03775460|DRUG|Placebo|Participants in the control arm will receive placebo along side prednisolone
58457391|NCT03775460|DRUG|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
58457392|NCT05603117|BEHAVIORAL|Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)|CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
58457393|NCT01102114|BIOLOGICAL|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
58457394|NCT01102114|BIOLOGICAL|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
58457395|NCT02521506|DEVICE|Verio Pattern Alert® activated|
58457396|NCT02521506|DEVICE|Verio Pattern Alert® deactivated|
58457397|NCT01905098|OTHER|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
58457398|NCT01905098|OTHER|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
58457399|NCT02981147|DRUG|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
58457400|NCT04471519|BIOLOGICAL|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
58457401|NCT04471519|BIOLOGICAL|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
58457402|NCT04471519|BIOLOGICAL|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
58457403|NCT04471519|BIOLOGICAL|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
58457404|NCT04471519|BIOLOGICAL|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
58457405|NCT04471519|BIOLOGICAL|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
58457406|NCT05443412|DIAGNOSTIC_TEST|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
58457407|NCT01301807|DRUG|Carfilzomib|Given IV
58457408|NCT01301807|DRUG|Panobinostat|Given PO
58457409|NCT02681198|DRUG|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
57764857|NCT03791502|OTHER|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
57764858|NCT06511999|DEVICE|Continuous SjO2 monitoring with a TriOx PICC catheter|The TriOx PICC catheter is capable of continuous, indwelling measurement of venous oxygen saturation, which is displayed on a bedside monitor connected by an optical cable. Enrolled participants will undergo continuous SjO2 measurement for 72 hours. Clinical care will not be directed by the continuous SjO2 values.
58129236|NCT04637438|OTHER|Placebo|Water infusion via colonoscopy
58457410|NCT02681198|DRUG|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
58457411|NCT04607044|DEVICE|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
58457412|NCT02027012|DEVICE|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
58457413|NCT05510063|DRUG|Humira (Adalimumab)|Subcutaneous (SC) injection
58457414|NCT05510063|DRUG|SB5 (Adalimumab Biosimilar)|Subcutaneous (SC) injection
58457415|NCT01174407|OTHER|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
58457416|NCT02753166|DRUG|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
58457417|NCT01591356|DRUG|EphA2-targeting DOPC-encapsulated siRNA|Given IV
57764859|NCT06511999|DIAGNOSTIC_TEST|Intermittent SjO2 monitoring with a TriOx PICC catheter|The TriOx PICC catheter is also capable of intermittent blood sampling enabling measurement of SjO2 on a laboratory blood gas analyzer. Enrolled participants will undergo intermittent SjO2 measurement every 4-6 hours for 72 hours. Clinical care will be directly by the intermittent values.
57764860|NCT00245401|DEVICE|CYPHERTM Sirolimus-Eluting Coronary Stent|
58457418|NCT01591356|OTHER|Laboratory Biomarker Analysis|Correlative studies
58457419|NCT01591356|OTHER|Pharmacological Study|Correlative studies
58457420|NCT05970575|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
58457421|NCT05182723|PROCEDURE|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
58457422|NCT00628017|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
58457423|NCT03014739|OTHER|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
58457424|NCT06464354|PROCEDURE|The mammary artery harvesting by the pedicle technique|The mammary artery harvesting by the pedicle technique was used in the LIMA pedicle study group.
58457425|NCT06464354|PROCEDURE|The mammary harvesting using the skeletonization technique|The mammary harvesting using the skeletonization technique was used in the LIMA skeletonized study group.
58457426|NCT06464354|PROCEDURE|No intervention|No intervention was used in the control study group.
58457427|NCT01429675|DRUG|bonviva|150mg Ibandronate once a month
58457428|NCT00564681|BIOLOGICAL|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
58457429|NCT00564681|BIOLOGICAL|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
58457430|NCT00564681|DRUG|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
58457431|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
57764861|NCT03842462|OTHER|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
57764862|NCT03842462|OTHER|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
57764863|NCT03842462|OTHER|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
58457432|NCT03271424|DIAGNOSTIC_TEST|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
58457433|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
57764864|NCT05733962|DEVICE|Use of the device DBL-4pen|"During the treatment period, the patient will use~* the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~* the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~* the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
57764865|NCT01502995|DEVICE|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
57764866|NCT05101135|DRUG|JT-001|Subjects take the investigational products once a day for 24 weeks.
57764867|NCT05101135|DRUG|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
58457434|NCT03744728|DIAGNOSTIC_TEST|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
58457435|NCT03744728|DIAGNOSTIC_TEST|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
58457436|NCT06327698|DRUG|Cadonilimab|Injectable solution
58457437|NCT06327698|DRUG|anlotinib|capsule
58457438|NCT03402334|BEHAVIORAL|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
58457439|NCT05543954|DRUG|68Ga-FAPI-RGD|Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
58457440|NCT05543954|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
58457441|NCT05543954|DRUG|68Ga-FAPI|Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
58129237|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
58129238|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
58457442|NCT05543954|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
58457443|NCT02986217|OTHER|regular structured assessment of surgical performance|
58457444|NCT04214223|OTHER|Pre-Anesthesic Consultation|Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
58457445|NCT04214223|OTHER|Pre-Anesthesic Numerical Evaluation|Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
58457446|NCT05389098|OTHER|Hand-Eating|eat-hands type food mode
58457447|NCT05389098|OTHER|Control|Usual eating mode
58457448|NCT00528957|DRUG|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
57764868|NCT01583439|DRUG|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
57764869|NCT02918500|DRUG|Nicoderm Patch|Nicotine replacement therapy patch
57764870|NCT03182140|DRUG|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
57764871|NCT01948180|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T-cells
57764872|NCT00876460|DRUG|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
57764873|NCT00876460|DRUG|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
57764874|NCT00876460|DRUG|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
57764875|NCT00876460|DRUG|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
57764876|NCT00876460|DRUG|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
57764877|NCT06439823|DEVICE|ActiMyo®/Syde®|Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
57764878|NCT04591977|DEVICE|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
57764879|NCT05827874|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
57764880|NCT05827874|BIOLOGICAL|Tdap|Tdap will be administered as an IM injection.
57764881|NCT05827874|BIOLOGICAL|PPSV23|PPSV23 will be administered as an IM injection.
57764882|NCT03126864|PROCEDURE|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.
57764883|NCT03126864|DRUG|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
57764884|NCT03126864|DRUG|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
57764885|NCT03126864|BIOLOGICAL|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.
57764886|NCT03311425|DRUG|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
57764887|NCT03311425|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
57764888|NCT01001481|OTHER|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
57764889|NCT00111124|DRUG|Enbrel®|
57764890|NCT02374632|OTHER|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
58457449|NCT00528957|DRUG|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
57764891|NCT02374632|OTHER|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
57764892|NCT02374632|OTHER|Sham feeding|
57764893|NCT04490135|BEHAVIORAL|Group psychotherapy|As described above
57764894|NCT02659917|OTHER|Glass ionomer|Application of preventive agent
57764895|NCT02659917|OTHER|Glass ionomer cement|Application of preventive agent
57764896|NCT02659917|OTHER|-Glass ionomer-|Atraumatic Restorative Treatment
57764897|NCT02659917|OTHER|-Glass ionomer cement-|Atraumatic Restorative Treatment
57764898|NCT03926793|DRUG|GB002|GB002 low dose or high dose for inhalation
57764899|NCT03926793|DRUG|Placebo|Placebo for inhalation
57764900|NCT03926793|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 or Placebo delivery
57764901|NCT04647422|BEHAVIORAL|Analysis of executive functioning and of social cognition processes|"Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes"
57764902|NCT05130255|DRUG|GD2-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
57764903|NCT03159897|DRUG|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
57764904|NCT03159897|DRUG|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
57764905|NCT03159897|DRUG|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
57764906|NCT03159897|DRUG|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
57764907|NCT05461105|DRUG|rencofilstat, 75 mg|1 softgel capsule
57764908|NCT05461105|DRUG|rencofilstat, 150mg|2 softgel capsules
58457450|NCT00528957|DRUG|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
58457451|NCT05800600|DRUG|Venofer|Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
57764909|NCT05461105|DRUG|rencofilstat, 225 mg|3 softgel capsules
57764910|NCT06365021|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.
57764911|NCT06365021|OTHER|Bipolar Disorder Psychoeducation Therapy|The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.
57764912|NCT03204084|DEVICE|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
57764913|NCT05885919|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
57764914|NCT05885919|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
57764915|NCT04244396|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
57764916|NCT00000230|DRUG|Buprenorphine|
57764917|NCT04479280|DEVICE|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
57764918|NCT00351897|DEVICE|pulsed dye (585nm) laser therapy|
57764919|NCT03311230|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
57764920|NCT03311230|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
57764921|NCT03311230|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
57764922|NCT03149016|PROCEDURE|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
57764923|NCT00191360|DRUG|Somatropin|
57764924|NCT06225414|OTHER|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
57764925|NCT06225414|BEHAVIORAL|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
57764926|NCT06225414|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
57764927|NCT06225414|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
57764928|NCT06225414|BEHAVIORAL|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
57764929|NCT06225414|BEHAVIORAL|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
57764930|NCT04163887|PROCEDURE|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
57764931|NCT04609124|DIAGNOSTIC_TEST|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
57764932|NCT05264610|OTHER|Data collection (Laboratory tests, Radiologic diagnostics, Patient data taken from existing medical charts)|Data collection: Bone turnover laboratory parameters: alkaline phosphatase (AP), calcium (corrected for albumin), PTH, Calcidiol (25-OH-D3), N-terminales Kollagen Typ 1 -. Propeptid (P1NP), glomerular filtration rate (GFR), calcium/creatinine (in urine); Radiologic diagnostics: Bone densitometry (DEXA), X-rays, computer tomograms, MRI for analysis of time of the bone healing (or a non-union); Patient data taken from existing medical charts: side effects, tolerability of PTH, patient compliance, presence of previous illnesses as risk factors for the formation of pseudoarthrosis, indication for therapy, time at which therapy started and length of therapy with PTH, precise characterization of the operation (type and whether it is a revision or first operation).
57764933|NCT05822336|OTHER|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
57764934|NCT02607657|DRUG|Eplerenone 25 mg|
57764935|NCT02607657|DRUG|Eplerenone 50 mg|
57764936|NCT02607657|DRUG|Eplerenone 100 mg|
57764937|NCT02607657|DRUG|Eplerenone 50 mg twice a day|
57764938|NCT02607657|DRUG|Eplerenone 25 mg twice a day|
57764939|NCT03290157|DEVICE|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
57764940|NCT00445198|DRUG|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 40 patients with SCLC"
57764941|NCT01907139|BEHAVIORAL|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
57764942|NCT01907139|BEHAVIORAL|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
57764943|NCT01907139|BEHAVIORAL|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
57764944|NCT00970125|BEHAVIORAL|video|outline of the goals of care
57764945|NCT02090335|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
57764946|NCT02090335|BEHAVIORAL|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
57764947|NCT03461848|OTHER|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
58457452|NCT02076607|PROCEDURE|Arthrodesis|Posterior approach to toracolumbar spine fusion.
58457453|NCT02076607|DEVICE|Brace|Toracolumbar imobilization
57764948|NCT03461848|OTHER|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
57764949|NCT03555825|DEVICE|Hocoma ArmeoSpring|A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
57764950|NCT00856661|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
57764951|NCT00856661|DRUG|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
58457454|NCT01366001|DRUG|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
58457455|NCT01366001|DRUG|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
57764952|NCT02617277|DRUG|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
57764953|NCT02617277|DRUG|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
57764954|NCT05967182|DRUG|Pembrolizumab|Given by IV (vein)
57764955|NCT05967182|DRUG|Gemcitabine|Given by IV (vein)
57764956|NCT05967182|DRUG|Cisplatin|Given by IV (vein)
57764957|NCT00594971|OTHER|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
57764958|NCT00594971|OTHER|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
57764959|NCT02716038|DRUG|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
58457456|NCT01366001|DRUG|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
58457457|NCT01207635|PROCEDURE|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
58457458|NCT05107544|OTHER|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
57764960|NCT02716038|DRUG|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
57764961|NCT02716038|DRUG|Nab-paclitaxel|Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
57764962|NCT06534905|OTHER|E-cigarette|Each participant assigned to the e-cigarette group will given a rechargeable NJOY Ace e-cigarette that is either tobacco or mint-flavored (based on their preference). Participants will also be given disposable pods prefilled with nicotine. When the pod is empty, the participant will throw it away and replace it with a new pod provided by the study staff. Participants will be asked to use as little or as much of the e-cigarette during their study participation, including choosing not to use the product. Participants will also be given information on the relative harms of nicotine and tobacco products as recommended by the American Society of Addiction Medicine.
57764963|NCT06534905|BEHAVIORAL|Control/Standard Advice|Brief advice to quit according recommendations from the American Society of Addiction Medicine
57764964|NCT01320423|PROCEDURE|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
57764965|NCT06396416|DRUG|Semaglutide|Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
57764966|NCT06396416|BEHAVIORAL|Virtual Weight Management Coaching|Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
57764967|NCT02629055|OTHER|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
57764968|NCT03027063|BEHAVIORAL|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
57764969|NCT03027063|BEHAVIORAL|Usual Care|Participants will receive the ACC/AHA exercise guidelines
57764970|NCT04232046|OTHER|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
57764971|NCT00877981|PROCEDURE|Minimal invasive Parathyroid surgery|
57764972|NCT01576718|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
57764973|NCT01576718|OTHER|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
57764974|NCT01576718|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
57764975|NCT01576718|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
57764976|NCT04047511|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
57764977|NCT04047511|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
57764978|NCT04047511|BEHAVIORAL|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
57764979|NCT06422702|OTHER|Psychosomatic Symptoms Intervention|Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.
57764980|NCT06422702|OTHER|Extended supportive care|The control group implemented continuity of supportive care based on primary care
58457459|NCT05919407|DRUG|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
57764981|NCT01750736|OTHER|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
57764982|NCT01750736|OTHER|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
57764983|NCT04143334|DIAGNOSTIC_TEST|Conventional survey|
57764984|NCT00380016|PROCEDURE|Percutaneous Transluminal Angioplasty|
57764985|NCT03993236|DRUG|Experimental: Rosuvastatin/Ezetimibe 10|"* Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days"
57764986|NCT03993236|DRUG|Active Comparator: Rosuvastatin 20mg|"* Rosuvastatin 20mg~* orally administered once daily for 90 days"
58129239|NCT03458871|DEVICE|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
58457460|NCT05919407|DRUG|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
57764987|NCT03013218|DRUG|Evorpacept (ALX148)|Evorpacept (ALX148)
57764988|NCT03013218|DRUG|Pembrolizumab|Keytruda
57764989|NCT03013218|DRUG|Trastuzumab|Herceptin
57764990|NCT03013218|DRUG|Rituximab|Rituxan
57764991|NCT03013218|DRUG|Ramucirumab + Paclitaxel|Standard of care chemotherapy
57764992|NCT03013218|DRUG|5-FU + Cisplatin|Standard of care chemotherapy
57764993|NCT00150995|DRUG|Tetrathiomolybdate|
57764994|NCT02066402|DRUG|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
57764995|NCT02066402|DRUG|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
57764996|NCT02066402|DRUG|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
57764997|NCT02066402|DRUG|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
57764998|NCT03352934|DRUG|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
57764999|NCT00299000|DRUG|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
57765000|NCT00003305|DRUG|aminopterin|
57765001|NCT00003305|DRUG|leucovorin calcium|
57765002|NCT06397274|BIOLOGICAL|Stemchymal|Patients will receive Stemchymal® through intravenous infusion
57765003|NCT06397274|BIOLOGICAL|Placebo|Patients will receive Placebo through intravenous infusion
57765004|NCT01919996|DRUG|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
57765005|NCT00813696|DRUG|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
57765006|NCT00813696|DRUG|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
57765007|NCT04381936|DRUG|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
57765008|NCT04381936|DRUG|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
57765009|NCT04381936|DRUG|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
57765010|NCT04381936|DRUG|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
57765011|NCT04381936|BIOLOGICAL|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
57765012|NCT04381936|DRUG|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
58457461|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
58457462|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
58457463|NCT02050477|PROCEDURE|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
58457464|NCT01969708|DRUG|aflibercept|
58457465|NCT01969708|DRUG|bevacizumab|
57765013|NCT04381936|BIOLOGICAL|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
57765014|NCT04381936|DRUG|Synthetic neutralising antibodies|Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
57765015|NCT04381936|DRUG|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
57765016|NCT04381936|DRUG|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
57765017|NCT04381936|DRUG|Baricitinib|UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
58457466|NCT06333249|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
58457467|NCT05239481|DEVICE|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
58457468|NCT05239481|DEVICE|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
57765018|NCT04381936|DRUG|Anakinra|For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
57765019|NCT04381936|DRUG|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
57765020|NCT04381936|DRUG|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
57765021|NCT04381936|DRUG|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
57961197|NCT00713583|BEHAVIORAL|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
57961198|NCT00713583|BEHAVIORAL|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
57961199|NCT04293770|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
58457469|NCT05638165|DRUG|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
58457470|NCT00101686|DRUG|Modified Bolus 5-FU/LV with Irinotecan|Day 1 \& 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID \[two times a day\] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
57765022|NCT04381936|DRUG|Sotrovimab|UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
57765023|NCT04381936|DRUG|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
57961200|NCT05339672|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
57765024|NCT04381936|DRUG|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
57765025|NCT04381936|DRUG|Baloxavir Marboxil|"Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4."
57765026|NCT04381936|DRUG|Oseltamivir|"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)"
57765027|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
57961201|NCT03726164|DEVICE|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
57961202|NCT03726164|DEVICE|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
57961203|NCT04327388|DRUG|Sarilumab SAR153191|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
57961204|NCT04327388|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
57961205|NCT04607083|DIAGNOSTIC_TEST|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
58457471|NCT00101686|DRUG|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID \[two times a day\] oral Every 2 weeks"
57765028|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
57765029|NCT03060564|PROCEDURE|tendon graft|JRF Orthopedics Tendon Graft
57765030|NCT03060564|OTHER|No intervention|No intervention
57765031|NCT02909036|DEVICE|Melphalan|
57765032|NCT02909036|DRUG|Pegfilgrastim|
57765033|NCT02909036|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|
57765034|NCT01790360|BEHAVIORAL|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
57765035|NCT01790360|BEHAVIORAL|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
57765036|NCT06438653|OTHER|No-intervenyion|No-intervenyion
57765037|NCT00538174|DRUG|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
57765038|NCT00538174|DRUG|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
57765039|NCT02504437|BIOLOGICAL|BMMSCs|
57765040|NCT00116402|DRUG|fluticasone and salmeterol|"1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
57765041|NCT01007240|DEVICE|polyethylenimine (PEI) nanoparticles.|
57765042|NCT05243381|BIOLOGICAL|20 ml blood test|20 ml blood test
57765043|NCT03102125|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
57765044|NCT04266288|DRUG|Ketamine|Active drug
57765045|NCT04266288|DRUG|Sodium Chloride 0.9%|Placebo
57765046|NCT02740855|DEVICE|Alcomed 3011®|Endtidal ethanol measurement
57765047|NCT01624649|DRUG|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
57765048|NCT01624649|DRUG|Atomoxetine|Form = tablet, route = oral;
57765049|NCT03528174|DEVICE|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
57765050|NCT03528174|DEVICE|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
57765051|NCT03776994|BIOLOGICAL|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
57765052|NCT00709748|DEVICE|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
57765053|NCT00709748|DEVICE|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
57765054|NCT06512103|DIAGNOSTIC_TEST|Apical periodontitis group|Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
57765055|NCT01023568|DEVICE|Macintosh blade|Intubation with Macintosh blade laryngoscope
57765056|NCT01023568|DEVICE|Glidescope|Intubation with Glidescope laryngoscope.
57765057|NCT01023568|DEVICE|Truview PCD|Intubation with Truview PCD laryngoscope.
57765058|NCT03353259|COMBINATION_PRODUCT|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
57765059|NCT04502056|BEHAVIORAL|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
57765060|NCT04502056|BEHAVIORAL|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
57765061|NCT04502056|BEHAVIORAL|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
57765062|NCT04502056|BEHAVIORAL|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
58129240|NCT05749172|OTHER|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
58129241|NCT05749172|OTHER|Controlled group|Two hours of parkour training for two days a week.
57765063|NCT04502056|BEHAVIORAL|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
57765064|NCT04502056|BEHAVIORAL|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
57765065|NCT04502056|BEHAVIORAL|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
57765066|NCT04502056|BEHAVIORAL|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
57765067|NCT04502056|BEHAVIORAL|Placebo videos|Videos not related to covid-19 will be shown
57765068|NCT02430363|DRUG|MK - 3475|Administered Intravenously
57765069|NCT02430363|BIOLOGICAL|Suppressor of the PI3K/Akt pathways|Capsules orally with food
57765070|NCT02895022|DRUG|Lidocaine 2% adrénalinée|
57765071|NCT02895022|DEVICE|Epidural catheter|
57765072|NCT02895022|PROCEDURE|Caesarean section|
57765073|NCT04886427|OTHER|No intervention|Measure the experiences of the current care
57765074|NCT03717402|BEHAVIORAL|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
57765075|NCT02424591|DRUG|Ketamine|Infusion at a rate of 10 mcg/kg/min
57765076|NCT02424591|OTHER|Placebo|Placebo IV
57765077|NCT02576158|PROCEDURE|TCT，HPV，colposcopic inspection|
57765078|NCT00771303|OTHER|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
58129242|NCT05162404|BEHAVIORAL|Video Education Program|"The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
58129243|NCT00968370|OTHER|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
58129244|NCT00968370|OTHER|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
57765079|NCT00041756|DRUG|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
57765080|NCT00041756|DRUG|Placebo|One placebo tablet, twice daily for for one year
57765081|NCT00041756|DRUG|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
57765082|NCT00041756|DRUG|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
57765083|NCT00041756|DRUG|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
57765084|NCT03498222|DRUG|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
58129245|NCT00639990|OTHER|PEEP|Application of positive end expiratory pressure
58129246|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
57765085|NCT03498222|DRUG|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
57765086|NCT03498222|DRUG|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
57765087|NCT03498222|DRUG|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
57765088|NCT03203694|BEHAVIORAL|Walking: Intervention arm in diabetics|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
57765089|NCT03203694|OTHER|Walking: No intervention in diabetics|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
57765090|NCT03203694|OTHER|Walking: Healthy cohort as reference controls|Subjects will be studied at one time only.
57765091|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in healthy subjects|This intervention consists of 60 minutes of lower body heating (40-42 degree C).
57765092|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in diabetics|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
57765093|NCT03203694|OTHER|Lower body heating: Healthy cohort as reference controls|Subjects will be studied at one time only.
57765094|NCT04479722|DEVICE|Left atrial appendage closure procedure|Implant LAAC system in LAA through percutaneous intervention
57765095|NCT04089098|DIAGNOSTIC_TEST|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
57765096|NCT06625957|DRUG|NTCB02-1|3 Days infusion
57765097|NCT06625957|DRUG|NTCB-C|3 Days infusion
58129247|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
58129248|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
58129249|NCT00442936|DRUG|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
58129250|NCT00442936|DRUG|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
57765098|NCT03193671|DIAGNOSTIC_TEST|Diagnosis|Improving diagnosis
57765099|NCT03288896|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
57765100|NCT05884229|OTHER|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
57765101|NCT06133842|DIAGNOSTIC_TEST|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
57765102|NCT01372605|OTHER|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
57765103|NCT01372605|OTHER|Enhanced Usual Care|
57765104|NCT02087501|DEVICE|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
57765105|NCT00084643|BIOLOGICAL|GTI-2040|Given IV
57765106|NCT00084643|DRUG|oxaliplatin|Given IV
57765107|NCT00084643|DRUG|capecitabine|Given orally
57765108|NCT00084643|OTHER|pharmacological study|Correlative studies
57765109|NCT00084643|OTHER|laboratory biomarker analysis|Correlative studies
57765110|NCT05982704|DRUG|tixagevimab/cilgavimab 150+150 mg|Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.
57765111|NCT05982704|DRUG|tixagevimab/cilgavimab 300+300 mg|Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.
57765112|NCT05982704|DRUG|regdanvimab|Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
57765113|NCT03202095|DRUG|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
57765114|NCT01361373|DRUG|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
57765115|NCT01361373|DRUG|placebo|placebo for 2 weeks
57765116|NCT04313569|PROCEDURE|Arthroscopic menisctomy|Arthroscopic medial menisctomy
57765117|NCT05787158|OTHER|Muscle energy techniques|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
57765118|NCT04140500|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
57765119|NCT05528718|DRUG|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
57765120|NCT05528718|DRUG|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
57765121|NCT03968315|PROCEDURE|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
57961206|NCT03649295|OTHER|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
57961207|NCT03649295|OTHER|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
58457472|NCT00101686|DRUG|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV \*over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID \[two times a day\] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID \[two times a day\] continues daily without interruption Every 3 weeks
57765122|NCT03968315|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57961208|NCT00015600|BEHAVIORAL|Behavior modification through social marketing|
57961209|NCT03315767|DIAGNOSTIC_TEST|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
57961210|NCT03315767|DIAGNOSTIC_TEST|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
57961211|NCT01841333|DRUG|PF-04449913|100mg given orally
58129251|NCT00442936|DRUG|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
58129252|NCT00442936|DRUG|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
57765123|NCT05897801|DIAGNOSTIC_TEST|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
57765124|NCT02646215|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
57765125|NCT04461795|DRUG|Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]|225 MG/1.5 ML Subcutaneous Solution
57765126|NCT03285841|DEVICE|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
57765127|NCT02676908|OTHER|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
57765128|NCT03963947|BIOLOGICAL|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
57765129|NCT04084977|DIAGNOSTIC_TEST|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
57765130|NCT02911350|DRUG|Hormone Suppressors|
58457473|NCT00101686|DRUG|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID \[two times a day\](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
57765131|NCT02911350|DRUG|Paclitaxel|
57765132|NCT02911350|RADIATION|Radiation Therapy|
57765133|NCT05096468|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
57765134|NCT05096468|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
57765135|NCT06324721|OTHER|Oedema measurements and sensory evaluations|"assessments of different types of arm and trunk/ breast oedema (self-reported swelling at arm and trunk/ breast, subjective arm lymphedema, subjective trunk/ breast lymphedema, objective arm lymphedema, objective trunk/ breast lymphedema))~clinical assessments for subclinical lymphedema and nociceptive, neuropathic and central sensory problems"
57765136|NCT05040022|DRUG|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
57765137|NCT05040022|DRUG|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
57961212|NCT02837315|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
58129253|NCT00442936|DRUG|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
57765138|NCT03311932|DRUG|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
57765139|NCT03311932|DRUG|Cortef®|Immediate release hydrocortisone tablets
57765140|NCT01686581|DRUG|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
57765141|NCT04301440|DEVICE|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
57765142|NCT04301440|DEVICE|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
57765143|NCT02018445|PROCEDURE|Posterolateral Fusion|
57765144|NCT03202472|DEVICE|Implanted Medical Device|Radiofrequency tag
57765145|NCT03202472|PROCEDURE|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
57765146|NCT03202472|OTHER|Questionnaire Administration|Ancillary studies
57765147|NCT03202472|PROCEDURE|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
57765148|NCT03202472|PROCEDURE|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
57765149|NCT02653573|BEHAVIORAL|Coaching|Self-management education
57765150|NCT01351025|DRUG|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
57765151|NCT01351025|DRUG|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
57765152|NCT01351025|DRUG|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
57765153|NCT02300012|PROCEDURE|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
57765154|NCT04318093|DRUG|BMS-986259|Specified dose on specified days
57765155|NCT04318093|OTHER|Placebo|Specified dose on specified days
57765156|NCT06210503|PROCEDURE|Pericapcelar group nerve block|In the supine position, a high-frequency linear sensor is placed in the anterior superior iliac spine and then aligned with the ramus of the pubis by rotating the probe counterclockwise approximately 45 degrees. The iliopsoas muscle and tendon, femoral artery, and pectineus muscle were observed in this view.The iliopsoas muscle and its tendon are visualized, as well as the vascular and nerve bundle: femoral artery, vein, and nerve. The needle is inserted laterally to medially in a planar approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the ramus pubis posteriorly. After negative aspiration, local anesthetic will be gradually injected aspirating every 3 mL.
58457474|NCT00101686|DRUG|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
58457475|NCT02429635|BEHAVIORAL|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
58457476|NCT04315155|DRUG|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
58457477|NCT04315155|DRUG|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
57765157|NCT06210503|PROCEDURE|Fascia iliaca compartment block|In the supine position, a high-frequency linear sensor is placed in the inguinal fold. Scan starting lateral to the femoral artery and the nerve in the inguinal crease to identify the sartorius muscle, tracing the muscle to its origin to the anterior superior iliac spine. A shadow of the iliac crest bone and iliacus muscle will be visible, with the end point of injection being deep in the fascia iliaca and above the iliacus muscle at the lateral aspect of the iliacus muscle. After negative aspiration, local anesthetic will be gradually injected under the fascial plane, aspirating every 3 mL.
57765158|NCT06071832|OTHER|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
57765159|NCT05389891|OTHER|Hemoglobinopathy Nursing Program|"Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2"
57765160|NCT00133536|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
57765161|NCT00133536|DRUG|Placebo|Normal saline administered intramuscularly.
57765162|NCT00004401|DRUG|botulism immune globulin|
57765163|NCT04758767|DRUG|CID-103|anti-CD38 antibody
57765164|NCT03170245|DIAGNOSTIC_TEST|Interleukin-6|serum samples used for doing the test by ELISA
57765165|NCT03170245|DIAGNOSTIC_TEST|HsC-RP|serum samples used for doing the test by ELISA
58457478|NCT04315155|DRUG|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
57765166|NCT03170245|DIAGNOSTIC_TEST|Adiponectin level|serum samples used for doing the test by ELISA
58457479|NCT04315155|DRUG|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
57765167|NCT03170245|DIAGNOSTIC_TEST|Carotid intima media thickness|Done by carotid doppler
57765168|NCT05125523|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
57765169|NCT00361101|DRUG|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
57765170|NCT00544960|DRUG|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
57765171|NCT00544960|DRUG|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
57765172|NCT03354728|OTHER|Laboratory Biomarker Analysis|Correlative studies
57765173|NCT03354728|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
57765174|NCT02176044|DRUG|Sodium Nitroprusside infusion|
57765175|NCT02176044|OTHER|Placebo|
58457480|NCT04315155|DRUG|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
58457481|NCT04136808|DRUG|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
57765176|NCT04978545|OTHER|calciumhydroxide, intracanal medicament|In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
57765177|NCT04978545|OTHER|chlorhexidine, intracanal medicament|, chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
57765178|NCT05252429|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
57765179|NCT05252429|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
57765180|NCT03472703|OTHER|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
57765181|NCT02707523|DRUG|Azithromycin 10 mg|
57765182|NCT02707523|DRUG|Azithromycin 20mg|
57765183|NCT02707523|DRUG|Placebo|
58129254|NCT00442936|DRUG|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
57765184|NCT02067234|OTHER|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
57765185|NCT02067234|BEHAVIORAL|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
57765186|NCT04481828|PROCEDURE|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
57765187|NCT02884414|DEVICE|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
57765188|NCT01704911|PROCEDURE|Transradial Coronary Intervention|
57765189|NCT01704911|PROCEDURE|Transfemoral Coronary Intervention|
57765190|NCT01704911|DEVICE|Coronary Stent System|Any kind of coronary stent system
57765191|NCT05295914|DIAGNOSTIC_TEST|TREAT-B score|TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis
57765192|NCT00608725|RADIATION|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
57765193|NCT00608725|PROCEDURE|QSweat|Quantitative Sweat Testing
58457482|NCT05986370|PROCEDURE|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
58457483|NCT05986370|PROCEDURE|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
58457484|NCT05986370|PROCEDURE|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
57765194|NCT00608725|DRUG|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
58457485|NCT05691881|DRUG|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
57765195|NCT01052909|DRUG|Glimepiride|Glimepiride tablets 1 mg
57765196|NCT03301090|OTHER|Placebo|Placebo
57765197|NCT03301090|BIOLOGICAL|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
57765198|NCT03301090|BIOLOGICAL|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
57765199|NCT05957302|DRUG|Ketamine|100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
57765200|NCT05957302|DRUG|Fentanyl|100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
57765201|NCT05917223|DIETARY_SUPPLEMENT|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
57765202|NCT05917223|DIETARY_SUPPLEMENT|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
57765203|NCT05917223|DIETARY_SUPPLEMENT|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
57765204|NCT05917223|DIETARY_SUPPLEMENT|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
57961213|NCT02837315|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
57765205|NCT00737412|OTHER|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
57765206|NCT00737412|OTHER|Placebo|Matching capsules devoid of microorganisms
57765207|NCT00365378|BIOLOGICAL|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
57765208|NCT00365378|BIOLOGICAL|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
57765209|NCT03180671|DEVICE|Deprogramer Sliding Guide|Use of the intraoral device.
57765210|NCT03180671|DEVICE|Deprogrammer Dawson B-Splint|Use of the intraoral device.
57765211|NCT03180671|DEVICE|Deprogrammer Kois|Use of the intraoral device.
57961214|NCT02837315|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
57765212|NCT05487430|BEHAVIORAL|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
57765213|NCT03648125|DEVICE|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
57765214|NCT03648125|DEVICE|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
57765215|NCT02230436|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
57765216|NCT02230436|OTHER|Late drain removal|Removing drain(s) on postoperative day 4 or later
57765217|NCT04731415|DEVICE|Optical coherence tomography and optical coherence tomography angiography (Optovue®)|"Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
57765218|NCT03746184|OTHER|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
58129255|NCT00442936|DRUG|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
58129256|NCT02193438|OTHER|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
58129257|NCT02193438|OTHER|Placebo|Tomato juice intake
58129258|NCT01189123|BIOLOGICAL|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
57765219|NCT03690219|OTHER|no intervention|no intervention
57765220|NCT05441618|DEVICE|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
57765221|NCT03274154|DIETARY_SUPPLEMENT|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
57765222|NCT04082520|RADIATION|Gallium Ga 68-DOTATATE|Given IV
57765223|NCT04082520|DRUG|Lutetium Lu 177 Dotatate|Given IV
57765224|NCT04082520|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
57765225|NCT04082520|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
57765226|NCT04082520|OTHER|Questionnaire Administration|Ancillary studies
57765227|NCT04082520|PROCEDURE|Computed Tomography|Undergo PET/CT and/or SPECT/CT
57765228|NCT04082520|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57765229|NCT04082520|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
57765230|NCT05885282|DEVICE|paraspinal vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
57765231|NCT05885282|DEVICE|gastrosoleus muscle complex vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
57765232|NCT05885282|OTHER|Control Exercise|Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
57765233|NCT04996134|DRUG|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
57765234|NCT04588233|DIETARY_SUPPLEMENT|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
57765235|NCT04588233|OTHER|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
57765236|NCT02995902|DEVICE|FLT-PET|
58129259|NCT01189123|BIOLOGICAL|fluzone by sanofi pasteur|standard dose fluzone
58129260|NCT00048568|DRUG|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
58129261|NCT00048568|DRUG|Methotrexate|Tablets, Oral, \>= 15 mg, weekly, 1 year
57765237|NCT02995902|DEVICE|MRI|
57765238|NCT04990141|PROCEDURE|Peripheral blood collection in cases group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group
57765239|NCT04990141|PROCEDURE|Peripheral blood collection in control group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
57765240|NCT06625450|DRUG|Tofacitinib|Tofacitinib alone will be continued at a dose of 11 mg once a day
57765241|NCT06625450|DRUG|Tofacitinib plus mesalamine|Both tofacitinib 11 mg once a day and mesalamine will be continued
57765242|NCT02344537|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
57765243|NCT01215214|DRUG|midazolam|midazolam: 3mg iv
57765244|NCT03237520|OTHER|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
57765245|NCT03237520|OTHER|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
57765246|NCT01535742|DEVICE|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
57765247|NCT01535742|DEVICE|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
57765248|NCT01535742|DEVICE|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
57765249|NCT01535742|DEVICE|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
57765250|NCT03135561|BEHAVIORAL|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
57765251|NCT03135561|BEHAVIORAL|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
57765252|NCT06257355|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
57765253|NCT00242801|DRUG|Gefitinib|
57961215|NCT01030510|DRUG|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
58457486|NCT05261386|DRUG|CBT-008|Treat MGD
57961216|NCT03283176|DIAGNOSTIC_TEST|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
58457487|NCT04139226|DRUG|CC-11050|CC-11050
58457488|NCT01904409|DRUG|Placebo|
58457489|NCT01904409|DRUG|Rifaximin SSD 40 mg IR tablet|
58457490|NCT01904409|DRUG|Rifaximin SSD 80 mg IR tablet|
58457491|NCT01904409|DRUG|Rifaximin SSD 40 mg SER tablet|
58457492|NCT01904409|DRUG|Rifaximin SSD 80 mg SER tablet|
58457493|NCT01904409|DRUG|Rifaximin SSD 80mgIR/80mgSER tablet|
58457494|NCT06389630|OTHER|video-assisted training group|This group will be taught subcutaneous insulin injection through video-supported training.
58457495|NCT06389630|OTHER|low fidelity simulation model group|This group will be taught subcutaneous insulin injection on a low-fidelity simulation model.
58457496|NCT04369378|BEHAVIORAL|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
57765254|NCT00642798|DRUG|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
57765255|NCT04035200|DRUG|V117957 tablets|V117957 tablets taken orally at bedtime
57765256|NCT04035200|DRUG|Placebo|Tablets to match V117957
57765257|NCT02893306|BIOLOGICAL|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
57765258|NCT02565121|DRUG|corticosteroids|
57765259|NCT02565121|BEHAVIORAL|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
58457497|NCT01853826|DRUG|afatinib|Patients will receive afatinib once daily
58457498|NCT00118183|DRUG|docetaxel|Given IV
58457499|NCT00118183|BIOLOGICAL|cetuximab|Given IV
58457500|NCT00118183|DRUG|bortezomib|Given IV
58457501|NCT05228665|BEHAVIORAL|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
57765260|NCT04402658|DRUG|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately \~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
57765261|NCT05745428|OTHER|molecular and cellular analyses|sample blood
57765262|NCT00002537|DRUG|topotecan hydrochloride|
57765263|NCT00002537|RADIATION|radiation therapy|
57765264|NCT06389097|RADIATION|Radium-223|"Radium-223 will be given as per standard of care or other clinical trial. It is typically administered intravenously via slow injection once every 4 weeks with a dosage of 55 kBq/kg per cycle. Patients typically receive up to six cycles unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. These will be performed at 2-4 hr, 24 hr, and 48 hr after any cycle of Radium-223. Protocol preference is for imaging with 2 cycles, ideally cycle 1 and cycle 6, but imaging with any one or two cycle(s) is acceptable.~The imaging time at each time point is approximately 30 minutes per field of view with two fields of view (1 hr total) typically collected sequentially (i.e., without repositioning the patient on the imaging table)."
57765265|NCT06389097|RADIATION|177Lu-DOTATATE|"177Lu-DOTATATE to be given as Standard of Care (SOC) or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes with peptide co-infusion prior and during the infusion.~Patients will receive 4 cycles of 177Lu-DOTATATE administered approximately every 8 weeks. Treatment cycle is defined as 8 consecutive weeks (D1-D56) following a dose of 177Lu-DOTATATE. Patients receive up to four infusions of 7.4 GBq (200 mCi) every 8 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is \~ 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
58129262|NCT00048568|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
58457502|NCT03007550|PROCEDURE|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
58457503|NCT03007550|PROCEDURE|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
57961217|NCT03887754|DRUG|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
57961218|NCT03887754|DEVICE|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
57961219|NCT03887754|DRUG|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
57961220|NCT00132132|BEHAVIORAL|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
58457504|NCT02159586|DEVICE|gastric electrical stimulator|
58457505|NCT01043172|DRUG|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
58457506|NCT02796677|DRUG|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
58457507|NCT02796677|DRUG|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
58457508|NCT02796677|DRUG|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
58457509|NCT02796677|OTHER|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
58457510|NCT02796677|DRUG|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
57961221|NCT05072132|OTHER|Personal information on genetic susceptibility to arsenic toxicity|The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
58457511|NCT02796677|OTHER|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
57961222|NCT05072132|OTHER|standard information on arsenic exposure reduction|In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
57961223|NCT02816918|DEVICE|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
57765266|NCT06389097|RADIATION|177Lu-PSMA-617|"177Lu-PSMA-617 will be given as per SOC or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes.~Up to 6 cycles of 177Lu- PSMA-617 will be administered approximately every 6 weeks. Treatment cycle is defined as 6 consecutive weeks (D1-D42) following a dose of 177Lu- PSMA-617. Patients will receive up to six infusions of 7.4 GBq (200 mCi) every 6 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is approximately 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
57765267|NCT04586413|OTHER|No intervention - quality of life measure|Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
57765268|NCT00284141|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
57765269|NCT01356953|OTHER|Aerobic exercise|Intensity of aerobic exercise
57765270|NCT03276637|GENETIC|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
57765271|NCT05674890|DIAGNOSTIC_TEST|SmartSystem VR Headset perimeter|Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
57765272|NCT00737880|OTHER|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
57765273|NCT03809884|BEHAVIORAL|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
57765274|NCT03809884|DRUG|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
57765275|NCT04099602|OTHER|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
57765276|NCT00410787|DRUG|OROS hydromorphone HCI (slow release)|
57765277|NCT04170686|BEHAVIORAL|Zemedy App for Irritable Bowel Syndrome|The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
58457512|NCT05114824|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
58457513|NCT03349723|DRUG|BI 1265162|Single rising dose groups
58457514|NCT03349723|DRUG|Placebo|Single rising dose groups
58457515|NCT04790175|DRUG|Tolvaptan (SAMSCA)|The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.
58457516|NCT03454295|BEHAVIORAL|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
58457517|NCT03454295|BEHAVIORAL|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
58457518|NCT03454295|BEHAVIORAL|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
58457519|NCT04516720|OTHER|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
58457520|NCT01892670|OTHER|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
58457521|NCT00415948|DEVICE|Biomarkers|
58457522|NCT04006418|OTHER||
58457523|NCT05117541|OTHER|Interview|Participate in interviews
58457524|NCT05117541|PROCEDURE|Biospecimen Collection|Undergo collection of hair samples
58457525|NCT05117541|OTHER|Electronic Health Record Review|Medical records are reviewed
57765278|NCT04954586|OTHER|Pain Informed Movement|Participants will attend a twice weekly exercise program.
57765279|NCT02094521|DRUG|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
57765280|NCT04438902|DRUG|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
57765281|NCT02468102|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
57765282|NCT02468102|DRUG|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
57765283|NCT04257708|DIAGNOSTIC_TEST|ultrasound|Transvaginal us to assess the cavity
57765284|NCT00815035|DRUG|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
57765285|NCT00815035|DRUG|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
57765286|NCT03454464|PROCEDURE|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
57765287|NCT03454464|PROCEDURE|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
57765288|NCT04235582|BEHAVIORAL|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
57765289|NCT04235582|BEHAVIORAL|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
57765290|NCT00793221|DEVICE|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
57765291|NCT00793221|DEVICE|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
57765292|NCT03861806|BEHAVIORAL|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
57765293|NCT03861806|BEHAVIORAL|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
57765294|NCT05272670|BEHAVIORAL|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
57765295|NCT03892629|BEHAVIORAL|Baduanjin exercise|Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
57765296|NCT03892629|DEVICE|Instrument rehabilitation|Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
58457526|NCT05826483|DRUG|Almonertinib|Almonertinib Mesilate Tablets
57765297|NCT02852122|DRUG|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
57765298|NCT00005816|BIOLOGICAL|therapeutic autologous dendritic cells|
57765299|NCT00005816|PROCEDURE|conventional surgery|
57765300|NCT00780182|DRUG|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
57765301|NCT01920425|DEVICE|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
57765302|NCT01920425|OTHER|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
57765303|NCT05591625|BEHAVIORAL|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
57765304|NCT03221010|BEHAVIORAL|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
57765305|NCT03221010|BEHAVIORAL|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
57765306|NCT04344041|DRUG|cholecalciferol 200,000 IU|Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
57765307|NCT04344041|DRUG|cholecalciferol 50,000 IU|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
57765308|NCT05966935|COMBINATION_PRODUCT|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
57765309|NCT06383702|DRUG|pregabalin sustained-release tablets|Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
57765310|NCT06383702|DRUG|Placebo|Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
57765311|NCT03027414|DRUG|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
57765312|NCT03027414|DEVICE|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
57765313|NCT05582980|DEVICE|HD-tDCS|See detail in arm/group descriptions regarding the intervention.
57765314|NCT06335732|DIAGNOSTIC_TEST|Cross section study; single group related measurement design.|Two hundred pediatric physiotherapists from both genders were participated in the current study. They were selected randomly from the Outpatient Clinic of pediatric physiotherapists of Hospitals of Ministry of Health in Cairo-Egypt, the duration of this study was six months started from December 2022 to June 2023
57765315|NCT01934413|BEHAVIORAL|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
57765316|NCT01934413|OTHER|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
57765317|NCT03614962|DEVICE|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
57765318|NCT03614962|DEVICE|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
57765319|NCT03614962|DEVICE|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
57765320|NCT03614962|DEVICE|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
57765321|NCT03614962|DEVICE|control|No warmth pad and TENS electrodes presented in the cap.
57765322|NCT00004390|DRUG|desipramine|
57765323|NCT00004390|DRUG|methadone|
57765324|NCT00004390|DRUG|morphine|
57765325|NCT00004390|DRUG|nortriptyline|
57765326|NCT05453175|OTHER|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
57765327|NCT02456805|OTHER|Infant Formula 1|Feed ab libitum
57765328|NCT02456805|OTHER|Infant Formula 2|Feed ab libitum
57961224|NCT02816918|DEVICE|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
57961225|NCT00243659|BIOLOGICAL|ReFacto AF|
57765329|NCT01712243|OTHER|Light|
57765330|NCT02206308|BIOLOGICAL|Chimeric anti-CD20 monoclonal antibody|
57765331|NCT02786264|DRUG|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
57765332|NCT02786264|DRUG|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
57765333|NCT03154372|OTHER|Expert supervised practice with validated metrics|
57765334|NCT03154372|OTHER|self guided practice with validated metrics|
57765335|NCT03516864|DEVICE|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
57765336|NCT03516864|DEVICE|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
57765337|NCT02041923|BEHAVIORAL|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
57765338|NCT02041923|OTHER|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
57765339|NCT03328143|DRUG|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
57765340|NCT01068301|DRUG|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
57765341|NCT01540994|RADIATION|radiation therapy|Stereotactic Body Radiation Therapy
57765342|NCT00628836|DEVICE|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
57765343|NCT00357045|DRUG|Paroxetine|
57765344|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
57765345|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
57765346|NCT00698386|DIETARY_SUPPLEMENT|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
57765347|NCT00698386|DIETARY_SUPPLEMENT|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
57765348|NCT00744263|BIOLOGICAL|VACCINE: placebo|0.5 mL, single intra-muscular injection
57765349|NCT00744263|BIOLOGICAL|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
57765350|NCT03622879|BEHAVIORAL|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
57765351|NCT03622879|DEVICE|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
57765352|NCT03622879|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
57961226|NCT03536455|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
57961227|NCT03536455|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
57961228|NCT00993746|DRUG|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
57765353|NCT00517985|DRUG|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
58457527|NCT03659318|PROCEDURE|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
57765354|NCT01865305|DRUG|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
57765355|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
57765356|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
57765357|NCT01865305|DRUG|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
57765358|NCT01865305|DRUG|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
57765359|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
57765360|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
57765361|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
57765362|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
57765363|NCT03735160|DEVICE|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
57765364|NCT01391923|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
57765365|NCT03729024|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
57765366|NCT05477147|DEVICE|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
57765367|NCT04670003|OTHER|users|Data of users of the web-application
57765368|NCT06152016|OTHER|BE-FAST|This intervention includes those randomized to the education with the BE-FAST mnemonic.
57765369|NCT06152016|OTHER|FAST|This intervention includes those randomized to the education with the FAST mnemonic.
57765370|NCT04380532|BIOLOGICAL|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
58457528|NCT03659318|PROCEDURE|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
57765371|NCT03966222|DEVICE|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
57765372|NCT03966222|OTHER|Open vein harvest|Open vein harvest
57765373|NCT03788460|OTHER|no intervention|no intervention
57765374|NCT00267696|DRUG|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
57765375|NCT00267696|DRUG|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
57765376|NCT00267696|DRUG|Carboplatin|
57765377|NCT02775318|PROCEDURE|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
57765378|NCT02775318|DRUG|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
57765379|NCT02775318|PROCEDURE|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
57765380|NCT02775318|PROCEDURE|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
57765381|NCT06261047|RADIATION|radiotherapy|radiotherapy
58457529|NCT04739826|DRUG|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
57765382|NCT05309538|OTHER|Modified eply & Semont maneuver|repositioning maneauvers
57765383|NCT05309538|OTHER|betahistine & Modified eply & Semont maneuver|antihistamine plus repositioning maneuvers
57765384|NCT01406002|DRUG|darexaban|oral
57765385|NCT01406002|DRUG|Rifampicin|oral
57765386|NCT05596513|OTHER|motor learning and occupational therapy|"1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)"
57765387|NCT05596513|OTHER|Motor Learning Approaches From Working on a Vertical Surface|"1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls"
57765388|NCT04930744|DRUG|Isoniazid|Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.
57765389|NCT04930744|DRUG|Rifampicin|Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.
57765390|NCT04930744|DRUG|Ethambutol|Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.
57765391|NCT04930744|DRUG|Pyrazinamide|Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.
57765392|NCT04930744|DRUG|Metformin hydrochoride|Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
57765393|NCT04676490|OTHER|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
57765394|NCT04676490|OTHER|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
57765395|NCT02255396|OTHER|ESTRADIOL|
57765396|NCT04156997|OTHER|No intervention is involved in this study|No intervention is involved in this study
57765397|NCT06129201|OTHER|Tongue image|Using intelligent imaging devices to collect subject tongue images
57961229|NCT00993746|DRUG|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
57961230|NCT02921971|DRUG|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
57961231|NCT02921971|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
57961232|NCT00513760|DIETARY_SUPPLEMENT|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
57961233|NCT00513760|DIETARY_SUPPLEMENT|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
57961234|NCT00513760|DIETARY_SUPPLEMENT|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
57961235|NCT02977169|RADIATION|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
58457530|NCT04739826|DRUG|Nilotinib Pill|Nilotinib Capsules 300mg bid
58457531|NCT02996201|OTHER|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
58457532|NCT04985526|OTHER|Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)|Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
58457533|NCT02633670|DEVICE|Hemopatch|
57765398|NCT03279848|OTHER||Stroke rehabilitation
57765399|NCT03184896|PROCEDURE|Hip Fracture Surgery|Hip Fracture Surgery
57765400|NCT02961374|DRUG|Erlotinib|Given PO
57765401|NCT02961374|DRUG|Erlotinib Hydrochloride|Given PO
57765402|NCT01619332|DRUG|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
57765403|NCT01619332|DRUG|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
57765404|NCT01619332|DRUG|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
57765405|NCT05536102|DRUG|PLD|20mg/m2, day 1, q3w
57765406|NCT05536102|DRUG|Oxaliplatin|130 mg/m2, day 1, q3w
57765407|NCT05536102|DRUG|Capecitabine|1000 mg/m2, days 1-14, q3w
57765408|NCT05536102|DRUG|Tislelizumab|200 mg, day 1, q3w
57765409|NCT04244435|PROCEDURE|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
57765410|NCT04244435|DRUG|thoracic epidural analgesia|thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
57765411|NCT04244435|DRUG|analgesia of opioids|Opioids will be used for perioperative analgesia
57765412|NCT01262443|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
57765413|NCT00500721|DRUG|HCV-796|HCV-796 500mg BID x 14 days
57765414|NCT00500721|DRUG|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
57765415|NCT04466215|DRUG|Miricorilant|900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
57765416|NCT04466215|DRUG|Placebo oral tablet|Six placebo tablets taken orally once daily for two weeks
57765417|NCT04963361|OTHER|patients were exposed to fear of movement|Patients completed the questionnaires independently
57765418|NCT04963361|OTHER|patients were not exposed to fear of movement|Patients completed the questionnaires independently
58457534|NCT02633670|DEVICE|No Hemopatch|
58457535|NCT06021925|OTHER|Obstetrical history|Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.
58457536|NCT06021925|OTHER|Anti-HLA Antibody tests|Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.
58457537|NCT00278577|BIOLOGICAL|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
58457538|NCT03072446|DEVICE|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
57765419|NCT04215263|OTHER|Questionaire|Patient was assessed using mini international neuropsychiatric interview
57765420|NCT03889613|OTHER|prospective follow-up with videocapsule|prospective follow-up with videocapsule
58457539|NCT00849940|DEVICE|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
57765421|NCT04903223|DRUG|Rosuvastatin 10mg|Rosuvastatin will be administered to all participants on Study Day #2
57765422|NCT01635075|BEHAVIORAL|Exercise|1-mile treadmill walk
57765423|NCT01635075|BEHAVIORAL|passive control|20 min inactivity
57765424|NCT01129635|PROCEDURE|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate"
57765425|NCT00891306|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
57765426|NCT00891306|DRUG|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
57765427|NCT00891306|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
57765428|NCT00891306|DRUG|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
57765429|NCT05819814|GENETIC|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
57765430|NCT05208853|BIOLOGICAL|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
57765431|NCT00529919|DIETARY_SUPPLEMENT|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
57765432|NCT01222221|BIOLOGICAL|glioblastoma multiforme multipeptide vaccine IMA950|
57765433|NCT01222221|BIOLOGICAL|sargramostim|
57765434|NCT01222221|DRUG|temozolomide|
57765435|NCT01222221|OTHER|laboratory biomarker analysis|
57765436|NCT01222221|OTHER|pharmacological study|
57765437|NCT01222221|PROCEDURE|adjuvant therapy|
57765438|NCT01222221|RADIATION|radiation therapy|
57765439|NCT04591535|DRUG|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
58457540|NCT03444610|BIOLOGICAL|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
58457541|NCT03668795|PROCEDURE|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
58457542|NCT02843230|RADIATION|Avastin|
58457543|NCT02843230|RADIATION|Lomustine|
58457544|NCT02843230|RADIATION|Temozolomide|
57765440|NCT01083641|DRUG|Estradiol|10mg oral three times daily
57765441|NCT02462850|DRUG|CL-108|
57765442|NCT02377037|OTHER|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
57765443|NCT06266091|DRUG|M701|Intra-peritoneal infusion of M701 combined with system therapy
57765444|NCT06266091|DRUG|paracentesis|paracentesis combined with system therapy
57765445|NCT02966002|DRUG|Aspirin|
57765446|NCT05852028|DRUG|Selinexor|this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
57765447|NCT05797792|DRUG|Intraarterial alteplase|See arm/group descriptions.
57765448|NCT00192062|DRUG|gemcitabine|
57765449|NCT00192062|DRUG|vinorelbine|
57765450|NCT06622720|PROCEDURE|surgery|The colorectal surgery of any type conducted in any approach in the timeframe
57765451|NCT00314067|PROCEDURE|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
57765452|NCT00314067|PROCEDURE|Physician training|
57765453|NCT00314067|PROCEDURE|Practice team training|
57765454|NCT01226914|DRUG|EVICEL|EVICEL
57765455|NCT04113681|PROCEDURE|Geniculate Artery Embolization|"1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)"
57765456|NCT04313959|DRUG|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
57765457|NCT04313959|DRUG|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
57765458|NCT01516411|BEHAVIORAL|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
57765459|NCT04923295|DRUG|Dapagliflozin 10Mg Tab|Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
57765460|NCT03940508|BEHAVIORAL|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
57765461|NCT03940508|BEHAVIORAL|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
57765462|NCT05156463|COMBINATION_PRODUCT|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
57765463|NCT00811447|DRUG|5-fluorouracil|600 mg/m²/day intravenous
57765464|NCT00811447|DRUG|Cisplatin|60 mg/m² or 75 mg/m² intravenous
57765465|NCT00811447|DRUG|Docetaxel|60 mg/m² intravenous
57765466|NCT04322006|DRUG|TJ004309|Antibody to CD73
57765467|NCT04322006|DRUG|Toripalimab|Humanized monoclonal antibody to PD-1
57765468|NCT02692690|DEVICE|Stimulette r4x|
57765469|NCT00622713|DRUG|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm\^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\^2.
57765470|NCT01782742|DRUG|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
57765471|NCT01782742|DRUG|Placebo|
57765472|NCT02750176|OTHER|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
57765473|NCT02672384|PROCEDURE|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
57765474|NCT03696797|PROCEDURE|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
57765475|NCT03696797|PROCEDURE|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
57765476|NCT03724396|BEHAVIORAL|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
57765477|NCT03724396|BEHAVIORAL|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
57765478|NCT01047722|DRUG|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
57765479|NCT01047722|PROCEDURE|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
57765480|NCT00002093|DRUG|Daunorubicin (liposomal)|
57765481|NCT00002093|DRUG|Bleomycin sulfate|
57765482|NCT00002093|DRUG|Vincristine sulfate|
57765483|NCT00002093|DRUG|Doxorubicin hydrochloride|
57765484|NCT01007968|DRUG|LBH589|
57765485|NCT04402528|BEHAVIORAL|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
57765486|NCT00685321|DEVICE|H1 deep TMS coil|20 daily deep rTMS treatment
57765487|NCT00685321|DEVICE|Sham|inactive treatment
57765488|NCT00247364|DRUG|Levetiracetam (Keppra)|
58457545|NCT02843230|DEVICE|MRI|
58457546|NCT02843230|DEVICE|MRS|
58457547|NCT02843230|DEVICE|DSC|
57765489|NCT02405364|DRUG|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
57765490|NCT06040996|BEHAVIORAL|Improving Parenting Skills adult ADHD (IPSA)|Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.
57765491|NCT06040996|OTHER|Continued Routine Services|Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
57765492|NCT01327118|DRUG|Prostaglandin F2alpha|intravenous injection
57765493|NCT01327118|DRUG|Isoton sodium chloride|intravenous injection
57765494|NCT01396395|DRUG|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
58457548|NCT04388761|DRUG|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
58457549|NCT00002044|DRUG|Zidovudine|
57765495|NCT01396395|DRUG|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
57765496|NCT00007280|DEVICE|Bioengineered skin|
57765497|NCT02408237|DEVICE|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
58457550|NCT00792012|RADIATION|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
57765498|NCT02408237|DEVICE|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
57765499|NCT02408237|DEVICE|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
57765500|NCT02408237|DEVICE|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
57765501|NCT00596596|DRUG|prucalopride|0,5 mg once daily
57765502|NCT00596596|DRUG|prucalopride|1 mg once daily
57765503|NCT00596596|DRUG|2 mg prucalopride|2 mg once daily
57765504|NCT00596596|DRUG|4 mg prucalopride|4 mg once daily
57765505|NCT00596596|OTHER|Placebo|placebo once daily
57765506|NCT00259415|BEHAVIORAL|Caregiver support via telephone|
57765507|NCT02629211|DEVICE|NaviAid™ AB|NaviAid™ AB Procedure
57765508|NCT02387996|DRUG|Nivolumab|
57765509|NCT00001202|DRUG|Spironolactone|
57765510|NCT00001202|DRUG|Testolactone|
57765511|NCT00001202|DRUG|Deslorelin|
57765512|NCT06481579|BIOLOGICAL|IVX-A12|IVX-A12 IM injection.
58457551|NCT00792012|DRUG|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
58457552|NCT01665196|DRUG|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
57765513|NCT06481579|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV Vaccine IM injection.
57765514|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
57765515|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
57765516|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
58457553|NCT03899714|OTHER|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
58457554|NCT00018148|DRUG|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
58457555|NCT00018148|DRUG|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
58457556|NCT00528112|DRUG|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
58457557|NCT00528112|DRUG|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
58457558|NCT02735239|DRUG|Durvalumab|Anti PD-L1 antibody
58457559|NCT02735239|DRUG|Tremelimumab|Anti CTLA-4 antibody
57765517|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
57765518|NCT03921346|DEVICE|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
57765519|NCT03921346|DEVICE|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
57765520|NCT03921346|DEVICE|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
57765521|NCT03921346|DEVICE|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
58457560|NCT02735239|DRUG|Oxaliplatin|IV administered chemotherapy
57765522|NCT06623201|DRUG|aminolevulinic acid HCL (ALA)|Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
57765523|NCT06623201|DEVICE|BLU-U device model 4170E|Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
57765524|NCT04034459|DRUG|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1
57765525|NCT04034459|DRUG|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
57765526|NCT04034459|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
57765527|NCT04034459|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² day 1
57765528|NCT04034459|DRUG|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
57765529|NCT04034459|DRUG|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
57765530|NCT05834036|DRUG|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
57765531|NCT02339896|BIOLOGICAL|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
57765532|NCT02844491|OTHER|additional biological samples|blood and tissue samples
57765533|NCT00647101|DRUG|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
57765534|NCT06625489|DRUG|Part A: Placebo|Placebo will be administered.
57765535|NCT06625489|DRUG|Nintedanib|Nintedanib will be administered.
57765536|NCT06625489|DRUG|GSK3915393|GSK3915393 will be administered.
57765537|NCT03185832|DEVICE|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
57765538|NCT03185832|DEVICE|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
57765539|NCT03185832|DEVICE|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
57765540|NCT03185832|OTHER|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
57765541|NCT01478711|OTHER|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
57765542|NCT00654134|BIOLOGICAL|Clinical Center Reference Endotoxin|20,000 EU inhaled
57765543|NCT06096324|BEHAVIORAL|Job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages|Participants will receive job announcements plus educational sessions, mentoring, a micro-grant, and behavioral economic text messages.
57765544|NCT06096324|BEHAVIORAL|Job announcements|Participants will receive job announcements only.
57961236|NCT02977169|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
58457561|NCT02735239|DRUG|Capecitabine|orally-administered chemotherapy
57765545|NCT05661721|OTHER|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
57765546|NCT05661721|OTHER|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
57765547|NCT03315936|DRUG|BI 894416|powder for oral solution
57765548|NCT03315936|DRUG|Placebo|Oral solution
57765549|NCT03315936|DRUG|BI 894416|Tablet
57765550|NCT06017830|DEVICE|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
57765551|NCT06230614|OTHER|Colistin 1 MU in normal saline 1 ml|Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
57765552|NCT06230614|OTHER|Colistin 1 MU in normal saline 2 ml|Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
57765553|NCT01231841|DRUG|cyclosporine|Given orally
57765554|NCT01231841|BIOLOGICAL|anti-thymocyte globulin|Given IV
57765555|NCT04888247|DEVICE|CLARITY|Trans-septal mitral valve replacement
57765556|NCT04568967|DIAGNOSTIC_TEST|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
57765557|NCT04568967|DIAGNOSTIC_TEST|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
57765558|NCT02691195|DRUG|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
57765559|NCT02691195|DRUG|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
57765560|NCT02390427|DRUG|Taselisib|
57765561|NCT02390427|DRUG|Trastuzumab emtansine|
57765562|NCT02390427|DRUG|Pertuzumab|
57765563|NCT02390427|DRUG|Trastuzumab|
57765564|NCT02390427|DRUG|Paclitaxel|
57765565|NCT05624840|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir (Paxlovid)
58457562|NCT02735239|RADIATION|Radiotherapy|
58457563|NCT02735239|DRUG|Paclitaxel|IV administered chemotherapy
57765566|NCT06481254|OTHER|Hawthorn Vinegar Group|To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
57765567|NCT06481254|OTHER|Black Mulberry Syrup Group|To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
57765568|NCT06481254|OTHER|Green Tea Group|To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
57765569|NCT00208585|DRUG|sertraline|
57765570|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg \[3.7 MBq/kg\] (minimum dose 1mCi \[37MBq\] but not to exceed 5 mCi \[185 MBq\]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
57765571|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed \> 23 Gy to the kidneys, \> 30 Gy to the liver, or \> 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
57765572|NCT03046511|DRUG|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
58457564|NCT02735239|DRUG|Carboplatin|IV administered Chemotherapy
58457565|NCT02735239|DRUG|5-fluorouracil (5-FU)|IV administered chemotherapy
58457566|NCT02735239|DRUG|Leucovorin|chemo-protective agent
58457567|NCT02735239|DRUG|Docetaxel|IV administered chemotherapy
58457568|NCT01643668|DRUG|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
58457569|NCT01643668|DRUG|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
58457570|NCT01643668|PROCEDURE|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
58457571|NCT00738998|BEHAVIORAL|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
57765573|NCT04297618|DRUG|Xiidra|Xiidra (lifitegrast 5% ophthalmic solution)
57765574|NCT04456335|GENETIC|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
57765575|NCT04637165|OTHER|This is a non-interventional study|This is a non-interventional study
58457572|NCT00738998|OTHER|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
58457573|NCT02153268|PROCEDURE|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
57765576|NCT02964455|DRUG|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
57765577|NCT02964455|DRUG|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
57765578|NCT02964455|RADIATION|chest radiation|continuous chest radiation at 64 Gy/32f
57765579|NCT02177539|DRUG|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
57765580|NCT02177539|DRUG|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
57765581|NCT05975437|OTHER|personalized surveillance plans (PSP) and personalized aftercare plans (PAP)|The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
57765582|NCT06461819|RADIATION|Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.|this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
57765583|NCT05553847|OTHER|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
57765584|NCT01222429|OTHER|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
57765585|NCT01222429|OTHER|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
57765586|NCT02543320|OTHER|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
58457574|NCT01350999|DRUG|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
58457575|NCT01350999|DRUG|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
57765587|NCT02543320|OTHER|Questionnaire Administration|Ancillary studies
57765588|NCT01736501|OTHER|Genetics education at baseline|
57765589|NCT01736501|OTHER|Hypothetical genomic scenarios at follow-up|
57961237|NCT02896595|DEVICE|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
57765590|NCT00984321|BEHAVIORAL|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
57765591|NCT00984321|BEHAVIORAL|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
57765592|NCT00984321|BEHAVIORAL|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
57765593|NCT05326763|DRUG|Platelet Rich Plasma|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
57765594|NCT05326763|DRUG|Dextrose 50%|The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
57765595|NCT01765595|OTHER|DDI+|
57765596|NCT03233178|OTHER|Non-interventional|
57765597|NCT04803617|OTHER|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
57765598|NCT02553811|DIAGNOSTIC_TEST|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
57765599|NCT05008029|PROCEDURE|In situ immobilization|Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
57765600|NCT05008029|PROCEDURE|Reduction under general anesthesia|The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
57765601|NCT04508296|DIAGNOSTIC_TEST|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
58457576|NCT01228279|OTHER|DIANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
57765602|NCT02708433|DRUG|Lidocaine|Lidocaine
57765603|NCT05520385|DIAGNOSTIC_TEST|blood group and Rh|check of blood group , Rh for patient and control
57765604|NCT01616576|DEVICE|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
57765605|NCT01616576|DEVICE|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
57765606|NCT02385019|BIOLOGICAL|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells"
57765607|NCT03342053|DRUG|RO7234292 (RG6042)|Intrathecal injection
57765608|NCT01876641|DRUG|Vemurafenib + Cobimetinib, Decitabine|
57765609|NCT00167895|PROCEDURE|Adding platelet concentrate to the wound|
57765610|NCT02601898|DEVICE|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
57765611|NCT02601898|DRUG|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
57765612|NCT00199498|DEVICE|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
57765613|NCT00199498|DEVICE|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
57765614|NCT05138159|DRUG|Donafenib|Donafenib: 200mg po bid.
57765615|NCT05138159|DRUG|S1|S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
57765616|NCT05189054|RADIATION|stereotacitic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
57765617|NCT00951262|BEHAVIORAL|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
57765618|NCT00724139|DEVICE|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
57765619|NCT03107819|DIAGNOSTIC_TEST|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
57765620|NCT05458596|BEHAVIORAL|Screen-based simulation|In the research, training will be given to the sample group on intimate partner violence against women through screen-based simulation.
57765621|NCT05876611|DEVICE|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
57765622|NCT00874432|DRUG|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
57765623|NCT00874432|DRUG|lisinopril|1 x 40 mg per day
57765624|NCT02670252|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
57765625|NCT02670252|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
57765626|NCT02670252|RADIATION|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
57765627|NCT05007561|DRUG|Naltrexone Hydrochloride|oral naltrexone
57765628|NCT05007561|DRUG|Placebo|oral sugar pill
57765629|NCT01657630|DEVICE|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
57765630|NCT02186080|DRUG|Gemigliptin|
57765631|NCT02186080|DRUG|Placebo|
57765632|NCT02901145|DRUG|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
57765633|NCT02757924|OTHER|Infant formula supplemented with prebiotics|Sole source nutrition
57765634|NCT01547299|DRUG|Enzalutamide|
57765635|NCT01547299|DRUG|Leuprolide|
57765636|NCT01547299|DRUG|Dutasteride|
57765637|NCT02413463|PROCEDURE|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
57765638|NCT02413463|PROCEDURE|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
57765639|NCT04268992|OTHER|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
57765640|NCT03735563|DRUG|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
57765641|NCT03735563|DRUG|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
57765642|NCT04399551|DRUG|CAB OLI|CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
57765643|NCT04399551|DRUG|CAB LA|CAB LA 600 mg will be administered as intramuscular (IM) injection.
57765644|NCT04399551|DRUG|RPV OLI|RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
57765645|NCT04399551|DRUG|RPV LA|RPV LA 900 mg will be administered as IM injection.
57765646|NCT04399551|OTHER|Continuous Quality Improvement (CQI) calls|CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
57765647|NCT01078662|DRUG|olaparib|Tablets Oral BID
57961238|NCT02896595|DEVICE|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
57961239|NCT01527474|DRUG|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
57765648|NCT02578914|DRUG|NS2 Ophthalmic Drops (0.5%)|
57765649|NCT02578914|DRUG|NS2 Ophthalmic Drops Vehicle (0.0%)|
57765650|NCT02006121|DRUG|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
57765651|NCT02006121|DRUG|Placebo|Sodium chloride 9 mg/ml
57765652|NCT03495804|DRUG|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
57765653|NCT03495804|DRUG|mannitol|Active comparator group was given mannitol as oral contrast agent.
57765654|NCT06272305|PROCEDURE|This research does not require any specific investigation and does not imply any modification of treatment.|Collection of data from the medical record for patients with a non specific carotid endarterectomy
58457577|NCT01228279|OTHER|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
58457578|NCT03829085|OTHER|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
57765655|NCT06307119|BEHAVIORAL|Occupational Therapy and Relaxation Group|"MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds."
57765656|NCT06307119|BEHAVIORAL|Relaxation Group|Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
57765657|NCT04596137|BEHAVIORAL|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
57765658|NCT00997737|DEVICE|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
57765659|NCT01160484|DRUG|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
57765660|NCT03548116|DEVICE|Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
57765661|NCT03548116|DEVICE|Sham Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
57765662|NCT01336959|DRUG|BCT197 Part A|open label single dose administration of 10mg BCT197, 2 hours prior to surgery
57765663|NCT01336959|DRUG|Placebo|Single dose matching placebo administered 2 prior to surgery
57765664|NCT01336959|DRUG|BCT197 Part B|BCT197 50mg single dose administered 2 hours prior to surgery
57765665|NCT01291316|DRUG|Clonazepam|clonazepam, 1 mg, single oral dose
57765666|NCT01291316|DRUG|Tolterodine|Tolterodine 1,37mg, single oral dose
57765667|NCT01291316|DRUG|clobazam|clobazam 20 mg, single oral dose
57765668|NCT05600725|OTHER|novel atrial pacing approach|See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
57765669|NCT05600725|OTHER|sham pacing approach|A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
57765670|NCT03177889|COMBINATION_PRODUCT|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics \[ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid\];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
58457579|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
58457580|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
58457581|NCT05967598|DEVICE|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
57765671|NCT02322814|DRUG|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
57765672|NCT02322814|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
57765673|NCT02322814|DRUG|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
57765674|NCT02322814|DRUG|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
57765675|NCT02322814|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
57765676|NCT05707611|OTHER|Running|The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
57765677|NCT05707611|OTHER|Cycling|The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
57765678|NCT05707611|OTHER|Swimming|The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
57765679|NCT01716143|PROCEDURE|radiofrequency catheter ablation|
57765680|NCT03462134|OTHER|Survey|Survey amongst orthopaedic surgeons
57765681|NCT01069575|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
57765682|NCT03133104|OTHER|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
57765683|NCT05244811|DRUG|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
57765684|NCT05244811|DRUG|Progestin|effect of progestin in treatment of ovarian cystn
57765685|NCT01811979|DIETARY_SUPPLEMENT|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
57765686|NCT01811979|DIETARY_SUPPLEMENT|Steril water|steril water plus topical anesthetics
57765687|NCT00069602|DEVICE|Continuous Glucose Monitoring System (CGMS)|
57765688|NCT00069602|DEVICE|GlucoWatch G2TM Biographer (GW2B)|
57765689|NCT00179530|BEHAVIORAL|Relaxation Response|Relaxation training
57765690|NCT03579290|BEHAVIORAL|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~* Understanding and changing patterns of drug use,~* Coping with craving,~* Substance refusal skills,~* Seemingly irrelevant decisions,~* Planning for emergencies, and~* Problem-solving skills.~* Staying Safe"
57765691|NCT06104514|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
57765692|NCT05489939|DRUG|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
57765693|NCT05106114|OTHER|Intensive gait training rehabilitation protocole|6 weeks of intensive gait training : 4 weeks at the center and 2 weeks of home-based telerehabilitation
57765694|NCT05480670|DIETARY_SUPPLEMENT|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
57765695|NCT05768724|BEHAVIORAL|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
57961240|NCT05132244|PROCEDURE|Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)|Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
57961241|NCT05132244|OTHER|Standard Care|Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
58457582|NCT03262220|RADIATION|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
57765696|NCT05768724|BEHAVIORAL|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
57765697|NCT01622543|DRUG|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
57765698|NCT01622543|DRUG|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
58457583|NCT05572008|BEHAVIORAL|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
58457584|NCT04678583|PROCEDURE|Resection of colorectal liver metastases|Comparison of two liver surgery methods
58457585|NCT00071227|DRUG|Triamcinolone Acetonide (TAC-PF)|
58457586|NCT02738008|DRUG|ARC-520 Injection|IV injection
58457587|NCT02738008|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
58457588|NCT02738008|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
58457589|NCT02738008|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
57765699|NCT02601937|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
58457590|NCT00637078|OTHER|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
58129263|NCT05434481|OTHER|Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases|"* For each patient: a segment of aorta will be sampled and cutted into 4 parts~  * 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.~ * 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.~ * 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.~* For each patient, 2 arterial blood samples will be collected before general anaesthesia~  * One tube of whole blood stored at -80°C for metabolomic analysis.~ * One tube of blood stored at -80°C for plasma cytokines"
58129264|NCT04087395|DEVICE|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
58457591|NCT02608944|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
58457592|NCT02608944|DRUG|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
58457593|NCT02608944|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
58457594|NCT02608944|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
58457595|NCT02608944|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
58457596|NCT00282139|DRUG|Aripiprazole|
58457597|NCT00647179|PROCEDURE|Transsphenoidal adenomectomy|Surgery
58457598|NCT03759834|DEVICE|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
58457599|NCT02451085|BEHAVIORAL|training with video therapy|training with video therapy
57765700|NCT04374396|PROCEDURE|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
58457600|NCT02451085|BEHAVIORAL|conventional exercise|training in conventional way
57765701|NCT04374396|RADIATION|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
57765702|NCT04764292|DEVICE|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
57765703|NCT04764292|DRUG|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
57765704|NCT04318730|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
57765705|NCT06002191|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
57765706|NCT06002191|BEHAVIORAL|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
57765707|NCT03503539|PROCEDURE|Mini percutaneous nephrolithotomy|
57765708|NCT03503539|PROCEDURE|Retrograde intrarenal surgery|
57765709|NCT04100512|DEVICE|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
57765710|NCT04100512|DEVICE|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
57765711|NCT01616875|DRUG|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
57765712|NCT00439829|DRUG|Gonal F|"* 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
57765713|NCT00439829|DRUG|Luveris|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
57765714|NCT00439829|DRUG|Cetrotide|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
57765715|NCT00439829|DRUG|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter"
57765716|NCT00056758|BIOLOGICAL|Autologous Dendritic Cell HIV Vaccination|
57765717|NCT04953338|OTHER|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
57765718|NCT00054925|BEHAVIORAL|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
57765719|NCT00054925|BEHAVIORAL|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
57765720|NCT03179813|PROCEDURE|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
57765721|NCT03179813|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group
57765722|NCT02640391|OTHER|colonoscopy|
57765723|NCT04204213|BEHAVIORAL|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
57765724|NCT04045210|OTHER|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
57765725|NCT06320925|DEVICE|Standard of Care Treatment|Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
57765726|NCT03881319|DRUG|Conventional gynecologic treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
58129265|NCT04087395|DEVICE|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
57765727|NCT03881319|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
57765728|NCT03881319|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
57765729|NCT06624917|PROCEDURE|Green Breast Surgery Protocol|A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
57765730|NCT06134323|DEVICE|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
57765731|NCT06134323|DEVICE|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
57765732|NCT06091462|OTHER|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
57765733|NCT01222923|DRUG|Risperidone|1 mg orally disintegrating tablets
57765734|NCT02579018|BEHAVIORAL|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
57765735|NCT05996952|DRUG|RC48-ADC|Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
57765736|NCT03597035|DRUG|Spironolactone|The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
57765737|NCT01261715|PROCEDURE|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
57765738|NCT02912468|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
57765739|NCT02912468|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
57765740|NCT02912468|DRUG|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
57765741|NCT04848883|BEHAVIORAL|Advanced AMS program|"1. - Telephone acces to infectious disease experts to discuss patients' therpies during working days.~2. - Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
57765742|NCT04848883|BEHAVIORAL|Standard AMS program|"1. - Educational materials.~2. - Updated local antibiotic guidelines.~3. - Promotion of delayed antibiotic prescription.~4. - Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. - Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. - Quarterly reports to prescribers of AMS outcomes at the centre-level."
57765743|NCT01358838|DEVICE|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
57765744|NCT02218840|OTHER|Smoking topography|Evaluation of cigar smoking topography
57765745|NCT04062708|DRUG|Durvalumab|"Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
57765746|NCT04062708|PROCEDURE|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
57765747|NCT04062708|RADIATION|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
57765748|NCT03906305|OTHER|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
57765749|NCT03906305|OTHER|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
58129266|NCT02295878|DIETARY_SUPPLEMENT|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
58129267|NCT02295878|DIETARY_SUPPLEMENT|Placebo|
58129268|NCT02223000|DRUG|BIBV 308 SE solution|
58129269|NCT02223000|DRUG|BIBV 308 SE capsule 1|
58129270|NCT02223000|DRUG|BIBV 308 SE capsule 2|
58129271|NCT04741100|OTHER|Ex-vivo analysis|Ex-vivo analysis
58457601|NCT01427582|DRUG|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
57765750|NCT04822740|DEVICE|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
57765751|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765752|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765753|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765754|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765755|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765756|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765757|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
57765758|NCT03230383|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
57765759|NCT02687321|OTHER|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
57765760|NCT06422455|OTHER|Best Practice|Receive provider-based genetic counseling
57765761|NCT06422455|OTHER|Educational Intervention|Receive genetics education
57765762|NCT06422455|OTHER|Electronic Health Record Review|Ancillary studies
57765763|NCT06422455|OTHER|Genetic Counseling|Receive provider-based genetic counseling
57765764|NCT06422455|OTHER|Interview|Ancillary studies
57765765|NCT06422455|OTHER|Survey Administration|Ancillary studies
57765766|NCT01985828|RADIATION|CyberKnife|
57765767|NCT01985828|OTHER|Androgen Deprivation Therapy (ADT)|
57765768|NCT01985828|RADIATION|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
57765769|NCT02710786|PROCEDURE|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
57765770|NCT03035305|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
57765771|NCT03035305|DRUG|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
57765772|NCT00603265|DRUG|ADL5859|
57765773|NCT00603265|DRUG|Duloxetine|
58457602|NCT01525836|DRUG|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 29th day)
58457603|NCT01525836|DRUG|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
58457604|NCT03662958|DRUG|Lutrate|a novel leuprolide acetate 3.75mg depot
58457605|NCT03662958|DRUG|Enantone|market reference leuprolide acetate 3.75 mg depot
57765774|NCT00603265|DRUG|Placebo|
57765775|NCT00944658|DRUG|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
57765776|NCT00944658|DRUG|Placebo (sugar pill)|twice a day
57765777|NCT01674621|DRUG|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Active Patch
57765778|NCT01674621|DRUG|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Active Patch
57765779|NCT01674621|DRUG|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Active Patch
57765780|NCT01674621|DRUG|Abaloparatide Injection (80 mcg)|Abaloparatide Subcutaneous Injection
57765781|NCT01674621|DRUG|Abaloparatide Placebo|Abaloparatide Transdermal Microneedle Placebo Patch
57765782|NCT00276107|BIOLOGICAL|Prevenar|
57765783|NCT06031597|RADIATION|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
57765784|NCT06031597|DRUG|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
57765785|NCT06031597|DRUG|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
57765786|NCT06031597|DRUG|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
57765787|NCT05963152|BEHAVIORAL|Habitual Physical Activity|Participants will be asked to maintain their normal activity levels
57765788|NCT05963152|BEHAVIORAL|Morning Exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
57765789|NCT05963152|BEHAVIORAL|Afternoon Exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
57765790|NCT02410967|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
57765791|NCT02410967|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
57765792|NCT01788696|RADIATION|Group A - Early Imaging|Total of 3 scans
57765793|NCT01788696|RADIATION|Group B - Delayed Imaging|Total of 2 scans
57765794|NCT01161472|DRUG|4mg fesoterodine|4mg tablet once daily for 6 days
57765795|NCT01161472|DRUG|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
57765796|NCT01161472|DRUG|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
57765797|NCT01161472|DRUG|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
57765798|NCT06230458|DIAGNOSTIC_TEST|FeNO-test|Fractional Exhaled Nitric Oxide (FeNO)- test
57765799|NCT00056940|BEHAVIORAL|Stages of Change|
57765800|NCT00056940|BEHAVIORAL|Safety Check approach|
57765801|NCT02842944|DEVICE|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
57765802|NCT02842944|OTHER|Routine care|Standardized routine care
57765803|NCT05529784|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
57765804|NCT02872298|DEVICE|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
57765805|NCT06257368|DEVICE|Coloplast TFL Drive|Thulium Fiber laser
57765806|NCT01216163|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
57765807|NCT01216163|DRUG|Acetaminophen|Single-dose of acetaminophen (1000mg)
57765808|NCT01216163|DRUG|Placebo|Single-dose of placebo
57765809|NCT04652830|BEHAVIORAL|Naprapathy training|Active training aimed at strengthening the abdominal muscles
57765810|NCT04652830|OTHER|Control group|No change of daily routines in regard to training
57765811|NCT02218528|DIETARY_SUPPLEMENT|Plant-based ingredient|
58457606|NCT00844844|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
57765812|NCT02218528|DIETARY_SUPPLEMENT|No Plant-based ingredient|
58129272|NCT03958825|PROCEDURE|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
57765813|NCT04826328|DRUG|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
57765814|NCT04826328|DRUG|Normal Saline|Single peripheral nerve injection
57765815|NCT05854030|DIAGNOSTIC_TEST|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
57765816|NCT04902820|OTHER|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
57765817|NCT04902820|OTHER|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
57765818|NCT00894634|DRUG|Brompheniramine maleate|
57765819|NCT02118337|BIOLOGICAL|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
57765820|NCT02118337|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
57765821|NCT02118337|BIOLOGICAL|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
57765822|NCT02081222|PROCEDURE|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
57765823|NCT03515057|DIAGNOSTIC_TEST|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
57765824|NCT00480896|DRUG|tacrolimus ointment|Topical application
57765825|NCT00480896|DRUG|Placebo ointment|Topical application
57765826|NCT05912478|OTHER|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
57765827|NCT05912478|OTHER|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
57765828|NCT02093676|BEHAVIORAL|"experimental protocol treatment The New Authority"|
57765829|NCT06624852|OTHER|Screening for coronary artery revascularization based on TMT-ECG|Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT
57765830|NCT04757818|OTHER|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
57765831|NCT04757818|OTHER|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
57765832|NCT01017978|PROCEDURE|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
57765833|NCT05973318|DRUG|Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
57765834|NCT05973318|DRUG|Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
57765835|NCT06390514|OTHER|vibrating floor|activities with vibrating floor
57765836|NCT06390514|OTHER|No vibrating floor|activities without vibrating floor
57765837|NCT02026232|DRUG|Hydroxychloroquine|200mg twice daily
57765838|NCT02026232|OTHER|Hydroxychloroquine Placebo|200mg placebo twice daily
57765839|NCT05147727|DRUG|Fluconazole、Famitinib|Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
57765840|NCT02932839|DEVICE|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
57765841|NCT00303563|DRUG|P38 Inhibitor (4)|50mg po qd
57765842|NCT00303563|DRUG|P38 Inhibitor (4)|150mg po qd
57765843|NCT00303563|DRUG|P38 Inhibitor (4)|300mg po qd
58457607|NCT04816448|OTHER|cervical mobilization (Headache SNAG)|For cervical mobilization the patient's position is sitting on a chair in the erect posture. The therapist handled C2 spinous process with the middle phalanx of one hand. With the other hand, he performed ventral glide asked the patient to move neck in all directions (Flexion, Extension, Side bending and rotation) one by one and then slowly move the neck back to its starting position while the therapist maintained the ventral glide.
58457608|NCT04816448|OTHER|Sub-occipital myofascial release|"For the application of the technique , the patient position is supine lying with the head fully supported on therapist's hands and therapist places 3 middle fingers just inferior to the nuchal line, lifts the fingers tips towards the ceiling while resting the head on the table and then therapist will apply a gentle upward pull. This procedure done for 2 to 3 minutes and 5 to 7 repetitions, 3 sessions per week on alternate days were given for 6 weeks.~Evaluation was done before treatment, during treatment at 4th week and after treatment at 6th week. Outcomes will be measured by NDI, PNRS and Universal Goniometer."
58457609|NCT00115440|RADIATION|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
58457610|NCT03146611|DIAGNOSTIC_TEST|nCD64|neutrophil CD64
57765844|NCT00303563|DRUG|Placebo|po qd
57765845|NCT05172895|OTHER|Presence, prevalence, severity, and morphological characteristics of anemia|Evaluation of the presence, prevalence, severity, and morphological characteristics of anemia, trying to define, when possible, the underlying pathogenetic mechanisms, paying particular attention to the characteristics of menstrual cycles, the iron, folate and vitamin B12 metabolism, any chronic inflammatory state, and thyroid hormones.
57765846|NCT05172895|OTHER|Effect of gluten-free diet on anemia|Evaluation of the therapeutic responses (i.e., improvement/regression) of anemia after at least one year of GFD.
57765847|NCT04789902|OTHER|SurgeCon|The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
57765848|NCT02766816|BIOLOGICAL|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
57765849|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
57765850|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
57765851|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
57765852|NCT02766816|BIOLOGICAL|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
57765853|NCT02766816|BIOLOGICAL|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
58129273|NCT03958825|PROCEDURE|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
58129274|NCT00854321|DRUG|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
57765854|NCT00694382|DRUG|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
57765855|NCT00694382|DRUG|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
57765856|NCT06505694|DIETARY_SUPPLEMENT|Alcohol Alternative Herbal Tincture (Test Product)|The test product contains organic vegetable glycerin, distilled water, organic elderberries, organic bilberries, organic beetroot juice powder, organic California poppy (whole plant), organic tart cherry, organic hawthorn berries, organic blue vervain (aerial parts), organic ceylon cinnamon bark, organic black pepper fruit, and L-theanine.
57765857|NCT06505694|DIETARY_SUPPLEMENT|Placebo|The placebo is designed to match the test product in appearance and taste but does not contain the active herbal ingredients. Participants will take 2 ml of the placebo directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks. The placebo contains organic vegetable glycerin, distilled water, organic beet juice powder, organic tart cherries, organic ceylon cinnamon chips, and natural green food coloring (derived from spirulina and turmeric).
57765858|NCT03810222|OTHER|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
57765859|NCT01809041|DRUG|Sevoflurane|
57765860|NCT01809041|DRUG|propofol|
57765861|NCT01809041|DRUG|remifentanil|
57765862|NCT01610154|DRUG|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
57765863|NCT03522077|DEVICE|RadAR EasyCLik plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
57765864|NCT03522077|DEVICE|TR BAND® Compression device plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
57765865|NCT03522077|DEVICE|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
57765866|NCT03522077|DEVICE|VascBand™ Hemostat|The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
57765867|NCT02500914|DRUG|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
57765868|NCT05988970|OTHER|Blood samples will be collected at two times before the treatment initiation:|"* at 4:00 a.m.~* at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
57765869|NCT04395183|DRUG|5-Hydroxytryptophan 100 MG|5-HTP 100mg PO BID
57765870|NCT04395183|DRUG|Creatine monohydrate|Creatine monohydrate 5g PO qday
57765871|NCT04395183|DRUG|placebo matched to 5-HTP|placebo matched to 5-HTP
57765872|NCT04395183|DRUG|Placebo|Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
57765873|NCT02232841|DEVICE|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
57765874|NCT02232841|DEVICE|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
58457611|NCT03146611|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
58457612|NCT03091725|PROCEDURE|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
58457613|NCT03091725|BEHAVIORAL|Very low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
57765875|NCT04125524|DIAGNOSTIC_TEST|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
57765876|NCT05030259|PROCEDURE|fasciotomy|To perform fasciotomy
57765877|NCT03733743|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
57765878|NCT04836117|OTHER|SomaSignal Test Results|SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
57765879|NCT01134601|PROCEDURE|Radiation Therapy|
57765880|NCT01134601|DRUG|Capecitabine|
57765881|NCT01134601|DRUG|AZD6244|
57765882|NCT05244148|DEVICE|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
57765883|NCT05244148|DEVICE|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
57765884|NCT05244148|BEHAVIORAL|Standard of Care|hydration + rest at home + if needed paracetamol
58129275|NCT00854321|DRUG|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
58129276|NCT04440254|DIAGNOSTIC_TEST|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
58457614|NCT04673214|DRUG|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
58457615|NCT04673214|DRUG|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
57765885|NCT05891626|BEHAVIORAL|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~1. missed opportunities and doubts/hesitancy about immunization as a whole;~2. specific questions with regard to specific vaccines;~3. health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~4. challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
57765886|NCT05822921|BEHAVIORAL|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
57765887|NCT05822921|BEHAVIORAL|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
57765888|NCT05822921|BEHAVIORAL|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
57765889|NCT02384525|PROCEDURE|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
57765890|NCT02384525|PROCEDURE|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
57765891|NCT02991443|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
57765892|NCT05559853|DIAGNOSTIC_TEST|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
57765893|NCT03716674|DEVICE|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
57765894|NCT05341102|DRUG|LY3556050|Administered orally.
58129277|NCT02705053|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
58457616|NCT05305352|OTHER|Very low carbohydrate dietary intervention|The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
58457617|NCT05653414|OTHER|short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife|4 consultations with a psychologist over 2 months maximum
58457618|NCT05653414|OTHER|encouragement of early support consultation with generalist practitioner or midwife|encouragement of early support consultation with generalist practitioner or midwife
58457619|NCT02230735|DRUG|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
58457620|NCT02230735|DRUG|Normal Saline|(placebo for bupivacaine)
58457621|NCT00961311|PROCEDURE|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
58457622|NCT00961311|DEVICE|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
57765895|NCT05341102|DRUG|Placebo|Administered orally.
57765896|NCT00133939|PROCEDURE|Mechanical ventilation|
57765897|NCT00826163|DRUG|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
57765898|NCT05561777|OTHER|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
58457623|NCT03597815|DRUG|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
57765899|NCT00347581|PROCEDURE|Base-in prism glasses for reading|
57765900|NCT00347581|PROCEDURE|Placebo reading glasses|
57765901|NCT01800695|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
57765902|NCT01800695|DRUG|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
57765903|NCT01800695|RADIATION|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
57765904|NCT00011830|DRUG|G-CSF|
57765905|NCT00011830|PROCEDURE|Apheresis|
57765906|NCT00001565|DRUG|phenylbutyrate|
57765907|NCT03108495|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
57961242|NCT02991092|PROCEDURE|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
57961243|NCT01197287|DRUG|QAK423A|
57961244|NCT01197287|DRUG|QAK423A|
57961245|NCT01197287|DRUG|QAK423A|
58457624|NCT03597815|DIAGNOSTIC_TEST|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
58457625|NCT03597815|DEVICE|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
58457626|NCT02050061|OTHER|compression stocking|study the impact of compression stocking
58457627|NCT03398304|OTHER|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
57765908|NCT03108495|BIOLOGICAL|LN-145 + pembrolizumab|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
57765909|NCT02986061|DEVICE|Urinary catheter|
57765910|NCT00675155|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
57765911|NCT06326710|BEHAVIORAL|mHealth|"Participants receive 4 sessions of face-to-face or online delivered workshop on how to use the mobile app Outdoor Rehab-Fit to support their daily PA level. In addition to the workshop, participants have to go to public parks to practice what they have learnt from the mobile app."
57765912|NCT06326710|BEHAVIORAL|Health Talk|Participants receive 4 sessions of face-to-face or online delivered health talks on the benefits different types of modified exercises for frail older adults (chair yoga, seated eight-section brocades, Otago and seated multi-component exercise). Each talk has an experiential session.
57765913|NCT02378532|DRUG|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
57765914|NCT02378532|RADIATION|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
57765915|NCT02378532|DRUG|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
57765916|NCT00248196|DEVICE|Reprieve Endovascular Temperature Therapy System|
57765917|NCT01402596|DRUG|Midazolam|0,4 mg per kg - intranasal midazolam - once
57765918|NCT01402596|DRUG|Chloral Hydrate|50 mg per kg, rectal
57765919|NCT00515437|BIOLOGICAL|Botulinum Toxin Type B (Myobloc)|
57765920|NCT00515437|BIOLOGICAL|Matched placebo to Myobloc|
57765921|NCT00181038|DEVICE|Peri-Neuronal Catheter|
57765922|NCT03158389|DRUG|APG101|weekly i.v.
57765923|NCT03158389|DRUG|Alectinib|twice daily (oral)
57765924|NCT03158389|DRUG|Idasanutlin|orally on 5 days of a 28 days cycle
57765925|NCT03158389|DRUG|Atezolizumab|i.v. every 3 weeks
57765926|NCT03158389|DRUG|Vismodegib|daily orally
57765927|NCT03158389|DRUG|Temsirolimus|weekly i.v.
57765928|NCT03158389|DRUG|Palbociclib|orally on 21 days of a 28 days cycle
57765929|NCT01121484|DRUG|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
57765930|NCT01121484|DRUG|placebo|Placebo tablets taken orally once daily.
57765931|NCT02048748|DEVICE|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
57765932|NCT02048748|DEVICE|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
57765933|NCT02086552|OTHER|Laboratory Biomarker Analysis|Correlative studies
57765934|NCT02086552|DRUG|Lenalidomide|Given PO
58457628|NCT03398304|OTHER|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
58457629|NCT05089006|PROCEDURE|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
57765935|NCT02086552|DRUG|Sonidegib|Given PO
57765936|NCT05905497|DRUG|Bemnifosbuvir (BEM)|BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
57765937|NCT05583214|DRUG|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
57765938|NCT05583214|DRUG|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
57765939|NCT05583214|DRUG|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
57765940|NCT05971823|OTHER|Tobacco product administration and assessment|Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
57765941|NCT05974995|PROCEDURE|Robot-assisted surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
57765942|NCT05974995|PROCEDURE|Laparoscopic surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
57765943|NCT05020262|OTHER|CT Image reconstruction|Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
57765944|NCT01338922|DEVICE|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
57765945|NCT01338922|DEVICE|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
57765946|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
57765947|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
57765948|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
57765949|NCT02328703|OTHER|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
57765950|NCT03908073|DEVICE|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
57765951|NCT06053554|PROCEDURE|Phakoemulsification|Femtolaser is used to perform a standard 5.0mm CCC centred on the pupil or limbus and to fragment the lens nucleus toguarantee reproducible results in every eye.After the CCC and nucleus fragmentation the anterior segment is filled with viscoelastics, the rhexis lenticule is removed and hydrodisection of the nucleus is performed. Subsequently phacoemulsification for nucleus and irrigation/aspiration of the lens cortex is performed. The capsular bag and AC is then filled with a cohesive viscoelastic and the IOL is implanted with the haptics in the back or with the haptics in the sulcus. At the end of surgery, the viscoelastic is removed using the irrigation aspiration probe, intracameral antibiotic is instilled, the CCI and paracenteses are hydrated and sealed.
57765952|NCT06053554|DEVICE|Ziemer Z8 Femtolaser|The femto second laser used for certain steps (capsulorhexis, nucleus fragmentation) of the cataract surgery.
57765953|NCT06053554|DEVICE|Kowa Avansee Preset|The used 3 piece intra ocular lens
58457630|NCT00000214|DRUG|Buprenorphine|
57765954|NCT05680961|DEVICE|Monitoring Device|Monitoring Device
57765955|NCT02885493|BEHAVIORAL|tests|
57765956|NCT04723043|DEVICE|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
57765957|NCT02715817|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
57961246|NCT00942474|DEVICE|Facilitate nerve stimulation lead placement with the nerve access tool|
58457631|NCT01074775|BIOLOGICAL|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
58457632|NCT05805423|PROCEDURE|bilateral superficial cervical plexus blocks and local wound infiltration|10mL bupivacaine at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
58457633|NCT05805423|PROCEDURE|placebo injection and local wound infiltration|10mL normal saline at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
58457634|NCT00105911|BEHAVIORAL|Cognitive Behavioral Therapy|
57765958|NCT02715817|OTHER|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
57765959|NCT02715817|OTHER|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
57765960|NCT05733975|OTHER|Decision Making Guide|The tool will be used by parent(s) to help guide them in discussion with their infant's clinicians.
57765961|NCT04866004|BEHAVIORAL|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
57765962|NCT06625502|BEHAVIORAL|Culturally-Affirming Racial Equity Framework|The CARE framework is a process-focused, protocol- based, and modular approach to culturally-affirming mental health care for racial and ethnic minority populations to promote racial equity. It focuses on cultivating the cross-racial/cross-cultural therapeutic alliance in the first 3-4 treatment sessions, the critical window for engaging patients in care. Target processes include transparent communication, client-centeredness, client activation, and a culturally-affirming and anti-oppressive approach to assessment and treatment planning. Case conceptualization and treatment planning is collaborative, and guided by the individual clinician based on evidence-based treatments. The therapist receives ongoing biweekly supervision in Alliance-Focused Training and cultural consultation sessions with a cultural expert.
57765963|NCT05291221|DRUG|intratracheal saline|At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
57765964|NCT05291221|DRUG|intratracheal Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
57765965|NCT05291221|DRUG|intratracheal Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
57765966|NCT03028402|PROCEDURE|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
57765967|NCT02294188|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
57765968|NCT02294188|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
57765969|NCT02294188|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
57765970|NCT02693301|OTHER|Exercise program|
57765971|NCT03169634|PROCEDURE|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
57765972|NCT03169634|PROCEDURE|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
57765973|NCT03169634|PROCEDURE|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
57765974|NCT05508906|DRUG|OP-1250|OP-1250 is a small molecule and a CERAN being developed for the treatment of patients with advanced or metastatic ER+ and HER2- breast cancer.
57765975|NCT05508906|DRUG|Ribociclib|All subjects in Treatment Group 1 will receive OP-1250 in combination with ribociclib.
57765976|NCT05508906|DRUG|Alpelisib|All subjects in Treatment Group 2 will receive OP-1250 in combination with alpelisib.
57765977|NCT05508906|DRUG|Everolimus|All subjects in Treatment Group 3 will receive OP-1250 in combination with everolimus.
57765978|NCT02626858|DEVICE|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
57765979|NCT03606122|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
57765980|NCT06233643|DRUG|Phloroglucinol|The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
57765981|NCT06233643|COMBINATION_PRODUCT|Acupuncture Combined Intradermal Sterile Water|Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
57765982|NCT02566798|DRUG|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
57765983|NCT02566798|DRUG|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
57765984|NCT03779139|PROCEDURE|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
57765985|NCT03779139|PROCEDURE|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
57765986|NCT03779139|OTHER|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
57765987|NCT02821624|DRUG|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
57765988|NCT02821624|DRUG|Placebo|Placebo
57765989|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
58457635|NCT02167308|DEVICE|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
58457636|NCT00002643|BIOLOGICAL|filgrastim|
58457637|NCT00002643|DRUG|amifostine trihydrate|
58457638|NCT00002643|DRUG|cyclophosphamide|
58457639|NCT00002643|DRUG|doxorubicin hydrochloride|
58457640|NCT00002643|DRUG|etoposide|
57765990|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
57765991|NCT01492491|DEVICE|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
57765992|NCT02040558|DRUG|MNK-010|
58457641|NCT00002643|DRUG|ifosfamide|
58457642|NCT00002643|DRUG|topotecan hydrochloride|
58457643|NCT00002643|DRUG|vincristine sulfate|
58457644|NCT00002643|PROCEDURE|conventional surgery|
58457645|NCT00002643|RADIATION|low-LET cobalt-60 gamma ray therapy|
58457646|NCT00002643|RADIATION|low-LET electron therapy|
58457647|NCT00002643|RADIATION|low-LET photon therapy|
58457648|NCT04261686|DEVICE|Covera Vascular Covered Stent|This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
58457649|NCT05866666|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
58457650|NCT00103168|DRUG|imatinib mesylate|400 mg/day for 2 years
58457651|NCT01602224|DRUG|Placebo|Administered IV
58457652|NCT01602224|DRUG|Dexamethasone|Administered orally
57765993|NCT03729102|BIOLOGICAL|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
57765994|NCT00499850|DRUG|ZD6474 (vandetanib)|once daily oral dose
57765995|NCT00499850|DRUG|5-Fluorouracil|intravenous infusion
58457653|NCT01602224|DRUG|Bortezomib|Administered SQ
58457654|NCT01602224|BIOLOGICAL|Tabalumab|Administered IV
58457655|NCT06215534|DIETARY_SUPPLEMENT|first reference product series 1|dextrose (containing 25 grams of carbohydrates)
58457656|NCT06215534|DIETARY_SUPPLEMENT|second reference product seies 1|dextrose (containing 25 grams of carbohydrates)
58457657|NCT06215534|DIETARY_SUPPLEMENT|third reference product series 1|dextrose (containing 25 grams of carbohydrates)
58457658|NCT06215534|DIETARY_SUPPLEMENT|first concept product series 1|Standard tube feed (containing 25 grams of carbohydrates)
58457659|NCT06215534|DIETARY_SUPPLEMENT|second concept product series 1|Tube feed with added fibers (containing 25 grams of carbohydrates)
58457660|NCT06215534|DIETARY_SUPPLEMENT|third concept product series 1|Tube feed with extra energy (containing 25 grams of carbohydrates)
58457661|NCT06215534|DIETARY_SUPPLEMENT|4th concept product seris 1|Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)
57765996|NCT00499850|DRUG|Leucovorin|intravenous infusion
58457662|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 1|Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates
58457663|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 1|Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates
58457664|NCT06215534|DIETARY_SUPPLEMENT|1st reference product series 2|dextrose (containing 25 grams of carbohydrates)
58457665|NCT06215534|DIETARY_SUPPLEMENT|2nd reference product series 2|dextrose (containing 25 grams of carbohydrates)
58457666|NCT06215534|DIETARY_SUPPLEMENT|3rd reference product series 2|dextrose (containing 25 grams of carbohydrates)
58457667|NCT06215534|DIETARY_SUPPLEMENT|1st concept product series 2|High energy plant based tube feed (containing 25 grams of carbohydrates)
58457668|NCT06215534|DIETARY_SUPPLEMENT|2nd concept product series 2|High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)
58457669|NCT06215534|DIETARY_SUPPLEMENT|3rd concept product series 2|High protein tube feed (containing 25 grams of carbohydrates)
58457670|NCT06215534|DIETARY_SUPPLEMENT|4th concept product series 2|High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)
58457671|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 2|Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)
58457672|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 2|Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)
58457673|NCT02511379|OTHER|Propylene Glycol 0.6% eye drops|
58457674|NCT06296017|OTHER|Experimental: Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
58457675|NCT06296017|OTHER|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
58457676|NCT06296017|OTHER|Extracorporeal Shock Wave Therapy+ Trigger Finger Splint|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
58457677|NCT02422706|DRUG|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
58457678|NCT02422706|DRUG|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
58457679|NCT02422706|DRUG|Omeprazole|Omeprazole 20 twice daily
58457680|NCT02422706|DRUG|Clarithromycin|KLacid twice daily
58457681|NCT02422706|DRUG|Levofloxacin|Tavanic. Tavacin
58457682|NCT02422706|DRUG|Doxicycline|Vibramycin 100 mg twice daily
57765997|NCT00499850|DRUG|Oxaliplatin|intravenous infusion
57765998|NCT03260127|BEHAVIORAL|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
57765999|NCT03260127|BEHAVIORAL|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
57766000|NCT04409548|OTHER|All of the spatial and Temporal Gait parameters|
57766001|NCT01341977|DEVICE|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
57766002|NCT01341977|DEVICE|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
57766003|NCT05053243|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
57766004|NCT05635292|BEHAVIORAL|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
57766005|NCT04402164|DEVICE|Herbst appliance|telescopic appliance for mandibular advancement
57766006|NCT02698683|OTHER|lymphocyte count|lymphocyte count
57766007|NCT05712746|DRUG|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
57766008|NCT03780127|DRUG|Fenfluramine Hydrochloride|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
57766009|NCT06023901|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
57766010|NCT03497507|DEVICE|Sham bracelet|Patients will wear bracelets on both hands
57766011|NCT03497507|DEVICE|Acupressure bracelet|Patients will wear bracelets on both hands.
57766012|NCT04061720|BEHAVIORAL|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
57766013|NCT04061720|BEHAVIORAL|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
58457683|NCT00596414|PROCEDURE|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
57766014|NCT00755014|OTHER|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
57766015|NCT03517618|DRUG|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
57766016|NCT00669903|DRUG|AZD0328|
57766017|NCT00669903|DRUG|Placebo|
57766018|NCT04570774|PROCEDURE|Repetitive transcranial magnetic stimulation|rTMS over cerebral motor cortex and cerebellar hemisphere
57766019|NCT04662463|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
57766020|NCT04662463|BEHAVIORAL|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
58457684|NCT00596414|DRUG|placebo|
58457685|NCT00596414|DRUG|midazolam|
58457686|NCT00596414|DRUG|midazolam + pethidine|
58457687|NCT06474624|OTHER|Cardio Rehabilitation program|A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.
57766021|NCT00494533|DRUG|Remodulin (treprostinil sodium)|
57766022|NCT01257659|PROCEDURE|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
57766023|NCT01257659|PROCEDURE|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
57766024|NCT02354963|PROCEDURE|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
57766025|NCT00831363|PROCEDURE|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
57766026|NCT00831363|PROCEDURE|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
57766027|NCT03511417|DEVICE|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
57766028|NCT02698449|PROCEDURE|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
57766029|NCT02698449|PROCEDURE|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
57766030|NCT02698449|PROCEDURE|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
58457688|NCT06474624|OTHER|Cycling for 20-30 minutes|Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.
57766031|NCT02698449|PROCEDURE|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
57766032|NCT02698449|RADIATION|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
57766033|NCT02611050|BEHAVIORAL|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
57766034|NCT02611050|BEHAVIORAL|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
58457689|NCT06474624|OTHER|Cycling a total of 4 cycles|Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
58457690|NCT01329978|DRUG|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
57766035|NCT01057030|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
57766036|NCT01057030|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
57766037|NCT00004935|DRUG|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
57766038|NCT00004935|DRUG|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
57766039|NCT03129529|DEVICE|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
57766040|NCT03129529|DEVICE|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
57766041|NCT04999371|BEHAVIORAL|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
57766042|NCT04999371|BEHAVIORAL|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
57766043|NCT02773680|DEVICE|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
57766044|NCT02055937|PROCEDURE|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
57766045|NCT02266602|RADIATION|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
57766046|NCT01187329|OTHER|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is \<110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose \> 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
57766047|NCT01187329|OTHER|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose \>150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose \< 180 mg/dL.
57766048|NCT06626178|DIAGNOSTIC_TEST|Computed tomography (CT) scan low dose|The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.
57766049|NCT06626178|PROCEDURE|Blood sampling|Peripheral venous blood sampling (20 ml)
57766050|NCT06626178|PROCEDURE|Tissue sampling (lung)|sampling of tumor and healthy tissue during surgery
57961247|NCT04693000|DRUG|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
57961248|NCT01375764|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
57961249|NCT01375764|DRUG|Ezetimibe|Administered orally once a day
58457691|NCT01329978|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
58457692|NCT01329978|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
57766051|NCT06626178|OTHER|Spirometry|Spirometry measurement using spirometer
57766052|NCT06626178|OTHER|Questionnaires|Compilation of epidemiological questionnaire, quality of life questionnaires
57766053|NCT06626178|OTHER|Smoking cessation program|Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases
58457693|NCT00539981|BIOLOGICAL|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
57766054|NCT06626178|OTHER|Carbon monoxide measurment|Measurment of Carbon monoxide (CO)
57766055|NCT06626178|OTHER|Cardiovascular primary prevention|Intervention done in order to find the presence of coronary calcifications
57766056|NCT06321978|DEVICE|Mepilex Border Flex|Usage of Mepilex Border Flex according to intended use and standard of care.
57766057|NCT04315025|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
57766058|NCT04315025|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
57766059|NCT01810627|RADIATION|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
57766060|NCT01138930|DRUG|Berberine|1.5g daily for 3 month
57766061|NCT01138930|DRUG|Placebo|placebo daily
57766062|NCT00802555|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
57766063|NCT04315532|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
57766064|NCT04315532|OTHER|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
57766065|NCT04315532|OTHER|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
57766066|NCT06075563|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant
57766067|NCT06613126|BEHAVIORAL|Symptom Management APP group|Based on symptom management theory and the relevant literature, the researcher designed a symptom management APP. The APP includes a symptom recording system, symptom management skills, and Tourette Syndrome knowledge information to facilitate parents' and children's joint learning.
57766068|NCT06613126|OTHER|health education instructions group|To receive outpatient verbal and paper health education guidance from healthcare providers.
58457694|NCT00539981|BIOLOGICAL|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
57766069|NCT06423053|BEHAVIORAL|Biology Course with Integrated Mindfulness|This intervention is a college biology course with embedded mindfulness practice. There are 17 class sessions, each 1 hr and 50 min. long, over 9.5 weeks. Students will be taught human physiology through didactic lectures, laboratory activities, and written tests typical for a college course. Each class meeting will have \~20 min. of mindfulness practice in Thich Nhat Hanh's Plum Village tradition. Students are recommended to practice mindfulness for 15 minutes daily. Students are assigned a daily log of their mindfulness practice, and they are given full credit for each log completion regardless of the minutes of mindfulness practices. Students are assigned a weekly written reflection to reflect on the physiology course content and/or their mindfulness practice. All students in the class are required to attend a 4-hr mindfulness retreat Students in the intervention arm will also receive university wellness resources as usual as described for the control arm below.
57766070|NCT05936632|OTHER|Discrete Choice Experiment (DCE)|DCE survey experiment
57766071|NCT05826015|DRUG|Paclitaxel|IV over 3 hours
57766072|NCT05826015|DRUG|Batiraxcept|IV over 60 minutes
57766073|NCT03427190|OTHER|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
57766074|NCT05201911|DRUG|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
57766075|NCT00616564|DRUG|GM-CSF|Concomitant Priming with GM-CSF
57766076|NCT05341323|DRUG|Ketamine.|Peritonsillar infiltration of ketamine
57766077|NCT05341323|DRUG|Bupivacaine|peritonsillar infiltration of Bupivacaine
57766078|NCT02916797|OTHER|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
57766079|NCT04713787|DRUG|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
57766080|NCT04713787|DRUG|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
57766081|NCT05024422|DRUG|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
57766082|NCT05024422|DRUG|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
58457695|NCT05235126|DEVICE|Decoria intense|All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
58457696|NCT00069446|DRUG|rhuMAb VEGF (telbermin)|
57766083|NCT03815084|DRUG|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
57766084|NCT03357367|DEVICE|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
57766085|NCT04644640|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
57766086|NCT04644640|OTHER|In-person Rehabilitation Therapy|Range of motion exercises for the knee, proprioception and balance training
57766087|NCT03373864|PROCEDURE|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
57766088|NCT03373864|PROCEDURE|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
57766089|NCT01400230|PROCEDURE|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
57766090|NCT03644069|BIOLOGICAL|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
57766091|NCT03644069|BIOLOGICAL|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
57766092|NCT01676948|DRUG|ACZ885|
57766093|NCT01676948|DRUG|Canakinumab|
57766094|NCT01676948|DRUG|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
57766095|NCT01676948|DRUG|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
57766096|NCT00002159|DRUG|Itraconazole|
57766097|NCT00002159|DRUG|Amphotericin B|
57766098|NCT01461330|OTHER|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
57766099|NCT01461330|OTHER|ADA diet|Adoption of ADA diet.
57961250|NCT01375764|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
57961251|NCT04750538|DEVICE|BreEStim 120|120 BreEStim stimuli will applied for about 10 minutes.
58457697|NCT00792844|DIETARY_SUPPLEMENT|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
58457698|NCT00792844|DIETARY_SUPPLEMENT|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
58457699|NCT04752163|DRUG|DS-1594b|Given DS-1594b PO
58457700|NCT04752163|DRUG|Azacitidine|Given IV or SC
57766100|NCT04404478|BEHAVIORAL|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
57766101|NCT04404478|BEHAVIORAL|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
57766102|NCT04394845|DIAGNOSTIC_TEST|[18F]GTP1|\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
57766103|NCT01971190|DRUG|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
57766104|NCT01971190|DRUG|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
57961252|NCT04750538|DEVICE|BreEStim 240|240 BreEStim stimuli will applied for about 20 minutes.
57961253|NCT04926974|BEHAVIORAL|Low Vision Rehabilitation|Smart phone App
57961254|NCT03213873|BEHAVIORAL|HiBalance|Intervention of highly challenging balance training for 10 weeks.
57961255|NCT03213873|BEHAVIORAL|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
57961256|NCT03405623|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
57961257|NCT03405623|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
57766105|NCT01971190|PROCEDURE|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
57766106|NCT04632732|DIAGNOSTIC_TEST|COVID-19 test|Nasal pharyngeal swab
57766107|NCT04632732|DIAGNOSTIC_TEST|Blood sampling|20cc of blood will be collected each 7 days during 28 days.
57766108|NCT04511416|DRUG|Metformin XR, 500-2000mg nocte|Metformin XR, 500-2000mg nocte
57766109|NCT03317028|DRUG|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
57766110|NCT02803060|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
57766111|NCT00462722|DRUG|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
57766112|NCT00462722|DRUG|Placebo|with each exercise session (up to 5 days per week) for 9 months
57766113|NCT00462722|BEHAVIORAL|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
57766114|NCT02231229|OTHER|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
57766115|NCT02231229|DRUG|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
57766116|NCT05250713|DEVICE|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
57766117|NCT04505436|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
57766118|NCT04505436|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
57766119|NCT05918562|DIETARY_SUPPLEMENT|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
57766120|NCT05918562|DIETARY_SUPPLEMENT|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
57766121|NCT03417921|DRUG|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
57766122|NCT03417921|DRUG|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
57766123|NCT01686165|DRUG|belinostat|Given IV
57766124|NCT01686165|BIOLOGICAL|rituximab|Given IV
57766125|NCT01686165|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
57766126|NCT01928680|DRUG|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
57766127|NCT03675451|DRUG|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
57766128|NCT03675451|DRUG|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
57766129|NCT00610064|RADIATION|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
57766130|NCT00610064|RADIATION|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
58457701|NCT04752163|DRUG|Cyclophosphamide|Given IV
57766131|NCT00803101|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
57766132|NCT00803101|BIOLOGICAL|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
57766133|NCT00744328|DRUG|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
57766134|NCT00744328|DRUG|Sertraline|Sertraline dose will range from 50 - 200 mg/day
57766135|NCT00744328|OTHER|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
57766136|NCT01347385|PROCEDURE|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
57766137|NCT01347385|PROCEDURE|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
57766138|NCT01012570|DRUG|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
57766139|NCT00940238|DRUG|Citalopram Hydrobromide|
57766140|NCT00810758|DRUG|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
57766141|NCT00810758|DRUG|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
57766142|NCT00810758|DRUG|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
57766143|NCT01025622|BIOLOGICAL|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
57961258|NCT03678805|PROCEDURE|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
58457702|NCT04752163|DRUG|Cytarabine|Given IT
57766144|NCT00280826|DRUG|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
57766145|NCT03383003|DRUG|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
57766146|NCT03383003|DRUG|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
57766147|NCT03383003|DRUG|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
57766148|NCT03383003|DRUG|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
57766149|NCT02392611|DRUG|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
57766150|NCT02392611|DRUG|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
57766151|NCT02392611|DRUG|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
57766152|NCT02542839|DEVICE|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
57766153|NCT02542839|DEVICE|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
57766154|NCT02542839|OTHER|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
57766155|NCT02542839|OTHER|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
57766156|NCT02542839|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
57766157|NCT02542839|PROCEDURE|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
57766158|NCT03554993|DRUG|CC-99677|CC-99677
57766159|NCT03554993|OTHER|Placebo|Placebo
57766160|NCT04240990|OTHER|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~* TB contact history~* Suggestive TB symptoms in the previous 4 weeks~* Physical examination~* Clinical, anthropometric and biochemical assessment of malnutrition~* Clinical assessment for other non-dietary causes of malnutrition~* Digitalized CXR~* Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~* Mycobacterial culture performed on two GAs~* Abdominal ultrasonography~* QuantiFERON®-TB Gold IGRA~* Monocyte-to-Lymphocyte Ratio (MLR)~* C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
57766161|NCT05637411|OTHER|Predictive model|We will define and validate predictive models of risk of exacerbations in asthmatic patients
57766162|NCT02734108|DEVICE|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
57766163|NCT00001444|DRUG|7-hydroxystaurosporine (UCN-01)|
58129278|NCT02705053|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
57766164|NCT02166957|PROCEDURE|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
57766165|NCT01279733|GENETIC|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
57766166|NCT04031521|DIAGNOSTIC_TEST|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
58129279|NCT04705142|DRUG|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
58129280|NCT04955262|BIOLOGICAL|Bempegaldesleukin (NKTR-214)|Specified dose on specified days
57766167|NCT04712201|PROCEDURE|En bloc transurethral resection of bladder tumor (TURBT)|En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
57766168|NCT04712201|PROCEDURE|Conventional TURBT|Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
58129281|NCT04955262|BIOLOGICAL|Nivolumab|Specified dose on specified days
57766169|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 10 or 20 mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
57766170|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|"For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
57766171|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 5 or 10mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
58457703|NCT04752163|DRUG|Dexamethasone|Given PO or IV
58457704|NCT04752163|BIOLOGICAL|Filgrastim|Given SC
57766172|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
57766173|NCT00988221|DRUG|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
57766174|NCT00988221|DRUG|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
57766175|NCT01038258|PROCEDURE|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
57766176|NCT06559943|OTHER|Traditional Physiotherapy + Placebo Kinesio Tape|"Following a total of 15 sessions of electrophysical agent and exercise training, 5 days a week, for 3 weeks, each session lasting 45 minutes, followed by traditional physiotherapy, 2 days a week, for 3 weeks, a total of 6 times, with 0% tension applied to the trapezius muscle in the neck region (I). Kinesiotape will be applied.~The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application."
57766177|NCT06559943|OTHER|Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method|In addition to a total of 15 sessions of electrophysical agents and exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, kinesio tape will be applied 6 times in total, 2 days a week. Kinesiotape will be cut into an (I) shape (15 cm) with 50% tension and adhered laterally to the C7 joint. In acute cases such as overuse and muscle spasm, it is recommended to apply an inhibition technique that will inhibit the muscle. In the inhibition technique, the direction of the tape should be from the entry point of the muscle to the starting point and the application should be done with very light or light (15 - 25%) tension. In chronic cases, a facilitation technique should be applied to stimulate the weak muscle. The direction of the tape should be from the starting point of the muscle to the attachment point and the application should be done with light or moderate tension (25 - 50%).
57766178|NCT04859439|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
57766179|NCT01639105|PROCEDURE|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
57766180|NCT00345163|DRUG|bevacizumab|Intravenous repeating dose
57766181|NCT00345163|DRUG|irinotecan|Intravenous repeating dose
58129282|NCT04955262|DRUG|⁸⁹Zr-Df-IAB22M2C|Specified dose on specified days
58129283|NCT02822248|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-64-R84-070)
58457705|NCT04752163|DRUG|Leucovorin|Given IV or PO
58457706|NCT04752163|DRUG|Mesna|Given IV
58457707|NCT04752163|DRUG|Methotrexate|Given IT
58457708|NCT04752163|DRUG|Posaconazole|Given PO
58457709|NCT04752163|DRUG|Prednisone|Given PO
58457710|NCT04752163|BIOLOGICAL|Rituximab|Given IV
58457711|NCT04752163|DRUG|Venetoclax|Given PO
58457712|NCT04752163|DRUG|Vincristine|Given IV
58457713|NCT04752163|DRUG|Voriconazole|Given PO
58457714|NCT01054105|DRUG|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
58457715|NCT06412510|OTHER|Prehabilitation|"Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy"
57766182|NCT04011332|OTHER|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
57766183|NCT01047644|OTHER|Reduced port-flush schedule|3-month port-flushing
57961259|NCT03678805|PROCEDURE|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
57961260|NCT00448188|PROCEDURE|central venous catheter application|
57961261|NCT02474329|OTHER|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.
57961262|NCT02474329|DEVICE|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
58457716|NCT02978417|DRUG|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
58129284|NCT00534703|GENETIC|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
58457717|NCT02978417|DRUG|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
58457718|NCT05084040|OTHER|90 days interval between catheter maintenance|Length of time between catheter maintenances extended from 60 days to 90 days
58457719|NCT03838185|DRUG|J147|Single oral dose of J147
58457720|NCT03838185|DRUG|Placebo|Single oral dose of corn oil
58457721|NCT02926872|OTHER|There is no intervention in the study|
58457722|NCT06430996|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
58457723|NCT01255423|DRUG|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
58457724|NCT01255423|DRUG|Placebo|Placebo, 4 times daily
58457725|NCT03549221|DRUG|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
57766184|NCT03349268|DEVICE|Pulsed xenon ultraviolet (PX-UV) Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
57766185|NCT03349268|DEVICE|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
57766186|NCT01462162|DRUG|Tocilizumab|
57766187|NCT06000982|DRUG|PTCY|PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
57766188|NCT02205801|PROCEDURE|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
57766189|NCT02205801|PROCEDURE|Local Wound Infiltration|0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
57766190|NCT02205801|DRUG|0.9% saline|
58457726|NCT00841334|BEHAVIORAL|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
57766191|NCT02205801|DRUG|Marcaine|
57766192|NCT04247399|OTHER|Simulation-based learning|Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
57766193|NCT00105586|DRUG|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
57766194|NCT05134662|DRUG|ALT-801|Injected subcutaneously (SC)
57766195|NCT05134662|OTHER|Placebo|Injected subcutaneously (SC)
57766196|NCT04966780|PROCEDURE|acute abdominal surgery|Acute surgery for acute abdominal disease
57766197|NCT06624943|DRUG|biosimilar insulin glargine|Once daily injection of biosimilar insulin glargine via reusable pen
57766198|NCT06283797|DEVICE|OmniPod 5|Participants will be trained to use OmniPod 5 to treat type 1 diabetes for 1 year
57766199|NCT06283797|DEVICE|Dexcom G6|Participants will use Dexcom G6 for continuous glucose monitoring
58129285|NCT00534703|DRUG|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
58129286|NCT01056796|DEVICE|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
58129287|NCT02524223|OTHER|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
58457727|NCT00841334|BEHAVIORAL|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
58457728|NCT02309944|PROCEDURE|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.
58457729|NCT02309944|DEVICE|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
58457730|NCT02461667|DRUG|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
58457731|NCT02461667|DRUG|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
57766200|NCT06283797|OTHER|PAID questionnaires|At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
57766201|NCT05025501|BEHAVIORAL|Family based Executive Function Training|Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
57766202|NCT00518934|OTHER|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
57766203|NCT00930943|DRUG|Oxymorphone ER|40 mg qd twice
57766204|NCT05829291|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|"Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device."
57766205|NCT05741905|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
57766206|NCT05741905|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
57766207|NCT04989985|DRUG|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
57766208|NCT04989985|DRUG|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
57766209|NCT03899961|DRUG|Oxytocin|Oxytocin 2.5 U i.v.
57766210|NCT03899961|DRUG|Carbetocin|Carbetocin 100 µg i.v.
57766211|NCT01472562|DRUG|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
57766212|NCT01472562|BIOLOGICAL|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
57766213|NCT01391325|DRUG|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
57766214|NCT02088203|DIETARY_SUPPLEMENT|Dose 1|Russian Tarragon Nutrasorb 0.3 g
57766215|NCT02088203|DIETARY_SUPPLEMENT|Dose 2|Russian Tarragon Nutrasorb 1 g
57766216|NCT02088203|DIETARY_SUPPLEMENT|Dose 0|Placebo
57766217|NCT02088203|DIETARY_SUPPLEMENT|Dose 3|Russian Tarragon Nutrasorb 3 g
57766218|NCT02088203|DIETARY_SUPPLEMENT|Dose 4|Russian Tarragon Nutrasorb 10 g
57766219|NCT02088203|DIETARY_SUPPLEMENT|Dose 5|Russian Tarragon Nutrasorb 20 g
57766220|NCT02088203|DIETARY_SUPPLEMENT|Dose 6|Russian Tarragon Nutrasorb 30 g
57766221|NCT03372837|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
57766222|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
57766223|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
57766224|NCT01247714|DIETARY_SUPPLEMENT|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
57766225|NCT01247714|DIETARY_SUPPLEMENT|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
57766226|NCT01789996|PROCEDURE|alternative six minute walk test|"Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
57766227|NCT01789996|PROCEDURE|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
57766228|NCT02861144|OTHER|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
57766229|NCT02861144|OTHER|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
57766230|NCT04596826|DRUG|Dronabinol 5 MG|oral administration
57766231|NCT04596826|DRUG|Dronabinol 10 MG|oral administration
57766232|NCT04596826|DRUG|Placebo|oral administration
57766233|NCT06054971|OTHER|Remote Administration of NSAA|Remote Administration of NSAA
57766234|NCT05508386|OTHER|MATLAB-based interface, showing 50 EEG traces, classification of the EEG-pattern as Burst Suppression possible, yes, no.|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
57766235|NCT05072184|PROCEDURE|ESP block|ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
57766236|NCT04476420|DIETARY_SUPPLEMENT|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
57766237|NCT04476420|DRUG|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
57766238|NCT05228002|OTHER|sFlt-1/PlGF ratio - Active Comparator: Standard|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation"
57766239|NCT05228002|OTHER|sFlt-1/PlGF ratio - Experimental: Biomarkers|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation."
57766240|NCT04318028|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7 Tesla MRI
57766241|NCT02520648|OTHER|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
57766242|NCT02520648|OTHER|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
57766243|NCT02520648|OTHER|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
57766244|NCT01334944|DRUG|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
57766245|NCT01380886|OTHER|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
57766246|NCT01380886|OTHER|Infant formula powder|powdered infant formula to be fed ad libitum
57766247|NCT03019003|DRUG|Oral Decitabine|Hypomethylating agent
57766248|NCT03019003|DRUG|Durvalumab|anti-PD-L1
57766249|NCT01115985|DRUG|ASP1585|oral
57766250|NCT01115985|DRUG|atorvastatin|oral
57766251|NCT05580159|BIOLOGICAL|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
57766252|NCT05580159|BIOLOGICAL|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
57766253|NCT02350920|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
57766254|NCT02269761|DEVICE|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
57766255|NCT06303544|BEHAVIORAL|Wedge 1|Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
57766256|NCT03653832|DRUG|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
57766257|NCT03653832|DRUG|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
58457732|NCT02461667|DRUG|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
58457733|NCT03636555|DRUG|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
57766258|NCT03653832|DRUG|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
57766259|NCT02820584|BIOLOGICAL|GSC-loaded autologous dendritic cells|
57766260|NCT01719601|DRUG|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
57766261|NCT02471859|DRUG|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
57766262|NCT02471859|DRUG|Placebo|Placebo at various doses, depending on the cohort and treatment period
58457734|NCT03636555|DRUG|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
58457735|NCT06514872|OTHER|prevalance and determinants of home accidents|home accidents among Turkish older
58129288|NCT02524223|OTHER|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
58129289|NCT02524223|OTHER|systematic HPV Status in newborns in case of pregnancy|
58457736|NCT01889823|OTHER|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
58457737|NCT01889823|OTHER|Hyperoxia|Subjects will be breathing 100% oxygen
58457738|NCT02246049|BIOLOGICAL|Bevacizumab|Given IV
58457739|NCT02246049|DRUG|5-fluorouracil|Given IV
58457740|NCT02246049|DRUG|Irinotecan hydrochloride|Given IV
58457741|NCT02246049|DRUG|Leucovorin calcium|Given IV
58457742|NCT02246049|DRUG|Oxaliplatin|Given IV
58457743|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
57766263|NCT03484338|BEHAVIORAL|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
57766264|NCT05011825|BEHAVIORAL|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
57766265|NCT05624866|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
57766266|NCT05624866|DRUG|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
57766267|NCT00582530|OTHER|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
57766268|NCT01705808|DRUG|Protein C concentrate|
57766269|NCT06315803|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
57766270|NCT03617159|DEVICE|Magnetic Resonance Imaging|Diagnostic Modality
57766271|NCT02329301|DRUG|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
57766272|NCT02329301|DRUG|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
57766273|NCT01139190|DRUG|PL3100|Oral administration
57766274|NCT01139190|DRUG|Naproxen|Oral administration
57766275|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
57766276|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
57766277|NCT01557621|BEHAVIORAL|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
57766278|NCT04530539|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C, at bedtime
57766279|NCT04530539|DIETARY_SUPPLEMENT|melatonin|10mg melatonin, at bedtime
57766280|NCT04530539|DIETARY_SUPPLEMENT|Placebo|Placebo at bedtime
57766281|NCT04530539|OTHER|Symptom Survey|Daily symptom survey to be completed by patient electronically
57766282|NCT03097861|DRUG|Lubiprostone|24 mcg administered orally BID
57766283|NCT03097861|DRUG|Placebo|24 mcg administered orally BID
57766284|NCT01860586|DRUG|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
57766285|NCT03748602|PROCEDURE|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
57766286|NCT06339554|DRUG|Alectinib 150 MG [Alecensa]|First line treatment for cohorts A and B
58129290|NCT02524990|BEHAVIORAL|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
57766287|NCT01835600|OTHER|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
57766288|NCT03381222|DIAGNOSTIC_TEST|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
57766289|NCT03716544|DEVICE|Amplification with hearing aid|Use of hearing aids
57766290|NCT03716544|DEVICE|Customized music|Customized music delivered via an iPod
57766291|NCT02088632|BIOLOGICAL|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
57766292|NCT02088632|OTHER|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
58129291|NCT05387902|DEVICE|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
58129292|NCT03577964|DIAGNOSTIC_TEST|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
58457744|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
57766293|NCT06160752|DRUG|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
57766294|NCT06160752|DRUG|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
57766295|NCT06625853|OTHER|Mtwo R files with Xp-Endo finisher file|"XP-endo Finisher file will be inserted without rotation into the root canals filled with 2.5% NaOCl and will be activated (800 rpm; torque of 1 N.cm) for~1 min in each canal using slow and gentle 7-8 mm lengthwise movements."
57766296|NCT06625853|OTHER|Mtwo R files|obturation material will be removed using Mtwo R (VDW, Munich, Germany)files attached to an endodontic motor (Ecube, seachin, Korea) with a constant speed of 280 rpm, as suggested by the manufacturer. Mtwo R 25/0.05 will be used to empty the coronal and middle thirds of the root. Mtwo R 15/0.05 will be used to reach the working length.
57766297|NCT02641457|DRUG|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
57766298|NCT02641457|DRUG|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
57766299|NCT06009640|DEVICE|Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine|Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.
57766300|NCT06006923|DRUG|Regorafenib|A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also have immunomodulatory affect in the tumor microenvironment.
57766301|NCT06006923|DRUG|Pembrolizumab|An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.
57766302|NCT06196125|OTHER|Four body positions|Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
57766303|NCT02970513|OTHER|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
57766304|NCT05396092|BEHAVIORAL|Integrated mindfulness-based Tai Chi Chuan|MBTCC will integrate components from both the MBI and TCC groups. The entire intervention consists of eight weekly sessions of two-and-a-half to three hours each.
57766305|NCT05396092|BEHAVIORAL|Mindfulness-based intervention|The MBI group is mainly based on the basic theory and research of the foundational mindfulness-based stress reduction program. The intervention consists of eight weekly sessions of two to two-and-a-half hours each.
57766306|NCT05396092|BEHAVIORAL|Tai Chi Chuan|TCC is mainly based on a nine-form Yang-style form of TCC, which is a brief and modified version of 64-form Yang-style TCC. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
57766307|NCT05396092|BEHAVIORAL|Sleep Hygiene Education|SHE is based on principles used in stimulus control and sleep hygiene education, which has previously been used as the control group in sleep-related research. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
57766308|NCT03055611|DRUG|ELOCTA|Extended half-life factor VIII product
57766309|NCT03055611|DRUG|ALPROLIX|Extended half-life factor IX product
57766310|NCT04093921|BEHAVIORAL|MET-based therapy|see previous
57766311|NCT04093921|BEHAVIORAL|Standard Care|To include all recommended outpatient treatments
57766312|NCT05120648|BEHAVIORAL|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
57766313|NCT02579356|DRUG|Telmisartan|
58457745|NCT06293521|PROCEDURE|Pulpotomy|After the chamber is deroofed and coronal pulp is amputated using a round-end fissure bur in a high-speed handpiece with adequate water spray and light pressure until canal orifices were reached, The access cavity is flushed with sterile normal saline solution. Saline-wetted cotton pellets were placed for about 5 minutes over amputation sites applying moderate pressure to control pulpal hemorrhage. After discarding the pellets, blood oozing was present, MTA+ Cerkamed will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by application of glass ionomer cement.
57766314|NCT02579356|DRUG|Atorvastatin|
57766315|NCT06625281|PROCEDURE|Epleys Maneuver|"* The patient begins in an upright sitting posture, with the legs fully extended and the head rotated 45 degrees towards the affected side.~* The patient is then quickly and passively forced down backwards by the therapist performing the treatment into a supine position with the head held approximately in a 30-degree neck extension~* The therapist observes the patient's eyes for primary stage nystagmus. The patient remains in this position for 1-2 minutes.~* The patient's head is then turned 90 degrees to the opposite direction so that the unaffected ear faces the ground, for 1-2 minutes.~* Keeping the head and neck in a fixed position relative to the body, the individual rolls onto their shoulder, rotating the head another 90 degrees in the direction they are facing. The patient is now looking downwards at a 45-degree angle.~* The eyes should be immediately observed by the therapist for secondary stage nystagmus. The patient remains in this position for 1-2 minutes."
58129293|NCT02518581|PROCEDURE|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
58129294|NCT06396468|DRUG|sevoflurane|sevoflurane (1-1.2 MAC)
58129295|NCT06396468|DRUG|propofol|100-400 mcg/kg /min of propofol
57766316|NCT06625281|PROCEDURE|Semont-plus maneuver|"* The Semont-plus maneuver includes the upright position with turning of the head by 45° toward the non-affected side.~* Then movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move and since the clot is beyond the vertex, the movement of body by 240° moves the clot into the direction of the vestibulum."
57766317|NCT06625281|PROCEDURE|Brandt-Daroff exercises|"* Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes."
57766318|NCT02122341|DEVICE|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
57766319|NCT06400966|OTHER|Training method|Jigsaw Technique
57766320|NCT02176421|DEVICE|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
57766321|NCT00896428|DRUG|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
57766322|NCT00896428|DRUG|Placebo.|1 tablet morning and evening for 12 months
57766323|NCT00633932|DRUG|Esomeprazole|20mg once daily
57766324|NCT00633932|DRUG|Esomeprazole|40 mg once daily
57766325|NCT00633932|DRUG|Omeprazole|20mg once daily
57766326|NCT03501043|DRUG|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
57766327|NCT02358798|OTHER|3 years-assessment of respiratory function|
57766328|NCT01052402|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
57766329|NCT06275425|DRUG|Total intravenous anesthesia with Byfavo|General anesthesia is maintained with intravenous continuous administration of Byfavo.
57766330|NCT06275425|DRUG|Inhalation anesthesia with Sevoflurane|General anesthesia is maintained with Sevoflurane.
57766331|NCT03417037|DRUG|BMS-986205|Administered orally daily, 100 mg
57766332|NCT03417037|BIOLOGICAL|Nivolumab|Specified dose on specified days
57766333|NCT03417037|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
57766334|NCT01077479|DRUG|Metformin|Metformin 1500mg nocte for 6 months
57766335|NCT05401435|OTHER|Resting measurement of blood pressure and heart rate|Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
57766336|NCT01108458|DRUG|Pertuzumab|iv, 840 mg, 420 mg
57766337|NCT01108458|DRUG|Erlotinib|PO, 150 mg
57766338|NCT02810067|PROCEDURE|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
57766339|NCT02810067|PROCEDURE|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
57766340|NCT01110083|DRUG|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
57766341|NCT00345384|DRUG|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
57766342|NCT00345384|OTHER|Placebo (Normal Saline)|
58129296|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
58129297|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
57766343|NCT04398615|DEVICE|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
58129298|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
58129299|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
57766344|NCT06081335|DEVICE|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
57766345|NCT06081335|DEVICE|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
57766346|NCT03207646|OTHER|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
57766347|NCT04779905|DIAGNOSTIC_TEST|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
58129300|NCT00004099|DRUG|cisplatin|
58129301|NCT00004099|DRUG|fluorouracil|
58129302|NCT00004099|DRUG|leucovorin calcium|
57766348|NCT03607201|OTHER|No intervention|Routine care
57766349|NCT05344963|DRUG|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
57766350|NCT05915728|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
57766351|NCT05915728|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
57766352|NCT05915728|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
57766353|NCT05915728|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
57766354|NCT01349894|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
57766355|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
58129303|NCT00004099|PROCEDURE|neoadjuvant therapy|
57766356|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
57766357|NCT01913158|DRUG|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
57766358|NCT01913158|DRUG|Placebo suppository|Hydrogenated palm kernel oil suppositories
57766359|NCT06266663|OTHER|Survey|A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.
57766360|NCT03148977|PROCEDURE|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
57766361|NCT06624904|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg), encapsulated identically to placebo.
57766362|NCT06624904|OTHER|Placebo|Single tablet encapsulated identically to placebo.
57766363|NCT04426344|DEVICE|ensoETM device|Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\[41\] If patient temperature increases above this range and reaches 39.8°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).
57766364|NCT00668499|DRUG|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
57766365|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted
57766366|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted.
57766367|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
57766368|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
57766369|NCT06311656|DRUG|Placebo|Administered orally.
57766370|NCT02539836|DIETARY_SUPPLEMENT|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
57766371|NCT02539836|DIAGNOSTIC_TEST|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
58129304|NCT03372538|PROCEDURE|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
58129305|NCT01811043|BEHAVIORAL|Guided Meditation|
57766372|NCT06493136|DRUG|lidocaine gel|questionnaire
57766373|NCT04596033|BIOLOGICAL|GEN-011|Personalized neoantigen adoptive cell therapy (ACT)
57766374|NCT04596033|DRUG|IL-2|Cytokine
57766375|NCT04596033|DRUG|Fludarabine|Lymphodepletion drug
57766376|NCT04596033|DRUG|Cyclophosphamide|Lymphodepletion drug
57766377|NCT03282279|PROCEDURE|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
57766378|NCT02287350|DRUG|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
57766379|NCT02359643|DRUG|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
57766380|NCT02998021|DEVICE|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
57766381|NCT02998021|DEVICE|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
57766382|NCT02784223|DEVICE|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
57766383|NCT06358911|OTHER|Poly amido amine dendrimer (PAMAM)|"Desensitizing agents was applied once after the bleaching procedure,as follows:~1-Bleaching/PAMAM group, patients received bleaching followed by the application of PAMAM for 30 minutes according to previous studies."
57766384|NCT06358911|OTHER|Manufacturer's desensitizing agent, Ultra EZ|"Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes."
58129306|NCT01811043|BEHAVIORAL|Music|
58129307|NCT01811043|BEHAVIORAL|Supportive Dialogue|
58129308|NCT05886426|DIAGNOSTIC_TEST|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
57766385|NCT06358911|OTHER|MI paste plus, desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes."
57766386|NCT06358911|OTHER|Hydroxyapatite and F (ReminPro), desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes"
57766387|NCT00687336|OTHER|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
57766388|NCT00687336|OTHER|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
57766389|NCT03847038|PROCEDURE|Preventive strategies advice and dementia risk estimate disclosure|The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
57766390|NCT01396577|DRUG|perampanel|3 x 2 mg perampanel once per day
57766391|NCT01396577|DRUG|perampanel|6 mg perampanel once per day
57766392|NCT02724722|BEHAVIORAL|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
57766393|NCT02724722|BEHAVIORAL|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
57766394|NCT03254953|BEHAVIORAL|self-monitoring of body weight|- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
57766395|NCT03254953|BEHAVIORAL|self-monitoring of diet|"* track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm"
57766396|NCT03254953|BEHAVIORAL|weekly personalized feedback + lessons + action plans|- these are additional evidence-based intervention components
57766397|NCT04396080|PROCEDURE|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
57766398|NCT01294501|OTHER|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
57766399|NCT01586312|OTHER|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
57766400|NCT01586312|DRUG|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
57766401|NCT00002757|BIOLOGICAL|filgrastim|
57766402|NCT00002757|DRUG|cyclophosphamide|
57766403|NCT00002757|DRUG|cytarabine|
57766404|NCT00002757|DRUG|doxorubicin hydrochloride|
57766405|NCT00002757|DRUG|etoposide|
58129309|NCT01151748|PROCEDURE|Intra-arterial infusion of chemotherapy|
57766406|NCT00002757|DRUG|methotrexate|
58129310|NCT01433666|DRUG|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
58129311|NCT01433666|DRUG|Placebo|Acute intervention: single administration, capsulated form.
58129312|NCT01433666|DRUG|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
57766407|NCT00002757|DRUG|prednisolone|
57766408|NCT00002757|DRUG|prednisone|
57766409|NCT00002757|DRUG|therapeutic hydrocortisone|
57766410|NCT00002757|DRUG|vincristine sulfate|
57766411|NCT00114634|DIETARY_SUPPLEMENT|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
57766412|NCT00114634|DIETARY_SUPPLEMENT|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
57766413|NCT03265990|PROCEDURE|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
57766414|NCT03265990|PROCEDURE|Conventional haemorrhoidectomy|"According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
57766415|NCT02038686|DEVICE|PFN-A|
57766416|NCT01759069|PROCEDURE|Surgical treatment with microscope|
57766417|NCT00792558|DRUG|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
57766418|NCT02493049|DRUG|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
58129313|NCT06545201|BIOLOGICAL|RE001 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
58129314|NCT01447563|DRUG|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
58129315|NCT01447563|DRUG|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
57766419|NCT06018909|BEHAVIORAL|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
57766420|NCT01456234|DRUG|Oseltamivir|Oseltamivir 75 mg BID
57766421|NCT01042743|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
57766422|NCT01042743|PROCEDURE|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
57766423|NCT03453827|OTHER|no intervention|no intervention
57766424|NCT02152501|OTHER|Exercise Energy Expenditure 300 kcal/day|
57766425|NCT02152501|OTHER|Exercise Energy Expenditure 600 kcal/day|
57766426|NCT04535336|OTHER|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
57766427|NCT04535336|OTHER|Control|Participants maintained their daily activities.
57766428|NCT03794258|DRUG|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
57766429|NCT03794258|DRUG|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
57766430|NCT05108207|OTHER|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
57766431|NCT05108207|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
57766432|NCT05108207|OTHER|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
57766433|NCT04688593|DEVICE|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
57766434|NCT00101660|DRUG|Dasatinib|Tablets; oral; 70 mg BID, depending on response
57766435|NCT01374802|DRUG|Darunavir|400 mg tablet for oral administration
57766436|NCT01374802|DRUG|Ritonavir|tablet for oral administration
57766437|NCT01374802|DRUG|BI 201335|
57766438|NCT04844918|DRUG|Tirzepatide|Administered SC
57766439|NCT04844918|OTHER|Placebo|Administered SC
57766440|NCT01097252|RADIATION|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
57766441|NCT01097252|DRUG|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
57766442|NCT01097252|DRUG|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
57766443|NCT02254083|DRUG|BIBT 986 BS - low|
57766444|NCT02254083|DRUG|BIBT 986 BS - high|
57766445|NCT02254083|DRUG|Placebo|
57766446|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
57766447|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
57766448|NCT04200313|OTHER|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
57766449|NCT04200313|OTHER|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
57766450|NCT00650390|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
57766451|NCT04488003|DRUG|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
57766452|NCT04488003|DRUG|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
57766453|NCT02853266|OTHER|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
57766454|NCT02914184|BIOLOGICAL|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
57766455|NCT02914184|BIOLOGICAL|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
57766456|NCT06010290|DRUG|18F-SMBT-1|Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
57766457|NCT03002038|DRUG|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
57766458|NCT03002038|DRUG|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
57766459|NCT03941613|PROCEDURE|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
58129316|NCT05150964|DEVICE|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
57766460|NCT03941613|PROCEDURE|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
57766461|NCT05157516|PROCEDURE|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
57766462|NCT05157516|PROCEDURE|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
57766463|NCT03101241|DRUG|CX-8998|T-type calcium channel blocker
57766464|NCT03101241|DRUG|Placebo|Placebo comparator
57766465|NCT05514574|OTHER|Music|"hussoni duseni  music"
57766466|NCT05514574|OTHER|Stress ball|Stress ball squeeze
57766467|NCT04822480|BEHAVIORAL|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
57766468|NCT01090310|DRUG|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
57766469|NCT01090310|DRUG|Placebo|Matching placebo to AIN457
57766470|NCT00238381|PROCEDURE|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
57766471|NCT00238381|PROCEDURE|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
57766472|NCT00238381|PROCEDURE|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
57766473|NCT04885114|GENETIC|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
57766474|NCT06336980|BEHAVIORAL|Increasing Inclusionary Practices in Faith Communities|Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
57766475|NCT01380301|DRUG|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
57766476|NCT01380301|DRUG|Miltefosine alone|short course (half)
58457746|NCT06293521|PROCEDURE|Partial Pulpectomy|"Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of Zinc oxide and eugenol.~The tooth with then be restored with stainless steel crown"
57766477|NCT05079815|DIAGNOSTIC_TEST|CBC and serum ferritin|take blood sample for CBC and serum ferritin
57766478|NCT03491345|DRUG|Avelumab|avelumab 10mg/kg, IV, q 2 weeks
57766479|NCT01072123|OTHER|Quest for the Code|interactive asthma-based computer program
57766480|NCT02477891|DRUG|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
57766481|NCT04922996|DRUG|Calcium Dobesilate|Dosage of calcium dobesilate in different tissues
57766482|NCT02965755|OTHER|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
57766483|NCT04094337|BEHAVIORAL|Internet-assisted treatment|Internet-assisted treatment
57766484|NCT00602680|DRUG|SSR180711C|duration of treatment: 4 weeks
57766485|NCT00602680|DRUG|donepezil|duration of treatment: 4 weeks
57766486|NCT00602680|DRUG|placebo|duration of treatment: 4 weeks
57766487|NCT01305746|DRUG|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
57766488|NCT01305746|DRUG|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
57766489|NCT01305746|DRUG|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
57766490|NCT02435472|BEHAVIORAL|Exercise|This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
57766491|NCT02435472|OTHER|Cardiopulmonary Exercise Test (CPET)|Exercise capacity test to assess peak oxygen consumption (VO2peak)
58457747|NCT02697266|OTHER|No intervention|This is an observational study.
58457748|NCT04687657|DRUG|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
58457749|NCT00000235|DRUG|Buprenorphine|
57766492|NCT05903716|DIAGNOSTIC_TEST|Hormone|At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients
57766493|NCT05903716|DRUG|Isotretinoin|İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
57766494|NCT06037174|PROCEDURE|minimally invasive procedure|different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)
57766495|NCT06037174|PROCEDURE|Conventional Open Surgery|Conventional Open Surgery
57766496|NCT02310451|BIOLOGICAL|blood test|blood test to J0-M3-M6-M12
57766497|NCT02354716|DEVICE|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
57766498|NCT01458184|BEHAVIORAL|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
57766499|NCT05486442|BEHAVIORAL|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
57766500|NCT05479604|DEVICE|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
57766501|NCT05479604|DEVICE|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
58457750|NCT03084796|DRUG|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
58457751|NCT03084796|DRUG|Placebo|Placebo Control
57766502|NCT01534884|BIOLOGICAL|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
57766503|NCT04483934|BIOLOGICAL|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
57766504|NCT04483934|DEVICE|LED phototherapy|LED phototherapy
57766505|NCT01356992|DRUG|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
57766506|NCT00310323|DRUG|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
57766507|NCT00310323|DRUG|Caffeine|Administered as 4 ounces of Coca-Cola
57766508|NCT02714868|BEHAVIORAL|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
57766509|NCT02714868|BEHAVIORAL|Matched Comparison|Participants set goal to try a new activity in the community
58457752|NCT03084796|DRUG|Tiotropium Bromide 18 µg Inhalation Capsule|Active Control
58457753|NCT01916135|RADIATION|[18F]-SKI-249380|
58457754|NCT01916135|PROCEDURE|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
58457755|NCT01916135|OTHER|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic \& metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
58457756|NCT00964496|DRUG|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
58457757|NCT00964496|DRUG|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
58457758|NCT06059365|BEHAVIORAL|Hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward
57766510|NCT01735396|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
57766511|NCT02803567|BEHAVIORAL|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
57766512|NCT01422369|DRUG|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
57766513|NCT01422369|DRUG|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
57766514|NCT04106843|DRUG|Lutetium Lu 177 Dotatate|Given IV
57766515|NCT00737425|DEVICE|PainShield|
57766516|NCT00737425|DEVICE|Sham PainShield|
57766517|NCT05872529|BEHAVIORAL|Education|The education which consists processed EEG monitoring and SBI approach
57766518|NCT04463121|DEVICE|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
57766519|NCT04463121|DEVICE|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
57766520|NCT05064111|DIAGNOSTIC_TEST|TRUS biopsy|The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
57766521|NCT05516017|DEVICE|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
57766522|NCT05516017|DEVICE|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
57766523|NCT06035614|DEVICE|exciplex|exciplex, excimer lamp 308nm produced by clarteis
57766524|NCT06035614|DRUG|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
57766525|NCT04340908|DRUG|Dapagliflozin 10 MG|10 mg tablet, oral, once daily, 1-year treatment, postoperation
57766526|NCT04340908|DRUG|Placebos|matching placebo tablet, oral, once daily, 1-year treatment, postoperation
57766527|NCT03122730|COMBINATION_PRODUCT|VentaProst|Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
57766528|NCT02557490|DRUG|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
57766529|NCT04672096|DEVICE|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
57766530|NCT03963661|BEHAVIORAL|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
57766531|NCT00402337|DRUG|linaclotide acetate|oral, once daily.
57766532|NCT00402337|DRUG|Matching placebo|oral, once daily
57766533|NCT04105530|DEVICE|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
58457759|NCT06059365|BEHAVIORAL|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
57766534|NCT04105530|DEVICE|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
57766535|NCT04105530|DEVICE|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
57766536|NCT04105530|OTHER|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
57766537|NCT04105530|OTHER|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
57766538|NCT04105530|OTHER|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
57766539|NCT04105530|OTHER|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
57766540|NCT04940013|DRUG|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
57766541|NCT01283321|DRUG|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
57766542|NCT01283321|OTHER|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
57766543|NCT02664701|OTHER|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
57766544|NCT02664701|OTHER|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
57766545|NCT02664701|OTHER|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
57766546|NCT02664701|OTHER|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
57766547|NCT03486925|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
57766548|NCT03486925|DRUG|placebo treatment|intranasal administration of placebo
57766549|NCT00426322|DEVICE|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
57766550|NCT04875364|DRUG|Eszopiclone|2mg of Eszopiclone just before going to sleep.
57766551|NCT04875364|OTHER|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
57766552|NCT04875364|DEVICE|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
57766553|NCT00429689|PROCEDURE|Saliva sample|
57766554|NCT00957164|BEHAVIORAL|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
57766555|NCT00957164|BEHAVIORAL|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
57766556|NCT00957164|BEHAVIORAL|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
57766557|NCT01659398|DEVICE|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
58457760|NCT00659061|DIETARY_SUPPLEMENT|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
57766558|NCT00230139|DEVICE|SPECT/CT|
57766559|NCT05168917|DIAGNOSTIC_TEST|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
57766560|NCT02204137|OTHER|Falls Risk Questionnaire|
57766561|NCT02204137|OTHER|Cancer and Aging Research Group Geriatric Assessment|
57766562|NCT02204137|OTHER|Falls Efficacy Scale-International (FES-1)|
58129317|NCT01241968|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
58457761|NCT00659061|BEHAVIORAL|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
58457762|NCT01120366|DRUG|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
57766563|NCT02204137|OTHER|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
57766564|NCT00032045|BIOLOGICAL|gp100 antigen|
57766565|NCT00032045|BIOLOGICAL|incomplete Freund's adjuvant|
57766566|NCT00032045|BIOLOGICAL|ipilimumab|
57766567|NCT02815787|DRUG|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
57766568|NCT02815787|DRUG|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
57766569|NCT05164432|DIAGNOSTIC_TEST|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
57766570|NCT04731233|BIOLOGICAL|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
57766571|NCT04731233|DRUG|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
57766572|NCT03505450|OTHER|Population Sample|full sample of recruited participants
57766573|NCT03505450|OTHER|Purposive sample|purposive sample of recruited participants
57961263|NCT06221163|OTHER|collection of biographical and sociological data|collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
57961264|NCT06538701|PROCEDURE|Anterolateral advancement pharyngoplasty|Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
57961265|NCT01698528|DEVICE|Tablet Computer|
57961266|NCT05168358|PROCEDURE|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
58457763|NCT01120366|DRUG|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
57766574|NCT01250964|PROCEDURE|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
57766575|NCT02973555|OTHER|PRP injection|autologous intrauterine infusion of PRP
57766576|NCT00640796|PROCEDURE|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
57766577|NCT00640796|DRUG|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
57766578|NCT00640796|DEVICE|CliniMACS|Cell selection system based on magnetic-activated cell sorting
57766579|NCT01805817|DRUG|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
57766580|NCT01805817|DEVICE|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
58129318|NCT01241968|DEVICE|Placebo|Placebo
57766581|NCT01805817|DEVICE|levonorgestrel-releasing system|intrauterine device
57766582|NCT05336201|BEHAVIORAL|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
57766583|NCT02876172|DRUG|MDMA|Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg MDMA (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
57766584|NCT02876172|BEHAVIORAL|CBCT|A three-phase, 15-session, manualized treatment from the CBCT manual
57766585|NCT02876172|BEHAVIORAL|Therapy|Non-directive therapy (from the Multidisciplinary Association for Psychedelic Studies MDMA-assisted therapy treatment manual)
57766586|NCT01496716|PROCEDURE|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
57766587|NCT04309929|DRUG|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
57766588|NCT04612855|OTHER|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
57766589|NCT00675194|DRUG|Cisplatin, Irinotecan, Capecitabine|
57766590|NCT00720902|PROCEDURE|Blood draws|Subjects will have serum cardiovascular markers assessed
58129319|NCT00788125|DRUG|carboplatin|
58457764|NCT06058975|OTHER|Observational|Review the management of duodenal trauma in France
58457765|NCT04265196|OTHER|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
58457766|NCT04265196|OTHER|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
57766591|NCT00720902|DRUG|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
57766592|NCT00720902|PROCEDURE|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
57766593|NCT00720902|PROCEDURE|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
57766594|NCT00720902|PROCEDURE|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
57766595|NCT02578511|DRUG|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
57766596|NCT03885011|DRUG|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
57766597|NCT03885011|DRUG|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
57766598|NCT03885011|DRUG|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
57766599|NCT06577766|DRUG|NNC0638-0355|NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
57766600|NCT06577766|DRUG|Placebo (NNC0638-0355)|Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
57766601|NCT01659658|DRUG|IXAZOMIB|IXAZOMIB capsules
57766602|NCT01659658|DRUG|Dexamethasone|Dexamethasone tablets
57766603|NCT01659658|DRUG|Melphalan|Melphalan tablets
57766604|NCT01659658|DRUG|Cyclophosphamide|Cyclophosphamide tablets
57766605|NCT01659658|DRUG|Thalidomide|Thalidomide capsules
57766606|NCT01659658|DRUG|Lenalidomide|Lenalidomide capsules
57766607|NCT04268901|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
57766608|NCT04268901|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
57766609|NCT04268901|DEVICE|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
57766610|NCT00458913|DRUG|bortezomib|
57766611|NCT00458913|DRUG|cisplatin|
57766612|NCT01567865|BIOLOGICAL|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
57766613|NCT01567865|BIOLOGICAL|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
57766614|NCT02337712|RADIATION|q.d. RT|65 Gy in 26 fractions
57766615|NCT02337712|RADIATION|b.i.d.RT|45 Gy in 30 fractions
57766616|NCT02337712|DRUG|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
57766617|NCT05762614|OTHER|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
57961267|NCT03269760|DRUG|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
58129320|NCT00788125|DRUG|dasatinib|
58129321|NCT00788125|DRUG|etoposide phosphate|
57766618|NCT03068806|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
57766619|NCT05266014|DRUG|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
57766620|NCT00960921|DRUG|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
57766621|NCT00960921|DRUG|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
57766622|NCT03127189|DRUG|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
57766623|NCT03127189|DRUG|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
57766624|NCT01152294|BEHAVIORAL|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
57766625|NCT00926003|BEHAVIORAL|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
57766626|NCT00926003|BEHAVIORAL|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
57766627|NCT00728117|OTHER|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
57766628|NCT00728117|OTHER|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
57766629|NCT04424875|DRUG|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
57766630|NCT04424875|DRUG|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
57766631|NCT00612222|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
57766632|NCT00612222|BIOLOGICAL|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
57766633|NCT00612222|BIOLOGICAL|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
57766634|NCT00612222|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
57766635|NCT00612222|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
57766636|NCT04732429|DRUG|HST5040|Liquid solution
57766637|NCT04732429|DRUG|Placebo|Liquid solution
57766638|NCT00494260|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
57766639|NCT00494260|BEHAVIORAL|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
57766640|NCT01422135|DRUG|AG200-15|A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
57766641|NCT06316219|DRUG|Nomegestrol Acetate/Estradiol 2.5mg/1.5mg|hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
57766642|NCT05739435|DRUG|ESK-001|Oral tablet
57766643|NCT00581633|OTHER|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
57766644|NCT03669653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
57766645|NCT03669653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
57766646|NCT02592200|DIETARY_SUPPLEMENT|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
57766647|NCT02592200|DIETARY_SUPPLEMENT|Placebo|Two doses per day for 28 days
57766648|NCT05763953|DRUG|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
57766649|NCT01860014|DRUG|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
57766650|NCT01860014|DRUG|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
57766651|NCT01413230|DRUG|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
57766652|NCT00319059|DRUG|systemic administration of 99mTc-HYNIC-Annexin A5|
57766653|NCT00319059|BEHAVIORAL|10 minutes of ischemic handgripping|
57766654|NCT04379037|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
57766655|NCT00642135|DRUG|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
57766656|NCT00642135|DRUG|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
57766657|NCT01982877|BEHAVIORAL|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
57766658|NCT01982877|BEHAVIORAL|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
57766659|NCT02760758|DRUG|CDI-31244|NNI
57766660|NCT02760758|DRUG|Placebo|no active ingredients
57766661|NCT06163053|DRUG|Immunotherapy|Immune checkpoint inhibitors in approved indications
57766662|NCT01988363|PROCEDURE|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
57766663|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
57766664|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
57766665|NCT00467064|BEHAVIORAL|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
57766666|NCT00467064|OTHER|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
57766667|NCT03380663|PROCEDURE|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
57766668|NCT00058227|DRUG|alvocidib|Given IV
57766669|NCT00058227|DRUG|fludarabine phosphate|Given IV
57766670|NCT00058227|BIOLOGICAL|rituximab|Given IV
57766671|NCT00058227|OTHER|pharmacological study|Correlative studies
57766672|NCT01282671|OTHER|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
57766673|NCT03912623|OTHER|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
57766674|NCT03912623|OTHER|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
57766675|NCT05844930|DRUG|Corticosteroid|Triamcinolone 20 mg (1cc)
57766676|NCT05844930|OTHER|ActiveMatrix|1cc ActiveMatrix (Skye Biologics, Inc.)
57766677|NCT05844930|DRUG|Lidocaine|Lidocaine 10 mg/mL (5cc)
57766678|NCT05038852|DEVICE|smartphone applications|app is designed to help you learn relaxation skills.
57766679|NCT05038852|DEVICE|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
58129322|NCT00788125|DRUG|ifosfamide|
57766680|NCT02825901|DIETARY_SUPPLEMENT|Placebo|Ingest placebo drink 100ml/day for 8 weeks
57766681|NCT02825901|DIETARY_SUPPLEMENT|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
57766682|NCT02825901|DIETARY_SUPPLEMENT|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
57766683|NCT04319601|DRUG|Rituximab|a new chemotherapy regimen
57766684|NCT05995431|PROCEDURE|scaling and root planing|All the participants will undergo scaling and root planing
57766685|NCT05995431|PROCEDURE|Subgingival instrumentation|All the participants will undergo subgingival instrumentation
57766686|NCT03065114|OTHER|PGS|chromosome abnormality test from PGS and relationship between embryo development
57766687|NCT04220814|RADIATION|MRI|MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done
57766688|NCT04220814|OTHER|Electrophysiology|Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
57766689|NCT04564950|OTHER|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
57766690|NCT03820323|DIAGNOSTIC_TEST|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL\>1000 copies/mL) is detected.
57766691|NCT03820323|DIAGNOSTIC_TEST|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
57766692|NCT01302561|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose twice daily for 24 weeks
57766693|NCT01302561|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
57766694|NCT02459093|DEVICE|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
57766695|NCT02459093|DEVICE|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
57766696|NCT05651360|DIAGNOSTIC_TEST|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
57766697|NCT04069260|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
57766698|NCT02044458|DEVICE|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
57766699|NCT05330416|DEVICE|Group Reference Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.
57766700|NCT05330416|OTHER|Group Test Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
57766701|NCT04995237|BEHAVIORAL|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
57766702|NCT01803295|DEVICE|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
57766703|NCT01803295|OTHER|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
57766704|NCT01803295|DEVICE|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
57766705|NCT04520555|DEVICE|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
57766706|NCT04520555|DEVICE|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
57766707|NCT00829686|DRUG|Septra|(800/125) PO BID X 7 days
57766708|NCT03983993|DRUG|Niraparib|Given PO
57766709|NCT03983993|BIOLOGICAL|Panitumumab|Given IV
57766710|NCT00172120|DRUG|ALX1-11|
57766711|NCT04277455|DEVICE|Laser ablation of benign thyroid nodule|Ablating symptomatic benign thyroid nodules using laser
57766712|NCT04133103|PROCEDURE|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
57766713|NCT02733705|OTHER|Control|normal saline IV
57766714|NCT02733705|DRUG|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
57766715|NCT02733705|DRUG|propofol|propofol infusion
57766716|NCT05469542|DEVICE|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
57766717|NCT05268575|OTHER|performing endoscopy|Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
57766718|NCT05439239|OTHER|Repeated sprint training|"Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7."
57766719|NCT05168605|OTHER|Home visit|Patients receiving home Visits
57766720|NCT06342427|DIAGNOSTIC_TEST|DESTINEX|A panel of microRNA, whose expression level is tested in serum samples.
57766721|NCT01031875|DRUG|pazopanib hydrochloride|
57766722|NCT01031875|RADIATION|fludeoxyglucose F 18|
57766723|NCT00860067|BIOLOGICAL|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
57766724|NCT00860067|BIOLOGICAL|FluMist/B/Yamagata|0.2 mL dose at Day 0
57766725|NCT00860067|BIOLOGICAL|FluMist/B/Victoria|0.2 mL dose at Day 0
57766726|NCT03842553|OTHER|No Intervention: anonymous online survey|
57766727|NCT02523521|BEHAVIORAL|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
57766728|NCT05835882|BIOLOGICAL|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~1. Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~2. Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~3. Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
57766729|NCT04289701|OTHER|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
57766730|NCT01589562|DRUG|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
57766731|NCT01589562|DRUG|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
57766732|NCT03066622|DRUG|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
57766733|NCT03066622|DRUG|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
57766734|NCT04738721|BEHAVIORAL|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
57766735|NCT05031676|OTHER|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
57766736|NCT01540565|OTHER|Laboratory Biomarker Analysis|Correlative studies
57766737|NCT01540565|DRUG|Veliparib|Given PO
57766738|NCT02783222|DRUG|Nab-paclitaxel|comparison of different dosages of drug
57766739|NCT06287684|DIAGNOSTIC_TEST|Blood transcriptomics and BAL protein profiling|Paxgene blood tubes will be used for RNA transcriptomics to classify patients as endotypes. BAL fluid will be used to measure protein levels by ELISA.
57766740|NCT00032344|PROCEDURE|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
57766741|NCT05263999|BIOLOGICAL|Itolizumab|Itolizumab \[Bmab600\]
57766742|NCT05263999|DRUG|EQ001 Placebo|EQ001 Placebo
57766743|NCT01788345|OTHER|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
57766744|NCT05068739|PROCEDURE|PA-EMR|Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
57766745|NCT05068739|PROCEDURE|NKF|The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
57766746|NCT04522180|DRUG|GHR-LRX|GHR-LRX was administered by SC injection.
57766747|NCT00977769|DRUG|carbetocin 100 µg|Hemodynamic effect of
57766748|NCT00977769|DRUG|oxytocin 5 u|Hemodynamic effect of
57766749|NCT00977769|DRUG|placebo (NaCl)|Hemodynamic effect of
57766750|NCT01566929|DIETARY_SUPPLEMENT|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
57766751|NCT06463821|OTHER|observational questionnaires|Patient data were collected from questionnaires.
57766752|NCT02768948|DRUG|telmisartan during 6 months|telmisartan during 6 months
57961268|NCT04992728|OTHER|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
58129323|NCT00788125|GENETIC|microarray analysis|
57766753|NCT02768948|DRUG|Losartan during 6 months|Losartan during 6 months
57766754|NCT02768948|PROCEDURE|blood sample|blood sample
57766755|NCT04695340|DIETARY_SUPPLEMENT|Psyllium|Psyllium is given to patients
57766756|NCT04501133|DEVICE|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
57766757|NCT04501133|DEVICE|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
57766758|NCT02826369|OTHER|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
57766759|NCT02748694|DRUG|TAK-041|TAK-041 tablets or oral suspension.
57766760|NCT02748694|DRUG|TAK-041 Placebo|TAK-041 placebo-matching suspension or tablet.
57766761|NCT00713674|OTHER|Theraworx|Theraworx swab intranasal BID for 5 days
57766762|NCT00713674|DRUG|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
57766763|NCT03996941|BEHAVIORAL|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
57766764|NCT03996941|OTHER|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
57766765|NCT04780698|DIAGNOSTIC_TEST|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
57766766|NCT03278301|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
57766767|NCT04988425|DRUG|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
57766768|NCT04988425|DRUG|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
57766769|NCT04988425|DRUG|Saline|Injection of the same volume of saline immediately after admission before surgery
57766770|NCT03070509|DRUG|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
57766771|NCT05799937|PROCEDURE|Non Surgical Root Canal Treatment|After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
57766772|NCT04770753|DRUG|Placebo Matching Mitapivat|Tablets
57766773|NCT04770753|DRUG|Mitapivat|Tablets
58129324|NCT00788125|GENETIC|western blotting|
57766774|NCT03739775|PROCEDURE|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
57766775|NCT03072225|DRUG|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
57766776|NCT03072225|DRUG|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
57766777|NCT02133482|DRUG|Placebo|placebo solution
57766778|NCT02133482|DRUG|BI 639667|oral solution BI 639667, single rising doses
57766779|NCT04306939|OTHER|venipuncture|Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
57766780|NCT04306939|BEHAVIORAL|Questionnaires|PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
57766781|NCT04306939|OTHER|Additional Sample Collections|We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
58129325|NCT00788125|OTHER|immunohistochemistry staining method|
57766782|NCT03241602|DRUG|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
57766783|NCT03241602|PROCEDURE|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
58129326|NCT00788125|OTHER|laboratory biomarker analysis|
58129327|NCT00788125|PROCEDURE|therapeutic conventional surgery|
58129328|NCT00788125|RADIATION|radiation therapy|
58129329|NCT03732170|DEVICE|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
58129330|NCT03732170|DEVICE|AH plus® sealer|The participant will be treated with AH plus® sealer.
58129331|NCT06195943|BEHAVIORAL|Exercise Intervention with use of El-Fit App|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
57766784|NCT03241602|COMBINATION_PRODUCT|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
57766785|NCT03798834|DRUG|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
57766786|NCT03798834|OTHER|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
57766787|NCT02172703|DEVICE|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
57766788|NCT02932969|DRUG|BMS-986231|
57766789|NCT02932969|DRUG|BMS-986231 Placebo|
57766790|NCT04022005|DRUG|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
57766791|NCT03533634|PROCEDURE|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
57766792|NCT03533634|PROCEDURE|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
57766793|NCT04154865|OTHER|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
57766794|NCT04154865|DEVICE|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
57766795|NCT04154865|DEVICE|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
57766796|NCT04154865|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
57766797|NCT04566588|PROCEDURE|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
57766798|NCT04566588|PROCEDURE|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
57766799|NCT00166686|DRUG|Clonidine|
57766800|NCT00316030|DRUG|Bexarotene|
57766801|NCT04235634|DRUG|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
57766802|NCT04535323|OTHER|Quality-of-Life Assessment|Ancillary studies
57766803|NCT04535323|OTHER|Questionnaire Administration|Ancillary studies
57766804|NCT04535323|BIOLOGICAL|Therapeutic Autologous Platelet-rich Plasma|Given via injection
57766805|NCT03592277|DRUG|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
57766806|NCT03592277|DRUG|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
57766807|NCT03018301|DRUG|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
57766808|NCT03018301|OTHER|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
57766809|NCT02917941|DRUG|Ixazomib|Ixazomib capsules
57766810|NCT02917941|DRUG|Lenalidomide|Lenalidomide capsules
57766811|NCT02917941|DRUG|Dexamethasone|Dexamethasone Tablets
57766812|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 100|
57766813|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 300|
57766814|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 1000|
57766815|NCT02712593|OTHER|Placebo|
57766816|NCT01351532|BEHAVIORAL|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
57766817|NCT01351532|BEHAVIORAL|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
57766818|NCT04723849|DIETARY_SUPPLEMENT|Auxilie® Immuplus, Envicon Medical, Verona, Italy|"Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT)."
57766819|NCT06626477|DEVICE|Intra nasal mechanical stimulation treatment (INMEST)|The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.
57766820|NCT06626477|DEVICE|Sham (No Treatment)|A modified Walther System not delivering active treatment manufactured by Abilion Medical Systems AB.
57766821|NCT06625580|PROCEDURE|transverse thoracic muscle plane and serratus anterior plane block|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with 0.25% bupivacaine
57766822|NCT06625580|PROCEDURE|erector spinae plane block|ultrasound guided erector spinae plane block will be performed with 0.25% bupivacaine
57766823|NCT01080651|DRUG|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
57766824|NCT02007408|DRUG|Paracervical block|
57766825|NCT02007408|DRUG|Lidocaine spray|
57766826|NCT02007408|DRUG|Paracervical block + lidocaine spray|
57766827|NCT01365533|DRUG|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
57766828|NCT01365533|DRUG|Placebo|Placebo, one tablet once daily, orally
57766829|NCT05474729|DRUG|minocycline|minocycline capsule 100mg per day orally
57766830|NCT01978080|DEVICE|Kinesia HomeView|
58129332|NCT05258864|BEHAVIORAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
57766831|NCT06304662|OTHER|Yoga intervention|Over 12 weeks, students will attend 50-minute yoga sessions twice a week. Sessions start with 10 minutes of mindful breathing and gentle warm-up movements, followed by 30 minutes of tailored yoga postures for relaxation and stretching. Students progress from basic to advanced postures, with adaptations for individual needs. Each session ends with a guided meditation for inner calm. A 10-minute cool-down encourages deep relaxation. Emphasis is on stress reduction, flexibility, and mindfulness, tailored to university life challenges. Continuous assessment ensures sessions meet students' evolving needs and optimize yoga's benefits in the university setting.
57766832|NCT00282724|DRUG|Liarozole|
57766833|NCT04513678|BEHAVIORAL|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
57766834|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
57766835|NCT02243774|BEHAVIORAL|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
57766836|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
57766837|NCT02243774|BEHAVIORAL|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
57766838|NCT05145842|PROCEDURE|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
57766839|NCT05145842|PROCEDURE|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
57766840|NCT04598893|BIOLOGICAL|Teplizumab|Received teplizumab in PROTECT Study
57766841|NCT04598893|OTHER|Placebo|Received placebo in PROTECT study
57766842|NCT02332018|RADIATION|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
57766843|NCT04989075|OTHER|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
57766844|NCT05667701|DRUG|Soy isoflavone|Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
57766845|NCT05667701|DRUG|matching placebo|A matching placebo also administered twice daily.
57766846|NCT02127619|DEVICE|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
57766847|NCT02306265|DEVICE|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
57766848|NCT02306265|DEVICE|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
57766849|NCT04527848|DRUG|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
58129333|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 1|TEST
58457767|NCT04731389|BEHAVIORAL|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
58129334|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 2|CONTROL
58129335|NCT00094302|DRUG|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
58129336|NCT00094302|DRUG|Placebo|Placebo of spironolactone
58129337|NCT03141203|DRUG|Romidepsin|10mg vial for Injection
57766850|NCT01756820|PROCEDURE|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
57766851|NCT01756820|PROCEDURE|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
57766852|NCT06624436|DRUG|Dexamethasone|Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
57766853|NCT06624436|DRUG|Tocilizumab|Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
57766854|NCT06624436|DRUG|Anakinra|Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
57766855|NCT06624436|DRUG|Placebo|Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
57766856|NCT06624436|BIOLOGICAL|LPS|This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.
57766857|NCT03107377|DRUG|EVO100|5 g dose applied up to 1 hour prior to coitus
57766858|NCT03107377|DRUG|Placebo|5 g dose applied up to 1 hour prior to coitus
57766859|NCT05710705|DEVICE|portable prototype of bioimpedance measurement|"The device will be installed during the patient's operation. It will be attached to the healthy skin of the flap (without wound or scar) by sterile glue. It will then be covered with a self-adhesive tegaderm type dressing. The wound will be isolated from the device with a hermetic silicone dressing of the Mepilex type, for example. There will therefore be no communication between the measuring device and the surgical wound."
57766860|NCT06178783|DRUG|Brensocatib|Brensocatib oral solutions will be expectorated following the tasting.
57766861|NCT06624956|DRUG|glucose, insulin, and potassium (GIK)|"GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV."
57766862|NCT06624956|DRUG|Crystalloid Infusion|placebo
57766863|NCT05942755|OTHER|Concurrent evaluation of blood and CSF ionograms to determine if there is a correlation between CSF change and the development of hyoponatremia between day 0 and day 14.|"Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral routine.~The ionic composition of CSF from patients with SAH will be compared with a control population of patients hospitalized with normal pressure hydrocephalus. A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine its ionic composition"
57766864|NCT00025584|DRUG|bortezomib|Given IV
57766865|NCT00025584|OTHER|laboratory biomarker analysis|Correlative studies
57766866|NCT03872388|DRUG|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
57766867|NCT03872388|DRUG|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
58129338|NCT03141203|DRUG|Carfilzomib|60mg vial for injection
57766868|NCT01725386|DRUG|Capecitabine|Oral tablet(s) administered according to prescribing information
57766869|NCT02378519|BEHAVIORAL|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
57766870|NCT02378519|BEHAVIORAL|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
57766871|NCT03115554|PROCEDURE|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
57766872|NCT03115554|PROCEDURE|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
57766873|NCT02888717|PROCEDURE|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~* Slices A and C are sent OSNA analysis~* Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~* Free (-): \<250 copies~* Micrometastatic (+): 250 ≤ - \<5,000 copies,~* Macrometastatic (++): ≥ 5000 copies."
57766874|NCT04145037|DRUG|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
57766875|NCT01170195|DIETARY_SUPPLEMENT|Calmera-Licorice Root Extract (Licogen)|100 mg per day
57766876|NCT06616311|DEVICE|Radiofrequency microneedling|The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
57766877|NCT04678622|DEVICE|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
57766878|NCT04929093|BIOLOGICAL|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
57766879|NCT04929093|BIOLOGICAL|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
57766880|NCT04929093|BIOLOGICAL|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
57766881|NCT06394765|BEHAVIORAL|Mindful Mapping|Participants in the Mindful Mapping condition will receive a 5-minute, therapist-guided mindfulness intervention for chronic pain. During this training they will learn the 30-second Mindful Mapping technique, which they will be instructed to use each time they experience a painful sensation over the next 2 weeks. The Mindful Mapping technique consists of focusing on five basic characteristics (shape, weight, density, temperature, movement) of the most intense sensation in the body as it emerges in the present moment while remaining equanimous, i.e., preventing the learned reaction.
58457768|NCT04731389|BEHAVIORAL|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
57766882|NCT06394765|BEHAVIORAL|Serial Sevens|"Participants in the control condition will receive a 5-minute, therapist-guided serial sevens intervention for chronic pain. During this training, participants will be instructed that each time they experience pain, they will count backwards in their heads by 7 from 100 for 30 second."
57766883|NCT02402296|DRUG|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
57766884|NCT02402296|OTHER|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
57766885|NCT01048645|DRUG|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
57766886|NCT01048645|OTHER|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
57766887|NCT02999425|OTHER|Education|Educational intervention
58457769|NCT00707785|DIETARY_SUPPLEMENT|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
57766888|NCT00433953|DRUG|Mycophenolate Mofetil (CellCept)|
57766889|NCT00433953|BEHAVIORAL|Dietary Monitoring|
57766890|NCT00433953|BEHAVIORAL|Drug Diary|
58129339|NCT03247556|DRUG|Placebo|Placebo was administered once daily
58129340|NCT03247556|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to Placebo
58457770|NCT04559854|BEHAVIORAL|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
58457771|NCT02647307|DRUG|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
58457772|NCT00725777|DRUG|artemether-lumefantrine|Standard artemether-lumefantrine treatment
58457773|NCT03166514|DIETARY_SUPPLEMENT|Commercially Available Food Bar|
58457774|NCT03166514|DIETARY_SUPPLEMENT|Placebo|
58457775|NCT05817656|DRUG|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
58457776|NCT05709860|BEHAVIORAL|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
57766891|NCT00433953|PROCEDURE|Blood Sampling|
57766892|NCT00301080|DRUG|D-cycloserine|
57766893|NCT00301080|OTHER|Placebo|
57766894|NCT03485274|DRUG|Vortioxetine|oral medication taken once daily
57766895|NCT03485274|OTHER|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
57766896|NCT05324345|BEHAVIORAL|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
57766897|NCT05696561|DEVICE|Canaloplasty Device|Canaloplasty
57766898|NCT03980184|DRUG|Guanfacine|Guanfacine 3mg/day Versus Placebo
57766899|NCT03980184|OTHER|Behavioral Counseling|placebo
57766900|NCT02924389|DRUG|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
58129341|NCT03247556|DRUG|600mg SPN-812|600mg SPN-812 was administered once daily and compared to Placebo
58457777|NCT05709860|BEHAVIORAL|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
58457778|NCT02102295|DRUG|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
57766901|NCT02924389|DRUG|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
57766902|NCT02924389|DRUG|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
58457779|NCT02102295|DRUG|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
58457780|NCT02971423|DRUG|ETX2514|
57766903|NCT02092246|DEVICE|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
57766904|NCT02092246|DEVICE|Unguided injection|Needle placement will take place without ultrasound machine guidance
57766905|NCT06051487|OTHER|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
57766906|NCT04242420|DIAGNOSTIC_TEST|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
57766907|NCT04242420|DIAGNOSTIC_TEST|Lung function|Spirometry,
57766908|NCT04242420|DIAGNOSTIC_TEST|Microbiology|Bacterial culture from Sputum or swab
57766909|NCT04242420|DIAGNOSTIC_TEST|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
57766910|NCT04242420|DIAGNOSTIC_TEST|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
57766911|NCT01350141|OTHER|Placebo|An infusion lasting approximately 60 minutes
57766912|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
57766913|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
57766914|NCT06413784|OTHER|Morning chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of morning chronotype individuals were examined.
57766915|NCT06413784|OTHER|Intermediate chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of intermediate chronotype individuals were examined.
57766916|NCT06413784|OTHER|Evening chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of evening chronotype individuals were examined.
57766917|NCT00003315|BIOLOGICAL|sargramostim|
57766918|NCT00003315|DRUG|liposomal amphotericin B|
57766919|NCT02710695|BEHAVIORAL|Control|This group will receive a standardized 10 minute discussion.
57766920|NCT02710695|BEHAVIORAL|Intervention|This group will receive a standardized 10 minute discussion
57766921|NCT01713699|PROCEDURE|lumbar puncture|
57766922|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
57766923|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
57766924|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
57766925|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
57766926|NCT04141020|PROCEDURE|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
58457781|NCT02971423|DRUG|Placebo|matching placebo infusion
58457782|NCT02971423|DRUG|Sulbactam|
57766927|NCT04141020|PROCEDURE|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
57766928|NCT04141020|DRUG|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
57766929|NCT04853147|DRUG|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
57766930|NCT04853147|DRUG|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
57766931|NCT02475317|DRUG|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
57766932|NCT02475317|DRUG|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
57766933|NCT02475317|DRUG|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
57766934|NCT03004313|PROCEDURE|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
57766935|NCT03004313|PROCEDURE|MRI scan|
57766936|NCT03004313|PROCEDURE|Quantitative Sensory Testing (QST)|
57766937|NCT02814474|OTHER|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
57766938|NCT02814474|OTHER|Saline|Infusion of 0.9 % saline
57766939|NCT05260372|DIAGNOSTIC_TEST|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
57766940|NCT00653549|DRUG|Torsemide|Tablets, 20 mg, single-dose
57766941|NCT00653549|DRUG|Demadex|tablets, 20 mg, single-dose
57766942|NCT00525265|DRUG|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
57766943|NCT00525265|DRUG|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
57766944|NCT05177731|DRUG|Venetoclax|Orally by mouth
57766945|NCT05177731|DRUG|Decitabine for Injection|Intravenous infusion
57766946|NCT05177731|DRUG|Cytarabine|Intravenous infusion
58457783|NCT02971423|DRUG|Imipenem/Cilastatin|
58457784|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
58457785|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
57766947|NCT05177731|DRUG|Idarubicin|Intravenous infusion
57766948|NCT05177731|DRUG|Gilteritinib|Orally by mouth
57766949|NCT06459830|OTHER|Mime Therapy with Neural Mobilization|"Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
57766950|NCT06459830|OTHER|Mime Therapy with Placebo Mobilization|"Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
57766951|NCT04406350|PROCEDURE|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
57766952|NCT02379065|DEVICE|The Aerogen Aeroneb Solo©|
57766953|NCT02379065|DEVICE|Phillips Respironic© mask|
57766954|NCT00193713|DRUG|bifeprunox|
57766955|NCT03369184|DRUG|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
57766956|NCT03369184|OTHER|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
57766957|NCT00847795|DRUG|Avotermin|Intradermal administration
57766958|NCT00847795|DRUG|Placebo|Placebo
57766959|NCT06006702|DRUG|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
57766960|NCT04935138|GENETIC|cfDNA analysis|sequencing data from cfDNA analysis
57766961|NCT01373996|DEVICE|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
57766962|NCT02811757|PROCEDURE|tenotomy|
57766963|NCT02811757|PROCEDURE|tenodesis|
57766964|NCT02696044|DRUG|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
57766965|NCT03785457|OTHER|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
57766966|NCT03785457|OTHER|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
57766967|NCT02419430|BEHAVIORAL|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
58457786|NCT03979898|BIOLOGICAL|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10\^7cells/5mL 15kg \~ 25kg : 1x10\^8cells/10mL 25kg over : 1.5x10\^8cells/15mL
58457787|NCT04511481|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
58457788|NCT04070365|DEVICE|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
58457789|NCT02558517|DRUG|prednisone discontinuation|randomization
57766968|NCT02419430|BEHAVIORAL|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --\> Happier~  + Exercising --\> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation"
57766969|NCT02419430|BEHAVIORAL|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
57766970|NCT01108757|DRUG|Bactrim|Bactrim DS BID for 3 days
57766971|NCT01108757|OTHER|Placebo|Corn starch capsules
58457790|NCT00006000|DRUG|cisplatin|
58457791|NCT00006000|DRUG|irinotecan hydrochloride|
57766972|NCT05983744|OTHER|0 Hz Control|Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
57766973|NCT05983744|OTHER|0.1 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
57766974|NCT05983744|OTHER|0.05 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
57766975|NCT03564782|BIOLOGICAL|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
57766976|NCT02823964|DRUG|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
57766977|NCT01737996|DRUG|BI 207127 + faldaprevir|fixed dose combination
57766978|NCT06038890|PROCEDURE|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
57766979|NCT05809349|DEVICE|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
57766980|NCT06028074|DRUG|GIM122|GIM-122 administered IV once every 3 weeks
57766981|NCT00119990|DRUG|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
57766982|NCT00119990|DRUG|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
57766983|NCT03264768|DEVICE|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
57766984|NCT03264768|BEHAVIORAL|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
57766985|NCT03264768|PROCEDURE|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
57766986|NCT00563225|DRUG|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
57766987|NCT02372760|DEVICE|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
57766988|NCT02372760|OTHER|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
57766989|NCT02372760|DRUG|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
58129342|NCT05813028|OTHER|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
58129343|NCT00796822|DRUG|Pentoxifylline|400 mg three times a day for 8 weeks
58129344|NCT00796822|DRUG|Placebo|One pill three times a day for 8 weeks
58129345|NCT02397733|RADIATION|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
58457792|NCT00006000|DRUG|semaxanib|
58457793|NCT01663870|BEHAVIORAL|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
57766990|NCT03600896|DRUG|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
57766991|NCT06082414|OTHER|no interventions|no interventions because of an observational study
57766992|NCT00192023|DRUG|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
57766993|NCT00192023|DRUG|placebo|
57766994|NCT00192023|DRUG|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
57766995|NCT00192023|DRUG|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
57766996|NCT06158425|RADIATION|long-leg radiograph|A flat-panel digital radiography(DR) equipment (Siemens DR AXIOM Aristos AX/VX) was used to capture full-length bipedal lower extremities in a standing position. The technician moved the detector from top to bottom, capturing four parts: the bilateral hip joints, femur, tibia and fibula and ankle joint. The exposure parameters for each part were as follows: 1st exposure - 85kV, 75mAs; 2nd exposure - 80kV, 50mAs; 3rd exposure - 75kV, 40mAs; 4th exposure - 68kV, 20mAs. The distance from the source (kv-kg) was 300cm, and the field of view was 43.18cm x 43.18cm. All 4 X-rays were stitched using the Siemens DR Station.
57766997|NCT05420441|DEVICE|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
57766998|NCT05420441|DEVICE|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
57766999|NCT05420441|PROCEDURE|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
57767000|NCT01503840|DRUG|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
57767001|NCT01503840|DRUG|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
57767002|NCT04218773|DRUG|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
57767003|NCT04218773|DRUG|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
57767004|NCT01909570|PROCEDURE|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
57767005|NCT01909570|PROCEDURE|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
58129346|NCT02397733|RADIATION|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
58129347|NCT04260204|PROCEDURE|Pediatric cardiac surgery|
58457794|NCT01663870|BEHAVIORAL|Focus Group Session|Focus group session taking 60-90 minutes.
58457795|NCT01663870|OTHER|Website Session|10-15 minute session with the HealthATM website.
58457796|NCT01663870|BEHAVIORAL|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
57767006|NCT00006432|PROCEDURE|very low fat diet|
57767007|NCT05520840|DIAGNOSTIC_TEST|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
57767008|NCT02105441|DEVICE|Cochlear implant|Implantable hearing device
57767009|NCT00913185|DRUG|Acne Free, Proactiv|
57767010|NCT05275491|DIAGNOSTIC_TEST|Calcium|Free calcium serum levels
57767011|NCT05275491|DIAGNOSTIC_TEST|Fibroblast growth factor 23|Serum level
57767012|NCT05275491|DIAGNOSTIC_TEST|Sclerostin|Serum level
57767013|NCT05275491|DIAGNOSTIC_TEST|parathyroid hormone|serum level
57767014|NCT06289634|BEHAVIORAL|Man-made sounds|Participants will be asked to listen to the assigned sounds (relaxing music) for 30 minutes a day for 15 days.
57767015|NCT06289634|BEHAVIORAL|Natural sounds|Participants will be asked to listen to the assigned sounds (birds, ocean, wind) for 30 minutes a day for 15 days.
57767016|NCT02312401|DEVICE|multi-parametric MRI(MP-MRI)|
57767017|NCT02312401|DEVICE|dynamic contrast-enhanced MRI (DCE)|
57767018|NCT02312401|PROCEDURE|biopsy|
57767019|NCT00369681|DRUG|Bleomycin|
57767020|NCT00369681|BIOLOGICAL|Rituximab|
57767021|NCT00369681|DRUG|Dacarbazine|
57767022|NCT00369681|DRUG|Doxorubicin|
57767023|NCT00369681|DRUG|Vinblastine|
57767024|NCT02500563|OTHER|Amino acid based infant formula|
57767025|NCT02500563|OTHER|Extensively hydrolyzed casein infant formula|
57767026|NCT02500563|OTHER|Mother's own breast milk|
57767027|NCT05375435|DRUG|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
57767028|NCT05375435|DRUG|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
57767029|NCT00765297|DEVICE|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
57767030|NCT00765297|DEVICE|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
57767031|NCT05971342|DRUG|Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)|The experimental group
57767032|NCT05971342|DRUG|Gelatin sponge only （Kuaikang®)|The positive control group
57767033|NCT03408743|BEHAVIORAL|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
57767034|NCT03408743|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767035|NCT03408743|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
58129348|NCT05670652|OTHER|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
58457797|NCT05860088|OTHER|Beef Diet|Controlled-Feeding Diet Intervention
58457798|NCT05860088|OTHER|Vegetarian Diet|Controlled-Feeding Diet Intervention
58457799|NCT00213616|PROCEDURE|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
58457800|NCT03986996|DRUG|amoxicillin, metronidazole and doxycycline|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
58457801|NCT03986996|DRUG|amoxicillin and doxycyclin|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
57767036|NCT03408743|BEHAVIORAL|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767037|NCT03408743|BEHAVIORAL|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
57767038|NCT03408743|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767039|NCT03408743|BEHAVIORAL|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767040|NCT03408743|BEHAVIORAL|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767041|NCT03408743|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
58457802|NCT05665439|RADIATION|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
58457803|NCT00110539|BEHAVIORAL|Complementary and alternative medicine education|
58457804|NCT03149055|DRUG|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
58457805|NCT00669890|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
58457806|NCT00669890|DRUG|Busulfan|Conditioning Regimen
58457807|NCT00669890|DRUG|Cyclophosphamide|Conditioning Regimen
58457808|NCT00669890|DRUG|Thymoglobulin|(Unrelated Donors only)
58457809|NCT00669890|DRUG|Tacrolimus|GVHD Prophylaxis
58457810|NCT00669890|DRUG|Mycophenolate Mofetil|GVHD Prophylaxis
57767042|NCT03408743|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767043|NCT03408743|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767044|NCT03408743|BEHAVIORAL|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
58457811|NCT00669890|DRUG|Methotrexate|GVHD Prophylaxis
58457812|NCT01840007|DRUG|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
57767045|NCT03408743|BEHAVIORAL|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
58129349|NCT00599209|OTHER|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
58129350|NCT00622232|GENETIC|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
58457813|NCT01222013|DRUG|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
58457814|NCT05296265|BEHAVIORAL|VR treatment for phantom limb pain|8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention
58457815|NCT01911715|DRUG|MDV3100|Oral
58457816|NCT04396535|DRUG|Bintrafusp Alfa|Given IV
58457817|NCT04396535|DRUG|Docetaxel|Given IV
58457818|NCT00952991|DRUG|LAF237 = vildagliptin|
58457819|NCT03826940|DRUG|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
58457820|NCT03826940|DRUG|Placebos|60 MG Placebo per day for 3 consecutive days
58457821|NCT01290107|GENETIC|DNA analysis|
58457822|NCT01290107|GENETIC|gene rearrangement analysis|
58457823|NCT01290107|GENETIC|microarray analysis|
58457824|NCT01290107|GENETIC|polymerase chain reaction|
58457825|NCT01290107|OTHER|immunological diagnostic method|
58457826|NCT01290107|OTHER|laboratory biomarker analysis|
58457827|NCT00588926|DRUG|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
57767046|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767047|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767048|NCT03408743|BEHAVIORAL|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767049|NCT03408743|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
57767050|NCT03408743|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767051|NCT03408743|BEHAVIORAL|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767052|NCT03408743|BEHAVIORAL|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767053|NCT03408743|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
57767054|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767055|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767056|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767057|NCT03408743|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
57767058|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767059|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767060|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
58457828|NCT00475670|DRUG|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
58457829|NCT00475670|DRUG|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
58457830|NCT06045312|OTHER|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
57767061|NCT03408743|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
58129351|NCT04607720|PROCEDURE|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
58457831|NCT05413668|DRUG|RVP-001|Intravenous administration of RVP-001
57767062|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
58457832|NCT05413668|DRUG|Placebo|Intravenous administration of saline placebo
57767063|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
57767064|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
57767065|NCT06133114|DRUG|Clonazepam|0.5 mg twice a day (1 mg a day)
57767066|NCT06133114|DRUG|Olanzapine|2.5 mg once a day of Olanzapine
57767067|NCT06133114|DRUG|Buprenorphine|2 mg once a day of Buprenorphine
57767068|NCT02948959|DRUG|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
57767069|NCT02948959|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
57767070|NCT02948959|DRUG|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
57767071|NCT02948959|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
57767072|NCT00621907|DRUG|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
57767073|NCT00621907|DRUG|sodium chloride|sodium chloride : 0,9% 30 ml
57767074|NCT02810314|BEHAVIORAL|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
57767075|NCT02810314|OTHER|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
57767076|NCT02672501|DRUG|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
57767077|NCT00875732|DEVICE|Bi Ventricular Pacing|
58457833|NCT05568446|BEHAVIORAL|Social virtual reality|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
57767078|NCT00875732|DEVICE|Right Ventricular Pacing|
58129352|NCT04607720|PROCEDURE|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
58457834|NCT05568446|BEHAVIORAL|Traditional social skills|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
58457835|NCT04258423|DRUG|Tacrolimus|Low dose Tacrolimus
58457836|NCT04258423|DRUG|Everolimus|Everolimus
58457837|NCT03793348|DEVICE|MCD|Micro coring skin removal with automated coring device
58457838|NCT00733785|DRUG|Rosiglitazone XR|Rosiglitazone extended release formulation
58457839|NCT02519439|DRUG|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
58457840|NCT04320004|BEHAVIORAL|Education|Subject receives education
58457841|NCT04320004|BEHAVIORAL|Education with Reminder|Subject receives education with reminder
58457842|NCT04320004|BEHAVIORAL|Education + Disposal Bag|Subject receives education and disposal bag
57767079|NCT02139475|PROCEDURE|Colonoscopy|
57767080|NCT02643719|BEHAVIORAL|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
57767081|NCT02643719|DRUG|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
57767082|NCT02643719|DRUG|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
57767083|NCT02643719|DRUG|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
57767084|NCT05043402|DRUG|navicixizumab|navicixizumab IV
57767085|NCT05043402|DEVICE|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
57767086|NCT02183116|DRUG|Meloxicam|
57767087|NCT05287516|OTHER|Breakfast meal|A meal consisting of breakfast biscuits and water.
57767088|NCT04278677|DIETARY_SUPPLEMENT|melatonin|Melatonin capsules to be taken for 6 weeks
57767089|NCT01291238|BEHAVIORAL|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
57767090|NCT00840008|OTHER|Educational intervention|As per detailed protocol.
58129353|NCT04296903|DEVICE|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
58457843|NCT04320004|BEHAVIORAL|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
58457844|NCT01577017|DRUG|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
58457845|NCT02730481|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
57767091|NCT05844891|BEHAVIORAL|Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)|TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine, featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
57767092|NCT05844891|BEHAVIORAL|Enhanced Care (EC)|Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
57767093|NCT01030978|BEHAVIORAL|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
57767094|NCT01030978|BEHAVIORAL|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
57767095|NCT04902417|OTHER|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
57767096|NCT03222258|BEHAVIORAL|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
57767097|NCT03222258|BEHAVIORAL|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
57767098|NCT02066896|DEVICE|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
57767099|NCT02066896|DEVICE|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
57767100|NCT04068363|OTHER|non interventional|non interventional study
57767101|NCT00482638|DRUG|MK0493|
58457846|NCT00660725|DRUG|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
58457847|NCT00660725|DRUG|Gemcitabine|30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.
57767102|NCT05182073|DRUG|FT576 (Allogenic CAR NK cells with BCMA expression)|Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
57767103|NCT05182073|DRUG|Cyclophosphamide|Conditioning Agent
57767104|NCT05182073|DRUG|Fludarabine|Conditioning Agent
57767105|NCT05182073|DRUG|Daratumumab|Anti-CD38 Monoclonal Antibody
58129354|NCT03515395|BEHAVIORAL|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
58457848|NCT00660725|DRUG|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
58457849|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
58457850|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
58457851|NCT03976479|OTHER|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
58457852|NCT00921271|DEVICE|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
57767106|NCT05182073|DRUG|Bendamustine|Conditioning Agent
57767107|NCT03612427|DIETARY_SUPPLEMENT|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
57767108|NCT03062774|BIOLOGICAL|PB-119 injection|
57767109|NCT01022801|DRUG|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
57767110|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
57767111|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
57767112|NCT05699122|OTHER|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
57767113|NCT05699122|OTHER|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
57767114|NCT00632008|DRUG|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
57767115|NCT00632008|DRUG|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
57767116|NCT04865211|DRUG|Liposomal bupivacaine|Use of liposomal bupivicaine as intraoperative local anesthesia
57767117|NCT04865211|DRUG|Bupivacaine Injection|Use of bupivicaine as intraoperative local anesthesia
57767118|NCT04865211|DRUG|Placebo|Use of saline as placebo for local anesthesia
57767119|NCT03973866|DEVICE|Alfapump|Implantation of alfapump
57767120|NCT02436083|DRUG|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
57767121|NCT01771822|DRUG|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
57767122|NCT01771822|DRUG|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
57767123|NCT01771822|DRUG|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
57767124|NCT01771822|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
57767125|NCT04065217|PROCEDURE|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
57961269|NCT03715283|OTHER|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
57961270|NCT03715283|OTHER|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
57767126|NCT05222035|DRUG|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
57961271|NCT02394977|DEVICE|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
57961272|NCT02394977|OTHER|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
57961273|NCT03784014|DRUG|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57767127|NCT05222035|DRUG|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
57767128|NCT04243460|PROCEDURE|Xenogeneic collagen matrix (XCM) graft augmentation|"12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:"
57767129|NCT04243460|PROCEDURE|Connective tissue graft augmentation (CTG)|12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
57767130|NCT01369238|DEVICE|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2\~3days/wk, for 1 month
57767131|NCT01369238|DRUG|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
57767132|NCT06355635|OTHER|Choice and Monitoring|current practive of vasoactive and inotrope drugs
57767133|NCT03163576|DRUG|Niacin|tablets
57767134|NCT03163576|DRUG|Phosphate Binder|tablets
57767135|NCT01993017|OTHER|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
57767136|NCT01993017|DRUG|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
57767137|NCT01993017|OTHER|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
57767138|NCT01993017|OTHER|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
57767139|NCT01993017|OTHER|No intervention|
57767140|NCT03277378|DEVICE|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
57767141|NCT05763758|OTHER|No intervention|No intervention involved in this study
57767142|NCT01445223|DRUG|Lopinavir ritonavir|400mg BD 100mg BD
58129355|NCT02422823|DRUG|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
58129356|NCT02422823|DRUG|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
57767143|NCT01445223|DRUG|Atazanavir ritonavir|300mg QD 100mg QD
57767144|NCT01445223|DRUG|Efavirenz|600mg QD
57767145|NCT01729117|OTHER|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
58129357|NCT02422823|DRUG|Epinephrine|
58129358|NCT04611256|BIOLOGICAL|MSC|Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach
58129359|NCT04611256|DRUG|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
57767146|NCT01729117|OTHER|Standard Care|Standard Care only
57767147|NCT01401413|DRUG|ramelteon|8 mg nightly for 30 nights
57767148|NCT01401413|DRUG|placebo|placebo control i pill nightly for 30 nights
57767149|NCT04986735|DRUG|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
57767150|NCT01737281|BEHAVIORAL|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
57767151|NCT01737281|BEHAVIORAL|Usual care|Usual smoking cessation care from VA clinical staff.
57767152|NCT01861574|DEVICE|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
57767153|NCT01861574|DEVICE|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
58129360|NCT01951846|DRUG|BIBF 1120|
58129361|NCT05400876|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
58129362|NCT05400876|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
57767154|NCT01861574|DEVICE|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
57767155|NCT01861574|DEVICE|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
57767156|NCT00553098|BIOLOGICAL|Alemtuzumab|Given IV
57767157|NCT00553098|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo HCT
57767158|NCT00553098|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
57767159|NCT00553098|DRUG|Cyclosporine|Given PO or IV
57767160|NCT00553098|DRUG|Fludarabine Phosphate|Given IV
57767161|NCT00553098|OTHER|Laboratory Biomarker Analysis|Correlative study
58457853|NCT05474352|DEVICE|Allon System|Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
58457854|NCT03083925|DEVICE|TIPS|Transjugular Intrahepatic Portosystemic Shunt
58457855|NCT02883231|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
58457856|NCT01154868|PROCEDURE|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
58457857|NCT04546035|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
58457858|NCT00681044|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
58457859|NCT00681044|DRUG|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
58457860|NCT00681044|PROCEDURE|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
58457861|NCT00558246|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
58457862|NCT00558246|DEVICE|Suture|Topical Suturing
58457863|NCT02624271|OTHER|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
57767162|NCT00553098|DRUG|Mycophenolate Mofetil|Given PO or IV
57767163|NCT00553098|RADIATION|Total-Body Irradiation|Undergo low dose TBI
57767164|NCT05458167|DEVICE|Hedia Diabetes Assistant bolus calculator with a physical activity module|Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
57767165|NCT01552122|DRUG|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
57767166|NCT01552122|DRUG|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
57767167|NCT01552122|OTHER|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
58457864|NCT01439516|BEHAVIORAL|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
58457865|NCT00274248|DRUG|MLN518|
58457866|NCT02222935|BEHAVIORAL|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
58457867|NCT02222935|BEHAVIORAL|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
57767168|NCT01552122|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
57767169|NCT01552122|DIETARY_SUPPLEMENT|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
57767170|NCT01552122|OTHER|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
57767171|NCT01295567|DRUG|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
57767172|NCT01295567|DRUG|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
57767173|NCT02420756|DEVICE|PET Scan|
57767174|NCT03346213|DRUG|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
57767175|NCT05622448|OTHER|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
57767176|NCT05622448|OTHER|RPD with metallic framework|removable partial denture with cobalt chromium framework
57767177|NCT00146250|DRUG|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
57767178|NCT00708526|OTHER|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
57767179|NCT00708526|DEVICE|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
57767180|NCT03942679|OTHER|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
57767181|NCT03942679|OTHER|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
57767182|NCT02351323|DRUG|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
57767183|NCT02351323|BEHAVIORAL|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
57767184|NCT04627519|DIETARY_SUPPLEMENT|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
57767185|NCT00852826|PROCEDURE|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
57767186|NCT00852826|PROCEDURE|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
57767187|NCT05538260|PROCEDURE|Repair of ocular trauma in children below 16 years old|Diagnosis and repair of pediatric ocular trauma
57767188|NCT05188755|OTHER|Indirect calorimetric test during submaximal exercise|"* metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity"
57767189|NCT02795208|PROCEDURE|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
57767190|NCT06015555|BEHAVIORAL|TAMO|TAMO therapy
57767191|NCT06015555|BEHAVIORAL|Postural Control exercises|Postural Control exercises
57767192|NCT05606263|DRUG|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
57767193|NCT00509002|DRUG|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
57767194|NCT03881930|OTHER|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
57767195|NCT03881930|OTHER|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
57767196|NCT02321280|DRUG|Denosumab|Single dose subcutaneous administration
57767197|NCT02687490|DRUG|Abraxane|125 mg/m2, D1, D8, D15
57767198|NCT03216902|DRUG|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
58129363|NCT02162069|DEVICE|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
57767199|NCT03216902|DRUG|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
57767200|NCT03216902|DRUG|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
58129364|NCT04817007|DRUG|BMS-986158|Specified dose on specified days
57767201|NCT03216902|DRUG|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
57767202|NCT03216902|DRUG|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
57767203|NCT03216902|DRUG|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
57767204|NCT01562535|OTHER|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
58129365|NCT04817007|DRUG|Ruxolitinib|Specified dose on specified days
58129366|NCT04817007|DRUG|Fedratinib|Specified dose on specified days
57767205|NCT01562535|OTHER|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
57767206|NCT02291432|BIOLOGICAL|autologous muscle-derived cells (AMDC)|Cell treatment
57767207|NCT03646630|PROCEDURE|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
57767208|NCT03646630|PROCEDURE|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
57767209|NCT03720418|DRUG|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
57767210|NCT03720418|OTHER|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
57767211|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
58457868|NCT05532826|OTHER|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
58457869|NCT03121859|OTHER|Neck stabilization exercise|Exercise
58457870|NCT03121859|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS)
58457871|NCT03121859|OTHER|IFC|Interferential current therapy(IFC)
58457872|NCT02888106|DRUG|Myrcludex B|Lyophilised powder for solution for subcutaneous injection
58457873|NCT02888106|DRUG|PEG IFN alfa-2a|solution for subcutaneous injection, once per week
58457874|NCT02888106|DRUG|Tenofovir|Film-coated tablets, 300 mg, per os, once daily
58457875|NCT01099371|OTHER|exercise|progressive resistance training
58457876|NCT02362321|DRUG|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
58457877|NCT02362321|OTHER|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
58457878|NCT01964508|OTHER|Fine needle aspiration|
57767212|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-7
57767213|NCT00868699|DRUG|Placebo|Placebo Comparator
58457879|NCT05378685|PROCEDURE|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
58457880|NCT02752594|BIOLOGICAL|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
58457881|NCT02752594|OTHER|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
58457882|NCT00956735|OTHER|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
58457883|NCT02621112|BIOLOGICAL|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
58457884|NCT02621112|BIOLOGICAL|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
57767214|NCT05102123|DRUG|Cytisine|Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
57767215|NCT05102123|BEHAVIORAL|Video Messaging|Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
57767216|NCT03748836|DRUG|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
57767217|NCT03748836|DRUG|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
57767218|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
57767219|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
57767220|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
57767221|NCT00462254|DRUG|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
57767222|NCT00462254|DRUG|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
57767223|NCT04380298|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
57767224|NCT04380298|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
57767225|NCT04380298|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
57767226|NCT02252614|DRUG|naproxen sodium codein|Pain intensity, contramal consumption
57767227|NCT02252614|DRUG|paracetamol codein|Pain intensity, contramal consumption
57767228|NCT02252614|DRUG|Placebo|Pain intensity, contramal consumption
58457885|NCT02621112|BIOLOGICAL|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
58457886|NCT02004730|DEVICE|ABSORB implantation|ABSORB implantation for long (\> 24mm) single vessel disease
58457887|NCT03642873|DRUG|Humibid®|Humibid® 1200 mg (single extended release) tablet
58457888|NCT03642873|DRUG|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
58457889|NCT03642873|DRUG|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
58457890|NCT01404039|BEHAVIORAL|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
58457891|NCT01404039|BEHAVIORAL|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
57767229|NCT04959760|DIAGNOSTIC_TEST|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
57767230|NCT00303160|DRUG|vitamin C & E supplements|
57767231|NCT03357120|OTHER|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
57767232|NCT04066140|OTHER|No intervention|No Intervention. Observational Study.
57767233|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
57767234|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
57767235|NCT02571790|BEHAVIORAL|Relaxation optimized virtual reality|
57767236|NCT02571790|BEHAVIORAL|Classical relaxation (without Virtual Reality)|
57767237|NCT03090581|PROCEDURE|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
57767238|NCT03090581|PROCEDURE|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
57767239|NCT06622278|BEHAVIORAL|Flipped Classroom|The flipped classroom educational model requires participants to independently review educational material before class, and class time with the health educator is spent engaging in group and individual skills-based activities and problem-solving assignments. The theoretical basis for the development of active learning is to elicit higher cognitive learning, according to the revised Bloom's taxonomy and shift independent student time to passive learning (remembering and understanding) and collaborative student and educator time to active learning (applying, analyzing, evaluating, and creating). Thus, the weight management education will include: case vignettes, group debates/discussions, think-pair-share activities, gamification of health-related topics, creation of meal and physical activity, problem-solving barriers to a healthy diet and physical activity, and hands-on worksheets.
57767240|NCT06319235|DRUG|IMP|DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
57767241|NCT06319235|DRUG|Placebo|0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
57767242|NCT01062763|DRUG|spironolactone|25 to 50 mg once daily
58457892|NCT01404039|BEHAVIORAL|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
57767243|NCT01062763|DRUG|placebo|addition of placebo 1 to 2 tablets daily
57767244|NCT03535402|DRUG|Sarilumab|SC administration of 200 mg twice a week
57767245|NCT05384665|DRUG|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
57767246|NCT05384665|DRUG|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
57767247|NCT05384665|DRUG|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
57767248|NCT00816387|PROCEDURE|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
57767249|NCT00816387|PROCEDURE|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
57767250|NCT01834222|BIOLOGICAL|Non-intervention|Non-intervention
57767251|NCT02020980|BIOLOGICAL|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
57767252|NCT03093740|DRUG|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
57767253|NCT03093740|DRUG|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
57767254|NCT04929808|OTHER|Hydrating emollient for acute radiodermatitis|"The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist."
57767255|NCT04929808|OTHER|Standard institutional skin care|The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
57767256|NCT06294912|OTHER|Plasmodium falciparum|Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
57767257|NCT06294912|DRUG|MK-7602|Capsules to be administered orally.
57767258|NCT06294912|DRUG|Artemether/lumefantrine|Tablets to be administered orally as definitive antimalarial treatment.
57767259|NCT06294912|DRUG|Primaquine|Tablets to be administered orally as definitive antimalarial treatment.
57767260|NCT06294912|DRUG|Artesunate|Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
57767261|NCT06294912|DRUG|Atovaquone/proguanil|Tablets to be administered orally as definitive antimalarial treatment.
57767262|NCT03068013|BEHAVIORAL|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
57767263|NCT03068013|BEHAVIORAL|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
57767264|NCT06528548|DIAGNOSTIC_TEST|DBS card|Collection of a second DBS card
57767265|NCT06528548|BIOLOGICAL|Blood samples|Blood samples taken from child and parents
57767266|NCT06024772|PROCEDURE|ultiparametric Magnetic Resonance Imaging|Undergo mp-MRI
57767267|NCT06024772|DRUG|Perflutren lipid microsphere|Given IV
57767268|NCT06024772|PROCEDURE|Transrectal Ultrasound|Undergo transrectal mp-US
57767269|NCT06024772|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsies
57767270|NCT00879996|DRUG|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
57767271|NCT00879996|DRUG|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
57767272|NCT03361826|DEVICE|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
57767273|NCT03361826|BEHAVIORAL|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
57767274|NCT02139423|OTHER|CMV PCR|
57767275|NCT04100109|DIETARY_SUPPLEMENT|Polylactose|Polylactose 15 g/day
57767276|NCT04100109|OTHER|Placebo|Cellulose 15 g/day
57767277|NCT01858480|DRUG|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
57767278|NCT01858480|OTHER|Placebo|Placebo dosage form designed to mock active.
57767279|NCT03719053|DRUG|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
57767280|NCT04157465|OTHER|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
57767281|NCT01742637|DRUG|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
57767282|NCT01742637|DRUG|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
57767283|NCT01742637|DRUG|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
57767284|NCT06414512|DRUG|AMBITION trial control|Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
57767285|NCT06414512|DRUG|Flucytosine|Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
57767286|NCT05368181|DRUG|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
57767287|NCT00347243|PROCEDURE|phacoemulsification (cataract surgery)|
57767288|NCT02268617|OTHER|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
57767289|NCT04533451|DRUG|Pembrolizumab|Given IV
57767290|NCT04533451|DRUG|Pemetrexed|Given IV
57767291|NCT04533451|DRUG|Carboplatin|Given IV
57767292|NCT04533451|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
57767293|NCT04533451|OTHER|Questionnaire Administration|Ancillary studies
57767294|NCT04533451|OTHER|Quality-of-Life Assessment|Ancillary studies
57767295|NCT03579914|DRUG|intravenous Placebo|Patients receive intravenous Placebo (saline) injection
57767296|NCT03579914|DRUG|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
57767297|NCT03579914|DEVICE|Romote Ischemic Conditioning (RIC)|Patients receive RIC treatment
57767298|NCT03579914|COMBINATION_PRODUCT|Metoprolol & RIC|Patients receive Metoprolol \& RIC treatment
57767299|NCT02826590|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
57767300|NCT02826590|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
57767301|NCT05784805|DEVICE|PLIFU|Participants will be treated with up to 2 sessions of PLIFU (on the same day), while monitored with surface EEG and will be observed for the remainder of the hospital stay as deemed by the primary care team. The system non-invasively delivers ultrasound sonications intracranially that selectively target specific areas of the brain.
57767302|NCT06624813|PROCEDURE|Robot-assisted partial prostatectomy|Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
57767303|NCT06626308|OTHER|brain functional MRI|visual protocol stimulation during brain functional MRI
57767304|NCT05453916|DRUG|Nitazoxanide 500Mg Oral Tablet|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
57767305|NCT05453916|DRUG|Rifaximin 550Mg Tab|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
57767306|NCT00274690|DRUG|GW679769|
57767307|NCT01589952|DRUG|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
57767308|NCT05238064|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
57767309|NCT05238064|DRUG|CHOP|Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
57767310|NCT01616771|DEVICE|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
57767311|NCT01616771|DEVICE|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
57767312|NCT01616771|DEVICE|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
57767313|NCT06625749|DEVICE|Accurasee™ IOPCL|Intraocular pseudophakic capsular lens (IOPCL)
57767314|NCT02746913|DEVICE|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
57767315|NCT02746913|DEVICE|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
57767316|NCT00073827|DRUG|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
57767317|NCT00073827|DRUG|racemic albuterol MDI|racemic albuterol 180 mcg QID
57767318|NCT00073827|DRUG|Placebo|Placebo MDI QID
57767319|NCT00326638|RADIATION|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16"
57767320|NCT00326638|OTHER|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
57767321|NCT06624826|DEVICE|Emmetropic modality|PureSee IOL, emmetropic modality
57767322|NCT06624826|DEVICE|Monovision modality|PureSee IOL, monovision modality
57767323|NCT05969821|OTHER|observational cohort study|observational cohort study
57767324|NCT01473472|DRUG|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
57767325|NCT01473472|DRUG|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
57767326|NCT05680974|OTHER|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
58457893|NCT01404039|BEHAVIORAL|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
57767327|NCT00458614|DRUG|Lansoprazole|
57767328|NCT00647634|DRUG|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
57767329|NCT00647634|DRUG|Xanax XR® Tablets (3 mg|3mg, single dose fasting
57767330|NCT00827593|BEHAVIORAL|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
57767331|NCT00827593|BEHAVIORAL|Weight Watchers|Participants will receive 12 months of Weight Watchers
57767332|NCT00827593|BEHAVIORAL|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
57767333|NCT05942352|DRUG|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
57767334|NCT05942352|DRUG|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
57767335|NCT05942352|DRUG|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
57767336|NCT05942352|DRUG|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
57767337|NCT05817578|DEVICE|Quantitative Sensory Testing / Dynamometry / Goniometry|Testing procedures that follow previously used protocols of the literature for all the Quantitative Sensory Testing, Dynamometry \& Goniometry
57767338|NCT05014321|DEVICE|EC16 medical device (CE marked)|Application on brown spots located on the face (1 treatment during the study).
57767339|NCT05014321|DEVICE|device prototype (810A-v1)|Application on brown spots located on the face (4 treatments during the study).
58457894|NCT01404039|DEVICE|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
58457895|NCT04389359|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
58457896|NCT01668459|DRUG|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
57767340|NCT05014321|DEVICE|device prototype (810B-v1)|Application on brown spots located on the face (4 treatments during the study).
57767341|NCT05014321|DEVICE|device prototype (810C-v1)|Application on brown spots located on the face (4 treatments during the study).
57767342|NCT03059875|BEHAVIORAL|Medical consultation for a Standardized Geriatric Evaluation|
57767343|NCT05199805|BEHAVIORAL|Mindfulness-based pain management|The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
57767344|NCT01103960|DRUG|Telmisartan80mg+Amlodipine5mg|combination therapy
57767345|NCT01103960|DRUG|amlodipine 5mg|monotherapy
57767346|NCT01103960|DRUG|Telmisartan80mg+Amlodipine 5mg|combination therapy
57767347|NCT04998305|DRUG|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
57767348|NCT04998305|DRUG|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
57767349|NCT02904902|DRUG|adalimumab|Subcutaneous Injection
57767350|NCT02117934|BIOLOGICAL|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
57767351|NCT02117934|BIOLOGICAL|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
57767352|NCT05141903|DIETARY_SUPPLEMENT|Dietary supplement, probiotic, antibiotic conditioning -all groups|Dietary supplement, probiotic, antibiotic conditioning -all groups
57767353|NCT00019032|BIOLOGICAL|monoclonal antibody Mik-beta-1|
57767354|NCT05977920|OTHER|Caffeine|s. description
57767355|NCT06428461|PROCEDURE|Supraclavicular brachial plexus block|A supraclavicular brachial plexus block will be performed under ultrasound guidance. The patient will be taken to the preoperative block room, positioned supine with the bed elevated at a 30° angle, and the head turned away from the arm being blocked. To avoid intraneural injection, the block will use both ultrasound and a nerve stimulator (Plexygon, Vygon-Italy) with a 22G 50 mm 20° stimulating needle (Echoplex, Braun-France). A low-frequency ultrasound probe will be placed above the clavicle to visualize the subclavian artery and vein. Using an in-plane approach, the needle will be inserted laterally to medially from the mid-clavicular point through the skin and subcutaneous tissue. Under ultrasound guidance, the needle will be advanced towards the anatomical corner where the brachial plexus and subclavian artery are adjacent (corner pocket), and a local anesthetic agent will be injected to perform the block.
57767356|NCT06428461|DEVICE|Measurement of Optic Nerve Sheath Diameter (ONSD) Using B-Mode Ultrasound|Before the block, both eyes will be measured for optic nerve sheath diameter (ONSD) using B-mode ultrasound (USG) with a GE LOGIQ E device. The patient will be supine with the bed elevated at a 30° angle, eyes closed, and a protective barrier applied. Both globes will be filled with water-soluble ultrasound gel, and imaging will be done with a 7.5 MHz linear probe at a 7 cm depth. For transverse ONSD measurement, the probe will be placed transversely in the coronal plane, with the marker notch pointing right. When the optic nerve entry into the globe is clear, transverse ONSD will be measured 3 mm below. For sagittal measurement, the probe will be placed sagittally in the coronal plane, with the marker notch pointing towards the body. Sagittal ONSD will be measured 3 mm below the entry point. Both internal and external diameters of the optic nerve sheath will be measured in transverse and sagittal planes, and the transverse diameter of the globe will also be measured.
57767357|NCT06428461|DEVICE|Assessment of Peripheral Nerve Block Success Using Perfusion Index Measurement|Investigator plan to measure the Perfusion Index (PI) as an objective method for determining the success of peripheral nerve blocks, different from traditional tests. PI is an indicator of peripheral perfusion that can be continuously measured non-invasively with a pulse oximeter. PI represents the ratio of pulsatile blood flow to non-pulsatile blood flow in peripheral tissue. The Mindray uMEC 12 device will be used for this measurement.
57767358|NCT06428461|DEVICE|End-Tidal Carbon Dioxide (EtCO2) Measurement|End-tidal carbon dioxide (EtCO2) measurement: The Medtronic Capnostream 35 device will be used for EtCO2 measurements. All patients will receive oxygen support at a rate of 1-2 L/min. If peripheral oxygen saturation falls below 95%, oxygen support will be increased to 3-6 L/min via nasal cannula.
57767359|NCT04435171|PROCEDURE|Renal transplantation|Open or robot assisted renal transplantation
57767360|NCT00184483|PROCEDURE|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
57767361|NCT00184483|PROCEDURE|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
57767362|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
57767363|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
57767364|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
58457897|NCT01668459|OTHER|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
58457898|NCT04986202|DRUG|AZD4831|AZD4831
58457899|NCT04986202|OTHER|Placebo|Placebo
57767365|NCT00683280|BEHAVIORAL|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
57767366|NCT00683280|OTHER|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
57767367|NCT00683280|OTHER|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
57767368|NCT02507882|BIOLOGICAL|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
57767369|NCT02507882|BIOLOGICAL|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
57767370|NCT00002502|DRUG|busulfan|
57767371|NCT00002502|DRUG|cyclophosphamide|
57767372|NCT00002502|DRUG|cytarabine|
57767373|NCT00002502|PROCEDURE|allogeneic bone marrow transplantation|
57767374|NCT01118455|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
57767375|NCT01118455|DRUG|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
57767376|NCT02650232|DEVICE|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
57767377|NCT02650232|PROCEDURE|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position"
57767378|NCT02650232|DEVICE|Finapres Nova device (FMS system)|
57767379|NCT06624397|OTHER|CAREFREE Carer's Programme|This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
57767380|NCT02190825|DEVICE|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
57767381|NCT03191929|OTHER|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
57767382|NCT03191929|OTHER|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
57767383|NCT00994786|DRUG|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
57767384|NCT00994786|DRUG|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
57767385|NCT04293588|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
57767386|NCT05424224|DEVICE|MagVita|rTMS system
57767387|NCT03455296|OTHER|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
57767388|NCT02467322|DRUG|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
57767389|NCT02467322|DRUG|ascitic fluid|
57767390|NCT01802814|DRUG|SR-A + Epratuzumab|
57767391|NCT01802814|DRUG|SR-B + Epratuzumab|
57767392|NCT02420145|BEHAVIORAL|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
57767393|NCT03542097|OTHER|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
57767394|NCT01780129|DRUG|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
57767395|NCT05761574|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
57767396|NCT05761574|DRUG|Naproxen Sodium|Naproxen Sodium will be administered orally.
57767397|NCT05761574|DRUG|Acetaminophen|Acetaminophen will be administered orally.
57767398|NCT05761574|DRUG|Placebo|Placebo will be administered orally.
57767399|NCT05646394|DRUG|Dual antiplatelet therapy|Aspirin plus any of clopidogrel, ticagrelor or prasugrel
57767400|NCT05646394|DRUG|Combined antithrombotic therapy|Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.
57767401|NCT05646394|DRUG|Vitamin K antagonist standard intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
57767402|NCT05646394|DRUG|Vitamin K antagonist high intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
57767403|NCT02238717|DRUG|PF-06372865 (65mg)|single oral dose (65 mg)
57767404|NCT02238717|DRUG|PF-06372865 (15mg)|single oral dose (15mg)
57767405|NCT02238717|DRUG|Pregabalin|single oral dose (300mg)
57767406|NCT02238717|DRUG|Placebo|matching oral placebo
57767407|NCT04710043|DRUG|BNT152|intravenous
57767408|NCT04710043|DRUG|BNT153|intravenous
57767409|NCT02035332|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
57767410|NCT01533571|PROCEDURE|Immediate implant placement with simultaneous bone grafting|"* Flapless surgery is used for surgical implant installation.~* Implant is placed in the cingulum position of adjacent teeth incisal edge.~* After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~* Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
57767411|NCT02424409|BEHAVIORAL|2: Intervention|"1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
57767412|NCT02424409|BEHAVIORAL|1: Control|patients without discharge protocol
57767413|NCT02479516|BEHAVIORAL|Community Health Assessment Program Philippines (CHAP-P)|
57767414|NCT04496141|DIAGNOSTIC_TEST|SARS-CoV-2 antibody immunoassays|Different commercial SARS-CoV-2 antibody immunoassays
57767415|NCT06203652|OTHER|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
57767416|NCT02990416|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
57767417|NCT02990416|BIOLOGICAL|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
57767418|NCT02990416|RADIATION|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
57767419|NCT00412633|BEHAVIORAL|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
57767420|NCT00412633|BEHAVIORAL|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
57767421|NCT03758014|DRUG|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
57767422|NCT03758014|DRUG|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
57767423|NCT06425926|DRUG|GIM-531|GIM-531 administered orally daily
57767424|NCT06425926|DRUG|Anti-PD-1 monoclonal antibody|Continued treatment with anti-PD-1 therapy
57767425|NCT03736564|COMBINATION_PRODUCT|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
57767426|NCT01965158|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
57767427|NCT01965158|DRUG|Placebo|Placebo tablet taken orally once a day
57961274|NCT03784014|DRUG|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57767428|NCT04811963|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
57767429|NCT06615505|OTHER|VIA Disc NP|Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).
57767430|NCT06615505|OTHER|Sham Injection|"Participants will receive the sham procedure at 1 or 2 levels.~The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc."
57767431|NCT00615134|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
57767432|NCT00615134|DRUG|Optimized background ARV therapy|As prescribed
57767433|NCT05516368|BEHAVIORAL|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
57767434|NCT02704897|OTHER|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
57767435|NCT05981963|DRUG|[14C]-BMS-986196|Specified dose on specified days
57767436|NCT03788005|PROCEDURE|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
57767437|NCT04506749|DIETARY_SUPPLEMENT|Dietary supplement consumption|The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
57767438|NCT02863718|DRUG|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
57767439|NCT02863718|DRUG|Placebo|Placebo 420mg daily
57767440|NCT05598177|DRUG|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
57767441|NCT05598177|DRUG|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
57767442|NCT00000561|DEVICE|pacemaker, artificial|
57767443|NCT03811106|DEVICE|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
57767444|NCT03811106|OTHER|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
57767445|NCT04203537|DRUG|CA-008|Local administration during surgery
57767446|NCT04203537|DRUG|Placebo|Local administration during surgery
57767447|NCT04530357|BIOLOGICAL|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
57767448|NCT04530357|OTHER|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
57767449|NCT02599103|OTHER|Fat-free milkshake|participants drinks a fat-free milk shakes
57767450|NCT02599103|OTHER|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
57767451|NCT02599103|OTHER|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
57767452|NCT02599103|OTHER|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
57767453|NCT02599103|OTHER|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
57767454|NCT02599103|OTHER|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
57767455|NCT02599103|OTHER|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
57767456|NCT02599103|OTHER|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
57767457|NCT02599103|OTHER|Tallow|participants drinks the milk shakes prepared from 60g of tallow
57767458|NCT02599103|OTHER|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
57767459|NCT01108835|OTHER|Comprehensive care programme|"Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
57767460|NCT02348398|DRUG|Pazopanib|600 mg by mouth daily in a 28 day cycle.
57767461|NCT02348398|DRUG|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
57767462|NCT02348398|BEHAVIORAL|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
57767463|NCT04741802|BEHAVIORAL|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
57767464|NCT01861821|DEVICE|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
57767465|NCT01861821|DEVICE|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
57767466|NCT01007890|OTHER|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
57767467|NCT03697980|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
57767468|NCT03739294|DRUG|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
57767469|NCT05754684|BIOLOGICAL|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
57767470|NCT05754684|DRUG|Dinutuximab beta|Dinutuximab beta iv for 5 days
57767471|NCT05754684|DRUG|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
57767472|NCT05754684|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
57767473|NCT05754684|DRUG|Spironolactone|Spironolactone po three time daily
57767474|NCT05754684|DRUG|Naxitamab|Naxitamab iv for 4 days (as alternative for dinutuximab)
57767475|NCT03469349|DRUG|Actovegin|Actovegin intravenous infusion and tablets.
57767476|NCT03469349|DRUG|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
57767477|NCT03486587|DRUG|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
57767478|NCT01777321|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
57767479|NCT01008475|DRUG|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
57767480|NCT01008475|DRUG|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
57767481|NCT01008475|DRUG|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
57767482|NCT01008475|DRUG|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
57767483|NCT01008475|DRUG|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
57767484|NCT01008475|DRUG|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
57767485|NCT03808337|RADIATION|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
57767486|NCT03808337|DRUG|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
57767487|NCT02283359|DRUG|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
57767488|NCT02283359|DRUG|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
57767489|NCT05838924|OTHER|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
57961275|NCT03784014|DRUG|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57767490|NCT05838924|OTHER|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
57767491|NCT00399763|DRUG|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
57767492|NCT00399763|DRUG|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
57767493|NCT06213194|OTHER|MindZone|The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
57767494|NCT05250401|DIAGNOSTIC_TEST|liver functions and thyroid functions|laboratory tests
57767495|NCT06382909|DIETARY_SUPPLEMENT|Inflammatory level|Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
57767496|NCT06382909|DIETARY_SUPPLEMENT|Cognitive assessment|Neurological assessment Psychiatric assessment
57767497|NCT06382909|DIETARY_SUPPLEMENT|Pedagogical assessment|Sociopedagogical assessment
57767498|NCT06243107|BEHAVIORAL|Tai-chi|Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
57767499|NCT00274001|DRUG|Nevirapine|
57767500|NCT01441817|PROCEDURE|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
58457900|NCT01139814|DEVICE|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
58457901|NCT05824364|OTHER|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
57767501|NCT06619730|DEVICE|Sedline Brain Function Monitor|The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
57767502|NCT04515121|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
57961276|NCT03784014|DRUG|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57961277|NCT03784014|DRUG|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57961278|NCT03784014|COMBINATION_PRODUCT|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
57961279|NCT03784014|COMBINATION_PRODUCT|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57961280|NCT03784014|DRUG|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
57961281|NCT03784014|DRUG|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
57961282|NCT03784014|DRUG|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
57961283|NCT03784014|OTHER|Next Generation sequencing exome|Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
57961284|NCT04886687|PROCEDURE|mechanical thrombectomy|mechanical thrombectomy
57961285|NCT01216436|BIOLOGICAL|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
57767503|NCT04515121|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
57767504|NCT04515121|OTHER|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
57767505|NCT04122235|OTHER|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
57767506|NCT06625801|DEVICE|IVUS|Intravascular Ultrasound
57767507|NCT01973036|DEVICE|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
57767508|NCT01973036|DRUG|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
57767509|NCT00152009|DRUG|SPD503 (Guanfacine hydrochloride) (2 mg)|
57767510|NCT00152009|DRUG|SPD503 (3 mg)|
57767511|NCT00152009|DRUG|SPD503 (4 mg)|
57767512|NCT00152009|DRUG|Placebo|
57767513|NCT04877093|DRUG|Clonidine Pill|The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
57767514|NCT04877093|OTHER|Placebo|Blinded placebo capsules will be provided to participants.
57767515|NCT01654991|BEHAVIORAL|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
57767516|NCT01654991|BEHAVIORAL|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
57767517|NCT02581332|BEHAVIORAL|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
57767518|NCT04000594|DRUG|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
57767519|NCT04181840|DIAGNOSTIC_TEST|Blood and faeces tests|During V1 - Laboratory tests, particularly for calprotectin concentration assessment
57767520|NCT04181840|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of anal sphincter muscles will be measured
57767521|NCT04181840|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
57767522|NCT04181840|DIAGNOSTIC_TEST|Transanal ultrasonography|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
57767523|NCT04181840|DIAGNOSTIC_TEST|Anorectal manometry|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
57767524|NCT04181840|OTHER|Determining the degree of sphincter injury|During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
57767525|NCT03075241|DRUG|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
57767526|NCT03075241|DRUG|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
57767527|NCT03075241|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
57961286|NCT03315923|DRUG|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
57961287|NCT03315923|DRUG|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
57961288|NCT03790683|DEVICE|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
57961289|NCT03790683|DEVICE|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
57961290|NCT03923205|OTHER|Dietary Intervention|The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
57961291|NCT04223960|DRUG|EA1080|EA1080 Formulation A.
57961292|NCT04223960|DRUG|EA1080|EA1080 Formulation B.
57767528|NCT01129505|BEHAVIORAL|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
57767529|NCT06416813|PROCEDURE|GDMT+DCB|Preventive Intervention on Eligible Vulnerable Plaques Using DCB
57767530|NCT03634501|BIOLOGICAL|Activated NK|Cell suspension
57767531|NCT04275843|DIETARY_SUPPLEMENT|Traditional Diet|Consuming an traditional whole foods based diet for 4 weeks.
57767532|NCT04275843|DIETARY_SUPPLEMENT|Modern Diet|Consuming an processed formulation of the traditional diet for 4 weeks.
57767533|NCT05016544|DRUG|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
57767534|NCT05016544|DRUG|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
57767535|NCT03711474|DRUG|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
57767536|NCT03711474|DRUG|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgey
57767537|NCT04278378|DIETARY_SUPPLEMENT|Riboflavin|1.6 mg riboflavin / day for 24 weeks
58457902|NCT05824364|OTHER|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
58457903|NCT02492178|DRUG|Intrarectal artesunate|
57767538|NCT04278378|DIETARY_SUPPLEMENT|Folic acid|0.4 mg folic acid / day for 24 weeks
57767539|NCT04278378|DIETARY_SUPPLEMENT|Placebo|
57767540|NCT00102479|DRUG|Aripiprazole|
57767541|NCT03806504|OTHER|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
57767542|NCT03806504|OTHER|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
57767543|NCT00621296|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
57767544|NCT04404088|DRUG|Acalabrutinib|Given PO
57767545|NCT04404088|DRUG|Lenalidomide|Given PO
57767546|NCT04404088|BIOLOGICAL|Rituximab|Given IV
57767547|NCT02192775|DRUG|MV-NIS|one dose in conjunction with a 4 day course intravenously
58457904|NCT02492178|DRUG|Intravenous artesunate|
58457905|NCT02492178|DRUG|Intravenous quinine|
58457906|NCT06061952|BEHAVIORAL|Customized Adherence Enhancement for Schizophrenia (CAE-S)|6-session series spaced out over approximately 6-10 weeks
58457907|NCT06061952|OTHER|Enhanced Treatment as Usual (eTAU)|eTAU participants will view a pre-taped series of 6 videos
57767548|NCT04437225|DIETARY_SUPPLEMENT|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
57767549|NCT04437225|OTHER|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
57767550|NCT04437225|OTHER|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
57767551|NCT04437225|OTHER|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
57767552|NCT03560245|DRUG|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
57767553|NCT03560245|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
58457908|NCT03771755|DRUG|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
58457909|NCT03771755|DRUG|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
58457910|NCT03984110|DRUG|Ozurdex|Intravitreal injection
58457911|NCT03984110|DRUG|Eylea|Intravitreal injection
57767554|NCT06361667|OTHER|Arts|Arts (music, cinema, dance).
57767555|NCT00960752|DRUG|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
57767556|NCT00960752|DRUG|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
57767557|NCT00960752|DRUG|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
57767558|NCT03659253|DIAGNOSTIC_TEST|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
57961293|NCT04223960|DRUG|EA1080|EA1080 Formulation C.
57961294|NCT04223960|DRUG|EA1080|EA1080 Formulation D.
57961295|NCT04223960|DRUG|EA1080-matching placebo|EA1080-matching placebo.
57961296|NCT04223960|DRUG|EA1080|EA1080 Formulation E.
58457912|NCT02903160|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
58457913|NCT02903160|DRUG|Prednisone|5 mg PO twice a day
58457914|NCT02903160|DRUG|Radium-223 dichloride|50 kBq/kg IV monthly
58457915|NCT02903160|DRUG|cabazitaxel|25 mg/m2 IV every 3 weeks
58457916|NCT02903160|DRUG|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
58457917|NCT02903160|DRUG|Enzalutamide|160 mg PO daily
57767559|NCT03659253|PROCEDURE|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
57767560|NCT03659253|PROCEDURE|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
57767561|NCT03659253|BEHAVIORAL|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
57767562|NCT03659253|PROCEDURE|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
57767563|NCT02487550|BIOLOGICAL|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
57767564|NCT02487550|BIOLOGICAL|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
57767565|NCT02536001|DEVICE|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
57767566|NCT02536001|DEVICE|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
57767567|NCT00157807|PROCEDURE|bipolar radiofrequency ablation of persistent and permanent AF|
57767568|NCT04804774|BEHAVIORAL|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
57767569|NCT05633407|DRUG|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
57767570|NCT05633407|DRUG|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
57767571|NCT05304715|DRUG|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
57767572|NCT05304715|DRUG|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
57767573|NCT03355755|DEVICE|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
57767574|NCT02076074|RADIATION|accelerated partial breast irradiation|Undergo HG-PBI
57767575|NCT02372864|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
57767576|NCT02873026|DRUG|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
57767577|NCT06329674|DRUG|AJU-A51|Subjects take the investigational products once a day for 24 weeks.
58457918|NCT00793858|DRUG|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
58457919|NCT01813396|OTHER|joint mobilization plus massage|
57767578|NCT06329674|DRUG|A51R2|Subjects take the investigational products once a day for 24 weeks.
57767579|NCT06329674|DRUG|A51R3|Subjects take the investigational products once a day for 24 weeks.
58457920|NCT01813396|OTHER|joint mobilization/shoulder physical activity guide|
58457921|NCT03776695|BIOLOGICAL|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
58457922|NCT03776695|OTHER|Placebo|0.9% Saline
57767580|NCT06329674|DRUG|AJU-A51 Placebo|Subjects take the investigational products once a day for 24 weeks.
57767581|NCT06329674|DRUG|A51R2 Placebo|Subjects take the investigational products once a day for 24 weeks.
57767582|NCT02206022|DRUG|Remifentanil|Pain's evaluation for Remifentanil Group
57767583|NCT02206022|DRUG|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
57767584|NCT06220383|PROCEDURE|Hall technique|Prepless crown technique
57767585|NCT06220383|PROCEDURE|Conventional technique|1 or 1,5 mm preparation on mesial, distal and occlusal of the tooth
58457923|NCT01538069|OTHER|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
57767586|NCT04139148|DEVICE|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
57767587|NCT04139148|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
57767588|NCT04762225|BIOLOGICAL|RPTR-168|Escalating doses of RPTR-168 as a monotherapy
57767589|NCT04095221|DRUG|Prexasertib|"DOSE LEVELS FOR PATIENTS \> 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
57767590|NCT04095221|DRUG|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
57767591|NCT02820805|OTHER|Meal Skipping|No meal
57767592|NCT02820805|OTHER|French fries|50g of available carbohydrates meal
57767593|NCT02820805|OTHER|Mashed potatoes|50g of available carbohydrates meal
57767594|NCT02820805|OTHER|Hash browns|50g of available carbohydrates meal
57767595|NCT02820805|OTHER|Rice|50g of available carbohydrates meal
57767596|NCT02820805|OTHER|Beans|50g of available carbohydrates meal
57767597|NCT03862196|BEHAVIORAL|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
57767598|NCT03061448|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
57767599|NCT05431634|DRUG|Experimental drug: ESK-001|Multiple doses of ESK-001
57767600|NCT05431634|OTHER|Placebo|Placebo
57767601|NCT05318534|DRUG|GL-0719|Administration route: intravenous infusion and subcutaneous injection
57767602|NCT05318534|DRUG|Placebo|Administration route: intravenous infusion and subcutaneous injection
57767603|NCT01992705|OTHER|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
57767604|NCT01992705|DRUG|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
57767605|NCT01992705|DRUG|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
57767606|NCT01992705|DRUG|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
57961297|NCT04223960|DRUG|EA1080|EA1080 Formulation F.
57961298|NCT04222595|OTHER|Fluenz Tetra nasal spray suspension|Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
57961299|NCT02228863|OTHER|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
57961300|NCT02228863|OTHER|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
57961301|NCT02228863|OTHER|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
57961302|NCT02228863|OTHER|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
57961303|NCT03089073|DRUG|Desmopressin|60μg or 120μg once daily at bedtime
57961304|NCT03618511|BEHAVIORAL|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
57961305|NCT03618511|BEHAVIORAL|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
57961306|NCT03618511|BEHAVIORAL|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
57961307|NCT03618511|BEHAVIORAL|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
57767607|NCT06172608|OTHER|psychoeducational intervention|". Intervention group (I) will receive psychosocial education which will be consist of two parts. 1) Face to Face 2) Community based intervention.~1. Face to face: This face to face session will be consisting of 30-minute session soon after inclusion into the study. A leaflet consisting of all information will be provided to all the patents taking part in the study.~2. Community Based Intervention: In community based interventions prerecorded videos about all the topics covered in face to face session will be made available to parents via a secure online platform. Parents can easily browse it easily when they need it. These videos will be recorded in local language (Urdu), which is easy to understand for almost all the people."
57767608|NCT06625359|DRUG|Thiotepa in conditioning before transplantation|"For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen."
57767609|NCT03692221|DRUG|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
57767610|NCT03692221|DRUG|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
57767611|NCT03692221|OTHER|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
57767612|NCT03062059|DRUG|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
57767613|NCT03062059|OTHER|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
57767614|NCT03651063|OTHER|social robot|Reach To Grasp games with a social robot
57767615|NCT03651063|OTHER|computer group|reach to grasp games with a computer screen
57767616|NCT00977496|PROCEDURE|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
57767617|NCT02128256|DEVICE|Cerament G|
57767618|NCT02419729|DEVICE|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
57767619|NCT02419729|DRUG|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
57767620|NCT02419729|DRUG|Placebo of Estrogen|Placebo of topical estrogen cream.
57767621|NCT02419729|DEVICE|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
57767622|NCT03581123|BEHAVIORAL|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
57767623|NCT03581123|OTHER|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
57767624|NCT03581123|COMBINATION_PRODUCT|SMT + SSM|Combination Treatment
57767625|NCT03581123|DRUG|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
57767626|NCT05036928|DIAGNOSTIC_TEST|Monocyte distribution width (MDW）|All enrolled patients will receive test with MDW.
57767627|NCT02568579|PROCEDURE|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
57767628|NCT01032044|DEVICE|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
57767629|NCT01032044|DEVICE|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
57767630|NCT02091739|DRUG|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
57767631|NCT02091739|DRUG|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
57767632|NCT02091739|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
57767633|NCT00003344|DRUG|irinotecan hydrochloride|
57767634|NCT00003344|RADIATION|radiation therapy|
57767635|NCT03820479|OTHER|Protocol|Best practice of protocol
57767636|NCT04772053|PROCEDURE|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
57767637|NCT06432660|OTHER|Data collection|Information about radiation therapy via eye plaque brachytherapy and follow up
57767638|NCT04813601|DEVICE|ATLAS 2030|The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
57767639|NCT01468779|DIETARY_SUPPLEMENT|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
57767640|NCT01468779|DIETARY_SUPPLEMENT|Sugar pill|
57767641|NCT04454086|OTHER|Aerobic Exercise|Undergo aerobic exercise
57767642|NCT04454086|OTHER|Exercise Counseling|Receive behavioral activity counseling
57767643|NCT04454086|OTHER|Nutritional Assessment|Receive nutritional counseling
57767644|NCT04454086|OTHER|Quality-of-Life Assessment|Ancillary studies
57767645|NCT04454086|OTHER|Questionnaire Administration|Ancillary studies
57767646|NCT04454086|OTHER|Resistance Training|Undergo resistance exercises
57767647|NCT05716620|DIAGNOSTIC_TEST|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
57767648|NCT05434221|OTHER|COPE|"The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months."
57767649|NCT03325205|OTHER|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
57767650|NCT03325205|OTHER|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
57767651|NCT01905254|DEVICE|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
57767652|NCT01905254|OTHER|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
57767653|NCT04169919|DRUG|Povidone-Iodine|Povidone-Iodine 5% eye wash
57767654|NCT04169919|DRUG|Normal Saline Flush|Normal Saline eye wash
57767655|NCT02974530|OTHER|Neurological evaluation|
57767656|NCT02974530|OTHER|Laryngological evaluation|
57767657|NCT02974530|OTHER|MRI evaluation|
57767658|NCT02974530|OTHER|Breathing investigation|
57767659|NCT02974530|OTHER|MRI and articulatory investigation|
57767660|NCT02974530|OTHER|Postural investigation|
57767661|NCT02974530|OTHER|Voice and soundscape investigation|
57767662|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
57767663|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
57767664|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
57767665|NCT02875834|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
57767666|NCT01556698|DRUG|NVN1000|
57767667|NCT01556698|DRUG|Vehicle|Placebo
57767668|NCT03313102|BIOLOGICAL|blood samples|sample of 16 blood tubes
57767669|NCT01377558|OTHER|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
57767670|NCT01377558|OTHER|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
57767671|NCT01377558|OTHER|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
57767672|NCT01779479|DRUG|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
57767673|NCT01779479|DRUG|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
57767674|NCT01119014|DRUG|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
57767675|NCT01119014|DRUG|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
57767676|NCT00981396|BEHAVIORAL|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
57767677|NCT00981396|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
57767678|NCT02111226|OTHER|SMS text messaging|short message service
57767679|NCT03056664|PROCEDURE|Routine drainage surgery|
57767680|NCT03056664|BIOLOGICAL|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
57767681|NCT03056664|BIOLOGICAL|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
57767682|NCT03056664|OTHER|placebo|NS injection instead of MSC
57767683|NCT06625190|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
57767684|NCT06625190|DRUG|Zoledronic acid|"All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion."
57767685|NCT02122653|OTHER|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
57767686|NCT02122653|DEVICE|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
57767687|NCT00206154|DRUG|Budesonide/formoterol pMDI|
57767688|NCT00206154|DRUG|Budesonide pMDI|
57767689|NCT00206154|DRUG|Formoterol Turbuhaler|
57767690|NCT03086018|DEVICE|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
57767691|NCT02260505|DRUG|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
57767692|NCT03607825|DEVICE|Neurapheresis System|CSF filtration system and lumbar catheter
57767693|NCT03846414|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
57767694|NCT03987126|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
57767695|NCT03987126|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
57767696|NCT01720784|DIETARY_SUPPLEMENT|Alginate dietary fiber|
57767697|NCT01720784|DIETARY_SUPPLEMENT|Placebo|
57767698|NCT01751230|BEHAVIORAL|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
57767699|NCT00077311|BIOLOGICAL|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL
57767700|NCT00077311|BIOLOGICAL|pegfilgrastim|6 mg sub Q day 2 of each cycle
57767701|NCT00077311|DRUG|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
57767702|NCT00077311|DRUG|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
57767703|NCT00077311|DRUG|BNP7787|40 g IV over 30 min Day 1 of each cycle
57767704|NCT03429790|COMBINATION_PRODUCT|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
58457924|NCT01538069|OTHER|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
57767705|NCT03429790|COMBINATION_PRODUCT|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
57767706|NCT03555630|DIAGNOSTIC_TEST|Thromboelastogram|Blood sample processing for thromboelastogram
57767707|NCT04117269|DEVICE|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
57767708|NCT03556358|BIOLOGICAL|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
57767709|NCT03556358|BIOLOGICAL|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
57767710|NCT03556358|DRUG|Paclitaxel|175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
58457925|NCT01538069|OTHER|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
57767711|NCT03556358|DRUG|Epirubicin|75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
57767712|NCT03556358|DRUG|Cyclophosphamide|600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
57767713|NCT02961881|DRUG|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
57767714|NCT06525558|PROCEDURE|Intestinal resection|This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
57767715|NCT00005028|DRUG|bryostatin 1|
57767716|NCT00005028|DRUG|paclitaxel|
57767717|NCT06625879|PROCEDURE|Serratus Anterior Plane Block (SAPB)|"Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection."
57767718|NCT06625879|PROCEDURE|Midpoint transverse process to pleura (MTP) block|In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
57767719|NCT04114747|OTHER|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
57767720|NCT03657459|OTHER|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
57767721|NCT06369246|DEVICE|Stereotactic Body Radiation Therapy|Undergo Radiation Therapy
57767722|NCT01333878|BIOLOGICAL|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
57767723|NCT04492150|DRUG|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
57767724|NCT04492150|DRUG|Saline|250 mL/hour of normal saline intravenous drip
57767725|NCT01126060|DRUG|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
57767726|NCT01126060|PROCEDURE|Thyroidectomy|surgical removal of bilateral thyroid glands
57767727|NCT00750282|DRUG|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
57767728|NCT02980003|DRUG|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
58457926|NCT03186300|DEVICE|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
58457927|NCT03295396|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
58457928|NCT01548547|OTHER|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
58457929|NCT02418572|DRUG|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
58457930|NCT02418572|DRUG|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
58457931|NCT03520881|OTHER|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
58457932|NCT00466544|DEVICE|Plasmaknife|
58457933|NCT00466544|DEVICE|Monopolar|
58457934|NCT00644358|DRUG|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
58457935|NCT01571102|BEHAVIORAL|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
58457936|NCT01571102|BEHAVIORAL|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
58457937|NCT06394037|PROCEDURE|Active surveillance|Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
58457938|NCT00003574|PROCEDURE|surgical procedure|
57767729|NCT02980003|DRUG|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
57767730|NCT02980003|DRUG|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
57767731|NCT03479190|PROCEDURE|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
57767732|NCT03479190|PROCEDURE|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
57767733|NCT06312982|DRUG|Tislelizumab|Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
57767734|NCT06153823|OTHER|virtual reality glasses|child behavior management will be done by using VR glasses distraction
57767735|NCT06153823|OTHER|Tell Show and Do|child behavior management will be done by using tell show and do technique
57767736|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
58457939|NCT00003574|RADIATION|brachytherapy|
58457940|NCT00003574|RADIATION|intraoperative radiation therapy|
58457941|NCT00003574|RADIATION|iodine I 125|
57767737|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
57767738|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
57767739|NCT01254864|DRUG|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
57767740|NCT01254864|DRUG|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
57767741|NCT01254864|DRUG|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
57767742|NCT01254864|DRUG|Dasatinib|100 mg by mouth each day of a 28 day cycle.
57767743|NCT02142582|DIETARY_SUPPLEMENT|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
57767744|NCT02142582|DIETARY_SUPPLEMENT|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
57767745|NCT00572338|OTHER|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
57767746|NCT00476619|DRUG|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
57767747|NCT06435780|PROCEDURE|DIPRF|Denuded interpositional pedicled rolled flap technique
57767748|NCT01548859|DRUG|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
57767749|NCT01548859|DRUG|Sevoflurane|end tidal concentration of % 0,5-8
57767750|NCT01233609|DRUG|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
57767751|NCT01233609|DRUG|Placebo|Dosage per subject weight- same schedule as the active comparator
57767752|NCT02768558|RADIATION|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
57767753|NCT02768558|DRUG|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
57767754|NCT02768558|DRUG|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
57767755|NCT02768558|DRUG|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
57767756|NCT02768558|OTHER|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
57767757|NCT06376981|DRUG|Hyaluronic acid injection|An injection of 2 ml of Acid hyaluronic
57767758|NCT06376981|DRUG|Corticosteroid injection|An injection of 1 ml of corticosteroids
57767759|NCT06376981|DRUG|Placebo injection|An injection of 2 ml of placebo (physiological serum)
57767760|NCT04183907|BEHAVIORAL|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
57767761|NCT03798704|DIAGNOSTIC_TEST|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
57767762|NCT02667886|DRUG|X4P-001|Continuous, oral dosing
57767763|NCT02667886|DRUG|axitinib|Continuous, oral dosing
57767764|NCT04325087|DEVICE|iTBS|Administration of an iTBS protocol over the dlPFC
57767765|NCT04325087|DEVICE|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
57767766|NCT00557609|DRUG|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
57767767|NCT02481843|OTHER|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
57767768|NCT04619953|OTHER|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
57767769|NCT04619953|OTHER|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
57767770|NCT04619953|OTHER|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
57767771|NCT05032118|DRUG|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
57767772|NCT05032118|DRUG|Propofol|Standard of care titratable propofol infusion.
57767773|NCT05899660|DIETARY_SUPPLEMENT|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
57767774|NCT05899660|DIETARY_SUPPLEMENT|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
57767775|NCT01653808|DEVICE|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
57767776|NCT01653808|PROCEDURE|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
57767777|NCT01653808|PROCEDURE|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
58457942|NCT03833492|BEHAVIORAL|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
57767778|NCT04426084|OTHER|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
57767779|NCT04426084|OTHER|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
57767780|NCT04426084|OTHER|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
57767781|NCT04426084|DRUG|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
57767782|NCT04426084|DRUG|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
57767783|NCT04426084|OTHER|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
57767784|NCT03329430|OTHER|Foot orthoses|Customized foot orthoses
57767785|NCT04107896|DRUG|Silodosin|Cap silodosin
57767786|NCT04107896|DRUG|Tamsulosin|Cap tamsulosin
57767787|NCT06617234|OTHER|Nurse-led Intervention Program|"Nurse-led Intervention Program: This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.~LINEbot Automated Robot System: This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management."
57767788|NCT06617234|OTHER|LINEbot Automated Robot System|Participants in this group will use the \&amp;#34;LINEbot\&amp;#34; automated robot system, which sends push notifications through the LINE app. The system delivers education messages, exercise guidance, and health tracking prompts. It provides daily reminders for cardiac rehabilitation participation, as well as customized messages on health management, such as diet, medication, and self-care. The system also allows users to log health data like blood pressure and heart rate.
57767789|NCT03424486|OTHER|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
57767790|NCT04168372|OTHER|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
57767791|NCT04168372|OTHER|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
57767792|NCT04168372|OTHER|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
57767793|NCT04168372|OTHER|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
57767794|NCT01099930|OTHER|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
57767795|NCT01099930|OTHER|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
57767796|NCT03604757|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
57767797|NCT03604757|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
57767798|NCT02819856|DRUG|Placebo|0 mg SPI-1005 bid po x 21d
57767799|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
57767800|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
57767801|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
57767802|NCT02011425|DEVICE|mandibular advancement appliance|mandibular advancement appliance
57767803|NCT02689934|DIETARY_SUPPLEMENT|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
57767804|NCT02689934|DIETARY_SUPPLEMENT|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
57767805|NCT00248300|OTHER|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
57767806|NCT00284908|DRUG|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
57767807|NCT05013866|PROCEDURE|Repair resin composite proximal|Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
57767808|NCT00979602|BIOLOGICAL|GSK2340274A|One intramuscular injection
57767809|NCT00979602|BIOLOGICAL|GSK2340273A|One intramuscular injection
57767810|NCT00400543|DEVICE|Continuous positive airway pressure (CPAP)|
57767811|NCT06091657|DRUG|Ketamine Hydrochloride|intravenous injection
57767812|NCT02220504|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
57767813|NCT02220504|OTHER|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
57767814|NCT01211236|OTHER|application of wound dressing made of bio-bags (vitapads) containing maggots|
57767815|NCT01211236|OTHER|application of classical hydrogel/alginate wound dressing|
58457943|NCT06143358|DRUG|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
57767816|NCT03313258|DEVICE|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
57767817|NCT03313258|DEVICE|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
57767818|NCT05907460|DEVICE|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
57767819|NCT01412814|DEVICE|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
57767820|NCT01412814|OTHER|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
57767821|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
57767822|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
58457944|NCT06143358|OTHER|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
57767823|NCT03560258|BIOLOGICAL|Full-length p55^gag pDNA vaccine|4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
57767824|NCT03560258|BIOLOGICAL|Placebo|1 mL placebo administered by one injection/electroporation
57767825|NCT00714532|BEHAVIORAL|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
57767826|NCT00714532|BEHAVIORAL|Enhanced Expert System|"The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
57767827|NCT06625346|DRUG|Fixed-Dose Combination of Amlodipine/Valsartan|Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
57767828|NCT01006317|BEHAVIORAL|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
57767829|NCT01006317|BEHAVIORAL|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
58129367|NCT01890239|OTHER|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
58457945|NCT04551040|DRUG|Terazosin|Terazosin 1 mg oral capsule
58457946|NCT04484558|DRUG|Actilyse|Infusion
58457947|NCT02971917|RADIATION|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
58457948|NCT02971917|RADIATION|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image"
57767830|NCT01006317|OTHER|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
57767831|NCT05423327|PROCEDURE|No Intervention|Single blood draw
57767832|NCT04924686|OTHER|Observational studies, no intervention|Observational studies, no intervention
57767833|NCT06280495|DRUG|Oxaliplatin|5 mg/m2 IV on day 1
57767834|NCT06280495|DRUG|Fluorouracil|400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
57767835|NCT06280495|DRUG|Serplulimab|200 mg IV infusion on day 1
57767836|NCT06280495|DRUG|Bevacizumab|5 mg/kg IV infusion on day 1
57767837|NCT05815901|DRUG|Epaminurad 6 mg|Epaminurad 6 mg tablet
57767838|NCT05815901|DRUG|Epaminurad 9 mg|Epaminurad 9 mg tablet
57767839|NCT05815901|DRUG|Febuxostat 40 mg|Febuxostat 40 mg tablet
57767840|NCT05815901|DRUG|Febuxostat 80 mg|Febuxostat 80 mg tablet
57767841|NCT05815901|DRUG|Epaminurad 6 mg placebo|Placebo tablet
57767842|NCT05815901|DRUG|Epaminurad 9 mg placebo|Placebo tablet
57767843|NCT05815901|DRUG|Febuxostat 40 mg placebo|Placebo tablet
57767844|NCT05815901|DRUG|Febuxostat 80 mg placebo|Placebo tablet
57767845|NCT03211715|OTHER|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
57767846|NCT02900612|OTHER|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
57767847|NCT02900612|OTHER|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
57767848|NCT02900612|OTHER|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
57767849|NCT00000508|BEHAVIORAL|smoking cessation|
57767850|NCT00000508|BEHAVIORAL|diet, reducing|
57767851|NCT00000508|BEHAVIORAL|exercise|
57767852|NCT00000508|BEHAVIORAL|diet, fat-restricted|
57767853|NCT04922190|BEHAVIORAL|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
57767854|NCT00674323|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
57767855|NCT00674323|DRUG|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
57767856|NCT04733911|OTHER|75 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
57767857|NCT04733911|OTHER|150 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
57767858|NCT04733911|OTHER|300 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
58129368|NCT01659307|DRUG|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
58129369|NCT01659307|DRUG|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
58129370|NCT01659307|DRUG|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
58129371|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
57767859|NCT00179712|DRUG|CC-5013|
57767860|NCT00179712|DRUG|topotecan|
57767861|NCT01621204|DRUG|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
57767862|NCT01621204|DRUG|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
57767863|NCT00233441|DRUG|CELIVARONE (SSR149744C)|
57767864|NCT00010439|DRUG|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
57767865|NCT01091896|DRUG|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
57767866|NCT01091896|DRUG|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
57767867|NCT04570995|DIETARY_SUPPLEMENT|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
57767868|NCT04570995|DIETARY_SUPPLEMENT|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
57767869|NCT00888758|DEVICE|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
57767870|NCT00888758|DEVICE|everolimus|200 patients with STEMI will be treated with PROMUS DES.
57767871|NCT02772575|PROCEDURE|Hepatic trans-arterial embolization (TAE)|
57767872|NCT02772575|DEVICE|MRI/CT scan|
57767873|NCT02772575|PROCEDURE|biopsy|
57767874|NCT02772575|OTHER|blood draw|
57767875|NCT00004202|DRUG|carboplatin|
57767876|NCT00004202|DRUG|chemotherapy|
57767877|NCT00004202|DRUG|efaproxiral|
57767878|NCT00004202|DRUG|paclitaxel|
57767879|NCT00004202|RADIATION|radiation therapy|
57767880|NCT00174603|DRUG|quetiapine|
57767881|NCT05620901|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
57767882|NCT05620901|DRUG|Pred Forte|To treat perioperative ocular inflammation and pain;
57767883|NCT05016414|OTHER|Lower body negative pressure|lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
57767884|NCT05303597|DIAGNOSTIC_TEST|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
57767885|NCT00136032|DRUG|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
57767886|NCT00136032|DRUG|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
57767887|NCT01959191|DRUG|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
57767888|NCT01414426|DRUG|vandetanib|Given PO
57767889|NCT01414426|OTHER|placebo|Given PO
57767890|NCT01414426|OTHER|immunohistochemistry staining method|Correlative studies
57767891|NCT01414426|OTHER|laboratory biomarker analysis|Correlative studies
57767892|NCT01414426|PROCEDURE|biopsy|Correlative studies
57767893|NCT01414426|OTHER|pharmacological study|Correlative studies
58457949|NCT02971917|RADIATION|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
58457950|NCT01882673|BEHAVIORAL|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
57767894|NCT02477397|DRUG|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
57767895|NCT02477397|DRUG|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
57767896|NCT05520502|OTHER|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
57767897|NCT03772951|OTHER|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
57767898|NCT03772951|DRUG|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
57767899|NCT01678443|BIOLOGICAL|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
57767900|NCT01678443|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
57767901|NCT01678443|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
57767902|NCT02446925|DEVICE|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
57767903|NCT02446925|DEVICE|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
57767904|NCT03394456|OTHER|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
58457951|NCT01882673|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
57767905|NCT03394456|OTHER|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
57767906|NCT02746042|DRUG|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
57767907|NCT02746042|DRUG|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
57767908|NCT06383325|COMBINATION_PRODUCT|Chemotherapy|Detection of hepatotoxicity in acute leukemia patients during chemotherapy
57767909|NCT00885352|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
57767910|NCT00885352|DRUG|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
57767911|NCT00885352|DRUG|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
57767912|NCT00885352|DRUG|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
57767913|NCT00885352|DRUG|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
58457952|NCT03400618|OTHER|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
58457953|NCT03400618|OTHER|Higher carbohydrate diet|50 E % carbohydrates included in the diet
58457954|NCT05599308|DEVICE|OMRON blood pressure monitor with AFib screening feature|Blood pressure measurement by an oscillometric blood pressure monitor
57767914|NCT03781089|DRUG|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
57767915|NCT00805493|DRUG|Riluzole|
57767916|NCT00453479|DRUG|GSK233705B|
57767917|NCT02086162|BEHAVIORAL|Web-based motivational decision support system|
57767918|NCT02086162|BEHAVIORAL|NCI Education|
57767919|NCT01778946|DRUG|Low Dose Nicotine (7mg)|
57767920|NCT01778946|DRUG|Moderate Dose Nicotine (14mg)|
57767921|NCT01761539|OTHER|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
57767922|NCT01761539|OTHER|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
57767923|NCT02827318|DIETARY_SUPPLEMENT|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
57767924|NCT02827318|DIETARY_SUPPLEMENT|Glucose|75g Glucose (high glycaemic load intervention)
57767925|NCT02827318|DIETARY_SUPPLEMENT|Sweetened water|Sweetened water will be used as a control
57767926|NCT02571946|RADIATION|Proton beam therapy|
57767927|NCT02762838|BIOLOGICAL|BCD-055|BCD-055 is infliximab biosimilar
57767928|NCT02762838|BIOLOGICAL|Remicade®|
57767929|NCT02762838|DRUG|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
57767930|NCT02762838|DRUG|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
57767931|NCT06351644|DRUG|ON 123300|"dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study."
57767932|NCT06351644|DRUG|Dexamethasone|Weekly oral dexamethasone 20mg
57767933|NCT06014736|DRUG|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
57767934|NCT06014736|DRUG|Placebo|Placebo contains only excipients.
57767935|NCT00273559|DRUG|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
57767936|NCT05434299|DRUG|TFX05-01|TFX05-01 for intravenous
57767937|NCT00892190|DRUG|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
58457955|NCT05599308|DEVICE|Microlife WatchBP Home A|Blood pressure measurement by an oscillometric blood pressure monitor
57767938|NCT00892190|DRUG|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
57767939|NCT02429687|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
57767940|NCT02429687|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
57767941|NCT02429687|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
57767942|NCT02429687|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
57767943|NCT02429687|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
57767944|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
57767945|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk with added egg yolk|Buttermilk with added egg yolk
57767946|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
57767947|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
57767948|NCT00544544|DRUG|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
57767949|NCT06561217|OTHER|Chart review|Chart review
57767950|NCT03708588|DRUG|Ticagrelor|Chewed
57767951|NCT03708588|DRUG|Ticagrelor|Integral
57767952|NCT02978053|BEHAVIORAL|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
57767953|NCT02978053|BEHAVIORAL|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
57767954|NCT02207439|DRUG|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
57767955|NCT02207439|OTHER|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
57767956|NCT02379559|BEHAVIORAL|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
57767957|NCT02379559|BEHAVIORAL|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
57767958|NCT03248609|OTHER|Milano grapes|Milano grapes to test post-prandial glycemic response
57767959|NCT03248609|OTHER|Table grapes|Table grapes to test post-prandial glycemic response
57767960|NCT03248609|OTHER|Grape juice|Grape juice to test post-prandial glycemic response
57767961|NCT03248609|OTHER|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
58457956|NCT03167385|DRUG|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
58457957|NCT00657540|DRUG|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
57767962|NCT00308737|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
57767963|NCT00308737|DRUG|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
57767964|NCT04692844|DRUG|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
57767965|NCT04692844|DRUG|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
57767966|NCT03491098|DRUG|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
57767967|NCT03491098|DRUG|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
57767968|NCT03491098|DRUG|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
57767969|NCT05531019|DIETARY_SUPPLEMENT|Echinochrome A|Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.
57767970|NCT05531019|OTHER|Control|Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
57767971|NCT04595539|BEHAVIORAL|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
57767972|NCT02069574|PROCEDURE|non-surgical periodontal therapy|
57767973|NCT03267823|DIAGNOSTIC_TEST|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
57767974|NCT00994773|DRUG|Simvastatin|daily doses for 14 days
57767975|NCT00994773|DRUG|Tenofovir|
57767976|NCT00994773|DRUG|Entecavir|Entecavir
57767977|NCT01570595|BEHAVIORAL|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
57767978|NCT01570595|BEHAVIORAL|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
57767979|NCT01821898|DRUG|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
57767980|NCT01821898|OTHER|Elimination diet|This group will receive an elimination diet
57767981|NCT02862041|DEVICE|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
57767982|NCT02862041|DEVICE|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
57767983|NCT00672958|DRUG|Vortioxetine|Encapsulated immediate-release tablets.
57767984|NCT00672958|DRUG|Placebo|Vortioxetine placebo-matching capsules.
57767985|NCT03324503|DRUG|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
57767986|NCT05749601|OTHER|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
57767987|NCT05749601|OTHER|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
57767988|NCT05749601|OTHER|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
57767989|NCT00460317|DRUG|AMG 706|125 mg QD orally every day
57767990|NCT00460317|DRUG|placebo|125 mg QD orally every day
57767991|NCT00460317|DRUG|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
57767992|NCT00460317|DRUG|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
57767993|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
57767994|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
57767995|NCT02671318|DRUG|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
57767996|NCT02671318|DRUG|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
57767997|NCT00984360|DRUG|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
58457958|NCT00657540|DRUG|Saline|50 mL of saline infused over 10 minutes
57767998|NCT03800979|DRUG|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
57767999|NCT03120208|BEHAVIORAL|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
57768000|NCT03120208|BEHAVIORAL|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
57768001|NCT03120208|BEHAVIORAL|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
57768002|NCT03120208|BEHAVIORAL|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
57768003|NCT03120208|BEHAVIORAL|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
57768004|NCT05962320|OTHER|Education and counselling|Education and counselling of patients and their parents
57768005|NCT05962320|OTHER|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
57768006|NCT05962320|OTHER|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
57768007|NCT05962320|OTHER|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
57768008|NCT05962320|OTHER|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
57768009|NCT05962320|OTHER|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
57768010|NCT05962320|OTHER|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
57768011|NCT05962320|OTHER|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
57768012|NCT05962320|OTHER|Management of thirsty|Management of thirsty
57768013|NCT05962320|OTHER|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
57768014|NCT00315588|DRUG|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
57768015|NCT06143657|DIAGNOSTIC_TEST|Automated Gram Staining Machine analysis|Measure urine and sputum specimens using this device.
57768016|NCT00381355|PROCEDURE|Written Action Plan for Acute Asthma|
57768017|NCT06419218|BEHAVIORAL|School meal messages|Messages focused on the benefits of children consuming school lunch and breakfast, using text and images developed based on parent interviews. Participants will view a total of 10 messages.
57768018|NCT06419218|BEHAVIORAL|Control (neutral) messages|Control messages approximately matched to the intervention messages on length and design, but discussing a neutral topic unrelated to school meals (reading). Participants will view a total of 10 messages.
57768019|NCT02386917|PROCEDURE|Gastric bypass|Weight loss surgery
57768020|NCT02386917|BEHAVIORAL|Very low calorie diet|Non-surgical weight loss procedure
57768021|NCT05367609|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
57768022|NCT05677802|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57768023|NCT05677802|OTHER|Medical Chart Review|Undergo medical cart review
57768024|NCT05677802|PROCEDURE|Stress Management Therapy|Receive biobehavioral stress reduction intervention
57768025|NCT05677802|OTHER|Survey Administration|Ancillary studies
57768026|NCT00715572|DRUG|thyroxine|monotherapy with thyroxine
57768027|NCT00715572|DRUG|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
57768028|NCT04588818|DRUG|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
57768029|NCT05650944|DIAGNOSTIC_TEST|Hemogram|Sysmex XN-1000 hematological analyzer
57768030|NCT01302938|DRUG|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
57768031|NCT01302938|DRUG|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
57768032|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a prefilled syringe presentation|efgartigimod PH20 SC as a prefilled syringe presentation
57768033|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a vial + syringe presentation|efgartigimod PH20 SC as a vial + syringe presentation
57768034|NCT06124742|DEVICE|clear aligners|taste perception will be evaluated before and after using clear aligners.
57768035|NCT01916941|DRUG|Prazosin|
57768036|NCT01916941|DRUG|Placebo|
57768037|NCT00548067|DRUG|Valsartan/hydrochlorothiazide (HCTZ)|
57768038|NCT00548067|DRUG|Valsartan/amlodipine|
57768039|NCT00548067|DRUG|Amlodipine/hydrochlorothiazide(HCTZ)|
57768040|NCT00548067|DRUG|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
57768041|NCT03791203|BEHAVIORAL|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
57768042|NCT02621736|OTHER|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
57768043|NCT01392716|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
57768044|NCT03659643|DIAGNOSTIC_TEST|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
57768045|NCT05427513|DRUG|Tranexamic acid injection|will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss
57768046|NCT05427513|OTHER|normal saline|normal saline will be injected to ensure placebo
57768047|NCT01207323|DRUG|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
57768048|NCT05690061|DIETARY_SUPPLEMENT|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
57768049|NCT05690061|DIETARY_SUPPLEMENT|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
57768050|NCT05690061|DIETARY_SUPPLEMENT|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
57768051|NCT03027687|DEVICE|tDCS|tDCS is an electrical brain stimulation method
57768052|NCT05538182|DEVICE|Spectacles|Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
57768053|NCT02287116|DEVICE|Easy Flow system and INCA® nasal cannulae set|
57768054|NCT03295266|DRUG|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
57768055|NCT03696719|DEVICE|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
57768056|NCT03696719|BIOLOGICAL|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
57768057|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
57768058|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
57768059|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
57768060|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
57768061|NCT02899364|DRUG|Sodium thiosulfate|see description under experimental arm
57768062|NCT02899364|DRUG|Sodium chloride 0.9%|see description under placebo comparator arm
57768063|NCT02899364|PROCEDURE|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
57768064|NCT02899364|OTHER|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
57768065|NCT02687412|PROCEDURE|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
57768066|NCT02687412|PROCEDURE|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
57768067|NCT02687412|PROCEDURE|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
57768068|NCT02687412|PROCEDURE|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
57768069|NCT02687412|PROCEDURE|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
57768070|NCT02687412|PROCEDURE|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
57768071|NCT02687412|PROCEDURE|Postoperative glycaemic control|Postoperative glycaemic control;
57768072|NCT02687412|PROCEDURE|postoperative nausea and vomiting (PONV) control;|
57768073|NCT02687412|PROCEDURE|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
57768074|NCT02687412|PROCEDURE|pre-operative fasting at least 8h|
57768075|NCT02687412|PROCEDURE|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
57768076|NCT02687412|PROCEDURE|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
57768077|NCT05059912|BIOLOGICAL|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
57768078|NCT02221245|PROCEDURE|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
57768079|NCT01619657|DRUG|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
57768080|NCT01619657|DRUG|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
57768081|NCT02128165|DEVICE|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
57768082|NCT02128165|DEVICE|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
58457959|NCT06423365|OTHER|Virtual Statin Management (VSM)|"VSM is a web-based decision aid to help manage statin therapy after experiencing muscle pain perceived to be caused or worsened by their statin therapy. The introduction will feature a brief explanation of the tool and what they can expect. The modules are:~1. General education (lipids, heart disease, medications)~2. Side effects (causes, diagnosis).~3. Statin modifications. VSM will guide patients to understand their lipid-lowering options, particularly their statin options that may best match patients' stated preferences.~4. ASCVD risk \& statin benefit. Finally, the VSM experience will end by providing the patient with a summary of the results of their use of the tool, which can be used during discussions with their healthcare provider. The information gathered from the VSM will remain confidential and will not be disclosed to anyone other than the patient."
58457960|NCT01383603|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
57768083|NCT05942079|OTHER|REİKİ|Reiki is applied as an alternative and complementary treatment method.
57768084|NCT02712398|DEVICE|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
57768085|NCT01617317|DRUG|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
57768086|NCT01617317|DRUG|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
57768087|NCT05164497|OTHER|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
57768088|NCT05164497|OTHER|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
57768089|NCT06546553|DRUG|PF-07826390|PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors
57768090|NCT06546553|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
57768091|NCT06546553|OTHER|SOC (anti-PD-1 + platinum -based chemo)|Standard of Care (anti-PD-1 + platinum -based chemo)
57768092|NCT03311022|DRUG|Nefopam Hydrochloride 30mg Tablets|
57768093|NCT03311022|DRUG|Acupan® 30mg Tablets|
57768094|NCT05114694|PROCEDURE|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
57768095|NCT05114694|PROCEDURE|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
57768096|NCT02341287|DEVICE|Warming hydrogel glove|Subjects wore the warming hydrogel glove in either the first or second two-week period.
57768097|NCT02341287|DEVICE|Non-thermal glove|Subjects wore the non-thermal glove in either the first or second two-week period.
57768098|NCT03088358|DRUG|TeaRx|
57768099|NCT03088358|DRUG|Enoxaparin|
57768100|NCT06062901|OTHER|Educational Intervention|Receive educational intervention
57768101|NCT06062901|OTHER|Interview|Participate in one-on-one interview
57768102|NCT06062901|OTHER|Survey Administration|Ancillary studies
57768103|NCT06561230|OTHER|Chart review|Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
58457961|NCT03710148|OTHER|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet \& drinking water, and of excessive iodine intake from drinking water
57768104|NCT00829205|BIOLOGICAL|filgrastim|
57768105|NCT00829205|BIOLOGICAL|rituximab|
57768106|NCT00829205|DIETARY_SUPPLEMENT|Se-methyl-seleno-L-cysteine|
57768107|NCT00829205|DRUG|carboplatin|
57768108|NCT00829205|DRUG|etoposide|
57768109|NCT00829205|DRUG|ifosfamide|
57768110|NCT00829205|OTHER|laboratory biomarker analysis|
57768111|NCT00829205|OTHER|pharmacological study|
57768112|NCT00762840|DEVICE|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
57768113|NCT00762840|PROCEDURE|Conventional endodontic procedure|Standard root canal treatment
58129372|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
57768114|NCT01408758|OTHER|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
57768115|NCT01408758|OTHER|No VCRT, only physician counseling at visits|No intervention
57768116|NCT03150927|DIETARY_SUPPLEMENT|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
57768117|NCT03150927|DIETARY_SUPPLEMENT|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
57768118|NCT04671043|DIETARY_SUPPLEMENT|Caffeine and glucose|Caffeine and glucose powder dissolved in water
58129373|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
58129374|NCT03400384|OTHER|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
57768119|NCT04671043|DIETARY_SUPPLEMENT|Glucose alone|Glucose powder dissolved in water
57768120|NCT04671043|DIETARY_SUPPLEMENT|Placebo|Artificial sweetener dissolved in water
57768121|NCT02882711|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
57768122|NCT01850368|RADIATION|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
57768123|NCT04192474|DEVICE|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
58129375|NCT03348943|BEHAVIORAL|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
58129376|NCT03348943|BEHAVIORAL|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
58129377|NCT03348943|BEHAVIORAL|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
58129378|NCT03348943|BEHAVIORAL|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
58129379|NCT03003338|DRUG|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
58129380|NCT03003338|DRUG|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
58129381|NCT01972022|DEVICE|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
58129382|NCT01972022|DEVICE|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
57768124|NCT04297787|DEVICE|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
57768125|NCT05415033|OTHER|BREAST-Q|arabic version of breast questionnaire
57768126|NCT01744925|DRUG|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
57768127|NCT01744925|DRUG|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
57768128|NCT01767935|PROCEDURE|cryosurgery|Undergo cryosurgery
57768129|NCT01767935|RADIATION|radiation therapy|Undergo radiation therapy
57768130|NCT01767935|PROCEDURE|quality-of-life assessment|Ancillary studies
57768131|NCT02421900|OTHER|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
57768132|NCT00201864|DRUG|Exemestane|25 mg orally per day
57768133|NCT00201864|DRUG|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
57768134|NCT00663377|DRUG|losartan|losartan 50-100mg for 16 weeks
57768135|NCT05533359|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
57768136|NCT05533359|BEHAVIORAL|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
57768137|NCT05533359|BEHAVIORAL|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
57768138|NCT05107479|BEHAVIORAL|COVID-19 Vaccine IVR Training|The intervention consists of 5 interactive voice response (IVR) modules conveying information about COVID-19 vaccines and vaccine administration best practices. Module topics include the following: 1) the importance of COVID-19 vaccines and recipient eligibility, 2) overview of and differences between approved COVID-19 vaccines , 3) surveillance of adverse vaccine events, 4) organizing a vaccination site, and safe storage and handling COVID-19 vaccines, and 5) micro planning and communication strategies for COVID-19 vaccination efforts. The training will be offered in five local languages: French, Lingala, Swahili, Kikongo, and Tshiluba.
57768139|NCT05107479|BEHAVIORAL|Control Condition|The control arm will receive the COVID-19 Vaccine IVR Training after an estimated month-long delay. The control arm will be told upon completion of the baseline survey that the training will commence at a later estimated date and will not receive any additional information until the treatment group completes training.
57768140|NCT00010686|DRUG|Dietary Phytoestrogens|
57768141|NCT01003600|BEHAVIORAL|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
57768142|NCT05401032|DRUG|Tamsulosin|Oral medication, once a day for 6 months.
57768143|NCT05401032|DRUG|5-hidroxitriptophan|Oral medication, 3 times a day for 6 months.
57768144|NCT03329521|OTHER|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
57768145|NCT03690934|PROCEDURE|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
57768146|NCT03690934|PROCEDURE|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
57768147|NCT00762021|DEVICE|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
57768148|NCT00762021|DEVICE|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
57768149|NCT04778514|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
57768150|NCT04778514|DRUG|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
57768151|NCT03164941|PROCEDURE|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
57768152|NCT03243643|DRUG|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
58457962|NCT05454774|GENETIC|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
57768153|NCT03243643|DRUG|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
57768154|NCT00002928|DRUG|paclitaxel|
57768155|NCT02040272|PROCEDURE|(Extended) pleurectomy decortication|
57768156|NCT06442540|PROCEDURE|Physical Agents|Hot pack
57768157|NCT06442540|PROCEDURE|Manipulation|HVLA manipulation of SI joint
57961308|NCT03618511|BEHAVIORAL|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
57961309|NCT03618511|BEHAVIORAL|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
57961310|NCT02113631|DRUG|Telaprevir|
57961311|NCT02113631|DRUG|Boceprevir|
57961312|NCT02113631|DRUG|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
57961313|NCT02113631|DRUG|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
58129383|NCT02385097|DRUG|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
58457963|NCT00756249|DRUG|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
58457964|NCT00756249|DRUG|Placebo|Vials with solution for IV infusion
58457965|NCT06473922|PROCEDURE|Reginal anesthesia|General anesthesia
57768158|NCT06442540|PROCEDURE|Core Stability Exercises|Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.
58457966|NCT00587717|DRUG|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
58457967|NCT00587717|DRUG|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
58457968|NCT02655848|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
58457969|NCT02655848|PROCEDURE|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
58457970|NCT02655848|PROCEDURE|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
58457971|NCT03743441|OTHER|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
58457972|NCT03743441|OTHER|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
58457973|NCT03743441|OTHER|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
58457974|NCT03743441|OTHER|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
58457975|NCT00980187|DRUG|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
58457976|NCT00980187|DRUG|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
58457977|NCT03414775|OTHER|Nourish|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
58457978|NCT03414775|OTHER|Pediasure|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
58457979|NCT06181526|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
58457980|NCT06181526|DEVICE|intravenous injection|According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping
58457981|NCT06181526|DEVICE|intrathecal injection|According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.
58457982|NCT03527849|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
58457983|NCT03527849|BEHAVIORAL|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
58457984|NCT00672555|PROCEDURE|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
58457985|NCT00562367|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
58457986|NCT00491465|BEHAVIORAL|Intensive Physical activity|
58457987|NCT00491465|BEHAVIORAL|Control- regular physical activity|
58457988|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
58457989|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
58457990|NCT01431612|DRUG|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
58457991|NCT01431612|DRUG|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
58457992|NCT01431612|DRUG|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
58129384|NCT02385097|DRUG|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
58457993|NCT02718521|PROCEDURE|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
58457994|NCT02718521|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
58457995|NCT02718521|DRUG|0.9% sodium chloride ﬂuid administration|
58457996|NCT02718521|DRUG|isosorbide dinitrate|
58457997|NCT02271464|DRUG|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
58457998|NCT02271464|DRUG|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
57768159|NCT06442540|PROCEDURE|Intramusular electrotherapy|Intramuscular electrotherapy/ 3 sessions per week
57768160|NCT06442540|PROCEDURE|Soft tissue mobility|Stretching and Myofacial Release of piriformis and erector spinae
58129385|NCT01824758|DRUG|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
57768161|NCT03038984|BEHAVIORAL|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
57768162|NCT03038984|BEHAVIORAL|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
57768163|NCT03967990|OTHER|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
57768164|NCT03967990|OTHER|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
57768165|NCT03967990|OTHER|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
57768166|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
57768167|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
57768168|NCT00298142|PROCEDURE|Usual Care provided by a medical doctor (GP or Neurologist)|
57768169|NCT00298142|PROCEDURE|Usual care plus Physio-/ Manual Therapy|
57768170|NCT03116490|PROCEDURE|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
57768171|NCT04725968|PROCEDURE|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
57768172|NCT04071977|DRUG|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
57768173|NCT04071977|OTHER|Placebo|It consists in a capsule with 100 mg of magnesium oxide
57768174|NCT05258123|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract with 360mg was administered
57768175|NCT05258123|DRUG|Placebo oral tablet|Placebo with nine tables was administered
57768176|NCT05890625|OTHER|On going treatment|No additional attempts will be made by the investigator on the cases in the control group. These cases will only benefit from the services in the clinic.
57961314|NCT02163473|PROCEDURE|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
57768177|NCT05890625|OTHER|InT-mAp|InT-mAp, the content of which will be created as a result of the evaluation of the nursing needs of infertile women, consists of a web-based training and online consultancy platform. The treatment plan specific to each participant will be entered into the web base individually, and the participants will be able to follow and manage the treatment protocols and appointments under their own control. InT-mAp is a guide that helps breakers about the intended use, effects, side effects of the drugs under treatment and how to self-administer, especially for women.
57768178|NCT03762629|BEHAVIORAL|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
57768179|NCT02606955|DEVICE|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
57768180|NCT05196048|OTHER|No Intervention|No Intervention
57961315|NCT02163473|PROCEDURE|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
57961316|NCT05086445|DRUG|LY3502970|Administered orally
57961317|NCT05086445|DRUG|Placebo|Administered orally
58129386|NCT01824758|DRUG|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
57961318|NCT03011333|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
57961319|NCT03011333|DRUG|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
57961320|NCT03011333|DRUG|Saline Placebo|Saline placebo via nerve block.
57961321|NCT04415476|DRUG|Assigned Interventions|This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
57961322|NCT04278612|OTHER|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
57961323|NCT03017053|RADIATION|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
57768181|NCT05220007|DIAGNOSTIC_TEST|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
57768182|NCT04342624|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon supplement
57768183|NCT04342624|OTHER|Placebo|Placebo
57768184|NCT02702700|DRUG|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
57768185|NCT02702700|DRUG|Verteporfin|Visudyne® IV 3 mg/m2
57768186|NCT02702700|DEVICE|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
57768187|NCT04810039|OTHER|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
57768188|NCT02800603|BEHAVIORAL|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
57768189|NCT03366220|DRUG|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
57768190|NCT03366220|DRUG|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
57768191|NCT05309460|DRUG|Labetalol Oral Tablet|See Labetalol arm.
57768192|NCT05309460|DRUG|NIFEdipine ER|See Nifedipine arm.
57768193|NCT02603315|OTHER|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
57768194|NCT04407351|DEVICE|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
57768195|NCT04407351|DEVICE|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
57768196|NCT03326947|DRUG|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
57768197|NCT04654247|BEHAVIORAL|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
57768198|NCT04654247|BEHAVIORAL|Control|None feedback.
57768199|NCT06619457|OTHER|Mitopure (Urolithin A) Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
57768200|NCT06619457|OTHER|Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
57768201|NCT06207643|PROCEDURE|carotid endarterectomy|removing carotid artery atheromatous plaque surgically
57768202|NCT01947595|BEHAVIORAL|intensified lifestyle intervention|"* physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
57768203|NCT01947595|BEHAVIORAL|normal lifestyle intervention|"* physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
57768204|NCT01947595|BEHAVIORAL|Single lifestyle advice|"- Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25\> kg/m²)"
57768205|NCT05236621|DRUG|Pomalidomide|4 mg pomalidomide capsules administered orally
57768206|NCT05236621|DRUG|Dexamethasone|40 mg dexamethasone tablets administered orally
57768207|NCT02172300|DRUG|Tiotropium inhalation capsules|
57768208|NCT02172300|DRUG|Placebo inhalation capsules|
58129387|NCT01824758|DRUG|rocuronium|0.05 mg/kg rocuronium
58129388|NCT01824758|DRUG|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
58457999|NCT05261555|DEVICE|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
58458000|NCT03752138|DRUG|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
57768209|NCT05310201|BEHAVIORAL|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
57768210|NCT01354275|OTHER|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
57768211|NCT01354275|OTHER|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
57768212|NCT00221949|DEVICE|Ultrasound|
57768213|NCT01112696|DEVICE|Sensor wear|All subjects to wear sensors
57768214|NCT03584776|DEVICE|Virtual Reality|Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
57768215|NCT03596437|DEVICE|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
57768216|NCT05985603|OTHER|CIMT Group|In this group of patients CIMT technique will be used for treatment
57768217|NCT05985603|OTHER|Mirror Therapy group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
57768218|NCT05761145|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
57768219|NCT05258747|DRUG|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
57768220|NCT05258747|DRUG|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
57768221|NCT01027364|DRUG|Factor IX (rFIXFc)|
58458001|NCT03752138|DRUG|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
57768222|NCT01027364|DRUG|rFIX|
57768223|NCT06162338|BIOLOGICAL|LY-M001 Injection|With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
57768224|NCT03101124|DRUG|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
57768225|NCT03101124|DRUG|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
57768226|NCT03101124|DRUG|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
57768227|NCT01375205|OTHER|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
57768228|NCT01375205|OTHER|Standard of Care|Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
57768229|NCT00421525|BIOLOGICAL|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
57768230|NCT05436379|DEVICE|Theta Burst Stimulation|TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
57768231|NCT04598932|DEVICE|Brillouin microscopy|The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
57961324|NCT03017053|PROCEDURE|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
57961325|NCT05370859|OTHER|There is no intervention for this study|There is no intervention or exposure for this study
57961326|NCT01473797|DRUG|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
57961327|NCT03771365|PROCEDURE|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
58458002|NCT03752138|DRUG|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
58458003|NCT03752138|DRUG|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
57961328|NCT03771365|PROCEDURE|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
57961329|NCT03771365|PROCEDURE|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
57961330|NCT04690972|PROCEDURE|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
57961331|NCT04690972|PROCEDURE|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
57768232|NCT05625581|DRUG|tofacitinib|All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
57768233|NCT02220296|DRUG|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
57768234|NCT02220296|DRUG|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
57768235|NCT02220296|DRUG|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
57768236|NCT02220296|DRUG|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
57768237|NCT03861520|DEVICE|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
57768238|NCT03861520|GENETIC|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
57768239|NCT01913639|DRUG|Regorafenib|
57768240|NCT01913639|DRUG|5-Fluorouracil|
57768241|NCT01913639|DRUG|Leucovorin|
57768242|NCT01913639|DRUG|Oxaliplatin|
57768243|NCT01719237|DRUG|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
57961332|NCT04690972|DIAGNOSTIC_TEST|Blood sample during diagnostic test|Blood sample as part of the care
58458004|NCT03752138|DRUG|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
57768244|NCT01719237|DRUG|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
57768245|NCT01862991|OTHER|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
57768246|NCT01862991|DRUG|Misoprostol|400 mcg buccal misoprostol 90 pre-op
57768247|NCT01862991|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
57768248|NCT01862991|DRUG|Mifepristone|200 mcg Mifepristone orally
57768249|NCT03450681|PROCEDURE|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
57768250|NCT03450681|PROCEDURE|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
58458005|NCT03752138|DRUG|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
57768251|NCT06417541|DIAGNOSTIC_TEST|Diseased patients with an indwelling central venous catheter who is referred to autopsy|Photon counting CT is performed and the results are compared to the results of the autopsy
57768252|NCT06417541|RADIATION|Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast|Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
57768253|NCT02548858|PROCEDURE|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
57768254|NCT02548858|PROCEDURE|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
57768255|NCT05660954|DRUG|Cabozantinib|"* All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose."
57768256|NCT00702416|PROCEDURE|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
57961333|NCT01770925|DEVICE|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
57961334|NCT01770925|DEVICE|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
57961335|NCT01770925|DEVICE|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
57961336|NCT03136315|OTHER|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
58458006|NCT03752138|DRUG|Part 2: TK216|Recommended dose from Part 1.
58458007|NCT01339689|DRUG|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
57768257|NCT00702416|PROCEDURE|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current \<0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
57768258|NCT00702416|DRUG|Ropivacaine|"Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min"
57768259|NCT00702416|DRUG|Paracetamol|1 g iv q8h
57768260|NCT00702416|DRUG|Morphine|5 mg im prn q1h (in the postoperative period)
57768261|NCT00702416|DRUG|Fentanyl|50 µg iv prn (in the intraoperative period)
57768262|NCT00702416|PROCEDURE|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
57768263|NCT00957931|PROCEDURE|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
57768264|NCT00957931|BIOLOGICAL|Mesenchymal Stromal Cells|
57768265|NCT03155230|OTHER|no intervention|no intervention
57768266|NCT05303064|DRUG|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
57768267|NCT05303064|DRUG|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
57768268|NCT05065190|DRUG|nintedanib|nintedanib
57768269|NCT05065190|DRUG|Placebo|Placebo
57768270|NCT02344394|DEVICE|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
58458008|NCT01339689|DRUG|Placebo|capsules, bid, up to 12 weeks
57768271|NCT02344394|DEVICE|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
58458009|NCT04260685|DRUG|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
57768272|NCT02344394|DEVICE|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
57768273|NCT03283696|DRUG|Olaratumab|Administered IV
57768274|NCT03283696|DRUG|Doxorubicin|Administered IV
57768275|NCT03283696|DRUG|Ifosfamide|Administered IV
57768276|NCT03283696|DRUG|Mesna|Administered per standard of care
57768277|NCT00791323|DRUG|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
58458010|NCT04260685|DRUG|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
58458011|NCT03539406|BIOLOGICAL|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
58458012|NCT03539406|DRUG|Chemotherapy|Cyclofosfamide/fludarabine treatment
57768278|NCT00791323|DRUG|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
57768279|NCT02958462|PROCEDURE|Biospecimen Collection|Undergo blood sample, hair follicle, and saliva collection
57768280|NCT02958462|PROCEDURE|Bone Marrow Biopsy|Undergo a bone marrow biopsy
57768281|NCT02958462|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
57768282|NCT02958462|PROCEDURE|Buccal Swab|Undergo a saliva or buccal swab
57768283|NCT02958462|OTHER|Clinical Evaluation|Undergo clinical assessment
57768284|NCT02958462|OTHER|Genetic Counseling|Receive genetic counseling
57768285|NCT02958462|OTHER|Quality-of-Life Assessment|Ancillary studies
57768286|NCT02958462|OTHER|Electronic Health Record Review|Ancillary studies
57768287|NCT00001866|PROCEDURE|horizontal muscles of the eye will be cut and then reattached in the same position|
57768288|NCT06205797|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA"
57768289|NCT06205797|DRUG|Xeomin®|"Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA"
57768290|NCT03841123|OTHER|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
57768291|NCT01098149|OTHER|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
57768292|NCT01394484|OTHER|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
57768293|NCT01394484|DIETARY_SUPPLEMENT|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
57768294|NCT06158763|BEHAVIORAL|Web-based CBT guided self-help Interventions|An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
57768295|NCT04394507|DIAGNOSTIC_TEST|Near-Infrared Fluorescence imaging|.Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.
57768296|NCT04394507|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
57768297|NCT04250337|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
57768298|NCT04250337|OTHER|Placebo|Subcutaneous injection
57768299|NCT04250337|OTHER|Topical Corticosteroid|Topical Corticosteroid
57768300|NCT00409786|BEHAVIORAL|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
57768301|NCT01876563|DIETARY_SUPPLEMENT|vitamin D|one tab 4000 IU/day vitamin D
57768302|NCT01876563|DIETARY_SUPPLEMENT|placebo|one tab per day placebo
57768303|NCT04464616|PROCEDURE|spinal anaesthesia|spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
57768304|NCT02635724|DRUG|Peramivir|
57768305|NCT05121623|OTHER|Questionnaire|Online auto-administered Questionnaire
57768306|NCT03176446|DEVICE|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
57768307|NCT03176446|DEVICE|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
57768308|NCT03176446|DEVICE|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
57768309|NCT03176446|DRUG|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
57768310|NCT03176446|DRUG|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
57768311|NCT06199661|BEHAVIORAL|APEX|Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
57768312|NCT04049903|DRUG|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
57768313|NCT00227500|DRUG|Pravastatin|
57768314|NCT04925674|DRUG|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
57768315|NCT06201221|PROCEDURE|single-port laparoscopy surgery|The two groups underwent different surgical procedures.
57768316|NCT06201221|PROCEDURE|multiport laparoscopy surgery|The two groups underwent different surgical procedures.
57768317|NCT06295614|DEVICE|ARC-IM System implantation|Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
57768318|NCT02492113|PROCEDURE|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
57768319|NCT02492113|PROCEDURE|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
57768320|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
57768321|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
57768322|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
57768323|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
57768324|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
57768325|NCT05080881|DIAGNOSTIC_TEST|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
57768326|NCT02144948|DRUG|e.-coli-nissle|1 ml qd for 24 weeks
57768327|NCT00941564|OTHER|Infant Formula milk based|Consume ad lib
57768328|NCT00941564|OTHER|Infant formula milk based|consume ad lib
57768329|NCT05232513|OTHER|Hand massage|Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
57768330|NCT04182880|DRUG|CPL-01|CPL-01 will be administered
57768331|NCT04182880|DRUG|Placebo|Placebo will be administered
57768332|NCT05730790|OTHER|Cognitive-motor dual task training (DTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
57768333|NCT05730790|OTHER|Cognitive single task training (CSTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
58458013|NCT06410430|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
58458014|NCT02211794|OTHER|data collection|
58458015|NCT04265014|OTHER|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
58458016|NCT04265014|OTHER|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
58458017|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath) + Scapular Training|The Bobath concept for 40 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed with 20 minutes scapular training including scapular exercise such as Proprioceptive Neuromuscular Facilitation (PNF), dynamic hug, towel-wall slide, scapular punch exercises etc. 3 days a week for 8 weeks.
58458018|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath)|The Bobath concept for 60 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed 3 days a week for 8 weeks.
58458019|NCT05398367|DIETARY_SUPPLEMENT|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
58458020|NCT06012682|DRUG|Metformin Hydrochloride|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
58458021|NCT06012682|DRUG|Placebo|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
58458022|NCT00938184|DRUG|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
58458023|NCT00938184|DRUG|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
57961337|NCT02184871|OTHER|exposure to different risk factors and molecular assessment|
57961338|NCT00974987|RADIATION|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
57961339|NCT00974987|RADIATION|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
57961340|NCT00974987|DRUG|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
57768334|NCT05730790|OTHER|Motor single task training (MSTT)|For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
58458024|NCT00938184|DRUG|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
58458025|NCT01467141|DRUG|insulin aspart|Injected s.c. (under the skin) three times a day
58458026|NCT01467141|DRUG|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
57768335|NCT01760018|DRUG|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
57768336|NCT01760018|DRUG|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
57768337|NCT00003216|DRUG|fluorouracil|
57768338|NCT00003216|DRUG|gemcitabine hydrochloride|
57768339|NCT00003216|RADIATION|radiation therapy|
57768340|NCT02590692|BIOLOGICAL|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
57768341|NCT06089174|OTHER|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
57768342|NCT01293019|PROCEDURE|Osteopathic treatment|Real treatment of osteopathy
57768343|NCT01293019|PROCEDURE|Sham Placebo|Sham treatment of osteopathy
57768344|NCT01293019|PROCEDURE|Usual care|Classical treatment of pain in cystic fibrosis patients
57768345|NCT03350243|OTHER|CCENT Intervention|"1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
57768346|NCT00332605|DRUG|Naltrexone plus N-Acetyl Cysteine|daily
57768347|NCT00332605|DRUG|Placebo|daily
57768348|NCT02673905|OTHER|Tissue Engineered Product|Implantation of tissue engineered products
57768349|NCT04408547|DEVICE|embryo transfer catheter|undergoing embryo transfer
57768350|NCT05091944|DEVICE|web-based birth decision aid|Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
57768351|NCT04323228|DIETARY_SUPPLEMENT|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
57768352|NCT04323228|DIETARY_SUPPLEMENT|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
57768353|NCT03917641|BIOLOGICAL|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
57768354|NCT02678767|DRUG|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
57768355|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
57768356|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
57768357|NCT00068380|DRUG|imatinib mesylate|Given orally
58458027|NCT01467141|DRUG|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
57768358|NCT00068380|OTHER|laboratory biomarker analysis|Correlative studies
57768359|NCT05403060|BEHAVIORAL|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
57961341|NCT00725075|DRUG|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
57961342|NCT00725075|DRUG|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
57961343|NCT00725075|DRUG|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
58458028|NCT01945021|DRUG|Crizotinib|
58458029|NCT00628121|DRUG|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
58458030|NCT05020977|OTHER|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
58458031|NCT05990387|DRUG|Mirabegron|Dose-response effect on thermogenesis
58458032|NCT05990387|DRUG|Placebo|Placebo control condition
58458033|NCT02916966|OTHER|Patient Registry|Patient Registry
57768360|NCT05914025|BEHAVIORAL|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
57768361|NCT03321006|DEVICE|Phonak Audeo B-R 90 hearing aid device (Active)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
57768362|NCT03321006|DRUG|Duloxetine or escitalopram|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
57768363|NCT03321006|DEVICE|Audeo B-R 90 hearing aid device (Sham)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
57768364|NCT01679301|DEVICE|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
57768365|NCT01679301|DEVICE|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
57768366|NCT03274219|BIOLOGICAL|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
57768367|NCT02676193|BEHAVIORAL|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
57768368|NCT02679521|DEVICE|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
57768369|NCT02679521|DEVICE|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
57768370|NCT03240536|OTHER|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
57768371|NCT01346514|BEHAVIORAL|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
57768372|NCT01346514|BEHAVIORAL|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
57768373|NCT02200939|DEVICE|Bioinductive implant|
57768374|NCT02200939|DEVICE|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
57768375|NCT00884858|DRUG|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
57768376|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
57768377|NCT05157841|DRUG|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
57768378|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
57768379|NCT06626217|OTHER|Resting conditions|The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch
57768380|NCT06626217|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.
57768381|NCT06626217|OTHER|Circulation constriction|The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.
57768382|NCT06626217|OTHER|Physical exercise|The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
57768383|NCT04488367|DRUG|Tranexamic acid|10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
57768384|NCT04488367|DRUG|Normal Saline|100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
57768385|NCT02039661|DRUG|Lidocaine Spray|These patients received 2 puff lidocaine spray
57768386|NCT02039661|DRUG|Placebo|
58458034|NCT00629863|DRUG|cisplatin|
57768387|NCT02679534|OTHER|hand massage|
57768388|NCT02679534|OTHER|hand holding|
58458035|NCT00629863|DRUG|fluorouracil|
58458036|NCT00629863|OTHER|questionnaire administration|
58458037|NCT00629863|PROCEDURE|diagnostic endoscopic procedure|
58458038|NCT00629863|PROCEDURE|neoadjuvant therapy|
58458039|NCT00629863|PROCEDURE|quality-of-life assessment|
58458040|NCT00629863|PROCEDURE|therapeutic conventional surgery|
58458041|NCT00629863|PROCEDURE|therapeutic endoscopic surgery|
58458042|NCT00629863|PROCEDURE|ultrasound imaging|
58458043|NCT00629863|RADIATION|radiation therapy|
58458044|NCT00629863|RADIATION|radioisotope therapy|
58458045|NCT03326596|DRUG|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
58458046|NCT02919644|BIOLOGICAL|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
58458047|NCT02919644|DRUG|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
58458048|NCT00555412|DRUG|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
58458049|NCT00555412|DRUG|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
58458050|NCT00555412|DRUG|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
58458051|NCT00555412|DRUG|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
58458052|NCT05790889|BIOLOGICAL|Rabies vaccine|Vaccine
57768389|NCT02679534|OTHER|application of unscented hypoallergenic cream|
57768390|NCT02679534|OTHER|environmental adjustments|
57768391|NCT05191641|OTHER|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
57768392|NCT05482737|OTHER|no intervention|This is an observational retrospective study (meta-analysis)
57768393|NCT00088179|DRUG|pexelizumab in conjunction with CABG|
57768394|NCT02566070|OTHER|Continuous Gastric Feeding|
57768395|NCT02566070|OTHER|Bolus Gastric Feeding|
57768396|NCT04191681|DRUG|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
57768397|NCT04191681|DRUG|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
58458053|NCT05790889|BIOLOGICAL|RH5.1 10μg adjuvated with 50μg Matrix-M|Vaccine
57768398|NCT06342895|DEVICE|Nutritional support prescription and delivery monitoring feedback|Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device
57768399|NCT06342895|DEVICE|Usual care|Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
57768400|NCT05494229|OTHER|Pars-plana vitrectomy|Pars-plana vitrectomy
57768401|NCT00119925|BEHAVIORAL|patient education|patient leaflets about national guideline contents
57768402|NCT00119925|BEHAVIORAL|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
57768403|NCT00119925|BEHAVIORAL|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
57768404|NCT00119925|OTHER|information tools|tools and checklists to improve information provision
57768405|NCT04372160|OTHER|Dietary assessment|24-hr dietary recall
57768406|NCT06625736|DRUG|Xenical|The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
57768407|NCT06625736|DIETARY_SUPPLEMENT|The dandelion extract|The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
57768408|NCT02273297|OTHER|Maternal factors|
58458054|NCT05790889|BIOLOGICAL|RH5.2 5μg adjuvated with 50μg Matrix-M|Vaccine
58458055|NCT06133335|OTHER|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
58458056|NCT01480661|DRUG|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
58458057|NCT01480661|DRUG|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
58458058|NCT01480661|RADIATION|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
58458059|NCT00959608|BEHAVIORAL|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
58458060|NCT00959608|BEHAVIORAL|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
58458061|NCT04277728|DIAGNOSTIC_TEST|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
58458062|NCT01590979|DRUG|Ranolazine|1000mg, two times a day, 12 hour intervals
58458063|NCT01590979|DRUG|Placebo|two times a day, 12 hour intervals
58458064|NCT05106127|DRUG|EG-007|A Repurposed Drug
58458065|NCT05106127|DRUG|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
58458066|NCT05106127|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
58458067|NCT02520817|DIETARY_SUPPLEMENT|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
58458068|NCT02520817|DIETARY_SUPPLEMENT|Lactulose|
58458069|NCT04894721|DRUG|Ivermectin|0,6mg/kg of weight orally on days 1 and 7
57768409|NCT01743300|DRUG|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
57768410|NCT01743300|DRUG|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
57768411|NCT01743300|OTHER|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
57768412|NCT01743300|OTHER|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
57768413|NCT05321706|DRUG|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
57768414|NCT05321706|DRUG|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
57768415|NCT02443506|DRUG|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
57768416|NCT02443506|DRUG|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
58458070|NCT04894721|OTHER|Placebo|A substance with similar physical characteristics as ivermectin, without the active drug ingredient
58458071|NCT00702702|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
58458072|NCT00702702|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
58458073|NCT00702702|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
58458074|NCT02732600|OTHER|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
58458075|NCT04173806|OTHER|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
58458076|NCT04173806|OTHER|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
57768417|NCT03386955|DRUG|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
57768418|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
57768419|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
57768420|NCT03555357|OTHER|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
57768421|NCT03555357|OTHER|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
57768422|NCT02887469|DRUG|3% hypertonic saline|The same as above
58458077|NCT02533414|DEVICE|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
58458078|NCT02533414|DEVICE|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
58458079|NCT01119053|DEVICE|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
58458080|NCT01119053|DEVICE|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
58458081|NCT00531284|DRUG|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
58458082|NCT00531284|DRUG|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
58458083|NCT01244685|DEVICE|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
57768423|NCT04935723|OTHER|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
57768424|NCT01190215|BIOLOGICAL|FluarixTM|One Intramuscular injection
57768425|NCT01190215|BIOLOGICAL|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
57768426|NCT00882921|BIOLOGICAL|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
57768427|NCT02342665|DRUG|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
57768428|NCT01508013|BEHAVIORAL|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
57768429|NCT01508013|BEHAVIORAL|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
57768430|NCT02223754|DEVICE|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
57768431|NCT02223754|DEVICE|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
57768432|NCT01097486|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
57768433|NCT01097486|PROCEDURE|Allograft|Single Dose Allograft Surgical Implantation
57768434|NCT04548271|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
57768435|NCT04548271|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
57768436|NCT04315103|COMBINATION_PRODUCT|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
57768437|NCT02544802|DRUG|Adipose-Derived Mesenchymal Stem Cells|
57768438|NCT04485715|OTHER|AI system|The real-time assistance of AI system
57768439|NCT03091101|DEVICE|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
57768440|NCT01450605|DRUG|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
57768441|NCT04996290|PROCEDURE|PENG + LFCN block|Regional anesthesia technique
57768442|NCT04996290|DRUG|Ropivacaine injection|Local anesthetic used for peripheral nerve block.
57768443|NCT04898712|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets
57768444|NCT04898712|DRUG|Placebo|The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
57768445|NCT00988546|OTHER|Computer based template for exam documentation|exam documentation performed using computer based template
57768446|NCT00988546|OTHER|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
57768447|NCT03418870|BEHAVIORAL|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
57768448|NCT03817021|BEHAVIORAL|CORE NAP SACC|Modify the food environment following a self-assessment of current food conditions
57768449|NCT03817021|BEHAVIORAL|ECE Provider|Provide online training for Head Start educators
57768450|NCT03817021|BEHAVIORAL|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
57768451|NCT03817021|BEHAVIORAL|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
57768452|NCT05902221|DRUG|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
57768453|NCT05902221|DRUG|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
57768454|NCT04719403|OTHER|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
57768455|NCT01836627|OTHER|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
57768456|NCT05632536|PROCEDURE|SACRAL ESP AND CAUDAL BLOCK|Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
57768457|NCT03236922|PROCEDURE|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
57768458|NCT03236922|PROCEDURE|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
57768459|NCT05730530|BEHAVIORAL|Nutrition education curriculum|This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
57768460|NCT04962438|DRUG|Anti-VEGF|Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
57768461|NCT01203839|RADIATION|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
57768462|NCT04707690|DEVICE|Intraurethral laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
57768463|NCT04707690|DEVICE|Intraurethral SHAM laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
57768464|NCT00095914|DRUG|paclitaxel|
57768465|NCT00095914|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
57768466|NCT02617264|PROCEDURE|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
57768467|NCT03380793|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
57768468|NCT04060225|OTHER|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
57768469|NCT05334927|BEHAVIORAL|Medicine Overuse Headache/New Daily Persistent Headache|At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
57768470|NCT05334927|BEHAVIORAL|Chronic Migraine|long-term follow-up
57768471|NCT05334927|BEHAVIORAL|Patients with other types of primary headache|No collection Brain imaging、Cognitive function test、Biological sample
57768472|NCT00006232|DRUG|dexamethasone|
57768473|NCT00006232|DRUG|doxorubicin hydrochloride|
57768474|NCT00006232|DRUG|idarubicin|
57768475|NCT00006232|DRUG|vincristine sulfate|
57768476|NCT04703634|PROCEDURE|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
57768477|NCT05332977|DEVICE|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
57768478|NCT05332977|DEVICE|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
57768479|NCT00003415|DRUG|amifostine trihydrate|
57768480|NCT00003415|DRUG|topotecan hydrochloride|
57768481|NCT04590859|PROCEDURE|Block performed|Comparing block performed with penile blood flow
57768482|NCT04590859|DEVICE|LMA placement|Placement of LMA for airway securement
57768483|NCT02281760|DRUG|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
57768484|NCT02281760|DRUG|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
57768485|NCT05425030|DIETARY_SUPPLEMENT|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
57768486|NCT05425030|BEHAVIORAL|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
58458084|NCT04510714|DEVICE|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
58458085|NCT04894032|PROCEDURE|Combination of Laparoscopic Uterosacral Ligament and Round Ligament Plication.|Laparoscopic Uterosacral Ligament Plication, Fixation of PVC fascia and the combination with round ligament plication
57768487|NCT03697382|BEHAVIORAL|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
57768488|NCT03697382|BEHAVIORAL|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
57768489|NCT03697382|BEHAVIORAL|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
58458086|NCT01160276|DRUG|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
58458087|NCT01160276|DRUG|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
58458088|NCT00923923|BEHAVIORAL|stress|compare levels of stress
58458089|NCT05837338|DRUG|BXP154|BXP154 will be self-administered topically following wound induction
57768490|NCT02082626|DRUG|Eribulin mesylate|
57768491|NCT05021003|OTHER|pressure biofeedback|: Core stabilization training with pressure biofeedback unit
57768492|NCT05021003|OTHER|core stabilization exercises|: Core stabilization training without pressure biofeedback unit
57768493|NCT04464837|DEVICE|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
57768494|NCT05660915|PROCEDURE|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
57768495|NCT05660915|PROCEDURE|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
57768496|NCT06547372|OTHER|Dietary Intervention on Atopy|The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
57768497|NCT02357810|DRUG|Pazopanib Hydrochloride|Given PO
57768498|NCT02357810|DRUG|Oral Topotecan Hydrochloride|Given PO
57768499|NCT02357810|OTHER|Laboratory Biomarker Analysis|Correlative studies
57768500|NCT03178513|OTHER|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team"
57768501|NCT01469455|DRUG|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
57768502|NCT01863927|OTHER|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
57768503|NCT00714623|DEVICE|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
57768504|NCT03904511|OTHER|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
57768505|NCT03904511|OTHER|Placebo|Placebo
57768506|NCT04478513|DRUG|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
57768507|NCT04478513|DRUG|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
57768508|NCT03456167|OTHER|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
57768509|NCT06047236|OTHER|Sampling|Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
57768510|NCT06281223|OTHER|intraoperative neuroelectrophysiological monitoring|"The procedure involves intraoperative neuroelectrophysiological monitoring. The aim is to record the electrical activity of the central and peripheral nervous system at several levels during a neurosurgical procedure.~The equipment used comes from INOMED and consists of :~* a recording station (ISIS)~* scalp corkscrew electrodes (2 to 4 electrodes)~* a 4-pin FSR spinal cord electrode (Ad-Tech)~* hook electrodes for roots/radicles (X2)~* needle electrodes for muscles (X18)~Electrode placement and recording take place in the operating room while the patient is under general anaesthetic (intubated and sedated)."
57768511|NCT01884714|OTHER|High fat/high calorie meal|All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
57768512|NCT01974505|DEVICE|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
57768513|NCT06371365|PROCEDURE|Free Flap surgery|No intervention, this is an observational study
57768514|NCT00825032|PROCEDURE|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
57768515|NCT00825032|PROCEDURE|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
57768516|NCT00847990|OTHER|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
57768517|NCT04412590|OTHER|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
57768518|NCT04412590|OTHER|Treatment as Usual|Pediatric care as usual.
58129389|NCT03250533|DEVICE|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
58458090|NCT05837338|DRUG|Placebo|Placebo will be self-administered topically following wound induction
58458091|NCT00881517|DRUG|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
58458092|NCT00881517|DRUG|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
58458093|NCT04610359|DRUG|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
57768519|NCT02019784|DRUG|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
57768520|NCT02019784|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
57768521|NCT00242749|DRUG|Gefitinib, Cisplatin and Radiotherapy|
57768522|NCT05801458|PROCEDURE|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
57768523|NCT05801458|PROCEDURE|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
58458094|NCT02316028|DRUG|Decitabine|"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"
58458095|NCT00113841|DRUG|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
58458096|NCT00113841|DRUG|Bioperine|5 mg (Tablets) orally twice daily
58458097|NCT02542865|DIETARY_SUPPLEMENT|Fortified malt based food|Fortified malt based food
58458098|NCT02922530|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|
58458099|NCT02922530|OTHER|Commercially available computerized training|
58458100|NCT06288555|DIAGNOSTIC_TEST|Ipswich touch test|"Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses."
58458101|NCT02693808|PROCEDURE|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
57768524|NCT00001064|DRUG|Allogenic Dendritic Cells|
57768525|NCT01427192|DRUG|acetazolamide|250 mg bid
57768526|NCT01427192|OTHER|Supplemental oxygen|Oxygen deliverded by nasal cannula
57768527|NCT01427192|PROCEDURE|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
57768528|NCT01427192|OTHER|Room air|Room air applied via sham oxygen concentrator
57768529|NCT01427192|DRUG|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
57768530|NCT05936229|BIOLOGICAL|Interferon Beta-1A|Given IV
57768531|NCT05936229|PROCEDURE|X-Ray Imaging|Undergo x-ray
57768532|NCT05936229|PROCEDURE|Echocardiography|Undergo ECHO
57768533|NCT05936229|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57768534|NCT05936229|PROCEDURE|Computed Tomography|Undergo CT
57768535|NCT05936229|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58129390|NCT03250533|DEVICE|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
58458102|NCT02693808|PROCEDURE|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
57768536|NCT05936229|PROCEDURE|Lumbar Puncture|Undergo LP
57768537|NCT05936229|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
57768538|NCT05936229|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57768539|NCT05936229|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
57768540|NCT05936229|PROCEDURE|Biopsy|Undergo tissue biopsy
57768541|NCT01517243|DRUG|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
57768542|NCT01517243|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
57768543|NCT03048084|DRUG|Levetiracetam|Antiepileptic drug levetiracetam
57768544|NCT03048084|DRUG|Valproic Acid|Antiepileptic drug valproic acid
57768545|NCT05315661|DRUG|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
57768546|NCT01878123|BIOLOGICAL|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
57768547|NCT01878123|OTHER|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
57768548|NCT00981474|DRUG|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
57768549|NCT00981474|DEVICE|Control group|Institutional standard of care.
57768550|NCT04446780|PROCEDURE|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
57768551|NCT01199458|DRUG|alfentanil|20 mikrogr/kg
57768552|NCT01199458|DRUG|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
57768553|NCT02139358|DRUG|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
57768554|NCT02139358|DRUG|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
57768555|NCT02139358|DRUG|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
57768556|NCT05108064|DIAGNOSTIC_TEST|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
57768557|NCT04296890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
57768558|NCT00203151|DRUG|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
57768559|NCT02001974|DRUG|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
57768560|NCT03847467|DRUG|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
57768561|NCT03847467|OTHER|Placebo|Dextrose
57768562|NCT01562912|DEVICE|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
57768563|NCT01562912|DEVICE|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
57768564|NCT05434143|BEHAVIORAL|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises."
57768565|NCT02540785|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
57768566|NCT02540785|PROCEDURE|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
57768567|NCT01729234|DIETARY_SUPPLEMENT|Nitrate|Dietary Supplement
58458103|NCT04936607|PROCEDURE|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
57768568|NCT01729234|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement
58129391|NCT01836419|PROCEDURE|classic LMA insertion|
58458104|NCT04936607|PROCEDURE|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
58458105|NCT01815723|DRUG|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
57768569|NCT03341663|COMBINATION_PRODUCT|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
57768570|NCT03846505|DRUG|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
57768571|NCT03846505|OTHER|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
57768572|NCT04575727|DRUG|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)
57768573|NCT05402540|OTHER|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
57768574|NCT05402540|OTHER|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
57768575|NCT03966079|DRUG|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
57768576|NCT04540484|OTHER|Screening|Blood test screening for covid
57768577|NCT00211978|DRUG|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
57768578|NCT00211978|DRUG|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
57768579|NCT02328092|DEVICE|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
57768580|NCT00389181|PROCEDURE|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
57768581|NCT00389181|OTHER|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
57768582|NCT03301727|OTHER|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
57768583|NCT06392672|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
57768584|NCT05142982|RADIATION|Radiotherapy|A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
57768585|NCT02554630|OTHER|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
57768586|NCT02554630|OTHER|Blood Collection|Blood collection will be performed on all groups.
57768587|NCT04453215|DEVICE|GaAlAs semiconductor diode laser device|low-level laser therapy
57768588|NCT00597714|DRUG|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
57768589|NCT05727943|DRUG|Clioquinol|add on clioquinol to concomitant ASM
57768590|NCT02917577|BIOLOGICAL|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
57768591|NCT02917577|BIOLOGICAL|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
57768592|NCT01512745|DRUG|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
57768593|NCT01512745|DRUG|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
57768594|NCT00305500|DRUG|escitalopram|
57768595|NCT03545373|DRUG|Azithromycin|Azithromycin tablet taken orally
57768596|NCT03545373|DRUG|Amoxicillin|Amoxicillin tablets taken orally
57768597|NCT03788902|DRUG|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
57768598|NCT02724813|BEHAVIORAL|Cognitive Orientation to Occupational Preformance (COOP)|
57768599|NCT01231503|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=\<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =\< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
58458106|NCT01815723|DRUG|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
57768600|NCT01231503|BIOLOGICAL|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
57768601|NCT01231503|BIOLOGICAL|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
58458107|NCT01815723|DRUG|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
58458108|NCT01815723|DRUG|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
57768602|NCT01231503|BIOLOGICAL|BCG|1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)
57768603|NCT01231503|BIOLOGICAL|OPV|4 doses, orally, at birth (=\< 7 days of age) and at 6, 10 and 14 weeks of age
57768604|NCT01231503|BIOLOGICAL|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
57768605|NCT04931394|OTHER|Adjuvant chemotherapy guided by organoid drug sensitivity test|Adjuvant chemotherapy guided by organoid will be given to pancreatic cancer patients.
57768606|NCT05640622|OTHER|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
57768607|NCT00004650|DRUG|conjugated estrogens|
57768608|NCT00004650|DRUG|Medroxyprogesterone|
57768609|NCT06189118|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
58458109|NCT05118191|OTHER|OOLER|Following the baseline block (first four weeks), participants will use the OOLER device to power a cooling mattress pad each night during sleep for four weeks.
57768610|NCT01335503|DIETARY_SUPPLEMENT|AN-PEP|Endoprotease enzyme (AN-PEP)
57768611|NCT01290822|DEVICE|BiVP|Biventricular pacing
57768612|NCT01290822|DEVICE|AAI Pacing|Atrial pacing
57768613|NCT06327763|PROCEDURE|ilioinguinal nerve section|patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
57768614|NCT03405272|BIOLOGICAL|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
57768615|NCT05799664|DEVICE|TLD|Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
57768616|NCT05799664|OTHER|Sham TLD procedure|Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
57768617|NCT05799664|OTHER|Standard of care|Patients will also receive standard of care that meet the recommendations of GOLD guideline.
57768618|NCT01286220|OTHER|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
57768619|NCT01286220|OTHER|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
57768620|NCT04458116|DIETARY_SUPPLEMENT|Curcumin|Participants will receive 1.5 grams of turmeric 95% curcumin for 1 month (3 capsules / day containing 500mg each for 4 weeks).
57768621|NCT02482272|DRUG|Lamivudine|Lamivudine 100mg/day orally
57768622|NCT02482272|DRUG|Adefovir|Adefovir 10mg/day orally
57768623|NCT02482272|DRUG|Entecavir|Entecavir 1mg/day orally
57768624|NCT04727476|DRUG|Lisdexamfetamine|Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
57768625|NCT05429658|DEVICE|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
57768626|NCT01879423|DRUG|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
57768627|NCT01879423|DRUG|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
57768628|NCT03661034|DEVICE|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
57768629|NCT04221282|DRUG|Zebinix|ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
57768630|NCT04116528|DRUG|Ketamine|0.5mg/kg
57768631|NCT04116528|DRUG|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
57768632|NCT04116528|DRUG|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
57768633|NCT02415374|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
57768634|NCT04924972|PROCEDURE|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
57768635|NCT01774318|OTHER|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
57768636|NCT04856943|PROCEDURE|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
57768637|NCT04856943|OTHER|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
58458110|NCT05118191|OTHER|EmbrWave|Following the baseline block (first four weeks), participants will use the Embr Wave 2 device to provide pulsed warm sensations to the inner wrist each night during sleep for four weeks.
58458111|NCT02418871|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
57768638|NCT04937426|DIAGNOSTIC_TEST|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|Diagnostic laboratory test for detection of helicobacter pylori
57768639|NCT05017324|DEVICE|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
57768640|NCT06299514|DEVICE|Pace and Ablate|BiVentricular Pacing (BiVP) or Conduction System Pacing(CSP) followed by AtrioVentricular Node Ablation (AVNA)
57768641|NCT06299514|DRUG|Medication|Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
57768642|NCT00812188|OTHER|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
57768643|NCT00812188|OTHER|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
57768644|NCT03748238|PROCEDURE|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
57768645|NCT06249490|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
57768646|NCT06249490|DEVICE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
57768647|NCT06249490|DRUG|Lidocaine Hydrochloride Injection|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
57768648|NCT03084497|PROCEDURE|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
57768649|NCT03942380|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
57768650|NCT02970032|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
57768651|NCT02970032|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
57768652|NCT05307328|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
58458112|NCT02418871|PROCEDURE|Cataract surgery|Performed using standard microsurgical techniques
58458113|NCT03439501|DRUG|avelumab|"* Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
58458114|NCT05239052|OTHER|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
57768653|NCT05307328|DRUG|Placebo|Inactive tablets identical to SPI-62 tablets
57768654|NCT02989272|DRUG|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
57768655|NCT02989272|OTHER|saline group|saline group (30 patients) who will receive pretreatment by saline solution
57768656|NCT06076356|OTHER|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
57768657|NCT06076356|OTHER|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
57768658|NCT00610701|DEVICE|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
57768659|NCT00610701|DEVICE|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
57768660|NCT00613288|DRUG|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment."
57768661|NCT04482829|DRUG|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
58458115|NCT05239052|OTHER|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
58458116|NCT06251063|BEHAVIORAL|Web-based psychoeducational resource|"The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement"
58458117|NCT03596905|DRUG|Plecanatide|Taken orally daily for 4 weeks
58458118|NCT03596905|DRUG|Matching placebo|Taken orally daily for 4 weeks
58458119|NCT02153632|DRUG|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
58458120|NCT02153632|DRUG|Placebo|subjects are given an identical placebo tablet
58458121|NCT00239239|DRUG|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
58458122|NCT05001334|BEHAVIORAL|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
57768662|NCT04482829|DRUG|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
57768663|NCT06167551|OTHER|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
57768664|NCT06167551|OTHER|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
57768665|NCT06167551|OTHER|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
57768666|NCT06167551|OTHER|Contol Group|No intervation
57768667|NCT02168543|DRUG|Alendronate|
57768668|NCT02168543|DRUG|Placebo|
57768669|NCT02400437|DRUG|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
57768670|NCT02400437|DRUG|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
57768671|NCT02400437|DRUG|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
57768672|NCT03266185|OTHER|Shorter PICT|Shorter post-infusion cooling time
57768673|NCT05958329|BEHAVIORAL|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
57768674|NCT03857412|PROCEDURE|Capsular polishing|Capsular polishing taking place during cataract surgery
57768675|NCT03857412|OTHER|Non capsular polishing|No capsular polishing taking place during cataract surgery
57768676|NCT00818103|DRUG|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
57768677|NCT00818103|DRUG|β-interferon|β-interferon 50ug i.m. qod for 2 years
57768678|NCT00818103|DRUG|EPO|EPO 10000U i.h. bid for 5 days
57768679|NCT02641249|DEVICE|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
57768680|NCT03615521|OTHER|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
57768681|NCT03615521|OTHER|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
57768682|NCT03615521|OTHER|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
57768683|NCT03615521|OTHER|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
57768684|NCT03615521|OTHER|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
57768685|NCT02120664|DRUG|Florbetapir (18F)|
57768686|NCT02120664|DRUG|11C-PiB|
57768687|NCT06128174|DEVICE|Farawave PFA catheter|The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.
57768688|NCT04746651|OTHER|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
57768689|NCT02778399|DRUG|Placebo|Placebo tablets for oral administration once daily
57768690|NCT02778399|DRUG|OBE2109|OBE2109 tablets for oral administration once daily
57768691|NCT02185885|PROCEDURE|Increased bloodpressure during CPB.|
57768692|NCT06250647|OTHER|vitamin K diet|500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
57768693|NCT04337086|DEVICE|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
57768694|NCT04337086|DEVICE|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
57768695|NCT03244293|OTHER|no intervention|
57768696|NCT01381874|DRUG|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
57768697|NCT01381874|DRUG|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
57768698|NCT01381874|DRUG|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
57768699|NCT02826525|DRUG|AZD4076|Investigational product
57768700|NCT02826525|DRUG|Placebo|Control
57768701|NCT02756832|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
57768702|NCT04172493|PROCEDURE|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
57768703|NCT04172493|DEVICE|White Light Endoscopy (WLE)|Undergo white light endoscopy
57768704|NCT05477706|OTHER|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
58458123|NCT01860664|DRUG|hydrocortisone ophthalmic ointment 0.5%|"* Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
57768705|NCT05477706|OTHER|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
57768706|NCT02348853|BEHAVIORAL|Healthy Weight for Living (HWL)|
57768707|NCT02348853|BEHAVIORAL|Current Best Practice (CBP)|
57768708|NCT02401308|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
57768709|NCT04651114|BEHAVIORAL|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
57768710|NCT01024790|BEHAVIORAL|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
57768711|NCT02340702|OTHER|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
57768712|NCT02478021|OTHER|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
57768713|NCT01255553|RADIATION|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
57768714|NCT00245856|DRUG|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
57768715|NCT00245856|DRUG|Warfarin|Titrated to INR 2-3 through study month 3
57768716|NCT04613882|DEVICE|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
57768717|NCT04613882|DEVICE|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
57768718|NCT04613882|DEVICE|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
57768719|NCT00965003|PROCEDURE|MRI scan|Standard of Care
58458124|NCT01860664|DRUG|placebo|Mineral oil and white petrolatum
58458125|NCT04657471|OTHER|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score \<2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
57768720|NCT04930770|DRUG|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
57768721|NCT01535274|OTHER|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
57768722|NCT03312686|DIAGNOSTIC_TEST|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
57768723|NCT00811421|DRUG|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
58458126|NCT00166218|DEVICE|near-infrared spectroscopy|
58458127|NCT06528366|DIETARY_SUPPLEMENT|Chlorella pyrenoidosa|Functional food, organically pressed into tablets (Registration with Anvisa/MS/Brazil: 6.7273.000)
58458128|NCT06528366|DEVICE|High Definition Transcranial Direct Current Stimulation|Neuromodulation Technics, non invasive, target and safety
58458129|NCT05049590|BIOLOGICAL|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
58458130|NCT04033562|DRUG|Lidocaine patch|Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
57768724|NCT00811421|DRUG|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
57768725|NCT00811421|DRUG|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
57768726|NCT00811421|DRUG|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
57768727|NCT00811421|DRUG|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
57768728|NCT03946514|DRUG|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
57768729|NCT03946514|DRUG|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
57768730|NCT03492892|DEVICE|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
57768731|NCT03492892|DEVICE|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
57768732|NCT04783298|OTHER|App|An application to deliver a series of behavioral questionnaires and decision-making game
57768733|NCT06041958|DEVICE|Extracorporeal shock wave therapy|2 times/week for 12 weeks
57768734|NCT06041958|DEVICE|Pulse electromagnetic field therapy|2 times/week for 12 weeks
57768735|NCT06041958|OTHER|Rehabilitation|2 times/week for 12 weeks
57768736|NCT01370603|DRUG|Atorvastatin|40 mg tablet administered orally once daily
57768737|NCT01370603|DRUG|Ezetimibe|10 mg tablet administered orally once daily
57768738|NCT01370603|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
57768739|NCT01370603|DRUG|Placebo to atorvastatin|Administered orally once daily
57768740|NCT01370603|DRUG|Placebo to ezetimibe|Administered orally once daily
57768741|NCT01370603|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
57768742|NCT06159374|OTHER|exercise and environmental conditions|Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
57768743|NCT03082833|DRUG|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
57768744|NCT02080195|DRUG|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
57768745|NCT02080195|DRUG|Fludarabine|30 mg/m\^2/day on Days -6 through -2.
57768746|NCT02080195|DRUG|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
57768747|NCT02080195|DRUG|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
57768748|NCT02080195|DRUG|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
58458131|NCT04033562|DEVICE|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
58458132|NCT05930119|DRUG|HMPL-453|300 mg HMPL-453
58458133|NCT05930119|DRUG|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
57768749|NCT02080195|RADIATION|Total body irradiation|200 centigray on Day -1.
58458134|NCT04220216|OTHER|H4H fitness program|4 weekly, 1 hour exercise sessions
58458135|NCT05794035|OTHER|Surgery with additional moderate hypofractionation RT (15 fractions)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed."
58458136|NCT05794035|OTHER|Surgery alone, without radiation post surgery|Arm A: Surgery alone followed by surveillance
57768750|NCT02080195|BIOLOGICAL|Allogeneic bone marrow transplant|Infusion on Day 0.
57768751|NCT04851860|DRUG|sublingual immunotherapy|sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
57768752|NCT01603563|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
57768753|NCT01603563|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
57768754|NCT03020329|DRUG|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
57768755|NCT03020329|DRUG|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
57768756|NCT03020329|DRUG|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
57768757|NCT03020329|RADIATION|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
57768758|NCT02560935|DRUG|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
57768759|NCT02560935|DRUG|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
57768760|NCT03835936|OTHER|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
57768761|NCT03835936|OTHER|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
57768762|NCT02766179|DEVICE|CPAP|CPAP is used for 6 weeks
57768763|NCT02766179|DEVICE|Somnoguard|Somnoguard is used for 6 weeks
57768764|NCT04805463|OTHER|Control group|The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
57768765|NCT04805463|OTHER|PRF group|The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
57768766|NCT04805463|OTHER|CGF group|The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
57768767|NCT04805463|OTHER|AFG group|The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
57768768|NCT02922790|BEHAVIORAL|standard health information|Subjects will review standard health information
57768769|NCT02922790|BEHAVIORAL|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
57768770|NCT02922790|BEHAVIORAL|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
57768771|NCT06160622|DRUG|Leritrelvir|Oral
57768772|NCT06626386|DIAGNOSTIC_TEST|PSA testing|PSA Testing in venipunctate and capillary blood
57768773|NCT02225977|DRUG|Gilenya|
57768774|NCT06215651|DRUG|Cadonilimab lenvatinib|±TACE/HAIC
58458137|NCT05794035|RADIATION|Surgery with extreme hypo fractionation treatment (HF)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed."
58458138|NCT00425035|DRUG|Panitumumab (ABX-EGF)|
57768775|NCT01339598|DEVICE|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
57768776|NCT04561882|DEVICE|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
57768777|NCT02703207|DEVICE|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
57768778|NCT02703207|DEVICE|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
57768779|NCT05635136|OTHER|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
57768780|NCT04707911|BEHAVIORAL|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
57768781|NCT03781765|DRUG|Methylphenidate|stimulant medication
58458139|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
58458140|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
58458141|NCT00683878|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
58458142|NCT00683878|DRUG|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
58458143|NCT00461006|DRUG|Actos|45mg po daily
57768782|NCT03781765|DRUG|Atomoxetine|non-stimulant medication
57768783|NCT06625840|DRUG|MK-1167|Oral Administration
57768784|NCT06625840|DRUG|Placebo|Oral Administration
57768785|NCT05675865|DEVICE|cryoablation procedure|ablation procedure for VT using the investigational device
57768786|NCT05124041|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
57768787|NCT00006115|DRUG|FOLFIRI regimen|
57768788|NCT00006115|DRUG|FOLFOX regimen|
57768789|NCT00006115|DRUG|fluorouracil|
57768790|NCT00006115|DRUG|irinotecan hydrochloride|
57768791|NCT00006115|DRUG|leucovorin calcium|
57768792|NCT00006115|DRUG|oxaliplatin|
57768793|NCT01454674|OTHER|2, 5 & 10 Vegetable doses|2,5 \& 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers \& tomatoes consumed for 3 week intervals
57768794|NCT00295438|DEVICE|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
57768795|NCT00295438|DEVICE|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
57768796|NCT05711888|BEHAVIORAL|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
57768797|NCT04581200|BEHAVIORAL|Lift|The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
57768798|NCT05085821|DEVICE|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
57768799|NCT05085821|DEVICE|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
57768800|NCT00989586|BIOLOGICAL|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
58458144|NCT00461006|DRUG|aleglitazar|0.6mg po daily
57768801|NCT00989586|BIOLOGICAL|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
57768802|NCT00989586|PROCEDURE|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
57768803|NCT00989586|PROCEDURE|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
57768804|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
57768805|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
57768806|NCT00989586|PROCEDURE|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
57768807|NCT00989586|BIOLOGICAL|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
57768808|NCT00975988|DRUG|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
57768809|NCT06434597|DRUG|SPH5030|SPH5030：Oral, QD, 600mg
57768810|NCT05015764|OTHER|Fluid Management|Removal of excess extracellular fluid using diuretics
57768811|NCT05015764|DEVICE|Reprieve Cardiovascular System|System with Fluid Management Module
57768812|NCT03028090|DEVICE|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
57768813|NCT05414097|OTHER|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
57768814|NCT05414097|OTHER|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
57768815|NCT05414097|OTHER|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
57768816|NCT05414097|OTHER|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
57768817|NCT05414097|OTHER|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
57768818|NCT00706225|DRUG|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
57768819|NCT00218803|BEHAVIORAL|Nurse asthma education intervention|Asthma Education
57768820|NCT00218803|BEHAVIORAL|Control Group|Asthma Education
57768821|NCT03387241|DRUG|Fluticasone/ Formoterol|See above
57768822|NCT03387241|DRUG|fluticasone/ salmeterol|See above
58129392|NCT04216069|OTHER|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
58458145|NCT05324111|DEVICE|Kardia 6L|The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
58458146|NCT06012123|PROCEDURE|Aortoiliac angioplasty and stenting|Covered endovascular reconstruction of aortic bifurcation (CERAB) in patient with aorto-iliac occlusive disease
57768823|NCT02387216|DRUG|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
57768824|NCT02387216|DRUG|Docetaxel|approved chemotherapy treatment for NSCLC
57768825|NCT00231660|DRUG|topiramate|
57768826|NCT02281526|DRUG|BIA 2-093|
57768827|NCT01842737|PROCEDURE|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
57768828|NCT01842737|PROCEDURE|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
57768829|NCT06624462|OTHER|Treatment in the Meta Care Clinic|"* Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention."
58458147|NCT05354817|DRUG|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
58458148|NCT05400655|DRUG|L9LS|Administered subcutaneously.
57768830|NCT06624462|OTHER|Standard care with general practitioner and/or outpatient clinics|"Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes."
57768831|NCT01357590|DEVICE|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
57768832|NCT03195465|DIETARY_SUPPLEMENT|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
57768833|NCT03047772|DRUG|Atorvastatin|Routine dose of Atorvastatin therapy
57768834|NCT03047772|DRUG|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
57768835|NCT03047772|DRUG|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
57768836|NCT03047772|DRUG|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
57768837|NCT03047772|DRUG|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
57768838|NCT03047772|DRUG|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
57768839|NCT05581615|OTHER|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
57768840|NCT00420134|PROCEDURE|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
57768841|NCT04187820|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
57961344|NCT06436378|BEHAVIORAL|Music intervention in person|The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
57961345|NCT03938493|OTHER|monitoring of the endotracheal tube cuff|We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
57961346|NCT01845038|DRUG|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
57961347|NCT01845038|DRUG|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
57961348|NCT01845038|DRUG|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
57961349|NCT06269445|DRUG|Icaritin Combined With Bevacizumab and FOLFIRI|Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
58458149|NCT05400655|OTHER|Normal Saline|Administered subcutaneously.
57961350|NCT04983160|DRUG|Allopurinol|Allopurinol
57961351|NCT04983160|DRUG|Placebo|Placebo
57768842|NCT06568744|OTHER|Intervention resuscitation|"In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: \>14, or an increase \>4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk \>14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk \> 15 mmHg or \>5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed."
57768843|NCT06568744|OTHER|Standard of Care resuscitation|In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
57768844|NCT02790073|DRUG|SNF472|SNF472 for calciphylaxis
57768845|NCT03383796|PROCEDURE|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
57768846|NCT03383796|PROCEDURE|Open resection for pCCA|Open resection for pCCA
57768847|NCT04538989|DRUG|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
57768848|NCT04538989|DRUG|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
57768849|NCT04538989|DRUG|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
57768850|NCT04538989|DRUG|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
57768851|NCT00857805|PROCEDURE|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
57768852|NCT00857805|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
57768853|NCT06493123|OTHER|Conventional Cardiopulmonary Rehabilitation|Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises
57768854|NCT06493123|OTHER|Bottle P.E.P. (Pozitive Expiratory Pressure)|"The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant."
57768855|NCT06493123|OTHER|Early Mobilization|"The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)"
57768856|NCT05357937|BEHAVIORAL|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
57768857|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
57768858|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
57768859|NCT05282849|PROCEDURE|ultrasound guided fascia iliaca block|ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
57768860|NCT05282849|PROCEDURE|ultrasound guided quadratus lumborum block|ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
57768861|NCT01476488|DRUG|tacrolimus|
57768862|NCT01706419|DIETARY_SUPPLEMENT|Fortified rice cold extruded kernel|
57768863|NCT01706419|DIETARY_SUPPLEMENT|fortified rice warm extruded kernel|
57768864|NCT01706419|DIETARY_SUPPLEMENT|fortiified rice hot extruded kernel|
57768865|NCT01381627|DRUG|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
57768866|NCT01381627|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
57768867|NCT02873130|BEHAVIORAL|Telepractice Global Voice Prevention Model|
57768868|NCT02873130|BEHAVIORAL|In-person Global Voice Prevention Model|
57768869|NCT02873130|BEHAVIORAL|Telepractice, Vocal Hygiene and Vocal Education|
57768870|NCT04919174|DRUG|Remimazolam|Sedation with remimazolam
57768871|NCT04919174|DRUG|Dexmedetomidine|Sedation with dexmedetomidine
57768872|NCT06136715|BEHAVIORAL|blood products as a part of Massive Transfusion Protocol|This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement
57768873|NCT05041816|DEVICE|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
57768874|NCT00288028|DRUG|bortezomib|Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
57768875|NCT02690077|PROCEDURE|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
58458150|NCT04634084|PROCEDURE|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
57768876|NCT02690077|PROCEDURE|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
57768877|NCT04430413|BIOLOGICAL|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
57768878|NCT04904081|DRUG|Indocyanine green|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
57768879|NCT05232474|DEVICE|KomPas+|KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
57768880|NCT05232474|DEVICE|KomPas|KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
57768881|NCT01486134|PROCEDURE|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
57768882|NCT04547270|OTHER|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
57768883|NCT02751918|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
57768884|NCT02751918|DRUG|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
57768885|NCT01090908|DRUG|Antibiotic|
57768886|NCT02732093|PROCEDURE|stellate block|
57768887|NCT02732093|DRUG|Na.Cl 0.9% (placebo)|
57768888|NCT02732093|DRUG|lidocaine 2%|
57768889|NCT00405353|DRUG|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
57768890|NCT03949088|OTHER|UF and Na profiling|Modulation of UF and dialysate sodium
57768891|NCT00244374|BIOLOGICAL|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects\>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
58458151|NCT04634084|PROCEDURE|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
58458152|NCT02513563|DRUG|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
57768892|NCT00244374|BEHAVIORAL|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
58458153|NCT02513563|DRUG|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
58458154|NCT02513563|DRUG|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
58458155|NCT01299844|BEHAVIORAL|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
58458156|NCT03341416|DEVICE|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
58458157|NCT03341416|DEVICE|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
58458158|NCT05529498|BEHAVIORAL|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
58458159|NCT05529498|BEHAVIORAL|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
58458160|NCT06239584|PROCEDURE|Biopsies performed via bronchoscopy|An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
58458161|NCT04228588|DRUG|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
58458162|NCT03796507|DRUG|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
58458163|NCT03935126|DIAGNOSTIC_TEST|Diagnostics|Diagnostics
58458164|NCT05651282|DRUG|Provera|Progesterone Challenge Test
58458165|NCT01307826|OTHER|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
58458166|NCT01307826|OTHER|massage|classical massage (Swedish massage)
58458167|NCT00839189|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
58458168|NCT03426670|DEVICE|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
58458169|NCT04473209|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
58458170|NCT03929185|DIAGNOSTIC_TEST|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
58458171|NCT03929185|DIAGNOSTIC_TEST|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
58458172|NCT03226717|DRUG|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
58458173|NCT04051359|OTHER|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)
58458174|NCT01122641|DRUG|Vildagliptin|Vildagliptin 50mg bid
58458175|NCT01122641|DRUG|Placebo|Matched tablets
58458176|NCT03831477|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
58458177|NCT00062712|DRUG|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
58458178|NCT04260893|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
58458179|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 12 g polydextrose|12 g polydextrose
58458180|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
58458181|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
58458182|NCT02314936|DIETARY_SUPPLEMENT|Placebo|12 g Maltodextrin
58458183|NCT00152503|DRUG|Seletracetam (UCB44212)|"* Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration"
58458184|NCT04338672|OTHER|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
58458185|NCT04279886|OTHER|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
57768893|NCT00244374|BEHAVIORAL|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
57768894|NCT00244374|BEHAVIORAL|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
57768895|NCT03096171|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
57768896|NCT06422403|DRUG|Extended Dosing Interval - A|Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
57768897|NCT06422403|DRUG|Extended Dosing Interval - B|Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
57768898|NCT06422403|DRUG|Extended Dosing Interval - C|Pembrolizumab 200mg 6 weekly (up to 2 years)
57768899|NCT06422403|DRUG|Standard of Care - A|Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
57768900|NCT06422403|DRUG|Standard of Care - B|Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
57768901|NCT06422403|DRUG|Standard of Care - C|Pembrolizumab 200mg 3 weekly (up to 2 years)
57768902|NCT00477477|OTHER|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
57768903|NCT00477477|OTHER|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
57768904|NCT03360877|OTHER|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
57768905|NCT04023097|DEVICE|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
57768906|NCT00542841|PROCEDURE|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
57768907|NCT06017674|PROCEDURE|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
57768908|NCT06017674|DRUG|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
57768909|NCT00002658|BIOLOGICAL|filgrastim|
57768910|NCT00002658|DRUG|amsacrine|
58458186|NCT02609308|OTHER|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
57768911|NCT00002658|DRUG|cyclophosphamide|
57768912|NCT00002658|DRUG|cytarabine|
57768913|NCT00002658|DRUG|daunorubicin hydrochloride|
57768914|NCT00002658|DRUG|etoposide|
57768915|NCT00002658|DRUG|idarubicin|
57768916|NCT00002658|DRUG|mitoxantrone hydrochloride|
57768917|NCT00002658|DRUG|thioguanine|
57768918|NCT00002658|DRUG|tretinoin|
57768919|NCT00002658|PROCEDURE|allogeneic bone marrow transplantation|
57768920|NCT00002658|PROCEDURE|autologous bone marrow transplantation|
57768921|NCT00002658|PROCEDURE|peripheral blood stem cell transplantation|
57768922|NCT00002658|RADIATION|radiation therapy|
57768923|NCT04696718|DIETARY_SUPPLEMENT|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
57768924|NCT00708721|DRUG|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
57768925|NCT04341155|DRUG|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
57768926|NCT04341155|DRUG|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
57768927|NCT00864526|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
57768928|NCT00864526|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
57768929|NCT02047565|DRUG|60mg edoxaban|
57768930|NCT02047565|DRUG|180mg edoxaban|
57768931|NCT02047565|DRUG|50 IU/kg Beriplex P/N|
57768932|NCT02047565|DRUG|25 IU/kg Beriplex P/N|
57768933|NCT02047565|DRUG|10 IU/kg Beriplex P/N|
58458187|NCT02609308|PROCEDURE|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
58458188|NCT03886506|BIOLOGICAL|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
57768934|NCT00260819|DRUG|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
57768935|NCT00260819|DRUG|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
57768936|NCT03361696|OTHER|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
57768937|NCT02163655|DRUG|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
57768938|NCT02163655|DRUG|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
57768939|NCT01923896|BEHAVIORAL|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
57768940|NCT01923896|DRUG|d-cycloserine (DCS)|
57768941|NCT01923896|DRUG|Placebo|lactose powder
57768942|NCT03939247|OTHER|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
57768943|NCT03939247|OTHER|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
58129393|NCT04216069|OTHER|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
58129394|NCT00438828|DRUG|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
58129395|NCT06093425|DRUG|TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
58129396|NCT06093425|DRUG|Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
58129397|NCT04325074|OTHER|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
58129398|NCT04325074|OTHER|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
57768944|NCT03939247|OTHER|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
57768945|NCT02576782|DRUG|Perineural Dexamethasone and bupivacaine|
57768946|NCT02576782|DRUG|Systemic Dexamethasone plus perineural bupivacaine|
57768947|NCT02576782|DRUG|intravenous saline plus perineural bupivacaine|
57768948|NCT01468532|DRUG|docetaxel|Given IV
57768949|NCT01468532|DRUG|pasireotide|Given IM
57768950|NCT01468532|DRUG|prednisone|Given PO
57768951|NCT01362556|DRUG|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1"
57768952|NCT01362556|DRUG|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1"
57768953|NCT02111837|OTHER|Standard infant formula|
57768954|NCT02111837|OTHER|Standard infant formula with PL1|
57768955|NCT02111837|OTHER|Standard infant formula with PL2|
57768956|NCT00332332|BIOLOGICAL|etanercept|etanercept subcutaneous injection
57768957|NCT00251927|DRUG|esomeprazole|40 mg oral tablet administered daily
57768958|NCT00251927|PROCEDURE|Laparoscopic fundoplication (surgery)|Surgery
57768959|NCT02829333|OTHER|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
57768960|NCT02829333|OTHER|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
57768961|NCT05666687|DRUG|MIJ821|MIJ821 will be administered as an i.v. infusion
57768962|NCT05919147|DRUG|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
57768963|NCT05919147|DRUG|Placebo|Placebo will have the same appearance as the active drug.
57768964|NCT00332683|PROCEDURE|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
57768965|NCT00332683|PROCEDURE|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
57768966|NCT02442635|BEHAVIORAL|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
57768967|NCT02176681|DRUG|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
57768968|NCT02176681|DRUG|Insulin|Insulin
57768969|NCT01806740|DRUG|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
57768970|NCT05241561|DRUG|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
57768971|NCT05241561|BIOLOGICAL|Blood sample|biomonitoring and pharmacokinetics
57768972|NCT05241561|OTHER|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
57768973|NCT06624046|BEHAVIORAL|Sleep stability intervention|The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.
57768974|NCT01679236|BEHAVIORAL|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
57768975|NCT01679236|BEHAVIORAL|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
57768976|NCT02826980|OTHER|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
57768977|NCT02841293|PROCEDURE|Biological mesh|The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
57768978|NCT02841293|PROCEDURE|Primary perineal wound closure|The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
57768979|NCT04022837|DRUG|Pantoprazole 40mg|effect of this drug on renal function
57768980|NCT03363659|DRUG|Disulfiram|Disulfiram is taken orally, twice daily.
57768981|NCT03363659|DIETARY_SUPPLEMENT|Copper gluconate|Copper gluconate is taken orally, twice daily
58129399|NCT04325074|OTHER|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
58129400|NCT03238066|RADIATION|Brachytherapy|HDR/PDR brachytherapy
57768982|NCT03363659|DRUG|Temozolomide|Temozolomide is taken once daily
57768983|NCT01758874|PROCEDURE|phlebotomy|repeated phlebotomy for 4 weeks
57768984|NCT05204641|BIOLOGICAL|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
57768985|NCT00612157|DRUG|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
57768986|NCT00612157|DRUG|Placebo control|Matching placebo
57768987|NCT03655990|DEVICE|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
57768988|NCT04446715|DRUG|sufentanil|Patients will receive sufentanil in spinal anesthesia
57768989|NCT04446715|DRUG|meperidine|Patients will receive meperidine in spinal anesthesia
57768990|NCT04446715|DRUG|Bupivacaine|Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
57768991|NCT03924713|BEHAVIORAL|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
57768992|NCT02751463|DRUG|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
57768993|NCT02751463|OTHER|Untreated skin|One site is patched without treatment as control
57768994|NCT00819403|DRUG|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
57768995|NCT00819403|DRUG|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
57768996|NCT00009581|DRUG|L-NMMA|
57768997|NCT00009581|DRUG|Acetylcholine|
57768998|NCT00154310|DRUG|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
57768999|NCT00154310|DRUG|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
57769000|NCT00154310|DRUG|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
57769001|NCT00154310|DRUG|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
57769002|NCT02835846|DRUG|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
57769003|NCT04082091|BEHAVIORAL|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium - receive fasting glucose test and BP measurement; and low risk. All subjects in each category will be enrolled in an e_Prescription intervention for lifestyle change tailored to their individual risk profile."
57769004|NCT00234156|PROCEDURE|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
57769005|NCT00877903|DRUG|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
57769006|NCT00877903|DRUG|Placebo|Intravenous infusion of excipients of Prochymal®
57769007|NCT02302066|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
57769008|NCT02302066|BIOLOGICAL|TDV Placebo|Placebo-matching vaccine
57769009|NCT03562455|OTHER|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
57769010|NCT03562455|BEHAVIORAL|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
57769011|NCT04031430|DEVICE|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
57769012|NCT04031430|OTHER|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
57769013|NCT04031430|OTHER|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
57769014|NCT00684762|DRUG|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
57769015|NCT00684762|DRUG|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
57769016|NCT00781066|PROCEDURE|Controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure."
57769017|NCT00781066|PROCEDURE|No controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
57769018|NCT04235101|DRUG|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
57769019|NCT03734991|DRUG|Ibrexafungerp|Ibrexafungerp 300 mg BID for 1 day
57769020|NCT03734991|DRUG|Placebo|Matching placebo
57769021|NCT06381011|OTHER|Local Vibration|The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
57769022|NCT03572855|COMBINATION_PRODUCT|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
58458189|NCT00498940|DEVICE|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
57769023|NCT02254421|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
57769024|NCT02254421|DRUG|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
57769025|NCT04997044|OTHER|Concomitant physical rehabilitation|Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.
58129401|NCT03238066|OTHER|Hyperthermia|Interstitial hyperthermia
58458190|NCT00498940|DEVICE|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
58458191|NCT04122365|OTHER|Chest Wall Mobilization Program|Soft tissue therapy and joints mobilization
58458192|NCT04122365|OTHER|Control|Routine limbs exercises and education
57769026|NCT04997044|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.
57769027|NCT04997044|OTHER|selective dorsal rhizotomy|The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
57769028|NCT01918319|BEHAVIORAL|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
57769029|NCT00526383|DRUG|Tricyclic antidepressants|antidepressant version medical dispositive
57769030|NCT04515667|BEHAVIORAL|Mindfulness|Participants will view a brief mindfulness video
57769031|NCT04515667|BEHAVIORAL|Video|Participants will view a control video
57769032|NCT01740102|PROCEDURE|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
57769033|NCT01976364|DRUG|Tofacitinib|Tofacitinib 5 mg tablet twice daily
57769034|NCT01976364|DRUG|Tofacitinib|Tofactinib 10 mg tablet twice daily
57769035|NCT01976364|DRUG|Methotrexate|Methotrexate 7.5-20 mg weekly
57769036|NCT01976364|DRUG|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
57769037|NCT01904214|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
57769038|NCT01852656|BEHAVIORAL|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
57769039|NCT01852656|BEHAVIORAL|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
57769040|NCT01852656|BEHAVIORAL|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
57769041|NCT01610232|DEVICE|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
57769042|NCT01610232|OTHER|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
57769043|NCT02777996|DEVICE|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
57769044|NCT04000932|DRUG|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
57769045|NCT04000932|DRUG|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
57769046|NCT00877578|DIETARY_SUPPLEMENT|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
57769047|NCT00877578|DIETARY_SUPPLEMENT|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
57769048|NCT02762734|OTHER|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
57769049|NCT00545363|DRUG|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
57769050|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769051|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769052|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769053|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769054|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769055|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769056|NCT00847821|DRUG|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769057|NCT00847821|DRUG|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
57769058|NCT04607824|BEHAVIORAL|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
57769059|NCT04607824|BEHAVIORAL|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
57769060|NCT00278590|BIOLOGICAL|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
57769061|NCT02568332|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
57769062|NCT02568332|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
57769063|NCT03354130|OTHER|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
57769064|NCT00001266|DRUG|Suramin|
57769065|NCT04178538|PROCEDURE|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
57769066|NCT04178538|PROCEDURE|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
57769067|NCT00103337|DRUG|cilengitide|Given IV
57769068|NCT00103337|OTHER|laboratory biomarker analysis|Correlative studies
57769069|NCT01332396|DRUG|Lapatinib|
57769070|NCT00469469|DRUG|Bevacizumab|
57769071|NCT05417984|DEVICE|Restoris MCK|During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.
57769072|NCT00001010|DRUG|Zidovudine|
57769073|NCT00001010|DRUG|Acyclovir|
57769074|NCT04559282|DEVICE|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
57769075|NCT05067946|BIOLOGICAL|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
57769076|NCT05067946|OTHER|Placebo|GX-19N formulation buffer
57769077|NCT03784235|OTHER|18F NaF-PET/CT and cone beam CT scans|Cross sectional measures of 18F NaF-PET/CT and cone beam CT scans
57769078|NCT01433393|DRUG|TAK-875|
57769079|NCT01433393|DRUG|TAK-875|
57769080|NCT01433393|DRUG|Placebo|
57769081|NCT04015700|BIOLOGICAL|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
57769082|NCT04015700|DEVICE|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
57769083|NCT04015700|DRUG|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
57769084|NCT04707339|PROCEDURE|Appendicectomy|Laparoscopic or Open Appendicectomy
58129402|NCT05249413|PROCEDURE|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
58129403|NCT03159156|BEHAVIORAL|Applied Tension|Described above.
57769085|NCT01364974|DRUG|ASP015K|oral
57769086|NCT01364974|DRUG|Placebo|oral
57769087|NCT03614338|BEHAVIORAL|Small changes weight loss program|"This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions."
57769088|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
57769089|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
58129404|NCT03159156|BEHAVIORAL|Respiration Control|Described above.
57769090|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
57769091|NCT01651273|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
57769092|NCT01946581|PROCEDURE|Cataract Surgery|
57769093|NCT05425849|OTHER|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
57769094|NCT00764374|DRUG|YM443|oral
57769095|NCT04581473|DRUG|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
57769096|NCT04581473|DRUG|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
57769097|NCT04745494|OTHER|OT administration|OT nasal administration
57769098|NCT04745494|OTHER|Placebo administration|Placebo nasal administration
57769099|NCT05231265|OTHER|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
58458193|NCT05887869|BEHAVIORAL|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
57769100|NCT06273982|BEHAVIORAL|STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)|STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
57769101|NCT06273982|BEHAVIORAL|ARC (assisted referral to community care)|ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
57769102|NCT01269008|DEVICE|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
57769103|NCT00905502|DRUG|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
57769104|NCT00905502|DRUG|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
57769105|NCT01583023|DRUG|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
57769106|NCT01583023|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
57769107|NCT01583023|OTHER|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
57769108|NCT01583023|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
57769109|NCT03184090|DRUG|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
57769110|NCT03184090|DRUG|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
57769111|NCT03184922|PROCEDURE|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
57769112|NCT02354924|DEVICE|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
57769113|NCT02354924|DEVICE|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
58129405|NCT03159156|BEHAVIORAL|Applied Tension/Respiration Control|Described above.
58458194|NCT04013607|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
57769114|NCT02042638|DRUG|hCG 1500 IU three times a week|
57769115|NCT02042638|DRUG|Pregnyl (hCG) ampule 1500 IU/three times a week|
57769116|NCT03679767|DRUG|Retifanlimab|Retifanlimab administered intravenously at 500 mg every 4 weeks
57769117|NCT01625923|DRUG|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
57769118|NCT04683809|OTHER|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
57769119|NCT01240954|DRUG|OSIRIS|OSIRIS current practice
57769120|NCT01240954|DRUG|OSIRIS other concentration 1|OSIRIS new concentration 1
57769121|NCT01240954|DRUG|OSIRIS other concentration 2|OSIRIS new concentration 2
57769122|NCT05790213|DRUG|Apalutamide Oral Product|Apalutamide 240 mg by mouth daily for a total of 6-months.
57769123|NCT05790213|DRUG|Androgen Deprivation Therapy (ADT)|ADT therapy will consist of any generic luteinizing hormone-releasing hormone agonist which will provide either 6-months of treatment or two injections every 3-months. (e.g., one injection with a treatment period of 6 months or two injections, one at drug start and one 3-months later).
58458195|NCT02364908|OTHER|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
58458196|NCT01147666|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arms.
58458197|NCT01147666|DRUG|Epoetin Alfa|Epoetin Alfa will be administered per dose and schedule specified in the arms.
58458198|NCT01147666|OTHER|Placebo|Placebo matching to roxadustat will be administered per schedule specified in the arm.
58458199|NCT00101231|DRUG|alvocidib|Given IV
58458200|NCT00883779|DRUG|Placebo|po on days 15-28 of each 4 week cycle until disease progression
57769124|NCT05790213|PROCEDURE|Focal Therapy|Focal therapy to be completed within 8- to 12-weeks of the initiation of apalutamide but after the completion of the 8-week mpMRI to allow for it to be used in FT planning.
57769125|NCT02918734|DEVICE|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
58458201|NCT00883779|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
57769126|NCT02918734|DEVICE|Metal interference screw|ACL reconstruction with metal interference screw
57769127|NCT01893827|DRUG|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
57769128|NCT01893827|DRUG|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
57769129|NCT05023967|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
57769130|NCT05023967|DRUG|Extended Release Metformin Hydrochloride|Given PO
57769131|NCT05023967|OTHER|Monitoring|Use continuous glucose monitoring system
57769132|NCT05023967|OTHER|Nutritional Assessment|Receive nutritional counseling
57769133|NCT05023967|OTHER|Short-Term Fasting|Perform intermittent fasting
57769134|NCT02527837|DRUG|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
57769135|NCT02527837|DRUG|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
57769136|NCT03705455|BEHAVIORAL|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
57769137|NCT02556437|DRUG|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
57769138|NCT02556437|DRUG|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
57769139|NCT04684082|DEVICE|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
57769140|NCT06291662|DEVICE|3D printer applications|Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
57769141|NCT01784432|DEVICE|Low-level laser therapy and training|
57769142|NCT01784432|OTHER|Training|
57769143|NCT02409550|OTHER|CARATKids Questionnaire|
57769144|NCT02790723|DRUG|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
57769145|NCT01280734|DRUG|Circadin (R) 2 mg|One 2 mg tablet at 23:00
57769146|NCT01280734|DRUG|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
57769147|NCT01280734|DRUG|Placebo|One tablet or encapsulated tablet at 23:00
57769148|NCT04500860|DRUG|Low dose tadalafil 5 mg|Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
57769149|NCT04500860|DRUG|Tolterodine 4 Mg Oral Capsule, Extended Release|To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
57769150|NCT04500860|DRUG|Placebo|Placebo drugs
57769151|NCT04169711|DRUG|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
57769152|NCT00749216|DRUG|Solanezumab|
57769153|NCT01208155|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
57769154|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
58458202|NCT00883779|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
58458203|NCT00883779|DRUG|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
58458204|NCT02003235|DEVICE|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
57769155|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
57769156|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
57769157|NCT01222468|DRUG|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
57769158|NCT01222468|DRUG|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
57769159|NCT00003759|BIOLOGICAL|BCG vaccine|
57769160|NCT00003759|DRUG|valrubicin|
57769161|NCT00003759|PROCEDURE|conventional surgery|
57769162|NCT01900574|DRUG|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
57769163|NCT02294474|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
57769164|NCT02294474|DRUG|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
57769165|NCT02294474|DRUG|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
57769166|NCT05905419|OTHER|Opioid Phase|"Opioid-taking patients are assigned to take their prescribed opioid medication before (peak opioid phase) during 1 scan and after (trough opioid phase) during the other MRI scan"
57769167|NCT00204126|DEVICE|Treadmill with partial body weight support|
57769168|NCT00204126|DEVICE|Surface Functional Electrical Stimulation|
57769169|NCT00747123|BIOLOGICAL|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
57769170|NCT00747123|BIOLOGICAL|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
57769171|NCT06625996|DIETARY_SUPPLEMENT|carbohydrate loading|Preoperative carbohydrate loading
57769172|NCT01083147|DEVICE|FORESEE HOME|Home Monitoring
57769173|NCT01596218|DRUG|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
57769174|NCT00335686|DRUG|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
57769175|NCT00335686|DRUG|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
57769176|NCT03430063|DRUG|SDREGN2810|Standard dose intravenous (IV) infusion
57769177|NCT03430063|DRUG|SDREGN2810/ipi|Combination therapy dose IV
57769178|NCT03430063|DRUG|HDREGN2810|High dose IV
58458205|NCT01100866|DIETARY_SUPPLEMENT|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
58458206|NCT01100866|OTHER|Placebo|placebo capsules
58458207|NCT05861596|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
57769179|NCT01338558|DRUG|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
57769180|NCT01338558|DRUG|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
57769181|NCT01338558|DRUG|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
57769182|NCT04717973|DIAGNOSTIC_TEST|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
57769183|NCT04824248|BEHAVIORAL|Pain Neuroscience Education|Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.
57769184|NCT04824248|BEHAVIORAL|Cognition-targeted exercise therapy|Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.
57769185|NCT04824248|BEHAVIORAL|Behavioral weight reduction program|Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.
57769186|NCT02732613|DEVICE|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
57769187|NCT03997058|OTHER|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
57769188|NCT03997058|DRUG|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
57769189|NCT06399367|DIAGNOSTIC_TEST|MSOT|The MSOT system used consists of a laser in the visible near-infrared and far-infrared wavelength range (660nm-1300nm) and an ultrasonic sensor connected to a computer. Using optical components, the area to be measured is illuminated with ultra-short light pulses of selectable wavelength. The light is absorbed to varying degrees inside the object - depending on the properties of the tissue. The absorption of light leads to local microscopic volume fluctuations and thereby emits pressure waves in the ultrasonic range (photoacoustic effect). MSOT enables non-invasive, non-ionizing 2D imaging with high spatial resolution (80 μm), which enables specific visualization of endogenous tissue pigments such as collagen fibers, fat, melanin, oxyhemoglobin and deoxyhemoglobin.
57769190|NCT01720823|DEVICE|home polysomnography (GETEMED)|
57769191|NCT01720823|DEVICE|standard polysomnography (BRAINNET II)|
57769192|NCT00747526|DRUG|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
57769193|NCT00747526|DRUG|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
57769194|NCT00282997|DRUG|pregabalin|
57769195|NCT00497965|PROCEDURE|Chiropractic Manipulation|
57769196|NCT00497965|BEHAVIORAL|Balance Exercises|
57769197|NCT05943275|DEVICE|Magnetic sensor|During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
57769198|NCT04748419|RADIATION|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
57769199|NCT04748419|DRUG|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
57769200|NCT01416701|DIETARY_SUPPLEMENT|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
58458208|NCT05861596|DEVICE|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
57769201|NCT01416701|DIETARY_SUPPLEMENT|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
57769202|NCT03100994|DRUG|Bupivacaine|injecting anesthetics to different local
57769203|NCT03100994|DEVICE|Ultrasound|Ultrasound guided nerve block
57769204|NCT02478125|DRUG|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
57769205|NCT02478125|DRUG|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
57769206|NCT02478125|DRUG|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
57769207|NCT02140710|PROCEDURE|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
57769208|NCT01411501|OTHER|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
58458209|NCT00000547|DRUG|enalapril|
58458210|NCT04980534|DIETARY_SUPPLEMENT|Viusid and Asbrip|Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
58458211|NCT04980534|DRUG|COVID-19 Standard Therapy|Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
58458212|NCT02920892|DRUG|AFQ056|12.5 mg - 100 mg oral suspension (liquid)
58458213|NCT02920892|DRUG|Placebo|Placebo oral suspension (liquid)
57769209|NCT01411501|DRUG|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
57769210|NCT05636150|DRUG|Fruquintinib in Combination with S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
57769211|NCT04245085|DRUG|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
57769212|NCT04245085|DRUG|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
57769213|NCT04245085|DRUG|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
57769214|NCT04245085|DRUG|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
57769215|NCT04245085|DRUG|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
57769216|NCT02403843|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
57769217|NCT01582789|DEVICE|enfilcon A|enfilcon A daily wear soft contact lens
57769218|NCT01582789|DEVICE|senofilcon A|senofilcon A daily wear soft contact lens
57769219|NCT00363337|DRUG|aripiprazole|open label treatment with aripiprazole
57769220|NCT02024035|RADIATION|Radiotherapy|
58458214|NCT02920892|OTHER|Language Intervention|"All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children."
57769221|NCT00152971|DRUG|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
57769222|NCT00152971|DRUG|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
57769223|NCT00152971|DRUG|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
57769224|NCT00152971|DRUG|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
57769225|NCT00152971|DRUG|Enoxaparin|30 mg subcutaneously twice daily
57769226|NCT01167283|DEVICE|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
57769227|NCT01167283|DEVICE|Sham stimulation|Sham stimulation: 1 h; 5 times/week
57769228|NCT02012192|DRUG|Ganetespib|
57769229|NCT02012192|DRUG|Paclitaxel|
57769230|NCT00371852|DRUG|lactoserum|
57769231|NCT00675415|DIAGNOSTIC_TEST|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
57769232|NCT02732626|PROCEDURE|radiofrequency ablation|
57769233|NCT04599738|OTHER|Wheat muffin|Participants consumed a control muffin made of wheat flour.
57769234|NCT04599738|OTHER|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
57769235|NCT03413254|OTHER|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
57769236|NCT03413254|PROCEDURE|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
57769237|NCT03413254|PROCEDURE|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
57769238|NCT06340165|DRUG|Anlotinib|Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
57769239|NCT00037557|DRUG|BeneFIX|
57769240|NCT00659594|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
57769241|NCT00659594|DRUG|Placebo|placebo
58458215|NCT02313701|OTHER|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
58458216|NCT00768417|BEHAVIORAL|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
58458217|NCT00768417|BEHAVIORAL|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
57769242|NCT04990206|BEHAVIORAL|TranS-C|"TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change."
57769243|NCT05989373|DIAGNOSTIC_TEST|Scratch collapse test|Scratch test performed by the surgeon but with a dynamometer
57769244|NCT02529878|DRUG|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
57769245|NCT02527070|DEVICE|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
57769246|NCT02527070|DEVICE|Quantum Warp10 (Red LED)|
57769247|NCT02527070|DEVICE|Omnilux new-U (Near Infrared LED)|
57769248|NCT02527070|OTHER|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
57769249|NCT02681705|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
57769250|NCT02681705|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
58458218|NCT00768417|BEHAVIORAL|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
58458219|NCT03798717|DIAGNOSTIC_TEST|Heating|Warm water immersion
58458220|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
58458221|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
57769251|NCT04180735|PROCEDURE|Liver transplantation|Liver transplantation
57769252|NCT04199533|BEHAVIORAL|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
57769253|NCT04199533|BEHAVIORAL|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
57769254|NCT01998490|OTHER|Animal-assisted activity|
57769255|NCT01998490|OTHER|Robot-assisted activity|
57769256|NCT00911313|DRUG|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
57769257|NCT00911313|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
57769258|NCT00911313|DRUG|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
57769259|NCT02611830|DRUG|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
57769260|NCT02611830|DRUG|Placebo IV|Vedolizumab intravenous infusion placebo
57769261|NCT02611830|DRUG|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
57769262|NCT02611830|DRUG|Placebo SC|Vedolizumab subcutaneous injection placebo
57769263|NCT03590665|OTHER|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
57769264|NCT03447730|DRUG|SYNB1020|SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
57769265|NCT03447730|OTHER|Placebo|Subjects received placebo orally in a chilled buffered solution (100 mL).
57769266|NCT04299334|PROCEDURE|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
57769267|NCT03491423|OTHER|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
57769268|NCT03491423|BIOLOGICAL|glucose meter|glucose meter to measure lactatemia
57769269|NCT03491423|OTHER|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
57769270|NCT03491423|OTHER|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
57769271|NCT03491423|OTHER|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
57769272|NCT01947660|DRUG|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
57769273|NCT01947660|DRUG|Systemic analgesia|Systemic analgesia as usual
57769274|NCT04549311|DRUG|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
57769275|NCT04549311|DRUG|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
57769276|NCT06279572|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57769277|NCT06279572|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
57769278|NCT06279572|OTHER|Electronic Health Record Review|Medical records are reviewed
57769279|NCT06251739|DRUG|Ivermectin 6 Mg Oral Tablet|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
57769280|NCT06251739|DRUG|Miltefosine Oral Capsule|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
57769281|NCT04956978|OTHER|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
57769282|NCT01067027|DIETARY_SUPPLEMENT|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
57769283|NCT06314490|DRUG|nL-SCN2A-002|Personalized antisense oligonucleotide
57769284|NCT06202183|BEHAVIORAL|Exercise Program|A 12 week, home-based, virtually supervised, aerobic and resistance exercise training program comprised of 36 sessions. Participants will be provided with a home stationary bike, resistance bands, and Fitbit. Virtually supervised sessions will be accessible via Zoom platform. For participants who do not have a device, a Wi-Fi-enabled tablet will also be provided.
57769285|NCT05930418|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance provides more sensitive measure of ventricular volume and ejection fraction as well as novel markers of tissue characterization and edema assessment.
57769286|NCT05800808|PROCEDURE|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
57769287|NCT05800808|PROCEDURE|Moderate Exercise|81 minutes of cycling at 50% VO2peak
57769288|NCT02019134|BEHAVIORAL|relaxation exercise|relaxation exercise
58458222|NCT05559177|BIOLOGICAL|Chimeric exosomal tumor vaccines|Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
58458223|NCT02784886|BIOLOGICAL|Women at high risk of MAP|Blood sample
58458224|NCT02172430|DRUG|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
58458225|NCT02172430|DRUG|Tersigan®|2 puffs of oxitropium three times daily via MDI
57769289|NCT02019134|OTHER|ususal care|
57769290|NCT05027399|BEHAVIORAL|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
57769291|NCT01155661|DRUG|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
58458226|NCT03186209|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
58458227|NCT03186209|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
58458228|NCT04871841|BIOLOGICAL|Sputnik V|Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
58458229|NCT03605667|DRUG|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
58458230|NCT03605667|DRUG|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
58458231|NCT04970277|OTHER|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
58458232|NCT04970277|OTHER|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
58458233|NCT06276322|OTHER|Low back pain group|The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
58458234|NCT06276322|OTHER|Healthy group|Low back pain kinematics compare them with asymptomatic kontrols
57769292|NCT01155661|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
57769293|NCT04968262|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
57769294|NCT04968262|OTHER|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
57769295|NCT00591123|DRUG|FOLFOX|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
57769296|NCT00591123|DRUG|5-FU|5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
57769297|NCT00591123|DRUG|Erlotinib|All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
58458235|NCT06325059|OTHER|Study of renal progenitors|Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
58458236|NCT03780049|PROCEDURE|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
58458237|NCT03780049|DRUG|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
58458238|NCT03780049|DRUG|Placebos|Patients receive normal saline 10ml in each session of HAIC
58458239|NCT01581918|DRUG|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
58458240|NCT05525377|BEHAVIORAL|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
58458241|NCT03034486|DRUG|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
58458242|NCT04085419|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|denosumab 60 mg subcutaneously every 6 months
58458243|NCT04085419|DRUG|Zoledronic Acid|zoledronic acid 5 mg intravenously once a year
58458244|NCT05574478|BEHAVIORAL|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
58458245|NCT05042674|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 2 additional blood draws
58458246|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams|after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws
58458247|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams, daily for 1 week|a blood draw will be administered after a week of consuming 25mg ergothioneine daily
58458248|NCT05383209|DRUG|EYP-1901|Intravitreal Injection
58458249|NCT05383209|OTHER|Sham IVT|Sham IVT
58458250|NCT01062750|BIOLOGICAL|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
58458251|NCT00818610|DRUG|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
58458252|NCT00818610|DRUG|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
58458253|NCT00254319|DRUG|Avastin, Alimta|
58458254|NCT02413307|OTHER|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
58458255|NCT01847352|DRUG|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
57769298|NCT01420263|PROCEDURE|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
58458256|NCT01847352|OTHER|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
58458257|NCT06452537|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
58458258|NCT06452537|DRUG|Prednisone|Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
58458259|NCT01361971|PROCEDURE|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
58458260|NCT02538744|DRUG|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
58458261|NCT02538744|DRUG|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
58458262|NCT02538744|DRUG|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
58458263|NCT02538744|DRUG|Placebo|
58458264|NCT02119871|PROCEDURE|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
58458265|NCT02119871|PROCEDURE|Right Pleura Open|Right pleura open Left ventricular apical drainage
58458266|NCT02826746|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
58458267|NCT02826746|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
58458268|NCT04515004|DRUG|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
58458269|NCT06244004|DRUG|Antiandrogen Therapy|Undergo SOC ADT
58458270|NCT06244004|PROCEDURE|Bone Scan|Undergo bone scan
58458271|NCT06244004|PROCEDURE|Computed Tomography|Undergo CT
58458272|NCT06244004|DRUG|Cytotoxic Chemotherapy|Receive SOC cytotoxic chemotherapy
58458273|NCT06244004|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
58458274|NCT06244004|RADIATION|Radiation Therapy|Undergo MDRT
58458275|NCT03679975|DRUG|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
58458276|NCT02343042|DRUG|Selinexor|Oral tablets
58458277|NCT02343042|DRUG|Dexamethasone|Oral tablets
58458278|NCT02343042|DRUG|Lenalidomide|Oral capsule
57769299|NCT01420263|PROCEDURE|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
57769300|NCT02367716|DEVICE|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
57769301|NCT01930630|DEVICE|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
57769302|NCT06379256|RADIATION|Photon or proton radiotherapy|"* 39.6-72.6 Gy (or Cobalt Gray Equivalent, CGE) in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy (or CGE) in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-60 Gy (or CGE) in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
57769303|NCT00034645|DRUG|Posaconazole oral suspension|
57769304|NCT01083420|DRUG|Minocycline|Minocycline 0.2% mouthwash
57769305|NCT01083420|DRUG|Dexamethasone|Dexamethasone 0.01% mouthwash
57769306|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
57769307|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
57769308|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
57769309|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
57769310|NCT02608905|DRUG|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
57769311|NCT02608905|DRUG|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
57769312|NCT04821271|OTHER|Placebo|Arm 1 and 2 Control Intervention
57769313|NCT04821271|DRUG|TS-161 (50 - 100 mg)|Arm 1 and 2 Experimental Intervention
57769314|NCT02005315|DRUG|Vantictumab|Administered intravenous (IV) infusion.
57769315|NCT02005315|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
57769316|NCT02005315|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
57769317|NCT04610216|DEVICE|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
57769318|NCT01935921|BIOLOGICAL|Cetuximab|Given IV
57769319|NCT01935921|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
57769320|NCT01935921|BIOLOGICAL|Ipilimumab|Given IV
57769321|NCT01935921|OTHER|Laboratory Biomarker Analysis|Correlative studies
57769322|NCT03720782|DEVICE|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
57769323|NCT01312987|DIETARY_SUPPLEMENT|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
57769324|NCT04112940|OTHER|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
57769325|NCT04112940|OTHER|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
57769326|NCT04154215|DIAGNOSTIC_TEST|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
57769327|NCT03679195|DIETARY_SUPPLEMENT|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
58129406|NCT06179238|OTHER|Education|Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.
58129407|NCT06179238|OTHER|without patient education|without patient education
58129408|NCT03969953|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban is an orally administered selective direct factor Xa inhibitor.
58129409|NCT03969953|OTHER|Placebo|Rivaroxaban matched placebo
58458279|NCT02343042|DRUG|Pomalidomide|Oral tablets
58129410|NCT04989036|PROCEDURE|pulpotomy|Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
58129411|NCT02834000|DEVICE|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
57769328|NCT03679195|DIETARY_SUPPLEMENT|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
57769329|NCT01678820|DRUG|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
57769330|NCT01678820|DRUG|Sitagliptin|Sitagliptin 100 mg tablet
57769331|NCT01678820|DRUG|Simvastatin|Simvastatin 40 mg tablet
57769332|NCT01678820|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
57769333|NCT01678820|DRUG|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
57769334|NCT01678820|DRUG|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
57769335|NCT01678820|DRUG|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study
57769336|NCT01678820|DRUG|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
57769337|NCT03620643|DRUG|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
57769338|NCT03620643|DRUG|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
57769339|NCT04780724|OTHER|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
57769340|NCT04780724|OTHER|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
57769341|NCT04780724|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
58129412|NCT02210403|DEVICE|transcranial direct current stimulation (tDCS)|
58458280|NCT02343042|DRUG|Bortezomib|Subcutaneous Injection (single use vial)
57769342|NCT01265589|DRUG|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
57769343|NCT01265589|DRUG|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
57769344|NCT06325137|DIAGNOSTIC_TEST|Transcriptome analyses|A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
57769345|NCT02958618|PROCEDURE|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
57769346|NCT02958618|PROCEDURE|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
57769347|NCT02958618|PROCEDURE|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
57769348|NCT01305278|OTHER|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
57769775|NCT06319768|DRUG|platelet rich plasma|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
58129413|NCT01484405|PROCEDURE|posterior approach|Surgical approach for Total Hip Arthroplasty
58129414|NCT01484405|PROCEDURE|anterolateral approach|anterolateral surgical approach
58129415|NCT01225146|DRUG|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
58458281|NCT02343042|DRUG|Daratumumab|Intravenous Infusion
58458282|NCT02343042|DRUG|Carfilzomib|Intravenous infusion
58458283|NCT02343042|DRUG|Ixazomib|Oral capsule
57769349|NCT03594903|BEHAVIORAL|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
57769350|NCT03594903|BEHAVIORAL|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
57769351|NCT03305224|DRUG|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
57769352|NCT03239873|BIOLOGICAL|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
57769353|NCT03239873|BIOLOGICAL|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
57769354|NCT03239873|BIOLOGICAL|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
57769355|NCT01382485|OTHER|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
57769356|NCT01382485|OTHER|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
57769357|NCT06125743|BEHAVIORAL|Usual Care|Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
57769358|NCT06125743|BEHAVIORAL|In-Person LEF-SMP|Participants will receive the in-person LEF-SMP intervention.
57769359|NCT06125743|BEHAVIORAL|Telehealth LEF-SMP|Participants will receive the telehealth LEF-SMP intervention.
57769360|NCT01949597|PROCEDURE|laparoscopic surgery for deep endometriosis|
58129416|NCT02393040|OTHER|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
58129417|NCT00870870|DRUG|Gemcitabine|"1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]"
58129418|NCT00870870|DRUG|Cisplatin|"75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]"
57769361|NCT03764423|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
58129419|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]"
58129420|NCT00870870|BIOLOGICAL|Cetuximab|"400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]"
58129421|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
58129422|NCT00870870|BIOLOGICAL|Cetuximab|"500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
57769362|NCT03764423|DIETARY_SUPPLEMENT|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
57769363|NCT01754454|BIOLOGICAL|Human Umbilical Cord Derived MSC|1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
57769364|NCT00376051|DRUG|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
57769365|NCT02396537|DRUG|Lidocaine|Administered intranasally prior to Midazolam administration.
57769366|NCT02396537|DRUG|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
57769367|NCT02396537|DRUG|0.9% Saline|Administered intranasally prior to Midazolam administration.
57769368|NCT02835456|DEVICE|Sharklet Catheter insertion|
57769369|NCT02835456|DEVICE|Silicone Foley Catheter insertion|
58458284|NCT02343042|DRUG|Elotuzumab|Intravenous infusion
58458285|NCT02343042|DRUG|Clarithromycin|Tablets
58458286|NCT02343042|DRUG|Belantamab Mafodotin|Intravenous infusion
58458287|NCT02343042|DRUG|Mezigdomide|Oral Capsules
58458288|NCT04896996|DIETARY_SUPPLEMENT|whole eggs|whole eggs
57769370|NCT05217836|DIAGNOSTIC_TEST|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
57769371|NCT05349721|DRUG|PTC857|PTC8657 will be administered as an oral solution twice a day.
57769372|NCT05349721|DRUG|Placebo|Matching placebo will be administered as an oral solution twice a day.
58458289|NCT04896996|DIETARY_SUPPLEMENT|yolk-free egg substitutes|yolk-free egg substitutes
57769373|NCT03337191|DRUG|Levobupivacaine|% 0,125 levobupivacaine
57769374|NCT03337191|DRUG|Morphine Sulfate|10 mq/kg morphine sulfate
57769375|NCT03337191|DEVICE|Ultrasound|Ultrasound guided caudal block
57769376|NCT00211341|DIETARY_SUPPLEMENT|Vitamin A|Weekly single oral dose 7000 micrograms
58458290|NCT00960375|BEHAVIORAL|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
57769377|NCT05033080|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
57769378|NCT05033080|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
57769379|NCT05033080|DRUG|IVA|Tablet for oral administration.
57769380|NCT05033080|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
57769381|NCT05033080|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
57769382|NCT05033080|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
57769383|NCT05777954|OTHER|Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage|"Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques"
57769384|NCT05777954|OTHER|Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines|Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
57769385|NCT04303312|OTHER|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
57769386|NCT04303312|COMBINATION_PRODUCT|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
57769387|NCT04485130|DRUG|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
57769388|NCT04485130|DRUG|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
57769389|NCT02281175|BEHAVIORAL|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
57769390|NCT02281175|BEHAVIORAL|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
57769391|NCT06480682|RADIATION|Dual x-ray scan|Annual whole body scan monitoring bone mineral density for whole body, radius, L1-4 and femur and body composition
58129423|NCT00870870|DRUG|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin"
57769392|NCT06480682|DIAGNOSTIC_TEST|Blood screen|Three times a year blood samples will be taken to measure: full blood count, ferritin, B12, folate, erythrocyte sedimentation rate (ESR), renal function, liver function, thyroid stimulating hormone (TSH), Free thyroxine (T4), luteinizing hormone (LH), oestradiol, testosterone, follicle-stimulating hormone (FSH), coeliac screen, vitamin D (25(OH)D), Leptin and Ghrelin
57769393|NCT06480682|OTHER|Questionnaires|Informed consent; Low energy availability questionnaires for males and females; General health including menstrual status (females)
57769394|NCT06480682|OTHER|Anthropometric measurements|Three times a year participant's measurements will be taken: stature, body mass and body composition (bio-impedence)
57769395|NCT06480682|PROCEDURE|Resting Metabolic rate|Resting metabolic rate will be measured by resting gas analysis. Each participant will lie down for a period of 15 minutes, in the final 5 minutes their expired gases are analysed using a breath-by-breath gas analyser (Cortex).
57769396|NCT06480682|OTHER|Energy expenditure|Energy expenditure was estimated using accelerometery (Genieactive) and activity logs in the participants' normal environment, assessed during 3 weekdays of scheduled dance training and 2 weekend days without scheduled dance training. Focus is on daily energy expenditure
57769397|NCT00125580|BEHAVIORAL|Infant sleep instruction|
57769398|NCT03774602|BEHAVIORAL|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
58129424|NCT05856045|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week."
57769399|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
57769400|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
57769401|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
57769402|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
57769403|NCT00735644|BIOLOGICAL|Hepatitis A vaccine|0.5 mL, Intramuscular
57769404|NCT02618720|DRUG|ornidazole|
57769405|NCT02618720|DRUG|Placebo|
57769406|NCT03331185|BIOLOGICAL|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
57769407|NCT03331185|BIOLOGICAL|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
57769408|NCT01115543|DRUG|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
57769409|NCT04262492|DRUG|Rivaroxaban|Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID
57769410|NCT05097768|DRUG|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
57769411|NCT05097768|DRUG|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
57769412|NCT05097768|DRUG|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
57769413|NCT05097768|DRUG|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
57769414|NCT05097768|DRUG|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
57769415|NCT05765084|BIOLOGICAL|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
57769416|NCT05765084|DRUG|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
58458291|NCT00960375|BEHAVIORAL|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
58458292|NCT04608981|DRUG|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
57769417|NCT05765084|DRUG|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
57769418|NCT06177236|DIAGNOSTIC_TEST|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
57769419|NCT01515904|BEHAVIORAL|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
57769420|NCT04706741|DRUG|Izokibep|Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously
57769421|NCT04706741|DRUG|Prednisone/Prednisolone|Background Corticosteroid
57769422|NCT04229030|DRUG|RZL-012|small synthetic molecule for the treatment of Dercum's Disease lipomas
57769423|NCT04229030|DRUG|Vehicle|Vehicle of RZL-012 drug product
57769424|NCT00583232|DRUG|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
57769425|NCT05824390|DRUG|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
57769426|NCT03180879|DRUG|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
58458293|NCT04608981|DRUG|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
58458294|NCT04608981|DRUG|Placebo|Starch
58458295|NCT00799201|DRUG|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
58458296|NCT05958940|PROCEDURE|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
58458297|NCT05958940|DEVICE|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
58458298|NCT02398916|BEHAVIORAL|Music listening|
58458299|NCT03222635|PROCEDURE|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
58458300|NCT05846126|BEHAVIORAL|RehabCovid_Telematic|A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
58458301|NCT05846126|BEHAVIORAL|RehabCovid_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
58458302|NCT05846126|BEHAVIORAL|Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
58458303|NCT06079788|DRUG|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion."
57769427|NCT03180879|DRUG|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
57769428|NCT03180879|DRUG|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
57769429|NCT03290560|DRUG|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
57769430|NCT03290560|OTHER|Placebo|Placebo Comparator: Phosphate buffered saline
57769431|NCT00299195|DRUG|sulindac|Sulindac 150 mg po bid x 24 weeks
57769432|NCT00299195|DRUG|Placebo|Placebo bid x 24 weeks
57769433|NCT03303586|OTHER|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
58129425|NCT05856045|OTHER|PBBT (pertubation based balance training)|"Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week."
58129426|NCT05856045|OTHER|PNF and PBBT intervention group|proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
57769434|NCT03303586|OTHER|Control|Participants will not wearing compression stockings for two weeks.
57769435|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II)|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II)."
57769436|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II), Famitinib|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib."
57769437|NCT04437147|DIETARY_SUPPLEMENT|Placebo|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
57769438|NCT04437147|DIETARY_SUPPLEMENT|3 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
57769439|NCT04437147|DIETARY_SUPPLEMENT|8 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
57769440|NCT06259734|BEHAVIORAL|Transfusion Camp Rwanda education|Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
57769441|NCT01568632|DRUG|Imetelstat|
57769442|NCT04773639|BEHAVIORAL|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
57769443|NCT04773639|BEHAVIORAL|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
57769444|NCT03146832|BEHAVIORAL|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
57769445|NCT03146832|BEHAVIORAL|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
58129427|NCT01323764|DEVICE|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
58129428|NCT00000566|PROCEDURE|ventilation-perfusion ratio|
58129429|NCT00000566|PROCEDURE|angiography|
58129430|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
58129431|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
57769446|NCT03173781|DRUG|droxidopa|medication
57769447|NCT03173781|DRUG|Placebo|medication
57769448|NCT05236413|BEHAVIORAL|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
57769449|NCT05236413|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
57769450|NCT05236413|BEHAVIORAL|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
57769451|NCT01045122|DRUG|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
57769452|NCT01045122|DRUG|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
57769453|NCT05527730|DEVICE|Comparison of PRO-FIT or SELF-FIT fitting|add
57769454|NCT05351645|BEHAVIORAL|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
57769455|NCT00284869|DRUG|LPS|
57769456|NCT00668824|DRUG|Vasovist|
57769457|NCT01435434|DEVICE|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
57769458|NCT04774822|PROCEDURE|Color Fundus Photography|Stereoscopic Fundus photography
57769459|NCT04774822|DRUG|Mydriatics Agent|Eye dilating agent
57769460|NCT04774822|PROCEDURE|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
57769461|NCT00702182|DRUG|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
57769462|NCT00702182|DRUG|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
57769463|NCT00702182|DRUG|Erlotinib|Daily Oral Erlotinib 100 mg
57769464|NCT05790564|OTHER|Almond|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
57769465|NCT05790564|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
57769466|NCT05039762|PROCEDURE|Extracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
57769467|NCT05039762|PROCEDURE|Intracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
57769468|NCT00482274|DRUG|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
57769469|NCT02799303|DEVICE|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
57769470|NCT02799303|OTHER|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
57769776|NCT06319768|DRUG|combined pentoxifylline and platelet rich plasma|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
57769777|NCT06286540|DEVICE|Lymphoblock|1 time per surgery with the exposition for 20 minutes.
57769778|NCT06286540|DEVICE|Placebo|1 time per surgery with the exposition for 20 minutes.
58458304|NCT06079788|DRUG|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
57769471|NCT03128437|BEHAVIORAL|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
57769472|NCT01070823|DRUG|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
57769473|NCT03465449|BEHAVIORAL|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
57769474|NCT03465449|OTHER|usual care|Nephrologist based usual care
57769475|NCT04186403|DRUG|Brexpiprazole|Administered as tablets.
57769476|NCT02146222|DRUG|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
57769477|NCT02146222|DRUG|docetaxel|Given IV
57769478|NCT02146222|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
57769479|NCT02146222|PROCEDURE|positron emission tomography/computed tomography|Undergo FLT PET/CT
57769480|NCT02146222|OTHER|pharmacological study|Correlative studies
57769481|NCT02146222|OTHER|laboratory biomarker analysis|Correlative studies
57769482|NCT03580213|OTHER|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
57769483|NCT03580213|OTHER|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
57769484|NCT02496403|BEHAVIORAL|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
57769485|NCT06081374|DEVICE|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
57769486|NCT05242016|OTHER|structured individual reminiscence|reminiscence therapy
57769487|NCT05242016|OTHER|unstructured social interview|placebo
57769488|NCT04246515|DEVICE|Blood Flow Restriction Training|Vascular occlusion of the injured limb.
57769489|NCT04246515|DEVICE|Sham Blood Flow Restriction Training|Blood Flow Restriction material will be attached to the limb without vascular occlusion.
57769490|NCT04246515|OTHER|Classic rehabilitation|Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
57769491|NCT06474689|OTHER|EMDR|EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.
57769492|NCT06474689|OTHER|CBT|CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
58458305|NCT04213547|BEHAVIORAL|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
58458306|NCT05718973|OTHER|short, animated storytelling video (intervention video)|Participants in the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital.
57769779|NCT06488183|PROCEDURE|preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q|preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
57769780|NCT05426382|DEVICE|A digital care solution for patients with NAFLD|A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
57769781|NCT04380337|DRUG|FOLFOXIRI|Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
58458307|NCT05718973|OTHER|short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
58458308|NCT02527681|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
57769493|NCT04646200|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
57769494|NCT04646200|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
57769495|NCT04041440|BEHAVIORAL|clEAR auditory training|Children play auditory brain training computer games
57769496|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (low dose).
57769497|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (high dose).
57769498|NCT02040987|DRUG|Placebo|Placebo oral solution - one single dose
57769499|NCT02040987|DRUG|Moxifloxacin|Moxifloxacin tablet - one single dose
57769500|NCT01376960|PROCEDURE|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
57769501|NCT03719365|DEVICE|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
57769502|NCT00790153|DRUG|Insulin|Insulin infusion given during 3 hours at one occasion.
57769503|NCT00790153|DRUG|AZD1656|Single dose oral suspension given at one occasion.
57769504|NCT03278886|DRUG|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
57769505|NCT03278886|DRUG|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
57769506|NCT01086605|DRUG|pixantrone dimaleate|Given IV
57769507|NCT03218332|DIAGNOSTIC_TEST|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
57769508|NCT01569035|DRUG|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
57769509|NCT05417334|DEVICE|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
57769510|NCT03813342|BEHAVIORAL|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
57769511|NCT03077620|DRUG|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
57769512|NCT03077620|DRUG|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
57769513|NCT05406960|DIETARY_SUPPLEMENT|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
57769514|NCT05817305|OTHER|Medical history and functional evaluation|During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
57769515|NCT05817305|OTHER|Health education|Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
57769516|NCT01676532|OTHER|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
57769517|NCT05393271|DRUG|VH4011499|VH4011499 will be administered.
57769518|NCT05393271|DRUG|Placebo|Placebo will be administered.
57769519|NCT05393271|DRUG|Midazolam|Midazolam will be administered
57769520|NCT00376441|PROCEDURE|Vaginal Surgery|patients undergoing vaginal surgery
57769521|NCT04642586|DIAGNOSTIC_TEST|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
58458309|NCT05765682|OTHER|Mepivacaine Spinal|spinal block using 60mg of mepivacaine
58458310|NCT05765682|OTHER|Bupivacaine Spinal|spinal block using 10mg of bupivacaine
58458311|NCT00973726|OTHER|Glucose test|Subjects ingest an oral glucose tolerance test.
58458312|NCT03303326|BEHAVIORAL|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
57769522|NCT04642586|DIAGNOSTIC_TEST|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
57769523|NCT04642586|DIAGNOSTIC_TEST|neuropsychological assessment|neuropsychological assessment
57769524|NCT00976469|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
57769525|NCT00976469|BIOLOGICAL|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
57769787|NCT00423293|RADIATION|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes \> 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
57769788|NCT01998594|PROCEDURE|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
57769789|NCT02145078|DRUG|docetaxel|Given IV
57769790|NCT02145078|DRUG|pemetrexed disodium|Given IV
57769791|NCT02145078|DRUG|gemcitabine hydrochloride|Given IV
57769792|NCT02145078|OTHER|laboratory biomarker analysis|Correlative studies
57769793|NCT00049998|DRUG|topotecan|
57769794|NCT01662531|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
57769795|NCT00960674|PROCEDURE|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
57769796|NCT00960674|BEHAVIORAL|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
57769797|NCT02929550|OTHER|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
57769798|NCT01051063|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
57769799|NCT05833243|OTHER|modified diaphragmatic training|Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
57769800|NCT05833243|OTHER|standard diaphragmatic training|"standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist."
58458765|NCT03925623|OTHER|Novel approaches for the design of child resistant closures|"Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system."
58458766|NCT00455299|PROCEDURE|Laparoscopic ventral hernia repair|
57769801|NCT04248842|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
57769802|NCT00004924|DRUG|irinotecan hydrochloride|
57769803|NCT00004924|DRUG|paclitaxel|
57769804|NCT00764192|PROCEDURE|blood sample|blood sample before and after a single HD
57769805|NCT00764192|PROCEDURE|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
58458767|NCT05901987|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
58138123|NCT03172351|DEVICE|EDoF1|extended depth of focus IOL - EDoF1
58458768|NCT02462044|DRUG|240 mg Iodine|
58138124|NCT03172351|DEVICE|Monofocal|Monofocal IOL
58458769|NCT02462044|DRUG|300 mg Iodine|
58458770|NCT02462044|DRUG|370 mg Iodine|
57769806|NCT00562978|BIOLOGICAL|filgrastim|
57769807|NCT00562978|DRUG|cyclophosphamide|
57769808|NCT00562978|DRUG|etoposide|
57769809|NCT00562978|PROCEDURE|AHSCT|
57769810|NCT00562978|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
58138125|NCT03172351|DEVICE|EDoF2|Comparison EDoF2 IOL
58458771|NCT05738135|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
58458772|NCT05738135|DRUG|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
58458773|NCT04555395|OTHER|survival rates|survival rates
58458774|NCT04634461|DEVICE|Cardiac Monitor|RHYTHMSTAR Mobile Cardiac Monitoring System
58458775|NCT03002961|DRUG|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
58458776|NCT03002961|DRUG|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
58458777|NCT03561675|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
57769811|NCT05082142|DRUG|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
57769812|NCT04944030|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
57769813|NCT04378660|DIAGNOSTIC_TEST|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
57769814|NCT00885989|DRUG|SLV338|5 - 1000 mg IV
57769815|NCT00885989|DRUG|Placebo|Placebo
57769816|NCT05278052|RADIATION|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
57769817|NCT05278052|DRUG|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
57769818|NCT05146960|OTHER|Temporal summation|Temporal summation will be evoked in each predetermined area
57769819|NCT05146960|OTHER|Placebo|PPTs will be assessed once in each predetermined area
57769820|NCT04147182|DRUG|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
57769821|NCT03108729|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
57769822|NCT02721641|DRUG|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
57769823|NCT03918954|DEVICE|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
57769824|NCT03918954|OTHER|Sensory room|A room with calming elements that patients can use to feel calm.
57769825|NCT00101335|DRUG|celecoxib|
57769826|NCT04855110|DRUG|Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
57769827|NCT04855110|DRUG|Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
57769828|NCT05437822|DRUG|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
57769829|NCT00318149|BIOLOGICAL|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
58458778|NCT03561675|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
58458779|NCT00531765|OTHER|sodium bicarbonate infusion|short infusion of sodium bicarbonate
58458780|NCT05569434|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
58458781|NCT05721495|OTHER|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
57769830|NCT00318149|BIOLOGICAL|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
57769831|NCT00318149|BIOLOGICAL|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
57769832|NCT00318149|BIOLOGICAL|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
57769833|NCT00318149|BIOLOGICAL|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
57769834|NCT02340754|BEHAVIORAL|Mindfulness-based Stress Reduction|
57769835|NCT02340754|BEHAVIORAL|MS Education Control|
57769836|NCT04249219|OTHER|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
57769837|NCT01356667|BEHAVIORAL|DARTNA|3-hour protocol provided 2x/week over 12 weeks
57769838|NCT01356667|BEHAVIORAL|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
57769839|NCT06438419|OTHER|Electrophysiological recordings|"Electrophysiological recordings will be made during a motor task in four different conditions:~1. without pharmacological treatment and without stimulation (Off condition),~2. without pharmacological treatment and during stimulation (DBS condition),~3. during pharmacological treatment and without stimulation (DOPA condition),~4. during pharmacological treatment and stimulation (DOPA+DBS condition)."
57769840|NCT00402545|DRUG|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
57769841|NCT00402545|DRUG|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
57769842|NCT00402545|DRUG|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
58458782|NCT05721495|OTHER|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
58458783|NCT02866058|PROCEDURE|Cesarean Section|
57769843|NCT00402545|DRUG|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
57769844|NCT04932005|DRUG|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
57769845|NCT04932005|DRUG|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
58458784|NCT01308736|DRUG|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
58458785|NCT01308736|DRUG|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
57769846|NCT02827942|DRUG|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
58458786|NCT05342961|PROCEDURE|spinous balloon dilatation catheter (Plastic-Blade)|To treat Coronary artery disease
57769847|NCT02827942|DRUG|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
57769848|NCT02827942|DRUG|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
57769849|NCT02827942|DRUG|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
57769850|NCT02827942|DRUG|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
57769851|NCT05594849|DRUG|Budesonide Orodispersible Tablets (Jorveza)|Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
57769852|NCT03141710|DIETARY_SUPPLEMENT|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
57769853|NCT03609554|OTHER|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
57769854|NCT00098163|BIOLOGICAL|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
57769855|NCT00098163|BIOLOGICAL|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
57769856|NCT01486602|DRUG|carboplatin|IV
57769857|NCT01486602|DRUG|paclitaxel|IV
57769858|NCT01486602|RADIATION|radiation therapy|Defined per the protocol
57769859|NCT01798186|DRUG|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
57769860|NCT02461927|DRUG|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
57769861|NCT02461927|DRUG|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
57769862|NCT02461927|DRUG|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
57769863|NCT04078035|BEHAVIORAL|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
57769864|NCT04078035|BEHAVIORAL|Control, Quiet Rest|5-minute quiet rest period.
57769865|NCT03965819|DIETARY_SUPPLEMENT|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
57769866|NCT03965819|OTHER|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
57769867|NCT03965819|OTHER|Placebo|No active ingredients
57769868|NCT02349464|OTHER|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
57769869|NCT03709290|RADIATION|mri|mri brain \& spinal cord
57769870|NCT01732146|DRUG|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
57769871|NCT01732146|DRUG|Placebo|
57769872|NCT01246180|DRUG|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
57769873|NCT01246180|DRUG|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
57769874|NCT04733196|DRUG|Essential oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
57769875|NCT04733196|DRUG|Essential oils in combination with chlorhexidine 0,12%|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
57769876|NCT04733196|DRUG|Placebo mouthwash|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
57769877|NCT04733196|DRUG|Chlorhexidine 0,20 % in combination with aroma oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
57769878|NCT04733196|DRUG|Prebiotic|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
57769879|NCT04733196|DRUG|Hydrogen peroxide 0,8 %|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
58458787|NCT05342961|PROCEDURE|spinous balloon dilatation catheter(lacrosse NSE)|To treat Coronary artery disease
57769880|NCT03605160|PROCEDURE|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
58458788|NCT05405010|OTHER|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
58458789|NCT05405010|OTHER|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
58458790|NCT05405010|OTHER|Seated control|Seated control
58458791|NCT02680522|OTHER|Exercise|exercise training with virtual reality in videogame
58458792|NCT01402440|DRUG|AEB071|
58458793|NCT04277949|DEVICE|Erbium:YAG|Treatment with Erbium:YAG laser
58458794|NCT04277949|DRUG|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
57769881|NCT03605160|PROCEDURE|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
58458795|NCT02907034|PROCEDURE|Virtual reality experimentation sequency (VR)|
58458796|NCT02907034|PROCEDURE|Classical narrative approach (CN)|
58458797|NCT03599206|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
57769882|NCT02743715|DEVICE|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
57769883|NCT02743715|DEVICE|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
57769884|NCT00027638|DRUG|thalidomide|
57769885|NCT06152523|DRUG|Monalizumab/MEDI5257|Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
57769886|NCT06400680|DEVICE|Spine Kinematic Assessment with Optoelectronic system|"All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators."
57769887|NCT03792217|OTHER|1.3% NaOCl|Endodontic irrigant
57769888|NCT03792217|OTHER|5.25% NaOCl|Endodontic irrigant
57769889|NCT03501693|DEVICE|DBT plus S-View|DBT plus S-View images
57769890|NCT03501693|DEVICE|FFDM Alone|FFDM alone images
57769891|NCT02737020|DRUG|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
57769892|NCT02737020|DRUG|Placebo|up to four times a day
57769893|NCT04876651|OTHER|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
57769894|NCT04876651|DRUG|Standard of Care|enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
57769895|NCT00509158|BIOLOGICAL|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
57769896|NCT00509158|BIOLOGICAL|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
57769897|NCT00617721|OTHER|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
57769898|NCT03428126|DRUG|Durvalumab|Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
57769899|NCT03428126|DRUG|Trametinib|"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."
57769900|NCT03954457|BEHAVIORAL|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
57769901|NCT03954457|BEHAVIORAL|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
57769902|NCT04665310|DRUG|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
58458798|NCT03599206|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
58458799|NCT00664547|BEHAVIORAL|Diet Weight Loss|
57769903|NCT01291225|OTHER|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
58458800|NCT00664547|BEHAVIORAL|Exercise Weight Loss|
58458801|NCT00664547|BEHAVIORAL|Exercise Without Weight Loss|
58458802|NCT03913858|PROCEDURE|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
58458803|NCT03913858|PROCEDURE|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
57769904|NCT01291225|BEHAVIORAL|Educational campaign|Educational materials will be developed and distributed in Ross County.
57769905|NCT01930435|DEVICE|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
58458804|NCT00317473|BIOLOGICAL|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
58458805|NCT00317473|BIOLOGICAL|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
58458806|NCT05753410|BEHAVIORAL|Mindful Courage|Self-guided online intervention
57769906|NCT02751736|DIETARY_SUPPLEMENT|CJLP243|Perioperative administration till postoperative weeks 3
57769907|NCT02751736|DIETARY_SUPPLEMENT|Placebo|Perioperative administration till postoperative weeks 3
57769908|NCT01100060|DRUG|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
57769909|NCT01100060|DRUG|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
57769910|NCT01100060|DRUG|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
57769911|NCT01100060|DRUG|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
57769912|NCT01082146|DRUG|Lurasidone|40 mg suspension, PO, for 7 days
57769913|NCT04652141|DIAGNOSTIC_TEST|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
57769914|NCT03214510|DRUG|Bupivacaine|Given via thoracic epidural catheter or TAP block
57769915|NCT03214510|DRUG|Fentanyl|Given via thoracic epidural catheter
57769916|NCT03214510|DRUG|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
57769917|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of thoracic epidural catheter
57769918|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
57769919|NCT03214510|DRUG|Liposomal Bupivacaine|Given via TAP block
58458807|NCT03257761|BIOLOGICAL|Durvalumab|Given IV
57769920|NCT03214510|BEHAVIORAL|Questionnaire|Ancillary studies
57769921|NCT06080932|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
57769922|NCT06080932|OTHER|NIH Toolbox|IPAD-based assessments that examines cognitive function
57769923|NCT06080932|OTHER|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
57769924|NCT06080932|OTHER|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
57769925|NCT06080932|OTHER|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
57769926|NCT06080932|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
57769927|NCT06080932|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
57769928|NCT06080932|OTHER|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
57769929|NCT06080932|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
57769930|NCT06080932|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
57769931|NCT06080932|BEHAVIORAL|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
57769932|NCT06080932|BEHAVIORAL|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
57769933|NCT06080932|BEHAVIORAL|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
57769934|NCT01305928|OTHER|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~* Assess withdrawal, need for medication change~* Describe warm hand-off process~* Provide 2-page flyer~* Perform call, leave room~* Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~* Collect minimum data set~* Explore thoughts/feelings toward quitting~* Provide medication education~* Build plan to stay quit~* Schedule next call~Staff check-back (5 min):~* Ask patient how session went~* Ask if patient requests cessation medication script on discharge"
57769935|NCT01305928|OTHER|Fax|"Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge"
58458808|NCT03257761|DRUG|Guadecitabine|Given SC
58458809|NCT05265975|DRUG|ATG-010|Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
58458810|NCT05265975|DRUG|Lenalidomide|Oral administration,QD, Days 1-21 of each cycle
58458811|NCT05265975|DRUG|Rituximab|Intravenous injection Days 1 of each cycle, Cycles 1-6
58458812|NCT05983419|PROCEDURE|ESD|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
58458813|NCT01356160|DRUG|GS-5885|tablet, 30 mg QD
57769936|NCT01107743|DRUG|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
57769937|NCT00753883|DRUG|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
57769938|NCT00753883|DRUG|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
57769939|NCT02443922|DRUG|Glimepiride|Glimepiride 2mg qam
57769940|NCT02443922|DRUG|Sitagliptin|Sitagliptin 100mg qam
57769941|NCT02443922|DRUG|Metformin|Metformin as prescribed
57769942|NCT04577313|BEHAVIORAL|Behavioral Self-Regulation Adherence Counseling|Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
57769943|NCT05966961|DEVICE|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
57769944|NCT05966961|DEVICE|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
57769945|NCT03746743|DIAGNOSTIC_TEST|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
57769946|NCT00210522|DRUG|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
57769947|NCT01516203|DRUG|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
57769948|NCT01516203|DRUG|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
57769949|NCT02896816|OTHER|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
57769950|NCT02896816|OTHER|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
58458814|NCT01356160|DRUG|GS-9451|tablet, 200 mg QD
58458815|NCT01356160|BIOLOGICAL|peginterferon alfa-2a|(solution for injection) 180 µg/week
57769951|NCT06321432|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
57769952|NCT06321432|BEHAVIORAL|Usual care|Usual care
57769953|NCT02305381|DRUG|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
57769954|NCT02305381|DRUG|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
57769955|NCT05240378|OTHER|Surgery|Surgery for cancer as per the stage of the disease and protocol
58458816|NCT01356160|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
58458817|NCT01356160|DRUG|GS-9451 Placebo|Placebo to match GS-9451 QD
58458818|NCT02629029|PROCEDURE|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
58458819|NCT02629029|DEVICE|Computed tomography angiography (CTA)|
58458820|NCT00871910|DRUG|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
58458821|NCT00871910|DRUG|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
58458822|NCT00871910|DRUG|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
58458823|NCT00871910|DRUG|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
58458824|NCT00871910|DRUG|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
58458825|NCT00871910|DRUG|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
58458826|NCT00871910|DRUG|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
58458827|NCT01478971|DRUG|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
58458828|NCT01478971|DRUG|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
57769956|NCT04795817|DEVICE|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
57769957|NCT06150989|BEHAVIORAL|Observational Group|"All participants will go through a series of lab-based assessments to evaluate their vascular health. These assessments include: heart rhythm/rate, blood pressure, large blood vessel flow, central aortic blood pressure and pulse wave velocity, brain blood flow, carbon dioxide concentration, flow mediated dilation/blood vessel responsiveness, breathing rate, and cerebral vasomotor reactivity. In addition, venous blood sample will be taken to identify biomarkers that are associated with elevating blood pressure and decreasing blood flow.~The 10-day monitoring period includes a wrist-worn activity tracker and a blood pressure monitor bracelet; a smartphone app that will prompt surveys up to 6 times a day to assess behaviors, social/physical context, mood/stress, and experience of racial discrimination/microaggression. Participants will also collect saliva samples on three consecutive days during the 10-day monitoring period."
57769958|NCT03508999|DRUG|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
57769959|NCT03508999|OTHER|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
57769960|NCT03508999|OTHER|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
57769961|NCT01306175|DRUG|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
57769962|NCT01306175|DRUG|Digoxin|Digoxin 0.5 mg as single dose
57769963|NCT02781896|DEVICE|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
57769964|NCT02781896|DEVICE|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
57769965|NCT05510726|DEVICE|shearwave elastography|shearwave elastography on upper or lower limb
57769966|NCT01356641|DRUG|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
57769967|NCT01356641|PROCEDURE|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
57769968|NCT03222544|COMBINATION_PRODUCT|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
57769969|NCT03222544|COMBINATION_PRODUCT|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
57769970|NCT02131038|OTHER|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
57769971|NCT02943889|BIOLOGICAL|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
57769972|NCT02682212|OTHER|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
57769973|NCT00563589|DRUG|mycophenolate mofetil, methotrexate, cyclosporin|
57769974|NCT00563589|DRUG|Methotrexate and cyclosporin|
57769975|NCT04102436|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
57769976|NCT04102436|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
57769977|NCT04102436|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
57769978|NCT04102436|BIOLOGICAL|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
58458829|NCT00855959|DRUG|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
58458830|NCT00855959|DRUG|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
58458831|NCT02867410|OTHER|No intervention|
58458832|NCT04349072|DRUG|Mavacamten|Mavacamten Capsules Other names: MYK-461
57769979|NCT02486549|PROCEDURE|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
57769980|NCT02486549|PROCEDURE|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
57769981|NCT02486549|DRUG|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
57769982|NCT02486549|DEVICE|Ultrasound|The Ultrasound will be used for brachial plexus visualization
57769983|NCT02674932|BEHAVIORAL|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
57769984|NCT02674932|BEHAVIORAL|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
57769985|NCT02674932|BEHAVIORAL|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
57769986|NCT05373134|DRUG|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
57769987|NCT05373134|OTHER|Placebo|Placebo
57769988|NCT02891239|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
57769989|NCT00190905|DRUG|duloxetine HCl|
57769990|NCT06112639|DEVICE|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
57769991|NCT06112639|DEVICE|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
57769992|NCT06112639|DEVICE|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
57769993|NCT04230460|DRUG|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
57769994|NCT04230460|DRUG|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
57769995|NCT04230460|DRUG|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
57769996|NCT04230460|DRUG|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
57769997|NCT02471885|PROCEDURE|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
57769998|NCT02471885|OTHER|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
58458833|NCT04349072|DRUG|Placebo|Placebo
57769999|NCT00054964|DRUG|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
58458834|NCT05243875|BEHAVIORAL|Navigation|COVID education for people with lupus plus tailored guidance in ordering COVID tests and making testing and vaccination appointments.
57770000|NCT00054964|DRUG|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
57770001|NCT00914290|DRUG|IPX056|IPX056 ER capsule containing 10 mg baclofen
57770002|NCT00914290|DRUG|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
57770003|NCT00914290|DRUG|Placebo IPX056|Placebo capsule for IPX056
57770004|NCT00914290|DRUG|Placebo IR|Placebo encapsulated baclofen placebo tablet
58458835|NCT05243875|BEHAVIORAL|Education|COVID education for people with lupus.
58458836|NCT05208905|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
57770005|NCT02508922|DIETARY_SUPPLEMENT|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
57770006|NCT02508922|DIETARY_SUPPLEMENT|Placebo|Matching placebo drops will be taken daily for 20 weeks
58490156|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
58490157|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
57770007|NCT03864601|DRUG|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
57770008|NCT00216450|DRUG|rabeprazole sodium|
57770009|NCT02134210|DRUG|Etanercept|Head-to-head comparison
57770010|NCT02134210|DRUG|CHS-0214|
57770011|NCT01163110|DIETARY_SUPPLEMENT|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
57770012|NCT00641758|DRUG|Pycnogenol|Pycnogenol 100mg twice daily
57770013|NCT00641758|DRUG|Placebo|Placebo 100mg twice daily
57770014|NCT00655330|DRUG|Valsartan|Valsartan (160mg/day)
57770015|NCT00655330|DRUG|Placebo|Placebo
57770016|NCT00655330|DRUG|Probucol|Probucol (750mg/day)
57770017|NCT00871403|DRUG|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
57770018|NCT00871403|DRUG|pemetrexed and cisplatin|pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
57770019|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
57770020|NCT02021539|BIOLOGICAL|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
57770021|NCT02021539|DRUG|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
57770022|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
57770023|NCT03936140|DRUG|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
57770024|NCT03936140|DRUG|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
57770025|NCT00345813|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
57770026|NCT00345813|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
57770027|NCT00345813|OTHER|placebo|Given orally
57770028|NCT03219268|BIOLOGICAL|tebotelimab 1 mg|1 mg IV every other week
57770029|NCT03219268|BIOLOGICAL|tebotelimab 3 mg|3 mg IV every other week
57770030|NCT03219268|BIOLOGICAL|tebotelimab 10 mg|10 mg IV every other week
57770031|NCT03219268|BIOLOGICAL|tebotelimab 30 mg|30 mg IV every other week
57770032|NCT03219268|BIOLOGICAL|tebotelimab 120 mg|120 mg IV every other week
57770033|NCT03219268|BIOLOGICAL|tebotelimab 300 mg|300 mg IV every other wee
57770034|NCT03219268|BIOLOGICAL|tebotelimab 400 mg|400 mg IV every other wee
57770035|NCT03219268|BIOLOGICAL|tebotelimab 600 mg|600 mg IV every other week
57770036|NCT03219268|BIOLOGICAL|tebotelimab 800 mg|800 mg IV every other week
57770037|NCT03219268|BIOLOGICAL|tebotelimab 1200 mg|1200 mg IV every other week
57770038|NCT03219268|BIOLOGICAL|margetuximab|15 mg/kg IV every 3 weeks
57770039|NCT03097003|DRUG|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
57770040|NCT02292810|DEVICE|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
57770041|NCT02292810|DEVICE|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
57770042|NCT05358587|OTHER|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
57770043|NCT05358587|OTHER|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
57770044|NCT04653636|OTHER|Arthrographic distension|"The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance"
58490158|NCT00973232|DRUG|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
57770045|NCT04653636|OTHER|Immediate joint mobilization|"This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period."
57770046|NCT01330693|DRUG|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
57770047|NCT01330693|DRUG|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
57770048|NCT02920151|OTHER|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
57770049|NCT06436963|BEHAVIORAL|narrative medicine training combined with CBL training|The experimental group received narrative medicine training combined with CBL training.
57770050|NCT06436963|BEHAVIORAL|CBL training|The control group received normal CBL training.
57770051|NCT03691948|OTHER|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
57770052|NCT03691948|OTHER|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
57770053|NCT06186557|OTHER|No intervention|No intervention
57770054|NCT02433548|PROCEDURE|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
57770055|NCT02433548|PROCEDURE|Sham injection|subcutaneous of 5 cc of normal saline
57770056|NCT04418713|OTHER|active video-games|An intervention with active video-games to increase physical activity and improve body composition
57770057|NCT02441946|DRUG|Abemaciclib|Administered orally
57770058|NCT02441946|DRUG|Loperamide|Administered orally
57770059|NCT02441946|DRUG|Anastrozole|Administered orally
57770060|NCT03693274|BEHAVIORAL|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
57770061|NCT01393041|DEVICE|Angio-Seal VIP|Vascular Closure Device
57770062|NCT00547690|OTHER|Acupuncture and Strengthening|Acupuncture and strengthening
57770063|NCT00547690|OTHER|Strengthening Alone|Strengthening training program
57770064|NCT05562063|DRUG|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
57770065|NCT05562063|DRUG|Placebo|Matching placebo for 6 months.
57770066|NCT04170868|OTHER|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
57770067|NCT02340520|DRUG|Theophylline|Oral
57770068|NCT02340520|DRUG|Roflumilast|Oral
57770069|NCT04760730|BIOLOGICAL|AZD1222|"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
57770070|NCT04760730|BIOLOGICAL|rAd26-S|"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
57770071|NCT04176159|OTHER|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
57770072|NCT02254837|DEVICE|Zilver PTX Drug-Eluting Stent|
58490159|NCT00973232|DRUG|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
57770073|NCT04551196|DRUG|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
57770074|NCT04551196|DRUG|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
57770075|NCT01899066|DRUG|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
57770076|NCT01899066|DRUG|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
57770077|NCT03813212|DEVICE|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
57770078|NCT02108145|PROCEDURE|bilateral metal stent insertion|
57770079|NCT02108145|PROCEDURE|unilateral metal stent insertion|
57770080|NCT04662671|DEVICE|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
57770081|NCT02075021|DRUG|Lenalidomide|
57770082|NCT02075021|DRUG|nab-paclitaxel|
57770083|NCT05449886|PROCEDURE|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
57770084|NCT05097118|DRUG|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
57770085|NCT00401102|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
57770086|NCT04096573|DRUG|LC51-0255|LC51-0255
57770087|NCT04096573|DRUG|Placebo|Placebo
57770088|NCT02774603|OTHER|Aquatic Locomotor Training|
57770089|NCT02774603|OTHER|Land Locomotor Training|
57770090|NCT06379113|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
58490160|NCT00973232|DRUG|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
57770091|NCT06379113|DRUG|Letrozole 2.5mg|2.5mg po qd.
57770092|NCT01110343|BEHAVIORAL|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
57770093|NCT01110343|BEHAVIORAL|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
57770094|NCT02117232|DEVICE|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
57770095|NCT02117232|DEVICE|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
57770096|NCT02733302|BEHAVIORAL|Hope theory|Adapted Physical Activity
57770097|NCT04453241|BIOLOGICAL|NBP615|Intramuscular injection, 0.5ml
57770098|NCT04453241|BIOLOGICAL|Gardasil|Intramuscular injection, 0.5ml
57770099|NCT02409303|BEHAVIORAL|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
57770100|NCT05699915|PROCEDURE|Cardiology consultation|"* Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio \> 15 and left atrial (LA) area \> 30 cm2."
57770101|NCT05699915|DIAGNOSTIC_TEST|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
57770102|NCT05699915|PROCEDURE|Non-invasive endothelial function tests|"* FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
57770103|NCT05699915|PROCEDURE|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
57770104|NCT05699915|DIAGNOSTIC_TEST|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
57770105|NCT05531474|PROCEDURE|Bariatric Surgery|Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
57770106|NCT05531474|BEHAVIORAL|Medical Weight Management|The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
57784357|NCT03709875|DEVICE|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
58490161|NCT00973232|DRUG|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
57770107|NCT03958240|OTHER|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
57770108|NCT01305096|OTHER|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
57770109|NCT01872637|BEHAVIORAL|Progressive Multi-Component Intervention|
57770110|NCT01872637|BEHAVIORAL|Usual Care|
57770111|NCT00758160|DRUG|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
57770112|NCT05724056|DEVICE|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
57770113|NCT05724056|DEVICE|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
57770114|NCT02494921|DRUG|Docetaxel-PNP|Given IV
57770115|NCT02494921|DRUG|Ribociclib|Given Orally
57770116|NCT02494921|DRUG|Prednisone|Given Orally
57770117|NCT02494921|DRUG|Filgrastim|Given IV
57770118|NCT05059054|OTHER|Strengthening exercise|"Strengthening exercise program Participants performed this protocol at home for 3 times per day. The participants progress their exercise based on the achievement of the previous level of each exercise protocol. The physical therapist recorded the level of each exercise for each participant during eight times of treatment. Total time for this section is approximately 30 minutes. Detail of the strengthening exercise is in the following.~1. Toe curl exercise (toe flexors strengthening)~2. Ankle evertor exercise (peroneal strengthening)~3. Ankle invertor exercise (tibialis posterior strengthening)~4. Heel raise exercise (high-load strength training)"
57770119|NCT05059054|OTHER|Insole (CFO) group|"The CFO insole group The participants will receive the foot assessment before making the CFO for each participant. The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC) and one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort.~The participants will be asked to use the CFO in daily life during weight-bearing activities."
57770120|NCT00474721|DRUG|ibuprofen|
57770121|NCT00474721|DRUG|acetaminophen with codeine|
57770122|NCT02941068|DRUG|fluconazole and caspofungin|
57770123|NCT05920525|DEVICE|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
57770124|NCT05920525|PROCEDURE|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
57770125|NCT05828849|BEHAVIORAL|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
57770126|NCT04859894|DIAGNOSTIC_TEST|Physiological testing|Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
57770127|NCT03297008|OTHER|No internvetion|No intervention, this is an observational study
57770128|NCT06547398|RADIATION|Adaptive radiotherapy +/- Margin Reduction|Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
57770129|NCT06547398|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for prostate cancer
57770130|NCT04861870|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
57770131|NCT04386226|DIETARY_SUPPLEMENT|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
57770132|NCT04386226|DIETARY_SUPPLEMENT|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
57770133|NCT04386226|OTHER|Placebo|Maltodextrin
57770134|NCT03103230|DEVICE|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
57770135|NCT00023842|BIOLOGICAL|BCG vaccine|
57770136|NCT00023842|DRUG|mitomycin C|
57770137|NCT00023842|PROCEDURE|adjuvant therapy|
57770138|NCT00023842|PROCEDURE|conventional surgery|
57770139|NCT03015116|OTHER|Stretching|Daily foot and ankle stretching protocol
57770140|NCT03015116|OTHER|Cryotherapy|Daily cryotherapy in conjunction with stretching
57770141|NCT03015116|DEVICE|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
57770142|NCT03015116|DEVICE|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
57770143|NCT06285942|DRUG|Edoxaban|To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
57770144|NCT06285942|DRUG|No Edoxaban|Other DOACs through PEG or subcutaneous heparin or LMWH
57770145|NCT01832103|DRUG|MK-7145|
57770146|NCT06487819|PROCEDURE|Application of a rubber dam during dental treatments for varying durations.|Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
57770147|NCT02397265|DEVICE|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
57770148|NCT02397265|DEVICE|Standard opened loop pump|Using a standard opened loop pump
57770149|NCT02397265|DEVICE|Insulin closed loop|Using a closed loop
57770150|NCT02468934|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
57770151|NCT00194480|DRUG|Pegylated Interferon|Weekly injections of pegIntereferon
57770152|NCT02043262|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
57770153|NCT02043262|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
57770154|NCT04977518|OTHER|no intervention|no intervention
57770155|NCT01694810|DRUG|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
58490162|NCT00973232|DRUG|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
57770156|NCT01694810|DRUG|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
57770157|NCT01694810|DRUG|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
57770158|NCT01694810|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
57770159|NCT05158881|DEVICE|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
57770160|NCT02107248|BEHAVIORAL|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
57770161|NCT02107248|BEHAVIORAL|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
57770162|NCT00708305|DRUG|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
57770163|NCT00708305|DRUG|Placebo|Fluoride free toothpaste (0ppmF)
57770164|NCT03246243|DEVICE|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
57770165|NCT05012449|PROCEDURE|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
57770166|NCT00727818|DEVICE|guided bone regeneration|
57770167|NCT04359030|DIAGNOSTIC_TEST|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
57770168|NCT04359030|DIAGNOSTIC_TEST|Transthoracic stress echocardiography|Transthoracic stress echocardiography
57770169|NCT01333540|DRUG|TD-1211|Escalating doses
57770170|NCT01333540|DRUG|Placebo|Placebo once daily
57770171|NCT03075501|BEHAVIORAL|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
57770172|NCT03075501|DRUG|Stimulant or sedative|CS+ for paired, CS0 for unpaired
57770173|NCT03075501|DRUG|Placebo|CS- for paired, CS0 for unpaired
57770174|NCT00819065|DRUG|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
57784358|NCT05251064|DEVICE|Suture|Standard suture wound closure device.
57784359|NCT05251064|DEVICE|Clozex|Interlaced adhesive wound closure device.
57784360|NCT05251064|DEVICE|Zipline|Adhesive wound closure device using zip-tie like strips.
58490163|NCT05150899|DRUG|Tamsulosin Hcl 0.4Mg Cap|alpha blocker
58490164|NCT05150899|DRUG|fexofenadine 180 mg Oral tablet|antihistaminic
58490165|NCT00947882|DRUG|Placebo|Mannitol 50 mg/mL solution
57770175|NCT00819065|DRUG|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
57770176|NCT05863286|DRUG|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
57770177|NCT05429164|OTHER|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
57770178|NCT05429164|OTHER|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
57770179|NCT05429164|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
57770180|NCT03976895|PROCEDURE|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
57770181|NCT03976895|PROCEDURE|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
57770182|NCT00077636|DRUG|Copegus|400mg po bid for 16 weeks
57770183|NCT00077636|DRUG|Copegus|400mg po bid for 24 weeks
57770184|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
57770185|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
57770186|NCT00997256|DRUG|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
57770187|NCT00997256|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 3 days
57770188|NCT03853317|BIOLOGICAL|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
57770189|NCT03853317|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
57770190|NCT03853317|BIOLOGICAL|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
57770191|NCT01844115|DRUG|Placebo|
58490166|NCT00947882|DRUG|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
57770192|NCT01844115|DRUG|Vilazodone|Viibryd
57770193|NCT02796963|BEHAVIORAL|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
57770194|NCT02796963|BEHAVIORAL|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
57770195|NCT02261090|DRUG|Formulation B: Pramipexole Slow release (SR) tablet|
57770196|NCT02261090|DRUG|Formulation C: Pramipexole Slow release tablet|
57770197|NCT02261090|DRUG|Formulation D: Pramipexole Slow release tablet|
57770198|NCT02261090|DRUG|Formulation E: Pramipexole Slow release tablet|
57770199|NCT02261090|DRUG|Formulation F: Pramipexole Slow release tablet|
57770200|NCT02261090|DRUG|Formulation G: Pramipexole Slow release tablet|
57770201|NCT02261090|DRUG|Formulation H: Pramipexole Slow release tablet|
57770202|NCT02261090|DRUG|Pramipexole immediate release (IR) tablets|
57770203|NCT00421226|DRUG|ACZ885|
57770204|NCT03355963|OTHER|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
57770205|NCT03355963|BIOLOGICAL|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
57770206|NCT03355963|BIOLOGICAL|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
57770207|NCT02674490|DEVICE|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
58490167|NCT00947882|DRUG|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
58490168|NCT00947882|DRUG|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
58490169|NCT00545259|DRUG|AEB071|
58490170|NCT03290599|OTHER|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
58490171|NCT03073941|DEVICE|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
57770208|NCT02674490|BEHAVIORAL|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
57770209|NCT02674490|DEVICE|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
57770210|NCT00553202|BIOLOGICAL|anti-thymocyte globulin|Given IV
57770211|NCT00553202|DRUG|busulfan|Given IV
57770212|NCT00553202|DRUG|cyclophosphamide|Given IV
57770213|NCT00553202|DRUG|cyclosporine|Given IV or orally
57770214|NCT00553202|DRUG|methotrexate|Given IV
57770215|NCT00553202|DRUG|methylprednisolone|Given IV
57770216|NCT00553202|DRUG|tacrolimus|Given IV
57770217|NCT00553202|OTHER|laboratory biomarker analysis|Correlative studies
57770218|NCT00553202|OTHER|pharmacological study|Correlative studies
57770219|NCT00553202|PROCEDURE|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
57770220|NCT00553202|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
57770221|NCT05436964|OTHER|saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
57770222|NCT05436964|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
57770223|NCT01403441|DEVICE|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
57770224|NCT01058434|DRUG|TKI258|
57770225|NCT05472337|DRUG|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
57770226|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from honey chlorella|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
57770227|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from faba bean meat analogue|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
57770228|NCT04719663|BEHAVIORAL|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
57770229|NCT04719663|BEHAVIORAL|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
57770230|NCT04719663|DRUG|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
57770231|NCT04719663|BEHAVIORAL|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
58458837|NCT06090604|OTHER|High intensity gait training in a balance challenging Movement amplification environment|For Aim 2, each participant will engage in ten 45-min high-intensity gait training sessions performed in a Movement Amplification Environment (MAE). Training sessions will occur 2x/week and led by a licensed Physical Therapist. The goal of each training session is to achieve 40-min of stepping practice within a targeted range of heart rate (HR) of 70 to 80% of estimated age-predicted HR max and perceived excursion (RPE) in a MAE. Each session will begin and end with a 2.5-min warm-up and cool down, with 40-min of training using two 10-min Speed-training blocks and two 10-min Balance-training blocks. Balance training activities will include lateral maneuvers, head turns, obstacle negotiation, and backward walking. The MAE gain, training speeds and balance activities will be progressively increased within and across sessions to challenge the participant.
57770232|NCT00974701|DEVICE|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
57770233|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 1
57770234|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 2
57770235|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 3
57770236|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 1
57770237|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 2
57770238|NCT00158210|DRUG|Rivastigmine|
57770239|NCT02300285|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
57770240|NCT03017144|OTHER|Pit crew model education|A pit crew model for resuscitation is educated to all resuscitation team members.
57770241|NCT04499339|DRUG|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
57770242|NCT00204269|DRUG|Testosterone Gel Wolff|
57770243|NCT03091673|DRUG|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
57770244|NCT00329121|DRUG|PEP005|
57770245|NCT01633216|BIOLOGICAL|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
57770246|NCT01633216|BIOLOGICAL|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
57770247|NCT01633216|BIOLOGICAL|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
58458838|NCT04458155|DEVICE|Siemens® Point-of-care high sensitive troponin I analyzer|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
58458839|NCT03315741|DRUG|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
57770248|NCT01633216|BIOLOGICAL|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
57770249|NCT01633216|BIOLOGICAL|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
57770250|NCT00073879|BIOLOGICAL|alemtuzumab|
57770251|NCT00073879|BIOLOGICAL|graft-versus-tumor induction therapy|
57770252|NCT00073879|DRUG|cyclophosphamide|
57770253|NCT00073879|DRUG|fludarabine phosphate|
57770254|NCT00073879|PROCEDURE|allogeneic bone marrow transplantation|
57770255|NCT00073879|PROCEDURE|peripheral blood stem cell transplantation|
57770256|NCT03951935|OTHER|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
57770257|NCT03951935|DIAGNOSTIC_TEST|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
57770258|NCT01212406|DRUG|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
57770259|NCT06522243|BEHAVIORAL|8-week mindful parenting program|The current study adopts the Mindful Parenting program developed by Prof Susan Bögels (Bögels \& Restifo, 2013), which is an application of mindfulness-based intervention which aims to improve parenting by reducing parents' own stress levels, decreasing parental automatic reactivity, increasing open and unbiased attitudes towards children, and decreasing inter-generational dysfunctional parenting (Bögels et al., 2014). The program consists of eight consecutive weeks of parent groups and one follow-up session two months after the last session. Each parent group will include 15-20 participants. The original Mindful Parenting Program will last for around 3 hours for each session, with the longest practice of 40 minutes. Considering parents recruited in the study may have a higher risk of psychiatric conditions than the general population, each session of mindful parenting group will be reduced to 2 to 2.5 hours with the longest mindfulness practice of 30 minutes (Baer et al., 2019).
58458840|NCT00453154|DRUG|Carboplatin|Given IV
58458841|NCT00453154|DRUG|Cisplatin|Given IV
58458842|NCT00453154|DRUG|Etoposide|Given IV
57770260|NCT02784470|DEVICE|gastroduodenal stent placement|
57770261|NCT02784470|PROCEDURE|gastrojejunostomy|
57770262|NCT00446940|DRUG|rosuvastatin|
57770263|NCT00446940|DRUG|atorvastatin|
57770264|NCT00549887|DRUG|Analog or Human Insulin|prescribed in accordance with usual clinical practice
57770265|NCT05208619|PROCEDURE|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
57770266|NCT04872244|DEVICE|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
57770267|NCT04872244|DRUG|Levonorgestrel Drug Implant Product|intrauterine administration
57770268|NCT03150524|DIAGNOSTIC_TEST|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
57770269|NCT03150524|BEHAVIORAL|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
58458843|NCT00453154|OTHER|Laboratory Biomarker Analysis|Correlative studies
58458844|NCT00453154|OTHER|Placebo Administration|Given PO
58458845|NCT00453154|DRUG|Sunitinib Malate|Given PO
58458846|NCT03636074|PROCEDURE|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
58458847|NCT00168441|DRUG|Botulinum Toxin Type A|
58458848|NCT06368102|DRUG|Ampicillin|Total 2g vs 3g
58458849|NCT03812380|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
58458850|NCT03812380|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
58458851|NCT02289664|DEVICE|MAC|Direct-Laryngoscopy
58458852|NCT02289664|DEVICE|Coopdech|Video-Laryngoscopy -1
58458853|NCT02289664|DEVICE|CoPilot|Video-Laryngoscopy -2
57770270|NCT03150524|OTHER|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
57770271|NCT03150524|DIAGNOSTIC_TEST|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
57770272|NCT03150524|DRUG|Nimodipine|Participants will be administered nimodipine every 4 hours.
57770273|NCT03150524|DRUG|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
57770274|NCT06140563|OTHER|anticoagulation dosing|In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
57770275|NCT00965796|DRUG|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
57770276|NCT02084719|DEVICE|Oraquick HCV Rapid Antibody Test|
57770277|NCT02084719|DEVICE|Standard algorithm|
57770278|NCT05185596|DEVICE|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
57770279|NCT04362657|DIAGNOSTIC_TEST|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
57770280|NCT00002163|DRUG|Abacavir sulfate|
57770281|NCT02674360|BEHAVIORAL|SDM Training|
57770282|NCT01183650|DRUG|Tadalafil|5 mg, administered orally, daily for 10 days
57770283|NCT00844740|DRUG|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
58458854|NCT02289664|DEVICE|Intubrite|Video-Laryngoscopy -3
58458855|NCT06527339|OTHER|Dry Needling with Vibration|In the PS+V technique, no movements will be performed with the needle once it is correctly inserted. Instead, only vibratory stimulus will be applied for 10 minutes. Since this is a completely novel technique, the optimal duration of application is not yet known; however, it is considered that 10 minutes may be sufficient to demonstrate an effect.
58458856|NCT06527339|OTHER|Conventional Dry Needling|"In the conventional PS technique, the needle will be inserted into the MTrP using the fast-in and fast-out technique described by Hong (1994) at an approximate frequency of 1 insertion per second (1 Hz) without completely withdrawing the needle from the skin. This technique will be maintained for 30 seconds in an attempt to elicit a local twitch response. After the procedure, the treated area will be firmly compressed with a cotton pad for three seconds."
58458857|NCT04264858|DRUG|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
58458858|NCT04264858|DRUG|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
57770284|NCT04389333|DEVICE|non-contact magnetically-controlled capsule endoscopy|The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
57770285|NCT01351428|DRUG|Nifedipine|30-60 mg, twice daily
57770286|NCT04130334|PROCEDURE|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
57770287|NCT04130334|PROCEDURE|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
57770288|NCT00282815|DEVICE|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
57770289|NCT00282815|DEVICE|sham CPAP|sham CPAP
58458859|NCT02542657|DRUG|Clarithromycin|Given PO
58458860|NCT02542657|DRUG|Dexamethasone|Given PO
57770290|NCT03676920|BEHAVIORAL|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
58458861|NCT02542657|DRUG|Ixazomib Citrate|Given PO
58458862|NCT02542657|DRUG|Pomalidomide|Given PO
58458863|NCT05294926|DRUG|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure \< 60 mmHg and heart rate \< 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate \< 40 bpm) are used to prevent hypotension or bradycardia
58490172|NCT03073941|DEVICE|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
57770291|NCT04080310|DRUG|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
57770292|NCT01619046|BIOLOGICAL|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min
57770293|NCT01619046|BIOLOGICAL|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
57770294|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
57770295|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
57770296|NCT00406419|DRUG|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
57770297|NCT00406419|DRUG|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
57770298|NCT00406419|DRUG|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
57770299|NCT04180241|PROCEDURE|POEM|Peroral endoscopic myotomy
57770300|NCT03804190|OTHER|questionaire|dutch musculoskeletal questionaire
57770301|NCT01472913|DRUG|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
57770302|NCT01472913|DRUG|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
57770303|NCT03539367|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
57770304|NCT03539367|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
57770305|NCT05145946|BEHAVIORAL|Video Game Training Group 1|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week.
57770306|NCT05145946|BEHAVIORAL|Video Game Training Group 2|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week.
57770307|NCT03826511|OTHER|Tiszasüly hot mud-pack therapy|Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
57770308|NCT03826511|OTHER|Kolop mud-pack|Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
57770309|NCT05296096|OTHER|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
57770310|NCT03917810|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
57770311|NCT02885727|DRUG|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
57770312|NCT02885727|RADIATION|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
57770313|NCT00079456|DRUG|temsirolimus|Given IV
57770314|NCT00079456|OTHER|pharmacological study|Correlative studies
57770315|NCT00079456|OTHER|laboratory biomarker analysis|Correlative studies
57770316|NCT03221062|DEVICE|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
57770317|NCT04735042|DRUG|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
57770318|NCT04735042|DRUG|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
57770319|NCT00786890|OTHER|observational, no intervention needed|observational, no intervention needed
57770320|NCT03395834|DEVICE|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
57770321|NCT06626048|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
57770322|NCT06626048|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
58490173|NCT05214820|BIOLOGICAL|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
58490174|NCT00047164|BIOLOGICAL|ipilimumab|
57770323|NCT00014196|DRUG|cisplatin|
57770324|NCT00014196|DRUG|docetaxel|
57770325|NCT00014196|RADIATION|radiation therapy|
57770326|NCT02714101|OTHER|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
57770327|NCT01393080|DRUG|Nimotuzumab and TP regimen|"1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
57770328|NCT01393080|DRUG|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
58490175|NCT02843516|OTHER|No intervention|No intervention
57770329|NCT01113658|DEVICE|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
57770330|NCT03534765|DIAGNOSTIC_TEST|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
57770331|NCT03534765|DIAGNOSTIC_TEST|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
57770332|NCT03534765|PROCEDURE|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
57770333|NCT04930237|DRUG|Relistor Injectable Product|12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
57770334|NCT04930237|DRUG|Docusate Calcium|Standard of care
57770335|NCT04930237|DRUG|Bisacodyl|Standard of Care
57770336|NCT04930237|DRUG|Milk of magnesia|Standard of Care
57770337|NCT04930237|DRUG|Magnesium citrate|Standard of Care
57770338|NCT04930237|DRUG|Senna|Standard of Care
57770339|NCT04930237|DRUG|Enema|Standard of Care
57770340|NCT05404880|DEVICE|EDWARDS INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
57770341|NCT05081505|BEHAVIORAL|Structural exercise course|12-week structured exercise class, team competition, social support, and incentive strategy
58490176|NCT02239549|DEVICE|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
57770342|NCT05081505|BEHAVIORAL|Autonomous group class|12-week autonomous group class, team competition, social support, and incentive strategy
57770343|NCT02561143|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
57770344|NCT02561143|DIETARY_SUPPLEMENT|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
57770345|NCT02561143|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
57770346|NCT02561143|OTHER|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
57770347|NCT06130813|OTHER|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
57770348|NCT05194189|DRUG|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
57770349|NCT05194189|DRUG|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
57770350|NCT05534880|OTHER|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
57770351|NCT02467413|DRUG|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
58490177|NCT02239549|DEVICE|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
57770352|NCT02467413|OTHER|BAC Matched Vehicle|BAC Matched Vehicle
57770353|NCT00779584|DRUG|MK-8776|IV infusion
57770354|NCT00779584|DRUG|Gemcitabine|IV infusion
57770355|NCT06391216|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052 and Bifidobacterium longum R0175|8-week supplementation (56 days); 3 × 10\^9 CFU/day
57770356|NCT06391216|DIETARY_SUPPLEMENT|Placebo|8-week supplementation (56 days)
57770357|NCT00741715|DRUG|AVE5530|oral administration once daily in the evening with dinner
57770358|NCT00741715|DRUG|atorvastatin|oral administration once daily in the evening with dinner
57770359|NCT00741715|DRUG|placebo|oral administration once daily in the evening with dinner
57770360|NCT01710917|DRUG|Targinact® (oxycodon/naloxon)|
57770361|NCT01478113|DRUG|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
57770362|NCT01478113|DRUG|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
57770363|NCT01478113|BEHAVIORAL|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
57770364|NCT01044342|DRUG|AZD1446|capsule; single oral dose
57770365|NCT01044342|DRUG|AZD1446|capsule, single oral dose
57770366|NCT01044342|DRUG|donepezil|capsule, single oral dose
57770367|NCT01044342|DRUG|Placebo|capsule, single oral dose
57770368|NCT06609499|DEVICE|Flexible-tip Bougie|The device is used for intubation and then the manikin is ventilated
57770369|NCT06609499|DEVICE|Gum-elastic Bougie|The device is used for intubation and then the manikin is ventilated
57770370|NCT04686279|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
57770371|NCT04261660|OTHER|NO intervention|NO INTERVENTION
57770372|NCT06503679|DRUG|LY4100511 (DC-853) Dose 1|Administered orally
57770373|NCT06503679|DRUG|LY4100511 (DC-853) Dose 2|Administered orally
57770374|NCT06503679|DRUG|LY4100511 (DC-853) Dose 3|Administered orally
57770375|NCT06503679|DRUG|Midazolam|Administered orally
57770376|NCT06503679|DRUG|Repaglinide|Administered orally
57770377|NCT06503679|DRUG|Digoxin|Administered orally
57770378|NCT06503679|DRUG|Rosuvastatin|Administered orally
57770379|NCT00477906|BIOLOGICAL|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
57770380|NCT02049710|BEHAVIORAL|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
57770381|NCT02049710|BEHAVIORAL|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
58129566|NCT04104568|BEHAVIORAL|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
58458864|NCT05294926|DEVICE|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
57770382|NCT06286514|OTHER|No intervention|This is an observational study
57770383|NCT02384967|DRUG|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
57770384|NCT03008720|DEVICE|Transcranial direct current stimulation (tDCS)|
57770385|NCT03008720|DEVICE|Functional electrical stimulation (FES)|
57770386|NCT03008720|DEVICE|Sham stimulation|
57770387|NCT02970253|PROCEDURE|Capsular resection|Capsular resection
57770388|NCT02970253|PROCEDURE|Capsular retention|Capsular retention
57770389|NCT00393523|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
57770390|NCT00393523|BIOLOGICAL|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
57770391|NCT06226428|OTHER|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
57770392|NCT06226428|OTHER|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
57770393|NCT06226428|OTHER|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
57770394|NCT00507221|DRUG|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
57770395|NCT00507221|DRUG|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
57770396|NCT00507221|DRUG|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
57770397|NCT01254890|DRUG|Azacitidine|75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
57770398|NCT01254890|DRUG|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
57770399|NCT00730314|PROCEDURE|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
57770400|NCT00932334|BEHAVIORAL|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
57770401|NCT00932334|BEHAVIORAL|TALK Standard|Participants receive and educational video and booklet about living kidney donation
57770402|NCT00932334|BEHAVIORAL|Usual Care|Participants receive their usual care
57770403|NCT04049292|OTHER|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
57770404|NCT04049292|OTHER|Usual care|Usual care is determined by the treating health care professional
57770405|NCT06459895|DIAGNOSTIC_TEST|Long non-coding MALAT1 gene expression assay:|RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
57770406|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
57770407|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
57770408|NCT05738460|DRUG|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
57770409|NCT03298503|OTHER|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
57770410|NCT06158308|PROCEDURE|Laproscopic Appendicectomy|A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
57770411|NCT06158308|PROCEDURE|Open Appendicectomy|A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
57770412|NCT04346550|OTHER|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS \> 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS\<3, no fever and tolerating oral intake
57770413|NCT02447835|DRUG|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
57770414|NCT05788276|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin active tablets
57770415|NCT05788276|DRUG|Placebo|Matched placebo tablets
57770416|NCT01532817|DEVICE|AlphaCore|A single 90 second stimulation to the vagus nerve on the right side of the neck
57770417|NCT03389607|DIAGNOSTIC_TEST|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
57770418|NCT01496534|DRUG|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
57770419|NCT01496534|DRUG|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
57770420|NCT03075904|DRUG|ALXN1830|Administered via IV infusion.
57770421|NCT02475525|DIETARY_SUPPLEMENT|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
57770422|NCT01252121|OTHER|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
57770423|NCT01252121|OTHER|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
57770424|NCT01252121|OTHER|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
57770425|NCT05386251|BEHAVIORAL|BPT/OST|See Arm description.
57770426|NCT05386251|BEHAVIORAL|Peer Support|See Arm description
58458865|NCT04319367|DRUG|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
58458866|NCT05260047|BEHAVIORAL|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
58458867|NCT05260047|BEHAVIORAL|Telehealth MAT|Describe what is the Telehealth MAT briefly
58458868|NCT05260047|BEHAVIORAL|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
57770427|NCT03378843|OTHER|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
57770428|NCT03324711|DIAGNOSTIC_TEST|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
57770429|NCT04745299|BIOLOGICAL|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
57770430|NCT04745299|DRUG|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
58458869|NCT06040411|OTHER|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
58458870|NCT02892994|OTHER|ultrasound|
58490178|NCT04532606|DRUG|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
57770431|NCT04745299|DRUG|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
57770432|NCT01868035|DRUG|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
57770433|NCT05385094|DIAGNOSTIC_TEST|S Creatinine concentration|
57770434|NCT05385094|DIAGNOSTIC_TEST|Serum Cystatin C concentration|
57770435|NCT05385094|DIAGNOSTIC_TEST|Urinary Creatinine Clearance|
57770436|NCT00641173|DRUG|paroxetine|treatment with SSRI paroxetine
58458871|NCT01102335|PROCEDURE|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
57770437|NCT00641173|DRUG|placebo|treatment with placebo
57770438|NCT06457100|DRUG|Esmolol Injection|Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.
57770439|NCT06457100|DRUG|Lidocaine IV|Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
57770440|NCT04797325|DRUG|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
57770441|NCT04797325|DRUG|Prednisolone|tablet prednisolone plus infliximab in severe cases.
57770442|NCT05878782|OTHER|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
57770443|NCT05878782|OTHER|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
57770444|NCT00720174|BIOLOGICAL|Cixutumumab|Given IV
57770445|NCT00720174|DRUG|Doxorubicin Hydrochloride|Given IV
57770446|NCT00720174|OTHER|Laboratory Biomarker Analysis|Correlative studies
57770447|NCT02918240|PROCEDURE|Appointment intervals|
57770448|NCT02918240|DEVICE|fixed orthodontic braces|
57770449|NCT01241253|OTHER|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
57770450|NCT05684562|OTHER|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
57770451|NCT05684562|OTHER|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
57770452|NCT05684562|OTHER|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
57770453|NCT06354335|OTHER|Employees exposed to a major hospital reorganisation|Occupational exposure
57770454|NCT04771338|BEHAVIORAL|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
57770455|NCT00766896|DRUG|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
57770456|NCT00569803|DRUG|belatacept|single dose, 116 days
57770457|NCT00569803|DRUG|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
57770458|NCT03054688|DEVICE|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
57785279|NCT06387498|PROCEDURE|Testicular tissue biopsy and cryopreservation|Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.
58458872|NCT01102335|DRUG|Telbivudine|anti-HBV drug
57770459|NCT04444687|DIAGNOSTIC_TEST|Test for SARS-CoV-2|"* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
57770460|NCT00692406|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
58458873|NCT05392608|DRUG|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
57770461|NCT01077726|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
57770462|NCT02101918|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
57770463|NCT02101918|OTHER|Laboratory Biomarker Analysis|Correlative studies
57770464|NCT02101918|BIOLOGICAL|Ziv-Aflibercept|Given IV
57770465|NCT01629056|PROCEDURE|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
57770466|NCT01629056|PROCEDURE|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
57770467|NCT03298620|OTHER|Electric toothbrush|
57770468|NCT03298620|OTHER|Control|Manual toothbrush
57770469|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
57770470|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
57770471|NCT02314988|DRUG|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
57770472|NCT02314988|DRUG|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
57770473|NCT03987230|DRUG|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
57770474|NCT03987230|OTHER|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
57770475|NCT03987230|OTHER|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
57770476|NCT03987230|OTHER|Blephadex Lid Wipes|Blephadex Lid Wipes
57770477|NCT03987230|OTHER|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
57770478|NCT03987230|OTHER|Blephademodex|Blephademodex
57770479|NCT03777865|BIOLOGICAL|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
57770480|NCT01186614|DEVICE|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
57770481|NCT01186614|DEVICE|ECMO|Insertion of peripheral VA ECMO
57770482|NCT01186614|PROCEDURE|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
57770483|NCT01186614|PROCEDURE|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
57770484|NCT03893825|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm description.
57770485|NCT03893825|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
57770486|NCT02247804|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
57770487|NCT02247804|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
57770488|NCT02247804|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
57770489|NCT02247804|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
57770490|NCT02110524|DEVICE|Percutaneous Transluminal Angioplasty|
57770491|NCT03457272|OTHER|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
58458874|NCT05392608|DRUG|Fulvestrant|Fulvestrant 300mg 1x/four weeks
58458875|NCT06021314|OTHER|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
58458876|NCT00546624|DRUG|MK0777|
57770492|NCT05731284|PROCEDURE|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
57770493|NCT05731284|PROCEDURE|Placebo|Normal saline Injection
57770494|NCT05202990|DRUG|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
57785280|NCT00178256|DRUG|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
58458877|NCT02656277|OTHER|Decision Tool|
58458878|NCT02656277|OTHER|Information on Shoulder Dislocation|
58458879|NCT02962258|DRUG|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
58458880|NCT02962258|DRUG|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
57770495|NCT05202990|DRUG|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
57770496|NCT00595972|DRUG|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
57770497|NCT02057289|DRUG|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
57770498|NCT03671733|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
57770499|NCT03671733|DRUG|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
57770500|NCT03671733|DRUG|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
57770501|NCT01965964|PROCEDURE|Questionnaire|
57770502|NCT03218696|DEVICE|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
57770503|NCT03218696|DEVICE|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
57770504|NCT01348776|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
57770505|NCT01267981|DRUG|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
57770506|NCT01267981|DRUG|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
57770507|NCT01267981|DRUG|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
57770508|NCT04868643|DEVICE|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
57770509|NCT01413672|DEVICE|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
57770510|NCT00543660|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
57770511|NCT01837290|DRUG|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
57770512|NCT01837290|DRUG|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
57770513|NCT01837290|DRUG|saline infusion|Saline infusion to facilitate blinding
57770514|NCT01837290|DRUG|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
57770515|NCT05639621|PROCEDURE|Accompaniment|presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
58458881|NCT04077021|DRUG|CCW702|Investigational immunotherapy for prostate cancer
58458882|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
57770516|NCT03214289|BIOLOGICAL|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
57770517|NCT02712671|RADIATION|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
57770518|NCT02712671|PROCEDURE|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
57770519|NCT02712671|PROCEDURE|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
57770520|NCT02712671|PROCEDURE|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
57770521|NCT02712671|OTHER|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
57770522|NCT02712671|PROCEDURE|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
57770523|NCT03684720|OTHER|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
57770524|NCT06489691|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
57770525|NCT00344006|DRUG|chlorproguanil-dapsone-artesunate|
57770526|NCT00344006|DRUG|artemether-lumefantrine|
57770527|NCT00147225|DRUG|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
57770528|NCT00147225|DRUG|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
57770529|NCT00147225|DRUG|Adriamycin|75-90 mg/m\^2 IV
57770530|NCT00147225|DRUG|Ifosfamide|10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
57770531|NCT02593305|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
57770532|NCT02593305|DIETARY_SUPPLEMENT|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
57770533|NCT02891044|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
57770534|NCT00416260|OTHER|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
57770535|NCT04111523|DRUG|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
57770536|NCT02384655|DRUG|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
57770537|NCT04639089|DRUG|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
58458883|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
58458884|NCT03936998|COMBINATION_PRODUCT|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
57770538|NCT05198193|BEHAVIORAL|No Message Given|Participants in this arm are not given any intervention.
57770539|NCT05198193|BEHAVIORAL|Positive Message Given - Older Adults|Participants in this arm are given a positively framed message from an older adult's point of view.
57770540|NCT05198193|BEHAVIORAL|Negative Message Given - Older Adults|Participants in this arm are given a negatively framed message from an older adult's point of view.
57770541|NCT05198193|BEHAVIORAL|Positive Message Given - Younger Adults|Participants in this arm are given a positively framed message from an adult child's point of view.
57770542|NCT05198193|BEHAVIORAL|Negative Message Given - Younger Adults|Participants in this arm are given a negatively framed message from an adult child's point of view.
57770543|NCT04471779|OTHER|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
57770544|NCT00985543|DRUG|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
57785281|NCT00178256|PROCEDURE|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
57785282|NCT00023439|OTHER|Nucleic Acid Amplification Methods for diagnosis|no intervention
57785283|NCT00807222|DRUG|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
58458885|NCT03936998|COMBINATION_PRODUCT|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
58458886|NCT00908453|DRUG|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
58458887|NCT01636765|DRUG|No Intervention|No intervention.
58458888|NCT03656003|DEVICE|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
58458889|NCT03656003|DEVICE|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
58458890|NCT00721006|BIOLOGICAL|MESENDO|40 subcutaneous injections of biological product
58458891|NCT00721006|BIOLOGICAL|Placebo|40 subcutaneous injections of placebo
58458892|NCT04808817|DIAGNOSTIC_TEST|calorimetry, impedance measurement at baseline and after 3 months of treatment|biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
57770545|NCT01197820|DEVICE|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
57770546|NCT05351619|PROCEDURE|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
57770547|NCT04910815|DEVICE|Atmo Gas Capsule|The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
57770548|NCT04910815|DIAGNOSTIC_TEST|Glucose Breath Test|Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
57770549|NCT04910815|DIAGNOSTIC_TEST|Fructoolifosaccharides (FOS) Breath Test|FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
57770550|NCT04910815|PROCEDURE|Jejunal Aspiration and culture|Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
57770551|NCT04910815|DRUG|Rifaximin|Rifaximin (550g) 1 capsule twice a day for 14 days.
57770552|NCT04910815|DRUG|Placebo|randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
57770553|NCT00279656|BEHAVIORAL|Pharmaceutical care|
57770554|NCT00967213|DRUG|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
57770555|NCT04395859|PROCEDURE|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
57770556|NCT04395859|OTHER|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
57770557|NCT03178955|DRUG|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
57770558|NCT03767634|OTHER|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
57770559|NCT02952664|BEHAVIORAL|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
57770560|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
57770561|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
57770562|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
57770563|NCT00517075|DEVICE|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
57770564|NCT03661996|DRUG|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
57770565|NCT03661996|DRUG|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
58458893|NCT04687306|DIAGNOSTIC_TEST|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
58458894|NCT01018030|DRUG|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
57770566|NCT03661996|DEVICE|ElastoGel|Cooling Device
57770567|NCT03661996|DEVICE|Breg Ice Water Pump|Cooling Device
57770568|NCT03326817|OTHER|Control Group|Patients receive standard care
57770569|NCT03326817|DEVICE|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
57770570|NCT00179790|PROCEDURE|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
57770571|NCT04182230|OTHER|No intervention. This study was an evalution with no intervention.|Not an interventional study
57770572|NCT02638623|DRUG|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
57770573|NCT02638623|DRUG|Placebo|No additional fluids will be administered
57770574|NCT05268484|DEVICE|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
57770575|NCT04765241|BEHAVIORAL|Physical Activity|The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
57770576|NCT05289284|OTHER|No intervention|No intervention
57770577|NCT01337830|OTHER|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
57770578|NCT01337830|OTHER|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
57770579|NCT02245763|DEVICE|Leaflet Clip|
57770580|NCT00171132|DRUG|valsartan|
58458895|NCT01018030|DRUG|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
58458896|NCT01018030|DRUG|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
58458897|NCT00252421|DRUG|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
58458898|NCT00252421|DRUG|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
58458899|NCT05411718|DRUG|Naproxen|Given by PO
58458900|NCT05411718|DRUG|Aspirin|Given by PO
57770581|NCT00171132|DRUG|atenolol|
57770582|NCT00171132|DRUG|hydrochlorothiazide|
57770583|NCT02208570|OTHER|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
57770584|NCT02208570|DRUG|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
57770585|NCT02208570|OTHER|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
57770586|NCT00383240|DRUG|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
57770587|NCT00383240|DRUG|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
57770588|NCT00383240|DRUG|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
57770589|NCT00383240|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
57770590|NCT02770508|DRUG|darunavir/ritonavir|
57770591|NCT02770508|DRUG|Lamivudine|
57770592|NCT02770508|DRUG|emtricitabine-tenofovir(FTC/TDF)|
57770593|NCT05988164|OTHER|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
57770594|NCT02914379|DRUG|[¹⁴C]-LY3337641|Administered orally
57770595|NCT01112514|DRUG|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
57770596|NCT02317224|PROCEDURE|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
57770597|NCT02317224|PROCEDURE|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
57770598|NCT02317224|PROCEDURE|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
58458901|NCT06085534|DRUG|LNK01001|Capsules for oral use
58458902|NCT06085534|DRUG|Placebo|Capsules for oral use
58458903|NCT03296514|BEHAVIORAL|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
58458904|NCT02849379|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
58458905|NCT02849379|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
58458906|NCT04227470|DRUG|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
58458907|NCT01931540|BEHAVIORAL|Exercise Training|Three times a week, for four months.
58458908|NCT05416138|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be performed at either peaks or troughs of ongoing prefrontal theta oscillations (3-7 Hz) concurrently with the cognitive test at the beginning of every test trial. Theta oscillations will be monitored in real-time at the left dorsolateral prefrontal cortex using electroencephalography (EEG).
58458909|NCT04345341|DRUG|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
57770599|NCT06121960|DIAGNOSTIC_TEST|spirometry|"Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance"
57770600|NCT04658186|DRUG|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
57770601|NCT04658186|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
57770602|NCT01025934|DRUG|Bevacizumab|
57770603|NCT01025934|OTHER|sham|
57770604|NCT00580996|OTHER|water high dose|water 16 oz PO x 1
57770605|NCT00580996|OTHER|water tiny dose|water 1 oz PO x 1
57770606|NCT03855410|BEHAVIORAL|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
57770607|NCT03855410|BEHAVIORAL|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
57770608|NCT03860038|DRUG|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
57770609|NCT06163352|DRUG|Norepinephrine|The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
57770610|NCT04263298|DRUG|Fulvestrant|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
57770611|NCT04263298|DRUG|Capecitabine Oral Product|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
57770612|NCT02289989|DRUG|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
57770613|NCT02289989|DRUG|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
57770614|NCT02654093|DRUG|Cholecalciferol|
57770615|NCT02654093|DRUG|Raloxifene|
57770616|NCT02654093|DRUG|Cholecalciferol and Raloxifene co-administration|
57770617|NCT00983489|BEHAVIORAL|video demonstration|video will be shown to mothers
57770618|NCT00983489|BEHAVIORAL|counselling|breast feeding counselling
57770619|NCT02890238|DRUG|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
57770620|NCT02890238|DRUG|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
57770621|NCT02890238|DRUG|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
57770622|NCT01671748|DEVICE|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
57770623|NCT01671748|OTHER|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
57770624|NCT05544552|DRUG|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
57770625|NCT00634985|DRUG|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
57770626|NCT01225913|DRUG|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
57770627|NCT01225913|DRUG|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
57770628|NCT01129531|DRUG|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
57770629|NCT01129531|DRUG|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
57770630|NCT03879603|BIOLOGICAL|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
57770631|NCT03879603|OTHER|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
57770632|NCT00596024|DIETARY_SUPPLEMENT|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
57770633|NCT00596024|DIETARY_SUPPLEMENT|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
57770634|NCT06268444|DEVICE|7-day actimetry sleep recording|7-day actimetry sleep recording
58458910|NCT04761263|OTHER|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
57770635|NCT06268444|OTHER|Determination of environmental pollutants in breast milk|Determination of environmental pollutants in breast milk
57770636|NCT06268444|OTHER|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
57770637|NCT06268444|OTHER|Continuous recording of the child&#39;s temperature for 7 days|Continuous recording of the child\&#39;s temperature for 7 days
57770638|NCT06268444|OTHER|Use of a sleep diary for 7 days|Use of a sleep diary for 7 days
57770639|NCT06268444|OTHER|Parental questionnaire of environmental exposure|Parental questionnaire of environmental exposure
57770640|NCT05168813|BIOLOGICAL|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
57770641|NCT05168813|BIOLOGICAL|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
57770642|NCT05168813|BIOLOGICAL|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
57770643|NCT00175461|PROCEDURE|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
57770644|NCT03457285|OTHER|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
57770645|NCT01547520|DRUG|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
57770646|NCT01547520|DRUG|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
57770647|NCT02014090|OTHER|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
57770648|NCT04538924|OTHER|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
57770649|NCT05147519|BEHAVIORAL|Novel interventions to achieve HIV remission|To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
57770650|NCT00796432|DRUG|OROS paliperidone|
57770651|NCT05083260|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
57770652|NCT05083260|DRUG|placebo|Hard gelatin capsule containing only common excipients for oral formulations
57770653|NCT01280318|PROCEDURE|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
57770654|NCT02058290|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
57770655|NCT02058290|DRUG|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
57770656|NCT00539643|DEVICE|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
57770657|NCT00539643|OTHER|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
57770658|NCT01880372|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Same as Arm description
57770659|NCT01161693|DEVICE|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
57770660|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
57770661|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
57770662|NCT01198860|DRUG|CTH Chronic Hepatitis B|"Drug:~* Tenofovir/ 300mg daily~* Phyllanthus Urinaria/300mg daily~* Adenosma Glutinosum/150mg daily~* Eclipta Prostrata/150mg daily~* Ascorbic Acid / 500mg daily"
57770663|NCT03001232|BEHAVIORAL|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
57770664|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT)|Diagnostic test
57770665|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat|Diagnostic test - repeat for biological variability deterination
57770666|NCT04373915|BEHAVIORAL|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
57770667|NCT05847322|BIOLOGICAL|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
57770668|NCT05847322|DRUG|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
57770669|NCT01040767|OTHER|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
57770670|NCT06296914|DEVICE|POTSapp|"Participants will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months. T"
57770671|NCT06296914|DEVICE|Waitlist Control|"Participants will receive educational information about online support for POTS via email. Starting at month 4, participants will receive equipment will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months."
58458911|NCT04761263|OTHER|Selected Physical therapy program|"* Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Facilitation of protective reaction from standing position by pushing the child in different directions.~* Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~* Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~* Jumping in place and jumping a board."
57770672|NCT03176589|DEVICE|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
57770673|NCT03176589|DEVICE|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
57770674|NCT03176589|OTHER|Deep breathing maneuvers|deep breathing maneuvers 3 times 10 breahs without any device at expiration
57770675|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
57770676|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
57770677|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
57770678|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
57770679|NCT02053025|DIETARY_SUPPLEMENT|mycoprotein|
57770680|NCT02053025|DIETARY_SUPPLEMENT|control protein|
58458912|NCT02804334|PROCEDURE|Psychiatric Questionnaires|
58458913|NCT02804334|PROCEDURE|Blood draw|
58458914|NCT05539885|PROCEDURE|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
58458915|NCT05539885|PROCEDURE|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
58458916|NCT03224130|OTHER|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
57770681|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
57770682|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
58458917|NCT03224130|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
57770683|NCT01332890|OTHER|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770684|NCT01332890|OTHER|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770685|NCT01332890|OTHER|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770686|NCT01332890|OTHER|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770687|NCT01332890|OTHER|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770688|NCT01332890|OTHER|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
57770689|NCT02569359|DIETARY_SUPPLEMENT|shea nut oil extract|
57770690|NCT02569359|OTHER|Placebo|
57770691|NCT00811746|DRUG|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
57770692|NCT00811746|DRUG|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
57770693|NCT00811746|OTHER|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
57770694|NCT04097405|DRUG|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
57770695|NCT04097405|DRUG|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
57770696|NCT01982214|DEVICE|sedentary|No intervention
57770697|NCT01982214|DEVICE|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
57770698|NCT03380780|DRUG|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
57770699|NCT03806868|OTHER|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
57770700|NCT03806868|OTHER|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
58458918|NCT01575821|DIETARY_SUPPLEMENT|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
58458919|NCT01575821|DIETARY_SUPPLEMENT|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
57770701|NCT04408027|BEHAVIORAL|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
57770702|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
57770703|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
57770704|NCT05867485|OTHER|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~1. Information about the spread of the virus and precautions to be taken.~2. Guidelines for cleanliness and disinfection of the environment.~3. Precautions regarding personal and wearable items.~4. Information about food and beverages.~5. Guidelines for personal hygiene practices.~6. Information about quarantine and isolation.~7. Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
57770705|NCT02936713|OTHER|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
57770706|NCT04015115|BEHAVIORAL|Youth Opioid Recovery Support service model|see arm 1 description
57770707|NCT04557527|PROCEDURE|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
57770708|NCT04557527|DEVICE|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
58458920|NCT01575821|DIETARY_SUPPLEMENT|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
58458921|NCT01575821|DIETARY_SUPPLEMENT|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
58458922|NCT00057863|DRUG|Paclitaxel|Given IV
58458923|NCT00057863|DRUG|Oxaliplatin|Given IV
58458924|NCT06411639|DRUG|ianalumab|ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
58458925|NCT06343246|DEVICE|Inspiratory muscle training with device|: A randomized, controlled three-arm study. Forty-five patients with HT randomized three group: Group 1 will receive IMT (7 days/8 weeks) with function and POWERbreathe® Classic LR device, group 2 will reviece only IMT with 50 % maximal inspiratory pressure (MIP), n: 15) and control group will recieve breathing exercises(7 days/8 weeks).
58458926|NCT01403623|PROCEDURE|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
58458927|NCT01403623|PROCEDURE|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
57770709|NCT05904860|OTHER|Backward Gait Training|Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
57770710|NCT05904860|OTHER|Forward Gait Training|Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
57770711|NCT00132379|DRUG|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
57770712|NCT00132379|DRUG|docetaxel|75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
57770713|NCT03622203|DEVICE|Biofreedom|Use of Biofreedom in real life patients
57770714|NCT02542540|OTHER|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
57770715|NCT01086566|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
58458928|NCT00826644|DRUG|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
58458929|NCT00826644|DRUG|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
58458930|NCT00826644|DRUG|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
58458931|NCT04777617|OTHER|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
58458932|NCT00006269|DRUG|irinotecan hydrochloride|
58458933|NCT00006269|DRUG|octreotide acetate|
58458934|NCT04696081|OTHER|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
57770716|NCT06053060|OTHER|Randomisation Standard Dynacup or Dynacup One C|Randomisation
58458935|NCT02407223|DRUG|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
58458936|NCT02407223|DRUG|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
58458937|NCT02407223|DRUG|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
58458938|NCT01772446|BEHAVIORAL|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
57770717|NCT00997724|PROCEDURE|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
57770718|NCT00460148|DRUG|Ropinirole|
57770719|NCT01177839|OTHER|Screening sheets|Reviewing screening sheets
57770720|NCT01361620|DRUG|aspirin|aspirin 81mg, 7-10 days
58458939|NCT04566471|OTHER|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
57770721|NCT01551316|DRUG|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
57770722|NCT01551316|DRUG|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
57770723|NCT03580616|DRUG|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
57770724|NCT03643146|BEHAVIORAL|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
57770725|NCT03643146|BEHAVIORAL|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
57770726|NCT00786201|DRUG|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
57770727|NCT00786201|DRUG|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
57770728|NCT00786201|DRUG|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
57770729|NCT00786201|DRUG|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
57770730|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
57770731|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
57770732|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
57770733|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
57770734|NCT04404608|DIAGNOSTIC_TEST|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
57770735|NCT03568721|DRUG|Ibuprofen|prescription of ibuprofen 400 mg
57770736|NCT03568721|DRUG|Acetaminophen|prescription of acetaminophen 500 mg
57770737|NCT03568721|OTHER|Chewing gum|prescription of one tablet of chewing gum
57770738|NCT05756452|DIAGNOSTIC_TEST|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
57770739|NCT03836508|DEVICE|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
57770740|NCT03836508|DEVICE|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
57770741|NCT00688090|BIOLOGICAL|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
57770742|NCT00688090|BIOLOGICAL|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
58458940|NCT02414815|DEVICE|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
58458941|NCT01562808|DRUG|Aripiprazole|single oral administration of aripiprazole
57770743|NCT05721443|DRUG|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
57770744|NCT02712697|DRUG|WM (Shentong Granules)|Shentong Granules with Prednisone
58458942|NCT00323141|DEVICE|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
57770745|NCT02712697|DRUG|Hormone (prednisone)|Oral prednisone
57770746|NCT04316390|DIETARY_SUPPLEMENT|Control|study drink (two weeks)
57770747|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
57770748|NCT04316390|DIETARY_SUPPLEMENT|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
57770749|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
58458943|NCT01302483|DRUG|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
58458944|NCT01302483|DRUG|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
57770750|NCT02235701|DRUG|170 mg/m2 aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
57770751|NCT02235701|DRUG|250 mg/m2 aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
57770752|NCT05264233|DIETARY_SUPPLEMENT|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
57770753|NCT05264233|DIETARY_SUPPLEMENT|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
57770754|NCT05264233|DIETARY_SUPPLEMENT|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
57770755|NCT00896623|GENETIC|mutation analysis|
57770756|NCT00896623|GENETIC|polymorphism analysis|
57770757|NCT00896623|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
57770758|NCT01166490|DRUG|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
57770759|NCT00181090|BEHAVIORAL|Modified Atkins diet|
57770760|NCT04866862|DRUG|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
58458945|NCT01590264|DEVICE|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
57770761|NCT05115019|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
57770762|NCT05115019|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
58458946|NCT01254253|DEVICE|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
57770763|NCT04296474|DRUG|ALK Alutard 5-grasses and birch|Intralymphatic injections
57770764|NCT04296474|DRUG|ALK Diluent|intralymphatic injections
57770765|NCT03857841|BIOLOGICAL|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
57770766|NCT03857841|BIOLOGICAL|Phosphate-buffered saline|Phosphate-buffered saline
57770767|NCT01122004|DRUG|Pregabalin|
57770768|NCT01122004|DRUG|Pregabalin|
58458947|NCT01500772|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
57770769|NCT01100047|DRUG|AZD5069|Oral suspension
57770770|NCT01100047|DRUG|Placebo|Oral suspension
57770771|NCT01141270|DRUG|AFOLIA|single sc injection, 225 IU
57770772|NCT01141270|DRUG|Gonal-f|single sc injection, 225IU
57770773|NCT00220961|DRUG|Pioglitazone|Pioglitazone tablets - 45 mg/day
57770774|NCT00220961|DRUG|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
57770775|NCT05165953|OTHER|no intervention|there was no intervention in the study
57770776|NCT01751815|PROCEDURE|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
57770777|NCT01751815|PROCEDURE|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
57770778|NCT00144872|DRUG|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
57770779|NCT00823420|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
57770780|NCT00101309|BIOLOGICAL|aldesleukin|
57770781|NCT00101309|BIOLOGICAL|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
57770782|NCT00101309|BIOLOGICAL|therapeutic autologous lymphocytes|
58458948|NCT01500772|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
57770783|NCT02440594|BEHAVIORAL|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
57770784|NCT02440594|BEHAVIORAL|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
57770785|NCT05083624|BEHAVIORAL|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
57770786|NCT06356727|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
57770787|NCT02285595|DEVICE|Sonendo GentleWave™ System|
57770788|NCT00947037|DRUG|AP-CD/LD|
57770789|NCT02798029|RADIATION|Frameless Fractionated Stereotactic Radiation Therapy|
57770790|NCT05095129|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
58458949|NCT01500772|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
57770791|NCT00346801|DRUG|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
57770792|NCT00346801|DRUG|Cisplatin|25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8
57770793|NCT00346801|DRUG|CPT-11|30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
57770794|NCT00346801|RADIATION|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
57770795|NCT05304923|PROCEDURE|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
57770796|NCT05304923|PROCEDURE|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
57770797|NCT04978259|DRUG|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
57770798|NCT00049400|DRUG|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
57770799|NCT00902941|DRUG|Azilect 1mg|1 mg daily orally for 120 days
57770800|NCT00902941|DRUG|Placebo|1 mg daily orally for 120 days
57770801|NCT01091623|OTHER|training|
57770802|NCT01091623|OTHER|training|
57770803|NCT01091623|OTHER|training|
57770804|NCT05713760|DRUG|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
57770805|NCT01989286|OTHER|Assessment|The posture, motor development and balance are going to be assessed.
57770806|NCT03472573|DRUG|Palbociclib|Given PO
57770807|NCT03472573|DRUG|Dexamethasone|Given PO
57770808|NCT03949660|DEVICE|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
57770809|NCT03949660|DEVICE|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
57770810|NCT03949660|DEVICE|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
57770811|NCT03949660|DEVICE|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
57770812|NCT02388074|DEVICE|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
58458950|NCT00639197|PROCEDURE|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
58458951|NCT00639197|PROCEDURE|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
57770813|NCT05310396|OTHER|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
57770814|NCT05310396|OTHER|Control Formula|Cow's milk-based infant formula with standard nutritional composition
57770815|NCT03717662|DRUG|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
57770816|NCT00874653|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
57770817|NCT06255821|BEHAVIORAL|Exposure|One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
57770818|NCT00671632|DRUG|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
57770819|NCT00747318|DRUG|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
57770820|NCT04293523|DRUG|ELOCTA|Extended half-life factor VIII product
57770821|NCT06175273|DIETARY_SUPPLEMENT|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
57770822|NCT06175273|DIETARY_SUPPLEMENT|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
57770823|NCT06175273|DRUG|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
57770824|NCT06175273|DRUG|Olanzapine|2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
57770825|NCT06175273|OTHER|Standard of Care|Diet education on high protein, high calorie food consumption
58458952|NCT01532947|PROCEDURE|post placement|placement of an endocanalar post
57770826|NCT04216979|PROCEDURE|laparoscopy entry policy|"Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site."
57770827|NCT02959671|DEVICE|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
57770828|NCT05950269|DEVICE|Walking aid|A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).
58458953|NCT05512754|DRUG|Ibuprofen 400 mg|400 mg tablet
58458954|NCT04590014|DEVICE|Conventional Precision Flow|Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
57770829|NCT05950269|OTHER|Telemonitoring|Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.
57770830|NCT05950269|OTHER|Guidance on safe walking and risk of falling|Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
57770831|NCT00195390|BIOLOGICAL|Prevenar|Prevenar 0.5ml/ Vial and PFS
57770832|NCT02568943|DRUG|Panobinostat|Panobinostat (PAN \[LBH589\]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
57770833|NCT00157651|DRUG|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
57770834|NCT00157651|DRUG|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
57770835|NCT02761889|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
58458955|NCT04590014|DEVICE|HVNI HVT2.0 Device|Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
58458956|NCT01112137|DRUG|Clopidogrel|
57770836|NCT02761889|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
57770837|NCT02761889|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
57770838|NCT02761889|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
57770839|NCT02997839|BEHAVIORAL|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
57770840|NCT04004572|DRUG|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
57770841|NCT06385002|DRUG|Remimazolam|After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
57770842|NCT01549522|BEHAVIORAL|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
58458957|NCT01112137|DRUG|Clopidogrel|
57770843|NCT01549522|BEHAVIORAL|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
57770844|NCT00633737|BEHAVIORAL|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
57770845|NCT03855163|BEHAVIORAL|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
57770846|NCT03855163|BEHAVIORAL|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
57770847|NCT03855163|BEHAVIORAL|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
57770848|NCT01234649|DRUG|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
58458958|NCT01112137|DRUG|Clopidogrel|
58458959|NCT01112137|DRUG|Clopidogrel|
58458960|NCT03761927|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
58458961|NCT03761927|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
58458962|NCT03761927|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
58458963|NCT04589858|OTHER|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
58458964|NCT04589858|OTHER|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
58458965|NCT01404169|DRUG|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
58458966|NCT01404169|DRUG|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
58458967|NCT01895075|DRUG|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
58458968|NCT01895075|DRUG|Normal saline|2 ml normal saline by inhalation
57770849|NCT01234649|DRUG|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
57770850|NCT02459184|OTHER|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
57770851|NCT02892682|OTHER|BLOOD TEST|
57770852|NCT04278417|BIOLOGICAL|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
57770853|NCT04278417|PROCEDURE|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
57770854|NCT02307513|DRUG|Apremilast|Tablets for oral administration
57770855|NCT02307513|DRUG|Placebo|Tablets for oral administration
57770856|NCT06624410|OTHER|Educational Intervention|"Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital."
57770857|NCT03207217|OTHER|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
57770858|NCT04801745|OTHER|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
57770859|NCT04801745|OTHER|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
57770860|NCT04801745|OTHER|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
57770861|NCT05484583|DRUG|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
57770862|NCT05484583|RADIATION|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
57770863|NCT05484583|DRUG|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
57770864|NCT00579982|DRUG|Lamotrigine|Experimental formulation
57770865|NCT02888067|DRUG|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
57770866|NCT02888067|DRUG|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
57770867|NCT02888067|DRUG|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
57770868|NCT02888067|DRUG|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
57770869|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
57770870|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
57770871|NCT05445856|DRUG|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
57770872|NCT05445856|DRUG|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
57770873|NCT03948087|DEVICE|Vacuum Removable Rigid Dressing (VRRD)|Intra-operative application of device.
57770874|NCT06450574|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
57770875|NCT06450574|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
57770876|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|10 weeks after Chemoradiotherapy
57770877|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery|Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
57770878|NCT05855902|BEHAVIORAL|group art therapy|Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
57770879|NCT06131996|OTHER|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
57770880|NCT06131996|OTHER|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
57770881|NCT06447064|OTHER|Cases & Controls|Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will need to provide a photo ID and utility bill for ID verification. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
57770882|NCT03152045|BEHAVIORAL|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
57770883|NCT00070993|DRUG|creatine monohydrate|
57770884|NCT03923010|DRUG|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
57770885|NCT05742230|DRUG|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
57770886|NCT05742230|DRUG|blank control|standard treatment
57770887|NCT05100719|DRUG|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
57770888|NCT05100719|DRUG|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
57770889|NCT02870504|PROCEDURE|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
57770890|NCT02870504|PROCEDURE|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
57770891|NCT02870504|PROCEDURE|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
57770892|NCT03290573|DEVICE|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
57770893|NCT02762344|DRUG|heparin|routinary heparin administration during coronary angiography/PCI
57770894|NCT02779595|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
57770895|NCT01915433|OTHER|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
57770896|NCT01915433|OTHER|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
57770897|NCT03758027|BEHAVIORAL|CARESS|"The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing."
57770898|NCT03758027|BEHAVIORAL|Isometric Exercise|5-minute protocol for cravings management and affect regulation
57770899|NCT03581877|DRUG|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
57770900|NCT03581877|DEVICE|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
57770901|NCT03485430|BEHAVIORAL|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
57770902|NCT01216293|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg capsules
57770903|NCT01216293|DRUG|Esomeprazole|Esomeprazole 40 mg capsules
57770904|NCT01216293|DRUG|Placebo|Placebo-matching capsules
57770905|NCT02095795|DEVICE|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
57770906|NCT02095795|OTHER|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
57770907|NCT02852018|GENETIC|Identification of genetic polymorphisms|
57770908|NCT03259529|DRUG|Bendamustine hydrochloride|70 mg/m2 by intravenous (IV) infusion for up to 2 cycles
57770909|NCT03259529|DRUG|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
57770910|NCT03259529|DRUG|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
58129567|NCT04104568|OTHER|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
57770911|NCT03259529|DRUG|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
57770912|NCT03259529|DRUG|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
57770913|NCT03259529|DRUG|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
57770914|NCT01561092|DRUG|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
57770915|NCT01561092|DRUG|Placebo|Tablets
58129568|NCT02559583|OTHER|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
57770916|NCT05510635|OTHER|interactive bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
57770917|NCT05510635|OTHER|reading bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
57770918|NCT00592319|DRUG|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
57770919|NCT00592319|DEVICE|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
57770920|NCT00592319|PROCEDURE|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
57770921|NCT01537679|BEHAVIORAL|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
57770922|NCT01537679|BEHAVIORAL|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
57770923|NCT01581697|DIETARY_SUPPLEMENT|Oat bran|
57770924|NCT02936037|DRUG|MD1003 100mg capsule|
57770925|NCT02936037|DRUG|PLACEBO|an inactive substance
57770926|NCT02041247|BIOLOGICAL|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
57770927|NCT05417451|OTHER|Acupuncture|All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)
57770928|NCT05668936|DRUG|Cotadutide|Participants will receive a subcutaneous injection of cotadutide.
57770929|NCT05668936|DRUG|Cotadutide-placebo|Participants will receive a subcutaneous injection of cotadutide-placebo.
57770930|NCT05668936|DRUG|Moxifloxacin|Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
57770931|NCT05668936|DRUG|Moxifloxacin-placebo|Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
57770932|NCT03083392|PROCEDURE|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
57770933|NCT03083392|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
57770934|NCT04062435|DRUG|Drop application in the inferior fornix|See Arms
57770935|NCT04062435|DRUG|Drop application on the cornea|See Arms
57770936|NCT01515189|BIOLOGICAL|Ipilimumab|
57770937|NCT05992714|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
57770938|NCT05992714|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
57770939|NCT04121039|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
57770940|NCT04121039|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
57770941|NCT00152763|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
57770942|NCT00152763|OTHER|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
57770943|NCT04714437|BEHAVIORAL|F|The participant will be asked to chew the latex bag naturally.
57770944|NCT04714437|BEHAVIORAL|R|The participant will be asked to chew the latex bag unilaterally on the right-side.
57770945|NCT04714437|BEHAVIORAL|L|The participant will be asked to chew the latex bag unilaterally on the left-side.
57770946|NCT04714437|BEHAVIORAL|A1|The participant will be asked to chew the latex bag changing the side once.
57770947|NCT04714437|BEHAVIORAL|A3|The participant will be asked to chew the latex bag changing the side three times.
57770948|NCT04714437|BEHAVIORAL|A5|The participant will be asked to chew the latex bag changing the side five times.
57770949|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
57770950|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
57770951|NCT01821430|DRUG|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
57770952|NCT01821430|DRUG|Placebo|Placebo group will follow the same titration as the pregabalin group
58129569|NCT02559583|OTHER|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
58458969|NCT06050317|DRUG|Sintilimab Plus mFFN and Radiation|Sintilimab Plus mFFN and Radiation
57770953|NCT03930134|PROCEDURE|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
57770954|NCT03930134|PROCEDURE|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
57770955|NCT01709305|DRUG|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
57770956|NCT01709305|DRUG|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
57770957|NCT01709305|DRUG|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
57770958|NCT01709305|DRUG|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
57770959|NCT01709305|DRUG|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
57770960|NCT01709305|DRUG|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
57770961|NCT05423522|DRUG|NanoLithium® NP03|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
57770962|NCT05423522|DRUG|Placebo|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
57770963|NCT02960763|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
57770964|NCT02960763|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
57770965|NCT02960763|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
57770966|NCT02960763|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
57770967|NCT02960763|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
57770968|NCT02169037|PROCEDURE|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
57770969|NCT02169037|PROCEDURE|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
57770970|NCT04737772|BEHAVIORAL|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
57770971|NCT04737772|BEHAVIORAL|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
57770972|NCT03458559|DRUG|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
57770973|NCT03458559|DRUG|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
57770974|NCT03037879|OTHER|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
57770975|NCT03037879|OTHER|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
57770976|NCT03037879|OTHER|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
57770977|NCT03037879|OTHER|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
57770978|NCT05443087|OTHER|Blood sampling to build population pharmacokinetics model|"Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received"
57770979|NCT01920503|DRUG|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
57770980|NCT06109090|OTHER|Neuropsychological testing|"In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis."
57770981|NCT05535140|OTHER|G8 Screening Tool|Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients \>65y/o who are scheduled with the medical oncology department.
57770982|NCT01566630|DRUG|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
57770983|NCT01566630|DRUG|RLX030|RLX030 1 mg/mL vials
58129570|NCT02559583|OTHER|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
57770984|NCT05664139|DRUG|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
57770985|NCT02887989|DEVICE|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
57770986|NCT02887989|DEVICE|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
57770987|NCT00390455|DRUG|Fulvestrant|Given IM
57770988|NCT00390455|OTHER|Laboratory Biomarker Analysis|Correlative studies
57770989|NCT00390455|DRUG|Lapatinib Ditosylate|Given PO
57770990|NCT00390455|OTHER|Placebo Administration|Given PO
57770991|NCT01759615|OTHER|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
57770992|NCT01759615|OTHER|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
57770993|NCT05408143|OTHER|CC|To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).
57770994|NCT05408143|DEVICE|enhanced telemedicine (ETM)|"An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, \& ears, auscultate the heart \& lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations."
57770995|NCT03160300|DEVICE|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
57770996|NCT03160300|DEVICE|Music|Relaxing music without a binaural beat component
57770997|NCT01031472|DRUG|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
57770998|NCT01031472|DRUG|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
57770999|NCT01031472|DRUG|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
57771000|NCT01031472|DRUG|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
57771001|NCT04976595|DRUG|Natesto|Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
57771002|NCT04544228|PROCEDURE|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
57771003|NCT04544228|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
57771004|NCT04544228|DRUG|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
57771005|NCT04544228|DRUG|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
57771006|NCT04544228|DRUG|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
57771007|NCT02872727|OTHER|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
57771008|NCT05943314|BIOLOGICAL|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
57771009|NCT05149781|PROCEDURE|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
57771010|NCT03335930|BEHAVIORAL|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
57771011|NCT05050266|BEHAVIORAL|EBQI|"EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity)."
57771012|NCT05050266|BEHAVIORAL|REP|The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
57771013|NCT01727492|DRUG|Antioxidantia|
57771014|NCT04020159|OTHER|Patient Registry|No intervention/treatment
57771015|NCT01762423|DEVICE|Active Device (IVIVI SofPulse)|
57771016|NCT01762423|DEVICE|Sham Device|
57771017|NCT05126043|DIAGNOSTIC_TEST|Triglycerides/high density lipoprotein ratio|Lipid profile
57771018|NCT01381952|RADIATION|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
57771019|NCT01381952|RADIATION|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
57771020|NCT05492812|OTHER|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
57771021|NCT05492812|DRUG|Chloral Hydrate|Chloral Hydrate
57771022|NCT05492812|DRUG|Hydroxyzine|Hydroxyzine
57771023|NCT05492812|DRUG|Melatonin|Melatonin
57771024|NCT05176782|DRUG|HTK cardioplegia|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
57771025|NCT05176782|DRUG|Cold Cadioplegia|as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
57771026|NCT05763082|DRUG|roflumilast cream 0.3%|test product
57771027|NCT05763082|DRUG|Zoryve|Reference Listed Drug product
57771028|NCT05763082|DRUG|Placebo|placebo
57771029|NCT02280057|DRUG|Metformin|Metformin 1500 mg (=2 pills) per day in six months
57771030|NCT02280057|DRUG|Placebo|2 pills per day in six months; pills look like metformin pills
57771031|NCT04381260|OTHER|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
57771032|NCT04381260|OTHER|Interview|Key Informant Interview
57771033|NCT04381260|OTHER|Survey|Stakeholder survey
57771034|NCT01588990|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
57771035|NCT01588990|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
57771036|NCT01588990|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
57771037|NCT01588990|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
57771038|NCT01588990|DRUG|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
57771039|NCT01588990|DRUG|Irinotecan|Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
57771040|NCT03218761|DIAGNOSTIC_TEST|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
57771041|NCT03218761|DIAGNOSTIC_TEST|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
57771042|NCT03218761|DIAGNOSTIC_TEST|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
57771043|NCT03377868|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
57771044|NCT03377868|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
57771045|NCT01261143|DRUG|BK-C-0701|tablet, 8 weeks
57771046|NCT00773058|DRUG|hydrocortisone|hydrocortisone 100mg q8h
57771047|NCT00773058|DRUG|placebo|normal saline 100ml q8h
57771048|NCT01719224|PROCEDURE|elevated body position|45 degrees elevated upper body position
57771049|NCT01719224|PROCEDURE|supine body position|non-elevated upper body position
57771050|NCT05822843|DRUG|ESG206|Administered via intravenous (IV) infusion
57771051|NCT02586337|DRUG|Anlotinib|Anlotinib p.o. qd
57771052|NCT02586337|DRUG|Placebo|Placebo p.o. qd
57771053|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
57771054|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
57771055|NCT00285181|DRUG|Simvastatin|
36727695|NCT06442839|OTHER|No specific interventions.|No specific interventions.
57771056|NCT02168790|DEVICE|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
58458970|NCT04301375|DRUG|Pertuzumab and trastuzumab FDC subcutaneous|Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
57771057|NCT05088837|OTHER|muscle energy technique|MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
57771058|NCT05088837|OTHER|ice and heat packs|Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
57771059|NCT01083940|OTHER|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
57771060|NCT05800782|BEHAVIORAL|Face Memory Training|Computer-based training using faces targeting face memory
57771061|NCT05800782|BEHAVIORAL|Face Perception Training|Computer-based training using faces targeting improving face perception
57771062|NCT05800782|BEHAVIORAL|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
57771063|NCT01048606|BEHAVIORAL|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
57771064|NCT01048606|DIETARY_SUPPLEMENT|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
57771065|NCT01048606|OTHER|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
57771066|NCT06380634|BEHAVIORAL|Experimental group- Motivational Interview|Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
57771067|NCT00748124|DEVICE|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
57771068|NCT00748124|PROCEDURE|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
57771069|NCT02366936|DEVICE|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
57771070|NCT04930328|DRUG|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
57771071|NCT05092243|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
57771072|NCT00807521|DRUG|Dexamethasone|Single high dose bolus of dexamethasone before surgery
57771073|NCT00807521|DRUG|Placebo|Placebo for dexamethasone
57771074|NCT01715337|OTHER|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
57771075|NCT00956696|DRUG|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
57771076|NCT01464008|DRUG|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
57771077|NCT03786120|DRUG|Zolpidem|PO sleep aid in various doses
57771078|NCT04023149|DRUG|recombinant human interleukin-2 (rhIL-2)|Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
57771079|NCT04023149|DRUG|placebo|Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
57771080|NCT00115219|DRUG|Etanercept|
58458971|NCT04301375|DRUG|Paclitaxel|80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
58458972|NCT04301375|DRUG|TDM1|3,6 mg/kg, 14 adjuvant cycles if not complete response
58458973|NCT04301375|DRUG|Endocrine therapy|Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
57771081|NCT03444935|BEHAVIORAL|Follow-up phone call|Please see arm/group description.
57771082|NCT01468896|BIOLOGICAL|Cetuximab|Given IV
57771083|NCT01468896|BIOLOGICAL|Edodekin alfa|Given SC
57771084|NCT01468896|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771085|NCT02761460|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
57771086|NCT01926522|DEVICE|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
57771087|NCT01926522|OTHER|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
57771088|NCT04091360|DRUG|Part A: RPL554|Single dose RPL554 via metered dose inhaler.
57771089|NCT04091360|DRUG|Placebos|Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
57771090|NCT04091360|DRUG|Part B: RPL554|Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
57771091|NCT05256693|DRUG|Vancomycin|Oral vancomycin (powder) 125mg twice a day
57771092|NCT05256693|DRUG|Placebo|Vancomycine placebo (powder) twice a day
57771093|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg BID
57771094|NCT01057108|OTHER|FOSTRAP Chewing Gum|40 mg BID
57771095|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
57771096|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
57771097|NCT01057108|OTHER|Placebo chewing gum|
57771098|NCT00810082|DEVICE|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
57771099|NCT00810082|OTHER|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
57771100|NCT04192630|DEVICE|CVisc50 OVD|Bausch + Lomb CVisc50 Cohesive OVD
57771101|NCT04192630|DEVICE|ProVisc OVD|ProVisc OVD
57771102|NCT04192630|PROCEDURE|Cataract Surgery|Cataract Surgery
57771103|NCT05250258|OTHER|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
57771104|NCT04022460|DIAGNOSTIC_TEST|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
57771105|NCT04022460|DIAGNOSTIC_TEST|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
57771106|NCT04022460|OTHER|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
58129571|NCT04270305|OTHER|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
57771107|NCT00798031|DEVICE|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
57771108|NCT00798031|DEVICE|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
57771109|NCT00798031|DEVICE|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
57771110|NCT03467308|GENETIC|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods."
58129572|NCT04270305|OTHER|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
58129573|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
57771111|NCT03096301|DEVICE|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
57771112|NCT03096301|DEVICE|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
57771113|NCT03096301|DEVICE|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
57771114|NCT06367387|DRUG|Patient-Oriented Dosing (POD)|"Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference."
57771115|NCT06367387|BEHAVIORAL|Pain Self-Management (PSM)|"Pain self-management (PSM) is a manualized behavioral intervention consisting of 12 sessions, comprising 6 group and 6 individual sessions. The first session will be individual, followed by a group session, and then alternating weekly for the remainder of the intervention.~Individual sessions will be led by a staff Interventionist trained in the pain self-management intervention. The interventionist will guide participants through a PSM study manual, providing education, teaching associated skills, and assisting with goal setting.~Group sessions will be led by a Peer Facilitator who has experience with chronic pain, opioid use disorder, and buprenorphine treatment. These sessions will not have specific content but will serve as supportive forums for participants to discuss their experiences with the intervention, share tips for managing chronic pain, and provide mutual support."
57771116|NCT06367387|BEHAVIORAL|Usual Care|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions."
57771117|NCT06367387|DRUG|Standard Buprenorphine Dosing Condition|Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
57771118|NCT04334421|DEVICE|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
57771119|NCT05147168|OTHER|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
57771120|NCT03780270|DEVICE|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
57771121|NCT03780270|DEVICE|Curodont Repair|P11-4 (monomeric peptide) - for professional use
57771122|NCT03780270|DEVICE|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
57771123|NCT03648593|BEHAVIORAL|work recovery intervention|Recover! app: one hour weekly for two months
57771124|NCT03648593|BEHAVIORAL|waiting list control|no treatment during 6 months,then Recover! app
57771125|NCT04258085|OTHER|Early diagnosis program combined with electronic medical record|Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
57771126|NCT01442272|DRUG|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
57771127|NCT01442272|DRUG|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
57771128|NCT01442272|DRUG|Habitual medication|Habitual medication
57771129|NCT04597502|DIETARY_SUPPLEMENT|Terminalia Chebula fruit extract|Oral TC fruit extract supplement taken by mouth twice per day
57771130|NCT04597502|DIETARY_SUPPLEMENT|Placebo|Oral placebo taken by mouth twice per day
57771131|NCT04597502|OTHER|Topical Terminalia Chebula|Applied to both forearms and dorsal hands
57771132|NCT04597502|OTHER|Topical Placebo|Applied to both forearms and dorsal hands
57771133|NCT01033292|DRUG|BSI-201|IV infusion, 5.6 mg/kg
57771134|NCT03767985|OTHER|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
57771135|NCT03767985|OTHER|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
57771136|NCT05281003|DRUG|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
57771137|NCT05281003|DRUG|Paclitaxel|Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
57771138|NCT05281003|DRUG|Cisplatin|Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
57771139|NCT01352143|DRUG|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
57771140|NCT01352143|DRUG|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
57771141|NCT03331627|DRUG|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
57771142|NCT04878016|BIOLOGICAL|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
57771143|NCT04878016|DRUG|Placebo|Patients will receive placebo administered by IV infusion every 21days.
58129574|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
57771144|NCT04878016|DRUG|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
57771145|NCT04878016|DRUG|Etoposide|"Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
57771146|NCT01440127|DRUG|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
57771147|NCT03470714|OTHER|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
57771148|NCT03470714|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
57771149|NCT03350659|DRUG|Midodrine|Midodrine single 5mg/day
57771150|NCT03350659|DRUG|Atomoxetine|Atomoxetine single 18mg/day
57771151|NCT05240833|DIAGNOSTIC_TEST|VExUS Score|"The VExUS-Guided Arm care team will be informed of the Day 0 VExUS immediately after the ultrasound is performed and given a suggested target for the following 48 hours as follows:~* VExUS 0: There is no evidence of venous congestion.~* VExUS 1: There is evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: There is evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis.~* If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
57771152|NCT02319733|DEVICE|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
57771153|NCT00235443|DRUG|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
57771154|NCT06109506|PROCEDURE|Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess|Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.
57771155|NCT03609125|OTHER|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
57771156|NCT00734214|DRUG|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
57771157|NCT00734214|DRUG|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
57771158|NCT05464576|DIAGNOSTIC_TEST|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
57771159|NCT00003329|GENETIC|gene mapping|
57771160|NCT04959149|DEVICE|AirTraq videolaryngoscope|intubation of morbidly obese patient using Airtraq videolaryngoscope
57771161|NCT05505253|DRUG|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
57771162|NCT05505253|DRUG|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
57771163|NCT03771157|DRUG|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
57771164|NCT02318719|DRUG|Placebo|Placebo
57771165|NCT02318719|DRUG|DS-5565|
57771166|NCT01296490|OTHER|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
57771167|NCT02569450|BEHAVIORAL|Surgical outcomes monitoring using Shewhart control chart|"* Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization"
57771168|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
57771169|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
57771170|NCT06155084|DRUG|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
57771171|NCT06211387|PROCEDURE|Resistance Exercise Training|Resistance Exercise Training for knee
57771172|NCT06211387|PROCEDURE|Joint Mobilization|Tibiofemoral and Patellofemoral Joint Mobilization
57771173|NCT02380508|DRUG|BCG SSI|Intradermal injection
57771174|NCT02380508|OTHER|No vaccination|
57771175|NCT02380508|DRUG|BCG Sii|intradermal injection
57771176|NCT02859467|OTHER|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia."
57771177|NCT02859467|OTHER|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
57771178|NCT03523182|DIETARY_SUPPLEMENT|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
57771179|NCT03523182|DIETARY_SUPPLEMENT|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
57771180|NCT03675074|DEVICE|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
57771181|NCT05928715|OTHER|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
57771182|NCT02587559|PROCEDURE|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
57771183|NCT00061230|BEHAVIORAL|biofeedback-monitored relaxation training|
57771184|NCT01696318|BEHAVIORAL|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
57771185|NCT05261503|OTHER|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
57771186|NCT05261503|OTHER|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
57771187|NCT00849082|DRUG|cyproterone acetate|
57771188|NCT00849082|DRUG|goserelin acetate|
57771189|NCT00849082|RADIATION|radiation therapy|
57771190|NCT00240526|BIOLOGICAL|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
57771191|NCT00240526|BIOLOGICAL|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
57771192|NCT06488521|BIOLOGICAL|Complarate|Complarate solution, a subcutaneous injection at a single dose of 162 mg.
57771193|NCT06488521|BIOLOGICAL|Actemra®|Actemra® solution, subcutaneous injection at a single dose of 162 mg.
57771194|NCT05859633|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio in acute pancreatitis|role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
57771195|NCT04070677|COMBINATION_PRODUCT|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
57771196|NCT05964881|PROCEDURE|sacrospinous hysteropexy|sacrospinous hysteropexy
57771197|NCT04514471|OTHER|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
57771198|NCT04514471|OTHER|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
57771199|NCT01154894|OTHER|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
57771200|NCT00002536|DRUG|cisplatin|
57771201|NCT00002536|DRUG|vincristine sulfate|
57771202|NCT00002536|PROCEDURE|surgical procedure|
57771203|NCT00002536|RADIATION|radiation therapy|
57771204|NCT03240341|BEHAVIORAL|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
57771205|NCT01562002|PROCEDURE|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
57771206|NCT06241690|OTHER|the cold applications in post-suture pain reduces the child's pain|The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
57771207|NCT02394041|DEVICE|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
57771208|NCT02394041|DEVICE|Sham acupuncture|Sham acupuncture with sham needles
57771209|NCT03790514|OTHER|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
57771210|NCT02450864|OTHER|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
57771211|NCT02761174|DRUG|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
57771212|NCT02761174|OTHER|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
57771213|NCT02430818|DRUG|ketamine|
57771214|NCT02430818|DRUG|morphine|
57771215|NCT01247519|OTHER|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
57771216|NCT02822560|DEVICE|pEVAR|percutaneous femoral access using a suture-mediated closure device
57771217|NCT02822560|PROCEDURE|open femoral access|cutdown to femoral artery and surgical closure
57771218|NCT04867876|BEHAVIORAL|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
57771219|NCT05605717|RADIATION|Fibroscan|Liver fibroscan and ultrasonography
57771220|NCT05276063|DRUG|Linsitinib|Study medication taken twice daily by mouth
57771221|NCT05276063|DRUG|Placebo|Placebo taken twice daily by mouth
57771222|NCT04736017|DEVICE|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
57771223|NCT05713812|PROCEDURE|Kinesiotaping|Kinesiotape will be applied
57771224|NCT05713812|PROCEDURE|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
58129575|NCT03220919|OTHER|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
58458974|NCT04301375|PROCEDURE|Omission surgery|Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
58458975|NCT05007613|DRUG|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
57771225|NCT05697549|BEHAVIORAL|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
57771226|NCT02810730|PROCEDURE|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
57771227|NCT04071119|DRUG|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
57771228|NCT04071119|DRUG|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
57771229|NCT00380120|DRUG|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
57771230|NCT00380120|DRUG|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
57771231|NCT06320522|DIETARY_SUPPLEMENT|Ketone Monoester|Commercial dietary supplement intended raise blood ketone body levels
57771232|NCT06320522|DIETARY_SUPPLEMENT|Placebo|Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
57771233|NCT00812513|DRUG|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
57771234|NCT06323811|DIAGNOSTIC_TEST|CMR|Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
57771235|NCT01287637|PROCEDURE|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
57771236|NCT01287637|PROCEDURE|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
57771237|NCT00957788|DRUG|NST-001|Comparison of different dosages of drug.
57771238|NCT04636606|PROCEDURE|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
57771239|NCT04636606|PROCEDURE|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
57771240|NCT04636606|PROCEDURE|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
57771241|NCT00612703|DRUG|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
57771242|NCT01828190|OTHER|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
57771243|NCT03621722|OTHER|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
57771244|NCT02749058|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
57771245|NCT02749058|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
57771246|NCT05634720|DRUG|HA Chemotherapy|On Day 1 of the treatment period, patients will undergo standard-of-care diagnostic laparoscopy to confirm the absence of metastatic disease not seen on staging imaging, as well as tissue acquisition (blood and liver biopsies) for pre-specified correlative scientific studies. On Day 2 (±1 day), patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy. On Day 14 (±5 business days), patients will undergo standard-of-care resection of their primary tumor, as well as tissue acquisition (blood, liver biopsies, primary tumor, regional lymph nodes) for pre-specified correlative scientific studies.
57771247|NCT00478764|DRUG|intraocular triamcinolone and gatifloxicin|
57771248|NCT04835896|DRUG|M7824+paclitaxel|M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
57771249|NCT04192513|DRUG|J. lividum|Investigational Product
57771250|NCT05343117|DRUG|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
57771251|NCT05343117|DRUG|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
57771252|NCT04033172|DRUG|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
57771253|NCT01243073|DRUG|Imetelstat|
57771254|NCT02532959|DEVICE|Diagnostic Breath Analysis|Conduct exhaled breath samples
57771255|NCT05561062|DRUG|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
57771256|NCT05407532|PROCEDURE|Group with oral management|The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
57771257|NCT05407532|PROCEDURE|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
58458976|NCT05007613|DRUG|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
58458977|NCT01512199|DRUG|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
58458978|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
58458979|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
57771258|NCT03786796|DRUG|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
57771259|NCT04177381|PROCEDURE|Cesarean section|"1. Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~2. The fascia will be then incised sharply at the midline~3. The transversalis fascia and pre peritoneal fat will be dissected carefully~4. The peritoneum will be then incised.~5. Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~6. Delivery of the Fetus and placenta.~7. Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
57771260|NCT04177381|PROCEDURE|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
57771261|NCT04177381|DEVICE|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
57771262|NCT05054127|OTHER|foiiow up patients|observational study
57771263|NCT03169192|DRUG|Zoledronic Acid|intravenous injections once every 3 months
57771264|NCT02257255|PROCEDURE|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
57771265|NCT02257255|PROCEDURE|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
57771266|NCT03959592|DRUG|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
57771267|NCT03959592|OTHER|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
57771268|NCT04563390|BEHAVIORAL|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
57771269|NCT04563390|BEHAVIORAL|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
57771270|NCT03320460|DRUG|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
57771271|NCT03320460|DEVICE|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
57771272|NCT03320460|OTHER|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
57771273|NCT03320460|OTHER|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
57771274|NCT02384317|DRUG|CCX168|CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
57771275|NCT06471244|OTHER|Finger tapping|The volunteer is tapping with his/her right hand index finger.
57771276|NCT06471244|OTHER|Median nerve stimulation|Electrical pulses are applied at the wrist to the median nerve.
57771277|NCT06471244|OTHER|Speech processing|German sentences are played to the volunteers and the volunteers have to fulfill a semantic task.
58129576|NCT03220919|OTHER|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, \>10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, \> 20 mmol/L."
58129577|NCT00623779|DRUG|AZD0837|ER formulation
57771278|NCT05805683|DRUG|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
58129578|NCT00623779|DRUG|Aspirin|Oral form
57771279|NCT05805683|DRUG|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
58129579|NCT03392909|DRUG|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
58129580|NCT03614520|OTHER|Administration of olive oil|25 mL of extra virgin olive oil
58129581|NCT03614520|OTHER|Administration of red wine|150 mL or Red Wine
58129582|NCT03614520|OTHER|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
58129583|NCT03614520|OTHER|Water|Mineral water will be given as placebo
57771280|NCT04691713|DRUG|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
57771281|NCT00406458|DRUG|SB-509|60 mg dose
57771282|NCT00406458|OTHER|Normal Saline|
57771283|NCT05518760|OTHER|no intervention|no intervention
57771284|NCT05960383|DIAGNOSTIC_TEST|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
57771285|NCT01572246|OTHER|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
57771286|NCT03678259|DRUG|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
57771287|NCT01925261|DRUG|TPX-100 50mg|
57771288|NCT01925261|DRUG|TPX-100 100mg|
57771289|NCT01925261|DRUG|TPX-100 200mg|
57771290|NCT01925261|DRUG|TPX-100 20mg|
57771291|NCT01925261|DRUG|Placebo|
57771292|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
57771293|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
57771294|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
57771295|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
57771296|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension BID
57771297|NCT04105972|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
57771298|NCT04105972|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
57771299|NCT04105972|DRUG|IVA|Mono tablet for oral administration.
58458980|NCT01512199|DRUG|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
57771300|NCT01827254|OTHER|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
57771301|NCT01391143|BIOLOGICAL|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
58458981|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
57771302|NCT02238197|DRUG|Atrovent® Inhalation Solution|
57771303|NCT03103022|DRUG|Acetaminophen|Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
57771304|NCT03103022|DRUG|ibuprofen|Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
58129584|NCT03614520|OTHER|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
58458982|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
58458983|NCT01512199|DRUG|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
58458984|NCT05164393|DRUG|AVX001|Topical gel treatment for once daily application
58458985|NCT02259673|OTHER|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
58458986|NCT02259673|OTHER|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
57771305|NCT00095823|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
57771306|NCT00095823|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
57771307|NCT01996072|DRUG|EC17|
57771308|NCT04261179|DRUG|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
57771309|NCT04261179|DRUG|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
57771310|NCT01053754|BIOLOGICAL|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
57771311|NCT04545216|OTHER|Long-distance mountain running|Impact of a mountain race on the knee cartilage
57771312|NCT04021992|DRUG|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
57771313|NCT03933332|OTHER|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
57771314|NCT03933332|OTHER|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2
57771315|NCT03933332|OTHER|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm\^2
58129585|NCT03614520|OTHER|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
58458987|NCT02319200|DRUG|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
58458988|NCT02319200|DRUG|placebo tablet|4 tablets per day for 36 months
58458989|NCT01259817|DRUG|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
58458990|NCT01259817|DRUG|Aspirin|81 or 100 mg daily.
57771316|NCT03933332|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
57771317|NCT04100460|DIETARY_SUPPLEMENT|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
57771318|NCT04100460|DIETARY_SUPPLEMENT|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
57771319|NCT04100460|DIETARY_SUPPLEMENT|Control - No Arabinoxylan|Participants are given no Arabinoxylan
57771320|NCT01325649|PROCEDURE|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
57771321|NCT01325649|RADIATION|long course 5-FU bases radiochemotherapy|
57771322|NCT01267253|DRUG|Brivanib Alaninate|Given PO
57771323|NCT01267253|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771324|NCT01642082|BIOLOGICAL|Dalantercept|Given SC
58458991|NCT00474955|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
58458992|NCT02546232|DRUG|Carboplatin|Chemotherapy
58458993|NCT02546232|DRUG|Paclitaxel|Chemotherapy
58458994|NCT00240058|DRUG|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
58458995|NCT03106571|DRUG|Pomaglumetad methionil|Tablets twice daily
58458996|NCT03106571|DRUG|Placebo|1-4 tablets twice daily
58458997|NCT03106571|DRUG|Methamphetamine|intravenous methamphetamine
58458998|NCT04578275|OTHER|diagnostic strategy using ECGI|"Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.~ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure."
58458999|NCT02413918|DRUG|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
58459000|NCT06524102|DEVICE|Magnetic Activated Cell Sorting|"The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use."
58459001|NCT01848665|DRUG|Indomethacin|
58459002|NCT01848665|DRUG|Placebo|
58459003|NCT00981149|DRUG|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
58459004|NCT00981149|DRUG|Placebo|Placebo match duloxetine for 6 week period.
58459005|NCT04072926|DRUG|BioRoot|Influence of biomaterial BioRoot on periapical healing
58459006|NCT03476200|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
58459007|NCT03512834|DRUG|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
57771325|NCT01642082|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771326|NCT04825444|DEVICE|Photoacoustic inspection|Use photoacoustic imaging system to image breast blood vessels
58129586|NCT03614520|OTHER|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
58459008|NCT03512834|DRUG|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
57771327|NCT02109198|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
57771328|NCT02109198|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
57771329|NCT00472771|DRUG|INNO-206|
57771330|NCT01493960|DRUG|Cobitolimod|30 mg rectal dose at week 0 and 4
57771331|NCT01493960|DRUG|Placebo|Rectal dose at week 0 and 4
57771332|NCT03452605|DIETARY_SUPPLEMENT|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
57771333|NCT05444400|OTHER|Strengthening|Strengthening
57771334|NCT05444400|OTHER|Conventional protocol|Conventional protocol
57771335|NCT01642069|OTHER|laboratory biomarker analysis|Correlative studies
58129587|NCT03556566|BIOLOGICAL|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
58459009|NCT05582486|BEHAVIORAL|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
58459010|NCT02682953|DRUG|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
58459011|NCT02682953|PROCEDURE|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
58459012|NCT02682953|DRUG|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
57771336|NCT04940182|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
57771337|NCT04940182|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 full days
57771338|NCT06468072|OTHER|Expressivity protocol for children with autism|The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
57771339|NCT06468072|OTHER|Expressivity protocol for non-autistic children|The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
57771340|NCT01255943|BEHAVIORAL|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
57771341|NCT00003379|DRUG|cisplatin|
57771342|NCT00003379|DRUG|paclitaxel|
57771343|NCT00003379|RADIATION|brachytherapy|
57771344|NCT00003379|RADIATION|radiation therapy|
57771345|NCT03239405|DEVICE|Suction callibrated system|One-step suction callibrated SG system
57771346|NCT03118375|DEVICE|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
57771347|NCT03895736|BIOLOGICAL|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
57771348|NCT05126979|BIOLOGICAL|Inactivated Split Influenza Vaccine|
57771349|NCT05126979|BIOLOGICAL|Placebo|
57771350|NCT04573413|DEVICE|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
58129588|NCT01568164|DEVICE|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
58129589|NCT02906709|DRUG|Omarigliptin|Omarigliptin, 25 mg orally once weekly
58459013|NCT00543257|OTHER|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
58459014|NCT00543257|OTHER|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
58129590|NCT02906709|DRUG|Placebo|Placebo to omarigliptin orally once weekly
58459015|NCT05833958|DRUG|GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin|As described previously
58459016|NCT05833958|DRUG|Metformin|As described previously - Experimental Arm, 175mg at night
58459017|NCT05833958|DRUG|Metformin|As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
58459018|NCT01810484|DEVICE|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
58459019|NCT01810484|DEVICE|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
58459020|NCT01810484|DEVICE|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
57771351|NCT04573413|DEVICE|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
57771352|NCT00172081|DRUG|placebo|Daily subcutaneous injection with placebo
57771353|NCT00172081|DRUG|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
57771354|NCT01421485|BEHAVIORAL|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
57771355|NCT01421485|BEHAVIORAL|Treatment as Usual|Treatment in community, case management
57771356|NCT01085565|DEVICE|ExAblate 2100|Conformal Bone System
57771357|NCT01684995|BEHAVIORAL|Brief physician advice|Brief physician advice to quit smoking
57771358|NCT01684995|DRUG|nicotine patch|nicotine patch
57771359|NCT01684995|BEHAVIORAL|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
57771360|NCT03696875|OTHER|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
57771361|NCT03696875|OTHER|Standard of care|Standard of care
58129591|NCT02906709|BIOLOGICAL|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
58129592|NCT01819623|OTHER|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
58459021|NCT04745364|BEHAVIORAL|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
58459022|NCT06129526|DIETARY_SUPPLEMENT|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
58459023|NCT06129526|DIETARY_SUPPLEMENT|Corn Oil|Corn Oil
57771362|NCT03393338|BEHAVIORAL|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
58129593|NCT03658837|PROCEDURE|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
58459024|NCT02476786|BEHAVIORAL|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
58459025|NCT02476786|DRUG|Goserelin|
57771363|NCT03085251|DEVICE|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
57771364|NCT04422639|RADIATION|SRS/SRT|Comparing pre-operative SRS/SRT to post-operative SRS/SRT
57771365|NCT05813626|DRUG|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
57771366|NCT02183870|DRUG|Crizotinib|250mg crizotinib bid until end of treatment
57771367|NCT00676975|DRUG|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
57771368|NCT00676975|DRUG|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
57771369|NCT00953914|DRUG|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
57771370|NCT00953914|DRUG|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
57771371|NCT03961113|OTHER|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
57771372|NCT05591560|DRUG|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
57771373|NCT05591560|DRUG|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
58459026|NCT02476786|DRUG|Anastrozole|
58459027|NCT02476786|DRUG|Exemestane|
58459028|NCT02476786|DRUG|Fulvestrant|
57771374|NCT03032874|PROCEDURE|Colonoscopy|They all had screening colonoscopy
57771375|NCT05394233|DRUG|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
58129594|NCT00424203|DRUG|AC regimen|
58459029|NCT02476786|DRUG|Tamoxifen|
58459030|NCT02476786|OTHER|Archived tissue collection|
58459031|NCT02266316|DEVICE|Air warming mask|Mask that warms air at the mouth
58459032|NCT02571426|DRUG|Sevoflurane|anesthetic agent
58459033|NCT02571426|DRUG|propofol|anesthetic agent
58129595|NCT00424203|DRUG|cyclophosphamide|
58459034|NCT02753946|DRUG|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
58459035|NCT02753946|DRUG|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
58459036|NCT04914780|BEHAVIORAL|Education|Education intervention with mobile application for 4 weeks
58459037|NCT06446921|DIETARY_SUPPLEMENT|Ginger formula|supplement delivering a minimum of 20 mg of gingeroids / d
57771376|NCT02969031|BEHAVIORAL|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
57771377|NCT02969031|BEHAVIORAL|Standard Communication training|Standard Communication training
57771378|NCT02010697|BEHAVIORAL|Messages targeting nonsmokers|
57771379|NCT02010697|BEHAVIORAL|Messages targeting smokers|
57771380|NCT00265707|DEVICE|Blood pressure measurement|
58129596|NCT00424203|DRUG|doxorubicin hydrochloride|
58129597|NCT00424203|PROCEDURE|adjuvant therapy|
58129598|NCT00424203|PROCEDURE|cognitive assessment|
58459038|NCT06446921|DIETARY_SUPPLEMENT|Placebo|arabic gum
58459039|NCT03920111|BIOLOGICAL|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
58490179|NCT04532606|DRUG|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
57771381|NCT00247819|PROCEDURE|Blood draw|
58491251|NCT01349400|PROCEDURE|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
57771382|NCT02498379|DRUG|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
57771383|NCT00781534|DRUG|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
57771384|NCT00781534|DRUG|Ginseng|
57771385|NCT00781534|DRUG|ginsenoside RE|active metabolite of ginseng
57771386|NCT00781534|DIETARY_SUPPLEMENT|Placebo (sugar pill)|placebo group
57771387|NCT02221856|PROCEDURE|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
57771388|NCT02221856|PROCEDURE|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
57771389|NCT00128011|BIOLOGICAL|killed oral cholera vaccine|
57771390|NCT01127906|DRUG|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
57771391|NCT01127906|DRUG|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
57771392|NCT01127906|DRUG|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
57771393|NCT01127906|DRUG|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
57771394|NCT01127906|DRUG|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
57771395|NCT04837001|DRUG|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
57771396|NCT04837001|OTHER|Placebo|Placebo will be administered as a single bolus injection.
57771397|NCT03812211|DIETARY_SUPPLEMENT|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
57771398|NCT03812211|DIETARY_SUPPLEMENT|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
57771399|NCT04542408|DRUG|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
57771400|NCT04542408|DRUG|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
57771401|NCT04421742|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
57771402|NCT03491748|DRUG|ETX0282|Oral Gelatin capsules
57771403|NCT03491748|DRUG|Cefpodoxime proxetil|Oral tablets
57771404|NCT03491748|DRUG|Placebo|Oral Gelatin capsules
57771405|NCT01598428|PROCEDURE|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
57771406|NCT03804996|DRUG|TG-1801|Intravenous infusion over 1 hour every 4 weeks
57771407|NCT03804996|BIOLOGICAL|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
57771408|NCT05443425|DRUG|Cholestyramine|Given PO
57771409|NCT05443425|DRUG|Leflunomide|Given PO
57771410|NCT05443425|DRUG|Steroid Therapy|Given steroid therapy
57771411|NCT01803841|PROCEDURE|Transradial coronary angiography and intervention|
57771412|NCT01803841|PROCEDURE|Transfemoral coronary angiography and intervention|
57771413|NCT03176095|DIETARY_SUPPLEMENT|Probiotic|
57771414|NCT03176095|DIETARY_SUPPLEMENT|Placebo|
57771415|NCT06312293|DEVICE|Transcutaneous Vagus Nerve Stimulation|All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
57771416|NCT05374759|DIAGNOSTIC_TEST|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
57771417|NCT05374759|DIAGNOSTIC_TEST|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
57771418|NCT02831829|OTHER|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
57771419|NCT02831829|OTHER|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
57771420|NCT02275247|DRUG|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
57771421|NCT00611117|OTHER|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
57771422|NCT00624325|DRUG|interferon alfa-2b|12 MU daily continuously subcutaneous
57771423|NCT00624325|DRUG|interferon alfa-2b|9 MU daily continuously subcutaneous
57771424|NCT00624325|DRUG|interferon alfa-2b|6 MU daily continuously subcutaneous
57771425|NCT01908673|BEHAVIORAL|HRV biofeedback|
57771426|NCT01908673|BEHAVIORAL|ASTM|
57771427|NCT01630590|DRUG|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
57771428|NCT01630590|DRUG|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
57771429|NCT04173312|COMBINATION_PRODUCT|Bupivacaine infusion|Local systemic Infusion of anesthetic
57771430|NCT04173312|COMBINATION_PRODUCT|Saline|Local systemic infusion of saline
58129599|NCT00424203|PROCEDURE|management of therapy complications|
57771431|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by Nurea System|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea
57771432|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by hospital practitioner|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
57771433|NCT04667845|DEVICE|Home Ovulation Test|Digital read home ovulation test
57771434|NCT01596283|PROCEDURE|Standard fluid management|The patient will receive standard fluid management
57771435|NCT01596283|DEVICE|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
57771436|NCT04000659|DEVICE|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
57771437|NCT04000659|PROCEDURE|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
57771438|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
57771439|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
57771440|NCT00872014|DRUG|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
57771441|NCT02252458|DRUG|Fentanyl|
57771442|NCT04316728|DEVICE|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
57771443|NCT03013686|PROCEDURE|Interval appendectomy|Laparoscopic appendectomy
57771444|NCT03013686|PROCEDURE|Follow-up with MRI|Abdominal MRI
57771445|NCT06099951|DRUG|Serplulimab + FOLFOXIRI|Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
57771446|NCT06099951|RADIATION|Radiation therapy|Radiation therapy
57771447|NCT01803230|DIETARY_SUPPLEMENT|creatine supplementation|creatine supplementation
57771448|NCT01803230|DIETARY_SUPPLEMENT|Placebo|
57771449|NCT00684086|BEHAVIORAL|Diabetes Self Management Program|
57771450|NCT01782040|OTHER|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
57771451|NCT04394520|OTHER|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
57771452|NCT04394520|OTHER|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
57771453|NCT04394520|OTHER|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
57771454|NCT04394520|OTHER|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
57771455|NCT03273140|DEVICE|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
57771456|NCT00317174|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
57771457|NCT04789213|OTHER|Liver Transplantation|Liver Transplantation
57771458|NCT02132533|DRUG|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
57771459|NCT02132533|DRUG|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
57771460|NCT02132533|OTHER|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
57771461|NCT03176043|PROCEDURE|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
57771462|NCT05392140|BEHAVIORAL|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
57771463|NCT05392140|BEHAVIORAL|Standart care|Standart care
57771464|NCT03389841|OTHER|Education|Education of the caregiver about early symptoms and signs of heart failure
58129600|NCT00424203|PROCEDURE|psychosocial assessment and care|
58129601|NCT00424203|PROCEDURE|quality-of-life assessment|
57771465|NCT06217887|DRUG|loxenatide Group|Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
57771466|NCT06217887|DRUG|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
57771467|NCT00125593|DRUG|Simvastatin 20 mg|Once daily
57771468|NCT00125593|DRUG|Ezetimibe 10mg|Once daily
57771469|NCT00125593|DRUG|Placebo|Once daily
57771470|NCT00098254|DRUG|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
57771471|NCT05412459|DRUG|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
57771472|NCT03579797|BEHAVIORAL|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
57771473|NCT05913284|DRUG|Methadone|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
57771474|NCT05913284|DRUG|Morphine|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
57771475|NCT02906202|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
57771476|NCT04823559|OTHER|ThinkCancer workshop|The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
57771477|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
57771478|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
57771479|NCT06210451|OTHER|Sterile water-based gel|Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
57771480|NCT00739895|PROCEDURE|Cardiac magnetic Resonance study|follow-up studies
57771481|NCT00739895|PROCEDURE|Blood testing|Blood sample tested for myocardial biomarkers
57771482|NCT02501213|DRUG|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
57771483|NCT02529397|BEHAVIORAL|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
57771484|NCT02529397|BEHAVIORAL|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
57771485|NCT02127320|DRUG|Rosuvastatin 20mg|
57771486|NCT02127320|DRUG|Ezetimibe 10mg|
57771487|NCT02127320|DRUG|Rosuvastatin 20mg + Ezetimibe 10mg|
57771488|NCT04599686|DRUG|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
57771489|NCT04599686|RADIATION|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
57771490|NCT04529603|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
57771491|NCT04848181|DRUG|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
57771492|NCT04848181|DRUG|finasteride|two weeks finasteride administration before TURP
57771493|NCT04848181|DRUG|no treatment received|no treatment received before TURP
58129602|NCT04041570|BIOLOGICAL|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
58491252|NCT03502356|DRUG|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
58491253|NCT00499083|BIOLOGICAL|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
58129603|NCT04913909|DIETARY_SUPPLEMENT|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
58129604|NCT00003313|BIOLOGICAL|filgrastim|
57771494|NCT02394899|BEHAVIORAL|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
57771495|NCT02394899|OTHER|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
57771496|NCT01613027|BIOLOGICAL|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
57771497|NCT03008421|DIETARY_SUPPLEMENT|Astarte® (HSO Health Care GmbH, Vienna, Austria)|oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described
57771498|NCT03008421|OTHER|Placebo|Identical-looking oral potato-maltodextrin-based placebo
57771499|NCT03900377|DRUG|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
57771500|NCT00974519|DRUG|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
57771501|NCT00974519|DRUG|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
57771502|NCT00974519|DRUG|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
57771503|NCT02495896|DRUG|Cisplatin|Given IV
57771504|NCT02495896|DRUG|Docetaxel|Given IV
57771505|NCT02495896|DRUG|Gemcitabine Hydrochloride|Given IV
57771506|NCT02495896|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771507|NCT02495896|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
58129605|NCT00003313|DRUG|amifostine trihydrate|
58129606|NCT00003313|DRUG|carboplatin|
58129607|NCT00003313|DRUG|paclitaxel|
57771508|NCT02495896|OTHER|Pharmacological Study|Correlative studies
57771509|NCT02495896|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
57771510|NCT03053921|PROCEDURE|recession coverage|recession coverage done using Zuchellis technique
57771511|NCT03053921|PROCEDURE|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
57771512|NCT03791385|BEHAVIORAL|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
57771513|NCT04650971|BIOLOGICAL|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
57771514|NCT04650971|BIOLOGICAL|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
57771515|NCT06187571|OTHER|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
57771516|NCT06187571|OTHER|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
58129608|NCT00003313|RADIATION|radiation therapy|
58129609|NCT06266962|DRUG|1% Atropine drops|Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
58129610|NCT06266962|DRUG|Epinephrine|Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
58129611|NCT03304600|DEVICE|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
58129612|NCT03304600|DEVICE|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
58129613|NCT03493737|BEHAVIORAL|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
57771517|NCT05115409|DRUG|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
57771518|NCT05935462|COMBINATION_PRODUCT|Digital Learning Aids|Recruitment is currently underway for special children undergoing outpatient early intervention. Among the recruited participants, five children between the ages of 6 and 9, who are receiving early intervention, were screened. After obtaining their consent to participate in this study, their basic information was recorded, including gender, age, education, diagnosis, Movement Assessment Battery for Children (MABC-2), Visual-Motor Integration (VMI) test, and Children's ABILHAND questionnaire for manual ability. Once the collection of basic information is completed, a trial of digital aids will be conducted, and a trial feedback questionnaire will be administered. The trial period will consist of a 20-minute session and 2-3 sessions (per week) of home (or therapy room) use.
57771519|NCT02364232|BEHAVIORAL|bilateral training with and without mirror feedback|
57771520|NCT06495255|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMOs)|HMOs will be applied as a neutral-flavoured powder
57771521|NCT06495255|DIETARY_SUPPLEMENT|Control|will be applied as powder
57771522|NCT04874376|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
57771523|NCT05730738|DRUG|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
57771524|NCT05730738|DRUG|Placebo|placebo similar to Dalfampridine capsule
57771525|NCT00428064|DRUG|Sirolimus|
57771526|NCT00428064|DRUG|cyclosporine|
57771527|NCT04151875|DEVICE|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
57771528|NCT04151875|DEVICE|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
57771529|NCT02354859|DRUG|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
57771530|NCT02354859|DRUG|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
57771531|NCT04955704|DEVICE|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
57771532|NCT06236360|BEHAVIORAL|Mediterranean Diet Intervention|The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
57771533|NCT04380896|OTHER|Blood test|Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
57771534|NCT04380896|OTHER|Standardised questionnaires|It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
57771535|NCT02223247|DRUG|TVB-2640|
57771536|NCT03403777|DRUG|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
57771537|NCT02141958|DRUG|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
57771538|NCT02141958|DRUG|Placebo|A matching placebo will be used to keep the study double-blind.
57771539|NCT05889819|DIETARY_SUPPLEMENT|Almond orange potato cookies for stunted under-five children|"Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study."
57771540|NCT01360567|DIETARY_SUPPLEMENT|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
57771541|NCT01360567|DIETARY_SUPPLEMENT|Placebo|500 mg . one capsule of placebo, 3 times per day
57771542|NCT03835637|DRUG|ORIC-101|Capsule or oral suspension
58129614|NCT06413225|DEVICE|Synergy cervical disc system|motion preservation disc
57771543|NCT00296387|DRUG|Rosuvastatin|
57771544|NCT00296387|DRUG|Atorvastatin|
57771545|NCT01382940|DRUG|rituximab|1000 mg in 250 mL intravenous infusion
57771546|NCT01382940|DRUG|methotrexate|10 to 25 mg/week (oral or parenteral)
57771547|NCT01382940|DRUG|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
58129615|NCT05822232|DEVICE|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
58129616|NCT05822232|DEVICE|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
57771548|NCT01382940|DRUG|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
58129617|NCT05822232|DEVICE|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
57771549|NCT01382940|DRUG|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
57771550|NCT00034840|DRUG|telmisartan, valsartan|
57771551|NCT03119610|DRUG|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
57771552|NCT03119610|DRUG|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
57771553|NCT03001713|BEHAVIORAL|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
57771554|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
57771555|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
57771556|NCT01463293|DIETARY_SUPPLEMENT|Placebo|Capsule containing no probiotic once a day
57771557|NCT01432015|DRUG|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
57771558|NCT01432015|DRUG|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
57771559|NCT01432015|OTHER|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
57771560|NCT01432015|OTHER|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
57771561|NCT05534321|RADIATION|Prophylactic Radiotherapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
57771562|NCT05534321|DRUG|Standard of care systemic therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
57771563|NCT05833516|DIAGNOSTIC_TEST|Cardiac Catheterization|"The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study."
57771564|NCT04595734|OTHER|No intervention due to observational methods of study|No intervention due to observational methods of study
57771565|NCT04294394|OTHER|rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
57771566|NCT04294394|OTHER|erector spinae block|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area
57771567|NCT04294394|OTHER|control|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
57771568|NCT04152850|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
57771569|NCT01426282|OTHER|no intervention|no intervention
57771570|NCT01426282|OTHER|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
57771571|NCT04938115|BIOLOGICAL|CD7 CART|Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
57771572|NCT00799734|DRUG|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
57771573|NCT04930107|DRUG|Fluconazole 150 mg|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
57771574|NCT04930107|DRUG|Boric Acid Supp,Vag|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
57771575|NCT02735837|DRUG|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
57771576|NCT02735837|DRUG|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
57771577|NCT04005937|DIAGNOSTIC_TEST|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
57771578|NCT04780217|BIOLOGICAL|T3011|T3011 will be administered through IV drip or pumping.
57771579|NCT02365974|DEVICE|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
57771580|NCT02365974|DEVICE|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
57771581|NCT03487718|BIOLOGICAL|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
57771582|NCT03487718|DEVICE|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
57771583|NCT06476626|OTHER|Maternal Reflective Function Workshop|4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
57771584|NCT04932382|DRUG|Misoprostol|will be used 3 h before IUD insertion
57771585|NCT04932382|DEVICE|IUD|a copper T380A IUD
57771586|NCT01216891|BEHAVIORAL|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
57771587|NCT06026722|BEHAVIORAL|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
57771588|NCT01146574|BIOLOGICAL|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
57771589|NCT01146574|BIOLOGICAL|Placebo|Placebo
57771590|NCT04358796|DEVICE|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
57771591|NCT04358796|DEVICE|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
57771592|NCT03333174|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
57771593|NCT01698086|OTHER|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
58459040|NCT04142034|BEHAVIORAL|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
58459041|NCT04142034|BEHAVIORAL|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
57771594|NCT00064025|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771595|NCT00064025|DRUG|Medroxyprogesterone|Given IM
57771596|NCT00064025|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
57771597|NCT03136835|DRUG|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
58459042|NCT04142034|OTHER|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
58459043|NCT04142034|OTHER|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
58459044|NCT00055302|DRUG|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
58459045|NCT06317558|DRUG|Neoadjuvant immunotherapy|Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.
58459046|NCT06317558|DRUG|Other drugs for neoadjuvant treatment|Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
58459047|NCT04299165|DEVICE|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
58459048|NCT04299165|OTHER|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
58459049|NCT03446872|DRUG|ONIVYDE|irinotecan liposome injection
57771598|NCT02300337|DEVICE|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
57771599|NCT03412162|BEHAVIORAL|Ethnic and Racial Identity Promotion|See arm description
57771600|NCT03412162|BEHAVIORAL|Academic Skills Promotion|See arm description
57771601|NCT04806230|DRUG|sertraline, mirtazapine, venlafaxine, citalopram, escitalopram|Naturalistic treatment
57771602|NCT03285295|DEVICE|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771603|NCT03285295|DEVICE|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771604|NCT03285295|DEVICE|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771605|NCT03285295|DEVICE|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771606|NCT03285295|DEVICE|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771607|NCT03285295|DEVICE|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
57771608|NCT02482636|BIOLOGICAL|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
57771609|NCT02482636|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
57771610|NCT02482636|BIOLOGICAL|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
57771611|NCT02482636|BIOLOGICAL|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
57771612|NCT02482636|BIOLOGICAL|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
57771613|NCT02482636|BIOLOGICAL|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
57771614|NCT00514046|DRUG|Vandetanib|once daily continuously (28 day cycles)
57771615|NCT02699541|BEHAVIORAL|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
57771616|NCT02374190|OTHER|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
57771617|NCT02324764|DEVICE|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
57771618|NCT02324764|DEVICE|standard 6- French radial sheath|
57771619|NCT05468515|DIAGNOSTIC_TEST|pulse oxygen saturation|preductal oxygen saturation
57771620|NCT04290065|OTHER|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
57771621|NCT03072381|BIOLOGICAL|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
57771622|NCT03072381|DRUG|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
57771623|NCT00198601|DRUG|Gentamicin in Uniject Pre-filled syringe|
57771624|NCT02009696|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
57771625|NCT02009696|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
57771626|NCT03431051|OTHER|Healthy Beverage Initiative|A Healthy Beverage Initiative will be instituted at two hospital campuses.
57771627|NCT05819853|DRUG|Semaglutide Injectable Product (Wegovy and/or Ozempic)|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
57771628|NCT02406209|DRUG|NS2|NS2 ophthalmic drops (0.5%)
57771629|NCT02406209|DRUG|Prednisolone acetate ophthalmic suspension (1%)|
57771630|NCT03292146|DRUG|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
57771631|NCT03292146|DRUG|Placebo Injection|Placebo Injection at baseline and 6 months
57771632|NCT03292146|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
57771633|NCT00405704|DRUG|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
57771634|NCT00405704|DRUG|Placebo|Cherry flavored liquid suspension matched to active comparator.
57771635|NCT04469699|DRUG|Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
57771636|NCT04469699|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
57771637|NCT06489665|DIAGNOSTIC_TEST|Experimental Intervention|Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
57771638|NCT03903679|DEVICE|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
57771639|NCT03903679|DEVICE|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
57771640|NCT05371119|OTHER|Exercise Intervention|Training with light load with blood flow restriction (BFR)
58459050|NCT03446872|DRUG|5-fluorouracil|a nucleoside metabolic inhibitor
58459051|NCT03446872|DRUG|Leucovorin|an active metabolite of folic acid
57771641|NCT00004221|DRUG|Carboplatin|Given IV
57771642|NCT00004221|DRUG|Cyclophosphamide|Given IV
57771643|NCT00004221|BIOLOGICAL|Filgrastim|Given SQ
57771644|NCT00004221|DRUG|Paclitaxel|Given IV
57771645|NCT00004221|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
57771646|NCT00004221|DRUG|Topotecan Hydrochloride|Given IV
57771647|NCT00082602|DRUG|galantamine ER|
57771648|NCT00829608|BIOLOGICAL|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
57771649|NCT01231243|PROCEDURE|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
57771650|NCT03149263|BEHAVIORAL|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
57771651|NCT05780502|BEHAVIORAL|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
57771652|NCT00571779|DEVICE|AtriCure Bipolar System|
57771653|NCT03508336|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
57771654|NCT04076020|BEHAVIORAL|Relational agent/AliveCor Kardia - Intervention|Use of the relational agent and Kardia daily for 120 days.
57771655|NCT04076020|BEHAVIORAL|Usual Care|Use of the WebMD app daily for 120 days.
57771656|NCT02743286|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
57771657|NCT02743286|BEHAVIORAL|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
57771658|NCT02743286|BEHAVIORAL|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
57771659|NCT00924469|DRUG|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
57771660|NCT00924469|DRUG|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
57771661|NCT00924469|DRUG|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
57771662|NCT00419653|DRUG|Amisulpride|
57771663|NCT00419653|DRUG|Olanzapine|
57771664|NCT00419653|DRUG|Haloperidol|
57771665|NCT04874324|DRUG|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
57771666|NCT04874324|OTHER|Placebo Oral|Subjects will receive matching placebo
57771667|NCT01973491|DRUG|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
57771668|NCT03869645|DEVICE|CAPERE Thrombectomy System|Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System
58459052|NCT02670486|OTHER|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
58459053|NCT00547274|DRUG|MK0767|
58459054|NCT00379665|DRUG|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
58459055|NCT06151548|DRUG|THYROX (Atlantic krill oil).|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
57771669|NCT01855581|DRUG|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
57771670|NCT05151042|PROCEDURE|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
57771671|NCT05151042|PROCEDURE|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
57771672|NCT05808530|BEHAVIORAL|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
57771673|NCT02302950|DRUG|raltegravir|HIV therapy component
58459056|NCT06151548|DRUG|Placebo|The control capsules will be made of olive oil of equal size and color.
58459057|NCT04604535|DIETARY_SUPPLEMENT|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
57771674|NCT06280456|DRUG|Tranexamic Acid Powder|10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
57771675|NCT02653040|OTHER|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
57771676|NCT02405117|BEHAVIORAL|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
57771677|NCT06199947|OTHER|Biopsies and Blood collection|Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
57771678|NCT05692453|DIAGNOSTIC_TEST|Arterial blood gas with co-oximetry|1 mL blood sample for ABG-CoOx analysis to obtain co-oximetry measured arterial oxygen saturation (SaO2C) and standard ABG derived arterial oxygen saturation (SaO2S).
57771679|NCT05542407|DRUG|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
57771680|NCT05542407|DRUG|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
57771681|NCT05713734|DIAGNOSTIC_TEST|Thrombin generation|Measurement of thrombin generation by ST Genesia
57771682|NCT05713734|DIAGNOSTIC_TEST|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
57771683|NCT05713734|DIAGNOSTIC_TEST|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
57771684|NCT05713734|DIAGNOSTIC_TEST|Coated platelets|Measurement of coated platelets by flow cytometry
57771685|NCT06341426|DRUG|Single Psychedelic Dose Psilocybin|One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
57771686|NCT06341426|DRUG|Two Psychedelic Doses Psilocybin|Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
57771687|NCT01874106|OTHER|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
58459058|NCT04604535|DIETARY_SUPPLEMENT|Placebo|70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
58459059|NCT04361734|OTHER|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
58459060|NCT05775068|RADIATION|Radiotherapy|Radiotherapy
58459061|NCT04129593|BEHAVIORAL|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
57771688|NCT01874106|OTHER|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
57771689|NCT03804515|DRUG|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
57771690|NCT05433402|DRUG|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
57771691|NCT05433402|DRUG|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
57771692|NCT06062940|BEHAVIORAL|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
57771693|NCT03475719|DRUG|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
57771694|NCT03475719|DRUG|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
57771695|NCT03408834|OTHER|pulse variability index|fluid management with pulse variability index or conventional
57771696|NCT06115850|PROCEDURE|Music|In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
57771697|NCT02726061|BEHAVIORAL|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
57771698|NCT03135704|DEVICE|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
57771699|NCT03135704|OTHER|Physiotherapy|Usual protocol for treatment of low back pain
58459062|NCT04129593|BEHAVIORAL|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
57771700|NCT02089581|DRUG|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
57771701|NCT02089581|DRUG|MRXXX|MRXXX
57771702|NCT02089581|DRUG|MR1XXX|
57771703|NCT02089581|DRUG|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
57771704|NCT03567954|DIAGNOSTIC_TEST|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
58129618|NCT05886543|BEHAVIORAL|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
58459063|NCT01731912|DRUG|Degarelix|Given SC
58459064|NCT01731912|RADIATION|External Beam Radiation Therapy|Undergo standard EBRT
58459065|NCT01731912|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771705|NCT02951351|DRUG|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
57771706|NCT02951351|PROCEDURE|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
57771707|NCT03240939|DRUG|Dutasteride 0.5 mg|single dose
57771708|NCT03240939|DRUG|Tadalafil 5 mg|single dose
57771709|NCT03240939|DRUG|YY-201|single dose
57771710|NCT00723424|DRUG|AZD5672|50 mg, for 13 days
57771711|NCT00723424|DRUG|Digoxin|0.5mg dose
57771712|NCT06161805|DRUG|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].
57771713|NCT06161805|DRUG|Placebo|8 hour infusion with saline (NaCl 0.9%)
58459066|NCT03255239|PROCEDURE|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
58459067|NCT00464698|DRUG|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
58491254|NCT00499083|DRUG|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
58491255|NCT00499083|DRUG|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
57771714|NCT01350622|DRUG|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
57771715|NCT01350622|DRUG|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
57771716|NCT05185518|DEVICE|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
57771717|NCT05284305|OTHER|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
57771718|NCT02693834|DEVICE|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
57771719|NCT02693834|DEVICE|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
57771720|NCT03681795|DIAGNOSTIC_TEST|Experimental MRI exam and PET scan exam with radiotracer|MRI exam and PET scan exam with radiotracer
57771721|NCT03044262|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
57962338|NCT05868850|BEHAVIORAL|auricular point sticking|"1. Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~2. Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~3. Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
58459068|NCT02367508|BEHAVIORAL|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
58459069|NCT04803877|DRUG|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
58459070|NCT04803877|DRUG|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
57771722|NCT03044262|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
57771723|NCT00038441|DRUG|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
57771724|NCT02676323|DRUG|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
57771725|NCT02676323|DRUG|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).
57771726|NCT02676323|DRUG|Cytarabine|Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).
57771727|NCT02676323|DRUG|Intrathecal Triples|Given intrathecally (IT).
57771728|NCT02676323|DRUG|Leucovorin|Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
57771729|NCT05290610|OTHER|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
57771730|NCT00869882|PROCEDURE|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
57771731|NCT00869882|PROCEDURE|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
57771732|NCT03093857|DIAGNOSTIC_TEST|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
57771733|NCT01628627|DEVICE|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
57771734|NCT01628627|DEVICE|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
57771735|NCT03301688|BIOLOGICAL|Toripalimab|To compare the different drug batch number with different process
57771736|NCT02631421|PROCEDURE|Blood Sampling|
57771737|NCT02631421|OTHER|Cardiac MRI|
57962339|NCT02997995|DRUG|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
58459071|NCT04803877|DRUG|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
58459072|NCT02848469|DIETARY_SUPPLEMENT|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
58459073|NCT05421741|DRUG|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
58459074|NCT05421741|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
57771738|NCT06106815|OTHER|Rehabilitation exercises|The Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve upper extremity function in individuals with stroke. The GRASP program includes exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
57771739|NCT06106815|OTHER|Usual Care|Usual Care
57771740|NCT05707013|DEVICE|HP Arize 3D-Printed Orthotics|Custom 3D-printed orthotics manufactured by HP.
57771741|NCT05707013|DEVICE|Traditional Orthotics|Traditionally fabricated custom orthotics manufactured by a local supplier.
57771742|NCT01800708|DRUG|Triamcinolone acetonide|
57771743|NCT01800708|DRUG|Prednisolone syrup|
57771744|NCT04057911|DEVICE|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
57771745|NCT04057911|DEVICE|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
57771746|NCT00738452|OTHER|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
58129619|NCT05886543|BEHAVIORAL|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
58129620|NCT03634709|BEHAVIORAL|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
58129621|NCT03475784|DRUG|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
58459075|NCT00213512|DRUG|Mabthera|
58459076|NCT04645368|DRUG|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
58459077|NCT01233804|OTHER|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
58459078|NCT04864756|OTHER|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
57771747|NCT00738452|OTHER|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
57771748|NCT00738452|PROCEDURE|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
57771749|NCT00738452|PROCEDURE|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
57771750|NCT00738452|RADIATION|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
58459079|NCT02097862|PROCEDURE|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
58459080|NCT05650008|DRUG|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
58459081|NCT01481922|DEVICE|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
58459082|NCT01481922|DEVICE|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
58459083|NCT01941511|DRUG|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
58459084|NCT00947375|DRUG|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
58459085|NCT00947375|DRUG|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
58459086|NCT00509184|DRUG|Rituximab|375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap
58459087|NCT00830999|BEHAVIORAL|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
58491256|NCT00499083|DRUG|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
58491257|NCT00499083|DRUG|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
57771751|NCT00738452|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
57771752|NCT01448954|DRUG|ADC3680B oral|Once daily for 28 days
57771753|NCT01448954|DRUG|Placebo oral|Once daily for 28 days
57771754|NCT03954158|DRUG|Crisaborole ointment 2%|BID regimen
57771755|NCT03954158|DRUG|Vehicle|BID regimen
57771756|NCT03954158|DRUG|Crisaborole ointment 2%|QD regimen
57771757|NCT03954158|DRUG|Vehicle|QD regimen
57771758|NCT01324479|DRUG|INC280|
57771759|NCT00836173|DRUG|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
57771760|NCT00836173|DRUG|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
57771761|NCT02543021|DEVICE|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
57771762|NCT02543021|PROCEDURE|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
57771763|NCT01336881|GENETIC|RNA analysis|
57771764|NCT01336881|GENETIC|gene expression analysis|
57771765|NCT01336881|GENETIC|microarray analysis|
57771766|NCT01336881|GENETIC|nucleic acid sequencing|
57771767|NCT01336881|OTHER|diagnostic laboratory biomarker analysis|
57771768|NCT02581176|DRUG|Apixaban|
57771769|NCT03179943|DRUG|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
57771770|NCT03179943|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
57771771|NCT05905991|OTHER|Enhanced Stress Resilience Training|"The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week."
57771772|NCT03247374|DEVICE|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
57771773|NCT03247374|OTHER|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
57771774|NCT02294110|OTHER|spinal anesthesia|non diabetes mellitus
57771775|NCT05351060|OTHER|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
57771776|NCT01073839|DRUG|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
57771777|NCT00794001|BEHAVIORAL|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
57771778|NCT00189111|PROCEDURE|Cardiac Imaging + Treatment|
57771779|NCT06170736|PROCEDURE|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
57962340|NCT02997995|DRUG|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
57962341|NCT02997995|PROCEDURE|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
57962342|NCT03667066|DRUG|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
57962343|NCT02059083|BEHAVIORAL|Heart rate variability biofeedback|
57962344|NCT02059083|BEHAVIORAL|CBT|
57962345|NCT05322239|DEVICE|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
57962346|NCT05322239|DEVICE|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
57962347|NCT05994378|DRUG|SHR7280；Ganirelix Acetate Injection simulant|SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;
57962348|NCT05994378|DRUG|SHR7280 simulant； Ganirelix Acetate Injection|SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
57962349|NCT03644238|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|75g of glucose is consumed
57962350|NCT03644238|BEHAVIORAL|Inactivity|Lying or sitting down.
57962351|NCT03644238|BEHAVIORAL|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
57962352|NCT04377451|DRUG|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
57962353|NCT05328037|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for dosage of vitamin C
57771780|NCT06170736|PROCEDURE|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
57771781|NCT00595829|DRUG|XL019|XL019 capsules administered orally
57771782|NCT00852670|DRUG|ACT-128800|ACT-128800 administered orally once daily
57771783|NCT00852670|DRUG|Placebo|Matching placebo capsules administered orally once daily
57771784|NCT03644355|BEHAVIORAL|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
57771785|NCT00837525|PROCEDURE|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
57771786|NCT03747770|BIOLOGICAL|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
57771787|NCT01912781|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
58459088|NCT00830999|BEHAVIORAL|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
58459089|NCT00830999|BEHAVIORAL|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
57771788|NCT01912781|DEVICE|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
57771789|NCT01912781|DEVICE|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
57771790|NCT02293837|DRUG|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
57771791|NCT02293837|DRUG|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
57771792|NCT02293837|OTHER|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
57771793|NCT01311362|DRUG|St. Johns wort|"* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
58459090|NCT00830999|BEHAVIORAL|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
58459091|NCT00830999|BEHAVIORAL|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
58459092|NCT03174184|DRUG|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
57771794|NCT00721656|DRUG|Placebo|
57771795|NCT00721656|DRUG|KLS-0611|
57771796|NCT00840372|PROCEDURE|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
57771797|NCT01646684|DRUG|SOM230|
57771798|NCT00227760|DRUG|Cediranib Maleate|Given PO
57771799|NCT00227760|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
57771800|NCT00227760|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771801|NCT00227760|OTHER|Pharmacological Study|Correlative studies
57771802|NCT05645289|DRUG|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
57771803|NCT05645289|DRUG|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
57771804|NCT00717678|DRUG|Prograf-XL|oral
57771805|NCT00717678|DRUG|Prograf|oral
57771806|NCT00717678|DRUG|MMF|oral
57771807|NCT04707131|DRUG|LEM-S401|siRNA encapsulated in DegradaBALL®
57771808|NCT04707131|DRUG|Placebo|Placebo
57771809|NCT05493982|BEHAVIORAL|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
57771810|NCT06448455|OTHER|Observation|Collect relevant data of patients
57771811|NCT01560260|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771812|NCT01560260|DRUG|Linsitinib|Given PO
57771813|NCT01560260|OTHER|Pharmacological Study|Correlative studies
57771814|NCT00216762|DRUG|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
57771815|NCT00726349|OTHER|No intervention|Observational study.
57771816|NCT01791634|PROCEDURE|proximal chevron osteotomy|
57771817|NCT01791634|PROCEDURE|proximal open wedge osteotomy with LPS system|
57771818|NCT04361032|DRUG|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
58459093|NCT03174184|DRUG|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
58459094|NCT03174184|DRUG|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
57771819|NCT04361032|DRUG|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
57771820|NCT02265081|PROCEDURE|ultrasound|pelvic floor ultrasound
58459095|NCT03174184|DRUG|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
58459096|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
57771821|NCT02265081|PROCEDURE|uroflow-meter|uroflow meter: measurement of passed urine volume
57771822|NCT05315284|PROCEDURE|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
57771823|NCT03229434|BEHAVIORAL|Mountain hiking|Compare arm description
57771824|NCT06267443|PROCEDURE|Comparison of erector spina plane block, parasternal block plus local infiltration to the tube sides for postoperative analgesia|"Group 1: erector spina plane block: With USG guidance at the thoracal level of 4-5, with 20ml 2.5% bupivacaine ESPB will be performed. after surgery in the ICU pain score and atelectasia will be evaluated.~Group 2: With USG guidance parasternal block will be performed after intubation bilaterally with 10 ml 0.25% bupivacaine each side. at the end of the surgery infiltration of chest tube sides will be performed with 10 ml 2.5% bupivacain."
57771825|NCT03462706|PROCEDURE|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
57771826|NCT03462706|PROCEDURE|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
57771827|NCT03462706|PROCEDURE|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
57771828|NCT03462706|PROCEDURE|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
57771829|NCT00986115|DRUG|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
57771830|NCT00986115|DRUG|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
57771831|NCT04536571|DEVICE|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
57771832|NCT04536571|DEVICE|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
57771833|NCT04996199|DRUG|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
57771834|NCT04996199|DRUG|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
57771835|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer FDG PET/CT Exam|"The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
57771836|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Cu64-DOTATATE PET/CT Exam|"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
57771837|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Ga68-DOTATATE PET/CT Exam|"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
57771838|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer PSMA PET/CT Exam|"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
57771839|NCT01002664|DRUG|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
57771840|NCT01002664|DRUG|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
58459097|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
58459098|NCT05217277|DIAGNOSTIC_TEST|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
58459099|NCT03690817|BEHAVIORAL|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
58459100|NCT02831621|BEHAVIORAL|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
58459101|NCT00467077|BIOLOGICAL|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
58459102|NCT00467077|DRUG|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
58459103|NCT03070288|OTHER|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
57771841|NCT02035813|DRUG|Ribociclib|Ribociclib/Everolimus in combination with endocrine therapy
57771842|NCT02035813|DRUG|Eribulin|
57771843|NCT01200030|BEHAVIORAL|electrical stimulation with exercises|electrical stimulation with exercises
57771844|NCT01200030|BEHAVIORAL|placebo stimulation with exercises|placebo stimulation with exercises
57771845|NCT03672513|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
57771846|NCT03672513|DIETARY_SUPPLEMENT|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
57771847|NCT03672513|DIETARY_SUPPLEMENT|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
57771848|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham|"With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
57771849|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine|"With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
57771850|NCT04337060|OTHER|Pain follow-up and monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
57771851|NCT01278108|DRUG|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
57771852|NCT01278108|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
57771853|NCT01278108|DRUG|GLPG0778|multiple dose, capsule, 7 days
57771854|NCT01278108|DRUG|placebo|multiple dose, capsule, 7 days
57771855|NCT03847623|DIETARY_SUPPLEMENT|Curcumin|Natural compound, active ingredient of turmeric, in bi-daily dosing
57771856|NCT03847623|OTHER|Placebo|Placebo tablets at bi-daily dosing
57771857|NCT03550586|OTHER|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
57771858|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
57771859|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
57771860|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
57771861|NCT00944281|DIETARY_SUPPLEMENT|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
57771862|NCT00325936|DRUG|Cilnidipine|10\~20mg, qd, po for 3 months or 12 months.
57771863|NCT05854212|BEHAVIORAL|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
57771864|NCT01414413|OTHER|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
57771865|NCT01414413|OTHER|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
57771866|NCT00000343|BEHAVIORAL|counseling|
57771867|NCT06624501|OTHER|Observational cohort study|
57771868|NCT04299477|PROCEDURE|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
57771869|NCT00575068|DRUG|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
57771870|NCT06072820|DEVICE|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
57771871|NCT01317290|DIETARY_SUPPLEMENT|n-3 PUFA free olive oil|negative control
57771872|NCT01317290|DIETARY_SUPPLEMENT|linseed oil|
57771873|NCT05009706|OTHER|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
58129622|NCT03475784|DRUG|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
57771874|NCT02390843|DRUG|Simvastatin|The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
57771875|NCT02390843|DRUG|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
57771876|NCT02390843|DRUG|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
57771877|NCT02390843|DRUG|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
57771878|NCT00561444|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
57771879|NCT01200537|DRUG|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
57771880|NCT01200537|DRUG|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
57771881|NCT00367913|DRUG|Addition of clarithromycin to rifampicin and ethambutol|
57771882|NCT00367913|DRUG|Addition of Ciprofloxacin to rifampicin and ethambutol|
57771883|NCT00367913|BIOLOGICAL|Vaccination with M.vaccae|
57771884|NCT06437730|OTHER|Integrated Neuromuscular Inhibition Technique:|MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint. Compression will be increased gradually until first resistance will feel and maintained until it resolves, further increases then until no tissue resistance will be felt under thumb. This process is maintained for 30sec and repeated 3-5 times per session. Positional release technique: after applying pressure on trigger point, patient will acquire position of ease that is maintained for 20 sec whether its extension or flexion of knee. This process is repeated 3-5 times per session. Muscle Energy Technique will be applied on the muscle in which isometric contraction is maintained for 7-10sec against 20-25% strength. After completion of muscular contraction, the limb is moved away for muscular stretch and then position is maintained for 30 seconds
57771885|NCT06437730|OTHER|Dry needling:|"Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.~For vastus laterals patient is supine line with knee extended performing an isometric quadriceps contraction, maintaining a clean technique by using gloves and performing an alcohol wipe down bracket the tissue to be treated and inserting needle with direct approach towards the femur, performing pistoning. For vastus medialis patient is supine line with 30 degrees of knee flexion. A headless 0.25x25mm needle fixed between the fingers of non-dominant hand and inserted perpendicularly to the MTrPs with metacarpophalangeal flexion extension of 1st and 2nd fingers of dominant hand. For Gastrocnemius patient is prone lying and bolstered supported slight knee bend, for the upper part anterior medial approach is used and center of muscle belly slight medial anterior approach is used."
57771886|NCT04048252|OTHER|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
57771887|NCT04048252|OTHER|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
57771888|NCT02153359|DEVICE|High Efficiency Particulate Air Cleaner|
57771889|NCT02153359|DEVICE|Sham air cleaner|
57771890|NCT00412035|DRUG|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
57771891|NCT00412035|DRUG|saline injection|10 units per kilo to maximum of 400 units
57771892|NCT00749801|DRUG|Nattokinase|2 capsules in the morning and before bed-time daily
57771893|NCT03585491|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
57771894|NCT03585491|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
57771895|NCT00291655|DRUG|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
57771896|NCT05716841|OTHER|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
57771897|NCT01536145|DRUG|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
57771898|NCT03942913|OTHER|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
57771899|NCT00012181|DRUG|alvocidib|Given IV
58459104|NCT04668469|DRUG|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
58459105|NCT04668469|DRUG|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
57771900|NCT00012181|OTHER|pharmacological study|Correlative studies
57771901|NCT06108089|DIAGNOSTIC_TEST|[18F]MISO-PET/CT|18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
57771902|NCT00350701|DRUG|androgel|androgel 5g
57771903|NCT00350701|DRUG|androgel 10g|androgel 10g
57771904|NCT00350701|DRUG|placebo|placebo
57771905|NCT01937637|BEHAVIORAL|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
57771906|NCT02556905|DRUG|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
57771907|NCT02556905|DRUG|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
57771908|NCT05428462|OTHER|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
57771909|NCT03869515|OTHER|No intervention|It's an observational study, so no intervention will be carried out.
57771910|NCT02894996|DRUG|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
57771911|NCT03740880|OTHER|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
57771912|NCT03066570|BEHAVIORAL|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
57771913|NCT05532241|DEVICE|fixed metal orthodontic appliance|fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))
57771914|NCT05532241|DEVICE|fixed non-metal orthodontic appliance|fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), nylon thread, elastomeric ligatures (Elastomerics, American Orthodontics))
57771915|NCT05532241|PROCEDURE|oral hygiene|conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)
57771916|NCT05532241|DRUG|Chlorhexidine mouthwash|0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
57771917|NCT00599989|PROCEDURE|adjuvant therapy|
57771918|NCT00599989|PROCEDURE|conventional surgery|
57771919|NCT00599989|RADIATION|3-dimensional conformal radiation therapy|
57771920|NCT00599989|RADIATION|brachytherapy|
57771921|NCT00599989|RADIATION|intracavitary balloon brachytherapy|
57771922|NCT00599989|RADIATION|proton beam radiation therapy|
57771923|NCT02283437|BEHAVIORAL|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
57771924|NCT02283437|BEHAVIORAL|Behavioral Management and Education Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
57771925|NCT06374537|OTHER|Muscle Therapy|Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
57771926|NCT03532893|OTHER|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
57771927|NCT01465503|DRUG|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
57771928|NCT01465503|DRUG|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
57771929|NCT00397267|DRUG|inhalation of corticosteroids|
57771930|NCT04879316|OTHER|Resting Energy Expenditure measurement|Resting Energy Expenditure measurement using indirect calorimetry
57771931|NCT02735733|DEVICE|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
57771932|NCT04110366|BIOLOGICAL|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
57771933|NCT04110366|OTHER|Vehicle control|Vehicle control nasal challenge
57771934|NCT00210119|DRUG|Glivec|
57771935|NCT04639778|OTHER|Control Group|Clinical visits conducted by a multidisciplinary team every year
57771936|NCT04639778|OTHER|Intervention Group|Clinical visits are triggered by weight evolution measured by connected balance
57771937|NCT00602186|DRUG|tamsolusin|0.4 mg /day
57771938|NCT00602186|DRUG|prazosin|1 mg/day
57771939|NCT02085343|BEHAVIORAL|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
57771940|NCT02085343|BEHAVIORAL|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
57771941|NCT02085343|BEHAVIORAL|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
57771942|NCT00657514|DRUG|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
57771943|NCT00657514|DRUG|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
58459106|NCT04668469|BEHAVIORAL|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
57771944|NCT03677882|BEHAVIORAL|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
57771945|NCT04114240|DRUG|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
57771946|NCT02732860|OTHER|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
57771947|NCT05348408|DRUG|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
57771948|NCT05951725|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771949|NCT05951725|BIOLOGICAL|Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771950|NCT05951725|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771951|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771952|NCT05951725|BIOLOGICAL|DTaP-IPV-Hib|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771953|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
57771954|NCT00630058|DRUG|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
57771955|NCT00630058|DRUG|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
57771956|NCT03241524|OTHER|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
57771957|NCT03377790|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
57771958|NCT03377790|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
57771959|NCT04353193|DRUG|Terlipressin|Terlipressin 1mg IV bolus
57771960|NCT04353193|DRUG|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
57771961|NCT04353193|DRUG|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
57771962|NCT02406989|DRUG|MS-553|Study Drug
57771963|NCT02406989|DRUG|Placebo|Matching placebo to MS-553
57771964|NCT01342185|DEVICE|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
57771965|NCT01342185|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
57771966|NCT01342185|DRUG|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
58459107|NCT05659108|BEHAVIORAL|CPR|HIGH QUALITY CPR
58459108|NCT01582061|DRUG|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
58491258|NCT00499083|DRUG|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
57771967|NCT01931579|DEVICE|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
57771968|NCT01783353|DIETARY_SUPPLEMENT|Zinc gluconate|
57771969|NCT01783353|DIETARY_SUPPLEMENT|Corn starch pill|
57771970|NCT00004430|DRUG|Dihematoporphyrin derivative|
57771971|NCT00004430|DRUG|prednisolone|
57771972|NCT00004430|PROCEDURE|Laser surgery|
57771973|NCT04970095|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
57771974|NCT04970095|DEVICE|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
57771975|NCT04874064|OTHER|Liquid Biopsy|Blood collection and access to residual tumor.
57771976|NCT01989559|BIOLOGICAL|gp100:209-217(210M) Peptide Vaccine|Given SC
57771977|NCT01989559|BIOLOGICAL|HPV 16 E7:12-20 Peptide Vaccine|Given SC
57771978|NCT01989559|OTHER|Laboratory Biomarker Analysis|Correlative studies
57771979|NCT05125393|PROCEDURE|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
57771980|NCT02476214|BEHAVIORAL|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
57771981|NCT05539196|DEVICE|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
57771982|NCT01953770|DRUG|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
57771983|NCT01953770|DRUG|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
57771984|NCT01953770|DRUG|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
57771985|NCT01953770|DRUG|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
57771986|NCT01953770|DRUG|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
57771987|NCT01953770|DRUG|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
57771988|NCT01953770|RADIATION|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients \>3 years of age
57771989|NCT01953770|DRUG|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
57771990|NCT02215330|DRUG|Eplerenone|
57771991|NCT02215330|DRUG|Maltodextrin|
57771992|NCT01035333|DRUG|Orlistat|60mg capsule three times a day for up to 6 months
57771993|NCT02054312|BEHAVIORAL|Family Based Interpersonal Psychotherapy (FB-IPT)|
57771994|NCT02054312|BEHAVIORAL|Client Centered Therapy (CCT)|
57771995|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 3)|
57771996|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 5)|
57771997|NCT00110760|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
57771998|NCT00110760|DRUG|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
57771999|NCT03438240|DRUG|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
57772000|NCT03438240|DRUG|Fentanyl|Plus 50 µg fentanyl
57772001|NCT03438240|DRUG|Dexmedetomidine|Plus 50 µg dexmedetomidine
58491259|NCT00499083|GENETIC|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
57772002|NCT04827134|DRUG|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
57772003|NCT04827134|DRUG|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
57772004|NCT00452413|DRUG|enzastaurin|Administered orally
57772005|NCT00452413|DRUG|erlotinib|Administered orally
57772006|NCT01474460|DIETARY_SUPPLEMENT|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
57772007|NCT02381743|BEHAVIORAL|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
57772008|NCT02381743|BEHAVIORAL|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
57772009|NCT01040286|DRUG|Flurbiprofen|2.0 mg
57772010|NCT01040286|DRUG|Chlorhexidine|2.5mg
57772011|NCT04451343|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
57772012|NCT04278430|DEVICE|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
57772013|NCT04278430|DEVICE|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
57772014|NCT04809792|RADIATION|SBRT on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
57772015|NCT05341375|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
57772016|NCT05341375|DRUG|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
57772017|NCT05341375|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
57772018|NCT05341375|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
57772019|NCT02151019|RADIATION|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
57772020|NCT03230422|DEVICE|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
57772021|NCT03230422|DEVICE|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
57772022|NCT00315913|DRUG|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
57772023|NCT00315913|OTHER|IV Placebo|IV Saline Solution
57772024|NCT01014221|OTHER|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
57772025|NCT01014221|DRUG|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
57772026|NCT04324294|DRUG|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
57772027|NCT03729921|PROCEDURE|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
57772028|NCT03729921|PROCEDURE|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
57772029|NCT01988896|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
57772030|NCT01988896|DRUG|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
57772031|NCT02921373|BIOLOGICAL|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
57772032|NCT02921373|DEVICE|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
57772033|NCT02973360|DRUG|Docosahexaenoic Acid|Oral Capsule
57772034|NCT02973360|DRUG|Placebo|Oral Capsule
57772035|NCT06176820|DRUG|Vaginal Gel|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
57772036|NCT06176820|DRUG|Vaginal lubricant|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
57772037|NCT05246319|DIAGNOSTIC_TEST|preoperative imaging|evaluation of preoperative imaging (versus nodes observed on pathology)
57772038|NCT00519636|DRUG|FPNS|fluticasone propionate nasal spray
57772039|NCT00519636|DRUG|FFNS|fluticasone furoate nasal spray
57772040|NCT00519636|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
57772041|NCT00519636|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
57772042|NCT03267290|DIAGNOSTIC_TEST|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
57772043|NCT06364241|OTHER|Focus group|During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.
57772044|NCT06014619|PROCEDURE|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
57772045|NCT06014619|PROCEDURE|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
57772046|NCT00885573|DEVICE|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
57772047|NCT00082537|DRUG|caspofungin acetate|Duration of Treatment: 28-90 days
57772048|NCT00082537|DRUG|Comparator: AmBisome|Duration of Treatment: 28-90 days
57772049|NCT05046535|BEHAVIORAL|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
57772050|NCT05046535|GENETIC|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
57772051|NCT05046535|DIAGNOSTIC_TEST|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
57772052|NCT05046535|BEHAVIORAL|Smoking|Surveys that measure nicotine dependence and smoking behavior
57772053|NCT03716622|DRUG|Furazolidone|bismuth-furazolidone-containing quadruple regimens
57772054|NCT03716622|DRUG|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
57772055|NCT00692640|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
57772056|NCT00692640|DRUG|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
57772057|NCT00437021|DRUG|Placebo (subcutaneous)|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
57772058|NCT00437021|DRUG|Placebo (scarification)|Physiologic normal saline for injection.
57772059|NCT00437021|BIOLOGICAL|Dryvax®|Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
57772060|NCT00437021|BIOLOGICAL|IMVAMUNE®|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
57772061|NCT02377960|BEHAVIORAL|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
57772062|NCT02377960|BEHAVIORAL|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
57772063|NCT02377960|BEHAVIORAL|Usual care|Usual care
57772064|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
57772065|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
57772066|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
57772067|NCT00466674|DRUG|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
57772068|NCT04403958|PROCEDURE|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
57772069|NCT04403958|PROCEDURE|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
57772070|NCT01483157|OTHER|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
57772071|NCT01483157|OTHER|high intensity resistance training|twelve weeks of resistance training twice a week
57772072|NCT02692950|OTHER|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
57772073|NCT02692950|BEHAVIORAL|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
57772074|NCT03303677|DRUG|Saline Nasal|topical nasal saline rinses
57772075|NCT03303677|DRUG|Budesonide Nasal|saline + budesonide nasal saline irrigation
57772076|NCT03303677|DRUG|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
57772077|NCT00131859|PROCEDURE|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
57785284|NCT01356030|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
57772078|NCT05230979|OTHER|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
57772079|NCT05230979|OTHER|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
57772080|NCT05230979|OTHER|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
58459109|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
57772081|NCT05230979|OTHER|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
57772082|NCT05230979|OTHER|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
57772083|NCT05230979|OTHER|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
57772084|NCT02299258|DEVICE|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
57772085|NCT02299258|DEVICE|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
57772086|NCT04398693|DIETARY_SUPPLEMENT|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
57772087|NCT02518724|PROCEDURE|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
57772088|NCT02518724|PROCEDURE|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
57772089|NCT00674115|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
57772090|NCT00674115|DRUG|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
57772091|NCT00674115|DRUG|sodium bicarbonate|Sodium bicarbonate. Single dose.
57772092|NCT04397523|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
57772093|NCT05391321|OTHER|administration of the 4 quality of sexual life questionnaires|administration of the 4 quality of sexual life questionnaires
57772094|NCT06183086|DEVICE|Linovera®|Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
57772095|NCT00087789|GENETIC|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg
57772096|NCT05818059|DIAGNOSTIC_TEST|Diagnosis of Tuberculosis with computer-aided detection (CAD) software|"After enrolment, each subject will be assessed according to ARM 1 (assessment by clinician #1 without CAD) or ARM 2 (assessment by clinician #1 with CAD). Allocation to sequence ARM 1 or ARM 2 will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."
57772097|NCT02534532|OTHER|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
57772098|NCT05892523|PROCEDURE|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
57772099|NCT04219722|DEVICE|Injection of DESIRIAL®|"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
57772100|NCT04219722|OTHER|Injection of placebo|"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
57772101|NCT01266447|BIOLOGICAL|Filgrastim|Given SC
57772102|NCT01266447|OTHER|Laboratory Biomarker Analysis|Correlative studies
57772103|NCT01266447|BIOLOGICAL|Pegfilgrastim|Given SC
57772104|NCT01266447|DRUG|Topotecan Hydrochloride|Given IV
57772105|NCT01266447|DRUG|Veliparib|Given PO
57772106|NCT01289041|DRUG|BKM120|
57772107|NCT01643941|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
57772108|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
57772109|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
57772110|NCT01643941|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
57772111|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
57772112|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
57772113|NCT01643941|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
57772114|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
57772115|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
57772116|NCT01643941|BIOLOGICAL|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
57772117|NCT01643941|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
57772118|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
57772119|NCT01643941|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
57772120|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
57772121|NCT01643941|PROCEDURE|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
57772122|NCT05150587|DRUG|Rifaximin|Rifaximin tablets
57772123|NCT05150587|DRUG|Placebo|Placebo tablets
57772124|NCT04963673|OTHER|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
57772125|NCT02934113|BEHAVIORAL|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
57772126|NCT02934113|BEHAVIORAL|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
57772127|NCT05553158|DEVICE|Compression pants|Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.
57772128|NCT05553158|DEVICE|Embolization coils|Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.
57772129|NCT03984032|DEVICE|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
57772130|NCT03984032|DEVICE|LMA Supreme|Assessing the clinical performance of LMA Supreme
57772131|NCT04785326|DRUG|DMB-3115|45mg or 90mg dose subcutaneous administration
57772132|NCT04785326|DRUG|Stelara|45mg or 90mg dose subcutaneous administration
57772133|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
57772134|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
57772135|NCT05739032|OTHER|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
57772136|NCT02546154|DRUG|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
57772137|NCT05781893|OTHER|Digital intervention (DiLCoS)|The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.
57772138|NCT05781893|OTHER|Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
57772139|NCT05016037|BEHAVIORAL|Lexically based speech recast|a child's spontaneous or elicited production containing phonological errors is immediately followed with a clinician model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as \[be\] would be the whole lexeme bake \[bek\] rather than production drill on \[k\] in isolation.
57772140|NCT01229982|DRUG|Latanoprost-PPDS|Punctal Plug
57772141|NCT02461875|DRUG|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
57772142|NCT02461875|DRUG|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
57772143|NCT04711603|DRUG|MR13A9|Intravenous administration
57772144|NCT04711603|DRUG|Placebo|Intravenous administration
57772145|NCT01811940|DRUG|Adderall-ER|MAS-ER 60mg/day
57772146|NCT01811940|DRUG|Topiramate|Topiramate 100 mg bid.
57772147|NCT01811940|OTHER|Placebo|Placebo
57772148|NCT01074749|DEVICE|Accent Pacemaker|Implantation of pacemaker
57772149|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
57772150|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
57772151|NCT05317546|DRUG|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
57772152|NCT02468609|RADIATION|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
57772153|NCT04459559|DEVICE|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
57772154|NCT05295563|OTHER|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
57772155|NCT03870178|DEVICE|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
57772156|NCT04572919|PROCEDURE|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
57772157|NCT04572919|PROCEDURE|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
57785285|NCT01356030|PROCEDURE|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
57772158|NCT06386029|BEHAVIORAL|Power Down bedtime manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
57772159|NCT01324219|BEHAVIORAL|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
57772160|NCT01324219|BEHAVIORAL|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
57772161|NCT01614977|DRUG|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
57772162|NCT01168063|DRUG|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
57772163|NCT01168063|DRUG|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days"
57772164|NCT04658303|DRUG|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
57772165|NCT02385578|OTHER|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
57772166|NCT03341650|BEHAVIORAL|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
57772167|NCT03341650|BEHAVIORAL|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
57772168|NCT04096989|OTHER|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
57772169|NCT04096989|OTHER|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
57772170|NCT04147767|DIETARY_SUPPLEMENT|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols"
57772171|NCT04147767|DIETARY_SUPPLEMENT|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
57772172|NCT02099435|DEVICE|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
57772173|NCT03710213|BEHAVIORAL|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
57772174|NCT04925596|BEHAVIORAL|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
57772175|NCT04925596|BEHAVIORAL|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
57772176|NCT04661475|DRUG|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
57772177|NCT04661475|DRUG|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
57772178|NCT06382285|DRUG|Continues peripheral block|ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
57772179|NCT02459249|OTHER|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
57772180|NCT02459249|OTHER|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
57772181|NCT02140346|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
57772182|NCT02140346|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
57772183|NCT02106689|DEVICE|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
57772184|NCT02106689|DEVICE|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
57772185|NCT05983926|PROCEDURE|Subtotal colectomy was performed|"Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements."
57772186|NCT04992936|DIETARY_SUPPLEMENT|Extract from the wine industry|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
57772187|NCT04992936|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
57772188|NCT00517465|DRUG|Placebo|po bid
57772189|NCT00517465|DRUG|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
57772190|NCT05885113|BEHAVIORAL|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
57772191|NCT02678689|BIOLOGICAL|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
57772192|NCT02678689|DEVICE|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
57772193|NCT06317064|DRUG|Ibuprofen and Aprepitant|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
57772194|NCT00808301|OTHER|Gluten-free products|Gluten-free bakery products containing oatmeal.
57772195|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
57772196|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
57772197|NCT02490891|DEVICE|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
57772198|NCT03934632|OTHER|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
57772199|NCT03934632|OTHER|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
57772200|NCT03934632|PROCEDURE|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
58459110|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
58491260|NCT00499083|GENETIC|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
58459111|NCT00621374|BEHAVIORAL|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
58459112|NCT00621374|BEHAVIORAL|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
57772201|NCT03313219|DRUG|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
57772202|NCT02186509|RADIATION|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
57772203|NCT02186509|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
57772204|NCT02186509|DRUG|Alisertib|Given PO
57772205|NCT02186509|PROCEDURE|Quality-of-life assessment|Ancillary studies
57772206|NCT03723135|DRUG|CC-486|Oral azacitidine administered as directed by treating physician.
57772207|NCT04737213|DRUG|SGM-101|Fluorescence guided surgery
57772208|NCT03987256|OTHER|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
57772209|NCT03987256|PROCEDURE|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
57772210|NCT03987256|PROCEDURE|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
57772211|NCT00003458|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
57772212|NCT01209481|BEHAVIORAL|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
57772213|NCT05238532|GENETIC|CT303|"Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg"
57772214|NCT00665990|DRUG|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
57772215|NCT00665990|DRUG|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
57772216|NCT00665990|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
57772217|NCT02020499|DRUG|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
57772218|NCT02138747|DRUG|Mirabegron|Oral
57772219|NCT02138747|DRUG|Tolterodine ER|Oral
57772220|NCT04978610|BEHAVIORAL|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
57772221|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
57772222|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
57772223|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
57772224|NCT04103424|BEHAVIORAL|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
57785286|NCT04554485|DRUG|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
58459113|NCT02733263|DIETARY_SUPPLEMENT|15 g RMD|15 grams of resistant maltodextrin
58459114|NCT02733263|DIETARY_SUPPLEMENT|25 g RMD|25 grams of resistant maltodextrin
57772225|NCT05051332|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
57772226|NCT05051332|PROCEDURE|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
57772227|NCT00185510|DRUG|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
57772228|NCT00185510|DRUG|Placebo|2 days a week Vehicle (Advabase)
57772229|NCT05056064|OTHER|Oral exercise|exercise remain tongue
57772230|NCT00592046|DRUG|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
57772231|NCT01097213|DRUG|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
57772232|NCT01097213|DRUG|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
57772233|NCT01539174|BIOLOGICAL|rituximab|Given IV
57772234|NCT01539174|DRUG|cyclophosphamide|Given IV
57772235|NCT01539174|DRUG|doxorubicin hydrochloride|Given IV
57772236|NCT01539174|DRUG|vincristine sulfate|Given IV
57772237|NCT01539174|DRUG|prednisone|Given PO
57772238|NCT01539174|OTHER|laboratory biomarker analysis|Correlative studies
57772239|NCT01539174|OTHER|pharmacological study|Correlative studies
58459115|NCT02733263|DIETARY_SUPPLEMENT|0 g RMD|0 grams of resistant maltodextrin
57772240|NCT05099913|DRUG|Deanxit|Central neuromodulators was applied in refractory FD patients for different time
57772241|NCT02207517|PROCEDURE|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
57772242|NCT05000489|OTHER|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
57772243|NCT04362137|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets
57772244|NCT04362137|DRUG|Placebo|Matching-image placebo
57772245|NCT02977884|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
57772246|NCT00552773|DRUG|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
57772247|NCT00195715|BIOLOGICAL|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
57772248|NCT01987830|DEVICE|MRI-PET|"* \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide"
57772249|NCT01987830|DEVICE|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
58459116|NCT02831764|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
57772250|NCT00432510|DRUG|C1 esterase inhibitor [human] (C1INH-nf)|
57772251|NCT01738893|DRUG|Gabapentin 300 mg|Test product
57772252|NCT01738893|DRUG|Gabapentin 300 mg|Reference product
57772253|NCT01082172|DEVICE|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
57772254|NCT02608489|DRUG|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
57772255|NCT02608489|DRUG|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
57772256|NCT00624715|DRUG|THC|"* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
57772257|NCT00624715|DRUG|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
57772258|NCT02811016|DRUG|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
57772259|NCT02811016|DRUG|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
57772260|NCT02811016|DRUG|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
57772261|NCT05539521|DRUG|Remimazolam Besylate|sedation drugs
57772262|NCT05539521|DRUG|Propofol|Propofol
57772263|NCT05284019|DRUG|Eptinezumab|Concentrate for solution for IV infusion
57772264|NCT05284019|DRUG|Erenumab|Solution for SC Injection
57772265|NCT05284019|DRUG|Onabotulinumtoxin-A|Solution for IM Injection
57772266|NCT05284019|DRUG|Fremanezumab|Solution for SC Injection
57772267|NCT05284019|DRUG|Galcanezumab|Solution for SC Injection
57772268|NCT00782977|OTHER|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
57772269|NCT02161861|OTHER|cFFE increase the fusiogenic capacities of a gamete|
57772270|NCT02559609|BEHAVIORAL|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
57772271|NCT02559609|BEHAVIORAL|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
57772272|NCT02559609|BEHAVIORAL|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
57772273|NCT03926065|OTHER|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
57772274|NCT03926065|OTHER|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
57772275|NCT03926065|OTHER|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
57772276|NCT03926065|OTHER|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
57772277|NCT05228093|PROCEDURE|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
57772278|NCT05228093|PROCEDURE|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
57772279|NCT00022217|DRUG|carboplatin|
57772280|NCT00022217|DRUG|cisplatin-e therapeutic implant|
57772281|NCT00022217|DRUG|paclitaxel|
57772282|NCT02182219|DRUG|BIBF 1120|
57772283|NCT03316417|OTHER|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
57772284|NCT00941538|DIAGNOSTIC_TEST|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
58459117|NCT02831764|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
57772285|NCT01486615|DRUG|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
57772286|NCT01486615|DRUG|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
57772287|NCT01486615|DRUG|(alprax) alprazolam|0.5 mg alprazolam
57772288|NCT01486615|DRUG|placebo|similar looking placebo tablet
58491261|NCT00499083|GENETIC|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
57772289|NCT01794117|DRUG|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
57772290|NCT02608762|RADIATION|standard adjuvant local radiation therapy or cranial radiation therapy|
57772291|NCT03446105|BEHAVIORAL|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
58459118|NCT02831764|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
58459119|NCT05360927|DRUG|BDB-001 injection|Intravenous injection
58459120|NCT05360927|DRUG|Placebo|Intravenous injection
57772292|NCT03446105|BEHAVIORAL|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
57772293|NCT01149213|DEVICE|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
58459121|NCT02760940|DRUG|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
57772294|NCT01458990|DRUG|Omeprazole|20mg PO BID for 20 days
57772295|NCT03497494|PROCEDURE|2 cm away from the pylorus edge|2 cm away from the pylorus edge
57772296|NCT03497494|PROCEDURE|4 cm away from the pylorus edge|4 cm away from the pylorus edge
57772297|NCT03497494|PROCEDURE|6 cm away from the pylorus edge|6 cm away from the pylorus edge
57772298|NCT03497494|PROCEDURE|LRYGB|laparoscopic Roux-en-Y gastric bypass
57772299|NCT06020664|DRUG|NOX-1416+SOC|NOX1416+SOC as provided in Arm/group description
57772300|NCT06020664|OTHER|Placebo+SOC|Placebo+SOC as provided in Arm/group description
57772301|NCT04370743|OTHER|No intervention|
57772302|NCT04178512|DRUG|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
57772303|NCT04694729|OTHER|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
57772304|NCT04694729|OTHER|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
57772305|NCT02418975|OTHER|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
57772306|NCT02418975|OTHER|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
57772307|NCT02083003|DIETARY_SUPPLEMENT|Polyamine low-diet|
57772308|NCT02083003|DIETARY_SUPPLEMENT|Liberal alimentation|
57772309|NCT00543400|DRUG|M118|intravenous (IV) infusion
57772310|NCT00543400|DRUG|Unfractionated Heparin|IV infusion
57772311|NCT04017390|DRUG|Theraworx Foam|Apply Theraworx Foam alone
58459122|NCT02575534|DRUG|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
58459123|NCT00804726|DEVICE|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
58459124|NCT05413746|DEVICE|Reoxcare antioxidant dressing|After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
58459125|NCT04681235|OTHER|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
57772312|NCT04017390|DRUG|Placebo Foam|Apply placebo foam alone
57772313|NCT04017390|OTHER|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
57772314|NCT04017390|OTHER|Placebo Foam and night time splint|Apply placebo foam and night time splint
57772315|NCT06291675|DRUG|gender-affirming hormone therapy|We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
57772316|NCT00047983|DIETARY_SUPPLEMENT|Canola oil|
57772317|NCT00047983|DIETARY_SUPPLEMENT|Arginine|
57772318|NCT00047983|DIETARY_SUPPLEMENT|Fish oil emulsion|
57772319|NCT05842460|BEHAVIORAL|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
57772320|NCT05842460|BEHAVIORAL|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
57772321|NCT06016270|DRUG|hSTC810 400 mg + Paclitaxel|"hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion"
57772322|NCT06016270|DRUG|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
57772323|NCT02104830|BIOLOGICAL|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
57772324|NCT02104830|BIOLOGICAL|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
57772325|NCT02104830|BIOLOGICAL|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
57772326|NCT02104830|BIOLOGICAL|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
58459126|NCT04361435|PROCEDURE|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
58459127|NCT04537975|DEVICE|C2Rx|Hemofiltration
58459128|NCT04537975|OTHER|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
57772327|NCT02104830|BIOLOGICAL|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
57772328|NCT01950442|DEVICE|Balloon dilation|
57772329|NCT03154359|DRUG|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
57772330|NCT02931890|DRUG|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
57772331|NCT02931890|DRUG|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
57772332|NCT02931890|DRUG|Capecitabine|oral capecitabine in arm 1 and 2
58459129|NCT00074165|DRUG|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
57772333|NCT02931890|PROCEDURE|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
57772334|NCT02931890|RADIATION|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
57772335|NCT02931890|DRUG|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
58459130|NCT00074165|DRUG|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
57772336|NCT02931890|DRUG|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
57772337|NCT05622890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
57772338|NCT02191384|DRUG|Orcinoside|oral, twice per day
57772339|NCT03396432|DEVICE|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
57772340|NCT03396432|DEVICE|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
57772341|NCT04140825|DEVICE|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
57772342|NCT03464604|DIAGNOSTIC_TEST|active|Pre-screening for melanoma by qualified nurse
57772343|NCT06024629|DEVICE|cOCT and LC-OCT|"cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)"
57772344|NCT05448586|DRUG|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
57772345|NCT03499379|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
57772346|NCT03499379|DEVICE|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
57772347|NCT00026520|BIOLOGICAL|recombinant interferon alfa|
57772348|NCT00026520|DRUG|thalidomide|
57772349|NCT02483013|OTHER|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
57772350|NCT02483013|OTHER|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
58459131|NCT00074165|DRUG|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
58459132|NCT00074165|DRUG|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
58459133|NCT00074165|DRUG|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
58459134|NCT00074165|DRUG|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
58459135|NCT00074165|DRUG|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
58459136|NCT00074165|DRUG|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
58459137|NCT00074165|DRUG|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
58459138|NCT00311766|DRUG|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
58459139|NCT00311766|DRUG|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
58459140|NCT02587221|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
58459141|NCT02587221|BIOLOGICAL|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
58459142|NCT00000140|DRUG|Perfluoropropane|
57772351|NCT04660019|OTHER|Scalp and auricular acupuncture|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.
57772352|NCT04660019|OTHER|Seed acupressure|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
57772353|NCT03621293|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
57772354|NCT03547284|DRUG|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
57772355|NCT06207370|DRUG|Tafenoquine|Oral Tafenoquine
57772356|NCT06207370|OTHER|Placebo|Placebo
57772357|NCT05763992|DIETARY_SUPPLEMENT|Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)|Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
57772358|NCT05430048|DRUG|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
57772359|NCT05091866|OTHER|Quality-of-Life Assessment|Ancillary studies
57772360|NCT05091866|OTHER|Questionnaire Administration|Ancillary studies
57772361|NCT05091866|BIOLOGICAL|Therapeutic Progesterone|Given SC
58459143|NCT00000140|DRUG|Sulfur Hexafluoride|
57772362|NCT03769805|DRUG|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
57772363|NCT06148675|OTHER|No Intervention|No intervention,data collection
57772364|NCT06029491|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulse TM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
57772365|NCT02199821|DIETARY_SUPPLEMENT|Formula with soybean oil, medium-chain triglycerides|
57772366|NCT02199821|DIETARY_SUPPLEMENT|Soybean oil formula commonly used in the hospital|
57772367|NCT05635318|DEVICE|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
57772368|NCT05635318|DRUG|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
57772369|NCT01850082|PROCEDURE|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
57772370|NCT02780622|DRUG|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
57772371|NCT02780622|DRUG|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
57772372|NCT01265823|BIOLOGICAL|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
57772373|NCT01756560|DRUG|dexamethsone|
57772374|NCT01756560|DRUG|Bupivacaine|
57772375|NCT02210819|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
58459144|NCT00000140|DRUG|Silicone Oil|
57772376|NCT02210819|DRUG|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
57772377|NCT00853281|OTHER|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
57772378|NCT00853281|OTHER|Standard vector control measures|Insectice-treated net
58459145|NCT00348712|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
58459146|NCT00348712|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
58459147|NCT00348712|DRUG|metformin|Tablets, 2000 mg/day.
58459148|NCT01258777|DRUG|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
57772379|NCT02133924|DRUG|natalizumab|Natalizumab 300mg on days 0 and 14.
57772380|NCT02133924|DRUG|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
57772381|NCT04610762|DIAGNOSTIC_TEST|GeneXpert HCV VL Fingerstick test|The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
57772382|NCT00141882|DRUG|memantine|
57772383|NCT00363194|DRUG|Pazopanib (GW786034)|Pazopanib (GW786034)
57772384|NCT02526056|OTHER|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
57772385|NCT02526056|OTHER|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
57772386|NCT03784092|OTHER|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
58459149|NCT01258777|DRUG|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
57772387|NCT05565235|DRUG|patients will receive intraoperative serratus block with bupivacaine|no additives
57772388|NCT05565235|DRUG|serratus block with bupivacaine /magnesium|magnesium added
57772389|NCT05565235|DRUG|serratus block with bupivacaine with nalbuphine|nalbuphine added
57772390|NCT00263120|BEHAVIORAL|Pain Questionnaire|
57772391|NCT04896125|DRUG|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
57772392|NCT06083675|DRUG|Semaglutide|Administered as oral tablets.
57772393|NCT06083675|DRUG|Empagliflozin|Administered as oral tablets.
57772394|NCT06083675|DRUG|Metformin|Administered as oral tablets.
57772395|NCT02519647|DEVICE|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
57772396|NCT02519647|DEVICE|Tracheal intubation with S-guide|Tracheal intubation with S-guide
57772397|NCT00563849|DRUG|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
57772398|NCT02381990|PROCEDURE|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
57772399|NCT05222438|DRUG|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
57772400|NCT03406702|DRUG|CX-8998|T-type calcium channel blocker
57772401|NCT00754975|DEVICE|JACTAX LD DES|Drug Eluting Stent
57772402|NCT00754975|DEVICE|TAXUS™ Libertè™ DES|Drug Eluting Stent
57772403|NCT00003048|DRUG|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
57772404|NCT01950273|DRUG|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
57772405|NCT01950273|DRUG|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
57772406|NCT00057187|BEHAVIORAL|Contracting, Prompting and Reinforcing|
57772407|NCT02104635|BEHAVIORAL|Delivery of a Post-Partum Package|
57772408|NCT06429332|OTHER|Reversal of Oral anticoagulation within 30 minutes|In situations of either an elevated INR with the use of warfarin - treatment with either 3- or 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) within 30 minutes of hospital arrival to reach and maintain an INR target \<1.3; or where there has been recent use (\<48 hours) of a direct oral anticoagulant (DOAC), use of an appropriate reversal agent within 30 minutes, where available, and according to local approvals.
57772409|NCT06429332|OTHER|Early intensive blood pressure lowering|A systolic blood pressure (BP) target of 130-140 mmHg within 30 minutes of commencing treatment is strived for, and to maintain this BP level for the first 7 days (for patients presenting with blood pressure \<200 mmHg). If blood pressure ≥200 and \<220, a target BP of 160 mmHg should be targeted at 30 minutes, and 130-140 mmHg should be achieved in 60 minutes. If BP ≥220, target BP of 160 mmHg and should be achieved in 60 minutes.
57772410|NCT06429332|OTHER|Treatment of pyrexia|To achieve a body temperature target \<37.5 °C
58459150|NCT05717361|DRUG|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
57772411|NCT06429332|OTHER|Hyperglycemia treatment|To maintain a blood glucose level 7-10 mmol/L
57772412|NCT06429332|OTHER|Do-not-resuscitate (DNR) or withdrawal of care|Refrain from the use of DNR or withdrawal of care orders for 48 hours
57772413|NCT06429332|OTHER|Referral to Intensive Care|Immediate (\<30 min) referral to intensive care if airway, breathing and/or circulation are compromized
57772414|NCT06429332|OTHER|Referral to Neurosurgery|"Immediate (\<30 min) referral to neurosurgery if any of the following criteria are fulfilled:~* Large and/or rapidly evolving supratentorial ICH (\>20 ml volume)~* Any intraventricular extension~* Posterior fossa bleed, irrespective of volume~* Suspicion of a vascular malformation, independent of volume or location~* Reduction in reaction to sensory stimulation or drowsiness"
57772415|NCT06429332|DIAGNOSTIC_TEST|Repeat brain imaging|Repeat 6-12-hour brain imaging with the physicians choice of modality, preferably computed tomography (CT), if clinical deterioration or the patient received OAC reversal treatment
57785287|NCT05819060|DRUG|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
58459151|NCT05717361|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
58459152|NCT06405360|DIETARY_SUPPLEMENT|Egg consumption|Participants in the intervention group will be provided two eggs to consume daily.
57772416|NCT06429332|OTHER|Standard care|For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
57772417|NCT02524132|BEHAVIORAL|Physical Activity|
57772418|NCT01451736|DRUG|paliperidone palmitate|long-acting injectable
57772419|NCT01451736|DRUG|risperidone|oral
57772420|NCT03636035|DIETARY_SUPPLEMENT|Tregocel®|Coated tablet (oral)
57772421|NCT01584492|DRUG|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
57772422|NCT01584492|DRUG|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
57772423|NCT01584492|DRUG|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
57772424|NCT01584492|DRUG|Formoterol + Beclomethasone dipropionate|"* Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation"
57772425|NCT01584492|DRUG|Placebo (6 inhalations)|Matched placebo via pMDI
57772426|NCT05974579|DRUG|89Zr-DFO-AP-101|"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."
57772427|NCT00375141|DEVICE|Pulsed dye laser, Intense pulsed light|
57772428|NCT00744315|PROCEDURE|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
57772429|NCT04239729|BEHAVIORAL|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
57772430|NCT02783118|OTHER|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts"
57772431|NCT03662360|OTHER|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
57772432|NCT04759742|DRUG|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
57772433|NCT04496843|DIAGNOSTIC_TEST|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
57772434|NCT00664820|DIETARY_SUPPLEMENT|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
57772435|NCT00707213|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
57772436|NCT03545113|PROCEDURE|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
57772437|NCT03545113|PROCEDURE|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
57772438|NCT04107623|DIAGNOSTIC_TEST|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
57772439|NCT05626972|DRUG|Tenecteplase|Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
58459153|NCT05033197|BEHAVIORAL|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
57772440|NCT04683523|OTHER|Exercise|Resistance training using dumbbells and therabands
57772441|NCT06442644|OTHER|Live music in the intensive care unit|To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
58459154|NCT00948064|DRUG|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
58459155|NCT00948064|DRUG|Azacitidine|75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
58459156|NCT02571114|DIETARY_SUPPLEMENT|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
58459157|NCT02571114|DIETARY_SUPPLEMENT|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
57772442|NCT01797341|DRUG|Tacrolimus|
57772443|NCT01797341|DRUG|Tacrolimus|
57785288|NCT05275270|OTHER|oxytocin gel|The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
57785289|NCT05275270|OTHER|placebo gel|The placebo gel (B) consisted of the gel alone
57785290|NCT00147043|PROCEDURE|Leukapheresis|
57772444|NCT06393218|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
57772445|NCT06393218|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
57772446|NCT06393218|BEHAVIORAL|Routine rehabilitation|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
57772447|NCT01015807|DRUG|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
57772448|NCT01015807|DRUG|Clonidine Placebo|2 x 1mL 0.9% NaCl
57772449|NCT01015807|DRUG|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
57772450|NCT01015807|DRUG|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
57772451|NCT00002456|DRUG|cyclosporine|
57772452|NCT00002456|DRUG|methotrexate|
57772453|NCT00002456|PROCEDURE|allogeneic bone marrow transplantation|
57772454|NCT03577574|PROCEDURE|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
57772455|NCT03577574|PROCEDURE|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
57772456|NCT03577574|PROCEDURE|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
57772457|NCT04602897|OTHER|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
57772458|NCT01673074|DRUG|(PDT) Photodynamic therapy|photosensitizer
57772459|NCT01938105|OTHER|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------"
57772460|NCT04075799|OTHER|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
57772461|NCT05764291|BEHAVIORAL|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
58459158|NCT02571114|DIETARY_SUPPLEMENT|Control 1|White bread (serving size = 25 g available carbohydrate)
57772462|NCT04845035|DRUG|Dasatinib|By mouth
57772463|NCT04845035|DRUG|Ponatinib|By mouth
57772464|NCT04845035|DRUG|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
57772465|NCT04845035|DRUG|Methotrexate and Cytarabine|Intrathecal
57772466|NCT04711460|BEHAVIORAL|Younger participants|Younger Participants 19-29 years received TAU + Tx over 5 weeks
58459159|NCT02571114|DIETARY_SUPPLEMENT|Control 2|White bread (serving size = 25 g available carbohydrate)
58459160|NCT03249636|DIAGNOSTIC_TEST|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
58459161|NCT00713609|DRUG|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
58459162|NCT00713609|DRUG|Clindamycin gel|1% clindamycin phosphate applied topically once a day
57772467|NCT04711460|BEHAVIORAL|Older participants|older participants 30-54 years received TAU + Tx over 5 weeks
57772468|NCT04711460|BEHAVIORAL|TAU|Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
57772469|NCT04711460|BEHAVIORAL|TAU + MIndfulness practice|Participants received TAU + mindfulness training
57772470|NCT03519698|OTHER|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
57772471|NCT03519698|OTHER|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
57772472|NCT03519698|OTHER|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
57772473|NCT06624332|BEHAVIORAL|e-SBI main session|Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.
57772474|NCT06624332|BEHAVIORAL|e-SBI Booster Session|A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.
57772475|NCT06624332|BEHAVIORAL|Text messaging|4 weeks of daily automated text messages that reinforce content from the e-SBI main session.
57772476|NCT04394091|DEVICE|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
57772477|NCT01728805|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
57772478|NCT01728805|DRUG|Vorinostat|
57772479|NCT02023879|DRUG|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
57772480|NCT02023879|DRUG|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
57772481|NCT02023879|DRUG|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
57772482|NCT02023879|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
57772483|NCT05197257|DRUG|Ga-PSMA-11|The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
57772484|NCT03984019|DIAGNOSTIC_TEST|Cardiac condition measurements|Cardiac MRI, ECG, echocardiography, cardiac blood markers
57772485|NCT00000517|DRUG|warfarin|
57772486|NCT05719623|OTHER|CUEVAS MEDEK EXERCISES|stretchings/strengthening
57772487|NCT05719623|OTHER|BALANCE AND POSTURAL|BALANCE AND POSTURAL
57772488|NCT01380990|GENETIC|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously
57772489|NCT01380990|OTHER|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
57772490|NCT01380990|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
57772491|NCT01380990|DRUG|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
58459163|NCT00713609|DRUG|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
58459164|NCT00713609|DRUG|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
57772492|NCT02070120|DRUG|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
57772493|NCT02070120|PROCEDURE|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
57772494|NCT02964715|DRUG|Empagliflozin|25 mg daily for 6 months
58459165|NCT00713609|DRUG|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
58459166|NCT03755206|OTHER|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
58459167|NCT05255146|DEVICE|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
57772495|NCT04310943|DRUG|Tislelizumab|Tislelizumab, 200mg, Q3W ,use until disease progression
57772496|NCT03759613|OTHER|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
57772497|NCT01176604|RADIATION|Yttrium Y 90 Glass Microspheres|Given via catheter
57772498|NCT06489574|PROCEDURE|thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour)."
57772499|NCT06489574|PROCEDURE|thoracic epidural with fentanyl in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour)."
57772500|NCT02361060|DRUG|Neostigmine|40mcg/kg
57772501|NCT02361060|DRUG|Sugammadex|4mg/kg
57772502|NCT02361060|DRUG|Atropine|10 mcg/kg
57772503|NCT05625919|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
57772504|NCT02571205|DRUG|Sustanon (testosterone)|Standard incremental regimen of Sustanon
57785291|NCT00147043|PROCEDURE|Infusion of stem cells via image guided scan|
57772505|NCT05991973|DRUG|Chidamide|In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
57772506|NCT03758118|DIETARY_SUPPLEMENT|Citicoline|Citicoline administered in oral solution
58459168|NCT03195881|OTHER|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
58459169|NCT01650298|OTHER|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
57772507|NCT03813550|DIAGNOSTIC_TEST|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
57772508|NCT03135457|PROCEDURE|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
57772509|NCT03135457|PROCEDURE|Saline transfusion|Saline transfusion 300ml 10ml/min
57772510|NCT00217880|PROCEDURE|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
57772511|NCT00743990|OTHER|Ointment containing camphor, eucalyptus oil, and menthol|One time use
57772512|NCT00743990|OTHER|Petroleum jelly|One time use
58459170|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
58459171|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
58459172|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
58459173|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 30 mg (2\*15 mg) oral capsules.
58459174|NCT04999839|OTHER|Placebo|Placebo matched to NDI-034858 oral capsules.
58459175|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
58459176|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
58459177|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
58459178|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
57772513|NCT04655079|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
57772514|NCT04655079|DEVICE|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
57772515|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Group Treatment|group treatment
57772516|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Individual Treatment|individual treatment
57772517|NCT01885273|PROCEDURE|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
57772518|NCT01885273|PROCEDURE|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
57772519|NCT05619913|DRUG|Eribulin Mesylate|Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
57772520|NCT05619913|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
57772521|NCT03331133|OTHER|No intervention|
57772522|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
57772523|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
58459179|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
58459180|NCT00399516|DEVICE|Precision|
58459181|NCT03695224|DIAGNOSTIC_TEST|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
58459182|NCT05412147|DIETARY_SUPPLEMENT|RECO-18|4 pills daily, oral
58459183|NCT05412147|DIETARY_SUPPLEMENT|Multi-vitamins|one tablet daily, oral
58459184|NCT04618146|DRUG|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
58459185|NCT04618146|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
58459186|NCT04401735|DRUG|Polydeoxyribonucleotides|PDRN injection to epidural space
58459187|NCT04401735|DRUG|Normal saline|Normal saline
58459188|NCT03655145|OTHER|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
57772524|NCT02444988|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
57772525|NCT02444988|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
58459189|NCT03655145|OTHER|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
58459190|NCT01808196|DRUG|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
58459191|NCT02818309|DRUG|Lesogaberan|120 mg bid
57772526|NCT01999062|OTHER|IMRT + CT + MR scan|
57772527|NCT06280287|DIAGNOSTIC_TEST|FAPI PET|68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
57772528|NCT03545815|BIOLOGICAL|anti-mesothelin CAR-T cells|Cells will be infused on day 0.
57772529|NCT04015791|OTHER|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
57772530|NCT01207050|DRUG|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
57772531|NCT01207050|DIETARY_SUPPLEMENT|Placebo|Control treatment
57772532|NCT03992885|DRUG|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
57772533|NCT03115749|OTHER|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
57772534|NCT03115749|OTHER|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
57772535|NCT01474616|OTHER|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
57772536|NCT00525603|DRUG|Cyclophosphamide|200 mg/m\^2/day 3-5 IV 5-30 minutes
57772537|NCT00525603|DRUG|Fludarabine|20 mg/m\^2/day 3-5 IV 5-30 minutes
57772538|NCT00525603|DRUG|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
57772539|NCT00525603|DRUG|Rituximab|375 mg/m\^2/day 2 IV 4-6 hours
57772540|NCT06211062|DRUG|Floradapt Intensive GI|one capsule daily for the eight week intervention
57772541|NCT06211062|OTHER|Placebo|one capsule daily for the eight week intervention
57772542|NCT00073437|DRUG|Infliximab|
57772543|NCT00099450|DRUG|INS50589 Intravenous Infusion|
58459192|NCT02818309|DRUG|Placebo|Placebo
58459193|NCT00656929|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
58459194|NCT00656929|OTHER|Placebo|Placebo tablets
58459195|NCT04396366|DRUG|Active drug|QBW251 Capsule 300mg Oral use, one capsule twice daily.
58459196|NCT04396366|DRUG|Placebo|Placebo Capsule 300mg Oral use, one capsule twice daily.
57772544|NCT00459303|DEVICE|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
57772545|NCT00459303|DEVICE|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
57772546|NCT02327819|DIETARY_SUPPLEMENT|Branched-chain amoni acids (BCAA)|
57772547|NCT02327819|DIETARY_SUPPLEMENT|non-BCAA protein supplement|
57772548|NCT00043888|DRUG|fosamprenavir|
57772549|NCT00043888|DRUG|COMBIVIR|
57772550|NCT00043888|DRUG|ritonavir|
58459197|NCT03081702|DRUG|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
58459198|NCT03081702|DRUG|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
58459199|NCT04907734|OTHER|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
58459200|NCT06217965|OTHER|survey|The study will involve patients completing a questionnaire on a secure online platform (such as RedCap)
57772551|NCT00043888|DRUG|TRIZIVIR|
57772552|NCT00749385|DRUG|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
57772553|NCT00749385|DRUG|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
57772554|NCT00749385|DRUG|EC naproxen|Enteric-coated naproxen tablet (500mg)
57772555|NCT00749385|DRUG|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
57772556|NCT06495437|BIOLOGICAL|Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.|The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
57772557|NCT00936221|DRUG|AZD6244|oral capsules, 75mg twice daily
57772558|NCT00936221|DRUG|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
57772559|NCT00936221|DRUG|Placebo|Placebo
57772560|NCT05106985|DEVICE|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
57772561|NCT00454428|PROCEDURE|pulsatile intra-aortic balloon pump|
57772562|NCT03856996|BIOLOGICAL|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
57772563|NCT03856996|BIOLOGICAL|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
57772564|NCT03856996|BIOLOGICAL|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
57772565|NCT04878419|OTHER|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
57772566|NCT05064553|DEVICE|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
57772567|NCT05064553|DEVICE|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
57772568|NCT05064553|DIAGNOSTIC_TEST|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
57772569|NCT05714995|OTHER|hypnosis|"The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
57772570|NCT05714995|OTHER|Hypnosis with aromatherapy|"for patients in the hypnosis with aromatherapy group, before starting the hypnosis session, they will first choose an essential oil among the 5 proposed.~They will pour a drop on their wrist then they will rub it and inhale deeply.~The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
57772571|NCT03656731|OTHER|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session."
57772572|NCT03863197|BEHAVIORAL|Progressive strength training|Progressive Supervised Home-based Strength Training
57772573|NCT01590771|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
57772574|NCT01590771|DRUG|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
57772575|NCT01590771|DRUG|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
57772576|NCT01590771|DRUG|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
57772577|NCT01590771|DRUG|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
57772578|NCT05844761|RADIATION|Triggered imaging on TrueBeam with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
57772579|NCT05844761|RADIATION|Synchrony MLC tracking on fiducials with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
57772580|NCT05844761|RADIATION|Synchrony MLC tracking and lung adaptive model with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
57772581|NCT00572624|BEHAVIORAL|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
57772582|NCT00572624|PROCEDURE|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
57772583|NCT04903834|DIAGNOSTIC_TEST|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
57772584|NCT04903834|DIAGNOSTIC_TEST|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
57772585|NCT02992522|DRUG|Lenalidomide|Given PO
57772586|NCT02992522|BIOLOGICAL|Obinutuzumab|Given IV
57772587|NCT02992522|DRUG|Venetoclax|Given PO
57772588|NCT03355105|OTHER|Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
57772589|NCT03355105|OTHER|Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|"The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient."
57772590|NCT00636792|DRUG|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
57772591|NCT00636792|DRUG|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
57772592|NCT00636792|DRUG|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
57772593|NCT02572843|DRUG|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
57785292|NCT02687503|DIETARY_SUPPLEMENT|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
57772594|NCT04432064|DEVICE|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
57772595|NCT04432064|OTHER|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
57772596|NCT04432064|DEVICE|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
57772597|NCT04744181|DRUG|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
57772598|NCT04744181|DRUG|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
57772599|NCT04744181|DRUG|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
57772600|NCT05247827|OTHER|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
57772601|NCT05340218|OTHER|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
57772602|NCT04764929|DEVICE|Helmet CPAP|Vyatil nonpowered oxygen tent system
57772603|NCT01484795|DEVICE|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
57772604|NCT01484795|DEVICE|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
57772605|NCT01015313|OTHER|intensive sodium management|"1. dietary sodium restriction~2. avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
57772606|NCT04760990|OTHER|data collection|clinical data collection regarding COVID-19 suggestive symptoms or confirmed SARS-CoV-2-infections (medical events), recorded comorbidities (concomitant diseases relevant to MS and COVID-19) and recorded vaccinations (other treatments). This information is systematically collected during the routine clinical visits of the patient within the SMSC every 6-12 months.
57772607|NCT04760990|OTHER|analysis of blood samples|analysis of archived serum samples collected every 6-12 months within the SMSC for measurement of anti-SARS-CoV-2 antibodies in pre-pandemic reference samples and prospectively determine the anti-SARS-CoV-2-serostatus during the study period.
57772608|NCT05063305|DIETARY_SUPPLEMENT|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
57772609|NCT05063305|DIETARY_SUPPLEMENT|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
57772610|NCT04161807|DEVICE|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
57772611|NCT01639794|DRUG|Vesitirim™ (Solifenacin)|Oral
57772612|NCT05438225|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
57772613|NCT05353959|OTHER|No intervention|No intervention
57772614|NCT02172456|DRUG|99mTc-radiolabelled tiotropium|
57772615|NCT02172456|DRUG|non-radiolabelled tiotropium|
57772616|NCT04330014|BEHAVIORAL|vaccine|affect vaccination on children
57772617|NCT00252213|DRUG|Human BNP|
57772618|NCT05672303|BEHAVIORAL|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
57772619|NCT05075343|DEVICE|Custom foot orthoses|"3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could."
57772620|NCT02768415|DRUG|Apatinib|
57772621|NCT02768415|DRUG|Oral Vinorelbine|
57772622|NCT01127217|DRUG|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
57772623|NCT01127217|DRUG|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
57785293|NCT05995340|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
57772624|NCT05246072|DRUG|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
57772625|NCT05246072|DRUG|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
57772626|NCT01405755|BEHAVIORAL|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
57772627|NCT01574430|PROCEDURE|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
57772628|NCT05240274|DRUG|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
57772629|NCT05240274|DRUG|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
57772630|NCT01424436|BIOLOGICAL|GSK933776|1mg/kg dose group
57772631|NCT01424436|BIOLOGICAL|GSK933776|3mg/kg dose group
57772632|NCT01424436|BIOLOGICAL|GSK933776|6mg/kg dose group
57772633|NCT05053217|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
57772634|NCT00566358|PROCEDURE|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
57772635|NCT01026714|DRUG|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
57772636|NCT01026714|DRUG|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
57772637|NCT01026714|DRUG|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
57772638|NCT05769751|OTHER|Electronic medical record and hospital information system or other available resources|This is a non-interventional study. No study medication will be provided to the participants.
57772639|NCT01995019|DRUG|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
57772640|NCT01995019|DRUG|Physiologic saline|1 ml intra-articular placebo
57772641|NCT05319561|OTHER|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
57772642|NCT04981522|BEHAVIORAL|Indigenously adapted problem management plus (IA-PM+)|The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
57772643|NCT01410825|BIOLOGICAL|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
57772644|NCT01805882|DRUG|Sofosbuvir|
57772645|NCT01805882|DRUG|Ledipasvir|
57772646|NCT01805882|DRUG|GS-9669|
57772647|NCT01805882|DRUG|GS-9451|
57772648|NCT04737317|DIAGNOSTIC_TEST|ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy|ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
57772649|NCT02452866|DRUG|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
57772650|NCT02222519|DRUG|Rocuronium|Rocuronium 0.6mg/kg iv single dose
57772651|NCT06019013|DRUG|QLF3108|QLF3108 will be administered independent of body weight.
57772652|NCT03324399|DIETARY_SUPPLEMENT|probiotic|a proprietary probiotic formulation
57772653|NCT01849120|DEVICE|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
57772654|NCT01717183|DEVICE|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
57772655|NCT01717183|DEVICE|Placebo URGO 310 3113 dressing|
57772656|NCT04949139|DRUG|Dextrose 5% in water|Reducing the sodium concentration
57772657|NCT05666544|OTHER|Web-based patient decision aid|After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
57772658|NCT05666544|OTHER|Written health education leaflets|After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
57772659|NCT02231437|DRUG|Berodual®|
57772660|NCT01564745|OTHER|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
57772661|NCT02359019|BIOLOGICAL|Pembrolizumab|Given IV
57772662|NCT02359019|OTHER|Laboratory Biomarker Analysis|Correlative studies
57772663|NCT04946955|OTHER|Application and website with or without promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
57772664|NCT04220671|BIOLOGICAL|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
57772665|NCT04220671|OTHER|Saline|0.9% NaCl
57772666|NCT04237974|DEVICE|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
57785294|NCT05995340|OTHER|Saline Active Control|Intradermal Injections
57772667|NCT06489093|DRUG|NSF|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
57772668|NCT06489093|DRUG|SDF+KI|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
57772669|NCT06489093|OTHER|Control group|Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
57772670|NCT00296842|BEHAVIORAL|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
57772671|NCT05880953|BEHAVIORAL|Parent-to-parent coaching|Parents and parent coaches will meet as needed via the family's preferred method. Engagement may include text messaging, phone conferencing, Zoom conferencing, or occasional in-home or hospital visiting as preferred. Coaching sessions will vary based on family desired frequency and location, but may include: on-site in the family home or hospital room, telephone or video conferencing, or asynchronous contacts via email or text messaging. The template for the intervention includes an initial introductory session which is intended to build rapport and orient the parent to our program. Subsequent session topics may include: addressing specific needs including topics of interviewing and selecting home health agencies, expectation setting for home based nursing care, recruiting for home health team from inpatient settings, and recruiting for home health team from professional and personal networks.
57772672|NCT02224482|BEHAVIORAL|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
57772673|NCT05623137|DEVICE|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
57772674|NCT05623137|DEVICE|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy \& Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
57772675|NCT05623137|OTHER|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
57772676|NCT04109742|DRUG|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
57772677|NCT04109742|DRUG|Placebo curcumin capsule|matching placebo to active curcumin capsules
57772678|NCT00258440|DRUG|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
57772679|NCT00258440|DRUG|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
57772680|NCT06257719|OTHER|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
57772681|NCT05912114|DRUG|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
57772682|NCT05912114|DRUG|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
57772683|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream|Patients using Hirudoid® alone
57772684|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
57772685|NCT04555512|OTHER|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
58459201|NCT06107777|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
57772686|NCT04555512|OTHER|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
57772687|NCT02611310|OTHER|No intervention|No intervention administered in this study.
57772688|NCT05858203|OTHER|ATAC-seq and ChIP-seq|CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.
57772689|NCT00996580|DRUG|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
58459202|NCT06107777|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
57772690|NCT01923428|DRUG|AZD1722|
57772691|NCT01923428|DRUG|Placebo|
57772692|NCT01170884|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
57772693|NCT01170884|DRUG|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
57772694|NCT05216926|OTHER|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
57772695|NCT05216926|OTHER|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
57772696|NCT00675727|BIOLOGICAL|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
57772697|NCT03497884|DEVICE|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
57772698|NCT00624663|DRUG|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
57772699|NCT04931459|DRUG|ACU193|Intravenous ACU193
57772700|NCT04931459|DRUG|Placebo|Intravenous Placebo
57772701|NCT04375982|DIAGNOSTIC_TEST|Venepuncture|Blood tube will be collected from standard venepuncture
57772702|NCT04375982|DIAGNOSTIC_TEST|Fingerstick|Capillary blood will be collected by fingerstick
57772703|NCT02963051|DRUG|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
57772704|NCT02963051|DRUG|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
57772705|NCT02963051|DRUG|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
57772706|NCT04066985|BEHAVIORAL|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
57772707|NCT04066985|BEHAVIORAL|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
57772708|NCT04066985|BEHAVIORAL|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
57772709|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
57772710|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
57772711|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
57772712|NCT04789577|BIOLOGICAL|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
57772713|NCT04789577|BIOLOGICAL|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
57772714|NCT04789577|DRUG|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
57772715|NCT04202744|OTHER|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
57772716|NCT04083963|DRUG|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
57772717|NCT04083963|DRUG|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
57772718|NCT04083963|DRUG|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
57772719|NCT04083963|DRUG|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
58459203|NCT01890343|DRUG|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
58459204|NCT01890343|DRUG|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
58459205|NCT03587376|DRUG|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
58459206|NCT00217958|BEHAVIORAL|SHS reduction intervention based on social cognitive learning theory|
58459207|NCT02490683|DIETARY_SUPPLEMENT|Luna Rich X|
58459208|NCT02490683|DIETARY_SUPPLEMENT|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
58459209|NCT02490683|DIETARY_SUPPLEMENT|Reliv Now|
58459210|NCT01912066|DRUG|Stillen|
58459211|NCT01912066|DRUG|Cytotec (reference drug)|
58459212|NCT01912066|DRUG|NSAID (Aceclofenac)|
57772720|NCT04155437|BEHAVIORAL|Health Facility Level Interventions|"* Intensified counseling on maternal dietary diversity and quality using job aids~* Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~* Distribution/prescription of IFA tablets at each ANC visit~* Use of pill card/reminders for pregnant women and their spouses~* Monthly IFA tablet stock monitoring to assure sufficient supplies~* Measurement of weight gain during each ANC visit and advise on healthy weight gain~* Checks for functioning scales and use of monitoring sheets~* Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~* Reminder on importance of early ANC attendance and 4+ visits"
57772721|NCT04155437|BEHAVIORAL|Community Level Interventions|"* Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~* Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~* Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~* Early identification of pregnant women~* Support women's group discussions~* 2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
58459213|NCT02517918|DRUG|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
58459214|NCT04789707|BEHAVIORAL|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
58459215|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
58459216|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
58459217|NCT03678272|PROCEDURE|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
58459218|NCT03678272|PROCEDURE|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
58459219|NCT05233865|BEHAVIORAL|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
58459220|NCT05233865|BEHAVIORAL|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
58459221|NCT02468817|PROCEDURE|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
58459222|NCT02468817|PROCEDURE|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
58459223|NCT01045486|DRUG|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
58459224|NCT01045486|DRUG|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
58459225|NCT01045460|BIOLOGICAL|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
58459226|NCT01045460|BIOLOGICAL|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
58459227|NCT01045460|DRUG|Cyclophosphamide|Administered at 2.5 g/m\^2.
58459228|NCT01045460|BIOLOGICAL|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
58459229|NCT01045460|PROCEDURE|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
58459230|NCT01045460|DRUG|Melphalan|100 mg/m\^2/day given on Days -2 and -1.
58459231|NCT01045460|BIOLOGICAL|Autologous stem cell transplant|Infused on Day 0.
58459232|NCT05093816|BEHAVIORAL|Common Elements Toolbox|The Common Elements Toolbox (COMET) is an online single-session intervention. It is entirely self-guided and lasts about 60 minutes. Participants complete a series of reading and writing exercises focused on four modules: cognitive restructuring, behavioral activation, gratitude, and self-compassion. The intervention is entirely unguided and completed in a single sitting.
58459233|NCT02160756|DRUG|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
58459234|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
58459235|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
58459236|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
58459237|NCT01469221|DRUG|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
58459238|NCT01469221|DRUG|Placebo|6 weekly multi-instillation of matching placebo in 40mL
58459239|NCT01417546|DRUG|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
58459240|NCT02542046|DRUG|Barium|Administration of barium oral contrast agent prior to CT scan
58459241|NCT02542046|DRUG|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
58459242|NCT02542046|DRUG|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
58459243|NCT04875884|DEVICE|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
57772722|NCT04155437|BEHAVIORAL|Health System Level Interventions|"* Training on nutrition interventions during ANC for all ANC providers and community health workers~* Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~* Quarterly supportive supervision of health facility staff by the health district management team~* Monthly supportive supervision of ASBCs~* Monthly review between health facilities and ASBCs~* Training and use of data registers~* Training and use of mother's cards to record up to 8 ANC visits and nutrition services~* Training on data utilization to improve coverage and quality"
57772723|NCT01500746|PROCEDURE|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
57772724|NCT01500746|OTHER|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
57772725|NCT05808335|DRUG|Standard of care|"The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)"
57772726|NCT06042868|OTHER|Nursing protocol|Emergency nursing protocol
57772727|NCT04854538|DRUG|Ekmasonid|1 extended release tablet contains 9 mg Budesonide
57772728|NCT04854538|DRUG|Uceris (first dose)|1 extended release tablet contains 9 mg Budesonide
57772729|NCT04854538|DRUG|Uceris (second dose)|1 extended release tablet contains 9 mg Budesonide
57772730|NCT04009005|BEHAVIORAL|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
57772731|NCT03183557|DRUG|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
57772732|NCT03183557|DRUG|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
57772733|NCT02329106|DEVICE|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
57772734|NCT06309030|DRUG|Bushen quhan zhiwang decoction|Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
57772735|NCT06309030|DRUG|Bushen quhan zhiwang decoction placebo|Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
57772736|NCT02926664|OTHER|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
57772737|NCT05142670|PROCEDURE|experimental group: task-oriented training individualized by the gravity perception|All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
57772738|NCT05142670|PROCEDURE|control group: visual feedback treatment|Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
57772739|NCT02312674|DIETARY_SUPPLEMENT|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
57772740|NCT05565274|DRUG|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
57772741|NCT03978026|BEHAVIORAL|Nap|Each participant is compared to himself in 4 conditions,
57772742|NCT05865457|DEVICE|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
57772743|NCT05865457|DEVICE|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
57772744|NCT00361361|DEVICE|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
57772745|NCT04583683|BEHAVIORAL|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
57772746|NCT04583683|PROCEDURE|Metabolic Surgery|Patients will undergo metabolic surgery
57772747|NCT04093141|PROCEDURE|IRE|in situ irreversible electroporation
57772748|NCT03816241|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
57772749|NCT03816241|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
57772750|NCT01719900|DIETARY_SUPPLEMENT|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
57772751|NCT01719900|DIETARY_SUPPLEMENT|Control|Control biscuit with no yellow pea hull fibre.
57772752|NCT04563806|DEVICE|Magnetic Resonance Imaging|Undergo MRI-guided surgery
57772753|NCT04563806|PROCEDURE|Therapeutic Conventional Surgery|Undergo spinal surgery
57772754|NCT04830605|BEHAVIORAL|Internet-based treatment|The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
57772755|NCT04581902|DEVICE|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
57772756|NCT01763788|DRUG|Necitumumab|Administered IV
57772757|NCT01763788|DRUG|Gemcitabine|Administered IV
57772758|NCT01763788|DRUG|Cisplatin|Administered IV
57772759|NCT01113619|DRUG|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
57772760|NCT01113619|DRUG|RP-G28 or placebo|Daily dosing
57772761|NCT02301637|DEVICE|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
57772762|NCT06289790|PROCEDURE|Erector Spinae Plane (ESP) block|Erector Spinae Plane (ESP) block for pain management in VATS procedure
57772763|NCT06289790|DRUG|Lignocaine|Lignocaine bolus and infusion for pain management in VATS procedure
57772764|NCT03558958|DRUG|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
57772765|NCT01824914|DEVICE|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
57772766|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
57772767|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
57772768|NCT02076867|BEHAVIORAL|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
57772769|NCT02076867|BEHAVIORAL|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
57772770|NCT03436160|DRUG|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
57772771|NCT03436160|DRUG|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
57772772|NCT03436160|DRUG|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
57772773|NCT00863889|DRUG|Depomedrol injection|1 cc of Depomedrol 80
57772774|NCT00863889|DRUG|Lidocaine, Marcaine|4 cc of each local anesthetic
57772775|NCT03396536|OTHER|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
57772776|NCT04734535|DEVICE|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
57772777|NCT04734535|DEVICE|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
57772778|NCT00183456|BEHAVIORAL|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
57772779|NCT00183456|BEHAVIORAL|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
57772780|NCT03714022|DRUG|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
57772781|NCT01352702|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
57772782|NCT01352702|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
57772783|NCT02909023|BIOLOGICAL|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
57772784|NCT01435057|PROCEDURE|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
57772785|NCT00237484|DRUG|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
57772786|NCT00237484|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
57772787|NCT04392232|DRUG|Convalescent Plasma|"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."
57772788|NCT03694457|PROCEDURE|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
58459244|NCT06316908|DRUG|Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.
58459245|NCT06316908|DRUG|Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
57772789|NCT03694457|PROCEDURE|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
58459246|NCT04827108|OTHER|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
58459247|NCT01271777|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
58459248|NCT01271777|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
58459249|NCT03755921|OTHER|bried and intensive therapy|Speech Therapy Exercises
58459250|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
58459251|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
58459252|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
58459253|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
58459254|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
58459255|NCT03111875|DEVICE|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
58459256|NCT03111875|DEVICE|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
58459257|NCT05606666|OTHER|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
58459258|NCT05234411|OTHER|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
58459259|NCT01572181|DRUG|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"* IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
58459260|NCT05320081|BIOLOGICAL|CD30 CAR-T|"Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10\^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition."
58459261|NCT05320081|DRUG|Camrelizumab|Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
58459262|NCT03742765|BEHAVIORAL|Incentivizing planning|Participants receive bonus incentives for planning their workouts
58459263|NCT03742765|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
57772790|NCT02851160|OTHER|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
57772791|NCT02851160|OTHER|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
57772792|NCT04358341|DRUG|Irinotecan|150 mg/m2 ivdrip every 14 days
57772793|NCT04358341|DRUG|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
57772794|NCT04358341|DRUG|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
57772795|NCT05263076|OTHER|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
57772796|NCT03938064|DRUG|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
57772797|NCT02601586|DRUG|PR Oxycodone|PR Oxycodone
57772798|NCT02601586|DRUG|Levodopa|Levodopa
57772799|NCT02601586|DRUG|Oxycodone Placebo|Placebo of PR Oxycodone
57772800|NCT02601586|DRUG|Levodopa placebo|
57772801|NCT00937170|DEVICE|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
57772802|NCT00937170|DEVICE|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
57772803|NCT00937170|DEVICE|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
57772804|NCT03600038|BEHAVIORAL|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
57772805|NCT03600038|BEHAVIORAL|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
57772806|NCT00424853|DRUG|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
57772807|NCT00424853|DRUG|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
57772808|NCT00594906|DRUG|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
57772809|NCT00594906|DRUG|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
57772810|NCT02368002|BEHAVIORAL|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
57772811|NCT02368002|BEHAVIORAL|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
57772812|NCT02368002|BEHAVIORAL|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
57772813|NCT05611905|COMBINATION_PRODUCT|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
57772814|NCT05611905|DRUG|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
57772815|NCT04478084|BIOLOGICAL|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form:freeze-dried Route of administration: intradermal
57772816|NCT04478084|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried Route of administration: intradermal
57772817|NCT04478084|BIOLOGICAL|Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)|Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular
57772818|NCT04478084|BIOLOGICAL|Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)|Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
57772819|NCT01862458|BIOLOGICAL|tPA alone|
57772820|NCT01862458|BIOLOGICAL|tPA plus dornase|
57772821|NCT02925260|OTHER|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
57772822|NCT03915119|OTHER|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
58459264|NCT00073658|DRUG|Citalopram|
58459265|NCT00073658|DRUG|Risperidone|
57772823|NCT01197989|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
57772824|NCT01197989|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
57772825|NCT04177914|PROCEDURE|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
58459266|NCT02432326|DRUG|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
57772826|NCT04177914|DEVICE|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
57772827|NCT05766072|OTHER|EMOTION Kids coping with anxiety and depression (Kendall et. al, 2013) (Mestrende barn in Norwegian) Martinsen et al, 2014|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
57772828|NCT00073385|DRUG|Pivanex|
57772829|NCT00073385|DRUG|Docetaxel|
57772830|NCT03713372|DRUG|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
57772831|NCT00969345|OTHER|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
57772832|NCT00969345|OTHER|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
57772833|NCT04876885|OTHER|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
57772834|NCT03276663|OTHER|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
57772835|NCT06489340|DRUG|2HPβCD|2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
57772836|NCT02415920|DRUG|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
57772837|NCT02415920|DRUG|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
57772838|NCT02110446|DRUG|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
57772839|NCT02110446|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
57772840|NCT06044220|BEHAVIORAL|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
58459267|NCT02432326|DRUG|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
58459268|NCT04371575|DRUG|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
58459269|NCT02494193|OTHER|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
58459270|NCT02494193|OTHER|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
58459271|NCT02494193|OTHER|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
58459272|NCT02494193|OTHER|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
58459273|NCT02494193|OTHER|Definitive restoration|Definite restoration will be performed using composite.
58459274|NCT06162585|BIOLOGICAL|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
58459275|NCT02987231|PROCEDURE|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
58459276|NCT02987231|DEVICE|ES|Local electric stimulation for 120 seconds, once a day for a week
57772841|NCT06044220|OTHER|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
57772842|NCT03963323|DIETARY_SUPPLEMENT|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
57772843|NCT03963323|OTHER|Placebo|Given PO
57772844|NCT06297681|DRUG|Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin|The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
57772845|NCT02120885|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
57772846|NCT04439006|OTHER|Best Practice|Receive usual care
57772847|NCT04439006|DRUG|Ibrutinib|Given PO
57772848|NCT01446263|PROCEDURE|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
57772849|NCT03853122|OTHER|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
57772850|NCT03853122|OTHER|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
57772851|NCT04912596|DRUG|Albuterol Sulfate inhalation aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
57772852|NCT04912596|DRUG|Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
57772853|NCT04912596|OTHER|Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo|MDI
57772854|NCT04912596|OTHER|Albuterol Sulfate inhalation Placebo|MDI
57772855|NCT04912596|OTHER|Methacholine|Methacholine 100 mg/vial
57772856|NCT06316505|BEHAVIORAL|Oral hygiene motivation with individual oral photograps|Oral photograps was taken at control sessions.
57772857|NCT05713682|PROCEDURE|alveolar ridge preservation|bone grafting at extracted sites
57772858|NCT05284292|DEVICE|GUARDIAN platform|The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
57772859|NCT02401958|OTHER|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
58459277|NCT02987231|DEVICE|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
57772860|NCT00761917|DEVICE|Tear Film Analyzer|tear film images
57772861|NCT01563978|DRUG|fostamatinib|fostamatinib 100 mg twice daily
57772862|NCT01563978|DRUG|placebo|placebo
57772863|NCT03151395|OTHER|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
57772864|NCT01677780|DRUG|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
58459278|NCT01791244|DRUG|Rebif®|
57772865|NCT05428904|OTHER|Virtual Reality Simulation|Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
57772866|NCT04287959|DEVICE|High flow nasal cannula support|airvo2 highflow devices will be used.
57962354|NCT04418700|DEVICE|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
58459279|NCT01067378|OTHER|Peer-led debriefing|
58459280|NCT01067378|OTHER|Expert instructor debriefing|
58459281|NCT01071044|DRUG|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
57772867|NCT06108115|BEHAVIORAL|CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
57772868|NCT01465139|DRUG|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
57772869|NCT04691297|OTHER|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
57772870|NCT04691297|OTHER|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
57772871|NCT05096676|DRUG|Oxytocin: Including placebo|Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
57772872|NCT06124482|DEVICE|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
57772873|NCT01234766|DRUG|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
57772874|NCT01234766|DRUG|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
57772875|NCT01234766|RADIATION|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
57772876|NCT00582491|DRUG|Modafinil|Modafinil 400mg orally every day for 16 days
57772877|NCT00582491|DRUG|Placebo|Placebo orally everyday for 16 days
57772878|NCT01752595|BEHAVIORAL|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
58459282|NCT01071044|DRUG|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
57772879|NCT01752595|OTHER|Preference Based Music Intervention|
57772880|NCT04857112|DRUG|Low Dose MT-1303|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
57772881|NCT04857112|DRUG|High Dose MT-1303|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
57772882|NCT04857112|DRUG|Placebo|Matching placebo, QD (Day 1-85)
57772883|NCT05972733|BIOLOGICAL|HIL-214|HIL-214
57772884|NCT02826018|DRUG|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
57772885|NCT02826018|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
57772886|NCT01735357|DIETARY_SUPPLEMENT|EPA-rich triacylglycerol oil|
57772887|NCT01735357|DIETARY_SUPPLEMENT|Placebo - olive oil (BP specification)|
57772888|NCT01735357|DIETARY_SUPPLEMENT|DHA-rich triacylglycerol oil|
57772889|NCT03760744|PROCEDURE|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
57772890|NCT03760744|PROCEDURE|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
57772891|NCT03488524|DRUG|AMX0035|A combination therapeutic of TUDCA and Sodium Phenylbutyrate
57772892|NCT00951509|OTHER|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
57772893|NCT00004736|DRUG|Nelfinavir mesylate|
57772894|NCT00004736|DRUG|Ethambutol hydrochloride|
57772895|NCT00004736|DRUG|Isoniazid|
57772896|NCT00004736|DRUG|Pyrazinamide|
57772897|NCT00004736|DRUG|Lamivudine|
57772898|NCT00004736|DRUG|Rifabutin|
57772899|NCT00004736|DRUG|Stavudine|
57772900|NCT00004736|DRUG|Zidovudine|
57784395|NCT05656638|BEHAVIORAL|Speech and language therapy|"The treatment focuses on grammatical time marking. The aim of the treatment is to train underlying grammatical time marking processes, which were identified as deficient during a preliminary evaluation. The intervention is composed of 4 steps inspired by models and hypotheses from the literature on the subject. Step 1: temporal adverbial selection, subject must identify the tense encoded in sentences and select the correct adverbial among those proposed. Step 2: selection of inflected verb forms, subject must identify the tense encoded in the sentence and select the correct verb form among those proposed. Step 3: production of inflected verb forms, subject must identify the tense encoded in the sentence and produce inflected verbs. Step 4: semantic narration, subject must describe scenes using verbs inflected according to the previously defined reference time."
57772901|NCT05193084|DEVICE|Heartfelt Device|"The Heartfelt Device is a CE marked device that measures the volume of the foot/lower leg. By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Feet identification software, complemented by manual checks, ensures that photographs are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. For this study, no personal identifiable data will be stored on the device or on the servers used by the device.~The volume readings collected can be presented to the clinical team on a web interface. This is not presented against identifiable data, but only participant ID. However, in the current pilot, volume readings will not be reviewed by the clinical team until the point of data analysis, after the study period."
57772902|NCT05193084|DEVICE|Connected weighing scales|"The connected weighing scales are Xiaomi Smart Scales (CE marked, manufactured by Anhui Huami Informeyshn Technologies).~The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional(s) (the fact that a participant has not used scales regularly in the past is not an exclusion criteria). The weighing scales display weight so that the participants can record the weight in their own heart failure records (paper weight diary).~The study team will check the patient's paper weight diary in case they choose to use another set of scales.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will record patient weight as well as the date and time of the measurements."
57772903|NCT00216320|DEVICE|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
57772904|NCT00216320|DEVICE|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
57772905|NCT00216320|DEVICE|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
57772906|NCT02066532|DRUG|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
57772907|NCT02066532|DRUG|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab \> 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
57772908|NCT00039156|DRUG|ortataxel|
57772909|NCT00361075|DRUG|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
57772910|NCT01228344|OTHER|Artemether-lumefantrine|
57772911|NCT03509792|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
57772912|NCT03509792|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
57772913|NCT02378402|OTHER|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
57772914|NCT04485650|OTHER|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
57772915|NCT04485650|OTHER|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
57772916|NCT04485650|OTHER|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
57772917|NCT02045433|RADIATION|SABR Boost Therapy|"1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
57772918|NCT01250119|DRUG|erlotinib [Tarceva]|150 mg daily, orally
57772919|NCT04529720|BIOLOGICAL|Biological/Vaccine: Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
57772920|NCT04529720|BIOLOGICAL|Biological/Vaccine: Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
57772921|NCT04529720|BIOLOGICAL|Biological/Vaccine: Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
57784396|NCT02344303|DRUG|TRV130|
58129623|NCT00248638|DRUG|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
58459283|NCT04096014|DIETARY_SUPPLEMENT|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
58459284|NCT04096014|OTHER|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
58459285|NCT05767008|OTHER|Sunscreen -R43|Long wear metal oxide particles
58459286|NCT04441359|OTHER|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
58459287|NCT04441359|OTHER|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
57772922|NCT01436123|OTHER|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
57772923|NCT01436123|DEVICE|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
57772924|NCT02030912|DRUG|3 doses of amoxicillin daily for 7 days|
57772925|NCT02030912|DRUG|2 doses of minocycline daily for five days|
57772926|NCT02030912|OTHER|2 doses of placebo daily for five days|
57772927|NCT04532021|DIAGNOSTIC_TEST|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
57772928|NCT01114750|DRUG|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
57772929|NCT02211534|DEVICE|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
57772930|NCT02211534|DEVICE|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
57772931|NCT02951559|DEVICE|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
57772932|NCT04975828|DIAGNOSTIC_TEST|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
57772933|NCT05686525|PROCEDURE|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
57772934|NCT05686525|PROCEDURE|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
57772935|NCT04842864|BEHAVIORAL|Fasting|23 hours fasting
57772936|NCT00277589|DRUG|Levothyroxin-Na|1 tablet 30 minutes before breakfast
58459288|NCT02149381|BEHAVIORAL|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
57772937|NCT00277589|DRUG|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
57772938|NCT00277589|DRUG|Iodide|1 tablet 30 minutes before breakfast
57772939|NCT00277589|DRUG|Placebo|1 tablet 30 minutes before breakfast
57772940|NCT04750993|DIAGNOSTIC_TEST|musculoskeletal ultrasonography|The presence of subclinic synovitis findings in the hand joints was evaluated with musculoskeletal ultrasonography.
57784397|NCT02344303|DRUG|Moxifloxacin|
57784398|NCT02344303|DRUG|Placebo|
58459289|NCT02149381|BEHAVIORAL|Befriending|Social support intervention, sessions once per week
58459290|NCT02149381|OTHER|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
58459291|NCT00697502|DRUG|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
58459292|NCT02424773|DEVICE|High Flow Nasal Canula (HFNC)|
58459293|NCT02424773|DEVICE|Venturi mask|
58459294|NCT02424773|DRUG|Oxygen|
58459295|NCT05966649|OTHER|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
58459296|NCT05966649|OTHER|Placebo|Matching placebo
58459297|NCT00258141|DRUG|Rupatadine|
58459298|NCT00258141|DRUG|Placebo|
58459299|NCT00001572|DRUG|Id-KLH Vaccine|
58459300|NCT00001572|DRUG|QS-21 (Stimulation-QS-21) Drug|
58459301|NCT05534217|BIOLOGICAL|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
58459302|NCT05994612|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
57772941|NCT04415697|DIAGNOSTIC_TEST|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
58459303|NCT05994612|BEHAVIORAL|Services as Usual|Participants will receive services that they would normally receive in the community.
57772942|NCT02313818|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
57772943|NCT04639518|OTHER|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
57772944|NCT04639518|OTHER|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
57772945|NCT03312179|DEVICE|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
57772946|NCT03312179|DRUG|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
57772947|NCT05890898|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
57772948|NCT05890898|DRUG|Nitrous Oxide|Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
57772949|NCT01864863|DRUG|HGP1206|One Bosentan 125 mg tablet
57772950|NCT01864863|DRUG|Traclear|Two Bosentan 62.5 mg tablets
57772951|NCT06028581|OTHER|breastfeeding support system|Using the breastfeeding support system
57772952|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
57772953|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
57772954|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
57772955|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
57772956|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
57772957|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
57772958|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
57772959|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
57772960|NCT02654223|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
57772961|NCT02654223|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
58459304|NCT05244616|OTHER|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
58459305|NCT03958383|BIOLOGICAL|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
57772962|NCT01745315|DEVICE|Advanced bipolar devices|
57772963|NCT04013490|DIETARY_SUPPLEMENT|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
57772964|NCT02795260|BIOLOGICAL|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
57772965|NCT02795260|BIOLOGICAL|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
58459306|NCT03958383|RADIATION|Radiation Therapy|Palliative radiation therapy
58459307|NCT03958383|BIOLOGICAL|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
58459308|NCT03958383|BIOLOGICAL|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
57772966|NCT05232435|OTHER|pilate mat exercise will be performed|pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)
57772967|NCT05232435|OTHER|MET|Will receive MET for hamstring and erectorspinae plus standard treatment
57772968|NCT05232435|OTHER|control group receive standard treatment|electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
57772969|NCT05285254|OTHER|Certified Child Life Specialist Support|Provides psychosocial care to children and families confronting stressful and painful situations
57772970|NCT04213313|DRUG|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
57772971|NCT04213313|DRUG|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
57772972|NCT04213313|DRUG|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
57772973|NCT04213313|DIAGNOSTIC_TEST|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
57772974|NCT04213313|OTHER|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
57772975|NCT04307498|BEHAVIORAL|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, \& Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
57772976|NCT01863043|PROCEDURE|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
57772977|NCT01863043|PROCEDURE|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
57772978|NCT00423852|BIOLOGICAL|filgrastim|
57772979|NCT00423852|DRUG|carboplatin|
57772980|NCT00423852|DRUG|ifosfamide|
57772981|NCT00423852|DRUG|paclitaxel|
57772982|NCT00423852|PROCEDURE|autologous hematopoietic stem cell transplantation|
57772983|NCT00423852|PROCEDURE|peripheral blood stem cell transplantation|
57772984|NCT04356339|DRUG|Interferon-beta-1b (BETASERON, BAY 86-5046)|Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
57772985|NCT03695016|BEHAVIORAL|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
57772986|NCT02096614|DRUG|TBI-1201|TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
57772987|NCT02096614|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
57772988|NCT02096614|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
57772989|NCT01984424|DRUG|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
57772990|NCT01984424|DRUG|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
57772991|NCT01984424|OTHER|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
57772992|NCT01984424|DRUG|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
57772993|NCT01984424|OTHER|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
57772994|NCT01984424|DRUG|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
57772995|NCT02494206|DRUG|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
57772996|NCT05689086|OTHER|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
57772997|NCT05521295|OTHER|no intervention|no intervention in this study
57772998|NCT04205929|DRUG|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
57772999|NCT04205929|DRUG|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
57773000|NCT02150265|BEHAVIORAL|SMART manual cognitive behavioral therapy|
57773001|NCT06050291|DRUG|Fixed-Dose Combination (FDC) Tablet|Obicetrapib/Ezetimibe FDC tablet
57773002|NCT04175353|DIETARY_SUPPLEMENT|Dairy snack|The effects of dairy snack are compared with orange juice.
57773003|NCT04175353|DIETARY_SUPPLEMENT|Berry snack|The effects of two berry snacks are compared with berry soup.
57773004|NCT00224523|DRUG|GW685698X|
57773005|NCT00224523|DRUG|mometasone furoate|
57773006|NCT02204293|DRUG|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
57773007|NCT02204293|DRUG|Placebo|Matching placebo administered subcutaneously.
57773008|NCT04264234|DIAGNOSTIC_TEST|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
57773009|NCT04264234|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
57773010|NCT03379064|BEHAVIORAL|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
57773011|NCT01133574|DRUG|SLV354 capsules|20 mg
57773012|NCT01133574|DRUG|SLV354 capsules|60 mg
57773013|NCT01133574|DRUG|SLV354 capsules|120 mg
57773014|NCT01133574|DRUG|SLV354 capsules|250 mg
57773015|NCT01133574|DRUG|SLV354 capsules|500 mg
57773016|NCT01133574|DRUG|SLV354 capsules|750 mg
57773017|NCT01133574|DRUG|SLV354 capsules|1000 mg
57773018|NCT01133574|DRUG|SLV354 capsules|1250 mg
57773019|NCT01133574|DRUG|Placebo capsules|placebo
57773020|NCT01133574|DRUG|SLV354 capsules|low dose group 1
57773021|NCT01133574|DRUG|SLV354 capsules|high dose group 1
57773022|NCT01133574|DRUG|SLV354 capsules|low dose group 2
57773023|NCT01133574|DRUG|SLV354 capsules|high dose group 2
57773024|NCT01133574|DRUG|Placebo capsules|placebo
57773025|NCT01018563|DRUG|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
57773026|NCT00462046|DRUG|Berberine|
57773027|NCT01235130|DRUG|OMEGA-3|600mg, 2 caps, twice a day
57773028|NCT01235130|DRUG|Placebo soybean oil|600mg, 2caps twice a day
57773029|NCT04376294|DEVICE|Extracorporeal Shockwave Therapy(ESWT)|Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
57773030|NCT04376294|OTHER|Eccentric training of the calf muscle:|The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
57773031|NCT04376294|OTHER|Gastrocnemius, soleus, and hamstring stretch|Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
57773032|NCT02357680|OTHER|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
57773033|NCT05171868|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Each participant in the intervention group will receive 8 individual, weekly EMDR sessions over 8 weeks. Each session will take approximately 60-90 minutes. The sessions will be delivered at a place convenient to the participant. Trained EMDR therapists will deliver the intervention.
57773034|NCT02355522|DRUG|Intrauterine lidocaine|
57773035|NCT02355522|DRUG|Lidocaine gel|
57773036|NCT02355522|DRUG|KY jelly|
57773037|NCT02355522|DRUG|Intrauterine normal saline|
57773038|NCT03112200|PROCEDURE|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
57773039|NCT03112200|PROCEDURE|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
57773040|NCT01673360|DEVICE|Elevate PC|List of AMS prolapse products
57773041|NCT01673360|DEVICE|Mini Arc Pro|List of AMS Urinary Incontinence devices
57773042|NCT01673360|DEVICE|RetroArc|List of AMS Urinary Incontinence devices
57773043|NCT01284140|BEHAVIORAL|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
57773044|NCT01284140|BEHAVIORAL|Usual care|Usual care.
57773045|NCT04738890|BEHAVIORAL|Mindfulness-based cognitive therapy|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing
57773046|NCT04738890|OTHER|Treatment as usual|Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
57773047|NCT01340911|DRUG|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
57773048|NCT01340911|DRUG|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
57773049|NCT04366570|OTHER|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
57773050|NCT05728593|OTHER|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
57773051|NCT05728593|OTHER|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
58459309|NCT02773186|OTHER|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
57773052|NCT03313115|BEHAVIORAL|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
57773053|NCT06274164|DIAGNOSTIC_TEST|Electroencephalography/Polysomnography (EEG/PSG)|Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.
57773054|NCT06274164|PROCEDURE|Skin Biopsy|A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.
57773055|NCT06274164|DIAGNOSTIC_TEST|Blood draw|A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
57773056|NCT01475916|BEHAVIORAL|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
57773057|NCT05924282|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
57773058|NCT00852137|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
57773059|NCT00852137|DRUG|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
57773060|NCT05080673|PROCEDURE|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
57773061|NCT01108510|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
57773062|NCT01108510|DRUG|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
57773063|NCT01108510|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
57773064|NCT01108510|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
57773065|NCT01108510|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
57773066|NCT01108510|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
57773067|NCT06004284|OTHER|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
57773068|NCT06004284|OTHER|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
57773069|NCT02109796|DEVICE|transcranial Direct current stimulation|
57773070|NCT05065385|DIAGNOSTIC_TEST|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
57773071|NCT04263090|DRUG|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
57773072|NCT04263090|DRUG|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
57773073|NCT02802319|DEVICE|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
58459310|NCT04532307|BEHAVIORAL|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
57773074|NCT02802319|DEVICE|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
57773075|NCT01017653|DRUG|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
57773076|NCT01017653|DRUG|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
57773077|NCT05094193|PROCEDURE|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
57773078|NCT05094193|PROCEDURE|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
57773079|NCT05094193|PROCEDURE|Trocar site infiltration placebo|20 mL of normal saline
57773080|NCT05094193|PROCEDURE|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
57773081|NCT05559437|DRUG|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
57773082|NCT00828906|DRUG|DuoTrav|DuoTrav Eye Drops
57773083|NCT06038903|OTHER|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
57773084|NCT02571621|DEVICE|Combitube|Intubation with Combitube
57773085|NCT01018641|BIOLOGICAL|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
57773086|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
57773087|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
57773088|NCT01018641|BIOLOGICAL|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
57773089|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
57773090|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
57773091|NCT01018641|BIOLOGICAL|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
57773092|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
58459311|NCT04532307|BEHAVIORAL|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
58459312|NCT04532307|BEHAVIORAL|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
58459313|NCT04532307|BEHAVIORAL|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
58459314|NCT01991392|DEVICE|Nasogastric tube|For nasogastric decompression.
58459315|NCT01991392|DEVICE|No nasogastric tube|For nasogastric decompression.
57773093|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
57773094|NCT01018641|BIOLOGICAL|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
57773095|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
57773096|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
57773097|NCT01018641|PROCEDURE|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
57773098|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
57773099|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
57773100|NCT05490693|OTHER|Experimental group|Experimental group: 26 control group group: 26
57773101|NCT04911062|DRUG|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
57773102|NCT04911062|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
57773103|NCT04911062|DEVICE|Luer Lock Applicator|Applicator for instillation.
57773104|NCT04867785|DRUG|LY3437943|Administered SC
58459316|NCT01207700|BEHAVIORAL|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
58459317|NCT03206216|DIAGNOSTIC_TEST|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
57773105|NCT04867785|DRUG|Dulaglutide|Administered SC
57773106|NCT04867785|DRUG|Placebo|Administered SC
57784399|NCT01439711|DRUG|letrozole|
57784400|NCT01439711|PROCEDURE|MRI|
57784401|NCT01439711|PROCEDURE|conventional surgery|
57784402|NCT00555204|DRUG|ABT-089|10 mg - capsules once daily for 12 weeks
57784403|NCT00555204|DRUG|ABT-089|5 mg - capsules once daily for 12 weeks
57784404|NCT00555204|DRUG|ABT-089|15 mg - capsules once daily for 12 weeks
57784405|NCT00555204|DRUG|ABT-089|20 mg - capsules once daily for 12 weeks
57784406|NCT00555204|DRUG|ABT-089|30 mg - capsules once daily for 12 weeks
57784407|NCT00555204|DRUG|ABT-089|35 mg - capsules once daily for 12 weeks
58459318|NCT03327909|BEHAVIORAL|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
57773107|NCT04255082|OTHER|assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.|"Effectiveness of the mindfulness-based intervention which will be assessed by:~Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.~Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study."
57773108|NCT02861391|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
57773109|NCT02861391|DEVICE|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
57773110|NCT01004250|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
57773111|NCT01004250|DRUG|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
57773112|NCT01004250|DRUG|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
57773113|NCT06122532|PROCEDURE|Stem cell preparation combined with Reticular skin|The dose of transplanted stem cells per wound (100cm2) is 1×10\^6, then cover the wound with autologous regular skin.
57773114|NCT06122532|PROCEDURE|Stem cell preparation combined with MEEK skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous MEEK skin.
57773115|NCT06122532|PROCEDURE|Stem cell preparation combined with split-thickness skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous split-thickness skin.
57773116|NCT06122532|PROCEDURE|autologous skin grafting|After cleaning the wound, use autologous skin (Reticular skin/MEEK skin/split-thickness skin) grafting and cover the wound surface。
57773117|NCT05716789|PROCEDURE|CPR|CPR in cardiac arrest patients
57773118|NCT01335295|DRUG|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
57773119|NCT00599547|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
57773120|NCT01808976|OTHER|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
57773121|NCT01808976|BEHAVIORAL|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
57773122|NCT01808976|BEHAVIORAL|Basic health push app|This is an app that send daily tips for improving your mood.
57773123|NCT04180839|BEHAVIORAL|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
57773124|NCT04180839|BEHAVIORAL|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
57773125|NCT03548064|OTHER|Placebo|Placebo
57773126|NCT03548064|OTHER|Placebo|Placebo
57773127|NCT03548064|OTHER|Placebo|Placebo
57773128|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
57773129|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
57784408|NCT00555204|DRUG|placebo|placebo - capsules once daily for 12 weeks
57962355|NCT01307969|DRUG|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
58459319|NCT00634439|DRUG|atomoxetine|
58459320|NCT00634439|DRUG|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
58459321|NCT00634439|OTHER|No intervention (general population)|
58459322|NCT04421079|DIETARY_SUPPLEMENT|Trans-resveratrol|150mg, 300mg, 450mg
58459323|NCT04421079|DIETARY_SUPPLEMENT|Concord grape juice|8 oz, 16 oz, 24 oz
58459324|NCT04421079|DIETARY_SUPPLEMENT|Grape seed polyphenol extract|450mg, 900mg, 1200mg
58459325|NCT04421079|DRUG|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
58459326|NCT00004838|DRUG|succimer|
58459327|NCT04942587|BEHAVIORAL|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
58459328|NCT02322281|DRUG|Rociletinib|
58459329|NCT02322281|DRUG|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
58459330|NCT00875186|OTHER|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
58459331|NCT00875186|OTHER|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
57773130|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
57773131|NCT04421937|BEHAVIORAL|Procedure: Traditional Dysphagia Therapy (TDT)|"Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks."
57773132|NCT04421937|DEVICE|Procedure: Neuromuscular Electrical Stimulation with TDT|The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
57773133|NCT03712540|DRUG|BMS-986278|Oral administration 30 mg
57773134|NCT03712540|DRUG|Rifampin|Oral administration 600 mg
57773135|NCT00211601|BEHAVIORAL|Disease Management Assessment|
57773136|NCT03636945|OTHER|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
57773137|NCT01247493|DRUG|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
57773138|NCT03514407|DRUG|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
57773139|NCT00335205|DRUG|ropinirole|
57773140|NCT04132570|DRUG|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.
57773141|NCT04132570|OTHER|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.
57773142|NCT05896917|DEVICE|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
57773143|NCT05896917|DEVICE|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
57773144|NCT00479089|DRUG|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
57773145|NCT00479089|DRUG|ZD1839|250 mg by mouth daily, without break.
57773146|NCT00479089|DRUG|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
57773147|NCT02600182|DEVICE|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
57773148|NCT01290536|DEVICE|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
57773149|NCT02004743|BEHAVIORAL|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
58459332|NCT02843724|OTHER|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
58459333|NCT02843724|OTHER|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
57773150|NCT02004743|OTHER|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
58459334|NCT06234033|BEHAVIORAL|Discrimination Acuity test|Estimating the just-noticeable difference of auditory loudness and vibrotactile displacement to fit a psychometric function for each modality with parameters: threshold, slope, sensitivity, and response criterion.
58459335|NCT06234033|DIAGNOSTIC_TEST|Transiently Evoked Otoacoustic Emission|Examination of integrity of outer hair cells in the inner ear; with and without contralateral suppression.
58459336|NCT06234033|OTHER|Questionnaires|Caregiver questionnaires send to parents online to acquire demographic information Autism Quotient (AQ), Child Behavior Checklist (CBCL6-16), Sensory Profile 2 (SP-2).
57773151|NCT01770990|BEHAVIORAL|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
57773152|NCT01770990|BEHAVIORAL|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
57773153|NCT01242176|DRUG|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
57773154|NCT01242176|DRUG|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
57773155|NCT05646992|PROCEDURE|Uterine Allotransplantation|Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
58459337|NCT06234033|BEHAVIORAL|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|Estimates intelligence quotient
58459338|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ASD|Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2)
58459339|NCT06234033|OTHER|Electroencephalography (EEG) with auditory or vibrotactile stimuli|Two paradigms will be used: an auditory frequency tagging paradigm with interspersed pitch oddballs and a classical sensory gating paradigm with either vibrotactile stimuli or auditory clicks.
58459340|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ADHD|ADHD-Rating Scale (ADHD-RS)
57773156|NCT05646992|DRUG|Tacrolimus|Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
57773157|NCT05646992|DRUG|Imuran|Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
58459341|NCT02773381|DRUG|semaglutide|Oral administration once-daily.
58459342|NCT02773381|DRUG|placebo|Oral administration once-daily.
58459343|NCT04562922|DIETARY_SUPPLEMENT|Lifemel|
58459344|NCT02805686|DEVICE|spectral domain optical coherence tomography|
58459345|NCT02805686|DEVICE|multifocal electroretinogram|
58459346|NCT03651635|DIAGNOSTIC_TEST|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1
58459347|NCT04974736|BEHAVIORAL|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
58459348|NCT04527640|DIETARY_SUPPLEMENT|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
58459349|NCT04527640|OTHER|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
58459350|NCT05876481|DRUG|Psilocybin|Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
58459351|NCT02536612|OTHER|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
58459352|NCT02536612|OTHER|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
58459353|NCT03602677|DEVICE|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
58459354|NCT02656017|DRUG|Metformin|Monitoring of tolerability and symptoms.
58459355|NCT02656017|OTHER|Placebo|Monitoring of tolerability and symptoms.
58459356|NCT04504422|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
58459357|NCT01526447|PROCEDURE|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
58459358|NCT01526447|PROCEDURE|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
58459359|NCT05681650|BIOLOGICAL|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D
58459360|NCT05681650|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
58459361|NCT05681650|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
58459362|NCT05681650|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
58459363|NCT04772872|OTHER|Assessment by Brazelton neonatal behavior for group A,Band C|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
58459364|NCT06119126|DRUG|SDF1|Topical SDF application
58459365|NCT06119126|DEVICE|Diode Laser|Irradiating Enamel by Diode laser
58459366|NCT06119126|DRUG|Pit Fissure Sealant|Sealing occlusal pits and fissures
58459367|NCT04675970|OTHER|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
58459368|NCT00430105|DRUG|cyclophosphamide|
57773158|NCT00084734|DRUG|capecitabine|Oral
57773159|NCT00084734|DRUG|cisplatin|IV
57773160|NCT00084734|DRUG|docetaxel|IV
57773161|NCT02562963|BIOLOGICAL|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
57773162|NCT00398775|PROCEDURE|antibiotic discontinuation|
57773163|NCT00362102|DRUG|Cetuximab|
57773164|NCT00385450|DRUG|Nelfinavir/placebo|1250mg/twice each day/four days.
57773165|NCT02765490|DRUG|AL-335|AL-335 800 mg (2\*400) tablet will be administered once daily.
57773166|NCT02765490|DRUG|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
57773167|NCT02765490|DRUG|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
57773168|NCT01839968|OTHER|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
57773169|NCT05012215|PROCEDURE|Paravertebral|Ultrasound-guided paravertebral block
57773170|NCT05012215|PROCEDURE|Caudal block|Caudal block
57773171|NCT01586338|DRUG|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
57773172|NCT02693340|BIOLOGICAL|sampling|"• Sampling period(s):~* Blood: W0, W6, W14, W30 and W52 and relapse.~* Biopsies and fecal: W0, W14 and M52 and relapse."
57773173|NCT04035655|BEHAVIORAL|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
57773174|NCT04035655|DIAGNOSTIC_TEST|Electrophysiological recordings|"The electrophysiological assessment consisted of:~* a 5 minutes resting state high-density EEG recording~* a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
57773175|NCT00404534|DRUG|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
57773176|NCT04596787|PROCEDURE|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
57773177|NCT01607385|DRUG|GSK2330672|BID, repeat doses
57773178|NCT01607385|DRUG|Placebo|BID, repeat doses
57773179|NCT01607385|DRUG|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
57773180|NCT05183737|DIETARY_SUPPLEMENT|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
57773181|NCT05142410|DIAGNOSTIC_TEST|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
57773182|NCT05857579|PROCEDURE|Microblepharoexfoliation|MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
57773183|NCT05857579|PROCEDURE|Intense pulse light|IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
57773184|NCT05857579|PROCEDURE|Meibomian gland expression|Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
57773185|NCT05857579|DRUG|Home-based therapy|Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
57773186|NCT02271750|PROCEDURE|lumbar puncture|for spinal fluid
57773187|NCT02894320|BEHAVIORAL|Behavioral observation|
57773188|NCT05364619|DRUG|Qingre Huashi Granules combined the modified dual therapy|Qingre Huashi Granules combined the modified dual therapy for 14 days
57773189|NCT05364619|DRUG|Bismuth containing quadruple therapy|Bismuth containing quadruple therapy for 14 days
57773190|NCT00380341|PROCEDURE|Instrument-applied spinal manipulative therapy|
57773191|NCT03117517|DRUG|Metformin|Metformin (1000 mg)
57773192|NCT03117517|DRUG|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
57773193|NCT04848662|DRUG|BDA MDI (PT027) 160/180 μg|Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
57773194|NCT04848662|DRUG|Pulmicort Respules 0.5 MG/ML Inhalation Suspension|Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
57773195|NCT04396223|DRUG|Avelumab Injection|Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
57773196|NCT04396223|DRUG|Methotrexate 1 GM Injection|methotrexate administration at 1mg/kg/day during 4 months ½ (median)
57773197|NCT06528561|PROCEDURE|Sef-care program with exercise|Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
57773198|NCT03711864|BIOLOGICAL|IM21 CAR-T cells|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
57773199|NCT02677363|OTHER|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
57773200|NCT05866250|DIAGNOSTIC_TEST|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
57773201|NCT02066350|PROCEDURE|Single pancreas transplantation|
57773202|NCT03930914|DEVICE|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
57773203|NCT05571995|BEHAVIORAL|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
57773204|NCT04453514|BEHAVIORAL|Trauma-informed yoga video recording|Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
57773205|NCT02352662|OTHER|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
57773206|NCT03880318|PROCEDURE|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
57773207|NCT05971134|BEHAVIORAL|Acupreesure applied|Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
58459369|NCT03342586|DIAGNOSTIC_TEST|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
57773208|NCT03434613|DRUG|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
57773209|NCT03434613|DRUG|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
57773210|NCT01703702|DRUG|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
57773211|NCT05756543|BEHAVIORAL|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
58459370|NCT03342586|OTHER|Auditory Attention and Executive Functions Test|"* Trail Making Test (Parts A \& B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~* Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~* Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
57773212|NCT06208345|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
57773213|NCT00332215|DRUG|Inhaled Sodium Pyruvate|
57773214|NCT05158439|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58459371|NCT03342586|OTHER|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
57773215|NCT05643963|OTHER|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
57773216|NCT05285202|OTHER|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
57773217|NCT04315246|BIOLOGICAL|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
57773218|NCT06159413|DEVICE|VIRTUAL REALITY|LUMBAR MULTIFIDUS MUSCLES FUNCTION AMONG PATIENTS WITH LOW BACK PAIN: VIRTUAL REALITY VERSUS STABILIZATION EXERCISES.
57773219|NCT04718714|DRUG|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
57773220|NCT04718714|DRUG|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
57773221|NCT04718714|DRUG|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
57773222|NCT06012864|PROCEDURE|PNL|percutaneous extraction of the stones in the kidney
57773223|NCT05891418|BEHAVIORAL|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
58459372|NCT03342586|OTHER|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
57773224|NCT05891418|BEHAVIORAL|Standard notice of eligibility determination|No extra outreach during intervention period.
57773225|NCT05882084|DIETARY_SUPPLEMENT|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
57773226|NCT05882084|DIETARY_SUPPLEMENT|Placebo|Placebo
57773227|NCT04622137|PROCEDURE|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
57773228|NCT02351440|DRUG|duloxetine|patients will be randomized to receive either duloxetine or placebo
57773229|NCT02351440|DRUG|placebo|placebo
57773230|NCT03126032|OTHER|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
57773231|NCT01183702|PROCEDURE|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
57773232|NCT01183702|OTHER|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
57773233|NCT01333085|DRUG|carboplatin|
57773234|NCT01333085|DRUG|RAD001|
57773235|NCT01333085|DRUG|paclitaxel|
57773236|NCT03452176|DEVICE|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
57773237|NCT03452176|DEVICE|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
57773238|NCT03452020|DEVICE|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
57773239|NCT05046977|PROCEDURE|Single osteotomy|Single tibial osteotomy
57773240|NCT05046977|PROCEDURE|Double Osteotomy|Double Tibial Osteotomy
57773241|NCT01520389|DRUG|MM-151|MM-151
57773242|NCT01520389|DRUG|MM-151 + irinotecan|MM-151 + irinotecan
57773243|NCT00773955|DRUG|R-(-)-gossypol acetic acid|Given orally
57773244|NCT00773955|OTHER|pharmacological study|Correlative studies
57773245|NCT00773955|OTHER|laboratory biomarker analysis|Correlative studies
57773246|NCT06343337|DIAGNOSTIC_TEST|Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman|Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
57773247|NCT04387539|DRUG|SOF/SMV/DCV/RBV|SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
57773248|NCT03324737|DEVICE|Interactive Smartphone App|"There are six main components to the APP.~* Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~* Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~* Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~* Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~* Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
57773249|NCT04517422|DIETARY_SUPPLEMENT|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
57773250|NCT04517422|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
57773251|NCT05486429|COMBINATION_PRODUCT|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~* Complete history taking with stress on:~  * Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~ * History of intake of lipid lowering drugs.~* Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~* Laboratory Investigation:~  1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~  .2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~* Radiological Investigation:~  1.Abdominal ultrasound.~* FIB - 4 it combines platelets count, ALI, AST and age.~* AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10\^9/L) ×100."
57773252|NCT04756011|OTHER|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
57773253|NCT04521517|BEHAVIORAL|pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning|a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
57773254|NCT05540743|DRUG|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
57773255|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
57773256|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
57773257|NCT01421589|DRUG|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
57773258|NCT03885856|OTHER|single row repair technique|single row repair technique
57773259|NCT03885856|OTHER|double row repair technique|double row repair technique
58129624|NCT00248638|DRUG|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
58129625|NCT01074710|DRUG|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
57773260|NCT03263234|OTHER|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
57773261|NCT04880161|BIOLOGICAL|Ampion|Inhaled Ampion
57773262|NCT04880161|OTHER|Placebo|Inhaled Placebo
58459373|NCT03342586|OTHER|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
57773263|NCT02757521|DRUG|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
57773264|NCT02757521|DRUG|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
57773265|NCT04980716|DRUG|"Multiple cardiovascular drugs related to Golden Triangle"|Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
57773266|NCT04542226|DRUG|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
57773267|NCT02855164|DRUG|Tropifexor (LJN452)|Comparison of different doses of drug
57773268|NCT02855164|DRUG|Placebo|Comparator
57773269|NCT03072758|BEHAVIORAL|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
57773270|NCT04612816|OTHER|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
57773271|NCT00242203|DRUG|Zometa|
57773272|NCT00242203|DRUG|Epirubicin|
57773273|NCT00242203|DRUG|Docetaxel|
57773274|NCT00242203|DRUG|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
57773275|NCT00242203|RADIATION|External beam radiation|
58459374|NCT00510835|PROCEDURE|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
58459375|NCT00510835|PROCEDURE|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
57773276|NCT00242203|PROCEDURE|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
57773277|NCT02489825|PROCEDURE|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
57773278|NCT02489825|PROCEDURE|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
57773279|NCT03029247|DRUG|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
57773280|NCT03029247|DRUG|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
57773281|NCT01763528|OTHER|nutrition intervention|high protein diet
57773282|NCT00641186|DRUG|sodium oxybate|4.5 to 9.0 grams per night
57773283|NCT05286515|OTHER|Hybrid Peroperative PT|The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
57773284|NCT05286515|OTHER|Standard Clinical Practice PT|This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
57773285|NCT04318756|BEHAVIORAL|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
57773286|NCT02906085|DRUG|Endothelin-1|
57773287|NCT02906085|DRUG|Placebo|Isotonic saline
57773288|NCT05225233|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
57773289|NCT05225233|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
57773290|NCT05056090|PROCEDURE|Patients will receive MV in PP|Putting the patient in a prone position
57773291|NCT00899587|DRUG|enalapril|enalapril 5 mg every night
57773292|NCT00899587|OTHER|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
57773293|NCT00899587|DRUG|placebo|
57773294|NCT03897205|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
58129626|NCT01074710|DRUG|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
57773295|NCT03897205|OTHER|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
57773296|NCT06109844|OTHER|Standard of Care|Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
57773297|NCT02858765|OTHER|Application of white polychromatic light for 2h30 at different times of day|
57773298|NCT02817620|DIETARY_SUPPLEMENT|Spirulysat®|
57773299|NCT02817620|DIETARY_SUPPLEMENT|Placebo|
57773300|NCT01989598|OTHER|Laboratory Biomarker Analysis|Correlative studies
57773301|NCT01989598|OTHER|Pharmacological Study|Correlative studies
58459376|NCT00510835|PROCEDURE|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
58459377|NCT00801736|DRUG|Cisplatin, Paclitaxel|"* Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1"
57773302|NCT01989598|DRUG|Trametinib|Given PO
57773303|NCT01989598|DRUG|Uprosertib|Given PO
57773304|NCT06031168|OTHER|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
57773305|NCT06031168|OTHER|uncoated hydrophilic dental implants|Patients treated by uncoated implants
57773306|NCT00439166|DRUG|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
57773307|NCT00439166|DRUG|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
57773308|NCT00439166|DRUG|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
57773309|NCT00439166|DRUG|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
57773310|NCT06611098|DEVICE|Viscosupplements|intra-articular injection
57773311|NCT02164097|DRUG|ODSH|
57773312|NCT00946179|BIOLOGICAL|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
57773313|NCT00467922|DRUG|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
57773314|NCT00467922|DRUG|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
57773315|NCT06469411|BIOLOGICAL|Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)|Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
57773316|NCT06469411|OTHER|4 cc distilled water dissolved in albumin 20%|Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
57773317|NCT00162643|DRUG|zidovudine+lamivudine+lopinavir/ritonavir|
57773318|NCT00162643|DRUG|zidovudine + lamivudine + efavirenz|
57773319|NCT01354106|DEVICE|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
57773320|NCT03559439|BIOLOGICAL|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
57773321|NCT04522713|BEHAVIORAL|Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material|Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
57773322|NCT02626702|OTHER|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
57773323|NCT00519896|DRUG|sunitinib malate|Given PO
57773324|NCT00440089|BEHAVIORAL|Hands-on-Healing|
57773325|NCT03350113|DEVICE|Blood sampling for analysis|Blood Sampling for Analysis
57773326|NCT00817804|DEVICE|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
57773327|NCT03263182|BEHAVIORAL|Introduction of the Safe Childbirth Checklist|"1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
57773328|NCT03603392|OTHER|Physical activity program|
58459378|NCT05851118|BEHAVIORAL|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
58459379|NCT03546985|DEVICE|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
58459380|NCT03546985|DEVICE|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
57773329|NCT03918538|BEHAVIORAL|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
58459381|NCT01428258|OTHER|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
57773330|NCT00841516|OTHER|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
57773331|NCT00841516|BIOLOGICAL|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
57773332|NCT05208385|PROCEDURE|video-assisted umbilical closure|video-assisted umbilical closure
57773333|NCT00701337|DRUG|oestradiol|oestradiol 2 mg oral route 30 days
57773334|NCT00701337|DRUG|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
57773335|NCT03431090|DEVICE|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
57773336|NCT02349724|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
57773337|NCT03304860|OTHER|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
57773338|NCT03459703|BEHAVIORAL|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
57773339|NCT03459703|BEHAVIORAL|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
57773340|NCT03459703|BEHAVIORAL|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
57773341|NCT02696330|DRUG|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
57773342|NCT02696330|DRUG|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
58459382|NCT01428258|OTHER|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
57773343|NCT02696330|DRUG|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
57773344|NCT02105636|DRUG|Nivolumab|
57773345|NCT02105636|DRUG|Cetuximab|
57773346|NCT02105636|DRUG|Methotrexate|
57773347|NCT02105636|DRUG|Docetaxel|
57773348|NCT01473381|DRUG|Vilazodone|Vilazodone was supplied as film-coated tablets.
58459383|NCT03274323|DEVICE|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
58459384|NCT03274323|PROCEDURE|Trabeculectomy|Standard trabeculectomy
58459385|NCT06303336|OTHER|NMES with Dynamic Bracing|The group will receive NMES along with dynamic bracing
58459386|NCT06303336|OTHER|NMES without Dynamic Bracing|The participants will receive NMES on the lower extremity
58459387|NCT06303336|OTHER|Dynamic Bracing Only|This group will receive dynamic bracing only on the lower limb.
57773349|NCT01473381|DRUG|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
57773350|NCT01473381|DRUG|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
57773351|NCT01473381|DRUG|Citalopram|Citalopram was supplied as encapsulated tablets.
57773352|NCT02429245|OTHER|Retrospective study|
57773353|NCT00554333|BIOLOGICAL|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
57773354|NCT00554333|BIOLOGICAL|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
57773355|NCT04813757|OTHER|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
57773356|NCT04813757|OTHER|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
57773357|NCT02851836|BEHAVIORAL|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
57773358|NCT02629068|BEHAVIORAL|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
57773359|NCT03022240|DRUG|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
57773360|NCT03022240|DRUG|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
57773361|NCT03022240|DRUG|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
57773362|NCT03022240|DRUG|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
57773363|NCT02274649|BEHAVIORAL|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
57773364|NCT02274649|BEHAVIORAL|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
57773365|NCT05235763|OTHER|activity coach|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
57773366|NCT05235763|OTHER|sham activity coach|The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
57773367|NCT04282590|DRUG|TRK-750/Placebo|Powder for oral solution
57773368|NCT04282590|DRUG|Placebo/TRK-750|Powder for oral solution
57773369|NCT06305689|PROCEDURE|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
57773370|NCT06305689|PROCEDURE|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
57773371|NCT00661258|BEHAVIORAL|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
57773372|NCT01790321|DEVICE|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
57773373|NCT01617005|DRUG|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
57773374|NCT03892369|OTHER|Ethanol|Ethanol administration
57773375|NCT04048759|BEHAVIORAL|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
57773376|NCT04048759|BEHAVIORAL|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
57773377|NCT04048759|BEHAVIORAL|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
57773378|NCT06479681|BEHAVIORAL|Peer recovery coaching (PRC)|The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.
57773379|NCT06479681|BEHAVIORAL|Brief Intervention (SBIRT)|The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
57773380|NCT03687450|BEHAVIORAL|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
57773381|NCT04248465|DRUG|Placebo|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
57773382|NCT04248465|BIOLOGICAL|Ravulizumab|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
57773383|NCT02591680|OTHER|Neuromuscular training|
57773384|NCT02591680|OTHER|Muscle strengthening|
57773385|NCT02591680|DEVICE|Sensorimotor|
57773386|NCT01539863|OTHER|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
57773387|NCT01539863|OTHER|Treatment as needed|Participants may never receive treatment, there is no upper limit
57773388|NCT02245100|OTHER|Cytology specimen|Correlative studies
57773389|NCT02245100|OTHER|Laboratory biomarker analysis|Correlative studies
57773390|NCT03244241|DRUG|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
57773391|NCT05881135|DRUG|Citicoline|i.v. bolus administration every 12 hours for 5 days.
57773392|NCT05881135|DRUG|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
57773393|NCT01643746|DEVICE|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
57773394|NCT01643746|DEVICE|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
58459388|NCT03296917|DRUG|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
58459389|NCT03296917|DRUG|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
58459390|NCT03154866|DIETARY_SUPPLEMENT|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
58459391|NCT03154866|DIETARY_SUPPLEMENT|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
58459392|NCT01139502|BEHAVIORAL|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
58459393|NCT01139502|BEHAVIORAL|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
58459394|NCT00192881|DEVICE|Bx Sonic & Cypher stent from Cordis|
58459395|NCT00788463|DRUG|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
58459396|NCT00788463|DRUG|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
58459397|NCT02578407|OTHER|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
58459398|NCT02972775|OTHER|no interventions. observational study|
58459399|NCT01848158|DEVICE|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
58459400|NCT01848158|DEVICE|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
58459401|NCT04814303|PROCEDURE|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
58459402|NCT04814303|PROCEDURE|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
58459403|NCT04814303|PROCEDURE|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
57773395|NCT00798486|DEVICE|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
57773396|NCT05913856|OTHER|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
57773397|NCT05913856|OTHER|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
57773398|NCT02770092|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
57773399|NCT03662997|DEVICE|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
57773400|NCT03662997|DEVICE|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
57773401|NCT03662997|DEVICE|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
57773402|NCT05878223|DEVICE|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
57773403|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
57773404|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
57773405|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
57773406|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
57773407|NCT02600858|BEHAVIORAL|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
57773408|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.M., single or multiple-dose
57773409|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.N., single or multiple-dose
57773410|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.H., single or multiple-dose
57773411|NCT04453397|DRUG|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
57773412|NCT05815732|OTHER|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
58459404|NCT04549285|BIOLOGICAL|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10\^6 cells/kg (up to a maximum dose of 100x10\^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
57773413|NCT02918929|DRUG|EDP 305|
57773414|NCT02918929|DRUG|Placebo|placebo to match EDP 305
57773415|NCT01117753|BEHAVIORAL|OutPatient Treatment for Adolescents (OPT-A)|
57773416|NCT01117753|BEHAVIORAL|Treatment As Usual|
57773417|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
57773418|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity and healthy eating|"Behavioural Experimental: guidelines-based physical activity:~Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.~Behavioural Experimental: guidelines-based healthy eating:~One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide."
57773419|NCT06345937|BEHAVIORAL|Behavioural: Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
57773420|NCT02011256|DEVICE|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
57773421|NCT04204772|BIOLOGICAL|Activated charcoal and Tap Water|12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
57773422|NCT04204772|BIOLOGICAL|Activated Charcoal and Apple Juice|12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
57773423|NCT04553263|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
57773424|NCT04553263|DRUG|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
57773425|NCT05905887|DRUG|Rivoceranib Mesylate, Paclitaxel|"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."
58459405|NCT02264275|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
57773426|NCT00029575|DEVICE|Surgi-Vision Guidewire Coil|
57773427|NCT00347100|DRUG|Insulin Glargine|Throughout study period
57773428|NCT00347100|DRUG|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
57773429|NCT00347100|DRUG|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
58459406|NCT00190437|DRUG|Amoxicillin-clavulanic|Amoxicillin-clavulanic
58459407|NCT00499486|DRUG|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
58459408|NCT04564664|DRUG|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
58459409|NCT00332072|DRUG|bimatoprost/timolol fixed combination|
58459410|NCT01285141|BIOLOGICAL|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
58459411|NCT04467749|OTHER|Suspension Wheel|Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
57773430|NCT00347100|DRUG|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
57773431|NCT00347100|DRUG|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
57773432|NCT00347100|DRUG|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
57773433|NCT00900081|OTHER|immunohistochemistry staining method|
57773434|NCT00900081|OTHER|laboratory biomarker analysis|
57773435|NCT00900081|OTHER|medical chart review|
57773436|NCT01567943|BEHAVIORAL|Contingency Management|Behavioral reinforcement for alcohol abstinence
57773437|NCT04914052|OTHER|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
57773438|NCT03257293|BEHAVIORAL|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
57773439|NCT03257293|BEHAVIORAL|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
57773440|NCT00003143|DRUG|Amifostine|
57773441|NCT00003143|DRUG|DHAP|
57773442|NCT05351138|DEVICE|TENS|In the study, CE certified tens device with Biolito brand, which is used specifically for incontinence treatment, will be used. The electrodes used during the intervention will be placed to the parasacral region (S2-S4). While the current is given, the power of the device will be gradually increased in 1 mA intervals. The lower value of the stimulation will be 10 mA and the upper value will be 25 mA, and the treatment will be continued with any value that the child can tolerate in this range.
57773443|NCT05351138|OTHER|Massage|The massage will be applied to the abdominal area between the subcostal lower border and the anterior superior of the spina iliaca. Massage techniques are as follows: Abdominal patting, colon patting, colon kneading, colon patting again, abdominal patting again. It will be advanced with deep abdominal strokes, then the starting point will be returned with transverse superficial strokes for the transversus abdominis muscle and oblique superficial strokes for the rectus abdominis muscle, and these strokes will be repeated 3 times each, a total of 6 times. Afterwards, 3 times column brushing, 3 times column kneading and 3 times column plastering will be done, respectively. At the end, a total of 6 abdominal strokes will be performed for both the transversus abdominis and oblique abdominal muscles as in the beginning.
57773444|NCT02952911|DEVICE|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
57773445|NCT01424059|OTHER|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
57773446|NCT04505995|DRUG|Azacitidine and homoharringtonine|Concommitant use of azacitidine and homoharringtonine
57773447|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
57773448|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
57773449|NCT02869113|DRUG|BAY98751 (Y65-110)|10 µL in one eye
57773450|NCT02869113|DRUG|BAY 98751 (Y65-102)|10 µL in one eye
57773451|NCT02869113|DRUG|BAY 98751 (Y65-106)|10 µL in one eye
57773452|NCT02869113|DRUG|Standard shampoo mixture (Control)|10 µL in other eye
57773453|NCT02397460|DRUG|Gefapixant|Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
57773454|NCT02397460|DRUG|Placebo|
57773455|NCT01088529|DRUG|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
57773456|NCT01088529|DRUG|Prednisone|5 mg orally daily.
58459412|NCT04190459|PROCEDURE|LSG|Bariatric surgery
57773457|NCT01088529|DRUG|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
57773458|NCT05653271|DRUG|Cyclophosphamide|Lymphodepleting agent
57773459|NCT05653271|DRUG|Fludarabine|Lymphodepleting agent
57773460|NCT05653271|DRUG|ACE1831|Allogeneic gamma delta T (gdT) cell therapy
57773461|NCT05653271|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
57773462|NCT03108963|DRUG|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
57773463|NCT03108963|DRUG|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
57773464|NCT02778191|DRUG|cisplatin|100 mg/m2 day 1, 22 and 43
58459413|NCT04190459|PROCEDURE|LRYGB|Bariatric surgery
58459414|NCT03935958|DIETARY_SUPPLEMENT|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
58459415|NCT03935958|OTHER|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
58459416|NCT01620060|DRUG|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
58459417|NCT03263546|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
58459418|NCT03263546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
57773465|NCT02778191|DRUG|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
57773466|NCT02778191|DRUG|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
57773467|NCT02694484|OTHER|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
57773468|NCT03957135|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
57773469|NCT03957135|PROCEDURE|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
57773470|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
57773471|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
57773472|NCT01143623|OTHER|Placebo|Placebo
57773473|NCT06061874|DIAGNOSTIC_TEST|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
57773474|NCT04736550|BEHAVIORAL|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
57773475|NCT04736550|BEHAVIORAL|Psychotherapy for Pain (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
57773476|NCT02018237|BEHAVIORAL|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
57773477|NCT02018237|BEHAVIORAL|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
57773478|NCT06449885|OTHER|patients receive optimal treatment or follow-up according to the characteristics of the disease|Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.
57773479|NCT00026897|PROCEDURE|Gamma-camera imaging|
57773480|NCT00026897|PROCEDURE|Low-risk biopsy|
57773481|NCT00586079|PROCEDURE|Deep brain stimulation surgery.|Deep brain stimulation surgery.
57773482|NCT00089895|DRUG|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
57773483|NCT00089895|DRUG|Placebo|intravenous; delivery to match eptifibatide to maintain blind
57773484|NCT04722861|OTHER|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
57773485|NCT02660762|DRUG|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
57773486|NCT02660762|DRUG|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
57773487|NCT02660762|DRUG|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
57773488|NCT02660762|DRUG|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
57773489|NCT02660762|DRUG|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
57773490|NCT02660762|DRUG|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
57773491|NCT02660762|DRUG|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
57773492|NCT02660762|DRUG|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
57773493|NCT02660762|DRUG|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
57773494|NCT02660762|DRUG|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
58459419|NCT04449913|BEHAVIORAL|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
57773495|NCT02660762|DRUG|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
57773496|NCT02660762|DRUG|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
57773497|NCT02660762|DRUG|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
57773498|NCT05410236|OTHER|3D bronchial tree model|A detachable 3D printed bronchial tree model
57773499|NCT02207374|DRUG|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
57773500|NCT02207374|DRUG|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
57773501|NCT03249376|DRUG|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate)
57773502|NCT03249376|OTHER|Placebo|Placebo
58459420|NCT04449913|BEHAVIORAL|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
58459421|NCT05698849|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
58459422|NCT04076085|OTHER|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
58459423|NCT04957446|DEVICE|Sculptra Aesthetic|Injectable implant containing microparticles of poly-L-lactic acid (PLLA)
58459424|NCT04957446|OTHER|Placebo|Saline solution
58459425|NCT03576508|DRUG|CNTX-4975-05|1 mg (2mL) IA injection
58459426|NCT03576508|DRUG|Qutenza|8% topical patch
58459427|NCT03576508|DRUG|Lidocaine (without epinephrine)|15 mL IA injection of 2% lidocaine (without epinephrine)
57773503|NCT03225521|BEHAVIORAL|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
57773504|NCT05765097|DEVICE|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
57773505|NCT00057603|PROCEDURE|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
57773506|NCT04948879|PROCEDURE|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
57773507|NCT05751538|OTHER|No intervention|No intervention
57773508|NCT02978989|PROCEDURE|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
57773509|NCT02978989|PROCEDURE|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
57773510|NCT02341144|PROCEDURE|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
57773511|NCT02341144|PROCEDURE|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
57773512|NCT02341144|DRUG|Ropivacaine|
58459428|NCT04032067|DRUG|GV1001 placebo|0.9 % Normal Saline
58459429|NCT04032067|DRUG|Proscar placebo|PO
58459430|NCT03088891|OTHER|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
58459431|NCT03088891|OTHER|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
58459432|NCT01772966|PROCEDURE|Spinal manipulation|
58459433|NCT04896528|DRUG|Avatrombopag|"* Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment."
58459434|NCT04820595|DIAGNOSTIC_TEST|RASS|Richmond Agitation-Sedation Scale
58459435|NCT04820595|DIAGNOSTIC_TEST|CAM-ICU|Confusion Assessment Method for the ICU
58459436|NCT00056095|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58459437|NCT00056095|DRUG|cyclophosphamide|
58459438|NCT00056095|DRUG|cyclosporine|
58459439|NCT00056095|DRUG|fludarabine phosphate|
58459440|NCT00056095|PROCEDURE|allogeneic bone marrow transplantation|
58459441|NCT00056095|PROCEDURE|peripheral blood stem cell transplantation|
58459442|NCT01865422|OTHER|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
58459443|NCT03536013|OTHER|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
58459444|NCT05323136|DRUG|MT1002 for Injection|single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
58459445|NCT02325596|GENETIC|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
58459446|NCT02372643|OTHER|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
58459447|NCT02834481|DEVICE|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
58459448|NCT01723098|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
57773513|NCT03675243|DIAGNOSTIC_TEST|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
57773514|NCT04887181|OTHER|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
57773515|NCT04887181|OTHER|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
57773516|NCT04887181|OTHER|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
57773517|NCT04651270|DEVICE|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
57773518|NCT04804813|DRUG|Cabozantinib|Cabozantinib tablets
57773519|NCT00839774|OTHER|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
57773520|NCT00839774|OTHER|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
57773521|NCT00839774|OTHER|White wheat flour|White wheat flour will be administered at 50 g/day
57773522|NCT02952573|DRUG|JNJ-42756493|Once daily dosing
58459449|NCT01153386|DRUG|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
57773523|NCT02952573|DRUG|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
57773524|NCT04974814|DRUG|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
57773525|NCT04974814|DRUG|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
57773526|NCT04974814|DRUG|Control Test|patients in control arm will not preloaded with statin in ER before PCI
57773527|NCT01037959|DRUG|Norfloxacin|400 mg/day (per os) for 6 months
57773528|NCT01037959|DRUG|Placebo|1 pill/day (per os) for 6 months
57773529|NCT02546063|OTHER|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
57773530|NCT05178264|DRUG|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
57773531|NCT00859092|DIETARY_SUPPLEMENT|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
57773532|NCT05668364|OTHER|Outdoor cold air exposure|Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
57773533|NCT01758861|DRUG|EPO group|
58459450|NCT00895635|BEHAVIORAL|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
58459451|NCT00895635|BEHAVIORAL|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
58459452|NCT00895635|BEHAVIORAL|Usual Care|Usual care for PAD
58459453|NCT04247386|DRUG|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
58459454|NCT04247386|DRUG|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
58459455|NCT06125366|DRUG|BAY1747846|Single dose; IV injection.
58459456|NCT06125366|DRUG|Matching placebo|Single dose; IV injection.
57773534|NCT01758861|DRUG|Placebo|
57773535|NCT06144944|DRUG|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
57773536|NCT06144944|DRUG|Epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
57773537|NCT03161314|PROCEDURE|Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program|(Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
57773538|NCT03117465|OTHER|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
57773539|NCT03117465|OTHER|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
57773540|NCT06001281|OTHER|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
57773541|NCT03437928|DEVICE|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
57773542|NCT03482817|DRUG|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
57773543|NCT03482817|DRUG|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
57773544|NCT03029260|OTHER|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
57773545|NCT03029260|OTHER|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
57773546|NCT02708589|DIETARY_SUPPLEMENT|probiotic|
57773547|NCT02708589|OTHER|Placebo|
57773548|NCT02685371|BEHAVIORAL|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
57773549|NCT03250351|OTHER|Neural mobilization group|See arm/group descriptions
57773550|NCT03250351|OTHER|Control group|See arm/group descriptions
57773551|NCT01540396|BEHAVIORAL|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
57773552|NCT06310603|OTHER|Low-Processed Food Diet|Participants that receive intervention will be instructed to eat a diet rich in unprocessed/minimally-processed foods, as described by the NOVA food classification system
57773553|NCT05072522|DRUG|SKLB1028|SKLB1028 capsules, oral, once daily in continuous 28-day cycles
57773554|NCT00472186|DRUG|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
57773555|NCT00472186|DRUG|Placebo|Placebo will also be administered based on weight.
57773556|NCT00071240|DRUG|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
57773557|NCT05735457|OTHER|A short, animated storytelling video on dietary sodium|Participants in the Intervention Arm will view a short, animated storytelling video on dietary sodium and the risks of cardiovascular disease due to increased intake of sodium.
57773558|NCT05735457|OTHER|A short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
57773559|NCT03622385|OTHER|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
57773560|NCT06376643|DEVICE|Augmented reality supportive tool|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario.~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
57773561|NCT06376643|OTHER|Conventional method (AHA pocket reference card)|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
57773562|NCT02310893|BEHAVIORAL|Combined Contingency Management and Peer Navigation|
57773563|NCT02310893|BEHAVIORAL|Contingency Management|
57773564|NCT02310893|BEHAVIORAL|Peer Navigation|
57773565|NCT01247441|OTHER|Clinical data|
57773566|NCT02655471|DRUG|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
57773567|NCT00385853|DRUG|PTK787/ZK 222584|Twice daily for each 28-day cycle
57773568|NCT00385853|DRUG|Temozolomide|Daily for each 28-day cycle
57773569|NCT00385853|PROCEDURE|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
57773570|NCT01269814|PROCEDURE|Gastroscopy|Gastroscopy
57773571|NCT04859530|DIAGNOSTIC_TEST|AVC test|The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
57773572|NCT04684641|DRUG|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
57773573|NCT04684641|OTHER|Placebo|Participants will be randomized to receive the placebo.
57773574|NCT02910986|BEHAVIORAL|Written educational brochure|Written educational brochure about breast density
57773575|NCT02910986|BEHAVIORAL|Promotora interaction|Promotora education about breast density
57773576|NCT02406313|OTHER|CTS|Standardized Thermal Cure
57773577|NCT02406313|OTHER|ETP|Patient Therapeutic Education
58129627|NCT03019965|DRUG|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
58129628|NCT03019965|DRUG|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
57773578|NCT01322438|DRUG|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
57773579|NCT00002214|DRUG|Capravirine|
57773580|NCT06384378|DRUG|11C-ER176|ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
57773581|NCT05344989|DRUG|APNmAb005|Administered by IV infusion
57773582|NCT05344989|DRUG|Placebo|Administered by IV infusion
57773583|NCT03418935|DRUG|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
57773584|NCT03418935|DRUG|Ringer's Solution|Intravenous infusion, 400 or 800 ml
57773585|NCT04967625|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
57773586|NCT04967625|DRUG|Anlotinib hydrochloride|A tyrosine kinase inhibitor selectively targeting VEGFR-2
57773587|NCT01486758|DRUG|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
57773588|NCT01486758|DRUG|Placebo|
57773589|NCT03192540|OTHER|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
57773590|NCT02307747|OTHER|blood samples|Blood samples will be collected every 4 hours during 24 h
57773591|NCT00505167|DRUG|Memantine|Patients randomized to receive either memantine or donepezil
57773592|NCT00505167|DRUG|Donepezil|Patients randomized to receive either memantine or donepezil
57773593|NCT04777929|OTHER|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
57773594|NCT02686541|DEVICE|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
57773595|NCT00649389|DRUG|Olmesartan medoxomil|40mg olmesartan medoxomil
57773596|NCT00649389|DRUG|Amlodipine|Amlodipine 10mg
57773597|NCT00649389|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
57773598|NCT00836654|BIOLOGICAL|Catumaxomab (Removab)|Puncture free survival
57773599|NCT00836654|PROCEDURE|paracentesis|
57773600|NCT02162992|OTHER|No intervention|Observational
57773601|NCT05389527|DRUG|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
57773602|NCT02999711|DRUG|REGN3500|REGN3500 dose
57773603|NCT02999711|DRUG|Placebo|Matching placebo
57773604|NCT03940235|DRUG|Androgen deprivation therapy (ADT)|SBRT + ADT
57773605|NCT03940235|RADIATION|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
57773606|NCT04186650|BIOLOGICAL|COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
57773607|NCT05085535|OTHER|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
57773608|NCT05085535|OTHER|Exercise|Exercises for body mobility and muscle toning, Sophrology
57773609|NCT00584805|BIOLOGICAL|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is \< 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
57773610|NCT00566943|DEVICE|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
57773611|NCT00566943|PROCEDURE|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
57773612|NCT04950556|OTHER|Exercise|Pelvic floor muscle exercise will be given to the exercise group
57773613|NCT04950556|OTHER|Control|No intervention
57773614|NCT06056986|DIAGNOSTIC_TEST|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
57773615|NCT03664219|OTHER|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
57773616|NCT03966612|OTHER|Questionnaires|"Questionnaires about:~* Socio-professional situation~* Lifestyle~* Health~* NME 1~* specific breast cancer survey~* Imaging"
58129629|NCT03019965|DRUG|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
58129630|NCT03019965|DRUG|Extended Imipenem|Imipenem administered in 6 hours infusion.
58129631|NCT03019965|DRUG|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
57773617|NCT02938936|OTHER|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
57773618|NCT02540395|DRUG|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
57773619|NCT02540395|DRUG|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
57773620|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
57773621|NCT02540395|DRUG|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
57773622|NCT02540395|DRUG|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
57773623|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
57773624|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
57773625|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
57773626|NCT00710112|GENETIC|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
57773627|NCT06420674|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|"The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments."
57773628|NCT01987596|BIOLOGICAL|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
57773629|NCT03375125|DIETARY_SUPPLEMENT|Probiotic|L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
57773630|NCT03375125|OTHER|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
57773631|NCT00474929|DRUG|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
57773632|NCT00474929|DRUG|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
57773633|NCT00255658|DRUG|sorafenib tosylate|Given orally
57773634|NCT00255658|DRUG|temsirolimus|Given IV
57773635|NCT00255658|OTHER|laboratory biomarker analysis|Correlative studies
57773636|NCT03411824|OTHER|no intervention|Non applicable
57773637|NCT05222425|DRUG|Xagrotin|A herbal compound
57773638|NCT05222425|DRUG|Green tea|Normal green tea
57773639|NCT05389020|OTHER|Newly developed real-size infant's arm and leg manikin|The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
57773640|NCT03034213|DEVICE|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
57773641|NCT03034213|DEVICE|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
57773642|NCT05089058|BEHAVIORAL|Brief, digitally delivered imagery-competing task intervention package, comprised of:|"Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) task procedure: a memory cue followed by playing imagery-competing computer game task with mental rotation instructions. Monitoring of intrusive memories to select hotspot cue, and which intrusion to target.~(ii) accompanying information, including rationale for the brief cognitive task.~(iii) option to use the brief cognitive task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
57773643|NCT05089058|BEHAVIORAL|Brief, digitally delivered relaxation task intervention, comprised of:|"Brief, digitally delivered relaxation task intervention, comprised of:~Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) relaxation exercise task using instruction components from progressive muscle relaxation~(ii) accompanying information, including rationale for the brief relaxation exercise task.~(iii) option to use the brief relaxation exercise task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
57773644|NCT04555590|BEHAVIORAL|H-HOPE Intervention|The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
57773645|NCT02055573|OTHER|Ready To Learn (RTL)|See arm description
57773646|NCT02055573|OTHER|All Babies Cry (ABC)|See arm description
57773647|NCT03039543|DRUG|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
57773648|NCT03039543|DRUG|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
57773649|NCT02071550|DEVICE|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
57773650|NCT02071550|DEVICE|FORESIGHT and INVOS monitor|
57773651|NCT03650660|OTHER|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
57773652|NCT00040092|DRUG|Virulizin®|
57773653|NCT05787938|DEVICE|MRI|A procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. A contrast agent, such as gadolinium, may be injected into a vein to help the tissues and organs show up more clearly in the picture. MRI may be used to help diagnose disease, plan treatment, or find out how well treatment is working. It is especially useful for imaging the brain and spinal cord, the heart and blood vessels, the bones, joints, and other soft tissues, the organs in the pelvis and abdomen, and the breast. Also called magnetic resonance imaging, NMRI, and nuclear magnetic resonance imaging.
57773654|NCT05900219|DRUG|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
57773655|NCT03375632|DRUG|FYU-981|Oral daily dosing for 14 weeks
57773656|NCT03648203|BEHAVIORAL|Technology Enabled Asthma Management System|See description of arm
57773657|NCT06184490|PROCEDURE|Prone position with thoraco-abdominal cushion|Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
57773658|NCT00924560|DRUG|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
57773659|NCT00924560|DRUG|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
57773660|NCT06110741|OTHER|Blood and saliva sampling|Collecting blood and saliva sample
57773661|NCT06110741|OTHER|Survey|Collecting data on infectious diseases during the study period
57773662|NCT01010477|DRUG|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
57773663|NCT01010477|BEHAVIORAL|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
57773664|NCT00282360|DRUG|Trimetazidine|
57773665|NCT05762536|DRUG|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
57773666|NCT05762536|DRUG|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
57962356|NCT04651387|DIETARY_SUPPLEMENT|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
57962357|NCT00445133|DEVICE|Magnetic Sleep Pad|
57773667|NCT02780986|BEHAVIORAL|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
57773668|NCT02780986|BEHAVIORAL|Heterosexual men intervention group|"This will be delivered via 3 main activities:~1. Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~2. Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~3. Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
57773669|NCT00450320|DRUG|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
57773670|NCT01317875|DRUG|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
58459457|NCT01213394|DRUG|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
57773671|NCT03191357|OTHER|n/a observational|Observational study
58459458|NCT01213394|OTHER|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
57773672|NCT04772885|DRUG|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
57773673|NCT04772885|DRUG|KT-474|KT-474 oral tablet(s)
57773674|NCT00723333|PROCEDURE|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
57773675|NCT00042796|DRUG|decitabine|Given IV
57773676|NCT00042796|OTHER|pharmacological study|Correlative studies
57773677|NCT00042796|OTHER|laboratory biomarker analysis|Correlative studies
57773678|NCT05731882|DEVICE|E-SeaLA, CardioPulse PFA system|First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
57773679|NCT05099016|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
57773680|NCT05099016|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
57773681|NCT00018005|BEHAVIORAL|Self-Management|18 in-person group sessions providing self-management training.
57773682|NCT00018005|OTHER|attention control|18 educational mailings follow by a a telephone call.
57773683|NCT03766893|DRUG|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
57773684|NCT03766893|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
58459459|NCT00734435|DRUG|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
57773685|NCT03766893|OTHER|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
57962358|NCT00002559|BIOLOGICAL|filgrastim|
57773686|NCT04186676|OTHER|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
57773687|NCT04186676|DIAGNOSTIC_TEST|CCTA Phenotypes|"1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges"
57773688|NCT04017429|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.
57773689|NCT04017429|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
57773690|NCT03376802|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
57773691|NCT03376802|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
57773692|NCT02609659|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
57773693|NCT02609659|DRUG|ribavirin|Tablet
57773694|NCT05438030|DIAGNOSTIC_TEST|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
57773695|NCT05438030|DIAGNOSTIC_TEST|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
57773696|NCT04114136|DRUG|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
57773697|NCT04114136|DRUG|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
57773698|NCT04114136|DRUG|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
57773699|NCT03124628|OTHER|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
57773700|NCT03124628|OTHER|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
57773701|NCT00192140|BIOLOGICAL|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
57773702|NCT03634137|DRUG|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
57773703|NCT03634137|DRUG|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
57773704|NCT06123572|OTHER|Placebo|Placebo Comparator
57773705|NCT06123572|OTHER|Anti-Ageing and Skin Brightening Gel|Anti-Ageing and Skin Brightening Gel.
57773706|NCT00157274|DRUG|alemtuzumab|
57773707|NCT01647308|DRUG|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
57773708|NCT01647308|DRUG|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
57773709|NCT04526405|DIAGNOSTIC_TEST|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
57773710|NCT03826589|DRUG|Avelumab|an anti-programmed cell death ligand 1
57773711|NCT03826589|DRUG|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
57773712|NCT04752891|OTHER|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
57773713|NCT04752891|OTHER|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
58459460|NCT00734435|DRUG|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
57773714|NCT02125123|OTHER|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
57773715|NCT02125123|OTHER|Counseling|Dietary counseling
57773716|NCT02228473|DRUG|Glycopyrrolate|Glycopyrrolate will be administered.
58459461|NCT03547778|DRUG|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
58459462|NCT03547778|DRUG|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
58459463|NCT02269124|DEVICE|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
58459464|NCT01003158|DRUG|AZD8931|Tablet Oral bid
57773717|NCT02228473|DRUG|Atropine|Atropine will be administered.
57773718|NCT04136652|PROCEDURE|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
57773719|NCT04906109|DRUG|Vemlidy Tab|1T
57773720|NCT04906109|DRUG|DA-2803 Tab|1T
57773721|NCT06421753|DEVICE|SDSS|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
57962359|NCT00002559|DRUG|cisplatin|
57962360|NCT00002559|DRUG|ifosfamide|
57962361|NCT00002559|DRUG|paclitaxel|
57773722|NCT06421753|DEVICE|Standard Electrical Stimulation During Functional Electrical Stimulation|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
57773723|NCT05271838|DIETARY_SUPPLEMENT|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test \>25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
57773724|NCT05271838|DIETARY_SUPPLEMENT|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
57773725|NCT01160120|DRUG|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
57773726|NCT02327273|DRUG|BMS-963272|
57773727|NCT02327273|DRUG|Placebo|
57773728|NCT04188236|DEVICE|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
57773729|NCT04743375|OTHER|wound dressing application|Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
57773730|NCT01432535|DRUG|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
57773731|NCT06076473|DIAGNOSTIC_TEST|Untargeted metabolomics|Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
57773732|NCT03799679|DRUG|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
57773733|NCT03802162|DRUG|CKD-355A (D797/Memantine HCl 20mg)|once a day
57773734|NCT03802162|DRUG|CKD-355B (D797/Memantine HCl 20mg)|once a day
57773735|NCT03802162|DRUG|D797|once a day
57773736|NCT03802162|DRUG|D324 (Memantine HCl 10mg)|twice a day
57773737|NCT02314741|PROCEDURE|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
57773738|NCT01272882|DEVICE|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
57773739|NCT04654546|OTHER|Ultrasound abdominal scan|"A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system."
57773740|NCT01606956|PROCEDURE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
57773741|NCT01606956|PROCEDURE|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
57773742|NCT03358329|COMBINATION_PRODUCT|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
57773743|NCT06275659|DEVICE|CT-100-004-A|Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
57773744|NCT06275659|DEVICE|CT-100-004-B|The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
57773745|NCT02181972|DRUG|Gingko biloba|
57773746|NCT02181972|DRUG|Placebo|
57773747|NCT00722995|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
57773748|NCT00722995|PROCEDURE|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
57773749|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
57773750|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
57773751|NCT02941393|DEVICE|Intrauterine pressure catheter|
57773752|NCT02941393|DEVICE|External tocodynamometry|
57773753|NCT02857660|OTHER|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
58459465|NCT01003158|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off
57773754|NCT02857660|DIETARY_SUPPLEMENT|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
58459466|NCT00111514|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
58459467|NCT00291135|DRUG|letrozole|Letrozole 2.5 mg daily
58459468|NCT04102397|PROCEDURE|Vojta therapy after standard therapy|Vojta Therapy \~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
58459469|NCT04102397|PROCEDURE|Standard therapy|"\~50 minutes/session:~* TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~* Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~* Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~* Cryotherapy (5 minutes)."
58459470|NCT02360566|BEHAVIORAL|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
58459471|NCT04144153|COMBINATION_PRODUCT|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
58459472|NCT04144153|COMBINATION_PRODUCT|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
58459473|NCT05208502|DEVICE|DSA monitor|Next Generation SedLine features an enhanced signal processing engine, which provides processed EEG parameters. This four channel EEG monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan
58459474|NCT00132392|DRUG|ALGRX 4975|
58459475|NCT03481894|DRUG|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
58459476|NCT03481894|DRUG|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
58459477|NCT03268772|DRUG|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
58459478|NCT04126694|BEHAVIORAL|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
57773755|NCT04708301|DIAGNOSTIC_TEST|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
57773756|NCT00115362|DRUG|venlafaxine|
57773757|NCT00735449|DRUG|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
58459479|NCT04199507|OTHER|physical fitness assessment|assessment
58459480|NCT01235091|BEHAVIORAL|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
58459481|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
58459482|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
58459483|NCT01019187|PROCEDURE|Quality-of-Life Assessment|Ancillary Studies
57773758|NCT00735449|DRUG|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
57773759|NCT00735449|DRUG|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
58129632|NCT03019965|DRUG|Extended Meropenem|Meropenem administered in 8 hours infusion.
57773760|NCT03562260|PROCEDURE|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
57773761|NCT05859802|DRUG|Dalfampridine Pill|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
57773762|NCT05859802|DRUG|Placebo|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
57773763|NCT04845295|OTHER|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
57773764|NCT00886262|DRUG|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
57773765|NCT00886262|DRUG|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
57773766|NCT05334823|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
57773767|NCT02240719|DRUG|everolimus|Given PO
57773768|NCT02240719|DRUG|bendamustine hydrochloride|Given IV
57773769|NCT04797819|DIAGNOSTIC_TEST|Coronary plaque components|Coronary plaque components were detected by CCTA method
57773770|NCT04788030|OTHER|Nerve reconstruction|Nerve bridging with muscle-in-vein conduits
57773771|NCT01313611|DRUG|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
57773772|NCT06226142|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
57773773|NCT04783064|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is performed at ipsilateral side of the affected shoulder.
57773774|NCT02359591|OTHER|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
57773775|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the DMPFC or left DLPFC
57773776|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the left DLPFC
58129633|NCT01653665|DRUG|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
58459484|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
58459485|NCT01019187|OTHER|Placebo|Given orally
57773777|NCT02807740|OTHER|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
57773778|NCT02807740|OTHER|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
57773779|NCT01428674|OTHER|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
57773780|NCT01428674|OTHER|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
57773781|NCT04755439|PROCEDURE|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
57773782|NCT05957757|DRUG|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
57773783|NCT05957757|DRUG|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
57773784|NCT02571439|PROCEDURE|Surgical TAP block|surgeon administered TAP block
57773785|NCT02571439|PROCEDURE|Conventional TAP block|Anesthesiologist administered TAP block
57773786|NCT02571439|DRUG|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
58129634|NCT01653665|DRUG|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
58129635|NCT02116803|DRUG|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
58129636|NCT02116803|DRUG|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
58129637|NCT05141864|BIOLOGICAL|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
58459486|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
58459487|NCT01019187|PROCEDURE|Sleep Disorder Therapy|
58459488|NCT01019187|DRUG|Armodafinil|Given orally
58459489|NCT01019187|PROCEDURE|Quality-of-life assessment|Ancillary studies
58459490|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
58459491|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
58459492|NCT01019187|PROCEDURE|Management of Therapy|
58459493|NCT01019187|PROCEDURE|Sleep disorder therapy|
58459494|NCT01019187|PROCEDURE|cognitive assessment|
58459495|NCT01019187|PROCEDURE|Quality of Life assessment|Ancillary Studies
58459496|NCT01019187|OTHER|Questionnaire Administration|Ancillary studies
57773787|NCT06529549|OTHER|Organoid-Based Drug Sensitivity Screening|Residual tissue of bone metastatic sites from biopsies for genetic testing will be collected to culture organoid and perform drug sensitivity screening
57773788|NCT00798356|OTHER|Yoga training|Yoga training for 12 weeks
58459497|NCT01019187|OTHER|Placebo|Given orally
57773789|NCT04142060|DRUG|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
57773790|NCT05789862|BEHAVIORAL|Counseling Sessions|Virtual sessions
57773791|NCT05789862|BEHAVIORAL|Quality of Life Questionnaires|Self administered questionnaires
57773792|NCT04041752|BEHAVIORAL|SOLID|condition with a classical meal served using solid food items
57773793|NCT04041752|BEHAVIORAL|LIQUID_P|condition with a liquid meal served using a powder solution
57773794|NCT04041752|BEHAVIORAL|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
57773795|NCT02218385|DEVICE|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
57773796|NCT01225822|DRUG|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
57773797|NCT01225822|DRUG|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
57773798|NCT01225822|DRUG|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
57773799|NCT01225822|DRUG|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
57773800|NCT01225822|DRUG|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
57773801|NCT02611544|BEHAVIORAL|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
57773802|NCT02611544|BEHAVIORAL|Survivorship Education|6-week survivorship education group (SE; n=32)
57773803|NCT02611544|BEHAVIORAL|Enhanced Usual Care|enhanced usual care (EUC; n=26)
58459498|NCT01019187|PROCEDURE|Fatigue assessment and management|
58459499|NCT01019187|PROCEDURE|Management of therapy and complications|
57773804|NCT03354637|DRUG|ATI-50002 high dose|Topical solution
57773805|NCT03354637|DRUG|ATI-50002 low dose|Topical solution
57773806|NCT03354637|DRUG|Placebo|Topical solution
57773807|NCT05085743|DIAGNOSTIC_TEST|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
57773808|NCT02351882|DRUG|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
57773809|NCT02351882|DRUG|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
57773810|NCT00953420|DRUG|Docetaxel|60 mg/m2 IV on Day 1
57773811|NCT00953420|DRUG|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
57773812|NCT00953420|DRUG|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
57773813|NCT00953420|BIOLOGICAL|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
57773814|NCT00953420|BIOLOGICAL|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for \> 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC \> 2500 cells/ul x 2 days after nadir.
57773815|NCT05002374|OTHER|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
57773816|NCT05002374|OTHER|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
57773817|NCT05568836|DIETARY_SUPPLEMENT|vitamin D supplementation|Intervention group will receive a single IM injection of 300000 IU vitamin D
57773818|NCT05568836|OTHER|control|control group will receive nothing
57773819|NCT01676025|PROCEDURE|PRA|
57773820|NCT01676025|PROCEDURE|LA|
57773821|NCT01927731|DRUG|Eltrombopag Olamine|Given PO
57773822|NCT01927731|OTHER|Laboratory Biomarker Analysis|Correlative studies
57773823|NCT02720289|OTHER|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
57773824|NCT02720289|OTHER|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
57773825|NCT01528644|DIETARY_SUPPLEMENT|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
57962362|NCT00540254|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
58459500|NCT01019187|PROCEDURE|Sleep disorder therapy|
58459501|NCT01019187|DRUG|Armodafinil|Given orally
58459502|NCT01019187|PROCEDURE|Cognitive Assessment|
58459503|NCT01019187|PROCEDURE|Quality of Life Assessment|Quality of Life Assessment
58459504|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
58459505|NCT01019187|PROCEDURE|Fatifue assessment and management|
58459506|NCT05873049|DEVICE|MolecuLight|MolecuLight is a handheld fluorescence imaging device that is utilized to help real-time visualize clinically undetectable fluorescent bacteria in wounds. It emits a 405 nm wavelength of safe violet light, which interacts with the wound tissue and bacteria causing certain bacteria to emit red or cyan fluorescence. The fluorescence signals were then captured by MolecuLight and those with bacteria at levels of ≥ 10\^4 colony forming units per gram (CFU/g) will be detected and displayed on the screen.
57773826|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
57773827|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
58129638|NCT05141864|DRUG|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
57773828|NCT01528644|DIETARY_SUPPLEMENT|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
57773829|NCT00003050|DRUG|cyclophosphamide|
57773830|NCT00003050|DRUG|doxorubicin hydrochloride|
57773831|NCT00003050|DRUG|paclitaxel|
57773832|NCT00003050|DRUG|tamoxifen citrate|
57773833|NCT00003050|PROCEDURE|surgical procedure|
57773834|NCT00003050|RADIATION|radiation therapy|
57773835|NCT01159223|DRUG|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
57773836|NCT00796536|BEHAVIORAL|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
57773837|NCT00796536|BEHAVIORAL|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
57773838|NCT06317350|DRUG|GNS-212-E1|Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.
57773839|NCT06317350|DRUG|GNS-212-E2|Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.
57773840|NCT06317350|DRUG|GNS-212-ER|Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
57773841|NCT02796287|PROCEDURE|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
57773842|NCT02796287|PROCEDURE|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
58129639|NCT05141864|OTHER|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
58129640|NCT04137211|BEHAVIORAL|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
57773843|NCT02796287|RADIATION|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
57773844|NCT01535131|PROCEDURE|palatoplasty|procedure to close cleft palate
57773845|NCT00165295|DRUG|Sildenafil citrate (Viagra)|
57773846|NCT00180713|DRUG|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
57773847|NCT00180713|DRUG|Placebo|Placebo tablet once daily.
57773848|NCT02184663|OTHER|without APA program|Control Arm : chemotherapy alone
57773849|NCT02184663|OTHER|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
57773850|NCT01939782|OTHER|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
57773851|NCT01939782|OTHER|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
57773852|NCT01213043|BIOLOGICAL|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
58129641|NCT04137211|BEHAVIORAL|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
57773853|NCT01213043|BIOLOGICAL|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
57773854|NCT03321513|DRUG|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
57773855|NCT03321513|DRUG|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
57773856|NCT02596022|DRUG|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
57773857|NCT02596022|DRUG|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
57773858|NCT03125590|OTHER|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
57773859|NCT01231685|DRUG|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
57773860|NCT01231685|DRUG|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
57773861|NCT06247332|OTHER|Review of available clinical data sources related to use cases|There will be a review of available clinical data sources related to use cases. In addition, this information will be complemented by a cohort of anonymized retrospective data of 100 cases obtained from the clinical information resulting from the assistance to COVID-19 patients managed by the Primary Care Health District of Sevilla Norte and the Infectious Diseases Department of the Virgen Macarena University Hospital
57773862|NCT03929926|OTHER|Best Practice|receive usual care
57773863|NCT03929926|BEHAVIORAL|Cancer Educational Materials|Receive educational materials via mail
58129642|NCT04137211|BEHAVIORAL|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
58129643|NCT00003584|DRUG|estramustine phosphate sodium|
58129644|NCT00003584|DRUG|prednisone|
58129645|NCT00003584|DRUG|vinorelbine tartrate|
58129646|NCT05425667|OTHER|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
58459507|NCT01101399|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
57773864|NCT03929926|OTHER|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
57773865|NCT03929926|OTHER|Counseling|Undergo decision counseling session
57773866|NCT02892487|OTHER|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
57773867|NCT05950854|DIAGNOSTIC_TEST|Weight-bearing MRI|Four MRI scans with 0.25T scanner: weight-bearing and non-weight-bearing with flexed and extended knee
57773868|NCT04208360|DEVICE|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
57773869|NCT04585490|DRUG|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
57773870|NCT04585490|DRUG|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
57773871|NCT04585490|DRUG|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
57773872|NCT04585490|DRUG|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
57773873|NCT04585490|DRUG|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
57773874|NCT04585490|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
57773875|NCT04585490|DRUG|Tremelimumab|not to exceed 75mg IV on Day 1 of every 21-day cycle
57773876|NCT03259282|BIOLOGICAL|Analysis of gamma globulin|Electrophoresis of proteins
57773877|NCT04249336|DRUG|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
57773878|NCT04249336|DRUG|8% Arginine based dentifrices|Tubular occluding formulation
57773879|NCT04249336|DRUG|8% Strontium Acetate|Tubular occluding formulation
57773880|NCT04249336|DRUG|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
57773881|NCT00720408|DRUG|Prograf-XL|oral
57773882|NCT00720408|DRUG|Prograf|oral
57773883|NCT00720408|DRUG|MMF|oral
57773884|NCT04361513|DRUG|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
57773885|NCT04361513|DRUG|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
57773886|NCT00783471|DRUG|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
57773887|NCT00783471|DRUG|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
57773888|NCT00170937|DRUG|valsartan plus hydrochlorothiazide|
57773889|NCT05414838|DIETARY_SUPPLEMENT|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
57773890|NCT02649387|DRUG|Ibrutinib|Given PO
57773891|NCT02649387|OTHER|Laboratory Biomarker Analysis|Correlative studies
57773892|NCT05843890|BEHAVIORAL|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
57773893|NCT05843890|BEHAVIORAL|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. Participants will be asked to complete surveys over 24 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
57773894|NCT04029558|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
57773895|NCT04029558|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
57773896|NCT01494714|DRUG|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
57773897|NCT01494714|DRUG|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
57773898|NCT01494714|DRUG|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
57773899|NCT01494714|DRUG|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
57773900|NCT01494714|DRUG|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
57773901|NCT01097395|DRUG|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
57773902|NCT02917265|DEVICE|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
57773903|NCT02917265|DEVICE|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
57773904|NCT03511872|OTHER|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
57773905|NCT01381835|DRUG|TMC435|150 mg capsule once daily for 7 days
57773906|NCT00346996|DRUG|insulin levemir / aspart|for subcutaneous injection
57773907|NCT00346996|DRUG|human insulin /insulin isophane|for subcutaneous injection
57773908|NCT00807690|DRUG|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
57773909|NCT00253279|PROCEDURE|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
57773910|NCT03423875|DIAGNOSTIC_TEST|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
57773911|NCT00001495|DRUG|irinotecan (CPT-11)|
57773912|NCT01049061|DRUG|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
57773913|NCT00004220|DRUG|gemcitabine hydrochloride|
57773914|NCT00004220|DRUG|oxaliplatin|
57773915|NCT02381002|OTHER|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
57773916|NCT03728114|DEVICE|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
57773917|NCT03728114|DEVICE|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
57773918|NCT02500212|DRUG|ENVARSUS®|
57773919|NCT02500212|DRUG|ADVAGRAF®|
57773920|NCT00305864|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
57773921|NCT00305864|DRUG|Motexafin Gadolinium|Given IV
57773922|NCT00305864|DRUG|Temozolomide|Given orally
57773923|NCT05596357|OTHER|questionnaires|The patient must answer questionnaires before and after reconstructive surgery
57773924|NCT04666922|DRUG|BI 765080|BI 765080
57773925|NCT04666922|DRUG|Placebo|Placebo; 0.9% saline for injection
57773926|NCT00744237|DRUG|Nebivolol|"* Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
57773927|NCT00744237|DRUG|Metoprolol ER|"* Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
57773928|NCT00744237|DRUG|HCTZ|"* HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
57773929|NCT04896944|OTHER|No intervention|No intervention
57773930|NCT05179044|DEVICE|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
57773931|NCT04367402|OTHER|BioMedomics COVID-19 IgM-IgG Rapid Test|Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
57773932|NCT04723160|DIAGNOSTIC_TEST|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
57773933|NCT05522751|DEVICE|DBS|Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
57773934|NCT04443387|DRUG|Vitamin D|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
57773935|NCT04443387|OTHER|Placebo|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
57773936|NCT00730301|PROCEDURE|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
57773937|NCT04560205|DRUG|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
57773938|NCT02487940|DRUG|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
58129647|NCT02199392|DRUG|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
58129648|NCT05717777|OTHER|There is no intervention, only observational study|There is no intervention, only observational study
58129649|NCT02973893|BIOLOGICAL|Placebo|Placebo
58129650|NCT02973893|BIOLOGICAL|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
58129651|NCT02973893|BIOLOGICAL|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
58129652|NCT00098371|DRUG|alvocidib|
58129653|NCT03714165|DIAGNOSTIC_TEST|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
58129654|NCT05019066|DIETARY_SUPPLEMENT|Herbal Supplementation|A proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa.
57773939|NCT02487940|DRUG|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
57773940|NCT03691285|PROCEDURE|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
57773941|NCT04894461|DEVICE|Moxibustion|The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
57773942|NCT02584855|DRUG|Ixekizumab|Administered SC
57773943|NCT02584855|DRUG|Placebo|Administered SC
57773944|NCT04906369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57773945|NCT00678990|PROCEDURE|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
57773946|NCT04393740|DIAGNOSTIC_TEST|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
57773947|NCT05016011|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
57773948|NCT05016011|PROCEDURE|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
57773949|NCT02406885|DRUG|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
57773950|NCT06428838|BIOLOGICAL|Eptinezumab|The study treatment consists of a single infusion of eptinezumab (100mg/mL).
57773951|NCT06428838|OTHER|Standard of Care|SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.
57773952|NCT05171140|PROCEDURE|Triangular Nail Placement of Femoral Neck|Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
57773953|NCT02746757|OTHER|Remote conditioning|
57773954|NCT02746757|DRUG|Exendin 9-39|
57773955|NCT02715895|DIETARY_SUPPLEMENT|Friso|Friso formula feeding on demand for 3 months
57773956|NCT02715895|DIETARY_SUPPLEMENT|Wyeth|Wyeth formula feeding on demand for 3 months
57773957|NCT02715895|DIETARY_SUPPLEMENT|Breast milk|Breast milk feeding on demand
57773958|NCT03535584|BEHAVIORAL|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
57773959|NCT05624723|DRUG|INCB054707|INCB054707 75 mg will be administered orally
57773960|NCT03901469|DRUG|ZEN003694|PO QD
57773961|NCT03901469|DRUG|Talazoparib|PO QD
57773962|NCT00002499|DRUG|asparaginase|
57773963|NCT00002499|DRUG|cytarabine|
57773964|NCT00002499|DRUG|daunorubicin hydrochloride|
57773965|NCT00002499|DRUG|dexamethasone|
57773966|NCT00002499|DRUG|methotrexate|
57773967|NCT00002499|DRUG|prednisone|
57773968|NCT00002499|DRUG|vincristine sulfate|
57773969|NCT00002499|RADIATION|radiation therapy|
57773970|NCT03225846|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
57773971|NCT03225846|DRUG|Placebo|0.9% Sodium Chloride
57773972|NCT03262090|DRUG|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
57773973|NCT03262090|DRUG|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
57773974|NCT03262090|DRUG|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
57773975|NCT03262090|DRUG|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
57773976|NCT03262090|DRUG|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
57773977|NCT02123537|DEVICE|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
57773978|NCT02520180|DEVICE|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
57773979|NCT02520180|DEVICE|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
57773980|NCT04479241|BIOLOGICAL|lerapolturev|Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
57773981|NCT04479241|BIOLOGICAL|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
57773982|NCT04808128|OTHER|Drink A + SC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
57773983|NCT04808128|OTHER|Drink B + SC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
57773984|NCT04808128|OTHER|Drink C + SC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
57773985|NCT04808128|OTHER|Drink A + CC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
57773986|NCT04808128|OTHER|Drink B + CC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
57773987|NCT04808128|OTHER|Drink C + CC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
57773988|NCT06106035|BEHAVIORAL|low-fat vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
57773989|NCT02134119|DIETARY_SUPPLEMENT|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
58459508|NCT03155165|DEVICE|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
57773990|NCT02134119|DRUG|Placebo|Sugar pill manufactured to mimic dietary supplement
57773991|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
57773992|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
57773993|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
57773994|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
57773995|NCT06130163|PROCEDURE|endoscopic retrograde cholangiopancreatography|endoscopical clearance of the common bile duct
57773996|NCT02544269|PROCEDURE|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
57773997|NCT02544269|PROCEDURE|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
57773998|NCT03881033|OTHER|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
57773999|NCT03881033|OTHER|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
57774000|NCT06180941|DRUG|magnesium sulfate.|magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
57774001|NCT06180941|DRUG|clonidine.|clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
57774002|NCT03753711|PROCEDURE|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
57774003|NCT00128622|BIOLOGICAL|denileukin diftitox|
57774004|NCT00128622|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
58459509|NCT03985241|DIAGNOSTIC_TEST|Functional Assessment of Myocardial Ischemia by icECG|
57774005|NCT00128622|BIOLOGICAL|therapeutic autologous dendritic cells|
57774006|NCT05950022|PROCEDURE|Endoscopic tenotomy surgery of the iliopsoas tendon|The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
57774007|NCT00289237|BEHAVIORAL|Lifestyle intervention|
57774008|NCT00324012|DRUG|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
57774009|NCT04363385|BIOLOGICAL|Biological test|Blood sample
57774010|NCT05774496|OTHER|Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.|All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
57774011|NCT01042899|BEHAVIORAL|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
58459510|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
57774012|NCT01042899|BEHAVIORAL|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
57962363|NCT00540254|OTHER|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
57962364|NCT00598416|BEHAVIORAL|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
57962365|NCT02232386|DRUG|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
57962366|NCT02232386|DRUG|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
57962367|NCT03400722|DRUG|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
57962368|NCT03400722|DRUG|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
58459511|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
58459512|NCT02701517|DRUG|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
58459513|NCT02701517|DRUG|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
57774013|NCT01042899|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
57774014|NCT01886638|DRUG|Abacavir|
57774015|NCT02821832|PROCEDURE|Saliva collection|For biomarker assessments
57774016|NCT02821832|PROCEDURE|Urine collection|For biomarker assessments
57774017|NCT02821832|PROCEDURE|Sputum collection|For primary endpoint assessments and other biomarker assessments
57774018|NCT02821832|PROCEDURE|Blood Collection|For biomarker and eligibility assessments
57774019|NCT02821832|RADIATION|PET/CT Scan|Imaging of the lungs to establish disease extent and severity
57774020|NCT02821832|DRUG|Isoniazid, Rifampicin, Pyrazinamide and Ethambutol|Treatment-standard of care
57774021|NCT00004399|DRUG|magnesium sulfate|
57774022|NCT00004399|DRUG|nimodipine|
57774023|NCT02223065|DRUG|Saxagliptin|
57774024|NCT02223065|DRUG|Dapagliflozin|
57774025|NCT05691348|PROCEDURE|Ambulatory appendectomy|Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
57774026|NCT05691348|PROCEDURE|Conventional appendectomy|Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
57774027|NCT05937009|OTHER|Orienteering exercise program|Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
57774028|NCT04013958|DRUG|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
57774029|NCT04013958|DRUG|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
57774030|NCT01578096|BEHAVIORAL|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
57774031|NCT05039177|DRUG|ERAS-007|Administered orally
57774032|NCT05039177|DRUG|Encorafenib|Administered orally
57774033|NCT05039177|DRUG|Cetuximab|Administered via intravenous infusion
57774034|NCT05039177|DRUG|Palbociclib|Administered orally
57774035|NCT05402800|OTHER|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
57774036|NCT05253690|PROCEDURE|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
57774037|NCT00765427|DRUG|QLT091001|7-day repeated dose
57774038|NCT06274580|DEVICE|embolization of the middle meningeal artery|Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
57774039|NCT00107744|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
57774040|NCT00107744|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
58459514|NCT02955056|DRUG|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
58459515|NCT02424396|DRUG|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
58459516|NCT02424396|DRUG|Placebo|
58459517|NCT04579146|OTHER|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
57774041|NCT00107744|DIETARY_SUPPLEMENT|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
57774042|NCT04674774|DRUG|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
57774043|NCT04674774|DRUG|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
57774044|NCT05755230|OTHER|No intervention|No intervention
57774045|NCT04141072|DIAGNOSTIC_TEST|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
57774046|NCT05295303|DEVICE|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
57774047|NCT03251560|DRUG|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
57774048|NCT03251560|DRUG|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
58459518|NCT05070936|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
57774049|NCT05391022|DRUG|Pelabresib|Pelabresib monohydrate tablets
57774050|NCT00518713|DRUG|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
57774051|NCT00518713|DRUG|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
57774052|NCT00518713|DRUG|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
57774053|NCT00518713|DRUG|Placebo|tablets; orally; daily for 15-18 weeks
57774054|NCT03687268|DRUG|Naloxone HCl PR tablets|oral administration
57774055|NCT03687268|DRUG|Placebo Oral Tablet|Placebo
57774056|NCT01422681|DEVICE|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
57774057|NCT00373932|BEHAVIORAL|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
57774058|NCT00373932|BEHAVIORAL|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
57774059|NCT00779558|DRUG|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
57774060|NCT00779558|DRUG|Placebo infusion|Infusion of normal saline
57774061|NCT04506996|BEHAVIORAL|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
57774062|NCT04506996|BEHAVIORAL|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
57774063|NCT04506996|BEHAVIORAL|Educational Materials|After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
57774064|NCT06250543|DRUG|AbobotulinumtoxinA 300 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
57774065|NCT06250543|DRUG|IncobotulinumtoxinA 100 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
57774066|NCT06250543|DRUG|Lidocain|30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
57774067|NCT06250543|OTHER|placebo|30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
57774068|NCT03049657|DEVICE|Angiolite|Percutaneous coronary intervention
57774069|NCT03049657|DEVICE|Xience|Percutaneous coronary intervention
57774070|NCT00049686|DRUG|laromustine|
57774071|NCT01219595|OTHER|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
57774072|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
57774073|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
57774074|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
57774075|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
57774076|NCT01219595|OTHER|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
57774077|NCT02709642|BEHAVIORAL|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
57774078|NCT03571984|BEHAVIORAL|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
57774079|NCT05404867|OTHER|fMRI|fMRI scan for 1 hour
57774080|NCT03953729|DRUG|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
57962369|NCT02903680|DRUG|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
57962370|NCT02903680|DRUG|Placebo group|Normal Saline 0,9% same volume
57774081|NCT03953729|DRUG|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
58459519|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|This is dose level 0 (de-escalation).
57774082|NCT02438150|BEHAVIORAL|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
57774083|NCT02438150|BEHAVIORAL|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
57774084|NCT01304082|DRUG|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
57774085|NCT01304082|DRUG|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
57774086|NCT01304082|DRUG|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
57774087|NCT03178084|DRUG|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
57774088|NCT03178084|DRUG|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
57774089|NCT03178084|DRUG|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
57774090|NCT00089713|DRUG|alagebrium chloride (ALT-711)|
57774091|NCT01157741|BEHAVIORAL|C-C|Mx as H-C plus positioning follow up in the community clinic
57774092|NCT01157741|OTHER|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
57774093|NCT01157741|OTHER|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
57774094|NCT01157741|OTHER|As C-C but with both SF & PS (C-SF+PS)|Giving both SF \& PS
57774095|NCT01157741|OTHER|H-C|Follow-up at Hospital
57774096|NCT05787795|OTHER|biological samples|blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
57774097|NCT03741244|DRUG|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
58459520|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|This is dose level 1, the starting dose.
58459521|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|This is dose level 2.
58459522|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|This is dose level 3.
57774098|NCT03741244|DRUG|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
57774099|NCT00962585|DRUG|Placebo|
57774100|NCT00962585|DRUG|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)"
57774101|NCT01163903|DRUG|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
57774102|NCT01163903|DRUG|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
57774103|NCT02801474|PROCEDURE|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
57774104|NCT02801474|PROCEDURE|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
58459523|NCT05976555|BIOLOGICAL|Maximum tolerated dose|The maximum tolerated dose is yet to be determined.
58459524|NCT05565365|PROCEDURE|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
58459525|NCT05565365|PROCEDURE|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
58459526|NCT05544526|BIOLOGICAL|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
57774105|NCT00417014|DRUG|chlorambucil|
57774106|NCT00417014|DRUG|prednisolone|
57774107|NCT00417014|DRUG|procarbazine hydrochloride|
57774108|NCT00417014|DRUG|vinblastine sulfate|
57774109|NCT00417014|RADIATION|radiation therapy|
57774110|NCT01782963|DRUG|Lenalidomide|
57774111|NCT01782963|DRUG|Bortezomib|
57774112|NCT01782963|DRUG|Dexamethasone|
57774113|NCT06380660|DRUG|ACE-86225106 tablet|ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
57774114|NCT04611113|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
58459527|NCT01777308|BIOLOGICAL|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
57774115|NCT04611113|DIETARY_SUPPLEMENT|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
57774116|NCT05170308|DEVICE|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
57774117|NCT05582213|DIAGNOSTIC_TEST|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
57774118|NCT03213496|BEHAVIORAL|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
57774119|NCT03213496|OTHER|Conventional care|Patient do not walk before surgery
57774120|NCT02049060|DRUG|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
57774121|NCT05100836|DEVICE|Impella 5.5|Impella 5.5 mechanical circulatory support
57774122|NCT05849532|DEVICE|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
57774123|NCT04221061|DRUG|18F-FluorThanatrace|18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
57774124|NCT02089815|BEHAVIORAL|Home based exercise|modified Otago exercise program to simple designed home based exercise program
57774125|NCT02089815|OTHER|fall prevention education and counseling|
57774126|NCT04037995|OTHER|No intervation|No intervation
57774127|NCT04912141|DRUG|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
57774128|NCT04898842|OTHER|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
57774129|NCT05970835|OTHER|Control group|Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.
57774130|NCT05970835|OTHER|Experimental group|"Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement."
57774131|NCT04343443|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
57774132|NCT04343443|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
58459528|NCT04323696|PROCEDURE|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
57774133|NCT04343443|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
57774134|NCT04343443|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
57774135|NCT04343443|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
57774136|NCT03402373|DIETARY_SUPPLEMENT|Lycoderm|soft gel contains nutritional supplement
57774137|NCT03402373|DIETARY_SUPPLEMENT|Placebo|soft gel without active ingredients
57774138|NCT04175418|OTHER|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
57774139|NCT04175418|OTHER|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
57774140|NCT03593993|PROCEDURE|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
57774141|NCT03109340|OTHER|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
57774142|NCT03109340|DEVICE|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
57774143|NCT04232189|OTHER|no intervention|no intervention, just specimen collection
57774144|NCT03228017|DRUG|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
57774145|NCT00910637|DRUG|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
57774146|NCT04484766|OTHER|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~* Physical examination: height, weight, BMI, blood pressure~* Cardiac examination: cardiac output~* Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~* Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
57774147|NCT03331029|DEVICE|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
57774148|NCT05230862|DIETARY_SUPPLEMENT|Ladder Supplement|Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
57774149|NCT05230862|DIETARY_SUPPLEMENT|Placebo|Placebo
57774150|NCT06421909|BEHAVIORAL|mindfulness-based educational intervention|Mindfulness-based educational intervention is a structured program that incorporates principles of mindfulness to help individuals develop greater awareness and acceptance of their thoughts, feelings, and bodily sensations. The intervention typically includes mindfulness meditation practices, cognitive-behavioral techniques, and educational components about stress management and emotional regulation. By fostering a non-judgmental and present-focused attitude, participants learn to manage their symptoms more effectively and improve their overall quality of life.
57774151|NCT01175772|DRUG|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
57774152|NCT02572817|BIOLOGICAL|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
57774153|NCT02572817|BIOLOGICAL|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
57774154|NCT05498896|DRUG|Atezolizumab|IV infusion
57774155|NCT05498896|DRUG|Ipatasertib|Oral
57774156|NCT05498896|DRUG|Paclitaxel|IV infusion
57774157|NCT05498896|DRUG|Doxorubicin|IV infusion
57774158|NCT05498896|DRUG|Cyclophosphamide|IV infusion
57774159|NCT06475287|DRUG|HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450|The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
57774160|NCT03122756|DRUG|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
58459529|NCT01335776|BEHAVIORAL|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
58459530|NCT01335776|BEHAVIORAL|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
58459531|NCT04870658|PROCEDURE|Dental implant treatment|Patients who receive one o more dental implant treatment to restore oral function.
57774161|NCT03122756|OTHER|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
57774162|NCT02574676|OTHER|non-interventional|
57774163|NCT00910520|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
57774164|NCT00910520|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
57774165|NCT01123460|OTHER|enzyme-linked immunosorbent assay|
58459532|NCT04273607|DRUG|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
58459533|NCT06417840|DIETARY_SUPPLEMENT|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (\>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.
58459534|NCT06417840|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control
58459535|NCT00232622|DRUG|Streptokinase|Accelerated infusion of streptokinase
58459536|NCT00232622|DRUG|Streptokinase|Standard dose streptokinase
57774166|NCT01123460|OTHER|laboratory biomarker analysis|
57774167|NCT01584830|DRUG|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
57774168|NCT01584830|DRUG|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
57774169|NCT02342925|OTHER|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
57774170|NCT02342925|DRUG|RG1662|Oral administration twice daily
57774171|NCT02342925|DRUG|metformin|Single 850 mg dose of metformin
57774172|NCT04586777|DEVICE|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
57774173|NCT04657523|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
57774174|NCT01383057|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
57774175|NCT00003220|DRUG|bryostatin 1|
57774176|NCT01034579|OTHER|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
57774177|NCT01034579|OTHER|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
57774178|NCT02813967|RADIATION|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
57774179|NCT02813967|RADIATION|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
57774180|NCT02813967|DRUG|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
57774181|NCT00547911|DRUG|Droxidopa|
57774182|NCT00547911|DRUG|Carbidopa|
57774183|NCT00547911|DRUG|Entacapone|
57774184|NCT03338205|DRUG|Ketamine|1 mg/kg ketamine bolus IV
57774185|NCT04561011|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
57774186|NCT01556815|PROCEDURE|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
57774187|NCT01556815|OTHER|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
57774188|NCT02550873|BIOLOGICAL|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
57774189|NCT02550873|OTHER|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
57774190|NCT01448421|DEVICE|Keystone Heart Embolic Deflection Device|The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
57774191|NCT01133860|DRUG|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
57774192|NCT03229616|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
57774193|NCT03229616|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
57774194|NCT03229616|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
57774195|NCT06390930|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
57962371|NCT04582578|DEVICE|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
58459537|NCT04366414|OTHER|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
57774196|NCT06390930|OTHER|Sham Acute Intermittent Hypoxia|During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
57774197|NCT02783820|DRUG|MMV390048 40 mg|
57774198|NCT02783820|DRUG|Placebo to match MMV390048 40 mg|
57774199|NCT02783820|DRUG|MMV390048 80 mg|
57774200|NCT02783820|DRUG|Placebo to match MMV390048 80 mg|
57774201|NCT02783820|DRUG|MMV390048 120 mg|
57774202|NCT02783820|DRUG|Placebo to match MMV390048 120 mg|
57774203|NCT00284765|PROCEDURE|flector|
57774204|NCT03387514|DRUG|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
57774205|NCT04229680|OTHER|High Salt|Consumption of pills containing table salt for 10 days.
57774206|NCT04229680|OTHER|Recommended Salt|Consumption of pills containing dextrose for 10 days.
57774207|NCT02684903|BEHAVIORAL|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
57774208|NCT01941550|DRUG|Cabazitaxel chemotherapy|given in 6 cycles
57774209|NCT01254565|DRUG|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
57774210|NCT01254565|DRUG|Placebo|Administered intravenously at the end of hemodialysis
57774211|NCT04503538|OTHER|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
57774212|NCT04703803|COMBINATION_PRODUCT|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
57774213|NCT05345288|DEVICE|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
57774214|NCT05345288|DEVICE|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
57774215|NCT01865123|BEHAVIORAL|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
57774216|NCT01865123|BEHAVIORAL|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
57774217|NCT01865123|BEHAVIORAL|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
57774218|NCT00873301|PROCEDURE|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
57774219|NCT01609530|PROCEDURE|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
57774220|NCT01609530|PROCEDURE|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
57774221|NCT05320016|DRUG|Remimazolam|Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
57774222|NCT02669303|DRUG|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
57774223|NCT02669303|DRUG|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
57774224|NCT05666414|PROCEDURE|sandwich interpositional bone grafting computer guided|performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
58459538|NCT04366414|OTHER|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
57774225|NCT05666414|PROCEDURE|conventional interpositional bone grafting|performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
57774226|NCT04987190|PROCEDURE|alveolar bone graft|alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
57774227|NCT00871351|DRUG|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
57774228|NCT00871351|DRUG|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
57774229|NCT00871351|DRUG|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
57774230|NCT00871351|DRUG|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
57774231|NCT00249093|DRUG|oxygen|
57774232|NCT03868241|DEVICE|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
57774233|NCT03868241|DEVICE|Control|Devices without coating available at each participating intensive care unit
57774234|NCT00159978|PROCEDURE|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
57774235|NCT06251258|DIAGNOSTIC_TEST|Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)|Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)
57774236|NCT00932646|DRUG|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
57774237|NCT00932646|DRUG|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
57774238|NCT00932646|DRUG|Placebo|Placebo Respimat once daily and placebo Foradil
57774239|NCT00932646|DRUG|Foradil|12 mcg twice daily and placebo Respimat
57774240|NCT05694975|DRUG|Vitamin C|The total dosage of vitamin C for the treatment group is 24 g per day.
57774241|NCT05694975|DRUG|Placebo|The total dosage of placebo(5% glucose) for the control group is 24 g per day.
58459539|NCT05868603|OTHER|Remineralization gel|Remineralization gel
58459540|NCT03901417|DEVICE|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
58459541|NCT03901417|DEVICE|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
57774242|NCT04174235|DEVICE|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
57774243|NCT05764226|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
57774244|NCT04232098|OTHER|Heat to ankle|Heat administered via hot water to ankle level
57774245|NCT04232098|OTHER|Heat to calf|Heat administered via hot water to calf level
57774246|NCT01476436|OTHER|Low carbohydrate dietary advice|Dietary advice
57774247|NCT01476436|OTHER|Continue usual diet|Dietary advice
57774248|NCT05860725|BEHAVIORAL|PSA Development|Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
57774249|NCT05860725|BEHAVIORAL|HPV vaccination focused social marketing campaign|Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
57774250|NCT00814515|DRUG|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
57774251|NCT00814515|DRUG|NOVA22007|Vehicle
57774252|NCT05643417|DRUG|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
58459542|NCT03287401|DEVICE|Electroencephalography|Patients electroencephalogram will be recorded
58491284|NCT01383148|BIOLOGICAL|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
57774253|NCT04095572|DRUG|intravesical instillation with HA-CS|intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
57774254|NCT04095572|DRUG|intravesical instillation of sterile purified water|intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
57774255|NCT02491892|DRUG|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
57774256|NCT02773706|OTHER|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
57774257|NCT02773706|OTHER|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
57774258|NCT03079505|DRUG|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
57774259|NCT03079505|DRUG|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
57774260|NCT02443025|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
57774261|NCT06131541|PROCEDURE|autogenous tooth graft|undemineralized autogenous tooth graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
57774262|NCT06131541|PROCEDURE|autogenous bone graft|autogenous bone graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
57774263|NCT05690542|OTHER|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
57774264|NCT02836327|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
57774265|NCT02221323|DRUG|Insulin LISPRO|
57774266|NCT05891821|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
57774267|NCT00030433|DRUG|gemcitabine hydrochloride|
57774268|NCT00030433|DRUG|irinotecan hydrochloride|
57774269|NCT02839122|DRUG|Tadalafil|
57774270|NCT02839122|DRUG|Dutasteride|
57774271|NCT06192615|DRUG|Intravenous Dexmedetomidine|Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
57774272|NCT06192615|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine (120 μg)
57774273|NCT06192615|DRUG|Intravenous Placebo|Intravenous placebo of 0.9% saline administered over 40 minutes
57774274|NCT06192615|DRUG|Sublingual Placebo|Inert sublingual film
57774275|NCT05987501|DIAGNOSTIC_TEST|Multimodal ultrasound|Contrast enhanced ultrasound and shear wave elastography on target intestinal loop are perfomed before and at different timepoints after treatment induction
57774276|NCT01985477|DRUG|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
57774277|NCT01985477|DRUG|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
57774278|NCT01985477|DRUG|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
57774279|NCT02129816|DRUG|Bryophyllum|
58491285|NCT01383148|DRUG|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1"
58491286|NCT01237769|DRUG|Vitamin D3|2200 IU/day
57774280|NCT03165006|PROCEDURE|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
57774281|NCT03165006|PROCEDURE|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
57774282|NCT05927376|BEHAVIORAL|Mediterranean diet|All foods, meal plans and instructions provided.
57774283|NCT05927376|BEHAVIORAL|Western diet|All foods, meal plans and instructions provided.
57774284|NCT04588896|DEVICE|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
57774285|NCT04588896|BEHAVIORAL|Lifestyle modification programme|Lifestyle modification programme
57774286|NCT01410461|DEVICE|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
57774287|NCT01410461|DEVICE|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
57774288|NCT04639921|DIAGNOSTIC_TEST|positive test followed by gluten-free diet|DBPCFC with gluten
57774289|NCT04639921|DIETARY_SUPPLEMENT|Placebo|Placebo
57774290|NCT01342887|DRUG|cyclosporine|Given IV
57774291|NCT01342887|DRUG|pravastatin sodium|Given PO
57774292|NCT01342887|DRUG|mitoxantrone hydrochloride|Given IV
57774293|NCT01342887|DRUG|etoposide|Given IV
57774294|NCT01342887|PROCEDURE|bone marrow aspiration|Correlative studies
57774295|NCT01273532|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
57774296|NCT01273532|DRUG|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
57774297|NCT00818909|OTHER|Systane|Systane prescription
57774298|NCT04598737|PROCEDURE|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
57774299|NCT04598737|PROCEDURE|Lithium disilicate|Lithium disilicate laminate veneer treatment
57774300|NCT04139915|DRUG|Dactolisib|TORC1 inhibitor
57774301|NCT04139915|DRUG|Placebo|Placebo capsule
57774302|NCT02512510|DRUG|TD-4208|
57774303|NCT02512510|DRUG|Placebo|
57774304|NCT01982396|DRUG|ABC Twice Daily|
57774305|NCT01982396|DRUG|ABC Once Daily|
57774306|NCT01982396|DRUG|3TC Once Daily|
57774307|NCT01982396|DRUG|3TC Twice Daily|
57774308|NCT04276662|DRUG|DS-3201b|1 dose of 50 mg DS-3201b
57774309|NCT03343860|PROCEDURE|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
57774310|NCT03343860|PROCEDURE|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
57774311|NCT03343860|PROCEDURE|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
57774312|NCT03343860|PROCEDURE|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
57774313|NCT03343860|PROCEDURE|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
57774314|NCT03343860|PROCEDURE|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
57774315|NCT03343860|PROCEDURE|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
57774316|NCT03343860|PROCEDURE|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
57774317|NCT03343860|PROCEDURE|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
57774318|NCT03343860|PROCEDURE|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
57774319|NCT06098495|GENETIC|search for epigenetic profile of infertility|examine the epigenetic profile of DNA extracted from MGCs and blood sample
58490180|NCT04685889|PROCEDURE|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
58490181|NCT03436290|BEHAVIORAL|Palliative Care Intervention|These patients will receive the palliative care intervention.
57774320|NCT02326116|OTHER|Trachael Preparation Education|
57774321|NCT05271682|DRUG|FHND6091|FHND6091 capsules
57774322|NCT02854358|DRUG|mixed powder of A. digitata and M. sylvestris|
57774323|NCT02854358|DRUG|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
57774324|NCT03499626|DRUG|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
57774325|NCT01950117|PROCEDURE|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
58459543|NCT05948241|OTHER|Online psychological support group|"1. st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~2. nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments"
58459544|NCT05948241|OTHER|Standard multidisciplinary care|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
57774326|NCT01950117|PROCEDURE|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
57774327|NCT02312180|BIOLOGICAL|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
57774328|NCT00458679|BIOLOGICAL|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
57774329|NCT03169270|OTHER|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
57774330|NCT04358419|DIAGNOSTIC_TEST|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
57774331|NCT04358419|DIAGNOSTIC_TEST|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
57774332|NCT03209401|DRUG|Niraparib|an oral PARP inhibitor
57774333|NCT03209401|DRUG|Carboplatin|a platinum-based injection
57774334|NCT00936520|DRUG|SAR 1118 0.1%|Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
57774335|NCT00936520|DRUG|SAR 1118 1.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
57774336|NCT00936520|DRUG|SAR 1118 5.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
57774337|NCT05521594|PROCEDURE|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
57774338|NCT01768754|BEHAVIORAL|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
57774339|NCT00238420|DRUG|Paclitaxel|Given IV
57774340|NCT00238420|RADIATION|Radiation Therapy|Undergo radiation therapy
57774341|NCT00238420|BIOLOGICAL|Trastuzumab|Given IV
57774342|NCT06055192|OTHER|Survey|Survey
57774343|NCT01339988|DRUG|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
58459545|NCT00663364|DRUG|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
58459546|NCT03289793|OTHER|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
58490182|NCT02736318|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
58490183|NCT04615052|OTHER|Exercise training|A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
58490184|NCT05855148|PROCEDURE|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
57774344|NCT02265029|OTHER|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
58459547|NCT03289793|OTHER|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
57774345|NCT02265029|OTHER|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
57774346|NCT00179699|DRUG|CC-5013|
57774347|NCT00179699|DRUG|pemetrexed|
57774348|NCT04422366|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
57774349|NCT04422366|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
57774350|NCT01193543|DIETARY_SUPPLEMENT|calanus oil|1 gram twice daily
57774351|NCT01193543|DIETARY_SUPPLEMENT|olive oil|1 gram twice daily
57774352|NCT05790226|DEVICE|Sentry System|any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
57774353|NCT01961596|OTHER|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
57774354|NCT01961596|OTHER|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
57774355|NCT02989896|DEVICE|perfusion index|
57774356|NCT06172218|OTHER|Flo|sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
57774357|NCT06172218|OTHER|Saline|sterile, preservative free 0.9% NaCl
57774358|NCT02707419|DEVICE|Experimental group|Video of the exercises
57774359|NCT02707419|DEVICE|Control group|video of nature scenes
57774360|NCT02707419|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
57774361|NCT06353659|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
57774362|NCT02710994|DRUG|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
57774363|NCT02710994|DRUG|Losec|Losec 40 mg
57774364|NCT06026527|DRUG|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
57774365|NCT06026527|DRUG|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
58459548|NCT03289793|OTHER|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
58459549|NCT02386046|OTHER|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
58459550|NCT01456286|DRUG|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
58491287|NCT01237769|BEHAVIORAL|Lifestyle advice|Diet and exercise
57774366|NCT04088474|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
57774367|NCT04088474|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
57774368|NCT05512728|DEVICE|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
57774369|NCT05512728|DRUG|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
57774370|NCT01156077|DRUG|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
57774371|NCT01156077|DRUG|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
57774372|NCT04343222|DRUG|Bromfenac|An NSAID used to treat eye pain and swelling
57774373|NCT04343222|DRUG|Artificial tears|eye drops to lubricate the eye and maintain moisture
57774374|NCT05907577|OTHER|Observational|No interventions.
57774375|NCT02088827|OTHER|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
57774376|NCT02088827|OTHER|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
57774377|NCT04283344|OTHER|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
57774378|NCT04672109|DEVICE|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
57774379|NCT03876938|DRUG|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
57774380|NCT03876938|DRUG|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
57774381|NCT03876938|DRUG|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
57774382|NCT04657549|PROCEDURE|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
57774383|NCT04657549|PROCEDURE|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
57774384|NCT03623880|BEHAVIORAL|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
57774385|NCT03623880|BEHAVIORAL|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
57774386|NCT05330130|DRUG|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
57774387|NCT05330130|DRUG|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
57774388|NCT02788006|DRUG|Regorafenib 160 mg|
57774389|NCT04188483|DIETARY_SUPPLEMENT|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
57774390|NCT04188483|BIOLOGICAL|Influenza vaccination|Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
57774391|NCT01161004|DRUG|Sugammadex - Nacl 9/00|"* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~* Nacl 9/00: same volume as Sugammadex"
57774392|NCT01161004|DRUG|Nacl 9/00 - sugammadex|"* Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
57774393|NCT04516421|DIETARY_SUPPLEMENT|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
57774394|NCT04516421|DIETARY_SUPPLEMENT|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
57774395|NCT00000143|DEVICE|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
57774396|NCT00000143|DRUG|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
57774397|NCT05134714|DEVICE|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
57774398|NCT05134714|DEVICE|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
57774399|NCT02942680|DRUG|acetylsalicylic acid started for 24 hours before surgery|
57774400|NCT02942680|DRUG|acetylsalicylic acid stayed for 5 days before surgery|
58459551|NCT02389166|DEVICE|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
57774401|NCT01591460|DRUG|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
58459552|NCT02389166|DEVICE|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
58459553|NCT02699658|DRUG|Levofloxacin|
58459554|NCT03057093|OTHER|Non interventional study|retrospective noninterventional study
57774402|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
58459555|NCT01418144|PROCEDURE|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
58459556|NCT01418144|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
58459557|NCT05668949|DRUG|TTI-101|Given by PO
58459558|NCT05668949|DRUG|Pembrolizumab|Given by IV (vein)
57774403|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
57774404|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
57774405|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
57774406|NCT06257901|OTHER|Interviews/Focus groups/Participatory workshops|Qualitative study (no intervention delivered)
57774407|NCT03504735|BEHAVIORAL|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
57774408|NCT03504735|DRUG|Caduet Pill|Take once daily.
57774409|NCT03504735|DRUG|Placebo|Take once daily.
57774410|NCT00763399|DIETARY_SUPPLEMENT|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
57774411|NCT03971812|BIOLOGICAL|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
57774412|NCT04694482|OTHER|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
57774413|NCT02268318|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
57774414|NCT02268318|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
57774415|NCT04328558|OTHER|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
57774416|NCT04882761|DEVICE|Dental implant|Comparative
57774417|NCT04343482|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
58459559|NCT01069484|OTHER|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
58459560|NCT01702844|DRUG|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
57774418|NCT00675506|DRUG|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
57774419|NCT00675506|DRUG|Placebo|2-mg sub-cutaneous injections once daily for 12 months
57774420|NCT05858489|OTHER|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
57774421|NCT00791921|DRUG|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
57774422|NCT00791921|DRUG|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
57774423|NCT04445155|BEHAVIORAL|Modified DECIDE Parent and Provider Intervention|The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
57774424|NCT03702101|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
57774425|NCT01572324|DRUG|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
57774426|NCT02899871|OTHER|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies."
57774427|NCT03436134|OTHER|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
58459561|NCT04735835|OTHER|Dietary Intervention|To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
57774428|NCT03436134|OTHER|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
57774429|NCT00453310|DRUG|sunitinib malate|
57774430|NCT01061437|DRUG|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
57774431|NCT01061437|DRUG|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
57774432|NCT01061437|DRUG|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
57774433|NCT05174104|PROCEDURE|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
57774434|NCT04297241|DRUG|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
57774435|NCT00504296|DRUG|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
57774436|NCT00504296|OTHER|immunoenzyme technique|
57774437|NCT00504296|OTHER|immunohistochemistry staining method|
57774438|NCT00504296|OTHER|immunologic technique|
57774439|NCT00504296|OTHER|laboratory biomarker analysis|
57774440|NCT00504296|OTHER|liquid chromatography|
57774441|NCT00504296|OTHER|mass spectrometry|
57774442|NCT00504296|OTHER|pharmacological study|
57774443|NCT02954900|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
57774444|NCT02954900|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
57774445|NCT03882671|DEVICE|EpiTel Epilog|EEG recording device
58459562|NCT05749146|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
57774446|NCT03882671|DEVICE|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
57774447|NCT03882671|DEVICE|GENEActiv|Temperature, light level and accelerometry recording device
57774448|NCT00000990|DRUG|Zidovudine|
58459563|NCT04098822|DEVICE|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
58459564|NCT05075408|DRUG|Nemolizumab|Participants will receive 2 subcutaneous injections for a total dose of 30 milligrams (mg) of nemolizumab every 4 weeks (Q4W), with a loading dose of 60 mg at baseline for a period of 12 weeks with an 8 week follow-up.
57774449|NCT01232309|DIETARY_SUPPLEMENT|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
57774450|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
57774451|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
57774452|NCT01232309|DIETARY_SUPPLEMENT|Placebo|3 x 500 mg capsules (tid)
57774453|NCT01625624|OTHER|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
57774454|NCT01625624|OTHER|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
57774455|NCT00214032|DRUG|Pycnogenol|pycnogenol 300 mg daily
57774456|NCT00214032|DRUG|Placebo|placebo 3 capsules daily
57774457|NCT06139991|DRUG|Treatment A (BDA MDI HFO)|Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
57774458|NCT06139991|DRUG|Treatment B (BDA MDI HFA)|Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
57774459|NCT02649322|DEVICE|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
57774460|NCT02649322|DEVICE|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
57774461|NCT01873547|BIOLOGICAL|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
57774462|NCT01873547|OTHER|rehabilitation|Patients only receive rehabilitation of limb function.
57774463|NCT00321204|PROCEDURE|TZD reducing the incidence of atrial arrhythmias|
57774464|NCT02222896|DRUG|Chlorhexidine Gluconate|2% CHG solution on cloth
57774465|NCT02222896|OTHER|Vehicle|Excipients of CHG product only
57774466|NCT02222896|DRUG|DynaHex-2|2% CHG solution
57774467|NCT04539119|DRUG|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.
58459565|NCT05075408|DRUG|Nemolizumab|Participants will receive 2 subcutaneous injections of 30 mg of nemolizumab Q4W starting at baseline for a period of 12 weeks with an 8 week follow-up.
58459566|NCT05075408|DRUG|Placebo|Participants will receive 2 subcutaneous injections of 30 mg of placebo-matched to nemolizumab Q4W for a period of 12 weeks with an 8 week follow-up.
58459567|NCT00984984|DRUG|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
57774468|NCT04539119|DRUG|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
57774469|NCT04266041|DIAGNOSTIC_TEST|High-density electroencephalogram (HD-EEG)|This study will focus on obtaining a special type of high-density scalp electroencephalography (HD-EEG) recordings in patients with neurological disorders (i.e., epilepsy, brain tumor, stroke, etc.) and appropriately matched controls. HD-EEG is a scalp EEG which uses up to 256 channels compared to the standard 21 channels used for routine clinical applications. The reason for using more channels to record is for more precise localization of epileptogenic foci and/or more precise mapping of brain functions. This type of EEG requires the use of patient's own MRI scan to precisely localize activity. Therefore, all patients and controls getting an HD-EEG will require a structural MRI scan.
57774470|NCT03498326|DRUG|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
57774471|NCT03498326|DRUG|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
57774472|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
57774473|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding self-harm
57774474|NCT00512551|PROCEDURE|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
57774475|NCT03591757|DRUG|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
57774476|NCT03073460|OTHER|Ultrasound examination|This exam is performed at 40 weeks gestation
57774477|NCT05106153|DRUG|Suvorexant|Suvorexant will be administered orally as per assigned treatment sequence.
58459568|NCT00984984|DRUG|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
58459569|NCT03658421|DRUG|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
57774478|NCT05106153|DRUG|Zolpidem|Zolpidem will be administered orally as per assigned treatment sequence.
57774479|NCT05106153|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
57774480|NCT05106153|DRUG|Placebo|Placebo will be administered orally as per assigned treatment sequence.
57774481|NCT01409421|BEHAVIORAL|motivational interviewing|counseling intervention
57774482|NCT01409421|BEHAVIORAL|three phone calls to remind patients to take their eye drops|reminder phone calls
57774483|NCT00063817|DRUG|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
57774484|NCT05686915|DIAGNOSTIC_TEST|MARS MRI|metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities
57774485|NCT05686915|DIAGNOSTIC_TEST|Titanium Labs|Labs to look at titanium levels in blood
57774486|NCT05686915|DIAGNOSTIC_TEST|Cobalt Labs|Labs to look at cobalt levels in blood
57774487|NCT05686915|DIAGNOSTIC_TEST|Chromium Labs|Labs to look at chromium levels in blood
57774488|NCT01627080|OTHER|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
57774489|NCT02831309|BEHAVIORAL|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
57774490|NCT02831309|BEHAVIORAL|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
57774491|NCT02831309|BEHAVIORAL|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
57774492|NCT02831309|BEHAVIORAL|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
57774493|NCT01882595|OTHER|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
57774494|NCT01882595|OTHER|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
58459570|NCT03658421|PROCEDURE|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
57774495|NCT02343588|BEHAVIORAL|The Health Lifestyles Interventions|"1. Creating supportive school and family environment, whole intervention periods;~2. Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~3. Instruct and promote school physical education, whole intervention periods;~4. The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
57774496|NCT05994261|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
57774497|NCT01134133|OTHER|Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
57774498|NCT06038812|DIAGNOSTIC_TEST|GCF sample collection|collecting GCF from deepest sites by paper points
57774499|NCT06038812|PROCEDURE|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
57774500|NCT02881190|DRUG|RC48-ADC|
57774501|NCT00245375|DRUG|Tylenol #3|
57774502|NCT00245375|DRUG|Combination Tylenol and Ibuprofen|
57774503|NCT03164915|BIOLOGICAL|LIV-GAMMA SN Inj.|
57774504|NCT06429358|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|The probiotic supplement was delivered in the form of easy-to-swallow capsules.
57774505|NCT06429358|OTHER|Control Group|Participants in the control group were given a placebo that looked, tasted, and felt just like the probiotic pill.
57774506|NCT02216747|DRUG|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
57774507|NCT02216747|DRUG|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
57774508|NCT02216747|DRUG|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
57774509|NCT03030547|DEVICE|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
57774510|NCT03859687|BIOLOGICAL|Vitamin A supplementation|liquid oral vitamin A supplementation
57774511|NCT03859687|BIOLOGICAL|No vitamin A supplementation|No vitamin A supplementation
57774512|NCT02632019|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
57774513|NCT02632019|BIOLOGICAL|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
57774514|NCT00857441|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
57774515|NCT00857441|DEVICE|Liberté|Bare metal stent
57774516|NCT00857441|DEVICE|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
57774517|NCT00857441|DEVICE|Taxus|Paclitaxel eluting stent
57774518|NCT00030368|DRUG|bortezomib|Given IV
57774519|NCT00030368|DRUG|paclitaxel|Given IV
57774520|NCT00030368|OTHER|laboratory biomarker analysis|Correlative studies
58459571|NCT03658421|DEVICE|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
57774521|NCT05359185|BEHAVIORAL|Family Wellness|https://familywellness.com/
57774522|NCT05359185|BEHAVIORAL|Career Coaching|Individualized career coaching and employment services.
57774523|NCT05359185|BEHAVIORAL|Financial Planning|Individualized financial planning services.
57774524|NCT04927039|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
57774525|NCT04927039|DRUG|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
57774526|NCT02391870|BEHAVIORAL|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
57774527|NCT01714102|DIETARY_SUPPLEMENT|Placebo|Placebo manufactured to mimic resveratrol tablet
57774528|NCT01714102|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol PO BID for 30 days
57774529|NCT05838274|OTHER|Alcohol vs. Placebo beverage conditions|Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.
57774530|NCT00981825|DRUG|Fluoride|Whole mouth brushing for 7 days
57774531|NCT00981825|DRUG|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
57774532|NCT06244121|DRUG|Pyridoxine|pyridoxine (Vitamin B6) will be given as an anti oxidant.
57774533|NCT06244121|DRUG|Placebo|Placebo will be given in control group
57774534|NCT06393686|OTHER|yoga|The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
57774535|NCT05138484|DRUG|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
57774536|NCT04524572|BEHAVIORAL|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
57774537|NCT04346641|DIAGNOSTIC_TEST|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
57774538|NCT03122262|DRUG|Dolutegravir|DTG 50mg Oral Tablet once daily
57774539|NCT03122262|DRUG|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
57774540|NCT03122262|DRUG|Truvada|
57774541|NCT03122262|DRUG|Atripla|
57774542|NCT05108584|PROCEDURE|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
57774543|NCT05108584|PROCEDURE|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
57774544|NCT05108584|PROCEDURE|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
57774545|NCT06241196|DEVICE|implant|Implant will be placed through the surgical guide in the extraction socket
57774546|NCT06241196|PROCEDURE|Vestibular Socket Therapy|tunnel incision will be made in labial vestibule
57774547|NCT06241196|DRUG|Alloderm|allogenic soft tissue substitute
57774548|NCT06241196|DRUG|Xenogenic bone membrane shield|xenogenic bone membrane
57774549|NCT06241196|PROCEDURE|Connective tissue graft|soft tissue harvesting from palate
57774550|NCT00000342|DRUG|Risperidone|
57774551|NCT04315623|PROCEDURE|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
57774552|NCT04315623|PROCEDURE|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
58459572|NCT03658421|PROCEDURE|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
57774553|NCT00250172|DRUG|[C-11](R)-rolipram|
57774554|NCT02597933|DRUG|Nintedanib|
57774555|NCT02597933|DRUG|Placebo|
57774556|NCT02969980|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
57774557|NCT01147211|DRUG|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
57774558|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
57774559|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
57774560|NCT02641951|OTHER|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
57774561|NCT02641951|OTHER|Pecs II block|Ultrasound guided Pecs II block
57774562|NCT04913818|BEHAVIORAL|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.
58459573|NCT00743002|DRUG|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
58459574|NCT00743002|DRUG|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
57774563|NCT04913818|OTHER|Control arm (Usual care)|Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
57774564|NCT02476097|DRUG|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
57774565|NCT02476097|OTHER|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
58491288|NCT02663401|BEHAVIORAL|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
57774566|NCT02476097|DRUG|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
57774567|NCT01568827|DIETARY_SUPPLEMENT|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
57774568|NCT04726475|BEHAVIORAL|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
57774569|NCT04726475|DIETARY_SUPPLEMENT|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
57774570|NCT04726475|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of MCT coconut oil.
57774571|NCT06309095|DEVICE|use of VDW Silver Endodontic motor|All patients will be subjected to local anesthesia with articaine hydrochloride (Maxicaine, Istanbul) containing 1:100,000 adrenaline. After the entrance cavities of the teeth are opened, a rubber dam will be applied to the relevant teeth for isolation from the oral environment. After the entrance cavity is opened, the working length of the canals will be determined with the help of a No. 10 K-file (Dentsply Maillefer, Ballaigues, Switzerland) canal file and an electronic apex finder (Woodpex III, Woodpecker Medical Instrument Co, Guilin, China). In both groups, it was planned to use the NiTi rotary instrument system using V Taper Gold (Fanta Dental Material, Shanghai, China) files with the help of VDW.Silver endomotor (VDW, München, Germany). The endodontic motor will be used to adjust different speed and torque values during root canal treatment. Post-operative pain caused by different speed and torque values will be compared.
57774572|NCT01168674|DRUG|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
57774573|NCT01168674|DRUG|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
57774574|NCT02864043|DEVICE|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
57774575|NCT02864043|PROCEDURE|esophagogastroduodenoscopy (EGD)|Standard of care EGD
57774576|NCT02054078|DRUG|Bevacizumab|Bevacizumab200mg by intrapleural administration
57774577|NCT02054078|DRUG|Pulvis talci|Pulvis talci 4g by intrapleural administration
57774578|NCT02435771|DRUG|Ergocalciferols|Treatment 1- 400,000 IU
58459575|NCT02446184|PROCEDURE|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
58459576|NCT02446184|PROCEDURE|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
58459577|NCT01703078|DRUG|Ingenol once daily for two consecutive days|
57774579|NCT02435771|DRUG|Ergocalciferols|Treatment 2- 800,000 IU
57774580|NCT02501759|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
57774581|NCT02501759|RADIATION|Gadodiamide|Given IV
57774582|NCT02501759|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
57774583|NCT02501759|PROCEDURE|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
57774584|NCT02501759|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
57774585|NCT03136796|DRUG|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
57774586|NCT01194882|DRUG|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
57774587|NCT01194882|DRUG|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
57774588|NCT00651443|DRUG|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
57774589|NCT03923218|OTHER|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
57774590|NCT03923218|OTHER|Serum Vitamin D3 levels|Collected serum
58129655|NCT04056143|DIAGNOSTIC_TEST|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
57774591|NCT03923218|OTHER|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
58129656|NCT02126865|DRUG|Placebo to BI 1060469|tablet
58129657|NCT02126865|DRUG|BI 1060469 Healthy|tablet
58459578|NCT03701776|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
58459579|NCT03701776|BEHAVIORAL|Balance Training|Standard of care
58459580|NCT02051764|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
58459581|NCT02051764|DRUG|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
58459582|NCT02051764|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
58459583|NCT03760029|OTHER|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
58459584|NCT06252181|OTHER|electromagnetic pulsed therapy|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
57774592|NCT03435601|DRUG|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
57774593|NCT03435601|DRUG|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
58459585|NCT06252181|OTHER|elliptical exercise|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
58459586|NCT04757506|DRUG|Naltrexone|opioid receptor antagonist
58459587|NCT04757506|DRUG|Placebo|
58459588|NCT04859322|DRUG|Glucagon|Pancreatic clamp
58459589|NCT00471653|DRUG|temozolomide|
58459590|NCT00471653|GENETIC|comparative genomic hybridization|
58459591|NCT00471653|GENETIC|polymorphism analysis|
58459592|NCT00471653|OTHER|laboratory biomarker analysis|
58459593|NCT00471653|OTHER|pharmacological study|
58459594|NCT00471653|RADIATION|radiation therapy|
58459595|NCT02913703|DRUG|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
57774594|NCT03132623|DRUG|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
57774595|NCT03132623|DRUG|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
57774596|NCT03606941|DEVICE|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
58129658|NCT02126865|DRUG|Placebo to BI 1060469 asthmatics|tablet
58129659|NCT02126865|DRUG|BI 1060469 asthmatics|tablet
58129660|NCT03057899|DRUG|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
58459596|NCT02913703|OTHER|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
58459597|NCT01473771|BEHAVIORAL|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
58459598|NCT02338726|OTHER|Gynecological examination|Comparison of questionnaires and gynecological examination
58459599|NCT05494840|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
58459600|NCT00126035|DEVICE|Migraid|
58459601|NCT01410942|OTHER|Placebo|Capsules by mouth twice daily.
58459602|NCT01410942|DRUG|Methylphenidate|Starting dose 5 mg by mouth twice daily.
58459603|NCT01410942|BEHAVIORAL|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
58459604|NCT01410942|OTHER|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
58459605|NCT01410942|OTHER|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
58459606|NCT01410942|OTHER|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
58459607|NCT03340389|PROCEDURE|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
58459608|NCT02559102|DRUG|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
58459609|NCT02559102|DRUG|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
58459610|NCT02559102|PROCEDURE|Caudal anaesthesia|single shot caudal anaesthesia
58459611|NCT02559102|PROCEDURE|Inguinal hernia surgery|Infant inguinal hernia repair.
58459612|NCT00292240|BEHAVIORAL|Brief motivational substance use intervention|
58459613|NCT05678179|BEHAVIORAL|Telehealth|Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
58459614|NCT05678179|BEHAVIORAL|In Person (Face-2-Face)|Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
58459615|NCT01673607|PROCEDURE|Biopsie liver|
58459616|NCT06240637|OTHER|Telemonitoring|A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
58459617|NCT06510933|DEVICE|Heel cups in different BMI index and its correlation to physical activity in children|Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
58491289|NCT02403440|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
58491290|NCT00436345|DRUG|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
58491291|NCT00436345|DRUG|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
57774597|NCT03606941|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
57774598|NCT02443662|OTHER|Catheterization|Routine catheterization during follow up.
57774599|NCT05677737|OTHER|Education|"Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months."
57774600|NCT03319186|PROCEDURE|EDIT Management|"EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
57774601|NCT03319186|PROCEDURE|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
57774602|NCT03204695|DEVICE|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
57774603|NCT03204695|DRUG|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
57774604|NCT05540093|OTHER|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
57774605|NCT05540093|OTHER|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
57774606|NCT04213586|DIETARY_SUPPLEMENT|Whey protein supplementation|35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
57774607|NCT04213586|DIETARY_SUPPLEMENT|Collagen supplementation|35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
57774608|NCT02171182|DRUG|Qutenza|capsaicin patch
57774609|NCT02055703|DRUG|E2609|
58459618|NCT05364671|DRUG|Raphamin|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
57774610|NCT02055703|DRUG|itraconazole|
57774611|NCT02055703|DRUG|rifampin|
57774612|NCT02055703|DRUG|digoxin|
57774613|NCT02055703|DRUG|donepezil|
57774614|NCT06117748|OTHER|Pressure controlled ventilation-volume guaranteed|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
58129661|NCT03057899|DRUG|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
58459619|NCT05364671|DRUG|Placebo|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
58459620|NCT00751686|PROCEDURE|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
57774615|NCT06117748|OTHER|Volume controlled ventilation|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
58129662|NCT05628636|DRUG|AC-OLE-01-VA|formulation of tricaprilin
58459621|NCT00751686|OTHER|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
58459622|NCT05581602|DEVICE|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
58459623|NCT01570413|PROCEDURE|No Pelvic Exam|Will not receive pelvic examination.
58129663|NCT04281706|DRUG|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
58129664|NCT06487676|PROCEDURE|Toe transfer|Toe-to-hand transfer
57774616|NCT00933842|DRUG|LACTIC ACID(ND)|Treatment duration: 5 weeks
57774617|NCT03696277|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
57774618|NCT01474447|BEHAVIORAL|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
57774619|NCT05723848|DEVICE|Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
57774620|NCT02493218|BEHAVIORAL|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
57774621|NCT02493218|BEHAVIORAL|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
57774622|NCT02193802|DEVICE|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
57774623|NCT01533714|BIOLOGICAL|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
57774624|NCT00313911|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
57774625|NCT00313911|BIOLOGICAL|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
57774626|NCT04908124|DEVICE|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
57774627|NCT04908124|DEVICE|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
57774628|NCT04908124|DEVICE|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
57774629|NCT04908124|DEVICE|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
57774630|NCT04908124|DEVICE|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
57774631|NCT03069560|DEVICE|SMS|SMS contact from the caregiver with patient after discharge in intervention group
57774632|NCT02500875|DEVICE|PTNiA|
57774633|NCT02500875|DEVICE|PTNiB|
58459624|NCT01570413|PROCEDURE|Pelvic Examination|Pelvic examination will be performed.
57774634|NCT02500875|DEVICE|PTN|
57774635|NCT01003184|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once a week
57774636|NCT01003184|DRUG|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
57774637|NCT06114563|OTHER|Spirulina yogurt|High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
57774638|NCT06114563|OTHER|Conventional yogurt|High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
58129665|NCT06487676|PROCEDURE|Replantation|Finger or thumb replantation after amputation
58129666|NCT02636816|DRUG|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
58459625|NCT06053853|BIOLOGICAL|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~1. Perform sensitivity tests, and desensitization if necessary.~2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~3. The recommended DAT treatment dosage ranges (pediatric and adult) are:~   * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~  * Nasopharyngeal disease 40,000 - 60,000 unit~  * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~  * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
57774639|NCT05938725|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
57774640|NCT05938725|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
57785295|NCT02923219|BIOLOGICAL|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
58129667|NCT03196947|DRUG|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
58129668|NCT06082258|OTHER|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
58129669|NCT06082258|OTHER|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
58129670|NCT05912322|DIETARY_SUPPLEMENT|Black chokeberry juice|100ml black chokeberry juice/day
58459626|NCT00414635|DRUG|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
57774641|NCT00255697|PROCEDURE|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
57774642|NCT00255697|PROCEDURE|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
57774643|NCT02875561|DEVICE|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
57774644|NCT02875561|DEVICE|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
57774645|NCT03655522|DRUG|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
57774646|NCT03655522|DRUG|Placebo|There were two Placebos per group.
57774647|NCT04328818|DIAGNOSTIC_TEST|indwelling device biofilm identification|performance of the NGS-based identification technique in comparison with the conventional culture-based one, for the same indwelling device biofilm sample
57774648|NCT05050214|DRUG|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
57774649|NCT00231270|DEVICE|Cordis Nitinol Stent|
57774650|NCT00231270|DEVICE|PRECISE tapered stent|
57774651|NCT00231270|DEVICE|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
57774652|NCT01141335|DEVICE|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
57774653|NCT01141335|DEVICE|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
57774654|NCT05022602|DEVICE|Imagio|Imagio - both ultrasound probe and Duplex OA probe
57774655|NCT05314556|BEHAVIORAL|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
57774656|NCT01582880|DRUG|Riboflavin|Used to treat donor cornea before implantation
57774657|NCT01373710|DRUG|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
57774658|NCT05225402|DRUG|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
57774659|NCT00274170|DRUG|Octreotide|
57774660|NCT03758820|BEHAVIORAL|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
57774661|NCT02165904|BIOLOGICAL|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
57774662|NCT05200936|DRUG|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
57774663|NCT05200936|OTHER|Placebo|A treatment which is designed to have no therapeutic value.
57774664|NCT02374593|DRUG|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
57774665|NCT02374593|DEVICE|Ultrasound|
57774666|NCT05903690|DRUG|RAG-17|RAG-17 60mg is used
57774667|NCT00925782|DRUG|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
57774668|NCT00925782|DRUG|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
57774669|NCT05392387|OTHER|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
58459627|NCT04834817|DEVICE|Celluma POD|A blue and near infrared handheld LED device
57774670|NCT00363896|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
57774671|NCT00363896|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
57774672|NCT03623932|DRUG|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
57774673|NCT03623932|BEHAVIORAL|Hypnosis|8 hypnosis group sessions during 2 months
57774674|NCT01842087|OTHER|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
57774675|NCT01842087|OTHER|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
57774676|NCT04152785|BEHAVIORAL|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
57774677|NCT04055168|DRUG|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
57774678|NCT04055168|DRUG|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
57774679|NCT01713790|DEVICE|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
57774680|NCT01713790|DEVICE|Exergame|training program over 10 weeks, three times a week.
57774681|NCT01713790|DEVICE|Leg press|training program over 10 weeks, three times a week.
57774682|NCT00861926|DRUG|Ventolin|Ventolin : salbutamol sulfate 100µg
57774683|NCT00861926|DRUG|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
57774684|NCT00556374|DRUG|Placebo|
57774685|NCT00556374|BIOLOGICAL|Denosumab|Administered as a subcutaneous injection
57774686|NCT00556374|DRUG|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
57774687|NCT00556374|DRUG|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
58459628|NCT02344108|DEVICE|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
58459629|NCT02211053|DRUG|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
58459630|NCT02211053|DRUG|placebo|
58459631|NCT00466232|DRUG|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
58459632|NCT00466232|DRUG|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
58459633|NCT04580355|PROCEDURE|One-Stage Full Mouth Debridement|Periodontal debridement
57774688|NCT00556374|OTHER|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
57774689|NCT03784352|DEVICE|Virtual Reality|A calming virtual reality game will be played
57774690|NCT00631384|BEHAVIORAL|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
57774691|NCT00631384|BEHAVIORAL|Individual VCT|Women to receive individual VCT
58459634|NCT04580355|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
58459635|NCT04580355|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
57774692|NCT04386590|OTHER|Manual Therapy Plus Pulmonary Rehabilitation|Manual therapy combined with Pulmonary Rehabilitation
57774693|NCT04386590|OTHER|Sham Intervention|Detuned US plus Pulmonary Rehabilitation
57774694|NCT02840396|DEVICE|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
57774695|NCT02840396|DEVICE|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
57774696|NCT03051490|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
57774697|NCT03051490|DRUG|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
57774698|NCT01404611|DRUG|DF289|Ear drops
57774699|NCT01404611|DRUG|DF277|Ear drops
58459636|NCT04580355|DRUG|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
58459637|NCT04580355|DRUG|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
57774700|NCT01404611|DRUG|DF289 plus DF277|Ear drops
57774701|NCT05593211|DEVICE|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
57774702|NCT05206864|OTHER|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
57774703|NCT05206864|OTHER|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
57774704|NCT01321398|OTHER|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
58459638|NCT04296656|BEHAVIORAL|The 5 S's infant calming intervention|5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
58459639|NCT03623243|DRUG|Siponimod|Siponimod 2mg tablets taken once daily
57774705|NCT04547426|OTHER|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
57774706|NCT01426490|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C, 100 mg/d
57774707|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6, 50mg/d
58459640|NCT01985295|DRUG|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
58459641|NCT02022137|DIETARY_SUPPLEMENT|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
57774708|NCT01426490|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 microgram/d
57774709|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
57774710|NCT01053637|DRUG|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
57774711|NCT01053637|DRUG|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
57774712|NCT03056859|DEVICE|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
57774713|NCT01634958|BIOLOGICAL|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
57774714|NCT05955521|PROCEDURE|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
57774715|NCT05312437|OTHER|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (\>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~1. Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~2. Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~3. Disagree with alert and provide a rationale for disagreement (CDS complete)~4. Indicate suicide risk face-to-face screening has already occurred (CDS complete)~5. Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
57774716|NCT05312437|OTHER|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (\>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
57774717|NCT01971606|DRUG|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
57774718|NCT03162757|PROCEDURE|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
57774719|NCT05044975|BEHAVIORAL|Sleep restriction|Participants will receive sleep restriction intervention
58459642|NCT02022137|DIETARY_SUPPLEMENT|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
57774720|NCT05044975|BEHAVIORAL|Stimulus control|Participants will receive stimulus control intervention
57774721|NCT05044975|BEHAVIORAL|Systematic light exposure|Participants will receive systematic light exposure intervention
57774722|NCT06339125|OTHER|Fall prevention algorithm|Algorithm generates fall prevention alerts to nurses in real time, using evidenced based electronic health record information regarding changes in care that may suggest the need for additional fall prevention strategies
57774723|NCT06339125|OTHER|Inspiren camera visualization|The Inspiren computer camera visualization is an additional strategy for nurses to employ when there is a change in a patient's fall risk.
58459643|NCT02022137|DIETARY_SUPPLEMENT|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
58459644|NCT03494868|DIETARY_SUPPLEMENT|Carbohydrate Drink|2 - 12 oz drinks
57774724|NCT02111213|BEHAVIORAL|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
57774725|NCT02111213|BEHAVIORAL|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
57774726|NCT02319343|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
57774727|NCT02319343|DRUG|Isotonic Sodium Chloride|Placebo
57774728|NCT03656458|OTHER|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
58459645|NCT05473988|OTHER|Admission to General Ward|Admission to General Ward
58459646|NCT05473988|OTHER|Admission to Intensive Care Unit|Admission to Intensive Care Unit
58459647|NCT05473988|OTHER|30 Day Mortality|30 Day Mortality
58459648|NCT01405768|DRUG|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
57774729|NCT03656458|OTHER|Conventional Balance Training|"Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training"
57774730|NCT03656458|OTHER|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
57774731|NCT01003639|DRUG|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
57774732|NCT01003639|DRUG|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
57774733|NCT01003639|BEHAVIORAL|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
57774734|NCT02530138|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
57774735|NCT02530138|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules per day for 28 weeks
57774736|NCT00462436|BEHAVIORAL|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
57774737|NCT01148342|DRUG|MDMA|
57774738|NCT01148342|DRUG|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 \&amp; 1.6 mg/kg
57774739|NCT06476795|OTHER|Chardonnay Marc|Food product made from Chardonnay wine grapes
57774740|NCT02979626|PROCEDURE|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
57774741|NCT00827151|DRUG|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
57774742|NCT02625194|DRUG|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
57774743|NCT04831008|OTHER|Figure-of-eight suture|Using the figure-of-eight closure technique when closing access for structural heart therapies.
57774744|NCT04831008|OTHER|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
57774745|NCT02934360|DEVICE|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
57774746|NCT03019120|DRUG|Vitamin D|"1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
57774747|NCT03906513|DEVICE|OMK2|OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
57774748|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; coronary artery status|
57774749|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
57774750|NCT00974636|DIETARY_SUPPLEMENT|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
57774751|NCT00974636|DIETARY_SUPPLEMENT|Usual Salt Diet|Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
57774752|NCT06459791|PROCEDURE|Biopsy|The recommandation done based on informative tumorogram is up to study investigator
58459649|NCT01405768|DRUG|Non-buffered lidocaine|
57774753|NCT03535051|DEVICE|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
57774754|NCT03535051|DRUG|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
57774755|NCT01805193|OTHER|Computed tomography myocardial perfusion imaging|
58459650|NCT04299373|DRUG|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
57774756|NCT01805193|OTHER|Oxygen 15 labelled water positron emission tomography|
57774757|NCT00464035|BEHAVIORAL|high calcium intake|
57774758|NCT06386081|DIETARY_SUPPLEMENT|Citrus pectin with low DE|Dietary intervention with citrus pectin with low DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
57774759|NCT06386081|DIETARY_SUPPLEMENT|Apple pectin with high DE|Dietary intervention with apple pectin with high DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
57774760|NCT06386081|DIETARY_SUPPLEMENT|Placebo|Participants will orally take the placebo (maltodextrin) twice a day, after dissolving it in 100ml of water, for 2 months. Maltodextrin is highly digestible and in small amounts will have limited impact on gut microbiome.
58459651|NCT04299373|DRUG|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
58459652|NCT01311817|BIOLOGICAL|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
58459653|NCT06182878|BEHAVIORAL|Tender loving care intervention|Receiving weekly prenatal care counseling messages
57774761|NCT03051126|OTHER|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
57774762|NCT00505726|PROCEDURE|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
57774763|NCT00241137|DRUG|valsartan|
57774764|NCT01654237|OTHER|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
57774765|NCT03388112|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
57774766|NCT06306950|DEVICE|Near infrared spectroscopy neuromonitor to prevent cerebral desaturation|patients were assigned into active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA) \[17\]. After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors.
57774767|NCT03281278|OTHER|standard treatment|standard medical treatment
57774768|NCT04683302|DEVICE|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
57774769|NCT04683302|DEVICE|2D US catheterization|2D short axis internal jugular vein catheterization
57774770|NCT00856934|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
57774771|NCT00856934|BIOLOGICAL|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
57774772|NCT00856934|OTHER|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
57774773|NCT04908683|BIOLOGICAL|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
57774774|NCT04908683|BIOLOGICAL|Placebo|Participants will receive a single IM injection of matching placebo.
57774775|NCT02137538|DRUG|Letrozole|
58459654|NCT05555303|DRUG|Amikacin|"In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration."
57774776|NCT02137538|DRUG|Anastrozole|
57774777|NCT00410631|BIOLOGICAL|filgrastim|
57774778|NCT00410631|DRUG|carboplatin|
57774779|NCT00410631|DRUG|cisplatin|
57774780|NCT00410631|DRUG|cyclophosphamide|
57774781|NCT00410631|DRUG|dacarbazine|
57774782|NCT00410631|DRUG|doxorubicin hydrochloride|
57774783|NCT00410631|DRUG|etoposide phosphate|
57774784|NCT00410631|DRUG|ifosfamide|
57774785|NCT00410631|DRUG|isotretinoin|
57774786|NCT00410631|DRUG|melphalan|
57774787|NCT00410631|DRUG|topotecan hydrochloride|
57774788|NCT00410631|DRUG|vincristine sulfate|
57774789|NCT00410631|DRUG|vindesine|
57774790|NCT00410631|PROCEDURE|autologous hematopoietic stem cell transplantation|
57774791|NCT00410631|PROCEDURE|conventional surgery|
57774792|NCT00410631|PROCEDURE|peripheral blood stem cell transplantation|
57774793|NCT00410631|RADIATION|iobenguane I 131|
57774794|NCT00410631|RADIATION|radiation therapy|
57774795|NCT02058420|DRUG|Low tocotrienols group|300 mg tocotrienols daily
58459655|NCT00204152|BEHAVIORAL|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
57774796|NCT02058420|DRUG|High tocotrienols group|600 mg tocotrienols daily
57774797|NCT03910348|DEVICE|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
57774798|NCT03910348|OTHER|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
57774799|NCT02415998|PROCEDURE|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
57774800|NCT05280405|DRUG|Infliximab|Infliximab
57774801|NCT05775835|OTHER|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
57774802|NCT05775835|OTHER|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
57785296|NCT05451511|OTHER|Door-In-The-Face Technique|Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.
57774803|NCT05775835|OTHER|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
57774804|NCT02878070|BEHAVIORAL|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
57774805|NCT00674635|DRUG|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
57774806|NCT00674635|DRUG|Placebo|matching placebo
57774807|NCT02904291|DRUG|Amlodipine|Patients are tested for their normal prescription amlodipine medication
57774808|NCT00062621|PROCEDURE|Combined bone marrow and kidney transplant|
57774809|NCT03051659|DRUG|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
57774810|NCT03051659|DRUG|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
57774811|NCT05816148|OTHER|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
57774812|NCT02237339|DRUG|Allopurinol|Uric acid lowering medication.
57774813|NCT02237339|DRUG|Placebo|
57774814|NCT01980901|DEVICE|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
57774815|NCT05620030|OTHER|Univentricular Heart|Prevention of complications when discovered
57774816|NCT05287230|BEHAVIORAL|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
57774817|NCT05287230|BEHAVIORAL|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
57774818|NCT04470219|OTHER|Cognitive support by RemindMe|
57774819|NCT04924140|DRUG|Aducanumab|Administered as specified in the treatment arm
57774820|NCT02025920|OTHER|Salmon Group|
57774821|NCT02025920|OTHER|Cod Group|
58459656|NCT04480489|OTHER|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
58459657|NCT04480489|OTHER|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
58459658|NCT02823769|DEVICE|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
57774822|NCT02025920|OTHER|Meat Group|
57774823|NCT01339364|OTHER|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
57774824|NCT01339364|OTHER|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
57774825|NCT01339364|OTHER|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
57774826|NCT02561351|OTHER|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
57774827|NCT00306904|DRUG|bevasiranib|
57774828|NCT03765762|DRUG|GRF6019|GRF6019 for IV infusion
57774829|NCT03765762|OTHER|Placebo|Placebo for IV infusion
57774830|NCT03524313|DIAGNOSTIC_TEST|End tidal carbon monoxide|"* Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~* Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~* Evaluation of femoral veinous velocity"
57774831|NCT01849796|DEVICE|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
57774832|NCT01933503|DRUG|OCA 5 mg|
57774833|NCT01933503|DRUG|OCA 10 mg|
57774834|NCT01933503|DRUG|OCA 25 mg|
57774835|NCT06276127|DRUG|Oral Bisoprolol|Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
57774836|NCT06276127|DRUG|Intravenous Diltiazem|Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
57774837|NCT04761055|OTHER|Clinical Breast exam (CBE)|The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.
57774838|NCT04761055|DEVICE|iBreastExam device|The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.
57774839|NCT04761055|DIAGNOSTIC_TEST|mammogram|All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
57774840|NCT02115997|DRUG|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
57774841|NCT02115997|DRUG|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
58459659|NCT02823769|DEVICE|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
57774842|NCT02115997|DRUG|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
57774843|NCT00027521|BIOLOGICAL|bleomycin sulfate|
57774844|NCT00027521|DRUG|electroporation therapy|
57774845|NCT05591469|DEVICE|IR Camera|the respiration parameters are measured using an IR camera.
57774846|NCT05591469|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
57774847|NCT00163891|BEHAVIORAL|Chest physiotherapy|
57774848|NCT00072852|DRUG|Irinotecan|
57774849|NCT06441058|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
57774850|NCT04321993|DRUG|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
57774851|NCT04321993|DRUG|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
57774852|NCT04321993|DRUG|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
57774853|NCT04321993|DRUG|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
57774854|NCT02934477|OTHER|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
57774855|NCT02240589|DRUG|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
57774856|NCT02240589|DRUG|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
57774857|NCT04773886|DRUG|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
58459660|NCT00367328|DEVICE|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
58459661|NCT03741088|DEVICE|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
58459662|NCT04086017|OTHER|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
57774858|NCT04773886|DRUG|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
57774859|NCT04773886|BIOLOGICAL|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
57774860|NCT05843474|BEHAVIORAL|Take it Personal!|Take it Personal! is a six-week indicated prevention program for youth with a mild intellectual disability or borderline intellectual functioning. The program aims to teach youngsters skills to reduce their substance use (alcohol, cannabis, and other drugs). The prevention program differentiates four personality profiles associated with a higher risk for problematic substance use: sensation seeking, impulsivity, anxiety sensitivity and negative thinking. For each of the four personality profiles, different program outlines were developed that are similar in structure but have their own personality-specific materials, games and (psychomotor) exercises. There are weekly individual- and group sessions with three to four participants, led by a clinical psychologist and a psychomotor therapist. Motivational interviewing and cognitive behavioral therapeutic principles are applied, both of which have proven effectiveness in decreasing substance use the target group.
57774861|NCT04833101|BIOLOGICAL|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
57774862|NCT04833101|BIOLOGICAL|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
57774863|NCT04833101|BIOLOGICAL|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
57774864|NCT01784315|DRUG|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
58459663|NCT05736874|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
57774865|NCT01784315|DRUG|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
57774866|NCT02678520|RADIATION|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
57774867|NCT02678520|RADIATION|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
57774868|NCT02678520|DRUG|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
57774869|NCT04915703|PROCEDURE|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
57774870|NCT05257759|OTHER|Usual care|Standard management offered in the intensive care unit
57774871|NCT05257759|OTHER|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
57774872|NCT05257759|OTHER|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
57774873|NCT03220945|OTHER|Yoga|Receive yoga instruction
57774874|NCT03481790|DRUG|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
57774875|NCT03481790|DRUG|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
57774876|NCT03411889|DIAGNOSTIC_TEST|MRI scanning|MRI scanning during tear drainage
57774877|NCT00171405|DRUG|aliskiren|
57774878|NCT05947773|OTHER|Learning to walk with a robot|The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)
58459664|NCT05736874|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
57774879|NCT05947773|OTHER|Walking group|The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.
57774880|NCT05947773|OTHER|Control group|The control group performed the physiotherapy treatment for 3 weeks.
57774881|NCT01429506|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
57774882|NCT01429506|DRUG|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
57774883|NCT00818064|DRUG|anti-IL-20|Single s.c. injection (per dose cohort)
57774884|NCT00818064|DRUG|placebo|Single s.c. injection (per dose cohort)
57774885|NCT01757067|DEVICE|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
57774886|NCT03688711|DRUG|Dasiglucagon|Glucagon analogue
58459665|NCT00754702|DRUG|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
58459666|NCT00754702|DRUG|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
58459667|NCT02564666|OTHER|telephone counseling|regular telephone counseling for compliance and advese event
57774887|NCT03688711|DRUG|Placebo|Placebo for dasiglucagon
57774888|NCT05834816|BEHAVIORAL|Negative Affect Task|fMRI stress task
57774889|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
57774890|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
57774891|NCT03999905|BEHAVIORAL|Counseling training|Online training using Moodle.
57774892|NCT03713814|OTHER|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
58459668|NCT02620501|DRUG|Lidocaine|topical lidocaine
57774893|NCT02088775|PROCEDURE|PET scan|Undergo PET-CT scan
57774894|NCT02088775|PROCEDURE|CT Scan|Undergo PET-CT scan
57774895|NCT02088775|PROCEDURE|hepatic artery embolization|Undergo standard radioembolization
57774896|NCT03160482|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
57774897|NCT06091618|PROCEDURE|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
57774898|NCT06091618|PROCEDURE|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
57774899|NCT04410887|DRUG|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
57774900|NCT03935464|BEHAVIORAL|PUMA|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
57774901|NCT03898180|BIOLOGICAL|Pembrolizumab|IV infusion
57774902|NCT03898180|DRUG|Lenvatinib|oral capsule
57774903|NCT03898180|DRUG|Placebo for lenvatinib|oral capsule
57774904|NCT02304328|OTHER|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
57774905|NCT06222008|OTHER|no Intervention|Observational study, no intervention
57774906|NCT01534455|DRUG|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
57774907|NCT01534455|DRUG|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
58459669|NCT02620501|DRUG|Placebo|0.45% Normal Saline
58459670|NCT03431298|BEHAVIORAL|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training"
58459671|NCT03431298|BEHAVIORAL|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down"
58459672|NCT02552966|DEVICE|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
58459673|NCT01927497|PROCEDURE|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
57774908|NCT05192772|DEVICE|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
57774909|NCT03116503|OTHER|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
57774910|NCT04921514|BEHAVIORAL|SASRQ questionnaire|"During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5)."
57774911|NCT04921514|BEHAVIORAL|PCL-5 with LEC-5 questionnaire|"This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD."
57774912|NCT06488560|DIETARY_SUPPLEMENT|commercial blenderized tube feed (CBTF)|Based on assessment by a dietician the participant will be fed the commercial blenderized formula to meet their caloric needs
57774913|NCT06488560|DIETARY_SUPPLEMENT|commercial formulas (CF)|Participant will be fed the commercial formula to meet their caloric needs per standard of care
57774914|NCT02662803|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
57774915|NCT02662803|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
57774916|NCT00128245|DRUG|Pimecrolimus|
57774917|NCT00128245|DRUG|Vehicle|Placebo
57774918|NCT03422458|DEVICE|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
57774919|NCT03754361|PROCEDURE|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
57774920|NCT03754361|PROCEDURE|IHD|HD 4hour 2-3times per week
57774921|NCT03987568|OTHER|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
57774922|NCT03987568|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
57774923|NCT02708602|GENETIC|β2AR polymorphism|
57774924|NCT04517370|DEVICE|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
57774925|NCT00845871|DRUG|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
57774926|NCT02330419|DRUG|Placebo|
57774927|NCT02330419|DRUG|Naltrexone|
57774928|NCT00125099|BIOLOGICAL|VRC-HIVDNA009-00-VP|
57774929|NCT02244099|OTHER|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
57774930|NCT01099540|DRUG|Pazopanib|Pazopanib 800 mg qd daily
57774931|NCT05175534|PROCEDURE|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
57774932|NCT04572256|DRUG|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
57774933|NCT04572256|DRUG|Placebo|An oral placebo will be taken daily for 6 months post surgery.
57774934|NCT04562103|DRUG|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
57774935|NCT04562103|DRUG|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
57774936|NCT01532180|DEVICE|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
57774937|NCT00393744|DRUG|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
57774938|NCT00393744|DRUG|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
57774939|NCT01556763|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
57774940|NCT01556763|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
57774941|NCT01556763|DRUG|Placebo|Matching placebo was administered as one capsule per day for 21 days.
57774942|NCT01556763|DRUG|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
57774943|NCT02857803|PROCEDURE|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
57774944|NCT02857803|PROCEDURE|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
57774945|NCT02857803|PROCEDURE|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
57774946|NCT04853901|DRUG|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
57774947|NCT04853901|DRUG|Standard of care_1|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
57774948|NCT04853901|DRUG|Standard of care_2|Methylprednisolone 1-2mg/kg for 5-7 days
57774949|NCT04653298|OTHER|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
57774950|NCT04758234|DRUG|LY3549492|Administered orally.
57774951|NCT04758234|DRUG|Placebo|Administered orally.
57774952|NCT05817669|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
57774953|NCT05817669|BIOLOGICAL|Placebo|Patients receiving placebo infusions
57774954|NCT03459313|OTHER|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
57774955|NCT02161601|PROCEDURE|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
57774956|NCT05122572|BIOLOGICAL|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
57774957|NCT01740011|PROCEDURE|Laparoscopic surgery|
57774958|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
57774959|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
57774960|NCT01974466|OTHER|Goal A|controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
57774961|NCT01974466|OTHER|Goal B|"controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
57774962|NCT04020003|DRUG|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
57774963|NCT06317519|PROCEDURE|Physical Rehabilitation|5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
57774964|NCT06317519|DEVICE|Gait Real-time Analysis Interactive Lab|5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
57774965|NCT06392685|OTHER|Silane coupling agent|Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done
57774966|NCT06392685|OTHER|Adhesive containing silane.(Intervention 1 )|Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
57774967|NCT06392685|OTHER|Acid resistance silane containing adhesive.(Intervention 2)|Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
57774968|NCT01428804|DEVICE|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
57774969|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
57774970|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
57774971|NCT03860064|OTHER|Non intervention|Non
57774972|NCT05092425|OTHER|no intervention|no intervention
57774973|NCT06238063|BEHAVIORAL|Nurse-led Advance Care Planning (ACP) Intervention|An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
57774974|NCT05871931|OTHER|Tidal Model-based psychiatric nursing approach|8 meetings in 2 month
57774975|NCT00452179|DRUG|APD125|
57774976|NCT04170296|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
57774977|NCT04672889|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 1 months
57774978|NCT04672889|DIETARY_SUPPLEMENT|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
57774979|NCT06360003|PROCEDURE|Right Ventricular Outflow Tract Posterior Septum Pacing|The Right Ventricular Outflow Tract (RVOT) posterior septum pacing is routinely performed to observe the QRS complex characteristics of the 12 lead ECG (with a focus on comparing their differences with the R-wave amplitude of spontaneous ventricular arrhythmias in the right chest (V1\~V3) leads). When the pacing-induced R-wave amplitudes are all lower than spontaneous VAs in V1\~V3, we predict the origin of Left Ventricular Outflow Tract (LVOT), mapping and ablation in LVOT; otherwise we predict the origin of RVOT, mapping and ablation in RVOT.If fails, go to the opposite site to do mapping and ablation. If still fails, go to distal great cardiac vein (DGCV) to do mapping and ablation.
57774980|NCT06360003|PROCEDURE|systemic mapping and ablation|The TC or ST ablation catheter is delivered to ventricular outflow tract (VOT) to perform systemic mapping and ablation.
57774981|NCT04976569|DEVICE|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
57774982|NCT05274308|PROCEDURE|Blood sampling|Blood sampling from all eligible transplantation patients according to the protocol
57774983|NCT00791115|PROCEDURE|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
57774984|NCT00839917|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
57774985|NCT00839917|BIOLOGICAL|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
57774986|NCT05904743|BIOLOGICAL|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
57774987|NCT05904743|BIOLOGICAL|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
57774988|NCT05904743|BIOLOGICAL|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
57774989|NCT05904743|BIOLOGICAL|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
57774990|NCT00670696|DRUG|Rapydan|Topical anaesthetic plaster
57774991|NCT00670696|DRUG|tetracaine gel|Topical tetracaine gel
57774992|NCT05655104|OTHER|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
57774993|NCT04320615|DRUG|Tocilizumab (TCZ)|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
58459674|NCT01927497|PROCEDURE|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
57774994|NCT04320615|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
58459675|NCT01361022|DRUG|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
58459676|NCT01361022|DRUG|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
58459677|NCT03449758|DRUG|SARILUMAB|Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
57774995|NCT03681483|DRUG|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
57774996|NCT06365606|DEVICE|iStatis Syphilis Ab Test|Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.
57774997|NCT02587689|BIOLOGICAL|anti-MUC1 CAR T Cells|
57774998|NCT02323503|DEVICE|CRT-D device replacement|
57774999|NCT00846833|BIOLOGICAL|Haploidentical NK cell|"1. Collection of PBMCs by leukapheresis~2. CD3+ depletion of apheresis product using CliniMACS®"
57775000|NCT01227408|DRUG|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
57775001|NCT05270317|PROCEDURE|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
57775002|NCT01223222|DRUG|LTX-109|Topical administration. 3 times daily. 5 days.
57775003|NCT02746575|DRUG|metoprolol|
57775004|NCT01977001|DEVICE|MigraineBoxTM|
57775005|NCT06266702|OTHER|Experimental Oil with Phospholipids|Consumed on white bread
57775006|NCT06266702|OTHER|Control Polyunsaturated Oil Blend|Consumed on white bread
57775007|NCT00309608|DRUG|Linagliptin|Linagliptin medium dose tablet once daily
57775008|NCT00309608|DRUG|Linagliptin|Linagliptin high dose tablet once daily
57775009|NCT00309608|DRUG|Linagliptin|Linagliptin low dose tablet once daily
57775010|NCT00309608|DRUG|Placebo|Placebo tablets once daily
57775011|NCT00309608|DRUG|Glimepiride|Glimepiride tablets once daily
57775012|NCT02991235|DIETARY_SUPPLEMENT|PRJ212|6 capsules of study product will be taken daily and orally.
57775013|NCT02991235|DIETARY_SUPPLEMENT|Placebo|6 capsules of study product will be taken daily and orally.
57775014|NCT03917160|DEVICE|EMS device|EMS treatment will be performed
57775015|NCT01700673|DRUG|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
57775016|NCT01700673|BIOLOGICAL|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
57775017|NCT04268953|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
57775018|NCT04739683|DEVICE|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
57775019|NCT04739683|DEVICE|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
57775020|NCT05504382|DEVICE|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
57775021|NCT05261932|PROCEDURE|AI-assisted guided biopsy|The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
57775022|NCT06529354|BEHAVIORAL|Moderate-intensity Group|In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
57775023|NCT06529354|BEHAVIORAL|High-intensity Group|In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
57775024|NCT01421082|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
57775025|NCT06414564|DEVICE|Medtronic 780G insulin pump|Subjects on insulin infusion by 780G AHCL system
57775026|NCT05393362|PROCEDURE|Cardiac Rehabilitation Program (CR)|"Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end."
57775027|NCT05393362|BEHAVIORAL|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
57775028|NCT02910518|DRUG|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57775029|NCT02910518|DRUG|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57775030|NCT02910518|DRUG|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
57775031|NCT02910518|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57775032|NCT02910518|DRUG|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
58459678|NCT03449758|DRUG|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
57775033|NCT02910518|DRUG|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
57775034|NCT02910518|DRUG|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
57775035|NCT03722719|OTHER|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
57775036|NCT03722719|OTHER|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
57775037|NCT03722719|OTHER|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
57775038|NCT04840888|DRUG|LY3484356|Administered orally.
57775039|NCT04840888|DRUG|Omeprazole|Administered orally.
58459679|NCT03449758|DRUG|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
58459680|NCT03449758|DRUG|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
58459681|NCT03449758|DRUG|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
57775040|NCT04840888|DRUG|Itraconazole|Administered orally.
57775041|NCT04840888|DRUG|Carbamazepine|Administered orally.
58459682|NCT03449758|DRUG|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
58459683|NCT03449758|DRUG|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
57775042|NCT05159206|PROCEDURE|CT group|This group will do a preoperative CT scan for templating. The same scan is then used for per-operative navigation. After surgery, a postoperative CT will validate the templating/navigation, and then subsequent CT scans (postoperative, 3 months, 1 and 2 years) will be done to measure prosthetic migration over time.
57775043|NCT00975572|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
57775044|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
57775045|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
57775046|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
57775047|NCT00975572|BIOLOGICAL|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
57775048|NCT00975572|BIOLOGICAL|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
57775049|NCT02797223|BEHAVIORAL|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
57775050|NCT01738022|OTHER|Administration of gas mixtures|
57775051|NCT03577808|OTHER|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
57775052|NCT02140294|DIETARY_SUPPLEMENT|Polymeric nutritional supplements|
57775053|NCT02140294|DIETARY_SUPPLEMENT|Standard Nutrional Treatment|
57775054|NCT00204659|DRUG|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
57775055|NCT03045393|DRUG|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
57775056|NCT03306043|DRUG|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
57775057|NCT02843958|DEVICE|HEMOPTIC|
57775058|NCT02976597|DRUG|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
58459684|NCT01762553|BEHAVIORAL|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
58459685|NCT04834570|BEHAVIORAL|Quality of life in Breast Cancer Survivors|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B"
58459686|NCT02462694|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
58459687|NCT02462694|BEHAVIORAL|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
57775059|NCT02976597|DRUG|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
57775060|NCT02976597|DRUG|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
57775061|NCT02341456|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
57775062|NCT02341456|DRUG|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
57775063|NCT02341456|DRUG|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
57775064|NCT06369025|BEHAVIORAL|Interaction Competencies with Children|"Interaction Competencies with Children - for Teachers (ICC-T) Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~Interaction Competencies with Children - for Parents (ICC-P) Core training components include parents-child interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the home"
58459688|NCT04569877|DRUG|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
58459689|NCT04569877|OTHER|Placebo nebuliser solution|Placebo nebulised seven times within 7 days via rapid nebuliser system
58459690|NCT02219646|DRUG|Vardenafil|Vardenafil 10 mg twice daily for six months
58459691|NCT02219646|DRUG|Placebo|Placebo two tablets daily for 6 months
58459692|NCT02767817|PROCEDURE|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
57775065|NCT00429494|DRUG|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
57775066|NCT00429494|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
57775067|NCT00429494|PROCEDURE|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
57775068|NCT01062412|DEVICE|LensAR Laser System|Laser treatment of the crystalline lens
57775069|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
57775070|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
57775071|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
57775072|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
57775073|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
57775074|NCT05914831|RADIATION|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
57775075|NCT05914831|RADIATION|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
57775076|NCT00552786|DRUG|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
57775077|NCT00552786|DRUG|glucose|1 gm glucose capsule
57775078|NCT01760746|OTHER|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
57775079|NCT06044363|OTHER|Satir group|Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
57775080|NCT05327335|DEVICE|Intelligent robotics for elderly assistance - sarcopenia|Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype. The system, connected to mobile apps and the Internet, will serve as a platform to measure and record data on how the participants engage in pre-specified activities. The experiment will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the design specifications for functionalities and reliability, user experiences, system security and privacy.
57775081|NCT02307110|OTHER|cross-sectional observation|cross-sectional opthalmic examination
57775082|NCT01216176|DRUG|Anastrozole|
57775083|NCT01216176|DRUG|AZD0530 (saracatinib)|
58129671|NCT06246032|OTHER|Modified feeding Protocol|"Initiation of feeding (fixed): 10cc/kg~Advancement based on birthweight (fixed):~\<750g: 15cc/kg/d 750-999g: 20cc/kg/d 1000-1249g: 25cc/kg/d 1250-1499g: 25cc/kg/d 1500-1749g: 35cc/kg/d 1750-2000g: 35cc/kg/d~Starting Human milk fortification when feed reach at 70cc/kg/d"
57775084|NCT01216176|DRUG|Placebo|
57775085|NCT05078528|DEVICE|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
57775086|NCT01857830|BEHAVIORAL|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
57775087|NCT01857830|BEHAVIORAL|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
57775088|NCT02971059|DIETARY_SUPPLEMENT|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
57775089|NCT02767635|DRUG|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
57775090|NCT02767635|DRUG|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
57775091|NCT02767635|DRUG|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
57775092|NCT00706784|DRUG|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
57775093|NCT05262426|BEHAVIORAL|Behavioral: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
57785297|NCT05451511|OTHER|Foot-In-The-Door Technique|Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
58129672|NCT04736992|OTHER|No intervention involved|No intervention involved
58129673|NCT04870190|DRUG|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
58129674|NCT04870190|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
57775094|NCT05262426|BEHAVIORAL|Enhanced YaCool|Enhanced YaCool is mobile application developed to support transgender women self-management of their gender and sexual health, including PrEP use. YaCool is a passcode-protected app that allows users to personalized text messaged reminders to take PrEP and/or clinic appointments, record PrEP adherence and sexual activity, and track lab tests. The application is set up to provide personalized recommendations for PrEP regimen, confirmed by clinic healthcare staff. Participants will be asked to download Enhanced YaCool to support PrEP use and gender/sexual health self-management between MES-PrEP sessions for 30 days, and thereafter until the end of Month 12 (if desired).
57775095|NCT05262426|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3, 6, 9 and 12. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
57775096|NCT02521324|DEVICE|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
57775097|NCT05039034|OTHER|Advice according to primary prevention guidelines on stroke of China|
57775098|NCT03018743|DRUG|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
57775099|NCT04166929|BIOLOGICAL|Haplo SCT with NK cells|Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
57775100|NCT04166929|BIOLOGICAL|Haplo SCT|Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
57775101|NCT01288781|DRUG|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
57775102|NCT01288781|DRUG|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
57775103|NCT02013973|OTHER|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
57775104|NCT03307915|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
57775105|NCT03307915|BIOLOGICAL|MVA-Mosaic|Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.
57775106|NCT03307915|BIOLOGICAL|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
57775107|NCT03307915|DRUG|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
57775108|NCT03118544|DEVICE|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
57775109|NCT04328363|BEHAVIORAL|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
57775110|NCT05045911|PROCEDURE|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
58459693|NCT02767817|BIOLOGICAL|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
58129675|NCT02323490|PROCEDURE|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
57775111|NCT01447849|DRUG|lubiprostone|24mcg twice a day (BID) 1 week
57775112|NCT01447849|DRUG|placebo|Placebo pills twice a day for one week.
58459694|NCT02767817|BIOLOGICAL|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
58459695|NCT01445444|BEHAVIORAL|Habit Reversal Training|"* 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
58129676|NCT02323490|PROCEDURE|without microfractures|standard procedure meniscal repair without augmentation.
58459696|NCT03776864|BIOLOGICAL|Pembrolizumab|Given IV
58459697|NCT03776864|DRUG|Umbralisib|Given PO
58459698|NCT04839341|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
58459699|NCT02193776|DRUG|PA-824|oral
57775113|NCT03381508|DEVICE|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
57775114|NCT02831179|DRUG|Capecitabine|Given PO
57775115|NCT02831179|DRUG|Temozolomide|Given PI
57775116|NCT02831179|DRUG|Veliparib|given PO
57775117|NCT02831179|OTHER|Pharmacological Study|Correlative studies
57775118|NCT02831179|OTHER|Laboratory Biomarker Analysis|Correlative studies
57775119|NCT03434236|DIETARY_SUPPLEMENT|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
57775120|NCT03434236|DIETARY_SUPPLEMENT|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
57775121|NCT03434236|DIETARY_SUPPLEMENT|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
57775122|NCT01706965|DRUG|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
57775123|NCT01706965|DRUG|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
57775124|NCT01406717|DRUG|SPIL1033|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
57775125|NCT01406717|DRUG|Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
57775126|NCT05542732|DEVICE|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
57775127|NCT06488794|DRUG|colistimethate sodium|30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for 3 days for eligible ventilated children starting from day 3 of mechanical ventilation.
58138126|NCT01942863|PROCEDURE|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
57775128|NCT06488794|DRUG|0.9% Saline|Nebulization of 3 ml of 0.9% saline twice a day for 3 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
57775129|NCT04243889|DEVICE|NEOX Cord 1K|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
57775130|NCT01427335|DRUG|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
57775131|NCT01427335|DRUG|0.9 % saline|0.9 % saline intravenous infusion
57775132|NCT02701751|OTHER|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
57775133|NCT01594177|DRUG|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
57775134|NCT01594177|DRUG|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
57775135|NCT01594177|DRUG|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
57775136|NCT01594177|DRUG|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
57775137|NCT01594177|DRUG|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
57775138|NCT03948425|RADIATION|spectral CT|Head spectral CT
57775139|NCT05172830|DEVICE|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
57775140|NCT03752762|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
57775141|NCT03752762|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
57775142|NCT01698658|OTHER|ultrasound tomography|Undergo ultrasound tomography using SoftVue
57775143|NCT01698658|PROCEDURE|magnetic resonance imaging|Undergo MRI of the breast
57775144|NCT02913521|DRUG|Diclofenac Sodium Gel 1%|
57775145|NCT02913521|DRUG|Voltaren Gel|
57775146|NCT02913521|DRUG|Placebo|
58459700|NCT02193776|DRUG|bedaquiline|oral
58459701|NCT02193776|DRUG|moxifloxacin|oral
57775147|NCT04221750|BEHAVIORAL|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
57775148|NCT04221750|DRUG|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
58459702|NCT02193776|DRUG|pyrazinamide|oral
57775149|NCT04221750|DRUG|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
58459703|NCT02193776|DRUG|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
57775150|NCT04221750|BEHAVIORAL|Healthy Lifesylte|Group educational sessions that focus on healthy diet, exercise, and social support once a month
57775151|NCT02710760|OTHER|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
57775152|NCT02710760|OTHER|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
57775153|NCT04961736|OTHER|no intervention|This is an observation study, with no intervention
57775154|NCT04757467|OTHER|Standard physiotherapy neuro-rehabilitation|Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education
57775155|NCT04757467|OTHER|Repetition-CIMT|"In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant"
57775156|NCT04757467|OTHER|Hour-CIMT|A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
57775157|NCT01705275|DRUG|ONO-8539|ONO-8539
57775158|NCT01705275|OTHER|Placebo|Identical to ONO-8539 tablet but without active ingedient
57775159|NCT05471258|OTHER|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
57775160|NCT05471258|OTHER|Control: Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
57775161|NCT04513457|OTHER|Liver resection and Neoadjuvant chemotherapy|
57775162|NCT04513457|OTHER|Liver resection and Adjuvant chemotherapy|
57775163|NCT04513457|OTHER|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
58129677|NCT04346706|DEVICE|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
58138127|NCT01942863|PROCEDURE|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
58459704|NCT03045367|PROCEDURE|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
58459705|NCT04601935|BIOLOGICAL|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
58459706|NCT00768612|DRUG|SCA-136 50mg/day|
58459707|NCT00768612|DRUG|SCA-136 150 mg/day|
58459708|NCT00768612|DRUG|SCA-136 300mg/day|
57775164|NCT04513457|PROCEDURE|Liver resection|
57775165|NCT03414697|OTHER|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
57775166|NCT03414697|PROCEDURE|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
57775167|NCT01807221|DRUG|Finerenone (BAY94-8862)|
57775168|NCT01807221|DRUG|Placebo|
57775169|NCT01807221|DRUG|Inspra (eplerenone)|
58459709|NCT00768612|DRUG|Risperidone 4mg/day|
57775170|NCT05693493|DEVICE|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
57775171|NCT01898520|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
57775172|NCT01898520|DRUG|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
57775173|NCT03121534|DRUG|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
57775174|NCT03121534|DRUG|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for \>4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
57775175|NCT03121534|DRUG|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
57775176|NCT03121534|DRUG|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
57775177|NCT01830881|DRUG|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
57775178|NCT01830881|DRUG|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
57775179|NCT01830881|OTHER|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
57775180|NCT01830881|DRUG|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
57775181|NCT00005991|DRUG|gemcitabine hydrochloride|
58129678|NCT04346706|DEVICE|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
58459710|NCT06380153|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
58459711|NCT06416566|DRUG|Subcutaneous Enoxaparin|Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
58459712|NCT04040374|DIAGNOSTIC_TEST|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
58459713|NCT04040374|DIAGNOSTIC_TEST|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
58459714|NCT04355234|DIAGNOSTIC_TEST|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
57775182|NCT00005991|DRUG|pegylated liposomal doxorubicin hydrochloride|
57775183|NCT03748979|DRUG|TAK-925|TAK-925
57775184|NCT03748979|DRUG|Placebo|TAK-925 Placebo
57775185|NCT04772690|OTHER|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
57775186|NCT05438615|OTHER|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
57775187|NCT05438615|OTHER|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
57785298|NCT06387732|OTHER|Aerobic exercise|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
57775188|NCT03893864|DIETARY_SUPPLEMENT|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, \> 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
57775189|NCT03893864|PROCEDURE|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
57775190|NCT03893864|DIAGNOSTIC_TEST|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
57775191|NCT03893864|DIAGNOSTIC_TEST|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
57775192|NCT04286230|BEHAVIORAL|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
57775193|NCT04286230|BEHAVIORAL|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
57775194|NCT04410328|DRUG|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
57775195|NCT04410328|OTHER|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.
57775196|NCT04343781|OTHER|observation|observation of clinical symptoms related to COVID-19 disease
57775197|NCT06381817|BIOLOGICAL|Haplo-cord HCT|Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit
57775198|NCT06381817|BIOLOGICAL|Haplo-HCT|Hematopoietic cell transplantation will be performed with a haploidentical donor
57775199|NCT03154840|DRUG|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
57775200|NCT04713085|DEVICE|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
57775201|NCT04713085|DEVICE|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
57775202|NCT04621136|DRUG|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
57775203|NCT04466423|BEHAVIORAL|Small group meetings (COMPASS: COlleagues Meeting to Promote And Sustain Satisfaction)|The first 15 minutes of each session will be semi-structured discussion involving i) check in and ii) dialogue about the assigned question. Group leaders will be provided 3-4 discussion questions for each session. The group (or the leader) can choose the one they are most interested in and will then spend 10-15 minutes discussing the question together. Questions will touch on key themes for discussion (see the attached topics list) and are derived from our previous intervention studies. The remainder of the time can be used for socializing and building relationships with colleagues.
57775204|NCT01488864|BEHAVIORAL|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
57775205|NCT05765188|OTHER|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
58459715|NCT04355234|BIOLOGICAL|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
58459716|NCT01005251|DRUG|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
58459717|NCT01005251|DRUG|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
58459718|NCT01005251|DRUG|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
58459719|NCT01005251|DRUG|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
58459720|NCT01005251|DRUG|Placebo|oral,capsules, bid for 4 w
58459721|NCT01672385|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
58459722|NCT04939766|DEVICE|Activation of a closed loop device in an insulin pump device with GCM|After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
58459723|NCT02919774|DRUG|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
58459724|NCT02919774|DRUG|placebo|matching placebo tablets
58459725|NCT01502748|OTHER|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
58459726|NCT04078802|PROCEDURE|VNOTES/VH|same as above
57775206|NCT05727033|BEHAVIORAL|Participatory teaching group|"The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence."
57775207|NCT05727033|BEHAVIORAL|Sham control group|"The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective."
57775208|NCT01983137|DRUG|Targinact® (oxycodone/naloxone)|
57775209|NCT03862703|DEVICE|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
57775210|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775211|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775212|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775213|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775214|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775215|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
57775216|NCT05136911|BEHAVIORAL|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
57775217|NCT01248962|DRUG|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
57775218|NCT01248962|DRUG|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
57775219|NCT00196989|DRUG|Pioglitazone|
57775220|NCT00196989|DRUG|GW677954|
57775221|NCT02811900|PROCEDURE|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
57775222|NCT02811900|PROCEDURE|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
57775223|NCT02811900|PROCEDURE|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
57775224|NCT02811900|PROCEDURE|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
57775225|NCT00557622|DRUG|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
57775226|NCT00557622|OTHER|placebo|placebo
57775227|NCT01440582|DRUG|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
57775228|NCT01440582|DRUG|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
57775229|NCT01440582|DRUG|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
57775230|NCT01440582|DRUG|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
57775231|NCT01440582|BEHAVIORAL|Symptom Questionnaire|Completed on day 1 of each cycle.
57775232|NCT04570345|DRUG|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
57775233|NCT04570345|DRUG|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
57775234|NCT06218134|BIOLOGICAL|human Wharton's jelly-derived mesenchymal stem cells|human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
57775235|NCT03492619|BEHAVIORAL|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
57775236|NCT03492619|BEHAVIORAL|Non-Intensive Intervention|Group sessions for healthy lifestyle
57775237|NCT02423590|DRUG|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
57775238|NCT02423590|DRUG|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
57775239|NCT02423590|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
57775240|NCT01729897|DRUG|Etomidate|
57775241|NCT01729897|DRUG|Fentanyl|
57775242|NCT01729897|DRUG|Propofol|
58459727|NCT06391554|OTHER|PRT|An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week. The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks. After the 12 weeks, participants will receive 8 booster sessions and are given a membership to a fitness center where they will be encouraged to continue the exercise program on their own.
58459728|NCT06391554|OTHER|EDU|Three EDU sessions provided by a trained physiotherapist involving important disease-specific information. The sessions will address knowledge of OA, treatment options with a specific focus on physical activity recommendations, advice on self-management and more. All three sessions will emphasize on engaging the participants actively and sharing experiences with each other.
58459729|NCT01862146|PROCEDURE|smoke expose|
58459730|NCT00666666|DRUG|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
57775243|NCT00664703|DRUG|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
57775244|NCT00664703|DRUG|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
57775245|NCT00664703|DRUG|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
57775246|NCT05245799|BEHAVIORAL|Speech Language Therapy|Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.
57775247|NCT05245799|BEHAVIORAL|Digital Software Application|The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
57775248|NCT02893683|OTHER|Paris Visual Learning Test|
57775249|NCT00464919|DRUG|Sorafenib|
57775250|NCT00464919|DRUG|tegafur/uracil (UFUR®)|
57775251|NCT05088967|DRUG|IBI110|R2PD d1 IV every 3 weeks
57775252|NCT05088967|DRUG|sintilimab|200mg d1 IV every 3 weeks
57775253|NCT04532437|OTHER|artificial intelligence-based skin aging simulation|Photographs of the volunteers' facial skin will be taken in the Department of Dermatology at baseline using a modern skin analysis photo system (VISIA®, Canfield Scientific, Parsippany, NJ, USA) and afterwards a simulation of the participants' facial skin aging will be performed with the VISIA® photo analysis System.
57775254|NCT04532437|OTHER|electronic questionnaire 1|Electronic questionnaire about current sun-related knowledge and protective behaviours via link with smartphone before and after the skin aging simulation.
58459731|NCT00666666|DRUG|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
58459732|NCT00666666|OTHER|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
57775255|NCT04532437|OTHER|electronic questionnaire 2|Participants report their perception of the interventions and their motivation for improved sun protection by completing an electronic questionnaire after the skin aging simulation.
57775256|NCT05858320|OTHER|SmartHF application|Adaptive medication recommendations that can be shared with the participants HF provider.
57775257|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
57775258|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with DracoBelleTM Nu.|Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
58459733|NCT05919342|DIAGNOSTIC_TEST|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
58459734|NCT04921943|DRUG|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
58459735|NCT04921943|DRUG|Azithromycin|Standard of care
58459736|NCT04921943|DRUG|Ethambutol|Standard of care
58459737|NCT04921943|DRUG|Rifampin|Standard of care
57775259|NCT02413684|BEHAVIORAL|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
58459738|NCT03200444|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
57775260|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy - Pain|Pain treatment
57775261|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy-Integrated|Integrated treatment
57775262|NCT00127413|BEHAVIORAL|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
57775263|NCT00127413|BEHAVIORAL|Treat as Usual|Treatment as usual
57775264|NCT05420324|DRUG|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
57775265|NCT05420324|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
57775266|NCT05420324|DRUG|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
57775267|NCT05853757|DRUG|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
57775268|NCT02390063|BIOLOGICAL|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
57775269|NCT02390063|BIOLOGICAL|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
57775270|NCT02390063|DRUG|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
57775271|NCT00074243|DRUG|CC-8490|
57775272|NCT01749501|DRUG|Rocuronium|0.6 mg/Kg once
58459739|NCT03200444|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
58459740|NCT03200444|OTHER|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
58459741|NCT03200444|OTHER|P-4|Newly developed adhesive P-4
58459742|NCT03200444|OTHER|P-15|Newly developed adhesive P-14
57775273|NCT01749501|OTHER|Placebo|Normal saline same amt as 0.6mg/kg of study drug
57775274|NCT01952964|OTHER|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
57775275|NCT01863641|DRUG|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
57775276|NCT01863641|DRUG|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
57775277|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
57775278|NCT01730014|DRUG|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
57775279|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
58459743|NCT03200444|OTHER|P-16|Newly developed adhesive P-8
57775280|NCT01730014|DRUG|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
57775281|NCT01730014|DRUG|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
57775282|NCT01730014|DRUG|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
57775283|NCT02612896|DRUG|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
57775284|NCT02612896|BEHAVIORAL|Health education|in all study arms, using village meetings, posters, pamphlets.
57775285|NCT06240858|PROCEDURE|Laparoscopic transabdominal preperitoneal hernia repair.|The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.
57775286|NCT06240858|PROCEDURE|Lichtenstein hernia repair.|The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
57775287|NCT02127827|DEVICE|Automated Ambulatory Glycemic Controller (AAGC)|
57775288|NCT02691351|OTHER|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
57775289|NCT02827786|DEVICE|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
57775290|NCT00485056|DRUG|Pioglitazone|45mgs daily
57775291|NCT00977405|DEVICE|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
57775292|NCT04435392|DRUG|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
57775293|NCT04435392|DRUG|Placebo|Placebo
58459744|NCT03691493|DRUG|Anastrozole|Given PO
58459745|NCT03691493|DRUG|Exemestane|Given PO
58459746|NCT03691493|DRUG|Fulvestrant|Given IM
58459747|NCT03691493|DRUG|Letrozole|Given PO
58459748|NCT03691493|DRUG|Palbociclib|Given PO
58459749|NCT03691493|RADIATION|Radiation Therapy|Undergo radiation therapy
58459750|NCT03691493|DRUG|Tamoxifen|Given PO
58459751|NCT00228280|PROCEDURE|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
57775294|NCT01368211|BIOLOGICAL|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
57775295|NCT01368211|BIOLOGICAL|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
57775296|NCT00451841|DEVICE|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
57775297|NCT04956263|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
57775298|NCT04956263|DRUG|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
57775299|NCT03567993|BEHAVIORAL|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
57775300|NCT03567993|BEHAVIORAL|Intervention|"Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
57775301|NCT00007475|PROCEDURE|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
57775302|NCT00007475|DRUG|Cyclophosphamide|For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
57775303|NCT05177575|PROCEDURE|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
57775304|NCT06265883|PROCEDURE|Len+DEB-TACE+HAIC|Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
57775305|NCT06265883|PROCEDURE|Len+DEB-TACE|Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
57775306|NCT01190332|PROCEDURE|endoscopic sphincterotomy by conventional method|
57775307|NCT01190332|PROCEDURE|endoscopic sphincterotomy by rendezvous method|
57775308|NCT03781115|DRUG|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
57775309|NCT03781115|DRUG|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
57775310|NCT03781115|DRUG|Placebo Comparator|A non drug oral placebo capsule will be given as a control
57775311|NCT05826522|OTHER|observationnal|cohort of blood collection and severals exams
57775312|NCT00358150|DRUG|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
57775313|NCT03781232|DEVICE|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
57775314|NCT06138275|DRUG|Elranatamab|subcutaneous (under the skin) injection
57785299|NCT06387732|OTHER|Stretching and relaxation|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
57785300|NCT02430636|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
57785301|NCT02430636|DEVICE|NanoKnife|
58459752|NCT03816735|DEVICE|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
58459753|NCT03816735|DEVICE|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
58459754|NCT01009060|DRUG|GSK239512|Histamine H3 Antagonist
58459755|NCT01009060|DRUG|Placebo|Placebo to match GSK239512
58459756|NCT05647681|DRUG|Douloff|topic gel
58459757|NCT05647681|DRUG|paracetamol|tablets
58459758|NCT02918617|DRUG|Control toothpaste containing Novamin® technology|
57775315|NCT00615394|PROCEDURE|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
57775316|NCT05214014|BIOLOGICAL|Autologous Regulatory Т-cells|Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
57775317|NCT05214014|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Systemic Sclerosis according to the clinical protocols
57775318|NCT01993823|DRUG|G238|Five drops into the ear canal twice daily for 14 days
57775319|NCT01993823|DRUG|Clotrimazole|Five drops into the ear canal twice daily for 14 days
57775320|NCT04825821|PROCEDURE|Clinical and ultrasonographic assessment|Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
57775321|NCT03915080|DRUG|Oktokog alpha|adjusting dose and dose interval according to MyPKFIT
57775322|NCT00322608|DRUG|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
57775323|NCT03768999|DIAGNOSTIC_TEST|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
57775324|NCT05740761|OTHER|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
57775325|NCT02758574|PROCEDURE|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
57775326|NCT02758574|PROCEDURE|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
57775327|NCT02790593|DEVICE|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
57775328|NCT02790593|DEVICE|Standard Compression|Compression bandaging
58459759|NCT02918617|DRUG|Control toothpaste containing 1500 ppm fluoride as MFP|
58459760|NCT02918617|DRUG|Test toothpaste with nano-HAP (high concentration)|
58459761|NCT02918617|DRUG|Test toothpaste with nano-HAP (low concentration)|
57775329|NCT02790593|DEVICE|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
57775330|NCT02790593|DEVICE|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
57775331|NCT05024149|OTHER|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
57775332|NCT04315415|DEVICE|Silk Voice|Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
57775333|NCT00114309|DRUG|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
57775334|NCT00114309|DRUG|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
57775335|NCT06208072|DRUG|Irbesartan 150mg|Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
57775336|NCT06208072|DRUG|Eplerenone 25 mg|Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
57775337|NCT03050437|DRUG|Cisplatin|cisplatin is added to Pem/cis arm
58459762|NCT02918617|DRUG|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
58459763|NCT02918617|DRUG|Control toothpaste without nano-HAP|
58459764|NCT02918617|DRUG|Test toothpaste with nano-HAP (medium concentration)|
57775338|NCT03050437|DRUG|Pemetrexed|Pem is applied to both arms
57775339|NCT02905123|BEHAVIORAL|Check Your Drinking|
57775340|NCT03770013|DRUG|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
57775341|NCT03770013|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
57775342|NCT03770013|DRUG|clonidine|1ug/kg clonidine
57775343|NCT03770013|DRUG|placebo|add placebo 9normal saline)
57785570|NCT06220786|DEVICE|"Fake low-level laser therapy"|Identical laser pen without production of low-level laser therapy
58459765|NCT02918617|DRUG|Test cream with nano-HAP (higher concentration)|
58459766|NCT02918617|DRUG|Control cream without nano-HAP|
58459767|NCT02137863|DRUG|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
58459768|NCT02137863|DRUG|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
58459769|NCT02137863|DRUG|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
58459770|NCT01229189|DIETARY_SUPPLEMENT|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
58459771|NCT01229189|DIETARY_SUPPLEMENT|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
57775344|NCT02811094|OTHER|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
57775345|NCT01275196|DRUG|Nilotinib|
57775346|NCT01275196|DRUG|Imatinib|
57775347|NCT02339701|RADIATION|IMRT|
57775348|NCT02339701|RADIATION|SBRT|
58459772|NCT03324607|DRUG|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
57775349|NCT00994474|PROCEDURE|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
57775350|NCT00994474|PROCEDURE|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
57775351|NCT02338518|DRUG|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
57775352|NCT02338518|DRUG|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
57775353|NCT02338518|DRUG|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
57775354|NCT02338518|DRUG|S-1|80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
57775355|NCT05943418|BEHAVIORAL|Wysa for Worry|"The Wysa for Worry cCBT program is a week-based cCBT programme consisting of specialised cognitive behavior therapy (CBT) interventions delivered through a conversational agent.~Each week of the programme focuses on a different CBT technique or intervention, which is explained in a short weekly video. Following each video, the technique or intervention is discussed and practiced with Wysa's AI chatbot."
57775356|NCT05943418|BEHAVIORAL|App-based Psychoeducation|The control will include the weekly delivery of active psychoeducational resources.
57775357|NCT05071274|DEVICE|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
57775358|NCT03084939|BIOLOGICAL|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
57775359|NCT03084939|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
57775360|NCT03084939|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
57775361|NCT06241261|DRUG|Silver diamine fluoride gel|Application of 38% SDF gel every 6 months
57775362|NCT06241261|DRUG|Silver diamine fluoride solution|Application of 38% SDF solution every 6 months
57775363|NCT04156152|OTHER|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
57775364|NCT04156152|OTHER|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
57775365|NCT00823732|OTHER|educational intervention|Undergo individualized interdisciplinary palliative care intervention
57775366|NCT00823732|OTHER|medical chart review|Ancillary studies
57775367|NCT00823732|OTHER|questionnaire administration|Ancillary studies
57775368|NCT00823732|PROCEDURE|end-of-life treatment/management|Undergo end-of-life treatment/management
57775369|NCT00823732|PROCEDURE|psychosocial assessment and care|Undergo psychosocial assessment and care
57775370|NCT00823732|PROCEDURE|quality-of-life assessment|Ancillary studies
57775371|NCT00823732|PROCEDURE|management of therapy complications|Undergo management of therapy complications
57775372|NCT00823732|PROCEDURE|assessment of therapy complications|Undergo assessment of therapy complications
57775373|NCT01468922|DRUG|Pazopanib|Vascular endothelial growth factor (VEGFR) inhibitor
57775374|NCT01468922|DRUG|ARQ 197|Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
57775375|NCT03077373|BEHAVIORAL|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
57775376|NCT01495182|OTHER|Dietary fiber|A proprietary fiber will be given to subjects
57775377|NCT01479686|PROCEDURE|iMRI|3.0TiMRI guided resection in adults with glioma
57775378|NCT01479686|PROCEDURE|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
58459773|NCT03324607|DRUG|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
58459774|NCT00329966|BIOLOGICAL|Surface Antigen, Inactivated, Influenza (form.2006-07)|
57775379|NCT01397565|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
57775380|NCT01397565|PROCEDURE|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
57775381|NCT02583568|DRUG|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
57775382|NCT06255093|BEHAVIORAL|Community-based recreation program referral|Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
57775383|NCT06255093|BEHAVIORAL|Pre-surveys only|Receive online wellness education and anxiety treatment options information
57775384|NCT03988010|DRUG|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
57775385|NCT03988010|DRUG|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
57775386|NCT02189096|OTHER|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
57775387|NCT02189096|OTHER|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
57775388|NCT05287568|DRUG|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
57775389|NCT05287568|DRUG|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
57775390|NCT02258464|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)
57775391|NCT02258464|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
57775392|NCT02258464|OTHER|Background hormonal therapy|Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
57775393|NCT01991249|OTHER|blood draw|
57775394|NCT01046461|DRUG|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
57775395|NCT00404482|DRUG|Cyclosporine A|
57775396|NCT03394261|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
57775397|NCT05925738|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
57775398|NCT00850044|DRUG|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
57775399|NCT00850044|DRUG|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
57775400|NCT00850044|DRUG|placebo for ABT-450|capsules, QD, one dose
57775401|NCT00850044|DRUG|Placebo for ritonavir|capsules, QD, one dose
57775402|NCT04571632|DRUG|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
57775403|NCT04571632|DRUG|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
57775404|NCT04571632|DRUG|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
57775405|NCT04571632|OTHER|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
57775406|NCT00139022|DEVICE|Continuous Positive Airway Pressure|
57775407|NCT04799860|BEHAVIORAL|health promotive work-way|"Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations"
58459775|NCT00497029|DRUG|fluoride varnish|
57775408|NCT05561348|DEVICE|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
57775409|NCT05989165|DRUG|Minoxidil 5% Topical Solution|Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
57775410|NCT05989165|DEVICE|microneedling|Patient will be given microneedling treatment every 4 weeks
57775411|NCT06071520|DRUG|Fostamatinib|Patient treated with fostamatinib in the period described
57775412|NCT03652194|OTHER|in vitro evaluation of epithelial immune response during C. glabrata infection|"1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method"
57775413|NCT03652194|OTHER|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model."
57775414|NCT06198296|GENETIC|21.15.GPC3-CAR T cells|"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2"
57775415|NCT00161096|DRUG|pantoprazole 20 mg (drug)|
57775416|NCT03549234|DRUG|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
57775417|NCT03549234|DRUG|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
57775418|NCT05223842|BEHAVIORAL|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
57775419|NCT05223842|BEHAVIORAL|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
57775420|NCT00111254|PROCEDURE|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
57775421|NCT00715741|OTHER|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
57775422|NCT00715741|OTHER|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
57775423|NCT00715741|OTHER|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 \>0.9 with 3-5 cm water PEEP
58459776|NCT00497029|BEHAVIORAL|patient education|
57775424|NCT00715741|OTHER|FiO2 >0.9 without PEEP|FiO2 \>0.9 without PEEP
57775425|NCT00406471|DRUG|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
57775426|NCT00917267|DRUG|exenatide once weekly|2.0mg subcutaneous injection, once a week
57775427|NCT00917267|DRUG|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
57775428|NCT04193748|DRUG|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
57775429|NCT01666054|OTHER|PSV|Pressure Support Ventilation will be used until patient is extubated
57775430|NCT01666054|OTHER|PAV|Proportional Assist Ventilation will be used until patient is extubated.
57775431|NCT06489054|OTHER|Peer education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the experimental group (peer-based education). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
57775432|NCT06489054|OTHER|Conventional education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the control group (dentist lecture). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
57775433|NCT01042990|OTHER|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
57775434|NCT04981132|BEHAVIORAL|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
57775435|NCT04981132|BEHAVIORAL|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
57775436|NCT04788069|DIETARY_SUPPLEMENT|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
57775437|NCT04788069|DIETARY_SUPPLEMENT|Sourdough bread|180g sourdough bread/day + fixed portion at test day
58459777|NCT06062654|OTHER|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
58459778|NCT06062654|OTHER|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
58459779|NCT00000669|DRUG|Didanosine|
57775438|NCT04788069|DIETARY_SUPPLEMENT|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
57775439|NCT00099723|DRUG|VSL#3|
57775440|NCT04114851|DEVICE|NoL|NoL active
57775441|NCT03651232|BEHAVIORAL|yoga|once weekly group yoga class for 12 weeks
57775442|NCT03651232|BEHAVIORAL|support group|once weekly group support class for 12 weeks
57775443|NCT02769065|DRUG|TAK-071|TAK-071 capsules
57775444|NCT02769065|DRUG|Donepezil|Donepezil over-encapsulated tablet
57775445|NCT02769065|DRUG|TAK-071 Placebo|TAK-071 placebo-matching capsules
57775446|NCT02769065|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
57775447|NCT03653663|DRUG|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
57775448|NCT03653663|DRUG|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
57775449|NCT03698760|DIAGNOSTIC_TEST|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
57775450|NCT01865617|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
57775451|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for CSII users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal"
57775452|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL"
57775453|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL"
57775454|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for MDI users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal"
57775455|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal"
57775456|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal"
57775457|NCT05011916|DRUG|KDR2-2 suspension eye drops|All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
57775458|NCT04191070|DEVICE|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
58459780|NCT05350722|RADIATION|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
57775459|NCT04191070|DEVICE|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
57775460|NCT04014478|DEVICE|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
57775461|NCT05936203|OTHER|Insulin therapy adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
57775462|NCT05936203|OTHER|Nutritional adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
57775463|NCT05936203|OTHER|Combination of strategies|Strategies used to manage glucose control during a prolonged aerobic exercise
57775464|NCT01554943|OTHER|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
57775465|NCT03612518|BEHAVIORAL|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
57775466|NCT03612518|BEHAVIORAL|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
58490185|NCT01317277|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
58490186|NCT01317277|BEHAVIORAL|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
57775467|NCT03909802|BEHAVIORAL|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
57775468|NCT03909802|OTHER|Usual care|Usual care
57775469|NCT02922985|DRUG|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
57775470|NCT02922985|DRUG|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
57775471|NCT02922985|DRUG|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
57775472|NCT02922985|DRUG|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
57775473|NCT03217734|BIOLOGICAL|Adalimumab|Subcutaneous Injection
57775474|NCT03217734|DRUG|Methotrexate|Oral Tablet
57775475|NCT03217734|DRUG|Placebo|Oral Tablet
57775476|NCT04623411|BEHAVIORAL|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
57775477|NCT04623411|BEHAVIORAL|Control Group|Neonatal resuscitation training with classical method
58459781|NCT00911118|RADIATION|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
58459782|NCT03550118|DEVICE|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
57775478|NCT05867264|OTHER|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is ≥ 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
57775479|NCT05867264|COMBINATION_PRODUCT|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
57775480|NCT05867264|OTHER|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
57775481|NCT00976703|OTHER|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
57775482|NCT00976703|OTHER|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
57775483|NCT00820820|BIOLOGICAL|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (\>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
57775484|NCT00820820|BIOLOGICAL|placebo|Vehicle (water for injection), 0.5 ml, once
57775485|NCT04901364|BEHAVIORAL|Sensitivity and specificity of risk factors for degeneration of IPMNs|Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen
57775486|NCT01297530|DRUG|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
57775487|NCT01674933|DRUG|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
57775488|NCT01674933|BEHAVIORAL|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
57775489|NCT01812005|DRUG|alisertib|Given PO
57775490|NCT01812005|BIOLOGICAL|rituximab|Given IV
57775491|NCT01812005|OTHER|laboratory biomarker analysis|Laboratory correlative studies will be performed
57775492|NCT04676711|DRUG|GFH312|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
57775493|NCT04676711|DRUG|Placebo|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
57775494|NCT00451568|DRUG|Metformin|500 mg 2 tablets 2 times a day
57775495|NCT00451568|DRUG|Desorelle|1 tablet/day in 21 days
58459783|NCT04203511|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
58459784|NCT04203511|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
58459785|NCT04203511|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
57775496|NCT01967264|DRUG|Udenafil|Udenafil tablets
57775497|NCT01967264|DRUG|Placebo|Placebo tablets
57775498|NCT03607903|BIOLOGICAL|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
57775499|NCT03607903|BIOLOGICAL|Adalimumab SC|Adalimumab subcutaneous using regular needle
57775500|NCT03607903|OTHER|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
57775501|NCT03607903|OTHER|Saline SC|Saline subcutaneous using regular needle
57775502|NCT05921071|DRUG|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
57775503|NCT05921071|DRUG|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
58129679|NCT01353495|DEVICE|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
57775504|NCT06048757|DEVICE|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
57775505|NCT02582164|DEVICE|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
57775506|NCT00822003|DRUG|Oral GLP-1|GLP-1 tablet (2mg)
57775507|NCT00822003|DRUG|Placebo|Control tablet
57775508|NCT01556074|BEHAVIORAL|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
57775509|NCT00284089|DRUG|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
57775510|NCT01601444|DEVICE|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
57775511|NCT00001626|DRUG|antithymocyte globulin|antithymocyte globulin
57775512|NCT00001626|DRUG|cyclophosphamide|cyclophosphamide
57775513|NCT00001626|DRUG|cyclosporine|cyclosporine
57775514|NCT01812538|DRUG|DIC075V|"Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments."
57775515|NCT05047562|OTHER|Pilates Group|16 Pilates exercise sessions twice a week for 2 months.
57775516|NCT05047562|OTHER|Segmental Stabilization group|16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
57775517|NCT04676009|OTHER|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
57775518|NCT02282319|DRUG|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
57775519|NCT02282319|OTHER|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
57775520|NCT02282319|DRUG|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
57775521|NCT04575649|OTHER|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
57775522|NCT00895843|DRUG|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
57775523|NCT00895843|DRUG|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
57775524|NCT00895843|DRUG|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
57775525|NCT00593320|RADIATION|Stereotactic Radiosurgery|
57775526|NCT03810313|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
57775527|NCT03810313|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
57775528|NCT03810313|OTHER|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
57775529|NCT01775930|DRUG|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
57775530|NCT03729011|DRUG|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
57775531|NCT03729011|DRUG|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
57775532|NCT05239416|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
57775533|NCT02690636|RADIATION|radiotherapy|daily fractions, five fractions per week.
57775534|NCT06345222|PROCEDURE|Prolotherapy|"The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament."
58129680|NCT01353495|OTHER|Wound Debridement|Wounds debrided in both arms of study
58129681|NCT03189706|DRUG|Irinotecan|50mg/m\^2/day IV will be administered from day 1-5
57775535|NCT03570125|DIETARY_SUPPLEMENT|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
57775536|NCT01226979|RADIATION|High-dose endorectal brachytherapy (HDRBT)|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
57775537|NCT01755520|DRUG|Ticagrelor|90mg twice daily dose
57775538|NCT01755520|DRUG|Aspirin|Aspirin 100mg once daily
57775539|NCT01755520|DRUG|Placebo - Ticagrelor|Placebo
57775540|NCT01755520|DRUG|Placebo - Aspirin|Placebo
57775541|NCT06261463|BEHAVIORAL|CAFES2|The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
57775542|NCT05197790|DEVICE|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
57775543|NCT02443103|DRUG|Guanabenz acetate|
57775544|NCT02762383|DRUG|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
58459786|NCT04203511|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
57775545|NCT01743690|BIOLOGICAL|Probiotic lactobacilli reuteri|
57775546|NCT01743690|DRUG|Nystatin|
57775547|NCT01743690|DRUG|fluocinolone|
57775548|NCT05140811|DRUG|IMM01|IMM01 is intravenously once a week, every 28 days for a treatment cycle;
57775549|NCT05140811|DRUG|Azacitidine|Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
57775550|NCT00002215|DRUG|Emivirine|
57775551|NCT00002215|DRUG|Nelfinavir mesylate|
57775552|NCT05689814|DEVICE|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
58459787|NCT04203511|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
57775553|NCT00960102|DEVICE|cochlear implant|Multichannel Nucleus cochlear implant
57775554|NCT00960102|DEVICE|hearing aid|Phonak hearing aid
57775555|NCT01435044|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
57775556|NCT01435044|DRUG|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
57775557|NCT01435044|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
58459788|NCT04203511|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
58459789|NCT04203511|DRUG|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
57775558|NCT01435044|DRUG|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
57775559|NCT01435044|DRUG|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
57775560|NCT01342029|DRUG|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks"
57775561|NCT01342029|DRUG|Placebo|500-1,000 mg po bid for 2 weeks
57775562|NCT06413550|BIOLOGICAL|Hibiscus Sabdariffa|The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
57775563|NCT05401370|PROCEDURE|Methylene blue dye|For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
57775564|NCT03585114|DRUG|[F-18] DCFPyL|\[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
58459790|NCT04203511|RADIATION|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
57775565|NCT03585114|PROCEDURE|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
58129682|NCT03189706|DRUG|temozolomide|(given concurrently with Irinotecan) 150mg/m\^2/day orally
58129683|NCT03189706|BIOLOGICAL|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
58129684|NCT03189706|DRUG|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
58129685|NCT04558307|DIAGNOSTIC_TEST|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
58459791|NCT05941416|DIAGNOSTIC_TEST|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
57775566|NCT03200301|PROCEDURE|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
57775567|NCT03171558|PROCEDURE|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
57775568|NCT03171558|PROCEDURE|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
57775569|NCT02337478|DRUG|Vincristine Sulfate Liposome|Given via injection
57775570|NCT02337478|OTHER|Laboratory Biomarker Analysis|Correlative studies
57775571|NCT04047381|OTHER|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
57775572|NCT05366049|OTHER|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
57775573|NCT04291235|PROCEDURE|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
57775574|NCT04291235|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
57775575|NCT04911257|DEVICE|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
57775576|NCT01764373|OTHER|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
57775577|NCT01425164|DRUG|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
57775578|NCT01425164|DRUG|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
57775579|NCT03863743|OTHER|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
57775580|NCT03863743|OTHER|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
57775581|NCT05794282|PROCEDURE|the robot assisted total hip arthroplasty|the robot assisted total hip arthroplasty
57775582|NCT05794282|PROCEDURE|the conventional total hip arthroplasty|the conventional total hip arthroplasty
57775583|NCT03969082|BEHAVIORAL|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
57775584|NCT00368862|DRUG|Ebixa (memantine hydrochloride)|
58459792|NCT02257398|DRUG|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
58459793|NCT02257398|DRUG|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
57775585|NCT00368862|DRUG|Cipralex (escitalopram)|
57775586|NCT01715623|BIOLOGICAL|a blood sample|Dosage of Ig
57775587|NCT06077916|DRUG|Azithromycin|azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
57775588|NCT06077916|DRUG|Saline solution|placebo consisting of saline solution 250 mL is administered
57775589|NCT02792985|BEHAVIORAL|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
57775590|NCT02792985|BEHAVIORAL|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
58129686|NCT04558307|OTHER|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
58129687|NCT01092351|DRUG|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
58129688|NCT05251103|OTHER|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
58459794|NCT02257398|DRUG|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
57775591|NCT02349568|PROCEDURE|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
57775592|NCT02349568|PROCEDURE|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
57775593|NCT02155959|DEVICE|toric intraocular lens|toric intraocular lens
57775594|NCT04730921|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
57775595|NCT04730921|DEVICE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
57775596|NCT00431639|BEHAVIORAL|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
57775597|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
57775598|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
57775599|NCT02383511|DRUG|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
57775600|NCT03765463|BEHAVIORAL|Habit Reversal Training|4 sessions of habit reversal training
57775601|NCT02377713|DRUG|KHK6640|Single ascending dose administration
57775602|NCT02377713|DRUG|Placebo|Single ascending dose administration
57775603|NCT04974541|OTHER|Heart Health Yoga|Yoga-based digital intervention
57775604|NCT04974541|OTHER|Psychosocial education|Standard psychosocial education component
57775605|NCT02663375|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
57775606|NCT01821443|OTHER|Stereotactic radiosurgery (SRS)|"Dose \& prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% \[maximum=100%\]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
57775607|NCT02513992|PROCEDURE|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
57775608|NCT02513992|DRUG|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
57775609|NCT02513992|DEVICE|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
57775610|NCT02513992|DEVICE|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
57775611|NCT01886963|DEVICE|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
57775612|NCT01886963|DEVICE|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
57775613|NCT02500485|DRUG|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
57775614|NCT05509543|DRUG|IY-NT-T|Ilaprazole 20mg
58459795|NCT02257398|DRUG|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
57775615|NCT05509543|DRUG|IY-NT-R|Ilaprazole 10mg
57775616|NCT01077362|DRUG|placebo|SC injections
57775617|NCT01077362|DRUG|ustekinumab 45 mg|SC injections
57775618|NCT01077362|DRUG|ustekinumab 90 mg|SC injections
57775619|NCT02731313|BIOLOGICAL|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
57775620|NCT05764239|DRUG|SYNB1934v1|SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
57775621|NCT05764239|DRUG|Placebo|Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
58459796|NCT03065816|DRUG|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
58459797|NCT03065816|DRUG|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
57775622|NCT03395210|DRUG|Rilzabrutinib|BTK inhibitor
57775623|NCT00829361|OTHER|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
57775624|NCT04533776|BEHAVIORAL|Celiac Disease Definition, Symptoms and Treatment|"* Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
57775625|NCT04533776|BEHAVIORAL|Difficulties Due to Celiac Disease|"* Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
57775626|NCT04533776|BEHAVIORAL|Gluten Free Diet in Celiac Disease|"* Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
58129689|NCT01406678|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
57775627|NCT04533776|BEHAVIORAL|Difficulties Related to Disease in School and Social Life|"* Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
57775628|NCT04533776|BEHAVIORAL|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"* Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
57775629|NCT04533776|BEHAVIORAL|Celiac Diseae anf Future Goals|"* General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
57775630|NCT04533776|OTHER|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
57775631|NCT05597800|DRUG|Nivolumab and Ipilimumab|"Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles)."
57775632|NCT02806284|BIOLOGICAL|PPSV23, Act-HIB|"described in Arm description"
57775633|NCT05733819|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
57775634|NCT05733819|BEHAVIORAL|Active Walking|Walking without RAS cueing
57775635|NCT02951910|DEVICE|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
57775636|NCT00102050|DRUG|NM-702 (phosphodiesterase inhibitor)|
57775637|NCT02076685|DRUG|isoniazid|dose adjustment according to the pharmacogenomic results
57775638|NCT04545294|DEVICE|Theta tACS|See detail in arm/group descriptions regarding the intervention.
57775639|NCT03009890|PROCEDURE|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
57775640|NCT03009890|PROCEDURE|Cast treatment|Hospitals may use their preferred protocol
57775641|NCT00432835|DEVICE|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
57775642|NCT01282320|BEHAVIORAL|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
57775643|NCT02334527|DRUG|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
57775644|NCT03906981|OTHER|Plaque from each subject will be collected but there will be no intervention|No intervention
57775645|NCT05476991|DRUG|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
57775646|NCT05476991|DRUG|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
57775647|NCT05476991|DRUG|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
57775648|NCT01682564|DRUG|Candemore tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
57775649|NCT01682564|DRUG|Atacand tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
57775650|NCT03989635|DRUG|QAW039|QAW039 450mg
57775651|NCT05592080|RADIATION|MRI|MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
57775652|NCT03337880|OTHER|instrumental delivery|the birth was assisted with an extractor.
57775653|NCT04081298|BEHAVIORAL|Health Education|Attend nutrition and PA classes, and cooking sessions
57775654|NCT04081298|OTHER|Physical Activity|Participate in physical activities
57775655|NCT04081298|OTHER|Health Promotion and Education: Text Messages|Receive motivational text messages
57775656|NCT04081298|OTHER|Health Promotion and Education: Web Site|Given access to nutrition website
57775657|NCT04081298|OTHER|Quality-of-Life Assessment|Ancillary studies
57775658|NCT04081298|OTHER|Questionnaire Administration|Ancillary studies
57775659|NCT01644474|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
57775660|NCT01644474|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
57775661|NCT01644474|DRUG|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
57775662|NCT01644474|DRUG|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
57775663|NCT05690789|OTHER|No treatment given|No treatment given
57775664|NCT04905732|DEVICE|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
57775665|NCT04905732|DEVICE|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
57775666|NCT02290366|RADIATION|Focal prostate brachytherapy with Cesium-131|
57775667|NCT03180216|BIOLOGICAL|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
57775668|NCT03859375|OTHER|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
57775669|NCT04140890|BEHAVIORAL|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
57775670|NCT04140890|BEHAVIORAL|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
57775671|NCT03525574|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
57775672|NCT03525574|DRUG|IVA|Tablet for oral administration.
57775673|NCT04398784|DIETARY_SUPPLEMENT|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
57775674|NCT04398784|DIETARY_SUPPLEMENT|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
57775675|NCT00079443|DRUG|romidepsin|Given IV
57775676|NCT00079443|BIOLOGICAL|rituximab|Given IV
57775677|NCT00079443|DRUG|fludarabine phosphate|Given IV
57775678|NCT00079443|OTHER|laboratory biomarker analysis|Correlative studies
58459798|NCT02284204|DRUG|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
58459799|NCT02284204|DRUG|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
57775679|NCT00175968|PROCEDURE|bed rest, hypocaloric nutrition|
57775680|NCT04329858|PROCEDURE|silver modified glass ionomer|occlusal cavity filled with silver modified
57775681|NCT04329858|PROCEDURE|zinc modified|occlusal cavity filled with zinc modified
57775682|NCT04329858|PROCEDURE|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
57775683|NCT05164731|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
57775684|NCT04288674|OTHER|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
57775685|NCT04288674|OTHER|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
57775686|NCT04288674|OTHER|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
57775687|NCT02746822|OTHER||
57775688|NCT03232320|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
57775689|NCT03232320|DRUG|Placebo|Placebo (Normal saline)
57775690|NCT02429921|DIETARY_SUPPLEMENT|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
57775691|NCT02429921|DIETARY_SUPPLEMENT|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
57775692|NCT06294015|BIOLOGICAL|20% ASED + AT|Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.
57775693|NCT06294015|DRUG|0.9% NS + AT|Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
57775694|NCT01026675|PROCEDURE|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
57775695|NCT03849716|OTHER|Blood sample|Blood samples obtained for biomarker analyses
57775696|NCT03849716|OTHER|Cheek swab|Cheek swab obtained for genetic analysis
57775697|NCT03665883|PROCEDURE|Monopolar energy|Monopolar energy in TEP for inguinal hernia
57775698|NCT03665883|PROCEDURE|Blunt dissection|Blunt dissection in TEP for inguinal hernia
57775699|NCT03550430|BEHAVIORAL|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
58129690|NCT01406678|PROCEDURE|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
57775700|NCT03550430|BEHAVIORAL|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
57775701|NCT03550430|OTHER|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
57775702|NCT05892835|OTHER|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
57775703|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
57775704|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
57775705|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
57775706|NCT05799300|PROCEDURE|Intrathecal anaesthesia|Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
57775707|NCT05242575|BEHAVIORAL|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
57775708|NCT00395915|DRUG|aripiprazole|
57775709|NCT06187350|DEVICE|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score \> 7 will be double-reviewed as normal.
57775710|NCT02008968|DRUG|allopurinol 300 mg./day|
57775711|NCT02008968|OTHER|No intervention|
57775712|NCT02008968|DRUG|Normouricemic|
57775713|NCT01405794|DRUG|32ppm Silver Particle|Oral silver dose of 32ppm
57775714|NCT01405794|DRUG|Placebo|Sterile Water No Silver
57775715|NCT03746977|DIETARY_SUPPLEMENT|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
57775716|NCT03746977|BEHAVIORAL|Walking|Walking with a volume corresponding to 250 kcal/d
57775717|NCT03746977|BEHAVIORAL|WB-EMS application|WB-EMS application 1.5x 20 min/week
57775718|NCT00003284|BIOLOGICAL|filgrastim|
57775719|NCT00003284|DRUG|carboplatin|
57775720|NCT00003284|DRUG|etoposide|
57775721|NCT00003284|DRUG|ifosfamide|
57775722|NCT00003284|DRUG|paclitaxel|
57775723|NCT00003284|PROCEDURE|peripheral blood stem cell transplantation|
57775724|NCT00003284|RADIATION|radiation therapy|
57775725|NCT02357043|DEVICE|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
57775726|NCT02357043|DEVICE|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
57775727|NCT04324255|PROCEDURE|LT|Liver transplantation
57775728|NCT03524456|OTHER|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
57775729|NCT02424552|DRUG|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
57775730|NCT02424552|DRUG|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
57775731|NCT04980768|PROCEDURE|Root canal treatment|Patients with apical periodontitis will undergo root canal treatment.
57775732|NCT03410914|DEVICE|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
57775733|NCT05768516|OTHER|Implementation of best practice for low back pain in primary care|"1. Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~2. Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~3. Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~4. Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
57775734|NCT03093519|DRUG|KHK6640|Intravenous administration
57775735|NCT03093519|DRUG|Placebo|Intravenous administration
58459800|NCT04087980|DEVICE|Poseidon System|Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
58459801|NCT02559622|DRUG|Secukinumab|300 mg secukinumab
58459802|NCT02559622|OTHER|Placebo|Placebo followed by 300 mg secukinumab
58459803|NCT02559622|OTHER|Placebo|Placebo followed by 150 mg secukinumab
58459804|NCT02559622|DRUG|Secukinumab|150 mg secukinumab
58459805|NCT02648204|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
57775736|NCT05874271|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total) (Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
57775737|NCT03655873|DRUG|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
57775738|NCT03655873|DRUG|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
57775739|NCT04877574|PROCEDURE|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.
57775740|NCT04877574|PROCEDURE|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
57775741|NCT01708889|BIOLOGICAL|BMS-914143 (Peginterferon Lambda-1a)|
57775742|NCT02406118|PROCEDURE|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
57775743|NCT01443975|PROCEDURE|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
57775744|NCT06398028|DRUG|Indocyanine green|Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
57775745|NCT00579540|DIETARY_SUPPLEMENT|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
57775746|NCT00579540|DIETARY_SUPPLEMENT|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
57775747|NCT00579540|DIETARY_SUPPLEMENT|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
57775748|NCT04572529|PROCEDURE|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
57775749|NCT00469781|DRUG|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
57775750|NCT00469781|DRUG|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
57775751|NCT01899274|DEVICE|bant iPhone application|
58459806|NCT02648204|DRUG|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
57775752|NCT03518528|DRUG|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
57775753|NCT03518528|DRUG|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
57775754|NCT00151918|DRUG|Lanthanum carbonate|
58459807|NCT02436525|DEVICE|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
58459808|NCT02436525|DEVICE|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
58459809|NCT02436525|DEVICE|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
57775755|NCT05399992|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive inclisiran are eligible to enroll into this study.
57775756|NCT05297617|DRUG|Anti-aromatase inhibitor|"Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily"
57775757|NCT05769699|PROCEDURE|blood sample|blood sample
58459810|NCT02904798|DRUG|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
58459811|NCT02715739|OTHER|No intervention|
58459812|NCT06373016|DIETARY_SUPPLEMENT|Glucose|A glucose drink is administered midway through one of the scan sessions.
58459813|NCT06373016|DIETARY_SUPPLEMENT|Ketones|A ketone drink is administered midway through one of the scan sessions.
58459814|NCT03660462|DIETARY_SUPPLEMENT|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
58459815|NCT03660462|DIETARY_SUPPLEMENT|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
58459816|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
57775758|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
57775759|NCT04181424|BEHAVIORAL|Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
57775760|NCT04181424|BEHAVIORAL|Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
57775761|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
57775762|NCT05330741|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
57775763|NCT05330741|OTHER|Whole-Body Vibration|"The designed physical therapy program (mentioned before)~+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively."
57775764|NCT05330741|OTHER|Gravity Force Stimulation|"The designed physical therapy program (mentioned before)~+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)"
57775765|NCT04284761|COMBINATION_PRODUCT|Bicalutamide implant|Biolen bicalutamide implant
57775766|NCT00000782|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
57775767|NCT00000782|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
57775768|NCT05388994|OTHER|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
57775769|NCT05036889|DIAGNOSTIC_TEST|Mind.Px Report|Use of Mind.Px report as a reference for potential better matching of biologics to patients.
57775770|NCT05774405|DRUG|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
57775771|NCT05774405|OTHER|Hydrogel patch|Adhesive Hydrogel patch
57775772|NCT02762981|DRUG|Relacorilant with nab-paclitaxel|Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
57775773|NCT01448720|DRUG|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
57775774|NCT02265224|DRUG|N-acetylcysteine|The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
57775775|NCT04440644|BEHAVIORAL|BBI|administration of psychometric test
57775776|NCT03601104|OTHER|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
57775777|NCT03601104|OTHER|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
57775778|NCT03601104|OTHER|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
57775779|NCT03601104|OTHER|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
57775780|NCT01159535|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
57775781|NCT01159535|BEHAVIORAL|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
57775782|NCT01159535|BEHAVIORAL|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
57775783|NCT03632434|DEVICE|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
57775784|NCT03775408|DEVICE|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
57775785|NCT02867969|OTHER|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
57775786|NCT01266993|BIOLOGICAL|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
57775787|NCT01266993|BIOLOGICAL|Menjugate|Intramuscular, 1 dose
57775788|NCT03343405|BEHAVIORAL|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
57775789|NCT03743363|OTHER|Exergame 2/week|virtual training 2 times a week(8 week-long)
58459817|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
57775790|NCT03743363|OTHER|Exergaming 3/week|virtual training 3 times a week(8 week-long)
57775791|NCT03743363|OTHER|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
57775792|NCT02718534|BEHAVIORAL|stroke rehabilitation|Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
57775793|NCT01954524|DRUG|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
57775794|NCT00982982|DRUG|THC and Iomazenil|"* Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
57775795|NCT00982982|DRUG|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
57775796|NCT03393403|DRUG|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
57775797|NCT03393403|DRUG|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group
57775798|NCT01419860|PROCEDURE|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
57775799|NCT06141304|DRUG|Plerixafor|Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
57775800|NCT00110513|BIOLOGICAL|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is \> 80% and \< 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at \> 80% and \< 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
57775801|NCT06531148|OTHER|Chemo-mechanical caries removal|Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.
57775802|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to \< 212 days of age"
57775803|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to \< 12 months of age"
58129691|NCT01406678|DRUG|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
58459818|NCT06072911|BEHAVIORAL|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
57775804|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to \< 24 months of age"
57775805|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to \< 72 months of age"
57775806|NCT04415385|DRUG|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
57775807|NCT04415385|DRUG|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
58459819|NCT06072911|BEHAVIORAL|General exercise|A general progressive resistance exercise program
58459820|NCT06072911|BEHAVIORAL|Physical Activity Counseling|Advice on increasing physical activity
58459821|NCT05802004|DEVICE|Acoustic Stimulation (STIM)|During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
58459822|NCT05802004|DEVICE|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
58459823|NCT05802004|DEVICE|Daily acoustic stimulation (STIM2)|During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
58459824|NCT05802004|DEVICE|No daily acoustic stimulation (SHAM2)|During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
57775808|NCT04504318|DRUG|Apixaban 2.5 MG Oral Tablet|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
57775809|NCT04504318|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
57775810|NCT01217489|PROCEDURE|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
57775811|NCT05141981|DEVICE|inbody device|measure muscle mass
57775812|NCT05199909|DRUG|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
57775813|NCT00354133|DEVICE|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
57775814|NCT00354133|DRUG|Best Medical Treatment|Patients in this arm get best medical treatment only
57775815|NCT05005949|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter System|Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
57775816|NCT00135746|DRUG|nicotine transdermal system|
57775817|NCT03743662|RADIATION|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
57775818|NCT03743662|DRUG|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
57775819|NCT03743662|DRUG|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
57775820|NCT03743662|PROCEDURE|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
57775821|NCT01737060|DEVICE|Reverse total shoulder arthroplasty|
57775822|NCT02538679|OTHER|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
57775823|NCT02538679|DRUG|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
57775824|NCT02538679|DRUG|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
57775825|NCT05461014|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
57775826|NCT01026909|DRUG|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
57775827|NCT01824563|OTHER|Observational study|
58459825|NCT04554420|BEHAVIORAL|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
57775828|NCT00802828|DRUG|Famotidine Tablets, 40 mg|
57775829|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
57775830|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
57775831|NCT02038764|DRUG|Placebo|Placebo
57775832|NCT02038764|BIOLOGICAL|PF-06342674 Dose A|Multiple SC Doses
57775833|NCT02038764|BIOLOGICAL|PF-06342674 Dose B|Multiple SC Doses
57775834|NCT02038764|BIOLOGICAL|PF-06342674 Dose C|Multiple SC Doses
57775835|NCT02038764|BIOLOGICAL|PF-06342674 Dose D|Multiple SC Doses
58459826|NCT05489848|DRUG|Paclitaxel|Paclitaxel: paclitaxel dose of 135\~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
58459827|NCT05489848|DRUG|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
58459828|NCT05489848|DRUG|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
57775836|NCT05501171|BEHAVIORAL|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
57775837|NCT05501171|BEHAVIORAL|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~1. Education about general wellness.~2. Nutrition.~3. Exercise.~4. Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
57775838|NCT03005093|OTHER|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
57775839|NCT03005093|OTHER|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
57775840|NCT06023355|PROCEDURE|HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
57775841|NCT01504451|DEVICE|ILR insertion|Insertion of implantable loop recorder
57775842|NCT01504451|PROCEDURE|AF ablation|AF ablation
57775843|NCT00721643|DIETARY_SUPPLEMENT|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
57775844|NCT00721643|DIETARY_SUPPLEMENT|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
57775845|NCT02631811|OTHER|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
57775846|NCT04864041|OTHER|Evaluation of global longitudinal strain using routinely recorded echocardiography images|There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
57775847|NCT00099593|BIOLOGICAL|Autologous Dendritic Cell Vaccine|
57775848|NCT02327624|DRUG|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
57775849|NCT02327624|DRUG|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
57775850|NCT02327624|DRUG|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
57775851|NCT05627401|PROCEDURE|Modified multiple orbital wall decompression|Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
57775852|NCT01777243|DRUG|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
57775853|NCT01777243|DRUG|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
57775854|NCT00482222|BIOLOGICAL|cetuximab|
57775855|NCT00482222|DRUG|capecitabine|
57775856|NCT00482222|DRUG|fluorouracil|
57775857|NCT00482222|DRUG|leucovorin calcium|
57775858|NCT00482222|DRUG|oxaliplatin|
57775859|NCT00482222|OTHER|study of socioeconomic and demographic variables|
57775860|NCT00482222|PROCEDURE|adjuvant therapy|
57775861|NCT00482222|PROCEDURE|neoadjuvant therapy|
57775862|NCT00482222|PROCEDURE|quality-of-life assessment|
57775863|NCT04399187|DRUG|Sodium hypochlorite gel application|Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
58138128|NCT01942863|OTHER|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
58138129|NCT02236247|DRUG|ivabradine|5 mg oral twice daily
58459829|NCT05489848|RADIATION|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
58459830|NCT05489848|RADIATION|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
58459831|NCT04325802|DRUG|Naltrexone|50mg Naltrexone daily
58459832|NCT04325802|OTHER|Placebo|Placebo (Mannitol) daily
58138130|NCT02236247|DRUG|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
58459833|NCT06088862|DRUG|Nicoderm|21mg nicotine patch daily; maximum usage 9 weeks
57775864|NCT02701946|PROCEDURE|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
57775865|NCT02701946|PROCEDURE|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
57775866|NCT04325464|DEVICE|PEAR-003A|PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
57775867|NCT03257423|DRUG|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
57775868|NCT03257423|DRUG|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
57775869|NCT03257423|PROCEDURE|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
57775870|NCT03257423|OTHER|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
57775871|NCT04412252|DRUG|Tofacitinib|10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
57775872|NCT04412252|OTHER|Placebo|Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
57775873|NCT04663568|DEVICE|Levonorgestrel-releasing intrauterine system|Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
57775874|NCT01611818|OTHER|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
57775875|NCT01611818|OTHER|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
57775876|NCT01611818|OTHER|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
57775877|NCT06013332|DEVICE|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
57775878|NCT06013332|DEVICE|Sculptra®|Sculptra®
57775879|NCT02293525|DEVICE|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
57775880|NCT02293525|DRUG|Ropivacaine|
57775881|NCT02293525|DRUG|Saline|
57775882|NCT02293525|DRUG|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
57775883|NCT02293525|DRUG|Oxycodone|10mg every 4-6 hours
58459834|NCT06088862|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
58459835|NCT06088862|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
58459836|NCT06088862|OTHER|BIDI e-cigarette|BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks
58459837|NCT06088862|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks
58459838|NCT01153165|DRUG|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
57775884|NCT03133949|OTHER|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
57775885|NCT00859508|DEVICE|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
57775886|NCT00859508|DEVICE|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
57775887|NCT03063970|DEVICE|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
57775888|NCT03063970|OTHER|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
58459839|NCT01153165|DRUG|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
58459840|NCT04434079|OTHER|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
57775889|NCT03086915|DRUG|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
57775890|NCT06177301|DRUG|Tislelizumab combined with GX|"Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
58459841|NCT01334060|BIOLOGICAL|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
57775891|NCT06177301|DRUG|Tislelizumab combined with GP|"Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles."
57775892|NCT00206388|DRUG|Zolendric acid|IV, 2mg/m2/dose on day 0
57775893|NCT00206388|DRUG|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
57775894|NCT05119413|DRUG|New trio de Kligman|Once daily application in addition to the same sunscreen
57775895|NCT05119413|DRUG|Trio Kligman|Once daily application in addition to the same sunscreen
57775896|NCT00445263|DRUG|TIROFIBAN|intravenous infusion
57775897|NCT00445263|PROCEDURE|CORONAROGRAPHY|standard procedure of coronarography
57775898|NCT02323035|DEVICE|Headgear|Investigative Headgear with CPAP Mask.
57775899|NCT04003662|DEVICE|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
57775900|NCT00536068|DRUG|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"1. Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~2. Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~3. Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~4. Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
57775901|NCT04672356|BIOLOGICAL|IBI939|IBI939 injection
57775902|NCT04672356|BIOLOGICAL|Sintilimab|Sintilimab injection
57775903|NCT04280718|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
57775904|NCT02934516|PROCEDURE|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
57775905|NCT01778062|DRUG|Indacaterol|Indacaterol 150µg once daily oral inhalation
57775906|NCT01778062|DRUG|Control|Placebo once daily oral inhalation
57775907|NCT05390138|BEHAVIORAL|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
57775908|NCT05390138|BEHAVIORAL|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
57775909|NCT05424445|DRUG|Misoprostol|Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
57775910|NCT00880321|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
57775911|NCT00880321|DRUG|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
57775912|NCT00880321|DRUG|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
57775913|NCT05666375|PROCEDURE|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
57775914|NCT01349413|DRUG|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
57775915|NCT01349413|OTHER|Placebo|Identical looking placebo
57775916|NCT01903408|RADIATION|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
58459842|NCT00001944|DRUG|Vinorelbine|
57775917|NCT02557906|PROCEDURE|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
57775918|NCT02557906|PROCEDURE|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
57775919|NCT02557906|PROCEDURE|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
58138131|NCT01013025|PROCEDURE|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
58459843|NCT00001944|DRUG|XR9576|
58459844|NCT03320668|OTHER|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
57775920|NCT01664936|RADIATION|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
57775921|NCT00855868|DRUG|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
57775922|NCT00855868|DRUG|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB
57775923|NCT01395043|PROCEDURE|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
57775924|NCT01395043|DRUG|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
57775925|NCT00387257|DRUG|Rilapladib (SB-659032)|
57775926|NCT00268619|DRUG|Ramipril|
57775927|NCT00953095|BEHAVIORAL|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
57775928|NCT01476917|DEVICE|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
57775929|NCT01226628|BIOLOGICAL|CNTO 2476|
57775930|NCT01226628|PROCEDURE|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
57775931|NCT05348343|BIOLOGICAL|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
57775932|NCT01551303|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
57775933|NCT01551303|DRUG|Placebo|Matched nasal spray placebo
57775934|NCT06110845|DEVICE|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
57775935|NCT05273086|BEHAVIORAL|Sleep Intervention Group|"The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system."
58459845|NCT05030025|COMBINATION_PRODUCT|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
58459846|NCT05030025|COMBINATION_PRODUCT|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
58459847|NCT00003343|DRUG|endocrine-modulating drug therapy|
57775936|NCT04963972|BEHAVIORAL|Behavioral Intervention|Participate in Lucid Lane therapy program
57775937|NCT04963972|OTHER|Best Practice|Receive standard of care opioid education
57775938|NCT04963972|OTHER|Questionnaire Administration|Ancillary studies
57775939|NCT05745480|OTHER|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
57775940|NCT06144268|DEVICE|ZyMōt Multi (850µL)|An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.
58138132|NCT01529060|DRUG|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
58459848|NCT00003343|DRUG|mitoxantrone hydrochloride|
58459849|NCT00003343|DRUG|prednisone|
58459850|NCT00003343|DRUG|prinomastat|
57775941|NCT06144268|OTHER|Density Gradient Centrifugation|"The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure."
57775942|NCT05391360|DRUG|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
57775943|NCT05391360|DRUG|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
57775944|NCT05391360|DRUG|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
57775945|NCT05391360|DRUG|entecavir tablets|once daily for consecutive 28 days
57775946|NCT03551808|DRUG|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
57775947|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
58459851|NCT03833323|COMBINATION_PRODUCT|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
58459852|NCT04050046|DEVICE|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
57775948|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
57775949|NCT02123290|DRUG|DSM265 400mg|
57775950|NCT02123290|DRUG|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
57775951|NCT02123290|DRUG|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
57775952|NCT00004203|DRUG|oxaliplatin|
57775953|NCT05216224|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
57775954|NCT05216224|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
57775955|NCT05266651|DRUG|Tadalafil 5mg|oral tablets for one month duration
57775956|NCT05266651|DRUG|Placebo|oral tablets for one month duration
57775957|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 1, once daily
57775958|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 2, once daily
57775959|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 3, once daily
57775960|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 4, once daily
57775961|NCT01119339|DRUG|LAS 41004|LAS 41004 , dosage 5, once daily
57775962|NCT01119339|DRUG|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
57775963|NCT01119339|DRUG|Placebo|Placebo, once daily
57775964|NCT01119339|DRUG|Reference|Reference, once daily
57775965|NCT00854295|DEVICE|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
57775966|NCT03119337|OTHER|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
57775967|NCT03912220|DRUG|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
57775968|NCT03912220|DRUG|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
57775969|NCT06031909|DIAGNOSTIC_TEST|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~* Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~* Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~* Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~* Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~* Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
57775970|NCT01868074|DEVICE|Insole|Custom-molded arch-supporting insole
57775971|NCT00900575|DEVICE|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
57775972|NCT00900575|DEVICE|Portable Optical Spectrometer|This device is a portable optical spectrometer
57775973|NCT00900575|DEVICE|Transvaginal colposcope|
57775974|NCT04702100|OTHER|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
57775975|NCT04702100|OTHER|integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
57775976|NCT04702100|OTHER|conventional therapy|the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
57775977|NCT03352063|BEHAVIORAL|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
57775978|NCT03352063|BEHAVIORAL|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
57775979|NCT06229184|DIAGNOSTIC_TEST|Fecal Calprotectin Test|Fecal samples are taken fom obese and healthy adolescents for study
57775980|NCT02578225|OTHER|Non interventional study|
57775981|NCT04160611|DRUG|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
58459853|NCT04050046|BEHAVIORAL|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
58459854|NCT05135871|DRUG|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
58459855|NCT03438617|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
57775982|NCT03288389|DIETARY_SUPPLEMENT|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
57775983|NCT03288389|DIETARY_SUPPLEMENT|Placebo|Placebo wafers
57775984|NCT03764358|DEVICE|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
57775985|NCT03764358|DEVICE|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
57775986|NCT03165162|BEHAVIORAL|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
57775987|NCT05989321|PROCEDURE|PVI alone|pulmonary vein isolation
58459856|NCT00790946|DRUG|Valsartan|Valsartan 80 to 160 mg
58459857|NCT05763017|OTHER|Relative Motion Splint|Six weeks relative motion splint wear.
58459858|NCT05763017|OTHER|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
57775988|NCT05989321|PROCEDURE|PVI + SPs ablation|pulmonary vein isolation + SPs ablation
57775989|NCT03698864|DRUG|PCS499|PCS499 900mg twice a day with food
57775990|NCT04883593|DRUG|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
57775991|NCT04883593|DRUG|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
58459859|NCT04445961|DIAGNOSTIC_TEST|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
58459860|NCT04445961|DIAGNOSTIC_TEST|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
58459861|NCT03678207|OTHER|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
58459862|NCT05919576|DEVICE|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
58459863|NCT06349564|DEVICE|Pico 4 Enterprise headset with noise cancelling headphones|The device includes a computer tablet and virtual reality headset.
57775992|NCT01614574|BIOLOGICAL|velaglucerase alfa|60 U/kg every other week intravenous infusion
57775993|NCT03477786|COMBINATION_PRODUCT|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
57775994|NCT04360122|DRUG|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
57775995|NCT04360122|DRUG|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
57775996|NCT04360122|DRUG|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
57775997|NCT03509376|PROCEDURE|Suture repair|The diastasis is repaired with continous nylon suture
57775998|NCT03509376|PROCEDURE|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
57775999|NCT02446093|BIOLOGICAL|Aglatimagene besadenovec|Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
57776000|NCT02446093|RADIATION|Chemoradiation|CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
57776001|NCT02446093|RADIATION|Stereotactic body radiation therapy|SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
57776002|NCT02446093|PROCEDURE|Surgery|Surgical resection should be performed within 8 weeks after completing CR or SBRT.
57776003|NCT00453102|DRUG|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
57776004|NCT00453102|DRUG|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
57776005|NCT00759772|DRUG|Placebo|sc daily for 6 months
57776006|NCT00759772|DRUG|Teriparatide|20 mcg sc daily for 6 months
57776007|NCT02589041|PROCEDURE|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
58459864|NCT05683847|OTHER|User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)|Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
58459865|NCT03424564|DRUG|Perampanel|Oral Tablet
57776008|NCT02589041|DRUG|Ropivacaine 1%|
57776009|NCT04724356|OTHER|Virtual Reality|Intervention was led once per day, five days a week, over 8 weeks.
57776010|NCT04724356|OTHER|Resistance Exercise|Intervention was led once per day, five days a week, over 8 weeks.
57776011|NCT02392884|BEHAVIORAL|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
57776012|NCT00334867|DRUG|cyclophosphamide|Given IV
57776013|NCT00334867|DRUG|dexrazoxane hydrochloride|Given IV
57776014|NCT00334867|DRUG|doxorubicin hydrochloride|Given IV
57776015|NCT00334867|DRUG|etoposide|Given IV
57776016|NCT00334867|DRUG|ifosfamide|Given IV
57776017|NCT00334867|DRUG|topotecan hydrochloride|Given IV
57776018|NCT00334867|DRUG|vincristine sulfate|Given IV
58459866|NCT06081296|PROCEDURE|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
58459867|NCT06081296|PROCEDURE|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
57776019|NCT00334867|PROCEDURE|conventional surgery|Patients undergo surgery in week 18
57776020|NCT00334867|PROCEDURE|radiation therapy|Patients undergo radiation therapy in week 19
57776021|NCT02450773|DRUG|Furosemide|40 mg furosemide on postpartum day 1-6
57776022|NCT02450773|DRUG|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
57776023|NCT02450773|DRUG|Placebo #1|Placebo (for furosemide)
57776024|NCT02450773|DRUG|Placebo #2|Placebo (for KCl)
57776025|NCT00966862|OTHER|Other: Dietary Fibers|
57776026|NCT03629990|BEHAVIORAL|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
57776027|NCT03629990|BEHAVIORAL|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
57776028|NCT03629990|BEHAVIORAL|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
57776029|NCT02930564|OTHER|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
57776030|NCT03115008|BEHAVIORAL|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
57776031|NCT03198793|DRUG|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
57776032|NCT02085837|OTHER|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
57776033|NCT02085837|OTHER|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
57776034|NCT02085837|OTHER|Universal Dietary education|To improve diet and health
57776035|NCT02085837|OTHER|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
57776036|NCT02085837|OTHER|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
57776037|NCT02085837|OTHER|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
57776038|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 1|\~125 g fresh weight (1 cup equivalent)
57776039|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 2|\~250 g fresh weight (2 cup equivalent)
57776040|NCT02479035|DIETARY_SUPPLEMENT|Control meal|0 g red raspberry
57776041|NCT01874093|DEVICE|The Ischemic Stroke System|SPG stimulation and standard of care
57776042|NCT01874093|DEVICE|Sham control|Sham stimulation and standard of care
57776043|NCT04263792|DRUG|[18F]fluoropropyl-trimethoprim|\[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
57776044|NCT03308760|OTHER|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
57776045|NCT03308760|OTHER|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
57776046|NCT03308760|OTHER|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
57776047|NCT01248520|OTHER|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
57776048|NCT01248520|OTHER|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
57776049|NCT02848612|DRUG|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
57776050|NCT01917305|DEVICE|platform-shifted implant|
57776051|NCT03349372|PROCEDURE|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
57776052|NCT05473091|OTHER|no intervention|retrospective analysis
57776053|NCT02144519|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
57776054|NCT01829893|DRUG|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
57776055|NCT01829893|DRUG|GL2701 capsule|oral medication with 240 mL water
57776056|NCT05433896|DRUG|Dasatinib ASD|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
57776057|NCT05433896|DRUG|Omeprazole 40 MG|Omeprazole Delayed Release Capsules, USP 40 mg
57776058|NCT01501916|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
57776059|NCT01501916|DIETARY_SUPPLEMENT|Placebo|daily intake of placebo
57776060|NCT04149041|DIAGNOSTIC_TEST|ultrasound|POCUS is applied to adult patients in an emergency department.
57776061|NCT03625505|DRUG|Venetoclax|tablet, oral
57776062|NCT03625505|DRUG|Gilteritinib|tablet, oral
57776063|NCT04448236|DEVICE|Blood flow restriction resistance exercise|"Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension"
57776064|NCT03621982|DRUG|ADCT-301|intravenous infusion
57776065|NCT03621982|BIOLOGICAL|Pembrolizumab|intravenous infusion
57776066|NCT02096133|DRUG|Cholecalciferol|Vitamin D3 solution
57776067|NCT02096133|OTHER|Placebo comparator|Placebo comparator
57776068|NCT00822315|DRUG|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
57776069|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
57776070|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
57776071|NCT00204308|DRUG|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
57776072|NCT04998695|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
57776073|NCT04998695|OTHER|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
57776074|NCT05200637|DEVICE|Orsiro stent|Orsiro stent
57776075|NCT05200637|DEVICE|Xience stent|Xience stent
57776076|NCT05200637|DEVICE|Any drug-eluting stent|Any drug-eluting stent
57776077|NCT01990820|DEVICE|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
57776078|NCT01990820|PROCEDURE|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
57776079|NCT02930642|BEHAVIORAL|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
57776080|NCT02930642|OTHER|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
57776081|NCT02444234|DRUG|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
57776082|NCT02444234|DRUG|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
57776083|NCT02818660|DRUG|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
57776084|NCT00060463|BEHAVIORAL|Increased access to emergency contraceptive pills|
57776085|NCT06526702|DEVICE|High-flux hemodialysis|FX CorDiax 100 dialyzer
57776086|NCT06526702|DEVICE|Post-dilution hemodiafiltration|FX CorDiax 1000 dialyzer
57776087|NCT01598974|PROCEDURE|Traditional Acupuncture|
57776088|NCT01598974|PROCEDURE|Laser Acupuncture|
57776089|NCT04136535|DRUG|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
57776090|NCT04136535|DRUG|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
57776091|NCT04136535|DRUG|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
57776092|NCT03900143|DEVICE|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
57776093|NCT01898143|OTHER|Whole body vibration|
57776094|NCT01054872|BIOLOGICAL|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
57776095|NCT01054872|BIOLOGICAL|HIV-1 recombinant Ad5 vaccine|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
57776096|NCT00955734|OTHER|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
57776097|NCT00955734|OTHER|Immobilization|This set of patients will be casted for 6 weeks after surgery.
57776098|NCT04027205|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
57776099|NCT04027205|PROCEDURE|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation
57776100|NCT03781713|OTHER|KDIGO|Interventions to prevent renal replacement therapy
58459868|NCT06081296|PROCEDURE|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
57776101|NCT03781713|OTHER|Delta SOFA|interventions to improve SOFA score
57776102|NCT03781713|COMBINATION_PRODUCT|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
57776103|NCT03781713|DRUG|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
57776104|NCT03781713|DRUG|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
57776105|NCT04704401|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
57776106|NCT04939311|DRUG|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
57776107|NCT04939311|DRUG|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
57776108|NCT01674257|OTHER|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
57776109|NCT01674257|RADIATION|18f-Fluoride PET/CT scan|
57776110|NCT01674257|RADIATION|18F-Flurodeoxyglucose PET/CT scan|
57776111|NCT05700006|DRUG|Aromatase inhibitor|Standard of care anastrozole, exemestane, or letrozole
57776112|NCT03417882|BIOLOGICAL|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
57776113|NCT03817346|DRUG|GT-002|Single ascending dose
57776114|NCT03817346|DRUG|Placebo oral capsule|Comparator single ascending dose
57776115|NCT00450515|DRUG|capecitabine|
57776116|NCT00450515|DRUG|vinflunine|
57776117|NCT06102031|DEVICE|ReDS-Guided|"ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization."
57776118|NCT06102031|OTHER|Usual care|ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
57776119|NCT05887284|RADIATION|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
57776120|NCT05887284|RADIATION|mock radiation treatment|6 times 0.0 Gy
57776121|NCT05887284|RADIATION|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
57776122|NCT00028314|DRUG|Abacavir sulfate|
57776123|NCT00028314|DRUG|Atazanavir/Ritonavir|
57776124|NCT00028314|DRUG|Lopinavir/Ritonavir|
57776125|NCT00028314|DRUG|Nevirapine|
57776126|NCT03732586|DIETARY_SUPPLEMENT|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
57776127|NCT03732586|OTHER|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
57776128|NCT03967405|DEVICE|MolecuLight PID|Hand-held, real-time fluorescence imaging device
57776129|NCT01315275|DRUG|Ranibizumab|
57776130|NCT02353832|DEVICE|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
57776131|NCT01948362|DRUG|Sulforadex|Active compound
57776132|NCT01948362|DRUG|Alpha cyclodextrin|Placebo control
57776133|NCT00245336|BIOLOGICAL|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
57776134|NCT00245336|DRUG|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
58459869|NCT06081296|PROCEDURE|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
57776135|NCT06030453|COMBINATION_PRODUCT|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
57776136|NCT06030453|COMBINATION_PRODUCT|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
57776137|NCT02208882|DRUG|BMS-986120|
57776138|NCT02208882|DRUG|Placebo|
57776139|NCT02208882|DRUG|Midazolam|
57776140|NCT02999620|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
57776141|NCT02999620|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
57776142|NCT00004003|DRUG|cisplatin|
57776143|NCT00004003|DRUG|fluorouracil|
57776144|NCT00004003|DRUG|gemcitabine hydrochloride|
57776145|NCT05287334|DEVICE|Electrical impedance tomography measurement|During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
57776146|NCT01418612|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
57776147|NCT01622348|DRUG|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
57776148|NCT01622348|DRUG|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
57776149|NCT01622348|DRUG|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
57776150|NCT05445024|PROCEDURE|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
57776151|NCT05445024|PROCEDURE|sufentanil group|sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
57776152|NCT02556515|PROCEDURE|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
57776153|NCT02556515|PROCEDURE|Total joint replacement|Total joint replacement
57776154|NCT02556515|DEVICE|Elektra prosthesis|Elektra prosthesis
57776155|NCT00762684|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
57776156|NCT00762684|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
57776157|NCT04162990|BEHAVIORAL|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
57776158|NCT04162990|BEHAVIORAL|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
58459870|NCT05962866|OTHER|I and II. Performing Leopold Maneuvers by the pregnant|24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
58459871|NCT00670215|DRUG|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
57776159|NCT02092038|DRUG|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
57776160|NCT02092038|RADIATION|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
57776161|NCT02092038|PROCEDURE|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
57776162|NCT02092038|PROCEDURE|craniotomy and tumor resection|maximal safe resection
57776163|NCT05345457|DRUG|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
57776164|NCT05345457|DRUG|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
57776165|NCT04436796|DEVICE|interoperable Artificial Pancreas System (iAPS)|Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.
57776166|NCT04436796|OTHER|Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)|Use of personal pump with study CGM \& glucometer at home for 13 weeks.
57776167|NCT03102658|DRUG|Micafungin|Administration of study drug
57776168|NCT02636894|DEVICE|Restylane Silk|
57776169|NCT04534335|DEVICE|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
57776170|NCT01493661|OTHER|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
57776171|NCT00000390|DRUG|Imipramine hydrochloride|
57776172|NCT06116214|OTHER|Vachellia Nelotica|As a root canal irrigant (herbal)
57776173|NCT06116214|OTHER|sodium hypochlorite|As a root canal irrigant
57776174|NCT03757806|OTHER|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
57776175|NCT03022838|DRUG|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
57776176|NCT02391935|DRUG|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
57776177|NCT02391935|DRUG|Placebo|Cryomedium
57776178|NCT02391935|DEVICE|Sham injection|skin penetration of the needle without injection of liquid
57776179|NCT02213055|DRUG|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
57776180|NCT02213055|DRUG|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
57776181|NCT00266474|OTHER|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
57776182|NCT05851924|DRUG|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle"
57776183|NCT05851924|COMBINATION_PRODUCT|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
57776184|NCT03514264|PROCEDURE|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
57776185|NCT03514264|PROCEDURE|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
57776186|NCT06328166|PROCEDURE|Sono-guided injection with ES135|Sono-guided injection with ES135 between carpal tunnel and median nerve
57776187|NCT06328166|PROCEDURE|Sono-guided injection with placebo|Sono-guided injection with placebo between carpal tunnel and median nerve
57776188|NCT02604836|DRUG|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
57776189|NCT01087723|DRUG|Bivalirudin|
57776190|NCT01087723|DRUG|Heparin|
57776191|NCT04206137|OTHER|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
58138133|NCT01529060|DRUG|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
58138134|NCT01960569|DRUG|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
58459872|NCT00670215|DRUG|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
58459873|NCT00001959|DRUG|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
58459874|NCT05895474|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
58459875|NCT01772628|BEHAVIORAL|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
58459876|NCT01772628|BEHAVIORAL|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
58138135|NCT01960569|OTHER|Placebo assigned to arm 2|
57776192|NCT04206137|OTHER|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
57776193|NCT02351596|OTHER|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
57776194|NCT02351596|OTHER|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
57776195|NCT00167986|DRUG|vancomycin-resistant enterococci and ESBL|
57776196|NCT05103813|DRUG|Beraprost Sodium Tablets|Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
57776197|NCT04039074|BEHAVIORAL|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
57776198|NCT04039074|BEHAVIORAL|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
57776199|NCT04039074|BEHAVIORAL|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
57776200|NCT01801553|OTHER|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
57776201|NCT01801553|OTHER|sham spinal manipulation|
57776202|NCT01801553|OTHER|Usual medical care|
57776203|NCT02230150|BEHAVIORAL|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
57776204|NCT00008047|DRUG|fluorouracil|
57776205|NCT00008047|DRUG|hydroxyurea|
57776206|NCT00008047|DRUG|paclitaxel|
57776207|NCT00008047|PROCEDURE|conventional surgery|
57776208|NCT00008047|RADIATION|radiation therapy|
57776209|NCT04681677|RADIATION|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
57776210|NCT04681677|DRUG|Bevacizumab|Bevacizumab
57776211|NCT00179348|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
57776212|NCT00179348|PROCEDURE|Yoga|Undergo a yoga-based rehabilitation program
58459877|NCT01772628|BEHAVIORAL|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
57776213|NCT05502224|OTHER|Ergospirometry|Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
57776214|NCT00991614|DEVICE|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
57776215|NCT00415974|BEHAVIORAL|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
57784409|NCT01907412|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
57776216|NCT00415974|BEHAVIORAL|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
57776217|NCT00415974|BEHAVIORAL|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
57776218|NCT00415974|BEHAVIORAL|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
57776219|NCT02006420|DEVICE|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
57776220|NCT05776082|OTHER|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
57776221|NCT03399149|OTHER|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
57776222|NCT02726399|DRUG|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
57776223|NCT02726399|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
57776224|NCT02726399|DRUG|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
57776225|NCT02726399|DRUG|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
57776226|NCT06294691|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
57776227|NCT03901599|OTHER|Alveolar ventilation monitoring estimated by the capnographic ventilation|Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
57776228|NCT02947464|PROCEDURE|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
57776229|NCT02947464|DEVICE|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
57776230|NCT03904342|BEHAVIORAL|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
57776231|NCT03904342|BEHAVIORAL|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
57776232|NCT06449014|DEVICE|Mini-implants assisted maxillary expansion|The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
57776233|NCT03289481|DIETARY_SUPPLEMENT|Active lozenge|nitric oxide generating lozenge
57776234|NCT03289481|DRUG|Placebo|placebo tablet
57776235|NCT01992549|BIOLOGICAL|Human-cl rhFVIII|
57776236|NCT05292196|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
57776237|NCT05292196|DRUG|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
57776238|NCT02037867|DEVICE|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
57776239|NCT01638468|DEVICE|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
57776240|NCT06391814|BIOLOGICAL|EBV-specific T cells|Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells
57776241|NCT03796013|DRUG|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
57776242|NCT03796013|DRUG|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
57776243|NCT04705220|DIETARY_SUPPLEMENT|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
57776244|NCT04705220|OTHER|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
57776245|NCT01962025|PROCEDURE|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
57776246|NCT01848834|BIOLOGICAL|Pembrolizumab|IV infusion
57776247|NCT05585190|OTHER|Control|No intervention.
57776248|NCT05585190|OTHER|2-Hour Stand Group|Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 2 hours each work day.
57776249|NCT05585190|OTHER|3-Hour Stand Group|Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 3 hours each work day.
57776250|NCT04126096|DIAGNOSTIC_TEST|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
57776251|NCT01936129|DRUG|Copaxone|
57776252|NCT01936129|DRUG|Placebo (buffered normal saline w/v)|
57776253|NCT03731130|OTHER|EORTC QLQ C30|standardized questionaire
57776254|NCT03731130|OTHER|EORTC QLQ CR29|standardized questionaire
57776255|NCT01910727|BEHAVIORAL|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
58459878|NCT01772628|BEHAVIORAL|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
58459879|NCT03467321|OTHER|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
57776256|NCT05269537|RADIATION|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
57776257|NCT05269537|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
57776258|NCT05269537|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
58459880|NCT02890797|RADIATION|radiology|The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
57776259|NCT05269537|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
57776260|NCT05269537|DRUG|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
57776261|NCT05269537|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
57776262|NCT05269537|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
57776263|NCT05269537|DRUG|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
57776264|NCT06109415|DRUG|HTX-011|400 mg
57776265|NCT06109415|DRUG|Bupivacaine Hydrochloride|100 mg
57776266|NCT06109415|DRUG|Ibuprofen|400 mg
57776267|NCT06109415|DRUG|Acetaminophen|1 g
57776268|NCT06109415|DEVICE|Luer lock applicator|Applicator for instillation
57776269|NCT05922163|DEVICE|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
57776270|NCT04758221|OTHER|Treatment by composite coronal build-up|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
57776271|NCT04548531|BEHAVIORAL|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
57776272|NCT02640976|DRUG|Human menopausal gonadotrophin (HMG)|\[Merional® 75 IU ampoules, IBSA institut\]
57776273|NCT02640976|DRUG|GnRH antagonist Cetrorelix|\[Cetrotide® 0.25 mg syringes, Merck Serono\]
57776274|NCT02640976|DRUG|Human chorionic gonadotrophin (hCG)|\[Choriomon® 5000 IU ampoules, IBSA institut\]
58459881|NCT01476670|OTHER|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
58459882|NCT05298488|BEHAVIORAL|Home office|Working from home
58459883|NCT05298488|BEHAVIORAL|Office|Working at the office
57776275|NCT03806946|DIAGNOSTIC_TEST|electroencephalography|diagnosis epileptic discharge
57776276|NCT03806946|DIAGNOSTIC_TEST|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
57776277|NCT03806946|OTHER|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
57776278|NCT05112341|RADIATION|radiation therapy|the patient first is simulated then delineation is done
57776279|NCT02225821|DRUG|Cephalozin|1000 mg Cephalozin
57776280|NCT02225821|OTHER|Sodium chloride|10 cc of NaCl 0.9%
57776281|NCT03125941|DRUG|Dexamethasone|pre-operative intravenous administration
57776282|NCT05450445|DEVICE|myHealthHub|myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
57776283|NCT05450445|DEVICE|TV-only|myHealthHub device equipped with the TV-only entertainment option.
57776284|NCT04380818|RADIATION|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
57776285|NCT04380818|DRUG|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
57776286|NCT04380818|DRUG|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
57776287|NCT04380818|DRUG|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
57776288|NCT04380818|DRUG|Azithromycin|500 mg/24h for 3 days
57776289|NCT04380818|DRUG|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
57776290|NCT04380818|DRUG|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
57776291|NCT04380818|DEVICE|Oxygen supply|Oxygen
57776292|NCT06012565|DRUG|KAND567|2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
57776293|NCT06012565|DRUG|Microcrystalline cellulose|Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
58459884|NCT05957679|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
58459885|NCT05957679|PROCEDURE|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
57776294|NCT05583851|DEVICE|Acceptance and Commitment Therapy|Smartphone app guided and manualized version of acceptance and commitment therapy.
57776295|NCT05583851|OTHER|Psychoeducation Active Control|Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
57776296|NCT04256590|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
57776297|NCT01936610|OTHER|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
57776298|NCT01936610|OTHER|lecture|Describe advantages and disadvantages in one 90-min session
57776299|NCT02223117|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
57776300|NCT02223117|BIOLOGICAL|Placebo|
57776301|NCT06364592|DEVICE|Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period)."
57776302|NCT06364592|DEVICE|Sham Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi."
58459886|NCT03552666|DIETARY_SUPPLEMENT|vitamin D3|
58459887|NCT02974998|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
58459888|NCT02974998|BEHAVIORAL|Standard HTC|Participants received the standard HTC available in South Africa for this population.
57776303|NCT00663962|DRUG|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
57776304|NCT00663962|DRUG|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
57776305|NCT03663777|OTHER|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
57776306|NCT03663777|OTHER|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
57776307|NCT00871819|DEVICE|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
57776308|NCT04048499|DEVICE|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
57776309|NCT03993899|DEVICE|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
57776310|NCT00832338|DRUG|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
57776311|NCT00832338|DRUG|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
57776312|NCT05082896|PROCEDURE|Type of anesthesia choice|Use of conscious sedation vs. general anesthesia
57776313|NCT00371527|DRUG|ipratropium|
57776314|NCT01254175|BIOLOGICAL|rHPIV3cp45 Vaccine|10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops
57776315|NCT01254175|BIOLOGICAL|Placebo Vaccine|Placebo vaccine, delivered as nose drops
57776316|NCT04259775|DEVICE|Automated Insulin Dose Adjustment|The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
57776317|NCT04259775|DEVICE|Control|Standard Care - change in therapy settings effected at regularly scheduled patient visits
57776318|NCT00991822|DRUG|Dorzolamide 2%|
57776319|NCT00991822|DRUG|Timolol 0.5%|
57776320|NCT06249620|DIETARY_SUPPLEMENT|Inmunoferon|The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
57776321|NCT06249620|DIETARY_SUPPLEMENT|Placebo|The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
57776322|NCT04524728|DRUG|Palbociclib|tablets
57776323|NCT04524728|DRUG|Letrozole 2.5mg|tablets
57776324|NCT04524728|DRUG|Fulvestrant|intramuscolar injections
57776325|NCT00245011|BIOLOGICAL|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
57776326|NCT00245011|DRUG|ifosfamide|Ifosfamide administered IV.
57776327|NCT00245011|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
57776328|NCT00245011|RADIATION|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
57776329|NCT00245011|RADIATION|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
57776330|NCT04854850|DEVICE|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
57776331|NCT04432402|DRUG|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
57776332|NCT03219450|DRUG|NeoVax|It stimulates the immune system to attack cancer cells.
57776333|NCT03219450|DRUG|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
57776334|NCT03219450|DRUG|Pembrolizumab|Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
57776335|NCT03729596|BIOLOGICAL|vobramitamab duocarmazine|Anti-B7H3 antibody drug conjugate
57776336|NCT03428568|OTHER|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
57776337|NCT03428568|DRUG|Nexium|omeprazole
57776338|NCT03428568|DRUG|Amoxil|Antibiotic
57776339|NCT03428568|DRUG|Clarithromycin|Antibiotic
57776340|NCT05793710|BEHAVIORAL|The principle of laughter plus Qigong|"The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes."
57784410|NCT06140160|PROCEDURE|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
57776341|NCT02291224|BEHAVIORAL|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
57776342|NCT02291224|BEHAVIORAL|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
57776343|NCT02291224|BEHAVIORAL|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
57776344|NCT00865891|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
57776345|NCT00865891|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
57776346|NCT01479491|OTHER|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
58459889|NCT06525285|PROCEDURE|Connective tissue graft wall technique|Harvested connective tissue graft will be placed over the exposed root surface like a wall to cover the gingival recession
57776347|NCT06487767|OTHER|Surgery|Surgery for operable cervical cancer
57776348|NCT00389090|DRUG|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
57776349|NCT00883103|DRUG|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
57776350|NCT00883103|DRUG|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
57776351|NCT02333734|OTHER|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
57776352|NCT02136498|DRUG|Varenicline|Standard 12 week course of varenicline, provided in both arms
57776353|NCT02136498|BEHAVIORAL|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
57776354|NCT02136498|BEHAVIORAL|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
58459890|NCT00646139|DRUG|Src kinase inhibitor KX2-391|
58459891|NCT00646139|OTHER|immunoenzyme technique|
58459892|NCT00646139|OTHER|pharmacological study|
58459893|NCT03186612|BEHAVIORAL|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
58459894|NCT04233008|DEVICE|Foley catheter length|see arm description
58459895|NCT04472052|OTHER|appendectomy|Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
58459896|NCT05706922|OTHER|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
58459897|NCT03567772|DEVICE|Wiifit Nintendo video game|
57776355|NCT02809508|DIETARY_SUPPLEMENT|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
57776356|NCT02809508|DIETARY_SUPPLEMENT|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
57776357|NCT05966376|DEVICE|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
58459898|NCT03567772|OTHER|Pulmonary rehabilitation program|
58459899|NCT00231777|DRUG|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
58459900|NCT00231777|DRUG|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
58459901|NCT00799682|DRUG|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
58459902|NCT00799682|DRUG|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
57776358|NCT01001780|DRUG|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
57776359|NCT04961320|BEHAVIORAL|Occupational Therapy|Participate in OT session
57776360|NCT04961320|OTHER|Questionnaire Administration|Complete questionnaires
57776361|NCT03871049|DRUG|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
57776362|NCT03871049|DRUG|Bupivacaine|bupivacaine
58459903|NCT02240485|BEHAVIORAL|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
57776363|NCT03518658|OTHER|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
57776364|NCT03518658|OTHER|Control Group (Historical)|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
57776365|NCT05261750|BIOLOGICAL|Auto-Dendritic Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
57776366|NCT05261750|BIOLOGICAL|Allo-Dendritic-Secretome Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
57776367|NCT02372123|OTHER|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
57776368|NCT02372123|OTHER|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
57776369|NCT02753725|DRUG|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
57776370|NCT02753725|DRUG|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
57776371|NCT04345198|PROCEDURE|Adrenal Artery Ablation|Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
57776372|NCT02591420|BIOLOGICAL|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
57776373|NCT02591420|BIOLOGICAL|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
58459904|NCT02240485|BEHAVIORAL|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
58459905|NCT00112736|DRUG|erlotinib|Given orally
58459906|NCT00112736|DRUG|temsirolimus|Given IV
58459907|NCT00112736|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
58459908|NCT00112736|OTHER|laboratory biomarker analysis|Correlative studies
58459909|NCT00112736|OTHER|pharmacological study|Correlative studies
58459910|NCT00778934|OTHER|Intimate Health Gel|Intimate Health Gel
57776374|NCT02591420|DRUG|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
57776375|NCT01226173|DEVICE|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
57776376|NCT03508804|DRUG|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
57776377|NCT03508804|DRUG|Placebo Cream|10ml of vaginally self-administered placebo cream
57776378|NCT03508804|DRUG|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
57776379|NCT03146858|DRUG|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
57776380|NCT03148847|OTHER|Baseline care|
57776381|NCT03148847|OTHER|Referential's dissemination|
57776382|NCT01464255|DEVICE|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
57776383|NCT01464255|DEVICE|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
57776384|NCT00252590|BEHAVIORAL|Health Motivational Feedback|Personalized feedback on health status
57776385|NCT00252590|BEHAVIORAL|Health Education|Generalized health education related to alcohol use
57776386|NCT00252590|BEHAVIORAL|Control - treatment as usual|Control group with no additional intervention
58459911|NCT03407898|OTHER|intubation time|intubation attempt number and intubation time
58459912|NCT00967564|OTHER|epidemiologic study|QoL assessment
58459913|NCT05091658|DEVICE|LH Urine Test|Test for qualitative detection of LH in urine
58459914|NCT02830737|PROCEDURE|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
58459915|NCT02830737|PROCEDURE|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
57776387|NCT04022889|DEVICE|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
57776388|NCT05294874|OTHER|gait training|walking forward, sideway and backward walking on balance board
57776389|NCT03488290|BEHAVIORAL|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
57776390|NCT03488290|OTHER|Treatment as Usual|The Treatment as Usual group will receive routine care
57776391|NCT01023880|DRUG|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
57776392|NCT01972334|BIOLOGICAL|FMT|as explained in study arm
57776393|NCT01972334|BIOLOGICAL|placebo|salt water or saline will be given as placebo
57776394|NCT01466296|DEVICE|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
57776395|NCT01466296|DEVICE|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
57776396|NCT01466296|DEVICE|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
57776397|NCT06339294|DRUG|Clotrimazole Cream|Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
57776398|NCT06339294|DRUG|Povidone-Iodine|Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
57776399|NCT06255847|DRUG|Pomalidomide, cyclophosphamide combined with dexametha|The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
57776400|NCT00023790|DRUG|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
57776401|NCT00229476|DRUG|sertraline (Zoloft)|
58459916|NCT04262700|DEVICE|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
58459917|NCT03880539|DRUG|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
58459918|NCT03880539|DRUG|Vancomycin Oral|SOC vancomycin pulse/taper
58459919|NCT03957148|BEHAVIORAL|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
57784411|NCT02529865|BIOLOGICAL|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
58459920|NCT00107692|BEHAVIORAL|Physical activity and diet|
58459921|NCT02467179|DEVICE|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
58459922|NCT02467179|DEVICE|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
58459923|NCT02952365|DRUG|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
58459924|NCT06064630|DEVICE|Automatic continuous positive airway pressure|Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
58459925|NCT06421857|PROCEDURE|suturing|laparoscopic cystectomy for endometrioma and hemostasis was done using suturing
57776402|NCT04870619|OTHER|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
57776403|NCT05744024|DEVICE|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.
57776404|NCT05744024|OTHER|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
57776405|NCT04669912|OTHER|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
57776406|NCT03507543|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
57776407|NCT01346761|BEHAVIORAL|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
57776408|NCT01346761|BEHAVIORAL|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
57776409|NCT02670538|DRUG|Cariprazine|Cariprazine capsule one per day orally.
57776410|NCT02670538|DRUG|Placebo|Matching placebo capsule one per day orally.
57776411|NCT00714350|BEHAVIORAL|New ICU Display Visualization|
57776412|NCT00078104|PROCEDURE|Extraction of wisdom teeth|
57776413|NCT01554982|DRUG|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
57776414|NCT03467438|DRUG|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
57776415|NCT03467438|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
57776416|NCT02142920|DRUG|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
57776417|NCT01482650|DEVICE|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
57776418|NCT04980235|DIAGNOSTIC_TEST|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
57776419|NCT00366860|BEHAVIORAL|Soy bread|
57776420|NCT01903343|DEVICE|shear wave elastography|ultrasound
57776421|NCT04406337|DEVICE|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.
57776422|NCT04406337|DEVICE|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
57776423|NCT00119119|DRUG|pentoxyphilline|
57776424|NCT00119119|DRUG|tocopherol|
57776425|NCT04842994|DEVICE|IONM tube|The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
57776426|NCT06230302|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
57776427|NCT06230302|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
57776428|NCT05595421|DEVICE|Transcranial direct current stimulation (tDCS)|See detail in arm/group descriptions regarding the intervention.
58459926|NCT06421857|PROCEDURE|bipolar electrocoagulation|laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
57776429|NCT01929330|DRUG|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
57776430|NCT01929330|DRUG|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
57776431|NCT00262288|DRUG|i.v. recombinant human C1 inhibitor|
57776432|NCT04466618|BIOLOGICAL|Saline|Saline infused during the study
57776433|NCT04466618|BIOLOGICAL|Exendin-9,39|Exendin-9,39 infused during the study
57776434|NCT04466618|BIOLOGICAL|Saline + Intralipid/Heparin|Saline infused during acute insulin resistance
57776435|NCT04466618|BIOLOGICAL|Exendin-9,39 + Intralipid/Heparin|Exendin-9,39 infused during acute insulin resistance
57776436|NCT00239785|DRUG|FTY720|
57776437|NCT03555578|DRUG|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
57776438|NCT02361593|PROCEDURE|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
57776439|NCT02361593|PROCEDURE|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
57776440|NCT02835443|DEVICE|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
57776441|NCT02036515|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
57776442|NCT02036515|DRUG|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
58459927|NCT02495428|PROCEDURE|Kinesio Tape Method|
57776443|NCT02036515|DRUG|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
57776444|NCT02036515|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
57776445|NCT02036515|DRUG|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
57776446|NCT02036515|DRUG|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
57776447|NCT02036515|BIOLOGICAL|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
57776448|NCT02036515|DRUG|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
57776449|NCT03681262|DEVICE|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
57776450|NCT03681262|DEVICE|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
57776451|NCT06286579|DEVICE|Immediately implant placement|After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
57776452|NCT06286579|DEVICE|Delayed|"After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered"
57776453|NCT00003534|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57776454|NCT05921721|DEVICE|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
57776455|NCT03948867|DRUG|Hydroxyurea|Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
57776456|NCT03948867|DIAGNOSTIC_TEST|Elevated Arm TCD Examination|"TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months."
57784412|NCT03706911|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
57784413|NCT01818700|DRUG|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
58459928|NCT01157702|BIOLOGICAL|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
57784414|NCT03990077|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
58459929|NCT00242671|PROCEDURE|Isocapnic Hyperponea|
58459930|NCT03557970|DRUG|Edicotinib|Given PO
58459931|NCT03557970|OTHER|Pharmacokinetic Study|Correlative studies
58459932|NCT00409071|DRUG|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
58459933|NCT00409071|DRUG|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
58459934|NCT06518356|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).
58459935|NCT06117735|DEVICE|Transjugular Intrahepatic Portosystemic shunt|The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
58459936|NCT01962792|DRUG|Ibrutinib|
58459937|NCT01962792|DRUG|Carfilzomib|
58459938|NCT01962792|DRUG|Dexamethasone|
58459939|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
58459940|NCT01363375|PROCEDURE|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
58459941|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
57776457|NCT03948867|DIAGNOSTIC_TEST|Normal Arm TCD Examination|TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
58459942|NCT00436150|BEHAVIORAL|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
57776458|NCT06174974|OTHER|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
57776459|NCT03050398|DRUG|Ribociclib|ribociclib + letrozole
57776460|NCT03050398|DRUG|letrozole|ribociclib + letrozole
57776461|NCT03619941|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
57776462|NCT03619941|DIETARY_SUPPLEMENT|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
57776463|NCT05667259|OTHER|Surgical resection for cancer rectum|Curative resection for cancer recum
57776464|NCT01454830|BEHAVIORAL|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
57776465|NCT01454830|OTHER|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
57776466|NCT06285617|DRUG|1-week predisone+1-week celecoxib|20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
57776467|NCT06285617|DRUG|6-weeks predisone|20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
57776468|NCT05334121|DIETARY_SUPPLEMENT|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
57776469|NCT05334121|OTHER|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
57776470|NCT03139838|BEHAVIORAL|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
57776471|NCT03139838|BEHAVIORAL|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
57776472|NCT05272423|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
57776473|NCT05950503|RADIATION|Hepatic MRI|The patients will undergo hepatic MRI in pre-established timepoints
57776474|NCT01722318|DRUG|Plecanatide|
57776475|NCT01722318|DRUG|Placebo|
57776476|NCT01487304|DRUG|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
58459943|NCT00436150|BEHAVIORAL|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
57776477|NCT04094701|OTHER|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
57776478|NCT04094701|OTHER|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
57776479|NCT01625936|DRUG|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
57776480|NCT01625936|DRUG|Bevacizumab|
57776481|NCT05408923|DRUG|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
58459944|NCT02583061|OTHER|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
58459945|NCT00167115|DRUG|Alcohol|
58459946|NCT02660788|OTHER|Standard Reminder Postcard|
57776482|NCT05408923|DRUG|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
57776483|NCT00840996|DRUG|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
58459947|NCT02660788|OTHER|Family Physician Reminder Letter|
58459948|NCT04862715|DRUG|Ferinject|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
58459949|NCT04862715|OTHER|Placebo: NaCl (sodium chloride 0.9%)|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
57776484|NCT00840996|DRUG|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
58459950|NCT03969914|PROCEDURE|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
58459951|NCT03212326|DRUG|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
57776485|NCT01219803|DRUG|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
57776486|NCT01219803|DRUG|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
57776487|NCT01219803|DRUG|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
57776488|NCT01219803|DRUG|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
57776489|NCT03219203|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
57776490|NCT00153946|DRUG|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
57776491|NCT01254305|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
57776492|NCT01254305|DRUG|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
58459952|NCT04247347|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
58459953|NCT04247347|OTHER|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
58459954|NCT04247347|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
58459955|NCT06077721|DRUG|Milrinone|giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
58459956|NCT02893319|BEHAVIORAL|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
58459957|NCT04532671|OTHER|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
58459958|NCT04532671|OTHER|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
57776493|NCT01254305|DRUG|Placebo|Matching placebo capsules, oral administration, once daily dosing
57776494|NCT03752619|DEVICE|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
57784415|NCT03990077|DRUG|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
57784416|NCT05878925|OTHER|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
57776495|NCT03752619|DEVICE|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
57776496|NCT03752619|OTHER|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
57776497|NCT00229619|DRUG|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
57776498|NCT05672004|OTHER|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
57776499|NCT05672004|OTHER|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
57776500|NCT00003792|BIOLOGICAL|MART-1 antigen|
57776501|NCT00003792|BIOLOGICAL|filgrastim|
57776502|NCT00003792|BIOLOGICAL|flu matrix peptide p58-66|
57776503|NCT00003792|BIOLOGICAL|gp100 antigen|
57776504|NCT00003792|BIOLOGICAL|recombinant MAGE-3.1 antigen|
57776505|NCT00003792|BIOLOGICAL|tyrosinase peptide|
57776506|NCT00003792|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
57776507|NCT01079624|OTHER|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
57776508|NCT04461925|PROCEDURE|Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|i/v infusions
57776509|NCT04461925|DRUG|Antibiotics|per os
57776510|NCT04461925|DRUG|Hormones|a moderate amount of dexamethasone i/v
57776511|NCT04461925|DRUG|Anticoagulant Therapy|Sub-Q
57776512|NCT04461925|DEVICE|Оxygen therapy|Оxygen therapy, mechanical ventilation and other supportive therapies
57776513|NCT06387589|PROCEDURE|Core stability exercises|"Core stability Exercises will include:~PLANK SIDE PLANK BIRD DOG MS GILL CURLUP PLANK + LEG RAISES SIDE PLANK + LEG RAISES PLANK + WALKS SIDE TO SIDE SIDE PLANK + TWIST BIRD DOG"
57776514|NCT06387589|PROCEDURE|Static Stretching of Iliopsoas|Static Stretching of Iliopsoas (Hold for 7-8s x 10 reps) Week 1 Lifting the leg while lying in a prone position with the knee bent Week 2 Lifting the leg in a prone position with a straight knee Week 3 Stretch in the modified Thomas test position Week 4 Modified launch stretch
57776515|NCT06387589|PROCEDURE|Post Facilitation Stretch of Iliopsoas|"Post Facilitation Stretch of Iliopsoas (5-10s x 10 reps) Patient's position supine at the edge of the table, non-effected hip and knee in flexion, experimental thigh and leg hang on the edge of table. Extend the hip of the opposite thigh up to the barrier. After that, the patient flexes the hip against maximal resistance (isometric) and breathes in for 5-10 seconds. Tell the patient Relax, whereas the therapist applies a rapid stretch to a new barrier and is held for 10 seconds."
58459959|NCT04532671|OTHER|indirect resin composite|CADCAM resin composite blocks using milling process
57776516|NCT02738671|BEHAVIORAL|Cognitive assessment|
57776517|NCT02738671|OTHER|functional magnetic resonance imaging|
57776518|NCT02738671|OTHER|olfactory function measurement|
57776519|NCT02738671|PROCEDURE|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
57776520|NCT01812382|DRUG|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
57776521|NCT05601921|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.
57776522|NCT05601921|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
57776523|NCT03106519|DRUG|Liposome bupivacaine + bupivacaine|
58459960|NCT02761226|PROCEDURE|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
58459961|NCT02761226|PROCEDURE|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
58459962|NCT00188552|DRUG|pentoxifylline|
58459963|NCT00188552|DRUG|α-Tocopherol|
57776524|NCT05102591|DRUG|Ketorolac|Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
57776525|NCT05102591|DRUG|Metoclopramide|Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
57776526|NCT05102591|DEVICE|Active Remote Electrical Neuromodulation Device|The REN device is a battery-powered, wirelessly controlled neuromodulation device that attaches via armband to the upper arm. The REN device is controlled by a smartphone application and administers electrical stimulation to the local C and Aδ nociceptive sensory nerves of the upper arm. This stimulation is achieved using a symmetrical, biphasic, square pulse, modulated at a frequency between 100-120 Hz. Each pulse has a width of 400 µs and the user, via the smartphone application, can adjust the output current to apply a maximum of 40 mA. Each stimulation session occurs over 45 minutes and each device can administer up to 12 stimulation sessions.
57776527|NCT05102591|DRUG|Placebo|0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
57776528|NCT05102591|DEVICE|Sham Remote Electrical Neuromodulation Device|The sham REN device is identical to the active REN device but the stimulation parameters are different, administering a modulated symmetrical biphasic square electrical pulse, modulated frequency of \~0.083 Hz and a modulated pulse width of 40-550 µ. These sham parameters are designed to induce a sensation that will be perceptible to participants, similar to stimulation from the active REN device, but at a frequency that is low enough so as to not modulate the nociceptive sensory nerves.
57776529|NCT01614847|DRUG|Artificial tears|At random, subjects will receive isotonic artificial tear or a control (normal saline).
57776530|NCT02766998|PROCEDURE|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
57776531|NCT03937323|OTHER|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
57776532|NCT01900054|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
57776533|NCT00282230|DRUG|FK778|
57776534|NCT03864926|DRUG|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
57776535|NCT03864926|DRUG|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
57776536|NCT01264029|BEHAVIORAL|Mindful Tai Chi Intervention|
57776537|NCT01264029|BEHAVIORAL|Mindfulness Meditation|
57776538|NCT01264029|BEHAVIORAL|Mall Walking|
57776539|NCT01264029|BEHAVIORAL|Weekly Discussion|
57776540|NCT01898975|OTHER|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
57776541|NCT06453018|DEVICE|Positional device, Rematee Bumper Belt or Night Shift|Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
57776542|NCT02214823|DEVICE|FES-Cycling|
57776543|NCT02214823|OTHER|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
58459964|NCT02348177|DRUG|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
58459965|NCT02348177|DRUG|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
58459966|NCT02476149|PROCEDURE|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
57776544|NCT00441051|DRUG|Diclofenac sodium 1mg/g|
57776545|NCT06348537|DIETARY_SUPPLEMENT|Olive Polyphenols|Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.
57776546|NCT06348537|DIETARY_SUPPLEMENT|Placebo|Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
57776547|NCT01830192|OTHER|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
57776548|NCT01830192|OTHER|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
57776549|NCT02654795|RADIATION|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
57776550|NCT01700348|DEVICE|Airflosser|Use of Philips Airflosser
57776551|NCT01700348|DEVICE|Manual Floss|Active Comparator
57776552|NCT00064272|DRUG|ginger extract|Given orally
57776553|NCT00064272|OTHER|placebo|Given orally
57776554|NCT00650494|DRUG|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
58459967|NCT01069432|OTHER|No Intervention|No Intervention
57776555|NCT00650494|DRUG|Valtrex® 1000 mg|1000mg, single dose fed
57784417|NCT05878925|OTHER|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
57784418|NCT06307483|BEHAVIORAL|Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
57776556|NCT04658732|DRUG|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
57776557|NCT01729728|DRUG|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
57776558|NCT00307099|DRUG|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
57776559|NCT00307099|DRUG|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
57776560|NCT05453981|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
57776561|NCT02087150|DEVICE|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
57776562|NCT00429260|DRUG|Saredutant|
57776563|NCT03905590|PROCEDURE|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
57776564|NCT03905590|PROCEDURE|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
57776565|NCT06146309|DRUG|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
57776566|NCT01566786|DRUG|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
57776567|NCT01566786|DRUG|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
57776568|NCT00569361|PROCEDURE|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
57776569|NCT02890914|OTHER|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
57776570|NCT06488391|BEHAVIORAL|Using a Portable Visualized Device for Self-Directed Breathing Training|Using a Portable Visualized Device for Self-Directed Breathing Training
57776571|NCT02101099|DEVICE|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
57776572|NCT00850720|OTHER|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
57776573|NCT04934774|BIOLOGICAL|CD7 CAR T cells|Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
57776574|NCT01672450|DRUG|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
57776575|NCT05923593|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
57776576|NCT04388930|OTHER|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
57776577|NCT04388930|OTHER|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
57776578|NCT04388930|OTHER|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
58459968|NCT04743115|DRUG|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
57776579|NCT04388930|OTHER|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
57776580|NCT04388930|OTHER|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
57776581|NCT04388930|OTHER|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
57776582|NCT05353543|DRUG|SSRIs|In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
57784419|NCT06307483|BEHAVIORAL|Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
57776583|NCT05353543|PROCEDURE|acupuncture (strong reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
57776584|NCT05353543|PROCEDURE|acupuncture (weak reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
57776585|NCT05353543|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
57776586|NCT03708419|OTHER|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
57776587|NCT03708419|OTHER|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
57776588|NCT03326089|PROCEDURE|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
57776589|NCT03173443|DEVICE|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
57776590|NCT03173443|DEVICE|double lumen tube|fiberoptic intubation with double umen tube
57776591|NCT05418777|DRUG|Trimethoprim Sulfamethoxazole|Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
57776592|NCT05418777|DRUG|Placebo|Receipt of suspension with placebo by mouth every 12 hours for 10 days
57776593|NCT00931450|DRUG|exemestane|Given orally
57776594|NCT00931450|DRUG|sunitinib malate|Given orally
57776595|NCT00931450|OTHER|placebo|Given orally
57776596|NCT01734850|DRUG|Busulfan|Intravenous busulfan
57776597|NCT01734850|BIOLOGICAL|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
57776598|NCT01734850|BIOLOGICAL|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
57776599|NCT04985734|DIAGNOSTIC_TEST|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
57776600|NCT00160160|DRUG|eprosartan/HCTZ|
57776601|NCT01933386|DEVICE|SoundBite|Non-surgical removable bone conduction device via the teeth.
57776602|NCT04374500|DRUG|Leptin infusion plus vasodilators in healthy men|This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
57776603|NCT04374500|DRUG|Leptin infusion in healthy men|This applies only to protocol 1 when only leptin was given
57776604|NCT04374500|DRUG|Vasodilators in CAD patients|This applies only to protocol 3
57776605|NCT03194074|DRUG|Propofol|In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
57776606|NCT03194074|DRUG|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
57776607|NCT00742105|DRUG|BGT226|
57776608|NCT05027737|PROCEDURE|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
57776609|NCT02183428|DRUG|BI 1356|
57776610|NCT02183428|DRUG|Glyburide|
57776611|NCT02183428|DRUG|BI 1356 + Glyburide|
57776612|NCT01706224|PROCEDURE|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
57776613|NCT01706224|OTHER|Data collection|Electronic Case Report Forms (eCRF)
57776614|NCT01706224|OTHER|Data collection|Questionnaires, active questioning.
57776615|NCT04577742|RADIATION|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
57776616|NCT05642546|DRUG|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
57776617|NCT05642546|DRUG|Placebo|Saline Placebo
57776618|NCT06420102|DIAGNOSTIC_TEST|Biophysical and biochemical skin assessment|Measurements are taken from the skin surface including transepidermal water loss, skin hydration and pH. In addition, non-invasive biofluid (sebum) is sampled from the skin to profile local inflammation. Skin surface cells were also stripped to assess corneocyte properties over the pressure ulcer and surrounding healthy skin.
57776619|NCT00759824|DRUG|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
57776620|NCT02479997|DRUG|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
57776621|NCT02479997|DRUG|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
57776622|NCT03580356|BIOLOGICAL|Ligelizumab|Liquid in vial
57776623|NCT03580356|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
57776624|NCT03580356|OTHER|Placebo|Liquid in vial
57776625|NCT05642273|DEVICE|oXiris membrane|oXiris membrane for 24h
57776626|NCT05642273|DIAGNOSTIC_TEST|Blood tests|Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
57776627|NCT01358448|BEHAVIORAL|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
57776628|NCT01358448|BEHAVIORAL|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
57776629|NCT04336423|DIAGNOSTIC_TEST|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
57776630|NCT04683289|PROCEDURE|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
57776631|NCT06355713|DEVICE|Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination|"An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over."
57776632|NCT06355713|BIOLOGICAL|blood sample|"Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)"
57776633|NCT06355713|BIOLOGICAL|urine collection|"Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)"
57776634|NCT06355713|BIOLOGICAL|Collection of a lock of hair|Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
57776635|NCT06355713|OTHER|questionnaire|"Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score"
58459969|NCT02743585|DEVICE|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in \< 1 - 1.5 hours
58459970|NCT02743585|DEVICE|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
57776636|NCT00273962|DRUG|ipratropium plus salbutamol UDV|
57776637|NCT00273962|DRUG|salbutamol UDV|
57776638|NCT04934137|BEHAVIORAL|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
57776639|NCT04934137|BEHAVIORAL|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
57776640|NCT00035503|DRUG|etiprednol dicloacetate|
57776641|NCT01427621|PROCEDURE|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
58459971|NCT04540263|DIAGNOSTIC_TEST|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
58491292|NCT06230237|BEHAVIORAL|Smiling is fun + professional support|"Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.~While they do the online program, they will receive periodically professional support. The professional support will be contacts of 20 minutes long, will take place every two weeks and will last 3 months."
57776642|NCT03745794|OTHER|Best Practice|Given standard of care
57776643|NCT03745794|DRUG|Quadratus Lumborum Block|Undergo QL block
57776644|NCT03745794|OTHER|Quality-of-Life Assessment|Ancillary studies
57776645|NCT03745794|OTHER|Questionnaire Administration|Ancillary studies
57776646|NCT04002180|DRUG|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
57776647|NCT03498014|OTHER|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
57776648|NCT03498014|OTHER|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
57776649|NCT03936296|PROCEDURE|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
57776650|NCT03936296|PROCEDURE|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
57776651|NCT01257139|PROCEDURE|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
57776652|NCT02693886|OTHER|doctor experience|
57776653|NCT03693716|PROCEDURE|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
57776654|NCT03008122|OTHER|Placebo|Placebo
57776655|NCT03008122|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
57776656|NCT00991159|BIOLOGICAL|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
57776657|NCT02868580|DRUG|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
57776658|NCT00061620|DRUG|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
58491293|NCT06230237|BEHAVIORAL|Smiling is fun|Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.
57776659|NCT03936413|DEVICE|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
57776660|NCT03936413|DEVICE|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
57776661|NCT03253770|DEVICE|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
57776662|NCT00654329|DRUG|Saline|Normal saline, given intranasally
57776663|NCT00654329|DRUG|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
57776664|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
57776665|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
57776666|NCT05297721|OTHER|Knowledge|Measuring the level of knowledge about skin tears
57776667|NCT06379230|OTHER|This study is purely descriptive study.|This study is purely descriptive study.
57776668|NCT01165840|DRUG|Dapsone|100 mg PO x 1 dose
57776669|NCT01622712|DEVICE|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
57776670|NCT03753607|OTHER|No intervention|No intervention
57776671|NCT02632786|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
57776672|NCT02632786|DRUG|Placebo|Saline Bag
57776673|NCT01079689|OTHER|needle stimulation|stimulation with acupuncture needles
57776674|NCT05741970|PROCEDURE|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
57776675|NCT00004811|DRUG|itraconazole|
57776676|NCT06475560|DIAGNOSTIC_TEST|CCE arm|Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.
57776677|NCT06475560|DIAGNOSTIC_TEST|OC arm|Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.
57776678|NCT05387486|PROCEDURE|Anatomical Landmark technique|anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin
57776679|NCT05387486|PROCEDURE|Ultrasound-guided pre location technique|In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.
57776680|NCT05387486|PROCEDURE|Ultrasound-guided real-time technique|In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
57776681|NCT06488768|OTHER|Radial nerve block|Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
57776682|NCT00684268|DRUG|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
57776683|NCT00684268|DRUG|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
57776684|NCT04171830|OTHER|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as \>0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~1. Edmonton Symptom Assessment System Revised: scores \>6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~2. 4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
57776685|NCT03953404|DIAGNOSTIC_TEST|SPLA2-IIA|bedside blood test
57776686|NCT04929366|PROCEDURE|Hypothermic dialysis followed with routine dialysis|Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)
57776687|NCT04929366|PROCEDURE|Routine dialysis followed with hypothermic dialysis|Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
57776688|NCT05480332|DEVICE|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
57776689|NCT04864821|DRUG|Targeting CD276 CAR T cells|Targeting CD276 autologous chimeric antigen receptor T cells
57776690|NCT01831414|OTHER|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
57776691|NCT01831414|OTHER|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
57776692|NCT03669094|DIETARY_SUPPLEMENT|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1\*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
57776693|NCT03669094|DIETARY_SUPPLEMENT|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
57776694|NCT05995613|DEVICE|MABOS|The novel pulse oximeter (MABOS) will be placed to acquire two biometrics: blood oxygen saturation and epidermal melanin concentration.
57776695|NCT05995613|DEVICE|Nonin PureSat|An FDA approved pulse oximeter will be placed to acquire blood oxygen saturation.
57776696|NCT00197301|BIOLOGICAL|Vaccination|
57776697|NCT05569824|DIAGNOSTIC_TEST|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
57776698|NCT04364321|DRUG|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
57776699|NCT04364321|DRUG|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
57776700|NCT00849680|OTHER|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
57776701|NCT00849680|BIOLOGICAL|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)
57776702|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)
57776703|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)
57776704|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)
57776705|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)
57776706|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)
57776707|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)
57776708|NCT00849680|BIOLOGICAL|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
57776709|NCT01054196|DRUG|lenalidomide|daily dose dependent on dose-escalation schedule
57776710|NCT01054196|DRUG|melphalan|100 mg/m2 given Days -2 and -1
57776711|NCT04888481|DRUG|68Ga-HA-DOTATATE|Tracer injection
57776712|NCT01792362|OTHER|Weight loss diet|Control the patients diet to make them loosing weight
57776713|NCT02067351|BEHAVIORAL|Mindfulness|Meditation, body scan, yoga.
57776714|NCT05048368|DRUG|Larotinib|Capsules, Oral, 350 mg, single dose, one day
57776715|NCT02456337|DEVICE|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
57776716|NCT02456337|DEVICE|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
57776717|NCT02456337|PROCEDURE|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
57776718|NCT01521325|DRUG|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
57776719|NCT03413410|DRUG|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
57776720|NCT03664037|DRUG|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
57776721|NCT03664037|DRUG|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
57776722|NCT02754414|PROCEDURE|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
57776723|NCT02754414|OTHER|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
57776724|NCT02754414|RADIATION|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
57776725|NCT02754414|OTHER|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
58491294|NCT00686114|DRUG|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
57776726|NCT00153335|BEHAVIORAL|patient-provider interaction|
57776727|NCT05752422|DEVICE|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
57776728|NCT00165867|DRUG|E7070|
57776729|NCT00249496|BEHAVIORAL|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
57776730|NCT00249496|BEHAVIORAL|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
57776731|NCT05515029|COMBINATION_PRODUCT|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
57776732|NCT06077435|DEVICE|AI|AI system
57776733|NCT01209338|BEHAVIORAL|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
57776734|NCT00284999|DRUG|Soothe|
57776735|NCT00284999|DRUG|Refresh Tears|
57776736|NCT03657927|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
57776737|NCT03657927|DEVICE|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
57776738|NCT01364727|DRUG|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
57776739|NCT00154063|DRUG|E2007|
57776740|NCT00154063|OTHER|Placebo|
57776741|NCT02385617|DRUG|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
57776742|NCT02385617|DRUG|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
57776743|NCT04763538|OTHER|Standard of care|Patients are treated according to the standard of care for each individual disease.
57776744|NCT03598218|RADIATION|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
57776745|NCT03598218|RADIATION|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
57776746|NCT03016117|PROCEDURE|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
57776747|NCT01061918|DEVICE|Tecnis MF|20 patients in the Tecnis MF group.
57776748|NCT01061918|DEVICE|ReSTOR|20 patients in the ReSTOR group.
57776749|NCT00786474|DRUG|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
57776750|NCT00786474|DRUG|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
57784420|NCT05263453|DRUG|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
57784421|NCT05263453|DRUG|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
57784422|NCT01976611|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
58491295|NCT00686114|DRUG|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
58491296|NCT00686114|DRUG|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
57776751|NCT04456582|PROCEDURE|Shear wave elastography|The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
57776752|NCT04906590|DRUG|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
57776753|NCT02951650|DEVICE|Cyberonics VNS|Vagus nerve stimulation
57776754|NCT04334785|DEVICE|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
57776755|NCT01927718|DRUG|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
57776756|NCT01927718|DRUG|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
57776757|NCT01927718|BEHAVIORAL|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
57776758|NCT04198740|DIAGNOSTIC_TEST|Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry|During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
57776759|NCT03479749|DEVICE|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
57776760|NCT01355874|DRUG|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
57776761|NCT01355874|DRUG|Placebo|Placebo ointment BID for 14 days during double blind.
57776762|NCT01355874|DRUG|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
57776763|NCT04765293|OTHER|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
57776764|NCT00649493|DRUG|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
57776765|NCT00649493|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
57776766|NCT00338793|DRUG|prednisolone|
58138136|NCT04350086|DRUG|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
57776767|NCT04957732|DEVICE|Standard of Care (SoC)|SoC consisted of irrigation with normal saline, using the same proprietary abscess irrigation tip as the Irrisept arm. SoC was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
57776768|NCT04957732|DEVICE|Irrisept Delivery System|Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
57776769|NCT04725630|BEHAVIORAL|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
57776770|NCT04725630|BEHAVIORAL|Healthy food prescription|A one-time healthy food prescription pamphlet
57776771|NCT02950935|DRUG|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
57776772|NCT02950935|DRUG|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
57784423|NCT03373474|OTHER|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
58138137|NCT01974297|DRUG|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
58138138|NCT01974297|DRUG|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
58459972|NCT02908022|DEVICE|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
58459973|NCT02908022|DEVICE|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
58459974|NCT01022021|DRUG|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
58459975|NCT01022021|DRUG|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
58459976|NCT04463472|BIOLOGICAL|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
58459977|NCT04463472|BIOLOGICAL|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
58459978|NCT01576341|DRUG|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
58491297|NCT00686114|RADIATION|Radiotherapy|Enlarged field radiotherapy
57776773|NCT02023216|DEVICE|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
57776774|NCT02834572|BEHAVIORAL|All About Me|Assessment and algorithm to determine recommended HIV testing approach
57776775|NCT02834572|BEHAVIORAL|Control|HIV testing information
57776776|NCT01474837|BEHAVIORAL|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
57776777|NCT05663983|BEHAVIORAL|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
57776778|NCT00001493|GENETIC|peripheral blood progenitor cells carrying MDR1|
57776779|NCT05976113|OTHER|Observation only|Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
57776780|NCT03587350|DEVICE|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
57776781|NCT00312858|BIOLOGICAL|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
57776782|NCT00312858|BIOLOGICAL|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
57776783|NCT00312858|BIOLOGICAL|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
57776784|NCT01165710|OTHER|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
57776785|NCT03001401|OTHER|iDesign|One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
57776786|NCT03001401|OTHER|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
57776787|NCT02053428|PROCEDURE|percutaneous image-guided gastrostomy|
57776788|NCT04037241|BIOLOGICAL|Anti-CEA CAR-T cells|Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
58459979|NCT00737113|DRUG|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
57776789|NCT04037241|DRUG|gemcitabine/nab paclitaxel|systemic chemotherapy regimen
57776790|NCT04037241|DRUG|NLIR+FU/FA|systemic chemotherapy regimen
58459980|NCT03177863|PROCEDURE|Expectancy|Clinical monitoring. See arm description
58459981|NCT06314386|OTHER|Systems Analysis and Improvement Approach for TB (SAIA-TB)|The Systems Analysis and Improvement Approach for TB (SAIA-TB) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by clinic staff with support from study personnel in intervention clinics. Components of the intervention include TB cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally optimize TB screening, evaluation, diagnosis, TB preventive therapy and TB disease treatment initiation, successful treatment, and TB-free survival among the population at the intervention clinics.
58459982|NCT00711698|PROCEDURE|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
58459983|NCT00711698|DRUG|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
58459984|NCT01528059|PROCEDURE|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
57776791|NCT04037241|DRUG|Capecitabine|systemic chemotherapy regimen
57776792|NCT04039178|DEVICE|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
57776793|NCT04039178|DEVICE|Sham|Sham BQ device
57776794|NCT03522987|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
57776795|NCT00188318|PROCEDURE|hyperfractionated accelerated radiotherapy|
57776796|NCT03862651|DRUG|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
57776797|NCT03040687|BIOLOGICAL|Anti CS6 BSIgG product (Lot PD1601105CS)|
57776798|NCT03040687|BIOLOGICAL|Anti B7A BSIgG product (Lot PD1601132ET)|
57776799|NCT03040687|BIOLOGICAL|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
57776800|NCT03040687|BIOLOGICAL|B7A- CS6-expressing ETEC challenge strain|
57776801|NCT00794820|DRUG|Fludarabine Phosphate|25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
57776802|NCT00794820|DRUG|Cyclophosphamide|250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
57776803|NCT00794820|DRUG|Rituximab|375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
57776804|NCT00278785|BEHAVIORAL|Brief Motivational Interview|10-20 minute brief motivational interview
57776805|NCT01159639|DRUG|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
57776806|NCT04930458|OTHER|Nanosilver fluoride|Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
58138139|NCT01661114|DRUG|Gemcitabine|
58138140|NCT01661114|DRUG|5-FU|
58138141|NCT01661114|DRUG|Cisplatin|
57776807|NCT04930458|OTHER|Sodium fluoride with casein phosphopeptides amorphous calcium phosphate|Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
57776808|NCT04930458|OTHER|Sodium fluoride varnish|Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
57776809|NCT04239456|DEVICE|RehaCom (software)|RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
57776810|NCT03694015|RADIATION|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
57776811|NCT03694015|RADIATION|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
57776812|NCT04641195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
57776813|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
58459985|NCT01722305|DRUG|Dexamethasone|Given PO
57776814|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
57776815|NCT04641195|OTHER|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
57776816|NCT04142814|PROCEDURE|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
57776817|NCT04142814|PROCEDURE|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
57776818|NCT05685771|DEVICE|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
57776819|NCT04327908|OTHER|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
57776820|NCT03604263|DEVICE|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
57776821|NCT06142435|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
57776822|NCT02161328|OTHER|EIT belt|
57776823|NCT02125032|DEVICE|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
57776824|NCT02125032|DEVICE|Placebo Transcranial low voltage electromagnetic fields|
58459986|NCT01722305|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58459987|NCT01722305|OTHER|Pharmacological Study|Optional correlative studies
57776825|NCT00099489|DRUG|Interferon Beta-1a|
57776826|NCT02473887|DRUG|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
57776827|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -active|with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
57776828|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -sham|The sham stimulation was performed using the same procedures, with the sham coil.
57776829|NCT05518422|DRUG|Hyperinsulinemic, euglycemic infusion|60 minute infusion
57776830|NCT00211237|DEVICE|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
57776831|NCT00211237|OTHER|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
57776832|NCT04453501|DRUG|favorable outcome|Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
57776833|NCT03562351|OTHER|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
57776834|NCT03562351|OTHER|Video Educational Intervention|Caregivers will undergo training with an educational video
57776835|NCT03562351|OTHER|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
57776836|NCT05998772|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Application of 82,5 g of glucose monohydrate solved in 300ml water
57776837|NCT05998772|OTHER|Placebo Oral Glucose Tolerance Test|Application of 125mg sucralose solved in 300ml water
57776838|NCT04262102|BEHAVIORAL|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
57776839|NCT04262102|BEHAVIORAL|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
57776840|NCT04262102|BEHAVIORAL|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
57776841|NCT04262102|BEHAVIORAL|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
58138142|NCT02561793|DRUG|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
58459988|NCT01722305|DRUG|Pomalidomide|Given PO
58459989|NCT01198197|DRUG|NOP-1A|
58491298|NCT00686114|RADIATION|Radiotherapy|Conventional field radiotherapy
57776842|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.
57776843|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
57776844|NCT00253786|OTHER|Intensive multifactorial therapy|Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
57776845|NCT00253786|OTHER|Standard therapy|Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
57776846|NCT00326768|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
57776847|NCT00326768|DRUG|Telmisartan 40 mg|
57776848|NCT00326768|DRUG|Telmisartan 80 mg/HCTZ 12.5 mg|
57776849|NCT05993286|BEHAVIORAL|Exposure Therapy|"At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions."
57776850|NCT05993286|OTHER|Sound Therapy|Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
57776851|NCT05993286|OTHER|Psychoeducation|A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
57776852|NCT03003546|OTHER|Laboratory Biomarker Analysis|Correlative studies
57776853|NCT03003546|DRUG|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
57776854|NCT03003546|OTHER|Pharmacological Study|Correlative studies
57776855|NCT05908890|DEVICE|Experimental Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
57776856|NCT05908890|DEVICE|Fixodent True Feel Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
57776857|NCT04219254|DRUG|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
57776858|NCT02663414|DEVICE|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
57776859|NCT01115491|DRUG|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
57776860|NCT01115491|DRUG|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
57776861|NCT01213862|BEHAVIORAL|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
57776862|NCT00065468|DRUG|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
57776863|NCT00065468|DRUG|CCI-779|25 mg of CCI-779 given Intra Venously once per week
57776864|NCT00065468|DRUG|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
57776865|NCT01492179|DRUG|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
57776866|NCT01492179|DRUG|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
57776867|NCT01492179|DRUG|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
57776868|NCT03181126|DRUG|Navitoclax|tablet
57776869|NCT03181126|DRUG|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
57776870|NCT03181126|DRUG|Venetoclax|tablet
57776871|NCT02304250|DRUG|Dexamethasone|dexamethasone 1ml (5mg)
57776872|NCT02304250|DRUG|saline|saline 1ml
57776873|NCT00303082|DRUG|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
57776874|NCT01272713|OTHER|Oxygen therapy|"* Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol"
57776875|NCT01272713|OTHER|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
57776876|NCT03424720|DEVICE|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
57776877|NCT02597205|BEHAVIORAL|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
57776878|NCT05771584|DRUG|AST-301|100 μg
57776879|NCT05771584|DRUG|rhuGM-CSF|100 μg
57776880|NCT05926128|DRUG|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
57776881|NCT01565200|DRUG|T-DM1|3.6 mg/kg iv every 3 weeks
57776882|NCT01565200|PROCEDURE|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
57776883|NCT01714973|BIOLOGICAL|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
57776884|NCT00170404|DRUG|Folic Acid|
57776885|NCT00170404|DRUG|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
57776886|NCT00170404|DRUG|Selenium|
57776887|NCT00170404|DRUG|Vitamin A|
57776888|NCT04670926|DIAGNOSTIC_TEST|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of \> 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of \> 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
57776889|NCT04670926|OTHER|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
57776890|NCT04192214|DRUG|BC 007|1350 mg of BC 007
57776891|NCT04106479|DEVICE|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
57776892|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
58459990|NCT02785848|OTHER|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
57776893|NCT02406261|DRUG|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
57776894|NCT02406261|DRUG|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
57776895|NCT02406261|DRUG|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
58138143|NCT02561793|DRUG|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
58459991|NCT00003605|BIOLOGICAL|rituximab|
58459992|NCT00003605|DRUG|cyclophosphamide|
58459993|NCT06279858|DIETARY_SUPPLEMENT|Probiotics|Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
58459994|NCT03118310|BEHAVIORAL|5:2 diet|Dietary intervention according to 5:2 diet during three months.
58459995|NCT03118310|BEHAVIORAL|LCHF|Dietary intervention according to LCHF diet during three months.
58459996|NCT03118310|BEHAVIORAL|Placebo diet|Placebo diet: normal dietary advice
57776896|NCT02406261|DRUG|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
57776897|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
57776898|NCT02141659|DRUG|TAK-385|TAK-385 Tablets.
57776899|NCT02807246|BIOLOGICAL|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
57776900|NCT02807246|OTHER|drops of saline|Dietary Supplement: Breast milk +drops of saline
57776901|NCT00323713|BEHAVIORAL|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
57776902|NCT00323713|BEHAVIORAL|Low protein diet|0.6 g of protein per kilo of body weight per day
58491299|NCT01871740|DRUG|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
58491300|NCT01871740|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
57776903|NCT03016793|DRUG|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
57776904|NCT03016793|DRUG|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
57776905|NCT03016793|DRUG|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
57776906|NCT02459080|DRUG|TD-4208|
57776907|NCT02459080|DRUG|Placebo|
57776908|NCT02571465|OTHER|Passive leg raising test and fluid challenge|
58138144|NCT02336165|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
58138145|NCT02336165|RADIATION|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
58491301|NCT05023668|OTHER|No intervention|No intervention
58459997|NCT05003375|BEHAVIORAL|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures"
58459998|NCT05671692|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
57776909|NCT00271414|DRUG|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
57776910|NCT03627611|DRUG|Levothyroxin|3 months
57776911|NCT03627611|DRUG|Liothyronine|3 months
58459999|NCT05671692|DRUG|Placebo|Same as active comparator, except placebo dispensed.
57776912|NCT00660920|DRUG|Ponatinib|Comparison of different dosages of drug given orally once per day.
57776913|NCT06460415|DEVICE|photobiomidulação|The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.
57776914|NCT06460415|OTHER|Placebo|The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
57776915|NCT01706211|DRUG|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
57776916|NCT01706211|DRUG|Placebo|
57776917|NCT04425993|DRUG|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
57776918|NCT04425993|DRUG|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
57776919|NCT04425993|DRUG|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
57776920|NCT04425993|DRUG|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
57776921|NCT06290921|OTHER|Ovulation triggering|Ovulation triggering when women only 2 dominant follicles as opposed to the clinic's standard of 3 follicles or more
58129692|NCT06069297|OTHER|Multimodal Prehabilitation|Preoperative multimodal intervention including exercise training, nutritional therapy and anxiety reducing techniques, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a two to three-day per week training for 4 weeks. Exercise modalities will be adapted to personal preference and patient conditions. Based on dietary habits, medical conditions and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Participants will be instructed by psychology-trained personnel on how to reduce anxiety.
58129693|NCT00818337|DRUG|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
58129694|NCT01471366|DIETARY_SUPPLEMENT|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
58129695|NCT01471366|DIETARY_SUPPLEMENT|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
58129696|NCT01471366|DIETARY_SUPPLEMENT|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
58129697|NCT01471366|DIETARY_SUPPLEMENT|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
58129698|NCT00280371|DRUG|Formoterol Fumarate|
58129699|NCT02268500|BIOLOGICAL|Influenza vaccine|Influenza vaccine
58129700|NCT01939197|DRUG|ABT-450/r/ABT-267|tablet
58129701|NCT01939197|DRUG|ABT-333|tablet
58129702|NCT01939197|DRUG|ribavirin|tablet
58129703|NCT00395226|DRUG|zinc sulfate|zinc sulfate 220 mg bis for 90 days
58129704|NCT00395226|DRUG|placebo|placebo bid for 90 days
58491302|NCT01252225|DRUG|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
58491303|NCT01252225|DRUG|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
58491304|NCT01252225|DRUG|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
58491305|NCT04105504|DRUG|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
58129705|NCT03110315|DRUG|Suvorexant|See detailed information in associated Arm Description.
58129706|NCT03110315|DRUG|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
58129707|NCT00186108|DRUG|Oral Triamcinalone|
58129708|NCT00413556|BIOLOGICAL|ALK Grass tablet|
58129709|NCT03207581|BEHAVIORAL|Professional Coaching|Professional, individualized coaching
58129710|NCT00928954|DRUG|gabapentin|increasing to 1200 mg/day
58129711|NCT00928954|DRUG|memantine|increasing to 40 mg/day
58129712|NCT01303978|DRUG|APD421|Single dose
58460000|NCT04789252|BIOLOGICAL|Bioinformatics analysis of single cell transcriptomics data|"1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry"
58460001|NCT00391885|DEVICE|Closed-loop anesthesia system|
58460002|NCT04931264|DIAGNOSTIC_TEST|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
58460003|NCT03517475|BEHAVIORAL|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
58460004|NCT06082934|DRUG|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
58460005|NCT06002412|OTHER|Image quality control|The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
58460006|NCT03598179|BIOLOGICAL|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10\^6 Acute lymphocytic leukemia 2×10\^6 Chronic lymphocytic leukemia 10×10\^6
57776922|NCT04287192|OTHER|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
58129713|NCT02403700|DEVICE|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
58460007|NCT00271635|DRUG|Placebo|Placebo 4 capsules b.i.d. during 1 year
58460008|NCT00271635|DRUG|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
58460009|NCT04669223|DEVICE|Seldinger chest drain insertion|Different sizes of chest drain will be inserted with seldinger technique
58460010|NCT00675714|PROCEDURE|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
57776923|NCT01377415|DRUG|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
57776924|NCT02722317|BEHAVIORAL|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
58129714|NCT01625637|BEHAVIORAL|AAT-experiment|This AAT condition trains kids to avoid cigarettes
58129715|NCT01625637|BEHAVIORAL|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
58129716|NCT04784000|DRUG|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
58129717|NCT04784000|DRUG|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
58129718|NCT04784000|DRUG|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
58460011|NCT00675714|PROCEDURE|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
58460012|NCT00675714|PROCEDURE|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
58460013|NCT00675714|DRUG|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
58460014|NCT00675714|DRUG|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
58460015|NCT00675714|DRUG|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
58460016|NCT00675714|DRUG|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
58460017|NCT00675714|DRUG|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
58460018|NCT00675714|DRUG|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
58460019|NCT00675714|DRUG|Placebo|placebo to be given once a day for up to two years post burn injury.
58460020|NCT00675714|BEHAVIORAL|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
58460021|NCT00675714|BEHAVIORAL|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
58460022|NCT05255523|DRUG|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
58460023|NCT01393834|PROCEDURE|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
57776925|NCT04396353|OTHER|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
57776926|NCT05148832|DRUG|Administration of Systemic Corticosteroid|10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
57776927|NCT06243848|PROCEDURE|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
57776928|NCT06243848|PROCEDURE|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
57776929|NCT02980796|BEHAVIORAL|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
57776930|NCT02980796|BEHAVIORAL|Practice|Each experimental day participants will complete a session of skilled motor practice.
57776931|NCT04465058|OTHER|COVID19|viral infection
57776932|NCT04403802|DEVICE|Voxx Human Performance Technology Socks|"Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
57776933|NCT04403802|DEVICE|Placebo Socks|"Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
57776934|NCT02400359|DRUG|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
57776935|NCT02400359|DRUG|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
58129719|NCT04784000|DRUG|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
58460024|NCT01393834|PROCEDURE|Milking of the cord|Milking of the cord 4 times in 10 seconds
58460025|NCT01519323|DRUG|vemurafenib|Cohort 1 (participants \>=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
57776936|NCT05276843|COMBINATION_PRODUCT|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
57776937|NCT01129336|DRUG|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
57776938|NCT01129336|DRUG|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
58129720|NCT02456948|DRUG|Minocycline|6 weeks 200mg/day Minocycline add-on
58460026|NCT05077826|DEVICE|North Coast Medical Activadose II|tES device model Activadose II (North Coast Medical, Morgan Hill, CA, USA) programed to deliver tES.
58460027|NCT04051398|OTHER|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
58460028|NCT02682381|DRUG|Teduglutide 0.05mg/kg|0.05 mg/kg
58460029|NCT02682381|DRUG|Teduglutide 0.025 mg/kg|0.025 mg/kg
58460030|NCT02682381|OTHER|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
58460031|NCT05062122|OTHER|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
57776939|NCT01693003|DRUG|Indacaterol|150 µg d.o. during the first 3 weeks
58129721|NCT02456948|DRUG|Placebo|6 weeks Placebo add-on
58129722|NCT03039309|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
58129723|NCT04896164|DRUG|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
58460032|NCT05062122|OTHER|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
58460033|NCT05062122|OTHER|control group|Manual dexterity was assessed before and after traditional physiotherapy.
57776940|NCT01693003|DRUG|Tiotropium|150 µg d.o. during 3 weeks
57776941|NCT00801424|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
57776942|NCT04720963|DRUG|Remimazolam|intranasal remimazolam
57776943|NCT04720963|OTHER|Distilled water for injection|intranasal distilled water for injection
57776944|NCT04720963|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
57776945|NCT00878358|OTHER|Hydrotherapy|
57776946|NCT00878358|OTHER|Physiotherapy|
58460034|NCT02529540|OTHER|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
58460035|NCT02529540|OTHER|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
58129724|NCT04896164|OTHER|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
58460036|NCT02529540|OTHER|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
58129725|NCT00269048|DRUG|SB-480848|SB-480848
58129726|NCT00269048|DRUG|placebo|placebo
58129727|NCT02373332|OTHER|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
58129728|NCT05080751|BEHAVIORAL|Eating Behaviors|Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
58129729|NCT00192608|DRUG|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
58129730|NCT00192608|DRUG|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
58129731|NCT03044548|OTHER|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
58129732|NCT01505530|DRUG|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
58129733|NCT01505530|DRUG|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
58129734|NCT01505530|DRUG|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
58129735|NCT04332978|DRUG|Fluticasone Propionate|
58129736|NCT00002005|DRUG|CD4 Antigens|
58129737|NCT06257290|BIOLOGICAL|blood sample|at Day 1 - date of patient inclusion at time of VTE diagnosis
58460037|NCT02855203|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
57776947|NCT05179941|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
57776948|NCT02246829|PROCEDURE|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
57776949|NCT04081519|DEVICE|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
58129738|NCT06257290|BIOLOGICAL|blood sample|at 6 months (in the patient follow-up)
58129739|NCT04005664|DRUG|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
58129740|NCT03022071|OTHER|Cognitive behavior therapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
58129741|NCT00626548|DRUG|ZD4054|10 mg once daily oral dose
58129742|NCT00626548|DRUG|Palcebo|Matching Plcebo oral tablet once daily
58129743|NCT04799600|OTHER|BRESCİA-COVİD Respiratory Severity Scale|KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
58129744|NCT02161913|BEHAVIORAL|Multi-Family Group Treatment|
58129745|NCT02161913|BEHAVIORAL|SCI Education Control Group|
58129746|NCT04903262|PROCEDURE|Ultraprotective ventilation with Extracorporeal CO2 removal|HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.
58129747|NCT04903262|PROCEDURE|Conventional protective ventilation|"Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)"
58129748|NCT06116409|DRUG|Bupivacain|Bupivacaine was used for postoperative analgesia block.
58129749|NCT00000132|DRUG|Betaxolol|
58129750|NCT00000132|PROCEDURE|Argon Laser Trabeculoplasty|
58129751|NCT00582088|BIOLOGICAL|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
58129752|NCT05417425|COMBINATION_PRODUCT|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
58129753|NCT01075581|DRUG|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
58129754|NCT01075581|DRUG|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
57776950|NCT04081519|DEVICE|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
58129755|NCT00003064|BIOLOGICAL|filgrastim|
58460038|NCT02855203|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
58460039|NCT00002998|DRUG|cisplatin|
58129756|NCT00003064|DRUG|carboplatin|
58129757|NCT00003064|DRUG|etoposide phosphate|
58460040|NCT00002998|DRUG|gemcitabine hydrochloride|
58129758|NCT00003064|DRUG|paclitaxel|
58129759|NCT00003064|DRUG|thiotepa|
58129760|NCT00003064|DRUG|topotecan hydrochloride|
58460041|NCT02153593|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
58460042|NCT02153593|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
58460043|NCT02153593|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
58460044|NCT06524609|DRUG|Epigallocatechin-3-Gallate|After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).
58460045|NCT06524609|DRUG|Alcohol|After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).
57776951|NCT04081519|DEVICE|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
57776952|NCT04081519|DEVICE|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
57776953|NCT04691882|BEHAVIORAL|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
57776954|NCT04691882|BEHAVIORAL|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
57776955|NCT06344611|OTHER|Other|It is an observational study. Subjects will receive the treatment as per institute protocol.
57784424|NCT03373474|OTHER|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
57784425|NCT00109928|DRUG|cisplatin|
57784426|NCT00109928|DRUG|etoposide|
57962372|NCT03962205|BEHAVIORAL|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
57962373|NCT03962205|BEHAVIORAL|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
57962374|NCT03962205|OTHER|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
57962375|NCT03428646|DRUG|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
57784427|NCT00109928|DRUG|gemcitabine|
58460046|NCT01814774|OTHER|No Intervention|No treatment (intervention) was administered.
58460047|NCT05255471|DRUG|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
58460048|NCT05255471|DRUG|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~* Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~* Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~* Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
58460049|NCT03481478|DIAGNOSTIC_TEST|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
58460050|NCT03399058|OTHER|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
57962376|NCT00079859|DRUG|Implitapide|
57962377|NCT03238287|DEVICE|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
57962378|NCT03238287|OTHER|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
57962379|NCT06398041|OTHER|Blood flow restriction training|standard physiotherapy 45 minutes per day, 5 day a week (GAPP) + 2 extra sessions of blood flow restriction training
57962380|NCT06398041|OTHER|Opinions|Healthcare workers in the geriatric rehabilitation ward and patients will be asked on their opinions on GAPP+Care concerning blood flow restriction training
57962381|NCT06467890|BEHAVIORAL|Educational programme about vital pulp therapy|An awareness educational material based on the recent AAPD and AAE guidelines on vital pulp therapy will be sent to the participants right after they answer the questionnaire for the first time
57776956|NCT02691104|DEVICE|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
57776957|NCT02691104|DEVICE|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
57776958|NCT03382600|BIOLOGICAL|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
57776959|NCT03382600|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
57776960|NCT03382600|DRUG|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
57776961|NCT03382600|DRUG|Cisplatin|60 mg/m\^2 Q3W on Day 1 by IV infusion
57776962|NCT06278116|OTHER|Aligners cleansing with water|The product is masked in a spraying bottle without any labels. Once a day, for 14 days, the patient sprays the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
57776963|NCT06278116|OTHER|Aligners cleansing with dish soap Svelto|the product is masked in a transparent bottle without any labels. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
57776964|NCT06278116|OTHER|Aligners cleansing with Polident Antibacterial Denture Cleaner|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the tablet in a glass full of warm water (30-35 °C), then the aligner is placed inside it for 5 minutes. Afterward the aligner is rinsed under fresh running water.
57776965|NCT06278116|OTHER|Aligners cleansing with Invisalign Cleaning Crystals|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the crystals in a glass full of warm water (30-35 °C) mixing with a spoon for 20 seconds; then, the aligner is placed inside the glass for 15 minutes. Afterward, the aligner is rinsed under fresh running water.
57776966|NCT06278116|OTHER|Aligners cleansing with Geldis|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
58460051|NCT03399058|BEHAVIORAL|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
58460052|NCT03399058|BEHAVIORAL|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
58460053|NCT06403007|BEHAVIORAL|Phonics plus morphology|This intervention trains teachers to teach phonics plus morphology to at-risk poor readers
57776967|NCT05854329|BEHAVIORAL|Virtual Reality Exposure|Virtual Reality device using the immersive dental game.
57776968|NCT00990301|DRUG|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
57776969|NCT00990301|DRUG|Uniretic® 15mg/25mg Tablets|reference drug
57776970|NCT04786470|DRUG|Ropivacaine|Ropivacaine infusion via transversus abdominis plane catheter.
57776971|NCT04786470|DRUG|Saline|Saline infusion via transversus abdominis plane catheter.
57776972|NCT00492934|DRUG|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
57776973|NCT03552705|DRUG|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
57776974|NCT03552705|DRUG|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
57776975|NCT03747289|OTHER|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
57776976|NCT03747289|OTHER|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
57776977|NCT00268931|BEHAVIORAL|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
58460054|NCT06403007|BEHAVIORAL|Phonics plus set-for-variability|This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
57776978|NCT00268931|BEHAVIORAL|Social Training|This group underwent special social interactions with their parents two times each day.
57776979|NCT02999893|DRUG|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
57776980|NCT04384458|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
57776981|NCT04384458|DRUG|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
57776982|NCT04217993|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
57776983|NCT01912222|DRUG|IXAZOMIB|
57784428|NCT00109928|DRUG|methylprednisolone|
57784429|NCT00252928|OTHER|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
58460055|NCT04046328|DRUG|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
58460056|NCT04046328|DRUG|Placebo|Enteric-Coated Delayed Release Placebo Capsules
57962382|NCT05408754|DEVICE|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
57962383|NCT01317342|DEVICE|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
57962384|NCT03017170|DRUG|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
57962385|NCT03017170|DRUG|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
57962386|NCT05178732|DIETARY_SUPPLEMENT|Dose of protein|One of three protein doses provided
57962387|NCT05178732|OTHER|Menstrual cycle phase|Different phase of the menstrual cycle
57962388|NCT05458414|DEVICE|Intra-operative Navigation System|In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
57962389|NCT04593069|BEHAVIORAL|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
57962390|NCT00441857|BEHAVIORAL|plant stanol consumption|
57962391|NCT01660074|OTHER|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
57962392|NCT03582670|BEHAVIORAL|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
57962393|NCT03582670|BEHAVIORAL|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
57962394|NCT03582670|BEHAVIORAL|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
57962395|NCT00865865|PROCEDURE|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
57962396|NCT00865865|PROCEDURE|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
57962397|NCT01751217|BEHAVIORAL|Functional Family Tx|
57962398|NCT01751217|BEHAVIORAL|Services as Usual|
57962399|NCT03934983|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
57962400|NCT01233778|DIETARY_SUPPLEMENT|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
57962401|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
57962402|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
57962403|NCT01233778|DIETARY_SUPPLEMENT|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
57962404|NCT01233778|DIETARY_SUPPLEMENT|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
57962405|NCT02916420|DRUG|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
57962406|NCT02916420|DRUG|Dexamethasone|≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
57962407|NCT01665807|BIOLOGICAL|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
57962408|NCT01665807|BIOLOGICAL|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
57962409|NCT04638569|PROCEDURE|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
57962410|NCT03188237|BEHAVIORAL|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
57962411|NCT02172859|DIETARY_SUPPLEMENT|lumiVida™|
57962412|NCT02172859|DIETARY_SUPPLEMENT|Placebo|
57784430|NCT00252928|OTHER|Placebo|Placebo
57962413|NCT04507984|DIAGNOSTIC_TEST|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
57776984|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
57776985|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
57776986|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
57776987|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
57776988|NCT01079143|DRUG|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
57776989|NCT01079143|DRUG|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
57776990|NCT01079143|DRUG|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
57776991|NCT01079143|DRUG|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
57776992|NCT01079143|DRUG|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
57776993|NCT03143335|PROCEDURE|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
57776994|NCT03143335|PROCEDURE|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
57776995|NCT03389685|BIOLOGICAL|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
57776996|NCT03389685|OTHER|Saline Placebo|saline solution
57776997|NCT00462644|DRUG|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
57776998|NCT00462644|DRUG|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
57776999|NCT01097460|DRUG|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
57784431|NCT03844516|OTHER|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
57784432|NCT03844516|OTHER|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
58129761|NCT00003064|PROCEDURE|peripheral blood stem cell transplantation|
58129762|NCT00150007|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
58138146|NCT02336165|BIOLOGICAL|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
58460057|NCT06253988|DRUG|Probiotic Formula|intra-pocket formula (local delivery drug)
57962414|NCT04507984|DIAGNOSTIC_TEST|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
57962415|NCT03017560|BEHAVIORAL|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
57962416|NCT05561790|BEHAVIORAL|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
57962417|NCT00637260|DEVICE|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
57962418|NCT00637260|DEVICE|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
57962419|NCT04434144|DRUG|Ivermectin + Doxycycline|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
57962420|NCT04434144|DRUG|Hydroxychloroquine + Azithromycin|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
57962421|NCT02439125|DRUG|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
57962422|NCT02439125|DRUG|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
57962423|NCT02439125|DRUG|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
57962424|NCT02439125|DRUG|Placebo|b.i.d. orally for 3 weeks
57962425|NCT00726466|DRUG|Efalizumab, Ranibizumab|
57962426|NCT06194396|OTHER|chlorhexidine|chlorhexidine will be used as skin disinfectant before insertion of CVC, PICC line, and umbilical catheter
58460058|NCT06253988|DRUG|placebo formula|intra-pocket formula (local delivery drug)
58460059|NCT02473081|BEHAVIORAL|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
58460060|NCT02473081|OTHER|Usual care|Usual care was given by their family physicians.
58491306|NCT04105504|DRUG|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
57777000|NCT05634122|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
57777001|NCT05634122|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment for patients with chronic pain
57777002|NCT00226473|DRUG|Cisplatin, Vindesine, Dacarbazine (drugs)|
57777003|NCT03317379|BEHAVIORAL|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
57777004|NCT03317379|BEHAVIORAL|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
57777005|NCT03317379|BEHAVIORAL|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
57777006|NCT04994041|OTHER|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
57777007|NCT04994041|OTHER|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
57777008|NCT06080230|BEHAVIORAL|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
57777009|NCT05239871|DIAGNOSTIC_TEST|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
57777010|NCT00407784|DRUG|eplerenone|
57777011|NCT01253122|DRUG|TRx0037|
57962427|NCT06194396|OTHER|alcohol|alcohol will be used as skin disinfectant before insertion of CVC ,PICC line and umbilical catheter
57962428|NCT01442259|DRUG|AFQ056|
57962429|NCT02568046|DRUG|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
57962430|NCT02568046|DRUG|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
58460061|NCT00763412|DRUG|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
58460062|NCT00763412|DRUG|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
58460063|NCT04578600|DRUG|Lenalidomide|Given PO
58460064|NCT04578600|BIOLOGICAL|Obinutuzumab|Given IV
58460065|NCT04578600|DRUG|Oral Azacitidine|Given PO
58460066|NCT04935996|DEVICE|Pleuropulmonary echography|Pleuropulmonary echography is performed, in addition of the chest X-ray already performed in routine care
58460067|NCT04801420|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
58460068|NCT04801420|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
58460069|NCT03617172|DRUG|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
58460070|NCT03617172|OTHER|Placebo|Two capsules twice per day
58460071|NCT01319981|DRUG|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
58460072|NCT01319981|DRUG|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
58460073|NCT01319981|DRUG|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
58460074|NCT01319981|DRUG|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
58460075|NCT01319981|DRUG|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
57777012|NCT02276378|DRUG|Telmisartan low|
57777013|NCT02276378|DRUG|Telmisartan high|
57777014|NCT02276378|DRUG|Hydrochlorothiazide (HCTZ)|
57777015|NCT02276378|OTHER|Japanese meal|
57777016|NCT02492646|PROCEDURE|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
58460076|NCT01319981|DRUG|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
58460077|NCT01319981|DRUG|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
58460078|NCT01319981|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
58460079|NCT01319981|DRUG|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
58460080|NCT01319981|DRUG|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.
58460081|NCT01319981|DRUG|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
58460082|NCT01319981|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
58460083|NCT04921202|OTHER|Metabolic syndrome and meniscus injuries|Metabolic syndrome
58460084|NCT06222632|OTHER|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
58460085|NCT06222632|OTHER|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 \&amp; 12 of the intervention.
58460086|NCT06222632|OTHER|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
58460087|NCT05363553|DIETARY_SUPPLEMENT|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
58460088|NCT05363553|DIETARY_SUPPLEMENT|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
58460089|NCT06185374|BEHAVIORAL|Text Message Instructions/Motivation|For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
58460090|NCT03913221|DRUG|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
58460091|NCT03913221|DRUG|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
58460092|NCT04686461|DRUG|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
58460093|NCT02560259|OTHER|Physiotherapy|Physiotherapy
58460094|NCT02560259|OTHER|Conservative treatment|Conservative treatment
58460095|NCT02836912|OTHER|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
58491307|NCT06433492|DEVICE|Intra-articular injection|Three doses of intra-articular injection administered in weekely intervals.
57962431|NCT04502407|RADIATION|Cisplatin-based Radiation Therapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
57962432|NCT04502407|DRUG|Cisplatin Chemotherapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
57962433|NCT03355989|OTHER|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
57962434|NCT03355989|OTHER|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
57962435|NCT03782935|DIETARY_SUPPLEMENT|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
57962436|NCT04461470|GENETIC|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
57962437|NCT01765673|DEVICE|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
57962438|NCT00917449|DRUG|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
57962439|NCT00917449|DRUG|Placebo|Oral Placebo BID for 18 months
57962440|NCT01256437|DRUG|Threolone ointment|ointment once daily for 1 month
57962441|NCT01256437|DRUG|ointment Synthomycine|ointment once daily for 1 month
57962442|NCT01256437|DRUG|Aqua cream|ointment once daily for 1 month
57962443|NCT05586633|PROCEDURE|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
57962444|NCT05586633|PROCEDURE|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
57962445|NCT02353533|DEVICE|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
57962446|NCT02353533|DEVICE|EMR|Standard endoscopic mucosal resection using a resection snare
57962447|NCT03233854|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
57962448|NCT03233854|DRUG|Cyclophosphamide|Given IV
57962449|NCT03233854|DRUG|Fludarabine Phosphate|Given IV
57962450|NCT03233854|OTHER|Laboratory Biomarker Analysis|Correlative studies
57962451|NCT03233854|OTHER|Questionnaire Administration|Ancillary studies
57962452|NCT03233854|DRUG|NKTR-255|Given IV
57962453|NCT04863703|DRUG|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
57962454|NCT04077905|DRUG|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
57962455|NCT04077905|DRUG|Etoposide|100mg/m² ivgtt on day 1
57962456|NCT04077905|DRUG|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
57962457|NCT05583942|DEVICE|trascutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
57962458|NCT05583942|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
58138147|NCT05245357|BEHAVIORAL|Lentil|Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.
58460096|NCT00623272|OTHER|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
57962459|NCT04219423|BEHAVIORAL|Multimodal physical therapy|see description in arm/group description
57962460|NCT05771610|BEHAVIORAL|Activity pattern in CVD|Only individuals who have had a cardiac event within the past twelve months upon recruitment will be included in this study.
58460097|NCT00388349|DRUG|Gemcitabine|
58460098|NCT00388349|DRUG|Vinorelbine|
58460099|NCT00388349|DRUG|Carmustine|
58460100|NCT00388349|DRUG|Etoposide|
58460101|NCT00388349|DRUG|Cyclophosphamide|
57962461|NCT03159858|DEVICE|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
58460102|NCT00388349|PROCEDURE|Autologous HCT|
58460103|NCT02268890|DRUG|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
58460104|NCT05971316|DEVICE|Foam Roller|General Warm-up + Foam Roller
58491308|NCT06522490|OTHER|Virtual discrete trial training|VDT was given to Experimental group.
58138148|NCT05245357|BEHAVIORAL|Control|Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
57777017|NCT02492646|PROCEDURE|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
57777018|NCT01158430|BEHAVIORAL|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
57777019|NCT06381440|DEVICE|Lokomat device (Hocoma AG, Volketswil, Switzerland).|Robot Assisted Gait Training device
57777020|NCT06381440|OTHER|Conventional walking training|Self-paced supervised walking training
57777021|NCT05033743|DRUG|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
57777022|NCT02290717|DEVICE|Fractional CO2 laser|
57962462|NCT05562986|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
57962463|NCT05582642|DEVICE|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
57962464|NCT03622697|BEHAVIORAL|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
57962465|NCT03694925|DIAGNOSTIC_TEST|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
57962466|NCT00555100|DRUG|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
57777023|NCT02290717|OTHER|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
57962467|NCT00555100|DRUG|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
57962468|NCT02433600|OTHER|Cow's milk-based infant formula|
57962469|NCT02433600|OTHER|Cow milk-based infant formula with enriched protein fractions|
57962470|NCT03099720|DRUG|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
57962471|NCT03099720|DRUG|Placebo|placebo fluid will be given at the site of operation locally
57962472|NCT05598892|DEVICE|Training with Robotic Hand Exoskeleton|The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
57962473|NCT02022982|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
57962474|NCT02022982|DRUG|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
57962475|NCT00784966|DRUG|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
57962476|NCT00784966|DRUG|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
57962477|NCT01918670|PROCEDURE|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
57962478|NCT05043415|PROCEDURE|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
57962479|NCT05043415|PROCEDURE|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
58129763|NCT05423808|OTHER|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
58129764|NCT05423808|DEVICE|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
58129765|NCT00637299|OTHER|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
58129766|NCT00637299|OTHER|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
58129767|NCT05706077|DEVICE|active tDCS|The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.
58129768|NCT05706077|DEVICE|sham tDCS|The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.
58129769|NCT05706077|OTHER|real Physical Therapy|Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.
58129770|NCT05706077|OTHER|placebo Physical Therapy|The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
58129771|NCT02330068|DRUG|citalopram|Cases
58129772|NCT01048437|BEHAVIORAL|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
58129773|NCT01048437|BEHAVIORAL|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
58129774|NCT02753842|DEVICE|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
58129775|NCT01802697|DRUG|IdeS|
58129776|NCT01802697|DRUG|Placebo|
58129777|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
58129778|NCT02227251|DRUG|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
58129779|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
58129780|NCT04480788|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
58129781|NCT00208286|DEVICE|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
58129782|NCT00208286|DEVICE|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
58129783|NCT04098536|BEHAVIORAL|Diesel exhaust|Exposure to diesel exhaust fumes
58129784|NCT06139003|DEVICE|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
58129785|NCT06139003|DEVICE|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
58129786|NCT00948519|DEVICE|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
58129787|NCT00948519|DEVICE|Laser only|same only without ICG
58460105|NCT06305156|DIAGNOSTIC_TEST|Bone Mineral Density quantification|"In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications."
58460106|NCT01412996|PROCEDURE|surgery|single ACCESS laparoscopic cholecystectomy
58460107|NCT01412996|OTHER|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
58460108|NCT02228707|DRUG|BIIB061|Participants receive BIIB061
58460109|NCT02228707|OTHER|Placebo|Matched placebo
58129788|NCT05829148|DRUG|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
58129789|NCT05829148|DRUG|Melatonin|Melatonin
58129790|NCT05829148|DRUG|Pregabalin|Pregabalin
58129791|NCT05829148|DRUG|Placebo|Placebo
58129792|NCT01215890|DRUG|risedronate|
58129793|NCT01215890|DRUG|placebo|
58129794|NCT01799681|BEHAVIORAL|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
58129795|NCT01799681|BEHAVIORAL|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
58129796|NCT05751382|DEVICE|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
58129797|NCT05751382|DEVICE|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
58129798|NCT00898079|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58129799|NCT00186290|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
58129800|NCT01453075|DRUG|Valacyclovir|Valacyclovir 1.5 mg po bid
58129801|NCT01453075|DRUG|Placebo|Matching placebo twice daily
58129802|NCT05055349|OTHER|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
58129803|NCT06300957|OTHER|Help Wanted Prevention Intervention|"The intervention includes an introductory welcome place, five training sessions that deliver core intervention content, and a resources page that provides links to external sources of support.~The Help Wanted Prevention Intervention is a free, online, self-help course to address the needs of people with a sexual attraction to children. Help Wanted aims to provide knowledge, skills, and resources to support help-seekers' commitments to living safe, healthy, and fulfilling lives."
58129804|NCT06300957|OTHER|Waitlist Control|Participants will be provided with information on how to access alternative resources and help lines to support mental health, suicide prevention, and child sexual abuse prevention. After one month, they will be granted access to Help Wanted.
58129805|NCT02242201|DRUG|PNB Bupivacaine|Infusion
58129806|NCT02242201|DRUG|PAI Ropivacaine|Injection
57777024|NCT02290717|DRUG|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
57777025|NCT03753217|DEVICE|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
58129807|NCT02242201|DRUG|PAI liposomal bupivacaine|Injection
58129808|NCT02242201|DRUG|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
58129809|NCT02242201|DRUG|Ketorolac|Injection, 30 mg
58129810|NCT04813809|DEVICE|BARRIER EasyWarm|Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
58129811|NCT03920007|DRUG|ATSN-101|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
58129812|NCT03920007|DRUG|ATSN-101 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
57777026|NCT02293174|DEVICE|Topcon TRC-NW400|Retinal Fundus Camera
57777027|NCT02293174|DEVICE|TRC-NW8|Retinal Fundus Camera
57777028|NCT02293174|DEVICE|TRC-NW400|Retinal Fundus Camera
57777029|NCT02293174|DEVICE|Canon-CR2|Retinal Fundus Camera
58129813|NCT03920007|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
58129814|NCT03920007|DRUG|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
58129815|NCT03920007|DRUG|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
58129816|NCT03920007|DRUG|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
58129817|NCT04996238|PROCEDURE|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
58129818|NCT03319056|OTHER|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
58129819|NCT03532321|OTHER|NA : non interventional study|NA : non interventional study
58129820|NCT04791553|DRUG|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
58129821|NCT02067364|DEVICE|Fit & Function test|
58129822|NCT00919464|DEVICE|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
58129823|NCT00919464|DEVICE|Compartmental fracture pressure monitoring|
58129824|NCT00919464|DEVICE|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
58129825|NCT00210548|DRUG|paliperidone palmitate|
58129826|NCT01879280|PROCEDURE|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
58129827|NCT01879280|PROCEDURE|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
58129828|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
57777030|NCT02293174|DEVICE|Zeiss Visucam PRO|Retinal Fundus Camera
57777031|NCT02668237|OTHER|OptiPAC|Molecular and urinary tests.
57777032|NCT02668237|OTHER|Usual care|Antibiotics for prevention.
57777033|NCT02372058|DEVICE|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
57777034|NCT03423160|OTHER|None--observational|Observational study of behavior and electrical brain activity
57777035|NCT02666963|DRUG|RTA 901 Capsules, 10 or 40 mg|
57777036|NCT02666963|DRUG|Placebo|
57777037|NCT00992160|DRUG|GW597599|GW597599 15mg tablet
57777038|NCT00992160|DRUG|Placebo|Placebo to match GW597599 15mg tablet
57777039|NCT03375684|OTHER|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
57777040|NCT03375684|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
57777041|NCT04376697|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment will be delivered by trained medical personnel.
57777042|NCT03335891|PROCEDURE|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
57777043|NCT03335891|PROCEDURE|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
57777044|NCT00436176|BEHAVIORAL|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
57777045|NCT04532242|BEHAVIORAL|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
57777046|NCT03043222|DEVICE|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
57777047|NCT03043222|DEVICE|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
57777048|NCT06048796|OTHER|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
57777049|NCT04806412|DIAGNOSTIC_TEST|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
57777050|NCT01805765|DRUG|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
57777051|NCT01805765|DRUG|Placebo|Containing 2% of Qing'E pills
57777052|NCT05447793|DEVICE|Fitostimoline plus|Formulation in gauzes and cream
57777053|NCT05447793|DEVICE|Connettivina bio plus|Formulation in gauzes and cream
57777054|NCT05774028|DRUG|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
57777055|NCT03299062|DIAGNOSTIC_TEST|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
57777056|NCT02814110|DRUG|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
57777057|NCT01101139|DRUG|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
57777058|NCT01101139|DRUG|Placebo|Placebo: single intravenous injection Saline 0.9%
57777059|NCT06315764|PROCEDURE|Reflexology|"Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology .~Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated as well as reflexology three times each week for eight weeks"
57777060|NCT01497405|BEHAVIORAL|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
58460110|NCT04400630|OTHER|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
58460111|NCT04428398|DIAGNOSTIC_TEST|Analysis of urine samples with flow cytometry|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
57777061|NCT01497405|BIOLOGICAL|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
57777062|NCT03836898|DEVICE|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
57777063|NCT00074074|BIOLOGICAL|infliximab|
58460112|NCT01535040|DRUG|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
58460113|NCT01535040|DRUG|placebo|Placebo by mouth through completion of 12 weeks.
58460114|NCT01329315|BEHAVIORAL|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
58460115|NCT01329315|BEHAVIORAL|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
58460116|NCT03623113|BEHAVIORAL|BCC intervention|Structured training and education i basic carbohydrate counting principles
58460117|NCT03623113|BEHAVIORAL|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
58460118|NCT03623113|BEHAVIORAL|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
58460119|NCT00001499|DRUG|paclitaxel|
58460120|NCT00001499|DRUG|cisplatin|
57777064|NCT06313996|DRUG|Cyclophosphamide|Specified dose on specified days
57777065|NCT06313996|DRUG|Doxorubicin|Specified dose on specified days
57777066|NCT06313996|DRUG|Vincristine|Specified dose on specified days
57777067|NCT06313996|DRUG|Rituximab|Specified dose on specified days
57777068|NCT06313996|DRUG|Prednisone|Specified dose on specified days
57777069|NCT06313996|DRUG|Bendamustine|Specified dose on specified days
57777070|NCT06313996|DRUG|Lenalidomide|Specified dose on specified days
58460121|NCT00001499|PROCEDURE|chest radiotherapy|
58460122|NCT02855008|BEHAVIORAL|STEPS|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius. We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.
58460123|NCT02855008|BEHAVIORAL|Food for Life|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
58460124|NCT05596955|DRUG|Buprenorphine injection|Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits
58460125|NCT05596955|DRUG|Naltrexone Injection|Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
58460126|NCT01626326|BEHAVIORAL|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
58460127|NCT06196385|DEVICE|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
58460128|NCT00724841|DRUG|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
57777071|NCT06313996|DRUG|Fludarabine|Specified dose on specified days
57777072|NCT06313996|DRUG|Liso-cel|Specified dose on specified days
57777073|NCT02590068|DRUG|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
57777074|NCT03895437|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
57777075|NCT03895437|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
57777076|NCT03972774|DIAGNOSTIC_TEST|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
57777077|NCT03972774|OTHER|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
57777078|NCT04039503|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
58460129|NCT00724841|DRUG|Temozolomide|
58460130|NCT01110824|DRUG|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
58129829|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
58129830|NCT00556049|DRUG|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
58129831|NCT00556049|DRUG|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
58129832|NCT00650000|DRUG|Modafinil Tablets 200 mg|200mg, single dose fasting
58129833|NCT00650000|DRUG|Provigil® Tablets 200 mg|200mg, single dose fasting
58129834|NCT00559481|DRUG|dexamethasone|
58129835|NCT00559481|DRUG|ketoconazole|
58129836|NCT00559481|DRUG|therapeutic hydrocortisone|
58129837|NCT00559481|PROCEDURE|pharmacological study|
58129838|NCT03238677|BEHAVIORAL|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
57777079|NCT04039503|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
57777080|NCT00894582|PROCEDURE|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
57777081|NCT02965118|DRUG|PAC-14028 cream 1.0%|topical application
57777082|NCT02965118|DRUG|PAC-14028 cream Vehicle|topical application
57777083|NCT03210688|DRUG|Prednisolone|Tablet prednisolone
57777084|NCT03210688|DRUG|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
57777085|NCT04397302|DIAGNOSTIC_TEST|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
58129839|NCT03238677|BEHAVIORAL|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
58129840|NCT03238677|BEHAVIORAL|Distributed Practice|2 sessions per week for 10 weeks
58129841|NCT03238677|BEHAVIORAL|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
58129842|NCT06096103|DIETARY_SUPPLEMENT|placebo|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
58129843|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardized for Iron + Vitamin C|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
58129844|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardised for Iron|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
58129845|NCT06196060|BEHAVIORAL|Visual perspective taking training|Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.
58129846|NCT06196060|BEHAVIORAL|Block building training|Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.
58129847|NCT06196060|BEHAVIORAL|Thought-bubble training|Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.
58129848|NCT06196060|BEHAVIORAL|Treatment as usual|Participants will continue to receive treatment as usual during the trial.
58129849|NCT00861809|DRUG|GSK962040 25 mg|25 mg
58129850|NCT00861809|DRUG|Placebo|placebo comparator
58129851|NCT00861809|DRUG|GSK962040 50 mg|50 mg
58129852|NCT00861809|DRUG|GSK962040 1250 mg|125 mg
58129853|NCT00925769|DRUG|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
58129854|NCT00925769|DRUG|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
58129855|NCT00925769|DRUG|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
58138149|NCT00262223|BEHAVIORAL|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
58138150|NCT00262223|DRUG|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
57777086|NCT04763083|DRUG|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
57777087|NCT05911490|BEHAVIORAL|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
57784433|NCT01406561|DRUG|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
57784434|NCT01406561|DRUG|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
57784435|NCT06139484|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
57777088|NCT05911490|BEHAVIORAL|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
57777089|NCT04924764|OTHER|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
57777090|NCT03646903|BEHAVIORAL|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
57777091|NCT03646903|BEHAVIORAL|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
57777092|NCT05148624|PROCEDURE|embryo transfer|immediate ambulation after embryo transfer
57777093|NCT00284375|PROCEDURE|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
57777094|NCT05229172|DEVICE|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
57777095|NCT00975221|DRUG|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
57777096|NCT00975221|DRUG|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
57777097|NCT04475848|DRUG|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
57777098|NCT04475848|DRUG|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
57777099|NCT04475848|DRUG|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
57777100|NCT00391014|DRUG|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
57777101|NCT01630343|DRUG|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
57777102|NCT01630343|DRUG|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
57777103|NCT03263143|OTHER|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
57777104|NCT04238403|BEHAVIORAL|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
57777105|NCT02904109|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
57777106|NCT02904109|DRUG|Placebo|Once daily oral administration of placebo mannitol for 8 days.
57777107|NCT02905019|BIOLOGICAL|R21 with Matrix-M1|Vaccine
57777108|NCT02905019|BIOLOGICAL|ChAd63 ME-TRAP|Vaccine
57777109|NCT02905019|BIOLOGICAL|MVA ME-TRAP|Vaccine
57777110|NCT04084782|DEVICE|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
57777111|NCT06281262|DIAGNOSTIC_TEST|Peripheral blood collection|"The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations."
57777112|NCT06281262|DIAGNOSTIC_TEST|Swab sample collection|Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
57777113|NCT04454905|DRUG|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
57777114|NCT04454905|DRUG|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
57777115|NCT03990363|DRUG|Verinurad|"Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9"
57777116|NCT03990363|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
57777117|NCT03990363|DRUG|Placebo for Verinurad|Matching Capsule
57777118|NCT03990363|DRUG|Placebo for Allopurinol|Matching tablet
58138151|NCT00262223|DRUG|Pill placebo|
58129856|NCT03858712|OTHER|Active Care Team Alert|"2) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
58129857|NCT03858712|OTHER|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
58129858|NCT00649870|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
58129859|NCT00649870|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fed
58129860|NCT06371248|BEHAVIORAL|Steady Feet|Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.
58129861|NCT06371248|OTHER|Usual care for fall prevention|CGH's usual care for fall prevention, which include fall prevention materials and advice.
58129862|NCT03089112|DRUG|HGP1607|Take it once per period
58129863|NCT03089112|DRUG|HGP1501|Take it once per period
58129864|NCT03089112|DRUG|HGP1607+HGP1501|Take it once per period
58129865|NCT00000866|BIOLOGICAL|MN rgp120/HIV-1|
58129866|NCT00000866|BIOLOGICAL|TBC-3B Vaccine|
58129867|NCT04060368|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
58129868|NCT04060368|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
58129869|NCT01264224|DRUG|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
57777119|NCT03729895|DEVICE|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
58129870|NCT01521195|DEVICE|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
58129871|NCT03621748|PROCEDURE|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
58129872|NCT03621748|PROCEDURE|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
58129873|NCT04090892|PROCEDURE|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
58129874|NCT00957047|DRUG|eslicarbazepine acetate|oral tablets
58460131|NCT05257278|DEVICE|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
58460132|NCT04386200|OTHER|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
58460133|NCT04386200|BEHAVIORAL|traditional approach|"traditional face-to-face educational approach"
58460134|NCT05746507|BEHAVIORAL|Night Respite Care|(see description above)
58460135|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339|Limosilactobacillus reuteri AMBV339 is a probiotic strain
57777120|NCT03820531|DIAGNOSTIC_TEST|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
57777121|NCT03820531|DIAGNOSTIC_TEST|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst"
57777122|NCT03820531|DIAGNOSTIC_TEST|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
57777123|NCT03820531|DIAGNOSTIC_TEST|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
58129875|NCT00957047|DRUG|placebo|once daily placebo comparator
58129876|NCT00957047|DRUG|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
58129877|NCT06291948|BIOLOGICAL|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose
58460136|NCT06425081|DIETARY_SUPPLEMENT|Humiome B2|Colon-delivered Riboflavin
58460137|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339 + Humiome B2|Combination of supplements used in arm 1 and 2
57777124|NCT04822935|PROCEDURE|Vertebral Body Tethering|VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
58129878|NCT06291948|BIOLOGICAL|Adalimumab Richmond [Test Product]|A single subcutaneous dose
58129879|NCT02827409|PROCEDURE|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
58460138|NCT06425081|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
58460139|NCT03238716|OTHER|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
58129880|NCT02827409|PROCEDURE|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
58129881|NCT05396430|DEVICE|Urinary catheter|Duration of planned urinary cathterization following cesarean delivery
58129882|NCT02003183|RADIATION|[F-18]FDDNP|Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
58129883|NCT06278142|OTHER|Internet Based Intervention - GUIDED|In the expert-supported application, each participant will be sent a folder to be shared by the user and the guide via Google Drive, and the user is expected to perform the application in the folder. A module is added to the folder every Monday and the participant is asked to complete the relevant module until Friday of the same week. In the following two days, a feedback message is provided by the expert, taking into account the user's responses.
58129884|NCT06278142|OTHER|Internet Based Intervention - WİTHOUT GUİDANCE|The developed implementation plan is communicated to the participants without expert support and their participation is ensured. A common folder will be created with the participants accepted to the study and in the group without expert support, and the process is managed by transmitting the module to the user via the folder every Monday.
57777125|NCT04679103|BIOLOGICAL|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
57777126|NCT02019602|PROCEDURE|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
57777127|NCT02019602|PROCEDURE|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
57777128|NCT02019602|PROCEDURE|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
57777129|NCT02019602|BIOLOGICAL|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use"
57777130|NCT00722813|OTHER|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
57777131|NCT00719303|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary intervention
57777132|NCT00719303|BEHAVIORAL|Compliance Monitoring|Complete daily fat gram and step diaries
57777133|NCT00719303|OTHER|Counseling|Undergo face-to-face and telephone counseling
57777134|NCT00719303|OTHER|Educational Intervention|Receive educational materials
57777135|NCT00719303|BEHAVIORAL|Exercise Intervention|Undergo physical activity intervention
57777136|NCT00719303|OTHER|Laboratory Biomarker Analysis|Correlative studies
57777137|NCT00719303|OTHER|Quality-of-Life Assessment|Ancillary studies
57777138|NCT00719303|OTHER|Questionnaire Administration|Ancillary studies
57777139|NCT03324542|DRUG|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
57777140|NCT03010579|DRUG|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
58129885|NCT03955770|COMBINATION_PRODUCT|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).
58129886|NCT03955770|COMBINATION_PRODUCT|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
58129887|NCT01825993|DRUG|L-BUPIVACAINE ; MORPHINE|
57777141|NCT03010579|DRUG|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
58129888|NCT01825993|DRUG|MORPHINE|
58129889|NCT04303988|DRUG|SHR-1316|IV
58129890|NCT04303988|DRUG|Bevacizumab|IV
58129891|NCT04303988|DRUG|Cisplatin/Carboplatin|IV
58129892|NCT02974075|PROCEDURE|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
58129893|NCT02325271|OTHER|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
58129894|NCT04457843|OTHER|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
57777142|NCT04958928|PROCEDURE|Catheter ablation|All patients received radiofrequncy ablation.
57777143|NCT02886546|PROCEDURE|pneumoperitoneum|
57777144|NCT02886546|DEVICE|oesophageal Doppler monitor|
57777145|NCT01033773|DRUG|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
57777146|NCT01033773|BEHAVIORAL|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
57777147|NCT05989867|DIAGNOSTIC_TEST|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
57777148|NCT05989867|DEVICE|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
57777149|NCT05451381|DRUG|Propofol|sedation after cardiac surgery
57777150|NCT05451381|DRUG|Dexmedetomidine|sedation after cardiac surgery
57777151|NCT05451381|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
57777152|NCT05078684|PROCEDURE|Left ganglion stellate block|Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
57777153|NCT05078684|PROCEDURE|Sham left ganglion stellate block|Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
57777154|NCT01276249|DEVICE|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
57777155|NCT03978390|BEHAVIORAL|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
57962480|NCT03107793|DRUG|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
57962481|NCT05122416|DEVICE|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
57962482|NCT05122416|DEVICE|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
57962483|NCT05122416|DEVICE|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
57962484|NCT05122416|DEVICE|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
57962485|NCT01251328|PROCEDURE|General anaesthesia|general anaesthesia is performed according to the hospitals standard
57962486|NCT01251328|PROCEDURE|Sedation|Sedation is performed according to the hospitals standard
57962487|NCT00613457|DRUG|dexamethasone|10 mg/sqm/day from for 21 days
57962488|NCT00613457|DRUG|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
57962489|NCT00613457|DRUG|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
57962490|NCT00613457|DRUG|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
57962491|NCT00613457|DRUG|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
57962492|NCT00613457|DRUG|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
57962493|NCT00613457|DRUG|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
57962494|NCT00613457|DRUG|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
57962495|NCT00613457|DRUG|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
57962496|NCT00613457|DRUG|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
57962497|NCT00613457|DRUG|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
57962498|NCT00613457|DRUG|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
57962499|NCT00613457|DRUG|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
57962500|NCT00613457|DRUG|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
57962501|NCT00613457|DRUG|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
57962502|NCT02916355|DRUG|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
57777156|NCT03978390|BEHAVIORAL|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
57777157|NCT03978390|BEHAVIORAL|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
57962503|NCT02916355|DRUG|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
57777158|NCT00618462|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
57777159|NCT00618462|BEHAVIORAL|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
57962504|NCT01772615|DRUG|Ciprofloxacin|Antibiotic
57962505|NCT01772615|DIETARY_SUPPLEMENT|E. coli Nissle|Probiotic
57962506|NCT01704352|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
57962507|NCT05484960|OTHER|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
57962508|NCT00264056|DEVICE|hyperthermia|
57962509|NCT01331356|DRUG|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
57962510|NCT01127724|DRUG|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
57962511|NCT02392182|OTHER|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
57962512|NCT03627845|DRUG|PHP-303|Investigational drug
57962513|NCT03627845|OTHER|Placebo|Matching placebo
57962514|NCT03643380|DEVICE|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
57962515|NCT00797732|DEVICE|Acupuncture|
57777160|NCT00618462|BEHAVIORAL|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
57777161|NCT00618462|BEHAVIORAL|Case management|Case management will assist participants in obtaining additional services from the community as needed.
57777162|NCT00618462|BEHAVIORAL|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
57777163|NCT02861677|OTHER|pharmaceutical care|
57777164|NCT02328976|OTHER|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
57777165|NCT03012789|PROCEDURE|Surgery|Surgical excision
57777166|NCT03070184|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
57777167|NCT03070184|DIETARY_SUPPLEMENT|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
57777168|NCT03070184|OTHER|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
57777169|NCT03070184|DRUG|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
57777170|NCT03558464|DIETARY_SUPPLEMENT|Intervention (integrated package)|"During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
57777171|NCT03558464|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
57777172|NCT00267111|DRUG|Eucerin plus|1g, single application
57777173|NCT00267111|DRUG|Amethocaine gel 4%|1 g, single application
57777174|NCT00231998|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
57777175|NCT00000206|DRUG|Buprenorphine|
57777176|NCT02484560|DRUG|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
57777177|NCT00627042|BIOLOGICAL|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
57777178|NCT01654822|DRUG|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
57777179|NCT01654822|DRUG|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
57777180|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
58129895|NCT01432795|DEVICE|Gliding aids for medical compression stockings|"Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)"
58129896|NCT00584311|OTHER|MRI and Ultrasound|MRI and US of the joint
57777181|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
57777182|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
57777183|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
57777184|NCT03132493|DRUG|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
57777185|NCT03901560|OTHER|Music Therapy|
57777186|NCT03266341|DIAGNOSTIC_TEST|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
57777187|NCT02450019|PROCEDURE|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
57777188|NCT02450019|PROCEDURE|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
57777189|NCT05092048|OTHER|questionnaire|PHQ-9 and GAD-7 questionnaire
57777190|NCT02029040|DRUG|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
57784436|NCT00386308|DRUG|Tranexamic acid tablets|3900 mg/Day
57784437|NCT00386308|DRUG|Placebo tablets|
58129897|NCT00881621|DRUG|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
58129898|NCT02063295|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
58129899|NCT02063295|DRUG|ZGN-440 for injectable suspension|
58129900|NCT05062850|OTHER|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
58129901|NCT03111043|DIAGNOSTIC_TEST|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
58129902|NCT03878095|PROCEDURE|Biopsy|Undergo tumor biopsies
58129903|NCT03878095|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58129904|NCT03878095|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
58129905|NCT03878095|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
58129906|NCT03878095|DRUG|Ceralasertib|Given PO
58129907|NCT03878095|PROCEDURE|Computed Tomography|Undergo CT scans
58129908|NCT03878095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
58129909|NCT03878095|DRUG|Olaparib|Given PO
58129910|NCT00357448|BIOLOGICAL|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
58129911|NCT00357448|PROCEDURE|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
58129912|NCT00357448|OTHER|laboratory biomarker analysis|Correlative studies
58129913|NCT00357448|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58129914|NCT00357448|OTHER|flow cytometry|Correlative studies
58129915|NCT05090657|COMBINATION_PRODUCT|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
58129916|NCT04366232|DRUG|Anakinra alone (stages 2b/3)|Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
57777191|NCT02029040|DRUG|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
57777192|NCT02043730|DRUG|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
57777193|NCT02043730|DRUG|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
58129917|NCT04366232|DRUG|Anakinra and Ruxolitinib (overcome stage 3)|Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
58129918|NCT04366232|OTHER|Standard of care|Routine clinical care for Covid-19
58129919|NCT03536338|OTHER|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
58129920|NCT03536338|OTHER|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
58129921|NCT02735746|RADIATION|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
57777194|NCT00447044|BEHAVIORAL|Resistance Exercise|Subjects will lift weights with their legs.
57777195|NCT00447044|DIETARY_SUPPLEMENT|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
57777196|NCT00447044|DIETARY_SUPPLEMENT|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
57777197|NCT06333990|DRUG|Quetiapine Fumarate|Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
57777198|NCT06333990|DRUG|TAU|Standard of care psychotropic medications for treatment of patients with mTBI.
57777199|NCT02398058|DRUG|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
57777200|NCT02398058|DRUG|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
57777201|NCT00874289|OTHER|NGAL kit|Kit to test NGAL levels in heart failure patients
57777202|NCT06477367|OTHER|Video-Based Breathing Exercises|Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day. The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
58129922|NCT02735746|RADIATION|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
58129923|NCT02735746|RADIATION|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
58129924|NCT02735746|DEVICE|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
58129925|NCT00302952|DRUG|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
58129926|NCT00302952|DRUG|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
58129927|NCT00820625|PROCEDURE|pulmonary vein isolation|common pulmonary vein isolation procedure
58129928|NCT00820625|PROCEDURE|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
58129929|NCT01936948|PROCEDURE|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
58129930|NCT03735602|BEHAVIORAL|perceptual training|orientation discrimination task
58129931|NCT04298164|BEHAVIORAL|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
58129932|NCT04298164|BEHAVIORAL|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
58129933|NCT05941221|PROCEDURE|pericapsular nerve group (PENG) block|patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
58129934|NCT03432013|BEHAVIORAL|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
58129935|NCT03432013|BEHAVIORAL|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
58460140|NCT03238716|OTHER|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
58460141|NCT03238716|OTHER|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
58460142|NCT03396796|PROCEDURE|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
58460143|NCT06112665|DRUG|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
58460144|NCT05036304|OTHER|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
58460145|NCT05036304|OTHER|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park)
58460146|NCT05227456|DRUG|Etonogestrel 68mg implant|Implant will be inserted
58460147|NCT05227456|DEVICE|Etonogestrel 68mg implant|Implant will be inserted
58460148|NCT05854108|DIAGNOSTIC_TEST|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
58460149|NCT05854108|DIAGNOSTIC_TEST|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
58460150|NCT03541122|DIAGNOSTIC_TEST|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
57777203|NCT04399239|COMBINATION_PRODUCT|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
57777204|NCT00988351|DEVICE|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
58460151|NCT05884086|OTHER||no intervention is necessary. Clinical observation and clinical examination only.
58460152|NCT05427981|DRUG|Belbuca Buccal Product|Buprenorphine Buccal Films
58460153|NCT05427981|OTHER|Placebo|Placebo Buccal Films
57777205|NCT00988351|DEVICE|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
57777206|NCT06106074|DRUG|Tolebrutinib|Tablet, oral
57777207|NCT06106074|DRUG|Placebo|Tablet, oral
57777208|NCT06050356|BIOLOGICAL|H107e|Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
58129936|NCT04844840|DRUG|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
58129937|NCT04844840|OTHER|Placebo|Saline
58129938|NCT05425147|OTHER|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
58129939|NCT02968485|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
58460154|NCT03604952|DIAGNOSTIC_TEST|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
58460155|NCT00287105|DRUG|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
58460156|NCT01671163|PROCEDURE|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
58460157|NCT00034307|DRUG|sitaxsentan sodium|
58460158|NCT05133024|DIETARY_SUPPLEMENT|concentrated beetroot juice|Nitrate supplementation; natural source of dietary nitrate
58460159|NCT04268186|DEVICE|Direct tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
58460160|NCT04268186|DEVICE|Indirect tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
58460161|NCT04268186|DEVICE|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
58460162|NCT04268186|DEVICE|Sham tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
58460163|NCT02336282|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level \< 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
58460164|NCT02336282|DEVICE|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
58460165|NCT02336282|OTHER|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
58460166|NCT02336282|OTHER|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
57777209|NCT06050356|BIOLOGICAL|CAF®10b|Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
58460167|NCT01077635|DRUG|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
58129940|NCT00270959|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
58129941|NCT00270959|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
58129942|NCT00270959|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
58460168|NCT04500366|BEHAVIORAL|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
57777210|NCT06050356|BIOLOGICAL|H107e/CAF®10b - low adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
57777211|NCT06050356|BIOLOGICAL|H107e/CAF®10b - full adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
58129943|NCT00270959|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
58460169|NCT04500366|BEHAVIORAL|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
58460170|NCT04500366|COMBINATION_PRODUCT|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
58460171|NCT04500366|BEHAVIORAL|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
58460172|NCT00002328|DRUG|Azithromycin|
58460173|NCT00003575|BIOLOGICAL|filgrastim|
58460174|NCT00003575|BIOLOGICAL|recombinant interleukin-12|
58129944|NCT01900509|DRUG|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
58129945|NCT01900509|DRUG|Clofarabine|Route of administration: IV days 1-5.
58129946|NCT01900509|DRUG|Etoposide|Route of administration: IV days 1-5.
58129947|NCT01900509|DRUG|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
58129948|NCT01900509|DRUG|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
58460175|NCT00003575|DRUG|etoposide|
58460176|NCT00003575|DRUG|ifosfamide|
58460177|NCT06162052|OTHER|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
58460178|NCT03161535|OTHER|exercise and dietary education|"1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet)."
58460179|NCT03161535|OTHER|weekly telephone consultations concerning exercise and diet.|For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
58129949|NCT04090086|DRUG|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
58129950|NCT04090086|DRUG|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
58460180|NCT03167892|DEVICE|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
58460181|NCT04633668|BEHAVIORAL|CBT for parasomnias (CBT-p)|Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
58460182|NCT04633668|BEHAVIORAL|Self-Monitoring|Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
58460183|NCT05771103|DEVICE|thermal Radiofrequency neurolysis of Stellate ganglion|Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
58460184|NCT03068871|OTHER|ACT|Psycho-educational group
58460185|NCT03068871|OTHER|CET|Psycho-educational group
58129951|NCT01954680|BEHAVIORAL|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
58129952|NCT01954680|BEHAVIORAL|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
58129953|NCT03561142|RADIATION|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
58129954|NCT03561142|DRUG|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
58129955|NCT03561142|OTHER|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
57777212|NCT06050356|BIOLOGICAL|Low dose intranasal H107e|Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
57777213|NCT06050356|BIOLOGICAL|Full dose intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
57777214|NCT06050356|BIOLOGICAL|H107e/CAF®10b|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
57777215|NCT06050356|BIOLOGICAL|i.m. placebo|Participants will receive two i.m. injections of placebo on Day 1 and Day 29
57777216|NCT06050356|BIOLOGICAL|BCG|Participants will receive one i.d. injection of BCG on Day 1
57777217|NCT06050356|BIOLOGICAL|i.d. placebo|Participants will receive one i.d. injection of placebo on Day 1
57777218|NCT06050356|BIOLOGICAL|Intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
57777219|NCT06529900|BEHAVIORAL|oral mastication training|Through specific exercises and techniques aimed at enhancing masticatory function and overall oral health.
57777220|NCT06529900|BEHAVIORAL|texture and diet education|Teach the knowledge and techniques of softening food textures.
57777221|NCT05552274|DRUG|ECC4703|ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
57777222|NCT05552274|DRUG|Placebo|Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
57777223|NCT00515398|OTHER|Observation|Ex vivo administration of AT2220
57777224|NCT03432949|DRUG|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
57777225|NCT00044460|DRUG|rosiglitazone|
57777226|NCT01820533|OTHER|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
57777227|NCT01702389|DRUG|Remifentanil|
57777228|NCT03751163|DRUG|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
57777229|NCT03751163|DRUG|Hydroquinone 4% Cream|Hydroquinone 4% Cream
57777230|NCT03751163|OTHER|Sunscreen|Sunscreen SPF 30
57777231|NCT03751163|DEVICE|Placebo|Encapsulated placebo
57777232|NCT00100139|DRUG|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
57777233|NCT00100139|DRUG|Paclitaxel for injection (Taxol)|
57777234|NCT00028860|BIOLOGICAL|filgrastim|
57777235|NCT00028860|DRUG|carboplatin|
57777236|NCT00028860|DRUG|gemcitabine hydrochloride|
58129956|NCT02041871|DIETARY_SUPPLEMENT|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
58129957|NCT02041871|DIETARY_SUPPLEMENT|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
58129958|NCT01164813|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
57777237|NCT00028860|DRUG|ifosfamide|
57777238|NCT00028860|DRUG|paclitaxel|
57777239|NCT00028860|PROCEDURE|adjuvant therapy|
57777240|NCT02865057|PROCEDURE|Vaginal assessment|Vaginal assessment of position prior to delivery
57777241|NCT04712474|BEHAVIORAL|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
57777242|NCT01806519|BEHAVIORAL|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
57777243|NCT01178437|DEVICE|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
57777244|NCT05706792|DEVICE|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
57777245|NCT06206980|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
57777246|NCT06206980|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
57777247|NCT04131283|DRUG|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
58129959|NCT01164813|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
58129960|NCT00947258|OTHER|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
58129961|NCT04113239|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
58129962|NCT04113239|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
58129963|NCT05067361|PROCEDURE|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
58129964|NCT05067361|PROCEDURE|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
58129965|NCT01621022|DRUG|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
58129966|NCT01621022|DRUG|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
58129967|NCT01621022|DRUG|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
58129968|NCT05341232|BEHAVIORAL|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
57777248|NCT02508766|PROCEDURE|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
58129969|NCT05341232|BEHAVIORAL|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
58129970|NCT05341232|BEHAVIORAL|Board Games|Participants will play board games with each other.
58129971|NCT01652079|DRUG|CRLX101|q 14 days
58129972|NCT00583258|DRUG|Alfuzosin (Xatral)|10 mg PO once a day
58129973|NCT00583258|DRUG|Placebo Alfuzosin|10 mg PO once a day
58129974|NCT02367638|BIOLOGICAL|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
58129975|NCT02367638|BIOLOGICAL|VARIVAX|VARIVAX is administered by subcutaneous injection
58129976|NCT06139237|OTHER|High-protein supplement|High protein supplement 200 mL
58129977|NCT06139237|OTHER|Balanced supplement|Balanced supplement 200 mL
58129978|NCT06248450|OTHER|Medical yoga|Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.
58129979|NCT03881826|OTHER|collection of clinical data and biological samples|"* nutritional assessement~* cachexia symptoms~* urine, feces and blood samples"
58129980|NCT04603092|BEHAVIORAL|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
58129981|NCT01642511|RADIATION|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
58129982|NCT01642511|PROCEDURE|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
58129983|NCT01642511|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
58129984|NCT01642511|DEVICE|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
58129985|NCT01642511|PROCEDURE|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
58129986|NCT01642511|PROCEDURE|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
58129987|NCT06486116|BEHAVIORAL|Task Specific Physical Therapy Home Program|Home exercise program based on specific findings from physical therapy evaluations.
58129988|NCT01072110|PROCEDURE|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
58129989|NCT01072110|PROCEDURE|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
58129990|NCT02187978|OTHER|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
58129991|NCT02187978|OTHER|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
58129992|NCT00188656|PROCEDURE|CT thorax|
58129993|NCT01601197|BEHAVIORAL|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
58129994|NCT01297049|BEHAVIORAL|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
58129995|NCT04078477|OTHER|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
58129996|NCT04149964|DRUG|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
58129997|NCT04149964|DRUG|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
58129998|NCT04149964|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
58460186|NCT02203734|PROCEDURE|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
58129999|NCT04149964|DRUG|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
58130000|NCT02366780|PROCEDURE|Pump|Breast milk expression using manually or using an electric pump
58130001|NCT06223451|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
58130002|NCT06223451|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
58130003|NCT00554151|DEVICE|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
58130004|NCT01008657|PROCEDURE|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
58130005|NCT03237819|DRUG|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
58130006|NCT03237819|DRUG|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
58130007|NCT02210715|DRUG|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
58130008|NCT02210715|OTHER|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
58130009|NCT00662025|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
58130010|NCT00662025|DRUG|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
58130011|NCT02310165|PROCEDURE|Z-tract Insertion Technique|
58130012|NCT02310165|PROCEDURE|Coaxial Insertion Technique|
58130013|NCT02115906|OTHER|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
58130014|NCT02115906|OTHER|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
58130015|NCT02115906|OTHER|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
58130016|NCT01544790|PROCEDURE|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
58130017|NCT00489203|DRUG|beclomethasone dipropionate|Given orally
58130018|NCT00489203|DRUG|placebo|Given orally
58491309|NCT02928016|OTHER|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
57777249|NCT06017687|DEVICE|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
58130019|NCT00489203|DRUG|tacrolimus|Given after transplant
58130020|NCT00489203|DRUG|methotrexate|Given after transplant
58130021|NCT00489203|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
58130022|NCT02754401|OTHER|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
58130023|NCT02754401|OTHER|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
58130024|NCT04338867|RADIATION|Whole-brain radiotherapy|Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
58130025|NCT02752126|RADIATION|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
58130026|NCT02752126|RADIATION|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
58130027|NCT02925442|PROCEDURE|t-RFA|standard thermal genicular radiofrequency ablation
58130028|NCT02925442|PROCEDURE|C-RFA|Cooled radiofrequency ablation
58130029|NCT02925442|PROCEDURE|Control|Simulated radiofrequency ablation for placebo controlled group
58130030|NCT04888910|OTHER|observational|observation of biomarkers in different asthma groups
58130031|NCT01333527|PROCEDURE|No Sling|Early range of motion
58130032|NCT01333527|PROCEDURE|Sling|Patients will use the sling for 6 weeks, as per usual care
58130033|NCT05395858|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
58130034|NCT05602519|DRUG|propofol, rocuronium and fentanyl|In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
58130035|NCT00440557|DRUG|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
58130036|NCT00440557|DRUG|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
58130037|NCT00440557|DRUG|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
58130038|NCT05287594|BEHAVIORAL|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
58130039|NCT00804661|DEVICE|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
58130040|NCT00883090|BIOLOGICAL|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
58130041|NCT05127577|OTHER|Abdominal massage|Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
58130042|NCT01806922|BEHAVIORAL|Yoga|
58130043|NCT01242865|BEHAVIORAL|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
58130044|NCT04646109|DRUG|Ivermectin|"Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions."
58130045|NCT05780541|DRUG|PF-07304814|PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
58130046|NCT05780541|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
58460187|NCT02203734|PROCEDURE|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
58130047|NCT05780541|BIOLOGICAL|Remdesivir|Antiviral agent
58130048|NCT01189669|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
58130049|NCT01189669|DIETARY_SUPPLEMENT|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
58130050|NCT03602326|OTHER|Neurodevelopmental Therapy-Bobath group|Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
58460188|NCT02237326|PROCEDURE|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
58130051|NCT03602326|OTHER|Standart Rehabilitation Group (SR group)|Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
58130052|NCT03030066|DRUG|DS-1001b|Generic not assigned
58130053|NCT05960526|DRUG|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
58130054|NCT05960526|DRUG|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
58130055|NCT00137397|DRUG|Tolterodine ER|
58130056|NCT00137397|DRUG|Placebo|
58130057|NCT03460197|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
58130058|NCT01822600|DRUG|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
58130059|NCT01822600|DRUG|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
58130060|NCT01739790|DRUG|N-Acetylcysteine|1800 mg twice daily for 8 weeks
58130061|NCT01739790|DRUG|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
58130062|NCT03815838|DIAGNOSTIC_TEST|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
58130063|NCT02485808|OTHER|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
58130064|NCT02485808|PROCEDURE|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
58130065|NCT02485808|OTHER|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
58130066|NCT02485808|OTHER|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
58130067|NCT02920996|DRUG|Merestinib|Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
58130068|NCT00339768|DRUG|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
58130069|NCT03272139|DRUG|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
58130070|NCT03272139|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
58130071|NCT05984420|DEVICE|LimpiAD 2,5% plus cream|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
58130072|NCT05984420|OTHER|Vehicle|"Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component."
58130073|NCT05984420|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
58460189|NCT02237326|PROCEDURE|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
57777250|NCT00872430|OTHER|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
57777251|NCT00872430|OTHER|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
57777252|NCT02803320|DRUG|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
58460190|NCT00537602|DRUG|miglustat|
57777253|NCT06401759|BEHAVIORAL|Podcast|Routine maintenance will be applied.
57777254|NCT04059393|OTHER|Internet-Based Intervention|Complete web-based legacy intervention
57777255|NCT04059393|OTHER|Best Practice|Receive standard of care
57777256|NCT04059393|OTHER|Quality-of-Life Assessment|Ancillary studies
57777257|NCT04059393|OTHER|Questionnaire Administration|Ancillary studies
58130074|NCT02471469|DRUG|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
58460191|NCT00537602|DRUG|placebo|
58460192|NCT00189098|DRUG|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
58460193|NCT00189098|DRUG|Placebo|
58130075|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
58130076|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
58130077|NCT03203915|DIETARY_SUPPLEMENT|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
58130078|NCT05679648|DIAGNOSTIC_TEST|ultrasonography|studying degree of steatosis
58130079|NCT04296149|DRUG|Y90-DOTA-Tyr3-Octreotide|Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
58130080|NCT01298388|OTHER|medical chart review|
58130081|NCT01298388|OTHER|questionnaire administration|
58130082|NCT01298388|OTHER|study of socioeconomic and demographic variables|
58130083|NCT04097600|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
58130084|NCT06056869|DRUG|hyoscine butylbromide|will be given during first stage of labor intravenously
58130085|NCT06056869|OTHER|normal saline|placebo
58130086|NCT01064128|PROCEDURE|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
58130087|NCT01064128|PROCEDURE|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
58130088|NCT04982848|DRUG|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
58130089|NCT02511405|DRUG|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
58130090|NCT02511405|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
58130091|NCT01356849|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
58130092|NCT01356849|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
58130093|NCT01272752|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
58460194|NCT02934802|DEVICE|Total Knee prothesis e motion PS Pro|
58460195|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
58130094|NCT01272752|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
58130095|NCT03682900|OTHER|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
58130096|NCT03682900|OTHER|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
58130097|NCT02042846|DEVICE|SportWelding Fiji Anchor|
58460196|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
58460197|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
58460198|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
57777258|NCT02664779|OTHER|Arrhythmia diagnosis with the 10 steps method|
57777259|NCT02664779|OTHER|Arrhythmia diagnosis with the 6 steps method|
57777260|NCT02664779|OTHER|Arrhythmia diagnosis with the 4 steps method|
57777261|NCT03636360|DEVICE|Light|15 hours of light exposure
58130098|NCT00720096|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
58130099|NCT00720096|DRUG|Topotecan|"1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
58130100|NCT05806710|DIETARY_SUPPLEMENT|GourMed© meal|patients receive GourMed© meal as lunch for 7 consecutive days
58130101|NCT02227121|DEVICE|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
58130102|NCT04785456|DEVICE|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
58130103|NCT04785456|DEVICE|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
58130104|NCT00411866|DRUG|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
58130105|NCT00411866|DRUG|Ketoconazole|Ketoconazole will be available as 200mg tablets.
58130106|NCT02840409|DRUG|Vinblastine|
58130107|NCT02840409|DRUG|Bevacizumab|
58130108|NCT05836805|DRUG|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
58130109|NCT06369948|PROCEDURE|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed with the patient in the supine position. A linear high-frequency ultrasound probe (GE LOGIQ/P7 ultrasound, korea/ L6-12RS probe) is initially placed in a transverse plane over the anterior inferior iliac spine (AIIS); the probe is turned slightly medial until the hyperechoic continuous shadow of the iliopubic eminence (IPE). The target will be the plane between the psoas tendon and pubic ramus. The skin puncture site will be anesthetized using lidocaine 2% after skin disinfection and draping. A 22-gauge, 100 mm echogenic needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, 25 mL of the local anesthetic solution (bupivacaine 0.5%) was injected in 5 mL increments while observing for adequate fluid spread in this plane.
58130110|NCT06369948|PROCEDURE|elective hip hemiarthroplasty without receiving a PENG block.|elective hip hemiarthroplasty without receiving a PENG block.
58130111|NCT06369948|DRUG|bupivacaine 0.5% injection|bupivacaine 0.5% injection
58130112|NCT03622658|BIOLOGICAL|Placebo|Placebo solution for subcutaneous injection.
58130113|NCT03622658|BIOLOGICAL|Namilumab|Namilumab solution for subcutaneous injection
58130114|NCT02464566|BEHAVIORAL|Intensive lifestyle intervention|
58130115|NCT02464566|OTHER|Health Education|
58130116|NCT04192500|BIOLOGICAL|OVX836|One single administration intramuscularly at Day 1.
58130117|NCT04192500|BIOLOGICAL|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
58130118|NCT03827109|BEHAVIORAL|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
58130119|NCT03827109|BEHAVIORAL|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
58130120|NCT03827109|BEHAVIORAL|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
58130121|NCT03827109|BEHAVIORAL|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
58130122|NCT03827109|BEHAVIORAL|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
58130123|NCT03827109|BEHAVIORAL|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
58130124|NCT04522609|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session."
58130125|NCT01282606|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
58130126|NCT06545253|DIAGNOSTIC_TEST|microRNAs analysis|Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
58130127|NCT03417544|DRUG|ATEZOLIZUMAB|(IV) every 3 weeks
58130128|NCT03417544|DRUG|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
58130129|NCT03417544|DRUG|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
58130130|NCT01574170|OTHER|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
58130131|NCT01964742|GENETIC|blood samples|
58130132|NCT05090332|OTHER|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
58130133|NCT05090332|OTHER|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
58130134|NCT04172363|DRUG|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
58130135|NCT04103177|OTHER|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
58130136|NCT05314400|DIAGNOSTIC_TEST|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
58130137|NCT05314400|DIAGNOSTIC_TEST|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
58130138|NCT02126306|DRUG|Beta Glucosylceramide|Beta Glucosylceramide
58130139|NCT02126306|DRUG|Placebo|normal saline
58130140|NCT06458439|DRUG|Epcoritamab|"* C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection"
58130141|NCT04505033|DRUG|HB0017|HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
58130142|NCT04505033|DRUG|placebo|A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
57777262|NCT03309163|DRUG|Tramadol|Patient-controlled intravenous analgesia with Tramadol
58130143|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
58130144|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
57777263|NCT03309163|DRUG|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
57777264|NCT03309163|DRUG|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
58130145|NCT00385684|DRUG|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
58130146|NCT00385684|DRUG|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
58130147|NCT00385684|DRUG|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
58130148|NCT00369590|BIOLOGICAL|ziv-aflibercept|Given IV
58130149|NCT00369590|OTHER|pharmacological study|correlative studies
58130150|NCT00369590|OTHER|laboratory biomarker analysis|correlative studies
58130151|NCT01256684|DRUG|Placebo|Placebo vaginal suppository
58130152|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
58130153|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
58130154|NCT02152878|DEVICE|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
58130155|NCT02152878|DEVICE|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
58130156|NCT03765632|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
58130157|NCT03765632|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
58130158|NCT03765632|DRUG|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
58130159|NCT04598984|DIAGNOSTIC_TEST|serum adipokines|Level of serum adipokines will be measured with flow cytometry
58130160|NCT03093506|DRUG|Low-dose rhEpo|60IU/kg/week
58130161|NCT03093506|DRUG|Micro-dose rhEpo|20IU/kg/week
58130162|NCT03093506|OTHER|Placebo Control|Saline
58130163|NCT02128152|DEVICE|Ekso exoskeleton|
58130164|NCT00914667|DRUG|warfarin|Single Dose Warfarin 25 mg on Day 1
58130165|NCT00914667|DRUG|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
58130166|NCT00005948|BIOLOGICAL|aldesleukin|
58130167|NCT00005948|BIOLOGICAL|recombinant interferon alfa|
58130168|NCT00005948|BIOLOGICAL|sargramostim|
58130169|NCT00005948|DRUG|busulfan|
58460199|NCT02038816|DRUG|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
58130170|NCT00005948|PROCEDURE|peripheral blood stem cell transplantation|
58130171|NCT03839706|DEVICE|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
58130172|NCT01365429|DEVICE|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
58130173|NCT01234103|BEHAVIORAL|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
58130174|NCT02101346|DIETARY_SUPPLEMENT|Mixed High Fat Diet|Healthy, Round 1
58130175|NCT02101346|DIETARY_SUPPLEMENT|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
58130176|NCT02101346|DIETARY_SUPPLEMENT|Monounsaturated fat diet|Healthy, Round 1
58130177|NCT02101346|DIETARY_SUPPLEMENT|Polyunsaturated fat diet|Healthy, Round 1
58130178|NCT02101346|DIETARY_SUPPLEMENT|Triolein 13C|Healthy, Round 2
58130179|NCT02101346|DIETARY_SUPPLEMENT|Low fat|Healthy, Round 1
58130180|NCT01617668|DRUG|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
58130181|NCT01617668|DRUG|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
58130182|NCT04457999|DEVICE|Lipiflow Thermal pulsation|Single vectored thermal pulsation treatment for dry eye
58130183|NCT01309607|DRUG|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously"
58130184|NCT05897398|OTHER|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
58130185|NCT05897398|OTHER|Blood sampling|Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)
58460200|NCT02038816|DRUG|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
58460201|NCT03810677|DEVICE|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
58460202|NCT03798106|DRUG|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
58460203|NCT06066177|DIAGNOSTIC_TEST|Triglyceride glucose index TyG|Triglyceride glucose index is an indicator of insulin resistance
58460204|NCT00251524|DRUG|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
58460205|NCT06381934|OTHER|Standard Care|Standard diagnosis and therapy procedures at physician's discretion.
57777265|NCT03685032|DRUG|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
57777266|NCT03685032|DRUG|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
57777267|NCT03685032|DRUG|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
57777268|NCT01013974|DRUG|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
57777269|NCT01013974|DRUG|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
57777270|NCT01013974|DRUG|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
57777271|NCT01013974|DRUG|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
57777272|NCT05408000|DRUG|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
57777273|NCT02811289|DRUG|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
57777274|NCT02811289|OTHER|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
57777275|NCT02811289|RADIATION|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
57777276|NCT02811289|RADIATION|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
57777277|NCT02811289|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
57777278|NCT02811289|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
57777279|NCT02811289|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
57777280|NCT04781647|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
57777281|NCT04781647|DRUG|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
57777282|NCT04781647|BIOLOGICAL|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
57777283|NCT05488938|OTHER|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
58460206|NCT06381934|OTHER|aSID/ChU Guided Therapy|"Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization."
58460207|NCT00358475|DRUG|GW685698|
58460208|NCT04641897|PROCEDURE|Respiratory rate modification|"During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate)."
58460209|NCT00454714|DRUG|single dose Sildenafil|Application of a single dose Sildenafil
57777284|NCT04565756|DRUG|EXN407|EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
57777285|NCT01313923|DRUG|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
57777286|NCT03803020|OTHER|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
57777287|NCT04095104|DRUG|Phentermine|Phentermine tablet
57777288|NCT04095104|DRUG|Immediate Release Topiramate|Topiramate tablet
57777289|NCT04095104|DRUG|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
57777290|NCT04095104|DRUG|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
57777291|NCT02250521|DEVICE|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
57777292|NCT03489005|DRUG|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"
57777293|NCT03489005|DRUG|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets"
57777294|NCT03489005|DRUG|Moxifloxacin 400 mg|"Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet"
57777295|NCT05586854|PROCEDURE|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
57777296|NCT04503382|OTHER|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
57777297|NCT04930666|OTHER|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
57777298|NCT04265443|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
57777299|NCT01015222|DRUG|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
57777300|NCT01015222|DRUG|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
57777301|NCT01015222|DRUG|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
57777302|NCT02773264|DEVICE|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
57777303|NCT02809586|BEHAVIORAL|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
57777304|NCT02809586|BEHAVIORAL|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
57777305|NCT00114842|PROCEDURE|MR colonography|
57777306|NCT02619227|OTHER|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
58130186|NCT05897398|OTHER|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
58460210|NCT00454714|DRUG|Single dose placebo|Application of a single dose placebo
58460211|NCT02598401|OTHER|observation|Observational study with no intervention
57777307|NCT05699902|PROCEDURE|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
57777308|NCT05699902|PROCEDURE|Sham block|Female undergone mastectomy and have received conventional analgesic methods
57777309|NCT02456974|PROCEDURE|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
57777310|NCT02456974|PROCEDURE|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
57777311|NCT02456974|PROCEDURE|blood sampling in patients receiving vancomycin as part of routine clinical care.|
57777312|NCT02456974|PROCEDURE|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
57777313|NCT02456974|PROCEDURE|blood sampling in patients receiving meropenem as part of routine clinical care.|
57777314|NCT02456974|PROCEDURE|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
57777315|NCT02456974|PROCEDURE|blood sampling in patients receiving amikacin as part of routine clinical care.|
57777316|NCT01315405|BEHAVIORAL|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
57784438|NCT01298180|DRUG|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
58130187|NCT04217408|DEVICE|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
58130188|NCT01840371|DRUG|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation"
58130189|NCT01840371|DRUG|Experimental sedation|"Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation"
58130190|NCT05344872|OTHER|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
58130191|NCT00539877|DRUG|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
58130192|NCT05866497|DIAGNOSTIC_TEST|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
58130193|NCT05866497|DIAGNOSTIC_TEST|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
58130194|NCT03091946|OTHER|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
58130195|NCT03091946|OTHER|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
58130196|NCT00637390|DRUG|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
58130197|NCT01184560|DRUG|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
58130198|NCT01184560|DRUG|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
58130199|NCT06324149|DIAGNOSTIC_TEST|completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis|The sub-investigator performs a multidimentional geriatric evaluation
58130200|NCT05904808|DRUG|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
58130201|NCT05904808|DRUG|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
58130202|NCT05904808|DRUG|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
57777317|NCT03758638|BEHAVIORAL|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an \~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
58130203|NCT05432011|PROCEDURE|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
58130204|NCT05432011|PROCEDURE|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
58130205|NCT05432011|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
58130206|NCT05881096|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
57777318|NCT03758638|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
57777319|NCT01777594|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
57777320|NCT00548041|OTHER|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
57777321|NCT01267825|DRUG|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
58130207|NCT05881096|OTHER|Sham Control|Practice of movement task without START
57777322|NCT01267825|DRUG|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
58130208|NCT03236181|OTHER|SFA|High saturated fatty acid/SFA oil source
58460212|NCT02111421|DRUG|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
58460213|NCT02111421|DRUG|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
57777323|NCT03461250|DIAGNOSTIC_TEST|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
57777324|NCT01731587|OTHER|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
57777325|NCT01731587|DRUG|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
57777326|NCT04519541|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
57777327|NCT06336499|OTHER|Multi-parametric MRI and image analysis by deep learning or machine learning algorithms|Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
57777328|NCT02532322|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
57777329|NCT02532322|DRUG|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
58460214|NCT06513494|BEHAVIORAL|Active Students Education plus Teacher Training|The teacher undergoes 30 hours of self-instructional training on vaccination through an online platform tailored for the relevant age group. Additionally, students receive active vaccinations and health education over two months
57777330|NCT02535559|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
57777331|NCT01818141|DRUG|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
57777332|NCT01818141|DRUG|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
57777333|NCT00019006|DRUG|Detox-B adjuvant|
57777334|NCT00019006|DRUG|ras peptide cancer vaccine|
57777335|NCT01169181|DEVICE|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
57777336|NCT00393094|BIOLOGICAL|Bevacizumab|10 mg/kg intravenous injection
57777337|NCT00393094|DRUG|Irinotecan hydrochloride|125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
57777338|NCT03958630|DRUG|11C-ER176|PET biomarker for inflammation
57777339|NCT03958630|DRUG|11C-PIB|PET biomarker for amyloid
57777340|NCT03958630|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
57777341|NCT05368506|DRUG|Wee1 Inhibitor ZN-c3|Given PO
57777342|NCT03514862|BEHAVIORAL|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
57777343|NCT03514862|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
57777344|NCT03514862|BEHAVIORAL|Self-Practice|4 weeks of self-practice after the MBI training.
58460215|NCT06513494|BEHAVIORAL|Active Students Education|Students receive active vaccinations and health education over two months.
58460216|NCT06513494|BEHAVIORAL|Basic Health Unit Active Orientation|Nurses from basic health units will conduct an active orientation session at schools about vaccination for students.
58460217|NCT06513494|OTHER|Usual care|No project interventions will be carried out.
57777345|NCT05517720|OTHER|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
57777346|NCT05969522|DRUG|GlucoCorticoid|The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
58130209|NCT03236181|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
58130210|NCT03236181|OTHER|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
58130211|NCT03236181|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
57784439|NCT01298180|PROCEDURE|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
57784440|NCT01298180|PROCEDURE|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
57784441|NCT02256774|DRUG|BILR 355 BS|
57784442|NCT02256774|DRUG|Combivir®|
57784443|NCT02256774|DRUG|Ritonavir|
57784444|NCT03268460|DIAGNOSTIC_TEST|Arterial blood gases|blood PH, HCO3
57784445|NCT03268460|DIAGNOSTIC_TEST|Blood anion gap|(Na+) - (Cl- + HCO3-)
57784446|NCT03268460|DIAGNOSTIC_TEST|serum electrolytes|Na+ , K+ , Cl- and calcium
57784447|NCT03268460|DIAGNOSTIC_TEST|renal function test|blood urea and serum creatinine
58130212|NCT01462214|DRUG|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
58130213|NCT02954757|PROCEDURE|HIFU treatment|High intensity focused ultrasound
58130214|NCT03735758|DRUG|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
58130215|NCT01667783|PROCEDURE|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
58130216|NCT01667783|BEHAVIORAL|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
58130217|NCT01667783|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
58130218|NCT05586009|DRUG|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
58130219|NCT04277910|DRUG|MT2004|MT2004 oral capsules
58130220|NCT04277910|DRUG|Placebo|Placebo oral capsules
58130221|NCT03270293|DEVICE|Profhilo|
58130222|NCT04525248|PROCEDURE|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
58130223|NCT04525248|PROCEDURE|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
58130224|NCT02512666|DEVICE|AM4113-N5UT Dino-Lite|
57777347|NCT01597661|DRUG|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
58130225|NCT04588753|OTHER|active isolated stretch|"Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
58130226|NCT04588753|OTHER|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
58130227|NCT02475915|DRUG|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
58130228|NCT02475915|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
58130229|NCT02475915|DRUG|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
58130230|NCT02475915|DRUG|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
58130231|NCT02475915|DRUG|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
58130232|NCT02475915|DRUG|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
58460218|NCT06582758|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
58460219|NCT06582758|BEHAVIORAL|Mindful Pain Management|In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.
58460220|NCT05201144|DRUG|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
58460221|NCT05201144|OTHER|Placebo|Equal volume of placebo
58460222|NCT00189540|GENETIC|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
58460223|NCT00189540|GENETIC|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
58460224|NCT00428766|DRUG|MORAb-003|
58130233|NCT02475915|DRUG|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
58130234|NCT00118053|BIOLOGICAL|herceptin|
58130235|NCT00118053|DRUG|carboplatin|
58130236|NCT00118053|DRUG|docetaxel|
58130237|NCT00118053|PROCEDURE|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
58130238|NCT00118053|PROCEDURE|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
58130239|NCT04347291|BEHAVIORAL|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
58130240|NCT04347291|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
58130241|NCT00188864|DRUG|dexamethasone|
58130242|NCT04849884|DEVICE|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
57777348|NCT01597661|DRUG|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
57777349|NCT01597661|OTHER|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
57777350|NCT03289390|DRUG|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
57777351|NCT02610218|OTHER|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
57777352|NCT01887314|DIETARY_SUPPLEMENT|Standardized Ginger extract|
57777353|NCT06119906|DEVICE|Hyper-Spectral Endoscopy|We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
57777354|NCT02916004|DEVICE|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
57777355|NCT02500979|DRUG|Pramlintide acetate|Pramlintide acetate administered by a separate pump
57777356|NCT02500979|DRUG|Placebo|Placebo administered by separate pump
57777357|NCT02500979|DRUG|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
57777358|NCT02500979|DRUG|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
57777359|NCT00993317|DRUG|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
57777360|NCT00993317|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
57962516|NCT05855447|OTHER|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (\> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
57962517|NCT05855447|OTHER|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
57962518|NCT05855447|OTHER|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
57777361|NCT00993317|DRUG|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
57777362|NCT00519259|DRUG|Lobeline|
57777363|NCT02569320|DRUG|Dexamethasone|Given PO
57962519|NCT02847130|OTHER|Informational Intervention|Participate in focus group
57962520|NCT02847130|OTHER|Interview|Undergo one-on-one interviews
57962521|NCT02847130|OTHER|Medical Chart Review|Review of medical chart
57962522|NCT02847130|OTHER|Questionnaire Administration|Ancillary studies
57962523|NCT03936504|BEHAVIORAL|Control Group ：conventional exercise rehabilitation programs (CERP)|The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
58130243|NCT04761731|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
58130244|NCT01282047|DRUG|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
58130245|NCT05268432|PROCEDURE|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
58130246|NCT00379600|DRUG|rosiglitazone XR|
58130247|NCT03209882|DEVICE|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
58130248|NCT03209882|DEVICE|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
58130249|NCT01217086|DRUG|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
58130250|NCT00001025|DRUG|Zidovudine|
58130251|NCT00001025|DRUG|Didanosine|
58130252|NCT00208988|PROCEDURE|Educational handout about prostate cancer screening|
58130253|NCT00208988|PROCEDURE|Simple cue for patient to talk to doctor|
58130254|NCT05289713|PROCEDURE|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
58130255|NCT03500692|DEVICE|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
58130256|NCT06144671|DRUG|GT201|Autologous tumor infiltrating lymphocyte injection
58130257|NCT00751465|BEHAVIORAL|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
58130258|NCT00751465|BEHAVIORAL|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
58130259|NCT05718778|DRUG|Piamprimab (AK105)|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
58130260|NCT05978427|PROCEDURE|interscalene block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.
58130261|NCT05978427|PROCEDURE|superior trunk block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
58130262|NCT02912897|BIOLOGICAL|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
58130263|NCT00160407|DRUG|Orlistat (Xenical)|
58130264|NCT00160407|BEHAVIORAL|1400 kcal diet (30% fat)|
58130265|NCT03450564|BEHAVIORAL|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
58130266|NCT03450564|BEHAVIORAL|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
58130267|NCT03450564|OTHER|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
58130268|NCT06254248|DRUG|Systemic therapy|"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."
58130269|NCT00128453|DRUG|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily
58130270|NCT00128453|DRUG|Placebo|placebo
57777364|NCT02569320|DRUG|HDAC Inhibitor AR-42|Given PO
58130271|NCT01991470|DEVICE|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
58130272|NCT03489759|DEVICE|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
58130273|NCT03489759|DEVICE|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
57777365|NCT02569320|OTHER|Laboratory Biomarker Analysis|Correlative studies
57777366|NCT02569320|DRUG|Pomalidomide|Given PO
58460225|NCT03573414|OTHER|raspberry powder, milled flaxseed and soy milk|"* The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples"
58460226|NCT05720286|DEVICE|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
57777367|NCT03296618|DRUG|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
57962524|NCT03936504|BEHAVIORAL|Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)|Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
57962525|NCT05882955|BEHAVIORAL|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
57962526|NCT05882955|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
57962527|NCT04092127|OTHER|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
57962528|NCT03511131|BEHAVIORAL|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
57962529|NCT03511131|BEHAVIORAL|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
57962530|NCT03511131|BEHAVIORAL|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
57962531|NCT03511131|BEHAVIORAL|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
57962532|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED)|Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
57962533|NCT01895127|DRUG|Eculizumab|
57962534|NCT01895127|BIOLOGICAL|Immunoglobulin|
57962535|NCT01895127|PROCEDURE|Plasmapheresis|
57962536|NCT02740088|OTHER|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
57962537|NCT00144898|PROCEDURE|Sentinel Node Resection|Sentinel Node Resection
57962538|NCT00144898|PROCEDURE|Conventional Axillary Dissection|Conventional Axillary Dissection
57962539|NCT03424759|DRUG|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
57962540|NCT02450578|DRUG|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
57962541|NCT02450578|DRUG|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
57962542|NCT02450578|BIOLOGICAL|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
57962543|NCT02450578|DRUG|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
57962544|NCT05179317|DRUG|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
57962545|NCT02866825|BIOLOGICAL|IFX-1|
57962546|NCT02866825|BIOLOGICAL|Placebo|
57962547|NCT05980715|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
57784448|NCT03268460|DIAGNOSTIC_TEST|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
57962548|NCT05980715|RADIATION|concurrent chemoradiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
57962549|NCT05231148|PROCEDURE|local debridement and local calcium sulfate loaded by antibiotics|debridement of infected non united fractures and placement of local calcium sulfate loaded by antibiotic then follow up at regular intervals
57962550|NCT05201833|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
57962551|NCT05201833|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
58130274|NCT04883801|DIAGNOSTIC_TEST|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
57962552|NCT05201833|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
57962553|NCT05201833|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
57962554|NCT05928455|BIOLOGICAL|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
57962555|NCT05928455|BIOLOGICAL|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
57962556|NCT00493870|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
57962557|NCT00493870|DRUG|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
57962558|NCT00493870|DRUG|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
57962559|NCT04270929|DRUG|FOLFIRI|During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
57962560|NCT04270929|DRUG|FOLFIRINOX|During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
58130275|NCT03677648|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
57962561|NCT04270929|DEVICE|TriSalus Infusion System|The TriSalus Infusion System administers therapeutics using PEDD technology.
58130276|NCT03677648|DRUG|Placebos|Placebos
58130277|NCT04355455|DRUG|Citalopram|40 mg citalopram intravenously
58460227|NCT00500916|DEVICE|ProSeal LMA|GEB vs digital vs introducer tool
57777368|NCT01419145|OTHER|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
57777369|NCT01419145|OTHER|Standard care|Standard cancer care
57777370|NCT05555862|DRUG|Artesunate|artesunate formulated as intra-anal suppositories
57777371|NCT05555862|DRUG|Placebo|placebo intra-anal suppository
57777372|NCT00192621|DRUG|Combivir (zidovudine [AZT] / lamivudine [3TC])|
57777373|NCT00192621|DRUG|Kaletra (lopinavir [LPVr])|
57777374|NCT02091869|OTHER|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
57777375|NCT02091869|DEVICE|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
57777376|NCT04797169|BEHAVIORAL|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
57777377|NCT04797169|BEHAVIORAL|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
57777378|NCT02509351|DRUG|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
57777379|NCT02509351|DRUG|placeboo|women will recive 2 identical tablets as placeboo
58130278|NCT04355455|DRUG|Placebo|Saline solution
58130279|NCT05163951|PROCEDURE|Trabeculectomy|trabeculectomy
58130280|NCT05163951|PROCEDURE|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
58130281|NCT00063206|DRUG|DVS-233 SR|
58130282|NCT00093925|DRUG|clevidipine|
58130283|NCT00093925|DRUG|nicardipine|
58130284|NCT04433910|DRUG|Convalesscent Plasma|Transfusion
58460228|NCT04038346|DRUG|Naproxen|Patients will be randomized to an NSAID (naproxen)
57777380|NCT02774408|DEVICE|Saturation sensitive backup ventilation|
57777381|NCT02210962|DIETARY_SUPPLEMENT|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
58130285|NCT00166842|DRUG|sirolimus, cyclosporine, tacrolimus|
58130286|NCT00638599|DEVICE|LMA®|LMA® is placed after anesthesia induction and removed after the operation
58130287|NCT00638599|DEVICE|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
58130288|NCT06217653|BEHAVIORAL|mother baby yoga|"Yoga Video Content Plan~* Mood Regulation: Abdominal/Belly Breathing~* Warm Touch from the Heart~* Chair Posture~* Bucket Wrapping~* Bukka Bukka (Heart)~* Vortex Generation~* Fertile Falls~* One Hand Two Hands~* Tiny Stretches~* Here and Now Awareness~* Dolphin Pose Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes."
58460229|NCT04038346|DRUG|Acetaminophen|Patients will be randomized to acetaminophen
57777382|NCT02210962|DIETARY_SUPPLEMENT|olive oil|Yellow capsules containing olive oil (placebo)
57777383|NCT02488382|DRUG|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
57777384|NCT05805111|DEVICE|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
58130289|NCT04265365|DEVICE|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58130290|NCT04265365|DEVICE|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58130291|NCT04265365|DEVICE|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58460230|NCT03741153|DEVICE|slit lamp|"1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma."
58460231|NCT06132269|DIETARY_SUPPLEMENT|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
58130292|NCT04265365|DEVICE|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58460232|NCT06132269|DIETARY_SUPPLEMENT|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
58460233|NCT04083976|DRUG|Erdafitinib|Participants will receive erdafitinib oral tablets.
58460234|NCT03741465|PROCEDURE|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
58460235|NCT03741465|PROCEDURE|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
58460236|NCT00003468|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
57777385|NCT04276090|DEVICE|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
57777386|NCT04276090|DRUG|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
57777387|NCT04276090|DRUG|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
57777388|NCT04276090|DRUG|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
57777389|NCT03472092|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
57777390|NCT03472092|DRUG|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
57777391|NCT03472092|DRUG|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
57777392|NCT03472092|BEHAVIORAL|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
57777393|NCT03472092|BEHAVIORAL|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
58130293|NCT04265365|DEVICE|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58130294|NCT04265365|DEVICE|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
58130295|NCT04265365|DEVICE|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
58460237|NCT00032669|DRUG|HAART|
58460238|NCT06490809|OTHER|Physiotherapy|Parkinson\&#39;s upper extremity rehabilitation generally consists of stretching, strengthening, coordination, recreational activities and skill activities. Exercises will be prescribed by the clinical specialist physician and physiotherapist.
57777394|NCT02221895|OTHER|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
57777395|NCT02221895|OTHER|Postpartum follow up 6-8wk after delivery|control arm
57777396|NCT06306560|DRUG|adebrelimab|adebrelimab IV
57777397|NCT06306560|DRUG|famitinib|famitinib PO
57777398|NCT06306560|DRUG|chemotherapy|chemotherapy IV
57777399|NCT04762329|OTHER|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
58130296|NCT04265365|DEVICE|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
57777400|NCT02053194|BEHAVIORAL|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
57777401|NCT01244139|DRUG|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
57777402|NCT01244139|DRUG|Placebo|IV infusion dummy drug
57777403|NCT01219621|PROCEDURE|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
57777404|NCT04732715|BEHAVIORAL|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
57777405|NCT06245265|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|In this study, 15 periodontitis patients with RA, 15 healthy individuals with RA, 15 systemic healthy periodontitis patients and 15 systemic periodontally healthy individuals will be included. ANGPTL-4 biomarker and other biomarkers (MMP-13, TNF-α, IL-6) that have not been previously analysed in the serum and saliva of both RA and periodontitis patients will be evaluated before and 3 months after COPT. Clinical parameters (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), biochemical evaluations of serum, saliva and gingival samples will be performed and correlated with clinical parameters at baseline and 3 months after COPT in all individuals with periodontitis included in the study.
57777406|NCT03989791|DIETARY_SUPPLEMENT|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
57777407|NCT03989791|DIETARY_SUPPLEMENT|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
57777408|NCT05435235|DRUG|Dapagliflozin 10mg Tab|One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.
57777409|NCT05652855|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
57777410|NCT02310126|DEVICE|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
57777411|NCT02310126|DEVICE|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
57777412|NCT01872780|DRUG|Rosiglitazone|single oral administration of 4mg of rosiglitazone
57777413|NCT01872780|GENETIC|CYP2C8 genotype|CYP2C8\*11.
57777414|NCT00287469|BIOLOGICAL|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
57777415|NCT00287469|OTHER|Placebo|PBS buffer placebo containing alum
57777416|NCT01173640|DRUG|Midazolam|2 mg oral dose
57777417|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (single dose)|1 g oral dose
57777418|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (multiple dose)|1 g oral dose for 8 days
57777419|NCT02456389|OTHER|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
57777420|NCT02456389|OTHER|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
57777421|NCT02456389|OTHER|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
57777422|NCT02456389|OTHER|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
58130297|NCT00257712|DRUG|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
58130298|NCT04551638|OTHER|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
58460239|NCT03493555|BEHAVIORAL|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
58460240|NCT01172106|BEHAVIORAL|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
58460241|NCT01172106|BEHAVIORAL|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
58460242|NCT01172106|BEHAVIORAL|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
57777423|NCT02456389|OTHER|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
57777424|NCT02456389|OTHER|Standard postoperative care|Routine postoperative care, as medically indicated
57777425|NCT05701722|DEVICE|Flourish HEC Vaginal Care System|BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
57777426|NCT05389969|OTHER|digital arch scanning|"Scanning of the maxillary and mandibular dental arch will be performed for the same group of patients twice. The first time is before bracket positioning using two different scanners and the three different techniques. The second time is after brackets positioning using the same two different scanners and the same three different scanning techniques.~Then these scans will be compared to by superimposition techniques and linear measurement techniques."
57777427|NCT02498730|BEHAVIORAL|Interval Training|High Intensity Interval Training at 100% VO2Max
57777428|NCT02498730|BEHAVIORAL|Continuous Training|Continuous Stimulous at 60% VO2Max
57777429|NCT02498730|BEHAVIORAL|Control|Only Dependent Variables Measures
57777430|NCT01759680|DEVICE|Vibrosphère device|Vertical Sinusoidal vibration
57777431|NCT05231564|OTHER|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
57777432|NCT03269448|DIAGNOSTIC_TEST|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
58130299|NCT05258942|OTHER|Observational|Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.
58130300|NCT05364957|DEVICE|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
58130301|NCT05364957|PROCEDURE|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
58130302|NCT05364957|PROCEDURE|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
58130303|NCT05473052|BEHAVIORAL|Preoperative home-based exercise training|"1) Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity:Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week~2) Weekly telephone supervision: A physical therapist carried out weekly telephone calls with all participants to monitor adverse events, give positive reinforcement and recommend strategies to overcome barriers that arise during the exercise program."
58130304|NCT04981899|DRUG|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
58130305|NCT04981899|DRUG|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
58130306|NCT04981899|DRUG|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
58130307|NCT04981899|DRUG|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
58130308|NCT01127022|DIETARY_SUPPLEMENT|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
58130309|NCT01127022|DIETARY_SUPPLEMENT|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
58130310|NCT02451605|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
58130311|NCT02451605|PROCEDURE|Total knee replacement surgery.|Total knee replacement surgery.
58130312|NCT04942756|DEVICE|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
58130313|NCT04942756|DEVICE|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
58130314|NCT01314690|OTHER|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
58460243|NCT03416868|BEHAVIORAL|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
58460244|NCT01718379|DRUG|Lenalidomide|Lenalidomide:10 mg per day during 21 days
58460245|NCT01718379|DRUG|Epoetin beta|Epoetin beta: 60,000 Units/week.
58460246|NCT04744675|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
58460247|NCT04744675|DRUG|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
58460248|NCT04744675|DRUG|Bupivacaine|Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
58460249|NCT04038502|DRUG|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
58460250|NCT04038502|DRUG|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
57777433|NCT05047796|OTHER|Intervention Protocol|The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
58130315|NCT05875337|OTHER|Acupressure|Before starting the acupressure point application, the area around the area where the pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.
58130316|NCT05875337|OTHER|Placebo acupressure|Before starting the application to the placebo acupressure point, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Light pressure will be applied to the determined points (1.5 cm away from LI4, LI11 and HT7 points) with the thumb, index or middle finger. Each point will be applied for 2 minutes and the application will last 12 minutes.
58130317|NCT00154180|DRUG|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
58130318|NCT00154180|DRUG|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
58130319|NCT00154180|DRUG|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
58130320|NCT00154180|DRUG|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
58130321|NCT00154180|DRUG|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
58130322|NCT03221374|BEHAVIORAL|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
58130323|NCT01440283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
58130324|NCT03156764|OTHER|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
58130325|NCT01775319|DIETARY_SUPPLEMENT|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
58130326|NCT01775319|DIETARY_SUPPLEMENT|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
58460251|NCT01755234|DRUG|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
58460252|NCT01755234|DRUG|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
58460253|NCT02994238|DEVICE|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
58460254|NCT05729282|DRUG|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
58130327|NCT01775319|DIETARY_SUPPLEMENT|Placebo|
58130328|NCT01734291|BEHAVIORAL|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
58130329|NCT04266210|DEVICE|Fuji Bulk|Restorative system
58130330|NCT04266210|DEVICE|G-ænial Posterior|Restorative system
58130331|NCT05291871|BIOLOGICAL|HPV vaccine|One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
58130332|NCT03418441|OTHER|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
58130333|NCT00262600|DRUG|warfarin|once a day
58130334|NCT00262600|DRUG|Dabigatran dose 1|twice daily
58130335|NCT00262600|DRUG|Dabigatran dose 2|twice a day
58130336|NCT00236457|DRUG|risperidone|
58130337|NCT02498964|OTHER|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
58130338|NCT05666583|OTHER|Art therapy|The intervention group is the group in which art therapy is applied. They receive chemotherapy.
58130339|NCT01616732|DRUG|Testosterone|TU im
58130340|NCT01616732|DRUG|placebo|placebo im
58130341|NCT05071937|DRUG|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
58130342|NCT05071937|DRUG|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
58130343|NCT04604704|DRUG|Naltrexone|Naltrexone at 4.5 mg/day
58130344|NCT04604704|DIETARY_SUPPLEMENT|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
58130345|NCT03237364|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
58130346|NCT02429271|DRUG|Ticagrelor|
58130347|NCT02429271|DRUG|Clopidogrel|
58130348|NCT02429271|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
58130349|NCT02429271|PROCEDURE|Coronary Angiography|
58130350|NCT05188937|PROCEDURE|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
58130351|NCT04066361|OTHER|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
58130352|NCT04066361|OTHER|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
58130353|NCT03799666|OTHER|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
58130354|NCT03799666|OTHER|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
58130355|NCT01654107|BEHAVIORAL|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
58130356|NCT01654107|BEHAVIORAL|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
58460255|NCT05729282|DRUG|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
57777434|NCT05047796|OTHER|Sham Protocol|The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
57777435|NCT03753282|OTHER|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication"
57777436|NCT03753282|OTHER|questionnaire for course of the disease|"questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions"
57777437|NCT02465021|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
57784449|NCT04592536|DRUG|CVL-865 High dose|High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
58130357|NCT01654107|DRUG|Nicotine lozenge|12-weeks 4mg nicotine lozenge
58130358|NCT04875065|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
58130359|NCT00714103|DRUG|8-Chloro-Adenosine|45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
58130360|NCT04458649|DEVICE|Dexcom continuous glucose monitor|Measurement of interstitial glucose
58130361|NCT05473169|DEVICE|Videofluoroscopy|Swallowing assessment
58130362|NCT01720082|PROCEDURE|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
58130363|NCT01720082|PROCEDURE|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
58130364|NCT02166697|DRUG|candesartan cilexetil|candesartan cilexetil tablets
58130365|NCT04908748|DRUG|Esflurbiprofen Hydrogel Patch|Esflurbiprofen is a cyclooxygenase (COX) inhibitor
58130366|NCT03194464|OTHER|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
58130367|NCT03165565|BEHAVIORAL|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
58130368|NCT03165565|BEHAVIORAL|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
58130369|NCT01365962|GENETIC|gene expression analysis|
58130370|NCT01365962|OTHER|immunohistochemistry staining method|
58130371|NCT01365962|OTHER|laboratory biomarker analysis|
58130372|NCT01365962|OTHER|mass spectrometry|
58460256|NCT05729282|DRUG|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
58460257|NCT05729282|DEVICE|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
58130373|NCT02946762|OTHER|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
58130374|NCT03501875|RADIATION|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
58130375|NCT02576249|DRUG|Ropivacaine|4cc 0.5% ropivacaine
58130376|NCT02576249|DRUG|Normal saline|4cc of sterile normal saline (0.9%)
58130377|NCT02576249|DRUG|Methylprednisolone|1cc 40mg methylprednisolone
58130378|NCT05048992|OTHER|ELDOA method|group A will receive
58130379|NCT05048992|OTHER|Post-facilitation stretching|Group B will receive
58130380|NCT00001221|DRUG|Growth Hormone (Humatrope)|
58130381|NCT01103505|DIAGNOSTIC_TEST|ForeseeHome AMD Monitoring Device|Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
58130382|NCT05962554|BEHAVIORAL|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
58130383|NCT02651441|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
58130384|NCT02651441|DRUG|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
58130385|NCT02651441|BIOLOGICAL|D-CIK|8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
58130386|NCT05641909|DRUG|Remifentanil|Remifentanil
58130387|NCT05641909|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
58130388|NCT03909516|DEVICE|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
58130389|NCT02745899|DIETARY_SUPPLEMENT|Cow milk|Ingestion of 240 ml cow milk
57777438|NCT03877705|DRUG|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
57777439|NCT03410238|BEHAVIORAL|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
58130390|NCT02745899|DIETARY_SUPPLEMENT|Soy milk|Ingestion of 240 ml soy milk
57777440|NCT00493337|BEHAVIORAL|advanced adherence counseling+reminder|
57777441|NCT00493337|DEVICE|Compliance Card|
57784450|NCT04592536|DRUG|Alprazolam 1mg XR|Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
57784451|NCT04592536|DRUG|Placebo|Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
58130391|NCT03059862|DIETARY_SUPPLEMENT|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
58130392|NCT03059862|DIETARY_SUPPLEMENT|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
58130393|NCT02494765|DEVICE|I-gel TM|Airway management with I-gel
58130394|NCT02494765|DEVICE|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
58130395|NCT02548507|OTHER|observational study, no intervention|
58130396|NCT02923947|DRUG|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
58130397|NCT03564548|DRUG|PPP001|Group assigned to PPP001
58130398|NCT03564548|DRUG|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
58130399|NCT02696681|BEHAVIORAL|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
58130400|NCT01074554|DRUG|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
58130401|NCT01074554|DRUG|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
58130402|NCT03377400|DRUG|Durvalumab|concurrent radiotherapy
58130403|NCT02208726|OTHER|Sucrose pillules|Unmedicated sucrose pillules
58130404|NCT02208726|OTHER|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
58130405|NCT04284488|DRUG|APG-1387 for Injection|APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.
58130406|NCT04284488|DRUG|Toripalimab|240 mg toripalimab IV on Day 1 of each 21-Day Cycle
57784452|NCT04592536|DRUG|CVL-865 low dose|Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
57784453|NCT00688506|DEVICE|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
58130407|NCT04607239|PROCEDURE|Telemonitoring|"* A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check."
58130408|NCT04607239|PROCEDURE|Usual Care without Telemonitoring|"* Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
58130409|NCT02799797|PROCEDURE|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
58130410|NCT02799797|PROCEDURE|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
58130411|NCT02799797|DEVICE|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
58130412|NCT02799797|DEVICE|PAJUNK Contiplex S Catheter|
58130413|NCT02799797|DRUG|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
58130414|NCT02799797|DRUG|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
58130415|NCT04602507|DRUG|Ivermectin|Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
58130416|NCT04602507|OTHER|Placebo|Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
58130417|NCT05757011|PROCEDURE|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
58130418|NCT02276196|DRUG|Lixisenatide|GLP-1 receptor agonist
58130419|NCT02276196|DRUG|Insulin glulisine|Insulin analogue
58130420|NCT05627609|DEVICE|311 nm narrowband UVB irradiation|Participants will be irradiated with 311nm UVB for 5 days per week and 4 weeks in total.
58130421|NCT02003053|DEVICE|Inspiratory Muscle Trainer|
58130422|NCT05146596|DEVICE|use low level light therapy,The Dr.Tai's energy cap|30 minutes each time, three times a week, a total of 12 times.
58130423|NCT02125266|DRUG|V404|Sustained Release
58130424|NCT00416481|BEHAVIORAL|quality of life questionnaires|
58130425|NCT00623207|DRUG|Atropine|I.V Atropine 0.5mg up to 2 mg
58130426|NCT01117610|DRUG|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
58130427|NCT01117610|DRUG|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
58130428|NCT01650922|PROCEDURE|phlebotomy|
58130429|NCT01650922|PROCEDURE|biopsy|
58130430|NCT04217447|DRUG|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
58130431|NCT04217447|DRUG|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
58130432|NCT04820803|OTHER|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
58130433|NCT04820803|OTHER|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
58130434|NCT03155984|DRUG|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
58130435|NCT02931318|BEHAVIORAL|Nevsehir|The data of the study were collected with the questionnaire
58130436|NCT05399264|BEHAVIORAL|Auditory-working memory training program|"The AT-WMT program is comprised of 1,200 daily used sentences either created or selected from newspapers, books, TV programs and magazines by the research assistants. The sentences are political-, cultural-, and religious-neutral sentences. Each of them contains 10 words. Noise was recorded from the upper and lower decks of a bus, in a café, a Chinese restaurant, an MTR (the Mass Transit Railway) carriage, and from a street.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
58130437|NCT05399264|BEHAVIORAL|Auditory training program|During the training, an adaptive speech-in-noise perception task will be administered. Specifically, the sentences in a sentence set will be presented binaurally using a headphone at a level the listeners felt is comfortable. The trainees are expected to immediately repeat each noise-masked sentence after hearing it. If they cannot repeat the sentence, then the sound intensity of the noise will be automatically decreased (step size = 2 dB) until the sentence can be correctly repeated. If the sentence can be repeated at the first attempt, then the intensity of the noise will be automatically increased by 2 dB in the next sentence. To provide feedback, the targeted sentence will be replaced by an asterisk and only shown after clicking the sentence.
58130438|NCT05399264|BEHAVIORAL|Mindfulness training program|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training.
58460258|NCT05729282|DRUG|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
58460259|NCT00148902|DRUG|lapatinib|lapatinib
58460260|NCT00148902|DRUG|docetaxel|docetaxel
57777442|NCT02320786|BEHAVIORAL|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
57777443|NCT05104918|DRUG|Vortioxetine|10 mg tablets
57777444|NCT05104918|DRUG|Venlafaxine|75 mg tablets
57777445|NCT03668730|RADIATION|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
57777446|NCT03668730|DRUG|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
57777447|NCT03668730|DRUG|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
57777448|NCT03668730|DRUG|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
57777449|NCT04199715|BIOLOGICAL|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
57777450|NCT05683522|OTHER|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
57777451|NCT05683522|OTHER|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
57777452|NCT05683522|OTHER|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
57777453|NCT02044419|DRUG|lomitapide|
57777454|NCT06100380|OTHER|Survey|Questionnaire
57777455|NCT04625647|DRUG|Sotorasib|Given PO
57777456|NCT05706181|OTHER|Home-based leg heat therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
57777457|NCT05706181|OTHER|Home-based sham therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
57777458|NCT05342116|OTHER|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
57777459|NCT05342116|OTHER|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
57777460|NCT01467258|DRUG|Amantadine|Single dose
57777461|NCT00719602|DRUG|Lamivudine|Taken orally twice daily
57777462|NCT00719602|DRUG|Lopinavir/Ritonavir|Taken orally twice daily
57777463|NCT00719602|DRUG|Nevirapine|Taken orally twice daily
57777464|NCT00719602|DRUG|Zidovudine|Taken orally twice daily
57777465|NCT02220335|PROCEDURE|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
58130439|NCT03682562|DIAGNOSTIC_TEST|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
57777466|NCT02220335|DRUG|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
57777467|NCT04610151|OTHER|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
57777468|NCT01039350|DRUG|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
57784454|NCT00688506|DEVICE|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
58460261|NCT03139760|BEHAVIORAL|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
58460262|NCT01863823|DRUG|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
58460263|NCT01863823|DRUG|Mouth washing|Two time washing mouth per day
57777469|NCT05859711|DRUG|thyme honey mouth rinse|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
57777470|NCT05859711|DRUG|saline mouth rinse|saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
58460264|NCT01828177|DRUG|PDI-320|
57777471|NCT03318211|DRUG|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
57777472|NCT02241720|DRUG|regorafenib|
57777473|NCT03615209|DEVICE|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
57777474|NCT03615209|DEVICE|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
57777475|NCT05372679|DEVICE|Renal denervation|The TIVUS system will be used for renal denervation
57777476|NCT02705040|OTHER|Normal|bone mineral density T\>=-1.0
57777477|NCT02705040|OTHER|Osteopenia|bone mineral density -1.0\>T\>=-2.5
57777478|NCT02705040|OTHER|Osteoporosis|bone mineral density T\<-2.5
57777479|NCT02774265|DRUG|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
57777480|NCT02774265|DRUG|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
57777481|NCT04543370|DRUG|Edasalonexent 2000 mg TID|CAT-1004 capsules
57777482|NCT04543370|DRUG|Midazolam 2 MG/ML|2 mg/ml syrup
57777483|NCT04543370|DRUG|Deflazacort 36Mg Tab|36 mg tablets
58460265|NCT01828177|DRUG|PDI-320 Monad #1|
57777484|NCT00861796|DRUG|CYR-101|Experimental arm
57777485|NCT00861796|DRUG|Placebo|Placebo comparator
57777486|NCT06189430|OTHER|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
57777487|NCT06189430|OTHER|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
57777488|NCT02874664|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
57777489|NCT05276323|DRUG|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
57777490|NCT05276323|DRUG|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
57777491|NCT05189509|DRUG|TNK-Tissue Plasminogen Activator|0.25 mg TNK thrombolysis
57777492|NCT04800757|BEHAVIORAL|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
58460266|NCT01828177|DRUG|PDI-320 Monad #2|
58460267|NCT01828177|DRUG|Vehicle|
58460268|NCT05905094|OTHER|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
58460269|NCT05866770|DEVICE|U8|The U8 Research System
58460270|NCT05866770|DEVICE|N8 sound processor|Nucleus 8 sound processor
58460271|NCT02174731|DRUG|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
58460272|NCT02174731|DRUG|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
58460273|NCT00097500|DRUG|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
58460274|NCT00097500|DRUG|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
58460275|NCT00097500|DRUG|Metformin|Patients usual dosage
58460276|NCT03095651|BIOLOGICAL|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
58460277|NCT03095651|BIOLOGICAL|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
58460278|NCT03095651|BIOLOGICAL|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
58460279|NCT03095651|BIOLOGICAL|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
58460280|NCT03095651|BIOLOGICAL|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
58460281|NCT03095651|BIOLOGICAL|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
58460282|NCT03095651|DRUG|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
58460283|NCT03095651|BIOLOGICAL|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
58130440|NCT05834283|OTHER|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
58130441|NCT05834283|OTHER|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
58130442|NCT00220337|DRUG|Lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
58130443|NCT04700826|DRUG|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
58130444|NCT04105881|DIETARY_SUPPLEMENT|Investigation|Cross sectional intervention
58130445|NCT01587222|DRUG|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
58130446|NCT01587222|DRUG|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
58130447|NCT01587222|DRUG|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
57777493|NCT04800757|BEHAVIORAL|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
58130448|NCT03772483|PROCEDURE|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
58130449|NCT03772483|DEVICE|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
58130450|NCT03711409|OTHER|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
58130451|NCT03711409|OTHER|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
58130452|NCT01485965|DRUG|SEN0014196|100 mg, immediate release tablets, once daily administration
58130453|NCT01610466|PROCEDURE|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
58130454|NCT04362397|BEHAVIORAL|FoCo|This is an attention, care and self-care training.
58130455|NCT04362397|BEHAVIORAL|No intervention|This is a waiting list
58130456|NCT02305966|PROCEDURE|surgery|All patients will receive a Delta XTEND reverse shoulder implant
58460284|NCT00287222|DRUG|Bevacizumab|15 mg/KG I.V. every 21 days
58460285|NCT00287222|DRUG|Erlotinib|150 mg orally every day
58130457|NCT02305966|DEVICE|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
58130458|NCT03083548|DIAGNOSTIC_TEST|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
58130459|NCT03083548|DIAGNOSTIC_TEST|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
58460286|NCT03723148|DRUG|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
58460287|NCT04362436|RADIATION|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
58460288|NCT01476722|DEVICE|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
58460289|NCT03920345|DEVICE|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
58130460|NCT03083548|DIAGNOSTIC_TEST|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
57777494|NCT04800757|BEHAVIORAL|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
57777495|NCT05542992|DIAGNOSTIC_TEST|CT-based deep learning model|CT-based deep learning model for pure-solid nodules classifications
57777496|NCT03137602|DEVICE|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
57777497|NCT00573950|DRUG|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
58130461|NCT04010799|DRUG|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
58130462|NCT04010799|DRUG|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
58460290|NCT03402542|PROCEDURE|Cholecystectomy|Cholecystectomy
57777498|NCT00573950|DRUG|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
57777499|NCT03881059|OTHER|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
58130463|NCT05617703|DRUG|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
58130464|NCT01636570|DRUG|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
58130465|NCT01636570|DRUG|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
58130466|NCT04071444|OTHER|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
58130467|NCT01492361|DRUG|AMR101|Parallel Assignment
58130468|NCT01492361|DRUG|Placebo|Parallel Assignment
58130469|NCT01492361|DRUG|Statin therapy|Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
58130470|NCT01491581|DIETARY_SUPPLEMENT|food bar|milk based food bar enriched with micronutrients
58130471|NCT04590378|OTHER|intensive care unit admission ratio|intensive care unit admission ratio
58130472|NCT03273322|DRUG|Rivaroxaban 10 mg qd|10mg qd
57777500|NCT03881059|DRUG|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
57777501|NCT03881059|DRUG|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
57777502|NCT03881059|DRUG|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
57777503|NCT03881059|OTHER|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
57777504|NCT00451217|DRUG|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
58130473|NCT03273322|DRUG|Rivaroxaban 15 mg qd|15mg qd
58130474|NCT03273322|DRUG|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
58130475|NCT00918567|DRUG|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
58130476|NCT00918567|BEHAVIORAL|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
58130477|NCT02917902|OTHER|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
58460291|NCT02528084|PROCEDURE|yoga|patients watch and follow an online yoga video.
58460292|NCT02528084|PROCEDURE|standard exercises|patients watch and follow an online standard exercises video.
57777505|NCT00451217|DRUG|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
57777506|NCT05299879|DIAGNOSTIC_TEST|Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization|Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
57777507|NCT01845948|BEHAVIORAL|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
58460293|NCT02577172|BEHAVIORAL|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
58130478|NCT04034576|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
58130479|NCT03062566|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
58130480|NCT05976399|OTHER|Connective Tissue Massage|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
58130481|NCT05976399|OTHER|Manual Lymph Drainage|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
58130482|NCT06148090|DIAGNOSTIC_TEST|clobetasol decreasing measurement|"At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month"
58130483|NCT02946125|COMBINATION_PRODUCT|MDD-administered EYN-1601|Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
58130484|NCT02946125|DRUG|Phenylephrine 2.5% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
58130485|NCT02946125|DRUG|Phenylephrine 10% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
58130486|NCT03652077|DRUG|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
58130487|NCT06317246|GENETIC|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
58130488|NCT00191932|DRUG|Duloxetine|
58130489|NCT04287426|DRUG|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
58130490|NCT04287426|DRUG|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
58130491|NCT00006174|DRUG|Letrozole|
57777508|NCT01845948|BEHAVIORAL|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
57777509|NCT05716737|RADIATION|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
57777510|NCT00664664|DRUG|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
57777511|NCT00664664|DRUG|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
57777512|NCT00664664|DRUG|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
57777513|NCT04827290|BEHAVIORAL|Low-AGE diet|Low-AGE diet during 24 months
58130492|NCT01475838|DRUG|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
57777514|NCT04827290|BEHAVIORAL|High-AGE diet|High-AGE diet during 24 months
57777515|NCT02743793|PROCEDURE|Blood Draw|
57777516|NCT02755454|DEVICE|Perfusion CT Imaging|
57777517|NCT04025203|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
57777518|NCT04025203|DRUG|Ibuprofen Arginine|Oral tablets
57777519|NCT04025203|DRUG|Gabapentin|oral capsules
58130493|NCT01475838|DRUG|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
57777520|NCT06092541|DRUG|Intervention Group: pericervical anesthesia|"Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours."
57777521|NCT06092541|OTHER|Nitroux Oxide anesthesia|Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
57777522|NCT03922802|DEVICE|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
57784455|NCT02688920|PROCEDURE|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
58130494|NCT01475838|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
58130495|NCT01475838|DRUG|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
58130496|NCT01502943|DRUG|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
58130497|NCT01502943|DRUG|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
58130498|NCT01502943|DRUG|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
58130499|NCT01502943|DRUG|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
58130500|NCT01502943|DRUG|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
58130501|NCT04909164|DRUG|Immunnotherapy group|Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
58130502|NCT01718639|DEVICE|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
58130503|NCT01718639|DEVICE|IQP-LH-101 liquid|Oral medical device in the form of a liquid
58130504|NCT01718639|OTHER|Placebo|
58130505|NCT04797403|BEHAVIORAL|Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
58130506|NCT02079532|DRUG|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
58130507|NCT05842538|DEVICE|Triathlon|Total knee arthroplasty
58130508|NCT06170866|BEHAVIORAL|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
58130509|NCT00970697|DRUG|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
58130510|NCT00970697|DRUG|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
58130511|NCT01975805|OTHER|Chlorhexidine Gluconate|
58130512|NCT01975805|OTHER|Povidone Iodine|
58130513|NCT03757364|DRUG|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
58460294|NCT02577172|BEHAVIORAL|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
58130514|NCT03055949|BEHAVIORAL|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
58130515|NCT00095381|DRUG|forodesine hydrochloride (BCX-1777)|
58130516|NCT02924948|PROCEDURE|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
58130517|NCT02829268|DRUG|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
58130518|NCT03239522|DRUG|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
58130519|NCT03239522|DRUG|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
58130520|NCT03239522|DRUG|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
58130521|NCT03165448|DIAGNOSTIC_TEST|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
58130522|NCT03165448|DIAGNOSTIC_TEST|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
58130523|NCT03165448|DIAGNOSTIC_TEST|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
58460295|NCT00655265|DRUG|Colesevelam hydrochloride film-coated tablets|tablets
58460296|NCT00655265|DRUG|Placebo|Tablets
58460297|NCT04714606|OTHER|Sibling support group|The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.
57777523|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
58130524|NCT03165448|DIAGNOSTIC_TEST|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
58130525|NCT01921920|DRUG|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
58130526|NCT02016170|DRUG|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
58130527|NCT02016170|DRUG|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
58130528|NCT02016170|DRUG|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
58130529|NCT04230226|DIETARY_SUPPLEMENT|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
58130530|NCT04230226|OTHER|Placebo|Placebo product consumed prior and after exercise
58130531|NCT03980483|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
58130532|NCT03980483|DRUG|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
58130533|NCT03980483|DRUG|Placebo|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
58130534|NCT03980483|DRUG|Placebo|Placebo cap (containing lactose) to be administered orally.
58130535|NCT01023074|BEHAVIORAL|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
58130536|NCT01023074|OTHER|MS: Control Activity|MS group not receiving auditory training, doing control activity
58130537|NCT02997800|DRUG|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
58130538|NCT02997800|DRUG|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
58130539|NCT02997800|DRUG|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
58130540|NCT02997800|OTHER|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
58130541|NCT02997800|OTHER|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
58130542|NCT04323202|DRUG|Pembrolizumab|Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)
58130543|NCT04323202|OTHER|Tissue collection|Non-marginal tissue as well as pre-op biopsy tissue to be stored
58130544|NCT05845996|DRUG|SAR441344|Solution for intravenous/subcutaneous injection
58130545|NCT05845996|DRUG|placebo|Solution for intravenous/subcutaneous injection
58130546|NCT05845996|BIOLOGICAL|Keyhole limpet hemocyanin|Subcutaneous Lyophilized powder for reconstitution
58130547|NCT04941248|DEVICE|total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)|This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
58130548|NCT01643707|BEHAVIORAL|Evidence based guidelines and tools|Education, guidelines, tools
58130549|NCT04630938|DRUG|Morphine Sulfate|intrathecal morphine will be added to anaesthetics
58130550|NCT04630938|DRUG|morphine+lidocaine|local anesthetic will be infused intravenously
58130551|NCT04630938|DRUG|Saline|intravenous saline infusion
58130552|NCT06256536|DRUG|GZR18|0.6 mg-30 mg
58130553|NCT06256536|OTHER|Placebo|administered the same volume as GZR18
58460298|NCT04714606|OTHER|None - control condition|The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
58130554|NCT03308019|DEVICE|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
58130555|NCT03308019|PROCEDURE|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
58130556|NCT01545076|BIOLOGICAL|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
58130557|NCT01545076|BIOLOGICAL|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
58130558|NCT01545076|BIOLOGICAL|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
58130559|NCT01545076|BIOLOGICAL|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
58130560|NCT06093997|OTHER|Massage treatment|The patient sits upright and the neck naturally relaxes. The doctor uses techniques such as pressing and kneading to relax the soft tissues of the neck, and massages points such as FengMen, FengChi, JingJiaji, JianJing,Tianzong and so on. The focus is on using muscle relaxation techniques around the soft tissues of spasms and pain areas to relax the patient's neck and shoulders. All procedures were performed from mild to severe, once a week for 15 minutes each time, for a total of 4 weeks of treatment.
58130561|NCT06093997|OTHER|Cupping|Use a 4-5cm diameter suction cupping for cupping. The treatment area is coated with glycerol, and the cupping is aspirated and adsorbed on the skin. The cupping is slowly pushed along the patient's neck, along the urinary bladder channel of Foot-Taiyang and governor's meridians from top to bottom, repeating back and forth 9 times. Once a week, for a total of 4 weeks of treatment.
58130562|NCT06093997|OTHER|Bloodletting|the doctor takes JianZhongShu, one on the left and one on the right, with a total of 2 acupoints. After disinfecting with 75% alcohol cotton balls, the patient is quickly pricked 5 times with a blood collection needle, and cupping is performed at the needle hole. After 5 minutes, remove the jar, wipe the blood clean, and disinfect the needle hole. Once a week, for a total of 4 weeks of treatment.
58130563|NCT03436680|OTHER|Best Practice|Receive standard of care
58130564|NCT03436680|BEHAVIORAL|Neurofeedback|Complete neurofeedback training sessions
58130565|NCT03436680|OTHER|Quality-of-Life Assessment|Ancillary studies
58130566|NCT03436680|OTHER|Questionnaire Administration|Ancillary studies
58130567|NCT00097695|DRUG|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
58130568|NCT00097695|DRUG|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
58130569|NCT04833998|DRUG|Extremecare|The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
58130570|NCT04833998|DRUG|Placebo|Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
58130571|NCT01439165|BIOLOGICAL|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
58130572|NCT01439165|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
58130573|NCT04217720|DRUG|SNS-301|SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
58130574|NCT06367829|PROCEDURE|Lubinus SPII hip stem 130mm|Shorter length of the SPII hip stem
58130575|NCT06367829|PROCEDURE|Lubinus SPII hip stem 150mm|Longer length of the SPII hip stem
58460299|NCT01968486|DRUG|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
58130576|NCT02146430|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
58130577|NCT02146430|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
58130578|NCT02146430|DRUG|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
58130579|NCT02146430|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
58130580|NCT05508100|BIOLOGICAL|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
58130581|NCT05508100|BIOLOGICAL|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
58130582|NCT05508100|BIOLOGICAL|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
58130583|NCT01880034|OTHER|Lipid Emulsion Survey|
58491310|NCT02928016|OTHER|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
57777524|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
57777525|NCT02926508|DIETARY_SUPPLEMENT|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
57777526|NCT02926508|OTHER|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
57777527|NCT01515345|DRUG|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
57777528|NCT01515345|DRUG|Clopidogrel|clopidogrel 75mg od for 12 month
57777529|NCT06321250|DRUG|JMKX003948|Subjects will receive JMKX003948 tablets until disease progression
57777530|NCT03147066|DRUG|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
57777531|NCT03147066|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
57777532|NCT01839357|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
57777533|NCT03241264|DRUG|ND-L02-s0201|Specified dose on specified day
57777534|NCT03953144|DEVICE|Synapse 3D Lung Modelling|The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
58130584|NCT03131180|OTHER|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
58130585|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
58130586|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
58130587|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
58130588|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
58130589|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
58130590|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
58130591|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
58130592|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
58130593|NCT00852436|DRUG|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
58130594|NCT00852436|DRUG|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
58130595|NCT02037997|DRUG|docetaxel|docetaxel 75mg/m2 ivgtt D1
58130596|NCT02037997|DRUG|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
58130597|NCT02037997|DRUG|Erlotinib|Erlotinib 150mg qd
58130598|NCT02395003|OTHER|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
58130599|NCT03724149|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
58130600|NCT03724149|DRUG|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
58130601|NCT04315857|OTHER|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
58130602|NCT03249064|DIAGNOSTIC_TEST|CD 91 levels|
58130603|NCT03249064|DIAGNOSTIC_TEST|Tregs|
58130604|NCT05703308|BIOLOGICAL|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
58130605|NCT00515203|DRUG|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
58130606|NCT00515203|DRUG|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
58130607|NCT05189184|DRUG|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
58130608|NCT04894747|DIETARY_SUPPLEMENT|Bolus ingestion of protein|Ingestion of 25g of protein
58130609|NCT01159548|DRUG|Promethazine|
58130610|NCT01159548|DRUG|Promethazine|
58130611|NCT01056770|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
58130612|NCT00733616|DRUG|DOX: Docetaxel, oxaliplatin, Capecitabine|"* Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
58130613|NCT04339465|BEHAVIORAL|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
58130614|NCT04339465|BEHAVIORAL|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
58130615|NCT02365207|DRUG|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
58130616|NCT02069626|PROCEDURE|compression time of the laparoscopic linear stapler|
58130617|NCT01659203|RADIATION|IG-IMPT|Daily, Monday-Friday for about 6 weeks
58130618|NCT01659203|RADIATION|IG IMRT|Daily, Monday-Friday for about 6 weeks
58130619|NCT03746353|PROCEDURE|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
58130620|NCT04652453|OTHER|Geriatrics Bundle|Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
58130621|NCT05865600|OTHER|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.
58130622|NCT05865600|DIAGNOSTIC_TEST|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
58130623|NCT05865600|DIAGNOSTIC_TEST|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
58460300|NCT01968486|DRUG|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
58130624|NCT05865600|OTHER|Standard of care|Standard of care
58130625|NCT00125424|DRUG|AQUAVAN® (fospropofol disodium) Injection|
58130626|NCT00125424|DRUG|Midazolam HCl|
58130627|NCT05896956|OTHER|no interventions|no interventions
58130628|NCT05228522|BEHAVIORAL|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
58130629|NCT04165538|PROCEDURE|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of \> 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
58130630|NCT01764438|PROCEDURE|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
58130631|NCT05825495|DRUG|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
58130632|NCT05825495|OTHER|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
58130633|NCT05133609|BIOLOGICAL|ChAdOx1 nCoV-19 vaccine (AZD1222)|ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
58130634|NCT01832701|OTHER|Coffee|coffee versus placebo
58130635|NCT01832701|OTHER|Placebo comparator|maltodextrine with caffeine
58130636|NCT03328780|DEVICE|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
58130637|NCT00098878|DRUG|carboplatin|
58138152|NCT03733197|BEHAVIORAL|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
58130638|NCT04835922|PROCEDURE|Intercostal Nerve Block|: Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)
58130639|NCT04835922|PROCEDURE|Peritract Infiltration|At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
58130640|NCT06131281|PROCEDURE|E-TORe|The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.
58130641|NCT06131281|PROCEDURE|c-TORe|The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
58130642|NCT03805438|DRUG|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
58130643|NCT04927533|OTHER|Ronnie Gardiner Method|"The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants."
58130644|NCT01464866|OTHER|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
58130645|NCT01464866|OTHER|Hospital food|Typical hospital food given daily at meals
58130646|NCT01976130|PROCEDURE|Bronchoscopy|
58130647|NCT02980978|BEHAVIORAL|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
58130648|NCT01887626|DRUG|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
58130649|NCT01887626|DRUG|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
58130650|NCT01887626|DRUG|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
58130651|NCT04946877|DIAGNOSTIC_TEST|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
58130652|NCT02607319|DRUG|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
58130653|NCT05616247|BEHAVIORAL|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
58130654|NCT05616247|BEHAVIORAL|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
58130655|NCT00002064|DRUG|Pyrimethamine|
58130656|NCT00002064|DRUG|Clindamycin|
58130657|NCT03080090|BEHAVIORAL|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
58130658|NCT03080090|BEHAVIORAL|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
58130659|NCT04856449|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.
58130660|NCT04856449|BEHAVIORAL|EMDR|EMDR sessions will be conducted to reprocess trauma-related memories.
58138153|NCT03733197|BEHAVIORAL|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
58138154|NCT04448106|BIOLOGICAL|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
58138155|NCT04607863|DIAGNOSTIC_TEST|Case control|Is a case-control research
57784456|NCT02593032|DEVICE|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
58130661|NCT05702567|DEVICE|RF + PFMT|"During each session the patient is lying face up, with knees bent and feet resting on the stretcher.~Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency. The device is started at 15% intensity and adapting to a 10-point Likert scale, at point 3 or 4 of intensity.~At the same time that the radiofrequency is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are three:~* 10 fast contractions of one second each, with 10 seconds of rest.~* 5 seconds of sustained contraction and 10 seconds of rest.~* 10 seconds of contraction maintained with 10 seconds of rest.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
58130662|NCT05702567|OTHER|PFMT + Placebo RF|"The intervention is exactly the same as the group RF + PFMT, unlike the non-functioning of the RF in the patients belonging to this group.~The patient is lying face up, with knees bent and feet resting on the stretcher. Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency, the device is started at 15% intensity, but in this case, the program does not work or apply radiofrequency to the patients.~At the same time, that the radiofrequency's probe is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are the three named in the Radiofrequency + PFMT.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
58130663|NCT04211818|BEHAVIORAL|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
58460301|NCT01968486|DRUG|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
58130664|NCT04211818|BIOLOGICAL|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
58130665|NCT06113653|OTHER|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
58460302|NCT05853016|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
58460303|NCT00149968|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
58460304|NCT00467246|DRUG|Levemir|
58460305|NCT02308956|BEHAVIORAL|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
58460306|NCT02308956|BEHAVIORAL|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
58130666|NCT05167357|BIOLOGICAL|COVID19|"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."
58130667|NCT02502253|DRUG|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
58130668|NCT02519322|BIOLOGICAL|Ipilimumab|Given IV
58130669|NCT02519322|OTHER|Laboratory Biomarker Analysis|Correlative studies
58130670|NCT02519322|BIOLOGICAL|Nivolumab|Given IV
58130671|NCT02519322|BIOLOGICAL|Relatlimab|Given IV
58130672|NCT02519322|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
58130673|NCT01166542|BIOLOGICAL|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
58130674|NCT01166542|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
58130675|NCT01166542|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
58130676|NCT01166542|DRUG|Placebo|Placebo
58130677|NCT05539820|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
58130678|NCT00146523|DRUG|Mifepristone|
58460307|NCT00701454|OTHER|No intervention|No intervention
58460308|NCT01754103|OTHER|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
57784457|NCT04636697|DRUG|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
58130679|NCT00146523|DRUG|placebo|
58460309|NCT02976337|DRUG|Naloxone|active drug infusion
58460310|NCT02976337|DRUG|Normal Saline|placebo comparator
58460311|NCT06276569|DRUG|Sivelestat|(1)Experimental group: Received intravenous sivelestat sodium within 6 hours of admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.
57784458|NCT04636697|BIOLOGICAL|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
57784459|NCT02382510|DRUG|TRN-157|
57784460|NCT02382510|OTHER|Placebo|
58460312|NCT06276569|OTHER|placebo|2)Control group: Receiving the same dose of placebo, 50 ml of saline, were administered intravenously at a rate of 0.2 mg/kg throughout the treatment period without any discernible impact on patient's regular treatment regimen.
58460313|NCT05372718|DRUG|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
58460314|NCT05372718|PROCEDURE|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
58460315|NCT04643808|DEVICE|transcutaneous auricular vagus nerve stimulation|Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
58460316|NCT04097431|BEHAVIORAL|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
58460317|NCT02425345|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
58460318|NCT04381858|DRUG|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction."
58460319|NCT04381858|DRUG|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
58460320|NCT00367575|PROCEDURE|Internet personalized alcohol feedback (PAF)|
58460321|NCT05514600|PROCEDURE|closure of parastomal hernia fascial defect|For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
58460322|NCT01323023|BEHAVIORAL|varies by project|
58460323|NCT04131023|BEHAVIORAL|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
58460324|NCT06276062|PROCEDURE|Distal radius fracture fixation in pediatrics.|using double short titanium elastic nails in treatment of pediatric distal radius fractures.
58460325|NCT05906030|DIAGNOSTIC_TEST|Diaphragm ultrasound|Diaphragm ultrasound will be used pre- and postoperatively. Diaphragm dysfunction will be diagnosed using the measurements diaphragm thickening fraction, diaphragm excursion and diaphragm density.
58460326|NCT05532644|OTHER|AD drugs|AD drugs
58460327|NCT01007903|BEHAVIORAL|Tai Chi exercise|12-week tai chi exercise class
58460328|NCT04614727|COMBINATION_PRODUCT|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
58460329|NCT00269971|DRUG|epoetin alfa|
58460330|NCT04529733|DEVICE|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
58460331|NCT03790566|DRUG|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
58460332|NCT03040141|DRUG|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
58460333|NCT03040141|DRUG|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
58460334|NCT03040141|DRUG|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
58460335|NCT00585481|PROCEDURE|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
58460336|NCT00585481|PROCEDURE|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
58460337|NCT04026321|DRUG|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
58460338|NCT04026321|DRUG|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
58460339|NCT04026321|DRUG|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
57784461|NCT02382510|DRUG|Tiotropium|
57784462|NCT00548275|BEHAVIORAL|Enhanced Sexual Risk Management|management of sexual risk
58460340|NCT04026321|DRUG|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
58460341|NCT04026321|DRUG|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
58460342|NCT00934453|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
58460343|NCT00934453|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
58460344|NCT00231426|DEVICE|ICD|
57784463|NCT00548275|BEHAVIORAL|Standard Sexual Risk Management|management of sexual risk
57784464|NCT01801384|BEHAVIORAL|Voucher-based incentives|
58460345|NCT00060645|DRUG|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
58460346|NCT02712346|DRUG|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
58460347|NCT02712346|DRUG|Placebo|One inactive pill daily for twelve weeks
58460348|NCT03382717|DEVICE|Excilor Forte|1 application per day during 6 months
58460349|NCT03382717|DRUG|Loceryl 5%|1 application per week during 6 months
58460350|NCT05683093|OTHER|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
58460351|NCT00829738|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
58460352|NCT02587741|DRUG|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
58460353|NCT02587741|DRUG|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
58460354|NCT02587741|DRUG|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
58460355|NCT01474525|DEVICE|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
58460356|NCT05093439|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
58460357|NCT00408122|PROCEDURE|PET/CT scan and EUS|
58460358|NCT06199934|BIOLOGICAL|Vaccination|BNT162b2 vaccination
58460359|NCT03305666|DRUG|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
58460360|NCT03305666|DRUG|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
57777535|NCT03953144|DRUG|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
57777536|NCT04221815|DEVICE|Eagle Eye Platinum digital IVUS catheter with optional SyncVision|IVUS catheter
57777537|NCT04221815|DEVICE|Resolute Onyx Drug Eluting Stent|Stent
57777538|NCT04221815|DEVICE|Onyx Frontier Drug Eluting Stent|Stent
57777539|NCT04221815|DEVICE|Onyx TruStar Drug Eluting Stent|Stent
57777540|NCT04221815|DEVICE|Onyx TruCor Drug Eluting Stent|Stent
58460361|NCT00659802|DRUG|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
58460362|NCT00659802|DRUG|Placebo|Matching dose of Placebo
57777541|NCT06022718|OTHER|Taping|Kinesio taping and Rigid taping was applied.
58460363|NCT00659802|DRUG|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
58460364|NCT00328939|DRUG|ARIXTRA infusion|
58460365|NCT00328939|DRUG|Enoxaparine infusion|
58460366|NCT02385929|BEHAVIORAL|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
58460367|NCT05604846|DIETARY_SUPPLEMENT|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
57777542|NCT05324501|DRUG|MTX110|Soluble panobinostat
57777543|NCT05324501|DEVICE|Programmable pump and catheter system|To allow Convection-Enhanced Delivery (CED)
57777544|NCT01945567|DEVICE|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
57777545|NCT01945567|DEVICE|Empirical unblinded deep brain stimulation programming|
58130680|NCT03527745|DRUG|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
58130681|NCT03527745|DRUG|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
58460368|NCT03870919|DRUG|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
58460369|NCT03870919|OTHER|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
58130682|NCT03527745|DRUG|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
58130683|NCT03527745|DRUG|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
58130684|NCT03527745|DRUG|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
58130685|NCT05739045|DRUG|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
58130686|NCT06257745|OTHER|Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019|Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
58130687|NCT04486196|DEVICE|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
58130688|NCT04486196|PROCEDURE|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
58130689|NCT05676866|PROCEDURE|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
58130690|NCT00368953|DEVICE|Yukon Choice stent system|coronary stent implantation
58130691|NCT00368953|DEVICE|Taxus Liberté stent system|coronary stent implantation
58130692|NCT00002595|DRUG|toremifene|
58130693|NCT00002595|PROCEDURE|conventional surgery|
58130694|NCT02849652|BEHAVIORAL|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
58130695|NCT02849652|BEHAVIORAL|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
58130696|NCT03765502|DEVICE|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
58130697|NCT03765502|DEVICE|GEK|Used to administer glucagon intramuscularly (IM)
58130698|NCT03765502|DRUG|IM Glucagon|Administered IM via GEK
58130699|NCT02450981|DRUG|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
58130700|NCT06433375|PROCEDURE|Non surgical debulking of periapical tissues|Non surgical debulking of periapical tissues
58130701|NCT06433375|PROCEDURE|Growth hormone application|Growth hormone application during non-surgical root canal treatment
58130702|NCT06433375|PROCEDURE|Non surgical debulking of periapical tissues with growth hormone application|Non-surgical debulking of periapical tissues with growth hormone application during non-surgical root canal treatment
58130703|NCT06433375|PROCEDURE|Root canal treatment|Teeth undergo conventional root canal treatment without any additional intervention
58130704|NCT03699644|DEVICE|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
58130705|NCT03699644|DEVICE|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
58460370|NCT01913561|DEVICE|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
58460371|NCT01913561|DEVICE|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
58460372|NCT06521710|PROCEDURE|Intraoperative Somatic-Autonomic Nerve Grafting|A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
58460373|NCT05587816|DEVICE|Validation of the PortionSize app|The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
58460374|NCT00866424|PROCEDURE|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
58130706|NCT03699644|DEVICE|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
58138156|NCT00283699|DRUG|albendazole|Active drug or placebo dosed bid p o for 8days
58138157|NCT00283699|OTHER|placebo|an inactive substance
58138158|NCT00537030|DRUG|Asparaginase|Given IM
58460375|NCT01285401|DRUG|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
58460376|NCT01285401|DRUG|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
58460377|NCT01285401|BIOLOGICAL|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
58460378|NCT00989001|DRUG|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
58460379|NCT00989001|DRUG|Placebo|Injection
58460380|NCT04924335|PROCEDURE|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
58460381|NCT00997035|DRUG|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
58460382|NCT00997035|DRUG|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
58460383|NCT05503836|PROCEDURE|abdominal surgeries|abdominal surgeries
58460384|NCT04397510|DRUG|Heparin|Nebulized Heparin
58460385|NCT04397510|DRUG|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
58460386|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
58460387|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
58460388|NCT03142386|OTHER|Osteopathic manipulative treatment|
58460389|NCT03142386|OTHER|Physiotherapy|
57777546|NCT03047174|OTHER|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
57777547|NCT03047174|OTHER|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
57777548|NCT04444375|DIAGNOSTIC_TEST|balance test|balance test
57777549|NCT00264472|DRUG|ADH300004|5 mg
58460390|NCT01766609|DRUG|Triamcinolone Acetonide|
58460391|NCT05868486|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58460392|NCT05868486|GENETIC|Genetic Testing for Cancer Risk|Undergo germline testing
58460393|NCT05868486|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy testing
58460394|NCT05868486|PROCEDURE|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
58460395|NCT05868486|OTHER|Survey Administration|Complete surveys
58460396|NCT03961334|DRUG|Dabigatran|150mg 2x/d
58460397|NCT03961334|DRUG|Apixaban|5mg 2x/d
58460398|NCT03961334|DRUG|Edoxaban|60mg 1x/d
58460399|NCT03961334|DRUG|Aspirin|100mg 1x/d
58460400|NCT03961334|DRUG|Clopidogrel|75mg 1x/d
58460401|NCT05632523|OTHER|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
57777550|NCT01776684|DRUG|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
57777551|NCT02796781|BIOLOGICAL|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
57777552|NCT00108121|DRUG|PEP005|
58460402|NCT05632523|OTHER|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
58460403|NCT05529108|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits everyday during intervention period.
57777553|NCT03760822|DRUG|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
57777554|NCT03760822|DRUG|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
57777555|NCT05895058|DEVICE|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
57777556|NCT05895058|DEVICE|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
58138159|NCT00537030|OTHER|Laboratory Biomarker Analysis|Correlative studies
58460404|NCT05529108|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
58460405|NCT05529108|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
58460406|NCT04146168|DIAGNOSTIC_TEST|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
58460407|NCT02973100|DRUG|Dulaglutide|Administered SC
58460408|NCT02973100|DRUG|Placebo|Administered SC
58460409|NCT00984477|DRUG|AZD5122|A single dose of oral suspension
58460410|NCT00984477|DRUG|Placebo|A single dose of oral suspension
58460411|NCT00984477|DRUG|AZD5122|A single intravenous infusion
58460412|NCT03607214|OTHER|Placebo|"Placebo nasal spray~Film Sequence"
58460413|NCT02282852|DEVICE|Wireless Capsule Endoscopy|
58460414|NCT02282852|DEVICE|Magnetically steerable capsule endoscopy|
58460415|NCT05842317|DRUG|Lenvatinib Plus Tislelizumab|Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
58460416|NCT05842317|DEVICE|Transarterial Chemoembolization(TACE)|A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
58460417|NCT02847962|OTHER|Corn Soy Blend Plus (CSB+)|
58460418|NCT02847962|OTHER|Corn Soy Blend 14 (CSB14)|
58460419|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 1|
58460420|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 2|
58460421|NCT02847962|OTHER|Red Sorghum Cowpea Blend|
58460422|NCT02847962|OTHER|White Sorghum Soy Blend|
58130707|NCT03699644|DIAGNOSTIC_TEST|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
58460423|NCT06187896|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
58460424|NCT06187896|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
58460425|NCT02517931|PROCEDURE|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
58460426|NCT02517931|PROCEDURE|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
58460427|NCT05409989|DEVICE|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
58460428|NCT01488604|DEVICE|Polymeric Nasal Spray|Experimental nasal spray
58130708|NCT03699644|DEVICE|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
58460429|NCT01488604|DEVICE|Sham Nasal Spray|Sham nasal spray
58460430|NCT04439136|DRUG|Afatinib Dimaleate|Given PO
58460431|NCT03667482|DRUG|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
58460432|NCT03667482|DRUG|Cetuximab|Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
58460433|NCT01419769|DEVICE|AXIOS Stent & Delivery System|"The AXIOS Stent \& Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
58460434|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
58130709|NCT00000949|DRUG|Aldesleukin|
58460435|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
58460436|NCT03196908|OTHER|Placebo|Lime juice, water, and cherry flavoring
58460437|NCT00011596|PROCEDURE|Gait Training|
58460438|NCT02463916|OTHER|Exercise|8 week structured exercise programme
58130710|NCT02787278|DRUG|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
58130711|NCT02787278|DRUG|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
58460439|NCT01640002|DRUG|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
58130712|NCT02787278|DRUG|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
57777557|NCT03100565|DRUG|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
57777558|NCT03100565|OTHER|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
58460440|NCT01640002|DRUG|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
58460441|NCT06523985|BEHAVIORAL|Push messages (standard)|Push messages will be developed based on best practice recruitment principles in cooperation with an external marketing team and then reviewed and finalized by the study team. Messages will be different each month and sent across 12 months. The monthly time frame was selected based on our need to balance contact with responders and research or expert opinions on push messaging saturation.
58460442|NCT06523985|BEHAVIORAL|Push messages (customized)|These messages are similar to content in the standard push messages but are customized to address common misperceptions about opioid overdose and naloxone.
58460443|NCT03217747|DRUG|Avelumab|Given IV
58460444|NCT03217747|BIOLOGICAL|Ivuxolimab|Given IV
58460445|NCT03217747|RADIATION|Radiation Therapy|Undergo radiation therapy
58460446|NCT03217747|BIOLOGICAL|Utomilumab|Given IV
58460447|NCT00208728|DEVICE|PC/SMART cardiopulmonary bypass circuit|
58460448|NCT00208728|DEVICE|PMEA modified cardiopulmonary bypass circuit|
58460449|NCT00208728|DEVICE|Standard of care uncoated cardiopulmonary bypass circuit|
58460450|NCT01559636|BIOLOGICAL|bivalent oral polio vaccine|vaccine given during immunization campaigns
58460451|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
58460452|NCT00768989|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
58460453|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
58460454|NCT00768989|DRUG|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
58460455|NCT00768989|DRUG|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
58460456|NCT04472611|DRUG|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
58460457|NCT02218684|DRUG|Telmisartan|
58460458|NCT02218684|DRUG|Lacidipine|
58460459|NCT02218684|DRUG|Placebo|
58460460|NCT00430469|DRUG|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
58460461|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
58460462|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
58460463|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
58460464|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
58460465|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
58130713|NCT02850770|BEHAVIORAL|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
58138160|NCT00537030|OTHER|Pharmacological Study|Correlative studies
58460466|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
58460467|NCT01998230|DIETARY_SUPPLEMENT|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
58460468|NCT05260268|BEHAVIORAL|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
58460469|NCT02318160|OTHER|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
58460470|NCT05081908|PROCEDURE|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
58460471|NCT05894460|DEVICE|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
58460472|NCT03874468|DEVICE|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
58460473|NCT04445935|DRUG|Bivalirudin Injection|The patients will receive iv Bivalirudin according to the institutional HIT protocol.
58460474|NCT04445935|DRUG|Standard treatment|This group will receive standard anticoagulation with LMWH/UFH
58460475|NCT03191617|DIETARY_SUPPLEMENT|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
58460476|NCT04826172|DRUG|IMB-1018972|Modified release (MR) oral tablet
58460477|NCT04826172|DRUG|Placebo|Matching oral tablet
58460478|NCT02470221|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
58460479|NCT02470221|OTHER|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
57777559|NCT03657381|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
57777560|NCT04537897|DRUG|BI 474121|BI474121
58460480|NCT04978896|DEVICE|Self-guided program on stress coping|This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.
58460481|NCT04978896|DEVICE|Self-guided program on cooperation|The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
58460482|NCT05085886|BEHAVIORAL|DepCare|Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.
58460483|NCT05085886|BEHAVIORAL|Enhanced Usual Care|Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
58460484|NCT01387828|PROCEDURE|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
58460485|NCT01387828|PROCEDURE|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
58460486|NCT04480320|PROCEDURE|pericapsular nerve group block|Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
58460487|NCT05244512|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
58460488|NCT05244512|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
58460489|NCT06208657|DRUG|Paxalisib, Irinotecan, Temozolomide|Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
58460490|NCT06208657|DRUG|Pimasertib|Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
58460491|NCT04694222|DEVICE|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
58460492|NCT03600909|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
58460493|NCT03600909|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
58460494|NCT03600909|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
58460495|NCT03600909|DRUG|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
58460496|NCT03600909|DEVICE|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
58460497|NCT03600909|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
58460498|NCT06353997|DRUG|Pembrolizumab|Drug will be delivered per standard-of-care as established by trial Keynote-522.
58460499|NCT06353997|DRUG|INBRX-106|INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
57777561|NCT04537897|DRUG|Midazolam|Midazolam
58130714|NCT02850770|BEHAVIORAL|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
58130715|NCT02850770|BEHAVIORAL|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
58130716|NCT04084483|DRUG|K-161|K-161 alternate dosage
57777562|NCT04537897|DRUG|Placebo|Placebo
57777563|NCT03406793|DIETARY_SUPPLEMENT|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
57777564|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
57777565|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
58460500|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snack with original level of sugar
58460501|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 2|Fruit snack with reduced level of sugar
58460502|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 3|Fruit snack with 0 added sugar - formulation 1
57777566|NCT03406793|DIETARY_SUPPLEMENT|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
57777567|NCT03406793|DIETARY_SUPPLEMENT|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
57777568|NCT03406793|DIETARY_SUPPLEMENT|Placebo powder|Daily provision of a placebo powder for 24 weeks.
57777569|NCT05155592|BIOLOGICAL|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
57777570|NCT03826134|DRUG|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
57777571|NCT04210193|DRUG|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
57777572|NCT04210193|DRUG|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
57777573|NCT02032173|DRUG|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
57777574|NCT03820791|DEVICE|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
57777575|NCT03656484|DRUG|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
57777576|NCT03656484|DRUG|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
57777577|NCT00243555|PROCEDURE|allergy skin testing|
57777578|NCT00243555|PROCEDURE|venepuncture|
57777579|NCT04418414|DRUG|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
57777580|NCT04418414|OTHER|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
57777581|NCT01680458|DRUG|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
57777582|NCT00896129|OTHER|HRQOL Survey Packet|Questionnaires
58130717|NCT04084483|OTHER|Placebo (Vehicle)|Placebo solution
58138161|NCT00986245|DRUG|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
58460503|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 4|Fruit snack with 0 added sugar - formulation 2
58460504|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 5|Fruit snack from raisins
58460505|NCT06458946|DIETARY_SUPPLEMENT|Confection control|confection
58460506|NCT05111860|DRUG|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
58460507|NCT00004652|DRUG|pimozide|
57777583|NCT05532020|DRUG|DCCR (diazoxide choline) extended-release tablets|All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
57777584|NCT05778331|PROCEDURE|Antagonist protocol for induction of ovulation|Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
57777585|NCT00183443|DRUG|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
57777586|NCT00183443|DRUG|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
57777587|NCT00183443|DRUG|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
57777588|NCT03246425|OTHER|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
57777589|NCT03246425|DEVICE|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
58138162|NCT02389491|DIETARY_SUPPLEMENT|normal density formula (Necocate)|In control group,there are 32 infants
58138163|NCT02389491|DIETARY_SUPPLEMENT|high density formula(Infatrini)|In intervention group,there are 32 infants
58460508|NCT04210648|DEVICE|Mobile app|Mobile app for self-managing emotional dysregulation
58460509|NCT04219774|PROCEDURE|Endovascular intervention|Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
58460510|NCT04219774|DRUG|Aspirin and Clopidogrel (maximal medical Therapy)|Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
57777590|NCT04455334|OTHER|Error-augmented treadmill training|walk on split-belt treadmill
57777591|NCT04455334|OTHER|active control group|walk on tie-belt treadmill
58130718|NCT06109103|PROCEDURE|telerehabilitation-based motor imagery training|"Motor imagery is defined as the mental thinking of a movement without actual movement being revealed. Many of the currently available physiotherapy and rehabilitation approaches are designed to stimulate damaged motor neural connections through neuroplasticity.~based on real movements. Studies have shown that similar brain regions are activated during motor imagery and real movement. By repeatedly visualizing the same movement, people can improve their motor activity skills such as lifting weights, playing the piano or performing surgery. These findings suggest that motor imagery provides motor learning by strengthening synaptic connections depending on activity."
58130719|NCT06109103|PROCEDURE|telerehabilitation-based physiotheraphy training|The telerehabilitation application will be carried out by video conference method, one of the image-based telerehabilitation technologies. The telerehabilitation-based physiotherapy program will be administered to both Group 1 and Group 2 children by a physiotherapist experienced in the physiotherapy of neuromuscular diseases, excluding the researchers who performed the randomization and evaluations.
58130720|NCT04008784|DRUG|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
58130721|NCT04008784|DRUG|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
58130722|NCT01362998|DRUG|Preservative free morphine|3mg given epidurally during the Cesarean section.
58130723|NCT01362998|DRUG|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
58130724|NCT02220868|DRUG|Sofosbuvir, Ribavirin, and Stribild|
58130725|NCT02550223|PROCEDURE|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
58130726|NCT03465566|DIAGNOSTIC_TEST|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
58130727|NCT00018252|BEHAVIORAL|exercise|
58130728|NCT06014437|DRUG|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
58130729|NCT06014437|DRUG|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
58130730|NCT01042483|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
58130731|NCT04997343|OTHER|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
58138164|NCT00000221|DRUG|Buprenorphine|
58138165|NCT02189941|DRUG|Deferiprone sustained-release|Deferiprone sustained-release tablets
58138166|NCT02189941|DRUG|Deferiprone immediate-release|Deferiprone immediate-release tablets
58460511|NCT04849208|OTHER|Presentation of fast and slow trials|"In each task trial participants will solve a reasoning problem. Half of the trials will be traditional Slow trials in which participants get ample time to deliberate (i.e., 20 s). The other half of the trials will be Fast trials in which people do not get sufficient time to deliberate (i.e., 4 s deadline) and need to rely on intuitive processing"
58460512|NCT03922581|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
58460513|NCT00831961|PROCEDURE|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
58460514|NCT05946655|DRUG|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
58460515|NCT02016781|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
58460516|NCT02016781|PROCEDURE|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
58460517|NCT03712943|DRUG|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
58460518|NCT03712943|DRUG|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
58138167|NCT05267691|PROCEDURE|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
57777592|NCT04455334|OTHER|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
57777593|NCT04455334|OTHER|conventional physical therapy group|conventional physical therapy
57777594|NCT04455334|OTHER|NO INTERVENTION|NO INTERVENTION
57777595|NCT02646306|OTHER|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
58460519|NCT04958824|DIAGNOSTIC_TEST|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
58460520|NCT02937337|DEVICE|Laryngeal mask insertion with videostylet guided technique|
58460521|NCT02937337|DEVICE|Laryngeal mask insertion with standard blind technique|
58460522|NCT00432484|DRUG|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
58460523|NCT03853330|DEVICE|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
58460524|NCT03853330|DRUG|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
58460525|NCT03853330|DRUG|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
58460526|NCT05441826|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
58460527|NCT04393675|DRUG|LT5001|Administered twice daily
58460528|NCT04393675|DRUG|Placebo|Administered twice daily
58460529|NCT01909895|OTHER|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
58460530|NCT01909895|OTHER|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
58460531|NCT01909895|OTHER|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
58460532|NCT01909895|OTHER|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
58460533|NCT00888693|DRUG|ABT-288|See Arm Description for details.
58460534|NCT00888693|DRUG|Placebo|See Arm Description for details.
58460535|NCT06523296|PROCEDURE|Adults with Alzheimer's disease|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
58460536|NCT06523296|PROCEDURE|Adults with Myasthenia|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
58460537|NCT06523296|OTHER|Healhty controls|Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
58460538|NCT00010400|DRUG|Cyclophosphamide|
58460539|NCT00010400|DRUG|filgrastim|
58460540|NCT06082206|PROCEDURE|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
58460541|NCT06082206|PROCEDURE|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
58460542|NCT06150950|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.
58460543|NCT06150950|OTHER|Usual care|For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.
58460544|NCT02021565|BEHAVIORAL|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
58460545|NCT02021565|OTHER|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
58460546|NCT05189743|PROCEDURE|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
58460547|NCT06413602|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
58460548|NCT06413602|OTHER|Neuromuscular Electrical Stimulation|During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
58460549|NCT06118385|DRUG|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
57777596|NCT04086979|BEHAVIORAL|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
58130732|NCT04997343|OTHER|clinical assessment|"Clinical evaluation, performed at each time point, will include:~* The assessment of clinical disability using EDSS score~* The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk \[T25FW\]), upper limbs (nine-hole peg test \[9HPT\]) and cognitive (three-second paced auditory serial addition test \[PASAT3\]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
58130733|NCT02621775|BEHAVIORAL|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
58130734|NCT02621775|BEHAVIORAL|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
58130735|NCT02621775|OTHER|Waiting list|The patients are followed by their General Practitioners without change in treatment .
58130736|NCT04745026|DRUG|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
58130737|NCT04745026|DRUG|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
58130738|NCT01076972|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
58130739|NCT01421706|DRUG|Sibutramine-clopidogrel|Sibutramine-clopidogrel
58130740|NCT01421706|DRUG|sibutramine-Clarithromycin|sibutramine-Clarithromycin
58130741|NCT03719222|OTHER|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
58130742|NCT01341366|OTHER|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
58130743|NCT01341366|OTHER|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
58130744|NCT03113006|PROCEDURE|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
58130745|NCT02687048|BEHAVIORAL|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
58130746|NCT02687048|BEHAVIORAL|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
58130747|NCT05666752|DIETARY_SUPPLEMENT|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
58130748|NCT05666752|DIETARY_SUPPLEMENT|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
58130749|NCT02975466|DEVICE|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
58130750|NCT02975466|DEVICE|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
58130751|NCT02975466|DEVICE|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
58130752|NCT03818802|DIETARY_SUPPLEMENT|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
58460550|NCT06118385|DRUG|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
58460551|NCT04760756|OTHER|Fragility Fracture Integrated Rehabilitation Management|"* At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)"
58460552|NCT04756765|DRUG|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
58460553|NCT05467592|OTHER|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
58460554|NCT01755364|BIOLOGICAL|AdimFlu-V|
58460555|NCT01994642|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
58460556|NCT01994642|DRUG|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
57777597|NCT04086979|BEHAVIORAL|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
58460557|NCT01994642|DRUG|Placebo Sterile Otic Suspension|
58460558|NCT00701285|DRUG|pitavastatin|pitavastatin 4mg once daily
58460559|NCT00701285|DRUG|pravastatin|pravastatin 10mg once daily
58460560|NCT05165160|DIAGNOSTIC_TEST|Blood sample|Pre- and postoperative blood sample
58460561|NCT03041688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58460562|NCT03041688|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58460563|NCT03041688|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58460564|NCT03041688|DRUG|Decitabine|Given IV
58460565|NCT03041688|DRUG|Navtemadlin|Given PO
58460566|NCT03041688|DRUG|Venetoclax|Given PO
58460567|NCT03212898|OTHER|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
58460568|NCT00435916|DRUG|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
58460569|NCT00651924|BEHAVIORAL|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
57777598|NCT00547105|DRUG|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
58130753|NCT03818802|DIETARY_SUPPLEMENT|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
58130754|NCT00060905|DRUG|Divalproex Sodium (Depakote ER)|
58460570|NCT00534326|PROCEDURE|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
58460571|NCT00534326|PROCEDURE|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
57777599|NCT00547105|RADIATION|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
57777600|NCT00649740|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
57777601|NCT00649740|DRUG|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
58460572|NCT03128515|DRUG|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
57777602|NCT06441825|OTHER|Increased multimodal observation including digital monitoring|Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
57777603|NCT01049074|OTHER|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
58460573|NCT04426734|DEVICE|Dextenza Dexamethasone Implant|The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.
58460574|NCT04426734|DRUG|Topical Prednisolone Acetate 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
58460575|NCT02263469|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
58460576|NCT03900494|DEVICE|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
58460577|NCT03900494|DEVICE|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
58460578|NCT00297219|DRUG|Low dialysate calcium|1.25 mmol/L dialysate calcium
58460579|NCT00297219|DRUG|high dialysate calcium|1.75 mmol/L dialysate calcium
58460580|NCT06435208|OTHER|Subgingival instrumentation|All the participants will undergo scaling and root planning with hand scalers, curettes and ultrasonic scaler.
58460581|NCT04346095|DRUG|Oral Sedatives with or Without Analgesia|The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
58460582|NCT04346095|DRUG|Intravenous Sedatives with or Without Analgesia|The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
58460583|NCT00461617|DRUG|Mitiglinide|10mg tablet, 10mg TID
58460584|NCT03441438|DIETARY_SUPPLEMENT|Water|Serum and urine markers will be obtained after drinking 5 oz of water
58460585|NCT03441438|DIETARY_SUPPLEMENT|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
58460586|NCT03441438|DIETARY_SUPPLEMENT|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
58460587|NCT00245323|BEHAVIORAL|Smoking status as a routine vital sign|
58460588|NCT04770532|DRUG|Insulin degludec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
58460589|NCT04770532|DRUG|Insulin Icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
58460590|NCT00407771|DRUG|Tirofiban|
58460591|NCT05072418|BEHAVIORAL|Eye-opened and Eye-closed|The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
58460592|NCT06302582|BIOLOGICAL|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm
58460593|NCT06302582|OTHER|Control group|Standard therapy for patients with stage 3 and 4 stress injury
58460594|NCT04604145|DIAGNOSTIC_TEST|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
58460595|NCT01936571|OTHER|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
58460596|NCT02990026|BEHAVIORAL|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
58460597|NCT04419831|DIAGNOSTIC_TEST|Yale Stress Pain Test (YSPT)|Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
58460598|NCT02745171|OTHER|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
58460599|NCT00002403|DRUG|Zintevir|
58460600|NCT02728115|BIOLOGICAL|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
58460601|NCT02728115|BIOLOGICAL|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
58460602|NCT01557153|DRUG|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
58460603|NCT01557153|DRUG|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
58460604|NCT06140602|OTHER|Intervention shake|The pecan shake contains 69g of pecans
57777604|NCT01049074|OTHER|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
58460605|NCT05724732|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
58460606|NCT05388786|BEHAVIORAL|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
58460607|NCT05830708|DIETARY_SUPPLEMENT|Lactobacillus sp. probiotic|The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
58491311|NCT02928016|OTHER|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
57777605|NCT00158522|DRUG|pegylated interferon alpha2a|
57777606|NCT03780595|DRUG|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
57777607|NCT03780595|DRUG|Control|Control pills administration up to 6 pills per day
58460608|NCT05830708|BEHAVIORAL|Acceptance and commitment therapy|The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
58460609|NCT05830708|DIETARY_SUPPLEMENT|Placebo|The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
58460610|NCT05544864|DEVICE|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
58460611|NCT05544864|DEVICE|Drug coated ballloon (DCB)|DCB angioplasty with any commercially available drug-coated balloon
58460612|NCT05118971|DIAGNOSTIC_TEST|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
58460613|NCT00434408|BEHAVIORAL|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
58460614|NCT00434408|BEHAVIORAL|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
58460615|NCT00434408|BEHAVIORAL|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
58460616|NCT05961267|BEHAVIORAL|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
58460617|NCT04970745|OTHER|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
58460618|NCT04970745|OTHER|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
58460619|NCT01166139|DRUG|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
58460620|NCT02634463|DRUG|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
58460621|NCT02634463|OTHER|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
58460622|NCT02634463|DRUG|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent \[eq.\] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
58460623|NCT02634463|DRUG|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
58460624|NCT04300985|DRUG|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
58460625|NCT04300985|DRUG|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
58460626|NCT04300985|DRUG|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
58460627|NCT05861076|OTHER|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
58460628|NCT05861076|OTHER|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
58460629|NCT05861076|OTHER|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
58460630|NCT03694561|OTHER|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
58460631|NCT00089596|PROCEDURE|Expansion of umbilical cord stem cells|
58460632|NCT04948216|OTHER|No intervention|No intervention
58460633|NCT03844776|DRUG|Co-Amoxiclav|amoxicillin + clavulanic acid orally
58460634|NCT03844776|DRUG|Paracetamol|paracetamol orally
58460635|NCT03844776|DRUG|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
58460636|NCT03844776|DRUG|Normal saline|0.9% normal saline irrigation
58460637|NCT03844776|DRUG|Amoxicillin 500 Mg|Amoxicillin 500 orally
58460638|NCT03844776|DRUG|Metronidazole|metronidazole 500 mg orally
58460639|NCT01204099|DRUG|Docetaxel|
58460640|NCT01204099|DRUG|PX-866|
58460641|NCT05113563|DEVICE|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
58460642|NCT04992572|DRUG|Propofol Injection|25mg Propofol administered by injection
58460643|NCT04992572|DRUG|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
58460644|NCT04998071|DRUG|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
58460645|NCT06404099|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
57777608|NCT04827563|DEVICE|EndoPAT|An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
57777609|NCT04827563|DEVICE|Blood Pressure Cuff|A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
57777610|NCT04827563|DIAGNOSTIC_TEST|Echocardiogram|A test used to conduct an ultrasound of participant's heart.
57777611|NCT04827563|OTHER|Quality of Life Assessment|A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
57777612|NCT04827563|OTHER|Blood Tests|Routinely collected for all participants who begin carfilzomib treatment.
57777613|NCT01428921|BEHAVIORAL|Theory based education and brief motivation interview|"* Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media."
57777614|NCT00011024|PROCEDURE|Self Hypnosis|
57777615|NCT00011024|PROCEDURE|Acupuncture|
57777616|NCT00011024|PROCEDURE|Osteopathic Manipulation|
57777617|NCT03675841|DRUG|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
57777618|NCT00609141|BIOLOGICAL|cixutumumab|Given IV
57777619|NCT00609141|OTHER|pharmacological study|Correlative studies
57777620|NCT00609141|OTHER|laboratory biomarker analysis|Correlative studies
57777621|NCT02248961|DRUG|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
57777622|NCT02248961|DRUG|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
57777623|NCT03954496|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
57777624|NCT03954496|BEHAVIORAL|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
57777625|NCT05139641|BEHAVIORAL|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
57777626|NCT04675112|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
57777627|NCT06231290|OTHER|Adult full pulpotomy procedure|The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
57777628|NCT03067103|DRUG|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
57777629|NCT03067103|DRUG|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
57777630|NCT03067103|DRUG|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
57777631|NCT01785628|DIETARY_SUPPLEMENT|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
57777632|NCT01785628|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo is dextrin composition.
57777633|NCT05275751|DRUG|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
57777634|NCT05275751|DRUG|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
57777635|NCT05275751|DRUG|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
57777636|NCT05275751|DRUG|Placebo|No pharmacological intervention
57777637|NCT05275751|DRUG|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
57777638|NCT00743587|DRUG|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
57777639|NCT00743587|DRUG|Oxycodone|Oral, 1 x 20mg controlled-release tablets
57777640|NCT00743587|DRUG|Tramadol|Oral, 2 x 50mg immediate release capsules
57777641|NCT00743587|DRUG|Naproxen|Oral, 1 x 500mg enteric-coated
57777642|NCT03159650|DEVICE|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
57777643|NCT03816891|DRUG|vixarelimab|solution for injection
57777644|NCT03816891|DRUG|Placebo|solution for injection
57777645|NCT00425217|DRUG|Rituximab|
57777646|NCT00345787|DRUG|Placebo|Corresponding placebo is applied for 12weeks
58460646|NCT06404099|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
58460647|NCT06404099|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
58460648|NCT06404099|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
58460649|NCT00930696|PROCEDURE|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
58460650|NCT00930696|PROCEDURE|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
58460651|NCT03855696|BIOLOGICAL|MG1113|MG1113
58460652|NCT03855696|OTHER|Placebo of MG1113|Placebo of MG1113
58460653|NCT01784991|DRUG|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
58460654|NCT01784991|DRUG|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
58460655|NCT02676414|BEHAVIORAL|Interactive hypertension education program of the DHL©|
57777647|NCT00345787|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
57777648|NCT00821132|OTHER|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
58460656|NCT06422377|DRUG|Soticlestat|Soticlestat tablets or mini-tablets
58460657|NCT02050113|DEVICE|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
58460658|NCT01415882|DRUG|Cyclophosphamide|Given PO
57777649|NCT04446910|BEHAVIORAL|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to promote attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
57777650|NCT04446910|BEHAVIORAL|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
58460659|NCT01415882|BIOLOGICAL|Daratumumab|Given IV
58460660|NCT01415882|DRUG|Dexamethasone|Given PO or IV
58460661|NCT01415882|DRUG|Ixazomib Citrate|Given PO
58460662|NCT01415882|OTHER|Laboratory Biomarker Analysis|Correlative studies
58460663|NCT03029806|OTHER|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
58460664|NCT03029806|OTHER|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
58460665|NCT03029806|OTHER|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
58460666|NCT06153134|DRUG|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
58460667|NCT06153134|DRUG|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
58460668|NCT01292135|DRUG|PCI-32765|420 mg daily
58460669|NCT00949182|DRUG|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
58460670|NCT00949182|OTHER|laboratory biomarker analysis|
58460671|NCT02254811|BIOLOGICAL|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
57777651|NCT03789643|DRUG|JTT-251|Active drug tablets containing JTT-251
57777652|NCT03789643|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
57777653|NCT03354520|BEHAVIORAL|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
57777654|NCT03354520|BEHAVIORAL|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
58460672|NCT05599750|PROCEDURE|Incisional hernia repair|Participants will undergo incisional hernia repair
58460673|NCT05477615|DRUG|Lazertinib|- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
58460674|NCT05477615|DRUG|Pemetrexed|- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
58460675|NCT05477615|DRUG|Carboplatin|- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
58460676|NCT01759043|PROCEDURE|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
58460677|NCT01759043|PROCEDURE|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
58460678|NCT06329908|DRUG|LG002|Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
58460679|NCT04283617|BEHAVIORAL|Intensification of insulin regimen/Nutrition|The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
58460680|NCT04936906|BEHAVIORAL|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
58460681|NCT04936906|OTHER|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
58460682|NCT06223711|RADIATION|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
58460683|NCT06223711|DRUG|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
58460684|NCT06223711|RADIATION|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
58460685|NCT06223711|DRUG|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
58460686|NCT03684863|DRUG|Capecitabine|observation
58460687|NCT00197314|BEHAVIORAL|circular muscle exercises versus pelvic floor exercises|
58460688|NCT04853758|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
58460689|NCT04853758|DRUG|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
58460690|NCT03402737|RADIATION|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy (day 1-4)~* 3x 6-8Gy (day 1-4-7)~* 3x 6-10Gy (day 1-4-7)~* 3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
58460691|NCT00923520|DRUG|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
58460692|NCT03762408|DEVICE|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
58460693|NCT03762408|DEVICE|Durolane|60 mg HA crosslinked in 3 ml
58460694|NCT03497065|PROCEDURE|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
58460695|NCT06385769|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|The TTNS will be conducted unilaterally, with the patient in a supine position, using a surface electrode dual stimulation channel stimulation device. Two self-adhesive round surface electrodes will be positioned with the negative electrode 2 cm behind the medial malleolus and the positive electrode 10 cm proximal to it. The ground electrode will be placed on the ipsilateral limb. Channel 1 will provide active stimulation, while channel 2 will remain inactive.
58460696|NCT06385769|OTHER|Sham Transcutaneous tibial nerve stimulation (TTNS)|Sham TTNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the TTNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
57777655|NCT03354520|BEHAVIORAL|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
57777656|NCT05754138|DEVICE|Sport SICD|Follow up
57777657|NCT03938948|DEVICE|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
58460697|NCT04486534|OTHER|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
58460698|NCT00263094|DRUG|Rofecoxib|
58460699|NCT01923506|RADIATION|stereotactic body radiation therapy|Undergo SBRT
58460700|NCT01923506|PROCEDURE|quality-of-life assessment|Ancillary studies
58460701|NCT01923506|OTHER|laboratory biomarker analysis|Correlative studies
58460702|NCT01434277|OTHER|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
57777658|NCT05913375|RADIATION|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
57777659|NCT00005973|DRUG|BMS-214662|Given IV
57777660|NCT00005973|OTHER|laboratory biomarker analysis|Correlative studies
58460703|NCT03293602|DEVICE|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
58460704|NCT06446401|DRUG|ADT + NHT + Docetaxel|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives the triple therapy, i.e. ADT, NHT and Docetaxel.
58460705|NCT06446401|DRUG|ADT + NHT|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.
58460706|NCT06169202|DEVICE|fruquintinib|4 mg orally once daily, D1-14, repeated every 3 weeks.
58460707|NCT06169202|DRUG|Irinotecan|180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
58460708|NCT06169202|DRUG|Capecitabine|1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
58460709|NCT03474614|DRUG|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
58460710|NCT03474614|GENETIC|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
58460711|NCT01273766|DRUG|deferasirox|Given orally
58460712|NCT01273766|OTHER|laboratory biomarker analysis|Correlative studies
58460713|NCT01273766|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58460714|NCT00426166|DEVICE|Low Level Laser Therapy|7500 megawatts with a 980 nm treatment beam every 48 hours for two weeks beginning at suture removal.
58460715|NCT02585401|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
58460716|NCT05262075|OTHER|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
58460717|NCT06217042|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|"Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks."
58460718|NCT06217042|DRUG|gemcitabine; capecitabine|Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
58460719|NCT03166917|PROCEDURE|3D printing implant|3D printing implants in bone defect
58460720|NCT03166917|PROCEDURE|autogenous bone grafting|3D printing implants in bone defect
58460721|NCT06457724|DIETARY_SUPPLEMENT|Levilactobacillus brevis CNCM I-5566|Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
58460722|NCT06457724|DIETARY_SUPPLEMENT|Placebo|Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
57777661|NCT03134378|DRUG|Rabeprazole Sodium 20mg|Twice daily
57777662|NCT03134378|DRUG|Clarithromycin 500mg|Twice daily
58460723|NCT06257550|BEHAVIORAL|THRIVE Intervention|"THRIVE Intervention includes:~1. Weekly Pulse Surveys~2. Adaptive culturally tailored messages~3. Personalized Dietitian Coaching~4. Produce Prescription FARMacy Mobile Market~5. Linkages to Social Services"
58460724|NCT06257550|BEHAVIORAL|Active Comparator|The Active Comparator arm will receive standard produce bags through our food is medicine partner, and will receive the linkages to needed social and health resources intervention components.
58460725|NCT02246725|OTHER|Contact with palliative care unit.|
58460726|NCT00211016|DRUG|doripenem|
58460727|NCT05041049|DEVICE|Comparing Visual Reality to High-fidelity mannequin Stimulation|"This is a prospective, randomized, non-inferiority study. VR will be compared to HFS, which will be considered the a priori gold standard for residents simulation training.~The study will be divided into two phases. In the pre-test phase, participants will be randomly allocated to receive either a VR or HFS scenario (scenario 1, see below). In the post-test phase, all participants (regardless the initial grouping) will undergo a HFS scenario (scenario 2, see below).~All scenarios have been chosen from critical events published by the Society of Pediatric Anesthesia48 and adult sources49.~The study will be conducted at the McGill University Health Center - Research Institute (MUHC-RI)."
57777663|NCT03134378|DRUG|Amoxicillin 500 Mg|Twice daily
57777664|NCT05886686|DEVICE|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
57777665|NCT01222611|DRUG|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
57777666|NCT04181541|PROCEDURE|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
57777667|NCT04181541|PROCEDURE|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
58460728|NCT00380237|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
58460729|NCT01739998|DIETARY_SUPPLEMENT|functional oil|
58460730|NCT01739998|DIETARY_SUPPLEMENT|Placebo|
58460731|NCT00210574|DRUG|topiramate|
58460732|NCT00473434|DRUG|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
58460733|NCT03433937|DEVICE|Negative pressure wound therapy|Wound dressing
58460734|NCT03433937|OTHER|Micropore tape|Wound dressing
57777668|NCT04205175|DRUG|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
57777669|NCT06526377|DRUG|Natrunix|Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.
57777670|NCT06526377|DRUG|Placebo|Placebo
57777671|NCT01993537|DRUG|Vitamin D|
57777672|NCT01718236|DRUG|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
57777673|NCT01718236|DRUG|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
57777674|NCT02397486|DRUG|Pentoxifylline|
57777675|NCT02397486|DRUG|Vitamin E|
57777676|NCT02397486|DRUG|Cisplatin|
57777677|NCT02397486|RADIATION|Radiation therapy|
57777678|NCT00002720|DRUG|tamoxifen citrate|
57777679|NCT00002720|PROCEDURE|conventional surgery|
57777680|NCT05172882|PROCEDURE|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
57777681|NCT05172882|PROCEDURE|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
57777682|NCT03786094|DRUG|Eribulin|Eribulin alone
57777683|NCT03786094|DRUG|Balixafortide|Balixafortide + Eribulin
57777684|NCT03450213|DEVICE|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
58460735|NCT03290846|DRUG|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
58460736|NCT03290846|DRUG|Saline Solution|Randomized, single-blinded saline infusion.
58460737|NCT03290846|OTHER|Cold exposure|All subjects will undergo a cold exposure PET scan.
58460738|NCT00594412|PROCEDURE|Diagnostic Radiology: 1H-MRS of the liver|
58460739|NCT03458338|DIAGNOSTIC_TEST|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
58460740|NCT03466385|DEVICE|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
58460741|NCT03466385|DEVICE|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
58460742|NCT02399215|OTHER|Laboratory Biomarker Analysis|Correlative studies
58460743|NCT02399215|DRUG|Nintedanib|Given PO
58460744|NCT02399215|OTHER|Pharmacological Study|Correlative studies
58460745|NCT02399215|OTHER|Quality-of-Life Assessment|Ancillary studies
58460746|NCT02547181|BEHAVIORAL|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
58460747|NCT02547181|BEHAVIORAL|Splint|fibreglass splint
58460748|NCT03869658|BEHAVIORAL|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
58460749|NCT01879111|OTHER|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
58460750|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
58460751|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
58460752|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
58460753|NCT04187898|BIOLOGICAL|Eflapegrastim|Administered in Cycles 1-4, 30 mins after TC chemotherapy.
58460754|NCT04187898|DRUG|Docetaxel|"75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
58460755|NCT04187898|DRUG|Cyclophosphamide|"600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
58460756|NCT03101280|DRUG|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
57777685|NCT02550132|PROCEDURE|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
58460757|NCT03101280|DRUG|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
58460758|NCT01596803|PROCEDURE|Taking of blood|Taking venous blood samples to analyse oxidant stress
58460759|NCT01596803|DIETARY_SUPPLEMENT|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
58460760|NCT01596803|DIETARY_SUPPLEMENT|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
58460761|NCT01596803|DIETARY_SUPPLEMENT|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
58460762|NCT04854018|DRUG|Indocyanine green|Intravenous or intraparenchymal injection
58460763|NCT01182636|DRUG|Adapalene|0.1% Topical Gel
58460764|NCT01182636|DRUG|Differin®|0.1% Topical Gel
58460765|NCT01182636|DRUG|Placebo|Gel Base
58460766|NCT05095636|DRUG|Apatinib Mesylate|oral Apatinib once everyday
58460767|NCT05095636|DRUG|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
58460768|NCT01762696|BEHAVIORAL|MET|Motivational Enhancement Therapy only
58460769|NCT01762696|BEHAVIORAL|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
58460770|NCT01383746|DEVICE|Yttrium microsphere injection|Radiation therapy
58460771|NCT00262496|DRUG|Botox|
58460772|NCT02763059|DRUG|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
58460773|NCT02763059|DRUG|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
58460774|NCT02763059|DRUG|Placebo|This group receives 1 hour before surgery placebo.
58460775|NCT02763059|DRUG|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
58460776|NCT04896086|OTHER|VRC-GENADJ0110-AP-NV|Adjuplex is an adjuvant, a sterile, pyrogen-free adjuvant solution produced by VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline at a pH of 6.5 plus or minus 0.3. Adjuplex adjuvant will be mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B, 6A-6B, and 8A-8B.
58460777|NCT04896086|BIOLOGICAL|Flucelvax|Flucelvax is a cell-based vaccine which contains the same four influenza strains selected by the WHO, and has shown better safety and immunogenicity profiles than the traditional licensed seasonal egg based vaccine.
58460778|NCT04896086|DRUG|VRC-FLUMOS0111-00-VP (FluMos-v1)|The VRC-FLUMOS0111-00-VP (FluMos-v1) vaccine is composed of engineered pentamer yeast C. albicans lumazine synthase assembled with 20 HA ectodomain trimers from the following influenza strains: Influenza A (H1: A/Idaho/07/2018, H3: A/Perth/1008/2019) and Influenza B (B/Victoria lineage: B/Colorado/06/2017, B/Yamagata lineage: B/Phuket/3073/2013)
58460779|NCT02529917|DIETARY_SUPPLEMENT|Hemp powder|Hemp powder supplement
58460780|NCT02529917|DIETARY_SUPPLEMENT|Soy Powder|Soy powder supplement
58460781|NCT04013308|PROCEDURE|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
58460782|NCT03913715|OTHER|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
58460783|NCT00207155|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
58460784|NCT04113850|DEVICE|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
58460785|NCT02455921|DRUG|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
58460786|NCT02455921|DRUG|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
58460787|NCT05625698|DRUG|MagTrace only|see information in arm descriptions
58460788|NCT05625698|COMBINATION_PRODUCT|MagTrace and Magseed|see information in arm descriptions
58491312|NCT02928016|OTHER|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
57777686|NCT02550132|DEVICE|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
57777687|NCT02870946|PROCEDURE|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
57777688|NCT02870946|PROCEDURE|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
57777689|NCT02640599|OTHER|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
57777690|NCT02640599|OTHER|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
57777691|NCT04285437|BEHAVIORAL|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
58130755|NCT06127498|BIOLOGICAL|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
58130756|NCT06127498|OTHER|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
58130757|NCT02786238|BEHAVIORAL|Standard Behavioral Treatment (SBT)|See description of treatment arm.
58130758|NCT02786238|BEHAVIORAL|Acceptance-Based Treatment (ABT)|See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
58130759|NCT00847548|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
58130760|NCT00847548|BEHAVIORAL|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
58130761|NCT05475353|BEHAVIORAL|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
58130762|NCT05475353|PROCEDURE|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
58130763|NCT01611389|DEVICE|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
58130764|NCT01611389|DEVICE|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
58130765|NCT04465409|DEVICE|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
58130766|NCT00331578|DEVICE|Excel drug-eluting coronary artery stent|
58130767|NCT01701726|OTHER|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
58130768|NCT01701726|OTHER|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
58130769|NCT01229852|DEVICE|DSF-rTMS|Effective Transcranial Magnetic Stimulation
58130770|NCT03535168|DRUG|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
58130771|NCT03535168|DRUG|Matching placebo|Matching placebo for BAY1902607
58130772|NCT03535168|DRUG|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
57777692|NCT02464111|OTHER|Treatment 1: Control|No supplement provided.
57777693|NCT02464111|DIETARY_SUPPLEMENT|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
58460789|NCT05847595|OTHER|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
58460790|NCT05847595|OTHER|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
58460791|NCT05847595|OTHER|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
58460792|NCT01766440|DRUG|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
58460793|NCT06219525|DIETARY_SUPPLEMENT|Higher dose of enteral zinc|Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
58460794|NCT06219525|DIETARY_SUPPLEMENT|Standard dose of enteral zinc|Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
58460795|NCT04420377|DIETARY_SUPPLEMENT|Carnipure|Supplement contains L-carnitine tartrate.
58460796|NCT04420377|OTHER|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
58130773|NCT03072680|BEHAVIORAL|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
58460797|NCT02757989|OTHER|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
58460798|NCT04730440|OTHER|AD-TAR|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
58460799|NCT04730440|OTHER|AD-Cognitive Stimulation|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
58460800|NCT06159088|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
58460801|NCT06159088|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
58460802|NCT06159088|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
58460803|NCT01468558|DRUG|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
58460804|NCT01468558|DRUG|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
58460805|NCT01468558|DRUG|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
58460806|NCT03572946|PROCEDURE|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
58460807|NCT03572946|PROCEDURE|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
58460808|NCT00382772|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
58460809|NCT05857735|OTHER|Observational registry with no intervention.|No intervention
58460810|NCT05697627|DEVICE|Computerized cognitive training (CCT) using EndeavorRx|"The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks"
58490187|NCT05363306|PROCEDURE|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
57777694|NCT02464111|DIETARY_SUPPLEMENT|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
57777695|NCT02912156|DRUG|Vaway FC Tablets 200mg (Voriconazole)|
58460811|NCT04976985|PROCEDURE|Osteopathic Manipulative Therapy (OMT)|"Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~1. Occipital- Alanto release~2. Muscle energy and soft tissue to mid trapezius muscle~3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~5. Soft tissue to cervical paraspinal muscles~6. Myo-fascial release of frontal forehead~7. CV4 cranial technique"
58460812|NCT04976985|OTHER|Standard of care|Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
58460813|NCT01950858|BIOLOGICAL|Weight reduction|
58460814|NCT04834180|DIETARY_SUPPLEMENT|Hypocaloric diet plan|The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
58460815|NCT04834180|OTHER|Auricular Acupuncture|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
58460816|NCT04834180|OTHER|Acupressure|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
58460817|NCT02350517|DRUG|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
58460818|NCT01393275|OTHER|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
58460819|NCT01393275|OTHER|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
58460820|NCT02361359|OTHER|Psychological questionnaires|
58460821|NCT02774460|DRUG|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
58460822|NCT02774460|DRUG|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
58460823|NCT02774460|DRUG|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
58460824|NCT02774460|DRUG|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
58460825|NCT02774460|DRUG|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
58460826|NCT02774460|DRUG|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
58460827|NCT02774460|DRUG|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
58460828|NCT00976846|DEVICE|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
58460829|NCT06394570|DRUG|Enfortumab vedotin|Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
58460830|NCT01784224|PROCEDURE|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
58460831|NCT00000376|BEHAVIORAL|Cognitive therapy|
58460832|NCT00000376|DRUG|Desipramine|
58460833|NCT01260493|OTHER|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
58460834|NCT03236896|BEHAVIORAL|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
58460835|NCT03236896|BEHAVIORAL|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
58460836|NCT03332381|BEHAVIORAL|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
58460837|NCT03332381|BEHAVIORAL|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
58460838|NCT02848820|DRUG|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
57777696|NCT02912156|DRUG|VFEND FC Tablets 200mg (Voriconazole)|
58460839|NCT02848820|PROCEDURE|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
58460840|NCT06553092|OTHER|Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey|The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
58460841|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Acute DVT
58460842|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Chronic DVT
58460843|NCT02244541|DRUG|ANAVEX2-73 Oral|
58460844|NCT02244541|DRUG|ANAVEX2-73 Intravenous|
58460845|NCT02244541|DRUG|ANAVEX2-73 Oral|30 mg hard gelatin capsule
58460846|NCT02244541|DRUG|ANAVEX2-73 Oral|50 mg hard gelatin capsule
58460847|NCT00952302|DRUG|Iron sucrose|Single intravenous infusion of iron 200 mg
58460848|NCT00952302|DRUG|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
58460849|NCT00952302|PROCEDURE|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
58460850|NCT00952302|DRUG|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
58460851|NCT00952302|DRUG|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
58460852|NCT02257593|OTHER|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
58460853|NCT04177706|DRUG|Ketamine Hydrochloride|Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
58460854|NCT04177706|DRUG|Placebo|Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
58460855|NCT05997602|DRUG|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
58460856|NCT03582215|DRUG|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
58460857|NCT03582215|DRUG|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
58460858|NCT03582215|DRUG|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
58460859|NCT03582215|DRUG|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
58460860|NCT03582215|DRUG|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
58460861|NCT03582215|DRUG|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
58460862|NCT03582215|DRUG|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
58460863|NCT03582215|DRUG|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
58460864|NCT06211608|DIAGNOSTIC_TEST|Two-dimensional and three-dimensional ultrasound of the female reproductive organ|Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer
58460865|NCT02096445|DEVICE|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
58460866|NCT02096445|OTHER|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
58460867|NCT00115570|DRUG|Insulin glulisine|Subcutaneous injection
58460868|NCT00115570|DRUG|insulin lispro|Subcutaneous injection
58460869|NCT00115570|DRUG|insulin glargine|Subcutaneous injection once daily
58460870|NCT00115570|DRUG|NPH insulin|subcutaneous injection twice daily
58460871|NCT02666781|OTHER|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
58460872|NCT02646826|OTHER|Placebo|Subjects are treated with Placebo tablets
58460873|NCT02646826|DRUG|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
58460874|NCT02646826|DRUG|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
58460875|NCT02646826|DRUG|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
58460876|NCT04033796|DIETARY_SUPPLEMENT|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);
58460877|NCT04033796|DIETARY_SUPPLEMENT|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);
58460878|NCT04033796|DIETARY_SUPPLEMENT|Placebo|A placebo (administered orally every two months) supplementation control group.
58460879|NCT00989911|DRUG|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
58460880|NCT05360069|DEVICE|Linear stapler|Linear stapler is adopted in esophagojejunostomy
58460881|NCT05360069|DEVICE|Circular stapler|Circular stapler is adopted in esophagojejunostomy
58460882|NCT02182622|DRUG|Docetaxel|
58460883|NCT02182622|DRUG|Prednisone|
58460884|NCT02182622|DRUG|LDE225|
58460885|NCT05246046|DRUG|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
58460886|NCT05314634|BEHAVIORAL|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
58460887|NCT05314634|BEHAVIORAL|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
58460888|NCT01387217|DRUG|GSK2018682|GSK2018682
58460889|NCT01387217|DRUG|Placebo|Matched Placebo
58460890|NCT03877276|DIETARY_SUPPLEMENT|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
58460891|NCT03877276|DIETARY_SUPPLEMENT|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
58460892|NCT03877276|DIETARY_SUPPLEMENT|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
58460893|NCT03877276|DIETARY_SUPPLEMENT|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
58460894|NCT03877276|DIETARY_SUPPLEMENT|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
58460895|NCT03877276|DIETARY_SUPPLEMENT|Sodium oxalate drink|a prepared sodium oxalate drink
57777697|NCT05140187|BIOLOGICAL|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10\^3/kg, 1×10\^5/kg, and 5×10\^5/kg CMV-TCR-T cells per dose.
58460896|NCT02723773|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
58460897|NCT01718288|DRUG|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
58460898|NCT01718288|DRUG|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
58460899|NCT00642356|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
58460900|NCT00642356|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
58460901|NCT02249338|DRUG|BIIL 284 BS|
58460902|NCT02249338|DRUG|Placebo|
58460903|NCT05193214|DRUG|Recombinant anti-PD-1 humanized monoclonal antibody injection|Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
58460904|NCT05535504|DEVICE|Low-frequency rTMS (experimental)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / Location: motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: tangential to scalp
58460905|NCT05535504|DEVICE|Low-frequency rTMS (sham comparator)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: vertical to scalp
58460906|NCT01274793|DRUG|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
58460907|NCT01274793|DEVICE|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
58460908|NCT01274793|DEVICE|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
58460909|NCT00127634|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
58460910|NCT00127634|DRUG|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
58460911|NCT00127634|DRUG|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
58460912|NCT05892224|PROCEDURE|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
58460913|NCT00397501|BIOLOGICAL|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
58460914|NCT00397501|DRUG|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
57777698|NCT03329313|DRUG|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
57777699|NCT03329313|DRUG|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
58460915|NCT00397501|DRUG|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
58460916|NCT00397501|DRUG|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
58460917|NCT03649542|OTHER|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
58460918|NCT01826396|DRUG|Irinotecan|Comparison of standard and high dose irinotecan
58460919|NCT00472108|RADIATION|Photodynamic Therapy (PDT)|
58460920|NCT00472108|DRUG|Metvix cream|
58460921|NCT00472108|DRUG|Placebo Cream|
58460922|NCT04388111|DRUG|Morphine|10mg of Morphine delivered Intraosseously
58460923|NCT02854046|OTHER|Calcific Uremic Arteriolopathy|
58490599|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
58460924|NCT00505271|GENETIC|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
58460925|NCT00956163|PROCEDURE|magnetic resonance imaging|Undergo whole-body MRI
58460926|NCT00956163|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
58460927|NCT00956163|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
58460928|NCT00956163|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
58460929|NCT00956163|RADIATION|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
58460930|NCT00956163|OTHER|laboratory biomarker analysis|Correlative studies
58130774|NCT03072680|BEHAVIORAL|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
58130775|NCT03072680|BEHAVIORAL|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
58130776|NCT03834805|OTHER|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
58130777|NCT04352361|DRUG|TVB-2640|TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
58130778|NCT04352361|DRUG|Placebo|Oral, matching number of placebo Tablets with active arm.
58130779|NCT05229757|OTHER|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
58130780|NCT05229757|OTHER|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
58130781|NCT06497153|PROCEDURE|lung ultrasound|lung ultrasound repeated according to protocol during the stay in the paediatric intensive care unit
58130782|NCT03204526|DEVICE|deep brain stimulation|
58130783|NCT03184441|DEVICE|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
58130784|NCT04460105|DRUG|Lanadelumab|Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
58130785|NCT04460105|OTHER|Placebo|Participants will receive placebo matching IV infusion on Day 1 and Day 4.
58130786|NCT02368405|BEHAVIORAL|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
58130787|NCT02368405|BEHAVIORAL|Eat Smart, Live Better|Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
58130788|NCT01513083|DRUG|trastuzumab emtansine|Multiple intravenous doses
58130789|NCT02720510|DRUG|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
58130790|NCT02720510|DRUG|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
58130791|NCT02720510|DRUG|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
58130792|NCT02720510|DRUG|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
58130793|NCT00755326|DRUG|HLXL|Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
58130794|NCT00197210|BIOLOGICAL|Rotavirus|
58130795|NCT02010762|DRUG|Vitamin D|25.000 IU oral drops
58130796|NCT02010762|DRUG|Placebo|placebo oral drops
58460931|NCT04595552|OTHER|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
58460932|NCT04703686|DRUG|Obinutuzumab|1000mg - prephase - one infusion at D-3
58460933|NCT04703686|DRUG|RO7082859|2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
58460934|NCT03042117|OTHER|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
58460935|NCT02953522|OTHER|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
58460936|NCT02953522|OTHER|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
58460937|NCT03636659|DRUG|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
58460938|NCT03636659|DRUG|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
58460939|NCT01609348|DRUG|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
58460940|NCT01609348|DRUG|Venlafaxine|225 mg daily for 12 weeks
58460941|NCT04645147|BIOLOGICAL|EBV gp350-Ferritin Vaccine|A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.
58460942|NCT04645147|OTHER|Matrix-M1|Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
58460943|NCT01611792|OTHER|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
58460944|NCT01611792|OTHER|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
58460945|NCT00339586|DRUG|Erlotinib|
58460946|NCT04077567|DRUG|TS-152|30mg,80mg
58460947|NCT03371836|DRUG|Clobazam|Clobazam is used as an adjunct medicine for all participants.
58460948|NCT03800095|DRUG|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
58460949|NCT04785495|OTHER|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
58460950|NCT05618522|PROCEDURE|vacuum-dehydrated amnion membrane (omnigen)|applying the lens loaded with Omnigen on the cornea
58460951|NCT05618522|DEVICE|the lens loaded with Omnigen|the lens loaded with Omnigen
58460952|NCT03122639|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
58460953|NCT03122639|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
58460954|NCT01556399|OTHER|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
58460955|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
58460956|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
58460957|NCT04004897|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
58460958|NCT01009541|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
58460959|NCT01009541|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
58460960|NCT01009541|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
58460961|NCT01009541|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
58460962|NCT03901170|DRUG|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
58460963|NCT01608711|BIOLOGICAL|AGS-1C4D4|Intravenous Infusion
58460964|NCT01608711|BIOLOGICAL|gemcitabine|Intravenous Infusion
58460965|NCT01188772|DRUG|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
58460966|NCT01188772|DRUG|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
58460967|NCT01188772|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
58460968|NCT01188772|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
58460969|NCT00811161|DEVICE|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
58460970|NCT04256694|DIAGNOSTIC_TEST|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
58460971|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 1
58460972|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 2
58460973|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 3
58460974|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 4
58460975|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 5
58460976|NCT04068896|BIOLOGICAL|NGM120|NGM120 Dose 6
58460977|NCT04068896|OTHER|Placebo|Placebo
58460978|NCT05306626|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
58460979|NCT06044025|DRUG|Metformin|Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
58460980|NCT06044025|DRUG|Turmeric|Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
58460981|NCT00359255|BEHAVIORAL|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
58460982|NCT00359255|BEHAVIORAL|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
58460983|NCT04446637|DRUG|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI|Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
58460984|NCT04446637|DRUG|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI|Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
58460985|NCT02250742|OTHER|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
58460986|NCT04361071|DEVICE|stent|stent
58460987|NCT04361071|DEVICE|plaque excision system|plaque excision system
58460988|NCT00591006|DRUG|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
58460989|NCT00591006|DRUG|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
58460990|NCT00591006|DRUG|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
58460991|NCT00141453|DRUG|olmesartan medoxomil|Tablets 10, 20, or 40 mg
58460992|NCT00141453|DRUG|Placebo Tablets|Matching placebo tablets
58460993|NCT04496817|OTHER|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
58460994|NCT04496817|OTHER|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
58460995|NCT01101217|DRUG|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
58460996|NCT01101217|DRUG|placebo|placebo daily for 6 weeks
57784465|NCT06201013|BEHAVIORAL|urotherapy|Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.
58460997|NCT03373578|DEVICE|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
58460998|NCT03359629|DEVICE|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
58460999|NCT03359629|DEVICE|YSI 2300 Stat Plus|Reference commercial glucometer
58461000|NCT03064802|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
58490600|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
58490601|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
57784466|NCT06201013|DRUG|Solifenacin Succinate|In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day
58461001|NCT03115359|BEHAVIORAL|Mindfulness Based Therapy|"The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
58461002|NCT03115359|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
58461003|NCT02832648|DIETARY_SUPPLEMENT|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
58461004|NCT05379088|BEHAVIORAL|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
58461005|NCT04148807|BEHAVIORAL|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
58461006|NCT04148807|BEHAVIORAL|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
58461007|NCT06376526|BIOLOGICAL|Linvoseltamab|"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"
58461008|NCT03354013|PROCEDURE|AOA|100% ICSI-AOA will be performed.
58461009|NCT03354013|DIAGNOSTIC_TEST|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
58461010|NCT03354013|DIAGNOSTIC_TEST|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
58461011|NCT03908034|OTHER|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
58461012|NCT03908034|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
58461013|NCT03560882|DRUG|Atorvastatin|Atorvastatin tablet, 80mg
58461014|NCT03397979|BEHAVIORAL|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
58461015|NCT02823509|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68_R84-089)
58461016|NCT06420804|DEVICE|ZIIP Acne Treatment Device|Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
58461017|NCT05248594|DRUG|HEMLIBRA|Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
58461018|NCT02122835|BEHAVIORAL|aerobic exercise training|12 weeks of supervised aerobic exercise training
58461019|NCT02758210|DEVICE|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
58461020|NCT02758210|DEVICE|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
58461021|NCT05633953|DRUG|Osilodrostat|oral administration
57784467|NCT06201013|DRUG|Vitamin D3|In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
57784468|NCT03615625|BEHAVIORAL|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
58461022|NCT05471765|DEVICE|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
58490602|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
58461023|NCT05471765|DEVICE|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
58461024|NCT00132743|DEVICE|Stent|Stent
57777700|NCT03952455|PROCEDURE|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
57777701|NCT04515563|BEHAVIORAL|Stretching exercise|Control Group
57777702|NCT04515563|BEHAVIORAL|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
57777703|NCT04515563|BEHAVIORAL|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
57777704|NCT04515563|BEHAVIORAL|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
57777705|NCT04515563|BEHAVIORAL|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
57777706|NCT01154049|BIOLOGICAL|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
57777707|NCT00519675|DRUG|alitretinoin|
57777708|NCT02167152|OTHER|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
57777709|NCT02953093|DRUG|Acarbose|see arm description
57777710|NCT02953093|OTHER|Placebo|See arm description
57777711|NCT00999973|DRUG|Mitomycin C 0.02%|
57777712|NCT00999973|DRUG|Placebo|
57777713|NCT02392767|DIETARY_SUPPLEMENT|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
57777714|NCT02392767|DIETARY_SUPPLEMENT|Placebo|corn starch
57777715|NCT02908854|OTHER|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
58461025|NCT00132743|BEHAVIORAL|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
58461026|NCT00132743|DRUG|Cilostazol|Cilostazol, 100 mg twice a day
57777716|NCT01372358|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
57777717|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
57777718|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
57777719|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
57777720|NCT02637050|OTHER|Standard of care|At the discretion of the attending physician.
57777721|NCT06106841|DRUG|400mg of TQB3909 tablets|TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
57777722|NCT06106841|DRUG|600mg of TQB3909 tablets|TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
57777723|NCT05918315|PROCEDURE|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
57777724|NCT01978275|DEVICE|stimulong 100, pajunk, germany|simulating catheter
57777725|NCT01978275|DEVICE|plexolong 100, pajunk, germany|nonstimulating catheter
57777726|NCT02698280|DRUG|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
57777727|NCT02698280|DRUG|Nimustine|Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
57777728|NCT04724720|DRUG|Famotidine|Standard or care treatment plus prescribed famotidine
57777729|NCT04724720|DRUG|Placebo|Standard of care treatment plus placebo
57777730|NCT02726776|OTHER|Suspension in a harness|
57777731|NCT02726776|OTHER|Climbing|
57777732|NCT00936494|PROCEDURE|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
57784469|NCT00577720|DRUG|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
57784470|NCT00577720|DRUG|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
58461027|NCT04982562|OTHER|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
58461028|NCT05213832|DRUG|Isoflurane Inhal Soln|Administration of isofluorane in patients with severe SAH
58461029|NCT00474123|DRUG|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
58461030|NCT00474123|DRUG|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
58461031|NCT02475590|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
58461032|NCT02475590|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
58461033|NCT04058444|COMBINATION_PRODUCT|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
58461034|NCT05219162|GENETIC|Gene Profile explore|The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.
57777733|NCT05853874|OTHER|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
57777734|NCT05853874|OTHER|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
57777735|NCT03414788|BIOLOGICAL|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
57777736|NCT03414788|BIOLOGICAL|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
57777737|NCT03868293|DEVICE|Focused ultrasound|Pulsed low intensity focused ultrasound
57777738|NCT02314221|DEVICE|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
57777739|NCT00781742|DRUG|AZD6765|IV once per dosing day, multiple times during the treatment period
57777740|NCT00781742|DRUG|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
57777741|NCT04213989|DEVICE|Flexitouch Plus and Conservative Care|A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
57777742|NCT04213989|OTHER|Conservative Care|May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
57777743|NCT05828225|DRUG|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
57777744|NCT01622101|DIETARY_SUPPLEMENT|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
57777745|NCT04024787|BEHAVIORAL|Cognitive-Behavioural therapy for insomnia (CBT-I)|"Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks."
58461035|NCT02359318|PROCEDURE|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
58461036|NCT02359318|PROCEDURE|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
57777746|NCT02810691|DIETARY_SUPPLEMENT|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
57777747|NCT02810691|DIETARY_SUPPLEMENT|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
57777748|NCT00124774|PROCEDURE|Nucleoplasty|
57777749|NCT00077350|DRUG|triapine|Given IV
57777750|NCT00077350|DRUG|gemcitabine hydrochloride|Given IV
57777751|NCT00077350|OTHER|laboratory biomarker analysis|Correlative studies
57777752|NCT00507741|DRUG|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
57777753|NCT00507741|DRUG|Ertafolide|
57777754|NCT06247670|DRUG|CMP-CPS-001|CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
57777755|NCT06247670|OTHER|Placebo|Placebo is 0.9% normal saline solution and will be administered subcutaneously.
57777756|NCT00259818|DRUG|EM-1421|
57777757|NCT01933347|DRUG|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
57777758|NCT05721573|DRUG|ABC008|Given by subcutaneous injection
58461037|NCT01517750|DEVICE|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
58461038|NCT01517750|DEVICE|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
58461039|NCT04481412|DRUG|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
58461040|NCT04481412|DRUG|Placebo|96% ethanol that will be applied once daily.
58461041|NCT04481412|DRUG|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
58461042|NCT01793428|OTHER|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
58461043|NCT00346216|DRUG|celecoxib|100 to 200 mg twice daily, taken by mouth
58461044|NCT00346216|DRUG|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
58461045|NCT00346216|DRUG|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
58461046|NCT04233801|DRUG|Empagliflozin|Empagliflozin
58461047|NCT04233801|DRUG|Placebo|Placebo
58461048|NCT04239001|DRUG|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
58461049|NCT00948753|DRUG|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
58461050|NCT00948753|DRUG|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
58461051|NCT00948753|DRUG|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
58461052|NCT05383469|OTHER|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
58461053|NCT05383469|OTHER|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
58461054|NCT05383469|OTHER|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
57777759|NCT00287248|DRUG|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
57777760|NCT00736073|DRUG|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
58461055|NCT05383469|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
58461056|NCT01381016|DRUG|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
58461057|NCT01381016|DRUG|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
57777761|NCT00736073|DRUG|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
58461058|NCT01381016|DRUG|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
58461059|NCT06427213|DRUG|Zanubrutinib,Obinutuzumab|"Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease； Obinutuzumab ：Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks，up to 20 doses. 1 cycle = 28 days.~Maintenance: Zanubrutinib, 160mg PO BID"
58461060|NCT06427213|DRUG|Zanubrutinib and R-BAC|"Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression"
58461061|NCT03693703|DIAGNOSTIC_TEST|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
58461062|NCT03693703|DIAGNOSTIC_TEST|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
57777762|NCT05955456|OTHER|No intervention|No intervention is applied to participants. The risk calculator score is not released to the participants or care providers. Participants are followed up for risk calculator accuracy and recalibration.
57777763|NCT06359600|DRUG|HS-10501 tablet|Administered orally
57777764|NCT06359600|DRUG|Placebo|Administered orally
57777765|NCT01620736|DRUG|Raltegravir|Raltegravir 400 mg po bid
57777766|NCT02984956|DEVICE|pleth variability index|
58461063|NCT02738801|DRUG|GLPG1690 600 mg QD|GLPG1690 capsules, administered at a dose of 600 mg, orally QD
58461064|NCT02738801|DRUG|Placebo QD|Matching placebo capsules, administered orally QD
58461065|NCT05416333|DRUG|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
58461066|NCT05416333|OTHER|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
58461067|NCT04350632|DIAGNOSTIC_TEST|Shear wave elastography assessment of the external anal sphincter|"Assessment of the external anal sphincter viscoelastic properties using shear wave elastography technology~* Women in lithotomy position with an empty bladder~* The linear probe is applied on transversal plane on the perineal with a transperineal approach~* The external anal sphincter will be identified in 2D ultrasound using a SL 18-5 linear probe~* Viscoelastic properties of the muscle will be assessed by measuring the shear modulus at rest, Valsalva maneuver and contraction~* Exactly the same investigations will be performed for the two visits planned in the protocol. In the first visit, it will be one single observer and for the second it will be 2 observers.~* Data about the mode of delivery and the occurrence of OASI will be collected into women's medical fil"
58461068|NCT04190602|DEVICE|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
58461069|NCT05195307|OTHER|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
58461070|NCT04739644|DEVICE|Specific wrist rehabilitation by WRISTBOT device|The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
58461071|NCT04739644|OTHER|Specific wrist rehabilitation performed by the physiotherapist|Passive, active and assisted mobilization
58461072|NCT04739644|OTHER|General rehabilitation|Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
58461073|NCT03164486|DRUG|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
58461074|NCT00723996|BEHAVIORAL|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
58461075|NCT00431990|DRUG|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
58461076|NCT00431990|DRUG|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
58461077|NCT00431990|DRUG|dexamethasone|20mg for 2 days with each dose of bortezomib
58461078|NCT03519074|DRUG|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
58461079|NCT00181896|DRUG|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
58461080|NCT06429150|BIOLOGICAL|CAR-T cells|Infusion of multi-CAR-T cells
58461081|NCT02333461|DIETARY_SUPPLEMENT|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
58461082|NCT02333461|DIETARY_SUPPLEMENT|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
58461083|NCT02333461|DIETARY_SUPPLEMENT|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
58461084|NCT02333461|DIETARY_SUPPLEMENT|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
58461085|NCT02333461|DIETARY_SUPPLEMENT|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
58461086|NCT00132574|BEHAVIORAL|Minimization of milk and dairy products in the diet|
58461087|NCT00096902|PROCEDURE|Tilt table test|
58461088|NCT00146094|PROCEDURE|BMD Measurement|
57784471|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
58138172|NCT01516983|DRUG|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
58461089|NCT00837902|DRUG|Atenolol (β-blocker)|25 mg tablet
58461090|NCT05476445|PROCEDURE|Control|Root canal treatment
58461091|NCT05476445|PROCEDURE|Laser|Root canal treatment+Laser application
58461092|NCT05476445|PROCEDURE|Cryotherapy|Root canal treatment + Cryotherapy application
58461093|NCT05246917|PROCEDURE|Handsewn anastomosis|To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
58461094|NCT01155713|DRUG|TKI258|
58461095|NCT05958901|OTHER|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
58461096|NCT03314493|DRUG|Spironolactone 25Mg Tablet|Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
58461097|NCT05269914|OTHER|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
58461098|NCT05355571|DIETARY_SUPPLEMENT|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
58461099|NCT05355571|DIETARY_SUPPLEMENT|Placebo|Placebo
58461100|NCT03947619|DEVICE|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
58461101|NCT02324946|OTHER|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
58461102|NCT06353178|BEHAVIORAL|Cancer Connect Program|Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.
57784472|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
58461103|NCT00333125|DRUG|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
58461104|NCT00333125|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
58461105|NCT00333125|OTHER|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
58461106|NCT05899153|DEVICE|Biomotum Spark: Robotic ankle resistance|Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.
58461107|NCT05899153|DEVICE|Audiovisual Biofeedback|Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
58461108|NCT05035524|DRUG|Sodium Bicarbonate Solution|Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
58461109|NCT05035524|DRUG|Placebo|Placebo
58461110|NCT04743362|DIAGNOSTIC_TEST|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
58461111|NCT04743362|DIAGNOSTIC_TEST|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
58461112|NCT04743362|DIAGNOSTIC_TEST|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
58461113|NCT04743362|DIAGNOSTIC_TEST|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
58461114|NCT04743362|DIAGNOSTIC_TEST|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
58461115|NCT04743362|DIAGNOSTIC_TEST|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
58461116|NCT04743362|DIAGNOSTIC_TEST|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
58461117|NCT04743362|DIAGNOSTIC_TEST|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
58461118|NCT04903210|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide supplied as 400mg capsule|NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
58461119|NCT04903210|BEHAVIORAL|Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
58461120|NCT04309292|DIETARY_SUPPLEMENT|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
58461121|NCT04309292|DIETARY_SUPPLEMENT|Protein supplement|commercially available protein supplementation with high leucine content
58461122|NCT04309292|DIETARY_SUPPLEMENT|Maltrodextrin (placebo)|Starchy substance
58461123|NCT04835311|PROCEDURE|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
57777767|NCT02384005|OTHER|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
57777768|NCT03108287|DRUG|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
57777769|NCT03108287|DRUG|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
57784473|NCT03658629|BIOLOGICAL|NanoFlu (Quad-NIV)|2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
57784474|NCT03658629|OTHER|Matrix-M Adjuvant|Adjuvant
57784475|NCT03658629|OTHER|Placebo|Placebo
58461124|NCT02337413|DRUG|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
58461125|NCT02337413|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
58461126|NCT02337413|BEHAVIORAL|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
58461127|NCT02253914|DRUG|BILR 355 BS, solution|
58461128|NCT02253914|DRUG|BILR 355 BS, tablet|
58461129|NCT02253914|DRUG|Ritonavir|
58461130|NCT02253914|DRUG|Placebo|
58461131|NCT02666872|BEHAVIORAL|Motivational interviewing|
58461132|NCT01526499|DRUG|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
58461133|NCT01526499|DRUG|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
57777770|NCT04430296|PROCEDURE|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
58461134|NCT06345716|DRUG|paracétamol tramadol|Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
58461135|NCT06345716|DRUG|Paracétamol cafeine|Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
58461136|NCT06345716|DRUG|Placebo|Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
58461137|NCT00884364|OTHER|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
58461138|NCT00884364|BEHAVIORAL|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
58461139|NCT03111238|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
58461140|NCT03111238|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
58461141|NCT01245309|PROCEDURE|scratching|endometrial scratching before COH in IVF
58461142|NCT01245309|PROCEDURE|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
58461143|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
58461144|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
58461145|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
58461146|NCT00605852|DRUG|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
58461147|NCT00605852|DRUG|Placebo|Placebo will be given to subjects.
58461148|NCT03316092|DIAGNOSTIC_TEST|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
58461149|NCT01810770|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
57777771|NCT03069820|DRUG|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
57777772|NCT04768933|DIETARY_SUPPLEMENT|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
57784476|NCT03658629|BIOLOGICAL|Fluzone HD|2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
58138173|NCT01516983|RADIATION|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
58461150|NCT05691595|OTHER|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
58461151|NCT03534609|DEVICE|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
58461152|NCT06023394|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
58461153|NCT06023394|DEVICE|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
58461154|NCT02326285|DRUG|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
58461155|NCT02326285|DRUG|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
58461156|NCT02326285|DRUG|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
58461157|NCT02326285|PROCEDURE|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
58461158|NCT03287791|DRUG|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
58461159|NCT03287791|DRUG|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
58461160|NCT03287791|DRUG|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
58461161|NCT03287791|OTHER|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
58461162|NCT03287791|OTHER|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
58461163|NCT03287791|OTHER|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
58461164|NCT03287791|OTHER|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
58461165|NCT04275323|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
58461166|NCT04275323|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
58461167|NCT01156662|DEVICE|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
58461168|NCT01156662|DEVICE|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
58461169|NCT02893917|DRUG|Cediranib|Given PO
58461170|NCT02893917|DRUG|Olaparib|Given PO
58461171|NCT05690984|DRUG|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
58461172|NCT05690984|DRUG|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
58461173|NCT05690984|DRUG|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
58461174|NCT05640323|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
58461175|NCT03974048|DIAGNOSTIC_TEST|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
58461176|NCT05161897|OTHER|Individualized Nutrition Therapy|Explained in arm/group description.
58461177|NCT04069559|OTHER|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
58461178|NCT04423718|DRUG|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
58461179|NCT04423718|DRUG|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
58461180|NCT01648712|DEVICE|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
58461181|NCT01648712|DEVICE|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
58461182|NCT06446817|DEVICE|LuxHighAdd IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
58461183|NCT06446817|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
58461184|NCT05765422|OTHER|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
58461185|NCT01615250|BIOLOGICAL|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
58461186|NCT03253393|DEVICE|Smart Touch Technology packaging|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
58461187|NCT03253393|DEVICE|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
58461188|NCT03253393|DEVICE|EDTA|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
57777773|NCT05980429|OTHER|Music Therapy, prescribed|"All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group."
57777774|NCT05980429|OTHER|Music Therapy, self-selected|All music pieces were self-selected by the participant
57777775|NCT05406037|BIOLOGICAL|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
58461189|NCT05611671|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
57777776|NCT03172741|DRUG|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
58461190|NCT05611671|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
58461191|NCT06152302|OTHER|Mobility study in dry conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.
58461192|NCT06152302|OTHER|Mobility study in water conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
58461193|NCT04662567|DRUG|acetaminophen|compare the postoperative pain 1 hour and \~24h post surgery
58461194|NCT01124110|BEHAVIORAL|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
58461195|NCT01124110|OTHER|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
58461196|NCT01449162|DRUG|Masitinib|6 mg/kg/day
58461197|NCT01449162|DRUG|Placebo|
58461198|NCT02126722|PROCEDURE|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
58461199|NCT02126722|DEVICE|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
58461200|NCT02126722|OTHER|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
58461201|NCT02126722|OTHER|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
58461202|NCT02326623|OTHER|distraction|distraction using an iPad with a selection of child-appropriate games
58461203|NCT02326623|OTHER|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
57777777|NCT03172741|DRUG|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
57777778|NCT00079794|DRUG|Iscar|
57777779|NCT00079794|DRUG|mistletoe|
58461204|NCT03488095|BEHAVIORAL|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
58461205|NCT06408870|DRUG|BI 1015550|BI 1015550
58461206|NCT06398210|OTHER|Cognitive Exercise Therapy Approach (BETY)|Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.
58461207|NCT00445549|DRUG|Vandetanib|300 mg daily dose, 28 day cycle
58461208|NCT06068868|DRUG|ABBV-787|Intravenous (IV) Infusion
58461209|NCT02560038|DRUG|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
58461210|NCT02560038|DRUG|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
58461211|NCT02560038|DRUG|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
58461212|NCT05440877|BEHAVIORAL|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
58461213|NCT05440877|BEHAVIORAL|Tutorial guide|A tutorial guide including description of the smokers' cases
58461214|NCT05574296|DRUG|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
58461215|NCT05574296|OTHER|Usual care|Usual care post-ECPR event, including targeted temperature management.
58461216|NCT04049708|OTHER|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
58461217|NCT04836468|DIAGNOSTIC_TEST|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
58461218|NCT03393585|OTHER|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
58461219|NCT02558725|DRUG|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
58461220|NCT01849510|RADIATION|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT
58461221|NCT01849510|RADIATION|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
58461222|NCT03313869|DIETARY_SUPPLEMENT|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
57777780|NCT06195124|DRUG|RGL-193（low-dose）|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.
58461223|NCT03313869|DIETARY_SUPPLEMENT|control diet|habitual diet to be followed
58461224|NCT06061991|BEHAVIORAL|Mobile instant messaging-based lifestyle intervention|Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.
57777781|NCT06195124|DRUG|RGL-193（high-dose）|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
58461225|NCT06061991|BEHAVIORAL|Text messaging reminders|Follow-up reminders via text messaging as attention control.
58461226|NCT06061991|BEHAVIORAL|Brief advice on GDM prevention|Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy
58461227|NCT06061991|BEHAVIORAL|Usual care|Usual care provided by the prenatal clinic.
58461228|NCT02782676|DEVICE|Investigational Healon5 OVD|ophthalmic viscosurgical device
58461229|NCT02782676|DEVICE|Healon5 OVD|ophthalmic viscosurgical device
58461230|NCT00058396|BIOLOGICAL|lumiliximab|
57777782|NCT05437042|OTHER|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
57777783|NCT04308538|PROCEDURE|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
57777784|NCT04308538|PROCEDURE|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
58461231|NCT03482726|BEHAVIORAL|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
58461232|NCT06408662|OTHER|mindfulness-based intervention for tics (MBIT)|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practice
58461233|NCT06408662|OTHER|psychoeducation with relaxation and supportive therapy (PRST)|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
58461234|NCT02861612|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
58461235|NCT04066868|OTHER|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
57777785|NCT01603420|DRUG|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
57777786|NCT01603420|DRUG|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
58461236|NCT04066868|OTHER|CTCAE rating|CTCAE Ratings are conducted by clinicians
58461237|NCT04066868|OTHER|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
58461238|NCT04333563|DEVICE|CPAP|Continuous positive airway pressure
58461239|NCT04333563|DEVICE|NIV NAVA|Non-invasive neurally adjusted ventilatory assist
58461240|NCT01692184|DRUG|50 mg AVL-292|
58461241|NCT01692184|DRUG|100 mg AVL-292|
58461242|NCT01692184|DRUG|200 mg AVL-292|
58461243|NCT01692184|DRUG|350 mg AVL-292|
58461244|NCT01692184|DRUG|Placebo capsules|
58461245|NCT01651481|DRUG|HCP1102|
58461246|NCT01651481|DRUG|Singulair and Xyzal|
58461247|NCT06340295|OTHER||
58461248|NCT02021201|DRUG|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
57777787|NCT01603420|OTHER|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
57777788|NCT05506267|DEVICE|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
58461249|NCT02021201|DRUG|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
57777789|NCT03680040|DIAGNOSTIC_TEST|Subjects previously implanted with a RESILIA aortic tissue valve.|Subjects to undergo multi-slice computed tomography and echocardiogram to assess predictors of valve durability in previously implanted Edwards aortic valves with RESILIA tissue.
58461250|NCT02571023|PROCEDURE|microscope surgery|
58461251|NCT02571023|PROCEDURE|neuroendoscope surgery|
58461252|NCT01706458|BIOLOGICAL|sipuleucel-T|Given IV
57777790|NCT03300375|OTHER|Home exercise program|Home-based, progressive exercise program using resistance bands
57777791|NCT03300375|OTHER|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
57777792|NCT00000611|DRUG|hormone replacement therapy|
58461253|NCT01706458|BIOLOGICAL|DNA Vaccine|Given ID
58461254|NCT01512485|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
57777793|NCT00000611|DRUG|estrogens|
57777794|NCT00000611|DRUG|progestins|
57777795|NCT00000611|DRUG|estrogen replacement therapy|
57777796|NCT00000611|BEHAVIORAL|diet, fat-restricted|
57777797|NCT00000611|DRUG|calcium|
57777798|NCT00000611|DRUG|vitamin D|
57777799|NCT00000611|BEHAVIORAL|dietary supplements|
57777800|NCT06270420|DEVICE|Technological Motor Rehabilitation|Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
58461255|NCT02660177|DRUG|Metamizole|metamizole IV administration
58461256|NCT06005415|DIETARY_SUPPLEMENT|Wire-cut cookie|Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
58461257|NCT01921205|DRUG|Lacosamide|"Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
58461258|NCT01921205|OTHER|Placebo|"Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
58461259|NCT05356286|DEVICE|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
58461260|NCT02857517|DRUG|conbercept|0.05ml conbercept
58461261|NCT06438822|COMBINATION_PRODUCT|Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil|cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 400 mg/m2 for 46 h every 2 weeks.
58461262|NCT04836052|DRUG|Omega 3 fatty acid|omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
57784477|NCT03658629|BIOLOGICAL|Flublok Quadrivalent|2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
58461263|NCT04558177|DEVICE|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
58461264|NCT05694390|OTHER|Use of sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
58461265|NCT04281407|DIETARY_SUPPLEMENT|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
58461266|NCT05011942|DEVICE|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
58461267|NCT00674479|DRUG|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
58461268|NCT05901701|RADIATION|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
58461269|NCT05901701|DEVICE|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
58461270|NCT03469752|BEHAVIORAL|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
58461271|NCT04169958|OTHER|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
58461272|NCT05425602|DRUG|MAX-40279-01: 50mg/70mg|\[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
58461273|NCT01145534|DRUG|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
57777801|NCT06545396|OTHER|Half-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.
57784478|NCT03658629|BIOLOGICAL|Influenza Vaccine|2018-19 Licensed Seasonal Influenza Vaccine
58461274|NCT01145534|OTHER|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
58461275|NCT04590664|DRUG|Verteporfin|Given IV
58461276|NCT04002960|DEVICE|INVSENSOR00036|Noninvasive regional oximeter
58461277|NCT04506840|OTHER|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
58461278|NCT03447002|DIAGNOSTIC_TEST|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
58461279|NCT05549726|DRUG|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
58461280|NCT05549726|OTHER|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
58461281|NCT05549726|OTHER|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
58461282|NCT00574808|OTHER|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
58461283|NCT00384345|DEVICE|Bright Light Therapy|
58461284|NCT00384345|BEHAVIORAL|Exercise|
58461285|NCT02763306|DEVICE|Dermal Cooling System|Treatment with dermal cooling system.
57784479|NCT01804673|DRUG|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
58138174|NCT03803800|OTHER|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
58461286|NCT04254393|BEHAVIORAL|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
58461287|NCT04254393|OTHER|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
58461288|NCT04647370|PROCEDURE|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
58461289|NCT04647370|PROCEDURE|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
58461290|NCT06132451|OTHER|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
58461291|NCT06144554|DEVICE|Omnipod 5|"The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs.~Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment."
58461292|NCT00308139|DRUG|exenatide, long acting release|
58461293|NCT00308139|DRUG|exenatide|
58461294|NCT05490186|PROCEDURE|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
58461295|NCT02570503|DRUG|Ropivacaine|Ropivacaine (5mg/ml)-50ml
58461296|NCT02570503|DRUG|Ketorolac|ketorolac (30mg/ml)- 1 ml
58461297|NCT02570503|DRUG|Clonidine|clonidine (0.1mg/ml)- 0.8ml
58461298|NCT02570503|DRUG|Epinephrine|epinephrine (1mg/ml)-1ml
58461299|NCT02570503|DRUG|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
58461300|NCT05356234|BEHAVIORAL|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
58461301|NCT00772538|DRUG|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
58461302|NCT00772538|DRUG|placebo|Matching placebo
58461303|NCT00524485|DRUG|aminolevulinic acid|
58461304|NCT00524485|PROCEDURE|laser therapy|
58461305|NCT03032562|DIAGNOSTIC_TEST|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
58461306|NCT01320189|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
58461307|NCT02433626|DRUG|COTI2|COTI-2 is a third generation thiosemicarbazone.
58461308|NCT02433626|DRUG|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
57777802|NCT06545396|OTHER|Full-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
57777803|NCT01095705|PROCEDURE|Conventional procedure|Local anaesthesia (Lidocaïne)
58461309|NCT00006016|DRUG|thalidomide|Given orally
58461310|NCT00006016|DRUG|doxorubicin hydrochloride|Given transarterially (chemoembolization)
58461311|NCT00006016|OTHER|laboratory biomarker analysis|Correlative studies
58461312|NCT01439789|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
58461313|NCT01439789|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
58461314|NCT04384809|BIOLOGICAL|Leukocyte rich platelet rich plasma|Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon
58461315|NCT04384809|DEVICE|Percutaneous Tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
58461316|NCT00310765|DRUG|Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
58461317|NCT00310765|DRUG|Placebo first followed by open label pregabalin|Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
58461318|NCT05034913|OTHER|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
58461319|NCT03532542|DRUG|Casimersen|Casimersen solution for IV infusion
58461320|NCT03532542|DRUG|Golodirsen|Golodirsen solution for IV infusion
58461321|NCT01938079|DRUG|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
58461322|NCT01938079|OTHER|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
58461323|NCT02759757|OTHER|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
58461324|NCT02759757|OTHER|Placebo|A micropore tape will be used as placebo
58461325|NCT03930836|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
58461326|NCT03930836|BEHAVIORAL|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
58461327|NCT03962465|DRUG|Inotuzumab ozogamicin|By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
58461328|NCT03962465|DRUG|Prednisone Pill|Taken daily days 1-28 by mouth
58461329|NCT03962465|DRUG|Daunorubicin|By IV, given on days 1, 8, 15, and 22
58461330|NCT03962465|DRUG|Vincristine|By IV, given on days 1, 8, 15, and 22
58461331|NCT03962465|DRUG|Cytarabine|Intrathecal, administered on day 1 only
57777804|NCT01095705|PROCEDURE|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
57777805|NCT05293288|DEVICE|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
58461332|NCT03962465|DRUG|Methotrexate|Intrathecal, administered on days 8 and 29
58461333|NCT03962465|DRUG|Pegaspargase|By IV, given on day 4
58461334|NCT05110638|DRUG|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
58461335|NCT03165617|BIOLOGICAL|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
58461336|NCT03165617|BIOLOGICAL|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
58461337|NCT04471077|PROCEDURE|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
57777806|NCT03741205|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
57777807|NCT02247414|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
57777808|NCT02247414|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
57777809|NCT02247414|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
57777810|NCT02247414|DRUG|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
57777811|NCT06112613|OTHER|Electronic Health Record Review|Ancillary studies
58461338|NCT06196736|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
58461339|NCT06196736|DRUG|Chemotherapy|75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
58461340|NCT04825626|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
58461341|NCT02099851|DEVICE|Carotid body ablation (Cibiem)|
58461342|NCT04823403|DRUG|Nivolumab|Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
58461343|NCT04823403|DRUG|Ipilimumab|"Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~* (D1) Starting dose : 50 mg; n=3 to 6~* (D2) 2nd dose-level : 100 mg; n=3 to 6~* (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)"
58461344|NCT00302809|DIETARY_SUPPLEMENT|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
58461345|NCT00083889|DRUG|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
58461346|NCT00083889|DRUG|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
58461347|NCT01413035|BIOLOGICAL|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
58461348|NCT05776017|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
58461349|NCT05776017|BIOLOGICAL|Anti-Rabies Vaccine|Control vaccine
58461350|NCT04653480|DRUG|Surufatinib|250mg per oral, once daily
58461351|NCT04653480|DRUG|Toripalimab|3mg/kg IV, once every 2 weeks
58461352|NCT04653480|DRUG|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
58461353|NCT01638455|DEVICE|Noninvasive device|Noninvasive device
58461354|NCT05711576|OTHER|Placebo mouthwash|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash
58461355|NCT05711576|OTHER|Full mouth disinfection|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
58461356|NCT04128137|DRUG|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
58461357|NCT04128137|OTHER|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
58461358|NCT06041568|DRUG|Imvotamab|Administered intravenously
58461359|NCT01539759|DEVICE|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
58461360|NCT00790803|DRUG|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
58461361|NCT05864729|DIAGNOSTIC_TEST|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
58461362|NCT04773951|BIOLOGICAL|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
58461363|NCT00000266|DRUG|Flupenthixol|
58461364|NCT04956536|OTHER|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
58461365|NCT02321241|DRUG|Aflibercept (EYLEA, BAY-86-5321)|"1. st year: 3 monthly injections followed by 1 injection every two months~2. nd year and following: injection according the visual and anatomical results observed the 1st year"
58461366|NCT02361385|OTHER|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
58461367|NCT05566535|DRUG|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
58461368|NCT03309020|PROCEDURE|Cataract surgery|Cataract surgery and aqueous humor sampling.
58461369|NCT05348902|OTHER|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
58461370|NCT01679288|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
58461371|NCT04041713|DRUG|Rett-T|antioxidant cocktail
58461372|NCT04041713|OTHER|Placebo|Placebo
58461373|NCT05817903|DRUG|Axitinib|Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
58461374|NCT05817903|DRUG|Nivolumab|Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
58461375|NCT06131632|PROCEDURE|Breast conserving surgery|Remove only a small part of the breast
58461376|NCT06131632|PROCEDURE|Radical modified mastectomy|Remove all the breast parenchyma, nipple and skin
58461377|NCT00976807|OTHER|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
58461378|NCT00886002|DRUG|Fentanyl; Buprenorphine; Naloxone|
57777812|NCT06112613|OTHER|Health Promotion and Education|Receive access to educational materials
57777813|NCT06112613|PROCEDURE|Health Telemonitoring|Utilize the WiseBag medication dispenser
58461379|NCT01486875|DRUG|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
58461380|NCT06334575|DRUG|Budesonide|receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
58461381|NCT05045768|DRUG|(Gelsectan, Devintec Sagl)|Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
58461382|NCT04050553|DRUG|Tirzepatide|Administered SC
58461383|NCT04050553|DRUG|Placebo|Administered SC
58461384|NCT03053375|DEVICE|MDCure|Battery powered portable pulsed electromagnetic therapy device
58461385|NCT03372785|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
58461386|NCT03372785|DEVICE|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
57777814|NCT06112613|OTHER|Interview|Complete an interview
57777815|NCT06112613|BEHAVIORAL|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
57777816|NCT06112613|OTHER|Survey Administration|Ancillary studies
58461387|NCT02503592|OTHER|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
57777817|NCT06112613|OTHER|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
57777818|NCT04672512|DRUG|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
58461388|NCT02489435|DRUG|VM-1500|VM-1500
58461389|NCT02489435|DRUG|Placebo|Placebo
58461390|NCT02655029|DRUG|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
58461391|NCT00409643|DRUG|valsartan+amlodipine combination|
58461392|NCT00409643|DRUG|valsartan|
58461393|NCT00409643|DRUG|amlodipine|
58461394|NCT06060236|DRUG|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
58461395|NCT06060236|DRUG|Dexketoprofen|Dexketoprofen 50 Mg İV
58461396|NCT03353675|BIOLOGICAL|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
58461397|NCT03353675|DRUG|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
58461398|NCT03353675|DRUG|Nivolumab|360 mg IV administration every 3 weeks
58461399|NCT05461859|PROCEDURE|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
58461400|NCT05039749|DEVICE|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
58461401|NCT04870762|OTHER|Best Practice|Receive standard of care
58461402|NCT04870762|OTHER|Medical Device Usage and Evaluation|Wear 3D printed oral stent
58461403|NCT05440097|OTHER|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
58461404|NCT05862753|DRUG|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
58461405|NCT04365972|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
58461406|NCT05399069|DRUG|VGR-R01|Gene Replacement Therapy
58461407|NCT06348771|BEHAVIORAL|monounsaturated fatty acids (MUFA) peanut meal|mixed meal tolerance test and postprandial measurements
58461408|NCT03563339|BEHAVIORAL|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
58461409|NCT03335384|DIAGNOSTIC_TEST|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
58461410|NCT03335384|DIAGNOSTIC_TEST|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
57777819|NCT04672512|DRUG|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
57777820|NCT04672512|DRUG|Prednisone|Prednisone tablet for oral administration
57777821|NCT01815814|OTHER|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
57784480|NCT04783324|BEHAVIORAL|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
58461411|NCT03335384|DIAGNOSTIC_TEST|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
58461412|NCT02160080|DRUG|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
58461413|NCT06070792|OTHER|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
58461414|NCT06070792|OTHER|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
58461415|NCT00184834|BEHAVIORAL|quality of life|
58461416|NCT03337308|COMBINATION_PRODUCT|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
58461417|NCT03337308|DRUG|Bempedoic Acid|bempedoic acid 180 mg tablet
58461418|NCT03337308|DRUG|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
58461419|NCT03337308|DRUG|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
58461420|NCT03597347|DRUG|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
58461421|NCT03597347|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
58461422|NCT01943344|DEVICE|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
58461423|NCT01011998|DRUG|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
58461424|NCT01205217|DRUG|Lapatinib|Lapatinib 1000 mg orally once daily continuously
58461425|NCT01205217|DRUG|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
58461426|NCT01205217|DRUG|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
58461427|NCT01205217|DRUG|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
58461428|NCT01205217|DRUG|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
58461429|NCT04479397|PROCEDURE|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
58461430|NCT04479397|PROCEDURE|No sling in postoperative care|No sling will be used in postoperative care.
58461431|NCT01384175|PROCEDURE|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
58461432|NCT01384175|PROCEDURE|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
58461433|NCT01384175|PROCEDURE|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
58461434|NCT04477486|DRUG|Ibrutinib|Capsule; Oral
58461435|NCT04477486|DRUG|Venetoclax|Tablet; Oral
58461436|NCT04103216|OTHER|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
58461437|NCT04103216|OTHER|Nitazoxanide|Nitazoxanide with placebo
58461438|NCT03784443|DRUG|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
58461439|NCT03784443|DRUG|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
58461440|NCT03784443|PROCEDURE|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
58461441|NCT01917617|DRUG|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
58461442|NCT01917617|DRUG|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
58461443|NCT04687475|OTHER|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
58461444|NCT04135807|COMBINATION_PRODUCT|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
58461445|NCT04325672|BIOLOGICAL|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.
58461446|NCT06374368|PROCEDURE|jejuno-ileal diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
58461447|NCT06374368|PROCEDURE|jejuno-colic diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
58461448|NCT03168477|OTHER|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
58461449|NCT03168477|OTHER|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
58461450|NCT03168477|OTHER|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
58461451|NCT03168477|OTHER|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
58461452|NCT03168477|OTHER|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
58461453|NCT04482140|DEVICE|Genta-Foil resorb®|Use of Genta-Foil resorb® to prevent adhesions in patients undergoing hand surgery
58461454|NCT01043575|DRUG|Rifapentine|During the first 8 weeks of therapy for TB participants \> 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants \< 45 kg participants will receive 450 mg orally given 5 days per week
58461455|NCT01043575|DRUG|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
58461456|NCT04796714|DRUG|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
58461457|NCT04796714|DRUG|Aspirin|One sachet of aspirin 160 mg per day during 3 months
58461458|NCT04796714|DEVICE|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
58461459|NCT04796714|OTHER|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
58461460|NCT04261556|DEVICE|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
58461461|NCT04261556|DEVICE|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
58461462|NCT04689659|BIOLOGICAL|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
58138175|NCT03803800|OTHER|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
58461463|NCT03350997|BEHAVIORAL|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
58461464|NCT03350997|BEHAVIORAL|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
58461465|NCT05500287|OTHER|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
58461466|NCT04084171|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
58461467|NCT01847521|DIETARY_SUPPLEMENT|Luteolin, Quercetin and Rutin combined in a capsule|
58461468|NCT04552951|DRUG|Cholecalciferol|Single doe of 100.000 IU
58461469|NCT01917058|DRUG|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
58461470|NCT01917058|DRUG|placebo|
58461471|NCT04785443|DRUG|ICG|"During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months."
58461472|NCT04785443|PROCEDURE|Control group|"During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months."
58461473|NCT04712188|DIAGNOSTIC_TEST|Musculoskeletal ultrasonography|The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
58461474|NCT04712188|OTHER|Wheelchair propelling test|Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
58461475|NCT01868490|DRUG|cytokine induced killer cells|at least 10\*9 CIK cells, IV on day 0, 14, 28
58461476|NCT04567069|BIOLOGICAL|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
58461477|NCT04567069|BIOLOGICAL|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
58461478|NCT04567069|DRUG|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
58461479|NCT03120884|PROCEDURE|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
58461480|NCT03120884|PROCEDURE|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
58490603|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
58490604|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
58490605|NCT04288284|PROCEDURE|Curative resection of colorectal cancer|
58490606|NCT04097574|DRUG|NPO-13: l-menthol|20 mL/site
58490607|NCT00677989|PROCEDURE|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
57777822|NCT00955006|BIOLOGICAL|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
57777823|NCT00955006|BIOLOGICAL|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
57777824|NCT01369056|BEHAVIORAL|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
58461481|NCT03205124|PROCEDURE|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
58461482|NCT03205124|PROCEDURE|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
58461483|NCT01472640|DRUG|liraglutide|1.8 mg sc QOD
58461484|NCT01472640|DRUG|placebo|1 U sc QOD
57777825|NCT01652820|DRUG|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
58461485|NCT06320054|BEHAVIORAL|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
58461486|NCT02319330|BEHAVIORAL|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
58461487|NCT02319330|BEHAVIORAL|Treatment as Usual|Routine HIV clinic-based counseling
58461488|NCT04735263|DRUG|Atorvastatin 80mg|Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
58461489|NCT05222581|DEVICE|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
58461490|NCT02655328|OTHER|blood sample|blood sample
58461491|NCT02655328|OTHER|urine sample|urine sample
57777826|NCT01652820|DRUG|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
58461492|NCT03725670|BIOLOGICAL|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral LV gene therapy to deliver high level lenviral vectors which carry normal ARSA gene at 1-2×10\^9 multiplicity of infection (moi)/ml per site.
58461493|NCT04123886|DRUG|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
57777827|NCT03227484|DRUG|Empagliflozin 25mg|Once daily over 8 weeks
58461494|NCT00308477|DRUG|dexamethasone|
58461495|NCT03192176|DRUG|Fezolinetant|Oral Capsule
58461496|NCT03192176|DRUG|Placebo|Oral Capsule
58461497|NCT04125563|DRUG|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
58461498|NCT04125563|DRUG|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
58461499|NCT00963417|OTHER|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
58461500|NCT00963417|PROCEDURE|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
58461501|NCT02931617|OTHER|Chest Physiotherapy|
58461502|NCT02931617|DEVICE|Post-therapy lung volume measurements|In both intervention groups.
58461503|NCT03301558|DRUG|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
58461504|NCT03301558|DRUG|High dose sodium bicarbonate|3000 mg sodium bicarbonate
58461505|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
58461506|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
58461507|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
58461508|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
57777828|NCT03227484|DRUG|Placebo Oral Tablet|Once daily over 8 weeks
57777829|NCT06197243|OTHER|Acupuncture|Patients will receive acupuncture for 12 weeks.
57777830|NCT06197243|OTHER|Yoga|Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.
57784481|NCT04572490|DIAGNOSTIC_TEST|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
58461509|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
58461510|NCT05280717|BIOLOGICAL|sotrovimab|via IV injection
57777831|NCT06197243|OTHER|Deprescribing|Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
57777832|NCT01997320|OTHER|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
57777833|NCT01997320|OTHER|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
57777834|NCT01448044|DRUG|BMS-790052 (NS5A Replication Complex Inhibitor)|
57777835|NCT01448044|DRUG|Placebo matching BMS-790052|
57777836|NCT01448044|DRUG|Pegylated-interferon alfa 2a|
57777837|NCT01448044|DRUG|Ribavirin|
57777838|NCT03864289|BEHAVIORAL|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
57777839|NCT03546361|BIOLOGICAL|Autologous Dendritic Cell-Adenovirus CCL21 Vaccine|Given via CT-guided or bronchoscopic IT injection
57777840|NCT03546361|BIOLOGICAL|Pembrolizumab|Given IV
57777841|NCT00321334|PROCEDURE|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
57777842|NCT00967018|DRUG|Degarelix|
57777843|NCT03653416|DEVICE|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
57777844|NCT03653416|DRUG|Bupivacaine|20 cc of bupivacaine(o.25%) injection
58461511|NCT05280717|BIOLOGICAL|sotrovimab|via IV infusion
58461512|NCT00589225|GENETIC|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
57777845|NCT03653416|PROCEDURE|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
57777846|NCT02218489|DRUG|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
57777847|NCT02218489|DRUG|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
57777848|NCT03529422|DRUG|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
57777849|NCT03529422|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
57777850|NCT00118144|DRUG|bortezomib|Given IV
57777851|NCT04241575|DIAGNOSTIC_TEST|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
57777852|NCT01649596|DEVICE|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
57777853|NCT01649596|OTHER|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
57777854|NCT01060020|DRUG|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
57777855|NCT04555915|OTHER|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
57777856|NCT04443439|DEVICE|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
57777857|NCT01225835|DRUG|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
58461513|NCT03449511|OTHER|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
58461514|NCT03449511|OTHER|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
58461515|NCT03449511|OTHER|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
58461516|NCT03449511|OTHER|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
58461517|NCT01150526|DIETARY_SUPPLEMENT|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
58461518|NCT01150526|DIETARY_SUPPLEMENT|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
58461519|NCT01150526|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
58461520|NCT01150526|DIETARY_SUPPLEMENT|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
58461521|NCT04740983|OTHER|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
58461522|NCT03631602|DRUG|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
58461523|NCT05656339|DIETARY_SUPPLEMENT|CHO+WP|Oral supplement containing carbohydrates plus whey protein
58461524|NCT05656339|DIETARY_SUPPLEMENT|CHO|Oral supplement containing carbohydrates
58461525|NCT05656339|DIETARY_SUPPLEMENT|Fast|Fast condition of 12 hours
58461526|NCT05627479|DRUG|GIK solution|Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
58461527|NCT05627479|DRUG|Isotonic Normal Saline Solution|Placebo injection - administered intravenously.
58461528|NCT00002022|DRUG|Epoetin alfa|
58461529|NCT01250808|DRUG|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
58461530|NCT00193336|DRUG|ZD1839|
58461531|NCT04386369|OTHER|Airway pressure release ventilation|Ventilator management strategy
58461532|NCT00534365|DEVICE|tension-free vaginal tape|Retropubic mid-urethral sling
58461533|NCT00534365|DEVICE|TVT-SECUR device|Mid-urethral mini-sling
58461534|NCT02893566|BEHAVIORAL|Mi Band Step Challenge|
58461535|NCT02216669|DRUG|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
58461536|NCT01392144|PROCEDURE|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
58461537|NCT01392144|BEHAVIORAL|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
58461538|NCT00793988|PROCEDURE|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
58461539|NCT00793988|PROCEDURE|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
57777858|NCT01225835|DRUG|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
57777859|NCT01225835|DRUG|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
57777860|NCT01225835|DRUG|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.
57777861|NCT01225835|DRUG|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
57777862|NCT00199030|DRUG|Alemtuzumab (MabCampath)|
57777863|NCT00199030|DRUG|Cladribine|
57777864|NCT02653014|DRUG|KBP-5074|
58461540|NCT04915183|OTHER|Placebo|Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
58461541|NCT04915183|DRUG|Atorvastatin|Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
58461542|NCT01798693|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|
58461543|NCT01798693|DIETARY_SUPPLEMENT|Multi-nutrient Blend|
58461544|NCT01866540|DRUG|FLUENZ|live attenuated influenza vaccine
57777865|NCT00747058|DRUG|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
57777866|NCT00747058|DRUG|Placebo|Placebo
57777867|NCT03896451|DEVICE|Total knee endoprothesis|Total knee endoprosthesis after knee joint osteoarthritis
57777868|NCT02342184|DRUG|GB-0998|
57777869|NCT01402258|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
57777870|NCT00002793|DRUG|fluorouracil|
57777871|NCT00002793|DRUG|leucovorin calcium|
57777872|NCT00583505|DEVICE|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
58138176|NCT03803800|DIETARY_SUPPLEMENT|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
58461545|NCT06098482|DEVICE|Mobile Research App (MRA)|The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
58461546|NCT06098482|OTHER|SOC/validated delivery of the speech perception test material|This involves the delivery of speech perception test material in the sound booth in a clinic.
58490608|NCT00677989|PROCEDURE|Open appendectomy|open appendectomy: did appendectomy by laparotomy
58461547|NCT01171859|DRUG|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
58461548|NCT05026528|OTHER|Digital diabetes self management education and support system|Digital diabetes self management and support system
58461549|NCT01811771|BIOLOGICAL|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
58461550|NCT03087396|DEVICE|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
58461551|NCT01022736|DRUG|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
58461552|NCT03273426|PROCEDURE|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
58461553|NCT03273426|PROCEDURE|wide excision|Surgical wide excision of the biopsied area.
58461554|NCT04034368|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
57777873|NCT06078930|DIAGNOSTIC_TEST|Tongue imaging, tougue coating, saliva, and feces|Tongue images, coating, saliva, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
58130797|NCT04788238|BEHAVIORAL|Dual-Task Zumba Gold|Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
58130798|NCT06224725|OTHER|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
58130799|NCT01052090|DRUG|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
58130800|NCT03189888|DEVICE|apheresis|
58130801|NCT03451201|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
58130802|NCT03451201|BEHAVIORAL|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
58130803|NCT03451201|OTHER|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
58130804|NCT05266248|OTHER|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
58130805|NCT02626949|BEHAVIORAL|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
58130806|NCT02626949|BEHAVIORAL|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
58130807|NCT00379756|DRUG|LEVITRA (vardenafil)|active comparator
58461555|NCT04515875|BEHAVIORAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
58490609|NCT01379508|DRUG|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
58490610|NCT01379508|DRUG|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
57777874|NCT06381362|PROCEDURE|Minimally invasive pancreatic surgery|Minimally invasive pancreatic surgery
58130808|NCT00379756|DRUG|placebo|placebo comparator
58461556|NCT04515875|BEHAVIORAL|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
58461557|NCT03151044|DRUG|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
58461558|NCT03151044|DRUG|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
58461559|NCT03630991|DRUG|Edetate Calcium Disodium|Given IV
58461560|NCT03630991|DIETARY_SUPPLEMENT|Multivitamin|Given PO
58461561|NCT03630991|DRUG|Succimer|Given PO
58130809|NCT03678636|DEVICE|Silver antimicrobial dressing|Silver dressing suitable for exudate level
58461562|NCT05055843|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D MRI
58461563|NCT03491059|DRUG|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
58461564|NCT03491059|RADIATION|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
58461565|NCT01651728|DRUG|Simvastatin|Tablet 20 mg once daily for 30 days
58461566|NCT01651728|DRUG|Placebo|daily for 30 days
58461567|NCT05150028|BEHAVIORAL|Patient participation|Questionnaire
58461568|NCT05150028|OTHER|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
58461569|NCT01319669|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
58461570|NCT02607059|OTHER|Registry|
58461571|NCT00777712|OTHER|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
58461572|NCT06048302|DRUG|Obicetrapib|1 single dose of obicetrapib
58461573|NCT04468646|DRUG|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
58461574|NCT04755816|BEHAVIORAL|Sodium intervention|The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.
58461575|NCT04755816|BEHAVIORAL|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
58461576|NCT04755816|BEHAVIORAL|Educational content|Standard heart failure educational information and a daily symptom survey.
58461577|NCT04658160|BEHAVIORAL|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
58461578|NCT05357573|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
58461579|NCT04283669|DRUG|Crizotinib|Oral
58461580|NCT06378775|PROCEDURE|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
58461581|NCT06378775|PROCEDURE|Robotically-assisted minimally-invasive direct coronary artery bypass|Robotically-assisted minimally-invasive direct coronary artery bypass
58461582|NCT06378775|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
58461583|NCT00584948|DRUG|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
58461584|NCT00584948|DRUG|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
58461585|NCT06213818|DRUG|INCB160058|Oral; Tablet
58461586|NCT06213818|DRUG|Placebo|Oral; Tablet
58461587|NCT06213818|DRUG|Esomeprazole|Oral; Capsule
58461588|NCT06213818|DRUG|INCB160058|Oral; soft gel capsule
58461589|NCT05429216|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
58130810|NCT03678636|DEVICE|Standard care|Usual care for wound type and condition
58461590|NCT05429216|PROCEDURE|ESD procedure|ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
58130811|NCT00449878|DRUG|Liprotamase|Administered orally
58130812|NCT00449878|DRUG|Placebo|Administered orally
58130813|NCT06137677|OTHER|Sweet Snack|A sweet food will be served for the snack
58130814|NCT06137677|OTHER|Savory Snack|A savory food will be served for the snack
58461591|NCT02946437|DRUG|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
58461592|NCT02946437|DRUG|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
58461593|NCT02946437|DRUG|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
58461594|NCT02946437|DEVICE|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
58461595|NCT03978130|OTHER|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
58461596|NCT04187118|OTHER|Quality of life|Quality of life one year post chemo-therapy
58461597|NCT01796340|BEHAVIORAL|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
58461598|NCT01796340|BEHAVIORAL|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
58461599|NCT01893541|PROCEDURE|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
58461600|NCT01893541|DRUG|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
57777875|NCT05385328|DEVICE|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
58461601|NCT01893541|DEVICE|a multiband ligation device|
58461602|NCT03909893|RADIATION|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
58461603|NCT04575506|OTHER|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
58461604|NCT02970799|DEVICE|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
58461605|NCT00449696|DEVICE|Gel-200|Single intra-articular injection
58461606|NCT00449696|DEVICE|Placebo|Single intra-articular injection
58461607|NCT01151488|OTHER|Resistance Training|RT 3x/wk for 4 months
57777876|NCT05385328|DEVICE|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
57777877|NCT01542541|DRUG|Rifaximin|550mg BID for 2 days
58461608|NCT02384551|OTHER|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
58461609|NCT04156061|OTHER|Delivery of CT scan results|Method of results delivery - verbal or visual.
58461610|NCT03337230|BEHAVIORAL|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
57777878|NCT01761786|GENETIC|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
58461611|NCT03337230|BEHAVIORAL|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
58461612|NCT03337230|BEHAVIORAL|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
58461613|NCT06094088|BEHAVIORAL|Heated Yoga|Heated yoga described in arm/group description
58461614|NCT06094088|BEHAVIORAL|Non-Heated Yoga|Non-heated yoga described in arm/group description
58461615|NCT06308822|PROCEDURE|Biopsy|Undergo tumor biopsy
58461616|NCT06308822|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58461617|NCT06308822|PROCEDURE|Computed Tomography|Undergo CT
58461618|NCT06308822|DRUG|Erdafitinib|Given PO
58461619|NCT06308822|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58461620|NCT05271981|OTHER|Retrospective data collection|Data collection from the medical file of the patients
58461621|NCT05271981|OTHER|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
58461622|NCT02616510|PROCEDURE|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
58461623|NCT04580238|DRUG|Botox 200 UNT Injection|"Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites"
58461624|NCT04580238|COMBINATION_PRODUCT|Non Botox based Standard of Care Treatments for Headache/Migraine|Control Group will receive normal standard of care Non-Botox based interventions.
58461625|NCT04984031|DIAGNOSTIC_TEST|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
58461626|NCT04416568|DRUG|Nivolumab|"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"
58461627|NCT04416568|DRUG|Ipilimumab|Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
58461628|NCT02113696|DIETARY_SUPPLEMENT|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
58461629|NCT02113696|DIETARY_SUPPLEMENT|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
58461630|NCT02745197|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
58461631|NCT02745197|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
58461632|NCT05312593|OTHER|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
58461633|NCT05312593|OTHER|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
58461634|NCT02500849|GENETIC|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
58461635|NCT03380650|DEVICE|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
58461636|NCT03380650|DEVICE|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
58461637|NCT05828862|PROCEDURE|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
58461638|NCT06602518|PROCEDURE|Orthodontic Treatment|All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
58461639|NCT05696483|DRUG|OLX-07010 Active|25 and 75 mg capsules
57777879|NCT01235975|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
57777880|NCT01235975|BIOLOGICAL|MencevaxACWY TM|Subcutaneous injection
58138177|NCT05070260|DRUG|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
58461640|NCT05696483|DRUG|OLX-07010 Placebo|25 and 75 mg capsules
58461641|NCT03882060|DRUG|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
58461642|NCT03882060|DRUG|Normal saline|Control group, no intervention.
58461643|NCT00005766|DRUG|Creatinine|
58461644|NCT05100342|DIAGNOSTIC_TEST|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
58461645|NCT03960541|DRUG|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
58461646|NCT03960541|DRUG|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
58461647|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (WT/OMI BA.2)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.2\]
58461648|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.1)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.1\]
58461649|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
58461650|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
58461651|NCT05472038|BIOLOGICAL|BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BNT162b6 Wild Type and BNT162b6 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
58461652|NCT05472038|BIOLOGICAL|BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BNT162b7 Wild Type and BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
58461653|NCT05472038|BIOLOGICAL|BNT162b7 Monovalent (OMI BA.4/BA.5)|BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
58461654|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
58461655|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
58461656|NCT01736111|BEHAVIORAL|one way text|
58461657|NCT01736111|BEHAVIORAL|Personal feedback|
58461658|NCT00900978|BIOLOGICAL|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
58461659|NCT05696249|DEVICE|OhmTrak device.|All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
58461660|NCT05696249|OTHER|Outpatient Physiotherapy|All probands will undergo six-week outpatient therapy once a week for an hour
58461661|NCT00572377|DRUG|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
58461662|NCT00572377|DRUG|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
58461663|NCT04103879|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
58461664|NCT05072639|BEHAVIORAL|Guided Meditation|23 minute audio recording
58461665|NCT04349891|DEVICE|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
58461666|NCT04349891|DEVICE|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
58461667|NCT05308875|BIOLOGICAL|PD1-BCMA-CART|Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
58461668|NCT00431561|DRUG|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
58461669|NCT00431561|DRUG|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
58461670|NCT00431561|DRUG|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
58461671|NCT00431561|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
58461672|NCT00431561|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
58461673|NCT05051748|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
58461674|NCT05051748|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
58461675|NCT05051748|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
58130815|NCT05770726|DIETARY_SUPPLEMENT|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
58138178|NCT05070260|DRUG|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
58461676|NCT05403996|BEHAVIORAL|Activa-Mente|Active break program
58461677|NCT00286858|DEVICE|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
58461678|NCT04272918|BEHAVIORAL|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
58461679|NCT04272918|BEHAVIORAL|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
58461680|NCT05620433|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
58461681|NCT05620433|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
58461682|NCT04149912|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
58461683|NCT06430697|DRUG|paracetamol administration|Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
58461684|NCT03044613|DRUG|Nivolumab|240mg or 1 mg/kg administered IV
58461685|NCT03044613|DRUG|Relatlimab|80mg administered IV
58461686|NCT03044613|DRUG|Carboplatin|standard care dose
58461687|NCT03044613|DRUG|Paclitaxel|standard care dose
58461688|NCT03044613|RADIATION|Radiation|standard care dose
58461689|NCT00388986|DRUG|GK Activator (2)|100mg po bid
58461690|NCT00388986|DRUG|Glyburide|10-20mg po daily
58490611|NCT02469545|DRUG|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
58461691|NCT06031519|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
58461692|NCT05213975|DEVICE|Kinesio tape|Kinesio taping
58461693|NCT04789603|OTHER|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
58461694|NCT04789603|OTHER|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
58461695|NCT04789603|OTHER|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
58461696|NCT01269593|DRUG|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
58461697|NCT05951400|DRUG|Dydrogesterone Tablets|used for pituitary suppression in ICSI cycle
58461698|NCT05951400|DRUG|Cetrorelix|GnRH antagonist for pituitary suppression
58461699|NCT05821699|BEHAVIORAL|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination"
58461700|NCT05821699|BEHAVIORAL|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
58461701|NCT01017484|OTHER|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
58461702|NCT02356822|OTHER|Patient registry|Oncology data registry
58461703|NCT05009498|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
58461704|NCT05009498|OTHER|Placebo|Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
58461705|NCT02595983|DRUG|Revusiran|500mg Revusiran by subcutaneous (sc) injection
58461706|NCT01290458|DIETARY_SUPPLEMENT|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
58461707|NCT04355754|DEVICE|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
57777881|NCT01618396|DRUG|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
58461708|NCT00670553|DRUG|panobinostat|
57777882|NCT02100540|DRUG|I placebo capsule|I placebo capsule
57777883|NCT02100540|DRUG|II RDC 0.3mg capsule|II RDC 0.3mg capsule
58461709|NCT01406886|BEHAVIORAL|Eating rate|
58461710|NCT04111627|BEHAVIORAL|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
58461711|NCT04111627|DRUG|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
58461712|NCT01147042|DRUG|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
58461713|NCT02994108|BEHAVIORAL|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
58461714|NCT02994108|BEHAVIORAL|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
57777884|NCT02100540|DRUG|III RDC 0.6mg capsule|III RDC 0.6mg capsule
57777885|NCT00431002|BEHAVIORAL|Resistance training|See Detailed Description.
57777886|NCT00488215|DRUG|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
58490612|NCT02469545|DRUG|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
58490613|NCT02469545|DRUG|Escitalopram|5-20mg daily
58490614|NCT02469545|DRUG|Sertraline|50-100mg daily
58461715|NCT05958615|BEHAVIORAL|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
58461716|NCT04931069|OTHER|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
58461717|NCT05971446|DEVICE|Visual Evoked Potential (VEP)|Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.
58461718|NCT05971446|DEVICE|Electroretinogram (ERG)|Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
58461719|NCT00798200|OTHER|Exercise program|All exercise programs will include endurance and strength exercises.
58461720|NCT01777035|OTHER|early PT OT|"1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
58461721|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
58461722|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
58461723|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
58461724|NCT05781178|DIETARY_SUPPLEMENT|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
58461725|NCT01304264|DEVICE|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
58461726|NCT02278406|OTHER|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
58461727|NCT02356458|DRUG|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
58461728|NCT02356458|DRUG|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
58461729|NCT03121313|DRUG|tegafur-uracil|
58461730|NCT03165487|OTHER|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
58461731|NCT03165487|OTHER|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
58461732|NCT05397327|OTHER|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
58461733|NCT06133244|DIAGNOSTIC_TEST|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
58461734|NCT04527952|BEHAVIORAL|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
58461735|NCT05495932|DIAGNOSTIC_TEST|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
58461736|NCT01453049|DRUG|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
58461737|NCT01453049|DRUG|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
58461738|NCT05397730|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
58461739|NCT00330577|DRUG|timolol maleate 0.5%|
58461740|NCT00330577|DRUG|latanoprost/timolol fixed combination|
58461741|NCT00330577|DRUG|placebo (artificial tears)|
58461742|NCT06019624|BEHAVIORAL|Fresh Takes!|Receipt of a fresh produce box, nutritional education and support in a 6 month program
57777887|NCT00488215|OTHER|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
57777888|NCT03786484|DRUG|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
58461743|NCT05942365|DRUG|ZSP1273|Drug Warfarin oral Drug midazolam oral
58461744|NCT01690052|DRUG|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
58461745|NCT01690052|DRUG|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
58461746|NCT05930821|BEHAVIORAL|Aerobic and Resistance Exercise Program (GEMS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
58461747|NCT05930821|BEHAVIORAL|Flexibility and Stretching Program (FLEX-MS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~* Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program."
58461748|NCT04989686|OTHER|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
58461749|NCT01048008|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
58461750|NCT01804478|BEHAVIORAL|Mild pneumatic compression|
58461751|NCT06423950|OTHER|Peds Evolutionary Tumor Board (pedsETB)|The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
58461752|NCT00434226|DRUG|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
58461753|NCT00434226|DRUG|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
58461754|NCT00434226|DRUG|carboplatin|On the first day of each cycle for 4 cycles
58461755|NCT00434226|DRUG|paclitaxel|On the first day of each cycle for 4 cycles
58461756|NCT05623332|DIAGNOSTIC_TEST|Maraciclatide|Imaging marker that binds to AVB3/5 lesions
58461757|NCT00102466|DRUG|vildagliptin|
58461758|NCT00102466|DRUG|Gliclazide|
58461759|NCT00102466|DRUG|Metformin|
58461760|NCT02588599|DEVICE|Erchonia LUNULA|Active low level laser light therapy
58461761|NCT02249416|DRUG|Tipranavir (TPV) low|
58138179|NCT05044221|OTHER|Former ICU patient and caregiver workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
58461762|NCT02249416|DRUG|Ritonavir (RTV) low|Norvir®
58461763|NCT02249416|DRUG|Tipranavir (TPV) high|Retrovir®
58461764|NCT02249416|DRUG|Ritonavir (RTV) high|
58461765|NCT02249416|DRUG|Zidovudine|
58461766|NCT02343263|DRUG|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
58461767|NCT02343263|BIOLOGICAL|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
58461768|NCT00457717|DRUG|0.25 % atropine|
58461769|NCT00457717|DRUG|0.5 % atropine|
58461770|NCT00457717|PROCEDURE|0.25 % atropine+auricular acupoints|
58461771|NCT03926286|DRUG|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
58461772|NCT02285855|DRUG|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
58461773|NCT02285855|OTHER|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
58461774|NCT02285855|RADIATION|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
58461775|NCT06176261|DRUG|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
58461776|NCT04742101|DRUG|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
58461777|NCT03663829|OTHER|Non-Interventional|Non-Interventional
58461778|NCT03663829|OTHER|Non-Interventional|Non-Interventional
58461779|NCT02636699|BIOLOGICAL|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
58461780|NCT02636699|BIOLOGICAL|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
58461781|NCT04124939|DRUG|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
58461782|NCT06550375|DEVICE|TECNIS Odyssey IOL|Implantation with the TECNIS Odyssey IOL
57777889|NCT01287793|DRUG|tigecycline|intravenous, 200 mg, single dose
58461783|NCT01095549|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
58461784|NCT01095549|DEVICE|Placebo device|A device without far infrared therapy
58461785|NCT02325934|DRUG|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
58461786|NCT02325934|DRUG|Stribild, crushed|Crushed Stribild tablet
58461787|NCT02386020|DRUG|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
58461788|NCT02386020|DRUG|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
58461789|NCT04055064|DIETARY_SUPPLEMENT|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
58461790|NCT06706479|DEVICE|high-definition transcranial direct current stimulation|High-definition transcranial direct current stimulation is a novel non-invasive brain stimulation technique based on the principle that when weak intensity electric currents are targeted on specific areas of the scalp, they cause underlying cortical stimulation. The anode increases cortical excitability, while cathode decreases cortical excitability.
58461791|NCT00974142|DRUG|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
58461792|NCT00974142|DRUG|Placebo|Fifteen patients will receive will receive placebo.
58461793|NCT03772899|DRUG|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
58461794|NCT03260881|DRUG|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
58461795|NCT03260881|DRUG|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
58461796|NCT02144181|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
58461797|NCT04070781|DRUG|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
58461798|NCT04070781|DRUG|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
58461799|NCT03383601|OTHER|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
58461800|NCT03383601|OTHER|Smoking combustible cigarettes|Current smoking of combustible cigarettes
58461801|NCT01442246|DRUG|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
58461802|NCT00402857|BEHAVIORAL|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
58461803|NCT05963334|DRUG|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
58461804|NCT01404507|DRUG|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
58130816|NCT02204969|DIETARY_SUPPLEMENT|Lithia water|"* Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
58138180|NCT05044221|OTHER|Health care professional workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
58461805|NCT01404507|DEVICE|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
58461806|NCT01404507|OTHER|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
58461807|NCT05824650|OTHER|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
58461808|NCT01944137|OTHER|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
58461809|NCT06009562|PROCEDURE|Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
58461810|NCT04741581|DIETARY_SUPPLEMENT|ThickenUp® Gel Express|Thickening gel
58461811|NCT02017197|DRUG|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
58461812|NCT02017197|DRUG|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
58461813|NCT02017197|DRUG|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
58461814|NCT00303823|DRUG|placebo|Given orally
58130817|NCT02204969|DEVICE|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
58461815|NCT00303823|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
58461816|NCT00303823|OTHER|laboratory biomarker analysis|Correlative studies
58461817|NCT04083781|DRUG|Concizumab|Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
58461818|NCT06214975|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on stroke related symptoms."
58461819|NCT03586765|OTHER|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
58461820|NCT00005984|DRUG|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
58461821|NCT00005984|DRUG|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
58461822|NCT00005984|DRUG|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
58461823|NCT00005984|PROCEDURE|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
58461824|NCT00005984|PROCEDURE|radiation therapy|total body irradiation twice a day on days -4 through -1
58461825|NCT05843435|BEHAVIORAL|Go-Nogo-task during functional magnetic resonance imaging|Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.
58461826|NCT05843435|OTHER|Resting-state functional magnetic resonance imaging|An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.
58461827|NCT03803306|COMBINATION_PRODUCT|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
58461828|NCT03803306|OTHER|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
58461829|NCT04468061|DRUG|Sacituzumab Govitecan|Intravenous Infusion
58461830|NCT04468061|DRUG|Pembrolizumab|Intravenous Infusion
58461831|NCT03964350|DRUG|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
58461832|NCT03964350|OTHER|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
58461833|NCT05086185|DIAGNOSTIC_TEST|Kalemic Response to Orange Juice|100% pulp-free orange juice
58461834|NCT05086185|DIETARY_SUPPLEMENT|Kalemic Response to Orange Juice with Fiber|100% pulp-free orange juice with psyllium-based fiber added
58461835|NCT00001832|DRUG|gp100:209-217 (210M)|"gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
58461836|NCT00001832|DRUG|Montanide ISA-51|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
58461837|NCT00001832|DRUG|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
58461838|NCT00001832|DRUG|MART-1:26-35(27L)|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
58461839|NCT00001832|BIOLOGICAL|Abl cells|Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
58461840|NCT00001832|DRUG|Fludarabine|5x25 mg/m\^2 intravenous
58461841|NCT00001832|DRUG|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
58461842|NCT00001832|BIOLOGICAL|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.
58461843|NCT00001832|PROCEDURE|Apheresis|
58461844|NCT03217344|PROCEDURE|conservative treatment|immobilization on sling of the injured arm
58461845|NCT05421949|OTHER|Exercise group|Incremental Shuttle Walking Test
58461846|NCT01028443|DRUG|Sandimmune|
58461847|NCT01028443|DRUG|Artelose|
58461848|NCT02647099|DRUG|Acetylsalicylic acid|
58461849|NCT02647099|DRUG|Placebo|
58461850|NCT03992053|OTHER|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
58461851|NCT00186576|PROCEDURE|nonmyeloablative allogeneic hematopoietic cell transplant|
58461852|NCT01064063|DEVICE|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
58461853|NCT01064063|DEVICE|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
58461854|NCT04457206|BEHAVIORAL|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
58461855|NCT06056310|DRUG|Xevinapant|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
58461856|NCT06056310|DRUG|Cisplatin|Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
58461857|NCT06056310|RADIATION|intensity-modulated radiation therapy (IMRT)|Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
58461858|NCT04481243|BIOLOGICAL|Pneumovax 23- pneumococcal polysaccharide|PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
58461859|NCT04481243|PROCEDURE|Blood draw|6 ml blood draw at baseline and 6 months post immunization
58461860|NCT00991861|DRUG|LAS41007 o.d.|Once daily, topical application
58461861|NCT00991861|DRUG|LAS41007 b.i.d.|Twice daily, topical application
58461862|NCT00991861|DRUG|LAS106521|Twice daily, topical application
58461863|NCT01161940|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
58461864|NCT01161940|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
58461865|NCT02571712|DRUG|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
58461866|NCT05149235|OTHER|early mobilization group|Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).
58461867|NCT05149235|DEVICE|physio adventure|The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.
58461868|NCT05149235|OTHER|placebo|Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
58461869|NCT05633563|DRUG|Trimetazidine|Oral intake of capsules
58461870|NCT05633563|DRUG|Placebo|Oral intake of capsules
58461871|NCT03253679|DRUG|Adavosertib|Given PO
58461872|NCT03460886|DEVICE|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
58130818|NCT02979353|BEHAVIORAL|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
58461873|NCT03460886|DEVICE|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
58461874|NCT03460886|OTHER|Walking on treadmill|walking on treadmill for 10 minutes
58461875|NCT06415890|OTHER|4-7-8 Breathing Technique|The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
58461876|NCT05318001|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
58461877|NCT05318001|OTHER|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
58461878|NCT05318001|OTHER|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
58461879|NCT05318001|OTHER|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
58461880|NCT06568016|OTHER|Best Practice|Receive clinical care consistent with current practice
58461881|NCT06568016|OTHER|Communication Intervention|Receive standardized communication from FIT QI champion
58461882|NCT06568016|OTHER|Communication Intervention|Receive coordination from GI liaisons
58461883|NCT06568016|OTHER|Coordination|Receive enhanced GI care coordination
58461884|NCT06568016|OTHER|Educational Intervention|Watch pre-colonoscopy educational video
58461885|NCT06568016|OTHER|Electronic Health Record Review|Undergo FIT result review by Primary Care FIT Tracker
58461886|NCT06568016|OTHER|Electronic Health Record Review|Ancillary studies
58461887|NCT06568016|OTHER|Informational Intervention|Undergo generation and review of GI FIT Tracker report
58461888|NCT06568016|OTHER|Informational Intervention|Receive informational sheet
58461889|NCT06568016|OTHER|Interview|Ancillary studies
58461890|NCT06568016|BEHAVIORAL|Patient Navigation|Receive navigation from GI liaisons
58461891|NCT06568016|OTHER|Referral|Receive referral
58461892|NCT06568016|OTHER|Referral|Receive referral per standardized template
58461893|NCT06568016|OTHER|Text Message-Based Navigation Intervention|Receive follow-up text message
58461894|NCT01172535|DRUG|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
58461895|NCT01723735|DRUG|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
58130819|NCT02377336|DRUG|GS-6615|GS-6615 tablets administered orally
58461896|NCT01723735|DRUG|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
58461897|NCT01723735|DRUG|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
58461898|NCT01723735|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
58461899|NCT03497663|OTHER|VIA Family intervention|Family based intervention
58461900|NCT03497663|OTHER|Treatment As Usual|Treatment As Usual
58461901|NCT01701206|BEHAVIORAL|HIV knowledge Intervention|
58461902|NCT03808090|DIETARY_SUPPLEMENT|Normal Individuals|"Controlled Dietary phase: Low oxalate fixed diet~4 days of fixed normal calorie diet with low oxalate (\< 60 mg/day), normal calcium (800-1200 mg/day)"
58461903|NCT05656417|BEHAVIORAL|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
58461904|NCT04319952|DEVICE|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
58461905|NCT01323582|DRUG|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
58491313|NCT02928016|OTHER|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
58461906|NCT01323582|DRUG|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
58461907|NCT02905097|PROCEDURE|Knee Replacement|Surgical replacement of arthritic knee with an implant
58461908|NCT03382132|BEHAVIORAL|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
58461909|NCT03382132|BEHAVIORAL|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
58461910|NCT00334217|BEHAVIORAL|Cognitive Remediation|PSS Cogrehab
58461911|NCT06297187|DEVICE|CUSA (Cavitronic Ultrasonic Surgical Aspirator)|CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
58461912|NCT00924521|DIETARY_SUPPLEMENT|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
58461913|NCT00924521|DIETARY_SUPPLEMENT|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
58461914|NCT03715517|PROCEDURE|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
58461915|NCT03715517|PROCEDURE|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
58461916|NCT03715517|DRUG|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
58461917|NCT03715517|DRUG|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
58461918|NCT03715517|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
58461919|NCT03715517|DRUG|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
58461920|NCT03715517|DRUG|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
58461921|NCT05952349|DRUG|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
58461922|NCT05952349|DRUG|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
58461923|NCT05288309|OTHER|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
57777890|NCT01287793|DRUG|tigecycline|intravenous, 50 mg, single dose
58461924|NCT05288309|OTHER|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
58461925|NCT05638932|DRUG|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
58130820|NCT02377336|DRUG|Placebo|Placebo to match GS-6615 tablets administered orally
58130821|NCT00682305|PROCEDURE|Hematopoietic stem cell transplantation|"conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT"
57777891|NCT01287793|DRUG|moxifloxacin|oral tablet, 400 mg, single dose
58130822|NCT04366141|DEVICE|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
58461926|NCT03866746|DRUG|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
58461927|NCT03866746|OTHER|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
58461928|NCT01552070|BEHAVIORAL|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
58461929|NCT01552070|OTHER|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
58461930|NCT03047941|DIAGNOSTIC_TEST|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
58461931|NCT03052790|PROCEDURE|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
58461932|NCT03052790|DEVICE|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
58461933|NCT04869982|BIOLOGICAL|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
58461934|NCT04869982|DRUG|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
58461935|NCT05236517|DRUG|Semaglutide D Dose 1|Tablet given orally
58461936|NCT05236517|DRUG|Semaglutide D Dose 2|Tablet given orally
58461937|NCT05236517|DRUG|Semaglutide D Dose 3|Tablet given orally
58461938|NCT05236517|DRUG|Semaglutide C Dose 4|Tablet given orally
58461939|NCT05236517|DRUG|Semaglutide C Dose 5 (50 mg)|Tablet given orally
58461940|NCT05236517|DRUG|Placebo (Semaglutide C)|Tablet given orally
58461941|NCT05236517|DRUG|Placebo ( Semaglutide D)|Tablet given orally
58461942|NCT03795571|DRUG|Rituximab|Rituximab 375mg/m2，d0
58461943|NCT03795571|DRUG|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
58461944|NCT03795571|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2，d1
58461945|NCT03795571|DRUG|Dexamethasone|Dexamethasone 40mg/d，d1\~d4
58461946|NCT03795571|DRUG|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle
58461947|NCT02799836|DEVICE|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
58461948|NCT05025839|OTHER|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
58461949|NCT01857219|BEHAVIORAL|Tai chi|
58461950|NCT04991870|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
58461951|NCT04991870|PROCEDURE|Resection|Undergo surgical resection
58461952|NCT01393158|DRUG|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
58461953|NCT03261336|DRUG|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
58461954|NCT00315835|DRUG|Buprenorphine transdermal delivery system|
58461955|NCT05688059|OTHER|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
58461956|NCT05403606|DEVICE|GASPARD®|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
58461957|NCT03318549|DIAGNOSTIC_TEST|Visual Performance tests|Participants came to the clinic in person for 2 hours for visual performance tests once every 6 months for up to 5 years. These tests included virtual reality tests and tests on a computer screen to investigate performance during simulated daily life activities, such as driving, situations of low contrast and glare.
57777892|NCT01287793|DRUG|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
57777893|NCT01287793|DRUG|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
58461958|NCT03318549|DEVICE|Brain-computer interface|The brain-computer interface (BCI) consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle. The test is done in person and may take up to 30 minutes, once every 6 months for up to 5 years.
58461959|NCT01071681|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
58461960|NCT05295212|DRUG|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
58461961|NCT05263739|DRUG|ESG206|Administered via intravenous (IV) infusion
58461962|NCT06593353|OTHER|Systems Analysis and Improvement Approach (SAIA)|SAIA an evidence-based, multi-prong, implementation strategy to improve systems thinking amongst frontline care teams to optimize care quality and continuity. The intervention includes monthly meetings where patient care cascades, process mapping and continuous quality improvement are used to identify bottlenecks and prioritize clinic based solutions.
58461963|NCT04213300|OTHER|Low carbohydrate diet|"Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) ."
58461964|NCT03293108|DRUG|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
58461965|NCT03293108|DIETARY_SUPPLEMENT|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
58461966|NCT03293108|DIETARY_SUPPLEMENT|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
58461967|NCT01095640|DRUG|adapalene 0.3% topical gel|once a day, 84 days
58461968|NCT04860323|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
58461969|NCT03872375|DIETARY_SUPPLEMENT|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
58461970|NCT03872375|BEHAVIORAL|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
58461971|NCT05222958|DEVICE|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
58461972|NCT06525415|DIAGNOSTIC_TEST|DCE MRI|the recruited patients should complete pre- and post-operative DCE MRI workshops
58461973|NCT00379847|DRUG|conivaptan|IV
58461974|NCT00282763|DRUG|MK0686|
58461975|NCT03863886|PROCEDURE|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
58461976|NCT03269526|DRUG|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
58461977|NCT06223334|OTHER|No intervention|observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
58461978|NCT06706388|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
58461979|NCT00828243|DRUG|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
58461980|NCT00004100|DRUG|cisplatin|
58461981|NCT00004100|DRUG|gemcitabine hydrochloride|
58461982|NCT00004100|DRUG|vinorelbine tartrate|
58130823|NCT03219398|PROCEDURE|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
58130824|NCT01566071|OTHER|Assessment of drive abilities|
58130825|NCT00101582|DRUG|Placebo|
58461983|NCT04296760|DIAGNOSTIC_TEST|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
58461984|NCT04296760|DIAGNOSTIC_TEST|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
58461985|NCT02923141|BEHAVIORAL|Neutral Writing|
58461986|NCT02923141|BEHAVIORAL|Expressive Writing|
58461987|NCT02923141|BEHAVIORAL|Contingency Management|
58461988|NCT03289208|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
58461989|NCT03863184|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
58461990|NCT03863184|DRUG|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
58461991|NCT03863184|DRUG|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
58130826|NCT00101582|DRUG|palifermin|
58130827|NCT00101582|DRUG|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
58461992|NCT04602403|PROCEDURE|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
58491314|NCT02928016|OTHER|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
58461993|NCT04923477|OTHER|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
58461994|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
58461995|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|"ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL"
58461996|NCT00686777|BIOLOGICAL|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
58461997|NCT00686777|DRUG|Ribavirin|Ribavirin 400 mg/day orally
58461998|NCT04392323|DIAGNOSTIC_TEST|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
58461999|NCT01308541|DRUG|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
58462000|NCT01308541|DRUG|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
58462001|NCT01308541|DRUG|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
58462002|NCT00739401|DEVICE|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
58462003|NCT00983346|DRUG|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
58462004|NCT01316523|DRUG|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
58462005|NCT01316523|DRUG|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
58462006|NCT05890248|PROCEDURE|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
58462007|NCT05757141|DRUG|Fosigotifator|Oral Use
58462008|NCT04587518|BEHAVIORAL|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
58462009|NCT03860792|BEHAVIORAL|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
58462010|NCT03860792|BEHAVIORAL|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
58462011|NCT03267368|BEHAVIORAL|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
58462012|NCT05484804|OTHER|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
58130828|NCT00101582|RADIATION|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
58130829|NCT00536900|BEHAVIORAL|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
58462013|NCT05484804|OTHER|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
58462014|NCT04907682|DRUG|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
58462015|NCT04907682|DRUG|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
58462016|NCT06381804|OTHER|shotblocker|shotblocker device
58462017|NCT06381804|OTHER|palm stimulator|palm stimulator
58462018|NCT03852602|DRUG|Preemptive Analgesics|Analgesic application15 minutes before the treatment
58462019|NCT03852602|DRUG|Control|Analgesic application15 minutes before the end of the treatment
58462020|NCT03701958|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
58462021|NCT03820609|BEHAVIORAL|Digital Intervention|This digital application for sexual assault prevention can be completed on a tablet computer.
58462022|NCT04776317|BIOLOGICAL|ChAdV68-S|Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
57777894|NCT01471158|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
58462023|NCT04776317|BIOLOGICAL|ChAdV68-S-TCE|Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
58462024|NCT04776317|BIOLOGICAL|SAM-LNP-S|Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
58462025|NCT04776317|BIOLOGICAL|SAM-LNP-S-TCE|Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
58462026|NCT04776317|OTHER|Sodium Chloride, 0.9%|The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
58462027|NCT02482376|RADIATION|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
58462028|NCT04053335|BEHAVIORAL|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~* Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~* Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~* Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~* Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~* Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
58462029|NCT03553901|PROCEDURE|Acupressure|Acupressure was performed before the injection onto GB30 point
58462030|NCT01274026|DRUG|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
58462031|NCT05790551|DEVICE|Addinex|Medication dispensing system for Suboxone
58462032|NCT03717688|DRUG|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
58462033|NCT03717688|DRUG|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
58462034|NCT03717688|DRUG|Placebos|No treatment
58462035|NCT05794425|DRUG|Cyclosporine A|3-5 mg per kilogram per day.
57777895|NCT01471158|DRUG|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
57784482|NCT03413605|BEHAVIORAL|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
58462036|NCT05794425|BIOLOGICAL|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
58462037|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
58462038|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
58462039|NCT02140047|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
58462040|NCT06532643|GENETIC|anti-CD20/CD30-CAR-T cells|"Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed."
58462041|NCT06532643|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
58462042|NCT06532643|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
58462043|NCT03806192|BEHAVIORAL|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
58462044|NCT03806192|OTHER|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
58462045|NCT03806192|OTHER|Questionnaire Administration|Ancillary studies
58462046|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462047|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462048|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462049|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462050|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462051|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
58462052|NCT05001035|OTHER|Time of assessment|Immediate and after one month and after two months
58462053|NCT02134223|BEHAVIORAL|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
58462054|NCT02134223|OTHER|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
58462055|NCT06253702|DRUG|Indomethacin|to inhibit cyclooxygenase (COX)
58462056|NCT06253702|DRUG|Placebo|Placebo
58462057|NCT06253702|DRUG|Orilissa|to suppress hormones 200mg dose 2x per day (all participants)
58462058|NCT06253702|DRUG|Testosterone gel|50 mg each morning for add back phase (male participants)
58462059|NCT06253702|DRUG|Anastrozole|1mg/day in men to prevent conversion of testosterone to estradiol
58462060|NCT06253702|DRUG|Estradiol|Women will receive oral estradiol 2mg/daily
58462061|NCT03820596|DRUG|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
58462062|NCT03820596|DRUG|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
58462063|NCT03608319|DRUG|A4250|9.6 mg
58462064|NCT01908426|DRUG|Cabozantinib tablets|
58462065|NCT01908426|DRUG|Placebo tablets|
58462066|NCT00647517|DRUG|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
58462067|NCT04482517|OTHER|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
58462068|NCT04482517|OTHER|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
58462069|NCT04482517|OTHER|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
58462070|NCT04482517|OTHER|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
58462071|NCT05306964|PROCEDURE|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
58462072|NCT05306964|PROCEDURE|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
58462073|NCT03667274|PROCEDURE|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
58462074|NCT03867214|DRUG|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
58462075|NCT03867214|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
58462076|NCT06322849|BEHAVIORAL|Psychoeducation|Psychoeducation is a potential active element of Project ABC. In psychoeducation, participants learn about the cognitive model of behavior and how they can take action to change their moods.
58462077|NCT06322849|BEHAVIORAL|Testimonials and Saying is believing exercises|Testimonials and Saying is believing exercises is a potential active element of Project ABC. In this element, participants learn about how others have taken action to improve their mood and complete one exercise where they give advice to a virtual peer who is stuck in a negative spiral.
58462078|NCT06322849|BEHAVIORAL|Action planning|Action planning is a potential active element of Project ABC. In this element, participants plan in detail an action they can take to get out of the negative mood spiral.
58462079|NCT06322849|BEHAVIORAL|Breathing exercise|Participants will be presented with a one-minute breathing exercise.
58462080|NCT01447654|DRUG|Losartan|100 mg for 12 months.
58462081|NCT01447654|DRUG|Placebo|100 mg for 12 months.
58462082|NCT00774046|DRUG|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
58462083|NCT00774046|DRUG|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
58462084|NCT00774046|DRUG|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
58462085|NCT00003122|PROCEDURE|surgical procedure|
58462086|NCT05400317|DRUG|AD-218|PO, Once daily(QD), 12weeks
58462087|NCT05400317|DRUG|AD-218A|PO, Once daily(QD), 12weeks
58462088|NCT00988832|BIOLOGICAL|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
58462089|NCT00994552|OTHER|Pressure support ventilation|Pressure support ventilation
58462090|NCT00994552|OTHER|Pressure control ventilation|Pressure control ventilation
58462091|NCT04498221|PROCEDURE|Imaging procedure|During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
58462092|NCT04498221|PROCEDURE|Surgical procedure|Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
58462093|NCT02641925|PROCEDURE|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
58462094|NCT02641925|PROCEDURE|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
58462095|NCT05732467|DEVICE|visual function training software|Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.
58462096|NCT05732467|OTHER|occlusion therapy|Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.
58462097|NCT05732467|OTHER|corrective glasses|corrective glasses
58462098|NCT02356276|PROCEDURE|D2 lymphadenectomy|
58462099|NCT02356276|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.
58462100|NCT02356276|DRUG|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
57777896|NCT02120989|BEHAVIORAL|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
58462101|NCT06166056|DRUG|CHF6333|CHF6333 Part I SAD; CHF6333 Part II MD.
58462102|NCT06166056|DRUG|CHF6333 Placebo|Placebo Part I SAD; Placebo Part II MD.
58462103|NCT05920798|PROCEDURE|Biopsy|Undergo biopsy
58462104|NCT05920798|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58462105|NCT05920798|PROCEDURE|Computed Tomography|Undergo CT
58462106|NCT05920798|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58462107|NCT05920798|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
58462108|NCT05920798|BIOLOGICAL|Pembrolizumab|Given IV
58462109|NCT05920798|PROCEDURE|Pheresis|Undergo apheresis
58462110|NCT01909440|BEHAVIORAL|exercise intervention|Receive whole body RT
58462111|NCT01909440|DIETARY_SUPPLEMENT|nutritional supplementation|Given whey protein supplementation PO
58462112|NCT01909440|PROCEDURE|quality-of-life assessment|Ancillary studies
58462113|NCT01909440|OTHER|questionnaire administration|Ancillary studies
58462114|NCT01909440|OTHER|pharmacological study|Correlative studies
58462115|NCT01909440|OTHER|laboratory biomarker analysis|Correlative studies
58462116|NCT02423850|DEVICE|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
58462117|NCT04783350|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
58462118|NCT02066363|DIETARY_SUPPLEMENT|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
58462119|NCT02066363|DIETARY_SUPPLEMENT|Parenteral nutrition|Supportive parenteral nutrition.
58491315|NCT05526963|OTHER|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
58462120|NCT06571305|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
58462121|NCT06571305|BEHAVIORAL|My Sleep Our Sleep (MSOS)|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
58462122|NCT03495661|PROCEDURE|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
58462123|NCT04711655|PROCEDURE|ARMA (antireflux ablation of the cardiac mucosa)|is an endoscopy in which argon gas ablation of the cardiac mucosa
58462124|NCT04711655|PROCEDURE|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
58462125|NCT00282035|RADIATION|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
58462126|NCT00282035|RADIATION|Whole breast irradiation|Whole breast irradiation
58462127|NCT01179724|DRUG|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
58462128|NCT01179724|DRUG|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
58462129|NCT04978350|BEHAVIORAL|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
58462130|NCT03964103|DIETARY_SUPPLEMENT|gQ-lab daily|probiotics
58462131|NCT03964103|DIETARY_SUPPLEMENT|Placebo|powdered skim milk, lactose
58462132|NCT02403557|BEHAVIORAL|Waitlist|Weekly check up.
58462133|NCT02403557|BEHAVIORAL|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
58462134|NCT06333106|OTHER|POCUS diagnostic value|Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room
58462135|NCT05359172|DRUG|Tranexamic acid|preoperative intravenous infusion
58462136|NCT03816033|PROCEDURE|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
58462137|NCT03816033|PROCEDURE|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
58462138|NCT04810650|OTHER|Mobility Dynamic Treatment Intervention|"1) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
58462139|NCT04810650|OTHER|Health Living Intervention for Heavy Alcohol Users|1) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
58462140|NCT04810650|OTHER|Hypertension Linkage|1) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
58462141|NCT04810650|OTHER|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
58462142|NCT04810650|OTHER|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
58462143|NCT04810650|OTHER|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
57777897|NCT04091906|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
58462144|NCT04810650|OTHER|Standard of Care|Local country standard of care protocols
58462145|NCT04810650|OTHER|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
58462146|NCT04818658|OTHER|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
58462147|NCT03351842|DRUG|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
58462148|NCT03351842|PROCEDURE|Undergo surgery|Therapeutic conventional surgery, R0 resection
58462149|NCT04642625|OTHER|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and \>7cm are the indicators of severe pain."
58462150|NCT04642625|OTHER|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
58462151|NCT05096624|OTHER|DD-TENS system|Use of DD-TENS system
58462152|NCT05096624|OTHER|Gold Standard|Gold standard
58462153|NCT05096624|OTHER|Digital Denture system|Use of Digital Denture system
58462154|NCT03991312|DRUG|itraconazole|Participants will receive an oral solution as described in the arm description.
58462155|NCT03991312|DRUG|rifampin|Participants will receive oral capsule(s) as described in the arm description.
58462156|NCT03991312|DRUG|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
58462157|NCT02969798|DRUG|Dapagliflozin|10mg/day
58462158|NCT02969798|DRUG|Saxagliptin|5mg/day
58462159|NCT02969798|DRUG|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
58462160|NCT02969798|DRUG|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
58462161|NCT02592291|DEVICE|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
58462162|NCT04975841|DEVICE|Adipose Derived Regenerative Cells|"The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility."
58462163|NCT03253796|BIOLOGICAL|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
58462164|NCT03253796|BIOLOGICAL|Placebo|Injections of matching placebo for golimumab.
58462165|NCT02883569|PROCEDURE|open or endoscopic discectomy|FDA approved surgical procedures
58462166|NCT02883569|PROCEDURE|epidural block|epidural block
58462167|NCT02883569|OTHER|exercise|educated exercise
58462168|NCT02883569|DRUG|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
58462169|NCT02883569|PROCEDURE|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
58462170|NCT02883569|PROCEDURE|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
58462171|NCT02883569|DRUG|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
58130830|NCT00536900|BEHAVIORAL|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
58462172|NCT02883569|PROCEDURE|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
58462173|NCT01673529|DRUG|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
58462174|NCT01673529|DRUG|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
58462175|NCT04451785|BIOLOGICAL|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
58462176|NCT04451785|DIAGNOSTIC_TEST|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
58462177|NCT02163902|DRUG|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
58462178|NCT02163902|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
58462179|NCT04134416|DRUG|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
57777898|NCT02404493|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
57777899|NCT02404493|DRUG|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
58130831|NCT03208543|DEVICE|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
58462180|NCT04134416|BEHAVIORAL|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
58462181|NCT04134416|DEVICE|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
58462182|NCT00173472|DRUG|Chemotherapy|
58462183|NCT02772601|DRUG|Caffeine|
58462184|NCT02772601|DRUG|Warfarin|
58462185|NCT02772601|DRUG|Omeprazole|
58462186|NCT02772601|DRUG|Metoprolol|
58462187|NCT02772601|DRUG|Midazolam|
58130832|NCT03795363|DRUG|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
58462188|NCT02772601|DRUG|Risankizumab|
58462189|NCT00812994|DRUG|Escitalopram|SSRI antidepressant
58462190|NCT00812994|DRUG|Placebo|
58462191|NCT06079138|DEVICE|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
58462192|NCT06079138|DEVICE|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
58462193|NCT06079138|OTHER|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
58462194|NCT05830058|PROCEDURE|Biospecimen Collection|Undergo blood collection
58462195|NCT05830058|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58462196|NCT05830058|PROCEDURE|Positron Emission Tomography|Undergo PET
58462197|NCT05830058|OTHER|Questionnaire Administration|Ancillary studies
58462198|NCT05830058|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58462199|NCT02352480|DEVICE|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
58462200|NCT02438176|PROCEDURE|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
58462201|NCT02438176|PROCEDURE|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
58462202|NCT01088789|BIOLOGICAL|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|"A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months."
58130833|NCT00048646|DRUG|IV Progesterone|
58462203|NCT00453895|DRUG|Sunitinib|50mg Sunitinib
58462204|NCT02847377|OTHER|Injection of [18F]-ODS2004436 radiotracer|
58462205|NCT06439095|GENETIC|Salivary Collection|Expression levels of IL-2, IL-5 and IL-17 in the saliva of individuals aged 7-13 years who underwent stainless steel crown will be recorded before and after the procedure. Before the saliva sample collection procedure, the patient will be asked to rinse their mouth with sterile water and then spit into sterile plastic cups. After collecting approximately 3 ml of saliva, the saliva will be transferred to appropriate eppendorfs and stored at -40 degrees Celsius. For the second post-procedure, the same algorithms will be applied for saliva collection seven days after the crown procedure.
58462206|NCT06439095|DIAGNOSTIC_TEST|Ph and ion level measurement of saliva|Salivary concentration of nickel, chrome, cobalt and palladium ions will be measured using an atomic absorption spectrophotometer. Salivary pH will be measured with the help of a digital pH meter
58462207|NCT00002298|DRUG|Ribavirin|
58130834|NCT05028842|OTHER|No intervention|None.This is an observational study
58462208|NCT06240052|BEHAVIORAL|Conditioning and active avoidance paradigm (CAAP)|On day 1 subjects will undergo image viewing, fear conditioning, and avoidance learning. Subjects will be instructed to passively view the images from 3 categories on the screen, with 2 of the 3 categories being paired with a mild shock to the subjects' foot. Then they will see a picture of a button on the screen together with all three categories. If they press the button, they may prevent the shock from occurring. Pressing the button for one of the conditioned categories will prevent the shock from happening. Pressing the button to the other conditioned cue will not prevent the shock .Pressing the button to the third category does nothing. On day 2, subjects will be given $5 and will be told that they can press a button to avoid a shock. The number of times the button was pressed will be counted and if it is less than the number by another randomly selected participant then the participant will get to keep the money.
58462209|NCT04291651|OTHER|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
58462210|NCT03596034|OTHER|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
58462211|NCT01832636|DIETARY_SUPPLEMENT|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
58462212|NCT00773448|DEVICE|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
58462213|NCT00773448|OTHER|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year."
58462214|NCT06204341|RADIATION|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
58462215|NCT00380939|DRUG|Atorvastatin|
58462216|NCT00380939|DRUG|Pravastatin|
58462217|NCT01889667|DRUG|ORMD-0801 Dose # 1|Oral Insulin Formulation
58462218|NCT01889667|DRUG|ORMD-0801 Dose # 2|Oral Insulin Formulation
58462219|NCT01889667|DRUG|Placebo|Oil Capsules
58462220|NCT03452540|DRUG|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
58462221|NCT03392103|DRUG|Raltitrexed|concurrent chemotherapy
58462222|NCT03392103|RADIATION|postoperative radiotherapy|concurrent postoperative radiation therapy
58462223|NCT03259230|OTHER|Blood Draws|
58462224|NCT03259230|OTHER|Data Collection|
58462225|NCT04453657|DEVICE|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
58462226|NCT01288235|RADIATION|Proton radiotherapy|5 days a week
58462227|NCT05112575|RADIATION|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
58462228|NCT02313766|OTHER|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
58462229|NCT02313766|OTHER|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
58462230|NCT02262585|DRUG|BIBR 277 tablet|
58462231|NCT02262585|DRUG|BIBR 277 capsule|
58462232|NCT03728868|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
58462233|NCT03728868|DIETARY_SUPPLEMENT|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
58462234|NCT03728868|DIETARY_SUPPLEMENT|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
58462235|NCT03446625|DRUG|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
58462236|NCT03446625|DRUG|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
58462237|NCT06102096|BEHAVIORAL|Culturally Adapted iCBT|A culturally adapted iCBT targeting mild to moderate mental health problems among Arabic-speaking refugee and migrant youth.
58462238|NCT06492005|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
58462239|NCT06492005|DRUG|PD-1 inhibitior|Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
58462240|NCT05980806|DRUG|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
58462241|NCT05980806|DRUG|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
58462242|NCT05980806|DRUG|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
58462243|NCT05980806|DRUG|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
58462244|NCT05980806|DRUG|Momelotinib|Participants will receive momelotinib 200 mg once daily.
58462245|NCT02856412|OTHER|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
58462246|NCT02856412|OTHER|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
58462247|NCT00777140|DRUG|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
58462248|NCT06093906|BEHAVIORAL|Positive Processes and Transition to Health|See arm/group description for details regarding this intervention
58462249|NCT06093906|BEHAVIORAL|Progressive Muscle Relaxation|See arm/group description for details regarding this intervention
58462250|NCT05963672|DEVICE|EEG-guided sleep protection|"The tablet will display a specific picture prioritize sleep or prioritize care depending on the patient status determined by the algorithm. When the picture favor/prioritize sleep is displayed, all caregivers and visiting family are asked to follow the sleep protection rules: refrain to enter the room for not urgent reasons, switch off television, reduced light in the room/corridor, reduce noise in front of the door, close curtain (if any), and delay non urgent care...etc; if caregivers have to enter the room, headlight and/or additional light will be favored. All these rules will be established collegially by nurses and doctors. Obviously, urgent care and reactions to alarms are maintained.~When the picture favor/prioritize care is displayed, all caregivers and visiting family are invited to perform non urgent care, cleaning, restocking perfusion needles, comfort care, visiting."
58462251|NCT05963672|OTHER|Control condition|the recording device will be placed on the patient to record sleep but the tablet will be masked and placed face down on the bench in the room, invisible from the door.
58462252|NCT05192200|DRUG|Anti-Beta Interferon (PF-06823859)|IV infusion
58462253|NCT03446755|DEVICE|intra uterine Cook balloon|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
57777900|NCT02951299|DRUG|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
58130835|NCT05020847|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml
58462254|NCT01716286|DIETARY_SUPPLEMENT|low fat vs. essence yoghurt|
58462255|NCT04149834|PROCEDURE|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
58462256|NCT04149834|PROCEDURE|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
58462257|NCT04068402|DEVICE|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
58130836|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 with CMV|Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
57777901|NCT01224808|BIOLOGICAL|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
57777902|NCT01832415|DRUG|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
57777903|NCT05743192|OTHER|Stop performing an antibiotic susceptibility test|Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
57777904|NCT00859131|DRUG|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
57777905|NCT00859131|DRUG|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
57777906|NCT03403257|OTHER|No interventions|No intervention
57777907|NCT01958762|OTHER|Invitation for oral cavity cancer screening|
58130837|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 without CMV|Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
58130838|NCT01504737|OTHER|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
58130839|NCT01504737|OTHER|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
58130840|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
58130841|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
58130842|NCT00571428|DRUG|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
58130843|NCT01345149|BEHAVIORAL|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
58462258|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
58462259|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
58462260|NCT05872685|DRUG|S1|S-1 orally intake as perioperative chemotherapy
58462261|NCT05872685|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
58462262|NCT05872685|DRUG|Serplulimab|Perioperative serplulimab, 300 mg IV infusion
58462263|NCT05872685|DRUG|Placebo|Perioperative placebo, 300 mg IV infusion
58491316|NCT05526963|BEHAVIORAL|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
58462264|NCT03866070|OTHER|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
58462265|NCT03866070|OTHER|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
58462266|NCT01589796|PROCEDURE|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
58462267|NCT00040586|DRUG|Monoclonal Antibody J591|
58462268|NCT00040586|DRUG|Recombinant Interleukin-2|
58462269|NCT05557916|OTHER|Standard rehab|Standard rehab protocol including knee orthosis following meniscal repair
58462270|NCT05557916|OTHER|accelerated rehab group|accelerated rehab group, no orthosis
58462271|NCT00240123|DRUG|Benadryl versus Placebo|
58462272|NCT02446977|DRUG|Vitamin B2 Streuli®|4ml IV
58462273|NCT02446977|OTHER|Solution for injection|4ml IV
58462274|NCT03086096|DEVICE|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
58462275|NCT04937985|OTHER|Performance Tests|Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
58462276|NCT03496259|DEVICE|On-Q pump|Type of pain control device used
58462277|NCT03496259|DEVICE|Epidural catheter|Type of pain control device used
58462278|NCT03593902|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
58462279|NCT03593902|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
58130844|NCT03673488|DEVICE|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
58130845|NCT06496061|DRUG|Norepinephrine|Norepinephrine infusion with 0.05 mg/kg/h
58130846|NCT06496061|PROCEDURE|Leg wrapping|Elastic leg wrapping
58130847|NCT01134523|DRUG|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
58130848|NCT01134523|DRUG|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
58130849|NCT03503448|PROCEDURE|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
58130850|NCT03503448|PROCEDURE|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
58130851|NCT04418726|OTHER|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
58130852|NCT03987009|DEVICE|Without RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
58130853|NCT03987009|DEVICE|With RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
58462280|NCT03593902|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
58462281|NCT03593902|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
58462282|NCT03593902|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
58462283|NCT03593902|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
58462284|NCT03593902|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
58462285|NCT03593902|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
58462286|NCT03593902|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
58462287|NCT05581173|DEVICE|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
58462288|NCT05749341|DIAGNOSTIC_TEST|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
58462289|NCT03727815|OTHER|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
58462290|NCT03727815|OTHER|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
58462291|NCT04006288|DRUG|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
58462292|NCT04006288|DRUG|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
58462293|NCT04006288|DRUG|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
58462294|NCT04006288|DRUG|aspirin|all patients will remain on aspirin
58462295|NCT04006288|DRUG|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
58462296|NCT00002088|DRUG|Saccharomyces boulardii|
58462297|NCT01841281|DRUG|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
58462298|NCT01841281|DRUG|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
58462299|NCT03650621|DEVICE|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
58462300|NCT03650621|DEVICE|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
58462301|NCT00149877|DRUG|Tegaserod|
58130854|NCT03987009|DEVICE|Without RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
58130855|NCT03987009|DEVICE|With RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
58462302|NCT03377582|OTHER|Exercise|Both interventions uses exercises
58462303|NCT05933746|BEHAVIORAL|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
58462304|NCT05933746|BEHAVIORAL|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
58462305|NCT04620785|OTHER|methylene blue / IPL|therapeutic
58462306|NCT04620785|OTHER|IPL|therapeutic
58462307|NCT04620785|OTHER|saline|placebo
58462308|NCT04587947|DRUG|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
58462309|NCT05301985|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
58462310|NCT02661321|OTHER|No intervention was used in this study, this was an observational study|
58462311|NCT02151487|DRUG|Ropivacaine|Ropivacaine alone
58462312|NCT02151487|DRUG|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
58462313|NCT02151487|DRUG|Ropivacaine and clonidine|Ropivacaine combination with clonidine
58130856|NCT02457429|DEVICE|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
58462314|NCT02151487|DRUG|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
58462315|NCT04722900|OTHER|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
58462316|NCT00525512|DRUG|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
58462317|NCT00525512|DRUG|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
58462318|NCT03082690|DRUG|DuoGel|1% IQP-0528 in gel formulation
58462319|NCT02616991|PROCEDURE|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
58462320|NCT02681809|DRUG|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
58462321|NCT02681809|DRUG|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
58462322|NCT02681809|DRUG|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
58462323|NCT04404179|OTHER|COVID-19 FACILITY|A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
58462324|NCT03577275|DRUG|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
58462325|NCT03577275|DRUG|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
58462326|NCT03577275|DRUG|Moxifloxacin 400mg|Active comparator with known effect on QT interval
58462327|NCT03577275|DRUG|NST-4016 2000mg|Supratherapeutic dose of NST-4016
58462328|NCT05594459|PROCEDURE|Mini invasive analgesic technique|patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
58462329|NCT05594459|DRUG|high opioids dosages|patients will be treated with high opioids dosages
58462330|NCT03901495|OTHER|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
58462331|NCT01366768|OTHER|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
58462332|NCT01366768|OTHER|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
58462333|NCT01422096|DRUG|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if \> 37.5 kg im once
58462334|NCT06211439|DEVICE|real transcranial alternating current stimulation|The alternating current was non-invasively delivered using an M×N five-channel high-definition transcranial electrical current stimulator (Soterix Medical). A BrainCap (Brain Vision) embedded with high-definition plastic holders consisted of five 12-mm-diameter Ag/AgCl ring electrodes, filled with conductive gel. During real HD-tACS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
58462335|NCT06211439|DEVICE|sham transcranial alternating current stimulation|For the sham condition(sham HD-tACS), the same electrode placement was used as in the stimulation condition, but the current was only applied during the first and last 30 seconds of the entire 20-minute stimulation period.
58462336|NCT03446235|BEHAVIORAL|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
58462337|NCT03446235|BEHAVIORAL|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
58462338|NCT00617786|PROCEDURE|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
58462339|NCT03819985|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
58462340|NCT03819985|OTHER|Quality-of-Life Assessment|Ancillary studies
58462341|NCT03819985|OTHER|Questionnaire Administration|Ancillary studies
58462342|NCT00400777|DRUG|Valsartan, hydrochlorothiazide and amlodipine|
58462343|NCT05968586|OTHER|Body positioning|Body positioning of infants prone vs supine.
58462344|NCT04251117|BIOLOGICAL|GNOS-PV02|GNOS-PV02 delivered by intradermal injection and electroporation
58462345|NCT04251117|BIOLOGICAL|INO-9012|INO-9012 delivered by intradermal injection and electroporation
58462346|NCT04251117|DRUG|Pembrolizumab|Pembrolizumab administered as an intravenous (IV) infusion
58462347|NCT04251117|DEVICE|CELLECTRA®2000 EP Device|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
58462348|NCT02113709|DEVICE|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
58462349|NCT02113709|DEVICE|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
58462350|NCT00708292|DRUG|AUY922|
58462351|NCT00708292|DRUG|Bortezomib|
58462352|NCT00708292|DRUG|Dexamethasone|
58462353|NCT05595837|OTHER|Standard organ transplant|Standard organ transplant procedures and follow up care
58462354|NCT00635414|DRUG|Esomeprazole|40mg oral
58462355|NCT00635414|DRUG|Esomeprazole|15 minute intravenous infusion
58462356|NCT02490436|DRUG|Cetuximab|Randomized cross-over between cetuximab and placebo
58462357|NCT02490436|DRUG|Placebo|Randomized cross-over between cetuximab and placebo
58462358|NCT05273567|DRUG|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
58462359|NCT05273567|OTHER|Placebo|placebo will be dispensed similar to the active arm.
58462360|NCT05419583|DIAGNOSTIC_TEST|Coronary computed tomography angiography|CT scan of the heart arteries
58462361|NCT05419583|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
58462362|NCT05419583|DIAGNOSTIC_TEST|Transthoracic echocardiography|Ultrasound scan of the heart
58462363|NCT05419583|DIAGNOSTIC_TEST|Cardiac MRI scan|An MRI scan to assess the heart structure and function
58462364|NCT05419583|DRUG|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
58462365|NCT05419583|DRUG|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
58462366|NCT05419583|DRUG|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
58462367|NCT05419583|DRUG|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
58462368|NCT05219851|RADIATION|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
58462369|NCT02212639|DRUG|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
58462370|NCT03046186|DIAGNOSTIC_TEST|Mixed meal test with double tracer technique|
58462371|NCT00003229|BIOLOGICAL|aldesleukin|
58462372|NCT00003229|BIOLOGICAL|gp100 antigen|
58462373|NCT00003229|BIOLOGICAL|tyrosinase peptide|
58462374|NCT04361708|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
58462375|NCT04361708|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
58462376|NCT04361708|DRUG|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
58462377|NCT04361708|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
58462378|NCT04361708|DRUG|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
58462379|NCT05829070|BEHAVIORAL|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
58462380|NCT05829070|BEHAVIORAL|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
58462381|NCT06705244|PROCEDURE|Trans-nasal sphenopalatine nerve block|"The patient was placed supine with shoulders slightly elevated to flex the neck and extend the head.~Then anterior nares were inspected for polyps, tumors, or significant septal deviation.~Long cotton-tipped applicators saturated with lidocaine 2% were inserted into each naris, until properly seated in the posterior nasopharynx.~These were left in place for 10 minutes to lubricate and anesthetize the mucous membrane, making the procedure more comfortable.~Then a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg were injected through the applicators in the sphenopalatine area in each nostril.~Then the patient was positioned sitting and pain assessments were recorded."
58462382|NCT06705244|PROCEDURE|Greater and lesser occipital nerve block|"The back of the head was sterilized with an antiseptic solution and the landmarks at the base of the skull were identified while the patient in the prone position.~The landmarks were located on the medial third of a line drawn from occipital protuberance to mastoid process. At this level, the greater and lesser occipital nerves lie along the superior nuchal line medial to the occipital artery, halfway between the occipital protuberance and mastoid process.~Under Ultrasound guidance, the skin was infiltrated with 1-2 mL of lidocaine 2%, using a 25-gauge needle. Then the block was performed in this area with a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg to block greater and lesser occipital nerves. Then the procedure was repeated on the other side.~After the procedure, the presence of bilateral occipital numbness was confirmed after 30 minutes. The patient was then positioned sitting and pain scoring was assessed."
58462383|NCT03201068|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement capsule
58462384|NCT03201068|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
58462385|NCT00582361|PROCEDURE|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
58462386|NCT00582361|DEVICE|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
58130857|NCT02457429|OTHER|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
58130858|NCT02457429|OTHER|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
58130859|NCT04048148|DEVICE|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
58130860|NCT00825708|DEVICE|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
58130861|NCT00825708|DEVICE|shamTMS|sham TMS session
58130862|NCT02296775|BIOLOGICAL|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
58130863|NCT02296775|BIOLOGICAL|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
58130864|NCT02296775|BIOLOGICAL|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
58138181|NCT01975688|DRUG|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
58138182|NCT03499847|BEHAVIORAL|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
58462387|NCT04819126|OTHER|Nintendo Wii Virtual Reality Application|The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
58462388|NCT05887882|BIOLOGICAL|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
58462389|NCT05887882|PROCEDURE|Implantation|Undergo placement of Ommaya reservoir
58462390|NCT05887882|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
58462391|NCT05887882|OTHER|Quality-of-Life Assessment|Ancillary studies
58462392|NCT02490735|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
58462393|NCT03804528|BEHAVIORAL|Aerobic Exercise|"Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines)."
58462394|NCT03753334|COMBINATION_PRODUCT|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
58462395|NCT03753334|DIETARY_SUPPLEMENT|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
58462396|NCT05482139|PROCEDURE|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
58462397|NCT04218201|BEHAVIORAL|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
58462398|NCT04218201|BEHAVIORAL|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
58462399|NCT04218201|BEHAVIORAL|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
58462400|NCT04218201|BEHAVIORAL|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
58462401|NCT05138302|OTHER|Observation|This study is an observe research
58462402|NCT02005549|DRUG|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
58462403|NCT02005549|DRUG|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
58462404|NCT02005549|DRUG|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
58462405|NCT04771832|PROCEDURE|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
58462406|NCT00579033|OTHER|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
58462407|NCT00579033|OTHER|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
57777908|NCT06424379|OTHER|Histopathological analysis|"Morphological analysis will include the description of architectural patterns and cytological features on formalin-fixed and paraffin-embedded (FFPE) tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud.~A panel of immunohistochemical staining will be analyzed including CD20, CD3, CD10, Bcl-6, Bcl-2, CD5, CD23, CD38, MUM1, Ig kappa, Ig lambda, MEF2B, LMO2, MNDA, IRTA1, P53, CMYC and Ki67 . /MIB1. Diffuse large B-cells lymphomas will be classified into two distinct subgroups: centro-germinative (GC) and non-centro-germinative (nGC), using the Hans algorithm."
57784483|NCT04223154|DEVICE|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
58462408|NCT06235372|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph .
58462409|NCT00747903|DRUG|aminolevulinic acid hydrochloride|
58462410|NCT04909736|OTHER|Music Exposure|Music will be played for participants.
58462411|NCT02163239|DEVICE|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
58462412|NCT00490087|DEVICE|Levonorgestrel intrauterine device (IUD)|
58462413|NCT03080857|OTHER|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
58462414|NCT03080857|DEVICE|AliveCor Heart Monitor|A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
58462415|NCT01762410|DRUG|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
58462416|NCT00383552|DRUG|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
58462417|NCT00383552|DRUG|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
58462418|NCT00383552|DRUG|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
58462419|NCT00383552|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
58462420|NCT05918640|DRUG|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
58462421|NCT04020029|OTHER|Mindset|Mindset Intervention will include watching three brief \~10-25 minute films
58462422|NCT04020029|OTHER|Reflection activities|Reflection activity include exercises to internalize the message
58462423|NCT00379535|DRUG|potassium iodide|per os
58462424|NCT00379535|DRUG|placebo|per os
58462425|NCT01241864|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
58462426|NCT01241864|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
58462427|NCT03995147|DRUG|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
58462428|NCT03995147|DRUG|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
58462429|NCT06009965|DRUG|CsA+ATG+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
58462430|NCT06009965|DRUG|CsA+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
58462431|NCT01198886|OTHER|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
58462432|NCT01198886|OTHER|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
58462433|NCT04201431|BIOLOGICAL|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
58462434|NCT06312150|OTHER|Analysis of peripheral blood (control group)|Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.
58462435|NCT06312150|OTHER|Analysis of biological sample (Substudy-solid neoplasms)|peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy
58462436|NCT06312150|OTHER|Analysis of biological sample (substudy-leukaemia patients)|sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
58462437|NCT00175526|BEHAVIORAL|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
58462438|NCT03621813|BEHAVIORAL|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
58462439|NCT03621813|OTHER|Control|Participants are instructed to maintain current activity level and are monitored for changes.
58462440|NCT05541926|BEHAVIORAL|e-Connect|Implementation of the e-Connect system
58462441|NCT03388034|PROCEDURE|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
58462442|NCT03388034|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
58462443|NCT06267742|DIAGNOSTIC_TEST|Complete Blood Count (CBC) with Differential|CBC with Differential including Monocyte Distribution Width (MDW)
58462444|NCT00441623|BEHAVIORAL|observational|effect of protein-bound uremic retention solutes
58462445|NCT00382486|PROCEDURE|Reduce the risk of allograft rejection|
58462446|NCT05379179|DRUG|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
58462447|NCT05379179|DRUG|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
58462448|NCT03628092|DEVICE|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
58462449|NCT03628092|DEVICE|Placebo|Sham Device
58462450|NCT04412759|OTHER|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
58462451|NCT03904017|OTHER|Oxygen|100% Oxygen air
58462452|NCT03904017|OTHER|placebo|medical air
58462453|NCT04508946|DRUG|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
58462454|NCT02481154|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
58462455|NCT06088498|BEHAVIORAL|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
58462456|NCT06088498|BEHAVIORAL|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
58462457|NCT06088498|BEHAVIORAL|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
58462458|NCT05685043|DEVICE|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients \> 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
58462459|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
58462460|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
58462461|NCT05830500|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
58462462|NCT04507412|DRUG|dexamethasone|perioperatively 9 mg i.v subministration
58462463|NCT02511665|DRUG|Metformin|Given metformin
58462464|NCT02511665|RADIATION|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
58462465|NCT02511665|DRUG|Placebo|Given placebo
58462466|NCT00774761|DRUG|fluticasone propionate/formoterol fumarate|inhalation suspension
58462467|NCT00774761|DRUG|fluticasone propionate|inhalation suspension
58462468|NCT00774761|DRUG|formoterol fumarate|inhalation solution
58462469|NCT05605678|OTHER|No Intervention|This is a non-interventional study.
58462470|NCT02819921|DRUG|Desvenlafaxine succinate 100mg|Pristiq 100mg
58462471|NCT02819921|DRUG|Desvenlafaxine succinate 50mg|Pristiq 50mg
58462472|NCT02819921|DRUG|Placebo|Placebo
58462473|NCT04921982|DRUG|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
58462474|NCT04921982|DRUG|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
58462475|NCT00582439|DEVICE|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
58462476|NCT06551051|DRUG|duloxetine|Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
58462477|NCT05408338|OTHER|Low Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)
58462478|NCT05408338|OTHER|High Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
57784484|NCT04223154|DEVICE|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
58462479|NCT02962401|DRUG|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
58462480|NCT02962401|DRUG|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
58462481|NCT03496493|DEVICE|All patients|Peripheral arterial oxygen saturation recording with both study devices
58462482|NCT04463771|DRUG|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
58462483|NCT04463771|DRUG|epacadostat|epacadostat will be administered orally BID.
58462484|NCT04463771|DRUG|pemigatinib|pemigatinib will be administered orally QD.
58462485|NCT04463771|DRUG|INCAGN02385|INCAGN2385 will be administered every 2 weeks
58462486|NCT04463771|DRUG|INCAGN02390|INCAGN2390 will be administered every 2 weeks
58462487|NCT04673318|BEHAVIORAL|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
58462488|NCT04673318|BEHAVIORAL|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
58491317|NCT02001636|DRUG|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
58462489|NCT06237725|OTHER|Nutrition of Continuous|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
58462490|NCT06237725|OTHER|Nutrition of Bolus|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
58462491|NCT01866332|OTHER|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
58462492|NCT01866332|DEVICE|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
58462493|NCT00280917|DRUG|CF101|
58462494|NCT02070575|OTHER|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
58462495|NCT02962700|DEVICE|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
58462496|NCT05605808|OTHER|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
58462497|NCT05605808|OTHER|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
58462498|NCT05298722|DIAGNOSTIC_TEST|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"* The images of CT-scans and MRI with DWI shall be processed with specific software to define the direction of diffusion tensors and indicate the direction (red, green, blue coloring for x,y,z, components of the vector) and intensity (anisotropy, brightness of voxels). Further analysis will be performed by fiber tracking which gives a clear indication of functional connectivity of adjacent tissues.~* Genetic profilling of liquid biopsies: evolution of the number CTCs in blood samples of patients and subsequent phenotyping of the cells; longitudinal analysis of driver mutations and epigenetic changes in cfDNA; genotyping of germline variations~* Questionnaires for patient reported outcomes and health economic analysis~  * EQ-5D-5L~ * PAN 26~ * HADS"
58462499|NCT03816696|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
58462500|NCT03816696|DRUG|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
58462501|NCT02590796|OTHER|No intervention given to participants|This is an observational study. Participants will receive no intervention.
58462502|NCT04522895|DRUG|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
58462503|NCT06432634|OTHER|Standard care|The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.
58462504|NCT06432634|OTHER|Comprehensive pulmonary rehabilitation programs|"1. Warm-up and cool-down exercises: stretching various muscle groups for a duration of 15 to 20 minutes and a slow 3-minute walk~2. Aerobic training: using a lower-limb cycle ergometer for a duration of 30 to 40 minutes. Initiated warm-up at 0 wattages for 5 minutes. Incrementally increased wattages within 5-10 minutes until reaching the 40-80% heart rate reserve or 4 to 6 of modified Borg scale for at least 20 minutes. Concludes with a 5-minute cool-down period at 10 wattages.~3. The resistance training involves both upper and lower limbs:~（1） Upper Limb Resistance Training: Shoulder lift, abduction, and horizontal abduction exercises are performed. Each exercise is repeated for three sessions comprising 10 repetitions each. A 0.5-2 kg dumbbell is utilized for resistance.~（2） Lower Limb Resistance Training: Sit-to-stand exercises are performed. Each session consists of three sets of 10 repetitions."
58462505|NCT00770653|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
58462506|NCT00770653|DRUG|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
58462507|NCT06155526|OTHER|Activity|patients taking an active rest after swimming sets
58491318|NCT02001636|DRUG|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
58491319|NCT02290678|BEHAVIORAL|Adventure-based Programming|
57784485|NCT02308501|DRUG|Lastacaft ®|
57784486|NCT02308501|DRUG|Tears Naturale ® (Placebo)|
58462508|NCT00841841|DRUG|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
58462509|NCT01260649|DRUG|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
58462510|NCT01260649|OTHER|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
58462511|NCT01260649|PROCEDURE|ECT|ECT will be administered as per standard of care
58462512|NCT01260649|DRUG|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
58462513|NCT01260649|DRUG|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
58462514|NCT05442840|COMBINATION_PRODUCT|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
58462515|NCT02547311|BEHAVIORAL|Team Clinic|
58462516|NCT05665036|COMBINATION_PRODUCT|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
57777909|NCT06424379|GENETIC|Molecular analysis|"Next-generation sequencing (NGS) analysis will be performed on FFPE tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud. A panel of 73 genes dedicated to lymphoma diagnosis determined by a consensus of French Lysa experts will be used. The identification of genetic variants will be followed by the attribution of pathogenicity class in accordance with the guidelines for validation of NGS-based oncology panels.~RNA extraction will classify DLBCLs into two distinct subgroups: germinal-centre B-cell-like (GCB-DLBCL) and activated B-cell-like (ABC-DLBCL)."
57777910|NCT04198532|OTHER|Contrast bath|Contrast bath (hot and cold therapy)
57777911|NCT03584893|PROCEDURE|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
57777912|NCT04001140|BEHAVIORAL|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
57777913|NCT04507360|BEHAVIORAL|Study 1, Generic Response|Participants will be provided with the generic/current response to screening.
58462517|NCT04761601|DRUG|UCT-01-097|Orally available kinase inhibitor
58462518|NCT04761601|DRUG|Gemcitabine|Gemcitabine injection for intravenous use.
58462519|NCT04761601|DRUG|Paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
58462520|NCT05400135|BEHAVIORAL|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
57777914|NCT04507360|BEHAVIORAL|Study 1, Tailored Response|Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes or no).
57777915|NCT04507360|BEHAVIORAL|Study 1, Generic Resources|Participants will be provided with links to a list of 4 generic Mental Health America (MHA) resources.
57777916|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Desired Resources|Participants will be provided with links to Mental Health America (MHA) resources aligned with their expressed interest (e.g., additional screening, self help tools).
57777917|NCT04507360|BEHAVIORAL|Study 1, Embedded single-question DIY|A single Do-It-Yourself (DIY) question will be embedded within the content page.
57777918|NCT04507360|BEHAVIORAL|Study 1, Embedded full DIY within content page|The full Do-It-Yourself (DIY) tool will be embedded within the content page.
57777919|NCT04507360|BEHAVIORAL|Study 1, Single question plus full DIY|A single question plus the full Do-It-Yourself (DIY) tool will be embedded within the content page.
58462521|NCT03732339|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
58462522|NCT02945579|RADIATION|External Beam Radiation Therapy|Undergo EBRT
58462523|NCT02945579|OTHER|Laboratory Biomarker Analysis|Correlative studies
57777920|NCT04507360|BEHAVIORAL|Study 1, Content-as-usual|The content page will not include any embedded Do-It-Yourself (DIY) tool.
57777921|NCT04507360|BEHAVIORAL|Study 2, Control|Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY).
57777922|NCT04507360|BEHAVIORAL|Study 2, DIY tool without AI|Participants in the Do-It-Yourself (DIY) tool without Artificial Intelligence (AI) group will be instructed to use the DIY tool 3 times a week.
57784487|NCT01074632|DRUG|Lurasidone HCl|
58462524|NCT02945579|OTHER|Quality-of-Life Assessment|Ancillary studies
58462525|NCT02945579|OTHER|Questionnaire Administration|Ancillary studies
58462526|NCT02945579|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
58462527|NCT06262152|DIAGNOSTIC_TEST|Actigraphy, blood and salivary sample, and sleep evaluation|"* For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment.~* 7 days actigraph recording through wearing of Actiwatch spectrum plus at home~* Standardized sleep questionnaire administration"
58462528|NCT00387881|DRUG|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
58462529|NCT00387881|DRUG|Placebo|Placebo to match Treximet tablets
58462530|NCT06378021|DRUG|Calcium Chloride|5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft
57777923|NCT04507360|BEHAVIORAL|Study 2, DIY tool with AI|Participants in the Do-It-Yourself (DIY) tool with Artificial Intelligence (AI) group will be instructed to use the DIY tool with AI 3 times a week.
57777924|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Demographics|Participants will be provided with links to MHA resources tailored to sexuality (Lesbian, Gay, Bisexual, Transgender, or Queer) status and age range.
57777925|NCT04250961|OTHER|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
58138183|NCT03499847|BEHAVIORAL|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
58462531|NCT06378021|DRUG|Sodium Chloride 0.9% Inj|0.9% sodium chloride injection during on pump during Coronary artery bypass graft
58462532|NCT02991183|BEHAVIORAL|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
58462533|NCT05526560|DEVICE|MITRIS RESILIA Mitral Valve, Model 11400M|Replacement of mitral valve with MITRIS RESLIA Mitral Valve
58462534|NCT00006088|DRUG|vinorelbine tartrate|
58462535|NCT03058120|OTHER|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
58462536|NCT05302674|OTHER|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
58462537|NCT01983475|DRUG|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
58462538|NCT01983475|DRUG|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
58462539|NCT00079326|BIOLOGICAL|trastuzumab|Given IV
58462540|NCT00079326|DRUG|ixabepilone|Given IV
58462541|NCT00079326|OTHER|laboratory biomarker analysis|Correlative studies
58462542|NCT00555958|DEVICE|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
58462543|NCT06676657|DEVICE|iPancreas automated insulin delivery system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The MPC has a new feature called hyperglycemia pattern detection and dosing algorithm that will analyze problem patterns associated with high blood sugar and automatically calculate and deliver a correction dose.
58462544|NCT04237467|OTHER|No intervention|There was no intervention.
58462545|NCT00298324|DRUG|Myfortic|1440mg twice daily
58462546|NCT00298324|DRUG|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
58462547|NCT02534376|DRUG|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
58462548|NCT05672251|PROCEDURE|Biopsy|Undergo biopsy
58462549|NCT05672251|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58462550|NCT05672251|PROCEDURE|Computed Tomography|Undergo PET/CT
58462551|NCT05672251|BIOLOGICAL|Loncastuximab Tesirine|Given IV
58462552|NCT05672251|BIOLOGICAL|Mosunetuzumab|Given IV
58462553|NCT05672251|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58462554|NCT01298479|OTHER|Uniject|single use container
58462555|NCT06482346|BIOLOGICAL|MT-3534|Solution for infusion; Intravenous (IV)
58462556|NCT06482346|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
58462557|NCT02544321|DRUG|Bromocriptine|
58462558|NCT02544321|OTHER|Placebo|
58462559|NCT00474812|DRUG|dasatinib|
58462560|NCT00474812|PROCEDURE|laboratory biomarker analysis|Correlative study
58462561|NCT00474812|PROCEDURE|physiologic testing|Correlative study
58462562|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
58462563|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
58462564|NCT02367573|PROCEDURE|2D laparoscopic TAPP inguinal hernia repair|
58462565|NCT02367573|PROCEDURE|3D laparoscopic TAPP inguinal hernia repair|
58462566|NCT01279434|DRUG|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
58462567|NCT01279434|DRUG|Vitamin E|Vitamin E 400 mg BD daily for 12 months
58462568|NCT02122016|DEVICE|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
58462569|NCT02122016|OTHER|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
58462570|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
58462571|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
58462572|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
58462573|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
58462574|NCT05716477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58462575|NCT05716477|OTHER|Survey Administration|Complete survey
58462576|NCT05690451|DIAGNOSTIC_TEST|non-contrast abbreviated MRI|"Liver MRI without contrast injection. The following sequences will be obtained from all of the participants.~* Axial heavily and regular T2 WI~* precontrast fat-suppressed T1 WI~* Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000"
58462577|NCT05690451|DIAGNOSTIC_TEST|Contrast enhanced liver CT|"Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained~* precontast, arterial phase, portal venous phase and delayed phase"
58462578|NCT03724942|DRUG|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
58462579|NCT03562195|DRUG|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
58462580|NCT03562195|DRUG|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
58462581|NCT03562195|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
58462582|NCT06379789|DRUG|REGV131|Single dose administered via intravenous (IV) infusion before LNP1265
58462583|NCT06379789|DRUG|LNP1265|Single dose administered via IV infusion following REGV131
58462584|NCT02787928|DRUG|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
58462585|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
58462586|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
58462587|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
58462588|NCT00442169|BIOLOGICAL|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
58462589|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
58462590|NCT00442169|BIOLOGICAL|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
58462591|NCT00691613|DRUG|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
58462592|NCT00691613|DRUG|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
58462593|NCT02928679|DRUG|Liraglutide 3 mg (Saxenda)|
58462594|NCT02928679|DRUG|Liraglutide 3 mg placebo|
58462595|NCT06159621|DRUG|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg
58462596|NCT06159621|DRUG|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
58462597|NCT00823862|DRUG|SD-101|Intramuscular (IM)
58462598|NCT00823862|DRUG|ribavirin|oral, 2 times per day, for 2 months
58462599|NCT05183061|DRUG|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
58462600|NCT05093855|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
58462601|NCT04202848|DIAGNOSTIC_TEST|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
58462602|NCT06173336|PROCEDURE|gastric per-oral endoscopic myotomy (G-POEM)|Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
58462603|NCT04024150|BIOLOGICAL|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
58462604|NCT04891614|DEVICE|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
58462605|NCT04662385|DRUG|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
58462606|NCT04662385|DRUG|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
58462607|NCT05241262|DRUG|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
58462608|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
58462609|NCT00231816|BIOLOGICAL|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
58462610|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
58462611|NCT05134688|DRUG|Magnesium sulfate|Tocolytic to stop preterm labor
58462612|NCT01064440|BIOLOGICAL|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
58462613|NCT01064440|BIOLOGICAL|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
58462614|NCT01064440|OTHER|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
58462615|NCT06117930|OTHER|Non-Interventional Study|Non-interventional study
58462616|NCT04291846|DRUG|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
58462617|NCT04291846|DRUG|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
58491320|NCT06443567|DEVICE|impedance threshold device|impedance threshold device (ResQPOD, Zoll) applied to airway
58491321|NCT04956913|DEVICE|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
58462618|NCT02457390|PROCEDURE|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
58462619|NCT02845323|DRUG|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
58462620|NCT02845323|DRUG|Nivolumab monotherapy|Two cycles of Nivolumab alone
58462621|NCT04094597|DRUG|Lactoferrin|lactoferrin is given orally in comparsion to placebp
58462622|NCT04094597|DRUG|Placebos|placebp is given in 2 ml saline
58462623|NCT03744910|BIOLOGICAL|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
58462624|NCT03744910|DRUG|Physiologic saline solution|Normal saline
58462625|NCT05535894|PROCEDURE|Ablation of Celiac Ganglion|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
58462626|NCT00003714|DRUG|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
58462627|NCT03921749|DEVICE|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
58462628|NCT05097820|DEVICE|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
58462629|NCT05230940|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
58462630|NCT05230940|BIOLOGICAL|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
58462631|NCT00142155|DRUG|Rituximab|
58462632|NCT00142155|DRUG|monoclonal antibodies|
58462633|NCT02916186|BIOLOGICAL|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
58462634|NCT02916186|PROCEDURE|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
58462635|NCT06123377|DIAGNOSTIC_TEST|Angiogenic factor|sFLt-1/PGIF below or equal to 33
58462636|NCT05836441|RADIATION|Exposure to white patches|Exposure to white patches
58462637|NCT05836441|RADIATION|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
58462638|NCT04579991|OTHER|Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel|Topical product, apply small amount on mucosal surface of vulva included clitoris once daily
58130865|NCT01643837|OTHER|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
58462639|NCT04579991|OTHER|Emulgel-only|Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
58462640|NCT04090918|DIAGNOSTIC_TEST|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
58462641|NCT05718947|DIAGNOSTIC_TEST|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
58462642|NCT04427527|BEHAVIORAL|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
58462643|NCT04640441|OTHER|Sit-to-stand care|"1. Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20\~30 min, once daily.~2. Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20\~30min, once daily.~3. Stepping exercise and sit-to-stand exercise, 20\~30min, once daily."
58462644|NCT03177902|DRUG|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
58462645|NCT05511181|DEVICE|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
58462646|NCT05511181|DEVICE|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
58462647|NCT03001557|DRUG|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
58462648|NCT03001557|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablets
58462649|NCT03001557|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablets
58462650|NCT03001557|DRUG|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
58462651|NCT03001557|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
58462652|NCT05645718|DRUG|Cyclophosphamide|Given by (IV) vein
58462653|NCT05645718|DRUG|Vincristine|Given by (IV) vein
58462654|NCT05645718|DRUG|Blinatumomab|Given by (IV) vein
58462655|NCT05645718|DRUG|Methotrexate|Given by (IV) vein
58462656|NCT05645718|DRUG|Cytarabine|Given by (IV) vein
58462657|NCT05645718|DRUG|Mercaptopurine|Given by (IV) vein
58462658|NCT05645718|DRUG|Prednisone|Given by PO
58462659|NCT05645718|DRUG|Pegfilgrastim|Given by (IV) vein
58462660|NCT05645718|DRUG|Inotuzumab ozogamicin|Given by (IV) vein
58462661|NCT05645718|DRUG|Rituximab|Given by (IV) vein
57777926|NCT00422799|DRUG|Bortezomib|Once weekly for 3 weeks
58462662|NCT05645718|DRUG|Dexamethasone|Given by (IV) vein
58462663|NCT05931081|DEVICE|Thermal imaging in diagnostics of chronic ulcers|atypical: vasculitic or pyoderma gangraenosum ulcers
58491322|NCT04956913|DEVICE|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
58462664|NCT06151522|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
58462665|NCT06151522|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
58462666|NCT06138899|OTHER|Club 25|The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
58462667|NCT00910104|DRUG|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
58462668|NCT00493493|PROCEDURE|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
58462669|NCT01725906|DRUG|empirical therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
58462670|NCT01725906|DRUG|Genotypic resistance guided therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
58462671|NCT03664297|DRUG|SHR1459|SHR1459 will be administered continually till disease progression or unacceptable toxicity.
58462672|NCT05198817|DRUG|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
58462673|NCT03820544|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
58462674|NCT03820544|OTHER|Standard of care|Undergo standard of care surgical resection
58462675|NCT04532268|DRUG|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
58462676|NCT03363737|BEHAVIORAL|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
58462677|NCT00210535|DRUG|Topiramate; Placebo|
58462678|NCT05620667|DIETARY_SUPPLEMENT|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
58462679|NCT05620667|DIETARY_SUPPLEMENT|placebo|Drink 25mL for once, and once a day.
58462680|NCT05620667|BEHAVIORAL|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
58462681|NCT03482622|DIAGNOSTIC_TEST|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
58462682|NCT05220722|DRUG|SD-101|SD-101 doses will be delivered via HAI using the PEDD method of administration.
58462683|NCT05220722|BIOLOGICAL|Pembrolizumab|During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
58462684|NCT05220722|BIOLOGICAL|Nivolumab|During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
58462685|NCT05220722|BIOLOGICAL|Ipilimumab|During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
58462686|NCT04635449|OTHER|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
58462687|NCT01998256|DEVICE|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
58462688|NCT00832663|DRUG|NSAID|Effect of NSAID ingestion on muscle regeneration
57777927|NCT00422799|DRUG|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
58462689|NCT00832663|DRUG|placebo|receive placebo
58462690|NCT03392935|DEVICE|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
58462691|NCT05485740|OTHER|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
58462692|NCT05485740|OTHER|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
58462693|NCT00625131|DRUG|Nicotine|Delivered through transdermal nicotine patch
58462694|NCT00625131|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
58462695|NCT00625131|DRUG|Bupropion Sustained Release (SR)|Antidepressant
58462696|NCT00625131|DRUG|Placebo patch|Pre-treatment placebo transdermal patch
58462697|NCT04828421|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
58462698|NCT04828421|DIETARY_SUPPLEMENT|Placebo|Placebo
58462699|NCT00938158|BIOLOGICAL|albiglutide|single dose of subcutaneously injected albiglutide
58462700|NCT01048879|PROCEDURE|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
58462701|NCT01048879|PROCEDURE|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
58462702|NCT04890652|BEHAVIORAL|Digital intervention|All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
58462703|NCT00297544|DRUG|Viagra|
58462704|NCT01898455|DEVICE|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
58462705|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
58462706|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
58462707|NCT06179108|DRUG|LB-102|LB-102 is a dopamine D2/3 and 5HT7 antagonist.
58462708|NCT02927301|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
58462709|NCT04839510|DRUG|MRG002|Administrated intravenously
58462710|NCT02515747|PROCEDURE|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
58462711|NCT02515747|PROCEDURE|coronary artery bypass grafting|elective surgical myocardial revascularisation
58462712|NCT03983733|OTHER|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
58462713|NCT00291616|DRUG|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
58462714|NCT00291616|DRUG|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
58462715|NCT04368026|OTHER|No intervention (survey study for medical doctors).|No intervention
58462716|NCT05711810|DRUG|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
58462717|NCT05711810|DIAGNOSTIC_TEST|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
58462718|NCT05711810|BEHAVIORAL|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
58462719|NCT05711810|DRUG|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
58462720|NCT05711810|DRUG|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
58462721|NCT05711810|DRUG|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
58462722|NCT05711810|DIETARY_SUPPLEMENT|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
58462723|NCT05711810|DIETARY_SUPPLEMENT|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
58462724|NCT05711810|DIETARY_SUPPLEMENT|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
58462725|NCT05711810|DRUG|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
58462726|NCT05711810|DRUG|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
58462727|NCT02149914|DEVICE|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
58462728|NCT02149914|DEVICE|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
58462729|NCT02149914|DEVICE|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
58462730|NCT02149914|OTHER|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
58462731|NCT02149914|DRUG|PPI|
58462732|NCT04392739|DRUG|Tpoxx|oral antiviral
58462733|NCT03327493|DIAGNOSTIC_TEST|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
58462734|NCT05332600|OTHER|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
58462735|NCT00908986|DRUG|Rituximab|375mg/m2 q week x 4; repeated in 6 months
58462736|NCT00783523|DRUG|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
58462737|NCT03763032|BEHAVIORAL|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
58462738|NCT06316830|DRUG|Buprenorphine|Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
58462739|NCT04762511|BIOLOGICAL|Lower dose formulation of HSV vaccine (GSK4108771A)|2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
58462740|NCT04762511|BIOLOGICAL|Low dose formulation of HSV vaccine (GSK4108771A)|2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
58462741|NCT04762511|BIOLOGICAL|Medium dose formulation of HSV vaccine (GSK4108771A)|2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
58462742|NCT04762511|BIOLOGICAL|High dose formulation of HSV vaccine (GSK4108771A)|2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
58462743|NCT04762511|DRUG|Placebo (saline)|2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
58462744|NCT03392064|BIOLOGICAL|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
58462745|NCT01075243|DRUG|Paracetamol 1000 mg|Paracetamol 1000mg
58462746|NCT01075243|DRUG|Paracetamol 650 mg|Paracetamol 650 mg
58462747|NCT01075243|DRUG|Placebo|Placebo
58462748|NCT01780311|DRUG|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
58462749|NCT01780311|PROCEDURE|Catheter Ablation|
58462750|NCT02022059|DRUG|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
58462751|NCT02022059|DRUG|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
58462752|NCT05597202|DRUG|Semaglutide, 2.0 mg/mL|Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
58462753|NCT04722614|OTHER|Music|Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property
58462754|NCT04722614|OTHER|Essential oil|Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.
58462755|NCT04722614|OTHER|Control|The routine intensive care unit sedation protocol
58462756|NCT00675181|DRUG|Melatonin|5mg per os
58462757|NCT00675181|DRUG|Placebo|per os
58462758|NCT04044690|DRUG|human immunoglobulin G|human immunoglobulin G administered subcutaneously
58462759|NCT04044690|DRUG|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
58462760|NCT00761475|PROCEDURE|mesh supported closure|onlay mesh supported closure midline laparotomy
58462761|NCT00761475|PROCEDURE|primary closure|primary closure of the midline
58462762|NCT00761475|PROCEDURE|mesh supported closure|sublay mesh supported closure midline laparotomy
58462763|NCT03255408|DRUG|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
58462764|NCT03255408|DRUG|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
58462765|NCT03255408|DRUG|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
58462766|NCT03255408|DRUG|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
57777928|NCT01915199|OTHER|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
57777929|NCT03589729|DRUG|Cladribine|Given IV
57777930|NCT03589729|DRUG|Cytarabine|Given IV
58462767|NCT06343831|PROCEDURE|2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)|The study participant will be requested to stand upright with hands comfortably behind their back and turn 45 degrees and 90 degrees in either direction for standard anteroposterior (AP), oblique and lateral photos. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers. The photographs will be acquired using a commercially available camera or study iPad device.
58462768|NCT06343831|PROCEDURE|3-Dimensional (3-D) Photographs (Visit 1- 6)|3-Dimensional surface scans of the participant's torso will be acquired using a commercially available handheld camera scanning device that offers texture, geometry, and color acquisition from any complex surface using white light technology, which is safe for exposure to skin and eyes. Prior to imaging, a pattern of lines and dots will be marked on the patient's breasts using a washable marker. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member moves around their torso with the handheld scanner. The exam room table will then be reclined to a lay-flat position such that the patient is laying supine, and breast imaging will be repeated. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers.
58462769|NCT06343831|PROCEDURE|Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)|The images will be acquired using a commercially available handheld ultrasound scanning device. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member obtains images of the specific area of the breast of chest wall to be grafted (V1) and that which was grafted (V4-6). Images usually take 5-10 minutes to acquire depending on the number of areas grafted.
58462770|NCT06343831|PROCEDURE|Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)|An MRI of the breast will be obtained around visit 1 and visits 4-6 timepoints. The images will be acquired in collaboration with the Breast Imaging Core and the Magnetic Resonance Research Imaging Center. Dr. Abe (co-investigator, radiology) will review the images to assess volume of the overall breast, the specific areas of the breasts that were grafted.
58462771|NCT06343831|PROCEDURE|BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)|"The BREAST-QTM measures three satisfaction domains and three quality of life (QoL) domains.6 For BREAST-QTM, each domain has a score range from 0 - 100. A difference in score, either positive or negative, of 10 points is considered clinically important; a difference of 20 points is considered clinically very important. This survey will be administered to participants via iPad during visit 1 and visits 4-6 and takes approximately 10-20 minutes to complete."
58462772|NCT04413071|OTHER|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
58462773|NCT01537666|DRUG|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
58462774|NCT01537666|DRUG|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
58462775|NCT03655132|BEHAVIORAL|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
58462776|NCT03813355|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
58462777|NCT05746611|BIOLOGICAL|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
58462778|NCT05746611|BIOLOGICAL|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
58462779|NCT04196686|DEVICE|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
58462780|NCT04196686|OTHER|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
58462781|NCT01358877|DRUG|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
58462782|NCT01358877|DRUG|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
58462783|NCT01358877|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
58462784|NCT01358877|DRUG|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
58462785|NCT01358877|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
58462786|NCT01358877|DRUG|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
58462787|NCT01358877|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
58462788|NCT01358877|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
58462789|NCT01358877|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
58462790|NCT01358877|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
58462791|NCT03159416|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
58462792|NCT03757546|OTHER|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
58462793|NCT00232765|DEVICE|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
58462794|NCT00232765|DEVICE|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
58462795|NCT05541458|OTHER|Food as medicine|"* Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~* Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~* Increase nutrition literacy.~* Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
58462796|NCT02493439|BEHAVIORAL|Best Possible Self|
58462797|NCT02493439|BEHAVIORAL|Daily Activities|
58462798|NCT04648280|DRUG|Fostemsavir|fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
58462799|NCT06177977|DEVICE|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
58462800|NCT05188586|OTHER|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
58462801|NCT01288573|DRUG|plerixafor|160 μg/kg subcutaneous (SC) injection
58462802|NCT01288573|DRUG|plerixafor|240 μg/kg subcutaneous (SC) injection
58462803|NCT01288573|DRUG|plerixafor|320 μg/kg subcutaneous (SC) injection
57777931|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
58462804|NCT05280340|DRUG|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
58462805|NCT00774371|BEHAVIORAL|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
58462806|NCT05763810|OTHER|Erector Spinae Plane Block|Erector Spinae Plane Block
58462807|NCT05763810|OTHER|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
58462808|NCT01380353|DRUG|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
58462809|NCT04516746|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
58462810|NCT04516746|BIOLOGICAL|Placebo|Commercially available 0.9% (n/V) saline for injection.
58462811|NCT03252769|OTHER|Self-sampling|
58462812|NCT00517296|PROCEDURE|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
58462813|NCT00517296|DRUG|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
58462814|NCT00517296|PROCEDURE|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
58462815|NCT05736666|BEHAVIORAL|Treadmill-based perturbation training|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. Through this task-specific training, participants should learn to control their trunk motion in a way that will cause them to avoid a trip or fall to the side.
58462816|NCT05736666|BEHAVIORAL|Education Control|Fall prevention educational material
58462817|NCT05094622|OTHER|Physical exercise program|A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
58462818|NCT00837382|BEHAVIORAL|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
58462819|NCT00837382|BEHAVIORAL|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
58462820|NCT02714400|DRUG|Venlafaxine|Venlafaxine 50mg before sleep
58462821|NCT02714400|DRUG|Placebo|One piece of placebo before sleep
58462822|NCT03114319|DRUG|TNO155|TNO155 for oral administration
58462823|NCT03114319|DRUG|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
58462824|NCT01045967|DRUG|Lansoprazole|30 mg delayed-release Capsule
58462825|NCT01045967|DRUG|Prevacid®|30 mg delayed-release Capsule
58462826|NCT04730908|OTHER|DENTIFRICE|GEL -DENTIFRICE FOR BRUSHING TEETH
58462827|NCT02914158|DRUG|Goserelin|
58462828|NCT02914158|DRUG|Tamoxifen|
58462829|NCT02914158|DRUG|Aromatase Inhibitors|
58462830|NCT02914158|DRUG|Leuprolide|
58462831|NCT03429335|BEHAVIORAL|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
58462832|NCT03429335|BEHAVIORAL|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
58462833|NCT03429335|BEHAVIORAL|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
58462834|NCT01404819|DRUG|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
58462835|NCT01404819|DRUG|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
58462836|NCT02456012|DRUG|oral esomeprazole 20 mg twice daily|for 36 weeks
57777932|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
57777933|NCT03589729|DRUG|Idarubicin|Given IV
58462837|NCT02456012|DRUG|oral esomeprazole 20 mg once daily|for 36 weeks
58462838|NCT05057091|OTHER|Lomber roll techniques group (n=23)|Direct manipulation will be applied to the lumbar region with the lumbar Roll technique. Painful segment will be determined.
58462839|NCT05057091|OTHER|Posterior- anterior central vertebral manipulation techniques (n=23)|After initial assessments were made, both groups had high velocity and low amplitude (HVLA) or V. Level manipulation will be applied in the form of 2 different direct manipulation techniques
58462840|NCT05000294|DRUG|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
58462841|NCT05000294|DRUG|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
58462842|NCT02868112|OTHER|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
58462843|NCT02868112|OTHER|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
58462844|NCT01994252|DEVICE|Optimal Medical therapy plus ICD|
58462845|NCT01994252|DEVICE|Optimal Medical therapy plus CRT/ICD|
58462846|NCT05517135|OTHER|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
58462847|NCT05517135|OTHER|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
58462848|NCT05517135|OTHER|Arm 3|"IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)"
58462849|NCT05517135|OTHER|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
58462850|NCT05517135|OTHER|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
58462851|NCT05454735|PROCEDURE|coronary artery bypass surgery|coronary artery bypass surgery
58462852|NCT05454735|PROCEDURE|aortic valve replacement surgery|aortic valve replacement surgery
58462853|NCT06275451|OTHER|Semi-structured interview|Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
58462854|NCT00788216|OTHER|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
58462855|NCT01089504|DRUG|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
58462856|NCT01089504|DRUG|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
58462857|NCT06294795|PROCEDURE|congenital/pediatric cataract surgery|All procedures are performed under general anesthesia according to the standard technique of congenital/pediatric cataract surgery with an intraocular lens (IOL) implantation. Paracentesis is performed at 2.30 o\&#39;clock using a 20-gauge straight microvitreoretinal (MVR) knife; a high molecular weight ophthalmic viscosurgical devices (OVD) is injected into the anterior chamber. Then a 2.4 mm corneal tunnel incision is made at 11 o'clock with a disposable keratome knife 2.2 mm. Circular continuous capsulorhexis (≈ 5.5 mm). Сortical cleaving hydrodissection is followed by bimanual phacoaspiration in irrigation-aspiration mode. OVD is injected in the anterior chamber and an IOL is implanted in the capsular bag. Residual OVD is aspirated from the anterior chamber and behind the IOL and followed by IOL alignment. The surgery is completed with corneal hydration at the tunnel incision site.
58462858|NCT06294795|DEVICE|Non-Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF for the non-toric group (Alcon Laboratories, Inc.) ARE implanted.
58462859|NCT06294795|DEVICE|Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx for the toric group (Alcon Laboratories, Inc.) were implanted.
58462860|NCT01925560|OTHER|Agave Inulin|3x3 Latin square with 3 periods
58462861|NCT01925560|OTHER|Placebo|control- 0 (zero) grams/day inulin
58462862|NCT00656357|DRUG|SYN117 Placebo|Placebo
58462863|NCT00656357|DRUG|SYN117 80 mg|SYN117 80 mg
58462864|NCT00656357|DRUG|SYN117 160 mg|SYN117 160 mg
58462865|NCT00656357|DRUG|Cocaine 10mg|IV Cocaine 10mg
58462866|NCT00656357|DRUG|Cocaine 20mg|IV Cocaine 20mg
58462867|NCT00656357|DRUG|Cocaine 40mg|IV Cocaine 40mg
58462868|NCT00656357|DRUG|Saline|IV Cocaine Placebo
58462869|NCT06065488|DEVICE|ankle kinesio tap|Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
58462870|NCT00979901|DRUG|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
58462871|NCT00979901|DRUG|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
58462872|NCT00979901|DRUG|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
58462873|NCT00979901|DRUG|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
58462874|NCT03566602|DEVICE|Dura Sealant Patch|Adjunctive bioresorbable patch
58462875|NCT03596216|OTHER|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
58462876|NCT03596216|OTHER|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
58462877|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor restricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
58462878|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor unrestricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
58462879|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor restricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
58462880|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
58462881|NCT00670423|DRUG|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
58462882|NCT00670423|DRUG|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
58462883|NCT00670423|DRUG|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
58462884|NCT04559568|DRUG|LY3522348|Administered orally.
58462885|NCT04559568|DRUG|Placebo|Administered orally.
58462886|NCT04559568|DRUG|Midazolam|Administered orally to some participants.
58462887|NCT01007201|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
58462888|NCT02437916|DRUG|AMG 228|AMG 228 will be administered intravenously
58462889|NCT04889417|BEHAVIORAL|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
58462890|NCT04889417|BEHAVIORAL|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
58462891|NCT05132153|DRUG|Milrinone|will be given by nebulization
58462892|NCT05132153|DRUG|Normal saline|will be given by nebuliztion
58462893|NCT00703456|BEHAVIORAL|Balance Training|balance training three days per week for 4 weeks during single limb standing
58462894|NCT02602366|OTHER|HEC Placebo Gel|
58462895|NCT02602366|OTHER|Placebo Vaginal Insert|
58462896|NCT02602366|OTHER|Placebo Vaginal Film|
58462897|NCT02602366|OTHER|Placebo Intravaginal ring (IVR)|
58462898|NCT00322777|BEHAVIORAL|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
58462899|NCT03585660|PROCEDURE|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
58462900|NCT03585660|PROCEDURE|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
58462901|NCT03585660|DEVICE|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
58462902|NCT05622630|PROCEDURE|Four-cell bath|Four-cell bath:Treatment with direct current
58462903|NCT05622630|PROCEDURE|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
58462904|NCT06212804|BIOLOGICAL|VIS954|A humanized IgG4 monoclonal antibody.
58462905|NCT06212804|OTHER|Placebo|VIS954 Placebo
58462906|NCT00121563|DRUG|Thalidomide, Ibuprofen or Diazepam|
58462907|NCT04055220|DRUG|Treatment by Regorafenib|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
58462908|NCT04055220|DRUG|Treatment by Placebo|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
58462909|NCT05095961|DRUG|Prednisone|5 day course of oral prednisone pre-operatively. 30mg per day.
58462910|NCT03647930|DEVICE|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
58462911|NCT02474446|DIETARY_SUPPLEMENT|Vitamin D|150,000 IU of Vitamin D3 Oral solution
58462912|NCT04637386|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
58462913|NCT04637386|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
58462914|NCT02211560|OTHER|Phosphatidylserine|
58462915|NCT02211560|OTHER|Placebo|
58462916|NCT03864835|BEHAVIORAL|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
58462917|NCT00360230|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
58462918|NCT00360230|BIOLOGICAL|Rabipur|3-dose intramuscular injection.
58462919|NCT02700308|DEVICE|Kyphoplasty|Placement and inflation of balloon prior to cement injection
58462920|NCT02700308|DEVICE|Conventional vertebroplasty|Conventional vertebroplasty
58462921|NCT05769296|DEVICE|Headpulse measurements|Placement of headset on subject
58462922|NCT05444556|DRUG|Imlunestrant|Administered orally.
58462923|NCT05444556|DRUG|Repaglinide|Administered orally.
58462924|NCT05444556|DRUG|Omeprazole|Administered orally.
58462925|NCT05444556|DRUG|Dextromethorphan|Administered orally.
58462926|NCT05444556|DRUG|Quinidine|Administered orally.
58462927|NCT05444556|DRUG|Rosuvastatin|Administered orally.
58462928|NCT05444556|DRUG|Digoxin|Administered orally.
58462929|NCT00517946|DRUG|pseudoephedrine hydrochloride|
58462930|NCT00517946|DRUG|cetirizine hydrochloride|
58462931|NCT06406712|OTHER|retroclavicular block|regional anesthesia
58462932|NCT02669810|DRUG|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
58462933|NCT02669810|DRUG|Standard Treatment for CHF post AMI|
58462934|NCT05478408|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
58462935|NCT02997215|DRUG|Lidocaine|lidocaine infusion during surgery
58462936|NCT02997215|DRUG|Saline Placebo|saline infusion at same rate as intervention group during surgery
58462937|NCT04637568|DIAGNOSTIC_TEST|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
58462938|NCT04865159|DRUG|Tipifarnib|Cardiac Safety of Tipifarnib
58462939|NCT01544296|DRUG|KHK6188|
58462940|NCT01544296|DRUG|Placebo|
58462941|NCT00299767|PROCEDURE|sequential cord blood transplantation|Infused on Day 0
58462942|NCT00894803|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
58462943|NCT00894803|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
58462944|NCT03533673|BIOLOGICAL|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
58462945|NCT04477265|DRUG|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
58462946|NCT04477265|BEHAVIORAL|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
58462947|NCT06360458|DRUG|Methylprednisolone sodium succinate|Intravenous injection of methylprednisolone sodium succinate (Chongqing Lai Mei Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomisation. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
58462948|NCT06360458|DRUG|Placebo (Methylprednisolone sodium succinate simulant)|Intravenous injection of placebo (methylprednisolone sodium succinate simulant) (Chongqing Lai Mei Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomisation. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
58462949|NCT03224208|DRUG|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
58462950|NCT03224208|DRUG|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
58462951|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
58462952|NCT00758732|DRUG|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
58462953|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
58462954|NCT00758732|DRUG|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
58462955|NCT05498649|DEVICE|DT1fA|DT1fA contact lenses
58462956|NCT05195164|OTHER|No intervention|There was no intervention
58462957|NCT02171221|DRUG|Oral DFP-11207|
58462958|NCT02421172|BIOLOGICAL|CJM112|CJM112 Fully human IgG1 monoclonal antibody
58462959|NCT02421172|DRUG|Placebo|
58462960|NCT01673308|DRUG|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
58462961|NCT00637611|DRUG|Fexofenadine HCl|
58462962|NCT04842747|DRUG|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
58462963|NCT03893071|DRUG|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
58462964|NCT03728907|DEVICE|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
58462965|NCT00623948|DEVICE|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
58462966|NCT03441477|DEVICE|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
58462967|NCT03441477|DEVICE|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
58462968|NCT03441477|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
58462969|NCT00937352|DRUG|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
58462970|NCT02454790|RADIATION|Radiotherapy|
58462971|NCT00436332|BIOLOGICAL|bevacizumab|
58462972|NCT00436332|DRUG|erlotinib hydrochloride|
58462973|NCT06366737|DEVICE|KILBON Appliance|palatal TAD assissted lingual appliance for en-mass retraction
58462974|NCT06366737|DEVICE|CAT appliance|palatal TAD assissted clear aligner
58462975|NCT00242268|DRUG|Simvastatin|
58462976|NCT06208553|OTHER|QI toolkit implementation|Patients and clinicians will have access to online toolkits of resources (e.g., video, checklist, rehabilitation tracker, quick guides) reflecting quality indicators for rehabilitation care after total hip and knee replacement surgery.
58462977|NCT03777358|DEVICE|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
58462978|NCT03223402|OTHER|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
58462979|NCT04978883|OTHER|No intervention|No intervention
58462980|NCT05329246|DEVICE|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
58462981|NCT01349959|DRUG|Azacitidine|Given SC
58462982|NCT01349959|DRUG|Entinostat|Given PO
58462983|NCT01349959|OTHER|Laboratory Biomarker Analysis|Correlative studies
58462984|NCT01349959|OTHER|Pharmacological Study|Correlative studies
58462985|NCT04306471|DRUG|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
58462986|NCT04306471|OTHER|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
58462987|NCT04236427|DRUG|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
58462988|NCT04236427|DRUG|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
58462989|NCT06269224|OTHER|Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.|The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
58462990|NCT04715620|DRUG|Niraparib|Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
58462991|NCT01391364|DEVICE|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
58462992|NCT01391364|DEVICE|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
58462993|NCT01861808|OTHER|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
58462994|NCT04199221|BEHAVIORAL|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
58462995|NCT04199221|BEHAVIORAL|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
58462996|NCT02332538|PROCEDURE|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
58462997|NCT02332538|PROCEDURE|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
58462998|NCT02332538|PROCEDURE|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
58462999|NCT00259545|DRUG|Retarded Release Phosphatidylcholine (rPC)|
58463000|NCT01187017|DRUG|Cyclophosphamide|60 mg/kg
58463001|NCT01187017|DRUG|Fludarabine|125 mg/m squared
58463002|NCT04087018|DRUG|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
58463003|NCT04889846|PROCEDURE|SAFE early intervention approach|SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
58463004|NCT03297957|DEVICE|Hands-free goggle system|-Manufactured at Washington University
58463005|NCT00935181|BEHAVIORAL|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
58463006|NCT01952132|DRUG|OMS643762|
58463007|NCT01952132|DRUG|Placebo|
58463008|NCT01628146|DEVICE|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
58463009|NCT03740048|OTHER|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
58463010|NCT03740048|DRUG|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
58463011|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
58463012|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
58463013|NCT02234843|DRUG|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
58463014|NCT02719808|DRUG|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
58463015|NCT02719808|DRUG|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
58463016|NCT02719808|DRUG|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
58463017|NCT02719808|DRUG|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
58463018|NCT01131975|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
58463019|NCT05595707|OTHER|Expert-Guided Early Tracheostomy|Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
58463020|NCT01218334|DEVICE|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
58463021|NCT06240234|DEVICE|Capnodynamic method|All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
58463022|NCT05732298|DEVICE|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
58463023|NCT04731636|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
58463024|NCT00286728|BEHAVIORAL|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
58463025|NCT01349608|BEHAVIORAL|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
58463026|NCT02125396|OTHER|Transarterial chemoembolization|Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
58463027|NCT02125396|OTHER|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
58463028|NCT02426580|BEHAVIORAL|wechat|The wechat model of dietary education every 1 month by cellphone
58463029|NCT01873937|RADIATION|Red LED|Phototherapy with red LED on temporomandibular area
58463030|NCT01873937|RADIATION|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
58463031|NCT01873937|RADIATION|LASER|Phototherapy with LASER INFRARED on temporomandibular area
58463032|NCT06460545|BIOLOGICAL|sIPV (booster dose at 18 months of age)|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose at 18 months of age for the booster one
58463033|NCT06460545|BIOLOGICAL|HepA-L|Freeze-dried/lyophilized live-attenuated hepatitis A virus vaccine, 1.0mL for each dose at 18 months of age
58463034|NCT06460545|BIOLOGICAL|HepA-I|Inactivated hepatitis A virus vaccine, 0.5mL for each dose, two doses at 18 and 24 months of age, respectively
58463035|NCT01943643|PROCEDURE|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
58463036|NCT03507257|DRUG|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
58463037|NCT03507257|DRUG|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
58463038|NCT03507257|DRUG|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
58463039|NCT04855916|DEVICE|ABLE Exoskeleton|Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
58463040|NCT04855916|DEVICE|KAFO Orthosis|Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
58463041|NCT03828032|PROCEDURE|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
58463042|NCT03828032|PROCEDURE|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
58463043|NCT04938908|DRUG|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
58463044|NCT04938908|DRUG|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
58463045|NCT04938908|DIETARY_SUPPLEMENT|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
58463046|NCT04938908|DIETARY_SUPPLEMENT|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
58463047|NCT03659266|OTHER|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
58463048|NCT03659266|OTHER|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
58463049|NCT02306330|DEVICE|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
58463050|NCT02306330|OTHER|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
58463051|NCT05933135|DRUG|Factor XIII Injection|Patients could have had an Factor XIII Injection in clinical routine
58463052|NCT02649413|DRUG|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
58463053|NCT02404961|OTHER|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
58463054|NCT01025908|BEHAVIORAL|Psychotherapy|Cognitive Behavioral Therapy
58130866|NCT01643837|OTHER|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
58463055|NCT01025908|BEHAVIORAL|Supportative psychotherapy|Supportative psychotherapy
58463056|NCT03341299|BIOLOGICAL|LY900014|Administered SC
58463057|NCT03341299|BIOLOGICAL|Insulin Lispro|Administered SC
58463058|NCT04108364|BEHAVIORAL|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
58463059|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
58463060|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
58463061|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
58463062|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
58463063|NCT04906928|DEVICE|MRI|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~* 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
58463064|NCT06473727|OTHER|Omnichoroma|Patients with anterior non-carious cervical lesions were treated with Omnichoroma. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
58463065|NCT06473727|OTHER|Charisma Topaz One|Patients with anterior non-carious cervical lesions were treated with Charisma Topaz One. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
58463066|NCT04663607|BEHAVIORAL|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
58463067|NCT00192933|PROCEDURE|NovoSeven treatment according to guideline|
58463068|NCT05953181|PROCEDURE|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
58463069|NCT03972059|OTHER|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
58463070|NCT03972059|OTHER|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
58463071|NCT03972059|OTHER|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
58463072|NCT03874546|OTHER|Questionnaire|"* Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
58463073|NCT04006041|DRUG|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
58463074|NCT04006041|DRUG|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
58463075|NCT04006041|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
58463076|NCT04006041|PROCEDURE|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
58463077|NCT06705751|DIAGNOSTIC_TEST|Autonomic response in AAOCA|"Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited.~Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch.~The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions."
58463078|NCT00928486|DRUG|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
58463079|NCT00928486|DRUG|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
58463080|NCT06705556|PROCEDURE|Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking|"The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day"
58463081|NCT06705556|PROCEDURE|incentive spirometer, percussion, 3-minute of walking|"The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day"
58463082|NCT02065830|DEVICE|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
58463083|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
58463084|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
58463085|NCT00556569|OTHER|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
58463086|NCT00576355|BEHAVIORAL|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
58463087|NCT00576355|BEHAVIORAL|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
58463088|NCT01319708|PROCEDURE|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
58463089|NCT01319708|PROCEDURE|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
58463090|NCT02685319|PROCEDURE|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
58463091|NCT01497041|DRUG|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
58463092|NCT01497041|DRUG|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
58463093|NCT01626014|BEHAVIORAL|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
58463094|NCT01626014|BEHAVIORAL|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
58463095|NCT02174965|DEVICE|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
58463096|NCT02174965|DEVICE|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
58463097|NCT05017415|DEVICE|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
58463098|NCT05017415|DEVICE|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
58463099|NCT02015273|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
58463100|NCT01446159|DRUG|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
58463101|NCT01446159|DRUG|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
58130867|NCT00805558|DRUG|moxifloxacin|400 mg moxifloxacin once daily for 7 days
58463102|NCT06279741|BIOLOGICAL|Endotracheopulmonary Instillation, Suspension|"The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant."
58463103|NCT06533475|DRUG|Minzasolmin tablet formulation under fasting condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
58463104|NCT06533475|DRUG|Minzasolmin Granules in capsule under fasting condition|Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition
58463105|NCT06533475|DRUG|Minzasolmin tablet formulation under fed condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition
58463106|NCT00981656|DRUG|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
58463107|NCT00981656|DRUG|5-fluorouracil|Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
58463108|NCT00981656|DRUG|Mitomycin|IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
58463109|NCT00981656|RADIATION|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
58463110|NCT00699036|DRUG|avandia|4 mg twice daily
58463111|NCT00699036|DRUG|metformin|500 mg twice daily for 48 weeks
58463112|NCT00699036|DRUG|losartan|losartan 50 mg once daily
58463113|NCT00927108|OTHER|Progenitor Stem Cell Culture|
58463114|NCT02064673|DRUG|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
58463115|NCT02064673|DRUG|placebo|placebo orally twice a day
58463116|NCT06172452|BEHAVIORAL|Project Body Neutrality SSI|Online, 30-minute self-guided intervention for youth ages 13-17
58463117|NCT06172452|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-guided activity for youth ages 13-17
58463118|NCT04011540|BEHAVIORAL|Digital data|Receiving digital data prior to a scheduled mental health session
58463119|NCT00001986|DRUG|1-Octanol|
58463120|NCT02923973|OTHER|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
58463121|NCT02339922|DRUG|Ixazomib Citrate|Given PO
58130868|NCT00805558|DRUG|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
58463122|NCT02339922|OTHER|Laboratory Biomarker Analysis|Correlative studies
58463123|NCT02339922|BIOLOGICAL|Rituximab|Given IV
58463124|NCT01419002|RADIATION|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
58463125|NCT01419002|PROCEDURE|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
58463126|NCT01176201|DRUG|SLV337 suspension|400 mg experimental
58463127|NCT01176201|DRUG|SLV337 capsule|5 x 200 mg immediate release capsule
58463128|NCT00727467|DEVICE|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
58463129|NCT03768414|DRUG|Cisplatin|Given IV
58463130|NCT03768414|DRUG|Gemcitabine Hydrochloride|Given IV
58463131|NCT03768414|DRUG|Nab-paclitaxel|Given IV
58463132|NCT02979977|DRUG|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
58463133|NCT02979977|DRUG|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
58463134|NCT05699187|PROCEDURE|Face allotransplantation|Facial allotransplantation
58463135|NCT04504500|BEHAVIORAL|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
58463136|NCT04504500|BEHAVIORAL|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
58463137|NCT04504500|BEHAVIORAL|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
58463138|NCT04504500|BEHAVIORAL|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
58463139|NCT04504500|BEHAVIORAL|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
58463140|NCT04504500|BEHAVIORAL|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
58463141|NCT04504500|BEHAVIORAL|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
58463142|NCT04504500|BEHAVIORAL|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
58463143|NCT04504500|OTHER|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
58463144|NCT04504500|OTHER|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
58463145|NCT04504500|OTHER|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
58463146|NCT04504500|OTHER|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
58463147|NCT04504500|OTHER|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
58463148|NCT04504500|OTHER|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
58463149|NCT04504500|OTHER|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
58463150|NCT04601818|PROCEDURE|Experimental: Preserving of Donor Lungs|lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
58463151|NCT05580523|DRUG|75 mg acetylsalicylic acid|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
58463152|NCT05580523|DRUG|1.5g Metformin|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g
58463153|NCT05580523|DRUG|150 mg acetylsalicylic acid|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
58463154|NCT05580523|DRUG|Placebo of acetylsalicylic acid and Metformin|Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
58463155|NCT02025686|DRUG|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
58463156|NCT02025686|OTHER|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
58463157|NCT06247995|DRUG|[68Ga]Ga-NeoB|68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
58463158|NCT06247995|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB is a radioligand therapy drug.
58463159|NCT06247995|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
58463160|NCT00617734|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
58463161|NCT00617734|BIOLOGICAL|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
58463162|NCT06581705|PROCEDURE|Video Laryngoscope|Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
58463163|NCT02903914|DRUG|INCB001158|Arginase Inhibitor
58463164|NCT02903914|DRUG|Pembrolizumab|PD-1 Inhibitor
58463165|NCT06116149|BEHAVIORAL|In-person health coach delivery of the GLB|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
58463166|NCT06116149|BEHAVIORAL|Technology-assisted health coach delivery of the GLB|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
58463167|NCT05019690|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
58463168|NCT05019690|DRUG|Albumin-Bound Paclitaxel|Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
58463169|NCT05071209|DRUG|Elimusertib|Given PO
58463170|NCT04663321|DRUG|MK-1942|MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
58463171|NCT04663321|DRUG|Placebo|Dose matched placebo capsules BID orally over 4 weeks.
58463172|NCT04031599|DEVICE|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
58463173|NCT04031599|DEVICE|Insulin pump|Tandem Diabetes Care
58463174|NCT04031599|DEVICE|Continuous glucose monitoring system|Dexcom G6
58463175|NCT04031599|DRUG|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
58463176|NCT04031599|OTHER|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
58463177|NCT04031599|OTHER|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
58463178|NCT04031599|OTHER|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
58463179|NCT04031599|OTHER|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
58463180|NCT04031599|OTHER|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
58463181|NCT04031599|OTHER|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
58463182|NCT03205800|DEVICE|Mini-screw|Placement of a mini-screw
58463183|NCT06100562|BEHAVIORAL|Adapted Dance Program|"* Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~* Each class will start with a 10 min warm-up that will include stretching and motor games.~* Learn a section of choreography every session using action-based intervention for 30 minutes.~* Break for 5 min.~* Improvisation part of class for 10 min.~* Cool-down for 5 min."
58463184|NCT05818488|OTHER|Experimental mind-body intervention|A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
58463185|NCT05789745|DRUG|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
58463186|NCT05789745|OTHER|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
58463187|NCT06445543|BEHAVIORAL|MFeast ENHANCED|The intervention group will initially receive 10 weekly prepared heart-healthy meals from MFeast; Lactation nutritional snack bundles to boost milk supply + structural support for breastfeeding/ pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (medically tailored via study team-crafted virtual grocery store) for 16 more weeks.
58463188|NCT06445543|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive 10 weekly prepared heart-healthy meals from MFeast."
58463189|NCT04830137|DRUG|NX-2127|Oral NX-2127
58463190|NCT00335699|DRUG|Rosuvastatin|
58463191|NCT06704828|DRUG|SHR-4602|SHR-4602
58463192|NCT02348476|OTHER|No Intervention|No study drug is administered in this study.
58463193|NCT05011981|DEVICE|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
58463194|NCT04281290|PROCEDURE|Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|"Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)"
58463195|NCT06536023|DRUG|IBI362|IBI362 SA.QW
58463196|NCT06536023|DRUG|IBI362 placebo|IBI362 placebo SA.QW
58463197|NCT00002649|BIOLOGICAL|aldesleukin|Given IV
58463198|NCT00002649|BIOLOGICAL|filgrastim|Given SC or IV
58463199|NCT00002649|DRUG|cyclophosphamide|Given IV
58463200|NCT00002649|DRUG|etoposide|Given IV
58463201|NCT00002649|RADIATION|radiation therapy|Undergo radiation therapy
58463202|NCT00002649|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
58463203|NCT00002649|PROCEDURE|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
58463204|NCT03188016|BEHAVIORAL|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
58463205|NCT03188016|BEHAVIORAL|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
58463206|NCT01199354|PROCEDURE|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
58463207|NCT06467981|OTHER|Retrospective study|The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.
58463208|NCT05009875|OTHER|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
58463209|NCT05009875|OTHER|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
58463210|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
58463211|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
58463212|NCT04986163|DEVICE|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
58463213|NCT02873871|DEVICE|Standardized compressive dressing|Standardized compressive dressing
58463214|NCT02873871|DEVICE|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
58463215|NCT05284773|OTHER|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
58463216|NCT05284773|OTHER|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
58463217|NCT04763980|OTHER|Educational Intervention|Participate in educational session with health coach
58463218|NCT04763980|OTHER|Genetic Testing|Undergo genetic testing
58463219|NCT04763980|OTHER|Survey Administration|Complete survey
58463220|NCT04819945|DEVICE|GATT-Patch|Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
58463221|NCT05034367|DIAGNOSTIC_TEST|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
58463222|NCT04351542|DIETARY_SUPPLEMENT|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
58463223|NCT04351542|OTHER|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
58463224|NCT06251167|DEVICE|Lateral wedge insoles (LWIs)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.
58463225|NCT06251167|DEVICE|Lateral wedge plus custom arch support (LWAS)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
58463226|NCT04337580|DRUG|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
58463227|NCT06617312|DRUG|Cytisinicline|Targets α4β2 nicotinic acetylcholine receptors
58463228|NCT06617312|DRUG|Placebo Oral Capsule|Matched to active drug, cytisinicline
58463229|NCT03299959|DEVICE|Agili-C implant|Agili-C implant
58463230|NCT03299959|PROCEDURE|SSOC|microfracture and/or debridement
58463231|NCT02721940|PROCEDURE|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
58463232|NCT02721940|BIOLOGICAL|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
58463233|NCT02721940|BIOLOGICAL|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
58463234|NCT02721940|DRUG|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
58463235|NCT02721940|DRUG|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
58463236|NCT04773392|DRUG|Twice-daily Tacrolimus|Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.
58463237|NCT04773392|DRUG|Once-daily envarsus XR|Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
58463238|NCT04773392|DRUG|Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)|Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.
57777934|NCT01914978|OTHER|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
58463239|NCT04773392|DRUG|Methylprednisolone, prednisone|Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.
58463240|NCT04773392|DRUG|Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)|Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
58463241|NCT04773392|DRUG|Azathioprine|Azathioprine (1-3 mg/kg) will be administered once a day.
58463242|NCT03080155|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
58463243|NCT06304103|DRUG|AND017|Administer AND017 once per day (QD)
58490615|NCT06516419|DRUG|Concentrated secretome Injection 2mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
58463244|NCT06552286|BEHAVIORAL|STRW-T|The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).
58463245|NCT06552286|BEHAVIORAL|PEERS-T|PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
58463246|NCT01657864|DRUG|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
58463247|NCT03562273|RADIATION|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
58463248|NCT06105060|DRUG|Rosuvastatin 20mg|to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
58463249|NCT05254678|BEHAVIORAL|general exercise|A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
58463250|NCT06632639|OTHER|Corrective exercise protocol|The program requires 60 minutes consisting of a ten-minute warm-up, a forty-minute Thera-band exercise, and a ten-minute cool-down. Thera-band exercises are to improve the external rotators, and the extensors and for strengthening the quadriceps and the gluteus. A set consists of 15 reps, each of the exercise methods consisted of three sets.
58463251|NCT06632639|OTHER|Lateral wedged insoles with subtalar strapping|A silicon rubber 10 mm lateral wedge has a 10 mm lateral elevation and a 75 mm width, which has an approximately 7.6 inclination. This silicon rubber material is usually used for cosmetic remodeling and has a natural form-fit to the skin. The 75 mm width silicon rubber is scaphoid shaped and it is suitable for attachment to a barefoot of all of the subjects. The rational for using this inclination is that 7.6 is approximately the median between 5 and 10. Patients will be instructed to use the wedge in an appropriate shoe (not high heels or narrow-toed shoes), 1 h a day during the first week. The duration of use gradually will be increased to the minimum of 8 h a day.
58463252|NCT04685798|DEVICE|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
58463253|NCT04685798|DEVICE|FDG PET/CT|Standard of care
58463254|NCT04706208|BEHAVIORAL|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
58463255|NCT04706208|OTHER|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
58463256|NCT04706208|BEHAVIORAL|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
58463257|NCT04706208|BEHAVIORAL|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
58463258|NCT04706208|OTHER|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
58463259|NCT06362746|DRUG|Non-immunogenic recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
58463260|NCT06362746|DRUG|Placebo|15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
58463261|NCT03344757|BEHAVIORAL|Cultural CBSM|The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
58463262|NCT03344757|BEHAVIORAL|Standard CBSM|The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
58463263|NCT05371613|DRUG|tividenofusp alfa|Intravenous repeating dose
58463264|NCT05371613|DRUG|idursulfase|Intravenous repeating dose
57777935|NCT01914978|OTHER|Food allergy treatment as usual|
58463265|NCT04056416|DEVICE|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
58463266|NCT05663710|DRUG|177Lu girentuximab|Given by IV (vein)
58463267|NCT05663710|DRUG|Nivolumab|Given by IV (vein)
58463268|NCT05663710|DRUG|Cabozantinib|Given by PO
58463269|NCT05663710|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
58463270|NCT00051870|DEVICE|Magstim Rapid Magnetic Stimulator|
58463271|NCT05553509|OTHER|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
58463272|NCT03751241|DEVICE|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
58463273|NCT01623102|DRUG|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
58463274|NCT01623102|DRUG|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
58463275|NCT02083471|DIETARY_SUPPLEMENT|Specific Oral Tolerance Induction with Egg or Cow's milk|
58463276|NCT06305286|DRUG|AT-1501|AT-1501 is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40.
58463277|NCT04917146|OTHER|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
58463278|NCT04749940|OTHER|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
58463279|NCT04544813|DRUG|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
58463280|NCT04544813|DRUG|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
58463281|NCT02341560|DRUG|QPI-1007 Injection - 1.5 mg|
58463282|NCT02341560|DRUG|QPI-1007 Injection - 3.0 mg|
58463283|NCT02341560|OTHER|Sham Injection Procedure|Sham Procedure
58463284|NCT06151418|DRUG|Novel hormonal therapy|As provided in real-world setting
58463285|NCT00771914|DRUG|Aspirin|Aspirin 81mg tablet
58463286|NCT00771914|DRUG|Lovaza|Lovaza 4 grams
58463287|NCT00771914|DRUG|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
58463288|NCT00771914|OTHER|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
58130869|NCT01893957|PROCEDURE|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
58463289|NCT01032616|OTHER|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
58463290|NCT01032616|OTHER|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
58463291|NCT02929953|OTHER|chart review|data from charts and from registries will be compared
58463292|NCT05267080|DEVICE|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
58463293|NCT04230187|DRUG|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
58463294|NCT04230187|DRUG|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
58463295|NCT06706375|PROCEDURE|Using ultrasound for penile nerve block|30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi
58463296|NCT06706375|PROCEDURE|Dorsal Penile Block Anesthesia using landmarks|Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
58463297|NCT02099240|DRUG|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
58463298|NCT02099240|PROCEDURE|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
58463299|NCT04861129|PROCEDURE|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
58463300|NCT04861129|PROCEDURE|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
58463301|NCT06304961|BIOLOGICAL|Tozorakimab|Tozorakimab will be administered as a single SC dose on Day 1.
58463302|NCT05410522|DEVICE|EMS Program|Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
58463303|NCT01346358|BIOLOGICAL|IMC-CS4|
58463304|NCT06033547|DRUG|Cabotegravir Formulation F|Cabotegravir Formulation F will be administered
58463305|NCT06033547|DRUG|Cabotegravir Formulation G|Cabotegravir Formulation G will be administered
58463306|NCT02492035|BEHAVIORAL|Lifestyle intervention|
58463307|NCT05831033|BIOLOGICAL|BEN101|"Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."
58463308|NCT04085575|DRUG|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
58463309|NCT05306925|DIETARY_SUPPLEMENT|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
58463310|NCT05795166|OTHER|No treatment given|No treatment given
58463311|NCT02570984|DRUG|Omalizumab|anti-ige injection
58463312|NCT02570984|DRUG|Placebo|placebo comparator arm, injection similar to active
58463313|NCT06301958|DRUG|Dextrose prolotherapy|A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
58463314|NCT06705309|BEHAVIORAL|Web-Based Education|The Effect of a Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer on Women's Prevention Methods
58463315|NCT06366607|OTHER|high-alert medication administration|high-alert medication administration
58463316|NCT03996070|PROCEDURE|Laser therapy|Erbium YAG laser
58463317|NCT05043363|DEVICE|LumenEye X1 digital rectoscope|The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
58463318|NCT00784563|BEHAVIORAL|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
58463319|NCT00784563|BEHAVIORAL|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
58463320|NCT05000021|BEHAVIORAL|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
58463321|NCT05000021|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
58463322|NCT03210948|DEVICE|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
58463323|NCT03210948|DEVICE|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
58463324|NCT05791253|OTHER|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
58463325|NCT05109364|DRUG|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
58463326|NCT01242423|DEVICE|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
58463327|NCT03043313|DRUG|Trastuzumab|Given intravenously (into the vein; IV)
58463328|NCT03043313|DRUG|Tucatinib|Given orally
58463329|NCT06202365|DEVICE|Whole body Vibration|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
58463330|NCT06202365|OTHER|Sham Whole body vibration|They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
58463331|NCT00168844|DRUG|Tiotropium Inhalation Solution|
58463332|NCT00168844|OTHER|Placebo|
58463333|NCT03023449|DRUG|Nitric Oxide|Inhaled Nitric Oxide gas
58463334|NCT01848015|OTHER|detection of CTCs|
58463335|NCT02722564|BEHAVIORAL|self estimation of breath alcohol content|
58463336|NCT02722564|DEVICE|breath alcohol content as measured by Alco Sensor IV device|
58463337|NCT02722564|OTHER|drink a beer|drink a beer, repeat until breath alcohol content 0.1
58463338|NCT05858086|OTHER|Novel same-day discharge protocol after total joint arthroplasty|Preoperative gait/stair training with physical therapy, then postoperative ambulation with nursing after total joint arthroplasty
58463339|NCT05858086|OTHER|Conventional postoperative physical therapy clearance|Physical therapy evaluation and clearance after total joint arthroplasty
58463340|NCT05842031|BEHAVIORAL|Quality of Life Questionnaires|Identify what interventions may be helpful in improving quality of life.
58463341|NCT05842031|BEHAVIORAL|Patient Educational Needs|Identify what interventions may be helpful in improving patient educational needs
58463342|NCT05842031|BEHAVIORAL|Symptom Management|Identify what interventions may be helpful in improving symptom management Improve symptom management
58463343|NCT03304678|DRUG|Sirolimus 2mg|Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.
58463344|NCT05108246|BEHAVIORAL|Dual-Task Exercise Training|Simultaneous cognitive-motor training
58463345|NCT05020028|DRUG|Cannabidiol (CBD)|Patients will be dispensed enough 25mg cannabidiol (CBD) Orally Disintegrating Tablets (ODT) to take a standard dose of 50mg three times daily for 84 days.
58463346|NCT05020028|DRUG|Placebo|25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
58463347|NCT00007202|DRUG|Atazanavir|
58463348|NCT00007202|DRUG|Stavudine|
58463349|NCT00007202|DRUG|Didanosine|
58463350|NCT05757505|DEVICE|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
58463351|NCT05757505|DEVICE|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
58463352|NCT04207034|PROCEDURE|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
58463353|NCT04207034|PROCEDURE|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
58463354|NCT04526106|DRUG|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
58463355|NCT06103396|BIOLOGICAL|Transplantation of autologous MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
58463356|NCT06103396|BIOLOGICAL|Transplantation of allogeneic MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
58463357|NCT04478201|OTHER|back sleep positioning|sleeping on the back.
58463358|NCT04478201|OTHER|side sleep positioning|sleeping on the side
58490616|NCT06516419|DRUG|Tranexamic acid injection|"1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject"
58463359|NCT05642351|OTHER|Autobiographical reminder|"The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)"
58463360|NCT03017963|DRUG|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
58463361|NCT06243198|DRUG|Lebrikizumab|Administered subcutaneously (SC)
58463362|NCT06243198|DRUG|Placebo|Administered subcutaneously (SC)
58463363|NCT00786669|DRUG|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
58463364|NCT00786669|DRUG|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
58463365|NCT00786669|DRUG|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
58463366|NCT00786669|DRUG|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
58463367|NCT00786669|DRUG|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
58463368|NCT01457651|PROCEDURE|Alveolar recruitment|"Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)"
58463369|NCT05559450|DRUG|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
58463370|NCT05559450|OTHER|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
58463371|NCT02675946|DRUG|CGX1321|
58463372|NCT02675946|DRUG|Pembrolizumab|
58463373|NCT02675946|DRUG|encorafenib|
58463374|NCT02675946|DRUG|cetuximab|
58463375|NCT06704555|RADIATION|radiation therapy|received radiation (dose:18～24Gy)
58463376|NCT06704555|DRUG|Tiselizumab|200 mg iv day 1
58463377|NCT06704555|DRUG|Rituximab|375 mg/m2 intravenous \[IV\] day 2
58463378|NCT06704555|DRUG|Cyclophosphamide|750 mg/m2 IV day 3
58463379|NCT06704555|DRUG|Doxorubicin|50 mg/m2 IV day 3
58463380|NCT06704555|DRUG|Vincristine|1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
58463381|NCT06704555|DRUG|Prednisone|100 mg oral days 3-7
58463382|NCT02014324|PROCEDURE|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)"
58463383|NCT02141087|DRUG|Pirfenidone|
58463384|NCT05714267|DEVICE|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
58463385|NCT05714267|DEVICE|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
58463386|NCT05714267|DEVICE|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
57777936|NCT04348682|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
57777937|NCT03126305|OTHER|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
58463387|NCT05805631|DRUG|Pemetrexed|Intrathecal Pemetrexed
58463388|NCT01231984|DEVICE|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
58463389|NCT01231984|DEVICE|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
58490617|NCT06516419|DRUG|Triple Combination Cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
58463390|NCT01231984|DEVICE|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
58463391|NCT06538584|DRUG|Caffeine citrate 10mg/kg|Subjects will be randomized prior to surgery into one of two arms. One arm will receive 10mg/kg Caffeine citrate 15 minutes post surgery.
58463392|NCT06538584|DRUG|0.9% Sodium Citrate|Subjects will be randomized prior to surgery into one of two arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
58463393|NCT01140308|DRUG|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
58463394|NCT01140308|DRUG|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
58463395|NCT00771394|DRUG|Tamsulosin hydrochloride|oral
58463396|NCT00771394|DRUG|Solifenacin succinate|oral
58463397|NCT03851445|DRUG|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
58463398|NCT04765371|DRUG|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
58463399|NCT04765371|DRUG|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
58463400|NCT05935553|DRUG|Baclofen 30 mg|"* baclofen 10 mg capsule (for the 30 mg-baclofen 30 mg arm)~* Dosage: 3 capsules of baclofen 10 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
58463401|NCT05935553|DRUG|Baclofen 60 mg|"* baclofen 20 mg capsule (for the 60 mg baclofen arm)~* Dosage: 3 capsules of baclofen 20 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
58463402|NCT05935553|DRUG|Placebo|"* placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
58463403|NCT04811703|DRUG|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
58463404|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
58463405|NCT04997317|DRUG|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
58463406|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
58463407|NCT06472661|DEVICE|Echopulse or Echopulse HD|The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.
58130870|NCT01893957|PROCEDURE|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
58463408|NCT06472661|DRUG|PolyICLC|PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
58463409|NCT06585878|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.
58463410|NCT02028806|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
58130871|NCT01893957|DEVICE|Neurodyn High Volt Model (IBRAMED)|
58130872|NCT05586022|PROCEDURE|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
58130873|NCT04834037|BEHAVIORAL|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
58463411|NCT04960527|DIETARY_SUPPLEMENT|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate \[CherryActive, UK\] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
58463412|NCT04960527|OTHER|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
58463413|NCT05382494|DRUG|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
58463414|NCT05382494|DRUG|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
58463415|NCT00689039|DRUG|AZD1305|ER tablet, administered as single and repeated doses.
58463416|NCT00689039|DRUG|Placebo|Tablet, administered as single and repeated doses.
58463417|NCT01667900|DRUG|Dulaglutide|
58463418|NCT01667900|DRUG|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
58463419|NCT01360697|OTHER|JADE|"1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information."
58463420|NCT01360697|OTHER|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
58463421|NCT03201796|DRUG|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
58463422|NCT03201796|DRUG|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
58463423|NCT05644834|OTHER|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
58463424|NCT01773681|DRUG|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
58463425|NCT01773681|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
58463426|NCT01773681|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
58463427|NCT03917849|BEHAVIORAL|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
58463428|NCT03469947|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
58463429|NCT06705049|RADIATION|MRI|On MRI, some lesions present as linear enhancement, while others exhibit nodular enhancement
58463430|NCT02363335|OTHER|Placebo|mixed meal
58463431|NCT02363335|OTHER|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
58463432|NCT02363335|OTHER|Sitagliptin|This is already known to increase GLP-1 \&amp; GIP secretion.
58463433|NCT02363335|OTHER|Roflumilast|This is already known to increase GLP-1 \&amp; GIP secretion
58463434|NCT04003285|DRUG|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
58463435|NCT04003285|DRUG|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
58463436|NCT04003285|DRUG|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
58463437|NCT01893463|DEVICE|iTClamp50|
58463438|NCT01598766|DEVICE|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
58463439|NCT00703014|DRUG|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
58463440|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
58463441|NCT00703014|DRUG|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
58463442|NCT00703014|DRUG|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
58463443|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
58463444|NCT00703014|DRUG|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
58463445|NCT00703014|BIOLOGICAL|hCG|In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
58463446|NCT00703014|BIOLOGICAL|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
58463447|NCT02474797|DEVICE|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7)."
58463448|NCT03107481|DRUG|Acetaminophen|Acetaminophen 1g IV
58463449|NCT03107481|DRUG|Hydromorphone|Hydromorphone 1mg IV
58463450|NCT00987376|DEVICE|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
58463451|NCT05449821|DIAGNOSTIC_TEST|Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum and saliva samples will be collected from both groups for biochemical analysis.
58463452|NCT05835505|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
58463453|NCT05835505|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
58463454|NCT05236270|BEHAVIORAL|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
58463455|NCT05236270|BEHAVIORAL|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
58463456|NCT05236270|BEHAVIORAL|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
58130874|NCT00175357|DRUG|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
58463457|NCT01303341|OTHER|Laboratory Biomarker Analysis|Correlative studies
58463458|NCT01303341|OTHER|Pharmacological Study|Correlative studies
58463459|NCT01303341|DRUG|Riluzole|Given PO
58463460|NCT01303341|DRUG|Sorafenib Tosylate|Given PO
58463461|NCT04545749|BIOLOGICAL|UB-612|UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
58463462|NCT05723653|BEHAVIORAL|Project nGage|"Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference."
58463463|NCT03674528|OTHER|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
58463464|NCT03674528|DIAGNOSTIC_TEST|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
58463465|NCT06459479|OTHER|Conversational Artificial Intelligence Simulations|Use of Conversational Artificial Intelligence Simulations generate medical scenario.
58463466|NCT02056743|DRUG|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
58463467|NCT02056743|DRUG|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
58463468|NCT02056743|DIETARY_SUPPLEMENT|Red ginseng|During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
58463469|NCT02056743|DIETARY_SUPPLEMENT|Fermented-red ginseng|During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
58463470|NCT04803383|OTHER|Tele-yoga|Tele-yoga training 3 days a week for 8 weeks
58463471|NCT06459375|OTHER|modified otago exercises|patients will receive modified Otago exercises with conventional treatment.
58463472|NCT06459375|OTHER|Action Observation Training|Patients will receive Action Observation Training with conventional treatment.
58130875|NCT00175357|DRUG|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
58463473|NCT00657319|DRUG|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
58463474|NCT05948267|DRUG|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
58463475|NCT05948267|DRUG|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
58463476|NCT06579755|BIOLOGICAL|TDV|TDV SC injection.
58463477|NCT06579755|OTHER|Placebo|Placebo SC injection.
58463478|NCT03919396|DEVICE|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material."
58463479|NCT05359458|BEHAVIORAL|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
58463480|NCT04391374|PROCEDURE|an arterial reconstructive procedure|
58463481|NCT00668421|DRUG|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
58463482|NCT03963765|PROCEDURE|Group I (Standard DL-PDT)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
58463483|NCT03963765|PROCEDURE|Group II (DL-PDT with microneedles)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
58463484|NCT03963765|PROCEDURE|Group III (DL-PDT with CO2 laser)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass
58463485|NCT03963765|PROCEDURE|Group IV (DL-PDT with microdermabrasion)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
58463486|NCT04228471|PROCEDURE|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
58463487|NCT04228471|PROCEDURE|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
58463488|NCT05621330|DRUG|QL0911|The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
58463489|NCT05621330|DRUG|Placebo comparator|The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
58463490|NCT05433246|BEHAVIORAL|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
58463491|NCT01904188|DEVICE|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
58463492|NCT05911542|BEHAVIORAL|Survey|Participants complete survey about pain management practices
58463493|NCT06549478|PROCEDURE|Computed Tomography|Undergo PET/CT
58463494|NCT06549478|RADIATION|Image Guided Radiation Therapy|Undergo BgRT
58463495|NCT06549478|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58463496|NCT06549478|OTHER|Questionnaire Administration|Ancillary studies
58463497|NCT02506894|DRUG|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
58463498|NCT02506894|OTHER|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
58463499|NCT02395458|DRUG|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
58463500|NCT02395458|DRUG|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
58463501|NCT05083416|BEHAVIORAL|Prolonged Nightly Fasting|Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
58463502|NCT05083416|BEHAVIORAL|Regular Eating pattern|Food intake not limited to a specific time during day/night.
58463503|NCT06706531|PROCEDURE|Standard treatment|All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
58463504|NCT06706531|PROCEDURE|Sham Dry needling|The sham dry needling group will also receive 6 sessions of sham dry needling on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes.Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm.The plantar and medial surface of the foot and ankle will be cleaned with alcohol. The sham dry needling will be performed for 5 minutes.
58463505|NCT06706531|PROCEDURE|Dry needling|The dry needling group will receive 6 sessions of dry needling using a standardized trigger point protocol on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes. Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm. The calf, plantar and medial surface of the foot and ankle will be cleaned with alcohol. Following insertion, needles will be manipulated bi-directionally to elicit a sensation of aching, tingling, deep pressure, heaviness or warmth. The needles will then left in situ for 5 minutes.
58463506|NCT01274949|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
58130876|NCT02384174|DIETARY_SUPPLEMENT|Resistant starch|
58463507|NCT03213340|OTHER|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
58463508|NCT03213340|OTHER|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
58463509|NCT03213340|OTHER|Flavonoid Cohort 3|- \~ 1 oz. serving consumed 30 minutes before meal
58463510|NCT03101969|OTHER|Call|not called, not reached, and spoken to
58463511|NCT03270943|BEHAVIORAL|MFY|Mindful Self-Compassion course for teens
58463512|NCT03270943|BEHAVIORAL|HLG|Healthy Lifestyles course for teens
58463513|NCT02632799|DEVICE|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
58463514|NCT02632799|DEVICE|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
58463515|NCT02632799|DEVICE|CPAP|Nsal CPAP 5cm H2o by face mask
58463516|NCT04923867|DEVICE|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
58463517|NCT06599736|DEVICE|RhinAer Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810).
58463518|NCT05641545|BIOLOGICAL|IVAC|IVAC is a personalized peptide vaccine
58463519|NCT05119777|DEVICE|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
58463520|NCT00865345|DEVICE|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
58463521|NCT03291067|DRUG|MT-8554 1mg|MT-8554 1mg QD, oral, 12 weeks
58463522|NCT03291067|DRUG|MT-8554 5mg|MT-8554 5mg QD, oral, 12 weeks
58463523|NCT03291067|DRUG|MT-8554 10mg|MT-8554 10mg QD, oral, 12 weeks
58463524|NCT03291067|DRUG|Placebo|Placebo QD, oral, 12 weeks
58463525|NCT01605006|DEVICE|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
58463526|NCT02250222|DRUG|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)
58463527|NCT02250222|DRUG|Placebo (Captisol ®)|betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
58463528|NCT06577259|DRUG|BMS-986435|Specified dose on specified days
58463529|NCT05948735|OTHER|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
58463530|NCT05948735|OTHER|Physical Therapy Exercise (PTE) only for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
58463531|NCT03285724|DEVICE|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
58463532|NCT06375200|OTHER|No intervention|Observational one-time questionnaire study without intervention
58463533|NCT01447589|DRUG|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
58463534|NCT01447589|RADIATION|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
58463535|NCT00176696|DEVICE|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
58463536|NCT04988295|DRUG|Lazertinib|Lazertinib will be administered orally.
58463537|NCT04988295|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion.
58463538|NCT04988295|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion.
58463539|NCT04988295|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
58463540|NCT04166812|DIAGNOSTIC_TEST|oscillometry|assessment of peripheral airway resistance using oscillometry
58463541|NCT04166812|DIAGNOSTIC_TEST|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
58463542|NCT04166812|DIAGNOSTIC_TEST|spirometry|assessment of lung function using spirometry
58463543|NCT04166812|DIAGNOSTIC_TEST|body plethysmography|assessment of lung function using body plethysmography
58463544|NCT04166812|DIAGNOSTIC_TEST|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
58463545|NCT04166812|DIAGNOSTIC_TEST|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
58463546|NCT04166812|DIAGNOSTIC_TEST|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])
58463547|NCT04166812|DIAGNOSTIC_TEST|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
58463548|NCT04166812|DIAGNOSTIC_TEST|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
58463549|NCT00781768|DRUG|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
58463550|NCT00781768|DRUG|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
58463551|NCT06334393|BIOLOGICAL|VLA1601|0.45mL (milliliter), Day 1 and 29
58463552|NCT06334393|BIOLOGICAL|CpG 1018®|CpG 1018® will be investigated in combination with VLA1601 Low dose
58463553|NCT06334393|BIOLOGICAL|3M-052-AF|3M-052-AF will be investigated in combination with VLA1601 Low dose
58463554|NCT03987360|OTHER|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
58463555|NCT06112171|PROCEDURE|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
58463556|NCT06112171|PROCEDURE|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
58463557|NCT03938311|OTHER|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
58463558|NCT05968820|BEHAVIORAL|Sleep Health Enhancement Intervention|The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
58463559|NCT04874714|BIOLOGICAL|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
58463560|NCT04874714|BIOLOGICAL|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
58463561|NCT04874714|BIOLOGICAL|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
58463562|NCT04874714|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
58463563|NCT00265694|DRUG|vinorelbine, gemcitabine and carboplatin|
58463564|NCT03631485|OTHER|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
58463565|NCT05249140|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
58463566|NCT05986916|DIAGNOSTIC_TEST|Liverscope® exam|Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
58463567|NCT05986916|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
58463568|NCT05986916|DIAGNOSTIC_TEST|FibroScan® exam (optional)|Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.
57777938|NCT06443203|OTHER|Trimodal prehabilitation|Trimodal prehabilitation program (4-week physical exercise before surgery, nutritional optimization, and psychological support) in patients undergoing ERAS colorectal resection for cancer
58463569|NCT05986916|OTHER|Blood draw|Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.
58463570|NCT05986916|OTHER|Body measurements|Participants will have their height, weight, waist circumference, and hip circumference measured.
58463571|NCT05986916|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
58463572|NCT04604600|DRUG|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
58463573|NCT04410497|OTHER|Porcine xenograft (wound dressings)|commercial porcine xenograft, derived from acellular dermis from porcine.
58463574|NCT04410497|OTHER|Silver foam (wound dressings)|commercial silver containing foam dressing
58463575|NCT03010696|OTHER|No interventions, questionnaire, collect specimen|
58463576|NCT03842696|DRUG|Vorinostat|"* HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
58463577|NCT03842696|PROCEDURE|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
58463578|NCT03842696|DRUG|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
58463579|NCT03842696|DRUG|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
58463580|NCT03842696|DRUG|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
58463581|NCT03842696|DRUG|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
58463582|NCT03298360|OTHER|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
58463583|NCT03290443|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
58463584|NCT03272750|DIETARY_SUPPLEMENT|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
58463585|NCT03272750|DIETARY_SUPPLEMENT|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
58463586|NCT03272750|DIETARY_SUPPLEMENT|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
58463587|NCT00481832|DRUG|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
58463588|NCT00481832|DRUG|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
58463589|NCT00481832|DRUG|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
58463590|NCT00481832|DRUG|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
58463591|NCT00481832|DRUG|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
58463592|NCT00481832|DRUG|Cyclosporine|5mg/kgbid,variable, po or IV
58463593|NCT00481832|DRUG|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
58463594|NCT00481832|DRUG|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
58463595|NCT00481832|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
58463596|NCT00481832|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
58463597|NCT00481832|PROCEDURE|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
58463598|NCT00481832|DRUG|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
58463599|NCT00481832|DRUG|Solu-Medrol|1 mg/kg, Day-11 to Day-7
58463600|NCT02043756|DRUG|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
58463601|NCT02043756|DRUG|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
58463602|NCT01820299|DRUG|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
58463603|NCT01820299|DRUG|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
58463604|NCT01322100|DEVICE|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
58463605|NCT01322100|DRUG|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
58463606|NCT03220971|OTHER|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
58463607|NCT04818268|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
58463608|NCT04818268|OTHER|cTBS|continuous theta-burst stimulation
58463609|NCT00002814|BIOLOGICAL|filgrastim|
58463610|NCT00002814|DRUG|paclitaxel|
58463611|NCT00002814|DRUG|topotecan hydrochloride|
57784488|NCT05039775|DEVICE|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
58463612|NCT01394055|DRUG|RM-131|100 μg subcutaneously once
58463613|NCT01394055|DRUG|Placebo|Matching placebo volume subcutaneously once
58463614|NCT01961505|DRUG|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
58463615|NCT01961505|DRUG|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
58463616|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
58463617|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
58463618|NCT06349798|DRUG|NaCl 0.9%|50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
58463619|NCT05814185|DEVICE|Periodontal distractor|different activation protocols of periodontal distractor
58463620|NCT05564104|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
58463621|NCT00301808|DRUG|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
58463622|NCT00301808|DRUG|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
58463623|NCT00301808|DRUG|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
58463624|NCT00301808|RADIATION|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
58463625|NCT05475249|OTHER|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
58463626|NCT05411562|DIAGNOSTIC_TEST|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
58463627|NCT06098469|DEVICE|Neurofeedback sessions|10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
58463628|NCT05937841|DRUG|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
58463629|NCT05757713|BIOLOGICAL|teplizumab|CD3-directed humanized monoclonal antibody
58463630|NCT05473026|BEHAVIORAL|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
58463631|NCT02251262|DEVICE|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
58463632|NCT04308421|DEVICE|Red light|Low irradiation 650 nm +/- 5 nm red light
58463633|NCT05245435|DIAGNOSTIC_TEST|FDHT-PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
58463634|NCT05245435|DIAGNOSTIC_TEST|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
58463635|NCT04892641|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
58463636|NCT04892641|DRUG|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
58463637|NCT04675593|BEHAVIORAL|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
58463638|NCT04675593|BEHAVIORAL|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
58463639|NCT00659412|DRUG|Alefacept|Intramuscular
58463640|NCT00659412|DRUG|Methotrexate|Oral
58463641|NCT00659412|DRUG|Placebo|Intramuscular
58463642|NCT06035562|BEHAVIORAL|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
58463643|NCT03278314|DRUG|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
58463644|NCT03863795|OTHER|Survey Administration|Respond to SurveyGizmo survey online
58463645|NCT04829734|DEVICE|Active PBMT-sMF|The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
58463646|NCT04829734|DEVICE|Placebo PBMT-sMF|The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
58463647|NCT03316196|BEHAVIORAL|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
58463648|NCT03316196|BEHAVIORAL|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
58463649|NCT04131413|DRUG|pNGVL4aCRTE6E7L2|The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
58463650|NCT02195765|DRUG|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
58463651|NCT02195765|PROCEDURE|Open flap debridement|Open flap debridement
58463652|NCT06044675|DRUG|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
58463653|NCT06044675|BEHAVIORAL|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
58463654|NCT03919773|DRUG|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
58463655|NCT03919773|DRUG|Albumin|This will be the matching placebo used in the study.
58463656|NCT03151629|OTHER|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
58463657|NCT05935761|DRUG|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
58463658|NCT05935761|DRUG|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
58463659|NCT05935761|DRUG|Placebo|Same as active comparator arms, except placebo dispensed
58463660|NCT05977413|OTHER|CAC Notification|Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
58463661|NCT05977413|OTHER|Clinician Guideline Reminder|The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
58463662|NCT04541589|DRUG|CFZ533 (iscalimab)|Biological
58463663|NCT04541589|OTHER|CFZ533 Placebo|Matching placebo
58463664|NCT04458636|DRUG|Prednisolone|Oral
58463665|NCT01844765|DRUG|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
58463666|NCT00468169|DRUG|Cetuximab|250mg/m2(day 1, weekly x 10);
58463667|NCT00468169|DRUG|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
58463668|NCT00468169|DRUG|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
58463669|NCT00468169|RADIATION|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
58463670|NCT00468169|DRUG|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
58130877|NCT02384174|DIETARY_SUPPLEMENT|Dietary fibre (arabinogalactan, gum guar, pectin)|
58463671|NCT00468169|RADIATION|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
58463672|NCT05583773|DRUG|ShengXian-QuYu Decoction|Specification: 30ml/bag, given twice daily, per oral use.
58463673|NCT05583773|OTHER|Placebo|Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
58463674|NCT01874197|DEVICE|B-TEVAR device|Implantation of the Branched Thorcoabdominal aortic anerysm device
58463675|NCT03922100|DRUG|NMS-03592088|Route of administration: Oral
58463676|NCT04421053|BEHAVIORAL|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
58463677|NCT05158270|PROCEDURE|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
57784489|NCT05039775|BEHAVIORAL|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
58130878|NCT01004211|PROCEDURE|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
58463678|NCT05158270|PROCEDURE|Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block|Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
58463679|NCT05158270|OTHER|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
58463680|NCT02570178|OTHER|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
58463681|NCT05178173|OTHER|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
58463682|NCT05178173|OTHER|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
58463683|NCT05178173|OTHER|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
58463684|NCT00173407|PROCEDURE|immunohistochemical, methylation, gene transfection|
58463685|NCT05603793|BEHAVIORAL|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
58463686|NCT05724277|BEHAVIORAL|Mindfulness Meditation|A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.
58463687|NCT05724277|BEHAVIORAL|Virtual Reality|A 10-minute virtual reality experience will be provided by using virtual reality glasses.
58463688|NCT05034146|DRUG|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
58463689|NCT05034146|DEVICE|PET/CT|68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
58463690|NCT03113851|RADIATION|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
58463691|NCT03113851|DRUG|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
58463692|NCT05708911|DEVICE|Pharyngeal exerciser|Pharyngo-esophageal manometry during lateral fluoroscopy
58463693|NCT02996344|OTHER|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
58463694|NCT02996344|OTHER|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
58463695|NCT04688450|DEVICE|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
58463696|NCT04056819|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
58463697|NCT05428332|DEVICE|Tri-Compartment Unloader Brace|Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
58130879|NCT01004211|PROCEDURE|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
58130880|NCT06356675|DRUG|Tislelizumab|200mg iv D1 Q3W
58130881|NCT06356675|DRUG|Anlotinib|Anlotinib 12mg D1-12 Q3W
58130882|NCT03689790|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
58130883|NCT03689790|PROCEDURE|gastric bypass|gastric bypass
58130884|NCT03103100|DRUG|1% Lidocaine|10 mL of 1% lidocaine
58130885|NCT03103100|DRUG|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
58130886|NCT03103100|DRUG|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
58130887|NCT00388180|DRUG|GW501516|
58463698|NCT04617782|COMBINATION_PRODUCT|Donepezil TDS|Transdermal Delivery System
58463699|NCT04617782|DRUG|Aricept|Oral
58463700|NCT03524846|DRUG|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
58463701|NCT03524846|DRUG|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
58463702|NCT03524846|DRUG|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
58463703|NCT06544174|OTHER|Percutaneous Coronary Intervention of CTO|CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
58463704|NCT04889872|DEVICE|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
58463705|NCT00114569|DRUG|lorazepam|
58463706|NCT03182374|DEVICE|nSTRIDE APS|Intra-articular injection
58463707|NCT03182374|DEVICE|Synvisc-One|Intra-articular injection
58463708|NCT06114121|PROCEDURE|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
58463709|NCT06114121|DRUG|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
58463710|NCT06114121|DRUG|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
58463711|NCT06114121|DRUG|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
58463712|NCT05595655|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
58463713|NCT05574322|OTHER|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology"
58463714|NCT05574322|OTHER|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
58463715|NCT00334880|DRUG|NRP104|
58463716|NCT00476125|BEHAVIORAL|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
58130888|NCT00388180|DRUG|GW590735|
58463717|NCT00476125|BEHAVIORAL|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
58463718|NCT00476125|BEHAVIORAL|16 Hour Fast|Subjects will fast for 16 hours.
58463719|NCT01572207|BEHAVIORAL|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
58463720|NCT01572207|BEHAVIORAL|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
58463721|NCT00099801|DRUG|FTY720|
58463722|NCT06362850|OTHER|Tele-support|via real-time audio-video connection through an experienced physician
58463723|NCT05983458|PROCEDURE|Transaortic valve replacement|"TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view."
58463724|NCT06486103|OTHER|MetSheFlora - Vaginal Health|Take one slow-release capsule twice a day, after meal.
58463725|NCT00028067|DRUG|Atazanavir|
58463726|NCT00028067|DRUG|Nelfinavir mesylate|
58463727|NCT02249364|PROCEDURE|Control|Routine practice
58463728|NCT02249364|PROCEDURE|Hypnosis|Hypnosis session before induction of anesthesia
58463729|NCT02249364|DRUG|propofol|Closed-loop administration of propofol for anesthesia induction
58463730|NCT06475664|OTHER|Personalized legal care services|Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
58463731|NCT04045535|OTHER|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
58463732|NCT04045535|OTHER|Usual care|Usual clinical care based on current clinical practice guidelines.
58130889|NCT02689908|RADIATION|computed tomography|low dose protocol of thorax ct
58463733|NCT02219464|DEVICE|Nasopharyngeal catheter|
58463734|NCT02219464|DEVICE|Nasal Cannula|
58463735|NCT02219464|PROCEDURE|Oxygen Supplementation|Initially set at 3 liters/minute
58463736|NCT02219464|PROCEDURE|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
58463737|NCT04156022|OTHER|Dystonia Coalition is an observational study.|This is not an interventional study.
58463738|NCT06404112|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
58463739|NCT06404112|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
58463740|NCT06404112|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
58463741|NCT06404112|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
58463742|NCT05179252|DRUG|Shen-Fu injection|Chinese patent medicine made by modern technology
58463743|NCT05179252|DRUG|normal saline|0.9% normal saline, used for sham control
58463744|NCT01950416|DRUG|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
58463745|NCT01950416|DRUG|Clopidogrel 600mg loading dose and 150mg maintenance dose|
58463746|NCT04487041|BIOLOGICAL|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
58463747|NCT04487041|BIOLOGICAL|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
58463748|NCT01740830|DEVICE|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
58463749|NCT05482308|DRUG|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
58463750|NCT05482308|DRUG|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
58463751|NCT03709680|DRUG|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
58463752|NCT03709680|DRUG|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
58463753|NCT03709680|DRUG|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
58463754|NCT03709680|DRUG|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
58463755|NCT03709680|DRUG|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
58463756|NCT05288816|DRUG|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
58463757|NCT00005906|DRUG|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
57784490|NCT03034317|DEVICE|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
58463758|NCT00683436|DRUG|Adipiplon|bilayer tablets 6 mg
58463759|NCT00683436|DRUG|Placebo|Placebo
58463760|NCT00683436|DRUG|Ambien CR|Ambien CR 12.5 mg
58463761|NCT00683436|DRUG|Adipiplon|bilayer tablets 9 mg
58463762|NCT06125522|DRUG|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
57784491|NCT05950048|OTHER|The web-based breastfeeding counseling|To the web-based breastfeeding counseling/experimental group (n =33), during the first 6 months after birth, they will be directed to the web-based breastfeeding consultancy website. On this page, mothers will receive counseling on breastfeeding (written, visual, audio materials and telephone counseling) from birth. In addition, the Web-based breastfeeding counseling/experimental group will fill out data collection forms in the first 24 hours, 1st, 2nd, 4th and 6th months after delivery.
57784492|NCT03504865|DRUG|Liposomal bupivacaine|Given at the end of the operation.
58130890|NCT02679001|DRUG|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
58463763|NCT06125522|DRUG|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
58463764|NCT03945383|DEVICE|Treatment with IPL device|Treatment with IPL device
58463765|NCT04738786|PROCEDURE|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
58463766|NCT04738786|PROCEDURE|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
58463767|NCT05490017|DRUG|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
58463768|NCT05490017|DRUG|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
58463769|NCT04935957|DEVICE|GLUCUBE device|device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
58463770|NCT00178477|PROCEDURE|MRI with breath-holding|Breath holding for diminished tumor motion.
58463771|NCT02217163|DRUG|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
58463772|NCT04935385|OTHER|Collecting blood specimens|Blood samples will be collected from all study participants at different required timelines
58463773|NCT03726489|DEVICE|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
58463774|NCT03726489|DEVICE|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
58463775|NCT03896139|DRUG|Kinase inhibitor|Patients treated with kinase inhibitors for cancer or other conditions
58463776|NCT03413007|DIAGNOSTIC_TEST|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
58463777|NCT04885569|BEHAVIORAL|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
58463778|NCT04885569|BEHAVIORAL|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
58463779|NCT04885569|BEHAVIORAL|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
58463780|NCT04027855|PROCEDURE|collection of peripheral blood mononuclear cells from healthy volunteers|"1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
58463781|NCT05732116|OTHER|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
58463782|NCT05371769|OTHER|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
58463783|NCT05371769|OTHER|No intervention|No intervention will be made.
58463784|NCT00671658|DRUG|Rituximab|375 mg/m2 by vein
58463785|NCT00671658|DRUG|Cyclophosphamide (CTX)|300 mg/m2 by vein
58463786|NCT00671658|DRUG|Doxorubicin|50 mg/m2 by vein
58463787|NCT00671658|DRUG|Vincristine|2 mg by vein
58463788|NCT00671658|DRUG|Dexamethasone|40 mg by vein or by mouth (P.O.)
58463789|NCT00671658|DRUG|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
58463790|NCT00671658|DRUG|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
58463791|NCT00671658|DRUG|G-CSF|10 ug/kg subcutaneous injection
58463792|NCT00671658|DRUG|Mesna|600 mg/m2 a day by vein
58463793|NCT00671658|DRUG|Pegylated asparaginase|2000 International units/m2 by vein
58463794|NCT00671658|DRUG|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
58463795|NCT00671658|DRUG|Solumedrol|40 mg by vein for Courses 2,4,6,8
58463796|NCT02407808|DRUG|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
58463797|NCT02407808|DRUG|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
58463798|NCT02343835|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
57777939|NCT05244590|OTHER|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
58463799|NCT04079439|BEHAVIORAL|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
58463800|NCT01028989|DIETARY_SUPPLEMENT|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories"
58463801|NCT01028989|DIETARY_SUPPLEMENT|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories"
58463802|NCT02780401|OTHER|Laboratory Biomarker Analysis|Correlative studies
58463803|NCT02780401|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
58463804|NCT02780401|BIOLOGICAL|Sargramostim|Given ID
58463805|NCT03432325|DEVICE|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
57777940|NCT05332951|OTHER|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
57784493|NCT03504865|DRUG|Standard bupivacaine|Given at the end of the operation.
58463806|NCT05384249|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
58463807|NCT05384249|DRUG|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
58463808|NCT00370058|PROCEDURE|ECT treatment|
58463809|NCT05397717|OTHER|observational|Observational, without interfering the patient care of treating doctors
58463810|NCT00933699|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
58463811|NCT01622439|DRUG|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
58463812|NCT01622439|DRUG|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
58463813|NCT01622439|DRUG|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
58463814|NCT01622439|DRUG|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
58463815|NCT01622439|DRUG|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
58463816|NCT01622439|DRUG|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
58463817|NCT00837252|DRUG|Finasteride|Participants received 5mg of oral finasteride daily for three months.
58463818|NCT05763563|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
58463819|NCT05763563|BEHAVIORAL|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
58463820|NCT05763563|BEHAVIORAL|Optional Aerobic Exercise Procedure|"Participants will be encouraged to complete 3 tele-supervised aerobic training sessions per week, each lasting 30 minutes. Participants will be encouraged to achieve moderate exercise intensity based on heart rate visualized on PM5 monitors. Participants will report their heart rates every 3-5 minutes during an exercise session and be encouraged to adjust pedaling cadence or flywheel resistance accordingly to achieve moderate intensity.~Exercise trainers will access logged heart rate ranges (64-76% of age-predicted maximum heart rate) to provide individualized and appropriate guidance during sessions.~Participants who are untrained or otherwise uncomfortable maintaining moderate aerobic intensity for 30 minutes will be encouraged to gradually increase the duration and intensity of their sessions until they are meeting these guidelines."
58463821|NCT05763563|RADIATION|Optional In-Person Exercise Sessions|Participants who prefer to complete RT and/or aerobic exercise sessions in-person will be allowed to do so. These sessions will be conducted in the Moffitt Promotes Resilience in Oncology Via Exercise (MPROVE) Laboratory using the same equipment participants would use for Zoom sessions, with guidance and supervision from certified exercise trainers.
58463822|NCT03572920|DEVICE|Objective sleep evaluation by actigraphy|Each subject will wear a wrist activity monitor (actigraphy) to detect his/her sleep behaviour during hospitalization.
58463823|NCT03572920|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Each subject will fill twice the Pittsburgh Sleep Quality Index (PSQI), before hospitalization and after the 10th day, to evaluate his/her subjective sleep quality.
58463824|NCT02136979|DRUG|Propofol|group of patients with propofol-based anesthesia
58463825|NCT02136979|DRUG|Sevoflurane|group of patients with sevoflurane-based anesthesia
58463826|NCT03688269|DRUG|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
58463827|NCT03688269|DRUG|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
58463828|NCT03688269|DRUG|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
58463829|NCT00002754|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
58463830|NCT06092762|DRUG|AK120|subcutaneous injection every 2 weeks
58463831|NCT04951115|DRUG|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
58463832|NCT04951115|DRUG|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
58463833|NCT04951115|DRUG|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
58463834|NCT04951115|DRUG|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
58463835|NCT04951115|RADIATION|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
58463836|NCT05829551|DRUG|RAY1216 dose 1|RAY1216 dose 1 or Placebo
58463837|NCT05829551|DRUG|RAY1216 dose 2|RAY1216 dose 2 or Placebo
58463838|NCT05829551|DRUG|RAY1216 dose 3|RAY1216 dose 3 or Placebo
58463839|NCT05829551|DRUG|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 \&ritonavir or Placebo
58463840|NCT05829551|DRUG|RAY1216 dose 5|RAY1216 dose 5 or Placebo
58463841|NCT05829551|DRUG|RAY1216 dose 6|RAY1216 dose 6 or Placebo
58463842|NCT05829551|DRUG|RAY1216 dose 7|RAY1216 dose 7 or Placebo
58463843|NCT05829551|DRUG|RAY1216 dose 8|RAY1216 dose 8 or Placebo
58463844|NCT05829551|DRUG|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
58463845|NCT05829551|DRUG|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
58463846|NCT03246971|DRUG|Wafermine™ 50 mg|Administered as needed for 12 hours
58463847|NCT03246971|DRUG|Wafermine™ 75 mg|Administered as needed for 12 hours
58463848|NCT03246971|DRUG|Placebos|Administered as needed for 12 hours
58463849|NCT03246971|DRUG|Wafermine™ 25 mg|Administered as needed for 12 hours
58463850|NCT06347731|DEVICE|Proton Radiation Therapy|All enrolled participants will be treated with Proton radiation therapy using the medical device Varian ProBeam360° Proton Therapy System. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up which is 3 months after treatment completion and long-term follow-up which is 5 years after treatment completion.
58463851|NCT03897426|BEHAVIORAL|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
58463852|NCT02574403|DRUG|eculizumab|eculizumab discontinuation
58463853|NCT05620108|PROCEDURE|Endotracheal Intubation at TOFC=1|Intubation using a video laryngoscopy will be performed after train-of-four (TOFC) stimulation indicates neuromuscular blockade
58463854|NCT05620108|PROCEDURE|Endotracheal Intubation 2 minutes after rocuronium administration|Intubation using a video laryngoscopy will be performed 2 minutes after administration of rocuronium at 0.6 mg/kg (usual current clinical routine)
58463855|NCT06359652|DEVICE|Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)|We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
58463856|NCT06186323|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
58463857|NCT06186323|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
58463858|NCT06186323|BEHAVIORAL|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
58463859|NCT02023424|DRUG|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
58463860|NCT06045988|DEVICE|Non-Contact Sleep Quality Monitor System|Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
58463861|NCT01924845|DRUG|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
58463862|NCT05528705|BIOLOGICAL|LAENNEC|Subacromial spatial administration
58463863|NCT05528705|OTHER|0.9% normal saline|Subacromial spatial administration
58463864|NCT05493709|DRUG|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
58463865|NCT01364896|PROCEDURE|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing"
58463866|NCT06566118|DEVICE|Auricular Vagus Nerve Stimülation|Both groups were subjected to exercise loading, then Group 1 was subjected to active auricular VSS, and Group 2 was subjected to sham VSS. The application was made simultaneously from both ears, with a pulse duration of 300 microseconds, a biphasic asymmetric waveform and a frequency of 25 Hz for a total of 20 minutes. All evaluations were recorded 3 times for both groups: at the beginning of the test, after exercise loading, and after active and sham VSS application. As a result of the evaluations made for both groups, comparisons were made between and within the groups.
58463867|NCT00161200|DRUG|Ranitidine & Pantoprazole|
58463868|NCT04416204|OTHER|glycogen loading|Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
58463869|NCT04416204|OTHER|No Glycogen Loading|Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
58463870|NCT01702974|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
58463871|NCT01702974|DRUG|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
58463872|NCT06479343|DEVICE|Liquid Embolic System (Tonbridge)|Endovascular treatment with Liquid Embolic System (Tonbridge).
58463873|NCT06479343|DEVICE|Onyx Liquid Embolic System (Medtronic)|Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
58463874|NCT00347789|PROCEDURE|Glaucoma surgery- Bleb revision|
58463875|NCT05226507|DRUG|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
58463876|NCT05589389|OTHER|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
58463877|NCT05589389|OTHER|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
57784494|NCT03504865|OTHER|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
57784495|NCT04616118|OTHER|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
57784496|NCT04616118|OTHER|Video Visit|Participants randomized to this arm will receive usual care via video call
58130891|NCT03651323|DEVICE|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
58463878|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
58463879|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
58463880|NCT04864522|DRUG|SLAMF7 FPBMC|Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
58463881|NCT03402217|BEHAVIORAL|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
58463882|NCT05460754|BEHAVIORAL|Conventional-fed beef|Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.
58463883|NCT05460754|BEHAVIORAL|Organic grass-fed beef|Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
58463884|NCT04426929|OTHER|Conventional exercise therapy|Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.
58463885|NCT04426929|OTHER|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
58463886|NCT04426929|OTHER|Video Based Exercise Group|Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
58463887|NCT01052155|OTHER|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
58463888|NCT05998369|BEHAVIORAL|Empowered Relief for Youth|The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
58463889|NCT02498925|BEHAVIORAL|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
58463890|NCT06464458|OTHER|management on hydroxyurea by therapeutic pharmacological monitoring|"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."
58463891|NCT01885429|DIETARY_SUPPLEMENT|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
58463892|NCT01885429|DIETARY_SUPPLEMENT|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
58463893|NCT01885429|DIETARY_SUPPLEMENT|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
58463894|NCT01885429|DIETARY_SUPPLEMENT|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
58463895|NCT01885429|DIETARY_SUPPLEMENT|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
58463896|NCT05224271|OTHER|Electronic Health Record Review|Medical records are collected
58463897|NCT05224271|OTHER|Medical Device Usage and Evaluation|Fitbit information is collected
58463898|NCT05224271|OTHER|Survey Administration|Complete surveys
57784497|NCT05405387|DRUG|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
58130892|NCT02620345|DRUG|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)"
58463899|NCT05441384|BEHAVIORAL|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
58463900|NCT00521950|GENETIC|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
58463901|NCT00521950|DRUG|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
58463902|NCT06015945|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study."
58463903|NCT01105819|PROCEDURE|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
58463904|NCT01105819|PROCEDURE|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
58463905|NCT01710345|DRUG|Sufentanil NanoTab 20 mcg|
58463906|NCT01710345|DRUG|Sufentanil NanoTab 30 mcg|
58463907|NCT01710345|DRUG|Placebo NanoTab|
58463908|NCT04543396|OTHER|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
58463909|NCT06032065|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
58463910|NCT06032065|BEHAVIORAL|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
58463911|NCT06032065|DIETARY_SUPPLEMENT|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
58463912|NCT03388632|DRUG|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
58463913|NCT03388632|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
58463914|NCT03388632|DRUG|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
58463915|NCT05027594|DRUG|NMS-03597812|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
58463916|NCT05027594|DRUG|NMS-03597812 + dexamethasone|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
58463917|NCT06334822|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
58463918|NCT06334822|OTHER|Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
58463919|NCT06334822|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
58463920|NCT06334822|DEVICE|Heartfelt Device in pharmacy|Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.
58463921|NCT06334822|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and medical professionals.
58463922|NCT00802581|PROCEDURE|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
58463923|NCT00802581|PROCEDURE|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
58463924|NCT04935346|OTHER|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
58463925|NCT02452307|BIOLOGICAL|Peptide vaccine|subcutaneous
58463926|NCT02452307|DRUG|Montanide ISA-51|subcutaneous
58463927|NCT02452307|DRUG|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
58463928|NCT02452307|DRUG|Imiquimod|epicutaneous
58463929|NCT02452307|DRUG|mRNA|subcutaneous
58463930|NCT02452307|DRUG|Protamin|subcutaneous
58463931|NCT02452307|PROCEDURE|local hyperthermia|
58463932|NCT03573882|DRUG|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
58463933|NCT06091475|DRUG|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
58463934|NCT04800965|BEHAVIORAL|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
58463935|NCT04800965|BEHAVIORAL|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
58463936|NCT04800965|BEHAVIORAL|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
58463937|NCT00259909|OTHER|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
58463938|NCT00259909|OTHER|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
58130893|NCT02620345|DRUG|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)"
58463939|NCT00259909|OTHER|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
58463940|NCT00259909|OTHER|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
58463941|NCT00176384|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
58463942|NCT00702481|DRUG|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
58463943|NCT00702481|DRUG|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
58463944|NCT00702481|RADIATION|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
58463945|NCT01237756|DEVICE|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
58463946|NCT05668234|OTHER|interview|semi-directive interview
58463947|NCT03033277|BIOLOGICAL|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
58463948|NCT03033277|BIOLOGICAL|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
58463949|NCT02638116|DRUG|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
58463950|NCT02638116|DRUG|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
58463951|NCT00206635|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
58463952|NCT06199635|DEVICE|Self-Forming Magnetic Anastomosis Device and Delivery System|Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
58463953|NCT01649895|DRUG|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
58463954|NCT01649895|DRUG|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
58463955|NCT01733420|DRUG|Biodentine pulpotomy|
58130894|NCT04605107|DRUG|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
58463956|NCT01733420|DRUG|White MTA pulpotomy|
58463957|NCT01733420|DRUG|Tempophore pulpotomy|
58463958|NCT05408377|OTHER|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
58463959|NCT05408377|OTHER|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
58463960|NCT02760459|DRUG|Dexamethasone|
58463961|NCT02760459|DRUG|Normal saline solution|
58463962|NCT01874236|DRUG|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
57784498|NCT05405387|DRUG|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
58130895|NCT04605107|DRUG|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
58463963|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
58463964|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
58463965|NCT05316948|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
58463966|NCT01766050|DRUG|Caffeine|
58463967|NCT01766050|DRUG|Losartan|
58463968|NCT01766050|DRUG|Omeprazole|
58463969|NCT01766050|DRUG|Dextromethorphan|
58463970|NCT01766050|DRUG|Midazolam|
58463971|NCT01766050|BIOLOGICAL|Belatacept|
58463972|NCT02249806|OTHER|PH target therapy according to physician|Patients receiving PH target therapy
58463973|NCT06066034|DIAGNOSTIC_TEST|HOMA-IR，ESHRE/ASRM|Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003
58463974|NCT03118414|OTHER|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
58463975|NCT03118414|OTHER|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
58463976|NCT03118414|OTHER|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
58463977|NCT04356222|DRUG|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
58463978|NCT04356222|DRUG|methotrexate|Intrathecal chemotherapy specified dose on specified days
58463979|NCT02654782|DRUG|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
58463980|NCT02654782|DRUG|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
58463981|NCT02969122|PROCEDURE|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
58463982|NCT02969122|PROCEDURE|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
58463983|NCT02969122|PROCEDURE|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
58463984|NCT02969122|OTHER|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
58463985|NCT02969122|OTHER|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
58463986|NCT04414241|DRUG|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
58463987|NCT06706362|DRUG|Bactrim or Macrobid|Participants will be assigned to Bactrim or Macrobid depending on participants' allergies
58463988|NCT06706362|DRUG|Placebo|Participants will be assigned to identical appearing placebo
58463989|NCT01280006|OTHER|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
58463990|NCT01280006|DRUG|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
58463991|NCT01280006|DRUG|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
58463992|NCT01280006|DRUG|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
58463993|NCT02381561|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58463994|NCT02381561|OTHER|Laboratory Biomarker Analysis|Correlative studies
58463995|NCT02381561|OTHER|Pharmacological Study|Correlative studies
58463996|NCT02381561|DRUG|Ropidoxuridine|Given PO
58463997|NCT05705024|BIOLOGICAL|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
58463998|NCT05705024|OTHER|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
58130896|NCT03127137|DRUG|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
58463999|NCT02228681|DRUG|Everolimus|10mg daily by mouth
58464000|NCT02228681|DRUG|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
58464001|NCT02228681|DRUG|Letrozole|2.5mg once a day by mouth
58464002|NCT02228681|DRUG|Medroxyprogesterone Acetate|200 mg daily by mouth
58464003|NCT01003301|DRUG|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
58464004|NCT01003301|DRUG|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
58464005|NCT06492330|DRUG|CS0159|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
57784499|NCT06395077|DIAGNOSTIC_TEST|CBCT low-dose protocol|The patient underwent two CBCT examinations (Accuitomo 170; J Morita Corp., Kyoto, Japan): one examination followed the clinical standard-dose protocol (exposure settings: 90 kV, 5 mA, and 9.4 s), and one, the low-dose protocol (90 kV, 2 mA, 9.4 s).
58464006|NCT06492330|DRUG|CS0159 placebo|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
58464007|NCT04842903|OTHER|Therapeutic Touch|Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
58464008|NCT00111046|DRUG|Ibuprofen|
58464009|NCT00111046|DRUG|Tramadol|
58464010|NCT06251557|OTHER|Lumbopelvic Massage|10 minutes abdominal massage and 10 minutes lower back massage will be applied in each session. It will take 20 minutes in total.
58464011|NCT06251557|OTHER|Exercise Training|Exercise training will last approximately 10 minutes in each session. In the exercise training, lumbopelvic stabilization exercises (bridge, cat-and-cow and squatting exercises) will be performed for 10 repetitions, lumbopelvic flexibility exercises (child position, happy baby position, adductor muscle stretching, psoas muscle stretching) will be performed for 20 seconds and 5 repetitions, and diaphragmatic breathing exercises will be performed for 5 repetitions in supine, side lying and sitting positions.
58464012|NCT06251557|DEVICE|Pelvic Floor Electromyography (EMG) Biofeedback Therapy|Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
58464013|NCT06251557|BEHAVIORAL|Standard Urotherapy|The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
58464014|NCT05119036|RADIATION|44 doses of radiation|Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
58464015|NCT05119036|RADIATION|54 doses of radiation|Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
58464016|NCT05282550|DRUG|Trazodone|50mg of trazodone administered for 4 weeks.
58464017|NCT05282550|DRUG|Placebo|Placebo administered for 4 weeks.
58464018|NCT02253225|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
58464019|NCT05752760|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
58464020|NCT05752760|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
58464021|NCT04007666|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
58464022|NCT04007666|BEHAVIORAL|Control Group|Coping-focused treatment.
58464023|NCT00301899|BIOLOGICAL|pertuzumab|
58464024|NCT00301899|BIOLOGICAL|trastuzumab|
58464025|NCT05644119|DEVICE|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
58464026|NCT05644119|DEVICE|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
58464027|NCT01099696|DIETARY_SUPPLEMENT|B. infantis 35624|B. infantis 35624 in white capsules
57784500|NCT05773898|OTHER|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
57784501|NCT00158080|PROCEDURE|hemofiltration|
58130897|NCT03127137|DRUG|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
58464028|NCT01099696|DIETARY_SUPPLEMENT|placebo|white placebo capsules
58464029|NCT03272802|DRUG|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
58464030|NCT03272802|DRUG|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
57784502|NCT02666586|OTHER|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
58130898|NCT01196052|DRUG|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
58464031|NCT03978936|BEHAVIORAL|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
58464032|NCT03978936|BEHAVIORAL|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
58464033|NCT04375384|DRUG|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
58464034|NCT04375384|OTHER|Questionnaire administration|Ancillary studies
58464035|NCT04375384|OTHER|Quality of life assessment|Ancillary studies
58464036|NCT06547437|DRUG|Papaverine|papaverine a smooth muscle relaxant
58464037|NCT06547437|DRUG|normal saline|normal saline 0.9% 100 cc
58464038|NCT00758017|OTHER|Acupuncture 1|Application of individualised acupuncture
58464039|NCT00758017|OTHER|Acupuncture 2|Application of standardised acupuncture
58464040|NCT02755428|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
58464041|NCT03737123|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
58464042|NCT03737123|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
58464043|NCT03737123|DRUG|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
58464044|NCT03737123|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
58464045|NCT05400291|DIAGNOSTIC_TEST|Chondroitin Sulfate Staining|Staining of histopathological slides
58464046|NCT06464497|BEHAVIORAL|Whole Foods MyPlate Group|Families will receive 4-weeks of rotating menus that have been designed as a part of our preliminary work and will be adapted to support adherence with the adolescent in mind (e.g., school lunch options, on-the-go snacks). Menus and diet recommendations will align with the current macronutrient nutritional goals outlined by the 2020-2025 DGA for age-sex groups. Participants will be encouraged to eat ad libitum (i.e., as desired until full) without calorie restrictions. MyPlate will be used by participants to implement the diet. During the study, adolescents and adults in the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs.
58464047|NCT04261439|DRUG|NIZ985|NIZ985 injection
58464048|NCT04261439|DRUG|Spartalizumab|Spartalizumab infusion
58464049|NCT04261439|DRUG|Tislelizumab|Tislelizumab infusion
58464050|NCT04895254|DEVICE|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
58464051|NCT04895254|PROCEDURE|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
58464052|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with obstetric care providers
57777941|NCT06118775|PROCEDURE|EaDyn Weaning Arm:|The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.
58464053|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with study RN.
58464054|NCT05533671|PROCEDURE|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
58464055|NCT05533671|PROCEDURE|Non-operative group|Physical therapy by following a specific regimen.
58464056|NCT06384079|PROCEDURE|Antegrade and retrograde pyelogram|Participation in the study will guarantee that participants will receive this procedure.
58464057|NCT05549895|DRUG|Dexamethasone|8 mg intrathecally
58464058|NCT05549895|DRUG|Bupivacaine Hydrochloride|0.5 % intrathecally
58464059|NCT06595888|RADIATION|Computed Tomography|X-ray by Computed Tomography
58464060|NCT01572597|DRUG|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
58464061|NCT01572597|DRUG|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
58464062|NCT04332822|DRUG|R-pola-mini-CHP|"* Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
58464063|NCT04332822|DRUG|R-mini-CHOP|"* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
58464064|NCT06561919|PROCEDURE|bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper|Best medical treatment according to widely accepted expert consensus Paper
58464065|NCT06561919|DRUG|best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper|Best medical treatment according to widely accepted consensus Paper
58464066|NCT05054075|BIOLOGICAL|Marine liquid and fluids|Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
58464067|NCT05054075|BIOLOGICAL|Impregnation|SARS / COVID-19 fluid/liquid - impregnation
58464068|NCT05054075|BIOLOGICAL|Incubation|SARS / COVID-19 fluid-bivalve-incubation
58464069|NCT05054075|BIOLOGICAL|Manipulation|Bivalve Manipulation - Stress inducing
58464070|NCT05054075|BIOLOGICAL|Refrigeration|Refrigerated fluid to check for maintained response
58464071|NCT05607407|DRUG|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
58464072|NCT05607407|PROCEDURE|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
58464073|NCT05607407|DIAGNOSTIC_TEST|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
58464074|NCT05427344|OTHER|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
58464075|NCT05427344|OTHER|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
58464076|NCT05427344|OTHER|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
58464077|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
58464078|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
58464079|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
58464080|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
58464081|NCT04443244|OTHER|Normal Saline|Placebo Comparator: Normal Saline
58464082|NCT05405920|BEHAVIORAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
58464083|NCT05405920|BEHAVIORAL|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
58464084|NCT05608434|BEHAVIORAL|Floreo Virtual Reality application|Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
58464085|NCT03797651|DRUG|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
58464086|NCT03797651|DRUG|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
58464087|NCT01500590|DRUG|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
58464088|NCT01500590|DRUG|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
58464089|NCT06478667|DRUG|levosemindan|inotropic agent
58464090|NCT06466577|DIAGNOSTIC_TEST|CT 5400 RT System|Computed Tomography X-RAY System is intended to produce images of the head and body by computer reconstruction of x-ray transmission data taken at different angles and planes.
58464091|NCT04467736|DEVICE|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
58464092|NCT05616104|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
58490618|NCT06355700|PROCEDURE|Liver biopsy|The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
58130899|NCT03832400|BIOLOGICAL|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
58464093|NCT06705361|DEVICE|Transparent Radial Artery Band (Screw-Type)|The researcher will randomly assign patients undergoing radial arterial line removal after open heart surgery into four groups: ice-bag pressure, transparent radial band compression device (screw type), transparent radial band compression device (air type), and control group. The researcher will assign specific card colors to each group: white for the control group, yellow for the ice-bag pressure group, pink for the Transparent Radial Band Compression Device - Screw Type group, and green for the Transparent Radial Band Compression Device - Air Type group. The researcher will place all these cards in a container, allowing the participant to select their preferred color, and then apply the intervention separately to each group.
58464094|NCT06034210|DEVICE|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
58464095|NCT06175767|DRUG|MT101-5|Tablet
58464096|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
58464097|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
58464098|NCT04366349|OTHER|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
58464099|NCT03918850|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
58464100|NCT03918850|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
58464101|NCT00971659|DRUG|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
58464102|NCT00971659|DRUG|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
58464103|NCT00971659|DRUG|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
58464104|NCT06102954|OTHER|Falls prevention intervention including exercise and educational components|This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
58464105|NCT05225311|OTHER|Observation|Patients will be followed by the registry for life-long outcomes.
58464106|NCT03629964|DEVICE|Wiersma Head Stabilizer|Experimental device attached to treatment table.
58464107|NCT03629964|DEVICE|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
58464108|NCT04993859|DIAGNOSTIC_TEST|Non-invasive Urodynamic Test (niUDS)|A noninvasive urodynamics is a simple test used to evaluate urinary flow.
58464109|NCT04993859|DIAGNOSTIC_TEST|Urinary proteomic screen|Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
58464110|NCT04993859|OTHER|Dysfunctional Voiding Symptom Score Survey (DVSS)|The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
58464111|NCT06352723|DRUG|Cenobamate|"Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7"
58464112|NCT03245203|PROCEDURE|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4\~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4\~8 weeks.
58464113|NCT03245203|PROCEDURE|CRT|total dose of radiotherapy was 40\~50Gy, a subdose of 1.8\~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
58464114|NCT00062439|DRUG|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes
58464115|NCT00062439|DRUG|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
58464116|NCT00062439|DRUG|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
58464117|NCT00062439|PROCEDURE|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
58490652|NCT01019083|DRUG|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
58490653|NCT01019083|DRUG|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
58464118|NCT00062439|RADIATION|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
58464119|NCT04808115|DRUG|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
58464120|NCT02236286|BEHAVIORAL|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
58464121|NCT03028311|PROCEDURE|Angiography|Undergo angiography
58464122|NCT03028311|PROCEDURE|Computed Tomography|Undergo SPECT-CT
58464123|NCT03028311|PROCEDURE|Planar Imaging|Undergo planar imaging
58464124|NCT03028311|RADIATION|Radioembolization|Undergo radioembolization
58464125|NCT03028311|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
58464126|NCT03028311|RADIATION|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
58464127|NCT03028311|OTHER|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
58464128|NCT03900832|OTHER|Without Heating|Subject will complete walking protocol without any heating procedure
58464129|NCT03900832|OTHER|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP \>20 mmHg), the subject will be removed from the bath even if the time is \<30 min."
58464130|NCT03900832|OTHER|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
58464131|NCT03900832|OTHER|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (\~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches \~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
58464132|NCT03900832|OTHER|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at \~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
58464133|NCT03900832|OTHER|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
58464134|NCT05830864|DRUG|Isoflurane|no other intervention
58464135|NCT05230134|PROCEDURE|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
58464136|NCT05493202|DEVICE|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
58464137|NCT06593171|BEHAVIORAL|Mentoring program|This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.
58464138|NCT06593171|BEHAVIORAL|Control (placebo) group|This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
58464139|NCT05955911|BEHAVIORAL|Exercise|20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.
58464140|NCT05955911|BEHAVIORAL|Coloring|20 minutes of coloring in adult coloring book
58464141|NCT04289181|OTHER|Medically Tailored Meals|4 weeks of medically tailored meals
58464142|NCT06005051|OTHER|Dietary intervention|Using different combination of foods to see if the glucose response to a load of carbohydrates can be mitigated.
58464143|NCT04877626|DRUG|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
58464144|NCT05808686|OTHER|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
57784503|NCT02666586|OTHER|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
58464145|NCT06539884|OTHER|Observational|Evaluating whether the 2005 SIRS - Sepsis diagnostic and grading criteria, pSOFA, PRISM III and PELOD scores are compatible and to compare their prognostic predictive power.
58464146|NCT01349426|DEVICE|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
58464147|NCT04785222|DRUG|dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine|Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
58464148|NCT04554784|OTHER|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
58464149|NCT04554784|PROCEDURE|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
58464150|NCT00982293|DEVICE|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
58464151|NCT00982293|DEVICE|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
58464152|NCT03486821|RADIATION|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
58464153|NCT03994874|DRUG|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
58130900|NCT03832400|DRUG|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
58464154|NCT06572865|OTHER|Screening for depression and anxiety|Parents respond to questionnaires assessing depression and anxiety.
58464155|NCT05034497|DRUG|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
58464156|NCT03323892|OTHER|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
58464157|NCT06289751|DRUG|Cadonilimab|10 mg/kg (body weight), 60 min, IV. Repeat every 3 weeks for a total of 3 cycles
58464158|NCT06289751|DRUG|Paclitaxel-albumin|260 mg/m2 for 30 min. Repeat every 3 weeks for a total of 3 cycles.
58464159|NCT06289751|DRUG|Cisplatin|75-80 mg/m2, IV, 1 mg/min. Repeat every 3 weeks for a total of 3 cycles.
58464160|NCT06289751|PROCEDURE|Extrafascial hysterectomy|Extrafascial hysterectomy + pelvic lymphadenectomy (or SLN mapping) (For participants who meet ConCerv criteria)
58464161|NCT06289751|PROCEDURE|Radical hysterectomy|Radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy (or SLN mapping) (For participants who do not meet ConCerv criteria)
58464162|NCT06289751|PROCEDURE|Cone biopsy|Cold knife conization (CKC) (For participants with tumor size ≤2 cm after 3 cycles of chemo-immunotherapy)
58464163|NCT00171379|DRUG|Enteric-Coated Mycophenolate Sodium|
58464164|NCT00182130|PROCEDURE|Quality Initiative in Rectal Cancer (QIRC) strategy|
58464165|NCT04949191|DRUG|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
58464166|NCT04949191|DRUG|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
58464167|NCT04949191|DRUG|Pembrolizumab|Commercially labeled products
58464168|NCT00837434|DRUG|Etanercept|50 mg dose of etanercept by subcutaneous injection
58464169|NCT00837434|DRUG|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
58464170|NCT04917172|DIAGNOSTIC_TEST|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell \[WBC\] count and C-Reactive Protein \[CRP\]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
58464171|NCT02958995|OTHER|No Intervention|
58464172|NCT02082496|DRUG|Liraglutide|S.c. liraglutide 3.0mg once daily
58464173|NCT04871906|OTHER|stretching exercises|Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
58464174|NCT04212416|DRUG|Leflunomide|Given PO
58464175|NCT06043024|DEVICE|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
58464176|NCT06296849|BEHAVIORAL|Financial Incentive Treatment (FIT)|In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
58464177|NCT05758116|DRUG|Tislelizumab|Tislelizumab: 200mg d1,q21d\*17
58464178|NCT01368588|RADIATION|radiation therapy|Undergo RT using IMRT or 3D-CRT
57784504|NCT02666586|OTHER|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
58464179|NCT01368588|RADIATION|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
58464180|NCT05480995|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
58464181|NCT06095986|DRUG|Aramchol meglumine|Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
58464182|NCT05484102|DIETARY_SUPPLEMENT|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
58464183|NCT05484102|DIETARY_SUPPLEMENT|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
58464184|NCT02854072|DRUG|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
58464185|NCT02854072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
58464186|NCT02854072|DRUG|Capecitabine|Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
58464187|NCT05524493|DIAGNOSTIC_TEST|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
58464188|NCT05524493|DIAGNOSTIC_TEST|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
58464189|NCT05524493|DIAGNOSTIC_TEST|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
58464190|NCT05524493|DIAGNOSTIC_TEST|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
57777942|NCT06118775|PROCEDURE|PAM Weaning Arm:|The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
58464191|NCT05524493|DIAGNOSTIC_TEST|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
58464192|NCT02107417|DEVICE|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
58464193|NCT02107417|DEVICE|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
58464194|NCT03969485|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser Device
58464195|NCT05672654|DIAGNOSTIC_TEST|Blood draw|Blood draw
58464196|NCT02008396|DRUG|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
57777943|NCT06740799|DRUG|Quizartinib|Participants will receive a single oral dose of 30 mg
57777944|NCT05752643|OTHER|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
57777945|NCT01449721|DRUG|Intravenous fluid|0.9% Sodium chloride intravenous fluid
58464197|NCT02008396|DRUG|Midomafetamine HCl|Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
58464198|NCT02008396|BEHAVIORAL|Therapy|Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
58464199|NCT02720393|OTHER|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
58464200|NCT02720393|OTHER|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
58490654|NCT01019083|OTHER|Arsenic|Participant will be selected from the Arsenic Contaminated Area
58490655|NCT02920242|DRUG|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
58490656|NCT02920242|DRUG|Rifaximin (Xifaxan)|200 mg tablet administered orally
58490657|NCT02920242|DRUG|Placebo|Matching Placebo tablet administered orally
58464201|NCT05301959|DEVICE|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
58464202|NCT05301959|DEVICE|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
58464203|NCT05301959|OTHER|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
58464204|NCT05202808|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
58464205|NCT05202808|DEVICE|Control IOL|Control treatment group will receive a Control IOL
58464206|NCT04564417|BIOLOGICAL|W0180|Participants will receive W0180 in a 21-day cycle.
58464207|NCT04564417|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
58464208|NCT04235140|DRUG|LUM/IVA|LUM/IVA granules for oral administration
58464209|NCT04938960|DIAGNOSTIC_TEST|blood draw|blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
58464210|NCT02787564|BEHAVIORAL|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
58464211|NCT05777408|PROCEDURE|Conventional Physical Therapy|"* 15 mins of TENS (frequency 100 Hz, phase duration 50 μs) with moist heat over the area of pain~* Isomeric Stretching of neck muscles followed by neck isometrics"
58464212|NCT05777408|PROCEDURE|Natural Apophyseal glides|-Will be applied in sitting position Therapist right hand would cradle the head such that the little finger would rest on the spinous process of the vertebra that is to be mobilized. The other hands thumb would be used to apply over pressure. Direction of force will be parallel to highly irritable-grossly restricted cervical facet joints. Intervention would involve 3 sets of 20 repetitions in 15minutes, 3 days a week for 2 weeks comprising of total 6 session.
58464213|NCT05777408|PROCEDURE|Cranial Base Release|Will be performed in lying position. therapist fingers will contact the sub occipital muscles and upward pressure would be given until the tissues and muscles relax. it will be given once daily for 3 days a week and will continue for 2 weeks
58464214|NCT05361395|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
58464215|NCT05361395|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
58464216|NCT05361395|DRUG|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
58464217|NCT05361395|DRUG|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
58464218|NCT05361395|DRUG|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
58464219|NCT03962062|DRUG|Moxidectin|2 mg tablets
58464220|NCT06549998|OTHER|Interprofessional Simulation Experience|"Phase 1 (Pre-Brief): Nursing and physical therapy students will have 10 minutes to gather as a group and prepare for the simulation experience.~The students will work together to review the simulated patient's medical chart, which includes a hand off report, physician orders, patient demographic data, disci-pline-specific progress notes, a physical therapy evaluation, and information from lab results posted on a tri-fold board.~Phase 2 (Simulation): After reviewing the chart and establishing a plan as a group for getting the simulated patient out of bed, the interprofessional team of nursing and physical therapy students will enter the simulated hospital room. The goal for the approximately 20-minute encounter is for the interprofessional group to help the simulated patient to get out of bed while closely monitoring the physiological responses to activity.~Phase 3: The simulation will conclude with a 30-minute faculty guided and structured debriefing session."
58464221|NCT06475352|DRUG|FOLFOX regimen|Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
58464222|NCT06475352|DRUG|CAPOX regimen|Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
58464223|NCT00918281|DRUG|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
58464224|NCT02488577|PROCEDURE|Transanal minimally invasive total mesorectal excision|
58464225|NCT02488577|PROCEDURE|transanal minimally invasive locoregional resection|
58464226|NCT05016479|DEVICE|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
57784505|NCT02666586|OTHER|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
58464227|NCT05858541|BEHAVIORAL|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
58464228|NCT05858541|BEHAVIORAL|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
58464229|NCT00407121|DRUG|Bevacizumab|
58464230|NCT00407121|PROCEDURE|Intravitreal Injection of Bevacizumab|
58464231|NCT03521349|OTHER|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
58464232|NCT03521349|OTHER|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
58464233|NCT04985929|DRUG|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
58464234|NCT04985929|DRUG|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
58464235|NCT03466658|DEVICE|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
58464236|NCT03228446|BEHAVIORAL|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
58464237|NCT03228446|BEHAVIORAL|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
58464238|NCT03228446|OTHER|no training (control)|no training applied
58464239|NCT05219825|BEHAVIORAL|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
58464240|NCT02262936|DRUG|Desmopressin|
58464241|NCT02262936|DRUG|Fesoterodine|
58464242|NCT02251015|PROCEDURE|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
58464243|NCT02251015|PROCEDURE|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
58464244|NCT03866122|DEVICE|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
58464245|NCT02568969|DEVICE|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
58464246|NCT00693407|PROCEDURE|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.
58464247|NCT04932395|DRUG|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
58464248|NCT04932395|DRUG|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
58464249|NCT06126614|DRUG|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
58464250|NCT06126614|DRUG|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
58464251|NCT06126614|OTHER|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
58464252|NCT06126614|OTHER|Saline|saline for irrigation
58464253|NCT06165809|DRUG|TQB3015 tablets|TQB3015 is a protein inhibitor
58464254|NCT06582212|DEVICE|Mymovesmatter mobile application|Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
58464255|NCT00317551|DEVICE|Aberration controlled contact lens|
58464256|NCT00317551|BEHAVIORAL|Vision training|
57784506|NCT02666586|OTHER|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
58464257|NCT02735863|DRUG|ABX464|50 mg or 150mg once daily for 28 days
58464258|NCT02735863|DRUG|Placebo|ABX464 matching placebo
58464259|NCT02529852|DRUG|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
58464260|NCT02529852|DRUG|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
58464261|NCT02529852|DRUG|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
58464262|NCT02529852|DRUG|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
58464263|NCT02529852|DRUG|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
58464264|NCT02529852|DRUG|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
57777946|NCT01438671|PROCEDURE|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
58464265|NCT04961710|DRUG|Hetrombopag Olamine|Hetrombopag Olamine; once daily
58464266|NCT04961710|DRUG|Placebo|Placebo; once daily
58464267|NCT03021057|DRUG|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
58464268|NCT06390397|OTHER|Produce prescription program|"Boxes of fresh fruit and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks. Participants will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
58464269|NCT06390397|OTHER|Standard of care|Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.
58464270|NCT05945784|OTHER|Use of Rare Beauty makeup products|Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
58464271|NCT05305443|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
58464272|NCT05305443|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
58464273|NCT05305443|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
58464274|NCT05305443|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
58464275|NCT03290937|BIOLOGICAL|Cetuximab|Given IV
58464276|NCT03290937|DRUG|Irinotecan Hydrochloride|Given IV
58464277|NCT03290937|OTHER|Pharmacodynamic Study|Correlative studies
58464278|NCT03290937|BIOLOGICAL|Utomilumab|Given IV
58464279|NCT06704568|OTHER|exercise|Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group: Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
58464280|NCT04850105|OTHER|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
58464281|NCT04857255|BEHAVIORAL|Technology assisted language intervention|speech language therapy that has integrated technology delivered through specific software on an iPad
58464282|NCT04857255|BEHAVIORAL|Treatment as usual|No change will occur to the current ongoing speech-language therapy being delivered.
58464283|NCT03346434|DRUG|Dupilumab|Solution for injection, subcutaneous (SC)
58464284|NCT03346434|DRUG|Matching placebo|Solution for injection, subcutaneous (SC)
57777947|NCT01438671|PROCEDURE|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
57784507|NCT02550275|BEHAVIORAL|neuropsychological test|
57784508|NCT02550275|RADIATION|MRI|
58464285|NCT03567564|DIAGNOSTIC_TEST|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
58464286|NCT03826706|DEVICE|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
58464287|NCT03826706|DEVICE|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
58464288|NCT00005567|BEHAVIORAL|Parental knowledge and beliefs about infant sleep position|
58464289|NCT01893996|DRUG|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
58464290|NCT01893996|DRUG|Placebo|
58464291|NCT06205992|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
58464292|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
58464293|NCT06205992|DEVICE|2D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
58464294|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
58464295|NCT04459143|BEHAVIORAL|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
58464296|NCT03489863|DRUG|Prasugrel|Maintenance dose will be maintained for 10±3 days.
58464297|NCT03489863|DRUG|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
58464298|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
58464299|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
58464300|NCT05062174|DRUG|Mifepristone 200 MG|Orally, one time dosage of 200 mg
58464301|NCT05062174|PROCEDURE|Prophylactic mastectomy|Planned prophylactic mastectomy (having one or both breasts removed).
58464302|NCT06508411|OTHER|Pain screening|exploration of the relationship between pain and sexual health
58464303|NCT06541938|DIETARY_SUPPLEMENT|low FODMAP diet|You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
58464304|NCT06541938|DIETARY_SUPPLEMENT|Lactose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk"
58464305|NCT06541938|DIETARY_SUPPLEMENT|Fructose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples"
58464306|NCT06541938|DIETARY_SUPPLEMENT|Sorbitol Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune"
58490658|NCT03240549|DRUG|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
57784509|NCT04995835|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
58464307|NCT06541938|DIETARY_SUPPLEMENT|Inulin Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic"
58464308|NCT06541938|DEVICE|AIRE-2 Portable breath analyzer|The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
58464309|NCT00187291|DEVICE|T-Wave Alternans test|
58464310|NCT03784872|PROCEDURE|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
58464311|NCT06026046|OTHER|Adapted sport program based on fencing|"This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters."
58464312|NCT00261690|BEHAVIORAL|Virtual Reality Distraction|Using virtual reality distraction during a procedure
58464313|NCT05196828|DEVICE|NTX100 Neuromodulation System|Active Noninvasive peripheral nerve stimulation device programmed to active mode
58464314|NCT05680714|OTHER|Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention|
58464315|NCT00939549|DRUG|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
58464316|NCT03604367|DEVICE|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
58464317|NCT02197312|DEVICE|NobelProcera Bridge Shaded Zirconia|
58464318|NCT00280982|BIOLOGICAL|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
58464319|NCT05206747|DEVICE|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
58464320|NCT05206747|DEVICE|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
58464321|NCT01991808|RADIATION|Radiotherapy|
58464322|NCT05766397|DRUG|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
58464323|NCT05323695|BEHAVIORAL|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
58464324|NCT05992675|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
58464325|NCT05992675|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
58464326|NCT04362839|BIOLOGICAL|Ipilimumab|Given IV
58464327|NCT04362839|BIOLOGICAL|Nivolumab|Given IV
58464328|NCT04362839|DRUG|Regorafenib|Given PO
58464329|NCT05930938|DRUG|Xevinapant|Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
58464330|NCT05930938|DRUG|Placebo|Xevinapant without active substance
58464331|NCT05930938|DRUG|cetuximab|cetuximab
58464332|NCT05930938|RADIATION|IMRT|IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
58464333|NCT01926223|OTHER|Home visiting|
58464334|NCT00246519|DRUG|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
58464335|NCT00246519|DRUG|Atenolol|atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
58464336|NCT03386981|OTHER|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
58464337|NCT04013386|DRUG|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
58464338|NCT04013386|DRUG|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
58464339|NCT04013386|DRUG|Dexamethasone|Dexamethasone 8 mg IVI
58464340|NCT04364477|PROCEDURE|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
58464341|NCT05830552|OTHER|Receving feedback|Receving regular feedback from a health provider
58464342|NCT05830552|OTHER|No regular feedback|No regular feedback from a health provider
58464343|NCT05301660|DRUG|Nicotine transdermal patch|14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
58464344|NCT03392896|DRUG|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
58464345|NCT03392896|DRUG|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
58464346|NCT06479590|DEVICE|tDCS|The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)
58464347|NCT06479590|OTHER|Sham tDCS|sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application
58464348|NCT01184586|DEVICE|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
58464349|NCT01184586|DEVICE|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
58464350|NCT01962935|DRUG|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
58464351|NCT01962935|DRUG|Placebo|Part A - multiple ascending dose daily
58464352|NCT01962935|DRUG|AZD5069|Part B - one dose decided after part A, twice a day
58464353|NCT03549923|DEVICE|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
58464354|NCT03549923|DEVICE|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
58464355|NCT03549923|DRUG|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
58464356|NCT03549923|DRUG|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
58464357|NCT05588336|DRUG|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
58464358|NCT06173830|OTHER|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
58464359|NCT06173830|OTHER|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
58464360|NCT02946086|BEHAVIORAL|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
58464361|NCT02946086|BEHAVIORAL|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
58464362|NCT02944409|DEVICE|total knee prothesis VEGA System|total knee replacement
58464363|NCT04180930|DIAGNOSTIC_TEST|CAPS-5|Clinician Administered PTSD Scale for DMS-5
58464364|NCT04180930|DIAGNOSTIC_TEST|PSSI-5|PTSD Symptom Scale Interview for DSM-5
58464365|NCT04180930|DIAGNOSTIC_TEST|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
58464366|NCT05979493|DRUG|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
58464367|NCT05979493|DRUG|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
58464368|NCT05292794|DEVICE|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
58464369|NCT05134935|DEVICE|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
58464370|NCT05134935|DEVICE|Orthokerathology lenses (OKL)|18 months of therapy.
58464371|NCT06596174|PROCEDURE|Transcutaneous spinal cord stimulation (tSCS)|The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).
58464372|NCT06596174|PROCEDURE|Short-term Machine-Assisted Ankle Movement Training with tSCS|The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time
58464373|NCT06596174|PROCEDURE|Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS|"The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS).~Each session will last for 30 minutes, conducted three times per week, over a period of four weeks."
58464374|NCT00451360|DRUG|diacerein|
58464375|NCT04913272|DRUG|US-APR2020|US-APR2020 capsules 45 billion CFUs of the LBT.
58464376|NCT04913272|DRUG|Placebo|Placebo
58464377|NCT06335641|DEVICE|External active conductive head cooling|Cooling is applied during the endovascular thrombectomy procedure for a maximum of 120 minutes
58464378|NCT06272799|DRUG|T-DM1 adjuvant|Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
58464379|NCT05401162|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
58464380|NCT00352508|BEHAVIORAL|Dietary advice|
58464381|NCT06693570|OTHER|Intact Fish Skin Graft (IFSG) + Standard of Care|Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58464382|NCT06693570|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58464383|NCT04710901|BEHAVIORAL|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
58464384|NCT04710901|BEHAVIORAL|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
58464385|NCT04710901|BEHAVIORAL|uTECH|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention."
58464386|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous
58464387|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous.
58464388|NCT04444817|DRUG|Tacrolimus|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
58464389|NCT00308802|PROCEDURE|Kidney transplantation|Participants in this study will have had a kidney transplant
58464390|NCT04297865|DRUG|A dose as CJ-15314|A dose as CJ-15314, 1 capsule
58464391|NCT04297865|DRUG|B dose as CJ-15314|B dose as CJ-15314, 1 capsule
58464392|NCT04297865|DRUG|C dose as CJ-15314|C dose as CJ-15314, 1 capsule
58464393|NCT04297865|DRUG|D dose as CJ-15314|D dose as CJ-15314, 2 capsules
58464394|NCT04297865|DRUG|E dose as CJ-15314|E dose as CJ-15314, 1 capsule
58464395|NCT04297865|DRUG|F dose as CJ-15314|F dose as CJ-15314, 2 capsules
58464396|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
58464397|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
58464398|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
58464399|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
58464400|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
58464401|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
58464402|NCT06211920|OTHER|Non-invasive ventilation|The application of NIV will be performed using af a facemask as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.
58464403|NCT04215224|DIAGNOSTIC_TEST|Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
58464404|NCT04915846|DRUG|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
58464405|NCT04915846|DRUG|Placebo|placebo comparator
58464406|NCT06215508|OTHER|Questionnaires|Questionnaires participants fill out at different study visits
58464407|NCT04823585|DRUG|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
58464408|NCT04823585|DRUG|Placebo|Solution. Subcutaneous.
58464409|NCT04162249|OTHER|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
58464410|NCT04162249|OTHER|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
58464411|NCT04162249|OTHER|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
58464412|NCT04162249|DIAGNOSTIC_TEST|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions \<72 hours after ablation.
58464413|NCT03985930|DEVICE|Distraction with virtual reality|Distraction content delivered through virtual reality goggles
58464414|NCT03985930|OTHER|Treatment as Usual|Treatment as Usual
58464415|NCT04156841|DIAGNOSTIC_TEST|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
58464416|NCT04156841|PROCEDURE|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
58464417|NCT02397798|BEHAVIORAL|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
58464418|NCT02397798|BEHAVIORAL|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
58130901|NCT03006016|DRUG|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
58464419|NCT04099563|DRUG|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
58464420|NCT02374697|DEVICE|During tele-expertise|
58464421|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
58464422|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
58464423|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
58464424|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
58464425|NCT03164668|OTHER|menthol flavored e-cigarette|menthol flavored e-cigarette
58464426|NCT03164668|OTHER|tobacco flavored e-cigarette|tobacco flavored e-cigarette
58464427|NCT02335619|BEHAVIORAL|Early palliative care|
58464428|NCT02997631|DEVICE|MEDi Robot|Distraction therapy using an interactive humanoid robot
58464429|NCT00315926|DRUG|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
58464430|NCT00315926|DRUG|Placebo|a mixture of ethanol and physiological saline
58464431|NCT00068068|DRUG|Talaporfin sodium (LS11)|
58464432|NCT00068068|DEVICE|LED-based light infusion device|
58464433|NCT00068068|DEVICE|Light emitting diodes (LED)|
58464434|NCT00068068|PROCEDURE|Photodynamic therapy|
58464435|NCT00068068|PROCEDURE|Phototherapy|
58464436|NCT00068068|PROCEDURE|Chemotherapy|
58464437|NCT03002441|DEVICE|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D\&E procedure
58464438|NCT03002441|DEVICE|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D\&E procedure
58464439|NCT05121766|DRUG|Omega-3 (EPA+DHA)|"Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA."
58464440|NCT05121766|DRUG|Placebo|3 Soybean Oil Placebo capsules
58464441|NCT06199570|BEHAVIORAL|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a 1-week pre-scan call, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a 1-week post-scan phone call, the stress management plan will be revisited for new concerns.
58464442|NCT06199570|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
58464443|NCT05128669|PROCEDURE|CPIP|CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.
58464444|NCT05128669|PROCEDURE|ECS|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
58464445|NCT00074711|DRUG|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
58464446|NCT00074711|DRUG|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
58464447|NCT04357743|OTHER|Chin supported Arm ergometry with pursed lip breathing|"The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week"
58464448|NCT04357743|OTHER|Arm ergometry with pursed lip breathing|"The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week."
58464449|NCT06236906|DEVICE|Device supported behavioural treatment|The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
58464450|NCT06272994|DIAGNOSTIC_TEST|MRSA Nasal Swab PCR|For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
58464451|NCT02425410|OTHER|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
58464452|NCT02425410|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
58464453|NCT05362487|DEVICE|Spiriva® Respimat®|Spiriva® Respimat®
58464454|NCT05362487|DEVICE|Spiriva® HandiHaler®|Spiriva® HandiHaler®
58464455|NCT05362487|DRUG|Tiotropium bromide|Tiotropium bromide
58464456|NCT05587270|OTHER|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
58464457|NCT05587270|RADIATION|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
58464458|NCT02845297|DRUG|pembrolizumab|Intravenous pembrolizumab
58464459|NCT02845297|DRUG|Azacitadine|Intravenous or subcutaneous
58464460|NCT01352117|DRUG|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
58464461|NCT01352117|DRUG|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
58464462|NCT00965601|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
58464463|NCT05594550|OTHER|Data collection|"Demographic data:~Age, Sex, weight, height, main history and treatments.~- Biological data: CRP, PCT, albumin, pre-albumin"
58464464|NCT05594550|OTHER|analysis of thoracic scans|muscle area calculated on the T7 and T12 thoracic slices
58464465|NCT06630598|BEHAVIORAL|Online Family Violence Education Resource|"The VEGA Family Violence Education Resources (© 2020 VEGA Project, McMaster University) is an on-line suite of educational resources that target professionals who are likely to encounter survivors of family violence in professional and clinical settings. The resources provide information about family violence, appropriate clinical responses, legal obligations, and more. The resources are broken down into several training modules and include three interactive learning scenarios. The training modules include:~Know About Family Violence in Canada Creating Safety Recognizing and Responding Safely to Child Maltreatment Recognizing and Responding Safely to Intimate Partner Violence Voices of those with Lived Experiences of Family Violence"
58464466|NCT04175249|OTHER|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
58464467|NCT00805350|DRUG|Eplivanserin|one 5 mg tablet once a day
58464468|NCT00805350|DRUG|Placebo|Placebo of Eplivanserin one tablet once a day
58464469|NCT06527898|DRUG|hypofractionated radiotherapy with immunotherapy|hypofractionated radiotherapy with Adebrelimab consolidation
58464470|NCT06435936|DRUG|Single Ascending Dose of SAB-176|Single ascending dose
58464471|NCT06435936|DRUG|Single Ascending Dose of Placebo|Single ascending dose
58464472|NCT05183178|DRUG|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
58464473|NCT05183178|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
58464474|NCT04310540|PROCEDURE|Biopsy|Undergo biopsy
58464475|NCT04310540|PROCEDURE|Computed Tomography|Undergo CT
58464476|NCT04310540|DRUG|Gallium Ga 68 Gozetotide|Given IV
58464477|NCT04310540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58464478|NCT04310540|PROCEDURE|Positron Emission Tomography|Undergo PET
58464479|NCT01275352|DRUG|Eplerenone|Eplerenone 50 mg/day
58464480|NCT01275352|DRUG|placebo|placebo
58464481|NCT01109264|DRUG|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
58464482|NCT01109264|DRUG|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
58464483|NCT00236223|DRUG|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
58464484|NCT00236223|DRUG|Placebo|Matching placebo
58464485|NCT06241742|DRUG|HT-6184|Single, oral dose of HT-6184
58464486|NCT06241742|DRUG|HT-6184 Placebo|Single, oral dose of placebo
58464487|NCT01402089|DRUG|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
58464488|NCT01402089|DRUG|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
58464489|NCT01402089|DRUG|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
58464490|NCT01402089|DRUG|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
58464491|NCT03803293|DIAGNOSTIC_TEST|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
58464492|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
58464493|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
58464494|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
58464495|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
58464496|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
58464497|NCT05123872|DEVICE|tDCS|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
58464498|NCT04040764|PROCEDURE|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
58464499|NCT04324034|DEVICE|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
57777948|NCT02635087|DEVICE|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
57777949|NCT05929365|PROCEDURE|colonoscopy|determine the mutation profile of resected colorectal neoplasia
58464500|NCT04324034|PROCEDURE|laparoscopy|The surgery by conventional laparoscopy is used
58464501|NCT04605601|OTHER|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
58464502|NCT04605601|OTHER|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
58464503|NCT06525428|DRUG|standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab|"First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT"
58464504|NCT01493323|BEHAVIORAL|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
58464505|NCT01493323|BEHAVIORAL|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
58464506|NCT01493323|BEHAVIORAL|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
58464507|NCT01493323|PROCEDURE|Cyber ball game|functional neuroimaging
58464508|NCT01493323|PROCEDURE|Iowa Gambling Task|functional neuroimaging
58464509|NCT01493323|PROCEDURE|Microcomputer|functional neuroimaging
58464510|NCT01493323|PROCEDURE|blood sample|blood sample
58464511|NCT03817164|DEVICE|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
58464512|NCT03817164|DEVICE|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
58464513|NCT02412306|DRUG|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
58464514|NCT05697770|DRUG|Sodium bicarbonate|Sodium bicarbonate 8.4% will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
58464515|NCT05697770|DRUG|5% Dextrose|5% dextrose will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
58464516|NCT03045744|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
58464517|NCT03064529|DEVICE|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
58464518|NCT04906499|BEHAVIORAL|Physical Activity Promotion|"After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (\<10 days with \<1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day."
57777950|NCT00675324|DRUG|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
57777951|NCT00675324|DIETARY_SUPPLEMENT|Fresubin Energy drink|30 kcal/kg\*day five days before colonoscopy
58464519|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting without the use of collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Suturing of the wound in the donor site."
58464520|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting with collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Adaptation of sterile collagen matrix to the donor site~4. Suturing of the wound in the donor site"
58464521|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
58464522|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
58464523|NCT03703700|DRUG|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
58464524|NCT03703700|DRUG|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
58464525|NCT04068025|OTHER|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
58464526|NCT06403787|DRUG|Aerobic exercise + Ginkgo Biloba Extract|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
58464527|NCT06403787|DRUG|Aerobic exercise + Calcined magnesia (placebo)|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
58464528|NCT06403787|DRUG|Aerobic exercise + Atorvastatin|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
58464529|NCT00209911|PROCEDURE|cardioversion|
58464530|NCT00217984|OTHER|Usual Care|Referral to smoking cessation clinic
58464531|NCT00217984|BEHAVIORAL|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
58464532|NCT02366494|DRUG|Bicalutamide|ANDROGEN BLOCKADE
58464533|NCT02366494|DRUG|Leuprolide|ANDROGEN BLOCKADE
58464534|NCT02366494|DRUG|Goserelin|ANDROGEN BLOCKADE
58464535|NCT02366494|DRUG|Triptorelin|ANDROGEN BLOCKADE
58464536|NCT02366494|DRUG|Docetaxel|Chemo hormonal therapy
58464537|NCT02366494|DRUG|Abiraterone|Chemo hormonal therapy
58464538|NCT02366494|DRUG|Apalutamide|Nonsteroidal antiandrogen medication
58464539|NCT02366494|DRUG|Enzalutamide|Nonsteroidal antiandrogen medication
58490659|NCT01974635|DEVICE|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
58490660|NCT06208371|PROCEDURE|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
57777952|NCT05086822|DRUG|Irinotecan liposome|Irinotecan liposome
57777953|NCT05515718|OTHER|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
58464540|NCT04072783|DIAGNOSTIC_TEST|MRI,DTI, functional MRI|"1. Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~2. Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~3. Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
58464541|NCT03449017|BEHAVIORAL|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
58464542|NCT03839940|DRUG|Dexamethasone|Given as mouthwash
58464543|NCT03839940|OTHER|Placebo|Given as mouthwash
58464544|NCT03839940|OTHER|Questionnaire|Ancillary studies
58464545|NCT03839940|OTHER|Quality-of-Life Assessment|Ancillary studies
58464546|NCT03839940|DRUG|Everolimus|Standard of care
58464547|NCT04571749|BEHAVIORAL|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
58464548|NCT04517123|OTHER|Prone Positioning|Prone Positioning
58464549|NCT06528288|PROCEDURE|Erector Spinae Plane Block|The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.
58464550|NCT06528288|PROCEDURE|Subcutaneous Anesthesia|Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
58464551|NCT06704789|DEVICE|Measurement of brain activity (fNIRS, EEG)|Brain activity assessments are conducted as a single session lasting approximately 60 minutes
58464552|NCT02779439|BIOLOGICAL|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
58464553|NCT03260946|OTHER|Complementary medicine use|The prevalence of complementary medicine use
58464554|NCT03772249|DRUG|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
58464555|NCT03772249|DRUG|Placebo for DCR-HBVS|Sterile 9% saline for injection.
58464556|NCT06523335|OTHER|Neuromuscular coordination-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
58464557|NCT06523335|OTHER|Force strengthening-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
58464558|NCT05626738|DEVICE|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
58464559|NCT05840198|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
58464560|NCT05840198|OTHER|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
58464561|NCT05023733|DEVICE|CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®|Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1
58464562|NCT02231112|RADIATION|Whole breast RT on prone position|
58464563|NCT06313892|BEHAVIORAL|Home based Exercise|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
58464564|NCT06514157|COMBINATION_PRODUCT|budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)|BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)
58464565|NCT06706674|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
58464566|NCT06706674|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
58464567|NCT06706674|DRUG|Placebo|Matching Placebo administered orally once daily
58464568|NCT04780867|BEHAVIORAL|Delayed vaccination|First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
58464569|NCT04723511|OTHER|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session"
58464570|NCT04723511|OTHER|Kendall exercises|"exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop."
58464571|NCT05286554|DRUG|gonadotropin releasing hormone-agonist|subcutaneous injection
58464572|NCT05286554|DRUG|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
58464573|NCT03808116|DEVICE|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process."
58464574|NCT04205240|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
58464575|NCT04205240|DRUG|Cyclophosphamide|Given IV
58464576|NCT04205240|BIOLOGICAL|Daratumumab|Given IV
58464577|NCT04205240|DRUG|Fludarabine|Given IV
58464578|NCT04205240|DRUG|Melphalan|Given IV
58464579|NCT04205240|DRUG|Mycophenolate Mofetil|Given IV or PO
58464580|NCT04205240|DRUG|Tacrolimus|Given PO or IV
58464581|NCT01941485|DEVICE|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
58464582|NCT01941485|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
58464583|NCT02670317|DRUG|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
58464584|NCT02670317|DRUG|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
58464585|NCT02670317|DRUG|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
58464586|NCT05231226|PROCEDURE|Immediately CR|Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD
58464587|NCT05231226|PROCEDURE|Staged (within 45 days) CR|Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
58464588|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
58464589|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
58464590|NCT00762359|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
58464591|NCT00762359|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
58464592|NCT02164253|DRUG|Deferiprone|30 mg/kg per day, oral use
58464593|NCT05955612|PROCEDURE|Procalcitonin measurement|Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
58464594|NCT05251714|DRUG|CFI-402257|Oral once daily in 28 day cycles
58464595|NCT05251714|DRUG|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
58464596|NCT04588246|DRUG|Memantine|Given PO
58464597|NCT04588246|OTHER|Quality-of-Life Assessment|Ancillary studies
58464598|NCT04588246|OTHER|Questionnaire Administration|Ancillary studies
58464599|NCT04588246|RADIATION|Stereotactic Radiosurgery|Undergo salvage SRS
58464600|NCT04588246|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
58464601|NCT04714840|OTHER|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
58464602|NCT04714840|OTHER|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
58464603|NCT04714840|OTHER|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
58464604|NCT02049775|PROCEDURE|NBI|
58464605|NCT05560425|BEHAVIORAL|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
58464606|NCT05560425|BEHAVIORAL|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
58464607|NCT02654886|OTHER|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
58464608|NCT06705686|DRUG|(R)-9bMS|(R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
58464609|NCT05406674|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
58464610|NCT05406674|DRUG|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
58464611|NCT04051996|DRUG|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
58464612|NCT04051996|DRUG|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
58464613|NCT00537134|DEVICE|Embolization, coiling|Endovascular embolization with platinum coils
58464614|NCT04612335|OTHER|Rate control|Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
58464615|NCT04612335|OTHER|Pharmacological or electrical cardioversion|Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
58464616|NCT01466608|DRUG|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
58464617|NCT01691534|DRUG|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
58464618|NCT01691534|DRUG|PA-824 (PA)|PA-824 200mg Days 1-14
58464619|NCT01691534|DRUG|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
58464620|NCT01691534|DRUG|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
58464621|NCT01691534|DRUG|Rifafour|Rifafour e-275 mg dosed by weight
58464622|NCT06230575|PROCEDURE|erector spinae block|Erector spinae plane block
58464623|NCT06230575|PROCEDURE|retrolaminar block|Retrolaminar block
58464624|NCT06230575|PROCEDURE|serratus anterior block|Serratus anterior plane block
58464625|NCT06230575|PROCEDURE|pectoral nerve block|Pectoral nerve block
58464626|NCT06547554|DRUG|Xeruborbactam|Experimental
58464627|NCT06547554|DRUG|Cefiderocol|Experimental
58464628|NCT06547554|DRUG|Xeruborbactam/Cefiderocol|A combination of Xeruborbactam and Cefiderocol.
58464629|NCT06547554|DRUG|Dextrose 5% in water|Placebo
57777954|NCT05515718|OTHER|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
57777955|NCT04447820|DRUG|K-877-ER (Dose A)|Dose A Oral Administration
58464630|NCT04079361|DIAGNOSTIC_TEST|Blood samples|Bood samples during prenatal and postnatal visits
58464631|NCT06583941|DIETARY_SUPPLEMENT|Low Dose Virtiva Plus|Participants will consume a low dose of Virtiva Plus (120mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (120mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
58464632|NCT06583941|DIETARY_SUPPLEMENT|High Dose Virtiva Plus|Participants will consume a high dose of Virtiva Plus (240mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (240mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
57777956|NCT04447820|DRUG|K-877-ER (Dose B)|Dose B Oral Administration
57777957|NCT04447820|DRUG|K-877-IR|K-877-IR Oral Administration
57777958|NCT05545969|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58464633|NCT04614311|DRUG|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
58464634|NCT03799146|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
57777959|NCT05545969|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
58464635|NCT03799146|OTHER|Waiting List|Waiting List control group
58464636|NCT03104881|DEVICE|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
58464637|NCT03104881|DEVICE|2D end-effector type robot|2 dimension end-effector type upper extremity robot
58464638|NCT04896866|BEHAVIORAL|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
58464639|NCT04860830|DRUG|BI 425809|BI 425809
58464640|NCT04860830|DRUG|Placebo|Placebo
58464641|NCT06705478|DRUG|Pramipexole ER|Tablets self-administered orally
58464642|NCT06705478|DRUG|Escitalopram|Tablets self-administered orally
58464643|NCT05343754|DRUG|Hyperbaric oxygen|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
58464644|NCT05343754|OTHER|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
58464645|NCT06582433|OTHER|Intervention|"1. Process: implementation of pre-tests~2. Process: Solution-focused counseling, 60 minutes once a week for a total of 6 sessions~3. Final test after 2 months"
58464646|NCT04748861|OTHER|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
58464647|NCT00095693|DRUG|sorafenib tosylate|Given PO
58464648|NCT00095693|OTHER|laboratory biomarker analysis|Correlative studies
58464649|NCT00095693|OTHER|pharmacological study|Correlative studies
58464650|NCT00095693|RADIATION|fludeoxyglucose F 18|Correlative studies
58464651|NCT00095693|PROCEDURE|positron emission tomography|Correlative studies
58464652|NCT00095693|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
58464653|NCT06424366|BEHAVIORAL|Ballet for All Kids|The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.
58464654|NCT00688896|DRUG|JTT-705 600 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
58464655|NCT00688896|DRUG|JTT-705 300 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
58464656|NCT00688896|DRUG|Placebo and pravastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
58464657|NCT01088568|PROCEDURE|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
58464658|NCT01088568|PROCEDURE|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
58464659|NCT03665636|DRUG|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
58464660|NCT06179407|DRUG|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
58464661|NCT06179407|DRUG|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
58464662|NCT05945420|DRUG|Desmopressin Acetate|This arm will receive tamsulosin and desmopressin acetate daily a
58464663|NCT05945420|DRUG|Placebo|This arm will receive tamsulosin and placebo
58464664|NCT03478540|DRUG|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
58464665|NCT05891600|DEVICE|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
58464666|NCT03935984|DRUG|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
58464667|NCT06615206|GENETIC|HG204|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
58464668|NCT02226367|DRUG|prazosin hydrochloride|study drug arm prazosin
58464669|NCT02226367|DRUG|placebo|study drug arm placebo
58464670|NCT00641771|DRUG|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
58464671|NCT00641771|DRUG|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
58464672|NCT05826912|DRUG|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
58464673|NCT05826912|DRUG|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
58464674|NCT05826912|DRUG|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
58464675|NCT05826912|DRUG|Placebo|Capsule, 2x/day for 28 days
58464676|NCT06399406|COMBINATION_PRODUCT|Medi-TBS|The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
58464677|NCT01052792|DRUG|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
58464678|NCT00323323|DRUG|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
58464679|NCT00323323|DRUG|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
58464680|NCT00323323|PROCEDURE|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
58464681|NCT05098028|DRUG|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
58464682|NCT05098028|DRUG|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
58464683|NCT05098028|DRUG|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
58464684|NCT05098028|DRUG|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
58464685|NCT05098028|DRUG|Placebo|Placebo Twice Daily
58464686|NCT05539066|DEVICE|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
58464687|NCT05512403|DRUG|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction"
58464688|NCT05057611|OTHER|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
58464689|NCT05057611|OTHER|Usual care (UC)|- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
58464690|NCT03441165|PROCEDURE|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
58464691|NCT02411630|DRUG|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
58464692|NCT01897025|DEVICE|real-tDCS with MI-BCI|As in Arm Description
58464693|NCT06357481|PROCEDURE|Endodontic Retreatment|A single operator procedured in one visit of non-surgical endodontic retreatment. Teeth were anesthetized using articaine hydrochloride with epinephrine 1:200,000 for mandibulary premolar teeth with one root canal. Each tooth was isolated with a rubber dam and then coronal restorations and caries were removed using sterile high-speed burs under water cooling. After preperation of the cavity access and localization of the canal orifice, all microorganisms that may have entered the root canal system are eliminated by removing the old canal filling with the One Flare and MicroMega REMOVER files in the MicroMega retreatment kit.
58464694|NCT02191462|DIETARY_SUPPLEMENT|Niagen 100mg|
58464695|NCT02191462|DIETARY_SUPPLEMENT|Niagen 300mg|
58464696|NCT02191462|DIETARY_SUPPLEMENT|Niagen 1000mg|
58464697|NCT01259063|DRUG|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
58464698|NCT04982731|OTHER|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
58464699|NCT05101590|DEVICE|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
58464700|NCT05616286|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
58464701|NCT00672698|PROCEDURE|SURGERY|ELECTIVE SURGICAL PROCEDURES
57777960|NCT03186326|DRUG|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
58464702|NCT04530123|DRUG|Placebo|TAK-101 placebo-matching intravenous infusion
58464703|NCT04530123|DRUG|TAK-101|TAK 101 intravenous infusion
58464704|NCT04530123|DIETARY_SUPPLEMENT|Gluten|Powder form (vital wheat gluten)
58464705|NCT06266481|DRUG|Topical dexamethasone|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
58464706|NCT06266481|DRUG|10% lidocaine was sprayed over the tube for the second group|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
58464707|NCT03758781|DRUG|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
57777961|NCT03186326|DRUG|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
57777962|NCT03186326|DRUG|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
58464708|NCT03758781|DRUG|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
58464709|NCT06151405|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
58464710|NCT06151405|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
58464711|NCT06151405|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
58464712|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
58464713|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
58464714|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
58464715|NCT05133297|DRUG|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
58464716|NCT04908423|DRUG|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
58464717|NCT05671107|DIAGNOSTIC_TEST|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
58464718|NCT00377520|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
58464719|NCT02254603|DEVICE|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
57777963|NCT03186326|DRUG|Panitumumab|Administered at 6 mg/Kg
57777964|NCT03186326|DRUG|Cetuximab|Administered at 500 mg/m²
57777965|NCT03186326|DRUG|Bevacizumab|Administered at 5 mg/Kg
57777966|NCT03186326|DRUG|Aflibercept|Administered at 4 mg/Kg
57777967|NCT03922828|DIAGNOSTIC_TEST|CT scans|CT surveillance, Lung biopsy, Lung resection
58464720|NCT02254603|BEHAVIORAL|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
58464721|NCT02620839|DRUG|Alpelisib|Given PO
58464722|NCT02620839|DRUG|Cisplatin|Given IV
58464723|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
58464724|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy combined with the local treatment of FES-negative lesions|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
58464725|NCT06195709|COMBINATION_PRODUCT|Chemotherapy|Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
58464726|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
58464727|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
58464728|NCT03028766|DRUG|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
58464729|NCT03028766|DRUG|Cisplatin|Chemotherapy drug
58464730|NCT03028766|RADIATION|Radiotherapy|Intensity Modulated Radiotherapy
58464731|NCT00474422|BEHAVIORAL|Proactive assignment to attend a breastfeeding clinic|
58464732|NCT05724940|OTHER|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~1. Thorough medical history of the patients~2. Full clinical examination including:~   1. General examination and vital signs.~  2. Complete rheumatological examination.~  3. SLE disease activity index SLEDAI (ref).~  4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~4. Renal investigations:~   1. Kidney functions~  2. Urine analysis~  3. 24 hours protein in urine and/or A/C ratio~  4. Renal biopsy if indicated.~5. ANA (Antinuclear Antibodies)test.~6. ANA profile for the most common 19 autoantibodies by immunoblot."
58464733|NCT05686239|DRUG|RL-007|investigational study drug
58464734|NCT05686239|DRUG|Placebo|placebo capsules matching the appearance and size of the active drug
58464735|NCT03868215|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
58464736|NCT04435925|DRUG|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
58464737|NCT04435925|DRUG|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
58464738|NCT02161770|DRUG|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
58464739|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
58464740|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
58464741|NCT05322707|DRUG|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
58464742|NCT05322707|DRUG|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
58464743|NCT05322707|DRUG|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
58464744|NCT00966836|DRUG|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
58464745|NCT00966836|DRUG|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
58464746|NCT00966836|DRUG|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
58464747|NCT00966836|DRUG|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
58464748|NCT01707342|DRUG|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
58464749|NCT04307797|DRUG|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
58464750|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
58464751|NCT04307797|DRUG|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
58464752|NCT04307797|DRUG|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
58464753|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
58464754|NCT04307797|DRUG|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
58464755|NCT02848131|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
58464756|NCT02848131|DRUG|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
58464757|NCT04623346|PROCEDURE|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
58464758|NCT06456567|BIOLOGICAL|Telitacicept|Subcutaneous injection
58464759|NCT06456567|DRUG|Placebo|Subcutaneous injection
58464760|NCT04888624|DEVICE|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
58464761|NCT04888624|DEVICE|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
58464762|NCT05574686|BEHAVIORAL|Telehealth Blood Pressure Monitoring and Food Insecurity|Telehealth Blood Pressure Monitoring and Food Insecurity
58464763|NCT05037240|DIETARY_SUPPLEMENT|Quercetin|Quercetin (500 mg), 2 times a day for 3 months
58464764|NCT05037240|COMBINATION_PRODUCT|Placebo|500 mg, 2 times a day for 3 months
58464765|NCT02602769|DIAGNOSTIC_TEST|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
58464766|NCT06445348|DEVICE|Cervical pedicle screw|cervical pedicle screw
58464767|NCT04819464|DRUG|Cenerimod|A single oral dose of 0.5 mg.
58464768|NCT02031575|BEHAVIORAL|Interactive Treatment|Mobile phone text messaging service about reproductive health
58464769|NCT02031575|BEHAVIORAL|Basic Treatment|Mobile phone text messaging service about reproductive health
58464770|NCT02031575|OTHER|Control, comparator arm|
58464771|NCT00647764|DRUG|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
58464772|NCT00566436|PROCEDURE|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
58464773|NCT00566436|PROCEDURE|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
57777968|NCT00794625|DRUG|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
58464774|NCT01126749|DRUG|Gemcitabine|Gemcitabine
58464775|NCT01126749|DRUG|E7389|E7389
57777969|NCT00794625|DRUG|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
57777970|NCT00794625|DRUG|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
58464776|NCT01126749|DRUG|Cisplatin|Cisplatin
58464777|NCT03092583|OTHER|Blood sample|35 mL, 7 tubes
58464778|NCT02989493|DRUG|Doxazosin|Doxazosin
58464779|NCT02989493|OTHER|Placebo|Placebo
58464780|NCT00000794|DRUG|Sulfadiazine|
58464781|NCT00000794|DRUG|Clarithromycin|
57777971|NCT00794625|DRUG|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
57777972|NCT00794625|BEHAVIORAL|Behavioral family counseling|Weekly behavioral counseling with a therapist
58464782|NCT00000794|DRUG|Atovaquone|
58464783|NCT00000794|DRUG|Pyrimethamine|
58464784|NCT00000794|DRUG|Leucovorin calcium|
58464785|NCT04564846|DRUG|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
58464786|NCT04564846|OTHER|Placebo|Placebo capsule (Fish Oil)
58464787|NCT03744312|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
58464788|NCT03744312|DRUG|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
58464789|NCT03010917|DRUG|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
58464790|NCT03010917|DRUG|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
58464791|NCT02870738|PROCEDURE|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
58464792|NCT02870738|DRUG|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
58464793|NCT03040999|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
58464794|NCT03040999|DRUG|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
58464795|NCT03040999|DRUG|Cisplatin|100 mg/m\^2 administered as an IV infusion Q3W
58464796|NCT03040999|RADIATION|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
58464797|NCT03040999|RADIATION|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
58464798|NCT04964635|DEVICE|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
58464799|NCT03610256|PROCEDURE|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI \< 50
58464800|NCT03610256|PROCEDURE|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
58464801|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
58464802|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
58464803|NCT05789524|DRUG|SerpinPC|Administered as SC injection.
58464804|NCT04424537|DIETARY_SUPPLEMENT|Control diet|Meal replacement beverages made with whey protein
58464805|NCT04424537|DIETARY_SUPPLEMENT|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
58464806|NCT04424537|DIETARY_SUPPLEMENT|Low protein diet|meal replacement beverages(MRBs) containing low protein
58464807|NCT05773846|DRUG|Ropivacaine|A long acting formulation of ropivacaine
58464808|NCT04206540|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Electrical stimulation of the vagus nerve around the external ear using a transcutaneous device. Electrical current will be increased in intensity based on subject feedback of a scale 0-10.~Electrical stimulation will be delivered for 2 minutes once the subject reports the maximum comfortable intensity."
58464809|NCT04206540|PROCEDURE|Vagal Stimulation|"Subjects will be asked to do the following in order to stimulate the vagus nerve:~* Cough 6 to 8 forceful coughs~* Have an ice cold wash cloth placed on their face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor is briefly inserted into the back of the mouth touching the bag of the throat.~* Valsalva maneuver: Subjects will be asked to bear down as if having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a device that measures how hard they are blowing. Alternatively, we can have them blow through the barrel of a 10 ml syringe for 15-20 seconds.~* Eating: Subjects will be asked to drink water and/or Ensure that has 220 calories after fasting overnight."
58464810|NCT01590030|PROCEDURE|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
58464811|NCT05767515|DRUG|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
58464812|NCT04045860|PROCEDURE|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
58464813|NCT04045860|OTHER|Observation|Standard of care is currently observation
58464814|NCT01305720|DEVICE|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
58464815|NCT04581278|DIAGNOSTIC_TEST|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
58464816|NCT03403803|DEVICE|Optune|"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."
58464817|NCT06313255|DRUG|PegIFNα2b|The patients receive PegIFNα2b therapy
58464818|NCT06313255|DRUG|PegIFNα2b+probiotics|The patients receive both PegIFNα2b and probiotics therapy
58464819|NCT06313255|DRUG|Nucleoside analog|The patients receive nucleoside analog therapy
58464820|NCT06313255|DRUG|Nucleoside analog+probiotics|The patients receive both nucleoside analog and probiotics therapy
58464821|NCT05083273|OTHER|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
58464822|NCT03439280|DRUG|Mezagitamab|Mezagitamab subcutaneously.
58464823|NCT03439280|DRUG|Pomalidomide|Pomalidomide orally.
58464824|NCT03439280|DRUG|Dexamethasone|Dexamethasone orally.
58464825|NCT02217839|DRUG|DG3173|
58464826|NCT02217839|DRUG|DG3173+Octreotide|
58464827|NCT02217839|DRUG|Octreotide|
58464828|NCT02217839|DRUG|DG3173 Placebo|
58464829|NCT02217839|DRUG|DG3173 Placebo+Octreotide Placebo|
58464830|NCT02217839|DRUG|Octreotide+DG3173 Placebo|
58464831|NCT00966186|PROCEDURE|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
58464832|NCT03459287|DEVICE|INTERCEPT|Pathogen reduced RBCs
58464833|NCT03459287|DEVICE|Control|Conventional RBCs
58464834|NCT05020821|PROCEDURE|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
58464835|NCT05020821|PROCEDURE|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
58464836|NCT06048133|DRUG|Gemcitabine|Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
58464837|NCT06048133|DRUG|Cisplatin|Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
58464838|NCT06048133|DRUG|Zimberelimab|Zimberelimab IV: Day 1 and 22 every 42 days
58464839|NCT06048133|DRUG|Quemliclustat|Quemliclustat IV: Day 1, 15, 29 every 42 days
58464840|NCT06105502|BEHAVIORAL|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
58464841|NCT01434017|DRUG|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
58464842|NCT01434017|DRUG|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
58464843|NCT01434017|DRUG|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
58464844|NCT06651749|DRUG|Propofol injection|hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
58464845|NCT05666323|BEHAVIORAL|Single Text Messaging (TM1)|Receives single text message
58464846|NCT05666323|BEHAVIORAL|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
58464847|NCT05666323|BEHAVIORAL|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
58464848|NCT06704425|OTHER|For observational studies, participants are not assigned an intervention as part of the study.|For observational studies, participants are not assigned an intervention as part of the study.
58464849|NCT03405883|OTHER|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
58464850|NCT00712751|BEHAVIORAL|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
58464851|NCT00712751|BEHAVIORAL|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
58464852|NCT05624580|DRUG|NNC0582-0001|Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.
58464853|NCT05624580|DRUG|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
58464854|NCT04734639|BEHAVIORAL|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
58464855|NCT04734639|BEHAVIORAL|Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.|Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
58464856|NCT04734639|BEHAVIORAL|Def-EI. Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
58464857|NCT00005780|DRUG|EPOCH-R|EPOCH-R for 6 cycles
58464858|NCT00005780|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
58464859|NCT00005780|BIOLOGICAL|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
58464860|NCT04180397|DRUG|Furosemide|Furosemide 10 mg/ml for injection/infusion
58464861|NCT04180397|DRUG|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
58464862|NCT04327206|DRUG|BCG Vaccine|"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection"
58464863|NCT04327206|DRUG|0.9%NaCl|0.9% Sodium Chloride Injection
58464864|NCT00253812|PROCEDURE|flexible sigmoidoscopy|
58464865|NCT05414526|OTHER|InterCARE package|"The InterCARE package includes:~1. Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~2. Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~3. Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
58464866|NCT03853473|PROCEDURE|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
58464867|NCT03676842|COMBINATION_PRODUCT|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
58464868|NCT02719535|OTHER|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
58464869|NCT03173885|DIAGNOSTIC_TEST|Preimplantation Genetic Screening|"* laser assisted hatching~* trophectoderm biopsy~* next generation sequencing"
58464870|NCT03581942|DRUG|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
58464871|NCT03581942|DRUG|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
58464872|NCT05497180|DEVICE|passive myofunctional appliance|passive myofunctional appliance
58464873|NCT05497180|DEVICE|standard oral appliance|standard oral appliance
58464874|NCT02324881|BEHAVIORAL|Telephone-Based Intervention|Use PSMA
58464875|NCT02324881|OTHER|Questionnaire Administration|Ancillary studies
58464876|NCT05088564|PROCEDURE|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
58464877|NCT05088564|PROCEDURE|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
58464878|NCT05623124|OTHER|No intervention|No intervention
58464879|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
58130902|NCT03006016|OTHER|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
58130903|NCT03180866|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
58130904|NCT03160352|OTHER|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
58130905|NCT05327699|DRUG|Ketamine|A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
58464880|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
58464881|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
58464882|NCT06077656|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
58464883|NCT01616966|DRUG|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
58464884|NCT01616966|DRUG|propofol|Maintenance of anesthesia with propofol
58464885|NCT02592031|DRUG|XM17|300 IU corresponds to an injection volume of 0.5 mL.
58464886|NCT02592031|DRUG|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
58464887|NCT02592031|DRUG|Zoladex®|3.6 mg
58464888|NCT06526494|DRUG|Metformin|Oral ingestion for 12 weeks
58464889|NCT06526494|OTHER|Placebo|Oral placebo for 12 weeks
58464890|NCT04912583|DEVICE|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
58464891|NCT04912583|DEVICE|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
58464892|NCT02988297|DRUG|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
58464893|NCT02988297|DRUG|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
58464894|NCT02182895|DRUG|Saxagliptin|2.5-5 mg daily
58464895|NCT06560203|PROCEDURE|Mechanical thrombectomy|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
58464896|NCT05795179|BEHAVIORAL|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
58464897|NCT05795179|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
58464898|NCT05795179|BEHAVIORAL|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
58464899|NCT05795179|BEHAVIORAL|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
58464900|NCT05795179|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
58464901|NCT05953545|DRUG|Peginterferon Lambda|Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
58464902|NCT01258543|OTHER|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
58464903|NCT03732573|BEHAVIORAL|Text messages|Text messages conveying 3 specific behaviour change techniques
58464904|NCT04827368|OTHER|Breath Test|Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.
58464905|NCT02060721|DRUG|Macitentan|Macitentan 10mg, oral tablet, once daily
58464906|NCT01097668|BIOLOGICAL|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
58464907|NCT05443191|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
58464908|NCT01809938|OTHER|Black tea|300ml of tea without milk
58464909|NCT01809938|OTHER|Tea with milk|250ml of black tea with 50ml of full fat milk
58464910|NCT06114238|DRUG|Itepekimab AI|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
58464911|NCT06114238|DRUG|Itepekimab PFS|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
58464912|NCT00287898|BEHAVIORAL|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
58464913|NCT00287898|BEHAVIORAL|Usual Care|subjects will receive standard in-person genetic counseling
57777973|NCT04814875|DRUG|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
58464914|NCT00654667|DRUG|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
58464915|NCT00654667|DRUG|Resveratrol|
58464916|NCT05334732|BEHAVIORAL|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
58464917|NCT05036252|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
58464918|NCT05036252|DIAGNOSTIC_TEST|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
58464919|NCT05036252|DIAGNOSTIC_TEST|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
58464920|NCT06244433|GENETIC|whole genome sequencing|Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
58464921|NCT03662867|BEHAVIORAL|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
58464922|NCT03662867|OTHER|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
58130906|NCT05327699|OTHER|Placebo|A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
58130907|NCT00000406|PROCEDURE|Progressive resistance exercise|
57777974|NCT03990714|PROCEDURE|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
58464923|NCT06510374|DRUG|Nadofaragene Firadenovec|Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
58464924|NCT05200143|DRUG|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
58464925|NCT05200143|DRUG|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
58464926|NCT05200143|DRUG|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
58464927|NCT05509595|DRUG|Burosumab|Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
58464928|NCT03859024|DRUG|Oxycodone|oxycodone tablet
58464929|NCT03859024|DRUG|Acetaminophen|acetaminophen tablet
58464930|NCT03859024|DRUG|Gabapentin|gabapentin tablet
58464931|NCT03859024|DRUG|celebrex|Celebrex tablet
58464932|NCT03859024|DRUG|Bupivacaine|bupivacaine injection
58464933|NCT03859024|DRUG|Ibuprofen 800 mg|ibuprofen tablet
58464934|NCT03859024|DRUG|Dexamethasone|Dexamethasone injection
58464935|NCT05412901|OTHER|discrimination task|Participants perform a discrimination task while their brain activity is recorded with EEG. Beta power will be estimated using spectral decomposition techniques, zooming in on subject specific bands in temporospatial windows of interest, and correlated with (1) WM content, (2) decision outcome, and (3) behavioral performance (i.e., accuracy and RT).
58464936|NCT05968274|DEVICE|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
58464937|NCT05968274|DEVICE|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
58464938|NCT00972413|RADIATION|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
58464939|NCT00972413|RADIATION|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
58464940|NCT00972413|RADIATION|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
58464941|NCT05584059|BEHAVIORAL|Focused Acceptance and Commitment Therapy|This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
58464942|NCT06406764|OTHER|Plyometric training|Participants undergo a plyometric training program. The plyometric training consists of exercises in the horizontal, lateral, and vertical directions of movement. Exercises are progressively focused on maximal performance with short ground contact (\<250 ms). The training sessions are twice per week.
57777975|NCT01751113|DRUG|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
57777976|NCT01751113|DRUG|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
58464943|NCT06406764|OTHER|Control training|Participants continues their regular sports activities without additional plyometric training. The training sessions are twice per week.
58464944|NCT04924062|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
58464945|NCT04924062|DRUG|Gemcitabine|Gemcitabine by IV infusion
58464946|NCT04924062|DRUG|Cisplatin|Cisplatin by IV infusion
58464947|NCT04924062|DRUG|Placebo|Placebo to pembrolizumab
58464948|NCT02246530|PROCEDURE|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
58464949|NCT02246530|DRUG|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
58464950|NCT03796273|OTHER|Best Practice|Undergo standard surgery
58464951|NCT03796273|DRUG|Ketoconazole|Given PO
58464952|NCT06430853|BEHAVIORAL|Step count goal|The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive weekly reminders that are tailored for their intervention arm. Intervention group participants will also receive a step count diary with motivational ideas of how to obtain step goals, which will be reviewed with a study team member every 2 weeks.
58464953|NCT06430853|DEVICE|Actigraph watch|Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
58464954|NCT01782898|DRUG|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
58464955|NCT01782898|DRUG|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
58464956|NCT03173924|DRUG|18F-NaF|Baseline IV followed by PET/CT IMAGING
58464957|NCT03173924|DRUG|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
58464958|NCT03173924|DRUG|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
58464959|NCT02898818|OTHER|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
58464960|NCT02898818|OTHER|papa smear|Papnicolaou Papa Smear test
58464961|NCT05883969|BEHAVIORAL|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
58464962|NCT05883969|BEHAVIORAL|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
58464963|NCT03452969|OTHER|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
58464964|NCT06437301|OTHER|Baseline measure of ETCO2 without mask|Baseline
58464965|NCT06437301|OTHER|Baseline ETCO2 with mask|Mask
58464966|NCT06437301|OTHER|ETCO2 after 200 meter walk with mask|200 meter walk and mask
58464967|NCT06437301|OTHER|ETCO2 after 200 meter walk without mask|200 meter walk
58464968|NCT05811442|DRUG|50561 high dose|study drug
58464969|NCT05811442|DRUG|50561 low dose|study drug
58464970|NCT05811442|DRUG|Placebo|Non-active study drug
58464971|NCT05989009|OTHER|Breastfeeding|Mothers will breastfeed their newborns
58464972|NCT03472625|DIAGNOSTIC_TEST|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
58464973|NCT03519269|DEVICE|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
58464974|NCT04101630|BEHAVIORAL|Activity Monitoring|Monitoring with FitBit
58464975|NCT05413590|OTHER|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
58464976|NCT05413590|OTHER|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
58464977|NCT05413590|OTHER|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
58464978|NCT06702319|OTHER|Exercise|Home exercises and home exercises with internal focus exercises or external focus exercises
58464979|NCT02973971|OTHER|volumeric MRI|
58464980|NCT04875325|OTHER|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
58464981|NCT01533792|PROCEDURE|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
58464982|NCT01533792|PROCEDURE|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
58464983|NCT00525720|DRUG|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
58464984|NCT00525720|BEHAVIORAL|Questionnaire|Questionnaires taking 30 total minutes.
58464985|NCT02873858|OTHER|smell and taste tests|
58464986|NCT02299596|OTHER|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
58464987|NCT06522906|BEHAVIORAL|Muscle Strengthening|Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
58464988|NCT06522906|BEHAVIORAL|General Physical Activity|The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
58464989|NCT06522906|BEHAVIORAL|Education|Administered by a promotora, treatment will include 4 live video educational sessions about OA
58464990|NCT04357717|DIAGNOSTIC_TEST|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
58464991|NCT05425784|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
58464992|NCT05425784|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
58464993|NCT06526260|BEHAVIORAL|Very Brief Exposure to Facial Expressions|In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
58464994|NCT06303960|DEVICE|Bilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
58464995|NCT06303960|DEVICE|Unilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
58464996|NCT06303960|DEVICE|Vagus Nerve Stimulation|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
58464997|NCT01293903|DRUG|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
58464998|NCT01293903|DRUG|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
58464999|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|"Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.~Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore \&amp;amp; Associates) to create a final 6-mm shunt."
58465000|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|After successful puncture, in the 8-mm shunt group, a balloon with a diameter of 6 mm was used to expand the shunt, and then an 8-mm covered stent was implanted (Viatorr; WL Gore \&amp; Associates, Inc.).
58465001|NCT02921035|DRUG|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
58465002|NCT00764699|DRUG|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
58465003|NCT05647135|OTHER|Medical food|enteral formulas with different protein composition
58465004|NCT04723992|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
58465005|NCT05816252|DRUG|SKB264|intravenous (IV) infusion (Q2W or Q3W)
58465006|NCT05816252|DRUG|Pembrolizumab|intravenous (IV) infusion (400mg, Q6W)
58465007|NCT05816252|DRUG|Carboplatin|intravenous (IV) infusion (AUC5, Q3W)
58465008|NCT05816252|DRUG|Osimertinib|80mg, QD
58465009|NCT05064735|DRUG|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
58465010|NCT05064735|DRUG|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
58465011|NCT04727970|DRUG|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
58465012|NCT04079296|BIOLOGICAL|ASP7517|Intravenous (IV)
58465013|NCT04053036|DRUG|MDMA|Participants will be given 1.5mg/kg of MDMA
58465014|NCT04053036|DRUG|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
57777977|NCT01751113|DRUG|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
58465015|NCT02553213|OTHER|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
58465016|NCT02553213|OTHER|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
58465017|NCT02553213|OTHER|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
58465018|NCT02553213|OTHER|easy digestible diet|
58465019|NCT06029426|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
58465020|NCT06029426|DRUG|Placebo|Placebo will be administered orally
58465021|NCT03807986|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
58465022|NCT03807986|PROCEDURE|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
58465023|NCT03807986|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
58465024|NCT03973229|DRUG|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
58465025|NCT03973229|OTHER|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
58465026|NCT05675059|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
58465027|NCT05675059|BEHAVIORAL|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
58465028|NCT05675059|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
58465029|NCT06591949|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
58465030|NCT06591949|OTHER|Control group|Control group will be followed up with a home exercise program, and notes will be taken.
58465031|NCT01286675|DRUG|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
58465032|NCT05730725|DRUG|BMS-986322|Specified dose on specified days
58465033|NCT05730725|OTHER|Placebo|Specified dose on specified days
58465034|NCT06601608|DRUG|Herbal therapy|rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
58465035|NCT06601608|DRUG|Placebo Drug|a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
58465036|NCT05941546|DIAGNOSTIC_TEST|anti-TBEV serology|we will measure by ELISA in microplates the anti-TBEV IgG as well as the anti-TBEV IgM on the sera + in TBEV IgG. We will then send a patient questionnaire with an information note to document the context of this TBEV seropositivity and to eliminate false-positivities (vaccination). Finally, we will perform PCR on CSF if serum positive and CSF available
58465037|NCT06600867|DIAGNOSTIC_TEST|Tooth mobility assessment|The examiner, holding the instruments (two clinical mirror handles), will apply labial/lingual or labial/palatal displacement movements using the subjective technique, just as routinely done. Using the endodontic spacer and the stop, the deflection will be measured in millimeters. Subsequently, the examiner, with the instruments in hand (tensiometer and dynamometer), will apply labial/lingual and labial/palatal displacement movements, determining the force required to achieve the same displacement previously established by the subjective method (reference/limit of displacement).
57777978|NCT05985993|DEVICE|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
57777979|NCT04625478|OTHER|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
58465038|NCT04675567|BEHAVIORAL|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
58465039|NCT06100900|DRUG|BCX10013|Multiple dose levels may be tested in this study.
58465040|NCT06068933|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
58465041|NCT06068933|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
58465042|NCT02329444|PROCEDURE|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
58465043|NCT02329444|PROCEDURE|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
57777980|NCT00152490|DRUG|Certolizumab Pegol (CDP870)|
58465044|NCT06285435|DIAGNOSTIC_TEST|prothrombin fragment 1+2|Blood sample
58465045|NCT03802578|BEHAVIORAL|HAND EXERCISE|
58465046|NCT06378944|OTHER|Application of green indocyanine colorant|The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
58465047|NCT06378944|DRUG|Technetium99|Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
58465048|NCT02893293|DRUG|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
58465049|NCT02893293|DEVICE|Magentic Resonance Imaging|Both arms will receive MRI
58465050|NCT06573996|DEVICE|Active TENS Device|"Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device"
58465051|NCT06573996|DEVICE|Intervention 2: Placebo/Sham Device|"The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device"
58465052|NCT02358473|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered by IV infusion.
58465053|NCT02358473|DRUG|Docetaxel|Docetaxel will be administered by IV infusion.
58465054|NCT04252547|OTHER|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
58465055|NCT04252547|OTHER|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
58465056|NCT06521086|DIETARY_SUPPLEMENT|Nutrition Supplements - Fresubin KCAL Drinks|Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
58465057|NCT02869711|OTHER|Health care quality management|
58465058|NCT05022550|DEVICE|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
58465059|NCT00262860|DRUG|bortezomib|
58465060|NCT00262860|DRUG|gemcitabine hydrochloride|
58465061|NCT06704958|OTHER|AMPERE EMA app|AMPERE EMA smartphone app using MyCap
58465062|NCT05135702|DIETARY_SUPPLEMENT|Sodium Propionate|a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
58465063|NCT05135702|DIETARY_SUPPLEMENT|Placebo|a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
58465064|NCT00269178|BEHAVIORAL|Peer Health Education Programme|
58465065|NCT05011188|BIOLOGICAL|FOR46|Given intravenously (IV)
58465066|NCT05011188|BIOLOGICAL|Enzalutamide|Given orally (PO)
58465067|NCT05011188|DRUG|Pegfilgrastim|Given subcutaneously (subQ)
58465068|NCT05011188|PROCEDURE|Blood Samples|Blood samples will be taken for correlative studies
58465069|NCT04464863|OTHER|Kinematic metrics|kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
58465070|NCT04024865|DRUG|Domperidone|Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
58465071|NCT04024865|DRUG|No domperidone|Women with no prescription for domperidone during the six months following delivery.
58465072|NCT05389293|DRUG|Mosunetuzumab|During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
58465073|NCT05389293|DRUG|Zanubrutinib|In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
57777981|NCT01896115|DEVICE|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
58465074|NCT06444516|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
58465075|NCT05104853|DRUG|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
57777982|NCT01394250|DEVICE|Buzzy|Cold, Vibrational Device
58465076|NCT05104853|DRUG|Placebo|CNP-104 Placebo
58465077|NCT01026844|DRUG|erlotinib|Taken orally once a day
58465078|NCT01026844|DRUG|hydroxychloroquine|Taken orally once a day
58465079|NCT04418791|BEHAVIORAL|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
58465080|NCT04418791|BEHAVIORAL|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
58465081|NCT06207786|OTHER|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
58465082|NCT06207786|DIAGNOSTIC_TEST|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
58465083|NCT06207786|DRUG|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
58465084|NCT05314868|DEVICE|PhotoFix|Surgical repair with patch.
58465085|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
58465086|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
58465087|NCT04752618|BEHAVIORAL|P-STAIR|PCIT+ STAIR
58465088|NCT04752618|BEHAVIORAL|Supportive Counseling|Non-trauma focused psychotherapy
58465089|NCT00148395|DRUG|Gemcitabine|
58465090|NCT00148395|DRUG|Navelbine|
58465091|NCT00148395|DRUG|Carboplatin|
58465092|NCT00148395|DRUG|Cisplatin|
58465093|NCT00148395|DRUG|Mitomycin|
58465094|NCT00148395|DRUG|Ifosfamide|
58465095|NCT02659163|BEHAVIORAL|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
58465096|NCT02659163|BEHAVIORAL|mHealth scale|A wireless scale used by participants to measure and record daily weight.
58465097|NCT02659163|BEHAVIORAL|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
58465098|NCT02659163|BEHAVIORAL|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
58465099|NCT02659163|BEHAVIORAL|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
58465100|NCT02659163|BEHAVIORAL|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
58465101|NCT01169103|DRUG|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
58465102|NCT01169103|DRUG|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
58465103|NCT00257413|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
58465104|NCT01615146|OTHER|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
58465105|NCT04931940|DIETARY_SUPPLEMENT|Usual Care|Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU
58465106|NCT04931940|DIETARY_SUPPLEMENT|Higher Protein/Amino Acid Group|Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
58465107|NCT04854135|DEVICE|CGM4Home|FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
58465108|NCT00791349|DRUG|Immediate release (IR) Paliperidone|
58465109|NCT04065139|DRUG|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
58465110|NCT04065139|DRUG|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
58465111|NCT06046040|DRUG|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
58465112|NCT05127044|DEVICE|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
58465113|NCT05127044|DIAGNOSTIC_TEST|BiliChek|BiliChek will be used as a control for determining bilirubin content.
58465114|NCT06706258|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 1 more day.
58465115|NCT06706258|DRUG|Pepcid (Famotidine) 20 mg q 12 hrs for 2 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 1 more day.
58465116|NCT05361551|PROCEDURE|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
58465117|NCT06120712|BIOLOGICAL|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
58465118|NCT06500390|DIAGNOSTIC_TEST|Examination of temporomandibular joint and masticator muscles|The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.
58465119|NCT03672331|OTHER|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
58465120|NCT03672331|OTHER|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
58465121|NCT03672331|OTHER|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
58465122|NCT03672331|OTHER|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
58465123|NCT05263934|BIOLOGICAL|Depemokimab|Depemokimab will be administered
58465124|NCT05263934|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered
58465125|NCT05263934|DRUG|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
58465126|NCT05263934|DRUG|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
58465127|NCT06308952|DRUG|Atorvastatin 20mg|Eligible subjects screened will enter the pretreatment period (days 1 to 4) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). At the same time, the patient was started on basic dual antibody therapy (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
58465128|NCT03535922|OTHER|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
58465129|NCT05252546|DRUG|pyrotinib tablet|single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
58465130|NCT05252546|DRUG|Montmorillonite Power|3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
58465131|NCT05252546|DRUG|Loperamide|4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
58465132|NCT03314103|BIOLOGICAL|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
58465133|NCT03314103|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
58465134|NCT06329440|DIAGNOSTIC_TEST|Ultrasonographic measurement of diaphragm thickness|Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
58465135|NCT04739982|DEVICE|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
58465136|NCT04790188|DIETARY_SUPPLEMENT|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
58465137|NCT04790188|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin lemon flavor (HSN®).
58465138|NCT06299683|BEHAVIORAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
58465139|NCT06299683|OTHER|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
58465140|NCT05782868|OTHER|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
58465141|NCT05782868|OTHER|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
58465142|NCT05782868|OTHER|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
58465143|NCT04696484|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.
58465144|NCT05602493|DRUG|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
58465145|NCT05602493|DRUG|sterile saline|sterile saline
58465146|NCT06593431|RADIATION|Consolidative Radiation|Participants will receive treatment through radiation therapy
58465147|NCT03770234|DRUG|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
58465148|NCT02718079|BIOLOGICAL|Plasma Exchange|
58465149|NCT02718079|OTHER|Management of cerebral edema/intracranial hypertension:|
58465150|NCT02718079|OTHER|Transfer to Intensive Care Unit|
58465151|NCT02718079|DRUG|Prophylactic Antibiotics|
58465152|NCT02718079|OTHER|Intubation of trachea|
58465153|NCT02718079|OTHER|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
58465154|NCT02718079|OTHER|Volume Replacement|
58465155|NCT02718079|OTHER|Pressor Support|
58465156|NCT02718079|DRUG|N-acetyl-L-cysteine|
58465157|NCT02718079|OTHER|Correction of metabolic parameters|
58465158|NCT02718079|DIETARY_SUPPLEMENT|Correction of nutrition|
58465159|NCT04756310|DIETARY_SUPPLEMENT|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
58465160|NCT04756310|DIETARY_SUPPLEMENT|Theavit|antioxidants micronutrients
58465161|NCT03316781|DRUG|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
58465162|NCT03316781|DRUG|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
58465163|NCT02640274|BEHAVIORAL|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
58465164|NCT02640274|OTHER|Usual care|
58465165|NCT05503030|DRUG|Nintedanib|Nintedanib
58465166|NCT04922086|PROCEDURE|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
58465167|NCT04922086|PROCEDURE|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
58465168|NCT06209658|DIAGNOSTIC_TEST|breastfeeding education of Teach Back|breastfeeding education simple explanation is given and the woman is asked to explain and practice.
58465169|NCT06209658|OTHER|breastfeeding education simple explanation|breastfeeding education simple explanation
58465170|NCT03193840|PROCEDURE|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
58465171|NCT04268459|DEVICE|Provox prosthesis exchange|Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
58465172|NCT06150612|BEHAVIORAL|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
58465173|NCT03796728|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
58465174|NCT05381948|DRUG|Eyp-1901|Intravitreal Injection
58465175|NCT05381948|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
58465176|NCT05101317|DRUG|HMI-115|HMI-115 is human monoclonal antibody
58465177|NCT05101317|DRUG|Placebo|Placebo
58465178|NCT02438163|DEVICE|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
58465179|NCT02731638|DRUG|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
58465180|NCT02731638|DRUG|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
58465181|NCT05142787|DEVICE|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
58465182|NCT05317104|OTHER|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
58465183|NCT06670001|BEHAVIORAL|Gamification plus social incentive|Participants in the Gamification plus social incentive intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
58465184|NCT06670001|BEHAVIORAL|Gamification plus competition|Participants in the Gamification plus competition intervention arm will receive gamification and a competition as part of the intervention. See arm descriptions for more detail.
58465185|NCT00980954|DRUG|carboplatin|Intravenously
58465186|NCT00980954|DRUG|cisplatin|Intravenously
58465187|NCT00980954|DRUG|paclitaxel|Intravenously
58465188|NCT00980954|RADIATION|intensity-modulated radiation therapy|Daily fractions
58465189|NCT00980954|RADIATION|standard external beam radiation therapy|Daily fractions
58465190|NCT00980954|RADIATION|Optional brachytherapy boost|Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.
58465191|NCT02365155|OTHER|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
58465192|NCT02365155|OTHER|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
58465193|NCT02365155|OTHER|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
58465194|NCT02365155|OTHER|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
58465195|NCT02365155|OTHER|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
58465196|NCT02365155|OTHER|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
58465197|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Full|Participants in this active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 2.0 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
58465198|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Sham|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) 21% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
58465199|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Partial Pressure|Participants in this partial treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
58465200|NCT04097678|OTHER|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
58465201|NCT04592874|DRUG|AL002|Administered via intravenous (IV) infusion
58465202|NCT04592874|DRUG|Placebo|Administered via intravenous (IV) infusion
58465203|NCT06705517|BEHAVIORAL|Mediterranean Diet|The MD emphasizes a plant-based approach, with a high consumption of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate amounts of fish, seafood, and dairy, while limiting meat, particularly red and processed varieties. Olive oil serves as the main fat source in the diet. In the case of this study participants will also be instructed to limit dairy intake, that although traditionally part of the MD, might exacerbate disease symptomatology in PD patients, likely due to the urate lowering effect of dairy.
58465204|NCT06538896|DRUG|Tislelizumab + Nab-Paclitaxel|Tislelizumab, 200mg, intravenous, every 3 weeks
58465205|NCT06538896|OTHER|Rankl inhibitor|RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
58465206|NCT06603038|DIETARY_SUPPLEMENT|Gainful Daily Performance Greens|Daily supplementation for 28 days
58465207|NCT02327546|DRUG|AKB-6548|
58465208|NCT02327546|DRUG|Ferrous Sulfate|
58465209|NCT02546167|BIOLOGICAL|CART-BCMA|
58465210|NCT03037996|OTHER|patients' response|patients' satisfaction to anesthesia services
58465211|NCT05951114|DIAGNOSTIC_TEST|Maximum inspiratory/Expiratory manoeuvre for patients can follow the order|Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre
58465212|NCT04133883|PROCEDURE|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
58465213|NCT06601257|DRUG|Vancomycin (IV)|Vancomycin weight-based or kidney function-based dosing
58465214|NCT03261648|OTHER|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
58465215|NCT03261648|OTHER|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
58465216|NCT04523688|BIOLOGICAL|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
58465217|NCT04523688|DRUG|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
58465218|NCT04175223|DIETARY_SUPPLEMENT|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
58465219|NCT06705803|PROCEDURE|Prostate Ablation|Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
58465220|NCT06255275|OTHER|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
58465221|NCT00435409|DRUG|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
58465222|NCT00435409|DRUG|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
58465223|NCT05988645|DEVICE|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
58465224|NCT06697717|OTHER|Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., \>0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen."
58465225|NCT06697717|OTHER|EIT-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes."
58465226|NCT05531786|DRUG|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
58465227|NCT02769923|DEVICE|Westpharma ID adapter|device used for administering intradermal injection
58465228|NCT02769923|DEVICE|Star ID syringe|device used for administering intradermal injection
58465229|NCT02769923|DEVICE|BCG NS|syringe used for administering intradermal injection
58465230|NCT04844814|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
58465231|NCT04844814|DRUG|Prednisone|Prednisone 30 mg/d
58465232|NCT04844814|DRUG|Placebo of Prednisone|Placebo of Prednisone
58465233|NCT04844814|DRUG|Placebo of Anakinra|Placebo of Anakinra
58465234|NCT04721860|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
58465235|NCT04721860|BEHAVIORAL|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
58465236|NCT05334368|DRUG|Depemokimab|Depemokimab will be administered.
58465237|NCT05334368|OTHER|Placebo|Matching placebo will be administered.
58465238|NCT01723241|DRUG|XAF5, concentration A|
58465239|NCT01723241|DRUG|XAF5, concentration B|
58465240|NCT01723241|DRUG|XAF5, concentration C|
58465241|NCT01723241|DRUG|Placebo|
58465242|NCT05959044|DRUG|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
58465243|NCT05959044|OTHER|Placebo|orally 5mg two times daily for 8weeks
58465244|NCT03977792|DRUG|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
58465245|NCT03977792|DRUG|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
58465246|NCT04392960|DRUG|[18F]Florbetaben|"Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
58465247|NCT06164951|DRUG|Infigratinib 0.25 mg/kg/day|Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
58465248|NCT06164951|DRUG|Placebo Comparator 0.25 mg/kg/day|Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
57777983|NCT01394250|DRUG|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
58465249|NCT06389396|DEVICE|CP362 Test Catheter|The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
58465250|NCT03827434|DEVICE|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
58465251|NCT03827434|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
58465252|NCT06455228|DEVICE|insert catheter|A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
58465253|NCT04733768|DIAGNOSTIC_TEST|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
58465254|NCT06577896|DEVICE|Onyx family|Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
58465255|NCT06525298|DRUG|EIS-12656|EIS-12656 tablets given daily
58465256|NCT06525298|DRUG|Olaparib|as per USPI/SmPC
58465257|NCT06525298|DRUG|Trastuzumab deruxtecan|as per USPI/SmPC
58465258|NCT03207126|DIAGNOSTIC_TEST|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
58465259|NCT00241384|PROCEDURE|External beam radiation|
58465260|NCT00241384|PROCEDURE|Pd-103|
58465261|NCT03939546|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
58465262|NCT03363373|BIOLOGICAL|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
58465263|NCT03633396|BIOLOGICAL|Imsidolimab|Administered by subcutaneous injection once a month
58465264|NCT03633396|DRUG|Placebo|Administered by subcutaneous injection once a month
58465265|NCT01378364|DRUG|AbGn-168H|single very low dose of AbGn-168H i.v.
58465266|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H i.v.
58465267|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
58465268|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
58465269|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
58465270|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
58465271|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H i.v.
58465272|NCT01378364|DRUG|AbGn-168H|single high dose of AbGn-168H i.v.
58465273|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H s.c.
58465274|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
58465275|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
58465276|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H s.c.
58465277|NCT00976274|DIETARY_SUPPLEMENT|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
58465278|NCT00976274|DIETARY_SUPPLEMENT|starch|5 capsules three times everyday for 12 weeks
58465279|NCT06700733|DEVICE|PEEK prosthesis|For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.
58465280|NCT06700733|DEVICE|Titanium prosthesis|For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
58465281|NCT06546163|BEHAVIORAL|Baseline survey|Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
58465282|NCT06546163|BEHAVIORAL|Heart rate variability biofeedback|Participants randomized to the intervention arm will receive a standardized HRV sensor and accompanying smartphone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be asked to practice their HRVB skills at home for 10 minutes for two weeks.
58465283|NCT06546163|BEHAVIORAL|Educational materials|Participants randomized to the waitlist control arm will receive educational materials on eating disorders and stress management and will be sent home with these materials after completing the baseline survey. They will be encouraged to read the materials over the next two weeks before coming in for T2 survey.
58465284|NCT01612338|BEHAVIORAL|Targeted|Targeted letter and booklet
58465285|NCT01612338|BEHAVIORAL|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
58465286|NCT04609098|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
58465287|NCT04609098|DRUG|Tafenoquine 100mg [Arakoda]|Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
58465288|NCT03590444|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
58465289|NCT01026545|DRUG|PF-04287881|500 mg once daily for 10 days
58465290|NCT01026545|DRUG|Placebo|To match 500 mg dose once daily for 10 days
58465291|NCT01026545|DRUG|PF-04287881|750 mg once daily for 10 days
58465292|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
58465293|NCT01026545|DRUG|PF-04287881|1100 mg once daily for 10 days
58465294|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
58465295|NCT01026545|DRUG|PF-04287881|Optional cohort with dose not greater than 1100 mg
58465296|NCT01026545|DRUG|Placebo|Optional cohort to match dose not greater than 1100 mg
58465297|NCT01026545|DRUG|PF-04287881|750 mg dose once daily for 10 days
58465298|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
58465299|NCT01026545|DRUG|PF-04287881|1100 mg dose once daily for 10 days
58465300|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
58465301|NCT05602298|OTHER|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
58465302|NCT05975723|BEHAVIORAL|MIND diet education|An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).
58465303|NCT05975723|BEHAVIORAL|Routine follow-up and general advice|Routine follow-up administered by trained staff.
58465304|NCT05899257|BEHAVIORAL|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
58465305|NCT04179552|DEVICE|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
58465306|NCT06690658|DEVICE|incorporating robotic system for upper body physical training of people with lower limb orthopedic condition|A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
58465307|NCT01853020|DRUG|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
58465308|NCT01853020|DRUG|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
58465309|NCT01395797|DRUG|PIO|0, 15, and 45 mg per day.
58465310|NCT01395797|DRUG|Placebo|Placebo
58465311|NCT05690841|DRUG|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by 9-11 month intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing)."
58465312|NCT00079469|BEHAVIORAL|smoking cessation intervention|
58465313|NCT00079469|DRUG|bupropion hydrochloride|
58465314|NCT03188094|BEHAVIORAL|CHW-Led Health Coaching|The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.
58465315|NCT03188094|OTHER|EHR Alerts|Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI \>23 kg/m2 and registries to track outcomes.
58465316|NCT05062655|OTHER|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
58465317|NCT03985761|BEHAVIORAL|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
58465318|NCT01489540|DEVICE|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
58465319|NCT05716958|RADIATION|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
58465320|NCT06594393|DRUG|TCP-25 gel|Topical gel
58465321|NCT06594393|DRUG|Vehicle (placebo)|Placebo gel
58465322|NCT02135861|PROCEDURE|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
58465323|NCT02135861|OTHER|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
58465324|NCT00157885|DRUG|Amodiaquine plus artesunate; Artekin|
58465325|NCT02686372|BIOLOGICAL|TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
58465326|NCT02686372|BIOLOGICAL|No intervention and TCR-T (at crossover)|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
58465327|NCT06487572|DRUG|Risankizumab|Intravenous (IV) Infusion
58465328|NCT06487572|DRUG|Risankizumab|Subcutaneous (SC) Injection
58465329|NCT02647125|DRUG|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
58465330|NCT02647125|RADIATION|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
58465331|NCT05555290|COMBINATION_PRODUCT|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
58465332|NCT05555290|COMBINATION_PRODUCT|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
58465333|NCT01650506|DRUG|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
58465334|NCT01650506|DRUG|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
58465335|NCT06309940|OTHER|Prognostic factors of surgical evacuation of basal ganglionic haemorrhage|Surgical evacuation of basal ganglionic haemorrhage
58465336|NCT05286814|DRUG|Floxuridine|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
58465337|NCT05286814|DRUG|5-Fluorouracil|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
58465338|NCT05286814|DRUG|Irinotecan|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
58465339|NCT05286814|DEVICE|Intera 3000 Hepatic Artery Infusion Pump (HAIP)|Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
58465340|NCT05286814|DRUG|Oxaliplatin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
58465341|NCT05286814|DRUG|Leucovorin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
58465342|NCT05286814|DRUG|PDS01ADC|PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
58465343|NCT05286814|DRUG|Gemcitabine|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
58465344|NCT05286814|DRUG|Dexamethasone|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
58465345|NCT06156020|PROCEDURE|Endoscopic endonasal surgery|Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
58465346|NCT05950464|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
58465347|NCT05950464|PROCEDURE|Biopsy|Undergo biopsy
58465348|NCT05950464|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58465349|NCT05950464|PROCEDURE|Computed Tomography|Undergo CT
58465350|NCT05950464|PROCEDURE|Electrocardiography|Undergo ECG
58465351|NCT05950464|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57777984|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 M probe|Measurement of liver stiffness
58465352|NCT05950464|DRUG|Tuvusertib|Given PO
58465353|NCT05950464|PROCEDURE|X-Ray Imaging|Undergo x-ray
58465354|NCT04377100|BEHAVIORAL|Computer task questionnaires|MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
58465355|NCT00500617|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
57777985|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 S probe|Measurement of liver stiffness
57777986|NCT04815486|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS in 10 daily sessions in two weeks of sequential application of: 90% RMT at 1Hz, 1000 pulses/day, 25s inter train on M1 of lesioned hemisphere and 90% RMT at 10Hz, 1000 pulses/day, 50s inter train on M1 of healthy hemisphere.
58465356|NCT02803788|DRUG|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
58465357|NCT00627393|DRUG|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
58465358|NCT00627393|BIOLOGICAL|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
58465359|NCT00627393|DRUG|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
58465360|NCT00627393|DEVICE|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
58465361|NCT06485635|DRUG|Nintedanib|Nintedanib
58465362|NCT06485635|DRUG|Pirfenidone|Pirfenidone
57777987|NCT04815486|DEVICE|Motor Imagery (MI) through a Brain-Computer Interface (BCI) training platform in Virtual Reality (VR) with NeuRow|It will consist of a combination of the bilateral rTMS protocol and the MI-neurofeedback training. During this therapy, the patient received 10 consecutive daily sessions of bilateral rTMS (Monday to Friday, two weeks), with the same stimulation parameters as another therapy, and 12 non-consecutive sessions of MI-neurofeedback (three times a week for four weeks). The first 6 MI-neurofeedback sessions were carried out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks.
58465363|NCT04719390|BEHAVIORAL|Maternal Message|Individuals randomized to this component will receive text messages that are focused on motherhood and the maternal role.
58465364|NCT04719390|BEHAVIORAL|Drinking Message|Individuals randomized to this component will receive text messages that are focused on reducing alcohol use.
58465365|NCT06705595|DRUG|Tracheo-Spray|Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
58465366|NCT06705595|DRUG|Lidocaine Spray on DLT|Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).
58465367|NCT06705595|DRUG|Saline (Placebo)|Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
58465368|NCT01874639|DEVICE|standard bipolar coagulation|
58465369|NCT01874639|DEVICE|Aquamantys® probe for liver hemostasis|
58465370|NCT06598969|DRUG|Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide|Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
58465371|NCT05081882|DRUG|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
58465372|NCT05081882|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
58465373|NCT04333914|DRUG|Autophagy inhibitor (GNS651)|Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
58465374|NCT04333914|OTHER|Standard of care|"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest."
58465375|NCT04333914|DRUG|Avdoralimab|Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
58465376|NCT04333914|DRUG|Monalizumab|Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
58465377|NCT03858049|DRUG|Crinone|Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
58465378|NCT03858049|DRUG|Duphaston|Participants received 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoign pregnancy was confirmed up to Day 63.
58465379|NCT06491030|DEVICE|Align PJK™ TLSO brace|Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.
58465380|NCT06491030|OTHER|Standard of Care|Patients will receive the standard of care postoperative instructions without a brace
58465381|NCT01102686|DRUG|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
58465382|NCT01102686|DRUG|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
58465383|NCT04684719|BIOLOGICAL|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
58465384|NCT04684719|BIOLOGICAL|Standard Care|crystalloid infusion or blood component transfusion resuscitation
58465385|NCT06655220|DRUG|Metformin hydrochloride|Metformin hydrochloride
58465386|NCT06655220|DRUG|BI 1815368|BI 1815368
58465387|NCT05014776|DRUG|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
58465388|NCT05014776|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
58465389|NCT05014776|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
58465390|NCT05014776|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 109 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
58465391|NCT03467958|DRUG|Ozanimod|Specified dose on specified days
58465392|NCT05979064|PROCEDURE|Laparoscopically harvested omental tissue autograft|"1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity."
58465393|NCT06706024|OTHER|breathing exercise|Patients Under Hemodialysis
58465394|NCT02558894|DRUG|MEDI4736 monotherapy|MEDI4736 via IV infusion.
58465395|NCT02558894|DRUG|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
58465396|NCT04855552|BEHAVIORAL|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
58465397|NCT04855552|BEHAVIORAL|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
58465398|NCT04855552|BEHAVIORAL|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram"
58465399|NCT05250505|DEVICE|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
58465400|NCT00882440|DRUG|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
58465401|NCT00882440|DRUG|Placebo|Placebo capsule to losartan
58465402|NCT00882440|DRUG|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
58465403|NCT04698343|DEVICE|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
58465404|NCT06190093|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
58465405|NCT06190093|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
58465406|NCT05317403|DRUG|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
58465407|NCT05317403|DRUG|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
58465408|NCT05317403|DRUG|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
58465409|NCT05317403|DRUG|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~1. - 1.99 years old: 30 mg~2. - 2.99 years old: 50 mg~   * 3 years old: 70 mg"
58465410|NCT05317403|DRUG|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
58465411|NCT05317403|DRUG|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
58465412|NCT05615818|DRUG|Futibatinib|Dose 20 mg once a day (QD)
58465413|NCT05615818|DRUG|Ivosidenib|Dose 500 mg QD
58465414|NCT05615818|DRUG|Zanidatamab|Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
58465415|NCT05615818|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
58465416|NCT05615818|DRUG|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
58465417|NCT05615818|DRUG|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
58465418|NCT05615818|DRUG|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
58465419|NCT05615818|DRUG|Niraparib|Dose: 200 mg QD or 300 mg QD
58465420|NCT05615818|DRUG|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
58465421|NCT05615818|DRUG|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
58465422|NCT04974671|RADIATION|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
58465423|NCT01598935|OTHER|nutrition|protein-based food
58465424|NCT03924622|DEVICE|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
58490661|NCT06208371|DRUG|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
58465425|NCT03924622|DEVICE|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
57777988|NCT05466903|DIETARY_SUPPLEMENT|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
58465426|NCT06580496|BEHAVIORAL|Mightier|Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
58465427|NCT05292326|DEVICE|PacePress|an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly
58465428|NCT05292326|DEVICE|standard compression band|standard used compression band/sand bag
58465429|NCT05272683|DRUG|GLPG3667|On day 1 and day 8, participants will receive a single dose
58465430|NCT05272683|DRUG|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
58465431|NCT06005688|DRUG|Vepdegestrant|Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.
58465432|NCT06005688|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
58465433|NCT06220032|DRUG|Dexrazoxane|Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.
58465434|NCT06220032|DRUG|Rituximab|Day 1 Cycle 1-6: 375 mg/m2 (iv)
58465435|NCT06220032|DRUG|Cyclophosphamide|Day 1 Cycle 1-6: 750 mg/m2 (iv)
58465436|NCT06220032|DRUG|Doxorubicin|Day 1 Cycle 1-6: 50 mg/m2 (iv)
58465437|NCT06220032|DRUG|Vincristine|Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)
58465438|NCT06220032|DRUG|Prednisolone|Day 1-5 Cycle 1-6: 100 mg (oral)
58465439|NCT06220032|DRUG|Lenalidomide|Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.
58465440|NCT06220032|DRUG|Pegfilgrastim|6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
58465441|NCT04390880|DRUG|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
58465442|NCT05493891|OTHER|Visual analogue scale (VAS)|VAS is a reliable and valid method for assessing the intensity of low back pain (LBP)
58465443|NCT05493891|DEVICE|Pressure Biofeedback Unit (PBU)|PBU is a valid and reliable instrument for measuring the maximal voluntary isometric contraction of both lumbar multifidus and transversus abdominis muscles (core muscle strength)
58465444|NCT05457790|BEHAVIORAL|ACT Intervention|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
58465445|NCT05457790|BEHAVIORAL|Waitlist|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
58465446|NCT04986007|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
58465447|NCT04866810|BEHAVIORAL|Intervention Arm|High fiber, plant based diet + exercise prescription with ACT sessions
58465448|NCT04866810|BEHAVIORAL|Control|Standard diet and exercise recommendations
58465449|NCT04058938|BEHAVIORAL|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
58465450|NCT04058938|BEHAVIORAL|Control|Standard patient counseling
58465451|NCT06092749|OTHER|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
58465452|NCT06092749|OTHER|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
58465453|NCT06594757|PROCEDURE|Toothbrushing with triple-headed manual toothbrush|Toothbrushing with triple-headed manual toothbrush
58465454|NCT06594757|PROCEDURE|Toothbrushing with standard manual toothbrush|Toothbrushing with tstandard manual toothbrush
58465455|NCT03111303|DEVICE|mechanical ventilation|Connection to mechanical ventilator
58490662|NCT02661334|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
58490663|NCT02661334|DIETARY_SUPPLEMENT|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
58490664|NCT00002618|BIOLOGICAL|filgrastim|
58490665|NCT00002618|DRUG|cytarabine|
58490666|NCT00002618|DRUG|doxorubicin hydrochloride|
58490667|NCT00002618|DRUG|leucovorin calcium|
57777989|NCT00767104|OTHER|Silk like Pillowcase|sleep on silk-like pillowcase each night
57777990|NCT00767104|OTHER|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
58465456|NCT03310138|DEVICE|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
58465457|NCT03310138|DEVICE|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
58465458|NCT01704027|RADIATION|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)"
58465459|NCT01704027|DRUG|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
58465460|NCT04657679|DRUG|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
58465461|NCT05845385|PROCEDURE|lumbar epidural analgesia with bupivacaine|postoperative analgesic method
58465462|NCT05845385|PROCEDURE|transversus abdominis plane block with bupivacaine|postoperative analgesic method
58465463|NCT05845385|PROCEDURE|wound infiltration with bupivacaine|postoperative analgesic method
58465464|NCT04467983|DRUG|Denosumab Injection|Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
58465465|NCT04467983|DRUG|Abaloparatide|Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
58465466|NCT04861597|BEHAVIORAL|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
58465467|NCT04861597|BEHAVIORAL|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
58465468|NCT06338774|BEHAVIORAL|Cognitive training|Computerized cognitive training completed on any computer or tablet with internet
58465469|NCT06338774|BEHAVIORAL|Exercise|Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
58465470|NCT06560385|DIETARY_SUPPLEMENT|BLHK03|BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds
58465471|NCT06560385|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 5mcg of Vitamin B7
58465472|NCT04251130|DRUG|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
58465473|NCT04921436|PROCEDURE|cardiac surgery|prophylactic use of antibiotic-inhibitors
58465474|NCT05687058|DRUG|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session under direct observation by a trained health care worker.
58465475|NCT05687058|DRUG|Empagliflozin 10 mg daily dosing|Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
58465476|NCT06285591|DIETARY_SUPPLEMENT|Lactobacillus Reuteri Tablets|Lactobacillus Reuteri lozenges (NOW Foods, Sweden) contained no less than 2×10\^8 CFU viable cells of Lactobacillus Reuteri as the active ingredient.
58465477|NCT06285591|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus Reuteri
58465478|NCT06285591|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
58465479|NCT02739230|DRUG|Exparel|
58465480|NCT02739230|DRUG|On-Q pain intra-articular catheter|
58465481|NCT06026592|GENETIC|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
58465482|NCT03770260|DRUG|Ixazomib Citrate|Given PO
58465483|NCT03770260|DRUG|Pevonedistat|Given IV
58465484|NCT06555068|DRUG|HRS-6209 in Combination with Fulvestrant|HRS-6209 in Combination with Fulvestrant
58465485|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
58465486|NCT06555068|DRUG|HRS-6209 in Combination with Letrozole|HRS-6209 in Combination with Letrozole
58465487|NCT06555068|DRUG|HRS-6209 in Combination with HRS-8080|HRS-6209 in Combination with HRS-8080
58465488|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
58465489|NCT03655340|DRUG|Alprolix|Extended half-life factor IX product
58465490|NCT06520787|COMBINATION_PRODUCT|ACDP® and pharmacological treatment for obesity|40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).
58490668|NCT00002618|DRUG|mercaptopurine|
58490669|NCT00002618|DRUG|methotrexate|
58490670|NCT00002618|DRUG|prednisone|
58490671|NCT00002618|DRUG|vincristine sulfate|
58490672|NCT00002618|RADIATION|low-LET cobalt-60 gamma ray therapy|
58490673|NCT00002618|RADIATION|low-LET electron therapy|
58465491|NCT04737512|BEHAVIORAL|Mindfulness-Based ADHD Treatment for Children|MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
58465492|NCT04737512|BIOLOGICAL|Goal-Standard Medication (Treatment as Usual)|"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."
58465493|NCT00006359|DRUG|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
58465494|NCT00006359|DRUG|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
58465495|NCT00006359|RADIATION|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
58465496|NCT00006359|RADIATION|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
58465497|NCT01033981|DRUG|Sunitinib|Treatment for mRCC as indication approved and physician criterium
58465498|NCT04648033|DRUG|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
58465499|NCT04648033|DRUG|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
58465500|NCT04648033|RADIATION|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
58465501|NCT03611738|DRUG|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
58465502|NCT03611738|DRUG|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
58465503|NCT05961553|BEHAVIORAL|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
58465504|NCT05961553|OTHER|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
58465505|NCT06453148|OTHER|Non-interventions|Usual care evaluations
58465506|NCT04242355|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
58465507|NCT05762679|DIAGNOSTIC_TEST|Imaging|Phase 1 is an imaging biomarker study.
58465508|NCT04728958|BEHAVIORAL|Gratitude|A positive psychology intervention using expressions of gratitude
57777991|NCT04977947|BEHAVIORAL|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
58465509|NCT02647281|DRUG|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
58465510|NCT02647281|DRUG|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
58465511|NCT04489316|OTHER|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
58465512|NCT03158844|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
58465513|NCT06704841|BEHAVIORAL|Music in combination with mindfulness|Participants will attend two in-person sessions per week over two consecutive weeks. Each session will be up to one hour in duration. During each session, participants will engage in a 20-minute guided meditation while listening to instrumental music.
58490674|NCT00002618|RADIATION|low-LET photon therapy|
57777992|NCT05601713|OTHER|No cooling (control)|Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
58465514|NCT05216016|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
58465515|NCT02588690|PROCEDURE|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
58465516|NCT02588690|OTHER|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
58465517|NCT02588690|PROCEDURE|Blood pressure measurement|Blood pressure measurement
58465518|NCT06706180|OTHER|Exercise for Mood video|As per arm of the same name
58465519|NCT06706180|OTHER|Exercise for Fitness video|As per arm of the same name
58465520|NCT05992883|DRUG|Ketorolac|Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
58465521|NCT05992883|DRUG|Triamcinolone|Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
58465522|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
58465523|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
58465524|NCT05684536|DEVICE|liagsure device|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
58465525|NCT04902053|DIAGNOSTIC_TEST|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
58465526|NCT04335656|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
58465527|NCT04335656|OTHER|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
58465528|NCT06704438|DIAGNOSTIC_TEST|D-Lactate|D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
58465529|NCT04448964|DRUG|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
58465530|NCT03965130|BIOLOGICAL|Glucagon|PINTA study with glucagon
58465531|NCT03965130|OTHER|Control Study|The same participants will not receive glucagon during the PINTA study
58465532|NCT02188264|DRUG|Cyclosporine|Given PO
58465533|NCT02188264|OTHER|Laboratory Biomarker Analysis|Correlative studies
57777993|NCT05601713|OTHER|Lower limb immersion|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.
58465534|NCT02188264|OTHER|Pharmacological Study|Correlative studies
58465535|NCT02188264|DRUG|Selumetinib|Given PO
58465536|NCT06159361|BEHAVIORAL|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
58465537|NCT00038753|PROCEDURE|Vision Screening|
58465538|NCT04482179|DEVICE|Active TMS|Active TMS will be delivered at 100% motor threshold
58465539|NCT04482179|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
58465540|NCT04482179|DEVICE|Sham TMS|Sham TMS will be administered
58465541|NCT01612351|DRUG|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
58465542|NCT01612351|DRUG|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
58465543|NCT01612351|DRUG|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
58465544|NCT01612351|DRUG|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
58465545|NCT01612351|DRUG|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
58465546|NCT01612351|RADIATION|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
58465547|NCT01612351|RADIATION|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
58465548|NCT01612351|PROCEDURE|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
58465549|NCT05614492|BEHAVIORAL|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
58465550|NCT05614492|BEHAVIORAL|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
58465551|NCT05614492|BEHAVIORAL|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
58465552|NCT04677647|OTHER|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
58465553|NCT04494256|DRUG|BIIB105|Administered as specified in the treatment arm.
58465554|NCT04494256|DRUG|Placebo|Administered as specified in the treatment arm.
58465555|NCT06009653|BEHAVIORAL|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
58465556|NCT06009653|BEHAVIORAL|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
58465557|NCT06009653|DRUG|Placebo|Participants will receive placebo subcutaneous injections.
58465558|NCT06009653|DRUG|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
58465559|NCT03685760|OTHER|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
58465560|NCT03685760|OTHER|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
58465561|NCT05506540|DRUG|ENN0403 1mg|ENN0403 capsules for oral use
58465562|NCT05506540|DRUG|ENN0403 4mg|ENN0403 capsules for oral use
58465563|NCT05506540|DRUG|ENN0403 10mg|ENN0403 capsules for oral use
58465564|NCT05506540|DRUG|ENN0403 20mg|ENN0403 capsules for oral use
58465565|NCT05506540|DRUG|ENN0403 30mg|ENN0403 capsules for oral use
58465566|NCT05506540|DRUG|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
58465567|NCT05506540|DRUG|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
58465568|NCT05506540|DRUG|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
57777994|NCT05601713|OTHER|Lower limb immersion + neck cooling|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
57777995|NCT05364918|DRUG|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
58465569|NCT05506540|DRUG|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
58465570|NCT05506540|DRUG|Placebo|Placebo capsules for oral use
58465571|NCT06097221|BEHAVIORAL|CRT-Advance|Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
58465572|NCT06097221|BEHAVIORAL|Treatment as usual|Treatment as usual in the outpatient psychiatric unit.
58465573|NCT04943744|DEVICE|Entero-tracker|Esophageal STRING test (Entero-tracker)
58465574|NCT04943744|BIOLOGICAL|omalizumab|Used in the parent study
58465575|NCT04943744|BIOLOGICAL|dupliumab|Used in the parent study
58465576|NCT06220721|DRUG|Nifedipine ER|Initiation of nifedipine ER postpartum at SBP ≥140 mmHg or DBP ≥90 mmHg and maintaining BP \<140/90 mmHg during the first 6 weeks postpartum.
58465577|NCT06706037|OTHER|Exercise|A 6 week reformer pilates exercise program
58465578|NCT06706713|DRUG|BEBT-109 Capsule|Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
58465579|NCT01711554|BIOLOGICAL|Dinutuximab|Given IV
58465580|NCT01711554|DRUG|Isotretinoin|Given PO
58465581|NCT01711554|OTHER|Laboratory Biomarker Analysis|Correlative studies
58465582|NCT01711554|DRUG|Lenalidomide|Given PO
58465583|NCT01711554|OTHER|Pharmacological Study|Correlative studies
58465584|NCT03679247|OTHER|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
58465585|NCT03679247|OTHER|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
58465586|NCT05876689|DEVICE|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
58465587|NCT05499832|DRUG|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
58465588|NCT06704308|BEHAVIORAL|Web Application|A web application for vaccine-hesitant parents and their teens with brief, 90-second narrative videos and tailored, motivational content
58465589|NCT06704308|BEHAVIORAL|Provider Elaborated Prompts|A component for providers that suggests elaborated prompts to be used with parents that align with the content of the web application, are tailored to parent concerns, and are motivational in nature
58465590|NCT04838171|OTHER|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
58465591|NCT05816395|DRUG|RHH646|RHH646 capsule for oral use
58465592|NCT05816395|DRUG|Placebo|RHH646 placebo capsule for oral use
58465593|NCT03078114|OTHER|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
58465594|NCT03078114|OTHER|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
58465595|NCT05656859|BEHAVIORAL|Single group|Survey
58465596|NCT05083351|DEVICE|MightySat|Noninvasive pulse oximeter
58465597|NCT06705725|DRUG|CBG002 CAR-T Cell Suspension|"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."
58465598|NCT04813588|OTHER|Pantomiming|Pantomiming with fluency shaping techniques
58465599|NCT04813588|OTHER|Easy onset|Easy onset method with breathing exercises
58465600|NCT03661723|DRUG|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
58465601|NCT03661723|DRUG|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
58465602|NCT03661723|RADIATION|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
58465603|NCT03096834|BIOLOGICAL|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
58465604|NCT03096834|BIOLOGICAL|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
58465605|NCT04151940|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
58465606|NCT04151940|PROCEDURE|Computed Tomography|Undergo PET/CT scan
58465607|NCT04151940|DRUG|Chemotherapy|Receive standard of care chemotherapy
58465608|NCT04151940|BIOLOGICAL|Immunotherapy|Receive standard of care immunotherapy
58465609|NCT04151940|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
58465610|NCT04002141|DRUG|Placebo oral tablet|1 tablet oral daily
58465611|NCT04002141|DRUG|Letrozole|5mg oral daily
58465612|NCT05821985|PROCEDURE|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
58465613|NCT05821985|PROCEDURE|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
58465614|NCT06705114|PROCEDURE|complete denture|Each patient received a newly constructed conventional complete denture with optimal denture extension and lingualized balanced occlusal concept
58465615|NCT06705114|PROCEDURE|implant overdenture|Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.After 3-4 months, the dental implants were exposed and ball abutments were screwed into the implants. The housing of the ball attachments were incorporated into the fitting surface of the mandibular denture using a direct pick-up technique (Fig. 1B). The mandibular overdenture was then inserted into the patient's mouth and occlusal adjustment was done using articulating paper to remove any occlusal interferences. Follow-up visits were scheduled.
58465616|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
58465617|NCT03184064|DIETARY_SUPPLEMENT|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
58465618|NCT03184064|DIETARY_SUPPLEMENT|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
58465619|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
58465620|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
58465621|NCT00139152|DRUG|Placebo|Saline, Sub-Cuteanous (SQ)
58465622|NCT00139152|DRUG|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
58465623|NCT03525444|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
58465624|NCT03525444|DRUG|IVA|Participants received IVA orally once daily in the evening
58465625|NCT03525444|DRUG|Placebo|Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
58465626|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
58465627|NCT05027321|BEHAVIORAL|Conversational Hypnosis|Conversational Hypnosis during examination
58465628|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
58465629|NCT05346120|BIOLOGICAL|allogeneic marrow stromal cells (MSCs)|stem cell infusion
58465630|NCT06584188|DRUG|anti-inflammatory ketorolac tromethamine|"* Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}."
58465631|NCT04875286|OTHER|Electronic Health Record Review|Medical records reviewed
58465632|NCT04875286|OTHER|Questionnaire Administration|Complete questionnaires
58465633|NCT02640586|DEVICE|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
58465634|NCT02340026|OTHER|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
58465635|NCT02340026|OTHER|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
58465636|NCT01680341|DRUG|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
58465637|NCT01680341|DRUG|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
58465638|NCT03589859|DIAGNOSTIC_TEST|VOR Test|Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
58465639|NCT03589859|OTHER|Computer Game|Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
58465640|NCT03589859|OTHER|Nausea Scale|Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
58465641|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
58465642|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day after transplant
58465643|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
58465644|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
58465645|NCT03497936|BEHAVIORAL|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
58465646|NCT03267277|DRUG|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
58465647|NCT00271674|DEVICE|Q-switched YAG laser|
58465648|NCT02535312|DRUG|Cisplatin|Given IV
58465649|NCT02535312|DRUG|Methoxyamine|Given PO
58465650|NCT02535312|DRUG|Pemetrexed Disodium|Given IV
58465651|NCT03694158|DRUG|Dupilumab|anti-IL4 receptor antagonist
57777996|NCT05551481|PROCEDURE|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
57777997|NCT06375135|BEHAVIORAL|TXTXT|Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.
58465652|NCT03694158|OTHER|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
58465653|NCT01935934|DRUG|Cabozantinib S-malate|Given PO
58465654|NCT01935934|OTHER|Laboratory Biomarker Analysis|Correlative studies
58465655|NCT01935934|OTHER|Pharmacological Study|Correlative studies
58465656|NCT04803318|DRUG|Combination of three inhibitors Trametinib, Everolimus and Lenvatinib|Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
58465657|NCT06173687|DEVICE|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
58465658|NCT05147220|DRUG|Remibrutinib|tablet taken orally
58465659|NCT05147220|DRUG|Teriflunomide|capsule taken orally
58465660|NCT05137041|DEVICE|ITP FIRTECH|Infrared Therapy Patch
58465661|NCT05622734|BEHAVIORAL|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
58465662|NCT05543603|DRUG|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
58465663|NCT05543603|DRUG|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
58465664|NCT05543603|DRUG|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
58465665|NCT05543603|DRUG|Distilled water|15 ml distilled water, one minute rinse
58465666|NCT02370329|OTHER|Laboratory Biomarker Analysis|Correlative studies
58465667|NCT02370329|OTHER|Quality-of-Life Assessment|Ancillary studies
58465668|NCT02370329|BIOLOGICAL|Ropeginterferon Alfa-2B|Given SC
58465669|NCT01052493|DRUG|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
58465670|NCT01052493|DRUG|Placebo|0.9% saline
58465671|NCT05470504|DRUG|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
58465672|NCT00179621|DRUG|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
58465673|NCT00179621|DRUG|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
58465674|NCT00179621|DRUG|Placebo|Placebo, matching to active study drug arms
58465675|NCT05222984|DRUG|Decitabine|Given IV
58465676|NCT05222984|BIOLOGICAL|Navitoclax|Given PO
58465677|NCT05222984|DRUG|Venetoclax|Given PO
58465678|NCT02138617|DRUG|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
58465679|NCT02138617|DRUG|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
58465680|NCT02138617|DRUG|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
58465681|NCT02138617|DRUG|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
58465682|NCT06706401|DRUG|Vesanoid|Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
58465683|NCT06706401|RADIATION|Standard radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
58465684|NCT06706401|RADIATION|Tailored radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 weeks (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
58465685|NCT06706401|DRUG|Cisplatin|"Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks)."
58465686|NCT06706401|DRUG|Cetuximab|"Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2."
58465687|NCT05914766|BEHAVIORAL|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of three components.
58465688|NCT05914766|OTHER|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
58465689|NCT06327100|DRUG|Ruxolitinib|Given by PO
58465690|NCT06327100|DRUG|Tasquinimod|Given by PO
58465691|NCT04398771|DRUG|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
58465692|NCT06706089|OTHER|Nurse-led educational intervention|"This nurse-led educational intervention included: a) an oral training session regarding glaucoma by the P.I. lasting 15 minutes, b) provision of printed informational material (leaflet) and c) provision of appropriately selected free informational videos from the World Glaucoma Association on the YouTube -online platform. All of the above mentioned educational methods focused on the disease, its treatment and its long-term management. The oral training session took place in an appropriate, quiet and clean area, respecting the patient's privacy. During this process, study participants had the opportunity and time to ask questions and ask for clarifications or additional information."
58465693|NCT05607446|DRUG|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
58465694|NCT05607446|DRUG|Placebo tablets|The intervention drug is placebo.
58465695|NCT05607446|DRUG|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
58465696|NCT05607446|DRUG|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
58130908|NCT06440564|PROCEDURE|Er:YAG Laser irradiation|The presented DALIR procedure differs in so far from a standard treatment that after exposure all accessible metal implant surfaces and the adjacent soft tissue is irradiated manually with the Er:YAG laser all over line-by-line with an intended overlap of approximately 10% at constant spot diameter.
58465697|NCT01414634|BIOLOGICAL|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
58465698|NCT06602986|DIAGNOSTIC_TEST|TACE|"study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima"
58465699|NCT02774759|DEVICE|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
58465700|NCT02774759|BEHAVIORAL|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
58465701|NCT02774759|BEHAVIORAL|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
58465702|NCT02774759|BEHAVIORAL|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
58465703|NCT02774759|BEHAVIORAL|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
58130909|NCT06080061|RADIATION|Hypofractionated accelerated radiation therapy|Hypofractionated accelerated radiation therapy
58465704|NCT02774759|BEHAVIORAL|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
58465705|NCT02774759|BEHAVIORAL|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
58465706|NCT01779830|DRUG|LY2624803 - Capsules|Administered orally as capsules.
58465707|NCT01779830|DRUG|Zolpidem - Tablets|Administered orally as tablets.
58465708|NCT01779830|DRUG|Placebo - Capsules|Administered orally as capsules.
58465709|NCT01779830|DRUG|Placebo - Tablets|Administered orally as tablets.
58465710|NCT04965142|BEHAVIORAL|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
58465711|NCT02360579|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
58465712|NCT06706232|DRUG|Psilocybin|Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
58465713|NCT06706232|BEHAVIORAL|Therapeutic Support|"Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before.~Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life.~If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not."
58465714|NCT06397781|DRUG|Skin Cleanser Combination No.1|"1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily."
58465715|NCT05126563|BIOLOGICAL|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
58465716|NCT05126563|OTHER|Placebo|Placebo comarator
58465717|NCT02726503|DRUG|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
58465718|NCT06374550|BEHAVIORAL|Jump Start on the Go|Centers will receive the Jump Start On The Go mental health program via a mobile app. This will entail receiving 12-24 mental health consultation sessions in which a licensed mental health consultant will use a mobile app that will provide directors and teachers with access to information such as videos, infographics, and an Artificial Intelligence Chatbot on how to work with children with challenging behaviors. Participants will receive the intervention once per week for up to 1 hour.
58465719|NCT06374550|BEHAVIORAL|Jump Start Plus Coronavirus Support|The Jump Start Plus Coronavirus Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
58465720|NCT00667628|DRUG|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
58465721|NCT00667628|DRUG|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
58465722|NCT05907759|DRUG|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
58465723|NCT05741424|DIAGNOSTIC_TEST|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
58465724|NCT05741424|DIAGNOSTIC_TEST|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
58465725|NCT00060528|DRUG|Recombinant Fowlpox-GM-CSF|
58465726|NCT00060528|DRUG|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
58465727|NCT00060528|DRUG|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
58465728|NCT00060528|DRUG|Recombinant Human GM-CSF|
58465729|NCT04387448|DRUG|GFB-887|Investigational Medicinal Product (IMP)
58465730|NCT04387448|DRUG|Placebo|Matching
58465731|NCT06602934|OTHER|Blood samples|Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
58465732|NCT06602934|OTHER|Oropharyngeal swabs|An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
58465733|NCT06602934|OTHER|Calcium score (CT scan)|A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
58465734|NCT06602934|OTHER|ECG|Performed at inclusion, M6, M18 and M30
58465735|NCT06602934|OTHER|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
58465736|NCT05214534|OTHER|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
58465737|NCT01568177|BEHAVIORAL|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
58465738|NCT01568177|OTHER|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
58465739|NCT01568177|OTHER|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
58465740|NCT01568177|OTHER|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
58465741|NCT01568177|PROCEDURE|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
58130910|NCT03399526|DRUG|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
58465742|NCT01942928|OTHER|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
58465743|NCT01942928|OTHER|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
58465744|NCT00119847|PROCEDURE|PCI|
58465745|NCT00119847|DRUG|Optimal Medical Therapy|Guideline-directed drug therapies after MI
58465746|NCT06600477|DRUG|olanzapine|7.5 mg
58465747|NCT01654354|DRUG|NEOVIST 370 INJ.(Iopromide 768.86mg)|
58465748|NCT01654354|DRUG|Ultravist 370 INJ.(Iopromide 768.86mg)|
58465749|NCT05208476|PROCEDURE|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
58465750|NCT06071845|DEVICE|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
58465751|NCT06071845|DIAGNOSTIC_TEST|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
58465752|NCT01881191|OTHER|MRI|
58465753|NCT04290130|OTHER|Measurement of brain activity using electrodes.|We will present audiovisual speech and record neural responses.
58465754|NCT05544240|DRUG|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
58465755|NCT00644423|DRUG|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
58465756|NCT00644423|DRUG|Placebo|Matching Placebo
58465757|NCT05939414|DRUG|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
58465758|NCT01383928|DRUG|Ixazomib|Ixazomib capsules
58465759|NCT01383928|DRUG|Lenalidomide|Lenalidomide capsules
58465760|NCT01383928|DRUG|Dexamethasone|Dexamethasone Tablets
58465761|NCT06593132|PROCEDURE|endoscopic breast conserving surgery|Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.
58465762|NCT05356702|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
58465763|NCT05940402|DRUG|Emraclidine|Oral tablets
58465764|NCT05895786|DRUG|PF-06823859|anti-interferon beta therapy
58465765|NCT05895786|DRUG|Placebo|Placebo for PF-06823859
58465766|NCT05390073|DIAGNOSTIC_TEST|growth hormone level and insulin like growth factor 1|laboratory test
58465767|NCT05632640|OTHER|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
58465768|NCT05632640|DEVICE|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
58465769|NCT05552027|DEVICE|CCS System- Prototype|Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
58465770|NCT05552027|DEVICE|CCS System- Control|The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
58465771|NCT03696160|DRUG|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
58465772|NCT03696160|DRUG|Symtuza|Protease inhibitor used to treat HIV-1 infection
58465773|NCT06705985|DEVICE|Implantation of lateral meniscus prosthesis|Implantation of a lateral meniscus prosthesis after meniscectomy.
58465774|NCT04952779|DRUG|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
58465775|NCT05889156|DRUG|NST-1024|400 mg BID
58465776|NCT05889156|OTHER|Placebo|matched placebo to active arm
58465777|NCT05993689|OTHER|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
58465778|NCT05993689|OTHER|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
58130911|NCT03399526|DRUG|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
58465779|NCT03237624|DEVICE|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
58465780|NCT03237624|DEVICE|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
58465781|NCT03237624|BEHAVIORAL|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
58465782|NCT05695950|DRUG|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
58465783|NCT05695950|DRUG|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
58465784|NCT06005194|BEHAVIORAL|InMotion|A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
58465785|NCT06474286|DRUG|Prucalopride 1 MG|The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
58465786|NCT06410248|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58465787|NCT06410248|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58465788|NCT06410248|OTHER|Questionnaire Administration|Ancillary studies
58465789|NCT06410248|PROCEDURE|Resection|Undergo surgical resection
58465790|NCT06410248|DRUG|Temozolomide|Given PO
58465791|NCT06410248|DRUG|Triapine|Given PO
58465792|NCT05625737|DRUG|Fruquintinib|Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
58465793|NCT05625737|DRUG|Sintilimab|Sintilimab will be administrated as 200mg once every 3 weeks.
58465794|NCT00706368|DEVICE|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
58465795|NCT04805502|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
58465796|NCT06299098|DRUG|Trevogrumab-Part A|Administered IV or SC in Part A
58465797|NCT06299098|DRUG|Trevogrumab-Part B and Part C|Administered SC in Part B, Part C
58465798|NCT06299098|DRUG|Garetosmab|Administered IV in Part B
58465799|NCT06299098|DRUG|Semaglutide|Administered SC in Part B and Part C
58465800|NCT06299098|DRUG|Matching Placebo-Part A|Administered IV or SC in Part A
58465801|NCT06299098|DRUG|Matching Placebo-Trevogrumab|Administered SC in Part B and Part C
57777998|NCT06375135|BEHAVIORAL|e-Navigation|"Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support."
58465802|NCT06299098|DRUG|Matching Placebo-Garetosmab|Administered IV in Part B
58465803|NCT04146181|DRUG|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
58465804|NCT03968679|RADIATION|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
58465805|NCT06383858|DIAGNOSTIC_TEST|Screening method|All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
58465806|NCT06383858|DIAGNOSTIC_TEST|Screening method|In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
58465807|NCT05601219|DRUG|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
58465808|NCT05601219|DRUG|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
58130912|NCT03399526|DRUG|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
58130913|NCT03399526|DRUG|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
58130914|NCT03399526|DRUG|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
58465809|NCT04484961|DEVICE|Blood flow restriction (BFR)|The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
58465810|NCT05930678|PROCEDURE|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
58465811|NCT05930678|PROCEDURE|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
58465812|NCT06633562|DRUG|Nezavist SDD|Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
58465813|NCT06633562|DRUG|Placebo|Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
58465814|NCT05806645|OTHER|Risk-guided transition of care intervention delivered through an integrated digital health strategy|The proposed experimental intervention will incorporate our risk prediction model which will be used to guide the hospital to home transition of care for medium and high-risk groups of patients. Patients will receive transition of care plans that are tailored to their risk and embedded within standardized discharge pathways within the electronic health record
58465815|NCT05000398|OTHER|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
58465816|NCT05000398|OTHER|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
58465817|NCT05000398|OTHER|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
58465818|NCT05000398|OTHER|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
58465819|NCT05000398|OTHER|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
58465820|NCT05000398|OTHER|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
58465821|NCT05000398|OTHER|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
58465822|NCT05000398|OTHER|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
58465823|NCT05000398|OTHER|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
58465824|NCT05387083|DRUG|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
58465825|NCT05387083|DRUG|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
58465826|NCT05387083|DRUG|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
58465827|NCT05498883|OTHER|Score completion|completion of the SRI score
58465828|NCT06404814|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|(TENS) is a method of pain relief involving the use of a mild electrical current
58465829|NCT06404814|DIAGNOSTIC_TEST|Muscle Energy Technique|n Spencer's technique, there are seven steps as follows: shoulder extension along with elbow flexion, shoulder flexion with elbow extension, circumduction with compression, circumduction with distraction, shoulder abduction and internal rotation with elbow flexion, shoulder adduction and external rotation with elbow
58465830|NCT05099770|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
58130915|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
58465831|NCT05099770|PROCEDURE|Sham Comparator|Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
58465832|NCT05551299|DRUG|Photosensitizer|A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
58465833|NCT05551299|PROCEDURE|Radiofrequency ablation (RFA)|RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.
58465834|NCT06368050|BEHAVIORAL|practice structure intervention|practice structure intervention
58465835|NCT05615376|DEVICE|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
58130916|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
58130917|NCT01641445|DRUG|Topiramate|Topiramate (200 mg daily)
58130918|NCT01641445|DRUG|Placebo|"Matching placebo capusules (sugar pills"
57777999|NCT06375135|BEHAVIORAL|Ecological Momentary Assessment (EMA) supported e-Navigation.|Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
57778000|NCT06161103|PROCEDURE|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
57778001|NCT06161103|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
58465836|NCT05615376|DEVICE|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
58465837|NCT02210572|DIETARY_SUPPLEMENT|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
58465838|NCT02210572|DIETARY_SUPPLEMENT|Low- FODMAPs diet|
58465839|NCT05003401|DEVICE|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
58465840|NCT04505059|PROCEDURE|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
58465841|NCT04505059|PROCEDURE|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
58465842|NCT05943964|BEHAVIORAL|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
58465843|NCT00704015|BEHAVIORAL|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
58465844|NCT05640830|DRUG|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
58465845|NCT06639594|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
58465846|NCT02300207|DEVICE|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
58465847|NCT04880980|DRUG|Terbinafine Pill|Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
58465848|NCT04880980|DRUG|Itraconazole capsule|Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
58465849|NCT03987035|DEVICE|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
58465850|NCT03646604|DRUG|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
58465851|NCT06595602|DEVICE|Artificial intelligence based decision support system (AI-DSS); software|"The device is intended for monitoring and recommending ventilator settings, ventilation mode to qualified Intensive Care Unit (ICU) health care professionals (HCP). This is for medical indications that require invasive mechanical ventilation of the respiratory system in the ICU under international / EU guidelines.~The device receives clinical data via the ICU's data integration platform that includes patient physical and demographic data as well as current vital signs, ventilation parameters, blood gas analysis, general blood laboratory reports, fluid balance and medication. Prediction models based on artificial intelligence algorithms are used to deduce therapy suggestions from received data. The algorithm is carried out on a secured cloud platform."
58465852|NCT06178419|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
58465853|NCT06178419|DEVICE|sham-RIC|Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
58465854|NCT04962776|DRUG|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
58465855|NCT04962776|DRUG|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
58465856|NCT04962776|OTHER|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
58465857|NCT06704412|BEHAVIORAL|floss band|"The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
58465858|NCT06704412|BEHAVIORAL|Sham (No Treatment)|The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
58465859|NCT03379818|BEHAVIORAL|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
58465860|NCT03379818|BEHAVIORAL|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
58465861|NCT05292586|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
58465862|NCT05292586|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
58465863|NCT05089019|DRUG|Selpercatinib|Administered orally
58465864|NCT05259566|BEHAVIORAL|menthol ban in cigarettes only|menthol ban in cigarettes only, menthol available in e-cigarette
58465865|NCT05259566|BEHAVIORAL|total menthol ban|menthol ban in both cigarettes and e-cigarettes
58465866|NCT03633370|OTHER|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
58465867|NCT05366335|DRUG|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
58465868|NCT05366335|DRUG|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
58465869|NCT05366335|DRUG|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
58465870|NCT05020951|OTHER|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
58465871|NCT04694534|DIAGNOSTIC_TEST|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
58465872|NCT04694534|DIAGNOSTIC_TEST|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
58465873|NCT06365879|DRUG|CMAB007|300mg, SC, Q4W
58465874|NCT06365879|DRUG|Xolair|300mg, SC, Q4W
58465875|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
58465876|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
57778002|NCT04387838|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
58130919|NCT05436756|OTHER|Biological sampling and collection|"* Biological sampling and collection:~  * whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~ * urine: 1 bottle of 30ml~* Freezing of serum after centrifugation~* Storage~* Collection of clinico-biological data on a dedicated eCRF"
58465877|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
58465878|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
58465879|NCT00868634|DRUG|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
58465880|NCT02642601|DRUG|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
58465881|NCT04757766|DRUG|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
58465882|NCT01751061|BEHAVIORAL|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
58465883|NCT01751061|OTHER|Usual care|usual ICU care
58465884|NCT06609174|DIAGNOSTIC_TEST|KardiaRx ECG Screening and AI interpretation of ECG|The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
58465885|NCT03379675|DRUG|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
58465886|NCT03379675|DRUG|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
58465887|NCT03379675|DRUG|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
58465888|NCT04531410|DIETARY_SUPPLEMENT|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
58465889|NCT04531410|DIETARY_SUPPLEMENT|oleic acid supplementation|Oils given at morning meal with extra enzymes
58465890|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
58465891|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
58465892|NCT06204679|DRUG|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
58465893|NCT06247917|DRUG|Fludarabine, Busulfan and Melphalan|Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
58465894|NCT05380973|OTHER|Short fiber resin composite|resin composite reinforced with short glass fibers
58465895|NCT05380973|OTHER|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
58465896|NCT05177510|DRUG|Mifepristone|Progestin Antagonist
58465897|NCT05177510|DRUG|Placebo|Placebo
58465898|NCT02331056|OTHER|fluid loading|"Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
58465899|NCT02331056|PROCEDURE|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
58465900|NCT02331056|PROCEDURE|thoracotomy|the patient group for scheduled open pulmonary lobectomy
58465901|NCT06512064|DIAGNOSTIC_TEST|AWARE|AWARE testing to estimate lung function and aid in disease diagnosis
58465902|NCT06704880|OTHER|rehabilitation|children in the CIMT group will RECIEVE lower limb CIMT for the non-hemiplegic limb using whole leg orthosis. Children in cross-education group will receive strengthening training for the non-hemiplegic lower limb
58465903|NCT03932903|BEHAVIORAL|ADAPTS (ADherence Assessments and Personalized Timely Support).|ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.
58465904|NCT03924661|DEVICE|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
58465905|NCT06474195|BEHAVIORAL|Cue based intervention|The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.
58465906|NCT06474195|BEHAVIORAL|Treatment as Usual|This group will not get any intervention but the usual treatment all assessments will continue
58465907|NCT00825292|PROCEDURE|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
58465908|NCT00825292|PROCEDURE|colon polyp removal|identify and remove polyp
58465909|NCT00825292|PROCEDURE|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
57778003|NCT04387838|OTHER|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
58465910|NCT02825498|DEVICE|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
58465911|NCT03485924|DIAGNOSTIC_TEST|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
58465912|NCT03485924|DIAGNOSTIC_TEST|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
58465913|NCT05351749|BEHAVIORAL|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
58465914|NCT05351749|BEHAVIORAL|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
58465915|NCT05351749|BEHAVIORAL|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
57778004|NCT02947607|PROCEDURE|Colon biopsies|
57778005|NCT05811429|OTHER|Aerobic exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
58465916|NCT05351749|BEHAVIORAL|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
58465917|NCT04575194|DRUG|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
58465918|NCT04575194|DRUG|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
58465919|NCT00003994|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
58465920|NCT00003994|DRUG|cisplatin|Given IV
58465921|NCT00003994|DRUG|vincristine sulfate|Given IV
58465922|NCT00003994|DRUG|fluorouracil|Given IV
58465923|NCT00003994|DRUG|amifostine trihydrate|Given IV
58465924|NCT00003994|DRUG|carboplatin|Given IV
58465925|NCT05748873|DRUG|SPVN06|AAV-RdCVF-RdCVFL
58465926|NCT04373902|PROCEDURE|Physiological-based cord clamping|See 'Arm'
58465927|NCT02943174|BEHAVIORAL|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
58465928|NCT02943174|OTHER|Treatment as Usual (TAU)|Standard personalized treatment of cancer
58465929|NCT00548665|DEVICE|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
58465930|NCT00548665|BEHAVIORAL|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
58465931|NCT05915806|DIETARY_SUPPLEMENT|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
58465932|NCT05915806|DIETARY_SUPPLEMENT|Control|Control with no or low-dose DHA.
58465933|NCT04026113|DRUG|Linaclotide|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
58465934|NCT04026113|DRUG|Placebo|Matching placebo
58465935|NCT06705790|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training 5x/week for 12-weeks
58465936|NCT06705322|DRUG|Cnidium Monnieri Detoxification Formula|"Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment."
58465937|NCT01660971|DRUG|Dasatinib|Given PO
58465938|NCT01660971|DRUG|Erlotinib Hydrochloride|Given PO
58465939|NCT01660971|DRUG|Gemcitabine Hydrochloride|Given IV
58465940|NCT03071120|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
58465941|NCT03892200|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.
58465942|NCT05523765|DRUG|Brepocitinib|Oral Brepocitinib
58465943|NCT06253351|DEVICE|Hybrid closed loop (HCL)|"* Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6"
58465944|NCT06131255|DRUG|Citalopram|Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
58465945|NCT05182086|OTHER|Group physical therapy and dietary improvements|20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
57778006|NCT05811429|OTHER|Pilates exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
57778007|NCT06330636|OTHER|D-Allulose|Test breakfast
58465946|NCT06704373|OTHER|thoracal manipulation|Thoracal manipulation will be applied only one session.
58465947|NCT06704373|OTHER|Exercise|Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.
58465948|NCT00698854|DEVICE|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
58465949|NCT00698854|DEVICE|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
58465950|NCT04165070|BIOLOGICAL|Pembrolizumab|IV infusion
58465951|NCT04165070|DRUG|Carboplatin|IV infusion
58465952|NCT04165070|DRUG|Paclitaxel|IV infusion
58465953|NCT04165070|DRUG|Pemetrexed|IV infusion
58465954|NCT04165070|BIOLOGICAL|Vibostolimab|IV infusion
58465955|NCT04165070|BIOLOGICAL|Boserolimab|IV infusion
58465956|NCT04165070|BIOLOGICAL|MK-4830|IV infusion
58465957|NCT04165070|BIOLOGICAL|MK-0482|IV Infusion
58465958|NCT04165070|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
58465959|NCT04165070|BIOLOGICAL|HER3-DXd|IV Infusion
58465960|NCT06245941|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
58465961|NCT06245941|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
58465962|NCT05206734|OTHER|Exposure of mental health condition|"Primary:~Composite of all chronic psychological conditions (depression, anxiety, eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorder, acute stress disorder, and post-traumatic stress disorder).~Major recurrent depression or treated depressive episode. Non-phobia related anxiety episode or disorder.~Secondary:~Self-harm, suicide attempt or suicide related codes, other chronic psychiatric conditions (eating disorders, body image disorders, attention-deficit disorder, behavioural disorders, adjustment disorders, acute stress disorder, schizophrenia, bipolar disorder and post-traumatic stress disorder. Problems with sleep."
58465963|NCT03735303|DIETARY_SUPPLEMENT|VD3 group|VD3 50000 IU/ week for 8 weeks
58465964|NCT03735303|DIETARY_SUPPLEMENT|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
58465965|NCT03735303|DIETARY_SUPPLEMENT|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
58465966|NCT03735303|OTHER|control group|no intervention was given
58465967|NCT05351944|BEHAVIORAL|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
58465968|NCT05351944|DRUG|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
58465969|NCT05892432|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
58465970|NCT05892432|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
58465971|NCT05892432|DRUG|Placebo|A medically inert placebo medication will be taken for 8 weeks.
58465972|NCT05363267|DIETARY_SUPPLEMENT|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
58465973|NCT06579768|DIAGNOSTIC_TEST|different types of computed tomography (CT) scans|For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
58465974|NCT06272240|OTHER|Ovarian Cancer Organoids|To characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
58465975|NCT05829694|OTHER|Parental Status|The aim of the study is to assess the impact parenthood has on health outcomes.
58465976|NCT05558696|DRUG|Bomedemstat|Oral tablet
58465977|NCT05672784|PROCEDURE|GNB plus standard analgesia|When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
58465978|NCT05672784|PROCEDURE|GNB plus IPACK block plus standard analgesia|IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
58465979|NCT05672784|DRUG|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
58465980|NCT04448002|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
58465981|NCT04448002|BEHAVIORAL|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
58465982|NCT06231381|DRUG|HB0034|Anti-IL-36R antibody
58465983|NCT06231381|OTHER|Placebo|non-biologically active drug
58465984|NCT05609565|DRUG|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
58465985|NCT05609565|DRUG|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
58465986|NCT06663670|OTHER|Intraneural Facilitation Therapy|"* The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure."
58465987|NCT06663670|OTHER|Nerve Flossing Technique|"Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload."
58465988|NCT06551272|DRUG|EXL01|EXL01 contains an unmodified single strain of F. prausnitzii
58465989|NCT04232319|BEHAVIORAL|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
58465990|NCT04474470|DRUG|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
57778008|NCT06330636|OTHER|Sodium Saccharin|placebo breakfast
58465991|NCT04474470|DRUG|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
58465992|NCT04474470|DRUG|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
58465993|NCT06706206|OTHER|Observational trial|"Observational clinical trial. Participants will undergo cardiovascular risk assessment (clinical and blood tests) and coronary CT angiogram.~These results will be compared to a control population without haemophilia (recruited as part of a different clinical trial)."
58465994|NCT05871541|BIOLOGICAL|JCXH-105|As IM injection
58465995|NCT05871541|BIOLOGICAL|Active Control (Shingrix)|As IM injection
58465996|NCT05154773|BEHAVIORAL|Kidney donation and transplant information made easy|Same as arm description
58465997|NCT01451606|DRUG|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
58465998|NCT01451606|DRUG|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
58465999|NCT05025787|DRUG|CNTX-6970|CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
58466000|NCT05025787|DRUG|Placebo|BID
58466001|NCT05961839|DRUG|SGR-2921|SGR-2921 will be administered orally.
58466002|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
58466003|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
58466004|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
58466005|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
58466006|NCT05682625|OTHER|No intervention|No intervention
58466007|NCT02944110|DRUG|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
58466008|NCT02944110|DRUG|Placebo|Oral dose of placebo tablets
57778009|NCT00469365|BEHAVIORAL|pharmacist contact with the patient via telephone|
57778010|NCT00469365|BEHAVIORAL|Pharmacist contact with the patient's physician via fax|
57778011|NCT00469365|BEHAVIORAL|Usual care|
58466009|NCT06311864|DRUG|Daridorexant 50 mg|As indicated by the physician
58466010|NCT05466422|BIOLOGICAL|MK-2214|MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57
58466011|NCT05466422|DRUG|Placebo|Placebo as an IV infusion on Days 1, 29, and 57
58466012|NCT06591169|BEHAVIORAL|diet restriction and exercise|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes
58466013|NCT06591169|BEHAVIORAL|diet restriction|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily) and program of low diet intake
58466014|NCT02145143|DRUG|Vemurafenib|
58466015|NCT02145143|DEVICE|serial 124I PET/CT|
58466016|NCT02145143|DRUG|thyrotropin alpha|
57778012|NCT03017989|DEVICE|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
57778013|NCT06233123|BEHAVIORAL|the Medisafe android application (https://www.medisafe.com).|software for Android mobile phones that can remind the patient of his treatment on time
57778014|NCT03188900|BIOLOGICAL|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
57778015|NCT01150578|DRUG|No intervention|No intervention
57778016|NCT02264496|BEHAVIORAL|Exercise|
58466017|NCT04930445|DRUG|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
58466018|NCT06296953|DEVICE|PERIsign examination|Patients will be examined with the new device, PERIsign
58466019|NCT04737616|DEVICE|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
58466020|NCT04737616|DEVICE|OCT|Optical coherence tomography endoscope
58466021|NCT03041038|DRUG|Secukinumab|Anti IL-17A antibody
58466022|NCT03041038|DRUG|Placebo|
58466023|NCT04231773|DRUG|Nitric Oxide|40 parts per million dosage
58466024|NCT04231773|DRUG|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
58466025|NCT05323253|DEVICE|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
58466026|NCT04529083|DEVICE|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
58466027|NCT05428501|OTHER|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
58466028|NCT00054886|DRUG|SU-011,248|
58466029|NCT03559114|DRUG|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
58466030|NCT03559114|DRUG|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
58466031|NCT06074835|DEVICE|Gamete preparation, ICSI, embryo culture and vitrification robot assistant|Patients undergoing an assisted conception treatment with medical indication to perform ICSI may be recruited in this study. The study will follow a sibling-oocyte and/or sibling embryo study design where oocytes and/or embryos obtained from a specific patient or couple will be randomly distributed across two groups (test and control) and undergo one or more elements of an automated assisted conception laboratory workflow (for the test group) or a standard assisted conception laboratory workflow (for the control group). Before distributing the samples, an embryologist will slightly blur the vision of the samples so that their morphology can no longer be clearly assessed. Robotic automation may include any of the following steps: robotic sperm preparation, robotic oocyte selection and denudation, robotic sperm injection, automated embryo culture, and automated cryopreservation. The resulting embryos may be employed for embryo transfer.
58466032|NCT06074835|OTHER|Routine Manual ICSI Workflow|Routine Manual Icsi Workflow
58466033|NCT03840317|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
58466034|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
58466035|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
58466036|NCT04887558|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
58466037|NCT06550934|PROCEDURE|Fracture stabilization|isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
58466038|NCT06554574|DRUG|LTG-305|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
58466039|NCT03497676|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
58466040|NCT03497676|DRUG|Oral Rilpivirine (RPV)|25 mg tablets administered orally
58466041|NCT03497676|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
58466042|NCT03497676|DRUG|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
58466043|NCT03497676|DRUG|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
58466044|NCT03960827|OTHER|EE Training|Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
57778017|NCT03053674|OTHER|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
58466045|NCT03960827|OTHER|RE Training|Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
58466046|NCT06705387|BIOLOGICAL|Dupilumab|Subcutaneous injection of 300mg per week for 16 weeks.
57778018|NCT03053674|OTHER|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
57778019|NCT03650595|DEVICE|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy"
57778020|NCT00259376|DRUG|Dronedarone (SR33589)|oral administration
58466047|NCT06705387|DRUG|Fluticasone|Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
58466048|NCT04965623|DEVICE|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
58466049|NCT05616624|DRUG|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
58466050|NCT05616624|DRUG|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
58466051|NCT05616624|DRUG|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
58466052|NCT03291535|OTHER|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
58466053|NCT03291535|OTHER|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
58466054|NCT06586073|OTHER|cosmetic products|All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream.
58466055|NCT04672239|BEHAVIORAL|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
58466056|NCT04672239|BEHAVIORAL|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
58466057|NCT04672239|BEHAVIORAL|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
58466058|NCT04265963|BIOLOGICAL|CD123 CAR-T cells|CD123 CAR-T cell therapy
58466059|NCT06652243|BIOLOGICAL|SN301A|"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."
58466060|NCT02010892|PROCEDURE|Stent Grafting (ESR)|
58466061|NCT02010892|PROCEDURE|Open Surgery (OSR)|
58466062|NCT05739981|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV
58466063|NCT05739981|DRUG|Carboplatin|Carboplatin AUC 5-6 IV
58466064|NCT05739981|DRUG|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
58466065|NCT05739981|DRUG|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
58466066|NCT04405791|PROCEDURE|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
58466067|NCT02333435|DIETARY_SUPPLEMENT|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
58466068|NCT02333435|DIETARY_SUPPLEMENT|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
58466069|NCT04721223|DRUG|JAB-3068|JAB-3068 administrated orally as a tablet.
58466070|NCT04721223|DRUG|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
58466071|NCT06453044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58466072|NCT06453044|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58466073|NCT06453044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58466074|NCT06453044|BIOLOGICAL|Mosunetuzumab|Given SC
58466075|NCT06453044|DRUG|Polatuzumab Vedotin|Given IV
58466076|NCT06453044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58466077|NCT06453044|OTHER|Questionnaire Administration|Ancillary Studies
58466078|NCT04014829|DIAGNOSTIC_TEST|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
58466079|NCT04014829|DIAGNOSTIC_TEST|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
58466080|NCT04014829|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
58466081|NCT04014829|DIAGNOSTIC_TEST|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
58466082|NCT04014829|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
58466083|NCT04014829|DIAGNOSTIC_TEST|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
58466084|NCT04014829|DIAGNOSTIC_TEST|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
58466085|NCT04014829|DIAGNOSTIC_TEST|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
58466086|NCT04014829|DIAGNOSTIC_TEST|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
58466087|NCT04014829|DIAGNOSTIC_TEST|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
58466088|NCT04014829|DIAGNOSTIC_TEST|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
58466089|NCT01351909|DRUG|Cyclophosphamide|Given PO
58466090|NCT01351909|OTHER|Laboratory Biomarker Analysis|Correlative studies
58466091|NCT01351909|DRUG|Veliparib|Given PO
58466092|NCT06392165|OTHER|self-adhesive device|Test device which is self-adhesive
58466093|NCT05863052|BIOLOGICAL|Immunotherapy|immunotherapy
58466094|NCT05595148|PROCEDURE|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
58466095|NCT05595148|OTHER|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
58466096|NCT01715181|OTHER|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
58466097|NCT05696236|DEVICE|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
58466098|NCT05696236|DEVICE|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
58466099|NCT06517082|OTHER|Artificial Intelligence|Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.
58466100|NCT02538510|OTHER|Laboratory Biomarker Analysis|Correlative studies
58466101|NCT02538510|BIOLOGICAL|Pembrolizumab|Given IV
58466102|NCT02538510|DRUG|Vorinostat|Given PO or via PEG
58466103|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
58466104|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
58466105|NCT03011008|DRUG|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
58466106|NCT03011008|DRUG|Insulin|Receive insulin following clinician's instruction.
58466107|NCT05157386|OTHER|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
58466108|NCT00379015|BIOLOGICAL|trastuzumab|
58466109|NCT00379015|DRUG|cyclophosphamide|
58466110|NCT00379015|DRUG|docetaxel|
57778021|NCT00259376|DRUG|placebo|oral administration
58466111|NCT00379015|DRUG|epirubicin hydrochloride|
58466112|NCT00379015|PROCEDURE|conventional surgery|
58466113|NCT00379015|PROCEDURE|neoadjuvant therapy|
58466114|NCT06518954|OTHER|Interview|The athletes contributes with experience exchange through individual interviews, following a interview template
58466115|NCT06506253|OTHER|Swedish Massage Therapy|Touch therapy
58466116|NCT06506253|OTHER|Light Touch Therapy|Touch therapy
58466117|NCT00771758|DRUG|oxycodone IR|maximum daily dose 450 mg
58466118|NCT00771758|DRUG|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
58466119|NCT00771758|DRUG|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
58466120|NCT05163041|DRUG|BT7480|Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
58466121|NCT05163041|DRUG|Nivolumab|Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
58466122|NCT02859922|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
58466123|NCT02859922|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
58466124|NCT00383786|DRUG|NK1 Antagoist (GR205171)|
58466125|NCT00383786|PROCEDURE|Psychophysiology (Trauma Script)|
58466126|NCT00383786|PROCEDURE|Psychophysiology (Verbal Threat)|
58466127|NCT00383786|PROCEDURE|Psychophysiology (Fear Conditioning)|
58466128|NCT00383786|PROCEDURE|Psychophysiology (Affective Modulation)|
58466129|NCT00383786|PROCEDURE|Psychophysiology (Heart rate variability)|
58466130|NCT00383786|PROCEDURE|Lumbar Puncture|
57778022|NCT04124874|OTHER|There will be no intervention|There will be no intervention
58466131|NCT00383786|PROCEDURE|24-hour plasma sampling|
58466132|NCT00383786|PROCEDURE|MRI|
58466133|NCT02375854|OTHER|Observation|
58466134|NCT02910817|DRUG|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
58466135|NCT02910817|OTHER|Placebo|Placebo
58466136|NCT05862766|DRUG|Isatuximab|The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.
58466137|NCT05862766|PROCEDURE|bone marrow biopsy|Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
58466138|NCT03317860|DEVICE|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
58466139|NCT03317860|DEVICE|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
58466140|NCT06706635|DEVICE|Application of App|Full Access to Mobile App
58466141|NCT03084211|OTHER|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
58466142|NCT06256185|PROCEDURE|esophagectomy|Resection of esophageal tumor and lymph node dissection
58466143|NCT06706648|BEHAVIORAL|Nursing-Led Psychological Capital Interventions|The participating nurses received session about Nursing-Led Psychological Capital Interventions
58466144|NCT05531656|DRUG|CT1812|Study Drug
58466145|NCT05531656|DRUG|Placebo|Non-active study drug
58466146|NCT05600543|DEVICE|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
58466147|NCT06031727|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
58466148|NCT03433651|DRUG|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
58466149|NCT03433651|DRUG|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
58466150|NCT05414500|DRUG|Mogamulizumab|Administered IV
58466151|NCT05414500|DRUG|Brentuximab vedotin|Administered IV
57778023|NCT00671996|DRUG|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
58466152|NCT06124807|DRUG|LY3305677|Administered SC
58466153|NCT06124807|DRUG|Placebo|Administered SC
58466154|NCT05198869|DEVICE|Spectral scan|Consenting participants will have a SpotLight-19 scan
57778024|NCT00671996|DRUG|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
57778025|NCT05409274|OTHER|No Intervention|No Intervention
58466155|NCT01277016|DRUG|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
58466156|NCT04798183|DIAGNOSTIC_TEST|3-dimensional scan|Facial 3-dimensional scan according to posture
58466157|NCT03550027|DEVICE|PleurX|Positioning of drainage PleurX
58466158|NCT03550027|DEVICE|Pleurocath|Positioning of drainage Pleurocath
58466159|NCT06537817|DRUG|HT-4253|HT-4253 Single or Multiple doses administered orally as a tablet
58466160|NCT06537817|DRUG|Placebo|Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
58466161|NCT01436149|DRUG|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
58466162|NCT01436149|DRUG|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
57778026|NCT03398915|PROCEDURE|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
57778027|NCT01189890|DRUG|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
58466163|NCT04829292|BEHAVIORAL|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
58466164|NCT01024517|DRUG|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
58466165|NCT01024517|DRUG|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
58466166|NCT02365649|DRUG|Placebo|Oral Dosing
58466167|NCT02365649|DRUG|ABT-494|Oral Dosing
58466168|NCT05099302|OTHER|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
58466169|NCT06705205|OTHER|SAS video|The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.
58466170|NCT06705582|OTHER|Fortified Bread|Intervention group will be supplied with fortified bread delivering 10 -15 μg (400-600 IU) vitamin D3 in a daily portion and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
58466171|NCT06705582|OTHER|Unfortified bread|Placebo control group will be supplied with unfortified bread and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
58466172|NCT02190526|DRUG|Mesalazine(asacol 800 mg)|
58466173|NCT02190526|DRUG|Amitriptyline|
58466174|NCT02190526|DRUG|placebo like asacol|
58466175|NCT02190526|DRUG|placebo like amitriptyline|
58466176|NCT05972278|DRUG|Obicetrapib|1 tablet daily
58466177|NCT06705127|DRUG|TORIPALIMAB INJECTION(JS001 )|"Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles."
58466178|NCT06705127|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
58466179|NCT05823116|DRUG|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
58466180|NCT05823116|DRUG|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
58466181|NCT06204965|BEHAVIORAL|Time-restricted eating|Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
58466182|NCT03710187|DRUG|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
58466183|NCT02991469|DRUG|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
58466184|NCT05975827|DEVICE|Sterile Wound Care Liquid Dressing|Sterile wound care liquid dressing is used in the wound treatment
58466185|NCT06108232|DRUG|Obinutuzumab|Given by IV (vein)
58466186|NCT06108232|DRUG|CC-99282|Given by PO
58466187|NCT02064803|PROCEDURE|Gastro-entero anastomosis only|Gastro-entero anastomosis only
58466188|NCT02064803|PROCEDURE|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
58466189|NCT04223115|BEHAVIORAL|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
58466190|NCT04223115|OTHER|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
58466191|NCT05906953|DRUG|HG004|Low dose Medium dose High dose
58466192|NCT04590274|DRUG|Hydroxychloroquine|Hydroxychloroquine
58466193|NCT04590274|DIETARY_SUPPLEMENT|Vitamins and Minerals|elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
58466194|NCT04590274|DRUG|Azithromycin|Azithromycin
58466195|NCT04419025|DRUG|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
58466196|NCT05542069|DEVICE|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
58466197|NCT03305614|PROCEDURE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
58466198|NCT03305614|PROCEDURE|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
58466199|NCT06413576|DIAGNOSTIC_TEST|homocysteine measurement|measuring the serum level of homocysteine
58466200|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
58466201|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
58466202|NCT06256458|DEVICE|NanoBone® Bone Graft|The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.
58466203|NCT05673928|DRUG|Trastuzumab emtansine|Given by IV (vein)
58466204|NCT05673928|DRUG|Tucatinib|Given by PO
58466205|NCT06399900|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
58490675|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
58466206|NCT06399900|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
58466207|NCT06399900|BEHAVIORAL|Home-based walking exercise|This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
58466208|NCT04337177|DRUG|VAL-413|a flavored preparation of orally administered irinotecan
58466209|NCT04337177|DRUG|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
58466210|NCT06699927|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
58466211|NCT00754663|BEHAVIORAL|exercise training|walking training at least 3 times a week
58466212|NCT06705660|OTHER|WEB-based progressive relaxation training|"WEB-based progressive relaxation training will be given for 8 weeks, 2 days a week for 30-45 minutes (16 sessions), following the menstrual cycles of women. Measurements will be taken before and after (at the end of) the intervention. Measurements will be taken 4 weeks after the next menstrual cycle to ensure follow-up.~Progressive relaxation training is an easy-to-learn, non-invasive and side-effect free method. PGE beginners will be trained for at least 30 minutes and practitioners who have learned the basics of the method will be trained to introduce PGE for 15 minutes. Prior to the PGE, individuals will be informed that they should not come overly hungry or overly full (eating should be finished 2 hours before), wear loose and comfortable clothes, avoid clothes that tightly wrap the abdomen (pants, dresses, belts), remove contact lenses, glasses, jewelry and tight shoes. PGE will be administered in a quiet, comfortable and dimly lit place. Women will perform PCI in the supine posit"
58466213|NCT06705660|OTHER|The WEB-based lifestyle interventions|The WEB-based lifestyle interventions will be administered to women by monitoring their menstrual cycles for 8 weeks, with sessions held twice a week for 30-45 minutes each (totaling 16 sessions). Measurements will be taken both before the intervention and after its completion. An additional measurement will be conducted during the following menstrual cycle, 4 weeks later, to ensure follow-up.In this study, telehealth and counseling services will be provided. Through telehealth and counseling, women will have the opportunity to communicate online with healthcare professionals and receive guidance on health goals, nutrition, exercise, and stress management
58466214|NCT01968447|OTHER|hypocapnia|Hyperventilation to the level of hypocapnia
58466215|NCT01968447|OTHER|normocapnia|Normal ventilation to the level of nromocapnia
58466216|NCT06018350|BEHAVIORAL|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
58466217|NCT02101775|DRUG|Adavosertib|Given PO
58466218|NCT02101775|DRUG|Gemcitabine Hydrochloride|Given IV
57778028|NCT01189890|DRUG|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
57778029|NCT01189890|DRUG|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
58466219|NCT02101775|OTHER|Laboratory Biomarker Analysis|Correlative studies
58466220|NCT02101775|OTHER|Pharmacological Study|Correlative studies
58466221|NCT02101775|OTHER|Placebo Administration|Given PO
58466222|NCT02101775|OTHER|Questionnaire Administration|Ancillary studies
58466223|NCT00684866|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
58466224|NCT00684866|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
58466225|NCT05856422|DEVICE|Respiratory rate measure based on PPG|"Testing was conducted under normal office environment conditions. Each subject was connected to the reference EtCO2 monitor (GE Datex-Ohmeda) and the Device Under Test, the Gabi SmartCare Gabi Band. A waveform collected from an EtCO2 measurement was used to determine performance of respiratory rate metrics. Each subject was given a nasal cannula that allowed for measurement of the EtCO2 respiratory rate.~The reference respiratory rate was measured simultaneously with the Device Under Test. Data was marked for stable quiet periods that were useable for analysis."
58466226|NCT04462640|OTHER|Management of Infant Digestive Disorders and Quality of Life|The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
58466227|NCT05676203|DRUG|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
57778030|NCT01189890|DRUG|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
57778031|NCT03086824|DEVICE|magnetic resonance-guided focused ultrasound|
57778032|NCT05372887|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
57778033|NCT05372887|DRUG|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
57778034|NCT04089774|BEHAVIORAL|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
57778035|NCT04138030|PROCEDURE|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
57778036|NCT04138030|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
58466228|NCT05676203|DRUG|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
58466229|NCT05676203|DRUG|Docetaxel|Docetaxel
58466230|NCT06435663|OTHER|Different methods of efficacy evaluation|When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
58466231|NCT04291547|DEVICE|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
58466232|NCT05537883|DRUG|Liposomal bupivacaine|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
58466233|NCT05537883|DRUG|Bupivacaine Injection|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
58466234|NCT05635344|DRUG|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
58466235|NCT06601413|OTHER|M-TAPA Block|M-TAPA block will administer ultrasound guided (Sonosite, Inc., Bothell, WA, USA) bilaterally by same anesthesiologist (E.E.) who had more than 10 years experience of regional anesthesia, before weaking from general anesthesia after the surgical procedure. A high-frequency (6-13 MHz) linear probe (HFL38) will be used to identify the transversus abdominis, internal oblique, and external oblique muscles on the costochondral angle in the sagittal plane at the 10th costal margin. In the midclavicular line, between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue, at the level of the 10th rib, 20 mL of 0.25 percent bupivacaine will be injected (arcus costarum). The same procedure will be followed on the other side.
58466236|NCT06601413|OTHER|Trocar site local anesthetic infiltration|At the end of surgery, infiltration analgesia will be applied to all trocar entry sites (4 port entries) by the surgeon with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
58466237|NCT01901445|BEHAVIORAL|Educational action with focal group|
58466238|NCT06555406|BEHAVIORAL|Time-restricted eating for 8 weeks|limiting food intake to 10 hours per day
58466239|NCT00915954|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
58466240|NCT00915954|DIAGNOSTIC_TEST|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
58466241|NCT00915954|DIAGNOSTIC_TEST|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
58466242|NCT00352768|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
58466243|NCT00352768|DRUG|Placebo|Placebo
58466244|NCT02918370|DRUG|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
58466245|NCT02918370|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
58466246|NCT05764525|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
57778037|NCT01478815|BEHAVIORAL|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
57778038|NCT01478815|OTHER|Standard Care|Standard Care
57778039|NCT01799720|DIETARY_SUPPLEMENT|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
58466247|NCT05764525|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
58466248|NCT00010816|DRUG|Herbal remedies|
58466249|NCT02539823|DRUG|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
58466250|NCT02539823|DRUG|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
57778040|NCT01799720|DIETARY_SUPPLEMENT|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
57778041|NCT01799720|DRUG|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
57778042|NCT03555604|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
57778043|NCT03511079|BEHAVIORAL|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
58466251|NCT02539823|DRUG|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
58466252|NCT04078841|DIETARY_SUPPLEMENT|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
58466253|NCT04078841|OTHER|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
58466254|NCT02202122|OTHER|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
58466255|NCT02133495|PROCEDURE|Non Cadaveric Human Acellular Dermal Tissue|
58466256|NCT02673372|DRUG|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
58466257|NCT02673372|DRUG|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
57778044|NCT04103554|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
57778045|NCT04103554|DRUG|Standard of care|standard of care used for treating BP
58466258|NCT05876078|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
58466259|NCT00002682|DRUG|Amoxicillin|
58466260|NCT00002682|DRUG|Bismuth Subsalicylate|
58466261|NCT00002682|DRUG|Clarithromycin|
58466262|NCT00002682|DRUG|Metronidazole Hydrochloride|
58466263|NCT00002682|DRUG|Omeprazole|
58466264|NCT00002682|DRUG|Tetracycline Hydrochloride|
58466265|NCT06147843|OTHER|Blood sample|Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss
58466266|NCT04841447|OTHER|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
58466267|NCT04197934|PROCEDURE|Biospecimen Collection - blood samples|Undergo collection of blood samples
58466268|NCT04197934|PROCEDURE|Biospecimen Collection - CSF samples|Undergo collection of CSF samples
58466269|NCT04197934|PROCEDURE|Computed Tomography|Undergo CT
58466270|NCT04197934|DRUG|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
58466271|NCT04197934|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58466272|NCT04197934|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
58466273|NCT03210558|DRUG|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
58466274|NCT03210558|DRUG|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
58466275|NCT06499844|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
57778046|NCT03171168|DEVICE|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
57778047|NCT03171168|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
57778048|NCT03993405|OTHER|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
57778049|NCT01918293|DEVICE|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
57778050|NCT06450587|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP)
57778051|NCT06450587|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
57778052|NCT06450587|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
57778053|NCT06450587|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
58466276|NCT01149850|BIOLOGICAL|bevacizumab|Given IV
58466277|NCT01149850|DRUG|temozolomide|Given orally
58466278|NCT01149850|OTHER|laboratory biomarker analysis|Correlative studies
58466279|NCT01149850|OTHER|immunohistochemistry staining method|Correlative studies
58466280|NCT01149850|GENETIC|microarray analysis|Correlative studies
58466281|NCT01149850|GENETIC|DNA methylation analysis|Correlative studies
58466282|NCT04696757|DRUG|Capecitabine|Capecitabine without surgery
58466283|NCT06396039|DRUG|BMS-986374|Specified dose on specified days.
58466284|NCT05176899|DEVICE|Use of Eko CORE electronic stethoscope|Recording of heart sounds using electronic stethoscope
58466285|NCT06470308|OTHER|Medication Reviews and Deprescribing|General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria and STOPP/START criteria.
58466286|NCT04768504|DRUG|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
58466287|NCT03534804|DRUG|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
58466288|NCT03534804|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
58466289|NCT02196896|OTHER|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
58466290|NCT02196896|OTHER|Information|The patients receive online information about depression once a week for 90 days.
58466291|NCT02913339|OTHER|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
58466292|NCT01095185|DRUG|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
58466293|NCT01095185|DRUG|Placebo|Simvastatin placebo
58466294|NCT01740167|BEHAVIORAL|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
58466295|NCT01964651|DRUG|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
58466296|NCT01964651|DRUG|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
58466297|NCT01964651|DRUG|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
58466298|NCT01964651|DRUG|Placebo|Matching placebo orally administered once daily for 10 days.
58466299|NCT05924984|DEVICE|perforator locator|During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
58466300|NCT00642200|PROCEDURE|Lichtenstein hernioplasty|
58466301|NCT00642200|PROCEDURE|Laparoscopic TEP|
58466302|NCT02443467|OTHER|No intervention|
58466303|NCT01611714|OTHER|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
58466304|NCT01611714|OTHER|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
58466305|NCT06114615|DEVICE|LiveCare|Patient use LiveCare device to monitor their blood pressure and data is transmitted to dashboard.
58466306|NCT06114615|BEHAVIORAL|Text Messages|Patients also receive text messages after their PCI procedure for follow up appointment reminders, enrollment in cardiac rehab, and diet and exercise counseling.
58466307|NCT06114615|OTHER|Conventional Care|No digital monitoring with LiveCare device and no text messages.
58466308|NCT05005260|DRUG|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
58466309|NCT05005260|DRUG|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
58466310|NCT06538480|DRUG|PRGN-2012|PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
58466311|NCT04426422|DRUG|Metformin Hydrochloride|treated with metformin 1500-2000mg daily
58466312|NCT00836368|DIETARY_SUPPLEMENT|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
58466313|NCT06356922|DRUG|Experimental drug [177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
58466314|NCT04904692|PROCEDURE|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
58466315|NCT04904692|PROCEDURE|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
58466316|NCT04904692|PROCEDURE|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
58466317|NCT05941793|DRUG|MBS-COV|MBS-COV for inhalation
57778054|NCT01875861|OTHER|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
58466318|NCT05941793|DRUG|Placebo|Placebo for inhalation
58466319|NCT04372017|DRUG|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
57778055|NCT00724425|DRUG|IPI-493|Capsules, Multiple Schedules
57778056|NCT00912821|DRUG|6 L dialysate|6 L peritoneal dialysis solution
58466320|NCT04372017|DIETARY_SUPPLEMENT|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
57778057|NCT00912821|DRUG|8 L dialysate|8 L peritoneal dialysis solution
57778058|NCT00818415|DRUG|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
58466321|NCT03183453|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
58466322|NCT04441307|BEHAVIORAL|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
58466323|NCT04441307|BEHAVIORAL|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
58466324|NCT02018562|DEVICE|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
58466325|NCT03074409|DRUG|oxytocin|self-administration of oxytocin (nasal spray)
58466326|NCT03074409|DRUG|placebo|self-administration of placebo (nasal spray)
58466327|NCT05955898|BEHAVIORAL|Parents THRIVE|Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.
58466328|NCT05955898|BEHAVIORAL|Sharing Feelings Project|Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
58466329|NCT05198921|DEVICE|repetitive Transcranial Magnetic Stimulation|"To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds"
58466330|NCT05198921|DEVICE|sham repetitive Transcranial Magnetic Stimulation|Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
58466331|NCT04583280|DRUG|Rilematovir|Participants of age group greater than or equal to (\>=) 28 days to less than (\<) 3 months (age group 1) or \>= 3 months to \< 6 months (age group 2) or \>= 6 months to less than or equal to (\<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.
58466332|NCT04583280|DRUG|Rilematovir X mg/kg|Participants of age group birth at term (after at least 37 weeks of gestation) to \< 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.
58466333|NCT04583280|DRUG|Placebo|Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
58466334|NCT06705088|DRUG|SUVN-I6107|SUVN-I6107 Tablet
58466335|NCT06705088|DRUG|Placebo|A look-alike tablet with no active ingredient.
58466336|NCT06002620|DIETARY_SUPPLEMENT|CSB+|standard care
58466337|NCT06002620|DIETARY_SUPPLEMENT|Enriched nutrition food (CEF)|enriched cricket flour at 20%
58466338|NCT06002620|BEHAVIORAL|Nutrition education|regular videos, sms reminders and face to face interaction
58466339|NCT06002620|COMBINATION_PRODUCT|Combined nutrition and education|combined enriched cricket flour and nutrition education
58466340|NCT02044354|DRUG|Taxotere|
58466341|NCT02044354|DRUG|Jevtana|
58466342|NCT05975671|BEHAVIORAL|Multifaceted de-implementation strategy to reduce vancomycin overuse|"* Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
58466343|NCT04244448|DRUG|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
58466344|NCT04244448|DRUG|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
58466345|NCT04244448|DRUG|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
58466346|NCT04160182|BEHAVIORAL|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
58466347|NCT03181022|BEHAVIORAL|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
58466348|NCT06600555|PROCEDURE|metabolic surgery with SLEEVE technique|metabolic surgery with SLEEVE technique
57778059|NCT00818415|DRUG|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
57778060|NCT04842396|OTHER|Experimental:Motorized cycle ergometer|Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
58466349|NCT06600555|PROCEDURE|metabolic surgery with BY-PASS technique|metabolic surgery with BY-PASS technique
58466350|NCT06705075|DRUG|Perfluten|Use of UCA Definity to evaluate uterine fibroids by contrast-enhanced ultrasound (CEUS) and subharmonic-aided pressure estimation (SHAPE) pre and post-uterine artery embolization (UAE).
58466351|NCT03572504|OTHER|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
58466352|NCT00754962|DRUG|protriptyline|10 mg tablet
58466353|NCT00436449|DRUG|Avotermin|
57778061|NCT03587805|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
58466354|NCT04844827|GENETIC|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
58466355|NCT06159335|RADIATION|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
58466356|NCT03742076|DIETARY_SUPPLEMENT|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
58466357|NCT03742076|DIETARY_SUPPLEMENT|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
58466358|NCT03742076|DIETARY_SUPPLEMENT|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
58466359|NCT05041413|BEHAVIORAL|Moms Quit|Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
58466360|NCT05041413|BEHAVIORAL|Text4Baby|Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
58466361|NCT06705257|DIAGNOSTIC_TEST|Studying the effects of varying levels of PEEP using Electrical impedance tomography|Feasibility of using EIT, to study the effect of varying levels of PEEP/Continous distending pressure on lung recruitment as measured by changes in functional lung scores and silent spaces in preterm infants (\<32 weeks) who are on mechanical ventilation or receiving primary or post extubation CPAP support.
58466362|NCT06334432|DRUG|NUV-1511|Novel small molecule
58466363|NCT02730858|BEHAVIORAL|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
58466364|NCT02730858|BEHAVIORAL|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
58466365|NCT03954639|DRUG|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
58466366|NCT03954639|DRUG|Bupivacaine Hydrochloride|Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
58466367|NCT04829136|DIETARY_SUPPLEMENT|Kate Farms 1.0|Given enteral nutrition via nasoenteric feeding
58466368|NCT04829136|DIETARY_SUPPLEMENT|Standard of Care Nutritional Support|Given standard of care, which may be parenteral nutrition
58466369|NCT04829136|OTHER|Survey Administration|Ancillary studies
58466370|NCT04829136|DIETARY_SUPPLEMENT|Dietary Supplement|Receive fiber supplementation orally or enterally
58466371|NCT04829136|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
58466372|NCT04829136|OTHER|Electronic Health Record Review|Ancillary studies
58466373|NCT04829136|OTHER|Fiber and Dietary Assessments|Ancillary studies
58466374|NCT04388592|OTHER|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
58466375|NCT04525755|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
58466376|NCT04525755|DRUG|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
58466377|NCT06228625|BEHAVIORAL|Conventional Exercise Group|"* Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep."
58466378|NCT06228625|BEHAVIORAL|Body Awareness Training Group|"* Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing."
58466379|NCT06228625|BEHAVIORAL|Rehabilitative Game Exercise Group|"* Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge."
58466380|NCT05194124|DRUG|Setmelanotide 2 mg|Administered as SC injection
58466381|NCT05194124|DRUG|Setmelanotide 2.5 mg|Administered as SC injection
58466382|NCT05194124|DRUG|Setmelanotide 3 mg|Administered as SC injection
58466383|NCT05194124|DRUG|Setmelanotide 20 mg|Administered as SC injection
58466384|NCT05194124|DRUG|Setmelanotide 25 mg|Administered as SC injection
58466385|NCT05194124|DRUG|Setmelanotide 30 mg|Administered as SC injection
58466386|NCT00755664|DIETARY_SUPPLEMENT|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
58466387|NCT04523194|OTHER|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
58466388|NCT04736888|OTHER|extended-reality CPR training|extended-reality technologies based CPR training module
58466389|NCT04736888|OTHER|conventional CPR training|conventional CPR training with video
58466390|NCT01584869|DEVICE|capsule endoscopy|
58466391|NCT00739921|PROCEDURE|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
58466392|NCT03028233|BEHAVIORAL|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
58466393|NCT03028233|BEHAVIORAL|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
58466394|NCT06705881|OTHER|Eccentric exercise program (EEP)|All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.
58466395|NCT06705881|OTHER|ESWT (Extracorporeal Shock Wave Therapy)|ESWT is a therapy method routinely used in private and public hospitals. Tendinopathy therapy parameters approved by the International Society for Medical Shock Wave Therapy (ISMST) for focused ESWT treatment are: 0.10-0.25 mJ/mm (dosing appropriate to pain), up to a maximum of 5 Hz, 1500-2500 pulses per session, 1-2 weeks apart. Accordingly, in our study, the focused ESWT dosage of the ESWT group will be applied as; 0.10-0.25 mJ/mm (dosing appropriate to pain), 4 Hz, 2000 pulses, 1 session per week for 3 weeks. No exercise will be done on the day of ESWT.
58466396|NCT03366545|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
57778062|NCT04402593|BEHAVIORAL|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
57778063|NCT00367393|DRUG|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
58130920|NCT04012697|BEHAVIORAL|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
58466397|NCT03773978|DRUG|Baricitinib|Administered orally.
58466398|NCT03773978|DRUG|Placebo|Administered orally.
58466399|NCT02470897|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
58466400|NCT02470897|RADIATION|SBRT|Undergo moderate dose SBRT with SIB
58466401|NCT02470897|RADIATION|SBRT|Undergo uniform dose SBRT
58466402|NCT03542487|BEHAVIORAL|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
58466403|NCT03542487|BEHAVIORAL|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
58466404|NCT03542487|BEHAVIORAL|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
58466405|NCT03542487|BEHAVIORAL|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
58466406|NCT02670447|PROCEDURE|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
58466407|NCT06378541|BEHAVIORAL|Virtual Hope Box Enhanced Facilitation|The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will receive a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
58466408|NCT06378541|BEHAVIORAL|Enhanced Usual Care|The EUC condition will involve a one-on-one, 30-minute session delivered prior to hospital discharge, during which the study interventionist will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).
58466409|NCT03576885|DRUG|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
58466410|NCT03576885|DRUG|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
58466411|NCT06704698|DRUG|Liposomal bupivacaine|Thoracic paravertebral block with liposomal bupivacaine.
58466412|NCT06704698|DRUG|Bupivacaine Hydrochloride|Epidural block with plane bupivacaine.
58466413|NCT02157818|DRUG|midazolam|
58466414|NCT02157818|DRUG|Dexmedetomidine|
58466415|NCT05816811|OTHER|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
58466416|NCT04649541|DRUG|MRX-8|novel semi-synthetic polymyxin B analog.
58466417|NCT04649541|DRUG|Placebo|5% dextrose in water
58466418|NCT05635786|DRUG|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
58466419|NCT05635786|DRUG|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
58466420|NCT04039087|DRUG|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
58466421|NCT04039087|DRUG|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
58466422|NCT05294588|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
58466423|NCT05294588|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
58466424|NCT05294588|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
58466425|NCT05294588|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
58466426|NCT05294588|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
58466427|NCT05294588|BIOLOGICAL|Influenza Vaccine|All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
58466428|NCT05294588|BIOLOGICAL|Tetanus-diptheria Vaccine|All participants will receive the Td vaccine, 0.5 mL intramuscularly.
57778064|NCT05316168|DRUG|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
58466429|NCT06420960|DEVICE|Wearing the connected watch|"All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance."
58466430|NCT05267262|DRUG|R3R01|R3R01 administered orally for 12 weeks
58466431|NCT05963880|DEVICE|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
58466432|NCT03322956|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
58466433|NCT05390372|OTHER|human milk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
58466434|NCT05390372|OTHER|Routine care group|cream applied as part of hospital routine practice
58466435|NCT06257303|OTHER|Frontal Plane Projection Angle|Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.
58466436|NCT02707627|DEVICE|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
58466437|NCT06706115|OTHER|Intranasal human breast milk|"The information in the Physiologic Parameter Follow-up Form will be recorded by the investigator just 5 minutes before the intervention. The researcher will drip 0.2 ml of breast milk at room temperature (approximately 22 °C) into the nose of the infant lying in the supine position, 0.1 ml in the right nose-0.1 ml in the left nose. 5 minutes after the intervention (T1), 15 minutes after the intervention (T2) and 30 minutes after the intervention (T3), the data in the Physiologic Parameter Follow-up Form will be recorded by the researcher. After intranasal breast milk administration, the baby will be fed by the neonatal nurse as in routine practice. The implementation of the intervention in the study will last for three days and this process will be repeated three times every day (09.00, 12.00 and 15.00)."
58466438|NCT05856500|DIETARY_SUPPLEMENT|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
58466439|NCT05856500|DIETARY_SUPPLEMENT|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
58466440|NCT04732520|DEVICE|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
58466441|NCT06704529|BEHAVIORAL|pitching motion|participants pitch fastball to the strike zone
58466442|NCT00756106|DRUG|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
58466443|NCT00756106|OTHER|Imaging biomarker analysis|MRI
58466444|NCT00756106|RADIATION|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
58466445|NCT06127784|OTHER|Motivational interviewing counselling session|Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
58466446|NCT01225874|DRUG|SC-PEG E. coli L-asparaginase|Given IM
58466447|NCT01225874|DRUG|cytarabine|Given IT
58466448|NCT01225874|DRUG|daunorubicin hydrochloride|Given IV
58466449|NCT01225874|DRUG|dexamethasone|Given orally
58466450|NCT01225874|DRUG|methotrexate|Given IT
58466451|NCT01225874|DRUG|pegaspargase|Given IM
58466452|NCT01225874|DRUG|prednisone|Given orally
58466453|NCT01225874|DRUG|vincristine sulfate|Given IV
58466454|NCT06399666|OTHER|Blood sampling|Blood sampling
58466455|NCT06219889|BEHAVIORAL|Frequency of neurochecks|the frequency with which a patient is awakened to perform serial examinations
58466456|NCT05831228|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
57778065|NCT05316168|DRUG|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
57778066|NCT05316168|PROCEDURE|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
57778067|NCT05316168|DRUG|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
57778068|NCT02733042|DRUG|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
57778069|NCT02733042|DRUG|Lenalidomide|Administered orally
57778070|NCT02733042|DRUG|Rituximab|Administered by intravenous infusion
57778071|NCT02733042|DRUG|Ibrutinib|Administered orally
57778072|NCT02733042|DRUG|Bendamustine|Administered as a 30-minute intravenous infusion
57778073|NCT03518736|BEHAVIORAL|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
57778074|NCT04767360|DEVICE|Bioness-300|Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
58466457|NCT05831228|DIETARY_SUPPLEMENT|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
58466458|NCT04576507|DRUG|Cannabis|Investigates two strengths of cannabis.
58466459|NCT00537394|DRUG|Enfuvirtide|90mg subcutaneously twice daily
58466460|NCT00537394|DRUG|Raltegravir|400 mg twice daily
58466461|NCT00537394|DRUG|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
58466462|NCT00537394|DRUG|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
58466463|NCT00537394|DRUG|Etravirine|Two 100-mg tablets twice daily
58466464|NCT00537394|DRUG|Maraviroc|Dosage dependent on regimen in which maraviroc is included
58466465|NCT03856060|OTHER|Questionnaire Administration|Complete questionnaires
58466466|NCT03856060|OTHER|Video|Watch videos of doctor and patient interaction in different settings
58466467|NCT05890833|DIAGNOSTIC_TEST|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
58466468|NCT03409796|DIETARY_SUPPLEMENT|Gluten|Gluten powder.
58466469|NCT00374140|DRUG|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
58466470|NCT06229626|OTHER|intensive reeducation|"* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks"
58466471|NCT05160337|DIAGNOSTIC_TEST|Biomarker based IVD tests|Biomarker based IVD tests
58466472|NCT03156101|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
58466473|NCT04475081|BIOLOGICAL|MMR vaccine|Merck MMR-II vaccine
58466474|NCT04841122|DEVICE|Camera observation|Supplemental camera observation directly linked to the nurse's phone
58466475|NCT01702207|DRUG|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
58466476|NCT01702207|DRUG|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
58466477|NCT00335491|BEHAVIORAL|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
58466478|NCT00335491|PROCEDURE|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
58466479|NCT00335491|PROCEDURE|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
58466480|NCT00335491|PROCEDURE|physical therapy|12 weeks of 3x/week training on the eccentron
58466481|NCT04745559|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
58466482|NCT04745559|BIOLOGICAL|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
58466483|NCT05897541|DRUG|S-217622|Administered as a tablet.
58466484|NCT05897541|DRUG|Placebo|Administered as a tablet.
58466485|NCT03264586|DRUG|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth."
58466486|NCT03264586|DRUG|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic"
58466487|NCT03264586|PROCEDURE|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
58466488|NCT04682197|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
58466489|NCT05699642|BEHAVIORAL|Tai chi + wearable|The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.
58466490|NCT06473233|DEVICE|TEG6S|Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician
58466491|NCT06230900|OTHER|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
58466492|NCT06230900|COMBINATION_PRODUCT|14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
58466493|NCT05927818|DIAGNOSTIC_TEST|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
58466494|NCT04120285|BEHAVIORAL|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
58466495|NCT06595173|BEHAVIORAL|Therapeutic Intervention|"group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated."
58466496|NCT06011759|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\]."
58466497|NCT06011759|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
58466498|NCT06026384|OTHER|text in non-narrative form|Participants will be asked to read a text and give feedback afterwards
58466499|NCT06026384|OTHER|text in narrative form|Participants will be asked to read a text and give feedback afterwards
58466500|NCT06026384|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and give feedback afterwards
58466501|NCT06026384|OTHER|animated video in narrative form|Participants will be asked to watch a video and give feedback afterwards
58466502|NCT06057753|BEHAVIORAL|MyStroke|Personalized video-based stroke education platform
58466503|NCT03378869|PROCEDURE|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
58466504|NCT06552273|BEHAVIORAL|Emotional Reasoning bias correction training|Emotional Reasoning Bias correction training involves 12 daily self-applied sessions focusing on psychoeducation about emotions and identifying ER biases and their impact on behaviour.
58466505|NCT06552273|BEHAVIORAL|Module of Mindfulness of the Transdiagnostic treatment|Module based on mindfulness using techniques for training in awareness and acceptance of experiences, observing experiences as they arise without judgment.
58466506|NCT04634097|OTHER|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
58466507|NCT04634097|OTHER|standrad group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
58466508|NCT04144569|DRUG|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
58466509|NCT06581835|DEVICE|Observational|The study objective requires placement of a jugular venous bulb catheter in the right or left jugular venous bulb with ultrasound guidance. A venous and radial arterial line will be placed. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
58466510|NCT00579774|OTHER|Low AGE Diet|Diet
58466511|NCT00579774|OTHER|Regular Diet|Diet
58466512|NCT02050438|PROCEDURE|Total Knee Arthroplasty|
58466513|NCT02814916|DRUG|Dalbavancin|Dalbavancin was administered intravenously over 30 (± 5) minutes.
58466514|NCT02814916|DRUG|Vancomycin|Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
57778075|NCT01414218|BEHAVIORAL|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
58466515|NCT02814916|DRUG|Oxacillin|Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
58466516|NCT02814916|DRUG|Flucloxacillin|Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
58466517|NCT02814916|DRUG|Cefadroxil|Cefadroxil was administered orally every 12 hours.
58466518|NCT02814916|DRUG|Clindamycin|Clindamycin was administered orally every 8 hours.
58466519|NCT06704763|DRUG|Orforglipron|Administered orally
58466520|NCT06704763|DRUG|Midazolam|Administered orally
58466521|NCT06704763|DRUG|Quinidine|Administered orally
58466522|NCT06706414|DRUG|Denosumab (Prolia)|Subcutaneous injection with 60 mg Denosumab once
58466523|NCT06702631|DRUG|Nitrous oxide|After a no-drug control period, subjects will inhale nitrous oxide, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the drug condition, subjects will receive low-dose nitrous oxide (% corresponding to Minimum Alveolar Concentration).
58466524|NCT06702631|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
58466525|NCT03745534|OTHER|eABR|eABR
58466526|NCT05375669|DEVICE|ISIS IOM System|"The constant-current TES stimulators will be used in this study with a high-precision oscilloscope. The calibration will assess 5-pulse trains with a 4 ms ISI and 100 mA output across a 1000 Ω resistor at 250, 500, and 1000 µs D. Measurements will include actual I and D of each pulse, and actual ISI.~Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement."
58466527|NCT04272294|DEVICE|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
57778076|NCT03074110|DEVICE|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
58130921|NCT05939674|DRUG|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
58466528|NCT03626727|DRUG|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
58466529|NCT02168868|DIAGNOSTIC_TEST|Blood draw|A blood sample (5 mL) will be collected.
58466530|NCT02168868|DIAGNOSTIC_TEST|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
58466531|NCT02168868|DIAGNOSTIC_TEST|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
58466532|NCT06705738|DIETARY_SUPPLEMENT|SUPOL|Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
58466533|NCT06705738|OTHER|Dietary Pattern: MeDi|Adherance to Mediterranean dietary pattern to be followed for 12 months.
58466534|NCT06651593|DRUG|SAR444881|Given by IV
58466535|NCT06651593|DRUG|Cemiplimab|Given by Iv
58466536|NCT06360302|DIAGNOSTIC_TEST|Exercise test|"Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes."
58466537|NCT06360302|DIAGNOSTIC_TEST|Blood sample|"A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements"
58466538|NCT06360302|DIAGNOSTIC_TEST|Impedancemetry|measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
58466539|NCT03117751|DRUG|Prednisone|Given orally (PO).
58466540|NCT03117751|DRUG|Vincristine|Given intravenously (IV).
58466541|NCT03117751|DRUG|Daunorubicin|Given IV.
58466542|NCT03117751|DRUG|Pegaspargase|Given IV or intramuscularly (IM) .
58466543|NCT03117751|DRUG|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
58466544|NCT03117751|DRUG|Cyclophosphamide|Given IV.
58466545|NCT03117751|DRUG|Cytarabine|Given IV or by subcutaneous injection (SQ).
58466546|NCT03117751|DRUG|Mercaptopurine|Given PO.
58466547|NCT03117751|DRUG|Dasatinib|Given PO.
58466548|NCT03117751|DRUG|Methotrexate|Given IV.
58466549|NCT03117751|DRUG|Blinatumomab|Given IV.
58466550|NCT03117751|DRUG|Ruxolitinib|Given PO.
58466551|NCT03117751|DRUG|Bortezomib|Given IV or subcutaneously (SQ).
58466552|NCT03117751|DRUG|Dexamethasone|Given PO.
58466553|NCT03117751|DRUG|Doxorubicin|Given IV.
58466554|NCT03117751|DRUG|Etoposide|Given IV.
58130922|NCT05939674|DRUG|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
58130923|NCT00732290|DRUG|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
58130924|NCT00732290|DRUG|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
58466555|NCT03117751|DRUG|Clofarabine|Given IV.
58466556|NCT03117751|DRUG|Vorinostat|Given PO.
58466557|NCT03117751|DRUG|Idarubicin|Given IV.
58466558|NCT03117751|DRUG|Nelarabine|Given IV.
58466559|NCT03117751|DRUG|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
58466560|NCT03117751|DRUG|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
58466561|NCT03117751|DRUG|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
58466562|NCT05192889|DRUG|Venetoclax|Given oral (PO).
58466563|NCT05192889|DRUG|Navitoclax|Given oral (PO).
58466564|NCT05192889|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
58466565|NCT05192889|DRUG|Vincristine|Given intravenously (IV).
58466566|NCT05192889|DRUG|Calaspargase Pegol|Given intravenously (IV).
58466567|NCT05192889|DRUG|Dasatinib|Given oral (PO).
58466568|NCT05192889|DRUG|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
58466569|NCT05192889|BIOLOGICAL|Blinatumomab|Given intravenously (IV).
58466570|NCT05192889|DRUG|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
58466571|NCT05192889|DRUG|Mercaptopurine|Given oral (PO).
58466572|NCT05192889|DRUG|Cyclophosphamide|Given intravenously (IV).
58466573|NCT05192889|DRUG|Etoposide|Given intravenously (IV).
58466574|NCT05192889|DRUG|Leucovorin|Given oral (PO) or intravenously (IV).
58466575|NCT05192889|DRUG|Intrathecal Triples|Given Intrathecal (IT).
58466576|NCT05192889|DRUG|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
58466577|NCT05192889|DRUG|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
58466578|NCT05192889|RADIATION|Radiation|See detailed description section.
58466579|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
58466580|NCT04146376|DRUG|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
58130925|NCT05194358|DRUG|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
58466581|NCT04146376|DRUG|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
58466582|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
58466583|NCT05131308|OTHER|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
58466584|NCT05090696|DEVICE|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
58466585|NCT03998410|DEVICE|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
58466586|NCT06582225|BEHAVIORAL|Internet-delivered exposure and response prevention (I-ERP)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks."
58466587|NCT06582225|BEHAVIORAL|Internet-delivered stress management (I-SM)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks."
58466588|NCT04105036|OTHER|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
58466589|NCT05604040|BEHAVIORAL|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
58466590|NCT06705699|PROCEDURE|Urethral mobilisation|Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
58466591|NCT06705699|PROCEDURE|Mathieu|Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
58466592|NCT06702644|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
58466593|NCT06702644|DEVICE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
58466594|NCT03479814|RADIATION|IMRT-SIB plus sequential IG-RT boost|
58466595|NCT06150040|DRUG|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
58466596|NCT06150040|DRUG|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
58466597|NCT06150040|DRUG|Venetoclax|Orally, 70 mg, every day on Days 1-28
58466598|NCT02236026|DRUG|Supratherapuetic dose of Nestorone|
58466599|NCT02236026|DRUG|Placebo|
58466600|NCT02236026|DRUG|Moxifloxacin|
58466601|NCT03244878|BEHAVIORAL|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
58466602|NCT05913882|DEVICE|Respiratory Muscle Strength Training (LVR+EMST)|Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
58466603|NCT04965987|DRUG|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
58466604|NCT04965987|DRUG|Placebo|Placebo
58466605|NCT04435704|DRUG|Oxytocin|Intravenous Oxytocin
58466606|NCT04927546|BEHAVIORAL|Exercise|Thirty minutes of aerobic exercise in a treadmill.
58466607|NCT05370495|DRUG|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
58466608|NCT05370495|DRUG|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
58466609|NCT05370495|DRUG|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
58466610|NCT05370495|DRUG|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
58466611|NCT03497637|DIAGNOSTIC_TEST|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
58466612|NCT03497637|DIAGNOSTIC_TEST|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
58466613|NCT05985954|DRUG|Cetuximab|Given by IV (vein)
58466614|NCT05985954|DRUG|Ulixertinib|Given by PO
58466615|NCT05985954|DRUG|Encorafenib|Given by PO
58466616|NCT05291520|BIOLOGICAL|VH3810109|VH3810109 was administered.
58466617|NCT05291520|BIOLOGICAL|rHuPH20|rHuPH20 was administered.
58466618|NCT05725395|BEHAVIORAL|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
58466619|NCT05725395|BEHAVIORAL|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
58466620|NCT06029296|DRUG|Diclofenac|100 mg
58466621|NCT06029296|DRUG|Placebo|Sugar pill
58466622|NCT05216250|BIOLOGICAL|BOTOX|Intramuscular injection
58466623|NCT05216250|DRUG|Placebo for BOTOX|Intramuscular injection
58466624|NCT05021354|DEVICE|Dry needling|dry needling, stretching and eccentric exercise
58466625|NCT05021354|DEVICE|Topical gel|aplication of topical gel to the epicondyle
58466626|NCT05021354|DRUG|NSAIDs|oral intake of NSAIDs
58466627|NCT06416306|BEHAVIORAL|Speech Intervention|The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.
58466628|NCT06211114|DRUG|PD-(L)1 inhibitor|Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks
58466629|NCT06211114|DRUG|Axitinib|axitinib 5mg orally twice daily
58466630|NCT06572631|BIOLOGICAL|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Given IV
58466631|NCT06572631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58466632|NCT06572631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58466633|NCT06572631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58466634|NCT06572631|PROCEDURE|Computed Tomography|Undergo PET/CT
58466635|NCT06572631|DRUG|Cyclophosphamide|Given IV
58466636|NCT06572631|DRUG|Decitabine|Given IV
58466637|NCT06572631|PROCEDURE|Echocardiography|Undergo ECHO
58466638|NCT06572631|DRUG|Fludarabine|Given IV
58130926|NCT03413046|DIAGNOSTIC_TEST|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
58466639|NCT06572631|PROCEDURE|Leukapheresis|Undergo leukapheresis
58466640|NCT06572631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58466641|NCT06572631|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58466642|NCT03631043|PROCEDURE|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
58466643|NCT03631043|DRUG|Lenalidomide|Given PO
58466644|NCT03631043|BIOLOGICAL|Vaccine Therapy|Given personalized vaccine SC
58466645|NCT05499910|BEHAVIORAL|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
58466646|NCT06345066|DRUG|Tirzepatide|Administered SC.
58466647|NCT06345066|DRUG|LY3841136|Administered SC.
58466648|NCT06345066|DRUG|Placebo|Administered SC.
58466649|NCT06592417|DRUG|JSKN016 injection|JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
58466650|NCT05007405|OTHER|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
58466651|NCT01827137|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
58466652|NCT01827137|BIOLOGICAL|GM-CSF|subcutaneous injection
58466653|NCT01827137|OTHER|Montanide|adjuvant
58466654|NCT01827137|DRUG|lenalidomide|optional post-ASCT therapy
58466655|NCT01827137|DRUG|bortezomib|optional post-ASCT therapy
58466656|NCT00558584|DEVICE|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
58466657|NCT00558584|DEVICE|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
58466658|NCT06706427|BIOLOGICAL|NGGT001|Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
58466659|NCT06601244|OTHER|Pharmacokinetic|Biliary and blood concentration of the DALBAVANCINE
58466660|NCT06245889|DRUG|Paclitaxel|chemotherapy
58466661|NCT06245889|DRUG|Carboplatin|chemotherapy
58466662|NCT06245889|DRUG|Pembrolizumab|immunotherapy
58466663|NCT06245889|DRUG|Doxorubicin|additional chemotherapy - neoadjuvant or adjuvant rescue
58466664|NCT06245889|DRUG|Cyclophosphamide|additional chemotherapy - adjuvant rescue
58466665|NCT06245889|DRUG|Olaparib|adjuvant rescue
58466666|NCT06245889|DRUG|Capecitabine|adjuvant rescue
58466667|NCT05876754|DRUG|Ivosidenib Oral Tablet|Ivosidenib 500 mg
58466668|NCT03284710|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
58466669|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
58466670|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection
58466671|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
58466672|NCT04706364|BEHAVIORAL|Neuropsychological Testing|Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
58466673|NCT04706364|GENETIC|(Optional) Saliva Collection|"The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes.~Genetic testing is funded by Boston Children's Hospital."
58466674|NCT04706364|DEVICE|Sensory Testing|"Three different tests will be completed:~the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold).~Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist).~The second sensory visit will be another version of the PPI testing involving hearing and sound."
58466675|NCT04706364|DEVICE|Electroencephalogram (EEG)|A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.
58466676|NCT04706364|DEVICE|Transcranial Magnetic Stimulation|"Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex.~There will be two - four identical TMS testing visits."
58466677|NCT04066439|OTHER|specimen|Immunohistochemistry analysis
58466678|NCT04675931|DRUG|KAE609|"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."
58466679|NCT04675931|DRUG|IV Artesunate|Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
58466680|NCT04675931|DRUG|Coartem|Oral Standard of Care
58466681|NCT06531395|DRUG|Abiprubart|humanized monoclonal antibody
58466682|NCT06531395|DRUG|Placebo|sterile preservative-free solution
58466683|NCT05989230|BEHAVIORAL|Emotional Awareness and Expression Therapy|The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
58130927|NCT05701371|OTHER|Biological samples collection|blood drawing + feces collection in a dedicated device
58466684|NCT05986240|DRUG|Danvatirsen|Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
58466685|NCT05986240|COMBINATION_PRODUCT|Danvatirsen + Venetoclax|"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
58466686|NCT06216925|BEHAVIORAL|#BabyLetsMove|Description of #BabyLetsMove
58466687|NCT06216925|BEHAVIORAL|WIC Antenatal Care|Description
58466688|NCT04822675|PROCEDURE|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
58130928|NCT01985802|OTHER|Pacing|
58130929|NCT05710978|OTHER|Work Protocol|Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
58130930|NCT02857270|DRUG|LY3214996|Administered orally
58130931|NCT02857270|DRUG|Midazolam|Administered orally
58130932|NCT02857270|DRUG|Abemaciclib|Administered orally
58130933|NCT02857270|DRUG|Nab-paclitaxel|Administered IV
58130934|NCT02857270|DRUG|Gemcitabine|Administered IV
58130935|NCT02857270|DRUG|Encorafenib|Administered orally
58130936|NCT02857270|DRUG|Cetuximab|Administered IV
58130937|NCT01124396|DRUG|DSP-3025|
58130938|NCT01124396|DRUG|Placebo|
58466689|NCT04822675|PROCEDURE|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
58466690|NCT04638088|OTHER|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
58466691|NCT05148286|DRUG|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
58466692|NCT05148286|DRUG|Placebo|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
58466693|NCT05823948|DRUG|Insulin Icodec|Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
58466694|NCT03366610|OTHER|Non-interventional|Non-interventional
58466695|NCT01824238|DRUG|Anacetrapib|
58466696|NCT01824238|DRUG|Placebo for anacetrapib|
58466697|NCT04195646|DEVICE|EndoVigilant CAD Software|The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
58466698|NCT06596083|DIETARY_SUPPLEMENT|Placebo supplement|oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water
58466699|NCT06596083|DIETARY_SUPPLEMENT|Ketone ester supplement|Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
58466700|NCT03986970|DRUG|Tenofovir|Pre-exposure prophylaxis
58466701|NCT04968990|DEVICE|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
58466702|NCT04968990|DRUG|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
58466703|NCT04968990|PROCEDURE|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
58466704|NCT04968990|PROCEDURE|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
58466705|NCT04968990|PROCEDURE|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
58466706|NCT05537753|DEVICE|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
58466707|NCT05537753|DEVICE|FDA-approved PFO closure device|Chosen by the investigator
58466708|NCT04607668|DRUG|Trilaciclib|Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
58466709|NCT04607668|DRUG|Placebo|Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
58466710|NCT02953652|DRUG|HBI-8000|Orally twice weekly
58466711|NCT01327625|DRUG|azithromycin + N-acetylcystein + inhaled corticosteroid|"* Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months"
58466712|NCT04495218|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
58466713|NCT05985161|DRUG|Selinexor|This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
58466714|NCT04864210|DRUG|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
58466715|NCT04864210|DRUG|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
58466716|NCT02543684|OTHER|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
58466717|NCT02543684|OTHER|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
58466718|NCT02543684|OTHER|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
58466719|NCT02543684|OTHER|oral glucose load|glucose load providing 50g of carbohydrates
58466720|NCT04647227|DRUG|coagulation factor VIIa [recombinant]-jncw|a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
58466721|NCT03547518|DEVICE|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
58466722|NCT03547518|DEVICE|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
58466723|NCT04141748|DEVICE|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
58466724|NCT04141748|PROCEDURE|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
58466725|NCT04204447|OTHER|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
58466726|NCT04204447|OTHER|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
58466727|NCT01810471|DEVICE|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
58466728|NCT06704893|DRUG|ASA injection 40 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
58466729|NCT06704893|DRUG|ASA injection 20 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
58466730|NCT06704893|DRUG|HA injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
58466731|NCT06704893|DRUG|Normal saline injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
58466732|NCT05324293|DRUG|HMI-115|Once Every 2 weeks, subcutaneously injection
58466733|NCT06329830|DRUG|177Lu-PSMA-617|7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
58466734|NCT06329830|DRUG|Niraparib abiraterone acetate|Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
58466735|NCT06329830|DRUG|Prednisone|5 mg orally twice per day
58466736|NCT03019406|DRUG|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
58466737|NCT03019406|DRUG|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
58466738|NCT03355976|DRUG|Nivolumab|240mg flat dose every 2 weeks
58466739|NCT03355976|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
58466740|NCT01384981|PROCEDURE|pulmonary rehabilitation|
58466741|NCT05544162|DIETARY_SUPPLEMENT|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
58466742|NCT01925885|PROCEDURE|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
58466743|NCT01925885|PROCEDURE|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
58466744|NCT03851458|BEHAVIORAL|Initial in-person individual diet and exercise counseling (N vs. Y)|Individual counseling utilizing MI has been effective in promoting behavioral change.18 A SANOS interventionist (MRNY promotora) will deliver a 45-60 minute counseling session, utilizing MI techniques, on diet and exercise, and how to stretch one's food dollars (see description of 10 modules described above under COMIDA Pilot). The promotora will evaluate the participant's diet based on the 24-hour dietary recall132 conducted at intake (see below), will compare diet composition to the USDA's MyPlate guidelines, and will then personalize education to address identiﬁed knowledge gaps and unhealthy food choices. Promotoras will focus on goal-setting, problem solving, selfeﬃcacy enhancements, selfmonitoring skills (i.e., participants will be taught how to monitor their diet, weight, and physical activity (PA), with simple pencil-and-paper logs or with 'Self-monitoring tools' if randomized to also receive that component), and modeling of healthy behaviors.
58466745|NCT03851458|BEHAVIORAL|Thrice weekly diet and exercise text messages (N vs. Y)|Text message interventions have been demonstrated to be effective in increasing self-eﬃcacy, weight loss, and PA.65-67 Participants will receive thrice weekly healthy eating, PA, and health care access text message tips. Links to additional information and videos will also be sent via text (e.g. local farmers markets, healthy recipes, free exercise classes, workout videos, video demonstrations of how to prepare healthy meals, etc.). Texts were developed and piloted in the COMIDA Pilot, are designed to promote goal-setting, problem-solving, self-monitoring, modeling, and self-eﬃcacy, and will be further reﬁned during the formative research phase (see below). Texts will be sent via Mosio Text Messaging Solutions. Messages will be concise, as longer messages have shown no demonstrable impact. Based on each participant's status at intake, tailored text messages will also encourage regular follow-up with PCPs. Text messages will be interactive.
58466746|NCT03851458|BEHAVIORAL|Weekly telephone support (N vs. Y)|Several lifestyle interventions including Hispanics have successfully incorporated telephone support.134-138 Weekly telephone support (or more frequently if requested) will be delivered by the promotoras throughout the 6-month intervention. Frequent and prolonged contact in behavioral interventions is more effective than single sessions; most interventions leading to diet or PA changes persisting for \>12 months have follow-up contact sessions for at least 4 months.18 Greater numbers of follow-up sessions facilitate success of behavior change, and initial behavior change can decrease with decreased contact.18,139 Telephone sessions (10-15 minutes) will use MI principles, will focus on goal-setting, problem solving, reviewing/integrating new diet/PA knowledge/skills (including self-monitoring) into individuals' daily routines, self-eﬃcacy enhancements, encouraging participants to seek opportunities for modeling and encouraging regular follow-up with PCPs.
58466747|NCT03851458|BEHAVIORAL|Self-monitoring tools (N vs. Y) (for diet and weight)|Self-monitoring is an important component in achieving behavioral change.18 Participants will be given a SANOS food diary (adapted for and pilot-tested at the VDS in our pilot work) and a digital scale. As part of VDS Mobile usual care, all participants will receive a pedometer to assess exercise behavior (secondary outcome), so additional self-monitoring tools for PA will not be included in this component.
58466748|NCT06384066|OTHER|GetWell Mobile Application|GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.
58466749|NCT06384066|OTHER|Standard of Care|Office Based Pathway
58466750|NCT06704581|DRUG|5 mg BGM0504 injection|5mg BGM0504 injection administered subcutaneously (SC) once a week.
58466751|NCT06704581|DRUG|10 mg BGM0504 injection administered subcutaneously (SC) once a week|10mg BGM0504 injection administered subcutaneously (SC) once a week.
58466752|NCT06704581|DRUG|15 mg BGM0504 injection|15mg BGM0504 injection administered subcutaneously (SC) once a week.
58466753|NCT06704581|DRUG|BGM0504 placebo|BGM0504 placebo administered SC once a week.
58466754|NCT04806386|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
58466755|NCT03189368|DEVICE|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~* Interpolar distance for the first left ventricular pulse \>30mm (i.e. non-sequential poles used)~* Nearly simultaneous (Δt=5msec) second left ventricular pulse and~* Threshold of ≤3.5V@0.5msec"
58466756|NCT04985604|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
58466757|NCT04985604|DRUG|Pimasertib|Pimasertib capsule for oral use.
58466758|NCT05488678|DRUG|VNRX-7145|single oral dose
58466759|NCT05488678|DRUG|Ceftibuten|single oral dose
58466760|NCT00629980|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
58466761|NCT05293769|OTHER|questionnaire|questionnaire will be filled in by all participants
58466762|NCT04107948|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
58466763|NCT04107948|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
58466764|NCT03035032|DRUG|Leuprolide|Subcutaneous Injection
58466765|NCT06586684|DRUG|Inclisiran|Patients with carotid plaques undergoing treatment with inclisiran
58466766|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (25 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
58466767|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (40 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
58466768|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
58466769|NCT06473246|DIETARY_SUPPLEMENT|CBD Broad Extract (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
58466770|NCT06473246|DIETARY_SUPPLEMENT|Placebo|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
58466771|NCT06700668|DEVICE|MIT Powered Knee|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
58466772|NCT05904158|BIOLOGICAL|Platelet-Rich Fibrin during Standard ACL reconstruction surgery|Plateleth-rich fibrin was obtained from patients own blood (40 cc) and applied to the tunnels which were drilled for ACL graft
58466773|NCT05904158|OTHER|Standard ACL reconstruction surgery|This was a control group where patients received Standard ACL reconstruction surgery
58466774|NCT06317181|DEVICE|Collection of elastography data|patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
58466775|NCT06317181|DEVICE|Collection of ultrasonic raw data|Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
58466776|NCT06250699|PROCEDURE|Tubeless laparoscopic adrenalectomy|No drainage tube placed after laparoscopic adrenalectomy
58466777|NCT06250699|PROCEDURE|Drainage tube|Placing drainage tubes after laparoscopic adrenalectomy
58466778|NCT06175338|DRUG|Rituximab|Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
58466779|NCT06175338|DRUG|MabThera®|MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
58466780|NCT06501001|BEHAVIORAL|High-Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.
58466781|NCT06501001|BEHAVIORAL|Experimental: Time-Restricted Eating|Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
58466782|NCT02400216|DRUG|dual cholate|test for defining disease severity
58466783|NCT03617562|PROCEDURE|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
58466784|NCT03617562|PROCEDURE|Partial Repair|Rotator cuff is repaired with residual defect remaining.
58466785|NCT06333184|OTHER|Food|Fruit ingested in whole form or as either commercially available, or home-made smoothies
58466786|NCT05993806|DRUG|L04RD1|1 tablet of L04RD1
58466787|NCT05993806|DRUG|L04TD3|1 tablet of L04TD3
58466788|NCT06527794|BEHAVIORAL|RHYTHM (Remote Hypertension Tracking Help Management)|Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners
58466789|NCT06527794|BEHAVIORAL|Enhanced usual care (UC)|All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.
58466790|NCT00609102|DRUG|Placebo|one capsule BID
58466791|NCT00609102|DRUG|n-aceylcysteine|450 mgm BID
58466792|NCT04990024|OTHER|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
58466793|NCT04990024|OTHER|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to \<130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
58466794|NCT05302089|OTHER|Pain management and shoulder bandage|All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
58466795|NCT05302089|OTHER|One-time physiotherapy instruction|Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
58466796|NCT05302089|OTHER|Usual rehabilitation care|At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
58466797|NCT05345444|DEVICE|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
58466798|NCT06699160|DEVICE|Revision arthroplasty|Hip or knee revision surgery resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains.
58466799|NCT04607005|DRUG|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
58466800|NCT04607005|DRUG|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
58466801|NCT04607005|DRUG|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
58466802|NCT06173947|DEVICE|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
58466803|NCT01415271|OTHER|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
58466804|NCT06584903|OTHER|Temperature Ramp Protocol|Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
58466805|NCT02595125|DEVICE|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
58466806|NCT01794429|DRUG|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
58466807|NCT01794429|DRUG|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
58466808|NCT04839705|DEVICE|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
58466809|NCT05940103|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
58466810|NCT06596369|DEVICE|Transcutaneous spinal cord stimulation|Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.
58466811|NCT06596369|OTHER|Upper extremity rehabilitation|Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
58466812|NCT05851651|BEHAVIORAL|Antenatal milk expression and breastfeeding self-efficacy enhancement|A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
58466813|NCT06434272|OTHER|Exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of Blood Flow Restriction Exercise (BFRE). Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is epmployed in both interventions arms (Early BFRE and Late BFRE)~The Early BFRE intervention comprises two exercises: Seated leg extension and seated heel-rise, performed at home.~The Late BFRE intervention comprises three exercises: Leg press in machine, heel-rise in machine, knee flexion in machine, performed at training facilities.~Each exercise, regardless of study arm, is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~Pause in between sets is 30 seconds. Pause in between exercises are 120 seconds."
58466814|NCT06277739|PROCEDURE|Spinal Manipulative Therapy|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment. If a cavitation (ie, an audible pop) occurred, the treatment was considered complete. If no cavitation was produced, the participant was repositioned and the manipulation was attempted again. A maximum of 2 attempts per side was permitted. If no cavitation was produced after the 4 attempts (ie, 2 per side), the treatment was considered complete.
58466815|NCT06277739|OTHER|Sham Laser Treatment|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
58466816|NCT04007692|PROCEDURE|Esophageal stent placement|Exposure of interest is standard of care esophageal stent placement
58466817|NCT04997486|BEHAVIORAL|Time restricted eating|Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
58466818|NCT03085004|DRUG|Ethanol|The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
58466819|NCT03085004|DRUG|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
58466820|NCT03085004|DRUG|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
58466821|NCT01511406|BEHAVIORAL|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
58466822|NCT03474588|BEHAVIORAL|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
58466823|NCT03474588|BEHAVIORAL|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
58466824|NCT05472090|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
58466825|NCT05472090|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
58466826|NCT03982355|DEVICE|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
58466827|NCT01082770|DEVICE|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
58466828|NCT01082770|DEVICE|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
58466829|NCT06483230|DEVICE|Intensive Visual Stimulation Device|The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
58466830|NCT02296164|DRUG|Valchlor|Valchlor gel 0.016%
58466831|NCT05926817|DEVICE|Placebo-VR headsets|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
58466832|NCT05926817|DEVICE|QTC-VR headsets|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
58466833|NCT04846829|DRUG|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
58466834|NCT04846829|DEVICE|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
58466835|NCT04846829|DRUG|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
58466836|NCT04846829|DEVICE|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
58466837|NCT03796559|DEVICE|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
58466838|NCT05502939|BEHAVIORAL|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
58466839|NCT05502939|BEHAVIORAL|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
58466840|NCT04101955|PROCEDURE|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
58466841|NCT04101955|PROCEDURE|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
58466842|NCT06170385|BEHAVIORAL|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
58466843|NCT06702722|BEHAVIORAL|Enhanced Friendship Bench|Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
58466844|NCT06702722|BEHAVIORAL|Enhanced usual care|Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
58466845|NCT06585241|BIOLOGICAL|mRNA-1273 Variant-containing Formulation|Sterile liquid for injection
58466846|NCT06612320|BEHAVIORAL|Questionnaire about acceptance|Questionnaire about acceptance
58466847|NCT06612320|BEHAVIORAL|Questionnaire about refusal|Questionnaire about refusal
58466848|NCT03239626|RADIATION|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
58466849|NCT04361396|OTHER|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
58466850|NCT04277975|OTHER|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
58466851|NCT04277975|OTHER|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
58466852|NCT05526716|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
57778077|NCT01625195|DIETARY_SUPPLEMENT|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
58466853|NCT05526716|BIOLOGICAL|QIV|Single 0.5 mL IM injection
58466854|NCT05526716|BIOLOGICAL|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
58466855|NCT06706349|BEHAVIORAL|APA managed by qualified instructor|Each session will be led by a qualified APA professional and will include a mix of aerobic, anaerobic, and 'mind-body' activities like yoga, tailored to participant preferences. Intensity will range from moderate to vigorous, with activities such as walking, cycling, and club-based exercises for at least 20 minutes per session. Participants will be progressively involved in session planning to support continued practice post-study. Heart rate monitoring will be used during exercises like the 6-minute walk test and chair rise test, while a daily activity calendar will help ensure adherence, documenting session dates, durations, subjective intensity, and activity type.
58466856|NCT06706349|BEHAVIORAL|Autonomous APA|A leaflet highlighting the importance of non-sedentary behavior according to WHO recommendations will be provided to them. They will have the opportunity to engage in physical activity autonomously according to their preference.
58466857|NCT04516447|DRUG|ZN-c3|Investigational drug
58466858|NCT04516447|DRUG|Carboplatin|Carboplatin is an approved drug
58466859|NCT04516447|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
58466860|NCT04516447|DRUG|Paclitaxel|Paclitaxel is an approved drug
58466861|NCT04516447|DRUG|Gemcitabine|Gemcitabine is an approved drug
58466862|NCT04516447|BIOLOGICAL|Bevacizumab|Combined with azenosertib
58466863|NCT06374836|DRUG|Phenylephrine|"At the OR, the patient will be sedated and have a transoesophageal echo (TEE) catether inserted, which is part of standard clinical care. When a patient becomes hypotensive and the attending anesthesiologist decides to infuse any of the following drugs (phenylephrine, ephedrine, norepinephrine, nitroprusside, or nicardipine), before infusion, the anesthesiolgist will acquire with TEE 10 beats of the thoracic ascending and descending aorta respectively. This is defined as one measurement. Five minutes after infusion the same measurement is repeated. A maximum of 10 measurements (5 before and 5 after infusion of a drug) per patient will be performed.~We want to explicitly mention that for study purposes the surgery or anesthesia will never be prolonged or modified, nor will any drugs be give for study purposes."
58466864|NCT05375539|DRUG|AGN-CognI.Q|Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
58466865|NCT06534372|PROCEDURE|Open cardiac surgery with sternotomy|Factors affecting the occurrence of chronic pain in patients undergoing open cardiac surgery with sternotomy will be investigated.
58466866|NCT06062420|DRUG|Dostarlimab|Dostarlimab will be administered.
58466867|NCT06062420|DRUG|Belrestotug|Belrestotug will be administered.
58466868|NCT06062420|DRUG|Nelistotug|Nelistotug will be administered.
58466869|NCT06062420|DRUG|GSK4381562|GSK4381562 will be administered.
58466870|NCT05391503|BEHAVIORAL|Light therapy|Morning bright light for 60 minutes after awakening
58466871|NCT05391503|BEHAVIORAL|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
58466872|NCT02884869|DEVICE|Intubating Laryngeal Mask|Direct laryngoscopy
58466873|NCT06163963|DIAGNOSTIC_TEST|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
58466874|NCT06163963|DIAGNOSTIC_TEST|charcoal injection to uterus to map sentinel lymph nodes|During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
58466875|NCT05407441|DRUG|Tazemetostat|oral, twice daily, dosage per protocol
58466876|NCT05407441|DRUG|Nivolumab|IV, dosage and schedule per protocol
58466877|NCT05407441|DRUG|Ipilimumab|IV, dosage and schedule per protocol
58466878|NCT06533969|PROCEDURE|Epidural Spinal Cord Stimulation|"This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days"
58466879|NCT06533969|DEVICE|Electrocorticographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
58130939|NCT00001849|DRUG|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
58466880|NCT06533969|DEVICE|Electroencephalographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
58466881|NCT04977375|DRUG|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
58466882|NCT04977375|RADIATION|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
58466883|NCT04977375|PROCEDURE|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
58466884|NCT01894139|OTHER|High-Protein/Low-GI Diet|
58466885|NCT01894139|OTHER|Low-protein/High-GI Diet|
58466886|NCT04258566|DEVICE|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
58466887|NCT04258566|RADIATION|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
58466888|NCT04104243|OTHER|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
58466889|NCT04166006|BIOLOGICAL|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
58466890|NCT04166006|DRUG|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
58466891|NCT06705712|BEHAVIORAL|Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.|"All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing."
58466892|NCT04867616|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
58466893|NCT04867616|BIOLOGICAL|Bepranemab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
58466894|NCT06369909|PROCEDURE|EUS-FNA|For patients with pancreatic masses, EUS-FNA is performed to confirm pathological diagnosis, and pancreatic biopsy samples and duodenal mucosal biopsy samples are collected.
58466895|NCT05370651|DEVICE|BTL Emsella Chair|Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
58466896|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
58466897|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
58466898|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
58466899|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
58466900|NCT03740022|PROCEDURE|ACL plasty|standard ligamentoplasty by Kenneth Jones
58466901|NCT03740022|PROCEDURE|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
58466902|NCT04942717|BEHAVIORAL|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
58466903|NCT04683627|DRUG|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
58466904|NCT04683627|DRUG|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
58466905|NCT04863170|PROCEDURE|orthognathic surgery|surgical intervention of the maxilla and / or mandible that includes orthodontic treatment before and after surgery
58466906|NCT05497830|OTHER|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
58466907|NCT06587685|DRUG|PG-011Gel|Twice daily for 52 weeks or 44 weeks
58466908|NCT06587685|DRUG|Vehicle|Vehicle Gel twice daily for 8 weeks
58466909|NCT04218968|DRUG|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
58466910|NCT04239898|OTHER|Red cabbage microgreens|2 cups per day
58466911|NCT04239898|OTHER|Red beet microgreens|2 cups per day
58466912|NCT06547619|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
58466913|NCT06699823|OTHER|Greek version of QoR-15|Greek version of QoR-15
57778078|NCT01625195|DIETARY_SUPPLEMENT|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
58466914|NCT04752215|DRUG|BI 765049|BI 765049
58466915|NCT04752215|DRUG|ezabenlimab|ezabenlimab
58466916|NCT05296226|PROCEDURE|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
58466917|NCT06552871|BEHAVIORAL|Forming Love around Autistic People to Prevent Suicide|Four-part virtual educational intervention
58466918|NCT06647394|PROCEDURE|Matrix Dressing|extracellular matrix dressing soaked in 4% topical lidocaine to the skin graft donor site
58466919|NCT04479358|DRUG|Tocilizumab|Tocilizumab 40mg
58466920|NCT04479358|DRUG|Tocilizumab|Tocilizumab 120mg
58466921|NCT04479358|OTHER|Standard of Care|Tocilizumab-Free Standard of Care
58466922|NCT04479358|OTHER|Standard of Care|Tocilizumab 400mg or 8mg/kg
58466923|NCT01364051|DRUG|Cediranib|Given PO
58466924|NCT01364051|DRUG|Cediranib Maleate|Given PO
58466925|NCT01364051|OTHER|Laboratory Biomarker Analysis|Correlative studies
58466926|NCT01364051|OTHER|Pharmacological Study|Correlative studies
58466927|NCT01364051|DRUG|Selumetinib|Given PO
58466928|NCT01364051|DRUG|Selumetinib Sulfate|Given PO
58466929|NCT05201547|DRUG|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
58466930|NCT05201547|DRUG|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
58466931|NCT05572359|DEVICE|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
58466932|NCT05139992|BIOLOGICAL|COVID-19 Vaccine|Vaccination against SARS-CoV-2
58466933|NCT03602612|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
58466934|NCT03602612|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
58466935|NCT03602612|BIOLOGICAL|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
57778079|NCT06410846|DEVICE|TopSpin360|Neck strength and conditioning device used during neck strengthening program.
57778080|NCT06410846|OTHER|Neck Strengthening Exercise Plan|Physical therapist designed neck strengthening program.
58466936|NCT00005800|BIOLOGICAL|Filgrastim|
58466937|NCT00005800|DRUG|Docetaxel|
58466938|NCT00005800|DRUG|Doxorubicin|
58466939|NCT00005800|PROCEDURE|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
58466940|NCT06706297|OTHER|pranayama breathing exercise|Normal breathing, focusing on breathing, Alternative Nose Breathing, Cooling Breath, Bee Buzzing Sound, A breathing exercise of 20 minutes in total, consisting of 5 stages: normal breathing and focusing on breathing.
58466941|NCT06024941|RADIATION|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
58466942|NCT04838782|PROCEDURE|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
58466943|NCT06704243|BEHAVIORAL|Peer Support|"The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable."
58466944|NCT06139328|DRUG|BI 765845|BI 765845
58466945|NCT06139328|DRUG|Placebo matching BI 765845|Placebo matching BI 765845
58466946|NCT04221945|BIOLOGICAL|Pembrolizumab|IV infusion
58466947|NCT04221945|DRUG|Placebo for pembrolizumab|IV infusion
58466948|NCT04221945|DRUG|Cisplatin|IV infusion
58466949|NCT04221945|RADIATION|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
58466950|NCT04221945|RADIATION|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
58466951|NCT03777306|OTHER|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
58466952|NCT03777306|OTHER|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
57778081|NCT03428815|DEVICE|Prosthesis suspension liner|Liners out of phase change material will be fitted
58466953|NCT03513770|OTHER|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
58466954|NCT03513770|DRUG|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
58466955|NCT03513770|DRUG|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
58466956|NCT06457373|PROCEDURE|Demineralized Dentin Allograft|20 sockets are randomly allocated to receive the Demineralized Dentin Allograft (split-mouth study)
58466957|NCT06457373|PROCEDURE|Demineralized Dentin Autograft|20 sockets are randomly allocated to receive the Demineralized Dentin Autograft (split-mouth study)
58466958|NCT00601224|BEHAVIORAL|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
58466959|NCT00601224|BEHAVIORAL|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
58466960|NCT05217615|BEHAVIORAL|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
58466961|NCT05217615|BEHAVIORAL|Coaching calls|The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
58466962|NCT05217615|BEHAVIORAL|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
58466963|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
58466964|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
58466965|NCT00878501|DRUG|Placebo|Oral, during 4 weeks
58466966|NCT01351103|DRUG|LGK974|
58466967|NCT01351103|BIOLOGICAL|PDR001|
58466968|NCT05577754|DRUG|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
58466969|NCT05577754|DRUG|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
58466970|NCT05577754|PROCEDURE|Optional lumbar puncture + blood sample|Between 6 and 24 months of treatment with Alpelisib
58466971|NCT06586125|OTHER|Powered Mobility Training|The study procedure aims to observe the partecipants' behaviour while using the Virtual Reality - Power Mobility Program (VR-PMP) simulator applied during Power Mobility Training in clinical practice for 15 sessions. Participants use either semi-immersive mode (laptop screen with VR-PMP simulator) or immersive mode (head-mounted display with VR-PMP simulator). Five out of ten children unable to use conventional VR controllers or alternative access technologies available on the market, use brain-computer interface (BCI) developed specifically for these children to control the VR-PMP simulator.
58466972|NCT05380466|OTHER|Quantum Touch|Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
58466973|NCT02218372|DRUG|Fidaxomicin oral suspension|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
58466974|NCT02218372|DRUG|Fidaxomicin tablets|Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
57778082|NCT03197103|DRUG|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
57778083|NCT00115375|DRUG|Clopidogrel (SR25990)|
58466975|NCT02218372|DRUG|Vancomycin oral liquid|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
58466976|NCT02218372|DRUG|Vancomycin capsules|Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
57778084|NCT00963989|DEVICE|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
57778085|NCT06007079|DEVICE|CPM Device|Wearable monitor
57778086|NCT01471067|DRUG|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
58466977|NCT00984256|DRUG|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
58466978|NCT00984256|OTHER|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
58466979|NCT03670823|DEVICE|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
58466980|NCT05655598|DRUG|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
58466981|NCT05655598|DRUG|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
58466982|NCT05655598|DRUG|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
58466983|NCT05655598|DRUG|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
57778087|NCT01471067|DRUG|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
58466984|NCT06587113|OTHER|Visual tasks|In the experiments, participants sit in front of a computer screen with their head in a chinrest to control for distance from the monitor and eye-tracking equipment. For the visual search task, participants will search for a visual target among distractors and make a response regarding its orientation. For the stop-signal task, participants will make an eye movement to a target that appears on the screen, except on trials where a visual signal appears indicating they should cancel this behavior. In the useful field of view task, participants will report the location of a briefly-presented and masked target, while also responding to the identify of a central target in some blocks.
58466985|NCT05719311|DRUG|adrulipase|Enteric microgranule formulation of adrulipase.
58466986|NCT06595043|DEVICE|the tip opening angle to the left|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.
58466987|NCT06595043|DEVICE|the tip opening angle to the right|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
58466988|NCT06320457|OTHER|Brief case management intervention|"The brief case management intervention aims to support patients during the difficult phase of involuntary hospitalisation and reduce the impact of this short-term event on their long-term recovery process. The intervention starts during the hospital stay, at the latest one week after admission, and lasts for a maximum of one month after discharge. The intervention consists of five sessions, the order of which may vary according to the specific needs of the patient:~1. Personal account of involuntary hospitalisation and its consequences~2. Presentation of the personal recovery model and the tools to promote it and prevent coercion~3. Introduction to the personal recovery plan~4. Network meeting and discussion on dignity of risk~5. Personal recovery plan"
58466989|NCT02004236|DEVICE|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
58466990|NCT02004236|DEVICE|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
58466991|NCT02004236|DEVICE|tRNS with sham|the subjects receive 35 session with sham
58466992|NCT05899634|BEHAVIORAL|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
58466993|NCT01239199|OTHER|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
58466994|NCT02610296|DRUG|QPI-1002|IV injection
58466995|NCT02610296|OTHER|Placebo|isotonic saline
58466996|NCT01003808|BIOLOGICAL|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
58466997|NCT06314711|DIAGNOSTIC_TEST|Ultrasound|High-frequency ultrasound of ex vivo specimen
57778088|NCT01471067|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
57778089|NCT01471067|DRUG|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
57778090|NCT01471067|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
57778091|NCT01471067|DRUG|Rituximab|375 mg/m\^2 by vein on Day -10 for B cell malignancy.
57778092|NCT01471067|DRUG|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
57778093|NCT01471067|DRUG|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
57778094|NCT01471067|DRUG|Clofarabine|30 mg/m\^2 IV Day -7 to Day -4;
57778095|NCT01471067|RADIATION|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
57778096|NCT00355407|DRUG|Darbepoetin alfa|
58466998|NCT06590636|PROCEDURE|Expressive touching|"Woman's anxiety level was measured with the State-Trait Anxiety Inventory scale Following these measurements, expressive touching that lasted 15-20 minutes was performed in the following manner.~The hands of the expressive touching performer warmed to body temperature (should not be cold).~The woman's hand close to the performer was placed between the hands of the expressive touching performer.~The woman's palm was gently grasped with the palms of the expressive touching performer.~The hand below was fixed and the upper part of the woman's hand was gently rubbed with the hand above.~Before and after massaging, the woman's arms and shoulders were touched at intervals.~During the procedure, the woman was called by her name, and verbal communication with the woman was continued by holding her hands firmly and sincerely as if a handshaking done.~Before the woman's discharge from the center, her anxiety level was measured with the State-Trait Anxiety Inventory scale"
58466999|NCT03330925|DEVICE|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
58467000|NCT06600451|OTHER|observational study, no intervention is required|"Retrospective chart review, investigators provides data after reviewing patient\&#39;s existing medical record; no interaction with patients is required.~Patients were treated as per standard of care"
58467001|NCT01365923|DRUG|remifentanil|remifentanil effect site-TCI 2-4ng/ml
58467002|NCT01365923|DRUG|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
58467003|NCT04765722|DRUG|Mepolizumab|Mepolizumab subcutaneous injection administered 3 times days 0, 28, 56 and 84 during 12 week treatment period.
58467004|NCT04765722|DRUG|Normal Saline|Placebo subcutaneous injection administered 3 times days 0, 28, 56 and 84 during 12 week treatment period.
58467005|NCT05831774|DRUG|Intervention - Intraosseous (IO) administration of vancomycin|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus"
58467006|NCT05831774|DRUG|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
58467007|NCT05031819|OTHER|Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.|"* TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH"
58467008|NCT06705868|OTHER|Diet-Time-restricted eating (TRE)|Ad libitum time-restricted scheme with a further time-restriction on fruit and vegetable consumption in participants with MASLD
58467009|NCT06705868|OTHER|Lifestyle Management|The SoC intervention refers to an adaptation of a healthier lifestyle in elements that have to do with weight management, adopting healthier dietary habits, alcohol intake reduction, increase physical activity levels.
58467010|NCT04471909|DEVICE|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
58467011|NCT05975476|BEHAVIORAL|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
58467012|NCT05975476|BEHAVIORAL|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
58467013|NCT05532566|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
58467014|NCT02659930|DRUG|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
58467015|NCT02659930|DRUG|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
58467016|NCT00456053|DRUG|FG2216|
58467017|NCT06512727|BEHAVIORAL|PROACTIVE Intervention|Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent self-management (SM) education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
58467018|NCT05138653|DRUG|CVL-354|Oral solution/suspension
58467019|NCT05138653|DRUG|Placebo|Placebo matched to CVL-354
58467020|NCT05138653|DRUG|CVL-354|Capsule
58467021|NCT03564600|OTHER|Aging Back Clinics management|Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
58467022|NCT05310279|OTHER|GAIMplank|The GAIMplank video game controller will be used to play active video games.
58467023|NCT02521285|DRUG|Aspirin|Given PO
58467024|NCT02521285|OTHER|Laboratory Biomarker Analysis|Correlative studies
58467025|NCT02521285|OTHER|Placebo Administration|Given PO
58467026|NCT02521285|OTHER|Questionnaire Administration|Ancillary studies
58467027|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
58467028|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
58467029|NCT00988494|DRUG|Placebo ophthalmic solution|Topical ocular application
58467030|NCT04364386|DEVICE|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
58467031|NCT06204068|DEVICE|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
58467032|NCT06204068|DEVICE|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
58467033|NCT06104228|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490
58467034|NCT04767659|DEVICE|MAMMOT2|Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
58467035|NCT04819217|DIETARY_SUPPLEMENT|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR \> 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
58467036|NCT04819217|DIETARY_SUPPLEMENT|Probiotics|Probiotics
58467037|NCT02167490|PROCEDURE|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
58467038|NCT04166643|BEHAVIORAL|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
58467039|NCT04166643|BEHAVIORAL|Education only control|Education at the start of the project
58467040|NCT06028919|DEVICE|Temperature controlled DiamondTemp (DT) ablation catheter|The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
58467041|NCT06028919|DEVICE|Tacticath/Tactiflex (TF) ablation catheter|The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
58467042|NCT05161377|PROCEDURE|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
58467043|NCT05161377|PROCEDURE|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
58467044|NCT05640271|DRUG|Tocilizumab|Tocilizumab 80 mg IV dose (one time per patient)
58467045|NCT04918420|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
58467046|NCT04729907|DRUG|Nusinersen|Administered as specified in the treatment arm
58467047|NCT06300580|DRUG|ABBV-932|Oral Capsule
58467048|NCT06672406|DIETARY_SUPPLEMENT|Lactobacillus reuterii|Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding \> 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics
58467049|NCT03766789|DEVICE|Cell phone application|cell phone to organize medications
58467050|NCT03054519|DRUG|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
58467051|NCT03054519|DRUG|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
58467052|NCT03754725|DRUG|Deferiprone pill|1000 mg of deferiprone (oral) BID (15 mg/Kg)
58467053|NCT03754725|DRUG|placebo|patients will receive placebo orally
58467054|NCT03754725|BEHAVIORAL|Montreal Cognitive Assessment|Neurocognitive assessment, lower score indicates lower cognitive level
58467055|NCT06390722|DRUG|Upadacitinib|Oral Tablet
58467056|NCT06390722|DRUG|Placebo for Upadacitinib|Oral Tablet
58467057|NCT06673017|DRUG|PTM-101|PTM-101, an absorbable drug product containing paclitaxel
58467058|NCT02455791|PROCEDURE|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
58467059|NCT06368700|DEVICE|Hyalex Knee Cartilage System|Surgical implantation of the Hyalex Knee Cartilage System
58467060|NCT06511973|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
58467061|NCT06511973|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
58467062|NCT06511973|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch
58467063|NCT06511973|DRUG|A solution of 0.2% SLS|0.2% SLS will be dispensed directly on the patch.
58467064|NCT04432935|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
58130940|NCT00001849|DRUG|18F-DOPA|18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
58467065|NCT04432935|OTHER|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
58467066|NCT06369870|DRUG|Levobupivacaine Hydrochloride 0.25 % Injectable Solution|After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
58467067|NCT06369870|DRUG|Sodium chloride 0.9%|Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the intervention description of the IPP-PSP block.
58467068|NCT03557749|DIAGNOSTIC_TEST|Blood Sample|60 ml heparinized blood 10 ml serum
58467069|NCT03557749|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount
58467070|NCT03557749|DIAGNOSTIC_TEST|Urine Sample|10 ml
58467071|NCT03557749|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) fluid|10 ml
58467072|NCT03557749|DIAGNOSTIC_TEST|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
58467073|NCT03557749|DIAGNOSTIC_TEST|Skin biopsy|2-4 mm punch
58467074|NCT03557749|DIAGNOSTIC_TEST|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
58467075|NCT03557749|DIAGNOSTIC_TEST|Apheresis Product|Up to 10 ml of apheresis product
58467076|NCT03557749|DIAGNOSTIC_TEST|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
58467077|NCT01468285|DRUG|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
58467078|NCT01468285|OTHER|placebo|placebo tablets b.i.d., six weeks treatment
58467079|NCT03507842|DRUG|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
58467080|NCT03507842|DRUG|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
58130941|NCT00001849|DEVICE|CT scan|CT scan of chest, abdomen, neck and /or pelvis
58130942|NCT00001849|DEVICE|MRI|MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis
58130943|NCT00001849|DRUG|18-FDG|FDG PET scan of body
58130944|NCT04912349|PROCEDURE|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
58467081|NCT03507842|DRUG|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
58467082|NCT06501534|DRUG|Febuxostat|Tablets, Once a day (QD), Per oral
58467083|NCT06501534|DRUG|IBI128|Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
58467084|NCT04934748|DRUG|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
58467085|NCT04934748|DRUG|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
58467086|NCT04934748|DRUG|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
58467087|NCT04934748|DRUG|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
58467088|NCT06194825|DRUG|Eplontersen|Eplontersen by subcutaneous injection
58467089|NCT06194825|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
58130945|NCT04912349|PROCEDURE|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
58130946|NCT04957108|OTHER|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
58130947|NCT02064595|PROCEDURE|External fixator|Treatment with external fixation
58130948|NCT02064595|PROCEDURE|Intramedullary nail|Fracture treated with intramedullary nail
58130949|NCT01357603|BIOLOGICAL|Glargine|dosage form: Subcutaneous injection
58130950|NCT00678366|PROCEDURE|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
58130951|NCT00678366|PROCEDURE|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
58130952|NCT05524103|DRUG|ALMB-0166|A single dose of ALMB-0166 injection.
58130953|NCT05883176|DRUG|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
58130954|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan + exercise group|Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
58467090|NCT03524612|DRUG|eltrombopag|12.5, 25, 50 and 75 mg tablets for oral use once daily
58467091|NCT06079008|OTHER|calcified cardiac valve|patients have cardiac cardiac valve before surgery
58467092|NCT00995761|DRUG|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
58467093|NCT05331638|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
58467094|NCT05331638|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
58467095|NCT06377176|OTHER|Massage therapy|the intervention group underwent ten sessions of twice-weekly mother and infant massage therapy for five weeks.
58467096|NCT06006208|DEVICE|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
58467097|NCT04909710|OTHER|Mobile Game System for Potential Treatment of Developmental Delays|Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
58467098|NCT06569238|DIAGNOSTIC_TEST|Conventional bacterial culture|Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).
58467099|NCT06569238|DEVICE|Rapid diagnostic group using mNGS technology|Participants will have DFU ulcer tissue collected and have metagenomics sequencing performed. The name of the devices listed for this study are the Illumina MiSeq System with MiSeq Reagent Kit V2 from Illumina and the MinION sequencer (Oxford Nanopore Technologies).
58467100|NCT04065048|OTHER|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
58467101|NCT04065048|OTHER|Non-soy based diet|Diet of identical composition to the soy diet with the exception of soy.
58467102|NCT05687604|BEHAVIORAL|multiple behavior change therapy|goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
58467103|NCT06296147|OTHER|Virtual Reality Headset|The interventions are for supportive care ONLY.
58467104|NCT06296147|OTHER|Aromatherapy Patch|The interventions are for supportive care ONLY.
58467105|NCT06296147|OTHER|Standard of Care|Participant will undergo a transperineal prostate biopsy.
58467106|NCT05318131|OTHER|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
58467107|NCT05318131|OTHER|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
58467108|NCT06600230|OTHER|Education and exercise|Training including information on pelvic floor and dysmenorrhea and exercise practices were given both theoretically and practically by physiotherapists.
58467109|NCT06600230|OTHER|Self-method like resting or heat|Classical self-methods such as rest and heat application were applied.
58467110|NCT06239272|PROCEDURE|Surgical resection|Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
58467111|NCT06239272|RADIATION|Proton beam radiation therapy|Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
58467112|NCT06239272|DRUG|Pazopanib|Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
58467113|NCT06239272|DRUG|Ifosfamide|Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
58130955|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan group|Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
58467114|NCT06239272|DRUG|Doxorubicin|Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
58467115|NCT06239272|DRUG|Selinexor|"High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3"
58130956|NCT05052164|BEHAVIORAL|Active Comparator: Celiac controls group|Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
58130957|NCT05075603|DRUG|Efineptakin alfa|NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
58130958|NCT05075603|DRUG|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
58130959|NCT05075603|DRUG|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
58467116|NCT04934800|DRUG|Cladribine|No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
58467117|NCT06593704|OTHER|PROSPERA-program|"The PROSPERA-program consists of the following components:~1. Health care provider training and education about U-Prevent and cardiovascular risk communication.~2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation.~3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation."
58467118|NCT02955589|DRUG|HBI-8000|Oral, twice weekly
58467119|NCT02455245|DRUG|Carboplatin and Vincristine|Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
58467120|NCT02455245|DRUG|Carboplatin|Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
58467121|NCT02890329|DRUG|Decitabine|Given IV
58467122|NCT02890329|BIOLOGICAL|Ipilimumab|Given IV
58467123|NCT03380728|DRUG|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
58467124|NCT06705933|OTHER|Core stability exercise|Lumbo-pelvic stabilizing exercises (posterior pelvic tilt, bilateral hip abduction, bilateral knee raise, bridging, hip shrugging) will be performed three times per week for eight weeks.
58467125|NCT06705933|OTHER|Myofascial release|The participants will receive myofascial release technique for 20 min for 3 times per week for 8 weeks.
58467126|NCT06705933|OTHER|Kinesiotaping|The participants will receive Kinesio-Taping over the sacroiliac joint and the hip region. Following a test trial of a small patch for 24 hours, they will be instructed to keep the tape on for 48 hours (it will be replaced after 48 hours) . It will be applied for 8 weeks.
58467127|NCT06037421|OTHER|Human breast milk sampling|Human breast milk sampling
58467128|NCT06037421|OTHER|Saddle sampling|Saddle sampling
58467129|NCT06037421|OTHER|Skin sampling|Skin sampling
58467130|NCT06037421|OTHER|Saliva sampling|Saliva sampling
58467131|NCT06037421|OTHER|blood sampling|blood sampling
58467132|NCT06136169|BEHAVIORAL|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
58467133|NCT05253209|DRUG|L-citrulline|Intravenous L-citrulline given for up to 48 hours
57778097|NCT04447443|DIETARY_SUPPLEMENT|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
57778098|NCT04447443|DIETARY_SUPPLEMENT|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
57778099|NCT04912622|DIAGNOSTIC_TEST|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
58130960|NCT05075603|DRUG|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
58130961|NCT01850420|DRUG|IMC-1|
58467134|NCT05253209|DRUG|Plasmalyte A|Intravenous Plasmalyte A given for up to 48 hours
58467135|NCT06592404|DEVICE|Robot Tessa|"Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale."
58467136|NCT01721135|DRUG|GSK2190915 100mg|Film coated oral tablet
58467137|NCT01721135|DRUG|GSK2190915 200mg|Film coated oral tablet
58467138|NCT01721135|DRUG|moxifloxacin 400mg|Film coated oral tablet
58467139|NCT01721135|DRUG|moxifloxacin placebo|Film coated oral tablet
58467140|NCT01721135|DRUG|GSK2190915 placebo|Film coated oral tablet
58467141|NCT06543953|DEVICE|HearCare MED-EL App|The main task of the HearCare MED-EL App is to perform technical checks on both implants and audio processors and create backups of audio processor configurations so that these configurations can be written on to an empty audio processor of the same type.
58467142|NCT03991780|DRUG|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
58467143|NCT01281618|PROCEDURE|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
58467144|NCT05239143|BIOLOGICAL|P-MUC1C-ALLO1 CAR-T cells|P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
58467145|NCT05239143|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
58467146|NCT06428110|OTHER||
58467147|NCT06705179|BEHAVIORAL|Behavioral task performance|Measures of performance on behavioral tasks
58467148|NCT01760057|BEHAVIORAL|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
58467149|NCT01760057|BEHAVIORAL|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
58467150|NCT03406884|BIOLOGICAL|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
58130962|NCT04122430|OTHER|Review of Health Information|
58467151|NCT02906514|DRUG|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
58130963|NCT03312530|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
58130964|NCT03312530|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
58130965|NCT03312530|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
58467152|NCT02906514|DRUG|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
58467153|NCT00182026|BEHAVIORAL|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
58467154|NCT06389526|BIOLOGICAL|CHS-1000|Specified dose on specified days
58467155|NCT06389526|BIOLOGICAL|Toripalimab|Specified dose on specified days
58467156|NCT02079896|DRUG|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
58467157|NCT02079896|DRUG|Placebo|
58467158|NCT06064929|DRUG|Felzartamab|Specified dose on specified days
58467159|NCT01584232|DRUG|LY2189265|
58467160|NCT01584232|DRUG|Insulin glargine|
58467161|NCT01584232|DRUG|Sulfonylureas (SU)|
58467162|NCT01584232|DRUG|Biguanide (BG)|
58467163|NCT01064388|DRUG|AZD9742|IV infusion, 15 days
58467164|NCT01064388|DRUG|Placebo|IV infusion, 15 days
58467165|NCT04892498|RADIATION|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
58467166|NCT04892498|DRUG|PD-1 inhibitor|q3w, until PD
58467167|NCT04892498|DRUG|GM-CSF|200μg, D1-D7, ≥8 cycles
58467168|NCT04892498|DRUG|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
58467169|NCT06706544|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
58467170|NCT06706544|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
58467171|NCT04742634|DRUG|DEC-C|"* DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant."
58467172|NCT04742634|DEVICE|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
58467173|NCT06564389|DRUG|PF-07832837|escalated doses of PF-07832837
58467174|NCT06564389|OTHER|Placebo|placebo
58467175|NCT03767933|DRUG|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
58467176|NCT03767933|DRUG|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
58467177|NCT03767933|DRUG|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
58467178|NCT03767933|DRUG|Acetaminophen placebo|Oral liquid
58467179|NCT03767933|DRUG|Hydromorphone placebo|Oral liquid
58467180|NCT04610346|BEHAVIORAL|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
58467181|NCT05954130|OTHER|Education|Sexual Health in Pregnancy
58467182|NCT05539625|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
58467183|NCT05539625|OTHER|Placebo|Placebo
58467184|NCT04318977|DEVICE|high-frequency rTMS|repetitive transcranial magnetic stimulation
58467185|NCT04318977|DEVICE|TBS|theta burst stimulation
58467186|NCT04318977|DEVICE|placebo|placebo transcranial magnetic stimulation
58130966|NCT00775177|DRUG|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
58130967|NCT00922909|BEHAVIORAL|Simon task|Reaction time task
58130968|NCT05783284|DEVICE|Holocare Studio 2 (HS2)|3D HV
58467187|NCT03466918|DEVICE|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
58467188|NCT03212911|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
58467189|NCT03793049|DEVICE|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
58467190|NCT05398757|BEHAVIORAL|Mini mental state exame (MMSE)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
58467191|NCT05398757|BEHAVIORAL|Digit Symbol Substitution Test (DSST)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
58467192|NCT05398757|DIAGNOSTIC_TEST|Numeric rating Scale (NRS)|4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
58467193|NCT05398757|DIAGNOSTIC_TEST|Postoperative inflammation|All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
58467194|NCT05398757|DRUG|Midazolam|For sedation during surgery, patients in midazolam group will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg after spinal anesthesia.
58467195|NCT05398757|DRUG|Propofol|For sedation during surgery, patients in propofol group will receive i.v. propofol in dose 25-27 mcg/kg/min.
58467196|NCT05398757|DRUG|Dexmedetomidin|For sedation during surgery, patients in dexmedetomidin gropu will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
58467197|NCT06462339|BEHAVIORAL|Experimental: Intervention Group|The group that will receive pilates training via telerehabilitation
58467198|NCT06700135|OTHER|sensorimotor stimulation program sessions|The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
58467199|NCT06071377|OTHER|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
58467200|NCT06469294|PROCEDURE|Control (C) - Saline Gel|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.
58467201|NCT06469294|PROCEDURE|Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue|After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
58467202|NCT05160480|DIAGNOSTIC_TEST|Total-body PET imaging|Total-body PET imaging at different timepoints
58467203|NCT06047834|DRUG|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).
58467204|NCT06047834|OTHER|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
58467205|NCT05358366|BEHAVIORAL|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
58467206|NCT06586996|OTHER|no intervention|no intervention
58467207|NCT06517160|OTHER|MedBook Portal|"Intervention Group (With MedBook Portal \&amp; MedBook Portal Notice)~1. MedBook Portal Notice in front of the patient home-based medical card~2. Discharge prescriptions are uploaded into MedBook Portal and can be retrieved by doctors \&amp; pharmacists.~MedBook portal (https://aplikasi.jknsarawak.moh.gov.my/medbook) is a webpage that enable sharing of patient medication records among healthcare facilities under Ministry of Health. Sarawak State Health Department owned and managed this portal. All the information is kept under their server. Doctors in the Health Clinics and Study Pharmacists will be given access to this portal whereby each of the healthcare providers shall log in using their Identification Number and the password created by them. Doctor shall log in to MedBook Portal to check on discharge medication list when reviewing the patient at health clinic. MedBook Portal can be accessed both using a smartphone or a computer."
58467208|NCT05788510|OTHER|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
58467209|NCT06441643|DRUG|AR-17043 Ophthalmic Solution|Investigational monotherapy supplied in three concentration levels: low, medium, high
58467210|NCT06441643|DRUG|PG043 Ophthalmic Solution|Investigational fixed dose combination supplied in two concentration levels: low and high
58467211|NCT06441643|DRUG|Latanoprost 0.005% Ophthalmic Solution|Marketed monotherapy
58467212|NCT06441643|DRUG|Netarsudil 0.02% Ophthalmic Solution|Marketed monotherapy
57778100|NCT00886470|BIOLOGICAL|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
57778101|NCT01633086|DRUG|nitric oxide gel|"1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days"
57778102|NCT01633086|DRUG|placebo gel|placebo gel,BID local use X 28 days
57778103|NCT01152541|DRUG|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
57778104|NCT01152541|DRUG|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
57778105|NCT02565355|OTHER|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
57778106|NCT02565355|OTHER|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
57778107|NCT00095030|DRUG|muraglitazar|
58130969|NCT00841100|DRUG|Kuvan|20mg/kg by mouth once daily
58467213|NCT06441643|DRUG|Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution|Marketed fixed dose combination
58467214|NCT06441643|DRUG|AR-17043 Vehicle|Placebo comparator
58467215|NCT05791981|BEHAVIORAL|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
58467216|NCT05791981|BEHAVIORAL|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
58467217|NCT05791981|DEVICE|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
58467218|NCT06340581|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
58467219|NCT06340581|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
58467220|NCT06340581|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
58467221|NCT06340581|DEVICE|AeroChamber Plus Flow-Vu Spacer|Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
58467222|NCT06700824|DEVICE|OTR4132|OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
58467223|NCT06700824|DEVICE|Placebo|saline solution
58467224|NCT04527796|OTHER|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
58467225|NCT05980260|OTHER|Symptom-based Dosing Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.
58467226|NCT05980260|OTHER|Scheduled Opioid Taper Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
58467227|NCT06569212|DRUG|Metoprolol|"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
58467228|NCT06569212|DRUG|Placebo|"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
58467229|NCT04539496|DRUG|XZP-3287|"* 20-560 mg QD, oral~* 240-480 mg BID, oral"
58467230|NCT04539496|DRUG|XZP-3287;Letrozole;Anastrozole;Fulvestrant|XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
58467231|NCT04539496|DRUG|XZP-3287|480 mg BID, oral
58467232|NCT06705101|DRUG|Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin|In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.
58467233|NCT06705101|OTHER|Placebo Oral Tablet|The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.
58467234|NCT05880199|DEVICE|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
58467235|NCT02931188|DRUG|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
58467236|NCT02931188|DRUG|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
58467237|NCT02931188|DRUG|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
58467238|NCT05153746|DEVICE|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
58467239|NCT04983017|DIETARY_SUPPLEMENT|Dietary supplement|iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
58467240|NCT04983017|OTHER|Placebo|Matched Placebo to Intervention
58467241|NCT03316924|PROCEDURE|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
58467242|NCT05890664|DRUG|Colchicine|"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."
58467243|NCT05890664|DRUG|Placebo|Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
58467244|NCT03359538|DRUG|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
58467245|NCT03359538|DRUG|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
58467246|NCT05820412|OTHER|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
58467247|NCT06444568|OTHER|Dietary Intervention|The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
58467248|NCT05797246|DRUG|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
58467249|NCT02250846|DRUG|EGFR-TKI|egfr-TKI treatment
58467250|NCT01402752|BIOLOGICAL|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
58467251|NCT03737695|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
58467252|NCT03737695|OTHER|Medical Chart Review|Undergo clinical information collection
58467253|NCT01004952|BEHAVIORAL|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
58467254|NCT05278962|DRUG|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
58467255|NCT05278962|OTHER|No SGLT2i|No SGLT2i
58467256|NCT05506683|OTHER|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
58467257|NCT05655351|BIOLOGICAL|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
58467258|NCT04049032|BEHAVIORAL|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
58467259|NCT04049032|BEHAVIORAL|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
58467260|NCT06223867|DEVICE|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
58467261|NCT06223867|BEHAVIORAL|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
58467262|NCT06529536|DIAGNOSTIC_TEST|Genotyping for CYP3A4 and CYP3A5 genes|"Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus."
58467263|NCT06529536|DEVICE|Use of NextDose platform|NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.
58467264|NCT06529536|DRUG|Tacrolimus|Tacrolimus is administered to all patients post SOT at RCH
57778108|NCT05480033|BEHAVIORAL|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
57778109|NCT00436579|DRUG|sorafenib tosylate|Given orally
58467265|NCT03629886|BIOLOGICAL|HPV (Types 16, 18) Vaccine, Adsorbed|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
58467266|NCT03648905|DRUG|13N-Ammonia|a perfusion imaging agent
58467267|NCT03648905|DRUG|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
58467268|NCT03648905|DRUG|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
58467269|NCT03648905|DRUG|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
58467270|NCT05516537|BEHAVIORAL|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
57778110|NCT00436579|OTHER|pharmacological study|
57778111|NCT00436579|PROCEDURE|assessment of therapy complications|Ancillary studies
58130970|NCT00841100|OTHER|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
58467271|NCT05516537|BEHAVIORAL|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
58467272|NCT03523819|DRUG|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
58467273|NCT03523819|DRUG|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
58467274|NCT04514185|DEVICE|Passive industrial exoskeleton for the upper limb|The goal is to compare the human response to the simulated industrial tasks
58467275|NCT04514185|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
58467276|NCT06069128|DEVICE|Neurotrigger Basic. eye blinking stimulator|NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
58467277|NCT05280496|DRUG|Metformin|Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
58467278|NCT03567733|DEVICE|XIENCE Sierra|Percutaneous coronary intervention
58467279|NCT06597851|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
58467280|NCT06597851|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic Clamp test|Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
58467281|NCT03757091|DEVICE|Laryngoscopy|Undergo video laryngoscopy
58467282|NCT03757091|PROCEDURE|Tracheal Intubation|Undergo flexible scope intubation
58467283|NCT02749396|DRUG|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467284|NCT02749396|DRUG|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467285|NCT02749396|DRUG|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467286|NCT02749396|DRUG|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467287|NCT02749396|DRUG|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467288|NCT02749396|DRUG|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467289|NCT02749396|OTHER|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
58467290|NCT00610870|DRUG|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
58467291|NCT05164120|DRUG|Belnacasan|Oral administration
58467292|NCT05164120|DRUG|Placebo|Tablet containing 0mg of API
58467293|NCT06362421|GENETIC|Pre-Radiation Dental Evaluation/Sample Collection|Collection of saliva samples and mouth swabs and pre-cancer dental evaluation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
58467294|NCT06362421|OTHER|Pre-Study Visit|Collection of vital signs, medical history and current medications
58467295|NCT06362421|GENETIC|Oral Medicine Consultation Visit/Sample Collection|Collection of saliva samples and mouth swab, complete oral medicine consultation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
58467296|NCT06348927|DRUG|sunvozertinib in combination with Anlotinib|"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."
58467297|NCT04430920|OTHER|Intensive intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 80 mmHg.
58467298|NCT04430920|OTHER|Conventional intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
58467299|NCT03638453|OTHER|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
58467300|NCT03638453|OTHER|Usual Care|Standard care per hospital guidelines.
58467301|NCT04519008|DEVICE|Mobile app|Medical device for improving emotion dysregulation
58467302|NCT04519008|COMBINATION_PRODUCT|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
58467303|NCT04106297|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
58467304|NCT04106297|DRUG|Placebo oral solution|Placebo for oral administration
58467305|NCT04106297|DRUG|GLPG3970 capsule|GLPG3970 for oral administration
58467306|NCT06340685|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
58467307|NCT04733638|DEVICE|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
58467308|NCT04195945|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
58467309|NCT04195945|DRUG|Cladribine|Given IV
58467310|NCT04195945|DRUG|Cytarabine|Given IV
58467311|NCT04195945|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
58467312|NCT04195945|DRUG|Mitoxantrone|Given IV
58467313|NCT04195945|OTHER|Questionnaire Administration|Ancillary studies
58467314|NCT04195945|OTHER|Quality-of-Life Assessment|Ancillary studies
58467315|NCT03075787|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
58467316|NCT03546023|OTHER|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
58467317|NCT05650710|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
58467318|NCT05992935|BIOLOGICAL|mRNA-1403|Sterile liquid for injection
58467319|NCT05992935|BIOLOGICAL|mRNA-1405|Sterile liquid for injection
58467320|NCT05992935|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58467321|NCT05219500|DRUG|FPI-2265|Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
58467322|NCT03422913|PROCEDURE|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still \>5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) \> 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
58467323|NCT06288581|OTHER|Traditional toothbrush group|Children in this group will use a traditional brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a U shaped brush with a traditional toothpaste for another 30 days.
58467324|NCT06288581|OTHER|U shaped toothbrush group|Children in this group will use a U shaped brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a traditional brush with a traditional toothpaste for another 30 days.
58467325|NCT06591390|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
58467326|NCT06591390|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
58467327|NCT03957551|DRUG|Cabozantinib|"Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle."
58467328|NCT03957551|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
58467329|NCT05682170|DRUG|ZN-d5 ZN-c3|Oral agent
58467330|NCT05682170|DRUG|ZN-c3|Oral agent
58467331|NCT06180135|OTHER|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
58467332|NCT06180135|OTHER|FENNEL TEA DRINK|FENNEL TEA DRINK
58467333|NCT05984121|DRUG|Local ozon injections|"Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively."
58467334|NCT05984121|DRUG|Local dextroz prolotherapy injections|Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
58467335|NCT05984121|OTHER|Exercise Group|Patients will receive a conventional therapy program consisting of exercises
58467336|NCT05983965|DRUG|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
58467337|NCT00558142|DRUG|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
58467338|NCT00558142|DRUG|Visipaque 320|100mls IV dose as single dose
58130971|NCT04088214|PROCEDURE|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
58467339|NCT00558142|DRUG|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
58467340|NCT02197884|DRUG|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
58467341|NCT02197884|DRUG|Itraconazole 200 mg|Itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.
58467342|NCT02197884|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
57778112|NCT00436579|OTHER|laboratory biomarker analysis|Correlative studies
58130972|NCT06387147|DRUG|Gentamicin|Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
58467343|NCT03600233|DRUG|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
58467344|NCT06541028|BEHAVIORAL|Rapid-Start ART (RS-ART)|ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
58467345|NCT01614249|DIETARY_SUPPLEMENT|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
58467346|NCT01614249|DIETARY_SUPPLEMENT|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
58467347|NCT03125928|DRUG|Atezolizumab|Monoclonal antibody
58467348|NCT03125928|DRUG|Paclitaxel|Chemotherapy
58467349|NCT03125928|DRUG|Trastuzumab|Monoclonal antibody
58467350|NCT03125928|DRUG|Pertuzumab|Monoclonal antibody
58467351|NCT02633059|DRUG|Dexamethasone|Given PO
58467352|NCT02633059|DRUG|Idasanutlin|Given PO
58467353|NCT02633059|DRUG|Ixazomib Citrate|Given PO
57778113|NCT01544621|OTHER|Smoking cessation|Smoking cessation
57778114|NCT06376318|DRUG|Inotrope|Vasopressors: Norepinephrine, vasopressin Inotropes: Epinephrine, Dobutamine, Milrinone
57778115|NCT06376318|DEVICE|Mechanical circulatory support|Intra-aortic balloon pump Extracorporeal membrane oxygenation (ECMO)
58467354|NCT02633059|OTHER|Laboratory Biomarker Analysis|Correlative studies
57778116|NCT06376318|DRUG|anti-bodies|Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
57778117|NCT04600297|DEVICE|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
57778118|NCT06134934|OTHER|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
57778119|NCT06134934|OTHER|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
57778120|NCT02881177|DRUG|Oxytocin|40 IU
58130973|NCT06387147|DRUG|Placebo|Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
58467355|NCT02633059|OTHER|Pharmacological Study|Correlative studies
58467356|NCT02192515|DRUG|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
58467357|NCT02192515|DRUG|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
58467358|NCT02192515|DRUG|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
58467359|NCT02192515|DRUG|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
58467360|NCT02192515|DRUG|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
58467361|NCT02192515|DRUG|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
58467362|NCT02192515|DRUG|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
58467363|NCT02192515|DRUG|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
58467364|NCT02620774|DRUG|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
58467365|NCT02620774|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
58467366|NCT04975698|BIOLOGICAL|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.
58467367|NCT04975698|BIOLOGICAL|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
58467368|NCT04182516|DRUG|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
58467369|NCT05324358|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
58467370|NCT05324358|DRUG|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
58467371|NCT05324358|OTHER|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
58467372|NCT05324358|OTHER|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
58467373|NCT04937036|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
57778121|NCT02881177|DRUG|Placebo|40 IU
57778122|NCT06291532|DEVICE|Rehabilitation with VRRS|"The patients underwent an experimental intervention lasting two months (9 sessions lasting about 40 minutes) integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.~The proposed exercises were 2D and the patient interacted with the scenarios through the touch screen. For all participants, the tasks were the same, but difficulty and duration varied according to the needs and goals to be achieved."
57778123|NCT00687661|DRUG|Bisphosphonate|35mg given orally once weekly for 24 months
57778124|NCT00687661|DRUG|Placebo|identical placebo pill once weekly for 24 months
57778125|NCT01750593|PROCEDURE|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
58467374|NCT06268236|OTHER|Electroacupuncture|Electro-acupuncture at Shuigou and Yintang.
58467375|NCT06268236|OTHER|Sham electroacupuncture|Sham-EA at sham-Shuigou and sham-Yintang.
58467376|NCT06600932|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
58467377|NCT06600932|PROCEDURE|control group|The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
58467378|NCT06704321|DIETARY_SUPPLEMENT|TOTUM-448|16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day)
58467379|NCT06704321|DIETARY_SUPPLEMENT|Placebo|16 weeks of placebo supplementation (8 capsules per day)
58467380|NCT06705647|OTHER|Chronic Obstructive Pulmonary Disease (COPD)|The base line acoustic and mel frequency ceprtum coefficients will be analysed statistically between COPD voices and healthy control groups to highlight the correlation between COPD and its effects on voice production.
58467381|NCT01672645|BIOLOGICAL|NIC7-001|Intramuscular, multiple dose
58467382|NCT01672645|BIOLOGICAL|NIC7-003|Intramuscular, multiple dose
58467383|NCT01672645|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
58467384|NCT05861466|DRUG|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
58467385|NCT05861466|PROCEDURE|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
58467386|NCT02183675|DRUG|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
58467387|NCT02183675|DRUG|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
58467388|NCT02183675|DRUG|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
58467389|NCT02891174|DRUG|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
58467390|NCT02891174|DRUG|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
58467391|NCT01539824|BIOLOGICAL|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
58467392|NCT01539824|RADIATION|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
58467393|NCT05462145|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
58467394|NCT05625360|OTHER|eHealth Mindful Movement and Breathing|The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
58467395|NCT05625360|OTHER|Life Impacts Reflection|"This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session."
58467396|NCT05625360|OTHER|PROMIS Questionnaires|Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
58467397|NCT06078241|DRUG|Intravenous lidocaine infusion|Intravenous lidocaine infusion
58467398|NCT06078241|OTHER|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
58467399|NCT06078241|OTHER|Intravenous infusion of normal saline|Intravenous infusion of normal saline
58467400|NCT06078241|OTHER|ESPB with normal saline|Unilateral ESPB with normal saline
58467401|NCT00001483|DRUG|buproprion (Wellbutrin)|
58467402|NCT00001483|DRUG|sertraline (Zoloft)|
58467403|NCT00001483|DRUG|venlafaxine (Effexor)|
58467404|NCT06599489|PROCEDURE|surgery ..operation|sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
58467405|NCT04894591|DRUG|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
57778126|NCT03549611|DRUG|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
57778127|NCT03549611|DRUG|Acetaminophen|Acetaminophen 975mg
57778128|NCT03929419|DRUG|intranasal insulin|application of 160 units human insulin
57778129|NCT03929419|DRUG|Placebo spray|nasal spray containing placebo solution
58467406|NCT06216613|BEHAVIORAL|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics (SEA) utilizes the Sensory Profile to individualize lessons based on children's sensory preferences. The program incorporates evidence-based approaches for autistic children, including: 1) visual supports, 2) sensory supports, 3) communication strategies, 4) behavioral strategies, and 5) modeling to maximize skill acquisition. Lessons will be 1:1 with social opportunities at the beginning and end of each lesson. Like standard swim lessons, skills are taught in progression from water orientation (e.g., blowing bubbles, submerging different body parts) to advanced swimming (e.g., swimming 15 or more yards of different swim strokes). All lessons include instruction of water safety skills. Each skill has been task analyzed by therapists so instruction can be graded according to children's ability. A social story is provided to transition children to lessons. SEA curriculum was reviewed by USA Swimming Foundation and is included as a Swim Lesson Network Provider.
58467407|NCT06216613|BEHAVIORAL|Standard Swim Lessons|Standard swim lessons will adhere to USA Swimming Foundation Swim Network Provider requirements ensuring lessons meet or exceed industry best practices. Lessons have up to a 1:5 instructor to child ratio and will focus on stroke development and water-safety with skills advancing from water-orientation to stroke technique and endurance.
58467408|NCT02163538|DEVICE|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
58467409|NCT02163538|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
58467410|NCT06342934|DIAGNOSTIC_TEST|Ultrasound|Ultrasound images are collected and stored. The images stored during your preoperative ultrasound will be exported in anonymous format from the ultrasound system, and sent to the coordinating center (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano). There, images will be submet to radiomic analysis through the application of a dedicated software; that will allow to evaluate the intrinsic characteristics of the tissue according to different parameters (shape, intensity, grade of heterogeneity and many others) of the 'pixels' (gray dots) that constitute the ultrasound imag
58467411|NCT05443308|DIAGNOSTIC_TEST|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral \[15O\]H2O PET before and after diamox infusion
58467412|NCT05764564|DIAGNOSTIC_TEST|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
58467413|NCT04758572|OTHER|Manual Therapy|Mobilization, massage and stretching
58467414|NCT04758572|OTHER|Massage muscle chain|Massage very soft following the directions of the muscle chains, massage and stretching
58467415|NCT04595071|DEVICE|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
58467416|NCT05738174|DEVICE|high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
58467417|NCT05738174|DEVICE|sham high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
58467418|NCT06539598|OTHER|Respiratory Strength Training (RST)|Respiratory Strength training involves inhaling/exhaling against a fix resistant to potentially increase respiratory strength
58467419|NCT03473756|DRUG|Rogaratinib (BAY1163877)|Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
58467420|NCT03473756|DRUG|Atezolizumab|Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
58467421|NCT04882735|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
58467422|NCT06592092|BIOLOGICAL|QH104 Cell injection|Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.
58467423|NCT06234059|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
58467424|NCT06234059|BEHAVIORAL|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
58467425|NCT03338777|BIOLOGICAL|Suicide plus immunogene therapy|"1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
58467426|NCT03516123|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
58467427|NCT06705283|PROCEDURE|yoga and home exercise|"The intervention period for the study was determined as 6 weeks. It has been decided that yoga practice will be done 3 times a week for 45 minutes.~Poses to be practiced in the yoga group:~1. Tadasana (mountain pose)~2. Utkatasana (chair pose)~3. Trikonasana (triangle pose)~4. Malasana (squat pose):~5. Viparita Karani Variation (legs up the wall pose)~6. Salamba Set Bandhasana (supported bridge pose)~7. Supta Baddha Konasana (reclining bound angle pose)~8. Savasana (dead pose)"
58467428|NCT06705283|PROCEDURE|whole body vibration training and home exercise|A total of 40-45 minutes of training was planned for WBVT, including warm-up (10 minutes), active phase (25-30 minutes) and cooling phase (5 minutes).
58467429|NCT06705283|PROCEDURE|home exercise group|Pelvic floor muscle training will be done in the home exercise group. This training will be done in the form of slow and fast contractions of the pelvic floor muscles in supine, chin up, sitting, squat and standing positions.
58467430|NCT01781936|DRUG|Fluocinolone Acetonide|
58467431|NCT06705231|BEHAVIORAL|The Aarhus-intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
58467432|NCT00000336|DRUG|Selegiline|
58467433|NCT05460104|DEVICE|Experimental|Virtual reality sessions with a psychologist (30 minutes per session) once a week for 10 weeks. Work of the psychologist on a virtual environment created for the protocol in partnership with the company.
58467434|NCT05460104|OTHER|Control|Standard care is medical follow-up, no specific psychological care.
58467435|NCT04028713|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
58467436|NCT04028713|PROCEDURE|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
58467437|NCT04028713|DRUG|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
58467438|NCT04096430|BEHAVIORAL|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
58467439|NCT05108870|DRUG|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
58467440|NCT05108870|DRUG|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
58467441|NCT05108870|DRUG|Carboplatin|Chemotherapy drug.
58467442|NCT05108870|DRUG|Paclitaxel|Chemotherapy drug.
58467443|NCT05108870|PROCEDURE|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
58467444|NCT03678064|DEVICE|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
58467445|NCT05668351|RADIATION|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
58467446|NCT06466746|OTHER|Raising the Pulse faba bean-enriched bread|100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
58467447|NCT06466746|OTHER|Conventional White Bread|100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
58467448|NCT05856877|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
58467449|NCT05856877|OTHER|Placebo|Single dose of placebo solution as nasal spray
58467450|NCT05891431|DEVICE|Untire mobile app|"The Untire app is an mHealth intervention (digitally delivered using a smartphone app).~Untire offers a comprehensive program to help you understand cancer fatigue and gives a physical activity program, stress reduction exercises and tips to manage your energy level."
58467451|NCT03743272|DEVICE|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
58467452|NCT00492817|PROCEDURE|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
58467453|NCT06031623|DEVICE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
58467454|NCT03730909|DRUG|Sodium Lactate|IV infusion
58467455|NCT03730909|DRUG|Sodium chloride|IV infusion
58467456|NCT03901274|BEHAVIORAL|Wellness|The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
58467457|NCT03901274|BEHAVIORAL|Partnership|The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
58467458|NCT05622864|DRUG|HRS-9821|HRS-9821
58467459|NCT05622864|DRUG|HRS-9821|HRS-9821
58467460|NCT02340793|DIETARY_SUPPLEMENT|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
58467461|NCT06070766|DRUG|Ketamine|The use of ketamine in chronic conditions.
58467462|NCT06571253|BEHAVIORAL|Digital Exercise Intervention|Participants in this intervention arm used the Fiziu Digital Physiotherapy Platform. This digital platform provided a structured 6-week corrective exercise program through visual and auditory-guided videos. The intervention included interactive features such as reminders and progress tracking to enhance adherence and engagement.
58467463|NCT06571253|BEHAVIORAL|Paper-Based Exercise Intervention|Participants in this intervention arm followed a traditional paper-based exercise program. This included printed exercise instructions and illustrations for a 6-week period. The program was designed to mimic standard physical therapy exercises without digital support.
58467464|NCT06047093|PROCEDURE|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
58467465|NCT06047093|BIOLOGICAL|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
57778130|NCT01548014|DIETARY_SUPPLEMENT|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
58467466|NCT06047093|OTHER|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and after the FNA has been performed.
58467467|NCT03888612|DRUG|ARV-110|"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"
58467468|NCT05247372|OTHER|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
58467469|NCT04519164|DRUG|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
58467470|NCT04519164|DRUG|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
58467471|NCT06465524|DEVICE|High-intensity laser therapy|High-intensity laser therapy (HILT), also referred to as Class IV laser therapy, involves the administration of collimated and monochromatic electromagnetic radiation within the infrared or red spectrum. It operates at power levels exceeding 500 milliwatts (0.5 W), leveraging both photobiomodulation and thermal effects. This distinguishes HILT from Class III lasers (low-level laser therapy, or LLLT), which lack photothermal effects when operating below 500 mW.
58467472|NCT06584539|BEHAVIORAL|Eco-Labels|"Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY."
58467473|NCT03808974|OTHER|Educational video|Short educational video describing the mid-urethral sling procedure
58467474|NCT03808974|OTHER|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
58467475|NCT06100588|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
58467476|NCT06100588|OTHER|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
58467477|NCT06490900|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.
58467478|NCT06490900|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
58467479|NCT06595472|DIETARY_SUPPLEMENT|Palm Oil Enriched with Plant Sterols|The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.
58467480|NCT06595472|DIETARY_SUPPLEMENT|Palm oil|The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
58467481|NCT04017221|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
58467482|NCT04017221|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
58467483|NCT04017221|DRUG|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
58467484|NCT03404817|DRUG|Original formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
58467485|NCT03404817|DRUG|New formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
58467486|NCT05881018|DIETARY_SUPPLEMENT|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
58467487|NCT05881018|DIETARY_SUPPLEMENT|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
58130974|NCT06387147|DRUG|Metronidazole|Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
58130975|NCT01624376|DRUG|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
58130976|NCT01624376|DRUG|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
58130977|NCT03680898|DEVICE|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
58130978|NCT03190577|GENETIC|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
58467488|NCT05881018|BEHAVIORAL|Physical activity|Participants will include physical activity units
58467489|NCT06547827|OTHER|robotic rehabilitation|"Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
58130979|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase Ib)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
58467490|NCT06547827|OTHER|traditional rehabilitation|"A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
58467491|NCT05058976|DRUG|Romosozumab|Monthly dose: 210 mg subcutaneous injection
58467492|NCT05058976|DRUG|Placebo|Monthly saline injection
58467493|NCT05058976|DRUG|Zoledronic acid|5 mg IV infusion at Month 12 Visit
58467494|NCT05058976|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
58467495|NCT00633477|DRUG|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
58467496|NCT00633477|DRUG|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
58467497|NCT00434746|DRUG|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
58467498|NCT05902169|DEVICE|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
58467499|NCT05902169|DRUG|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\]."
58467500|NCT05902169|DRUG|Lomustine|Dosed and administered per labelling.
58467501|NCT05902169|DRUG|Temozolomide|Dosed and administered per labelling.
58467502|NCT04720183|DRUG|Sulfasalazine|On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
58467503|NCT04720183|DRUG|GLPG3970|On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
58467504|NCT02878499|OTHER|polysomnography|
58467505|NCT06601036|DRUG|Sevoflurane|Patients will undergo fiberoptic intubation under sevoflurane sedation.
58467506|NCT06601036|DRUG|2% Xylocaine (2 ml )|Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
58467507|NCT04197700|OTHER|Target MAP Management|Target MAP Management
58467508|NCT04521790|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
58467509|NCT03630289|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
58467510|NCT03940963|DEVICE|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
58467511|NCT03940963|PROCEDURE|Standard Neurectomy|Surgical excision of symptomatic neuroma
58467512|NCT06077968|BIOLOGICAL|Prior standard of care receipt of Pfizer's ABRYSVO vaccine|Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
58467513|NCT05414461|DRUG|Combinations|PD-1 inhibitor-based combinaiton treatment
58467514|NCT01186263|DRUG|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
58467515|NCT01186263|DRUG|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
58467516|NCT04193046|OTHER|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
58467517|NCT06128382|BIOLOGICAL|OVX033|One single administration intramuscularly on Day 1
58467518|NCT06128382|BIOLOGICAL|Saline solution|One single administration intramuscularly on Day 1
58467519|NCT05874674|DRUG|Nafamostat Mesylate|Comparison effect of nafamostat and cnoxan
58467520|NCT06585566|PROCEDURE|Cortical-shell graft|Retromolar cortical shell graft technique for SABG
58467521|NCT02405689|DRUG|Remifentanil|
58467522|NCT02405689|DRUG|Dexmedetomidine|
58467523|NCT02405689|DRUG|Sevoflurane|
58467524|NCT05917899|BEHAVIORAL|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
58467525|NCT05691270|BEHAVIORAL|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
58467526|NCT06175676|DRUG|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
58467527|NCT06175676|DRUG|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
58467528|NCT06175676|DRUG|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
58467529|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
58467530|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
58467531|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
58467532|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
58467533|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
58467534|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
58467535|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
58467536|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
58467537|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
58467538|NCT04205227|DRUG|ENB003|ENB003 is selective Endothelin B Receptor Antagonist
58467539|NCT04205227|DRUG|Pembrolizumab|anti-PD1
58467540|NCT05386043|DRUG|FET F-18|PET scan with FET prior to biopsy
58467541|NCT05386043|DRUG|O-15 Radioisotope|PET scan with O-15 Water prior to biopsy
58467542|NCT05386043|PROCEDURE|CT scan|CT scan prior to biopsy
58467543|NCT05386043|PROCEDURE|MRI with gadolinium-based contrast|MRI prior to biopsy
58130980|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase II)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
58467544|NCT05386043|PROCEDURE|Biopsy Collection|Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
58467545|NCT05354661|DEVICE|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
58467546|NCT05254626|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
58467547|NCT05254626|DRUG|Pioglitazone 30 mg|Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
58467548|NCT05590481|DEVICE|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
58467549|NCT05590481|BEHAVIORAL|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
57778131|NCT02796547|DRUG|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
58130981|NCT00406913|DRUG|mupirocin ointment|
58130982|NCT00406913|OTHER|SOC sterilization|
58130983|NCT04183881|DRUG|Brodalumab 210mg SC|210 mg, subcutaneous dosing, every 2 weeks
58130984|NCT01751347|DRUG|Bupivacaine|Local anesthetics
58130985|NCT01751347|DRUG|Lidocaine|Local anesthetics
58130986|NCT01390363|OTHER|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
58467550|NCT05025059|PROCEDURE|Discussion|Participate in coaching sessions
58467551|NCT05025059|OTHER|Exercise Intervention|Perform walking exercise
58467552|NCT05025059|OTHER|Exercise Intervention|Perform strength exercises
58467553|NCT05025059|OTHER|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
58467554|NCT05025059|OTHER|Informational Intervention|Maintain exercise log
57778132|NCT02796547|OTHER|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
58467555|NCT05025059|OTHER|Medical Device Usage and Evaluation|Wear fitness tracker
58467556|NCT05025059|OTHER|Quality-of-Life Assessment|Complete questionnaires
58467557|NCT05025059|OTHER|Questionnaire Administration|Complete questionnaires
58467558|NCT04251052|PROCEDURE|Bilateral Salpingectomy|Undergo bilateral salpingectomy
58467559|NCT04251052|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
58467560|NCT04251052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58467561|NCT04251052|OTHER|Quality-of-Life Assessment|Ancillary studies
58467562|NCT04251052|OTHER|Questionnaire Administration|Ancillary studies
58467563|NCT04251052|PROCEDURE|Transvaginal Ultrasound|Undergo transvaginal ultrasound
58467564|NCT04251052|PROCEDURE|Ultrasound Imaging|Undergo pelvic ultrasound
58467565|NCT03915717|DEVICE|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
58467566|NCT03915717|DEVICE|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
58467567|NCT04848675|OTHER|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
58467568|NCT04848675|OTHER|Brisk walking|Participants will perform brisk walking.
58467569|NCT03524430|PROCEDURE|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at \~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
58467570|NCT02985827|DRUG|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
58467571|NCT02985827|DRUG|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
58467572|NCT06136871|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
58467573|NCT06136871|BEHAVIORAL|Inactive Control Group|An inactive control group will be used to control for maturation and testing effects. Weekly contact will be made via teleconferencing to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce PCS symptoms. The content of each of these meetings will be tracked in intervention notes. Each contact will be recorded for fidelity monitoring to ensure all active ingredients of the CO-OP intervention are avoided.
58467574|NCT00273221|PROCEDURE|Glaucoma Implant Surgery|
58467575|NCT00273221|PROCEDURE|trabeculectomy|
58467576|NCT00273221|PROCEDURE|phacoemulsification|
58467577|NCT05298579|OTHER|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
58467578|NCT06602076|BEHAVIORAL|ECHO (Empowering Our Community & Health Outcomes)|Additive intervention design wherein study participants receive remotely-delivered standard smoking cessation support (i.e., behavioral support plus nicotine replacement therapy) and engage in sexual and/or gender minoritized (SGM)-serving volunteer activities.
58467579|NCT04742556|DRUG|BI 3011441|BI 3011441
58467580|NCT03463057|DRUG|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
58467581|NCT01647789|DRUG|CFG920|
58467582|NCT05712460|DRUG|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
58467583|NCT05712460|DRUG|Placebo|Placebo for sisunatovir
58467584|NCT04043910|DEVICE|fNIRS|The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
58467585|NCT04043910|OTHER|Speech intelligibility|Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
58467586|NCT04043910|OTHER|Sound localisation|Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
58467587|NCT04043910|OTHER|Speech assessments|Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
58467588|NCT04043910|OTHER|Quality of Life|Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
58467589|NCT06121102|PROCEDURE|Supervoltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
58467590|NCT06121102|PROCEDURE|Standard voltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
58467591|NCT05661149|DEVICE|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
58467592|NCT00003127|DRUG|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
58467593|NCT00003127|DRUG|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
58467594|NCT00003127|DRUG|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
58467595|NCT00489996|DRUG|gemcitabine|
58467596|NCT00489996|DRUG|cisplatin|
58467597|NCT06088888|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
58467598|NCT05167851|DRUG|Lazertinib , a combination group of SBRT|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
57778133|NCT05823337|DIETARY_SUPPLEMENT|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
57778134|NCT05823337|DIETARY_SUPPLEMENT|only diet|diet suitable for pregnancy
57778135|NCT04685733|DEVICE|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
57778136|NCT02323893|DRUG|[18F]F-AraG|
58467599|NCT05167851|DRUG|Lazertinib single administration group|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
58467600|NCT01814111|PROCEDURE|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
58467601|NCT06154291|DRUG|XON7|The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
58467602|NCT06587009|PROCEDURE|Shock wave therapy|Received shock wave therapy 7 times a week and functional exercise therapy intervention
58467603|NCT06587009|PROCEDURE|Conventional conservative treatment|Conventional conservative treatment and functional exercise were given
58467604|NCT04776395|DRUG|Dexamethasone|Given PO
58467605|NCT04776395|DRUG|Iberdomide Hydrochloride|Given PO
58467606|NCT04776395|OTHER|Quality-of-Life Assessment|Ancillary studies
58467607|NCT04696120|DRUG|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
58467608|NCT04696120|DRUG|Placebo|All patients who are assigned to placebo group will receive placebo
58467609|NCT04309734|DRUG|AT-777|Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
58467610|NCT04309734|DRUG|Placebo|Administered orally, as one or two placebo capsules, depending on the arm.
58467611|NCT04309734|DRUG|AT-527|Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
58467612|NCT05130788|BEHAVIORAL|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (\<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
58467613|NCT05130788|BEHAVIORAL|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
58467614|NCT05130788|DRUG|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
58467615|NCT02086175|DRUG|Imprime PGG|
58467616|NCT02086175|DRUG|Rituximab|
58467617|NCT06222866|DIAGNOSTIC_TEST|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
58467618|NCT05404139|DRUG|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
58467619|NCT05404139|OTHER|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
58467620|NCT05516992|DRUG|SB-01 For Injection|Intradiscal injection
58467621|NCT05516992|DRUG|Sham Needle|Sham needle placement
57778137|NCT04831762|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
57778138|NCT04831762|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
57778139|NCT04831762|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
57778140|NCT04831762|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
58467622|NCT06704204|DRUG|The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks|To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
58467623|NCT02649166|DEVICE|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
58467624|NCT02649166|DEVICE|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
58467625|NCT04640025|DRUG|itacitinib|Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
58467626|NCT05361941|DEVICE|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a two-stage revision of an infected total joint.
58467627|NCT05361941|DEVICE|empty voids|Voids are left empty
58467628|NCT03542812|DRUG|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
58467629|NCT05141019|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
58467630|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
58467631|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
58467632|NCT06706583|BEHAVIORAL|Telematic educational interviews + standard training|"Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview.~In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA)."
58467633|NCT06706583|BEHAVIORAL|Standard training|Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).
58467634|NCT06513858|BEHAVIORAL|Communal Drumming|Communal drumming
58467635|NCT06513858|BEHAVIORAL|Communal drumming recordings|Recordings of drumming taken from the music made during a previous component of the study
58467636|NCT01343953|PROCEDURE|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
58467637|NCT04970134|OTHER|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
58467638|NCT04970134|OTHER|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
58467639|NCT04970134|OTHER|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
58467640|NCT01838395|DRUG|Ara-C|IV (intravenous administration)
58467641|NCT01838395|DRUG|BL-8040|SC (subcutaneous injection)
58467642|NCT06705816|OTHER|None interventional|This is an observational study
58467643|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
58467644|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
58467645|NCT00782535|DRUG|Placebo|Inhaled solution, single dose of placebo
58467646|NCT01869608|PROCEDURE|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
58467647|NCT05750251|PROCEDURE|levator muscle resection surgery|conventional ptosis surgery
58467648|NCT05750251|PROCEDURE|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
57778141|NCT04831762|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
58467649|NCT05750251|PROCEDURE|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
58467650|NCT05734768|BEHAVIORAL|State-Trait Anxiety Inventory - Y ou STAI-Y|Questionnaire
58467651|NCT05476289|OTHER|No intervention|No intervention
58467652|NCT04268641|OTHER|Arm 1|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
58467653|NCT04268641|OTHER|Arm 2|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion"
58467654|NCT04268641|OTHER|Arm 3|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair"
58467655|NCT04268641|OTHER|Arm 4|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
58467656|NCT04268641|OTHER|Arm 5|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion"
58467657|NCT04268641|OTHER|Arm 6|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair"
58467658|NCT03824223|DIAGNOSTIC_TEST|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
58467659|NCT06444308|OTHER|CommCare with Mobile Clinical Decision Support (CDS) Application|For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
58467660|NCT06444308|OTHER|Remote Supervision by Physicians|teleconsultation with a supervising physician
58467661|NCT06444308|OTHER|CommCare Application without CDS|The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
58467662|NCT01690143|DRUG|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
58467663|NCT01690143|DRUG|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
58467664|NCT03907852|BIOLOGICAL|gavo-cel|gavo-cel
58467665|NCT03907852|DRUG|fludarabine|lymphodepletion chemotherapy
58467666|NCT03907852|DRUG|cyclophosphamide|lymphodepletion chemotherapy
58467667|NCT03907852|DRUG|Nivolumab|immuno-oncology agent
58467668|NCT03907852|DRUG|Ipilimumab|immuno-oncology agent
58467669|NCT06701864|DIAGNOSTIC_TEST|Palpation|Identification of the cricothyroid membrane using PALPATION, a procedure used to prepare for front of neck airway access
58467670|NCT06701864|DIAGNOSTIC_TEST|Ultrasound|"Identification of the cricothyroid membrane, using ULTRASONOGRAPHY with either the String of pearls or TACA aproach as chosen by the participant , a procedure used to prepare for front of neck airway access"
58467671|NCT05355701|DRUG|PF-07799933|Tablet
58467672|NCT05355701|DRUG|binimetinib|Tablet
58467673|NCT05355701|BIOLOGICAL|cetuximab|Injection for intravenous use
58467674|NCT03511807|OTHER|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
58467675|NCT03511807|OTHER|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
58467676|NCT05491616|DRUG|Nivolumab|In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
58467677|NCT04750824|DRUG|Afatinib|Afatinib
58467678|NCT04750824|DRUG|other systemic therapy|other systemic therapy
58467679|NCT06589284|PROCEDURE|Silk 0-0 suture covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
58467680|NCT06589284|PROCEDURE|2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
58467681|NCT06581016|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
58467682|NCT06581016|DEVICE|Ambu aScope Gastro Large|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
58467683|NCT06581016|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
58467684|NCT06581016|DEVICE|Therapeutic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
58467685|NCT06008860|DRUG|Experimental: Primary Cohort|Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
58467686|NCT06008860|OTHER|Placebo Comparator: Primary Cohort - Placebo|A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
58467687|NCT00848809|PROCEDURE|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
58467688|NCT00848809|PROCEDURE|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
58467689|NCT05188222|DRUG|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
58467690|NCT05188222|DRUG|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
58467691|NCT05256901|DRUG|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.
58467692|NCT05256901|DRUG|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
58467693|NCT01334021|PROCEDURE|Biopsy|Undergo tumor biopsy
58467694|NCT01334021|PROCEDURE|Conventional Surgery|Undergo surgery
58467695|NCT01334021|OTHER|Genetic Testing|Undergo genetic testing
58467696|NCT05804747|DRUG|Edoxaban|This is observational, non-interventional study. No study drug will be administered during this study.
58467697|NCT01314196|OTHER|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
58467698|NCT01314196|OTHER|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
58467699|NCT06599190|OTHER|pelvic floor exercises, nutritional instructions|They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
58467700|NCT06599190|OTHER|abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions|consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.
58467701|NCT04697667|OTHER|Exercise|Supervised exercise program
58467702|NCT04697667|BIOLOGICAL|PRP|Intra-articular PRP injections to knee joint
58467703|NCT05872737|BEHAVIORAL|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
58467704|NCT05872737|BEHAVIORAL|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
58467705|NCT03288675|DEVICE|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
58467706|NCT03288675|BEHAVIORAL|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
58467707|NCT03288675|DRUG|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
58467708|NCT06704659|RADIATION|Breast conserving surgey and radiotherapy|The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
58467709|NCT06704659|PROCEDURE|Mastectomy|The patients will undergo mastectomy
58467710|NCT03851835|DRUG|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
58467711|NCT03851835|DRUG|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
58467712|NCT05036096|DEVICE|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
58467713|NCT05036096|DEVICE|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
58467714|NCT02558959|DRUG|Irinotecan|
58467715|NCT02558959|DRUG|Capecitabine|
58467716|NCT03839524|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
58467717|NCT02198014|OTHER|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
58467718|NCT02198014|OTHER|Educational Physiotherapy|"* Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
58467719|NCT05130008|OTHER|Digitally-enabled CHW Care|Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
58467720|NCT05130008|BEHAVIORAL|Usual CHW Care|Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
58467721|NCT06706193|PROCEDURE|Total hip arthroplasty using CPE|
58467722|NCT06706193|PROCEDURE|Total hip arthroplasty using HXLPE|
58467723|NCT06382168|DRUG|DFP-10917|DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.
58467724|NCT06382168|DRUG|Venetoclax|Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
58467725|NCT02437045|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
58467726|NCT02437045|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
58467727|NCT00717574|DRUG|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
58467728|NCT00717574|DRUG|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
58467729|NCT06597929|OTHER|Moderate-vigorous physical activity|The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
58467730|NCT03556228|DRUG|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
58467731|NCT04750317|DRUG|Tofacitinib|Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
58467732|NCT06602154|OTHER|Resin modified glass ionomer|"The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds."
58467733|NCT05973942|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
58467734|NCT05524025|DIAGNOSTIC_TEST|Salivary TTMV-HPV DNA Test|Mouthwash rinse
58467735|NCT05524025|DIAGNOSTIC_TEST|Blood TTMV-HPV DNA Test|Blood test
58467736|NCT04913610|DRUG|ABBV-4083|Oral Capsule
58467737|NCT04913610|DRUG|Placebo for ABBV-4083|Oral Capsule
58467738|NCT04913610|DRUG|Albendazole|Oral encapsulated tablets
58467739|NCT04913610|DRUG|Placebo for Albendazole|Oral Capsule
58467740|NCT05595486|OTHER|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
58467741|NCT02669953|DRUG|Aflibercept|
58467742|NCT06207188|OTHER|Non-Interventional Study|Non-interventional study
58467743|NCT06270147|DRUG|Bupivacaine-epinephrine|A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
58467744|NCT05237960|PROCEDURE|Biopsy|Undergo biopsy
58467745|NCT05237960|PROCEDURE|Biospecimen Collection|Correlative studies
58467746|NCT05237960|DRUG|Extended Release Metformin Hydrochloride|Given PO
58467747|NCT05237960|DRUG|Placebo Administration|Given PO
58467748|NCT04771494|OTHER|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP \> 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
58467749|NCT06027580|DEVICE|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
58467750|NCT06027580|OTHER|Standard Care Therapy option|Standard of care Therapy without the use of trunk orthosis
58467751|NCT05096195|DRUG|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
58467752|NCT05096195|OTHER|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
57778142|NCT04161417|OTHER|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
57778143|NCT00271869|PROCEDURE|Extracorporeal photoimmunotherapy|
57778144|NCT01822353|DIETARY_SUPPLEMENT|Dietary supplement|Milk, egg or nut oral immunotherapy
57778145|NCT06531135|BEHAVIORAL|T-CBSM|A 10-week remotely-delivered group, lasting about 120 minutes each session.
58467753|NCT05096195|DIAGNOSTIC_TEST|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
57778146|NCT06531135|BEHAVIORAL|Support group|Participants will receive weekly supportive-expressive group intervention for two hours per week for five weeks total.
57778147|NCT03380884|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
57778148|NCT01081353|DRUG|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
58467754|NCT05006352|DRUG|DNL343|Oral repeating dose
58467755|NCT05006352|DRUG|Placebo|Oral repeating dose
58467756|NCT04325789|DEVICE|nanofiber scaffold|Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
58467757|NCT04523714|BEHAVIORAL|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
58467758|NCT04523714|BEHAVIORAL|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
58467759|NCT05236556|BEHAVIORAL|Best practice advisory (BPA)|"For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider."
58467760|NCT02615600|DEVICE|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
58467761|NCT06702410|BEHAVIORAL|mental health gap action program intervention guide (mhGAP-IG)|The mhGAP-IG is an evidence-based intervention developed by WHO. It was designed for non-specialists to scale up high quality mental health services. Although more than 90 countries worldwide have implemented mhGAP-IG, this study is the first to evaluated if it works for scaling up CMBDs services in China. Investigators have cultrually adapted the mhGAP-IG according Chinese context.
58467762|NCT03949569|BEHAVIORAL|Therapy Dog|Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
58467763|NCT03949569|BEHAVIORAL|Stuffed Toy Dog|Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
58467764|NCT03949569|BEHAVIORAL|5 Minute Puppy Video|Children will watch a 5 minute puppy video.
58467765|NCT06387264|DEVICE|Medical Adhesive|Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.
58467766|NCT06387264|DEVICE|ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter|ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
57778149|NCT01081353|DRUG|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
58467767|NCT05131165|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
58467768|NCT05131165|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to draw a prize if they take their medication within +/- one hour of the stated existing routine to which pill-taking is anchored on at least 70% of days between recruitment and the 3-month study visit.
58467769|NCT05107336|DRUG|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
58467770|NCT05107336|DRUG|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
58467771|NCT06203054|DEVICE|Penditure™ Left Atrial Appendage (LAA) Exclusion System|Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
58467772|NCT05684055|DRUG|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
58467773|NCT05684055|OTHER|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
58467774|NCT04672642|DEVICE|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
58467775|NCT04641442|BIOLOGICAL|MAS825|Experimental drug
58467776|NCT04641442|BIOLOGICAL|Placebo|matching placebo
58467777|NCT04008940|DEVICE|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
58467778|NCT04540185|BIOLOGICAL|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
58467779|NCT04540185|BIOLOGICAL|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
58467780|NCT04540185|DRUG|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
58467781|NCT04540185|DRUG|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
58467782|NCT04540185|COMBINATION_PRODUCT|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
58467783|NCT04540185|COMBINATION_PRODUCT|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
58467784|NCT04785300|DRUG|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
58467785|NCT04785300|DRUG|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
58467786|NCT05393791|OTHER|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
58467787|NCT05393791|DRUG|Abiraterone acetate|Use of abiraterone or enzalutamide
58467788|NCT05393791|DRUG|Enzalutamide|Use of abiraterone or enzalutamide
58467789|NCT06704399|OTHER|Acceptance and Commitment Therapy-Based Psychoeducation|Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
58467790|NCT06704399|OTHER|control group|No intervention will be applied to the control group.
58467791|NCT05131204|DRUG|Cemdisiran|Administered per protocol
58467792|NCT05131204|DRUG|Eculizumab|Administered per protocol
58467793|NCT05131204|DRUG|Pozelimab|Administered per protocol
58467794|NCT05131204|DRUG|Ravulizumab|Administered per protocol
58467795|NCT00178295|RADIATION|Radiation Therapy|standard of care for the cancer being treated
58467796|NCT05889728|DRUG|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
58467797|NCT02938130|OTHER|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
57778150|NCT01081353|DRUG|Aspirin Migraine|One effervescent tablet under fasting conditions
57778151|NCT01081353|DRUG|Aspirin Aspro|One effervescent tablet under fasting conditions
57778152|NCT00249249|DRUG|Pitavastatin|
57778153|NCT00249249|DRUG|Atorvastatin|
57778154|NCT04493918|COMBINATION_PRODUCT|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
57778155|NCT04493918|COMBINATION_PRODUCT|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
58467798|NCT01593826|DRUG|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
58467799|NCT01593826|DRUG|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
58467800|NCT01593826|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
58467801|NCT01593826|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
58467802|NCT06425380|OTHER|Resistant Potato Starch|Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations.
58467803|NCT04575155|BEHAVIORAL|TEAM Strategy|"1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
58467804|NCT00116103|DRUG|Tacrolimus Inhalation Aerosol|
58467805|NCT05182372|BEHAVIORAL|Enhanced dCBT-I|Telehealth Coaching
58467806|NCT04982250|BEHAVIORAL|Formal peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
58467807|NCT04364867|DRUG|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
58467808|NCT04364867|DRUG|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
58467809|NCT06589492|DIAGNOSTIC_TEST|Measurement of MMP-9 and SIRT-1 levels in blood serum|Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
58467810|NCT06022861|DRUG|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
58467811|NCT06022861|DRUG|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
58467812|NCT06022861|DRUG|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
58467813|NCT06022861|DRUG|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
58467814|NCT03624881|DEVICE|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
58467815|NCT05531643|DEVICE|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
58467816|NCT05531643|DEVICE|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
58467817|NCT06586697|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
58467818|NCT06547684|DEVICE|fESWT|"Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle."
58467819|NCT04017052|DRUG|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
58467820|NCT04240210|DRUG|Symtuza|The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
58467821|NCT06458855|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
58467822|NCT00013572|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
58467823|NCT03600324|BEHAVIORAL|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
58467824|NCT05228574|DIETARY_SUPPLEMENT|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
58467825|NCT05228574|DIETARY_SUPPLEMENT|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
58467826|NCT05228574|DRUG|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
58467827|NCT06025916|DRUG|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
58467828|NCT06109467|DRUG|Neratinib|All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
58467829|NCT06109467|DRUG|Trastuzumab|All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
58467830|NCT06109467|DRUG|Oxaliplatin|All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
58467831|NCT06109467|DRUG|5-Fluorouracil + leucovorin|All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
58467832|NCT06109467|DRUG|Pembrolizumab|All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
58467833|NCT00174577|DRUG|Risperidone|
58467834|NCT03573648|DRUG|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
58467835|NCT03573648|DRUG|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
58467836|NCT03573648|DRUG|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
58467837|NCT06425861|DRUG|THB335 single dose|Single dose as oral capsule
58467838|NCT06425861|DRUG|Single dose placebo|Single dose as oral capsule
58467839|NCT06425861|DRUG|THB335 fasted/fed|Single dose fasted and fed as oral capsule
58467840|NCT06425861|DRUG|Placebo fasted/fed|Single dose fasted and fed as oral capsule
58467841|NCT06425861|DRUG|THB335 multiple dose|Multiple ascending doses oral capsule
58467842|NCT06425861|DRUG|Multiple dose placebo|Multiple doses oral capsule
58467843|NCT06433791|DRUG|Ascorbate-Meglumine|Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
58467844|NCT04701008|DRUG|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
58467845|NCT05495815|DRUG|6 months of SAT|6 months of oral suppressive antibiotic therapy
58467846|NCT05495815|DRUG|12 months of SAT|12 months of oral suppressive antibiotic therapy
58467847|NCT05495815|DRUG|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
58467848|NCT06706466|OTHER|observational study|Non-interventional
58467849|NCT06270784|PROCEDURE|Traditional Extraction|Participants in this group will undergo traditional extraction method. This method involves uncovering the impacted tooth and extracting the tooth with or without dividing it.
58467850|NCT06270784|PROCEDURE|Orthodontic Extraction|"Participants in this group will undergo orthodontic extraction method. In this method, a two-stage surgical procedure will be performed. In the first operation, the impacted tooth will be uncovered, and then a button will be placed on the tooth. For anchorage purposes, orthodontic mini screws will be placed in the mandibular ramus or zygomaticomaxillary buttress area. Elastics and/or ligature wires fixed to the button will be attached to the mini screw to provide force for the traction of the tooth.~Patients will be called for check-up appointments every two weeks, and the movement of the impacted tooth will be monitored with panoramic x-rays. The second operation will be planned when the tooth moves away from the inferior alveolar nerve. In the second operation, the tooth will be extracted in a similar way to the traditional extraction group."
58467851|NCT04555486|DRUG|DCR-PHXC|Intervention, drug, DCR-PHXC
58467852|NCT04555486|DRUG|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
58467853|NCT03748823|COMBINATION_PRODUCT|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
58467854|NCT03748823|BIOLOGICAL|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
58467855|NCT06647238|OTHER|Pharmacist Intervention in lipid therapy|Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
58467856|NCT05797233|BIOLOGICAL|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
58467857|NCT05797233|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
58467858|NCT05797233|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
58467859|NCT06705608|DRUG|Fingolimod|patients who received fingolimod for treating RRMS
58467860|NCT06705608|DRUG|Natalizumab|patients who received natalizumab for treating RRMS (active comparator)
58467861|NCT06705608|DRUG|Dimethyl fumarate (DMF)|patients who received dimethyl fumarate for treating RRMS (active comparator)
58467862|NCT06705608|DRUG|Alemtuzumab|patients who received alemtuzumab for treating RRMS (active comparator)
58467863|NCT06705608|DRUG|Teriflunomide|patients who received teriflunomide for treating RRMS (active comparator)
58467864|NCT03443141|DRUG|Vitamin E|The applied dressing will be embebbed in Vitamin E
58467865|NCT03443141|DRUG|Standard dressing|The applied dressing is a normal one without adding any product to it.
58467866|NCT03651700|DEVICE|Active TMS|Active TMS will be at 90% motor threshold
58467867|NCT03651700|DEVICE|Sham TMS|Sham TMS will be administered
58467868|NCT03651700|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
58467869|NCT05282095|OTHER|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
58467870|NCT04421677|DRUG|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
58467871|NCT06491186|OTHER|Point of Care Ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
58467872|NCT04188743|BIOLOGICAL|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
58467873|NCT04188743|BIOLOGICAL|Autologous FMT|Transplantation of autologous fecal microbiota
58467874|NCT06705335|OTHER|Blood sample|On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
58467875|NCT03302325|PROCEDURE|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
58467876|NCT05048979|OTHER|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
58467877|NCT06518824|DEVICE|DBS On|The DBS device will be turned on while the patient undergoes the working memory task.
58467878|NCT06518824|DEVICE|DBS Off|The DBS device will be turned off while the patient undergoes the working memory task.
58467879|NCT06705634|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the multifidus of the C5-C6 cervical muscles. Once the needle has been inserted, the needle will be pistoned in an up and down motion within the multifidus muscle at approximately 1Hz for 10 seconds and then left in-situ for 5 minutes.
58467880|NCT06704282|BEHAVIORAL|VR Mindfulness Meditation Program|A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
58467881|NCT06093282|BEHAVIORAL|ARCH|"ARCH is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* A 12-session adaptation of Behavioral Activation Treatment for Depression~* Weekly contacts from an outreach worker~* Optional resources aimed at promoting physical activity and weight management"
58467882|NCT06093282|BEHAVIORAL|Traditional Health Outreach|"The Traditional Health Outreach comparator is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* Support calls from an outreach worker at least once every 3 weeks"
58467883|NCT06600620|DEVICE|Monitoring patients heart rythms with a wireless patch device|The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
58467884|NCT03692208|BEHAVIORAL|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
58467885|NCT06442475|PROCEDURE|Biospecimen Collection|Undergo blood, oral, and/or rectal sample collection
58467886|NCT06442475|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
58467887|NCT06442475|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58467888|NCT06442475|BIOLOGICAL|Mosunetuzumab|Given IV
58467889|NCT06442475|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58467890|NCT06442475|OTHER|Questionnaire Administration|Ancillary studies
58467891|NCT05200208|DIETARY_SUPPLEMENT|Citicoline supplement|Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
58467892|NCT05200208|OTHER|Placebo|Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
58467893|NCT02402816|DEVICE|MultiPoint Pacing ON|MultiPoint Pacing ON
58467894|NCT02402816|DEVICE|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
58467895|NCT05203614|BEHAVIORAL|Household Contribution|Questionnaires
58467896|NCT05203614|BEHAVIORAL|Outside Contribution|Questionnaires
58467897|NCT05203614|BEHAVIORAL|Control|Questionnaires
58467898|NCT06254638|BEHAVIORAL|Multicomponent school-based intervention.|"Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the research team) are in charge of the physically active classes.~Active break: the intervention consists of 2 active pauses per day. The development of each pause is carried out through a specific digital platform in which students follow the instructions of an avatar, who is in charge of guiding the realization of the active break. Each active break takes a total of 4 minutes, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed.~Active break: The intervention consists of a daily active break, every school day of the week. The design and supervision of each active break will be carried out by the support technician and the teaching staff based on the students' tastes."
57784510|NCT01167179|BEHAVIORAL|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
58467899|NCT05575830|BIOLOGICAL|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
58467900|NCT04530981|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
58467901|NCT04530981|DRUG|Repaglinide|Oral antihyperglycemic agent
58467902|NCT02753270|PROCEDURE|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
58467903|NCT02753270|PROCEDURE|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
58467904|NCT06705270|BEHAVIORAL|Response-focused education|Once participants recover from sedation, they will receive education that is focused on their response to treatment.
58467905|NCT06705270|BEHAVIORAL|Diagnosis-focused education|Once participants recover from sedation, they will be provided education that is focused on their diagnosis of major depressive disorder.
57784511|NCT00697021|DRUG|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
58467906|NCT03800381|OTHER|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
58467907|NCT06503510|OTHER|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
58467908|NCT06503510|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
58467909|NCT06503510|OTHER|bovine adrenal medulla (BAM8-22)|A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
58467910|NCT06548126|BEHAVIORAL|Online Parenting Program|Online Parenting Program comprised of 12 online modules. Caregivers do one module per week for 12-15 weeks; each unit takes about 20 minutes to do. The Caregiver also practices the tools they learn for Parenting their Children between sessions.
58467911|NCT06548126|OTHER|No online parenting program|List of Parenting resources.
58467912|NCT04386993|RADIATION|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
58467913|NCT02173769|DRUG|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
58467914|NCT02173769|DRUG|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
58467915|NCT06629168|DIAGNOSTIC_TEST|lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.
58467916|NCT06629168|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
58467917|NCT06629168|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
58467918|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #1|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
58467919|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #2|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
58467920|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #3|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
58467921|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #4|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
58467922|NCT06629168|DIAGNOSTIC_TEST|Telemetric prechamber reading|Non-invasive reading of telemetric prechamber made during each follow-up control.
58467923|NCT06629168|OTHER|Valve setting change|Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
58467924|NCT04198870|DEVICE|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
58467925|NCT04198870|PROCEDURE|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
58467926|NCT03980509|DRUG|Curcumin|Curcumin is an extract from turmeric
58467927|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at camp with the guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at camp will follow the same principles as the usual HABIT-ILE. The therapy will take place in a rehabilitation center, and caregivers will provide therapy during the sessions, coached by trained supervisors on site~* The intervention day will then take place, lasting for 5 hours with the constant presence of supervisors. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
58467928|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at home with the online guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at home will follow the same principles as the usual HABIT-ILE. The therapy will take place at children's home, caregivers will provide therapy during the sessions, coached by trained supervisors online~* The intervention day will then take place, lasting for 5 hours with the supervisors through online setting. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
58467929|NCT03396809|DEVICE|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
58467930|NCT02081924|OTHER|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
58467931|NCT02081924|OTHER|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
58467932|NCT02081924|OTHER|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
58467933|NCT02081924|OTHER|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
58467934|NCT06599346|OTHER|Standard Care|Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.
58467935|NCT06599346|BIOLOGICAL|MSC Supernatant + Standard Care|"Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"
58467936|NCT04410991|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
58467937|NCT04410991|DRUG|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
58467938|NCT04410991|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
58467939|NCT04410991|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
58467940|NCT04506853|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
58467941|NCT06100887|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
58467942|NCT06100887|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
58467943|NCT06100887|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
58467944|NCT06100887|DRUG|Placebo|Placebo is administered orally once per day
58467945|NCT06560489|DRUG|Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
58467946|NCT04191538|PROCEDURE|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
58467947|NCT04191538|PROCEDURE|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
58467948|NCT04191538|PROCEDURE|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
58467949|NCT03901755|DRUG|Alprolix|Extended half-life factor IX product
58467950|NCT06198933|DEVICE|Pulsed-field ablation|Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
58467951|NCT06705855|DEVICE|NIRS sensor placement|After written informed consent, the patient will be brought to the operating room. Skin tone will be assessed using the Monk scale. Prior to induction of general anesthesia, the right kidney will be located by surface ultrasound, the distance between the renal capsule and the skin will be measured, and a NIRS sensor will be placed on the skin overlaying the kidney. If the patient has had a right nephrectomy, the left kidney will be used. Additional NIRS sensors will then be placed over the patient's ipsilateral biceps and vastus lateralis muscles. The distance from the skin to the muscle tissue will be measured and recorded using ultrasound. NIRS sensors will also be placed on the patient's forehead to measure cerebral oximetry as is current practice at our institution for all cardiac surgeries requiring cardiopulmonary bypass.
58467952|NCT02515916|OTHER|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
58467953|NCT04471714|DRUG|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
58467954|NCT04917107|BEHAVIORAL|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
58467955|NCT06123325|PROCEDURE|Clipping|Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
58467956|NCT06123325|PROCEDURE|Endovascular embolization|Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
58467957|NCT06123325|DIAGNOSTIC_TEST|Surveillance imaging|Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
58467958|NCT05659030|OTHER|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
58467959|NCT03270436|BEHAVIORAL|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
58467960|NCT03270436|BEHAVIORAL|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
58467961|NCT00948246|DEVICE|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
58467962|NCT05430854|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
58467963|NCT05330481|OTHER|Moderate-intensity (relative) exercise with glucose ingestion|120 minutes of cycling at 95% of lactate threshold ingesting 90 g/h of glucose
58467964|NCT05330481|OTHER|Moderate-intensity (absolute) exercise with glucose ingestion|120 minutes of cycling at a power matched to participant in the \<70 kg body mass group, ingesting 90 g/h of glucose
58467965|NCT05491265|BEHAVIORAL|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
58467966|NCT04076696|DEVICE|Scatter corrected s-DCT|All patients will have a breath held s-DCT scan in an anterior-posterior direction
58467967|NCT06594016|DRUG|Fosigotifator|Oral
58467968|NCT03538197|OTHER|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
58467969|NCT06589466|OTHER|Surgery|this study in observational study, no intervention.
58467970|NCT06705920|DRUG|topical oxygen gel|In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab
58467971|NCT06504628|DIAGNOSTIC_TEST|screening risk for falling and identifiy the risk level low-intermediate-high|"3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk"
58467972|NCT06504628|DIAGNOSTIC_TEST|3 mnth-follow-up|patient's phone call, and data collected from electronic medical record
58467973|NCT04571944|DRUG|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
58467974|NCT04571944|DRUG|Placebo|Suvorexant-matching placebo administered QD via oral tablet
58467975|NCT06704854|DIAGNOSTIC_TEST|Screening Platform|assessment of low-frequency fatigue using myocene
58467976|NCT00005942|DRUG|liposomal daunorubicin citrate|Given IV
58467977|NCT00005942|DRUG|semaxanib|Given IV
58467978|NCT00005942|OTHER|laboratory biomarker analysis|Correlative studies
58467979|NCT05065060|OTHER|Observation|Observation
58467980|NCT03350529|DEVICE|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
58467981|NCT04504253|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate loose powder
58467982|NCT04504253|DRUG|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
58467983|NCT06051305|BEHAVIORAL|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
58467984|NCT05552664|GENETIC|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
58467985|NCT04211961|DRUG|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
58467986|NCT04211961|OTHER|Placebo|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
58467987|NCT06705036|OTHER|surgery|Samples were obtained from patients by surgical excision and matched into groups
58467988|NCT06052475|DEVICE|Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
58467989|NCT06052475|DEVICE|Continued RV Pacing (Right Ventricular Pacing)|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
58467990|NCT05974241|DRUG|Methylphenidate, aripiprazole, and combination|Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
58467991|NCT05690139|PROCEDURE|Pre-operative LSG patients|Baseline
58467992|NCT05690139|PROCEDURE|Post-operative patients 1st month|1 month after surgery
58467993|NCT05690139|PROCEDURE|Post-operative patients 3rd month|3 months after surgery
58467994|NCT05690139|PROCEDURE|Post-operative patients 6th month|6 months after surgery
58467995|NCT01456637|BEHAVIORAL|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
58467996|NCT03796650|OTHER|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
58467997|NCT03796650|DRUG|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
58467998|NCT06581471|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
58467999|NCT02595892|DRUG|Berzosertib|Given IV
58468000|NCT02595892|DRUG|Gemcitabine|Given IV
58468001|NCT02595892|DRUG|Gemcitabine Hydrochloride|Given IV
58468002|NCT06692673|DRUG|Use of Linaclotide as a single agent Colonoscopy prep|We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
58468003|NCT02702492|DRUG|KPT-9274|
58468004|NCT02702492|DRUG|Niacin ER|
58468005|NCT02702492|DRUG|Nivolumab|
58468006|NCT04603846|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
58468007|NCT04603846|DRUG|albumin bound paclitaxel|Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
58468008|NCT05593380|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
58468009|NCT05593380|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
58468010|NCT05800210|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
58468011|NCT05552846|RADIATION|thoracic radiotherapy|Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
58468012|NCT05997225|OTHER|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
58468013|NCT05997225|OTHER|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
58468014|NCT05702463|DRUG|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
57784512|NCT00697021|DRUG|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
58468015|NCT05702463|DRUG|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
58468016|NCT05702463|DRUG|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
58468017|NCT05896163|DRUG|maplirpacept (PF-07901801)|Intravenous infusion
58468018|NCT05896163|DRUG|Glofitamab|Intravenous infusion
58468019|NCT05896163|DRUG|Obinutuzumab|Intravenous infusion
58468020|NCT04418024|DRUG|AG10|TTR stabilizer administered orally twice daily (BID)
58468021|NCT04418024|DRUG|Placebo|Non-active control
58468022|NCT06702072|DEVICE|Endobronchial valve treatment|Endobronchial valve treatment
58468023|NCT02061787|DEVICE|balloon pulmonary angioplasty|patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
58468024|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)"
58468025|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)"
58468026|NCT04440033|OTHER|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
57784513|NCT04471883|PROCEDURE|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
58468027|NCT04440033|OTHER|Speech assessments|"* Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)"
58468028|NCT04440033|OTHER|Audiology assessments|"* Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
58468029|NCT06178796|DEVICE|Dental implant|Dental implant placement
58468030|NCT03916133|DIAGNOSTIC_TEST|Intervention group|6s PBV mapping will be conducted
58468031|NCT03889184|OTHER|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
58468032|NCT03084146|OTHER|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
58468033|NCT06277687|DIAGNOSTIC_TEST|Virtual Augmented Reality Combined With Finder|After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
58468034|NCT06220214|DIAGNOSTIC_TEST|CEDM|Contrast Enhanced Digital Mammography
58468035|NCT06220214|DIAGNOSTIC_TEST|CEDBT|Contrast-Enhanced Digital Breast Tomosynthesis
58468036|NCT06220214|DRUG|Omnipaque 350mgI/mL Solution for Injection|Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
58468037|NCT04188912|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples
58468038|NCT04188912|PROCEDURE|Optical Coherence Tomography|Undergo optical coherence tomography
58468039|NCT04188912|PROCEDURE|Spirometry|Undergo portable spirometry
58468040|NCT04188912|OTHER|Survey Administration|Complete survey
58468041|NCT04188912|OTHER|Digital Photography|Undergo digital photography
58468042|NCT04188912|OTHER|Quality-of-Life Assessment|Ancillary studies
58468043|NCT04188912|OTHER|Medical Chart Review|Review of medical charts
58468044|NCT04172584|BEHAVIORAL|correct use of the contraceptions|know the emergency contraception and how to use
58468045|NCT04595773|OTHER|Aerobic Exercise Training|Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
58468046|NCT04595773|OTHER|Education|Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
58468047|NCT05010707|DRUG|Transdermal patch|Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
58468048|NCT05010707|DIAGNOSTIC_TEST|Pro-thrombotic markers|Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
58468049|NCT05010707|DIAGNOSTIC_TEST|Metabolic markers|Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
58468050|NCT05010707|DIAGNOSTIC_TEST|Hormone Profile|Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
58468051|NCT05010707|DRUG|Daily Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
58468052|NCT05010707|DRUG|BID Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
58468053|NCT05010707|DRUG|Spironolactone|All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
58468054|NCT04496960|DRUG|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
58468055|NCT04496960|OTHER|Placebo|white, round, film-coated tablet
58468056|NCT05652010|DEVICE|New 2-piece Coupling|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with new 50mm Ø coupling.
58468057|NCT05652010|DEVICE|SenSura Mio Click|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with 50mm Ø coupling.
58468058|NCT05757843|DIAGNOSTIC_TEST|Signatera ctDNA test|The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. ctDNA testing will be repeated approximately every 4 weeks until two consecutive negative analyses occur. ctDNA testing will be otherwise discontinued after progressive disease or after up to 1 year of consolidation treatment per standard medical practice is considered complete, whichever occurs first.
58468059|NCT05757843|DRUG|Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Durvalumab will be stopped after two consecutive negative ctDNA analyses occur.
58468060|NCT01787500|BIOLOGICAL|Cetuximab|Given IV
58468061|NCT01787500|DRUG|Irinotecan Hydrochloride|Given IV
58468062|NCT01787500|OTHER|Laboratory Biomarker Analysis|Correlative studies
58468063|NCT01787500|OTHER|Pharmacological Study|Correlative studies
58468064|NCT01787500|DRUG|Vemurafenib|Given PO
58468065|NCT03928132|BEHAVIORAL|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
58468066|NCT05264779|OTHER|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
58468067|NCT05296473|DEVICE|ADHD Therapy|investigational game-play therapy
58468068|NCT05296473|DEVICE|Control Therapy|control game-play therapy
58468069|NCT04377971|BEHAVIORAL|SOC education|Standard participant education from researcher
58468070|NCT04377971|BEHAVIORAL|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
58468071|NCT04377971|OTHER|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
58468072|NCT04377971|OTHER|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
58468073|NCT06477055|DRUG|Osimertinib|Osimertinib, 80mg, po, qd.
58468074|NCT06122688|BEHAVIORAL|Navigator Plus App Intervention|Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
58468075|NCT06091241|PROCEDURE|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
58468076|NCT06091241|PROCEDURE|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
58468077|NCT06589921|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
58468078|NCT06589921|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
58468079|NCT05795049|OTHER|Stool and saliva sample collection|Stool and saliva samples collection
58468080|NCT05795049|OTHER|Questionnaire completion|"Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®"
58468081|NCT01903356|DRUG|Trajenta duo|Linagliptin and Metformin
58468082|NCT04090203|DRUG|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
58468083|NCT06472284|DEVICE|TetraGraph|etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
58468084|NCT04907058|DEVICE|novel device with a comfortable mask|Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
58468085|NCT04533919|PROCEDURE|Biospecimen Collection|Undergo collection of dorsal root ganglia
58468086|NCT03526133|DIAGNOSTIC_TEST|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
58468087|NCT06147986|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
58468088|NCT06147986|OTHER|Control group|Standard-of-care for STEMI
58468089|NCT04504734|DRUG|Bucillamine|100mg tablets
58468090|NCT04504734|DRUG|Placebo|100mg tablets
58468091|NCT04504734|DRUG|Bucillamine|200mg tablets
58468092|NCT04584424|OTHER|The study does not required|The study is prospective multi-center COVID-19 patient cohort
58468093|NCT06569368|DRUG|Metronidazole|Given by PO
58468094|NCT06601283|DRUG|Vitmain C plus herbal medicine|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
58468095|NCT06596863|DIAGNOSTIC_TEST|The association of serum uromodulin with DN|Meta analysis of association of serum uromodulin with DKD
58468096|NCT06596863|DIAGNOSTIC_TEST|The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN|DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
58468097|NCT03381690|PROCEDURE|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
58468098|NCT05547347|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58468099|NCT05547347|PROCEDURE|Mammogram|Undergo a mammogram
58468100|NCT05547347|PROCEDURE|Ultrasound|Undergo a breast ultrasound
58468101|NCT05547347|PROCEDURE|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
58468102|NCT05547347|DEVICE|Twinkle marker|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
58468103|NCT04534075|BIOLOGICAL|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
58468104|NCT05635461|DRUG|CVN424|150 mg of either tablet or suspension formulation
58468105|NCT06520501|DIETARY_SUPPLEMENT|Herbal Medicine Sambiloto|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
58468106|NCT06520501|BEHAVIORAL|Brisk Walking|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
58468107|NCT06520501|COMBINATION_PRODUCT|Brisk Walking and Herbal Medicine Sambiloto|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute. Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days
58468108|NCT04337372|BEHAVIORAL|Book reading|Parent and their infant will read a short book in the laboratory. Books will include three labeling conditions expected to elicit different levels of attention.
58468109|NCT06005467|PROCEDURE|Open reduction and internal fixation of mandibular angle fracture using V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
58468110|NCT06600854|DEVICE|BoneTape|"BoneTape is a craniofacial fracture repair device intended for use in the fixation of non-load-bearing bones of the craniofacial and midfacial skeleton. It can be used in skeletally mature individuals but is not intended for use in the mandible and/or full load bearing procedures. It is composed of: 1) BoneTape implant (device), and 2) BoneTape applicator (applicator)."
58468111|NCT03893396|DEVICE|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
58468112|NCT06176118|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
58468113|NCT04991402|DEVICE|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
58468114|NCT03541850|DRUG|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
58468115|NCT03541850|OTHER|Quality-of-Life Assessment|Ancillary studies
58468116|NCT03541850|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
58468117|NCT06206447|PROCEDURE|Tunnel-cuffed Catheter|Tunnel-cuffed Catheter in right internal jugular vein
58468118|NCT06206447|PROCEDURE|Non-ccuffed Catheter|Non-ccuffed Catheter in right internal jugular vein
58468119|NCT03864783|DIETARY_SUPPLEMENT|Curcumin (Meriva®)|"Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)"
58468120|NCT03864783|DRUG|Placebo Oral Tablet|"Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®."
58468121|NCT05165667|OTHER|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
58468122|NCT05099809|OTHER|Hyperthermia|Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
58468123|NCT00759590|PROCEDURE|CT scan and Pressure volume curve|CT scan
58468124|NCT04175613|DRUG|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
58468125|NCT03306914|OTHER|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
58468126|NCT03306914|OTHER|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
58468127|NCT03306914|DRUG|Albumin 5%|Infusion of Albumin 5% intra-operatively
58468128|NCT03306914|DRUG|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
58468129|NCT01262417|PROCEDURE|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
58468130|NCT01262417|PROCEDURE|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
58468131|NCT06650514|DRUG|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
58468132|NCT06612944|DRUG|Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation|"1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1"
58468133|NCT03659188|PROCEDURE|Cortico-alveolar perforations|Mechanical drills will be used on a handpiece
58468134|NCT03659188|PROCEDURE|Traditional Corticotomy|Piezo-surgery will be employed following flaps' elevation.
58468135|NCT03626454|DRUG|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
58468136|NCT03626454|DRUG|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
58468137|NCT03626454|DRUG|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
58468138|NCT03626454|DRUG|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
58468139|NCT04267120|DRUG|Lenvatinib|Lenvatinib will be provided by Merck.
58468140|NCT04267120|DRUG|Pembrolizumab|Merck will provide pembrolizumab
58468141|NCT04267120|PROCEDURE|Research blood collection|-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
58468142|NCT04386317|DRUG|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
58468143|NCT02432443|BEHAVIORAL|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
58468144|NCT02432443|OTHER|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
58468145|NCT05172128|DIETARY_SUPPLEMENT|lyophilized blueberry supplement|lyophilized blueberry supplement bid
58468146|NCT06318741|OTHER|aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.|aerobic exercise on the treadmill
58468147|NCT06318741|OTHER|Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.|Walking at an intensity of 12-13 RPE
58468148|NCT05052268|DRUG|XTX202|XTX202 Monotherapy
58468149|NCT06511791|DRUG|FE 999302|Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
58468150|NCT06511791|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
58468151|NCT06511791|DRUG|Placebo FE 999302|No active ingredient, subcutaneous injection.
58468152|NCT05295849|BEHAVIORAL|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
58468153|NCT05141383|OTHER|Urine sampling|A blood sample and a urine sample after prostate massage will be carried out at baseline
58468154|NCT04642027|RADIATION|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
58468155|NCT04642027|RADIATION|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
58468156|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
58468157|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intravenously)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
58468158|NCT04908579|DRUG|bupivacaine(intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
58468159|NCT03959423|DEVICE|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
58468160|NCT06410027|OTHER|Pain Neuroscience Education + Virtual Reality + Therapeutic Exercise|Patients will receive 1-hour pain neuroscience education session + 30-minutes exposure to exercise with virtual reality + therapeutic exercise
58468161|NCT06410027|OTHER|Therapeutic Exercise|Patients will receive therapeutic exercise
58468162|NCT04784325|DIAGNOSTIC_TEST|Blood draw through TAP II|Two self-administered blood draws through TAP II device
58468163|NCT04784325|DIAGNOSTIC_TEST|Blood draw through ADx cardT|One self-administered ADx card blood draw
58468164|NCT04784325|DIAGNOSTIC_TEST|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
58468165|NCT05642728|OTHER|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
58468166|NCT04648462|OTHER|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
58468167|NCT06271408|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Aerosolized albuterol
58468168|NCT06271408|DEVICE|Vibrating Mesh Nebulizer|A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
58468169|NCT06271408|DEVICE|Metered Dose Inhaler|A metered dose inhaler will be used to deliver aerosolized albuterol
58468170|NCT06271408|DEVICE|Jet Nebulizer|A jet nebulizer will be used to deliver aerosolized albuterol
58468171|NCT04887116|BEHAVIORAL|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person.
58468172|NCT03662776|BEHAVIORAL|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
58468173|NCT03662776|BEHAVIORAL|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
58468174|NCT03243695|OTHER|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
58468175|NCT03243695|OTHER|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
58468176|NCT06323291|BEHAVIORAL|Coaching Sessions|"Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email."
58468177|NCT02657096|PROCEDURE|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
58468178|NCT02657096|PROCEDURE|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
58468179|NCT05174247|OTHER|FFRct analysis|Software analysis of Cardiac CT to show extent of pericardial stenoses
58468180|NCT05501236|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
58468181|NCT00783159|PROCEDURE|Power Training|Power training, Vitamin D substitution
57784514|NCT01293526|DEVICE|Control|Patients who respond will have leads will be placed using standard procedures.
58468182|NCT00783159|PROCEDURE|Strength Training|Strength training, Vitamin D substitution
58468183|NCT00783159|OTHER|Control|Vitamin D substitution, Lifestyle consultation
58468184|NCT05945121|OTHER|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
58468185|NCT05747443|OTHER|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
58468186|NCT05747443|OTHER|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
58468187|NCT01414868|DRUG|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
58468188|NCT03450161|DRUG|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
58468189|NCT05880979|BEHAVIORAL|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
58468190|NCT05880979|BEHAVIORAL|Regular well child care|Participants will receive their regularly scheduled well-child care
58468191|NCT05804188|OTHER|tracheal intubation|children between 0-16 requiring tracheal intubation
58468192|NCT03297047|DEVICE|combi cast|upper arm or forearm combi cast
58468193|NCT06690359|COMBINATION_PRODUCT|IM19 chimeric antigen receptor T cell injection|"IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose"
58468194|NCT00300417|DRUG|VRC-WNVDNA020-00-VP|
58468195|NCT06038409|DRUG|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
58468196|NCT00611936|DRUG|Placebo|Placebo
58468197|NCT00611936|DRUG|Atomoxetine|20mg maximum of d-amphetamine
58468198|NCT04413500|BEHAVIORAL|Reminder|A reminder to take the anti-hypertension medication with adjustable frequency.
58468199|NCT04413500|BEHAVIORAL|Educational message|An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.
58468200|NCT04413500|BEHAVIORAL|Motivational messages|The motivational short messages to increase the motivational levels.
58468201|NCT04413500|BEHAVIORAL|showing trends|Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
58468202|NCT03164616|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
58468203|NCT03164616|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
58468204|NCT03164616|DRUG|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
58468205|NCT03164616|DRUG|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
58468206|NCT03164616|DRUG|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
58468207|NCT03164616|DRUG|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
57784515|NCT01293526|DEVICE|Experimental|Patients who respond will have their leads placed based on study measurements.
57784516|NCT01293526|DEVICE|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
57784517|NCT02459509|DRUG|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
57784518|NCT04230980|DRUG|Gabapentin|Gabapentin 600mg tablet
58468208|NCT03164616|DRUG|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
58468209|NCT04993885|DRUG|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
58468210|NCT02187848|DRUG|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
58468211|NCT06459817|DEVICE|BB-02 therapy|Biophysical stimulation with magnetic fields
58468212|NCT03484130|DIETARY_SUPPLEMENT|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of \>180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
58468213|NCT03484130|DIETARY_SUPPLEMENT|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
58468214|NCT05501873|DEVICE|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
58468215|NCT05468814|PROCEDURE|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
58468216|NCT05468814|PROCEDURE|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
58468217|NCT05504070|DEVICE|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
58468218|NCT05504070|DEVICE|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
58468219|NCT06306599|DIAGNOSTIC_TEST|S-Detect for Thyroid|"Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS."
58468220|NCT05650606|OTHER|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
58468221|NCT05650606|OTHER|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
58468222|NCT03630354|BEHAVIORAL|Exercise Intervention|Complete supervised exercise
58468223|NCT03630354|BEHAVIORAL|Exercise Intervention|Complete unsupervised exercise
58468224|NCT03630354|OTHER|Informational Intervention|Receive instructional DVD
58468225|NCT03630354|OTHER|Questionnaire Administration|Ancillary studies
58468226|NCT05124925|BIOLOGICAL|Ianalumab|Ianalumab VAY736 150mg/1ml Solution for injection
58468227|NCT00392327|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58468228|NCT00392327|DRUG|Carboplatin|Given IV
58468229|NCT00392327|DRUG|Cisplatin|Given IV
58468230|NCT00392327|DRUG|Cyclophosphamide|Given IV
58468231|NCT00392327|BIOLOGICAL|Filgrastim|Given IV or SC
58468232|NCT00392327|DRUG|Isotretinoin|Given PO
58468233|NCT00392327|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
58468234|NCT00392327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58468235|NCT00392327|OTHER|Quality-of-Life Assessment|Ancillary studies
58468236|NCT00392327|RADIATION|Radiation Therapy|Undergo radiation therapy
58468237|NCT00392327|DRUG|Vincristine Sulfate|Given IV
58468238|NCT02403505|BIOLOGICAL|CEA protein antigen plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix"
58468239|NCT05605574|BEHAVIORAL|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
58468240|NCT03596502|DRUG|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
58468241|NCT03596502|DRUG|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
58468242|NCT06548230|DRUG|Nadunolimab|Give by IV
58468243|NCT06548230|DRUG|Azacitidine|Given by IV
58468244|NCT06548230|DRUG|Venetoclax|Given by mouth (PO
58468245|NCT06541990|BEHAVIORAL|HARMONY|A psychoeducational intervention for patients with HCC
58468246|NCT06541990|OTHER|Enhanced usual care|A supportive care resource guide
58468247|NCT03397966|DRUG|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
58468248|NCT03397966|DRUG|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
58468249|NCT03016156|OTHER|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
58468250|NCT03016156|OTHER|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
58468251|NCT05720182|DEVICE|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg."
58468252|NCT05720182|PROCEDURE|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
58468253|NCT05720182|OTHER|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
58468254|NCT06134180|BEHAVIORAL|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
58468255|NCT04170153|DRUG|M1774|M1774 will be administered orally throughout the study.
58468256|NCT04170153|DRUG|Niraparib|Niraparib will be administered orally throughout the study.
58468257|NCT06704230|DEVICE|video googles|Patients undergoing surgery use video googles and a headphone to distract from surgery
58468258|NCT03697304|DRUG|BI 754091|Solution for infusion
58468259|NCT03697304|DRUG|BI 754111|Solution for infusion
58468260|NCT03697304|DRUG|BI 836880|Solution for infusion
58468261|NCT04390529|OTHER|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
58468262|NCT04609956|OTHER|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
58468263|NCT04609956|OTHER|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
58468264|NCT06704711|DIETARY_SUPPLEMENT|Caffeine 300 MG|They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.
58468265|NCT06704711|COMBINATION_PRODUCT|Exercise|The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
58468266|NCT06704711|OTHER|Placebo|They will rinse 20 mL of distilled water in their mouth for 20 seconds.
58468267|NCT00492999|DRUG|dexamethasone|Given by hepatic arterial infusion
58468268|NCT00492999|DRUG|floxuridine|Given by hepatic arterial infusion
58468269|NCT00492999|DRUG|fluorouracil|Given IV
58468270|NCT00492999|DRUG|irinotecan hydrochloride|Given IV
57784519|NCT04230980|DRUG|Placebo|Placebo tablet
57784520|NCT01330043|DRUG|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
58468271|NCT00492999|DRUG|leucovorin calcium|Given IV
58468272|NCT00492999|DRUG|oxaliplatin|Given IV
58468273|NCT06704178|DIETARY_SUPPLEMENT|NuBest Tall Growth Protein Powder|NuBest Tall Growth Protein Powder includes a proprietary blend of vitamins, minerals, and probiotics designed to enhance children's health outcomes.
58468274|NCT06704178|DIETARY_SUPPLEMENT|Placebo Powder|The placebo powder is designed to mimic the appearance and taste of the NuBest Tall Growth Protein Powder but does not contain the active ingredients.
58468275|NCT06704984|BEHAVIORAL|Intervention Name: WeChat Intervention Based on the IMB Model|A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
58468276|NCT00497614|DRUG|adalimumab|
58468277|NCT04678895|DRUG|Naltrexone|Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
58468278|NCT04678895|DRUG|Placebo|Naltrexone matched placebo capsule.
58468279|NCT03821896|BEHAVIORAL|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
58468280|NCT03821896|BEHAVIORAL|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
58468281|NCT06513910|BEHAVIORAL|Music|Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
58468282|NCT04408313|DRUG|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
58468283|NCT04408313|DRUG|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
58468284|NCT02743208|DEVICE|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
58468285|NCT02743208|DEVICE|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
58468286|NCT03670680|DEVICE|Use of the Lina LibrataTM|Use of the Lina LibrataTM
58468287|NCT05678608|PROCEDURE|surgical excision|posterior midline approach and total excision for spinal cord tumors
58468288|NCT05656534|DRUG|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
58468289|NCT05656534|OTHER|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
58468290|NCT02537977|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
58468291|NCT06542029|BEHAVIORAL|Groups 4 Health (G4H)|"Groups 4 Health, G4H, (Ryhmät kuntoon) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention."
58468292|NCT06542029|BEHAVIORAL|The study psychologists' group intervention|University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
58468293|NCT06542029|BEHAVIORAL|Towards better well-being and studying -online course|"Towards better well-being and studying -online course (Kohti parempaa opiskelua) is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion."
58468294|NCT03388346|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
58468295|NCT02432703|DRUG|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
58468296|NCT02432703|DRUG|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
58468297|NCT01112826|DRUG|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
58468298|NCT05614531|GENETIC|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
58468299|NCT05442749|DRUG|Niraparib|"Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB \>1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB \>1.5 ULN and up to 3ULN and/or ASAT/ALAT \> 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin \< 1.5ULN) and 2) no grade \>1 related AE are reported."
58468300|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 30 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
58468301|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 100 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
58468302|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 300 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
58468303|NCT05471076|OTHER|Placebo|Administered via injection as a split dose into the deltoid muscle (both left and right).
58468304|NCT05471076|BIOLOGICAL|BG505|A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
58468305|NCT01243164|OTHER|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
58468306|NCT04916990|BEHAVIORAL|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
58468307|NCT05844501|DRUG|Ondansetron 8mg|Ondansetron 8 mg orally twice daily for 28 days
58468308|NCT05844501|DRUG|Placebo|Matched placebo orally twice daily for 28 days
58468309|NCT05661682|DRUG|Tralement|Tralement with Manganese Sulfate
58468310|NCT05661682|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
58468311|NCT05774353|OTHER|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
58468312|NCT00907595|DRUG|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
58468313|NCT00907595|DRUG|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
58468314|NCT05720897|OTHER|Auditory Alone|Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
58468315|NCT05720897|DEVICE|Relaxation Virtual Reality|Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
58468316|NCT01769742|BEHAVIORAL|Early mobility bundle|
58468317|NCT00785759|DRUG|AH110690 (18F) Injection|All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
58468318|NCT06599996|DEVICE|Testing artificial intelligence algorithms for interpreting gestures|The effectiveness of artificial intelligence algorithms for detecting and interpreting body-based gestures by individuals who have motor/visual impairments will be evaluated.
58468319|NCT00057200|PROCEDURE|Telephone, videophone care|
58468320|NCT06409169|OTHER|DBS TaT|Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
58468321|NCT06409169|OTHER|Usual Care|Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
58468322|NCT06433999|DRUG|Brepocitinib|Oral Brepocitinib PO QD
58468323|NCT02516696|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
58468324|NCT02516696|DRUG|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
58468325|NCT02516696|DRUG|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
58468326|NCT01808755|DIETARY_SUPPLEMENT|D Mannose|1 gr. every 8 hours
58468327|NCT01808755|DRUG|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
58468328|NCT03021200|DEVICE|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
58468329|NCT06593535|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 4 days (7 capsules per day)
58468330|NCT06593535|OTHER|Astaxanthin (AST trial)|The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
58468331|NCT06602336|DEVICE|Continuous Lactate Monitoring Device|Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
58468332|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to healthy controls|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain
58468333|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
58468334|NCT06041737|OTHER|consultation|nephrology consultation during 2020
58468335|NCT05532150|PROCEDURE|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
58468336|NCT05532150|PROCEDURE|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
58468337|NCT06446882|DEVICE|Personalized treatment according to molecular diagnosis with HER2DX|"Patients with HER2DX high-risk disease:~* Neoadjuvant treatment:~  * High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~ * Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.~ * Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.~* Adjuvant treatment:~  * pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).~ * No pCR at surgery: T-DM1 per 14 cycles.~Patients with HER2DX low-risk disease:~* Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~* Adjuvant treatment will be according to the pCR status at surgery:~  * pCR at surgery: trastuzumab or no adjuvant treatment.~ * No pCR at surgery: trastuzumab or T-DM1."
58468338|NCT06446882|OTHER|Treatment by physician´s choice, blinded to the diagnostic HER2DX test results|Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
58468339|NCT04644224|OTHER|Educational Activity|Attend health coaching session
58468340|NCT04644224|OTHER|Educational Intervention|Attend resource navigation session
58468341|NCT04644224|OTHER|Informational Intervention|Receive handbook
58468342|NCT04644224|OTHER|Questionnaire Administration|Ancillary studies
58468343|NCT04644224|PROCEDURE|Support Group Therapy|Attend support group
58468344|NCT05264857|BEHAVIORAL|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
58468345|NCT03009058|BIOLOGICAL|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
58468346|NCT03009058|DRUG|Gemcitabine|Standard of Care chemotherapy
58468347|NCT03009058|DRUG|Nab-paclitaxel|Standard of Care chemotherapy
58468348|NCT03009058|DRUG|Capecitabine|Standard of Care chemotherapy
58468349|NCT03009058|DRUG|Folinic Acid|Standard of Care chemotherapy
58468350|NCT03009058|DRUG|Fluorouracil|Standard of Care chemotherapy
58468351|NCT03009058|DRUG|Irinotecan|Standard of Care chemotherapy
58468352|NCT03009058|DRUG|Oxaliplatin|Standard of Care chemotherapy
58468353|NCT03009058|BIOLOGICAL|cetuximab|Standard of Care immunotherapy
58468354|NCT03009058|BIOLOGICAL|Anti-PD1|Standard of Care immunotherapy
58468355|NCT03009058|BIOLOGICAL|Ipilimumab|Standard of Care immunotherapy
58468356|NCT03009058|DRUG|Cyclophosphamide|Standard of Care chemotherapy
58468357|NCT06465589|OTHER|JOURNeY anonymous|"The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
58468358|NCT06465589|OTHER|JOURNeY standard|"The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
58468359|NCT05308537|BEHAVIORAL|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
58468360|NCT05575453|OTHER|Kvatchii Portal|Online education portal
58468361|NCT05900986|DRUG|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
58468362|NCT05900986|DRUG|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
58468363|NCT05900986|DRUG|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
58468364|NCT05900986|DRUG|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
58468365|NCT00521079|DEVICE|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
58468366|NCT00521079|DEVICE|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
58468367|NCT06108414|DRUG|low-dose rivaroxaban|Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
58468368|NCT06108414|DRUG|Standard-dose rivaroxaban|Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
57784521|NCT01330043|DRUG|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
58468369|NCT06271512|OTHER|No Intervention|This is non-interventional study.
58468370|NCT05387278|DRUG|EV-Pure™ and WJ-Pure™|The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
58468371|NCT05387278|DRUG|Placebo|Cryopreservation media plus standard care
58468372|NCT06018337|DRUG|DB-1303/BNT323|IV
58468373|NCT06018337|DRUG|Capecitabine|Oral
58468374|NCT06018337|DRUG|Paclitaxel|IV
58468375|NCT06018337|DRUG|Nab-paclitaxel|IV
58468376|NCT06577363|DRUG|Maribavir|Maribavir tablets
58468377|NCT05545930|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
58468378|NCT05545930|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
58468379|NCT06590519|OTHER|Date Seed Extract|"Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules."
58468380|NCT03501082|OTHER|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
58468381|NCT03501082|OTHER|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
58468382|NCT03501082|OTHER|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
58468383|NCT03501082|OTHER|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
58468384|NCT04500158|DRUG|Lidocaine|2% Lidocaine with 1:100,000 epi
58468385|NCT06172959|BEHAVIORAL|Vocal Intonation Therapy (VIT)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Vocal Intonation Therapy is a music therapy technique consisting of breathing and vocal exercises to target respiratory function and vocal quality.
58468386|NCT06172959|BEHAVIORAL|Therapeutic Singing (TS)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Therapeutic Singing is a music therapy technique used to work on the rehabilitation of vocal and respiratory function.
58468387|NCT06589219|DRUG|CMR316|CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
58468388|NCT06589219|DRUG|Placebo|Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
58468389|NCT03684616|DRUG|Statin|continuous statin treatment for 3 months prior to cardiac arrest
58468390|NCT02227914|DRUG|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
58468391|NCT02227914|DRUG|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
58468392|NCT03964727|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
58468393|NCT04586478|BIOLOGICAL|single dose of CNCT19|Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
58468394|NCT02177695|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
58468395|NCT02177695|DRUG|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
58468396|NCT02177695|DRUG|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
58468397|NCT02177695|DRUG|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
58468398|NCT02177695|DRUG|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
58468399|NCT02177695|DRUG|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
58468400|NCT05864274|DEVICE|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
58468401|NCT05341817|DRUG|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
58468402|NCT05341817|DRUG|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
58468403|NCT05763043|DRUG|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
58468404|NCT04790474|DRUG|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
58468405|NCT03957954|BIOLOGICAL|cLSC|Transplantation of cLSC
58468406|NCT03957954|DEVICE|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
58468407|NCT01746836|OTHER|Laboratory Biomarker Analysis|Blood draws.
58468408|NCT01746836|DRUG|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
58468409|NCT01746836|OTHER|Quality-of-Life Assessment|Surveys completed.
58468410|NCT04945746|PROCEDURE|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
58468411|NCT06218277|DIAGNOSTIC_TEST|ASTAR|Rapid AST with ASTAR
58468412|NCT05687851|DRUG|Cadonilimab（AK104）|q3w iv
58468413|NCT05687851|RADIATION|EBRT|45-50.4Gy
58468414|NCT05687851|RADIATION|BT|≥80Gy
58468415|NCT06119282|OTHER|inhaler|Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
58468416|NCT06119282|OTHER|Control Group|Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
58468417|NCT06119282|OTHER|massage|Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
58468418|NCT04435288|DRUG|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~1. In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~2. In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~3. In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
58468419|NCT04435288|DRUG|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
58468420|NCT04435288|DRUG|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~1. If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~2. If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~3. If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
58468421|NCT04435288|DRUG|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
58468422|NCT06604260|DIAGNOSTIC_TEST|68Ga-FAPi-46|68Ga FAPi PET-CT scan
58468423|NCT06462625|OTHER|High tibial osteotomy|Correction of lower limb malalignement with tibial bone wedge insertion/removal
58468424|NCT03537963|OTHER|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
58468425|NCT03537963|OTHER|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
58468426|NCT03537963|OTHER|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
58468427|NCT03537963|OTHER|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
58468428|NCT03537963|OTHER|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
58468429|NCT03537963|OTHER|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
58468430|NCT06601673|BEHAVIORAL|Cognitive training|The intervention consists of computer-based cognitive training in the areas of attention, processing speed, memory, emotional intelligence, reasoning and orientation. The training takes place under supervision for 120 minutes a day from the first to the fifth postoperative day.
58468431|NCT06601673|BEHAVIORAL|Listen to audio book|Here, an audio book is listened to for 2h daily for the first five postoperative days (or until discharge from hospital if earlier). The audio book is brought and set up by study staff.
58468432|NCT06529380|DEVICE|DBS ON|Electrical stimulation of the nucleus accumbens.
58468433|NCT06529380|DEVICE|DBS OFF|DBS will remain OFF (on at 0V).
58468434|NCT01648465|DRUG|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
58468435|NCT04127604|BEHAVIORAL|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
58468436|NCT04127604|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
58468437|NCT06577181|DRUG|hCG + estradiol|Human chorionic gonadotropins
58468438|NCT06577181|OTHER|Observation arm|estradiol only wuithout giving hcg
58468439|NCT05231954|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
58468440|NCT06598995|PROCEDURE|Coronary artery bypass grafting or unroofing|Patients had an MB with \&gt;75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \&lt; 5mm (whether deal with these MB with a depth \&lt;5mm depends on the surgeon and the period time of patients received a surgery).
58468441|NCT04218240|DRUG|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
58468442|NCT04218240|DRUG|Placebo oral tablet|oral Placebo
58468443|NCT04218240|DRUG|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
58468444|NCT06195748|OTHER|Kinesiotaping|According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
58468445|NCT06195748|OTHER|Placebo kinesiotaping|The same tape will be used for the interventional application with 0 tension.
58468446|NCT06595264|PROCEDURE|embolization therapy|Embolization in the neuroradiological department is the Golden Standard for the treatment of vein of Galen malformations.
58468447|NCT03745508|OTHER|Instant Coffee|Instant coffee prepared at different caffeine concentrations
58468448|NCT03286036|OTHER|biomarkers|This is an observational study, there is no intervention
58468449|NCT03572517|PROCEDURE|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
58468450|NCT03572517|PROCEDURE|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
58468451|NCT05643495|DRUG|VX-864|Tablets for oral administration.
58468452|NCT06584552|DIETARY_SUPPLEMENT|Lactobacillus Paracasei LPB27|Probiotic
58468453|NCT06584552|OTHER|Maltodextrin|Placebo
58468454|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
58468455|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
58468456|NCT00860873|DIETARY_SUPPLEMENT|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
58468457|NCT00860873|DIETARY_SUPPLEMENT|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
58468458|NCT06305650|DIETARY_SUPPLEMENT|Probiotic|Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.
58468459|NCT03779256|PROCEDURE|2D transvaginal ultrasound|"Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively."
58468460|NCT06587711|PROCEDURE|acupuncture treatment|Patients in experimental group received acupuncture at specific acupoint on the face, patients in control group received sham acupuncture at non-acupoint on the face.
58468461|NCT05655741|OTHER|Questionnaire|"Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round."
58468462|NCT05156281|DRUG|Remibrutinib|tablet taken orally
58468463|NCT05156281|DRUG|Teriflunomide|capsule taken orally
58468464|NCT05014256|BEHAVIORAL|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
58468465|NCT06510660|DRUG|adebrelimab|The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
58468466|NCT02439723|DRUG|Regorafenib|
58468467|NCT05226442|DRUG|Argatroban|Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
58468468|NCT05226442|DRUG|Unfractionated heparin|Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
58468469|NCT03454763|DRUG|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
58468470|NCT03454763|DRUG|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
58468471|NCT06649045|DRUG|Orforglipron|Administered orally.
58468472|NCT06649045|DRUG|Placebo|Administered orally.
58468473|NCT01235897|DRUG|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
58468474|NCT01235897|DRUG|Paclitaxel|80 mg/m2 weekly - paclitaxel
58468475|NCT01235897|DRUG|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
58468476|NCT06093100|DEVICE|wearable technology|Three wearable devices
58468477|NCT02700607|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58468478|NCT02700607|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
58468479|NCT04999462|OTHER|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
58468480|NCT04999462|OTHER|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
58468481|NCT04999462|OTHER|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
58468482|NCT05672381|PROCEDURE|Lower extremity and/or upper extremity surgery|Lower extremity and/or upper extremity surgery
58468483|NCT01146769|OTHER|Pelvic floor exercise|Pelvic floor strengthening exercise
58468484|NCT05134038|DIAGNOSTIC_TEST|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
58468485|NCT05017363|PROCEDURE|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
58468486|NCT04621981|DRUG|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
58468487|NCT04621981|DRUG|Normal Saline|This group was treated with normal saline.
58468488|NCT05619575|DEVICE|CP1170 sound processor|The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
58468489|NCT05619575|DEVICE|CP1150 Sound processor|Active comparator off the ear sound processor.
58468490|NCT02192580|DRUG|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
58468491|NCT01992796|DRUG|Irbesartan|75 mg/per os/for 15 days
58468492|NCT06253832|PROCEDURE|conservative surgery for placenta accreta spectrum|The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
58468493|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
58468494|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
58468495|NCT05054309|DIETARY_SUPPLEMENT|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
58468496|NCT00169182|DRUG|DOCETAXEL|75 mg/m 2 on day 1
58468497|NCT00169182|DRUG|Cisplatin|75 mg/m 2 on day 1
58468498|NCT00169182|DRUG|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
58468499|NCT05624606|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5410|Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
58468500|NCT05624606|BIOLOGICAL|Quadrivalent Recombinant Influenza vaccine RIV4|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
58468501|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza Standard Dose QIV-SD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
58468502|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose QIV-HD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
58468503|NCT03008291|PROCEDURE|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
58468504|NCT03008291|PROCEDURE|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
58468505|NCT03008291|PROCEDURE|Dual Chamber Pacemaker Implantation|
58468506|NCT04747041|COMBINATION_PRODUCT|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
58468507|NCT05728463|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
58468508|NCT06509659|DIAGNOSTIC_TEST|Methacholine Challenge Test|MCT with IOS alone versus MCT IOS and FEV1 combined
58468509|NCT06588556|BEHAVIORAL|ICUconnect|ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.
58468510|NCT06588556|OTHER|Usual care|Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
58468511|NCT02928068|BEHAVIORAL|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
58468512|NCT06548776|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS) Scan|Participants will receive MRS Scan
58468513|NCT06602557|DRUG|Amikacin|Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
58468514|NCT06602557|DRUG|Standard of care|Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
58468515|NCT00467688|DEVICE|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
58468516|NCT02476617|DRUG|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
58468517|NCT02476617|DRUG|dasabuvir|dasabuvir tablets
58468518|NCT02476617|DRUG|ribavirin|ribavirin tablets
58468519|NCT02318732|BEHAVIORAL|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
58468520|NCT03774654|GENETIC|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2."
58468521|NCT06246292|PROCEDURE|Ultrasound-guided ESPB|The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
58468522|NCT06246292|PROCEDURE|Anatomical landmark-guided ESPB|The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
58468523|NCT06590623|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
58468524|NCT04445753|OTHER|Tai Chi exercise|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
58468525|NCT04445753|BEHAVIORAL|Education (control group)|Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
58468526|NCT03415321|DEVICE|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
58468527|NCT04834102|DIAGNOSTIC_TEST|Blood Tests|Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity
58468528|NCT05015426|BIOLOGICAL|Gamma Delta T-Cell Infusion|Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
58468529|NCT04448886|DRUG|Pembrolizumab|(iv) fixed dose, administered once per cycle
58468530|NCT04448886|DRUG|Sacituzumab Govitecan|(iv) fixed dose, administered twice per cycle
58468531|NCT06604221|BEHAVIORAL|Resistance exercise intervention|The exercise prescription, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.
58468532|NCT06604221|BEHAVIORAL|Routine care|"1.Pre-dialysis Assessment:~1. Vital Signs: Monitor blood pressure, heart rate, temperature.~2. Access Care: Check the vascular access site for signs of infection and patency. 2.During Dialysis:~（1）Monitoring: Continuous vital signs and machine settings monitoring. （2）Fluid Management: Control fluid removal based on pre-dialysis weight. 3.Post-dialysis Care:~1. Observation: Monitor for complications like hypotension, cramps, or bleeding.~2. Weight Check: Weigh post-dialysis to verify fluid removal. 4.Education and Support:~（1）Diet: Educate on dietary restrictions (potassium, phosphorus, fluids). （2）Medications: Advise on medication adjustments. 5.Psychosocial Support:~（1）Provide emotional support and counseling."
58468533|NCT05578846|DRUG|Treatment A|Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
58468534|NCT05578846|DRUG|Treatment B|Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
58468535|NCT05578846|DRUG|Treatment C|Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
58468536|NCT05786625|DEVICE|Ablation|Bronchoscopy and microwave ablation of lung nodule
58468537|NCT03512821|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
58468538|NCT03512821|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
58468539|NCT03909152|DRUG|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
58468540|NCT03909152|DRUG|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
58468541|NCT06311838|BEHAVIORAL|Motivational Interviewing/Community Reinforcement Approach (MI/CRA)|MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.
58468542|NCT06311838|BEHAVIORAL|Strengths-Based Outreach and Advocacy (SBOA )|The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.
58468543|NCT06311838|BEHAVIORAL|Services as Usual (SAU)|Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.
58468544|NCT02157532|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
58468545|NCT02157532|DRUG|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
58468546|NCT00020800|BIOLOGICAL|rituximab|
58468547|NCT00020800|DRUG|fludarabine phosphate|
58468548|NCT06513845|BEHAVIORAL|Communal drumming recordings|Segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle. Segments will be categorized as highly synchronized
58468549|NCT04588545|RADIATION|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
58468550|NCT04588545|DRUG|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
58468551|NCT04588545|DRUG|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
58468552|NCT00202280|DRUG|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
58468553|NCT05139472|DRUG|Empagliflozin 10 MG|Daily Empagliflozin
58468554|NCT04093297|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
58468555|NCT04609943|DRUG|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
58468556|NCT06597045|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels)."
58468557|NCT03926208|PROCEDURE|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
58468558|NCT03926208|PROCEDURE|Clorhexadine scrub|Clorhexadine scrub (standard of care).
58468559|NCT06408558|OTHER|Hypobaric|The effects of ambient pressure changes on glucose metabolism will be studied
58468560|NCT06408558|OTHER|Ground level|The effects of ambient pressure changes on glucose metabolism will be studied
58468561|NCT05878418|DEVICE|Thoracolumbosacral Spinal Orthosis (TLSO)|In the TE, PR, PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
58468562|NCT05878418|OTHER|Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)|The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
58468563|NCT04163562|DRUG|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
58468564|NCT04163562|DRUG|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
58468565|NCT05846789|DRUG|Carboplatin|Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
58468566|NCT05846789|DRUG|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
58468567|NCT06583135|OTHER|Sleep hygiene education and motivational interviewing|The intervention group, will receive face-to-face sleep hygiene training and then 4 online motivational interviews will be held within 6 weeks. The online motivational interviews will be implemented in the 1st week (interview 1), 2nd week (interview 2), 4th week (interview 3), and 6th week (interview 4).
58468568|NCT06583135|OTHER|face-to-face sleep hygiene training|The control group receive face-to-face sleep hygiene training
58468569|NCT04788888|DEVICE|Navitor Transcatheter Aortic Valve and FlexNav Delivery System|"For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system"
58468570|NCT06594887|DEVICE|SpaceOAR Vue|Peri-rectal hydrogel spacer consists of a layer of polyethylene-glycol gel (SpaceOAR vue) in order to outdistance the prostate from anterior rectal wall
58468571|NCT06594887|DEVICE|BioProtect Balloon Implant System|The balloon spacer is a biodegradable balloon made of poly (L-Lactide-co-caprolactone) which is a co-polymer of Poly Lactide acid and epsilon Caprolactone (BioProtect Balloon Implant System, BioProtect Ltd) inflated with saline, providing around 18 mm space height , and can be deflated and repositioned if needed, both laterally and along the distal /proximal planes, for optimal uniformity of spacing.
58468572|NCT02718898|DRUG|Ixekizumab|Administered SC
58468573|NCT02718898|DRUG|Placebo|Administered SC
58468574|NCT06540053|OTHER|Active Static Hamstring Stretch Exercise|In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.
58468575|NCT06540053|OTHER|Waiting List|Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
58468576|NCT02706756|OTHER|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
58468577|NCT02706756|OTHER|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
58468578|NCT02706756|OTHER|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
58468579|NCT02706756|OTHER|Supervised neglect|Monitoring of group without formal intervention.
58468580|NCT06700473|OTHER|reiki|Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with a seventh VAS measurement and administration of the EC-4. The EC-4 will also be reassessed by the researchers online at six weeks postpartum
58468581|NCT06599229|DIAGNOSTIC_TEST|myocardial contrast echo|Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
58468582|NCT04231669|BEHAVIORAL|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
58468583|NCT04139733|PROCEDURE|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
58468584|NCT04139733|PROCEDURE|Supine positon|Conventional supine position ventilation, no prone position.
58468585|NCT04412863|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
58468586|NCT04412863|DRUG|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
58468587|NCT05415761|BEHAVIORAL|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
58468588|NCT05415761|BEHAVIORAL|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
58468589|NCT05415761|BEHAVIORAL|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
58468590|NCT01345240|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
58468591|NCT01345240|BIOLOGICAL|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
58468592|NCT01345240|BIOLOGICAL|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
58468593|NCT01345240|BIOLOGICAL|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
58468594|NCT01345240|BIOLOGICAL|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
58468595|NCT01345240|BIOLOGICAL|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
58468596|NCT01345240|BIOLOGICAL|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
58468597|NCT01345240|BIOLOGICAL|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
58468598|NCT05724134|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
58468599|NCT05724134|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
58468600|NCT05724134|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
58468601|NCT05724134|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
58468602|NCT05724134|OTHER|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
58130987|NCT01390363|OTHER|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
58130988|NCT00116922|DRUG|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
58130989|NCT03064022|OTHER|Growth|Some preterm infants grow at higher rates than others
58130990|NCT04917978|DIAGNOSTIC_TEST|Hematological Phenotype Analysis|Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio- Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).
58468603|NCT05724134|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
58468604|NCT05724134|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
58468605|NCT05724134|DIETARY_SUPPLEMENT|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
58468606|NCT05724134|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
58468607|NCT05724134|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
58468608|NCT06459674|DEVICE|PrO2 Fit (IMT Trainer)|The device is used four times a week over a period of 8 weeks.
58468609|NCT06706128|OTHER|reflex rolling technique|received reflex rolling technique for 20 min, 5 days a week, for 2 weeks.
58468610|NCT06706128|OTHER|lung squeezing technique|lung squeezing technique for 20 min, 5 days a week, for 2 weeks
58468611|NCT05958082|BEHAVIORAL|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
58468612|NCT05189275|DIETARY_SUPPLEMENT|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
58468613|NCT03598036|DRUG|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
58468614|NCT05789537|DRUG|SerpinPC|Administered as SC injection.
58468615|NCT04935606|BEHAVIORAL|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
58468616|NCT04935606|BEHAVIORAL|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
58130991|NCT03344445|OTHER|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
58130992|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field|
58468617|NCT04935606|BEHAVIORAL|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
58468618|NCT06196008|OTHER|Educational Intervention|Attend telephone-based coaching sessions
58468619|NCT06196008|OTHER|Educational Intervention|Receive written educational materials on physical activity and standard preoperative care
58468620|NCT06196008|OTHER|Exercise Intervention|Receive a personalized physical activity program, set fitness goals
58468621|NCT06196008|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
58468622|NCT06196008|OTHER|Physical Performance Testing|Ancillary studies
58468623|NCT06196008|OTHER|Quality-of-Life Assessment|Ancillary studies
58468624|NCT06196008|OTHER|Questionnaire Administration|Ancillary studies
58468625|NCT06406855|OTHER|BCI-TSCS|BCI-TSCS therapy, completed 3-4 times per week, that will include activity-based training, with TSCS activated by BCI system detecting movement attempt.
58468626|NCT02025543|DEVICE|MRI|R2 MRI scan
58468627|NCT06285396|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature.
58468628|NCT06285396|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature.
58468629|NCT06285396|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature.
58468630|NCT06285396|DRUG|Oxytocin|Oxytocin, at applicable concentrations based on literature.
58468631|NCT05592665|OTHER|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
58468632|NCT06592677|BEHAVIORAL|Condensed internet-delivered prolonged exposure (CIPE)|'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.
58468633|NCT06592677|BEHAVIORAL|Treatment-as-usual (TAU)|There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
58468634|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
58468635|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
58468636|NCT03016728|BEHAVIORAL|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
58468637|NCT04732845|BIOLOGICAL|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
58468638|NCT04732845|DRUG|Fludarabine|25 mg/m2 daily from day -5 to -3
58468639|NCT04732845|DRUG|Cyclophosphamide|60mg/Kg on day -6
58130993|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field Placebo Sham|
58468640|NCT05627830|PROCEDURE|Prolotherapy|Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
58468641|NCT06706011|OTHER|Virtual Patient|Interactive Educational Activity
58468642|NCT06472141|OTHER|Cervical stabilization exercises|Cervical Stabilization Exercises will be performed 3 days a week for 8 weeks.
58468643|NCT06472141|OTHER|Standard treatment (Education + home exercises)|Individuals will be informed about TMJ disorders, parafunctional activities (chewing gum, nail/pen biting, etc.) and recommendations. In addition, Rocabado exercises will be given as a home program.
58468644|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 0|"Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses."
58468645|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose -1|"Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
58130994|NCT00002662|DRUG|docetaxel|
58130995|NCT00002662|DRUG|paclitaxel|
58468646|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 1|"Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
58468647|NCT02339974|DEVICE|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
58468648|NCT03583099|OTHER|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
58468649|NCT03583099|OTHER|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
58468650|NCT06705777|DRUG|Combinations|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
58468651|NCT06578364|DEVICE|Educational Program about Preconception Care|The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
58468652|NCT06384495|PROCEDURE|REAL-A|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
58468653|NCT06384495|PROCEDURE|REAL-C|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
58468654|NCT06384495|PROCEDURE|SHAM|one session of sham tDCS for 20 minutes to the right ventro-lateral cerebellum.
58468655|NCT06473389|PROCEDURE|Suprascapular nerve pulse radiofrequency ablation|Pulse RF application will be applied to the suprascapular nerve once under US guidance with a TOP-TLG10 STP generator at a maximum temperature of 42 degrees, 2 Hz, 20 ms and 45 V for 2 minutes.
58468656|NCT06473389|PROCEDURE|Suprascapular Nerve Block Group|Suprascapular block will be applied once with a mixture consisting of 5 ml (1 ml betamethasone, 2% lidocaine 2 ml, 0.9% saline 2 ml).
58468657|NCT06473389|PROCEDURE|Steroid Group|Intra-articular steroid application will be made with a mixture consisting of 5 ml (2 ml of 2% lidocaine, 2 ml of 0.9% saline and 1 ml of betamethasone 5 mg).
58468658|NCT05177393|OTHER|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
58468659|NCT05710718|DEVICE|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC will be connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
58468660|NCT05710718|DEVICE|Hollister® Female Urinary Pouch External Collection Device|It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
58468661|NCT06572683|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
58468662|NCT00496522|PROCEDURE|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
58468663|NCT04843566|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
58468664|NCT04843566|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
58468665|NCT04843566|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
58468666|NCT06595225|BEHAVIORAL|Nutrition education sessions|Participants received nutrition education each month, covering topics ranging from general nutrition knowledge, nutrition knowledge related to their diagnosis of living with HIV infection whether during the acute or chronic phase. In addition, specific information was shared about other comorbidities the participant could be living with, finally information was shared on ways to improve mental health and enhance physical activity levels.
58468667|NCT06301490|OTHER|Myofascial Release|Myofascial release is a popular hands-on method manual therapy technique that uses carefully guided low load, long duration mechanical pressures to modify the myofascial complex (directly or indirectly), with the goal of restoring appropriate length, decreasing discomfort, and improving range of motion, muscle recovery, and physical performance in healthy persons.
58468668|NCT05371886|OTHER|Dose-effect relationship of morphine +/- midazolam administration|Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
58468669|NCT05077124|DEVICE|CytoSorb|Sorbent hemoperfusion system
58468670|NCT05567458|DRUG|Luspatercept|Specified dose on specified days
58468671|NCT05567458|DRUG|Placebo|Specified dose on specified days
58468672|NCT01419236|DRUG|Testosterone Solution 2%|Administered topically
58468673|NCT01419236|DRUG|Placebo Solution|Administered topically
58468674|NCT01544205|OTHER|fMRI-based neurofeedback|5 sessions lasting one hour each
58468675|NCT02452736|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
58130996|NCT01864330|DEVICE|Thealoz Duo®|Eye Drops
58130997|NCT01864330|DEVICE|Hyabak®|Eye Drops
58468676|NCT05291260|PROCEDURE|Cast immobilization|A cast to immobilize the MCP, in 10-30 degrees (slight) flexion (neutral position), and the CMC joint, in 30-40 degrees palmar abduction, is applied (IP joint is free).
58468677|NCT05291260|PROCEDURE|Surgical treatment|"In general, two surgical techniques are described in literature and used in daily clinical practice:~* If the UCL is ruptured in the middle of the ligament, sutures are used to reattach the ligament remnants together.~* When no viable UCL ligaments are present, the UCL is reattached directly to the bone using suture anchors."
58468678|NCT06614881|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
58468679|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
58468680|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
58468681|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
58468682|NCT06614881|DRUG|Normal saline|loading dose of saline was injected 10-min before induction of anesthesia.
58468683|NCT06264843|DEVICE|MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes|Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
58468684|NCT05891704|PROCEDURE|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
58468685|NCT05891704|PROCEDURE|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
58468686|NCT01864018|DRUG|Cyclophosphamide|Given PO
58468687|NCT01864018|DRUG|Dexamethasone|Given PO
58468688|NCT01864018|DRUG|Ixazomib Citrate|Given PO
58468689|NCT01864018|OTHER|Laboratory Biomarker Analysis|Correlative studies
58468690|NCT01864018|OTHER|Pharmacological Study|Correlative studies
58468691|NCT01864018|OTHER|Quality-of-Life Assessment|Ancillary studies
58468692|NCT01864018|OTHER|Questionnaire Administration|Ancillary studies
58468693|NCT04038359|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) inhibitor
58468694|NCT06510153|OTHER|Environmental Music Therapy|The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution during approximately 20 minutes.
58468695|NCT06510153|OTHER|Pre-recorded music|The protocol for pre-recorded music is the same as for EMT.
58468696|NCT06510153|OTHER|Standard care only|Standard care in the emergency room waiting room as provided by each hospital without being exposed to EMT or pre-recorded music.
58468697|NCT05278260|DIETARY_SUPPLEMENT|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
58468698|NCT05278260|DIETARY_SUPPLEMENT|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
58468699|NCT02250326|DRUG|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
58468700|NCT02250326|DRUG|CC-486|Oral CC-486
58468701|NCT02250326|DRUG|Duravalumab|
58468702|NCT06706050|BIOLOGICAL|Microbiome Therapeutic LP-51|Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis
58468703|NCT06706050|OTHER|placebo cream (M23004-03)|placebo cream (M23004-03) was applied on the participants
58468704|NCT05236816|OTHER|Fatigue (physical exercise)|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
58468705|NCT06388226|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
58468706|NCT06388226|DEVICE|Leg sham therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
58468707|NCT06016387|DRUG|Tucatinib 150 MG|Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
58468708|NCT06016387|DRUG|Trastuzumab|"MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations."
58468709|NCT06016387|DRUG|Capecitabine|Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
58468710|NCT06016387|RADIATION|Brain & Spinal Radiation|Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
58468711|NCT01657383|PROCEDURE|HPB Surgery|Hepatopancreatico Biliary Surgery
58468712|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 750 mg|750 mg administered orally
58468713|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 1500 mg|1500 mg administered orally
58468714|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 3000 mg|3000 mg administered orally
58468715|NCT06033222|DRUG|Placebo|Contains no active ingredient.
58468716|NCT04863729|BEHAVIORAL|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
58468717|NCT03891706|DRUG|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
58468718|NCT03891706|DRUG|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
58468719|NCT06219694|DEVICE|Laser Acupuncture|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
58468720|NCT06219694|DEVICE|Sham|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
58468721|NCT02546609|DRUG|Leu-Met-Sil 0.5|NS-0200 low dose
58468722|NCT02546609|DRUG|Leu-Met-Sil 1.0|NS-200 high dose
58468723|NCT02546609|DRUG|Placebo|Placebo
58468724|NCT06068309|OTHER|CareAide App Usage|The study participant uses the CareAide app in addition to prescribed usual therapeutic care
58468725|NCT04638907|PROCEDURE|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
58468726|NCT04718415|DRUG|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
58468727|NCT04718415|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
58468728|NCT05642676|OTHER|Clinics remodeling|changes to the clinics will be planned based on baseline surveys
58468729|NCT06458283|OTHER|hiybrid simulation|The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.
58468730|NCT06458283|OTHER|control grup|low fidelity simulator
58468731|NCT01264341|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
58468732|NCT01264341|DRUG|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
58468733|NCT06704750|BEHAVIORAL|6-minute walk test|patients were instructed to walk back and forth in a marked 30-meter-long straight corridor as fast as they could tolerate
58468734|NCT00079417|DRUG|Carboplatin|Given IV
58468735|NCT00079417|PROCEDURE|Cryosurgery|
58468736|NCT00079417|PROCEDURE|Infrared Laser Therapy|
58468737|NCT00079417|RADIATION|Iodine I-125|Undergo radioactive therapy
58468738|NCT00079417|RADIATION|Radiation Therapy|Undergo radioactive therapy
58468739|NCT00079417|RADIATION|Ruthenium Ru-106|Undergo radioactive therapy
58468740|NCT00079417|DRUG|Vincristine Sulfate|Given IV
58468741|NCT05507723|OTHER|Treat-to-target|Treatment to achieve urate target using supported self-management approach
58468742|NCT05507723|OTHER|Usual Care|Treatment escalation by GP based on usual clinical practice
58468743|NCT05650749|BIOLOGICAL|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
58468744|NCT04181359|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
58468745|NCT04181359|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
58468746|NCT05478265|DEVICE|RS-4i Plus|RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
58468747|NCT01561014|DRUG|erlotinib hydrochloride|Given PO
58468748|NCT01561014|DRUG|oxaliplatin|Given IV
58468749|NCT01561014|DRUG|fluorouracil|Given IV
58468750|NCT01561014|RADIATION|radiation therapy|Undergo radiotherapy
58468751|NCT01561014|PROCEDURE|conventional surgery|Undergo surgical resection
58468752|NCT01561014|OTHER|immunohistochemistry staining method|Correlative study
58468753|NCT01561014|PROCEDURE|positron emission tomography|Correlative study
58468754|NCT01561014|PROCEDURE|computed tomography|Correlative study
58468755|NCT01561014|PROCEDURE|laboratory biomarker analysis|Correlative study
58468756|NCT01561014|GENETIC|gene expression analysis|Correlative study
58468757|NCT01561014|RADIATION|fludeoxyglucose F 18|Undergo F18 PET and CT scan
58468758|NCT06705543|GENETIC|multi-omics genetic analyses included exome|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit. These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study.~* Trio exome study (parents-fetus)."
58468759|NCT06705543|GENETIC|multi-omics genetic analyses|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit; These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study."
58468760|NCT05568225|DRUG|Etavopivat|400 mg once daily
58468761|NCT05735327|DRUG|No intervention|As this is an observational study, no intervention will be administered.
58468762|NCT05388877|DRUG|Dabrafenib|Given PO
58468763|NCT05388877|DRUG|MEK-1/MEKK-1 Inhibitor E6201|Given IV
58468764|NCT05388877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58468765|NCT05388877|PROCEDURE|Computed Tomography|Undergo CT
58468766|NCT05388877|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58468767|NCT02648308|BEHAVIORAL|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
58468768|NCT03612817|DRUG|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
58468769|NCT05579678|BEHAVIORAL|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
58468770|NCT06706687|DIAGNOSTIC_TEST|DISBAND protocol|For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
58468771|NCT05139680|DRUG|tafamidis|80 or 61 milligrams (mg)
58468772|NCT06589544|DEVICE|Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)|"The CEREBRUM-VELA virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
58468773|NCT06589544|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)|"Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
58468774|NCT06589544|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
58468775|NCT06016517|DRUG|Etanercept|50 mg subcutaneously weekly
58468776|NCT06016517|DRUG|Adalimumab|40 mg subcutaneously every 2 weeks
58468777|NCT06016517|DRUG|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
58468778|NCT06016517|DRUG|Tocilizumab|4mg per kg IV every 4 weeks
58130998|NCT01864330|DEVICE|Hydrabak®|Eye Drops
58130999|NCT05123690|DEVICE|Neurofeedback|A device that assists in training patients in relaxing.
58131000|NCT03633890|DRUG|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
58131001|NCT03633890|DRUG|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
58468779|NCT05368038|DIAGNOSTIC_TEST|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
58468780|NCT05268809|OTHER|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
58468781|NCT04963920|DEVICE|Cytosorb® 300 ml|patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
58468782|NCT06235515|OTHER|rehabilitation program|conventional treatment (hotpack and TENS and exercise)
58468783|NCT06235515|OTHER|virtual reality|virtual reality treatment
58468784|NCT03101917|DEVICE|The Microtable® Stereotactic System|x
58468785|NCT06493760|DRUG|SSGJ-707|bispecific antibody
58468786|NCT06493760|DRUG|Bevacizumab|VEGF antibody
58468787|NCT06493760|DRUG|Oxaliplatin|chemotherapy
58468788|NCT06493760|DRUG|Capecitabine|chemotherapy
58468789|NCT06493760|DRUG|Calcium Folinate|chemotherapy
58468790|NCT06493760|DRUG|5-fluorouracil|chemotherapy
58468791|NCT04873037|DEVICE|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
58468792|NCT04873037|DEVICE|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
58468793|NCT06594731|OTHER|Hip belt squat training|Hip belt squat training performed twice per week for 6 weeks
58468794|NCT04477759|RADIATION|50 Gy Radiation Therapy|Ionizing radiation
58468795|NCT04477759|RADIATION|55 Gy Radiation Therapy|Ionizing radiation
58468796|NCT04477759|RADIATION|60 Gy Radiation Therapy|Ionizing radiation
58468797|NCT04477759|DRUG|Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
58468798|NCT00298012|DRUG|Methotrexate|
58468799|NCT05075265|DRUG|Methadone|Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
58468800|NCT05380427|DRUG|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
58468801|NCT04636814|DRUG|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
58468802|NCT04636814|DRUG|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
58468803|NCT04636814|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
58468804|NCT04636814|DRUG|Roflumilast|- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
58468805|NCT06527066|COMBINATION_PRODUCT|Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
58468806|NCT06527066|OTHER|Gel Sérum Biocompatível All.me Beauty®|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
58468807|NCT04077801|DIAGNOSTIC_TEST|diagnostic test|diagnostic test
58468808|NCT04077801|DIAGNOSTIC_TEST|Postpartum pain|test
58468809|NCT04077801|OTHER|Visual analogue scale|test TMJ /pelvic angle/lumber angle
58468810|NCT03735875|DRUG|Quizartinib|Given PO
58468811|NCT03735875|DRUG|Venetoclax|Given PO
58468812|NCT05241873|DRUG|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
58468813|NCT05241873|DRUG|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
58468814|NCT05241873|DRUG|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
58468815|NCT06599333|BEHAVIORAL|Adherence to Care|"Questionnaire to assess the perception and readiness of patients in Lebanon towards the effectiveness of digital marketing strategies to improve their adherence to medications they take chronically~The following sections will be considered:~* General Characteristics of the Participants~* Medical and medication history~* Assessment of adherence to chronic medications (Likert scale)~* Digital Marketing Strategies to improve adherence to chronic medications (Likert scale)~* Perceived barriers to adopting digital marketing strategies in Lebanon (Likert scale)"
58468816|NCT06050265|DEVICE|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
58131002|NCT03943056|DRUG|BIIB091|Administered as specified in the treatment arm.
58131003|NCT03943056|DRUG|Placebo|Administered as specified in the treatment arm.
58131004|NCT00169533|DRUG|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
58131005|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
58468817|NCT05665738|RADIATION|High Dose Rate Monotherapy|High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
58468818|NCT04125836|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
58468819|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage).|Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.
58468820|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).|Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
58468821|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
58468822|NCT06704490|OTHER|Cesarean section|Observational study without intervention
58468823|NCT05849454|DEVICE|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
58468824|NCT06366217|DEVICE|MydCombi Device|ophthalmic spray
58468825|NCT06366217|DRUG|MydCombi Drug|Tropicamide 1% and phenylephrine HCl 2.5%
58468826|NCT00562224|DRUG|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
58468827|NCT06596551|BEHAVIORAL|Pre-Post ARCH Intervention|Stroke dyads, consisting of a survivor and primary family caregiver, will engage in a 4 weekly, 1.5 hour experiential dyadic sessions, totalling 6 hours of participation. In Week 1, dyads acknowledge the losses occurring after the stroke to normalize feelings of grief and sadness and find comfort within the familial space. In Week 2, dyads interpret their post-stroke losses within the framework of their existing knowledge for managing adversities (strengths, resources, and values) and identify changes that are most meaningful to them. In Week 3, dyads set specific, measurable, and achievable goals to actualize the meaningful changes identified in Week 2. Finally in Week 4, dyads bring together their individually derived strengths from the previous sessions to culminate into strengthened dyadic bonds. The exercise will also encourage participants to expand beyond the dyadic space to seek support from their communities, social networks and care services that are available to them.
58468828|NCT04564898|DRUG|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
58468829|NCT04564898|DRUG|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
58468830|NCT04564898|DRUG|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
58468831|NCT01514799|PROCEDURE|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
58468832|NCT06590922|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
58468833|NCT06590922|DEVICE|The conventional endoscopic biting group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
58468834|NCT06587152|PROCEDURE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
58468835|NCT06592547|DRUG|Intravenous metoprolol tartrate|An intravenous beta-blockers, recieved FDA approval
58468836|NCT06592547|OTHER|Standard Care (in control arm)|Standard care according to surviving sepsis campaign
58468837|NCT04232566|PROCEDURE|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
58468838|NCT06292169|PROCEDURE|Pectoralis Minor Release|The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.
58468839|NCT06292169|PROCEDURE|RSA|RSA is the current Standard of Care (SOC)
58468840|NCT06487988|DEVICE|direct conventional laryngoscopy|direct conventional laryngoscopy will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.
58468841|NCT06487988|DEVICE|fiberoptic guided intubation|fiberoptic guided intubation will be performed.
58468842|NCT04993651|DEVICE|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
58468843|NCT06333314|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
58468844|NCT06333314|DRUG|Chemotherapy|"* mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin."
58131006|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
58468845|NCT06593483|BEHAVIORAL|Motivational Interview with Self-Talk Video|Participants will engage in an interview based in motivational interviewing techniques and then record a self talk video discussing their goals and reasons for reducing their drinking.
58468846|NCT06593483|BEHAVIORAL|Motivational Interviewing|Participants will engage in an interview based in motivational interviewing
58468847|NCT03879512|DRUG|depletion of regulatory T cells|oral metronomic cyclophosphamide
58468848|NCT03879512|PROCEDURE|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
58468849|NCT03879512|BIOLOGICAL|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
58468850|NCT03879512|BIOLOGICAL|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
58468851|NCT06587438|DEVICE|Sinocare iCan I3 CGM|Real-time Continuous glucose monitoring
58468852|NCT06587438|DEVICE|Sinocare jinzhi+Blood glucose meter|Self-monitoring of blood glucose
58468853|NCT05520203|OTHER|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
58468854|NCT06594718|PROCEDURE|Endoscopic diverticulotomy with Z-POEM|Endoscopic diverticulotomy with Z-POEM
58468855|NCT06594718|PROCEDURE|Endoscopic diverticulotomy using a non-tunnelization technique|Endoscopic diverticulotomy with diverticuloscope, Knife Septotomy, or Clutch Cutter
58468856|NCT04008368|DEVICE|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
58468857|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
58468858|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
58468859|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 3)|Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
58468860|NCT03955198|COMBINATION_PRODUCT|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
58468861|NCT00688116|DRUG|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
58468862|NCT04494841|DEVICE|Duotherm VibraCool Back Device|Low back plate belt with mechanicothermal and pressure intervention options.
58468863|NCT06590753|DEVICE|osseodensification bur|osseodensification bur
58468864|NCT05146388|OTHER|EHR-Based Approach|The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of \<= 1mL, optimal tool is 1 mL syringe, 2) for \>1 mL to 5 mL, use a 5 mL syringe, 3) for \>5mL to 10mL, use 10 mL syringe.
58468865|NCT06247813|DIETARY_SUPPLEMENT|Inflammation Support Formula|Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).
58468866|NCT06247813|DIETARY_SUPPLEMENT|Nerve Health Formula|Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).
58468867|NCT06247813|DIETARY_SUPPLEMENT|Redox Support Formula|N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).
58468868|NCT05976087|DEVICE|SensoExo|combination of sensory feedback and the use of soft exoskeleton
58468869|NCT04340895|OTHER|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
58468870|NCT04340895|OTHER|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
58468871|NCT04659044|DRUG|Polatuzumab Vedotin|Given IV
58468872|NCT04659044|BIOLOGICAL|Rituximab|Given IV
58468873|NCT04659044|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
58468874|NCT04659044|DRUG|Venetoclax|Given PO
58468875|NCT02444338|DEVICE|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
58468876|NCT02444338|OTHER|standard of care|
58468877|NCT06586892|BEHAVIORAL|Radiotherapy followed by chemotherapy|"Researchers would like to test the accuracy of the MRI data being used for this study. If you agree, you will have 2 additional MRI scans within 2 weeks before Visit 1.~The first 90 participants who agree will be selected to have the following scans:~* 35 participants will be scanned 2 times on one MRI device (Device #1).~* 35 participants will be scanned 2 times on another MRI device (Device #2).~* 20 participants will be scanned 1 time on both MRI devices (Device #1 and #2). If you agree and you are chosen, the study doctor will tell you if you will have scans on~  1. or 2 MRI devices."
58468878|NCT05865990|DRUG|Patritumab deruxtecan|HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
58468879|NCT06222099|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
58468880|NCT06222099|OTHER|Standard care|Remote patient monitoring companies in regular contact with patients as per their standard operating procedures. (RPMC do not receive measurement data from the Heartfelt device, but will get any other data they collect via their usual methods e.g. remotely monitored weight data)
58131007|NCT00991445|PROCEDURE|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
58468881|NCT06222099|DEVICE|Direct-to-patient alerts|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts).
58468882|NCT06222099|DEVICE|RPMC care|The RPMC receives measurement data and alert data from the device.
58468883|NCT06222099|OTHER|Questionnaires|Patients were presented with one or more optional questionnaires (some validated, some bespoke)
58468884|NCT06409806|OTHER|ECOG Array|"The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment.~Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference.~Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain."
58468885|NCT05255679|DEVICE|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
58468886|NCT05255679|DEVICE|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
58468887|NCT05590377|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion
58468888|NCT05590377|DRUG|Daratumumab|Daratumumab SC injection
58468889|NCT05100121|DEVICE|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
58468890|NCT05100121|OTHER|Supportive Care|During the health dialogues with the nurse, the patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patients health record.
58468891|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
58468892|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
58468893|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
58468894|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
58468895|NCT03300128|BEHAVIORAL|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
58468896|NCT03300128|OTHER|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
58468897|NCT04327700|DEVICE|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
58468898|NCT04327700|DRUG|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
58468899|NCT00242931|OTHER|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
58468900|NCT05238675|DRUG|BI 1291583|BI 1291583
58468901|NCT05238675|DRUG|Placebo|Placebo
58468902|NCT04676529|DRUG|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
58468903|NCT06594315|DRUG|Deuterated Glucose|Given orally
58468904|NCT06594315|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure performed at University of California, San Francisco
58468905|NCT06594315|PROCEDURE|Blood Sample|Capillary blood from the fingertip
58468906|NCT06594315|PROCEDURE|MR spectroscopy (MRS)|Imaging procedure performed at University of California, San Francisco
58468907|NCT01855529|DRUG|Ropivacaine in one arm and placebo (NaCl) in the other arm|
58468908|NCT06654011|DRUG|IN10018|100 mg, orally, once daily
58468909|NCT06654011|DRUG|Nab-paclitaxel|260 mg/m², IV infusion, Q3W
58468910|NCT06654011|DRUG|Cadonilimab|10 mg/kg, IV infusion, Q3W
58468911|NCT00541372|DEVICE|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
58468912|NCT05057637|DEVICE|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
58468913|NCT05520034|BEHAVIORAL|Health Education|The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
58468914|NCT06086795|OTHER|Whole eggs|3 large whole eggs per day for 4 weeks
58468915|NCT06086795|OTHER|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
58468916|NCT06086795|OTHER|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
58468917|NCT04534244|DEVICE|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
58468918|NCT03373240|BEHAVIORAL|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
58468919|NCT03373240|BEHAVIORAL|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
58468920|NCT02085460|DRUG|Placebo|
58468921|NCT02085460|DRUG|2% Rebamipide liquid|
58468922|NCT02085460|DRUG|4% Rebamipide liquid|
58468923|NCT05776940|DRUG|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
58131008|NCT00991445|PROCEDURE|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
58131009|NCT02695732|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
58131010|NCT02695732|DEVICE|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
58131011|NCT04314869|PROCEDURE|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
58468924|NCT05776940|DRUG|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
58468925|NCT02420717|DRUG|Cyclophosphamide|Given IV
58468926|NCT02420717|DRUG|Cytarabine|Given IV
58468927|NCT02420717|DRUG|Dasatinib|Given PO
58131012|NCT02328690|OTHER|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
58131013|NCT01717976|BEHAVIORAL|DISPO ED|primary care based nurse telephone support
58131014|NCT04003779|OTHER|Room configuration|Adjust distance, handrails, degrees of turn for participant
58468928|NCT02420717|DRUG|Dexamethasone|Given PO or IV
58468929|NCT02420717|DRUG|Doxorubicin|Given IV
58468930|NCT02420717|OTHER|Laboratory Biomarker Analysis|Correlative studies
58468931|NCT02420717|DRUG|Leucovorin|Given IV or PO
58468932|NCT02420717|DRUG|Mercaptopurine|Given PO
58468933|NCT02420717|DRUG|Methotrexate|Given IV and PO
58468934|NCT02420717|DRUG|Prednisone|Given PO
58468935|NCT02420717|BIOLOGICAL|Rituximab|Given IV
58468936|NCT02420717|DRUG|Ruxolitinib Phosphate|Given PO
58468937|NCT02420717|DRUG|Vincristine|Given IV
58468938|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
58468939|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
58468940|NCT05410743|DRUG|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
58468941|NCT05410743|DRUG|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.33GBq （90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
58468942|NCT05410743|DRUG|177Lu-LNC1010 3|The patients were intravenously injected with single dose 4.99GBq (135 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
58468943|NCT05410743|DRUG|177Lu-LNC1010 4|Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
58468944|NCT03457493|DRUG|DPA-714-PET/MRI|DPA-714-PET/MRI
58468945|NCT03457493|DRUG|5-year Follow-up DPA-714-PET/MRI|PET/MRI scan with DPA-714
58468946|NCT03457493|DRUG|DPA-714 Metabolite Analysis|Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
58468947|NCT02346123|GENETIC|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
58468948|NCT03555422|DRUG|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
58468949|NCT03555422|DRUG|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
58468950|NCT06590805|PROCEDURE|Electrotherapy using Chattanooga stimulation unit|Electroacupoint stimulation using the Chattanooga intellect transport 2-channel electrotherapy stimulation unit 2783. It uses the influences energy flows by needling the acupuncture points which lie along the body meridians to achieve a harmonious balance between physical, emotional, and spiritual states. The same effect can be achieved without the use of needles. These needleless stimulations are noninvasive and nontraumatic and are useful for individuals who are scared of needles. They are also associated with decreased risk of infection or bruise.
58468951|NCT06590805|DIETARY_SUPPLEMENT|Balanced Diet using domperidone drug, iron, and folic acid supplementation.|"Postnatal care diet in form of balanced diet using domperidone drug, iron, and folic acid supplementation. Additionally, drinking sufficient clean water and routine postnatal care.~It was performed by asking the participant to take ten mg domperidone three times a day after meals. Iron and folic acid supplementation were also continue for three months after birth."
58468952|NCT00129402|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
58468953|NCT00129402|DRUG|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
58468954|NCT00196547|DRUG|Montelukast (drug)|
58468955|NCT04156373|BEHAVIORAL|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
58468956|NCT03456128|OTHER|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
58468957|NCT01149096|PROCEDURE|Bone Marrow Donation|Undergo bone marrow harvest
58468958|NCT01149096|BIOLOGICAL|Filgrastim|Given subcutaneously
58468959|NCT01149096|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58468960|NCT06567145|BEHAVIORAL|Narrative Enhancement Cognitive Therapy (NECT)|The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
58468961|NCT06039579|DRUG|VH4004280|VH4004280 will be administered.
58468962|NCT06039579|DRUG|VH4011499|VH4011499 will be administered.
58468963|NCT06039579|DRUG|VH4004280 Matching Placebo|VH4004280 matching placebo will be administered.
58468964|NCT06039579|DRUG|VH4011499 Matching Placebo|VH4011499 matching placebo will be administered.
58468965|NCT02173080|OTHER|PLD-Q|polycystic liver disease questionnaire
58468966|NCT05031520|PROCEDURE|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
58468967|NCT05031520|DRUG|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
58468968|NCT05031520|DRUG|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
58468969|NCT05031520|DRUG|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
58468970|NCT06336005|DRUG|NNC6022-0001|Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
58468971|NCT06336005|DRUG|Placebo (NNC6022-0001)|Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
58468972|NCT06654492|PROCEDURE|The dimension of the window for lateral window maxillary sinus elevation surgery|The window size for a single implant site should not exceed 25 square millimeters, while the window size for consecutive multiple implant sites should not exceed 40 square millimeters.
58468973|NCT05502562|DRUG|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
58468974|NCT02300792|DIETARY_SUPPLEMENT|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
58468975|NCT02300792|DIETARY_SUPPLEMENT|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
58468976|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket wire in high level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in low level for the treatment of anterior deep bite .
58468977|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket with wire in low level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in high level for the treatment of anterior deep bite .
58468978|NCT05813574|OTHER|Observational patient reported outcomes|Of COVID-19 patients
58468979|NCT06594380|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination
58468980|NCT06594380|DEVICE|Endoscopic bite group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
58468981|NCT06424236|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
58468982|NCT06099184|DRUG|EYP-1901|Intravitreal Injection
58468983|NCT06099184|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
58468984|NCT04335253|DRUG|EOS884448|Multiple Ascending Dose
58468985|NCT06280924|BEHAVIORAL|Supported Exercise|Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.
58468986|NCT06280924|BEHAVIORAL|Standard Care|Participants will receive standard care
58468987|NCT06184529|BEHAVIORAL|Virtual Reality|The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
58468988|NCT05068752|DRUG|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
58468989|NCT05068752|DRUG|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
58468990|NCT03204188|DRUG|Ibrutinib|Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
58468991|NCT03204188|DRUG|Fludarabine|Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.
58468992|NCT03204188|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
58468993|NCT06357247|DEVICE|Sensory Threshold|Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits
58468994|NCT06357247|BEHAVIORAL|Nine Hole Peg Test|The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.
58468995|NCT06357247|BEHAVIORAL|Semmes Weinstein Monofilament Assessment|A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
58468996|NCT06345313|PROCEDURE|Day Group|Patient group that will be operated on between 08.00-12.00
58468997|NCT06345313|PROCEDURE|Night Group|Patient group that will be operated on between 18.00-22.00
58468998|NCT00619034|DRUG|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
58468999|NCT00619034|DRUG|Diclofenac|dicolfenac eyedrops twice daily i one eye
58469000|NCT00619034|DRUG|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
58469001|NCT03868423|DRUG|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
58469002|NCT03868423|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469003|NCT03868423|OTHER|Quality-of-Life Assessment|Ancillary studies
58469004|NCT03868423|OTHER|Questionnaire Administration|Ancillary studies
58469005|NCT05088876|DRUG|Placebo|Blinded withdrawal of regular co-medication with paracetamol
58131015|NCT01240005|BIOLOGICAL|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
58131016|NCT00113347|DRUG|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
58469006|NCT05088876|DRUG|Paracetamol|Paracetamol in the dose already used
58469007|NCT06521749|DEVICE|USB as a stylet|USB used as a bougie
58469008|NCT06521749|DEVICE|USB as a bougie|USB used as a bougie
58469009|NCT02968134|DRUG|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
58469010|NCT06594965|DRUG|HS-20106|HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
58469011|NCT01282034|PROCEDURE|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
58469012|NCT01282034|DEVICE|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
58469013|NCT06600022|DRUG|SCTB41|SCTB41 of different doses,IV,every 3 weeks
58469014|NCT03541083|DRUG|Blinatumomab|prephase and consolidation (I and II)
58469015|NCT03729453|DEVICE|SpyGlass|Visualization of main pancreatic duct with SpyGlass catheter.
58469016|NCT04084158|DRUG|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
58469017|NCT04084158|DRUG|Paclitaxel, Albumin-Bound|Paclitaxel
58469018|NCT04084158|RADIATION|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
58469019|NCT04084158|DRUG|Platinum-Based Drug|carboplatin
58469020|NCT04408989|DRUG|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
58469021|NCT04408989|DRUG|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
58469022|NCT04408989|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
58469023|NCT03178214|DRUG|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
58469024|NCT06593990|DEVICE|echocardography|"Patients will be subjected to transthoracic echocardiography including, the following parameters will be measured:~* Left ventricular (LV) dimensions: end diastolic and systolic dimensions and LV ejection fraction (EF).~* Trans- mitral Doppler flow velocities including early (E) and late(A) diastolic velocities, E/A ratio.~* LA anteroposterior diameter measure from 2D parasternal long axis view targeted M-mode.~* LA superior-inferior and medio-lateral diameters measure from the apical 4 chamber view.~* LA volume included:~* Maximal LA volume measure at the end of systole~* Minimal LA volume will be measured at end diastole just at the closure of the mitral valve.~* Pre contractile LA volume ( LAV pre-A\] measured at P-wave onset on ECG just before atrial contraction."
58469025|NCT06593990|DEVICE|musculoskeletal ultrasonography|Ultrasound detected synovitis t
58469026|NCT06593990|DIAGNOSTIC_TEST|lipid profile test|The lipid profile typically includes measurement of total cholesterol, HDL-cholesterol (often called good cholesterol), LDL-cholesterol (often called bad cholesterol), and triglycerides.
58469027|NCT06593990|DIAGNOSTIC_TEST|C reactive protein|A c-reactive protein test measures the level of c-reactive protein (CRP) in a sample of your blood. CRP is a protein that your liver makes. Normally, you have low levels of c-reactive protein in your blood. Your liver releases more CRP into your bloodstream if you have inflammation in your body. High levels of CRP may mean you have a serious health condition that causes inflammation.
58469028|NCT06593990|DIAGNOSTIC_TEST|Complete blood count CBC|"A complete blood count, or CBC, is a blood test that measures many different parts and features of your blood, including:~Red blood cells, which carry oxygen from your lungs to the rest of your body. White blood cells, which fight infections and other diseases. There are five major types of white blood cells. A CBC test measures the total number of white cells in your blood. A different test called a CBC with differential measures the number of each type of these white blood cells.~Platelets, which stop bleeding by helping your blood to clot. Hemoglobin, a protein in red blood cells that carries oxygen from your lungs to the rest of your body.~Hematocrit, a measurement of how much of your blood is made up of red blood cells.~Mean corpuscular volume (MCV), a measure of the average size of your red blood cells."
58469029|NCT06593990|DIAGNOSTIC_TEST|Erythrocyte sedimentation rate (ESR).|An erythrocyte sedimentation rate (ESR) is a blood test that that can show if you have inflammation in your body. Inflammation is your immune system\&#39;s response to injury, infection, and many types of conditions, including immune system disorders, certain cancers, and blood disorders.
58469030|NCT06593990|DEVICE|x ray of the hand|The X-ray may show a hand with advanced rheumatoid arthritis. \&#34;Bone erosion\&#34; means cartilage and bone are worn away. \&#34;Bone displacement\&#34; means that a bone has moved out of its normal position. This X-ray shows how bone erosion and bone displacement can change the shape of the hand.
58469031|NCT05177965|OTHER|Exposure to shift work|Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
58469032|NCT02784080|OTHER|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)"
58469033|NCT05699408|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
58469034|NCT05699408|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
58469035|NCT06592469|PROCEDURE|Ureteroscopy|URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter
58469036|NCT05975255|DRUG|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
58469037|NCT06601530|PROCEDURE|Transversus Thoracic Muscle Plane Block|Transversus thoracic muscle plane block is a single-shot nerve block technique that provides analgesia for the anterior chest wall Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
58469038|NCT06601530|DRUG|Tramadol|Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
58469039|NCT04717635|BIOLOGICAL|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
58469040|NCT03715556|DRUG|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
58469041|NCT03715556|DRUG|0.9% physiological solution|Administration of 0.9% physiological solution.
58469042|NCT06177483|DIETARY_SUPPLEMENT|95% curcumin extract powder|95% curcumin extract powder
58469043|NCT06177483|DIETARY_SUPPLEMENT|curQ+ curcumin formulation|curQ+ curcumin formulation
58469044|NCT01066013|OTHER|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
58469045|NCT06467825|DRUG|Potassium Supplement|Participants will be given a potassium supplement that will help prevent low blood potassium levels.
58469046|NCT06467825|DRUG|Furosemide 20 MG|Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
58469047|NCT06467825|DEVICE|Compression Garment|From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
58469048|NCT05077215|DRUG|EG-007|A Repurposed Drug
58469049|NCT05077215|DRUG|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
58469050|NCT05077215|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
58469051|NCT06476132|DRUG|Belumosudil|Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
58469052|NCT06476132|DRUG|Placebo for Belumosudil|Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
58469053|NCT06704737|DEVICE|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia
58469054|NCT06704737|DEVICE|Patching|Conventional patching therapy.
58469055|NCT05996575|OTHER|fNIRS measurement|Kernel Flow2 measurements.
58469056|NCT03293615|OTHER|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
58469057|NCT03361137|DRUG|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
58469058|NCT03389477|DRUG|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
58469059|NCT03389477|DRUG|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
58469060|NCT03389477|DRUG|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
58469061|NCT03389477|RADIATION|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
58469062|NCT03389477|PROCEDURE|Tumor biopsy|"* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
58469063|NCT03389477|PROCEDURE|Peripheral blood draw|Baseline and post-treatment
58469064|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (tablet)
58469065|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (capsule)
58469066|NCT04292275|DEVICE|Biobeat Wrist Watch|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.
58469067|NCT04292275|OTHER|Standard of Care|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
58469068|NCT02429323|DRUG|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
58131017|NCT00113347|DRUG|Docetaxel|15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
58469069|NCT04487366|OTHER|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
58469070|NCT04944277|OTHER|ThoughtFullChat Application|A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
58469071|NCT06432153|OTHER|observation|Participants who receive routine clinical care, without additional intervention from the study
58469072|NCT06179303|DRUG|Abemaciclib|Given PO
58469073|NCT06179303|DRUG|Anastrozole|Given PO
58469074|NCT06179303|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58469075|NCT06179303|PROCEDURE|Computed Tomography|Undergo PET/CT
58469076|NCT06179303|PROCEDURE|Diagnostic Imaging|Undergo clinical imaging for tumor assessment
58469077|NCT06179303|DRUG|Exemestane|Given PO
58469078|NCT06179303|OTHER|Fludeoxyglucose F-18|Given IV
58469079|NCT06179303|DRUG|Fluorine F 18 Fluoro Furanyl Norprogesterone|Given IV
58469080|NCT06179303|DRUG|Fulvestrant|Given IM injection
58469081|NCT06179303|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given GnRH analog
58469082|NCT06179303|DRUG|Letrozole|Given PO
58469083|NCT06179303|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58469084|NCT06179303|DRUG|Tamoxifen|Given PO
58469085|NCT06179303|DRUG|Therapeutic Estradiol|Given PO
58469086|NCT05313984|DEVICE|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
58469087|NCT05579782|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
58469088|NCT05865028|DRUG|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
58469089|NCT05119647|DEVICE|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
58469090|NCT06356337|DEVICE|Light goggles|Blue light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks.
58469091|NCT06356337|DEVICE|Orange glasses|Orange glasses that do not provide entrainment will be worn for 1 hour each morning to block morning light for two weeks.
58469092|NCT05514977|PROCEDURE|Erector spine plane block|Thoracic ESPB
58469093|NCT02741128|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
58469094|NCT02741128|BIOLOGICAL|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
58469095|NCT06067516|OTHER|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
58469096|NCT01506596|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
58469097|NCT06599216|DRUG|Adebrelimab+Dalpciclib+Standard Endocrine Therapy|Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
58469098|NCT05221931|PROCEDURE|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
58469099|NCT04126161|PROCEDURE|CT|standard of care CT prior to primary hip replacement
58469100|NCT04126161|DEVICE|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
57784522|NCT01330043|DRUG|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
58469101|NCT04339764|DRUG|iPSC-derived RPE/PLGA transplantation|iPSC-derived RPE/PLGA transplantation
58469102|NCT02278510|DRUG|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
58469103|NCT02278510|DRUG|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
58469104|NCT02278510|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
58469105|NCT06211179|DRUG|Treatment A: Mavacamten intact oral capsule|Specified dose on specified days
58131018|NCT00113347|RADIATION|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
58131019|NCT00864864|DRUG|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
58469106|NCT06211179|DRUG|Treatment B: Mavacamten open capsule in suspension|Specified dose on specified days
58469107|NCT06211179|DRUG|Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)|Specified dose on specified days
58469108|NCT03939143|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
58469109|NCT03939143|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
57784523|NCT05952115|OTHER|lumbar motor control exercises|"the patients will receive lumbar motor control exercises in the form of three exercises (Abdominal draw in maneuver, side-bridge, and quadruped) and the level of difficulty increased each week. For all exercises, the number of repetitions stayed the same, but the difficulty increased each week, and we progressed to the advanced level of each of the three exercises.~This training achieves co-contraction of the local/deep stabilizing muscles (Transversus abdominis and multifidus) and strengthening the global/large spinal stabilizers (erector spinae and obliques)."
58469110|NCT02908061|PROCEDURE|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
58469111|NCT02908061|PROCEDURE|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
58469112|NCT05942586|DIETARY_SUPPLEMENT|Probiotic capsule (L. reuteri PB-W1™), Placebo sachet|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
58469113|NCT05942586|DIETARY_SUPPLEMENT|Prebiotic sachet (Prebiotic Blend), Placebo capsule|Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
58469114|NCT05942586|COMBINATION_PRODUCT|Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
58469115|NCT05942586|DIETARY_SUPPLEMENT|Placebo sachet, Placebo capsule|Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
58469116|NCT06420882|OTHER|The experimental group.|In the experimental group, in addition to home exercises, patella mobilization, muscle strengthening exercises, range of motion exercises and home exercises will be performed 3 days a week for 3 sessions with a therapist.
58469117|NCT06420882|OTHER|The home exercise group|Participants in both groups will be included in a 3-week treatment programme.
58469118|NCT01251965|DRUG|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
58469119|NCT00148278|DRUG|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
58469120|NCT00148278|DRUG|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
58469121|NCT06345079|DRUG|Cessation of somatostatin analogues|Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
58469122|NCT06345079|DRUG|Continuation of somatostatin analogues|Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
58469123|NCT06101212|OTHER|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
58469124|NCT06222853|BIOLOGICAL|anti-CD19-CAR-T cells|Three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
58469125|NCT03299556|OTHER|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
58469126|NCT00575185|DRUG|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
58469127|NCT00575185|DRUG|placebo|Placebo tablets orally twice daily for 21 days.
58469128|NCT00683527|DRUG|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
58469129|NCT01440959|DRUG|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
58469130|NCT06706284|DRUG|Semaglutide Injectable Product|A GLP-1 inhibitor used to control T2DM
58469131|NCT06706284|OTHER|Placebo|Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
58469132|NCT05375461|DRUG|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
58469133|NCT05375461|DRUG|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
58469134|NCT05375461|DRUG|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
58469135|NCT06494020|OTHER|Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)|Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
58469136|NCT06512584|DRUG|PJ009|subcutaneous injections, 0.05 mg/kg once daily
58469137|NCT06512584|DRUG|PJ009 Placebo|subcutaneous injections, once daily
58469138|NCT04381832|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
58469139|NCT04381832|DRUG|Zimberelimab|Zimberelimab is an anti-PD-1 antibody
58469140|NCT04381832|DRUG|Quemliclustat|Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
58469141|NCT04381832|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor
58469142|NCT04381832|DRUG|Docetaxel|Docetaxel is type of chemotherapy
58469143|NCT04381832|DRUG|SG|Sacituzumab govitecan is an antibody-drug conjugate
58469144|NCT05794321|DRUG|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
58469145|NCT05321134|DEVICE|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety \& quality event rate for SP platform transabdominal and transanal colorectal operations."
58469146|NCT06592365|DIETARY_SUPPLEMENT|GTE|oral administration of GTE tablets once daily for 12 weeks
58469147|NCT06592365|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo tablets once daily for 12 weeks
58469148|NCT05743868|BEHAVIORAL|Standardized Dinner|De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
58469149|NCT05743868|BEHAVIORAL|Premeal exercise|DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
58469150|NCT03905707|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
58469151|NCT04005378|OTHER|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
58469152|NCT04005378|OTHER|Usual Care|Usual Care provided by CSC center
58469153|NCT02352025|DRUG|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
58469154|NCT02524327|OTHER|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
58469155|NCT02524327|OTHER|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
58469156|NCT05990296|BEHAVIORAL|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
58131020|NCT04137679|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
58469157|NCT05990296|BEHAVIORAL|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
58469158|NCT05990296|BEHAVIORAL|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
58469159|NCT04244253|DRUG|OPC-64005 20 mg , Once-daily|Active, High Dose
58469160|NCT04244253|DRUG|OPC-64005 10 mg , Once-daily|Active, Low Dose
58469161|NCT04244253|DRUG|Placebo, Once-daily|Placebo
58469162|NCT03904394|OTHER|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
58469163|NCT06567028|DIAGNOSTIC_TEST|OSFound-Enhanced AI Model|Analyze tumor images using the model developed in our study
58469164|NCT06491446|DRUG|ABI-2280|"Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered."
58469165|NCT01480154|DRUG|Akt Inhibitor MK2206|Given PO
58469166|NCT01480154|DRUG|Hydroxychloroquine|Given PO
58469167|NCT04942574|OTHER|Total sleep deprivation|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
58131021|NCT04137679|PROCEDURE|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
58469168|NCT04942574|OTHER|Normal sleep|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
58469169|NCT00599872|BIOLOGICAL|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
58469170|NCT00599872|BIOLOGICAL|Placebo|Placebo, sublingual oral
58469171|NCT04514887|OTHER|mild intraoperative hyperventilation|Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
58469172|NCT06565429|BEHAVIORAL|5-Step Method Intervention|The 5-Step Method (5SM) intervention is delivered through a self-help handbook: There are writing prompts for the affected family member (AFM) in each step. The steps end with a summary, a space to reflect and a statement that the step is complete but can be reviewed as needed. The steps are: 1.Explore how the relative's drug and/or alcohol misuse is affecting the family member, causing stress and strain. 2.Determine the information the AFM needs to understand the situation using evidence-based websites in the handbook. 3.Reflect on coping styles, and which ones might be useful. 4.Determine who is a source of positive social support, and who could be one that the AFM has not used yet. 5.Review steps 1-4 and determine if the AFM is feeling less stress and strain, or if more help is needed and use websites to look for additional help. The activities should take about 1 hour per week.
58469173|NCT04872413|PROCEDURE|Biospecimen Collection|Undergo blood, saliva or tissue sample collection
58469174|NCT04872413|OTHER|Follow-Up|Undergo follow-up
58469175|NCT03128866|PROCEDURE|Hemipelvectomy|Undergo hemipelvectomy
58469176|NCT03128866|DRUG|Tranexamic Acid|Given IV
58469177|NCT06271291|OTHER|Non-Interventional Study|Non-interventional study
58469178|NCT06363461|DRUG|TDM-180935 topical ointment 1.0%|Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
58469179|NCT06363461|DRUG|TDM-180935 topical ointment 2.0%|Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
58469180|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 1|Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
58469181|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 2|Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
58469182|NCT00375999|DRUG|Docetaxel and epirubicin|
58469183|NCT04456023|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of 0.6 - 6.0×10\^8 CAR positive viable T cells.
58469184|NCT03043014|DRUG|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
58469185|NCT04239911|BEHAVIORAL|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
58469186|NCT04239911|BEHAVIORAL|Virtual training course|Virtual training course on heart failure for home health aides.
58469187|NCT06066788|OTHER|CHAMPS|Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
58469188|NCT06587529|BEHAVIORAL|The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum|Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
58469189|NCT06268808|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
58469190|NCT03975010|DRUG|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
58469191|NCT04771156|DRUG|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
58469192|NCT04771156|DRUG|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
58469193|NCT05315102|OTHER|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
58469194|NCT05315102|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
58469195|NCT05315102|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
58469196|NCT05156047|DRUG|Open-label pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
58469197|NCT05156047|DRUG|Double-blind placebo|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
58469198|NCT05156047|DRUG|Double-blind pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
58469199|NCT03088696|OTHER|stimulation|activation of the acupuncture point
58469200|NCT03088696|OTHER|no stimulation|no activation of the acupuncture point
58469201|NCT06587802|DRUG|Triprolizumab|At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
58469202|NCT06587802|DEVICE|rodiotherapy|SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)
58469203|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469204|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469205|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469206|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469207|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469208|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
58469209|NCT02453737|RADIATION|Brachytherapy APBI|
58469210|NCT02453737|RADIATION|3D-CRT (photon) APBI|
58469211|NCT02453737|RADIATION|Proton APBI|
58469212|NCT03641417|DRUG|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
58469213|NCT03641417|OTHER|Placebo|Same as GLWL-01, but no active ingredient
58469214|NCT06191458|DRUG|Primaquine|Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
58469215|NCT00829569|DIETARY_SUPPLEMENT|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
58469216|NCT06598046|DRUG|Utidelone and capecitabine|Utidelone: intravenous capecitabine: oral
58469217|NCT04956120|DEVICE|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
58469218|NCT04956120|DEVICE|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
58469219|NCT02516280|DEVICE|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
58469220|NCT02516280|DEVICE|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
58469221|NCT05357625|BEHAVIORAL|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
58469222|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
58469223|NCT00746681|DRUG|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
58469224|NCT00746681|DRUG|Placebo|Placebo, Oral, twice daily for 4 weeks
58469225|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
58469226|NCT00746681|DRUG|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
58469227|NCT06579300|DRUG|ABBV-1088|Oral Capsule
58469228|NCT06579300|DRUG|Placebo for ABBV-1088|Oral Capsule
58469229|NCT06579300|DRUG|Itraconazole (ITZ)|Oral Capsule
58469230|NCT00259597|PROCEDURE|breast ductal lavage|breast ductal lavage and nipple aspiration done once
58469231|NCT05271578|DEVICE|Standardized Electronic Research Cigarette|Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)
58469232|NCT05271578|DEVICE|Nicotine Research Cigarette|Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
58469233|NCT02179697|OTHER|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
58469234|NCT02179697|PROCEDURE|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
58469235|NCT06419270|OTHER|Observation|Observational
58469236|NCT05163158|OTHER|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
58469237|NCT05810740|DRUG|Binimetinib 15 MG|Binimetinib 15 mg tablet
58469238|NCT05810740|DRUG|Binimetinib 45 MG|Binimetinib 45 mg tablet
58469239|NCT06423885|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
58469240|NCT06423885|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
58469241|NCT06423885|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
58469242|NCT03850379|DRUG|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
58469243|NCT03850379|DRUG|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
58469244|NCT04338321|DRUG|Esketamine 28 mg|Esketamine will be self-administered at a dose of 28 mg as nasal spray.
58469245|NCT04338321|DRUG|Esketamine 56 mg|Esketamine will be self-administered at a dose of 56 mg as nasal spray.
58469246|NCT04338321|DRUG|Esketamine 84 mg|Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
58469247|NCT04338321|DRUG|Quetiapine XR 50 mg|Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
58469248|NCT04338321|DRUG|Quetiapine XR 100 mg|Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
58469249|NCT04338321|DRUG|Quetiapine XR 150 mg|Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
58469250|NCT04338321|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
58469251|NCT05953389|DRUG|Pitolisant|histamine H3 receptor antagonist/inverse agonist
58469252|NCT05953389|DRUG|Placebo|Matching placebo of pitolisant tablets
58469253|NCT02262806|DRUG|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
58469254|NCT05289310|OTHER|Normobaric hypoxia (NH)|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
58469255|NCT05289310|OTHER|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
58469256|NCT02152891|BEHAVIORAL|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
58469257|NCT05215431|PROCEDURE|periodontal examination&amp;#39;s, determination of salivary antioxidants and cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid, Non-surgical therapy of periodontitis|Periodontal parameters has been recorded on six sites of each tooth using a manual periodontal probe. Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits. Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits . The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
58131022|NCT00825227|DRUG|Armodafinil 150 mg/day|"* 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
58469258|NCT05215431|DIAGNOSTIC_TEST|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA)|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits.
58469259|NCT05215431|DIAGNOSTIC_TEST|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits .
58469260|NCT05215431|PROCEDURE|Periodontal treatment|The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
58469261|NCT04436991|DIAGNOSTIC_TEST|Blood sampling|"At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day)."
58469262|NCT04436991|DIAGNOSTIC_TEST|Sputum sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
58469263|NCT04436991|DIAGNOSTIC_TEST|Hemoculture|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
58469264|NCT04436991|DIAGNOSTIC_TEST|Urine sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
58469265|NCT05005182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58469266|NCT05005182|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
58469267|NCT05005182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
58469268|NCT05005182|DRUG|Hydroxyurea|Given PO
58469269|NCT05005182|BIOLOGICAL|Luspatercept|Given SC
58469270|NCT05005182|OTHER|Questionnaire Administration|Ancillary studies
58469271|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle.
58469272|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
58469273|NCT05454033|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
58469274|NCT05454033|OTHER|Control|No-treatment control
58469275|NCT01708408|GENETIC|Biomarker studies|
58469276|NCT01452906|DRUG|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
58469277|NCT01452906|DRUG|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
58469278|NCT01452906|DRUG|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
58469279|NCT04930367|BEHAVIORAL|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
58469280|NCT04930367|BEHAVIORAL|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
58469281|NCT04930367|BEHAVIORAL|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
58469282|NCT04930367|BEHAVIORAL|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
58469283|NCT04930367|OTHER|Pill Container|A discreet pill container to support ART adherence.
58469284|NCT04930367|OTHER|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
58469285|NCT04930367|OTHER|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
58469286|NCT04930367|OTHER|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
58131023|NCT00825227|DRUG|Placebo,|"* placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
58469287|NCT04930367|OTHER|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
58469288|NCT04930367|BEHAVIORAL|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
58469289|NCT04930367|BEHAVIORAL|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
58469290|NCT04930367|BEHAVIORAL|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
58469291|NCT04930367|BEHAVIORAL|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
58469292|NCT04930367|BEHAVIORAL|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
58469293|NCT01375140|DRUG|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
58469294|NCT01375140|DRUG|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
58469295|NCT01375140|DRUG|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
58469296|NCT02574624|PROCEDURE|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
58469297|NCT04415944|PROCEDURE|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
58469298|NCT04415944|DRUG|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~* Extraperitoneal disease noted at the time of the second look procedure~* Macroscopic intraperitoneal disease which is not resectable to R1~* Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~* Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
58469299|NCT04415944|OTHER|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
58469300|NCT04776083|DRUG|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
58469301|NCT04776083|RADIATION|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
58469302|NCT06537726|DIAGNOSTIC_TEST|Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)|Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
58469303|NCT05487612|DEVICE|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
58469304|NCT05487612|DEVICE|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
58469305|NCT04515771|BEHAVIORAL|PARTNER-MH|The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
58469306|NCT05748275|DIAGNOSTIC_TEST|Argos|Biometry measurements first with the Argos device, then the IOLMaster 700 device.
58469307|NCT05748275|DIAGNOSTIC_TEST|IOLMaster 700|Biometry measurements first with the IOLMaster 700 device, then the Argos device.
58469308|NCT04092504|OTHER|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for elderly patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
58469309|NCT02916212|OTHER|Optimized alarm profiles|
58469310|NCT06592482|DRUG|AZD0780|"A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water."
58469311|NCT05924633|DIETARY_SUPPLEMENT|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
58469312|NCT05924633|DIETARY_SUPPLEMENT|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
58469313|NCT05176314|DRUG|Rosuvastatin|Administered Orally.
58469314|NCT05176314|DRUG|Pirtobrutinib|Administered Orally.
58469315|NCT04421950|DIETARY_SUPPLEMENT|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
58469316|NCT04421950|DIETARY_SUPPLEMENT|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
58469317|NCT06096519|BEHAVIORAL|Information, motivation, behavioral skills treatment arm|Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old gay, bisexual, and queer (GBQ) adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old GBQ adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of adolescent sexual minority men and transgender and gender diverse adolescents.
58469318|NCT06096519|BEHAVIORAL|Information only control arm|This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
58469319|NCT03025971|DEVICE|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
58469320|NCT06002919|BEHAVIORAL|MindWalk Intervention|The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
58469321|NCT04851691|BEHAVIORAL|EHR CDS|"When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation."
58469322|NCT04851691|OTHER|Usual Care|Patients will receive usual care from their physicians.
58469323|NCT05960097|BIOLOGICAL|CV0701 Bivalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469324|NCT05960097|BIOLOGICAL|CV0701 Bivalent Medium dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469325|NCT05960097|BIOLOGICAL|CV0701 Bivalent Low dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469326|NCT05960097|BIOLOGICAL|CV0601 Monovalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469327|NCT05960097|BIOLOGICAL|Control vaccine|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469328|NCT05960097|BIOLOGICAL|CV0801 Monovalent|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
58469329|NCT03525379|DRUG|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
58469330|NCT03525379|DRUG|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
58469331|NCT01527149|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
58469332|NCT01527149|DRUG|Cyclophosphamide|Given IV
58469333|NCT01527149|DRUG|Cytarabine|Given IV
58469334|NCT01527149|DRUG|Dexamethasone|Given IV or PO
58469335|NCT01527149|DRUG|Doxorubicin Hydrochloride|Given IV
58469336|NCT01527149|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469337|NCT01527149|DRUG|Methotrexate|Given IV
58469338|NCT01527149|BIOLOGICAL|Ofatumumab|Given IV
58469339|NCT01527149|DRUG|Vincristine Sulfate|Given IV
58469340|NCT06601452|DRUG|a compound prescription of Chinese medicine|The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
58469341|NCT04825574|DRUG|Avapritinib|avapritinib tablet
58469342|NCT03632135|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
58469343|NCT03632135|DRUG|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
58469344|NCT05907174|BEHAVIORAL|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
58469345|NCT05025020|OTHER|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
58469346|NCT05025020|OTHER|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
58469347|NCT05025020|OTHER|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
58469348|NCT05025020|OTHER|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
58469349|NCT06551610|OTHER|Triage Tool|Tool that uses patient characteristics to triage patients for an earlier procedure date vs the standard of care 12 week wait for procedure.
58469350|NCT05507541|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58469351|NCT05507541|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
58469352|NCT05507541|DRUG|Ontorpacept|Given IV
58469353|NCT05507541|BIOLOGICAL|Pembrolizumab|Given IV
58469354|NCT05507541|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
58469355|NCT05507541|DRUG|Maplirpacept|Given IV
58469356|NCT05507541|PROCEDURE|Biopsy|Undergo tumor biopsy
58469357|NCT05335330|OTHER|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
58469358|NCT04613362|BEHAVIORAL|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
58469359|NCT04613362|BEHAVIORAL|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
58469360|NCT05990179|OTHER|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
58469361|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
58469362|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
58469363|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
58469364|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
58469365|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
58469366|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
58469367|NCT06599112|OTHER|Densah Burs|Series of drilling burs inserted in the osteotomy with special design that have a large negative rake angle flute, a cutting chisel edge and a tapered shank, so as they enter deeper into the osteotomy and they have a progressively increasing diameter that controls the expansion process. These burs are used with a standard surgical engine and can densify bone by rotating in the noncutting direction (counterclockwise at 800-1,200 rotations per minute) or drill bone by rotating in the cutting direction (clockwise at 800-1,200 rotations per minute) with an in and out movement together with copious saline irrigation and increasing bone plasticity and ability to expand under rate dependent stress.
58469368|NCT06599112|OTHER|Osteotomes|The osteotomes kit are a series of tools that first designed by Summers in 1994. The concept was to maintain the existing bone by compressing trabecular bone laterally and apically with minimal trauma to improve the bone density. The condensed bone in this way will have to put in act a double repairing mechanism, from one side represented by the normal processes of osteointegration and on the other side from the processes of the reparation post fracture like that depends on BMU (bone modelling units) which create new spaces for the new vessels and afterwards filling all the gaps between the bone and the implant.
58469369|NCT06599112|OTHER|Conventional drilling|The implant drilling kit provided by the manufacturer will be used for the implant placement, using the pilot drill followed by consequent drills according to the size of the osteotomy needed.
58469370|NCT06335849|BIOLOGICAL|LYB004 25µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
58469371|NCT06335849|BIOLOGICAL|LYB004 50µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
58469372|NCT06335849|BIOLOGICAL|SHINGRIX|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
58469373|NCT01849263|DRUG|Ibrutinib|Given PO
58469374|NCT01849263|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469375|NCT05781542|BIOLOGICAL|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
58469376|NCT05781542|BIOLOGICAL|IL-12 DNA|0.1 mg or 0.4 mg
58469377|NCT05781542|BIOLOGICAL|Trimer 4571|100 mcg
58469378|NCT05781542|BIOLOGICAL|3M-052-AF|5 mcg
58469379|NCT05781542|DRUG|Alum|500 mcg
58469380|NCT06060899|PROCEDURE|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
58469381|NCT06060899|PROCEDURE|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
58469382|NCT04991649|BEHAVIORAL|Acceptance and Commitment Therapy-based Asthma Management Training Program|In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
58469383|NCT04991649|BEHAVIORAL|Treatment-as-usual Group|Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
58469384|NCT04907370|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
58469385|NCT04907370|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
58469386|NCT04907370|DRUG|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
58469387|NCT04907370|DRUG|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
58469388|NCT04907370|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
58469389|NCT04935658|DEVICE|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
58469390|NCT04935658|DRUG|local anesthesia|standard anesthesic procedure
58469391|NCT02135250|DRUG|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
58469392|NCT02135250|OTHER|placebo|the placebo is not drug.
58469393|NCT06367764|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
58469394|NCT06367764|BEHAVIORAL|STAIR Narrative Therapy|STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
58469395|NCT06412159|OTHER|Selective laser melting framework was fabricated using completely digital workflow|completely digital work flow Conventional technique versus complete digital technique
58469396|NCT01742143|BEHAVIORAL|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
58469397|NCT01742143|BEHAVIORAL|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
58469398|NCT04458051|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
58469399|NCT04458051|DRUG|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
58469400|NCT02020265|DEVICE|EEG neurofeedback|
58469401|NCT05404828|OTHER|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
58469402|NCT05404828|OTHER|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
58469403|NCT05404828|OTHER|Blood and urine sample|Na, K, Creat, Osm, Urea
58469404|NCT01782027|DRUG|3H-cholesterol bound to albumin|up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
58469405|NCT02893397|DEVICE|Activity Monitor|Wear a fitbit
58469406|NCT02893397|BEHAVIORAL|Exercise Intervention|Undergo supervised exercise sessions
58469407|NCT05728411|OTHER|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
58469408|NCT05728411|OTHER|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
58469409|NCT06597175|DEVICE|ORIGO|The device measurement is first performed on the breast area with the lesion, followed by the measurement of the corresponding area in the contralateral breast for comparison.
58469410|NCT02711891|DRUG|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
58469411|NCT02711891|DRUG|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
58469412|NCT06366711|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device for pregnancy care
58469413|NCT06366711|DRUG|Pulsenmore device|Remote ultrasound device for pregnancy care
58469414|NCT05690308|OTHER|Visual perturbation treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.
58469415|NCT05690308|OTHER|Regular treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill
58469416|NCT06194448|DRUG|Osimertinib|80 mg daily (or 40 mg daily for dose reduction)
58469417|NCT06194448|DRUG|Cisplatin or Carboplatin; Pemetrexed or Paclitaxel|Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
58469418|NCT06194448|DRUG|Radiation|"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
58469419|NCT01730599|OTHER|neurological exam|motor and cognitive functions
58469420|NCT04733326|DRUG|Ketorolac Tromethamine|final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
58469421|NCT04733326|OTHER|Cryotherapy|final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
58469422|NCT04733326|OTHER|Saline|final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
58469423|NCT06508333|BEHAVIORAL|alarm therapy|These patients will receive alarm therapy for 8 weeks.
58469424|NCT06508333|DRUG|Vitamin D3|These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) (combined with alarm therapy) for 8 weeks.
58469425|NCT04192565|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
58469426|NCT03401801|PROCEDURE|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
58469427|NCT03771716|BEHAVIORAL|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
58469428|NCT03771716|BEHAVIORAL|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
58469429|NCT04940299|BIOLOGICAL|Ipilimumab|Given IV
58469430|NCT04940299|BIOLOGICAL|Nivolumab|Given IV
58469431|NCT04940299|BIOLOGICAL|Tocilizumab|Given SC
58469432|NCT05287113|DRUG|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
58469433|NCT05287113|DRUG|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
58469434|NCT05287113|DRUG|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
58469435|NCT05287113|DRUG|Placebo|Placebo will be administered intravenously.
58469436|NCT02205736|OTHER|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
58469437|NCT04709068|DEVICE|Current Health|wearable device and tablet used to collect health measures at home
58469438|NCT06705400|BEHAVIORAL|Multi-behavioural|The Bloom Study is implemented in an existing and highly accepted health service delivered by community health nurses. Beyond focusing on food, meals, motor skills and movement, the intervention also target sleep and family sense of security. The intervention commence in pregnancy and continues until the child is 2½ years old.
58469439|NCT02587676|OTHER|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
58469440|NCT02898181|DEVICE|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
58469441|NCT04414111|DIAGNOSTIC_TEST|Highly suppressive Treg measurement|Circulating highly suppressive Treg measurement
58469442|NCT06226649|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
58469443|NCT04071990|BEHAVIORAL|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
58469444|NCT04071990|BEHAVIORAL|CBGT|CBGT for OCD patients, without involvement of family members
58469445|NCT04558060|OTHER|Virtual Standardized Patient|Computer program that presented a virtual human patient
58469446|NCT04558060|OTHER|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
58469447|NCT01441999|DEVICE|Less rigid rod|Titanium rod with semi rigid end
58469448|NCT01441999|DEVICE|Rigid Rod|Rigid Titanium rods
58469449|NCT04984616|DRUG|40 mg Atorvastatin/day for 120 days P.O.|Oral administration of Atorvastatin 40 mg/daily for 120 days
58469450|NCT04984616|DRUG|Atorvastatin 80|Oral administration of Atorvastatin 80 mg/daily for 120 days
58469451|NCT04984616|DRUG|Placebo|Oral administration of Placebo daily for 120 days
58469452|NCT06583668|OTHER|Therapeutic Story|Listening and watching the therapeutic story in digital media
58469453|NCT00648102|BIOLOGICAL|CDX-1307|
58469454|NCT04205448|BEHAVIORAL|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
58469455|NCT03333343|DRUG|EGF816|Study Drug
58469456|NCT03333343|DRUG|trametinib|Study Drug
58469457|NCT03333343|DRUG|ribociclib|Study Drug
58469458|NCT03333343|DRUG|LXH254|Study Drug
58469459|NCT03333343|DRUG|INC280|Study Drug
58469460|NCT03333343|DRUG|gefitinib|Study Drug
58469461|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
58469462|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
58469463|NCT00879736|OTHER|placebo|
58469464|NCT06602895|OTHER|Intensive short-term functional strength training|All players underwent a rigorous 2-week intensive short-term functional strength training program, with training sessions held for 5 days a week. One group engaged in intensive short-term functional strength training exercises, while the other group focused on balance training. The training regimen was then reversed for the two groups. Each daily training session lasted approximately 2 hours, with 1 hour of either intensive short-term functional strength training or balance training. Every intensive short-term functional strength training session spanned roughly 60 minutes, starting with a 10-minute warm-up followed by dynamic mobility exercises targeting key joints. During the 40-minute core segment of our intensive short-term functional strength training sessions, participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability.
58469465|NCT06602895|OTHER|Balance Training|Participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability ball exercises. This was followed by 15 minutes of multi-joint strength exercises, where athletes performed compound movements like squats, deadlifts, push-ups or bench presses, and pull-ups or lat pull-downs, each for t sets of 8-10 repetitions. The session concluded with 15 minutes of agility and coordination drills, incorporating high-intensity activities such as lateral sprints and rope pulling, specifically designed to improve quickness and neuromuscular coordination, thereby enhancing overall athletic performance. The session concluded with a 10-minute cooldown involving flexibility exercises for the limbs and trunk. Exercise intensity was regulated to correspond with a 6-7 on the repetitions in the reserve-based Rating of Perceived Exertion (RPE) scale, where a s indicates that the exerciser feels they could perform approximately.
58469466|NCT03818854|BIOLOGICAL|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
58469467|NCT03818854|BIOLOGICAL|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
58469468|NCT00002327|DRUG|Cidofovir|
58469469|NCT05884554|DRUG|PF-07817883|Experimental
58469470|NCT06026033|DRUG|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
58469471|NCT06610682|DRUG|Plixorafenib|BRAF-V600 ctDNA from CSF and blood at A) baseline (defined as C1D1 pre-treatment) and B) week 4 after treatment.
58469472|NCT05914623|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
58469473|NCT05914623|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
58469474|NCT00534612|PROCEDURE|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
58469475|NCT06378229|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
58469476|NCT05522660|RADIATION|Stereotactic radiosurgery|"The following SRS therapy is foreseen: Two fractionation schedules according to radiation oncologist's preferences and patterns of brain metastases: 1 x 18-22 Gy (18-22 Gy) or 5 x 6 Gy (30 Gy).~The following fractionation schedules will be allowed (based on the latest AAPM report on a systematic review and dose response modelling):~* Single fraction SRS (1 x 18-22 Gy) is the preferred schedule for 1-4 brain metastases, each with a longest diameter of ≤20 mm.~* Fractionated SRT (5 x 6 Gy) is preferred for lesions \>20 mm diameter or in case of the presence of 5-10 brain metastases.~* For resection cavity irradiation the same selection criteria may be chosen."
58469477|NCT05522660|DRUG|Immune checkpoint inhibitor|"Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients in cohort 1a (Melanoma, treated with ipilimumab plus nivolumab), systemic therapy consists of the combination of ipilimumab plus nivolumab.~* For patients in cohort 1b (Melanoma, treated with anti-PD-1/L1 monotherapy), systemic treatment consists of anti-PD-1/L1 monotherapy.~* For patients in cohort 2a (NSCLC, treated with targeted therapy), systemic therapy consists of targeted therapy (EGFR-, ALK- or ROS1-targeted treatment).~* For patients in cohort 2b (NSCLC, treated with anti-PD-1/L1 therapy with or without chemotherapy), systemic therapy consists of immune-checkpoint inhibition therapy (including an anti-PD-1/L1 compound) with or without chemotherapy."
58469478|NCT03536572|BEHAVIORAL|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
58469479|NCT06602323|COMBINATION_PRODUCT|TMLI/Flu/Mel|Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
58469480|NCT05703945|OTHER|Progressive training program|The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.
58469481|NCT05703945|OTHER|Control group|The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
58469482|NCT06472518|DEVICE|pharmaco mechanical thrombolysis|arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
58469483|NCT00687596|DRUG|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
58469484|NCT00687596|DRUG|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
58469485|NCT05943639|OTHER|The Cultural Marginality Theory-Based Education|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
58469486|NCT04725773|DEVICE|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
58469487|NCT03400735|COMBINATION_PRODUCT|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
58469488|NCT03400735|DRUG|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
58469489|NCT06351124|BIOLOGICAL|Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's|Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.
58469490|NCT04315948|DRUG|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
58469491|NCT04315948|DRUG|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
58469492|NCT04315948|DRUG|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
58469493|NCT04315948|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
58469494|NCT04315948|OTHER|Standard of care|Standard of care
58469495|NCT04315948|DRUG|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
58469496|NCT04315948|OTHER|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
58469497|NCT05877521|BEHAVIORAL|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
58469498|NCT05877521|OTHER|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
58469499|NCT06579261|OTHER|Core Shamanism|Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
58469500|NCT02242773|DEVICE|Multi-Parametric MRI|Multi-Parametric MRI
58469501|NCT02242773|DEVICE|MRI-Guided Biopsy|MRI-Guided Biopsy
58469502|NCT04606134|DEVICE|Hybrid fractional laser|two treatments given one month apart
58469503|NCT04606134|OTHER|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
58469504|NCT04606134|OTHER|Cetaphil face cream|applied twice daily
58469505|NCT03505762|DRUG|Cyclophosphamide|Given IV
58469506|NCT03505762|DRUG|Doxorubicin Hydrochloride|Given IV
58469507|NCT03505762|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469508|NCT03505762|DRUG|Prednisone|Given PO
58469509|NCT03505762|OTHER|Quality-of-Life Assessment|Ancillary correlative
58469510|NCT03505762|OTHER|Questionnaire Administration|Ancillary studies
58469511|NCT03505762|BIOLOGICAL|Rituximab|Given IV
58469512|NCT03505762|DRUG|Vincristine Sulfate|Given IV
58469513|NCT04985617|OTHER|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
58469514|NCT05866952|DIAGNOSTIC_TEST|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
58469515|NCT01231906|DRUG|Cyclophosphamide|Given IV
58469516|NCT01231906|DRUG|Dexrazoxane|
58469517|NCT01231906|DRUG|Doxorubicin Hydrochloride|Given IV
58469518|NCT01231906|DRUG|Etoposide|Given IV
58469519|NCT01231906|DRUG|Ifosfamide|Given IV
58469520|NCT01231906|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469521|NCT01231906|DRUG|Topotecan Hydrochloride|Given IV
58469522|NCT01231906|DRUG|Vincristine Sulfate|Given IV
58469523|NCT04088890|DRUG|Fludarabine|Fludarabine 30 mg/m2
58469524|NCT04088890|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2
58469525|NCT04088890|DRUG|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
58469526|NCT06595277|DIAGNOSTIC_TEST|Neuromuscular blockade|Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.
58469527|NCT05235009|DIAGNOSTIC_TEST|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
58469528|NCT06705829|BIOLOGICAL|Prothrombin|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
58469529|NCT06112093|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
58469530|NCT06112093|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
58469531|NCT06335329|BEHAVIORAL|Discussion of point-of-care ultrasound lung findings|"The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. \>3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present"
58469532|NCT03279081|DRUG|Cx601|Cx601 eASCs intralesional injection.
58469533|NCT03279081|OTHER|Placebo|Cx601 placebo-matching eASCs intralesional injection.
58469534|NCT05183828|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples
58469535|NCT05183828|DRUG|Letrozole|Given PO
58469536|NCT05183828|OTHER|Questionnaire Administration|Ancillary studies
58469537|NCT03590028|OTHER|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
58469538|NCT03590028|OTHER|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
58469539|NCT06071234|PROCEDURE|3D reconstruction technology|Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.
58469540|NCT06070454|DIAGNOSTIC_TEST|Vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
58469541|NCT00576706|DRUG|Rebamipide|Rebamipide 100㎎, 12 weeks
58469542|NCT00576706|DRUG|Misoprostol|Misoprostol 200㎍ 12 weeks
58469543|NCT04588922|DRUG|SLS009|Solution for injection
58469544|NCT04588922|DRUG|venetoclax|Tablets
58469545|NCT04588922|DRUG|azacitidine|Solution for injection
58469546|NCT05920590|OTHER|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~* Application of the hold - relax technique to increase the range of motion of knee flexion.~* Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~* Application of stabilizing reversals from a sitting and standing position.~* Application of dynamic reversals from a standing position.~* Rhythmic stabilization.~* Combination of isotonics.~* Gait retraining."
58469547|NCT05920590|OTHER|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
58469548|NCT05920590|OTHER|Control|Participants in this group will be given an exercise leaflet for home-based exercises and will be instructed to perform these exercises three times a week for the same period as the other two groups (6 weeks). They will also be given recommendations to maintain and increase their physical activity.
58469549|NCT06103591|DEVICE|The EmStop Embolic Protection System (EmStop System)|The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
58469550|NCT06545929|DRUG|Sunobinop|1 tablet taken orally at bedtime
58469551|NCT06545929|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
58469552|NCT05106959|BEHAVIORAL|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
58469553|NCT03117010|DRUG|Steroids|High dose dexamethasone 20 mg PO or IV
58469554|NCT03117010|DRUG|Etoposide|Etoposide 150mg/BSA
58469555|NCT06180343|OTHER|Mandala|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
58469556|NCT05957835|DIETARY_SUPPLEMENT|BR-HIGH|4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
58469557|NCT05957835|DIETARY_SUPPLEMENT|BR-MOD|2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
58469558|NCT05957835|DIETARY_SUPPLEMENT|BR-LOW|1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
58469559|NCT05957835|DIETARY_SUPPLEMENT|PL|4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
58469560|NCT06058533|OTHER|Previsit Imagery Picturebook|This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
58469561|NCT06269120|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
58469562|NCT04906668|PROCEDURE|Cryoballoon pulmonary-vein isolation|Electrical isolation of the pulmonary-veins using cryoenergy
58469563|NCT04906668|PROCEDURE|Pacemaker implantation and ablation of atrioventricular-node|Pacemaker implantation and ablation of atrioventricular-node
58469564|NCT05734027|DEVICE|Sectional matrix|The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion
58469565|NCT05734027|DEVICE|Circumferential matrix|Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
58469566|NCT06705452|OTHER|Additional 4D Flow MRI or additional 4D Flow sequence|Additional 4D Flow MRI or additional 4D Flow sequence
58469567|NCT02506543|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
58469568|NCT02506543|BEHAVIORAL|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
58469569|NCT06444659|BEHAVIORAL|Adaptive Physical Activity Classes|The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.
58469570|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk without vitamin D|710ml per day for 49 days
58469571|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
58469572|NCT00886379|DIETARY_SUPPLEMENT|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
58469573|NCT00886379|DIETARY_SUPPLEMENT|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
58469574|NCT00886379|DIETARY_SUPPLEMENT|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
58469575|NCT00886379|DIETARY_SUPPLEMENT|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
58469576|NCT06066697|BEHAVIORAL|SOVA Ambassador|"The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments."
58469577|NCT06066697|BEHAVIORAL|Self-Reflection|Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
58469578|NCT05753046|DRUG|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
58469579|NCT05753046|DRUG|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
58469580|NCT05464667|RADIATION|Radiation Therapy (RT)|"Dose Escalation: 5 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 45, 50 Gy in 5 fractions (Part 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)"
58469581|NCT04948645|DRUG|Fosigotifator|Oral
58469582|NCT04948645|DRUG|Placebo|Oral
58469583|NCT01283841|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
58469584|NCT03261271|BEHAVIORAL|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
58469585|NCT03261271|BEHAVIORAL|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
58469586|NCT03261271|BEHAVIORAL|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
58469587|NCT01630148|DRUG|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
58469588|NCT04031105|DEVICE|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
58469589|NCT04434482|DRUG|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
58469590|NCT00904943|DRUG|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
58469591|NCT00904943|DRUG|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
58469592|NCT04208919|BIOLOGICAL|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
58469593|NCT03216772|DEVICE|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
58469594|NCT04500912|DEVICE|Supraflex Cruz 60 Micron|percutaneous coronary intervention
58469595|NCT04500912|DEVICE|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
58469596|NCT05111210|OTHER|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
58469597|NCT05111210|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
58469598|NCT05111210|OTHER|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
58469599|NCT05791643|BEHAVIORAL|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
58469600|NCT05791643|BEHAVIORAL|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
58469601|NCT05791643|BEHAVIORAL|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
58469602|NCT05791643|BEHAVIORAL|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
58469603|NCT05791643|BEHAVIORAL|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
58469604|NCT05791643|BEHAVIORAL|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
58469605|NCT05791643|BEHAVIORAL|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
58469606|NCT05791643|BEHAVIORAL|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
58469607|NCT05791643|BEHAVIORAL|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
58469608|NCT01578447|DRUG|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
58469609|NCT01578447|DRUG|Intramuscular DMPA|Intramuscular DMPA
58469610|NCT06543745|BEHAVIORAL|Low-Resistance Training|"The following 6 exercises will be performed in 3 sets of 15-15-15 repetitions, 3 times per week for 12 weeks:~Elbow Flexion, Elbow Extension, Lateral Hip Extensions, Hip Extensions, Knee Extensions, Wall push-ups"
58469611|NCT01372709|DEVICE|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
58469612|NCT06308718|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
58469613|NCT06603415|PROCEDURE|Total thyroidectomy|Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
58469614|NCT06046924|OTHER|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
58469615|NCT06046924|DRUG|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
58469616|NCT06046924|OTHER|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
58469617|NCT06704685|DRUG|Butylphthalide|Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.
58469618|NCT06704685|DRUG|Butylphthalide placebo|Butylphthalide placebo
58469619|NCT04936945|PROCEDURE|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
58469620|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 Formulation 1|Participants receive two doses of the FLU Q-PAN H5N8 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
58469621|NCT05975840|BIOLOGICAL|AS03B|Participants receive two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
58469622|NCT05975840|BIOLOGICAL|AS03A|Participants receive two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
58469623|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 Formulation 2|Participants receive two doses of the FLU Q-PAN H5N8 Formulation 2 vaccine by intramuscular injection in the non dominant arm.
58469624|NCT06597825|DRUG|root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)|After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
58469625|NCT02677493|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
58469626|NCT02677493|BIOLOGICAL|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
58469627|NCT02677493|BIOLOGICAL|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
58469628|NCT05464680|OTHER|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
58469629|NCT05740137|DEVICE|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
58469630|NCT05243823|DRUG|Vagifem®|According to local clinical practice - independent of inclusion in this study
58469631|NCT05243823|DRUG|Non-Vagifem® LDVE, Estradiol|According to local clinical practice - independent of inclusion in this study
58469632|NCT03297450|DEVICE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
58469633|NCT03297450|BEHAVIORAL|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
58469634|NCT03297450|DEVICE|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
58469635|NCT05853497|BEHAVIORAL|Multi-Component Weight Loss Intervention|The intervention group will receive weekly 1-on-1 health coaching with a very-low calorie nutrition plan prior to total knee replacement and a conventional weight maintenance nutrition plan after surgery.
58469636|NCT03486912|DRUG|BMS-986036|Specified dose on specified days.
58469637|NCT03486912|OTHER|Placebo|Specified dose on specified days.
58469638|NCT04174417|PROCEDURE|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
58469639|NCT04174417|PROCEDURE|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
58469640|NCT06221995|DIAGNOSTIC_TEST|Indirect Calorimetry|Resting energy expenditure measurement
58469641|NCT05908487|BEHAVIORAL|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
58469642|NCT04324827|DEVICE|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
57784524|NCT05952115|OTHER|Cervical stabilization exercises|The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.
58469643|NCT04324827|OTHER|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
58469644|NCT06706245|BEHAVIORAL|SET-VR (computer)|Low-immersive version of the SET-VR program
58469645|NCT06706245|BEHAVIORAL|SET-VR (headset)|High-immersive version of the SET-VR program
58469646|NCT06595160|OTHER|Non-Interventional Study|Non-interventional study
58469647|NCT04935034|DIETARY_SUPPLEMENT|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
58469648|NCT06051201|OTHER|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
58469649|NCT06603506|OTHER|tumour and blood samples|Tumour and blood samples
58469650|NCT06179199|DEVICE|SOOMA™ tDCS™|The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
58469651|NCT02601612|BIOLOGICAL|D46cpΔM2-2 vaccine|Delivered as nose drops
58469652|NCT02601612|BIOLOGICAL|Placebo|Delivered as nose drops
58469653|NCT05983211|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks."
58469654|NCT04781478|OTHER|Application of Biorepair Gel|Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
58469655|NCT04781478|OTHER|Irrigation of Chlorhexidine 1.00% gel|Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
58469656|NCT04797611|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
58469657|NCT06182137|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.
58469658|NCT05032040|BIOLOGICAL|vudalimab|Monoclonal bispecific antibody
58469659|NCT02753283|DRUG|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
58469660|NCT02753283|DRUG|Placebo|Semi-annual saline injection
58469661|NCT02753283|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
58469662|NCT02616640|DRUG|Durvalumab|
58469663|NCT02616640|DRUG|Pomalidomide|
58469664|NCT02616640|DRUG|Dexamethasone|
58469665|NCT06211088|DRUG|famotidine plus10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine
58469666|NCT06211088|OTHER|10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo
58469667|NCT03095495|DEVICE|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
58469668|NCT03095495|DEVICE|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
58469669|NCT06290115|OTHER|Questionnaires set 1|Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
58469670|NCT06290115|OTHER|Questionnaires set 2|Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
58469671|NCT06290115|OTHER|Questionnaires set 3|Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
58469672|NCT05550779|BEHAVIORAL|Mental Exercise|Participant perform a 10-minute mental exercise
58469673|NCT00368888|DEVICE|Urine collection bag for infants|
58469674|NCT06604676|PROCEDURE|guided soft tissue grafting|guided soft tissue grafting techniquea special digital guide was fabricated for one intervention non-guided soft tissue grafting technique receive the traditional technique without guide
58469675|NCT06604676|PROCEDURE|non-guided soft tissue grafting technique|the graft was taken with traditional technique without guide
58469676|NCT02177123|DEVICE|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
58469677|NCT05131945|OTHER|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
58469678|NCT05131945|OTHER|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
58469679|NCT02046967|PROCEDURE|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
58469680|NCT02046967|PROCEDURE|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
58469681|NCT06582446|DRUG|Androgen Deprivation Therapy (ADT) - Goserelin|"The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.~* ADT will be applied for 24 months in total~* ADT must be given concurrently and adjuvant"
58469682|NCT06582446|RADIATION|High-Dose-Rate Interstitial Brachytherapy (HDR BRT)|HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)
58469683|NCT06582446|RADIATION|radiotherapy|EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction
58469684|NCT06623240|BIOLOGICAL|allogeneic Hope Biosciences adipose-derived mesenchymal stem cells|"Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)"
58469685|NCT06623240|OTHER|Normal Saline Solution 0.9%|Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)
58469686|NCT05120830|BIOLOGICAL|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
58469687|NCT05120830|OTHER|Normal Saline IV Administration|The administration of IV normal saline
58469688|NCT06596902|BEHAVIORAL|Physical Activity|The 12-month intervention will progressively increase in intensity and complexity to teach parents/children more complex sports skills and behavioral techniques, to prepare them to become future team leaders for nutrition education and sports sessions. In addition, the family Olympics events will take place after every 3-month to reinforce progression, social support; progressive improvements: Phase 1: Beginner (months 0-3) will focus on introductory concepts and basic sports skills and will focus on establishing consistent behavioral patterns and social support. Phase 2: Intermediate (months 4-6) will begin to introduce slightly more complex nutrition behavioral concepts and increase difficulty of sport skills, and reinforce behavioral patterns from phase 1. Phase 4: Advanced (months 10-12) will teach parents and children advanced sports skills ; nutrition knowledge so that they may become team leaders to help implement future activity sessions and nutrition education sessions.
58469689|NCT06521476|DRUG|Acetazolamide|Oral acetazolamide 250 mg daily for 7 days
58469690|NCT06521476|DRUG|Placebo|Oral placebo daily for 7 days
58469691|NCT05636748|DIAGNOSTIC_TEST|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
58469692|NCT05636748|DIAGNOSTIC_TEST|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
58469693|NCT05636748|DIAGNOSTIC_TEST|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
58469694|NCT05636748|DIAGNOSTIC_TEST|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
58469695|NCT06592729|BEHAVIORAL|education|intervention group was taken to scenario-based simulat
58469696|NCT05670093|DEVICE|Neural Pressure Support (mode of mechanical ventilation)|Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
58469697|NCT04227899|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
58469698|NCT04227899|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
58469699|NCT03980769|DRUG|Thiotepa|Given IV
58469700|NCT03980769|DRUG|Treosulfan|Given IV
58469701|NCT03980769|DRUG|Fludarabine Phosphate|Given IV
57784525|NCT05765435|OTHER|12-week exercise and walking program|The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.
58469702|NCT03980769|BIOLOGICAL|Rabbit Anti-Thymocyte Globulin|Given IV
58469703|NCT03980769|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
58469704|NCT03980769|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
58469705|NCT03980769|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
58469706|NCT03980769|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58469707|NCT03980769|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58469708|NCT06297083|DRUG|Peanut Oral Powder [PEANUT POWDER]|Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
57784526|NCT05765435|DEVICE|NMES|Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.
57784527|NCT05765435|DEVICE|FES|Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
58469709|NCT06297083|DIETARY_SUPPLEMENT|Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)|Probiotic or placebo-probiotic given daily for 18 months
58469710|NCT04595656|OTHER|verbal autopsy interview|The study involves filling of verbal autopsies for deaths in SEACTN villages. This is an observational study being conducted as a substudy of rural febrile project of SEACTN program.
58469711|NCT05722873|BEHAVIORAL|Fasting arm|Study participants will fast one day per week for 12 weeks
58469712|NCT05722873|BEHAVIORAL|Weight maintenance|Study participants will be counseled to maintain body weight
58469713|NCT05722873|BEHAVIORAL|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
58469714|NCT01761916|DRUG|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
58469715|NCT01761916|DRUG|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
58469716|NCT02363920|DEVICE|HOF|the addition of high oxygen flow to patients breathing spontaneously
58469717|NCT02363920|DEVICE|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
58469718|NCT05735743|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
58469719|NCT05684835|PROCEDURE|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
58469720|NCT04243564|DEVICE|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
58469721|NCT06706102|BIOLOGICAL|Biological tests|Biological tests : cell quantification et characterization
57784528|NCT03758924|DRUG|ANAVEX2-73|Liquid oral solution
58469722|NCT06706102|DIAGNOSTIC_TEST|MRI|MRI
58469723|NCT06706102|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests
58469724|NCT04699864|DIAGNOSTIC_TEST|Screening of DR and DME with artificial intelligence using NeoRetina|Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
58469725|NCT04699864|DIAGNOSTIC_TEST|Routine ophthalmological evaluation of DR and DME|Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
58469726|NCT04699864|DIAGNOSTIC_TEST|Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos|Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
58469727|NCT02374450|PROCEDURE|Blood collection|For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
58469728|NCT06376253|DRUG|[68Ga]Ga-EVS459|Radioligand imaging agent
58469729|NCT06376253|DRUG|[177Lu]Lu-EVS459|Radioligand therapy
58469730|NCT02554292|DEVICE|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
58469731|NCT05444465|DEVICE|Isolated Bioinductive Repair|Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant
58469732|NCT05444465|PROCEDURE|Completion and Repair|Standard surgical repair using the 'Completion and Repair' technique.
58469733|NCT06303869|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
58469734|NCT05731583|DEVICE|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
58469735|NCT04425967|RADIATION|pre-operative radiotherapy|pre-operative radiotherapy
58469736|NCT06592651|BEHAVIORAL|Play Therapy Workshop|"4 session group intervention foucused on psycho-educational knowledge regarding tools for effective emotional coping with stressful events in the context of the Iron Swords war, focusing on building mental resilience in the parent-child dyad through play therapy. Each group consists of 5 parent-child dyads with children aged 3-6 years, who have been evacuated from war zones in the northern and southern regions of the country."
58469737|NCT03361800|DRUG|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
58469738|NCT02689440|DRUG|Dasatinib|Given PO
58469739|NCT02689440|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469740|NCT02689440|DRUG|Venetoclax|Given PO
58469741|NCT06600880|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
58469742|NCT06600880|DRUG|Lumason|New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.
58469743|NCT06600880|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|"A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York."
57784529|NCT03758924|DRUG|Placebo|Liquid oral solution
57784530|NCT04192942|OTHER|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
58469744|NCT06600880|RADIATION|Positron Emission Tomography (PET)|A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
58469745|NCT06600880|DRUG|Amyvid|Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.
58469746|NCT06600880|DRUG|MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
58469747|NCT06600880|DRUG|Dotarem|FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.
58469748|NCT06600880|DIAGNOSTIC_TEST|Blood draw|Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.
58469749|NCT06600880|DEVICE|UR5e|Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.
57778156|NCT06370338|OTHER|Delphi Questionnaire|Experts will be approached to participate in the research via email. If the experts agree to participate they will check 'yes' in the email with the informed consent and will be directed to the Qualtrics survey. If the expert decides to decline consent they will check 'no' in the email and will not be enrolled. Subjects who agree to participate will undergo 2 phases of questions with three rounds of the same questions in each phase. This Delphi survey research involves Phase 1 and Phase 2 of questioning, each phase involves up to 3 rounds of questions to determine agreement or disagreement. Each round will take approximately 20 minutes to complete, and your responses will remain completely confidential. For both phases, the questions will either be 7-point Likert or multiple choices. For both phases, the group of questions will be sent up to three times until we obtain agreement (up to 80% of agreement consensus). Questions that have obtained agreement will be removed in each round.
57778157|NCT00000174|DRUG|Rivastigmine|
57778158|NCT00209274|DEVICE|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
57778159|NCT00209274|PROCEDURE|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
57778160|NCT03783481|DEVICE|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
57778161|NCT03783481|OTHER|No Mobile community|No Mobile community
57778162|NCT04662502|DIETARY_SUPPLEMENT|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month
57778163|NCT02260089|DRUG|Low dose of telmisartan|
57778164|NCT02260089|DRUG|High dose of telmisartan|
57778165|NCT02260089|DRUG|Placebo|
58469750|NCT06600880|DIAGNOSTIC_TEST|Urine test|Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
58469751|NCT05397145|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
58469752|NCT01703910|DRUG|Arm A chemotherapy|
58469753|NCT01703910|DRUG|arm B chemotherapy|
57778166|NCT05280847|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
57778167|NCT01397929|DRUG|BAL101553|Intravenous administration
57778168|NCT03454217|DRUG|Oxycodone|Postoperative pain treatment with oxycodone
57778169|NCT03454217|DRUG|Tramadol|Postoperative pain treatment with tramadol
57778170|NCT01429519|DRUG|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
57778171|NCT02092818|DRUG|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
57778172|NCT06208722|BEHAVIORAL|Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism|Information provided in arm descriptions.
57778173|NCT03859336|DEVICE|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
57778174|NCT03857581|DRUG|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
58469754|NCT06594211|BIOLOGICAL|ACT-001 CAR-NK cell|Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
58469755|NCT06502483|BEHAVIORAL|Promoting Resilience in Stress Management Program|Promoting Resilience in Stress Management (PRISM; Rosenberg et al., 2018; Rosenberg et al., 2021) is is an evidence-based skills-based resilience intervention. In the current study, PRISM sessions with be facilitated by a trained mental health provider to equip participants with skills for coping with anxiety, low mood, and adjustment to cancer diagnosis and to target four resilience resources (i.e., stress management, goal setting, cognitive reframing, and meaning-making). Sessions will be conducted by phone or Zoom, a HIPAA-compliant telemedicine platform. The optional mPRISM phone application includes 6 modules to practice PRISM skills and is available for iOS/Android.
58469756|NCT04137952|BEHAVIORAL|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
58469757|NCT05495789|OTHER|Virtual Reality|A relaxing video will be watched with virtual reality glasses.
58469758|NCT05495789|OTHER|Music|Relaxing music will be played by wearing headphones.
58469759|NCT05538325|DEVICE|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion of the lumbar spine
58469760|NCT02852655|DRUG|MK-3475|
57778175|NCT03857581|DRUG|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
57778176|NCT03315819|PROCEDURE|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
57778177|NCT03315819|PROCEDURE|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
57778178|NCT04668287|BEHAVIORAL|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
57778179|NCT06510491|DRUG|Epcoritamab|Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
57778180|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
57778181|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
58469761|NCT01325077|OTHER|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
58469762|NCT04126798|OTHER|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
58469763|NCT06704360|DEVICE|immersive VR pathfinding training|Pathfinding training with immersive VR.
58469764|NCT06704360|OTHER|Occupational therapy|Only receive conventional cognitive training group
58469765|NCT06593626|DRUG|[18F]Florbetazine|Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
57778182|NCT01185054|OTHER|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
57778183|NCT01185054|OTHER|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
57778184|NCT04619342|DEVICE|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
58469766|NCT06177132|BEHAVIORAL|VIS-REHAB protocol|The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasises gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
58469767|NCT05883501|BEHAVIORAL|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
58469768|NCT03818256|DRUG|Miricorilant|Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
58469769|NCT03818256|DRUG|Placebo|Placebo tablets for once-daily oral dosing
58469770|NCT06513871|BEHAVIORAL|Social perception tasks|social perception tasks
58469771|NCT06586749|OTHER|Group B: nurse-led education|Group B: nurse-led education No educational video, will be shown to this group of patients
57778185|NCT04619342|PROCEDURE|Surgical Resection|Surgical Resection of PVTT
57778186|NCT00976079|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
58469772|NCT06586749|OTHER|Group C: nurse-led education and implementation of teleinterventions|Group C: nurse-led education and implementation of teleinterventions An educational video, made for the purposes of the study only, will be shown to them. This is the difference between the two groups
58469773|NCT05317728|DEVICE|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
58469774|NCT05317728|DEVICE|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
58469775|NCT05317728|PROCEDURE|Cataract surgery|Phacoemulsification with a clear cornea incision
57778187|NCT00976079|DEVICE|Placebo TENS|Placebo TENS use
58469776|NCT03247647|BEHAVIORAL|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
58469777|NCT03247647|BEHAVIORAL|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
58469778|NCT06270888|RADIATION|Radiation|Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
58469779|NCT06281587|PROCEDURE|penetrating keratoplasty|replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
58469780|NCT06093477|DIETARY_SUPPLEMENT|Fast-Dissolve Melatonin Pill|Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.
58469781|NCT06093477|OTHER|Fast-Dissolve Placebo Pill|Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
58469782|NCT05196269|DEVICE|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and postoperative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have access to the software installed, and they will have access to all the information about the type of treatment they will receive. All the questions and questionnaires will be filled out online, and they can visualise the expected outcome from excellent to poor.
58469783|NCT05136976|DRUG|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
58469784|NCT05136976|DRUG|Placebo infusion|2 infusions of placebo at a 2 week interval.
58469785|NCT05136976|DRUG|Premedications|"Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
58469786|NCT03609645|PROCEDURE|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
58469787|NCT03609645|PROCEDURE|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
58469788|NCT00581308|DEVICE|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
58469789|NCT04629508|DRUG|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
58469790|NCT04819451|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
58469791|NCT05330897|PROCEDURE|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
58469792|NCT05330897|DEVICE|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
58469793|NCT05018624|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
58469794|NCT05018624|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
58469795|NCT05018624|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
58469796|NCT05018624|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
58469797|NCT05018624|BEHAVIORAL|General health through IM Apps|After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
58469798|NCT05018624|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
58469799|NCT06062433|DEVICE|AsthmaTuner|Phone application and spirometer for self-management of asthma
58469800|NCT06062433|OTHER|Asthma-Guidance and Prediction System|Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
58469801|NCT02362815|OTHER|Apple juice|Intervention consists in allowing drinks during labour
58469802|NCT05417438|BEHAVIORAL|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
58469803|NCT03582475|DRUG|Carboplatin|Given IV
57778188|NCT04089371|DEVICE|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
57778189|NCT04089371|DEVICE|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
57778190|NCT01804816|PROCEDURE|Acupuncture|Standardized acupuncture administration for 10 sessions.
58469804|NCT03582475|DRUG|Cisplatin|Given IV
57778191|NCT01804816|OTHER|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
58469805|NCT03582475|DRUG|Docetaxel|Given IV
58469806|NCT03582475|DRUG|Etoposide|Given IV
58469807|NCT03582475|BIOLOGICAL|Pembrolizumab|Given IV
58469808|NCT04431479|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58469809|NCT04431479|OTHER|Medical Chart Review|Review of medical chart
58469810|NCT04431479|OTHER|Quality-of-Life Assessment|Ancillary studies
58469811|NCT04431479|OTHER|Questionnaire Administration|Complete questionnaire
58469812|NCT05653492|DRUG|Sulforaphane|Dosing study one to four 30 mg/d tablets depending on weight
58469813|NCT06590571|DEVICE|TRAcelet™|The group using TRAcelet™ after transradial angiography/intervention receives 2 hours and 15 minutes of compression from the device, followed by 3 stepwise releases every 15 minutes. There are two sizes of TRAcelet™ available, large and medium. Assuming that a Korean adult's wrist size is smaller than that of the Western population, we used a medium-sized TRAcelet™.
57778192|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
57778193|NCT05153759|OTHER|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
57778194|NCT03973138|DRUG|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
58469814|NCT06590571|OTHER|Gauze pad|Patients received radial artery compression by a gauze pad fastened with 3M™ Durapore™ surgical tape. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
58469815|NCT04451525|DEVICE|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
58469816|NCT00979940|DRUG|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
58469817|NCT05556473|DRUG|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
58469818|NCT05070923|BEHAVIORAL|HealthyLifetime|HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
58469819|NCT06584695|DRUG|Transversus abdominis plane block|Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
58469820|NCT06584695|DRUG|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
58469821|NCT06584695|DRUG|Control group|"Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane."
58469822|NCT04250857|DEVICE|HeartStart FRX|Automated External Defibrillator
58469823|NCT04216524|DRUG|Cyclophosphamide|Given IV
57778195|NCT04869683|OTHER|description of MDS pzatient cohort|description of MDS patient cohort
57778196|NCT01364402|DRUG|Epoetin beta|50,000U intravenously
58469824|NCT04216524|DRUG|Cytarabine|Given IT or IV
58469825|NCT04216524|DRUG|Dexamethasone|Given PO or IV
58469826|NCT04216524|DRUG|Doxorubicin|Given IV
58469827|NCT04216524|DRUG|Mercaptopurine|Given PO
58469828|NCT04216524|DRUG|Methotrexate|Given IT, IV, or PO
58469829|NCT04216524|DRUG|Methylprednisolone|Given IV
58469830|NCT04216524|DRUG|Prednisone|Given PO
58469831|NCT04216524|BIOLOGICAL|Rituximab|Given IV
58469832|NCT04216524|BIOLOGICAL|Tagraxofusp-erzs|Given IV
58469833|NCT04216524|DRUG|Venetoclax|Given PO
58469834|NCT04216524|DRUG|Vincristine|Given IV
58469835|NCT04440475|PROCEDURE|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
58469836|NCT00003989|BIOLOGICAL|ISIS 3521|
58469837|NCT05632653|PROCEDURE|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
58469838|NCT04952922|OTHER|Treatment for recurrent oropharyngeal cancer (curative/ palliative)|Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.
58469839|NCT06603116|OTHER|treatment of class two cavities|restorations in class 2 cavities
58469840|NCT02226393|BEHAVIORAL|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
57778197|NCT01364402|DRUG|Saline 0.9%|normal saline intravenously
57778198|NCT04215185|DEVICE|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
57778199|NCT05363137|OTHER|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
57778200|NCT05363137|OTHER|Standard care|The physiotherpy treatment will be standard care
57778201|NCT03062098|DEVICE|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
57778202|NCT02444585|DRUG|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
57778203|NCT02790216|PROCEDURE|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
57778204|NCT03381014|DRUG|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
58469841|NCT02226393|BEHAVIORAL|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
58469842|NCT06596850|BEHAVIORAL|Wheelchair Skills Training Program|Participants will receive 5, 45-minute weekly WC skills training sessions that will take place in the community, in and around the participants home. Each session will be customized to the participant's' goals and based on the learner's impairments (i.e., weakness, spasticity, movement disorders \[e.g. ataxia, tremor\], contractures, cognition). The WSTP sessions will begin with a 5-minute review of goals/progress, followed by a 10-minute warm-up (wheeling activities, random practice of previously leaned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment.
58490676|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
57778205|NCT01359618|DRUG|TC-5214|Single dose, oral tablets
57778206|NCT01359618|OTHER|Placebo comparator|Single dose, oral tablets
57778207|NCT01359618|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
57778208|NCT01359618|OTHER|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
57778209|NCT03734159|DRUG|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
57778210|NCT03734159|DRUG|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
57778211|NCT03722264|DEVICE|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
57778212|NCT03722264|DEVICE|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
57778213|NCT03854240|OTHER|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
57778214|NCT02961855|DRUG|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
57778215|NCT02961855|DRUG|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
57778216|NCT04814927|DRUG|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
57778217|NCT04814927|DRUG|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
57778218|NCT04814927|DRUG|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
57778219|NCT04814927|DRUG|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
57778220|NCT00556348|DRUG|bevacizumab|1.25mg
57778221|NCT00000942|DRUG|Nevirapine|
57778222|NCT03441113|DRUG|MMB|Tablet(s) administered orally once daily
57778223|NCT01009047|DRUG|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
57778224|NCT01009047|DRUG|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
58469843|NCT06595316|OTHER|Exercise intervention group|"Exercise will consist of two supervised sessions per week. Starting with vital signs monitoring (blood pressure, temperature, blood oxygen levels, heart rate).~The aerobic component consists of a 5-minute warm-up, followed by 3 bouts of 4-minute cycling at an intensity of 60-65% HRR, with 2-minute active recovery periods in between and a 5-minute cool down. The goal is to increase up to an intensity of around 80%-85% HRR by weeks 16 to 18. Intensity will be monitored with The Borg Rating Scale of Perceived Exertion (RPE). The resistance component will consist of upper body and lower body exercises (door frame rows, wall push-ups, glute bridges, triceps lifts and squat to calf rise) starting on week one with a set of 12 repetitions of each exercise, with 2-minute recovery in between exercises aiming to increase the number of sets and reducing the number of repetitions."
58469844|NCT05537909|OTHER|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
58469845|NCT01450020|OTHER|educational intervention|Receive ACS material
58469846|NCT01450020|OTHER|questionnaire administration|Ancillary studies
58469847|NCT01450020|OTHER|counseling intervention|Undergo PN session
58469848|NCT01450020|OTHER|survey administration|Ancillary studies
58469849|NCT01450020|PROCEDURE|quality-of-life assessment|Ancillary studies
58469850|NCT01063049|DRUG|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
58469851|NCT01063049|DRUG|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
58469852|NCT01063049|DRUG|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
58469853|NCT01063049|DRUG|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
58469854|NCT03160638|DRUG|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
58469855|NCT05773937|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
57778225|NCT06196580|DRUG|repaglinide; midazolam; SHR4640|repaglinide; midazolam; SHR4640
57778226|NCT06196580|DRUG|repaglinide; midazolam; SHR4640; SHR4640 placebo|repaglinide; midazolam; SHR4640; SHR4640 placebo
57778227|NCT06196580|DRUG|repaglinide; midazolam; SHR4640 placebo|repaglinide; midazolam; SHR4640 placebo
57778228|NCT01047475|DRUG|MB-6|6# TID with meal
57778229|NCT01047475|DRUG|Placebo|6# TID with meal
58469856|NCT02449122|PROCEDURE|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
58469857|NCT04854174|DRUG|ZN-d5|Oral agent; 25 mg formulation
58469858|NCT00960622|DRUG|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
58469859|NCT00960622|DRUG|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
58469860|NCT00960622|DRUG|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
58469861|NCT04506437|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
58469862|NCT04506437|BEHAVIORAL|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
58469863|NCT06584006|DRUG|Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections|Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
57778230|NCT02444299|DEVICE|Shoulder hemi-arthroplasty|
57778231|NCT06145022|BEHAVIORAL|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
57778232|NCT06145022|BEHAVIORAL|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
57778233|NCT04227860|OTHER|Balance exercise program|"Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
57778234|NCT04227860|OTHER|Strengthening exercise program|"Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
57778235|NCT04539379|DRUG|Magnesium sulfate|intravenous infusion
58469864|NCT06584006|DRUG|Recombinant Human Interleukin-2 Injections|Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
58469865|NCT06582524|DRUG|Pegzilarginase|SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
58490677|NCT02858505|DRUG|27 mg elemental iron|
58469866|NCT04569240|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
58469867|NCT05525416|DRUG|Sodium Nitroprusside|A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
58469868|NCT05525416|DRUG|Phenylephrine Hydrochloride|A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
58469869|NCT05525416|DRUG|Phenylephrine Hydrochloride|Investigators will give three incremental doses via brachial artery catheter to observe α1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
58469870|NCT05525416|DRUG|Norepinephrine|Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
58469871|NCT05525416|OTHER|Isometric Handgrip and Post-Exercise Circulatory Occlusion|Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
58469872|NCT05525416|OTHER|Rhythmic Handgrip|Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
58469873|NCT05525416|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
58469874|NCT05525416|DRUG|Propranolol Hydrochloride|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
58469875|NCT05525416|DRUG|Phentolamine Mesylate|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
58469876|NCT03675126|DRUG|SRP-5051|SRP-5051 administered as an IV infusion.
58469877|NCT06586905|DEVICE|Medical Device|Multiplo Complete Syphilis (TP/nTP) Antibody Test
58469878|NCT04817670|DRUG|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
58469879|NCT04817670|DRUG|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
58469880|NCT04817670|DRUG|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
58469881|NCT04817670|DRUG|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
58469882|NCT04817670|DRUG|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
58469883|NCT06586060|OTHER|lung ultrasound guided fluid balance strategy|"Lung ultrasound (LUS) guided fluid management based on B-Line score assessment using LUS within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first~In patients with BLS = 0-14, a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with BLS ≥ 15, a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15. To reach daily targeted FB, furosemide-induced diuresis and RRT will be used In case of shocked patients with BLS \&amp;amp;lt; 15: they will receive fluid boluses and packed RBCs to achieve a Hb of 10 and a MAP of \&amp;amp;gt;65 mmHg.~In case of shocked patients with BLS ≥ 15: they will start norepinephrine infusion to reach a MAP of \&amp;amp;gt;65 mmHg."
58469884|NCT06586060|OTHER|usual care guided fluid balance strategy|fluid balance management will be guided to maintain an adequate intravascular volume while minimising weight gain within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values To reach daily targeted fluid balance, furosemide-induced diuresis and RRT will be used
58469885|NCT06360380|DEVICE|AquaPass System|a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
58490678|NCT02858505|DRUG|54 mg elemental iron|
58490679|NCT02038361|GENETIC|blood draw|
57778236|NCT04539379|DRUG|Labetolol|intravenous infusion
57778237|NCT04751175|DRUG|Ketamine|Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
57778238|NCT04751175|DRUG|Dexamethasone|"A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration"
57778239|NCT04751175|DRUG|Physiologic saline|placebo
57778240|NCT01028521|DRUG|CM3.1-AC100|Solution for sc injection, single ascending doses
57778241|NCT01028521|DRUG|Placebo|Solution for sc injection
57778242|NCT00715507|DEVICE|medication monitor|the medication monitor will aid in expertise and decision-making.
57778243|NCT03815279|DRUG|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
57778244|NCT03815279|DRUG|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
57778245|NCT03815279|DRUG|Dexamethasone|Dexamethasone will be administered weekly
58469886|NCT06439017|OTHER|Questionaire|The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
58469887|NCT06601881|OTHER|Experimental|"Thoracic mobilization exercises will include:~1. Thoracic Spine Extension exersice~2. Thoracic rotation exersice~3. Cat-Camel Exercise~4. Lateral Flexion of the Thoracic Spine~5. Muscules Psoas Stretching~6. Diaphragm Release Technique~Diaphragmatic Breathing Training will include:~1. Diaphragmatic Breathing~2. Crocodile Breathing Technique~3. Breathing with an exercise band~4. Pursed lip breathing"
58469888|NCT06601881|OTHER|Control (placebo) group|"Placebo Thoracic mobilization exercises will include:~1. Placebo Thoracic Spine Extension exersice~2. Placebo Thoracic rotation exersice~3. Placebo Cat-Camel Exercise~4. Placebo Lateral Flexion of the Thoracic Spine~5. Placebo Muscules Psoas Stretching~6. Placebo Diaphragm Release Technique~Placebo Diaphragmatic Breathing Training will include:~1. Placebo Diaphragmatic Breathing~2. Placebo Crocodile Breathing Technique~3. Placebo Breathing with an exercise band~4. Placebo Pursed lip breathing"
57778246|NCT04866511|OTHER|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
57778247|NCT02169947|BEHAVIORAL|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
57778248|NCT02169947|BEHAVIORAL|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
57778249|NCT04788290|OTHER|Observational|Rabone D®, Once daily administered per the locally approved product information
57778250|NCT06174935|DRUG|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
57778251|NCT05303038|COMBINATION_PRODUCT|Cryoablation Combined with Tirelizumab and Bevacizumab|"Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation."
57778252|NCT03647839|DRUG|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
57778253|NCT03647839|DRUG|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
57778254|NCT03647839|DRUG|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
57778255|NCT05251441|DIETARY_SUPPLEMENT|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
57778256|NCT03195920|DEVICE|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
57778257|NCT05377086|OTHER|Schroth 3-Dimensional scoliosis exercise|Schroth 3-Dimensional scoliosis exercises
57778258|NCT05377086|OTHER|conventional scoliosis exercise|conventional scoliosis exercise
57778259|NCT01449214|PROCEDURE|Ultrasound|Ultrasound-guided technique
57778260|NCT01449214|PROCEDURE|Landmarking|Landmark-guided technique
58469889|NCT06561295|OTHER|Later Morning Timing of Spontaneous Breathing Trials|Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
58469890|NCT03199976|DRUG|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
58469891|NCT03199976|DRUG|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
58469892|NCT03199976|DRUG|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
58469893|NCT06420947|OTHER|atomizer|Participants received 2% lidocaine by atomizer.
57778261|NCT01752413|DIETARY_SUPPLEMENT|Ferrous gluconate 325mg|Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
57778262|NCT01752413|BEHAVIORAL|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
57778263|NCT05681403|DRUG|Improved BEAM regimen|Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
57778264|NCT01388374|OTHER|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
57778265|NCT02624206|DIETARY_SUPPLEMENT|Juice A|Subjects to be given juice daily for 3 weeks.
57778266|NCT02624206|DIETARY_SUPPLEMENT|Juice B|Subjects to be given juice daily for 3 weeks.
57778267|NCT01628211|PROCEDURE|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
57778268|NCT01628211|PROCEDURE|peritonectomy|for patients with PCI \< 20
57778269|NCT01628211|DRUG|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI \< 20
57778270|NCT01628211|DRUG|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI \< 20
57778271|NCT01628211|DRUG|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI \< 20
57778272|NCT01628211|DRUG|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI \> 20
58469894|NCT04664517|PROCEDURE|Flexible intramedullary nail (FIN)|Both bone FIN
58469895|NCT04664517|PROCEDURE|Reduction auder general anesthesia and long arm cast|Reduction and cast
58469896|NCT04665401|BEHAVIORAL|Tailored MERIT|see arm description
58469897|NCT04665401|BEHAVIORAL|Standard MERIT|see arm description
58469898|NCT06603142|DRUG|Febuxostat 20MG Tablets|Febuxostat 20MG Tablets
58469899|NCT06603142|DRUG|Febuxostat 20MG Placebo|Febuxostat 20MG Placebo
57778273|NCT06362239|OTHER|Study Surveys|Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
57778274|NCT03614884|BEHAVIORAL|Gambling and Smoking Treatment|The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.
57778275|NCT03614884|BEHAVIORAL|Gambling only treatment|The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
57778276|NCT05008159|BEHAVIORAL|3 month community-based mobility and health intervention|"12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support"
57778277|NCT00871793|OTHER|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
57778278|NCT05718648|DRUG|BI 1015550|BI 1015550
57778279|NCT02169895|DRUG|BIA 9-1067|
57778280|NCT02169895|DRUG|Placebo|
57778281|NCT02169895|DRUG|Prolopa®|levodopa/benserazide 100/25 mg
57778282|NCT00035945|DRUG|ISIS 14803|
57778283|NCT02793635|DEVICE|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
57778284|NCT03543722|BEHAVIORAL|National Career Coach Program|Intensive employment services as described above.
57778285|NCT03543722|BEHAVIORAL|Local Community Resources Program|Usual employment services as described above.
57778286|NCT02846558|OTHER|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
57778287|NCT02846558|BEHAVIORAL|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
58469900|NCT06603142|DRUG|AR882 25MG|AR882 25 MG Capsules
58469901|NCT06603142|DRUG|AR882 12.5MG|AR882 12.5 MG Capsules
58469902|NCT06603142|DRUG|AR882 25MG Placebo|AR882 25MG Placebo
58469903|NCT06603142|DRUG|AR882 12.5MG Placebo|AR882 12.5MG Placebo
58469904|NCT06603142|DRUG|Febuxostat 40MG Tablets|Febuxostat 40MG Tablets
57778288|NCT02846558|DEVICE|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
57778289|NCT03179631|DRUG|Ataluren|10, 20 mg/kg
57778290|NCT03179631|DRUG|PLACEBO|10, 20 mg/kg
57778291|NCT02237378|RADIATION|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
57778292|NCT03146481|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
57778293|NCT03146481|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
57778294|NCT01605734|PROCEDURE|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
58469905|NCT06603142|DRUG|Febuxostat 40MG Placebo|Febuxostat 40MG Placebo
58469906|NCT05418179|DIETARY_SUPPLEMENT|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
58469907|NCT05418179|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (1 capsule/day)
58469908|NCT04214535|DEVICE|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
58469909|NCT03282656|BIOLOGICAL|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
58469910|NCT06602115|OTHER|Observational study, no interventions involved|Observational study, no interventions involved
58469911|NCT06446453|DIAGNOSTIC_TEST|Echography-guided Surfactant THERapy (ESTHER)|Decision to administer surfactant therapy using a semi-quantitative lung ultrasound score.
58469912|NCT01412697|BEHAVIORAL|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
58469913|NCT06599476|DEVICE|BioProtect Balloon Implant™ System|The BioProtect Balloon Implant System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, and by creating this space, to reduce the radiation dose delivered to the anterior rectum. The balloon is inserted into the perirectal space and inflated to its pre-defined size. The Balloon is made of biodegradable materials that maintain the space for the entire course of prostate radiation treatment and are absorbed by the patient's body over time
58469914|NCT06507943|BEHAVIORAL|Promotora Home Visit|For each participating family, Promotora home visits will be scheduled 6-8 weeks apart, with in-person or virtual visits conducted per the family's preference. The visits will begin with a survey which will evaluate concerns related to asthma for the child and the family, including their asthma control (via the ACT), their home environment (via screening for environmental exposures), and quality of life for the child. These surveys will be available in both online or physical forms for potential connectivity concerns, and Promotoras will have IPads for the online forms. The Promotoras, who have received specialized asthma training, will then address concerns raised by families, using the Clinical Pathway which will have resources for asthma-related concerns that are raised.
58469915|NCT06594328|BEHAVIORAL|mHealth|participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
58469916|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
58469917|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
58469918|NCT03439306|DEVICE|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
58469919|NCT05869708|DEVICE|Active RS-EFP|A minimum of 10 and up to 15 active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
58469920|NCT05869708|DEVICE|Sham RS-EFP|a minimum of 10 and up to 15 sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
58469921|NCT05222529|DRUG|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
58469922|NCT05222529|DRUG|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
58469923|NCT05222529|DRUG|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
58469924|NCT06603909|OTHER|group 1: Use AI to assist nutrition management|group1：AI-assisted nutrition management. group 2：Traditional nutrition management（through the hospital dietitian）.group 3:control.
58469925|NCT06603909|OTHER|group 2：Traditional nutrition management（through the hospital dietitian）|group 2：Traditional nutrition management（through the hospital dietitian）
58469926|NCT06588127|BEHAVIORAL|nudge|Nudge interventions are developed based on the scoping review and qualitative research by the research team, which involves commitment (behavioral contracts), norms (case and experience sharing), significance and framing effects (posters, health behavior identification posts), reminders, and incentives (arteriosclerosis detection). The content encompasses diet, physical activity, medication management, self-monitoring, and control of smoking and alcohol. From the viewpoint of bounded rationality in behavioral economics, and drawing on prior research that has pinpointed decision-making biases in patients' self-management behaviors, nudging strategies have been developed to assist individuals in overcoming these biases or to utilize the patterns of these biases to steer them toward making choices that are in line with their health.
58469927|NCT03628768|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
58469928|NCT05206708|BEHAVIORAL|Personalized psychotherapy|Strategy including personalized psychotherapy
58469929|NCT05206708|BEHAVIORAL|Standard of care|Strategy based standard intregrative psychodynamic therapy
58469930|NCT05160181|OTHER|Yogatherapy|Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
58469931|NCT03044509|DIAGNOSTIC_TEST|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
57778295|NCT01605734|DRUG|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
57778296|NCT04478227|DRUG|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
57778297|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
57778298|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
57778299|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
57778300|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
58469932|NCT03044509|DIAGNOSTIC_TEST|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
58469933|NCT05632159|DRUG|Mg sulphate|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
58469934|NCT05632159|DRUG|conventional anaesthesia|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
57778301|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
57778302|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
57778303|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
57778304|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
57778305|NCT03749460|BIOLOGICAL|Nivolumab|Given IV
57778306|NCT03749460|BIOLOGICAL|Ipilimumab|Given IV
57778307|NCT03749460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
57778308|NCT00164853|PROCEDURE|endoscopic balloon dilatation|Refer to description under arms
57778309|NCT00164853|PROCEDURE|Standard sphincterotomy|Refer to under arms
57778310|NCT01800149|PROCEDURE|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
57778311|NCT04642469|DRUG|Durvalumab|Intravenous administration of Durvalumab
57778312|NCT04642469|OTHER|Placebo|Placebo Comparator
57778313|NCT02480686|DRUG|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
57778314|NCT05640076|OTHER|24/7 Telephonic Palliative Care Service availability|"Metropolitan Palliative Care Service-implemented 24/7 telephonic availability service for the patients, their relatives, the EMS and Primary Care physicians taking care of them.~After consultation, if the information and medical suggestions are not sufficient, an urgent ambulatory or home visit could be planned."
57778315|NCT02328196|BEHAVIORAL|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
58469935|NCT04073875|DIAGNOSTIC_TEST|18F-GP1|18F-GP1 PET-CT scan
58469936|NCT02674035|PROCEDURE|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
58469937|NCT04370301|DRUG|Cyclophosphamide|Given IV
58469938|NCT04370301|DRUG|JAK Inhibitor|Given PO
58469939|NCT04370301|DRUG|Fludarabine|Given IV
58469940|NCT04370301|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
58469941|NCT04370301|DRUG|Melphalan|Given IV
58469942|NCT04370301|DRUG|Mycophenolate Mofetil|Given PO
57778316|NCT04228328|DIAGNOSTIC_TEST|The 6-minutes Walk Test|To walk for 6 minutes
57778317|NCT03800966|OTHER|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
57778318|NCT04157686|DRUG|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL area
58469943|NCT04370301|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
58469944|NCT04370301|DRUG|Tacrolimus|Given IV and PO
58469945|NCT04370301|RADIATION|Total-Body Irradiation|Undergo TBI
58469946|NCT04370301|PROCEDURE|Computed Tomography|Undergo CT
58469947|NCT04370301|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57778319|NCT04157686|DRUG|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL area
57778320|NCT04157686|DRUG|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
58469948|NCT04370301|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
57778321|NCT02324023|DEVICE|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
58469949|NCT04370301|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
58469950|NCT04370301|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58469951|NCT04370301|PROCEDURE|Echocardiography|Undergo ECHO
58469952|NCT04370301|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58469953|NCT06318468|OTHER|Nursing health assessment teaching and discussion using humanoid diagrams|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
58469954|NCT06318468|OTHER|Nursing health assessment teaching and discussion using case study|The comparison group will receive the nursing health assessment teaching for 50 minutes and discussion using case study for 40 minutes to learn comprehensive nursing assessment.
58469955|NCT04310462|OTHER|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
58469956|NCT05175547|DRUG|Clevidipine|Blood pressure management with Clevidipine
58469957|NCT04760613|DRUG|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
58469958|NCT04760613|DRUG|Placebo|identical capsules containing placebo (taken daily by mouth)
58469959|NCT05830812|DIAGNOSTIC_TEST|Invasiveness diagnosis|To predict the invasiveness of patients with small-sized lung adenocarcinoma intraoperatively based on multi-modal information.
58469960|NCT05542420|OTHER|No treatment given|The study will be based on data already recorded in the medical record
58469961|NCT05292664|DRUG|Venetoclax|Tablet taken orally
58469962|NCT05292664|DRUG|Azacitidine|Taken intravenously
58469963|NCT05292664|DRUG|Cytarabine|Lumbar Puncture
58469964|NCT05292664|DRUG|Methotrexate|Lumbar Puncture
58469965|NCT05292664|DRUG|Hydrocortisone|Lumbar Puncture
58469966|NCT05292664|DRUG|Leucovorin|Taken Orally or intravenously
58469967|NCT05292664|DRUG|Dexamethasone|Taken Orally or intravenously
58469968|NCT05292664|DRUG|Vincristine|Taken intravenously
58469969|NCT05292664|DRUG|Doxorubicin|Taken intravenously
58469970|NCT05292664|DRUG|Dexrazoxane|Taken intravenously
58469971|NCT05292664|DRUG|Calaspargase Pegol|Taken intravenously
58469972|NCT05292664|DRUG|Erwinia asparaginase|Given as intramuscular injection
58469973|NCT05642741|OTHER|Response to medical and research questionnaires|Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
58469974|NCT03571438|COMBINATION_PRODUCT|CK2 and ATM inhibitors serine/ threonin Kinase combination|Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
58469975|NCT03571438|DRUG|Sunitinib|Treatment of cell culture with Sunitinib
58469976|NCT03571438|DRUG|Pazopanib|Treatment of cell culture with Pazopanib
58469977|NCT03571438|DRUG|Temsirolimus|Treatment of cell culture with Temsirolimus
58469978|NCT06494267|BEHAVIORAL|Experimental (Video-Assisted Self-Assessment on Nasogastric Tube Insertion)|Students in the experimental group will be videotaped while practicing and students will make self-evaluations.
58469979|NCT05730023|DEVICE|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
58469980|NCT05730023|BEHAVIORAL|individualized language training|individualized language training
58469981|NCT05730023|DEVICE|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
58469982|NCT06122831|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
58469983|NCT06122831|DRUG|TQB3617 Capsules|TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
58469984|NCT04753190|BEHAVIORAL|Baseline Sleep Satiation and Phase Stabilization|All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
58469985|NCT04753190|BEHAVIORAL|Gradually Shifted Sleep|For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
58469986|NCT05204719|PROCEDURE|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
58469987|NCT02649582|BIOLOGICAL|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle"
58469988|NCT03160261|DRUG|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
58469989|NCT03008278|DRUG|Olaparib|Give PO
58469990|NCT03008278|BIOLOGICAL|Ramucirumab|Given IV
58469991|NCT02257138|DRUG|Decitabine|Given IV
58469992|NCT02257138|OTHER|Laboratory Biomarker Analysis|Correlative studies
58469993|NCT02257138|DRUG|Ruxolitinib Phosphate|Given PO
58469994|NCT06601582|DEVICE|Use of a operative blood salvage system|The surgical team will use a operative blood salvage system
58469995|NCT06565962|OTHER|Educaiton group|The experimental group will be made to watch training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles.
58469996|NCT06565962|OTHER|control group|No intervention will be performed in the control group.
58469997|NCT06212856|OTHER|Plyometric training|"The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws"
58469998|NCT06212856|OTHER|Conventional|"The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running"
58469999|NCT05620628|DRUG|Durvalumab|Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
58470000|NCT05620628|DRUG|Savolitinib|Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
58470001|NCT06210646|DRUG|Citicoline 2000|The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
58470002|NCT06210646|DRUG|citocoline 1000|The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
58470003|NCT05085353|PROCEDURE|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
57778322|NCT05733806|OTHER|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
57778323|NCT01216982|DRUG|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
57778324|NCT01216982|DRUG|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
57778325|NCT01576055|DEVICE|TIGRIS Vascular Stent|Implant
57778326|NCT01576055|DEVICE|BARD LifeStent|Implant
57778327|NCT00641849|BEHAVIORAL|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
57778328|NCT00641849|BEHAVIORAL|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
57778329|NCT02300389|RADIATION|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
57778330|NCT02300389|RADIATION|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
57778331|NCT03449537|DIETARY_SUPPLEMENT|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
57778332|NCT03449537|DIETARY_SUPPLEMENT|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
57778333|NCT05611970|DEVICE|Vaginal pessary|A reusable vaginal pessary for stress urinary incontinence
57778334|NCT05501769|DRUG|ARV-471 in combination with Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
57778335|NCT06458829|BEHAVIORAL|SEARCH-AF|SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
57778336|NCT00517426|DRUG|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
58470004|NCT06591429|RADIATION|Radiotracer [11C]-CS1P1|Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
58470005|NCT06591429|RADIATION|Radiotracer [11C]-DPA-713|Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
58470006|NCT06591429|DRUG|anti-CD20 MS treatment|MS treatment taken indepenently after initial testing
58470007|NCT06591429|RADIATION|Radiotracer [12F]-FDG|used in PET/CT scans of the head and neck Dose: 5 mCi
58470008|NCT04631510|DRUG|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
58470009|NCT05060211|OTHER|Vancouver symptom score for dysfunctional elimination syndroms|Validated questionnaire concerning bladder and bowel symptoms
58470010|NCT05060211|OTHER|Magnetic resonance imaging|Known MRI results of the patient file
58470011|NCT05809908|DRUG|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks."
57778337|NCT01448525|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
57778338|NCT01448525|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
57778339|NCT05386186|DRUG|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
57778340|NCT05386186|DRUG|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
57778341|NCT02693912|PROCEDURE|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
57778342|NCT03059693|DRUG|HAT1 topical cream|
57778343|NCT03059693|DRUG|Vehicle cream|
57778344|NCT03428282|PROCEDURE|VR Box|Distraction will be made during the injection of the drug using this method.
57778345|NCT03428282|PROCEDURE|Tablet Device|Distraction will be made during the injection of the drug using this method
57778346|NCT03428282|DRUG|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
57778347|NCT05819905|DIAGNOSTIC_TEST|PET/CT|Pre treatment staging 18F-FDG PET/CT
58470012|NCT05809908|DRUG|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks."
58470013|NCT06274060|BEHAVIORAL|Case management|Participants will receive case management delivered by a peer with PrEP experience/success for seven months, with the goal of improving self-efficacy to take PrEP. The intention of this intervention is to help participants to develop individualized strategies to address and overcome barriers to PrEP use, as well as develop disclosure strategies. This strategy includes weekly face-to-face support with the case manager for the first month of the trial, followed by monthly face-to-face support for the remainder of the trial follow up period. The strategy will also include client-initiated on-demand phone consultation with the case manager and mental health/substance use screening and referrals. Participants randomized to this strategy may also opt into daily timed PrEP pill-taking reminders via short message service (SMS).
58470014|NCT06274060|BEHAVIORAL|Food vouchers|Participants will be given food vouchers with a value of 200 South African Rand at the time of PrEP initiation and at 1- and 4-month standard of care visits at which clinical checkups and PrEP refills are provided. The goal of these vouchers is to improve participants' capacity to persist on PrEP. While PrEP can be taken without food, some experience increased side effects or prefer to take pills with food, making adherence difficult if they cannot afford food at times.
58470015|NCT06274060|BEHAVIORAL|PrEP support buddy|Participants will identify a person in their network (such as a friend, partner, parent) that they wish to support them in their PrEP usage, with the goal of improving participants' motivation and self-efficacy to persist on PrEP and providing social support to facilitate ongoing PrEP use. Support buddies selected by FSW and AGYW randomized to this intervention will receive a one-time training session on PrEP and support strategies as well as informational materials and text reminders to assist them in providing ongoing PrEP support.
58470016|NCT06274060|BEHAVIORAL|Community-based PrEP pickup points|Participants will be able to pick up PrEP from alternative pick-up points within the community that are convenient for them, with the goal of making PrEP more accessible to participants. Ten pickup points will be established at existing Hubs of Hope throughout the subdistricts served by the TB HIV Care programme. Hubs of Hope are based in the War Rooms within subdistricts, where the TB HIV Care programme operates, and serve as meeting places for service users to receive support searching for jobs, completing online courses, and other personal development activities to support a multi-sectoral approach to health. A TB HIV Care ambassador is based at each Hub of Hope to coordinate activities and provide support to service users. Participants who choose to use pick-up points will have the option of either completing an HIV self-test or testing with the on-site TB HIV Care staff to confirm HIV-negative status prior to receipt of PrEP refills.
58470017|NCT03814811|DIAGNOSTIC_TEST|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
58470018|NCT01607957|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
58470019|NCT01607957|DRUG|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
58470020|NCT01212835|PROCEDURE|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
58470021|NCT01212835|PROCEDURE|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
58470022|NCT06453746|OTHER|Home-based cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
58470023|NCT06453746|OTHER|Supervised cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
58470024|NCT05784844|DRUG|Meropenem|Carbapenem antibiotic
58470025|NCT05784844|DRUG|Micafungin|Echinocandin antifungal
58470026|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470027|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470028|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470029|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470030|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470031|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470032|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470033|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
58470034|NCT00941746|BIOLOGICAL|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
58470035|NCT02099864|DRUG|Enzalutamide|Given PO
58470036|NCT04199351|DRUG|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
58470037|NCT04199351|DRUG|Placebo|AMG 171 placebo
58470038|NCT06041763|PROCEDURE|Meniscal Repair Procedure|All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.
58470039|NCT06041763|DEVICE|BEAR Implant|The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
58470040|NCT03985839|DEVICE|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
58470041|NCT03985839|DEVICE|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
57778348|NCT04876560|OTHER|Application of CDSS to provide nutritional care in breast cancer patients from home|A personalised dietary plan was implemented by the CDSS. The CDSS estimated body mass index (BMI) and Total daily Energy Expenditure (TEE) according to individual's incorporated data. For overweight and obese patients, the CDSS produced a hypocaloric diet, in which daily energy intake was less than TEE by approximately -500 kcal/day. Nutrient distribution was in line with the Mediterranean dietary pattern. Patients received individual login passwords to CDSS allowing access to their personal profile from home. During the trial, patients were instructed to record food diaries in the CDSS every week, which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes.
57778349|NCT04876560|OTHER|General lifestyle advice to breast cancer patients by phone|General lifestyle guidelines were provided by phone and food diaries were sent via emails.
57778350|NCT02329600|DRUG|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
57778351|NCT02329600|DRUG|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
57778352|NCT05377840|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. standard CBT Participants will have individual weekly sessions lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
57778353|NCT05377840|BEHAVIORAL|Sudarshan Kriya Yoga|SKY Breath Meditation is a deep breathing and meditation technique that enables physiological changes leading to improved mental and physical health. Participants will first attend a 3-day online workshop (2.5 hours each day) delivered live by a certified instructor to learn the SKY Breath Meditation practice. Participants will then practice SKY 25 minutes daily for 6 weeks and 3-4 times per week up to 12 weeks.
57778354|NCT02112058|BEHAVIORAL|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
57778355|NCT01562847|DRUG|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
57778356|NCT04305899|DRUG|BMS-986165 Tablet formulation 1|Specified dose on specified days
57778357|NCT04305899|DRUG|BMS-986165 Tablet formulation 2|Specified dose on specified days
57778358|NCT04273503|BEHAVIORAL|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
57778359|NCT04825860|DRUG|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
57778360|NCT04825860|DRUG|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
57778361|NCT04825860|DRUG|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
57778362|NCT06204328|OTHER|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique \& mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
57778363|NCT03603015|DIAGNOSTIC_TEST|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
57778364|NCT05140213|DEVICE|Anti-infectious prescription support tool|"implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
57778365|NCT05706987|DRUG|Lidocaine|continuous lidocaine infusion perioperatively
57778366|NCT05706987|DRUG|Normal saline|normal saline
57778367|NCT01816763|BEHAVIORAL|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
57778368|NCT01816763|BEHAVIORAL|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
58470042|NCT03985839|DEVICE|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
58470043|NCT03496844|DIAGNOSTIC_TEST|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
58470044|NCT00445081|DRUG|Prednisolone|
58470045|NCT00445081|DRUG|Ciclosporine A|
58470046|NCT01856270|DRUG|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
58470047|NCT04771455|BEHAVIORAL|Behavioral weight loss|Participants will receive behavioral weight loss intervention
58470048|NCT04771455|BEHAVIORAL|Intervention component: Decrease overvaluation of weight and shape|Participants will receive an intervention component to decrease overvaluation of weight and shape
58470049|NCT04771455|BEHAVIORAL|Intervention component: Decrease unhealthy weight control practices|Participants will receive an intervention component to decrease unhealthy weight control practices
58470050|NCT04771455|BEHAVIORAL|Intervention component: Decrease negative affect|Participants will receive an intervention component to decrease negative affect
58470051|NCT01500733|DRUG|PCI 32765|420 mg daily
58470052|NCT05974722|DEVICE|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
58470053|NCT05974722|OTHER|Pledgeted sutures|Patient will receive pledgeted sutures
58470054|NCT05884307|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
58470055|NCT05313295|OTHER|Home-based physiotherapy|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
58470056|NCT05313295|OTHER|Usual Physiotherapy|Usual care provided for the management of neurological disorders in children
58470057|NCT06218316|DRUG|botulinum toxin A|Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
58470058|NCT06218316|DEVICE|Transcranial Magnetic Stimulation|Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
58470059|NCT06218316|OTHER|Rehabilitation Training Protocol|Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
58470060|NCT06591507|DIETARY_SUPPLEMENT|BCAA Nutritional Intervention|Patients will receive BCAA nutritional supplements. The supplement is taken orally twice daily, with each sachet containing 10g of powder, of which 6g is BCAA, and the remainder consists of preservatives and fruit flavorings to enhance palatability. The morning dose is taken with breakfast, and the second dose is taken as a late evening snack after dinner. For critically ill patients, enteral nutrition is provided instead. During each follow-up visit, patients are required to retain and submit all empty and unused sachets to accurately assess compliance. Dietitians will adjust the type and amount of food for each patient according to the guidelines of the European Society for Parenteral and Enteral Nutrition to ensure a total caloric intake of 35-40 kcal/kg and a protein intake of 1.2-1.5 g/kg (including BCAA supplements).
58470061|NCT06591507|BEHAVIORAL|Muscle Rehabilitation Training|Phase 1: Resistance Training (During Hospital Stay, First Month) Phase 2: Resistance Training (Home-Based, From Hospital Discharge Until 3 Months Post-Surgery) Phase 3: Physical Activity Training (Post-Surgery, After 3 Months)
58470062|NCT06591507|DIETARY_SUPPLEMENT|Standard Nutritional Therapy|Standard Nutritional Therapy
58470063|NCT05719103|BEHAVIORAL|With and Without Awake Prone Positioning|"1. HFNC flow at 60 L/min or maximum tolerable flow at supine position~2. HFNC flow at 60 L/min or maximum tolerable flow at prone position~3. CPAP with full face mask at 10 cmH2O at supine position~4. CPAP with full face mask at 10 cmH2O at prone position~5. MC at supine position~6. MC at prone position"
58470064|NCT06586567|OTHER|Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas|"2. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori"
58470065|NCT03995368|OTHER|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
58470066|NCT04879030|DRUG|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
58470067|NCT04879030|DRUG|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
58490680|NCT06471348|DRUG|Bupivacaine liposome injectable suspension|EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.
58490681|NCT06471348|DRUG|Bupivacaine Hydrochloride and Epinephrine Injection|Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).
58490682|NCT02111759|PROCEDURE|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
57778369|NCT01816763|BEHAVIORAL|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
57778370|NCT02593539|DRUG|Nemiralisib|Participants will be administered nemiralisib
58470068|NCT05682508|OTHER|Education group|"Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable."
58470069|NCT05202119|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.
57778371|NCT05165875|DRUG|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
57778372|NCT05165875|OTHER|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
57778373|NCT05471869|DIAGNOSTIC_TEST|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
57778374|NCT05856240|BEHAVIORAL|Managing Stress & Emotions Group (MSEG)|The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
57778375|NCT00881010|BEHAVIORAL|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
57778376|NCT00881010|BEHAVIORAL|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
57778377|NCT04375696|DRUG|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
57778378|NCT04375696|OTHER|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
57778379|NCT04441424|BIOLOGICAL|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
57778380|NCT04441424|DRUG|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
57778381|NCT00864838|DRUG|Acetazolamide|250 mg 1 hour before intravitreal injection
57778382|NCT00864838|DRUG|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
57778383|NCT00864838|PROCEDURE|Anterior chamber paracentesis|Immediately after bevacizumab injection
57778384|NCT02411591|DRUG|Necitumumab|Administered IV.
57778385|NCT02411591|DRUG|Abemaciclib|Administered orally.
57778386|NCT02622633|DEVICE|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
57778387|NCT00734513|BEHAVIORAL|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
57778388|NCT00734513|BEHAVIORAL|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
57778389|NCT05601492|DRUG|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
57778390|NCT05601492|BEHAVIORAL|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
57778391|NCT05601492|BEHAVIORAL|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
57778392|NCT04410679|BIOLOGICAL|injectable PRF|blood sample and centrifuged to obtain i-PRF
57778393|NCT01349660|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
57778394|NCT01349660|DRUG|BKM120|BKM120 orally (PO) once daily
57778395|NCT02531295|DRUG|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
57778396|NCT04594551|BIOLOGICAL|Purified vero rabies vaccine - serum free|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
58470070|NCT05202119|DEVICE|Sham Transcranial direct current stimulation|To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.
58470071|NCT05358236|OTHER|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area"
58470072|NCT06511258|BEHAVIORAL|Prehabilitation|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
58470073|NCT05638256|DRUG|68Ga-NY104|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
58470074|NCT01752426|OTHER|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
58470075|NCT01752426|DRUG|PCI-32765|420 mg orally once daily.
58470076|NCT06496620|DRUG|Biological: Solrikitug low dose|Solrikitug subcutaneous injection
58470077|NCT06496620|DRUG|Biological: Solrikitug high dose|Solrikitug subcutaneous injection
58470078|NCT06496620|OTHER|Placebo|Placebo subcutaneous injection
58470079|NCT05611151|DIAGNOSTIC_TEST|Computer Aided Detection (CADe)|Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
58470080|NCT05917626|BEHAVIORAL|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
58470081|NCT06079697|OTHER|Electronic Health Record Review|Ancillary studies
58470082|NCT06079697|OTHER|Exercise Intervention|Receive prehabilitation exercise intervention
58470083|NCT06079697|OTHER|Medical Device Usage and Evaluation|Wear Fitbits
58131024|NCT04033952|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
58470084|NCT06079697|OTHER|Survey Administration|Ancillary studies
58470085|NCT02864394|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
58470086|NCT02864394|DRUG|Docetaxel|Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
58470087|NCT01280903|BEHAVIORAL|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
58470088|NCT01280903|BEHAVIORAL|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
58470089|NCT05164289|OTHER|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
58470090|NCT05164289|OTHER|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
58470091|NCT04503070|BEHAVIORAL|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort"
58470092|NCT06297525|DRUG|STP938|Small molecule
58470093|NCT05649969|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.
58470094|NCT05649969|BEHAVIORAL|Daily Food Intake Diary with Fitbit smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks
58131025|NCT03061734|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
57778397|NCT04594551|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
58131026|NCT03061734|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
58131027|NCT03061734|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
57778398|NCT04594551|BIOLOGICAL|Human rabies immunoglobulins|Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
57778399|NCT01121718|DRUG|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
57778400|NCT05644405|DIAGNOSTIC_TEST|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
57778401|NCT04893070|OTHER|Questionnaires COVID+|"* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms"
57778402|NCT04893070|OTHER|Questionnaires COVID-|"* 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment"
57778403|NCT02325713|DRUG|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
57778404|NCT02325713|DRUG|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
57778405|NCT02325713|DRUG|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
57778406|NCT02325713|DRUG|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
57778407|NCT02325713|DRUG|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
57778408|NCT02325713|DRUG|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
57778409|NCT05769270|BEHAVIORAL|Peer Navigation and Coping Skills|Participants will receive 6 sessions of peer navigation and coping skills
57778410|NCT05769270|BEHAVIORAL|Treatment as Usual|Participants will receive referrals for PrEP and services
57778411|NCT01628302|BEHAVIORAL|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
57778412|NCT04972981|DRUG|ADCT-901|Intravenous infusion
57778413|NCT00247624|DRUG|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
57778414|NCT00247624|DRUG|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
58131028|NCT03061734|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
58131029|NCT03061734|DRUG|Matching Placebo|Two Placebo capsules
58131030|NCT00537147|BIOLOGICAL|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
57778415|NCT00247624|DRUG|Placebo|Placebo every night for 8 weeks
57778416|NCT04888637|DIAGNOSTIC_TEST|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
58131031|NCT00537147|BIOLOGICAL|Placebo|Placebo for WN/DEN4delta30 vaccine
58131032|NCT06441578|DRUG|Recombinant ADAMTS13|Recombinant ADAMTS13, Intravenous injection
58131033|NCT02166138|PROCEDURE|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
57778417|NCT04888637|BEHAVIORAL|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
58131034|NCT05334771|DEVICE|Dual band pure tune audiometer|Orbiter 922 Tympanometry
58131035|NCT02171052|DRUG|Dabigatran etexilate|
58131036|NCT02171052|DRUG|Digoxin|
58131037|NCT03965858|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
58131038|NCT03965858|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
58131039|NCT03965858|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
58131040|NCT03965858|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
58470095|NCT05649969|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
58131041|NCT05063409|OTHER|Treatment|Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
58131042|NCT01255878|DEVICE|occlusal stabilization splint|
58131043|NCT01255878|DRUG|Gabapentine|100 mg(1 capsule)three times per day for two months
58470096|NCT02946580|DRUG|MOVANTIK™ (naloxegol)|
58470097|NCT02946580|DRUG|Sugar Pill|
58470098|NCT00005975|DRUG|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
58470099|NCT00005975|DRUG|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
58470100|NCT00005975|DRUG|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
58470101|NCT00005975|DRUG|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
58470102|NCT04746391|DEVICE|Dialyzer type|Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers
58470103|NCT04746391|OTHER|Dialysis duration|Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
58470104|NCT03723655|DRUG|mavacamten|mavacamten capsules
58470105|NCT06588140|DEVICE|Duplicated refitted complete denture made from conventionally heat-cured polymethyl methacrylate.|The duplication of a refitted complete removable denture will be performed using conventional heat-cured polymethyl methacrylate through the conventional heat-cured polymerization technique.
58470106|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM pink polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed separately with pink polymethyl methacrylate resin, and the teeth are printed as a single unit using tooth-colored resin, followed by the assembly of the two components.
58470107|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM white polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink polymethyl methacrylate resin.
58470108|NCT02977663|OTHER|Magnetic Resonance Imaging (MRI)|"* Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit"
58470109|NCT06599450|DEVICE|Root form dental implant|Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
58470110|NCT04227808|DRUG|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
58470111|NCT04304768|BIOLOGICAL|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
58470112|NCT00072462|DRUG|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
58470113|NCT00072462|DRUG|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
58470114|NCT06423326|PROCEDURE|Biopsy|Undergo biopsy
58470115|NCT06423326|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58470116|NCT06423326|DRUG|Cisplatin|Given IV
58470117|NCT06423326|PROCEDURE|Computed Tomography|Undergo CT
58470118|NCT06423326|DRUG|Gemcitabine|Given IV
58470119|NCT06423326|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58470120|NCT06423326|DRUG|Nab-paclitaxel|Given IV
58470121|NCT06423326|PROCEDURE|Pancreatic Surgical Procedure|Undergo surgical resection
58470122|NCT03804840|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.
58470123|NCT03804840|DRUG|Placebo|Placebo
57778418|NCT04888637|BEHAVIORAL|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
57778419|NCT03179800|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
58470124|NCT01803009|BEHAVIORAL|Patient views NCI CRC RAT|
58470125|NCT01803009|BEHAVIORAL|View presentation regarding current chance of having an advanced adenoma|
58470126|NCT05713630|DRUG|Tranexamic acid (TXA)|GD-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo. Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.
58470127|NCT05713630|DRUG|Placebo|Placebo 500 mg consisting of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 mg/mL solution for injection via intravenous (IV) consisting of 0.9% sodium chloride (saline).
58470128|NCT04905134|DEVICE|Nasopharyngoscope|Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
58470129|NCT06596928|DIETARY_SUPPLEMENT|Essential Elements T-Hero Platinum|Participants will take two capsules daily for 90 days
58470130|NCT06596928|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take two placebo capsules daily for 90 days.
58470131|NCT04441905|OTHER|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
58470132|NCT04441905|BIOLOGICAL|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
58470133|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
58470134|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
58490683|NCT02111759|PROCEDURE|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
58490684|NCT02707822|OTHER|Clinical and genetic factors|
58470135|NCT06593145|BIOLOGICAL|FCTX-CL19-1 (Tarcidomgen Kimleucel)|"It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight"
58470136|NCT03558711|DIAGNOSTIC_TEST|18F-PSMA|18F-PET imaging
58470137|NCT05777187|OTHER|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
58470138|NCT06330805|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
58470139|NCT06330805|OTHER|Contrast Agent|Given IV
58470140|NCT06330805|DRUG|Leuprolide|Given injection
58470141|NCT06330805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58470142|NCT06330805|OTHER|Physical Performance Testing|Undergo functional fitness tests
58470143|NCT06330805|DRUG|Relugolix|Given PO
58470144|NCT06234228|BEHAVIORAL|Bluetooth Haptic Device (BHD)|The BHD will deliver constant low-frequency vibration (CF).
58470145|NCT06234228|BEHAVIORAL|BHD synced with mobile game|The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
58470146|NCT06401486|DEVICE|Videolaryngoscope|For patients assigned to the videolaryngoscope Group, the operator will use a video laryngoscope on the first laryngoscopy attempt.
58470147|NCT06401486|DEVICE|Macintosh laryngoscope|For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
58470148|NCT03910634|DRUG|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
58470149|NCT03910634|RADIATION|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
57778420|NCT03179800|OTHER|Sham Implantation|Sham Implantation
58470150|NCT03910634|DRUG|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
58470151|NCT04125589|BEHAVIORAL|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
58470152|NCT04125589|BEHAVIORAL|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
58470153|NCT04685863|OTHER|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
58470154|NCT04895644|OTHER|No Hard Collar|The patient in the intervention arm will not wear a Hard Collar for 12 weeks post injury
58470155|NCT04895033|BEHAVIORAL|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
58470156|NCT04782713|OTHER|Completing surveys|Completing surveys at baseline, 3, 6, 9, and 12 months
57778421|NCT04866914|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
57778422|NCT04866914|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
58470157|NCT04308122|DEVICE|Cervical Orthosis (CO)|Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
58470158|NCT04308122|DEVICE|No Orthosis|The NO group will have no specific precautions applied to their neck range of motion.
58470159|NCT03774732|RADIATION|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
58470160|NCT03774732|DRUG|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
58470161|NCT03774732|DRUG|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
58470162|NCT03882021|PROCEDURE|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
57778423|NCT00862953|DIETARY_SUPPLEMENT|Normal protein energy-restricted|Normal protein diet energy restricted
57778424|NCT00862953|DIETARY_SUPPLEMENT|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
58470163|NCT06603701|DIAGNOSTIC_TEST|Bioimpedancemetry|"2. Bioimpedancemetry at T1, T2, T3 ; the measurement will be~1. Squeletic mass (total and for each of the 4 limbs)~2. Angle phase (total and for each of the 4 limbs)"
58470164|NCT06603701|OTHER|Dynamometry|Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3
58470165|NCT05758168|PROCEDURE|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
58490685|NCT00621348|DRUG|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
58490686|NCT00621348|DRUG|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
58490687|NCT00621348|DRUG|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
58470166|NCT06435351|PROCEDURE|Leukapheresis|"Removal of white blood cells (leukocytes) from the blood. The dendritic cells are harvested from the white blood cells that are collected and trained to recognize the specific abnormal proteins found in the tumor sample.~One needle is inserted in each arm. An apheresis machine removes blood from the vein in one arm, separates and retains the leukocytes from the blood, and then returns the rest of the blood to the other arm."
58470167|NCT06435351|BIOLOGICAL|Dendritic Cell (DC) Vaccine|"The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance using a dose of 40-50 million cells three times spaced 2 weeks apart for the initial priming sequence.~3 doses of the priming vaccines are given once every 2 weeks. 2 booster shots (if available) will be given 6 months and 12 months following completion of initial priming vaccines."
58470168|NCT02137746|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
57778425|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0
57778426|NCT01450280|BIOLOGICAL|ChAd63 CS, MVA CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
57778427|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0
57778428|NCT01450280|BIOLOGICAL|ChAd63, MVA CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
57778429|NCT03413358|DRUG|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
57778430|NCT03413358|DRUG|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
57778431|NCT02892942|DRUG|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
57778432|NCT02892942|DRUG|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
57778433|NCT02892942|DRUG|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
57778434|NCT01463917|DRUG|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
57778435|NCT01463917|DRUG|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
57778436|NCT03841981|DIAGNOSTIC_TEST|Anthropometric and physical examination|"* Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\]."
57778437|NCT03841981|DIAGNOSTIC_TEST|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
58470169|NCT04156087|DRUG|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
58470170|NCT04156087|DRUG|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
58470171|NCT04156087|DRUG|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
57778438|NCT03841981|DIAGNOSTIC_TEST|Biochemical, hormonal and metabolic phenotyping|"* Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers."
57778439|NCT03841981|DIAGNOSTIC_TEST|Sonographic studies|"* Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
58470172|NCT04156087|PROCEDURE|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
58470173|NCT00641433|DEVICE|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
58470174|NCT00641433|DRUG|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
58490688|NCT04462588|DRUG|Cipro 400 MG in 200 ML Injection|medical tratment group
58490689|NCT04462588|DRUG|Flagyl I.V. RTU|medical tratment group
58490690|NCT04462588|PROCEDURE|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
57778440|NCT03841981|DIAGNOSTIC_TEST|24-hour Ambulatory blood pressure monitoring|A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).
57778441|NCT03841981|PROCEDURE|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
57778442|NCT03841981|DIAGNOSTIC_TEST|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
57778443|NCT03841981|DIAGNOSTIC_TEST|Oral smear and feces specimen|Microbiome studies.
57778444|NCT04228549|DEVICE|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
57778445|NCT04228549|DEVICE|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
57778446|NCT00002354|DRUG|Indinavir sulfate|
57778447|NCT00002354|DRUG|Stavudine|
58470175|NCT06591533|OTHER|Music therapy + standard care|In the pre-extubation and extubation phase, the musical characteristics will be based on a slow to medium tempo, simple harmonic structures (e.g., tonic-subdominant movements), fluid melodies, and avoiding large intervals or abrupt changes of tonalities. The musical instruments used will be a classical guitar with nylon strings (Yamaha C-40) and the voice of the music therapist without lyrics or words. In the post-extubation phase, the musical characteristics will be based on a moderate tempo, introducing chord progressions aiming at tension-resolution (e.g., dominant-tonic), and a more rhythmic application of melodic or harmonic material.
58470176|NCT06591533|OTHER|Standard Care (in control arm)|Standard care during the extubation process involves providing usual the medical care provided for patients according to each hospital's guidelines.
57778448|NCT05581238|OTHER|TRACK-TCT|An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
57778449|NCT02471404|DRUG|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
57778450|NCT02471404|DRUG|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
57778451|NCT02471404|DRUG|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
57778452|NCT02471404|DRUG|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
57778453|NCT02471404|DRUG|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
57778454|NCT02471404|DRUG|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
57778455|NCT04747275|DRUG|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
57778456|NCT04747275|DRUG|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
57778457|NCT01163747|BIOLOGICAL|tocilizumab|Intravenous repeating dose
57778458|NCT01163747|DRUG|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
57778459|NCT01163747|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
57778460|NCT01163747|BIOLOGICAL|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
57778461|NCT02868437|DEVICE|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
57778462|NCT05015673|DRUG|SEP363856|
57778463|NCT05015673|DRUG|Placebo|
57778464|NCT04151693|BEHAVIORAL|Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)|Adaptation (support own agency), rehabilitation and improvement of functional capacity.
57778465|NCT00518141|DRUG|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
57778466|NCT05611697|PROCEDURE|Single anastomosis sleeve ileal bypass|The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
57778467|NCT05611697|PROCEDURE|Sleeve gastrectomy|In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
58470177|NCT04036682|DRUG|CLN-081|CLN-081 tablets
57778468|NCT04499417|DEVICE|Electromyostimulation Whole-Body-Workout|Electromyostimulation - intensity 5 (muscle stimulation)
57778469|NCT04499417|DEVICE|Electromyostimulation Sham Whole-Body-Workout|Electromyostimulation - intensity 0 (no muscle stimulation)
57778470|NCT04404621|BEHAVIORAL|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
57778471|NCT02023138|OTHER|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
57778472|NCT02023138|OTHER|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
57778473|NCT04645524|DRUG|AD182|Oral capsule administered before bed
57778474|NCT04645524|DRUG|AD504|Oral capsule administered before bed
57778475|NCT04645524|DRUG|Placebo|Oral capsule administered before bed
57778476|NCT04645524|DIAGNOSTIC_TEST|Polysomnography|for all arms
57778477|NCT04888702|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
58470178|NCT03755934|DRUG|MEDI7352|Participants will receive IV infusion of MEDI7352 as stated in arm description.
58470179|NCT03755934|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
58470180|NCT05226624|BEHAVIORAL|Rooming-in care|Implementation of Rooming-in model of care
58470181|NCT05226624|BEHAVIORAL|Baseline standard of care|Baseline standard of care
58470182|NCT05799287|BIOLOGICAL|Telitacicept|Subcutaneous injection
58470183|NCT05799287|DRUG|Placebo|Placebo to Telitacicept
58470184|NCT01652235|DEVICE|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
58470185|NCT04699591|DRUG|Domperidone|Domperidone taken 4 times a day, dose based on body weight
58470186|NCT06008730|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58470187|NCT06008730|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
58470188|NCT06008730|OTHER|Radiology, Treatment Planning|Undergo radiation treatment planning
58470189|NCT06054126|OTHER|Echocardiography|Cardiac function was evaluated by echocardiography at one year follow-up.
58470190|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 3 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
58470191|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 5 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
58470192|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 7 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
58470193|NCT06586424|DIAGNOSTIC_TEST|Anion gap|Patient was taken blood examination before PPCI
58470194|NCT00563056|DRUG|Flutiform|
58470195|NCT00563056|DRUG|Flixotide plus Foradil|
58470196|NCT02484391|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
58470197|NCT02484391|DRUG|Cytarabine|Given IV
58470198|NCT02484391|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplant
58470199|NCT02484391|DRUG|Mitoxantrone Hydrochloride|Given IV
58470200|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
58470201|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
58470202|NCT06587737|DRUG|Colchicine 0.5 MG|colchicine 0.5mg once-daily
58470203|NCT06587737|DRUG|Placebo|matching placebo, lacking active ingredient, once-daily
58470204|NCT05062785|DRUG|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
58470205|NCT05916183|BEHAVIORAL|Fluid loss and consumption|Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
58470206|NCT06587581|OTHER|Control Group|Participants from the intervention group will receive the usual care over the 6-month intervention period
58470207|NCT06587581|OTHER|Intervention Group|Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
58470208|NCT00817297|DEVICE|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
58470209|NCT05552287|DRUG|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
58470210|NCT06269133|DRUG|REGN2810|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
58470211|NCT06269133|OTHER|Platinum-doublet chemotherapy|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
58470212|NCT04328714|DRUG|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
58470213|NCT05804591|DRUG|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
58470214|NCT05804591|DRUG|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
58470215|NCT06587698|DRUG|Sitagliptin|100 mg QD for 3 month
58470216|NCT06587698|DRUG|BeiDouGen|60 mg BID for 3 month
58470217|NCT06587698|DRUG|Sitagliptin+BeiDouGen|100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
58470218|NCT03939624|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
58470219|NCT03939624|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
58470220|NCT05498610|DRUG|NNC0480 0389|"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
58470221|NCT05498610|DRUG|Semaglutide|"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
58470222|NCT06604273|DIAGNOSTIC_TEST|Fibroblast Activation Protein Inhibitor|PET CT imaging using the fibroblast activation protein inhibitor tracer
58470223|NCT02439853|BEHAVIORAL|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
58470224|NCT05458908|DIAGNOSTIC_TEST|Non-contrast cranial MDCT head scan|Non-contrast cranial MDCT imaging for visualization of the brain parenchyma (the choice of the device is up to the investigator)
58470225|NCT05458908|DIAGNOSTIC_TEST|Non-contrast syngo DynaCT Sine Spin head scan and application software|Non-contrast syngo DynaCT Sine Spin imaging for visualization of the brain parenchyma with ARTIS icono biplane angiography system and syngo application software with syngo DynaCT Sine Spin 3-D head imaging protocol.
58470226|NCT05195398|DEVICE|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
58470227|NCT05195398|DEVICE|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
58470228|NCT06585046|PROCEDURE|pancreatic surgery|patients who did pancreas-related surgery
58470229|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule]|1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.
58470230|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]|"1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months."
58470231|NCT06587048|PROCEDURE|periapical surgery|In piezo group, the periapical surgery will be performed using piezoelectric device.
58470232|NCT06587048|PROCEDURE|periapical surgery|In conventional bur group, the periapical surgery will be performed using rotary burs.
58470233|NCT05118022|OTHER|Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system|Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
58470234|NCT01404741|PROCEDURE|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
58470235|NCT01404741|PROCEDURE|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
58470236|NCT06603441|DIAGNOSTIC_TEST|Samsung Galaxy Watch|Samsung Galaxy Watch technology to monitor sleep patterns, oxygen saturation, PPG, and heart rate variability amongst other physiologic parameters.
58470237|NCT00530478|DRUG|Donepezil|
58470238|NCT05225038|OTHER|Exercise|Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.
58470239|NCT05225038|DIETARY_SUPPLEMENT|Nutritional|Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.
58470240|NCT05225038|BEHAVIORAL|Behavioral Medicine|"Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support."
57778478|NCT05542381|DRUG|Loteprednol Etabonate Ophthalmic Gel [Lotemax]|Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
58470241|NCT05225038|BEHAVIORAL|Smoking Cessation|Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
58470242|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - curved 11508AAK|11508AAK Miniature straight forward telescope 0-degree set, curved, diameter 3.3 millimeter, length 30 centimeter, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 French., remote eyepiece, fiber optic light transmission incorporated.
58470243|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - straight 11506AAK|11506AAK Miniature straight forward telescope 0-degree, straight, diameter 3.3 millimeter, length 30 cm, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 french, remote eyepiece, fiber optic light transmission incorporated.
58470244|NCT06480747|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
58470245|NCT05048459|OTHER|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
58470246|NCT05048459|OTHER|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
58470247|NCT05048459|OTHER|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
58470248|NCT04097470|DRUG|Decitabine|Decitabine dosage 20mg/m2 i.v.
58470249|NCT04097470|DRUG|Midostaurin|Midostaurin 50 mg b.i.d.
58470250|NCT06599177|OTHER|Informational leaflet|"An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services."
58470251|NCT01870206|BIOLOGICAL|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
58470252|NCT01870206|BIOLOGICAL|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
58470253|NCT02800668|DEVICE|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
58470254|NCT04252911|OTHER|Bispectral index score|Bis value from two sites gives similar results
58470255|NCT00412984|DRUG|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
58470256|NCT00412984|DRUG|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
58470257|NCT06313736|BEHAVIORAL|Action Brings Change Project (15-minute adult version)|The ABC Project is a self-guided online single-session intervention based on principles of behavioral activation. In a slightly different form intended for adolescents, it has demonstrated efficacy in several studies. Its adult version has also shown some efficacy.
58470258|NCT06313736|BEHAVIORAL|Action Brings Change Project (10-minute adult version)|This is a 10-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
58470259|NCT06313736|BEHAVIORAL|Action Brings Change Project (6-minute adult version)|This is a 6-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
58470260|NCT06313736|BEHAVIORAL|Action Brings Change Project (2-minute adult version)|This is a 2-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
58470261|NCT05856734|DEVICE|Weight and body composition change|1- Anthropometric Measurements: Body Weight (BW), Body Mass Index (BMI), Sitting Height Ratio (SHR), Waist to Hip Ratio (WHR), Finger Ratio (FR), Body Fat (BF%), and Weight-for-age growth charts. (Single measure)
58470262|NCT05856734|BEHAVIORAL|Change in dietary intake|"1. 24-hour recalls using Intake24 (online survey) over 3-day.~2. Self reported questionnaire. (Single measure)"
58470263|NCT05856734|DEVICE|Change in physical activity|"1. ActiGraph GT9X Link accelerometer over 7-day.~2. Self reported questionnaire. (Single measure)"
58470264|NCT05856734|BEHAVIORAL|Change in stress|1- Self reported questionnaire. (Single measure)
58470265|NCT05856734|BEHAVIORAL|Change in socio-demographic characteristics|1- Self reported questionnaire. (Single measure)
58470266|NCT05856734|DEVICE|Change in sleep|ActiGraph GT9X Link accelerometer over 7-day. (Single measure)
58470267|NCT06405932|COMBINATION_PRODUCT|Mental Fitness Training Camp|The Mental Fitness Training camp employs and incorporates core learning content derived from Cognitive Behavioral Therapy and Mindfulness. The program comprises nine thought animations, emotional diary, daily breathing exercises, and pleasure lists.
58470268|NCT01861314|DRUG|Bortezomib|Given SC
58470269|NCT01861314|DRUG|Decitabine|Given IV
58470270|NCT01861314|OTHER|Laboratory Biomarker Analysis|Correlative studies
58470271|NCT01861314|OTHER|Pharmacological Study|Correlative studies
58470272|NCT01861314|DRUG|Sorafenib Tosylate|Given PO
58470273|NCT06184061|COMBINATION_PRODUCT|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
58470274|NCT06593964|DEVICE|Thermosensitive Nanogel Embolic Agent|Thermosensitive Nanogel Embolic Agent
58470275|NCT01460212|DRUG|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
58470276|NCT01460212|BEHAVIORAL|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
58470277|NCT02486718|DRUG|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
58470278|NCT02486718|DRUG|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
57778479|NCT05542381|OTHER|Refresh Lubricant Eye Drops [Artificial Tears]|REFRESH® Brand Lubricant Eye Drops are artificial tears. In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
58470279|NCT02486718|DRUG|Vinorelbine|Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
58470280|NCT02486718|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
57778480|NCT03435458|COMBINATION_PRODUCT|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
58470281|NCT02486718|DRUG|Gemcitabine|Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
58470282|NCT02486718|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
58470283|NCT03844347|BEHAVIORAL|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
58470284|NCT05760365|OTHER|3D printed educational model|3D printed cardiac catheterization model
58470285|NCT05760365|OTHER|Slide-based presention|Slide-based presention
58470286|NCT00580619|OTHER|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
58470287|NCT00580619|OTHER|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
58470288|NCT00580619|DRUG|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
58470289|NCT00580619|DRUG|methyldopa|Aldomet oral twice a day for 12 weeks
58470290|NCT05449418|BEHAVIORAL|Full Intervention|A small group of employees who work at facilities randomized to this arm will be invited to develop tailored COVID-19 vaccination promotion materials in teams with other long-term care staff sharing the same or similar language and/or cultural affinity. These employees will also help promote these materials to all of the employees who work at their facilities.
58470291|NCT05449418|OTHER|Enhanced Usual Care|Employees who work at facilities randomized to this arm will see COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention \[CDC\] or other national organization.
58470292|NCT03842358|DEVICE|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
58470293|NCT04019379|OTHER|High Phosphorus Diet|Controlled research diet of high phosphorus (with low calcium)
58470294|NCT04019379|OTHER|Low Phosphorus Diet|Controlled research diet of low phosphorus (with low calcium)
58470295|NCT06600061|OTHER|Erector Spinae Plane Block|Patients will receive erector spinae plane block after induction of anesthesia.
58470296|NCT06056596|DRUG|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
58470297|NCT06056596|DRUG|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
58470298|NCT05889104|OTHER|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
58470299|NCT05889104|OTHER|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
58470300|NCT02275702|DRUG|Dexamethasone IV|It will be administered at the induction of the anesthesia
58470301|NCT02275702|DRUG|Saline solution|
58470302|NCT03365414|BIOLOGICAL|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
58470303|NCT03365414|DRUG|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
58470304|NCT06070779|OTHER|neuro linguistic programming|neuro linguistic programming
58470305|NCT05857995|BEHAVIORAL|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program|KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
58470306|NCT05857995|BEHAVIORAL|Enhanced Usual Care|EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
58470307|NCT06600958|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
58470308|NCT00370734|DRUG|Botulinum toxin A injection|
58470309|NCT04557410|DRUG|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
58470310|NCT00000211|DRUG|Buprenorphine|
58470311|NCT03548532|DEVICE|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
58470312|NCT05535257|DEVICE|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
57778481|NCT03435458|DRUG|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
57778482|NCT04615208|DIAGNOSTIC_TEST|suspected of COVID-19 infection|suspected of COVID-19 infection
57778483|NCT02164162|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
57778484|NCT02164162|OTHER|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
57778485|NCT02878213|DEVICE|D700 System|Atrial Fibrillation Ablation Procedure
57778486|NCT02982720|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
57778487|NCT02982720|DRUG|Sylatron|Sylatron will be administered subcutaneously.
58470313|NCT06599528|DRUG|T-R (Test-Reference drug)|T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
57778488|NCT02228525|DRUG|selinexor (KPT-330)|
57778489|NCT05601635|DIETARY_SUPPLEMENT|ButyraGen™|ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
57778490|NCT02030275|DRUG|RXI-109|surgery.
57778491|NCT02030275|DRUG|Placebo|surgery.
57778492|NCT03410290|OTHER|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
57778493|NCT03902938|BIOLOGICAL|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
57778494|NCT03902938|OTHER|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
57778495|NCT00358215|DRUG|Darbepoetin alfa|Administered by subcutaneous injection
57778496|NCT00358215|DRUG|Placebo|Placebo subcutaneous injection
57778497|NCT02265380|DEVICE|Placement of IV catheter|
57778498|NCT02791490|DRUG|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
57778499|NCT02791490|DRUG|Placebo|Oral tablet, once daily at approximately the same time each day
57778500|NCT02791490|DRUG|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
57778501|NCT00910806|DRUG|TMC207; nevirapine|
57778502|NCT00867490|DRUG|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
57778503|NCT00867490|DRUG|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
57778504|NCT00867490|DRUG|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
57778505|NCT04293809|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
58470314|NCT06599528|DRUG|R-T (Reference-Test drug)|R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
57778506|NCT04293809|DRUG|Bupivacaine Hydrochloride|1.3%, 13.3 mg/mL
57778507|NCT06403839|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
57778508|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
57778509|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
57778510|NCT02040090|DRUG|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
58470315|NCT06247124|BEHAVIORAL|multi-channel communication campaign to promote HPV vaccination|High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
57778511|NCT05640167|BEHAVIORAL|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
57778512|NCT00259324|BEHAVIORAL|Diet and Activity|Diet and Activity
57778513|NCT05784662|BEHAVIORAL|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
57778514|NCT04333173|PROCEDURE|endovascular procedure|Endovascular therapies for erectile dysfunction
58470316|NCT04246788|OTHER|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
58470317|NCT04246788|OTHER|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
58470318|NCT03809728|PROCEDURE|endoscopic biopsy|Per-endoscopic biopsies
58470319|NCT03809728|PROCEDURE|samples of the oral cavity|7 samples of the oral cavity with a swab
58470320|NCT03809728|PROCEDURE|Samples of the resected specimen|if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
58470321|NCT01210313|OTHER|Physical exercise|Defined exercise program
58470322|NCT01729780|DEVICE|EEG-NF|
58470323|NCT03735537|DRUG|Teriparatide Pen Injector|
58470324|NCT03735537|DRUG|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
58470325|NCT06508385|OTHER|Breathing exercise|"Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds)."
58470326|NCT06250205|DRUG|Obicetrapib|oral administration
58470327|NCT06250205|DRUG|Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)|oral administration
58470328|NCT06250205|DRUG|Drospirenone / Ethinyl Estradiol (COC)|oral administration
58470329|NCT04759274|DEVICE|Diuretic Tuner|Mobile device application for diuretic dose titration
58470330|NCT04921241|OTHER|In Utero Exposure to SARS-CoV-2|Born to mother with SARS-CoV-2 infection during pregnancy
58470331|NCT06485479|BEHAVIORAL|Intervention ads|The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
58470332|NCT06485479|BEHAVIORAL|Control ads|The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
58470333|NCT06527560|DRUG|Cefuroxime|Intravenous cefuroxime 750 mg every 8 hours
58470334|NCT06527560|DRUG|Cefuroxime Axetil|Oral cefuroxime 500 mg every 12 hours
58470335|NCT00270985|BEHAVIORAL|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
57778515|NCT03202030|PROCEDURE|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
58470336|NCT00270985|BEHAVIORAL|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
58470337|NCT00001711|PROCEDURE|MRI|scan of healthy volunteers.
57778516|NCT03202030|PROCEDURE|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
57778517|NCT05298462|DIAGNOSTIC_TEST|Livzon Rapid Antibody Test for COVID-19|Point-of-care Rapid Antibody Test for COVID-19
58470338|NCT03020303|DRUG|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
58470339|NCT03020303|DRUG|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
58470340|NCT05407389|DRUG|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
58470341|NCT02338674|DRUG|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
58470342|NCT02338674|DRUG|Tenofovir|tenofovir administered at least 48 weeks
58470343|NCT05720143|PROCEDURE|Osseodensification|Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
58470344|NCT05720143|PROCEDURE|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
57778518|NCT06039228|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.
57778519|NCT00662493|BEHAVIORAL|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
57778520|NCT00662493|BEHAVIORAL|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
57778521|NCT00240838|DRUG|acetaminophen extended release caplets|
58470345|NCT05720143|PROCEDURE|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
58470346|NCT03173560|DRUG|lenvatinib|lenvatinib capsules.
58470347|NCT03173560|DRUG|everolimus|everolimus tablets.
58470348|NCT04615949|DRUG|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
58470349|NCT04615949|DRUG|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
58470350|NCT00543036|DEVICE|H-Coil deep TMS|
58470351|NCT06474676|DRUG|Cyclophosphamide|Given by IV
58470352|NCT06474676|DRUG|T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy|Given by IV
58470353|NCT03593525|OTHER|SPARK|see above
58470354|NCT06159790|DRUG|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
58470355|NCT06159790|DRUG|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
58470356|NCT06118866|DRUG|placebo-Q2W|placebo, 0mg，SC，Q2W，12 cycles
58470357|NCT06118866|DRUG|HMI-115-120mg-Q4W|HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
58470358|NCT06118866|DRUG|HMI-115-240mg-Q4W|HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
58470359|NCT06118866|DRUG|HMI-115, 240mg-Q2W|HMI-115, 240mg，SC，Q2W，12 cycles
58470360|NCT02548546|DEVICE|ECHO|Imaging
58470361|NCT02548546|DEVICE|ECG-gated MRA|Imaging
58470362|NCT06590844|DRUG|Injectable coenzyme I|On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
58470363|NCT05338528|BEHAVIORAL|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
58470364|NCT01700413|DRUG|Idarubicin|
58470365|NCT04576156|DRUG|Imetelstat|Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
58470366|NCT04576156|DRUG|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
58470367|NCT06592235|OTHER|No intervention|No intervention
58470368|NCT03076697|DIAGNOSTIC_TEST|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
58470369|NCT03016533|DRUG|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 50 mg tablets.
58470370|NCT03016533|DRUG|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
58470371|NCT03016533|DRUG|ABC/DTG/3TC immediate release tablets|ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
58470372|NCT03016533|DRUG|ABC/DTG/3TC film-coated dispersible tablets|ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
58470373|NCT06562205|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
58470374|NCT06562205|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
58470375|NCT05512897|PROCEDURE|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
58470376|NCT05514548|DRUG|INV-202|INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
58470377|NCT05514548|DRUG|Placebo|Placebo Matching size and number of tablets
58470378|NCT00459459|PROCEDURE|Fine needle aspiration of the thyroid|
58470379|NCT05379803|DRUG|Furmonertinib|furmonertinib 160 mg orally QD
58470380|NCT05543265|BEHAVIORAL|Default appointment scheduling|Default primary care appointment scheduling
58470381|NCT05543265|BEHAVIORAL|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
58470382|NCT05543265|BEHAVIORAL|Nudge Reminders|Primary care appointment reminders
58470383|NCT04515615|DRUG|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
58470384|NCT04515615|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
58470385|NCT04515615|DRUG|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
58470386|NCT05079334|BEHAVIORAL|MeTree Questionnaire|"MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature."
58470387|NCT05322343|OTHER|Questionnaires|"Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer):~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits.~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
57778522|NCT02552433|DIETARY_SUPPLEMENT|protein intake assessment and optimisation|
58490691|NCT03460262|DEVICE|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
57778523|NCT00502996|DRUG|Methotrexate|\>=15 mg po/week
58470388|NCT05322343|OTHER|Fasting blood sampling.|In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
58470389|NCT05322343|OTHER|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
58470390|NCT05322343|OTHER|Urine samples|During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
58470391|NCT05322343|OTHER|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
58470392|NCT05322343|OTHER|Nasal microbiota|Nasal or nasopharyngeal swab
58470393|NCT05322343|OTHER|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
58470394|NCT05322343|OTHER|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
58470395|NCT05322343|OTHER|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
58470396|NCT05882591|PROCEDURE|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
58470397|NCT03768128|DEVICE|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
58470398|NCT04786743|OTHER|endoscopic intervention|performing endoscopy
58470399|NCT04074044|BEHAVIORAL|BHmApp|Use of BHmApp for bladder education and training in pregnancy
58470400|NCT05058365|BEHAVIORAL|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
57778524|NCT00502996|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
57778525|NCT06210763|BEHAVIORAL|Threshold IMT and traditional physical therapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
57778526|NCT06210763|BEHAVIORAL|traditional physiotherapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
57778527|NCT02836613|BIOLOGICAL|Galcanezumab|Administered SC
57778528|NCT02044237|BEHAVIORAL|Decoupling|
58470401|NCT04640545|DRUG|LBL-007|LBL-007 will be administered intravenously every two weeks (Q2W) at doses of Dose A, Dose B, Dose C,Dose D .
58470402|NCT04640545|DRUG|Toripalimab|Toripalimab Injection will be administered by intravenously (Q2W) by the fixed dose of 3 mg/kg .
58470403|NCT04640545|DRUG|Axitinib Tablets|Axitinib Tablets 5mg and Axitinib Tablets 1mg(On-demand administration)
58470404|NCT06594484|OTHER|Ml Based Algorithm 1|The values in the ML algorithm were selected according to logistic regression analysis and the values used in the other six scores tested. The success rate of the constructed networks correct predictions was considered as the success rate of the algorithm. The usefulness of the test was determined through AUROC analysis. Two algorithms were tested in our study. In the first algorithm (ML1), the dependent variable was erythrocyte suspension (ES) consumption, and the independent variables included patients; demographic data, laboratory data, and operational data
58470405|NCT06594484|OTHER|Ml Based Algroithm 2|is an Ml algorithm created by combining commonly used bleeding scores
57778529|NCT02044237|BEHAVIORAL|Progressive relaxation|
57778530|NCT00002015|DRUG|Ganciclovir|
57778531|NCT03499574|BEHAVIORAL|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
57778532|NCT03499574|BEHAVIORAL|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
58470406|NCT06594484|OTHER|Bleeding Scores|ACTION CRUSCADE TRACK WILL-BLEED PAPWORTH TRUST ACTAPORT skores used to predict ES need
58470407|NCT05759728|BIOLOGICAL|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10\^7 cells - intravenous infusion
58470408|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10\^8 cells - intravenous infusion
58470409|NCT05759728|BIOLOGICAL|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10\^8 cells - intravenous infusion
58470410|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10\^9 cells - intravenous infusion
58470411|NCT05759728|BIOLOGICAL|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10\^7 cells - intravenous infusion
58470412|NCT06508580|BEHAVIORAL|Component 1: Calorie Goal Attainment|On weeks that participants are randomized to receive this component, they will be provided with feedback on the number of days that they met their calorie goal.
58470413|NCT06508580|BEHAVIORAL|Component 2: Diet Quality|On weeks that participants are randomized to receive this component, they will receive three comments regarding specific dietary choices that may impact weight loss success, including reinforcing comments for behaviors consistent with weight loss and potential areas for change.
58470414|NCT06508580|BEHAVIORAL|Component 3: Physical Activity Goal Attainment|On weeks that participants are randomized to receive this component, they will receive feedback related to attainment of that week's physical activity goal.
58470415|NCT06508580|BEHAVIORAL|Component 4: Goal Setting|On weeks that participants are randomized to receive the goal setting component, they will be asked to complete an open-text prompt encouraging them to set a specific weight-related behavior change goal for the next week.
58470416|NCT05519241|DRUG|PLZ4-coated paclitaxel-loaded micelles (PPM)|PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
58470417|NCT06588335|DRUG|BTLA inhibitor (JS004)|BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
58470418|NCT06588335|DRUG|Toripalimab|Toripalimab:240mg,intravenous infusion, d1, Q3W;
58470419|NCT06588335|DRUG|Paclitaxel, Cisplatin|Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
58470420|NCT01519908|DEVICE|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
58470421|NCT05300503|BEHAVIORAL|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
58470422|NCT03043794|RADIATION|Stereotactic Body Radiation Therapy SBRT|Stereotactic Body Radiation Therapy to the breast to 21 Gy
58470423|NCT05194969|DEVICE|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
58470424|NCT05194969|DEVICE|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
58470425|NCT03891134|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
58470426|NCT04150614|DRUG|Granisetron Transdermal Patch|Antiemetic
57778533|NCT00787722|PROCEDURE|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
57778534|NCT00787722|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
58470427|NCT04150614|DRUG|Intravenous Dexamethasone|Antiemetic
58470428|NCT04150614|DRUG|Ondansetron|ondansetron
58470429|NCT06088823|OTHER|Heart surgery|Adult cardiac surgery
58470430|NCT06339099|OTHER|Conventional physical therapy program|This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
58470431|NCT06339099|OTHER|Loaded gait training|An extra weight was added around the distal legs during gait training in the intervention group. This weight began at 0.5 kg and was gradually increased every two weeks to a maximum of 2 kg
58470432|NCT04673643|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
57778535|NCT00787722|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
57778536|NCT00787722|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
57778537|NCT00787722|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
57778538|NCT00787722|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
58470433|NCT04673643|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
58470434|NCT03494660|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
58470435|NCT05922137|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
58470436|NCT05922137|BEHAVIORAL|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
58470437|NCT04522765|DIAGNOSTIC_TEST|Assessment of 24 hour blood pressure and arterial stiffness|Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device
58470438|NCT06595979|DRUG|Polymyxin B|Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
58470439|NCT06600438|DEVICE|Slow-SPEED app|Gamified motivational smartphone app
58470440|NCT03848325|BEHAVIORAL|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
58470441|NCT05750264|DRUG|Ibuprofen|800 mg of IV ibuprofen
58470442|NCT00734149|DRUG|Bortezomib|
58470443|NCT00734149|DRUG|Melphalan|
58470444|NCT00734149|DRUG|Prednisone|
58470445|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 2 weeks
58470446|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 4 weeks
58470447|NCT06007872|DEVICE|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
58470448|NCT04742491|DRUG|Immediate Intervention Arm Truvada in the US|Truvada in the United States
58470449|NCT04742491|DRUG|Deferred Intervention Arm Truvada in the US|Truvada in the United States
58470450|NCT04742491|DRUG|Immediate Intervention Arm Truvada in Brazil|Truvada in Brazil
58470451|NCT04742491|DRUG|Deferred Intervention Arm Truvada in Brazil|Truvada in Brazil
58470452|NCT04742491|DRUG|Immediate Intervention Arm Descovy in the US|Descovy in the United States
58470453|NCT04742491|DRUG|Deferred Intervention Arm Descovy in the US|Descovy in the United States
58470454|NCT06598579|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a form of psychotherapy that combines principles of cognitive therapy with mindfulness practices focused on increasing non-judgemental awareness of the present moment. It was designed to help individuals, particularly those with depression, stop rumination and a cycle of negative thought patterns that lead to emotional distress including depression. It is a well established depression EBT. The Vietnamese version of the program (MBCT-VN) is a group treatment involving from five to ten participants (depending on how many participants are able to be recruited) per group.
58470455|NCT06598579|BEHAVIORAL|Treatment-as-usual involving Buddhist meditation|MBCT and other mindfulness interventions were originally derived from Buddhist meditation, modifed to be non-secular and focused on treatment of depression and other mental health and behavioral problems rather than on spiritual development. In the present study, a treatment-as-usual condition involving Buddhist meditation will be used. The project will assess the characteristics of the Buddhist meditation delivered for the control group participants at pagoda meditation retreats but will not influence this control condition in any way.
58470456|NCT05919875|BEHAVIORAL|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~1. Awareness and automatic pilot~2. Living in our heads~3. Being present in the body~4. Recognizing aversion~5. Allowing / Letting be~6. How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
58470457|NCT05919875|BEHAVIORAL|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
58470458|NCT06598163|DEVICE|Five Lives MED|"Five Lives MED is a mobile application that can be installed on smartphones and tablets using the Android and/or iOS operating systems for use at home.~The app offers structured sessions that can be completed once per day. Once the session is completed, the app also offers optional access to additional cognitive training exercises and educational articles.~The intervention sessions begins with a Habit Quest, a physical activity habit building tool delivered through a chat bot. Following the Habit Quest, the participant is guided through a series of gamified cognitive training exercises aimed at improving attention, memory, language and executive function."
58470459|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 4-7 days per week
58470460|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 1 day per week
58470461|NCT02194387|OTHER|Internet-Based Intervention|Receive email coaching
58470462|NCT02194387|OTHER|Internet-Based Intervention|Participate in social networking
58470463|NCT02194387|OTHER|Laboratory Biomarker Analysis|Correlative studies
58470464|NCT02194387|OTHER|Questionnaire Administration|Ancillary studies
58470465|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
58470466|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
58470467|NCT06600464|DIAGNOSTIC_TEST|Ultrasound|The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound.
58470468|NCT06600464|OTHER|Assessment of Muscle Strength in Both Hands|Muscle strength in both hands was evaluated using grip strength measured with a dynamometer (Jamar Hydraulic Hand Dynamometer, Nottinghamshire, UK)
58470469|NCT06600464|OTHER|Assessment of Pain Threshold|Pressure pain threshold (PPT) for painful and non-painful finger joints was assessed using a hand-held algometer
58470470|NCT04094285|DRUG|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
58470471|NCT04094285|DRUG|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
58470472|NCT06279351|DRUG|Thalidomide+cetuximab+FOLFOX/FOLFIRI|Thalidomide+cetuximab+FOLFOX/FOLFIRI
58470473|NCT06698653|DEVICE|SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
58470474|NCT06698653|DEVICE|Over bed pole hoist (control device)|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
58470475|NCT06477536|DRUG|HB0034|300mg, i.v. Q4W
58470476|NCT05583552|DRUG|Imetelstat sodium|Intravenous injection
58470477|NCT03270982|DEVICE|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
58470478|NCT00355108|DRUG|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
58470479|NCT02388308|DEVICE|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
58470480|NCT02798666|OTHER|High intensity exercise training|Exercise training using sprint interval exercise
58470481|NCT02798666|OTHER|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
58470482|NCT01263769|DRUG|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
58470483|NCT06463795|DEVICE|tDCS|active anodal tDCS
58470484|NCT06463795|DEVICE|Sham tDCS|sham anodal tDCS
58470485|NCT06403514|OTHER|Psychological Skills Training (PST)|PST will include self-talk, imagery, goal-setting and arousal regulation (Biofeedback)
58470486|NCT06261021|DRUG|Ruxolitinib 1.5% cream|Topical application of Ruxolitinib 1.5% cream
58470487|NCT06261021|PROCEDURE|Application without occlusion in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
58470488|NCT06261021|PROCEDURE|Application under occlusion at night in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
58470489|NCT06261021|PROCEDURE|Application under occlusion at night in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
58470490|NCT06261021|PROCEDURE|Application without occlusion in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
58470491|NCT06593340|BEHAVIORAL|Messenger 1|The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
58470492|NCT06593340|BEHAVIORAL|Messenger 2|The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
58470493|NCT06593340|BEHAVIORAL|Format 1|The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.
58470494|NCT06593340|BEHAVIORAL|Format 2|The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
58470495|NCT06592716|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free HPV-DNA.
58470496|NCT04196777|BEHAVIORAL|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
58470497|NCT00034177|DRUG|S-8184 Paclitaxel Injectable Emulsion|
58470498|NCT00034177|DRUG|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
58470499|NCT05225090|OTHER|Smartphone App|"Medisafe is a Med_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
58470500|NCT05743400|DRUG|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
58470501|NCT05743400|BIOLOGICAL|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~* 1 after each end of perfusion ;~* 1 though concentration before each perfusion ;~* 3 blood samples in 3 different days during the first week;~* 1 weekly for 2 weeks post HSCT."
58470502|NCT04375150|DRUG|Tyrosine kinase inhibitor (TKI)|TKIs
58470503|NCT04375150|DRUG|Immuno-oncology (IO)|IOs
58470504|NCT00671294|DRUG|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
58470505|NCT06478550|DRUG|Semaglutide|Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
58470506|NCT04513951|DRUG|5Fluorouracil|phase II
58470507|NCT04513951|DRUG|L-leucovorin|phase II
58470508|NCT04513951|DRUG|Irinotecan|phase II
58470509|NCT04513951|DRUG|Oxaliplatin|phase II
58470510|NCT04513951|DRUG|Cetuximab|phase II
58470511|NCT04513951|DRUG|Avelumab|phase II
58470512|NCT01504815|DRUG|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
58470513|NCT01504815|RADIATION|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
58470514|NCT01504815|RADIATION|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
58470515|NCT05628363|DEVICE|Ethos Varian treatment system|Device that will be used to administer radiotherapy
58470516|NCT05628363|RADIATION|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
57778539|NCT00787722|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
57778540|NCT01995357|DEVICE|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
57778541|NCT01995357|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
57778542|NCT01995357|DEVICE|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
57778543|NCT00489723|DRUG|tamsulosin 0.4mg|
57778544|NCT03851913|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
57778545|NCT02337205|DRUG|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
58470517|NCT05628363|DRUG|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
57778546|NCT02218021|DRUG|Samidorphan|
58470518|NCT04837443|BEHAVIORAL|Rubber hand illusion|Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
58470519|NCT06006299|DEVICE|transauricular Vagus Nerve Stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.
58470520|NCT02678182|DRUG|Capecitabine|1250 mg/m2/day, 21 day cycle
58470521|NCT02678182|DRUG|MEDI4736 (Durvalumab)|IV treatment on days 1\&15 of 28 day cycle
58470522|NCT02678182|DRUG|Trastuzumab|6mg/kg on day 1 cycle every 21 days
58470523|NCT02678182|DRUG|Rucaparib|600mg PO twice daily
57778547|NCT02218021|DRUG|Placebo|
57778548|NCT02218021|DRUG|Oxycodone|
57778549|NCT05184738|OTHER|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
57778550|NCT05184738|OTHER|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
57778551|NCT01651936|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
57778552|NCT01651936|DRUG|Methotrexate|MTX dosed at the stable dose received upon study entry
58470524|NCT02678182|DRUG|Ramucirumab|ramucirumab 8mg/kg IV day 1 and day 8
58470525|NCT03793244|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
58470526|NCT03153592|PROCEDURE|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
58470527|NCT03153592|PROCEDURE|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
58470528|NCT04979546|OTHER|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
58470529|NCT04979546|OTHER|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
58470530|NCT05662462|DEVICE|DEXCOM G7 PRO Continuous Glucose Monitor|Participants in the intervention arm will be provided with DEXCOM® G7 PRO CGM sensors and transmitters. The Dexcom G7 CGM system is accurate and safe in pregnant individuals with diabetes. Participants will be taught how to place and remove CGM sensors by a trained research nurse, and will be given sensors to change themselves at home every 10 days. Of note, the DEXCOM® G7 PRO can be applied as a patch on the abdomen, arm, or upper buttocks, is well-tolerated in pregnancy, and does not require calibration. Our mHealth app will allow for wireless synchronization with the CGM sensor so that data are seamlessly reported back to the healthcare team.
58470531|NCT05662462|DEVICE|Patient mHealth app linked to a provider dashboard|The mHealth app is based on our team's prototype intervention developed at our study site. The mHealth app provides diverse functions, including education, reminders, care goals, care pathway recommendations, CGM data and PROs reporting and monitoring, messaging and video conferencing, and a calendar function. Content is based on clinical guidelines for diabetes in pregnancy. Participants will be directed to appropriate resources and online learning to help them navigate the app and its resources. PROs in the mHealth app will be embedded to address health and social needs, and rule-based algorithms will provide tailored care goals, show care pathways, and establish the frequency of elicited PROs.
58470532|NCT05662462|BEHAVIORAL|Care team coaching for medical and social needs (HUB)|"Participants will be screened at enrollment and throughout the intervention for social needs using a survey adapted from validated instruments, such as the Accountable Health Communities Health-Related Social Needs Screening Tool. The care team will refer participants with affirmative responses to the HUB through the provider dashboard to address social needs (e.g., food insecurity, housing, employment). HUB community health workers will perform comprehensive social needs assessments and connect participants to community resources through care pathways, a defined action plan addressing patient needs which is recorded and tracked."
58470533|NCT05662462|DEVICE|Provider dashboard|The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
58470534|NCT06594120|BEHAVIORAL|Multimodal rehabilitation with additional work specific training|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
58470535|NCT04151212|DRUG|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
58470536|NCT05901298|DEVICE|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
58470537|NCT06603467|PROCEDURE|non-guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested without guide
58470538|NCT06603467|PROCEDURE|guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested with digital guide
58470539|NCT06585800|OTHER|sample collection|blood and/or tissue collection
58470540|NCT03733626|COMBINATION_PRODUCT|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
58470541|NCT03733626|COMBINATION_PRODUCT|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
58470542|NCT06036745|DRUG|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
58470543|NCT05734391|DIAGNOSTIC_TEST|Routine Infection control|routine part of hospital IPC activities
58470544|NCT04526730|DRUG|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3
58470545|NCT04526730|DRUG|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
57778553|NCT01651936|DRUG|Dose-match placebo|Dose-matched placebo dosed orally BID
57778554|NCT03652480|DRUG|MethylPREDNISolone Acetate 40 MG/ML|
58470546|NCT04526730|DEVICE|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
58470547|NCT06590012|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
58470548|NCT06590012|DRUG|Tertinat|Participants will take Tertinat capsules in addition to standard treatment for a year.
58470549|NCT03649880|DRUG|¹⁸F-Fluoromisonidazole|Given IV
58470550|NCT03649880|PROCEDURE|Computed Tomography|Undergo PET/CT
58470551|NCT03649880|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI or PET/CT
58470552|NCT03649880|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
58470553|NCT03649880|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
58470554|NCT05468099|OTHER|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
58470555|NCT05468099|DEVICE|High volume evacuator|High volume evacuator held by assistant to capture dental spray
58470556|NCT05468099|DEVICE|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
58470557|NCT05468099|DEVICE|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
58470558|NCT04251715|DRUG|Dexamethasone|Given intraarterially via HAI pump
58470559|NCT04251715|DRUG|Floxuridine|Given intraarterially via HAI pump
58470560|NCT04251715|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
58470561|NCT04251715|DRUG|Irinotecan|Given IV
58470562|NCT04251715|DRUG|Leucovorin|Given IV
58470563|NCT04251715|DRUG|Oxaliplatin|Given IV
58470564|NCT04251715|OTHER|Quality-of-Life Assessment|Ancillary studies
58470565|NCT04057144|BEHAVIORAL|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
58470566|NCT04057144|BEHAVIORAL|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
58470567|NCT04057144|BEHAVIORAL|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
58470568|NCT04434768|BIOLOGICAL|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
58470569|NCT04910048|OTHER|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
58470570|NCT04910048|OTHER|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
58470571|NCT06498583|DRUG|Ropivacaine|0.25 % ropivacaine ( 0.5ml / kg )
58470572|NCT06498583|PROCEDURE|erector spinae plane block|After the operation, unilateral erector spinae plane block was performed at the T5 level under ultrasound guidance.
58470573|NCT06498583|PROCEDURE|Incision infiltration of local anesthesia|After the operation, Incision infiltration of local anesthesia is performed around the surgical incisions.
58470574|NCT06602700|BEHAVIORAL|HIIT|high-intensity interval training
58470575|NCT06602700|BEHAVIORAL|MICT|moderate-intensity continuous training
58470576|NCT03679923|DIETARY_SUPPLEMENT|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
58470577|NCT03679923|DIETARY_SUPPLEMENT|Placebo|Placebo
58470578|NCT04892823|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58470579|NCT04892823|OTHER|Electronic Health Record Review|Review of medical records
58470580|NCT04892823|OTHER|Questionnaire Administration|Complete questionnaires
58470581|NCT00520949|DRUG|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
58470582|NCT00520949|DRUG|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
57778555|NCT02242240|DRUG|Formoterol twice daily|
57778556|NCT02242240|DRUG|Formoterol once daily|
57778557|NCT02242240|DRUG|Tiotropium once daily|
57778558|NCT02242240|DRUG|Placebo|
58470583|NCT00520949|DRUG|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
58470584|NCT00520949|DRUG|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
58470585|NCT06598345|BEHAVIORAL|Routine Pet Fish Care|Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.
58470586|NCT06598345|BEHAVIORAL|Collaborative Communication|Parents and participants in the Collaborative Communication group will be given recommendations for how to conduct weekly meetings in a collaborative approach based on a modified version of the Minute Meeting protocol.
58470587|NCT06598098|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
58470588|NCT06594302|OTHER|Functional performance tests and scales measuring biopsychosocial characteristics|Functional performance tests and scales applications
58470589|NCT06598956|DRUG|TQ05105|TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
58470590|NCT00626106|DRUG|AMG 479|AMG 479 administered with exemestane or fulvestrant
58470591|NCT00626106|DRUG|Placebo|Placebo administered with either exemestane or fulvestrant
58470592|NCT04586530|BEHAVIORAL|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
58470593|NCT04586530|BEHAVIORAL|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
58470594|NCT06527469|OTHER|PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP|Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
58470595|NCT04029233|DEVICE|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
58470596|NCT06091163|BEHAVIORAL|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
58470597|NCT06091163|BEHAVIORAL|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
58470598|NCT03792633|BIOLOGICAL|huCART19|huCART19 infusion
58470599|NCT04347798|OTHER|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
58470600|NCT03025282|DRUG|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
58470601|NCT03025282|DRUG|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
58470602|NCT03025282|DRUG|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
58470603|NCT03025282|DRUG|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
58470604|NCT03025282|DRUG|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
58470605|NCT03025282|DRUG|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
58470606|NCT02325102|OTHER|No intervention|As this is an observational study, no intervention was conducted.
58470607|NCT03657628|OTHER|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
58470608|NCT02740946|OTHER|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
58470609|NCT03502928|OTHER|Motor Control|Neck Motor Control
58470610|NCT03502928|OTHER|Manual Therapy|Massage + Joint Mobilizations
58470611|NCT03502928|OTHER|Dry Needling|Dry Needling in Neck Muscles
58470612|NCT06220643|OTHER|resistance exercise|Progressive resistance exercise for 12 weeks
58470613|NCT06220643|DRUG|triamcinolone acetonide plus lidocaine|40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
58470614|NCT04758351|OTHER|Usual clinical practice|Based on European Respiratory Society guidelines on management for chronic cough.
58470615|NCT06503263|DRUG|Zanubrutinib plus Lenalidomide as Maintenance Therapy|Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
58470616|NCT06595576|DRUG|Cannabis - Placebo Dose (0 mg)|Participants will consume placebo cannabis edibles.
58470617|NCT06595576|DRUG|Cannabis - Low Dose (2 mg)|Participants will consume a low dose (2 mg) of cannabis edibles.
58470618|NCT06595576|DRUG|Cannabis - Medium Dose (10 mg)|Participants will consume a medium dose (10 mg) of cannabis edibles.
58470619|NCT06595576|DRUG|Cannabis - High Dose (20 mg)|Participants will consume a high dose (20 mg) of cannabis edibles.
58470620|NCT04139330|DRUG|NPC-06|Infuse NPC-06 intravenously
58470621|NCT05998018|DEVICE|pdSTIM System Therapy|Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
58470622|NCT05562791|DRUG|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
58470623|NCT05562791|DIAGNOSTIC_TEST|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
58470624|NCT06474767|BEHAVIORAL|P-CGS (Pediatric Collaborative Goal Setting)|Electronic questionnaire sent to participants ahead of a pediatric primary care well child visit, assessing goals for themselves and the child's health with prompt to share with providers during visit
58470625|NCT05123001|DEVICE|Biostrap arm band|The Biostrap mobile app will connect with the Biostrap arm band and temperature sensor.
58470626|NCT02764385|OTHER|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
58470627|NCT02764385|OTHER|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
58470628|NCT03736863|DRUG|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
58470629|NCT03736863|DRUG|Apatinib+ SHR-1316（Adebrelimab）|Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
58470630|NCT03736863|DRUG|SHR-1316（Adebrelimab）+SHR-A2009|SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
58470631|NCT06262412|BEHAVIORAL|Internet-delivered cognitive-behaviour therapy (ICBT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD and strategies to resolve possible ambivalence towards psychological treatment. The main goal of the treatment is to help the young person to stop avoiding anxiety-provoking situations (e.g., going to school or participating in social situations) by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals (e.g., excessive mirror-checking, camouflaging), known as response prevention. Every module also contains homework tasks that are meant to be completed between modules and mainly consist of exposure and response prevention (ERP) tasks based on the young person's individual goals."
58470632|NCT06262412|BEHAVIORAL|Internet-delivered relaxation treatment (IRT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD, how anxiety and stress are major contributors to BDD symptoms, and that targeting and reducing stress will have a beneficial impact on those symptoms. The main goal of the treatment is to teach the young person to relax in order to cope with anxiety and appearance concerns. The intervention mainly consists of a relaxation treatment and includes different relaxation skills such as deep breathing, progressive muscle relaxation, and imagery (cognitive relaxation). Every module also contains homework tasks that are meant to be completed between modules and mainly consist of relaxation tasks."
58470633|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
58470634|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
58470635|NCT05941702|BEHAVIORAL|Body Signal Integration Training|Information and protocol uploaded to documents.
58470636|NCT03594513|PROCEDURE|MCAF|Periodontal surgical technique to treat gingival recessions.
58470637|NCT03594513|PROCEDURE|PR|Restorative procedure to treat tooth structure loss.
58470638|NCT03594513|PROCEDURE|CTG|Autogenous graft harvested from palate placed in the surgical site.
58470639|NCT03594513|PROCEDURE|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
58470640|NCT03594513|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
58470641|NCT03594513|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
58470642|NCT06016803|DEVICE|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
58470643|NCT02254863|BIOLOGICAL|DUOC-01|Intrathecal administration of DUOC-01
58470644|NCT05632042|BEHAVIORAL|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
58470645|NCT06224205|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
58470646|NCT05035537|PROCEDURE|PGDT|The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
58470647|NCT03112681|DRUG|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
58470648|NCT03112681|DRUG|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
58470649|NCT03112681|DRUG|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
58470650|NCT05038475|DIAGNOSTIC_TEST|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
58470651|NCT00834977|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
58470652|NCT00834977|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
58470653|NCT00400179|DRUG|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
58470654|NCT00400179|DRUG|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
58470655|NCT05700669|DRUG|AsiDNA|All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.
58470656|NCT05700669|DRUG|Olaparib|Olaparib is given orally in combination with AsiDNA
58470657|NCT04576988|BIOLOGICAL|Sotatercept|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
58470658|NCT04576988|DRUG|Placebo|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
58470659|NCT04576988|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
58470660|NCT05841186|OTHER|Timing of pegfilgrastim administration|Timing of pegfilgrastim administration
58470661|NCT05612854|PROCEDURE|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
58470662|NCT05612854|DEVICE|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
58470663|NCT04590885|BEHAVIORAL|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
58470664|NCT04590885|BEHAVIORAL|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
58470665|NCT03614182|DEVICE|physical training concurrent with cognitive training|The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
58470666|NCT03614182|DEVICE|physical training followed by cognitive training|The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
58470667|NCT03614182|DEVICE|physical training without cognitive training|The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
58470668|NCT05569759|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
58470669|NCT05569759|DRUG|placebo|Subcutaneous injection of placebo
58470670|NCT05569759|DRUG|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
58470671|NCT06570577|PROCEDURE|Inter-semispinalis Plane Block|A nerve block targeting the dorsal rami of the cervical spinal nerves can help alleviate postoperative incisional pain.
58470672|NCT06570577|DRUG|Opioids|Routine Pain Management
58470673|NCT04297904|BEHAVIORAL|Sedentary behaviour|To assess sedentary behaviour each participant will wear an activity monitor (PAL Technologies, Scotland). The resident will wear the monitor on their right thigh for 24 hours per day over seven days continuously.
58470674|NCT04297904|DIAGNOSTIC_TEST|Urinary Incontinence|The presence of IU, assessed by the Minimum Data Set (MDS) version 3.0, and used together with the International Consultation on Incontinence Questionnaire-Short Form to characterize the incontinence.
58470675|NCT04323956|DRUG|Cyclophosphamide|Given IV
58470676|NCT04323956|DRUG|Doxorubicin Hydrochloride|Given IV
58470677|NCT04323956|DRUG|Parsaclisib|Given PO
58470678|NCT04323956|BIOLOGICAL|Pegfilgrastim|Given SC
58470679|NCT04323956|DRUG|Polatuzumab Vedotin|Given IV
58470680|NCT04323956|DRUG|Prednisone|Given PO
58470681|NCT04323956|BIOLOGICAL|Rituximab|Given IV
58470682|NCT04323956|DRUG|Vincristine Sulfate|Given IV
58470683|NCT03448926|OTHER|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
58470684|NCT03448926|DEVICE|7-gene biosignature|Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
58470685|NCT03387670|DRUG|Simvastatin|"* One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months"
58470686|NCT03387670|DRUG|Placebo|"* One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months"
58470687|NCT06596967|DEVICE|Heat therapy|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will be set to warm the water to 42°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
58470688|NCT06596967|DEVICE|Sham|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will warm the water to 33°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
58470689|NCT06589362|DEVICE|Transcutaneous auricular vagus nerve stimulation|In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve. In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.
58470690|NCT06437769|OTHER|reiki|effect of reiki application to women who have been hospitalized by ceserean during the hospitlalization process on anxiety depression comfort and breastfeesing
58470691|NCT05374785|DRUG|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
58470692|NCT05374785|OTHER|Placebo|Tablets without CPL409116 as an active substance
58470693|NCT03012399|BEHAVIORAL|Hypnosedation|Undergo hypnosedation
58470694|NCT03012399|OTHER|Questionnaire Administration|Ancillary studies
58470695|NCT03012399|BEHAVIORAL|Verbal Support|Speak with min-body specialist
58470696|NCT05443295|OTHER|MoveUS Program|The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.
58470697|NCT05443295|OTHER|Control intervention|The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
58470698|NCT05018000|BEHAVIORAL|Financial navigation|The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.
58470699|NCT05018000|BEHAVIORAL|Enhanced usual care|The financial resource sheet lists and describes existing internal and community resources available to KP members
58470700|NCT06602661|PROCEDURE|Fissureless Lobectomy with Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler equipped with the ENDOPATH™ stapler line reinforcement. The ENDOPATH™ device uses bioabsorbable buttress material made from Polyglactin and Polydioxanone, designed to enhance the durability and effectiveness of the staple line.~The reinforcement tool is a novel preloaded device with a click and go mechanism, making it easy to load and use during surgery.~The primary objective is to reduce the average duration of hospital length of stay (LOS) directly caused by prolonged air leak (PAL). Secondary objectives include improving intraoperative characteristics (such as duration and amount of blood loss) and postoperative outcomes (such as incidence and duration of PALs, number of chest tube days, and incidence of hospital."
58470701|NCT06602661|PROCEDURE|Fissureless Lobectomy with Non-Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler without any additional reinforcement. This means the staple lines are created using the standard stapler without the use of bioabsorbable buttress materials.~The ECHELON™ 3000 stapler is used to divide the lung parenchyma, pulmonary artery branches, veins, and bronchus without any reinforcement, relying solely on the standard stapling mechanism."
58470702|NCT06369142|DEVICE|Intravascular lithotripsy (IVL)|Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
58470703|NCT06369142|DEVICE|Standard non-IVL methods|Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
58470704|NCT00742612|DRUG|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
58470705|NCT00742612|DRUG|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
58470706|NCT06590662|DRUG|Solriamfetol|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period."
58470707|NCT06590662|DRUG|Placebo|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period."
58470708|NCT04052334|DRUG|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
58470709|NCT04052334|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
58470710|NCT04052334|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
58470711|NCT04052334|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
58470712|NCT02380573|DRUG|Methylene Blue|
58470713|NCT02380573|DRUG|FD&C Blue # 2|
58470714|NCT02380573|DRUG|Phenazopyridine hydrochloride|
58470715|NCT02800538|DIETARY_SUPPLEMENT|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
58470716|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption|Volunteers were asked to consume lupins in brine for 4 weeks.
58470717|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption and dietary suggestion|Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
58470718|NCT06166654|DRUG|Acetazolamide|1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
58470719|NCT06166654|DRUG|Metolazone 2.5 MG|2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
58470720|NCT06166654|OTHER|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
58470721|NCT06593821|DEVICE|Occlusal splint|The occlusal splint was fabricated from a 2 mm hard splinting resin material on the plaster model obtained by taking impressions of the patients\&amp;#39; upper jaw.
58470722|NCT06593821|BEHAVIORAL|preventive advice|Control group given protective advice such as supporting the jaw when yawning, not chewing gum, not opening the mouth for too long and not opening it too wide, and chewing on both sides when eating.
58470723|NCT06593821|DRUG|Botulinum toxin|A total of 50 U of botulinum toxin, 25 U in each muscle, was injected
58470724|NCT03096808|RADIATION|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
58470725|NCT06052761|DEVICE|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
58470726|NCT06590207|DRUG|plasma rich with WNV neutralizing antibodies|200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
58470727|NCT06590207|DRUG|Saline|Placebo
58470728|NCT04966013|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
58470729|NCT04966013|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
58470730|NCT05159830|DRUG|Cannabidiol oral oil|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
58470731|NCT05159830|DRUG|Placebo oral oil|Placebo of similar cannabidiol galenic form
58470732|NCT06589622|PROCEDURE|Atraumatic Restorative Treatment|Caries excavation with hand instruments only and restoration with Glass ionomer filling
58470733|NCT06589622|PROCEDURE|Hall technique|Crown placement without tooth preparation
58470734|NCT04017546|DRUG|CYC065|intravenous infusion
58470735|NCT04017546|DRUG|Venetoclax|oral capsule
58470736|NCT04500587|DRUG|ZN-d5|Oral agent; 25 mg or 100 mg formulation
58470737|NCT06600386|OTHER|Alveolar recruitement|PEEP after alveolar reruitment maneuvres
58470738|NCT06600386|OTHER|Standard PEEP|PEEP 5 cmH2O
58470739|NCT03376880|OTHER|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
57778559|NCT05197686|DEVICE|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
58470740|NCT06594809|OTHER|PNF|Upper extremity PNF exercise is an exercise method that dynamically stabilizes the scapula and affect scapular muscles activity (Witt et al., 2011). Upper extremity PNF patterns consisted of four diagonal patterns (D1 flexion, D2 flexion, D1 extension, and D2 extension) and six key components manual contact, body position, verbal cues pattern of movement, timing of movement and resistance. Patient will be at sitting position with involved side up, head, spine, and scapula in neutral
57778560|NCT05197686|DEVICE|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
58470741|NCT06594809|OTHER|Traditional neck pain treatment|Cervical muscles stretch + Craniocervical retraction ex + Manual therapy
57778561|NCT05312515|OTHER|Warm Application to Feet|Warm Application to Feet after Cesarean Section
57778562|NCT02102464|DEVICE|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
57778563|NCT01951092|OTHER|Text messaging|
57778564|NCT06159296|DEVICE|Hydroxy gas|Hydroxy gas is a combination of hydrogen and oxygen together.
58470742|NCT06594809|OTHER|Traditional neck pain treatment + Blackburn scapular stabilization exercises|The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises). Blackburn exercises are one of the ways to treat scapular dyskinesia. Perform 2 sets of 20 repetitions of each exercise each session (3 sessions per week) for four weeks (panse et al .,2018). The exercise load will be 60% of the one-repetition maximum (1-RM) during the first week due to their first exposure to the exercises. The evaluation of one-repetition maximum (1-RM) will be every week for all exercises. From the second evaluation, more weight will be added (compare to the previous evaluation) to maintain the overload.
58470743|NCT03056794|OTHER|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
58470744|NCT05924243|DRUG|RO7486967|For up to approximately 28 days
58470745|NCT05924243|DRUG|Placebo|For up to approximately 28 days
58470746|NCT01876836|DEVICE|i-gel|i-gel placed after induction
58470747|NCT01876836|DEVICE|C-LMA|placed after induction
58470748|NCT00434317|DRUG|Zoledronic acid|
58470749|NCT06594172|DRUG|Memantine Oral Tablet|"Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily."
58470750|NCT06594172|DRUG|Pioglitazone 15mg|"Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily."
58470751|NCT06594172|RADIATION|Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)|Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).
58470752|NCT05446649|OTHER|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
58470753|NCT05446649|OTHER|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
58470754|NCT05446649|OTHER|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
58470755|NCT04086927|DEVICE|Unna Boot|The unna boot is a zinc coated compression dressing
58470756|NCT06589739|DEVICE|Virtual Reality Headset|A virtual reality headset will be placed on patients\&#39; head before and during chest drain insertion
58470757|NCT02052778|DRUG|Futibatinib|oral once daily dosing, 21-day cycle
58470758|NCT06029322|PROCEDURE|Socket seal after alveolar ridge preservation|Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
58470759|NCT02575586|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
58470760|NCT02575586|DEVICE|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
58470761|NCT04245111|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
58470762|NCT04488666|DEVICE|npSIMS|incisional NPWT
58470763|NCT03264404|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
58470764|NCT03264404|DRUG|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
58470765|NCT01502293|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
58470766|NCT01502293|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
58470767|NCT03991221|OTHER|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
58470768|NCT03991221|OTHER|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
58470769|NCT03991221|OTHER|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
58470770|NCT06052319|DEVICE|Care4Today® Connect CAD-PAD Mobile Application|Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
58470771|NCT06600035|DEVICE|Gastric ultrasound|A curved array, low-frequency (2-5 MHz) transducer providing a scan depth up to 30 cm will be used. Patients will be scanned in the supine position followed by right lateral decubitus (RLD) position. The sonographic appearance of the gastric antrum will be classified as Grade 0,1 or 2, signifying empty antrum, fluid detected in RLD position only and antral fluid in both supine and RLD positions, respectively, based on the appearance in both the positions. Cross-sectional area (CSA) will be calculated by using two perpendicular diameters-anteroposterior (AP) and craniocaudal (CC) and the formula for area of an ellipse:CSA = (AP × CC × π)/4
58470772|NCT06593613|BEHAVIORAL|RUBI-A|"The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills."
58470773|NCT06593613|BEHAVIORAL|R-ISLEA|R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
58470774|NCT05911984|DRUG|9MW3811 Injection|Intravenous injection
58470775|NCT05101902|OTHER|Pre-Screening|No intervention given
58470776|NCT06587867|BIOLOGICAL|efgartigimod|active drug efgartigimod to be administer
58470777|NCT05344950|BEHAVIORAL|Audio + Radio (AURA)|Participants will receive personalized self-care information based on their symptoms and signs of complications (e.g., fatigue) from interacting with our voice assistant device, connected to a system that integrating the patient-reported outcome and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home.
58470778|NCT03940352|DRUG|HDM201|Capsule
58470779|NCT03940352|BIOLOGICAL|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
58470780|NCT03940352|DRUG|Venetoclax|Tablet
58470781|NCT06599827|RADIATION|moderately hypofractionated radiotherapy|35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.
58470782|NCT06599827|DRUG|chemotherapy|CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
58470783|NCT06599827|DRUG|immunotherapy|Serplulimab 300 mg IV infusion on day 1 every 21 days.
58470784|NCT06599827|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
58470785|NCT06062563|DRUG|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
58470786|NCT06225128|OTHER|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, Day of post-cycle 1 and post-cycle 6 evaluation.
58470787|NCT06225128|OTHER|Bone marrow specimens|"Additional volume of 2mL (EDTA)~* at screening for correlative studies,at Day 7 for smears and for correlative studies.~* Post-cycle 1 and post-cycle 6 evaluations for correlative studies.~Optionnal :~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
57778565|NCT05592535|PROCEDURE|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
57778566|NCT00422370|DEVICE|lipid based additives based on vegetable oil & lecithin|
57778567|NCT03638635|DRUG|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
57778568|NCT03638635|DRUG|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
57778569|NCT05851911|BIOLOGICAL|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
58470788|NCT03269422|RADIATION|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
58470789|NCT05820581|BEHAVIORAL|Mentalisation|Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
58470790|NCT03733717|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
58470791|NCT05325736|PROCEDURE|sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery
58470792|NCT05325736|PROCEDURE|gastric bypass surgery|participants undergoing gastric bypass surgery
58470793|NCT05325736|PROCEDURE|control|cholecystectomy
58470794|NCT06485843|DRUG|OA-SYS|OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
58470795|NCT06000540|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
58470796|NCT01666249|BIOLOGICAL|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
58470797|NCT03792659|OTHER|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
58470798|NCT06587984|BEHAVIORAL|Text message reminder|One-time text message reminder with information about getting flu vaccine at CHOP
58470799|NCT06535880|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm
58470800|NCT00294450|DEVICE|Fistula Pouching System|3 different sizes of fistula pounching system
58470801|NCT05494788|DRUG|CardiolRx|Pharmaceutically produced Cannabidiol
58470802|NCT03353688|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
58470803|NCT05096403|DRUG|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
58470804|NCT05420935|DIAGNOSTIC_TEST|IgG group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml"
58470805|NCT05420935|DIAGNOSTIC_TEST|IgE group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling"
58470806|NCT05420935|DIAGNOSTIC_TEST|IgG group + IgE group|"* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling"
58470807|NCT05635656|DEVICE|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
58131044|NCT05717036|DEVICE|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
58131045|NCT00277381|BEHAVIORAL|Automated feedback regarding drug adherence|
58470808|NCT02435212|DRUG|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
58470809|NCT02435212|DRUG|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
58131046|NCT01677078|DEVICE|Neuronavigation system|Neuronavigation
58470810|NCT06371768|BEHAVIORAL|AYA Educational Information|AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions. Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.
58470811|NCT06371768|BEHAVIORAL|AYA STEPS|The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care. Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques. Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
58470812|NCT06384222|DRUG|Abiraterone acetate|Given orally
58470813|NCT06384222|DRUG|Prednisone|Given orally
58470814|NCT06384222|DRUG|Hyperpolarized [1-13C] pyruvate (HP 13C)|Given IV
58470815|NCT06384222|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
58470816|NCT06384222|PROCEDURE|Non-investigational radical prostatectomy (RP)|Planned, standard of care surgical procedure occurring outside of this study.
58470817|NCT06384222|PROCEDURE|Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)|Imaging procedure
58470818|NCT06655376|DRUG|Aspirin|81-100 mg, oral
58470819|NCT06655376|DRUG|Warfarin|Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
58470820|NCT05943834|OTHER|Series of cognitive tasks during a semi-automated call|"Tasks:~* Verbal learning recall (immediate) or Story Recall task (immediate)~* Narrative Storytelling /free speech~* Verbal fluency task~* Verbal learning recall (delayed) or Story Recall task (delayed)"
58470821|NCT01373021|DRUG|Fentanyl|Fentanyl 2500mcg+NS50ml
58470822|NCT01373021|DRUG|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
58470823|NCT02209714|DRUG|BIIF 1149 BS|
58470824|NCT02209714|DRUG|Placebo|
58470825|NCT04683042|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
58470826|NCT04683042|OTHER|PT only|Routine PT therapy only
58470827|NCT04957485|DRUG|Tecovirimat|oral antiviral
58470828|NCT04957485|DRUG|Smallpox and Mpox Vaccine|vaccine
58470829|NCT04957485|OTHER|Placebo|TPOXX Placebo
58470830|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
58470831|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
58470832|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
58470833|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
58131047|NCT01677078|DEVICE|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
58470834|NCT03240601|DEVICE|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
58470835|NCT02582528|BEHAVIORAL|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
58470836|NCT02582528|BEHAVIORAL|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
58470837|NCT05418816|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
58470838|NCT05586581|DRUG|SV2A PET|SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
58470839|NCT05586581|DRUG|TSPO PET|TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
58470840|NCT04040569|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
58470841|NCT04570371|BEHAVIORAL|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
58470842|NCT04104256|BEHAVIORAL|Nudge #1: Alert highlighting the safety/potential harms to patients of undergoing pre-op tests|"Nudge 1:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-op tests do NOT increase patient safety and go AGAINST local and national guidelines Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
58470843|NCT04104256|BEHAVIORAL|Nudge #2: Alert highlighting the financial harms to the patient experiencing pre-op tests|"Nudge #2:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can increase the patient's out-of-pocket costs without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Nudge includes hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
58470844|NCT04104256|BEHAVIORAL|Nudge #3: Alert highlighting potential psychological harms to the patient of experiencing pre-op tests|"Nudge 3:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can cause aggravation and psychological stress for the patient without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
58470845|NCT04104256|OTHER|Usual Care|Patients will receive usual care from their physicians.
58470846|NCT06589752|DRUG|TARPEYO 4 MG Delayed Release Oral Capsule|TARPEYO dispensing claim for any dose is exposure
58470847|NCT06589752|DRUG|RAS inhibitor|RASi dispensing claim for any dose is reference
58470848|NCT04856358|DRUG|GLPG3121|GLPG3121 modified-release tablet
58470849|NCT04856358|DRUG|Placebo|Matching placebo
58470850|NCT06588114|OTHER|Antistress Ball|Hemodialysis patients will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention
58470851|NCT06588114|OTHER|The Valsalva maneuver|The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm.
58470852|NCT06588114|OTHER|Skin cooling|Hemodialysis patients will be provided with lowering of skin temperature with a skin cooling device by the researcher for 10 minutes before arteriovenous fistula intervention is made to hemodialysis patients
58470853|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns with retention grooves|Zirconia-based primary anterior crowns with retention grooves
58470854|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns without retention grooves|Zirconia-based primary anterior crowns without retention grooves
58470855|NCT06603649|OTHER|ECPR for out-of-hospital cardiac arrest|Patient with out-of-hospital cardiac arrest enrolled in the ECPR protocol
58470856|NCT05270057|DRUG|Etoposide|Dose level -2=50 mg/m\^2; dose level -1=50 mg/m\^2; dose level 1=50 mg/m\^2; dose level 2=60 mg/m\^2; dose level 3=72 mg/m\^2; dose level 4=86.4 mg/m\^2; dose level 5=103.7 mg/m\^2; dose level 6=124.4 mg/m\^2; dose level 7=149.3 mg/m\^2
58470857|NCT05270057|DRUG|Doxorubicin|Dose level -2=10 mg/m\^2; dose level -1; dose level -1=10 mg/m\^2; dose level 1=10 mg/m\^2; dose level 2=12 mg/m\^2; dose level 3=14.4 mg/m\^17.3 mg/m\^2; dose level 4=17.3 mg/m\^2; dose level 5=20.7 mg/m\^2; dose level 6=24.8 mg/m\^2; dose level 7=29.8 mg/m\^2.
58470858|NCT05270057|DRUG|Cyclophosphamide|Dose level -2=480 mg/m\^2; dose -1=600 mg/m\^2; dose level 1=750 mg/m\^2; level 2=900 mg/m\^2; level 3=1080 mg/m\^2; level 4=1296 mg/m\^2; level 5=1555 mg/m\^2; level 6=1866 mg/m\^2; level 7=2239 mg/m\^2.
58470859|NCT05270057|DRUG|Rituximab|Level -2 through level 7: 375 mg/m\^2
58470860|NCT05270057|DRUG|Vincristine|Level -2 through level 7: 0.4 mg/m\^2/day
58470861|NCT05270057|DRUG|Prednisone|Level -2 through level 7: 60 mg/m\^2/twice daily (BID)
58470862|NCT05270057|DRUG|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
58470863|NCT05270057|DRUG|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
58470864|NCT05270057|DRUG|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
58470865|NCT06498349|PROCEDURE|bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment|according to widely accepted expert consensus paper
57778570|NCT02922673|DRUG|Aspirin|
57778571|NCT02922673|DRUG|Placebo|
58470866|NCT06498349|DRUG|best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations|according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
58470867|NCT06590324|DRUG|Apabetalone|100-mg capsule, twice daily oral administration with meals
58470868|NCT01076478|DRUG|Cilostazol|100 mg, 200mg tablet Cilostazol
58470869|NCT01705119|OTHER|Standing|
58470870|NCT04897711|BEHAVIORAL|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
58470871|NCT04865627|DEVICE|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
58470872|NCT03896438|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
58470873|NCT04638231|OTHER|Supportive messages|Daily supportive messages via SMS or email
58470874|NCT05322954|DRUG|Psilocybin|25mg orally followed by 25 mg or 50 mg orally
58470875|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58470876|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMPT
58470877|NCT01893307|OTHER|Laboratory Biomarker Analysis|Correlative studies
58470878|NCT01893307|RADIATION|Photon Beam Radiation Therapy|Undergo IMRT
58470879|NCT01893307|RADIATION|Proton Beam Radiation Therapy|Undergo IMPT
58470880|NCT01893307|OTHER|Quality-of-Life Assessment|Ancillary studies
58470881|NCT06299475|OTHER|Online counseling and invitation|"Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website"
58470882|NCT06294626|OTHER|Group 1|21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
58470883|NCT05178810|DRUG|FAB122|Daily dose 100 mg
58470884|NCT05178810|DRUG|Placebo|Daily dose
58470885|NCT05336864|OTHER|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
58470886|NCT05336864|OTHER|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL)"
58470887|NCT05336864|OTHER|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year MACE).
58470888|NCT05336864|OTHER|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
58470889|NCT03453164|RADIATION|Radiotherapy|Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.
58470890|NCT03453164|DRUG|Nivolumab|Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
58131048|NCT04642950|DRUG|Sargramostim|250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.
58470891|NCT06588569|DEVICE|Multi-mode tumor treatment system|The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.
58470892|NCT06588569|DEVICE|Radiofrequency ablation therapeutic apparatus|The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.
58470893|NCT06032871|PROCEDURE|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
58470894|NCT06032871|PROCEDURE|Chest physiotherapy|Participants received chest physiotherapy twice a day
58470895|NCT06588088|OTHER|Dietary|The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week, and in the second week, 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the nighttime eating syndrome (NES) criteria, after 20.30 in the evening.
58470896|NCT02939807|DRUG|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
58470897|NCT05932862|DRUG|XL309 (ISM3091)|XL309 will be administered orally once daily.
57778572|NCT03407261|PROCEDURE|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
58470898|NCT05932862|DRUG|Olaparib|Olaparib administered orally twice daily.
58470899|NCT01775501|DRUG|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58470900|NCT01775501|DRUG|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58470901|NCT01775501|DRUG|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58470902|NCT01775501|DRUG|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58470903|NCT02689427|PROCEDURE|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
58470904|NCT02689427|DRUG|Enzalutamide|Given PO
58470905|NCT02689427|OTHER|Laboratory Biomarker Analysis|Correlative studies
58470906|NCT02689427|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
58470907|NCT02689427|DRUG|Paclitaxel|Given IV
58470908|NCT02689427|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
58470909|NCT05615922|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
58470910|NCT05615922|BEHAVIORAL|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
58470911|NCT06139276|PROCEDURE|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
58470912|NCT06139276|OTHER|Standard treatment|Standard treatment
58470913|NCT05014971|BEHAVIORAL|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
58470914|NCT05071287|OTHER|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
58470915|NCT05071287|OTHER|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
58470916|NCT03668873|BEHAVIORAL|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
58470917|NCT03668873|BEHAVIORAL|Sleep Parent Education|SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
58470918|NCT02265458|BEHAVIORAL|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
58470919|NCT04060303|PROCEDURE|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
58470920|NCT05613569|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
58470921|NCT06604338|DIAGNOSTIC_TEST|Exome test|An exome will be performed on the participants of RPL group.
57778573|NCT01518660|BEHAVIORAL|Training|Bi-weekly progressive resistance training
58131049|NCT04642950|DRUG|Placebo|2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
58131050|NCT00241917|BEHAVIORAL|Hepatitis C educational video|
58131051|NCT00241917|OTHER|Video|Prevention education video about hepatitis C
58131052|NCT00352690|DRUG|Paclitaxel poliglumex|
58131053|NCT00352690|DRUG|Carboplatin|
58131054|NCT00352690|RADIATION|External beam radiation therapy|
58131055|NCT03131037|BIOLOGICAL|CAN-2409 + valacyclovir|CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
58131056|NCT03563105|DEVICE|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
58470922|NCT06604338|DIAGNOSTIC_TEST|Microbiota analysis|A cervical microbiota analysis will be performed in the RPL and control groups.
58470923|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
58470924|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
58470925|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
58470926|NCT04768738|DIAGNOSTIC_TEST|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
58470927|NCT01082861|BIOLOGICAL|Cervarix|Cervarix, HPV vaccin
58470928|NCT01082861|BIOLOGICAL|Engerix-B|Engerix-B, HBV vaccin
58470929|NCT06585657|DEVICE|brain visual perception training group|Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
58470930|NCT05101096|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously (IV)
58470931|NCT05762757|OTHER|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
58470932|NCT06414798|DRUG|Drug: ABBV-1088|• Oral Capsule
58470933|NCT06414798|DRUG|Drug: Placebo for ABBV-1088|• Oral Capsule
58470934|NCT05315414|DEVICE|PrimeTaper EV implant|Tapered dental implant developed by Dentsply Sirona
58470935|NCT06601426|PROCEDURE|CSP|cold snare polypectomy
58470936|NCT06151288|BIOLOGICAL|31 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-31 will be administered into the deltoid muscle at Day 1
58470937|NCT06151288|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
58470938|NCT02006472|DRUG|Pridopidine|22.5 mg and 45 mg capsules
58470939|NCT02006472|OTHER|Placebo|Capsules matching drug
58470940|NCT00628368|GENETIC|gene expression analysis|
58470941|NCT00628368|GENETIC|mutation analysis|
58470942|NCT00628368|GENETIC|polymorphism analysis|
58470943|NCT00628368|OTHER|laboratory biomarker analysis|
58470944|NCT00628368|PROCEDURE|biopsy|
58470945|NCT00628368|PROCEDURE|endoscopic biopsy|
58470946|NCT06555120|BIOLOGICAL|blood sample|A 5-ml blood sample in a dry tube (or 500-µl cone) is taken and sent to the biochemistry laboratory for lipid analysis.
58470947|NCT06291441|OTHER|No intervention|No intervention (observational study)
58470948|NCT06589375|DIAGNOSTIC_TEST|Sniffin'Sticks|The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.
58470949|NCT02818907|OTHER|Additional biological samples|blood and tumor tissue samples
58470950|NCT04346745|BEHAVIORAL|Peer Mentoring Program|The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
58470951|NCT06273774|DRUG|MK-8189|Oral Tablet
58470952|NCT06273774|DRUG|Placebo|Oral Tablet
58470953|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
58470954|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
58470955|NCT00498875|BEHAVIORAL|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
58470956|NCT00498875|BEHAVIORAL|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
58470957|NCT05708755|DEVICE|Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)|Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
58470958|NCT05708755|DIAGNOSTIC_TEST|Donor-Derived Cell-Free DNA (dd-cfDNA) Assay|Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
58470959|NCT05708755|DRUG|Valganciclovir|Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
58470960|NCT05467007|DIAGNOSTIC_TEST|BioFire® Respiratory Panel 2.1-EZ|BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
58131057|NCT02228382|DRUG|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
58470961|NCT04777851|DRUG|Regorafenib in combination with pembrolizumab|Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
58470962|NCT04777851|PROCEDURE|Loco-regional therapy|"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
58470963|NCT04584255|DRUG|Niraparib|Predetermined dosage PO Daily
58470964|NCT04584255|DRUG|Dostarlimab|Predetermined Dosage, IV,q3 weeks
58470965|NCT03932344|DRUG|Anakinra|Anakinra according to prescription
58470966|NCT05535387|BEHAVIORAL|FamilyNet smart speaker/mobile application|In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
58470967|NCT05109325|BEHAVIORAL|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing \[MI\] + cognitive behavioral therapy \[CBT\] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
58470968|NCT06431048|OTHER|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).
58470969|NCT06431048|OTHER|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
58470970|NCT02947685|DRUG|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
58470971|NCT02947685|DRUG|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
58470972|NCT02947685|DRUG|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
58470973|NCT02947685|DRUG|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
58470974|NCT02947685|DRUG|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
58470975|NCT02947685|DRUG|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
58470976|NCT02947685|DRUG|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
58470977|NCT04452721|OTHER|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
58470978|NCT03221556|BEHAVIORAL|Engagement-Focused Care Coordination (EFCC)|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
58470979|NCT03221556|BEHAVIORAL|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
58470980|NCT06061094|DRUG|Imatinib|Imatinib 600mg QD plus Chemotherapy
58470981|NCT06061094|DRUG|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
58470982|NCT06061094|DRUG|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
58470983|NCT06061094|OTHER|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
58131058|NCT06309706|OTHER|No intervention|Just observation
58470984|NCT06590779|OTHER|Aminexil® active+ lotion|Aminexil® active+ lotion
58470985|NCT06590779|OTHER|Finasteride 1mg|Finasteride 1 mg
58470986|NCT03026062|BIOLOGICAL|Durvalumab|Given IV
58470987|NCT03026062|BIOLOGICAL|Tremelimumab|Given IV
58470988|NCT06419465|BEHAVIORAL|Peer-Led Health Protection and Promotion Training Program|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with peers, encouraging physical activity using the Google Fit mobile application. In order to provide social interaction, walking with peer leaders, health protection and development issues, receiving questions and opinions and giving guidance by individual phone calls regarding E-Nabiz and Google Fit mobile applications, holding peer group meetings and any of the Health Protection and Development Training Program targets. It consists of interventions such as giving a success badge for the relevant behavior if it reaches someone. Individual phone calls are also included in the intervention program.
58470989|NCT06419465|BEHAVIORAL|Health Protection and Promotion Training Program under the Leadership of a Public Health Nurse|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with nurses, encouraging physical activity using the Google Fit mobile application. To achieve any of the Health Protection and Development Training Program targets by walking with the nurse, taking individual phone calls regarding health protection and promotion issues, E-Nabiz and Google Fit mobile applications, receiving questions and opinions and giving guidance, holding group meetings in order to provide social interaction and social interaction. It consists of interventions such as giving a success badge for the relevant behavior. Individual phone calls are also included in the intervention program.
58470990|NCT05220618|BEHAVIORAL|Autobiographical Memory Specificity and Savoring Training: PESCAR|An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
58470991|NCT03975491|BEHAVIORAL|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
58470992|NCT03975491|BEHAVIORAL|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
58470993|NCT04663763|DRUG|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
58470994|NCT04663763|DRUG|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
58470995|NCT04663763|DRUG|Oxaliplatin|Usage: 130mg/m2 d1 q3w
58470996|NCT04836429|DRUG|Porfimer Sodium|Given IV
58470997|NCT04836429|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
58470998|NCT04836429|DRUG|Photodynamic Therapy|Undergo photodynamic therapy
58470999|NCT04836429|DEVICE|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
58471000|NCT04142203|OTHER|23 h surgery|Patients were treated in 23 surgical unit
58471001|NCT00248625|DRUG|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
58471002|NCT00248625|DRUG|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
58471003|NCT05171816|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
58471004|NCT05171816|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
58471005|NCT06576505|PROCEDURE|peripheral blood sampling, bronchoscopy, upper airway and faeces sampling|"1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml/year but never more than 100 ml/ month.~2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times/year.~3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times/year.~4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment."
58471006|NCT04042441|DRUG|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
58471007|NCT06540742|DIAGNOSTIC_TEST|Artificial intelligence identifies liver hydatids|Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology
58471008|NCT04091620|PROCEDURE|Transanal Total Mesorectal Excision|As above
58471009|NCT04091620|PROCEDURE|Robotic Total Mesorectal Excision|As above
58471010|NCT04329247|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
58471011|NCT06600997|DEVICE|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms
58471012|NCT06600997|DEVICE|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms
58471013|NCT00896402|DRUG|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
58471014|NCT00896402|DRUG|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
58471015|NCT02582021|PROCEDURE|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
58471016|NCT02582021|PROCEDURE|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
58471017|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
58471018|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
58471019|NCT02582021|PROCEDURE|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
58471020|NCT02582021|PROCEDURE|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
58471021|NCT02582021|PROCEDURE|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
58471022|NCT04154072|DRUG|NLY01|exenatide and polyethylene glycol (PEG)
58471023|NCT04154072|DRUG|Vehicle|Saline (Sodium Chloride)
58471024|NCT05442554|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion.
58471025|NCT04081493|OTHER|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
58471026|NCT06147037|DRUG|FPI-2053|FPI-2053 is a bispecific antibody that targets EGFR and cMET
58471027|NCT06147037|DRUG|[111In]-FPI-2107|"\[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
58471028|NCT06147037|DRUG|[225Ac]-FPI-2068|"\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
58471029|NCT06313112|OTHER|Observational study|Observational study
58471030|NCT00297310|DRUG|tacrolimus|
58471031|NCT05684419|OTHER|Fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers|Evaluation of the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.
58471032|NCT03690193|BEHAVIORAL|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
58471033|NCT02535481|DEVICE|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
58471034|NCT02535481|PROCEDURE|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
58471035|NCT05928936|DRUG|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
58471036|NCT05928936|BEHAVIORAL|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
58471037|NCT05928936|DRUG|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
58471038|NCT05355532|GENETIC|different variants of SNPs that may be associated with the coronary microvascular obstruction development|Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
58471039|NCT01953640|OTHER|Laboratory Biomarker Analysis|Correlative studies
58471040|NCT01953640|OTHER|Quality-of-Life Assessment|Ancillary studies
58471041|NCT06589557|OTHER|Virtual Reality (VR) and Standard Rehabilitation|"VR Rehabilitation:~The VR therapy includes exercises designed to improve the range of motion, coordination, and spatial awareness of the cervical spine. Each patient will complete 15 training sessions over three weeks (5 sessions per week, 2 hours per session), with an additional 30 minutes of daily VR exercises.~Standard Rehabilitation Program:~Manual Therapy: Mobilization and manipulation techniques are applied to enhance the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises focus on improving body position awareness, movement, and balance.~Strengthening and Stretching Exercises: Individually tailored exercises are provided to strengthen and stretch the neck muscles."
58471042|NCT06589557|OTHER|Standard Rehabilitation|"Patients in this group will participate solely in the standard rehabilitation program.~Standard Rehabilitation Program:~Number of Sessions: Each patient will complete 15 training sessions, held 5 times per week for 3 weeks, with each session lasting 2 hours.~Program Components:~Manual Therapy: Mobilization and manipulation techniques will be applied to improve the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises aim to enhance body position awareness, movement control, and balance.~Strengthening and Stretching Exercises: Customized exercises will be provided to strengthen and stretch the neck muscles, tailored to individual needs."
57778574|NCT00652262|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
58471043|NCT06190158|DIAGNOSTIC_TEST|Oral sodium suppression test|Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
58471044|NCT06190158|DIAGNOSTIC_TEST|Saline suppression test|Saline suppression test (2 liters of saline)
58471045|NCT06190158|DIAGNOSTIC_TEST|Captopril suppression test|Captopril suppression test (50mg of captopril)
58471046|NCT06190158|DIAGNOSTIC_TEST|Dexamethasone suppression test|1mg of dexamethasone
58471047|NCT06190158|DIAGNOSTIC_TEST|Cosyntropin stimulation test|250mcg of cosyntropin
58471048|NCT04696692|OTHER|Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.|"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
58471049|NCT05804838|OTHER|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
58471050|NCT01285557|DRUG|S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
58471051|NCT01285557|DRUG|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
58471052|NCT03294707|DRUG|AG10 oral tablet|Active single ascending dose
58471053|NCT03294707|DRUG|Placebo Oral Tablet|Placebo single dose
58471054|NCT06590077|OTHER|Aromatherapy|The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
58471055|NCT06590077|OTHER|Control (placebo) group|Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
58471056|NCT05425979|DRUG|Mepivacaine|Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
58471057|NCT05425979|DRUG|Bupivacaine|Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
58471058|NCT04044950|BIOLOGICAL|E7 TCR|The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
58471059|NCT01874002|DEVICE|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
57778575|NCT00275496|PROCEDURE|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
57778576|NCT00275496|PROCEDURE|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
57778577|NCT00275496|PROCEDURE|Wide Excision|Subject has wide excision only for primary melanoma.
58471060|NCT06601491|BEHAVIORAL|Lifestyle Intervention|Participants in the intervention group receive structured, pesonalised lifestyle, dietary and physical activity consultations. They undergo various assessments such as aortic stiffness measurement, blood pressure measurement, and complete several questionnaires (e.g., whole exome sequencing, IPAQ, handgrip strength, socio-demographic, clinical history, quality of life, smoking, alcohol consumption, sleep patterns, stress assessment).
58471061|NCT05701423|DRUG|Natalizumab|Administered as specified in the treatment arm.
58471062|NCT03532451|DRUG|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
58471063|NCT03532451|DRUG|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
58471064|NCT04247139|OTHER|Kefir|commercial versus traditional kefir
58471065|NCT06595654|OTHER|repetitive Transcranial Magnetic Stimulation|"* Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized."
58471066|NCT06586619|BEHAVIORAL|Tai chi/qigong intervention group|The intervention is a tai chi/qigong intervention for older people living with HIV. This behavioral group-based intervention will be delivered through Zoom twice a week for 12 weeks. Each class lasts 45-60 minutes. Tai chi/qigong is a slow low impact meditative movement.
58471067|NCT06586619|BEHAVIORAL|Health Education group|Participants will be assigned to a health and wellness education group for older people living with HIV. This group will be delivered through Zoom twice a week for 12 weeks, and each class will last 45-60 minutes. Each group will learn about and discuss a health and wellness topic.
58471068|NCT02663492|DEVICE|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
58471069|NCT02663492|DRUG|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
58471070|NCT05618613|DRUG|Elacestrant|Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
58471071|NCT05618613|DRUG|Onapristone|Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
58471072|NCT05363020|DRUG|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
58471073|NCT05363020|DRUG|Placebo|400 mg identically appearing placebo
58471074|NCT06599931|DEVICE|tACS Transcranial alternating stimulation|session of 20 minutes
58471075|NCT05708196|OTHER|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
58471076|NCT05708196|OTHER|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
58471077|NCT06305364|DEVICE|Gixam|Participants will be required to extend their tongue in the Gixam device. Six images will be obtained and analyzed by the artificial intelligence (AI) model generating a prediction score for the presence of colorectal adenoma.
58471078|NCT02012439|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
58471079|NCT02012439|BEHAVIORAL|Cognitive Therapy|
58471080|NCT02541097|BEHAVIORAL|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
58471081|NCT04531176|OTHER|Weight Management Program (WMP)|Weight Management Program (WMP)
58471082|NCT04531176|OTHER|Traditional care|Traditional care
58471083|NCT04531176|DRUG|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
58471084|NCT04531176|DRUG|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
58471085|NCT04531176|DRUG|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
58471086|NCT04531176|DRUG|Orlistat|Medication for chronic weight management (Rx)
58471087|NCT05362656|DEVICE|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
58471088|NCT06596590|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
58471089|NCT03747549|OTHER|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
58471090|NCT03747549|OTHER|Home Exercise Alone|The prescribed home exercise program alone.
58471091|NCT06595017|DRUG|Magnesium sulphate|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
58471092|NCT06595017|DRUG|Lidocaine (drug)|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
57778578|NCT02169219|DRUG|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week"
57778579|NCT02169219|DRUG|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
57778580|NCT04183673|PROCEDURE|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
57778581|NCT04183673|PROCEDURE|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
58471093|NCT06595017|DRUG|Saline|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
58471094|NCT06604000|BEHAVIORAL|GMT Usual|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks."
58471095|NCT06604000|BEHAVIORAL|GMT Cuing|"The participants will receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP; as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends."
58471096|NCT06604000|BEHAVIORAL|GMT Boost|"After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
58471097|NCT06285825|DRUG|Emapalumab|Given by Infusion
58471098|NCT03459079|DRUG|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
58471099|NCT03459079|OTHER|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
58471100|NCT05902117|DIAGNOSTIC_TEST|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
58471101|NCT06292286|PROCEDURE|Carboplatin or cisplatin|Carboplatin of cisplatin for 3-6 cycles
58471102|NCT06292286|DRUG|Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar|Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
58471103|NCT06292286|DRUG|Bevacizumab or biosimilar|Optional
58471104|NCT06292286|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery after chemotherapy
58471105|NCT06406751|DEVICE|MI Paste|Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
58471106|NCT02039115|DRUG|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
58471107|NCT02039115|DRUG|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
58471108|NCT06604247|BEHAVIORAL|Cognitive Behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
58471109|NCT01962350|DEVICE|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
58471110|NCT06222554|DEVICE|MoveMend Health|Software-based therapeutic tool that offers gamified exercises and activities. The device is designed for deployment on tablets. The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
58471111|NCT04939610|DRUG|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
57778582|NCT00305682|BIOLOGICAL|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
57778583|NCT00305682|DRUG|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
57778584|NCT00305682|DRUG|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
57778585|NCT00305682|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
58471112|NCT04939610|DRUG|177Lu-FAP-2286|"Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose."
58471113|NCT03635892|DRUG|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
58471114|NCT03635892|DRUG|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
58471115|NCT04389775|DRUG|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
58471116|NCT04389775|DRUG|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
58471117|NCT04389775|DRUG|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
58471118|NCT04389775|DRUG|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
58471119|NCT06598644|OTHER|Cervical SNAGS (C3-C7) + Conventional PT|Cervical SNAGS at C3-C7 with active movements of lateral flexion and rotation with overpressure at the end range. .Frequency: 10 reps 3 times/week for 3 consecutive weeks Intensity: starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-hot pack for 10 minutes 2-Cervical Stretchings for levator scapulae and sternocleidomastoid 3-cervical isometric exercises, 4. Cervical Range of motion exercises
58471120|NCT06598644|OTHER|IASTM (ergon) + Conventional PT|IASTM, ergon applied at levator scapulae and sternocleidomastoid muscle, with 30 strokes at an angle. After that icing done at the levator scapulae and sternocleidomastoid muscle for 5-10 minutes using cold pack.
58471121|NCT06604494|BEHAVIORAL|early feeding resumption|Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.
58471122|NCT06604494|BEHAVIORAL|late feeding resumption|Resumption of food on the 7th day post-operatively with a mixed diet.
58471123|NCT05772390|RADIATION|Partial breast re-irradiation|partial breast re-irradiation
58471124|NCT05506384|BEHAVIORAL|Relaps Preventions Therapy|The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
58471125|NCT05506384|BEHAVIORAL|Treatment as usual|This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
58471126|NCT03160118|DRUG|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
58471127|NCT05536336|DEVICE|Condom|Contraception
58490692|NCT03460262|DEVICE|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
58490693|NCT04371393|BIOLOGICAL|Remestemcel-L|administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
58131059|NCT04835493|OTHER|Intervention|In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
58131060|NCT04259229|OTHER|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
58131061|NCT04259229|OTHER|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
58471128|NCT04162288|OTHER|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
58471129|NCT04162288|OTHER|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
58471130|NCT06088992|GENETIC|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
58471131|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
58471132|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
58471133|NCT03074136|DEVICE|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
58471134|NCT03074136|DEVICE|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
58471135|NCT03074136|DRUG|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
58471136|NCT05713656|OTHER|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
58471137|NCT00791635|OTHER|Quality-of-Life Assessment|Ancillary studies
58471138|NCT00791635|OTHER|Questionnaire Administration|Complete questionnaires
58471139|NCT03897777|BEHAVIORAL|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
58471140|NCT04305834|DRUG|Abemaciclib|Given PO
58471141|NCT04305834|OTHER|Questionnaire Administration|Ancillary studies
58490694|NCT04371393|DRUG|Placebo|administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
58490695|NCT03599219|BIOLOGICAL|sample|confirmation of platelet dysfunction
57778586|NCT00305682|PROCEDURE|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
58471142|NCT04570930|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
58471143|NCT04570930|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
58471144|NCT06597643|OTHER|Eccentric Training|"Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return"
58471145|NCT06597643|OTHER|Deep Friction Massage|The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
58471146|NCT04266067|OTHER|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
58471147|NCT04266067|OTHER|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
58471148|NCT06604377|OTHER|Observe|Ruijin
58471149|NCT06600841|DRUG|Immunotherapy（Adebrelimab）|Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
58471150|NCT06600841|DRUG|immunotherapy（Adebrelimab）|anti-PD-L1
58471151|NCT05354596|PROCEDURE|STRICT LUNG|Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
58471152|NCT05354596|PROCEDURE|STAR LUNG|Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
58471153|NCT01522222|PROCEDURE|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
58471154|NCT06597604|DEVICE|Intraoperative use of TenaTac in lung surgery|Use of innovative medical device : TenaTac
58471155|NCT06597604|DEVICE|Intraoperative use of usual sealant in lung surgery|Use of the usual scealant as a control
58471156|NCT06601127|DRUG|Tipidogrel|Day 1, loading dose of Tiprogrel followed by daily maintenance dose until day 90.
58471157|NCT06601127|DRUG|Tipidogrel|Day 1, loading dose of Tiprogrel followed by daily maintenance dose until day 90.
58471158|NCT06601127|DRUG|Clopidogrel|Day 1, loading dose of Clopidogrel followed by daily maintenance dose until day 90.
57778587|NCT00305682|RADIATION|total body irradiation|Administered Day -1, 200 cGy
58471159|NCT05617755|BIOLOGICAL|AB-1015|autologous T cell therapy
58471160|NCT01292486|DEVICE|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
58471161|NCT06470971|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody|Receive anti-PD-L1 monoclonal antibody therapy
58471162|NCT06470971|BIOLOGICAL|Anti-PD1 Monoclonal Antibody|Receive anti-PD1 monoclonal antibody therapy
58471163|NCT06470971|PROCEDURE|Biopsy|Undergo biopsy
58471164|NCT06470971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58471165|NCT06470971|PROCEDURE|Bone Scan|Undergo bone scan
58471166|NCT06470971|PROCEDURE|Computed Tomography|Undergo CT
58471167|NCT06470971|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58471168|NCT06470971|OTHER|Quality-of-Life Assessment|Ancillary studies
58471169|NCT06470971|BIOLOGICAL|Siltuximab|Given IV
58471170|NCT02367898|OTHER|Lumosity Cognitive Training|adaptive online cognitive training
58471171|NCT02367898|OTHER|Crossword Puzzles|timed online crossword puzzles
58471172|NCT06035068|DRUG|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
58471173|NCT05854966|DRUG|CPI 613|"For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent."
58490696|NCT01923272|DEVICE|AlphaCore Device|Active stimulation to the vagal nerve
58490697|NCT01923272|DEVICE|AlphaCore|Active AlphaCore treatment
58490698|NCT01877252|PROCEDURE|Surgical revascularization|
58490699|NCT01877252|PROCEDURE|Endovascular revascularization|
57778588|NCT00305682|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
58471174|NCT05854966|DRUG|Metformin|"For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent"
58471175|NCT05854966|BIOLOGICAL|Blood draws|In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
58471176|NCT05854966|PROCEDURE|Bone marrow biopsy|After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
58471177|NCT01375829|DRUG|Ixabepilone|Given IV
58471178|NCT01375829|OTHER|Pharmacological Study|Correlative studies
58471179|NCT01375829|DRUG|Temsirolimus|Given IV
58471180|NCT05884645|PROCEDURE|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
58471181|NCT00900653|DRUG|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
58471182|NCT06600828|OTHER|Data collection|Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
58471183|NCT06067802|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin
58471184|NCT06599814|PROCEDURE|vital pulp therapy|vital pulp therapy using two bioactive materials TheraCal and RetroMTA as direct pulp caping materials conventionally and test using Diode laser before application of these materials
58471185|NCT00632229|DRUG|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
58471186|NCT00632229|DRUG|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
58471187|NCT05777486|BEHAVIORAL|TikTok Ads - With Food|TikTok posts from influencers promoting food.
58471188|NCT05777486|BEHAVIORAL|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
58471189|NCT06589193|OTHER|HOCl|10ml,twice a day
58471190|NCT06589193|OTHER|CHX|10ml,twice a day
58471191|NCT06585098|OTHER|game based learning|"The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher."
58471192|NCT06588816|DEVICE|optical coherence tomography|"Optical coherence tomography (OCT) is a non-invasive imaging test . It uses light waves to take cross-section pictures of the retina .~With OCT, the ophthalmologist can see each of the retina's distinctive layers, and so we can use it to study the changes in pseudoexfoliation syndrome."
58471193|NCT06279000|DRUG|Colchicine|"Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion."
58471194|NCT06279000|DRUG|Placebo|"Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion."
58471195|NCT03038061|OTHER|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
58471196|NCT05962541|DRUG|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA \[TM\]).
58471197|NCT05962541|DEVICE|Power Led Saphira (TM)|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
58471198|NCT06030648|BIOLOGICAL|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
58471199|NCT05826314|OTHER|Boxing training|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
58471200|NCT05826314|OTHER|Exercise|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
58471201|NCT06592105|PROCEDURE|Endovascular aortic aneurysm repair (EVAR)|Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
58471202|NCT06599970|OTHER|No intervention|This is an observational study. No experimental interventions included. The mobility of people will be studied.
58490700|NCT01877252|OTHER|No vascular intervention|
58471203|NCT05733832|OTHER|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
58471204|NCT06603662|DRUG|Prednisone|Subjects assigned to the Intervention A group will receive oral prednisone 50 mg once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours for 5 days.
58471205|NCT06603662|DRUG|Dexamethasone|Subjects assigned to the Intervention B group will receive a single oral dose of dexamethasone 10 mg, plus standard ibuprofen 600 mg every 8 hours for 5 days.
58471206|NCT06603662|DRUG|Placebo|Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
58471207|NCT01485029|PROCEDURE|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
58471208|NCT00441909|DRUG|UC-781|0.1% UC-781 Vaginal Gel
58471209|NCT00441909|DRUG|UC-781 placebo|Vaginal Gel Placebo
58471210|NCT05223920|DRUG|Bomedemstat|Capsule (oral)
58471211|NCT01394016|DRUG|Abemaciclib|Administered orally.
58471212|NCT01394016|DRUG|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks in Part G only.
58471213|NCT05306899|DRUG|Ketamine|Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
58471214|NCT05306899|OTHER|0.9% Saline|Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
58471215|NCT06588803|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
58471216|NCT06591377|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
58471217|NCT06591377|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
58471218|NCT00269061|DRUG|pioglitazone|
58471219|NCT05823363|DRUG|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
58471220|NCT05823363|DRUG|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
58471221|NCT06587607|BEHAVIORAL|VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.|VA CALM is a 9 week mindfulness curriculum typically delivered at a once/week module pace in group settings during sessions that last approximately 60-90 minutes. Module topics include: Program Introduction, Why mindfulness, Perception, What Makes Something a Pleasant Experience?, Being Stuck, Getting Unstuck, Communication, Mindfulness in Daily Life, and Today is the First Dat of the Rest of Your Life.
58471222|NCT05294978|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Data of macular optical coherence tomography (OCT)
58471223|NCT02867436|OTHER|Gluten-free diet|
58471224|NCT06103500|OTHER|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
58471225|NCT01869907|DRUG|Minocycline|100 mg once daily by mouth during 14 days
58471226|NCT01869907|DRUG|placebo|once daily by mouth during 14 days
58471227|NCT01869907|DRUG|Amitriptyline|25mg once daily by mouth during 14 days
58471228|NCT02480972|PROCEDURE|magnetic resonance imaging|"multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   ------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
58471229|NCT06171009|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
58471230|NCT06171009|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
58471231|NCT06590909|COMBINATION_PRODUCT|Fractional CO2 laser assisted PDT|Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
58471232|NCT06600165|PROCEDURE|Ex vivo confocal microscopy|The aim is to use AI to assist surgeons in analyzing CLSM tissue slide images obtained during BCC surgeries with the aim to integrate it in real time. We plan to use AI to analyze CLSM images of BCCs and distinguish between tumor tissue, inflammatory tissue, and non-tumor/non-inflammatory tissue. This approach would provide surgeons with real-time feedback and automated image analysis, leading to a more targeted and efficient approach to tissue analysis. By improving the accuracy and speed of tissue analysis, our proposal could ultimately improve operative patient outcomes and benefit healthcare professionals.
58471233|NCT04340505|DRUG|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
58471234|NCT05433662|BEHAVIORAL|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
58471235|NCT05148156|DEVICE|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
58490701|NCT02238652|BEHAVIORAL|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
58471236|NCT06559267|BEHAVIORAL|Remaking Recess|Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
58471237|NCT06559267|OTHER|TEAM|Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
58471238|NCT06587126|DEVICE|Curie Artificial Intelligence (AI) cough monitor|All patients are given nighttime cough monitors for home use for 3-4 months
58471239|NCT06056297|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
58471240|NCT06056297|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
58471241|NCT01650532|BEHAVIORAL|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
58471242|NCT01650532|BEHAVIORAL|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
58471243|NCT06382727|OTHER|EN will be continued up to extubation (EN will not be withheld prior to extubation)|As per the arm/group descriptions.
58471244|NCT04370691|DEVICE|JETi Peripheral Thrombectomy System|The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
58471245|NCT02731469|BIOLOGICAL|BCD-131|
58471246|NCT02731469|BIOLOGICAL|Mircera®|
58471247|NCT02731469|BIOLOGICAL|Aranesp®|
58471248|NCT04476862|DRUG|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
58471249|NCT04476862|DEVICE|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
58471250|NCT04521413|DRUG|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
58471251|NCT04521413|DRUG|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
58471252|NCT04236817|BEHAVIORAL|Pre-packed blisters for distribution of medications|
58471253|NCT04236817|BEHAVIORAL|Routine distribution of medications|
58471254|NCT06602999|OTHER|Nutritional Intervention|Receive a booklet on nutrition and physical activity for cancer survivors
58471255|NCT06602999|OTHER|Instacart Voucher|Receive Instacart grocery delivery voucher
58471256|NCT06602999|BEHAVIORAL|Telephone-Based Intervention|Receive nutrition navigation phone calls
58471257|NCT05922878|DRUG|ALTO-300|ALTO-300 capsule QD
58471258|NCT05922878|DRUG|Placebo|Placebo capsule QD
58471259|NCT06526676|DEVICE|Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft|Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches
57778589|NCT06153940|DEVICE|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
58471260|NCT01474317|DEVICE|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
57778590|NCT02981485|DEVICE|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
58471261|NCT01831024|DEVICE|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
58471262|NCT01910285|DRUG|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
58471263|NCT01910285|DRUG|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
58471264|NCT03197298|DRUG|Clopidogrel|
58471265|NCT03197298|DRUG|Ticagrelor|
58471266|NCT00549146|DRUG|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
58471267|NCT00549146|DRUG|fluticasone propionate DISKUS 500mcg|
58471268|NCT05446129|DRUG|Ezabenlimab|Ezabenlimab
58471269|NCT05446129|DRUG|BI 765063|BI 765063
58471270|NCT05446129|DRUG|Pembrolizumab|Pembrolizumab
58471271|NCT06596252|DRUG|Budesonide|Twice daily intake of the tablet 30 min after a meal
58471272|NCT06582160|OTHER|Risk-Based Pre-conception Screening|A long form questionnaire screening questionnaire administered via tablet in health clinic waiting room. Offered to patients when patient checks-in for appointment.
58471273|NCT06582160|OTHER|Patient-centered Pre-conception Screening|A short form, 2 question screening administered via tablet in health clinic waiting room. Offered to patients when patient checks-in for appointment.
57778591|NCT04176133|DRUG|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
58490702|NCT02238652|BEHAVIORAL|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
58471274|NCT06593470|BEHAVIORAL|MINDS-UP|MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.
58471275|NCT06593470|BEHAVIORAL|Prevention Plus Wellness|PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45-60 minute session between an adolescent and a trained PPW teacher.
58471276|NCT06593470|DIAGNOSTIC_TEST|fMRI|Functional MRI to investigate preliminary neural mechanisms of MINDS-UP
58471277|NCT06597552|OTHER|Training Group|"Inspiratory muscle training (IMT) was performed using the Threshold IMT device using the threshold loading method. The IMT was administered to the patients in the training group at 30% of the MIP value, 5 days a week, twice a day, for 15 minutes for 8 weeks. The patients in the training group were called for a check-up once a week and the MIP value was re-evaluated. The training workload for that week was determined by taking 30% of the new measured MIP value.~During the training, the patients were asked to sit with their upper body (shoulders and upper chest) in a relaxed position, and after the nose was closed with the clip, the mouthpiece of the device was tightly closed with the lips. While in this position, the patient was asked to inhale and exhale 5 times into the device, then remove the device from their mouth and listen for 5 breaths, and continue this cycle for 15 minutes."
58471278|NCT06597552|OTHER|Control Group|The training intensity of the control group was given at the lowest load (9 cm H2O) for 8 weeks, five days a week, twice a day for 15 minutes. To eliminate the effect of learning, the MIP measure of the control group was measured once a week, but the intensity of the training was not increased during the 8 weeks.
58471279|NCT05097079|DRUG|MYOBLOC Low Dose|Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
58471280|NCT05097079|DRUG|MYOBLOC High Dose|Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
58471281|NCT05097079|DRUG|Placebo|Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
58471282|NCT02231086|PROCEDURE|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
58471283|NCT02231086|DRUG|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
58471284|NCT02231086|PROCEDURE|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
58471285|NCT05847517|DRUG|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
58471286|NCT05847517|DRUG|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
58471287|NCT03002870|OTHER|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
58471288|NCT06426342|BEHAVIORAL|metaverse-based blended online intervention|A new metaverse-based blended online intervention was developed using an online program and coaching via metaverse to prevent depression among Generation MZ Employees in South Korea.
58471289|NCT05207774|DRUG|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
58471290|NCT05207774|DRUG|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
58471291|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
57778592|NCT04176133|DRUG|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
57778593|NCT04176133|DRUG|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
57778594|NCT03935217|DRUG|Secnidazole|Oral Granules containing secnidazole
57778595|NCT03935217|DRUG|Placebo|Oral Granules of placebo manufactured to mimic secnidazole
57778596|NCT03154203|OTHER|No intervention in this study|No intervention in this study
57778597|NCT05554146|OTHER|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
58471292|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
58471293|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
58471294|NCT04583618|BIOLOGICAL|Pneumococcal 13 - valent conjugate vaccine-Prevnar 13|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
58471295|NCT04583618|BIOLOGICAL|Pneumococcal Vaccine Polyvalent-Pneumovax 23|Pharmaceutical form:Solution for injection Route of administration: intramuscular
58471296|NCT04272242|DRUG|Dolutegravir (DTG)|Administered orally
58471297|NCT04272242|DRUG|Isoniazid (INH)|Administered orally
58471298|NCT04272242|DRUG|Rifapentine (RPT)|Administered orally
58471299|NCT04272242|DRUG|Antiretroviral Therapy (ART)|Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
58471300|NCT04272242|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
58471301|NCT06603194|DIETARY_SUPPLEMENT|Bovine or Marine Collagen|Bovine or Marine Collagen
58471302|NCT03811821|BEHAVIORAL|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
58471303|NCT03811821|DEVICE|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
58471304|NCT06493864|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
58471305|NCT06589700|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
58471306|NCT05782283|DEVICE|ACE (AI-Cirrhosis-ECG) 2.0|An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
58471307|NCT00566774|OTHER|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
58471308|NCT00566774|OTHER|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
58471309|NCT05665634|DEVICE|Concurrent transcranial magnetic stimulation and electroencephalogram|Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
57778598|NCT05554146|OTHER|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
58471310|NCT06462937|BEHAVIORAL|Exercise with supervision|Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.
58471311|NCT06462937|BEHAVIORAL|Exercise without supervision|Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.
58471312|NCT02862678|OTHER|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
58471313|NCT05387122|DEVICE|mandibular advancement device (MAD)|mandibular advancement device (MAD) is a removable oral appliance. It is an alternative therapy for patients of Obstructive Sleep Apnea who are non compliant to Continuous positive airway pressure(CPAP) which is the most accepted therapy for Obstructive Sleep Apnea.
58471314|NCT04715191|GENETIC|CARE T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL0: 1x10\^7/m\^2 DL1: 3x10\^7/m\^2 DL2: 1x10\^8/m\^2 DL3: 3x10\^8/m\^2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
58471315|NCT04715191|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
58471316|NCT04715191|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
58471317|NCT04446416|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
57778599|NCT05554146|OTHER|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
58471318|NCT04446416|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
58471319|NCT06593184|DEVICE|Trans-spinal magnetic stimulation|Trans-spinal magnetic stimulation activate affertent spinal roots and increase cortical excitability.
58471320|NCT06593184|DEVICE|Sham Comparator|Masking for trans-spinal magnetic stimulation. The sound of stimulation persists even though no magnetic pulses are being delivered
58490703|NCT02238652|BEHAVIORAL|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
58471321|NCT06592170|DRUG|Linperlisib combination with obinutuzumab|"Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle."
58471322|NCT03136887|DEVICE|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
58471323|NCT01048593|DRUG|IBI-10090|Single intraocular injection
58471324|NCT03063528|BEHAVIORAL|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
58471325|NCT03063528|BEHAVIORAL|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
58471326|NCT06347705|BIOLOGICAL|2141-V11 Antibody|2141-V11 Antibody: Intratumor injection
58471327|NCT06498206|OTHER|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
58471328|NCT06498206|OTHER|Patching|Conventional patching therapy.
58471329|NCT06072794|DRUG|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
58471330|NCT06522256|PROCEDURE|High-resolution anoscopy|"The study includes 2 visits:~* a medical consultation for inclusion~* a proctology consultation including the performance of an AHR associated or not with biopsy sampling"
58471331|NCT02905461|BEHAVIORAL|Contraceptive text messages|
58471332|NCT02905461|OTHER|Text messages not about contraception|
58471333|NCT02208310|DRUG|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
57778600|NCT05554146|OTHER|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
58471334|NCT02208310|DRUG|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
58471335|NCT06601985|PROCEDURE|J-pouch anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
58471336|NCT06601985|PROCEDURE|direct anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
58471337|NCT05416203|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
58471338|NCT04146597|OTHER|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
58471339|NCT06598735|DRUG|HRS-4508|HRS-4508
58471340|NCT02678949|DRUG|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
57778601|NCT06207396|DIAGNOSTIC_TEST|serum and urine analysis|Spiking will be analyzed by immunoassay testing and high-resolution screening
57778602|NCT00372333|DRUG|IDEA-033|
57778603|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
57778604|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
58471341|NCT02678949|DRUG|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
58471342|NCT02678949|DRUG|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
57778605|NCT05975866|DIETARY_SUPPLEMENT|curcumin|Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
58471343|NCT06595186|DRUG|JK-1201I|JK-1201I will be administered.
58471344|NCT06595186|DRUG|Temozolomide (TMZ)|Temozolomide will be administered.
58471345|NCT06305182|DRUG|Metreleptin|"Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection."
57778606|NCT05975866|BEHAVIORAL|Anti-inflammatory diet|The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
57778607|NCT04246203|OTHER|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
58471346|NCT06305182|DRUG|Sodium chloride|The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
58471347|NCT03913936|OTHER|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
58471348|NCT05587764|DIAGNOSTIC_TEST|Standard of Care|Standard of care for emergency events per local guidelines.
58471349|NCT06399952|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Participants will undergo a 5-10 minute non-anesthesia brain MRI in order to evaluate for changes in brain structure. A 20 to 30 minutes 20 channel surface electroencephalography will be performed in the wake and sleep states.
58471350|NCT06399952|GENETIC|Whole Genome Sequencing|15 milliliters of blood will be collected at the initial visit. Blood samples will be centrifuged, and plasma stored in the University of Missouri Next Gen Precision Health building. Next generation whole genome sequencing and proteomics will be performed on plasma samples. Additional blood will be collected for the DNA biobank.
58471351|NCT06399952|OTHER|Induced Pluripotential Stem Cells|A 3 mm skin punch biopsy will be collected for developing induced pluripotential stem cells.
58471352|NCT04163341|BEHAVIORAL|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
58471353|NCT05589662|OTHER|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
58471354|NCT06603974|PROCEDURE|surgery|After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.
58471355|NCT06603974|DRUG|Benmelstobart|1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
58471356|NCT06603974|DRUG|tegafur|it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
58471357|NCT06603974|DRUG|oxaliplatin|130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
58471358|NCT06603974|DRUG|albumin paclitaxel|260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
58471359|NCT04011176|PROCEDURE|Standard treatment + placebo|Placebo microcurrent
58471360|NCT04011176|PROCEDURE|Standard treatment + Microcurrent Therapy|Actual microcurrent
58471361|NCT06122194|DRUG|Drug: PF-07817883|PF-07817883 tablet
58471362|NCT06595368|PROCEDURE|Vimala massage|The massage will be given three times per day, each lasting 15 minutes and planned one hour after the first feeding of each shift.
58471363|NCT06595368|PROCEDURE|Hydrotherapy|Hydrotherapy will be applied two times per day before feeding, each lasting 5-10 min.
58471364|NCT06210711|BEHAVIORAL|Treatment as Usual|Standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. At BUMC and FH/MCW, this may include an evaluation by a licensed psychologist or psychiatrist and continued follow-up psychotherapy and/or medication as needed. At BSWMC Temple this may include an evaluation by a licensed psychiatrist and follow up treatment as needed. In all locations this therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care.
58471365|NCT06210711|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes. The treatment is manualized and has been successfully implemented and evaluated in other challenging environments (i.e., Emergency Department. Trauma center). Brief PE includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo/behavioral exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises. This discussion addresses patients' unrealistic beliefs about themselves and the world. In addition, patients are given homework to complete between each session (breathing practice, listening to the session recording, and completing behavioral exposures).
58471366|NCT01729741|PROCEDURE|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
58471367|NCT05954468|OTHER|standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social \& health psychology
57778608|NCT00431977|PROCEDURE|coronary computed tomography angiography|
57778609|NCT02605382|DRUG|Chlorhexidine gluconate|
57778610|NCT02605382|DRUG|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
57778611|NCT03701009|PROCEDURE|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
57778612|NCT03701009|PROCEDURE|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
57778613|NCT03701009|PROCEDURE|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
57778614|NCT02547571|DRUG|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
57778615|NCT02547571|DRUG|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
57778616|NCT02547571|DRUG|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
57778617|NCT02547571|DRUG|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
57778618|NCT02547571|OTHER|Clear liquid diet|
57778619|NCT02547571|OTHER|Low residue diet|
57778620|NCT02547571|OTHER|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
57778621|NCT02547571|OTHER|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
57778622|NCT03490903|DEVICE|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
58471368|NCT03646877|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
58471369|NCT03646877|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
58471370|NCT05583422|GENETIC|DPYD or UGT1A1 variants|any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
58471371|NCT06537700|DRUG|OnabotulinumtoxinA OBT-A|Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
58471372|NCT01056822|DRUG|1|Continue with same dose of MMF as patient was taking before randomisation
58471373|NCT01056822|DRUG|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
58471374|NCT05591092|PROCEDURE|Computed Tomography|Undergo a SPECT/CT scan
58471375|NCT05591092|RADIATION|Iodine I-123|Given PO
58471376|NCT05591092|PROCEDURE|Planar Imaging|Undergo planar imaging
58471377|NCT05591092|PROCEDURE|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
58471378|NCT03354949|OTHER|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
58471379|NCT04261244|RADIATION|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
57778623|NCT03490903|DRUG|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
57778624|NCT03490903|DRUG|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
57778625|NCT02065570|DRUG|Adalimumab|
57778626|NCT02065570|DRUG|Placebo|
57778627|NCT04453670|PROCEDURE|autopsy|autopsy
57778628|NCT01439087|DEVICE|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
57778629|NCT06264934|DEVICE|Breast scan using the Z-scanner|Four repeated scans of both breasts using the Z-scanner.
57778630|NCT06264934|DEVICE|Breast scan using the Z-scanner|A scan of both breasts using the Z-scanner.
57778631|NCT04392440|BEHAVIORAL|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
57778632|NCT04392440|OTHER|usual care|regular nephrology care
57778633|NCT02329990|DIETARY_SUPPLEMENT|phosphorus|phosphorus supplement
57778634|NCT05495061|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
57778635|NCT05495061|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
57778636|NCT00865111|DRUG|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
57778637|NCT00865111|DRUG|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
57778638|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
57778639|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
57778640|NCT06089421|OTHER|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
57778641|NCT06089421|OTHER|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
57778642|NCT03085550|PROCEDURE|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
57778643|NCT03085550|PROCEDURE|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
57778644|NCT00406120|PROCEDURE|Fine needle aspiration biopsy|
57778645|NCT05285826|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
57778646|NCT05285826|OTHER|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
57778647|NCT04723251|BEHAVIORAL|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
57778648|NCT00253539|DRUG|arzoxifene hydrochloride|Given orally
57778649|NCT00253539|DRUG|tamoxifen citrate|Given orally
57778650|NCT00253539|OTHER|placebo|Given orally
57778651|NCT00875849|BIOLOGICAL|cetuximab|
57778652|NCT00875849|DRUG|cisplatin|
57778653|NCT00875849|RADIATION|radiation therapy|
57778654|NCT05758155|OTHER|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
58471380|NCT04261244|RADIATION|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
58471381|NCT05935735|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|4 in-person sessions; 1 individual and 3 group sessions
58490704|NCT02238652|BEHAVIORAL|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
57778655|NCT05758155|OTHER|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
57778656|NCT02753530|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
57778657|NCT02753530|OTHER|Placebo|2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
57778658|NCT01721395|DIETARY_SUPPLEMENT|Agave Syrup|
57778659|NCT00206960|DRUG|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
57778660|NCT00206960|DRUG|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
57778661|NCT00403975|DRUG|diquafosol tetrasodium ophthalmic solution, 2%|
57778662|NCT00972387|DIETARY_SUPPLEMENT|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
57778663|NCT00972387|DIETARY_SUPPLEMENT|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
57778664|NCT00972387|DIETARY_SUPPLEMENT|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
57778665|NCT00972387|DIETARY_SUPPLEMENT|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
57778666|NCT06548685|PROCEDURE|Bone Grafting|Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites
57778667|NCT06548685|OTHER|Vegetable Derived|Tooth extraction followed by socket preservation with vegetable ivory
57778668|NCT00245596|DRUG|sildenafil|
57778669|NCT04730063|DEVICE|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
57778670|NCT05595330|BEHAVIORAL|Lymphedema prevention protocols|"Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room."
57778671|NCT04883983|DRUG|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
57778672|NCT04883983|DRUG|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
57778673|NCT01863602|DRUG|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
57778674|NCT03266471|DIAGNOSTIC_TEST|Baseline blood sample|Blood sample for cytokine measurements and genetics.
57778675|NCT03266471|DIAGNOSTIC_TEST|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
57778676|NCT03266471|OTHER|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
57778677|NCT03266471|DIAGNOSTIC_TEST|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
57778678|NCT03266471|DIAGNOSTIC_TEST|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
57778679|NCT03266471|DIAGNOSTIC_TEST|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
57778680|NCT03266471|DIAGNOSTIC_TEST|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
57778681|NCT05643482|DEVICE|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
57778682|NCT05643482|OTHER|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
57778683|NCT00581113|RADIATION|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
57778684|NCT01425632|DRUG|TAU-284|TAU-284 Low
57778685|NCT01425632|DRUG|TAU-284|TAU-284 High
57778686|NCT01425632|DRUG|Placebo|Placebo
57778687|NCT02126787|BEHAVIORAL|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
57778688|NCT02126787|BEHAVIORAL|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
57778689|NCT02231372|DRUG|Berodual® Respimat® solution for inhalation|
57778690|NCT04161599|DRUG|Cefuroxime (750mg) I.V|Extra dosage
57778691|NCT04161599|PROCEDURE|Colonic Surgery|Colonic Surgery
57778692|NCT04161599|DRUG|Cefuroxime 750mg oral|Oral prophylaxis
57778693|NCT04161599|DRUG|Metronidazole 250 MG Oral Tablet [Flagyl]|Oral prophylaxis
57778694|NCT04161599|DRUG|Metronidazole 1 g Intravenous|IV prophylaxis
57778695|NCT04161599|DRUG|Cefuroxime 1,5 g Intravenous|IV prophylaxis
57778696|NCT04161599|DRUG|Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral|Laxative for bowel cleansing
57778697|NCT01013935|OTHER|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
57778698|NCT01013935|OTHER|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
58490705|NCT02238652|BEHAVIORAL|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
57778699|NCT03941314|DEVICE|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
58490706|NCT04472832|DRUG|Placebo for Treatment A|6 tablets matched to mitapivat tablet
58490707|NCT04472832|DRUG|Mitapivat 100 mg|Two 50-mg tablets
57778700|NCT03941314|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
57778701|NCT04716413|DRUG|Dsuvia|Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
57778702|NCT06355908|BIOLOGICAL|IL13Rα2 CAR-T|The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.
57778703|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 alone for 21 days
57778704|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
57778705|NCT05856474|OTHER|pancreatectomy|pancreaserving surgery, using end to side or end to end, pancreaticojejunostomy
57778706|NCT01304043|DRUG|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
57778707|NCT05409196|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
57778708|NCT05409196|DRUG|Placebo|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
57778709|NCT00746317|DRUG|GC33|IV administration at 4 escalating dose levels.
57778710|NCT04096807|OTHER|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
57778711|NCT02075190|OTHER|Therapeutic Computerized intervention|Remediation training intervention
57778712|NCT02075190|OTHER|Nontherapeutic computerized intervention|Online gaming intervention
57778713|NCT02916992|RADIATION|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
57778714|NCT02916992|GENETIC|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
57778715|NCT05217823|DEVICE|Er:YAG laser|
57778716|NCT05217823|OTHER|hand instruments|
57778717|NCT05773131|DEVICE|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
57778718|NCT04550273|BEHAVIORAL|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
57778719|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
57778720|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
57778721|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
57778722|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
57778723|NCT00788255|DRUG|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
57778724|NCT00788255|DRUG|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
57778725|NCT00788255|DRUG|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
57778726|NCT02226172|DRUG|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
57778727|NCT02226172|DRUG|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
57778728|NCT02915575|OTHER|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (\<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
57778729|NCT02915575|OTHER|Usual Care|Participants will be discharged as per usual ward discharge protocols.
57778730|NCT04196374|GENETIC|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
57778731|NCT05297916|OTHER|enteral feeding|to intake oral feeding or delay it
57778732|NCT05470413|DRUG|SHR0302|SHR0302 4 mg
57778733|NCT05470413|DRUG|SHR0302|SHR0302 8 mg
57778734|NCT05470413|DRUG|Placebo|Placebo
58490708|NCT04472832|DRUG|Placebo for Treatment B|4 tablets matched to mitapivat tablet
58490709|NCT04472832|DRUG|Mitapivat 300 mg|Six 50-mg tablets
58490710|NCT04472832|DRUG|Placebo for Treatment C|4 tablets matched to mitapivat tablet
58471382|NCT01312857|DRUG|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
57778735|NCT04684927|DEVICE|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
57778736|NCT03580460|BEHAVIORAL|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
57778737|NCT01529190|DRUG|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
57778738|NCT01529190|DRUG|Placebo|placebo
57778739|NCT06100601|BEHAVIORAL|ANS regulation therapy|innovative intervention for functional dysphonia
57778740|NCT06100601|BEHAVIORAL|conventional voice therapy (CVT)|conventional voice therapy traditionally provided for functional dysphonia
57778741|NCT06100601|BEHAVIORAL|ANS regulation therapy + CVT|combination of ANS regulation therapy and CVT
57778742|NCT04070053|OTHER|TheraPPP Pathway|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
57778743|NCT00936338|BEHAVIORAL|splint and joint mobilization self exercise|
57778744|NCT02635282|DRUG|intranasal ketamine|
57778745|NCT02635282|DRUG|intranasal fentanyl|
57778746|NCT02635282|DRUG|intranasal midazolam|
57778747|NCT04448431|DRUG|Vortioxetine|10 or 20 mg/day, capsules, orally
57778748|NCT04448431|DRUG|Desvenlafaxine|50 mg/day capsules, orally
57778749|NCT05538481|OTHER|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
57778750|NCT05538481|OTHER|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
57778751|NCT05538481|OTHER|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
57778752|NCT03262701|DRUG|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
57778753|NCT03262701|DRUG|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
57778754|NCT03262701|OTHER|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
57778755|NCT01503138|BEHAVIORAL|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
57778756|NCT02864511|PROCEDURE|Nefertiti lift|
57778757|NCT04472780|DEVICE|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
57778758|NCT03923361|DRUG|Diprivan|Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
57778759|NCT05255484|DRUG|LM-108|Administered intravenously
57778760|NCT05255484|DRUG|An Anti-PD-1 Antibody|Administered intravenously
57778761|NCT04181398|DIAGNOSTIC_TEST|Anthropometry|"* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference."
57778762|NCT04181398|DIAGNOSTIC_TEST|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
57778763|NCT04181398|DIAGNOSTIC_TEST|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
57778764|NCT04181398|OTHER|Questionnaire|General questionnaire on cardiovascular risk factors
57778765|NCT04181398|DIAGNOSTIC_TEST|Blood sample|Blood sample for hs-CRP
57778766|NCT01346670|DRUG|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
57778767|NCT05221749|DRUG|Nanosilver Fluoride (NSF)|Optimized synthesis of Nanosilver Fluoride
57778768|NCT05221749|DRUG|Silver diamine fluoride|Silver Diamine Fluoride
57778769|NCT03364439|DRUG|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
57778770|NCT05709691|OTHER|Oculomotor therapy|Visual exercise to improve oculomotor behavior.
57778771|NCT05709691|OTHER|Adapted yoga|Muscular Stretching Therapy, postural control, respiratory physiotherapy.
57778772|NCT02676986|DRUG|Enzalutamide|Anti-androgen
57778773|NCT02676986|DRUG|Exemestane|Hormonal therapy (Licenced)
57778774|NCT03587792|PROCEDURE|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
57778775|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
57778776|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
57778777|NCT00398398|DRUG|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
57778778|NCT06078592|DRUG|BRIDIN-plus Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
57778779|NCT06078592|DRUG|Combigan Eye drops|One drop in the eyes, twice a day, approximately 12 hours apart.
57778780|NCT03000673|DRUG|Enoxaparin|Specified dose of Enoxaparin on specified days
57778781|NCT03000673|DRUG|unfractionated heparin (UFH)|Specified dose of UFH on specified days
57778782|NCT03000673|DRUG|BMS-986177|Specified dose of BMS-986177 on specified day
57778783|NCT04005729|DRUG|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
57778784|NCT00492843|DRUG|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
58471383|NCT01312857|DRUG|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
57778785|NCT02126436|OTHER|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
57778786|NCT02126436|OTHER|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
57778787|NCT05825664|PROCEDURE|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
57778788|NCT02723279|BEHAVIORAL|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
57778789|NCT02723279|DRUG|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
57778790|NCT01815736|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
57778791|NCT01815736|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
58471384|NCT05082857|BEHAVIORAL|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
57778792|NCT01815736|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
57778793|NCT01815736|DRUG|RTV|100 mg tablet administered orally once daily
57778794|NCT01815736|DRUG|ATV|300 mg capsule administered orally once daily
57778795|NCT01815736|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
57778796|NCT01815736|DRUG|COBI|150 mg tablet administered orally once daily
57778797|NCT01973894|PROCEDURE|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
57778798|NCT02948348|DRUG|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
57778799|NCT02948348|DRUG|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
57778800|NCT03660033|DIAGNOSTIC_TEST|ECG in delivery room|See arm/group discussions
57778801|NCT05081375|DRUG|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
57778802|NCT05081375|DRUG|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
57778803|NCT00549419|DRUG|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
57778804|NCT00549419|DRUG|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
57778805|NCT00549419|DRUG|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
57778806|NCT04430335|BEHAVIORAL|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
57778807|NCT04430335|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
57778808|NCT03983902|PROCEDURE|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
57778809|NCT03983902|PROCEDURE|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
57778810|NCT03983902|PROCEDURE|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
57778811|NCT05967104|OTHER|Education based on the PLISSIT model|Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
57778812|NCT03237962|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
57778813|NCT03237962|DEVICE|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
57778814|NCT03006627|DRUG|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
57778815|NCT03941743|DRUG|Fingolimod|Given PO
57778816|NCT03941743|DRUG|Fingolimod Hydrochloride|Given PO
58471385|NCT05082857|BEHAVIORAL|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
58471386|NCT03613532|DRUG|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
58471387|NCT03613532|DRUG|Fludarabine|Given once daily for 4 days
58471388|NCT03613532|DRUG|Busulfan|Given twice daily for 4 days
58471389|NCT03613532|DRUG|Venetoclax|Part 2 and Part 3: 14 doses for 8-12 cycles depending on dose level assigned
57778817|NCT03941743|OTHER|Questionnaire Administration|Ancillary studies
57778818|NCT02589392|OTHER|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
57778819|NCT02589392|OTHER|Cetaphil® Restoraderm® body wash|
57778820|NCT00312975|DRUG|CP-675,206|Given intravenously every 3 months
57778821|NCT00312975|DRUG|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
57778822|NCT01054690|DEVICE|Bactiguard Infection Protection (BIP) Cathter.|
57778823|NCT01054690|DEVICE|Silicone Urinary Catheter|
58471390|NCT03613532|DRUG|Azacitidine|Part 2: 5 doses for 8-12 cycles depending on dose level assigned
57778824|NCT02032667|BEHAVIORAL|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
57778825|NCT01736358|DRUG|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
57778826|NCT01736358|DRUG|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
57778827|NCT00466258|DRUG|R-CHOP|"* Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5."
57778828|NCT00466258|DRUG|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
57778829|NCT00466258|DRUG|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
57778830|NCT00466258|DRUG|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
57778831|NCT06737315|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
57778832|NCT06268041|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
57778833|NCT06268041|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
57778834|NCT06463028|DRUG|Sapanisertib|Oral
58471391|NCT03613532|DRUG|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
58471392|NCT03874338|DRUG|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
58471393|NCT03716180|DRUG|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
57778835|NCT06463028|DRUG|Serabelisib|Oral
57778836|NCT06463028|DRUG|Paclitaxel|Infusion
57778837|NCT04240756|BEHAVIORAL|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
57778838|NCT04240756|DRUG|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
57778839|NCT06738368|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
57778840|NCT06738368|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57778841|NCT06738368|PROCEDURE|Bone Marrow Collection|Undergo bone marrow sample collection
57778842|NCT06738368|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58131062|NCT06114732|BEHAVIORAL|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
58131063|NCT05944107|OTHER|Activated Clotting Time measurements combined with heparin concentration monitoring|In the HC group, the initial heparin dose is calculated using the HepCon HMS Plus . Except for ACT, heparin concentration is measured to maintain target heparin levels during CPB. The protamine dose for reversal is computed based on actual measured heparin levels using the device. ACT is also performed in all instances.
58131064|NCT05944107|OTHER|Activated Clotting Time|The target ACT for procedures other than Coronary Artery Bypass Grafting (CABG) is 400s when Minimally Invasive Extracorporeal Circulation is used. A bolus of 300 International Units(IU)/kg heparin are administered to reach this target and initiate cardiopulmonary bypass (CPB). Repeated ACT measurements guide further heparin dose to maintain adequate anticoagulation. Then, at the end of the CPB, 0.75 mg of protamine are administered for every 100IU of the initial heparin bolus.
58131065|NCT03988127|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
58131066|NCT01229020|OTHER|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
58138974|NCT06214364|DEVICE|Active Transcranial Direct Current Stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
58471394|NCT03716180|DRUG|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
58471395|NCT03716180|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
58471396|NCT06150638|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
58471397|NCT06150638|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
58471398|NCT04825678|DRUG|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
58471399|NCT06592690|OTHER|Atrial pacing support|Use a pacing mode with atrial pacing including a rate-resposive sensor.
58471400|NCT06592690|OTHER|Atrial tracking pacing mode|A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
58471401|NCT04909450|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
57778843|NCT06738368|DRUG|Cyclophosphamide|Given IV
57778844|NCT06738368|DRUG|Doxorubicin|Given CIV
57778845|NCT06738368|DRUG|Etoposide|Given CIV
57778846|NCT06738368|BIOLOGICAL|Filgrastim|Given SC
57778847|NCT06738368|BIOLOGICAL|Pegfilgrastim|Given SC
57778848|NCT06738368|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57778849|NCT06738368|DRUG|Prednisone|Given PO
57778850|NCT06738368|BIOLOGICAL|Rituximab|Given IV
57778851|NCT06738368|DRUG|Vincristine|Given CIV
57778852|NCT03806465|OTHER|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
57778853|NCT03806465|OTHER|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
57778854|NCT03806465|OTHER|Community mortality surveillance|A verbal autopsy will be performed
58131067|NCT04193566|DRUG|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
58471402|NCT04909450|BIOLOGICAL|Vehicle Control|Matching vehicle control without the drug substance
58471403|NCT05455021|COMBINATION_PRODUCT|Vessel Restoration System (VRS)|"The VRS includes the following components:~* VRS 10-8-10 Dimer Coated Balloon Catheter~* VRS Light Fiber~* VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
58471404|NCT04914364|OTHER|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
58471405|NCT06220435|RADIATION|Ultra-hypofractionated radiotherapy regimen.|"* Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions"
58471406|NCT06603285|DRUG|Treprostinil|sc/iv continuously
58471407|NCT05358665|OTHER|mask use|long term mask use
58471408|NCT05520255|DRUG|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
58471409|NCT03911505|BIOLOGICAL|Cipaglucosidase Alfa|Enzyme Replacement Therapy via intravenous infusion
58131068|NCT03332693|OTHER|Exercise|Leg weight raising
58131069|NCT03332693|OTHER|No exercise|Volunteers will not participate in exercise
58131070|NCT00252980|BEHAVIORAL|Psychotherapy|
58131071|NCT03395106|BEHAVIORAL|Parent source|Having a parent feature prominently in a news story
58471410|NCT03911505|DRUG|Miglustat|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
58471411|NCT05630924|OTHER|SI! Program-NYC|SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
58471412|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
58471413|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
58471414|NCT00399308|DEVICE|Control (compression bandaging)|Multi-layer compression bandaging
58471415|NCT01043068|DRUG|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
58471416|NCT03123692|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
58471417|NCT03123692|DRUG|Placebo|14 days treatment with placebo
58471418|NCT03059849|DRUG|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
58471419|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
58131072|NCT03395106|BEHAVIORAL|Doctor source|Having a doctor feature prominently in a news story
58131073|NCT03395106|BEHAVIORAL|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
58471420|NCT01074970|DRUG|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
58471421|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
58471422|NCT05684237|PROCEDURE|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
58471423|NCT05817890|DRUG|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
58471424|NCT04986865|DRUG|ATG-101|ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
58471425|NCT04161859|DIETARY_SUPPLEMENT|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
58471426|NCT03241732|OTHER|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
58471427|NCT03241732|DIETARY_SUPPLEMENT|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
58471428|NCT03241732|BEHAVIORAL|Neuro Emotive Technique|Neuro Emotive Technique sessions
58471429|NCT06059482|OTHER|Assessment|Evaluations will be made once.
58471430|NCT01852877|BEHAVIORAL|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
58471431|NCT06603363|DRUG|Rosuvastatin 40mg|Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.
58471432|NCT06603363|DRUG|Placebo|Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.
58471433|NCT06603363|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (Coronary CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.
58471434|NCT06603363|DIAGNOSTIC_TEST|Blood test|Blood test at baseline, 3-month, and 24-month visits.
58131074|NCT03395106|BEHAVIORAL|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
58131075|NCT03977051|BEHAVIORAL|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
58471435|NCT03458676|PROCEDURE|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
58131076|NCT03361228|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
58131077|NCT03361228|DRUG|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
58131078|NCT03361228|DRUG|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
58131079|NCT05781282|DEVICE|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
58131080|NCT00003898|DIETARY_SUPPLEMENT|glutamine|Oral
58131081|NCT02219165|DRUG|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
58131082|NCT02219165|DRUG|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
58131083|NCT05493176|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
58131084|NCT03348670|DRUG|Abiraterone - Usual|"* Oral~* Abiraterone Combined Chemotherapy (high dose)"
58131085|NCT03348670|DRUG|Abiraterone - Study|"* Oral~* Abiraterone Combined Chemotherapy (low dose)"
58131086|NCT03393650|OTHER|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
58131087|NCT03393650|OTHER|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
58131088|NCT00925626|PROCEDURE|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
58131089|NCT00925626|PROCEDURE|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
58131090|NCT06354803|OTHER|proprioceptive training|Proprioceptive training using swiss ball for 12 sessions
58131091|NCT02401126|DIETARY_SUPPLEMENT|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
58131092|NCT02401126|DIETARY_SUPPLEMENT|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
58131093|NCT02329756|DRUG|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
58131094|NCT02329756|DRUG|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
58471436|NCT03458676|PROCEDURE|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
58471437|NCT03079921|DRUG|Phentolamine|Physiologic receptor blockade (α1-receptor).
58131095|NCT02354742|OTHER|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
58131096|NCT02354742|OTHER|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
58131097|NCT04494659|DRUG|Famitinib capsule|single dose and co-administrated with Rifampicin capsule
58131098|NCT04494659|DRUG|Rifampicin capsule|repeated doses of Rifampicin capsule
58131099|NCT03093324|DRUG|ALKS 8700|Administered as specified in the treatment arm.
58131100|NCT03093324|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
58131101|NCT02716870|OTHER|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
58131102|NCT00496444|DRUG|Azacitidine|Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
58131103|NCT00496444|DRUG|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
58131104|NCT01979081|OTHER|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
58471438|NCT03079921|DRUG|Propranolol|Physiologic receptor blockade (β2-receptor).
58471439|NCT03079921|DRUG|Placebo|100mL bag of Normal Saline Solution (NSS).
58471440|NCT00080158|DRUG|fluoxetine|
58471441|NCT00080158|DRUG|sertraline|
58471442|NCT00080158|DRUG|citalopram|
58471443|NCT00080158|DRUG|escitalopram|
58471444|NCT00080158|DRUG|bupropion|
58471445|NCT00080158|DRUG|mirtazapine|
58471446|NCT00080158|DRUG|venlafaxine|
58471447|NCT00080158|DRUG|lithium|
58471448|NCT00080158|BEHAVIORAL|Cognitive Behavioral Therapy|
58471449|NCT06589817|DRUG|Hydrochloride Carliprazine capsules|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
58471450|NCT06589817|DRUG|Aripiprazole tablets|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
57778855|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
57778856|NCT00197028|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
57778857|NCT00197028|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
57778858|NCT00197028|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
57778859|NCT05093751|OTHER|Observation|This study does not involve any intervention to subjects.
57778860|NCT05264493|DRUG|NaxRedy ™|5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
57778861|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg IM (2mg/2 mL) injection into gluteal muscle
57778862|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg bolus IV (2mg/2 mL)
57778863|NCT03677063|OTHER|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
57778864|NCT03684005|OTHER|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
57778865|NCT04842279|OTHER|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
57778866|NCT02765555|DRUG|RBP-7000|Single dose
57778867|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
57778868|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
57778869|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
57778870|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
57778871|NCT01155388|DRUG|Ferumoxytol|Experimental: Ferumoxytol
57778872|NCT01155388|DRUG|Oral Iron|Active Comparator: Oral iron
57778873|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
57778874|NCT02917044|DEVICE|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
57778875|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
57778876|NCT02917044|DEVICE|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
57778877|NCT04203927|DRUG|Empagliflozin 25 MG|SGLT-2 inhibitor
57778878|NCT02769611|DRUG|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
57778879|NCT01369173|OTHER|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
57778880|NCT02672163|PROCEDURE|CABG surgery|Elective CABG surgery
58471451|NCT01727284|PROCEDURE|MR-guided cryoablation|
58490711|NCT05091775|DRUG|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
58471452|NCT04956796|BEHAVIORAL|Airway Video Library Training|A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
58471453|NCT04956796|BEHAVIORAL|Conventional Airway Training|The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
57778881|NCT02672163|PROCEDURE|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
57778882|NCT05318846|DRUG|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
57778883|NCT05318846|DRUG|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
57778884|NCT01187290|RADIATION|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
57778885|NCT00919893|DRUG|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
57778886|NCT00919893|DRUG|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
57778887|NCT05974553|BEHAVIORAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
57778888|NCT05974553|BEHAVIORAL|Supportive Group Psychotherapy for Justice-Involved Veterans|16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
57778889|NCT01797796|DRUG|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
57778890|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
57778891|NCT01797796|DRUG|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
57778892|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
57778893|NCT03866642|DEVICE|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
57778894|NCT03509922|DRUG|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
57778895|NCT03509922|DRUG|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
57778896|NCT01402167|PROCEDURE|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
57778897|NCT01402167|PROCEDURE|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
57778898|NCT02552680|OTHER|Exercise|Physical Exercise
57778899|NCT02552680|OTHER|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
57778900|NCT02552680|OTHER|Brochure|Manual/brochure containing information about general health
57778901|NCT02254850|PROCEDURE|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
57778902|NCT02254850|DRUG|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
57778903|NCT02254850|DRUG|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
57778904|NCT02254850|DRUG|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
58471454|NCT06543940|DRUG|Vancomycin|vancomycin dose is 7.5 to 10 mg/kg
57778905|NCT02254850|DRUG|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
57778906|NCT05291884|DEVICE|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
57778907|NCT01818934|PROCEDURE|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
57778908|NCT05796960|PROCEDURE|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
57778909|NCT00326690|DEVICE|Blue Egg Device|
58138975|NCT06214364|DEVICE|Sham Transcranial Direct Current Stimulation|"The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
58471455|NCT02027155|DRUG|AR09 solution|moderate levels of sedation
58471456|NCT02027155|DRUG|placebo|Sterile Saline, USP
58471457|NCT04033926|DRUG|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
58471458|NCT04033926|DRUG|Placebo|Subcutaneous injection for 16 weeks
58471459|NCT01796145|OTHER|Fibroscan|
58471460|NCT02802306|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
58471461|NCT03063892|DRUG|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
58471462|NCT03063892|DRUG|Saline solution|Saline solution is used as the placebo comparator
58471463|NCT04794855|DIAGNOSTIC_TEST|laboratory tests|routine laboratory tests and biomarkers tests
58471464|NCT05879185|BIOLOGICAL|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
58471465|NCT04080635|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
58471466|NCT04080635|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
58471467|NCT02658526|BEHAVIORAL|anesthesia - surgery|
58471468|NCT06478420|BIOLOGICAL|Omicron BA.5 SARS-CoV-2 challenge virus|The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
58471469|NCT03198650|DRUG|Acalabrutinib|Acalabrutinib
58471470|NCT03198650|DRUG|Obinutuzumab|Obinutuzumab
58471471|NCT05546827|PROCEDURE|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
58471472|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)|625 mg/m2 IV over 30 minutes, q2weeks
58471473|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)|320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
58471474|NCT00904969|DEVICE|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
58471475|NCT00904969|DEVICE|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
58471476|NCT01649349|DEVICE|two-piece nasogastric tube|one week period
58471477|NCT05935670|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
58138976|NCT01346007|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
58471478|NCT05991414|DEVICE|Home blood pressure monitor|Participants provided home blood pressure monitor and instructions on use from pharmacist. They will measure home BP every 4-weeks for 7 days as per Hypertension Canada 7-day home BP protocol.
58471479|NCT05991414|PROCEDURE|Enhanced community pharmacist care|Pharmacist to follow up with participants every month to review home BP readings. Then the pharmacist will send home BP readings and recommendations for changes to antihypertensive medication regimen to participants prescribing clinician. Pharmacist will then advise participants to follow up with their prescribing clinician.
58471480|NCT05991414|PROCEDURE|Usual pharmacist care|Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
58471481|NCT00685230|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
58471482|NCT00685230|OTHER|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
58471483|NCT04006405|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
58138977|NCT00099047|DRUG|celecoxib|Given PO
58138978|NCT00099047|DRUG|placebo|Given PO
58138979|NCT00099047|OTHER|laboratory biomarker analysis|Correlative studies
58471484|NCT03913455|DRUG|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
58471485|NCT03913455|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 5
58471486|NCT05525897|OTHER|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
58471487|NCT06371612|OTHER|Standard Care|Parental Presence
58471488|NCT06371612|OTHER|Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use
58471489|NCT06371612|BEHAVIORAL|Ball Squeezing + Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
58471490|NCT06020014|DRUG|AZD4604|AZD4604
58471491|NCT06020014|OTHER|Placebo|Placebo
58471492|NCT05561920|DEVICE|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
58471493|NCT05561920|DEVICE|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
58471494|NCT05561920|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires
58471495|NCT05611931|DRUG|Selinexor|Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
58471496|NCT05611931|DRUG|Matching Placebo for selinexor|Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
58471497|NCT05995210|PROCEDURE|Kinesio taping|A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.
58471498|NCT05995210|PROCEDURE|Orthosis|They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.
58471499|NCT05995210|PROCEDURE|Control|An exercise program focused on the knee and hip muscles was given two days a week.
58471500|NCT05549960|DEVICE|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
58471501|NCT05475015|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
58471502|NCT05475015|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
58471503|NCT06327945|DEVICE|Lung uDCD Protocol|The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
58471504|NCT03558659|DEVICE|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
58471505|NCT04984551|OTHER|Extension of Community Health (ECHO) Telementoring Clinic|Participate in ECHO clinics presenting cases for guidance and feedback
58471506|NCT04984551|OTHER|In-Country Workshops|In-Country Workshops Participate in hands-on training and workshops
58471507|NCT04984551|OTHER|Professional Oncology Educations Programs|Receive 5 core online lectures
58471508|NCT04984551|OTHER|Medical Chart Review|Medical charts are reviewed for data collection
58471509|NCT04984551|OTHER|Questionnaire Administration|Complete questionnaire(s)
58471510|NCT05363527|BIOLOGICAL|Endotoxin|Endotoxin
58471511|NCT05363527|BIOLOGICAL|Placebo|Placebo
57778910|NCT01932138|OTHER|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
58471512|NCT03659396|OTHER|individualized Tai Chi|individualized Tai Chi training exercise
58471513|NCT03659396|OTHER|Entire Tai Chi|the classical Yang style Tai Chi program
58471514|NCT03659396|OTHER|home-based program|Home-based exercise
58471515|NCT06010654|DEVICE|Software as a Medical device|The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
58471516|NCT03134196|DRUG|Masked Placebo|Oral Placebo
58471517|NCT03134196|DRUG|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
58471518|NCT00896857|GENETIC|RNA analysis|
58471519|NCT00896857|GENETIC|polymerase chain reaction|
58471520|NCT00896857|GENETIC|protein expression analysis|
58471521|NCT00896857|GENETIC|reverse transcriptase-polymerase chain reaction|
58471522|NCT00896857|GENETIC|western blotting|
58471523|NCT00896857|OTHER|immunoenzyme technique|
58471524|NCT00896857|OTHER|immunohistochemistry staining method|
58471525|NCT00896857|OTHER|laboratory biomarker analysis|
58471526|NCT00896857|PROCEDURE|breast duct lavage|
58471527|NCT00801957|DRUG|tacrolimus ointment 0.03%|topical application
58471528|NCT00801957|DRUG|hydrocortisone acetate ointment 1%|topical application
58471529|NCT00801957|DRUG|hydrocortisone butyrate ointment 0.1%|topical application
58471530|NCT00801957|BIOLOGICAL|Meningitec|im injection
58471531|NCT00801957|BIOLOGICAL|AC VAX|im injection
58471532|NCT02681523|DRUG|Eribulin|
58471533|NCT04230304|BIOLOGICAL|Daratumumab|Given IV
58471534|NCT04230304|DRUG|Ibrutinib|Given PO
58471535|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
58471536|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
58471537|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
58471538|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
58471539|NCT03108807|DIAGNOSTIC_TEST|D-dimer test|D-dimer test
58471540|NCT03589716|OTHER|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
58471541|NCT03589716|OTHER|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
58131105|NCT02802436|PROCEDURE|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
58131106|NCT01967108|OTHER|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
58131107|NCT01402908|DRUG|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
58131108|NCT01402908|OTHER|Placebo|Lactose lyophilized powder
58131109|NCT03160677|OTHER|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
58131110|NCT03160677|OTHER|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
58131111|NCT03622866|DEVICE|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
58131112|NCT03622866|DEVICE|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
58131113|NCT02232100|BEHAVIORAL|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
58131114|NCT02232100|BEHAVIORAL|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
58131115|NCT00771537|BEHAVIORAL|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
58131116|NCT02296515|PROCEDURE|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
58131117|NCT05194748|OTHER|No intervention, observational only|No intervention, observational only
58131118|NCT02792205|OTHER|Non interventional study|no intervention
58131119|NCT02356471|DEVICE|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
58131120|NCT02356471|OTHER|Questionnaire Administration|Ancillary studies
58131121|NCT02356471|OTHER|Quality-of-Life Assessment|Ancillary studies
58131122|NCT02445664|BEHAVIORAL|Educational video|Video: Information on osteoporosis and alendronate treatment.
58131123|NCT02583503|RADIATION|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
58471542|NCT03589716|OTHER|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
58471543|NCT03589716|OTHER|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
58471544|NCT03589716|OTHER|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
58131124|NCT05083299|DRUG|Sarpogrelate|Anpl-one SR
58131125|NCT01259869|DRUG|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
58131126|NCT05925595|DEVICE|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
58131127|NCT01975064|DRUG|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
58131128|NCT01975064|DRUG|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
58131129|NCT01586247|DIETARY_SUPPLEMENT|Synbiotic|8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis
58131130|NCT01586247|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
58131131|NCT01586247|DIETARY_SUPPLEMENT|Prebiotic|8g/day galacto-oligosaccharide
58131132|NCT01586247|DIETARY_SUPPLEMENT|Probiotic|10\^9 CFU/day B.lactis
58131133|NCT01469364|DRUG|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
58131134|NCT01469364|PROCEDURE|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
58138980|NCT05941403|BEHAVIORAL|Enhanced Produce Prescription Implementation|Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
58471545|NCT06586866|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
58471546|NCT00907426|DRUG|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
58471547|NCT00907426|DRUG|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
58471548|NCT06601088|DEVICE|Neuromuscular Electrical Stimulation|Patients will be instructed to apply the wearable NMES-therapy continuously, both day and night at least 10h/daily.
58471549|NCT02129543|PROCEDURE|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
58471550|NCT06591013|PROCEDURE|Fecal microbiota transplantation|Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
58131135|NCT02294812|BEHAVIORAL|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
58131136|NCT05198050|DRUG|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
58131137|NCT05198050|DRUG|Misoprostol Tabets|a synthetic prostaglandin medication
57778911|NCT01932138|OTHER|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
57778912|NCT01034241|DIETARY_SUPPLEMENT|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
57778913|NCT01034241|DIETARY_SUPPLEMENT|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
57778914|NCT01034241|DIETARY_SUPPLEMENT|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
57778915|NCT01034241|DIETARY_SUPPLEMENT|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
57778916|NCT04275180|DRUG|Argatroban|Argatroban plus standard medical treatment
57778917|NCT00003320|PROCEDURE|surgical procedure|
57778918|NCT00003320|RADIATION|radiation therapy|
57778919|NCT00003320|RADIATION|stereotactic radiosurgery|
57778920|NCT04719936|PROCEDURE|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
57778921|NCT04719936|PROCEDURE|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
57778922|NCT00356486|DRUG|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
57778923|NCT00356486|DRUG|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
57778924|NCT05506865|DRUG|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
58471551|NCT06243458|DRUG|RVU120 (SEL120)|RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
58471552|NCT06310187|OTHER|High Oxidant Unflavored Little Cigar - Group A|Subjects will be provided with high oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant unflavored little cigar to use for outcome measure data collection in the lab)
57778925|NCT05506865|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
57778926|NCT04103320|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
57778927|NCT00474175|DRUG|Placebo gel|single dose (less than 1g) of a matching placebo gel
57778928|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
57778929|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
57778930|NCT04786522|DIAGNOSTIC_TEST|Bioimpedenziometry, Handgrip strenght evaluation|The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.
57778931|NCT04786522|DIAGNOSTIC_TEST|Evaluation on blood specimens|Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)
57778932|NCT03816592|PROCEDURE|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
57778933|NCT03816592|PROCEDURE|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
57778934|NCT01182727|DRUG|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
57778935|NCT01306721|DRUG|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
57778936|NCT01306721|DRUG|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
58131138|NCT05198050|DRUG|Placebo tablets|Placebo tables with a similar appearance to letrozole
58131139|NCT02423902|BIOLOGICAL|Ad-RTS-hIL-12|Approximately 1.0x10\^12 viral particles (vp) per injection
58131140|NCT02423902|DRUG|Veledimex|7 oral doses of veledimex
58131141|NCT06346210|PROCEDURE|Tracheostomy|Surgery for tracheostomy
58131142|NCT01575522|OTHER|Laboratory Biomarker Analysis|Correlative studies
58471553|NCT06310187|OTHER|Low Oxidant Unflavored Little Cigar - Group B|Subjects will be provided with low oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant unflavored little cigar to use for outcome measure data collection in the lab)
58131143|NCT01575522|DRUG|Tivantinib|Given PO
58131144|NCT00552331|DEVICE|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
58471554|NCT06310187|OTHER|High Oxidant Flavored Little Cigar - Group C|Subjects will be provided with high oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant flavored little cigar to use for outcome measure data collection in the lab)
58471555|NCT06310187|OTHER|Low Oxidant Flavored Little Cigar - Group D|Subjects will be provided with low oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant flavored little cigar to use for outcome measure data collection in the lab)
58471556|NCT06310187|OTHER|Usual Cigarette - Group E|Subjects will use one of their own cigarettes in the collection of outcome measure data in the lab.
58471557|NCT06310187|OTHER|Unlit Little Cigar - Group F|Subjects will be provided with an unlit little cigars to use for outcome measure data collection in the lab. This will be the control group for outcome measure data.
58471558|NCT05377996|DRUG|XMT-1660|XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
58471559|NCT06434116|DEVICE|Immersive virtual reality|"The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection."
58471560|NCT03560037|DEVICE|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
58471561|NCT06328686|DIETARY_SUPPLEMENT|Arginine|Given IV or PO
58471562|NCT06328686|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58471563|NCT06328686|PROCEDURE|Computed Tomography|Undergo CT
58471564|NCT06328686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58471565|NCT06328686|PROCEDURE|Spectroscopy|Undergo spectroscopy
58471566|NCT06328686|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
58471567|NCT06183762|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
58471568|NCT02717234|OTHER|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
58471569|NCT06597682|DRUG|Oral prednisone tablet treatment|Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
58471570|NCT06597682|DRUG|Inhalation treatment with budesonide/formoterol|Inhalation treatment with budesonide/formoterol powder inhaler (160µg; 4.5µg), inhaled twice daily, for a total duration of 2 weeks.
58471571|NCT06597682|DRUG|Combination therapy with cognitive enhancer drugs and oral prednisone|Combination therapy with cognitive enhancer drugs and oral prednisone , starting dose of prednisone is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
58471572|NCT06597682|DRUG|Oral placebo (cornstarch tablets)|Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
58471573|NCT06597682|DRUG|Inhalation of placebo (saline solution)|Inhalation of placebo (saline solution), inhaled twice daily, for a total duration of 2 weeks.
58471574|NCT06597682|DRUG|Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets)|Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets), starting dose of cornstarch tablets is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
58131145|NCT00552331|DEVICE|LISS|treatment of distal femur fractures with less invasive stabilization systems
58471575|NCT05228470|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
58471576|NCT05304039|BEHAVIORAL|Questionnaires|Questionnaires about asthma control and quality of life
58471577|NCT05304039|DEVICE|Spirometry|Spirometry monitoring at home
58471578|NCT05304039|DEVICE|Fractional Exhaled Nitric Oxide (FeNO)|Measuring fractional exhaled nitric oxide at home
58471579|NCT05304039|DEVICE|Corsano watch|Monitoring vital parameters at home
58471580|NCT05304039|DEVICE|e-Nose|Breathprint will be performed using e-Nose
58471581|NCT05304039|PROCEDURE|Nasopharyngeal swabs and nasal lining fluid|Nasopharyngeal swabs and nasal lining fluid will be performed
58471582|NCT05304039|DEVICE|Sputum culture|If patients produce sputum, the sputum will be analysed
58471583|NCT05304039|PROCEDURE|Blood sample|Blood sample for standard care and 10 ml extra will be taken
58471584|NCT05197426|DRUG|Oral Azacitidine|Specified dose on specified days
58471585|NCT05197426|OTHER|Placebo|Specified dose of specified days
58471586|NCT04731701|DIAGNOSTIC_TEST|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
58471587|NCT04922944|DRUG|COVID-19 vaccine|Two-dose COVID-19 vaccine
58471588|NCT06008951|OTHER|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
58471589|NCT06008951|OTHER|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
58471590|NCT01195766|DRUG|Ofatumumab|Ofatumumab in addition with ESHAP therapy
58471591|NCT05003505|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
58471592|NCT04080661|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
58471593|NCT04080661|OTHER|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
58471594|NCT01967849|DIAGNOSTIC_TEST|Oral Glucose tolerance test|
58471595|NCT06593743|DRUG|Perianal NRL001 Gel 3 strengths|A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.
58471596|NCT06593743|DRUG|Intraanal NRL001 Gel 2 strengths|A single application of 3.0% or 1.0% Gel
58471597|NCT06593743|DRUG|Intrarectal NRL001 Gel|A single application of 1.0% Gel
58471598|NCT06593743|DRUG|NRL001: 10mg suppository|NRL001 10mg suppository applied to rectum.
58471599|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
58471600|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
58471601|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
58471602|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
58471603|NCT05261646|DRUG|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
58471604|NCT05261646|DRUG|Matching placebo|Matching placebo（Stage 1；Stage 2）
58471605|NCT05546879|DRUG|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
58471606|NCT05546879|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
58471607|NCT05546879|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
58471608|NCT04774393|DRUG|Decitabine and Cedazuridine|Given PO
58471609|NCT04774393|DRUG|Enasidenib|Given PO
58471610|NCT04774393|DRUG|Ivosidenib|Given PO
58471611|NCT04774393|DRUG|Venetoclax|Given PO
58471612|NCT06594601|PROCEDURE|lung recruitment potential assessed by 3D EIT|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential."
58471613|NCT06594601|PROCEDURE|PEEP titration by 3D eit|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The PEEP titriatino by 3D EIT fwas as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. RM: PEEP was switched to a 21cmH2O for 2min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) ≥90%.~3. PEEP was stepwise decrease from 21 to 0 cmH2O PEEP in steps of 3cm H2O every 2min.~4. 3D EIT was used to monitor regional ventilation distribution during PEEP titration."
58471614|NCT06281756|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Subjects will receive therapy for 8 weeks
58471615|NCT06281756|DRUG|Trazodone|Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
58471616|NCT06281756|OTHER|Placebo|Non-remitting subjects will receive placebo for 8 weeks
58471617|NCT00270881|PROCEDURE|Cord blood transplantation|unrelated cord blood transplantation
58471618|NCT00270881|RADIATION|TBI|Total body irradiation (TBI) 12Gy
58471619|NCT00270881|DRUG|cyclophosphamide|cyclophosphamide 120mg/kg
58471620|NCT00270881|DRUG|cytarabine|cytarabine 3g/m2x4
58471621|NCT05929274|DEVICE|tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.
58471622|NCT05929274|DEVICE|sham tDCS|For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
58471623|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content, and Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms, in addition they also receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
58471624|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content|Participants receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
58471625|NCT06229444|BEHAVIORAL|Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms.
58471626|NCT06229444|BEHAVIORAL|No Intervention|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive IILI-related health educational content
58471627|NCT02814006|OTHER|health educational video|visualization of health educational video
58471628|NCT06593379|BEHAVIORAL|Safety planning|Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.
58471629|NCT06593379|BEHAVIORAL|Treatment as usual|This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans
58471630|NCT06593379|BEHAVIORAL|MIST Intervention|This is a mobile intervention designed to target and modify suicidal cognitions. Veteran in this condition will be asked to use the intervention 5 times a week for 4 weeks.
58471631|NCT06588920|BEHAVIORAL|Cognitive function, gait, and electroencephalogram|Measurement of cognitive function, gait performance, and electroencephalogram
58471632|NCT03558737|OTHER|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
58471633|NCT03558737|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
58471634|NCT05685914|PROCEDURE|endoscopic surgery|Emergency or elective surgery
58471635|NCT06135805|DRUG|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
58471636|NCT06135805|DRUG|Placebo|Application of placebo oral gel on oral lesions
58471637|NCT06601829|OTHER|abdominal ultrasound|abdominal ulterasound showing multiple cysts in the kidnets and hepatic fibrosis
58471638|NCT02783690|RADIATION|Hypofractionation|40 Gy (RBE) in 15 daily fractions
58471639|NCT03105713|OTHER|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
58471640|NCT06397456|BEHAVIORAL|In-Person Patient Education|In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
58471641|NCT06397456|BEHAVIORAL|Commitment to Change|Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
58471642|NCT06397456|BEHAVIORAL|Blood pressure monitoring|Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
58471643|NCT06397456|BEHAVIORAL|Written Patient Education|Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
58471644|NCT06397456|BEHAVIORAL|Text-based reinforcement for CKD self-management|Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
58471645|NCT06397456|BEHAVIORAL|Community-based education session, reinforcement for self-management|"Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection"
58471646|NCT06397456|BEHAVIORAL|Text-based reinforcement for general health self-management|Patient educator will use text messages to send general health management messages
58471647|NCT03280719|DEVICE|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
58471648|NCT03280719|RADIATION|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
58471649|NCT03280719|DEVICE|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
58471650|NCT03280719|RADIATION|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
58471651|NCT04876521|DRUG|Amisulpride|low dose of Amisulpride at 100-300 mg/day
58471652|NCT04876521|DRUG|Olanzapine-Fluoxetine Combination|Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
58471653|NCT00181168|DRUG|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
58471654|NCT05165134|OTHER|Kinesiotape|Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
58471655|NCT03988400|BEHAVIORAL|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
58471656|NCT03988400|BEHAVIORAL|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
58471657|NCT06289101|BEHAVIORAL|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
58471658|NCT02151864|DRUG|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
58471659|NCT05406232|PROCEDURE|Biopsy|Undergo tumor punch biopsy
58471660|NCT05406232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58471661|NCT05406232|RADIATION|Radiation Therapy|Undergo RT
58471662|NCT06524297|OTHER|Metaverse system (Patients)|The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.
58471663|NCT06524297|OTHER|Metaverse system (Resident Physician)|The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
57778937|NCT01306721|DRUG|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
58471664|NCT02043457|OTHER|phenotyping|
58471665|NCT01617824|DRUG|Linagliptin|Linagliptin 5 mg tablets for 4 days
58471666|NCT01617824|DRUG|Placebo|Placebo tablets for 4 days
58471667|NCT06184633|DRUG|Semaglutide 3.2 MG/ML|Intervention arm receives semaglutide in addition to combined lifestyle intervention
58471668|NCT06184633|DRUG|Placebo|Control arm receives placebo in addition to combined lifestyle intervention
58471669|NCT03982121|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
58471670|NCT03982121|DRUG|Nivolumab|Nivolumab 240 mg
58471671|NCT03982121|DRUG|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
58471672|NCT03982121|DRUG|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
58471673|NCT06398652|BIOLOGICAL|CMAB015|Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
58471674|NCT06398652|BIOLOGICAL|Secukinumab|Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
58471675|NCT06226129|DRUG|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
58471676|NCT04809987|OTHER|Virtual Gait|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.
58471677|NCT04809987|OTHER|Physical Exercise|Specific gait exercise was conducted.
58471678|NCT04809987|OTHER|Documental projection|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
58471679|NCT04777799|DEVICE|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
58471680|NCT05186233|BEHAVIORAL|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
58471681|NCT02273934|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
57778938|NCT01306721|DRUG|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
58471682|NCT02273934|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
58471683|NCT06350643|OTHER|Black Health Block Culturally Tailored training|This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening (HDLCS) training.
58471684|NCT06350643|OTHER|Health Disparities and Lung Cancer Screening training|The Health Disparities and Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
58471685|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in first stage|Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
58471686|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in second stage|Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
58471687|NCT03200249|RADIATION|Preoperative chemo-radiation with IG-IMRT dose escalation|
58471688|NCT03288532|DRUG|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
58471689|NCT03288532|DRUG|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
58471690|NCT03913533|DEVICE|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
58471691|NCT03913533|DEVICE|Heart rate assessment using Tap-based smartphone application|At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
58471692|NCT04179500|DRUG|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
58471693|NCT04179500|DRUG|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
58471694|NCT04179500|DRUG|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
58471695|NCT04179500|DRUG|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
58471696|NCT04403204|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
57778939|NCT04837521|BEHAVIORAL|Unified Protocol|Five session psychotherapy
58138981|NCT04953832|BEHAVIORAL|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
58471697|NCT04403204|OTHER|DCE-MRI|Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
58471698|NCT06578468|DEVICE|End-tidal oxygen monitor|"The only additional equipment required for this study is the Philips™ IntelliVue G7m Gas Analyser Module 866173. This provides a non-dispersive infrared measurement of respiratory gases and a paramagnetic measurement of oxygen. At Lincoln Medical Center, the gas analyser used will be a Philips G5 gas analyser connected to a Philips Intellivue MP 70. At the University of New Mexico Medical Center, the Masimo root monitor is used.~The gas analysers produce display waves for O2 and CO2, together with numerics for end-tidal values for O2 and CO2 and to our knowledge, there are no differences in values between the various devices used. The gas sampling occurs through a side-stream sampling tube at a rate of 200ml/min ±20 ml/min, which is either obtained from a nasal cannula in the spontaneously breathing patient or a sidestream line if connected to a BVM."
58471699|NCT06517446|OTHER|Optokinetic Virtual Reality Stimulation|"Optokinetic stimulation;~• A warning will be given by colored balloons rotating clockwise and counterclockwise, starting at 10°/second and gradually increasing up to 60°/second. • Optokinetic stimulation will start with 30 seconds and increase to 150 seconds as the sessions progress. • Patients are asked to focus on a balloon in the moving image. • Stimulations will be given when the patient is sitting, in a semi-tandem stance, in a tandem stance, or standing upright."
58471700|NCT06517446|OTHER|Conventional rehabilitation program based on Cawthorne Cooksey exercises|The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
58471701|NCT05467527|BEHAVIORAL|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
58471702|NCT05467527|BEHAVIORAL|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
58471703|NCT03729115|PROCEDURE|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
58471704|NCT04649229|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
58471705|NCT04649229|DRUG|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
58471706|NCT04649229|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
58471707|NCT04649229|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
58471708|NCT04649229|DRUG|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
58471709|NCT04334824|DRUG|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
58471710|NCT04334824|DRUG|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
58471711|NCT03933007|DRUG|Colchicine,|"the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
58471712|NCT03933007|DRUG|midazolam,|Midazolam 1 mg
58471713|NCT03933007|DRUG|fexofenadine|Fexofenadine 120 mg
58471714|NCT04109547|DRUG|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
58471715|NCT04109547|DRUG|Placebo|Tablets to be taken once-daily for 26 weeks
58471716|NCT06596746|OTHER|Observation|In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
58471717|NCT06588699|DRUG|Digoxin|Taken orally once daily
58471718|NCT06588699|DRUG|Placebo|Matched Placebo taken orally once daily
58471719|NCT06581211|PROCEDURE|Aromatherapy and Essential Oils|Inhale LA
58471720|NCT06581211|OTHER|Electronic Health Record Review|Ancillary studies
58471721|NCT06581211|OTHER|Jojoba Oil|Inhale jojoba oil aromatherapy
58471722|NCT06581211|OTHER|Lavender Oil|Inhale LAO
58471723|NCT06581211|OTHER|Questionnaire Administration|Ancillary studies
58471724|NCT04335669|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
58471725|NCT04335669|DRUG|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
58471726|NCT05083923|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
58471727|NCT05533385|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
58471728|NCT05823571|DRUG|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
58471729|NCT05272007|PROCEDURE|EUS-biliary drainage|EUS-GBD with LAMS
58471730|NCT02825693|PROCEDURE|Conventional cataract surgery (phacoemulsification)|
58471731|NCT02825693|PROCEDURE|Femtosecond laser assisted cataract surgery|
58471732|NCT04142606|OTHER|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
58471733|NCT04818671|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
58471734|NCT02415608|DRUG|Ibrutinib|Given orally in 28-day cycles
58471735|NCT04561206|DRUG|Brentuximab Vedotin|Given IV
58131146|NCT05994222|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
58471736|NCT04561206|BIOLOGICAL|Nivolumab|Given IV
58471737|NCT00417326|DRUG|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
58471738|NCT00417326|DRUG|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
58471739|NCT03104868|BEHAVIORAL|TAKE IT Strategy|"The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
58471740|NCT05523089|DRUG|Saline placebo|Sterile normal saline for injection
58471741|NCT05523089|COMBINATION_PRODUCT|CD388|CD388 liquid for injection
58471742|NCT03587844|DRUG|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
58471743|NCT03587844|DRUG|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
58471744|NCT03587844|DRUG|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
58131147|NCT01106326|BEHAVIORAL|Intervention|"Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
58471745|NCT02230410|DEVICE|CryoBalloon Focal Ablation|
58471746|NCT05923125|BEHAVIORAL|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
58471747|NCT04762290|OTHER|Dance|The intervention is a series of expressive dance movements.
58471748|NCT02514135|OTHER|No intervention|
58471749|NCT06569901|BEHAVIORAL|Hope Intervention|"Group meetings after hospital discharge reflecting on themes that may have an impact on hope.~The Hope Intervention consists of four group meetings and two individual conversations during a four week period."
58471750|NCT05522153|DRUG|Arista|hemostatic powder
58471751|NCT06358612|OTHER|Stress Balls|Patients in the experimental arm will receive a foam stress ball to squeeze during their biopsy procedure.
58471752|NCT00262340|OTHER|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
58471753|NCT06306105|DIETARY_SUPPLEMENT|Marine Collagen Peptides|consume 1 bottle per day
58471754|NCT06306105|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
58471755|NCT06586476|BEHAVIORAL|Nightly Timed Awakening|Patients in this arm will be awakened 1-hr after going to bed by their caregiver(s) to use the restroom and then returned to sleep. This awakening will occur every night.
58471756|NCT05562466|DRUG|QMF149|QMF149 75/40 μg o.d via Breezhaler
58131148|NCT02512978|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
58471757|NCT05562466|DRUG|Budesonide|Budesonide 200 μg o.d via Breezhaler
58471758|NCT04430452|BIOLOGICAL|Durvalumab|Given IV
58471759|NCT04430452|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
58471760|NCT04430452|BIOLOGICAL|Tremelimumab|Given IV
58471761|NCT05052125|DRUG|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
58471762|NCT03090360|DIETARY_SUPPLEMENT|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
58471763|NCT03090360|DIETARY_SUPPLEMENT|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
58471764|NCT06602375|OTHER|Standard care|The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
58471765|NCT06602375|OTHER|Physical Therapy (PT)|Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
58471766|NCT06600503|BEHAVIORAL|RehabLung mobile application|Participants in the intervention group will receive in-person pulmonary rehabilitation during their surgical admission and access to a mobile pulmonary rehabilitation application for self-training. This program begins one month before surgery and continues for seven weeks after surgery. The application is designed to encourage participants to engage in pulmonary rehabilitation exercises from preoperative preparation through postoperative care. It offers guided chest breathing exercises, using visual and movement instructions created and remotely prescribed by a physical therapist. Participants will receive daily breathing exercise prescriptions throughout the study period.
58471767|NCT06600503|BEHAVIORAL|Lung cancer postoperative standard care|Participants in the usual care group will receive in-person pulmonary rehabilitation during surgical admission, pre-operative healthcare, and guidance on breathing exercises to practice before surgery. They will also receive post-operative breathing exercise prescriptions to follow at home.
58471768|NCT06600503|OTHER|Healthcare interactive Web Platform|The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.
58471769|NCT06559696|RADIATION|internal mammary nodal irradiation|chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
58471770|NCT06559696|RADIATION|No internal mammary node irradiation|chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
58471771|NCT06601790|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
58471772|NCT06601790|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
58471773|NCT01772472|DRUG|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
58471774|NCT01772472|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
58471775|NCT04897997|PROCEDURE|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
58471776|NCT05773664|DRUG|Azeliragon|Given PO
58471777|NCT05773664|PROCEDURE|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
58471778|NCT05773664|PROCEDURE|Computed Tomography|Undergo CT scan
58471779|NCT05773664|DRUG|Dexamethasone|Given PO or IV
58471780|NCT05773664|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
58471781|NCT04786119|DEVICE|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
58471782|NCT06587477|OTHER|Hormonal profile|Blood for FSH, LH, testosterone
57778940|NCT03620682|BEHAVIORAL|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
58471783|NCT06587477|OTHER|Semen analysis|Semen analysis
58471784|NCT06587477|OTHER|Questionnaire|The European Male Ageing Study (EMAS) questionnaire
58471785|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
58471786|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
58471787|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
58471788|NCT03255603|OTHER|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
57778941|NCT03620682|BEHAVIORAL|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
57778942|NCT01389063|DRUG|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
58471789|NCT06593717|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
58471790|NCT06593717|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
58471791|NCT06593717|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
58471792|NCT06593717|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
58471793|NCT06593717|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
58471794|NCT06593717|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
58471795|NCT06593717|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
58471796|NCT06593717|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
58471797|NCT06593717|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
58471798|NCT02698215|DRUG|Varenicline|Varenicline 1 mg twice daily
58471799|NCT02698215|DRUG|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
58471800|NCT03548285|RADIATION|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
58471801|NCT06597357|PROCEDURE|Arthroscopy &amp; saline irrigation alone|the meniscus scaffold is aimed at replacing partial meniscus defect with a synthetic device.
58471802|NCT06192654|PROCEDURE|Small intestinal submucosa (SIS) graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
58471803|NCT06192654|PROCEDURE|Autologous oral bucal mucosa graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
58471804|NCT04780061|DRUG|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
58471805|NCT04780061|DIETARY_SUPPLEMENT|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
58471806|NCT04780061|DIETARY_SUPPLEMENT|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
58471807|NCT04780061|OTHER|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
58471808|NCT04780061|OTHER|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
58471809|NCT06705296|DEVICE|Open Label Deep Brain Stimulation|Patients will receive open label deep brain stimulation
58471810|NCT06705296|DEVICE|Double blinded Deep Brain Stimulation|Patients will receive double blinded deep brain stimulation
58471811|NCT06705296|BEHAVIORAL|Prolonged exposure therapy|Patients will receive prolonged exposure therapy
57778943|NCT00255229|DRUG|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
57778944|NCT00255229|OTHER|Placebo|Glutamine placebo
58471812|NCT06705296|DEVICE|Closed loop Deep brain stimulation|Patients will receive closed loop deep brain stimulation
58471813|NCT04058717|OTHER|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
58471814|NCT04058717|OTHER|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
58471815|NCT04058717|OTHER|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
58471816|NCT04058717|OTHER|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
58471817|NCT03317405|DRUG|Endoxifen Hydrochloride|Apply to the skin
58471818|NCT03317405|OTHER|Placebo Administration|Apply to the skin
58471819|NCT03317405|OTHER|Questionnaire Administration|Ancillary studies
58471820|NCT01473134|DEVICE|Oxford Cementless Partial Knee|Oxford Partial Knee applied without bone cement.
58471821|NCT01473134|DEVICE|Oxford Cemented Partial Knee|Oxford Partial Knee applied with bone cement.
58471822|NCT04291781|BIOLOGICAL|RC18 160mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
58471823|NCT04291781|BIOLOGICAL|RC18 240mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
58471824|NCT04291781|BIOLOGICAL|placebo|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
58471825|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
58471826|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
58471827|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
58471828|NCT04442022|DRUG|Placebo matching for Selinexor (combination therapy)|Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
58471829|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
58471830|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
58471831|NCT04442022|DRUG|Gemcitabine (combination therapy)|Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
57778945|NCT02869269|DEVICE|Early stage|patients who classed as clinical stage 1 and 2
57778946|NCT02869269|DEVICE|Late stage|patients who classed as clinical stage 3 and 4
57778947|NCT06358872|DRUG|Azithromycin for Oral Suspension|Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
57778948|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion low level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.
57778949|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion high level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.
58471832|NCT04442022|DRUG|Dexamethasone (combination therapy)|Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
58471833|NCT04442022|DRUG|Cisplatin (combination therapy)|Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
58471834|NCT04442022|DRUG|Selinexor (continuous therapy)|Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
58471835|NCT04442022|DRUG|Placebo matching for Selinexor (continuous therapy)|Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
58471836|NCT04644952|OTHER|Electronic Health Record Review|Review of medical records
58471837|NCT06206031|DEVICE|Intraosseous ultrasonography at tibia before, during, and after a physiological vascular stimulation (venous occlusions, arterial occlusion, handgrip)|"Timing for sub-protocol 1 (performed twice with 2-to-10-day interval): donning in supine position - rest 5 minutes - venous occlusion to 40 mmHg 3 minutes - rest 10 minutes - arterial occlusion to 200mmHg 2 minutes - post-occlusion period 10 minutes - rest 10 minutes - static handgrip 30% Maximum Voluntary Force 3 minutes - recovery 2 minutes and doffing.~Timing for sub-protocol 2 (performed once). First, two sequences of intraosseous ultrasonography are performed in 45° head-up tilt position, with 10-minutes rest between sequences: donning and rest 5 minutes - occlusion to 80 mmHg 2 minutes - rest 10 minutes - occlusion to 180 mmHg 2 minutes - rest 10 minutes. During the first sequence, ultrasonography probe is positioned between middle and lower third of tibia for cortical bone measurement; during the second - at distal epiphysis of the tibia for trabecular bone measurement. After ultrasonography, subject is sitting down for 10 minutes for computed tomography."
58471838|NCT06591494|DRUG|Classic quadruple therapy|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
58471839|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of bismuth|Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID
58471840|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of clarithromycin|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
58471841|NCT06580704|DRUG|Lumbosacral Erector Spinae Plane Block|Patients will receive ultrasound-guided lumbosacral erector spinae plane block.
58471842|NCT06580704|DRUG|Psoas Muscle Compartment With Sciatic Nerve Block|Patients will receive ultrasound-guided psoas muscle compartment with sciatic nerve block.
57778950|NCT04099381|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
57778951|NCT04315714|OTHER|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
57778952|NCT05759312|DRUG|Zimberelimab|Zimberelimab 240mg IV every 2 weeks
57778953|NCT05759312|DRUG|Metformin Hydrochloride|Metformin 2000mg PO QD
58131149|NCT05818696|BEHAVIORAL|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
58471843|NCT05136586|OTHER|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
58471844|NCT05136586|OTHER|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
58471845|NCT05136586|OTHER|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
58471846|NCT05136586|OTHER|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
58471847|NCT06145737|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|"One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module."
58471848|NCT04921670|DIAGNOSTIC_TEST|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
58471849|NCT05794620|OTHER|Stool sample|Stool sample
58471850|NCT03119259|BEHAVIORAL|ABC Clinical Program|"The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary."
58471851|NCT03119259|BEHAVIORAL|BCN|"BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others."
58471852|NCT06591702|OTHER|Questionnaire study|Questionnaire application
58471853|NCT05130580|OTHER|Enhanced Consultation|Attend an enhanced consultation with decision aid
58471854|NCT05130580|OTHER|Standard of Care Consultation|Attend standard of care consultation
58471855|NCT05130580|PROCEDURE|Conventional Imaging|Undergo 2D and 3D torso imaging
58471856|NCT05130580|OTHER|Educational Intervention|Receive educational materials
58471857|NCT05130580|OTHER|Questionnaire Administration|Ancillary studies
58471858|NCT03175679|BIOLOGICAL|iNKT cells|The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.
58471859|NCT03175679|DRUG|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
58471860|NCT03175679|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
58471861|NCT00174408|DRUG|Genotropin|
58490712|NCT05053958|OTHER|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
58490713|NCT03753113|DRUG|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
57778954|NCT03242603|BIOLOGICAL|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
58131150|NCT05818696|BEHAVIORAL|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
58131151|NCT03095222|DRUG|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
58471862|NCT06407921|DEVICE|Whole Body Vibration|On vibration plate pate child will do kneeling, and one leg standing, standing horizontally or vertically. Along routine physical therapy such as stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, elbow and wrist flexors, pronators, and ulnar deviators, each stretch will be given for 30 seconds with 3 repetitions.Strength training to hip flexor, knee extensor, and ankle dorsiflexors for 15 minutes 3 times a week for 8 weeks. Session will be of 30 minutes
58471863|NCT06407921|DEVICE|BOSU ball|Exercises such as (1) standing on a BOSU ball while throwing and catching a ball (2) 1-legged standing (affected leg) on the BOSU ball while throwing and catching a ball with therapist support; and (3) small jumps on the BOSU ball. Three sets of 6 repetitions for each exercise will be perform every 2 weeks up to a maximum of 10 repetitions if the participants were still able to perform the training easily. Total dose of balance training in 1 session will be 15 minutes
58471864|NCT04066283|OTHER|No intervention|There was no intervention in this study
58471865|NCT06594055|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring is a wearable device that continuously collects glucose data from interstitial fluid.
58471866|NCT06594055|DEVICE|Self-monitoring blood glucose|The control group used self-monitoring blood glucose (SMBG) for two weeks with a manual food diary, followed by diet education. They then repeated SMBG with a food diary three months later, with a final follow-up at the 6-month mark.
58471867|NCT06594055|DEVICE|AI food camera|The AI food camera automatically detects the contents and nutritional information of foods.
58471868|NCT06594055|DEVICE|Food diary|A food diary is a record in which the user manually writes down the consumed foods and their amounts.
58471869|NCT06590974|DRUG|Freeze-dried Human Protein C Concentrate|Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
58471870|NCT06113068|DEVICE|Fistura® procedure|The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
58471871|NCT00033332|DRUG|dexamethasone|
58471872|NCT00033332|DRUG|pamidronate disodium|
58471873|NCT00033332|DRUG|thalidomide|
58471874|NCT00033332|DRUG|zoledronic acid|
58471875|NCT05904704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58471876|NCT05904704|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
58471877|NCT06595849|BEHAVIORAL|4-week feeling tone intervention program|Participants will take part in a 4-week mindfulness of feeling tone intervention program taught by a registered mindfulness teacher, who is also a registered clinical psychologist. The intervention program includes 4 sessions, with each session lasting for about 2 hours. The program is taught in Cantonese, in a group setting, live online (via Zoom). Participants will practice meditation practices during the session, explore themes of the week, review and explore their meditation experiences. They will also practice meditation practices daily for at least 30 minutes at home, with meditation audio recordings provided by the teacher.
58471878|NCT02121223|DEVICE|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (\>=16atm) for at least 15 seconds.
58471879|NCT02121223|DEVICE|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
57778955|NCT02025452|OTHER|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
58131152|NCT03095222|DRUG|Opioids|Standard of care for pain management.
58471880|NCT06554873|DRUG|Nicoderm|Depending on responder status and group assignment the maximum amount of time nicotine patches will be used is 24 weeks. The final four weeks of nicotine patch treatment will comprise 2 weeks of 14 mg patches and two weeks of 7 mg patches.
58471881|NCT06554873|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 24 weeks.
58471882|NCT06554873|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 24 weeks.
58471883|NCT06554873|OTHER|NJOY e-cigarette|Each NJOY Classic Tobacco and Menthol pod is pre-filled with 1.9 mL of e-liquid with 5% nicotine (by weight); as needed maximum usage 24 weeks.
58471884|NCT06554873|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 24 weeks.
58471885|NCT05849142|DEVICE|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
58471886|NCT04599244|OTHER|emergency pulpotomy|removal of coronal pulp
58471887|NCT06599359|BEHAVIORAL|BLISS Questionnaire|"After extensive literature review and review from the IRB of the Lebanese University. A questionnaire was developed to assess the Intention to leave, job stress, burnout, and job satisfaction among pharmacists in Lebanon~The following sections will be considered:~* Socio-economic characteristics~* Work-related characteristics~* Job stress assessment (Likert scale)~* Burnout assessment (Likert scale)~* Intention to Leave assessment (Likert scale)"
58471888|NCT06510439|BEHAVIORAL|Need to Be Needed Intervention|Interventionist-supported volunteering intervention that targets opportunities creating social connections that matter through focus on kindness and gratitude throughout the intervention.
58471889|NCT06510439|OTHER|Active Control Group|Weekly non-directive listening support
58471890|NCT05367778|DRUG|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
57778956|NCT02025452|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
57778957|NCT02025452|OTHER|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
58131153|NCT02958709|DRUG|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
58471891|NCT02212015|DRUG|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
58471892|NCT05224973|BEHAVIORAL|speech therapy|speech therapy during 2 months
58471893|NCT02314468|PROCEDURE|Negative pressure wound therapy|NPWT changed twice a week.
58471894|NCT02314468|PROCEDURE|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
58471895|NCT06598839|DRUG|Thymosin Alpha1|subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
58471896|NCT01703195|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
58471897|NCT01703195|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
58471898|NCT03732417|OTHER|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
58471899|NCT06307340|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)|Adapted version of evidence-based behavioral PTSD intervention.
58471900|NCT06307340|BEHAVIORAL|Treatment as Usual|Treatment as usual.
58471901|NCT05722535|BEHAVIORAL|Media Discussion and Planning Tool (MDPT)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
58471902|NCT06599762|DRUG|Tranexamic acid|Tranexamic acid 1 gram orally twice daily
58471903|NCT06599762|DRUG|Placebo|Placebo orally twice daily
58471904|NCT05002127|DRUG|Evorpacept (ALX148)|IV Q2W
58471905|NCT05002127|DRUG|Trastuzumab|IV Q2W
58471906|NCT05002127|DRUG|Ramucirumab|IV Q2W
58471907|NCT05002127|DRUG|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
58471908|NCT04950127|DRUG|Linerixibat|Participants will receive linerixibat.
58471909|NCT04950127|DRUG|Placebo|Participants will receive placebo.
58471910|NCT02484248|DRUG|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
58471911|NCT02484248|DRUG|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
57778958|NCT01454180|DRUG|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
57784801|NCT00129675|DRUG|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
58471912|NCT06166732|BEHAVIORAL|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
58471913|NCT06166732|BEHAVIORAL|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
58471914|NCT06134518|OTHER|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
58471915|NCT06134518|OTHER|the initial orientation from the PHCs|the initial orientation from the PHCs
58471916|NCT06603545|OTHER|Digital education for osteoporosis patients|DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
58471917|NCT05432856|BEHAVIORAL|Time restricted eating, nutrition education, and sedentary time reduction strategies|"1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
58471918|NCT05279196|OTHER|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
58471919|NCT00107198|PROCEDURE|Conventional Surgery|Undergo surgery
58471920|NCT00107198|DRUG|Cyclophosphamide|Given IV
58471921|NCT00107198|DRUG|Doxorubicin Hydrochloride|Given IV
58471922|NCT00107198|DRUG|Prednisone|Given IV or PO
58471923|NCT00107198|RADIATION|Radiation Therapy|Undergo IFRT
58471924|NCT00107198|DRUG|Vincristine Sulfate|Given IV
58471925|NCT06213571|OTHER|Exercise Counseling|Participate in exercise coaching sessions
58471926|NCT06213571|OTHER|Exercise Intervention|Participate in home-based exercise program
58471927|NCT06213571|OTHER|Health Promotion and Education|Receive resistance band and exercise booklets
58471928|NCT06213571|OTHER|Interview|Ancillary studies
58471929|NCT06213571|OTHER|Physical Performance Testing|Ancillary studies
58471930|NCT06213571|OTHER|Questionnaire Administration|Ancillary studies
58471931|NCT06213571|OTHER|Telemedicine|Participate in sessions remotely
58471932|NCT06588023|OTHER|Observational study to evaluate professional practices|"It consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.~The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight)."
58471933|NCT04282486|OTHER|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
58471934|NCT06322199|BEHAVIORAL|ASSIP (Attempted Suicide Short Intervention Program) flex|"ASSIP is a specific therapy for patients after a suicide attempt. The brief therapy ASSIP consists of 3-4 sessions of approximately 50 min. each. ASSIP flex delivers ASSIP in the patient's personal environment as an outreach home treatment. The structure of the ASSIP is the same as in the regular ASSIP, but the program is delivered in the patient's environment.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her personal story, which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
58471935|NCT01967238|BIOLOGICAL|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
58471936|NCT05229887|PROCEDURE|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
58471937|NCT05229887|PROCEDURE|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
58471938|NCT04466943|DEVICE|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
58471939|NCT06598826|DEVICE|Graston technique (IASTM)|Group A includes 26 patients post ND who received Graston technique (IASTM) , in additional to traditional treatment (ROM exercise, strengthening exercise, and stretching exercise) for 1 month
58471940|NCT06598826|OTHER|Kinesio taping|Group B includes 26 patients who received Kinesiotaping, in addition to traditional treatment (ROM exercise, strengthening exercise, and stretching exercises) for 1 month
58471941|NCT06591065|BEHAVIORAL|Yoga Flow|The study participants were subjected to an intervention comprising hatha yoga sessions conducted twicw weekly over an twelve weeks period, with each session lasting 60 minutes.
58471942|NCT06591065|OTHER|Controlled|The control group did not receive any yoga training
58471943|NCT06406595|OTHER|Observation|This study is observational, therefore, there is no intervention included.
58471944|NCT03970746|BIOLOGICAL|PDC*lung01|PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
58471945|NCT03970746|DRUG|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
58471946|NCT03970746|DRUG|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
58471947|NCT05682430|BEHAVIORAL|Heart rate based HIIT|Week1,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week2,90% HRmax long duration HIIT + 90% long duration HRmax HIIT. Week3,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week4,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week5,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week6,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week7,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week8,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week9,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week10,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week11,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week12,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT.
58490714|NCT03753113|DRUG|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
58490715|NCT00939393|DEVICE|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
58490716|NCT00939393|DEVICE|Balloon Sinuplasty|Balloon dilatation of sinuses
57784802|NCT04268836|DEVICE|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
58471948|NCT05682430|BEHAVIORAL|VIFT speed-based HIIT with mechanical work|Week1,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week2,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week3,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week4,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week5,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week6,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week7,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week8,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week9,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week10,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week11,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT. Week12,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT.
58471949|NCT05328609|DIETARY_SUPPLEMENT|Semaine Hormonal Imbalance & The Daily|All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
58471950|NCT04265144|BIOLOGICAL|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
58471951|NCT04265144|OTHER|Biopsy|Skin biopsies only for volunteers among patients
58471952|NCT04265144|OTHER|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
58471953|NCT04265144|OTHER|Biopsy|Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
58471954|NCT05894109|DIETARY_SUPPLEMENT|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
58471955|NCT05894109|OTHER|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
58471956|NCT00809185|DRUG|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
58471957|NCT00809185|OTHER|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
58471958|NCT00809185|PROCEDURE|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
58471959|NCT06117306|DRUG|3,4 Methylenedioxymethamphetamine|1 MDMA session
58471960|NCT06117306|BEHAVIORAL|Prolonged Exposure|12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
58471961|NCT06281132|DRUG|CKD-341, D956|A single dose of 1 tablet under fasting condition
58471962|NCT06588179|DRUG|SHR-1501+SHR-2005|SHR-1501, instillation；SHR-2005, instillation
58471963|NCT02900729|DEVICE|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
58471964|NCT02900729|DRUG|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
58471965|NCT04877613|DRUG|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
58471966|NCT04877613|DRUG|Fludarabine|Lymphodepletion
58471967|NCT04877613|DRUG|Cyclophosphamide|Lymphodepletion
58471968|NCT06585111|OTHER|Intervention|"In the first motivational interview, the HAPA Model Prenatal Motivation Interview Questionnaire, the first part of the Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, and the Breastfeeding Intention Scale for Pregnant Women Expecting Twins were applied. A brochure on breastfeeding twin babies prepared by the researcher was distributed to women. In the second interview, the HAPA Model Postpartum Motivation Interview Scale, the second part of which was the Personal Information Form, Breastfeeding Follow-up Form, Breastfeeding Motivation Scale and Postpartum Breastfeeding Self-Efficacy Scale were applied. In the third meeting, the Breastfeeding Follow-up Form was applied. Breastfeeding Motivation Scale, Postpartum Breastfeeding Self-Efficacy Scale and Breastfeeding Follow-up Form were applied in the fourth and fifth interviews, and Breastfeeding Follow-up Form was applied in the sixth interview."
58471969|NCT04299464|DRUG|Placebo|Participants will receive oral placebo for approximately 12 weeks.
58471970|NCT04299464|DRUG|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
58471971|NCT04488679|OTHER|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
58471972|NCT06329817|PROCEDURE|Incidence of regurgitation in two different position.|Preventing aspiration pneumonia in general anaesthesia in two different position supine v/s semi - Fowler
58471973|NCT06342037|DRUG|Tiragolumab|600mg every 3 weeks (Q3W)
58471974|NCT06342037|DRUG|Atezolizumab|1200mg every 3 weeks (Q3W)
58471975|NCT06342037|DRUG|Ipilimumab|1 mg/kg, maximum of 4 cycles
58471976|NCT06090422|DRUG|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
58471977|NCT06090422|DRUG|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
58471978|NCT04686474|DRUG|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
58471979|NCT06604663|BEHAVIORAL|Activation of the CDSS system|Activation of the CDSS system, whereby outreach workers and clinicians have access to and ability to act upon lists of patients who are at highest risk of missing their upcoming clinical appointment.
58471980|NCT00453206|PROCEDURE|allogeneic bone marrow transplantation|
58471981|NCT00453206|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58471982|NCT00453206|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
58471983|NCT00453206|PROCEDURE|peripheral blood stem cell transplantation|
58471984|NCT01915784|DEVICE|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
58471985|NCT01915784|DEVICE|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
57784531|NCT03900312|BEHAVIORAL|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
58131154|NCT02958709|DRUG|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
58471986|NCT03702127|DEVICE|Transcranial magnetic stimulation|NIBS is applied to the brain.
58471987|NCT03773640|DEVICE|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
58471988|NCT03773640|DRUG|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
58471989|NCT02443688|DRUG|CTX-4430|
58471990|NCT02443688|DRUG|Placebo|
58471991|NCT05686603|DEVICE|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
58471992|NCT05686603|DEVICE|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
58471993|NCT06597812|PROCEDURE|Sevoflurane|Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).
58471994|NCT01885299|RADIATION|SRS/SBRT|Intervention varies by condition being treated.
58471995|NCT01863784|DRUG|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
58471996|NCT03177317|DRUG|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
58471997|NCT04542837|BIOLOGICAL|KN046|Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
58471998|NCT04542837|DRUG|Lenvatinib|Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW\<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
58471999|NCT03727217|DIAGNOSTIC_TEST|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
58472000|NCT04282187|DRUG|Decitabine|Given IV
58472001|NCT04282187|DRUG|Ruxolitinib|Given PO
58472002|NCT04282187|DRUG|Fedratinib|Given PO
58472003|NCT04282187|OTHER|Questionnaire Administration|Ancillary studies
58472004|NCT04282187|DRUG|Pacritinib|Given PO
58472005|NCT05914090|PROCEDURE|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
58472006|NCT02167971|OTHER|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
58472007|NCT02167971|OTHER|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
58472008|NCT02715609|DRUG|Disulfiram|
58472009|NCT02715609|DRUG|Copper Gluconate|
58472010|NCT02715609|PROCEDURE|Surgery|
58472011|NCT02715609|RADIATION|Radiation|
58472012|NCT02715609|DRUG|Temozolomide|
58472013|NCT06586294|DRUG|Drug: AK129 Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
58472014|NCT06586294|DRUG|Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
58472015|NCT06596655|DEVICE|Single use bronchoscope|Use of single use bronchoscopes for interventional pulmonology procedures instead of reusable bronchoscopes.
58472016|NCT04268979|BEHAVIORAL|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
58472017|NCT04268979|BEHAVIORAL|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
58472018|NCT05199337|DRUG|ZN-d5|ZN-d5 will be administered orally
58472019|NCT01223534|DRUG|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
58472020|NCT01223534|DRUG|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
58472021|NCT00541658|DRUG|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
58472022|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
58472023|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
58472024|NCT06407414|OTHER|control|classical physiotherapy methods
58472025|NCT06407414|OTHER|Exercise|In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
58472026|NCT05962528|DEVICE|Soft lens|Patients were randomly fitted with five different designs of soft lenses
58472027|NCT05908461|BEHAVIORAL|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
58472028|NCT00603317|DRUG|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
58472029|NCT00603317|DRUG|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
58472030|NCT03664531|OTHER|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
58472031|NCT03664531|OTHER|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
58472032|NCT03664531|OTHER|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
58472033|NCT04690686|DEVICE|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
58472034|NCT04690686|DEVICE|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
58472035|NCT04690686|DEVICE|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
58472036|NCT01527370|BIOLOGICAL|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
58472037|NCT03131024|DIETARY_SUPPLEMENT|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
58472038|NCT03131024|OTHER|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
58472039|NCT06601309|DRUG|Serplulimab|Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
58472040|NCT06601309|DRUG|Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
58472041|NCT06601309|DRUG|Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
58472042|NCT06601309|RADIATION|Radiotherapy|Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
58472043|NCT03072407|BIOLOGICAL|PB-119 injection|
58472044|NCT03072407|BIOLOGICAL|PB-119 injection placebo|
58472045|NCT05518812|DRUG|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
58472046|NCT04230759|DRUG|Chemotherapy|"Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
58131155|NCT02958709|DRUG|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
58472047|NCT04230759|RADIATION|Radiation|PTV_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
58472048|NCT04230759|DRUG|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
58472049|NCT03481088|PROCEDURE|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
58472050|NCT02453620|PROCEDURE|Biopsy|Undergo tissue biopsy
58472051|NCT02453620|OTHER|Blood Sample|Undergo blood sample collection
58472052|NCT02453620|PROCEDURE|Bone Scan|Undergo bone scan
58472053|NCT02453620|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58472054|NCT02453620|DRUG|Entinostat|Given PO
58472055|NCT02453620|BIOLOGICAL|Ipilimumab|Given IV
58472056|NCT02453620|BIOLOGICAL|Nivolumab|Given IV
58472057|NCT02453620|OTHER|Pharmacogenomic Study|Correlative studies
58472058|NCT02453620|OTHER|Pharmacological Study|Correlative studies
58472059|NCT02453620|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58472060|NCT05943691|DRUG|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
58472061|NCT05943691|DRUG|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
58472062|NCT04895891|DEVICE|EOS hand imaging|For each patient, EOS images are compared with CT images
58472063|NCT05933941|OTHER|Virtual reality|"This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility."
58472064|NCT05933941|OTHER|Exercises|The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
58472065|NCT06592560|DEVICE|ELISA|Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
58472066|NCT03562364|OTHER|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
58472067|NCT06234189|DEVICE|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|30 minutes without DIMS and 30 minutes with DIMS
58472068|NCT06650709|DRUG|Olaparib|Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
58472069|NCT06650709|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
58472070|NCT06650709|DRUG|Durvalumab|Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
58472071|NCT05558332|BEHAVIORAL|Youth-Nominated Support Teams for CHR|"Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk."
58472072|NCT01269203|DRUG|Curcumin|1000 mg per day
58472073|NCT01269203|OTHER|Placebo|Administered daily same as Curcumin.
58472074|NCT04665453|DIAGNOSTIC_TEST|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
58472075|NCT04665453|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
58472076|NCT04665453|DRUG|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
58472077|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
58472078|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
58472079|NCT06603051|PROCEDURE|Cryoneurolysis|Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
58472080|NCT06123338|DRUG|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
58472081|NCT06123338|DRUG|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
58472082|NCT06123338|DRUG|Oxaliplatin|Oxaliplatin every 3 weeks, +/-7 days
57784803|NCT05381428|DRUG|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
58472083|NCT06123338|DRUG|Capecitabine|Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
58472084|NCT06588777|PROCEDURE|Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)|transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
58472085|NCT06588777|PROCEDURE|Quadratus lumborum block|"using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle"
58472086|NCT04820075|BEHAVIORAL|improvement of preoperative shower|Process about preoperative shower
58472087|NCT05120180|PROCEDURE|axillary lymph node dissection with vein branches reservation|Spare the vein branches when ALND being performed
58472088|NCT05120180|PROCEDURE|axillary lymph node dissection without vein branches reservation|Don't spare the vein branches when ALND being performed
58472089|NCT01314183|OTHER|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
58472090|NCT01314183|OTHER|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
58472091|NCT06592612|RADIATION|SBRT and second-line systemic therapy|Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
58472092|NCT06592612|DRUG|Second-line systemic therapy|Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
58472093|NCT06092723|DIETARY_SUPPLEMENT|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
58472094|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 1,Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
58472095|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 2,Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
58472096|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
58490717|NCT04681976|BEHAVIORAL|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
57778959|NCT01454180|DRUG|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
58131156|NCT01124149|DRUG|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
58472097|NCT01183689|BEHAVIORAL|Small Behavior Changes|"The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level."
58472098|NCT01183689|BEHAVIORAL|Large Behavior Changes|"The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking."
58472099|NCT03894124|DRUG|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
58472100|NCT01553656|DRUG|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
58472101|NCT01553656|DRUG|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
58472102|NCT02581085|DRUG|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
58472103|NCT02581085|OTHER|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
58472104|NCT05249556|DRUG|Ganaxolone|Ganaxolone
58472105|NCT05249556|DRUG|Placebo|Placebo (for ganaxolone)
58472106|NCT02575963|DRUG|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
58472107|NCT02575963|BIOLOGICAL|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
58472108|NCT02575963|DRUG|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
58472109|NCT02575963|DRUG|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
58472110|NCT06592209|BEHAVIORAL|Sedentary Breaks|Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
58472111|NCT06246539|BEHAVIORAL|VR mindfulness|VR-based mindfulness
58472112|NCT06590506|DEVICE|Wearable|Continuous monitoring thought data recorded with wearable (Vivosmart Garmin bracelet)
58472113|NCT06600659|OTHER|Non-Interventional Study|Non-interventional study
58472114|NCT05903794|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
58472115|NCT03641755|DRUG|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
58472116|NCT03641755|DRUG|Olaparib|Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
58472117|NCT01128374|PROCEDURE|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
58472118|NCT04077073|DEVICE|ReIn-Hand|ReIn-Hand assists the hand opening
58472119|NCT04077073|DEVICE|Robot|Robot supports the shoulder load
58131157|NCT01684553|BEHAVIORAL|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
58472120|NCT06511037|DRUG|Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging|Given IV
58131158|NCT01684553|BEHAVIORAL|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
58131159|NCT00118105|BIOLOGICAL|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
58472121|NCT04474080|BEHAVIORAL|Virtual Peer Support Platform|The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
58472122|NCT04474080|BEHAVIORAL|Control Period|The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
58472123|NCT00593346|RADIATION|brachytherapy|brachytherapy (radioactive implants)
58472124|NCT06589609|BIOLOGICAL|FluBHPVE6E7|Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.
58472125|NCT06588439|OTHER|Cognitive-motor training|Cognitive-motor training is that cognitive tasks incorporated into motor tasks.
58472126|NCT06588439|OTHER|Conventional physiotherapy|Conventional physiotherapy includes stretching, ROM exercise, strengthening exercise, and eye-hand coordination.
58472127|NCT05372757|PROCEDURE|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
58472128|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Containing Milk|"Participants will be asked to drink 1% regular milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
58472129|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Free Milk|"Participants will be asked to drink 1% lactose-free milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
58472130|NCT02963246|BEHAVIORAL|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
58472131|NCT05750823|DRUG|Ruxolitinib Cream|Ruxolitinib cream will be applied twice daily for upto 48 weeks
58472132|NCT03768492|DRUG|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
58472133|NCT03768492|OTHER|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
58472134|NCT05005429|DRUG|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
58472135|NCT06590701|OTHER|Early dart throwing motion-mobilization|We compare two different mobilisations in the rehabilitation of patients following scapholunate ligament reconstruction
58472136|NCT06587880|DRUG|Chlorhexidine Gluconate|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction, the patient is instructed to pour 10 ml of the mouthwash into a measuring cup, rinse for 1 minute at an alternative time to teeth brushing. Do not eat or drink for 30 min after use.
58472137|NCT06587880|DRUG|Bone Bioactive Liquid|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
58472138|NCT06587880|DRUG|Hyaluronic Acid mouthwash|Prescribed for 7 days period 3-4 times a day starting 24 hours post-extraction, the patient is instructed to pour 20 ml of the mouthwash into a measuring cup and rinse for 1 minute, at an alternative time to teeth brushing. Do not eat or drink for 30 mins after use.
58472139|NCT06587880|DRUG|Warm Saline Mouth Rinse|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
58472140|NCT02662673|DEVICE|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
58472141|NCT04467437|OTHER|Gait Training|Training that targets rehabilitation of walking function
58472142|NCT04467437|DEVICE|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
58472143|NCT01682239|OTHER|RVAP|In this arm pacemaker leads will be placed in the RV apex.
58472144|NCT01682239|OTHER|RVSP|In this arm pacemaker leads will be placed in the RV septum.
58472145|NCT03041740|DRUG|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
58472146|NCT06359158|DEVICE|Digital stethoscope use|In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
58472147|NCT04375891|RADIATION|Radiation Therapy|30 Gy in 10 fractions of 3 Gy each
58472148|NCT04375891|RADIATION|Radiofrequency Ablation (RFA)|Radiofrequency Ablation (RFA) / Vertebral Augmentation
58472149|NCT02954536|DRUG|pembrolizumab|
58472150|NCT02954536|DRUG|trastuzumab|
58472151|NCT02954536|DRUG|capecitabine|
58472152|NCT02954536|DRUG|cisplatin|
58472153|NCT02954536|DRUG|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
58472154|NCT02954536|DRUG|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
58472155|NCT02610855|PROCEDURE|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
58472156|NCT02610855|OTHER|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
58472157|NCT02610855|DEVICE|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
58472158|NCT02610855|OTHER|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
58472159|NCT06493552|DRUG|SEphB4-HSA|A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
58472160|NCT06493552|DRUG|Pembrolizumab|Antibody to human PD-1.
58472161|NCT06493552|DRUG|Gemcitabine|A chemotherapy drug used to treat various types of cancer.
58472162|NCT06493552|DRUG|Cisplatin|A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
58472163|NCT06493552|DRUG|Enfortumab vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate.
58472164|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁷ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: single intradermal dose of 10⁷ PFU/0.2 ml of vaccinia virus."
58472165|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁶ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: two intradermal doses of 10⁶ PFU/0.2 ml of vaccinia virus (given 28 days apart)."
58472166|NCT05846243|BIOLOGICAL|Live Smallpox Vaccine|"Live smallpox vaccine (Smallpox vaccine) (manufactured by the Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of Russia).~Batch No. Т30 (expiry date: March, 2021). Dosage: Single 1x10⁶ PFU dose administered by multiple-pricking technique on the 30th/60th day after full series of vaccination with VAC∆6."
58472167|NCT05846243|OTHER|Placebo (Sodium chloride bufus, 0.9%)|"Sodium chloride bufus, a 0.9% solvent for the preparation of a dosage form for injections (manufactured by JSC Pharmaceutical manufacturing company Obnovlenie, Russia).~Batch: 391219 (expiry date: January, 2025)."
58472168|NCT04172181|PROCEDURE|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
58472169|NCT00456846|DRUG|ABI-007|100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
58472170|NCT06591676|BEHAVIORAL|Dysfunctional Attitude Scale (DAS)|Dysfunctional Attitude Scale (DAS) is a self-report scale designed to measure the presence and intensity of dysfunctional attitudes. It is widely used to assess impaired cognitive patterns associated with depression and other mental health conditions. Initially developed in English, its usefulness can be extended by translating and culturally adapting it into Urdu language.
58472171|NCT04160117|DRUG|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
58131160|NCT00118105|DRUG|capecitabine|Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
58131161|NCT00118105|DRUG|oxaliplatin|130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4
58131162|NCT00118105|PROCEDURE|conventional surgery|Resection
58131163|NCT00044226|DRUG|ML-04A|
58131164|NCT05233280|OTHER|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
58131165|NCT05054868|DRUG|Oxycodone|Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).
58472172|NCT04160117|DRUG|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
58472173|NCT06305702|DRUG|inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
58472174|NCT00522093|DRUG|TJ-100|TJ-100 2.5g three times per day for 6 weeks
58490718|NCT04235751|BEHAVIORAL|Professional Coaching|6 individualized professional coaching sessions via phone
58131166|NCT05054868|DRUG|Ketorolac|Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
58472175|NCT06379659|DRUG|Growh hormone|In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
58472176|NCT06379659|OTHER|Placebo|Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
58490870|NCT03755804|RADIATION|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
57778960|NCT05969938|DIAGNOSTIC_TEST|MRD detection|Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.
57778961|NCT02359383|OTHER|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
57778962|NCT01501422|DRUG|Estrogen patch|50 microgram estrogen patch weekly
57778963|NCT01501422|DRUG|Placebo|Placebo patch for 8 weeks
57778964|NCT02551744|DRUG|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
57778965|NCT02551744|DRUG|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
57778966|NCT02255630|OTHER|Cycling Exercise|
57778967|NCT04394741|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
57778968|NCT04394741|DEVICE|Control-Dry Needling|"Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times."
57778969|NCT04376229|OTHER|Registry|Registry of cancer patients who receive proton radiation therapy
57778970|NCT03298607|DIETARY_SUPPLEMENT|Placebo|2 months treatment
57778971|NCT03298607|DIETARY_SUPPLEMENT|Serelys PMS|2 months treatment
57778972|NCT04401553|DRUG|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
57778973|NCT04401553|DRUG|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
57778974|NCT03250026|BEHAVIORAL|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
57778975|NCT03250026|BEHAVIORAL|Care Manager|Regular contact Care Manager during around 12 weeks
57778976|NCT06275048|OTHER|Wrist/hand immobilization|Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
57778977|NCT04861662|PROCEDURE|Free gingival graft procedure|Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
57778978|NCT03048032|PROCEDURE|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
57778979|NCT03048032|PROCEDURE|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
58131167|NCT01678547|DEVICE|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
57778980|NCT01245868|DRUG|Lidocaine|
57778981|NCT01245868|DRUG|bupivacaine|
57778982|NCT00230321|DRUG|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
57778983|NCT01162941|OTHER|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
57778984|NCT05606315|DRUG|Remimazolam Besylate|NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
57778985|NCT05606315|DRUG|Propofol|Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
58131168|NCT01678547|DEVICE|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
57778986|NCT05606315|DRUG|Midazolam|Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
57778987|NCT05073744|DRUG|Nalbuphine|Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
58131169|NCT01678547|OTHER|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
58131170|NCT02909140|DRUG|Topical phenylephrine 2.5%|
58131171|NCT02909140|DRUG|Topical cyclopentolate 1%|
58131172|NCT02909140|DRUG|Intracameral Lidocaine 1%|
58472177|NCT04005846|DEVICE|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
58472178|NCT00278343|DRUG|cediranib maleate|30mg given PO, daily
58472179|NCT00278343|OTHER|laboratory biomarker analysis|Correlative studies
58472180|NCT06593847|BEHAVIORAL|Single-session VR exposure intervention|VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
58490871|NCT04424264|DRUG|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
58490872|NCT04424264|DRUG|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
57778988|NCT05073744|DRUG|Morphine|Morphine hydrochloride injection is used for perioperative tumor ablation
57778989|NCT01215708|DRUG|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
57778990|NCT03739320|DRUG|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
57778991|NCT01952301|DEVICE|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
57778992|NCT01952301|DEVICE|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
57778993|NCT01905579|PROCEDURE|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
57778994|NCT05802160|BEHAVIORAL|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
57778995|NCT00570661|DRUG|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
58131173|NCT02909140|DRUG|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
58131174|NCT02226458|DRUG|EPI-743|
58138982|NCT03536130|DEVICE|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
58138983|NCT03079050|DRUG|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
57778996|NCT01423864|DRUG|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
57778997|NCT01423864|DRUG|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
57778998|NCT01493830|GENETIC|fluorescence in situ hybridization|
57778999|NCT01493830|GENETIC|gene expression analysis|
57779000|NCT01493830|GENETIC|microarray analysis|
57779001|NCT01493830|GENETIC|mutation analysis|
57779002|NCT01493830|GENETIC|protein analysis|
57779003|NCT01493830|OTHER|immunohistochemistry staining method|
57779004|NCT01493830|OTHER|laboratory biomarker analysis|
57779005|NCT01493830|OTHER|microscopy|
57779006|NCT03541642|BEHAVIORAL|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
57779007|NCT03541642|BEHAVIORAL|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
57779008|NCT01387503|PROCEDURE|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
57779009|NCT05310032|DRUG|HSG4112|Once-daily oral adminstration
57779010|NCT05310032|DRUG|Placebo|Once-daily oral adminstration
57779011|NCT04681430|BIOLOGICAL|Convalescent plasma|transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)
57779012|NCT04681430|DRUG|Camostat Mesilate|Tablets over 7 days, daily dose of 600 mg split into 3 doses
57779013|NCT04681430|DRUG|Placebo for Camostat Mesilate|Placebo Tablets over 7 days, split into 3 doses
58131175|NCT06457945|BEHAVIORAL|ASRT|The task involves the presentation of a visual stimulus in one of four horizontal locations on the screen, and participants are instructed to indicate the location of the target stimulus by pressing the corresponding key on the keyboard. In case of correct response, the target stimulus disappears, and after a 120 ms interstimulus interval, the next stimulus appears. In case of an incorrect response, the target stimulus remains in place until the first correct response. The stimuli follow a probabilistic eight-element sequence, with pattern and random elements alternating with each other. Each participant will be assigned to one of 24 possible sequences throughout the task. The ASRT task will be composed of 25 blocks, with each block containing ten repetitions of the eight-element sequence. After each block, participants will have to take a short break and answer the thought probes before continuing. All patients will perform the task one time.
58131176|NCT06457945|BEHAVIORAL|Questionnaires|"All patients will have to fill questionnaire at the beginning of the study~* Spontaneous and Deliberate Mind Wandering Scales (SDMWS)~* Epworth Sleepiness Scale~* Narcolepsy Severity Index~* Idiopathic Hypersomnia Severity Scale~* Hospital Anxiety and Depression scale~* Horne \& Ostberg questionnaire~* Attention Deficit Hyperactivity Disorder (ADHD) auto-evaluation~* Pittsburgh Sleep Quality Index~* Insomnia Severity Index~* Psychotic-like experiences scale"
58131177|NCT06457945|DEVICE|Electrophysiological recordings|A subset of patients in each arm will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT
58131178|NCT02388763|DEVICE|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
58131179|NCT02388763|DEVICE|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
58131180|NCT01756937|DRUG|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
58131181|NCT01756937|DRUG|Placebo|1 capsule once daily for 24 weeks
58131182|NCT06350656|OTHER|Clinical data collection|Post-retrieval from the medical record
58131183|NCT06350656|OTHER|Therapeutic data collection|Post-retrieval from the medical record
58131184|NCT06350656|OTHER|IntraCranial Pression (ICP) values collection|Post-retrieval of ICP values from the monitor
58131185|NCT05814848|DRUG|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
57779014|NCT04681430|OTHER|Standard of Care (SoC)|Control Arm for convalescent plasma (CP)
57779015|NCT02810119|DRUG|LO2A|
58131186|NCT02719249|OTHER|Dried blood spot test|
58131187|NCT04043871|DIAGNOSTIC_TEST|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
58131188|NCT00220701|DRUG|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
58131189|NCT01274364|OTHER|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
58131190|NCT01274364|OTHER|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
58131191|NCT04839367|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
58131192|NCT02835482|PROCEDURE|Femtolaser surgery|
58131193|NCT02835482|PROCEDURE|Phacoemulsification|
57779016|NCT02810119|DRUG|Placebo|
57779017|NCT05192980|OTHER|No Intervention NA|Additional blood sampling (not mandatory)
58131194|NCT00290147|BIOLOGICAL|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
57779018|NCT01915147|DRUG|OXN PR followed by OxyPR tablets|
57779019|NCT01915147|DRUG|OxyPR followed by OXN PR tablets|
57779020|NCT06475469|BIOLOGICAL|Blood sampling & Chest CT without injection|Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
57779021|NCT05217069|DRUG|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
57779022|NCT05217069|DRUG|Folinic Acid|400mg/m2
57779023|NCT05217069|DRUG|Irinotecan|180 mg/m2
57779024|NCT05217069|DRUG|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
57779025|NCT05217069|DRUG|Avelumab|10mg/kg IV (day 1 q2w)
57779026|NCT01466764|DRUG|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
57779027|NCT01466764|OTHER|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
57784532|NCT01980979|DRUG|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
58131195|NCT02129348|DRUG|Lithium|
58131196|NCT02129348|DRUG|Placebo|
58131197|NCT00494975|DEVICE|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
58131198|NCT05589311|OTHER|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
58131199|NCT05589311|OTHER|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
58131200|NCT04304963|OTHER|NO intervention - observational study|NO intervention - observational study
58131201|NCT00940368|DIETARY_SUPPLEMENT|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
58138984|NCT01387022|DRUG|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
58472181|NCT04625946|DRUG|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
58490873|NCT04424264|DRUG|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
57779028|NCT05649488|DEVICE|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
57779029|NCT05649488|DEVICE|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
57779030|NCT04017702|DEVICE|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
57779031|NCT02697006|DEVICE|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
57779032|NCT02963688|GENETIC|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
57779033|NCT00780936|PROCEDURE|femoral nerve block|
57779034|NCT02506959|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
57779035|NCT02506959|DRUG|Busulfan|Given IV
57779036|NCT02506959|DRUG|Gemcitabine Hydrochloride|Given IV
57779037|NCT02506959|OTHER|Laboratory Biomarker Analysis|Correlative studies
57779038|NCT02506959|DRUG|Melphalan|Given IV
57779039|NCT02506959|DRUG|Panobinostat|Given PO
57779040|NCT02506959|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
57779041|NCT02506959|OTHER|Pharmacological Study|Correlative studies
57779042|NCT04453059|DRUG|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
57779043|NCT00549822|DRUG|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
57779044|NCT06413641|OTHER|Follow up at GP|As described before
57779045|NCT06413641|OTHER|Consultation|As described before
57779046|NCT06413641|OTHER|Visualization of CTA images|As described before
57779047|NCT04695158|DRUG|COVID-19 group (Group I)|Routine COVID-19 treatment
57779048|NCT04695158|DRUG|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
57779049|NCT05193721|DRUG|SHR-1901|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
57779050|NCT01927692|OTHER|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
57779051|NCT01927692|OTHER|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
57779052|NCT02398162|PROCEDURE|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
57779053|NCT02398162|PROCEDURE|Single Blood Collection|On the enrollment day
57779054|NCT03157024|DEVICE|Ring Sham (RS)|
57779055|NCT03157024|DEVICE|Real Needle (RN)|
57779056|NCT03157024|DEVICE|Kim Sham (KS)|
57779057|NCT04956861|BEHAVIORAL|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
57779058|NCT02618057|DRUG|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
57779059|NCT02618057|DRUG|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
57779060|NCT01604811|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
57779061|NCT01604811|DRUG|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
57779062|NCT01604811|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
57779063|NCT01604811|DRUG|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
57779064|NCT02710058|BEHAVIORAL|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
57779065|NCT00729690|DRUG|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
57779066|NCT00729690|DRUG|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
58131202|NCT04028453|OTHER|Survey|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
58138985|NCT00938834|OTHER|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
58472182|NCT04625946|BEHAVIORAL|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
58472183|NCT04625946|DEVICE|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
58472184|NCT06595550|DIETARY_SUPPLEMENT|Whey protein|Powder milk
58472185|NCT06595550|DIETARY_SUPPLEMENT|no Whey protein|Powder milk
58472186|NCT01684917|BEHAVIORAL|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
58472187|NCT04115761|BIOLOGICAL|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
58472188|NCT03756519|BEHAVIORAL|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
58472189|NCT03756519|BEHAVIORAL|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
58472190|NCT03756519|BEHAVIORAL|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
58472191|NCT03756519|OTHER|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
58472192|NCT05809934|DRUG|AZD2693|AZD2693 solution SC once per month
58472193|NCT05809934|OTHER|Placebo|Sodium chloride 0.9% solution SC once per month
57779067|NCT00729690|DRUG|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
57779068|NCT05636137|OTHER|Survey application|Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
57779069|NCT01928225|BIOLOGICAL|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
57779070|NCT04131959|DEVICE|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
57779071|NCT05221203|BEHAVIORAL|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
57779072|NCT05221203|BEHAVIORAL|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
57779073|NCT00798174|DEVICE|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
57779074|NCT01272986|DEVICE|ALOA IgG-Elisa|measurement of IgG Level in blood
57779075|NCT01272986|DEVICE|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
57779076|NCT03230864|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
57779077|NCT03230864|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
57779078|NCT03230864|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
57784533|NCT00299689|DRUG|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
57779079|NCT02685592|DRUG|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
58472194|NCT06061809|DRUG|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
58472195|NCT06061809|DRUG|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
58472196|NCT06061809|DRUG|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
58472197|NCT05665231|OTHER|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
58472198|NCT05665231|OTHER|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
58472199|NCT05665231|OTHER|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
58472200|NCT05665231|OTHER|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
58472201|NCT05665231|OTHER|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
58472202|NCT05665231|OTHER|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
58472203|NCT05665231|OTHER|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
58472204|NCT05665231|OTHER|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
58472205|NCT05665231|OTHER|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~1. interdental distance~2. bucco-palatal distance (BPD)~3. presence of papilla~r. global volume."
58472206|NCT05665231|OTHER|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
58472207|NCT05665231|OTHER|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~1. interdental distance;~2. bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
58472208|NCT05665231|OTHER|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
58472209|NCT04245150|OTHER|Stool sample|Stool sample
58472210|NCT04245150|OTHER|Skin Swab Sample|Skin Swab Sample
58472211|NCT03603782|DIETARY_SUPPLEMENT|2.5% protein|2.5%
58472212|NCT03603782|DIETARY_SUPPLEMENT|protein 5%|5%
57779080|NCT05602337|OTHER|Observational Study Only|Non-invasive Skin Sampling
57779081|NCT02328157|DEVICE|Vitrectomy with cataract surgery and toric IOL|
57779082|NCT02328157|DEVICE|Vitrectomy with cataract surgery and common IOL|
57779083|NCT00003384|OTHER|Cervical Papanicolaou Test|Undergo Pap smear
57779084|NCT00003384|PROCEDURE|Conization|Undergo cone biopsy
57779085|NCT00003384|OTHER|Laboratory Biomarker Analysis|Correlative studies
57779086|NCT02269943|DRUG|CC-486|
57779087|NCT06362343|DRUG|Rivaroxaban|Rivaroxaban
57779088|NCT01378520|DRUG|ketoconazole|600 mg capsule oral once
57779089|NCT01378520|DRUG|inert powder|oral once
58138986|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with lower limb cycle ergometer
58138987|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with upper limb cycle ergometer
58472213|NCT03603782|DIETARY_SUPPLEMENT|protein 10%|10%
58472214|NCT03603782|DIETARY_SUPPLEMENT|protein 15%|15%
58472215|NCT03603782|DIETARY_SUPPLEMENT|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
58472216|NCT03603782|DIETARY_SUPPLEMENT|B2: only breakfast (no product)|only breakfast
58472217|NCT03603782|DIETARY_SUPPLEMENT|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
58472218|NCT03603782|DIETARY_SUPPLEMENT|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
58472219|NCT05577247|OTHER|functional magnetic resonance imaging|Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
58472220|NCT03777982|DRUG|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
58472221|NCT03777982|DRUG|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
58472222|NCT03777982|DRUG|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
58472223|NCT03777982|DRUG|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
58472224|NCT06037161|PROCEDURE|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
58472225|NCT02470286|DRUG|SA001 60mg or Placebo|"* Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)"
58472226|NCT02470286|DRUG|SA001 120mg or Placebo|"* Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
58472227|NCT02470286|DRUG|SA001 180mg or Placebo|"* Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)"
58472228|NCT02470286|DRUG|SA001 240mg or Placebo|"* Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)"
58472229|NCT02470286|DRUG|SA001 300mg or Placebo|"* Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
58472230|NCT02612272|DRUG|Ketorolac|intra-articular ketorolac
58472231|NCT02612272|DRUG|Betamethasone|intra-articular betamethasone
58472232|NCT04126135|DRUG|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
57779090|NCT00487786|DRUG|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
57779091|NCT00487786|DRUG|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study
57779092|NCT04001764|PROCEDURE|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
57779093|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
57779094|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
57779095|NCT04829435|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
57779096|NCT04829435|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
57784534|NCT03478423|DRUG|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
57784535|NCT03478423|DRUG|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
58138988|NCT02809469|DRUG|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
58472233|NCT04126135|DRUG|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
58472234|NCT06212024|BEHAVIORAL|Mentalization Based Treatment-early|MBT-early is an early intervention program for young people at risk for developing BPD that has been developed as an adaptation of MBT, an empirically supported treatment for BPD. MBT-early is a time-limited intervention that has been designed for early-stage BPD and focuses on improving personality functioning. MBT-early is a two-phase treatment that integrates interventions at the individual, family, and context level. MBT-early provides a combination of treatment modalities, including individual and family sessions, case management, and treatment reviews. Interventions are tailored to the specific needs of the young person and his/her family. The treatment consists of 16 weekly individual sessions, 3 family sessions, and case management. The initial treatment phase (16 weeks) is followed by a booster period (6 months) with 4 booster sessions. Since MBT-early involves a flexible approach, this standard package may be downscaled in cases of rapid improvement, or upscaled when needed.
58472235|NCT06592950|OTHER|No treatment given|Online survey
58472236|NCT06592950|OTHER|No treatment given|Interviews
58472237|NCT04142931|COMBINATION_PRODUCT|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
58472238|NCT05432648|DIETARY_SUPPLEMENT|Green bean puree|Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
58472239|NCT04353141|DIAGNOSTIC_TEST|standardized Lung Ultrasound (LUS) examination|14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
58472240|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
58472241|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
58472242|NCT06597149|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
58472243|NCT06585839|BEHAVIORAL|Digital coaching solution to improve childbirth experience|Intervention provides coaching to improve the childbirth experience and offers comprehensive perinatal mental health support to pregnant and postpartum women. It features emotion tracking and exercise customization functionality, along with an avatar-based platform. The app includes digital psychotherapy exercises and psychoeducation. These core elements are complemented by exercises in mindfulness, relaxation, and self-soothing.
58472244|NCT06585839|OTHER|Application for the control group|Application for the control group including surveys.
58472245|NCT03969004|DRUG|Cemiplimab|Intravenous (IV) infusion over 30 minutes
58472246|NCT03969004|DRUG|Placebo|Intravenous (IV) infusion over 30 minutes
58472247|NCT02078206|OTHER|Neurocognitive stimulation|
58472248|NCT06594640|DRUG|Mitoxantrone Hydrochloride Liposome|assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2
58472249|NCT06594640|DRUG|Rituximab (R)|375mg/m2, D2
58472250|NCT06594640|DRUG|Cyclophosphamide (CTX)|750mg/m2, D2
58472251|NCT06594640|DRUG|Vincristin|1.2mg/m2, maximum 2mg， D2
58472252|NCT06594640|DRUG|Prednisolone|60mg/m2, D2-6
58472253|NCT04879589|DRUG|Abiraterone Acetate|ATRS-2002
58472254|NCT00761423|BIOLOGICAL|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
58472255|NCT00761423|BIOLOGICAL|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
58472256|NCT06655636|DEVICE|Device tuned to Assistance|The device spring components will be tuned to produce an assistive supination torque on the forearm.
58472257|NCT06655636|DEVICE|Device tuned to Sham (Slack Springs)|The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
58472258|NCT06655636|DEVICE|Device tuned to Anti-Assistance|The device spring components will be tuned to produce a resistive supination torque on the forearm.
58472259|NCT06592196|OTHER|stain|This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
58472260|NCT03730649|DRUG|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
57779097|NCT06002061|DEVICE|NovaResp MAPR System|"Baseline measurements will be taken while the subject is awake. Genioglossus activity with maximal tongue protrusion will be measured as well as the response to 1 to 2 pressure routines. Once the subject is sleeping, the operator will observe the PSG recording and determine sleep stage and respiratory phase (inspiration, expiration, between breaths). Test routines will be performed for each sleep stage and each respiratory phase. If the operator notices an apnea occurring, one of the routines will be applied. When all manual tests are complete, an automatic mode will be engaged for the remainder of the night. During this mode, a previously developed and trialled AI model will be used to predict if an obstructive apnea is upcoming. The operator will input which routine to test, and the routine will be automatically applied when a prediction occurs. There will be a minimum of 60 seconds between pressure routine applications."
58472261|NCT03730649|RADIATION|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
58472262|NCT06599437|PROCEDURE|laparoscopic cholecystectomy|Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.
58472263|NCT06599437|PROCEDURE|Late laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
58472264|NCT05819658|DRUG|GV1001 Placebo|0.9% normal saline
58472265|NCT05819658|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
57779098|NCT03945110|DEVICE|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
58472266|NCT05819658|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
58472267|NCT06540521|OTHER|No intervention|No intervention
58490874|NCT02749084|BIOLOGICAL|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
58472268|NCT06588062|OTHER|Picture Exchange Communication System (PECS)|Picture exchange communication System (PECS) is a widely useful tool for developing skills in ASD children. Visual supports rather work better for their intellectual level as these children usually respond less to verbal and written instructions. PECS is considered as an augmentative communication system commonly used with non-verbal ASD children. It is helpful for an individual with ASD to quickly acquire a functional means of communication. This is highly beneficial for the child to communicate with his parents and caregivers, as well as with their peers. Moreover, the pictorial approach of PECS is a source of facilitating element in attaining student's concentration. The reason for wide acceptance of this tool in clinical and social settings for children with ASD is its' ease of use, ability to teach two-way communication and inexpensiveness. PECS has demonstrated successful use in teaching various skills in ASD affected children lacking speech.
57779099|NCT00289770|BIOLOGICAL|Twinrix™|Intramuscular injection, 3 doses
57779100|NCT03874780|DEVICE|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
57779101|NCT01644396|BIOLOGICAL|Adalimumab|
57779102|NCT02382237|DEVICE|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
57779103|NCT05073068|BEHAVIORAL|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
57779104|NCT05073068|BEHAVIORAL|Control|No exercise
57779105|NCT05693467|DRUG|Dexamethasone palmitate emulsion(DXP) plus ropivacaine|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
57779106|NCT05693467|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 7.5mL of ropivacaine added to 22.5mL of saline for Group B . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
57779107|NCT03649269|DIETARY_SUPPLEMENT|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
57779108|NCT03649269|DRUG|Bezafibrate|Patients were prescribed 200 mg/day at night.
57779109|NCT00005108|DRUG|Estradiol|
57779110|NCT00005108|DRUG|Progesterone|
57779111|NCT03059160|DRUG|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
57779112|NCT06349122|DIAGNOSTIC_TEST|Vaginal flora abnormalities screening and quantification using molecular biology technique|Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.
57779113|NCT06349122|DRUG|Azithromycine|In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
57779114|NCT06349122|DRUG|Ceftriaxone|In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
57779115|NCT06349122|DRUG|Metronidazole|Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
57779116|NCT06349122|DRUG|Clotrimazole, Vaginal|In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
57779117|NCT06349122|OTHER|Usual Care|Patients will not be screened using molecular biology techniques in this group. The management of these patients is a matter of routine for health professionals. They will be free to prescribe a standard vaginal swab if symptoms are present and to treat their patients according to their usual protocols. No routine sampling is recommended in the absence of a history
57779118|NCT00679484|DRUG|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
57779119|NCT00679484|DRUG|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
57779120|NCT03646227|OTHER|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
58472269|NCT05257356|BEHAVIORAL|psychophysical tasks|"Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
57779121|NCT01157143|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
57779122|NCT03656393|DRUG|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
58138989|NCT03707912|DRUG|Anaferon|Oral administration.
57779123|NCT03656393|DRUG|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
57779124|NCT03656393|DRUG|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
57779125|NCT03664739|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
57779126|NCT03664739|DRUG|IDp-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
58138990|NCT03707912|DRUG|Placebo|Oral administration.
57779127|NCT02398682|OTHER|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1) Rapidly establish a credible diagnosis of the cause of AKI including:~1. Improved assessment of volume status~2. Standardised use of urine dipstick .~3. Appropriate sepsis investigations.~4. Urgent ultrasound with suspected obstruction."
57779128|NCT02398682|OTHER|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
57779129|NCT02398682|OTHER|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
57779130|NCT02398682|OTHER|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
57779131|NCT02398682|OTHER|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
57779132|NCT02398682|OTHER|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
58472270|NCT06570447|DRUG|Glofitamab|For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.
58472271|NCT06570447|DRUG|Chidamide|Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.
58472272|NCT04354129|DRUG|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
58472273|NCT05222451|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
58472274|NCT05222451|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
58472275|NCT05222451|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
58472276|NCT04841863|DEVICE|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
58472277|NCT04841863|OTHER|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
58472278|NCT04088877|BEHAVIORAL|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
57779133|NCT06445855|BEHAVIORAL|Interpersonal relationship-based intervention program|An interpersonal relations-based intervention program will be implemented with an online intervention platform.
57779134|NCT00696163|DRUG|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
58472279|NCT04088877|BEHAVIORAL|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
58472280|NCT01400308|DRUG|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
58472281|NCT01400308|DEVICE|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
58472282|NCT04689139|DIAGNOSTIC_TEST|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
58472283|NCT06295185|OTHER|application MARO|It is a mental healthcare application aim to improve mental health.
58472284|NCT06295185|OTHER|Sham application|It is a sham application in order to control spill over bias.
57779135|NCT02667444|DRUG|SB204 4%|Applied topically once daily
57779136|NCT02667444|DRUG|Vehicle Gel|Applied topically one daily
57779137|NCT05744882|PROCEDURE|coronectony|root canal treatment
57779138|NCT05744882|PROCEDURE|root canal treatment|root canal treatment
57779139|NCT03486899|DRUG|BMS-986036|Specified dose on specified days.
57779140|NCT03486899|OTHER|Placebo|Specified dose on specified days.
57779141|NCT05744050|BEHAVIORAL|Low energy density lunch|Particpants will be provided with a lunch low in energy density (\~1.1kcal/g)
57779142|NCT05744050|BEHAVIORAL|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(\~1.7kcal/g)
57779143|NCT05744050|BEHAVIORAL|High energy density lunch|Participants will be provided with a lunch high in energy density (\~3kcal/g)
57779144|NCT01154023|BEHAVIORAL|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
57779145|NCT06494319|BEHAVIORAL|Stress NAVIGATOR (Mobile Health Application)|Participants will be prompted to complete their assessments each week (or upon completion of each session) via the Stress NAVIGATOR mobile health app
57779146|NCT06494319|BEHAVIORAL|SIT NAVIGATOR|Participants will complete 11 self-paced virtual SIT sessions in the SIT-NAVIGATOR classroom. Participants will be asked to complete at least one session per week, in a minimum of 12 weeks and a maximum of 14 weeks.
58138991|NCT00138060|DRUG|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
57779147|NCT02441205|BEHAVIORAL|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
57779148|NCT00065416|PROCEDURE|massage|
57779149|NCT04773574|DEVICE|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
57779150|NCT01899118|RADIATION|Preoperative irradiation|50.4Gy/28F/5.5w
57779151|NCT01899118|DRUG|Nimotuzumab|400mg/w，0-5w
57779152|NCT01899118|DRUG|Oxaliplatin|130mg/m2 d1
57779153|NCT01899118|DRUG|Capecitabine|825mg/m2 bid d1-5/w,1-5w
57779154|NCT05715450|PROCEDURE|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
57779155|NCT06132672|BEHAVIORAL|Navigators (peer navigator) training|The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
57779156|NCT06132672|BEHAVIORAL|delayed-intervention|Those in the delayed-intervention group will be trained in year 5
57779157|NCT06529601|DEVICE|CAD/CAM mandibular fixed retainer|Keeppy is a Class IIa custom-made medical device manufactured by Digital Service Leone s.r.l. - via Pratese 160/b, Florence, Italy. The Keeppy is an individualized fixed retainer, made of a Nickel-free Chrome Cobalt alloy, produced with a CAD-CAM procedure starting from a digital impression made with an intraoral optical scanner (3 Shape), which allows a perfect adaptation to the lingual surfaces of the 6 lower anterior teeth on which it is bonded. The device is characterized by the presence of applicators that can be placed temporarily on the buccal surface of the canines, which facilitate the clinician in the precise application of the device and which are removed as soon as the bonding phase of the retainer is complete. Bonding is performed using classic composite resins following a preparation phase of the lingual surface of the tooth consisting of the application of etchant (37% orthophosphoric acid) for 30 seconds and adhesive (primer-bonding).
57779158|NCT06529601|DEVICE|Conventional mandibular fixed retainer|The standard control device, which is among the most commonly used in routine clinical practice, consists of a steel braided wire. The device selected for the Class IIa investigation is the Ortho Flex Tech manufactured by Reliance Orthodontic Products, Inc. 1540 West Thorndale Ave. Itasca, IL 60143 USA. The Ortho Flex Tech steel braided wire is manually shaped by the clinician and cut with a wire cutter so that it has the proper length to extend over the 6 dental elements. Once the correct length has been defined, it is then held in place on the lingual surface of the teeth by the use of 2 interdental wires passing doubly through the interdental area (between the lateral incisor and canine on one side and the other). This allows the device to be bonded using composite resin after etching the lingual surfaces of the lower anterior teeth.
57779159|NCT00550173|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
57779160|NCT00550173|DRUG|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
57779161|NCT02585037|OTHER|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
57779162|NCT02585037|OTHER|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
57779163|NCT02585037|OTHER|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
57779164|NCT03044353|DRUG|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
57779165|NCT03044353|BIOLOGICAL|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
57779166|NCT00274911|DRUG|cisplatin|
57779167|NCT00274911|DRUG|lomustine|
57779168|NCT00274911|DRUG|vincristine sulfate|
57779169|NCT00274911|PROCEDURE|adjuvant therapy|
57779170|NCT00274911|RADIATION|radiation therapy|
57779171|NCT05267314|DEVICE|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
57779172|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
57779173|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
57779174|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
57779175|NCT03837613|PROCEDURE|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
57779176|NCT01971580|DRUG|Ambrisentan|
57779177|NCT03376503|DRUG|Pegfilgrastim|PK,PD and safety assessment
57779178|NCT00438867|GENETIC|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
57779179|NCT00438867|GENETIC|Placebo|Control group
57779180|NCT02610712|DRUG|Ketamine|
57779181|NCT03203668|RADIATION|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
57779182|NCT06121518|DRUG|D064 and D702, QD|Experimental Group Subjects assigned to this group are treated with D064, D702
57779183|NCT06121518|DRUG|D064 and Placebo of D702, QD|Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
57779184|NCT06121518|DRUG|Placebo of D064 and D702, QD|Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
57779185|NCT01941004|DRUG|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
57779186|NCT01941004|DRUG|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
57779187|NCT01132638|DRUG|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
57779188|NCT01132638|DRUG|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
57779189|NCT06410378|PROCEDURE|Erector Spinae Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach
57779190|NCT06410378|PROCEDURE|Serratus Anterior Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
57779191|NCT06410378|PROCEDURE|controll group|patient will receive general anesthesia
57779192|NCT04057820|OTHER|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
57779193|NCT04057820|OTHER|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
57779194|NCT04088318|DRUG|OQL011|OQL011 is an ointment containing active ingredient.
57779195|NCT04088318|DRUG|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
57779196|NCT06171906|BIOLOGICAL|mesenchymal stromal cells|On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10\^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
57779197|NCT02377830|DEVICE|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
57779198|NCT02377830|OTHER|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
57779199|NCT05107245|DIAGNOSTIC_TEST|1test1|Loss of bacterial diversity diagnosis
57779200|NCT06352268|PROCEDURE|Pallidal, subthalamic or thalamic lesioning|Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders
57779201|NCT06381037|BEHAVIORAL|"How to improve your strengths and quality of life."|"The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop."
57779202|NCT03444220|BIOLOGICAL|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
57779203|NCT03444220|BIOLOGICAL|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
57779204|NCT06077669|DRUG|Methylphenidate|Single oral dose of methylphenidate (5mg or 10 mg)
58138992|NCT00138060|DRUG|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
58138993|NCT02134834|DRUG|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
58472285|NCT04424095|DIAGNOSTIC_TEST|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
58472286|NCT04424095|DIAGNOSTIC_TEST|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
58472287|NCT06345274|BEHAVIORAL|Measurement Based Care Training and Monthly Consultation|Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
57779205|NCT06077669|DRUG|Placebo|oral placebo
57779206|NCT04098640|GENETIC|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
57779207|NCT02702349|OTHER|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
57779208|NCT00625235|DIETARY_SUPPLEMENT|VLED followed by a high protein or high carbohydrate diet|
57779209|NCT02769299|RADIATION|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
57779210|NCT05475938|OTHER|Painting therapy and psychoanalysis|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
57779211|NCT03963882|DRUG|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
57779212|NCT03963882|DIAGNOSTIC_TEST|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
57779213|NCT03963882|DIAGNOSTIC_TEST|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
57779214|NCT03963882|DRUG|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
57779215|NCT03963882|PROCEDURE|RH|Radical hysterectomy
57779216|NCT03963882|RADIATION|Radiochemotherapy|Concurrent radiochemotherapy
57779217|NCT03963882|DIAGNOSTIC_TEST|Pathologic evaluation|Pathologic evaluation for RH patients
57779218|NCT01280240|DRUG|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
57779219|NCT00109551|DRUG|zinc sulphate dietary supplement|
57779220|NCT00109551|DRUG|iron sulphate-folic acid dietary supplement|
57779221|NCT05779839|BEHAVIORAL|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
57779222|NCT05779839|BEHAVIORAL|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
58138994|NCT02134834|DRUG|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
57779223|NCT03111758|DEVICE|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
58472288|NCT03774446|DRUG|Seliciclib|Drug: Seliciclib
57779224|NCT02595177|PROCEDURE|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
57779225|NCT00656916|DRUG|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
57779226|NCT03904537|BIOLOGICAL|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
57779227|NCT05279430|BEHAVIORAL|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
57779228|NCT03376841|DRUG|Cenicriviroc|1 tablet; single-dose oral administration
57779229|NCT01282476|DRUG|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
57779230|NCT02220686|BEHAVIORAL|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
57779231|NCT00472537|PROCEDURE|Retromuscular Mesh repair of midline incisional hernia|
57779232|NCT00472537|PROCEDURE|Laparoscopic repair of midline incisional hernia|
57779233|NCT03782896|OTHER|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
57779234|NCT04022642|OTHER|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of \>=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
57779235|NCT00491725|DRUG|repaglinide|
58472289|NCT04335721|DRUG|Voxelotor|Voxelotor 1500mg once a day
57779236|NCT00491725|DRUG|metformin|
57779237|NCT04683471|DEVICE|Stimulator|Neuromodulation
57779238|NCT04683471|DEVICE|Sham|Sham
57779239|NCT01482949|DRUG|AGS-003|Autologous Dendritic Cell Immunotherapy
57779240|NCT04235868|BIOLOGICAL|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
57779241|NCT04235868|BIOLOGICAL|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
57779242|NCT04635501|DEVICE|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
57779243|NCT02430922|DEVICE|iVolution nitinol stent|
58472290|NCT02700321|DEVICE|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
58472291|NCT02700321|PROCEDURE|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
58472292|NCT05144373|BEHAVIORAL|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
58472293|NCT06591052|OTHER|Passive stretching|The physiotherapist positioned each muscle in its maximum lengthened state and held it there for 30 seconds. This process was repeated three times, with a 30-second rest interval between each stretch of the different muscle groups.
57779244|NCT02977065|DRUG|Atorvastatin 20mg|PO daily for 4weeks
57779245|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
57779246|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
57779247|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
57779248|NCT02977065|DRUG|Rosuvastatin 10 mg|PO daily for 4weeks
57779249|NCT02977065|DRUG|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
57779250|NCT00658736|DRUG|Triamcinolone|Injection of bupivacaine and triamcinolone
57779251|NCT00658736|DRUG|Bupivicaine alone|Injection of bupivacaine
57779252|NCT05359835|DRUG|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
57779253|NCT02698436|DEVICE|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
57779254|NCT02698436|DRUG|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
57779255|NCT03666910|DIAGNOSTIC_TEST|Audiometer|detection of hearing problems
57779256|NCT01890902|DRUG|Ketoprofen 10% Cream|
57779257|NCT01890902|DRUG|Placebo|
57779258|NCT04690296|DEVICE|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
57779259|NCT02631083|OTHER|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
57779260|NCT02701322|BEHAVIORAL|Medical clown|
57779261|NCT02989363|PROCEDURE|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
57779262|NCT02989363|PROCEDURE|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
57779263|NCT02989363|PROCEDURE|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
57779264|NCT02989363|PROCEDURE|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
57779265|NCT06451575|DIAGNOSTIC_TEST|Blood collection|Blood collection
57779266|NCT02646111|DRUG|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
58131203|NCT03394209|DRUG|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
58131204|NCT03394209|DRUG|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
58131205|NCT05597345|DRUG|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
58131206|NCT04055402|OTHER|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
58131207|NCT04055402|OTHER|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
58131208|NCT03248063|DRUG|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
58490875|NCT02874976|DEVICE|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
57779267|NCT02646111|DRUG|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
57779268|NCT02646111|DRUG|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
57779269|NCT03844321|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
57779270|NCT03844321|BEHAVIORAL|Brief Mindfulness|3 sessions of online mindfulness therapy
57779271|NCT05050474|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
57779272|NCT04736589|DRUG|Inetetamab|Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
57779273|NCT04736589|DRUG|Rapamycin|Oral 2mg, once a day.
58138995|NCT01467765|OTHER|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
57779274|NCT04736589|DRUG|Pyrotinib|Oral 400mg, once a day.
57779275|NCT04736589|DRUG|Chemotherapy|Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
57779276|NCT01013532|DRUG|Cilostazol|Cilostazol 100mg bid
57779277|NCT01013532|DRUG|Probucol|Probucol 250mg bid
57779278|NCT01013532|DRUG|Aspirin|Aspirin 100mg qd
57779279|NCT01013532|DRUG|placebo of cilostazol|same shape and size of active cilostazol
57779280|NCT01013532|DRUG|placebo of aspirin|same size and shape of active aspirin 100mg
57779281|NCT01013532|DEVICE|ankle-brachial index (ABI)|measurement of ABI every years during follow up
57779282|NCT01013532|DEVICE|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
57779283|NCT01013532|DEVICE|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
57779284|NCT01013532|DEVICE|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
57779285|NCT02339389|OTHER|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
57779286|NCT04800523|DEVICE|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
57779287|NCT04607473|DEVICE|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
57779288|NCT00893568|OTHER|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
58138996|NCT02305706|PROCEDURE|starting position in colonoscopy|
58138997|NCT00062790|DRUG|Dutasteride|
58131209|NCT03248063|DRUG|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
57779289|NCT00589550|BIOLOGICAL|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
58131210|NCT02566824|BEHAVIORAL|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q\&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
58138998|NCT02698982|DEVICE|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
58138999|NCT02698982|PROCEDURE|moderate risk surgery|
58139000|NCT00164671|BEHAVIORAL|POWER|
57779290|NCT00589550|DRUG|Sorafenib|
57779291|NCT00589550|GENETIC|gene expression analysis|
57779292|NCT00589550|GENETIC|polymerase chain reaction|
57779293|NCT00589550|GENETIC|reverse transcriptase-polymerase chain reaction|
57779294|NCT00589550|OTHER|flow cytometry|
57779295|NCT00589550|OTHER|immunoenzyme technique|
57779296|NCT00589550|OTHER|laboratory biomarker analysis|
57779297|NCT00504465|DRUG|dinoprostone|
57779298|NCT04110873|DRUG|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
57779299|NCT04110873|DRUG|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
57779300|NCT04110873|DRUG|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
57779301|NCT02501135|PROCEDURE|Femoral nerve block with ropivacaine or bupivacaine|
57779302|NCT02694640|BEHAVIORAL|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
57779303|NCT02694640|BEHAVIORAL|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
57779304|NCT02694640|BEHAVIORAL|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
57779305|NCT00698321|BEHAVIORAL|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
57779306|NCT00698321|BEHAVIORAL|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
57779307|NCT00873093|DRUG|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
57779308|NCT00873093|DRUG|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
57779309|NCT00873093|DRUG|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
57779310|NCT00873093|DRUG|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
57779311|NCT00873093|DRUG|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
57779312|NCT00873093|DRUG|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
57779313|NCT00873093|DRUG|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
57779314|NCT00873093|DRUG|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
57779315|NCT00873093|DRUG|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
57779316|NCT00873093|DRUG|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
57779317|NCT00873093|DRUG|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
57779318|NCT00873093|BIOLOGICAL|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
57779319|NCT00873093|DRUG|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
57779320|NCT00873093|OTHER|laboratory biomarker analysis|Correlative studies
57779321|NCT00873093|DRUG|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
57779322|NCT04122560|DRUG|Fluconazole 200mg tab|PO dose of 400mg
57779323|NCT04122560|DRUG|Fluconazole 2 MG/ML|IV dose of 400mg
57779324|NCT05379140|BEHAVIORAL|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
58472294|NCT06591052|OTHER|PNF stretching|The physiotherapist initially positioned each muscle in its most extended state, similar to the positions used in passive stretching. In this extended position, the participants performed an isometric contraction against maximal resistance in the antagonist direction for 5-8 seconds. Following the isometric contraction, participants were instructed to actively relax, and after a 5-second waiting period to ensure complete relaxation, the movement range was passively increased. The new end point of the extended range of motion was held for 30 seconds. This stretching protocol was repeated three times for each muscle group, with a 30-second rest period between each stretch.
58472295|NCT03467750|DRUG|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
58472296|NCT03467750|DRUG|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
58472297|NCT03712813|DEVICE|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
58472298|NCT04069689|DRUG|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
58472299|NCT04069689|DRUG|Placebos|Placebo to match EPX-100
58472300|NCT01870349|PROCEDURE|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
58472301|NCT04853173|OTHER|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
58472302|NCT01190397|DEVICE|Warming goggles|
58472303|NCT01190397|DEVICE|warm and moist compresses|
58472304|NCT00020488|DRUG|FOLFIRI regimen|
58472305|NCT00020488|DRUG|fluorouracil|
58472306|NCT00020488|DRUG|irinotecan hydrochloride|
58472307|NCT00020488|DRUG|leucovorin calcium|
58472308|NCT05052996|DRUG|ISL|Capsules administered orally without regard to food
58472309|NCT05052996|DRUG|LEN|Tablets administered orally without regard to food
58472310|NCT05052996|DRUG|B/F/TAF|Tablets administered orally without regard to food
58472311|NCT05920759|DIAGNOSTIC_TEST|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
57779325|NCT05379140|BEHAVIORAL|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
57779326|NCT03379714|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
57779327|NCT02145793|BEHAVIORAL|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
57779328|NCT06115902|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
57779329|NCT03150680|GENETIC|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
58139001|NCT02134080|DRUG|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
58472312|NCT04717037|BIOLOGICAL|Olive Oil Massage|olive oil massage application.
58472313|NCT06588959|OTHER|validity and reliability study|Determination of strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. 6PBRT, which is one of the tests serving this purpose, has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma, but when the literature is reviewed, it is seen that 6PBRT has not been studied in patients with scleroderma. This study was planned as a non-interventional safety study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, the test will be performed 2 times with a 1-hour rest break. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The level of dyspnea and fatigue and baseline values of heart rate will be checked before the second trial to ensure patients are stable. All assessments will be performed by the same physiotherapist.
58472314|NCT06601920|BEHAVIORAL|Forest healing activities|The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.
58472315|NCT05058339|OTHER|Survey Administration|Complete survey
57779330|NCT05993195|DEVICE|Conduit Titanium Interbody Graft|The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
57779331|NCT05993195|DEVICE|Concorde Bullet Device|This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
57779332|NCT00004286|DRUG|immune globulin|
58131211|NCT02566824|BEHAVIORAL|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
58131212|NCT02566824|OTHER|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
58131213|NCT02566824|DRUG|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
58131214|NCT02339766|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
58131215|NCT02339766|PROCEDURE|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
58131216|NCT02339766|DRUG|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
58131217|NCT02339766|DRUG|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
58131218|NCT05527756|OTHER|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
58131219|NCT05527756|OTHER|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
58131220|NCT02256007|OTHER|Paper and Pencil Assessments|Videogame Assessments
58131221|NCT02999178|DRUG|Nintedanib|
58131222|NCT02999178|DRUG|Placebo|
58472316|NCT01394237|OTHER|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
58472317|NCT03030586|OTHER|volumetric MRI|
57779333|NCT04873622|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
57779334|NCT05536674|BEHAVIORAL|SMS reminder for the HPV vaccination|A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
57779335|NCT05462652|DEVICE|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
58131223|NCT06241378|DEVICE|perineometer device for physiotherapy|measuring the vaginal pressure for stress urinary incontinence patients
58139002|NCT02134080|DRUG|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
58472318|NCT06603948|DEVICE|Spectral Focused Imaging|Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy
58472319|NCT06603948|DEVICE|White Light Imaging|Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
58472320|NCT06131801|OTHER|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
58472321|NCT05322798|PROCEDURE|High-frequency SCS|Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
58131224|NCT05390437|DIETARY_SUPPLEMENT|Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination|4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
58131225|NCT05390437|DIETARY_SUPPLEMENT|Ready to use theraputic food (RUTF) and Starch (placebo)|Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
58131226|NCT03623048|OTHER|chlorhexidine|antibacterial and anti-inflammatory mouthwash
58131227|NCT03623048|OTHER|saline|anti-inflammatory cleansing mouthwash
58131228|NCT03623048|OTHER|Propolis extract|antibacterial mouthwash
58131229|NCT03623048|OTHER|pomegranate extract|antibacterial mouthwash
58131230|NCT01512407|PROCEDURE|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
58131231|NCT02415023|DRUG|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
58131232|NCT00125307|DRUG|tacrolimus|
57779336|NCT02708238|DIETARY_SUPPLEMENT|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
57779337|NCT02708238|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 (108 CFU)|
57779338|NCT02708238|DRUG|Simethicone|
58131233|NCT03825900|DEVICE|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
58131234|NCT03378466|DRUG|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
58131235|NCT03378466|OTHER|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
58131236|NCT05017857|DEVICE|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
58131237|NCT05017857|BEHAVIORAL|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
58131238|NCT02622945|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
57779339|NCT01088308|PROCEDURE|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
57779340|NCT01088308|PROCEDURE|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
57779341|NCT05401630|OTHER|Study Procedures|"All participants will answer a series of questionnaires that address a variety of factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours prior to testing. In addition, participants will undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use."
57779342|NCT01352234|DRUG|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
58131239|NCT02622945|DEVICE|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
58131240|NCT00973700|BIOLOGICAL|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
58131241|NCT00973700|BIOLOGICAL|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
58131242|NCT04238442|DEVICE|A&D TM-2657W oscillometric device|Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
57779343|NCT01352234|DRUG|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
57779344|NCT05758363|DIETARY_SUPPLEMENT|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
57779345|NCT05758363|OTHER|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
58131243|NCT02848326|DRUG|Atogepant|Atogepant capsule.
58131244|NCT02848326|DRUG|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
58131245|NCT04900584|OTHER|Checklist|Checklist of guideline-based treatment before discharge
58131246|NCT04900584|OTHER|Education|Heart failure education before discharge
58131247|NCT04900584|OTHER|Telephone monitoring|Telephone monitoring after discharge
58131248|NCT03797664|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
58131249|NCT03797664|DRUG|Placebo|Phosphate Buffer Diluent oral solution
58131250|NCT06423066|DIAGNOSTIC_TEST|Pleural ultrasound|Patients who examine pleural ultrasound preoperatively.
58131251|NCT04743258|PROCEDURE|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.
58131252|NCT04743258|PROCEDURE|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
58131253|NCT04023409|OTHER|NA: no intervention|NA: no intervention
58131254|NCT03155048|DRUG|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
58131255|NCT03155048|DRUG|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
58131256|NCT04259177|OTHER|Scale|This test is divided into 3 sections: neurological examination, developmental motor boundary stones and behavioral status, and consists of a total of 37 items. The first part consists of 26 items such as cranial nerve functions, posture, quality, amount of movements, muscle tone, reflex and reactions. The second part evaluates motor development boundary stones consisting of 8 items. The third part refers to the behavioral condition consisting of 3 items. These items can be easily scored. It can be rated as optimal or inadequate. Each item is scored separately (as 0, 1, 2, 3) and the final total score is calculated. The total score ranges from 0-78. The total score shows the global optimal scores.
58131257|NCT01278849|DRUG|ASA404|
58131258|NCT01626664|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
58131259|NCT01626664|DRUG|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
58131260|NCT01626664|DRUG|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
58131261|NCT01626664|DRUG|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
58131262|NCT03627585|DEVICE|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
58131263|NCT05497414|BEHAVIORAL|Sleep deprivation|Overnight sleep deprivation.
58131264|NCT03708211|DRUG|TAK-931 PIC|TAK-931 PICs.
58131265|NCT03708211|DRUG|TAK-931 Tablet|TAK-931 Tablets.
58131266|NCT03708211|DRUG|Esomeprazole|Esomeprazole Tablets.
58131267|NCT03840057|DRUG|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
58131268|NCT03840057|DRUG|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
58131269|NCT03840057|DRUG|Sodium chloride 0.9%|Normal saline is used as a placebo control.
58131270|NCT04500509|DRUG|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
58131271|NCT04500509|DRUG|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
58131272|NCT05007795|DIAGNOSTIC_TEST|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
58131273|NCT04285749|DRUG|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
58131274|NCT04285749|OTHER|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
58131275|NCT04285749|OTHER|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
58131276|NCT02899338|DRUG|BI695501 Prefilled syringe|
58131277|NCT02899338|DRUG|BI695501Autoinjector|
58131278|NCT00148681|DRUG|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
58131279|NCT00148681|DRUG|Navelbine|Intravenously every week for 12 weeks
58131280|NCT00148681|DRUG|Doxorubicin|Every 3 weeks for 12 weeks
58131281|NCT00148681|DRUG|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
58131282|NCT00148681|DRUG|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
58131283|NCT01444703|OTHER|licorice solution|licorice (0.5 g)
58131284|NCT01444703|OTHER|sugar solution|sugar (5 g).
58131285|NCT02227862|DRUG|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
58131286|NCT02227862|DRUG|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
58131287|NCT01434693|BIOLOGICAL|Trichuris suis ova|single dose
58131288|NCT01434693|OTHER|Placebo|
58472322|NCT05322798|PROCEDURE|Low-frequency SCS|Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
58472323|NCT06594224|DRUG|Ibuprofen|Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
58472324|NCT06594224|DRUG|Nalbuphine|Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
58472325|NCT01710982|DRUG|TZP-101|
58472326|NCT01710982|OTHER|Placebo|
58472327|NCT06378047|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that will be administered via IV infusion.
58472328|NCT06378047|DEVICE|Irreversible Electroporation|Participants will undergo IRE as standard of care treatment.
58472329|NCT06069193|BEHAVIORAL|Touch Intervention|"The participants will be examined, with various areas in the neck and upper back being palpated. Subsequently, the exercises to be performed at home will be demonstrated by the experimenter. The experimenter will ensure correct execution by touching specific areas in the neck and upper back of the participants. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
58472330|NCT06069193|BEHAVIORAL|Control|"The participants will be examined, and they will be asked to describe as accurately as possible the regions where they experience pain. Subsequently, the experimenter will demonstrate the exercises to be performed at home. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
58472331|NCT06059664|DRUG|Finerenone Oral Tablet|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
58472332|NCT06059664|DRUG|Placebo|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
58472333|NCT04385277|PROCEDURE|Biospecimen Collection|Correlative studies
58472334|NCT04385277|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
58472335|NCT04385277|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
58472336|NCT04385277|PROCEDURE|Computed Tomography|Undergo CT
58472337|NCT04385277|BIOLOGICAL|Dinutuximab|Given IV
58131289|NCT04117841|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
58131290|NCT06342076|PROCEDURE|Patients undergoing subcostal transversus abdominis plane block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a subcostal transversus abdominis plane block in addition to the posterior transversus abdominis plane block to a group of patients who underwent surgery with a midline incision due to major gynecological cancer.
58131291|NCT06342076|PROCEDURE|Patients undergoing rectus sheat block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a rectus sheath block in addition to the posterior transversus abdominis plane block to a group of patients who were operated on through a midline incision due to major gynecological cancer.
58131292|NCT04915352|DRUG|Nasal provocation test - 725 Dermatophagoides Pteronyssinus|"3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months"
58131293|NCT04915352|OTHER|Negative control|Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
58472338|NCT04385277|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
58472339|NCT04385277|RADIATION|Iobenguane I-123|Undergo 123I-MIBG
58472340|NCT04385277|DRUG|Irinotecan|Given IV
58472341|NCT04385277|DRUG|Isotretinoin|Given PO
58472342|NCT04385277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58472343|NCT04385277|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58472344|NCT04385277|BIOLOGICAL|Sargramostim|Given SC or IV
58472345|NCT04385277|DRUG|Temozolomide|Given PO or via enteral tube
58472346|NCT04634422|PROCEDURE|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
58472347|NCT05964842|BEHAVIORAL|SMS|Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
58131294|NCT01192646|BEHAVIORAL|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
58131295|NCT02921737|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
58131296|NCT00527800|DRUG|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
58131297|NCT00527800|DRUG|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
58131298|NCT00527800|DRUG|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
58131299|NCT01993875|DRUG|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
58131300|NCT01993875|DRUG|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
58131301|NCT01007500|DRUG|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
58131302|NCT01007500|DRUG|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
58131303|NCT05227625|BEHAVIORAL|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
58131304|NCT05227625|BEHAVIORAL|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
58131305|NCT05890066|PROCEDURE|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
58131306|NCT00005938|DRUG|exatecan mesylate|
58131307|NCT01909869|DEVICE|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
58131308|NCT02158832|DEVICE|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current \>sensation threshold \& maintained at a level that is comfortable/painless \& does not elicit skeletal muscle contractions (\~5mA, \<10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', \~15⁰ perpendicular to the skin, \~15⁰ lateral to the midline. Depth: \~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' \~15⁰ perpendicular to the skin, \~15⁰ medial. Depth: \~1.5 cm (secure anchorage)."
58131309|NCT00921193|DEVICE|Radiation Therapy Positioning System (RTPS)|
58131310|NCT04635618|BEHAVIORAL|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
58131311|NCT04635618|BEHAVIORAL|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
58131312|NCT04635618|BEHAVIORAL|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
58131313|NCT03263637|DRUG|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
58131314|NCT04558151|BEHAVIORAL|preoperative inspiratory muscle training|Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
58131315|NCT06247657|DRUG|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
58131316|NCT06269276|BEHAVIORAL|Caregiver Contribution to Self-Care in Ostomy Patient Index|This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.
58131317|NCT02349165|PROCEDURE|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
58131318|NCT02349165|DRUG|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
58131319|NCT02349165|DRUG|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
58131320|NCT02636907|DRUG|BI 695501 Autoinjector|
58131321|NCT02636907|DRUG|BI 695501 Prefilled syringe|
58139003|NCT01219322|DRUG|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
58139004|NCT01219322|DRUG|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
58139005|NCT03447262|DRUG|VX-659/TEZ/IVA|Fixed-dose combination tablets for oral administration qd in the morning.
58139006|NCT03447262|DRUG|IVA|IVA tablet qd in the evening.
58131322|NCT01239251|OTHER|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
58131323|NCT05577793|OTHER|Mother's Voice|The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.
58131324|NCT05577793|OTHER|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
58131325|NCT05577793|OTHER|Mother's Voice +Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
58131326|NCT05577793|OTHER|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
58131327|NCT01703832|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
58131328|NCT00458848|DRUG|asparaginase|
58131329|NCT00458848|DRUG|daunorubicin hydrochloride|
58131330|NCT00458848|DRUG|etoposide|
58131331|NCT00458848|DRUG|idarubicin|
58131332|NCT00458848|DRUG|imatinib mesylate|
58131333|NCT00458848|DRUG|mercaptopurine|
58131334|NCT00458848|DRUG|methotrexate|
58131335|NCT00458848|DRUG|methylprednisolone|
58131336|NCT00458848|DRUG|mitoxantrone hydrochloride|
58131337|NCT00458848|DRUG|prednisone|
58131338|NCT00458848|DRUG|vincristine sulfate|
58472348|NCT05964842|BEHAVIORAL|Phone call|Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
58131339|NCT00458848|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58131340|NCT00458848|PROCEDURE|autologous hematopoietic stem cell transplantation|
58131341|NCT00458848|PROCEDURE|peripheral blood stem cell transplantation|
58131342|NCT00458848|RADIATION|radiation therapy|
58131343|NCT05733572|DRUG|CHF6467|drug eyedrops
58131344|NCT05733572|DRUG|Placebo|placebo eyedrops
58131345|NCT02246920|DRUG|Fluticasone propionate|50 mcg/actuation Nasal Spray
57779346|NCT04349410|DRUG|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
57779347|NCT04349410|DRUG|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
57779348|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
57779349|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
58131346|NCT02246920|DRUG|Flonase®|50 mcg/actuation Nasal Spray
58131347|NCT02246920|DRUG|Placebo|Inactive Nasal Spray
58131348|NCT05701202|DIETARY_SUPPLEMENT|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
58131349|NCT05701202|DIETARY_SUPPLEMENT|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
58131350|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
58131351|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
58131352|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
58131353|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
58131354|NCT03855475|BEHAVIORAL|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
58131355|NCT03855475|BEHAVIORAL|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
58131356|NCT06148909|OTHER|Small Talk Motivational Interviewing|Combining small talks and skills on Motivational Interviewing in the smoking cessation services
58131357|NCT04898296|OTHER|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
58131358|NCT04898296|OTHER|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
58131359|NCT05575271|PROCEDURE|Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network|The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
58131360|NCT02236715|DRUG|Atrovent®|
58131361|NCT05871736|OTHER|Turkish version of Child Engagement in Daily Life Measure V2|Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.
58131362|NCT02210767|OTHER|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
58131363|NCT02210767|OTHER|Walnut Control Diet|2-3% ALA but no walnuts provided
58131364|NCT02210767|OTHER|Low ALA Diet|ALA replaced by oleic acid
58131365|NCT02344992|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
58131366|NCT02344992|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
58131367|NCT04892979|OTHER|Cardiopulmonary exercise (centre-based)|Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale \[10\], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
58131368|NCT04892979|OTHER|Cardiopulmonary exercise (online-based)|Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
58131369|NCT02636400|OTHER|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
58131370|NCT06452160|DRUG|BGC515|Capsules for oral administration
58131371|NCT03249584|DEVICE|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
58131372|NCT03255421|OTHER|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
58131373|NCT02545153|DRUG|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
58131374|NCT02545153|DRUG|Control|No fibrin sealant applied
58131375|NCT02173704|BIOLOGICAL|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
58131376|NCT02173704|BIOLOGICAL|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
58131377|NCT00193622|DRUG|Bevacizumab|
58131378|NCT00193622|DRUG|Erlotinib|
58131379|NCT00059852|DRUG|erlotinib hydrochloride|
58131380|NCT00059852|DRUG|gemcitabine hydrochloride|
58131381|NCT03038737|OTHER|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
58131382|NCT03038737|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
58131383|NCT05834231|DRUG|Memantine|oral
58131384|NCT05834231|DRUG|Placebo|oral
58131385|NCT05282160|DEVICE|Epino|The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
58131386|NCT05532085|OTHER|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
57779350|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
57779351|NCT04349410|DRUG|Remdesivir|FMTVDM Planar, SPECT, PET
57779352|NCT04349410|DRUG|Tocilizumab|FMTVDM Planar, SPECT, PET
57779353|NCT04349410|DRUG|Methylprednisolone|FMTVDM Planar, SPECT, PET
58131387|NCT05532085|OTHER|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
58131388|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
58131389|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
58131390|NCT00726700|BIOLOGICAL|pegfilgrastim|Given subcutaneously
58131391|NCT00726700|BIOLOGICAL|rituximab|Given IV
58131392|NCT00726700|DRUG|cyclophosphamide|Given IV
58131393|NCT00726700|DRUG|doxorubicin hydrochloride|Given IV
58131394|NCT00726700|DRUG|prednisone|Given orally
58131395|NCT00726700|DRUG|vincristine sulfate|Given IV
58131396|NCT02285738|DRUG|Aspirin|81mg/day for 4 weeks
58131397|NCT02285738|DRUG|Simvastatin|Daily dose of Simvastatin for 4 weeks
58131398|NCT02285738|OTHER|Observation|participants will be observed for thrombotic evens for 4 weeks
58131399|NCT04345965|PROCEDURE|Endovascular procedure|Endovascular therapies for erectile dysfunction
58131400|NCT04326998|PROCEDURE|solvent|using solvent (GuttaClear) in procedure
58131401|NCT04326998|PROCEDURE|non-solvent|non-solvent
58131402|NCT00114426|DEVICE|non-invasive mechanical ventilation|
58131403|NCT06235398|BIOLOGICAL|Hematopoietic stem-cell transplantation|Upfront related donor transplantation
58131404|NCT03252470|PROCEDURE|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
58131405|NCT01826383|BEHAVIORAL|Active-Video|This group will watch an active-video with pain management strategies for parents
58131406|NCT01826383|BEHAVIORAL|Placebo Video|This group will watch a placebo-video describing immunization generally.
58131407|NCT01132976|BEHAVIORAL|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
58131408|NCT01132976|BEHAVIORAL|Treatment as usual|No specific motivational interview
58131409|NCT03902171|DEVICE|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
58131410|NCT05319665|DEVICE|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
58131411|NCT03605043|OTHER|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
58131412|NCT00193141|DRUG|Paclitaxel|
58131413|NCT00193141|DRUG|Carboplatin|
58131414|NCT00193141|DRUG|5-Fluorouracil|
57779354|NCT04349410|DRUG|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
57779355|NCT04349410|DRUG|Losartan|FMTVDM Planar, SPECT, PET
58131415|NCT02434055|DEVICE|AVERT PLUS|
58131416|NCT03199274|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
58131417|NCT03199274|DRUG|Perflutren Protein-Type A Microspheres|Given IV.
58131418|NCT03199274|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
58131419|NCT03318796|DEVICE|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB \& SB
58131420|NCT01308593|DEVICE|Juvederm XC|Filler
58131421|NCT01308593|DRUG|Botox|26 units dosed one time
58131422|NCT05269381|DRUG|Cyclophosphamide|Given IV
58131423|NCT05269381|BIOLOGICAL|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
58131424|NCT05269381|BIOLOGICAL|Pembrolizumab|Given IV
58131425|NCT05269381|BIOLOGICAL|Sargramostim|Given SC
58131426|NCT00154102|DRUG|Cetuximab|Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
58131427|NCT00154102|DRUG|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
58131428|NCT04133376|OTHER|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
58131429|NCT04133376|OTHER|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
58131430|NCT03140007|DEVICE|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
58131431|NCT03140007|DEVICE|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
58131432|NCT06202716|DRUG|Cadonilimab plus CapeOX chemotherapy|Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
58131433|NCT05067764|PROCEDURE|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
58131434|NCT05067764|PROCEDURE|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
58131435|NCT01762748|DRUG|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
58131436|NCT02563197|DEVICE|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
58131437|NCT00458900|DRUG|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
58131438|NCT00957814|BEHAVIORAL|Nutritional education|Systematic nutritional orientation program
58131439|NCT04668105|OTHER|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
58131440|NCT04668105|OTHER|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
58131441|NCT00547677|RADIATION|stereotactic radiosurgery|
58131442|NCT05129852|OTHER|Sage oil group|Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
58131443|NCT05129852|BEHAVIORAL|Reiki group|Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
58131444|NCT03328260|DEVICE|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
58131445|NCT03879239|DEVICE|Vibrating capsule|Vibrating Capsule administered 5 times per week
58472349|NCT05964842|BEHAVIORAL|Mobile money incentive|Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
57779356|NCT04349410|DRUG|Convalescent Serum|FMTVDM Planar, SPECT, PET
57779357|NCT04261738|DEVICE|Hyperbaric Oxygen|Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
57779358|NCT00915902|DRUG|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
57779359|NCT00915902|DRUG|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
57779360|NCT06043063|PROCEDURE|Topical lidocaine|Topical anesthetic
57779361|NCT06043063|PROCEDURE|EMLA cream|Topical anesthetic
57779362|NCT06043063|PROCEDURE|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
57779363|NCT02118714|DRUG|Atrasentan|Atrasentan
57779364|NCT04384679|DEVICE|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
57779365|NCT03751540|PROCEDURE|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
57779366|NCT03751540|PROCEDURE|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
57779367|NCT01580098|OTHER|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
57779368|NCT01580098|OTHER|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
57779369|NCT00695682|DRUG|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
57779370|NCT03575689|DEVICE|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
57779371|NCT00802659|RADIATION|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
57779372|NCT05211375|PROCEDURE|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
57779373|NCT05211375|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
57779374|NCT03318952|DRUG|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
57779375|NCT03318952|DRUG|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
57779376|NCT00562068|BIOLOGICAL|alemtuzumab|
57779377|NCT00562068|DRUG|cyclophosphamide|
57779378|NCT00562068|DRUG|doxorubicin hydrochloride|
57779379|NCT00562068|DRUG|prednisolone|
57779380|NCT00562068|DRUG|vincristine sulfate|
57779381|NCT00562068|GENETIC|polymerase chain reaction|
57779382|NCT00562068|OTHER|flow cytometry|
57779383|NCT00562068|OTHER|laboratory biomarker analysis|
57779384|NCT00562068|OTHER|pharmacological study|
57779385|NCT06398340|OTHER|High Calorie Meal Intervention|Subjects will receive a unhealthy meal high in calorie, sugar and fat
57779386|NCT06398340|OTHER|Low Calorie Meal Intervention|Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre
57779387|NCT00823550|DRUG|Entecavir|entecavir 0.5 mg QD
57779388|NCT00823550|DRUG|Lamivudine|lamivudine 100 mg QD
57779389|NCT00088205|DRUG|enzastaurin|500 milligrams (mg), oral, daily, up to six 28-day cycles
57779390|NCT02166151|DRUG|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
57779391|NCT04052230|OTHER|ultrasound measure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
57779392|NCT02584764|BEHAVIORAL|Cognitive behavior therapy|
57779393|NCT02584764|BEHAVIORAL|Internet support|
57779394|NCT01260857|DRUG|Aldazide|Aldazide 25 mg OD
57779395|NCT01085929|PROCEDURE|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
57779396|NCT01085929|PROCEDURE|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
57779397|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57779398|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57779399|NCT05939817|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57779400|NCT03124030|PROCEDURE|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
57779401|NCT03188614|DRUG|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
57779402|NCT01710774|PROCEDURE|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
57784536|NCT03478423|DRUG|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
58131446|NCT03151278|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
58131447|NCT03151278|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
58131448|NCT02803242|OTHER|Patient Reported Outcomes|
58131449|NCT06159803|BEHAVIORAL|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
58131450|NCT04112082|BEHAVIORAL|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
58131451|NCT04112082|OTHER|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
58131452|NCT05277753|BIOLOGICAL|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
58472350|NCT01592734|DRUG|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
58472351|NCT01592734|DEVICE|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
58472352|NCT06603324|DEVICE|CVVHD treatment in paediatric mode with multiFiltratePRO|Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
58472353|NCT06592053|PROCEDURE|Breast Cancer Surgery Pain|Factors affecting the occurrence of chronic pain in patients undergoing elective mastectomy surgery will be investigated.
58472354|NCT06592352|DRUG|Modafinil Generis 100 mg|All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration
58472355|NCT06378008|DRUG|CSPS toothpaste|Toothpaste containing 5.0% weight/weight (w/w) CSPS.
58131453|NCT00105196|DRUG|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
58131454|NCT00105196|DRUG|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
58131455|NCT02480465|DRUG|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
58131456|NCT02480465|DRUG|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
58131457|NCT01722448|DIETARY_SUPPLEMENT|Choline|4 capsules with 480 mg choline per day
58131458|NCT01722448|DIETARY_SUPPLEMENT|Placebo|
58131459|NCT00055978|DRUG|celecoxib|Given orally. 400mg twice daily for 6 months.
58472356|NCT06378008|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
58131460|NCT00055978|OTHER|placebo|Given orally
58131461|NCT00002012|DRUG|Interferon alfa-n3|
58131462|NCT01881048|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Given PO
58131463|NCT01881048|DRUG|Celecoxib|Given PO
58131464|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
58131465|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
58131466|NCT01436422|BIOLOGICAL|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
58131467|NCT05559996|DEVICE|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
58472357|NCT06365697|DEVICE|Ton-bridge carotid stent|carotid artery stenting with Ton-bridge carotid stent
58472358|NCT06365697|DEVICE|WALLSTENT carotid stent|carotid artery stenting with WALLSTENT carotid stent
58472359|NCT03475004|DRUG|Pembrolizumab|An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58472360|NCT03475004|DRUG|Bevacizumab|The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
58472361|NCT03475004|DRUG|Binimetinib|Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
58472362|NCT06536101|DRUG|GIM-407|GIM-407 oral dose
58472363|NCT06536101|DRUG|Placebo|Matching placebo oral dose
58472364|NCT03579251|BEHAVIORAL|Black Men's Care|12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
58472365|NCT04531085|PROCEDURE|Operative treatment|Surgery
58472366|NCT04531085|PROCEDURE|Long arm cast|cast immobilization
58472367|NCT03884829|DRUG|CYC140|CYC140 single agent
58131468|NCT03380819|DIAGNOSTIC_TEST|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
58131469|NCT02173236|OTHER|platform-switched implants|
58131470|NCT02173236|OTHER|platform-matched implant|
58131471|NCT04963192|DEVICE|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
58131472|NCT04963192|DEVICE|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
58131473|NCT04963192|OTHER|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
58131474|NCT04963192|DEVICE|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
58131475|NCT04963192|DEVICE|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
58131476|NCT04963192|DEVICE|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
58131477|NCT04963192|DEVICE|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
58131478|NCT04963192|DEVICE|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
58131479|NCT04963192|OTHER|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
58131480|NCT04963192|OTHER|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
58131481|NCT04963192|OTHER|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
58131482|NCT04963192|OTHER|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
58131483|NCT04963192|OTHER|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
58131484|NCT00182442|DRUG|Olanzapine & Quetiapine|
58131485|NCT03532685|PROCEDURE|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
58131486|NCT06367452|DRUG|Sodium alginate + sodium bicarbonate + magaldrate + simeticone|Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
58131487|NCT06277193|DIAGNOSTIC_TEST|valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
58131488|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
58131489|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
58131490|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
58131491|NCT03305237|OTHER|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
58131492|NCT03305237|OTHER|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
58131493|NCT05851131|OTHER|Approach to Diagnosis and Treatment of Osteoporosis Questionnaire|"The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report."
57784537|NCT03848091|OTHER|Antibiotic pretreatment|a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
58131494|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
58131495|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
58131496|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
58131497|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
58131498|NCT02441972|DRUG|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
58131499|NCT00535808|DRUG|nitroprusside|Administration of nitroprusside
58131500|NCT00535808|DRUG|nitroglycerine|Administration of nitroglycerine
58131501|NCT00535808|DRUG|sevoflurane|Administration of Sevoflurane
58131502|NCT05873023|OTHER|Chewing gum|chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
58131503|NCT02597543|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
58131504|NCT02597543|DRUG|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
58472368|NCT06592885|PROCEDURE|Atraumatic Restorative Treatment in treatment of carious primary molars|ART, which took place in Tanzania during the mid-1980s, is a conservative approach involving the removal of carious lesions using hand instruments, followed by the application of a glass ionomer restoration. This technique aims to be minimally invasive, promoting the preservation of tooth structure. The ART technique, employed in situations where ideal clinical conditions are challenging to achieve, has demonstrated effectiveness as a reliable method for managing cases where conventional treatment methods face resistance from children . However, concerns exist regarding the longevity of ART restorations and the impact of operator skill on outcomes.
58472369|NCT06592885|PROCEDURE|Hall Technique in treatment of carious primary molars|"The Hall technique, proposed by Norna Hall in the 1980s, involves the placement of preformed metal crowns on primary molars without any tooth preparation or local anesthesia.~Advocates of the Hall technique emphasize its simplicity, reduced need for traditional drilling, and high reported success rates in clinical studies.~However, concerns have been raised regarding long-term aesthetics and potential psychological impacts due to the visibility of metal crowns."
58472370|NCT02473848|DRUG|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
58472371|NCT05954858|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
58472372|NCT00272584|DRUG|Risperidone|
58472373|NCT02130817|DRUG|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
58472374|NCT02130817|DRUG|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
58472375|NCT02130817|PROCEDURE|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
58472376|NCT02130817|DRUG|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
58472377|NCT02130817|DRUG|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
58472378|NCT02130817|DRUG|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
58472379|NCT03631940|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
58472380|NCT03631940|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
58472381|NCT04294134|BEHAVIORAL|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
58490876|NCT02874976|DEVICE|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
57779403|NCT05827666|DIETARY_SUPPLEMENT|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
57779404|NCT05827666|DIETARY_SUPPLEMENT|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
57779405|NCT05827666|DIETARY_SUPPLEMENT|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
57784538|NCT04877704|OTHER|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
58472382|NCT04294134|BEHAVIORAL|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based...model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
58472383|NCT00311675|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
58472384|NCT06053268|DEVICE|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
58472385|NCT04634071|DRUG|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
58472386|NCT04634071|DRUG|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
58472387|NCT04634071|DRUG|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
58472388|NCT04634071|BEHAVIORAL|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
58472389|NCT04634071|BEHAVIORAL|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
58472390|NCT04634071|OTHER|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
58472391|NCT04634071|DRUG|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
58472392|NCT06142786|BEHAVIORAL|attenuating individualized lower alpha neurofeedback|Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.
58472393|NCT06142786|BEHAVIORAL|Sham neurofeedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
58472394|NCT06502860|OTHER|skin to skin with sling|In the intervention group, skin-to-skin contact will be facilitated using a specially designed sling. This approach aims to enhance the quality and duration of skin-to-skin contact between the mother and the newborn.
58472395|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
58472396|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
58472397|NCT06588452|OTHER|RECTIFIER - a generative artificial intelligence screening tool|RECTIFIER is a large-language model based, generative artificial intelligence-enabled inclusion and exclusion criteria assessment tool.
58472398|NCT06588452|OTHER|Manual clinical trial screening by study staff|The current gold standard - study staff manually review potentially eligible patients through chart review.
58472399|NCT06276556|DRUG|ABP-671|"Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study."
58472400|NCT06276556|DRUG|Allopurinol|Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
58472401|NCT04300192|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
58472402|NCT06599086|DRUG|2 cc:(1 cc betamethasone dipropionate+1cc physiological saline)|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
58472403|NCT06602284|COMBINATION_PRODUCT|Dermapen 4™|Dermapen 4™ conjunction with MG-CLR
58472404|NCT04945681|BIOLOGICAL|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 15 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
58472405|NCT04797585|OTHER|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
58472406|NCT04797585|OTHER|Vaginal hysterectomy|Vaginal hysterectomy
58472407|NCT02121158|DEVICE|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
57784539|NCT04877704|OTHER|Placebo|Matched placebo to Symprove probiotic
58472408|NCT02121158|OTHER|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
58472409|NCT06597188|DEVICE|VitaFlow Liberty|All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty
58472410|NCT06597188|DEVICE|Commercially available surgical bioprosthetic valve|All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
58472411|NCT05773755|DEVICE|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
58472412|NCT06604741|OTHER|Assigned Interventions for LVIMT|"IMT is a form of exercise designed to strengthen the muscle involved inhalation, primarily the diaphragm and intercostal muscles.~The LVIMT group will perform IMT once daily, 5 days a week, maintaining 60% of maximal inspiratory pressure (MIP) throughout the 6-week intervention.~The intervals are typically longer in duration (e.g., 2-4 minutes) with a work-to-rest ratio of 1:1 or 1:0.5.~POSITION: rested and seated position. FREQUENCY: more frequency, once a day. 2-3 sessions per week. INTENSITY: Low resistance. Only 60%% MIP. TIME: shorter duration of 10-20 mint."
58472413|NCT06604741|OTHER|Assigned interventions for HVIMT|"The HVIMT group is trained twice daily, with the morning session matching the LV-IMT protocol, and an additional afternoon session. The HVIMT group also experienced a progressive increase in intensity, starting at 60% MIP and reaching 80% by the end of the study. LVIMT works for beginner or individuals with limited respiratory capacity while HVIMT is used for individual with high baseline respiratory fitness.~The intervals are typically shorter in duration (e.g., 30 seconds to 2 minutes) with a work-to-rest ratio of 1:1 or 1:2.~POSITION; Seated upright position. FREQUENCY: more frequency two session per week. 4-5 sessions per week. INTENSITY: high resistance. 60%-80% MIP.~(gradual increment the load by 10% every 2 weeks to reach 80% MIP)~TIME: longer duration 20-30 mint."
58472414|NCT04559815|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
58472415|NCT04981925|BEHAVIORAL|MBSR treatment|"Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up."
58472416|NCT06596512|DRUG|PARTICS using a single ICS add on|Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
58472417|NCT06596512|DRUG|MART|Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
58472418|NCT04791579|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic
58472419|NCT04791579|DRUG|Placebo|Placebo pill
58472420|NCT06038864|DIAGNOSTIC_TEST|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
58472421|NCT03435211|DEVICE|INVSENSOR00006|Noninvasive pulse oximeter sensor
58472422|NCT04555551|BIOLOGICAL|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
58472423|NCT05679388|DRUG|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
58472424|NCT05679388|DRUG|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
58472425|NCT05679388|DRUG|Itraconazole|A drug used to treat fungal infections.
58472426|NCT04359810|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
58472427|NCT04359810|BIOLOGICAL|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
58472428|NCT04638543|DRUG|ABP-671|ABP-671 Tablet
58472429|NCT04638543|DRUG|Placebo|Placebo
58472430|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
58472431|NCT05306873|DRUG|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
58472432|NCT05306873|DRUG|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
58472433|NCT05306873|DRUG|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
58472434|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
58472435|NCT01564160|DIETARY_SUPPLEMENT|Fish Oil|Source of omega-3 fatty acids.
58472436|NCT01564160|DIETARY_SUPPLEMENT|PCSO-524|Extract of Greenshell Mussel
57779406|NCT05827666|DIETARY_SUPPLEMENT|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
58472437|NCT06590090|DRUG|Natrunix|"The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.~Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0."
58472438|NCT06590090|DRUG|Placebo|Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
58472439|NCT05527015|DEVICE|Bifocal Spectacles|Bifocals with a +3.00 Diopter flat top 35
58472440|NCT05527015|DEVICE|Single Vision Lenses|Single vision lens as prescribed by provider
58472441|NCT06590142|PROCEDURE|Observational study of tissue specimens|No intervention will be made
58472442|NCT06007534|OTHER|Samples|Blood samples, urine samples and oropharyngeal swabs before taking 200mg of doxycycline and then 2h, 24h, 48h, 7 days, 14 days, 60 days and 90 days after the single dose of doxycycline Hair samples: at the time of doxycycline administration, 1 month and 3 months after the single dose of doxycycline
58472443|NCT02464696|DRUG|Methylprednisolone|IPS cohort only
58472444|NCT02464696|PROCEDURE|Oxygen Therapy|Receive high flow oxygen therapy
58472445|NCT02464696|DEVICE|Positive Air Pressure Device|Undergo NIPPV
58472446|NCT06313515|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin
58472447|NCT06313515|BEHAVIORAL|Arm-crank bike exercise|Exercise using an arm-bike to target cardiovascular functioning.
58472448|NCT06313515|OTHER|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin.
58472449|NCT05554133|DEVICE|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
58472450|NCT05554133|DEVICE|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
58472451|NCT05554133|DRUG|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
58472452|NCT04711746|BIOLOGICAL|blood sample|Blood sample withdrawal in order to perform DNA sequencing
58472453|NCT04298697|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
58472454|NCT03793946|OTHER|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
58472455|NCT02965911|DRUG|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
58472456|NCT02965911|DRUG|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
58472457|NCT06596200|DEVICE|Spinal Cord Stimulation Implant|Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord
58472458|NCT06157515|DEVICE|Breath-actuated vibrating mesh nebulizer|The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
58472459|NCT06157515|DEVICE|Continuous vibrating mesh nebulizer|When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
58472460|NCT06024408|DRUG|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
58472461|NCT06024408|DRUG|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
58472462|NCT06600113|OTHER|Education and teaching of coping strategies|the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
58472463|NCT05538741|DRUG|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
58472464|NCT05538741|DRUG|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
58472465|NCT06322160|OTHER|Interview|Interview with individual participant will take place via online videoconferencing MS Teams
58472466|NCT03396341|OTHER|Salvia sample|salvia sample
58472467|NCT03396341|BEHAVIORAL|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
58472468|NCT05227417|BEHAVIORAL|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
58472469|NCT01054014|DRUG|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
58472470|NCT01054014|DRUG|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
58472471|NCT01054014|DRUG|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
58472472|NCT03171402|DIAGNOSTIC_TEST|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
58472473|NCT04054557|OTHER|Telemedicine|Participate in virtual visits with oncologist
58472474|NCT04054557|OTHER|Best Practice|Receive 4 in-office visits with oncologist
58472475|NCT04054557|OTHER|Questionnaire Administration|Ancillary studies
58472476|NCT04054557|OTHER|Quality-of-Life Assessment|Ancillary studies
58472477|NCT04054557|OTHER|Survey Administration|Complete electronic survey
58472478|NCT04054557|BEHAVIORAL|Behavioral Intervention|Use smart pill bottle
58472479|NCT04054557|OTHER|Educational Intervention|Receives time-specific reminders and messages
58472480|NCT06139510|OTHER|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
58472481|NCT04444076|DEVICE|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
58472482|NCT06591689|OTHER|Evaluation of Cases with Quadriparetic Cerebral Palsy|20 quadriparetic cerebral palsy cases were evaluated with the Communication Function Classification System (CFCS), Pediatric Functional Independence Scale (WeeFIM) and Gross Motor Function Measure-88 (GMFM-88).
58472483|NCT03234699|DRUG|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
58472484|NCT03234699|DRUG|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
58472485|NCT03234699|DRUG|Warfarin Pill|5 mg (Days 7 and 105)
58472486|NCT03234699|DRUG|Omeprazole Pill|20 mg (Days 7 and 105)
58472487|NCT03234699|DRUG|Bupropion Pill|150 mg (Days 1 and 99)
58472488|NCT06174246|BEHAVIORAL|Pain self-management program|"Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/"
58472489|NCT06174246|BEHAVIORAL|Additional support for self-management program|"This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program."
58472490|NCT05722860|DRUG|L-Citrulline, capsule|5g/daily dose for the duration of 1 week intervention
58472491|NCT04200534|OTHER|Best Practice|Receive usual care counseling
58472492|NCT04200534|DRUG|Nicotine Patch|Given nicotine patches
58472493|NCT04200534|OTHER|Quality-of-Life Assessment|Ancillary studies
58472494|NCT04200534|OTHER|Questionnaire Administration|Ancillary studies
58472495|NCT04200534|OTHER|Tobacco Cessation Counseling|Receive counseling over the phone
58472496|NCT06589882|OTHER|Effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques|Evaluate the effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques practiced in French expert centers over the next 10 years with the rate of technical success (procedure completed) and clinical success (cure) of the digestive pathology presented by the patient who indicated endoscopy without recourse to a new intervention (endoscopic or surgical) within 30 days of the procedure.
58472497|NCT03744793|DRUG|Avelumab|Given IV
58472498|NCT03744793|DRUG|Pemetrexed|Given IV
58472499|NCT03317158|DRUG|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
58472500|NCT03317158|RADIATION|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
58472501|NCT03317158|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
58472502|NCT03317158|DRUG|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
58472503|NCT03317158|DRUG|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
58472504|NCT03317158|BIOLOGICAL|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
58472505|NCT03317158|DRUG|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
58472506|NCT03317158|OTHER|To be determined|Other regimens to be determined
58472507|NCT01841099|DRUG|Mesalamine|Mesalamine granules
58472508|NCT01841099|DRUG|Placebo granules|Provided by Ferring Pharma
58472509|NCT03645122|OTHER|Paired corticospinal-motoneuronal stimulation (PCMS)|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
58472510|NCT03645122|OTHER|Sham stimulation|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
58472511|NCT03537989|DRUG|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
58472512|NCT04287218|BEHAVIORAL|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
58472513|NCT04287218|BEHAVIORAL|aTAU|Active control group
58472514|NCT04998331|OTHER|No Intervention|This is a non-interventional study.
58472515|NCT06562790|BIOLOGICAL|Gamma PN3|500, 1000 or 1500 µg by IM injection on Days 1 and 29
58472516|NCT06562790|BIOLOGICAL|Prevnar|1 dose on Day 1 and saline placebo on Day 29
58472517|NCT04929249|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
58472518|NCT06556121|PROCEDURE|Saddle block|The injected solution will be comprised of 5mg of heavy Bupivacaine 0.75% plus 100mcg of Morphine will be injected into the intrathecal space.
58472519|NCT06556121|PROCEDURE|pudendal nerve block|As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.
58472520|NCT01805011|OTHER|minimum 4 months of breastfeeding|
58472521|NCT00437112|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
58472522|NCT00437112|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
58472523|NCT05907785|BEHAVIORAL|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
58472524|NCT00004217|BIOLOGICAL|filgrastim|5 μg/kg/day IV or SC
58131505|NCT02597543|PROCEDURE|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
58472525|NCT00004217|BIOLOGICAL|sargramostim|5 μg/kg/day IV or SC starting d 15
58472526|NCT00004217|DRUG|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
58472527|NCT00004217|DRUG|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
58472528|NCT00004217|DRUG|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
58472529|NCT06593028|BEHAVIORAL|Veggie Vouchers pilot|This intervention aims to increase awareness and use of a Supplemental Nutrition Assistance Program (SNAP) fruit and vegetable incentive program in South Carolina among families with young children experiencing food insecurity. To do so, brief education about this SNAP program is delivered by pediatricians to caregivers during well-child visits. Subsequently, caregivers are given 3 free produce boxes as a free trial of this program to incentivize first time use.
58472530|NCT06601972|PROCEDURE|Beautifil II LS (Low-Shrinkage)|The most remarkable feature of this light-cured universal composite for anterior and posterior restorations is its unique shrinkage of 0.85 percent by volume
58472531|NCT06601972|PROCEDURE|Nanohybrid resin composite|Nanohybrid resin composites are the most popular, because they improve the distribution of fillers in the matrix by combining nanoparticles with submicron particles to achieve better mechanical, chemical, and optical properties
58472532|NCT03779009|OTHER|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
58472533|NCT06600919|OTHER|Preoperative Music Therapy Session|"Upon admission to the operating room:~Patients in the music therapy group will undergo a 20-minute music therapy session while lying on a stretcher in a designated room. This session will be conducted using the Music Care® application (https://www.music.care).~The sessions are standardized and divided into several phases, following a U-shaped sequence. The effect of this U-sequence is first achieved by a phase of reduced tempo, instrumental density, frequency, and sound volume , followed by a phase of reactivation .~Patients will be allowed to choose the musical style based on their preferences (influenced by their musical tastes and ethnicity). Given the ethnically diverse population of Réunion Island, a wide range of musical preferences is expected."
58472534|NCT02759614|DRUG|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
58472535|NCT02759614|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
58472536|NCT06594536|DIETARY_SUPPLEMENT|Sulforaphane|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
58472537|NCT06594536|OTHER|Placebo|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
58472538|NCT06275685|DEVICE|SeizureWise algorithm|An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
58472539|NCT06275685|DEVICE|Multi-day Visualizations|Multi-day visualizations of sensor derived data
58472540|NCT03373123|PROCEDURE|Endoscopy|Endoscopy
58472541|NCT03373123|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
58472542|NCT06388512|DEVICE|prototype prone positioning device|The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
58472543|NCT06598683|OTHER|tDCS|Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation
58472544|NCT06598683|OTHER|Conventional|ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training
58472545|NCT02439697|OTHER|Darbepoetin alfa|Conversion from Aranesp® to NESP®
58472546|NCT03815929|DRUG|Estradiol 100 Micrograms Patch|Standard
58472547|NCT03815929|DRUG|Estradiol Patch|Individualized
58472548|NCT06210724|DIAGNOSTIC_TEST|Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome|Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
58472549|NCT06603233|DIAGNOSTIC_TEST|The Difference Between The AI Model and Dentists Group|The clinical feasibility of the best performing model, statistical hypothesis tests are performed that compares the predictions of the AI model with the assessments from three dentists.
58472550|NCT06603233|DIAGNOSTIC_TEST|Deep Learning Models|DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer were trained on 354 images and tested on 79 images.
58472551|NCT04238910|BEHAVIORAL|Maximizing Energy|The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
58472552|NCT04238910|BEHAVIORAL|Health Education|The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
58472553|NCT06599307|DRUG|Rituximab|Rituximab 1gm vial diluted on 500 ml normal saline 0.9%
58472554|NCT06599307|OTHER|Saline (NaCl 0,9 %) (placebo)|500 ml of normal saline 0.9%
58472555|NCT05737485|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
58472556|NCT02849418|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
58472557|NCT02849418|DRUG|Placebo|Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
58472558|NCT03521570|RADIATION|IMRT|Undergo intensity-modulated radiation therapy
58472559|NCT03521570|BIOLOGICAL|Nivolumab|Given IV
58472560|NCT00966654|DRUG|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
58472561|NCT00966654|DRUG|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
58472562|NCT05118945|DEVICE|Insulin pump Tandem: t:slim X2|"Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered."
58472563|NCT04890860|OTHER|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
58472564|NCT05958251|OTHER|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
58472565|NCT05958251|OTHER|Standard Care (in control arm)|Standard care
58472566|NCT02759419|DRUG|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
58472567|NCT05203302|OTHER|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
58472568|NCT05203302|OTHER|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
58472569|NCT05203302|OTHER|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
58472570|NCT05203302|OTHER|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
58472571|NCT06300697|OTHER|Data and biospecimen collection|Enrolled participants will have health-related information and blood specimens collected.
58472572|NCT06300697|OTHER|Skin biopsies|Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
58472573|NCT06300697|OTHER|Oral Food Challenge (OFC) procedures|Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
58472574|NCT05116384|DEVICE|catheter ablation|cryo energy via cryoballoon
58472575|NCT05116384|DEVICE|renal artery denervation|RF energy delivery to multiple sites within each major renal artery
58472576|NCT06266429|DIAGNOSTIC_TEST|Blood collection|Collecting blood pre-op and post-op for metabolite levels.
58472577|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock and pectointercostal block|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib and pectointercostal plane block (0,25% bupivacaine 15 ml) will perform at 4-5.th intercostal space. Both 2 blocks will perform bilaterally
58472578|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib to the all patients
58472579|NCT04810091|DRUG|Placebo Administration|Given PO
58472580|NCT04810091|OTHER|Questionnaire Administration|Ancillary studies
58472581|NCT04810091|DRUG|Telotristat Ethyl|Given PO
58472582|NCT03938233|BEHAVIORAL|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
58472583|NCT06592820|DEVICE|Shear Wave Elastography (EUS)|EUS combines ultrasound technology with endoscopy to gain an internal vantage point to obtain higher resolution ultrasound images. ShearWave is a software option on the ultrasound system which is being evaluated for use in assessing liver fibrosis.
58472584|NCT06592820|DEVICE|Fibroscan|A small ultrasound probe to measure the velocity of a sound wave passing through the liver. This is converted into kilopascals (kPa), which is used to assess liver fibrosis.
58472585|NCT06592820|DEVICE|EUS|A biopsy of liver tissue under endoscopic ultrasound guidance. Endoscopic Ultrasound (EUS) provides high resolution images of left lobe of the liver and a good portion of the right lobe of the liver. This, coupled with Doppler capability, allows the physician to direct the biopsy needle safely into the liver for sampling under real time image guidance.
58472586|NCT01829620|BEHAVIORAL|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
58472587|NCT01829620|BEHAVIORAL|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, \& 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
58472588|NCT06554795|DRUG|DB-1419|Administered Injection of Vein (I.V.)
57779407|NCT02313896|BEHAVIORAL|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
57779408|NCT05814757|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
57779409|NCT05814757|DRUG|Controlled Insertion|Collagen Punctal Plug 0.2mm (Controlled Insertion)
57779410|NCT05814757|DRUG|Collagen Punctal Plug|Collagen Punctal Plug 0.2mm (Full Insertion)
57779411|NCT02711176|DRUG|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
58472589|NCT00293098|DRUG|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
57779412|NCT02711176|DRUG|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
58472590|NCT06186050|DIETARY_SUPPLEMENT|Beetroot drink|Drink containing 10g of beetroot powder in 250 mL cold tap water
58472591|NCT06186050|DIETARY_SUPPLEMENT|Placebo|Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
57779413|NCT02711176|DRUG|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
57779414|NCT02711176|DRUG|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
57779415|NCT02711176|DRUG|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
57779416|NCT02711176|DRUG|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
57779417|NCT03542448|DEVICE|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
57784540|NCT03870503|DRUG|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
58472592|NCT06186050|DIETARY_SUPPLEMENT|Control|Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
58472593|NCT01239953|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
58472594|NCT01239953|DEVICE|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
58472595|NCT02234882|DRUG|Rosuvastatin|
58472596|NCT02234882|DRUG|BMS-663068|
58472597|NCT05094206|BIOLOGICAL|0.75x10^6 cells/kg CAR20.19.22 cells|"Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
58472598|NCT05094206|BIOLOGICAL|1x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
58472599|NCT05094206|BIOLOGICAL|2.5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
58472600|NCT05094206|BIOLOGICAL|5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
58472601|NCT05094206|BIOLOGICAL|Dose expansion: The maximum tolerated dose of CAR20.19.22 cells|Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
58472602|NCT06013735|DRUG|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
58472603|NCT06013735|DRUG|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
58472604|NCT06013735|DRUG|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
58472605|NCT06013735|OTHER|Distilled water|placebo distilled water
58472606|NCT02991768|DRUG|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
58472607|NCT02991768|DRUG|Placebos|Placebo is matched to the study drug.
58472608|NCT06595251|OTHER|Fit2Play curriculum|Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
58472609|NCT06591546|DEVICE|Telescoping nail|"The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc."
58472610|NCT04438486|BEHAVIORAL|Group A|specific dietary advice for Hyperuricemia
58472611|NCT04438486|DIETARY_SUPPLEMENT|Group B|Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
58472612|NCT00170586|DEVICE|Underglove coating (skin barrier)|
57784541|NCT03870503|DRUG|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
57784542|NCT03870503|DRUG|Carbetocin|The patient received Carbetocin 100 mic gm
58472613|NCT05762302|DIAGNOSTIC_TEST|MeMed BV test|Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
58472614|NCT02967991|DEVICE|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
58472615|NCT02569385|OTHER|Spontaneous breathing trial|
58472616|NCT02504593|DEVICE|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
58472617|NCT05387564|BEHAVIORAL|SCT Documentation and Disclosure Toolkit (SCT-DD)|A toolkit of implementation strategies
58472618|NCT02514083|DRUG|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
58472619|NCT02514083|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
57784543|NCT06279754|DRUG|Recombinant Human Endostatin Injection|Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle Evafolimab Injection：Subcutaneous injection on day 1, 8, and 15, once every three weeks cycle
58472620|NCT06591091|DRUG|Clemastine Fumarate|Listed in arm/group description
58472621|NCT05249582|OTHER|Virtual Reality|Virtual reality wireless headset
58472622|NCT05249582|OTHER|Television Condition|Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
58472623|NCT05902988|DRUG|VLS-1488|VLS-1488 tablets will be given orally.
58472624|NCT06012916|DRUG|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
58472625|NCT01581801|PROCEDURE|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
58472626|NCT01581801|PROCEDURE|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
58472627|NCT06514326|BEHAVIORAL|DPT-TP|"This intervention includes all the ingredients of DPT-STD, but with additional features that correspond to the conceptual model of therapeutic persuasiveness. Each theme in the program comprises a learning phase followed by a 1-2 week focusing phase.~Accordingly, the program utilizes the following features:~1. Call to action: Parents receive timely triggers via text messages that are related to the specific goals and therapeutic activities of the modules they have completed.~2. Monitoring and ongoing feedback of user state: Specific practices currently taught are documented within the system through a brief daily report, on which parents receive feedback.~3. Adaptation to user state: Parents' reports on their activities are used to acknowledge their success and to suggest additional actions based on the specific goals reported by parents. Effort related to desired therapeutic activities is adapted based on graded tasks."
58472628|NCT06514326|BEHAVIORAL|DPT-STD|"This intervention is similar in its features to other programs that deliver DPT, and is suitable for use on computers or on mobile devices. An icon is positioned on the mobile device home screen in order to enable quick access to the program. The DPT-STD comprises seven 10- to 25-minute modules, each corresponding to one of the themes mentioned above. Each module's content includes videos and texts guiding the parent through the training process, and interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials and a questions and answers section that contains frequently asked questions."
58472629|NCT06303115|OTHER|Nicotine Pouch P1312914, 4 mg nicotine|P1312914 pouch product
58472630|NCT06303115|OTHER|Nicotine Pouch P1312915, 8 mg nicotine|P1312915 pouch product
58472631|NCT06303115|OTHER|Nicotine Pouch P1013215, 8 mg nicotine|P1013215 pouch product
58472632|NCT06303115|OTHER|Nicotine Pouch P1013218, 10 mg nicotine|P1013218 pouch product
58472633|NCT06303115|OTHER|Nicotine Pouch P1012919, 12 mg nicotine|P1012919 pouch product
58472634|NCT06303115|OTHER|Smoking Abstinence|No tobacco/nicotine
58472635|NCT06303115|OTHER|Continued UB cigarette smoking|Usual Brand Cigarette
58472636|NCT03527420|OTHER|Exercise training|Twelve weeks of aerobic exercise training
58472637|NCT04443413|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
58472638|NCT04443413|OTHER|Questionnaire Administration|Ancillary studies
58472639|NCT04443413|RADIATION|X-ray Therapy|Undergo x-ray therapy
58472640|NCT06596720|OTHER|Aerobic Exercise|After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
58472641|NCT06088069|OTHER|Virtual reality|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
58472642|NCT06058299|DRUG|TBAJ-876|tablet
58472643|NCT06058299|DRUG|Pretomanid|200 mg
58472644|NCT06058299|DRUG|Linezolid|600 mg
57784544|NCT02524054|DRUG|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
58472645|NCT06058299|DRUG|Bedaquiline|200 mg for 8 weeks followed by 100 mg for 18 weeks
58472646|NCT06058299|DRUG|HRZE|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
58472647|NCT06058299|DRUG|HR|Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
58472648|NCT04331587|DEVICE|BF-P190 4 mm thin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
58472649|NCT04331587|DEVICE|BF-MP190F 3 mm ultrathin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
58472650|NCT04331587|DEVICE|Radial ultrasound probe (UM S20-17S)|-Olympus
58472651|NCT04331587|DEVICE|PeriView FLEX 21G Single Use Aspiration Needle|"* NA-403D-2021~* Gyrus ACMI, Inc."
57784545|NCT02524054|DRUG|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
58472652|NCT06587646|DIAGNOSTIC_TEST|Virtual Examination under Anaeastehtic - 3D reconstruction imaging|3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.
58472653|NCT06587646|DIAGNOSTIC_TEST|Standard Care - Written MRI report|A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
58472654|NCT05246592|PROCEDURE|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
58472655|NCT05246592|PROCEDURE|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
58472656|NCT06047210|OTHER|Blood Draws Data Collection|
58472657|NCT03875378|DRUG|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
58472658|NCT03875378|DRUG|Placebos|Placebo weekly patch
58472659|NCT06143566|DRUG|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
58472660|NCT03996824|OTHER|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
58472661|NCT06596486|OTHER|CoolStick|Assessment of block using CoolStick.
58472662|NCT06596486|OTHER|Ethyl Chloride|Assessment of block using ethyl chloride spray
58472663|NCT06596486|OTHER|Question|Participant will be asked if they felt pain or not.
58472664|NCT03587961|DRUG|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
58472665|NCT04730258|DRUG|CFI-400945|The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
58472666|NCT04730258|DRUG|Azacitidine|Azacitidine will be given at its labeled dose and schedule
58472667|NCT06602869|OTHER|Scheduled visit (V1)|During the scheduled visit (V1), as part of routine care, a blood draw will be performed. On this occasion, an additional 7 ml tube will be collected to perform serology and culture. This will help define the group (NTM+ Cases/NTM- Controls) and measure cellular biomarkers.
58472668|NCT06604611|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
58472669|NCT05642039|BEHAVIORAL|Mindfulness Course|Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.
58472670|NCT05642039|BEHAVIORAL|HS Educational Course|Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.
58472671|NCT05775367|DEVICE|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
58472672|NCT06628284|DEVICE|Dexcom G7|The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).
58472673|NCT06596057|BIOLOGICAL|CAR-T/CAR-NK cells|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion
58472674|NCT00006394|DRUG|growth hormone|
58472675|NCT06595407|DIAGNOSTIC_TEST|Blood analysis for loss-of-Y chromosome|Analysis for the percentage of circulating leukocytes with loss-of-y chromosome
58472676|NCT00281463|DEVICE|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
58472677|NCT05093270|DRUG|BGB-23339|Administered orally as a tablet
57784546|NCT03133143|BEHAVIORAL|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
58472678|NCT05093270|DRUG|Placebo|Administered orally as a tablet
58131506|NCT01471522|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
58472679|NCT06591988|BEHAVIORAL|Lifestyle factors|introduction of environmental risk mitigation policies, from data and evidence from case studies (several European cities) with different levels of exposure to environmental, health, geographic, and socioeconomic factors.
58472680|NCT06194864|DRUG|Itraconazole|itraconazole 200 mg QD Days 6 to 16
58472681|NCT06194864|DRUG|rifampicin|rifampicin 600 mg QD Days 6 to 20
58472682|NCT06194864|DRUG|Ecopipam|89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
58472683|NCT05378165|OTHER|Music group|The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The music group listened to Acemasiran-type classical Turkish music.Acemasiran-type music affects the human brain and provides a sense of creativity to people. This musical tone has pain- relieving and antispasmodic
58131507|NCT01471522|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
58131508|NCT01471522|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
58472684|NCT05378165|OTHER|Stress ball group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
58472685|NCT05378165|OTHER|Video group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Video group allowed to watch a licensed virtual reality application,A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
58472686|NCT05378165|OTHER|Control group|"The study was divided into three stages; (1) before; (2) during; and (3) after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Control group, without any additional intervention."
58472687|NCT03667378|BEHAVIORAL|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472688|NCT03667378|BEHAVIORAL|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472689|NCT03667378|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472690|NCT03667378|BEHAVIORAL|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472691|NCT03667378|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472692|NCT03667378|BEHAVIORAL|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
58472693|NCT03667378|BEHAVIORAL|visits with a supportive care clinician|Monthly visits with a supportive care clinician
58472694|NCT06588374|PROCEDURE|lateral internal sphincterotomy|Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
58131509|NCT01471522|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
58131510|NCT01471522|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
58131511|NCT04468802|OTHER|Case fatality rate|Mortality rate caused by SARS CoV-2
58131512|NCT00643877|PROCEDURE|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
58131513|NCT00643877|PROCEDURE|surgery|radical surgery only
58131514|NCT02841826|OTHER|IUD|
58131515|NCT02841826|OTHER|Uterine sounding|
58131516|NCT02841826|RADIATION|Transvaginal ultrasound|
58131517|NCT04533022|DRUG|C21|C21 b.i.d.
34994810|NCT00137618|BEHAVIORAL|Educational Intervention to Increase Informed Decision Making for Prostate Cancer Screening|
58472695|NCT06585995|DRUG|vitamin D (cholecalciferol) supplementation|"This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses"
58472696|NCT03409016|OTHER|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
58472697|NCT06593873|OTHER|Use of typodont head model in addition to theoretical periodontal education|Use of typodont phantom head model in addition to theoretical periodontal education
58472698|NCT06593873|OTHER|Theoretical periodontal education|Theoretical periodontal training only
58472699|NCT05783622|DRUG|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
58472700|NCT01821690|DRUG|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
58472701|NCT01821690|DRUG|Placebo|The placebo tablets taste and look identical to buspirone.
58472702|NCT05683028|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
58472703|NCT05683028|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
58131518|NCT00977288|DRUG|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
58472704|NCT05813106|DRUG|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
58472705|NCT05813106|DRUG|normal saline|normal saline
58472706|NCT01516905|DRUG|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
58472707|NCT04700098|BEHAVIORAL|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
58472708|NCT04700098|BEHAVIORAL|Online insomnia patient education|Online insomnia patient education
58472709|NCT04249999|BEHAVIORAL|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
58131519|NCT00977288|DRUG|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
58131520|NCT00977288|DRUG|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
58131521|NCT06091878|OTHER|Observation|Observational study, no intervention
58131522|NCT03163875|OTHER|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
58472710|NCT06592300|DRUG|Tenofovir Alafenamide Film coated Tablet|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
58472711|NCT06592300|DRUG|Vemlidy® film-coated tablets|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
58472712|NCT01243190|DRUG|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
58139007|NCT05813340|PROCEDURE|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
58139008|NCT02845739|OTHER|Kidney transplanted patients|
58472713|NCT00897481|GENETIC|gene expression analysis|
58472714|NCT00897481|GENETIC|mutation analysis|
58472715|NCT00897481|OTHER|diagnostic laboratory biomarker analysis|
58472716|NCT00897481|OTHER|immunohistochemistry staining method|
58472717|NCT00897481|PROCEDURE|sentinel lymph node biopsy|
58472718|NCT03094416|DRUG|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
58472719|NCT03094416|DRUG|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
58472720|NCT03094416|DRUG|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
58472721|NCT03557294|DRUG|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
58472722|NCT03557294|DRUG|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
58472723|NCT03557294|DRUG|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
58472724|NCT03133221|DRUG|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
58472725|NCT04989751|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
58472726|NCT04989751|DIAGNOSTIC_TEST|IDEAL MRI|Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
58472727|NCT06392841|DRUG|Androgen Deprivation Therapy (ADT)|Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)
58472728|NCT06392841|DRUG|Niraparib/Abiraterone Acetate DAT|Niraparib 200 mg/ Abiraterone acetate 1000 mg orally
58472729|NCT06392841|DRUG|Abiraterone Acetate|1000 mg orally
58472730|NCT06392841|DRUG|Prednisone|5 mg orally
58472731|NCT06392841|DRUG|Docetaxel|75 mg/m2 IV
58472732|NCT02474316|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
58472733|NCT02474316|DRUG|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
58472734|NCT02903771|DRUG|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
58472735|NCT02903771|DRUG|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
58472736|NCT06603272|DEVICE|The da Vinci robotic system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) was used for all robotic gastrectomy|"Surgical intervention was initiated after obtaining informed consent from all patients, which included the additional costs of robotic surgery, a comprehensive explanation of surgical risks, and potential alternative treatments, thus facilitating informed surgical approach choices (i.e., LG or RG) within the participating institutions. Adherence to the Japanese Gastric Cancer Treatment Guidelines was maintained for determining the extent of gastrectomy and lymphadenectomy."
58472737|NCT04865276|BEHAVIORAL|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
58472738|NCT06596837|DEVICE|virtual reality|"The investigators manipulated the following two variables within the experimental design:~Immersion in the virtual environment. This was a nominal variable with two levels: a low-immersive environment (Other group) and a highly immersive environment (Experimental group) using the Cold River application.~Order of virtual reality (VR) deployment during the first session. This was also a nominal variable with two levels: VR during the first part of the dressing change (removing the dressing) and VR during the second part of the dressing change (cleaning the wound and applying a new dressing). In each subsequent session, the order of VR deployment was swapped for each participant.~The values of both variables were assigned to participants according to their numbers (e.g., 1. highly immersive, VR first; 2. low immersive, VR first; 3. highly immersive, VR last; 4. low immersive, VR last, etc.)."
58472739|NCT02432378|BIOLOGICAL|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
58472740|NCT02432378|BIOLOGICAL|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
58472741|NCT04907799|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
58472742|NCT04907799|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
58472743|NCT06588361|OTHER|Training Based on Kolcoba Comfort Theory|Training Based on Kolcoba Comfort Theory
58472744|NCT05168839|DRUG|FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).|"In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded."
58472745|NCT04263623|DRUG|Dexmecamylamine HCl|Investigational drug
58472746|NCT04263623|OTHER|Placebo|Oral tablet containing no active drug.
58472747|NCT06593925|DEVICE|Production of polyoxymethylene telescopic denture|Remaining teeth will be prepared by conventional grinding technique, followed by impression, casting and scanning with extra oral scanner. Inner telescopic crowns will be made of cobalt-chromium alloy by milling technique and outer crowns together with denture framework will be made of polyoxymethylene by the method of single phase injection moulding. Denture delivery is done by inserting both inner and outer crown at the same time, during which the inner crown is cemented to the abutment tooth and the contact surfaces of the outer and inner crown are isolated so that the outer crown and denture framework can be removed.
58139009|NCT02133105|DRUG|Levosimendan|
58139010|NCT02133105|DRUG|Dobutamine|
58139011|NCT04963491|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
58139012|NCT04963491|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
58472748|NCT06593925|DEVICE|Production of conventional complex partial denture with clasps|A conventional complex partial denture is a removable partial denture with clasps combined with metal-ceramic surveyed crowns with milled surfaces for removable dentures. The metal-ceramic surveyed crowns are shaped in such a way that they build a morphological and functional whole with complementary elements of the removable partial denture's framework. In the control group, as well as in the experimental group, the remaining teeth are prepared using a conventional grinding technique, then an impression is taken for dedicated metal-ceramic crowns, casting, and milling of crowns, ceramic sintering, impression through the metal-ceramic surveyed crowns and fabrication of a removable partial denture's framework with clasps using the casting method. Dedicated fixed restorations will be made of Co-Cr alloy inside the crown and ceramic layer on the surface, and the framework and clasps of the removable partial denture will be made of Co-Cr-Mo alloy.
57779418|NCT01496508|DEVICE|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
57779419|NCT05291013|PROCEDURE|Gastric byspass|Test will be before and 9-12 month after gastric bypass
57779420|NCT06237374|BEHAVIORAL|Digital Vaccine Education Training & Patient-facing Chatbot Tool|The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
57779421|NCT06237374|BEHAVIORAL|Standard Training|All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
57779422|NCT05185128|BEHAVIORAL|PEERS social skills intervention|The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
57779423|NCT04100200|DIETARY_SUPPLEMENT|Mixed berries|Strawberry and red raspberry
57779424|NCT04100200|DIETARY_SUPPLEMENT|FOS|Fructo-oligosaccharide
57779425|NCT04100200|DIETARY_SUPPLEMENT|Control|Placebo similar in color to mixed berry supplement without any polyphenols
57779426|NCT04100200|DIETARY_SUPPLEMENT|Combination|Mixed berry composite + FOS
57779427|NCT02019563|PROCEDURE|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
57779428|NCT02019563|PROCEDURE|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
57779429|NCT03657264|DRUG|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
57779430|NCT03657264|DRUG|Moxifloxacin 400mg|One tablet per os
57779431|NCT03657264|DRUG|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
57779432|NCT03657264|DRUG|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
57779433|NCT00634322|DRUG|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
57779434|NCT00634322|DRUG|leucovorin|IV or po given every 6 hours
57779435|NCT06301659|BEHAVIORAL|routine rehabilitation therapy|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
57779436|NCT06301659|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
57779437|NCT01091428|DRUG|Alisertib|Alisertib tablets
57779438|NCT01091428|DRUG|Paclitaxel|Paclitaxel intravenous infusion
57779439|NCT01558674|DRUG|MK-7145|
57779440|NCT01558674|DRUG|Furosemide|
57779441|NCT01558674|DRUG|Torsemide|
57779442|NCT00007293|DEVICE|UV-B Lightsource and Fiber Optic Comb|
57779443|NCT01265030|DRUG|Sirolimus|"* Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
58139013|NCT03365115|DRUG|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
58139014|NCT03365115|DRUG|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
57779444|NCT05233722|OTHER|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
58131523|NCT06089538|DIAGNOSTIC_TEST|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
58131524|NCT02486822|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
57779445|NCT05233722|PROCEDURE|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
58131525|NCT02486822|DRUG|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
58131526|NCT02486822|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
58131527|NCT04527809|DEVICE|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
58131528|NCT04527809|DEVICE|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
58131529|NCT00005576|BIOLOGICAL|monoclonal antibody Ch14.18|Given IV
58131530|NCT00005576|DRUG|isotretinoin|Given orally
58131531|NCT00005576|BIOLOGICAL|aldesleukin|Given IV
58131532|NCT00005576|BIOLOGICAL|sargramostim|Given IV
58131533|NCT02164838|DRUG|Axitinib|
58131534|NCT02029105|BIOLOGICAL|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
58131535|NCT02080923|BEHAVIORAL|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
58131536|NCT04182009|DEVICE|Omron NE-U17 Ultrasonic nebuliser|The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.
58131537|NCT04182009|DEVICE|Akita Jet Inhalation System|The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
58131538|NCT03220867|DRUG|Risperidone: Xian Risperdal (test)|Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.
58131539|NCT03220867|DRUG|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
58131540|NCT05939180|DRUG|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
58131541|NCT05939180|DRUG|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
58131542|NCT05282485|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
58131543|NCT05282485|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
58131544|NCT01362725|DEVICE|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
57779446|NCT05233722|DRUG|Placebo|Administration of 800 mg of calcium tablets
57779447|NCT05233722|DRUG|Rapamycin|Administration of 16 mg of Rapamycin tablets
57779448|NCT01695122|DRUG|Valproic Acid|
58131545|NCT03535207|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
58131546|NCT03252964|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
58131547|NCT03252964|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
58131548|NCT03252964|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
58131549|NCT01648166|OTHER|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
58131550|NCT03528200|OTHER|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
58131551|NCT01173042|DIETARY_SUPPLEMENT|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
58131552|NCT01173042|DIETARY_SUPPLEMENT|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
58131553|NCT01173042|DIETARY_SUPPLEMENT|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
58139015|NCT03004820|DEVICE|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
58472749|NCT03990961|DRUG|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
57779449|NCT02812212|DEVICE|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
58131554|NCT02075437|BEHAVIORAL|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
58131555|NCT02075437|BEHAVIORAL|Treatment Strategies|"1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research."
58131556|NCT02548637|PROCEDURE|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
58131557|NCT05582460|DIAGNOSTIC_TEST|Reporter Gene Assay|Transcription factor reporter gene assay using luciferase
58131558|NCT05582460|DIAGNOSTIC_TEST|Flow Cytometry|Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
58131559|NCT02780336|OTHER|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
58131560|NCT00323193|BEHAVIORAL|MOVE!|group based psychoeducation, motivation and support
58131561|NCT01144936|DRUG|VX-985 or matching placebo|low dose
58131562|NCT01144936|DRUG|VX-985 or matching placebo|high dose
58131563|NCT01144936|DRUG|VX-985 or matching placebo|dose TBD
58131564|NCT04845165|OTHER|Biopsy|Biopsy of subcutaneous adipose tissue
58131565|NCT01139164|DRUG|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
58131566|NCT01139164|DRUG|Regimen B|Other malignancies not addressed in A or C
58131567|NCT01139164|DRUG|Regimen C|B-Cell Lymphomas
58131568|NCT05319990|DRUG|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
58131569|NCT05319990|DRUG|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
58472750|NCT01349543|BIOLOGICAL|RSV A Memphis 37|Intranasal administration
58472751|NCT01623570|DRUG|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
58472752|NCT01623570|DRUG|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
57779450|NCT02812212|DEVICE|diuretic renography|diuretic renography to measure the cortical transit time.
58131570|NCT05020548|OTHER|peak inspiratory pressure 10 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 10 cmH2O
58131571|NCT05020548|OTHER|peak inspiratory pressure 15 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 15 cmH2O
58131572|NCT05020548|OTHER|peak inspiratory pressure 20 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 20 cmH2O
58131573|NCT04647604|DRUG|Omegaven®|A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
58131574|NCT04647604|DRUG|Sodium chloride|intravenously administered 2 mL/kg/day
58131575|NCT03174119|DEVICE|Light therapy - active|Active light will be used for one week, as compared to placebo light.
58131576|NCT03174119|DEVICE|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
58131577|NCT06141070|OTHER|Standard systemic therapy + radiotherapy|Combined systemic therapy + radiation
58131578|NCT06141070|DRUG|Standard systemic therapy|Chemoimmunotherapy or immunotherapy
58131579|NCT05877170|DIETARY_SUPPLEMENT|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
58131580|NCT05877170|DRUG|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
58131581|NCT02041169|OTHER|Subsequent walking performance|Subsequent walking performance
58472753|NCT05446272|DEVICE|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
58472754|NCT05446272|DEVICE|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
58472755|NCT05138757|DRUG|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
58472756|NCT05138757|DRUG|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
58472757|NCT02811068|OTHER|venepuncture|single venepuncture
58472758|NCT06593509|DEVICE|Maquet,Servo I.|Model number: 06487800, Serial Number: 19761, SKU#: Inv-00344191, Made in Sweden
58472759|NCT06593509|DEVICE|Vapotherm|INC ,100 domain drive Exeter, NH 03833, Made in U.S.A
58472760|NCT06593509|DEVICE|venturi mask|Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK.,REF. 1107085, LOT,31757961
58131582|NCT01790568|DRUG|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
58131583|NCT01790568|DRUG|Tacrolimus|
58131584|NCT01790568|DRUG|Methotrexate|
58131585|NCT02572921|BEHAVIORAL|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
58131586|NCT02572921|BEHAVIORAL|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
58131587|NCT05575414|BEHAVIORAL|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
58131588|NCT05575414|BEHAVIORAL|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
58131589|NCT05618470|DRUG|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
58131590|NCT05618470|DRUG|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
58131591|NCT00304447|DRUG|Mylotarg|
58131592|NCT01622998|DRUG|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
58131593|NCT01622998|DRUG|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
57779451|NCT00972179|DRUG|Placebo|Administered by subcutaneous or intravenous injection.
57779452|NCT00972179|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
57779453|NCT03537261|BEHAVIORAL|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
57779454|NCT05392075|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
57779455|NCT05392075|BIOLOGICAL|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
57779456|NCT02415075|BEHAVIORAL|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
57779457|NCT02488694|DRUG|Afatinib|40 mg/d
57779458|NCT02488694|DRUG|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
57779459|NCT04584606|DIAGNOSTIC_TEST|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
57779460|NCT02724787|BEHAVIORAL|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
57779461|NCT06043596|BEHAVIORAL|SafeSpace Sexual Health|The overall goal of the program is to prevent adolescent pregnancy and STIs by increasing sexual agency, increasing the use of condoms and contraception, and promoting healthy relationships and healthy life skills among adolescents.
57779462|NCT06043596|BEHAVIORAL|SafeSpace General Health|This arm represents the comparison group. SafeSpace General Health will act as the active comparator, while providing youth with lessons, facts, and resources about general health topics.
58131594|NCT01743378|PROCEDURE|TAP Block Ropivacaine 0,75 %|
58131595|NCT01743378|PROCEDURE|TAP Block Saline 0,9 %|
58131596|NCT00662753|DEVICE|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
58131597|NCT00662753|OTHER|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
58131598|NCT02005536|BIOLOGICAL|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
58131599|NCT03325114|DRUG|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
58131600|NCT03980288|DRUG|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
57779463|NCT04299802|DRUG|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
57779464|NCT04299802|PROCEDURE|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
57779465|NCT06739928|DRUG|Irinotecan liposome (II) combined with adebrelimab and carboplatin|Irinotecan liposome (II) + adebrelimab + carboplatin
57779466|NCT06739928|DRUG|etoposide combined with adebrelimab and carboplatin|etoposide + adebrelimab + carboplatin
57779467|NCT03575637|DRUG|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
57779468|NCT01301768|OTHER|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
57779469|NCT04026282|PROCEDURE|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
57779470|NCT04026282|PROCEDURE|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
57779471|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
57779472|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
57779473|NCT06080737|OTHER|quality of life questionnaire|telephone interview to assess mortality and quality of life in the population included in a trial
57779474|NCT06739213|DRUG|SYHA1813|The starting dose of SYHA1813 is 20mg QD
57779475|NCT06739213|DRUG|Investigator's Choice Treatment|Investigator's Choice Treatment
57779476|NCT00516750|DRUG|cisplatin|
57779477|NCT00516750|DRUG|doxorubicin hydrochloride|
57779478|NCT00516750|DRUG|methotrexate|
57779479|NCT00516750|DRUG|vinblastine|
57779480|NCT00516750|GENETIC|gene expression profiling|
57779481|NCT00516750|PROCEDURE|neoadjuvant therapy|
57779482|NCT06739798|DIAGNOSTIC_TEST|Exp Group|Binocular Spectacle prescription are therapeutic tools used to correct refractive errors in visually impaired patients. They improve Visual acuity as well as other visual functions in Amblyopic and visual impairment patients. They stimulate weaker eye to generate visual impulse and stimulate visual cortex to improve stereopsis and fusion.
57779483|NCT06739798|DIAGNOSTIC_TEST|Control Group|Patching therapy is a gold standard tool used world wide to correct visual acuity in amblyopic patients. This tool is used by occluding stronger eye with a patch or bandage or fogging lens and stimulating amblyopic eye to generate visual stimulus to motivate visual cortex.
57779484|NCT03918239|DRUG|SHP643|Participants will receive injection of SHP643.
58131601|NCT03974256|OTHER|Training in the use of the automaton|2 days training on automaton use
58131602|NCT04774432|OTHER|GM-CSF group|GM-CSF added to CAPA and maturation medium
58131603|NCT04774432|OTHER|Control group|GM-CSF will not be added to CAPA and maturation medium
58131604|NCT03201302|OTHER|School physical education class|Children participated only in school physical education classes only.
58131605|NCT03201302|OTHER|Taekwondo|Children participated only in taekwondo training only.
58131606|NCT03201302|OTHER|Martial arts|Children participated only in martial arts training only.
58131607|NCT03201302|OTHER|Climbing|Children participated only in climbing training only.
58131608|NCT03201302|OTHER|Volleyball|Children participated only in volleyball training only.
58131609|NCT03201302|OTHER|Artistic gymnastics|Children participated only in artistic gymnastics training only.
58131610|NCT03201302|OTHER|Swimming|Children participated only in swimming training only.
57779485|NCT04817917|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
57779486|NCT04817917|OTHER|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
57779487|NCT01503541|GENETIC|DNA analysis|
57779488|NCT01503541|GENETIC|RNA analysis|
57779489|NCT01503541|GENETIC|gene expression analysis|
58131611|NCT03201302|OTHER|Dance|Children participated only in dance training only.
58131612|NCT03201302|OTHER|Basketball|Children participated only in basketball training only.
58131613|NCT03201302|OTHER|Wrestling|Children participated only in wrestling training only.
58131614|NCT03201302|OTHER|Football (soccer)|Children participated only in football (soccer) training only.
58131615|NCT03201302|OTHER|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
58131616|NCT03201302|OTHER|Track and field|Children participated only in track and field training only.
58131617|NCT03201302|OTHER|Tennis|Children participated only in tennis training only.
58131618|NCT03201302|OTHER|Combination of activities 1|Children participated in two weight-bearing activities.
58131619|NCT03201302|OTHER|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
58131620|NCT06315426|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
58131621|NCT06315426|BIOLOGICAL|Placebo|Placebo
58131622|NCT00431691|DRUG|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
58131623|NCT00431691|DRUG|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
58131624|NCT00431691|DRUG|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
58131625|NCT00431691|DRUG|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
58131626|NCT04631770|PROCEDURE|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
58131627|NCT04631770|PROCEDURE|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
58131628|NCT05893264|OTHER|Data collection|"Several data will be collected such as:~Age, weight, height, gender, previous spine surgery, skoliosis (Y/N), palpable spinous process (Y/N), experience in years of anesthesiologist, spine level of epidural placement~and the following sonographic parameters at the level of epidural placement: skin-spinous process distance (cm), skin-transversous process distance (cm), erector spinae plane distance (cm), superior to inferior spinous process distance (cm)"
58131629|NCT03955536|OTHER|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
58131630|NCT03955536|OTHER|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
58472761|NCT05525104|DEVICE|Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)|"This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration"
58131631|NCT03955536|OTHER|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
58131632|NCT02812849|DRUG|Cu-64 DOTATATE|
58131633|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58131634|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58472762|NCT03770546|BIOLOGICAL|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
58131635|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
58131636|NCT03143400|DRUG|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
58131637|NCT01101230|OTHER|Almonds|1.5 oz almonds/day
58131638|NCT05435300|OTHER|PET Scan|Participants will undergo two PET scans throughout the study.
58131639|NCT03227445|DEVICE|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
58131640|NCT03227445|DEVICE|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
58131641|NCT03227445|DEVICE|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
58131642|NCT03227445|OTHER|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
58472763|NCT03770546|DRUG|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
58131643|NCT06252025|COMBINATION_PRODUCT|Memo-gration|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
58131644|NCT06252025|OTHER|Picture reminiscence therapy|Picture reminiscence therapy
58131645|NCT04540640|DEVICE|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
58131646|NCT00355628|DRUG|KW-2246 (fentanyl citrate)|KW-2246
58131647|NCT05303909|DRUG|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
58131648|NCT05303909|DRUG|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
58131649|NCT00460304|DRUG|pramlintide|
58131650|NCT00460304|PROCEDURE|continuous glucose monitoring|
58131651|NCT02164279|OTHER|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)
58131652|NCT00917657|PROCEDURE|Photorefractive keratectomy|
58131653|NCT05467306|BEHAVIORAL|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
58131654|NCT02798484|DEVICE|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
58131655|NCT03508622|BEHAVIORAL|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
58131656|NCT03508622|BEHAVIORAL|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
58131657|NCT01779323|OTHER|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
58131658|NCT01936922|DEVICE|GaitAid®|Provides visual and auditory cues for walking.
58131659|NCT06240390|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
58472764|NCT06599775|DRUG|Adebrelimab injection|Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
57779490|NCT01503541|GENETIC|mutation analysis|
57779491|NCT01503541|GENETIC|polymerase chain reaction|
57779492|NCT01503541|OTHER|laboratory biomarker analysis|
57784547|NCT03133143|BEHAVIORAL|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
58131660|NCT06240390|DRUG|pharmacological treatment by Opioids|Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
58131661|NCT05273866|OTHER|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
58131662|NCT01188746|BEHAVIORAL|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
58131663|NCT00760266|DRUG|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
58131664|NCT00760266|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
58131665|NCT02092922|DRUG|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
58131666|NCT02092922|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
58131667|NCT04900090|OTHER|Epidemiological study|"* Clinical phenotypic assessment and neurosensory measures~* Biological, genetic and metabolomic evaluation~* Questionnaires (quality of life, gout, life habit, comorbidities)~* Morphological evaluation by Dual-energy CT scan"
58131668|NCT00620009|BEHAVIORAL|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
58131669|NCT03657056|DEVICE|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
58131670|NCT00153803|DRUG|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
58131671|NCT00153803|DRUG|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
58131672|NCT01509300|BIOLOGICAL|anti-thymocyte globulin|On days -10 to -9
58131673|NCT01509300|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
58131674|NCT01509300|RADIATION|Total body irradiation|2Gy D-6 to D-4
58131675|NCT01509300|DRUG|Fludarabine|30mg/M2 once daily IV on days -8 to -4
58131676|NCT01509300|DRUG|cyclophosphamide|60 mg/kg IV on day-3 and -2
58131677|NCT01509300|DRUG|Tacrolimus|begin on 0
58131678|NCT01509300|DRUG|Mycophenolate mofetil|begin on 0
58131679|NCT01509300|DRUG|Rituximab|375mg/m2 on day +21
58131680|NCT06191900|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
58131681|NCT00002579|DRUG|CMF regimen|
58131682|NCT00002579|DRUG|cyclophosphamide|
58131683|NCT00002579|DRUG|fluorouracil|
58131684|NCT00002579|DRUG|methotrexate|
58131685|NCT00002579|DRUG|tamoxifen citrate|
58131686|NCT00002579|PROCEDURE|conventional surgery|
58131687|NCT00002579|RADIATION|radiation therapy|
58131688|NCT03755609|DRUG|Oxycodone|0.1 mg/kg intravenously
58131689|NCT03755609|DRUG|fentanyl|1ug/kg intravenously
58131690|NCT00595608|DRUG|Sterimar Spray|Post-op nasal spray, three times a day
58472765|NCT06599775|DRUG|Albumin-Bound Paclitaxel|Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
58131691|NCT00595608|DRUG|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
58131692|NCT02530762|OTHER|Novel Fiber|novel fiber supplemented beverage provided in one serving
58131693|NCT02530762|OTHER|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
58131694|NCT02530762|OTHER|Negative Control|No added fiber beverage
58131695|NCT05323864|BIOLOGICAL|Hypoxia|Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
58131696|NCT00005778|DRUG|High-dose immunoablative therapy|"1. High dose cyclophosphamide for 4 days.~2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
58131697|NCT04347837|DEVICE|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
58131698|NCT04281563|OTHER|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
58131699|NCT05126056|OTHER|Plant stanol ester|Product with active ingredient vs product without active ingredient
58131700|NCT05126056|OTHER|Placebo|Placebo
58131701|NCT01894178|DEVICE|Parker Flex-Tip® tracheal tube|
58131702|NCT01894178|DEVICE|Portex® Tracheal Tube|
58131703|NCT00906425|DEVICE|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
58131704|NCT04018625|BEHAVIORAL|SMART Mom|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
58131705|NCT04018625|BEHAVIORAL|Mama Support|Participants will be enrolled in an 8-week time and attention matched, process-based support group.
58131706|NCT01893905|DRUG|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
58131707|NCT01893905|DRUG|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
58472766|NCT06599775|DRUG|Carboplatin injection|Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
58472767|NCT05929963|OTHER|HCV infection status|Divided into 3 groups based on HCVAb and HCVRNA status
58472768|NCT06410274|DEVICE|Transcranial Doppler ultrasonography (TCD)|TCD will be used to measure cerebral blood velocity (CBv) in the middle and posterior cerebral arteries (MCA and PCA). Following confirmation of a suitable TCD window, participants will undergo a ten-minute rest period in the supine or semi-supine position. Continuous measurements of CBv, blood pressure (BP), heart rate, and end-tidal carbon dioxide will be recorded. Baseline BP will be measured using an automated BP device prior to each recording to allow calibration of the files offline for analysis. This will occur at the first visit and at follow-up, 4-7 days post-onset of intracerebral haemorrhage.
58472769|NCT04532528|DRUG|Dabigatran|Dabigatran
58472770|NCT06603168|OTHER|Autonomic Recalibration Treatment|An initial history to r/o pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance throughout the myofascial system. The pattern of sympathetic dominance (pattern of trigger point) is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. The absence of a trigger point indicates that the treatment is complete.
58472771|NCT06590545|DRUG|KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy|A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
58472772|NCT04599010|OTHER|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
58472773|NCT06596421|OTHER|abdominal massage|abdominal massage
58472774|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
58472775|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg per day
58472776|NCT03162146|OTHER|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
58472777|NCT06603428|DEVICE|internal fixation by plate or screws|- Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
58472778|NCT06593197|COMBINATION_PRODUCT|Apremilast with NB-UVB|Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
58472779|NCT06593197|DEVICE|NB-UVB|NBUVB only will be given twice per week for 8 months
58472780|NCT02231515|DEVICE|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
58472781|NCT02231515|DEVICE|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
58472782|NCT04318678|DRUG|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
58472783|NCT04318678|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
58472784|NCT04318678|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
58472785|NCT04318678|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
58472786|NCT04318678|DRUG|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
58472787|NCT04611386|DRUG|computerized tomography|Anti Factor Xa level
58472788|NCT03889223|PROCEDURE|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
58472789|NCT06194188|DRUG|Subcutaneous injection of CU-20401|Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
58472790|NCT00998686|DRUG|dutogliptin|400 mg
58472791|NCT00998686|DRUG|sitagliptin|100 mg
58472792|NCT05220436|OTHER|DISCOVER workshop programme|See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance \& Commitment Therapy principles.
58472793|NCT04838405|DRUG|CT-388|Synthetic Peptide
58472794|NCT04838405|DRUG|Placebo|Placebo
58472795|NCT01969136|DRUG|Drug: EVP-6124|
58472796|NCT01969136|DRUG|Placebo|
58472797|NCT05805176|DEVICE|ADHD Therapy|investigational game-play therapy
58472798|NCT06601725|DIAGNOSTIC_TEST|Clusterin level|Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
58472799|NCT02081677|DEVICE|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
58472800|NCT02081677|DEVICE|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
58472801|NCT02081677|DEVICE|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
58472802|NCT02081677|DEVICE|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
58472803|NCT06587061|DRUG|HRS-4642|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.
58472804|NCT04639245|DRUG|Atezolizumab|Given IV
58472805|NCT04639245|DRUG|Cyclophosphamide|Given IV
58472806|NCT04639245|DRUG|Fludarabine|Given IV
57784548|NCT04004208|DRUG|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
58472807|NCT04639245|BIOLOGICAL|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
58472808|NCT04639245|BIOLOGICAL|PD1 Inhibitor|Given IV
58472809|NCT03798951|OTHER|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
58472810|NCT01254136|DRUG|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
58472811|NCT01254136|DRUG|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
58472812|NCT01254136|DRUG|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
58472813|NCT04023669|DRUG|Prexasertib|IV
58472814|NCT04023669|DRUG|Cyclophosphamide|IV
58472815|NCT04023669|DRUG|Gemcitabine|IV
58472816|NCT04023669|BIOLOGICAL|filgrastim|Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.
58472817|NCT04023669|BIOLOGICAL|peg-filgrastim|Given subcutaneously (SQ). Alternatively, filgrastim may be given.
58472818|NCT04701814|OTHER|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
58472819|NCT06595433|OTHER|Experimental|In the PAPE 90% protocol, participants performed a general warm-up (e.g., jogging on a treadmill) for 5 minutes and a weightlifting-specific warm-up for 5 minutes, followed by 2 minutes of rest. After resting, they were asked to perform ten repetitions of dip squats with body weight and rested for 1 minute.Then, unlike the unloaded protocol, they performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes. After resting, they performed a snatch to exhaustion with 75% of their maximum snatch weight. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions between sets was recorded.
58472820|NCT06595433|OTHER|Experimental|In the PAPE 50% protocol, 5 minutes of general warm-up (jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up were followed by 2 minutes of rest as in the other protocols. After resting, they were asked to perform ten repetitions of body-weighted dip squats and rested for 1 minute. Then, unlike the unloaded and PAPE 90% protocols, they performed eight repetitions of bottom squats with 50% of their maximal bottom squats for one repetition and rested for 4 minutes. After resting, they performed snatches with 75% of their maximum snatch weight until exhaustion. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions was recorded for statistical analysis.
58472821|NCT06595433|OTHER|unloaded protocol|In the unloaded protocol, subjects performed a 5-minute general warm-up (e.g., jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up followed by 2 minutes of rest. After resting, they performed ten repetitions of bottom squats with their body weight and then rested for 1 minute. After rest, they performed the snatch movement with 75% of their maximum snatch weight until exhaustion. Then, they rested for 2 minutes and again performed the snatch with 75% of their maximum snatch weight until exhaustion. The maximum number of snatch repetitions performed by the weightlifters was recorded for statistical analysis.
58472822|NCT05162781|BEHAVIORAL|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
58472823|NCT05162781|BEHAVIORAL|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
58472824|NCT05162781|BEHAVIORAL|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
58472825|NCT05162781|BEHAVIORAL|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
58472826|NCT05162781|BEHAVIORAL|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
58472827|NCT05162781|BEHAVIORAL|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
58472828|NCT05162781|BEHAVIORAL|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
58472829|NCT03994081|DEVICE|tACS|XCSITE100
58472830|NCT03994081|DEVICE|Sham tACS|XCSITE100
58472831|NCT04470154|DRUG|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
58472832|NCT04470154|DRUG|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
58472833|NCT04470154|DRUG|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
58472834|NCT04470154|DRUG|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
58472835|NCT04470154|DRUG|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
58472836|NCT04470154|DRUG|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
58472837|NCT00189722|DRUG|Tacrolimus|
58472838|NCT00169416|DRUG|valaciclovir HCl granules|
58472839|NCT04769479|DRUG|acoramidis|acoramidis
58472840|NCT04004234|DRUG|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
58472841|NCT04004234|DRUG|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
58472842|NCT04004234|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
58472843|NCT04004234|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
58472844|NCT05412082|RADIATION|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
58472845|NCT05412082|DRUG|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
58472846|NCT05412082|DRUG|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
58472847|NCT05412082|DRUG|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
58472848|NCT05412082|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
57784549|NCT04004208|PROCEDURE|Laser photocoagulation|Transpupillary conventional laser ablative therapy
58472849|NCT05412082|RADIATION|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions"
58472850|NCT04144686|OTHER|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
58472851|NCT04971746|DRUG|Pirfenidone|On Days 1 and 13, participants will receive an oral dose of pirfenidone.
58472852|NCT04971746|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 daily.
58472853|NCT04971746|DRUG|Nintedanib|On Days 1 and 13, participants will receive an oral dose of nintedanib.
58472854|NCT04211753|BEHAVIORAL|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
58472855|NCT04211753|DEVICE|Mobile app|Medical device for crisis intervention
58472856|NCT06158399|DRUG|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
58472857|NCT06588517|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
58472858|NCT06588517|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
58472859|NCT06591130|BEHAVIORAL|Youth culturally adapted manual assisted psychological intervention (Y-CMAP)|YCMAP (Youth culturally adapted manual assisted psychological intervention) is based on CBT principles. It comprises of 8-10 sessions delivered individually over 3 months (weekly for 1 month then fortnightly), lasting for 60 minutes. The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the self-harm attempt using virtual stories of four young people. Therapists and young person choose from a list of techniques those which are most relevant to the young person's problems. Therapy is therefore adapted to fit with the young person's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change. To help determine the most appropriate coping strategy a coping tree is designed. Training in assertiveness and anger management are offered to help the young person to develop resilience to cope with stress.
58472860|NCT06091111|DEVICE|THD, THN|New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
58472861|NCT01521117|DRUG|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
58472862|NCT01521117|DRUG|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
58472863|NCT05083741|DEVICE|Chitogel|post-operative dressing within standard of care
58472864|NCT05083741|DEVICE|Nexfoam|post-operative dressing within standard of care
58472865|NCT05485896|DRUG|Pembrolizumab plus Lenvatinib|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
58472866|NCT00579215|BEHAVIORAL|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
58472867|NCT00579215|BEHAVIORAL|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
58472868|NCT05798494|BEHAVIORAL|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
58472869|NCT01379898|DRUG|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
58472870|NCT01379898|DRUG|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
58472871|NCT06581328|DRUG|Vedolizumab IV|Vedolizumab IV infusion
58472872|NCT06581328|DRUG|Vedolizumab SC|Vedolizumab SC injection
58472873|NCT04986072|DRUG|Sodium Nitroprusside|Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
58472874|NCT04986072|DRUG|5% Dextrose solution|Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
58472875|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
58472876|NCT01747447|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
58472877|NCT01747447|DIETARY_SUPPLEMENT|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
58472878|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
58472879|NCT05557110|DRUG|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
58472880|NCT06589063|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with implantation of new-generation balloon-expandable or self-expandable bioprostheses
58472881|NCT01646580|DRUG|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
58472882|NCT02971748|BIOLOGICAL|Pembrolizumab|Given IV
58472883|NCT04985279|DEVICE|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
58472884|NCT04985279|DEVICE|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
58472885|NCT06604130|DIAGNOSTIC_TEST|Prostate cancer screening decision|The subjects would receive serum PSA test.
58472886|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
58472887|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
58472888|NCT05167409|DRUG|Evorpacept (ALX148)|IV QW
58472889|NCT05167409|DRUG|Cetuximab|IV QW
58472890|NCT05167409|DRUG|Pembrolizumab|IV Q3W
58472891|NCT04595968|DEVICE|Vestal DM Active device|Battery powered non-invasive neurostimulation device
58472892|NCT04595968|BEHAVIORAL|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
58472893|NCT04595968|DEVICE|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
58472894|NCT06592274|BIOLOGICAL|HB0017|300mg Q12W
58472895|NCT06592274|BIOLOGICAL|HB0017|HB0017 300mg Q8W
58472896|NCT06592274|BIOLOGICAL|HB0017|HB0017 150mg Q4W
58472897|NCT06595615|DEVICE|cardiovascular implantable electronic devices|Standard of care patients indicated for the devices
58472898|NCT06598267|PROCEDURE|SASI|single anastomosis sleeve ileal bypass
58472899|NCT06598267|PROCEDURE|RYGB|Roux-en-Y gastric bypass
58472900|NCT02608190|BEHAVIORAL|Working memory training|See protocol
58472901|NCT06242132|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
58472902|NCT06242132|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
58472903|NCT03828825|OTHER|Patent Foramen Ovale closure|"The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care."
58472904|NCT00022191|DRUG|cisplatin|
58472905|NCT00022191|DRUG|gemcitabine hydrochloride|
58472906|NCT00022191|DRUG|paclitaxel|
58472907|NCT06493578|DRUG|VYN201 Gel|VYN201 Gel is a topical formulation applied as a thin layer to affected areas.
58472908|NCT06493578|DRUG|Vehicle Gel|Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
58472909|NCT06654518|DIAGNOSTIC_TEST|Preoperative CBCT for Bone Density and Ridge Width Measurement|Participants in this arm underwent preoperative Cone Beam Computed Tomography (CBCT) scanning to evaluate bone density and alveolar ridge width. The CBCT scans provide high-resolution, 3D images, which was used to guide the planning and placement of dental implants. The primary goal of the intervention was to assess how well the measurements obtained from CBCT could predict the primary stability of the implants postoperatively.
58472910|NCT03691376|BIOLOGICAL|Aldesleukin|Given SC
58472911|NCT03691376|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
58472912|NCT03691376|OTHER|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
58472913|NCT03691376|DRUG|Melphalan|Given IV
58472914|NCT02042417|DEVICE|INRatio2 and CoaguChek|
58472915|NCT05452486|DIAGNOSTIC_TEST|English APD assessment|Materials presented in English
58472916|NCT05452486|DIAGNOSTIC_TEST|Spanish APD assessment|Materials presented in Spanish
58472917|NCT06374238|BEHAVIORAL|CBT+ Health coach|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in CBT w/ Health coach group will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. In addition participants will have weekly contact with a peer health coach.
58472918|NCT06374238|BEHAVIORAL|CBT w/o Health Coach ( self-guided)|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants CBT w/o Health coach groups will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool.
58472919|NCT06374238|BEHAVIORAL|Usual Care|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in the UC group will be asked to engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
58472920|NCT06604507|DEVICE|non-pharmacological app|Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
58131708|NCT02556944|DEVICE|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
58472921|NCT06462794|DRUG|CX-801|Investigational drug
58472922|NCT06462794|DRUG|pembrolizumab|Standard of Care Therapy
58472923|NCT05764265|DRUG|LTP001|LTP001 will be administered orally once daily in the morning
58472924|NCT06595498|DIAGNOSTIC_TEST|Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).
58472925|NCT06595498|DIAGNOSTIC_TEST|cobas® EGFR Mutation Test v2 (Roche)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
58472926|NCT06604702|PROCEDURE|Autologous Fat Injection for Rectocele|In this procedure, autologous fat is harvested from the patient\&#39;s lower abdomen using a multiport cannula. The fat is then processed via centrifugation to separate the viable fat cells, which are emulsified into nanofat. This nanofat is injected into the submucosal layer of the rectocele through the posterior vaginal wall, using an anoscope for guidance. The procedure is intended to reinforce the rectovaginal fascia, alleviate rectocele symptoms such as obstructive defecation and vaginal bulge, and reduce prolapse recurrence.
58472927|NCT03464734|DRUG|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
58472928|NCT05403385|DRUG|inupadenant|Adenosine 2a receptor antagonist
58472929|NCT05403385|DRUG|Placebo|matched placebo capsule to inupadenant
58472930|NCT05403385|DRUG|Carboplatin|standard of care chemotherapeutic, alkylating agent
58472931|NCT05403385|DRUG|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
58472932|NCT06591637|BEHAVIORAL|Fertility supportive behavior education based on Watson's Theory of Human Care|In this study, Watson's Theory of Human Caring guided the development of a care framework and nursing intervention for women with infertility. The researchers adapted the theory and focused on six of the ten carative factors : 1) Adopting values of humanity and devotion; 4) Developing supportive care relationships; 6) Using problem-solving methods for informed decisions; 7) Tailoring teaching to individual needs; 8) Creating a comfortable, peaceful environment; 9) Assisting with basic needs. The nursing care program, integrated with IVF treatments (14-18 days), involved four transpersonal interviews lasting 45-90 minutes each. These interviews were recorded in notes, used to individualize future sessions. The approach included active listening, empathy, and support, with participants encouraged to keep diaries for discussion. Communication was maintained in person, by phone, or email.
58472933|NCT06591637|PROCEDURE|Routine nursing care|"Routine nursing care during IVF treatment includes:~Pre-Treatment Counseling: Providing information and addressing patient questions.~Monitoring and Assessment: Regular checks of health, hormone levels, and ovarian function.~Medication Administration: Giving prescribed fertility drugs and other medications.~Assisting with Procedures: Preparing and assisting with egg retrieval and embryo transfer.~Emotional Support: Offering emotional and psychological support. Education: Instructing on medication use, self-care, and recognizing complications.~Follow-Up Care: Scheduling and managing follow-up appointments to monitor progress"
58472934|NCT06591637|DEVICE|"The booklet Fertility-Supporting Health Training"|This booklet was prepared in line with the relevant literature and contained educational content aimed at improving healthy lifestyle behaviours . The training booklet included information on the effects of factors such as obesity, weakness, exposure to environmentally harmful substances, smoking and caffeine use on fertility and the methods of coping with these factors. In addition, information on how to use proper nutrition, develop exercise habits and cope with stress was provided. The booklet was distributed to the women at at the onset of the study.
58472935|NCT03837041|OTHER|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
58472936|NCT04169035|DEVICE|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
58472937|NCT04169035|PROCEDURE|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
58472938|NCT04367727|DEVICE|Light emitting diode|Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
58472939|NCT03448406|DRUG|Empagliflozin|Film-coated tablet
58472940|NCT03448406|DRUG|Placebo|Film-coated tablet
58472941|NCT02568267|DRUG|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
58472942|NCT06594341|PROCEDURE|Visit frequency|"Fortnightly visit frequency for moderate phase~Nutritional supplement: 1 daily sachet of RUTF as soon as a child admitted with MUAC\<115mm or edema reaches a MUAC=\>115mm or absence of edema."
58472943|NCT06594341|DIETARY_SUPPLEMENT|Suppression of the transition period|Transitioning children admitted with MUAC\<115mm or edema to receiving 1 daily sachet of RUTF as soon as they reach a MUAC=\>115mm and absence of edema
58472944|NCT06594341|PROCEDURE|Simplified treatment|Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=\>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=\>125mm for 2 consecutive weeks.
57784550|NCT03041454|OTHER|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
58472945|NCT06212362|BEHAVIORAL|Step-by-step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
58472946|NCT06212362|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (90-120 minutes)"
58472947|NCT05408429|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
58472948|NCT05408429|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
58472949|NCT06595485|BEHAVIORAL|online mindfulness based intervention|We anticipate the online MBI to be 10-20 minutes once daily, at least 5 days per week, for 8 weeks. Online MBI will be available free of charge on iOS and Android platforms. Participants will be instructed to download the app and use for practices. The online MBI group will be introduced to practice including mindful breathing (simple attention to the flow of the breath, inhalations, and exhalations), body scan (attention and awareness of different body parts) and practice of non-judgement of thoughts and emotions and guided meditation (sitting meditation). In addition, we anticipate participants in MBI group will have a group discussion via skype, 30 minute a week for 8 weeks. Moreover, we anticipate participants in MBI group to record how they practice in each day (attendance) as home assignment using online MBI application. For the details of mindfulness practice, we will develop based on data from interview and focus group
58472950|NCT02925286|OTHER|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
58472951|NCT05179785|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
58472952|NCT05179785|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
58472953|NCT00144807|DRUG|rituximab|
58472954|NCT00144807|DRUG|doxorubicin|
58472955|NCT00144807|DRUG|cyclophosphamide|
58472956|NCT00144807|PROCEDURE|autologous stem cell transplantation|
58472957|NCT06601738|OTHER|Isomeric Hand Grip Exercises|Patients will be instructed to squeeze and sustain the dynamometer for 2 min at 30% M.V.C. The dynamometer pointer which read the scale provided visual feedback to the subjects for the maintenance of the 30% M.V.C. This procedure will be repeated twice for each training session with a 5-minute rest in between.
58472958|NCT06601738|OTHER|Dynamic Hand Grip Exercises|Dynamic handgrip exercise was performed with both-sided, metronome-guided rhythmic hand contractions for 2min. The handgrip ring, closest to 20% of MVC, was chosen for DHE which was performed at a frequency of 30/min, acoustically indicated by a metronome beat.
58472959|NCT00213044|DRUG|Carraguard (PC-515)|
58472960|NCT06140589|DRUG|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
58472961|NCT06604585|BEHAVIORAL|Parenthood - a journey together. Digital tool to increase security in parenthood, a way to promote public health..|"The project involved the development of an internet-based parental support program to be delivered via the national Support and Treatment (Sob) platform and used in primary care to enhance traditional parental support within child healthcare, as needed. The innovation has been developed in collaboration with the Innovation Fund in Västra Götaland. The aim is to increase the experience of parental competence and a sense of security in parenting by reflecting on attitudes and approaches in interaction with the child through an interactive, digital parental support program. The four themes in the parental support program, Parenthood a journey together, are named: Being a good enough parent, understanding one's child, interacting with one's child, and meeting daily challenges as a parent regarding food, sleep, play, screen time, and physical activity. The four modules will include explanatory and psychoeducational texts, written exercises, videos, and homework."
58472962|NCT06221280|PROCEDURE|Nerve block|"Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia."
57784551|NCT04780438|DRUG|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
58472963|NCT06591351|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
58472964|NCT06591351|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
58472965|NCT06522620|PROCEDURE|Posterior Femoral Cutaneous Nerve Combined With Proximal Sciatic and Saphenous Nerve Block|All nerve blocks were performed under ultrasound guidance，single supragluteal approach sciatic nerve block using a nerve stimulator, 20 ml of drug was injected around the sciatic nerve, the extent of drug diffusion was observed, the needle tip was turned into the deep surface of the gluteus maximus muscle below the deep gluteal artery and 5 ml of drug was injected, followed by a retractile canal saphenous nerve block injected with 15 ml of drug, and the difference in sensation of the posterior thighs of the bilateral thighs was measured after 15 min to ensure posterior femoral cutaneous nerve were blocked
58472966|NCT06522620|PROCEDURE|Simple Sciatic and Saphenous Nerve Blocks|All nerve blocks were performed under ultrasound guidance，single subgluteal approach sciatic nerve block using a nerve stimulator, with 25 ml of drug injected around the sciatic nerve, followed by a retractile canal saphenous nerve block with 15 ml of drug injection
58472967|NCT01221896|PROCEDURE|C11-Choline PET/CT|
58472968|NCT05760898|BEHAVIORAL|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
58472969|NCT04060498|BEHAVIORAL|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
58472970|NCT04060498|BEHAVIORAL|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
58472971|NCT04386304|DRUG|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
58472972|NCT05887375|DRUG|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
58472973|NCT05887375|DRUG|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
58472974|NCT05887375|DRUG|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
58472975|NCT05887375|DRUG|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
58472976|NCT06602505|PROCEDURE|Group A: Field Block Group|Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
58472977|NCT05403437|OTHER|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
58472978|NCT05403437|DIAGNOSTIC_TEST|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
58472979|NCT05403437|OTHER|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
58472980|NCT00593216|DEVICE|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
58472981|NCT05817058|DRUG|AFM28|AFM28 dose escalation
58472982|NCT03278457|DIAGNOSTIC_TEST|Positron Emission Tomography|Positron Emission Tomography
58472983|NCT03215056|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
58472984|NCT03215056|DRUG|Normal saline|Placebo
58472985|NCT00821795|DRUG|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
58472986|NCT00821795|DRUG|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
58472987|NCT04282161|DEVICE|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
58472988|NCT02796170|DRUG|Dapagliflozin|5mg pill taken once daily
58472989|NCT02796170|DRUG|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
58472990|NCT00915746|DRUG|JNJ-31001074; ketoconazole|
58472991|NCT06604637|OTHER|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|taVNS will be applied for a total of 12 sessions, 20 minutes each session, 3 days/week.
58472992|NCT00563875|DRUG|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
58472993|NCT01843829|DRUG|Oxaliplatin|
58472994|NCT01843829|DRUG|Capecitabine|
58472995|NCT01843829|DRUG|Carboplatin|
58472996|NCT01843829|DRUG|Paclitaxel|
58472997|NCT01843829|RADIATION|Radiotherapy|
58472998|NCT01843829|PROCEDURE|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
58472999|NCT04837716|BIOLOGICAL|Bevacizumab|Given IV
58473000|NCT04837716|DRUG|Carboplatin|Given IV
58473001|NCT04837716|DRUG|Ensartinib|Given PO
58473002|NCT04837716|DRUG|Pemetrexed|Given IV
58473003|NCT02002598|DRUG|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2"
58473004|NCT02002598|DRUG|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2"
58473005|NCT02002598|DRUG|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
58473006|NCT06599905|OTHER|Episodic Migraine (EM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
58473007|NCT06599905|OTHER|Chronic Migraine (CM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
58473008|NCT06047561|RADIATION|PET-CT|PET combined with CT or MRI
58473009|NCT03128294|OTHER|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
58473010|NCT05773729|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
58473011|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Superficial skin biopsy Skin swab
58473012|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
58473013|NCT06596044|BEHAVIORAL|VA BIC|VA BIC is a suicide prevention strategy that is designed to meet the needs of Veterans who receive acute psychiatric treatment. VA BIC can be delivered by a trained mental health provider (e.g., mental health nurse, social worker, psychologist, psychiatrist). VA BIC includes two synergistic elements to support the patient after a mental health discharge. The elements include a brief educational session, where the patient receives a one-on-one, one-hour, personalized educational session on suicide prevention. The session incorporates aspects of motivational interviewing. The patient then receives 7 regular follow-up contacts that are conducted by the interventionist. Here the interventionist monitors symptoms, assesses treatment adherence, reviews the safety plan, and assists the patient with engaging in steps to promote their well-being. The sessions incorporate aspects of motivational interviewing. Of note patients in this arm will also receive standard care.
58473014|NCT06596044|OTHER|Standard Care|Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.
58473015|NCT06591104|DIAGNOSTIC_TEST|24 hour urinary protein|proteinuria and renal function impairment will be detected in patients of four groups
58473016|NCT04558125|DRUG|TNKase|Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
58473017|NCT04558125|DRUG|Placebo|Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
58473018|NCT04558125|DRUG|Enoxaparin|All participants must also receive standard of care anticoagulation therapy.
58473019|NCT06019754|PROCEDURE|one point combined Lumbar and sacral plexus block|performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
58473020|NCT05820932|GENETIC|Blood-based assay|Blood samples will be collected
58473021|NCT05820932|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessments will be both participant- and partner-reported
58473022|NCT05820932|OTHER|Quality of Life Surveys|Participant-reported Quality of Life Surveys
58473023|NCT04593784|DRUG|Ciraparantag|Ciraparantag: 180 mg, intravenous
58473024|NCT04593784|DRUG|Placebo|Placebo: 0.9% sodium chloride, intravenous
58473025|NCT04593784|DEVICE|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
58473026|NCT06292260|DEVICE|mHealth app|The eSkinHealth app is a tablet application that can be used as a portable patient chart for dermatological conditions in areas with poor internet connectivity, and for teledermatology when in need.
58473027|NCT03945240|PROCEDURE|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
58473028|NCT03945240|PROCEDURE|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
58473029|NCT03945240|PROCEDURE|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
58473030|NCT06497543|DRUG|Intrathecal Pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
58473031|NCT05674656|DRUG|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
58473032|NCT03873883|DRUG|EOS100850|Oral administration
58473033|NCT03873883|DRUG|Pembrolizumab|IV Infusion
58473034|NCT03873883|DRUG|Chemotherapy|Standard of Care IV Infusion
58473035|NCT03635281|PROCEDURE|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
58473036|NCT03635281|PROCEDURE|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
58473037|NCT01933737|DEVICE|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
58473038|NCT01933737|DEVICE|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
58473039|NCT00125255|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
58473040|NCT00125255|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
58473041|NCT06586671|DRUG|Nemtabrutinib|Oral administration
58473042|NCT06599164|OTHER|Anthrogenic Muscle Inhibition (AMI) Assessment Protocol|This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.
58473043|NCT06227481|PROCEDURE|Scar subcision|"* Subcision will be performed with18 gauge cannula at the margin of the scars on both sides of the face.~* The cannula will be directed in a forward and backward motion producing a tunnel. Then, the it will be passed in sideways in a sweeping action to freeing up the scars from their bases.~* Once finish, the pressure will be applied to reduce the bleeding and swelling. The topical antibiotic will be applied for 3 days."
58473044|NCT06227481|PROCEDURE|Platelet rich plasma injection|• 20 ml of autologous whole blood will be collected into tubes containing acid citrate dextrose and centrifuged at 1500 rpm for 10 minutes in order to get PRP at the top of the test tube. Then, the PRP will be further centrifuged at 3700 rpm for 10 minutes at room temperature of 22°C in order to obtain a platelet count 4.5 times higher than the base line. Platelet-poor plasma (PPP) will be partly removed and partly used to resuspend the platelets. Calcium gluconate will be added as an activator (1:9), i.e., 1 ml of calcium gluconate in 9 ml of PRP
58473045|NCT06227481|PROCEDURE|Polydioxanone mono threads insertion|"* Topical anesthetic cream will be applied for halfan hour on the involved area.~* polydioxanone mono threads (50 mm, 27 G) will be inserted at 1-cm spacing into the dermal layer of the skin; the threads will be arranged in a transverse and vertical line in the form of a mesh similar to cross-hatching technique.~* The total numbers will range from 8 to 10 each side. The skin of the face will be stretched by the non-dominant hand of the physician and the needle will be inserted by the other hand through the required point."
58473046|NCT06227481|DEVICE|Fractional carbon dioxide laser|"* Topical anesthetic cream will be applied for 30 minutes before the procedure.~* BX300 device from AMI inc.,Korea will be used.~* Different settings will be used according to each individual case regarding the type of scar, severity and skin type fluence ranging from 36 to 42 j/cm2 will be used and pulse duration 1.8 ms.~* In an attempt to avoid common side effects that occur with fractional laser treatment, a lower fluence will be used in the first session and depending on the results, the fluence will be increased per treatment session."
58473047|NCT01779765|DIETARY_SUPPLEMENT|PHGG|
58473048|NCT01779765|DIETARY_SUPPLEMENT|Maltodextrin|
58473049|NCT04234113|DRUG|Nanrilkefusp alfa|A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
58473050|NCT04234113|DRUG|Pembrolizumab|A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
58473051|NCT06597253|DEVICE|Lactate sensor|Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
58473052|NCT04065269|DRUG|Ceralasertib|ATR inhibitor
58473053|NCT04065269|DRUG|Olaparib|PARP inhibitor
58473054|NCT04065269|DRUG|Durvalumab|Anti-PD-L1 immunotherapy
58473055|NCT06224413|OTHER|No Intervention|This is non-interventional study.
58473056|NCT04410978|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
58473057|NCT04410978|DRUG|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
58473058|NCT04410978|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
58473059|NCT04410978|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
58473060|NCT06311487|BEHAVIORAL|Fasted-AM|Participants will engage in aerobic exercise within 4 hours of waking up, following a \>10h overnight fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~08:00, \~13:00, and \~19:00. Plasma metabolite samples will be drawn immediately pre- and post- exercise.
58473061|NCT06311487|BEHAVIORAL|Fed-AM|Participants will engage in exercise within 4 hours of waking up, approximately 1h after consuming breakfast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
58473062|NCT06311487|BEHAVIORAL|Fasted-PM|Participants will engage in exercise between 8-12 hours after waking up, following a \~10h fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00 and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
58473063|NCT06311487|BEHAVIORAL|Fed-PM|Participants will engage in exercise between 8-12 hours after waking up, approximately 1h after consuming dinner across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
58131709|NCT03629093|DRUG|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
58473064|NCT05727306|OTHER|No intervention|Observational analysis of usual care only.
58473065|NCT06481163|DRUG|Telacebec|The test product will be supplied as Telacebec 100mg tablets.
58473066|NCT01058980|PROCEDURE|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
58473067|NCT01058980|PROCEDURE|No additional ablation|Presence of dormant PV conduction, no additional ablation.
58473068|NCT01058980|PROCEDURE|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
58473069|NCT01058980|PROCEDURE|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
58473070|NCT02405741|DEVICE|Hyperbaric chamber treatment|
58473071|NCT06591923|OTHER|No Interventions|No interventions.
58473072|NCT03081117|DRUG|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
58473073|NCT03081117|DRUG|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
58473074|NCT06596993|OTHER|IMU-based balance training|Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training
58473075|NCT06596993|OTHER|general health education or exercise training|general health education or exercise training
58473076|NCT04730609|DRUG|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
58473077|NCT03706417|DIAGNOSTIC_TEST|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
58473078|NCT06586944|BEHAVIORAL|Nursing Practices Based On Roy Adaptation Model Integrated With Virtual Reality|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group (Table...). In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals.Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions.
57779493|NCT06392061|DIETARY_SUPPLEMENT|Trilac|Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
57779494|NCT05781490|DRUG|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
57779495|NCT04295746|OTHER|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
58473079|NCT06586944|BEHAVIORAL|Roy Adaptation Model|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals
57779496|NCT04267575|DEVICE|Canady Helios Cold Plasma Scalpel|Device used to distribute cold plasma energy at the resected tumor margins.
57779497|NCT02300480|PROCEDURE|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
58131710|NCT06242405|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Umbilical cord mesenchymal stem cells injected through peripheral veins
58131711|NCT01575223|DEVICE|NeilMed sinus rinse|High volume saline irrigation
58131712|NCT01575223|DEVICE|Salinex|Low volume saline irrigation
58131713|NCT05063500|DRUG|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
58473080|NCT03651349|DRUG|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
58473081|NCT03651349|DRUG|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
58473082|NCT00611104|DIETARY_SUPPLEMENT|standardized freeze-dried table grape powder|
58473083|NCT00611104|OTHER|laboratory biomarker analysis|
58473084|NCT00611104|OTHER|pharmacological study|
58473085|NCT05083234|OTHER|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
58473086|NCT05083234|OTHER|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
58473087|NCT05083234|OTHER|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
58473088|NCT03363841|DRUG|SCY-078|Oral SCY-078
58473089|NCT04370210|BEHAVIORAL|Questionnaires|Child of both groups enrolled, and their parents, must complete online questionnaires
58473090|NCT03502005|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
58473091|NCT05893186|OTHER|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
58473092|NCT05893186|OTHER|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
58473093|NCT05893485|BEHAVIORAL|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
58473094|NCT06586437|BEHAVIORAL|Clinical Assessments|The participant will undergo a battery of clinical assessments to identify the upper extremity motor performance, sensory acuity, and ability to complete activities of daily living. Tests 1-5 will be completed separately for each hand. All participants will be video recorded while completing these assessments. The recordings will be used for grading tasks and data analysis: Box and Blocks, 9-hold peg board, Test of Arm Selective Control, Sensory Acuity Testing, KINARM End-Point Lab Sensory Test, Section GG of the inpatient Rehabilitaion Facility-Patient Assessment Instrument, NEURO-QOL Upper Extremity Function Scale, Edinburgh Handed Inventory
58473095|NCT06586437|BEHAVIORAL|Brain-Spinal Cord fMRI|Resting state, brain-spinal cord activity, spinal cord microstructure, magnetic resonance spectroscopy
58473096|NCT06586437|BEHAVIORAL|Hoffmann Reflex Assessments|Hmax 20-50 stimulations of increasing intensity. Next, the participant will sit quietly as 10 stimulations will be delivered at the participant's Hmax with an interstimulus interval of 15 seconds. Subsequently, stimulations at the participant's Hmax will be applied as the participants produce a contraction of 10-20% of their maximum voluntary contraction (MVC). The target contraction level will be shown in real-time based on the FCR EMG activity. The participant maintains their EMG activity at the target level for 6.5 seconds as 10 stimulations are delivered at the participants Hmax.
58473097|NCT06586437|BEHAVIORAL|MEG Imaging|Resting state, somatosensory, isometric force matching, entrainment
58473098|NCT06586437|BEHAVIORAL|Transcutaneous Current Stimulation|Cortical stimulation, spinal cord stimulation - sham and stim
58473099|NCT04981223|DEVICE|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
58473100|NCT06559826|DRUG|Ketamine|Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
58473101|NCT06559826|BEHAVIORAL|Psychotherapy|Each week following KAP, there will be a separate 60-minute integration session 1-6 days afterwards. Integration sessions will focus on processing experiences and material that emerged in KAP sessions (such as assimilating challenging experiences, making meaning of experiences and imagery, working through memories and emotions, and exploring emerging relational patterns) as well as strengthening insights. Within one week of the completion of all KAP sessions, there will be one additional integration session focused on consolidating the insights and improvements gained from KAP treatment.
58473102|NCT04977453|DRUG|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
58473103|NCT04977453|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
58473104|NCT04977453|DRUG|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
58473105|NCT04977453|RADIATION|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
58473106|NCT04977453|DRUG|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
58473107|NCT04119739|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
58473108|NCT04119739|DRUG|Ibuprofen Arginine|Oral tablets
58473109|NCT05602454|OTHER|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
58473110|NCT03793751|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
58473111|NCT05867407|DEVICE|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
58473112|NCT05867407|OTHER|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
58473113|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
58473114|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
58473115|NCT04562389|OTHER|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
58473116|NCT04562389|DRUG|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
58473117|NCT03271086|BEHAVIORAL|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
58473118|NCT03271086|BEHAVIORAL|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
58473119|NCT03271086|BEHAVIORAL|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
58473120|NCT04971642|DEVICE|Intraoral ultrasound|Intraoral ultrasound scanning of the periodontium complex
58473121|NCT06602713|OTHER|Questionnaires|Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
58473122|NCT06602713|OTHER|Exercices|isokinetic evaluation
58473123|NCT01423500|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
58473124|NCT01423500|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
58473125|NCT01423500|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
58473126|NCT01423500|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
58473127|NCT01423500|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
58473128|NCT01423500|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
58473129|NCT01423500|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
58473130|NCT04448392|DRUG|Valacyclovir|Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
58473131|NCT04827069|DRUG|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
58473132|NCT06597461|OTHER|Myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
58473133|NCT06597461|OTHER|Placebo myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.
58473134|NCT06597474|BEHAVIORAL|Food-Body-Mind|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
58490877|NCT02874976|DEVICE|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
57779498|NCT02300480|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
57779499|NCT06275672|OTHER|Adapted version of the mhGAP-IG|An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
57779500|NCT04438096|DRUG|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
57779501|NCT04438096|DRUG|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
58473135|NCT02694185|OTHER|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
58473136|NCT03351764|DEVICE|Sham TMS|Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.
58473137|NCT03351764|DEVICE|TMS|non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
58473138|NCT05002868|DRUG|RP12146|starting dose of 100 mg QD
58473139|NCT06599372|OTHER|The rTMS method|The patient receives treatment under naturalistic conditions in routine practice.
58473140|NCT06599372|OTHER|The cTBS method|The patient receives the treatment under naturalistic conditions in routine practice.
58473141|NCT06601855|PROCEDURE|Cholecystectomy|Cholecystectomy, whether open or laparoscopic
58473142|NCT04008745|OTHER|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
58473143|NCT01929421|DRUG|Gemcitabine/S-1|
58473144|NCT04834661|OTHER|surgery inside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
58473145|NCT04834661|OTHER|surgery outside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
58473146|NCT06586814|OTHER|Suture|Wound Closure
58473147|NCT06586814|OTHER|Staple|Wound Closure
58473148|NCT03902431|BEHAVIORAL|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
58473149|NCT06597162|BEHAVIORAL|education of patient safety|"For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group."
58473150|NCT06598917|DRUG|S-1|"Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request."
58473151|NCT06596343|DRUG|Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy|"1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors."
58473152|NCT06604650|BEHAVIORAL|Active older Adults|The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
58473153|NCT00360841|PROCEDURE|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
58473154|NCT00360841|PROCEDURE|Sham auricular acupuncture|
58473155|NCT05205031|DEVICE|Intraosseous access|Needle placed in the bone marrow.
58473156|NCT05205031|DEVICE|Intravenous|Needle placed in a vein.
58473157|NCT06603610|OTHER|Intensive geriatric service worker model of care|"Participants in the intervention group will receive care from an intensive geriatric service worker (IGSW), who will help the participant:~(i) Coordinate community resources and actively support participants' instrumental activities of daily living (IADLs) (e.g., linking participants with Meals-on-Wheels, taking participants to appointments) (ii) Advocate for support from home care for completing activities of daily living (ADLs) (iii) Implement patients' prioritized treatment recommendations made by healthcare professionals (e.g., supporting patients to purchase and install home safety equipment because this aligns with their values and preferences)."
57779502|NCT04438096|DRUG|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
57779503|NCT04438096|DRUG|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
58473158|NCT06603610|OTHER|Information brochure and telephone follow-up support|Participants will be e-mailed or mailed a booklet containing information about locally available resources including (1) meal preparation, (2) grocery delivery, (3) housekeeping, (4) pharmacies that deliver medications, (5) home care, and (6) Wheel-Trans. Participants will receive a scripted phone call from the study research coordinator one and three months after study enrolment to see if they have questions about the booklet material.
58473159|NCT00791934|DEVICE|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
58473160|NCT02357654|DRUG|GnRH|single shot of GnRH agonist
58473161|NCT02357654|DRUG|placebo|placebo
58473162|NCT02603146|DRUG|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
58473163|NCT02603146|DRUG|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
58473164|NCT01194830|DRUG|Linagliptin|Active drug 1 tablet PO QD
58473165|NCT01194830|DRUG|Placebo|1 Tablet PO QD
58473166|NCT06587893|OTHER|echography|performance of ultrasound of the scapular regions to identify and measure the suprascapular notch in our group of healthy adult volunteers.
58473167|NCT00087152|DRUG|Capecitabine|1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
58473168|NCT00087152|DRUG|Imatinib mesylate|400 mg by mouth daily
58473169|NCT05822804|DEVICE|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
58473170|NCT05822804|DEVICE|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
58473171|NCT05799820|DRUG|QL1706|5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
58473172|NCT05799820|DRUG|Bevacizumab|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
58473173|NCT05799820|DRUG|Oxaliplatin injection|130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
58473174|NCT05799820|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
58473175|NCT06263010|DRUG|Allopregnanolone|Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
58473176|NCT00412334|DRUG|Copegus|1200-1600mg/day po
58473177|NCT00412334|DRUG|Copegus|1000-1200mg/day po
58473178|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
58473179|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
57779504|NCT06465121|PROCEDURE|peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse|Intravenous catheterization using ultrasound-guidance to allow real-time visualization of target veins in pediatric patients with difficult intravenous access
58473180|NCT06586047|DIAGNOSTIC_TEST|PET imaging|Imaging with FDG PET/CT and Pyl PET/CT
57784552|NCT04780438|DRUG|Placebo|Patients rendomized in this arm will receive placebo.
57784553|NCT03671720|BIOLOGICAL|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
58473181|NCT04953104|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58473182|NCT04953104|BIOLOGICAL|Nivolumab|Given IV
58473183|NCT04953104|DRUG|Relatlimab|Given IV
58473184|NCT06599515|PROCEDURE|robotic surgical platform|robot-assisted laparoscopic inguinal hernia repair (rTAR)
58473185|NCT03954366|DRUG|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
58473186|NCT03954366|DRUG|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
58473187|NCT03954366|DRUG|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
58473188|NCT06587620|DRUG|Tranexamic acid|Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
58473189|NCT06587620|DRUG|Dexmedetomidine|Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
58473190|NCT06587620|OTHER|Saline (NaCl 0,9 %) (placebo)|IV infusion of 50 ml saline over 10 min before induction of anesthesia. IV saline infusion immediately after induction till 15 min before the end of surgery.
58473191|NCT05983757|DEVICE|Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion|"The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA)."
58473192|NCT05983757|OTHER|Standard medical management|All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
58473193|NCT03242915|DRUG|Pembrolizumab|200mg IV every 3 weeks
58473194|NCT03242915|DRUG|Carboplatin|AUC 5 IV every 3 weeks
58473195|NCT03242915|DRUG|Pemetrexed|500 mg/m\^2 IV every 3 weeks
58473196|NCT03537755|OTHER|Observation|Examine thoughts and behaviors
58473197|NCT05826743|DEVICE|COLO BT™|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
58473198|NCT05826743|OTHER|Stoma Creation|Protective ileostomy
58473199|NCT00901836|RADIATION|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
58473200|NCT00901836|PROCEDURE|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
58473201|NCT06598475|OTHER|Facilitator-driven provider- and practice-level implementation strategies for influencing provider recommendations and practice-level HPV vaccination rates|"The practice facilitator (UTHealth research staff) will implement the following 4 strategies with providers and immunization navigators at each practice:~* Facilitator-driven provider education: The practice facilitator will conduct one provider education module (5 total modules) over three months with health care providers using a booklet and resource binder.~* Facilitator-driven clinical practice plan: The practice facilitator will assist the implementation team in creating their clinical practice in two additional modules and encourage providers to identify strategies to increase HPV vaccination.~* Training and education for staff (Immunization Navigators): The facilitator will train immunization navigators to implement the plan, and practice immunization navigators will implement the plan.~* Technical assistance plus assessment and feedback: During implementation of the plan, the facilitator will provide technical assistance, ongoing assessment and feedback, and booster trainings."
58473202|NCT06591845|DRUG|Ziresovir 125 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
58473203|NCT06591845|DRUG|Ziresovir 500 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
58473204|NCT06591845|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
58473205|NCT06591845|DRUG|Moxifloxacin hydrochloride tablet 400 mg|Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
58473206|NCT00212108|DRUG|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
58473207|NCT05852119|OTHER|Outpatient treatment with standard anticoagulant therapy|All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
58473208|NCT05546853|DRUG|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
58473209|NCT05546853|DRUG|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
58473210|NCT05546853|DRUG|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
58473211|NCT05546853|DRUG|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
58473212|NCT05546853|DRUG|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
58473213|NCT01423175|DRUG|Clofarabine, ara-C|
58473214|NCT01423175|DRUG|FLAMSA|
58473215|NCT06599801|PROCEDURE|Thoracodorsal artery perforator flap reconstruction surgery|Oral squamous cell carcinoma patients underwent reconstruction with thoracodorsal artery perforator (TDAP) flaps following tumor resection.
58473216|NCT06599801|PROCEDURE|Forearm flaps reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
58473217|NCT06599801|PROCEDURE|Anterolateral thigh flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection
58473218|NCT06599801|PROCEDURE|Fibula flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with fibula flaps after tumor resection
58473219|NCT06599801|PROCEDURE|Forearm flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
58473220|NCT04756427|DRUG|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
58473221|NCT01899521|PROCEDURE|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
58473222|NCT01899521|DIETARY_SUPPLEMENT|Zinc sulfate 220 mg once daily|
58473223|NCT01899521|DIETARY_SUPPLEMENT|S-adenosylmethionine 400 mg twice daily|
58473224|NCT06234761|DRUG|Dupilumab|Patient who start to take dupilumab will be followed. This study is only observational
58473225|NCT05279651|DRUG|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
58473226|NCT05279651|DRUG|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
58473227|NCT01648751|DRUG|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
58131714|NCT05063500|DRUG|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
58131715|NCT05265806|DRUG|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
58131716|NCT05265806|DRUG|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
58131717|NCT05265806|DRUG|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
58131718|NCT00323349|PROCEDURE|Oral Glucose Tolerance Testing|
58131719|NCT00323349|BEHAVIORAL|Education tailored to learning style preferences|
58131720|NCT00131703|DRUG|Amodiaquine|
58131721|NCT00131703|DRUG|Sulphadoxine-pyrimethamine|
58131722|NCT00131703|DRUG|Chloroquine|
58131723|NCT03960970|DRUG|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
58131724|NCT03960970|DRUG|Mefoxin 2g|Standard Prophylaxis
58131725|NCT04752748|DRUG|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48."
58131726|NCT05019469|DEVICE|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
58131727|NCT03567642|DRUG|Osimertinib|Osimertinib 80mg daily
58131728|NCT03567642|DRUG|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
58131729|NCT03567642|DRUG|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
58131730|NCT06521983|OTHER|Whole body vibration|Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine
58131731|NCT05488197|OTHER|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
58131732|NCT01130688|DRUG|Zileuton|Imatinib combined with Zileuton
58131733|NCT05193019|OTHER|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
58131734|NCT05773183|DRUG|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
58131735|NCT05773183|DRUG|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
58131736|NCT04688697|PROCEDURE|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
58131737|NCT04688697|PROCEDURE|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
58131738|NCT03344510|DEVICE|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
58131739|NCT03344510|OTHER|Control|One injection will be administered without the kinetic anesthesia device.
58131740|NCT05209009|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
58131741|NCT05209009|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
58473228|NCT01648751|DRUG|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
58131742|NCT01988922|DRUG|ketamine|0.4 mg/kg oral racemic ketamine
58131743|NCT00147030|PROCEDURE|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
58131744|NCT02279797|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
58131745|NCT03340727|DRUG|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
58131746|NCT03340727|DRUG|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
58131747|NCT01295372|DRUG|Zicronapine|7.5 mg/day; orally
58131748|NCT01295372|DRUG|Risperidone|5 mg/day; orally
58131749|NCT01541280|DRUG|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
58131750|NCT01541280|OTHER|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of \>grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
58131751|NCT05942703|OTHER|saliva samples|Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
58131752|NCT04700254|OTHER|DASS questionnaire|The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
58131753|NCT04700254|OTHER|EAT-26 questionnaire|The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
58131754|NCT02930005|DRUG|Meclofenamic acid|
58131755|NCT02930005|DRUG|Pentosan polysulfate sodium|
58131756|NCT02995057|DEVICE|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
58131757|NCT01572948|DRUG|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
58131758|NCT01572948|DRUG|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
58131759|NCT06393088|DEVICE|IR REHAB|Participants undergo therapy sessions with active, dual frequency, low level laser therapy device
58131760|NCT06393088|DEVICE|Sham|Participants undergo therapy sessions with disabled device producing no laser energy
58131761|NCT02238145|DRUG|Atrovent® Inhaletten|
58131762|NCT05411692|OTHER|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
58131763|NCT05411692|OTHER|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
58131764|NCT05411692|OTHER|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
58131765|NCT04526496|DRUG|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
58131766|NCT04526496|DRUG|Placebo, single dose|Placebo matched to FTP-198, oral suspension
58131767|NCT04526496|DRUG|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
57784554|NCT04668989|DEVICE|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
58131768|NCT04526496|DRUG|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
58131769|NCT04180007|DRUG|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
58131770|NCT02499666|PROCEDURE|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
58131771|NCT02499666|DEVICE|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
58131772|NCT02499666|DRUG|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
58131773|NCT02070185|BEHAVIORAL|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
58131774|NCT02070185|BEHAVIORAL|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
58131775|NCT00085696|DRUG|VELCADE and rituximab|
58131776|NCT01697878|PROCEDURE|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
58131777|NCT01697878|PROCEDURE|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
58131778|NCT00912288|DRUG|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
58131779|NCT00912288|DRUG|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
58131780|NCT03009448|OTHER|Interview|Each subject will be interviewed using a semi constructed interview.
58131781|NCT05308043|DIAGNOSTIC_TEST|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
58473229|NCT06582901|BEHAVIORAL|Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)|Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
57784555|NCT04668989|DEVICE|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
58131782|NCT05098379|BEHAVIORAL|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
58131783|NCT01775592|DRUG|Arterakin (DHA-PPQ)|
58131784|NCT04569682|DEVICE|LifePort transrenal artery perfusion|transrenal artery perfusion group
58131785|NCT04569682|DEVICE|LifePort transrenal vein perfusion|transrenal vein perfusion group
58131786|NCT02199548|OTHER|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
58131787|NCT03614195|DEVICE|MCDTT|The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.
58131788|NCT03614195|DEVICE|MDTT|The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.
58131789|NCT03614195|DEVICE|CDTT|The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
58131790|NCT00404131|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
58131791|NCT02445456|DRUG|Sienna+ injection|Endoscopic injection of magnetic tracer
58131792|NCT02445456|OTHER|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
58131793|NCT02445456|PROCEDURE|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
58131794|NCT02445456|DEVICE|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
58131795|NCT06061666|OTHER|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
58473230|NCT06582901|BEHAVIORAL|Enhanced - Treatment as Usual|The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
58473231|NCT04088149|DRUG|GXNPC1|Autologous ADSCs
58473232|NCT06141226|DRUG|TQB2450 +Anlotinib+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug."
58473233|NCT06141226|DRUG|TQB2450 +Androtinib Placebo+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug."
58473234|NCT06008314|OTHER|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
58131796|NCT02529280|BEHAVIORAL|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
58131797|NCT04568408|DEVICE|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
58131798|NCT03895684|DRUG|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
58131799|NCT01220830|DEVICE|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
58131800|NCT02778919|DRUG|KLH-2109|
58131801|NCT02778919|DRUG|Placebo|
58131802|NCT02778919|DRUG|Leuprorelin acetate|
58131803|NCT01357707|GENETIC|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
58131804|NCT00876200|DRUG|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
58131805|NCT00876200|DRUG|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
58131806|NCT05331222|DRUG|JT-1|JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
58131807|NCT02769637|DRUG|PPI treatment|PPI treatment or no PPI treatment
58131808|NCT01880970|OTHER|starter infant formula with pro and prebiotics|
58131809|NCT01880970|OTHER|Placebo comparator|
58131810|NCT00590395|DRUG|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
58131811|NCT02771015|DEVICE|Mepilex Border®|randomization
58131812|NCT02771015|DEVICE|Cosmopor steril®|randomization
58131813|NCT00551499|DEVICE|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
58131814|NCT03423849|DRUG|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
58131815|NCT03423849|DRUG|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
58131816|NCT03423849|DRUG|Cisplatin|25mg/m2,day 1,every 3 weeks
58131817|NCT03423849|DRUG|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
58131818|NCT04218903|BEHAVIORAL|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
58131819|NCT04218903|BEHAVIORAL|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
58131820|NCT06234163|BEHAVIORAL|Assigned intervention|"Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition."
58131821|NCT02001948|DRUG|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
58131822|NCT02001948|DRUG|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
58131823|NCT02001948|DEVICE|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
58131824|NCT02001948|DRUG|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
58131825|NCT04008979|DRUG|Aspirin|Aspirin - lipid complex
58131826|NCT01909557|DRUG|Acetyl-L-carnitine|
58131827|NCT01909557|DRUG|placebo|
58131828|NCT03097393|DIAGNOSTIC_TEST|measure Serum procalcitonin level|measuring procalcitonin level
58131829|NCT02151032|BEHAVIORAL|Booklet|Participants read a booklet about colorectal cancer screening tests.
58131830|NCT02151032|BEHAVIORAL|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
58131831|NCT02151032|BEHAVIORAL|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
58131832|NCT02151032|BEHAVIORAL|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
58131833|NCT02151032|BEHAVIORAL|Questionnaires|Questionnaire completion before and after viewing the program.
58131834|NCT01807208|OTHER|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
58131835|NCT04114448|OTHER|Therapeutic exercise|Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
58131836|NCT04114448|OTHER|Usual physical therapy care|Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
58131837|NCT01872546|DRUG|HUMIRA 40mg|
58131838|NCT01471847|DRUG|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
58131839|NCT01471847|DRUG|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
58131840|NCT02737436|DRUG|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
58473235|NCT05862220|DIAGNOSTIC_TEST|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
58473236|NCT06191796|DRUG|zanzalintinib|Specified doses on specified days
58473237|NCT06191796|DRUG|AB521|Specified doses on specified days
58131841|NCT02737436|DRUG|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
58131842|NCT02737436|PROCEDURE|Functional MRI scanning|All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
58131843|NCT03883906|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
58131844|NCT02420210|DRUG|Bendamustine Hydrochloride|Given IV
58131845|NCT02420210|BIOLOGICAL|Obinutuzumab|Given IV
58131846|NCT02420210|DRUG|Dexamethasone|Given PO
58131847|NCT02420210|OTHER|Quality-of-Life Assessment|Ancillary studies
58131848|NCT02420210|OTHER|Laboratory Biomarker Analysis|Correlative studies
58131849|NCT01781637|DRUG|Omalizumab|subcutaneous injection
58131850|NCT01781637|DRUG|placebo|subcutaneous injection
58131851|NCT05894577|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
58131852|NCT05894577|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
58131853|NCT00000482|DRUG|estrogen|
58131854|NCT00000482|DRUG|clofibrate clofibrate|
58131855|NCT00000482|DRUG|dextrothyroxine sodium|
58131856|NCT00000482|DRUG|niacin|
58131857|NCT02929979|BEHAVIORAL|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
58131858|NCT02929979|BEHAVIORAL|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
58131859|NCT04872257|DRUG|Oral Vitamin D|Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
58131860|NCT04872257|PROCEDURE|NB-UVB Phototherapy|NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
58131861|NCT04872257|DRUG|Placebo|Administered orally daily for 6 months
58131862|NCT04033809|DIETARY_SUPPLEMENT|Multigrain powder (S)|A twice daily high fiber multigrain powder supplementation for 12 weeks
58131863|NCT00821028|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
58131864|NCT03371290|OTHER|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
58131865|NCT03371290|OTHER|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
58131866|NCT01170286|BIOLOGICAL|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
58131867|NCT01170286|BIOLOGICAL|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
58131868|NCT06021821|OTHER|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
58131869|NCT06021821|OTHER|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
58473238|NCT06191796|BIOLOGICAL|Nivolumab|Specified doses on specified days
58131870|NCT01989091|DEVICE|B-Lock|Antimicrobial Catheter Lock Solution
58131871|NCT01989091|DRUG|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
58131872|NCT04374084|OTHER|Moxibustion plus Cupping|"Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes."
58131873|NCT01651702|DEVICE|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
58131874|NCT01651702|DEVICE|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
58131875|NCT01891409|DEVICE|Male circumcision using the Shang Ring device|
58131876|NCT00818883|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
58131877|NCT00818883|DRUG|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
58131878|NCT06314503|DEVICE|WEAKID|"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"
58131879|NCT03486990|DRUG|TIMP-GLIA|intravenous infusion.
58473239|NCT06596330|BEHAVIORAL|Validation of language model prompts in increasing short-term physical activity|"Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change."
58473240|NCT06596330|BEHAVIORAL|Assessment of long-term changes to physical activity and glycemic control|"Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app)."
58473241|NCT05569044|OTHER|Control Group|No intervention
58131880|NCT03579771|DRUG|Cisplatin|Given IV
58131881|NCT03579771|DRUG|Gemcitabine|Given IV
58131882|NCT03579771|DRUG|Nab-paclitaxel|Given IV
58131883|NCT01631422|DRUG|RO4602522|Single radiolabeled dose
58131884|NCT05773079|DRUG|Toripalimab|Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
58131885|NCT00379340|RADIATION|3-Dimensional Conformal Radiation Therapy|
58131886|NCT00379340|PROCEDURE|Conventional Surgery|
58131887|NCT00379340|DRUG|Cyclophosphamide|Given IV
58131888|NCT00379340|BIOLOGICAL|Dactinomycin|Given IV
58131889|NCT00379340|DRUG|Doxorubicin Hydrochloride|Given IV
58131890|NCT00379340|DRUG|Etoposide|Given IV
58131891|NCT00379340|DRUG|Vincristine Sulfate Liposome|Given IV
58131892|NCT02581345|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
58131893|NCT02581345|BIOLOGICAL|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
58131894|NCT05017298|BIOLOGICAL|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
58131895|NCT01001845|DRUG|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
58131896|NCT01001845|DRUG|vit E|200 mg twice daily for 3 weeks
58131897|NCT01001845|DRUG|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
58131898|NCT06051240|DRUG|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
58131899|NCT06051240|DRUG|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
58131900|NCT00076102|DRUG|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
58131901|NCT02392793|DRUG|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
58131902|NCT02392793|DRUG|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
58131903|NCT02392793|DRUG|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
58131904|NCT02392793|DRUG|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.
58131905|NCT02392793|DRUG|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
58131906|NCT04168463|DEVICE|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
58131907|NCT03116386|OTHER|run-in period|observational time i.e. baseline situation
58131908|NCT03116386|DEVICE|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
58131909|NCT03116386|DEVICE|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
58131910|NCT05602064|DRUG|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
58131911|NCT05602064|DRUG|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
58131912|NCT05602064|OTHER|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
58131913|NCT00254956|DRUG|ciclesonide (XRP1526)|
58131914|NCT01395186|PROCEDURE|varicocelectomy|varicocelectomy for painful varicocele
58473242|NCT05569044|OTHER|Oral Rehydration Solution|Participants will be administered ORS during one of the study visits
58473243|NCT05569044|OTHER|Water|Participants will be administered water during one of the study visits
58473244|NCT00573222|DRUG|Symbicort|
58473245|NCT05494190|DRUG|Docetaxel|60 mg/m2 i.v. day 1
58473246|NCT05494190|DRUG|Cisplatin|60 mg/m2 i.v. day 1-3
58473247|NCT05494190|DRUG|Capecitabine|750 mg/m2 po bid day 1-14
58473248|NCT05494190|RADIATION|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
58473249|NCT05494190|PROCEDURE|Surgery|Neck dissection and primary tumor resection
58473250|NCT06594822|DIETARY_SUPPLEMENT|probiotic plus standard treatment|Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily
58131915|NCT05393960|OTHER|Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program.|Manual therapy, mobility exercise therapy and a home-based self-stretching program. Manual mobilization postero-anterior glides at lumber facets joints, Transverse glides at spinous process \& Posterior-anterior glides at SI joint. Glides will be performed 3 times with 5 repetitions. Mobility exercise therapy.
58131916|NCT05393960|OTHER|home based self strechings program only.|Home based self-stretching program includes 3 repetitions of 15 seconds duration stretch (with 20 seconds rest between each repetition). Repeat stretching exercises twice a day for 3 alternate days for 1 week. Piriformis stretch: in supine crook lying, placing the lateral side of the foot over the contralateral knee and pulling towards the chest with the hands. Quadriceps stretch: stand on your left leg, one knee touching the other, hold a chair or the wall to keep you steady if needed, grab your right foot, using your right hand, and pull it towards your butt. Hamstring stretch: To stretch the right leg, sit on the ground with the left leg bent at the knee with the foot facing inward. This is called the butterfly position. Extend the right leg, keeping it slightly bent at the knee. Bend forward at the waist, making sure to keep the back straight.
58131917|NCT02673580|OTHER|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
58473251|NCT06594822|DRUG|standard treatment|diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
58473252|NCT04971954|OTHER|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
58473253|NCT04971954|OTHER|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
58473254|NCT06367933|PROCEDURE|mini-invasive spine surgery|spine deformity correction using a mini-invasive technique
58473255|NCT06284005|DEVICE|WRL ATP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
58473256|NCT06599918|DRUG|Nicotinamide|Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
58473257|NCT06599918|DRUG|Placebo|Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
58473258|NCT05328102|BIOLOGICAL|Plamotamab|Biological
58473259|NCT05328102|BIOLOGICAL|Tafasitamab|Biological
58473260|NCT05328102|DRUG|Lenalidomide|Drug
58473261|NCT05756179|DRUG|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
58473262|NCT06497842|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
58473263|NCT06497842|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
58131918|NCT02673580|OTHER|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
58131919|NCT01350765|BEHAVIORAL|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
58131920|NCT01350765|BEHAVIORAL|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
58131921|NCT01735630|DRUG|ELND005|
58131922|NCT01735630|DRUG|Placebo|
58131923|NCT02877186|OTHER|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
58131924|NCT02877186|OTHER|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
58131925|NCT03232008|DIETARY_SUPPLEMENT|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
58131926|NCT03232008|DIETARY_SUPPLEMENT|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
58131927|NCT06242288|DRUG|ISOtretinoin 20 MG|Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
58131928|NCT05570149|DRUG|Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution|migraine prophylaxis
58131929|NCT02464709|DRUG|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
58131930|NCT02464709|DRUG|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
58131931|NCT00927992|OTHER|Epidemiological Non interventional|Epidemiological Non interventional
58131932|NCT04817709|OTHER|Educational Intervention|Review workbook
58131933|NCT04817709|OTHER|Usual Care|Receive educational materials
58131934|NCT04817709|OTHER|Media Intervention|Watch video
58131935|NCT04817709|OTHER|Medical Chart Review|Review of medical records
58131936|NCT04817709|OTHER|Questionnaire Administration|Complete questionnaires
58131937|NCT03309709|DRUG|subcutaneous progesterone|25mg daily for 7 days
58131938|NCT04916938|BEHAVIORAL|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
58131939|NCT04916938|BEHAVIORAL|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
58131940|NCT04916938|BEHAVIORAL|Interview|History and perception of the mother's issues.
58490878|NCT02874976|DEVICE|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
58131941|NCT04916938|BEHAVIORAL|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
58131942|NCT00193284|DRUG|Gefitinib|
58131943|NCT00193284|DRUG|Docetaxel|
58131944|NCT00193284|DRUG|Carboplatin|
58131945|NCT00193284|DRUG|Fluorouracil|
58131946|NCT00005520|DRUG|Hydrochlorothiazide|
58131947|NCT00005520|DRUG|Candesartan|
58131948|NCT03011684|DRUG|Tamoxifen|For ER Positive Randomization
58131949|NCT03011684|DRUG|Letrozole|For ER Positive Randomization
58131950|NCT02143765|DRUG|Mitiglinide|three times a day, orally, for 12 weeks
58131951|NCT02143765|DRUG|Acarbose|three times a day, orally, for 12 weeks
58131952|NCT03174756|DRUG|Hypochlorous Acid|Mouthwashes of antiplaque agents
58131953|NCT03174756|DRUG|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
58131954|NCT03174756|OTHER|Placebo|Sterile water as placebo
58131955|NCT05077566|OTHER|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
58131956|NCT05077566|OTHER|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
58131957|NCT04423237|DRUG|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
58131958|NCT02684344|DRUG|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
58131959|NCT02684344|OTHER|Education|Education about signs and symptoms of urinary retention
58131960|NCT03432845|OTHER|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
58131961|NCT01062256|DRUG|Placebo|One placebo tablet administered orally as a single dose
58131962|NCT01062256|DRUG|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
58131963|NCT01062256|OTHER|Buckwheat Honey|10 mL administered orally as a single dose
58131964|NCT00845156|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
58131965|NCT01247948|PROCEDURE|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
58131966|NCT01247948|PROCEDURE|traditional spine surgery|traditional spine surgery without navigation assist
58131967|NCT06369805|OTHER|there is no intervention|there is no intervention
58131968|NCT02007122|OTHER|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
58131969|NCT02007122|OTHER|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
58131970|NCT00141466|BEHAVIORAL|Education for professionals|
58131971|NCT00141466|BEHAVIORAL|Distribution of educational materials|
58131972|NCT00141466|BEHAVIORAL|Feedback for professionals|
58131973|NCT00141466|BEHAVIORAL|Reminders for professionals|
58131974|NCT00189709|DRUG|Micafungin|IV
58131975|NCT00189709|DRUG|fluconazole|IV
58131976|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 low dose
58131977|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
58131978|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
58131979|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
57784556|NCT04049201|PROCEDURE|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
58131980|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
58131981|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
58131982|NCT05571878|DRUG|Humalog|All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
58131983|NCT05571878|DRUG|Saline nasal spray|All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
58131984|NCT01208363|DIETARY_SUPPLEMENT|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
58131985|NCT01402947|DRUG|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
58131986|NCT01402947|DRUG|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
58131987|NCT01935440|BEHAVIORAL|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
58131988|NCT01935440|BEHAVIORAL|Prevention & Testing Control|7 group sessions
58131989|NCT00090857|DRUG|Letrozole|
58131990|NCT00090857|OTHER|Placebo|
58131991|NCT02060110|DEVICE|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
58131992|NCT02060110|DEVICE|MADIT-CRT ICD ONLY ARM|
58131993|NCT05823207|OTHER|sage essential oil|It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
58131994|NCT00002260|DRUG|Alovudine|
58131995|NCT01272336|DRUG|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
58131996|NCT01272336|OTHER|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
58131997|NCT02175264|GENETIC|Blood sample|
58131998|NCT05046548|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
58131999|NCT05046548|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
58132000|NCT03375593|DRUG|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
58473264|NCT06208514|BEHAVIORAL|Brief pain exposure therapy (BPET)|"Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol, and 7 for days post-treatment.~Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study."
57784557|NCT04049201|DRUG|Midazolam|Oral Midazolam
57784558|NCT04049201|DEVICE|Interactive Tablet|interactive Tablet containing many cartoon's videos
57784559|NCT01868789|RADIATION|Weightbearing CT|
58132001|NCT03375593|DRUG|Acetaminophen 500Mg Tab|tablet
58132002|NCT03375593|DRUG|Ibuprofen 600 mg tab|tablet
58132003|NCT03661528|DRUG|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
58132004|NCT03661528|DRUG|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
58132005|NCT02601495|BEHAVIORAL|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
58132006|NCT05084001|DRUG|silver diamine fluoride|topical application of the agent on tooth surface
58132007|NCT05084001|DRUG|sodium fluoride varnish|topical application of the agent on tooth surface
58132008|NCT05084001|OTHER|tonic water|topical application of tonic water on tooth surface
58132009|NCT05389943|DRUG|Oral administration of vitamin D3|the effect of oral supplement in postmenopausal women.
58132010|NCT05389943|DRUG|Vitamin D3 50000 UNT Oral Capsule|In postmenopausal women with BMD less than 32 ng/ml
58132011|NCT05389943|DIETARY_SUPPLEMENT|milk, Dietary and life style modifications.|Postmenopausal women with BMD greater than 32 ng/ml
58132012|NCT00003078|DRUG|cisplatin|
58132013|NCT00003078|DRUG|fluorouracil|
58132014|NCT00003078|RADIATION|brachytherapy|
58132015|NCT00003078|RADIATION|radiation therapy|
58132016|NCT03400930|OTHER|Severe Acute Malnutrition|
58132017|NCT02925364|RADIATION|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
58132018|NCT01424644|BIOLOGICAL|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
58132019|NCT01424644|BIOLOGICAL|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
58132020|NCT05318157|DRUG|AIT drops|Once a day
58132021|NCT05318157|DRUG|Clarityne, Rhinocort and Emedastine Difumarate Eye Drops|The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
58132022|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program|Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
58132023|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise|Passive knee flexion-extension movements + Incremental cycle ergometer exercise
58132024|NCT05178407|DIETARY_SUPPLEMENT|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
58132025|NCT05178407|DIETARY_SUPPLEMENT|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
58132026|NCT06198374|DIETARY_SUPPLEMENT|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
58132027|NCT06198374|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
58132028|NCT00605930|DIETARY_SUPPLEMENT|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
58132029|NCT00605930|DIETARY_SUPPLEMENT|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
58132030|NCT04791150|OTHER|Fill in a form|Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs
58132031|NCT02048306|BEHAVIORAL|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
58132032|NCT02048306|BEHAVIORAL|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
58132033|NCT00677365|DRUG|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
58132034|NCT00677365|DRUG|Placebo|same frequency as study drug using the same nebulizer
58132035|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
58132036|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
58132037|NCT02569073|DRUG|Dronabinol|Dronabinol 5 mg, every other night, orally
58132038|NCT02569073|DRUG|Placebo|Placebo--no drug
58132039|NCT05425888|OTHER|Hemophilia group|Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
58473265|NCT05698485|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
58132040|NCT04500470|DRUG|Ketoprofen + INH|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
58132041|NCT04500470|DRUG|Ketoprofen + placebo|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
58132042|NCT00414297|DEVICE|ECP Therapy|application of ECP Therapy to CAD Patients
58132043|NCT00258271|BIOLOGICAL|filgrastim|
58473266|NCT05698485|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
58132044|NCT00258271|DRUG|cladribine|
58132045|NCT00258271|DRUG|cytarabine|
58132046|NCT00258271|DRUG|imatinib mesylate|
58132047|NCT00301756|DRUG|Belinostat|Given IV
58132048|NCT00301756|OTHER|Laboratory Biomarker Analysis|Correlative studies
58132049|NCT00613470|DRUG|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5."
58473267|NCT05698485|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
58473268|NCT00687193|DRUG|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
58473269|NCT00687193|DRUG|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
58473270|NCT00687193|DRUG|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
58473271|NCT00687193|DRUG|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
58473272|NCT00687193|DRUG|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
58132050|NCT03377881|PROCEDURE|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.
58132051|NCT03377881|PROCEDURE|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
58132052|NCT02401386|BEHAVIORAL|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
58132053|NCT05960409|PROCEDURE|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
58132054|NCT06484114|DEVICE|Revita Duodenal Mucosal Resurfacing (DMR)|DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.
58132055|NCT06484114|DEVICE|Sham|An endoscopic review with non active catheter introduction
58132056|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
58132057|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
58132058|NCT00954915|BIOLOGICAL|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
58132059|NCT06375408|DEVICE|Real transcranial alternating electrical stimulation|The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
58473273|NCT00687193|DRUG|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
58132060|NCT06375408|DEVICE|Sham transcranial alternating electrical stimulation|The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
58132061|NCT06210269|DRUG|Moxifloxacin 400mg|Oral antibiotic
58132062|NCT06210269|OTHER|Placebo|Oral placebo
58132063|NCT01317927|DRUG|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
58132064|NCT03179345|DRUG|Gabapentin|
58132065|NCT03179345|DRUG|Pregabalin|
58132066|NCT03179345|OTHER|Placebo|
58132067|NCT01601678|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
58132068|NCT01601678|PROCEDURE|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
58132069|NCT02404948|OTHER|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
58473274|NCT02030808|DRUG|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
58473275|NCT02030808|DRUG|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
58473276|NCT05888038|DEVICE|virtual reality|virtual reality
58490879|NCT05532306|DRUG|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
58490880|NCT05532306|DRUG|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
58490881|NCT04444440|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic.
58132070|NCT05226169|DRUG|Ferinject|"* Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~* Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin \< 100 ng/mL or TSAT \< 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
58132071|NCT05226169|OTHER|Conservative management|"* Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~* If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
58132072|NCT05436002|DEVICE|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
58132073|NCT04462458|DEVICE|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
58132074|NCT04359641|DEVICE|CoMET Display|Display and presentation of predictive monitoring score CoMET
58132075|NCT04753788|DIAGNOSTIC_TEST|PCR|qPCR for T.pallidum
58132076|NCT04753788|DIAGNOSTIC_TEST|LAMP|LAMP assay for T.pallidum
58132077|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
58132078|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
58132079|NCT01826123|DEVICE|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
58132080|NCT01826123|DEVICE|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
58132081|NCT05479630|OTHER|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
58132082|NCT00016419|BIOLOGICAL|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
58132083|NCT00016419|DRUG|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
58132084|NCT01044732|DEVICE|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
58132085|NCT01126736|DRUG|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
58132086|NCT01126736|DRUG|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
58132087|NCT01126736|DRUG|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
58132088|NCT05554653|DIETARY_SUPPLEMENT|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
58132089|NCT05554653|DIETARY_SUPPLEMENT|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
58132090|NCT00352261|DRUG|Esomeprazole|
58132091|NCT00352261|DRUG|Lansoprazole|
58132092|NCT03048500|OTHER|Laboratory Biomarker Analysis|Correlative studies
58132093|NCT03048500|DRUG|Metformin Hydrochloride|Given PO
58132094|NCT03048500|BIOLOGICAL|Nivolumab|Given IV
58132095|NCT05898919|OTHER|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
58132096|NCT05898919|OTHER|Sham acupuncture|Participants will receive sham acupuncture at sham points.
58132097|NCT05898919|DRUG|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
58132098|NCT00683202|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
58132099|NCT00683202|DRUG|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
58132100|NCT01283919|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
58132101|NCT00728949|BIOLOGICAL|IMC-A12 (cixutumumab)|10 mg/kg I.V.
58132102|NCT00728949|DRUG|tamoxifen|Daily 20 mg, oral
58132103|NCT00728949|DRUG|Anastrozole|Daily 1 mg, oral
58132104|NCT00728949|DRUG|Letrozole|Daily 2.5 mg, oral
58132105|NCT00728949|DRUG|Exemestane|Daily 25 mg, oral
58132106|NCT00728949|DRUG|Fulvestrant|Monthly 250 mg, intramuscularly
58132107|NCT04111731|PROCEDURE|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
58132108|NCT04111731|PROCEDURE|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
58132109|NCT04111731|PROCEDURE|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
58132110|NCT04111731|PROCEDURE|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
58132111|NCT04066309|DEVICE|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
58132112|NCT04066309|DEVICE|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
58132113|NCT04066309|DEVICE|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
58132114|NCT04066309|DEVICE|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
58132115|NCT04999553|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
58132116|NCT04999553|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
58132117|NCT04999553|DEVICE|Low Frequency Right (LFR)|Low Frequency Right (LFR)
58132118|NCT03401112|DRUG|IMR-687|Oral administration of IMR-687 once daily with or without HU.
58132119|NCT03401112|DRUG|Placebo|Oral administration of placebo once daily with or without HU.
58132120|NCT02183064|DRUG|Meloxicam|
58132121|NCT02183064|DRUG|NSAID|
58132122|NCT02097290|DEVICE|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
58132123|NCT01578837|DIETARY_SUPPLEMENT|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
58132124|NCT01578837|DIETARY_SUPPLEMENT|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
58132125|NCT00463606|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
58132126|NCT00463606|DRUG|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
58132127|NCT00463606|DRUG|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
58132128|NCT04205942|DEVICE|Argon Plasma Jet|Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
58132129|NCT04205942|DEVICE|Placebo|Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
58132130|NCT03681509|DRUG|Pramipexole|Pramipexole
58132131|NCT03681509|DRUG|Placebo|Lactose placebo capsule
58132132|NCT03865654|OTHER|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
58490882|NCT04444440|OTHER|Placebo Pill|Placebo Pill
58132133|NCT04461665|OTHER|vitamin D|vitamin D supplement 10 μg daily for 2 months
58132134|NCT01288664|DRUG|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
58132135|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
58132136|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
58132137|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
58132138|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
58132139|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
58132140|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
58132141|NCT03542422|DRUG|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
58132142|NCT02122796|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
58132143|NCT05261685|PROCEDURE|Single-step transepithelial PRK|Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
58490883|NCT04213248|DRUG|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
58490884|NCT01417377|DRUG|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
58132144|NCT00000588|DRUG|Chelation therapy|After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
58132145|NCT00000588|OTHER|Placebo|Placebo given at same time points as the Intervetnion for each clinical condition.
58132146|NCT04112030|DIAGNOSTIC_TEST|Digital image analysis|
58132147|NCT00113425|DEVICE|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
58132148|NCT02480764|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
58132149|NCT02480764|DRUG|Valsartan|Valsartan 80 mg capsules
58132150|NCT02480764|DRUG|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
58132151|NCT02480764|DRUG|Valsartan Placebo|Valsartan placebo-matching capsules
58132152|NCT05916664|BEHAVIORAL|Kinto Care Coaching|Describe the basics of the intervention
58132153|NCT00003797|BIOLOGICAL|trastuzumab|
58132154|NCT00003797|DRUG|gemcitabine hydrochloride|
58132155|NCT00921336|DRUG|KW-2450|Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
58132156|NCT03386422|BEHAVIORAL|MSC|Mindfulness and Self-Compassion training
58132157|NCT03386422|BEHAVIORAL|CBT|Cognitive-behavioural techniques training
58132158|NCT04370665|DEVICE|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
58132159|NCT05540509|BEHAVIORAL|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
58132160|NCT05540509|BEHAVIORAL|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
58132161|NCT00890877|DRUG|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
58132162|NCT05750680|DRUG|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
58132163|NCT05993156|DEVICE|modified Fixed twinblock|modified fixed twin block functional appliance, with cemented bands on the first molars
58132164|NCT05993156|DEVICE|removable twin block|Conventional Removable Clark twin block myofunctional appliance
58132165|NCT01199861|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
58132166|NCT01199861|DRUG|Placebo|Matching placebo capsules for oral administration.
58132167|NCT01199861|BIOLOGICAL|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
58490885|NCT01235741|DRUG|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
57784560|NCT04126473|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
57784561|NCT04126473|DRUG|Ivacaftor|CFTR potentiator
58132168|NCT01199861|BIOLOGICAL|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
58132169|NCT00193037|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin
58132170|NCT00193037|DRUG|Docetaxel|Docetaxel
58132171|NCT01919190|DRUG|EXPAREL|TAP with EXPAREL
58132172|NCT01919190|DRUG|Placebo|Placebo
58132173|NCT01740661|OTHER|Cryotherapy|The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
58132174|NCT01740661|OTHER|Control|The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
58132175|NCT01520948|BEHAVIORAL|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
58132176|NCT01520948|BEHAVIORAL|Behavioral control|Mirrored star drawing
58132177|NCT02523105|DEVICE|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
58132178|NCT02707848|OTHER|No intervention|
58132179|NCT04638153|BIOLOGICAL|Recifercept|Recifercept
58132180|NCT00721604|DRUG|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
58132181|NCT03925870|DRUG|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
58132182|NCT03354026|DRUG|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
58132183|NCT03354026|DRUG|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
58132184|NCT03354026|DRUG|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
58132185|NCT03156062|DRUG|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
57779505|NCT04130711|OTHER|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
57779506|NCT04130711|OTHER|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
57779507|NCT04130711|OTHER|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
57779508|NCT01714596|OTHER|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
57779509|NCT02341911|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
57779510|NCT02341911|DRUG|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
57779511|NCT03979261|DIAGNOSTIC_TEST|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
57779512|NCT02360839|DEVICE|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
57779513|NCT06418958|DEVICE|Red Light|Light Curing with Red Light
57779514|NCT06418958|DEVICE|Blue Light|Light Curing with Blue Light
57779515|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Active DBS Therapy
57779516|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Implanted system but no stimulation
57779517|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization|Imaging, blood tests, LV pressure measurement
57779518|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)|Imaging and Blood tests
57779519|NCT00643500|DRUG|Levetiracetam|
57779520|NCT00351923|BIOLOGICAL|MeMuRu-OKA (study vaccine)|
57779521|NCT06223477|OTHER|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
57779522|NCT06223477|OTHER|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
57779523|NCT06691282|OTHER|Mindful self-compassion intervention|Participants will receive six weekly sessions of training by a trainer in mindful self-compassion (MSC). Each session lasting around 90 minutes and will be conducted face-to-face at the Hong Kong Metropolitan University. The content of the intervention will include an introduction of mindfulness and self-compassion, practice of body awareness and loving kindness, skills to deal with challenging experiences, and methods for relating to positive aspects of the self.
57779524|NCT01813032|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
57779525|NCT01813032|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
57779526|NCT00075569|BIOLOGICAL|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
57779527|NCT02427555|OTHER|Barley kernel bread|3 days intervention with barley kernel bread
57779528|NCT02427555|OTHER|white wheat bread|3 days intervention with white wheat bread
57779529|NCT04902170|PROCEDURE|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
57779530|NCT02369315|BEHAVIORAL|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
58132186|NCT03654625|BEHAVIORAL|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
58132187|NCT03654625|BEHAVIORAL|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
58132188|NCT03654625|BEHAVIORAL|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
58132189|NCT06150976|BEHAVIORAL|MAAT-YS|MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
58132190|NCT03970564|DIAGNOSTIC_TEST|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
58132191|NCT01806688|OTHER|gluten-free high protein snack #1|buckwheat groats 30g serving
58132192|NCT01806688|OTHER|gluten-free snack with similar energy density but 1/2 the protein as snack #1|32g serving of corn nuts
58132193|NCT01806688|OTHER|non-caloric control|water
58132194|NCT01806688|OTHER|gluten-free high protein and high fibre snack #2|buckwheat and pinto bean flour pita bread 50g serving
58132195|NCT01806688|OTHER|gluten-free snack with similar energy density, but less protein and fibre than snack #2|50g serving of rice bread
58132196|NCT04003090|DRUG|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
58132197|NCT02330848|DIETARY_SUPPLEMENT|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
58132198|NCT02330848|DIETARY_SUPPLEMENT|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
58132199|NCT00119886|DRUG|Botulinum toxin|
58132200|NCT05290181|OTHER|A support program with pilates exercise and whatsapp text message|Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
58132201|NCT06227247|BEHAVIORAL|Meals4Moms Intervention|A community-based, healthy living program including continued gestational diabetes (GDM) education, physical activity level monitoring, and delivery of medically-tailored GDM meals for the management of gestational diabetes in pregnant people.
58132202|NCT02019810|DRUG|Norepinephrine|
58132203|NCT02019810|DRUG|Dobutamine and norepinephrine|
58132204|NCT04448223|DRUG|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
58132205|NCT04448223|DRUG|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
58132206|NCT02786030|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
58132207|NCT02786030|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
58132208|NCT01720264|DRUG|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
58132209|NCT03437148|DEVICE|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
58132210|NCT03437148|DEVICE|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
58473277|NCT06473064|OTHER|Benelli technique for nipple sparing mastectomy in surgical treatment of grade 3 and 4 gynecomastia|".The Nipple areola complex (NAC )margins on both sides are marked as circular. -Around the initial circle, a second circle (external) was drawn 1 cm broader than the boundary.~* The skin was resected, with deepithelialization between the two circles.~* A transdermal incision was made through the border of the external circle.~  -. The breast tissue around the pedicle was lifted over the pectoral fascia and excised by preserving the NAC and the underlying breast pedicle~* The base of the mammary pedicle under the NAC was infixed at the farthest end of the mastectomy area by using 3/0 absorbable multifilament suture material~  * Hence, the space formed after mastectomy was filled with a breast pedicle located posterior to the NAC.~ * The closure of the circular deepithelialized area around the NAC with a diameter of 1 cm accomplished by using 4/0 absorbable monofilament suture material and the surgery was completed"
58473278|NCT06587958|DIETARY_SUPPLEMENT|Fermented plant-based foods|Participants will daily consume five different types of fermented plant-based foods, in addition to their habitual diet.
58490886|NCT01235741|DRUG|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
58132211|NCT04534010|DEVICE|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
58132212|NCT02767232|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
58132213|NCT02767232|DRUG|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
58132214|NCT02916290|DRUG|Fuzhenghuayu|
58132215|NCT02916290|DRUG|UDCA|
58132216|NCT03185065|DRUG|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
58132217|NCT03185065|DRUG|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
58132218|NCT03185065|DRUG|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
58132219|NCT03185065|DRUG|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
58132220|NCT05459727|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
58132221|NCT05459727|PROCEDURE|Control periodontal treatment|Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
58132222|NCT00045877|DRUG|Recombinant Human Interleukin-2 and Rituximab|
58132223|NCT00318994|DRUG|Meropenem|
58132224|NCT00766688|DRUG|AVE5530|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
58132225|NCT00766688|DRUG|Placebo|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
58132226|NCT01626079|DEVICE|MitraClip System|Percutaneous mitral valve repair using MitraClip System
58132227|NCT05293054|OTHER|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
58132228|NCT06015126|DRUG|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
58132229|NCT03604419|DRUG|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
58132230|NCT03604419|DRUG|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
58132231|NCT03604419|DRUG|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
58132232|NCT03604419|DRUG|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
58132233|NCT02448927|DEVICE|balloon aortic valvuloplasty|
58132234|NCT02448927|DEVICE|Transcatheter Aortic Valve Implantation|
58132235|NCT04247308|OTHER|Sensory Stimulation|Auditory, tactile, visual, vestibular and oro motor stimulation
58132236|NCT04247308|OTHER|Movement therapy|Passive range of movements, antigravity movements in prone and supine
58132237|NCT04247308|OTHER|Routine hospital care|Maintaining the vitals
58132238|NCT01494506|DRUG|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"
58132239|NCT01494506|DRUG|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
58132240|NCT01494506|DRUG|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
58132241|NCT00553280|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
58132242|NCT03806439|OTHER|Radical cystectomy.|Adult patients undergoing radical cystectomy.
58132243|NCT04219566|DEVICE|VeNS|Non-invasive electrical vestibular nerve stimulation
58473279|NCT06587958|DIETARY_SUPPLEMENT|Non-fermented plant-based foods|Participants will daily consume five different types of non-fermented plant-based foods, in addition to their habitual diet.
58473280|NCT06587958|OTHER|Habitual diet|Participants will follow their habitual diet.
58473281|NCT02928887|OTHER|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
58473282|NCT02199002|DEVICE|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
58132244|NCT04219566|DEVICE|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
58132245|NCT02270970|BIOLOGICAL|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
58132246|NCT00738803|PROCEDURE|Total hip replacement|Total hip replacement typically preformed for hip arthritis
58132247|NCT03169348|DRUG|sofosbuvir daclatasvir|oral tablets
58132248|NCT03169348|DRUG|Ledipasvir/sofosbuvir|oral tablets
58132249|NCT03933956|DRUG|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
58132250|NCT01190748|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
58490887|NCT03573271|DEVICE|MCD|Micro-coring skin removal with automated coring device
58132251|NCT01190748|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
58132252|NCT04734288|DIETARY_SUPPLEMENT|Vit.D3 5000 IU, Immune Active|"The subjects will receive monthly (for either 3 or 6 months):~1. Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.~2. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.~3. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire."
58132253|NCT03255148|DRUG|Oxytocin|Syntocinon nasal spray
58132254|NCT03255148|DRUG|Placebo|Placebo nasal spray
58132255|NCT00006106|DRUG|cisplatin|
58132256|NCT00006106|DRUG|fluorouracil|
58132257|NCT00006106|DRUG|ONYX-015|
58132258|NCT03893539|DEVICE|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
58132259|NCT03405402|PROCEDURE|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
58132260|NCT01465477|BIOLOGICAL|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
58132261|NCT01465477|BIOLOGICAL|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
58132262|NCT00677196|DEVICE|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
58132263|NCT00677196|DEVICE|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
58132264|NCT03157622|BEHAVIORAL|Exposure in vivo|10 sessions based on an individualized fear hierarchy
58473283|NCT05715931|DRUG|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
58473284|NCT05715931|DRUG|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
58132265|NCT03157622|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
58132266|NCT00264797|DRUG|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
58132267|NCT00264797|DRUG|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
58132268|NCT02402348|DRUG|Metformin|
58132269|NCT02079753|DEVICE|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
58132270|NCT02079753|DEVICE|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
58132271|NCT04172649|OTHER|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
58132272|NCT04172649|OTHER|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
58132273|NCT03370068|OTHER|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
58132274|NCT03370068|OTHER|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
58132275|NCT05991726|OTHER|Other: Survey|Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
58132276|NCT04867252|DRUG|Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)|51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
58132277|NCT04867252|DRUG|Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)|51 Patients with PCOS receiving Metformin and Pioglitazone 500 mg and 15 mg BD daily respectively
58132278|NCT06484933|BEHAVIORAL|Focus groups of health professionals and users of primary care|"2 phases of Focus Group will be organized :~* the participants of the first 4 Focus Groups will propose an operational definition of the notion of a professional team in primary care (validation by consensus based on the definitions in the literature)~* 12 subsequent Focus Groups will be organized in 12 primary care teams to describe the ways in which risks are managed in primary care"
58132279|NCT00002994|BIOLOGICAL|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
58132280|NCT00002994|BIOLOGICAL|rhuMAb|90 min IV infusion day 7 of each cycle
58473285|NCT05715931|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
58473286|NCT05978193|RADIATION|LDRT+CFRT|"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"
58473287|NCT05978193|DRUG|Immunotherapy|PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
58473288|NCT05978193|DRUG|Chemotherapy|Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
58473289|NCT02524925|PROCEDURE|fast track protocol|Evaluation of postoperative stress
58132281|NCT03299296|DRUG|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
57779531|NCT02369315|BEHAVIORAL|Control (Invited entry 2013)|Entry to music program offered in September 2013
58473290|NCT05473364|DRUG|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
58473291|NCT06284265|DRUG|Raphamin|Tablet for oral use.
58473292|NCT06284265|DRUG|Placebo|Tablet for oral use.
58473293|NCT05387239|DRUG|VL-PX10 and VL-P22 plus standard care|The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
58473294|NCT05387239|DRUG|Placebo|Saline plus standard care
58473295|NCT06596915|DRUG|BA1302|BA1302 administered intravenously
58490888|NCT03777891|COMBINATION_PRODUCT|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
57779532|NCT06712121|DRUG|decitabine plus venetoclax|decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
58473296|NCT06601361|DEVICE|Fibroscan|Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.
58473297|NCT03904849|DRUG|Cannabidiol|Cannabidiol oral solution
58473298|NCT03904849|DRUG|Placebo|Placebo oral solution
58473299|NCT04137068|BEHAVIORAL|Reduced Activity|Participants reduce their activity level to \<5,000 steps/day and \<50 % of baseline steps.
58473300|NCT03205423|DRUG|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
58473301|NCT06603350|OTHER|No intenvention|No intenvention
58473302|NCT06001047|PROCEDURE|Group A|Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
58473303|NCT06001047|DRUG|Group B|"The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol."
58473304|NCT06592807|OTHER|Perioperative Warm Socks|The socks to be used in the study were provided by the researcher. The socks were suitable for foot sizes 36-45. The socks were white and made of cotton fabric. The socks were sterilized in an autoclave before use. The socks were put on the patients just before the surgery. The socks were heated to 40 degrees with an intravenous fluid warming machine.The socks remained on the patients feet throughout the surgery. After the surgery, the patients socks were removed and new heated socks were put on. The socks were kept on the patients feet for 1 hour. All socks were used for single use.
58473305|NCT06595901|OTHER|Actigraph|Participants will wear an Actigraph hip-worn accelerometer on their non-dominant hip during all waking hours, and on the wrist while sleeping
58473306|NCT06595901|OTHER|Questionnaires|"* Patient Health Questionnaire Anxiety and Depression Scale30 (PHQ-ADS), a validated composite of anxiety and depressive symptoms.~* Self-reported cognition will be assessed by the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog)."
58473307|NCT06595901|OTHER|BrainBaseline application|Objective measures of cognitive function will include those from the BrainBaseline application, a validated research tool developed by Digital Artefacts to remotely measure domains of cognition
58473308|NCT06595901|OTHER|Semi-structured interviews|Semi-structured individual interviews will be conducted with up to 15 healthcare stakeholders and 15-30 patients with breast cancer at any time during the study period, as determined by participant preference.
58473309|NCT00100971|DRUG|autologous tumor cell vaccine|
58473310|NCT00100971|DRUG|therapeutic autologous dendritic cells|
58473311|NCT00100971|PROCEDURE|tumor cell-derivative vaccine therapy|
58473312|NCT06541574|DRUG|Methotrexate Injection|Methotrexate injection
58473313|NCT06541574|DRUG|Methotrexate Infusion|Methotrexate Infusion
58473314|NCT06541574|DRUG|Sham Injection|Sham Injection
58473315|NCT03760718|DRUG|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
58473316|NCT03760718|DRUG|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
58473317|NCT03760718|DRUG|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
58473318|NCT02102646|DRUG|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
58473319|NCT02102646|PROCEDURE|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
58473320|NCT03696836|DEVICE|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
58473321|NCT05030272|DEVICE|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
58473322|NCT05030272|BEHAVIORAL|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
58473323|NCT05030272|DRUG|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
58473324|NCT05030272|BEHAVIORAL|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
58473325|NCT05030272|DRUG|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
58473326|NCT05030272|DRUG|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
58473327|NCT04225195|DRUG|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
58473328|NCT04735471|GENETIC|ADI-001|Anti-CD20 CAR-T
58473329|NCT04735471|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
58473330|NCT04735471|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
58473331|NCT05540132|DIETARY_SUPPLEMENT|maltodextrin|Pre-exercise carbohydrate, fast-acting
58473332|NCT05540132|DIETARY_SUPPLEMENT|super starch|Pre-exercise carbohydrate, slow-acting
58473333|NCT05106647|BEHAVIORAL|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
58473334|NCT06599723|DRUG|Conventional lumbar steroid injections|Patients will receive conventional lumbar steroid injections.
58473335|NCT06599723|PROCEDURE|Racz catheter|Patients will receive lumbar epidural steroid using Racz catheter.
58473336|NCT06591520|DRUG|AK112, Gemcitabine, Cisplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
58473337|NCT06591520|DRUG|Durvalumab, Gemcitabine, Cisplatin|Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
58473338|NCT02623972|DRUG|Eribulin|administered IV for 4 cycles
58132282|NCT03299296|DRUG|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
58132283|NCT02391064|BEHAVIORAL|Cognitive evaluation|"* Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test"
58132284|NCT02391064|BEHAVIORAL|Expanded Disability Status Scale (EDSS) score|- EDSS score
58473339|NCT02623972|DRUG|Adriamycin|administered IV with cyclophosphamide for 4 cycles
58473340|NCT02623972|DRUG|Cyclophosphamide|administered IV with adriamycin for 4 cycles
58473341|NCT06597409|OTHER|Standard PR|(Aerobic exercise, PLB, ACBT, Education)
58473342|NCT06597409|OTHER|Standard PR plus Respiratory Muscle Stretching (RMS)|Standard PR plus Respiratory Muscle Stretching (RMS)
58473343|NCT05233189|OTHER|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
58473344|NCT05233189|OTHER|No intervention|Patients will be followed up until 18 months only
58473345|NCT06596122|DRUG|Vitamin D (Cholecalciferol )|In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.
58473346|NCT04827407|DEVICE|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
58473347|NCT04959435|OTHER|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
58473348|NCT05277766|DRUG|PIPAC with Nal-IRI|Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
58473349|NCT03446794|OTHER|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
58473350|NCT06588348|DRUG|Steroid treatment|All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.
58473351|NCT06588348|PROCEDURE|Esophageal Manometry|On the final day of Prednisone use, all subjects will undergo esophageal manometry testing to assess for treatment response.
58473352|NCT06588348|OTHER|Survey|All enrolled subjects will be asked to complete follow-up Eckardt and BEDQ surveys.
58473353|NCT00568295|DRUG|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
57779533|NCT02826148|OTHER|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
58132285|NCT03732105|RADIATION|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
58473354|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
58473355|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
58473356|NCT04515251|DIAGNOSTIC_TEST|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
58473357|NCT06046118|DEVICE|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~* 1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~* 2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
58473358|NCT06046118|DEVICE|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
58473359|NCT04967391|PROCEDURE|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
58473360|NCT04799964|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
58473361|NCT04799964|DEVICE|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
58473362|NCT05877924|DRUG|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
58473363|NCT06146907|OTHER|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
58473364|NCT06146907|OTHER|exergaming|Nintendo switch games that involve physical activity by participants to complete
58473365|NCT06244628|DRUG|Iguratimod|Oral administration of Iguratimod, 25mg twice daily
58473366|NCT05511415|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
58473367|NCT05511415|DRUG|Dexmedetomidine|Dexmedetomidine (10-9M to 10-4M)
58473368|NCT06118021|DRUG|HS-20094|Administered SC
58473369|NCT06118021|DRUG|Placebo|Administered SC
58473370|NCT04398433|DRUG|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
58473371|NCT04398433|DEVICE|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
58473372|NCT06589232|OTHER|Food allergy|Threshold dose to pistachio
58473373|NCT05979883|RADIATION|Machine Learning Assisted Radiation (MLAP) RapidPlan|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.
58473374|NCT05979883|RADIATION|Radiation Therapy Standard of Care (SOC)|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.
58473375|NCT05766800|DRUG|Serplulimab|Specified dose on specified days
58473376|NCT05766800|DRUG|Carboplatin|Specified dose on specified days
58473377|NCT05766800|DRUG|Pemetrexed|Specified dose on specified days
58473378|NCT05766800|DRUG|Nab-paclitaxel|Specified dose on specified days
58473379|NCT05766800|DRUG|Liposomal paclitaxel|Specified dose on specified days
58473380|NCT05766800|PROCEDURE|Surgery|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
58473381|NCT05766800|RADIATION|Radiotherapy|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
58473382|NCT06589856|DIETARY_SUPPLEMENT|Placebo|Placebo (300 mL salt water, NaCl) = CTR
58132286|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
58473383|NCT06589856|DIETARY_SUPPLEMENT|LAC5|5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
58473384|NCT06589856|DIETARY_SUPPLEMENT|LAC10|10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
58473385|NCT06589856|DIETARY_SUPPLEMENT|LAC20|20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
58473386|NCT05572255|DRUG|Cenobamate|200 mg Cenobamate Tablet
58473387|NCT04050358|DIETARY_SUPPLEMENT|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
58473388|NCT04050358|DIETARY_SUPPLEMENT|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
58473389|NCT05227196|DRUG|Semaglutide D Dose 1|Tablet given orally
58473390|NCT05227196|DRUG|Semaglutide D Dose 2|Tablet given orally
58132287|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
58132288|NCT00674999|DRUG|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
58132289|NCT04343690|BEHAVIORAL|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
58132290|NCT02707653|DRUG|Misoprostol|400 mcg sublingual misoprostol
58132291|NCT00583700|DRUG|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
58132292|NCT00583700|DRUG|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
58132293|NCT00212069|DRUG|gemcitabine, carboplatin|
58132294|NCT05796310|DIAGNOSTIC_TEST|Salivary collection|Collection of saliva via swab for miRNA processing
58132295|NCT05796310|DIAGNOSTIC_TEST|eye-tracking recorder|Administration of eye-tracking session recording Saccadic Eye Movements, fixation duration and pupillary response.
58132296|NCT05796310|DIAGNOSTIC_TEST|neuropsychological assessment|Administration of neuropsychological tests and collected patient medical history
58132297|NCT04855786|PROCEDURE|Thoracic duct drainage|drain placement into the thoracic duct
58132298|NCT02433678|DRUG|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
58132299|NCT02433678|DRUG|Placebo|
58132300|NCT02170688|DRUG|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
58132301|NCT02170688|OTHER|Weight calculation|
58132302|NCT05951049|DRUG|AT02|Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
58132303|NCT01997203|DRUG|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
58132304|NCT06059326|DRUG|HSK7653 10 mg|Tablet, HSK7653 10 mg Q2W, 12 weeks
58132305|NCT06059326|DRUG|HSK7653 25 mg|Tablet, HSK7653 25 mg Q2W, 12 weeks
58132306|NCT06059326|DRUG|HSK7653 50 mg|Tablet, HSK7653 50 mg Q2W, 12 weeks
58132307|NCT06059326|DRUG|Placebo|Tablet, 0 mg Q2W, 12 weeks
58473391|NCT05227196|DRUG|Semaglutide D Dose 3|Tablet given orally
58473392|NCT05227196|DRUG|Semaglutide Dose 4|Tablet given orally
58132308|NCT01740609|DRUG|Placebo|Placebo
58132309|NCT01740609|BIOLOGICAL|PF-06342674 Dose A|Single SC Dose
58132310|NCT01740609|BIOLOGICAL|PF-06342674 Dose B|Single SC Dose
58132311|NCT01740609|BIOLOGICAL|PF-06342674 Dose C|Single SC Dose
58132312|NCT01740609|BIOLOGICAL|PF-06342674 Dose D|Single SC Dose
58132313|NCT01740609|BIOLOGICAL|PF-06342674 Dose E|Single SC Dose
58132314|NCT01740609|BIOLOGICAL|PF-06342674 Dose F|Single IV Dose
58132315|NCT01740609|BIOLOGICAL|PF-06342674 Dose G|Single SC Dose
58132316|NCT01740609|BIOLOGICAL|PF-06342674 Dose H|Single IV Dose
58132317|NCT01740609|BIOLOGICAL|PF-06342674 Dose I|Single SC Dose
58132318|NCT01740609|BIOLOGICAL|PF-06342674 Dose J|Single IV Dose
58132319|NCT02716025|PROCEDURE|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
58132320|NCT05372666|OTHER|Standard white bread|Bread to be consumed within 10 minutes after 10h fasting
58132321|NCT05372666|OTHER|Experimental white bread|Bread to be consumed within 10 minutes after 10h fasting
58132322|NCT05372666|OTHER|Standard High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
58132323|NCT05372666|OTHER|Experimental High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
58132324|NCT04852003|DRUG|SHR0410 Injection|SHR0410 Injection
58132325|NCT04852003|DRUG|Placebo|Placebo for SHR0410 Injection
58132326|NCT04852003|DRUG|Morphine|Morphine
58132327|NCT03553160|OTHER|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
58132328|NCT00201305|DRUG|Gemcitabine+5FU+Leucovorin|
58132329|NCT01490944|DRUG|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
58132330|NCT01490944|DRUG|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
58132331|NCT06083337|DEVICE|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
58132332|NCT05865639|BEHAVIORAL|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
58132333|NCT05865639|BEHAVIORAL|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
58132334|NCT00414531|DRUG|Atorvastatin|20 to 80 mg per day
58132335|NCT03831048|DEVICE|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
58132336|NCT03831048|OTHER|Cold Storage|Active comparator intervention
58473393|NCT05227196|DRUG|Semaglutide Dose 5|Tablet given orally
58473394|NCT05227196|DRUG|Semaglutide Dose 6|Tablet given orally
58473395|NCT03844750|PROCEDURE|Hepatectomy|Undergo liver resection.
58473396|NCT03844750|BIOLOGICAL|Pembrolizumab|Given IV
58473397|NCT03844750|DRUG|Vactosertib|Given orally
58473398|NCT06598527|RADIATION|Stereotactic body radiotherapy (SBRT)|"Radiation source: 6MV photon linear gas pedal is used. Position immobilization: supine position, hands up, vacuum bag or styrofoam immobilization.~Radiotherapy plan design: 4DCT positioning, radiotherapy plan design at 20% respiratory time-phase CT, isocentric irradiation, IMRT or VMAT design.~Definition of target area:~Gross tumor volume (GTV) includes the primary tumor in the lung, excluding lymph nodes. Internal target volume (ITV); Internal target volume (ITV) is formed by the fusion of 10 respiratory phases of GTV; Planning target volume (PTV) is formed by expanding the ITV by 0.5 cm in all directions."
58473399|NCT06598527|DRUG|Tislelizumab|PD-L1 inhibitor
58473400|NCT06598527|DRUG|Chemotherapy|platinum-based double-agent chemotherapy
58132337|NCT02115646|DEVICE|fractionated carbon dioxide laser|patients will have serial laser treatments
58132338|NCT03057392|OTHER|immersion|participants will sit in a 34-35C while receive dialysis
58132339|NCT03057392|OTHER|sham session|dialysis while sitting in the dialysis chair
58132340|NCT02154321|DEVICE|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
58132341|NCT00275353|BEHAVIORAL|Individualized Symptom Education|
58132342|NCT05799781|DEVICE|MPC closed-loop system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled.
58132343|NCT05799781|DEVICE|t:slim X2 pump with Dexcom G6 CGM and Control IQ|The t:slim pump is a hybrid closed-loop system available to consumers for automated insulin delivery. Control IQ technology automatically adjusts insulin levels based on continuous glucose monitoring (CGM) readings from Dexcom G6.
58132344|NCT03299400|DEVICE|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
58132345|NCT05556109|DIAGNOSTIC_TEST|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
58132346|NCT02689297|OTHER|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
58132347|NCT02689297|OTHER|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
58132348|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
58132349|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
58132350|NCT00591643|PROCEDURE|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
58473401|NCT05814666|DRUG|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
58473402|NCT05814666|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
57779534|NCT02933190|PROCEDURE|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
58132351|NCT00591643|RADIATION|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
58473403|NCT06409533|OTHER|Rate control|Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
58473404|NCT05569408|DRUG|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
58473405|NCT06117605|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
58473406|NCT06117605|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
58473407|NCT04097938|DRUG|GLPG3667 oral suspension|GLPG3667 oral suspension
58473408|NCT04097938|DRUG|Placebos|Placebo oral suspension
58473409|NCT04097938|DRUG|GLPG3667 capsules|GLPG3667 capsules
58473410|NCT02854345|DEVICE|Tomoscintigraphic parathyroid imaging on a CZT camera|
58473411|NCT05360004|DRUG|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
58473412|NCT04089748|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
57779535|NCT00101569|DRUG|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
57779536|NCT00101569|DRUG|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
57779537|NCT00014690|DRUG|plevitrexed|
58473413|NCT04907357|DEVICE|rTMS|Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
58473414|NCT04907357|DEVICE|Sham (Placebo)|Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
58473415|NCT00495196|PROCEDURE|Experimental lung function test|Administration of several CO2 gas mixtures
58473416|NCT05994482|OTHER|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
58132352|NCT06315179|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy (EGD) with biopsy|Esophagogastroduodenoscopy (EGD) is a test procedure to examine the lining of the esophagus, stomach, and first part of the small intestine.
58132353|NCT06315179|DIAGNOSTIC_TEST|Colonoscopy w/ biopsy|Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
58132354|NCT05474248|BEHAVIORAL|Experimental group|Diaphragmatic Breathing Training
58132355|NCT02945215|DRUG|IBI301|IBI301 375mg/㎡
58132356|NCT02945215|DRUG|Rituximab|Rituximab 375mg/㎡
58132357|NCT01666730|DRUG|metformin hydrochloride|Given PO
58132358|NCT01666730|DRUG|oxaliplatin|Given IV
58132359|NCT01666730|DRUG|leucovorin calcium|Given IV
58132360|NCT01666730|DRUG|fluorouracil|Given IV
58132361|NCT01666730|OTHER|laboratory biomarker analysis|Correlative studies
58132362|NCT01171690|DRUG|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
58132363|NCT03934073|OTHER|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
58132364|NCT03934073|OTHER|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
58132365|NCT03934073|OTHER|CONTROLE|Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
58132366|NCT01867723|OTHER|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
58132367|NCT05124574|OTHER|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"* nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~* Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~* Sampling of amniotic fluid in case of cesarean section~* Sampling of the placenta for histological and virological study."
58132368|NCT05124574|OTHER|Samples concern newborns of SARS-COV-2 + mothers at birth|"* In the birth room:~  * Collection of gastric fluid (PCR SARS-COV-2),~ * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~* In the newborn at D3 of life:~  - 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~* In symptomatic newborns:~  * 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~ * nasopharyngeal PCR,"
58132369|NCT04276883|DRUG|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
58132370|NCT04276883|DRUG|Placebo Film|Placebo Film for BXCL501
58132371|NCT05735977|DIAGNOSTIC_TEST|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
58132372|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
58132373|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
58132374|NCT01051505|DRUG|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
58132375|NCT01051505|DRUG|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
58473417|NCT05994482|OTHER|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
58490889|NCT06022692|DEVICE|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
58132376|NCT04249973|OTHER|Collection of urine and feces|Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
58132377|NCT00872079|DEVICE|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
58132378|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
58132379|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
58132380|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
58473418|NCT05994482|OTHER|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
58473419|NCT06600594|OTHER|Beginners dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
58473420|NCT06600594|OTHER|Experience dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
58473421|NCT05356897|BIOLOGICAL|Trastuzumab|Given IV
58473422|NCT05356897|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
58473423|NCT05356897|DRUG|Tucatinib|Given PO
58473424|NCT06587243|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
58473425|NCT06587243|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
58473426|NCT04824339|BEHAVIORAL|Immediate Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
58473427|NCT04824339|BEHAVIORAL|Delayed Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
58473428|NCT06288997|DEVICE|Active transcranial alternating current stimulation|Hi-tACS with a current level of 15mA with a patented frequency of 77.5Hz.
58473429|NCT06288997|DEVICE|Sham transcranial alternating current stimulation|The device for the sham group has the same appearance and technical settings as the one used in the active group, designed to produce similar sensations on the scalp, but without effective penetration of the electric field into the brain.
58473430|NCT05954676|OTHER|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
58473431|NCT00976183|DRUG|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
58473432|NCT00976183|DRUG|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
58473433|NCT06397079|BEHAVIORAL|Electric toothbrush|Teach Bass brushing technique and bursh teeth using electric toothbrush dental hygiene three times a day.
58473434|NCT06397079|BEHAVIORAL|Soft bristle toothbrush|Teach Bass brushing technique and bursh teeth using soft bristle toothbrush dental hygiene three times a day.
58473435|NCT04536909|OTHER|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
58473436|NCT04536909|PROCEDURE|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
58473437|NCT05890729|DRUG|XTMAB-16 or Placebo|Infusion
58473438|NCT04544917|BEHAVIORAL|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
58473439|NCT04544917|BEHAVIORAL|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
58473440|NCT06592599|DRUG|Toripalimab|Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.
58473441|NCT06592599|RADIATION|Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation|"Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation."
58473442|NCT05860413|BEHAVIORAL|Intermittent energy restriction (IER)|During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.
57779538|NCT00014690|DRUG|topotecan hydrochloride|
57779539|NCT03821701|DRUG|Entresto|Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
58473443|NCT05860413|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
58473444|NCT06596824|BEHAVIORAL|Training intervention|Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
58473445|NCT03916770|DEVICE|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
58473446|NCT03916770|DEVICE|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
58473447|NCT00274586|DRUG|Aggrenox® modified release capsules|
58473448|NCT00274586|DRUG|Aggrenox® modified release capsules matching placebo|
58473449|NCT03789669|DEVICE|Cheetah femtosecond laser and Cheetah patient interface|Ophthalmic laser surgical system
58473450|NCT03789669|DEVICE|IntraLase iFS iFS femtosecond laser and patient interface|Commercial ophthalmic laser surgical system
58473451|NCT03789669|DEVICE|Cheetah femtosecond laser and cheetah patient interface|Ophthalmic laser surgical system
58473452|NCT06589869|DEVICE|EM Chair|Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
58473453|NCT06589869|OTHER|Standard of care|Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
58473454|NCT02780648|RADIATION|Stereotactic Body Radiation|
58473455|NCT03041519|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
58473456|NCT03041519|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
58473457|NCT03886285|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
58473458|NCT01664975|DRUG|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
58473459|NCT01664975|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
58473460|NCT06442943|BEHAVIORAL|Multi-domain Cognitive Intervention|"* Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly."
58473461|NCT06591273|BIOLOGICAL|Infliximab-dyyb Biosimilar (Remsima)|Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
58473462|NCT06057766|OTHER|Physical activity tele coaching program|"The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented."
58473463|NCT05949736|DEVICE|The Online intervention platform|Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.
58473464|NCT06589843|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
58473465|NCT01849146|DRUG|Adavosertib|Given PO
58473466|NCT01849146|RADIATION|Radiation Therapy|Undergo radiation therapy
58473467|NCT01849146|DRUG|Temozolomide|Given PO
58473468|NCT03515486|OTHER|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
58473469|NCT06587724|OTHER|Questionnaire study|Questionnaire application
58473470|NCT03052829|BEHAVIORAL|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
58473471|NCT03052829|BEHAVIORAL|Usual care|Subjects will undergo their usual care without intervention
58473472|NCT06597721|DRUG|AMT-754|Administered intravenously
58473473|NCT06600347|DIETARY_SUPPLEMENT|DASH diet|The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
58473474|NCT06600347|OTHER|Progressive muscle relaxation|The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
58132381|NCT03213886|DRUG|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
58132382|NCT01214226|DRUG|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
58132383|NCT01214226|DRUG|placebo|prolonged-release tablets 3 time per day for 1 month
58132384|NCT04031300|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
58132385|NCT01548677|DRUG|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
58473475|NCT06600347|DRUG|Anti hypertensive drugs|All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
58473476|NCT06602804|DEVICE|Trima Accel Auto RBC Collection|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.
58473477|NCT06599268|BEHAVIORAL|Survey using a questionnaire.|"Questionnaire to assess the barriers and enablers for women reaching top executive positions in pharmaceutical companies and pharmacies~The following sections will be considered:~* General Characteristics of the Participants~* Work-related characteristics~* Barriers faced by women to reach top executive positions (Likert scale)~* Enablers for women to reach top executive positions (Likert scale)~* Conception of women in the pharmaceutical sector (Likert scale)"
58473478|NCT04880278|DRUG|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
58473479|NCT04880278|DRUG|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
58473480|NCT00003149|BIOLOGICAL|recombinant interleukin-12|
58473481|NCT06588998|DEVICE|Xengenic Cortical membranes|soft tissue surgery around dental implant dehiscence
58132386|NCT00001805|DRUG|Rituximab|
58132387|NCT05669768|DRUG|Pamiparib/Tamoxifen|Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
58132388|NCT05839613|DIAGNOSTIC_TEST|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
58132389|NCT01408966|DIETARY_SUPPLEMENT|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
58132390|NCT01408966|DIETARY_SUPPLEMENT|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
58132391|NCT01653626|OTHER|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
58132392|NCT02715869|DRUG|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
58132393|NCT02715869|PROCEDURE|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
58132394|NCT05670171|PROCEDURE|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
58132395|NCT05670171|PROCEDURE|Stent Angioplasty|Nickel-titanium self-expanding bare stent
58132396|NCT04206644|OTHER|biological analysis|biological analysis of the Concentration of CCL18
58132397|NCT00242346|DRUG|candesartan cilexetil|
58132398|NCT00041808|DRUG|MTC-DOX for Injection|
58132399|NCT00041808|PROCEDURE|Chemotherapy|
58132400|NCT04639765|OTHER|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
58132401|NCT04639765|OTHER|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
58132402|NCT04639765|OTHER|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
58132403|NCT04639765|OTHER|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
58132404|NCT04639765|OTHER|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
58132405|NCT04639765|OTHER|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
58473482|NCT06588998|PROCEDURE|connective tissue graft|soft tissue surgery around dental implant dehiscence
58473483|NCT01278225|BEHAVIORAL|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
58473484|NCT01278225|BEHAVIORAL|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
58473485|NCT01278225|BEHAVIORAL|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
58473486|NCT04868786|DRUG|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
58473487|NCT04526340|DIAGNOSTIC_TEST|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
58473488|NCT04526340|DIAGNOSTIC_TEST|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
58473489|NCT04526340|DIETARY_SUPPLEMENT|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
58473490|NCT04526340|DIAGNOSTIC_TEST|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
58473491|NCT05661643|DRUG|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
58473492|NCT02559453|PROCEDURE|Debridement|Removing dead tissue from infected wounds.
58473493|NCT06106360|DEVICE|Locus Health iPhone App|In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
58473494|NCT04270266|OTHER|Educational Intervention|Attend educational sessions
58473495|NCT04270266|OTHER|Meditation Therapy|Attend meditation sessions
58473496|NCT04270266|OTHER|Questionnaire Administration|Ancillary studies
58473497|NCT06597630|OTHER|Tissue specimens were stained by histopathology of hematoxylin-eosin|Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing
58473498|NCT06588790|OTHER|Home-based rapid testing|Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.
58473499|NCT06588790|OTHER|Community health worker rapid testing|Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.
58473500|NCT06589947|OTHER|Intensified BP control|Treatment goal in the intensified group will be lowering BP ≤60th pct.
58473501|NCT06589947|OTHER|Standard Treatment|Standard treatment is to achieve BP levels \&lt;90th pct.
58473502|NCT06590870|DRUG|Fentanyl|The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
58473503|NCT06590870|DRUG|Normal saline|The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
58473504|NCT05978167|DRUG|Methylphenidate|Oral administration of 20 mg Methylphenidate
58473505|NCT05978167|BEHAVIORAL|Memory reconsolidation|Retrieval of drug-cue memories before extinction.
58132406|NCT03407365|BEHAVIORAL|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
58132407|NCT03407365|BEHAVIORAL|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
58132408|NCT00556127|DRUG|Rituximab|375 mg/m2 on day 1
58132409|NCT00556127|DRUG|Epirubicin|110 mg/m2 on day 3
58132410|NCT00556127|DRUG|Cyclophosphamide|1200 mg/m2 on day 3
58132411|NCT00556127|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
58132412|NCT00556127|DRUG|Prednisone|40 mg/m2 from day 1 to 5
58473506|NCT05978167|DRUG|Placebo|Matching placebo pill
58473507|NCT06589427|OTHER|Invasive ventilation.|Patients were subjected to invasive ventilation.
58473508|NCT06604182|OTHER|Community-based Simplified HCV Testing and Treatment Algorithm|The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
58473509|NCT06595446|PROCEDURE|Early Stent removal|Ureteral JJ stents removed 5-7 days after radical cystectomy and ileal conduit formation
58473510|NCT06595446|PROCEDURE|Late Stent removal|Ureteral JJ stents removed 4-6 weeks after radical cystectomy and ileal conduit formation
58473511|NCT06035159|BEHAVIORAL|online psychotherapy|6 modules
58473512|NCT05981235|BIOLOGICAL|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
58473513|NCT02364700|DEVICE|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)"
58473514|NCT00000827|DRUG|Anti-HIV Immune Serum Globulin (Human)|
58473515|NCT00811590|DRUG|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
58473516|NCT02952508|DRUG|Iopofosine I 131 single dose|Radiopharmaceutical
58473517|NCT02952508|DRUG|Iopofosine I 131 multiple dose|Radiopharmaceutical
58473518|NCT02952508|DRUG|Iopofosine I 131 fractionated dose|Radiopharmaceutical
58473519|NCT03955146|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
58473520|NCT03955146|DRUG|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
58473521|NCT06448559|OTHER|Semi-directive interview|Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis
58473522|NCT06594666|DEVICE|VR/AR visual training group|Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
58473523|NCT03861897|OTHER|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
58473524|NCT03861897|OTHER|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
58473525|NCT03598842|DIETARY_SUPPLEMENT|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
58473526|NCT03598842|DIETARY_SUPPLEMENT|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
58473527|NCT03598842|DRUG|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
58473528|NCT06104462|DEVICE|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10\*3\*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 \* (Dsitex - Dm1). Therefore, 2.8 \* 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
58473529|NCT04272086|DRUG|Bupivacaine|0.25%
58473530|NCT04272086|DRUG|Bupivacaine liposome|10mL
58473531|NCT04272086|DRUG|normal saline|10ml
58473532|NCT05155280|OTHER|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
58473533|NCT05155280|BEHAVIORAL|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
58473534|NCT05742542|OTHER|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
58473535|NCT05766592|BEHAVIORAL|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
58473536|NCT05766592|BEHAVIORAL|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
58473537|NCT02451722|DEVICE|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
58473538|NCT05173194|OTHER|Exercise|Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
58473539|NCT05398172|DEVICE|MorpheusV Applicator|Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
58473540|NCT03481400|DRUG|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
58473541|NCT03481400|OTHER|Placebo|Isotonic saline
58473542|NCT00007254|DRUG|Pain relief for pressure ulcers|
58132413|NCT00556127|DRUG|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
57779540|NCT03821701|DRUG|ACEI/ARB|Choose one of ACEI/ARB according to the clinical condition among the whole study.
58132414|NCT00556127|DRUG|Mitoxantrone|8 mg/m2 for 3-day
58132415|NCT00556127|DRUG|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
58132416|NCT00556127|DRUG|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
58132417|NCT00556127|DRUG|Carmustine BCNU|300 mg/m2 on day -7
58132418|NCT00556127|DRUG|Etoposide|100 mg/m2/12 hours
58473543|NCT06206564|DRUG|Artesunate ointment|Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
58473544|NCT06206564|DRUG|Placebo|Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
58473545|NCT03003026|OTHER|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
58473546|NCT03003026|OTHER|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
58473547|NCT03432676|DRUG|Epacadostat|Given PO
58473548|NCT03432676|BIOLOGICAL|Pembrolizumab|Given IV
58473549|NCT03819192|DIAGNOSTIC_TEST|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
58473550|NCT03819192|DIAGNOSTIC_TEST|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
58473551|NCT03819192|DIAGNOSTIC_TEST|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
58473552|NCT04218526|DEVICE|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
58473553|NCT06429917|OTHER|Subgingival instrumentation|All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
58473554|NCT03724136|PROCEDURE|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
58473555|NCT03724136|PROCEDURE|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
58473556|NCT03724136|PROCEDURE|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
58473557|NCT00055393|DRUG|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
58473558|NCT00055393|DRUG|Placebo|21 subjects received Placebo.
58473559|NCT05635019|BEHAVIORAL|BWL+VOUCHER|This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.
58132419|NCT00556127|DRUG|Melphalan|140 mg/m2 on day -2
58132420|NCT00556127|RADIATION|Radiotherapy|Involved Field Radiotherapy (IF-RT)
58132421|NCT00556127|PROCEDURE|PBSC reinfusion|ASCT
58473560|NCT05635019|BEHAVIORAL|BWL+HOME|This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.
58473561|NCT05635019|BEHAVIORAL|Behavioral weight loss counseling (BWL)|The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
58473562|NCT04410900|BIOLOGICAL|Wistar Rabies Virus Strain PM-1503-3M Vaccine|Given IM
58132422|NCT00448175|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
58473563|NCT04410900|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58473564|NCT03005444|DRUG|Rivaroxaban|10mg/day, for 2 years
58473565|NCT04489173|DRUG|trifluridine/tipiracil|"Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."
57779541|NCT01907074|DRUG|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
58132423|NCT00448175|DRUG|Tolterodine|
58132424|NCT05554770|DIAGNOSTIC_TEST|Examinations in a TRV chair|Positional tests (Dix-Hallpike and SRT) traditionally used to diagnose BPPV uwith a TRV chair.
58473566|NCT06600984|DEVICE|whole body vibration|On a vibration platform, the children went into a complete squat. The device was calibrated at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 minutes. After the vibration was turned on, the children were told to stay in the squatting position and to report any discomfort that could occur. The vibration automatically shut off after five minutes. The children then rested for a minute. Next, under the identical conditions as for the squatting position, they were instructed to stand on the vibration platform for five minutes with the therapist\&#39;s assistance. Consequently, WBV was applied for a total of 10 minutes during each session.
58473567|NCT06600984|OTHER|designed physiotherapy program|structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.
58473568|NCT02456415|DEVICE|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
58473569|NCT05074056|DRUG|Ketorolac|We will administer intraoperative ketorlac.
58473570|NCT03312231|DRUG|AS03|Oil-in-water emulsion based adjuvant system.
58473571|NCT03312231|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
58473572|NCT03312231|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
58473573|NCT05516446|DEVICE|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
58473574|NCT05516446|DEVICE|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
58473575|NCT06431594|DRUG|GSK5733584|GSK5733584 will be administered
58473576|NCT01735422|DRUG|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
58473577|NCT01735422|DRUG|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
58473578|NCT01735422|DRUG|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
58473579|NCT04436354|PROCEDURE|vaginoscopic office hysteroscopy|comparison of procedural time and pain scores of patients in different gynecologycal positions
58473580|NCT06596434|DRUG|Drug: 4-Aminopyridine|Active study drug
58473581|NCT06596434|OTHER|Placebo|Placebo comparator
58473582|NCT06654687|DEVICE|Transthoracic Echocardiography|Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.
58473583|NCT06654687|DRUG|Ringer lactate 1000 ml|Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.
58473584|NCT06654687|DRUG|Albumin|Patients will receive 250 mL of human albumin 5% over 10 minutes
58132425|NCT03538587|BEHAVIORAL|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
58132426|NCT03538587|BEHAVIORAL|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
58473585|NCT06654687|DRUG|Ringer lactate 750 ml|Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.
58132427|NCT01669538|DRUG|Galantamine|
58132428|NCT01669538|DRUG|Placebo|
58473586|NCT06587906|OTHER|Pulmonary ultrasound examination|All ultrasound scans were performed by the same anaesthetists. Pulmonary ultrasound examination was performed at two time points for each patient: 20 min before starting mechanical ventilation of the lungs when patients were placed in the supine position(preoperative), 20 min after after surgery end at the time the patient was placed in the supine position (postoperative), before Intubation and after extubation Patientswere scanned in the supine position following the pulmonary ultrasound examination method The thorax was divided by the anterior axillary line, the posterior axillary line, and a horizontal line beneath nipple. Twelve intercostal spaces of each area were scanned and analysed. Aeration loss was assessedby calculating the modified LUS score that is calculated mainly using the amount of B-line The pulmonary ultrasound score of the hemithorax (0-18).
58473587|NCT05655299|DRUG|VTX958 Dose A|Dose A
58473588|NCT05655299|DRUG|VTX958 Dose B|Dose B
58473589|NCT05655299|DRUG|VTX958 Dose C|Dose C
58473590|NCT05655299|DRUG|VTX958 Dose D|Dose D
58473591|NCT05655299|DRUG|Placebo|Placebo
58473592|NCT06058910|DIAGNOSTIC_TEST|Bilistick System 2.0 point-of-care testing device|The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
58132429|NCT00322257|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
58132430|NCT00322257|DRUG|insulin detemir|Injection s.c., 50% of daily dose
58132431|NCT00322257|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
58473593|NCT04327154|DEVICE|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
58473594|NCT01761877|DRUG|Sulindac|
58473595|NCT06586801|OTHER|Patient-reported outcome|"Patient-reported outcome data will be collected using the following instruments:EORTC QLQ-C30, EORTC QLQ-LC13, selected items from the PRO-CTCAE, EORTC-IL46.~The first collection of the information in questionnaires (EORTC QLQ-C30, EORTC QLQ-LC13, PRO-CTCAE \[select items\]), which defined as baseline- PROs, will be completed at Cycle 1, Day 1±7days prior to administration of study drug; then the rest times of collection will be completed at every two treatment cycle prior to administration of study drug (i.e., on Cycle 3, Day 1±7days; Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days) . EORTC-IL46 will be completed at Cycle 3, Day 1±7days (baseline) prior to administration of study drug; then at every other study treatment cycle prior to administration of study drug (i.e., on Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days)"
58473596|NCT00926237|DEVICE|Sham rTMS - Sham repetitive transcranial magnetic stimulation|Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
58473597|NCT00926237|DEVICE|Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
58473598|NCT00926237|DEVICE|Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
58473599|NCT04379414|BEHAVIORAL|YES portal|A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.
58473600|NCT02839096|DRUG|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
58473601|NCT02839096|DRUG|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
58473602|NCT02941081|DIETARY_SUPPLEMENT|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
58473603|NCT02941081|DIETARY_SUPPLEMENT|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
58473604|NCT02941081|OTHER|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
58473605|NCT06602765|OTHER|Tooth brushing, tooth paste containing 1450ppm fluoride|brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
58473606|NCT05146882|DRUG|Belcesiran|Belcesiran will be administered subcutaneously (SC) in the treatment arm.
58473607|NCT05232682|DIETARY_SUPPLEMENT|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
58473608|NCT02637245|OTHER|No intervention|No intervention
58473609|NCT06592872|BEHAVIORAL|Bullying prevention|The intervention utilizes a serious (educational) videogame and teacher-led, interactive class sessions. Students exposed to the intervention will learn to respond to in-person and online bullying from the perspectives of perpetrator, victim, and bystander. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
58473610|NCT06602687|DEVICE|PICSI|The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).
58473611|NCT00631514|DRUG|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
58132432|NCT01541150|BEHAVIORAL|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
58132433|NCT02396875|PROCEDURE|Blood sampling and exercise protocol pre and post CRT implant|
58473612|NCT00631514|DRUG|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
58473613|NCT00631514|DRUG|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
58473614|NCT05873751|BIOLOGICAL|Trumenba Vaccine|Trumenba vaccine given as standard of care
58473615|NCT05873751|BIOLOGICAL|MenACWY Vaccine|MenACWY Vaccine given as standard of care
58473616|NCT06407726|OTHER|virtual reality training group|Participants will receive 40-minute sessions five days per week for six weeks of Virtual Reality intervention and conventional therapy.
58132434|NCT02396875|PROCEDURE|Peripheral blood sampling|
58132435|NCT02396875|PROCEDURE|Central blood sampling pre and post CRT implant|
58132436|NCT02396875|PROCEDURE|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
58132437|NCT00628888|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
58132438|NCT05129098|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
58132439|NCT05129098|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
58473617|NCT06407726|OTHER|vestibular exercise group|Participants will receive 40-minute sessions five days per week for six weeks of Vestibular Exercises and conventional therapy.
58473618|NCT06604572|PROCEDURE|Transabdominal preperitoneal approach|The enrolled patients underwent either open tension-free hernia repair or Transabdominal preperitoneal approach
58473619|NCT06654804|DRUG|Perflutren lipid|Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
58473620|NCT05701748|OTHER|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
58473621|NCT05076006|DRUG|PF-06700841|Active study drug
58473622|NCT05076006|DRUG|Placebo|placebo comparator
58473623|NCT05462951|RADIATION|Standard|Radiation then brachytherapy
58473624|NCT06292351|DRUG|DMB-I (Dimebon)|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
58473625|NCT06292351|OTHER|Placebo|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
58473626|NCT01977547|BIOLOGICAL|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
58473627|NCT01033019|DRUG|LDE225 0.75%|0.75% cream
58473628|NCT01033019|DRUG|Vehicle|matching placebo cream to 0.75% LDE225 cream
58473629|NCT03003325|DRUG|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
58473630|NCT03003325|PROCEDURE|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
58473631|NCT03003325|DRUG|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
58473632|NCT05856721|DIAGNOSTIC_TEST|stool analysis|"Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients."
58473633|NCT06326411|DRUG|NST-628|NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
58473634|NCT00736541|DRUG|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
58473635|NCT04701827|COMBINATION_PRODUCT|AWARE intervention|Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
58473636|NCT05908916|DRUG|AtezoBev with combined radiotherapy|Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.
58473637|NCT05601232|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
58473638|NCT06290336|OTHER|Pre-operative exercise therapy and education|Pre-operative supervised exercise therapy consisting of individualized strength, mobility and balance exercises and continuous education through individual discussions of expectations of post-operative recovery, pain and swelling, course of rehabilitation, long term function and activity level etc. Twice a week, approximately one hour/session.
58473639|NCT06290336|OTHER|Standardized pre-operative information session|As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.
58473640|NCT02876510|DRUG|Fludarabine|Fludarabine infusion
58132440|NCT03772496|DIAGNOSTIC_TEST|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
58473641|NCT02876510|DRUG|Cyclophosphamide|Cyclophosphamide infusion
58473642|NCT02876510|BIOLOGICAL|IMA101 product|i.v. infusion of IMA101 product(s).
58473643|NCT02876510|BIOLOGICAL|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
58473644|NCT02876510|DIAGNOSTIC_TEST|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
58473645|NCT02876510|DRUG|Atezolizumab|Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
58473646|NCT06592326|DRUG|9MW2821|9MW2821, 1.25mg/kg, intravenous (IV) infusion
58473647|NCT06592326|DRUG|Toripalimab|Toripalimab, 240mg, intravenous (IV) infusion
58473648|NCT06592326|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, intravenous (IV) infusion
58473649|NCT06592326|DRUG|Cisplatin/Carboplatin|Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
58473650|NCT03589846|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
58473651|NCT02345447|DRUG|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
58473652|NCT02345447|DRUG|Placebo|Aqueous ethanol solution non-distinguishable from verum
58473653|NCT06236802|DEVICE|ProVee device|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
58473654|NCT04732312|OTHER|Home help|Setting up of a formal home help
58473655|NCT02891447|DRUG|Cisplatin|Given intraperitoneally
58473656|NCT02891447|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
58473657|NCT02891447|DRUG|Mitomycin|Given intraperitoneally
58473658|NCT06218056|DRUG|Cannabidiol (CBD) 400 mg or 800 mg|CBD (200 mg or 400 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
58473659|NCT06218056|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 56 days.
58473660|NCT03036098|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
58473661|NCT03036098|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
58473662|NCT03036098|DRUG|Gemcitabine|Specified Dose on Specified Days
58473663|NCT03036098|DRUG|Cisplatin|Specified Dose on Specified Days
58473664|NCT03036098|DRUG|Carboplatin|Specified Dose on Specified Days
58473665|NCT02388269|DEVICE|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
58473666|NCT04383600|PROCEDURE|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
58473667|NCT04692064|OTHER|There is no intervention|There is no intervention
58473668|NCT06591156|PROCEDURE|Root coverage|"Treatment of gingival recession, Miller\&#39;s Class I or Cairo\&#39;s RT1, which is the most predictable group to receive interventions without any impairment or problem for the patients.~After local anesthesia, a horizontal incision was made, delimitating the coronal part of the flap. This horizontal incision of the envelope flap consists of an oblique submarginal incision in the interdental areas that creates a surgical papilla. The incisions continue with the intrasulcular incision in the recession defects and are extended to form an envelope flap between the central and molar. This design facilitates the planned coronal repositioning of the flap tissue on the exposed root surfaces.~The apical gingival tissue at root exposures is raised to a full thickness to provide the critical part of the flap for root coverage with more thickness. Finally, the most apical portion of the flap is elevated in a split-thickness to facilitate coronal displacement of the flap."
58473669|NCT06591156|PROCEDURE|control group|Coronally advanced flap without any graft or biomaterial
58473670|NCT06600698|DRUG|INM176|The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.
58473671|NCT02723708|OTHER|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
58473672|NCT02105740|BEHAVIORAL|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
58473673|NCT02105740|BEHAVIORAL|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
58473674|NCT03365102|DEVICE|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
58473675|NCT03365102|DEVICE|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
58490890|NCT06022692|DRUG|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
58490891|NCT00818701|DRUG|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
58473676|NCT03365102|DEVICE|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
58473677|NCT06584968|OTHER|training with visual feedback|Training with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams.
58473678|NCT06584968|OTHER|classical learning|Study of the test with practical applications on the researcher who plays the role of the patient
58473679|NCT05271643|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
58473680|NCT02258737|BEHAVIORAL|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
58473681|NCT02258737|BEHAVIORAL|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
58473682|NCT06016114|DIAGNOSTIC_TEST|HIV Latency Diagnostic Sampling|This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.
58473683|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and placebo (NPL)|Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
58473684|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and ketones (NKE)|Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
58473685|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and placebo (HPL)|Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
58473686|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and ketones (HKE)|Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
58473687|NCT00751296|DRUG|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
58473688|NCT06591260|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
58473689|NCT04008472|OTHER|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
58473690|NCT04253691|DEVICE|Virtual Reality Mediated Relaxation|Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
58473691|NCT04003701|BEHAVIORAL|Usual care|Control group: minimal distraction
58473692|NCT04003701|BEHAVIORAL|Robot-assisted puncture procedure|Experimental group: distraction with robot
58473693|NCT05910073|DEVICE|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
58473694|NCT06597669|PROCEDURE|Placement of stainless steel crowns on primary molars|Preformed metal crowns have been placed to treat caries in primary molars
58473695|NCT05472779|DRUG|Periurethral application of estradiol cream|The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
58132441|NCT03772496|DIAGNOSTIC_TEST|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
58132442|NCT03417128|BEHAVIORAL|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
58473696|NCT05472779|DRUG|Intravaginal application of estradiol cream|The control group will apply 1 gram estradiol cream intravaginally using an applicator.
58490892|NCT00818701|DRUG|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
58490893|NCT02169427|DRUG|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
58473697|NCT04379700|PROCEDURE|Transcatheter arterial embolization|Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.
58473698|NCT04379700|DEVICE|Embozene™ Microspheres|Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
58473699|NCT04021719|OTHER|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
58473700|NCT04021719|OTHER|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
58473701|NCT02241824|DEVICE|In-elastic lumbar brace|
58473702|NCT02241824|DEVICE|Elastic abdominal binder|
58473703|NCT00509977|PROCEDURE|Light Treatment|Light treatment applied to half of the face at each study visit
58473704|NCT00509977|PROCEDURE|Laser Treatment|Laser treatment applied to half of the face at each study visit
58473705|NCT06116045|DRUG|BZ371A 7.5 mg (1.5 ml)|7.5 mg gel
58473706|NCT06116045|DRUG|BZ371A 5.0 mg (1.0 ml)|5.0 mg gel
58473707|NCT06116045|DRUG|BZ371A 2.5 mg (0.5 ml)|2.5 mg gel
58473708|NCT06116045|DRUG|Placebo (1.5 ml)|BZ371A-matched placebo
58473709|NCT06116045|DRUG|Placebo (1.0 ml)|BZ371A-matched placebo
58473710|NCT06116045|DRUG|Placebo (0.5 ml)|BZ371A-matched placebo
58473711|NCT06599645|OTHER|CST+BFR+Tai Chi+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~3. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~4. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
58473712|NCT06599645|OTHER|CST+BFR+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
58473713|NCT06599645|OTHER|Tai Chi +BFR+Education|"1. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
58473714|NCT06599645|OTHER|CST+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
58473715|NCT04298047|OTHER|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
58473716|NCT06258200|BEHAVIORAL|Gender and immunization activities|Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.
58473717|NCT06258200|OTHER|No intervention|Participants in the comparison group will not receive any intervention
58132443|NCT02051309|DRUG|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
58132444|NCT02051309|DRUG|Placebo|
58132445|NCT00377871|DEVICE|biological heart valve prosthesis|Two heart valve designs
58132446|NCT03280797|PROCEDURE|Blood sample|2ml blood taken into TruCulture tube
58473718|NCT06284382|OTHER|High score at Childhood Trauma Questionnaire.|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
58473719|NCT06284382|OTHER|Low score at Childhood Trauma Questionnaire.|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
58473720|NCT03271762|DEVICE|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
58473721|NCT03271762|PROCEDURE|cardiac surgery|mitral valve repair or mitral valve remplacement
58473722|NCT05491811|DRUG|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
58473723|NCT05491811|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
58473724|NCT06585956|BEHAVIORAL|Comminication via Telemedicine|Comminication via Telemedicine With Patients
58473725|NCT06585956|BEHAVIORAL|Information|Informing the patient and their relatives
58473726|NCT06588049|DIETARY_SUPPLEMENT|Beet Root|Beet Root powder used as a mouth rinse in suspension with water
58473727|NCT06588049|OTHER|Water|Water used as a mouth rinse
58473728|NCT00253149|DRUG|risperidone|
58473729|NCT04106557|DRUG|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
58473730|NCT04106557|DRUG|Placebo|Matching placebo capsules to OV101 capsules.
58473731|NCT06597786|OTHER|Exercise therapy|Patients will receive a study kit which includes a smart watch (for monitoring of mobility / lifestyle patterns), heart rate monitor, blood pressure cuff, scale, and e-tablet. Patients may receive a treadmill to perform exercise therapy sessions. The treadmills and study kits are MSK owned equipment that will be deployed to the patients' homes and returned at the end of the study.
58473732|NCT04971161|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
58473733|NCT04971161|DRUG|Placebo|One topical application with a syringe
58473734|NCT04973449|BIOLOGICAL|AZD1222|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
58473735|NCT04973449|BIOLOGICAL|AZD2816|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
58473736|NCT06604364|DEVICE|hypno VR|pre-surgery sedation using virtual reality headset
58473737|NCT03130738|DRUG|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
58473738|NCT03130738|DRUG|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
58473739|NCT03130738|DRUG|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
58473740|NCT06655753|OTHER|Reliability and Validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Temporomandibular Joint Disorders
58473741|NCT06203327|OTHER|Esophagogastroscopy (OLGA 0-Ⅰ)|Surveillance endoscopies at years 3-5.
58473742|NCT06203327|OTHER|Esophagogastroscopy (OLGA II)|Surveillance endoscopies at years 2-3.
58132447|NCT02359331|PROCEDURE|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
58132448|NCT02359331|DRUG|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
58132449|NCT02359331|DRUG|Metronidazole|
58132450|NCT02359331|DRUG|Tetracycline|
58473743|NCT06203327|OTHER|Esophagogastroscopy (OLGA III-IV)|Surveillance endoscopies every year.
58473744|NCT06540261|DRUG|ONO-7913|Specified dose on specified days
58473745|NCT06540261|DRUG|ONO-4538|Specified dose on specified days
58473746|NCT06540261|DRUG|Fluorouracil|Specified dose on specified days
58473747|NCT06540261|DRUG|Oxaliplatin|Specified dose on specified days
58473748|NCT06540261|DRUG|Levofolinate|Specified dose on specified days
58473749|NCT06540261|DRUG|Bevacizumab|Specified dose on specified days
57784562|NCT02468921|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
58473750|NCT06540261|DRUG|Cetuximab|Specified dose on specified days
58473751|NCT03712696|DEVICE|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
58473752|NCT06553703|OTHER|Acceptance and commitment therapy based group psychoeducation|Acceptance and commitment therapy-based group psychoeducation aimed at increasing nursing students' psychological flexibility and reducing their somatic symptoms.
58473753|NCT05584514|OTHER|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
58473754|NCT05584514|OTHER|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
58473755|NCT05271604|BIOLOGICAL|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
58473756|NCT05271604|BIOLOGICAL|Pembrolizumab|PD-1 inhibitor
58473757|NCT05271604|BIOLOGICAL|Evalstotug (BA3071)|Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody
58473758|NCT05271604|BIOLOGICAL|Cetuximab|Epidermal growth factor receptor (EGFR) antagonist
58490894|NCT00500435|PROCEDURE|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
58473759|NCT03011918|OTHER|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
58473760|NCT03011918|OTHER|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
58473761|NCT03011918|OTHER|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
58473762|NCT03011918|OTHER|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
58473763|NCT03924050|DRUG|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
58473764|NCT04562870|DRUG|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
58473765|NCT04562870|OTHER|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
58473766|NCT05781906|DRUG|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
58473767|NCT05781906|DRUG|150 µCi [14C]HMPL-523|D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
58473768|NCT04501042|PROCEDURE|Bariatric surgery|Bariatric surgery
58473769|NCT02064946|DIETARY_SUPPLEMENT|vitamin D|50,000IU/week of vitamin D3
58473770|NCT02064946|DIETARY_SUPPLEMENT|Placebo|
58473771|NCT01391962|DRUG|Cediranib|Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
58473772|NCT01391962|DRUG|Sunitinib|Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
58473773|NCT01391962|OTHER|Prochlorperazine|10mg every 6 hours orally as needed for nausea,
58473774|NCT01391962|OTHER|Promethazine|12.5-25mg intravenous every 6 hours as needed for nausea.
58473775|NCT01391962|OTHER|Benzodiazepine|If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.
58473776|NCT01391962|OTHER|Filgrastim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
58473777|NCT01391962|OTHER|Sargramostim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
58473778|NCT01391962|OTHER|Lomotil|2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.
58473779|NCT01391962|OTHER|Loperamide|4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.
58473780|NCT01391962|OTHER|Vitamin B6|50-150mg orally each day for hand-foot syndrome.
58473781|NCT01391962|OTHER|Aquaphor|Topical emollient for hand-foot syndrome.
58473782|NCT01391962|DRUG|Acetaminophen|Analgesic for hand foot syndrome as needed.
58473783|NCT01391962|DRUG|Levothyroxine|Replacement therapy for participants with increases in thyroid-stimulating hormone.
58473784|NCT01391962|DRUG|Warfarin|2mg daily for prophylaxis of thrombosis.
58473785|NCT03115866|BEHAVIORAL|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
58473786|NCT05035862|DRUG|Albuterol Sulfate|Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
58473787|NCT05035862|DRUG|Interferon gamma-primed mesenchymal stromal cells (MSCs)|IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
58473788|NCT05035862|DRUG|Prednisone|Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
58473789|NCT00312156|DRUG|insulin detemir|
58473790|NCT00312156|DRUG|insulin NPH|
58473791|NCT00312156|DRUG|insulin aspart|
58473792|NCT02689635|OTHER|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
58473793|NCT02689635|OTHER|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
58473794|NCT01710501|DRUG|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
58473795|NCT01710501|BIOLOGICAL|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
58473796|NCT01710501|DRUG|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
58473797|NCT01710501|DRUG|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
58473798|NCT06326060|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
58473799|NCT06326060|DRUG|Placebo|Placebo will be administered subcutaneously.
58473800|NCT06326060|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
58473801|NCT05636228|DRUG|INV-102|INV-102 Ophthalmic Solution
58473802|NCT05636228|DRUG|Vehicle|Vehicle Ophthalmic Solution
58473803|NCT01029275|DRUG|Pre-treatment with octreotide|Pre-treatment with octreotide
58473804|NCT04665141|BIOLOGICAL|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
58473805|NCT04665141|BIOLOGICAL|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
58473806|NCT04665141|BIOLOGICAL|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
58473807|NCT04665141|BIOLOGICAL|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
58473808|NCT04665141|BIOLOGICAL|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
58473809|NCT05260736|PROCEDURE|Infraclavicular brachial plexus block|Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
58473810|NCT05373537|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
58473811|NCT06470555|OTHER|A figure-of-eight suture secured with a three-way tap|Femoral haemostasis using a figure-of-eight suture technique
58473812|NCT06470555|OTHER|Shortened bed rest duration of 2-hours|Bed rest duration of 2-hours after initial haemostasis
58473813|NCT06470555|OTHER|Manual compression|Femoral haemostasis using manual compression
58473814|NCT06470555|OTHER|Conventional bed rest duration of 4-hours|Bed rest duration of 4-hours after initial haemostasis
58473815|NCT06602778|OTHER|Biomarkers / blood|Analysis of routine biochemical parameters
58473816|NCT06602778|OTHER|Questionnaire|Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.
58473817|NCT05911724|OTHER|Group I|Healthy Subjects
58473818|NCT05911724|OTHER|Group II|Stable Angina Patients
58473819|NCT05911724|OTHER|Group III|Heart Failure Patients
58473820|NCT06594900|BEHAVIORAL|resistance training intervention|"The RT intervention focuses on knee extensor muscles, following current guidelines. Children will attend two supervised 1-hour sessions per week, proven sufficient for adaptations. Trained coaches and a scientific assistant, supported by master students, will document the sessions. Sessions are spaced 48 hours apart, totaling 40 over 20 weeks, with eight sessions between PRE and MID.~Each session has three phases: warm-up, strength, and coordination. Warm-up involves whole-body games to increase heart rate and prepare for strength training. The strength phase, documented for effort and adjustments, includes squats, lunges, and step-ups, with intensity changes over time. Four sets of 8-12 repetitions per exercise are performed, aiming for strength increase and hypertrophy. Movements are done with great effort but not until voluntary failure.~The coordination phase focuses on age-appropriate strength and motor skills through a circuit of challenges."
58473821|NCT06181240|DEVICE|Intravascular lithotripsy|Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
58473822|NCT04701762|DEVICE|GlideScope videolaryngoscope (Verathon, Bothell, Washington 98011)|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, Washington 98011) is an FDA-cleared commercially available portable videolaryngoscope.
57779542|NCT00478608|DRUG|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
58473823|NCT04701762|DEVICE|Direct laryngoscopy|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
58473824|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
58473825|NCT04029883|BEHAVIORAL|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
58473826|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
58473827|NCT06583876|DEVICE|Coriofix System|Treatment of functional mitral regurgitation by reducing the mitral valve annular area through ablation of the posterior annulus.
58132451|NCT02359331|DRUG|tripotassium dicitrate bismuthate|
58473828|NCT06586502|OTHER|Model of Care|The intervention described in the RECOVER study involves developing, implementing, and evaluating a comprehensive Model of Care for childhood cancer survivors. This model, known as the RECOVER Model of Care, integrates digital health solutions and is co-designed with input from childhood cancer survivors, caregivers, and clinical experts. The intervention aims to address the long-term and late effects of cancer treatment by providing continuous, risk-based, interdisciplinary care. It includes steps such as identifying patients nearing the end of treatment, conducting health assessments, creating personalized care plans, and coordinating follow-up care through digital platforms. The study will assess the feasibility, acceptability, and effectiveness of this model in improving the quality of life and care experience for survivors and their families.
57779543|NCT06066489|OTHER|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
57779544|NCT01495221|DRUG|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
58132452|NCT02359331|DRUG|7 days tailored therapy Proton Pump Inhibitor|
58132453|NCT02359331|DRUG|Moxifloxacin|
58132454|NCT02359331|DRUG|Amoxicillin|
58473829|NCT04345796|DRUG|Carvedilol+Empagliflozin|Group A
58473830|NCT04345796|DRUG|Carvedilol|Group B
58473831|NCT04345796|DRUG|Empagliflozin|Group C
58473832|NCT04345796|DRUG|Placebo|Group D
58473833|NCT06600373|BEHAVIORAL|Mindful Walking meditation|Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.
58473834|NCT06600373|BEHAVIORAL|physical education group class|120 minutes physical education group class about volleyball.
58473835|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
58473836|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
58473837|NCT05349214|OTHER|Placebo|placebo s.c.
58473838|NCT05561478|DEVICE|Implantation of Synthesis Plus IOL (control device)|Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.
58473839|NCT05561478|DEVICE|Implantation of Synthesis Plus Toric IOL (investigational device)|Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
58473840|NCT02956395|OTHER|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
58473841|NCT06598865|OTHER|adapted physical activity|After the initial training in adapted physical activity (APA), patients will receive regular support from an APA instructor, and they will be asked to participate in 3 sessions per week of APA, if possible in a Sport-Health center close to their home, for the entire duration of the study. The content of the additional APA sessions (up to 2 additional sessions per week) can be discussed with the APA instructor. They will also be asked to return to the study center for a visit at 3 months (Visit 3) to assess the effect of the APA conducted during this period
58473842|NCT05967585|DEVICE|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
58473843|NCT01708200|OTHER|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
58473844|NCT01854411|OTHER|analgesic measure|ibuprofen and ketoprofen measured into breast milk
58473845|NCT04771806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58473846|NCT04771806|OTHER|Neurocognitive Assessment|Undergo neurocognitive testing
58473847|NCT04771806|OTHER|Quality-of-Life Assessment|Ancillary studies
58473848|NCT04771806|OTHER|Questionnaire Administration|Ancillary studies
58473849|NCT06603311|OTHER|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
58473850|NCT06595836|DEVICE|Silicone Lubricated Synthetic polyisoprine condom|Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity
58473851|NCT06595836|DEVICE|Silicone Lubricated Natural Rubber Latex Condom|Natural rubber latex condoms are made from natural rubber
58473852|NCT06591026|BEHAVIORAL|Standard Helpline (SH)|One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
58473853|NCT06591026|BEHAVIORAL|Motivational Interviewing (MI)|One digital helpline session that includes a structured motivational interviewing brief intervention.
58473854|NCT06591026|BEHAVIORAL|Coping Skills Training (CST)|One digital helpline session that includes a structured cognitive coping skills brief intervention.
58473855|NCT06591026|BEHAVIORAL|Automated Text Messaging (ATM)|Automated text messages are sent daily for 4 weeks.
58473856|NCT04158362|DRUG|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
58473857|NCT04158362|DRUG|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
58473858|NCT04158362|DRUG|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
58473859|NCT04158362|DRUG|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
58473860|NCT04158362|DRUG|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
58473861|NCT04158362|DRUG|Abemaciclib|Oral 150 mg BID continuous
58473862|NCT06583980|BEHAVIORAL|Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact|A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
58490895|NCT04828343|DRUG|rozanolixizumab|Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
58490896|NCT04828343|OTHER|Placebo|Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
58473863|NCT04793360|DEVICE|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
58473864|NCT03069937|DRUG|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
58473865|NCT03069937|DRUG|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
58473866|NCT06589336|OTHER|Dietary changes via Instacart vouchers|Instacart will provide consumers with the dignity of choice to shop at preferred retail stores, which is key for our behavioral change strategy. Delivery and service fees will be waived for patients, so 100% of the vouchers will be applied to groceries (all food products excluding alcohol and tobacco). The investigators will use a custom study store front with an integrated website and email option.
58473867|NCT06589336|OTHER|Dietary changes via access to Mid-Ohio Farmacy|Mid-Ohio Farmacy will provide healthy food provisions through a network of food banks with fresh produce and other items.
58473868|NCT06589336|OTHER|Behavior changes via access to Health Impact Ohio Hub|Health Impact Ohio Hub is a regional coordination entity that has connections with community care agencies that employ community health workers to assess social needs and make connections to resources to address social needs. The community health workers will conduct an initial needs assessment, and guide the participant through appropriate care pathways to address social needs.
58473869|NCT06589336|OTHER|Behavioral nutrition counseling|All dietary recommendations will be individualized and informed by existing guidelines to improve diet quality and cardiovascular health through the Mediterranean Diet.
58473870|NCT06589336|OTHER|Cooking classes|Registered dietician nutritionists will also lead cooking demonstrations every 2 weeks, focused on culinary education and building engagement among SUSTAIN participants.
58473871|NCT06589336|OTHER|Dietary changes to Delivery fees|Delivery fees will be supported for SUSTAIN participants.
58473872|NCT05886621|BEHAVIORAL|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
58473873|NCT05886621|BEHAVIORAL|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
58473874|NCT06588933|OTHER|completion of a questionnaire|completion of a questionnaire by participant
58473875|NCT01285323|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
58473876|NCT01285323|DRUG|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
58473877|NCT06065449|DRUG|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
58473878|NCT05913232|DRUG|H-1337 0.6%|ophthalmic solution
58473879|NCT05913232|DRUG|H-1337 1.0%|ophthalmic solution
58473880|NCT05913232|DRUG|H-1337 Placebo|ophthalmic solution
58473881|NCT05913232|DRUG|Timolol 0.5%|ophthalmic solution
58473882|NCT05316597|BEHAVIORAL|Forest bathing|Participants will be seated in a forest environment for an hour-long exposure to the forest
58473883|NCT04475458|PROCEDURE|Ultrasound-guided dorsal penile nerve block|This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
58473884|NCT00385216|DRUG|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
58473885|NCT00385216|OTHER|Placebo|Placebo nasal spray 0mg x 1 before surgery
58473886|NCT05255900|DRUG|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
58473887|NCT06235775|DRUG|GV1001 Placebo|0.9% normal saline
58473888|NCT06235775|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
58473889|NCT04286984|OTHER|unified protocol of Patient Blood Management measure|upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level \< 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb\<12g/dL and/or ferritin \<300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb \< 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb \< 7 g/dL for the rest of patients in absence of active bleeding.
58473890|NCT02479399|DRUG|ipragliflozin|Tablets
58473891|NCT04295148|PROCEDURE|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
58473892|NCT04295148|PROCEDURE|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
58473893|NCT06589206|OTHER|modified design of twin block|Vacuum formed twin block appliance with sagittal blocks
58473894|NCT06592898|BEHAVIORAL|straight leg raise|The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
58473895|NCT06592898|BEHAVIORAL|wall squat|The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.
58473896|NCT06592898|BEHAVIORAL|direct squat|The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle. The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
58473897|NCT06592898|BEHAVIORAL|wall squat assisted by elastic bands|Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
58473898|NCT03845205|BEHAVIORAL|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
58473899|NCT06602973|BEHAVIORAL|Rest|Participants will eat breakfast but abstain from exercise
58473900|NCT06602973|BEHAVIORAL|Fed Exercise|Participants will eat breakfast and engage in 30 minutes of physical activity at 75% of their personal V02max.
58473901|NCT06602973|BEHAVIORAL|Fasted Exercise|Participants will engage in 30 minutes of physical activity at their personal 75% V02max after abstaining from breakfast.
58473902|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia with AI chatbot|digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and patient-centered conversational agents
58473903|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia without AI chatbot|digital cognitive behavioral therapy for insomnia without two-way interactive, intelligent, and patient-centered conversational agents
58473904|NCT03995134|COMBINATION_PRODUCT|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
58473905|NCT05736380|DEVICE|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
58473906|NCT05736380|DEVICE|Sham cerebellar rTMS|Sham cerebellar rTMS
58473907|NCT06590727|OTHER|Distress Thermometer|Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.
58473908|NCT03902418|DRUG|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
58473909|NCT05400967|DRUG|68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
58473910|NCT06593301|OTHER|Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training|Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)
58473911|NCT02170376|DRUG|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
58473912|NCT02170376|DRUG|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
58473913|NCT02170376|DRUG|Placebo|PLC, placebo
58473914|NCT02170376|DRUG|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
58473915|NCT05726305|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
58473916|NCT05726305|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
57779545|NCT03004664|BEHAVIORAL|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
58473917|NCT04716764|OTHER|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
58473918|NCT01767090|DRUG|ASP1707|Oral
58473919|NCT01767090|DRUG|Placebo|Oral
57779546|NCT03004664|BEHAVIORAL|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
58473920|NCT01767090|DRUG|Leuprorelin acetate|subcutaneous
58473921|NCT06596109|BEHAVIORAL|honey intake and lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
58473922|NCT06596109|BEHAVIORAL|lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
58473923|NCT01915810|BEHAVIORAL|Exercise Intervention|Complete SCwPA intervention
58473924|NCT01915810|OTHER|Laboratory Biomarker Analysis|Correlative studies
58473925|NCT01915810|DRUG|Nicotine Patch|Receive nicotine patch
58473926|NCT01915810|OTHER|Questionnaire Administration|Ancillary studies
58473927|NCT01915810|OTHER|Tobacco Cessation Counseling|Receive smoking cessation counseling
58473928|NCT04232358|DRUG|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
58473929|NCT04232358|DRUG|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
58473930|NCT04386291|BEHAVIORAL|Anxiety Reduction Training|Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
58473931|NCT04386291|BEHAVIORAL|Kundalini Yoga and Anxiety Reduction Training|Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
58473932|NCT04386291|BEHAVIORAL|Meditation and Anxiety Reduction Training|Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
58473933|NCT04792645|DRUG|Placebo|Pill that contains no medicine
58473934|NCT04792645|DRUG|Memantine|Cognition-enhancing medication
58473935|NCT06597500|DRUG|GSK3923868|GSK3923868 will be administered.
58473936|NCT06597500|DRUG|Itraconazole|Itraconazole will be administered.
58473937|NCT01951443|DIETARY_SUPPLEMENT|Ginseng|400mg of encapsulated Rg3-KRG
58473938|NCT01951443|DIETARY_SUPPLEMENT|Wheat Bran|400mg of encapsulated wheat bran
58473939|NCT06600724|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
58473940|NCT06600724|OTHER|EPIEFFECT|Participants will receive weekly applications of EPIEFFECT and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
58473941|NCT06600724|OTHER|EPIXPRESS|Participants will receive weekly applications of EPIXPRESS and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
58473942|NCT06596733|DEVICE|Vit-A-Vision|Participants will apply Vit-A-Vision ointment on a daily basis, up to 3 times daily per eye, for at least 30 days.
58473943|NCT02181777|BEHAVIORAL|GRASP|GRoup trAining for Social skills in Psychosis
58473944|NCT02181777|BEHAVIORAL|Standard care|Treatment as usual
58473945|NCT06594939|DRUG|Polatuzumab Vedotin|A combination of a monoclonal antibody and a chemotherapy drug.
58473946|NCT06594939|DRUG|Mosunetuzumab|A monoclonal antibody.
58473947|NCT06594939|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent.
58132455|NCT01913990|DRUG|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
58473948|NCT06594939|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic.
58473949|NCT06594939|DRUG|Prednisone|Steroid, anti-inflammatory
58473950|NCT06594939|OTHER|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier.
58473951|NCT06326450|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of medical crisis scenarios
58473952|NCT06563700|OTHER|spectacle lens|one of ZEISS BD spectacle lens designs 1 to 5
58473953|NCT06563700|OTHER|single vision lens|single vision lens
58473954|NCT03103542|BIOLOGICAL|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
58473955|NCT01490151|DEVICE|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
58473956|NCT05885438|BEHAVIORAL|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
58473957|NCT04522388|DIETARY_SUPPLEMENT|Ensure Enlive|Ensure Enlive shake twice a day
58473958|NCT06591663|BEHAVIORAL|Cognitive Therapy Rating Scale (CTRS)|"CBT is the Cognitive Therapy Rating Scale (CTRS), an important assessment tool designed to assess the quality and effectiveness of cognitive therapy sessions.~Mental health professionals, such as therapists and psychologists, commonly use the CTRS to evaluate various aspects of a therapy session. This includes the extent to which the therapist adheres to CBT principles, their skill in applying cognitive and behavioral techniques, their ability to develop a therapeutic relationship with the client, and the overall quality of the session. The scale may also include specific criteria or items that another trained therapist or researcher observes based on their observations during the therapy session (Pingol, 2023)."
58132456|NCT01913990|OTHER|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
58132457|NCT03229005|PROCEDURE|implant insertion|during surgery soft tissues will be measured
58132458|NCT03229005|PROCEDURE|operculectomy|during second surgery soft tissues will be measured again
58132459|NCT03229005|PROCEDURE|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
58132460|NCT04661748|DEVICE|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
58473959|NCT06362824|BEHAVIORAL|De Pie Intervention|Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.
58473960|NCT06362824|OTHER|Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)|Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
58473961|NCT06590831|DRUG|Lactoferrin|to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
58473962|NCT06603740|DEVICE|Arthrex Nanoscope|Arthrex's all-in-one disposable, 2 mm, chip-on-tip camera system now allows surgeons to miniaturize their treatment solutions
58473963|NCT06603740|DEVICE|Conventional Arthroscopy without Arthrex Nanoscope|partial meniscectomy using conventional arthroscopy
58473964|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose
58473965|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, single dose
58473966|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, three times daily for a total of 8 days
58473967|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, six times daily for a total of 8 days
58473968|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, multiple doses
58473969|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose, tear samples will be collected
58473970|NCT06591715|OTHER|Home exercise program|The home exercise program routinely given to individuals with knee OA in addition to their medical treatment will consist of exercises routinely used in the BETY innovation.
58473971|NCT06490289|OTHER|Denpro oral gel|Experimental group was given Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan)
58473972|NCT06601777|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
58473973|NCT06601777|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
58473974|NCT03560297|BEHAVIORAL|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
58473975|NCT03560297|BEHAVIORAL|Delayed Intervention|Participants receive intervention after delay
58473976|NCT06597864|BEHAVIORAL|Seven-step phenomenological psychotherapy for self-disorders|Phenomenological exploration of anomalous self-experiences, meaning attributions and behavioral consequences. Psychoeducation. Dialogical approach focusing on self-narratives, searching for new meaning and understanding of self-disorders
58473977|NCT06588764|PROCEDURE|modified deep lateral and/or medial wall decompression|Modified deep lateral orbital wall decompression is based on traditional outer wall decompression with combined abrasion of the deep outer orbital wall (including the greater pterygoid wing) to achieve adequate enlargement of the orbital cavity.
58473978|NCT03175367|DRUG|Evinacumab|SC or IV administration
58473979|NCT03175367|DRUG|Matching placebo|SC or IV administration
58473980|NCT03175367|OTHER|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
58473981|NCT06202521|DRUG|CX-4945 (SARS-CoV-2 domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
58473982|NCT06202521|DRUG|Placebo (SARS-CoV-2 domain)|The dosage and frequency is the same as active drug.
58473983|NCT06202521|DRUG|CX-4945 (Influenza virus domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
58132461|NCT05944705|DIETARY_SUPPLEMENT|Immune Support Supplement|Cannabinoid and co-active emulsion
58473984|NCT06202521|DRUG|Placebo (Influenza virus domain)|The dosage and frequency is the same as active drug.
58473985|NCT05153694|PROCEDURE|Cystectomy|Removal of the urinary bladder
58473986|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
58473987|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
58473988|NCT05532189|OTHER|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
58473989|NCT06604039|DEVICE|Central venous catheter|Placement of a medical device to gain entry into the bloodstream, typically through a vein or artery, for the purpose of administering fluids, medications, blood products, or for hemodialysis
58473990|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
58473991|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
58473992|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (2 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
58473993|NCT06036225|BEHAVIORAL|Prehabilitation|Remote prehabilitation multi-component.
58473994|NCT01350947|DRUG|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
58473995|NCT06590714|DRUG|Experimental(Acelex cap m2mg)|"Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN)."
58132462|NCT00659321|DRUG|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
58132463|NCT00659321|DRUG|placebo|16 weeks treatment with placebo
58132464|NCT02603783|OTHER|Capsaicin|capsaicin 1,5 mg
58132465|NCT02603783|OTHER|Placebo|0,9% saline 75 ml
58132466|NCT02231645|DEVICE|STN DBS|The DBS device is turned on and off by the physician.
58473996|NCT06590714|DRUG|Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)|NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
58473997|NCT00603408|DRUG|Cisplatin|
58473998|NCT00603408|RADIATION|Radiation Therapy|
58473999|NCT00603408|PROCEDURE|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
58474000|NCT06600516|BEHAVIORAL|CBTi: Stimulus Control Core|Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
58474001|NCT06600516|BEHAVIORAL|CBTi: Sleep Restriction Core|Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
58474002|NCT06600516|BEHAVIORAL|CBTi: Sleep Compression Core|Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
58474003|NCT05939206|PROCEDURE|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
58474004|NCT06240260|DEVICE|TENS (transcutaneous electrical nerve stimulation) unit|"Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of a mild electrical current.~A TENS machine is a small, battery-operated device that has leads connected to sticky pads called electrodes."
58474005|NCT06240260|OTHER|Standard care|Paracervical block only or participant declines analgesia for IUD insertion
58474006|NCT06585397|OTHER|Grup 1|Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
58474007|NCT06100809|BEHAVIORAL|Personalized coaching|Personalized fatigue mitigation coaching.
58474008|NCT06100809|BEHAVIORAL|Nutrition handout|Nutrition handout
58474009|NCT05458128|DRUG|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
58474010|NCT02780843|OTHER|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
58474011|NCT02780843|OTHER|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
58490897|NCT02681354|OTHER|Biorescue training|
58132467|NCT06114706|BEHAVIORAL|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
58132468|NCT06114706|BEHAVIORAL|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
58132469|NCT06114706|BEHAVIORAL|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
58132470|NCT01843608|OTHER|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
58132471|NCT04012632|OTHER|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
58132472|NCT00998023|DEVICE|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
58132473|NCT00998023|DEVICE|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
58132474|NCT06412549|BEHAVIORAL|Health care practices and routines|"The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team."
58132475|NCT03187678|DRUG|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
58132476|NCT03187678|DRUG|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
58132477|NCT03443778|DRUG|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
58132478|NCT03443778|DRUG|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
58132479|NCT03443778|DRUG|Nacl 0,9 %|Injectable Solution
58132480|NCT02710201|BEHAVIORAL|Descriptive Social Norm|
58132481|NCT02710201|BEHAVIORAL|Descriptive-plus-Injunctive Social Norm|
58132482|NCT03157388|DRUG|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
58132483|NCT00477347|DEVICE|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
58132484|NCT00477347|DEVICE|Manual administration|intraoperative manual administration of propofol and remifentanil
58132485|NCT04137393|COMBINATION_PRODUCT|brushing|mechanical and chemical plaque removal
58132486|NCT02696070|DEVICE|Provant Therapy System|
58132487|NCT00996671|DRUG|GSK2256098|focal adhesion kinase inhibitor given as a single dose
58132488|NCT00996671|DRUG|Placebo|Placebo to be used as comparator for GSK2256098
58132489|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)
58132490|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
58132491|NCT01261078|DRUG|Placebo|intrathecal 8 mg of bupivacaine only
58132492|NCT01261078|DRUG|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
58132493|NCT01261078|DRUG|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
58132494|NCT01261078|DRUG|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
58132495|NCT01261078|DRUG|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
58132496|NCT05214768|DRUG|CC-93538|Specified dose on specified days
58132497|NCT05214768|DRUG|Placebo|Specified dose on specified days
58132498|NCT01973049|DRUG|Daclatasvir|
58474012|NCT05972317|OTHER|Low FODMAP dietary regimen|"intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2."
58132499|NCT01973049|DRUG|Asunaprevir|
58132500|NCT01973049|DRUG|BMS-791325|
58132501|NCT01973049|DRUG|Ribavirin|
58132502|NCT01973049|DRUG|Placebo matching Ribavirin|
58132503|NCT03257085|OTHER|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
58474013|NCT06603935|OTHER|QHSLab Digital Tools (AME and ARIS)|Participants will use the QHSLab digital platform, which includes two tools: the Allergy Management Evaluation (AME) and the Allergic Rhinitis Intervention Steps (ARIS). The AME provides a comprehensive digital assessment for identifying and monitoring allergic rhinitis symptoms. The ARIS offers personalized feedback based on patient-reported outcomes and continuously adjusts treatment recommendations through an algorithm. These tools support better symptom management, adherence to medication, and overall improvement in quality of life.
58132504|NCT03257085|OTHER|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
58132505|NCT02793453|OTHER|periodontal smears|
58132506|NCT02501057|BEHAVIORAL|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
58132507|NCT02501057|BEHAVIORAL|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
58132508|NCT02501057|BEHAVIORAL|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
58132509|NCT04757090|DRUG|89Zr-trastuzumab|"-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure."
58132510|NCT03096821|DRUG|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
58132511|NCT00969566|DRUG|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
58132512|NCT00683293|PROCEDURE|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
58132513|NCT00683293|PROCEDURE|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
58132514|NCT02679183|DIETARY_SUPPLEMENT|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
58132515|NCT02679183|OTHER|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
58132516|NCT00569062|DRUG|GW856553X|GW856553X 7.5mg BID for 6 weeks
58132517|NCT00569062|OTHER|Placebo|Placebo to match GW856553X
58132518|NCT01022047|DRUG|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
58132519|NCT01022047|DRUG|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
58132520|NCT04799028|OTHER|Traditional cow's milk|Fortified cow's milk
58132521|NCT04799028|OTHER|Experimental milk|Milk with synbiotics and fat blend
58132522|NCT04799028|OTHER|Habitual diet|Habitual diet
58132523|NCT04665947|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
58132524|NCT04208503|DIAGNOSTIC_TEST|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
58132525|NCT00081783|DRUG|Xcellerated T Cells|
58132526|NCT05339100|DRUG|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
58132527|NCT05339100|DEVICE|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
57779547|NCT06738147|OTHER|pelvic floor muscle training|pelvic floor muscle training (PFMT) for 30 min., 3 sessions/ week in addition to traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
58132528|NCT05339100|DEVICE|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
58132529|NCT06268522|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement: (MORE) group|Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
58132530|NCT06268522|BEHAVIORAL|Psychoeducation|Education on the neurobiology of pain, healthy eating, diet, sleep and stress
58132531|NCT02506582|DIETARY_SUPPLEMENT|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
58132532|NCT02506582|DIETARY_SUPPLEMENT|placebo|40 g powdered rice flour
58132533|NCT05097326|DRUG|Mifepristone|Mifepristone 200mg taken orally
58132534|NCT05097326|DRUG|Misoprostol|Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
58132535|NCT01870180|DEVICE|EyeBag|fabric bag of beads which can be heated in a microwave
58132536|NCT01870180|OTHER|Placebo|
58474014|NCT06246084|BEHAVIORAL|Endocrine Therapy Education Program|Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
58474015|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
58474016|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
58474017|NCT05030155|DRUG|Mepolizumab|300 mg/month subcutaneous
58132537|NCT03605238|BIOLOGICAL|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
58132538|NCT06160037|BEHAVIORAL|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
58474018|NCT05030155|DRUG|cyclophosphamide/azathioprine|Patients with FFS≥1 will receive cyclophosphamide then azathioprine
57779548|NCT06738147|OTHER|balance exercises|traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
57779549|NCT02120846|OTHER|Flywheel leg-press resistance exercise|
58132539|NCT06160037|BEHAVIORAL|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
58132540|NCT03889756|DRUG|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
58132541|NCT03889756|DRUG|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
58132542|NCT05240196|OTHER|music|playing binaural or non-binaural music
58474019|NCT05030155|DRUG|Placebo|Patients with FFS=0 will receive placebo
58474020|NCT04326972|DEVICE|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
58132543|NCT05681208|BEHAVIORAL|Motivational interview|"Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week."
58474021|NCT02938299|DRUG|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
58474022|NCT02938299|PROCEDURE|Surgery|Surgical resection of melanoma tumor lesions
58474023|NCT00103584|BIOLOGICAL|LC16m8 Smallpox Vaccine|
58474024|NCT06491238|BEHAVIORAL|Light Intensity Exercise|12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
58474025|NCT06491238|BEHAVIORAL|Moderate Intensity Exercise|12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
58474026|NCT06594952|OTHER|Questionnaire and Physical Exam|"Diagnosis of Anxiety using the state-trait anxiety inventory scale (STAI). Depression using Edinburgh Postnatal Depression Scale (EPDS)~* Coping using the Brief Coping Scale~* Socioeconomic using the Socioeconomic Scale of Egypt~* Personality using the short-form Eysenck Personality Questionnaire-Revised (EPQ-R)~* Behaviour using Impact of Erect Scale (IES-22)"
58474027|NCT06166992|DRUG|BI 1291583|BI 1291583
58474028|NCT06166992|DRUG|[14C]-BI 1291583|\[14C\]-BI 1291583
58474029|NCT00289653|DRUG|Nicoderm|
58474030|NCT04919109|BIOLOGICAL|CodaVax-RSV|live attenuated vaccine against RSV
58474031|NCT04919109|BIOLOGICAL|Normal Saline|Placebo comparator
58474032|NCT06345690|OTHER|VIA Disc NP|VIA Disc NP - Allograft tissue injection
58474033|NCT04662021|OTHER|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
58474034|NCT06598501|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|an open arm study of 10 gambling disorder subjects will be conducted to determine the efficacy and feasibility of a multimodalistic therapy of rTMS and Cognitive Behavioral Therapy (CBT) for gambling disorder in Indonesia.
58474035|NCT02792686|DRUG|ABX464|Single Administration
58474036|NCT00546806|OTHER|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
58474037|NCT05521607|DEVICE|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
58474038|NCT06494358|OTHER|liquid biopsies and surgery specimen analysis|liquid biopsies and surgery specimen analysis
58474039|NCT06592859|DIETARY_SUPPLEMENT|NMN|NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
58474040|NCT06592859|DIETARY_SUPPLEMENT|placebo|Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
58474041|NCT06084611|DEVICE|Provox Life|Compliant use of Provox Life HMEs
58474042|NCT02698696|OTHER|ECo program|
58474043|NCT02698696|OTHER|CRT program|
58474044|NCT02698696|OTHER|Supportive psychotherapy|
58474045|NCT06588478|DRUG|Pirtobrutinib|Administered Orally.
58474046|NCT06590857|DRUG|RYZ101|Ac-225
58474047|NCT06590857|DRUG|Pembrolizumab|Keytruda
58474048|NCT04494672|PROCEDURE|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
58474049|NCT04494672|PROCEDURE|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
58474050|NCT06009939|OTHER|Occlusion of the circulation in the arm and foot|A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
58474051|NCT01600326|PROCEDURE|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
58474052|NCT01600326|DRUG|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
58474053|NCT01341834|DRUG|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
58474054|NCT06252038|BEHAVIORAL|Zoom Group Video (GV)|Zoom delivery of the DPP. Participants have access to Prevent T2 Curriculum and connected technology to track weight and physical activity.
58474055|NCT06252038|BEHAVIORAL|Self Directed (SD)|Self directed delivery of the DPP. Participants have access to online curriculum, lifestyle coach and connected technology to track weight and physical activity.
58474056|NCT04091555|DIETARY_SUPPLEMENT|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
58132544|NCT05907616|BEHAVIORAL|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
58132545|NCT00020345|DRUG|fluorouracil|
58132546|NCT00020345|DRUG|gemcitabine|
57779550|NCT06527651|DRUG|Genicular blocks (dexamethazone and lidocaine)|Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
58132547|NCT01061125|OTHER|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
58132548|NCT00757874|DRUG|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
58132549|NCT00757874|DRUG|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
58474057|NCT06597240|DEVICE|AMCOR|Participants will collect biometric and quality of life data for 11 weeks at home. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.
58474058|NCT04945733|DRUG|Amivantamab|Amivantamab will be administered intravenously.
58474059|NCT00497094|DEVICE|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
58132550|NCT04947748|OTHER|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
58132551|NCT04902157|DIAGNOSTIC_TEST|Cycle threshold|cycle threshold number
58132552|NCT03165552|OTHER|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
58132553|NCT06225232|DRUG|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
58132554|NCT02183571|DRUG|Merck Glucophage® high dose|Part I: Treatment A
58474060|NCT01786005|DEVICE|Transcranial magnetic stimulation|
58474061|NCT03493997|COMBINATION_PRODUCT|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
58474062|NCT03493997|RADIATION|Radiotherapy only|Radiotherapy only
58474063|NCT03205709|OTHER|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
57779551|NCT05332574|BIOLOGICAL|GB263T|Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
57779552|NCT05043311|BIOLOGICAL|SCTV01C|intramuscular injection
57779553|NCT05043311|OTHER|Placebo|intramuscular injetion
57779554|NCT05013996|BEHAVIORAL|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
57779555|NCT05013996|BEHAVIORAL|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
57779556|NCT05266040|DRUG|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
57779557|NCT05266040|DRUG|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
58132555|NCT02183571|DRUG|BMS Glucophage® high dose|Part I: Treatment B
58132556|NCT02183571|DRUG|Merck Glucophage® low dose|Part II: Treatment C
58132557|NCT02183571|DRUG|BMS Glucophage® low dose|Part II: Treatment D
58132558|NCT06182020|DEVICE|Peripheral functional magnetic stimulation (ISKRA MEDICAL TESLA Former prestige Magneto therapy)|The peripheral functional magnetic stimulation will be conducted 30 minutes a session, 2 sessions per week, for consecutive 8 weeks. The stimulation will be placed over bilateral forearm flexor muscles and bilateral thighs over rectus femoris muscles.
58132559|NCT06182020|DIETARY_SUPPLEMENT|Nutritional supplementation (ENSURE HIGH CALCIUM)|"The nutritional supplementation includes 7 cans of ENSURE HIGH CALCIUM per week for 8 consecutive weeks."
58132560|NCT06182020|BEHAVIORAL|Education|The education includes a DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
58132561|NCT00584298|DRUG|SMS995|
58132562|NCT00584298|DRUG|Placebo|
58132563|NCT04855981|OTHER|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
58132564|NCT04855981|OTHER|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
58132565|NCT04855981|OTHER|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
58132566|NCT04986332|BEHAVIORAL|Physical activity program|24-weeks moderate-intensity physical activity program
58132567|NCT04986332|OTHER|Global therapeutic remodeling|Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
58132568|NCT01391793|DRUG|Placebo|Twice daily for 3 days
58132569|NCT01391793|DRUG|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
58132570|NCT03388320|DEVICE|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
58132571|NCT02351154|OTHER|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
58132572|NCT00708019|BEHAVIORAL|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls \[total time 12.3 hours\]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls \[8.0 hours\]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
58132573|NCT02171754|DRUG|BIBW 2992|
58132574|NCT02171754|DRUG|Ritonavir|
58132575|NCT02854579|BIOLOGICAL|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
58132576|NCT02854579|BIOLOGICAL|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
58132577|NCT02854579|BIOLOGICAL|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
58132578|NCT02398071|DEVICE|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
58132579|NCT01402037|DRUG|Glucose|Glucose 20% intravenous
58132580|NCT01402037|DEVICE|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
58132581|NCT04978532|OTHER|Guided Imagery|The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
58474064|NCT03205709|OTHER|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
58474065|NCT02472821|BEHAVIORAL|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
58474066|NCT02472821|BEHAVIORAL|Internet-based educational booster|Visit to an educational Web site focused on hearing health
58474067|NCT00027534|BIOLOGICAL|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
58474068|NCT06596070|OTHER|No intervention was carried out|This study is an observational study and no intervention was performed on the patients.
58474069|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
58474070|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
58474071|NCT04775381|DRUG|Vitamin D|Patients will receive a cholecalciferol supplementation added to a fruit juice.
58132582|NCT04978532|OTHER|Control Group|No intervention was made in the children.
58474072|NCT04009408|DEVICE|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
58474073|NCT05135000|DRUG|LTP001|LTP001 will be administered orally once daily in the morning
58474074|NCT05135000|DRUG|Placebo|Placebo to LTP001 will be administered once daily in the morning
58474075|NCT04524949|DRUG|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
58474076|NCT04524949|DRUG|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
58474077|NCT04524949|DRUG|Placebo|Solvent: alum hydroxide
58474078|NCT05891379|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
58132583|NCT06443307|DRUG|Irinotecan Liposome|The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
58132584|NCT01553838|DEVICE|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
58132585|NCT05833386|PROCEDURE|Ureteral access sheath placement during flexible ureteroscope for renal stones|Ureteral access sheath placement during flexible ureteroscope
58474079|NCT05891379|DRUG|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
58132586|NCT03597490|COMBINATION_PRODUCT|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
58132587|NCT02381171|DEVICE|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
58132588|NCT02381171|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
58132589|NCT02381171|DEVICE|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
58474080|NCT04552301|BEHAVIORAL|Cognitive Processing Therapy|Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
58474081|NCT04552301|BEHAVIORAL|Psychotherapy|The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
58132590|NCT02381171|DEVICE|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
58132591|NCT05868447|PROCEDURE|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
58132592|NCT05938556|BEHAVIORAL|hybrid asynchronous-synchronous group coaching program|A hybrid asynchronous-synchronous program. The synchronous part has two weekly recorded live group coaching calls for four months. The asynchronous consist of 1) on-demand replies to recorded coaching calls, 2) Self-coaching through weekly self-study modules and worksheets, and 3) written Ask A Coach. Content modified per needs of APPs by a physician, a certified coach, and an APP who is also a Co-I. The curriculum has weekly themes that build. Month-1 consists of 1) Introduction to the Model, 2) How to Feel Better, 3) Defining Your Purpose, and 4) Living Your Purpose. Month-2 consists of 1) Growth Mindset, 2) Welcoming Feedback and Assessment Bias, 3) Feeling Valued and Belonging, and 4) How to Deal with Hidden Expectations. Month-3 consists of 1) Imposter Syndrome, 2) Perfectionism, 3) Approval Addiction, and 4) How to Change Your Thoughts. Month-4 consists of 1) How to deal with Ambiguity, 2) Confidence, 3) Self-Appreciation and Self-Compassion, and 4) Celebrate the New You.
58132593|NCT05938556|OTHER|treatment as usual group (TAU)|The treatment as usual group will consist of any structural or programmatic interventions, resources, lectures, curriculum, etc. offered at the participants' hospital of employment. Thus, this active control is designed to represent a best-case alternative to group coaching, making it a more rigorous form of control. Participants randomly assigned to TAU will also continue any structural or programmatic interventions or resources they were previously participating in.
58132594|NCT02472522|DRUG|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
58132595|NCT02472522|OTHER|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
58132596|NCT02684578|DRUG|Metformin|
58132597|NCT02796664|DIETARY_SUPPLEMENT|Ginseng|Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
58132598|NCT02796664|DIETARY_SUPPLEMENT|Placebo|Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
58132599|NCT00770510|DRUG|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
58132600|NCT00770510|DRUG|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
58132601|NCT00770510|DRUG|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
58474082|NCT04552301|BEHAVIORAL|Targeted Asthma Education|The manualized 10-session program of asthma self-management
58132602|NCT00770510|DRUG|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
58474083|NCT04552301|BEHAVIORAL|General Asthma Education|A 10-session program of similar time
58474084|NCT06603389|OTHER|Psychiatric Non-Suicidal Self-Injury Risk Assessment Scale|sacles or questionnaires
58474085|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine and beetroot juice|Combined effect of beetroot juice and caffeine intake on muscular strength, power and endurance performance
58474086|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine|single effect of caffeine intake on muscular strength, power and endurance performance
58474087|NCT06596395|DIETARY_SUPPLEMENT|Acute beetroot juice|single effect of beetroot juice intake on muscular strength, power and endurance performance
58474088|NCT06596395|DIETARY_SUPPLEMENT|Placebo|single effect of placebo on muscular strength, power and endurance performance
58474089|NCT02828826|OTHER|telephone coaching|
58474090|NCT00497458|DRUG|Testosterone|testosterone 40 or 80 mg once a day
58132603|NCT00770510|DRUG|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
58132604|NCT02385396|DIETARY_SUPPLEMENT|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
58132605|NCT05437809|OTHER|Intake of nutritionally diverse ultra-processed foods|All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
58132606|NCT00762307|DEVICE|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
58132607|NCT00813046|BIOLOGICAL|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
58132608|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
58132609|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
58132610|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
58132611|NCT05639062|BEHAVIORAL|Narrative-based card game|This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
58132612|NCT00665730|DEVICE|Sepraspray|
58132613|NCT06497322|OTHER|Exercise intervention - High intensity interval training on a cycle-ergometer|The experimental group starts with 5 minutes of unloaded cycling, followed by 3 × 3-minute HIIT training sequences alternating between: i) 30 seconds at 90% of maximal PO (70 rpm for 30 seconds) and ii) 30 seconds of light pedaling at 20% of PO). Recent work suggests that this high-intensity approach to aerobic exercise is feasible and safe, even during acute oncology treatment. The HIIT sequences are interspersed with two 3-minute cycling sessions at moderate intensity. The training session will be concluded with a 5-minute cool-down by cycling (light pedaling) and stretching. This protocol will be performed twice a week throughout the study, and all patients who reach an 80% adherence threshold for the exercise intervention will be included in the final analysis.
58132614|NCT05064462|OTHER|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
58132615|NCT01820026|DRUG|Imipenem|second line therapy
58132616|NCT01820026|DRUG|Vancomycin|Second line therapy
58132617|NCT01820026|DRUG|azithromycin|Second line therapy
58132618|NCT01820026|DRUG|Cefotaxime|Standard antibiotic therapy
58132619|NCT01820026|DRUG|Amoxicillin|Standard therapy
58474091|NCT02933008|OTHER|aNMT Biofeedback|"aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention."
58132620|NCT02844803|DRUG|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
58132621|NCT02844803|DRUG|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
58132622|NCT05933005|DEVICE|D-kit/EF1|"D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills."
58132623|NCT05933005|DEVICE|Sham group program|The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
58490898|NCT02464280|OTHER|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
58132624|NCT01287013|DEVICE|Cone-beam computed tomography (CT)|Imaging
58132625|NCT01287013|DEVICE|Conventional Computed Tomography (CT)|Imaging
58132626|NCT03909659|BEHAVIORAL|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
58132627|NCT02582541|PROCEDURE|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
58132628|NCT02582541|PROCEDURE|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
58132629|NCT02886468|OTHER|skin ultrasound|
58132630|NCT05064319|DRUG|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
58132631|NCT05064319|DRUG|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
58132632|NCT01570699|GENETIC|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
58132633|NCT00620763|OTHER|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
58132634|NCT00620763|OTHER|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
58132635|NCT00012857|DRUG|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
58132636|NCT00365300|DRUG|pantoprazole|
58132637|NCT00365300|DRUG|Placebo|
58132638|NCT01581970|DRUG|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
58132639|NCT01581970|DRUG|Cetuximab|The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
58132640|NCT03618953|BIOLOGICAL|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
58132641|NCT03618953|BIOLOGICAL|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
58132642|NCT03618953|BIOLOGICAL|Atezolizumab|monoclonal antibody; checkpoint inhibitor
58132643|NCT02057848|OTHER|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
58132644|NCT02057848|OTHER|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
58132645|NCT02057848|OTHER|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
58132646|NCT03482063|DIETARY_SUPPLEMENT|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
58132647|NCT03482063|OTHER|Placebo|riboflavin (2.2mg)
58132648|NCT03619005|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
58132649|NCT03619005|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
58132650|NCT03482440|DRUG|Salsalate Oral Tablet|1500mg twice daily for 5 days prior to experimental testing
58474092|NCT02933008|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
58474093|NCT02933008|OTHER|Neuromuscular Training|Participants will complete a 12-session, pre-season training program, over 6 weeks.
58132651|NCT03482440|DRUG|Placebo Oral Tablet|Placebo oral table twice daily for 5 days prior to experimental testing
58132652|NCT04069637|COMBINATION_PRODUCT|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
58474094|NCT06586385|BEHAVIORAL|disaster education|The ADDIE Instructional Design Model will be used due to its suitability for adult education. General Disaster Awareness Training will be prepared according to the ADDIE instructional design model, which consists of five stages: analysis, design, development, implementation and evaluation. The trainings to be given will be given 1 week after the pre-test, 1 training per week, for a total of 3 trainings.
58132653|NCT03746093|DIETARY_SUPPLEMENT|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
58132654|NCT03746093|DIETARY_SUPPLEMENT|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
58474095|NCT04943952|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Participants will receive JZP458 via intramuscular injection.
58474096|NCT05179135|OTHER|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
58474097|NCT06592976|DIETARY_SUPPLEMENT|Multi-strain Oral Probiotic (CDS22-formula)|All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
58132655|NCT06263348|DRUG|Dorzagliatin tablets|During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
58132656|NCT03897088|DRUG|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
58132657|NCT03897088|DRUG|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
58132658|NCT02025465|DRUG|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
58132659|NCT02025465|DRUG|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
58132660|NCT02977026|BEHAVIORAL|CYD|
58132661|NCT02977026|BEHAVIORAL|AHC|
58132662|NCT05261464|DRUG|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
58132663|NCT05261464|DRUG|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
58132664|NCT05261464|DRUG|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
58132665|NCT04782648|PROCEDURE|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
58132666|NCT02012920|DRUG|Seviteronel: given orally once daily in 28 day cycles|
58132667|NCT04804800|OTHER|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
58132668|NCT04804800|OTHER|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
58132669|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
58132670|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
58132671|NCT02430870|DRUG|TAK-648|TAK-648 solution
58132672|NCT02430870|DRUG|Placebo|TAK-648 placebo-matching solution
58474098|NCT05876442|DEVICE|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
58132673|NCT01737190|OTHER|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
58132674|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
58132675|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
58132676|NCT05270005|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
58132677|NCT01398384|DRUG|Nitric Oxide|MI size at 48-72 hours
58132678|NCT01398384|DRUG|MI size at 48-72 hours|Placebo gas
58132679|NCT05096780|OTHER|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
58132680|NCT02230007|DRUG|MEOPA|3 sessions of reeducation using MEOPA
58132681|NCT02968186|BEHAVIORAL|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
58132682|NCT05284890|DRUG|CC-99677|Specified dose on specified days
58474099|NCT05876442|DEVICE|High Intensity Laser Therapy|High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
58474100|NCT05876442|OTHER|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
58474101|NCT05298514|OTHER|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
58474102|NCT06473181|OTHER|Core stability exercises|Exercises applied to trunk , pelvis and abdomen to improve ability to stand , walk and balance.
58474103|NCT04602663|DEVICE|Esophageal Variceal Band ligation|Band ligation of OV
58490899|NCT02464280|OTHER|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
58132683|NCT03365726|DIAGNOSTIC_TEST|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
58132684|NCT04908332|BEHAVIORAL|Kangaroo Baby Massage|The Kangaroo Baby Massage is an intervention that arose from nursing practice in 1996. It is a therapy that does not require an incubator, fuses massage, kangaroo position and music. KBM is available on video
58474104|NCT06197997|BEHAVIORAL|Chicago Parent Program (CPP)|The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.
58474105|NCT05431933|BIOLOGICAL|Eupolio|Inactivated Polio vaccine (Sabin strains)
58132685|NCT03354104|DEVICE|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
58132686|NCT03354104|DEVICE|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
58132687|NCT03748082|DRUG|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
58132688|NCT03748082|DIAGNOSTIC_TEST|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
58132689|NCT03748082|PROCEDURE|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
58132690|NCT06143722|RADIATION|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
58132691|NCT06143722|RADIATION|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
58132692|NCT05829122|PROCEDURE|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
58132693|NCT02645526|OTHER|Woolen cap|
58132694|NCT05334849|DEVICE|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
58132695|NCT02475083|OTHER|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
58132696|NCT02475083|OTHER|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
58474106|NCT05965258|DIAGNOSTIC_TEST|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
58474107|NCT01542047|DRUG|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
58474108|NCT01542047|DRUG|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
58474109|NCT05411016|DRUG|Placebo|Placebo is administered single dose or multiple dose by IV or SC injection
58474110|NCT05411016|DRUG|KK4277|KK4277 is administered single dose or multiple dose by IV or SC injection
58474111|NCT02866786|DRUG|Metformin|
58474112|NCT02866786|DRUG|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
58474113|NCT00870740|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
58474114|NCT00870740|DRUG|Placebo|Placebo SC injection
58474115|NCT06482944|BEHAVIORAL|Whole Foods for Families|"This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. During the partial feeding period (weeks 3-8), families will be asked to continue the whole foods diet with support that includes: 1) 3 weekly dinners of the families' choosing (described above), 2) rotating menus (\~3 weeks' worth) that will allow for customization (e.g., protein, vegetable, grain swaps) to support cultural/dietary preferences, and 3) dietetic support to help with customization and diet maintenance. Participants will be instructed by the registered dietitian nutritionist (RDN) on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled families in the study, the goal is to maintain complete diet adherence during the twelve-week intervention."
58474116|NCT01556022|DEVICE|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
58132697|NCT01210456|DRUG|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
58132698|NCT05887297|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
58132699|NCT01444443|DEVICE|Closed-loop control|Blood glucose controlled by algorithm
58132700|NCT01444443|OTHER|Open-loop control|Blood glucose controlled by patient
58132701|NCT05919966|OTHER|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
58132702|NCT03338972|BIOLOGICAL|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Given IV
58132703|NCT03338972|DRUG|Cyclophosphamide|Given IV
58132704|NCT03338972|DRUG|Fludarabine|Given IV
58132705|NCT03338972|PROCEDURE|Leukapheresis|Undergo leukapheresis
58132706|NCT06028607|DIETARY_SUPPLEMENT|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
58132707|NCT02590185|DRUG|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg"
58132708|NCT06004726|OTHER|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~* Orientation about Training Programme using PowerPoint slides~* Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~* Distribution of informational booklet on basics about substance abuse~Module 2:~* Role play to develop a positive attitude towards the prevention of substance abuse.~* Case-based scenario to increase resistance to peer pressure.~* Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
58132709|NCT01091090|BEHAVIORAL|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
58474117|NCT01556022|DEVICE|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
58474118|NCT00385671|DRUG|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
58474119|NCT00385671|DRUG|pregabalin|Pregabalin (PGB) orally (PO)
58132710|NCT01091090|BEHAVIORAL|Control|Treatment as usual
58132711|NCT00643578|DRUG|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
58132712|NCT00643578|DRUG|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
58132713|NCT00643578|DEVICE|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
58132714|NCT00394108|PROCEDURE|Determination of neuropsychological status|
58132715|NCT04038060|BEHAVIORAL|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
58132716|NCT04038060|BEHAVIORAL|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
58132717|NCT04038060|BEHAVIORAL|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
58474120|NCT00385671|DRUG|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
58474121|NCT06603714|OTHER|Instrument assisted soft tissue mobilization|We will perform instrument assisted soft tissue mobilization on calf muscles. The intervention will last 9 min. For the first minute of treatment light pressure will be applied for tissue preparation. Afterwards, four different strokes will be applied by maintaining the tool at a 30° of inclination for one minute. This will be repeated for a second set, with a tool inclination of 45°.
58132718|NCT04038060|BEHAVIORAL|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
58474122|NCT03651752|DRUG|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
58474123|NCT05048134|DRUG|HRS2300|HRS2300 monotherapy
58474124|NCT05048134|DRUG|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
58474125|NCT05048134|DRUG|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
58132719|NCT04842045|DRUG|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
58132720|NCT04762056|OTHER|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
58132721|NCT00936260|DRUG|alendronate|several duration of treatment
58132722|NCT02304588|BIOLOGICAL|Mesenchymal stem cells|10-20 x 10\^6 cells/20mL
58132723|NCT00462852|DRUG|dalteparin|
58132724|NCT00462852|DRUG|gemcitabine hydrochloride|
58132725|NCT00462852|OTHER|diagnostic laboratory biomarker analysis|
58132726|NCT03200067|BEHAVIORAL|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
58132727|NCT05008822|OTHER|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
58132728|NCT05008822|OTHER|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
58132729|NCT01014728|DRUG|propofol|100-200mcg/kg/min by infusion
58132730|NCT01014728|DRUG|sevoflurane|1-3% of sevoflurane (expired)
58132731|NCT01938482|DRUG|0.3% GSK1940029 gel|Will be supplied as gel for topical application
58132732|NCT01938482|DRUG|1% GSK1940029 gel|Will be supplied as gel for topical application
58132733|NCT01938482|DRUG|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
58132734|NCT02834611|DRUG|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
58132735|NCT05324735|DRUG|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
58132736|NCT05324735|DRUG|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
58132737|NCT04428541|OTHER|Questionnaire for visual function assessment of preverbal children|18 items questionnaire
58132738|NCT00665821|BEHAVIORAL|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
58474126|NCT05048134|DRUG|HRS2300、trametinib|HRS2300 combined with trametinib
58474127|NCT05048134|DRUG|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
58132739|NCT00665821|BEHAVIORAL|General health education|General health education: a booklet describing general norms for maintaining good health
58132740|NCT01695551|OTHER|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
58132741|NCT04529746|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
58132742|NCT00406848|DRUG|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
58132743|NCT00406848|DRUG|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
58132744|NCT00699322|DRUG|Sitagliptin|100mg P.O. per day for 1month
58132745|NCT00699322|DRUG|Glimepiride|2mg P.O. per day for 1 month
58132746|NCT05376683|DEVICE|Curate.AI|Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI
58132747|NCT05376683|BEHAVIORAL|Telemonitoring|Patients will report their blood pressure to a telemonitoring health platform
58132748|NCT03299907|DIAGNOSTIC_TEST|Spirometry|
58132749|NCT03487107|DRUG|SOF|400 mg tablet administered orally once daily
58132750|NCT03487107|DRUG|DAG181|100 mg capsule administered orally once daily
58132751|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D3|a single oral dose of vitamin D3
58132752|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D2|a single oral dose of vitamin D2
58132753|NCT01675557|DIETARY_SUPPLEMENT|Placebo|a single oral dose of placebo
58132754|NCT05756530|OTHER|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
58132755|NCT00319358|DIETARY_SUPPLEMENT|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
58132756|NCT00319358|DIETARY_SUPPLEMENT|Placebo|placebo
58474128|NCT03563014|DRUG|Radium-223 (Xofigo, Bay88-8223)|Follow the physician's prescription in routine clinical practice.
58474129|NCT01668784|BIOLOGICAL|Nivolumab|
58474130|NCT01668784|DRUG|Everolimus|
58132757|NCT06459388|OTHER|Stabilizing Reversals and Rhythmic Stabilization|3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.
58132758|NCT06459388|OTHER|Pelvic Proprioceptive Neuromuscular Facilitation|The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
58132759|NCT04524065|OTHER|Early rehabilitation protocol for children hospitalized in the PICU|The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
58132760|NCT04860219|DIETARY_SUPPLEMENT|Lactoferrin|7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
58132761|NCT02298322|DEVICE|CoolSculpting System|
58132762|NCT06361498|DEVICE|Ultrasound Imaging|Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
58132763|NCT00881270|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
58132764|NCT02539485|OTHER|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
58132765|NCT01994525|BIOLOGICAL|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
58132766|NCT01994525|BIOLOGICAL|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
58132767|NCT01994525|OTHER|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
58132768|NCT04452734|PROCEDURE|Platelet Rich Plasma (PRP)|PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
58132769|NCT04452734|PROCEDURE|Surgical Extraction|Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
58132770|NCT04448678|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group descriptions\]
58132771|NCT04448678|OTHER|Usual Care|\[See arm/group descriptions\]
58132772|NCT00263965|DRUG|Tesaglitazar|
58132773|NCT00263965|DRUG|Metformin|
58132774|NCT00263965|BEHAVIORAL|Dietary and lifestyle modification counseling|
58132775|NCT06485375|DIAGNOSTIC_TEST|EMG|Disposable bipolar surface electrodes will be used. The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres. Doing so the position of the electrodes results as follows: Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
58132776|NCT05015348|OTHER|fish oil with omega-3 PUFA|3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
58132777|NCT05015348|OTHER|placebo|palm oil as placebo
58132778|NCT01551095|DEVICE|PEGJ tube|The self-propelled PEGJ feeding tube
58132779|NCT01452451|DRUG|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
58132780|NCT01452451|DRUG|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
58132781|NCT00515645|OTHER|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
58132782|NCT01386047|OTHER|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
58132783|NCT01451762|DRUG|.9 normal saline|.9 normal saline administered before surgery.
58474131|NCT06603090|BEHAVIORAL|Text message influenza vaccine reminders|Text message influenza vaccine reminders
58474132|NCT06603090|BEHAVIORAL|Text message COVID-19 vaccine reminders|Text message COVID-19 vaccine reminders
58474133|NCT06603090|BEHAVIORAL|Text message influenza and COVID-19 vaccine reminders|Text message influenza and COVID-19 vaccine reminders
58474134|NCT00910650|BIOLOGICAL|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
58132784|NCT01451762|DRUG|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
58132785|NCT01451762|DRUG|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
58132786|NCT02352298|DEVICE|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
58132787|NCT02352298|DEVICE|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
58132788|NCT02101541|PROCEDURE|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
58132789|NCT03830164|DRUG|Atorvastatin|Given PO
58132790|NCT03830164|DRUG|Pentoxifylline|Given PO
58132791|NCT03830164|DIETARY_SUPPLEMENT|Vitamin E Compound|Given PO
58132792|NCT02745522|DRUG|Oxytocin|
58132793|NCT02745522|DRUG|Placebo|
58132794|NCT03190486|OTHER|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
58132795|NCT00524758|DEVICE|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
58132796|NCT00524758|DRUG|MMC in Trabeculectomy|MMC in Trabeculectomy
58132797|NCT00149500|BEHAVIORAL|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
58132798|NCT05891990|PROCEDURE|immediate implant augmented with sticky tooth|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~* Finally, the flap will be repositioned and sutured."
58132799|NCT05891990|PROCEDURE|immediate implant augmented with autogenous tooth graft|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~* Finally, the flap will be repositioned and sutured."
58132800|NCT05128981|BEHAVIORAL|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
58132801|NCT05104983|DRUG|Sirolimus|The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
58132802|NCT05104983|DRUG|Placebo|Matching placebo
58132803|NCT04382937|DRUG|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
58132804|NCT04382937|DRUG|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
58132805|NCT04848948|BEHAVIORAL|Calory Restriction (F.X. Mayr & VLCD)|"VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution."
58132806|NCT04848948|BEHAVIORAL|Biofeedback|Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
58132807|NCT00002725|DRUG|bryostatin 1|
58132808|NCT00002725|DRUG|chemotherapy|
58132809|NCT00482521|DRUG|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
58132810|NCT00929500|BEHAVIORAL|MAST program|MAST program: twice a week for 4 months
58132811|NCT00528242|DRUG|SLx-2101|
58474135|NCT00910650|DRUG|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
58132812|NCT00528242|DRUG|Placebo|
58132813|NCT02962297|DRUG|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
58132814|NCT02962297|DRUG|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
58132815|NCT01578694|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
58132816|NCT03914066|BEHAVIORAL|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
58132817|NCT05901948|OTHER|Classification|Novel Asherman Scoring Classification
58132818|NCT00620490|DRUG|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
58132819|NCT00620490|OTHER|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
58132820|NCT03180606|OTHER|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
58132821|NCT01351688|DRUG|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
58132822|NCT01747603|OTHER|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
58474136|NCT06590272|DEVICE|TECNIS PCB00 intraocular lens|In this study, we select TECNIS PCB00 IOL for inserting in the eyes during the cataract surgery
58132823|NCT04508998|DIAGNOSTIC_TEST|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
58474137|NCT06590272|DEVICE|HumanOptics Diff-Aay intraocular lens|In this study, we select HumanOptics Diff-Aay IOL for inserting in the eyes during the cataract surgery
58474138|NCT06590272|DEVICE|TECNIS Symfony ZXR00 intraocular len|In this study, we select TECNIS Symfony ZXR00 IOL for inserting in the eyes during the cataract surgery
58474139|NCT06590272|DEVICE|ZEISS AT LISA tri 839MP intraocular len|In this study, we select ZEISS AT LISA tri 839MP IOL for inserting in the eyes during the cataract surgery
58474140|NCT01495949|DRUG|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
58474141|NCT01495949|DRUG|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
58474142|NCT05657340|DIAGNOSTIC_TEST|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
58474143|NCT05043454|OTHER|High Intensity Interval Training (HIIT) Exercise|Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
58474144|NCT06283355|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
58474145|NCT06283355|BIOLOGICAL|Placebo|Placebo sterile swab
58474146|NCT04401813|DRUG|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
58474147|NCT00344201|DEVICE|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
58474148|NCT01426100|DRUG|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
58474149|NCT01426100|DRUG|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
58474150|NCT01426100|DRUG|Telmisartan 80mg|Telmisartan 80mg monotherapy
58474151|NCT06448117|BEHAVIORAL|Mind Nutrition|"The 6-month nutrition intervention includes two individual and three group dietary counseling sessions. During the first individual meeting, a research dietitian will assess the participants' diet quality and eating habits, and each participant will set personal goals in cooperation with the research dietitian. At the second individual meeting, the attainment of the goals will be evaluated, and potential challenges and solutions discussed. Each group session has its theme and content in the following chronological order:~1. Introduction to the theme and importance of a regular meal frequency~2. Principals of health-promoting diet, mindful eating~3. Successful eating regulation skills, psychology of the long-term lifestyle changes.~Additionally, participants receive home assignments and a workbook containing informational material and exercises."
58474152|NCT06324162|DEVICE|bracket removal pliers, LODI|Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
58474153|NCT02419495|DRUG|Capecitabine|Given PO
58474154|NCT02419495|DRUG|Carboplatin|Given IV
58474155|NCT02419495|DRUG|Cyclophosphamide|Given IV
58474156|NCT02419495|DRUG|Doxorubicin|Given IV
58474157|NCT02419495|DRUG|Eribulin|Given IV
58474158|NCT02419495|DRUG|Fluorouracil|Given IV
58474159|NCT02419495|BIOLOGICAL|Ipilimumab|Given IV
58474160|NCT02419495|DRUG|Irinotecan Hydrochloride|Given IV
58474161|NCT02419495|DRUG|Leucovorin Calcium|Given IV
58474162|NCT02419495|BIOLOGICAL|Nivolumab|Given IV
58474163|NCT02419495|DRUG|Olaparib|Given PO
58474164|NCT02419495|DRUG|Oxaliplatin|Given IV
58474165|NCT02419495|DRUG|Paclitaxel|Given IV
58474166|NCT02419495|BIOLOGICAL|Pembrolizumab|Given IV
58474167|NCT02419495|DRUG|Pemetrexed|Given IV
58474168|NCT02419495|DRUG|Selinexor|Given PO
58474169|NCT02419495|DRUG|Topotecan|Given IV
58474170|NCT04447807|BEHAVIORAL|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
58474171|NCT04447807|OTHER|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
58474172|NCT00794716|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
58474173|NCT06604208|DEVICE|Binaural Beats|"The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night."
58474174|NCT06604208|DEVICE|Placebo|Placebo
58474175|NCT06591143|PROCEDURE|ART|Caries excavation with hand instruments only and restoration with glass ionomer filling
58474176|NCT06591143|PROCEDURE|Hall technique|Stainless steel crown placement without tooth preparation
58490900|NCT02464280|OTHER|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
58490901|NCT02175030|DRUG|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
58490902|NCT02175030|DRUG|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
58490903|NCT00003013|DRUG|CMF regimen|
58490904|NCT00003013|DRUG|cyclophosphamide|
58490905|NCT00003013|DRUG|doxorubicin hydrochloride|
58490906|NCT00003013|DRUG|fluorouracil|
58490907|NCT00003013|DRUG|methotrexate|
58474177|NCT05056415|OTHER|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
58474178|NCT05056415|OTHER|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
58132824|NCT04508998|DIAGNOSTIC_TEST|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
58474179|NCT01459211|DRUG|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
58474180|NCT06284343|DRUG|Anticoagulant|Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
58132825|NCT01327963|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
58474181|NCT06590194|DRUG|PH009-1 tablet|PH009-1 will be administered in fasting state
58474182|NCT06601348|OTHER|Nutrition education, physical activity intervention, and health promoting school model trials|A nutrition education and physical activity intervention, combining a pilot health promoting school model that includes health education and recreational enhancement with the curriculum of a government-designated healthy school, was designed to reduce childhood overweight and obesity. The programme was implemented over 6 months. This program has been widely conducted in several countries, but there are still many differences from previous studies, especially in terms of strengthening qualitative studies in the first stage, then in the intervention stage using a Cluster Randomised Controlled Trial design. Another advantage of this study is the combination of intervention and health promoting school. In Indonesia, there are few intervention studies in reducing overweight and obesity in children, some only focus on descriptive studies such as nutritional knowledge, physical activity measures using questionnaires to determine the relationship or measure BMI.
58474183|NCT06417216|BEHAVIORAL|Head-cancelled virtual reality|Scene in virtual reality moves with the head while performing visual tasks.
58474184|NCT05754645|OTHER|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
58474185|NCT06474455|DRUG|SHR-9839 ；SHR-A2009|SHR-9839 combined with SHR-A2009
58474186|NCT06474455|DRUG|SHR-9839 ； SHR-A1921|SHR-9839 combined with SHR-A1921
58474187|NCT06474455|DRUG|SHR-9839 ； pemetrexed ；carboplatin|SHR-9839 combined with pemetrexed + carboplatin
58474188|NCT06474455|DRUG|SHR-9839 ； Almonertinib|SHR-9839 combined with Almonertinib
58474189|NCT04074720|PROCEDURE|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
58474190|NCT04074720|OTHER|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
58474191|NCT04074720|OTHER|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
58474192|NCT05450679|PROCEDURE|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at \> 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
58474193|NCT05714410|DIETARY_SUPPLEMENT|PHGG|PHGG
58474194|NCT06595641|DEVICE|Transfer Energy Capacitive Resistive Therapy|It's a physical treatment modality commonly used to treat musculoskeletal pain. It normally uses a longwave radiofrequency of \~0.5 MHz. The system consists of a neutral plate and two different electrodes that can transfer energy in two modalities: capacitive and resistive
58474195|NCT06595641|OTHER|strength training program|"Each session includes five exercises, each performed for three sets of 10 repetitions:~Shoulder Retraction - Strengthens muscles between shoulder blades. Shoulder Scaption - Improves stability and range of motion. Shoulder External Rotation from Side Lying - Targets rotator cuff muscles. Shoulder Protraction - Enhances shoulder blade function. Shoulder Extension - Strengthens posterior shoulder muscles"
58474196|NCT06597123|BEHAVIORAL|Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training|Basic participants will participate in two motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool (Real-time Evaluation of Dialogue in Motivational Interviewing), and both the spirit of MI and presence of bias as measured by Dougall GPT.
58490908|NCT00003013|DRUG|paclitaxel|
58490909|NCT00003013|DRUG|tamoxifen citrate|
58490910|NCT00003013|PROCEDURE|conventional surgery|
58490911|NCT00003013|RADIATION|radiation therapy|
58474197|NCT06597123|BEHAVIORAL|Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training|Plus participants will participate in four motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool, and both the spirit of MI and presence of bias as measured by Dougall GPT.
58474198|NCT00770263|DRUG|Erlotinib|
58474199|NCT00770263|DRUG|Temsirolimus|
58474200|NCT02023086|PROCEDURE|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
58474201|NCT02023086|PROCEDURE|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
58474202|NCT02023086|PROCEDURE|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
58474203|NCT02023086|PROCEDURE|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
58474204|NCT02023086|DRUG|Tropicamide|Used to dilate patient's pupil during testing
58474205|NCT02023086|DEVICE|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
58474206|NCT05523453|BEHAVIORAL|Processing of Positive Memories Technique (PPMT)|PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.
58474207|NCT05523453|BEHAVIORAL|Supportive Counseling (SC)|SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
58474208|NCT00418678|DRUG|Cesamet|2 mg BID on Days 2-5.
58474209|NCT06650527|BEHAVIORAL|Cognitive Empathy Training|Participants will engage in a mentalization activity by captioning photos of their care recipients, reflecting on what the care recipient might be thinking or feeling. Over 10 days, caregivers will take 3-5 daily pictures of their care recipient and caption each with descriptive text representing the recipient's inner voice. This task encourages caregivers to consider the care recipient's perspective and motivations behind their behavior or emotional experiences. Photos will be shared securely via encrypted email. Utilizing accessible smartphone technology, the study allows caregivers to capture and reflect on meaningful moments with their care recipients
58474210|NCT06650527|BEHAVIORAL|Control Condition|In the control condition, participants will be asked to take 3-5 daily photographs of nature over 10 days. They will be asked to caption each photo with a description of what they see. This exercise will involve many of the same activities as the cognitive empathy training, except that participants will not be mentalizing or taking the the perspective of their PLWD or anyone else.
58474211|NCT06650527|PROCEDURE|Pre and post intervention blood spot collection|At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.
58474212|NCT06650527|PROCEDURE|Pre and post intervention MRI session|In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.
58474213|NCT05818085|DRUG|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
58474214|NCT05818085|DRUG|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
58474215|NCT05818085|OTHER|Placebo|ABP-671 matching placebo
58474216|NCT04351334|DRUG|Alectinib|Observational treatment based on physician choice
58474217|NCT05444855|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
58474218|NCT00259662|DRUG|atorvastatin|
58132826|NCT05593965|DEVICE|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
57779558|NCT02746081|DRUG|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
58474219|NCT01411345|RADIATION|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
58474220|NCT01411345|RADIATION|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
58474221|NCT06478186|DRUG|triamcinolone acetonide extended-release injectable suspension; TCA-ER|Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
58474222|NCT06478186|DRUG|Triamcinolone Acetonide- Immediate Release;TCA-IR|Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
58474223|NCT06604455|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
58474224|NCT06604455|OTHER|acupressure/relaxation|The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
58474225|NCT05349591|BIOLOGICAL|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
58474226|NCT06589349|BEHAVIORAL|Kangaroo Care|Physiological parameters will be measured in the Day (10:00) - Night (22:00) cycle for 3 days, just before being taken into kangaroo care in the experimental group, and when the kangaroo care is terminated, the baby will be measured in the mother's arms. Then, the mother and baby will be placed in kangaroo care for a minimum of 70 minutes
58474227|NCT06555107|OTHER|questionnaire|Patients included in the study will be asked to complete a questionnaire 48 to 72 hours after surgery to assess their perception of pain and preoperative anxiety
58474228|NCT06555107|OTHER|phone call|Patients will then be interviewed by phone 3 months after their emergency surgery. During the interview, they will be questioned via a standardised questionnaire on the existence of CPSP
58474229|NCT06590948|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system
58474230|NCT05939453|OTHER|Sham Light|Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
58474231|NCT05939453|OTHER|Bright Light Therapy|Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
58474232|NCT06598748|OTHER|Mechanical Interface Mobilisation Technique|In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
58474233|NCT06598748|OTHER|Exercise Therapy|"Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26)."
58474234|NCT06653907|DRUG|Levothyroxine Sodium (LT4) Tablets|"Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
58474235|NCT06653907|DRUG|Placebo|"Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
58490912|NCT03975478|PROCEDURE|Gastric bypass|The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.
58474236|NCT06476106|DEVICE|Venoconstrictive Thigh Cuff (VTC)|The VTC is an adjustable fabric cuff that is worn on the upper thighs to retain some fluid in the legs. It consists of wide straps and a buckle which allow it to be tightened, then velcro to secure the strap in the tightened position. There is also lacing that can be tightened for micro adjustments. Imbedded within the fabric strap is a bladder that is not used for increasing tightness but allows the pressure of the cuff to be measured and tracked.
58132827|NCT05593965|DEVICE|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
58474237|NCT06473857|BEHAVIORAL|Mental health literacy intervention|Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games
58474238|NCT06473857|BEHAVIORAL|Non mental health intervention|Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
58474239|NCT05600634|PROCEDURE|Skin allotransplantation|Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
58474240|NCT03052270|DRUG|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
58474241|NCT04328805|DRUG|Ibuprofen Arginine tablets|oral tablet
58474242|NCT06588036|DRUG|Prebiotic|. The primary outcome measure will be the mean time from the initiation of treatment to the resolution of diarrhea symptoms. This objective seeks to provide evidence-based insights into the optimal management strategies for childhood diarrhea and inform clinical practice guidelines.
58132828|NCT05593965|DEVICE|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
58474243|NCT06588036|OTHER|Duration|every participant is alloted a group based on RCT.
58132829|NCT01498848|DIETARY_SUPPLEMENT|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
58474244|NCT06588036|DRUG|Smecta|Group 4 will be given smecta scahet
58474245|NCT06598020|BEHAVIORAL|Supportive Care|Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)
57779559|NCT05421520|DEVICE|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
57779560|NCT01674595|BIOLOGICAL|AVANZ olea|Immunotherapy Olea europaea
57779561|NCT04678869|DRUG|Ciprofloxacin|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
57779562|NCT04678869|DRUG|Antibiotic|Standard of care antibiotic as per local policy
57779563|NCT06082622|COMBINATION_PRODUCT|laxatives|triple therapy of drugs, behaviour and mental axis
58132830|NCT03913806|DRUG|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
58132831|NCT00376922|PROCEDURE|music therapy|music played for patient during bone marrow biopsy collection
58132832|NCT02216071|DRUG|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
58132833|NCT02216071|DRUG|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
58132834|NCT01631565|BEHAVIORAL|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
58132835|NCT01631565|BEHAVIORAL|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
58132836|NCT01631565|BEHAVIORAL|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
58132837|NCT00740493|DRUG|warfarin|18 months of warfarin therapy
58132838|NCT00740493|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy
58474246|NCT06413355|DRUG|[F-18]-FAPI-74|A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
58474247|NCT05444348|BEHAVIORAL|Advance consultation concerning your life and treatment (ACT )|The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
57779564|NCT02826564|DRUG|pembrolizumab|
57779565|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
57779566|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
57779567|NCT01948271|DRUG|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
57779568|NCT00941278|DRUG|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
57779569|NCT04267614|DRUG|Etanercept|Patients who received etanercept for RA
58132839|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
58132840|NCT00469586|DRUG|metformin|Tablets, 2000 mg/day.
58132841|NCT00469586|DRUG|glimepiride|Tablets, 4 mg/day.
58132842|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
58132843|NCT02017964|DRUG|Carboplatin|Given IV
58132844|NCT02017964|OTHER|Cognitive Assessment|Optional ancillary studies
58474248|NCT05920889|DRUG|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
58474249|NCT05996016|OTHER||
58474250|NCT04589741|DRUG|Toripalimab Combined With CAV/IE chemotherapy|"CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
58474251|NCT04589741|DRUG|CAV/IE alternate chemotherapy|"CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
58474252|NCT06331299|DRUG|UGN-103|UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
58474253|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
58474254|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
58474255|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
58474256|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
58474257|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
58474258|NCT02992288|DRUG|Placebo|Orally once daily for 20 weeks
58474259|NCT06591442|DIAGNOSTIC_TEST|This is an observational study|This study divides the elderly population into two groups: the Elderly group and the Advanced age group. By observing the enhanced recovery after spinal fusion surgery in these two distinct age groups of elderly patients, risk factors affecting postoperative enhanced recovery will be identified. Detection index: Blood routine examination, blood biochemistry, coagulation function, imaging examination (X-ray, CT 3D reconstruction), Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) pain score. The number of participants for all adverse events, serious adverse events, implant-related adverse events and drug-related serious adverse events, and the adverse events were summarized accordingly. The severity of adverse events will be rated according to NCI-CTCAE version 4.0.
58474260|NCT00364637|DRUG|Sevoflurane (Volatile Anesthetic)|
58474261|NCT00364637|DRUG|Total intravenous anesthesia|
58474262|NCT06609460|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
58474263|NCT06609460|COMBINATION_PRODUCT|Placebo|Placebo to match
58474264|NCT06594081|BEHAVIORAL|Intervention podcasts|Students in the experimental group will listen to podcasts.
58474265|NCT06425458|BEHAVIORAL|Co-Designed Strengths-Based Leadership Program|Please see arm description.
58474266|NCT03077971|BEHAVIORAL|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
58474267|NCT03077971|BEHAVIORAL|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
58474268|NCT05562999|DRUG|Rocuronium Bromide|Moderate NMB (TOF 1-2)
58474269|NCT05562999|DRUG|Rocuronium Bromide|Deep NMB (PTC 1-2)
58474270|NCT05484635|PROCEDURE|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
58474271|NCT05484635|PROCEDURE|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
58474272|NCT06590584|OTHER|Patients with obesity|Six-Minute Pegboard and Ring Test: It will be used to evaluate upper extremity exercise capacity. There are 20 rings on 4 iron bars on the board used and patients will be asked to attach the rings with both hands, first from top to bottom and then from bottom to top. At the end of the six minutes, the total number of rings attached will be recorded. Heart rate, blood pressure, respiratory rate, dyspnea and fatigue will be evaluated according to the Modified Borg Scale before and after the test.
58474273|NCT00006020|DRUG|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
58474274|NCT06235190|DEVICE|Felix NeuroAI Wristband|The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
58474275|NCT06235190|DEVICE|Sham Device|The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
58474276|NCT06594978|DEVICE|dual-site anodal tDCS over the M1|M1: motor cortex
58474277|NCT06594978|DEVICE|dual-site anodal tDCS over the DLPFC|DLPFC: dorsolateral prefrontal cortex
58474278|NCT06594978|DEVICE|sham tDCS|sham stimulation
58474279|NCT06119048|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
58474280|NCT01950182|DRUG|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
58132845|NCT02017964|DRUG|Cyclophosphamide|Given IV
58474281|NCT01950182|DRUG|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
58474282|NCT06504992|DRUG|Vancomycin 1000 MG|Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
58474283|NCT06177080|OTHER|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
58474284|NCT03413891|DRUG|Tranexamic Acid|Mouthwash
58132846|NCT02017964|DRUG|Etoposide|Given IV
58132847|NCT02017964|OTHER|Laboratory Biomarker Analysis|Correlative studies
58132848|NCT02017964|DRUG|Methotrexate|Given IV
58132849|NCT02017964|DRUG|Vincristine Sulfate|Given IV
58132850|NCT01492400|DRUG|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
58132851|NCT01492400|DRUG|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
58132852|NCT02395822|BIOLOGICAL|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
58132853|NCT05602688|DIETARY_SUPPLEMENT|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
58132854|NCT05602688|DIETARY_SUPPLEMENT|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
58132855|NCT05039502|OTHER|Protaper Universal Retreatment|D1-D2-D3 Retreatment files were used in 500 rpm and 3 Ncm with X-Smart endomotor
58132856|NCT05039502|OTHER|Reciproc|R25 retratment files were used with X-Smart endomotor in reciprocal motion
58132857|NCT05039502|OTHER|XP-Endo finisher R|XP-Endo finisher r file were used in 1000 rpm 1 Ncm with X-Smart endomotor
58132858|NCT03133195|DRUG|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
58132859|NCT03133195|DRUG|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
58474285|NCT03413891|OTHER|Placebo|Mouthwash
58474286|NCT04089787|OTHER|Intervention|Shortened antibiotic treatment of 5 days
58132860|NCT03133195|DIETARY_SUPPLEMENT|Calcium supplement|1000 mg/day of elemental calcium
58132861|NCT03133195|DIETARY_SUPPLEMENT|Vitamin D|20,000 IU/week of vitamin D2
58132862|NCT02606565|BIOLOGICAL|Intervention arm: 4% chlorhexidine|See previous description
58132863|NCT00003123|DRUG|amifostine trihydrate|
58132864|NCT05400148|DRUG|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)
58132865|NCT05224895|PROCEDURE|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
58132866|NCT03150602|DRUG|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
58132867|NCT00473356|DIETARY_SUPPLEMENT|receive amino acid supplement|Receive amino acid supplement
58132868|NCT03664908|OTHER|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
58132869|NCT02632136|DRUG|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
58132870|NCT02632136|DRUG|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
58132871|NCT04506866|DEVICE|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
58132872|NCT01934673|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
58132873|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
58132874|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
58132875|NCT03097120|DRUG|placebo tablets|two placebo tablets daily
58132876|NCT03695926|DRUG|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
58474287|NCT04089787|OTHER|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
58474288|NCT06589141|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin (500 to 2000 mg orally)
58132877|NCT03576846|OTHER|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
58132878|NCT03576846|OTHER|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
58132879|NCT05166265|DEVICE|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
58474289|NCT06589141|DRUG|GlyBURIDE 2.5 MG Oral Tablet|Glyburide (2.5 mg to 20 mg orally)
58474290|NCT05074979|OTHER|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
58132880|NCT02178722|DRUG|MK-3475|IV infusion
58132881|NCT02178722|DRUG|INCB024360|Oral daily dosing
58132882|NCT04981938|PROCEDURE|Lobectomy with pulmonary artery reconstruction|"Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space~Subgroups : different types of pulmonary artery reconstruction such as :~* Tangential vascular reconstruction with direct suture~* Circumferential resection and end-to-end anastomosis~* bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch"
58132883|NCT02287545|PROCEDURE|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
58132884|NCT00569374|DRUG|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
58132885|NCT02027909|DEVICE|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
58132886|NCT02927509|DRUG|TNF alpha blockers|
58132887|NCT02613156|PROCEDURE|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
58132888|NCT00813293|DRUG|Sorafenib|
58132889|NCT00813293|PROCEDURE|radiofrequency ablation|
58132890|NCT02771548|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
58132891|NCT04589910|DIAGNOSTIC_TEST|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
58132892|NCT05809765|OTHER|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
58132893|NCT05293249|COMBINATION_PRODUCT|dMAb AZD5396|Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
58132894|NCT05293249|COMBINATION_PRODUCT|dMAb AZD8076|Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
58132895|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
58132896|NCT05293249|DRUG|Hylenex|Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
58132897|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
58132898|NCT02272764|DRUG|Itraconazole|Administered orally in a crossover design
58132899|NCT02272764|DRUG|ALKS 5461|Administered sublingually in a crossover design
58132900|NCT00982553|DRUG|Ribavirin|800mg once daily
58132901|NCT00982553|DRUG|Raltegravir|400mg twice daily
57779570|NCT06738628|PROCEDURE|(Esophageal or Gastric) Per-Oral Endoscopic Myotomy|Performing Per-Oral Endoscopic Myotomy for the treatment of either achalasia of the esophagus, or gastroparesis of the stomach.
58474291|NCT05074979|OTHER|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
57779571|NCT00000700|DRUG|Zidovudine|
57779572|NCT00437125|DRUG|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
57779573|NCT03209713|BEHAVIORAL|HPV Vaccine Education|A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
57784804|NCT05381428|COMBINATION_PRODUCT|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
58132902|NCT00710229|DRUG|Ranibizumab|intravitreal injection
58132903|NCT00710229|DRUG|Bevacizumab|intravitreal injection
58132904|NCT01302496|BIOLOGICAL|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
58132905|NCT04205201|DRUG|Drugs, Investigational|To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
58132906|NCT03512405|BIOLOGICAL|Blinatumomab|Given IV
58474292|NCT05074979|OTHER|informed program|will informed after COVID 19
58474293|NCT03712358|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO.
58132907|NCT03512405|OTHER|Laboratory Biomarker Analysis|Correlative studies
58132908|NCT03512405|BIOLOGICAL|Pembrolizumab|Given IV
58132909|NCT06381609|BEHAVIORAL|Quality life questionnaire AQoLS|Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
58132910|NCT06381609|BEHAVIORAL|Quality life questionnaire Euroqol EQ-5D-5L|Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
58132911|NCT06381609|OTHER|Peer support consultations|"For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.~Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up"
58132912|NCT05106166|BEHAVIORAL|Occupational Therapy|occupational therapy sessions are based on the joint attention
58132913|NCT03107468|OTHER|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
58132914|NCT03107468|OTHER|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
58132915|NCT03341481|OTHER|Femaltiker|Patient had taken twice a day the product
58132916|NCT03341481|OTHER|Placebo|Patient had taken twice a day the placebo
58132917|NCT00041509|DRUG|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
58132918|NCT00041509|DRUG|Placebo|matching placebo, oral, BID for 28 days
58132919|NCT06329947|DRUG|Surufatinib 250mg/d qd once daily|mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
58132920|NCT00679965|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
58132921|NCT00679965|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
58132922|NCT00679965|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
58132923|NCT00679965|DRUG|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
58132924|NCT01273181|BIOLOGICAL|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
58132925|NCT01273181|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
58132926|NCT01273181|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
58132927|NCT01273181|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
58132928|NCT03536624|BEHAVIORAL|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
58132929|NCT04599699|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
58132930|NCT00762086|DEVICE|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
58132931|NCT00762086|OTHER|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
58132932|NCT04338126|DRUG|Tranexamic acid|previously described
58132933|NCT04338126|DRUG|Placebo oral tablet|previously described
58132934|NCT06485258|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
58132935|NCT06485258|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
58474294|NCT04475978|DEVICE|IVUS-guide DCB PTCA|IVUS-guide DCB PTCA
58474295|NCT04475978|DEVICE|Angio-guide DCB PTCA|Angio-guide DCB PTCA
58474296|NCT03098875|DRUG|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
58474297|NCT03098875|DRUG|Propofol|General anesthesia using propofol as a hypnotic agent
58474298|NCT03098875|DRUG|Remifentanil|General anesthesia using remifentanil as an analgesic.
58474299|NCT06317051|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin will be administered as a comparator to the placebo to assess its effects on weight reduction
58474300|NCT06317051|DRUG|Pitavastatin 4 Mg Oral Tablet|Pitavastatin tablets will be administered as a comparator to Rosuvastatin/Ezetimibe 10mg/10mg tablets to assess and compare their effects on LDL concentrations
58474301|NCT06317051|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin/Ezetimibe 10mg/10mg tablets will be administered as a comparator to pitavastatin to assess and compare their effects on LDL concentrations
58474302|NCT06317051|DRUG|Placebo|The placebo tablets are visually identical to the active drug tablets and will be administered as a comparator to Dapagliflozin.
58132936|NCT06485258|OTHER|Placebo|0.5 mL sterile saline administered via IM injection
58132937|NCT01417078|DRUG|Diazepam|single-dose; dosage in mg, based on patient body weight
58132938|NCT01751152|DRUG|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
58474303|NCT03193255|DEVICE|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
58474304|NCT06599151|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
58474305|NCT01742026|PROCEDURE|Aspergillus PCR technique|Aspergillus DNA PCR technique
58474306|NCT01742026|PROCEDURE|Aspergillus AGA technique|Aspergillus AGA technique
58474307|NCT06271993|DEVICE|ColActivePlus Collagen Matrix Dressing|The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
58474308|NCT02003924|DRUG|Enzalutamide|160 mg by mouth once daily
58474309|NCT02003924|DRUG|Placebo|Sugar pill to mimic enzalutamide
58474310|NCT04815876|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
58474311|NCT04815876|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
58474312|NCT04815876|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
58474313|NCT05452863|DEVICE|O2matic administered oxygen|Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
58474314|NCT05452863|DEVICE|Manual oxygen supply and adjustments|Oxygen supply is adjusted from manual measurements of the oxygen saturation
58474315|NCT06595927|DIAGNOSTIC_TEST|Cervical extensor endurance test|Monitoring the clinical parameters of head and neck immobility during the cervical extensor endurance test to correlate them with muscular activity by MRI and other cervical clinical tests
58474316|NCT06318143|BEHAVIORAL|TASSH|Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
58474317|NCT06587542|OTHER|Injection of protein purified derivative|Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion
58474318|NCT06518239|DEVICE|Peep Belt|Belt will be placed on the nipple line of the patient prior to the surgery start in the operating room. Data will be collected prior to the initial incision after the patient has been intubated, and then at the end of surgery before the patient has been extubated.
58474319|NCT06590649|BEHAVIORAL|Household-level effects|At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). The household participants will be analyzed side by side with the index participants.
58474320|NCT00688987|DRUG|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
58474321|NCT00688987|DIETARY_SUPPLEMENT|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
57779574|NCT03209713|BEHAVIORAL|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
58474322|NCT04047602|RADIATION|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
58474323|NCT02249663|DRUG|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
58474324|NCT02249663|DRUG|Dymista™|137/50 mcg Nasal Spray
58474325|NCT02249663|OTHER|Placebo|Nasal spray with no pharmaceutically active content
58474326|NCT06594991|DRUG|Fianlimab|Fianlimab IV given every three weeks
58474327|NCT06594991|DRUG|Cemiplimab|Cemiplimab IV given every three weeks
58474328|NCT06594991|DRUG|Ipilimumab|Ipilimumab will be give every 6 weeks continuously
58474329|NCT05438849|BEHAVIORAL|Mobile Health Application focused on behavioral treatments to treat urinary incontinence|Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans
58474330|NCT05438849|COMBINATION_PRODUCT|Practice Facilitation|The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
58474331|NCT00762164|DRUG|Vytorin|Vytorin 10/80 split into 4
58474332|NCT00762164|DRUG|Simvastatin|Simvastatin 20 milligrams
58474333|NCT01533207|OTHER|Clinical Observation|Patients followed clinically
58474334|NCT01533207|DRUG|Docetaxel|Given IV
58474335|NCT01533207|DRUG|Doxorubicin Hydrochloride|Given IV
58474336|NCT01533207|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
58474337|NCT01533207|DRUG|Gemcitabine Hydrochloride|Given IV
58474338|NCT01533207|BIOLOGICAL|Pegfilgrastim|Given SC
58490913|NCT03975478|PROCEDURE|Sleeve gastrectomy|The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
58474339|NCT05135533|DEVICE|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
58474340|NCT05135533|DEVICE|Sham|The Sham group will not receive electrical stimulation.
58474341|NCT05135533|OTHER|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
58474342|NCT06593795|PROCEDURE|ultrasound|"before ECV procedure, an ultrasound will be performed to evaluate~* fetal biometry (BPD, HC, AC, FL, EFW);~* Occiput position (right, left);~* Back position (anterior, posterior, right, left);~* Breech variant (footling, frank, complete);~* Fetal leg posture (extended, flexed)~* Placental localization;~* Amniotic Fluid Index (AFI);~* Fore-bag of amniotic fluid;~* Eventual presence of nuchal cords;~* Fetal head ballottement (yes, no);~* Occiput-spine angle These parameters will be compared to find predictive factors for successful ECV"
58474343|NCT03841461|OTHER|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
58474344|NCT03841461|OTHER|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; \>5 refers to poor sleep quality.
58474345|NCT03841461|OTHER|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
58474346|NCT03841461|OTHER|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
58474347|NCT01980017|BEHAVIORAL|Ottawa Model for Smoking Cessation|
58474348|NCT05536635|BEHAVIORAL|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
58474349|NCT03566290|DRUG|GTx-024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
58474350|NCT00771277|BEHAVIORAL|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
58474351|NCT06545188|OTHER|Mortality Attitudes Personality Survey|Two open questions about death and mortality will bei administered to trigger mortality salience
58474352|NCT06545188|OTHER|Dental treatment questions (control condition)|Two open questions about a dental treatment (control condition)
58474353|NCT06597708|BEHAVIORAL|keto diet|They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively.
58474354|NCT06597708|BEHAVIORAL|intermittent fasting with calorie restriction|The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period.
58474355|NCT00894816|DIETARY_SUPPLEMENT|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
58474356|NCT00894816|DIETARY_SUPPLEMENT|Placebo|Infant cereals without any addition
58474357|NCT06602882|BEHAVIORAL|chatbot-delivered screening and brief intervention|"1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking."
58474358|NCT00162487|DRUG|Albuterol (1,200 μg) through metered-dose inhaler|
58474359|NCT06596980|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
58474360|NCT03234595|DRUG|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
58474361|NCT05424081|BEHAVIORAL|EMBER|Self-help tool to increase weight management engagement
58474362|NCT05424081|BEHAVIORAL|Control|List of weight management programs
58474363|NCT06603129|DIAGNOSTIC_TEST|prognostic nutritional index|Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.
58474364|NCT01838694|BIOLOGICAL|Ala-Cpn10|
58474365|NCT01838694|DRUG|Placebo|
58474366|NCT05168202|DRUG|CC-95251|Specified dose on specified days
58474367|NCT05168202|DRUG|Azacitidine|Specified dose on specified days
58474368|NCT05168202|DRUG|Venetoclax|Specified dose on specified days
58474369|NCT06654479|OTHER|In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.|The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
58474370|NCT06586242|DRUG|Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin|200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
58474371|NCT06472362|DIAGNOSTIC_TEST|HRCT biomarkers|HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
58474372|NCT06586034|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for both English and Spanish languages and is culturally tailored for Hispanic/Latino/Latinx individuals who smoke. Impacto will be developed for both iOS and Android platforms. The mobile app aims to aid smoking cessation by targeting elevated anxiety sensitivity.
58474373|NCT06600542|DEVICE|Inari Medical Commercially Available Devices|Commercially approved Inari Medical devices
58474374|NCT03858179|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
58474375|NCT03858179|DEVICE|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
58474376|NCT03951103|OTHER|rFVIIIFc|Drug according to prescription
58474377|NCT06599294|PROCEDURE|Digital scanning|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
58474378|NCT06599294|PROCEDURE|Two digital impressions will be recorded, one with a conventional intra-oral scanner and another one with an intra-oral photogrammetry scanner.|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
58474379|NCT06586840|OTHER|rescue analgesia|. If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia
58474380|NCT06586840|PROCEDURE|Adductor Canal Block|For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.
57779575|NCT02572336|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
58474381|NCT06586840|PROCEDURE|Adding an IPACK Block to the Adductor Canal Block|For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
58474382|NCT04456504|BIOLOGICAL|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
58474383|NCT01751698|BEHAVIORAL|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
58474384|NCT01751698|BEHAVIORAL|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
58474385|NCT06597903|DRUG|NRL994|"In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid."
58474386|NCT06598618|OTHER|Graston technique+ Conventional PT|IASTM technique (graston technique) on iliotibial band. Frequency 2 sessions of stroking with 20 seconds rest in between 3 times/week for 3 consecutive weeks Intensity as tolerated by patient. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps
58474387|NCT06598618|OTHER|Muscle energy technique + Conventional PT|Muscle energy technique (post facilitation stretch) on iliotibial band. Frequency 10 repetitions 3 times/week for 3 consecutive weeks Intensity starting from 50 percent resistance across barrier provided by physiotherapist.. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps.
58474388|NCT01361230|DEVICE|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
58474389|NCT03307109|OTHER|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
58474390|NCT06597032|BEHAVIORAL|Resilience Challenge|We previously have tested this online program in people facing health- and work-related stressors (e.g., dementia caregivers, healthcare workers), and in 2020 we enrolled adults in a test of the online program to support coping with the stress of the COVID pandemic. This intervention has been tailored for a widespread, public audience (e.g., we have added a few other safety measures including limits on public forum posting and have clarified wording on some of the intervention content to make it clearer and easier to understand).
58474391|NCT01932593|PROCEDURE|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
58474392|NCT04162418|DEVICE|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
58474393|NCT06599242|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy is an exercise approach belonging to physiotherapists
58474394|NCT06599242|OTHER|American football team training|American football team training
58474395|NCT06184516|PROCEDURE|Reproductive organ sparing radical cystectomy|"Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool."
58474396|NCT06184516|PROCEDURE|Radical cystectomy|"Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool."
57779576|NCT02572336|DRUG|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
57779577|NCT02572336|DRUG|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
57779578|NCT05629442|OTHER|ctDNA|initial research biopsy, quality of life assessments and ctDNA collection
58474397|NCT02505607|OTHER|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
57779579|NCT02291289|DRUG|Cetuximab|500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
57779580|NCT02291289|DRUG|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
58132939|NCT01751152|DRUG|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
58132940|NCT02328443|DRUG|Midazolam|
58474398|NCT05881304|DEVICE|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
58474399|NCT03020251|OTHER|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
58474400|NCT03020251|OTHER|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
58474401|NCT06010160|BEHAVIORAL|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
58474402|NCT03162926|COMBINATION_PRODUCT|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
58474403|NCT01140529|DRUG|Dexmedetomidine|Bolus and continuous infusion
58474404|NCT01140529|DRUG|Haloperidol|Bolus doses
58474405|NCT01140529|DRUG|Saline|Bolus and continuous infusion
58474406|NCT06588972|DIETARY_SUPPLEMENT|Medium Chain Triglyceride solution|Placebo
58474407|NCT06588972|OTHER|Cannabis|Group 2: C. sativa extract with THC:CBD ratio 1:10 (2mg:20mg/day);
58132941|NCT02328443|DRUG|itraconazole|
58474408|NCT06588972|OTHER|Cannabis Sativa|Group 3: C. sativa extract with THC:CBD ratio 1:10 (4mg:40mg/day).
58474409|NCT04206124|PROCEDURE|Brown Fat Harvest During Anterior Neck Surgery|During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
58474410|NCT05330559|OTHER|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
58474411|NCT06586970|BEHAVIORAL|Meals + RD services|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
58474412|NCT06586970|BEHAVIORAL|Meals + OT services|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
58474413|NCT06586970|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
58474414|NCT05349487|DEVICE|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
58474415|NCT05349487|OTHER|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
58474416|NCT05349487|DEVICE|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
58474417|NCT04167657|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab."
58474418|NCT06595056|BEHAVIORAL|Multi-technology MVPA intervention|Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
58474419|NCT05927935|OTHER|Supervised strength exercise intervention|A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.
58132942|NCT02328443|DRUG|rifampicin|
58132943|NCT00302705|DRUG|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
58132944|NCT00302705|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
58132945|NCT00302705|PROCEDURE|Missing one dose|Patients skip the dose the second day of monitoring
58132946|NCT00811668|DEVICE|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
58474420|NCT05927935|OTHER|Minimal educational intervention (usual care)|Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, patients will receive a referral for physiotherapy and supplementary a minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like.
58474421|NCT02675465|DRUG|ATB200|
58474422|NCT02675465|DRUG|AT2221|
58474423|NCT05732311|DEVICE|intermittend theta burst stimulation|intermittend theta burst stimulation
58474424|NCT06145321|DEVICE|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
58474425|NCT06145321|DRUG|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
58474426|NCT03496311|DIAGNOSTIC_TEST|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
58474427|NCT04645355|DRUG|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
58474428|NCT06596265|BEHAVIORAL|Fit2Lead Group 1-2|"Each park serves anywhere from 2 to 9 feeder schools within these neighborhoods (a target population of 34 000 youth residents aged 12-17 years), and transportation from schools to parks is provided at no cost within a 3-mile radius of a program park. Fit2Lead participants can also enroll in the MDPROS youth summer camp at no charge.~Work assignments support MDPROS operations and recreation staff. Interns in Phase II rotate every 8 weeks for exposure to different job opportunities, supervisors, and mentors.~Duke is conducting a secondary data analysis on data collected as part of the Fit2Lead study."
58474429|NCT04474834|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40 %).
58474430|NCT05804136|DEVICE|Duramesh|Laparotomy closure with Duramesh
58474431|NCT05804136|DEVICE|Polydioxanone suture|Laparotomy closure with standard PDS
58474432|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
58474433|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
58474434|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
58474435|NCT03435250|DRUG|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
58474436|NCT03435250|DRUG|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
58474437|NCT03435250|DRUG|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
58474438|NCT05424406|BEHAVIORAL|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
58474439|NCT05424406|BEHAVIORAL|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
58474440|NCT05424406|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
58474441|NCT05424406|BEHAVIORAL|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
58474442|NCT06588881|DEVICE|nebulized application of the haemostatic surgical sealant after gastrointestinal endoscopic resection|ENDONEB, a nebulizing catheter containing the synthetic haemostatic-sealant Glubran®, is inserted in the operative channel of the endoscope until it is pushed out of the endoscope tip approximately 2 cm. The haemostatic-sealant is nebulized over the surface of the post resection mucosal defect by activating the propellant (medical-inert-gas) container. An amount of about 0.3 mL of Glubran® 2 (or more - depending on dimension of the lesion) is applied on mucosal or sub-mucosal defect in order to create a proper haemostaticsealant film.
58474443|NCT00023959|DRUG|hydroxyurea|Given orally
58474444|NCT00023959|DRUG|fluorouracil|Given IV
58474445|NCT00023959|BIOLOGICAL|bevacizumab|Given IV
58474446|NCT00023959|RADIATION|radiation therapy|Undergo radiotherapy
58474447|NCT00023959|BIOLOGICAL|filgrastim|Given subcutaneously
58474448|NCT00023959|OTHER|laboratory biomarker analysis|Correlative studies
58474449|NCT03167749|DIAGNOSTIC_TEST|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
58474450|NCT01060332|OTHER|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
58474451|NCT05902260|DIETARY_SUPPLEMENT|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
58474452|NCT05902260|DRUG|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
58474453|NCT04365725|DRUG|Remdesivir|Compassionate provision
58474454|NCT02953002|DEVICE|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
58474455|NCT06589011|OTHER|Pressure Support Ventilation|The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min
58132947|NCT00811668|DEVICE|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
58132948|NCT03946501|OTHER|Data collection|
58474456|NCT06589011|OTHER|spontaneously assisted breathing|The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
58474457|NCT02626312|OTHER|Laboratory Biomarker Analysis|Correlative studies
58474458|NCT02626312|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
58474459|NCT02626312|RADIATION|Radiation Therapy|Undergo radiation therapy
58474460|NCT02626312|OTHER|Survey Administration|Ancillary studies
58474461|NCT04883281|RADIATION|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
58474462|NCT04883281|DRUG|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
58132949|NCT05688306|DRUG|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
58132950|NCT03970122|DRUG|GFB-887|IMP
58474463|NCT06268704|DRUG|Dexamethasone|This is a non-particulate steroid commonly used to treat SI joint pain.
58474464|NCT06268704|DRUG|Methylprednisolone|This is a particulate steroid commonly used to treat SI joint pain.
58474465|NCT06268704|DRUG|2% Lidocaine HCl Injection|Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
58474466|NCT06595745|GENETIC|Wolbachia induced incompatible mating|The intervention will be performed by weekly release of male Aedes aegypti carrying Wolbachia (wAlbB strain) to mate with wild females, resulting in the death of their eggs for birth control. Before release, these males will be irradiated with X-rays to minimize the chance of any residual fertile female releases. The intervention will lead to Ae. aegypti population suppression or even elimination and preventing dengue transmission in release sites.
58474467|NCT06595745|COMBINATION_PRODUCT|Standard traditional chemical mosquito control|Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population
58474468|NCT05708053|DRUG|Metformin|Metformin 500 mg twice
58474469|NCT02063724|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
58474470|NCT06060925|DIAGNOSTIC_TEST|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
58474471|NCT06060925|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
58474472|NCT06060925|DIAGNOSTIC_TEST|Electromyography|High density electromyography
58474473|NCT06060925|DIAGNOSTIC_TEST|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
58474474|NCT06596408|OTHER|optical coherence tomography angiography|OCTA will be used to evaluate the macular vascular density and to exclude patients with pathological myopic maculopathy
58474475|NCT05430178|OTHER|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
58474476|NCT05430178|OTHER|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
58132951|NCT03970122|DRUG|Placebo|Matching
58132952|NCT03831451|BEHAVIORAL|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
58132953|NCT03831451|BEHAVIORAL|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
58132954|NCT04745962|DEVICE|Slimscope|Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
58132955|NCT02016612|DEVICE|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
58132956|NCT01483352|DEVICE|Accu-Chek DiaPort|
58132957|NCT00858156|DRUG|BG9928|Oral 75 mg single dose
58132958|NCT03948347|DRUG|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
58474477|NCT05430178|OTHER|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
58474478|NCT05834634|DEVICE|Ultrasound|The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
58474479|NCT05510583|OTHER|Control group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
58474480|NCT05510583|OTHER|Treated group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
58474481|NCT01484119|DRUG|ACT-129968|daily tablets
58474482|NCT01484119|DRUG|Placebo|matching placebo tablets and capsules
58474483|NCT01484119|DRUG|Cetirizine|daily capsules
58474484|NCT06331013|RADIATION|CyberKnife ultra-hypofractionated SBRT|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
58474485|NCT06085664|DRUG|REGN5678|Given by IV (vein)
58474486|NCT06085664|DRUG|Piflufolastat F18|Given by IV (vein)
58474487|NCT05641337|DRUG|Insulin Degludec and Insulin Aspart|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
58474488|NCT02080806|DEVICE|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
58474489|NCT02156843|DRUG|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
58474490|NCT02156843|DRUG|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
58474491|NCT03868995|PROCEDURE|Sham injection|Dextrose water injection to subcutaneous layer at tender point
58474492|NCT03868995|PROCEDURE|Tendon injection|Dextrose water injection to injured tendon
58474493|NCT06604468|DIAGNOSTIC_TEST|Thoracic bioimpedance tomography|Data collection using a thoracic bioimpedance tomography device
58474494|NCT02183662|DRUG|BI 224436|
58474495|NCT02183662|DRUG|Placebo to BI 224436|
58474496|NCT03772886|DEVICE|Peanut Ball|A peanut shaped exercise ball.
58474497|NCT05783141|DIETARY_SUPPLEMENT|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
58474498|NCT05783141|DIETARY_SUPPLEMENT|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
58474499|NCT06262815|PROCEDURE|Nasogastric tube placement|Conventional nasogastric tube placement done for decompression of small bowel obstruction
58474500|NCT06262815|DIAGNOSTIC_TEST|Clinical Frailty Scale|The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.
58474501|NCT06589401|DRUG|INP12|Oral paclitaxel
58474502|NCT04215731|DRUG|Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
58474503|NCT04215731|PROCEDURE|Restaging|Restaging by pelvic magnetic resonance imaging (MRI)
58474504|NCT04215731|RADIATION|Concomitant Chemoradiotherapy|Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
58474505|NCT04215731|PROCEDURE|Surgery|Radical surgery (TME or more extended surgery)
58474506|NCT04215731|RADIATION|Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)|Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
58474507|NCT04215731|DRUG|Induction chemotherpay with FOLFOX|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
58474508|NCT05405062|DEVICE|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
58474509|NCT06654882|DRUG|TNFi (Tumor Necrosis Factor inhibitor) medication|"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"
58474510|NCT06654882|DRUG|Abatacept|"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"
58474511|NCT06654882|DRUG|Tocilizumab|"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"
58474512|NCT06654882|DRUG|Tofacitinib|"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"
58474513|NCT02011906|DIETARY_SUPPLEMENT|omega 3|
58474514|NCT02011906|DIETARY_SUPPLEMENT|vitamin E|
58474515|NCT02011906|DIETARY_SUPPLEMENT|placebo of omega 3|
58474516|NCT02011906|DIETARY_SUPPLEMENT|placebo of vitamin E|
58474517|NCT04322890|DRUG|Osimertinib|Osimertinib 80mg, po, qd;
58474518|NCT04322890|DRUG|Alectinib 150 MG|Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
58474519|NCT04322890|DRUG|Crizotinib 250 MG|Crizotinib 250 MG po bid.
58474520|NCT04322890|DRUG|Savolitinib, Crizotinib.|Savolitinib, 300mg po qd.
58474521|NCT04322890|DRUG|Chemotherapy|500mg, ivgtt, every 21day.
58474522|NCT01481844|DRUG|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
58474523|NCT01481844|DRUG|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
58474524|NCT06586554|OTHER|Static stretching|The SS group received static stretching, which was applied with gentle and firm pressure while pulling opposite the hamstring muscle contraction.
58474525|NCT06586554|OTHER|Myofascial release|Myofascial release is applied with cross-handed stretches over hamstring muscle
58474526|NCT03206814|OTHER|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
58474527|NCT03206814|OTHER|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
58474528|NCT00190918|DRUG|Pemetrexed|
58474529|NCT04574271|BEHAVIORAL|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
58474530|NCT04574271|BEHAVIORAL|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
58474531|NCT02214797|DEVICE|Etafilcon A, Lotrafilcon B , Senofilcon A|
58474532|NCT00904982|BEHAVIORAL|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
58474533|NCT00904982|DEVICE|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
58474534|NCT00665652|DRUG|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
58474535|NCT06273800|PROCEDURE|Blood sample|Collection of serum sample at the day of start of neo adjuvant treatment
58474536|NCT04340752|DRUG|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
58474537|NCT04311099|DRUG|Active drug|Injection of Ropivacaine
58474538|NCT04311099|DRUG|Placebo|Injection of Saline solution
58474539|NCT04311099|PROCEDURE|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
58474540|NCT04311099|PROCEDURE|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
58474541|NCT04311099|PROCEDURE|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
58474542|NCT04311099|PROCEDURE|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
58474543|NCT04445285|DRUG|Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
58474544|NCT04445285|DRUG|0.9%sodium chloride|Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
58474545|NCT05179928|PROCEDURE|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
58474546|NCT05179928|PROCEDURE|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
58474547|NCT04543708|PROCEDURE|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
58474548|NCT04543708|PROCEDURE|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
58474549|NCT06586723|BEHAVIORAL|PBIS|Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.
58474550|NCT06586723|OTHER|HELM|Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
58474551|NCT05208060|BIOLOGICAL|MV130|Treatment administered sublingually
58474552|NCT05208060|OTHER|Placebo|Treatment administered sublingually
58474553|NCT03651310|OTHER|Music Listening Group|Waiting in preoperative area with music listening.
58474554|NCT06596161|DRUG|Iron sucrose|Receving iron
58474555|NCT06596161|DRUG|Placebo|Placebo
58474556|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
58474557|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
58474558|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
58474559|NCT05703607|BIOLOGICAL|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
58474560|NCT05703607|BIOLOGICAL|Shingrix|Intramuscular injection
58474561|NCT05703607|BIOLOGICAL|Selected Vaccine Candidate group (Dose level, Schedule)|Intramuscular injection
58474562|NCT05703607|BIOLOGICAL|Shingrix - SSB|Intramuscular injection
58474563|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
58474564|NCT01744262|DRUG|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
58474565|NCT01744262|DRUG|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
58474566|NCT04422184|DRUG|Sensodyne Repair and Protect|Dentifricie with NOVAMIN technology
58474567|NCT04422184|DRUG|Dentalclean Daily Regenerator|Dentifricie with Refix technology
58474568|NCT04422184|DRUG|Dentalclean Daily Regenerator with potassium citrate|Dentifricie with Refix technology+ potassium citrate
58474569|NCT00796939|DEVICE|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
58474570|NCT00796939|DEVICE|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
58474571|NCT05500794|OTHER|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~* Guided meditation practices;~* Mindfulness stretching and yoga;~* Reflection and group discussion periods aimed at promoting mindfulness in daily life;~* Practice instructions and opportunity to ask questions;~* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
58474572|NCT04800276|OTHER|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
58474573|NCT04800276|OTHER|global muscle strenghtening|global muscle strenghtening
58474574|NCT02993107|BIOLOGICAL|AR101|AR101 powder provided in capsules \& sachets
58474575|NCT05835284|DEVICE|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
58474576|NCT03564808|DRUG|MSC|Adipose tissue enriched with mesenchymal stem cells
58474577|NCT02372604|DRUG|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))"
58474578|NCT02372604|DRUG|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet"
58474579|NCT06599060|OTHER|Trinity Amputation and Prosthesis Experience Scale|Participants were administered a questionnaire.
58474580|NCT05383937|OTHER|Speech Therapy INTENS-DYS|During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
58474581|NCT01586546|BEHAVIORAL|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
58474582|NCT01586546|OTHER|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
58474583|NCT01586546|OTHER|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
58474584|NCT01586546|BEHAVIORAL|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
58474585|NCT06253442|PROCEDURE|Patients will receive Supra scapular nerve block and Axillary nerve block.|"Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique."
58474586|NCT06253442|PROCEDURE|Patients will receive Interscalene block.|Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
58132959|NCT06374615|DIAGNOSTIC_TEST|IgG and IgM search for specific Tick-Borne Patogens|"Ticks will be classified based on morphological characteristics by microscopy observation.~For TBP detection by molecular test, Nucleic acid extraction will be performed on ticks lysate or blood using kits MagMAX TM Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific) on MagEX STARlet platform from Hamilton. Species identification by molecular method will be performed by Sanger sequencing for Rickettsiae and Babesia, and Multi-Locus Sequence Typing will be used to characterize Borrelia.~Serum samples collected throughout the study will be tested to assess any seroconversions during the follow-up period.~Samples will be tested for the presence of specific IgG and IgM for the following TBPs: TBEV, R. typhi. R. conorii, Borrelia spp, Anaplasma, Ehrlichia and Babesia."
58474587|NCT04377126|DRUG|Ghrelin|Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.
58474588|NCT04377126|DRUG|Placebo|Placebo will consist of saline- no active ingredient.
58474589|NCT03459755|BEHAVIORAL|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
58474590|NCT02603887|OTHER|Laboratory Biomarker Analysis|Correlative studies
58474591|NCT02603887|BIOLOGICAL|Pembrolizumab|Given IV
58474592|NCT05625126|OTHER|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
58474593|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
58474594|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
58474595|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
58474596|NCT01488890|BIOLOGICAL|Yellow Fever|0.5 mL, Subcutaneous
58474597|NCT04457739|OTHER|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
58474598|NCT04457739|OTHER|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
58474599|NCT04457739|OTHER|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
58474600|NCT03880097|PROCEDURE|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
58474601|NCT01010880|DRUG|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
58474602|NCT01001026|BIOLOGICAL|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
58474603|NCT01001026|BIOLOGICAL|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
58474604|NCT03380312|PROCEDURE|rTARUP technique|robot-assisted rTARUP technique
57779581|NCT02291289|DRUG|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
57779582|NCT02291289|DRUG|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
57779583|NCT02291289|DRUG|Vemurafenib|960 mg vermurafenib BID by mouth
57779584|NCT02291289|DRUG|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
57779585|NCT02291289|DRUG|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
57779586|NCT02291289|DRUG|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
57779587|NCT02291289|DRUG|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
58474605|NCT05343182|OTHER|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
58474606|NCT05343182|OTHER|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
57779588|NCT02291289|DRUG|5-FU/LV|1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
58132960|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
58132961|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
58132962|NCT04453202|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
58474607|NCT06595914|OTHER|Clinical implementation strategies|Clinical implementation strategies, selected based on ED clinician survey/interview findings from Aim 1 using the Implementing Promoting Action on Research Implementation in Health Services (i-PARIHS) implementation science framework
58474608|NCT00135031|DRUG|Bifidobacterium infantis 35624|
58474609|NCT06591624|OTHER|Prolonged Mechanical Ventilation|The neurosurgical patients who could extubated within 24 h after surgery
58474610|NCT06591624|OTHER|remain intubation after surgery|could not extubated after surgery and prolong mechanical ventilation for 48 hours
58132963|NCT04453202|OTHER|Placebo|Participants will receive a single IM injection of placebo on Day 1.
58132964|NCT04617769|BEHAVIORAL|Psychoeducation|psychoeducational materials on trauma and safety behaviors
58132965|NCT04617769|BEHAVIORAL|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
58474611|NCT01774721|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
58474612|NCT01774721|DRUG|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
58474613|NCT06592638|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
58474614|NCT06590155|DRUG|Erythropoietin|the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy
58474615|NCT02491684|DRUG|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
58474616|NCT02491684|DRUG|Placebo|Placebo solution for once daily inhalation for 14 days
58474617|NCT05731986|DIAGNOSTIC_TEST|Orthostatic challenge|"Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation."
58474618|NCT05731986|DEVICE|Biostim-5 transcutaneous spinal stimulation - Mapping|Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
58474619|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Optimal testing"|Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
58474620|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Sham testing"|Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
58474621|NCT05128916|BIOLOGICAL|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
58474622|NCT05128916|DRUG|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
58474623|NCT03592186|BEHAVIORAL|Parenting Wisely+|Parenting Wisely+ experimental intervention
58474624|NCT03592186|BEHAVIORAL|Treatment as Usual|Treatment as Usual
58474625|NCT01071304|DRUG|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
58474626|NCT01071304|DRUG|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
58474627|NCT06595355|DRUG|bevacizumab with oral curcumin|According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
58474628|NCT06595355|DRUG|bevacizumab with oral placebo|Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
58474629|NCT01298089|DEVICE|Carriazo Pendular microkeratome|
58474630|NCT06588270|BEHAVIORAL|Virtual Reality Therapy for the Negative Symptoms of Schizophrenia|VRTNSS is a 12-session therapy using psychological intervention principles. Each therapy session will involve engaging with different VR based tasks where participants can experience different activities.
58474631|NCT06588270|BEHAVIORAL|Sham- VR|Patients will attend to VR sessions without the software created activities for treatment (sham-VR).
58474632|NCT06591117|DEVICE|Vizio Aqueous Microshunt|Ocular microshunt placement for the treatment of Glaucoma
58474633|NCT00256594|DEVICE|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
58474634|NCT06322186|OTHER|Ready-Heat Chemical Heating Blankets|Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.
58474635|NCT06322186|OTHER|Warmed blankets or FAWB|The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
58474636|NCT01152255|DRUG|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
58474637|NCT01152255|DRUG|Comparator: Placebo|Placebo tablets taken orally for seven day
58474638|NCT02167698|DEVICE|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
58474639|NCT02167698|OTHER|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
58474640|NCT02167698|DRUG|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
57779589|NCT02291289|DRUG|Capecitabine|1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
57779590|NCT00416871|BIOLOGICAL|aldesleukin|
58474641|NCT02167698|OTHER|Restrictive fluid therapy|Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
58474642|NCT02167698|DRUG|sedo-analgesia titration|
58474643|NCT02167698|OTHER|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
57779591|NCT00416871|BIOLOGICAL|recombinant interferon alfa|
58474644|NCT02167698|OTHER|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
58474645|NCT02167698|OTHER|Biomarker Assay|Biomarker Assay for patients in both arms
58474646|NCT00140452|DRUG|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
58474647|NCT02855125|DRUG|TAS-114|TAS-114 was a modulator of 5-fluorouracil (5-FU).
58474648|NCT02855125|DRUG|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
58474649|NCT02920632|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
58474650|NCT02920632|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
58474651|NCT06594653|OTHER|pre treatment assesment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
58474652|NCT06594653|OTHER|post treatment assessment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
58474653|NCT05526885|DIAGNOSTIC_TEST|CAD4TB|A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.
58474654|NCT05526885|DIAGNOSTIC_TEST|POC-CRP|A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing
58474655|NCT05526885|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra|Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
58474656|NCT03406377|DRUG|OPK-88003|OPK-88003 subcutaneous injection
58474657|NCT03406377|DRUG|Placebo|Placebo subcutaneous injection
58474658|NCT00144547|DRUG|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
58474659|NCT04080648|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
58474660|NCT04080648|OTHER|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
58474661|NCT00726063|DEVICE|Nanotite dental implant|Nanotite root form titanium dental implant
58474662|NCT00726063|DEVICE|Osseotite dental implant|Osseotite Root form titanium dental implant
58474663|NCT04909996|DEVICE|Sentinox--Group A|"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
58474664|NCT04909996|DEVICE|Sentinox--Group B|"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
58474665|NCT04546711|OTHER|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
57779592|NCT04779164|DIAGNOSTIC_TEST|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
57779593|NCT00697554|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
57779594|NCT00697554|BIOLOGICAL|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
57779595|NCT02712112|DRUG|Imatinib Mesylate|
57779596|NCT04299282|DEVICE|CanGaroo|CIED ECM envelope
58474666|NCT05518097|OTHER|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
58474667|NCT06600529|DEVICE|Photo-Biomodulation|Application at acupuncture points for 20 seconds each week. using 810nm Laser probe
58474668|NCT06600529|BIOLOGICAL|Autologous PRP|IV injection of Autologous Plasma Rich Platelets (PRP) on Days 0, 15, 30, and 45.
58474669|NCT06600529|BIOLOGICAL|Exosome Therapy|IV injection of Umbilical Cord-Derived Exosomes at laser acupuncture points Umbilical Cord-Derived Exosomes
58474670|NCT06600529|OTHER|Standard Care (in control arm)|Routine conventional including Applied Behavioral Analysis (ABA) for Autism Spectrum Disorder (ASD)
58474671|NCT05387200|DRUG|Masibone S|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
58474672|NCT05387200|DRUG|Fosamax|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
58474673|NCT03868514|DEVICE|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
58474674|NCT06594185|DEVICE|enVista Aspire EA or Aspire Toric ETA IOLs|enVista Aspire EA or Aspire Toric ETA IOLs
58474675|NCT00651742|DRUG|S-1|All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
58474676|NCT05766813|DRUG|Lenrispodun|Lenrispodun 30 mg tablets administered orally, once daily.
58474677|NCT05766813|DRUG|Placebo|Matching tablets administered orally, once daily.
58474678|NCT06600191|DEVICE|Capstan System transcatheter mitral valve replacement|This is a first human use trial exploring a novel transcatheter mitral valve replacement implant and electro-mechanical delivery system. The device offers a minimally invasive repair for patients who have at symptomatic regurgitation who are otherwise ineligable for surgical intervention, or who have no other prospects for treatment and in whom medical therapy has already been optimised.
58474679|NCT06600204|OTHER|lung scintigraphy|Use the SPECT/CT to predict pulmonary function
58474680|NCT04908631|DEVICE|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
58474681|NCT04908631|OTHER|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
58474682|NCT01010828|PROCEDURE|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
58474683|NCT01010828|PROCEDURE|Incision technique|Mini Mid-Vastus Approach
58474684|NCT04115306|DRUG|PMD-026|Investigational Drug
58474685|NCT04115306|DRUG|fulvestrant|SERDs
58474686|NCT05919186|DRUG|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
58474687|NCT05919186|DEVICE|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
58474688|NCT05919186|DEVICE|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
58474689|NCT02587637|DEVICE|Dorsal root ganglion (DRG) stimulation|The role the DRG plays in the development and maintenance of chronic pain, we have developed a neurostimulator system for the management of chronic intractable pain by electrically stimulating the DRG
58474690|NCT06448676|DRUG|Botulinum toxin type A|Head-to-head comparison of all commercially available botulinum neurotoxin type A products
58474691|NCT06597110|BEHAVIORAL|listened to ASMR|ASMR refers to a physiological sensation triggered by specific auditory stimuli.ASMR, characterized by low-frequency human voice and ambient sounds, has garnered significant attention across social media platforms, short and long-form video platforms, and podcasts, owing to its unique pleasurable and stimulating effects. listen to ASMR for 10mins.
58474692|NCT06492733|DEVICE|FastWire System - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
58474693|NCT00635206|DEVICE|BiPap auto with Fi Flex|"* MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3"
57779597|NCT00440180|DRUG|Anastrozole|1 mg qd for 4 months
57779598|NCT00440180|DRUG|Placebo|Placebo Comparator
57779599|NCT03552718|BIOLOGICAL|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
58474694|NCT00635206|DEVICE|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)
58474695|NCT06602531|BIOLOGICAL|ARCT-2304|Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.
58474696|NCT06602531|BIOLOGICAL|Control vaccine younger adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
58474697|NCT06602531|BIOLOGICAL|Control vaccine older adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
58474698|NCT06602531|OTHER|Placebo Vaccine|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
58474699|NCT04298320|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
58474700|NCT04298320|DRUG|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
58474701|NCT04003467|DRUG|EBP05|tablets
58474702|NCT04003467|DRUG|Placebo of EBP05|tablets
58474703|NCT06598904|OTHER|Aroma diffuser with single-note lavender essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.
58474704|NCT06598904|OTHER|Aroma diffuser with single-note orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
58474705|NCT06598904|OTHER|Aroma diffuser with deionized water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
58490914|NCT00220636|DRUG|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
58490915|NCT03791957|OTHER|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
58490916|NCT02707575|DRUG|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
58474706|NCT05527977|BEHAVIORAL|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H\&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
58474707|NCT05986955|OTHER|Diet|Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
58474708|NCT00730717|DRUG|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
58474709|NCT00730717|DRUG|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
58474710|NCT05854368|PROCEDURE|Additional blood collection as part of routine care|Collection of an additional blood volume (10mL) as part of a blood sampling performed during routine care or specific for the research if not part of routine care.
58474711|NCT05854368|PROCEDURE|Blood collection|Blood sample collection (10 mL)
58474712|NCT01624350|DEVICE|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
58474713|NCT04225585|BEHAVIORAL|CST-PSP|skills training and experiential learning exercises
58474714|NCT04225585|BEHAVIORAL|General health education|general health education intervention that focuses on improving overall health
58474715|NCT06591221|PROCEDURE|Chuna Maintenance Therapy|"it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner."
58474716|NCT06589635|DRUG|ADC-189 and Itraconazole|"Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals."
58474717|NCT04164875|DIAGNOSTIC_TEST|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
58474718|NCT01748747|DRUG|Montanide ISA 51 VG|Given SC
58474719|NCT01748747|BIOLOGICAL|MART-1 antigen|Given SC
58474720|NCT01748747|OTHER|laboratory biomarker analysis|Correlative studies
58474721|NCT01748747|BIOLOGICAL|Gag:267-274 peptide vaccine|Given SC
58474722|NCT01748747|DRUG|resiquimod|Applied topically
58474723|NCT06592625|DRUG|SHR-A1811|SHR-A1811
58474724|NCT06592625|DRUG|Adebrelimab|Adebrelimab
58474725|NCT02203396|DRUG|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
58474726|NCT06604052|PROCEDURE|Reduced-Port Fusion Surgery|(1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon\&#39;s trocar placement plan and the stoma therapist\&#39;s positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.
58474727|NCT06604052|PROCEDURE|Traditional surgery|(1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.
58132966|NCT05806203|DEVICE|Low intensity shockwave treatment to pelvic floor region plus typical physical therapy|Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes
58474728|NCT06503614|DRUG|Durvalumab|Durvalumab 1500mg IV
58474729|NCT06503614|DRUG|Monalizumab|Monalizumab 1500mg IV
58474730|NCT03146585|DEVICE|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
58474731|NCT06053307|BEHAVIORAL|Acceptance commitment therapy|The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
58490917|NCT03768648|OTHER|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
58132967|NCT05806203|DEVICE|Sham shockwave treatment plus typical physical therapy|Inactive dose of shockwave treatment
58132968|NCT00156247|DRUG|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
58132969|NCT02292745|RADIATION|stereotactic radiotherapy|
58132970|NCT04177290|DRUG|Sintilimab (M1b)|Intravenous infusion
58132971|NCT04177290|DRUG|Sintilimab (approved)|Intravenous infusion
58132972|NCT02441478|RADIATION|functional magnetic resonance imaging exam|
58490918|NCT03768648|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
58474732|NCT05348538|OTHER|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~1. Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~2. Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~3. Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
58474733|NCT05187689|BEHAVIORAL|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
58474734|NCT05187689|BEHAVIORAL|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
58474735|NCT06211361|OTHER|Cardiac rehabilitation|Physical exercise intervention within a cardiac rehabilitation program, lasting 2 months, 3 days per week. The intervention consists of a first part of warm up the large muscle groups, accompanied by breathing exercises, followed by a part of strength and muscular resistance training exercises (upper and lower limbs and abdominal muscles), another part of aerobic exercise part (continuous and interval), using a treadmill or cycle ergometer, and finally a part of stretching exercises and a cool-down phase.
58474736|NCT01887327|PROCEDURE|Phototherapy|Phototherapy starts within 30 minutes before or after injection
58474737|NCT01887327|DRUG|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
58474738|NCT01887327|DRUG|Placebo|Matching placebo administered by IM injection
58474739|NCT06593444|PROCEDURE|Thalamic Ventral Intermediate-DBS|Participants will undergo Thalamic Ventral Intermediate-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
58474740|NCT01751529|PROCEDURE|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
58474741|NCT01751529|DRUG|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
58474742|NCT06589037|OTHER|shock wave treatment control group|The control group, consisting of 24 people, will receive shock wave treatment on the sole of the foot to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
58474743|NCT06589037|OTHER|shock wave treatment experimental group|The experimental group, consisting of 24 people, will receive shockwave treatment on the back of the leg to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
58474744|NCT06058923|PROCEDURE|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
58490919|NCT03768648|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
58132973|NCT02348385|DRUG|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
58132974|NCT05745805|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
57779600|NCT05947123|BEHAVIORAL|Patient health care observational follow up after 2 prophylactic tratments|Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
58474745|NCT06058923|PROCEDURE|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
58474746|NCT06655675|DEVICE|Ultrasound|Ultrasound scan of the umbilical artery
58474747|NCT06596876|DRUG|HRG2010; Sustained-release Carbidopa/Levodopa administered placebo|Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
58474748|NCT06596876|DRUG|Sustained-release Carbidopa/Levodopa; HRG2010 placebo|Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
58474749|NCT06598215|PROCEDURE|Duckett urethroplasty|hybrid duckett urethroplasty vs modified duckett urethroplasty
58474750|NCT00523510|PROCEDURE|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
58474751|NCT02589938|OTHER|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
58474752|NCT02589938|OTHER|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
58474753|NCT02589938|OTHER|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
58474754|NCT06597214|DEVICE|AVACore Technologies, Inc. warmUP Sleeve|AVAcore Technologies's warmUP (WU-20) Temperature Management System was developed based on work with the Aquarius Medical Acrotherm device and prior human hypothermic subject data showing a rewarming rate of \~1ºC in 5 minutes when heat and vacuum application was tested. AVAcore Technologies received FDA acceptance of its Section 510(k) premarket notification for the warmUP (vH1) Temperature Management System in 2005. This product was used on over 100 patients in the US in 2005-2006 timeframe.
58474755|NCT06597214|DEVICE|Arizant Healthcare Bair Hugger®|The Arizant Healthcare Bair Hugger® Temperature Management System proposed for use in this study is a 'forced air' system providing convective warming via the circulation of warmed air through a specially designed blanket which is placed over a portion of the patient's body. This product has been in use in the US for over 20 years in a majority of hospitals.
58474756|NCT03011320|DRUG|EC1456|intravenous (IV) bolus dose
58474757|NCT03011320|DRUG|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
58474758|NCT00000385|DRUG|Lithium|Lithium 600 mg to 2700 mg per day
58474759|NCT00000385|DRUG|Placebo|Matching placebo
58474760|NCT06413992|DRUG|Fluzoparib|During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
58474761|NCT06413992|DRUG|Camrelizumab|During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
58474762|NCT06413992|DRUG|paclitaxel (albumin bound)|Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
58474763|NCT06413992|DRUG|Carboplatin injection|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
58474764|NCT06413992|DRUG|Carboplatin|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
58474765|NCT06413992|RADIATION|External irradiation|Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
58474766|NCT05530252|DRUG|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
58474767|NCT05530252|DRUG|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
58474768|NCT05530252|OTHER|SRP|only scaling and root planning was performed on the patient
58132975|NCT01238237|DRUG|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
58474769|NCT00536744|DEVICE|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
58474770|NCT00536744|OTHER|Sham|Non-energized (inactive - Sham) application + standard of care
58474771|NCT04909047|DEVICE|parassacral transcutaneous electrostimulation|Use of parassacral transcutaneous electrostimulation
58132976|NCT02446626|PROCEDURE|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
58132977|NCT02446626|PROCEDURE|Blood draw|Peripheral blood draws will be performed.
58474772|NCT01651156|DRUG|Tolvaptan|oral taken
58474773|NCT01651156|DRUG|Placebo|
58474774|NCT01062932|DRUG|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
58474775|NCT01062932|DRUG|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
58474776|NCT05733546|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
58474777|NCT05383196|DRUG|Onvansertib|oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
58474778|NCT05383196|DRUG|Paclitaxel|once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
58474779|NCT03956849|OTHER|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
58474780|NCT03992560|DEVICE|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
58474781|NCT05910684|DIAGNOSTIC_TEST|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
58474782|NCT04046367|BEHAVIORAL|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
58474783|NCT04046367|BEHAVIORAL|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
58474784|NCT00394017|BEHAVIORAL|Reminder letters|3 mailed reminder letters
58474785|NCT02718404|PROCEDURE|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
58474786|NCT02718404|DRUG|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
58474787|NCT02718404|PROCEDURE|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
58474788|NCT06597136|OTHER|Diaphragmatic kinesiology taping|The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.
58474789|NCT06597136|OTHER|Accessory respiratory muscle kinesiology taping|Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.
58474790|NCT06597136|OTHER|Sham kinesiology taping|Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.
58474791|NCT05961722|OTHER|preoperative IV 0.9% saline 400 ml|Group 1 will be infused with IV 0.9% saline 400 mL.
58474792|NCT05961722|OTHER|preoperative dextrose 5% 400 ml|Group 2 will be infused with dextrose 5% Dekstroz 400 ml.
58474793|NCT05961722|OTHER|preoperative and intraoperative dextrose 5% 400 ml|Group 3 will be infused with dextrose preoperative 200 ml and intraoperative 200 ml 5% dextrose infusion.
58490920|NCT03768648|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
58490921|NCT03768648|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
58490922|NCT00541801|DEVICE|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
58490923|NCT01920672|BEHAVIORAL|Timed Planned Activity|
58490924|NCT01920672|BEHAVIORAL|Home Safety and Education Program|
57779601|NCT06740175|DEVICE|Multispectral optoacoustic tomography|If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
58474794|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using closing system|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the SDD group prior to the procedure, the femoral access will be closed with a closure system. Ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
58474795|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using figure-of-eight stitch|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the ONS group prior to the procedure, the femoral access will be closed with a figure-of-eight suture. The ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
58474796|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
58474797|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
58474798|NCT04502030|BIOLOGICAL|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
58474799|NCT04502030|OTHER|Placebo|Placebo
58474800|NCT04465344|DEVICE|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
58474801|NCT04465344|DEVICE|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
58474802|NCT01955135|DRUG|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
58474803|NCT01955135|DRUG|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
58474804|NCT01955135|DRUG|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
58474805|NCT03674411|DRUG|Fludarabine (FLU)|25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)
58474806|NCT03674411|DRUG|Cyclophosphamide (CY)|60 mg/kg IV over 2 hours
58474807|NCT03674411|DRUG|Total Body Irradiation (TBI)|165 cGy twice daily
58474808|NCT03674411|DRUG|Tacrolimus (Tac)|Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
58474809|NCT03674411|DRUG|Mycophenolate Mofetil (MMF)|MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
58132978|NCT02446626|DEVICE|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
58132979|NCT00162123|DRUG|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
58474810|NCT03674411|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5 ug/kg/d until the absolute neutrophil count (ANC) is \>2500/uL for 2 consecutive days
58474811|NCT03674411|DRUG|Busulfan (BU)|BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
58474812|NCT03674411|DRUG|Melphalan|50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min
58474813|NCT03674411|DRUG|MGTA 456 Infusion|The target cell dose is \>10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
58474814|NCT06590363|OTHER|Listening to zen music|We conducted a quasi-randomized controlled clinical trial with two groups: Intervention Group (I), which corresponded to patients and doctors who underwent the period of musical listening in the office; and the Control Group (C), composed of patients and doctors who did not undergo the period of musical listening.
58474815|NCT06069843|DRUG|IV Ketamine|0.5 mg/kg IV Ketamine
58474816|NCT00906204|BIOLOGICAL|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
58474817|NCT00906204|BIOLOGICAL|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
58132980|NCT00455351|DRUG|Vorinostat|Increasing dosing, phase I
58132981|NCT05885165|BEHAVIORAL|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
58474818|NCT04484077|BIOLOGICAL|hCT-MSC|2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
58474819|NCT02015260|DRUG|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
58474820|NCT02015260|DRUG|Placebo|Placebo
58474821|NCT04323124|DRUG|PF-07059013|Participants will recieve PF-07059013
58474822|NCT04323124|DRUG|Placebo|Participants will recieve placebo
58474823|NCT06587828|PROCEDURE|Companion blood samples with procedure|Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.
58474824|NCT03435796|GENETIC|Gene-modified (GM) T cell therapy|No investigational product will be administered
58474825|NCT03606369|DRUG|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
58474826|NCT03606369|DRUG|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
58474827|NCT06601153|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to characterize coronary atherosclerosis
58474828|NCT06595732|BEHAVIORAL|Pelvic floor and abdominal training|Participants in this group will undergo 12 weeks of in-person training, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. Exercises will target both the pelvic floor muscles and the abdominal muscles. The exercises will be divided into three phases, with progressively increasing difficulty each month. The progression will be achieved by increasing the load, the number of repetitions, and the complexity of the exercises.
58474829|NCT06595732|BEHAVIORAL|Abdominal Hypopressive Technique Exercises|Participants in this group will perform Hypopressive Abdominal Gymnastics exercises as proposed by Marcel Caufriez (1997). The training will last 12 weeks and be conducted in person, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by changing body positions, increasing the number of repetitions, and extending the duration of inspiratory apnea.
58474830|NCT06595732|OTHER|Pelvic floor muscle training|Participants in this group will undergo 12 weeks of in-person training, supervised by a specialist physical therapist, in groups of up to four women. Specific exercises targeting the pelvic floor muscles will be performed, with voluntary and maximal contractions, without involving other muscle groups. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by increasing the load (transitioning from gravitational to antigravitational positions), increasing the number of repetitions, and combining sustained and rapid contractions to enhance the difficulty of execution.
58474831|NCT06592430|OTHER|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
58474832|NCT06592430|OTHER|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
58474833|NCT04202601|DRUG|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
58474834|NCT04202601|DRUG|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
58474835|NCT06593002|BEHAVIORAL|Therapeutic play|The children in the experimental group were given a therapeutic toy designed for them by the student nurse half an hour before the treatment, the toy and game were introduced, and they were allowed to play with this toy for half an hour, accompanied by the student nurse.
58474836|NCT03173248|DRUG|AG-120|Tablets administered orally
58474837|NCT03173248|DRUG|Placebo|Tablets administered orally
58474838|NCT03173248|DRUG|Azacitidine|Administered SC or IV
58474839|NCT04760808|DIAGNOSTIC_TEST|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
58474840|NCT04760808|RADIATION|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
58474841|NCT04760808|DIAGNOSTIC_TEST|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
58474842|NCT04760808|RADIATION|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
58474843|NCT03249207|DRUG|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
58474844|NCT03249207|DRUG|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
58132982|NCT05885165|BEHAVIORAL|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
58474845|NCT05206565|PROCEDURE|Neurotization - Autologous Reconstruction with DIEP/TRAM|"* Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~* Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~* Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
58474846|NCT02529072|DRUG|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
58474847|NCT02529072|BIOLOGICAL|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
58474848|NCT02345135|PROCEDURE|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
58474849|NCT02345135|PROCEDURE|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
58474850|NCT02345135|BEHAVIORAL|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
58474851|NCT00811122|RADIATION|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
58474852|NCT00811122|RADIATION|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
58474853|NCT02488915|DEVICE|EmboTrap® Revascularization Device|
58474854|NCT06586463|OTHER|kinitic control training|"kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation."
58474855|NCT02708836|PROCEDURE|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
58474856|NCT02708836|DEVICE|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
58474857|NCT02708836|DEVICE|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
58474858|NCT02708836|PROCEDURE|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
58474859|NCT02708836|PROCEDURE|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
58474860|NCT02708836|PROCEDURE|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
58474861|NCT02708836|PROCEDURE|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
58474862|NCT02708836|PROCEDURE|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
58474863|NCT06500338|PROCEDURE|free-fall|"The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, hypergravity), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas."
58132983|NCT01768806|BEHAVIORAL|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
58474864|NCT06486025|DRUG|maintenance magnesium sulphate1g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
58474865|NCT06486025|DRUG|maintenance magnesium sulphate2g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
58474866|NCT04959994|DEVICE|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
58474867|NCT05121064|BEHAVIORAL|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
58474868|NCT05121064|BEHAVIORAL|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
58474869|NCT05121064|BEHAVIORAL|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
58474870|NCT02530515|BIOLOGICAL|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
58474871|NCT02530515|OTHER|Laboratory Biomarker Analysis|Correlative studies
58474872|NCT03645824|DRUG|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
58474873|NCT03365271|PROCEDURE|drainage|Applying a drain tube during TKA procedure
58474874|NCT03365271|PROCEDURE|non-drainage|No drain tube will be applied during TKA procedure
58474875|NCT06655168|DEVICE|Video Laryngoscopy|orotracheal intubation by C-Mac ( Video laryngoscopy)
58474876|NCT06655168|DEVICE|Direct Laryngoscopy|Orotracheal intubation using Direct Laryngoscopy
58474877|NCT06585813|PROCEDURE|dental implant|we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery
58474878|NCT06585813|PROCEDURE|Fibrogide membrane|we were comparing the efficacy of Fibrogide with the Connective tissue graft
58474879|NCT06585813|PROCEDURE|connective tissue graft|the control group was the connective tissue graft group and the test group was the Fibrogide group
58474880|NCT06585813|PROCEDURE|second stage|second stage to determine the thickness gained after the graft and to place a healing abutment
58474881|NCT06587594|BEHAVIORAL|Solution Focused Brief Therapy|A behavioral health intervention designed to help autistic adults to make a positive change in their life using strength-based approach.
58474882|NCT03379181|DRUG|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
58474883|NCT03931941|DRUG|RBX2660|RBX2660 is a microbiota suspension administered as an enema
57779602|NCT06736600|BEHAVIORAL|Goal Attainment Scaling (GAS)|Goal-setting tele-coaching and the well-studied Patient Priorities Care framework will assist participants with bothersome CIPN identify their most important health goals and scale them into specific, measurable, achievable, relevant, and time-bound (SMART) goals
57779603|NCT01836458|DRUG|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
57779604|NCT04843865|DIETARY_SUPPLEMENT|Chinese Herbs|Chinese Herbs
57779605|NCT06739252|COMBINATION_PRODUCT|Gemcitabine Oxaliplatin and 5FU|The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.
58132984|NCT01768806|BEHAVIORAL|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
58474884|NCT00517387|DRUG|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
58474885|NCT04968002|DRUG|pablizumab combined with apatinib and neoadjuvant chemotherapy|The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
58474886|NCT06588465|DEVICE|On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
58474887|NCT06588465|DEVICE|low dose On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
58474888|NCT06559683|OTHER|Sensory Assessment|Patients scheduled for open-heart surgery will receive a deep/superficial parasternal intercostal plane block preoperatively, and sensory block status will be evaluated after 30 minutes.
58474889|NCT00344409|DRUG|darbepoetin alfa|
58474890|NCT01456884|BEHAVIORAL|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
58474891|NCT01456884|BEHAVIORAL|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
58474892|NCT05163080|BIOLOGICAL|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
58474893|NCT04633265|DEVICE|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
58474894|NCT05534165|DRUG|Tecovirimat|600 mg po BID
58474895|NCT05534165|DRUG|Placebo|identical placebo 600 mg po BID
58474896|NCT06601205|DRUG|Flutamide|1 tablet daily until the day before surgery
58474897|NCT06601205|DRUG|Finasteride|1 tablet daily until the day before surgery
58474898|NCT06601205|OTHER|Placebo|1 tablet daily until the day before surgery
58474899|NCT06590766|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
58474900|NCT04486768|OTHER|Survey Instrument|This registry contains several surveys that will be released for patient/caregiver completion at enrollment and at time points following enrollment. These surveys can be completed on any computer that is connected to the internet.
58474901|NCT03682419|PROCEDURE|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
58474902|NCT03682419|PROCEDURE|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
58474903|NCT00150085|DRUG|cyclosporine micro-emulsion|
58474904|NCT05447052|DEVICE|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
58474905|NCT05447052|DEVICE|Innova Stent|Innova Stent implantation
58474906|NCT03814603|PROCEDURE|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
58474907|NCT03814603|DRUG|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
58474908|NCT05893888|DRUG|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
58474909|NCT05893888|DRUG|PRV111 (Cisplatin Transmucosal System)|PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
58474910|NCT05154786|OTHER|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
58474911|NCT05154786|OTHER|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
58474912|NCT03198715|DRUG|DS1040b|DS-1040b in solution for intravenous infusion
58474913|NCT03198715|DRUG|Placebo|Saline solution for intravenous infusion
58474914|NCT06188637|DRUG|Ozanimod Oral Capsule|open label ozanimod
58474915|NCT03264326|OTHER|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
58474916|NCT03264326|OTHER|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
58474917|NCT03264326|OTHER|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
58474918|NCT06340802|DEVICE|VNS Treatment|Vagus nerve stimulation is started 2-week after the implantation
58490925|NCT00958906|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
58490926|NCT03323281|OTHER|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
58474919|NCT03255122|BEHAVIORAL|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
58474920|NCT03255122|BEHAVIORAL|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
58474921|NCT02835378|OTHER|No intervention|
58474922|NCT05803252|BEHAVIORAL|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~1. Awareness: Able to experience the present moment, able to take perspective on self~2. Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~3. Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
58474923|NCT05803252|OTHER|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
58474924|NCT05156567|DIAGNOSTIC_TEST|Deep Learning System|The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
58474925|NCT03460795|BIOLOGICAL|MSC and Tregs|conventional plus MSC and Tregs or placebo treatment
58474926|NCT06597305|BEHAVIORAL|Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)|Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.
58474927|NCT06590129|PROCEDURE|hydrodissection of median nerve|Ultrasound guided hydrodissection of median nerve in carpal tunnel with 5% dextrose solution
58474928|NCT06590129|OTHER|Physiotherapy|5-20 sessions in rehabilitation area with physical media: paraffin glove (10 coats for 15min), mobilizations of wrist and fingers, strectching of wrist and fingers tendons/muscles, muscle stregthening whit isometric or isotonic excercises to intrinsic muscles of the hand an forearm, and occupational therapy with techniques for sensory return, nerve and tendon sliding techniques, activities aimed at improving basic hand functions and work simulation activities.
58474929|NCT05964218|BEHAVIORAL|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
58474930|NCT05388110|BEHAVIORAL|SKY Breath Intervention|Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
58474931|NCT05740254|BEHAVIORAL|Early Time Restricted Eating|Early Time Restricted Eating 7 AM to 3 PM
58474932|NCT05740254|BEHAVIORAL|Late Time Restricted Eating|Late Time Restricted Eating 12 PM to 8 PM
58474933|NCT04335006|DRUG|Carelizumab|Participants receive SHR-1210 intravenously (IV)
58474934|NCT04335006|DRUG|Nab-paclitaxel|administered intravenously every 4-week cycle
58132985|NCT04629404|DRUG|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
58474935|NCT04335006|DRUG|Apatinib|administered orally every 4-week cycle
58474936|NCT06591247|DEVICE|Double Baloon Catheter|A double Baloon Catheter will be inserted for 12 hours to one of the arms of the study
58474937|NCT06591247|PROCEDURE|Membrane Stripping|Stripping will be considered as 3-5 rotations of separating the amniotic sac from the cervix and will be perfomed twice (every 4-6 hours)
58474938|NCT00393159|DEVICE|Ear Popper|
58474939|NCT04901793|BEHAVIORAL|Virtual Reality Headset and handheld remote control.|Brand name: Oculus Quest
58490927|NCT02663713|DRUG|Ticagrelor|Ticagrelor 60mg twice daily
58132986|NCT04629404|DRUG|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
58132987|NCT01223365|DRUG|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
58132988|NCT00799656|DRUG|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
58132989|NCT00799656|DRUG|placebo|oral administration once daily for 28 days
58132990|NCT02458482|DEVICE|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
58132991|NCT02458482|DRUG|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
58474940|NCT04865770|DRUG|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
58474941|NCT04865770|DRUG|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
58474942|NCT02940795|OTHER|Coke|Patients were given a 20 ounce bottle of Coke Cola.
58474943|NCT02940795|OTHER|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
58474944|NCT06600048|DRUG|Hyperbaric prilocaine|Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.
58474945|NCT06600048|DRUG|Hyperbaric bupivacaine|Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
58474946|NCT06600178|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10mg oral
58132992|NCT05398822|DIAGNOSTIC_TEST|MRI|Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
58474947|NCT06600178|DRUG|Placebo|Placebo tablet given to subject vs. active drug.
58474948|NCT03882294|OTHER|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
58132993|NCT00391105|DRUG|Remifentanil|
58132994|NCT03476460|DRUG|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
58474949|NCT03882294|OTHER|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
58474950|NCT03476486|PROCEDURE|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
58474951|NCT06594276|OTHER|Local instillation of antibiotics|Systemic antibiotics are usually used with needle aspiration of breast abscess. However local instillation of antibiotics will be an in intervention in this study.
58474952|NCT06598111|OTHER|Amplified Benefits|Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.
58132995|NCT03476460|DRUG|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
58474953|NCT06598111|OTHER|Amplified Consequences|Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.
58474954|NCT06598111|OTHER|Control|Participants write a brief narrative considering a future free of concern about finances.
58474955|NCT01084655|DRUG|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
58474956|NCT01084655|DRUG|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
58474957|NCT01084655|DRUG|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
58474958|NCT06281925|DEVICE|Cryotherapy Gloves|All patients in the intervention group will receive cryotherapy with cold packs enclosed in a fabric envelope (gloves). The fabric envelope (gloves) will be patient specific.
58474959|NCT06445530|BEHAVIORAL|MFeast ENHANCED|Intervention group will initially receive prepared MTF (low carbohydrate, low-fat meals, which have been shown to improve glycemia in people with prediabetes) delivered by MFeast (10 meals weekly); Tailored Medical Nutrition Therapy (MNT) delivered by dieticians from MFeast via monthly phone calls and focused on only: ↓sugar-sweetened beverages and ↑fruit and vegetable consumption; Lactation snack bundles to boost milk supply + structural support for breastfeeding/pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (via study team-crafted virtual grocery store) for 16 more weeks.
58474960|NCT06445530|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive prepared MTF delivered by MFeast and as needed MNT from 1 to 24 weeks postpartum."
58474961|NCT01724346|DRUG|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
58132996|NCT03362437|DRUG|BMS-986177|Form A
58132997|NCT03362437|DRUG|BMS-986177|Form B
58474962|NCT01724346|DRUG|Next-line ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
58490928|NCT02663713|DRUG|Clopidogrel|Clopidogrel 75 mg once daily
58132998|NCT02319148|DRUG|itraconazole|itraconazole dosed at 200 mg
58132999|NCT02319148|DRUG|diltiazem|diltiazem dosed at 240 mg
58133000|NCT02319148|DRUG|SR verapamil|SR verapamil dosed at 240 mg
58133001|NCT02319148|DRUG|PF-00489791|PF-00489791 20 mg single dose administration
58133002|NCT05203393|DEVICE|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
58133003|NCT05978479|OTHER|Teach-Back Method|No intervention will be given to the patients in the control group.
58133004|NCT00716495|BIOLOGICAL|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
58474963|NCT03216525|DRUG|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
58474964|NCT03216525|DRUG|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
58474965|NCT06402656|DEVICE|Customized facemask|The customized face mask will be fabricated from a 3D digital image of the patient's face obtained by means of a 3D scanner. Such a scanner consists of 6 digital SLR cameras and software capable of processing a 3-D image of the patient's face exportable as an stl file.
58474966|NCT06402656|DEVICE|Standard facemask|The standard facemask is the commercially available Petit standard facemask
58474967|NCT01615484|PROCEDURE|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
58474968|NCT01615484|DEVICE|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
58474969|NCT05512884|BEHAVIORAL|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
58474970|NCT05671146|DEVICE|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
58474971|NCT05671146|OTHER|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
58474972|NCT05671146|OTHER|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
58474973|NCT05525325|PROCEDURE|General Anesthesia|Patients randomized to the GA arm are intubated after anesthetic induction. For this purpose, they are pre-oxygenated with an oxygen mask and non-invasive monitoring is established. After sufficient pre-oxygenation has been applied, analgesic and sedative medication are administered. If the patient is sufficiently long nil by mouth they are manually ventilated before a muscle relaxant is administered. A rapid-sequence induction is performed with administration of an opioid, sedative and muscle relaxant in rapid succession and without intermediate manual ventilation in non-nil by mouth patients. To secure the airway, an endotracheal tube is inserted into the trachea with the aid of a laryngoscope. After insertion of the endotracheal tube, its endotracheal position is confirmed with auscultation and capnography. GA maintenance therapy with opioids, sedatives and catecholamines, if needed, will then be started.
58474974|NCT03361761|OTHER|Health education program|formalized/official Health education program
58474975|NCT03361761|OTHER|Health education program|non formalized/official Health education program
58474976|NCT06594835|BEHAVIORAL|Better Together|Better Together (BT) is a 90-min, age-appropriate, culturally relevant prevention intervention to prevent substance use among Black youth experiencing household challenges (ages 11-13) by addressing the multilevel influences of substance use.
58474977|NCT06594835|BEHAVIORAL|Youth In the Media (YM)|Delivered in eight in-person, 90-minute sessions concurrently with BT sessions, the YM program was designed to (1) increase participants' awareness of and access to the different types of media and free resources available at the participants local libraries, (2) discuss different types of media that center stories and experiences of Black youth, and (3) expose participants to careers in media.
58474978|NCT04733469|BEHAVIORAL|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~* A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~* Take-home and online copies of the video for repeat viewing~* A video summary~* A question prompt list patients can use to ask clinicians more questions about palliative care~* Contact information and brochures for local palliative care programs"
58474979|NCT04733469|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~* Usual care~* A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
58474980|NCT06590103|BEHAVIORAL|Physically Active Lessons|Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the Physical Education teacher) are in charge of designing and delivering the physically active classes.
58490929|NCT05470023|OTHER|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
58490930|NCT04153552|DIETARY_SUPPLEMENT|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
57779606|NCT06739967|BEHAVIORAL|Behavioral Treatment|"The SLT intervention will be entirely administered online through a web-based platform. While each of the treatments will engage semantics, phonology, and orthography, the protocols will be tailored relative to the characteristics of each PPA variant. Patients with svPPA and lvPPA will undergo a lexical retrieval training (LRT) intervention implemented using a training cascade.~Patients with nfvPPA will undergo Video-implemented Script Training (VISTA), a choral reading approach training accurate production of functional scripts. The method is based on that implemented in American-English individuals with PPA and aims at improving grammar and motor aspects of speech production by taking advantage of repetitive practice and automaticity."
57779607|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
57779608|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
58474981|NCT06150391|DEVICE|Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks|Visionary exercises are computer gammified activities that run on a computer with internet connection to facilitate home therapy. Patient must wear anaglyph glasses. Visual stimuli consists in dichoptic Gabor Patches presented to the amblyopic eye. Frequency is adjusted to actual patient visual acuity, and contrast to actual patient performance (contrast sensitivity). A band-filtered noise mask at the same frequency than the Gabor patch is presented to the fellow eye in certain ocassions.
58474982|NCT06150391|DEVICE|Patching|PEDIG (Pediatric Eye Disease Investigator Group) recommended amblyopia treatment. Consist on covering a child's better-seeing eye with a patch for 2 hours per day for mild and moderate amblyopia or 6 hours per day for severe amblyopia
58474983|NCT01981408|DRUG|[^14C]-LY2801653|Administered orally
58474984|NCT06593223|DEVICE|Assess Non-invasive filling pressure(NIFP) in heart failure patients|Assess Non-invasive filling pressure(NIFP) in outpatients with stable heart failure and inpatients with acute heart failure in ward
58474985|NCT03546309|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
58474986|NCT03546309|OTHER|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists
58474987|NCT04730804|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
58474988|NCT04730804|DRUG|Placebo|Placebo will be administered as SC infusion(s).
58474989|NCT06375161|BIOLOGICAL|anti-CD19-CAR-T cells|"Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc."
58474990|NCT04983680|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
58474991|NCT06199843|DRUG|Rifaximin|Rifaximin 550 mg BD
58474992|NCT06199843|DRUG|Norfloxacin|Norfloxacin 400 mg OD
58474993|NCT06084026|OTHER|ActivPal|Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
58133005|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
58133006|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
58133007|NCT03110003|DRUG|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
58133008|NCT03110003|DRUG|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
58474994|NCT01131507|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
58133009|NCT01638988|DRUG|Metformin|"1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
58133010|NCT01638988|DRUG|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
58474995|NCT02947321|PROCEDURE|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
58474996|NCT02947321|PROCEDURE|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
58133011|NCT04433871|OTHER|No intervention, observational|No intervention, observational
58133012|NCT00007436|DRUG|Tenofovir disoproxil fumarate|
58133013|NCT02066922|DEVICE|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
58133014|NCT02066922|DEVICE|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
58474997|NCT04278599|DRUG|Oral Zinc supplementation|In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
58490931|NCT03593616|PROCEDURE|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
58133015|NCT02066922|DEVICE|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
58133016|NCT03920137|BEHAVIORAL|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
58133017|NCT03920137|BEHAVIORAL|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
58133018|NCT03920137|DEVICE|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
58133019|NCT03923179|DRUG|Pyrotinib|Pyrotinib, 400mg qd
58133020|NCT03923179|DRUG|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
58133021|NCT02665143|DRUG|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
58133022|NCT01690494|BEHAVIORAL|PACT|Couple-based behavioral HIV/STI preventive intervention
58133023|NCT01690494|BEHAVIORAL|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
58133024|NCT02983110|PROCEDURE|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
58133025|NCT02983110|PROCEDURE|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
58133026|NCT02983110|PROCEDURE|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
58133027|NCT02717390|BEHAVIORAL|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
58133028|NCT02717390|BEHAVIORAL|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
58133029|NCT01372579|DRUG|eribulin mesylate|Given IV
58133030|NCT01372579|DRUG|carboplatin|Given IV
58133031|NCT01372579|PROCEDURE|biopsy|Correlative studies
58133032|NCT01390337|DRUG|AC220|Oral Liquid
58133033|NCT01390337|DRUG|daunorubicin|Intravenous Infusion
58133034|NCT01390337|DRUG|cytarabine|Intravenous Infusion
58133035|NCT01799798|DRUG|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
58133036|NCT05210322|PROCEDURE|Percutaneous cholangiopancreatoscopy|Per standard treatment protocol for percutaneous cholangiopancreatoscopy, access will be gained into the biliary system using the biliary tube or into the gallbladder using the cholecystostomy tube. After access has been secured, through a peel-away sheath a Spy Glass Discover Digital Catheter will be introduced. Next, either, the stones will then be removed from the biliary system or gallbladder using a combination of baskets, and lithotripsy equipment as required, or in case of biliary strictures, a clamshell biopsy will be taken from the stricture site as identified on endoscopic visualization and cross-sectional imaging. Further intervention maybe performed for the stricture based on operator preference. After the complete stone removal/ stricture management the cholecystostomy/ biliary tube will be removed after the patient passes a clinical capping trial.
58133037|NCT01292330|PROCEDURE|nutritional support before operation|nutritional support before operation for more than 4 days
58133038|NCT02707978|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
58133039|NCT01987271|DEVICE|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
58133040|NCT02749513|DRUG|Itraconazole|
58490932|NCT04341519|BEHAVIORAL|PTSD|"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days"
58133041|NCT00812734|PROCEDURE|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
58133042|NCT04493723|PROCEDURE|Surgery|To collect tumour tissue
58133043|NCT04493723|PROCEDURE|Venepuncture|To collect blood samples
58133044|NCT04709809|DEVICE|Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating|Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
58133045|NCT03187002|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
58133046|NCT03187002|DRUG|Moderate IV Sedation|IV sedation with fentanyl and versed
58133047|NCT03187002|OTHER|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
58133048|NCT03187002|OTHER|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
58133049|NCT01382719|DRUG|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
58133050|NCT05703048|DRUG|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
58133051|NCT05703048|DRUG|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
58133052|NCT05961930|BEHAVIORAL|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
58133053|NCT02372630|DRUG|Linagliptin|5 mg daily oral tablets of linagliptin
58133054|NCT02372630|DRUG|Placebo|matching placebo giving orally daily
58133055|NCT01900730|DRUG|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
58133056|NCT01900730|DRUG|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
58133057|NCT01900730|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
58133058|NCT01900730|BEHAVIORAL|Pill Diary|Patient given a pill diary to record the time each dose taken.
58133059|NCT01900730|BEHAVIORAL|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
58133060|NCT03463278|DIAGNOSTIC_TEST|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
58133061|NCT03973177|DRUG|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
58133062|NCT03973177|DRUG|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
58133063|NCT00376623|DRUG|BI 2536|Intravenous Infusion
58133064|NCT04233320|DEVICE|silicone cream containing Allium Cepa extract|silicone cream containing Allium Cepa extract contains 10% of Allium cepa bulb extract.
58133065|NCT04233320|DEVICE|Commercial scar gel|Commercial scar gel is a topical silicone gel. It contains cyclic and polymeric siloxanes and Vitamin C ester.
58133066|NCT05702424|DRUG|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
58133067|NCT05290194|RADIATION|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
58133068|NCT05290194|DRUG|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
58133069|NCT05290194|DRUG|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
58133070|NCT04067102|DRUG|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
58133071|NCT04067102|DRUG|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
58133072|NCT01845363|DRUG|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
58133073|NCT06496542|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
58133074|NCT06496542|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
58474998|NCT04278599|DRUG|Oral placebo supplementation|In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
58474999|NCT00500123|PROCEDURE|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
58490933|NCT04341519|BEHAVIORAL|Burnout|Symptoms of burnout as assessed by the Maslash Burnout Inventory
58490934|NCT00002272|DRUG|Foscarnet sodium|
58490935|NCT01851603|DEVICE|AVL-3288|Drug
58475000|NCT06065670|DRUG|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
58475001|NCT06065670|DRUG|Placebo|Matched sugar tablet
57779609|NCT06198426|DRUG|IBI3004|IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
57779610|NCT06559475|PROCEDURE|Super-Bore Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.
57779611|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
57779612|NCT06397287|OTHER|Observation of patients undergoing sugery|All patients undergoing urological surgery or treatment receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up,
57779613|NCT05645003|DEVICE|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
57779614|NCT05645003|DEVICE|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
57779615|NCT04277741|DIETARY_SUPPLEMENT|RS4 bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
57779616|NCT04277741|DIETARY_SUPPLEMENT|Control bar|The control group will consume one native wheat starch bar per day.
57779617|NCT06737081|DRUG|SAL-0951 tablets 4mg|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
57779618|NCT06737081|DRUG|SAL-0951 tablets 5mg|initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
57779619|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
57779620|NCT06508021|DRUG|Andecaliximab|Dose level A or B
57779621|NCT06508021|DRUG|Placebo|Blinded
57779622|NCT06508021|DRUG|Andecaliximab|Dose level A or B (or age adjusted dose)
57779623|NCT02689791|DIETARY_SUPPLEMENT|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
57779624|NCT04701593|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
57779625|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
57779626|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
57779627|NCT06740227|PROCEDURE|Virtual Reality-Based Balance Training|Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.
58475002|NCT02242604|OTHER|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)"
58475003|NCT05544019|DRUG|SGR-1505|SGR-1505 will be administered orally.
57779628|NCT06740227|PROCEDURE|Conventional Balance Training|one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
57779629|NCT05744921|DRUG|Pozelimab|Administered subcutaneously (SC) every 4 weeks (Q4W)
57779630|NCT05744921|DRUG|Cemdisiran|Administered SC Q4W
58475004|NCT03549936|OTHER|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
57779631|NCT05617547|DIAGNOSTIC_TEST|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
57779632|NCT02460081|DRUG|PDA-002|
57779633|NCT02460081|DRUG|Placebo|
57779634|NCT02270073|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
58475005|NCT05759026|OTHER|Accompaing cares|"After signing the consent form, the patient will be randomised. The ones randomised in VR groups will choose their preferred environment (e.g. landscapes, animals...).~The participant will be managed during 1 care (one care in control condition (no material used), care with the VR headset, one care with the VR set and the prefered environnent of the patient) for an average of 30 minutes (including the completion of the scales and questionnaires)."
58133075|NCT06430437|DRUG|SHR-A1811|Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
58133076|NCT06430437|DRUG|Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin|"Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)"
58133077|NCT00152035|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
58133078|NCT03414749|PROCEDURE|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
58133079|NCT03414749|PROCEDURE|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
58133080|NCT00924326|DRUG|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
58133081|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
58133082|NCT00924326|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
58133083|NCT00924326|DRUG|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
58133084|NCT00924326|DRUG|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
58133085|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
58133086|NCT01787708|PROCEDURE|Red light|
58133087|NCT05777707|DRUG|PD-1 blockade|PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
58133088|NCT05777707|DRUG|Albumin paclitaxel|Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
58133089|NCT05777707|DRUG|Carboplatin/Nedaplatin|Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
58133090|NCT02193880|DEVICE|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
58133091|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
58133092|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
58133093|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
58133094|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
58133095|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
58133096|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
58133097|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
58133098|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
58133099|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
58490936|NCT01851603|DRUG|Placebo|Identical diluent to that used for AVL-3288
58490937|NCT03245489|DRUG|Pembrolizumab|200mg intravenous (IV) over 30 minutes
58133100|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
58133101|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
58133102|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
58133103|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
58133104|NCT03272048|BEHAVIORAL|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, \& Rudd, 2011; Jin, Khazem, \& Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, \& Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
58133105|NCT03129425|BEHAVIORAL|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
58133106|NCT03129425|OTHER|General Educational Program|5 sessions in groups of 15-20 people
58490938|NCT03245489|DRUG|Clopidogrel|75mg/day oral
57779635|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
57779636|NCT06741345|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles for oral administration
58133107|NCT06344624|BEHAVIORAL|CBT group|Brief cognitive behavioral therapy
58133108|NCT06344624|BEHAVIORAL|Laughter group|Laughter yoga therapy
58133109|NCT05250245|DRUG|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
58133110|NCT05250245|OTHER|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
58133111|NCT03694665|OTHER|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
58133112|NCT01320696|BIOLOGICAL|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
58133113|NCT06048146|DRUG|Experimental: FOLFOXIRI and Lateral lymph node dissection|Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
58133114|NCT06048146|DRUG|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
58133115|NCT00139178|DRUG|Different HAART regimens|
58133116|NCT05335408|DEVICE|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
58133117|NCT05335408|DEVICE|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
58133118|NCT00266006|DRUG|eptacog alfa (activated)|
58133119|NCT03416647|PROCEDURE|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
58133120|NCT01522664|DRUG|DEDN6526A|Multiple ascending doses
58133121|NCT00000957|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
58133122|NCT03131310|OTHER|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
58133123|NCT03006419|DRUG|Basiliximab|Standard induction therapy
58133124|NCT03006419|DRUG|Thymoglobulin|Induction therapy
58133125|NCT06451861|DRUG|Chidamide|Induction Therapy
58133126|NCT06451861|DRUG|Venetoclax|Induction Therapy
58133127|NCT06451861|DRUG|azacitidine|Induction Therapy
58133128|NCT06451861|DRUG|Anthracyclines or anthraquinones|Induction Therapy
58133129|NCT06451861|DRUG|cytarabine|Induction Therapy
58133130|NCT00832377|DRUG|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
58133131|NCT03637582|DRUG|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
58133132|NCT03637582|OTHER|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
58133133|NCT01221376|DRUG|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
58133134|NCT00854100|DRUG|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
58133135|NCT00854100|DRUG|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
58133136|NCT00854100|DRUG|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
58133137|NCT00002349|DRUG|Stavudine|
58133138|NCT00595166|DEVICE|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
58133139|NCT01876706|DEVICE|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
58133140|NCT06389409|OTHER|Observation of testicular cancer patients|Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
58133141|NCT02977520|PROCEDURE|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
58133142|NCT00755196|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
58133143|NCT00755196|DRUG|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
58133144|NCT03729297|DRUG|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
58133145|NCT00346814|DRUG|intravitreal injection|
58133146|NCT05853484|OTHER|Bimodal lifestyle program|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
58133147|NCT00306371|DEVICE|1450nm diode laser|
58133148|NCT02625454|DRUG|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
58133149|NCT02625454|DRUG|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
58133150|NCT05340010|DRUG|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
58133151|NCT00759928|DRUG|Erlotinib|150 mg once daily by mouth
58133152|NCT00759928|DRUG|Sorafenib|400 mg twice daily by mouth
58133153|NCT03846388|DIAGNOSTIC_TEST|follicular stimulating hormone|in the serum of our patients
58133154|NCT03846388|DIAGNOSTIC_TEST|Anti-mullerian hormone|in the serum of our patients
58133155|NCT03846388|RADIATION|Basal antral follicle count|by ultrasound
58133156|NCT02503943|DRUG|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
58133157|NCT02503943|DRUG|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
58475006|NCT00003475|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57779637|NCT06738693|PROCEDURE|External Fixation|External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.
57779638|NCT06738693|PROCEDURE|Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate|ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
57779639|NCT06739265|DRUG|Golidocitinib plus CHOP|Phase 1: dose escalation phase. Drug Golidocitinib: 2 dose level of 150 mg qod and 150 mg qd; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle. Phase 2: dose expansion phase. Drug Golidocitinib: RP2D established in the phase I study; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle.
57779640|NCT01285193|BEHAVIORAL|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
57779641|NCT01770249|PROCEDURE|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
57779642|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
57779643|NCT02178436|DRUG|gemcitabine hydrochloride|Given IV
57779644|NCT02178436|DRUG|Selinexor|Given IV
57779645|NCT02178436|OTHER|Pharmacological Study|Correlative studies
57779646|NCT02178436|OTHER|Laboratory Biomarker Analysis|Correlative studies
57779647|NCT02178436|DRUG|Nab paclitaxel|Given IV
57779648|NCT03673371|OTHER|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
57779649|NCT06740500|DIETARY_SUPPLEMENT|Probiotic|probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
57779650|NCT06740500|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
57779651|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
57779652|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
57779653|NCT03103932|OTHER|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
57779654|NCT05176080|DRUG|Famitinib|Famitinib orally, daily or every other day
57779655|NCT05176080|DRUG|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
57779656|NCT05176080|DRUG|Fulvestrant|Fulvestrant
58133158|NCT02503943|DRUG|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
58133159|NCT00048126|DRUG|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
58133160|NCT00048126|DRUG|capecitabine [Xeloda]|1000mg po bid
58133161|NCT03845790|OTHER|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
58133162|NCT01790581|BEHAVIORAL|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
58475007|NCT01630369|DRUG|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58475008|NCT05879354|OTHER|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
58475009|NCT05823480|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
58475010|NCT05823480|DRUG|Azacitidine|Given IV
57779657|NCT05015660|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
57779658|NCT05015660|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
57779659|NCT06736652|OTHER|Parabolic flight|Preflight each individual was exposed to the 3 Other Interventions and monitored for changes in behavioral performance and neurophysiological responses. In-flight the same monitoring was conducted during partial-gravity (0.25, 0.5. 0.75g) and microgravity (\~0g).
57779660|NCT02284919|DRUG|[18F]ISO-1|\[18F\]ISO-1 PET/CT scan
57779661|NCT03294213|DEVICE|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
57779662|NCT06738030|DEVICE|Transcranial current stimulation|The transcranial alternating current stimulation is delivered during the speech stimulus and the current matches the envelope of the target speech
57779663|NCT06738030|BEHAVIORAL|Auditory training|An at-home auditory training program that adaptively and interactively trains the listener in degraded speech, cognitive skills, and communication strategies
57779664|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
57779665|NCT02825953|DRUG|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
57779666|NCT02825953|DEVICE|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
57779667|NCT02825953|DEVICE|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
57779668|NCT02825953|DEVICE|Neopuff|Fisher and Paykel, Auckland, New Zealand
57779669|NCT02825953|DEVICE|neonatal ventilator|GE Healthcare, Madison, USA
57779670|NCT06117995|OTHER|Assessment the pre-washed sperm motility before IUI|The pre-washed sperm motility will be assessed by using WHO 2021 guidelines, stratified into four groups.
57779671|NCT05785611|DRUG|Filgotinib|Tablets administered orally once daily
57779672|NCT05785611|DRUG|Placebo|Tablets administered orally once daily
57779673|NCT02071563|DIETARY_SUPPLEMENT|CSB14|
57779674|NCT02071563|DIETARY_SUPPLEMENT|RUSF1|
57779675|NCT02071563|DIETARY_SUPPLEMENT|SC+|
57779676|NCT04489589|DRUG|Midodrine|10mg PO/NG q8h
57779677|NCT04489589|DRUG|Placebo|10mg PO/NG q8h
57779678|NCT06736847|PROCEDURE|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer
57779679|NCT04340843|DRUG|Belinostat|Given IV
57779680|NCT04340843|PROCEDURE|Biopsy|Undergo biopsy
57779681|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58475011|NCT05823480|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57779682|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
57779683|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
57779684|NCT04340843|DRUG|Guadecitabine|Given SC
57779685|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57779686|NCT06428383|DRUG|Vericiguat tablet|Vericiguat tablet at doses 2.5 mg, 5 mg, or 10 mg taken orally once daily
57779687|NCT06428383|DRUG|Vericiguat suspension|"Vericiguat suspension at doses 0.2 mg/mL,~1 mg/mL taken orally once daily"
58475012|NCT05823480|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
57779688|NCT06740019|DRUG|JMKX000197|for pleural perfusion
57779689|NCT06740019|PROCEDURE|Tube thoracostomy drainage|Tube thoracostomy drainage
57779690|NCT01634711|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
57779691|NCT02212938|DRUG|BI 14332 CL|
57779692|NCT02212938|OTHER|high fat breakfast|
57779693|NCT06738615|DIAGNOSTIC_TEST|Pressure volume loop evaluation|During the left heart catheterization there are catheters which are introduced into the left ventricle to measure left ventricular pressures and into the coronary arteries to assess their patency. This study will require the placement of an additional specialized catheter made into the left ventricle to measure the change of pressure and volume during the cardiac cycle. This will allow the measurement of heart muscle stiffness.
57779694|NCT06738615|DIAGNOSTIC_TEST|cardiovascular magnetic resonance imaging|Patients will undergo standard cardiovascular magnetic resonance imaging of their heart to measure their heart size, heart function, and severity of mitral regurgitation. In addition, contrast will be administered and heart tissue will be assessed for scarring or fibrosis.
57779695|NCT06738615|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|A CPET will be performed to objectively measure a patient ability to perform exercise.
58475013|NCT05823480|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
58133163|NCT01790581|BEHAVIORAL|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
58133164|NCT00003422|DRUG|fluorouracil|
58133165|NCT00003422|DRUG|leucovorin calcium|
57779696|NCT06738615|DIAGNOSTIC_TEST|Kansas City Cardiomyopathy Questionairre|This is a short questionnaire which objectively quantifies symptom burden
58133166|NCT00003422|PROCEDURE|adjuvant therapy|
58133167|NCT00003422|PROCEDURE|conventional surgery|
58133168|NCT00003422|PROCEDURE|neoadjuvant therapy|
58133169|NCT00003422|RADIATION|radiation therapy|
58133170|NCT02520505|DRUG|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
58133171|NCT02520505|BEHAVIORAL|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
58133172|NCT02520505|PROCEDURE|Intrauterine Insemination|Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
58133173|NCT06496646|BEHAVIORAL|Reminders|We will send daily text messages to participants for 12 weeks reminding them to take their antidepressant medication. These reminders will be tailored, personalized and patient-centric, grounded in behavioral economics principles.
58133174|NCT06496646|BEHAVIORAL|Incentives|In addition to daily text messages, participants will receive financial incentives for 6 weeks based on contingency management principles. Participants assigned to the Reminders and Incentives arm of the study will receive a $2/day incentive, increasing by $1/day conditioned on each week that they consistently take their antidepressant over the first 6 weeks, for a maximum total payment of $189 ($2, $3, $4, $5, $6, $7 in weeks 1 through 6, respectively).
57779697|NCT02919943|PROCEDURE|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
57779698|NCT04381767|DEVICE|EYE-SYNC|Evaluation of oculomotor performance using visual presentation and eye tracking analysis
57779699|NCT05290597|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
57779700|NCT05827822|DEVICE|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
57779701|NCT04350476|DIAGNOSTIC_TEST|VitalConnect Vital Sign Patch|"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."
57779702|NCT06740136|OTHER|Exercise|Muscle induced-damage eccentric exercise
57779703|NCT01326793|OTHER|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
57779704|NCT06129760|DEVICE|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
57779705|NCT03760471|OTHER|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
57779706|NCT02800824|DRUG|Budesonide|
57779707|NCT02800824|DRUG|Uceris|
57779708|NCT06741358|OTHER|Glialia|Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.
57779709|NCT06741358|OTHER|Placebo|Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.
58133175|NCT04774757|PROCEDURE|Para-aortic lymph node dissection|Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
58133176|NCT04662996|BIOLOGICAL|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
58133177|NCT01148082|PROCEDURE|Self administered Surveys|
58133178|NCT01148082|PROCEDURE|Interviews|
58133179|NCT02779543|DEVICE|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
58133180|NCT02779543|DEVICE|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
58475014|NCT05823480|PROCEDURE|Echocardiography|Undergo ECHO
58475015|NCT05823480|BIOLOGICAL|Magrolimab|Given IV
58475016|NCT05823480|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
58475017|NCT05823480|OTHER|Questionnaire Administration|Ancillary studies
58490939|NCT03245489|DRUG|acetylsalicylic acid|81mg/day oral
58490940|NCT00106899|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scans
58133181|NCT02779543|DEVICE|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
58133182|NCT06325189|OTHER|Aerobic Interval Training|Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
58133183|NCT03741348|PROCEDURE|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
58133184|NCT03741348|PROCEDURE|control|in control group, Erector Spinae Plane Block will not be done
58133185|NCT05328804|DRUG|rhTPO|subcutaneous injection
58133186|NCT05328804|DRUG|Herombopag|Orally by mouth
58133187|NCT02597998|DRUG|14C-BI 409306|
58133188|NCT06006364|OTHER|Survey|"The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire"
58133189|NCT00425672|BIOLOGICAL|ONTAK|Given IV
58133190|NCT00425672|OTHER|flow cytometry|Correlative studies
58133191|NCT00425672|OTHER|immunohistochemistry staining method|Correlative studies
58133192|NCT00425672|OTHER|enzyme-linked immunosorbent assay|Correlative studies
58133193|NCT00425672|OTHER|laboratory biomarker analysis|Correlative studies
58133194|NCT00425672|GENETIC|protein expression analysis|Correlative studies
58133195|NCT02830022|OTHER|physiological explorations|
58133196|NCT03998865|DEVICE|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
58475018|NCT06604013|PROCEDURE|non-surgical full-mouth periodontal therapy without using adjunct disinfectants|Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
58475019|NCT06604013|DIAGNOSTIC_TEST|GCF level of adiponectin and resistin|Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
58133197|NCT00694551|BIOLOGICAL|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
58475020|NCT04764799|PROCEDURE|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
58475021|NCT00015210|DRUG|Nefazodone|
58475022|NCT00015210|BEHAVIORAL|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
58475023|NCT05075980|DRUG|Cisplatin|Given IV
58475024|NCT05075980|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
58475025|NCT05075980|OTHER|Quality-of-Life Assessment|Ancillary studies
58475026|NCT05075980|OTHER|Questionnaire Administration|Ancillary studies
58133198|NCT00694551|DRUG|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
58133199|NCT01521988|PROCEDURE|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
58133200|NCT01521988|PROCEDURE|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
58133201|NCT00008736|DRUG|metoclopramide|
58475027|NCT05075980|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
58475028|NCT05075980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
58475029|NCT05075980|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
58475030|NCT05075980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58475031|NCT05075980|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
58475032|NCT00136396|DRUG|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
58475033|NCT04712682|OTHER|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
58475034|NCT03745014|DIAGNOSTIC_TEST|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
58475035|NCT03745014|DIAGNOSTIC_TEST|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
58475036|NCT06603870|DRUG|Apixaban|Apixaban is Health Canada approved for routine treatment and secondary prevention of VTE. Upon enrollment and during follow-up, patients will be managed with a prophylactic dose of apixaban (2.5 mg orally twice daily) as long as either a CVC or active cancer is present. Apixaban will be stopped at the time of CVC removal and when cancer is in remission. Patients will be instructed to contact the study team when their CVC is removed (to determine if apixaban should be continued, based on cancer status at the time), or any thrombotic or bleeding concerns were to occur in between visits. The investigators will record loss to follow-up, drop out, or death during the study.
58490941|NCT00106899|PROCEDURE|Positron Emission Tomography (PET)|PET scans
57779710|NCT06741358|OTHER|Control|Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
57779711|NCT02606747|OTHER||routine blood sugar control
57779712|NCT03997162|OTHER|Best Practice|Complete standard of care enhanced recovery after surgery protocol
57779713|NCT03997162|OTHER|Quality-of-Life Assessment|Ancillary studies
57779714|NCT03997162|OTHER|Questionnaire Administration|Ancillary studies
57779715|NCT01628380|PROCEDURE|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
57779716|NCT01628380|PROCEDURE|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
57779717|NCT06738238|OTHER|ELDOA|"In this, each position will be maintained for 1 minute Level: C0/C1/C2 The patient is side lying with bottom arm folded under the head and maintain the neck in a horizontal position with the spine. the bottom leg is bent to stabilize the torso in a vertical position.~Level: C4/C5 Patient lying in supine position and raise both hand arm towards the roof of the room with extended wrist. Bilateral knee to chest with planter flexion at ankle joint.~Level: C5/C6 Same position as for c4/c5 with the arms will be elevated 120 degree Level C6/C7 Supine position with one arm abducted 90 degree and wrist joint at extension and the other hand abducted 30degrees with wrist joint at extension and one leg knee to chest and one leg raise with knee extension and planter flexion at ankle joint.~Level: T4/T5 Quadruped position with one arm abducted 90degrees with wrist at extension Level: T6/T7. Conventional TX is Hot Pack, Tens for 10min. Patient is assessed through baseline, week 1, week 2 and week 4."
57779718|NCT06738238|OTHER|CORRECTIVE EXERCISES|All position will be held for 10 seconds. Initial phase Duration of this phase is 2 weeks. Exercise 1: lying supine on a foam roll with different abduction angles Exercise 2: side lying with external rotation Exercise 3: side lying with forward flexion Exercise 4: standing diagonal flexion Exercise 5: military press Improvement phase. Duration of this phase is 1 week we only add thera- band and dumbbells to the previously mentioned exercises Exercise 1: side lying external rotation with dumbbell Exercise 2: side lying forward flexion with dumbbell Exercise 3: standing diagonal flexion with thera-band Exercise 4: standing external rotation with thera band. Exercise 5: abduction in sitting on training ball. Exercise 6: lying prone on foam ball with different abduction angles Maintenance phase. Duration of this phase is 1 week. Conventional treatment Hot Pack, Tens for 10 minutes Patient is assessed through baseline, week 1, week 2 and week 4.
57779719|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
57779720|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
57779721|NCT02312505|DEVICE|COPFX|cardiac Output by semi-invasive pulse contour analysis
57779722|NCT06424288|DRUG|BI 690517|BI 690517
57779723|NCT06424288|DRUG|Empagliflozin|Empagliflozin
57779724|NCT06424288|DRUG|Placebo|Placebo matching BI 690517
57779725|NCT00776100|OTHER|clinical observation|Patients undergo observation for 6 weeks.
57779726|NCT00776100|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
57779727|NCT06736834|OTHER|Babao Congee and Youtiao(deep-fried dough sticks) with different cooking conditions|Babao Congee and deep-fried dough sticks with different cooking conditions
57779728|NCT05575674|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
57779729|NCT01310868|DRUG|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
57779730|NCT01310868|DRUG|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
58133202|NCT06202196|PROCEDURE|Risk prevention session|"The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS)."
58490942|NCT00106899|PROCEDURE|Lumbar Puncture (LP)|collection of cerebrospinal fluid
58490943|NCT03633539|PROCEDURE|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
57779731|NCT01310868|RADIATION|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
57779732|NCT01310868|DRUG|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
57779733|NCT01310868|DRUG|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
57779734|NCT06739018|OTHER|pentacam scheimpflug tomography|"Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy."
57779735|NCT06738173|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
57779736|NCT02190760|DRUG|Dexamethasone|
57779737|NCT02190760|DRUG|Bupivacaine|
57784805|NCT05353738|BIOLOGICAL|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
58133203|NCT06202196|PROCEDURE|Usual Therapeutic Patient Education (TPE) management|The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
58133204|NCT04095871|OTHER|Observational study|No intervention, patients record the time of CISC
58133205|NCT05733715|DRUG|Pembrolizumab infusion|100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
58133206|NCT05733715|DRUG|Lenvatinib tablet|10mg and 4mg daily for 21 days
58133207|NCT00995553|BEHAVIORAL|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
58133208|NCT00995553|BEHAVIORAL|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
58133209|NCT05948891|DRUG|Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)|observational, prospective, multicentric, international, cohort study
58133210|NCT05427656|RADIATION|[18F] TRACK|We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.
58133211|NCT05427656|DEVICE|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
58133212|NCT00604500|DRUG|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
58133213|NCT04175548|OTHER|Data extraction from medical files|Data extraction from medical files
58133214|NCT05283005|PROCEDURE|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
58133215|NCT06486610|BEHAVIORAL|Fish-shaped nebulizer and fish-shaped toy|In order to reduce the child's fear and anxiety, it is planned to apply inhalation therapy using a nebulizer with a red fish figure and an amigurumi toy with a red fish figure.
58133216|NCT06486610|DEVICE|Silent nebulizer|It is planned to apply inhalation therapy using a silent nebulizer to reduce the child's fear and anxiety.
58133217|NCT02513797|DEVICE|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
58490944|NCT03633539|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
58490945|NCT04835506|DRUG|Infliximab|infliximab
58133218|NCT02513797|DEVICE|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
58133219|NCT05554809|OTHER|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
58133220|NCT03119480|DEVICE|electronic alerts|electronic alerts for AKI
58133221|NCT04154033|DRUG|Naltrexone|Topical naltrexone cream (1%)
58133222|NCT04154033|OTHER|Placebo Cream|Topical placebo cream
58133223|NCT06261892|DIAGNOSTIC_TEST|Collect HPV DNA from urine|Use a sample collector to collect urine
58133224|NCT02853279|BEHAVIORAL|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
58133225|NCT02853279|BEHAVIORAL|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
58133226|NCT02067793|DRUG|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
58133227|NCT02067793|DRUG|Placebo|Single intravenous injection into the arm on Day 0
58133228|NCT02067793|DRUG|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
58133229|NCT02067793|DRUG|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
58133230|NCT03904303|DRUG|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
58133231|NCT04351516|DRUG|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
58133232|NCT04351516|OTHER|Placebo|Placebo: Film Coated Tablette
58133233|NCT04792944|DRUG|Urokinase|Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
58133234|NCT04792944|PROCEDURE|Endovascular treatment|Aneurysm treatment through endovascular methods
58133235|NCT04792944|PROCEDURE|Clipping|Surgical clipping of brain aneurysms
58133236|NCT04792944|PROCEDURE|External ventricular drain|Insertion of an external ventricular drain to treat acute hydrocephalus
58133237|NCT05589415|DEVICE|High-definition Transcranial Direct Current Stimulation|"High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps."
58133238|NCT05589415|DEVICE|Conventional Transcranial Direct Current Stimulation|Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
58133239|NCT05642494|DEVICE|SDF|Silver Diamine Fluoride 38% (Applied bianually)
58475037|NCT03536156|OTHER|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
58133240|NCT05642494|DEVICE|NaF|Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
57784806|NCT05353738|OTHER|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
58133241|NCT05552781|DRUG|H002 capsule|Small molecule, Capsule
58133242|NCT05853328|PROCEDURE|Epley Maneuver|"The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward."
58133243|NCT05853328|PROCEDURE|SemontPLUS maneuver|The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
58133244|NCT05513742|DRUG|CTX-009|IV infusion administered on day 1 and 15 of every 28-day cycle
58133245|NCT02510547|PROCEDURE|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
58133246|NCT02510547|PROCEDURE|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
58133247|NCT03533465|BEHAVIORAL|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
58133248|NCT03983564|OTHER|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
58133249|NCT02463695|PROCEDURE|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
58475038|NCT05023551|DRUG|DSP-0390|DSP-0390 administered orally
58133250|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy|"the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
58133251|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel|"The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
58133252|NCT05252130|DEVICE|NoaScope|Smart digital stethoscope
58133253|NCT00886171|BEHAVIORAL|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
58133254|NCT00886171|BEHAVIORAL|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
58133255|NCT02096510|DRUG|Solu-Cortef|administration by pump for minimum 2 weeks
58133256|NCT02096510|DRUG|Cortef|tablet treatment 2 ro 3 times per day for 14 days
58133257|NCT00620048|BIOLOGICAL|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
58133258|NCT02936856|DEVICE|Hepatic Arteriography|
58133259|NCT03021538|DEVICE|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
58133260|NCT03021538|DEVICE|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
58133261|NCT02652026|PROCEDURE|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
58133262|NCT02652026|PROCEDURE|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
58133263|NCT01415700|DEVICE|Functional electrical stimulator|The stimulator is surgically implanted
58133264|NCT01415700|DEVICE|feet orthosis|feet orthosis specifically mold
58133265|NCT06354504|PROCEDURE|Non-surgical periodontal treatment|Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
58133266|NCT02719223|DEVICE|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
58133267|NCT01094067|DRUG|ACT-050089|5 mg/h intravenously, Tezosentan
58133268|NCT01094067|OTHER|Placebo|Matching placebo
58133269|NCT04732195|DEVICE|Pilocarpine microneedle patch|Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
58133270|NCT04732195|DEVICE|Pilocarpine Iontophoresis|Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
58133271|NCT05061290|OTHER|Control Porridge|Maize porridge containing 54Fe as iron sulfate
58133272|NCT05061290|OTHER|Reference Porridge A|Maize porridge counting 58Fe as iron sulfate with ascorbic acid
58133273|NCT05061290|OTHER|Test Porridge B|Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
58133274|NCT05061290|OTHER|Test Porridge C|Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
58133275|NCT05061290|OTHER|Test Porridge D|Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
58133276|NCT00242788|DRUG|Gefitinib and capecitabine|
58133277|NCT04179045|DEVICE|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
58475039|NCT00359645|PROCEDURE|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
58475040|NCT06577610|BEHAVIORAL|Feedback from colonoscopy monitoring program|Adenoma detection rate feedback from colonoscopy monitoring programs
57784833|NCT02460471|RADIATION|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
58133278|NCT01705769|OTHER|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
58133279|NCT01705769|OTHER|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
58133280|NCT01705769|OTHER|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
58133281|NCT00006734|BIOLOGICAL|filgrastim|Given IV
58133282|NCT00006734|DRUG|cyclophosphamide|Given IV
58133283|NCT00006734|DRUG|doxorubicin hydrochloride|Given IV
58133284|NCT00006734|DRUG|etoposide|Given IV
58133285|NCT00006734|DRUG|ifosfamide|Given IV
58133286|NCT00006734|DRUG|vincristine sulfate|Given IV
58133287|NCT00006734|PROCEDURE|adjuvant therapy|
58133288|NCT00006734|PROCEDURE|conventional surgery|
58133289|NCT00006734|PROCEDURE|neoadjuvant therapy|
58133290|NCT00006734|RADIATION|brachytherapy|
58475041|NCT04965818|DRUG|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
58475042|NCT05697328|DRUG|Pseudoephedrine Pill|One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
58475043|NCT05697328|DRUG|Placebo|One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
58475044|NCT01412502|OTHER|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
58475045|NCT00992108|DRUG|lidocaine|1cc 1%
58475046|NCT00992108|DRUG|chemodenervation|botulinum toxin
58475047|NCT05024539|OTHER|nonintervention|
58475048|NCT06474026|DEVICE|ExAblate 4000 Type 2.1|"In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments."
58475049|NCT05479877|DRUG|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
58475050|NCT05479877|DRUG|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
58475051|NCT06585917|DEVICE|7F Thin-Walled Sheath|The 7F Thin-Walled Sheath is used during coronary intervention procedures via distal radial artery access. This device has a smaller outer diameter compared to traditional 7F sheaths, designed to reduce the risk of vascular complications while allowing for the performance of complex coronary interventions.
58475052|NCT06585917|DEVICE|6F Thin-Walled Sheath|The 6F Thin-Walled Sheath is the standard device used in coronary intervention procedures via distal radial artery access. It is employed as a control in this study to compare its efficacy and safety against the 7F Thin-Walled Sheath.
58475053|NCT00471939|DRUG|I-020502|1 mcg/mL TG-PDGF.AB
58475054|NCT06503874|OTHER|Attention Training|The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).
58475055|NCT06503874|OTHER|Music Group|This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.
58475056|NCT01773044|DRUG|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
58475057|NCT01773044|DRUG|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
58475058|NCT01773044|DRUG|Placebo (for alcalinized lidocaine)|
58475059|NCT05371626|PROCEDURE|Suture-less surgical procedure|Suture-less technique will be used in treatment for cicatricial upper eyelid entropion
58475060|NCT03850756|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
58133291|NCT00006734|RADIATION|radiation therapy|
58475061|NCT03850756|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
58475062|NCT03850756|DIAGNOSTIC_TEST|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
58475063|NCT05743491|OTHER|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
58475064|NCT05743491|BEHAVIORAL|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
58475065|NCT03521128|PROCEDURE|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
58475066|NCT03521128|PROCEDURE|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
58475067|NCT02403128|DRUG|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
58475068|NCT06603454|RADIATION|Preoperative CT|Preoperative contrast enhanced CT
57784834|NCT06479473|RADIATION|Radiotherapy to all residual lesions|Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
58475069|NCT01995708|BIOLOGICAL|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
58475070|NCT01995708|OTHER|Standard of care|No vaccines
58475071|NCT03010449|DEVICE|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
58475072|NCT06590597|BEHAVIORAL|EDUCATIONAL INTERVENTION FOR MALARIA PREVENTION|The intervention consisted of 4 modules administered in the same number of face-to-face sessions in which educational strategies such as classes, guided discussions, workshops and a booklet designed for the study were used.
58475073|NCT04407754|DIETARY_SUPPLEMENT|Inositol supplement|Inositol supplements given to inositol arm
58475074|NCT04407754|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement given to placebo arm
58475075|NCT01185236|DRUG|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
58475076|NCT01185236|DRUG|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
58475077|NCT05933317|DIAGNOSTIC_TEST|Functional lung MRI|Functional lung MRI
58475078|NCT05170919|DRUG|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
58475079|NCT05170919|DRUG|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
58475080|NCT01891253|DEVICE|non-invasive determination of cardiac output|
58475081|NCT00460876|DRUG|Topotecan|
58475082|NCT00283296|DEVICE|Endeavor|Collapsible, forward folding manual wheelchair
58475083|NCT00551642|DRUG|Nitric oxide|Nitric Oxide vapour (gas) for inhalation (400 ppm)
58475084|NCT00551642|DRUG|Placebo|Placebo gas for inhalation
58475085|NCT06586177|DRUG|Anti-CD20 antibody|Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
58475086|NCT00524511|DEVICE|Surgical skin staples|Standard method to close abdominal surgical wounds
58475087|NCT00524511|DEVICE|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
58475088|NCT05130528|BEHAVIORAL|Sensorimotor Intervention|Infants in the experimental group will receive 2 sensorimotor intervention sessions in the Neonatal Intensive Care Unit (NICU) and 8 sensorimotor intervention sessions in the home or in a clinic (parent choice) at 1, 3, 5, 8, 11, 15, 20, 26 weeks post NICU discharge. The 2 intervention sessions in the NICU will consist of collaborating with parents to recognize their infant's cues to engage in interaction, readiness for sensory exposures, and anticipatory guidance on the transition to home. The 8 intervention sessions in the home will focus on supporting the parents to read their infant's cues to identify the ideal times for interaction and provide 20 minutes of daily intervention addressing four key principles: encourage 1) self-initiated movement, 2) movement variability, 3) visual and manual object interaction, and 4) social interaction. Parents are encouraged not to impose movement on the infant but to encourage movement through environmental enrichment
58475089|NCT02998463|DEVICE|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
58475090|NCT01318577|DEVICE|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
58475091|NCT01318577|DEVICE|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
58475092|NCT05127954|DRUG|Ubrogepant|Oral Tablet
58475093|NCT05329948|OTHER|Haptonomy application|Feeling the fetus by touching the mother's womb with meditation
58475094|NCT05689372|DRUG|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
58475095|NCT04951921|DRUG|Hyperpolarized 13C Pyruvate|Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
58475096|NCT00433173|PROCEDURE|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
58475097|NCT00433173|DRUG|testosterone|transdermal 7.5 g/per day for 3 months
58475098|NCT00433173|DRUG|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
58475099|NCT00433173|DRUG|goserelin acetate implant|single depot injection 10.8 mg 3 months
58475100|NCT00433173|PROCEDURE|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
58475101|NCT00433173|PROCEDURE|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
58475102|NCT00433173|PROCEDURE|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
58475103|NCT00433173|PROCEDURE|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
58475104|NCT00433173|PROCEDURE|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
58475105|NCT00433173|PROCEDURE|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
58133292|NCT03947242|DRUG|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
58133293|NCT01479738|PROCEDURE|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
58133294|NCT03787680|DRUG|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
58133295|NCT03787680|DRUG|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
58133296|NCT03725605|COMBINATION_PRODUCT|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
58133297|NCT04999709|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
58133298|NCT03597334|BEHAVIORAL|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
58133299|NCT00000961|DRUG|Anti-HIV Immune Serum Globulin (Human)|
58133300|NCT00000961|DRUG|Zidovudine|
58133301|NCT04978649|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
58133302|NCT04978649|DRUG|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
58133303|NCT04400123|DRUG|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
58133304|NCT01888081|DRUG|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
58133305|NCT01888081|RADIATION|Ionizing Radiation|
58133306|NCT03119935|DEVICE|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
58133307|NCT03119935|DEVICE|Ambu bag|Participants ventilated the simulated patients by ambu bag
58133308|NCT04797130|DEVICE|Hospital Fit 2.0|HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
58133309|NCT05483153|BEHAVIORAL|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
58133310|NCT04349592|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
58133311|NCT04349592|DRUG|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
58133312|NCT04349592|OTHER|Placebo Tablet|Oral, one tablet three times a day for 7 days
58133313|NCT04349592|OTHER|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
58133314|NCT05267366|DRUG|PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed|PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
58133315|NCT00605709|DRUG|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
58133316|NCT02417636|OTHER|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
58475106|NCT06591585|RADIATION|Fracture Healing|"A-Clinical evaluation~1. Patients will be recruited for evaluation of documented short / long term complications:~   * subcutaneous haematoma~  * pin tract infection~  * surgical site infection~  * limb length discrepancy~  * arthritis of the hip and spine~  * SI joint pain or fusion~  * scoliosis~2. Visually assisted gait analysis B- Radiographic evaluation~1-Radiographic evaluation of pelvic integrity by plain X-ray ( Antero-posterior . inlet . outlet views) 2- Long film for limb length discrepancy 3- plain x ray whole spine Anterior -posterior \&amp; lateral for scoliosis"
58475107|NCT00131222|PROCEDURE|Food supplement: fortified spread|
58475108|NCT00131222|PROCEDURE|Food supplement: maize and soy flour|
58133317|NCT02186730|BEHAVIORAL|Stressbusters|cCBT
58133318|NCT02186730|BEHAVIORAL|Websites|Self help websites
58133319|NCT03356821|BIOLOGICAL|Mesenchymal Stem Cells|One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
58475109|NCT06591000|PROCEDURE|tricuspid valve replacement|Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
58133320|NCT04999670|PROCEDURE|Fascial closure method during caesarean section via pfannenstiel incision.|Comparison of three different methods of fascial closure.
58133321|NCT05629884|OTHER|COPERIA-REHAB|"After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week)."
58133322|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -B|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
58133323|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -A|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
58133324|NCT00607230|BIOLOGICAL|BCG|BCG vaccination at 0 and 4 weeks
58133325|NCT00607230|BIOLOGICAL|Saline|Saline vaccination at 0 and 4 weeks
58133326|NCT06360913|DIAGNOSTIC_TEST|High resolution mass spectrometry|Metabolomics study
58133327|NCT01419106|DEVICE|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
58133328|NCT01437501|DRUG|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
58133329|NCT01437501|DRUG|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
58133330|NCT03963063|PROCEDURE|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2"
58133331|NCT03963063|PROCEDURE|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg"
58133332|NCT00920764|DRUG|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
58133333|NCT00920764|DRUG|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
58133334|NCT00920764|DRUG|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
58133335|NCT00920764|DRUG|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
58133336|NCT04480073|PROCEDURE|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
58133337|NCT01123681|DEVICE|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
58133338|NCT02107300|DRUG|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
58133339|NCT02107300|DRUG|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
58133340|NCT00950625|DRUG|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
58133341|NCT00950625|DRUG|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
58133342|NCT00005856|DRUG|oxaliplatin|Given IV
58133343|NCT00005856|OTHER|pharmacological study|Correlative studies
58133344|NCT01382290|PROCEDURE|MRI|
58133345|NCT03362736|DRUG|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to \[\<=\] 55 kilogram \[kg\] will receive 260 milligram \[mg\] ustekinumab; \> 55 kg to \<= 85 kg will receive 390 mg ustekinumab; and \> 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
58133346|NCT05000840|BEHAVIORAL|Enrollment in existing SDRI diabetes education programs|Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
58133347|NCT02293668|DRUG|FSH 225IU and hMG 225IU|
58133348|NCT02293668|DRUG|FSH 150IU and hMG 150IU|
58133349|NCT02293668|DRUG|Letrozole 5mg and hMG 150IU|
58133350|NCT00032903|DRUG|Gimatecan® (ST 1481)|
58133351|NCT06318702|OTHER|Education|is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
58133352|NCT01218165|DIETARY_SUPPLEMENT|Probiotic drink|This group receives a probiotic drink daily for 6 week.
58475110|NCT05030337|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
57784835|NCT06479473|DRUG|Chemoimmunotherapy|atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
58133353|NCT01218165|OTHER|Control Group|without intervention
58133354|NCT02359981|BEHAVIORAL|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
58133355|NCT02359981|BEHAVIORAL|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
58133356|NCT02359981|DEVICE|Smartphone|An Android Smartphone with operating system version higher than 2.2
58133357|NCT00893256|DRUG|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
58133358|NCT00893256|DRUG|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
58133359|NCT00893256|DRUG|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
58133360|NCT00893256|DRUG|Placebo|Placebo: once daily
58133361|NCT03322709|PROCEDURE|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
58133362|NCT06295653|PROCEDURE|implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane|assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
58475111|NCT04567628|OTHER|No Intervention|As this was an observational study, no intervention was administered.
58133363|NCT01400022|OTHER|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
58133364|NCT01400022|OTHER|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
58133365|NCT00483899|DRUG|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
58133366|NCT00483899|DRUG|Placebo|Placebo matching GW870086X will be administered by subjects
58133367|NCT05116670|OTHER||this is an observation study, no intervention is needed
58133368|NCT01215409|DRUG|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
58133369|NCT01901666|DRUG|Growth Hormone|"All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
58133370|NCT01424839|RADIATION|craniospinal irradiation|"* Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~* Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
58133371|NCT01424839|DRUG|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
58133372|NCT01424839|RADIATION|ventricular irradiation|"* Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
58133373|NCT01424839|DRUG|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
58133374|NCT01424839|DRUG|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
58133375|NCT01424839|RADIATION|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
58133376|NCT00076050|DIETARY_SUPPLEMENT|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
58133377|NCT00076050|DIETARY_SUPPLEMENT|Placebo|Placebo soy isoflavones
58133378|NCT06246474|PROCEDURE|physical therapy program|Arm Description: Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
58133379|NCT05954325|PROCEDURE|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
58133380|NCT04462406|BIOLOGICAL|Ipilimumab|Given IV
58133381|NCT04462406|BIOLOGICAL|Nivolumab|Given IV
58475112|NCT03043872|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
57784922|NCT03908281|BEHAVIORAL|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
58133382|NCT04462406|OTHER|Patient Observation|Undergo active surveillance
58133383|NCT04462406|BIOLOGICAL|Pembrolizumab|Given IV
58133384|NCT03052309|DEVICE|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
58133385|NCT01876576|OTHER|Clear liquids|Clear liquids
58133386|NCT01876576|OTHER|Low residue breakfast and lunch|Low residue
58133387|NCT03018834|DRUG|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
58475113|NCT03043872|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
58475114|NCT03043872|DRUG|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
58133388|NCT03018834|DRUG|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
57779738|NCT06740903|DRUG|inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
57784923|NCT00002813|DRUG|cisplatin|
57784924|NCT00002813|DRUG|vinorelbine tartrate|
58133389|NCT01353469|DRUG|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
58133390|NCT01353469|DRUG|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
58133391|NCT00051025|DRUG|ONTAK|
58133392|NCT05901857|DIAGNOSTIC_TEST|convolutional neural network|A deep learning model for dental age classification from panoramic images
58133393|NCT00630305|DEVICE|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
58133394|NCT00630305|DEVICE|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
58133395|NCT00630305|DEVICE|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
58133396|NCT03994432|BEHAVIORAL|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
58133397|NCT04494867|DEVICE|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
58133398|NCT04494867|OTHER|Standard of Care|Standard temperature management and treatment
58133399|NCT00276757|DRUG|leucovorin calcium|
58133400|NCT00276757|DRUG|methotrexate|
58133401|NCT00276757|DRUG|prednisolone|
58133402|NCT00276757|DRUG|vinblastine sulfate|
58133403|NCT01866449|DRUG|Cabazitaxel|
58133404|NCT01459874|BEHAVIORAL|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
58475115|NCT03043872|DRUG|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
58475116|NCT03043872|DRUG|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
58475117|NCT03059134|DRUG|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
58475118|NCT02516137|PROCEDURE|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
58133405|NCT02091882|DRUG|Placebo|Oral placebo-embedded IEM tablet.
58133406|NCT02091882|COMBINATION_PRODUCT|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
58133407|NCT00575406|DRUG|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
58133408|NCT00575406|DRUG|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
58133409|NCT00575406|DRUG|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
58133410|NCT00575406|DRUG|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
58133411|NCT00575406|DRUG|Vincristin|i.v., 2mg, d1 of each treatment cycle
58133412|NCT00575406|DRUG|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
58133413|NCT05385068|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
58133414|NCT00973193|DRUG|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
58133415|NCT01203878|DRUG|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
58133416|NCT01203878|DRUG|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
58133417|NCT00679367|DRUG|dexamethasone|40 mg once weekly
58133418|NCT00679367|DRUG|lenalidomide|10 mg/day D1-21
58133419|NCT00679367|DRUG|melphalan|5 mg/m2 D1-4
58133420|NCT03450070|DEVICE|Light Therapy Mask Cream|test panel
58133421|NCT00004825|DRUG|recombinant human insulin-like growth factor I|
58133422|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
58133423|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
58133424|NCT04328532|DEVICE|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
58133425|NCT02735174|DEVICE|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
58133426|NCT02735174|OTHER|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
58133427|NCT02735174|BEHAVIORAL|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
58133428|NCT02735174|OTHER|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
58133429|NCT05577845|DRUG|Ramosetron|Ramosetron, 4 weeks
58133430|NCT01408199|DRUG|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
58133431|NCT02852980|OTHER|gestational diabetes women|No intervention.
58133432|NCT00118547|BEHAVIORAL|In home monitoring with feedback|Behavioral counseling
58133433|NCT04729660|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
58133434|NCT05247658|OTHER|Therapeutic lens alone|Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
58133435|NCT05247658|OTHER|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
58133436|NCT04349735|OTHER|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
58133437|NCT05091385|BIOLOGICAL|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
58133438|NCT04661878|BEHAVIORAL|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
58133439|NCT04661878|BEHAVIORAL|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
58133440|NCT04661878|BEHAVIORAL|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
58133441|NCT04661878|BEHAVIORAL|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
58133442|NCT00386009|DRUG|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
58133443|NCT00386009|DRUG|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
58133444|NCT03741595|BEHAVIORAL|Item spacing|Spatial proximity of items to one another
58133445|NCT03688126|BEHAVIORAL|Self-Guided Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
58133446|NCT03688126|BEHAVIORAL|Structured Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
58133447|NCT00993252|PROCEDURE|CT Scan|CT scan
58133448|NCT05442866|DEVICE|Virtual reality experience for 10 minutes|Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
58490946|NCT04521504|DEVICE|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
58490947|NCT03572595|DIAGNOSTIC_TEST|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
58133449|NCT01829308|BEHAVIORAL|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
58133450|NCT01829308|BEHAVIORAL|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
58133451|NCT03663803|BEHAVIORAL|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
58133452|NCT04175964|BEHAVIORAL|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
58133453|NCT04175964|COMBINATION_PRODUCT|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
58133454|NCT04175964|BEHAVIORAL|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
58133455|NCT03261323|PROCEDURE|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
58133456|NCT03261323|PROCEDURE|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
58133457|NCT03261323|OTHER|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
58133458|NCT05901922|BEHAVIORAL|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
58133459|NCT02985593|DRUG|KHK4083|
58133460|NCT02985593|DRUG|Placebo|
58133461|NCT05380271|DRUG|sequential DEB-BACE and Arotinib and Tirelizumab|DEB-BACE+Arotinib + Tirelizumab
58133462|NCT05380271|DRUG|DEB-BACE alone|DEB-BACE alone
58133463|NCT05723809|DEVICE|Percussive Therapy Device|Same as group description
57779739|NCT06740903|DRUG|inj. lignocaine infusion @1-2 mg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
57779740|NCT04989530|DEVICE|Extracorporeal Shock Wave Therapy|different energy levels of ESWT
57779741|NCT06737965|OTHER|Medical abortion|"Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory."
58133464|NCT05723809|BEHAVIORAL|Physical Therapy|Same as group description
58133465|NCT01149629|DRUG|Droxidopa|One capsule containing 300 mg droxidopa, given once
58133466|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
58133467|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
58133468|NCT01027780|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
58133469|NCT03760211|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
58133470|NCT03760211|BEHAVIORAL|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
58133471|NCT02627209|OTHER|spectrophotometric assay|measurement of enzyme activity in the serum
58133472|NCT02627209|OTHER|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
58133473|NCT00907998|DRUG|APL180|
58133474|NCT00907998|DRUG|APL180|
58133475|NCT00907998|DRUG|Placebo|
58133476|NCT01820923|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
58133477|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
58133478|NCT01820923|DEVICE|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
58133479|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
58133480|NCT02410928|DEVICE|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
58133481|NCT02410928|DEVICE|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
58133482|NCT02410928|DEVICE|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
58133483|NCT03365037|DRUG|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
58133484|NCT03365037|DRUG|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
58133485|NCT03210636|DEVICE|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
58133486|NCT00072124|DRUG|cisplatin|
58133487|NCT00072124|DRUG|dacarbazine|
58133488|NCT00072124|PROCEDURE|conventional surgery|
58133489|NCT02869646|PROCEDURE|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
58133490|NCT02869646|PROCEDURE|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
58133491|NCT04513379|DRUG|Efavirenz 600mg|EFV 600 mg per day given orally
58133492|NCT04513379|DRUG|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
58133493|NCT05383222|BEHAVIORAL|Technical task|Simulated insertion of a central venous catheter
58133494|NCT05383222|BEHAVIORAL|Administrative task|Requesting a battery of investigations on the EPR
58133495|NCT03553823|PROCEDURE|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
58133496|NCT02589171|DEVICE|Neo Close Abdominal Closure|Neo Close Abdominal Closure
58133497|NCT02589171|DEVICE|Carter Thomason Device|Carter Thomason Device
58133498|NCT03943433|PROCEDURE|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
58133499|NCT03943433|PROCEDURE|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
58133500|NCT06261229|BEHAVIORAL|Intermittent fasting|The participant will consume food about/ within 8-hour per day
58133501|NCT06261229|BEHAVIORAL|Intermittent fasting + Behavioral economic|The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week
58133502|NCT06261229|BEHAVIORAL|Intensive Lifestyle Modification|Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
58133503|NCT05532332|DRUG|Fluoxetine 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
58133504|NCT05532332|DRUG|Prozac® 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
58133505|NCT06547944|DRUG|Zanubrutinib|160mg bid/d, from C1 to CR and MRD-negative or C24
57779742|NCT06737965|OTHER|Foetopathology exam|"Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution."
57779743|NCT06737965|OTHER|Outcomes mesurement|"* From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone."
57779744|NCT03309124|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
57779745|NCT03309124|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
57779746|NCT03309124|OTHER|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
57779747|NCT03309124|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
57779748|NCT03309124|OTHER|Meal skipping|No food given
57779749|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
57779750|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
57779751|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
57779752|NCT01096199|DRUG|TS-ONE, Cisplatin, RAD001|
57779753|NCT06737133|PROCEDURE|Surgery|Rhinoplasty
57779754|NCT00673634|PROCEDURE|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
57779755|NCT00673634|PROCEDURE|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
57779756|NCT00344370|DRUG|Pitavastatin|Pitavastatin 4 mg QD
57779757|NCT00344370|DRUG|Atorvastatin|Atorvastatin 40 mg
58133506|NCT06547944|DRUG|Lenalidomide|From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
58133507|NCT06547944|DRUG|Obinutuzumab|1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
58490948|NCT01148979|DRUG|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
57779758|NCT00432679|DRUG|Rosiglitazone (BRL49653C)|study drug
58133508|NCT03100305|OTHER|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
58133509|NCT02869425|DRUG|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
58133510|NCT02869425|DRUG|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
58133511|NCT03056781|BEHAVIORAL|social interaction|Participants will engage in a social interaction with another person
58133512|NCT03056781|BEHAVIORAL|food consumption|Participants will be offered food stuffs to eat/drink
58133513|NCT02918994|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
58133514|NCT06361225|DIAGNOSTIC_TEST|evaluation with RUSH protocol|Daily evaluation of the patient via ultrasound using the RUSH protocol
58133515|NCT04697498|PROCEDURE|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
58133516|NCT04697498|PROCEDURE|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
58133517|NCT03587649|DRUG|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
58133518|NCT04738032|OTHER|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
58133519|NCT03472365|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
58133520|NCT03472365|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
58133521|NCT03472365|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
58133522|NCT03472365|DRUG|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
58133523|NCT02962570|DEVICE|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
58133524|NCT02962570|DEVICE|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
58133525|NCT02962570|DEVICE|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
58133526|NCT03784664|DIAGNOSTIC_TEST|Arterial blood gas|arterial blood sample with puncture of the radial artery
58133527|NCT03784664|DIAGNOSTIC_TEST|Veinous blood gas|veinous blood sample using peripheral venepuncture
58133528|NCT05552001|DRUG|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
58133529|NCT00486109|DEVICE|I-Port(TM) Injection Port|
58133530|NCT03281109|DIAGNOSTIC_TEST|diagnosis|diagnosis with ELISA
58133531|NCT04155281|OTHER|urine analysis|New Psychoactive Substances research in urine at admission in unit care
58133532|NCT00720265|DRUG|Prograf|oral
58133533|NCT00720265|DRUG|MR4|oral
57779759|NCT01165346|RADIATION|Fiducials|Implantation of fiducials
57779760|NCT01165346|RADIATION|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
57779761|NCT00391456|BEHAVIORAL|Animal-assisted Therapy|
58133534|NCT04933825|BIOLOGICAL|ET-02|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
58133535|NCT04332302|OTHER|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
58133536|NCT04538170|BEHAVIORAL|pain after surgery|
58133537|NCT01671514|DIETARY_SUPPLEMENT|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
58133538|NCT01671514|OTHER|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
58133539|NCT00527423|DRUG|VEGF Trap Eye|Intravitreal injection
58133540|NCT01206257|DRUG|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
58133541|NCT04569942|DRUG|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
58133542|NCT04569942|OTHER|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
58133543|NCT00543686|DRUG|Montelukast|Intake of Montelukast
58133544|NCT00543686|DRUG|Fluticasone|Intake of Fluticasone
58133545|NCT00083785|DRUG|Talaporfin sodium (LS11)|
58133546|NCT00083785|DEVICE|LED-based light infusion device|
57779762|NCT06737211|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
57779763|NCT02035215|DRUG|Atorvastatin 20mg|
57779764|NCT02035215|DRUG|Omega-3-acids ethylesters 90 4g|
57779765|NCT02035215|OTHER|Placebo(Omega-3-acids ethylesters 90)|
57779766|NCT06206746|DEVICE|May Health System|The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
57779767|NCT06738940|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 48 weeks
57779768|NCT00670462|BEHAVIORAL|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
57779769|NCT00670462|BEHAVIORAL|Maintenance-Tailored Treatment (MTT)|
57779770|NCT05668858|DRUG|SI-B001|Administration by intravenous infusion
58133547|NCT00083785|DEVICE|Light emitting diodes (LED)|
58133548|NCT00083785|PROCEDURE|Photodynamic therapy|
58133549|NCT00083785|PROCEDURE|Phototherapy|
58133550|NCT00083785|PROCEDURE|Chemotherapy|
58133551|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
58133552|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
58133553|NCT01674530|DRUG|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
58133554|NCT00731926|DIETARY_SUPPLEMENT|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
58133555|NCT00731926|DIETARY_SUPPLEMENT|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
58133556|NCT00731926|OTHER|placebo|twice a day for 1 month
58133557|NCT00242866|DRUG|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
58133558|NCT00242866|OTHER|Placebo|Placebo to Match GW274150
58133559|NCT03940001|BIOLOGICAL|Sintilimab|Other Name: (IBI308)
58133560|NCT03940001|DRUG|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
58133561|NCT03940001|RADIATION|Radiation|IMRT or VMAT
58133562|NCT04586088|DRUG|Apatinib plus Camrelizumab|Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
58475119|NCT02516137|PROCEDURE|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
58490949|NCT01148979|DRUG|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
58490950|NCT03196349|DRUG|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
58490951|NCT03196349|DRUG|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
57779771|NCT05668858|DRUG|SI-B003|Administration by intravenous infusion
58133563|NCT00024453|BIOLOGICAL|teicoplanin|
58133564|NCT00047606|DRUG|IOP Lowering Medications|
58133565|NCT01075711|DRUG|Prednisone|According to SPC
58133566|NCT03267745|DIETARY_SUPPLEMENT|Amino Acid|23.7 g amino acid 3 times daily for 28 days
58133567|NCT03267745|DEVICE|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
58133568|NCT03267745|OTHER|Placebo|Excipient-matched placebo 3 times daily for 28 days
58133569|NCT00983710|BEHAVIORAL|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
58133570|NCT00983710|BEHAVIORAL|Usual care|Booklet on coping with localized prostate cancer
58133571|NCT00843323|OTHER|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
58133572|NCT01436032|DRUG|N1539|IV
58133573|NCT01436032|DRUG|N1539|IV
58133574|NCT01436032|DRUG|N1539|IV
58133575|NCT01436032|DRUG|Ketorolac Tromethamine|IV
58133576|NCT01436032|DRUG|Placebo|IV
58133577|NCT02845895|OTHER|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
58133578|NCT02845895|OTHER|Classic strategy|Classic organization with the training of the department team
58133579|NCT04348162|OTHER|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
58133580|NCT03716141|OTHER|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
58133581|NCT03716141|OTHER|Conventional Saline dressing|saline dressing of diabetic wounds will be done
58133582|NCT04251390|DEVICE|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
58133583|NCT02757248|DRUG|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
58133584|NCT02757248|DRUG|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
58133585|NCT00396526|DRUG|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
58133586|NCT01284205|BIOLOGICAL|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
58133587|NCT01284205|BIOLOGICAL|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
58133588|NCT05285085|DRUG|Statin|Statin use
58133589|NCT00601302|DRUG|Amlodipine|
58133590|NCT00144625|DRUG|MRA(Tocilizumab)|8mg/kg/4weeks
58133591|NCT06025448|PROCEDURE|BIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).
58133592|NCT06025448|PROCEDURE|MIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).
58133593|NCT01674582|OTHER|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
58133594|NCT01340430|DRUG|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
58133595|NCT00995410|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
58133596|NCT06025838|BEHAVIORAL|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
58133597|NCT01674556|DRUG|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
58133598|NCT01195298|DRUG|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
58133599|NCT04692610|BEHAVIORAL|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
58133600|NCT04692610|BEHAVIORAL|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
58133601|NCT04692610|BEHAVIORAL|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
58133602|NCT04692610|BEHAVIORAL|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
58133603|NCT01313416|BIOLOGICAL|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
58133604|NCT01313416|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
58133605|NCT00003666|DRUG|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
58133606|NCT04234256|OTHER|Static stretching exercise|Standing quadriceps stretch, Gastrocnemius stretch, Standing split, Adductor stretch, Half kneeling groin stretch, Hamstring stretch on the bench, Prayer squat, Seated adductor and hamstring stretch, Hurdle seat, Seated glute stretch, Lying glute stretch, Seated groin abduction, Soleus stretch, Half kneeling quad stretch, Split hamstring stretch
58133607|NCT04234256|OTHER|Dynamic stretching exercise|Downward dog to runner's lunge, Dynamic squat stretch, Crescent to hamstring stretch, Half kneeling hamstring stretch, Side to side lunge with reach, Standing calf and hamstring stretch, Hurdles, Side to side lunge with step, IT band stretch, Walking quad stretch, Swing the leg forward and back, Swing the leg cross, Knee pull, Standing quat stretch, Standing gluteus stretch
58133608|NCT06496035|DEVICE|Blood Flow Restriction with low load exercise|Cuff/tourniquet will be applied to proximal leg at hip crease and inflated to 60-80% of limb occlusion pressure to decrease venous blood flow in the limb while performing exercise.
58133609|NCT06496035|OTHER|Therapeutic Exercise|Exercise performed at appropriate load as guided by physical therapist
58133610|NCT01064349|DRUG|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
58133611|NCT01200043|OTHER|fructose restriction diet|fruits and vegetables only
58133612|NCT00669630|BEHAVIORAL|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
58133613|NCT03971825|DRUG|CC-92252|CC-92252
58133614|NCT03971825|OTHER|Placebo|Placebo
58133615|NCT05353452|BEHAVIORAL|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
57779772|NCT06574425|OTHER|long-term, high blood flow hemoadsorption therapy|Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
57779773|NCT06741137|PROCEDURE|inhaled nitric oxide combined with prone position ventilation|inhaled nitric oxide combined with prone position ventilation
57779774|NCT05586737|DRUG|Rituximab|1 gram rituximab twice with two weeks interval
57779775|NCT05865418|OTHER|Loaded high intensity training|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.
57779776|NCT05865418|OTHER|High intensity circuit training (HICT)|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
57779777|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
57779778|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
57779779|NCT06737718|OTHER|Eye tracking|"The eye-tracking session will take place in the Pediatric Radiology department of Necker Hospital. The child will be seated in front of a computer screen. Films and images with social and/or non-social content will be shown to the children. The session will be unique, will last approximately 15 minutes and will not involve any constraints for the child.~Eye tracking allows to measure where and how a person looks. An infrared light is emitted towards the subject's eye. It is reflected there and a camera records the reflections generated, allowing a real-time calculation of the position of the gaze. The technique is harmless and non-invasive."
57779780|NCT06737718|OTHER|Data collection from patients' medical files|"Data collection from patients' medical files:~* Brain imaging data if this examination was carried out as part of the patient's care,~* Angelman syndrome genotypes."
57779781|NCT06739642|OTHER|Education|caregivers in the intervention group received an individualized educational program intervention. The content of the educational program was developed by the researcher through a review of the literature and interviews with caregivers. The educational program, during three months, was delivered in 6 sessions of 40 minutes each. The topics of the training content were as follows: 1. General Nutrition Information, 2. Changes Affecting Nutrition During Old Age and Nutrition Principles, 3. Anthropometric Measurements and Scans, 4. Nutritional Problems in the Patient with Dementia, Dementiamendations for Increasing Nutritional Intake in Dementia Patients, 6. Alternatives for Severe Feeding Problems. Covering general topics was held as group education; carried out in two separate groups. Another individual session was planned for caregivers who could not attend the group education program, and the missing topics were completed.
57779782|NCT00658671|DRUG|ENMD-2076|Capsules, daily dosing in 28 day cycles
57779783|NCT06027775|DRUG|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
57779784|NCT04765592|DEVICE|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
57779785|NCT02918890|OTHER|Constraint-induced Movement Therapy|
57779786|NCT02918890|OTHER|Hand-arm Bimanual Intensive Therapy|
57779787|NCT00982150|DRUG|Talampanel|50mg capsules tid
57779788|NCT02978313|DRUG|Cetuximab|anti-EGFR monoclonal antibody
57779789|NCT02978313|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
57779790|NCT02978313|DRUG|FOLFIRI|Irinotecan+LV5FU2
57779791|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
57779792|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
57779793|NCT00806624|DRUG|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
57779794|NCT06738186|OTHER|Video-based exercise program|"The video-based exercise program - Bliib fit -mach mit! focuses on mobilization, muscle strengthening (focus on lower and upper extremities), coordination, balance, and relaxation. Each participant requires the use of a chair for support and to perform exercises in a seated position, if required. The group sessions are supervised by a care professional or registered activation specialist of the residential care facility."
58475120|NCT02516137|PROCEDURE|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
58490952|NCT03196349|DRUG|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
57784925|NCT01283217|DRUG|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
58133616|NCT05353452|BEHAVIORAL|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
58475121|NCT02516137|OTHER|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
58133617|NCT01148095|DRUG|AZD2516|Oral, single, daily, 11 days
58475122|NCT00101179|DRUG|Azacitidine|Given SC
58475123|NCT00101179|DRUG|Entinostat|Given orally
58475124|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
58475125|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
58475126|NCT00210496|DRUG|topiramate; almotriptan malate|
58475127|NCT05585905|DEVICE|Virtual Reality|The VR system will be worn for approximately 5-10 minutes during dental sealant application
58475128|NCT05585905|BEHAVIORAL|Basic Behavior Guidance Techniques|Basic behavior guidance techniques will be used as a distraction technique when the VR system is not used during the dental sealant application
58475129|NCT04267354|OTHER|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
58475130|NCT06597318|OTHER|Hospitalization|The investigators collect PROMs amongst up to 1000 patients in general internal medicine divisions of all five Swiss university hospitals
58475131|NCT02092610|DEVICE|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
58475132|NCT02092610|DEVICE|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
58475133|NCT04953858|OTHER|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
58475134|NCT03377608|DRUG|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
58475135|NCT03377608|DRUG|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
58475136|NCT05222334|PROCEDURE|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
58475137|NCT05222334|PROCEDURE|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
58475138|NCT05222334|DRUG|Bupivacaine|bupivacaine
58475139|NCT03708900|DRUG|LCI699|osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
58475140|NCT06594003|PROCEDURE|Radiofrequency|There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves . Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support
57784926|NCT01283217|DRUG|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
58133618|NCT01148095|DRUG|Placebo|
58133619|NCT00860223|DRUG|Digoxin|
58133620|NCT00860223|DRUG|Neratinib|HKI-272
58133621|NCT04578158|DRUG|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
58133622|NCT04578158|DIETARY_SUPPLEMENT|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
58133623|NCT01985893|DRUG|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
58133624|NCT05760872|OTHER|Placing esophageal probe|Placing an esophageal probe through the mouth
58475141|NCT03013998|BIOLOGICAL|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
58475142|NCT03013998|BIOLOGICAL|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
58475143|NCT03013998|OTHER|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
58475144|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
58475145|NCT03013998|DRUG|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
58475146|NCT03013998|DRUG|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
58475147|NCT03013998|DRUG|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
58475148|NCT03013998|DRUG|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
58475149|NCT03013998|DRUG|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
58475150|NCT03013998|DRUG|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
58475151|NCT03013998|DRUG|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
58475152|NCT03013998|DRUG|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
58475153|NCT03013998|DRUG|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
58475154|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
58475155|NCT03013998|DRUG|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance \>30 mL/min and \<50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
58475156|NCT03013998|DRUG|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
58475157|NCT03013998|DRUG|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
58475158|NCT03013998|DRUG|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
58475159|NCT03013998|DRUG|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
58475160|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
58475161|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
58490953|NCT01017380|DRUG|Celecoxib|celecoxib 400 mg 1 cap before surgery
58490954|NCT01017380|DRUG|etoricoxib|120 mg 1 tab before surgery
57779795|NCT06738186|OTHER|Caregiver-led activation program|The caregiver-led activation program (DESKK- Demenzspezifisches Kurzzeitpflegekonzept) is instructed and carried out by care professionals (e.g., nursing staff) as optimized standard care conducted individually or in groups.
58475162|NCT03013998|DRUG|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression \[if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored\]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
58475163|NCT03013998|DRUG|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
58475164|NCT03013998|DRUG|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
58475165|NCT03013998|DRUG|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
58475166|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
58475167|NCT03013998|DRUG|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
58475168|NCT03013998|DRUG|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
58475169|NCT03013998|DRUG|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
58475170|NCT03013998|DRUG|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
58475171|NCT03013998|DRUG|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
58475172|NCT03013998|DRUG|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 or days 1 through 14 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
58490955|NCT04783090|DRUG|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
58490956|NCT05636449|OTHER|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
58490957|NCT05636449|OTHER|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
58490958|NCT00509145|DRUG|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
57779796|NCT00771693|DRUG|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
57779797|NCT03223272|DRUG|Reserpine|Open label reserpine 0.1 mg pill orally
57779798|NCT04439487|DIAGNOSTIC_TEST|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
57784927|NCT01912820|DIETARY_SUPPLEMENT|green tea extract|Given PO
57784928|NCT01912820|DRUG|quercetin|Given PO
57784929|NCT01912820|OTHER|placebo|Given PO
58475173|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
58475174|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
58475175|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
58475176|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
58475177|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
58475178|NCT03013998|DRUG|ZE46-0134 (BAML-16-001-S21)|10 mg or 50 mg oral on Days 1-28 of each 28-day cycle for up to 24 cycles. On the first day of Cycle 1, a loading dose of 30 mg to 150 mg will be administered, after which the daily maintenance dose of 10 mg to 100 mg will be administered on days 2-28 of Cycle 1. Maintenance dose continues in subsequence cycles, for up to 24 cycles total.
58475179|NCT06593678|OTHER|Telerehabilitation Program|Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
58475180|NCT06593678|OTHER|Booklet-based rehabilitation program|Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
58475181|NCT02601846|OTHER|No intervention|This is an observational study, without any specific intervention.
58475182|NCT03011099|DEVICE|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
58475183|NCT03011099|OTHER|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
58475184|NCT04900324|DEVICE|MRI guidance|Injections of botulinum toxin performed using MRI guidance
58475185|NCT04900324|DEVICE|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
58475186|NCT05050331|PROCEDURE|Muscle Energy Technique|MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening
58475187|NCT05050331|PROCEDURE|Trigger Point Release|Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.
58475188|NCT05050331|PROCEDURE|Self-Stretching of Calf and Plantar Fascia|Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily
58475189|NCT05327296|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
58475190|NCT05327296|DRUG|Propofol|Intravenous infusion of propofol
58475191|NCT05664737|BIOLOGICAL|Luspatercept|Specified dose on specified days
58133625|NCT03389438|BIOLOGICAL|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
58475192|NCT05664737|DRUG|Placebo|Specified dose on specified days
58475193|NCT03518853|RADIATION|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
58475194|NCT04495023|PROCEDURE|Left elective colectomy|Open or laparoscopic left elective colectomy with colo-rectal anastomosis
58490959|NCT00509145|OTHER|Placebo|oral, once daily, capsule
57784930|NCT01912820|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
58133626|NCT01471093|DRUG|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
58475195|NCT01825460|OTHER|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
58475196|NCT01825460|OTHER|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
58475197|NCT06597227|PROCEDURE|Proximal radical gastrectomy|Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\&#39;s habit.
58475198|NCT06597227|PROCEDURE|Total radical gastrectomy|total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended
58475199|NCT06242574|OTHER|Survey|Each group will have to complete a questionnaire online, taking about 30 minutes.
58475200|NCT02195518|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
58475201|NCT04911140|RADIATION|Photobiomodulation twice a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
58475202|NCT04911140|RADIATION|Photobiomodulation three times a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
58475203|NCT04911140|OTHER|Simulated Photobiomodulation|Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
58475204|NCT06593392|DRUG|Difelikefalin|The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
58475205|NCT06269432|DRUG|Precision Antiplatelet Therapy Trial Group|Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
58475206|NCT06269432|DRUG|Traditional Antiplatelet Therapy Control Group|No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
58475207|NCT00159393|OTHER|registry and database|data collection
58475208|NCT06133179|PROCEDURE|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
58475209|NCT00685412|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
58475210|NCT04672863|BEHAVIORAL|Dietary Intervention|Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
58475211|NCT01452438|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
58475212|NCT06356454|OTHER|Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease|"Creating the questionnaire: The self-administered questionnaire was designed based on literature review. The questions of the questionnaire were based on the 3 main components of the World Health Organisation's Knowledge, Attitude and Practice framework. The questions were evaluated by experts in the field such as cardiologists working in paediatric cardiology. The questionnaire, which was finalised with the questions updated according to expert opinions, has 5 sections:~* Section 1: Socio-demographic questions~* Section 2: Questions on the level of knowledge about CR~* Section 3: Questions on attitudes about CR~* Section 4: Questions on Practices about CR"
58475213|NCT05427422|DIAGNOSTIC_TEST|MRI recording|MRI imaging was performed using a 3 Tesla Siemens Prisma system with a 64-channel head/neck coil (Siemens Medical Systems, Erlangen, Germany). The MRI protocols included as follows: (i) Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes: TR/TE/ TI1/TI2 = 5000/2.98/700/2500 ms, voxel size = 1.0 × 1.0 × 1.0 mm3, FOV = 256 × 240 × 176 mm3; (ii)Gradient-echo EPI: TR 720 ms, TE 33.1 ms, flip angle 52 deg, FOV 208x180 mm, Matrix 104x90, Slice thickness 2.0 mm; 72 slices; 2.0 mm isotropic voxels, Multiband factor 8, Echo spacing 0.58 ms, BW 2290 Hz/Px; (iii) DSI : TR/TE = 3300/73 ms, FOV = 220 × 220 × 60 mm3, voxel size = 2 × 2 × 2 mm3, 128 diffusion direction, b-max = 3000 sec/mm2, AT = 7:22 min); (iv) T2-weighted fluid-attenuated inversion recovery: TR/TE = 9000/84 ms, FOV = 270 × 320 × 22 mm2, voxel size = 0.72 × 0.72 × 6.6 mm3.
58133627|NCT01471093|DRUG|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
58475214|NCT05427422|DIAGNOSTIC_TEST|EEG recording|"EEG was performed using a BrainAmp MR 32 amplifier (BrainProducts GmbH, München, Germany). The EEG protocols included as follows: (i) EEG-fMRI fusion: Sampling rate: 5000 Hz, low cut off-high cut off: DC-1000Hz;(2) EEG-fMRI fusion: Sampling rate: 1000 Hz, low cut off-high cut off: DC-1000Hz.~In (i) an ECG channel would be used to collect artifact of pulse and not used in (ii)."
57784931|NCT01912820|OTHER|laboratory biomarker analysis|Correlative studies
57784932|NCT01632358|DRUG|TAP311 capsules|
57784933|NCT01632358|DRUG|Placebo|
57784934|NCT02522338|DRUG|iohexol|10 ml de l'iohexol (300 mgI/ml)
58133628|NCT00301769|DRUG|SJG-136|Given IV
58475215|NCT03391362|RADIATION|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
58475216|NCT06025032|GENETIC|HG205|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
58475217|NCT05826639|PROCEDURE|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
58475218|NCT05826639|OTHER|No intervention|No intervention
58475219|NCT06593561|OTHER|Breast Edema Questionnare|The Breast Edema Questionnaire, developed to evaluate breast edema in women undergoing breast cancer surgery, will be applied.
58475220|NCT06654167|OTHER|Low temperature (16℃) group|The exposure group will be exposed to low temperature (16℃) in a chamber for about 2 hours, resting during the whole period.
58475221|NCT06654167|OTHER|Moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
58475222|NCT04262388|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
58475223|NCT04262388|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
58475224|NCT02574117|PROCEDURE|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
58475225|NCT05975203|PROCEDURE|skin-to-skin contact|Immediately after delivery the infant will receive skin-to-skin contact with the mother.
58475226|NCT06594874|DRUG|HS-10370|HS-10370 administered orally every day
58475227|NCT06594874|DRUG|Adebrelimab|Administered intravenously every 21 days; dose by label.
58475228|NCT06594874|DRUG|Cisplatin|Administered intravenously every 21 days; dose by label.
58475229|NCT06594874|DRUG|Carboplatin|Administered intravenously every 21 days; dose by label.
58475230|NCT06594874|DRUG|Pemetrexed|Administered intravenously every 21 days; dose by label.
58475231|NCT01682434|PROCEDURE|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
58475232|NCT03481777|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
58475233|NCT03481777|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
58475234|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
58475235|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice placebo|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
58475236|NCT01955252|DRUG|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
58475237|NCT06185816|DEVICE|Active Treatment|The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
58475238|NCT06185816|DEVICE|Non-active Treatment|The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
58475239|NCT00728689|DRUG|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
58475240|NCT00728689|DRUG|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
58475241|NCT00743834|DRUG|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
58475242|NCT00743834|BEHAVIORAL|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
58475243|NCT03278275|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
58475244|NCT03278275|DEVICE|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
58475245|NCT04643210|BEHAVIORAL|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
58475246|NCT04643210|OTHER|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
58475247|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
58475248|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
58475249|NCT03457896|DRUG|Trastuzumab|Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
58475250|NCT03457896|DRUG|Cetuximab|Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
58475251|NCT03457896|DRUG|Neratinib|240 mg taken by mouth daily until disease progression.
58475252|NCT03457896|DIAGNOSTIC_TEST|Guardant360 Diagnostic Test|Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
58475253|NCT05309070|DIETARY_SUPPLEMENT|N-acetyl cysteine|Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
58475254|NCT05309070|OTHER|placebo|Control group will receive a placebo, in unmarked boxes, during two months
58475255|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)|"Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
58475256|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Live (ORCA-L)|"A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
58475257|NCT03820843|OTHER|Art therapy and standard orthophonic rehabilitation|In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
58475258|NCT05771987|PROCEDURE|pace maker implant guided by acute hemodynamic testing|To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
58475259|NCT00807508|DIETARY_SUPPLEMENT|placebo|wheat meal capsules with each main meal
58475260|NCT00807508|DIETARY_SUPPLEMENT|leucine|daily leucine capsules with each main meal
58475261|NCT00915252|DRUG|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
58475262|NCT00915252|DRUG|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
58475263|NCT04951947|DRUG|JS201 combine with Lenvatinib|JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
58475264|NCT01783613|DIETARY_SUPPLEMENT|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
58475265|NCT01783613|DIETARY_SUPPLEMENT|Placebo: 50 mg/kg/day during 12 months|
58475266|NCT06601062|DEVICE|Tele-BE|Clinicians and their patients use the newly developed telehealth tool to support their use of CBT during session
58475267|NCT01186289|DRUG|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
58475268|NCT05207488|DIETARY_SUPPLEMENT|Fructooligosaccharides (FOS)|FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
58475269|NCT05207488|BEHAVIORAL|Exercise|During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
58475270|NCT05207488|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
58475271|NCT00967746|DRUG|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
58475272|NCT00967746|DRUG|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
58475273|NCT00967746|DRUG|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
58475274|NCT00967746|DEVICE|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
58475275|NCT00852683|DRUG|Pregabalin|75 mg twice a day
58475276|NCT00852683|DRUG|Placebo|75 mg twice a day
58475277|NCT06592183|BEHAVIORAL|Smart-phone based, self-driven speech rehabilitation|Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
58475278|NCT03085095|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
58475279|NCT03085095|DRUG|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
58475280|NCT06602843|PROCEDURE|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
58475281|NCT01968200|DRUG|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
58475282|NCT05813236|DEVICE|Novosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
58475283|NCT05813236|DEVICE|Monosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
58475284|NCT06592287|DRUG|Adebrelimab + Apatinib + Lrinotecan liposome|"Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
58475285|NCT06595537|DEVICE|Hand held ultrasound|Determination of gastric feeding tube position with the use of Lumify handheld ultrasound
58475286|NCT02266368|DEVICE|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
57779799|NCT04439487|OTHER|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
58475287|NCT06442046|OTHER|Active Case Management|A case manager will work with families post-discharge to ensure that youth are connected to an appropriate community support. Case managers will also work with families to identify any social needs and provide support in accessing services as needed.
58475288|NCT06442046|OTHER|Treatment as usual|Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.
58475289|NCT05323227|DIAGNOSTIC_TEST|Coronary CTA|Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
58475290|NCT06436131|BEHAVIORAL|In-phase Bilateral Exercise|"The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks."
58475291|NCT06436131|BEHAVIORAL|Conservative exercises|The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.
58475292|NCT02220920|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
58475293|NCT02220920|DRUG|Placebo|The patients will receive Placebo orally for 16 weeks
58475294|NCT02220920|DRUG|Insulin|
58475295|NCT05957380|DRUG|DA-2803|All participants are administered one tablet per day for 48 weeks
58475296|NCT05957380|DRUG|DA-2803-R|All participants are administered one tablet per day for 48 weeks
58475297|NCT05957380|DRUG|Placebo of DA-2803|All participants are administered one tablet per day for 48 weeks
58475298|NCT05957380|DRUG|Placebo of DA-2803-R|All participants are administered one tablet per day for 48 weeks
57779800|NCT06736795|OTHER|Exercise|All participants will be instructed in a progressive Achilles tendon loading exercise program.
58475299|NCT02151058|DRUG|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
58475300|NCT02151058|DRUG|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
58475301|NCT02151058|OTHER|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
58475302|NCT06279234|DRUG|Placebo|Oral tablet
58475303|NCT06279234|DRUG|Rosuvastatin|Oral tablet
58475304|NCT06279234|DRUG|Midazolam|Oral suspension
58475305|NCT06279234|DRUG|Omeprazole|Oral tablet
58475306|NCT06279234|DRUG|PF-06954522|Oral tablet
58475307|NCT03085043|PROCEDURE|Bone Scan|Undergo bone scan
58475308|NCT03085043|PROCEDURE|Computed Tomography|Undergo CT of the abdomen and pelvis
58475309|NCT03085043|PROCEDURE|Magnetic Resonance Imaging|Undergo pelvic MRI
58475310|NCT03085043|PROCEDURE|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
58475311|NCT06536673|BEHAVIORAL|Intervention to reduce infectious complications of peritoneal dialysis|"* Before catheter placement: The nurse and doctor provide the patient and/or caregiver with a PD simulation.~* Initial training: from the placement of the catheter to the beginning of the technique at home, approximately 4 weeks, 6 and 7 sessions, duration 1-2 hours per session. Individualized learning taking into account learning abilities and education. It includes the explanation of the PD and the display of informational pictograms/capsules.~* Step-by-step teaching: peritoneal exchange, peritoneal orifice care, administration of intraperitoneal medication, recording of constants, detection of complications and risk behaviors.~* Nutritional education and water intake.~* Administration of the Objective Structured Assessment (OSA) checklist.~* Retraining: between the 1st and 3rd month of the start, after an episode of peritonitis and/or hospitalization, risk behaviors, functional/cognitive impairment, passivity/demotivation behaviors, and regularly once the year."
58475312|NCT06536673|BEHAVIORAL|Data collection from the patient's clinical history|Data collection from the patient's clinical history because this new standardized educational intervention was not used.
58475313|NCT06604351|DRUG|Sintilimab, Nab-Paclitaxel, and Carboplatin|Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
58475314|NCT05609487|OTHER|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
58475315|NCT05609487|DEVICE|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
58475316|NCT05162976|BIOLOGICAL|Nivolumab|Given IV
58475317|NCT05162976|DRUG|Oral Azacitidine|Given PO
58475318|NCT05324462|DRUG|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
58475319|NCT04223479|DRUG|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
58475320|NCT04223479|DRUG|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
58475321|NCT05274997|DRUG|YY-20394|Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
58475322|NCT04230629|DEVICE|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
58475323|NCT04230629|DEVICE|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
58475324|NCT00828594|DRUG|RAD001|
58475325|NCT00828594|DRUG|RAD001, sorafenib|
58475326|NCT04862585|DRUG|Cimetidine|Given IV and/or PO
58475327|NCT04862585|DRUG|Dexamethasone|Given IV and/or PO
58475328|NCT04862585|DRUG|Diphenhydramine|Given IV and/or PO
58475329|NCT04862585|DRUG|Famotidine|Given IV and/or PO
58475330|NCT04862585|DRUG|Paclitaxel|Weekly or every 14 day dosing
58475331|NCT04862585|OTHER|Quality-of-Life Assessment|Ancillary studies
58475332|NCT04862585|DRUG|Ranitidine|Given IV and/or PO
58475333|NCT06603779|DEVICE|Ultasound Therapy|a device that transmit ultrasound waves to the participant through direct contact
58475334|NCT06603779|OTHER|Integrated Neuromuscular technique|Integrated Neuromuscular technique is a kind of Manual therapy which include Ischemic Compression, Strain counter-strain and muscle energy technique
58475335|NCT06603779|OTHER|Cervical and Scapular Stabilization exercises|Cervical and Scapular Stabilization exercises are a group of therapeutic exercises.
58475336|NCT06591962|OTHER|Questionnaire application for diabetes mellitus|Scales will be applied to individuals diagnosed with diabetes mellitus
58475337|NCT06591962|OTHER|Questionnaire application for without diabetes mellitus|Scales will be applied to individuals diagnosed without diabetes mellitus
58475338|NCT03842527|DEVICE|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
58475339|NCT00570986|DRUG|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
58475340|NCT00570986|BIOLOGICAL|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
58475341|NCT00570986|BIOLOGICAL|ABT-874|100mg every 12 weeks.
58475342|NCT05657002|OTHER|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
58490960|NCT04059315|OTHER|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
58490961|NCT03399929|OTHER|Post Acute Rehabiltation|
58475343|NCT05657002|OTHER|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
58475344|NCT05657002|OTHER|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
58475345|NCT05657002|OTHER|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
58475346|NCT05839964|DIETARY_SUPPLEMENT|CBN and CBD|CBN and CBD in Gummy Format
58475347|NCT06590493|DRUG|doxecitine and doxribtimine|TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.
58475348|NCT03149562|DRUG|plasma transfusions|These critical ill neonates with plasma transfusions
58475349|NCT03149562|DRUG|non-plasma transfusions|These critical ill neonates without plasma transfusions
58475350|NCT06210568|OTHER|no intervention|no intervention
58475351|NCT02946723|PROCEDURE|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
58475352|NCT02946723|PROCEDURE|X-ray|Lead implantation surgery for SNM using X-ray technique
58475353|NCT05742685|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
58475354|NCT00914849|DRUG|AMD3100|
58475355|NCT00914849|PROCEDURE|Leukopheresis|
58475356|NCT00914849|PROCEDURE|Stem cell transplant|
58475357|NCT04222309|PROCEDURE|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
58475358|NCT05801120|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
58475359|NCT01635166|DEVICE|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
57779801|NCT06736795|OTHER|Education|All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.
57779802|NCT06741085|DRUG|osimertinib|oral EGFR-TKI
57779803|NCT06741085|RADIATION|stereotactic radiosurgery (SRS)|"0-20mm-18Gy x 1, 21Gy x 1 ,9Gy x 3~20mm or larger- 9Gy x 3, 6Gy x 5, 5Gy x 5"
58133629|NCT02589223|OTHER|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
58475360|NCT04856046|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
58475361|NCT04856046|OTHER|Electronic Health Record Review|Review of medical records
58475362|NCT04895839|BEHAVIORAL|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
58475363|NCT05440942|DRUG|Trametinib|Trametinib will be administered orally once daily via tablet.
58475364|NCT05440942|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily (BID) via tablet.
58475365|NCT05440942|DRUG|Retifanlimab|Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
57779804|NCT01662622|DRUG|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
58475366|NCT05778604|BEHAVIORAL|Physio-feedback|"The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9."
58475367|NCT05778604|BEHAVIORAL|Cognitive reframing|Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
58475368|NCT05778604|BEHAVIORAL|Peer-led exercises|The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
58475369|NCT05778604|BEHAVIORAL|CDC older adults fall prevention|Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
58475370|NCT03136744|BEHAVIORAL|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
58475371|NCT06588231|BEHAVIORAL|Individual rehabilitation exercise training|Under the guidance of a specialist, medium-and high-intensity interval training was conducted for 16 weeks, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period, during which the exercise included 4 intervals, with the 85-95% pre intensity of HR reserve for 15-18 minutes, and then with the 50-70% pre intensity of HR reserve for 12-14 minutes, exercise for 3 minutes, and so on for 4 times. Warm-up and cooling-off periods can be done through stretching exercises, flexibility exercises (that is, neck, shoulders, upper back, buttocks and ankles) and low and medium intensity (50-70% heart rate reserve)
58475372|NCT06588231|DRUG|optimal medical therapy ：aspirin, clopidogrel, statins.|those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
58475373|NCT05515965|OTHER|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
58475374|NCT05515965|OTHER|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
58475375|NCT00723736|DRUG|Desloratadine|2.5 ml (1.25 mg) once daily
58475376|NCT02234167|BEHAVIORAL|Risk behaviour and infectious diseases|through counselling, testing vaccination
58475377|NCT00217399|DRUG|sorafenib tosylate|Given orally
58475378|NCT00217399|DRUG|anastrozole|Given orally
58475379|NCT03404193|DRUG|Decitabine|Given IV
58475380|NCT03404193|OTHER|Laboratory Biomarker Analysis|Correlative studies
58475381|NCT03404193|DRUG|Venetoclax|Given PO
58475382|NCT01089101|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58475383|NCT01089101|DRUG|Selumetinib|Given PO
58475384|NCT06601049|DIETARY_SUPPLEMENT|ResArgin|Resveratrol-based supplement
57779805|NCT06737237|PROCEDURE|cervical plexus block|local anesthetic (10ml of bupivacaine 5mg/ml)
57779806|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|local anesthetic (20ml of bupivacaine 2.5mg/ml)
57779807|NCT06737237|PROCEDURE|cervical plexus block|placebo (10ml of 0.9% sodium chloride)
57779808|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|placebo (20ml of 0.9% sodium chloride)
58475385|NCT03840018|OTHER|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
58475386|NCT02454088|OTHER|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
58475387|NCT02454088|DEVICE|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
58475388|NCT02786017|BIOLOGICAL|Conventional therapy|Patients will receive the conventional therapy.
58475389|NCT02786017|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
58475390|NCT00630838|DRUG|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
58475391|NCT00630838|DRUG|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
58475392|NCT00389610|BIOLOGICAL|GVAX pancreas vaccine|Given intradermally
58475393|NCT02376998|DEVICE|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
58475394|NCT04165577|DEVICE|rTMS|1-Hz rTMS targeting frontal pole
58475395|NCT04165577|DEVICE|sham rTMS|sham rTMS targeting frontal pole
58475396|NCT03831152|DRUG|ADV7103|Single group assignment
58475397|NCT02984813|DRUG|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
58475398|NCT02984813|DRUG|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
57784935|NCT05175443|OTHER|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
58475399|NCT02984813|DRUG|Placebo|No active ingredients
58475400|NCT05458713|DEVICE|Laser acupuncture|Irradiate acupoints with low power laser
58475401|NCT02273479|DRUG|Asasantin®|Asasantin® extended release (RAD-SP)
58475402|NCT02273479|DRUG|Placebo|
58475403|NCT00222612|OTHER|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
58475404|NCT00222612|DRUG|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
58475405|NCT00222612|DRUG|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
58475406|NCT00265603|PROCEDURE|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
58475407|NCT03480581|BEHAVIORAL|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
57784936|NCT03390361|DEVICE|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
58133630|NCT02589223|OTHER|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
58475408|NCT03480581|BEHAVIORAL|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
58475409|NCT05867368|BEHAVIORAL|HABIT-VR|HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
58475410|NCT05867368|BEHAVIORAL|Standard HABIT|HABIT is a camp where children play self-select activities that require both hands to succeed.
58475411|NCT06593548|DRUG|Ivosidenib (AK112)|Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
58475412|NCT03184688|PROCEDURE|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
58475413|NCT03184688|DRUG|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
58475414|NCT04693767|DEVICE|Mechanical thrombectomy|"1. Clot specimen collection~2. Extracranial blood collection"
58475415|NCT04693767|OTHER|Minimally invasive surgery|"1. Clot specimen collection~2. Arterial blood collection"
58475416|NCT03599674|BEHAVIORAL|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
58475417|NCT06603584|RADIATION|Chest x- Rays|prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
58475418|NCT06592391|OTHER|educational innovation dynamic school day|Schools will form a community of practice, and will be supported with regular workshop to develop a dynamic school day that matches the local context.
58475419|NCT06592391|OTHER|e-learning on a dynamic school day|Schools will form a community of practice, and will develop a dynamic school day that matches their local context using e-learning materials
58475420|NCT06592391|OTHER|expert schools|Schools that have developed a local dynamic school day without additional support
58475421|NCT03561220|RADIATION|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
58475422|NCT03561220|RADIATION|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
58475423|NCT03561220|RADIATION|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
58475424|NCT03561220|RADIATION|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
58475425|NCT06592573|OTHER|CBT_ONLINE|10-12 sessions of cognitive behavioural therapy conducted online
58475426|NCT06592573|OTHER|CBT_IN PERSON|10-12 sessions of cognitive behavioural therapy conducted in-person.
58475427|NCT00690508|PROCEDURE|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
58475428|NCT06598085|DEVICE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
58475429|NCT01466712|DRUG|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
58475430|NCT01466712|DRUG|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
58475431|NCT00561925|DRUG|nevirapine IR|200 mg BID
58475432|NCT00561925|DRUG|nevirapine XR|400 mg QD
58475433|NCT05098834|DEVICE|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
58475434|NCT05397925|BEHAVIORAL|ADSProgram - Self management for substance dependence program|GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
58475435|NCT05397925|BEHAVIORAL|Treatment as usual - Regular nursing consultation on a medication-based program|Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
57784937|NCT03390361|PROCEDURE|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
58475436|NCT06653075|PROCEDURE|mandibular advancement with acrylic splint Herbst Appliance|Mandibular advancement with acrylic splint Herbst Appliance
58475437|NCT06652893|DRUG|Sinovial|"A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea"
58475438|NCT02512822|PROCEDURE|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
57784938|NCT00068666|DRUG|temozolomide|
57784939|NCT00068666|RADIATION|radiation therapy|
57784940|NCT00248521|DRUG|alvespimycin hydrochloride|
58475439|NCT01051895|OTHER|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
58475440|NCT01051895|OTHER|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
58133631|NCT03548389|OTHER|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
58475441|NCT06601816|PROCEDURE|maxillary sinus lift with reamer|Lateral window created with specially designed burs for lateral sinus lift
58475442|NCT06601816|PROCEDURE|maxillary sinus lift with piezzo|lateral window was created using piezo surgery and surgical guide
58475443|NCT06601816|PROCEDURE|maxillary sinus lift with conventional burr|the lateral window was created with conventional rotary instrument burs
58475444|NCT05270759|DIAGNOSTIC_TEST|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
58475445|NCT05270759|DIAGNOSTIC_TEST|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
58475446|NCT01811992|BIOLOGICAL|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
58475447|NCT06600607|DRUG|pregabalin 300 mg|pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain
58475448|NCT06600607|OTHER|Placebo|biologically inactive placebo comparator
58475449|NCT00678782|DRUG|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
58475450|NCT00678782|DRUG|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
58475451|NCT00830882|DRUG|levosalbutamol|2 puffs four times a day for 2 weeks
58475452|NCT00830882|DRUG|racemic salbutamol|2 puffs four times a day for 2 weeks
58475453|NCT00830882|DRUG|placebo|2 puffs four times a day for 2 weeks
58475454|NCT00578539|DRUG|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
58475455|NCT00578539|DRUG|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
58475456|NCT00578539|DRUG|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
58475457|NCT00578539|RADIATION|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
58475458|NCT00578539|BIOLOGICAL|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
58475459|NCT00578539|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
58475460|NCT04501523|DRUG|Tislelizumab|200mg, q3w, for 1 year
58475461|NCT04501523|DRUG|capecitabine|600-750 mg/m2 PO Bid，continuous, for 1 year
58475462|NCT05370196|DEVICE|Test Product|Synthetic Male Condom
58475463|NCT05370196|DEVICE|Control Product|Latex Male Condom
58475464|NCT04362241|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
57779809|NCT06736639|PROCEDURE|Anchor Suture with Titanium Cable Cerclage|This intervention involves the use of \*\*anchor suture fixation combined with titanium cable cerclage\*\* for the treatment of inferior pole patellar fractures (IPPF). The anchor suture provides stable fixation of fracture fragments by anchoring directly into the bone, while the titanium cable cerclage offers additional reinforcement around the patella to enhance stability and minimize fragment displacement. This method is specifically designed to address the limitations of traditional Kirschner-wire tension band techniques, such as hardware irritation and infection, by using biocompatible and low-profile materials.
57784941|NCT00306514|BIOLOGICAL|CYT004-MelQbG10|
58133632|NCT03206866|DIAGNOSTIC_TEST|serum regucalcin antibody|serum regucalcin antibody
58133633|NCT02857088|BEHAVIORAL|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
58133634|NCT02857088|BEHAVIORAL|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
58475465|NCT02317900|BIOLOGICAL|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
58475466|NCT02317900|BIOLOGICAL|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
58475467|NCT02317900|BIOLOGICAL|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
58475468|NCT00499070|GENETIC|polymerase chain reaction|
58475469|NCT00499070|OTHER|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
58475470|NCT00499070|OTHER|immunologic technique|
58475471|NCT00499070|PROCEDURE|biopsy|
58475472|NCT06347380|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
58475473|NCT06590896|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
58475474|NCT05433181|DRUG|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
58475475|NCT05433181|OTHER|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
58475476|NCT02473536|RADIATION|Stereotactic ablative radiation therapy|SABR
58475477|NCT06038643|BEHAVIORAL|Motivational behavioural intervention and daily activities monitoring|Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.
58475478|NCT06038643|BEHAVIORAL|Active Control|Daily activities monitored through accelerometry.
58475479|NCT06654817|DRUG|Ofatumumab subcutaneous injection|To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
58475480|NCT02671708|DRUG|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
58475481|NCT02671708|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
58475482|NCT02671708|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
58475483|NCT01167075|DIETARY_SUPPLEMENT|Fresubin Original|
58475484|NCT01167075|DIETARY_SUPPLEMENT|Intestamin plus Fresubin Original|
58475485|NCT05106426|BEHAVIORAL|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
58475486|NCT05106426|BEHAVIORAL|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
58475487|NCT00284947|DRUG|basiliximab|40 mg once every 28 days intravenously for 24 weeks
58475488|NCT00284947|DRUG|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
58475489|NCT00284947|DRUG|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
58475490|NCT04596267|DRUG|Pitolisant|8.9mg Pitolisant for 5 days
58475491|NCT04596267|DRUG|Placebo|Inert ingredients
58475492|NCT01207414|DRUG|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
58475493|NCT06588985|BEHAVIORAL|Emotion Coaching Parent Training Workshop|Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.
58475494|NCT06588985|BEHAVIORAL|Waitlist Control|Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
58475495|NCT03138369|DEVICE|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
58475496|NCT03138369|DEVICE|Sham vestibular stimulation|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
58475497|NCT01796808|PROCEDURE|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
58475498|NCT01796808|OTHER|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. \<200ml). Only a few cc's of fat are needed for injection into the foot."
58475499|NCT04670302|PROCEDURE|Tendon repair procedure|"Tendon repair procedure:~1. Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~2. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~3. Then, double suturing of the supraspinatus tendon is performed."
58475500|NCT04670302|PROCEDURE|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
58475501|NCT05383118|BEHAVIORAL|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors"
58475502|NCT05383118|BEHAVIORAL|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment"
58475503|NCT04662489|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy
58475504|NCT04662489|PROCEDURE|Radial ablation|Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.
58475505|NCT04506229|GENETIC|Whole exome sequencing|MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
58475506|NCT02561884|DRUG|Olostar Tab.|
58475507|NCT02561884|DRUG|Co-administration of Olmetec and Crestor|
58475508|NCT02364375|DEVICE|Menai mask (full face)|Prototype mask system (full face variant) with novel vent and humidification system
58475509|NCT02364375|DEVICE|Menai Standard mask (full face)|Prototype mask system (full face variant) with conventional vent and humidification system
58475510|NCT02364375|DEVICE|Menai mask (nasal)|Prototype mask system (nasal variant) with novel vent and humidification system
58475511|NCT02364375|DEVICE|Menai Standard mask (nasal)|Prototype mask system (nasal variant) with conventional vent and humidification system
58475512|NCT02364375|DEVICE|Menai mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
58475513|NCT02364375|DEVICE|Menai Standard mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
58475514|NCT02576483|BEHAVIORAL|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
58475515|NCT04911296|OTHER|Mock-RP|Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
58475516|NCT04939714|BEHAVIORAL|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
58475517|NCT06587815|OTHER|musical starry sky projector|Children in intervention group received musical starry sky projector during their sleep time
58475518|NCT01046396|DRUG|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
58475519|NCT01046396|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
58475520|NCT06586775|PROCEDURE|Pulpotomy|complete pulpotomy
58475521|NCT05036863|BEHAVIORAL|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
58475522|NCT04836650|DIAGNOSTIC_TEST|Postural stability assessment with a force platform.|The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.
58475523|NCT04836650|DIAGNOSTIC_TEST|Muscular assessment with a electromyograph|The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
58475524|NCT05036018|DEVICE|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
58475525|NCT05036018|PROCEDURE|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Presence of an anesthesiologist is optional. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
58475526|NCT05036018|DEVICE|CoreValve Evolut Pro and Pro+|The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
57779810|NCT06736639|PROCEDURE|Kirschner wire tension band + cerclage cable|This intervention uses \*\*Kirschner wire tension band combined with cerclage cable\*\* to treat inferior pole patellar fractures (IPPF). The Kirschner wires are positioned across the fracture site to form a tension band, which transforms tensile forces into compressive forces, promoting fracture stability. The cerclage cable is added to reinforce the fixation by encircling the patella, providing additional stability to comminuted or complex fractures.
58475527|NCT05036018|PROCEDURE|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
58475528|NCT00648063|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
58475529|NCT00648063|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
58475530|NCT03276338|BEHAVIORAL|HOLA|To increase condom use and HIV testing
58475531|NCT06604312|OTHER|Sacroiliac Joint Manipulation|Sacroiliac manipulation was performed using manual treatment method by lying patients on their sides. First, the patient was positioned firmly on the edge of the examination table, while the restricted sacroiliac joint remains on the upper side. Then, the physician's hand was positioned on the patient's hip, and the flexion was made on the lumbar spine with the movement from the hip to the upper thigh, and the impulse given by the HVLA technique was applied in the anteroinferior direction to the iliac crest and trochanter major.
58475532|NCT03711968|OTHER|Rehabilitative treatment protocol|A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
58475533|NCT01524575|DRUG|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
58475534|NCT00003403|DRUG|GPX-100|
58475535|NCT04238923|DRUG|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
58475536|NCT00207077|DRUG|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
58475537|NCT00937313|OTHER|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
58475538|NCT06414590|DRUG|Tebentafusp-Tebn|Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
58475539|NCT06600568|OTHER|Translation analysis|Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
58475540|NCT05558527|BEHAVIORAL|social support|social support is provided in the form of social touch (hand holding)
58475541|NCT02594124|DRUG|nusinersen|Administered by intrathecal (IT) injection
58475542|NCT04395976|OTHER|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
58475543|NCT01988155|OTHER|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
58475544|NCT01988155|OTHER|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
58475545|NCT03056222|DEVICE|Ablation catheter|Ablation of paroxysmal atrial fibrillation
58475546|NCT02596867|DRUG|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
58475547|NCT03877510|DRUG|IPX203|IPX203 extended release capsules
58475548|NCT00411684|DRUG|CDB-2914|
58475549|NCT00928408|DRUG|Cinacalcet|
58475550|NCT05997290|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|BNT162b2 monovalent (Omicron XBB.1.5)
58475551|NCT05997290|BIOLOGICAL|BNT162b2 (Omi JN.1)|BNT162b2 monovalent (Omicron JN.1)
58475552|NCT05997290|BIOLOGICAL|BNT162b2 (Omi KP.2)|BNT162b2 monovalent (Omicron KP.2)
58475553|NCT06594419|BEHAVIORAL|Healthy Mother Healthy Baby Toolkit|Customized bowl with markings to indicate the recommended amount of food that participants should consume in pregnancy and while exclusively breastfeeding in the first 6 months, as well as how much they should feed their babies at 6-8 months, 9-12 months, and 1-2 years respectively. The toolkit also includes a spoon used to test and ensure adequate thickness of the meals fed to infants \>6mos and a counseling card that indicates the frequency of meals, recommended food groups for meeting daily nutrient needs, and hand hygiene and hygienic food preparation
58475554|NCT06594419|OTHER|Standard of care|The Ethiopian government and Saving Little Lives Initiative (SLL) standard of care includes maternal and infant nutrition education and counseling, iron and folic acid supplementation, as well as training on effective Kangaroo Mother Care (KMC), primarily defined as exclusive breastfeeding and skin-to-skin contact ≥ 8 hours per day-in the event of Low birth weight (LBW) or preterm delivery.
58475555|NCT01972217|DRUG|Olaparib|Olaparib bid
58475556|NCT01972217|DRUG|Placebo|Placebo bid
58475557|NCT01972217|DRUG|Abiraterone|Abiraterone 1000 mg
58475558|NCT01972217|DRUG|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
58475559|NCT05134584|DRUG|Linaclotide|290μg once daily, 4 weeks
58475560|NCT05134584|DRUG|Lactulose|20mL once daily, 4 weeks
58475561|NCT05134584|DRUG|Omeprazol|20mg twice daily for the first 10 days
58475562|NCT05134584|DRUG|Itopride|50mg three times daily for the first 10 days
58475563|NCT06595511|DEVICE|Sensory Entrainment-Integrated Cognitive Game Kit|Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.
58475564|NCT01245530|DRUG|Aricept|Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks
58475565|NCT01245530|DRUG|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
58475566|NCT02302599|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Infusion treatment
58475567|NCT02302599|BIOLOGICAL|Controlled suspension liquid|Infusion treatment
58475568|NCT03625349|DRUG|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
58475569|NCT04788316|BEHAVIORAL|CBI and Text messaging|A computerized brief intervention (2 sessions) followed by six months of personalized text messaging
58475570|NCT02633163|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
58475571|NCT02633163|DRUG|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.
58475572|NCT02633163|DRUG|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
58475573|NCT06382597|OTHER|Nordic hamstring exercise|Nordic Hamstring Exercise involves a controlled descent of the upright torso from a vertical kneeling position forward towards the ground (parallel to the ground) and returning to the starting position. The ankle joints are stabilized by the other person's grip during a series of exercises.
58475574|NCT06600789|DRUG|CT7439 Capsules (0.5 mg, 1mg, 3mg)|CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed.
58475575|NCT06601400|COMBINATION_PRODUCT|Erythropoietin (EPO) with xenograft|After atraumatic extraction of the non-restorable tooth, Implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft and erythropoietin.
58475576|NCT06601400|OTHER|Xenograft alone|After atraumatic extraction of the non-restorable tooth, implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft alone.
58475577|NCT05733286|DRUG|Suvorexant 20 mg|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
58475578|NCT05733286|DRUG|Placebo|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
57779811|NCT03888508|OTHER|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
57779812|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
57779813|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
58475579|NCT06592118|OTHER|Different Pathological Types (FTC vs PTC)|Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients
58475580|NCT04592939|PROCEDURE|immediate weight bearing after surgery|immediate weight bearing
58475581|NCT04592939|PROCEDURE|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
58475582|NCT04411641|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
58475583|NCT04411641|DRUG|Placebo to match Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
58475584|NCT00667199|DRUG|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
58475585|NCT05313971|OTHER|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
58490962|NCT04437667|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application. Participants will be instructed to engage in a minimum of 10 hours of gameplay over the holiday period each year. The game will automatically collect for analysis data related to participants' in-game behavior, e.g. time spent playing, scores on knowledge-based mini-games, choices made in the narrative game, components to which the player was exposed. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma; and promote parent-child dialogue.
58475586|NCT06655103|OTHER|Educational movie|There are three groups in this research. The 1st group will be shown an educational movie about intrathecal chemotherapy treatment before intrathecal chemotherapy treatment, the 2nd group will be shown a cartoon movie before intrathecal chemotherapy treatment, and the 3rd group will not receive any intervention before intrathecal chemotherapy treatment. In all groups, measurements will be made in parallel; fear and pain scales as well as electrodermal activity, pulse, respiration and O2 saturation values 30 minutes before IT chemotherapy treatment, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
58475587|NCT05074992|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
58475588|NCT06591312|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
58475589|NCT06591312|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
58475590|NCT02536976|DRUG|mirabegron|
58475591|NCT02536976|DRUG|Placebo|
58475592|NCT03818646|DIAGNOSTIC_TEST|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
58475593|NCT00077246|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
58475594|NCT02859220|OTHER|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
58475595|NCT02859220|OTHER|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
58475596|NCT06474338|DIAGNOSTIC_TEST|detection by artificial intelligence|The bladder lesion(s) are detected by artificial intelligence algorithm.
58475597|NCT06474338|DIAGNOSTIC_TEST|detection by urologists|The bladder lesion(s) are detected by urologists.
58475598|NCT04214821|DRUG|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
58475599|NCT04214821|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
58475600|NCT00732056|DRUG|GRN163L|25% dose escalation infused over 2 hours weekly
58475601|NCT06600295|OTHER|tests/questionnaires|EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
58475602|NCT06600295|BIOLOGICAL|biological samples|blood, saliva, tongue mucus
58133635|NCT02857088|BEHAVIORAL|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
58475603|NCT06600295|OTHER|evaluation|strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
58475604|NCT03998306|DIETARY_SUPPLEMENT|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
58475605|NCT03998306|OTHER|No intervention|No intervention
58475606|NCT04587336|BEHAVIORAL|Cognitive Interview|Cognitive Interviews: Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
58475607|NCT04587336|BEHAVIORAL|Baseline Survey|Conduct Baseline Survey: Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
58475608|NCT04587336|BEHAVIORAL|Qualitative Interviews|Qualitative Interviews: Describe self-management challenges and preferred learning strategies to inform intervention components and delivery approach for Veterans with T2D.
58475609|NCT04587336|BEHAVIORAL|TARDIS Photo Elicitation|TARDIS Photo Elicitation: Using visual-based qualitative methods to help identify and more robustly describe DD in Veterans.
58475610|NCT04587336|BEHAVIORAL|TARDIS Intervention|TARDIS Intervention: Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with T2D, to promote engagement in self-management behaviors
58475611|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
58475612|NCT01503203|OTHER|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
58475613|NCT01503203|OTHER|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
58475614|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
58133636|NCT02303548|DRUG|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
58475615|NCT01503203|OTHER|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
58490963|NCT04437667|BEHAVIORAL|Control Mobile Phone Game|Independent gameplay of control game. Total respondent burden: participants will be invited to engage in at least 10 hours of gameplay during each long school holiday (November-December).
58490964|NCT00000955|DRUG|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
58475616|NCT06646614|BEHAVIORAL|Group Advance Care Planning Education|Those assigned to the group ACP arm will participate in a virtual or in-person session every 4 weeks (2 sessions total) led by a trained health educator who is a staff member. Sessions will introduce advanced care planning, help veterans determine their goals of care and learn how to raise this with their oncologist, and discuss creating or updating an advanced directive. Participants will be surveyed and interviewed to learn about their satisfaction with 1:1 and group advance care planning education and their degree of activation in care by a research staff member.
58475617|NCT06144619|GENETIC|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
58475618|NCT05179226|DRUG|Ferric Derisomaltose|All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
58475619|NCT01113255|PROCEDURE|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
58475620|NCT03480048|BEHAVIORAL|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
58475621|NCT04734691|PROCEDURE|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
58475622|NCT00646165|DRUG|Forodesine|
58475623|NCT03493464|DRUG|BR55|A novel targeted ultrasound contrast agent
58475624|NCT02289586|PROCEDURE|invasive ventilation|
58475625|NCT02289586|PROCEDURE|interventional bronchoscopy|
58475626|NCT02289586|DEVICE|noninvasive ventilation|
58475627|NCT02289586|DRUG|sedation(dezocine and midazolam)|
58475628|NCT02289586|DRUG|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
58475629|NCT04451044|DEVICE|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
58475630|NCT04451044|PROCEDURE|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
58475631|NCT04885907|BIOLOGICAL|mRNA-1273 vaccine|COVID vaccine 3rd dose
58475632|NCT04885907|OTHER|Normal Saline Placebo|Normal Saline Placebo
58475633|NCT06595524|BEHAVIORAL|online mindfulness-based intervention|The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
58475634|NCT06118138|COMBINATION_PRODUCT|Hyperbaric oxygen therapy (HBOT)|"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."
58475635|NCT01999881|BEHAVIORAL|exercise intervention|Receive aerobic and exercise intervention
58475636|NCT01999881|PROCEDURE|standard follow-up care|Receive usual care
58475637|NCT01999881|PROCEDURE|quality-of-life assessment|Ancillary studies
58475638|NCT01999881|OTHER|laboratory biomarker analysis|Correlative studies
58475639|NCT06604390|DIETARY_SUPPLEMENT|catechin extracts (health food)|"Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;"
58475640|NCT06604390|OTHER|plasebo|Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.
58475641|NCT06052579|PROCEDURE|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
58475642|NCT05516381|DEVICE|Optetrak Logic CR Knee System|The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
58475643|NCT03783572|OTHER|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
58490965|NCT01192685|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
58490966|NCT01192685|DEVICE|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
58133637|NCT02303548|DRUG|Normal saline|Placebo
58133638|NCT03313609|BEHAVIORAL|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
58133639|NCT03731598|PROCEDURE|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
58133640|NCT00419770|DRUG|deferasirox|20 mg/kg enterally per day
58133641|NCT00419770|DRUG|Placebo|
58133642|NCT00419770|DRUG|Liposomal amphotericin B|
58133643|NCT00822926|DRUG|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
58133644|NCT00822926|DRUG|Saline|Subcutaneous injection of saline into scar tissue
58133645|NCT04107974|DEVICE|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
58475644|NCT03783572|OTHER|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
58475645|NCT05320445|BEHAVIORAL|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
58475646|NCT02427308|DRUG|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
58475647|NCT04828681|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
58475648|NCT00602602|BIOLOGICAL|bevacizumab|
58475649|NCT00602602|DRUG|fluorouracil|
58475650|NCT00602602|DRUG|gemcitabine hydrochloride|
58475651|NCT00602602|DRUG|oxaliplatin|
58475652|NCT00602602|OTHER|immunohistochemistry staining method|
58475653|NCT00602602|OTHER|laboratory biomarker analysis|
58475654|NCT00602602|PROCEDURE|conventional surgery|
58475655|NCT00602602|PROCEDURE|endoscopic biopsy|
58475656|NCT00602602|PROCEDURE|laparoscopy|
58475657|NCT00602602|RADIATION|radiation therapy|
58475658|NCT01241721|DEVICE|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
58475659|NCT04372381|DEVICE|Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro|Treatment of aortic valve stenosis using transcatheter aortic valve replacement
58475660|NCT01569191|OTHER|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
58475661|NCT01569191|DEVICE|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
58475662|NCT01569191|DRUG|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
58475663|NCT04861103|DRUG|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
58475664|NCT04228523|OTHER|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~* A first round table is organized to know the needs and issues related to drug management of patients.~* The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~* The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~* The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
58475665|NCT04228523|OTHER|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
58475666|NCT03264677|COMBINATION_PRODUCT|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
57779814|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
57779815|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
58133646|NCT04107974|PROCEDURE|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
58475667|NCT03264677|COMBINATION_PRODUCT|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
58475668|NCT03264677|COMBINATION_PRODUCT|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
58475669|NCT02761330|DRUG|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
58475670|NCT02761330|PROCEDURE|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
58475671|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
58475672|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
58475673|NCT05371717|OTHER|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
58475674|NCT05371717|OTHER|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
58475675|NCT00265993|DRUG|enoxaparin|"* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
58475676|NCT04412512|PROCEDURE|VATS approach|video-assisted thoracic surgery approach
58475677|NCT04412512|PROCEDURE|Thoracotomy approach|
58475678|NCT06189521|OTHER|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
58475679|NCT06189521|OTHER|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
58475680|NCT06189521|OTHER|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
58475681|NCT01074502|DRUG|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
58475682|NCT05580653|OTHER|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
58475683|NCT05580653|OTHER|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
58475684|NCT02629718|DRUG|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
58475685|NCT02629718|PROCEDURE|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
58475686|NCT00832702|PROCEDURE|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
58475687|NCT05318313|OTHER|Telerehabilitation|The TR PT evaluation and follow-up visits will be performed via Zoom software
58475688|NCT06051890|DRUG|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
58475689|NCT06051890|DRUG|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
58475690|NCT05815147|DIETARY_SUPPLEMENT|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
58475691|NCT04006587|DEVICE|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
58475692|NCT05897658|DRUG|Levetiracetam|Tablets
58475693|NCT05897658|OTHER|Placebo|Tablets
58475694|NCT00842114|BIOLOGICAL|R+CVP+IFN|Immunochemotherapy
58475695|NCT05459363|OTHER|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
58475696|NCT05321901|OTHER|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
58475697|NCT05321901|OTHER|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
58475698|NCT03871777|OTHER|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
58475699|NCT03871777|OTHER|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
58475700|NCT03398317|OTHER|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
57779816|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
58475701|NCT03398317|OTHER|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
58475702|NCT03292926|DRUG|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
58475703|NCT03292926|DEVICE|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
58475704|NCT03292926|DRUG|Dexamethasone|Dexamethasone will be used to prolong block duration
58475705|NCT03817216|DEVICE|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
58475706|NCT01723982|DRUG|Barusiban (FE 200440)|
58475707|NCT01723982|DRUG|Placebo Comparator|
57779817|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
57779818|NCT06737432|OTHER|RKP Monitoring Software|Use of RKP alerting and monitoring software.
58475708|NCT05650736|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
58475709|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT)|2x8 weeks of high-intensity interval training (HIIT)
58475710|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT) + intermittent fasting|2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
58475711|NCT03836313|DEVICE|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
58475712|NCT06655454|DRUG|Supplemental Postoperative Bupivacaine|This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention.
58475713|NCT06655454|DRUG|Placebo Injection|This intervention will appear to give patients an additional injection, but no additional drug will be given.
58475714|NCT04144608|DRUG|Toripalimab|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
58475715|NCT02132962|DIETARY_SUPPLEMENT|Amino acid infusion|
58475716|NCT02132962|OTHER|Bloodsamples, Biopsies.|
58475717|NCT02264730|DRUG|ClotFoam|Patient has not received blood products between screenings
58475718|NCT05082610|DRUG|HMBD-002|IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
58475719|NCT05082610|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
58475720|NCT00161759|DRUG|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
58475721|NCT01317472|DRUG|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
58475722|NCT01317472|DRUG|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
58475723|NCT00904449|DRUG|Oxymorphone ER|10mg, 20mg, and 40mg PO
58475724|NCT04762095|OTHER|mindfulness stress reduction program|mindfulness stress reduction program
58475725|NCT02552043|OTHER|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
58475726|NCT02871986|DRUG|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
58475727|NCT02318316|OTHER|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
58475728|NCT00367822|DRUG|Lisuride|
58475729|NCT00367822|DRUG|Ropinirole|
58475730|NCT00367822|DRUG|Placebo|
58475731|NCT06322966|OTHER|Air Action Curriculum|"The goal of integrating a new curriculum into classrooms is to improve student knowledge on the health effects of air pollution, specifically of wildfire smoke.~The goal is to implement a student-designed and student-driven air quality study in each school that will lead to improved air quality and health impacts in schools, promote health equity, and train young people to be more informed about their health and proactive citizens in their school community and beyond."
57779819|NCT01388530|DEVICE|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
57779820|NCT03604913|PROCEDURE|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
57779821|NCT03604913|PROCEDURE|Bentall operation|Aortic root replacement with replacement of aortic valve
57784563|NCT06363955|DEVICE|Carbamide Peroxide Mouthwash|The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
58475732|NCT05715099|DRUG|Saffron|Dietary Supplement: saffron supplement for IBD
58475733|NCT05715099|DRUG|Placebo|Dietary Supplement: placebo for IBD
58475734|NCT00485979|DRUG|larotaxel (XRP9881)|intravenous administration
58475735|NCT00485979|DRUG|docetaxel|intravenous administration
58475736|NCT00485979|DRUG|trastuzumab|intravenous administration
58475737|NCT00222300|BEHAVIORAL|Strength training program|
58475738|NCT03593369|DEVICE|KLOX BioPhotonic System (single treatment)+SOC|"KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
58475739|NCT03593369|DEVICE|KLOX BioPhotonic System (consecutive treatments)+SOC|"In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
58475740|NCT03593369|OTHER|Standard of Care (SOC)|Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
58475741|NCT06593080|OTHER|The comprehensive TDA based approach|"The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively.~Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB."
58475742|NCT03115710|DIAGNOSTIC_TEST|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
58475743|NCT06591208|DEVICE|pulsed dye laser|PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm
58475744|NCT06591208|DEVICE|Carboxytherapy|"carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic popcorn appearance."
58475745|NCT03043417|BEHAVIORAL|CHC's given the intervention|CHC's NOT given the intervention
58133647|NCT04988061|OTHER|counselling|Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
58475746|NCT00430014|DRUG|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
58475747|NCT02365025|OTHER|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
58475748|NCT01128933|PROCEDURE|Renal artery stenting|
58475749|NCT04794777|COMBINATION_PRODUCT|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
58475750|NCT04794777|RADIATION|Standard salvage therapy|Standard salvage radiotherapy
58475751|NCT05164003|DRUG|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
58475752|NCT05164003|DRUG|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
58475753|NCT05683457|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
58475754|NCT05683457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
58475755|NCT06651541|DRUG|BZ371A|Formulation with the active ingredient
58475756|NCT06651541|DRUG|Placebo|Formulation without the active ingredient
58475757|NCT04984746|DIETARY_SUPPLEMENT|No Intervention: (control group)|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
58475758|NCT04984746|DIETARY_SUPPLEMENT|Experimental: intervention group|"Molybdenum Iodine group~Lettuces with Iodine and Molybdenum biofortification was assigned to each participant belonging to the intervention group which ate 100gr of each type of lattuce every day for 10 days"
58490967|NCT02869737|DEVICE|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
58490968|NCT05405686|DRUG|Lutropin alfa|addition of recombinant luteinizing hormone
58475759|NCT01553084|DRUG|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
58475760|NCT01553084|DRUG|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
58475761|NCT01553084|DRUG|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
58475762|NCT05122975|DRUG|S48168 (ARM210)|Ryanodine Receptor modulator
58475763|NCT05122975|DRUG|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
58475764|NCT03895203|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
58475765|NCT03895203|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
58475766|NCT03895203|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
58475767|NCT00037843|DRUG|I-131 Iodocholesterol|
58475768|NCT04992312|DRUG|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
58475769|NCT05310955|OTHER|daily rehabilitation interventions|including Naikan therapy, Morita therapy, group art therapy, group painting therapy
58475770|NCT05310955|OTHER|shen-based Qigong exercise|a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
58475771|NCT01948596|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
58475772|NCT03520998|DRUG|GRF6019|GRF6019 for IV infusion
58475773|NCT04450238|BEHAVIORAL|Routine care inpatient treatment|All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
58475774|NCT02389296|OTHER|Questionnaire|Questionnaires will be distributed to nursing staff
58475775|NCT04699617|DEVICE|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
58475776|NCT04103138|DEVICE|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
58475777|NCT04103138|DEVICE|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
58475778|NCT05406817|DRUG|Revumenib|Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
58475779|NCT05122806|GENETIC|RNAseq|"1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
58475780|NCT00061438|DRUG|meropenem|
58475781|NCT00325897|DRUG|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
58475782|NCT00325897|DRUG|Placebo|Placebo taken on a daily basis
58475783|NCT00655902|DIETARY_SUPPLEMENT|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
58475784|NCT00655902|DIETARY_SUPPLEMENT|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
57784564|NCT06363955|DEVICE|Placebo mouthwash|Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
58475785|NCT03432598|DRUG|Tislelizumab|Administered 200 mg intravenously (IV) as specified in the treatment arm
58133648|NCT04949698|DEVICE|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
58133649|NCT00910364|OTHER|Exercise|Exercise
58475786|NCT03432598|DRUG|Paclitaxel|Administered 175 mg/m² IV as specified in the treatment arm
58475787|NCT03432598|DRUG|Gemcitabine|Administered 1250 mg/m² IV as specified in the treatment arm
58475788|NCT03432598|DRUG|Etoposide|Administered 100 mg/m2 IV as specified in the treatment arm
58475789|NCT03432598|DRUG|Pemetrexed|Administered 500 mg/m² IV as specified in the treatment arm
58475790|NCT03432598|DRUG|Cisplatin|Administered 75 mg/m²/day IV as specified in the treatment arm
58475791|NCT03432598|DRUG|Carboplatin|Administered AUC 5 as specified in the treatment arm
58475792|NCT05951933|OTHER|Strenghtening + TES|Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)
58475793|NCT05240820|PROCEDURE|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
58475794|NCT04046497|OTHER|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
58475795|NCT04046497|OTHER|Usual Care|Usual Care provided by CSC clinic
58475796|NCT02495506|OTHER|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
58490969|NCT05405686|DRUG|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
58490970|NCT05405686|DIAGNOSTIC_TEST|Endometrial biopsy|pipelle de cornier biopsy
58475797|NCT02495506|OTHER|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
58475798|NCT01586364|DRUG|Ospemifene 60Mg Oral Tablet|
58475799|NCT04894968|DIAGNOSTIC_TEST|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~1. Symptoms of heart failure (e.g. dyspnea on extertion)~2. Preserved ejection fraction (Left ventricular ejection fraction ≥50%~3. NT-proBNP ≥125 pg/mL~4. Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~   * Left atrial volume index \>34 mL/m²~  * Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~  * E/e' ≥13~  * Septal e' \<9 cm/s"
58475800|NCT06396884|DEVICE|Oscillometric intermittent non-invasive blood pressure|The hemodynamic management followed liberal fluid therapy, as determined by the attending anesthetist's discretion
58475801|NCT06396884|DEVICE|ClearSight|The hemodynamic management will be conducted in accordance to a goal-directed fluid therapy (GDFT) utilizing the Clearsight system monitoring.
58475802|NCT02077010|DRUG|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
58475803|NCT03673800|OTHER|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
58475804|NCT03673800|OTHER|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
58475805|NCT04314284|BEHAVIORAL|I Can PIC|-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
58475806|NCT04314284|OTHER|Historical control survey|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
58475807|NCT04314284|OTHER|Post-intervention survey (I Can PIC participants)|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
58475808|NCT04314284|OTHER|Follow-Up survey (I Can PIC participants)|-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
58475809|NCT02744053|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
58475810|NCT02744053|OTHER|Laboratory Biomarker Analysis|Correlative studies
58475811|NCT02744053|RADIATION|Scintimammography|Undergo MBI
58475812|NCT02744053|DRUG|Technetium Tc-99m Sestamibi|Given via injection
58475813|NCT03125486|DRUG|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
58475814|NCT02496286|DRUG|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
57784942|NCT06357546|PROCEDURE|Spontaneous urination during the hour before caesarean section.|Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.
58475815|NCT02783534|DEVICE|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
58475816|NCT02783534|DEVICE|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
58475817|NCT02783534|BEHAVIORAL|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
58475818|NCT02211846|DRUG|Mirabegron|oral
58475819|NCT05535946|DRUG|ABX464|Administered once daily, preferably in the morning, with food
58475820|NCT05535946|DRUG|Placebo|Administered once daily, preferably in the morning, with food
58475821|NCT02170623|DRUG|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
58475822|NCT02170623|DRUG|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
58475823|NCT02170623|DRUG|Pantoprazole|40 mg pantoprazole
58475824|NCT02170623|DRUG|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
58475825|NCT00150436|DRUG|Pregabalin|
58475826|NCT05733351|DRUG|Abiraterone|Given PO
58475827|NCT05733351|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
58133650|NCT05687630|OTHER|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
58133651|NCT03843593|BEHAVIORAL|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
58133652|NCT03843593|BEHAVIORAL|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
58133653|NCT03843593|BEHAVIORAL|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
58133654|NCT03843593|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
58133655|NCT03843593|BEHAVIORAL|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].
58133656|NCT03843593|BEHAVIORAL|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
58133657|NCT01054534|PROCEDURE|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
58133658|NCT01366508|OTHER|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
58133659|NCT01366508|OTHER|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
58133660|NCT05904730|DRUG|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
58133661|NCT00414466|DRUG|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
58133662|NCT00165594|DRUG|E7070|
58133663|NCT02609464|DEVICE|Interrupted Knotted Sutures|
58133664|NCT02609464|DEVICE|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
58133665|NCT03802370|PROCEDURE|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
58133666|NCT05583318|OTHER|Data collection|Data from hematological malignancy registries
58475828|NCT05733351|PROCEDURE|Bone Scan|Undergo bone scan
58475829|NCT05733351|PROCEDURE|Computed Tomography|Undergo CT
58475830|NCT05733351|DRUG|Docetaxel|Given IV
58133667|NCT05583318|OTHER|Questionnaires|"9 questionnaires were sent out:~1. QLQ-C30 and SF-12 Quality of Life Questionnaire.~2. Oral quality of life questionnaire QLQ-OH15~3. Sexuality questionnaire SHQ-C22~4. Anxiety and depression questionnaire HADS,~5. Rosenberg Self-Esteem Questionnaire~6. RNLI Reintegration to Normal Life Questionnaire~7. Social Support Questionnaire SSQ6,~8. Socio-economic status questionnaire EPICES,~9. Complementary questionnaire collecting data on socio-professional status."
58133668|NCT02012244|DRUG|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
58133669|NCT02012244|DRUG|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
58133670|NCT04317066|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
58133671|NCT04091971|DRUG|Ketamine|"Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks)."
58133672|NCT04766281|DIETARY_SUPPLEMENT|MLC901|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
58133673|NCT04766281|GENETIC|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
58133674|NCT06096740|BEHAVIORAL|Cognitive Processing Therapy|"Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms."
58133675|NCT00909402|DRUG|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
58133676|NCT00909402|DRUG|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
58133677|NCT00909402|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
58133678|NCT05523271|DIAGNOSTIC_TEST|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
58475831|NCT05733351|DRUG|Enzalutamide|Given PO
58475832|NCT05733351|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
58475833|NCT05733351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58475834|NCT05733351|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
58475835|NCT05733351|DRUG|Vudalimab|Given IV
58475836|NCT05056935|DRUG|LB1148|A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
58475837|NCT05056935|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
58133679|NCT02353169|DRUG|Dexmedetomidine|
58133680|NCT02353169|DRUG|Saline|
58133681|NCT03021720|PROCEDURE|Arterial access|Location of arterial puncture
58133682|NCT05561426|OTHER|Ad libitum breakfast and dinner meals for 12 days|Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
58133683|NCT03006965|DRUG|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
58133684|NCT03006965|DRUG|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
58133685|NCT01087970|DRUG|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
58133686|NCT01087970|DRUG|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
58133687|NCT01087970|DRUG|Carboplatin|Administered intravenously, for a maximum of 6 cycles
58133688|NCT01087970|DRUG|Cisplatin|Administered intravenously, for a maximum of 6 cycles
58133689|NCT06023147|PROCEDURE|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
58133690|NCT03256942|DEVICE|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
58133691|NCT04826809|DEVICE|N95 mask|Standard 1870 N95 one time use mask
58133692|NCT04826809|DEVICE|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
58133693|NCT04826809|DEVICE|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
58133694|NCT04329208|DEVICE|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
58133695|NCT01828996|DEVICE|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
58133696|NCT01828996|DEVICE|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
58133697|NCT01851577|BEHAVIORAL|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
58133698|NCT01851577|BEHAVIORAL|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
58133699|NCT03649048|DRUG|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
58133700|NCT03649048|DRUG|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
58133701|NCT03649048|RADIATION|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
58133702|NCT05614570|DEVICE|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
58133703|NCT05614570|OTHER|SCAT5|The Sport Concussion Assessment Tool version 5
57784943|NCT06357546|PROCEDURE|Systematic bladder catherization during caesarean section.|After implementation of loco-regional analgesia by spinal anesthesia, the patient will be positioned, with a perineal toilet and installation of a bladder catheter type Foley ch. 16.
57784944|NCT04592133|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography Examination
58133704|NCT03931642|DRUG|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
58133705|NCT03931642|DRUG|Blinatumomab|Blinatumomab by continuous vein infusion
58133706|NCT01278056|DRUG|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
58133707|NCT00378690|DRUG|leuprorelin acetate|LHRH antagonist
58133708|NCT06362486|OTHER|Severity of infection, time of infection.|Severity of infection, time of infection.
58133709|NCT06362486|OTHER|Mental health assessment|Mental health assessment
58133710|NCT06362486|OTHER|biological|Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
58133711|NCT00331526|BIOLOGICAL|aldesleukin|
58133712|NCT00331526|BIOLOGICAL|therapeutic autologous lymphocytes|
58133713|NCT00331526|PROCEDURE|adjuvant therapy|
58133714|NCT00331526|PROCEDURE|conventional surgery|
58133715|NCT00486837|DRUG|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
58133716|NCT05293847|BEHAVIORAL|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
58133717|NCT00405314|DEVICE|Continuous positive airway pressure ventilation mask|
58133718|NCT00625443|DRUG|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
58133719|NCT00625443|DRUG|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
58133720|NCT00625443|DRUG|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
58133721|NCT03043547|DRUG|nal-IRI|nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
58133722|NCT03043547|DRUG|5-FU|5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)
58133723|NCT03043547|DRUG|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
58133724|NCT04088773|DIAGNOSTIC_TEST|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
58133725|NCT04088773|DIAGNOSTIC_TEST|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
58133726|NCT04088773|DIAGNOSTIC_TEST|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
58133727|NCT05975853|OTHER|Binaural beat music group (BBM group)|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
58133728|NCT05975853|OTHER|Control group|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
58133729|NCT05699005|DRUG|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
58133730|NCT04450043|BEHAVIORAL|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
58133731|NCT04450043|BEHAVIORAL|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
58133732|NCT04450043|BEHAVIORAL|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
58133733|NCT01449630|DRUG|LY3031207|Administered orally
58133734|NCT01449630|DRUG|Placebo|Administered orally
58133735|NCT01449630|DRUG|Celecoxib|Administered orally
57779822|NCT04944225|OTHER|Opioid Reduction Strategy|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
57779823|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
57779824|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
57779825|NCT06442072|BEHAVIORAL|guided online self-help program|16 weeks of training and application of psychotherapeutic methods
57779826|NCT06737757|DEVICE|Artificial polymer heart valves|The experimental group will use polymer material surgical aortic valves(PoliaValve, Hearthill Medical) for aortic valve replacement
57779827|NCT06737757|DEVICE|Bovine pericardial aortic valve|The control group will undergo aortic valve replacement using bovine pericardial aortic valve
58133736|NCT02522806|PROCEDURE|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
57779828|NCT06122181|DRUG|HS-10384 tablets|Multiple dosing of HS-10384 orally in a fasting state
57779829|NCT06122181|DRUG|HS-10384-matched placebo tablets|Multiple dosing of HS-10384-matched placebo orally in a fasting state
57779830|NCT06741124|PROCEDURE|Channel Esophagogastrostomy|Channel Esophagogastrostomy
57779831|NCT06741124|PROCEDURE|Double Tract Reconstruction|Double Tract Reconstruction
57779832|NCT04855487|BEHAVIORAL|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
57784945|NCT01767129|DRUG|AVP-923-45|One capsule twice daily for 14 days
57784946|NCT01767129|DRUG|Placebo|One capsule twice daily for 14 days
58133737|NCT04734184|DIAGNOSTIC_TEST|DCFPyL|Single dose injection
58133738|NCT00004579|BIOLOGICAL|gp160 MN/LAI-2|
58133739|NCT00004579|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
58133740|NCT02770963|PROCEDURE|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
58133741|NCT02770963|PROCEDURE|Sham acupuncture|"Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
58133742|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 1 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
58133743|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 2 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
58133744|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection placebo combined with Linezolid|After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
58133745|NCT04234100|OTHER|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
58133746|NCT06305416|DRUG|Ranibizumab 10mg/ml Injection|Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
58133747|NCT06305416|DRUG|Lucentis|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
58133748|NCT03123237|DIAGNOSTIC_TEST|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.
58133749|NCT03985670|DRUG|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
58133750|NCT03985670|DRUG|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
58133751|NCT01295853|PROCEDURE|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
58133752|NCT01295853|PROCEDURE|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
58133753|NCT00284674|DEVICE|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
58133754|NCT02507427|DEVICE|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
58133755|NCT05045118|OTHER|Digital Structured Patient Education Material|Participants of home-based Cardiac Rehabilitation Program that are included in this research will be provided with a digital Structured Patient Education Material at the beginning of the program, and will be followed up for 12 weeks duration
58133756|NCT00868010|DRUG|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
58133757|NCT00868010|DRUG|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
58133758|NCT05020925|DRUG|SHR-1701|Intravenous (IV) on Day 1 of each cycle
58133759|NCT05020925|DRUG|Famitinib|Famitinib, po, qd
57779833|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
57779834|NCT06273579|BEHAVIORAL|Experimental Group - Verbal expert instructor feedback in AI's words|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the expert instructor must deliver this command in the same words as the ICEMS.
57779835|NCT06273579|BEHAVIORAL|Experimental Group - Verbal expert instructor feedback in expert's own words|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the expert will deliver feedback in their own words.
57779836|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
57779837|NCT06740045|BIOLOGICAL|Tezepelumab|10 patients will receive teszpire
57779838|NCT02862275|DRUG|Atezolizumab|Given IV
57779839|NCT02862275|PROCEDURE|Biopsy|Undergo tissue biopsy
57779840|NCT02862275|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
57779841|NCT02862275|PROCEDURE|Computed Tomography|Undergo CT scan
57779842|NCT02862275|OTHER|Laboratory Biomarker Analysis|Correlative studies
57779843|NCT02862275|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57779844|NCT06293482|DEVICE|Cochlear™ Nucleus® System|The Cochlear™ Nucleus ® System is a commercially available system intended for restoration of hearing sensation through electrical stimulation of the auditory nerve in adult patients with bilateral symmetrical sensorineural hearing loss.
58133760|NCT02321384|DRUG|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
58133761|NCT02321384|DRUG|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
58133762|NCT02321384|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
58133763|NCT02321384|DRUG|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
58133764|NCT03931876|DRUG|Placebos|Single ascending dose administration
57779845|NCT06364358|BEHAVIORAL|Computerized CKD Education|The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.
57779846|NCT06364358|BEHAVIORAL|Usual Hospital Care|Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
57779847|NCT06369961|DRUG|transdermal fentanyl|Adult cancer pain patients switched from oral opioid to TDF
57779848|NCT05028010|BEHAVIORAL|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
57779849|NCT03360279|DEVICE|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
57779850|NCT03360279|DEVICE|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
57779851|NCT01335308|BEHAVIORAL|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
57779852|NCT01335308|BEHAVIORAL|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
57779853|NCT01335308|BEHAVIORAL|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
57779854|NCT05071066|OTHER|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month \[T1\], and 6-month \[T2\]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
57779855|NCT06740812|DRUG|Fosaprepitant|Fosaprepitant 150mg IV administered over 15 minutes
57779856|NCT06740812|DRUG|Metoclopramide|Metoclopramide 10mg IV administered over 15 minutes
57779857|NCT05176704|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
57779858|NCT06633016|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
57779859|NCT06633016|OTHER|Placebo|Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
57779860|NCT06349200|BEHAVIORAL|432 Hz music|Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality
57779861|NCT06349200|BEHAVIORAL|Binaural beats|Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds
57779862|NCT06349200|BEHAVIORAL|White noise|White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
57779863|NCT03502733|PROCEDURE|Biopsy|Undergo tumor biopsy
57779864|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57779865|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
57779866|NCT03502733|DRUG|Copanlisib|Given IV
57779867|NCT03502733|PROCEDURE|Echocardiography|Undergo ECHO
58133765|NCT03931876|DRUG|AV-006|Single ascending dose administration
58133766|NCT04095117|PROCEDURE|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
58133767|NCT04659421|DRUG|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
58133768|NCT01257009|DRUG|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
58133769|NCT00552669|DRUG|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
57779868|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
58133770|NCT00552669|DEVICE|Drug Eluting stent|Any Drug eluting stent
58133771|NCT04109222|BIOLOGICAL|Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58133772|NCT04109222|BIOLOGICAL|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
58133773|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
58133774|NCT01121276|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
58133775|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
58133776|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
58133777|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
58133778|NCT02702817|DRUG|Naproxen|pale blue oval tablets
58133779|NCT02702817|DRUG|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
58133780|NCT04892511|OTHER|Adjusted medication|"In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~* Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~* Patients with TICI 2c-3: systolic blood pressure \<140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered."
58133781|NCT00375700|DIETARY_SUPPLEMENT|Nutritional Supplement|
57779869|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57779870|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
57779871|NCT06741111|OTHER|No treatment given|No treatment given
57779872|NCT06740656|OTHER|No Interventions|no intervention
57779873|NCT04266795|DRUG|Pevonedistat|Pevonedistat IV infusion.
57779874|NCT04266795|DRUG|Venetoclax|Venetoclax tablets.
57779875|NCT04266795|DRUG|Azacitidine|Azacitidine IV or SC injection.
57779876|NCT03813095|DRUG|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
57779877|NCT03813095|DRUG|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
58133782|NCT01194492|RADIATION|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
58133783|NCT06223347|DIAGNOSTIC_TEST|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
58133784|NCT03830125|DRUG|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
58133785|NCT03830125|DRUG|Placebo group|Placebo matched to BBT-877, oral capsule
58133786|NCT03830125|DRUG|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
58133787|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
58133788|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
58133789|NCT05504603|DRUG|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
58133790|NCT05504603|DRUG|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
58133791|NCT04574648|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
58133792|NCT04048005|DIAGNOSTIC_TEST|Fractional flow reserve|
58133793|NCT02853162|RADIATION|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
58133794|NCT00122629|DRUG|peg-interferon alfa-2b|
58133795|NCT00122629|DRUG|ribavirin|
58133796|NCT00122629|DRUG|amantadine|
58133797|NCT00064753|DRUG|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
58133798|NCT00064753|DEVICE|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
58133799|NCT03289156|BEHAVIORAL|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
58133800|NCT03289156|BEHAVIORAL|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
58133801|NCT04810416|OTHER|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
58133802|NCT04810416|OTHER|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
58133803|NCT04810416|OTHER|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
58133804|NCT04810416|OTHER|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
58133805|NCT00169195|DRUG|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
58133806|NCT03178500|DRUG|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
58133807|NCT02730078|BEHAVIORAL|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
58133808|NCT02730078|BEHAVIORAL|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
58133809|NCT01949194|DRUG|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
58133810|NCT05697471|DRUG|Dienogest|Dienogest 2 mg per day
58133811|NCT05697471|DRUG|Danazol|Danzol 200MG per day
58133812|NCT03463369|BIOLOGICAL|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
58133813|NCT03463369|BIOLOGICAL|Placebo|Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
58133814|NCT03463369|DRUG|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
58133815|NCT03959878|DEVICE|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
58133816|NCT04470791|BIOLOGICAL|F(ab)2 antivenom therapy (antivipmyn®).|Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
58133817|NCT04470791|PROCEDURE|Local cryotherapy.|Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
58133818|NCT02892500|DRUG|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
58133819|NCT02892500|DRUG|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
58133820|NCT05687864|DIAGNOSTIC_TEST|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
58133821|NCT04168788|OTHER|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
58133822|NCT04283084|DEVICE|Virtual Reality Based Balance and Coordination Exercises|With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
58133823|NCT02462330|DRUG|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
58133824|NCT02462330|DRUG|Placebo comparator|injections of human albumin
58133825|NCT04341740|PROCEDURE|Bone Marrow Aspirate|bone marrow aspiration
58133826|NCT04887077|DEVICE|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
58133827|NCT04887077|BEHAVIORAL|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
58133828|NCT04882332|OTHER|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
58133829|NCT04882332|OTHER|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
58133830|NCT02456714|DRUG|FOLFIRINOX|
58133831|NCT06126848|DEVICE|Ambient sensor system|Main study: A contactless non-intrusive ambient sensor system including infrared motion sensors combined with a contactless Emfit bed sensor will be installed in the home of single living study patients by using a commercially available System (Domo Health®, Lausanne) after informed consent has been obtained. Sensor data are prospectively followed over 3-6 months for predefined indicators of health deterioration. If indicators for health deterioration are present, patients will be called in to the hospital for cardiology consult by the study team including blood analysis for follow-up of BNP values and if necessary, therapy adaption.
58475838|NCT05721456|BIOLOGICAL|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
58133832|NCT02077270|PROCEDURE|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
58133833|NCT05723588|DEVICE|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
58133834|NCT05723588|DEVICE|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
58133835|NCT05723588|BEHAVIORAL|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
58133836|NCT05723588|DRUG|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
58133837|NCT01566318|BEHAVIORAL|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
58133838|NCT00429364|DRUG|Losartan Potassium|Losartan .3 - 1.4 mg/kg
58133839|NCT00429364|DRUG|Atenolol|Atenolol .5 - 4 mg/kg
58133840|NCT02139553|PROCEDURE|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
58133841|NCT05155306|DRUG|BI 1358894, intended Commercial Formulation (iCF) (T)|Test Treatment (T)
58133842|NCT05155306|DRUG|BI 1358894, Trial Formulation 2 (TFII) (R)|Reference Treatment (R)
58133843|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
58133844|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
58133845|NCT00454909|BIOLOGICAL|Meningococcal vaccine 134612|Single dose intramuscular injection.
58133846|NCT00454909|BIOLOGICAL|Menactra®|Single dose intramuscular injection.
58133847|NCT02024087|DRUG|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
58133848|NCT04334590|PROCEDURE|Cleft Lip/Nose Repair without PSIO|Standard of care surgical repair of cleft lip/nose without PSIO.
58133849|NCT04334590|PROCEDURE|Presurgical Infant Orthopedic Therapy|Standard of care surgical repair of cleft lip/nose with PSIO.
58133850|NCT00946803|BEHAVIORAL|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
58133851|NCT03388307|PROCEDURE|unilateral laminotomy|minimally invasive technique
58133852|NCT03388307|PROCEDURE|decompressive laminectomy|classic surgery
58133853|NCT03202914|BEHAVIORAL|Usual protein and phosphorus diet|Diet intervention
58133854|NCT03202914|BEHAVIORAL|Low protein and phosphorus diet|Diet intervention
58133855|NCT03202914|BEHAVIORAL|Very low protein and phosphorus|Diet intervention
58133856|NCT00984295|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
58133857|NCT00984295|BIOLOGICAL|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
58133858|NCT00984295|BIOLOGICAL|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
58133859|NCT00984295|BIOLOGICAL|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
58133860|NCT00984295|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
58133861|NCT03861065|PROCEDURE|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
58133862|NCT03861065|PROCEDURE|Historical Wound Closure|Participants wounds are left partially open to heal.
58133863|NCT04008498|DIAGNOSTIC_TEST|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
58133864|NCT02468739|DRUG|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
58133865|NCT02468739|DRUG|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
58133866|NCT04351204|RADIATION|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
58133867|NCT01917838|BEHAVIORAL|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
58133868|NCT00939653|DRUG|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
58133869|NCT00939653|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
58133870|NCT00939653|DRUG|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
58133871|NCT00939653|DRUG|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.
58133872|NCT00939653|DRUG|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age"
58133873|NCT05184842|DRUG|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)
58475839|NCT02143804|BIOLOGICAL|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
58133874|NCT05184842|DRUG|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
58133875|NCT04504396|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
58133876|NCT04504396|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
58133877|NCT03571048|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
58133878|NCT03571048|BEHAVIORAL|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
58133879|NCT04980001|BEHAVIORAL|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
58133880|NCT00849459|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
58133881|NCT01507857|BIOLOGICAL|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
58133882|NCT01507857|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
58133883|NCT03708835|OTHER|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
58133884|NCT00281866|DRUG|erlotinib hydrochloride|
58133885|NCT03884166|DIAGNOSTIC_TEST|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
58133886|NCT05987371|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
58133887|NCT05987371|DRUG|TQC3721 matching placebo for inhalation|Placebo without active substance.
58133888|NCT05987371|DRUG|Salbutamol sulfate inhalation aerosol|Salbutamol is short-acting β2 receptor agonists.
58475840|NCT05614817|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection
58475841|NCT05614817|DRUG|Placebo|subcutaneous(SC) injection
58133889|NCT04699149|OTHER|Transcranial magnetic stimulation|Non-invasive brain stimulation
58133890|NCT04699149|OTHER|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
58133891|NCT02351024|DRUG|OXP005|
58475842|NCT00133484|BIOLOGICAL|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
58475843|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Bacillus anthrax|
58133892|NCT02351024|DRUG|Naprosyn®|
58133893|NCT01719406|BEHAVIORAL|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
58133894|NCT00086762|BEHAVIORAL|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
58133895|NCT00086762|BEHAVIORAL|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
58133896|NCT00086762|BEHAVIORAL|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
58133897|NCT00086762|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
58133898|NCT03420300|DRUG|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
58133899|NCT01706471|DRUG|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
58475844|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Escherichia coli|
58475845|NCT03911167|PROCEDURE|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
58475846|NCT03586661|DRUG|Copanlisib|Given IV
58475847|NCT03586661|DRUG|Niraparib|Given PO
58475848|NCT00279175|BIOLOGICAL|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
58475849|NCT00279175|BIOLOGICAL|Placebo medium supplemented with autologous serum|
58475850|NCT01713920|DRUG|SEVIKAR|
58475851|NCT05902910|DEVICE|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
58475852|NCT01067053|DRUG|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
58133900|NCT01706471|DRUG|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
58133901|NCT01407536|DEVICE|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
58133902|NCT00000462|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
58133903|NCT00000462|PROCEDURE|coronary artery bypass|
58133904|NCT05192330|DEVICE|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
58133905|NCT05192330|BEHAVIORAL|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
58133906|NCT03077516|DEVICE|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
58133907|NCT03675828|BEHAVIORAL|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
58133908|NCT04088760|DRUG|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
58133909|NCT04318665|DIAGNOSTIC_TEST|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
58133910|NCT03043924|DRUG|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
58133911|NCT03043924|DRUG|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
58133912|NCT06090149|DEVICE|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
58133913|NCT06090149|DEVICE|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
58133914|NCT02879682|PROCEDURE|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
58133915|NCT02879682|PROCEDURE|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
58133916|NCT05427383|DRUG|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
58133917|NCT05427383|DRUG|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
58133918|NCT05427383|DRUG|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
58133919|NCT05427383|DRUG|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
58133920|NCT01459328|RADIATION|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days"
58133921|NCT01459328|RADIATION|Radiotherapy|"Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
58133922|NCT05316922|DRUG|Levothyroxine|Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
58133923|NCT05734222|PROCEDURE|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
58133924|NCT03729310|DEVICE|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
58490971|NCT05357001|OTHER|Connective tissue manipulation|to remove muscle spasticity
58133925|NCT03729310|DRUG|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
58133926|NCT03729310|DEVICE|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
58133927|NCT02550574|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
58133928|NCT02550574|PROCEDURE|Wound Closure with 5-0 Vicryl Sutures|
58133929|NCT06484647|PROCEDURE|Percutaneous Coronary Intervention|"Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique."
58133930|NCT04085107|BEHAVIORAL|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
58133931|NCT03090932|OTHER|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
58133932|NCT02458638|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
58133933|NCT00115882|BEHAVIORAL|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
58133934|NCT02149888|DRUG|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
58133935|NCT01453556|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
58133936|NCT05047107|OTHER|No intervention|Non-interventional study
58133937|NCT04671888|OTHER|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
58475853|NCT03846492|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
58475854|NCT00048425|DRUG|Levosimendan|
58475855|NCT03541551|PROCEDURE|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
58475856|NCT03541551|PROCEDURE|Trab Trab|combined trabeculotomy with trabeculectomy
58475857|NCT01670084|DRUG|nilotinib|Given PO
57779878|NCT03941574|DRUG|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
58133938|NCT01097408|DRUG|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
58133939|NCT01097408|DRUG|Placebo comparator|Placebo capsules
58133940|NCT04220151|GENETIC|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
58133941|NCT03339856|DEVICE|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
58133942|NCT02020707|BIOLOGICAL|Bevacizumab|Given IV
58133943|NCT02020707|OTHER|Laboratory Biomarker Analysis|Correlative studies
58133944|NCT02020707|DRUG|Nab-paclitaxel|Given IV
58133945|NCT02020707|OTHER|Pharmacological Study|Correlative studies
58133946|NCT02472184|PROCEDURE|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
58133947|NCT02472184|PROCEDURE|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
58475858|NCT01670084|BIOLOGICAL|rituximab|Given IV
58475859|NCT01670084|DRUG|cyclophosphamide|Given IV
58475860|NCT01670084|DRUG|doxorubicin hydrochloride|Given IV
58475861|NCT01670084|DRUG|vincristine sulfate|Given IV
58475862|NCT01670084|DRUG|methotrexate|Given IV or IT
58475863|NCT01670084|DRUG|cytarabine|Given IV or IT
58475864|NCT01670084|DRUG|prednisone|Given PO
58475865|NCT01670084|DRUG|mesna|Given IV
58475866|NCT01670084|DRUG|dexamethasone|Given IV or PO
58475867|NCT01670084|DRUG|leucovorin calcium|Given IV
58475868|NCT05078047|DRUG|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
57779879|NCT02954575|DRUG|Wilate|
57779880|NCT00433576|DRUG|resveratrol|Given orally
57779881|NCT00433576|OTHER|pharmacological study|Correlative studies
58475869|NCT00746382|DRUG|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
58475870|NCT00746382|DRUG|Placebo cream|Placebo cream
58475871|NCT04311021|OTHER|No intervention|No intervention
57779882|NCT00433576|OTHER|laboratory biomarker analysis|Correlative studies
57779883|NCT05219799|DRUG|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
58133948|NCT03905486|DRUG|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
58133949|NCT03905486|DRUG|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
58133950|NCT06360627|RADIATION|Computed Tomography|Computed Tomography CHEST
58133951|NCT02208492|DRUG|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
58133952|NCT02208492|DRUG|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
58133953|NCT01050647|DRUG|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
58133954|NCT01050647|OTHER|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
58475872|NCT04760782|DRUG|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
58475873|NCT04760782|DEVICE|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
57779884|NCT05219799|DRUG|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
57779885|NCT05219799|DRUG|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
57779886|NCT05219799|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
58475874|NCT01347112|DRUG|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
58475875|NCT01347112|DRUG|placebo|sugar pill twice daily for 12 weeks
58490972|NCT05357001|OTHER|stretching exercises|to remove muscle spasticity
58490973|NCT02814552|OTHER|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
58490974|NCT02814552|OTHER|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
57779887|NCT06739915|OTHER|TUTT-PT Intervention|All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
57779888|NCT05113264|DEVICE|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
57779889|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
58133955|NCT01212874|DRUG|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
58133956|NCT01212874|DRUG|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
58133957|NCT04165148|DEVICE|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
58133958|NCT04165148|DEVICE|conventional laparoscopy|conventional laparoscopy
58133959|NCT04165148|OTHER|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
58490975|NCT00517855|BIOLOGICAL|PRTX-100 (Staphylococcal protein A)|
58133960|NCT04165148|OTHER|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
58133961|NCT04165148|OTHER|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
58133962|NCT05406349|BEHAVIORAL|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
58133963|NCT05406349|BEHAVIORAL|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
58133964|NCT01740219|BEHAVIORAL|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
58133965|NCT01740219|BEHAVIORAL|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
58133966|NCT03947138|BIOLOGICAL|GC3107|BCG Vaccine
58133967|NCT03947138|BIOLOGICAL|Intradermal BCG SSI inj.|BCG Vaccine
58133968|NCT05536518|BEHAVIORAL|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
58133969|NCT04127045|PROCEDURE|IMN-Group|Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
58475876|NCT05728437|PROCEDURE|Resistance exercise|The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
57779890|NCT06736977|BEHAVIORAL|The Onsite Nurse-Led Education Programme on IPC|"The programme was designed to enhance CCWs' IPC knowledge and attitudes through lectures, interactive discussions, information sharing, and Q\&A sessions. It also aims to improve their IPC practices and self-efficacy through demonstrations, role-playing exercises, and a work assignment focused on IPC self-monitoring.~The programme includes five educational sessions totalling 12 hours, along with one session for work assignment on daily self-monitoring of IPC practices over five days. The educational sessions cover the following topics:~1. General concepts of infectious diseases~2. Vaccination~3. Standard precautions: The use of personal protective equipment, environmental cleaning and disinfection, handling food and feeding, and waste management~4. Standard precautions: Hand hygiene~5. Common infectious diseases in DCCs and management."
58133970|NCT04127045|PROCEDURE|HA-Group|In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
58133971|NCT01050803|BEHAVIORAL|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
58133972|NCT01050803|BEHAVIORAL|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
58133973|NCT02161848|OTHER|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
58133974|NCT05299047|OTHER|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
58475877|NCT03908801|BEHAVIORAL|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
58475878|NCT06587932|OTHER|brain gym exercises|It is comprised very easy body movements which have been designed to coax the two hemispheres of the brain to work in synchronization. (Tanaya et al., 2018)
58475879|NCT06587932|OTHER|Traditional treatments|traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other
58475880|NCT06164106|BEHAVIORAL|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
58475881|NCT06164106|BEHAVIORAL|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
58475882|NCT06164106|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
58475883|NCT06654908|PROCEDURE|resisted exercise using sand bags,resistance machines and elastic bands|Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
58475884|NCT04400877|DIAGNOSTIC_TEST|Diagnostic examination for venous thromboembolism|Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
58475885|NCT06594029|BEHAVIORAL|Community Navigator Intervention|see previous section
58475886|NCT06594029|OTHER|Control Group|Participants receive information on how to increase their community participation
58475887|NCT00126243|DRUG|rituximab|
58475888|NCT00126243|DRUG|CHOP|
58475889|NCT01106612|PROCEDURE|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
58475890|NCT01106612|PROCEDURE|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
58475891|NCT04083612|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
58475892|NCT04083612|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
58475893|NCT02929394|DRUG|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
58475894|NCT06651853|DRUG|Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab|"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."
58475895|NCT06602609|OTHER|Remote Patient Monitoring Strategy|Continuous remote monitoring with the SmartCardia device includes continuous heart rate and cardiac conduction rhythm tracking through a 7-lead ECG enhanced by machine learning. This system can detect cardiac rhythm disturbances, measure breathing and heart rate, and provide live-alert notifications. Daily 12-lead ECG will be collected from each patient for 7 days after discharge; patients are instructed to perform a daily 12-lead ECG on the SHL device, along with recording blood pressure and oxygen saturation levels. Each ECG is interpreted by the trial team, and a cardiologist\&#39;s interpretation is confirmed, and patients will undergo remote consultations with a cardiologist or research nurse each day if needed. During the initial 30 days of patient recruitment, if the individual exhibits potential cardiac symptoms, they can activate a remote consultation by performing an extra 12-lead ECG and recording blood pressure and oxygen saturation levels.
58475896|NCT06602609|OTHER|Standard Medical Therapy|No intervention is required. Patients in this arm will fill out a self-reported anxiety report (SHAI form) and provide recent admission information
58475897|NCT04970485|BEHAVIORAL|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
58475898|NCT06326814|DRUG|Humanized anti-Factor Bb monoclonal antibody|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
58475899|NCT06326814|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
58475900|NCT02874521|OTHER|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
58475901|NCT02874521|OTHER|Intra-dialytic cycle training|Cycle training during haemodialysis
58490976|NCT01644357|OTHER|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
58490977|NCT01677377|DRUG|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
58475902|NCT06286202|BEHAVIORAL|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.
58475903|NCT06286202|BEHAVIORAL|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
58475904|NCT03761992|DIETARY_SUPPLEMENT|Gingko Baloba|Tablets
58475905|NCT03761992|OTHER|Placebo|Tablets
58475906|NCT02012140|DRUG|ticagrelor|
58475907|NCT06590740|DRUG|Budesonide-Formoterol treatment|Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
58475908|NCT02586298|OTHER|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
58475909|NCT02586298|OTHER|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
58475910|NCT06452563|DIETARY_SUPPLEMENT|ketoanalogue supplementation|This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021
58475911|NCT06452563|OTHER|intradialytic exercise|low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
58475912|NCT04293575|DEVICE|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
58475913|NCT06597201|DRUG|amino acid (15) peritoneal dialysis solution|Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
58475914|NCT06597201|DRUG|glucose peritoneal dialysis solution|Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
58475915|NCT05906719|OTHER|video recording|Patients' performance of MDS-UPDRS III will be recorded.
58475916|NCT02404935|DRUG|Cetuximab|
58475917|NCT02404935|DRUG|FOLFIRI and cetuximab|
58475918|NCT00460161|PROCEDURE|acupuncture|2 treatments/week for 4 weeks
58475919|NCT00460161|OTHER|placebo/sham acupuncture|2 treatments/week for 4 weeks
58475920|NCT01135173|BEHAVIORAL|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
58475921|NCT06079112|DRUG|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
58475922|NCT06079112|DRUG|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
58475923|NCT06590168|PROCEDURE|Socket Preservation by vestibular socket therapy|Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
58475924|NCT06590168|PROCEDURE|Socket Preservation by icecream cone technique|Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
58475925|NCT04100083|DRUG|Spironolactone 50 MG|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
57779891|NCT06736977|BEHAVIORAL|The Online Nurse-Led Education Programme on IPC|The online version of the nurse-led education programme was conducted using an online meeting platform. It includes the same content, learning activities, and materials as the onsite delivery programme, except for the practice stations, which cannot be provided to participants in the online delivery. Additionally, all documents will be available for download via the online platform.
57779892|NCT00213330|PROCEDURE|rectal distension|
58475926|NCT04100083|DRUG|Spironolactone 100mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
58475927|NCT04100083|DRUG|Spironolactone 200 mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
58475928|NCT03736590|BEHAVIORAL|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
58475929|NCT02072668|DRUG|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
58475930|NCT02072668|DRUG|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
58475931|NCT03027609|DRUG|AR-105|monoclonal antibody
58475932|NCT03027609|DRUG|Placebo|matching placebo (+ SOC antibiotics)
58475933|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
58475934|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
58475935|NCT05356377|DRUG|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
58475936|NCT06434519|DRUG|Metronidazole cream|After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
58475937|NCT06434519|OTHER|Cetaphil moisturizer|1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
58475938|NCT06434519|OTHER|CeraVe moisturizer|1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
58475939|NCT06434519|OTHER|Eucerin Healing Lotion moisturizer|1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
58475940|NCT06434519|OTHER|Aveeno Calm and Restore Oat Gel moisturizer|1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
58475941|NCT01283139|BIOLOGICAL|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
58475942|NCT01283139|BIOLOGICAL|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
58475943|NCT01283139|BIOLOGICAL|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
58475944|NCT01283139|OTHER|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
58475945|NCT00628420|DRUG|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
58475946|NCT00628420|DRUG|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
58475947|NCT00628420|DRUG|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
58475948|NCT00231738|DRUG|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
57779893|NCT06738069|OTHER|Participants are not assigned an intervention as a part of the study|Participants are not assigned an intervention as a part of the study
58475949|NCT00001188|PROCEDURE|radiation therapy following surgery|
58475950|NCT06599385|OTHER|Platelet transfusion if platelet count ≤ 10 G/L|Platelet transfusion as soon as platelet count falls ≤ 10 G/L
58475951|NCT06599385|OTHER|Platelet transfusion when platelet count ≤ 20 G/L|Platelet transfusion will be initiated immediately after randomisation
58475952|NCT01484587|DRUG|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
58475953|NCT01484587|DRUG|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
58475954|NCT01416220|DRUG|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
58475955|NCT01416220|DRUG|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
58475956|NCT04796155|DIAGNOSTIC_TEST|Intrapartum ultrasound|Intrapartum ultrasound will be performed by suprapubic and transperineal approach for 30 seconds.
58475957|NCT03666754|PROCEDURE|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
58475958|NCT03666754|PROCEDURE|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
58475959|NCT00307801|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
58475960|NCT00307801|DRUG|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
58475961|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
58475962|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
58475963|NCT01457508|BIOLOGICAL|Hib (Hiberix™)|Three doses administered intramuscularly
58475964|NCT04382950|COMBINATION_PRODUCT|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
58475965|NCT06598657|OTHER|Mobilization with Movement MWM|Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.
58475966|NCT06598657|OTHER|Conventional Treatment|"* Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week"
58475967|NCT00821548|PROCEDURE|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
58475968|NCT05628064|DEVICE|1C70|Investigational energy storage and return prosthetic foot with using novel elastic elements.
58475969|NCT05628064|DEVICE|Pro-Flex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
58475970|NCT06654063|PROCEDURE|non-surgical periodontal therapy (SRP)|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage."
57779894|NCT06739395|DRUG|Olaparib tablet|Usage and dosage: The recommended dosage is 200mg, twice a day, equivalent to a total daily dose of 400mg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided(from the I-PREDICT study).
58475971|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Omega-3|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure."
58475972|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Vitamin D|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups."
58475973|NCT03278249|OTHER|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
58475974|NCT00888173|DRUG|Brivanib Alaninate|Given PO
58475975|NCT00888173|OTHER|Laboratory Biomarker Analysis|Correlative studies
58475976|NCT02546518|DEVICE|Moniri Otovent|Please see Arm Description.
58475977|NCT02546518|DEVICE|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
58475978|NCT03484754|BIOLOGICAL|botulinum toxin|injection of botulinum toxina in two different facial sites
58475979|NCT05323812|DRUG|TW001|daily dose of 100 mg TW001/placebo
58475980|NCT05323812|DRUG|Placebo|daily dose of 100 mg TW001/placebo
58475981|NCT06588543|DEVICE|Endovascular treatment|Endovascular treatment
58475982|NCT05936580|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
58475983|NCT01178047|DRUG|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
58475984|NCT06586203|DEVICE|Polygenic Risk Score|The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
58475985|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Escalation)|Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.
58475986|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Expansion)|Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
58475987|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
58475988|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
58475989|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
57779895|NCT06739395|DRUG|Temozolomide capsule|Administration method and dosage: 75mg/m2, orally administered for 7 consecutive days, with a treatment cycle of every 21 days.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
58475990|NCT06596278|DEVICE|Memesto|Memesto wearable audio player
58475991|NCT06586333|DRUG|stress ulcer prophylaxis|In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines
58475992|NCT06035016|DRUG|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
58475993|NCT06035016|DRUG|treatment of physician's choice|Treatment of physician's choice
58475994|NCT03384615|BEHAVIORAL|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
58475995|NCT06161246|DEVICE|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
58475996|NCT00817843|DRUG|Simvastatin|6 weeks of treatment with simvastatin 80 mg
58475997|NCT00817843|DRUG|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
58475998|NCT05068297|OTHER|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
58475999|NCT05068297|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
58476000|NCT06101784|DRUG|Avenanthramide|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
58476001|NCT06101784|DRUG|Placebo|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
58476002|NCT04909463|DEVICE|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
58476003|NCT06597981|BEHAVIORAL|Dyadic empowerment-based sport stacking|For the intervention group, the care dyads will receive an 18-week dyadic empowerment-based sport stacking program, which is divided into two phases: the active phase (weeks 1-12) and the maintenance phase (weeks 13-18). In the active phase, the care dyads will engage in three online sessions in small groups (3-5 dyads/group) and three check-up/support sessions. Three online sessions will be scheduled at weeks 1, 3, and 9 during the 12-week active phase. They will also be required to engage in self-practice at home for at least 30 minutes per day, five times per week during this time according to their training schedule. In the maintenance phase, there will be three online sessions in small groups (3-5 dyads/group). Three online sessions will be scheduled at weeks 13, 16, and 18. The dyads will continue their self-practice at home (at least 30 minutes/day, five times/week) for 6 weeks.
58476004|NCT06597981|OTHER|Basic education|Participants in the control group will receive basic education on dementia caregiving, which will comprise three group-based (3-5 dyads/group) online meetings in the same schedule as the intervention group (1st, 3rd, 9th week).
58476005|NCT05696288|PROCEDURE|Respiratory Gas Delivery System|Oxygen therapy during general anesthesia for ENT panendoscopy
58476006|NCT02320084|DRUG|Nitisinone|Nitisinone according to prescription
58476007|NCT00441077|BEHAVIORAL|Education|
58476008|NCT06520033|DEVICE|humanoid robot|"The humanoid robot will execute an educational hydration plan that will be integrated into the usual dynamics of the residence. In order to increase the fluid intake of the residents, stimulation activities will be proposed that will be carried out by the robot such as reminders, interactive activities and positive reinforcement. It will also allow the daily recording fluid intake of each residents.~This intervention will last two months."
58476009|NCT06520033|OTHER|Usual care|The center's usual hydration plan
58476010|NCT06173323|BEHAVIORAL|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
58476011|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)
58476012|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
58476013|NCT00247663|DRUG|Letrozole|
58476014|NCT00700479|DRUG|aldosterone|4 hour infusion
58476015|NCT00700479|DIETARY_SUPPLEMENT|low or high sodium diet|
58476016|NCT00700479|DRUG|placebo|placebo
58476017|NCT02599571|OTHER|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
58476018|NCT02599571|OTHER|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
58476019|NCT02700061|PROCEDURE|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
58476020|NCT02700061|PROCEDURE|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
58476021|NCT06193096|DIETARY_SUPPLEMENT|Experimental product|Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.
58476022|NCT06193096|DIETARY_SUPPLEMENT|Control product|"Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks"
58476023|NCT02968758|DEVICE|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
58476024|NCT02084992|OTHER|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
58476025|NCT02084992|OTHER|Telephonic disease management|
58476026|NCT00595088|BIOLOGICAL|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
58476027|NCT06591299|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
58476028|NCT06591299|DRUG|Clopidogrel 75mg|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
58476029|NCT00004688|DRUG|carmustine|
58476030|NCT00004688|DRUG|mercaptopurine|
58476031|NCT00004688|DRUG|streptozocin|
58476032|NCT04734028|DRUG|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
58476033|NCT04906811|DEVICE|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
58476034|NCT04906811|DEVICE|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
58476035|NCT03331315|DRUG|Celecoxib|
58476036|NCT03331315|DRUG|Ketorolac|
58476037|NCT05902364|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops|commercially available eye drops
58476038|NCT06346717|BEHAVIORAL|"Knee Prosthesis-M mobile application service"|"In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks."
58476039|NCT06389422|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
58490978|NCT01677377|DRUG|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
58476040|NCT06389422|DRUG|Pembrolizumab|One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
58476041|NCT06262321|RADIATION|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
58476042|NCT05833763|DRUG|Glofitamab|Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
58476043|NCT05833763|DRUG|Pirtobrutinib|Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
58476044|NCT05833763|DRUG|Obinutuzumab|Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
58476045|NCT05833763|DRUG|Tocilizumab|Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
58476046|NCT00853307|DRUG|Alisertib|Alisertib capsules
58476047|NCT04021654|PROCEDURE|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
58476048|NCT06450899|DRUG|Prochlorperazine Maleate|Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.
58476049|NCT06450899|DRUG|Placebo|The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
58476050|NCT06473740|DRUG|Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)|"The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection."
58476051|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
58476052|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
58476053|NCT06601439|OTHER|Observational Study|Observational Study
58476054|NCT03823521|DRUG|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
58476055|NCT06394050|DIAGNOSTIC_TEST|Diagnostic Test|there is no intervention
58476056|NCT04030143|DRUG|Aripiprazole|Administered as an intramuscular (IM) depot injection.
58476057|NCT04030143|DRUG|Aripiprazole|Administered as an IM depot injection.
58476058|NCT04069234|DRUG|Ticagrelor|ticagrelor 60 mg BID for 30 days
58476059|NCT04069234|DRUG|Clopidogrel|clopidogrel 75mg OD for 30 Days
58476060|NCT02949336|RADIATION|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
58476061|NCT05469386|DRUG|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
58476062|NCT05469386|BEHAVIORAL|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
58476063|NCT05469386|DRUG|Placebo|Placebo capsule
58476064|NCT05469386|BEHAVIORAL|General Classroom|General education classroom procedures
58476065|NCT05469386|BEHAVIORAL|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
58476066|NCT01801163|DRUG|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
58476067|NCT01801163|RADIATION|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
58476068|NCT02124369|DRUG|Abraxane|125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
58476069|NCT02124369|DRUG|Gemcitabine|1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
58476070|NCT01843621|BIOLOGICAL|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
58476071|NCT05413759|OTHER|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
58476072|NCT01001221|DRUG|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1"
58476073|NCT01001221|DRUG|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1."
58476074|NCT05710224|BIOLOGICAL|V181|0.5 mL SC dose of V181
58476075|NCT05710224|BIOLOGICAL|Butantan-DV|0.5 mL SC dose of Butantan-DV
58476076|NCT03056092|DRUG|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
58476077|NCT03479255|BEHAVIORAL|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.
58476078|NCT03479255|BEHAVIORAL|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
58476079|NCT02991222|DRUG|SPARC001 type I|Treatment type I
58476080|NCT02991222|DRUG|SPARC001 type II|Treatment type II
58476081|NCT02991222|DRUG|Reference001 type I|Hydrocodone-Acetaminophen
58476082|NCT02991222|DRUG|Reference001 type II|Hydrocodone-Acetaminophen
58476083|NCT00620451|DRUG|larazotide acetate|gelatin capsule
58476084|NCT00620451|DRUG|placebo|gelatin capsule
58476085|NCT03706755|DRUG|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
58476086|NCT03706755|DRUG|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
58476087|NCT04475367|OTHER|App hypercross group|hypertensive patients using HyperCrossApp
58476088|NCT04475367|OTHER|without App hypercross group|Interdisciplinary health care
58476089|NCT01451112|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
58476090|NCT06577155|DRUG|Levobupivacaine|Regional anesthesia / analgesia
58476091|NCT06577155|DRUG|Levobupivacaine plus nalbuphine|Regional anesthesia / analgesia
58476092|NCT03299166|DRUG|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
58476093|NCT03299166|DRUG|Placebo|Matching capsule once daily (QD)
58476094|NCT02835248|OTHER|Fall Detection|All participants will wear a device configured to detect falls.
58476095|NCT03629977|DEVICE|CRRT|Continuous Renal Replacement Therapy
58133975|NCT05299047|OTHER|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
58476096|NCT00696072|DRUG|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
58476097|NCT00696072|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
58476098|NCT02017405|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
58476099|NCT02017405|OTHER|Matching Placebo|
58476100|NCT05855798|DRUG|Bupivacain|Bupivacaine is a local anesthetic agent commonly used in ESP block.
58476101|NCT05855798|DRUG|Magnesium sulfate|Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
58476102|NCT05855798|DRUG|Ketamine Hydrochloride|Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
58476103|NCT00004563|DRUG|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
58476104|NCT00004563|DRUG|Placebo|Matching gelcaps 25 mgs
58476105|NCT03960749|DEVICE|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
58476106|NCT03960749|DEVICE|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
58476107|NCT03960749|DEVICE|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
58476108|NCT03960749|DEVICE|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
58476109|NCT03960749|DEVICE|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
58476110|NCT03960749|DEVICE|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
58476111|NCT06603025|OTHER|chewing gum|Preoperative intervention group patients will chew sugarless gum for at least 30 minutes 30-60 minutes before surgery. The gum will be removed before going to the operating room.
58476112|NCT02799446|DRUG|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
58476113|NCT02799446|DRUG|Placebo|Matching Placebo intravenous (IV)
58476114|NCT04123470|GENETIC|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
58476115|NCT04123470|BIOLOGICAL|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
58476116|NCT04207814|BIOLOGICAL|biological sample|biological samples will be taken from the subjects included
58476117|NCT03745612|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
58476118|NCT03745612|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
58476119|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
58476120|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
58476121|NCT06593782|DRUG|Dolasetron|"1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
58476122|NCT06597084|DRUG|ESL 800 mg|800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
58476123|NCT06597084|DRUG|Placebo|Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
58476124|NCT04423666|BEHAVIORAL|Walking using a wireless pedometer|See arm/group
58476125|NCT00736021|DRUG|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
58476126|NCT06602310|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application. Telematic non-face-to-face preoperative assessment.
58476127|NCT05132556|OTHER|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
58476128|NCT03852056|DRUG|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
58476129|NCT03852056|DRUG|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
58476130|NCT06599788|BEHAVIORAL|Self-paced work|Participants will choose their own pace during the box-lifting protocol
58476131|NCT06599788|BEHAVIORAL|Reduced-pace work|Participants will work at a 25% reduced pace during the box-lifting protocol
58476132|NCT06599788|BEHAVIORAL|Increased-pace work|Participants will work at a 25% increased pace during the box-lifting protocol
58476133|NCT06599788|BEHAVIORAL|Additional rest breaks|Participants will choose their own pace during the box-lifting protocol and have superimposed 5 minutes of rest every 15 minutes.
58476134|NCT02085967|DRUG|rifampin 600 mg|
58476135|NCT02085967|DRUG|itraconazole 200 mg|
58476136|NCT02085967|DRUG|midazolam 2 mg with bupropion 75 mg|
58476137|NCT02085967|DRUG|E2006|
58476138|NCT03013231|BEHAVIORAL|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
58476139|NCT01342861|DIETARY_SUPPLEMENT|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
58476140|NCT06429280|DEVICE|N/A this is an observational study of Standard of Care|Medical Device which treats unilateral amblyopia through therapeutic software which stimulate vision
58476141|NCT05625113|DEVICE|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
58476142|NCT03544749|DEVICE|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
58476143|NCT03544749|DEVICE|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
58476144|NCT00896077|DRUG|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
58476145|NCT02086578|DEVICE|Breast MRI|
58476146|NCT02086578|BEHAVIORAL|Breast-Q© questionnaire|
58476147|NCT02086578|RADIATION|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
58476148|NCT00464633|DRUG|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
58476149|NCT04777331|DRUG|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
58476150|NCT04777331|DRUG|Placebo|Prasinezumab placebo will be administered to participants.
58476151|NCT06587945|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral Nicotinamide Riboside, 2g daily for 4 weeks followed by 1g daily for 16 weeks
58476152|NCT06587945|OTHER|Placebo|Matched placebo
58476153|NCT06587945|PROCEDURE|Vitrectomy and Gas tamponade|Standard of care Vitrectomy surgery for retinal reattachment
58476154|NCT05122338|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
58476155|NCT05122338|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
58476156|NCT05122338|DRUG|Compound lidocaine|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
58476157|NCT05122338|DRUG|Esketamine|Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
58476158|NCT06591832|OTHER|Exercise|Virtual reality based progressive relaxation exercise
58476159|NCT06519942|DIAGNOSTIC_TEST|Blood sampling|Fasting blood samples will be obtained.
58476160|NCT06519942|DIAGNOSTIC_TEST|Electromyoneurography (EMNG)|Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
58476161|NCT06519942|PROCEDURE|Muscle biopsy|Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
58476162|NCT06519942|RADIATION|Quantitative peripheral computed tomography (qPCT)|A qPCT scan of the calf will be performed.
58476163|NCT06519942|DEVICE|Mechanography|Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
58476164|NCT06519942|DIAGNOSTIC_TEST|Electrocardiography (ECG)|A 15-minute resting ECG will be performed.
58476165|NCT06519942|OTHER|Questionnaires|Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
58476166|NCT06519942|OTHER|Anthropometry|Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.
58476167|NCT03865979|DEVICE|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
58476168|NCT00307710|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
58476169|NCT06594861|OTHER|No intervention|No intervention.
58476170|NCT06204757|OTHER|questionary|questionary relating to birth trauma are completed by midwives and patients
58476171|NCT06585852|DRUG|RGD|Study group main material
58476172|NCT06585852|DRUG|Xenograft|Scaffold material of choice
58476173|NCT06585852|PROCEDURE|Split crest technique|Piezoelectric surgery
58476174|NCT03546686|DRUG|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
58476175|NCT03546686|PROCEDURE|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
58476176|NCT03546686|PROCEDURE|Breast Surgery|Standard-of-care definitive surgery.
58476177|NCT03546686|DRUG|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
58476178|NCT03546686|DRUG|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
58133976|NCT01052116|DRUG|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
58476179|NCT01374438|DRUG|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
58476180|NCT01374438|DRUG|Placebo|Placebo capsules given once daily for 90 days
58476181|NCT03583892|DRUG|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
58476182|NCT02431637|BIOLOGICAL|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
58476183|NCT02431637|DRUG|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
58476184|NCT03051178|DEVICE|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
58476185|NCT06125041|DRUG|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
58476186|NCT06587022|RADIATION|Target volume delineation|Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
58476187|NCT01114243|DEVICE|Ultrasound imaging|
58476188|NCT04125927|DRUG|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
58476189|NCT04084236|DEVICE|electrical stimulation|electrical stimulation
58476190|NCT04084236|DEVICE|Sham|no stimulation
58133977|NCT01052116|DRUG|Placebo|Placebo
58476191|NCT01941810|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|Given PO
58476192|NCT01941810|OTHER|questionnaire administration|Ancillary studies
58476193|NCT01941810|PROCEDURE|quality-of-life assessment|Ancillary studies
58476194|NCT01941810|OTHER|laboratory biomarker analysis|Correlative studies
58476195|NCT02749422|DIAGNOSTIC_TEST|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
58476196|NCT04900116|DRUG|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
58476197|NCT04900116|DRUG|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
58476198|NCT04900116|DRUG|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
58476199|NCT04900116|DRUG|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
58476200|NCT05574387|DRUG|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
58476201|NCT05788770|OTHER|FEops HEARTGuide|FEops HEARTGuide added to routine preoperative CT imaging. Results of the computer modelling will be discussed with TAVR implanting team prior to and during the procedure.
58476202|NCT03530215|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
58476203|NCT06422819|OTHER|Heart rate variability Biofeedback [HRV-BFB]|"Biofeedback (BFB), sometimes referred to as biological feedback technique, is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population."
58476204|NCT06422819|OTHER|Pseudo HRV-BFB|The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.
58476205|NCT04276896|BIOLOGICAL|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
58476206|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
58476207|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
58476208|NCT03100149|DRUG|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
58476209|NCT03067077|PROCEDURE|SMILE|SMILE surgery
58476210|NCT03067077|PROCEDURE|LASIK|LASIK surgery
58476211|NCT06603480|BEHAVIORAL|Exercise|Aerobic exercise (moderate intensity) at 50-70% of maximum heart rate for 60 minutes, 3 days a week for 12 weeks
58476212|NCT06603480|OTHER|Metformin|Patients who started Metformin 2\*1
58476213|NCT06599593|DIETARY_SUPPLEMENT|SQ-LNS|CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories).
58476214|NCT06599593|OTHER|Integrated Nutritional Screening|In conjunction with SMC administration, CHWs screen children for MUAC. CHW refers children with MUAC \&lt;12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.
58476215|NCT05800080|DRUG|Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
58476216|NCT01052727|PROCEDURE|Laparoscopic Cholecystectomy|
58476217|NCT05899426|OTHER|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 2 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
58476218|NCT05899426|OTHER|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
58476219|NCT01456039|DRUG|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
58476220|NCT05809557|OTHER|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
58476221|NCT05809557|OTHER|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
58476222|NCT03806361|PROCEDURE|Fat grafts supplemented with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
58476223|NCT03806361|PROCEDURE|Structural fat grafting|Fat grafts without supplementation of ADRC
58476224|NCT01217229|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
58476225|NCT06507111|DIETARY_SUPPLEMENT|Lab4P|"Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20 and Bifidobacterium animalis subsp. lactis CUL-34 at a dose of 50 billion bacteria per/ day combined with vitamin C (80 mg/day), Vitamin D (400 IU/day) and Zinc (10 mg/day) on a microcrystaline cellulose (MCC) base~Daily dose: 50 billion bacteria per day"
58476226|NCT06507111|OTHER|Placebo|MCC alone
58133978|NCT05655832|DEVICE|Vivalink wearable device|a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
58476227|NCT02961894|DEVICE|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
58476228|NCT03217604|DRUG|Placebo|Treatment with placebo
58476229|NCT03217604|DRUG|PF-06852231|Treatment with PF-06852231
58476230|NCT06655051|DEVICE|endoscopic retrograde biliary drainage (single plastic stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A single plastic stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
58476231|NCT06655051|DEVICE|endoscopic retrograde biliary drainage ( fully covered self-expanding metal stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A fully covered self-expanding metal stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
58476232|NCT04530617|DRUG|Camostat Mesilate|Tablets
58476233|NCT04530617|DRUG|Artemisia Annua Leaf|Tea bags
58476234|NCT05423210|COMBINATION_PRODUCT|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
58476235|NCT04558619|BEHAVIORAL|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
58476236|NCT01748292|DRUG|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
58476237|NCT01632696|DRUG|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
58476238|NCT06654128|DIAGNOSTIC_TEST|artificial intelligence|patients will undergo tandem colonoscopy with artificial intelligence
58476239|NCT03609073|DEVICE|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
58476240|NCT04502095|DRUG|Clindamycin|Given PO
58476241|NCT04502095|OTHER|Diary|Complete drug diary
58476242|NCT04502095|DRUG|Ertapenem|Given PO
58476243|NCT04502095|DRUG|Levofloxacin|Given PO
58476244|NCT04502095|DRUG|Nitrofurantoin|Given PO
58476245|NCT04502095|DRUG|Trimethoprim-Sulfamethoxazole|Given PO
58476246|NCT04013997|DEVICE|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
58476247|NCT06601595|DRUG|TNF inhibitors|tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
58476248|NCT06601595|DRUG|conventional ibd medical treatment|Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
58476249|NCT03800992|OTHER|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
58476250|NCT05855707|BIOLOGICAL|WJ-MSC infusion|cellular therapy
58476251|NCT04080505|DRUG|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
58133979|NCT05915403|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire|diagnostic tests
58133980|NCT05124184|DEVICE|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
58133981|NCT05124184|DEVICE|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
58133982|NCT00305045|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
58476252|NCT02360254|DRUG|Insulin degludec|Once daily injection of insulin degludec
58133983|NCT02194998|DRUG|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
58133984|NCT02194998|DRUG|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
58476253|NCT04475146|OTHER|video vizualisation|video vizualisation
58476254|NCT06586645|BEHAVIORAL|Safety Planning|Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.
58476255|NCT06586645|BEHAVIORAL|Give to Others Module|"The Give to Others Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief phone follow-up."
58476256|NCT06603766|DRUG|IV Magnesium Sulfate|MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
58476257|NCT06603766|DRUG|Inhalational magnesium sulfate|It gives us the same mechanism of action as IV MgSO4 with less side effects.
58476258|NCT03730753|DEVICE|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
58476259|NCT03730753|DEVICE|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
58476260|NCT05930223|DRUG|VAL-1221|VAL-1221 20mg/kg intravenous (IV) infusion every other week
58476261|NCT02515370|OTHER|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
58476262|NCT01473888|DRUG|T89(Dantonic)|capsule, 225mg B.I.D.
58476263|NCT06414369|OTHER|Diathermy|A DT equipment (CET 400 VA - RET 130 Watts - Winback, France), with a frequency of 500 kHz and intensity at 40% will be used. It will be applied utilizing a flat capacitive head 4 cm in diameter. It will be applied using longitudinal and transverse movements and a conductive cream for DT. DT will be used over the TP of the right and left trochanteric prominence. The settings will be calibrated so that patients fell no more than mild warmth during the treatment.
58476264|NCT06414369|OTHER|Simulated Diathermy|This same intervention that has been given to the experimental group, will be simulated as placebo in the control group; the DT will not be activated during administration.
58476265|NCT06595797|DRUG|HRS9531|HRS9531
58476266|NCT06595797|DRUG|HRS9531placebo|HRS9531placebo
58476267|NCT04611646|BEHAVIORAL|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
58476268|NCT04611646|BEHAVIORAL|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
58476269|NCT06587841|DEVICE|Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)|The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
58476270|NCT04857476|DIAGNOSTIC_TEST|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
58476271|NCT04029636|OTHER|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
58476272|NCT03889808|DIAGNOSTIC_TEST|Determination of serum anti-toxin Abs for C. difficile|
58476273|NCT00524836|DRUG|levocetirizine dihydrochloride|
58476274|NCT05005234|DRUG|GFH925|Administered as an oral tablet formulation
58476275|NCT05196152|BEHAVIORAL|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
58476276|NCT05196152|BEHAVIORAL|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
58476277|NCT04257357|BEHAVIORAL|8-weeks supervised exercise program|Please refer to group description
58476278|NCT04257357|BEHAVIORAL|Active control|Please refer to group description
58476279|NCT06594198|DEVICE|Cerebral monitor|The study procedure consists of monitoring the values of 3 cerebral parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor. These 3 parameters will be recorded and compared after the intervention with 3 parameters considered as standard: SctO2 measured by the INVOS 7100 cerebral oximeter, the bispectral index (BIS) measured by the BIS monitor and the ANI measured by the MDoloris monitor. These 3 reference parameters are once again usually monitored and recommended for all cardiac surgery.
58476280|NCT06590259|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.
58476281|NCT06590259|DRUG|Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab|Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
58476282|NCT01670344|PROCEDURE|Treatment with investigational method (virtual implant positioning system)|
58476283|NCT01670344|PROCEDURE|Treatment with surgical standard of care|
58490979|NCT02516852|OTHER|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
58490980|NCT01757925|BEHAVIORAL|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
58490981|NCT01757925|OTHER|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
58476284|NCT03371667|DRUG|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
58476285|NCT03371667|DRUG|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
58476286|NCT00406250|DRUG|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
58476287|NCT00406250|DRUG|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
58476288|NCT06591559|DEVICE|Permobil Explorer Mini|The Explorer Mini (Permobil AB, Sweden) is a commercially available, FDA approved powered mobility device intended for young children between 12-36 months of age with mobility limitations (weight limit: 35 lbs; height limit: 39.4 inches). It is lightweight (52 lbs. including battery) and fits in most automobiles (length: 25 inches; width: 19 inches; adjustable height: 29-37 inches). The Explorer Mini runs on a 12-volt battery with a driving range of 3.5 miles and a maximum speed of 1.5 mph, is controlled via a joystick with a 360-degree turning radius, has proportional speed control with 5 speed options, and can be used in a seated or standing position.
58476289|NCT06591559|DEVICE|Portable Mobility Aid for Children (PUMA)|The Portable Mobility Aid for Children (PUMA; Enliten LLC) is a portable canopy system that utilizes an overhead support rail structure and a counterweight. The rail structure consists of two rigid parallel beams that mount to the canopy structure and one perpendicular mobile beam that allows for freedom of movement in one direction. Freedom of movement in the opposite direction is achieved by a system of pulleys along the movable beam that connects the harness to a counterweight. The counterweight provides a passive vertical force, counteracting gravity. The PUMA provides 2-dimensional mobility support over 81 ft2 (9 ft x 9 ft). The overhead bar is connected at 4 points to a child-worn harness. Children are free to move through many postures including sitting, crawling, standing, and walking.
58476290|NCT05283031|DIAGNOSTIC_TEST|Modified Diurnal Tension Curve|The modified diurnal tension curve (mDTC), an alternative that involves IOP measurements every 2 or 3 hours during office hours, is more feasible and may provide better information regarding the IOP profile than single IOP measurements.
58476291|NCT06428968|DRUG|160 units nasal insulin spray|Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.
58476292|NCT05408741|OTHER|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
58476293|NCT05408741|OTHER|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
58476294|NCT03928184|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
58476295|NCT03928184|DRUG|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
58476296|NCT05419895|BEHAVIORAL|Early Diagnostic Response Model (EDRM)|Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
58476297|NCT06477120|BEHAVIORAL|Time Restricted Eating|The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
58476298|NCT06587451|DRUG|JPB898 (Induction and Maintenance)|Induction and Maintenance: Intravenous (IV)
58476299|NCT06587451|DRUG|Opdivo-EU (Induction)|Induction: Intravenous (IV)
58476300|NCT06587451|DRUG|Opdivo-US (Induction)|Induction: Intravenous (IV)
58476301|NCT06587451|DRUG|Yervoy-EU (Induction)|Induction: Intravenous (IV)
58476302|NCT06587451|DRUG|Opdivo-EU (Maintenance)|Maintenance: Intravenous (IV)
58476303|NCT02731586|DRUG|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
58476304|NCT03104127|DEVICE|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
58476305|NCT03104127|OTHER|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
58476306|NCT00084071|DRUG|Tifacogin|
58476307|NCT05955716|DEVICE|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
58476308|NCT02851277|DRUG|ASP0892 Intradermal|Intradermal injection
58476309|NCT02851277|DRUG|ASP0892 Intramuscular|Intramuscular injection
58476310|NCT02851277|DRUG|Placebo Intradermal|Intradermal injection
58133985|NCT02194998|DRUG|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
58133986|NCT04280757|PROCEDURE|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
58476311|NCT02851277|DRUG|Placebo Intramuscular|Intramuscular injection
58476312|NCT05189717|DRUG|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
58476313|NCT06603896|OTHER|Aromatherapy|Aromatherapy and placebo patches will be used
58476314|NCT05087706|DRUG|Pyrotinib|Pyrotinib 400mg qd po
58476315|NCT05087706|DRUG|Bicalutamide|Bicalutamide was administered orally at a daily dose of 50 mg
58476316|NCT05087706|DRUG|Leuprorelin|Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
58476317|NCT02269969|DRUG|Tobramycin|
58476318|NCT01479296|BIOLOGICAL|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
58476319|NCT01479296|BIOLOGICAL|rAd5 env A|Given intramuscularly
58476320|NCT01479296|BIOLOGICAL|rAd5 env B|Given intramuscularly
58476321|NCT01479296|BIOLOGICAL|rAd5 env C|Given intramuscularly
58476322|NCT01479296|BIOLOGICAL|rAd5 gag-pol|Given intramuscularly
58476323|NCT01479296|BIOLOGICAL|Placebo Vaccine|Given intramuscularly
58476324|NCT03422900|DIETARY_SUPPLEMENT|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
58476325|NCT03422900|DIETARY_SUPPLEMENT|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
58476326|NCT05784480|DIAGNOSTIC_TEST|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
58476327|NCT05705934|OTHER|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
58476328|NCT04403334|DRUG|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
58476329|NCT04403334|DRUG|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
58476330|NCT06654154|DIAGNOSTIC_TEST|variation of serum level vitamine B12|"There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture"
58476331|NCT05135767|BEHAVIORAL|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
58476332|NCT03715114|DRUG|GV-971|Oral GV-971
58476333|NCT03715114|DRUG|Placebo|Oral Placebo
58476334|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
58476335|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
58476336|NCT03697148|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
58476337|NCT02631408|DRUG|Vancomycin|Locally, intrawound applied vancomycin powder
58476338|NCT04317287|DIETARY_SUPPLEMENT|Cardio formulation|Tomato-based formulation with dietary supplement softgels
58476339|NCT04317287|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
58476340|NCT04119115|DEVICE|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
58476341|NCT04119115|OTHER|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
58133987|NCT06196801|DRUG|Triple-combination therapy|phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
58133988|NCT00912353|DRUG|AZD7268|Single Oral
58476342|NCT04944992|DRUG|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
58476343|NCT04944992|DRUG|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
58476344|NCT01706133|OTHER|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
58476345|NCT01883258|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
58490982|NCT00473382|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
58490983|NCT00473382|DRUG|Sham injection|
58476346|NCT01883258|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
58476347|NCT00502476|PROCEDURE|Bathing with Chlorhexidine Impregnated Washcloths|
58476348|NCT06604156|DEVICE|EEG monitoring|During gastrointestinal endoscopy, electroencephalogram (EEG) monitoring will be conducted using qCON and qNOX technologies to assess patients\&amp;amp;#39; sedation and analgesia status while they undergo painless gastrointestinal endoscopy. This will be combined with visual assessments (such as cough reflex, respiratory depression, and limb movement) and clinical physiological monitoring (including vital signs and pulse oximetry) to explore and establish a stable and optimal depth of sedation for anesthesia.
58476349|NCT06600360|OTHER|Teledentistry|Measuring the accuracy of the mobile photographic method of teledentistry for dental caries diagnosis and treatment need
58476350|NCT02309346|DRUG|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
58476351|NCT06313307|COMBINATION_PRODUCT|topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.
58476352|NCT06313307|DEVICE|Thulium 1927-nm Fractional Laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
58476353|NCT02850653|BIOLOGICAL|PCR : 16S ribosomal DNA and real-time targeted PCR|
58476354|NCT02850653|BIOLOGICAL|Sampling of aqueous humour|
58476355|NCT06595329|PROCEDURE|Epidural analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned puncture. The epidural space will be identified at the level of the tenth thoracic intervertebral space using the loss of resistance technique and an 18G Tuohy epidural needle. After placing the epidural catheter, 4 ml of local anesthetic Levobupivacaine 0.25% will be administered into the epidural space. After inducing general anesthesia, an additional 4 ml of Levobupivacaine 0.25% will be administered before the surgical incision. Subjects in the control group will receive an infusion of 0.125% Levobupivacaine for 24 hours after the procedure.
58476356|NCT06595329|PROCEDURE|Intrathecal opioid analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned intrathecal puncture. Subsequently, at the selected site, the dura will be punctured using a spinal needle (25G Quincke spinal needle), and 0.3 mg of morphine will be administered to the patient. Following the intervention, the patient will be induced into general anesthesia.
58476357|NCT05121272|BEHAVIORAL|cognitive task|cognitive task
58476358|NCT06104826|DRUG|Emicizumab|Emicizumab in Hemophilia A
58476359|NCT05972655|RADIATION|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
58476360|NCT05972655|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
58476361|NCT05972655|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
58476362|NCT05972655|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
58476363|NCT06078501|DRUG|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
58476364|NCT06078501|DRUG|Placebo|Placebo buccal administration 2-3 hours prior to procedure
58476365|NCT04739761|DRUG|Trastuzumab Deruxtecan|Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
58476366|NCT00000996|DRUG|Doxorubicin hydrochloride|
58476367|NCT00361296|BIOLOGICAL|K562/GM-CSF cell vaccine|
58476368|NCT00117351|DRUG|VELCADE|
58476369|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58133989|NCT00912353|DRUG|Placebo|Single Oral
58476370|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476371|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476372|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58476373|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476374|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476375|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476376|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476377|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58476378|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476379|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58476380|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476381|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476382|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58476383|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476384|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
58476385|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
58476386|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
58476387|NCT05271240|DRUG|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
58476388|NCT05271240|DRUG|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
58476389|NCT03902444|DEVICE|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
58476390|NCT04719078|DIAGNOSTIC_TEST|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
58476391|NCT01393821|DRUG|menadione topical lotion|Given topically
58476392|NCT01393821|OTHER|placebo|Given topically
58476393|NCT01393821|OTHER|questionnaire administration|Ancillary studies
58476394|NCT01393821|PROCEDURE|management of therapy complications|Given menadione topical lotion
58476395|NCT06601023|BEHAVIORAL|Psychosocial intervention|The PM+MiLE is a low-intensity intervention. The intervention will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The problem management ambit will include understanding adversity, managing stress, managing problems, getting going and keep doing, strengthening social support and staying well and looking forward, including positive behaviour modification.The intervention will also incorporate child development and building positive parenting interactions with children.
58476396|NCT04011046|DEVICE|Stent|
58476397|NCT03574584|DRUG|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
58476398|NCT03574584|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
58476399|NCT03574584|DRUG|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
58476400|NCT06603922|BEHAVIORAL|Psychological treatment (P-MCT)|Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.
58476401|NCT06603922|BEHAVIORAL|Psychological treatment (MCT)|"Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center."
58476402|NCT06587503|BIOLOGICAL|BioNTech - Pfizer COVID-19 vaccine|Vaccine for protection from COVID-19
58476403|NCT06587503|BIOLOGICAL|1mL saline solution|Placebo
58476404|NCT06587503|BIOLOGICAL|rVSV∆G-ZEBOV-GP|Vaccine for protection from Zaire Ebola virus
58476405|NCT02113982|DRUG|Tagraxofusp|
58476406|NCT04051424|DEVICE|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
58476407|NCT04051424|DEVICE|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
58476408|NCT04051424|DEVICE|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
58476409|NCT01069003|DRUG|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
58476410|NCT01069003|DRUG|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
58476411|NCT01069003|DEVICE|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
58476412|NCT06245954|OTHER|simulated training|Simulation training of bronchoscopists by means of simulators and extracorporeal lungs
58476413|NCT06245954|OTHER|traditional bedside teaching|TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
58476414|NCT01452698|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
58490984|NCT04786535|PROCEDURE|Expanded Hemodialysis|"* Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
58476415|NCT01452698|DRUG|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
58476416|NCT01452698|DRUG|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
58476417|NCT01452698|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
58476418|NCT06109896|OTHER|Self Report Questionaires|Collection and analysis of information from patient self-report assessments and integration with clinical information from assessments performed routinely during cancer treatment.
58476419|NCT04533503|DEVICE|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
58476420|NCT06542835|BEHAVIORAL|Video text message|Video text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.
58476421|NCT06542835|BEHAVIORAL|In-clinic CRC screening promotion|Stool-test orders, colonoscopy referrals.
58476422|NCT06542835|BEHAVIORAL|Mailed FIT|Mailed FIT kits.
58476423|NCT06542835|BEHAVIORAL|Social needs navigation|Patient navigation to address social needs.
58476424|NCT06542835|BEHAVIORAL|Reminders|Centralized text and/or telephone reminders for ordered tests.
58476425|NCT02083900|DEVICE|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
58476426|NCT02083900|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
58476427|NCT06214689|OTHER|biomarkers analysis|IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
58476428|NCT05174416|DRUG|Mavacamten|Mavacamten Capsules
58476429|NCT05174416|DRUG|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
58476430|NCT06604559|OTHER|Discharge using Apollo application|Discharge using Apollo application
58476431|NCT06604559|OTHER|Regular discharge|Discharge with the regular process
58476432|NCT06597071|OTHER|NeuraLight PD|NeuraLight software-based platform for PD patients
58476433|NCT06597071|OTHER|NeuraLight PSP|NeuraLight software-based platform for PSP patients
58476434|NCT06597071|OTHER|NeuraLight MSA|NeuraLight software-based platform for MSA patients
58476435|NCT06597071|OTHER|NeuraLight|NeuraLight software-based platform
58476436|NCT06594471|OTHER|Questionnaire on late-term physical effects|Patients will be asked to indicate any potential late-term physical effects following cancer treatment: neurocognitive, auditory, ocular, oral/dental, dermatologic, cardiovascular, pulmonary, gastro-intestinal, urinary tract, genital, endocrine/metabolic, musculoskeletal, neurological, immune disorders and occurrence of any subsequent malignant neoplasms.
58476437|NCT06594471|OTHER|Questionnaire on sexual and reproductive health outcomes|Patients will be asked to complete the following questionnaires: Body Appreciation Scale-2 (BAS-2), Body Image Scale (BIS), EORTC QLQ-SH22, Body Image Scale in Gynecological Cancer (SABIS-G). Patients who underwent a fertility-sparing procedure will be asked to fill out the Reproductive Concerns after Cancer (RCAC) and Decision Regret Scale (DRS), whereas those who experienced iatrogenic menopause will complete the MENQOL questionnaire to assess menopause-related quality of life.
58476438|NCT06594471|OTHER|Questionnaire on psychological outcomes|Patients will be asked to complete the following questionaires: EORTC QLQ-C30, Clinical outcomes in Routine Evaluation (CORE-OM), Ten Item Personality Inventory (TIPI), Hospital Anxiety and Depression Scale (HADS), General Self-Efficacy (GSE) Scale, Mini-Mental Adjustment to Cancer (Mini-MAC), Cancer Worry Scale (CWS), Multidimensional Scale of Perceived Social Support (MSPSS), the Patient Health Engagement scale and the Supportive Care Needs Survey-Short Form (SCNS-SF34).
58476439|NCT06594471|OTHER|Questionnaire on social outcomes|Patients will be asked to complete the following questionaires: Medical Consumption Questionnaire (iMCQ), Productivity Cost Questionnaire (iPCQ) and the Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire.
58476440|NCT02584686|DRUG|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
58476441|NCT02584686|DRUG|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
58476442|NCT04263285|DEVICE|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
58476443|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
58476444|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
58476445|NCT03742557|DRUG|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
58490985|NCT04786535|PROCEDURE|High-flux Conventional Hemodialysis|"* Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
58476446|NCT05104112|OTHER|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
58476447|NCT06604403|OTHER|Massage|After the hemodialysis, the patients will receive a 15-20 minute hand and foot massage. This application will be applied to the patients in two weekly dialysis sessions for a total of 8 sessions for four weeks. Before starting the massage applications, the patient's hands and feet will be washed and dried thoroughly. The patients will be given a semi-sitting or lying position that they can feel comfortable in. Before starting the hand and foot massage, the researcher will gently rub and warm their hands and wrists. The massages will start with a hand massage. A foot massage will be performed after the hand massage. 3-5 drops of baby oil applied at room temperature will be used to reduce friction during the massage. Effleurage, petrissage and friction styles of the massage will be applied.
58476448|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
58476449|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
58476450|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
58476451|NCT03545555|DIETARY_SUPPLEMENT|Placebo|Effect of placebo on lipid status
58476452|NCT06592989|DRUG|sorafenib, gefitinib|Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
58476453|NCT04537624|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
58476454|NCT05613140|DRUG|sacubitril/valsartan|Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
58476455|NCT06592131|DRUG|BF844|BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
58476456|NCT06521398|OTHER|Doula Support|Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
58476457|NCT04874025|DRUG|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
58476458|NCT01222689|DRUG|erlotinib hydrochloride|Given PO
58476459|NCT01222689|DRUG|selumetinib|Given PO
58476460|NCT01222689|OTHER|laboratory biomarker analysis|Correlative studies
58476461|NCT04269668|DEVICE|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
58476462|NCT04269668|DEVICE|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
58476463|NCT05701189|DRUG|Efgartigimod Alfa-Fcab|Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
58476464|NCT05701189|DRUG|Intravenous Immunoglobulin (IVIg)|IVIg is the standard-of-care treatment for GBS.
58476465|NCT02889952|DEVICE|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
58476466|NCT01256788|DEVICE|Euflexxa|4 injections of 2ml of Euflexxa
58476467|NCT01256788|OTHER|Saline|4 injections of 3 ml of sterile saline
58476468|NCT02757235|PROCEDURE|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
58476469|NCT02757235|PROCEDURE|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
58476470|NCT01806441|OTHER|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
58476471|NCT01806441|OTHER|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
58476472|NCT03729739|DIAGNOSTIC_TEST|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
58476473|NCT03729739|DIAGNOSTIC_TEST|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
58476474|NCT06598566|OTHER|Nottingham Hip Fracture Score (NHFS) score|Nottingham Hip Fracture Score (NHFS) score in patients above 60 years undergoing hip fracture surgery.
58476475|NCT06598566|OTHER|Acute Physiology and Chronic Health Evaluation (APACHE)-II score|Acute Physiology and Chronic Health Evaluation (APACHE)-II score in patients above 60 years undergoing hip fracture surgery
58490986|NCT04786535|PROCEDURE|Hemodiafiltration|"* Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
58476476|NCT06586307|OTHER|quantitative analysis of DNA methylation at single-base resolution (QASM)|qPCR-based quantitative analysis for single-base methylation (QASM) The methylation percentage of each candidate CpG site was determined in multiple cohorts using a MethyLight-based QASM assay that has been developed and validated in our previous work. In short, the bisulfite-converted DNA was amplified, in which we exploited the locus-specific PCR primers flanking a pair of methylated and unmethylated probes labeled with the fluorescent dyes 6-carboxyfluorescein (6-FAM) and 2-chloro-7phenyl-1,4-dichloro-6-carboxyfluorescein (VIC), respectively. The methylation percentage was calculated by methylation/(methylation+unmethylation)×100%. QASM was performed using the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (Thermo).
58476477|NCT03227913|OTHER|Two samples of saliva|"1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
58476478|NCT03227913|OTHER|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
58476479|NCT03227913|OTHER|Study of the food bolus|"* Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying"
58476480|NCT03656159|BEHAVIORAL|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
58476481|NCT03656159|BEHAVIORAL|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
58476482|NCT01263080|DRUG|mirtazapine|mirtazapine 30mg QD
58476483|NCT01263080|DRUG|folic acid placebo|folic acid placebo 1 tablet QD
58476484|NCT01263080|DRUG|mirtazapine placebo|mirtazapine placebo 1 tablet QD
58476485|NCT01263080|DRUG|folic acid|folic acid 0.4mg QD
58476486|NCT02201953|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
58476487|NCT02201953|DRUG|SOF|400 mg tablet administered orally once daily
58476488|NCT02201953|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
58476489|NCT04369404|BEHAVIORAL|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
58476490|NCT04369404|BEHAVIORAL|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
58476491|NCT04369404|BEHAVIORAL|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
58476492|NCT03659045|OTHER|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
58476493|NCT00854750|DRUG|ACTHAR|SQ weekly injections
58476494|NCT00854750|DRUG|ACTHAR|SQ weekly injections
58476495|NCT00854750|DRUG|ACTHAR|SQ weekly injections
58476496|NCT00854750|DRUG|ACTHAR|SQ weekly injection
58476497|NCT04234477|DRUG|Beta-blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
58476498|NCT04234477|DRUG|Calcium channel blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
58476499|NCT04234477|DRUG|Physician preference strategy|"This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil."
58476500|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
58476501|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
58476502|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
58476503|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
58476504|NCT00375063|PROCEDURE|Percutaneous Coronary Intervention|
58476505|NCT00375063|PROCEDURE|Coronary Artery Bypass Grafting|
58476506|NCT04804241|DRUG|Senicapoc|10 mg oral tablet
58476507|NCT04804241|OTHER|Placebo Tablet|Placebo Oral Tablet
58476508|NCT00423579|DRUG|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
58476509|NCT00423579|DRUG|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
58476510|NCT06599892|OTHER|Intervention mapping|Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
58476511|NCT01781546|PROCEDURE|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).
58476512|NCT01781546|PROCEDURE|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).
58476513|NCT06588621|OTHER|Questionnaire on physical and mental health among healthcare professionnals|Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting
58133990|NCT01406795|DEVICE|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
58133991|NCT05330754|DIETARY_SUPPLEMENT|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
58133992|NCT01931033|DRUG|Intranasal Oxytocin|
58133993|NCT04963309|OTHER|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
58133994|NCT02820922|PROCEDURE|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
58133995|NCT00487500|DEVICE|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
58133996|NCT04734665|DRUG|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
58133997|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
58133998|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
58133999|NCT00565448|DRUG|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
58134000|NCT00565448|DRUG|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
58134001|NCT00565448|DRUG|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
58134002|NCT01001208|DRUG|Methotrexate|Methotrexate tablets over-encapsulated for blinding
58134003|NCT01001208|DRUG|Etanercept|1 mL for subcutaneous injection
58134004|NCT01001208|DRUG|Placebo|Matching placebo to methotrexate capsules
58134005|NCT04420923|OTHER|Observe and Plan|First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.
58134006|NCT04420923|OTHER|Treat-and-Extend|"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."
58134007|NCT01926548|DRUG|CJ Imatinib mesylate tablet|
58134008|NCT01926548|DRUG|Gleevec film-coated tablet 2 x 100mg|
58134009|NCT00411203|DRUG|Tamoxifen Citrate|
58476514|NCT00656448|DRUG|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
58134010|NCT00411203|DRUG|Placebo|
58134011|NCT04305145|DRUG|Infliximab|Infusion
58134012|NCT04305145|DRUG|Methylprednisolone|Infusion
58134013|NCT04305145|DRUG|Prednisone|Orally
58476515|NCT01128634|DRUG|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
58476516|NCT01128634|DRUG|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
58134014|NCT03988270|OTHER|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
58134015|NCT03474510|DRUG|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
58134016|NCT03474510|OTHER|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
58134017|NCT04426799|OTHER|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
58134018|NCT05210738|DEVICE|Single incision sling|Single incision sling is used to treat occult SUI
58134019|NCT05210738|DRUG|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
58476517|NCT04565132|DEVICE|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
58490987|NCT01980667|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
58490988|NCT01980667|DRUG|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
58476518|NCT06603792|BEHAVIORAL|EEG-neurofeedback|Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.
58476519|NCT06587672|DEVICE|Micra AV implantation|Patients received Micra AV implantation
58476520|NCT02202421|BEHAVIORAL|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
58476521|NCT05994196|BEHAVIORAL|Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)|Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
58476522|NCT03604783|DRUG|TP-1287|TP-1287 by oral administration
58476523|NCT03521284|OTHER|Parental educational program|Behavior: psychotherapy, life hygiene advice
58476524|NCT03521284|OTHER|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
58476525|NCT06594692|DRUG|Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab|"Radiotherapy Protocol:~Short-course radiotherapy using three-dimensional conformal or intensity-modulated radiation therapy techniques. The radiation field will be limited to the tumor bed of the primary colon lesion, excluding surrounding draining lymph nodes and enlarged lymph nodes. The dose is fractionated as 5Gy per fraction, for a total of 25Gy over 5 fractions. Titanium clips will be placed on the proximal and distal ends of the colonic lesion via colonoscopy to guide radiation therapy positioning.~Chemotherapy Protocol (CAPOX Regimen):~1. Oxaliplatin: 130 mg/m², administered intravenously (ivgtt), on day 1 (d1).~2. Capecitabine: 1000 mg/m², orally (po), twice daily (bid), from day 1 to day 14 (d1-14).~Immunotherapy Protocol:~During preoperative treatment, Sintilimab (immune checkpoint inhibitor) will be administered concurrently with each chemotherapy cycle."
58476526|NCT06594692|DRUG|CAPOX Chemotherapy|Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
58476527|NCT02703597|BEHAVIORAL|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
58476528|NCT02703597|BEHAVIORAL|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
58476529|NCT02703597|BEHAVIORAL|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
58476530|NCT01314586|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
58476531|NCT01553890|OTHER|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
58476532|NCT00860860|DRUG|TF2|TF2: 75-300 mg
58476533|NCT00860860|DRUG|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
58476534|NCT06319690|OTHER|Lion's Breath Technique|"Patients receive training in Lion's Breath Technique, emphasizing deep diaphragmatic breathing and controlled exhalation.~Daily supervised Lion's Breath Technique sessions for 20 minutes for 1 week"
58476535|NCT06319690|OTHER|Chest Percussion Therapy|"Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week."
58476536|NCT04420234|DRUG|narfurine hydrochloride orally disintegrating tablets|Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
58476537|NCT06474832|OTHER|High-intensity interval training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform HIIT with 5 intervals at 80% heart rate reserve (HRR), each interval lasting 4 minutes, with 3-minute intervals at 40% HRR between each interval.
58134020|NCT03727568|PROCEDURE|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
58134021|NCT00591630|DRUG|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
58134022|NCT00591630|DRUG|Carmustine|300 mg/m\^2 by vein.
58134023|NCT00591630|DRUG|Etoposide|200 mg/m\^2 by vein every 12 hours.
58476538|NCT06474832|OTHER|Moderate intensity continuous training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform continuous exercise at 59% HRR for 35 minutes.
58476539|NCT05333263|DEVICE|Treadmetrix|Programmable treadmill that delivers controlled postural disturbances
58134024|NCT00591630|DRUG|Cytarabine|200 mg/m\^2 by vein every 12 hours.
58134025|NCT00591630|DRUG|Melphalan|140 mg/m\^2 by vein.
58134026|NCT00591630|DRUG|Rituximab|"Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
58134027|NCT00591630|PROCEDURE|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
58134028|NCT01652001|DRUG|Malic Acid|Oral spray for application into the oral cavity
58134029|NCT01652001|OTHER|Placebo|Oral spray for application into the oral cavity
58134030|NCT05425381|BEHAVIORAL|Enhanced version of Interconnected Systems Framework|"* District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~* Detailed memoranda of understanding between schools and collaborating mental health centers~* Community mental health clinicians meaningfully participate in MTSS teams~* Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~* Universal screening of students' social, emotional, behavioral, and academic functioning~* Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~* Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~* Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~* A Community of Practice (Wenger, 2010) among the ISFE schools"
58134031|NCT05425381|BEHAVIORAL|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"* PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai \& Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~* SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
58134032|NCT02866188|DEVICE|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
58134033|NCT04792749|DRUG|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
58134034|NCT01051570|DRUG|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
58134035|NCT01051570|DRUG|RAD 001|5 mg orally starting on Day 2 then continuous
58134036|NCT01051570|DRUG|prednisone|5 mg orally twice a day starting on Day 1 then continuous
58134037|NCT01051570|OTHER|laboratory biomarker analysis|Samples will be collected from archival tissue.
58134038|NCT01051570|OTHER|pharmacological study|Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
58134039|NCT01168505|DRUG|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
58134040|NCT06486480|PROCEDURE|Using robot assisted endoscopy to clear intraventricular hemorrhage|More advanced surgical auxiliary instruments are used to improve surgical accuracy
58134041|NCT00769964|DRUG|VA111913 TS / placebo|
58134042|NCT05227820|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
58134043|NCT05371444|BEHAVIORAL|Training with restriction of the DoF|The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
58134044|NCT05371444|BEHAVIORAL|Training without restriction of the DoF|The intrevention is based in the training of the upper extremity movements without the restriction of DoF
58476540|NCT00573508|DRUG|Placebo|Oral Administration
58476541|NCT00573508|DRUG|Solifenacin Succinate|Oral Administration
58134045|NCT05386589|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
58476542|NCT05695521|BIOLOGICAL|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
58476543|NCT05695521|OTHER|Excipient|Excipient
58476544|NCT06331819|DIAGNOSTIC_TEST|In-lab polysomnography|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
58476545|NCT06331819|DEVICE|Continuous positive airway pressure|A machine that uses air pressure to keep breathing airways open while patients sleep.
58476546|NCT06331819|DIAGNOSTIC_TEST|Home sleep study device|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
58476547|NCT01907854|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
58476548|NCT01907854|DRUG|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
58476549|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
58476550|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
58476551|NCT01151189|BIOLOGICAL|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
58476552|NCT01151189|BIOLOGICAL|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
58476553|NCT06591910|DRUG|Chemoimmunotherapy|Induction Serplulimab combined with chemotherapy
58476554|NCT06591910|PROCEDURE|Surgery|After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
58476555|NCT06591910|RADIATION|Radiation|After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.
58476556|NCT02878031|DRUG|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
58476557|NCT01961037|OTHER|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
58476558|NCT05963711|OTHER|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
58476559|NCT05895188|DEVICE|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
58476560|NCT04415372|DIAGNOSTIC_TEST|MRI|The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
58476561|NCT04415372|DIAGNOSTIC_TEST|Neuropsychological Testing|A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
58476562|NCT01895413|PROCEDURE|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
58476563|NCT06591416|PROCEDURE|minimally invasive surgical technique|minimally invasive surgical technique
58476564|NCT06591416|PROCEDURE|minimally invasive surgical technique with granulation tissue preservation|minimally invasive surgical technique with granulation tissue preservation
58476565|NCT06117618|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
58476566|NCT06117618|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
58476567|NCT00331201|DRUG|SAFEstart|
58476568|NCT06589570|DEVICE|Removable Partial Denture|A removable partial denture (RPD) is a dental prosthesis designed to replace one or more missing teeth in the mouth. Unlike full dentures, which are used when all teeth are missing, an RPD is specifically made for patients who still have some of their natural teeth remaining. It restores both function and aesthetics, allowing patients to chew, speak, and smile with greater confidence.
58476569|NCT00974792|BIOLOGICAL|pegfilgrastim|
58476570|NCT00974792|BIOLOGICAL|rituximab|
58476571|NCT00974792|DRUG|cyclophosphamide|
58476572|NCT00974792|DRUG|cytarabine|
58476573|NCT00974792|DRUG|doxorubicin hydrochloride|
58476574|NCT00974792|DRUG|etoposide phosphate|
58476575|NCT00974792|DRUG|ifosfamide|
58476576|NCT00974792|DRUG|leucovorin calcium|
58476577|NCT00974792|DRUG|methotrexate|
58476578|NCT00974792|DRUG|vincristine sulfate|
58476579|NCT00237302|DRUG|topiramate|
58476580|NCT06001918|DRUG|Nectero EAST System|Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
58476581|NCT06184022|COMBINATION_PRODUCT|Augmented reality serious game design for promoting children's science education cognition:|"The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing.~The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter, and the children's behavioral characteristics were recorded. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test. Before and after the intervention, each participant's performance on the game was recorded."
58476582|NCT06287580|DRUG|chlorthalidone 25 mg|chlorthalidone, 25 mg orally once daily
58476583|NCT06287580|OTHER|Placebo|Placebo tablet taken orally once daily
58476584|NCT00648440|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
58476585|NCT00648440|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
58476586|NCT05038098|PROCEDURE|Gastrectomy|Undergo surgery
58476587|NCT05038098|DRUG|Indocyanine Green|Given peritumorally
58476588|NCT05038098|OTHER|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
58476589|NCT05258721|DRUG|ClōSYS® Sensitive Fluoride Toothpaste|ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
58476590|NCT05258721|OTHER|ClōSYS® Sensitive Rinse|ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
58476591|NCT06600399|DIAGNOSTIC_TEST|glioblastoma|All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval
58476592|NCT06377540|DRUG|Pembrolizumab|"Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year."
58476593|NCT06377540|PROCEDURE|Autologous stem cell transplant|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
58476594|NCT06377540|DRUG|Carmustine|Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
58476595|NCT06377540|DRUG|Etoposide|Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
58476596|NCT06377540|DRUG|Cytarabine|Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
58476597|NCT06377540|DRUG|Melphalan|Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
58476598|NCT06589765|DRUG|HRS-7535 tablet|HRS-7535 tablet
58476599|NCT06589765|DRUG|dapagliflozin tablet|dapagliflozin tablet
58476600|NCT05944302|BEHAVIORAL|EMDR group|Eye Movement Desensitization and Reprocessing
58476601|NCT04718077|OTHER|Intraosseus|IO dexamethasone injection Dexamethasone 4 mg
58476602|NCT04718077|OTHER|Submucoal|SM dexamethasone injection Dexamethasone 4 mg
58476603|NCT05286749|PROCEDURE|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
58476604|NCT05286749|DEVICE|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
58134046|NCT02300090|DEVICE|Test Group|Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
58476605|NCT05286749|DIAGNOSTIC_TEST|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
58476606|NCT06604065|DRUG|AMS2434 (amino acids)|The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.
58476607|NCT06604065|DRUG|Placebo|Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
58476608|NCT03111823|BEHAVIORAL|Exercise Intervention|Undergo aerobic exercise sessions
58476609|NCT03111823|OTHER|Quality-of-Life Assessment|Ancillary studies
58476610|NCT03111823|OTHER|Questionnaire Administration|Ancillary studies
58476611|NCT04345120|DRUG|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
58476612|NCT04345120|DRUG|SY-008 matching placebo|SY-008 matching placebo
58476613|NCT03164265|BIOLOGICAL|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
58476614|NCT06351228|OTHER|Conization plus nodal evaluation|Conization plus nodal evaluation
58476615|NCT06553937|DRUG|Macitentan and Tadalafil|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
58476616|NCT06553937|DRUG|PrOpsynvi® Film-Coated Tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
58476617|NCT06655519|BIOLOGICAL|CAR-T（RD140 injection）|"This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once."
58476618|NCT05847192|DIAGNOSTIC_TEST|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.
58476619|NCT01105481|DRUG|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
58476620|NCT01105481|DRUG|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
58134047|NCT02300090|OTHER|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
58134048|NCT02465567|DRUG|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
58476621|NCT04560400|DIAGNOSTIC_TEST|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
58476622|NCT04560400|DIAGNOSTIC_TEST|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
58476623|NCT05954637|DEVICE|Optical coherence tomography|Heidelberg Engineering Spectralis
58476624|NCT02190695|DRUG|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
58476625|NCT02190695|DRUG|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
58476626|NCT02190695|DRUG|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
58476627|NCT03591406|DRUG|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
58476628|NCT03591406|DRUG|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
58476629|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
58476630|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is greater than 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.
58476631|NCT05270434|DRUG|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
58476632|NCT01817153|DRUG|hydrocortison hemisuccinate|
58476633|NCT01817153|DRUG|placebo followed by hydrocortisone hemisuccinate|
58476634|NCT00089297|BIOLOGICAL|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
58476635|NCT00089297|DRUG|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
58476636|NCT00089297|DRUG|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
58476637|NCT00089297|RADIATION|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
58476638|NCT01980563|PROCEDURE|ultrasound|
58476639|NCT01980563|PROCEDURE|combined monitoring|
58476640|NCT03846336|OTHER|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
58134049|NCT02465567|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
58134050|NCT02465567|DRUG|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
58476641|NCT03846336|OTHER|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
58476642|NCT01409707|BEHAVIORAL|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
58476643|NCT01409707|BEHAVIORAL|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
58476644|NCT01409707|BEHAVIORAL|Healthy lifestyles sessions|
58476645|NCT00535496|DRUG|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
58476646|NCT06384196|BEHAVIORAL|Identity-Based Transdiagnostic Therapy (IBTT)|In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
58476647|NCT06384196|BEHAVIORAL|Unified Protocol|In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
58476648|NCT04032301|DRUG|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
58476649|NCT04032301|OTHER|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
58476650|NCT04306276|DRUG|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
58476651|NCT04271878|OTHER|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
58476652|NCT00168584|DRUG|Vitamin A|
58476653|NCT04073173|PROCEDURE|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
58476654|NCT04073173|PROCEDURE|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
58476655|NCT04073173|DRUG|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
58476656|NCT02582775|DRUG|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
58476657|NCT02582775|DRUG|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
58476658|NCT02582775|DRUG|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
58476659|NCT02582775|RADIATION|Total Body Irradiation|See arm description for dosing.
58476660|NCT02582775|PROCEDURE|Bone marrow infusion|Bone marrow infusion on Day 0
58476661|NCT02582775|DRUG|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.
58476662|NCT02582775|DRUG|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
58476663|NCT02582775|BIOLOGICAL|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
58476664|NCT02582775|DRUG|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
58134051|NCT02465567|DRUG|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
58476665|NCT06654466|DEVICE|Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.|The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
58476666|NCT00129246|DRUG|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
58476667|NCT00129246|DRUG|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
58476668|NCT06472609|BEHAVIORAL|enhanced interactive education|The present study is a prospective randomized open-label study. Patients with diabetes mellitus who have HbA1c% more than 9% during the recent 1 year are enrolled. The intervention group receives, besides routine medical control of diabetes,enhanced interactive education program through weekly phone call for 12 weeks.
58476669|NCT00303069|BIOLOGICAL|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
58476670|NCT00303069|BIOLOGICAL|Comparator: Placebo|Single dose of saline placebo intramuscularly
58476671|NCT03212274|PROCEDURE|Biopsy|Undergo tissue biopsy
58476672|NCT03212274|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58476673|NCT03212274|PROCEDURE|Computed Tomography|Undergo a CT scan
58476674|NCT03212274|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
58476675|NCT03212274|DRUG|Olaparib|Given PO
58476676|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (neoadjuvant)|Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
58476677|NCT05724329|PROCEDURE|surgery|Standard of care
58476678|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (adjuvant)|Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
58476679|NCT06596239|DEVICE|lower-clear-plate-based intermaxillary traction (LCP-IMT)|The patient is instructed to apply elastics between the upper molar bands and the hooks on the lower clear plates.
58476680|NCT06596239|DEVICE|Removable mandibular retractor (RMR)|An appliance is worn on the upper jaw, which affects the lower jaw by using an inferiorly extended labial bow.
58476681|NCT04459884|PROCEDURE|mechanical ventilation|mechanical ventilation \> 48h
58476682|NCT04246684|DRUG|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
58476683|NCT04246684|DRUG|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
58476684|NCT04246684|DRUG|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
58476685|NCT04246684|DRUG|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
58476686|NCT04246684|DRUG|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
58476687|NCT04246684|DRUG|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
58476688|NCT04246684|RADIATION|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
58476689|NCT04246684|DRUG|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
58476690|NCT04246684|DRUG|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
58476691|NCT04246684|RADIATION|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
58476692|NCT04246684|DRUG|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
58476693|NCT04246684|DRUG|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
58476694|NCT05382845|DIAGNOSTIC_TEST|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
58134052|NCT03230149|DIAGNOSTIC_TEST|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
58476695|NCT03026595|OTHER|no intervention|no intervention
58476696|NCT03304626|DRUG|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
58476697|NCT03304626|DRUG|Standard of Care Prednisone|Prednisone taper (Standard of Care)
58476698|NCT00810563|DRUG|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
58476699|NCT00810563|DRUG|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
58476700|NCT03208829|OTHER|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
58476701|NCT03208829|OTHER|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
58476702|NCT06596707|PROCEDURE|Zirconomer|zirconia modified glass ionomer
58476703|NCT06596707|PROCEDURE|Nanohybrid composite|conventional composite
58476704|NCT02158546|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58134053|NCT00709553|DRUG|midazolam|
58134054|NCT00709553|DRUG|ZD4054|ZD4054 10 mg od
58476705|NCT02158546|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
58476706|NCT03469557|DRUG|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
58476707|NCT03469557|DRUG|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
58476708|NCT03469557|DRUG|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
58476709|NCT03469557|DRUG|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
58476710|NCT03469557|DRUG|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
58476711|NCT03891407|DIAGNOSTIC_TEST|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
58476712|NCT03923166|DRUG|Pyrotinib|400mg qd
58476713|NCT03923166|DRUG|capecitabine|capecitabine 500mg tid
58476714|NCT04271852|DEVICE|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
58476715|NCT06380621|PROCEDURE|Totally Extra Peritoneal repair (TEP) repair|TEP repair
58476716|NCT05127733|BEHAVIORAL|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
58476717|NCT05127733|BEHAVIORAL|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
58476718|NCT05127733|BEHAVIORAL|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
58476719|NCT00999102|DRUG|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
58476720|NCT00999102|DRUG|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
58476721|NCT03193957|DRUG|Etanercept|Etanercept PFS and Autoinjector
58476722|NCT03193957|DEVICE|Autoinjector|Autoinjector
58476723|NCT06070883|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
58476724|NCT06331936|BEHAVIORAL|Emotion regulation|Each participant will attend four intervention sessions. They will also be invited to a booster Session, where they will be invited for interviews to share what they have gained from the sessions. The contents of the intervention and the booster session are as follows: (1) understand emotions, (2) attention and positivity, (3) emotional regulation, (4) connectedness and intimacy, and (5) review and sharing.
58476725|NCT06003972|DRUG|Copaxone|Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
58476726|NCT06003972|DRUG|guideline directed medical therapy (GDMT)|GDMT for heart failure according to the AHA guidelines.
58476727|NCT04624126|DEVICE|3D-Erect|3D-printed erectile device for intercourse
58476728|NCT04400643|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV is software accessory that automatically adjust ventilation and oxygenation variables to keep the patient within clinician-set target ranges.
58476729|NCT04400643|DEVICE|Non-automated ventilation|In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
58476730|NCT06592157|OTHER|NewEpi Plus Liquid Wound Dressing|"1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions."
58476731|NCT06592157|OTHER|standard wound care|The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
58476732|NCT03907904|DEVICE|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
58476733|NCT00907335|DRUG|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
58476734|NCT00907335|DRUG|Vehicle control|Color-matched facial gel vehicle control used once daily
57779896|NCT06739395|DRUG|Anlotinib|Usage, dosage, and administration method: Take orally once a day before breakfast. Take the medication continuously for 2 weeks and stop taking it for 1 week, that is, 3 weeks (21 days) is one course of treatment. Until disease progression or intolerable toxic side effects occur.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
58476735|NCT04789070|DRUG|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
58134055|NCT04677764|OTHER|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
58476736|NCT04789070|DRUG|Placebo|Placebo
58476737|NCT06514950|BEHAVIORAL|Ujjayi Yogic Breathing|Participants will undergo 6 weeks of resistive yogic breathing (Ujjayi) upon exhalation (first three weeks) and upon inhalation and exhalation (second three weeks).
58476738|NCT05311709|DRUG|sotorasib|single group, all patients receive sotorasib
58476739|NCT06016309|OTHER|There is no intervention.|There is no intervention.
58476740|NCT04764071|PROCEDURE|percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.
58134056|NCT04677764|OTHER|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
58134057|NCT00507234|DRUG|formoterol fumarate inhalation solution|
58134058|NCT02107690|PROCEDURE|Low temperature lidocaine injection|4 °C
58476741|NCT04764071|PROCEDURE|ultra-mini percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
58476742|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from optoelectronic system|The raw data acquired from motion capture system were processed with Smart Analyzer software (BTS Bioengineering, Milano, Italy). First, the 3D data were filtered and interpolated in case of missing data for short time. Then spatial-temporal parameters (cycle duration, cadence, gait speed, stance phase, swing phase, double-support phase, stride length and step width) and conventional kinematic parameters of traditional Davis marker-set protocols were computed.
58476743|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from markerless system|The two videos were elaborated using OpenPose that returns a set of 25 2D keypoints coordinates for body pose estimation for each video. Key-points were located in relevant body landmarks and it were used to determine the 2D Cartesian coordinates on the sagittal plane and on the frontal plane. The data calculated with routines were filtered and interpolated in case of missing data. With respect to kinematic parameters, the segment and joint angles were measured from the estimated feature points of each joint. Spatiotemporal gait parameters were calculated using successive heel strike and toe-off events.
58476744|NCT04902976|OTHER|CPC+ZN|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the solution for 30 s
58476745|NCT04902976|OTHER|CPC|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the proposed solution for 30 s;
58476746|NCT04902976|OTHER|Negative Control|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of distilled water for 30 s.
58476747|NCT03137381|DRUG|CTP-543|Administered as tablets.
58476748|NCT03137381|DRUG|CTP-543 matching placebo|Administered as tablets.
58476749|NCT06654986|DRUG|Salmeterol + amino acid availability|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
58476750|NCT06654986|DRUG|Salmeterol + placebo|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
58476751|NCT06654986|DRUG|Placebo + placebo|The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
58476752|NCT02677441|PROCEDURE|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
58476753|NCT02677441|PROCEDURE|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
58476754|NCT06489951|DRUG|Solifenacin|The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
58476755|NCT06489951|DIETARY_SUPPLEMENT|vitamin D|The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants
58476756|NCT06489951|BEHAVIORAL|Standard behavioral therapy|Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
58476757|NCT01708356|BEHAVIORAL|Cycling on a residential route|
58476758|NCT04806685|BEHAVIORAL|Sleep education|Medical nutrition therapy plus behavior-based sleep education intervention
58134059|NCT02107690|PROCEDURE|Room temperature lidocaine injection|20 °C
58476759|NCT04806685|BEHAVIORAL|Diet only|No sleep education
58476760|NCT06182254|BEHAVIORAL|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
58476761|NCT06182254|OTHER|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
58476762|NCT04854187|DEVICE|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
58476763|NCT04003246|RADIATION|Thoracic RT and Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation
58476764|NCT04003246|DRUG|Consolidative Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year
58476765|NCT05673967|OTHER|Non-Interventional|No study treatment will be administered on this study.
58476766|NCT05640193|BIOLOGICAL|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
58476767|NCT00656513|DRUG|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
58476768|NCT00656513|PROCEDURE|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
58134060|NCT02107690|PROCEDURE|Body temperature lidocaine injection|37 °C
58476769|NCT06306807|OTHER|Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications|Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
58476770|NCT06306807|OTHER|PNF exercise program|The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
58476771|NCT01795677|DRUG|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
58476772|NCT00488371|BIOLOGICAL|Pneumococcal Conjugated Vaccine (Prevnar®)|
58476773|NCT02856568|DRUG|Cisplatin|Given IV
58476774|NCT02856568|DRUG|Gemcitabine Hydrochloride|Given IV
58476775|NCT02856568|OTHER|Laboratory Biomarker Analysis|Correlative studies
58476776|NCT02856568|OTHER|Pharmacological Study|Correlative studies
58476777|NCT02856568|DRUG|Ricolinostat|Given PO
58476778|NCT03878563|DEVICE|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
58476779|NCT02638194|OTHER|Active smoking of Tobacco Hookah for 2 hours|
58476780|NCT02638194|OTHER|Exposure to tobacco hookah second hand smoke|
58476781|NCT02638194|OTHER|Visit a win bar|Participants will visit a wine bar for food and/or drinks
58476782|NCT03513159|BEHAVIORAL|Pathfinder support|A pathfinder will support the patient with structured activities.
58476783|NCT03350594|BEHAVIORAL|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
58476784|NCT03350594|BEHAVIORAL|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
58476785|NCT01816217|DEVICE|Intubation with The McGrath Mac videolaryngoscope|
58476786|NCT06332599|DRUG|BQT|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
58476787|NCT06332599|DRUG|PBM4M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
58476788|NCT06332599|DRUG|PBM3M3|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
58476789|NCT06332599|DRUG|PBM2M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
58476790|NCT06332599|DRUG|PBM2M3|PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
58476791|NCT05396547|DEVICE|Treated with Ledinbio device|Treated with Ledinbio device
58476792|NCT02116036|DRUG|Rivaroxaban|
58476793|NCT05984017|OTHER|No treatment is included in this study|No drug intervention or tissue sampling will be included in this study.
58476794|NCT01253837|DRUG|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
58476795|NCT03000608|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
58476796|NCT03000608|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
58476797|NCT03933202|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
58476798|NCT02254070|DRUG|BIBT 986 BS|
58476799|NCT00586378|DEVICE|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
58476800|NCT02631239|DRUG|Methotrexate|1g/m2/d IV \*1d
58476801|NCT02631239|DRUG|Etoposide|200mg/d PO \*3d
58476802|NCT02631239|DRUG|Dexamethasone|40mg/d PO \*3d
58476803|NCT02631239|DRUG|Pegaspargase|2500IU/m2/d IM \*1d
58476804|NCT02631239|RADIATION|Radiotherapy|50-56Gy
58476805|NCT04885998|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
58476806|NCT04885998|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
58476807|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
58476808|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
58476809|NCT03873116|DRUG|Placebo oral capsule|Matching placebo capsules administered orally once daily
58476810|NCT02166346|DRUG|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
58476811|NCT02166346|DRUG|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
58476812|NCT04730102|PROCEDURE|Rectal washout|Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
58476813|NCT02798627|DRUG|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
58476814|NCT02798627|DRUG|placebo|Placebo pills identical in appearance to the NS2359 will be provided
58476815|NCT01148368|DRUG|fimasartan|single administration of fimasartan 120mg
58476816|NCT05706298|BEHAVIORAL|Active Breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
58476817|NCT01222052|DRUG|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
58476818|NCT04230889|OTHER|Usual Diet Group|three main meals and two snacks
58476819|NCT04230889|OTHER|Group 1 Nutritional Shake|2 servings per day
58476820|NCT04230889|OTHER|Group 2 Nutritional Shake|2 servings per day
58476821|NCT04231578|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
58476822|NCT06474247|DEVICE|Postbiotic|Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
58476823|NCT06474247|DEVICE|Placebo|Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
58476824|NCT05285371|DIAGNOSTIC_TEST|Urinalysis (UA)|Urinalysis will be performed twice daily starting on Postoperative Day 0.
58476825|NCT05285371|DIAGNOSTIC_TEST|Complete Metabolic Panel (CMP)|A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
58476826|NCT05285371|DIAGNOSTIC_TEST|Glucose Stick Test (d-Stick)|A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
58476827|NCT05285371|OTHER|Medical Chart Review|A medical chart review will be performed for all subjects enrolled.
58476828|NCT05159440|DRUG|TORL-2-307-MAB|monoclonal antibody
58476829|NCT02680249|DRUG|CTP-656|
58476830|NCT03642587|OTHER|There is no intervention in this study.|There is no intervention in this study.
58476831|NCT06586099|DRUG|Aza, tislelizumab|combination chemotherapy for the refractory/relapsed AML
58476832|NCT02987426|BEHAVIORAL|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
58476833|NCT05794958|DRUG|Axicabtagene Ciloleucel|Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
58476834|NCT06594458|PROCEDURE|Observation of newborn with respiratory distress in the delivery room|Newborn manifesting tachypnea or respiratory distress at birth (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians. A clinical evaluation will be carried out every 15 minutes, with the detection of vital parameters. In case of clinical improvement and suspension of oxygen therapy, the newborn will be transferred to the Neonatal Observation Ward to perform multiparameter monitoring of vital signs up to 6 hours of life and then be reunited with the mother. In case of clinical worsening, a bedside thoracic ultrasound will be carried out and depending on the result and the lung ultrasonography score, it will be evaluated whether to continue the observation in the delivery room or to admit the newborn in the Neonatal Care, Neonatal Sub-Intensive Care or Neonatal Intensive care Units
58476835|NCT06202482|OTHER|Connect Active Program|Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
58476836|NCT04829201|PROCEDURE|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
58476837|NCT02435953|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
58476838|NCT02435953|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
58476839|NCT04268004|BEHAVIORAL|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
58476840|NCT01310777|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
58476841|NCT01310777|DRUG|Brinzolamide 1% ophthalmic suspension|
58476842|NCT01310777|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
58476843|NCT05557084|PROCEDURE|laparoscopic vertical clip gastroplasty (LVCG) with Bariclip.|The investigator performed laparoscopic vertical clip gastroplasty, This procedure consists of a nonadjustable clip that is vertically placed around the stomach, parallel to the lesser curvature, mimicking the effect of sleeve gastrectomy. The clip restricts oral intake, the anatomy of the stomach is not permanently changed, the small bowel remains untouched, the digestive pathway is not diverted, no stapling or resection are required and the magnitude of restriction is supposed to remain constant during the years. The vertical clip is thus placed without risks of staple line leak, malabsorption side effects, changes in anatomy, and is potentially reversible \[9\]. creating a 4-cm window to enter the lesser sac while lifting the stomach to create sufficient space to be able to suture. Plication of the antrum for 3-5 cm is performed. Fluid testing for patency is performed with methylene blue or normal saline and the procedure is terminate.
58476844|NCT05030129|DRUG|5-Hydroxytryptophan|5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
58476845|NCT05030129|DRUG|Ergoloid Mesylates|Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
58476846|NCT05030129|DRUG|Matching placebo for Ergoloid mesylates|Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
58476847|NCT05030129|DRUG|Matching placebo for 5-Hydroxytryptophan|Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
58476848|NCT05649215|OTHER|No intervention will be applied.|This is a questionnaire study.
58476849|NCT06603805|PROCEDURE|MAST group|
58476850|NCT06603805|PROCEDURE|breast-conserving surgery plus adjuvant radiotherapy|Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
58476851|NCT06397170|OTHER|Graded repetitive arm supplementary program|Patients in Group A will receive Graded repetitive arm supplementary program
58476852|NCT06397170|OTHER|Task based training|Patients in Group B will receive Task based training.
58476853|NCT06590285|BEHAVIORAL|App-based Educational Intervention|"The program's educational content is designed to engage patients in the science of sleep and recovery. Segments like The Sleep Adventure demystify complex neurobiological processes in an accessible format, aligning with emerging trends in patient education that focus on engagement and knowledge empowerment. Concurrently, the program's physical activity component is meticulously crafted, offering safe, supportive exercises that correspond with the treatment stages of alloHSCT patients. This aspect draws upon evidence highlighting the importance of sustained physical activity during intensive treatments to enhance overall recovery and quality of life. Additionally, the program comprehensively addresses sleep disturbances, prevalent in HSCT patients, through in-depth exploration and evidence-based, non-pharmacologic management strategies, reflecting the significant impact of sleep quality on patient recovery and long-term health outcomes."
58476854|NCT06599853|OTHER|Fever Education|Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
58476855|NCT04467593|DEVICE|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
58476856|NCT04467593|DRUG|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
58476857|NCT00897832|OTHER|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
57779897|NCT06739395|DRUG|Trametinib tablet|Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
58134061|NCT03595657|BIOLOGICAL|CS1001|monoclonal antibody
58134062|NCT05083598|OTHER|6 Minute walking test|The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
58476858|NCT03010215|OTHER|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
58476859|NCT06591611|OTHER|PEEK reinforced fixed all-on-four prosthesis|Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK
58476860|NCT03524508|DRUG|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
58476861|NCT03524508|DRUG|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
58476862|NCT01709721|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
58476863|NCT01709721|DEVICE|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
58476864|NCT04384484|DRUG|Loncastuximab Tesirine|Intravenous Infusion
58476865|NCT04384484|DRUG|Rituximab|Intravenous Infusion
58476866|NCT04384484|DRUG|Gemcitabine|Intravenous Infusion
58476867|NCT04384484|DRUG|Oxaliplatin|Intravenous Infusion
58476868|NCT06603376|DRUG|FOLFIRI + Vemurafenib + Cetuximab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
58476869|NCT06603376|DRUG|FOLFIRI ± Bevacizumab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
58476870|NCT06595771|DEVICE|continuous positive airway pressure|continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
58476871|NCT06595771|DEVICE|Polysomnography|"Polysomnography measures Apnea-hypopnea index (Minutes)~Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):~1. Apnea-hypopnea index: 5-14.9 olan; mild OSAS~2. Apnea-hypopnea index: 15-29.9: moderate OSAS~3. Apnea-hypopnea index ≥30: severe OSAS measures duration and percentage of time oxygen saturation dropped below 90% the total minutes of sleep"
58476872|NCT06543199|PROCEDURE|local application of hyaluronic acid agent to the wound site|Evaluation of the effect of local use of hyaluronic acid agent on wound healing
58476873|NCT06543199|PROCEDURE|Local application of hypericum perforatum L to the wound site|Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi
58476874|NCT06543199|PROCEDURE|wound healing monitoring|Doctor visit on days 3, 7, 14, 21 and 28
58476875|NCT02425293|BEHAVIORAL|asthma patient education|
58476876|NCT02345070|DRUG|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58476877|NCT02345070|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
58476878|NCT04953494|DIAGNOSTIC_TEST|Patient information collection, exon sequencing and follow-up.|Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
58476879|NCT04102098|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
58476880|NCT04102098|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
58476881|NCT03439228|DEVICE|Lumbar brace|3 months of lumbar brace wear
58476882|NCT04018755|BIOLOGICAL|anakinra|anakinra single-use prefilled glass syringes
58476883|NCT04882202|DRUG|Acetaminophen|Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
58476884|NCT04882202|OTHER|Placebo|Normal saline 100 ml (equal amount of acetaminophen) IV every 6 hours
58134063|NCT05083598|OTHER|Frailty questionaires|Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
58476885|NCT02506088|BEHAVIORAL|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
58476886|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies.
58476887|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies with Prefabricated Landmarks|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies with prefabricated landmarks in place.
58476888|NCT06592066|DEVICE|Splinted Open Top Tay Conventional Impression Technique|Splinted open-top tray conventional impression technique will be preformed by using medium body silicone impression material.
58476889|NCT02080715|DRUG|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
58476890|NCT02080715|DRUG|Placebo|
58476891|NCT04020809|DRUG|Atezolizumab|Anti-PD-L1 monoclonal antibody
58476892|NCT01011894|DRUG|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
58476893|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
58476894|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
58476895|NCT02294708|BEHAVIORAL|postoperative postures|two postoperative postures: supine and temporal-lateral
58476896|NCT01164514|BIOLOGICAL|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
58476897|NCT01164514|BIOLOGICAL|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
58476898|NCT01164514|DRUG|Placebo|Normal saline.
58476899|NCT06441201|DIAGNOSTIC_TEST|Pulse flowmeter|Measures peripheral pulse volumes by an electrode applied non-invasively to the lower extremity (left or right) at the beginning of the endoscopic evaluation for the duration of the procedure, and up to 2 hours after the completion of the procedure.
58476900|NCT01236209|OTHER|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
58476901|NCT01236209|OTHER|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
58476902|NCT05838846|DRUG|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization (21-23), inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
58476903|NCT05838846|DRUG|IV Milrinone|Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
58476904|NCT06595667|PROCEDURE|Pulse pressure variation|Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.
58476905|NCT06595667|PROCEDURE|Central venous pressure|Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
58476906|NCT05180227|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
58476907|NCT05180227|DIAGNOSTIC_TEST|Orthostatic tilt|perform an orthostatic tilt without and with stimulation.
58476908|NCT06451406|DRUG|Selective serotonin re-uptake inhibitor|Patients received selective serotonin re-uptake inhibitor as medical treatment for treatment of premature ejaculate.
58476909|NCT06451406|DRUG|Hyaluronic acid|Patients received injection of glans penis with hyaluronic acid
58476910|NCT05559749|BEHAVIORAL|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
58476911|NCT05559749|BEHAVIORAL|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
58476912|NCT02323789|DRUG|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
58476913|NCT01031212|DRUG|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
58476914|NCT01031212|DRUG|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
58476915|NCT01031212|DRUG|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
58476916|NCT01031212|DRUG|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
58476917|NCT00346580|DRUG|Nelfinavir|
58476918|NCT05984576|RADIATION|Reirradiation|Reirradiation recurrent rectal cancer
58476919|NCT04351581|OTHER|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
58476920|NCT04351581|OTHER|Continuation of ACEi/ARB|Continuation of ACEi/ARB
58476921|NCT05880134|PROCEDURE|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
58491323|NCT04990804|DRUG|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
58476922|NCT05880134|PROCEDURE|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
58476923|NCT00508794|BEHAVIORAL|Yoga Group|3 sessions of yoga each week for 6 weeks.
58476924|NCT00508794|BEHAVIORAL|Stretching Control Group|3 sessions of stretching each week for 6 weeks
58476925|NCT00508794|BEHAVIORAL|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
58476926|NCT00508794|OTHER|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
58476927|NCT03501498|DRUG|Loperamide|Alters intestinal transit time.
58476928|NCT03501498|DRUG|Senna|Alters intestinal transit time.
58476929|NCT05647408|DRUG|Dexamethasone|The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
58476930|NCT05411029|DIAGNOSTIC_TEST|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
58476931|NCT05411029|DIAGNOSTIC_TEST|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
58476932|NCT06470711|OTHER|Non-Interventional Study|Non-interventional study
58476933|NCT01499836|OTHER|PVB|paravertebral block
58476934|NCT04383210|DRUG|Seribantumab|Anti-HER3 monoclonal antibody
58476935|NCT05409625|DEVICE|Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)|Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
58476936|NCT05409625|DEVICE|Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)|Intraoral camera used for caries detection in the occlusal and proximal surfaces.
58476937|NCT05409625|DEVICE|X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)|X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
58476938|NCT05409625|PROCEDURE|Oral cleaning|Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
58476939|NCT02528994|DIETARY_SUPPLEMENT|L-serine|Participants will take dietary serine supplementation daily
58476940|NCT02351817|DEVICE|Test A|Ostomy appliance
58476941|NCT02351817|DEVICE|Test B|Ostomy appliance
58476942|NCT02351817|DEVICE|Baseline|Ostomy appliance
58476943|NCT03964831|DEVICE|P200TxE|The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
58476944|NCT03964831|DEVICE|P200DTx|The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
58476945|NCT03375788|DRUG|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
58476946|NCT03375788|DRUG|Identical Placebo|Placebo injection daily
58476947|NCT04220307|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration
58476948|NCT05967507|DEVICE|Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
58476949|NCT05967507|DEVICE|High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
58476950|NCT06597877|RADIATION|CT|Patients with unilateral ear pathology will be randomly assigned to do CT temporal bone, The presence of five variants was determined. These variants were: a high dehiscent jugular bulb, an anteriorly located sigmoid sinus, a deep sinus tympani, an enlarged cochlear aqueduct, and an enlarged internal auditory meatus (IAM). A GE LightSpeed 16, four-slice, helical CT scanner (Fairfield, Connecticut, USA) was used for all patients. The scan parameters were as follows: 1 mm slices, smart Ma (50-250 Ma), 120 kV, 0.8-second rotation time, 0.562:1 pitch factor, and 5.62 mm rotation speed. All scans covered an area from 1 cm inferior to the mastoid tip to 1 cm superior to the petrous temporal bone.
58476951|NCT06597799|DRUG|MRT-6160|Orally administered tablets of MRT-6160
58476952|NCT06597799|DRUG|Placebo|Orally administered tablets of placebo
58476953|NCT02931877|DRUG|sevoflurane|
58476954|NCT02931877|DRUG|propofol|
58476955|NCT00228267|DRUG|Propofol|
58476956|NCT00169286|PROCEDURE|Telephone care management|
58476957|NCT00169286|PROCEDURE|peer-led chronic disease self-management workshop|
58476958|NCT00169286|PROCEDURE|professionally-led cognitive behavioral psychotherapy group|
58476959|NCT02787902|BEHAVIORAL|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
58476960|NCT02787902|BEHAVIORAL|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
58476961|NCT06587178|DIETARY_SUPPLEMENT|peptison liquid|CD patients requiring bowel resection and preoperative EEN were randomized to receive peptison liquid for 6 weeks.
58476962|NCT06587178|DIETARY_SUPPLEMENT|Enteral nutritional suspension|CD patients requiring bowel resection and preoperative EEN were randomized to receive enteral nutritional suspension for 6 weeks.
58476963|NCT04692259|DIAGNOSTIC_TEST|MRI|Liver MRI before liver resection
58476964|NCT03942796|DRUG|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
58476965|NCT03942796|PROCEDURE|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
58476966|NCT03104907|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
58476967|NCT01629264|DEVICE|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
58476968|NCT01629264|DEVICE|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
58476969|NCT01629264|OTHER|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
58476970|NCT01808586|PROCEDURE|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
58476971|NCT01808586|PROCEDURE|Dexamethasone|4mg/mL
58476972|NCT01808586|PROCEDURE|Intramuscular Lidocaine|2%
58476973|NCT01808586|BEHAVIORAL|Home Exercise|Standardized home exercise program
58476974|NCT06064279|DRUG|Poly ICLC|Tol like receptor 3 agonist
58476975|NCT06064279|DRUG|IVIG|pooled IVIG
58476976|NCT04106492|DRUG|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
58476977|NCT00702221|BIOLOGICAL|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
58476978|NCT00702221|BIOLOGICAL|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
58476979|NCT05380180|OTHER|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
58476980|NCT05380180|OTHER|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
58476981|NCT02144610|BIOLOGICAL|HGF Plasmid (AMG0001)|IM
58476982|NCT02144610|BIOLOGICAL|Matching Placebo|IM
58476983|NCT02819011|DEVICE|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
58476984|NCT02819011|OTHER|Control|Subjects will be provided with a pair of New Balance 813 shoes
58476985|NCT01213888|DRUG|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
58476986|NCT01213888|DRUG|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
58476987|NCT05903898|DEVICE|AI software StrokeSens (Circle NVI)|Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
58476988|NCT02741739|DRUG|REGN1033|
58476989|NCT02059278|DRUG|T-2345|T-2345 Ophthalmic Solution
58476990|NCT02059278|DRUG|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
58476991|NCT03149679|DRUG|Cyclophosphamide|Chemotherapy
58476992|NCT02642185|PROCEDURE|Microwave ablation|CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
58476993|NCT02642185|PROCEDURE|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
58476994|NCT04094558|DEVICE|Ingestible capsule|Participants will swallow capsules and collect in stool concurrent with stool samples
58476995|NCT04094558|PROCEDURE|Sedated EGD|Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.
58476996|NCT04094558|DIAGNOSTIC_TEST|Lactulose Breath Test|Hydrogen and methane breath test with lactulose substrate
58476997|NCT03135327|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
58476998|NCT00780312|OTHER|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
58476999|NCT02944149|PROCEDURE|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
58477000|NCT06061796|PROCEDURE|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~* ratio P/F \> 150 mm Hg~* FiO2 \< 60%~* PEEP ≤ 10 cm d'H2O"
58477001|NCT02191111|BEHAVIORAL|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
58477002|NCT06600256|BEHAVIORAL|Viz HCM ECG Review|Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&amp;#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.
58477003|NCT06600256|BEHAVIORAL|Baseline Effectiveness Cohort|A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.
58477004|NCT00363259|DRUG|Peginterferon alfa-2b|
58477005|NCT00363259|DRUG|Ribavirin|
58477006|NCT00005966|BIOLOGICAL|recombinant interferon alfa|
58477007|NCT00005966|DRUG|thalidomide|
58477008|NCT05338684|DEVICE|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
58477009|NCT04636125|DRUG|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
58477010|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow|All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.
58477011|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol|For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
58477012|NCT03324269|DEVICE|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase."
58477013|NCT01615939|DRUG|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
58477014|NCT01615939|DRUG|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
58477015|NCT04514861|DEVICE|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
58477016|NCT05493917|BIOLOGICAL|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
58477017|NCT02396576|BEHAVIORAL|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
58477018|NCT03497624|OTHER|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
58477019|NCT04043299|DRUG|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
58477020|NCT04043299|DRUG|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
58477021|NCT05277415|BIOLOGICAL|Ghrelin|Ghrelin infusion
58477022|NCT05277415|BIOLOGICAL|Placebo|Placebo
58477023|NCT01910298|PROCEDURE|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
58477024|NCT01910298|PROCEDURE|Two Stage Breast Reconstruction|
58477025|NCT04790617|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
58477026|NCT02383576|OTHER|No Intervention|No intervention administered in this study.
58477027|NCT04647188|OTHER|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
58477028|NCT05716802|BEHAVIORAL|dance/movement therapy|dance/movement therapy plus treat as usual
58477029|NCT05716802|BEHAVIORAL|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
58477030|NCT06338098|BEHAVIORAL|8-week wellness and relaxation meditation program|Heartfulness Meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
58477031|NCT02887677|DRUG|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
58477032|NCT02887677|DRUG|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
58477033|NCT02283853|DRUG|dimethyl fumarate|administered orally
58477034|NCT02283853|DRUG|Interferon β-1a|administered by intramuscular injection
58477035|NCT06507774|DEVICE|3D Reconstruction Technology|Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.
58477036|NCT06507774|DEVICE|No 3D reconstruction is used|This group did not use 3D reconstruction for surgical navigation
58477037|NCT06587971|PROCEDURE|Standard periodontal treatment protocol|Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.
58477038|NCT06587971|BEHAVIORAL|Oral hygiene education|Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
58477039|NCT03525236|OTHER|Tasting of flavours|"* Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
58477040|NCT03405246|BEHAVIORAL|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
58477041|NCT03405246|BEHAVIORAL|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
58477042|NCT04135274|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
58477043|NCT05625308|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
58477044|NCT00812708|DEVICE|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
58477045|NCT00338845|BEHAVIORAL|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
58477046|NCT00338845|BEHAVIORAL|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
58491892|NCT06464783|OTHER|Comprehensive Corrective Exercise Program|"Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps)."
58134064|NCT02366949|DRUG|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 \> (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
58134065|NCT02366949|DRUG|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
58134066|NCT00167505|BEHAVIORAL|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
58134067|NCT00167505|BEHAVIORAL|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
58134068|NCT01412580|OTHER|observational follow-up|observational follow-up
58134069|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
58134070|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
58134071|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
58134072|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
58134073|NCT05452226|DEVICE|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
58134074|NCT03246100|BEHAVIORAL|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
58134075|NCT04064632|DRUG|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
58134076|NCT03422211|OTHER|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
58134077|NCT01844219|PROCEDURE|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
58134078|NCT04791670|OTHER|survey study|The surveys will include general data, the type of electronic devices in possession and the purpose of use. eHealth literacy will be assessed with the eHeals questionnaire. Platform's ease of use will be assessed with the System Usability Scale, and participants´ opinion about the digital path utility with six questions. These items will be answered with a Likert-scale. Finally, we added an open question for qualitative analysis.
58134079|NCT05094713|OTHER|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
58134080|NCT05094713|OTHER|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
58134081|NCT03423225|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
58134082|NCT05526118|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
58134083|NCT06054581|BEHAVIORAL|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
58134084|NCT03733509|PROCEDURE|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
58134085|NCT03733509|PROCEDURE|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
58134086|NCT03733509|PROCEDURE|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
58134087|NCT03733509|PROCEDURE|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
58134088|NCT04115280|DIAGNOSTIC_TEST|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
58134089|NCT04864548|BIOLOGICAL|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
58134090|NCT04751578|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
58134091|NCT06307925|DRUG|HC010|HC010 Q2W/28d intravenous infusion
58134092|NCT06138184|BEHAVIORAL|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
58134093|NCT06138184|BEHAVIORAL|Control Group: Standard of Care|This will be the current practice for patient education
58134094|NCT01135927|DRUG|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
58134095|NCT01135927|DRUG|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
58134096|NCT00191295|DRUG|Atomoxetine|
58134097|NCT00191295|DRUG|Placebo|
58134098|NCT05216081|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
58134099|NCT00822874|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
58134100|NCT01767428|DRUG|Paracetamol|500 mg immediate release paracetamol formulations
58134101|NCT04768179|DRUG|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
58134102|NCT00899028|GENETIC|comparative genomic hybridization|
58134103|NCT00899028|GENETIC|fluorescence in situ hybridization|
58134104|NCT00899028|GENETIC|gene expression analysis|
58134105|NCT00899028|GENETIC|microarray analysis|
58134106|NCT00899028|GENETIC|protein expression analysis|
58134107|NCT00899028|OTHER|immunohistochemistry staining method|
58134108|NCT00899028|OTHER|laboratory biomarker analysis|
58134109|NCT00899028|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
58134110|NCT00899028|OTHER|medical chart review|
58134111|NCT00899028|PROCEDURE|diagnostic bronchoscopy|
58134112|NCT03509103|OTHER|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
58134113|NCT01449071|BIOLOGICAL|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
58134114|NCT01449071|BIOLOGICAL|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
58134115|NCT01449071|BIOLOGICAL|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
58134116|NCT01449071|BIOLOGICAL|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
58134117|NCT01449071|BIOLOGICAL|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
58134118|NCT03732443|DIAGNOSTIC_TEST|FAM-CAM|Family Confusion Assessment Method
58134119|NCT05287438|DIAGNOSTIC_TEST|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
58134120|NCT05287438|DIAGNOSTIC_TEST|Standard Culture|Standard of care culture and sensitivity
58134121|NCT02068248|DIETARY_SUPPLEMENT|Soluble Fibre|
58134122|NCT04066166|DIAGNOSTIC_TEST|Palpation|All healthy subjects palpated
58134123|NCT03317548|DIAGNOSTIC_TEST|progesterone|according progesterone level to decide fresh or frozen embryo transfer
58134124|NCT03317548|DIAGNOSTIC_TEST|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
58134125|NCT03986177|BEHAVIORAL|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager"
58134126|NCT03836066|DRUG|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
58134127|NCT00003237|DRUG|cisplatin|
58134128|NCT00003237|DRUG|paclitaxel|
58134129|NCT00003237|PROCEDURE|surgical procedure|
58134130|NCT03500861|OTHER|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
58134131|NCT02808065|DRUG|Tacrolimus|Administered dose were individualized according to their own prescription
58134132|NCT02808065|DRUG|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
58134133|NCT02262377|BEHAVIORAL|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
58134134|NCT03079271|DRUG|Lacrisert, 5 Mg Ophthalmic Insert|
58134135|NCT01474564|OTHER|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
58134136|NCT04744909|DEVICE|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
58134137|NCT01563965|DIETARY_SUPPLEMENT|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
58134138|NCT01563965|OTHER|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
58134139|NCT04784598|OTHER|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
58134140|NCT05627141|OTHER|Photobiomodulation; Cryotherapy, Massage|"Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session."
58134141|NCT03559023|PROCEDURE|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
58134142|NCT03559023|PROCEDURE|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
58134143|NCT03559023|PROCEDURE|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
58134144|NCT03559023|PROCEDURE|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
58134145|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
58134146|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
58134147|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
58134148|NCT01460797|OTHER|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
58134149|NCT02598479|OTHER|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
58134150|NCT04170309|DRUG|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
58134151|NCT03804359|DRUG|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
58134152|NCT05732766|BIOLOGICAL|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
58134153|NCT01223612|DRUG|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
58134154|NCT01223612|PROCEDURE|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
58134155|NCT02766075|BEHAVIORAL|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
58477047|NCT05007054|PROCEDURE|PCI or CABG|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
58477048|NCT01826019|OTHER|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
58477049|NCT01826019|OTHER|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
58477050|NCT01184157|BEHAVIORAL|Home screening|
58477051|NCT01184157|BEHAVIORAL|Clinic screening|
58477052|NCT01782378|DEVICE|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
58477053|NCT01782378|DEVICE|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
58477054|NCT04323969|BEHAVIORAL|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
58477055|NCT04323969|BEHAVIORAL|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
58477056|NCT04682366|DRUG|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
58477057|NCT04682366|DRUG|Placebo|Oral drug: 10 days of identical-appearing placebo
58477058|NCT00121498|DRUG|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
58477059|NCT02023463|DRUG|Enzalutamide|Given PO
58477060|NCT02023463|DRUG|Goserelin acetate|Given SC
58477061|NCT02023463|DRUG|Leuprolide acetate|Given IM or SC
58477062|NCT02023463|RADIATION|Radiation therapy|Undergo image-guided radiation therapy
58477063|NCT06582927|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT)|"MBAT is an evidence-based program that comprises 4, 2-hour sessions virtual delivered across 4 consecutive weeks.~The 4 sessions correspond to 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others."
58477064|NCT05511233|DIETARY_SUPPLEMENT|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
58477065|NCT05806580|DRUG|Relma-cel|Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
58477066|NCT00199381|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
58477067|NCT00231569|DRUG|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
58477068|NCT00231569|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
58134156|NCT04764565|DIETARY_SUPPLEMENT|Nuun Instant|Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
58134157|NCT04764565|OTHER|Water|water
58134158|NCT04764565|DIETARY_SUPPLEMENT|Nuun Electrolyte|Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
58134159|NCT04109469|DEVICE|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
58134160|NCT03657979|DRUG|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
58134161|NCT03657979|DRUG|Placebo|TAP-block with placebo
58134162|NCT02473640|DRUG|SYN-004|
58134163|NCT02473640|DRUG|Esomeprazole|
58134164|NCT02473640|DRUG|Ceftriaxone|
58477069|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
58477070|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
58477071|NCT00231569|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
58477072|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
58477073|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
58477074|NCT02008799|PROCEDURE|Bone marrow stem cell injection|Injection should be in testis and testicular artery
58477075|NCT05270720|BIOLOGICAL|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
58477076|NCT02491632|DRUG|Dexamethasone|Given PO
58477077|NCT02491632|BEHAVIORAL|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
58477078|NCT02491632|OTHER|Laboratory Biomarker Analysis|Correlative studies
58477079|NCT02491632|OTHER|Quality-of-Life Assessment|Ancillary studies
58477080|NCT02491632|OTHER|Questionnaire Administration|Ancillary studies
58477081|NCT03536208|DRUG|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
58477082|NCT06430970|DEVICE|endoscopy|upper and lower endoscopy
58477083|NCT06600009|DRUG|Secukinumab|Patients had received secukinumab per their dosing regimens prior to this observational study.
58477084|NCT06600009|DRUG|Adalimumab|Patients had received adalimumab per their dosing regimens prior to this observational study.
58477085|NCT04849247|DRUG|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
58477086|NCT01141517|BEHAVIORAL|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
58477087|NCT05707728|DEVICE|intraoperative ultrasound|intraoperative cranial ultrasound
58477088|NCT04964180|DRUG|Indomethacin suppository|two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
58477089|NCT04964180|DRUG|Lidocaine 2% Injectable Solution|200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
58477090|NCT01323114|PROCEDURE|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
58134165|NCT03165058|DIAGNOSTIC_TEST|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
58477091|NCT01323114|OTHER|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
58477092|NCT06593730|DRUG|NRL001 cream 0.5%w/w|
58477093|NCT06593730|DRUG|NRL001 cream 0.75%w/w|
58477094|NCT06593730|DRUG|NRL001 cream 1.0%w/w|
58477095|NCT06593730|DRUG|NRL001 cream 1.5%w/w|
58477096|NCT06593730|DRUG|NRL001 cream 2.0%w/w|
58477097|NCT06593730|DRUG|NRL001 cream 2.5%w/w|
58477098|NCT02241616|DRUG|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
58477099|NCT02172274|DRUG|[14C]-BI 10773 - oral solution|
58477100|NCT05900596|DIAGNOSTIC_TEST|Fetal blood sampling|Fetal scalp blood sampling and analysis
58477101|NCT01780974|DRUG|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
58477102|NCT01780974|DRUG|Placebo|placebo capsules
58477103|NCT00512889|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
58477104|NCT00512889|GENETIC|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
58477105|NCT00512889|DRUG|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
58477106|NCT00512889|RADIATION|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
58477107|NCT06271577|DEVICE|AliveCor 12-lead ECG|The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
58477108|NCT06146920|OTHER|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
58477109|NCT01770418|RADIATION|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
58477110|NCT06654778|OTHER|PEEP|Patients will be ventilated with PEEP of 8 cm H2O and fluid management: 500 ml of Ringer's lactate in the recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery.
58477111|NCT06654778|OTHER|PEEP/RM|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and fluid management: 500 ml of Ringer's lactate in recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery
58477112|NCT06654778|OTHER|PEEP/RM/RF|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and restrictive fluid management (RF). Ringer's lactate at a rate of 3 mL/kg/hour from the beginning to the end of the surgery
58477113|NCT06651944|DEVICE|Invisalign® System with mandibular advancement featuring occlusal blocks|Class II correction using the Invisalign® System with mandibular advancement featuring occlusal blocks
58477114|NCT00122083|DEVICE|Health education information|
58477115|NCT06072053|PROCEDURE|Burr Hole Craniostomy and Postoperative Exhaustive Drainage Strategy|According to the preoperative CT results, drilling and drainage was performed at the thickest level of the hematoma; during the operation, the hematoma cavity was adequately flushed with saline and a drainage tube was left in the hematoma cavity; after the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
58477116|NCT06072053|PROCEDURE|YL-1 puncture needle and Postoperative Exhaustive Drainage Strategy|Based on preoperative CT, the thickest level of the hematoma was selected and localized. During the operation, an electric drilling needle was used to rapidly break through the skull and dura to enter the cavity of the subdural hematoma, and the puncture needle was fixed to the skull to drain the subdural hematoma. After the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
58477117|NCT02307825|DRUG|Azithromycin|The drug will be taken three times a week for four months.
58477118|NCT02307825|DRUG|Placebo|The placebo will be taken three times a week for four months.
58477119|NCT02739906|DRUG|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
58477120|NCT02739906|DRUG|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
58477121|NCT02739906|DRUG|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
58477122|NCT06513091|DEVICE|OCS Lung|The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
58477123|NCT02512705|DEVICE|Pinel Restraints|
58477124|NCT02512705|BEHAVIORAL|Seclusion Room|
58477125|NCT01655459|PROCEDURE|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
58477126|NCT00305513|PROCEDURE|The phasic alerting treatment|
58477127|NCT02446964|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
58477128|NCT02446964|DRUG|Cyclophosphamide|Given IV
58477129|NCT02446964|DRUG|Fludarabine Phosphate|Given IV
58477130|NCT02446964|OTHER|Laboratory Biomarker Analysis|Correlative studies
58477131|NCT02446964|DRUG|Mycophenolate Mofetil|Given PO or IV
58477132|NCT02446964|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
58477133|NCT02446964|DRUG|Tacrolimus|Given IV and PO
58477134|NCT02446964|RADIATION|Total Marrow Irradiation|Undergo TMLI
58477135|NCT04730700|PROCEDURE|Radiofrequency Ablation with MEE|RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
58477136|NCT04730700|BEHAVIORAL|Conventional Medical Management|Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
58477137|NCT01605708|DRUG|REGN846|Dose 1
58477138|NCT00403377|BEHAVIORAL|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
58477139|NCT02187419|OTHER|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
58477140|NCT04538521|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
58134166|NCT00519142|DRUG|placebo for mitiglinide|three times a day with meals
58134167|NCT00519142|DRUG|mitiglinide|three times a day with meals
58134168|NCT00519142|DRUG|mitiglinide|two times a day with meals
58477141|NCT06259916|OTHER|Alcohol|Participants in this condition will receive the standard alcohol dose
58477142|NCT06259916|OTHER|Cannabis|Participants in this group will self-administer legal-market flower cannabis
58477143|NCT00181272|DRUG|azithromycin|
58477144|NCT04054986|DIAGNOSTIC_TEST|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
58477145|NCT04054986|OTHER|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
58477146|NCT04670588|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
58477147|NCT05796583|DEVICE|Active Pulsed Shortwave Treatment|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
58477148|NCT05796583|DEVICE|Sham Treatment|Application of 8 days of a nonfunctional sham device
58477149|NCT06654245|BEHAVIORAL|Telephone based interview|Receive SHAREDCare navigator calls
58477150|NCT06654245|OTHER|Survey using a questionnaire.|Ancillary studies
58477151|NCT06654245|OTHER|Electronic health record review|Ancillary studies
58477152|NCT06654245|OTHER|Referral|Receive standard of care automated referrals
58477153|NCT06467227|OTHER|exercise modality|exercise using legs and arms
58477154|NCT06601803|DRUG|sterile saline solution|The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
58477155|NCT06601803|DRUG|Surgiphor|The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant
58477156|NCT06601803|PROCEDURE|Sample Collection|During the surgical procedure, 4 swabs of the surgical wound will be taken at various times throughout the procedure
58477157|NCT03713736|DIAGNOSTIC_TEST|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
58477158|NCT03713736|DIAGNOSTIC_TEST|Pregnancy test|Urinary pregnancy test
58477159|NCT03713736|BEHAVIORAL|Sexual activity questionnary|Sexual activity questionnary
58477160|NCT06184217|OTHER|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
58477161|NCT06184217|OTHER|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
58477162|NCT02614001|DEVICE|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
58477163|NCT02614001|OTHER|post-stroke rehabilitation program|
58477164|NCT00802308|DRUG|Morphine sulphate|Extended release tablet combined with alcohol or water
58477165|NCT04461275|OTHER|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
58477166|NCT06565949|OTHER|Education group|aregivers in the experimental group will be given a detailed and planned training programme on pressure sores. The trainings will be held in a total of four sessions, with twenty minutes in each session, two weeks apart.
58477167|NCT06565949|OTHER|control group|In the first stage of the study, the participants in the experimental and control groups were asked to complete the 'Introductory Information Form' and '' Pressure sore knowledge test' will be completed. In the second stage of the research, no intervention will be made to the caregivers in the control group, and in the last stage of the research, 'Pressure sore knowledge test' will be filled in as post-test data for all participants.
58477168|NCT00023660|DRUG|celecoxib|
58477169|NCT00023660|DRUG|cisplatin|
58477170|NCT00023660|DRUG|fluorouracil|
58477171|NCT00023660|RADIATION|brachytherapy|
58477172|NCT00023660|RADIATION|radiation therapy|
58477173|NCT03568214|OTHER|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
58477174|NCT03802006|DIAGNOSTIC_TEST|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
58477175|NCT05826938|DEVICE|Virtual reality technology|Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
58477176|NCT02784756|DEVICE|Quantiferon-CMV assay|
58477177|NCT04645758|COMBINATION_PRODUCT|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
58477178|NCT00707083|DRUG|dexamethasone|Given oral
58477179|NCT00707083|DRUG|mercaptopurine|Given orally
58477180|NCT00707083|DRUG|methotrexate|Given orally
58477181|NCT00707083|DRUG|vincristine sulfate|Given IV
58477182|NCT03925012|BEHAVIORAL|Intervention|
58477183|NCT01499940|DRUG|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
58477184|NCT06370806|BEHAVIORAL|Weight loss and lifestyle intervention|Interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
58477185|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
58477186|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
58477187|NCT01352715|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
58477188|NCT01352715|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
58477189|NCT01352715|DRUG|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
58477190|NCT01352715|DRUG|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
58477191|NCT01352715|DRUG|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
58477192|NCT01352715|DRUG|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
58477193|NCT01352715|DRUG|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
58477194|NCT01352715|DRUG|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
58477195|NCT06591039|PROCEDURE|The study did not involve intervention in the patient's treatment regimen|This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.
58477196|NCT05074290|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
58477197|NCT05074290|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
58477198|NCT06592378|DEVICE|Addinex|Medication dispensing system to control and monitor opioid use
58477199|NCT06592378|DEVICE|Standard Pill Bottle|Access and use of opioids in a standard pill bottle.
58477200|NCT04869826|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD_2020 universal protocol.
58477201|NCT03431259|OTHER|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
58477202|NCT05637710|DRUG|Administration of investigation of Eurofarma drug|Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.
58477203|NCT05637710|DRUG|Administration of Comparator|Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.
58477204|NCT04464486|OTHER|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
58477205|NCT05361668|DRUG|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
58477206|NCT05361668|DRUG|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
58477207|NCT06592339|DRUG|MK-0616|oral administration
58477208|NCT06588595|DRUG|Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
58477209|NCT06588595|DRUG|Aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
58477210|NCT02667119|BEHAVIORAL|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
58477211|NCT02667119|BEHAVIORAL|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
58477212|NCT02252666|DEVICE|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
58477213|NCT01750151|DIETARY_SUPPLEMENT|Glucose Beverage|
58477214|NCT01750151|BEHAVIORAL|Video Game Playing|
58477215|NCT01750151|DIETARY_SUPPLEMENT|Control Beverage|
58477216|NCT06200662|OTHER|Analgesic strategies during the S visit:|Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.
58477217|NCT06200662|OTHER|Analgesic strategies at visit M|Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
58477218|NCT02904681|OTHER|No intervention. Observational and descriptive study|
58477219|NCT02450370|BEHAVIORAL|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
58477220|NCT02450370|BEHAVIORAL|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
58477221|NCT05459181|DIAGNOSTIC_TEST|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
58477222|NCT05156385|BIOLOGICAL|Blood sample for the determination of antihypertensives or their metabolites.|15 ml of Blood sample for the determination of antihypertensives or their metabolites
58477223|NCT05156385|BEHAVIORAL|Questionnaire on sexual activity|Questionnaire on sexual activity in women
58477224|NCT05156385|BEHAVIORAL|Scale on hospital anxiety and depression|Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
58477225|NCT05156385|BEHAVIORAL|Morisky Questionaire|anti-hypertensive medication compliance questionnaire
58477226|NCT06597890|BEHAVIORAL|educational content (sleep hygiene)|app-based sleep hygiene-related educational content
58477227|NCT06597890|BEHAVIORAL|sleep hygiene strategies|app-based self-selection of sleep hygiene strategies
58477228|NCT06597890|BEHAVIORAL|reminders|daily reminders sent via push notifications
58477229|NCT06597890|BEHAVIORAL|review of behavioural goal|app-based review of behavioural goal
58477230|NCT06597890|BEHAVIORAL|educational content (sleep guidelines)|app-based educational content on recommended sleep guidelines
58477231|NCT06597890|BEHAVIORAL|comparison of current behaviour to ideal behaviour|use of smartwatch/smartphone data to assess current behaviour and compare it to ideal behaviour
58477232|NCT06597890|BEHAVIORAL|goal setting|prompt participant to set a goal in relation to targeted behaviour
58134169|NCT04712422|OTHER|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
58477233|NCT06597890|BEHAVIORAL|educational content (Vigorous Intermittent Lifestyle Physical Activity (VILPA))|app-based educational content on VILPA
58477234|NCT06597890|BEHAVIORAL|screentime breaks|repeated daily reminders to break up screentime
58477235|NCT04614363|DRUG|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
58477236|NCT02943434|OTHER|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
58477237|NCT06604091|OTHER|Treatment protocol|The treatment protocols of ovarian stimulation include long protocol and antagonist protocol. The protocols for frozen embryo transplantation include natural protocol, mild ovarian stimulation, hormone replacement treatment (HRT) protocol and down-regulation combining with HRT protocol. The treatment protocols are refined in above protocols. Treatment of patients follow the principle of clinical practice in real world.
58477238|NCT02435186|DRUG|p53 gene|p53 gene will be given intraperitoneally.
58477239|NCT02435186|DRUG|Cisplatin|150 mg/m\^2 cisplatin will be given intraperitoneally.
58477240|NCT02435186|DRUG|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
58477241|NCT06073938|DRUG|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
58477242|NCT05375032|OTHER|Cycling combined with cognitive tasks|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
58477243|NCT05375032|OTHER|Cycling|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
58477244|NCT03888443|DEVICE|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
58477245|NCT04862468|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
58477246|NCT04862468|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
58477247|NCT01995838|DRUG|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
58477248|NCT01995838|DRUG|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
58477249|NCT06600139|BEHAVIORAL|The Collaboration-Screening-Referral (SSH) model|The SSH aims to identify parents in need of mental health support and to strengthen social workers' competence in addressing mental illness. The SSH includes three components: 1) Collaborating - establishing collaboration with local services offering support to adults with mental illness, 2) Screening - using screening instruments for depression (the Patient Health Questionnaire - PHQ-9) and anxiety (GAD-7) to identify symptoms of mental illness among parents, and 3) Referral - Discussing the results of the screening with parents and referring to appropriate services. Techniques from motivational interviewing are included. Social workers receive training and material to administer the screening and refer parents in need of support.
58477250|NCT03519035|OTHER|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
58477251|NCT06595628|PROCEDURE|Lichtenstein Mesh-Based Hernioplasty|This is a tension-free hernioplasty procedure that uses a synthetic mesh to reinforce the inguinal canal floor. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, creating a barrier to prevent hernia recurrence. It is considered the gold standard for inguinal hernia repair and is widely used for its effectiveness in reducing recurrence rates and postoperative complications.
58477252|NCT06595628|PROCEDURE|Combined Modified Guarnieri-Desarda Tissue-Based Hernioplasty|This technique combines elements of the Guarnieri and Desarda tissue-based repairs. It does not involve the use of synthetic mesh, relying instead on the patient's own tissues to reinforce the inguinal canal. The Guarnieri technique reshapes the internal ring to improve the inguinal canal's shutter mechanism, while the Desarda technique reinforces the posterior wall using the external oblique aponeurosis. This approach aims to preserve natural anatomy and minimize complications associated with mesh use.
58477253|NCT00000982|DRUG|Zidovudine|
58477254|NCT00000982|DRUG|Didanosine|
58477255|NCT06446661|OTHER|High Intensity|Daily texts
58477256|NCT06446661|OTHER|No Text Messagings|Standard Care
58477257|NCT06446661|OTHER|Low Intensity Text Messaging|Weekly Texts
58477258|NCT05007769|DRUG|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
58477259|NCT05007769|DRUG|Atezolizumab|Atezolizumab will be commercially available.
58477260|NCT05007769|DRUG|N-803|Will be supplied free of charge to the participants by ImmunityBio
58477261|NCT02922244|OTHER|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
58477262|NCT02922244|OTHER|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
58477263|NCT02922244|OTHER|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
58477264|NCT02922244|OTHER|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
58477265|NCT00569400|DRUG|human insulin|
58477266|NCT04631419|OTHER|Flapless laser corticotomy|The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
58477267|NCT04631419|OTHER|Canine retraction|canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
58477268|NCT06142058|DIAGNOSTIC_TEST|RecistTM criteria|RecistTM criteria and RECIST criteria were used to evaluate the efficacy of targeted therapy for NSCLC with positive driving gene.
58477269|NCT05626621|DRUG|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
58477270|NCT05626621|DRUG|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
58477271|NCT05626621|DRUG|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
58477272|NCT04716231|BIOLOGICAL|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
58477273|NCT04716231|OTHER|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
58477274|NCT02328924|OTHER|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
58477275|NCT04369573|COMBINATION_PRODUCT|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
58477276|NCT04369573|OTHER|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
58477277|NCT04041635|PROCEDURE|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
58477278|NCT04041635|PROCEDURE|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
58477279|NCT00935584|BEHAVIORAL|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
58477280|NCT05024968|DRUG|Sintilimab|Given by IV
58477281|NCT03133793|DRUG|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
58477282|NCT03133793|DRUG|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
58477283|NCT03133793|OTHER|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
58477284|NCT03133793|OTHER|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
58477285|NCT05610345|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
58477286|NCT05610345|PROCEDURE|Placenta Blood Not Drained|Placenta Blood Not Drained
58477287|NCT01850667|RADIATION|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
58477288|NCT05533606|DRUG|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
58477289|NCT00960999|RADIATION|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
58477290|NCT00960999|RADIATION|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
58477291|NCT06155292|BEHAVIORAL|Standard Communication Email|This is a standard quarterly email communication without personalized performance metrics.
58477292|NCT06155292|BEHAVIORAL|Personalized Report Card Email|This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.
58477293|NCT06155292|BEHAVIORAL|Bottom-Up Framing|"The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback."
58477294|NCT02809235|DIETARY_SUPPLEMENT|coconut oil|3 tablespoons per day of supplemental coconut oil
58477295|NCT03672578|OTHER|loss-frame|loss frame label
58477296|NCT03672578|OTHER|gain-frame|gain frame label
58477297|NCT03672578|OTHER|text-only|text-only label
58477298|NCT03672578|OTHER|icon|label with icon and text
58477299|NCT03672578|OTHER|attribution|label with attribution
58477300|NCT03672578|OTHER|no attribution|label with no attribution
58477301|NCT03672578|OTHER|No label|No label
58477302|NCT05672758|BEHAVIORAL|Sprint training|One-year cycle including specific sprint-oriented athletic training
58477303|NCT05672758|BEHAVIORAL|Endurance training|One-year cycle including specific endurance-oriented athletic training
58477304|NCT05672758|BEHAVIORAL|Recreational Training|One year of nonspecific recreational training
58477305|NCT01396304|DEVICE|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
58477306|NCT01396304|DEVICE|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
58477307|NCT06599398|OTHER|Jeroen Pit Huis|The JPH is a unique and innovative Transitional Care Unit (TCU) situated in close proximity of the AUMC. In this TCU, patients and their family reside in separate private home-like apartments. The families can stay while practising in, and adapting to, their new reality until they are ready to transition home. A multidisciplinary team of healthcare experts (nurses, psychosocial care workers, family counsellors, and paediatricians) are gradually guiding parents towards taking on the role of their child's primary caregiver. This process is guided by a newly developed seven phase care path.One condition for staying in the JPH is that one parent is always present. In this form (24/7 parental stay and nursing care directly available under the supervision of pediatricians) the JPH is unique in the Netherlands.
58477308|NCT05197972|OTHER|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
58477309|NCT03077334|DEVICE|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
58477310|NCT06388993|DEVICE|Bone Marrow Collection|Comparing the two collection systems for bone marrow aspirate
57779898|NCT06739395|DRUG|Dabrafenib|Usage and dosage: Take 150mg orally twice a day, with an interval of about 12 hours.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. When this product is used in combination with trametinib, it should be taken once a day at the same time, along with this product administered in the morning or evening.The dosage for combined use will be adaptively adjusted by the researcher.
58477311|NCT05176288|DRUG|Axitinib|Taken Orally
58477312|NCT05176288|DRUG|Palbociclib|Taken Orally
58477313|NCT05176288|DRUG|Avelumab|Intravenous infusion
58477314|NCT03416985|DEVICE|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
58477315|NCT03416985|DEVICE|BURST Sonic Oral Care|Electric sonic toothbrush
58477316|NCT03416985|DEVICE|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
58477317|NCT04859907|DEVICE|Clamp-like system|Craniotomy closure
58477318|NCT04859907|DEVICE|Plates and screws|Craniotomy closure
58477319|NCT05419050|DRUG|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
58477320|NCT05465317|DRUG|Empagliflozin|Empagliflozin
58477321|NCT05465317|DRUG|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
58477322|NCT06594432|DRUG|R-CHOP+Z+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
58477323|NCT06594432|DRUG|R-CHOP+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
58477324|NCT06654921|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
58477325|NCT06654921|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
58477326|NCT06654921|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
58477327|NCT01798043|OTHER|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
58477328|NCT01798043|OTHER|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
58477329|NCT01720108|DRUG|rivaroxaban and ASA|
57779899|NCT06739395|DRUG|Vebreltinib Enteric Capsules|Usage and dosage: The recommended starting dose is 200 mg/time, taken orally twice a day (once in the morning and once in the evening), until disease progression or intolerable toxicity occurs.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
58477330|NCT06600646|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in patients with refractory or unexplained chronic cough and healthy controls.
58477331|NCT05985499|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
58477332|NCT05985499|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
58477333|NCT04683484|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
58477334|NCT04683484|BIOLOGICAL|Placebo|0,5 mg Al PO4
58477335|NCT05376150|DRUG|XEN1101 10 mg|XEN1101 oral capsule
58477336|NCT05376150|DRUG|XEN1101 20 mg|XEN1101 oral capsule
58477337|NCT05376150|DRUG|Placebo|Placebo capsule
58477338|NCT04197245|DRUG|saline injection therapy in post-acne atrophic scars|saline injection contains 0.9% isotonic sodium chloride solution
58477339|NCT05992922|DRUG|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice a day
58477340|NCT05992922|DRUG|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice a day
58477341|NCT04032964|DRUG|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
58477342|NCT04032964|DRUG|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
58477343|NCT03675347|OTHER|angioplasty|angioplasty
58477344|NCT01183806|DRUG|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
58477345|NCT01183806|OTHER|Exercise training program|Exercise training program
58477346|NCT06601114|DRUG|Paracetamol Group|Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
58477347|NCT06601114|DRUG|Ibuprofen group|Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
58477348|NCT04062630|DEVICE|iFuse 3-D in Bedrock Configuration|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
58477349|NCT04062630|PROCEDURE|Multilevel Lumbar Fusion surgery|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
58477350|NCT06591325|OTHER|exercise|The RT program was performed in the morning and in groups, three days per week (Mondays, Wednesdays, and Fridays), in the University fitness facility over 12 weeks. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise session) with substantial RT experience to ensure consistent and safe exercise performance. Throughout the intervention period, the RT program was carried out on machines and free weights (Ipiranga Fitness, Presidente Prudente, SP, Brazil). The training program was carried out in groups. Participants performed four exercises for the trunk and upper limbs (chest press, seated row, triceps pushdown, preacher curl) and four exercises for the lower limbs (horizontal leg press, leg extension, lying leg curl, seated calf raise) in three sets of 10-15 repetitions based on previous guidelines (9,22).
58477351|NCT06591325|OTHER|Control|maintaining the daily routine
58477352|NCT05659953|DRUG|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
58477353|NCT05659953|DRUG|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
58477354|NCT04799834|OTHER|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
58477355|NCT04181333|DRUG|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
58477356|NCT00686413|DRUG|AZD3480|single dose, oral
58477357|NCT00686413|RADIATION|2-[18F]-F-A85380|Single dose, IV
58477358|NCT03782246|BEHAVIORAL|MBCT|Mindfulness- based Cognitive Therapy
58477359|NCT03782246|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
58477360|NCT06243536|DRUG|Semaglutide|Semaglutide will be administered through 12 weeks.
58477361|NCT06243536|DRUG|standard of care|Patients not assigned to receive semaglutide will receive standard of care.
57784565|NCT04532151|DIAGNOSTIC_TEST|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
58477362|NCT06601231|DIAGNOSTIC_TEST|GAAD score|In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).
57784566|NCT02080520|DIETARY_SUPPLEMENT|Nattokinase|
58477363|NCT01966016|PROCEDURE|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
58477364|NCT01669837|DEVICE|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
58477365|NCT00237406|PROCEDURE|interactive voice response|
58477366|NCT00751582|DIETARY_SUPPLEMENT|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
58477367|NCT00751582|BEHAVIORAL|Nutrition education|Nutrition education for children for three months
58477368|NCT00751582|OTHER|Control Group|No Nutrition Education
58477369|NCT03576586|BEHAVIORAL|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
58477370|NCT03576586|BEHAVIORAL|Attention placebo control|Brief cognitive task plus usual care in the maternity department
58477371|NCT05353270|BEHAVIORAL|Yoga|Yoga sessions will be completed 5 times per week for 4 weeks.
58477372|NCT05353270|BEHAVIORAL|Waitlist control|Waitlisted participants will maintain their normal exercise and diet for 4 weeks. After follow up testing at week 4, participants will be rerandomized to the yoga condition.
58477373|NCT02995746|DRUG|Dexamethasone|"* On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~* Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~* Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~* Anticipated duration of the study: 6 months"
58477374|NCT02558088|DRUG|Salmeterol|
58477375|NCT02886819|OTHER|vibration|Whole body vibration
58477376|NCT04529902|DRUG|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
58477377|NCT04529902|DRUG|Abatacept|Abatacept claim is used as the exposure group.
58477378|NCT06038110|DIAGNOSTIC_TEST|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
58477379|NCT00905164|DRUG|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
58477380|NCT00905164|DRUG|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
58477381|NCT06300463|DRUG|Botensilimab|75 mg IV Q6W
58477382|NCT06300463|DRUG|Balstilimab|450 mg IV Q3W
58477383|NCT06300463|DRUG|AGEN1423|30 mg/kg IV Q3W
58477384|NCT06300463|RADIATION|Radiation|8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
58477385|NCT06654973|OTHER|GMP-produced SARS-CoV-2 Delta strain|The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.
58477386|NCT02546388|DRUG|Indium-111 Pentreotide|
58477387|NCT02546388|DRUG|Gallium-68 DOTATATE|
58477388|NCT06446089|BEHAVIORAL|THP: cognitive behavior therapy and behavioral activation|The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
58477389|NCT04608552|BEHAVIORAL|OMT Exercises|Oral and oropharyngeal exercises
58477390|NCT04608552|BEHAVIORAL|Nasal Breathing Exercises|Nasal breathing exercises each week
58477391|NCT04608552|OTHER|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
58477392|NCT06593899|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiotherapy Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume
58477393|NCT06593899|DRUG|3 cycles of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)
58477394|NCT06588309|BEHAVIORAL|Eye movement desensitization and reprocessing (EMDR)|Integrated addiction and traumafocused treatment.
58477395|NCT06588309|BEHAVIORAL|CRA|CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.
58477396|NCT03776968|DRUG|HC1119|oral
58477397|NCT04765683|OTHER|questionnaire|Survey of views on outpatient consultation format
58477398|NCT04179136|DIETARY_SUPPLEMENT|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
58477399|NCT04179136|DIETARY_SUPPLEMENT|Placebo treatment matching intervention|Placebo treatment matching intervention
58477400|NCT05092100|BEHAVIORAL|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
58477401|NCT05092100|OTHER|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
58477402|NCT05092100|BEHAVIORAL|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
58477403|NCT00124943|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
58477404|NCT03953352|OTHER|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
58477405|NCT04994509|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
58477406|NCT04994509|DRUG|Subcutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
58477407|NCT04994509|DRUG|F/TAF|Tablets administered orally
58477408|NCT04994509|DRUG|F/TDF|Tablets administered orally
57784567|NCT02080520|OTHER|Placebo|
58477409|NCT04994509|DRUG|Placebo SC LEN|Administered via SC injections
58477410|NCT04994509|DRUG|PTM Oral LEN|Tablets administered orally
58477411|NCT04994509|DRUG|PTM F/TAF|Tablets administered orally
58477412|NCT04994509|DRUG|PTM F/TDF|Tablets administered orally
58477413|NCT02636595|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
58477414|NCT01722617|OTHER|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
58477415|NCT01748734|PROCEDURE|quality-of-life assessment|Ancillary studies
58477416|NCT01748734|OTHER|questionnaire administration|Ancillary studies
58477417|NCT01748734|OTHER|counseling intervention|Undergo cognitive behavioral therapy
58477418|NCT01748734|BEHAVIORAL|behavioral intervention|Undergo cognitive behavioral therapy
58477419|NCT01695226|DRUG|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
58477420|NCT01695226|DRUG|Placebo|pre-operative placebo twice daily for two to three weeks
58477421|NCT05148468|DEVICE|Active spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
58477422|NCT05148468|DEVICE|Sham spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
58477423|NCT02123901|OTHER|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
58477424|NCT02123901|OTHER|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
58477425|NCT02123901|OTHER|No exercise|Sedentary life style.
58477426|NCT04177823|DRUG|Belantamab mafodotin|Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
58477427|NCT03922386|DEVICE|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
58477428|NCT04133818|BEHAVIORAL|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation"
58477429|NCT01809600|OTHER|No intervention (observational study)|
58477430|NCT00836693|DRUG|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
58477431|NCT00836693|DRUG|placebo|tablet administered orally once a day for 12 weeks.
58477432|NCT01763697|BEHAVIORAL|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
58477433|NCT01763697|BEHAVIORAL|Recorded meal|
58477434|NCT05386420|DRUG|Hymecromone tablets|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
58477435|NCT05386420|OTHER|Placebo|Conventional treatment combined with Placebo.
58477436|NCT01873872|DIETARY_SUPPLEMENT|Theralac probiotic|
58477437|NCT01873872|DIETARY_SUPPLEMENT|Culturelle probiotic|
58477438|NCT01873872|OTHER|placebo|
58477439|NCT06208969|BEHAVIORAL|intensive nutrition counseling|individualized regular nutrition education
58477440|NCT03405792|DRUG|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
58477441|NCT03405792|DEVICE|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
58477442|NCT03405792|DRUG|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
58477443|NCT00698763|DRUG|Levosimendan|from 0.125 mg to 2 mg in escalating doses
58477444|NCT00698763|DRUG|Placebo|Placebo capsules are identical in appearance to active capsules
58477445|NCT00782990|PROCEDURE|Surgical treatment: TVT|
58477446|NCT00782990|PROCEDURE|Surgical treatment: colposuspension|
58477447|NCT06169969|DEVICE|magnetic therapy|Kegel exercises
58477448|NCT05467059|OTHER|Napping|Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
58477449|NCT00330434|OTHER|Trial Withdrawn 1|Trial Withdrawn 1
58477450|NCT00330434|OTHER|Trial Withdrawn 2|Trial Withdrawn 2
58477451|NCT06600945|OTHER|Cataract surgery|With local anesthetic in peribulbar anesthesia
58477452|NCT03146923|OTHER|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives"
58477453|NCT03146923|OTHER|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio"
58477454|NCT04322526|DRUG|Naltrexone 50 Mg Oral Tablet|Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
58477455|NCT04322526|DRUG|Placebo oral tablet|Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
58477456|NCT02821234|OTHER|MRI|
58477457|NCT04356898|OTHER|No intervention|No intervention
58477458|NCT04020549|BEHAVIORAL|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
58477459|NCT04020549|BEHAVIORAL|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
58477460|NCT03414502|DRUG|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
58477461|NCT03414502|DRUG|Abatacept|Starting dose which may be adjusted as needed at the discretion of the investigator
58477462|NCT03414502|DRUG|Adalimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477463|NCT03414502|DRUG|Azathioprine|Starting dose which may be adjusted as needed at the discretion of the investigator
58477464|NCT03414502|DRUG|Baricitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
58477465|NCT03414502|DRUG|Certolizumab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477466|NCT03414502|DRUG|Etanercept|Starting dose which may be adjusted as needed at the discretion of the investigator
58477467|NCT03414502|DRUG|Golimumab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477468|NCT03414502|DRUG|Hydroxychloroquine|Starting dose which may be adjusted as needed at the discretion of the investigator
58477469|NCT03414502|DRUG|Infliximab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477470|NCT03414502|DRUG|Leflunomide|Starting dose which may be adjusted as needed at the discretion of the investigator
58477471|NCT03414502|DRUG|Minocycline|Starting dose which may be adjusted as needed at the discretion of the investigator
58477472|NCT03414502|DRUG|Rituximab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477473|NCT03414502|DRUG|Sarilumab|Starting dose which may be adjusted as needed at the discretion of the investigator
58477474|NCT03414502|DRUG|Sulfasalazine|Starting dose which may be adjusted as needed at the discretion of the investigator
58477475|NCT03414502|DRUG|Tofacitinib|Starting dose which may be adjusted as needed at the discretion of the investigator
58477476|NCT06029946|DIAGNOSTIC_TEST|elastography, ultrasound|First local anesthesia with lidocaine 2%, then 3 smears will be obtained for each nodule using a 20-22 gauge needle, multiple passes within the lesion will be made to obtain sufficient cells, the aspirate will be spread over a glass, fixed with ethanol 95% and submitted to the pathology department to be reported.
58477477|NCT05907863|OTHER|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
58477478|NCT06494449|OTHER|Higher protein|An acute mixed meal containing higher protein
58477479|NCT06494449|OTHER|Lower protein|An acute mixed meal containing lower protein
58477480|NCT00394095|DRUG|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
58477481|NCT00394095|DRUG|Placebo|Matched placebo to Experimental arm
58477482|NCT06655259|PROCEDURE|TURP|Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor
58477483|NCT06655259|DRUG|Standard Medical Therapy|Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
58477484|NCT06080334|DEVICE|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
58477485|NCT06080334|DEVICE|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
58477486|NCT03410277|OTHER|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
58477487|NCT02398890|OTHER|routine care|routine care
58477488|NCT06597773|OTHER|Online patient navigation and supportive care referrals|In the online patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to web-based, systematic supportive care resources consisting of pre-recorded videos led by specialists and which will be available on a study-specific website, allowing each participant to access the resources as soon as they receive a referral. Additionally, online support groups will be held monthly to complement the supportive care programs.
58477489|NCT06597773|OTHER|In-person patient navigation and supportive care referrals|In the in-person patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to supportive care services available at their healthcare institution.
58477490|NCT02342808|BEHAVIORAL|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
58477491|NCT02342808|BEHAVIORAL|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
58477492|NCT06263582|DRUG|Artesunate pessary|Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
58477493|NCT06263582|DIAGNOSTIC_TEST|blood draws for pharmacokinetics of the study drug|On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
58477494|NCT00985764|PROCEDURE|cesarean delivery|
58477495|NCT03401346|COMBINATION_PRODUCT|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
58477496|NCT03401346|DRUG|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
58477497|NCT03401346|COMBINATION_PRODUCT|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
58477498|NCT01954498|DIETARY_SUPPLEMENT|Walnuts|
58477499|NCT01954498|DIETARY_SUPPLEMENT|OTC multivitamin|
58477500|NCT01328886|DRUG|Omalizumab|omalizumab lyophilized 150 mg injection
58477501|NCT00832299|DRUG|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
58477502|NCT00832299|PROCEDURE|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
58477503|NCT02894346|OTHER|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
58477504|NCT06586632|DEVICE|AID technology|Automated insulin delivery system combined with a CGM
58477505|NCT06586632|DEVICE|CGM|CGM alone
58477506|NCT06651684|BEHAVIORAL|CanCEASE with Health Navigator|"CanCEASE is a digital intervention to identify parents who smoke, assess their motivation and willingness to quit, as well as to provide direct linkage to evidence-based smoking interventions, including effective behavioural and pharmacological resources that can be used alone or in combination.~Participants will have the choice to receive CanCEASE at three timepoints (0, 6 and 12 months). CanCEASE will be combined with an offer of support sessions with a Health Navigator.~Health Navigators will be research personnel hired specifically for this study and trained formally in health navigation, tobacco cessation counseling and strategies to address unmet social needs. The investigators will leverage knowledge and experience of two ongoing RCTs of HNs in pediatrics to inform training strategies."
58477507|NCT04976621|BEHAVIORAL|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.
58477508|NCT04976621|OTHER|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
58477509|NCT06594250|DIAGNOSTIC_TEST|Nasal swab|Nasal swab to detect nasal carriage of S. aureus
58477510|NCT06594250|BIOLOGICAL|Venous sampling|Peripheral venous sampling to collect peripheral blood mononuclear cells.
58477511|NCT06594250|BIOLOGICAL|Antibiotic treatment|Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus
58477512|NCT06594250|DEVICE|Nasal swab|A new nasal swab will be taken using the same technique, to see whether or not the carriage persists
58477513|NCT06594250|BIOLOGICAL|Intracellular reservoir test|In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.
58477514|NCT00425269|BEHAVIORAL|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
58477515|NCT02067078|DRUG|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
58477516|NCT02067078|DRUG|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
58477517|NCT02067078|DRUG|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
58477518|NCT05666869|DRUG|Esketamine perfusion|Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
58477519|NCT06368635|DIAGNOSTIC_TEST|Coronary angiography|target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8； or severe stenosis（\>80%）after successful PCI(percutaneous coronary intervention) and FFR ≥0.8
58477520|NCT00093041|DRUG|Zalutumumab|Weekly infusion
58477521|NCT01611844|DEVICE|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
58477522|NCT01611844|DEVICE|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
58477523|NCT00807911|DRUG|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
58477524|NCT00807911|DRUG|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
58477525|NCT05686902|OTHER|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
58477526|NCT06654414|BEHAVIORAL|PRIDE QUIT|"This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will likely receive 6-10 weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session."
58477527|NCT06654414|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|Brief counseling, the option of nicotine replacement therapy, and referral to the Quit Line.
58477528|NCT00921375|DRUG|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
58477529|NCT06653959|DEVICE|active Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.
58477530|NCT06653959|DEVICE|sham Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.
58477531|NCT00349518|DRUG|Dasatinib|
58477532|NCT06163443|DIETARY_SUPPLEMENT|Vitamin B|MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription
58477533|NCT06163443|DIETARY_SUPPLEMENT|Placebo|MTHFR, MTR, and MTRR polymorphysm based placebo prescription
58477534|NCT06653972|DRUG|Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.|Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
58477535|NCT04632680|DEVICE|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
58477536|NCT05228587|DRUG|Indocyanine green|Indocyanine green will be injected in all donor
58477537|NCT06521125|DIAGNOSTIC_TEST|High resolution Computed Tomography (HRCT) scans of the Chest|A chest high-resolution computed tomography (HRCT) scan will be performed
58477538|NCT06521125|DIAGNOSTIC_TEST|Pulmonary Function Testing (PFTs)|Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
58477539|NCT06521125|DIAGNOSTIC_TEST|Digital lung sounds auscultation|Lung sounds will be recorded using a manual approach with a digital stethoscope
58477540|NCT06521125|DIAGNOSTIC_TEST|Laboratory Assessments|Clinical laboratory tests will be collected from each participant
58477541|NCT06521125|GENETIC|DNA sequencing|A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
58477542|NCT06655246|DRUG|ziftomenib|menin inhibitor
58477543|NCT06655246|DRUG|imatinib mesylate|kinase inhibitor
58477544|NCT03542877|DRUG|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
58477545|NCT00625170|DRUG|olanzapine|olanzapine 10 mg/day for 8 days
58477546|NCT00625170|DRUG|Haloperidol|haloperidol 3 mg/day for 8 days
58477547|NCT06070064|OTHER|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
58477548|NCT01287962|DRUG|apatinib|750 mg，po，QD； 28 days every cycle
58477549|NCT01287962|DRUG|placebo|po，QD； 28 days every cycle
58477550|NCT05310019|OTHER|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
58477551|NCT05310019|OTHER|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
58477552|NCT01122238|DRUG|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
58477553|NCT01122238|DRUG|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
58477554|NCT01122238|BEHAVIORAL|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
58477555|NCT01122238|BEHAVIORAL|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
58477556|NCT01122238|OTHER|No Intervention|No Intervention
58477557|NCT01122238|DRUG|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
58477558|NCT04774094|DRUG|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
58477559|NCT05279755|DRUG|prosetin|oral solution
58477560|NCT05279755|DRUG|placebo|oral solution
58477561|NCT00264186|DRUG|LPS 2 ng/kg intravenous (IV) bolus|
58477562|NCT00264186|DRUG|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
58477563|NCT00264186|DRUG|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
58477564|NCT00264186|DRUG|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
58477565|NCT00264186|DRUG|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
58477566|NCT02088008|DRUG|cinidipine, valsartan|
58477567|NCT06651606|BEHAVIORAL|Progressive Ratio Training (PRT)|"Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc."
58477568|NCT06651606|BEHAVIORAL|Differential Reinforcement of Alternative (DRA) Behavior with Extinction|In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
58477569|NCT03925090|DRUG|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
58477570|NCT03925090|DRUG|Cisplatin+placebo|chemotherapy
58477571|NCT06319014|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
58477572|NCT03760094|DEVICE|Colour Doppler|evaluation of lymph nodes by Doppler
58477573|NCT05798767|BEHAVIORAL|Neuropsychological tests|"Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium."
58477574|NCT00424684|PROCEDURE|collection of blood sample|
58477575|NCT04927195|DRUG|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
58477576|NCT04927195|DRUG|Placebo|Placebo oral capsule
58477577|NCT02458313|DRUG|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
58477578|NCT02458313|OTHER|Placebo|Placebo capsules b.i.d. for 12 weeks
58477579|NCT06492902|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in four weeks using patches (four sessions), each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. The patch with the needle will remain in place for one week.
58477580|NCT06492902|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for four weeks using patches (four sessions), each with a square shape and a side length of 10 mm. The patches will not contain any needles and will remain in place for one week.
57784568|NCT04894578|PROCEDURE|reverse distal metatarsal minimal-invasive osteotomy|minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
57784569|NCT04894578|PROCEDURE|tarsometatarsal fusion|open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
57784570|NCT03305302|PROCEDURE|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
58477581|NCT03159429|BEHAVIORAL|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
58477582|NCT03159429|BEHAVIORAL|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
58477583|NCT04232722|DRUG|Arsenicals|As4 S4
58477584|NCT02480387|DRUG|Ledipasvir/Sofosbuvir FDC|
58477585|NCT03910244|DRUG|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
58477586|NCT03910244|DRUG|Placebo oral capsule|Matching placebo will be given.
58477587|NCT03722238|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
58477588|NCT06655441|DRUG|3% trehalose|ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
58477589|NCT00474487|BIOLOGICAL|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
58477590|NCT00474487|BIOLOGICAL|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
58477591|NCT00474487|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
58477592|NCT00474487|BIOLOGICAL|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
58477593|NCT03228550|DIETARY_SUPPLEMENT|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
58477594|NCT03228550|BEHAVIORAL|Aerobic exercise|Static exercise cycle
58477595|NCT03228550|DIETARY_SUPPLEMENT|Placebo multinutrient|Placebo multinutrient supplement
58477596|NCT04788329|BEHAVIORAL|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
58477597|NCT04788329|BEHAVIORAL|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
58477598|NCT03276507|DIAGNOSTIC_TEST|Pulmonary function studies|
58477599|NCT03276507|DIAGNOSTIC_TEST|Echocardiogram|
58477600|NCT03276507|DIAGNOSTIC_TEST|Electrocardiogram|
58477601|NCT03276507|DIAGNOSTIC_TEST|Chest radiography|
58477602|NCT03276507|DIAGNOSTIC_TEST|Blood test|
58477603|NCT03276507|BEHAVIORAL|Quality of life questionnaire|
58477604|NCT02706977|DRUG|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
58477605|NCT02706977|DRUG|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
58477606|NCT02706977|DEVICE|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
58477607|NCT02706977|OTHER|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
57784571|NCT03470285|PROCEDURE|Multiparametric MR imaging (mpMRI)|The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
58477608|NCT02706977|OTHER|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
58477609|NCT01697670|DRUG|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
58477610|NCT02743052|DRUG|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
58477611|NCT05767749|DRUG|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
58477612|NCT05767749|DRUG|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
58477613|NCT05767749|DRUG|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
58477614|NCT04524780|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
58477615|NCT03109496|OTHER|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
58477616|NCT05916235|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
58477617|NCT01152957|BEHAVIORAL|CARIÑO Project|Care Attention Resources Information Nutrition \& Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
58477618|NCT01152957|BEHAVIORAL|Enhanced Usual Care|Usual care plus 4 health education brochures
58477619|NCT02948127|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
58477620|NCT02948127|BIOLOGICAL|Placebo|Administered as nose drops
58477621|NCT02781714|BEHAVIORAL|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered"
58477622|NCT05535725|DRUG|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
58477623|NCT03790202|DEVICE|VistaCare®|Controlled atmosphere wound healing device
58477624|NCT00944853|DIETARY_SUPPLEMENT|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
58477625|NCT00944853|DIETARY_SUPPLEMENT|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
58477626|NCT00944853|DIETARY_SUPPLEMENT|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
58477627|NCT06599424|OTHER|Observational|Observational
58477628|NCT01761968|DRUG|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
58477629|NCT06590311|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability evaluation through different domains
58477630|NCT01135550|DRUG|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
57784572|NCT03911193|DRUG|Cabozantinib|Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
58134170|NCT04712422|OTHER|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
57784573|NCT01564082|DEVICE|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
57784574|NCT03393299|PROCEDURE|STOPP/START criteria|software which helps to do the drug reconciliation
58477631|NCT01135550|DRUG|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
58477632|NCT00347022|DRUG|Xenetix|300 mg of iodine/ml
58477633|NCT00347022|DRUG|Visipaque|270 mg of iodine/ml
58477634|NCT03248908|DIAGNOSTIC_TEST|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
58477635|NCT03248908|OTHER|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
58477636|NCT05900167|BEHAVIORAL|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
58477637|NCT03207971|PROCEDURE|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
58477638|NCT05479695|DEVICE|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
58477639|NCT05479695|DEVICE|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
58477640|NCT02939287|DRUG|o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1|Add aprepitant to anti-emetic regimen
58477641|NCT02939287|DRUG|Olanzapine10 mg orally daily on Days -1,0,+1 and +2|add olanzapine to anti-emetic regimen
58477642|NCT02939287|DRUG|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
58477643|NCT01815918|DRUG|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
58477644|NCT01815918|DRUG|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
58477645|NCT04402138|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
58477646|NCT02786849|OTHER|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
58477647|NCT02786849|OTHER|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
58477648|NCT06296069|OTHER|exergame-based cognitive-motor training on an unstable surface|"The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side."
58477649|NCT06296069|OTHER|exergame-based cognitive-motor training on an stable surface|"The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces."
58477650|NCT04469907|DRUG|AZD9977|Participants will receive a single oral dose of AZD9977 under fasted conditions.
58477651|NCT01951963|DRUG|Ketamine|
58477652|NCT01951963|DRUG|Morphine|
58477653|NCT00828776|BIOLOGICAL|Heparin sodic - Cristália|5000UI/mL
58477654|NCT00828776|BIOLOGICAL|heparin - Liquemine (Roche)|5000UI/mL
58477655|NCT05202886|DIAGNOSTIC_TEST|Liver from deceased donors|Liver donors photographed
58134171|NCT01042886|BEHAVIORAL|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
58134172|NCT01042886|BEHAVIORAL|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
58134173|NCT01724502|BEHAVIORAL|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
58477656|NCT03785015|OTHER|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
58134174|NCT05564247|BEHAVIORAL|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
58477657|NCT03785015|OTHER|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
58477658|NCT02288741|DRUG|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
58477659|NCT02288741|DRUG|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
58477660|NCT02288741|DRUG|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
58477661|NCT02288741|PROCEDURE|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
58477662|NCT02288741|DRUG|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
58477663|NCT02288741|PROCEDURE|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
58477664|NCT04852172|DRUG|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
58477665|NCT04852172|OTHER|D5 1/2NS|Saline
58477666|NCT01065727|OTHER|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
58477667|NCT01065727|OTHER|natalizumab|monthly natalizumab during 3 years
58477668|NCT00941213|DEVICE|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
58477669|NCT00941213|DEVICE|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
58477670|NCT01187355|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
58477671|NCT01187355|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
58477672|NCT01187355|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
58477673|NCT05270395|BEHAVIORAL|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
58477674|NCT04506411|DIETARY_SUPPLEMENT|Turmipure GOLD®|TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
58477675|NCT04506411|DIETARY_SUPPLEMENT|Turmeric rhizome PE 95% curcuminoids|STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
58477676|NCT04506411|DIETARY_SUPPLEMENT|Placebo|Placebo: Maltodextrin - 4 capsules once daily- as prescribed
58477677|NCT06653998|OTHER|Early mobilization and rehabilitation|"In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity."
58477678|NCT05417620|BEHAVIORAL|Social Media Campaign|PrEP social influence campaign, which will use online approaches to promote PrEP within communities in addition to the standard of care activities. Messaging crafted with community input will be geographically targeted to women, parents/mentors, and male partners on Facebook, Instagram, and Whatsapp, all with the intention to promote PrEP for women at high risk of HIV infection and change community norms and influence around PrEP. A combination of static imagery and brief videos will be used to engage these groups via social media platforms. A Facebook page will be created and maintained that can be accessed by anyone anywhere, but will only be advertised/promoted in the intervention districts.
58477679|NCT05417620|BEHAVIORAL|PrEP Champions|Within venues served by the FSW and AGYW programs, the team will identify and train 1 venue-based PrEP champion per venue who will receive supplies (e.g. a hat, pin and posters, flyers, IEC material) to wear to promote PrEP, facilitate linkage between women interested in PrEP and the TB HIV Care PrEP programme. PrEP champions will be either peers with experience taking PrEP, venue managers or local influencers (e.g. women running shops next to the mobile serving AGYW) that have repeated contact with the women the programme is intended to serve. The final selection of PrEP champions will be made in consultation with the Community Advisory Groups, venues and by the programme who works closely with each of the sites.
58477680|NCT05417620|BEHAVIORAL|Community Mobilization|A PrEP community mobilization team (2 peers, including one woman and one man) will be recruited within each ward to promote PrEP. The team will present information about PrEP and the PrEP programme at the ward councilors meeting, at Learning Support Agent meetings with parents/guardians, at local events/fairs, community meetings and through engaging men, women and parents across the community through informal conversations. Teams will be wearing branded material and will focus on presenting factual information and decreasing PrEP stigma. Each team will focus on promoting PrEP within their own ward over the 6-month period.
58134175|NCT00465010|BEHAVIORAL|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
58134176|NCT04829227|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
58477681|NCT05417620|OTHER|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
58477682|NCT02110069|DRUG|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
58477683|NCT02110069|DRUG|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
58477684|NCT05947357|OTHER|Nutrition Assistance Program|Patients will receive in the intervention group a $40.00 per month voucher for 6 months for use in the produce section of a local grocery store.
58477685|NCT00017212|DRUG|exatecan mesylate|
58477686|NCT06082362|OTHER|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
58477687|NCT05483777|PROCEDURE|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
58477688|NCT02923726|DEVICE|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
58477689|NCT02923726|DEVICE|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
58477690|NCT04568616|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
58477691|NCT02870595|DEVICE|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
58477692|NCT02870595|DEVICE|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
58477693|NCT03131323|PROCEDURE|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~* Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~* The camera: fitted with Three-CCD (Charged Couple Device) sensors.~* A high resolution monitor.~* A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required \[8\].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
58477694|NCT00631072|BIOLOGICAL|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
58477695|NCT00631072|DRUG|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
58477696|NCT06595199|OTHER|Online peer support|A closed online peer support group
58477697|NCT04145661|DEVICE|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
58477698|NCT04145661|DEVICE|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
58477699|NCT04790916|DRUG|RO7049665|RO7049665, subcutaneous injection, Q2W.
58477700|NCT04790916|OTHER|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
58477701|NCT01940952|DRUG|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
58477702|NCT01940952|DRUG|Placebo + Donepezil 5mg or 10mg|
58477703|NCT01940952|DRUG|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
58477704|NCT04381364|DRUG|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
58477705|NCT06508190|BEHAVIORAL|continuous positive airway pressure|continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night
58477706|NCT06508190|BEHAVIORAL|free walking exercise and continuous positive airway pressure|patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
58477707|NCT03755713|DRUG|ASP0892|Intradermal
58477708|NCT03755713|DRUG|Placebo|Intradermal; normal saline solution
58477709|NCT04117555|DIAGNOSTIC_TEST|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
58477710|NCT06116838|DEVICE|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
58477711|NCT06116838|DEVICE|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
58477712|NCT04409925|DRUG|rhDNase I|Inhaled nebulisations
58477713|NCT01434615|DEVICE|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
58477714|NCT01434615|OTHER|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
58477715|NCT06655779|DIAGNOSTIC_TEST|Acoustic Detection of Blood Flow|Subject will have the acoustic device scoring performed prior to a Coronary CTA. No treatment decisions will be based upon the acoustic device score.
58477716|NCT05684822|OTHER|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
58134177|NCT02748161|PROCEDURE|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
58134178|NCT02942953|DEVICE|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
58134179|NCT06304701|DIAGNOSTIC_TEST|Cognitive and writing tests|"* Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing"
58134180|NCT04719000|DRUG|rhFSH+rhLH|300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
58134181|NCT04719000|DRUG|rhFSH|300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
58134182|NCT04191980|OTHER|Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists|"The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes"
58134183|NCT00503152|DRUG|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58134184|NCT00503152|DRUG|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58134185|NCT00503152|DRUG|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
58134186|NCT04926883|OTHER|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
58477717|NCT00574197|DRUG|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
58134187|NCT02631629|OTHER|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
58134188|NCT02631629|OTHER|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
58134189|NCT02445300|OTHER|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
58134190|NCT02445300|OTHER|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
58134191|NCT04995822|DEVICE|hip arthroplasty|Hip prosthesis surgery
58134192|NCT05813548|OTHER|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
58134193|NCT05813548|OTHER|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
58477718|NCT00434291|DRUG|TG-873870(Nemonoxacin)|
58477719|NCT02578069|DEVICE|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
57779900|NCT06739395|DRUG|Alpelisib Pill|Usage and dosage: The recommended dosage is 300mg (two 150mg film tablets), taken once a day with food; Continue treatment until the disease worsens or unacceptable toxicity occurs.Administration method: Patients should take aspirin at approximately the same time every day and swallow the entire aspirin tablet (the tablet should not be chewed, crushed, or separated before swallowing).The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779901|NCT06739395|DRUG|Sacituzumab Govitecan-Hziy 180 MG|Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779902|NCT06739395|DRUG|Lenvatinib Capsules|Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779903|NCT06739395|DRUG|Pazopanib Pill|"Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided."
57779904|NCT06739395|DRUG|Palbociclib Pill|Usage, dosage, and administration method: 100mg, orally administered once daily for 21 consecutive days, followed by a 7-day discontinuation; Every 28 days is a treatment cycle.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779905|NCT06739395|DRUG|Chidamide|Usage and dosage: It is recommended to take 30mg (6 tablets) each time, twice a week, with an interval of no less than 3 days between each dose (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). It should be taken 30 minutes after breakfast.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779906|NCT06739395|DRUG|PD-1/PD-L1/PD-1&CTLA4 inhibitor|Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779907|NCT06739395|DRUG|Target Gene|Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
57779908|NCT06739226|BIOLOGICAL|Antigen-specific CAR T, CTL and DCvac to treat melanoma.|Antigen-specific CAR T, CTL and DCvac to treat melanoma.
57779909|NCT02576834|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
57779910|NCT02576834|OTHER|Services as Usual|Services as usually provided in the community
57779911|NCT05697939|DIAGNOSTIC_TEST|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
57779912|NCT05678673|DRUG|XL092|Specified doses on specified days
57779913|NCT05678673|DRUG|Nivolumab|Specified doses on specified days
58477720|NCT02578069|DEVICE|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
57779914|NCT05678673|DRUG|Sunitinib Malate|Specified doses on specified days
57779915|NCT01824472|DEVICE|CPAP|Treatment for sleep apnea
57779916|NCT01824472|BEHAVIORAL|CBT|Treatment for insomnia
57779917|NCT01824472|DEVICE|sham CPAP|Placebo for sleep apnea
57779918|NCT01824472|BEHAVIORAL|CC|Placebo (sham) for insomnia
57779919|NCT05921630|OTHER|Education|Patient education before pulmonary function test
57779920|NCT06741150|BIOLOGICAL|NWRD09 administered by intramuscular injection|Intramuscular injection administration was carried out according to the protocol design.
57779921|NCT04667468|BIOLOGICAL|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
57779922|NCT04667468|BIOLOGICAL|Standard Care|standard care including blood and blood component therapy
57779923|NCT04048070|DRUG|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
57779924|NCT04048070|DRUG|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
57779925|NCT04048070|BEHAVIORAL|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
57779926|NCT04048070|BEHAVIORAL|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
57779927|NCT04048070|BEHAVIORAL|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
57779928|NCT04048070|BEHAVIORAL|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
57779929|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
57779930|NCT04361474|DRUG|Budesonide Nasal|Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
57779931|NCT04361474|OTHER|Physiological serum|Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
57779932|NCT04426006|OTHER|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire"
57779933|NCT04345874|BEHAVIORAL|Nutrition technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
57779934|NCT04345874|BEHAVIORAL|Children's environmental health technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
57779935|NCT06737341|DRUG|Bupivacaine Liposomes(BL)|20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.
57779936|NCT06737341|DRUG|Bupivacaine(B)|10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
57779937|NCT03316612|DIETARY_SUPPLEMENT|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
57779938|NCT03316612|DIETARY_SUPPLEMENT|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
57779939|NCT06728332|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Providers in the study recruitment network will recruit eligible patients through an existing visit. After this referral, the study is conducted entirely electronically.
57779940|NCT06688786|DRUG|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy|Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
57779941|NCT04574154|PROCEDURE|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
57779942|NCT04574154|PROCEDURE|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
57779943|NCT04574154|PROCEDURE|spinal anesthesia|bupivacaine 0,5% 2.2 ml
57779944|NCT06527079|OTHER|Opioid Tapering Pathway Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
57779945|NCT04345913|PROCEDURE|Biopsy|Undergo biopsy
57779946|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57779947|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
57779948|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
57779949|NCT04345913|DRUG|Eribulin Mesylate|Given IV
57779950|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57779951|NCT05958407|DRUG|Tralokinumab|After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks
57779952|NCT05958407|DRUG|Placebo|After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
57779953|NCT06738862|OTHER|PET|\[18F\] - FD17 PET/MRI imaging
57779954|NCT06104124|DRUG|Dazodalibep|IV infusion
57779955|NCT06104124|DRUG|Placebo|IV infusion
57779956|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
57779957|NCT05987618|DEVICE|Oral appliance with elastic bands|"The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16)."
57779958|NCT05987618|DEVICE|Oral appliance without elastic bands|The oral appliance without the elastic bands.
57779959|NCT01347853|DRUG|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
57779960|NCT01347853|DRUG|Placebo|Intranasal post-surgery for up to 5 days total
57779961|NCT01564719|BEHAVIORAL|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
57779962|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
57779963|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
57779964|NCT01398436|PROCEDURE|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
57779965|NCT06479720|DRUG|Combined pharmacotherapy with Solifenacin and Mirabegron|Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
57779966|NCT06479720|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
57779967|NCT06479720|DRUG|Mirabegron with vaginal estrogen cream|Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
57779968|NCT04063111|DEVICE|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
57779969|NCT04063111|DEVICE|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
57779970|NCT05509712|BEHAVIORAL|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
57779971|NCT05509712|BEHAVIORAL|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
57779972|NCT00652925|DRUG|Celecoxib|Higher dose, 6 mg/kg/dose BID
57779973|NCT00652925|DRUG|Celecoxib|Active drug at lower dose
57779974|NCT00652925|DRUG|Naproxen|Control comparator, 15 mg/kg/dy target dose
57779975|NCT01430312|DRUG|azelaic acid pre-foam formulation|
57779976|NCT01430312|DRUG|Vehicle pre-foam formulation|
57779977|NCT01430312|DRUG|Water|
57779978|NCT01430312|DRUG|Sodium lauryl sulfate|
57779979|NCT06272019|OTHER|Iodine gargle|Iodine gargle 0.2 %
57779980|NCT03312465|DEVICE|AS Domelock System|Hemi or Total Shoulder Arthroplasty
57779981|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
57779982|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
57779983|NCT06170957|OTHER|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
58134194|NCT03596190|DIAGNOSTIC_TEST|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
58477721|NCT06541548|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
57779984|NCT06731452|BEHAVIORAL|Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance|"Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience."
57779985|NCT05249296|OTHER|Nature based solution for stress reduction|participation in nature activities: daily 30 min walking in nature
57779986|NCT06097637|OTHER|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection achieves similar rates of complete resection with comparable safety, with lower rates of recurrence and fewer repeat procedures.
57779987|NCT06097637|OTHER|hot snare polypectomy|Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
57779988|NCT00897728|OTHER|laboratory biomarker analysis|
57779989|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
57779990|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
57779991|NCT06714552|DIETARY_SUPPLEMENT|Galacto-Oligosaccharide|24.0 g Oligomate® in 100 mL water
57779992|NCT06714552|OTHER|Glucose|17.8 g glucose in 100 mL water
57779993|NCT05818189|DEVICE|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
57779994|NCT05818189|DEVICE|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
57779995|NCT06671093|GENETIC|Tune-401|Epigenetic gene silencing therapy
57779996|NCT06294678|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
57779997|NCT06677203|DRUG|ASN51|Oral capsules
57779998|NCT06677203|DRUG|Placebo|Oral capsules
57779999|NCT03226457|DRUG|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
57780000|NCT03226457|DRUG|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
57780001|NCT03226457|DRUG|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
57780002|NCT00445601|DRUG|gemcitabine hydrochloride|Given intravesically
57780003|NCT00445601|OTHER|placebo|Given intravesically
57780004|NCT00927043|OTHER|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
57780005|NCT04857190|DEVICE|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
57780006|NCT04857190|DEVICE|Conventional Malleable Stylet|Conventional Malleable Stylet
57780007|NCT03314623|BEHAVIORAL|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
57780008|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
57780009|NCT04938167|OTHER|95% - 99% SpO2 target|If the infant is randomized to the intervention arm, the oxygen saturation goal will be changed from the standard goal of 91% - 95% to the experimental goal of 95%-99%. The treating medical team will then adjust the oxygen and respiratory support to maintain these goals (SpO2 alarm levels will be set at 93% and 100%).
57780010|NCT04431687|DRUG|CKD 501|QD, PO
57780011|NCT04431687|DRUG|D759, D150|QD, PO
57780012|NCT04431687|DRUG|CKD-501, D759, D150|QD, PO
57780013|NCT03396731|DEVICE|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
57780014|NCT04069221|DRUG|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
57780015|NCT04069221|DRUG|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
57780016|NCT04069221|DRUG|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
57780017|NCT04069221|DRUG|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
57780018|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
57780019|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
57780020|NCT01854294|DRUG|GM604|GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
57780021|NCT01854294|DRUG|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
57780022|NCT03355365|BIOLOGICAL|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
57780023|NCT03355365|OTHER|Intrathecal saline injection|Placebo
57780024|NCT03285113|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
57780025|NCT02688374|OTHER|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
57780026|NCT02688374|OTHER|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
57780027|NCT02688374|OTHER|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
57780028|NCT01945762|DRUG|Vandetanib 300 mg|Vandetanib commercial tablets
57780029|NCT00205231|DRUG|etanercept|
57780030|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
57780031|NCT01000376|DRUG|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
57780032|NCT01000376|DRUG|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
57780033|NCT06737848|PROCEDURE|Single catheter adrenal vein sampling|The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.
57780034|NCT06737848|PROCEDURE|Double catheters adrenal vein sampling|The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.
57780035|NCT04019600|OTHER|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
57780036|NCT03982888|PROCEDURE|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
57780037|NCT03982888|DEVICE|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
57780038|NCT02074540|OTHER|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
57780039|NCT00601718|DRUG|vorinostat|Given PO
57780040|NCT00601718|BIOLOGICAL|rituximab|Given IV
57780041|NCT00601718|DRUG|ifosfamide|Given IV
57780042|NCT00601718|DRUG|carboplatin|Given IV
57780043|NCT00601718|DRUG|etoposide|Given IV
57780044|NCT00601718|OTHER|pharmacological study|Correlative studies
57780045|NCT00601718|OTHER|laboratory biomarker analysis|Correlative studies
57780046|NCT00601718|GENETIC|gene expression analysis|Correlative studies
57780047|NCT06720389|RADIATION|peri implant bone loss was assessed by CBCT|using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)
57780048|NCT06720389|OTHER|posterior ridge resorption was assessed by CBCT|posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
57780049|NCT05209074|DRUG|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
57780050|NCT05209074|DRUG|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
57780051|NCT02829710|BEHAVIORAL|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
57780052|NCT06737224|OTHER|Fasting + Exercise (FAST+EX): fasting + exercise condition|Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.
57780053|NCT06737224|OTHER|Fasting only (FAST): Non-exercise fasting condition|Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.
57780054|NCT05463614|DRUG|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
57780055|NCT02971384|DRUG|Echinaforce|
57780056|NCT06737471|OTHER|Intensive rehabilitation treatment|"A 3-hour daily rehabilitation treatment will be delivered to each patient 5 days a week for 5 weeks (45 hours) in the care units of the Hospital.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
57780057|NCT06737471|OTHER|Extensive rehabilitation treatment|"A 3-hour weekly rehabilitation treatment will be delivered to each patient for 15 weeks (45 hours) in an outpatient setting.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
57780058|NCT04266093|DRUG|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
57780059|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
58134195|NCT00826930|DRUG|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
58134196|NCT01396278|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
58134197|NCT01396278|DRUG|Fluticasone propionate|Fluticasone propionate HFA MDI
58134198|NCT01396278|DRUG|BI 54903|BI 54903 via Respimat inhaler
58134199|NCT00444197|BEHAVIORAL|Mentoring and violence prevention curriculum with parental monitoring|
58134200|NCT06150326|DEVICE|medical honey Activon® 25g Tube|no blinding procedures will be set up for the adminisration of the treatement
58134201|NCT06150326|DEVICE|standard of care|no blinding procedures will be set up for the adminisration of the treatement
58134202|NCT01922648|PROCEDURE|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
58134203|NCT01918800|BEHAVIORAL|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
58134204|NCT01918800|BEHAVIORAL|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
58134205|NCT05542108|BEHAVIORAL|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
58134206|NCT05542108|BEHAVIORAL|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
58134207|NCT06088420|DRUG|intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .|Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
58134208|NCT02587962|DRUG|Birinapant|Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
58134209|NCT02587962|DRUG|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
58134210|NCT00401804|DRUG|Dexamethasone, Bortezomib, Doxorubicin|
58134211|NCT01316445|DRUG|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
58134212|NCT03841188|OTHER|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
58134213|NCT03807141|OTHER|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
58134214|NCT01069926|DRUG|AZD1656|Single dose oral tablet
58134215|NCT00028691|DRUG|chlorambucil|
58134216|NCT00028691|RADIATION|radiation therapy|
58134217|NCT06215079|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that modulates the cortical excitability of the targeted motor area. While single-pulse TMS is generally used to explore the functioning of the brain, repetitive TMS is employed to induce lasting changes in brain activity. High-frequency rTMS leads to an increase in excitability in the motor cortex, whereas low-frequency application results in inhibition of motor cortical excitability. Theta-burst stimulation (TBS) is a form of rTMS that can be delivered continuously (cTBS) or intermittently (iTBS), thus modulating the excitability of corticospinal neurons beneath the stimulation area to either decrease or increase. rTMS is a growing research area in pain management, proven to be a safe and well-tolerated method. Studies have shown that rTMS applied to the motor cortex is a promising treatment method for chronic pain
58477722|NCT06541548|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
57780060|NCT05583448|DEVICE|ExploR Radial Head|Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
58134218|NCT06215079|DEVICE|Sham transcranial magnetic stimulation|Patients in the control group will receive sham transcranial magnetic stimulation with sham coil for 35 minutes a day, 5 sessions in total, together with conventional rehabilitation.
58134219|NCT06215079|DEVICE|conventional rehabilitation program|Patients will receive 5 minutes of continuous ultrasound (1MHz, 2W/cm2, 1:4)), followed by a 20-minute contrast bath, and 15 minutes of TENS (frequency: 100 Hz; pulse duration: 50-100 ms; and amplitude adjusted to avoid discomfort or muscle contraction to the patient).
58134220|NCT04520386|DRUG|OMT-111|Pre-filled Syringe
58134221|NCT05999006|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
58134222|NCT02379247|DRUG|BYL-719 (alpelisib)|Oral PI3K inhibitor
58134223|NCT02379247|DRUG|Nab-paclitaxel|IV taxane
58134224|NCT03382548|DRUG|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
58477723|NCT06541548|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
57780061|NCT06090331|DIAGNOSTIC_TEST|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
57780062|NCT06741319|BEHAVIORAL|Demographic characteristics|"* Gender identity~* Sex assigned at birth~* Age~* Address~* History of study enrollment(s)"
58134225|NCT03382548|DRUG|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
57780063|NCT06741319|BEHAVIORAL|Social and sexual behaviors|"* Places where clients go for shopping, dining out, exercise, entertainment~* Places where clients meet their sexual partner(s)~* Places where clients obtain condoms and lubricants~* Social networking and other online services clients regularly use and purposes of using~* Lifetime and current sexual practices and condom use~* Number and types of sexual partners~* Self-perceived HIV risk level~* Disclosure of HIV or sexual orientation status"
57780064|NCT06741319|BEHAVIORAL|Psychosocial characteristics|"* Sexual orientation~* Educational level~* Occupation and income~* Attitude towards and use of HIV testing and sexual health services~* Use of injecting drugs, recreational drugs, and alcohol"
57780065|NCT06741319|BEHAVIORAL|Clinical characteristics|"* Medical history, including gender dysphoria and hormone therapy~* HIV counseling and testing~* Diagnosis and treatment of sexually transmitted diseases (STD)~* Sample collection information~* Laboratory results~* Gender dysphoria and mental health history~* Body hair pattern~* Bridging therapy~* Fertility and reproductive issues~* Gender transition effects"
57780066|NCT06741319|BEHAVIORAL|Referral and linkage to care for HIV-positive clients|"* Health insurance scheme~* Initiation and continuation of antiretroviral treatment"
57780067|NCT06741319|BEHAVIORAL|Characteristics associated with service implementation|- Facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation as identified by clients and healthcare providers
57780068|NCT05870787|DIAGNOSTIC_TEST|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
57780069|NCT02548559|DRUG|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
57780070|NCT02548559|DRUG|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
57780071|NCT02548559|DRUG|Placebo|Placebo solution.
57780072|NCT06738706|DEVICE|intermittent hypoxia-hyperoxia treatment|The intermittent hypoxia-hyperoxia training refers to 4 cycles of 10-minute hypoxia inhalation interspersed with 20-minute hyperoxia, which is performed once daily for 14 days within 2 to 3 weeks.
57780073|NCT01295346|OTHER|Head CT scan and blood draw|
57780074|NCT00656461|DRUG|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
57780075|NCT02348437|PROCEDURE|Repair|An on-going suture technique with minimum four stitches.
57780076|NCT02348437|PROCEDURE|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
57780077|NCT06739564|PROCEDURE|ICE PACKING|ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.
57780078|NCT06739564|PROCEDURE|DRY NEEDLING|DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
57780079|NCT04769713|PROCEDURE|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
57780080|NCT04769713|DRUG|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
57780081|NCT04769713|DRUG|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
57780082|NCT06393127|DRUG|BI 1015550 Formulation C2|BI 1015550 Formulation C2
57780083|NCT06393127|DRUG|BI 1015550 Formulation C1|BI 1015550 Formulation C1
57780084|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
57780085|NCT06237309|DRUG|Placebo|Single dose IV infusion
57780086|NCT03285451|DIAGNOSTIC_TEST|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
57780087|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
57780088|NCT00967174|DRUG|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
57780089|NCT00967174|DRUG|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
57780090|NCT00967174|DRUG|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
57780091|NCT06527430|PROCEDURE|4 mg bupivacaine|Spinal anesthesia was applied to the patients with 4 mg bupivacaine in the lateral decubitus position.
57780092|NCT06527430|PROCEDURE|6 mg bupivacaine|Spinal anesthesia was applied to the patients with 6 mg bupivacaine in the lateral decubitus position.
57780093|NCT02490696|DEVICE|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
57780094|NCT02490696|DEVICE|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
57780095|NCT00320476|DRUG|Velcade|
57780096|NCT00904228|OTHER|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
57780097|NCT00904228|OTHER|placement of routine cap during delivery room stabilization|
57780098|NCT06738758|DRUG|PCSK9 inhibitor|The patient used PCSK9 inhibitor (with or without statins) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
58477724|NCT03938259|DRUG|Fentanyl|identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
58477725|NCT03898544|DEVICE|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
58477726|NCT03898544|DEVICE|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
58477727|NCT01716377|DRUG|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
58477728|NCT02706106|DEVICE|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
58477729|NCT03207295|DRUG|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
58477730|NCT03207295|DRUG|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
58134226|NCT02777060|PROCEDURE|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
58134227|NCT02777060|PROCEDURE|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
58477731|NCT06591793|BIOLOGICAL|AAVB-081|Single subretinal administration
58477732|NCT04139798|DRUG|NOV03|100% Perfluorohexyloctane
58477733|NCT04139798|DRUG|Placebo|Saline solution (0.6% sodium chloride solution)
58477734|NCT03626103|BEHAVIORAL|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
58477735|NCT03626103|BEHAVIORAL|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
58134228|NCT01619800|DEVICE|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
58134229|NCT01619800|DEVICE|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
58134230|NCT02865408|DIETARY_SUPPLEMENT|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
58134231|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
58134232|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
58477736|NCT05650697|BIOLOGICAL|Group 1 cannabidiol (CBD) oil with silicone ointment|CBD oil with silicone ointment will be used on either the top half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.
58477737|NCT05650697|BIOLOGICAL|Group 2 cannabidiol (CBD) oil with silicone ointment|CBD oil with silicone ointment will be used on either the bottom half of a forehead scar. Specific placement instructions will be given to the participant. They will treat the scar the same way for 7 months.
58477738|NCT02741063|BEHAVIORAL|screen low autistic subjects|screen subjects with low ASQ score
58477739|NCT02741063|BEHAVIORAL|screen high autistic subjects|screen subjects with high ASQ score
58477740|NCT02741063|DRUG|oxytocin|intranasal administration of oxytocin (24 IU)
58477741|NCT02741063|DRUG|placebo|intranasal administration of placebo (24 IU)
58477742|NCT03430297|BIOLOGICAL|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
58477743|NCT03430297|DRUG|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = \[body surface area (BSA) x (1000mg/m2)\].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184\* (cm0.725) \* (kg0.425)"
58134233|NCT01128686|OTHER|No intervention|This study is retrospective chart review
58134234|NCT01387737|DRUG|TA-7284-Low|TA-7284-Low
58134235|NCT01387737|DRUG|TA-7284-High|TA-7284-High
58134236|NCT00095212|DRUG|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
58134237|NCT00095212|DRUG|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
58134238|NCT01130025|DRUG|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
58134239|NCT01130025|DRUG|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
58134240|NCT02788448|DEVICE|VIVASURE CLOSURE DEVICE|Large hole closure device
58134241|NCT00048581|DRUG|Abatacept|Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
58134242|NCT00048581|DRUG|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
58134243|NCT00048581|DRUG|Abatacept|Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
58134244|NCT02544594|DEVICE|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
58134245|NCT01399736|PROCEDURE|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
58134246|NCT01399736|PROCEDURE|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
58134247|NCT04840251|OTHER|Well-being review and rehabiliation|"For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~* how they are~* what they can do for themselves~* what it is challenging for them to do~* how active they are~* if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes."
58134248|NCT04840251|OTHER|Qualitative Interviews|Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
58134249|NCT03025594|DRUG|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
58477744|NCT04201262|BIOLOGICAL|Ravulizumab|Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
58134250|NCT03025594|DRUG|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
58134251|NCT00376948|DIETARY_SUPPLEMENT|genistein|
58134252|NCT00376948|DRUG|erlotinib hydrochloride|
58134253|NCT00376948|DRUG|gemcitabine hydrochloride|
58134254|NCT01706536|DRUG|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
58134255|NCT01706536|DRUG|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
58134256|NCT01706536|DRUG|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
58134257|NCT01706536|DRUG|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
58134258|NCT01706536|DRUG|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
58134259|NCT04549844|DRUG|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
58477745|NCT04027517|DRUG|JTZ-951|"Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
58134260|NCT01938586|OTHER|Steri-Strip|
58134261|NCT01938586|OTHER|Superficial sutures|
58134262|NCT04010331|DIETARY_SUPPLEMENT|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
58134263|NCT04010331|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
58134264|NCT00023309|DRUG|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
58134265|NCT00023309|DRUG|Adefovir alone|Adefovir (10 mg/day)
58134266|NCT00957151|DRUG|Creon|
58134267|NCT03756857|PROCEDURE|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
58134268|NCT03756857|PROCEDURE|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
58134269|NCT00370006|BIOLOGICAL|Towne CMV vaccine|
58134270|NCT04473170|BIOLOGICAL|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
58134271|NCT04473170|DRUG|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
58134272|NCT00996320|OTHER|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
58134273|NCT04759248|DRUG|Atezolizumab + Trastuzumab + Vinorelbine|"* Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
58134274|NCT05585866|DRUG|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
58134275|NCT02268032|DRUG|DHEA|DHEA 2.2 g in vaginal ring
58134276|NCT02268032|DRUG|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
58134277|NCT02268032|DRUG|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
58134278|NCT01357278|PROCEDURE|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
58134279|NCT03622138|OTHER|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
58134280|NCT03182322|DRUG|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
58134281|NCT03182322|OTHER|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
58134282|NCT06001034|DEVICE|Occlusion training|Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
58134283|NCT04403880|OTHER|Sample collection|"* Optional nasal specimen(s)~* Blood collection"
58134284|NCT01174680|PROCEDURE|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
58134285|NCT02828709|DEVICE|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
58134286|NCT03026270|OTHER|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
58134287|NCT02738242|DEVICE|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
58134288|NCT03432897|DRUG|Olaparib Pill|300 mg BID
58134289|NCT03432897|PROCEDURE|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
58134290|NCT02665013|BEHAVIORAL|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
58134291|NCT02665013|BEHAVIORAL|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
58134292|NCT01079988|DRUG|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
58134293|NCT01079988|DRUG|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
58134294|NCT01079988|DRUG|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
58134295|NCT01079988|DRUG|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
58134296|NCT01079988|DRUG|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
58134297|NCT03992066|DRUG|Vadadustat|oral 150 mg tablet
58477746|NCT04027517|DRUG|Darbepoetin Alfa|"Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
58477747|NCT00911170|DRUG|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
58477748|NCT00911170|DRUG|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
58134298|NCT03992066|DRUG|Darbepoetin alfa|solution intravenous injection
58134299|NCT03992066|DRUG|Epoetin alfa|solution for intravenous injection
58134300|NCT03365375|BEHAVIORAL|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
58134301|NCT03365375|OTHER|Usual Care Referral|Referral to PCP or Psychiatry
58134302|NCT05462561|OTHER|Quality-of-Life Assessment|Ancillary studies
58134303|NCT05462561|PROCEDURE|Robotic Vascularized Composite Bladder Allograft Transplantation|Undergo robotic VCBA transplantation.
58134304|NCT01297036|DRUG|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
58477749|NCT00911170|BIOLOGICAL|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
58477750|NCT00911170|DRUG|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
58477751|NCT00648609|OTHER|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
58134305|NCT01297036|DRUG|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
58134306|NCT02686333|OTHER|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
58134307|NCT05515926|PROCEDURE|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
58134308|NCT05515926|PROCEDURE|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
58134309|NCT05830019|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
58134310|NCT01416766|OTHER|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
58134311|NCT00017953|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
57780099|NCT06738758|DRUG|Statin+Ezetimibe compound|The patient used statins and ezetimibe in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
57780100|NCT06738758|DRUG|Statin|The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
57780101|NCT03873246|DRUG|OC-01 0.1% 0.6 mg/ml|OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
57780102|NCT03873246|DRUG|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
57780103|NCT03873246|OTHER|placebo comparator|vehicle control
57780104|NCT04396925|OTHER|Point-of care Ultrasonography|GPs using POCUS and how it affects clinical judgement
57780105|NCT01038674|DRUG|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
58134312|NCT00017953|BEHAVIORAL|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
58477752|NCT00648609|OTHER|Standard of care|Usual care for COPD patients
58477753|NCT02770014|DRUG|Erlotinib|
58477754|NCT01023763|OTHER|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
58477755|NCT04049786|PROCEDURE|Digestive biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
58477756|NCT04049786|DRUG|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
58477757|NCT04049786|PROCEDURE|Serial blood sampling for PK analysis|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
58477758|NCT04049786|DRUG|Metoprolol 100 mg for CYP2D6 phenotyping|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
58134313|NCT03469297|DEVICE|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
58134314|NCT04772105|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
58134315|NCT04772105|DRUG|4.0mg of BAT5906|Specification: 4.0mg of BAT5906
58134316|NCT05512026|DEVICE|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
58134317|NCT00500487|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
58134318|NCT00500487|BEHAVIORAL|HIV Prevention Skills|12-session group intervention including sexual health skills training.
58477759|NCT04049786|DRUG|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
58477760|NCT04049786|DRUG|Midazolam 2 mg for CYP3A4 phenotyping|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
58477761|NCT04049786|OTHER|Genotyping|Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
58477762|NCT00006396|DRUG|Nevirapine|
58477763|NCT00006396|DRUG|Zidovudine|
58477764|NCT06079814|OTHER|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
58477765|NCT01367106|PROCEDURE|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
58477766|NCT02976038|DRUG|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
58477767|NCT03788512|OTHER|observational only- no intervention|observational only- no intervention
58134319|NCT00500487|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of health topics.
58134320|NCT05367388|DRUG|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
58477768|NCT03753802|OTHER|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
58477769|NCT03753802|OTHER|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
58477770|NCT01355952|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
58477771|NCT05695378|DRUG|KM-819|Subjects will receive KM-819 400 mg orally daily.
58477772|NCT05695378|DRUG|Placebo|Subjects will receive Placebo orally daily.
58477773|NCT01094236|BEHAVIORAL|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
58134321|NCT05367388|DRUG|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
58134322|NCT03117569|DRUG|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
58134323|NCT05532527|DRUG|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
58134324|NCT03132727|OTHER|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
58134325|NCT05395247|OTHER|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
58134326|NCT04517019|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
58134327|NCT06424145|DIAGNOSTIC_TEST|Superior radial artery|Upper radial artery, 1 ml of lidocaine
58134328|NCT06424145|DIAGNOSTIC_TEST|Right side of radial artery|Right side of the radial artery,1ml of lidocaine
58134329|NCT04223440|OTHER|MRI|MRI on both shoulder
58134330|NCT04223440|OTHER|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
58134331|NCT01727271|DRUG|Tenofovir|
58134332|NCT01727271|BIOLOGICAL|Pegylated interferon alpha-2b|
58477774|NCT00061087|DRUG|Methylphenidate|Methylphenidate 80mg/day
58477775|NCT00061087|DRUG|Bupropion|Bupropion 400mg/day
58134333|NCT02177981|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
58134334|NCT02177981|PROCEDURE|Control|The cuff will be placed around the arm but not inflated.
58477776|NCT00061087|OTHER|Placebo|Placebo
58477777|NCT04764708|BEHAVIORAL|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
58477778|NCT04764708|BEHAVIORAL|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
58477779|NCT03614650|BIOLOGICAL|engineered immune cells|Engineered immune effector cells (EIE)
58477780|NCT02553226|DRUG|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
58477781|NCT02553226|DRUG|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
58134335|NCT06301698|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
58134336|NCT06301698|PROCEDURE|Injection|the patients in the observation group were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58134337|NCT06301698|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58134338|NCT01002638|OTHER|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
58134339|NCT01002638|PROCEDURE|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
58134340|NCT02175706|DEVICE|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
58134341|NCT02175706|DEVICE|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
58134342|NCT04549883|OTHER|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
58134343|NCT03902496|OTHER|HIT-6 Questionnaire|Headache Impact Test
58134344|NCT03902496|DEVICE|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
58134345|NCT03902496|DEVICE|Sham Spectacles|Sham
58134346|NCT03171493|BIOLOGICAL|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
58134347|NCT06287905|DRUG|Prazosin Oral Tablet|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
58134348|NCT02768064|DEVICE|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
58134349|NCT02543671|OTHER|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
58134350|NCT02543671|OTHER|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
58134351|NCT01925092|DRUG|mifepristone|tablets
58134352|NCT02015390|PROCEDURE|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
58134353|NCT02015390|PROCEDURE|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
58134354|NCT00219830|BEHAVIORAL|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
58134355|NCT02426710|DEVICE|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
58134356|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|10 mEq/day
58134357|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|300 mEq/day
58477782|NCT06054490|BEHAVIORAL|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
58134358|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|150 mEq/day dietary sodium
58134359|NCT00005006|DRUG|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
58134360|NCT00005006|DRUG|Alendronate|Alendronate 70mg/week
58477783|NCT06054490|OTHER|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
58134361|NCT00005006|DRUG|Teriparatide|Teriparatide 20mcg/day
58134362|NCT00866593|DRUG|Generic Escitalopram|10mg/d or 20mg/d
58134363|NCT00866593|DRUG|Innovator Escitalopram|10mg/d or 20mg/d
58477784|NCT03882606|DEVICE|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
58477785|NCT00733018|BEHAVIORAL|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
58134364|NCT02702960|PROCEDURE|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for \>3 wks
58134365|NCT02702960|RADIATION|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
58134366|NCT02702960|PROCEDURE|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
58134367|NCT02702960|DRUG|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
58134368|NCT02702960|DRUG|Mesna|administered on Days 3 and 4 with PTCy
58134369|NCT02702960|DRUG|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
58134370|NCT02702960|DRUG|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
58134371|NCT02702960|DRUG|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
58134372|NCT02702960|DRUG|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
58134373|NCT02702960|DRUG|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
58134374|NCT02702960|DRUG|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
58134375|NCT03661047|DRUG|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
58134376|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
58134377|NCT01188837|OTHER|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
58134378|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
58134379|NCT00204139|PROCEDURE|Routine midtrimester pregnany ultrasound scan|
58134380|NCT02835261|OTHER|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
58134381|NCT04842162|DRUG|indocyanine green|indocyanine green (INFRACYANINE© 25mg/10mL).
58134382|NCT03608878|BIOLOGICAL|adagloxad simolenin/OBI-821|"Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration."
58134383|NCT03608878|PROCEDURE|TACE|Transarterial chemoembolization
58134384|NCT01781286|BEHAVIORAL|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
58134385|NCT01781286|BEHAVIORAL|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
58134386|NCT05354232|DEVICE|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
58134387|NCT05354232|DEVICE|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
58477786|NCT03230461|BEHAVIORAL|Compression depth|
58134388|NCT05354232|DEVICE|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
58134389|NCT00448097|DRUG|cetuximab|No verifiable data available, PI relocated
58134390|NCT00448097|DRUG|docetaxel|No verifiable data available, PI relocated
58134391|NCT05570084|DRUG|Silodosin|Cap silodosin for medical expulsion therapy
58134392|NCT05570084|DRUG|Tamsulosin|Cap tamsulosin
58134393|NCT03382002|DIAGNOSTIC_TEST|TCL|evaluation of oxidative status
58134394|NCT01493752|DIETARY_SUPPLEMENT|beetroot juice|250mls daily beetroot juice
58134395|NCT05558891|BEHAVIORAL|THRIVE|Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).
58134396|NCT05558891|BEHAVIORAL|Usual Care|Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
58134397|NCT02465697|BEHAVIORAL|Reappraisal Training|
58134398|NCT02157220|DEVICE|Fixed bearing prosthesis|
58134399|NCT02157220|DEVICE|Mobile bearing prosthesis|
58477787|NCT03889496|RADIATION|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
58134400|NCT04232605|OTHER|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
58134401|NCT04232605|OTHER|Placebo|Receive intravenous infusion saline
58134402|NCT04125706|DRUG|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
58134403|NCT04125706|DRUG|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
58134404|NCT03437356|OTHER|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm
58134405|NCT03437356|DRUG|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, \>70kg, except 80 mg OD if female \>70 years or Cr \>1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
58134406|NCT02123979|DRUG|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
58134407|NCT05533502|DIETARY_SUPPLEMENT|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
58134408|NCT05533502|DIETARY_SUPPLEMENT|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
58134409|NCT04392271|DRUG|LY3372689|Administered orally.
58134410|NCT04392271|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered intravenously (IV).
58134411|NCT05332015|OTHER|Hypotonic (distilled) water|orally given daily two liters of distilled water
58134412|NCT05332015|OTHER|Normal water|orally given daily two liters of normal water
58134413|NCT02989688|DIETARY_SUPPLEMENT|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
58134414|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
58134415|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
58134416|NCT00205049|DRUG|pentoxifylline|daily dosing
58134417|NCT02246478|DRUG|TAS-205|"* Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
58134418|NCT02246478|DRUG|Placebo|"* Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
58134419|NCT02301676|BEHAVIORAL|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
58134420|NCT02301676|DRUG|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
58134421|NCT02301676|DRUG|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
57780106|NCT01038674|DRUG|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
58134422|NCT02301676|DEVICE|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
57780107|NCT06740526|DRUG|Sibeprenlimab|"Sibeprelimab SC (Period 1)~Sibeprelimab SC (Period 2)"
58134423|NCT02947243|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
58134424|NCT02947243|DRUG|Morphine|As per unit's protocol
58134425|NCT03083171|DRUG|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
58134426|NCT03083171|DRUG|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
58134427|NCT03083171|DRUG|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
58134428|NCT02242292|DRUG|Hyoscine butylbromide|
58134429|NCT02242292|DRUG|Placebo|
58491893|NCT06464783|OTHER|Thoracic Exercise Program|"Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)"
58477788|NCT04197596|BIOLOGICAL|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
58477789|NCT06599944|DIAGNOSTIC_TEST|Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale|Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.
58477790|NCT03643848|BEHAVIORAL|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
58477791|NCT03643848|BEHAVIORAL|Sleep with Sham Cues|Sham manipulation
58477792|NCT00000306|DRUG|Dextroamphetamine|
58477793|NCT03780244|DEVICE|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
58477794|NCT03780244|DEVICE|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
58477795|NCT05482971|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
58477796|NCT02142699|DRUG|Heme arginate|
58477797|NCT03857854|DRUG|Pirfenidone|treatment group
58477798|NCT03857854|DRUG|Placebos|placebo group
58477799|NCT03301311|OTHER|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
58477800|NCT03301311|OTHER|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
58477801|NCT03772392|PROCEDURE|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
57780108|NCT06738160|DRUG|nalusobasumab|Patients with advanced bone metastases who have not received any prior systemic therapy for non-small cell lung cancer will receive first-line treatment with nalusolimab and bone target lesion SBRT plus conventional dose immune checkpoint inhibitors and chemotherapy, including nalproxolimab 120 mg/time, subcutaneous injection, administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24 Gy/3 F is used for spinal metastases, and 30 Gy/5 F or 35 Gy/5 F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines until progression.
57780109|NCT06738199|DIETARY_SUPPLEMENT|dietary iron supplementation|This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).
57780110|NCT04860843|DRUG|Thoracic paravertebral block|Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
57780111|NCT04860843|DRUG|Pecs block|Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
57780112|NCT04860843|DRUG|Sham Pecs block|Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
57780113|NCT06739070|OTHER|Plyometric|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
57780114|NCT06739070|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
57780115|NCT06739070|OTHER|Control group (no intervention)|In control group no intervention would be given. Initial test would be performed at 4th and 8th week and then results would be compared with experimental group.
58477802|NCT01745939|OTHER|Lumbar Manipulation|Manual therapy intervention
58477803|NCT01745939|OTHER|Sham manipulation|Manual therapy intervention
58477804|NCT04772001|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
58477805|NCT04772001|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
58477806|NCT04772001|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
58477807|NCT06169371|DRUG|Abemaciclib|Week 1 50mg orally BID
58477808|NCT06169371|DRUG|Abemaciclib|Week 2 100mg orally BID
58477809|NCT06169371|DRUG|Abemaciclib|Week 3+ 150mg orally BID
58477810|NCT01517399|DRUG|tivantinib|three oral 120 mg tablets administered twice a day
58477811|NCT01517399|DRUG|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
58477812|NCT01517399|DRUG|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
58477813|NCT01517399|DRUG|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
58477814|NCT01517399|DIETARY_SUPPLEMENT|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
58477815|NCT01517399|DRUG|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
58477816|NCT01517399|DRUG|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
58491894|NCT00102583|DRUG|Subconjunctival Cyclosporine Implant|
58491895|NCT04312646|DEVICE|Elastography .|Performance of US, elastography
58477817|NCT01016249|DRUG|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
58477818|NCT01016249|DRUG|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
58477819|NCT01016249|DRUG|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
58477820|NCT05304754|BIOLOGICAL|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
58477821|NCT05304754|BIOLOGICAL|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
58477822|NCT02756286|OTHER|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
58477823|NCT01752335|OTHER|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
58477824|NCT06591650|DRUG|gemcitabine hydrochloride|800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
58477825|NCT06591650|DRUG|Cisplatin|25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.
58477826|NCT06591650|DRUG|Nab-paclitaxel|100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
58477827|NCT06591650|DRUG|Durvalumab|1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.
58477828|NCT03431207|OTHER|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
58477829|NCT02612779|DRUG|Elotuzumab|
58477830|NCT02612779|DRUG|Pomalidomide|
58477831|NCT02612779|DRUG|Dexamethasone|
58477832|NCT02612779|DRUG|Nivolumab|
58477833|NCT05902689|PROCEDURE|alveolar ridge preservation with bio-oss collagen|Alveolar ridge preservation with bio-oss collagen is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting bio-oss collagen in the socket and covering the biological barrier membrane.
58477834|NCT05902689|PROCEDURE|alveolar ridge preservation with sticky bone|Alveolar ridge preservation with sticky bone is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting sticky bone in the socket and covering the biological barrier membrane.
58477835|NCT02651207|OTHER|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
58477836|NCT05777499|BEHAVIORAL|Music Therapy|Music Therapy will comprise individual and group sessions 20-45 minutes. Participants usually have 1-2 individual sessions, and 1 group session/week. Group sessions include 2-6 participants. On average, participants receive an average 1 hour 30 minutes Music Therapy/week, timetabled when they would not otherwise be undergoing any therapy sessions. The Music Therapist will use the Nordoff Robbins approach and work flexibly as a musician. Techniques include (but are not limited to) empathic listening, musically matching, turn taking and sequencing, call and response. Sessions may also involve songwriting, singing familiar songs, listening to, sharing and discussing music, developing specific musical skills of interest to the participant, structured musical games and activities, joint working with other members of the therapy team in sessions focused on functional development and communication skills.
58477837|NCT05777499|BEHAVIORAL|Control Therapy|Control Therapy sessions will be carried out by a member of the clinical team, matched in duration and number to Music Therapy sessions as closely as possible. Participants will usually have 1-2 individual sessions and 1 group session/week. Group sessions include 2-6 participants. The Control Therapy intervention will continue throughout participant's rehabilitation program until participants have completed a total of 15 hours intervention, which will usually take 10 weeks to complete. The content of sessions is designed to reflect 'usual care' however control therapy sessions will not include access to specific specialist equipment such as MOTOmed, therabike or neuro-muscular electrical stimulation, to ensure the control group does not get additional specialist intervention beyond usual care. Content of control therapy sessions will therefore be restricted to the following five domains: gaming, education, mindfulness, current affairs discussions, and passive and dynamic stretching.
58477838|NCT02420821|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
58477839|NCT02420821|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
58477840|NCT02420821|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
58477841|NCT03913520|OTHER|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
57780116|NCT01115023|OTHER|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
57780117|NCT02651285|OTHER|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
58477842|NCT00515372|OTHER|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
58477843|NCT00515372|OTHER|Usual Care|Lists of professional resources and referral recommendations will be provided.
57780118|NCT02651285|OTHER|Control|incubation of IVF embryos with a medium without G-CSF
58134430|NCT01185808|BIOLOGICAL|Vitamin D|Vitamin D 5000IU/day for 6 weeks
58134431|NCT04335578|DRUG|Zampilimab|Participants will receive zampilimab (UCB7858) at pre-specified time-points.
58477844|NCT06293599|OTHER|scapular stabilization exercises|the patients will receive scapular stabilization exercises in the form of scapular orientation exercises,Forward/Backward Bear Crawls,Lateral Bear Crawls and assisted stretch for pectoralis minor
58477845|NCT06293599|OTHER|virtual reality exercises|"The exercises described were done in a consistent manner, emphasizing low intensity, and using lightweight dumbbells (range, 3 to 30 pounds). The weight of the dumbbell was individually selected by the subject for each exercise.~1. elevation of the arm in the sagittal plane (shoulder flexion~2. elevation of the arm in the scapular plane with humeral external rotation (shoulder scaption~3. elevation of the arm in the coronal plane (shoulder abduction)~4. rowing~5. horizontal shoulder abduction~6. horizontal abduction with humeral external rotation~7. push-up with hands apart~8. push-up with a plus-normal push-up adding maximum shoulder and scapular protraction with elbows fully extended~9. dumbbell bench press~10. dumbbell military press~11. shoulder shrug~12. deceleration exercise-simulating the pitching followthrough~13. shoulder extension prone~14. shoulder internal rotation~15. shoulder external rotation~16. press-up"
58477846|NCT06293599|OTHER|regular routine exercises|the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,
58477847|NCT00887809|DRUG|gemcitabine|
58477848|NCT00887809|DRUG|docetaxel|
58477849|NCT00887809|DRUG|bevacizumab|
58477850|NCT05397951|DEVICE|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
58477851|NCT05397951|DEVICE|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
58477852|NCT05397951|DEVICE|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
58477853|NCT05397951|DEVICE|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
58477854|NCT00538902|BIOLOGICAL|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
58477855|NCT00538902|BIOLOGICAL|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
58477856|NCT00538902|BIOLOGICAL|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
58477857|NCT05069948|OTHER|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
58477858|NCT06600308|OTHER|Walk tests|"Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).~At the end of each walking test, measurement of the difficulty of exertion using the Borg scale."
58477859|NCT06600308|OTHER|ecological (real-life) assessment of walking ability|Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days
58477860|NCT04495244|DIAGNOSTIC_TEST|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
58477861|NCT04862546|DEVICE|Laser Acupoint|Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject
58477862|NCT04862546|DEVICE|Tap water iontophoresis|"Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes."
58477863|NCT06554184|DRUG|HR20013 + dexamethasone + palonosetron placebo|HR20013 + dexamethasone + palonosetron placebo
58477864|NCT06554184|DRUG|Palonosetron + dexamethasone + HR20013 placebo|Palonosetron + dexamethasone + HR20013 placebo
58477865|NCT02614300|OTHER|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
58477866|NCT02614300|OTHER|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
58477867|NCT02614300|OTHER|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
58477868|NCT00053651|BEHAVIORAL|Survival Skills for Moms with New Babies|
58477869|NCT04294043|DRUG|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
58477870|NCT00520182|BEHAVIORAL|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids \[MUFA\]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
58477871|NCT00520182|BEHAVIORAL|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
58134432|NCT04335578|DRUG|Placebo|Participants will receive matching placebo (PBO) at pre-specified time-points.
58134433|NCT02244034|PROCEDURE|hypothermia|
58134434|NCT06266052|PROCEDURE|Triangular Flap|Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
58134435|NCT06266052|PROCEDURE|Berwick Flap|Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
58134436|NCT06266052|PROCEDURE|Saurez Flap|In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
58134437|NCT06266052|PROCEDURE|Heitz Flap|Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
58134438|NCT01522352|PROCEDURE|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
58134439|NCT05352386|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
58134440|NCT02724800|BEHAVIORAL|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
58134441|NCT02724800|BEHAVIORAL|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
58134442|NCT01024439|PROCEDURE|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
58134443|NCT01024439|PROCEDURE|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
58134444|NCT04038710|DRUG|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
58134445|NCT01379664|DRUG|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
58134446|NCT01379664|DRUG|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
58134447|NCT03228693|PROCEDURE|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
58134448|NCT03228693|PROCEDURE|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
58134449|NCT05328141|OTHER|Bread and butter|A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
58134450|NCT05328141|OTHER|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
58134451|NCT05328141|OTHER|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
58134452|NCT04922424|DRUG|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
58134453|NCT04922424|OTHER|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
58134454|NCT03004300|PROCEDURE|Rapid maxillary expansion|Device
58134455|NCT03004300|PROCEDURE|Adenotonsillectomy|Surgery
58134456|NCT05471817|DRUG|Elinzanetant (BAY3427080)|Capsule, oral, single dose
58134457|NCT05471817|DRUG|Dabigatran etexilate|Capsule, oral, single dose
58134458|NCT01856309|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
58477872|NCT00520182|BEHAVIORAL|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
58491896|NCT01296672|DRUG|Finasteride|Finasteride 5mg every day by mouth for 3 months
58134459|NCT01856309|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
58134460|NCT01856309|DRUG|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
58477873|NCT02704325|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
58134461|NCT05469009|DRUG|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening
58134462|NCT05469009|DEVICE|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.
58134463|NCT05469009|DRUG|Lecanemab|Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
58134464|NCT00628199|PROCEDURE|Improving the scientific process of human cell reprogramming|
58134465|NCT05520788|GENETIC|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
58134466|NCT05885139|DEVICE|Exopulse Mollii Suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
58134467|NCT05885139|DEVICE|Sham Exopulse Mollii Suit|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
58134468|NCT04418388|DRUG|PBK-1801|Administered orally
58134469|NCT04418388|DRUG|PBK-1801|Administered orally
58134470|NCT04418388|DRUG|PBK-1801|Administered orally
58134471|NCT02404194|BEHAVIORAL|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
58134472|NCT02404194|BEHAVIORAL|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
58134473|NCT01902680|RADIATION|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
58134474|NCT04040348|BIOLOGICAL|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
58134475|NCT01661452|OTHER|Referral to counseling services if desired|
58134476|NCT01604850|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
58134477|NCT01604850|DRUG|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
58134478|NCT01604850|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
58134479|NCT01604850|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
58134480|NCT02898909|DEVICE|nuclear lens fragmentation in 8 pieces|
58134481|NCT02898909|DEVICE|nuclear lens fragmentation in 16 pieces|
58134482|NCT01692405|DEVICE|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
58134483|NCT01692405|PROCEDURE|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
58134484|NCT02303678|DRUG|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
58477874|NCT02704325|OTHER|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
58477875|NCT06594562|DIAGNOSTIC_TEST|Telementored eFAST|Ultrasound examination guided in real-time by a remote expert for detecting free fluid.
58134485|NCT01458405|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
58134486|NCT01458405|DRUG|Placebo|Single, blinded, intracoronary infusion of a placebo solution
58477876|NCT04663204|DRUG|Sparsentan|Target dose of 400 mg daily
58477877|NCT03529695|BEHAVIORAL|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
58134487|NCT05567614|RADIATION|Liver Fibroscan|Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
58134488|NCT03223233|OTHER|procalcitonin level|serum procalcitonin level will be measured in both groups.
58491897|NCT01296672|DRUG|Placebo|Placebo every day by mouth for 3 months
58491898|NCT02717806|BEHAVIORAL|PATHway|Patients will use the PATHway platform for 6 months
58491899|NCT03743857|PROCEDURE|Manual Therapy|AP ankle mobilization
58477878|NCT03529695|BEHAVIORAL|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
58477879|NCT06654219|OTHER|Prolonged fasting|NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.
58477880|NCT06654219|OTHER|Standard NPO|NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids
58477881|NCT04139057|DRUG|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
58477882|NCT03819439|OTHER|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
58477883|NCT05674786|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
58477884|NCT03239392|DRUG|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
58477885|NCT03725397|BEHAVIORAL|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
58477886|NCT03725397|BEHAVIORAL|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
58477887|NCT03484208|OTHER|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
58477888|NCT05455879|OTHER|Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
58477889|NCT03733015|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
58477890|NCT04499326|OTHER|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
58134489|NCT00790959|BEHAVIORAL|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
58477891|NCT01959503|DEVICE|Progel Vascular Sealant|
58477892|NCT01959503|DEVICE|Gelfoam Plus|
58477893|NCT05417646|OTHER|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
58477894|NCT05417646|DRUG|Placebo|Placebo comparator to empagliflozin
58477895|NCT05417646|DRUG|Empagliflozin|Single-dose, 25 mg, two hours before clamp
58477896|NCT03554525|DIETARY_SUPPLEMENT|Fat-binder damm|3 sticks every day during 12 months
58477897|NCT03554525|DIETARY_SUPPLEMENT|Placebo|3 sticks every day during 12 months
58134490|NCT00790959|OTHER|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
58477898|NCT02368587|BIOLOGICAL|WJMSCs Vs. placebo|WJMSCs Vs. placebo
58477899|NCT02368587|BIOLOGICAL|Placebo|WJMSCs Vs. placebo
58477900|NCT01264796|BEHAVIORAL|culturally tailored diabetes education|lifestyle modification group education
58477901|NCT04798196|BEHAVIORAL|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
58477902|NCT04798196|BEHAVIORAL|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
58477903|NCT04798196|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual (TAU)
58477904|NCT05908825|DRUG|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
58134491|NCT04963725|DRUG|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
58134492|NCT00113789|OTHER|PI Discretion|PI Discretion
58477905|NCT05908825|DRUG|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
58477906|NCT05791708|DRUG|Sutimlimab|CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
58477907|NCT04756856|OTHER|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
58477908|NCT04280250|OTHER|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
58477909|NCT04280250|OTHER|Control condition|Psychoeducational self-help sheet
58477910|NCT00002485|PROCEDURE|psychosocial assessment and care|
58477911|NCT05924217|OTHER|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
58477912|NCT06653985|DRUG|Hyaluronic and corticosteroid injection|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.
58477913|NCT06653985|OTHER|Physical Therapy|Patients will receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
58477914|NCT03220035|OTHER|Laboratory Biomarker Analysis|Correlative studies
58477915|NCT03220035|DRUG|Vemurafenib|Given PO
58477916|NCT02633150|OTHER|Supplementation with red grapes polyphenol|
58477917|NCT02267551|OTHER|Mimic dv-Trainer|
58477918|NCT02267551|OTHER|daVinci Skills Simulator|
58477919|NCT04680468|DRUG|Belantamab mafodotin|2.5 mg/kg IV
58477920|NCT05572073|OTHER|Natural History Study|Natural History Study
58477921|NCT06515197|OTHER|Motivational Music|Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
58477922|NCT06515197|OTHER|Self-Selected Music|Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
58477923|NCT04636684|DIAGNOSTIC_TEST|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
58477924|NCT05577299|DEVICE|PET/CT|18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
58477925|NCT00804076|BIOLOGICAL|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
58134493|NCT05677698|OTHER|Lemon oil|Lemon oil with massage
58134494|NCT05677698|OTHER|peppermint oil|peppermint oil with massage
58477926|NCT05864859|OTHER|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
58477927|NCT06651619|OTHER|Water|Prescribed amount of bottled water the evening prior and 2 hours prior to team practice
58477928|NCT06651619|OTHER|Hydration Education|30-60 minutes
58477929|NCT03469453|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
58477930|NCT06300112|BEHAVIORAL|YOGA|Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
58477931|NCT06598150|OTHER|Shoulder Abduction|Individuals will be visually cued to perform short, unilateral, isometric shoulder abduction tasks. A visual display will provide real-time feedback of the shoulder abduction torque, to help the participant target a predetermined torque level.
58477932|NCT04312178|OTHER|cash incentive|cash incentive (20€ gift card)
58477933|NCT04312178|OTHER|no intervention|no intervention
58477934|NCT04312178|OTHER|return vaginal self-swab kit in person|hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
58477935|NCT05987930|DEVICE|bone lid technique|group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
58477936|NCT05987930|DEVICE|standard technique|group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
58477937|NCT06596681|GENETIC|GA+clozapine|Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
58134495|NCT05677698|OTHER|Almond oil|Almond oil massage
58134496|NCT04059965|OTHER|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
58134497|NCT04059965|OTHER|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
58134498|NCT02291900|PROCEDURE|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
58477938|NCT05514886|DEVICE|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
58477939|NCT01622166|BEHAVIORAL|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
58477940|NCT01138449|DRUG|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
58477941|NCT05991635|BEHAVIORAL|Gatekeeper training (e-learning)|"The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care"
58477942|NCT01580163|DRUG|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
58477943|NCT01580163|DRUG|Methadone|Oral Solution，1mg/ml
58477944|NCT01580163|DRUG|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
58477945|NCT05809375|OTHER|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
58134499|NCT04714047|OTHER|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
58477946|NCT03545958|BEHAVIORAL|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
58477947|NCT03545958|BEHAVIORAL|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
58477948|NCT01673542|DRUG|Lidocaine-Prilocaine 5%|
58477949|NCT01673542|DRUG|DEXERYL|
58477950|NCT02746653|DEVICE|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
58477951|NCT02952820|DRUG|lemborexant|
58477952|NCT02952820|DRUG|Placebo|
58491900|NCT02538913|BEHAVIORAL|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
58491901|NCT02538913|PROCEDURE|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
57780119|NCT06139263|DEVICE|a percussion massage gun (Compex Fix 2.0)|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
57780120|NCT06139263|OTHER|conventional treatment program|In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
57780121|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
57780122|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT)|This application includes rehabilitation methods frequently used in pediatric rehabilitation.
58134500|NCT04714047|OTHER|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
58134501|NCT04714047|OTHER|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
58138184|NCT04660656|DIAGNOSTIC_TEST|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
58477953|NCT05992831|DEVICE|Accelerated iTBS|The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
58477954|NCT05992831|DEVICE|Sham Comparator|To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
58477955|NCT06142682|DEVICE|Cochlear Implant|cochlear implantation with dexamethasone eluting electrode
58477956|NCT00002534|BIOLOGICAL|anti-thymocyte globulin|
58477957|NCT00002534|DRUG|cyclophosphamide|
58477958|NCT00002534|DRUG|cytarabine|
58477959|NCT00002534|DRUG|methylprednisolone|
58477960|NCT00002534|DRUG|thiotepa|
58477961|NCT00002534|PROCEDURE|allogeneic bone marrow transplantation|
58477962|NCT00002534|PROCEDURE|in vitro-treated bone marrow transplantation|
58477963|NCT00002534|RADIATION|low-LET electron therapy|
58477964|NCT00002534|RADIATION|low-LET photon therapy|
58477965|NCT03441321|OTHER|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
58477966|NCT03441321|OTHER|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
58477967|NCT03441321|OTHER|Survey Administration|Ancillary studies
58477968|NCT01884467|DRUG|Gentamicin|Comparison of Gentamicin versus placebo
58477969|NCT01884467|DRUG|Placebo|
58477970|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
58477971|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
58477972|NCT04379856|DRUG|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
58477973|NCT06387693|DIAGNOSTIC_TEST|Holter monitoring, intracoronary ECG|Holter monitoring device to track ECG abnormalities during spontaneous chest pain in the outpatient setting. Intracoronary ECG to evaluate perprocedural ECG responses
58477974|NCT05251558|OTHER|Telerehabilitation|The telerehabilitation platform is used to deliver the home exercise program.
58477975|NCT05251558|OTHER|Conventional Education Program|The patient is given education about the points to be considered for the disease and the exercises to be applied.
58477976|NCT06590051|DRUG|UPLIZNA|
58477977|NCT02964689|DRUG|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
58477978|NCT02964689|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
58477979|NCT02964689|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
58477980|NCT01703143|PROCEDURE|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
58134502|NCT04714047|OTHER|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
58134503|NCT06234670|OTHER|No intervertion|This study is a retrospective observational study without intervention.
58134504|NCT02048111|BIOLOGICAL|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
58134505|NCT05169554|DRUG|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
58134506|NCT05169554|DRUG|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
58134507|NCT02339233|DEVICE|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
58134508|NCT00050297|DRUG|YM598|
58134509|NCT04212949|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
58134510|NCT04212949|DRUG|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
58134511|NCT00517647|DRUG|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
58134512|NCT05575180|DRUG|Acetazolamide 250Mg Tab|Oral acetazolamide
58134513|NCT05575180|DRUG|Methazolamide Pill|Oral Methazolamide
58134514|NCT05575180|DRUG|Placebo|Oral placebo
58134515|NCT03727100|COMBINATION_PRODUCT|Clonidine Micropellets|Injection
58134516|NCT03727100|OTHER|Sham|Injection
58134517|NCT01422538|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
58134518|NCT01422538|DRUG|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
58134519|NCT01422538|OTHER|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
58134520|NCT00448695|PROCEDURE|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
58134521|NCT05696639|PROCEDURE|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
58134522|NCT00291057|DRUG|MALG|30 minute application
58134523|NCT03306160|OTHER|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
58134524|NCT02102425|PROCEDURE|Patients with or without bandage over exit site|
58134525|NCT03759678|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
58134526|NCT01891266|PROCEDURE|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
58134527|NCT01891266|PROCEDURE|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
58477981|NCT03854175|DRUG|sildenafil citrate|25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
58477982|NCT03854175|DRUG|Estradiol Valerate 2 MG|2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
58134528|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 0cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
58134529|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 40cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
58134530|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 60cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
58134531|NCT00115726|DRUG|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
58134532|NCT00115726|DRUG|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
58134533|NCT05865691|OTHER|biomarker assay|blood sample on the day of inclusion
58134534|NCT00054106|DRUG|buserelin|
58134535|NCT00054106|DRUG|custirsen sodium|
58134536|NCT00054106|DRUG|flutamide|
58134537|NCT00054106|PROCEDURE|conventional surgery|
58134538|NCT00054106|PROCEDURE|neoadjuvant therapy|
58134539|NCT04663360|OTHER|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
58134540|NCT00945165|BEHAVIORAL|Exercise intervention|various exercise characteristics
58134541|NCT00945165|BEHAVIORAL|No exercise|No exercise control period
58134542|NCT01293422|DRUG|Rifampicin|Rifampicin 600 mg daily for a week
58134543|NCT02911597|DRUG|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
58134544|NCT02965326|PROCEDURE|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
58134545|NCT01769183|DRUG|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
58134546|NCT06280690|DRUG|SGM-101|SGM-101 is cea-targeted fluorescent dye
58134547|NCT02996656|DRUG|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
58134548|NCT02996656|DRUG|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
58134549|NCT01535859|DRUG|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
58134550|NCT01535859|DRUG|Placebo|1 tablet daily for 8 days.
58134551|NCT00944203|DRUG|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
58134552|NCT04562662|DEVICE|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
58134553|NCT00660426|DRUG|Oxaliplatin|
58134554|NCT00660426|DRUG|Gemcitabine|
58134555|NCT00660426|DRUG|Capecitabine|
58134556|NCT02066207|DRUG|Fenofibrate|
58134557|NCT02066207|DRUG|Atorvastatin|
58134558|NCT03499171|DRUG|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
58477983|NCT00765206|DRUG|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
58134559|NCT03499171|DRUG|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
58134560|NCT03282838|DRUG|DFN-15 (fasted)|DFN-15 administered to fasted subjects
58134561|NCT03282838|DRUG|DFN-15 (fed)|DFN-15 administered to fed subjects
58134562|NCT03282838|DRUG|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
58134563|NCT01536626|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
58134564|NCT00905125|BIOLOGICAL|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
58134565|NCT00905125|BIOLOGICAL|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
58134566|NCT05522062|PROCEDURE|surgical treatment for humerus shaft fracture|surgical treatment for humerus shaft fracture
58134567|NCT05966571|PROCEDURE|Ovary Biopsie|Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
58134568|NCT05710341|DIETARY_SUPPLEMENT|Water with added nitrate|Water with added nitrate
58134569|NCT05710341|DIETARY_SUPPLEMENT|Water without added nitrate|Water without added nitrate
58134570|NCT00962260|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
58134571|NCT01465295|DEVICE|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
58134572|NCT05455073|DIETARY_SUPPLEMENT|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
58134573|NCT05455073|COMBINATION_PRODUCT|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
58134574|NCT05455073|COMBINATION_PRODUCT|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
58134575|NCT05455073|BEHAVIORAL|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
58134576|NCT05455073|BEHAVIORAL|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
58134577|NCT02136095|PROCEDURE|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
58134578|NCT00388544|BEHAVIORAL|Activity matched to interest|Recreational activities are tailored to subject's style of interest
58134579|NCT00388544|BEHAVIORAL|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
58134580|NCT00388544|BEHAVIORAL|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
58134581|NCT05738525|DEVICE|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
58134582|NCT01709032|DRUG|Deferasirox and deferiprone|
58134583|NCT02329678|PROCEDURE|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
58134584|NCT04922112|DIAGNOSTIC_TEST|Obstructive sleep apnea testing|"* Functional Outcomes of Sleep Questionnaire (FOSQ-10)~* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)~* Epworth Sleepiness Scale (ESS)~* Adult Comorbidity Evaluation (ACE 27)~* University of Washington Quality of Life Questionnaire (UW-QOL)~* Chronic Pain Assessment Questionnaire"
58134585|NCT04259528|DEVICE|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
58134586|NCT01159132|DRUG|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
58134587|NCT05682118|PROCEDURE|roadmap|"FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg."
58134588|NCT05682118|PROCEDURE|iFR/FFR|Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
58134589|NCT01180569|DRUG|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
58134590|NCT05081258|PROCEDURE|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
58134591|NCT05081258|PROCEDURE|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
58134592|NCT00403039|DRUG|Ranibizumab (Lucentis )|
58134593|NCT00076947|BIOLOGICAL|EnvPro|
58134594|NCT01582672|DRUG|Standard Treatment|Standard treatment for Renal Cell Carcinoma
58477984|NCT00765206|DRUG|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
58134595|NCT01582672|BIOLOGICAL|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
58134596|NCT06212453|PROCEDURE|Targeted Microwave Ablation|3D ultrasound-guided focal thermal ablation of the prostate transition zone
58134597|NCT05165056|DEVICE|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
58134598|NCT05968209|DIETARY_SUPPLEMENT|Lab4P|"Probiotic containing:~Lactobacillus acidophilus - CUL 60 Lactobacillus acidophilus - CUL 21 Bifidobacterium bifidum - CUL 20 Bifidobacterium animalis subsp. lactis - CUL34 Lactobacillus plantarum - CUL 66"
58134599|NCT05968209|OTHER|Placebo|Placebo
58477985|NCT00371150|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
58134600|NCT00006495|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
58134601|NCT00006495|BIOLOGICAL|HIV-1 Immunogen|
58134602|NCT05826262|PROCEDURE|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
58134603|NCT04887142|OTHER|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
58134604|NCT03127904|PROCEDURE|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
58477986|NCT06591754|BEHAVIORAL|ISTDP|Both the individual therapy and the group therapy is based on ISTDP (Intensive Short-Term Dynamic Psychotherapy), an affect-focused psychodynamic therapy method. The therapy focus on the relationship between feelings, anxiety and dysfunctional emotion regulation (i.e. defenses). The purpose is to increase the capacity of anxiety regulation in the patient and to help the patient identify the dysfunctional patterns developed to avoid internal stress and then gradually approach previously warded of feelings. The individual therapy consists of 25 weekly sessions. The group treatment consists of 18 weekly sessions and is structured in three phases. Phase one: Psychoeducation about anxiety and exercises in anxiety regulation. Phase two: patients takes turn to observe their own anxiety and defenses together with a therapist. Phase three: Every session two patients will work with a chosen problem and identify defenses, anxiety and feelings together with a therapist in front of the group.
58477987|NCT01553968|OTHER|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
58477988|NCT06595680|DRUG|Medialipide 20% perfusion|Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
58477989|NCT06595680|DRUG|NaCl 0,9%|Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
58477990|NCT06595680|BIOLOGICAL|Blood sample|Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.
58477991|NCT04257110|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
58477992|NCT02705742|BIOLOGICAL|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
58477993|NCT04424134|DRUG|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
58134605|NCT03127904|PROCEDURE|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
58134606|NCT02347501|DRUG|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
58134607|NCT01374750|DRUG|Sirolimus|Sirolimus
58134608|NCT01374750|DRUG|m-TOR inhibitor free|calcineurin inhibitors
58134609|NCT02138669|DEVICE|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
58134610|NCT01523626|OTHER|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
58134611|NCT01523626|OTHER|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
58134612|NCT04499170|OTHER|Muscular Energy Technique G1|Group of older (G1) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
58134613|NCT04499170|OTHER|Muscular Energy Technique G2|Group of young people (G2) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
58134614|NCT03613259|DRUG|Fluorothymidine F-18|Given IV
58134615|NCT03613259|OTHER|Laboratory Biomarker Analysis|Correlative studies
58134616|NCT03613259|PROCEDURE|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
58134617|NCT03816371|OTHER|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
58134618|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
58134619|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
58134620|NCT05286957|DRUG|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
58134621|NCT02218580|OTHER|Massage therapy|
58134622|NCT02218580|OTHER|Standard care|
58134623|NCT00048958|GENETIC|cytogenetic analysis|
58134624|NCT02911805|BEHAVIORAL|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
58134625|NCT02911805|BEHAVIORAL|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
58134626|NCT03749369|DRUG|Salvadora Persica Root|Salvadora Persica Gel
58134627|NCT03749369|PROCEDURE|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
58134628|NCT04992052|DEVICE|Bone wax|The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
58134629|NCT00999037|DRUG|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
58134630|NCT00999037|OTHER|Placebo|1 inert tablet tid x 12 weeks
58134631|NCT05179681|OTHER|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
58134632|NCT04971668|OTHER|Aromatherapy|Three drops of the designated blend aromatherapy (ginger \& lavender) will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
58134633|NCT04971668|OTHER|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
58134634|NCT04971668|OTHER|Controlled|Patients will inhale deeply with inert gauze and simulate like chewing gum for 5 minutes.
58134635|NCT02460159|DRUG|EZ 10 mg/Atorva 20 mg FDC|
57780123|NCT06740487|BEHAVIORAL|Traditional ET Treatment|Traditional ET includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), and (d) relapse prevention strategies and further treatment planning (session 10).
58134636|NCT02460159|DRUG|EZ 10 mg/Atorva 10 mg FDC|
58134637|NCT01355081|DRUG|Vortioxetine|Vortioxetine tablets
58134638|NCT01355081|DRUG|Placebo|Vortioxetine placebo
58134639|NCT03002779|DRUG|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
58134640|NCT03619746|BEHAVIORAL|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
58134641|NCT04910230|DRUG|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
58134642|NCT00324168|DRUG|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
58134643|NCT00324168|DRUG|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
58134644|NCT00324168|DRUG|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
58134645|NCT06403761|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
58134646|NCT06403761|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
58134647|NCT06403761|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
58134648|NCT06403761|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
58134649|NCT01491880|BEHAVIORAL|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
58134650|NCT01491880|BEHAVIORAL|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
58134651|NCT05613894|DRUG|Cabozantinib|(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.
58134652|NCT06129227|BEHAVIORAL|Dual-task training|This group will receive 30 min of dual-task exercise training and 30 min of stretching exercises in each session. The dual-task component involves walking activities performed in conjunction with cognitive activities. For the stretching exercise component, no cognitive load will be added.
58138927|NCT02404662|OTHER|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
58134653|NCT06129227|BEHAVIORAL|Single-task training|This group will undergo 30 min of single-task mobility training and another 30 min of single-task cognitive activities. The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately. No extra cognitive load will be imposed during the mobility exercises. No additional motor demand will be imposed during the cognitive exercises, as the participants will be sitting.
58134654|NCT06129227|BEHAVIORAL|Control group|This group will undergo 30 min of stretching exercises (same as the dual-task group) and another 30 min of upper limb strengthening exercises performed primarily in the sitting or lying position. No cognitive load will be added.
58134655|NCT02073604|OTHER|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
58134656|NCT02073604|OTHER|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
58134657|NCT06030505|OTHER|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
58134658|NCT03025880|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
58134659|NCT03025880|DRUG|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
58134660|NCT04862702|DEVICE|mechanical instrumentation using rotary file system|the mechanical preparation will be performed using rotary file system
58134661|NCT00389064|DRUG|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
58134662|NCT00389064|DRUG|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
58134663|NCT01165671|RADIATION|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
58134664|NCT01165671|RADIATION|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
58134665|NCT02433106|OTHER|GAA 15|Neuromuscular injury prevention training
58134666|NCT02433106|OTHER|Control|Usual training
58134667|NCT00214422|RADIATION|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
58134668|NCT03977649|DRUG|erenumab|erenumab 140 mg sc every 4 weeks
58134669|NCT03977649|DRUG|placebo|placebo sc every 4 weeks
58134670|NCT03010098|DEVICE|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
58134671|NCT03010098|DEVICE|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
58134672|NCT03386019|OTHER|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
58134673|NCT03386019|OTHER|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
58134674|NCT03386019|OTHER|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
58134675|NCT00385593|DRUG|Symbicort (budesonide/formoterol) Turbuhaler|
58134676|NCT00385593|DRUG|Conventional treatment|
58134677|NCT04751669|DIETARY_SUPPLEMENT|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
57784947|NCT06193759|BIOLOGICAL|Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)|Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.
58134678|NCT04751669|DIETARY_SUPPLEMENT|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
58134679|NCT04320173|DRUG|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
58134680|NCT04320173|DRUG|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
58134681|NCT04320173|DRUG|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
58134682|NCT04875793|DIAGNOSTIC_TEST|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
58134683|NCT03227198|BIOLOGICAL|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
58134684|NCT03227198|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
58134685|NCT00715065|PROCEDURE|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
58477994|NCT04424134|DRUG|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
58477995|NCT06652932|OTHER|Low temperature (16°C) group|The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
58477996|NCT06652932|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
58477997|NCT03747562|DRUG|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
58477998|NCT03747562|OTHER|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
58477999|NCT05670301|DIAGNOSTIC_TEST|cytokine and lipidomic profiling|"* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~* Serum amyloid A~* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~* Lipidomics"
58478000|NCT00514839|BEHAVIORAL|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
58478001|NCT03399019|DRUG|Dexmedetomidine|initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
58478002|NCT03399019|DRUG|Propofol|continuous infusion (0.75-3mg/kg/hr)
58478003|NCT03399019|DRUG|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
58478004|NCT02300961|BEHAVIORAL|Cognitive rehabilitation program|
58134686|NCT03589534|DIAGNOSTIC_TEST|home pregnancy test|Each participant will use 4 different home pregnancy tests
58134687|NCT00252811|DRUG|Gefitinib|
58134688|NCT05463653|DEVICE|Experimental|A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
58134689|NCT06140264|OTHER|Acupuncture dry needle|The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
58134690|NCT02256293|BEHAVIORAL|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
58134691|NCT02533362|DRUG|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
58134692|NCT02629757|DRUG|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
58134693|NCT02195245|DEVICE|memsorb|
58134694|NCT01539915|DRUG|BCT194|Topically applied BCT194 cream (0.5%)
58134695|NCT01410630|DIAGNOSTIC_TEST|FLT-PET/CT|Standard of Care
58134696|NCT01410630|DIAGNOSTIC_TEST|FDG-PET/CT|Standard of Care
58134697|NCT01410630|DRUG|FLT|5 mCi IV
58134698|NCT03626649|DEVICE|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~* DiamondTemp Ablation Catheter~  o Unidirectional and Bidirectional models~* DiamondTemp Catheter-to RFG Cable~* DiamondTemp GenConnect Cable~* DiamondTemp FASTR Generator with Footswitch~* DiamondTemp Irrigation Pump~* DiamondTemp Irrigation Tubing Set"
58134699|NCT00481520|DRUG|SAM-531|
58134700|NCT00481520|OTHER|placebo|
58134701|NCT02392364|DRUG|Intravitreal Aflibercept Injection|
58134702|NCT03476980|PROCEDURE|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
58134703|NCT03476980|PROCEDURE|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
57784948|NCT06392516|DRUG|Ketoacid|250 ml ketoacid two hours before the hemodialysis session ended
58478005|NCT06604117|DRUG|Statin|Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.
57780124|NCT06740487|BEHAVIORAL|ARET + Traditional ET Treatment|ARET + Traditional ET includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), (d) relapse prevention strategies and further treatment planning (session 10), and (e) 30 minutes of each 90 minute session dedicated to ARET. During ARET, the clinician guides participant, who is wearing AR goggles, through preset scenarios during which characters mingle with each other (e.g., grocery store, social gathering), as well as custom scenarios where participant can interact with the character.
57780125|NCT06290102|DRUG|TEV-56248|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
57780126|NCT06290102|DRUG|Fp MDPI|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
57780127|NCT05239793|DRUG|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
57780128|NCT06731049|OTHER|Treadmill-based Training Group|The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.
57780129|NCT06731049|OTHER|Dual-Task Treadmill-based Training Group|In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.
57780130|NCT00283465|DRUG|Epoetin alfa|
57780131|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
57780132|NCT05746429|BEHAVIORAL|Cognitive Behavior Therapy|Receive mobile CBT
57780133|NCT05746429|DEVICE|Transcranial Direct Current Stimulation|Undergo active tDCS
57780134|NCT05746429|OTHER|Interview|Attend virtual meetings and focus groups
57780135|NCT05746429|DRUG|Placebo Administration|Undergo sham tDCS
57780136|NCT05746429|OTHER|Questionnaire Administration|Ancillary studies
57780137|NCT06697197|DRUG|BMS-986482|Specified dose on specified days
57780138|NCT06697197|DRUG|Nivolumab and rHuPH20|Specified dose on specified days
57780139|NCT06697197|DRUG|Nivolumab/relatlimab/rHuPH20|Specified dose on specified days
57780140|NCT06697197|DRUG|Bevacizumab|Specified dose on specified days
57780141|NCT05511740|RADIATION|Afternoon Radiation|Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
57780142|NCT02991690|OTHER|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification \[510(k), K030421\]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
57780143|NCT06741293|OTHER|No intervention: observational study|No intervention: observational study
57780144|NCT04853862|OTHER|questionnaire|Questionnaire for health-related quality of life evaluation
57780145|NCT06738420|DIETARY_SUPPLEMENT|ABB S3|Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
57780146|NCT06738420|DIETARY_SUPPLEMENT|ABB C22|Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
57780147|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
57780148|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
57780149|NCT00319605|DRUG|Levetiracetam|
57780150|NCT02262260|DRUG|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
57784949|NCT03524820|DRUG|Cetuximab|Administration of drug
57784950|NCT02696720|DRUG|Lidocaine|
57784951|NCT02696720|OTHER|Sham|
57784952|NCT02408549|DRUG|Lacosamide Tablet|"* Active substance: Lacosamide~* Pharmaceutical form: Tablet~* Concentration: 50 mg and 100 mg~* Route of Administration: Oral administration"
58134704|NCT00941837|DIETARY_SUPPLEMENT|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
58134705|NCT03546777|DEVICE|magnetic resonance imaging|magnetic resonance imaging of shoulder
58134706|NCT01743508|PROCEDURE|Misoprostol treatment by midwife|Misoprostol treatment by midwife
58134707|NCT02084004|DRUG|Bifidobacterium viable pharmaceutics|
58134708|NCT02084004|DRUG|Berberine Hydrochloride|
58134709|NCT04271722|OTHER|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
58134710|NCT00769041|DRUG|moxifloxacin|400mg
58134711|NCT00769041|DRUG|avanafil|100mg single dose
58134712|NCT00769041|DRUG|avanafil|800mg single dose
58134713|NCT00769041|DRUG|sugar pill|single dose
58134714|NCT01887145|PROCEDURE|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
57784953|NCT02408549|DRUG|Lacosamide Oral Solution|"* Active substance: Lacosamide~* Pharmaceutical form: Oral solution~* Concentration: 10 mg/ml~* Route of Administration: Oral administration"
57784954|NCT06464679|DRUG|CD19 CAR NK cells|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
58134715|NCT01887145|PROCEDURE|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
58134716|NCT03991494|DRUG|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
58134717|NCT05719090|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
58134718|NCT00442390|DRUG|hydrocortisone substitution therapy versus withdrawal|
58134719|NCT01924078|DRUG|Capecitabine|metronomic use: capecitabine 500mg/tid
58134720|NCT01924078|DRUG|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
58134721|NCT05723445|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
58134722|NCT06440447|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
58134723|NCT06440447|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
58134724|NCT02032888|DRUG|Daclatasvir|
58134725|NCT02032888|DRUG|Sofosbuvir|
58134726|NCT00239421|DRUG|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
58134727|NCT00239421|DRUG|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
58134728|NCT05701670|BEHAVIORAL|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
58134729|NCT02290171|BEHAVIORAL|Activity groups|Children attend to activity groups weekly during the intervention periode.
58134730|NCT02290171|BEHAVIORAL|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
58134731|NCT02290171|BEHAVIORAL|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
58134732|NCT01965522|DRUG|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
58134733|NCT01965522|DRUG|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
58134734|NCT01965522|DRUG|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
58134735|NCT01965522|DRUG|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
58134736|NCT06171139|OTHER|Counseling Tool|Non-therapeutic educational intervention
58134737|NCT06171139|OTHER|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
58134738|NCT01474122|DRUG|Macitentan 3 mg|Macitentan 3-mg tablet once daily
58134739|NCT01474122|DRUG|Macitentan 10 mg|Macitentan 10-mg tablet once daily
58134740|NCT01474122|DRUG|Placebo|Placebo tablet matching macitentan tablet, once daily
58134741|NCT04702971|DRUG|Flunarizine|The flunarizine will be given per clinical routine
57780151|NCT02262260|DRUG|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
57780152|NCT06241703|PROCEDURE|ICCAUT|For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
57780153|NCT06241703|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
57780154|NCT06737926|BEHAVIORAL|Sensorimotor Training Exercise|Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
57780155|NCT06737926|BEHAVIORAL|Conventional Exercise Therapy|Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
57780156|NCT06740253|DEVICE|Placebo intravaginal ring (IVR)|Antibody-Based Nonhormonal Placebo Contraceptive Intravaginal Ring
57780157|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
57780158|NCT06690424|DRUG|Remimazolam|remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
57780159|NCT06690424|DRUG|Propofol|Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
57780160|NCT06740370|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
57780161|NCT06740370|DRUG|Lenvatinib|(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
57780162|NCT06740370|DRUG|PD-1 Inhibitors|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
57780163|NCT00615433|DRUG|Lurasidone|120mg/day
57780164|NCT00615433|DRUG|Olanzapine|15mg/day
57780165|NCT00615433|DRUG|Placebo comparator|Placebor Comparator
57780166|NCT00615433|DRUG|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
57780167|NCT06737679|BEHAVIORAL|Body Scan|"Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online."
57780168|NCT06737250|DRUG|R2P -> RP|"Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14"
57780169|NCT06738875|DEVICE|manometre|Increases in peak and mean airway pressures of ETT cuff pressures will be monitored in patients undergoing laparoscopic bariatric surgery
57780170|NCT06738524|BEHAVIORAL|Fighting with Digital Addiction|The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.
57780171|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
57780172|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
57780173|NCT01689740|DRUG|Active Placebo Dose MDMA (25 mg)|Initial dose of 25 mg MDMA administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg MDMA 1.5 to 2.5 hours later.
57780174|NCT01689740|DRUG|Full Dose MDMA (125 mg)|Initial dose of 125 mg MDMA administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.
57780175|NCT01689740|DRUG|Open Label Full Dose MDMA (125 mg)|Initial dose of 125 mg MDMA administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.
57780176|NCT01689740|BEHAVIORAL|Psychotherapy|Non-directive psychotherapy will be conducted throughout the study.
57780177|NCT02903589|OTHER|observational|
57780178|NCT04678336|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
57780179|NCT02671721|OTHER|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
57784955|NCT03262337|OTHER|none, this is an observational study|none, this is an observational study
58134742|NCT04702971|OTHER|healthy control|no intervention for healthy control
58134743|NCT02086188|DRUG|Mirabegron|see detailed information in associated Arm Description
58134744|NCT02086188|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
58134745|NCT02495857|DEVICE|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
58134746|NCT02495857|DEVICE|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
58134747|NCT02495857|DEVICE|Placebo|0.9% sodium chloride, sterile
58134748|NCT00245609|DRUG|Pregabalin|
58134749|NCT00245609|DRUG|Alprazolam|
58134750|NCT00245609|DRUG|Placebo|
58134751|NCT04714307|DIAGNOSTIC_TEST|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
58134752|NCT04714307|DIAGNOSTIC_TEST|Cognitive Testing|"Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test"
58134753|NCT04714307|DIAGNOSTIC_TEST|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
58134754|NCT04714307|DIAGNOSTIC_TEST|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
58134755|NCT04714307|DIAGNOSTIC_TEST|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
58134756|NCT04714307|DIAGNOSTIC_TEST|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
58134757|NCT05841225|BEHAVIORAL|Food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
58134758|NCT05841225|BEHAVIORAL|Non-food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
58134759|NCT05685979|PROCEDURE|Robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
58134760|NCT00322465|DRUG|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
58134761|NCT00322465|OTHER|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
58134762|NCT00322465|DRUG|Doxycycline|100 mg orally, twice daily for 7 days.
58134763|NCT00322465|DRUG|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
58134764|NCT01538251|DRUG|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
58134765|NCT01538251|DRUG|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
58134766|NCT02562365|DRUG|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
58134767|NCT06328348|DIETARY_SUPPLEMENT|supplementation|group receiving a course of Black Cohosh, Soy Isoflavones, and SDG Lignans
58134768|NCT06328348|OTHER|placebo|placebo
58134769|NCT04173754|PROCEDURE|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
58134770|NCT01488630|OTHER|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
58134771|NCT00304083|BIOLOGICAL|filgrastim|Given subcutaneously
57780180|NCT02671721|OTHER|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
57780181|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 1|Investigational varicella vaccine of Lot 1 administered subcutaneously.
57780182|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 2|Investigational varicella vaccine of Lot 2 administered subcutaneously.
58134772|NCT00304083|DRUG|doxorubicin hydrochloride|Given IV
58134773|NCT00304083|DRUG|etoposide|Given IV
58134774|NCT00304083|DRUG|ifosfamide|Given IV
58134775|NCT00304083|PROCEDURE|conventional surgery|Patients undergo surgery
58134776|NCT00304083|RADIATION|radiation therapy|Patients undergo radiotherapy
58134777|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
58134778|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
58134779|NCT04332627|DRUG|Sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
58134780|NCT04332627|DRUG|Neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
58134781|NCT00617305|DRUG|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
58134782|NCT00617305|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
58134783|NCT00617305|DRUG|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
58134784|NCT00617305|DRUG|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
57780183|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 3|Investigational varicella vaccine of Lot 3 administered subcutaneously.
57780184|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 1|Marketed varicella vaccine of Lot 1 administered subcutaneously.
57780185|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 2|Marketed varicella vaccine of Lot 2 administered subcutaneously.
57780186|NCT06740630|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
57780187|NCT06740630|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
57780188|NCT06740630|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
57780189|NCT06740630|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
57780190|NCT06740630|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
57780191|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
57780192|NCT02988206|BEHAVIORAL|Personalized Objects|personalized objects are based on the observation or the reports from family
58134785|NCT03260465|DEVICE|seleXys PC|Total hip arthroplasty using the seleXys PC cup
58134786|NCT03260465|DEVICE|RM|Total hip arthroplasty using the RM cup
58134787|NCT00046527|DRUG|ABI-007|
58134788|NCT01376102|DRUG|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
58134789|NCT02648620|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
58134790|NCT02648620|PROCEDURE|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
58134791|NCT00182806|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
58134792|NCT00182806|DRUG|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
58134793|NCT05070611|DEVICE|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
58134794|NCT06213844|DRUG|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
58134795|NCT06213844|DRUG|Placebo|Single dose of Placebo, administered subcutaneously on Day 1
58134796|NCT00176306|DRUG|Levofloxacin 750 mg IV|PK in obesity
58134797|NCT01833052|DEVICE|TAVI (Medtronic CoreValve)|
58134798|NCT01833052|DEVICE|Claret-Filter|
58134799|NCT01696097|BEHAVIORAL|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
58134800|NCT02337309|DRUG|SF1126|SF1126 in IV form with be given to patients on this study.
58134801|NCT04849520|DEVICE|High flow nasal cannula|Oxygen supplement via high flow nasal cannula at a rate of 2 liters/kg/min
58134802|NCT04849520|DEVICE|Buccal oxygenation|Oxygen supplement intra-orally via oral Ring-Adair-Elwyn endotracheal tube connected to oxygen at a rate of 0.5 liters/kg/min
58134803|NCT06125483|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
58134804|NCT05440539|OTHER|Written Handouts|The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
58134805|NCT05440539|OTHER|Interactive Workshop|Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
58134806|NCT02589964|DIETARY_SUPPLEMENT|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
58134807|NCT02589964|OTHER|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
58134808|NCT00360360|DRUG|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
58134809|NCT00360360|DRUG|carboplatin|Carboplatin AUC 6.0 IV Day 1
58134810|NCT00360360|DRUG|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
58134811|NCT00360360|DRUG|erlotinib|Erlotinib 150 mg by mouth daily
58134812|NCT04181190|DIAGNOSTIC_TEST|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
58134813|NCT04181190|DIAGNOSTIC_TEST|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
58134814|NCT04181190|DIAGNOSTIC_TEST|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
58134815|NCT04181190|DIAGNOSTIC_TEST|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
58134816|NCT01513070|DRUG|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
57780193|NCT02988206|BEHAVIORAL|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
58134817|NCT01513070|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
58134818|NCT01513070|DRUG|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
58134819|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
58134820|NCT01513070|DRUG|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
58134821|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
58134822|NCT02635243|DRUG|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
58134823|NCT02635243|DRUG|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
58134824|NCT02635243|DRUG|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
58134825|NCT02324803|DRUG|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
58134826|NCT05567874|OTHER|Nosocomial SARS-COV 2 Infection proportion|Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
58134827|NCT03621800|OTHER|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
58134828|NCT06260488|PROCEDURE|Endovascular surgery|routine endovascular surgery and FPAS harvesting from amputated limbs to evaluate the technical feasibility of histological segmentation by the FPAS algorithm from CT
58134829|NCT06346223|BEHAVIORAL|Mindfulness and psychoeducation|The single-session mindfulness intervention includes a 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit. All of the teaching contents will be closely related to dementia caregiving and delivered by a mindfulness teacher who has received 40 hours training in dementia caregiving. A weekly mindfulness practice reminder will be sent to the participants through SMS for 8 weeks. The caregivers will also be provided with access to a social media online platform for sharing their practice experience with their classmates online. The interventionist will address their difficulties and challenges via the platform to reinforce skill mastery.
58134830|NCT06346223|BEHAVIORAL|Psychoeducation|The caregivers in the control group will receive brief education on dementia with the same group size and of the same duration (90-minutes) as the sessions in the intervention arm. The nurse will deliver brief education (15 minutes) on dementia in the session, followed by group sharing and discussion on their daily caregiving experience. The caregivers in the control group will be provided with a toolkit with education materials about the common health problems of older adults and also be given access to a social media platform in which they can communicate and share their caregiving experiences with classmates.
58134831|NCT01888263|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
58134832|NCT03515967|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
58134833|NCT02726230|BEHAVIORAL|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
58134834|NCT01520623|OTHER|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
58134835|NCT02359305|DRUG|Acetaminophen|Acetaminophen given by IV
58134836|NCT02359305|DRUG|Acetaminophen|Acetaminophen suppository given rectally
58134837|NCT04815083|DRUG|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
58134838|NCT04815083|DEVICE|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
58134839|NCT04815083|DRUG|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
58134840|NCT02904837|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
58134841|NCT02904837|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
58134842|NCT00803803|DRUG|Pilocarpine Concentration|Varying concentration 0.5 to 8%
58134843|NCT00803803|DRUG|Pilocarpine Frequency|1 to 4 times daily
58134844|NCT04901221|DEVICE|Extrusion arch|one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
58134845|NCT04331665|DRUG|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
58134846|NCT03884439|DRUG|Infliximab [infliximab biosimilar 3]|\<Crohn's disease\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
58134847|NCT03456570|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
58134848|NCT03456570|DRUG|Placebo Oral Tablet|oral tablets twice daily
58134849|NCT02865746|DRUG|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
58134850|NCT02865746|DRUG|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
58491902|NCT02471599|PROCEDURE|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
57780194|NCT06741332|DEVICE|Methinks software|Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.
58134851|NCT02045927|OTHER|sedation monitoring with RASS score|
58134852|NCT02045927|OTHER|sedation monitoring with BIS-Guided monitoring|
58134853|NCT04920877|OTHER|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
58134854|NCT01767298|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
58134855|NCT01767298|DRUG|Valsartan|Valsartan alone
58134856|NCT01767298|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
58134857|NCT03435705|BEHAVIORAL|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
58134858|NCT04294108|OTHER|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
58134859|NCT05689463|BIOLOGICAL|characterisation of immunoglobulin subclasses|For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed
58134860|NCT01616602|OTHER|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
58134861|NCT01616602|OTHER|Standard Position|The traditional left-lateral decubitus position
58134862|NCT03085056|DRUG|Trametinib|trametinib orally 2mg daily during each 4 week cycle
58134863|NCT03085056|DRUG|Paclitaxel|paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
58134864|NCT03659656|BEHAVIORAL|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
58134865|NCT03659656|DEVICE|Fitbit usage|The participants will have a Fitbit to use for 3 months.
58134866|NCT01132963|OTHER|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
58134867|NCT01132963|OTHER|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
58134868|NCT01954264|PROCEDURE|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
58134869|NCT01954264|OTHER|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
57780195|NCT06741332|OTHER|Normal CT scans evaluation|The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.
57780196|NCT03726021|DRUG|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
57780197|NCT06737705|DRUG|Baritinib|Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
57780198|NCT06739824|DIAGNOSTIC_TEST|Conventional Treatment(CI)|Patients receive a corticosteroid injection followed by conventional treatment, such as standard physical therapy exercises focused on range of motion and strengthening, without the specific manual techniques of the Spencer method.
57780199|NCT06739824|COMBINATION_PRODUCT|Spencer Technique (CI)|Patients receive a corticosteroid injection followed by the Spencer technique, which involves a series of specific manual mobilization maneuvers aimed at improving shoulder mobility and reducing pain.
57780200|NCT02850328|OTHER|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%."
57780201|NCT06737406|DRUG|Topical 5% fluorouracil cream|Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)
57780202|NCT06737406|DRUG|Topical 0.005% calcipotriol ointment|Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
57780203|NCT06737406|DRUG|Placebo|A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.
57780204|NCT06737406|DRUG|Placebo|A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
57780205|NCT04047004|DRUG|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
57780206|NCT04047004|DRUG|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
57780207|NCT06739551|DRUG|Methotrexate (drug)|oral methotrexate 10 mg per week for 12 weeks
57780208|NCT06739551|DRUG|Acitretin|oral acitretin 50 mg once daily for 12 weeks
57780209|NCT06738095|DEVICE|daily low-level red-light|Daily low-level red-light is a kind of myopia intervention. Red-light typically using 650-nm wave of length. The treatment duration last 3 minutes each time, every day children were anticipated to use two times, at home.
57780210|NCT01621958|BEHAVIORAL|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
57780211|NCT01621958|BEHAVIORAL|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
57780212|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
57780213|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
57780214|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
57780215|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
57780216|NCT05479994|DRUG|BGB-11417|Administered orally
57780217|NCT04416581|DRUG|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
57780218|NCT04416581|DRUG|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
57780219|NCT06696326|DIAGNOSTIC_TEST|standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
57780220|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
57780221|NCT06739187|DEVICE|Virtual reality platform on head mounted display|Enhance Virtual Reality platform on a Meta Quest head mounted display
58134870|NCT02541149|PROCEDURE|blood sample|
58134871|NCT05060315|COMBINATION_PRODUCT|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
58134872|NCT01959256|BEHAVIORAL|Visual perceptual learning|24 times of training for visual perceptual learning
58134873|NCT04661397|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
58134874|NCT04661397|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
58134875|NCT04661397|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
58134876|NCT04661397|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
58134877|NCT04545762|DRUG|Fludarabine|Given intravenously (IV)
58134878|NCT04545762|DRUG|Cyclophosphamide|Given intravenously (IV)
58134879|NCT04545762|BIOLOGICAL|anti-CD19 CAR-T cells|Single infusion
58134880|NCT01112280|DEVICE|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
58134881|NCT00465881|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
58134882|NCT04055337|PROCEDURE|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
58134883|NCT00163605|DEVICE|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
58134884|NCT00081952|DRUG|L-norleucine|
58134885|NCT02780570|PROCEDURE|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
58134886|NCT04185909|DEVICE|Renuvion Dermal System|The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
58478006|NCT06604117|DRUG|Probucol|Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.
58478007|NCT05162963|OTHER|fixed implant denture|Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
58478008|NCT05162963|OTHER|removable implant denture|removable implant denture
58478009|NCT05692375|OTHER|"Invitation to play the game Save the shame!"|The experimental group was asked to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform . The control group neither used nor had access to the game. Afterwards both groups performed the ALS knowledge assessment test. It is a test with 20 multiple choice questions each scored as right (0.5 points) or wrong (0 points).
58478010|NCT04592302|DIAGNOSTIC_TEST|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
58478011|NCT06521320|DIAGNOSTIC_TEST|speaking valve combined with airway pressure|All patients were given speaking valves and airway pressure was measured to assess upper airway patency.
58478012|NCT06521320|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
58134887|NCT06404307|BEHAVIORAL|Self-administration|patients will self administer their antimicrobial treatment
58134888|NCT04542603|DRUG|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
58134889|NCT02721264|BIOLOGICAL|Fecal Microbiota Transplant|
58134890|NCT02721264|OTHER|Standard Medical Treatment|
58134891|NCT06320977|OTHER|Static Stretching|"The static stretching protocol will include the following muscle groups of the dominant lower limb:~* Gastrocnemius - Participants will assume a bipedal position facing a wall. Then, the leg that is not being stretched will be placed forward, with the knee in semi-flexion, and the leg that is being stretched, behind, with the knee in full extension. Instructions will be given in order to keep the calcaneus on the floor;~* Tibialis anterior - Participants will be facing a wall, with the entire foot in touch with the ground and toes pointing forward. Then, they will secure themselves to a handrail and project the hips back.~These stretchings will be held in a position where the participants refer discomfort, and will be maintained for 30 seconds or 90 seconds according to the condition."
58138928|NCT03370549|BEHAVIORAL|AWARE intervention|Group psychotherapy for Asian-American women
58478013|NCT06590792|OTHER|exhaustive exercise training session|Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.
58478014|NCT00758667|DRUG|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
58478015|NCT03501849|DEVICE|Polypectomy using a cold snare|Polypectomy by cold-snare technique
58478016|NCT04912258|DRUG|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
58478017|NCT03122509|DRUG|durvalumab|1500 mg durvalumab via IV infusion
57780222|NCT05580640|PROCEDURE|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
57780223|NCT00675545|DRUG|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
57780224|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
57780225|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
57780226|NCT02438774|BEHAVIORAL|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
57780227|NCT02438774|BEHAVIORAL|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
57780228|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
57780229|NCT00027690|DRUG|Gefitinib|Given orally
57780230|NCT00027690|OTHER|Laboratory Biomarker Analysis|Correlative studies
57780231|NCT06741098|BIOLOGICAL|NCR100|Subjects will receive multiple intra-articular NCR100 injections.
57780232|NCT06741098|OTHER|0.9% Normal saline|Subjects will receive multiple intra-articular 0.9% Normal saline injections.
57780233|NCT03537053|BEHAVIORAL|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
57780234|NCT06736353|DRUG|Beta Blocker Therapy or No Therapy (Control)|Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
57780235|NCT06736353|DRUG|RAAS blocker Therapy or No therapy (Control)|RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
57780236|NCT06736353|DRUG|Statin Therapy or No Therapy (Control)|Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
57780237|NCT06736353|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or no Single Antiplatelet Therapy therapy initiated after type 2 myocardial infarction
57780238|NCT06736353|DRUG|Dual Antiplatelet Therapy or No Therapy (Control)|Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
57780239|NCT03626038|DEVICE|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
57784956|NCT01077024|OTHER|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
58138929|NCT03393728|DRUG|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
58478018|NCT03122509|DRUG|tremelimumab|75 mg tremelimumab via IV infusion
58478019|NCT03122509|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
58478020|NCT03122509|PROCEDURE|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
58478021|NCT04784247|DRUG|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
58478022|NCT04784247|DRUG|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
58478023|NCT06590246|BIOLOGICAL|Armored and GPC3-targeted autologous CAR T-cell|Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.
58478024|NCT01857492|DEVICE|tDCS|
58478025|NCT01857492|BEHAVIORAL|Meditation|Both Active and SHAM groups will receive Meditation.
58478026|NCT06590818|PROCEDURE|High tibial osteotomy (HTO|To investigate the effect of body mass index (BMI) on the early efficacy of high tibial osteotomy (HTO) in the treatment of varus knee osteoarthritis
58478027|NCT00744497|DRUG|Placebo|
58134892|NCT04343066|DEVICE|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
58134893|NCT05416164|RADIATION|Omission of radiotherapy|Omission of radiotherapy
58134894|NCT03318471|DRUG|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
58478028|NCT00744497|DRUG|Dasatinib|
58478029|NCT00744497|DRUG|Docetaxel|
58134895|NCT03318471|DRUG|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
58478030|NCT00744497|DRUG|Prednisone|
58478031|NCT04886635|OTHER|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
58478032|NCT00948376|GENETIC|IFT80 screening|Natural History
58478033|NCT02065037|DEVICE|room temperature air insufflation|control arm
58134896|NCT04190693|DRUG|IMCY-0098 or placebo|Long-term follow-up
58134897|NCT01941966|DRUG|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
58134898|NCT01941966|DRUG|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
58134899|NCT01941966|RADIATION|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
58478034|NCT02065037|DEVICE|warmed carbon dioxide insufflation|comparator arm
58478035|NCT06599281|OTHER|Physiotherapy|The physical therapy program was applied for 3 months, 6 days a week, 2 sessions per day, and an average session duration of 45 minutes. Each neurodevelopmental exercise and proprioceptive exercise was applied for 10 minutes, and stretching exercises were applied for 45 seconds and 3 repetitions. The exercises included functional rotation, sitting with or without arm support, crawling, kneeling, half kneeling, standing up by holding on, and sequencing exercises. Stretching exercises were mostly positional stretches aimed at lateral flexion of the spine.
58478036|NCT03216512|OTHER|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
58478037|NCT05602246|PROCEDURE|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
58478038|NCT05602246|PROCEDURE|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
58478039|NCT04593862|OTHER|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
58478040|NCT04467905|DRUG|Etripamil|The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
58134900|NCT01698476|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
58134901|NCT01698476|DRUG|Placebo tablets|
58134902|NCT02932696|OTHER|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
58134903|NCT01246830|RADIATION|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
58134904|NCT01246830|RADIATION|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
58134905|NCT01469767|DRUG|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
58134906|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
58134907|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
57780240|NCT06741215|OTHER|Hand Rehabilitation|"Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week."
57780241|NCT06117774|DRUG|Tarlatamab|Intravenous (IV) infusion
57780242|NCT06117774|DRUG|Placebo|IV infusion
57780243|NCT04091776|RADIATION|CT scan|"1. Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~2. Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~3. Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~4. Assessment of fixation failure in fixed fractures if occurred.~5. Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
57780244|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
57780245|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
57780246|NCT04704661|PROCEDURE|Biopsy|Undergo tissue biopsy
57780247|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57780248|NCT04704661|DRUG|Ceralasertib|Given PO
57780249|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57780250|NCT04704661|PROCEDURE|Echocardiography|Undergo ECHO
57780251|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57780252|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57780253|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
57780254|NCT03448393|BIOLOGICAL|CD19/CD22 CAR T-Cells|CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
57780255|NCT03448393|DRUG|Fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
57780256|NCT03448393|DRUG|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
57780257|NCT06280963|BEHAVIORAL|muscle energy technique|in muscle energy technique, the target is gluteus maximus muscle ( hip extension ) and repeat the method from three to five times .
57780258|NCT06280963|BEHAVIORAL|posterior innominate mobilization|in posterior innominate mobilization ( grade 3 mobilization ) , frequency of mobilizations is 30 oscillations , 3 sets per session ( every set has 30 oscillations )
58134908|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
57780259|NCT06280963|BEHAVIORAL|conventional treatment|"conventional treatment include~* TENS ( 45 minutes of conventional TENS )~* Ultrasound (pulsed mode 1:1 ,5 min .1.5W/cm2 )~* Stretching exercises ( hamstrings ,hip flexors and hip adductors)~* Strengthening exercises (lower abdomen and glutes muscles )~* Lumpopelvic stabilization exercise"
57780260|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
57780261|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
57780262|NCT03959774|DEVICE|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
57780263|NCT06467175|BIOLOGICAL|blood sampling for high molecular weight DNA extraction|2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
57780264|NCT06737861|OTHER|Buerger Exercises with Whole Body Vibration (WBV) Therapy|Participants will perform Buerger exercises three times daily, with each session including three cycles. Additionally, they will receive Whole Body Vibration therapy at a frequency of 25 Hz, three times per week. Each WBV session will last 12 minutes, divided into four 3-minute bouts, aiming to improve pain, balance, and lower limb circulation in diabetic peripheral neuropathy patients.
57780265|NCT06737861|OTHER|Buerger Exercises Only|Participants will perform Buerger exercises three times daily, with each session consisting of three cycles. This exercise regimen is aimed at assessing its effectiveness on pain, balance, and circulation in diabetic peripheral neuropathy patients, serving as a comparison to the combined intervention with WBV therapy.
57780266|NCT06739135|BEHAVIORAL|Visual feedback training|Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees
57780267|NCT06739655|RADIATION|Preoperative radiotherapy|"In this study the patients assigned to the experimental treatment arm will receive preoperative radiotherapy instead of postoperative radiotherapy.~This preoperative radiotherapy will follow the standard of care (SoC) principles as they are defined for postoperative radiotherapy in breast cancer, as defined by international guidelines."
57780268|NCT06739655|RADIATION|Postoperative radiotherapy|Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
57784957|NCT01874327|BEHAVIORAL|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
58134909|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
58134910|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
58134911|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
58478041|NCT04467905|DRUG|Placebo|The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
58478042|NCT01560663|DRUG|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
58478043|NCT04965701|DRUG|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
58478044|NCT03829228|DIETARY_SUPPLEMENT|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
58478045|NCT02386397|DRUG|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
58478046|NCT02386397|DRUG|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
58478047|NCT03580811|DEVICE|Dental Implant &ADMG|A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
58478048|NCT03580811|DEVICE|Dental implant & ADMG & BDX|Dental Implant will be placed with ADMG that covers the BDX
58478049|NCT06654869|BEHAVIORAL|lauhgter yoga|include laughter yoga effects on cancer patients' symptom management
58478050|NCT02775786|OTHER|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
58478051|NCT06257433|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
58478052|NCT05842616|OTHER|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
58478053|NCT05842616|OTHER|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
58478054|NCT03171363|BEHAVIORAL|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
58478055|NCT02392637|DRUG|Cisplatin|Given IV
58478056|NCT02392637|DRUG|Gemcitabine Hydrochloride|Given IV
58478057|NCT02392637|OTHER|Laboratory Biomarker Analysis|Correlative studies
58478058|NCT02392637|DRUG|Nab-paclitaxel|Given IV
58478059|NCT03129568|BIOLOGICAL|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
58478060|NCT00091949|DRUG|pioglitazone|a thiazolidinedione drug
58478061|NCT00091949|DRUG|placebo|an inactive substance
58478062|NCT01437657|DRUG|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
58478063|NCT01437657|DRUG|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
58478064|NCT01437657|DRUG|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
58478065|NCT00412009|PROCEDURE|Comprehensive package of activities|
57780269|NCT06739655|PROCEDURE|Immediate breast reconstruction|In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
58478066|NCT05482997|DIETARY_SUPPLEMENT|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
58478067|NCT05482997|DIETARY_SUPPLEMENT|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
58478068|NCT04493008|BEHAVIORAL|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
58478069|NCT01502826|DIETARY_SUPPLEMENT|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
58478070|NCT01820338|BEHAVIORAL|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
58478071|NCT01820338|BEHAVIORAL|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
58491903|NCT02471599|OTHER|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
58478072|NCT01820338|OTHER|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains \& carbohydrates. Topics will also include use of vitamin \& mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
58478073|NCT03632850|OTHER|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
58478074|NCT06600334|DIAGNOSTIC_TEST|dexa scan|Bone density scans
58478075|NCT03525678|DRUG|Belantamab mafodotin frozen liquid|Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
58478076|NCT03525678|DRUG|Belantamab mafodotin lyophilized powder|Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
58478077|NCT01224145|DRUG|5x5cm bupivacaine collagen sponges|
58478078|NCT05519982|BEHAVIORAL|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
58478079|NCT05519982|BEHAVIORAL|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
58478080|NCT06591195|DEVICE|Distraction by use of kaleidoscope|"À kaleidoscope is an optical device consisting of mirrors that reflect images of bits of coloured glass in a symmetrical geometric design through a viewer.~A kaleidoscope was selected as the non-electronic method of distraction, because of its wide availability due to low costs, its evolving and colourful visual stimuli, the fact that is blocks out any visualisations from the environment when used properly, and because it requires active participation (i.e., greater attention) from the subject."
58478081|NCT00535639|DRUG|Betula Verrucosa allergen extract|
58478082|NCT03208946|OTHER|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
58478083|NCT03208946|OTHER|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
58478084|NCT04833582|DRUG|ZN-c3|ZN-c3 is an investigational drug.
58478085|NCT04833582|DRUG|Gemcitabine|Gemcitabine is an approved drug
58478086|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
58478087|NCT03980080|DRUG|Placebo|Vehicle study drug
58478088|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
58478089|NCT03737929|PROCEDURE|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
58478090|NCT03737929|PROCEDURE|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
58478091|NCT00174187|DRUG|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
58478092|NCT00860093|OTHER|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
58478093|NCT00860093|DRUG|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
58478094|NCT03833505|OTHER|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
58134912|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
58478095|NCT05247671|GENETIC|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
58478096|NCT05247671|GENETIC|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
58478097|NCT06654609|COMBINATION_PRODUCT|Insoles for Foot|Assess the condition of foot ulcers in patients, beginning with creating a cast of the affected foot. After the initial rectification, necessary modifications are made to prepare the rough insole. The size and fit of the insole are then carefully checked against the patient's foot. I use local silicone materials, secured with lady socks or stockinette to ensure the insole stays in place and provides durability.
58478098|NCT00671736|DRUG|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
58478099|NCT00671736|DRUG|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
58478100|NCT05910996|PROCEDURE|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
58478101|NCT05410210|OTHER|Pharmaceutical care|The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
58478102|NCT01625299|DIETARY_SUPPLEMENT|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
58478103|NCT01625299|DIETARY_SUPPLEMENT|Placebo|Rice flour 1.0 g/kg/day
58478104|NCT06417424|DEVICE|gastrointestinal external stimulation|We used the device Gastrointestinal multifunctional therapeutic instrument. The positive pole was placed 1 to 2cm above the umbilicus, and the negative pole was placed 4 to 10 cm to the right of the midpoint between the xiphoid process and the umbilicus.
58478105|NCT02875353|DEVICE|Doppler Endoscopic Probe|A colon length catheter (probe).
58478106|NCT00507780|DRUG|GnRH antagonist|
58478107|NCT02604394|PROCEDURE|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
58478108|NCT02604394|PROCEDURE|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
58478109|NCT06587165|OTHER|N15-thymidine|50mg/kg (oral administration)
58478110|NCT03841396|DRUG|Sodium chloride|All participants received a single dose of sodium chloride as placebo
58478111|NCT05535296|BEHAVIORAL|Risk profile|Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
58478112|NCT02550639|OTHER|BIOMARKER- elispot test|ELISPOT TEST
58478113|NCT04281862|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
58478114|NCT04281862|DRUG|Topical Prednisolone|Standard of care topical drop treatment
58478115|NCT05481151|DRUG|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
58478116|NCT05481151|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
58478117|NCT06175806|DRUG|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
58478118|NCT06175806|DRUG|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
58478119|NCT06188910|OTHER|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
58478120|NCT06188910|OTHER|Health education|Health education on mobile phone addiction
58478121|NCT06655571|PROCEDURE|Ultrasound guided caudal Block|caudal block using Ultrasound
58134913|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
58134914|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
58134915|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
58134916|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
58478122|NCT06655571|PROCEDURE|Conventionel|Caudal Block based on anatomical landmarks
58478123|NCT02415322|OTHER|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
58478124|NCT04404491|DRUG|Procedural death 1|200mg,d1,15,29,43,57,I.V
58478125|NCT04404491|DRUG|Capecitabine|Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
58478126|NCT04404491|RADIATION|Radiotherapy|radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
58478127|NCT04404491|DRUG|Placebo|placebo: 200mg,d1,15,29,43,57,I.V
58478128|NCT04971434|DEVICE|laser stimulation for acupoints|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
58478129|NCT04971434|OTHER|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
58478130|NCT00598338|DRUG|Prucalopride|4 mg o.d.
58478131|NCT00598338|OTHER|Placebo|o.d.
58478132|NCT06524843|OTHER|Analysis|Analysis and review of imaging and clinical data
58478133|NCT06655012|DRUG|Salmeterol|Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
58478134|NCT06655012|DRUG|Placebo|Participants are administered placebo (8 puffs) from a MDI device
58478135|NCT00571493|DRUG|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
58478136|NCT00571493|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
58478137|NCT04769934|DEVICE|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
58478138|NCT05784038|DIAGNOSTIC_TEST|Viral genomic|Evaluation of mpox viral genomic
58478139|NCT05784038|DIAGNOSTIC_TEST|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
58478140|NCT00106704|DRUG|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
58478141|NCT00106704|DRUG|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
58478142|NCT00106704|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
58478143|NCT01942694|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
58478144|NCT01942694|OTHER|Placebo|Administered as one soft-gel pill daily by mouth
58478145|NCT05274815|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
58478146|NCT01463501|OTHER|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
58478147|NCT01463501|OTHER|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
57780270|NCT06739655|PROCEDURE|Immediate or delayed breast reconstruction|In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
57780271|NCT05345184|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
58478148|NCT03957928|OTHER|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
58478149|NCT03957928|OTHER|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
58478150|NCT02606643|PROCEDURE|Slight traction|Slight traction will be applied to the balloon catheter
58478151|NCT02606643|PROCEDURE|Foley Catheter to no traction|Foley Catheter to no traction
58478152|NCT05599893|OTHER|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
58478153|NCT05599893|OTHER|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
58478154|NCT06655818|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
57780272|NCT05345184|BEHAVIORAL|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
58478155|NCT06655818|DRUG|Dostarlimab|Dostarlimab will be administered.
58478156|NCT06506812|BIOLOGICAL|High-Dose Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
58478157|NCT06506812|BIOLOGICAL|Standard-Dose Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the governmental influenza vaccine programs may be used.
58478158|NCT05913765|DEVICE|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
58478159|NCT00587522|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
58478160|NCT03012503|DRUG|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
58478161|NCT03012503|DRUG|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
58478162|NCT04052854|DRUG|Zanubrutinib|Zanubrutinib will be orally administered in participants with treatment naive or R/R WM
58478163|NCT06591871|OTHER|Self-management educational program for post mastectomy lymphedema women|"The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage)."
58478164|NCT04959877|BEHAVIORAL|health education|data collect / Telemedicine
58478165|NCT03631251|DRUG|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
58478166|NCT06655025|DRUG|Dexmedetomidine|Dexmedetomidine infusion during open heart surgery
58478167|NCT03102437|DEVICE|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
58478168|NCT06522646|DEVICE|SPCM|During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis
58478169|NCT06522646|DEVICE|Usual Prothesis|During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
58478170|NCT06341257|RADIATION|Stereotactic Central/Core Ablative Radiation Therapy (SCART)|The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
58478171|NCT04496713|OTHER|Internet-connected computer tablet|An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
58478172|NCT04930471|DRUG|Metformin|Treatment with Metformin as prescribed by the treating physician.
58478173|NCT04163016|DRUG|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
58478174|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
58478175|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
58478176|NCT00495313|DRUG|doxycycline|COL-101, QD plus metronidazole
58478177|NCT00495313|DRUG|doxycycline|40 mg with metronidazole QD
58478178|NCT03171649|DEVICE|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
58478179|NCT03171649|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
58478180|NCT02611297|PROCEDURE|Cryoprobe|
58478181|NCT04103619|DEVICE|AccuTite|Subjects will undergo treatment with AccuTite
58478182|NCT04103619|DEVICE|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
58478183|NCT06492239|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
58478184|NCT06492239|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
58478185|NCT03171961|BEHAVIORAL|online visit group|subjects has online visit with dietitian every 2 weeks+diet
58478186|NCT03171961|BEHAVIORAL|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
58478187|NCT03171961|BEHAVIORAL|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
58478188|NCT01780506|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
58478189|NCT01780506|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
58478190|NCT01780506|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
58478191|NCT01780506|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
58491904|NCT06383312|DEVICE|Reflexologic Magnetic Insole Group|Reflexologic magnetic insole will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
58491905|NCT06383312|DEVICE|Orthopedic Insole Group|Orthopedic insole (sham) will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
58478192|NCT05369741|OTHER|TIME™ at Home|"Components of each 1.5-hour session:~1. Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~2. Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~3. Post-class social time (15 min): Structured and unstructured social interactions~4. Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~5. Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
58478193|NCT06103435|PROCEDURE|Extent od surgical resection|
58478194|NCT04249245|OTHER|Nasal Swab|All
58478195|NCT04053660|PROCEDURE|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
58478196|NCT02691507|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
58478197|NCT02691507|DRUG|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
58478198|NCT02000206|DRUG|Propofol|
58478199|NCT02000206|DRUG|Ketamine|
58478200|NCT02000206|DRUG|Alfentanil|
58478201|NCT03371498|DRUG|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
58478202|NCT03371498|DRUG|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
58478203|NCT01815346|PROCEDURE|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
58478204|NCT01815346|BEHAVIORAL|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
58478205|NCT01815346|OTHER|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
58478206|NCT02833233|PROCEDURE|Cryoablation|
58478207|NCT02833233|DRUG|Ipilimumab|
58478208|NCT02833233|DRUG|Nivolumab|
58478209|NCT04402034|BEHAVIORAL|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
58478210|NCT00002894|DRUG|carboplatin|
58478211|NCT00002894|DRUG|cisplatin|
58478212|NCT00002894|DRUG|paclitaxel|
58478213|NCT02769117|PROCEDURE|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
58478214|NCT02769117|PROCEDURE|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
58478215|NCT03110523|DRUG|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
58478216|NCT05747235|RADIATION|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
58478217|NCT00674817|DRUG|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
58478218|NCT00674817|DRUG|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
58478219|NCT04254003|DEVICE|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
58478220|NCT04254003|DEVICE|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
58478221|NCT04417517|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
58478222|NCT04417517|DRUG|azacitidine|Hypomethylating agent (HMA)
58478223|NCT01481753|PROCEDURE|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
58478224|NCT01481753|PROCEDURE|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
58478225|NCT06655272|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
58478226|NCT06655272|DRUG|Placebo|Matching placebo.
58478227|NCT02201394|DRUG|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
58478228|NCT02201394|DRUG|Aspirin loading dose|Single loading dose of Aspirin 325 mg
58478229|NCT02201394|DRUG|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
58478230|NCT02201394|DRUG|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
58478231|NCT02115048|DRUG|Letrozole|
58478232|NCT02115048|DRUG|Afatinib|
58478233|NCT04617678|OTHER|Prehabilitation Program|We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
58478234|NCT04155762|OTHER|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
58478235|NCT04155762|OTHER|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
58478236|NCT06314802|OTHER|no intervention|No intervention
58478237|NCT02037971|PROCEDURE|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
58478238|NCT02037971|OTHER|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
58478239|NCT03865901|DIAGNOSTIC_TEST|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
58478240|NCT04986904|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
58478241|NCT06390436|DIAGNOSTIC_TEST|Blood sample|A blood sample will be taken, in addition to blood samples taken for the usual follow-up, with 4 dry tubes for the determination of ADA and anti-ADA antibodies and for bio-collection.
58478242|NCT06390436|DRUG|Adalimumab Injection|Adalimumab Injection
58478243|NCT01804400|DRUG|QAW039|
58478244|NCT01804400|DRUG|Montelukast|
58478245|NCT01804400|DRUG|Placebo|
58478246|NCT06403397|OTHER|Experimental group: CEASE Care Package and Remember Me Tool|"Before the intervention, the intervention group will first undergo the 'Nurse Identification Form' and the 'Alarm Fatigue Scale'. The current root cause analysis of monitor alarms in the clinical setting will be conducted through the 'CEASE Care Package' and the 'Current Situation Analysis Form'. Each patient monitor in the intensive care unit will be observed and recorded by two observers for a period of 24 hours.The Monitor Alarm Control Tool - Remember Me will be attached beneath each monitor to facilitate easier monitoring by nurses. Nurses are expected to use the tool for a period of 15 days. After intervention; Two observers will conduct a re-evaluation using the CEASE Care Package and the Current Status Analysis Form. Monitor alarms will be continuously assessed and recorded for 24 hours. Following the completion of this stage, the Alarm Fatigue Scale will be reapplied to the intervention group."
58478247|NCT04513223|DRUG|SHR-A1811|There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
58478248|NCT04907136|OTHER|Preferred ENDS|Preferred ENDS without HWL on device
58478249|NCT04907136|OTHER|Preferred ENDS with HWL|Preferred ENDS with a HWL on device
58478250|NCT00566319|BEHAVIORAL|PREPARE with pedometer|Structured educational programme with pedometer use
58478251|NCT00566319|BEHAVIORAL|PREPARE|Structured educational programme
58478252|NCT00949702|DRUG|vemurafenib|960 mg b.i.d. continuous oral dosing
58478253|NCT04978168|BEHAVIORAL|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
58478254|NCT04978168|BEHAVIORAL|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 6 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
58478255|NCT04978168|BEHAVIORAL|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
58478256|NCT01958164|DRUG|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
58478257|NCT01958164|DRUG|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
58478258|NCT01958164|DRUG|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
58478259|NCT01958164|DRUG|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
58478260|NCT02120898|DRUG|Imiquimod|Cream, generic formulation of the brand product.
58478261|NCT02120898|DRUG|Zyclara®|Cream, brand product.
58478262|NCT02120898|DRUG|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
58478263|NCT04633278|DRUG|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
58478264|NCT04633278|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
58478265|NCT05830396|DRUG|Ambroxol Hydrochloride|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
58478266|NCT05830396|DRUG|Placebo|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
58478267|NCT05589857|DEVICE|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
58478268|NCT05589857|DEVICE|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
58478269|NCT03530982|OTHER|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
58478270|NCT06589908|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
58491927|NCT03652285|DEVICE|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
58478271|NCT04500899|DRUG|Mydfrin|A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. BP will be monitored after each bolus of phenylephrine. Subsequent Mydfrin injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
58478272|NCT05828147|DRUG|Rituximab|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
58478273|NCT05786651|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
58478274|NCT03039218|DEVICE|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
58478275|NCT03039218|DEVICE|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
58478276|NCT06231589|DEVICE|Sperm Selection|Sperm selection using physiological intracytoplasmic sperm injection (PICSI dish) or magnetic-activated cell sorting (MACS) for selecting sperm with high-quality, better morphology and lower DNA fragmentation.
58478277|NCT05311488|DIAGNOSTIC_TEST|neurofilament light chain|Blood test
58478278|NCT05311488|DIAGNOSTIC_TEST|In-vivo Meissner Corpuscle imaging|Imaging
58478279|NCT05311488|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study
58478280|NCT05758194|OTHER|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
58478281|NCT05758194|OTHER|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
58478282|NCT06603857|DRUG|CE Ferulic|CE Ferulic serum regimen combined with laser treatment
58478283|NCT06603857|DRUG|Sham Comparator|Vehicle serum regimen combined with laser treatment
58478284|NCT06603857|DEVICE|1927nm (Clear and Brilliant Perméa®)|non-ablative fractional diode laser
58478285|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
58478286|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
58478287|NCT02135796|OTHER|Echocardiography|
58478288|NCT02897323|OTHER|description|
58478289|NCT06650579|DRUG|Abiraterone Acetate|Given abiraterone acetate
58478290|NCT06650579|DRUG|Bicalutamide|Given PO
58478291|NCT06650579|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58478292|NCT06650579|PROCEDURE|Computed Tomography Angiography|Undergo CCTA
58478293|NCT06650579|DRUG|Leuprolide|Given IM or SC
58478294|NCT06650579|DRUG|Prednisone|Given prednisone
58478295|NCT06650579|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
58478296|NCT06650579|DRUG|Relugolix|Given PO
58478297|NCT03622489|DRUG|Acetaminophen|mentioned above
58478298|NCT03622489|DRUG|Ibuprofen 400 mg|mentioned above
58478299|NCT03622489|DRUG|Dipyrone|mentioned above
58478300|NCT03622489|DRUG|Tramadol|mentioned above
58478301|NCT03622489|DRUG|Morphine|mentioned above
58478302|NCT03622489|DRUG|Tramal|mentioned above
58478303|NCT01584375|OTHER|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~--------------------------------------------------------------------------------"
58478304|NCT01584375|OTHER|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
58478305|NCT06053671|GENETIC|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
58478306|NCT03902977|PROCEDURE|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
58478307|NCT03902977|PROCEDURE|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
58478308|NCT05056233|OTHER|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
58478309|NCT05999357|DRUG|JDQ443|JDQ443 tablets, orally administered
58478310|NCT01812863|PROCEDURE|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
58478311|NCT01310452|DRUG|insulin detemir|insulin detemir once daily with metformin
58478312|NCT01310452|DRUG|neutral protamine insulin|neutral protamine insulin once daily with metformin
58478313|NCT04728633|DRUG|Carmustine|Given via infusion
58478314|NCT04728633|DRUG|Ethiodized Oil|Given via infusion
58478315|NCT04728633|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
58478316|NCT04728633|OTHER|Medical Device Usage and Evaluation|Given gelatin sponge via injection
58478317|NCT06474715|BEHAVIORAL|Arms|The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
58478318|NCT03150953|DEVICE|MRI-safe bore covering|
58478319|NCT00295555|DRUG|Effects of doxazosin on morning surge in diabetic patients|
58478320|NCT01469169|DRUG|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
58478321|NCT02246790|PROCEDURE|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
58478322|NCT02246790|PROCEDURE|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
58478323|NCT06593756|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
58478324|NCT06593756|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
58478325|NCT06593756|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
58478326|NCT06593756|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
58478327|NCT06593756|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
58478328|NCT06593756|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
58478329|NCT06593756|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
58478330|NCT06593756|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
58478331|NCT06593756|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning
58478332|NCT03987269|BEHAVIORAL|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
58478333|NCT03987269|BEHAVIORAL|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
58134917|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
58134918|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
57780273|NCT01309490|DRUG|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
58134919|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
58134920|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
58134921|NCT04626856|BIOLOGICAL|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
58134922|NCT04626856|BIOLOGICAL|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
58478334|NCT01529892|DRUG|A single oral 5 mg of duterium labeled methamphetamine|
58478335|NCT06086717|OTHER|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
58478336|NCT06086717|OTHER|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
58478337|NCT03516188|DRUG|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
58478338|NCT03516188|DRUG|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
58478339|NCT06593860|BEHAVIORAL|Remote speech rehabilitation|Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
58478340|NCT02580539|BIOLOGICAL|Group A|Peptide-stimulated T cells 2 x 10\^7/m\^2
58478341|NCT02580539|BIOLOGICAL|Group B|Peptide-stimulated T cells per dose-escalation protocol
58478342|NCT01850121|DRUG|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
58478343|NCT04363008|DIAGNOSTIC_TEST|serum inflammatory biomarkers|Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)
58478344|NCT01477398|DEVICE|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
58478345|NCT04530214|OTHER|Blood collection|Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
58478346|NCT04530214|OTHER|Saliva collection|Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
58478347|NCT04530214|OTHER|Electrocardiography (ECG)|Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability
58478348|NCT04530214|BEHAVIORAL|Questionnaires|Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)
58478349|NCT03071588|DEVICE|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
58478350|NCT03071588|DEVICE|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
58478351|NCT04931563|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
58478352|NCT04931563|DRUG|placebo|Intravenous infusion (IV)
58478353|NCT01598532|DEVICE|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
58478354|NCT03448796|PROCEDURE|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
58478355|NCT03448796|OTHER|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
58478356|NCT05488665|DEVICE|Crush technique|Treatment for bifurcation with the Crush technique
58478357|NCT05488665|DEVICE|Culotte technique|Treatment for bifurcation with the culotte technique
58478358|NCT03384134|OTHER|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
58478359|NCT06389955|DRUG|TP 3654|TP 3654 is an investigational orally delivered drug
57784958|NCT01874327|BEHAVIORAL|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
58134923|NCT01762085|PROCEDURE|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
58134924|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
58478360|NCT02969746|DRUG|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
58478361|NCT04536558|DRUG|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
58134925|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
58478362|NCT04536558|DRUG|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
58478363|NCT06038539|BIOLOGICAL|PERT-IJS plus trastuzumab, carboplatin and docetaxel|PERT-IJS is a monoclonal antibody, which has been developed by Biocon Biologics (earlier in collaboration with Viatris) as a proposed biosimilar to European Union (EU)-approved and United States (US) licensed Perjeta.
58478364|NCT06038539|BIOLOGICAL|Perjeta plus trastuzumab, carboplatin and docetaxel|EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).
58478365|NCT00653510|DRUG|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
58478366|NCT03962036|DEVICE|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
58478367|NCT03886896|DRUG|Lidocaine|Lidocaine infusion during surgery
58478368|NCT03075072|RADIATION|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
58478369|NCT03075072|RADIATION|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
58478370|NCT04618536|OTHER|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
58478371|NCT04618536|OTHER|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
58478372|NCT06566989|DRUG|[¹⁴C]Opevesostat|Oral solution
58478373|NCT06566989|DRUG|Prednisone|Tablet
58478374|NCT06566989|DRUG|Fludrocortisone|Tablet
58478375|NCT01318915|DRUG|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
58478376|NCT01318915|DRUG|Rituximab|375 mg/m\^2 IV infusion on day -6 before transplant and on day 1 after transplant.
58478377|NCT01318915|DRUG|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
58478378|NCT01318915|DRUG|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
58478379|NCT01318915|DRUG|MMF|1 g twice daily on days 0 through 12
58478380|NCT03429699|BEHAVIORAL|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
58478381|NCT03429699|BEHAVIORAL|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
58478382|NCT06025773|DRUG|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
58478383|NCT06025773|DRUG|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
58478384|NCT06653361|PROCEDURE|Green laser|Green Laser
58478385|NCT03939689|DRUG|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.
58478386|NCT03939689|DRUG|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
58478387|NCT06327269|DRUG|Lenvatinib 10 mg|Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
58478388|NCT03762057|DIAGNOSTIC_TEST|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
58478389|NCT05848557|BEHAVIORAL|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
58478390|NCT06023238|PROCEDURE|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
58491928|NCT05033704|DRUG|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
57785191|NCT05158257|DEVICE|balloon and Stent|balloon dilatation combined stent angioplasty
58478391|NCT01213563|DRUG|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
58478392|NCT01213563|DRUG|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
58478393|NCT03887923|BEHAVIORAL|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
58478394|NCT00320450|DRUG|SB-681323|
58478395|NCT01694914|PROCEDURE|corneal graft|
58478396|NCT03303963|DIAGNOSTIC_TEST|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
58478397|NCT03303963|DIAGNOSTIC_TEST|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis"
58478398|NCT00368407|DEVICE|308-nm excimer laser|
58478399|NCT01040910|DRUG|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
58478400|NCT01040910|DRUG|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
58478401|NCT06094478|BEHAVIORAL|HI-SPEED Protocol|The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool. This protocol will be implemented at each participating health system in clusters of 2 health systems.
58478402|NCT02667795|OTHER|Monitored walking based exercise|Monitored walking based exercise
58478403|NCT04646473|BEHAVIORAL|SweetGoals app|App offers goal setting and feedback
58478404|NCT04646473|BEHAVIORAL|Coaching|Web health coaching
58478405|NCT04646473|BEHAVIORAL|Incentives|Financial incentives for meeting goals
58478406|NCT03140241|PROCEDURE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
58478407|NCT02628288|DEVICE|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
58478408|NCT01294553|DRUG|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
58478409|NCT01457703|DRUG|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
58478410|NCT01457703|DRUG|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
58478411|NCT01457703|DRUG|Recombinant LH|Used to stimulate ovarian function in women.
58478412|NCT01457703|DRUG|Letrozole|An aromatase inhibitor.
58478413|NCT00577889|DRUG|gemcitabine hydrochloride|750 mg/m2 Given IV
58478414|NCT00577889|DRUG|tanespimycin|154 mg/m2 Given IV
58478415|NCT02323217|RADIATION|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
58478416|NCT02323217|DRUG|Idazoxan|Idazoxan block of \[11C\]BU99008
58478417|NCT02323217|DRUG|Isocarboxazid|Isocarboxazid block of \[11C\]BU99008
58478418|NCT02963506|OTHER|Placebo|
58478419|NCT02963506|DRUG|Bimekizumab|Bimekizumab in different dosages.
58478420|NCT00945958|DRUG|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
58478421|NCT02386475|OTHER|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
58478422|NCT02386475|DRUG|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
58478423|NCT02386475|DRUG|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
58478424|NCT00963859|PROCEDURE|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
58491929|NCT02246413|BEHAVIORAL|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
58491930|NCT04082819|DEVICE|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
58478425|NCT04817163|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
58478426|NCT04817163|BEHAVIORAL|Professionally-administered booster face-to-face CBT-I sessions|"Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment."
58478427|NCT04684888|PROCEDURE|Visumax Femto-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
58478428|NCT04684888|PROCEDURE|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
58478429|NCT02665390|PROCEDURE|Percutaneous cryoablation|Percutaneous cryoablation
58478430|NCT05370638|OTHER|Rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
58478431|NCT00301314|PROCEDURE|Autologous stem cell transplant|
58478432|NCT06655506|COMBINATION_PRODUCT|ERAS group|This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
58478433|NCT06655506|COMBINATION_PRODUCT|Control group|This group will include patients that do not follow the predetermined criteria of ERAS protocols
58478434|NCT03723642|DIAGNOSTIC_TEST|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
58478435|NCT03723642|DIAGNOSTIC_TEST|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
58478436|NCT03723642|DIAGNOSTIC_TEST|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
58478437|NCT03723642|DIAGNOSTIC_TEST|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
58478438|NCT03723642|DIAGNOSTIC_TEST|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
58478439|NCT03723642|DIAGNOSTIC_TEST|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
58478440|NCT03723642|DIAGNOSTIC_TEST|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
58478441|NCT03723642|DIAGNOSTIC_TEST|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
58478442|NCT03723642|DIAGNOSTIC_TEST|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
58478443|NCT03723642|DIAGNOSTIC_TEST|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
58478444|NCT03723642|DIAGNOSTIC_TEST|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
58478445|NCT03723642|DIAGNOSTIC_TEST|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
58478446|NCT02279914|DRUG|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D\&E procedure
58478447|NCT02279914|DRUG|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D\&E procedure
58478448|NCT06586450|DEVICE|Low level laser therapy|The participants will receive Low Level Laser on lumbo-pelvic region for 20 min/sessions,3 sessions / week for 12 weeks, with the following parameters: Wavelength: 808 nm, continuous mode, Output power: 160 mw, Penetration depth: 4 cm, Power density:0.16 J/cm2.
58478449|NCT06586450|DEVICE|Interferential current|All participants will receive interferential current on lumbopelvic region ( quadripolar technique) for 25 min/session, 3 sessions/week for 12 weeks, with the following parameters: carrier frequency of 4 KHZ and sweep frequency 95 HZ, intensity based on patient's tolerance without muscle contraction.
58478450|NCT06586450|OTHER|Core stability exercise|The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.
58478451|NCT05259189|DRUG|NBL-012 Injection|a single subcutaneous injection
58478452|NCT05259189|DRUG|Placebo|a single subcutaneous injection
58478453|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
58478454|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
58478455|NCT00313014|DRUG|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
58478456|NCT02567669|RADIATION|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
58478457|NCT01765283|BIOLOGICAL|HepaStem|
58478458|NCT03271658|BEHAVIORAL|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
58478459|NCT03271658|BEHAVIORAL|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
58478460|NCT01658033|DRUG|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
58478461|NCT04170608|DEVICE|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
58478462|NCT04994288|BIOLOGICAL|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
58478463|NCT04994288|OTHER|placebo injection|placebo injection 0.5ml
58478464|NCT02644655|BIOLOGICAL|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
58478465|NCT00183040|DRUG|Topical testosterone|
58478466|NCT00183040|DRUG|Recombinant human growth hormone|
58478467|NCT02261935|OTHER|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
58478468|NCT02261935|OTHER|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
58478469|NCT01002339|DRUG|Tacrolimus with rapid steroid withdrawal|"* Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
58478470|NCT01002339|DRUG|Tacrolimus with steroids minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
58478471|NCT01002339|DRUG|CsA with steroid minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d"
58478472|NCT02621450|BIOLOGICAL|standart dialysis|dialysate sodium consentration 140 mEq
58478473|NCT02621450|BIOLOGICAL|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
58478474|NCT02633124|DEVICE|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
58478475|NCT02633124|DEVICE|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
58478476|NCT06326320|PROCEDURE|Combined SAPB|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the supine position. 40 ml of 0.25% bupivacaine will be used in applications.
58478477|NCT02379728|DEVICE|PrenaBelt|"The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine."
58491931|NCT04082819|DEVICE|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
58491932|NCT03714581|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
57785192|NCT05158257|DEVICE|endovascular debulking and DCB|endovascular debulking combined drug-coated balloon
57785193|NCT05540717|BIOLOGICAL|PQ Grass|Suspension for Injection
57785194|NCT05540717|BIOLOGICAL|Placebo|Solution for injection
58478478|NCT02379728|DEVICE|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
58478479|NCT02379728|DEVICE|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
58478480|NCT01679314|DEVICE|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
58478481|NCT05250284|BEHAVIORAL|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
58478482|NCT05250284|BEHAVIORAL|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
58478483|NCT06276829|DIAGNOSTIC_TEST|LDH/albumin ratio|LDH/Albumin ratios of patient and control groups were recorded.
58478484|NCT04184700|DIETARY_SUPPLEMENT|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
58478485|NCT04184700|DIETARY_SUPPLEMENT|RHF|Rice hydrolysed formula
58478486|NCT04184700|DIETARY_SUPPLEMENT|SF|Soy formula
58478487|NCT04184700|DIETARY_SUPPLEMENT|EHWF|extensively hydrolysed whey formula
58134926|NCT06180512|DIETARY_SUPPLEMENT|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
58134927|NCT04484545|DIAGNOSTIC_TEST|Prognostic score|Validation of scores of systemic inflammatory response
58478488|NCT04184700|DIETARY_SUPPLEMENT|AAF|amino acid based formula
58478489|NCT00071890|DRUG|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
58478490|NCT00071890|DRUG|HAART|HAART from week 0 to week 24
58478491|NCT00071890|DRUG|Treatment interruption|HAART is interrupted from week 24 in both arms
58478492|NCT06215170|DEVICE|SafeMedWaste|SafeMedWaste opioid disposal kit
58478493|NCT03938090|DEVICE|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
58478494|NCT03938090|DEVICE|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
58478495|NCT06205277|PROCEDURE|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
58478496|NCT00305188|DRUG|Xaliproden (SR57746A)|oral administration
58478497|NCT00305188|DRUG|Placebo|oral administration
58478498|NCT00305188|DRUG|Oxaliplatin|IV administration
58478499|NCT00305188|DRUG|5-Fluorouracil|IV administration
58478500|NCT00305188|DRUG|Leucovorin|IV administration
58478501|NCT06593808|PROCEDURE|Weaning from the incubator to open coat at a weight greater than or equal to 1400 grams|They will be dressed in a woolen hat and dress, wrapped in a blanket and placed in crib with preheated mattress.Vital signs will be monitored daily.Axillary temperature will be measured every 3 hours for the first 12 hours, if above or equal to 36.5°C it will be measured every 6 hours for the next 36 hours. If normothermia for 48 hours, the preheated mattress will be turned off and temperature monitoring will be continued every 3 hours for 24 hours.If greater than or equal to 36.5°C, thermal control will be continued every 8 hours for 48 hours, at the end of which time, if normothermic, care will be confirmed.If not it will be placed back in the crib with heated mattress.If temperature still below 36.5°C, an additional blanket will be placed and it will be rechecked after 2 hours.If it remains below 36.5°C, the infant will be placed under a radiant lamp and the temperature will be checked after 3 hours.If hypothermia persists, the infant will be transferred back to the incubator.
58134928|NCT05797558|PROCEDURE|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
58478502|NCT04062539|DEVICE|Sentinel and Spider|Dual filter and single filter
58478503|NCT03762811|DEVICE|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
58478504|NCT06655350|OTHER|MRI|Morphological data on the tendon (appearance) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
58478505|NCT06655350|OTHER|Measure|Morphological data on the tendon (diameter) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
58478506|NCT04819607|OTHER|model of care|Multidisciplinary model of care for BMFS patients.
58478507|NCT02946658|PROCEDURE|lipoaspiration|Closed syringe harvesting subdermal fat
58478508|NCT02946658|PROCEDURE|ADcSVF|Isolation of AD-cSVF
58478509|NCT02946658|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
58478510|NCT06440434|BEHAVIORAL|Time of night shift|Early vs. late night split night shift
58478511|NCT01123798|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
58478512|NCT04575389|DIAGNOSTIC_TEST|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
58478513|NCT03755310|DRUG|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
58478514|NCT03755310|DRUG|Placebo|Equivalent dosage, route of administration and dose regimen
58478515|NCT06359730|OTHER|LARS score questionnaire|LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life
58478516|NCT00815659|DRUG|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
58478517|NCT06655805|DEVICE|Non-invasive ventilation, Invasive mechanical ventilation, high-flow nasal oxygen|No intervention is intended by the nature of this observational study.
58478518|NCT00469599|DRUG|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
58478519|NCT00469599|DRUG|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
58478520|NCT06305728|DIAGNOSTIC_TEST|89Zr-DFO-HuMab-5B1 immunoPET|Participants who choose to will undergo immunoPET before surgery.
58478521|NCT06305728|DIAGNOSTIC_TEST|HP MRI|Participants who choose to will undergo HP MRI before surgery.
58478522|NCT06305728|COMBINATION_PRODUCT|Blood assay|Will be drawn within 6 weeks of surgery and annually as post operative care
58478523|NCT04949490|BIOLOGICAL|BNT162b2s01|intramuscular (IM) injection
58478524|NCT04949490|BIOLOGICAL|BNT162b2|IM injection
58478525|NCT01101867|DRUG|Aspart fixed dose|fixed dose
58478526|NCT01101867|DRUG|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
58478527|NCT05751187|BIOLOGICAL|Pembrolizumab|Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
58478528|NCT05751187|BIOLOGICAL|Bevacizumab|Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
58478529|NCT05751187|DRUG|Pemetrexed|Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
58478530|NCT05751187|DRUG|Cisplatin|Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
58478531|NCT05751187|DRUG|Carboplatin|Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
58478532|NCT05751187|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
58478533|NCT05751187|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
58478534|NCT05751187|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
58478535|NCT04030507|DEVICE|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
58478536|NCT06218797|OTHER|a routine sedation protocol|In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.
58478537|NCT06218797|DRUG|Nebulized with dexmedetomidine|Patients will be received nebulisation with dexmedetomidine 2mcg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
58478538|NCT01253278|DRUG|LY2393910|as capsules, administered orally once daily for two weeks
58478539|NCT01253278|DRUG|Placebo|as capsules, administered orally once daily for two weeks
58478540|NCT05743335|BIOLOGICAL|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
58478541|NCT05743335|OTHER|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
58478542|NCT01704716|DRUG|Vincristine|given during Rapid COJEC and modified N7 therapy
58478543|NCT01704716|DRUG|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
58478544|NCT01704716|DRUG|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
58478545|NCT01704716|DRUG|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
58478546|NCT01704716|DRUG|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
58478547|NCT01704716|DRUG|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
58478548|NCT01704716|DRUG|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
58478549|NCT01704716|DRUG|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
58478550|NCT01704716|DRUG|G-CSF|G-CSF is given during Induction Treatment
58478551|NCT01704716|DRUG|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
57785195|NCT00179010|DRUG|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
58478552|NCT01704716|DRUG|Melphalan|Melphalan is given during MAT treatment
58478553|NCT03397069|PROCEDURE|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
58491933|NCT01041963|DRUG|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
58491934|NCT01041963|DRUG|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
58478554|NCT03397069|PROCEDURE|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
58478555|NCT03397069|PROCEDURE|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
58478556|NCT05438862|PROCEDURE|State of art aortic valve surgery|Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
58478557|NCT03523988|DRUG|Acetaminophen|Acetaminophen gel capsule
58478558|NCT03523988|DRUG|Ibuprofen|Ibuprofen gel capsule
58478559|NCT02271269|BEHAVIORAL|Value Pricing Subsidies|"* Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
58478560|NCT04617626|DRUG|Azithromycin|Single dose of azithromycin suspension
58478561|NCT03234322|OTHER|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
58478562|NCT04004741|PROCEDURE|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
58478563|NCT04004741|PROCEDURE|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
58478564|NCT00848601|DRUG|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
58478565|NCT01008020|DIETARY_SUPPLEMENT|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
58478566|NCT05678881|DRUG|High dose RLS103|8 mg CBD inhaled powder
58478567|NCT05678881|DRUG|placebo inhaled powder|placebo inhaled powder
58478568|NCT05678881|DRUG|Low dose RLS103|4 mg CBD inhaled powder (open label)
58478569|NCT05607381|BEHAVIORAL|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
58478570|NCT05607381|OTHER|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
58478571|NCT06228170|BEHAVIORAL|Rehabilitation therapy|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
58478572|NCT06228170|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
58478573|NCT00993577|OTHER|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
58478574|NCT00993577|DEVICE|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
58478575|NCT00993577|DEVICE|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
58478576|NCT02046577|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol administration
58478577|NCT02046577|DIETARY_SUPPLEMENT|Placebo|Placebo liquid
58478578|NCT06595134|OTHER|Non Interventional|Screening (Day -7 to Day -1) Visit 1 (Day 0) Visit 2 (Month 3 +/- 7 days) Visit 3 (Month 6 +/- 7 days) Visit 4 (Month 12 +/- 7 days) Visit 5 (Month 24 +/- 7 days) Visit 6 (Month 60 +/- 30 days; end of study)
58478579|NCT02946138|RADIATION|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
58478580|NCT04252144|PROCEDURE|Dietary assessment|Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
58478581|NCT00389259|DRUG|Placebo|IV placebo q4h
58478582|NCT01352793|BIOLOGICAL|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
58478583|NCT01352793|BIOLOGICAL|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
58478584|NCT04894266|DRUG|Apabetalone|Apabetalone 100mg BID
58478585|NCT04894266|OTHER|Standard of care|Standard of Care
58478586|NCT03223896|DRUG|Naloxone hydrochloride 20mg/ml|Nasal spray
58478587|NCT01440894|DEVICE|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
58478588|NCT02826070|DRUG|Telbivudine|Telbivudine, 600mg, oral, daily
58478589|NCT02826070|DRUG|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
58478590|NCT02826070|OTHER|off-treatment follow-up|
58478591|NCT06303388|OTHER|Bruegger,s Exercise|Bruegger's Exercise protocol along with conventional Physiotherapy.
58478592|NCT06303388|OTHER|Egoscue Exercise|Egoscue Exercise along with conventional Physiotherapy.
58478593|NCT00424710|DRUG|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
58478594|NCT02293694|DRUG|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
58478595|NCT05510388|DEVICE|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
58478596|NCT05510388|DEVICE|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
58478597|NCT05972980|OTHER|COVID-19|The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
58478598|NCT01540552|OTHER|medical chart review|
58478599|NCT01540552|PROCEDURE|computed tomography|
58478600|NCT01540552|PROCEDURE|computer-aided detection/diagnosis|
58478601|NCT02135432|DRUG|Ivacaftor|
58478602|NCT02135432|DRUG|Placebo|
58478603|NCT00001614|DRUG|Chicken type II collagen|
58478604|NCT05254535|OTHER|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
58478605|NCT00783068|DRUG|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
58478606|NCT00783068|DRUG|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
58478607|NCT00783068|DRUG|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
58478608|NCT06653114|OTHER|Education in Chronic Musculoskeletal Pain|Improving Knowledge and Skills in Chronic Musculoskeletal Pain (Assessment and Management)
58478609|NCT06653114|OTHER|Education in Communication Skills|Developing Communication Skills (Empathy, Motivational Interviewing, Shared Decision-making)
58478610|NCT04906564|OTHER|Identification of genetic variants|Identification of genetic variants
58478611|NCT06566456|PROCEDURE|The puncture site is within 2-4 cm above the second wrist transverse crease|The ultrasound-guided radial artery puncture site is within 2-4 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.
58478612|NCT06566456|PROCEDURE|The puncture site is within 0-1.9 cm above the second wrist transverse crease|The ultrasound-guided radial artery puncture site is within 0-1.9 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.
58478613|NCT01213680|DRUG|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
58478614|NCT01213680|DRUG|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
58478615|NCT05760040|OTHER|vırtual reality|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
58478616|NCT05760040|OTHER|Control Group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
58478617|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.
58478618|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
58478619|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
58478620|NCT04438265|DRUG|levobupivacaine|local anesthetic
58478621|NCT04438265|DEVICE|ultrasound device|scream
58478622|NCT00614302|DRUG|TPV|
58478623|NCT02772458|OTHER|Dodecanoate acid and saline|Test drink
58478624|NCT03763084|DRUG|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
58478625|NCT03763084|DRUG|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
58478626|NCT00646048|DEVICE|TriVascular Stent-Graft System|TriVascular Stent-Graft System
58478627|NCT03470610|DRUG|Progesterone|6 mg estradiol and vaginal and rectal progesterone
58478628|NCT02578147|BEHAVIORAL|Mighty Girls|
58478629|NCT02578147|BEHAVIORAL|Game Girls|
58478630|NCT02987712|OTHER|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
58478631|NCT05836506|DRUG|ABBV-903 Tablet Form 1|Oral Tablets
58478632|NCT05836506|DRUG|ABBV-903 Tablet Form 2|Oral Tablets
58478633|NCT00986765|DRUG|Lovenox® (enoxaparin)|Injectable solution 4000 UI
58478634|NCT00986765|DRUG|Aspegic ® (Aspirin)|100 mg/day
58478635|NCT01094119|DEVICE|heated blanket|heated blanket
58478636|NCT01094119|DEVICE|heated pad|patients will be warmed with a heated pad during surgery.
58478637|NCT02177032|BIOLOGICAL|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
58478638|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
58478639|NCT02177032|BIOLOGICAL|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
58478640|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
57785196|NCT00179010|DRUG|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
57785197|NCT00917228|DEVICE|recordings with device equipped|
57785198|NCT00917228|DEVICE|Control|Recording without device equipped
57785199|NCT03623412|DIAGNOSTIC_TEST|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
58138930|NCT01163825|DRUG|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
58478641|NCT04199806|OTHER|Questionnaire review|Review data from questionnaires received about MMS experience.
58478642|NCT05100550|DIETARY_SUPPLEMENT|Zinc|Zinc is given as written in the arm description, two hours after lunch
58478643|NCT05100550|OTHER|Control|This group will not receive zinc
58478644|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
58478645|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
58478646|NCT06589076|DIAGNOSTIC_TEST|Clinical and Radiographic assessment + Questionnaires|"* Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression."
58478647|NCT04552652|BEHAVIORAL|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
58478648|NCT04552652|BEHAVIORAL|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
58478649|NCT04111380|DRUG|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
58478650|NCT06029348|BEHAVIORAL|Paced Auditory Serial Addition Task|Study volunteers will be asked to complete a 4-minute Paced Auditory Serial Addition Task, which is a standardized task that is widely used to study cardiovascular responses to acute psychological challenges (or stressors) in a laboratory setting.
58478651|NCT02353208|OTHER|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
58478652|NCT02353208|OTHER|Placebo|Participants will not be asked to chew bacon bits
58478653|NCT02466893|OTHER|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
58478654|NCT02559284|OTHER|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
58478655|NCT03525795|DRUG|CPI-1205|Administered orally
58478656|NCT03525795|DRUG|ipilimumab|Administered intravenously
58478657|NCT01582477|DRUG|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
58478658|NCT01582477|DRUG|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
58478659|NCT03740451|OTHER|Active mobilization of soft tissues|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
58478660|NCT03740451|OTHER|Passive mobilization|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
58478661|NCT03817359|COMBINATION_PRODUCT|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
58478662|NCT04349267|BIOLOGICAL|BMS-986315|Specified dose on specified days
58478663|NCT04349267|BIOLOGICAL|nivolumab|Specified dose on specified days
58478664|NCT04349267|BIOLOGICAL|cetuximab|Specified dose on specified days
58478665|NCT02930863|OTHER|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
58478666|NCT02930863|BEHAVIORAL|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
58478667|NCT02930512|PROCEDURE|DXA scan|
58478668|NCT02930512|PROCEDURE|pQCT scan|
58478669|NCT06558643|DRUG|MMV371 LAI|Single intra-muscular dose
58478670|NCT06558643|DRUG|Placebo for MMV371|Single intramuscular dose
58478671|NCT02724891|OTHER|paper form|questionnaires in paper form
57785200|NCT03623412|DIAGNOSTIC_TEST|75g GTT|post-partum GTT
58138931|NCT03049384|OTHER|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
58478672|NCT02724891|OTHER|web/smartphone form|questionnaires in web/smartphone
58478673|NCT04077099|DRUG|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
58478674|NCT04071717|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
58478675|NCT04071717|BEHAVIORAL|Sham NIRS neurofeedback|Sham NIRS neurofeedback
58478676|NCT06007950|BEHAVIORAL|Time-restricted eating 10-hr|Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
58478677|NCT06474611|BEHAVIORAL|Patient nudge|Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
58478678|NCT05163522|DRUG|VH4004280|VH4004280 will be administered.
58478679|NCT05163522|DRUG|Placebo|Placebo will be administered.
58478680|NCT05163522|DRUG|Midazolam|Midazolam will be administered
58478681|NCT00000197|DRUG|Propranolol|
58478682|NCT06037902|DEVICE|CPAP|patients undergo simulation twice, with and without CPAP
58478683|NCT04642092|BEHAVIORAL|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
58478684|NCT04642092|BEHAVIORAL|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
58491935|NCT01041963|DRUG|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
58491936|NCT00580528|BEHAVIORAL|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
58478685|NCT06185725|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve Block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
58478686|NCT06185725|OTHER|Transversus Abdominal Plane Block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
58478687|NCT04123197|OTHER|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
58478688|NCT03774576|DRUG|RO7017773|Single doses of RO7017773
58478689|NCT03774576|DRUG|Itraconazole|Multiple doses of Itraconazole
58478690|NCT04143035|OTHER|No Intervention|No Intervention
58478691|NCT01114698|DRUG|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
58478692|NCT01114698|DRUG|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
58478693|NCT01114698|DRUG|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
58478694|NCT05939882|DRUG|low concentration atropine (0.01%)|low concentration atropine (0.01%)
58478695|NCT05939882|DRUG|low concentration atropine (0.02%)|low concentration atropine (0.02%)
58478696|NCT05939882|DRUG|low concentration atropine (0.04%)|low concentration atropine (0.04%)
58478697|NCT05939882|DRUG|Placebo|Placebo eye drop
58478698|NCT02080598|BEHAVIORAL|2 cigarettes in 15 minutes|
58478699|NCT06325813|DEVICE|Active repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.
58478700|NCT06325813|DEVICE|Sham repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
58478701|NCT02540629|PROCEDURE|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
58478702|NCT06160843|DRUG|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
58478703|NCT00622050|BEHAVIORAL|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
58478704|NCT00622050|BEHAVIORAL|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
58478705|NCT02660151|DEVICE|Hyper-CL™ lens|
58478706|NCT02660151|DEVICE|Regular soft contact lens|
58478707|NCT02660151|DRUG|Salt solution|
58478708|NCT05132907|BIOLOGICAL|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
58478709|NCT02817646|OTHER|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
58478710|NCT02817646|DIETARY_SUPPLEMENT|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
58478711|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
58478712|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
58478713|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
58478714|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
58478715|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
58478716|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
58478717|NCT00312429|PROCEDURE|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
58491937|NCT00580528|BEHAVIORAL|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
58491938|NCT00003280|BIOLOGICAL|rituximab|
58478718|NCT03543644|OTHER|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
58478719|NCT03543644|OTHER|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
58478720|NCT03543644|OTHER|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
58478721|NCT03544684|BEHAVIORAL|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
58478722|NCT04960202|DRUG|PF-07321332|PF-07321332 (tablet)
58478723|NCT04960202|DRUG|Ritonavir|Ritonavir (capsule)
58478724|NCT04960202|DRUG|Placebo|Placebo (tablet or capsule)
58478725|NCT00133783|BEHAVIORAL|intermedin|
58134929|NCT05797558|DRUG|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
58478726|NCT03780140|DRUG|Cefiderocol|Cefiderocol for intravenous infusion
58478727|NCT01334177|DRUG|TLR8 agonist VTX-2337|Given SC
58478728|NCT01334177|BIOLOGICAL|cetuximab|Given IV
58478729|NCT01334177|OTHER|laboratory biomarker analysis|Correlative studies
58478730|NCT01334177|OTHER|pharmacogenomic studies|Correlative studies
58478731|NCT01619280|DRUG|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
58478732|NCT00414596|DEVICE|DRX9000™|Device is designed to apply spinal decompressive forces.
58478733|NCT03561480|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
58478734|NCT03561480|DRUG|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
58478735|NCT03054246|OTHER|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
58478736|NCT00904605|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
58478737|NCT00904605|DRUG|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
58478738|NCT03645720|DEVICE|Plastic cannula|puncture using plastic cannula
58478739|NCT02902458|OTHER|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
58478740|NCT00006445|PROCEDURE|Ultrasound|
58478741|NCT00006445|PROCEDURE|Serum screen|
58478742|NCT02277938|DRUG|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
58478743|NCT04291469|DRUG|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
58478744|NCT04291469|DIETARY_SUPPLEMENT|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
58478745|NCT04291469|DIETARY_SUPPLEMENT|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
58478746|NCT04313244|BIOLOGICAL|9vHPV Vaccine|9vHPV intramuscular injection
57785201|NCT04745104|DRUG|SHR-1707|SHR-1707 will be administered through IV infusion
57785202|NCT04745104|DRUG|Placebo|Placebo will be administered through IV infusion
58134930|NCT00547781|PROCEDURE|PGD|
58138932|NCT03049384|OTHER|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
58138933|NCT00716248|DRUG|bucillamine|bucillamine 100 mg, twice a day
58138934|NCT00716248|DRUG|methotrexate|methotrexate 6 mg or more per week
58138935|NCT03507335|DEVICE|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
58478747|NCT04313244|BIOLOGICAL|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
58478748|NCT04190641|DEVICE|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
58478749|NCT03772158|DRUG|Cetirizine 10mg|Chewable tablet
58478750|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
58478751|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
58478752|NCT06592586|BIOLOGICAL|GBS-NN/NN2 vaccine|0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)
58478753|NCT05310240|PROCEDURE|Hip arthroscopy|Arthroscopic surgery of the hip
58478754|NCT05855811|DRUG|Dostarlimab|Dostarlimab should initiated within 6 months after the end of treatment for FPC.
58478755|NCT04935710|BEHAVIORAL|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
58478756|NCT04935710|GENETIC|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
58478757|NCT02937116|DRUG|IBI308|
58478758|NCT02937116|DRUG|IBI308\Cisplatinum\Pemetrexed|
58478759|NCT02937116|DRUG|IBI308\cisplatin\gemcitabine|
58478760|NCT02937116|DRUG|IBI308\oxaliplatin\capecitabine|
58478761|NCT02937116|DRUG|IBI308\etoposide\cisplatin|
58478762|NCT02937116|DRUG|IBI308\irinotecan\5-FU|
58478763|NCT05132023|DRUG|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
58478764|NCT05132023|DRUG|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
58478765|NCT02734875|OTHER|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
58478766|NCT03829540|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
58478767|NCT01062958|OTHER|Neevo® (a medical food)|
58478768|NCT01062958|OTHER|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
58478769|NCT05266989|OTHER|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
58478770|NCT03613441|BEHAVIORAL|Mindful Awareness Practices (MAPs)|Please refer to arm description
58478771|NCT03915197|DIAGNOSTIC_TEST|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
58478772|NCT00000817|DRUG|Amitriptyline hydrochloride|75 mg oral tablet taken daily
58478773|NCT00000817|DRUG|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
58478774|NCT00000817|PROCEDURE|Point acupuncture|Standardized or alternate acupuncture procedure
58478775|NCT06655857|OTHER|Usual Care|Participants are provided care as usual. Clinicians (CKD, HD, KTx) will educate participants on the kidney transplant process. Clinician will receive the education intervention to provide participants at study end.
58478776|NCT06655857|OTHER|Community Health Worker Assistance|Community health worker will address unmet social needs and participant symptoms through evaluations and intake to clinical and community services
58478777|NCT06655857|OTHER|Intervention Providers|Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
58478778|NCT03585881|DEVICE|3DPrinted Windowed Bracket- Positioning tray|3 D printed tray with windows for accurate positioning of brackets
58478779|NCT01417806|DRUG|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
58478780|NCT06651905|DRUG|Dexmedetomidine|The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
58478781|NCT06651905|DRUG|Superior laryngeal nerve block|The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
58478782|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
58478783|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
58138936|NCT02047071|DEVICE|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
58134931|NCT05137925|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
58134932|NCT05137925|BEHAVIORAL|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
58134933|NCT03205254|OTHER|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
58134934|NCT03205254|OTHER|Fast food diet|four days of participant-scaled isocaloric fast food meals
58134935|NCT02885077|DEVICE|High-intensity IMT + combined exercise|
58134936|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
58134937|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
58134938|NCT06294080|OTHER|Dance|Exercise intervention
58134939|NCT06294080|OTHER|Tai Chi|Exercise intervention
58134940|NCT01543880|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
58134941|NCT04932252|DRUG|A4368 or placebo tablet|orally administered
58134942|NCT03005522|DRUG|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
58134943|NCT03005522|DRUG|Placebo Oral Capsule|dosed with placebo
58134944|NCT00262964|DRUG|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
58134945|NCT00262964|DRUG|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
58134946|NCT00262964|DRUG|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
58134947|NCT00894283|DRUG|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
58478784|NCT06602622|DRUG|Integrase inhibitor|Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
58478785|NCT06602622|DRUG|Doravirine + tenofovir DF + lamivudine|Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
58134948|NCT00894283|DRUG|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
58134949|NCT03109132|DEVICE|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
58134950|NCT03109132|DEVICE|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
58134951|NCT03109132|DEVICE|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
58134952|NCT03109132|DEVICE|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
58478786|NCT02322632|DRUG|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
58478787|NCT05094362|BEHAVIORAL|Spinal Reflex Operant Down Conditioning|This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
58134953|NCT03109132|DEVICE|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
58134954|NCT03109132|DEVICE|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
58134955|NCT00030446|DRUG|carboplatin|
58134956|NCT00030446|DRUG|erlotinib hydrochloride|
58134957|NCT04182152|DEVICE|Indocyanine green (ICG)|Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
58134958|NCT04182152|DEVICE|Electromagnetic navigation bronchoscopy|Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
58134959|NCT04182152|DEVICE|Hook wire|Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
58134960|NCT03963206|DRUG|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
58134961|NCT05506462|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
58134962|NCT04177368|DIETARY_SUPPLEMENT|Theragran 60ml|history,examination and biochemical values
58134963|NCT02038608|DEVICE|PET|
58478788|NCT02426021|DRUG|MLN1202|Subcutaneous administration of MLN1202
58478789|NCT02426021|DRUG|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
58134964|NCT03411330|DRUG|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
58134965|NCT03411330|DRUG|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
58134966|NCT03411330|DRUG|Bupivacaine|bupivacaine (0.5%)
58134967|NCT05165680|COMBINATION_PRODUCT|combination of aerobic exercise and healthy diet|"The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks"
58134968|NCT05266430|OTHER|Standard of Care|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
58134969|NCT05266430|DRUG|AU-011|Previously received
58134970|NCT02524197|DRUG|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
58134971|NCT02524197|DRUG|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
58134972|NCT02524197|DRUG|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
58134973|NCT02524197|DRUG|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
58134974|NCT05267236|OTHER|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
58134975|NCT05267236|OTHER|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
58134976|NCT01056965|DRUG|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
58134977|NCT01056965|DRUG|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
58134978|NCT00615069|DEVICE|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
58134979|NCT04559347|DRUG|Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single shot for erector spinae block
58134980|NCT04559347|DRUG|Ropivacaine (0.5% bolus followed by 0.2% infusion)|Continuous catheter infusion for erector spinae plane block
58134981|NCT04053348|PROCEDURE|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
58134982|NCT00073177|DRUG|Roflumilast|
58134983|NCT03657160|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
58134984|NCT03657160|DRUG|Vedolizumab|Vedolizumab IV infusion.
58134985|NCT04764916|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
58134986|NCT04764916|DRUG|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
57785203|NCT06483412|BEHAVIORAL|Healthy Futures: Alternative-to-Suspension Curriculum|Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.
57785204|NCT03135548|DRUG|Spesolimab (low dose)|12 weeks treatment
58134987|NCT04061005|PROCEDURE|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
58134988|NCT04061005|PROCEDURE|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
58134989|NCT04061005|PROCEDURE|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
58134990|NCT05859386|BEHAVIORAL|Mindfulness maintenance program|"1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
58134991|NCT01384838|BEHAVIORAL|Counseling|Nutritional, lifestyle and sports counseling
58134992|NCT01384838|BEHAVIORAL|physical activity|counseling and controlled physical activity
57785205|NCT03135548|DRUG|Placebo|12 weeks treatment
57785206|NCT03135548|DRUG|Spesolimab (high dose)|12 weeks treatment
58134993|NCT01962337|DRUG|FPA008|Infusion
58134994|NCT01962337|DRUG|Placebo|Infusion
58134995|NCT03328936|OTHER|Laboratory Biomarker Analysis|Correlative studies
58134996|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
58134997|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
58134998|NCT03328936|OTHER|Pharmacological Study|Correlative studies
58134999|NCT04365309|DRUG|Aspirin 100mg|on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
58135000|NCT06311942|DRUG|HAIC plus PD-1 inhibitors plus lenvatinib|Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
58135001|NCT06311942|DRUG|PD-1 inhibitors plus lenvatinib|The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
58135002|NCT04235881|BEHAVIORAL|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
58135003|NCT04235881|BEHAVIORAL|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
58135004|NCT04341285|PROCEDURE|ECMO Implantation|Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
58135005|NCT01395030|DIAGNOSTIC_TEST|Computed Tomography|Undergo FCH PET/CT
58135006|NCT01395030|DRUG|18F-fluoromethylcholine|Undergo FCH PET/CT
58135007|NCT01395030|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo FCH PET/CT
58135008|NCT02581748|DRUG|HLX02|
58135009|NCT02581748|DRUG|Herceptin|
58135010|NCT01743326|PROCEDURE|Radio Frequency Denervation|
58135011|NCT01743326|PROCEDURE|Local Anesthesia|
58135012|NCT01174134|OTHER|Nutritional beverage|
58135013|NCT06403930|DEVICE|Maxillary Obturator|Maxillary obturators are prosthetic devices used to close maxillary defects resulting from surgical removal of part or all of the maxilla bone due to conditions like tumors or congenital anomalies. They separate the oral and nasal cavities, restore speech, swallowing, and mastication functions, provide facial support, and improve aesthetics and quality of life.
58135014|NCT02992093|OTHER|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
58135015|NCT05956678|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
58135016|NCT05956678|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
58135017|NCT04019678|PROCEDURE|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
58135018|NCT02272777|DRUG|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
58135019|NCT02272777|DRUG|Nilotinib|Nilotinib 300mg BID or 400mg QD
58135020|NCT02342054|RADIATION|MRI-TRUS fusion guided Single Frac HDR|
58135021|NCT03900624|DRUG|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
58135022|NCT05452447|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
58478790|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 16mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
58478791|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 8mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
58478792|NCT06519604|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU
58478793|NCT02481674|DRUG|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
58135023|NCT05452447|DEVICE|Placebo|Passive emanator with formulated inert ingredients
58135024|NCT01190293|DRUG|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
58135025|NCT01821144|BEHAVIORAL|Salt reduction|Salt reduction
58135026|NCT01821144|OTHER|Control|No salt awareness education
58135027|NCT02011204|DEVICE|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
58135028|NCT00320112|BEHAVIORAL|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
58135029|NCT00320112|BEHAVIORAL|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
58135030|NCT00320112|BEHAVIORAL|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
58138937|NCT03608722|OTHER|SLUMS|A pen and paper screening tool of cognitive impairment
58138938|NCT03608722|OTHER|MMSE|A pen and paper screening tool of cognitive impairment
58138939|NCT03608722|OTHER|MoCA|A pen and paper screening tool for cognitive impairment
58138940|NCT03608722|DEVICE|BrainCheck|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
58135031|NCT06011122|PROCEDURE|Distal radius fracture ORIF with a specific volar plate|Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
58135032|NCT05047003|DIAGNOSTIC_TEST|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
58135033|NCT04250662|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
58135034|NCT04250662|DEVICE|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
58135035|NCT04250662|DEVICE|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
58135036|NCT04250662|DEVICE|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
58135037|NCT03444116|DIAGNOSTIC_TEST|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
58135038|NCT03444116|DIAGNOSTIC_TEST|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
58135039|NCT03444116|BEHAVIORAL|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
58135040|NCT02109042|DRUG|Blosozumab|Administered subcutaneously
58135041|NCT02127281|DEVICE|Prevena|Device will be applied at end of procedure over closed incision.
58135042|NCT05867576|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
58135043|NCT01889836|BIOLOGICAL|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
58135044|NCT01889836|BIOLOGICAL|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
58135045|NCT04062890|DRUG|Vigabatrin Pill|Oral Vigabatrin Pill
58135046|NCT04062890|DRUG|Placebo oral tablet|Oral Placebo Pill
58135047|NCT02491346|PROCEDURE|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
58135048|NCT02491346|PROCEDURE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
58135049|NCT02865564|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|
58135050|NCT02865564|DIETARY_SUPPLEMENT|Placebo|
58135051|NCT02865564|DRUG|ampicillin and gentamicin|
58135052|NCT01311804|PROCEDURE|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
58135053|NCT01311804|PROCEDURE|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
58478794|NCT02481674|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
58478795|NCT01487798|DRUG|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
58478796|NCT01487798|DRUG|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
58135054|NCT01130623|DRUG|Pazopanib (GW786034)|
58135055|NCT01504698|PROCEDURE|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
58135056|NCT01504698|PROCEDURE|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
58138941|NCT02620891|DEVICE|helium oxygen mixture|
58135057|NCT05369247|OTHER|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
58135058|NCT05369247|OTHER|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
58135059|NCT00470769|PROCEDURE|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
58135060|NCT02552342|DRUG|methylprednisolone|
58135061|NCT02552342|DRUG|Normal saline|
58135062|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
58135063|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
58135064|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
58135065|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
58135066|NCT00816504|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
58135067|NCT01472393|DIETARY_SUPPLEMENT|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
58135068|NCT01472393|DIETARY_SUPPLEMENT|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
58135069|NCT01336660|BIOLOGICAL|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
58135070|NCT01336660|OTHER|Intensive care support plus placebo|Intensive care support as needed plus placebo
58135071|NCT00002654|DRUG|chemotherapy|
58135072|NCT00002654|DRUG|cisplatin|
58135073|NCT00002654|RADIATION|low-LET cobalt-60 gamma ray therapy|
58135074|NCT00002654|RADIATION|low-LET electron therapy|
58135075|NCT00002654|RADIATION|low-LET photon therapy|
58135076|NCT02348983|BEHAVIORAL|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
58135077|NCT05989893|BEHAVIORAL|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
58135078|NCT05763238|OTHER|INTERVENTION GROUP|"Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup"
58135079|NCT05763238|OTHER|CONTROL GROUP|"Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup"
58135080|NCT00999050|PROCEDURE|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
58135081|NCT03619408|DRUG|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
58135082|NCT02528760|DRUG|Metaclopramide|23. Metoclopromide to be given 10mg iv 8 hourly
58135083|NCT02528760|DRUG|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
58135084|NCT02528760|OTHER|Placebo|
58135085|NCT04200417|PROCEDURE|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
58135086|NCT04200417|DRUG|Mitomycin C|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
58135087|NCT04200417|DRUG|Lipiodol|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
58135088|NCT04200417|DRUG|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
58135089|NCT04751734|BIOLOGICAL|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
58135090|NCT01729377|OTHER|Interview|
58135091|NCT00526786|DEVICE|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
58135092|NCT01087476|DRUG|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
58135093|NCT00863746|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
58135094|NCT00863746|DRUG|Placebo|Placebo - 2 tablets twice daily (BID)
58135095|NCT00077948|DRUG|Enoximone|Enoximone administered orally
58135096|NCT00077948|DRUG|Metoprolol succinate|Metoprolol succinate administered orally
58135097|NCT00077948|DRUG|Placebo to match enoximone|Placebo to match match enoximone administered orally
58135098|NCT00077948|DRUG|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
58138942|NCT05792397|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
58135099|NCT01417390|DRUG|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
58135100|NCT01417390|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
58135101|NCT01059903|DRUG|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
58135102|NCT05573620|BEHAVIORAL|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
58135103|NCT05573620|BEHAVIORAL|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
58135104|NCT05573620|BEHAVIORAL|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
58135105|NCT02291562|DRUG|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
58135106|NCT02291562|DRUG|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
58135107|NCT02291562|DRUG|placebo|placebo (capsule, once) oral intake
58135108|NCT05847205|DRUG|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
58135109|NCT03396523|DRUG|Losartan|administration of losartan (50 mg) (oral)
58135110|NCT03396523|DRUG|Placebo Oral Tablet|administration of placebo (oral)
58135111|NCT04606420|BEHAVIORAL|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds \& nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
58135112|NCT04949620|BEHAVIORAL|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
58135113|NCT04949620|BEHAVIORAL|Online parenting program|The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
58135114|NCT02674477|DEVICE|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
58135115|NCT02674477|OTHER|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
58491939|NCT01396070|DRUG|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
58135116|NCT02222155|DRUG|CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
58135117|NCT02222155|DRUG|CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids|
58135118|NCT02222155|OTHER|Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
58135119|NCT00992771|DRUG|varenicline|up to 1mg BID for 8 weeks
58135120|NCT00992771|DRUG|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
58135121|NCT03382756|DIETARY_SUPPLEMENT|High fat diet|A diet consisting of more than 900kcal and 35% of fat
58135122|NCT03382756|DRUG|CKD-337|Test Drug
58135123|NCT05417100|DRUG|Methadone|methadone 0.2 mg/kg IV.
58135124|NCT05436509|BIOLOGICAL|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
58135125|NCT05909124|DEVICE|MCE|underwent MCE examination
58135126|NCT01122485|OTHER|PG201|two tablets
58135127|NCT01122485|OTHER|Placebo|two tablets
58135128|NCT01228409|DRUG|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
58135129|NCT01884090|BEHAVIORAL|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
58135130|NCT00002889|DRUG|flutamide|
58135131|NCT00002889|DRUG|goserelin|
58135132|NCT00002889|DRUG|leuprolide acetate|
58135133|NCT00002889|RADIATION|low-LET photon therapy|
58135134|NCT01762709|PROCEDURE|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
58135135|NCT01762709|PROCEDURE|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
58135136|NCT01762709|PROCEDURE|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
58135137|NCT00949312|GENETIC|RNA marker analysis of lymph node and primary tumors|
58135138|NCT00949312|GENETIC|microarray profiling of primary tumors|
58135139|NCT00949312|GENETIC|reverse transcriptase-polymerase chain reaction of lymph node specimens|
58135140|NCT00949312|OTHER|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
58135141|NCT00949312|PROCEDURE|regional lymph node dissection|
58135142|NCT00949312|OTHER|lymph node staining for H&E and pancytokeratin IHC|
58135143|NCT05306470|PROCEDURE|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
58135144|NCT05306470|PROCEDURE|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
58135145|NCT05221242|PROCEDURE|Conventional Resin Cement vs Preheated Resin Composite|For this study, variolink esthetic resin cement will be used to bond ceramic partial laminate veneers in one side of the maxillary anterior teeth (left or right upper incisors and canines), while, the other side will receive ceramic partial laminate veneers bonded with a preheated resin composite
58135146|NCT05128812|DIETARY_SUPPLEMENT|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
58135147|NCT03967730|COMBINATION_PRODUCT|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
58135148|NCT03088670|DRUG|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
58135149|NCT03088670|DRUG|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
58135150|NCT03088670|DRUG|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
58135151|NCT02393482|DRUG|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
58135152|NCT02393482|DRUG|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
58135153|NCT02393482|DRUG|Add back therapy 1 (tibolone)|tibolone 5 mg/die
58135154|NCT02393482|DRUG|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
58478797|NCT03898739|OTHER|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
58135155|NCT03996109|BEHAVIORAL|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 6 months. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
58135156|NCT03996109|BEHAVIORAL|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 6 months. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
58135157|NCT05266521|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
58135158|NCT01975207|BEHAVIORAL|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
58478798|NCT06590415|PROCEDURE|Subcutaneous adipose tissue biopsy|Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
58478799|NCT06590415|OTHER|Blood sampling|One 4 mL tube of blood will be collected
58478800|NCT03063177|PROCEDURE|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
58478801|NCT02972437|OTHER|sample taking|throat culture and oral cavity sample
58135159|NCT01975207|BEHAVIORAL|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
58135160|NCT01975207|BEHAVIORAL|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
58135161|NCT06368037|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
58135162|NCT05420805|DIETARY_SUPPLEMENT|ALAC, inulin, FOS, and sodium butyrate|Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
58135163|NCT05420805|DIETARY_SUPPLEMENT|Sodium butyrate and zinc oxide|Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
58135164|NCT01980732|DRUG|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
58478802|NCT00966134|OTHER|exposure to high altitude|
58135165|NCT00003186|DRUG|isosulfan blue|
58135166|NCT00003186|PROCEDURE|lymphangiography|
58478803|NCT03123731|BEHAVIORAL|Control Arm|Wearing Physical Activity Monitor
58478804|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity Intervention
58135167|NCT00003186|PROCEDURE|sentinel lymph node biopsy|
58135168|NCT03110302|BEHAVIORAL|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
58135169|NCT01848301|DEVICE|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
58478805|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity and Diet Intervention
58135170|NCT01848301|DRUG|Acetylcholine|Infusion in the coronary artery to study endothelial function
58478806|NCT02888600|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
58135171|NCT01848301|PROCEDURE|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
58135172|NCT02958111|DRUG|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
58478807|NCT02888600|BEHAVIORAL|Health Education|Guided health education and stress management training
58478808|NCT01546610|OTHER|insoles intervention|EVA insole with arch support and bar retrocapital
58478809|NCT01546610|OTHER|placebo insole|EVA insole flat
58478810|NCT02906748|PROCEDURE|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
58478811|NCT02906748|PROCEDURE|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
58478812|NCT00458263|DRUG|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
58478813|NCT01407432|DRUG|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
58478814|NCT01407432|DRUG|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
58478815|NCT02842619|BIOLOGICAL|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
58478816|NCT01698333|DRUG|122-0551|Applied twice daily for 2 weeks
58478817|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
58478818|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
58478819|NCT01107054|DRUG|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
58478820|NCT01107054|DRUG|placebo|A single oral dose of non-matched placebo on Day 4.
58478821|NCT05039086|DRUG|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
58135173|NCT03097900|DRUG|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
58135174|NCT03097900|OTHER|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
58135175|NCT03923465|PROCEDURE|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
58135176|NCT03923465|DEVICE|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
58135177|NCT03923465|DEVICE|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
58135178|NCT01790204|DIETARY_SUPPLEMENT|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
58135179|NCT05065229|DEVICE|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
58135180|NCT04828720|DRUG|ozonated oil|All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
58135181|NCT06035445|BEHAVIORAL|In-person adolescent-friendly service (iPAS) intervention|Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
58138943|NCT03846765|DRUG|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
58478822|NCT05039086|DRUG|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
58478823|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
58478824|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
58478825|NCT00034502|DRUG|ALIMTA|
58478826|NCT00034502|DRUG|irinotecan|
58478827|NCT03135600|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
58478828|NCT04668456|DRUG|Dexmedetomidine|the drug administered either subtenon ot iv
58478829|NCT04668456|DRUG|lidocaine 2%|subtenon injection
58478830|NCT04668456|DRUG|bupivacine 0.5%|subtenon injection
58478831|NCT04668456|DRUG|Normal saline|either subtenon or iv
58478832|NCT03096288|DRUG|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
58491940|NCT00256672|DEVICE|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
58135182|NCT06035445|BEHAVIORAL|mHealth (InTSHA) intervention|The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
58135183|NCT06035445|BEHAVIORAL|Standard of Care|Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
58135184|NCT05371665|BEHAVIORAL|Culturally Adapted Compass for Courage|COMPASS is an indicated prevention and early intervention program for 8-13-year-old youth with higher anxiety. Our CAB has decided to adapt it as a universal prevention and early intervention for all NA youth in the tribal community. It is delivered across six weeks with 30 min weekly sessions. Youth engage in games (e.g., WorryHeads Board Game) and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involves introductions, relaxation training, and discussing emotions. Session 2 teaches youth about worries and how to handle them. Session 3 focuses on having conversations with others. Session 4 teaches youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 teaches youth how to face their fears. Session 6 is a review session. Parents and teachers are sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
58135185|NCT00902109|DEVICE|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
58135186|NCT00902109|DEVICE|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
58135187|NCT00902109|DEVICE|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
58135188|NCT05706337|DRUG|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
58135189|NCT05706337|DRUG|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
58135190|NCT01085825|PROCEDURE|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
58135191|NCT04526210|DRUG|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
58135192|NCT04526210|DRUG|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
58135193|NCT03283254|BEHAVIORAL|Practical Resources for Effective Postpartum Parenting (PREPP)|A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
58135194|NCT03283254|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|"Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate."
58135195|NCT03705897|OTHER|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
58135196|NCT03705897|OTHER|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
58135197|NCT03705897|OTHER|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
58135198|NCT00206583|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
58135199|NCT04697745|DRUG|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
58478833|NCT03096288|OTHER|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
58135200|NCT04697745|DRUG|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
58135201|NCT03494322|DRUG|Avelumab|Avelumab 10 mg/kg given IV
58135202|NCT03494322|DRUG|Cetuximab|"Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in."
58135203|NCT04107454|DEVICE|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
58135204|NCT04107454|DEVICE|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
58478834|NCT06491277|OTHER|Flossband|The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.
58478835|NCT06491277|OTHER|Controlled Group|Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
58478836|NCT02435992|DRUG|RPC1063|
58478837|NCT02435992|DRUG|Placebo|
58478838|NCT06654427|BEHAVIORAL|Obstetric Trauma Informed Care Toolkit|The OB-TIC toolkit will include provider and staff training on trauma- informed care and information on trauma-related perinatal concerns; trauma assessment tools; trauma-informed procedure modifications; clinical language guides; patient-facing resources including birth strategies, referral resources, and education; and clinical language. The OB-TIC intervention will utilize the toolkit to integrate trauma-informed care into clinical practice. Implementation strategies will be assessed to determine the most effective method for integrating OB-TIC content into practice.
58135205|NCT05451446|DIETARY_SUPPLEMENT|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
58135206|NCT05451446|OTHER|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
58135207|NCT05451446|OTHER|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
58135208|NCT00025896|DRUG|recombinant human acid alpha-glucosidase (rhGAA)|
58135209|NCT02841488|PROCEDURE|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
58478839|NCT02324101|DEVICE|Hsp90|Detect plasma Hsp90α concentration
58478840|NCT00628667|DRUG|Esomeprazole|40mg orally twice daily
58478841|NCT00628667|DRUG|Placebo|
58478842|NCT04557891|DEVICE|Active LIFUP Treatment|8 LIFUP Treatments
58478843|NCT04557891|DEVICE|Sham LIFUP Treatment|8 sham LIFUP treatments
58478844|NCT03044106|DEVICE|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
58478845|NCT02194335|DRUG|BIBN 4096 BS - in single rising doses|
58478846|NCT02194335|DRUG|Placebo|
58135210|NCT02841488|DRUG|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
58135211|NCT02841488|DRUG|Ropivacaine|
58135212|NCT02841488|DEVICE|Perineural catheter|
58135213|NCT05325047|PROCEDURE|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
58135214|NCT05856903|DIAGNOSTIC_TEST|ACT|"ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers"
58135215|NCT00581646|BEHAVIORAL|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
58135216|NCT00488748|DEVICE|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
58135217|NCT00488748|DEVICE|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
58135218|NCT05566015|OTHER|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
58135219|NCT04549584|DIAGNOSTIC_TEST|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
58135220|NCT04136899|OTHER|Dukes scale|collection of questionnaires
58135221|NCT03415997|DRUG|Iohexol|Iodinated contrast media
58135222|NCT03094312|PROCEDURE|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
58135223|NCT04138732|BEHAVIORAL|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
58135224|NCT01822548|DRUG|Vildagliptin|100 mg daily
58478847|NCT04337645|PROCEDURE|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
58478848|NCT00912808|DRUG|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
58478849|NCT00912808|DRUG|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
58478850|NCT00017576|DIETARY_SUPPLEMENT|calcitriol|
58478851|NCT00017576|DRUG|carboplatin|
58478852|NCT03848728|OTHER|SEARCH Youth combination intervention|"* Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
58478853|NCT05200403|DRUG|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
58478854|NCT05200403|DRUG|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
58135225|NCT01822548|DRUG|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
58135226|NCT01822548|DRUG|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
58135227|NCT01798212|PROCEDURE|endoscopic full thickness plication|
58478855|NCT05200403|DEVICE|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
58478856|NCT05200403|DEVICE|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
58135228|NCT04752462|BEHAVIORAL|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
58135229|NCT03581422|DRUG|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
58135230|NCT00735904|DRUG|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
58135231|NCT00735904|DRUG|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
58135232|NCT00735904|DRUG|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
58135233|NCT03938922|DRUG|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
58135234|NCT03546842|BIOLOGICAL|9vHPV vaccine|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
58135235|NCT04048369|DIAGNOSTIC_TEST|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
58135236|NCT02376348|BEHAVIORAL|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
58135237|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
58135238|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
58135239|NCT06222749|DRUG|Intranasal oxytocin administration|24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
58135240|NCT06222749|DRUG|Intranasal placebo administration|Nasal spray solution; Placebo will be administered as the placebo controlled condition.
58135241|NCT02192047|OTHER|Palm Olein|8 weeks
58135242|NCT02192047|OTHER|IE Palm olein|8 weeks
58135243|NCT02192047|OTHER|IE soybean oil-based|8 weeks
58135244|NCT03482427|BEHAVIORAL|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
58135245|NCT01374919|DRUG|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
58135246|NCT02539589|BEHAVIORAL|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
58478857|NCT01532596|BEHAVIORAL|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
58135247|NCT02539589|BEHAVIORAL|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
58478858|NCT03428984|DRUG|EXPAREL|EXAPREL 266 mg in 20 mL
58478859|NCT00859196|DRUG|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
58478860|NCT00859196|DRUG|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
58478861|NCT03346538|DRUG|Continuous infusion high-dose MCI-186|intravenous injection
58478862|NCT03346538|DRUG|Continuous infusion low-dose MCI-186|intravenous injection
58478863|NCT03346538|DRUG|Continuous infusion placebo|intravenous injection
58478864|NCT03346538|DRUG|Approved dosing regimen MCI-186|intravenous injection
58478865|NCT03346538|DRUG|Approved dosing regimen placebo|intravenous injection
58478866|NCT06375967|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
58135248|NCT01264120|BEHAVIORAL|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
58135249|NCT00001748|PROCEDURE|Peripheral blood progenitor cell transplant|
58135250|NCT03608215|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
58135251|NCT03608215|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
58135252|NCT01220076|DRUG|tamoxifen|
58478867|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm."
58478868|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
58478869|NCT06654635|DRUG|Rhomboid intercostal plane block|The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
58135253|NCT00242021|BEHAVIORAL|Fatty acid composition of a margarine (spread)|
58135254|NCT01434121|DRUG|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
58478870|NCT06654635|OTHER|Erector spinae plane block|The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. Erector spinae plane block will be performed at the level of T9 bilaterally.
58135255|NCT01434121|DRUG|Placebo|
58135256|NCT05193279|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
58135257|NCT02602925|OTHER|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
58135258|NCT02602925|OTHER|Usual care|Usual care
58135259|NCT04675580|BEHAVIORAL|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
58135260|NCT02492568|DRUG|pembrolizumab|
58135261|NCT02492568|RADIATION|Stereotactic Body Radiation Therapy|
58135262|NCT01450085|OTHER|GeneXpert|Point of care GeneXpert
58135263|NCT01450085|OTHER|LED Microscopy|Point of care LED Microscopy
58135264|NCT04509180|PROCEDURE|Catheter ablation|Endovascular approach
58478871|NCT06654635|OTHER|Control group|No block will be performed, and patient will receive general anesthesia (GA) only.
58478872|NCT05990010|DIAGNOSTIC_TEST|Berlin Questionnaire|The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
58478873|NCT03788213|RADIATION|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
58135265|NCT04509180|PROCEDURE|Convergent procedure|Surgical and endovascular approach
58135266|NCT01806805|DRUG|zonegran|
58135267|NCT01806805|DRUG|placebo|
58135268|NCT04109521|OTHER|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
58135269|NCT01823965|DRUG|ranibizumab|
58135270|NCT04271826|PROCEDURE|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
58135271|NCT03142360|DRUG|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
58135272|NCT04489264|DRUG|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
58135273|NCT00002549|BIOLOGICAL|filgrastim|
58135274|NCT00002549|DRUG|busulfan|
58135275|NCT00002549|DRUG|cyclophosphamide|
58135276|NCT00002549|DRUG|cytarabine|
58135277|NCT00002549|DRUG|daunorubicin hydrochloride|
58135278|NCT00002549|DRUG|etoposide|
58135279|NCT00002549|DRUG|idarubicin|
58135280|NCT00002549|DRUG|mesna|
58135281|NCT00002549|DRUG|mitoxantrone hydrochloride|
58135282|NCT00002549|PROCEDURE|allogeneic bone marrow transplantation|
58135283|NCT00002549|PROCEDURE|autologous bone marrow transplantation|
58135284|NCT00002549|PROCEDURE|peripheral blood stem cell transplantation|
58135285|NCT00002549|RADIATION|radiation therapy|
58135286|NCT02171793|DRUG|BI 1744 CL|
58135287|NCT02171793|DRUG|Placebo|
58478874|NCT03788213|RADIATION|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
58135288|NCT04949932|OTHER|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
58135289|NCT04949932|OTHER|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
58135290|NCT03480425|DIAGNOSTIC_TEST|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
58135291|NCT02183688|DRUG|Low dose ASA|
58135292|NCT02183688|DRUG|High dose ASA|
58135293|NCT02183688|DRUG|Low dose paracetamol|
58135294|NCT02183688|DRUG|High dose paracetamol|
58135295|NCT02183688|DRUG|Caffeine|
58135296|NCT02183688|DRUG|Placebo|
58135297|NCT00175617|DRUG|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
58478875|NCT03406312|DIAGNOSTIC_TEST|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
58478876|NCT02161016|DEVICE|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
58478877|NCT04244292|OTHER|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
58478878|NCT05023642|OTHER|resistance training|"Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
58478879|NCT04428853|BEHAVIORAL|iyengar yoga|different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
58478880|NCT05609292|DEVICE|observational|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
58478881|NCT02303496|BIOLOGICAL|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
58135298|NCT00175617|DRUG|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
58135299|NCT04901962|DEVICE|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
58135300|NCT06077526|BEHAVIORAL|P.E.A.K. Rx|Pain Education + Physical Activity Group Based Intervention
58135301|NCT06077526|OTHER|Usual Care|Participants will receive the community hospital's usual care.
58135302|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
58478882|NCT02303496|BIOLOGICAL|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
58478883|NCT06533787|DEVICE|Echocardiography|Functional echocardiography assessment
58478884|NCT03298334|BIOLOGICAL|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
58478885|NCT03298334|OTHER|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
58478886|NCT05557188|OTHER|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
58478887|NCT05557188|OTHER|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
58478888|NCT01028820|DRUG|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
58478889|NCT04013477|DRUG|DA-5207|DA-5207 Transdermal Delivery System
58478890|NCT04013477|DRUG|Donepezil Hydrochloride|donepezil HCl 10mg QD
58478891|NCT04181658|OTHER|Real tDCS and Physical Therapy|The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
58478892|NCT04181658|OTHER|Sham stimulation and Physical Therapy|The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
58478893|NCT06139120|DIAGNOSTIC_TEST|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
58478894|NCT04050735|OTHER|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
58478895|NCT04050735|OTHER|Placebo|Placebo beverage
58478896|NCT06239675|DEVICE|tDCS|tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.
58478897|NCT06239675|BEHAVIORAL|CIMT|CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
58478898|NCT06239675|DEVICE|sham tDCS|sham tDCS
58478899|NCT05562895|DEVICE|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
58478900|NCT00568022|DRUG|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
58478901|NCT00568022|DRUG|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
58478902|NCT01341353|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
58478903|NCT01341353|DRUG|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
58478904|NCT00000393|DRUG|Peptide T|
58478905|NCT03469414|OTHER|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
58478906|NCT03469414|OTHER|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
58478907|NCT03469414|OTHER|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
58478908|NCT03469414|OTHER|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
58478909|NCT03469414|OTHER|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
58478910|NCT03469414|OTHER|PART-O|The PART-O is a community participation measure.
58478911|NCT03469414|OTHER|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
58478912|NCT03860649|OTHER|Nordic Walking|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
58478913|NCT03860649|OTHER|Jogging|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
58478914|NCT03860649|OTHER|Dance|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
58478915|NCT03860649|OTHER|Pilates Training|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
58478916|NCT06310031|DEVICE|BrioVAD System|Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
58478917|NCT06310031|DEVICE|HeartMate 3|Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
58478918|NCT06592937|OTHER|Invasive ventilation|Invasive ventilation and respiratory support
58478919|NCT04870047|DEVICE|Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device|Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
58478920|NCT03773224|PROCEDURE|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
58478921|NCT03839160|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
58478922|NCT03839160|DRUG|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
58478923|NCT02405078|DRUG|Chemotherapy|Given standard salvage chemotherapy
58478924|NCT02405078|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT scan
58478925|NCT02405078|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
58478926|NCT02405078|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT scan
58478927|NCT06042205|DEVICE|TISSIUM™ Atraumatic Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
58491941|NCT01929811|DRUG|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
58491942|NCT01929811|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
58478928|NCT03697252|DRUG|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
58478929|NCT03697252|DRUG|Placebo Capsules|Placebo Capsules
58478930|NCT00799786|BEHAVIORAL|Building Better Caregivers Online Workshop|
58478931|NCT01696110|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
58478932|NCT01696110|DRUG|heparin|heparin monotherapy
58478933|NCT01696110|DRUG|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
58478934|NCT05442853|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
58478935|NCT05442853|DEVICE|Point of care glucose monitoring|Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
58478936|NCT00224575|OTHER|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
58478937|NCT00224575|OTHER|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
58478938|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
58478939|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
58478940|NCT06071078|BEHAVIORAL|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
58478941|NCT06274645|DEVICE|The OptiCross High Definition (60 MHz) and OptiCross (40MHz) Intravascular Ultrasound (IVUS) catheter from Boston Scientific|The IVUS-guided PCI procedure includes the use of IVUS before PCI (highly recommended) and after PCI (mandatory)
58478942|NCT03208010|BEHAVIORAL|Diabetes Prevention Intervention|"* Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
58478943|NCT03208010|OTHER|Enhanced Usual Care|"* Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials"
58478944|NCT02768857|BEHAVIORAL|Sensorimotor reeducation programs|
58478945|NCT00267059|DRUG|Lenalidomide|10 mg/day, orally once a day for 28 days
58478946|NCT03586492|DIAGNOSTIC_TEST|CZT SPECT acquisition|CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
58478947|NCT05050318|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
58478948|NCT05050318|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
58478949|NCT05133388|GENETIC|ARMS PCR|ARMS PCR using primer pairs that only amplify individual alleles
58135303|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
58478950|NCT06651840|PROCEDURE|"bipolar diathermy Standard technique."|"The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
58491943|NCT01929811|DRUG|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
58491944|NCT01929811|DRUG|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
58478951|NCT06651840|PROCEDURE|coblation technique.|"The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
58478952|NCT04318353|OTHER|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
58478953|NCT03415685|DEVICE|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
58478954|NCT05099952|PROCEDURE|Biospecimen Collection|Undergo collection of cheek cell and blood samples
58478955|NCT05099952|OTHER|Counseling|Meet with therapist
58478956|NCT05099952|OTHER|Educational Intervention|Participate in BBT-CI sessions
58478957|NCT05099952|OTHER|Electronic Health Record Review|Medical records are reviewed
58478958|NCT05099952|OTHER|Medical Device Usage and Evaluation|Wear actigraphy watch
58478959|NCT05099952|OTHER|Questionnaire Administration|Ancillary studies
58478960|NCT02643914|DRUG|Nicotine|
58478961|NCT02643914|DEVICE|MR Compatible Nicotine Delivery Device|
58478962|NCT01703234|DRUG|Ramipril|ramipril 10 mg/day during 3 months
58478963|NCT02864784|DRUG|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
58478964|NCT02864784|OTHER|Placebo|microcrystalline cellulose
58478965|NCT03505502|DRUG|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
58478966|NCT02876432|DEVICE|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
58478967|NCT02876432|DRUG|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
58478968|NCT02876432|OTHER|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
58478969|NCT01392339|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
58478970|NCT03371069|OTHER|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
58478971|NCT01281514|DRUG|everolimus|Given PO
58478972|NCT01281514|DRUG|carboplatin|Given IV
58478973|NCT01281514|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
58478974|NCT01281514|OTHER|laboratory biomarker analysis|Correlative studies
58478975|NCT04467203|DRUG|Fadanafil|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
58478976|NCT06586710|OTHER|Assessment activation of interferon pathway|"* Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed."
58490989|NCT05345340|OTHER|Telemedicine|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days)."
57784575|NCT03215121|PROCEDURE|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
58478977|NCT05698550|DRUG|Erzhi Tiangui Granule|The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
58478978|NCT05698550|DRUG|Erzhi Tiangui Placebo|The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
58478979|NCT03843814|PROCEDURE|APT MRI|
58478980|NCT06064721|OTHER|Buerger-Allen Exercise|Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
58478981|NCT03113461|DEVICE|CPAP|non-invasive positive airway pressure applied using an oronasal mask
58478982|NCT02372188|OTHER|water|Control
58478983|NCT02372188|DIETARY_SUPPLEMENT|caffeine|
58478984|NCT02372188|DIETARY_SUPPLEMENT|caffein + homoeriodictyol sodium salt|
58478985|NCT02372188|DIETARY_SUPPLEMENT|homoeriodictyol sodium salt|
58478986|NCT01334450|DEVICE|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
58478987|NCT05681182|COMBINATION_PRODUCT|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
58478988|NCT04762602|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
58478989|NCT05993858|DRUG|3cycles (Toripalimab + cetuximab)|"Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9."
58478990|NCT05993858|PROCEDURE|Surgery|After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
58478991|NCT05993858|RADIATION|Radiotherapy or chemoradiotherapy|Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
58478992|NCT02146066|BIOLOGICAL|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
58478993|NCT06587087|DEVICE|Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.|The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
58478994|NCT02170571|DRUG|Dabigatran etexilate|
58478995|NCT05690802|DRUG|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
58478996|NCT05147363|DEVICE|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
58478997|NCT04684836|OTHER|Exposure to telemedicine, after the onset of the pandemic|The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
58478998|NCT05663606|COMBINATION_PRODUCT|Happy Bob|Application, which gives stars when subject reachs Time In Range
58478999|NCT05663606|DEVICE|CGM|Dexcom CGM
58479000|NCT04363970|OTHER|removal of the urinary catheter|in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
58479001|NCT06593119|BEHAVIORAL|Telemedicine management of Hypertension|TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care
58479002|NCT06593119|BEHAVIORAL|Usual Care|This includes usual clinic based HTN care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.
58479003|NCT04664686|PROCEDURE|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
58479004|NCT04664686|PROCEDURE|AV node ablation|AV node ablation
58479005|NCT00003469|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
58479006|NCT01831388|OTHER|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
58479007|NCT01831388|BEHAVIORAL|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
58479008|NCT00941096|DRUG|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
58479009|NCT04488614|PROCEDURE|Breast Concervative or Meastectomy|National treatment guidelines in Norway
58479010|NCT04893369|OTHER|The Low Back Pain and Disability Drivers Management model|"PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability."
58479011|NCT04893369|OTHER|Low back pain clinical practice guidelines|For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
58479012|NCT02536053|PROCEDURE|Limb salvage|
58479013|NCT04225897|DRUG|RV521|RV521 is an RSV F protein inhibitor administered orally
58479014|NCT04225897|DRUG|Placebo|vehicle administered orally
58479015|NCT05922917|DEVICE|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
58479016|NCT01047358|DRUG|Aromasin|25 mg table QD
58479017|NCT01047358|DRUG|Aromasin|25 mg table QD
58479018|NCT03430284|BEHAVIORAL|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
58479019|NCT03430284|DRUG|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
58479020|NCT03430284|OTHER|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
58479021|NCT03430284|OTHER|General treatment|General treatment is carried out based on the device from the general practitioners at present.
58479022|NCT03651479|OTHER|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
58479023|NCT03651479|OTHER|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
58479024|NCT02153086|DRUG|Ramelteon|Ramelteon tablets 8 mg
58479025|NCT02678026|DEVICE|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
58479026|NCT06112808|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
58479027|NCT06112808|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
58479028|NCT00400465|PROCEDURE|Normal dressing|Normal dressing
58479029|NCT00400465|PROCEDURE|Pressure dressing|Pressure dressing
58479030|NCT03787511|OTHER|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
58479031|NCT03787511|OTHER|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
58479032|NCT03787511|OTHER|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
58479033|NCT01353898|DRUG|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
58479034|NCT01353898|DRUG|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
58479035|NCT02007096|DRUG|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight \>100kg: 60ml total
58479036|NCT02007096|DRUG|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight \>100kg: 60ml
58479037|NCT04985123|DEVICE|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
58479038|NCT03390946|DRUG|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
58479039|NCT03390946|DRUG|Good responder group adjuvant chemotherapy|"Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
58479040|NCT06530446|OTHER|one group. observational study|observational study of this group
58479041|NCT02490098|OTHER|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
58479042|NCT02490098|OTHER|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
58479043|NCT02490098|OTHER|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
58479044|NCT02490098|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
58479045|NCT02490098|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
58479046|NCT02490098|DEVICE|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
58479047|NCT02490098|DEVICE|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
58479048|NCT06026917|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|D1\~D6, 40mg/ tablet, 1 tablet per time, once a day, D7\~D10, 80mg/ tablet, 1 tablet per time, once a day, D11\~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11\~D42, 80mg/ tablet, one tablet each time, once a day.
58479049|NCT03711513|BEHAVIORAL|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
58479050|NCT00321620|DRUG|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
58479051|NCT00321620|BIOLOGICAL|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
58479052|NCT01857817|DRUG|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
58479053|NCT01857817|DRUG|Placebo|The placebo capsules will be prepared to match the active drug.
58479054|NCT02726568|DRUG|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
58479055|NCT02726568|RADIATION|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
58479056|NCT00066157|DRUG|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
58479057|NCT00066157|DRUG|Medroxyprogesterone|2.5mg tablet daily for 12 months
58479058|NCT00066157|DRUG|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
58479059|NCT00066157|DRUG|Placebo|Placebo tablet daily for 12 months
58479060|NCT01615120|DRUG|GTx-758 125 mg|One 125 mg tablet once a day
58479061|NCT01615120|DRUG|GTx-758 250 mg|two 125 mg tablets once daily
58479062|NCT04442295|DRUG|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
58479063|NCT04442295|DRUG|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
58479064|NCT01189032|DRUG|DE-089 ophthalmic solution|
58479065|NCT01189032|DRUG|DE-089 ophthalmic solution|
58479066|NCT01189032|DRUG|Placebo ophthalmic solution|
58479067|NCT04434937|DRUG|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
58479068|NCT01300754|PROCEDURE|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
58479069|NCT01300754|PROCEDURE|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
58479070|NCT01300754|OTHER|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
58479071|NCT01697917|OTHER|Total Gastrectomy or Proximal Gastrectomy|
58479072|NCT01967940|DRUG|TAF|25 mg tablet administered orally once daily with food
58479073|NCT01967940|DRUG|Placebo|Tablets to match TAF administered orally once daily with food
58479074|NCT01967940|DRUG|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
58479075|NCT01967940|DRUG|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
58479076|NCT01967940|DRUG|ATV|300 mg tablet administered orally once daily.
58479077|NCT06527950|OTHER|no intervention|observational study , no intervention
58479078|NCT06499064|PROCEDURE|mHealth|"Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference."
58479079|NCT03021785|BIOLOGICAL|TK001|TK001 will be administered intravitreal injection.
58479080|NCT00436696|OTHER|Laboratory Biomarker Analysis|Correlative studies
58479081|NCT02633514|DRUG|Cisplatin|25mg/m2,iv gtt,d1-3
58479082|NCT02633514|DRUG|Etoposide|75mg/m2,iv gtt,d1-3
58479083|NCT02633514|RADIATION|radiotherapy|60Gy/30Fx
58479084|NCT06595563|DRUG|Trastuzumab emtansine|T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
58479085|NCT05236582|DRUG|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
58138944|NCT03846765|DRUG|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
58479086|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
58479087|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
58479088|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
58479089|NCT00043862|DRUG|topotecan|
58479090|NCT04081103|DRUG|Nexagon® (lufepirsen) High Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
58479091|NCT04081103|DRUG|Nexagon® (lufepirsen) Low Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
58479092|NCT04081103|DRUG|Vehicle|Vehicle is administered topically in the affected eye three (3) times over 28 days.
58479093|NCT04081103|DRUG|Open-label Nexagon® (lufepirsen)|Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
58479094|NCT05313555|DEVICE|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
58479095|NCT05313555|DEVICE|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
58479096|NCT03656289|DRUG|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
58479097|NCT00959855|OTHER|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
58479098|NCT01872416|DEVICE|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
58479099|NCT02933749|DEVICE|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
58479100|NCT02933749|DEVICE|BIS|Bispectral index
58479101|NCT00196482|DRUG|changing of fortifier|
58479102|NCT02547818|DRUG|ALZT-OP1a|1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
58479103|NCT02547818|DRUG|ALZT-OP1b|Anti-inflammatory
58479104|NCT02547818|OTHER|Placebo ALZT-OP1a|Non-active capsules
58479105|NCT02547818|OTHER|Placebo ALZT-OP1b|Non-active tablets
58479106|NCT02354898|DRUG|BBI503|
58479107|NCT02354898|DRUG|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
58479108|NCT03410706|DRUG|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
58479109|NCT06233136|DEVICE|Leg pedalling exercise|Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
58479110|NCT06233136|OTHER|The designed physical therapy program|"It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises"
58479111|NCT02233777|DRUG|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
58479112|NCT02233777|DRUG|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
58479113|NCT00565188|DRUG|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
58479114|NCT03483857|BEHAVIORAL|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
58479115|NCT06184776|OTHER|Lumbar Stiffness Disability Index|The development and evaluation of the Turkish version of the Lumbar Stiffness Disability Index (LSDI) are planned. After ensuring the eligibility of adult participants included in the study, language validity will be established for the Turkish version of LSDI, and internal consistency will be assessed using Cronbach's alpha coefficient. Additionally, the test-retest reliability of the index will be evaluated by reapplying it to participants with a one-week interval. For external structure validity, LSDI scores will be correlated with Oswestry Disability Index, Functional Reach Test, and goniometric measurements. The study will include demographic data and measurements to examine the eligibility of individuals with specific medical conditions for the intervention.
58479116|NCT05182593|OTHER|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
58479117|NCT05182593|OTHER|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
58479118|NCT05761782|BEHAVIORAL|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
58479119|NCT02066181|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
58479120|NCT02066181|OTHER|Placebo Administration|Given PO
58479121|NCT02066181|OTHER|Quality-of-Life Assessment|Optional ancillary studies
58138945|NCT03699020|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
58479122|NCT02066181|DRUG|Sorafenib Tosylate|Given PO
58479123|NCT05577507|DRUG|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
58479124|NCT05577507|DRUG|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcimate 500 mg three times daily within meals
58479125|NCT03969212|DRUG|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
58479126|NCT03969212|DRUG|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
58479127|NCT02729532|DEVICE|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
58491945|NCT04310371|BEHAVIORAL|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
58491946|NCT00250328|DEVICE|LapCAC Laparoscopic Compression Anastomosis Clip|
58479128|NCT02826317|PROCEDURE|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS \>0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS \>0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
58479129|NCT03184168|DRUG|[14C]lorlatinib|Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
58479130|NCT00023777|BIOLOGICAL|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
58479131|NCT00023777|BIOLOGICAL|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
58479132|NCT00023777|DRUG|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
58479133|NCT00023777|DRUG|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
58479134|NCT00459316|BIOLOGICAL|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
58479135|NCT06609577|DEVICE|Diaphragm Ultrasound-Guided External Diaphragm Pacing|This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
58479136|NCT02891499|PROCEDURE|Low-level laser therapy|"1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
58479137|NCT02891499|PROCEDURE|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
58479138|NCT00710697|DRUG|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
58479139|NCT05442957|BEHAVIORAL|BRIGHT|BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
58479140|NCT05442957|BEHAVIORAL|Attention Control|AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
58479141|NCT01458392|BIOLOGICAL|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
58479142|NCT01526863|DIETARY_SUPPLEMENT|HA egg|Daily dose of HA egg or placebo for 6 months
58479143|NCT06597578|DEVICE|Extraction tools|The effect of different extraction tools on outcome parameters will be evaluated
58479144|NCT06049849|DEVICE|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
58479145|NCT01113086|DEVICE|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
58479146|NCT06011187|PROCEDURE|Routine care|Fluid administration will be given per routine care MAP between 65 - 70 mmHg
58479147|NCT06011187|DEVICE|AFM|AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg
58479148|NCT06201026|OTHER|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
58479149|NCT06201026|OTHER|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
58479150|NCT01928212|DEVICE|Optical coherence tomography|
58479151|NCT03141827|DRUG|Insulin|Insulin 40 IU, nasal spray, single dose
58479152|NCT03141827|DRUG|Placebo|Placebo, nasal spray, single dose
58479153|NCT00791505|DRUG|ciprofloxacin|1500 mg a day for 10 days
58479154|NCT00791505|DRUG|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
58479155|NCT03621475|DEVICE|Novel restraint|Use of a novel arm restraint
58479156|NCT00224640|DRUG|Iron chelating intervention|Iron chelating intervention
58479157|NCT03516630|DRUG|Trazodone 20 mg|Oral drops
58479158|NCT03516630|DRUG|Trazodone 60 mg|Oral drops
58479159|NCT03516630|DRUG|Trazodone 140 mg|Oral drops
58479160|NCT03516630|DRUG|Placebo|Oral drops
58479161|NCT03516630|DRUG|Moxifloxacin 400mg|Tablet
58479162|NCT01639378|PROCEDURE|Renal Denervation|Symplicity Catheter System
58479163|NCT05795036|DEVICE|mHealth 1|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks.
58479164|NCT05795036|DEVICE|mHealth 2|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks. In addition, they will receive daily motivational text message.
58479165|NCT05183360|DRUG|BI 706321|BI 706321
58479166|NCT05183360|DRUG|Placebo|Placebo
58479167|NCT05917197|OTHER|survey based information|Only survey based information collected
58479168|NCT05670886|PROCEDURE|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
58479169|NCT05373459|BIOLOGICAL|Third COVID-19 booster|Third COVID-19 booster
58479170|NCT02835287|OTHER|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
58479171|NCT00269217|DRUG|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
58479172|NCT00269217|DRUG|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
58479173|NCT00269217|DRUG|Comparator: simvastatin|Duration of Treatment 12 Weeks
58479174|NCT06498076|DRUG|Norepinephrine|injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
58479175|NCT06498076|DRUG|Ephedrine|injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
58479176|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
58479177|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
58479178|NCT00445042|DRUG|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
58479179|NCT05318586|PROCEDURE|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
58479180|NCT05318586|PROCEDURE|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
58479181|NCT03238378|RADIATION|Brachytherapy|Brachytherapy d 1-5(6)
58479182|NCT03238378|OTHER|Hyperthermia|Hyperthermia d 2 + 5
58479183|NCT00669734|BIOLOGICAL|Falimarev|Given intratumorally or SC
58479184|NCT00669734|BIOLOGICAL|Inalimarev|Given SC
58135304|NCT04836000|OTHER|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
58135305|NCT04142970|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
58135306|NCT01598701|DRUG|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
58479185|NCT00669734|OTHER|Laboratory Biomarker Analysis|Correlative studies
58479186|NCT00669734|BIOLOGICAL|Sargramostim|Given SC
58479187|NCT06061926|DRUG|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
58479188|NCT06061926|DRUG|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
58479189|NCT01184963|DIETARY_SUPPLEMENT|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
58479190|NCT01184963|DIETARY_SUPPLEMENT|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
58479191|NCT05969496|DRUG|Axitinib|Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
58479192|NCT05969496|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
58479193|NCT03959514|BIOLOGICAL|NovoRapid|Rapid acting prandial insulin aspart
58479194|NCT03959514|BIOLOGICAL|Fiasp|Fast acting prandial insulin aspart
58479195|NCT03959514|BIOLOGICAL|AT247|Ultra rapid acting prandial insulin aspart
58479196|NCT05893784|OTHER|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
58479197|NCT02939911|DEVICE|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
58479198|NCT06071247|OTHER|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
58479199|NCT05940220|OTHER|Acetazolamide|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm
58479200|NCT05940220|OTHER|placebo|placebo
58479201|NCT03213691|OTHER|Laboratory Biomarker Analysis|Correlative studies
58479202|NCT03213691|DRUG|Selumetinib|Given PO
58479203|NCT03213691|DRUG|Selumetinib Sulfate|Given PO
58479204|NCT05717153|PROCEDURE|Biospecimen Collection|Undergo collection of blood
58479205|NCT05717153|PROCEDURE|Computed Tomography|Undergo CT
58479206|NCT05717153|DRUG|Eflornithine|Given PO
58479207|NCT05717153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58479208|NCT05717153|DRUG|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Given PO
58479209|NCT05717153|PROCEDURE|Resection|Undergo surgical resection
58479210|NCT05717153|DEVICE|Microdialysis|Undergo Microdialysis
58479211|NCT05717153|PROCEDURE|Placement|Undergo placement of catheters
58479212|NCT03182049|PROCEDURE|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
58479213|NCT03182049|PROCEDURE|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
58479214|NCT00863278|PROCEDURE|pulsed dye laser treatment|On one side of the face according to Arm placement.
58479215|NCT00863278|DRUG|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
58479216|NCT03594630|DRUG|Chemotherapy|Receive chemotherapy
58479217|NCT03594630|OTHER|Patient Observation|Receive active surveillance
58479218|NCT03594630|OTHER|Questionnaire Administration|Ancillary studies
57785207|NCT04316767|BEHAVIORAL|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
58135307|NCT01598701|DRUG|Placebo|100 mL 0.9% Sodium Chloride
58135308|NCT02456779|OTHER|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
58135309|NCT02456779|OTHER|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
58479219|NCT03594630|PROCEDURE|Resection of Rectum|Undergo surgical resection
58479220|NCT01198795|DRUG|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
58479221|NCT04002232|DEVICE|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
58479222|NCT01446055|DEVICE|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
58479223|NCT01446055|DEVICE|Ficoll conventional cell processing method|Comparison of different cell processing methods
58479224|NCT05299307|DIAGNOSTIC_TEST|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
58479225|NCT02900378|DRUG|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
58479226|NCT02900378|DRUG|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
58135310|NCT02456779|OTHER|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
58135311|NCT01239121|OTHER|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
58479227|NCT02900378|DRUG|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
58479228|NCT02900378|DRUG|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
58479229|NCT03251495|DRUG|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
58479230|NCT06654453|PROCEDURE|Thrombectomy|Manual thrombectomy followed by Percutaneous Coronary Intervention (PCI), a procedure involving mechanical removal of thrombus before stent placement in coronary arteries to restore blood flow in STEM
58479231|NCT06654453|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.
58479232|NCT03694353|DRUG|Pegvaliase|40-60mg/day
58479233|NCT04551547|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml
58479234|NCT04551547|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml
58479235|NCT04551547|OTHER|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
58479236|NCT06053502|OTHER|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
58479237|NCT03779295|DEVICE|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
58479238|NCT03779295|DRUG|Clindamycin|The entire face (both halves) will receive clindamycin.
58479239|NCT01419964|DRUG|Group 01|ACH24
58479240|NCT01419964|DRUG|Group 02|Placebo
58479241|NCT05935124|DIAGNOSTIC_TEST|WLE first, then B-NBI|
58479242|NCT04226599|DEVICE|Dissolve AVF|Subjects in the test group will be treated with peripheral scoring drug balloon.
58479243|NCT04226599|DEVICE|Armada 35|Subjects in the test group will be treated with plain balloon catheter.
58479244|NCT05471323|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
58479245|NCT01970293|OTHER|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
58479246|NCT06245343|DEVICE|Functional inspiratory muscle training group|"Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients."
58479247|NCT06245343|DEVICE|Control group|The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
58479248|NCT02485873|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
58479249|NCT02485873|DRUG|Vitamin K antagonists|As prescribed by treating physicians
58479250|NCT06595862|BEHAVIORAL|EA-Avatar|The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
58479251|NCT03351725|DEVICE|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
58479252|NCT03354195|PROCEDURE|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
58479253|NCT06594679|DRUG|Niraparib Tosylate Monohydrate|Combination of niraparib and abemaciclib
58479254|NCT03473054|OTHER|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
58479255|NCT02336152|DEVICE|Anaesthesia, Teles Pro, Body suit|
58479256|NCT04744246|OTHER|load carriage|35 pound load carried on the back
58479257|NCT01203202|DRUG|Clomipramine|15mg and 30mg on demand
58479258|NCT06346418|GENETIC|WES analysis|"Whole-exome sequencing will be performed as the first approach in all the recruited patients. First, we will analyze different subsets of genes, belonging to:~1. Maternal effect genes as SCMC components and other related genes;~2. Genes essential in the maturation of the oocyte and zygote progression through the early phases of the embryogenesis or highly expressed at different stages of oocyte maturation;~3. Genes with known and potential roles in the establishment and control of genomic imprinting and involved in DNA methylation reactions.~Subsequently, variants with a high pathogenicity score will be analyzed, to identify any genes that may be associated with the phenomenon, but do not belong to the previously described categories of genes. Finally, we will conduct a whole genome sequencing (WGS) analysis on a selected subgroup of BWS mothers with peculiar clinical histories and negative WES analysis, to explore all the noncoding and regulatory regions not targeted by WES."
58479259|NCT06346418|GENETIC|whole-genome methylation analysis|A whole-genome methylation analysis will be performed to identify methylation changes in women with reproductive problems including those with offspring affected by BWS
58479260|NCT04318873|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
58479261|NCT06497270|PROCEDURE|Theca and Granulosa Cell Isolation|These patients will receive standard procedure during the risk reducing surgery but their ovaries will be used to extract theca and granulosa cells which will be used for the 3D bioprinted device's realisation.
58479262|NCT05414409|DRUG|Metformin|Metformin is an oral medication that improves insulin sensitivity.
58491947|NCT03783715|DRUG|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
57785208|NCT02986828|DRUG|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
57785209|NCT02986828|DRUG|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
58135312|NCT01239121|OTHER|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
58479263|NCT05621434|DRUG|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
58479264|NCT06599541|BEHAVIORAL|Hypopressive Exercise|A hypopressive exercise program will be carry out.
58479265|NCT06599541|BEHAVIORAL|Pilates Exercise|A pilates exercise program will be carry out.
58479266|NCT01851642|PROCEDURE|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
58479267|NCT01851642|PROCEDURE|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
58479268|NCT01851642|PROCEDURE|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
58479269|NCT01851642|DRUG|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
58479270|NCT02713893|DRUG|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
58479271|NCT02713893|DRUG|Placebo plus Econazole nitrate 1% intravaginal cream|
58479272|NCT02713893|DRUG|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
58479273|NCT02713893|DRUG|Placebo intravaginal cream|
58479274|NCT00192985|DEVICE|Nitrofuranzone coated bladder catheter|
58479275|NCT01599637|DRUG|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
58479276|NCT01599637|DRUG|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
58479277|NCT02936596|DRUG|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
58479278|NCT02936596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid
58479279|NCT04672668|DIAGNOSTIC_TEST|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
58479280|NCT01271946|DEVICE|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
58479281|NCT05893745|OTHER|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
58479282|NCT05893745|OTHER|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
58479283|NCT04119414|BEHAVIORAL|Spear and Shield (S&S) Program|The S\&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
58479284|NCT04119414|BEHAVIORAL|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
58479285|NCT06294106|DEVICE|Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)|EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
58479286|NCT05116852|OTHER|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
58479287|NCT01403532|DRUG|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
58479288|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
58479289|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
58479290|NCT05902247|RADIATION|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer
57785210|NCT02986828|DEVICE|Ultrasound|
58479291|NCT01312532|DEVICE|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
58479292|NCT01312532|DEVICE|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
58479293|NCT05740072|OTHER|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
58479294|NCT05740072|OTHER|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
58479295|NCT04336774|DEVICE|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
58479296|NCT00025688|DRUG|carboplatin|
58479297|NCT00025688|DRUG|paclitaxel|
58479298|NCT03256461|BEHAVIORAL|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
58479299|NCT03256461|BEHAVIORAL|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
58479300|NCT03256461|BEHAVIORAL|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
58479301|NCT04498832|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
58479302|NCT04498832|BIOLOGICAL|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
58479303|NCT04934540|PROCEDURE|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
58479304|NCT04301960|OTHER|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
58479305|NCT04301960|OTHER|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
58479306|NCT03606902|PROCEDURE|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
58479307|NCT03606902|DRUG|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
58479308|NCT03606902|DRUG|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
58479309|NCT03606902|PROCEDURE|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
58479310|NCT05506124|DEVICE|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
58479311|NCT05506124|DEVICE|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
58479312|NCT02628912|OTHER|blood draw|
58479313|NCT02628912|BEHAVIORAL|study questionnaire|
58479314|NCT02628912|OTHER|cardiopulmonary exercise testing (CPET)|
58479315|NCT02628912|OTHER|DXA (dual-energy x-ray absorptiometry) scan|
58479316|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
58479317|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
58479318|NCT01134185|DRUG|prucalopride|single dose of 2 mg prucalopride
58479319|NCT02158442|PROCEDURE|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
58479320|NCT02158442|DRUG|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
58479321|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
58135313|NCT02360462|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
58135314|NCT02360462|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
58479322|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
58479323|NCT03352102|PROCEDURE|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
58479324|NCT06589973|OTHER|Study Cohort|Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.
58479325|NCT03329157|OTHER|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
58479326|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 1
58479327|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 2
58479328|NCT06310876|DRUG|Placebo|• single oral dose
58479329|NCT06310876|DRUG|Moxifloxacin 400mg|• single oral dose
58479330|NCT01081652|DRUG|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
58479331|NCT01081652|DRUG|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
58479332|NCT04178668|OTHER|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
58479333|NCT04336553|BEHAVIORAL|Social prescribing in Sweden (SPiS)|Social prescribing in sweden (SPiS)
58479334|NCT03747861|DEVICE|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
58479335|NCT06654583|BEHAVIORAL|Interactive Play Mat|Use of developed interactive play mat that utilizes haptic feedback vibrations to assist children with delayed milestones in achieving Gross Motor Skills. The play mat aims to provide a therapeutic and engaging experience by incorporating visuals, sounds, and lights to encourage movement that might otherwise be challenging for these children.
58479336|NCT06654583|BEHAVIORAL|Conventional Physical Therapy|Stretching and Strengthening exercises
58479337|NCT00888134|DRUG|Selumetinib|Given PO
58479338|NCT04824924|DRUG|The combination of HHT, venetoclax, AZA, G-CSF|HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
58479339|NCT01314313|DEVICE|TAVR Implantation with SAPIEN XT|Operable Group with SAPIEN XT
58479340|NCT01314313|DEVICE|SAVR Implantation|Control Group
58479341|NCT01712477|DRUG|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
58479342|NCT01712477|DRUG|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
58479343|NCT04169217|BEHAVIORAL|Prehabilitation|"A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform."
58479344|NCT02310698|DEVICE|contrast enhanced digital mammography (CEDM)|
58479345|NCT02310698|DEVICE|whole breast screening ultrasound (WBUS)|
58479346|NCT01723384|DRUG|Intermittent Oral Naltrexone|
58479347|NCT01723384|DRUG|Placebo|
58479348|NCT00873483|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
58479349|NCT05739721|BEHAVIORAL|Attractiveness|Visual attractiveness scale 0-7
58479350|NCT05739721|BEHAVIORAL|Self-Esteem|Self Esteem scale
58479351|NCT05739721|BEHAVIORAL|Trustworthiness|Trustworthiness scale 0-7
58479352|NCT05405803|BEHAVIORAL|Web-App based Lifestyle Physical Activity Promotion Program|"WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences.~The program includes 3 components in 2 languages (English and Korean):~1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers.~2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity.~3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.).~Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls."
58479353|NCT05405803|BEHAVIORAL|The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines|A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.
58479354|NCT02032732|OTHER|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
58479355|NCT04689607|OTHER|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
58479356|NCT04689607|OTHER|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
58479357|NCT02004093|DRUG|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
58479358|NCT02004093|DRUG|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
58479359|NCT02004093|DRUG|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
58479360|NCT02004093|DRUG|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
58479361|NCT03315663|OTHER|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
58479362|NCT03315663|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
58479363|NCT03771924|DIETARY_SUPPLEMENT|inorganic phosphate|Sodium phosphate
58479364|NCT03771924|DIETARY_SUPPLEMENT|placebo|Sodium chlorid
58479365|NCT03524976|DEVICE|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
58479366|NCT03968393|DRUG|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
58479367|NCT01815970|BEHAVIORAL|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
58479368|NCT02858622|DRUG|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
58479369|NCT02858622|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
58479370|NCT02858622|DRUG|perfalgan|intravenous paracetamol
58479371|NCT02858622|DRUG|fentanyl|
58479372|NCT06173102|DEVICE|Cranial Orthosis|Early versus usual reception of orthosis.
58479373|NCT00785785|DRUG|Nilotinib (AMN107)|
58479374|NCT00785785|DRUG|imatinib (STI571)|
58479375|NCT05962060|OTHER|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
58479376|NCT05962060|OTHER|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
58479377|NCT01099722|DRUG|Flutiform|inhaler 2 puffs bd daily
58479378|NCT01099722|DRUG|Symbicort Turbohaler|2 puffs bd daily
58479379|NCT06463808|DRUG|Recombinant Human Brain Natriuretic Peptide|we divide our subjects into two groups;one is required to take recombinant human brain natriuretic peptide,the other is not required to take recombinant human brain natriuretic peptide
58479380|NCT02545088|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
57784576|NCT03215121|PROCEDURE|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
58479381|NCT02545088|OTHER|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
58479382|NCT02545088|OTHER|2nd control group|The 2nd control group will not receive an intervention.
58479383|NCT03217071|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
58479384|NCT03217071|RADIATION|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
58479385|NCT03217071|PROCEDURE|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
58479386|NCT05077202|DEVICE|ultra sound|chest ultrasound
58479387|NCT02643212|DRUG|Rivaroxaban|
58479388|NCT02643212|DRUG|Placebo|
58479389|NCT05765916|BEHAVIORAL|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
58491948|NCT02472067|BEHAVIORAL|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
58135315|NCT02683967|PROCEDURE|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
58491949|NCT04875143|DIETARY_SUPPLEMENT|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
58479390|NCT03013270|OTHER|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
58479391|NCT03013270|OTHER|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
58479392|NCT03013270|OTHER|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
58479393|NCT03013270|OTHER|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
58479394|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate|
58479395|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate - double dose|
58479396|NCT02147639|DIETARY_SUPPLEMENT|Placebo|
58479397|NCT02147639|PROCEDURE|Increased exercise intensity|
58479398|NCT01510483|BEHAVIORAL|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
58479399|NCT01510483|BEHAVIORAL|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
58479400|NCT04616456|DRUG|[F-18]PBR06|PET radiopharmaceutical
58479401|NCT04616456|DRUG|Verdiperstat|verdiperstat targets microglial inflammation in the brain
58479402|NCT00602017|DRUG|Amlodipine|
58479403|NCT01986426|DRUG|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
58479404|NCT01986426|DRUG|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
58479405|NCT01986426|DRUG|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
58479406|NCT01986426|DRUG|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
58479407|NCT01777386|PROCEDURE|preexpanded perforator flap surgery|
58479408|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
58479409|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
58479410|NCT00637975|DRUG|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
58479411|NCT00637975|DRUG|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
58479412|NCT01578486|DRUG|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
58479413|NCT04871126|OTHER|inflammatory indexes and CHA2DS2-VASc score|inflammatory indexes and CHA2DS2-VASc score
58479414|NCT03281798|DEVICE|Fetoscopes|Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.
58479415|NCT03281798|PROCEDURE|Fetal Cystoscopy|A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.
58479416|NCT04950647|DRUG|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
58479417|NCT04950647|DRUG|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
58479418|NCT04950647|DRUG|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
58479419|NCT06516380|DEVICE|Combined treatment of Cyberdyne HAL single joint with TecnoBody D-Wall and Walker View 3.0 SCX devices|HAL-SJ sessions were conducted 5 days a week for 3 months and 2 hours a day for a total of 60 sessions. HAL-SJ application was performed in cybernic voluntary control (CVC) mode for 90 minutes. In addition to each HAL-SJ session, balance exercises were performed with TecnoBody D-Wall for 30 minutes net.
58479420|NCT04166422|OTHER|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
58479421|NCT04166422|OTHER|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
58491950|NCT02334540|DIETARY_SUPPLEMENT|purses|food intake
58491951|NCT02334540|DIETARY_SUPPLEMENT|a calorie/protein matched smoothie|
58491952|NCT03458195|OTHER|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
58479422|NCT00188344|PROCEDURE|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
58479423|NCT00188344|PROCEDURE|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
58479424|NCT01100619|DRUG|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
58479425|NCT01100619|DRUG|XL184|dosed with capsules daily
58479426|NCT04698369|DEVICE|Vibration Massage Therapy|WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
58479427|NCT05026593|DRUG|Carboplatin|Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
58479428|NCT05026593|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
58479429|NCT05026593|DRUG|Etoposide|Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
58479430|NCT05026593|DRUG|Sintilimab|Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
58479431|NCT05026593|DRUG|IBI110|IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
58479432|NCT03719079|DEVICE|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
58479433|NCT06392477|DRUG|DR-0201|DR-0201 is a bispecific antibody
58479434|NCT03824249|DIAGNOSTIC_TEST|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
58479435|NCT02057250|DRUG|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
58479436|NCT02057250|DEVICE|Auto-Injector Device (AID)|
58479437|NCT02057250|DEVICE|Pre-filled Syringe (PFS)|
58479438|NCT02057250|DRUG|Methotrexate|Dispensed according to local practice.
58479439|NCT02057250|DRUG|Sulfasalazine|Dispensed according to local practice.
58479440|NCT02057250|DRUG|Leflunomide|Dispensed according to local practice.
58479441|NCT02057250|DRUG|Hydroxychloroquine|Dispensed according to local practice.
58479442|NCT02700906|DRUG|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
58479443|NCT02700906|DRUG|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
58479444|NCT05647317|OTHER|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
58479445|NCT02815501|BIOLOGICAL|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
58479446|NCT03413488|OTHER|kinesio taping|Apply exercise and kinesio taping for intervention
58479447|NCT03413488|OTHER|exercise|Apply only exercise intervention
58479448|NCT01595542|BEHAVIORAL|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~1. Cover letter~2. Vaccine promotional flyer~3. Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~4. Improved consent form~5. Note advertising a lottery for free movie tickets for returning the consent form~6. Self-addressed stamped envelope"
58479449|NCT02904278|OTHER|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
58479450|NCT02904278|OTHER|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
58479451|NCT00855881|DRUG|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
58479452|NCT03397810|RADIATION|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
58479453|NCT01574469|OTHER|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
58479454|NCT01574469|OTHER|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
58479455|NCT04889638|OTHER|Cessation Intervention|"1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging"
58479456|NCT00437229|DRUG|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
58479457|NCT00437229|DRUG|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
58479458|NCT00437229|DRUG|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
58479459|NCT03340675|DRUG|Ifetroban|Weight based, once daily oral ifetroban
58479460|NCT03340675|DRUG|Placebo|Matching oral placebo
58479461|NCT01434212|DRUG|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
58479462|NCT04235608|DRUG|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
58479463|NCT04235608|DRUG|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
58479464|NCT02106598|DRUG|fluorescent cRGDY-PEG-Cy5.5-C dots|
58479465|NCT05114954|DEVICE|CardioPulsesTM pulsed field ablation system|Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
58479466|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
58479467|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
58479468|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
58479469|NCT03755778|DRUG|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
58479470|NCT03755778|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
58479471|NCT03755778|DRUG|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
58479472|NCT00897494|GENETIC|protein expression analysis|Venous blood collection
58479473|NCT00897494|OTHER|laboratory biomarker analysis|Venous blood collection
58479474|NCT00897494|OTHER|mass spectrometry|Venous blood collection
58479475|NCT00897494|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
58479476|NCT02061488|OTHER|open-loop night|During the open-loop night the patient is using his insulin pump as usual
58479477|NCT02061488|OTHER|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
58479478|NCT06044779|PROCEDURE|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
58479479|NCT06044779|PROCEDURE|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
58479480|NCT04613648|DIAGNOSTIC_TEST|Imaging|Ultrasonographic imaging of the shoulder
58479481|NCT00131079|BEHAVIORAL|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
58479482|NCT00131079|BEHAVIORAL|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
58479483|NCT04046913|BEHAVIORAL|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
57785211|NCT05079880|DRUG|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
57785212|NCT05079880|DRUG|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
58479484|NCT04240535|DRUG|OnabotulinumtoxinA 50 UNT [Botox Cosmetic]|Injections to the Depressor Anguli Oris
58479485|NCT00842335|DRUG|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
58479486|NCT04114760|DEVICE|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
58479487|NCT04114760|DEVICE|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
58479488|NCT06409546|DRUG|Tocopherol and pentoxifilline topical gel|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
58479489|NCT06409546|DRUG|Placebo|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
58479490|NCT02686749|DEVICE|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
58479491|NCT02686749|DRUG|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
58479492|NCT01238068|DEVICE|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
57785213|NCT00130650|DEVICE|Pain Ease|
57785214|NCT05556746|DRUG|Bedaquiline|Daily therapy for 12 weeks
58479493|NCT04254458|DIAGNOSTIC_TEST|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
57785215|NCT05556746|DRUG|Clofazimine|Daily therapy for 12 weeks
57785216|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 12 weeks
58479494|NCT00761995|DRUG|Azopt|topical eye drop dosed 1 drop 3 times daily
58479495|NCT00761995|DRUG|Cosopt|topical eye drop dosed 1 drop 2 times daily
58479496|NCT04757168|DEVICE|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
58479497|NCT05468996|DRUG|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
58479498|NCT02382536|DEVICE|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
58479499|NCT02382536|DEVICE|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
58479500|NCT03160443|BEHAVIORAL|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
58479501|NCT04942821|PROCEDURE|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
58479502|NCT04942821|PROCEDURE|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
58479503|NCT03693924|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
58479504|NCT00491634|DRUG|treosulfan|12 g/m2 x 3 days
58479505|NCT00491634|DRUG|Treosulfan|12 g/m2 x 3
58479506|NCT02936804|DEVICE|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
58479507|NCT01614886|DRUG|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
58479508|NCT01614886|DRUG|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
58479509|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose A - single-dose intravenous infusion
58479510|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose B - single-dose subcutaneous injection
58479511|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose C - single-dose subcutaneous injection
58479512|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose D - single-dose subcutaneous injection
58479513|NCT06655129|DEVICE|intense pulsed light|intense pulsed light (IPL) using the Medical Device Anthelia
58479514|NCT01660048|PROCEDURE|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
58479515|NCT01660048|PROCEDURE|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
58479516|NCT03426891|DRUG|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
58479517|NCT03426891|DRUG|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
58491953|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
58491954|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
58479518|NCT03426891|DRUG|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
58479519|NCT03426891|RADIATION|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
58479520|NCT05784493|OTHER|Study group|Washing by heated saline group
58479521|NCT04393454|DRUG|Sirolimus 2mg Tablet|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
58479522|NCT01181063|DRUG|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
58479523|NCT06526039|OTHER|a novel short regimen|An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
58479524|NCT00914316|DRUG|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
58479525|NCT00914316|DRUG|Placebo|twice daily
58479526|NCT00057720|DRUG|TLK286 HCl for injection|
58479527|NCT00057720|DRUG|topotecan hydrochloride for injection|
58479528|NCT00057720|DRUG|doxorubicin HCl liposome injection|
58479529|NCT03678493|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Oral Capsule
58479530|NCT03678493|OTHER|Placebo|Oral Capsule
58479531|NCT04418648|DRUG|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
58479532|NCT01063751|DEVICE|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
58479533|NCT05338346|DRUG|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
58479534|NCT05379374|COMBINATION_PRODUCT|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
58479535|NCT01025726|BEHAVIORAL|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
58479536|NCT01025726|BEHAVIORAL|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
58479537|NCT01025726|BEHAVIORAL|General Health Education|Host community events for chronic disease education
58479538|NCT01082016|OTHER|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
58479539|NCT03549182|DRUG|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
58479540|NCT03549182|DRUG|placebo treatment|oral administration of placebo (102.3g)
58479541|NCT00335088|DRUG|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
58479542|NCT01929317|DRUG|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
58479543|NCT01929317|DRUG|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
58479544|NCT01929317|DRUG|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
58479545|NCT00003449|DRUG|dexamethasone|
58479546|NCT00003449|DRUG|gemcitabine hydrochloride|
58479547|NCT00003449|DRUG|paclitaxel|
58479548|NCT00752778|OTHER|pet-scan FDG-F18|
58479549|NCT06530147|OTHER|Transversalis Fascia Plane Block|One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
58479550|NCT06530147|OTHER|Transversus Abdominis Plane Block|One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
58479551|NCT04681443|DRUG|Crystallized phenol application|Crystallized phenol application into the sinus tract
58479552|NCT06232304|BEHAVIORAL|TEACH|TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
58479553|NCT05373407|OTHER|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
58479554|NCT02928042|OTHER|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
57785217|NCT05556746|DRUG|Delamanid|Daily therapy for 12 weeks
57785218|NCT05556746|DRUG|Rifampin|Daily therapy for 26 weeks
57785219|NCT05556746|DRUG|Isoniazid|Daily therapy for 26 weeks
58479555|NCT06379204|BEHAVIORAL|the maximum physiological value standardized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and HRR heart rate reserve method, gradually increasing.
58479556|NCT06379204|BEHAVIORAL|the ventilatory threshold individualized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and three zone threshold model, gradually increasing.
58479557|NCT06127030|BEHAVIORAL|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
58479558|NCT06127030|BEHAVIORAL|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
58479559|NCT02952404|PROCEDURE|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
58479560|NCT01812252|DRUG|Azacitidine (AZC)|Given IV or SC
58479561|NCT01812252|DRUG|Decitabine|Given IV or SC
58479562|NCT01812252|OTHER|Quality-of-Life Assessment|Ancillary studies
58479563|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
58479564|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
58479565|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
58479566|NCT05304195|DIAGNOSTIC_TEST|Glucocerebrosidase|Blood sample (10ml) for GCase activity
58479567|NCT05304195|GENETIC|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
58479568|NCT05304195|DIAGNOSTIC_TEST|Macrophage biomarkers|Blood sample (20ml) for macrophage biomarkers
58479569|NCT00169897|BEHAVIORAL|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
57785220|NCT05556746|DRUG|Ethambutol|Daily therapy for 8 weeks
57785221|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 8 weeks
58135316|NCT05979779|DRUG|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
58135317|NCT05979779|OTHER|Placebo|Placebo
58135318|NCT04583852|OTHER|AIVÍA, Ultra-Brightening Spot Micro-needle Patch|a dissolving micro-needle patch, contains active ingredients
58479570|NCT02252003|OTHER|Pain scales testing|
58479571|NCT03837223|DRUG|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
58479572|NCT00180778|DRUG|Low dose steroids|
58479573|NCT03343912|DRUG|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
58479574|NCT03343912|DRUG|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
58479575|NCT03343912|DRUG|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
58479576|NCT00658385|GENETIC|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
58479577|NCT05956015|OTHER|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
58479578|NCT02751723|OTHER|validated questionnaires|
58479579|NCT00334048|DRUG|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
57785222|NCT01611103|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
57785223|NCT02268396|DRUG|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
58135319|NCT04583852|OTHER|Placebo Micro-needle Patch|matching placebo will be provided as a dissolving micro-needle patch
58135320|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
58135321|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
57785224|NCT03413371|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
58479580|NCT05201313|DRUG|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
58479581|NCT05201313|DRUG|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
58479582|NCT03826303|OTHER|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
58479583|NCT03826303|OTHER|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
58479584|NCT03826303|OTHER|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
58479585|NCT03826303|OTHER|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
58479586|NCT04146948|OTHER|no intervention|no intervention in this study
58479587|NCT05505955|DRUG|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
58479588|NCT05505955|DRUG|Placebo|Subjects took Placebo in Part 1 and Part 2.
58479589|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
58479590|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
58479591|NCT00135824|DRUG|Povidone K25 eye drops (povidone)|
58479592|NCT02348749|RADIATION|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
58479593|NCT02348749|DEVICE|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
58479594|NCT02348749|OTHER|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
58479595|NCT02352896|DRUG|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
58479596|NCT05813600|DRUG|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
58479597|NCT00684021|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
58479598|NCT00684021|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
58479599|NCT02785549|DRUG|Ibuprofen|600 mg/8hours
58479600|NCT02785549|DRUG|Acetaminophen|1 g/8 hours
58479601|NCT02785549|DRUG|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
58479602|NCT00225316|PROCEDURE|Acupuncture|See Detailed Description.
58479603|NCT02070536|OTHER|sRAGE|
58479604|NCT03975985|OTHER|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
58135322|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
58479605|NCT03975985|OTHER|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
58479606|NCT01656408|DRUG|MK-8150|
58479607|NCT01656408|DRUG|Placebo for MK-8150|
58479608|NCT03119987|DIAGNOSTIC_TEST|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
58479609|NCT04495595|OTHER|No intervention|There is no intervention due to the observational, cross-sectional design of the study
58479610|NCT02282618|DEVICE|Cardiac Sympathetic Blockade|
58479611|NCT00784914|DRUG|temsirolimus|Receive temsirolimus IV
58479612|NCT00784914|OTHER|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
58479613|NCT00784914|OTHER|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
58479614|NCT02267837|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
58479615|NCT04855851|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
58479616|NCT04855851|PROCEDURE|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
58479617|NCT05153616|DIAGNOSTIC_TEST|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
58479618|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous KR|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
58479619|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous PS|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous PS femoral component"
58479620|NCT06373965|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
58479621|NCT05755516|DEVICE|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
58479622|NCT05755516|DEVICE|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
58479623|NCT02762916|OTHER|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
58479624|NCT04771117|BEHAVIORAL|Fear of Covid-19 Scale|"The Fear of Covid-19 Scale (FCV-19S) is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. The FVC-19S consists of seven items, such as It makes me uncomfortable to think about coronavirus-19, I am afraid of losing my life because of coronavirus-19, and When watching news and stories about coronavirus-19 on social media, I become nervous or anxious, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19."
58479625|NCT02556177|PROCEDURE|MRI|MRI scanning
58479626|NCT02704364|BIOLOGICAL|NGM282|
58479627|NCT02704364|OTHER|Placebo|
58479628|NCT06016504|BEHAVIORAL|Health Education|Participate in an adaptive virtual consultation
58479629|NCT06016504|BEHAVIORAL|Health Education|Participate in a non-adaptive virtual consultation
58479630|NCT06016504|OTHER|Informational Intervention|Given information-only
58479631|NCT06016504|OTHER|Survey Administration|Ancillary studies
58479632|NCT05647798|OTHER|Blood sugar check every 2 hours|Blood sugar check every 2 hours
58479633|NCT05647798|OTHER|Blood sugar check every 4 hours|Blood sugar check every 4 hours
58479634|NCT06164002|OTHER|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
58479635|NCT02917096|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
58479636|NCT02917096|DRUG|Fludarabine|Given IV
58479637|NCT02917096|DRUG|Fludarabine Phosphate|Given IV
58479638|NCT02917096|OTHER|Laboratory Biomarker Analysis|Correlative studies
58479639|NCT02917096|DRUG|Melphalan|Given IV
58479640|NCT02917096|OTHER|Pharmacological Study|Correlative studies
58135323|NCT05240222|BEHAVIORAL|Pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
58479641|NCT02917096|DRUG|Ruxolitinib|Given PO
58479642|NCT02917096|DRUG|Ruxolitinib Phosphate|Given PO
58479643|NCT02917096|DRUG|Sirolimus|Given PO
58479644|NCT02917096|DRUG|Tacrolimus|Given IV and PO
58479645|NCT00416910|BIOLOGICAL|Filgrastim|
58479646|NCT00416910|DRUG|Fludarabine|
58479647|NCT00416910|DRUG|Cyclophosphamide|
58479648|NCT00416910|DRUG|Mitoxantrone|
58479649|NCT06298799|GENETIC|DNA Sequencing and Analysis|DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
58479650|NCT06298799|GENETIC|differential expression analysis with RNA-sequencing (RNA seq) experiments|Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
58479651|NCT06047015|COMBINATION_PRODUCT|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
58479652|NCT06047015|COMBINATION_PRODUCT|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
58479653|NCT02874040|PROCEDURE|Endoresection|Endoresection of the tumor scar
58479654|NCT02874040|PROCEDURE|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
58479655|NCT03856788|DRUG|Saline|40 mL sterile normal saline
58479656|NCT03856788|DRUG|Bupivacaine|40 mL 0.25% bupivacaine
58479657|NCT04815941|OTHER|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
58479658|NCT01112917|DEVICE|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
58479659|NCT01112917|PROCEDURE|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
58479660|NCT02868593|OTHER|Pharyngeal swab|
58479661|NCT04324437|OTHER|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
58479662|NCT00494676|DEVICE|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
58479663|NCT00494676|DEVICE|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
58479664|NCT06654284|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at predeifined time points (baseline, 3 months, 1 year, 3 year, 6 year, 9 year and 12 year) collecting a complete overview of different aspects of quality of life, including: - Florida patient acceptance score (FPAS) - Short Form Health Survey (SF-12) - Kansas City Cardiomyopathy Questionnaire (KCCQ-12) - Hospital Anxiety and Depression Scale (HADS) - Florida Shock Acceptance score (FSAS) - Steinke Sexual Concerns Inventory - the Good Death questionnaire"
58479665|NCT01520506|DEVICE|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
58479666|NCT00005804|DRUG|cyclophosphamide|
58479667|NCT00005804|PROCEDURE|allogeneic bone marrow transplantation|
58479668|NCT00005804|RADIATION|radiation therapy|
58479669|NCT05876182|DRUG|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
58479670|NCT05876182|OTHER|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
58479671|NCT06284889|BEHAVIORAL|Behavioural activation|"Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log;~Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
58479672|NCT06284889|OTHER|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
58479673|NCT02141295|DRUG|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
58479674|NCT02141295|DRUG|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
58138946|NCT03699020|OTHER|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
58479675|NCT02141295|DRUG|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
58479676|NCT02141295|DRUG|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
58479677|NCT02141295|DRUG|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
58479678|NCT05689476|DEVICE|NAVA GROUP|NAVA ventilation: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
58479679|NCT05234307|DRUG|Adenosine A2B Receptor Antagonist PBF-1129|Given PO
58479680|NCT05234307|PROCEDURE|Biospecimen Collection|Correlative studies
58479681|NCT05234307|BIOLOGICAL|Nivolumab|Given IV
58479682|NCT00912535|DRUG|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
58479683|NCT00912535|DRUG|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
58479684|NCT02987686|DRUG|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
58479685|NCT02585856|DEVICE|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
58479686|NCT02585856|DEVICE|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
58479687|NCT06110026|OTHER|Brunkow Exercise Program|The brunkow exercise program will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
58479688|NCT06110026|OTHER|Lumbar Stabilization Exercises|The lumbar stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
58479689|NCT01626469|DRUG|Captopril|25mg Captopril
58479690|NCT01626469|DRUG|placebo|placebo
58479691|NCT01701947|BIOLOGICAL|Hemoleven|Replacement therapy
58479692|NCT01840241|DRUG|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
58479693|NCT01840241|DRUG|normal saline|
58479694|NCT05318417|DEVICE|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
58479695|NCT06055946|DEVICE|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
58479696|NCT04004988|DRUG|Tirzepatide|Administered SC
58479697|NCT04004988|DEVICE|Prefilled syringe (PFS)|PFS used to administer tirzepatide
58479698|NCT04004988|DEVICE|Auto-injector (AI)|AI used to administer tirzepatide
58479699|NCT00419406|PROCEDURE|UVA1 phototherapy|
58479700|NCT00419406|PROCEDURE|NB-UVB phototherapy|
58479701|NCT06654362|BEHAVIORAL|nutritional interventions include education and modifying company's restaurant menu|"* Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake."
58479702|NCT03909789|DIETARY_SUPPLEMENT|Plant based bioequivalent Nitrate supplementation|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
58479703|NCT03909789|DIETARY_SUPPLEMENT|Placebo|Placebo
58479704|NCT00872820|BEHAVIORAL|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
58479705|NCT00872820|BEHAVIORAL|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
58479706|NCT06600893|DEVICE|Low intensity shockwave therapy (LiSWT)|The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment
58479707|NCT06600893|DEVICE|Sham|With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.
58479708|NCT06514625|DEVICE|splint|ready night splints
58479709|NCT04785313|BIOLOGICAL|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
58479710|NCT04785313|OTHER|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
58479711|NCT00668278|DEVICE|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
58479712|NCT00668278|DEVICE|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
58479713|NCT00668278|OTHER|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
58479714|NCT04268667|OTHER|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
58479715|NCT02732574|DEVICE|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
58479716|NCT02732574|DEVICE|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
58479717|NCT01874899|DEVICE|RestoreSensor Neurostimulation|
58479718|NCT02237417|DRUG|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
58479719|NCT02237417|DRUG|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
58479720|NCT02237417|OTHER|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
58479721|NCT04139018|DRUG|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
58479722|NCT04139018|DRUG|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
58479723|NCT02951377|OTHER|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
58479724|NCT02951377|DRUG|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
58479725|NCT03672708|DIAGNOSTIC_TEST|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
58479726|NCT03863080|DRUG|RVT-1401|Subcutaneous administration of RVT-1401
58479727|NCT03863080|DRUG|Placebo|Subcutaneous administration of Placebo
58479728|NCT00961077|DRUG|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
58479729|NCT02628990|OTHER|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
58479730|NCT02628990|OTHER|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
58479731|NCT02628990|OTHER|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
58479732|NCT02628990|OTHER|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
58479733|NCT02628990|OTHER|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
58135324|NCT05240222|OTHER|Sham comparator|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
58479734|NCT06297369|DRUG|N acetyl cysteine|N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
58479735|NCT04497259|OTHER|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
58479736|NCT04497259|OTHER|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
58479737|NCT04497259|OTHER|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
58479738|NCT00905944|OTHER|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
58479739|NCT06615349|BEHAVIORAL|DigiPall|DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.
58479740|NCT06486194|DEVICE|Targeted breast milk fortification using preemie device|Mother's breast milk will have additional macronutrient added to it based on analysis with the Preemie device, to ensure it meets current European recommendations for nutrient intakes for preterm infants
58479741|NCT06486194|DIETARY_SUPPLEMENT|Standard Breast milk fortification|Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants
58479742|NCT05642403|DRUG|XW001|Inhaled XW001
58135325|NCT05696470|DEVICE|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
58135326|NCT04443660|OTHER|Blood test|Blood samples taken to test levels of autophagy and apoptosis
58135327|NCT00172055|DRUG|Zoledronic acid|
58135328|NCT01809171|DRUG|Vitamin D3|ampoule
58479743|NCT05642403|DRUG|Placebo|Matched inhaled placebo
58479744|NCT02531802|BIOLOGICAL|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~* Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~* E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~* E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~* E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~* E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
58479745|NCT02531802|BIOLOGICAL|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
58479746|NCT02531802|OTHER|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
58135329|NCT01809171|DRUG|Placebo|ampoule
58479747|NCT06267755|OTHER|Extracorporeal Shockwave therapy|the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
58479748|NCT06267755|OTHER|Traditional physical therapy|the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
58479749|NCT05760339|BEHAVIORAL|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
58135330|NCT05354648|PROCEDURE|Hypoxic-hyperoxic preconditioning|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
58479750|NCT05760339|DIETARY_SUPPLEMENT|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
58479751|NCT00936286|DEVICE|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
58479752|NCT01074814|DRUG|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
58479753|NCT06371092|DRUG|UltraEZ|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
58479754|NCT06371092|DRUG|Placebo|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
58479755|NCT00289042|DRUG|Enoxaparin|
58479756|NCT04336917|DRUG|Rhomboid Intercostal and Subserratus Plane Block with local anesthetic|Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
58479757|NCT04461717|DEVICE|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
58479758|NCT01491607|BIOLOGICAL|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
58479759|NCT01682889|DIETARY_SUPPLEMENT|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
58479760|NCT01682889|DIETARY_SUPPLEMENT|Placebo|NaCl 0.9% intravenously for 24h
58479761|NCT05251480|PROCEDURE|Standard of Care|debridement, wound dressings, offloading
58479762|NCT05251480|OTHER|DermGEN™|Decellularized human dermal matrix created from donated human skin
58479763|NCT03503032|PROCEDURE|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]
58479764|NCT03503032|PROCEDURE|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
58479765|NCT05327348|DRUG|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
58479766|NCT05327348|DRUG|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
58479767|NCT03959891|DRUG|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
58479768|NCT03959891|DRUG|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
58479769|NCT03959891|DRUG|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
58479770|NCT03959891|DRUG|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
58138947|NCT06346730|DEVICE|Virtual reality glasses to intervention group|experimental and control ,a randomized pretest-posttest study to examine
58479771|NCT05101122|DRUG|Dosing 1: Atomoxetine|Oral administration at bedtime
58479772|NCT05101122|DRUG|AD313|Escalating dose of AD313; Oral administration at bedtime
58479773|NCT03472885|DRUG|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
58479774|NCT03472885|DRUG|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
58479775|NCT03056196|DIAGNOSTIC_TEST|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
58479776|NCT06086769|DEVICE|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
58479777|NCT01735006|BIOLOGICAL|HPV Vaccine|3 doses at month 0,1 and 6
58479778|NCT01735006|BIOLOGICAL|HEV vaccine|3 doses at month 0,1 and 6
58479779|NCT06573879|BEHAVIORAL|Eccentric Exercise|It was investigated whether volleyball athlete participants would develop muscle architecture, muscle strength and performance parameters differently from the control group by performing eccentric exercises in addition to their exercise routines.
58479780|NCT02808598|BEHAVIORAL|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
58479781|NCT01109472|OTHER|patient magazine|patient magazine individually tailored to patient's prior feedback
58479782|NCT03713658|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
58479783|NCT03713658|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
58479784|NCT03713658|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
58479785|NCT03713658|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
58479786|NCT03713658|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
58479787|NCT03713658|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
58479788|NCT03713658|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
58479789|NCT03713658|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
58479790|NCT03713658|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
58479791|NCT04806464|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
58479792|NCT04845282|DIETARY_SUPPLEMENT|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
58479793|NCT04845282|DIETARY_SUPPLEMENT|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
58479794|NCT00003553|OTHER|HLA Matched Peripheral BLood Stem Cells|Cell Product
58479795|NCT01703767|BEHAVIORAL|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
58479796|NCT04293406|OTHER|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
58479797|NCT04659876|DIAGNOSTIC_TEST|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
58479798|NCT06315712|OTHER|inspiratory exercise|The training consisted of 6 sets of 30 breaths per day, divided into 2 sessions per day. A one-minute rest interval between each set. Training was prescribed 5 days a week for 8 weeks
58479799|NCT06315712|OTHER|Pulmonary rehabilitation|Four resistive exercises, aerobic exercise, and deep breathing exercises, five sessions per week for 8 weeks
58479800|NCT02372955|DRUG|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
58479801|NCT02372955|DRUG|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
58479802|NCT00013533|PROCEDURE|Stem cell transplantation|\>3 x 106/kg CD34+ stem cells by IV infusion
58479803|NCT00220896|DRUG|Donepezil|
58479804|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
58479805|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
58479806|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
58479807|NCT01046487|PROCEDURE|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
58479808|NCT02911844|DRUG|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
58479809|NCT00232661|DRUG|ARIMIDEX (anastrazole)|
58479810|NCT00232661|DRUG|NOLVADEX (tamoxifen)|
58479811|NCT06586983|DRUG|Tenofovir Disoproxil Fumarate|300 mg po OD
58479812|NCT03052075|OTHER|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
58479813|NCT06655597|DIETARY_SUPPLEMENT|REDS Powder|Dietary supplement powder
58479814|NCT01590719|DRUG|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479815|NCT01590719|DRUG|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479816|NCT01590719|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479817|NCT01590719|DRUG|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479818|NCT01590719|DRUG|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479819|NCT01590719|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
58479820|NCT03912194|BEHAVIORAL|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
58479821|NCT03912194|BEHAVIORAL|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
58479822|NCT03912194|BEHAVIORAL|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
58479823|NCT03631992|BEHAVIORAL|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
58479824|NCT03631992|BEHAVIORAL|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
58479825|NCT03859934|DRUG|Melatonin|Melatonin treatment
58479826|NCT03859934|DRUG|Placebo Oral Tablet|Placebo treatment
58479827|NCT01087463|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
58479828|NCT04949997|OTHER|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
58479829|NCT06655116|BEHAVIORAL|Diabetic Foot Education|"Patients in the intervention group will be interviewed and their diabetic foot knowledge will be evaluated. During the interview, the individual's knowledge about the definition of diabetic foot, risk factors, symptoms, treatment, complications, care and prevention will be evaluated.~In order to systematically plan, implement and evaluate the training to be used in the intervention, it is aimed to implement androgogical training based on the 'Interpersonal Relations Theory'. In this context, the stages in the theory will be followed as follows."
58479830|NCT04804384|DEVICE|Prehension neuroprosthesis|"The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive."
58479831|NCT02266511|DRUG|Flomax®, Norman II facility|
57785225|NCT03413371|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
58135331|NCT05354648|PROCEDURE|Placebo|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
58479832|NCT02266511|DRUG|Flomax®, Nishine facility|
58479833|NCT00494728|BEHAVIORAL|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
58479834|NCT00494728|DRUG|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
58479835|NCT00494728|BEHAVIORAL|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
58479836|NCT05689996|DRUG|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
58479837|NCT05371652|DRUG|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
58479838|NCT02040324|DEVICE|Laryngeal mask with gastric access|
58479839|NCT02040324|DEVICE|Endotracheal tube|
58479840|NCT02132026|DRUG|Denosumab|
58479841|NCT02132026|DRUG|Alendronic Acid|
58479842|NCT02132026|DRUG|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
58479843|NCT02132026|DRUG|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
58479844|NCT00119184|PROCEDURE|External cephalic version|7.5 mg bupivacaine intrathecally
58479845|NCT00119184|DRUG|spinal anesthesia|spinal anesthesia
58479846|NCT05590923|DRUG|OLA group: Olanzapine|"OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)."
58479847|NCT05590923|DRUG|DEX group: Dexamethasone|"DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC)."
58479848|NCT00389038|BEHAVIORAL|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
58479849|NCT00389038|BEHAVIORAL|Headache Education|Behavioral Treatment 2 (headache education)
58479850|NCT00389038|DRUG|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
58479851|NCT03529032|DRUG|Methadone|methadone for control postoperative pain
58479852|NCT01839955|DRUG|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
58479853|NCT01839955|DRUG|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
58479854|NCT01839955|OTHER|laboratory biomarker analysis|Correlative studies
58479855|NCT01839955|OTHER|pharmacological study|Correlative studies
58479856|NCT01839955|DRUG|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
58479857|NCT05365425|DRUG|Choline fenofibrate|choline fenofibrate 178.8mg (135mg as fenofibric acid)
58479858|NCT05365425|DRUG|Policosanol|policosanol 10mg
58479859|NCT01099176|DRUG|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
58479860|NCT05929300|BEHAVIORAL|Yoga|The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.
58479861|NCT05929300|OTHER|Usual Care|"This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
58479862|NCT05333198|OTHER|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
58479863|NCT05333198|OTHER|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
58479864|NCT05654974|OTHER|measurements and questionnaire|paper-based survey administration; erect penis length and girth measurements
58479865|NCT01444612|DRUG|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
58479866|NCT01444612|DRUG|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
58479867|NCT01444612|DRUG|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
58479868|NCT01444612|DRUG|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
58479869|NCT00519753|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
58479870|NCT00740038|BEHAVIORAL|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, \& provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
58479871|NCT00740038|BEHAVIORAL|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
58479872|NCT00740038|BEHAVIORAL|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
58479873|NCT00740038|BEHAVIORAL|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
58479874|NCT03715348|DRUG|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
58479875|NCT03715348|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
58479876|NCT06590298|DRUG|Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females|The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
58479877|NCT02317471|BIOLOGICAL|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
58479878|NCT02317471|DRUG|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
58479879|NCT06602947|OTHER|Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation|"1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
58479880|NCT02651675|GENETIC|AAV directed hLDLR gene therapy|AAV directed hLDLR gene therapy is a novel adeno-associated viral (AAV8) vector with human low-density lipoprotein receptor (hLDLR) gene
58479881|NCT05257850|DEVICE|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
58479882|NCT05257850|DEVICE|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
58479883|NCT02271204|DRUG|Ibandronic acid|As prescribed by physician
58479884|NCT05322681|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
58479885|NCT00260533|DRUG|atomoxetine|Flexible dose, up to 50 mg per day
58479886|NCT00260533|DRUG|placebo|placebo (matching to atomoxetine)
58479887|NCT03510546|DRUG|Pyridostigmine|Study dose as per protocol.
58479888|NCT03510546|DRUG|Placebo oral capsule|Study dose as per protocol.
58479889|NCT01161277|DRUG|Aripiprazole|Dose: 5-10 mg depending on subject weight
58479890|NCT01161277|DRUG|Haloperidol|Dose: 1-2 mg depending on subject weight
58479891|NCT01161277|DRUG|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
58479892|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Single Dose|Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
58479893|NCT04277897|DRUG|Placebo|Placebo to match Hepenofovir Fumarate Tablets
58479894|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Dose4|Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
58479895|NCT06655766|PROCEDURE|socket-plug technique with putty bone|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material."
58479896|NCT06655766|PROCEDURE|Ice cream cone technique|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane"
58479897|NCT03758053|OTHER|No intervention|No intervention
58479898|NCT06520917|DEVICE|Locator-Positioner (LOPO) Guide Device|Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
58479899|NCT00002476|BIOLOGICAL|bleomycin sulfate|
58135332|NCT04231084|DRUG|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
58479900|NCT00002476|DRUG|fluorouracil|
58479901|NCT00002476|DRUG|leucovorin calcium|
58479902|NCT00002476|DRUG|methotrexate|
58479903|NCT00002476|DRUG|vincristine sulfate|
58479904|NCT00002476|RADIATION|low-LET cobalt-60 gamma ray therapy|
58479905|NCT00002476|RADIATION|low-LET photon therapy|
58479906|NCT00002476|RADIATION|radiation therapy|
58479907|NCT04074889|DIETARY_SUPPLEMENT|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
58479908|NCT04074889|OTHER|Placebo|Placebo sachet with no microbial cell preparation
58479909|NCT04718155|DRUG|Atorvastatin|will receive 40 mg atrorvastatin 2 days
58479910|NCT04718155|OTHER|placebo|will receive 40 mg placebo 2 days
58479911|NCT05703711|BEHAVIORAL|mHealer|MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
58479912|NCT05846984|BEHAVIORAL|Learning Skills Together Intervention|Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.
58479913|NCT05846984|BEHAVIORAL|Caregiver Healthy Living Intervention|Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
58479914|NCT01131832|DIETARY_SUPPLEMENT|Plant sterol|
58479915|NCT01131832|DIETARY_SUPPLEMENT|Placebo|
58479916|NCT00999804|DRUG|Lapatinib|1000 mg of Lapatinib by mouth daily
58479917|NCT00999804|DRUG|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
58479918|NCT00999804|DRUG|Trastuzumab|6 mg/kg intravenously, every 3 weeks
58479919|NCT00722072|DRUG|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
58479920|NCT00722072|DRUG|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
58479921|NCT02048670|DEVICE|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
58479922|NCT03612934|PROCEDURE|Specialist Palliative Care|In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
58479923|NCT03367793|DEVICE|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
58479924|NCT03367793|DEVICE|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
58479925|NCT03367793|DEVICE|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
58479926|NCT02129699|DRUG|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
58479927|NCT02129699|OTHER|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
58479928|NCT02557139|DRUG|Belumosudil Tablet|
58479929|NCT02557139|DRUG|Belumosudil Capsule|
58479930|NCT01054989|BIOLOGICAL|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
58479931|NCT05931302|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
58479932|NCT06654661|DEVICE|3D-Printed Mechanical Balancer|The 3D printed mechanical balancer is a surgeon-controlled handheld intraoperative tool used that provides a quantifiable measurement of force differences on the medial and lateral sides to guide achievement of a balanced knee. It will be used at one timepoint during scheduled TKA surgery while the patient is under anesthesia. Readings will be taken at 0, 45, and 90 degrees of flexion.
58479933|NCT02510521|DEVICE|acute muscle exercise by NMES|
58479934|NCT02510521|DEVICE|daily workout sequence with NMES in one week|
58479935|NCT02510521|OTHER|rest situation|
58479936|NCT05860946|DEVICE|Remote ischemic conditioning|The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
58479937|NCT00492258|DRUG|sorafenib tosylate|
58479938|NCT00492258|PROCEDURE|adjuvant therapy|
58479939|NCT00391586|DRUG|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
58479940|NCT00391586|DRUG|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
58479941|NCT05072600|DRUG|Pembrolizumab|pembrolizumab 200 mg Q3W
58479942|NCT01547611|OTHER|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
58479943|NCT01547611|OTHER|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
58479944|NCT02915822|PROCEDURE|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
58479945|NCT02915822|PROCEDURE|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
58479946|NCT03219723|DRUG|Vonoprazan|Vonoprazan tablets
58479947|NCT03219723|DRUG|Amoxicillin hydrate|Amoxicillin hydrate (potency)
58479948|NCT03219723|DRUG|Clarithromycin|Clarithromycin (potency)
58479949|NCT03219723|DRUG|Metronidazole|Metronidazole
58479950|NCT05623878|DRUG|68Ga-labeled NY108|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
58479951|NCT05567783|BIOLOGICAL|VIR-2482 (450 mg)|VIR-2482 450mg given by intramuscular injection
58479952|NCT05567783|BIOLOGICAL|VIR-2482 (1200 mg)|VIR-2482 1200 mg given by intramuscular injection
58479953|NCT05567783|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
58479954|NCT00871975|DEVICE|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
58479955|NCT06129708|OTHER|Aquatic Exercise|The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and
58479956|NCT06129708|OTHER|Aerobic Exercise|The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).
58479957|NCT02864290|DRUG|ASP1235|intravenous (IV) infusion
58479958|NCT04491318|OTHER|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
58479959|NCT04668755|DEVICE|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
58479960|NCT04668755|DEVICE|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
58479961|NCT03854266|DRUG|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
58479962|NCT03854266|DRUG|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
58479963|NCT03854266|DEVICE|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
58479964|NCT02243995|OTHER|Physical training|
58479965|NCT02243995|BEHAVIORAL|Physical training|
58479966|NCT00551317|DRUG|Darapladib (SB480848)|
58479967|NCT06598176|DEVICE|Colli-Pee 20mL device with UCM|Women will collect a first-void urine (the initial part of the urine stream) sample at home the day before a hospital appointment using the 20mL Colli-Pee device prefilled with urine conservation medium (UCM, Novosanis, Belgium).
58479968|NCT06598176|DEVICE|Evalyn Brush|Women will collect a vaginal self-sample using the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before a hospital appointment.
58479969|NCT03109964|DEVICE|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
58479970|NCT03109964|DEVICE|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
58479971|NCT02917122|DEVICE|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
58479972|NCT02917122|DRUG|Sertraline|Patients will take Sertraline.
58479973|NCT02917122|DEVICE|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
58479974|NCT06380491|DRUG|Melatonin 3 MG Oral Tablet|Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
58479975|NCT05722392|PROCEDURE|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
58479976|NCT05682716|COMBINATION_PRODUCT|Controlled low central venous pressure (CLCVP) technology|Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.
58479977|NCT05682716|DRUG|Nitroglycerin|nitroglycerin (0.2-1 ug/kg \* min)
58479978|NCT06249802|DRUG|Nebivolol|12-month intake of medication
58479979|NCT06249802|DRUG|Placebo|12-month intake of matching placebo
58479980|NCT01004068|OTHER|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
58479981|NCT01004068|DRUG|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
57785226|NCT03413371|DRUG|1 % ropivacaine with of 2% lidocaine|in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
58479982|NCT01004068|BEHAVIORAL|Structured exercise program plus hypocaloric diet|SET plus diet
58479983|NCT01203969|PROCEDURE|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
58479984|NCT01203969|PROCEDURE|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
58479985|NCT03378986|PROCEDURE|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
58479986|NCT03378986|PROCEDURE|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
58479987|NCT04603599|DIAGNOSTIC_TEST|serum soluble L1CAM (sL1CAM)|blood sample
58479988|NCT05183035|DRUG|Fludarabine|Intravenous (IV) infusion
58479989|NCT05183035|DRUG|Cytarabine|Intravenous (IV) infusion
58479990|NCT05183035|DRUG|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
58479991|NCT05183035|DRUG|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
58479992|NCT05183035|DRUG|Venetoclax|Orally via tablet or powder suspension
58479993|NCT06587373|OTHER|Assessment of the quality of mother-child dyadic relationships|Filling out questionnaires
58479994|NCT05471466|PROCEDURE|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
58479995|NCT05929482|BEHAVIORAL|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
58479996|NCT03212742|DRUG|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
57785227|NCT03413371|DRUG|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
57785228|NCT03413371|DRUG|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
58135333|NCT04231084|DRUG|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
57785229|NCT03325621|BIOLOGICAL|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
58479997|NCT03212742|DRUG|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
58479998|NCT03212742|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
58479999|NCT05344313|DIETARY_SUPPLEMENT|Ensure Plus Advance|as in the arm description of the intervention
58480000|NCT01427764|DEVICE|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
58480001|NCT04652752|DEVICE|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
58480002|NCT03944577|DRUG|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
58480003|NCT02784548|OTHER|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
58480004|NCT06163690|COMBINATION_PRODUCT|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
58480005|NCT02338596|PROCEDURE|Total hip replacement|"1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
58480006|NCT00026260|DRUG|semaxanib|
58480007|NCT04958473|DRUG|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
58480008|NCT04958473|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
58480009|NCT05874635|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
58480010|NCT06655064|OTHER|None- Observational|None- Observational
58480011|NCT04588064|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
58480012|NCT01454102|BIOLOGICAL|Nivolumab|
58480013|NCT01454102|DRUG|Gemcitabine|
58480014|NCT01454102|DRUG|Cisplatin|
58480015|NCT01454102|DRUG|Pemetrexed|
58480016|NCT01454102|DRUG|Paclitaxel|
58480017|NCT01454102|DRUG|Carboplatin|
58480018|NCT01454102|DRUG|Bevacizumab|
58480019|NCT01454102|DRUG|Erlotinib|
58480020|NCT01454102|BIOLOGICAL|Ipilimumab|
58480021|NCT04663009|DEVICE|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
58480022|NCT04195763|DRUG|asfotase alfa|This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
58480023|NCT01287702|DIETARY_SUPPLEMENT|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
58480024|NCT01287702|DIETARY_SUPPLEMENT|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
57785230|NCT03325621|BIOLOGICAL|PRS-080-Placebo#001|Placebo Comparator
57785231|NCT05183009|DEVICE|eXciteOSA|eXciteOSA
57785232|NCT02748564|BIOLOGICAL|Aldesleukin|Given IV
57785233|NCT02748564|OTHER|Laboratory Biomarker Analysis|Correlative studies
57785234|NCT02748564|BIOLOGICAL|Pembrolizumab|Given IV
57785235|NCT01406860|DRUG|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
58135334|NCT03663478|DRUG|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
58480025|NCT01287702|DIETARY_SUPPLEMENT|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
58480026|NCT01523366|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
58480027|NCT01523366|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
58480028|NCT00525161|DRUG|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
58491955|NCT04484220|DEVICE|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.
58480029|NCT03367988|DRUG|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
58480030|NCT03367988|DRUG|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
58480031|NCT05494515|PROCEDURE|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
58480032|NCT06130488|BEHAVIORAL|KMC|KMC implementation as per protocol
58480033|NCT00567814|DRUG|Metyrapone|Twice daily
58480034|NCT00567814|DRUG|Oxazepam|Twice Daily
58480035|NCT00567814|DRUG|Placebo|Twice daily
58480036|NCT03126591|DRUG|Olaratumab|Administered IV
58480037|NCT03126591|DRUG|Pembrolizumab (KEYTRUDA®)|Administered IV
58480038|NCT04396756|DRUG|PLN-74809|PLN-74809
58480039|NCT04396756|DRUG|Placebo|Placebo
58480040|NCT06116669|DIETARY_SUPPLEMENT|Iron supplementation|Iron supplements as 100 mg oral iron as FeSO4 given daily
58480041|NCT06116669|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
58480042|NCT06116669|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
58480043|NCT06116669|OTHER|Placebo|matching placebo capsules given daily
58480044|NCT06116669|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
58480045|NCT05642364|BEHAVIORAL|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
57785236|NCT01406860|DRUG|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
58480046|NCT05642364|OTHER|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
58480047|NCT05019144|PROCEDURE|Face-to-face burn care|If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.
58480048|NCT05019144|PROCEDURE|Telemedicine enhanced burn care|Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
58480049|NCT04978675|DRUG|Fluorine F 18 rhPSMA-7.3|Given IV
58480050|NCT04978675|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
58480051|NCT04978675|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
58480052|NCT01096875|DRUG|Atorvastatin|40mg/day once daily for two weeks prior to surgery
58480053|NCT01096875|DRUG|Placebo|1tb/day once daily for two weeks prior to surgery
58480054|NCT00551811|DRUG|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
58480055|NCT00551811|DRUG|Placebo|Placebo tablets will be intended to be administered orally.
58480056|NCT03583814|BEHAVIORAL|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
58480057|NCT03583814|BEHAVIORAL|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
58480058|NCT02633904|PROCEDURE|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
58480059|NCT02633904|PROCEDURE|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
58491956|NCT02909543|OTHER|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
58135335|NCT03663478|DRUG|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
58480060|NCT05595213|DEVICE|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
58480061|NCT05595213|DEVICE|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
58480062|NCT05595213|OTHER|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
58480063|NCT03203096|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate / Magnesium oxide
58480064|NCT03203096|DIETARY_SUPPLEMENT|Placebo|
58480065|NCT04961775|DRUG|Perflubutane Microspheres for Injection|16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.
58480066|NCT02156076|DRUG|BMS-919373|
58480067|NCT02156076|DRUG|Placebo (Matching with BMS-919373)|
58480068|NCT00826202|DRUG|D-serine|60 mg/kg/day
58480069|NCT00826202|OTHER|Placebo|Inert Placebo
58480070|NCT02735811|DEVICE|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
58480071|NCT06655311|BIOLOGICAL|Enlicitide Chloride|Oral administration
58480072|NCT06655311|OTHER|Placebo|Oral administration
58480073|NCT06655688|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
58480074|NCT04479995|BEHAVIORAL|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
58480075|NCT04479995|BEHAVIORAL|Usual Care|Standard medical visits with additional paper or electronic booklet.
58480076|NCT06016049|OTHER|EMLA® adjuvant|cutaneous forearm deafferentation
58480077|NCT06016049|BEHAVIORAL|Sensory training|Sensibility training of the median nerve
58480078|NCT06654115|DEVICE|Wireless Physiologic Monitoring|YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
58480079|NCT04941209|DEVICE|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
58480080|NCT04941209|DIAGNOSTIC_TEST|(PPA >95%) FDA EUA RT-PCR|Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
58480081|NCT04941209|RADIATION|HR-CT-scan|High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
58480082|NCT02015637|DRUG|Delafloxacin|single dose
58480083|NCT02015637|DRUG|Ceftriaxone|single dose
58480084|NCT06074341|BEHAVIORAL|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
58480085|NCT06074341|BEHAVIORAL|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
57785237|NCT00677456|PROCEDURE|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
58480086|NCT04845568|BEHAVIORAL|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
58480087|NCT03879772|DRUG|Mometasone furoate nasal spray|intranasal administration
58480088|NCT03879772|DRUG|Beclomethasone dipropionate nasal spray|intranasal administration
58480089|NCT03879772|DRUG|Placebo nasal spray|intranasal administration
57785238|NCT00677456|PROCEDURE|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
58480090|NCT03879772|DRUG|Chlorpheniramine maleate syrup|oral administration
58480091|NCT04053777|DEVICE|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
58480092|NCT03674853|DRUG|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
58480093|NCT03674853|DRUG|Oryzanol|take oryzanol in active comparator group for 2 months
58480094|NCT00157131|BIOLOGICAL|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
58480095|NCT00157131|OTHER|Staples|Administration by mechanical/multiple point fixation.
58480096|NCT02633098|DRUG|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
58480097|NCT02633098|DRUG|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
58480098|NCT06411262|OTHER|Parkiboks|A non-contact boxing sessions for individuals with Parkinson disease, made-up of 3 sections: a warm-up, a boxing section, a cool-down. Each section is split into a range of exercises. The session is led by a boxing coach with training and expertise in Parkinson disease.
58480099|NCT04705831|DRUG|Ruconest|C1 Esterase Inhibitor
58480100|NCT00763035|DRUG|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
58480101|NCT00763035|DRUG|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
58480102|NCT00994513|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|1200 mg/day
58480103|NCT00994513|DIETARY_SUPPLEMENT|Placebo|1200 mg/day
58480104|NCT00539591|DRUG|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
58480105|NCT00539591|DRUG|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
58480106|NCT00539591|DRUG|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
58480107|NCT05003843|DEVICE|Indigo Aspiration System|Indigo Aspiration System
58480108|NCT04280510|GENETIC|Blood sample collection; gastrointestinal biopsy|Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
58480109|NCT02545985|DEVICE|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
58480110|NCT01185210|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
58480111|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
58480112|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
58480113|NCT02121535|DRUG|T80/A5 mg FDC tablet|
58480114|NCT02121535|DRUG|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
58480115|NCT02121535|DRUG|H12.5 mg tablet|
58480116|NCT02121535|DRUG|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
58480117|NCT02121535|DRUG|H12.5 mf tablet|A HCTZ 12.5 mg tablet
58480118|NCT02121535|DRUG|T80/A5/H12.5 mg FDC tablet|
58480119|NCT05294549|OTHER|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
58480120|NCT01662765|PROCEDURE|Surgery|modified umbilectomy
58480121|NCT01662765|OTHER|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
58480122|NCT00503763|DRUG|Simvastatin|
58480123|NCT02433418|PROCEDURE|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
58480124|NCT02433418|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
58480125|NCT05609552|COMBINATION_PRODUCT|18F-Pretomanid PET/CT|A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
58480126|NCT06066320|BEHAVIORAL|MMST|Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones
58480127|NCT06066320|BEHAVIORAL|TSST|Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
58480128|NCT06404450|BEHAVIORAL|Digital CBT|The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
58480129|NCT02622126|DRUG|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
58480130|NCT02622126|DRUG|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
58480131|NCT02622126|DRUG|Morphine|Sub arachnoid 200 meg morphine
58480132|NCT02622126|DRUG|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
58480133|NCT02622126|DRUG|Ephedrine|If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
58480134|NCT02622126|DRUG|Atropine|Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
58480135|NCT02254135|DRUG|BEA 2180 BR - rising dose|
58480136|NCT02254135|DRUG|Placebo|
58480137|NCT06587425|DRUG|LM-302+Candonilimab+Capecitabine|LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
58480138|NCT04316845|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
58480139|NCT06004739|DRUG|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
58480140|NCT06004739|OTHER|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
58480141|NCT06516900|DEVICE|OrthoFeet HandsFree Therapeutic Shoe|Patients with foot pain will be recruited for this study and will go for an intervention of wearing OrthoFeet therapeutic shoes for 6 weeks. Each patient will be evaluated and will participate in data collection before and after intervention.
58480142|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
58480143|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
58480144|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
58480145|NCT05603702|DRUG|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
58480146|NCT03210194|BEHAVIORAL|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
58480147|NCT03210194|BEHAVIORAL|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
58480148|NCT05679752|OTHER|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
58480149|NCT05679752|OTHER|Massage therapy|frictional massage to stimulate the weak muscle groups
58480150|NCT06210997|BEHAVIORAL|Questionaires|The questionnaire was done online by the participants from second to fifth-year medical students.
58480151|NCT02368834|BEHAVIORAL|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
58480152|NCT00495352|DRUG|Hihg-doseNRT, Low-dose NRT, bupropion|
58480153|NCT01868997|DRUG|teprotumumab|
58480154|NCT01868997|DRUG|normal saline|
58480155|NCT05355246|OTHER|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
58480156|NCT05355246|OTHER|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
58480157|NCT02570607|BIOLOGICAL|BNP dosage|
58480158|NCT03481595|DEVICE|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
58480159|NCT04748198|PROCEDURE|Intracorneal ring segment implantation|Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
58480160|NCT06614790|DRUG|Niraparib 200/300 MG|"We expect to enroll approximately 300 patients from about 10 sites. Treatment part of study.~Part I- looking retrospectively at the time period JAN 2021-MAR 2023. The retrospective data will include patients who are enrolled in niraparib treatment:~* under the EAP (started in JAN 2021, in continuation)~* under the B.50 drug program, which began in January 2022 Of note, the retrospective multi-center observational study will involve about 30 patients treated with niraparib in EAP (FIGO III R0 after PDS included) and patients who were treated with niraparib before starting RWE (about 120 pts) (JAN 2021- MAR 2023) by the drug program B.50 which has been started to adapt on 1st of Jan, 2022.~FIGO III PDS to R0 patients are included to this study. Part II- looking prospectively at the time period APR 2023 to DEC 2025. The prospective data will include patients who are enrolled in niraparib treatment under the B.50 drug program.~The prospective multi-center observational study will i"
58480161|NCT06418802|PROCEDURE|STN-DBS surgery|bilateral subthalamic nucleus deep brain stimulation surgery
58480162|NCT06418802|DEVICE|pulse width|a short pulse width (30s)
58480163|NCT06418802|DEVICE|frequency|frequency parameters of STN-DBS (60,100, and 130HZ)
58480164|NCT02981446|DRUG|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
58480165|NCT02981446|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
58480166|NCT00149266|PROCEDURE|Surgery: abdominal and transhiatal approach|
58480167|NCT00149266|PROCEDURE|Surgery: left thoraco-abdominal approach|
58480168|NCT05357651|DRUG|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
58480169|NCT01108016|BEHAVIORAL|Videoconferencing support group|
58492280|NCT05355883|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
58480170|NCT04436757|BEHAVIORAL|IPS program : Self-image and body representation|"The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network"
58480171|NCT04436757|BEHAVIORAL|TAU|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
58480172|NCT00224822|DRUG|Aripiprazole|
58480173|NCT03107871|DRUG|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
58480174|NCT03107871|DRUG|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
58480175|NCT06318949|PROCEDURE|blood sampling|If the patient does not object to participating in the study, a blood sample is taken at each visit (an additional tube may be added to a routine blood sample taken for standard care), or a residual blood sample is reused after routine tests have been performed, and data is collected from the medical record.
58480176|NCT01269021|DRUG|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d
58480177|NCT01269021|DRUG|Prednisone in full dose|0.8-1mg/kg/d
58480178|NCT03902353|OTHER|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
58480179|NCT03497195|DIAGNOSTIC_TEST|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
58480180|NCT03420599|PROCEDURE|splenectomy|Traumatic patients who performed total splenectomy
58480181|NCT06109571|DEVICE|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
58480182|NCT05417516|RADIATION|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
58480183|NCT05417516|RADIATION|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
58480184|NCT04434443|OTHER|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
58480185|NCT04434443|OTHER|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
58480186|NCT00597220|DIETARY_SUPPLEMENT|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
58480187|NCT00597220|DRUG|Placebo|Placebo
58480188|NCT05464342|BEHAVIORAL|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
58480189|NCT05464342|BEHAVIORAL|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
58480190|NCT05464342|BEHAVIORAL|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
58480191|NCT03989258|DIAGNOSTIC_TEST|Mammography outside official screening|Radiologic study
58480192|NCT01930006|DRUG|MGCD265|
58480193|NCT04257448|DRUG|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
58480194|NCT04257448|DRUG|Azacitidine|Powder for suspension for injection; Subcutaneous use
58480195|NCT04257448|DRUG|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
58480196|NCT04257448|DRUG|Gemcitabine|Powder for solution for infusion; Intravenous use
58480197|NCT04257448|DRUG|Durvalumab|Concentrate for solution for infusion; Intravenous use
58480198|NCT04257448|DRUG|Lenalidomide capsule|Hard capsule for oral use
58480199|NCT05505084|PROCEDURE|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
58480200|NCT05433207|DRUG|Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)
58492281|NCT05355883|BEHAVIORAL|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
58480201|NCT06213857|DIETARY_SUPPLEMENT|Silymarin|Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
58480202|NCT05856617|DRUG|Remimazolam besylate|Remimazolam besylate anesthesia induction
58480203|NCT03095859|OTHER|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
58480204|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with analogic guide|coDiagnostix9® planning software
58480205|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with CAD-CAM surgical guide|coDiagnostix9® planning software
58480206|NCT02955667|PROCEDURE|invivo microscopy group|patients receive invivo micro-colposcopy examination
58480207|NCT02955667|PROCEDURE|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
58480208|NCT00893438|BEHAVIORAL|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
58480209|NCT00893438|OTHER|Usual care|Usual care treatment for adolescents with CFS
58480210|NCT03812731|DRUG|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
58480211|NCT03812731|DRUG|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
58480212|NCT02286349|DEVICE|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
58480213|NCT02286349|DEVICE|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
58480214|NCT04307329|BIOLOGICAL|Monalizumab|Monalizumab 750 mg every two weeks
58480215|NCT04307329|BIOLOGICAL|Trastuzumab|Trastuzumab 4 mg/kg every two weeks
58480216|NCT04730453|PROCEDURE|ENB-guided ablation therapy combined with VATS|After receiving multidisciplinary assessments, Lesion A will receive ENB-guided ablation therapy and Lesion B will receive VATS at the same time.
58480217|NCT00251732|DRUG|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
58480218|NCT00251732|DRUG|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
58480219|NCT00251732|DRUG|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
57780274|NCT05365113|PROCEDURE|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
58135336|NCT04603209|RADIATION|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
58135337|NCT04344847|PROCEDURE|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
58480220|NCT05609591|DIETARY_SUPPLEMENT|Liquid diet group|Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.
58480221|NCT05609591|DIETARY_SUPPLEMENT|Enteral nutrition group|100% short peptide enteral nutrition are given to children for bowel preparation
58480222|NCT05609591|DIETARY_SUPPLEMENT|Low residual diet group|Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
58480223|NCT05061511|OTHER|Analysis of inflammasome expression|RNA isolation, spectrophotometric quantification, reverse transcription to cDNA and relative quantification of gene expression using a quantitative reverse transcription polymerase chain reaction (qRT-PCR). Specific inflammasome-related transcripts will be investigated, including ASC, caspase-1, IL-1beta, IL-18, NLRP3, NLRP2, AIM2, POP1, POP2, CARD16, CARD18, TRIM16, and TRIM20. A qRT-PCR System (e.g. StepOne Plus, Applied Biosystems) will be used for the amplification and analysis of the PCR products. Expression data will be reported as the ratio between each investigated target gene and GAPDH (used as housekeeping endogenous control).
58480224|NCT05061511|OTHER|Histological analysis|"gingival tissue samples will be prepared for paraffin inclusion and different stains will be used to evaluate the histological features of the tissues, distribution of inflammatory cells and alignment of collagen fibers.~Moreover, a trained examiner will assess semi-quantitatively the inflammatory infiltrate under light microscopy.~The expression of inflammatory/immune-related proteins such as NLRP3, ASC-2, IL-1beta and IL-18 protein expressions will be compared among the three groups by immunodetection methods"
58480225|NCT00566761|DRUG|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
58480226|NCT00135551|DRUG|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
58480227|NCT00135551|DRUG|β-blockers|benidipine+β-blockers, titlation scheme
58480228|NCT00135551|DRUG|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
58492282|NCT01747395|OTHER|Exercise training|The heart failure patients are subjected to differents protocols of physical training
58480229|NCT06514066|DRUG|Cannabidiol Oil|The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.
58480230|NCT03058146|BEHAVIORAL|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
58480231|NCT03058146|BEHAVIORAL|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
58480232|NCT04429711|DRUG|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
58480233|NCT04820569|PROCEDURE|Resection and chemotherapy|
58480234|NCT04476797|DRUG|GC4711 +SBRT|15 minute IV Infusion prior to SBRT
58480235|NCT04476797|DRUG|Placebo +SBRT|15 minute IV infusion prior to SBRT
58480236|NCT06095063|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
58480237|NCT06095063|DEVICE|Sham Brainsway H7-Coil Deep TMS System|In addition to the active H-coil, a sham coil is included in the system. The active and sham coils are connected to a control switch, which alternates between real and sham operation modes. The sham treatment will be administered daily for 4 consecutive weeks.
58480238|NCT06095063|OTHER|Cognitive Training|Cognitive training will be conducted using the BrainHQ software program.
58480239|NCT05434286|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
58480240|NCT05019326|DRUG|Andrographis Paniculata|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
58480241|NCT05019326|DRUG|Boesenbergia|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
58480242|NCT05019326|OTHER|Standard supportive treatment|as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
58480243|NCT00460616|DRUG|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
58480244|NCT02191735|DEVICE|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
58480245|NCT02191735|DEVICE|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
58480246|NCT05605002|DRUG|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
58480247|NCT05605002|PROCEDURE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
57784577|NCT03215121|PROCEDURE|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
57784578|NCT01785641|DRUG|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
58480248|NCT05605002|PROCEDURE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
58480249|NCT01143376|BEHAVIORAL|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
58480250|NCT01143376|BEHAVIORAL|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
58480251|NCT01143376|BEHAVIORAL|Moderate intensity exercise|
58492283|NCT00946153|DRUG|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
58480252|NCT05867238|OTHER|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
58480253|NCT01286480|BEHAVIORAL|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
58480254|NCT03228225|BEHAVIORAL|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
58480255|NCT01371396|OTHER|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
58480256|NCT01371396|OTHER|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
58480257|NCT00306501|PROCEDURE|Swallowing Training|Swallowing Training with press of button
58480258|NCT00684931|OTHER|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
58480259|NCT05447780|PROCEDURE|regional anesthesia|regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
58480260|NCT03687060|BEHAVIORAL|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
57780275|NCT04715087|OTHER|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
57784579|NCT01785641|DRUG|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
57784580|NCT01785641|DRUG|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
57784581|NCT01785641|DRUG|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
57784582|NCT03375814|DRUG|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
57784583|NCT03375814|DRUG|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
58135338|NCT06114251|DIAGNOSTIC_TEST|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
58480261|NCT03687060|BEHAVIORAL|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
58480262|NCT03687060|BEHAVIORAL|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
58480263|NCT06361069|OTHER|distraction cards, kaleidoscope and finger puppet|"A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions."
58480264|NCT03527108|DRUG|Nivolumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
58135339|NCT00500474|PROCEDURE|endolymphatic sac drainage with steroids|
58135340|NCT02226185|DRUG|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
58135341|NCT02226185|DRUG|placebo|supplement of placebo two times per day for 2-3 years
58138948|NCT04699747|DRUG|F-18 3F4AP|Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
58480265|NCT03527108|DRUG|Ramucirumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
58480266|NCT03394820|DRUG|Dexamethasone|The intervention is the time when dexamethasone is administered
58480267|NCT04046809|OTHER|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
58480268|NCT04046809|OTHER|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
58480269|NCT06177496|PROCEDURE|local ablation|treatment of HCC
58480270|NCT06177496|PROCEDURE|TACE|treatment of HCC
58480271|NCT06177496|DRUG|Sorafenib|treatment of HCC
58480272|NCT02157025|DEVICE|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
58480273|NCT02157025|OTHER|Usual Care procedures during Humphrey perimetry for children|
58480274|NCT03675997|OTHER|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
58480275|NCT04684277|DRUG|antidepressant treatment|depression recieve antidepressant treatment
58480276|NCT04684277|OTHER|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
58480277|NCT06019702|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
58480278|NCT04690023|PROCEDURE|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
58480279|NCT04690023|PROCEDURE|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
58480280|NCT04690023|DRUG|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
58480281|NCT04690023|DRUG|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
58480282|NCT00549835|PROCEDURE|Real Acupuncture|
58480283|NCT00549835|PROCEDURE|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
58480284|NCT05661617|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|"Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests."
58480285|NCT06341478|DRUG|various neoadjuvant therapies|Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
58480286|NCT02397577|OTHER|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
58480287|NCT00240513|DRUG|Minocycline|100 mg capsules OD for 3 months
58480288|NCT00240513|DRUG|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
58480289|NCT02659254|DEVICE|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
58480290|NCT01919502|DEVICE|Semi-quantitative urine pregnancy test|
58480291|NCT02057185|BEHAVIORAL|Study questionnaire|Questionnaire based on work situation of enrolled patients.
58480292|NCT02057185|BEHAVIORAL|SF-36 Questionnaire|Version 1.6
58480293|NCT05024019|DRUG|Nimotuzumab|The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
58480294|NCT00613873|PROCEDURE|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
58480295|NCT02098785|DRUG|Caffeine citrate|Oral solution
58480296|NCT00000715|DRUG|Pentamidine isethionate|
58480297|NCT00000715|DRUG|Sulfamethoxazole-Trimethoprim|
58480298|NCT00643747|BIOLOGICAL|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
58480299|NCT03848026|OTHER|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
58480300|NCT03848026|OTHER|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
58480301|NCT03957577|OTHER|Prospective observational cohort study|Prospective observational cohort study
58480302|NCT00533455|DRUG|Gabapentin|
58480303|NCT02507232|DEVICE|NovoTTF-200A|12 cycles
58480304|NCT02507232|DRUG|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
58480305|NCT00918255|BIOLOGICAL|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
58480306|NCT00918255|DRUG|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
58480307|NCT00716417|DRUG|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
58480308|NCT00716417|DRUG|BIBW 2992|low to high dose, daily
58480309|NCT01507259|OTHER|cocoa|70% versus 34%
58480310|NCT00384670|BIOLOGICAL|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
58480311|NCT00384670|BIOLOGICAL|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
58480312|NCT02873416|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
58480313|NCT02873416|BIOLOGICAL|Precision Cells|Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
58480314|NCT04465708|BEHAVIORAL|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
58480315|NCT01303016|DIETARY_SUPPLEMENT|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
58480316|NCT00335036|DEVICE|ICD lead implant|Randomization of ICD lead type at implant
58480317|NCT00335036|DEVICE|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
58480318|NCT04979312|DEVICE|LabClasp|Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
58480319|NCT05540938|DRUG|Wangbi granules|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
58480320|NCT05540938|DRUG|Wangbi granules simulant|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
58480321|NCT00286247|GENETIC|INGN 201|
58480322|NCT02695108|OTHER|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
58480323|NCT02695108|OTHER|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
58480324|NCT04579107|COMBINATION_PRODUCT|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
58480325|NCT03252379|PROCEDURE|hepaticojejunostomy|"* Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
58480326|NCT03252379|PROCEDURE|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
58480327|NCT03252379|PROCEDURE|modified hepaticojejunostomy with gastric access loop|"* In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
58480328|NCT01601236|DRUG|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].
58480329|NCT01601236|DRUG|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
58135342|NCT02970656|BEHAVIORAL|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
58135343|NCT04770883|BEHAVIORAL|Internet based cognitive behavioral therapy.|Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.
58480330|NCT06266247|DIAGNOSTIC_TEST|Take blood samples|Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
58480331|NCT05085938|PROCEDURE|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
58480332|NCT00212641|DRUG|ONO-5129|
58480333|NCT03520829|DEVICE|Intuitive Plan|dosimetric planning software
58480334|NCT03038100|DRUG|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
58480335|NCT03038100|DRUG|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
58135344|NCT04770883|DIETARY_SUPPLEMENT|Low FODMAP diet therapy|Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.
58135345|NCT02704182|DEVICE|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
58135346|NCT02704182|DEVICE|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
58135347|NCT01985347|DEVICE|CPAP|Continuous positive airway pressure( CPAP)
58480336|NCT03038100|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
58480337|NCT03038100|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
58138949|NCT06036082|OTHER|Conventional physical therapy|"* Standing with feet together .~* Step standing .~* High step standing and trying to keep balanced.~* Single leg stance unilateral standing with assistance.~* Standing on a declined surface by using wedge.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
58138950|NCT04720638|OTHER|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
58138951|NCT04720638|OTHER|Conventional resin composite restoration|Microhybrid resin composite
58480338|NCT03038100|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
58480339|NCT06649578|PROCEDURE|Metabolic-bariatric surgery|Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
58480340|NCT02951000|PROCEDURE|platysma suture|
58480341|NCT02951000|PROCEDURE|no platysma suture|
58480342|NCT05403346|DEVICE|CoviDx™ Covid-19 Antigen Self-Test|All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing
58480343|NCT05753943|DRUG|QUALI|Medication 1 pill at night
58480344|NCT04248426|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
58480345|NCT04248426|DRUG|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
58480346|NCT02144896|OTHER|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
58480347|NCT01853670|RADIATION|concurrent chemo + IGRT|
58480348|NCT01853670|RADIATION|neoadjuvant chemo + IGRT|
58480349|NCT02032017|PROCEDURE|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
58480350|NCT02032017|PROCEDURE|Percutaneous assisted approach|
58480351|NCT02032017|PROCEDURE|Anterolateral approach|
58480352|NCT02032017|OTHER|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
58480353|NCT04154904|OTHER|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
58480354|NCT02501291|DRUG|Thalidomide|
58480355|NCT03197896|OTHER|Educational Intervention|Review prostate cancer information
58480356|NCT03739268|DRUG|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
58480357|NCT03739268|DRUG|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
58480358|NCT01798771|PROCEDURE|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
58480359|NCT01798771|PROCEDURE|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
58480360|NCT04077216|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
58480361|NCT02512783|DRUG|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
58480362|NCT02512783|DRUG|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
58480363|NCT02512783|DRUG|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
58480364|NCT06655662|OTHER|β-globin restored autologous hematopoietic stem cells|Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
58480365|NCT04509726|DRUG|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
58480366|NCT06459206|DEVICE|Pulse oximeter|Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
58480367|NCT02817048|DEVICE|chest tube|
58480368|NCT02817048|PROCEDURE|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
58480369|NCT02817048|PROCEDURE|VATS with chest tube placement|
58480370|NCT06440616|DEVICE|Spectral CT images generated by a photon counting CT scanner|The reading radiologist will in the experimental arm have access to spectral CT images in the form of low virtual monoenergetic images, virtual non-contrast images, iodine maps and effective atomic number. In the non-interventional arms the reading radiologist will only have access to conventional CT images.
58480371|NCT03429114|OTHER|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
58480372|NCT03337477|DRUG|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
58480373|NCT03337477|DRUG|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
58480374|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
58480375|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
58480376|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
58480377|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
58480378|NCT02609919|DRUG|Gadoteric Acid|MRI Contrast Agent
58480379|NCT00107341|DRUG|bortezomib|
58480380|NCT00107341|DRUG|carboplatin|
58480381|NCT00107341|DRUG|paclitaxel|
58480382|NCT02699749|DRUG|TAK-931|TAK-931 oral capsules.
58138952|NCT06095076|DIAGNOSTIC_TEST|Skin swabbing|Skin swabbing will be performed on CVC insertion site before CVC placement (baseline), and then every 3 days (or when dressing is changed) while CVC is in place, then at ICU discharge. Bacterial metagenomics using bacterial DNA extraction, 16S PCR amplification and Nanopore sequencing will allow for description of cutaneous microbiota and diversity evaluation through Shannon index. Evolution of alpha-diversity will be evaluated through time-series data analysis: comparison of Shannon index at various time points with baseline Shanonn index (before CVC placement). Standard microbiologic culture of skin swabbing will be performed.
58138953|NCT06095076|OTHER|Data collection|General patient characteristics and informations relative to CVC infection and treatment will be collected.
58480383|NCT01655485|OTHER|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
58480384|NCT02202200|DRUG|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
58480385|NCT03131570|DRUG|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
58480386|NCT03131570|DRUG|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
58480387|NCT03114683|DRUG|PD1|IBI308 200mg/3 weeks
58480388|NCT04448535|DIETARY_SUPPLEMENT|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
58480389|NCT06277427|DRUG|PRG-1801 （CAR-T against BCMA）|Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
58480390|NCT02364570|OTHER|Glucose (100g)|Ingestion of glucose (100g)
58480391|NCT02364570|OTHER|Glucose (75g)|Ingestion of glucose (75g)
58480392|NCT02364570|OTHER|Whole Eggs|Ingestion of 1.5 whole eggs
58480393|NCT02364570|OTHER|Egg Whites|Ingestion of 7 egg whites
58480394|NCT02364570|OTHER|Egg Yolks|Ingestion of 2 egg yolks
58480395|NCT02119377|OTHER|questionnaire|
58480396|NCT04382040|DRUG|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
58480397|NCT04382040|DRUG|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
58480398|NCT03763838|OTHER|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
58480399|NCT03763838|OTHER|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
58480400|NCT03763838|OTHER|Standard of Care|Fatigue management provided by participants' health care providers.
58480401|NCT01549899|BEHAVIORAL|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education \& hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
58480402|NCT01549899|BEHAVIORAL|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
58480403|NCT02794909|DEVICE|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
58480404|NCT03024476|BEHAVIORAL|Behavioral intensification|"Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
58480405|NCT03024476|DRUG|Pharmacological intensification based on olmesartan|"* Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
58480406|NCT03024476|DEVICE|Bluetooth-equipped sphygmomanometer|"* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
58480407|NCT02083354|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
58480408|NCT02083354|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
58480409|NCT03408392|DRUG|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
58480410|NCT03408392|DRUG|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
58480411|NCT05233306|DEVICE|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
58480412|NCT02346058|DRUG|Esarin Gel|
58480413|NCT02524782|BIOLOGICAL|MEDI-4166|MEDI-4166 administered subcutaneously
58480414|NCT02524782|BIOLOGICAL|Placebo|Placebo administered subcutaneously
58480415|NCT03499483|DRUG|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
58480416|NCT00767364|BIOLOGICAL|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
58480417|NCT01702311|DRUG|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
58480418|NCT06166615|DRUG|Ramosetron|Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
58480419|NCT06166615|DRUG|Psyllium|Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
58492284|NCT05522348|PROCEDURE|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|two patient fitted custom made plates will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
58480420|NCT05393440|BIOLOGICAL|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
58480421|NCT01686919|DIETARY_SUPPLEMENT|milk-free|milk-free diet during 8 preoperative weeks
58480422|NCT02131259|DRUG|Afatinib dimaleate|20mg - 50mg
58480423|NCT03873142|BEHAVIORAL|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
58480424|NCT00382707|DEVICE|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
58480425|NCT01387477|DRUG|Lactate|Infusion of 66 mmol of lactate
58480426|NCT01387477|DRUG|Glucose|Infusion of 33 mmol of glucose
58480427|NCT00732030|DEVICE|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
58480428|NCT00670254|DRUG|Placebo|Application is identical to experimental arm
58480429|NCT00670254|DRUG|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
58480430|NCT02878343|BEHAVIORAL|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
58480431|NCT02878343|BEHAVIORAL|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
58480432|NCT00402948|DRUG|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
58480433|NCT00402948|DRUG|ASM8|inhalation 0.25mg daily for 14 days
58480434|NCT04144790|DIETARY_SUPPLEMENT|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
58480435|NCT05114421|DRUG|Lenvatinib|Given PO
58480436|NCT05114421|BIOLOGICAL|Pembrolizumab|Given IV
58480437|NCT01475760|OTHER|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
58480438|NCT01475760|OTHER|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
58480439|NCT00910416|DRUG|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
58480440|NCT00910416|DRUG|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
58480441|NCT00910416|DEVICE|EEG monitoring|simultaneous monitoring with Bis and Neurosense
58480442|NCT03125395|DRUG|LUM/IVA|Participants received LUM/IVA every q12h.
58480443|NCT05395975|DEVICE|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
58480444|NCT00497081|DRUG|mirtazapine|mirtazapine 30 mg daily for 3 months
58480445|NCT00497081|DRUG|placebo|placebo 30 mg daily for 3 months
58480446|NCT05482126|DIAGNOSTIC_TEST|Intraoperative Behavioral Testing|During DBS surgery, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
58480447|NCT05482126|DIAGNOSTIC_TEST|Behavioral Testing|In the lab, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
58480448|NCT06025214|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
58480449|NCT06025214|DRUG|ADVAIR DISKUS® 500/50|2 inhalations in one study period
58480450|NCT04171843|GENETIC|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
58480451|NCT04171843|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
58480452|NCT04171843|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
58480453|NCT04171843|DRUG|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
58138954|NCT01933373|PROCEDURE|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
58480454|NCT02869152|OTHER|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
58480455|NCT02869152|OTHER|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
58480456|NCT02869152|OTHER|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
58480457|NCT02869152|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
58480458|NCT02869152|PROCEDURE|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
58480459|NCT02869152|PROCEDURE|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
58480460|NCT00408317|DRUG|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
58480461|NCT00408317|DRUG|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
58480462|NCT00130572|DRUG|Pimecrolimus|
58480463|NCT04677088|BIOLOGICAL|TCR-T cells|Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
58480464|NCT03500718|DEVICE|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
58480465|NCT04124809|DEVICE|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
58480466|NCT05173558|BEHAVIORAL|Uninterrupted motionless standing|Participants remained 20 minutes of uninterrupted motionless standing
58480467|NCT05173558|BEHAVIORAL|Uninterrupted motionless sitting|Participants remained 20 minutes of uninterrupted motionless sitting
58480468|NCT05173558|BEHAVIORAL|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
58480469|NCT03743168|OTHER|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
58480470|NCT03743168|OTHER|Continuous stretch|2 minutes continuous stretch
58480471|NCT02851615|BEHAVIORAL|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
58480472|NCT02476253|DRUG|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
58480473|NCT03857867|DEVICE|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
58480474|NCT04881994|DRUG|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
58480475|NCT06431152|BIOLOGICAL|UC-MSC sEV|Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
58480476|NCT01322620|OTHER|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
58480477|NCT00078585|BIOLOGICAL|PROSTVAC®-VF/TRICOM™|
58480478|NCT04725578|BEHAVIORAL|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
58480479|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
58480480|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
58480481|NCT01021020|DRUG|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
58480482|NCT00940771|DRUG|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
58480483|NCT02796599|DEVICE|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
58480484|NCT02919995|DRUG|RPL554|RPL554 suspension administered using a nebuliser
58480485|NCT02919995|DRUG|Placebo|Placebo solution administered using a nebuliser
58480486|NCT01254617|BIOLOGICAL|Cetuximab|Given IV
58480487|NCT01254617|OTHER|Laboratory Biomarker Analysis|Correlative studies
58480488|NCT01254617|DRUG|Lenalidomide|Given PO
58480489|NCT02919839|OTHER|non-Interventional|
58480490|NCT06431997|BEHAVIORAL|Time-limited eating|All participants will be instructed to follow a diet of 1800-2200 kcal/d (45-50% of energy from carbohydrate, 15-20% from protein, 25-30% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
58480491|NCT06588946|DIETARY_SUPPLEMENT|Ketone monoester (KME) supplement|15g of a KME supplement orally consumed 3x daily for 14 days
58480492|NCT06588946|DIETARY_SUPPLEMENT|Placebo supplement|50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days
58480493|NCT01383356|DRUG|Metformin Single Tablet|Metformin medium doseTablet
58480494|NCT01383356|DRUG|Linagliptin/Metformin Combo|Fixed dose combination
58480495|NCT01383356|DRUG|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
58492285|NCT05522348|PROCEDURE|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|one patient fitted custom made plate will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
58480496|NCT04793217|BEHAVIORAL|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
58480497|NCT04793217|BEHAVIORAL|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
58480498|NCT01875653|BIOLOGICAL|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
58480499|NCT01875653|BIOLOGICAL|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
58480500|NCT01532986|OTHER|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
58480501|NCT01532986|OTHER|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
58480502|NCT00004854|DRUG|Carvedilol|
58480503|NCT05606445|BEHAVIORAL|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
58480504|NCT02202759|DRUG|MLN0264|MLN0264 IV infusion
58480505|NCT02755246|DIETARY_SUPPLEMENT|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
58480506|NCT02755246|DIETARY_SUPPLEMENT|Placebo supplementation|3 months of placebo intake (3 capsules/day)
58480507|NCT01834989|DRUG|Insulin-like growth factor I|
58480508|NCT01834989|DRUG|Placebo|
58480509|NCT00425802|BIOLOGICAL|anti-thymocyte globulin|
58480510|NCT00425802|BIOLOGICAL|filgrastim|
58480511|NCT00425802|BIOLOGICAL|graft-versus-tumor induction therapy|
58480512|NCT00425802|BIOLOGICAL|rituximab|
58480513|NCT00425802|DRUG|cyclophosphamide|
58480514|NCT00425802|DRUG|cyclosporine|
58480515|NCT00425802|DRUG|fludarabine phosphate|
58480516|NCT00425802|DRUG|mycophenolate mofetil|
58480517|NCT00425802|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
58480518|NCT00425802|RADIATION|total-body irradiation|
58480519|NCT05072236|PROCEDURE|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
58480520|NCT03408093|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
58135348|NCT06447883|BEHAVIORAL|Lifestyle modification program|The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
58480521|NCT04819542|DEVICE|Bandage|Bandage
58480522|NCT04819542|DEVICE|No bandage|No bandage
58135349|NCT01175616|DRUG|Creatine|Oral Creatine 5 grams daily.
58480523|NCT04646421|BEHAVIORAL|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
58480524|NCT01497496|DRUG|High Dose Methylprednisolone (HDMP)|1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
58480525|NCT01497496|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
58480526|NCT01497496|DRUG|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
58480527|NCT04436952|DEVICE|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
58480528|NCT04436952|DEVICE|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
58480529|NCT04436952|BEHAVIORAL|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
58480530|NCT02655120|PROCEDURE|Drilling|
58480531|NCT02655120|BIOLOGICAL|Bone Marrow +BMP7|
58480532|NCT06469034|DEVICE|conventional ultrasound|The operators in the control group will perform the procedure by visualizing the conventional ultrasound images displayed directly on the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. To standardize the approach, the ultrasound machine will be placed just to the right of the patient and operators will be asked to stand at the head of the patient and perform the procedure on the patient's internal jugular vein. Each operator could determine the height of the surgical table, and the posture during the procedure that will be most familiar to him/her to increase the success rate. Every procedure will be recorded by focusing on the participant's hands and faces.
58480533|NCT06469034|DEVICE|Mixed reality and head-mounted display ultrasound|In the MR + HMD group, the ultrasound machine will be located behind the operator to remove the distraction, and the operator will not be allowed to see the ultrasound screen during the procedure. The operators randomized into the MR+HMD group will use a MR ultrasound machine. Images from the MR ultrasound machine will be transmitted to HMD via a novel connection developed specifically for this purpose. The operator will wear a pair of HMD and perform the procedure by visualizing the ultrasound images displayed on their HMD screen instead of the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. Every procedure will be recorded by focusing on the participant's hands and faces.
58480534|NCT06256406|OTHER|in the field of rehabilitation and neonatal care: the combination of Kangaroo care method and music therapy|Kangaroo care is a practice involving skin-to-skin contact between the infant and a caregiver,. Music therapy is a therapeutic approach that utilizes the expressive and emotional qualities of music to address physical, emotional, cognitive needs of individuals.
58480535|NCT03426748|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
58480536|NCT03426748|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
58480537|NCT05669274|OTHER|Milk containing A1 and A2 beta-casein|Milk dose for 2 weeks
58480538|NCT05669274|OTHER|Milk containing only A2 beta-casein|Milk dose for 2 weeks
58480539|NCT00497484|DRUG|recombinant human somatotropin|
58480540|NCT00381901|BIOLOGICAL|trastuzumab|
58480541|NCT00381901|GENETIC|polymorphism analysis|
58480542|NCT00381901|PROCEDURE|adjuvant therapy|
58480543|NCT06654596|DRUG|Telitacicept 240mg|Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
58480544|NCT06654596|DRUG|Glucocorticoid|Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
58480545|NCT03581279|DEVICE|T2Lyme Panel testing|The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
58480546|NCT05738486|DRUG|Donanemab|Administered IV
57780276|NCT04715087|OTHER|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
58480547|NCT05738486|DRUG|Placebo|Administered IV
58480548|NCT01075529|DRUG|fluoxetine|fluoxetine 20 mg/d
58480549|NCT02239419|PROCEDURE|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
58480550|NCT02239419|PROCEDURE|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
58492286|NCT02549924|DRUG|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
57780277|NCT06192355|DEVICE|Endoscopic hemostasis using a Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
57780278|NCT06379750|OTHER|Nurse-delivered care using WelTel check-ins and BCC SMS|Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS
58135350|NCT06157710|BEHAVIORAL|Digital intervention through modules|"* Introduction~* Goal Setting Techniques~* Motivation~* Barriers to Action~* Managing Maladaptive Thoughts and Beliefs~* Value Clarification~* Moving Forward"
58135351|NCT01929122|DIETARY_SUPPLEMENT|Placebo-Control Meals and Snacks|
58135352|NCT01929122|DIETARY_SUPPLEMENT|Cooked Navy Bean Powder Meals and Snacks|
58135353|NCT01929122|DIETARY_SUPPLEMENT|Rice Bran Meals and Snacks|
58135354|NCT05926479|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
58135355|NCT05926479|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
58135356|NCT05926479|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
58135357|NCT04745546|DEVICE|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
58135358|NCT06439966|DRUG|ABBV-787|Intravenous (IV) Infusion
58480551|NCT04466319|OTHER|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
58135359|NCT01716793|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics."
58135360|NCT01716793|OTHER|Autologous transplantation|"* In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling."
58135361|NCT01716793|OTHER|Allogeneic HLA-identical sibling transplantation|"* Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
58135362|NCT01716793|OTHER|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
58135363|NCT04074174|DRUG|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
58135364|NCT04074174|DRUG|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
58135365|NCT04074174|DRUG|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
58135366|NCT02059746|OTHER|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
58135367|NCT06158516|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
58135368|NCT06158516|DRUG|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
58135369|NCT03087747|PROCEDURE|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
58135370|NCT00921622|DIETARY_SUPPLEMENT|Vitamin D|1000 IU twice daily for up to 10 days
58480552|NCT04402372|DEVICE|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
58480553|NCT02481219|DEVICE|PillCam® COLON 2 procedure-CONTROL|
58135371|NCT00921622|DIETARY_SUPPLEMENT|Vitamin C|500 mg twice daily for up to 10 days
58135372|NCT04046211|DRUG|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
58135373|NCT06367400|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire|Questionnaire with 22 questions of symptoms of OSDB
58135374|NCT02144753|DIETARY_SUPPLEMENT|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
58480554|NCT02481219|DRUG|Senna tablets|
58480555|NCT02481219|DRUG|PEG|
58480556|NCT02481219|DRUG|Metoclopramide|
58480557|NCT02481219|DRUG|Erythromycin|
58480558|NCT02481219|DRUG|SUPREP oral sulfate solution|
58480559|NCT02481219|DRUG|Bisacodyl|
58135375|NCT02144753|DRUG|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
58138955|NCT01933373|PROCEDURE|Dor|Anterior partial fundoplication plus myotomy.
58135376|NCT02812732|BEHAVIORAL|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
58135377|NCT03815669|PROCEDURE|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
58135378|NCT00190814|DRUG|duloxetine|
58135379|NCT00190814|DRUG|placebo|
58135380|NCT03357003|OTHER|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
58135381|NCT03627780|DIAGNOSTIC_TEST|DNA extraction|DNA will be extracted from white cells
58135382|NCT04734145|DIAGNOSTIC_TEST|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
58135383|NCT04047147|OTHER|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
58135384|NCT04047147|OTHER|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
58135385|NCT03104101|COMBINATION_PRODUCT|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
58135386|NCT03104101|DEVICE|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
58135387|NCT02767310|DRUG|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
57780279|NCT06379750|OTHER|Community-based peer-support model|Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring
57780280|NCT06737809|DEVICE|IP Plasmafit® Revision cup (and stem) system|Revision total hip arthroplasty (THA) due to periprosthetic joint infection
57780281|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
58135388|NCT02767310|DRUG|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
58135389|NCT05986448|BEHAVIORAL|Tai-chi exercise|Traditional Chinese Tai Chi Movement
58135390|NCT03806803|BIOLOGICAL|Lyophilized fecal microbiota transplant|15 capsules
58135391|NCT03806803|BIOLOGICAL|Lyophilized sterile fecal filtrate|15 capsules
58135392|NCT02654912|DRUG|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
58135393|NCT01627457|DEVICE|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
58135394|NCT06191939|BEHAVIORAL|Mindful Self-Compassion for Lung Cancer (MSC-LC)|"The overall goal of this 10-week, group-based, virtually-delivered, psychosocial intervention is to enhance recognition and responsiveness to difficult thoughts and emotions and to build self-compassion skills that facilitate patients' ability to turn inward to those thoughts and feelings with mindfulness, connectedness, and self-kindness. Each weekly session is designed to be 90 minutes and follows an agenda with highly structured scripts covering self-compassion topics (e.g., pain of disconnection, listening with compassion), which are carefully organized to build upon one another. In each session, didactic topics (e.g., What is self-compassion?) taught by trained interventionists lead into guided experiential learning practices (e.g., guided meditation), which are then followed by inquiry into the participants' direct experiences of the practices. The treatment manual is adapted based on the Mindful Self-Compassion Teacher Guide (from the Center for Mindful Self-Compassion)."
58135395|NCT06191939|OTHER|Enhanced standard of care with waitlist|Participants in the enhanced standard of care control condition will be provided with an information sheet from the NCI about how to find helpful organizations and resources in their community. Self-report will be used to describe any supportive care services pursued by the participant. Additionally, control participants will be added to a waiting list for receiving the MSC-LC intervention program. After completing all questionnaire assessments (16 weeks following study entry), the study team will offer the MSC-LC intervention program to participants on the waiting list.
58135396|NCT00480350|BEHAVIORAL|rice based food supplement|
58480560|NCT02481219|DRUG|SUPREP oral sulfate solution with Gastrografin|
58480561|NCT06603519|DIETARY_SUPPLEMENT|Modified Plant-Based Mediterranean Diet|Two-week dietary intervention after the participants' scheduled colonoscopy consisting of vegetarian high-fiber meals. These meals are designed to provide a substantial intake of dietary fiber through a variety of plant-based foods, including whole grains, legumes, fruits, vegetables, nuts, and seeds. Meals will be delivered bi-weekly, and compliance will be monitored through regular check-ins with a study dietitian.
58492287|NCT02549924|DRUG|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
57780282|NCT00555789|DRUG|AEB071|200mg oral b.i.d.
58135397|NCT00006194|BEHAVIORAL|Exercise|
58135398|NCT03100630|DRUG|RO7239361|Specified dose on specified days
58135399|NCT02392897|BEHAVIORAL|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
58135400|NCT02392897|BEHAVIORAL|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
58135401|NCT05050448|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
58135402|NCT05050448|DRUG|1% Diclofenac Topical Gel|Topical pain-relief gel
58135403|NCT05087693|DRUG|Salbutamol|Inhaling 200ug of salbutamol
58135404|NCT05087693|DRUG|Placebo medication|Inhaling placebo medication
58135405|NCT05087693|OTHER|Ozone|Breathing 170ppb ozone
58135406|NCT05087693|OTHER|Filtered Air|Breathing filtered air
58135407|NCT05087693|OTHER|Exercise|Cycling at 60% of VO2max on a cycle ergometer
58135408|NCT06039982|OTHER|no intervention|no intervention
58135409|NCT02120443|DEVICE|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
58135410|NCT01852435|DRUG|R-CEOP-70|
58135411|NCT01852435|DRUG|R-CEOP-90|
58135412|NCT01852435|DRUG|R-CHOP-50|
58135413|NCT06347042|OTHER|qigong exercise + routine medical treatment +Anti-inflammatory diet|1. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.
58135414|NCT06347042|OTHER|routine medical treatment +Anti-inflammatory diet only|"1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment"
58135415|NCT02087904|BIOLOGICAL|ABT-981|
58135416|NCT02087904|OTHER|Placebo|
58135417|NCT02185690|DRUG|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
58135418|NCT02185690|DRUG|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
58135419|NCT02185690|DRUG|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
58135420|NCT00429000|DEVICE|thermospot|
58135421|NCT05233163|DRUG|Empagliflozin|Empagliflozin 10 mg oral daily for 12 weeks
58135422|NCT04753437|DRUG|Clarithromycin|Clarithromycin tablets.
58135423|NCT04753437|DRUG|Amoxicillin|Amoxicillin capsules.
58480562|NCT01295814|DRUG|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
58480563|NCT01295814|OTHER|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
58480564|NCT05265429|GENETIC|Data and Specimen Collection|"* Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
58135424|NCT04753437|DRUG|Bismuth potassium citrate|Bismuth potassium citrate tablets.
57780283|NCT00555789|DRUG|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
58135425|NCT04753437|DRUG|Esomeprazole|Esomeprazole tablets.
58135426|NCT04753437|DRUG|Vonoprazan|Vonoprazan tablets.
58135427|NCT04119349|BEHAVIORAL|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
58135428|NCT02226952|DRUG|BILN 2061 W, low dose|
58135429|NCT02226952|DRUG|BILN 2061 W, medium dose|
58135430|NCT02226952|DRUG|BILN 2061 W, high dose|
58135431|NCT02226952|DRUG|Placebo|
58135432|NCT00493142|OTHER|Exercise|
58135433|NCT00493142|OTHER|Usual care|
58135434|NCT01388465|BEHAVIORAL|Mobile phone text messaging|Daily assessment followed by feedback
58135435|NCT05922449|PROCEDURE|Thoracic Paravertebral Block|Patients randomly assigned to PV group will be placed in lateral position, and punctured using the out of plane technique guided by ultrasound (Shenzhen Huasheng Navi low-frequency convex array probe). 15 ml of 0.5% ropivacaine was administered to the T4 and T7 thoracic paravertebral spaces respectively, for a total of 30 ml. After injection, the pleura of the punctured segment and adjacent segments could be obviously moved down. Upon successful puncture, the patient was transferred to the supine position. After 5, 10, and 15 minutes, the range of sensory blockage was tested at T3\~T8 to cover the surgical area.
58135436|NCT03164772|DRUG|Durvalumab|anti-PD-L1
58135437|NCT03164772|DRUG|Tremelimumab|anti-CTLA-4
58135438|NCT03164772|BIOLOGICAL|BI 1361849|mRNA Vaccine
58135439|NCT03164772|DEVICE|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
58135440|NCT02992678|DRUG|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
58135441|NCT02992678|DRUG|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
58135442|NCT02751398|DRUG|Dapagliflozin 10mg|
58135443|NCT02751398|DRUG|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
58135444|NCT02924038|BIOLOGICAL|IMA950|IMA950 vaccine
58135445|NCT02924038|BIOLOGICAL|poly-ICLC|poly-ICLC vaccine
58135446|NCT02924038|BIOLOGICAL|Varlilumab|Intravenous solution
57780284|NCT06740032|OTHER|Transcutaneous vagus nerve stimulation|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
57780285|NCT06740032|OTHER|Deep breath exercise|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
57780286|NCT06053814|DRUG|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
57780287|NCT06053814|DRUG|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
57780288|NCT06739811|DEVICE|Implantable Insulin Pump System|Medtronic Implantable Insulin Pump System (MIIPS 2020)
57780289|NCT03368924|OTHER|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, ... Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein ... The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
57780290|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57780291|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
57780292|NCT06015880|DRUG|Lenalidomide|Given PO
57780293|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
57780294|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
57780295|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57780296|NCT00545142|DRUG|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
57780297|NCT00545142|DRUG|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
57780298|NCT06737796|BEHAVIORAL|Finger Feeding|feeding method
57780299|NCT06737796|BEHAVIORAL|syringe feeding|feeding method
57780300|NCT05753748|PROCEDURE|Endoscopic Eradication Therapy|Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
57780301|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
57780302|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
57780303|NCT00439179|DRUG|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
57780304|NCT00439179|DRUG|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
57780305|NCT00439179|DRUG|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
57780306|NCT00439179|DRUG|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
58480565|NCT00422682|DRUG|bsi-201 + topotecan|21 day cycle
58480566|NCT00422682|DRUG|bsi-201 + temozolomide|28 day cycle
58480567|NCT00422682|DRUG|bsi-201 + gemcitabine|28 day cycle
57780307|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment and application of H42® hydrogel to the peri-implant pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
57780308|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of periodontal pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant.
57780309|NCT06740123|PROCEDURE|Non-surgical periodontal treatment and application of H42® hydrogel to the periodontal pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
58135447|NCT01333150|DRUG|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
58480568|NCT00422682|DRUG|bsi-201 + carboplatin/paclitaxel|21 day cycle
58480569|NCT00025181|BIOLOGICAL|MART-1 antigen|
58480570|NCT00025181|BIOLOGICAL|gp100 antigen|
58480571|NCT00025181|BIOLOGICAL|incomplete Freund's adjuvant|
58480572|NCT00025181|BIOLOGICAL|ipilimumab|
58480573|NCT00025181|BIOLOGICAL|tyrosinase peptide|
58480574|NCT00025181|PROCEDURE|adjuvant therapy|
58135448|NCT01333150|DRUG|Placebo|One single dose of placebo
58135449|NCT02218411|OTHER|Exercise training|Exercises routine based on the Otago exercise programme
58135450|NCT03157856|OTHER|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
58135451|NCT04470934|DEVICE|SeQuent® SCB drug-coated balloon catheter|"treatment of coronary artery disease with SeQuent® SCB of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
58135452|NCT03105830|DRUG|iv paracetamol|iv paracetamol
58135453|NCT01911520|DRUG|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
58135454|NCT01911520|DRUG|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
58135455|NCT01911520|PROCEDURE|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
58135456|NCT01911520|PROCEDURE|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
58135457|NCT04680715|RADIATION|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
58135458|NCT00540501|DRUG|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
58135459|NCT01884740|DRUG|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
58135460|NCT00363506|BEHAVIORAL|Serotona Plus and dietary behavior management|
58135461|NCT06157749|OTHER|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
58135462|NCT06305897|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
58135463|NCT06305897|DEVICE|CRYONOVE (EC+05_1osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
58135464|NCT06305897|DEVICE|CRYONOVE (EC+05_2osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
58135465|NCT00002345|DRUG|Megestrol acetate|
58135466|NCT02923388|DRUG|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
58135467|NCT02923388|DRUG|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
58135468|NCT02923388|DRUG|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
58135469|NCT02923388|DRUG|Placebo pill|Placebo pill orally thrice daily for 5 weeks
58135470|NCT05108571|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
58135471|NCT05108571|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
58135472|NCT06032533|DEVICE|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
58135473|NCT06032533|DEVICE|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
58135474|NCT02978586|DEVICE|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
58135475|NCT03133364|OTHER|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
58135476|NCT06063005|PROCEDURE|Translocation ILM Flap|After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
58135477|NCT06063005|PROCEDURE|ILM Peeling|After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
58135478|NCT03607032|DEVICE|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
58135479|NCT03607032|OTHER|usual treatment|medical aerosol session followed by aspiration or not, as required
58135480|NCT04148391|DRUG|Placebo Oral Capsule|Matching placebo capsules.
58135481|NCT04148391|DRUG|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
58135482|NCT03301285|DRUG|Zoledronic Acid|Treatment of osteoporosis
58480575|NCT06002880|DEVICE|Optibond Universal|OBU™ will be used used for the cementation of indirect restorations (ceramic restorations, composite, zirconia and metal crowns) and pretreatment for indirect restoration, according to manufacturer's Instruction For Use in self-etch and total-etch modes.
58135483|NCT01861262|DEVICE|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
58135484|NCT03827863|DEVICE|TTE|TTE to detect the heart function
58135485|NCT03820466|DRUG|Aspirin|Once daily application of platelet inhibiting medication
58135486|NCT03820466|DRUG|Atorvastatin|Once daily application of lipid lowering medication
58480576|NCT00643864|BEHAVIORAL|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
58135487|NCT03820466|DRUG|Placebo Aspirin|Once daily application of placebo
58135488|NCT03820466|DRUG|Placebo Atorvastatin|Once daily application of placebo
58135489|NCT01914497|DEVICE|Acutus Medical System Mapping|
58135490|NCT00839605|DRUG|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
58135491|NCT05288127|DRUG|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
58135492|NCT00723528|DRUG|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
57780310|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of peri-implant pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant.
58135493|NCT00723528|DRUG|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
58135494|NCT00723528|DRUG|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
58135495|NCT00723528|DRUG|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
58135496|NCT00723528|DRUG|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
58135497|NCT00723528|DRUG|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
58135498|NCT00723528|DRUG|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
58135499|NCT04206410|DIETARY_SUPPLEMENT|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
58135500|NCT04206410|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
58135501|NCT06370221|BEHAVIORAL|The effect of psoriatic Arthritis|to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.
58135502|NCT03267628|PROCEDURE|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
58135503|NCT03267628|PROCEDURE|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
58135504|NCT03267628|PROCEDURE|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
58480577|NCT02982746|OTHER|gPCC (Gothenburg Person Centred Care)|
57780311|NCT05830266|BEHAVIORAL|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
58135505|NCT03267628|PROCEDURE|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
58480578|NCT06316102|BEHAVIORAL|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|Multilevel intervention with 4 components
58135506|NCT06199297|DRUG|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
58135507|NCT06199297|DRUG|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
58135508|NCT06199297|PROCEDURE|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
58135509|NCT03169205|OTHER|observation registry|observation registry
58135510|NCT05297032|DIETARY_SUPPLEMENT|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
58135511|NCT00213421|DRUG|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
58135512|NCT03310697|OTHER|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
58135513|NCT03310697|OTHER|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
58135514|NCT01974648|DRUG|propofol|
58135515|NCT01974648|DRUG|propofol and remifentanil|
58135516|NCT04885296|DEVICE|TRP-200|JJVC Investigational Contact Lens
58135517|NCT04885296|DEVICE|JJVC Marketed Contact Lens|ACUVUE Oasys 1-Day
58135518|NCT00428857|PROCEDURE|non invasive ventilation|non invasive ventilation
58135519|NCT01459003|OTHER|beauty care|beauty care performed before each chemo cycle
58135520|NCT01288131|DRUG|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
58135521|NCT01288131|DRUG|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
58135522|NCT05727137|PROCEDURE|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
58135523|NCT05727137|PROCEDURE|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
58135524|NCT05908864|DRUG|Magnesium sulfate|Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
58135525|NCT00743548|DEVICE|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
58492288|NCT01048034|DRUG|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
58135526|NCT00743548|DEVICE|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
58135527|NCT03446248|DEVICE|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
58135528|NCT03446248|DEVICE|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
58135529|NCT04257474|BEHAVIORAL|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
58135530|NCT04257474|BEHAVIORAL|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
58135531|NCT01653353|BEHAVIORAL|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
58135532|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
58135533|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
58135534|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
58135535|NCT05527678|OTHER|Questionnaires|Written or by phone
58135536|NCT03635359|DIAGNOSTIC_TEST|blood test|analysis of cell-free DNA in maternal plasma
58135537|NCT02648880|BEHAVIORAL|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
58492289|NCT01048034|DRUG|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
57780312|NCT05830266|BEHAVIORAL|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
57780313|NCT03528928|DEVICE|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
57780314|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
57780315|NCT05832229|DRUG|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
57780316|NCT03713255|PROCEDURE|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
57780317|NCT03713255|PROCEDURE|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
57780318|NCT03713255|PROCEDURE|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
57780319|NCT03875911|DRUG|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
57780320|NCT05539690|BEHAVIORAL|Balance training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks"
57780321|NCT06738680|DIAGNOSTIC_TEST|LAFOV system (an innovative, latest-generation system) scan|To collect data from the LAFOV system (an innovative, latest-generation system) during the PET scan planned as part of your treatment.
57780322|NCT06740279|OTHER|Assessment of upper limb function|Observational study of the changes in upper limb after SCI paralysis
57780323|NCT04687631|DRUG|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
57780324|NCT04687631|DRUG|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
57780325|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
57780326|NCT06608966|BEHAVIORAL|Epilepsy Journey web-based modules|Participants assigned to Epilepsy Journey modules will independently review web-based EJ modules focused on executive functioning skills. The modules cover 10 topic areas: Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Participants will complete 10 modules (\~15-30 minutes each session) within a 14-week time frame. The goal is to complete one module per week.
57780327|NCT06608966|BEHAVIORAL|Telehealth with a therapist|Therapist will cover 10 areas of executive functioning during telehealth sessions, including Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Telehealth sessions with a therapist will occur via HIPAA-compliant videoconference (e.g. Microsoft Teams) each week ideally over the course of 14 weeks.
57780328|NCT03133663|OTHER|Electrocardiogram group|Experimental
57780329|NCT03133663|OTHER|Pulse oximeter and auscultation group|Control
57780330|NCT01969162|PROCEDURE|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
57780331|NCT06739044|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
57780332|NCT06739044|DRUG|HDG1901|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
57780333|NCT06259162|PROCEDURE|LAG-3 expression / immune checkpoint protein expression|Evaluate the tissue and blood before and after chemotherapy
57780334|NCT06739707|DRUG|MD-18|MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
57780335|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
57780336|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
57780337|NCT00925340|BEHAVIORAL|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
57780338|NCT00925340|BEHAVIORAL|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
58492290|NCT02871908|DRUG|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8
57780339|NCT06740357|OTHER|Tumor response monitoring program|three steps of tumor response evaluation (STEP 1 at 2 months, STEP 2 at 4 months, STEP 3 at 6 months after completion of neoadjuvant treatment): STEP 1: digital rectal examination, pelvic MRI, rectoscopy, TAP scan STEP 2: DRE, pelvic MRI, rectoscopy STEP 3: DRE, pelvic MRI, rectoscopy, TAP or PET scan
57780340|NCT06740357|OTHER|Standard evaluation of tumor response|Assessment at 2 months (+/- 7 days) after neoadjuvant treatment: digital rectal exam, pelvic MRI, rectoscopy, TAP scan
57780341|NCT06740357|OTHER|Shared decision-making|At each stage of the monitoring program and depending on the clinical and oncological results, the decision to preserve the rectum will be discussed with the patient according to a shared-decision program.
57780342|NCT06740357|OTHER|Decision-making according to national recommendations|The decision to preserve the rectum is based on assessment at 2 months after completion of neoadjuvant treatment (standard of care since the GRECCAR2 trial).
57780343|NCT06740357|OTHER|Follow-up|Every 3 months for 2 years, then every 6 months for the third year
57780344|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
57780345|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
57780346|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
57780347|NCT02862847|OTHER|stool samples|
57780348|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
57780349|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
57780350|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
57780351|NCT06739694|BEHAVIORAL|PNE|A manual therapy(Mulligan´s Mobilization with Movement) and 4 sessions of strenght exercises program was administered for both groups. In addition, a pain neuroscience education protocol was administered for the experimental group for a whole period of 4 weeks (1 session/week, 75mins per session).
57780352|NCT06739694|PROCEDURE|Manual therapy|5 sessions of Mulligan´s Mobilization with Movement and 4 sessions of strenght exercises
57780353|NCT04821141|DRUG|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
57780354|NCT06739668|DEVICE|Pascal device|The study devices consist of a tabletop Console with user interface and a head-worn applicator (Headset) that is connected via coaxial cable. The Headset is positioned on the head per instructions, and then the study subject powers on the device by pressing the power button and initiates a 15-minute treatment by pressing the start button. LED lights on the console count down during the treatment to indicate time remaining and, once the treatment is complete, the device automatically powers off.
57780355|NCT06739668|DEVICE|Sham Device|The sham device will look identical to the active device and will have the same indicator lights and sounds, but will not emit magnetic field therapy.
57780356|NCT00604786|DRUG|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
57780357|NCT00604786|DRUG|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
57780358|NCT01281553|DRUG|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
57780359|NCT01281553|DRUG|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
57780360|NCT03869060|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
57780361|NCT06134362|DRUG|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
57780362|NCT06029530|DRUG|Atropine Ophthalmic|eye drops to be administered once daily
57780363|NCT03981536|DRUG|AP-101|Administered by intravenous infusion (IV)
57780364|NCT06737666|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang granules were taken 2 bags at a time, 2 times per day at 1h after meal for 4 weeks.
57780365|NCT03728192|OTHER|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
57780366|NCT02250495|DEVICE|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
57780367|NCT01727518|OTHER|As the LEAD study is an observational cohort study, there is no intervention to report.|As the LEAD study is an observational cohort study, there is no intervention to report.
57780368|NCT01843075|DRUG|Liraglutide|Daily subcutaneous injection
57780369|NCT01843075|DRUG|Placebo|Daily subcutaneous injection
57780370|NCT00355017|PROCEDURE|BNP-guided care in addition to multidisciplinary management|
57780371|NCT06422793|PROCEDURE|No NG tube gastric decompression|Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
58492291|NCT02871908|DRUG|Placebo|Placebo
58492292|NCT00133068|BEHAVIORAL|Computer|Computer intervention only
58492293|NCT00133068|BEHAVIORAL|Reduction in financial barrier|Copay only
58492294|NCT00133068|BEHAVIORAL|Computer intervention & reduction of financial barrier|computer intervention \& copay
58492295|NCT00133068|BEHAVIORAL|Control|No intervention
58135538|NCT02648880|OTHER|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
58135539|NCT04192006|DEVICE|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
58135540|NCT00719316|DRUG|Aliskiren|Aliskiren 300mg per day for 6 weeks
58135541|NCT01393678|DRUG|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
58135542|NCT01393678|DRUG|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
58135543|NCT01700621|BIOLOGICAL|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
58135544|NCT01700621|BIOLOGICAL|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
58135545|NCT02274129|DEVICE|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
58135546|NCT05414760|DEVICE|Womed Leaf|Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
58135547|NCT00259012|DRUG|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
58135548|NCT04840264|DRUG|Docetaxel|25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
58135549|NCT04840264|DRUG|Oxaliplatin|85 mg/msquare metre, D1, D15, repeat every 4 weeks.
58135550|NCT04840264|DRUG|Fluorouracil|1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
58135551|NCT00803764|DRUG|Naproxen Tablets, 500 mg|
58135552|NCT04158570|PROCEDURE|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~* Guy's scoring system (GSS).~* Seoul renal stone complexity scoring system (S-ReSC).~* S.T.O.N.E. nephrolithometry scoring system.~* CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
58135553|NCT00817193|BEHAVIORAL|Physical Activity|Physical Activity program
58135554|NCT00817193|BEHAVIORAL|Wellness|Wellness program
58135555|NCT02830386|DEVICE|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
58135556|NCT06327191|OTHER|No intervention as the study is observational.|No intervention as the study is observational.
58135557|NCT00893464|DRUG|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
58135558|NCT01722877|DEVICE|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
58135559|NCT01492894|DRUG|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
58135560|NCT01492894|DRUG|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
58135561|NCT05480657|BIOLOGICAL|AT-1501 IV Infusion|Investigational study drug
58135562|NCT05480657|BIOLOGICAL|Isolated cadaveric islet cells|Infusion of human cadaveric islet cells into the portal vein
58135563|NCT05621265|BEHAVIORAL|Automated Text messaging|daily text message
58135564|NCT01855932|BEHAVIORAL|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
58135565|NCT00085150|BIOLOGICAL|LMB-2 immunotoxin|
58135566|NCT01244126|DRUG|Intranasal fentanyl|2mcg/kg fentanyl IN
58135567|NCT01244126|DRUG|morphine IM|0.1 mg/kg morphine IM for postop pain
58135568|NCT01244126|DRUG|IV morphine|0.1 mg/kg morphine IV
58135569|NCT04865952|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
58135570|NCT04865952|OTHER|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
58135571|NCT01454544|BIOLOGICAL|AIT Tablet|1 tablet per day in 12 months
58135572|NCT06031792|PROCEDURE|Piezo endodontic surgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex, the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth using piezotome. apical preparation will be performed and Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament suture will be applied. Finally, Post-operative parallel Digital view.
58135573|NCT06031792|PROCEDURE|Conventional endodontic surgery|After the soft tissue curettage and exposure of the root apex, the osteotomy will be performed using a conventional surgical handpiece. The same steps will be followed to prepare and restore the root, as well as to reposition the flap.
58135574|NCT00812266|DRUG|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
58135575|NCT00812266|DRUG|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
58135576|NCT04439396|DRUG|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
58135577|NCT04439396|OTHER|Saline|saline fluid injection
57780372|NCT06391229|BEHAVIORAL|Project Support|"Caregivers will receive up to four, 60- to 90-minute sessions focused on teaching two parenting skills - attentive listening and comforting. Attentive listening involves providing accurate and timely responses to show interest and keep the child engaged until they are ready to end the conversation. Comforting involves using the same attentive listening skills when the child is upset or distressed. Effective mastery of the listening and comforting skills also requires caregivers to withhold any non-listening or non-comforting responses (e.g., interruptions, criticisms).~The program is individually tailored such that caregivers with stronger skills could complete the program in less time (i.e., fewer sessions). Service providers educate caregivers about the skills, then engage in an iterative process of modeling the skills, engaging the caregivers in behavioral practice, and providing tailored, supportive feedback to help caregivers gain mastery."
57780373|NCT06606886|DRUG|Tablet Metformin (Group A)|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
57780374|NCT06606886|DRUG|Tablet Hydroxyurea (Group B)|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
57780375|NCT06740721|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
57780376|NCT05740475|DRUG|9MW3811 injection|Single dose intravenously infused on day 1
57780377|NCT05740475|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
57780378|NCT00521872|PROCEDURE|STARR Operation|
57780379|NCT03679013|DRUG|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
57780380|NCT03679013|DRUG|Opiate based pain regimen.|Standard of care opiate based pain regimen.
57780381|NCT06741202|BEHAVIORAL|Men's MST Group|see above
57780382|NCT06741202|BEHAVIORAL|Present-Centered Group Therapy|see above
57780383|NCT01274130|DRUG|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
57780384|NCT05694715|DRUG|Niraparib|Given orally
57780385|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
57780386|NCT05638880|DRUG|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
57780387|NCT05638880|DRUG|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
57780388|NCT05638880|DRUG|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
57780389|NCT01191684|OTHER|laboratory biomarker analysis|Correlative studies
57780390|NCT01191684|OTHER|enzyme-linked immunosorbent assay|Correlative studies
57780391|NCT01191684|OTHER|flow cytometry|Correlative studies
57780392|NCT01191684|OTHER|immunoenzyme technique|Correlative studies
57780393|NCT01191684|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
57780394|NCT06736756|OTHER|Stretch Exercise|To stretch Tensor fascia lata muscle,each participant starts with side lying position with the tested limb upmost. The lower limb (non-tested) is kept in hip and knee flexion to ensure stability. The tested limb is then taken into hip extension and adduction with knee extended. The exercise is held for 60 seconds and repeated 5 times with 10 seconds break intervals.
57780395|NCT01722916|DRUG|Hyaluronidase|
57780396|NCT02787720|OTHER|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
57780397|NCT02787720|OTHER|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
57780398|NCT03241043|DRUG|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
57780399|NCT03241043|DRUG|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
57780400|NCT04765865|OTHER|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
57780401|NCT05967130|BIOLOGICAL|Phage|Inserting specific specimen of phages in to the bladder
57780402|NCT02826304|PROCEDURE|Vaginal hysterectomy|"All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and"
57780403|NCT02826304|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|"1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
57780404|NCT00259493|PROCEDURE|Off-Pump Coronary Artery Bypass Graft Surgery|
58492296|NCT03204864|DEVICE|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
58492297|NCT03204864|DEVICE|Conventional CS lead placement|Clinical Practice
58492298|NCT00063765|DRUG|Ciliary Neurotrophic Factor Implant NT-501|
58492299|NCT00243438|DEVICE|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
58135578|NCT04227639|PROCEDURE|T-piece trial|T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
58135579|NCT04227639|PROCEDURE|Pressure-support trial|Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
58135580|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
58135581|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.
58135582|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
58135583|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
58135584|NCT02193178|DEVICE|comfilcon A Toric|Contact lenses
58135585|NCT01083277|DEVICE|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
58135586|NCT01083277|OTHER|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
58135587|NCT01139437|BIOLOGICAL|Standard Dose HPIV2 Vaccine|10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
58135588|NCT01139437|BIOLOGICAL|Low dose HPIV2 vaccine|10\^5 TCID50 administered in a single dose
58135589|NCT01139437|OTHER|Placebo|Matched placebo
58135590|NCT04680364|OTHER|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
58135591|NCT02008565|DRUG|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
58135592|NCT02008565|DRUG|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
58135593|NCT02008565|BEHAVIORAL|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
58135594|NCT02008565|BEHAVIORAL|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
58135595|NCT06188091|BEHAVIORAL|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
58135596|NCT03347032|PROCEDURE|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
58135597|NCT03347032|PROCEDURE|Control|Serial inflations and deflations as detailed in the arm/group descriptions
58135598|NCT04362891|PROCEDURE|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
58135599|NCT03581448|BEHAVIORAL|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
58492300|NCT01274689|OTHER|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
58135600|NCT05805657|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
58135601|NCT05805657|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
58135602|NCT05805657|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
58135603|NCT02745925|DRUG|Ibuprofen|
58135604|NCT04164745|DRUG|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
58135605|NCT04164745|BIOLOGICAL|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
58135606|NCT05506280|PROCEDURE|blood prolactin levels|The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
58135607|NCT00366899|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
58135608|NCT00366899|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
58135609|NCT04157348|BIOLOGICAL|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
58492301|NCT03163797|DIAGNOSTIC_TEST|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
58135610|NCT04157348|BIOLOGICAL|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
58135611|NCT04157348|BIOLOGICAL|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
58135612|NCT04157348|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
57785239|NCT00677456|PROCEDURE|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
58135613|NCT05451030|DEVICE|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
58135614|NCT03049488|BIOLOGICAL|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
58135615|NCT03049488|OTHER|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
58135616|NCT00074906|DRUG|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
58135617|NCT03265080|BIOLOGICAL|ADXS-NEO|Intravenous infusion
58135618|NCT03265080|BIOLOGICAL|Pembrolizumab|Intravenous infusion
58135619|NCT06218680|DRUG|Propofol|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
58135620|NCT06218680|DRUG|Normal saline|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
58135621|NCT01449266|DRUG|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
58135622|NCT02268422|DRUG|Buprenorphine|7 day patch
58135623|NCT00983684|DEVICE|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
58135624|NCT00983684|RADIATION|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
58135625|NCT03930498|DRUG|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
58135626|NCT03930498|DRUG|Chemotherapy|Cisplatin and Gemcitabine
58135627|NCT03930498|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
58135628|NCT04622657|OTHER|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
58135629|NCT04221425|PROCEDURE|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
58135630|NCT04221425|PROCEDURE|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
58135631|NCT03412357|PROCEDURE|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
58135632|NCT03412357|PROCEDURE|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
58135633|NCT01020734|BIOLOGICAL|anti-thymocyte globulin|
58135634|NCT01020734|DRUG|busulfan|
58135635|NCT01020734|DRUG|cyclophosphamide|
58135636|NCT01020734|DRUG|cyclosporine|
58135637|NCT01020734|DRUG|fludarabine phosphate|
58135638|NCT01020734|DRUG|methotrexate|
58135639|NCT01020734|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
58135640|NCT00976664|DEVICE|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
58135641|NCT00976664|DEVICE|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
58135642|NCT05317078|DRUG|AMG 794|Short-term intravenous (IV) infusion.
58135643|NCT02506309|DEVICE|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
58135644|NCT02506309|DEVICE|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
58135645|NCT05137483|OTHER|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
58135646|NCT03639311|DRUG|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
58135647|NCT03639311|DRUG|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
58135648|NCT03639311|DRUG|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
58135649|NCT03639311|DRUG|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
58135650|NCT04944537|OTHER|No Intervention|No Intervention
58135651|NCT02359617|DRUG|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
58135652|NCT02359617|DEVICE|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
58135653|NCT03560544|BEHAVIORAL|Breaking up sitting|"A three-part behaviour change intervention, including:~1. Supportive organisational culture and knowledge of consequence of prolonged sitting~2. Environmental Modification~3. Behavioural Changes"
58135654|NCT05486637|BEHAVIORAL|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
58135655|NCT05486637|BEHAVIORAL|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
58135656|NCT02234050|DRUG|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
58135657|NCT02234050|OTHER|Local standard of care|Left to the discretion of the investigator
58135658|NCT04590300|OTHER|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
58135659|NCT02522234|BIOLOGICAL|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
58135660|NCT02522234|BIOLOGICAL|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
58135661|NCT01312922|DRUG|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
58135662|NCT01312922|DRUG|Citalopram|oral once daily administration
58135663|NCT01312922|DRUG|Pipamperone|oral once daily administration
58135664|NCT03814239|OTHER|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was \>15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained \>15%, administration of noradrenaline infusion was considered.
57780405|NCT02818075|OTHER|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
57780406|NCT02818075|OTHER|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
57780407|NCT02640651|DEVICE|DC-Stimulator (PLUS version)|transcranial direct current stimulation
57780408|NCT06738303|DRUG|Cabazitaxel and carboplatin|Given IV
57780409|NCT06738303|DRUG|Lu-PSMA-617|Given IV
57780410|NCT02895490|OTHER|educational intervention|Receive a DVD containing educational information and communication skills
57780411|NCT02895490|OTHER|communication skills training|Receive a DVD containing educational information and communication skills
57780412|NCT02895490|OTHER|educational intervention|Receive information about the LINC group
57780413|NCT02895490|OTHER|questionnaire administration|Ancillary studies
57780414|NCT02895490|OTHER|quality-of-life assessment|Ancillary studies
57780415|NCT06740734|BEHAVIORAL|Stress ball|Sterile Stress ball for pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands.
57780416|NCT06740734|BEHAVIORAL|Expressive touch applications|During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes
57780417|NCT01635361|OTHER|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
57780418|NCT06736717|DRUG|Onvansertib|"20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle."
57780419|NCT06736717|DRUG|NALIRIFOX|"Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle."
57780420|NCT02499328|DRUG|AZD9150|AZD9150
57780421|NCT02499328|DRUG|MEDI4736|MEDI4736
57780422|NCT02499328|DRUG|AZD5069|AZD5069
57780423|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
57780424|NCT06740097|DEVICE|Aspirate tissue monitoring|This multicenter controlled clinical trial investigates the clinical performance and outcomes from using an aspirate tissue monitor (ATM, Marginum Ltd HIVEN™) that detects cancerous tissue from the suction waste during the surgical treatment of suspected high-grade gliomas. The ATM provides near real-time audible feedback to the surgeon when tumor-related fluorescence is detected in the aspirated tissues. The trial investigates if the use of ATM to detect 5-ALA induced fluorescence contributes to faster tumor removal, less blood loss, less unintended residual tumor, less morbidity, longer survival and the frequency of local reoperations. The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls). The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
57780425|NCT06740097|DEVICE|Fluorescence-guided surgery|Resection utilizing conventional visual fluorescence-guided surgery.
57780426|NCT06129409|DRUG|NT-0796|Orally administered capsules
57780427|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
57780428|NCT03685708|BIOLOGICAL|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
57780429|NCT00974103|OTHER|exercise advise|Exercises
57780430|NCT00974103|OTHER|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
57780431|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
57780432|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
57780433|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
57780434|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
57780435|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
57780436|NCT06046443|DRUG|LB54640|Oral daily administration
57780437|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
57780438|NCT05468775|BEHAVIORAL|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
57780439|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
57780440|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
57780441|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
57780442|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
57780443|NCT06740344|PROCEDURE|Two-handed facemask hold|Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver PIP via the T-piece.
57780444|NCT06740344|PROCEDURE|Control: One-handed facemask hold|One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering PPV via the T-piece.
57780445|NCT01233167|DRUG|clopidogrel|clopidogrel 75 mg po per day for 12 months
57780446|NCT01233167|DRUG|placebo|placebo 75mg po per day for 12 months
57780447|NCT01233167|DRUG|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
58480579|NCT04087109|OTHER|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
58135665|NCT03329027|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
58480580|NCT04004364|OTHER|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
58135666|NCT03329027|DEVICE|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
58135667|NCT04165564|OTHER|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
58135668|NCT04165564|OTHER|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
58135669|NCT02994186|PROCEDURE|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
58135670|NCT02994186|OTHER|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
58135671|NCT05754008|BEHAVIORAL|AURORA Care Strategy|Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
58135672|NCT04526964|BEHAVIORAL|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
58135673|NCT03136666|DRUG|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
58135674|NCT03648944|OTHER|Accelerated Rehabillitation|
58135675|NCT03648944|OTHER|Non-Accelerated Rehabillitation|
58135676|NCT02879877|DRUG|UCB7858|
58135677|NCT02879877|DRUG|Placebo|
58480581|NCT02118584|DRUG|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
58480582|NCT00912197|DIETARY_SUPPLEMENT|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
58135678|NCT05844722|BEHAVIORAL|Mindfulness-based intervention therapy|Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
58480583|NCT00912197|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
58480584|NCT04255238|DRUG|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
57780448|NCT04898894|DRUG|Venetoclax|Given orally (PO)
58135679|NCT05844722|OTHER|usual care|Usual care means received standard multidisciplinary stroke care
58135680|NCT00208026|DRUG|Pimecrolimus 1% Cream|Open label single arm
58135681|NCT03693430|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
58135682|NCT03693430|DRUG|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
58135683|NCT02326610|DRUG|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
58135684|NCT01285037|DRUG|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
58135685|NCT01285037|DRUG|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
58135686|NCT01285037|DRUG|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
58480585|NCT04255238|DRUG|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
58480586|NCT02844569|DEVICE|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
58480587|NCT02844569|DEVICE|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
58480588|NCT02844569|DEVICE|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
58480589|NCT00661050|PROCEDURE|Alternative Medicine|
58480590|NCT00661050|PROCEDURE|Tai Chi instruction and class participation or walking exercise and sitting meditation|
58480591|NCT04693819|DIAGNOSTIC_TEST|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
58480592|NCT05087004|BEHAVIORAL|Teen Council|Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
58480593|NCT00400166|BEHAVIORAL|Recovery Mentor|Provided Recovery Mentor services
58480594|NCT01590355|RADIATION|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
58480595|NCT01590355|PROCEDURE|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
58480596|NCT00153244|DRUG|Lamotrigine|
58480597|NCT01498068|DRUG|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
58480598|NCT01498068|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
58480599|NCT01498068|DRUG|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
58480600|NCT00638677|DIETARY_SUPPLEMENT|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
58480601|NCT00638677|DIETARY_SUPPLEMENT|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
58480602|NCT00638677|DIETARY_SUPPLEMENT|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
58480603|NCT01544257|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
58480604|NCT01544257|PROCEDURE|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
58480605|NCT01765933|DIETARY_SUPPLEMENT|DMAA|no placebo
58480606|NCT02839200|DRUG|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
58480607|NCT02839200|DRUG|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
58135687|NCT01285037|DRUG|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
58138956|NCT05778422|DRUG|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
58480608|NCT02839200|DRUG|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
58480609|NCT02839200|DRUG|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
58480610|NCT02839200|DRUG|Placebo 1|Placebo capsules matching ACT-541468 capsules
58480611|NCT02839200|DRUG|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
58480612|NCT01213472|BIOLOGICAL|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
58480613|NCT01238926|DIETARY_SUPPLEMENT|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
58480614|NCT01238926|OTHER|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
58480615|NCT01238926|OTHER|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
58480616|NCT02875236|DRUG|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
58480617|NCT02875236|DRUG|Ringer-acetat|Crystalloid used as standard of care.
58480618|NCT01658436|DRUG|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
58480619|NCT05021406|DRUG|Carvedilol 12.5 MG|Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
58480620|NCT05849493|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
58480621|NCT05849493|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
58480622|NCT01881828|DRUG|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
58480623|NCT01881828|OTHER|oral placebo|
58480624|NCT04866784|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
58480625|NCT05287906|OTHER|Water|Each subject will receive one control and three treatments in the crossover design. The control contains water only.
58480626|NCT05287906|OTHER|Glucose|Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
58480627|NCT05287906|OTHER|Steviol Glycosides|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
58480628|NCT05287906|OTHER|Steviol Glycosides plus glucose|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
58480629|NCT05287906|OTHER|Rebaudioside A|A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
58480630|NCT04135417|BIOLOGICAL|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
58480631|NCT01017302|DRUG|Placebo|Subcutenaous once weekly for 4 weeks
58480632|NCT01017302|DRUG|Placebo|Single subcutaneous dose in week 5
58480633|NCT01017302|DRUG|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
58480634|NCT01017302|DRUG|RO5095932|Single subcutenaous dose in week 5
58480635|NCT02892344|DRUG|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
58480636|NCT02892344|DRUG|MF 200 μg|MF 200 μg o.d. via Twisthaler®
58480637|NCT02074501|OTHER|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
58480638|NCT01745458|DRUG|SB-659032|
58480639|NCT01745458|DRUG|Placebo|Matched placebo
58480640|NCT04284228|BIOLOGICAL|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
58480641|NCT01829958|DRUG|rituximab|
58480642|NCT01829958|DRUG|prednisone|
58480643|NCT01829958|BEHAVIORAL|Geriatric Assessment|
58138957|NCT05778422|PROCEDURE|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
58480644|NCT05906706|DRUG|dupilumab|Subcutaneous (SC) administration
58480645|NCT00002337|DRUG|Vesnarinone|
58480646|NCT02233517|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
57780449|NCT04898894|DRUG|Selinexor|Given Orally (PO)
57780450|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
57780451|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
58480647|NCT02233517|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
58480648|NCT05306535|PROCEDURE|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
58480649|NCT01523912|DEVICE|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
58480650|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
58480651|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
58480652|NCT06373367|OTHER|Illustration based application|Illustrations regarding the cause, risks, and warning signs of preeclampsia
58480653|NCT06373367|OTHER|Text based application|Standard preeclampsia discharge instructions
58480654|NCT00462995|DRUG|Erlotinib|150mg once a day for 28 days
58480655|NCT00462995|DRUG|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
58480656|NCT01249261|DRUG|Risedronate|5 mg/day
58480657|NCT01249261|DRUG|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
58480658|NCT00013221|BEHAVIORAL|Exercise|
58480659|NCT06306716|DEVICE|RENASYS Film with AIRLOCK Technology|RENASYS Film with AIRLOCK Technology intended for use with Smith+Nephew RENASYS NPWT Systems
58480660|NCT00095888|DRUG|triapine|Given IV
58480661|NCT00095888|DRUG|gemcitabine hydrochloride|Given IV
58480662|NCT00095888|OTHER|laboratory biomarker analysis|Correlative studies
58480663|NCT00095888|OTHER|pharmacological study|Correlative studies
58480664|NCT00612144|DRUG|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
58480665|NCT00612144|DRUG|Metformin HCl|"Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
58480666|NCT01202968|PROCEDURE|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
58480667|NCT01197118|RADIATION|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
58480668|NCT01197118|DRUG|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
58480669|NCT01487343|BEHAVIORAL|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
58480670|NCT04899596|OTHER|No intervention|No intervention
58480671|NCT04570007|PROCEDURE|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
58480672|NCT02351622|DRUG|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
58480673|NCT02351622|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
58480674|NCT02351622|DRUG|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
58480675|NCT03834181|DEVICE|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate"
58480676|NCT05827172|PROCEDURE|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
58480677|NCT05827172|OTHER|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
58480678|NCT00036985|DRUG|cyclophosphamide|
58480679|NCT00036985|DRUG|doxorubicin hydrochloride|
58480680|NCT00036985|PROCEDURE|conventional surgery|
57780452|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
57780453|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
58480681|NCT00036985|PROCEDURE|neoadjuvant therapy|
58480682|NCT00036985|PROCEDURE|thermal ablation therapy|
58480683|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
58480684|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
58480685|NCT00533208|DRUG|MK0524|
58480686|NCT00076635|DRUG|Interferon gamma-1b|200 mcg, SQ, 3x per week
58480687|NCT03136510|DRUG|Apixaban 5 mg|"Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month"
58480688|NCT04220463|OTHER|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
58480689|NCT04220463|OTHER|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
58480690|NCT01198496|DRUG|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|\<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
58480691|NCT02148874|BIOLOGICAL|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
58480692|NCT00472576|DRUG|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
58480693|NCT00472576|DRUG|Placebo|Daily double-blind administration of placebo
58480694|NCT04073108|DIAGNOSTIC_TEST|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
58480695|NCT03086811|BEHAVIORAL|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips."
58480696|NCT01356628|DRUG|PD-0332991|PD-0332991, 125mg, 3 cycles
58480697|NCT02902289|DRUG|Ibuprofen 200 mg/5 mL oral suspension|
58480698|NCT02902289|DRUG|MOMENT 200 mg coated tablet|
58480699|NCT06654336|RADIATION|Recurrence-directed therapy (RDT)|RDT options include radiotherapy or surgical resection.
58480700|NCT06654336|DRUG|ELIGARD 22.5mg|ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
58480701|NCT01470521|BIOLOGICAL|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
58480702|NCT01470521|BIOLOGICAL|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
58480703|NCT03768934|OTHER|1X airtime incentive|An incentive given in the form of airtime.
58480704|NCT03768934|OTHER|2X airtime Incentive|An incentive given in the form of airtime.
58480705|NCT03768934|OTHER|Lottery airtime incentive|An incentive given in the form of airtime.
58480706|NCT05330286|DRUG|LMI070|oral solution
58480707|NCT05330286|DRUG|LMI070|Oral solution
58480708|NCT05330286|DRUG|LMI070|Oral solution given in fasted state
58480709|NCT05330286|DRUG|LMI070|Oral solution given in fed state
58480710|NCT05799885|OTHER|Neuro-vestibular-ocular group|Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training
58480711|NCT05799885|OTHER|Myofascial Release group|Manual myofascial release will be applied by the physiotherapist.(30 football players)
58480712|NCT03925285|DRUG|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
58480713|NCT04591613|OTHER|Questionnaire|Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
58480714|NCT04591613|OTHER|Biocollection|Total serum, plasma samples will be collected
58480715|NCT04591613|OTHER|Follow-up visit|All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
57780454|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
58480716|NCT00587314|OTHER|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
58480717|NCT03388710|RADIATION|XRay|Xray to confirm the location of the endotracheal tube
58480718|NCT00131768|DEVICE|Synvisc (hylan G-F 20)|
58480719|NCT05073874|OTHER|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
58480720|NCT01642576|BEHAVIORAL|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
58480721|NCT01486719|PROCEDURE|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
58480722|NCT06242652|DRUG|608 Dose A|608 subcutaneous (SC) injection.
58480723|NCT06242652|DRUG|608 Dose B|608 subcutaneous (SC) injection.
58480724|NCT06242652|DRUG|608 Dose C|608 subcutaneous (SC) injection.
58480725|NCT06242652|DRUG|Adalimumab|Adalimumab subcutaneous (SC) injection.
58480726|NCT06242652|DRUG|Placebo|Placebo subcutaneous (SC) injection.
58480727|NCT00577304|DRUG|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
58480728|NCT00577304|DRUG|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
58480729|NCT01162096|DEVICE|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
58480730|NCT05847946|OTHER|Kinesio tape application and Core stabilization home program|Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.
58480731|NCT05847946|OTHER|Core stabilization home program|Core stabilization exercises will be given to the participants as a home exercise program.
58480732|NCT02922322|OTHER|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
58480733|NCT05048277|BEHAVIORAL|Single Session Consultation|"Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources."
58480734|NCT04876820|OTHER|Pharmacist intervention|"In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist.~An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done.~An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done.~An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done."
58480735|NCT04876820|OTHER|Standard of care|An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
58480736|NCT04341246|DEVICE|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
58480737|NCT02910479|DEVICE|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
58480738|NCT02910479|DEVICE|Rectal thermometer|
58480739|NCT02910479|DEVICE|Esophageal thermometer|
58480740|NCT02910479|DEVICE|Vital sense capsule thermometer|
58480741|NCT03824769|BEHAVIORAL|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
58480742|NCT03824769|BEHAVIORAL|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
58480743|NCT04591808|DRUG|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
58480744|NCT04591808|DRUG|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
58480745|NCT04591808|DRUG|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
58480746|NCT03638193|BIOLOGICAL|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
58480747|NCT00942604|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
58480748|NCT00942604|DRUG|Vehicle gel|two day treatment
58480749|NCT05216549|OTHER|Water-based exercise|8 weeks x 2 times per week for 45 min
58480750|NCT05216549|OTHER|Land-based exercise|8 weeks x 2 times per week for 45 min
58480751|NCT04374669|PROCEDURE|Neuroplasty with Racz catheter|The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
58480752|NCT03414983|BIOLOGICAL|Nivolumab|Specified dose on specified days
58480753|NCT03414983|DRUG|Oxaliplatin|Specified dose on specified days
58480754|NCT03414983|DRUG|Leucovorin|Specified dose on specified days
58480755|NCT03414983|DRUG|Fluorouracil|Specified dose on specified days
58480756|NCT03414983|DRUG|Bevacizumab|Specified dose on specified days
58480757|NCT01849991|BIOLOGICAL|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
58480758|NCT01849991|BIOLOGICAL|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
58480759|NCT00610298|DEVICE|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
58480760|NCT05104138|DRUG|Eplerenone|The patients underwent eplerenone treatment for 6 months
58480761|NCT05104138|DEVICE|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
58480762|NCT01371357|DRUG|TEST 1|2.4 g/day of guanidinoacetic acid
58480763|NCT01371357|DRUG|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
58480764|NCT01371357|DRUG|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
58480765|NCT01371357|DRUG|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
58480766|NCT06654193|DRUG|Allogeneic HB-adMSCs|Allogeneic HB-adMSCs
58135688|NCT01285037|DRUG|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
58135689|NCT01342328|OTHER|Normal saline infusion|Normal saline infusion
58480767|NCT06654193|DRUG|Normal Saline|Sterile Saline Solution
58480768|NCT05490225|DEVICE|Ark|The Ark will be surgically implanted at the access site in subjects undergoing routine hemodialysis. The Ark is expected to provide a target to aid in long-term cannulation success.
58480769|NCT02559141|DRUG|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
58480770|NCT06589323|PROCEDURE|Coronary artery bypass graft|All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
58480771|NCT05432440|BEHAVIORAL|The digital asthma education program|The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
58480772|NCT05462522|DRUG|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
58480773|NCT05462522|DRUG|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
58480774|NCT00432172|DRUG|Epirubicin|
58480775|NCT00432172|DRUG|Cyclophosphamide|
58480776|NCT00432172|DRUG|Docetaxel|
58480777|NCT00432172|DRUG|Exemestane|
58480778|NCT00432172|DRUG|Goserelin|
58480779|NCT00432172|DRUG|Carboplatin|
58480780|NCT03771664|DRUG|SAGE-217|Administered as capsules.
58138958|NCT05487547|DEVICE|IPL_RF_MGX|intense pulsed light followed by Radiofrequency followed by meibomian gland expression
58480781|NCT03771664|DRUG|Placebo|Administered as capsules.
58480782|NCT01080079|DRUG|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
58480783|NCT01080079|OTHER|Purified Water|Purified Water
58480784|NCT00686712|DRUG|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
58480785|NCT00686712|DRUG|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
58480786|NCT00686712|DRUG|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
58480787|NCT01219881|DRUG|Desflurane|5.4 to 7.4% desflurane
58480788|NCT01219881|DRUG|Sevoflurane|1.4 to 2.5% Sevoflurane
58480789|NCT05110924|OTHER|Standard of care|Patients in the treatment arm will receive standard care.
58480790|NCT05110924|OTHER|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
58480791|NCT00518102|DRUG|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
58480792|NCT00518102|OTHER|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
58480793|NCT04634253|DRUG|Placebo|Given IV
58480794|NCT04634253|DRUG|LY3462817|Given IV
58480795|NCT01780740|DRUG|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
58480796|NCT01780740|DRUG|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
58480797|NCT00242502|DRUG|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
58480798|NCT00242502|DRUG|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
58480799|NCT01621269|DRUG|Fingolimod|
58480800|NCT04247685|DEVICE|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
58480801|NCT04247685|DEVICE|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
58480802|NCT04588038|BIOLOGICAL|Efineptakin alfa|Given via intramuscular injection
58480803|NCT06025864|OTHER|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
58480804|NCT02096302|DIETARY_SUPPLEMENT|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
58480805|NCT02096302|DIETARY_SUPPLEMENT|Standard formula|Standard formula without probiotics
58480806|NCT05511584|PROCEDURE|VO2 estimation|"1. st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) \* minute volume (Volmin)~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
58480807|NCT05511584|PROCEDURE|SEVOup estimation|"1. st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) \* Volmin~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
58480808|NCT01394796|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
58480809|NCT01394796|DRUG|Placebo|No active treatment is given.
58480810|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
58480811|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
58480812|NCT02260687|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
58480813|NCT00042822|DRUG|romidepsin|
58480814|NCT02071394|DRUG|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
58480815|NCT02071394|OTHER|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
58480816|NCT03891381|DEVICE|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
58480817|NCT00545636|OTHER|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
58480818|NCT00760032|DRUG|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
58480819|NCT00760032|DRUG|Placebo|Placebo capsules, one capsule per day during four weeks.
58480820|NCT04299607|DIAGNOSTIC_TEST|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
58480821|NCT01958372|DIETARY_SUPPLEMENT|soy isoflavones|Given PO
58480822|NCT01958372|DRUG|cisplatin|Given IV
58480823|NCT01958372|DRUG|etoposide|Given IV
58480824|NCT01958372|DRUG|pemetrexed disodium|Given IV
58480825|NCT01958372|RADIATION|radiation therapy|Undergo RT
58480826|NCT02132988|BIOLOGICAL|OPT-822/OPT-821|
58480827|NCT00068692|RADIATION|Radiotherapy|Undergo external beam radiation therapy
58480828|NCT00068692|DRUG|Fluorouracil|Given IV
58480829|NCT00068692|DRUG|Leucovorin Calcium|Given IV
58480830|NCT00068692|DRUG|Oxaliplatin|Given IV
58480831|NCT00068692|DRUG|Irinotecan|Given IV
58480832|NCT05656144|DEVICE|Cadonilimab|AK104, 6mg/kg, Q2W
58480833|NCT02195102|DEVICE|Transcatheter aortic valve Replacement|
58480834|NCT06591338|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
58480835|NCT06591338|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
58480836|NCT02220543|OTHER|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
58480837|NCT02220543|OTHER|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
58480838|NCT01704599|DRUG|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
58480839|NCT02863419|DRUG|semaglutide|Oral semaglutide once-daily.
58480840|NCT02863419|DRUG|liraglutide|Subcutaneous (s.c.) injection once-daily.
58480841|NCT02863419|DRUG|placebo|Placebo once-daily.
58480842|NCT04892381|DIAGNOSTIC_TEST|Skin Biopsy|"* Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP"
58480843|NCT03053817|OTHER|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
58480844|NCT03303976|BIOLOGICAL|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
58480845|NCT03303976|BIOLOGICAL|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
58480846|NCT00923793|DEVICE|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
58480847|NCT00923793|DEVICE|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
58480848|NCT03623165|DEVICE|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
58480849|NCT03835195|OTHER|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
58480850|NCT03835195|OTHER|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
58480851|NCT04690049|OTHER|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
58480852|NCT04690049|OTHER|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
58480853|NCT05205122|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
58480854|NCT02994446|DEVICE|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
58480855|NCT00960882|DRUG|DMMET-01|1050.6 mg daily for 30 days
58480856|NCT02647619|DRUG|Xiapex|Injection of collagenase of primary dupytren cord
58480857|NCT02647619|PROCEDURE|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
58480858|NCT05987553|OTHER|e-learning program|All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.
58480859|NCT02242526|DEVICE|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
58480860|NCT02242526|DEVICE|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
58480861|NCT01512615|OTHER|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
58480862|NCT01512615|OTHER|Control group|Usual care, clinical control as provided by treating heart centre
58480863|NCT00755053|DRUG|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
58480864|NCT00755053|DRUG|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
58480865|NCT02446522|PROCEDURE|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
58480866|NCT02446522|PROCEDURE|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
58480867|NCT06595212|OTHER|multiomic profile to assess genetic and environmental risk factiors|Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
58480868|NCT01281124|DRUG|Azacitidine|Given subcutaneously
58480869|NCT01281124|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58480870|NCT01281124|OTHER|Pharmacological Study|Correlative studies
58480871|NCT03760042|DRUG|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
58480872|NCT03760042|DRUG|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
58480873|NCT05536401|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
58480874|NCT05536401|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
58480875|NCT05950815|DRUG|CD73 Antigen|subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.
58480876|NCT02079246|DRUG|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
58480877|NCT04033497|DEVICE|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
58480878|NCT02664935|DRUG|AZD4547|FGFR Inhibitor
58480879|NCT02664935|DRUG|Vistusertib|MTORC1/2 Inhibitor
58480880|NCT02664935|DRUG|Palbociclib|CDK4/6 Inhibitor
58480881|NCT02664935|DRUG|Crizotinib|ALK/MET/ROS1 Inhibitor
58480882|NCT02664935|DRUG|Selumetinib|MEK Inhibitor
58480883|NCT02664935|DRUG|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
58480884|NCT02664935|DRUG|AZD5363|AKT Inhibitor
58480885|NCT02664935|DRUG|Osimertinib|EGFRm+ T790M+ Inhibitor
58480886|NCT02664935|DRUG|Durvalumab|Anti-PDL1
58480887|NCT02664935|DRUG|Sitravatinib|VEGFR Inhibitor
58480888|NCT02664935|DRUG|AZD6738|ATR inhibitor
58480889|NCT01337960|BEHAVIORAL|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
58480890|NCT01337960|BEHAVIORAL|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
58480891|NCT01337960|BEHAVIORAL|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
58480892|NCT05618977|BEHAVIORAL|Dramatization simulation|Ethical attitudes of nursing students will be evaluated with dramatization simulation application.
58480893|NCT05618977|BEHAVIORAL|In-class case studies|In-class case studies will be conducted with the control group students.
58138959|NCT00524264|DRUG|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
58480894|NCT05604170|DRUG|Ganaxolone|GNX will be administered.
58480895|NCT06203743|PROCEDURE|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
58480896|NCT06203743|PROCEDURE|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
58480897|NCT02930824|GENETIC|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
58480898|NCT06237985|PROCEDURE|ProTaper Gold file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.
58480899|NCT06237985|PROCEDURE|OneShape file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.
58480900|NCT06237985|PROCEDURE|TruNatomy file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
58480901|NCT02015910|DRUG|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
58480902|NCT02015910|DRUG|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
58480903|NCT02199184|DRUG|Cyclophosphamide|Given IV
58480904|NCT02199184|DRUG|Doxorubicin Hydrochloride|Given IV
58480905|NCT02199184|DRUG|Etoposide|Given IV
58480906|NCT02199184|BIOLOGICAL|Ofatumumab|Given IV
58480907|NCT02199184|DRUG|Prednisone|Given PO
58480908|NCT02199184|BIOLOGICAL|Rituximab|Given IV
58480909|NCT02199184|DRUG|Vincristine Sulfate|Given IV
58480910|NCT03475147|DEVICE|eyeFusion|Smartphone app based flicker fusion test.
58480911|NCT06516679|DRUG|Consolidation #4(without daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
58480912|NCT06516679|DRUG|Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
58480913|NCT06516679|DRUG|Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation"
58480914|NCT01499355|BIOLOGICAL|BIIB023|
58480915|NCT01499355|BIOLOGICAL|Placebo|
58480916|NCT01499355|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
58480917|NCT01499355|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
58480918|NCT05006638|DRUG|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
58480919|NCT05006638|DRUG|Atropine|a drug used as an antidote for some types of pesticides
58138960|NCT06034119|BEHAVIORAL|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
58480920|NCT05006638|DRUG|Toxogonin|a drug used as an antidote for some types of pesticides
58480921|NCT05006638|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
58480922|NCT04180761|DRUG|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
58480923|NCT03632889|BEHAVIORAL|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
58480924|NCT00393731|DRUG|Misoprostol|
58480925|NCT00393731|DRUG|oxytocin|
58480926|NCT06654180|DEVICE|Orthokeratology|Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.
58480927|NCT06654180|DEVICE|defocus-incorporated multiple segment lenses (DIMS) spectacles|It is the special lenses with peripheral lots of tiny segments of plus lenses around the center
58480928|NCT06654180|DEVICE|DISK|SVS
58480929|NCT06654180|DEVICE|Single-focus spectacles|Myopic Glasses with mono-focus in each eye
58480930|NCT05670067|PROCEDURE|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
58480931|NCT05670067|PROCEDURE|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
58480932|NCT04687982|BIOLOGICAL|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
58480933|NCT04005131|DEVICE|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
58480934|NCT04005131|DEVICE|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
58480935|NCT00370968|DRUG|Zinc sulphate|
58480936|NCT03420118|PROCEDURE|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
58480937|NCT03420118|PROCEDURE|Blood draws|"Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
58480938|NCT02757209|DEVICE|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
58480939|NCT02757209|DEVICE|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
58480940|NCT02757209|DEVICE|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
58480941|NCT06655584|DEVICE|Virtual reality headset Bliss DTX|The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
58480942|NCT01957007|DRUG|Docetaxel|Docetaxel will be administered IV.
58480943|NCT01957007|DRUG|vantictumab|Vantictumab will be administered intravenously
58480944|NCT04594980|PROCEDURE|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
58480945|NCT00570830|DEVICE|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
58480946|NCT05623046|BEHAVIORAL|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
58480947|NCT00255489|DRUG|Gefitinib|
58480948|NCT00255489|PROCEDURE|palliative thoracic radiotherapy|
58480949|NCT02630615|OTHER|Blood draw|Whole blood will be collected using standard phlebotomy procedures
58480950|NCT03703284|OTHER|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
58480951|NCT00506363|PROCEDURE|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
58480952|NCT00928239|PROCEDURE|laparoscopic sacropexy with mid vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
58480953|NCT00928239|PROCEDURE|laparoscopic sacropexy with caudal vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
58492302|NCT05765513|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
58492303|NCT00262626|DRUG|Intraocular pressure reduction|
58492304|NCT00262626|PROCEDURE|Argon laser trabeculoplasty|
58492305|NCT00262626|PROCEDURE|Trabeculectomy|
58480954|NCT05448196|OTHER|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
58480955|NCT00533117|DRUG|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
58480956|NCT00533117|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
58135690|NCT01342328|DRUG|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
58135691|NCT01342328|DRUG|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
58135692|NCT00242060|PROCEDURE|MRI|
58135693|NCT05037006|DRUG|Sevoflurane - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
58480957|NCT00533117|BEHAVIORAL|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
58480958|NCT02928614|DRUG|Liraglutide 3 mg (Saxenda)|
58480959|NCT02928614|DRUG|Liraglutide 3 mg placebo|
58480960|NCT03918837|OTHER|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
58480961|NCT03918837|OTHER|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
58480962|NCT05142813|DIAGNOSTIC_TEST|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
58480963|NCT04605172|OTHER|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
58480964|NCT05461209|DRUG|Talquetamab|Talquetamab will be administered as subcutaneous injection.
58480965|NCT05461209|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
57780455|NCT06526754|DEVICE|3D-Printed Liver Model|Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.
57780456|NCT06526754|PROCEDURE|Digital Simulation-Based Surgical Planning|Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
57780457|NCT00654693|OTHER|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
57780458|NCT05203510|DRUG|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
58135694|NCT05037006|DRUG|Sevoflurane - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
58480966|NCT02416336|DEVICE|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
58480967|NCT05955248|DIETARY_SUPPLEMENT|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
58480968|NCT05955248|OTHER|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
58480969|NCT05955248|DIETARY_SUPPLEMENT|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
58480970|NCT06097494|OTHER|No intervention|Observational analysis of usual care only.
58480971|NCT00519441|OTHER|pH study|All patients will have 48 hour pH study
58480972|NCT00112996|DRUG|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
58480973|NCT00112996|OTHER|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
58480974|NCT00936767|DRUG|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
58480975|NCT00936767|DRUG|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
58480976|NCT01432041|BEHAVIORAL|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
58480977|NCT03218046|BEHAVIORAL|EMDR|Eye Movement Desensitisation and Reprocessing
58480978|NCT03905018|DRUG|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
58480979|NCT00059462|DRUG|Interleukin-2 SA|HAART and Bay 50-4798
58480980|NCT00059462|DRUG|HAART|HAART alone
58480981|NCT06414629|OTHER|Simulation Based Mentorship Program|"In this program, local level mentors were developed to provide regular mentorship on low-dose high-frequency approach in contrast to one-time coaching in a long gap. This program combined the existing package of the continuum of care along with Helping Babies Survive (HBS) \& Helping Mothers Survive (HMS) guidelines, adopting a simulation-based onsite mentoring and coaching approach. The mentors provided monthly mentorship on following seven modules topics to the nurses of the intervention birthing centers:~1. Infection prevention~2. Antenatal care and counseling~3. Essential care of labor and birth~4. Helping babies breathe~5. Bleeding after birth~6. Essential care of labor and birth~7. Postnatal care and counseling~Every monthly session was followed by four weekly practice sessions. The nurses from intervention birthing centers were also called mentees."
58480982|NCT06655649|DIETARY_SUPPLEMENT|Ketone-IQ (1,3 Butanediol)|Ketone-IQ (1,3 Butanediol) 20 or 40 g will be ingested (open-label) before bedtime.
58480983|NCT02511548|OTHER|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
58480984|NCT04444726|DEVICE|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
58480985|NCT04444726|DEVICE|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
58480986|NCT04444726|DRUG|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
58480987|NCT01910363|DRUG|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
58480988|NCT01910363|DRUG|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
58480989|NCT06268275|PROCEDURE|Scalp block|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
58480990|NCT06268275|DRUG|Esmolol|Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
58480991|NCT05862077|DEVICE|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
57780459|NCT05203510|DRUG|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
57780460|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
58480992|NCT05862077|BEHAVIORAL|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
58480993|NCT05862077|BEHAVIORAL|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
58480994|NCT05862077|DEVICE|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
58480995|NCT05064215|PROCEDURE|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
58480996|NCT00988806|DRUG|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
58480997|NCT00988806|DRUG|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
58480998|NCT04874246|DRUG|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
58480999|NCT02290769|DEVICE|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
58481000|NCT02290769|DEVICE|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
58135695|NCT05037006|DRUG|Sevoflurane - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
58481001|NCT03338192|OTHER|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
58481002|NCT06207591|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
58481003|NCT03862326|BEHAVIORAL|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
58481004|NCT00120302|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
58481005|NCT00120302|DRUG|Placebo|Matching vehicle cream
58481006|NCT00608374|DRUG|chlorambucil|
58481007|NCT00608374|DRUG|fludarabine phosphate|
58481008|NCT00608374|PROCEDURE|quality-of-life assessment|
58481009|NCT03079622|PROCEDURE|Electric Vacuum Aspiration|
58481010|NCT03079622|PROCEDURE|Manual Vacuum Aspiration|
58481011|NCT03112603|DRUG|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
58481012|NCT03112603|DRUG|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
58481013|NCT03112603|DRUG|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481014|NCT03112603|DRUG|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481015|NCT03112603|DRUG|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481016|NCT03112603|DRUG|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481017|NCT03112603|DRUG|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481018|NCT03112603|DRUG|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481019|NCT03112603|DRUG|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481020|NCT03112603|DRUG|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
58481021|NCT03524729|DEVICE|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
58481022|NCT03524729|DEVICE|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
58481023|NCT03524729|DEVICE|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
58481024|NCT02233686|DRUG|XEN-D0501|
58481025|NCT02233686|DRUG|Placebo|
58481026|NCT06365424|DRUG|Fenofibrate|Fenofibrate (200 mg/day)
58481027|NCT06365424|DRUG|UDCA|Ursodeoxycholic acid (13-15 mg/kg/day)
58481028|NCT05592106|DIAGNOSTIC_TEST|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
58481029|NCT02516241|DRUG|MEDI4736 (Durvalumab)|IV infusion
58481030|NCT02516241|DRUG|Tremelimumab|IV infusion
58481031|NCT02516241|DRUG|Cisplatin|IV infusion
58481032|NCT02516241|DRUG|Carboplatin|IV infusion
58481033|NCT02516241|DRUG|Gemcitabine|IV infusion
58481034|NCT06655402|BEHAVIORAL|CARE-CITE|"CARE-CITE is a post-stroke family education program, to support care partners (CPs) in aiding stroke survivors (SS) during rehabilitation. Utilizing autonomy-supportive strategies, CARE-CITE emphasizes empathy, choice, and problem-solving while minimizing controlling language.~The program features a user-friendly web-based platform with interactive videos that guide CPs in providing support for SS. Over four weeks, CPs engage in two virtual home visits and two phone check-ins. During the initial visit, CPs review online modules, set collaborative goals, and co-create a home exercise plan targeting upper extremity (UE) activities. The second and third weeks involve structured phone calls to discuss autonomy-supportive strategies and address challenges.~The final visit reinforces strategies, assesses SS progress, and adjusts rehabilitation goals. Each module is designed to foster motivation and effective practice in daily activities."
58481035|NCT06655402|BEHAVIORAL|Attention Control Group|"Over a similar 4-week period, the SS and CP will receive the same number of structured virtual weekly visits as the CARE-CITE group without the review of CARE-CITE modules.~The CP will receive a brochure with general caregiving information and website resources. At week 1, a separate control group intervention therapist will deliver a 2-hour virtual home visit to evaluate SS UE function and assess safety concerns. Based on SS impairments, a home exercise program will be prescribed for flexibility, strength, and coordination (6-8 exercises, 2 sets of 10 reps). SS will be encouraged to practice daily (targeting 30 min/day). Weeks 2 and 3: CP Phone check-ins \[15-minute\]. The intervention therapist will review safety, assess adverse events, and CP's use of web resources. Week 4 Virtual Home visit (2 hours). Review SS's progress with the UE activity home exercise program, discuss safety concerns, and progress UE exercises as appropriate."
58481036|NCT06655402|OTHER|Actigraph GT3X+|Accelerometry data will be collected using Actigraph GT3X+ wearable sensors, approved by the FDA. The device does not collect or store individually identifiable health information (IIHI), private health information (PHI), or sensitive data. It is not intended for diagnosing, treating, or preventing diseases. These small, wrist-worn monitors document physical movement for physiological monitoring, including tracking movement during sleep. They can analyze circadian rhythms and assess activity in situations where quantifiable analysis of physical motion is needed.
58481037|NCT00167843|DRUG|sulfadoxine-pyrimethamine|
58481038|NCT03633032|DIAGNOSTIC_TEST|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
58481039|NCT02134158|DEVICE|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
58481040|NCT05784896|DIAGNOSTIC_TEST|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of \>96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
58481041|NCT00740649|DRUG|HSD-016|
58481042|NCT00740649|DRUG|placebo|
58481043|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 1)|0.5ml/vial
58481044|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 2)|0.5ml/vial
58481045|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 3)|0.5ml/vial
58481046|NCT04713241|PROCEDURE|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
58481047|NCT04713241|OTHER|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
58481048|NCT05064436|DRUG|11C-BMS-986196|Specified dose on specified days
58481049|NCT03650231|OTHER|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
58481050|NCT03290885|COMBINATION_PRODUCT|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
58481051|NCT03290885|DEVICE|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
58481052|NCT04731818|BIOLOGICAL|ZB-06|ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
58481053|NCT05973032|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
58481054|NCT06654843|BEHAVIORAL|Comparator Arm|In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.
58481055|NCT06654843|BEHAVIORAL|Enhanced intervention arm|"In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages."
58481056|NCT03319147|DIETARY_SUPPLEMENT|Active|4g of essential amino acids
58481057|NCT03319147|DIETARY_SUPPLEMENT|Placebo|4g of maltdextrin
58481058|NCT06064214|PROCEDURE|u/s guided intermediate cervical plexus block|The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
58481059|NCT02134496|PROCEDURE|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
58481060|NCT00852449|OTHER|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
58481061|NCT00740246|DRUG|VIT-45|
58481062|NCT01698840|DIETARY_SUPPLEMENT|Vitamin D|
58481063|NCT01698840|DIETARY_SUPPLEMENT|Placebo|
58481064|NCT03265314|BEHAVIORAL|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
58481065|NCT03265314|BEHAVIORAL|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
58481066|NCT01772316|DRUG|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
58481067|NCT06104800|OTHER|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
58481068|NCT06104800|OTHER|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
58481069|NCT06091488|OTHER|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
58481070|NCT05408078|DEVICE|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
58481071|NCT05408078|OTHER|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
58481072|NCT00787644|DRUG|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
58481073|NCT00787644|DRUG|Placebo|Matching placebo (inert tablet)
58481074|NCT03405194|DRUG|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
58481075|NCT03405194|DRUG|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
58481076|NCT05060367|DIETARY_SUPPLEMENT|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
58481077|NCT05060367|DIETARY_SUPPLEMENT|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
58481078|NCT03863106|OTHER|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
57780461|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
58135696|NCT05037006|DRUG|TIVA - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
58481079|NCT01238367|DRUG|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
58481080|NCT05973617|DIAGNOSTIC_TEST|Measurement of corneal biomechanical properties|Measurement of corneal biomechanics
58481081|NCT05991271|DEVICE|Venus-Vitae Transcatheter Heart Valve System|The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
58481082|NCT05581342|DIAGNOSTIC_TEST|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
58481083|NCT06143332|OTHER|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
58481084|NCT01440777|BEHAVIORAL|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~* Daily articles~* Daily activities to help get the sleep you need~* Daily sleep improvement recommendations~* Audio recorded relaxation exercises~* Daily e-mails from your program coach~* Personal progress charts~* An online sleep log and daily sleep score"
58481085|NCT03604302|DEVICE|fMRI Paradigms|T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
58481086|NCT02809482|OTHER|Eucaloric feeding|3 days of a diet designed to maintain energy balance
58481087|NCT02809482|OTHER|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
58481088|NCT01068847|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
58481089|NCT06374563|OTHER|group 1 received topical Bee venom gel|Group 1 received a topical application of Bee Venom gel, 3 times per weeks. The wound dressing changed day after day and was cleaned every time with normal saline.
58481090|NCT06374563|OTHER|Group 2: Phonophoresis of Bee Venom gel|group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per weeks
58481091|NCT03585764|DRUG|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
58492306|NCT03801044|DIAGNOSTIC_TEST|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
58481092|NCT03585764|DEVICE|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
58481093|NCT02648919|DRUG|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
58481094|NCT01795053|BEHAVIORAL|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
58481095|NCT01795053|BEHAVIORAL|Placebo open play session|
58481096|NCT02846025|DIETARY_SUPPLEMENT|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
58481097|NCT02846025|DIETARY_SUPPLEMENT|Folate and placebo|rich diet aministracao folate and placebo
58481098|NCT02846025|DIETARY_SUPPLEMENT|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
58481099|NCT01875094|OTHER|Self-Management / MTM using Health IT|
58481100|NCT03997188|DEVICE|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
58135697|NCT05037006|DRUG|TIVA - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
58135698|NCT05037006|DRUG|TIVA - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
58135699|NCT02804737|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
58135700|NCT01760408|OTHER|all patients on Home Parenteral Nutrition|
58135701|NCT02754622|OTHER|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
58138961|NCT06034119|BEHAVIORAL|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
58481101|NCT06137937|BEHAVIORAL|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
58481102|NCT05199103|DRUG|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
58481103|NCT03013803|DIETARY_SUPPLEMENT|Nutricomp Drink Plus Fibre|
58481104|NCT02902237|BIOLOGICAL|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
58481105|NCT03347721|DRUG|lidocaine gel|2% lidocaine jelly, injected into the urethra
58481106|NCT03347721|DRUG|Lubricant Gel|Lubricating gel
58481107|NCT04746677|DEVICE|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
58481108|NCT03743181|OTHER|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
58481109|NCT00897234|OTHER|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
58481110|NCT05871216|DIAGNOSTIC_TEST|Clinical tests and balance evaluation using the Delos Proprioceptive System|Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
58481111|NCT01662102|DRUG|Zevalin|Zevalin administered intravenously.
58481112|NCT01662102|DRUG|Rituximab|Rituximab administered intravenously.
58481113|NCT00489658|DRUG|Eflornithine plus Nifurtimox combination therapy|
58481114|NCT06333912|PROCEDURE|dental implant placement with ridge splitting.|ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement
58481115|NCT00100269|DRUG|Menevit anti-oxidant|
58481116|NCT00438009|DRUG|Coxsackievirus A21|Two doses of drug, separated by 48 hours
58481117|NCT04575948|DRUG|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
58481118|NCT04575948|DRUG|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
58481119|NCT04575948|DRUG|Base formula|Base formula is a negative control
58481120|NCT05976412|RADIATION|Regional lymph node radiotherapy|Regional lymph node radiotherapy
58481121|NCT05976412|RADIATION|chest/whole breast irradiation|chest/whole breast irradiation
58481122|NCT02341677|PROCEDURE|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
58481123|NCT06286345|BEHAVIORAL|GLI-LEEF|"GLI-LEEF is an 18-week program, during which various lifestyle topics are discussed, such as nutrition, exercise, sleep, relationships and intimacy, and specific education about depression and its influence on lifestyle. GLI-LEEF is aimed at improving the activity level, quality of life and (cardiovascular) health of patients and thus increasing the general functioning and well-being of patients and at the same time reducing psychological complaints.~GLI-LEEF consists of 14 group meetings and 4 individual meetings, the group meetings last 90 minutes, the individual meetings 30 minutes. Patients are asked to wear a FitBit and to complete short homework assignments. Each group contains 8-10 patients. Patients are asked to find a buddy who can support them during the program."
58135702|NCT04354532|PROCEDURE|Laparoscopic Banded Sleeve Gastrectomy|The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
58135703|NCT03818230|OTHER|None (observational study)|None (observational study)
58135704|NCT01124929|DRUG|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
58135705|NCT01124929|DRUG|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
58135706|NCT03716011|DEVICE|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
58135707|NCT03991026|BEHAVIORAL|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
58135708|NCT00610090|DEVICE|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
58135709|NCT04558905|OTHER|Face-to-face medical visits|Face-to-face medical visits
58135710|NCT04558905|OTHER|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
58135711|NCT02778230|DIETARY_SUPPLEMENT|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
58135712|NCT02778230|DIETARY_SUPPLEMENT|Control|Snacks (2 baked goods) without fiber fortification.
58135713|NCT01475396|BEHAVIORAL|exercise|
58135714|NCT06310460|PROCEDURE|Papillectomy|Papillectomy prior to bile duct cannulation during ERCP
58135715|NCT03585530|DRUG|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
58135716|NCT01434108|DRUG|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
58135717|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
58481124|NCT03262480|OTHER|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
58135718|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
58135719|NCT05173207|DIAGNOSTIC_TEST|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
58135720|NCT00828035|PROCEDURE|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
58135721|NCT04556240|DEVICE|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
58135722|NCT00537225|BEHAVIORAL|exercise|tailored multifactor CVD risk reduction
58135723|NCT01245322|DRUG|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
58135724|NCT04879888|BIOLOGICAL|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
58135725|NCT03554707|GENETIC|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
58135726|NCT03554707|RADIATION|Radiation|Standard radiation plan
58135727|NCT03554707|DRUG|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
58135728|NCT03554707|DRUG|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
58135729|NCT03554707|DRUG|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
58135730|NCT00150462|DRUG|Carfilzomib|Administered as an IV bolus dose
58135731|NCT00150462|DRUG|Dexamethasone|Administered orally prior to carfilzomib
58135732|NCT01099943|OTHER|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
58135733|NCT06202443|OTHER|Early PT|Physical therapy delivered within the first three months after surgery.
58135734|NCT06202443|OTHER|Delayed PT|Physical therapy delivered greater than 3 months after surgery.
58135735|NCT01076452|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
58481125|NCT02556385|DEVICE|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
58481126|NCT02556385|DEVICE|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
58481127|NCT02454517|BEHAVIORAL|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
58481128|NCT02454517|BEHAVIORAL|Exercise Intervention|Undergo DPP lifestyle intervention
58481129|NCT02454517|OTHER|Informational Intervention|Receive oral and written guidelines and meet with dietician
58481130|NCT02454517|OTHER|Laboratory Biomarker Analysis|Correlative studies
58481131|NCT02454517|OTHER|Quality-of-Life Assessment|Ancillary studies
58481132|NCT02454517|OTHER|Questionnaire Administration|Ancillary studies
58481133|NCT01177371|DRUG|busulfan|Given orally
58481134|NCT01177371|DRUG|cyclophosphamide|Given IV
58481135|NCT01177371|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
58481136|NCT01177371|DRUG|methylprednisolone|Given IV or orally
58481137|NCT01177371|DRUG|methotrexate|Given IV
58481138|NCT01177371|DRUG|cyclosporine|Given IV or orally
58481139|NCT02865447|DEVICE|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
58481140|NCT00361348|DRUG|Palifermin|
57780462|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
58481141|NCT00361348|DRUG|Heparin|
58481142|NCT01721044|DRUG|Placebo|Administered orally
58481143|NCT01721044|DRUG|Baricitinib|Administered orally
58481144|NCT01721044|DRUG|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
58481145|NCT06210217|DRUG|Dobutamine hydrochloride, Injectable|In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.
58481146|NCT06210217|DRUG|0.9% normal saline|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
58481147|NCT05894915|PROCEDURE|open surgery|Open surgery is a traditional surgery method.
58481148|NCT05894915|PROCEDURE|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
58481149|NCT03694886|DRUG|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
57784584|NCT03076658|RADIATION|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
58481150|NCT03694886|OTHER|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
58481151|NCT03694886|DRUG|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
58481152|NCT03694886|OTHER|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
58481153|NCT03553355|DEVICE|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
58481154|NCT03553355|DEVICE|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
58481155|NCT03327662|OTHER|Active CTC Assessment|CTC Counts used to guide treatment switch
58481156|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
58481157|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
58481158|NCT02692521|DIETARY_SUPPLEMENT|Human Milk|
58481159|NCT06313671|DIAGNOSTIC_TEST|Perfusion index|"The perfusion index (PI) is derived from the plethysmography signal and represents the ratio of pulsatile to non-pulsatile light absorbance of the plethysmography signal.~PPG signal."
58481160|NCT00705016|DRUG|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
58481161|NCT00705016|DRUG|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
58481162|NCT00705016|DRUG|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
58481163|NCT00705016|DRUG|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
58481164|NCT00705016|DRUG|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
58481165|NCT03290066|DEVICE|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
58481166|NCT03290066|OTHER|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
58481167|NCT06299059|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
58481168|NCT06299059|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
58481169|NCT05484752|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
58481170|NCT05484752|BEHAVIORAL|Education|Conventional exercise and life style modification
58481171|NCT02341183|DEVICE|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
58481172|NCT02341183|DEVICE|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
58481173|NCT00638014|DEVICE|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
58481174|NCT00638014|DEVICE|Conventional wire closure|Conventional wire closure of sternum
58481175|NCT02353975|DRUG|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
58481176|NCT01495403|DRUG|Hydroxychloroquine|daily dosing
58481177|NCT00169065|DRUG|Clozapine|
58481178|NCT00169065|DRUG|Olanzapine|
58481179|NCT04636268|BIOLOGICAL|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
58481180|NCT04641182|OTHER|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
58481181|NCT05609331|OTHER|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
58481182|NCT05609331|RADIATION|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
58481183|NCT01526304|OTHER|no intervention|No intervention, only observational study
58481184|NCT06507189|OTHER|Combined endurance and resistance training|ET will consist of 3x/wk training (MWF) with MF being steady state cycling, treadmill, or elliptical at 70-75% HRR for 30 min and the W session being a 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) targeting 85-90% HRR. The treadmill and elliptical on M or F will be provided for variety but the mainstay will be cycle ergometry. On MF participants will complete 3 sets x 8-12 repetitions for leg press, knee extension, hamstring curl, chest press, seated row, overhead press, lat pulldown, triceps push-down, and biceps curl in superset fashion \[i.e., alternate between opposing muscle groups without rest (chest press followed by seated row)\] with a 60 s rest between supersets. Sets will be performed with load progression to ensure volitional fatigue in the 8-12 rep range. Core exercises (trunk flexion and extension) will also be included using bodyweight only for 3 sets.
58481185|NCT06236269|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
57784585|NCT04640571|DRUG|pravastatin and chenodeoxycholic acid, after metformin and placebo|single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
58481186|NCT00874510|BEHAVIORAL|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
58481187|NCT02529969|DIETARY_SUPPLEMENT|curcumin|
58481188|NCT02529969|DIETARY_SUPPLEMENT|Placebo|
58481189|NCT04062786|OTHER|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
58481190|NCT00724698|DRUG|Desloratadine|Desloratadine 5 mg once daily
58481191|NCT06595875|OTHER|m-tapa block|Patients in Group M were placed in the supine position. After skin antisepsis with 5% povidone-iodine, a sterile drape was placed. The high-frequency (8-13 MHz) linear ultrasound (USG) probe was covered with a sterile sheath, and the transversus abdominis, internal oblique, and external oblique muscles were identified at the 10th costal margin in the sagittal plane at the costochondral angle. The probe was angled sagittally to visualize the costochondral angle at the edge of the 10th rib and to display the posterior surface of the rib cartilage in the midline. Using an in-plane technique, a 22-gauge, 100-millimeter (mm) Stimuplex A peripheral nerve block needle was advanced cranially, and the needle tip was directed towards the posterior surface of the 10th costal cartilage. After negative aspiration, 20 mL of 0.25% bupivacaine was injected under the lower surface of the costal cartilage. The same procedure was repeated on the opposite side.
58481192|NCT04411498|DIAGNOSTIC_TEST|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
58481193|NCT06299046|PROCEDURE|robot-assisted radical prostatectomy|surgical removal of the entire prostate and the seminal vesicles, followed by the vescico-urethral anastomosis to restore the continuity of the lower urinary tract performed using Da Vinci Si and Xi Surgical System (Intuitive Surgical, Sunnyvale, California, USA)
58481194|NCT00770419|OTHER|medical chart review|
58481195|NCT00770419|OTHER|questionnaire administration|
58481196|NCT00770419|PROCEDURE|psychosocial assessment and care|
58481197|NCT00335777|DRUG|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
58481198|NCT00335777|DRUG|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
58481199|NCT03094325|DEVICE|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
58481200|NCT03094325|DEVICE|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
58481201|NCT03094325|DEVICE|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
58481202|NCT03094325|DEVICE|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
58481203|NCT02656771|DEVICE|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
58481204|NCT00512213|DIETARY_SUPPLEMENT|Immunonutrition for 5 days preoperative|Impact vs Meritene
58481205|NCT00512213|DIETARY_SUPPLEMENT|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
58481206|NCT00742495|DRUG|Forodesine|PK study
58481207|NCT02575638|DRUG|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
58481208|NCT04731558|DRUG|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
58481209|NCT04731558|DRUG|No intervention|No preoperative thromboprophylaxis.
58481210|NCT00003523|DRUG|aminocamptothecin colloidal dispersion|
58481211|NCT04137640|DRUG|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
58481212|NCT04137640|DRUG|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
57784586|NCT04640571|DRUG|valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo|single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
57784587|NCT02838225|DRUG|Docetaxel, Doxorubicin|
57784588|NCT02838225|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|
58481213|NCT03918564|DEVICE|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
58481214|NCT05445271|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
58481215|NCT04069702|BEHAVIORAL|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
58481216|NCT04782869|DEVICE|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
58481217|NCT01747876|DRUG|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
58481218|NCT03754621|DIAGNOSTIC_TEST|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
58481219|NCT03121053|DRUG|sodium bicarbonate|
58481220|NCT03121053|DRUG|hypotone saline|
58481221|NCT01043419|DRUG|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
58481222|NCT04674423|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
58481223|NCT04380285|DEVICE|Custom heel pads and modified soft molded orthotics|
58481224|NCT04380285|DEVICE|Custom hard orthotic|
58481225|NCT05251168|PROCEDURE|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
58481226|NCT05251168|PROCEDURE|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
58481227|NCT05521308|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
58481228|NCT05521308|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
58481229|NCT05521308|DEVICE|Hearing Aid - Variation #2|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
58481230|NCT05521308|DEVICE|Hearing Aid - Variation #3|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
58481231|NCT05521308|DEVICE|Hearing Aid - Variation #4|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
58481232|NCT03144154|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
58481233|NCT03821402|BIOLOGICAL|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
58481234|NCT03821402|BIOLOGICAL|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
58481235|NCT03821402|BIOLOGICAL|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
58481236|NCT03821402|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
58481237|NCT01194856|DRUG|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
58481238|NCT01194856|DRUG|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
58481239|NCT06654375|PROCEDURE|Endovascular Thrombectomy|"Endovascular thrombectomy (EVT) in this clinical trial involves the mechanical removal of a thrombus from a blocked large cerebral artery using specialized devices like stent retrievers or aspiration catheters. Key distinguishing features of this EVT protocol include:~* Extended Time Window: Unlike standard EVT, which is typically performed within 24 hours after symptom onset, this intervention targets patients presenting beyond 24 hours.~* Collateral Circulation Assessment: Multi-phase CT angiography (CTA) is employed to evaluate collateral flow, prioritizing patients with favorable collateral grades. This selection process helps ensure the identification of patients most likely to benefit from EVT despite the late presentation."
58481240|NCT03879161|DEVICE|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
58481241|NCT00086632|DRUG|oregovomab|
58481242|NCT03619382|RADIATION|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
58481243|NCT03619382|RADIATION|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
58481244|NCT02992795|DEVICE|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
58481245|NCT04237116|BIOLOGICAL|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
58481246|NCT04237116|BIOLOGICAL|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
58135736|NCT03455348|OTHER|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
58135737|NCT02763111|DRUG|BCD-085|
58135738|NCT02763111|OTHER|Placebo|
58135739|NCT05319938|PROCEDURE|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
58481247|NCT03033095|DRUG|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
58135740|NCT05319938|PROCEDURE|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
58135741|NCT05319938|PROCEDURE|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
58135742|NCT04761965|DIAGNOSTIC_TEST|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
58135743|NCT04347642|PROCEDURE|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
58135744|NCT04347642|PROCEDURE|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
58135745|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
58135746|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
58135747|NCT05890157|OTHER|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
58135748|NCT02733120|OTHER|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
58135749|NCT06132698|DRUG|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
58135750|NCT05564819|DRUG|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
58135751|NCT05564819|DRUG|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
58135752|NCT05402852|DRUG|EuBone ® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
58135753|NCT05402852|DRUG|placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
58481248|NCT06175884|OTHER|Video about pain neuroscience education with enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will show evidence-based communication skills to effectively convey information to patients.
58481249|NCT06175884|OTHER|Video about pain neuroscience education without enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will not show evidence-based communication skills to effectively convey information to patients.
58481250|NCT03980054|DRUG|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
58481251|NCT03980054|DRUG|Placebo|placebo 400mg, orally once daily for one year
58481252|NCT05204277|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
58481253|NCT05204277|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
58481254|NCT05204277|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
58481255|NCT03904914|OTHER|TOCI|TOCI staging evaluated
58481256|NCT06087653|DRUG|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
58481257|NCT06217510|DEVICE|Test Brace|Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
58481258|NCT02153320|PROCEDURE|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
58135754|NCT04528420|OTHER|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
58135755|NCT04347746|BEHAVIORAL|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
58135756|NCT04347746|BEHAVIORAL|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
58135757|NCT04200482|BEHAVIORAL|One Diet and Physical Activity Session|Attend 1 remote diet and physical activity session
58135758|NCT04200482|OTHER|Electronic (e) Health (eHealth) Communication Intervention|Receive eHealth communication intervention
58135759|NCT04200482|BEHAVIORAL|Twelve Diet and Physical Activity Group Sessions|Attend 12 remote diet and physical activity sessions in 6 months
58135760|NCT04200482|OTHER|Questionnaire Administration|Ancillary studies
58135761|NCT04200482|OTHER|Quality-of-Life Assessment|Ancillary studies
58135762|NCT04104165|DEVICE|Foley Catheter|Foley catheter used for treatment of urinary retention
58135763|NCT02164448|DRUG|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
58135764|NCT02164448|DRUG|the control group|saline infusion from induction of anesthesia to end of surgery
58135765|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
58481259|NCT05812729|BEHAVIORAL|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
58135766|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine|
58135767|NCT01815073|BIOLOGICAL|live attenuated JE vaccine|
58481260|NCT03531346|OTHER|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
58481261|NCT01973764|PROCEDURE|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
58481262|NCT01973764|PROCEDURE|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
57785240|NCT00677456|PROCEDURE|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
58135768|NCT05251025|OTHER|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
58481263|NCT05859503|OTHER|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
58481264|NCT05859503|OTHER|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
58481265|NCT03470389|PROCEDURE|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
58135769|NCT05251025|OTHER|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
58135770|NCT05738382|DRUG|BG2109|oral administration once daily
58135771|NCT05738382|DRUG|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
58481266|NCT04387604|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF\>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
58481267|NCT00736762|OTHER|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
58481268|NCT03519633|DRUG|Sugammadex|Reversal of deep NMB
58481269|NCT03519633|DRUG|Neostigmine|Reversal of moderate NMB
58481270|NCT03979287|OTHER|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
58481271|NCT03979287|OTHER|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
58481272|NCT05528315|DRUG|ABX-002|ABX-002
58481273|NCT05528315|DRUG|Placebo|Placebo
58481274|NCT00494793|PROCEDURE|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
58481275|NCT00006461|DRUG|cisplatin|Given IV
58481276|NCT00006461|DRUG|cyclophosphamide|Given IV
58481277|NCT00006461|DRUG|vincristine sulfate|Given IV
58481278|NCT00006461|DRUG|etoposide|Given PO
58481279|NCT00006461|PROCEDURE|therapeutic conventional surgery|Undergo surgery
58481280|NCT00006461|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
58481281|NCT04522232|PROCEDURE|conventional Total laparoscopic hysterectomy|"the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached."
58481282|NCT04522232|PROCEDURE|Total laparoscopic hysterectomy with prior uterine artery ligation at its origin|"the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy"
58481283|NCT03631888|DIAGNOSTIC_TEST|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
58481284|NCT02575157|OTHER|No intervention|No intervention
58481285|NCT00984217|RADIATION|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
58481286|NCT00984217|DRUG|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
58481287|NCT05612477|PROCEDURE|Autotransfusion|blood is collected from the surgical field, washed, processed and transfused back into the patient
58481288|NCT03841604|DRUG|Safinamide Methanesulfonate|50 mg, 100 mg
58481289|NCT03841604|OTHER|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
58481290|NCT00456222|BEHAVIORAL|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
58481291|NCT02877407|PROCEDURE|patient who undergo laparoscopic/robotic-assisted hysteropexy|
57785241|NCT04882020|DIAGNOSTIC_TEST|cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha|compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
58481292|NCT02877407|PROCEDURE|patient who undergo vaginal hysterectomy|
58481293|NCT05565625|OTHER|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
58481294|NCT05565625|OTHER|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
58481295|NCT05565625|OTHER|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
58481296|NCT05565625|OTHER|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
58481297|NCT05565625|OTHER|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
57785242|NCT03753880|DEVICE|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
58135772|NCT01697696|DRUG|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
58481298|NCT05565625|OTHER|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
58481299|NCT06603688|DRUG|esomeprazole|Esomeprazole 40mg, twice daily for 14 days.
58481300|NCT06603688|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
58481301|NCT06603688|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
58481302|NCT06603688|DRUG|clarithromycin|clarithromycin 500mg, twice daily for 14 days.
58481303|NCT06603688|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
58481304|NCT06603688|DRUG|Minocycline|Minocycline 100 mg, twice daily for 14 days
58481305|NCT00218868|PROCEDURE|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
58481306|NCT05385770|DRUG|AZM X mg + AML Y mg|tablet, single dose, QD, oral administration
58481307|NCT05385770|DRUG|AZM X mg + AML Y' mg|tablet, single dose, QD, oral administration
58481308|NCT05385770|DRUG|AZM X' mg + AML Y mg|tablet, single dose, QD, oral administration
58481309|NCT05385770|DRUG|AZM X' mg + AML Y' mg|tablet, single dose, QD, oral administration
58481310|NCT05385770|DRUG|AZM X mg|tablet, single dose, QD, oral administration
58481311|NCT05385770|DRUG|AZM X' mg|tablet, single dose, QD, oral administration
58481312|NCT05385770|DRUG|AML Y mg|tablet, single dose, QD, oral administration
58481313|NCT05385770|DRUG|AML Y' mg|tablet, single dose, QD, oral administration
58481314|NCT05949333|DRUG|Eflapegrastim|long-acting granulocyte-colony stimulating factor
58481315|NCT01585376|GENETIC|mutation analysis|
58481316|NCT01585376|GENETIC|nucleic acid sequencing|
58481317|NCT01585376|OTHER|laboratory biomarker analysis|
58481318|NCT05710237|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
58481319|NCT05710237|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
58481320|NCT05710237|DRUG|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
58481321|NCT05393102|OTHER|No interventions|No interventions
58481322|NCT01094847|DRUG|DWJ1252|tablet(oral) administration following the schedule of each arm
58481323|NCT03155906|OTHER|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
58481324|NCT05651503|DIETARY_SUPPLEMENT|Prodilac Oral, Frezyderm|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
58481325|NCT05651503|DIETARY_SUPPLEMENT|placebo lozenges|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
58481326|NCT02690948|BIOLOGICAL|Pembrolizumab|Given IV
58481327|NCT02690948|DRUG|Vismodegib|Given PO
58481328|NCT05166772|DRUG|Donafenib|200 mg BID，oral administration will start before the first HAIC treatment.
58481329|NCT05166772|DRUG|Sintilimab|200 mg，Q3W，Intravenous infusion will performe before HAIC treatment.
58481330|NCT05166772|OTHER|HAIC|Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
58481331|NCT06592456|BIOLOGICAL|Chickenpox Vaccines|The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
58481332|NCT04657393|PROCEDURE|mechanical ventilation|change of ventilation frequency
58481333|NCT05979246|DEVICE|Lance CLEAR dental implant|The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
58481334|NCT03822117|DRUG|Pemigatinib|Pemigatinib administered orally once daily (QD).
58135773|NCT01697696|DRUG|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
58135774|NCT01697696|DRUG|Placebo|Placebo to match QAB149
58481335|NCT02847052|OTHER|Non interventional study|
58481336|NCT06555549|DRUG|DEH113|tablets
58481337|NCT06555549|DRUG|Placebo|tablets
58481338|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
58481339|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
58481340|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
58135775|NCT01058278|PROCEDURE|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
57780463|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
57780464|NCT00485576|DRUG|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
58135776|NCT00098826|DRUG|ispinesib|Given IV
58135777|NCT00098826|OTHER|laboratory biomarker analysis|Correlative studies
58481341|NCT03367663|DRUG|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
58135778|NCT00098826|OTHER|pharmacological study|Correlative studies
58135779|NCT03236207|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
58135780|NCT03236207|OTHER|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
58135781|NCT03920657|DRUG|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
58135782|NCT03395444|DEVICE|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
58492307|NCT03801044|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
57780465|NCT03351998|DRUG|Lipitor 20Mg Tablet|20 mg/day pills.
58135783|NCT01728922|DIETARY_SUPPLEMENT|5000IU vitamin D|Vigantol Oil
57780466|NCT03351998|DRUG|Lipitor 80Mg Tablet|80 mg/day pills.
57780467|NCT03351998|DRUG|Placebo Oral Tablet|Matching placebo pill.
57780468|NCT05389332|BEHAVIORAL|Hispanics Skin Cancer intervention|With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
58135784|NCT01728922|DIETARY_SUPPLEMENT|10000IU vitamin D|Vigantol Oil
58135785|NCT01728922|OTHER|Placebo|Placebo Oil
58135786|NCT01247545|PROCEDURE|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
58135787|NCT01247545|PROCEDURE|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
58135788|NCT01851733|DEVICE|MRI-guided Laser Heat Ablation (MLA)|
58135789|NCT01851733|DRUG|Doxorubicin|
57780469|NCT05389332|BEHAVIORAL|Control group: physical activity and nutrition for Hispanics|Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
57780470|NCT03257995|DRUG|Indacaterol maleate|150 μg via Concept1 device
58135790|NCT01851733|OTHER|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
58135791|NCT01851733|DEVICE|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
58135792|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
58135793|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
58135794|NCT01646788|DEVICE|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
58135795|NCT05350137|PROCEDURE|100% oxygen|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
58135796|NCT05350137|PROCEDURE|Carbon dioxide|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
58135797|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
58135798|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
58135799|NCT03338660|BIOLOGICAL|Placebo|Subjects will receive infusion placebo (saline).
58135800|NCT02567838|DRUG|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
58135801|NCT02567838|DRUG|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
58135802|NCT03203447|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
58135803|NCT03203447|DRUG|suprachoroidal sham|sham suprachoroidal procedure
58135804|NCT03203447|DRUG|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
58135805|NCT00878397|DEVICE|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
58135806|NCT01101802|DRUG|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
58135807|NCT01101802|DRUG|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
58135808|NCT04286802|DEVICE|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
58135809|NCT04286802|BEHAVIORAL|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
58135810|NCT06134778|OTHER|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
58135811|NCT04172454|BIOLOGICAL|AK104|AK104, 6mg/kg, Q2W
58135812|NCT05280262|DIAGNOSTIC_TEST|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
58135813|NCT05498805|RADIATION|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
58135814|NCT04925648|DRUG|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
58135815|NCT04925648|DRUG|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
57780471|NCT03257995|DRUG|Indacaterol acetate|150 μg via Concept1 device
58135816|NCT04929626|DRUG|Magnesium Sulfate 500 mg/ml+ ventolin|3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
58135817|NCT04929626|DRUG|Ventolin|it will be given to control group in nebulized form after every 20 min in 1st hour
58135818|NCT05141097|OTHER|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
58135819|NCT02592161|DRUG|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
58135820|NCT06413290|OTHER|PIFP block group|Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery
58135821|NCT06413290|OTHER|Control group|No intervention
58135822|NCT06292871|BEHAVIORAL|Additional GDM management through social media|Usual care provided by a diabetes nurse educator and dietitian. Additional educational resources for dietary management care received, and for any queries to be addressed by dietitian via social media platform from baseline to one-month follow-up visit.
58135823|NCT06292871|BEHAVIORAL|Usual care|Usual care provided by a diabetes nurse educator and dietitian.
58135824|NCT05297266|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
58138962|NCT01416584|BEHAVIORAL|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
58138963|NCT01416584|BEHAVIORAL|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
58135825|NCT05847062|PROCEDURE|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
58135826|NCT05575219|DRUG|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
58135827|NCT05575219|DRUG|Clonidine (protocolized initiation)|"* Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of \>/= 168 hours or with infusion time of 120-167 hours at doses \>/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
58135828|NCT02259270|OTHER|Record review|Record review. No intervention with patient or physician. No effect on outcome.
58135829|NCT02259270|OTHER|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
58135830|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
58135831|NCT02609139|DRUG|PF-06650833|100mg modified release tablet administered under fasted conditions
58135832|NCT02609139|DRUG|PF-06650833|20mg modified release tablet administered under fasted conditions
58135833|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
58135834|NCT02609139|DRUG|PF-06650833|100mg modified released tablet administered with high fat meal food intake
58135835|NCT02609139|DRUG|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
58135836|NCT02961309|DRUG|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
58135837|NCT02359474|DRUG|Trabectedin|
58135838|NCT02359474|GENETIC|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
58135839|NCT02859662|PROCEDURE|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
58135840|NCT02203448|DEVICE|Facet Wedge spinal system|
58135841|NCT05729061|DEVICE|Assist-Knee|Investigational prosthetic knee-ankle device
58135842|NCT05729061|DEVICE|Prosthetic Knee|Commercially available prosthetic knee devices
58135843|NCT05729061|DEVICE|Prosthetic Ankle|Commercially available prosthetic ankle devices
58135844|NCT05729061|DEVICE|Prosthetic Foot|Commercially available prosthetic foot devices
58135845|NCT05729061|DEVICE|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
58135846|NCT04983706|PROCEDURE|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
58135847|NCT01658293|BEHAVIORAL|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
58135848|NCT01658293|BEHAVIORAL|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
57780472|NCT03257995|DRUG|Placebo|Capsule containing no active ingredients delivered via Concept1 device
58135849|NCT01161615|DRUG|MRX-7EAT|Application of up to two patches for up to 7 days.
58135850|NCT01161615|DRUG|Placebo|Application of up to two patches for up to 7 days.
58135851|NCT00854308|DRUG|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
58135852|NCT00854308|DRUG|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
58135853|NCT00854308|DRUG|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
57780473|NCT01990300|DRUG|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
58135854|NCT03443765|DIAGNOSTIC_TEST|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
58135855|NCT03443765|DIAGNOSTIC_TEST|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
58138964|NCT02363634|DIETARY_SUPPLEMENT|magnesium threonate|nutritional product
58138965|NCT00633399|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
58481342|NCT03367663|DRUG|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
58481343|NCT06171243|DRUG|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours."
58481344|NCT03258385|DIETARY_SUPPLEMENT|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
58135856|NCT03859466|DEVICE|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
58135857|NCT02700464|DEVICE|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
58135858|NCT02700464|PROCEDURE|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
58135859|NCT01066806|BEHAVIORAL|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
58135860|NCT01066806|OTHER|observation|observe normal dairy intake
58135861|NCT00952406|OTHER|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
58135862|NCT02808702|BEHAVIORAL|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
58135863|NCT00481780|DEVICE|plain balloon angioplasty|
58135864|NCT00481780|DEVICE|cutting balloon angioplasty|
58135865|NCT03300934|DEVICE|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
58135866|NCT00338481|DRUG|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
58481345|NCT03258385|DIETARY_SUPPLEMENT|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
58481346|NCT04072900|DRUG|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
57780474|NCT01991197|DRUG|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
58135867|NCT00338481|DRUG|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
58135868|NCT03688373|BEHAVIORAL|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
58135869|NCT02693210|DRUG|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
58135870|NCT02693210|DRUG|Methotrexate|Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks
57780475|NCT01991197|DRUG|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
58135871|NCT02693210|OTHER|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
57780476|NCT01991197|DRUG|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
57780477|NCT01991197|DRUG|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
58135872|NCT02693210|OTHER|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
58135873|NCT02693210|OTHER|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
58135874|NCT02693210|DRUG|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
58135875|NCT04096703|PROCEDURE|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is \> 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
58135876|NCT02079766|DRUG|florbetapir F 18|370 megabecquerel (MBq) IV single-dose
58481347|NCT04072900|DRUG|Anti-PD-1|3mg/kg, ivgtt, Q2w
58481348|NCT04072900|DRUG|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
58481349|NCT04072900|DRUG|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
58481350|NCT02874378|DRUG|Dexmedetomidine|
58481351|NCT02874378|DRUG|0.9%NaCl solution|
58481352|NCT03002337|BEHAVIORAL|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
58481353|NCT03002337|BEHAVIORAL|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
58481354|NCT03308071|BEHAVIORAL|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
58481355|NCT05352503|DEVICE|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
58481356|NCT06088121|DEVICE|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
58481357|NCT06088121|DEVICE|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
58481358|NCT06088121|DEVICE|ATNC BN-V1|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
58481359|NCT06088121|DEVICE|ATNC BN-V2|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
58481360|NCT06651866|DRUG|D-CMG|"Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study."
58481361|NCT03023397|BIOLOGICAL|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
58481362|NCT02516761|OTHER|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
58481363|NCT02516761|OTHER|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
58481364|NCT02516761|OTHER|Control group|With this group no intervention is done, but they are assessed like the other groups.
58481365|NCT04078906|OTHER|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
58481366|NCT04842812|BIOLOGICAL|TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3|TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
58481367|NCT04237597|DRUG|K-877|K-877 tablets
58481368|NCT04237597|DRUG|CSG452|CSG452 tablets
58481369|NCT00629070|OTHER|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
58481370|NCT00629070|OTHER|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
58481371|NCT04346381|DRUG|Camrelizumab|Intravenous (IV) camrelizumab on Day 1 of each cycle
58481372|NCT04346381|DRUG|Famitinib|famitinib po qd
58481373|NCT03074513|DRUG|Atezolizumab|Given IV
58481374|NCT03074513|BIOLOGICAL|Bevacizumab|Given IV
58481375|NCT03074513|OTHER|Laboratory Biomarker Analysis|Correlative studies
58481376|NCT03074513|OTHER|Pharmacological Study|Correlative studies
58481377|NCT06655038|BEHAVIORAL|Advocacy coalition|"* set up a task force composed of school stakeholders (students, teachers, educators, principle,...). These stakeholders will meet 4 times a year to improve the implementation and enforcement of TFSP through rules that are accepted, adopted and to which all school actors adhere.~* share of good practices in implementation with the other schools of the intervention arm through a sharing platform and two annual meetings.~* support to reffer nicotine-dependant students and staff members to smoking cessation programs.~* support in the implementation of TFSP and in getting all school actors on board, by the research team, but also by local health promotion partners."
58481378|NCT06655038|BEHAVIORAL|Feedback|Feedback on the basis of the audit and the surveys
57780478|NCT02701582|DRUG|Phenylephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered
58135877|NCT02079766|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
58135878|NCT00654264|PROCEDURE|Water immersion|Subjects will sit in tub for four hours.
58135879|NCT03291548|DIETARY_SUPPLEMENT|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
58135880|NCT03291548|DIETARY_SUPPLEMENT|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
58135881|NCT02967159|DRUG|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
58135882|NCT02967159|DRUG|AZD7594|Treatment B: AZD7594 440 μg via DPI
58135883|NCT02967159|DRUG|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
58135884|NCT02967159|DRUG|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
58135885|NCT01780415|OTHER|blastocoele aspiration|
58135886|NCT02183415|DRUG|BI 1356 BS, low dose|
58135887|NCT02183415|DRUG|BI 1356 BS, medium dose|
58135888|NCT02183415|DRUG|BI 1356 BS, high dose|
58135889|NCT02183415|DRUG|Placebo|
58135890|NCT02344784|DEVICE|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
58135891|NCT02344784|DRUG|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
58135892|NCT05353764|OTHER|scalp nerve block combined with intercostal nerve block using 0.5% ropivacaine|Participants randomized to the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine, which was performed exclusively by an attending anesthesiologist.An attending anesthesiologist will select the site of SNB based on the surgical incision site. Scalp nerve was blocked including greater occipital nerve (2-3ml), superficial temporal nerve (2-3ml), trochlear nerve (2-3ml) and supraorbital nerve (2-3ml). The total volume in scalp nerve block will not exceed 10 ml.Ultrasound-guided unilateral ICNB will be performed at the level of T4-T5 next to the sternum.10-15ml of 0.5% ropivacaine will be injected into the intercostal spaces where incision locates after negative aspiration.
58135893|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit|Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
58135894|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit + Food Care|Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
58135895|NCT02298465|PROCEDURE|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
58135896|NCT02298465|PROCEDURE|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
58135897|NCT02298465|DEVICE|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
58481379|NCT00395031|DRUG|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
58481380|NCT04670978|DRUG|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
58481381|NCT00567099|DRUG|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
58135898|NCT05449249|PROCEDURE|Long-term fasting|The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
58135899|NCT03855332|DRUG|Sildenafil|See above
58135900|NCT03855332|DRUG|Cilostazol|See above
58135901|NCT03855332|DRUG|Placebo|Overencapsulated placebo
58135902|NCT02661529|PROCEDURE|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
58135903|NCT02661529|PROCEDURE|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
58135904|NCT02661529|OTHER|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
58135905|NCT02661529|OTHER|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
58135906|NCT05632770|BEHAVIORAL|Stepped Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
58135907|NCT05632770|BEHAVIORAL|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
58135908|NCT00122798|PROCEDURE|Stroke treatment|
58135909|NCT06399822|DIAGNOSTIC_TEST|Nail capillaroscopy|"The intervention studied as part of the project is capillaroscopy. This examination consists of visualizing the capillaries located at the base of the nail using a device called a capillaroscope. This device magnifies the image of the capillaries to clearly visualize them. Capillaries are the smallest blood vessels, which allow the passage of only one red blood cell at a time. At the nail bed, they form a network of loops and are aligned next to each other. This alignment allows them to be viewed over their entire length. Researchers have described abnormalities in capillaries that are associated with certain diseases involving microvascular damage.~The results of capillaroscopy will be reported qualitatively, for all eight long fingers examined."
58135910|NCT05735925|DIAGNOSTIC_TEST|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
58135911|NCT02005705|OTHER|Outpatient Management of Low-risk Patients|"* Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30"
58135912|NCT02005705|OTHER|Inpatient Management of Low-risk Patients|"* Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30"
58135913|NCT04570904|BIOLOGICAL|Influenza vaccination at different time points|All HCWs will receive the seasonal influenza vaccine but at two different time points.
58135914|NCT03733925|DRUG|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
58135915|NCT02729376|DRUG|galeterone|
58135916|NCT00555230|DRUG|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
58135917|NCT00555230|DRUG|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
58135918|NCT01033565|DRUG|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
58135919|NCT00440297|BIOLOGICAL|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
58135920|NCT00440297|BIOLOGICAL|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
58135921|NCT03615300|DIAGNOSTIC_TEST|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
58135922|NCT00905853|PROCEDURE|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
58135923|NCT00905853|DRUG|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
58135924|NCT02305823|DRUG|Aripiprazole|
58135925|NCT02305823|DRUG|Quetiapine|
58135926|NCT02305823|DRUG|Ziprasidone|
58135927|NCT05586256|RADIATION|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
58135928|NCT03769285|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
58135929|NCT03769285|DRUG|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
58135930|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
58135931|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
58135932|NCT01565096|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
58135933|NCT01565096|DRUG|Glimepiride|Glimepiride at individual dose
58135934|NCT01771705|OTHER|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
58135935|NCT03750097|BEHAVIORAL|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
58135936|NCT03750097|BEHAVIORAL|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
58135937|NCT03750097|BEHAVIORAL|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
58135938|NCT03599505|PROCEDURE|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
58135939|NCT00686959|DRUG|Pemetrexed|infusion over 10 minutes
58135940|NCT00686959|DRUG|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
58135941|NCT00686959|DRUG|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
58135942|NCT00686959|DRUG|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
58135943|NCT00686959|DRUG|Paclitaxel|administered as a 3-hour infusion
58135944|NCT00686959|DRUG|Carboplatin|administered per local practice guidelines over 30 minutes
58135945|NCT00686959|RADIATION|Thoracic Radiation Therapy (TRT)|
58135946|NCT01709474|DRUG|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
58135947|NCT01709474|DRUG|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
58135948|NCT03101878|DRUG|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
58135949|NCT03101878|DRUG|Placebo|Saline .9%
58135950|NCT01475448|OTHER|Long distance training|Long distance training during four months, 3 times per week
58135951|NCT01475448|OTHER|Walking training|Walking training during four months, three times per week
58135952|NCT03151057|DRUG|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
58135953|NCT03151057|DRUG|Placebo Oral Tablet|placebo
58135954|NCT00867542|OTHER|no intervention|no intervention
58135955|NCT04353791|DRUG|OST-122|Active dose
58135956|NCT04353791|DRUG|Placebo|Placebo
58135957|NCT01781598|DEVICE|Total knee arthroplasty (TKA) (Smith &Nephew®)|
58135958|NCT02719522|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
58135959|NCT04351074|PROCEDURE|LIFT|ligation of the intersphincteric fistula track
58135960|NCT04351074|PROCEDURE|fistulectomy|excision of the fistulous track with its internal and external orifices
58135961|NCT01798836|PROCEDURE|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
58135962|NCT01798836|PROCEDURE|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
58135963|NCT04843878|DIAGNOSTIC_TEST|COVID Detect|The study is determining the efficacy of a new rapid COVID testing method.
58135964|NCT06131502|DEVICE|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
58135965|NCT00902876|DEVICE|Mucograft|Collagen Matrix for soft tissue regeneration
58135966|NCT00902876|PROCEDURE|Coronally advanced flap (CAF)|
58135967|NCT00758186|PROCEDURE|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
58481382|NCT03351452|DEVICE|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
58135968|NCT00758186|PROCEDURE|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
58135969|NCT04810377|PROCEDURE|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
58135970|NCT06219473|DRUG|Fascia lata membrane|novel allogenic derived acellular matrix produced from human fascia lata allograft
58135971|NCT06219473|DRUG|Platlet Rich fibrin membrane|Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
58135972|NCT06219473|DRUG|subepithelial connective tissue graft|The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
58135973|NCT01307098|DRUG|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
58481383|NCT03351452|DEVICE|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
58481384|NCT03351452|DEVICE|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
58481385|NCT05663658|OTHER|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
58481386|NCT05663658|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
58481387|NCT05701995|DRUG|Deucravacitinib|Specified dose on specified days.
58481388|NCT05701995|OTHER|Placebo|Specified dose on specified days.
58481389|NCT04542317|BEHAVIORAL|REACH VN|4-6 sessions delivered over the course of 2-3 months.
58135974|NCT01307098|DRUG|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
58135975|NCT01307098|DRUG|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
58135976|NCT01205295|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
58135977|NCT03245086|DEVICE|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
58135978|NCT03245086|PROCEDURE|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
58135979|NCT01787058|OTHER|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
58135980|NCT03084081|DEVICE|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
58135981|NCT03084081|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
58135982|NCT03084081|DEVICE|Thermocoagulator|Thermoablation
58135983|NCT06213688|OTHER|blood sampling|blood sampling at inclusion
58135984|NCT06213688|OTHER|urine sampling|urine sampling at inclusion
58135985|NCT05833594|DIETARY_SUPPLEMENT|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs|The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
58135986|NCT04245566|PROCEDURE|Prostatic Artery Embolization (PAE)|Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
58135987|NCT04245566|DRUG|Pharmacotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
58135988|NCT01624064|DRUG|Enalapril|2.5-20 mg/day
58135989|NCT01624064|DRUG|Calcium Supplement|Calcium 2.5-20 mg/day
58135990|NCT06155630|OTHER|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
58135991|NCT00968552|PROCEDURE|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
58135992|NCT01655628|DRUG|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
58135993|NCT01655628|DRUG|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
58135994|NCT01702584|PROCEDURE|stent assisted embolization|stent assisted embolization and anti-thrombotic management
58135995|NCT05525026|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
58135996|NCT03456947|DRUG|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
58481390|NCT04542317|BEHAVIORAL|Enhanced control|A single session providing education about dementia
58135997|NCT04131751|DIAGNOSTIC_TEST|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
58135998|NCT00281125|DRUG|PTK787 and Pemetrexed with or without Cisplatin|
58135999|NCT02781727|DRUG|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
58136000|NCT02781727|DRUG|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
58136001|NCT02873910|DIETARY_SUPPLEMENT|IQP-AS-119|
58136002|NCT02873910|DIETARY_SUPPLEMENT|Placebo|
58481391|NCT01649778|DRUG|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
57780479|NCT02701582|DRUG|Epinephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
58136003|NCT02637232|OTHER|Mirvaso® / Onreltea TM|
58136004|NCT02578953|DRUG|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
58138966|NCT00633399|DRUG|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
58136005|NCT02578953|DRUG|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
58136006|NCT00191022|DRUG|LY686017|
58136007|NCT00191022|DRUG|paroxetine|
58136008|NCT00191022|DRUG|placebo|
58136009|NCT05940662|PROCEDURE|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
58481392|NCT05226806|OTHER|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
58481393|NCT05226806|OTHER|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
58481394|NCT03595683|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks.
58481395|NCT03595683|BIOLOGICAL|EDP1503|Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).
58481396|NCT01075490|DRUG|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
58481397|NCT01075490|DRUG|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
58481398|NCT02960581|BIOLOGICAL|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
58136010|NCT05940662|PROCEDURE|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
58136011|NCT05940662|PROCEDURE|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
58481399|NCT02960581|BIOLOGICAL|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
58481400|NCT02960581|BIOLOGICAL|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
58481401|NCT02960581|BIOLOGICAL|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
58481402|NCT02960581|BIOLOGICAL|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
58481403|NCT05537662|DEVICE|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
58481404|NCT06653179|PROCEDURE|Sacral Erector Spinae Plane Block|The patient is placed in the prone positionon a procedure table. The sacral region is exposed, and the area is prepped with antiseptic solution under sterile conditions. The ultrasound high-frequency linear transducer is placed transversely over the sacrum. The sacral cornua are typically seen as bony structures adjacent to the sacral hiatus, appearing as two hyperechoic structures. Rotate the ultrasound probe to a sagittal position over the sacrum to align with the fourth and fifth sacral vertebrae. Under continuous ultrasound guidance, block needle is inserted in-plane with the ultrasound probe. Direct the needle through the soft tissue towards the plane between the erector spinae muscle and the sacrum. After confirming needle placement, the injectate mixture of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is administered. A total volume of 10 mL is injected, and real-time ultrasound is used to observe the spread of the injectate within the target tissue plane.
58481405|NCT06653179|PROCEDURE|Caudal Epidural Injection|The patient is positioned in the prone position on the procedure table, and the sacral region is exposed and prepped with antiseptic solution under sterile conditions. The fluoroscope is positioned laterally to visualize the sacral hiatus. Under fluoroscopic guidance, the block needle is inserted through the skin and advanced toward the sacral hiatus. Continuous fluoroscopy is used to ensure correct needle placement, typically visualized at the level of the sacral canal. After confirming the appropriate position with contrast media, the injectate consisting of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is slowly administered, with a total volume of 10 mL. During injection, careful monitoring of the needle position is performed to avoid intravascular injection. After the procedure, patients are monitored for potential complications such as hypotension and allergic reactions.
58481406|NCT02064023|DEVICE|insulin pump|subjects in the experimental arm will administer insulin using a pump
58481407|NCT02064023|OTHER|multiple daily insulin injection|Subjects will continue with usual insulin injections
58481408|NCT00679900|DRUG|eplivanserin (SR46349)|5 mg/day
57780480|NCT02701582|OTHER|Albumin|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
58136012|NCT02550340|OTHER|acute alcohol intake|Smart phone based ECG recording
58136013|NCT03898297|RADIATION|[18F]FPEB|Radiotracer: \[18F\]FPEB
58136014|NCT03898297|RADIATION|[11C]APP311|Radiotracer: \[11C\]APP311, \[11C\]UCB-J
58136015|NCT05688514|DEVICE|Innovalve MR system|Innovalve MR system
58136016|NCT02441309|DRUG|Mifamurtide|
58136017|NCT02441309|DRUG|Ifosfamide|
58136018|NCT03512366|PROCEDURE|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
58136019|NCT03512366|PROCEDURE|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
58136020|NCT05007288|OTHER|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
58136021|NCT05007288|OTHER|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
58136022|NCT03583606|BIOLOGICAL|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).
58136023|NCT03583606|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).
58136024|NCT03583606|OTHER|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
58136025|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype AA|
58136026|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype BB|
58136027|NCT02377622|DEVICE|FX CorDiax 80 Dialyzer|
58136028|NCT02377622|DEVICE|FX CorDiax 800 Dialyzer|
58136029|NCT01976286|OTHER|Salicylic Acid Peels|
58136030|NCT01976286|OTHER|Glycolic Acid Peels|
58136031|NCT00822497|BEHAVIORAL|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
58136032|NCT00822497|BEHAVIORAL|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
58136033|NCT02750124|DEVICE|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
58136034|NCT02750124|OTHER|Routine practice|The standard, annual renewed invitation to cervical screening.
58136035|NCT05915702|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
58136036|NCT05915702|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
58136037|NCT05915702|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
58136038|NCT05915702|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
58136039|NCT05313698|DIAGNOSTIC_TEST|No intervention|cross-sectional study/psychometric study
58136040|NCT05494567|DRUG|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
58136041|NCT05494567|DRUG|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
58136042|NCT05494567|DRUG|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
58136043|NCT06165562|PROCEDURE|PSV|Pressure support ventilation applied from the start of subcutaneous suture until extubation.
57780481|NCT02701582|OTHER|Voluven|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
58136044|NCT06165562|PROCEDURE|Intermittent Manual Assistance|Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.
58136045|NCT06165562|PROCEDURE|EEG-Guidance|Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64
58136046|NCT06165562|PROCEDURE|Obey Command|Extubation criteria include obeying commands (eye-opening or handgrip).
58136047|NCT06165562|PROCEDURE|Spontaneous Respiration|"Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min"
58136048|NCT03358849|BIOLOGICAL|Natural killer cell|Patients who received natural killer cell injection
58136049|NCT01682083|DRUG|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
58136050|NCT01682083|DRUG|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
58136051|NCT01682083|DRUG|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
58136052|NCT05918263|BEHAVIORAL|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
58136053|NCT05214001|DRUG|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
58136054|NCT05214001|DRUG|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
58136055|NCT00138515|DRUG|vildagliptin|
58136056|NCT03333291|DIETARY_SUPPLEMENT|fecal suspension|helathy donor fecal suspension administered by duodenal scope
58136057|NCT05412173|DRUG|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
58481409|NCT00679900|DRUG|lormetazepam|1 mg/day
58136058|NCT01072708|OTHER|Prospective cohort with an annual follow-up|"Annualfollow-up including :~* oral glucose tolerance test~* dietary survey~* biological evaluation~* bacteriological and respiratory measures~* dual-energy x-ray absorptiometry~* physical activity survey"
58136059|NCT02588677|DRUG|Masitinib (4.5)|4.5 mg/kg/day
58136060|NCT02588677|DRUG|Riluzole|
58136061|NCT02588677|DRUG|Placebo|
58136062|NCT02588677|DRUG|Masitinib (3.0)|3 mg/kg/day
58136063|NCT01807637|DEVICE|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
58136064|NCT03643328|BIOLOGICAL|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
58136065|NCT03643328|BIOLOGICAL|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
58136066|NCT00278018|PROCEDURE|Immunotherapy treatment for solid tumors|
58136067|NCT02252731|DRUG|Warfarin|Oral
58136068|NCT02252731|DRUG|FG-4592|Oral
58136069|NCT02253797|DRUG|14C-Tipranavir|
58136070|NCT02253797|DRUG|Tipranavir|
58136071|NCT02253797|DRUG|Ritonavir|
58136072|NCT03726788|DRUG|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
58136073|NCT03726788|DRUG|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
58136074|NCT03726788|DRUG|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
58136075|NCT04408404|PROCEDURE|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
58136076|NCT00741871|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
58136077|NCT00202982|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
58136078|NCT00202982|DRUG|glatiramer acetate 40 mg|glatiramer acetate 40 mg
58136079|NCT02731157|DRUG|Rejuvesol|
58136080|NCT02731157|PROCEDURE|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
58136081|NCT00760110|DEVICE|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
58136082|NCT01141426|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
58136083|NCT01141426|BEHAVIORAL|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
57780482|NCT02701582|OTHER|Normal Saline|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
57780483|NCT02701582|OTHER|Packed Red Blood Cells|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
57780484|NCT02701582|DEVICE|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
58136084|NCT03657329|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
58136085|NCT00847678|BIOLOGICAL|Efungumab (Mycograb)|
58136086|NCT00847678|BIOLOGICAL|placebo|
58136087|NCT00847678|BIOLOGICAL|Amphotericin B|
58136088|NCT00847678|BIOLOGICAL|5 flucytosine|
58136089|NCT03447678|DRUG|Pembrolizumab|humanized antibody used in cancer immunotherapy
58136090|NCT03629249|DRUG|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
58136091|NCT03629249|DRUG|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
58136092|NCT03629249|DRUG|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
58136093|NCT04475965|OTHER|Isometric exercise for shoulder external rotators|The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
58136094|NCT05110677|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
58136095|NCT00056160|DRUG|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
58136096|NCT00056160|DRUG|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
58136097|NCT05488613|DRUG|Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
58136098|NCT02019056|DRUG|Placebo /bid P.O|
58136099|NCT02019056|DRUG|MG-1|
58136100|NCT02019056|DRUG|MG-2 : MG1000mg, Placebo /bid P.O|
58136101|NCT02019056|DRUG|metadoxine|
58136102|NCT00855738|DRUG|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"* Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d"
58136103|NCT00677118|DRUG|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
58136104|NCT00677118|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
58481410|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
58481411|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
58481412|NCT00035243|DRUG|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
58481413|NCT03873077|PROCEDURE|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
58481414|NCT00199212|DRUG|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
58481415|NCT03387085|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
58481416|NCT03387085|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
58481417|NCT03387085|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
58481418|NCT03387085|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
58481419|NCT03387085|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
58481420|NCT03387085|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
58481421|NCT03387085|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
58481422|NCT03387085|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
58481423|NCT03387085|BIOLOGICAL|haNK for Infusion|NK-92 \[CD16.158V, ER IL-2\]
58481424|NCT03387085|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
58481425|NCT03387085|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
58481426|NCT03387085|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
58136105|NCT02419456|DRUG|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
58136106|NCT02419456|DRUG|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
58136107|NCT03704220|DRUG|Warfarin|Removal of anticoagulation with warfarin
58136108|NCT03095846|PROCEDURE|Cooling|Individualized cooling protocol
58136109|NCT03000296|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
58136110|NCT00862550|OTHER|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
58136111|NCT04089982|DRUG|Varenicline|Chantix
58136112|NCT04089982|DRUG|Placebo oral tablet|Placebo
58136113|NCT04063358|DRUG|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
58481427|NCT03387085|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
58481428|NCT03387085|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
58481429|NCT03387085|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
58481430|NCT03387085|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
58481431|NCT03387085|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
58481432|NCT03387085|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
58481433|NCT04948372|DRUG|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
58481434|NCT04948372|DRUG|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
58481435|NCT00453141|DRUG|dosing of Betamethasone|
58481436|NCT06299332|DEVICE|Device treatment|20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit
58481437|NCT05513534|OTHER|Yoga|A standard yoga program will be provided using Hatha poses.
58136114|NCT05526950|DEVICE|Device: CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
58136115|NCT04031131|DRUG|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
58136116|NCT04031131|OTHER|KY Gel|Lubricant Gel
58136117|NCT04167410|OTHER|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
58136118|NCT06312371|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
58136119|NCT06312371|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
58136120|NCT04519437|DRUG|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
58136121|NCT04519437|DRUG|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
58136122|NCT04322500|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
58136123|NCT04322500|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
58136124|NCT05980156|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
58136125|NCT05980156|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
58136126|NCT05980156|DRUG|Sulfadoxine pyrimethamine|Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
58136127|NCT04196322|OTHER|observational study|observational study
58136128|NCT02515422|DRUG|Ketamine|Subcutaneous infiltration of ketamine
58136129|NCT02515422|DRUG|Bupivacaine|Subcutaneous infiltration of bupivacaine
58136130|NCT02515422|DRUG|Placebo (0.9% saline solution)|
58136131|NCT04464798|DRUG|CC-220|Oral
58136132|NCT04464798|DRUG|Rituximab|SC and IV infusion
58136133|NCT04464798|DRUG|Obinutuzumab|IV Infusion
58136134|NCT03100903|DRUG|BI 655130|single dose
58136135|NCT05815056|DEVICE|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
58136136|NCT05815056|DRUG|drug intervention|using sufentanyl 5mg intravenously during the surgery
58136137|NCT03481205|DEVICE|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
58136138|NCT04978766|BEHAVIORAL|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
58136139|NCT00280904|DEVICE|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
58136140|NCT01973348|DEVICE|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
58481438|NCT05513534|OTHER|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
58481439|NCT00235274|DRUG|Subcutaneous Secretin|
58136141|NCT01973348|DEVICE|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
58481440|NCT00112619|DRUG|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
58136142|NCT01973348|DEVICE|2-hour patching|2-hour patching for moderate amblyopia
58136143|NCT01973348|DEVICE|6-hour patching|6-hour patching for severe amblyopia
58136144|NCT02437279|PROCEDURE|Surgery of the tumor|
58136145|NCT02437279|DRUG|Infusion with ipilimumab 3 mg/kg q3wks|
58136146|NCT02437279|DRUG|Infusion with nivolumab 1 mg/kg q3wks|
58136147|NCT05888870|DRUG|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
58136148|NCT05888870|DRUG|SCT800|SCT800 50IU/kg TIW alone
58136149|NCT06078956|DEVICE|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
58136150|NCT04510285|DRUG|Trastuzumab|Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
58136151|NCT04510285|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
58136152|NCT01409486|OTHER|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
58136153|NCT05087134|DRUG|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
58136154|NCT02829970|BEHAVIORAL|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).
58136155|NCT02829970|BEHAVIORAL|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
58136156|NCT02682602|DEVICE|DePuy Synthes total hip arthroplasty|
58136157|NCT02682602|RADIATION|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
58136158|NCT02682602|RADIATION|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
58136159|NCT02188641|OTHER|Diet|
58136160|NCT02188641|OTHER|Exercise|
58136161|NCT02188641|OTHER|Diet and Exercise|
58136162|NCT02188641|OTHER|Healthy Lifestyle (Control) Group|
58136163|NCT06495905|PROCEDURE|transbronchoscopic interventional debridement|"1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement"
58136164|NCT05375201|OTHER|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
57780485|NCT01592695|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
58136165|NCT03863730|DIETARY_SUPPLEMENT|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
58136166|NCT03863730|DIETARY_SUPPLEMENT|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
58136167|NCT01771965|BEHAVIORAL|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
58136168|NCT00448578|DRUG|Quetiapine Fumarate|
58136169|NCT00448578|DRUG|Lithium|
58136170|NCT03968549|DIETARY_SUPPLEMENT|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
58136171|NCT03968549|OTHER|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
58136172|NCT04966455|DIETARY_SUPPLEMENT|Raisins|Daily supplementation of 50 g of rainsins for 3 months
58136173|NCT03205553|PROCEDURE|SoC Staged Silo Closure|Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
58138967|NCT03002597|DEVICE|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
58138968|NCT03497247|BEHAVIORAL|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
58138969|NCT02687074|DEVICE|HFNC|patients treated with high flow nasal cannula
58138970|NCT02687074|DEVICE|NIV|patients treated with noninvasive ventilation
57780486|NCT01592695|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
57780487|NCT01592695|BEHAVIORAL|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
57780488|NCT01592695|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
58136174|NCT03205553|DRUG|Peritoneal Dialysis Solution/Dextrose 1.5%|Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
58136175|NCT06427057|DRUG|Cadonilimab plus chemotherapy|AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）
58136176|NCT06427057|DRUG|Cadonilimab plus TKI|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)
58136177|NCT05177588|DRUG|Metformin Hydrochloride|Metformin 2000 mg/day
58136178|NCT02209480|BEHAVIORAL|Alexander Technique|
58136179|NCT02209480|DEVICE|Heat pad application|
58136180|NCT02209480|BEHAVIORAL|guided imagery|
58136181|NCT04835246|DEVICE|Spectra IMDx system|The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
58136182|NCT03555305|DRUG|Insulin Glargine|Administered SC
58136183|NCT03555305|DRUG|Lantus|Administered SC
58136184|NCT05641103|OTHER|Patient with splenomegaly or splenectomy|No interventional study
58136185|NCT03806777|DRUG|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
58136186|NCT03099174|DRUG|Xentuzumab|Once weekly administrated through one hour intravenous infusion
58136187|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
58136188|NCT03099174|DRUG|Letrozole|Once a day
58136189|NCT03099174|DRUG|Anastrozole|Once a day
58136190|NCT03099174|DRUG|Fulvestrant|Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
58136191|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
58136192|NCT00076934|DRUG|RG2077 (CTLA4-IgG4m)|RG2077
58136193|NCT04041843|DRUG|Apixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
58136194|NCT00126932|DEVICE|SonoPrep|
58136195|NCT02636959|OTHER|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
58136196|NCT03397862|DRUG|Donepezil TDS|Donepezil patch
58136197|NCT03397862|DRUG|Vehicle TDS|Placebo patch
58136198|NCT03252353|DRUG|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
58136199|NCT03252353|DRUG|Matching placebo|Matching placebo capsules
58136200|NCT03460951|DIAGNOSTIC_TEST|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
58136201|NCT05498480|BIOLOGICAL|Relatlimab|Specified dose on specified days
58136202|NCT05498480|BIOLOGICAL|Nivolumab|Specified dose on specified days
58136203|NCT05374590|BIOLOGICAL|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
58136204|NCT01346397|DRUG|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
58136205|NCT01389102|DRUG|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
58136206|NCT01389102|DRUG|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
58136207|NCT01389102|DRUG|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
58136208|NCT01389102|DRUG|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
58136209|NCT01389102|DRUG|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
58136210|NCT01389102|DRUG|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
58136211|NCT04657770|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
58136212|NCT03588624|DEVICE|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
58136213|NCT00397488|DRUG|sunitinib malate|
58136214|NCT05000619|BEHAVIORAL|Outreach mailer|Postcard or letter
58136215|NCT05000619|BEHAVIORAL|Humor/Salience|Funny cartoon
58136216|NCT05000619|BEHAVIORAL|Doctor's authority|Letter from a doctor
58136217|NCT05000619|BEHAVIORAL|Information|Information about benefits of the appointment
58136218|NCT05493930|OTHER|The hospital where the treatment is performed|
58136219|NCT01934621|BEHAVIORAL|Strategy Training|
58136220|NCT01934621|BEHAVIORAL|Attention Control|
58136221|NCT05537051|DRUG|PM1021, PM8001|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
58136222|NCT00882180|DRUG|ALN-VSP02|IV infusion administered every two weeks
58136223|NCT03124420|DRUG|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
58136224|NCT03124420|DRUG|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
58136225|NCT03124420|DRUG|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
58136226|NCT04423263|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
58136227|NCT04423263|PROCEDURE|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
58136228|NCT01532674|DEVICE|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~* Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~* Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~* All the periodontal pockets will be treated subgingivally~* Elimination of the photosensitive by irrigation"
58136229|NCT01532674|PROCEDURE|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~\* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
58481441|NCT05022576|DIAGNOSTIC_TEST|Robotic arm assisted PSMA PET/CT guided prostate biopsy|The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
58136230|NCT01944267|PROCEDURE|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
58481442|NCT04467684|DRUG|CB-0406 100 mg|Single oral dose
58481443|NCT04467684|DRUG|CB-0406 200 mg|Single oral dose
57780489|NCT01592695|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
58136231|NCT01944267|PROCEDURE|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
58138971|NCT00184600|DRUG|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
58138972|NCT00184600|DRUG|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
58138973|NCT00184600|DRUG|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
58481444|NCT04467684|DRUG|CB-0406 400 mg|Single oral dose
58481445|NCT04467684|DRUG|CB-0406 800 mg|Single oral dose
57780490|NCT01592695|DRUG|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
57780491|NCT01592695|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
57780492|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
58136232|NCT01944267|PROCEDURE|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
58136233|NCT04213690|OTHER|No Intervention|There is no intervention for this study
58136234|NCT03206177|DRUG|Galunisertib|Galunisertib 150mg po BID day 4-17
58136235|NCT03206177|DRUG|Paclitaxel|IV Day 1: Paclitaxel 175 mg/m2 over 3 hours
58136236|NCT03206177|DRUG|Carboplatin|IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
58136237|NCT03952143|DRUG|LY900014|Administered SC
58136238|NCT03952143|DRUG|Insulin Lispro|Administered SC
58136239|NCT03952143|DRUG|Insulin Glargine|Administered SC
58136240|NCT03952143|DRUG|Insulin Degludec|Administered SC
58136241|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
58136242|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
58136243|NCT01071122|DRUG|Valsartan|Valsartan 160mg, Once daily
58136244|NCT00951925|OTHER|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
58136245|NCT04770961|PROCEDURE|Erector spinae plane catheter with 0.5% Ropivacaine|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.
58136246|NCT04770961|PROCEDURE|Erector spinae plane catheter with saline|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
58136247|NCT05363878|BEHAVIORAL|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
58136248|NCT02697331|DRUG|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
58136249|NCT02697331|OTHER|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
58136250|NCT03649971|DRUG|Guselkumab|Guselkumab SC will be administered every 4 weeks.
58136251|NCT03649971|DRUG|Placebo|Placebo SC will be administered every 4 weeks.
58136252|NCT03202576|DEVICE|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
58136253|NCT04633109|PROCEDURE|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
58136254|NCT04633109|DIAGNOSTIC_TEST|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
58136255|NCT04633109|DIAGNOSTIC_TEST|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
58136256|NCT04633109|DIAGNOSTIC_TEST|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
58136257|NCT04633109|DIAGNOSTIC_TEST|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
58136258|NCT04633109|DIAGNOSTIC_TEST|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
57780493|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
58136259|NCT04633109|OTHER|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
57780494|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
58136260|NCT04633109|OTHER|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
58136261|NCT02008305|DEVICE|protocol of optimization ALARA|
58136262|NCT02008305|DEVICE|protocol of optimization Philips|
58136263|NCT01361802|DRUG|Ambroxol Spray|low dose Ambroxol Spray
58136264|NCT01361802|DRUG|Ambroxol Spray|medium dose Ambroxol Spray
58136265|NCT01361802|DRUG|Ambroxol Spray|high dose Ambroxol Spray
58136266|NCT01361802|DRUG|Placebo Spray|Placebo Spray
58136267|NCT06302374|BIOLOGICAL|GR2001|intramuscular injection
58136268|NCT06302374|BIOLOGICAL|Placebo|intramuscular injection
58136269|NCT06302374|BIOLOGICAL|HTIG|intramuscular injection
58136270|NCT06302374|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
58136271|NCT03894605|DEVICE|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
58136272|NCT06433674|DRUG|Zinc Sulfate|The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
58136273|NCT06433674|OTHER|Sterile Water|The placebo group with will receive a similar amount of sterile water in a colored syringe
58136274|NCT04707040|OTHER|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
58136275|NCT02099981|DRUG|Aminoguanidine|
58136276|NCT03401996|DEVICE|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
58136277|NCT05539222|OTHER|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
58136278|NCT02738190|DRUG|Albumin|Albumin 5% added to blood priming solution
58136279|NCT02738190|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
58136280|NCT01544127|BEHAVIORAL|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
58136281|NCT01544127|BEHAVIORAL|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
58136282|NCT01544127|OTHER|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
58136283|NCT01506466|OTHER|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
58136284|NCT05378126|OTHER|Neurological assessment|"No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation."
58136285|NCT06250010|DIAGNOSTIC_TEST|tissue samples (healthy and tumor taken from the same patient) and tissue samples (decidualized endometrium and trophoblast taken from it patient)|Correlation between the immuno-score results of each patient with his prognosis, in terms disease-free survival, overall survival, relapse-free survival, disease-specific survival cancer, distant and/or local free survival, to validate their potential role independent in the progression of endometrial cancer; later, for a better characterization of the various ones risk classes, we will combine our immuno-score with the already known risk factors, included in the ESMO-ESGO-ESTRO classification and in the biomolecular classification of endometrial cancer, to investigate whether the Microenvironmental immunological factors in endometrial cancer could allow better stratification of patients in risk classes.
58481446|NCT04467684|DRUG|CB-0406 1,000 mg|Single oral dose
58481447|NCT04467684|DRUG|Matched placebo|Color and size matched placebo
58136286|NCT04786184|BEHAVIORAL|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
58481448|NCT05063058|DRUG|Molecular guided therapy|Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
58481449|NCT04763369|BIOLOGICAL|Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
58481450|NCT04763369|BIOLOGICAL|Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa|Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
58481451|NCT04053803|DRUG|IMR-687|Oral administration of once daily IMR-687
58481452|NCT02965014|BEHAVIORAL|Face-to-Face Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
58481453|NCT02965014|BEHAVIORAL|mHealth Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
58481454|NCT02965014|BEHAVIORAL|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing (HCT).
58481455|NCT02778737|BEHAVIORAL|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
58481456|NCT02778737|BEHAVIORAL|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
58481457|NCT03283501|PROCEDURE|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
58481458|NCT05287620|DEVICE|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
58481459|NCT05533736|OTHER|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
58481460|NCT05808231|DRUG|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
58481461|NCT05808231|DRUG|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
58481462|NCT03863158|OTHER|No intervention|No intervention / medical records only
58481463|NCT01698398|DEVICE|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
58481464|NCT00536419|DRUG|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
58481465|NCT00536419|OTHER|Placebo|Placebo, daily dose, 4 days, oral administration
58481466|NCT00887536|DRUG|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
58481467|NCT00887536|DRUG|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
58481468|NCT00887536|DRUG|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
58481469|NCT00887536|DRUG|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
58481470|NCT00887536|DRUG|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]
58481471|NCT02721329|DEVICE|APAP|Automatic Continuous Positive Airway Pressure
58481472|NCT02721329|DEVICE|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
58481473|NCT02558296|DRUG|Bexagliflozin|20 mg, tablet
58481474|NCT02558296|DRUG|Placebo|20 mg tablet to match active comparator
58481475|NCT01244893|DEVICE|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
58481476|NCT01244893|DEVICE|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
58481477|NCT04347122|DRUG|Tranexamic Acid (TXA)|Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
58481478|NCT01732289|GENETIC|genes|Draw blood for genetic screening
58481479|NCT01123902|DEVICE|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
58136287|NCT04786184|BEHAVIORAL|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
58136288|NCT00604877|BEHAVIORAL|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
58136289|NCT00604877|BEHAVIORAL|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
58136290|NCT05376007|BEHAVIORAL|Serious game 'Broodles'|The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson \& Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
58136291|NCT03785548|OTHER|Usage of a mirror|using a mirror during the pelvic examination
58136292|NCT01463761|DEVICE|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
58136293|NCT02815319|DRUG|Dexamethasone|Steroid prophylaxis
58136294|NCT00959660|BEHAVIORAL|Exercise|walking, treadmill and bicycle exercise
58136295|NCT00959660|DIETARY_SUPPLEMENT|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
58136296|NCT00959660|BEHAVIORAL|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
58136297|NCT00959660|OTHER|Attention Control|control group- continue their previously randomized life style
58136298|NCT05194722|BEHAVIORAL|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
58136299|NCT01038791|DEVICE|heated humidification|temperature 35°
58136300|NCT01038791|DEVICE|heat and moisture exchanger|single patient device
58136301|NCT01038791|DEVICE|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
58136302|NCT04742478|PROCEDURE|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
58136303|NCT05364632|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
58136304|NCT05364632|OTHER|Aerobic Training|The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
58136305|NCT05290311|BEHAVIORAL|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
58136306|NCT03438253|PROCEDURE|spinal anaesthesia|
58136307|NCT00778505|DRUG|Propofol|closed-loop administration using bispectral index as the controller
58136308|NCT00778505|DRUG|remifentanil|closed-loop administration using bispectral index as the controller
58136309|NCT00778505|DRUG|Propofol|manual administration according bispectral index values
58136310|NCT00778505|DRUG|Remifentanil|manual administration according bispectral index values
58136311|NCT00011570|DEVICE|Bladder & Bowel Control|
58136312|NCT06327607|OTHER|Control Group|Standard care for breast cancer
58136313|NCT06327607|OTHER|Psychosexological intervention|The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.
58136314|NCT04807621|BIOLOGICAL|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
58136315|NCT04807621|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
58136316|NCT02680626|DRUG|Magnesium Sulfate|Given via transversus abdominis plane block
58136317|NCT02680626|DRUG|Ropivacaine|Given via transversus abdominis plane block
58136318|NCT05342285|DIAGNOSTIC_TEST|Flow mediated dilation|flow mediated dilation in brachial artery
58136319|NCT00350246|PROCEDURE|Laser Refractive Surgery|
58136320|NCT00874237|DRUG|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
58136321|NCT00874237|DRUG|Inhaled placebo|Inhaled Staccato placebo single dose
58136322|NCT00874237|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg
58136323|NCT00874237|DRUG|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
58136324|NCT00672178|RADIATION|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
58136325|NCT06119841|PROCEDURE|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
58136326|NCT06119841|PROCEDURE|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
58136327|NCT00206544|DRUG|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
58136328|NCT00206544|DRUG|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
58136329|NCT00206544|OTHER|placebo|adjunctive placebo daily in oral capsule
58136330|NCT06491524|DEVICE|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone <2cm|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
58136331|NCT03962023|OTHER|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
58136332|NCT01167309|DRUG|LEO 27847|First in patient
58136333|NCT02039362|DRUG|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
58136334|NCT00969800|DEVICE|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
58136335|NCT00969800|DEVICE|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
58481480|NCT01123902|DEVICE|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
58481481|NCT06177548|PROCEDURE|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
58481482|NCT05183867|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
57780495|NCT01592695|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
58136336|NCT01824537|BIOLOGICAL|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
57780496|NCT01592695|BEHAVIORAL|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
58136337|NCT01824537|BIOLOGICAL|Hepatitis A vaccine|Provided by Sanofi Pasteur.
58136338|NCT01165905|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
58136339|NCT01165905|DRUG|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
58136340|NCT01861210|BEHAVIORAL|Couples Voluntary HIV Counseling and Testing|
58136341|NCT01861210|BEHAVIORAL|Individual Counseling and Testing|
58136342|NCT03148704|DRUG|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
58136343|NCT05924763|DEVICE|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
58136344|NCT01096420|PROCEDURE|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
58136345|NCT01096420|DRUG|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
58136346|NCT02598882|DEVICE|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
58136347|NCT02598882|DEVICE|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
58481483|NCT00843596|PROCEDURE|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
58481484|NCT06655844|DEVICE|Sana Pain Reliever|The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).
58136348|NCT02763085|DEVICE|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
58136349|NCT05873881|DRUG|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
58136350|NCT05873881|DRUG|Colchicine placebo|Placebo colchicine daily
58136351|NCT05873881|DRUG|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
58136352|NCT00134394|DRUG|Etanercept plus tacrolimus|
58136353|NCT01276730|DRUG|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
58136354|NCT01276730|DRUG|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
58136355|NCT01763385|DRUG|Erlotinib|
58136356|NCT01763385|RADIATION|concurrent brain radiotherapy|
58136357|NCT01763385|RADIATION|secondary brain radiotherapy|
58136358|NCT04734964|BEHAVIORAL|exercise training|Exercise training session for 45 minutes.
58136359|NCT01709760|DRUG|Methotrexate|Methotrexate 15-25 mg/week
58136360|NCT01709760|DRUG|ENIA11|ENIA11 25 mg, sc twice weekly
58136361|NCT01709760|DRUG|Placebo|Placebo, sc twice weekly
58136362|NCT01367340|BEHAVIORAL|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
58136363|NCT01367340|BEHAVIORAL|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
58136364|NCT03828734|DEVICE|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
58136365|NCT03828734|DEVICE|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
58136366|NCT03828734|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
58136367|NCT04920708|DRUG|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
58136368|NCT04920708|DRUG|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
58136369|NCT04920708|DRUG|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
57780497|NCT01592695|BEHAVIORAL|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
58136370|NCT04920708|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
58136371|NCT00533663|PROCEDURE|Healing Touch|every other week (during their infusion)
58136372|NCT00533663|OTHER|Standard care|Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
58136373|NCT00533663|PROCEDURE|guided relaxation|
58136374|NCT04857125|OTHER|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
58136375|NCT04857125|OTHER|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
58136376|NCT04342481|OTHER|Educational Screening tool|Educational Screening tool
58136377|NCT01643005|BEHAVIORAL|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
58136378|NCT01643005|BEHAVIORAL|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
57780498|NCT05195593|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
57785243|NCT04583319|DIAGNOSTIC_TEST|EasyCov POC|Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
58136379|NCT00054873|DRUG|tezacitabine|
58136380|NCT00054873|DRUG|5-fluorouracil|
58481485|NCT06655844|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
58481486|NCT03029871|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
57780499|NCT06738576|DRUG|allogeneic mesenchymal stem cells|"Cell implantation is carried out in the following steps:~1. - Patient anesthesia~2. - Identification of the external urinary sphincter and the incompetent area responsible for incontinence through intraurethral cystoscopy.~3. - Resuspension of the cells by gentle manual shaking of the vials. Once the cells are resuspended, they will be used immediately.~4. - Injection of the cell suspension with a long, fine needle (those usually used in endoscopic puncture, \<22G) at 2 points of the sphincter that will coincide with the 3 o'clock and 9 o'clock position of the hands of a clock). The injection will be superficial, trying not to go deeper than 2 mm to create a wheal in each injection visible endoscopically.~5. - Cellular remains, if any, and the vials used will be eliminated following the usual procedures used for the management of hospital surgical waste."
57780500|NCT06738576|DRUG|Placebo|Placebo implantation is carried out in the same way as the drug implantation
57780501|NCT06738394|BEHAVIORAL|High-Velocity Resistance Training|High-velocity resistance training for patients with non-dialysis dependent chronic kidney disease Stages 4-5 with mobility limitations.
57780502|NCT06738394|BEHAVIORAL|Attention|Dedicated contact, information, and motivation throughout the course of the study via weekly group sessions and informational handouts.
57780503|NCT05886777|BIOLOGICAL|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
57780504|NCT05886777|BIOLOGICAL|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
57780505|NCT05886777|BIOLOGICAL|RSVpreF|RSVpreF given as an intramuscular injection
57780506|NCT05886777|BIOLOGICAL|QIV|Licensed QIV given as an intramuscular injection
57780507|NCT05886777|BIOLOGICAL|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
57780508|NCT02822170|OTHER|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
57780509|NCT06739200|PROCEDURE|Platelet-Rich Fibrin (PRF) Membrane|The Platelet-Rich Fibrin (PRF) membrane is a biocompatible material derived from the participant's own blood and prepared through centrifugation. It is applied at the surgical site during periapical surgery to promote tissue regeneration, enhance wound healing, and reduce postoperative swelling and pain. Unlike synthetic materials, PRF is autologous and does not require additional chemical additives or processing. This study aims to evaluate its effectiveness in improving recovery outcomes compared to surgery without PRF membrane placement.
57780510|NCT01084590|BEHAVIORAL|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
57780511|NCT01084590|BEHAVIORAL|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
57780512|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
57780513|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
57780514|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
57780515|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
57780516|NCT03140917|DIAGNOSTIC_TEST|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
58136381|NCT03737578|OTHER|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
58481487|NCT04029402|OTHER|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
58481488|NCT04818853|OTHER|Observation to monitor patients for these infections|We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
58481489|NCT01887535|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
58481490|NCT01887535|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
58481491|NCT01887535|DRUG|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
58481492|NCT01887535|DRUG|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
57780517|NCT04627727|OTHER|low FODMAP diet|low FODMAP diet
57780518|NCT03292042|BEHAVIORAL|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)"
57780519|NCT06740188|DRUG|5-hydroxytryptamine balanced antidepressants trazodone|The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
57780520|NCT06740188|DRUG|Citalopram hydrobromide combined with zolpidem|the control group was given citalopram hydrobromide combined with zolpidem
57780521|NCT04575935|DRUG|Chemotherapy|Receive standard of care chemotherapy
57780522|NCT04575935|PROCEDURE|Laparotomy|Undergo laparotomy
57780523|NCT04575935|PROCEDURE|Minimally Invasive Surgery|Undergo MIS
57780524|NCT04575935|OTHER|Quality-of-Life Assessment|Ancillary studies
57780525|NCT04575935|OTHER|Questionnaire Administration|Ancillary studies
57780526|NCT05776979|DRUG|Isatuximab|Given by vein over about 75 minutes
58136382|NCT02223741|OTHER|Korean medical treatment|acupuncture and herbal drugs
57780527|NCT05776979|DRUG|lenalidomide|Given by PO
58136383|NCT00075543|DRUG|docetaxel|
58136384|NCT00075543|DRUG|oxaliplatin|
58136385|NCT05056077|OTHER|Counseling|Receive support person coaching
58136386|NCT05056077|OTHER|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with a history of cancer
58136387|NCT05056077|BEHAVIORAL|Health Education|Receive health coaching
58136388|NCT05056077|OTHER|Health Promotion and Education - Direct Text Messaging|Receive text messages
58136389|NCT05056077|OTHER|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
58136390|NCT05056077|OTHER|Questionnaires|Quality of Life and Behavioral Questionnaires
58136391|NCT05056077|PROCEDURE|Optional Blood Specimen|Ancillary studies
58136392|NCT05056077|PROCEDURE|Optional Stool Specimens|Ancillary studies
58136393|NCT01735409|DRUG|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
58136394|NCT01735409|DRUG|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
58136395|NCT01735409|DRUG|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
58136396|NCT00055315|BEHAVIORAL|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
58136397|NCT00055315|BEHAVIORAL|Treatment As Usual (TAU)|
58136398|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
58136399|NCT00819741|DRUG|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
58481493|NCT01887535|DRUG|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
58481494|NCT01887535|DRUG|Placebo|Matching placebo will be administered as an oral suspension formulation.
58136400|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
58136401|NCT01237522|DRUG|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
58136402|NCT01167205|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin 20mg for 12 weeks
58136403|NCT00384852|DRUG|rhBMP-2/CPM|
58136404|NCT03706989|PROCEDURE|EEG|EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
58136405|NCT03706989|GENETIC|Apolipoprotein genotype|APOE genotyping will be performed for each patient
58136406|NCT03706989|BIOLOGICAL|Serum NfL measurements|5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
58136407|NCT03706989|OTHER|Preoperative neurocognitive evaluation|Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
58136408|NCT00488865|DEVICE|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
58136409|NCT00814463|BEHAVIORAL|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
58136410|NCT00814463|BEHAVIORAL|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
58136411|NCT00814463|PROCEDURE|MRI|MRI done every 3 months for the length of the study.
58136412|NCT00814463|RADIATION|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
58136413|NCT01085045|DRUG|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
58136414|NCT01085045|DRUG|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
58136415|NCT01085045|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
58136416|NCT01085045|DRUG|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
58136417|NCT01085045|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
58136418|NCT01085045|DRUG|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
57780528|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
57780529|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
57780530|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
57780531|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
57780532|NCT05235295|PROCEDURE|Ultrasound-guided sacroiliac joint injection|Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
58136419|NCT03079128|BEHAVIORAL|Intervention|Weight Watchers Intervention
58136420|NCT05625022|DRUG|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
58136421|NCT00986297|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
58136422|NCT02853682|BIOLOGICAL|plasma|assesment of glycocalyx protein
58136423|NCT03171155|DEVICE|XPro System|Implantation of the XPro System
58136424|NCT00714740|DRUG|acetazolamide|acetazolamide 2 times 250mg per day
58136425|NCT00724230|DRUG|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
58136426|NCT00724230|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
58136427|NCT00715702|DRUG|AZD5672|100 mg oral single dose
58481495|NCT04057326|DRUG|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
57780533|NCT05235295|PROCEDURE|Flouroscopy-guided sacroiliac joint injection|Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
58481496|NCT04057326|DRUG|Placebo|2 tablets/time, 3 times daily,Oral Administration.
58481497|NCT03530072|DIAGNOSTIC_TEST|Karius Test|Next Generation Sequencing
57780534|NCT04241874|OTHER|Mechanical Ventilation|Respiratory support through mechanical ventilator
57780535|NCT06738121|PROCEDURE|Infra-umbilical incision|Traditional curvilinear infra-umbilical incision is used to repair the umbilical hernia
57780536|NCT06738121|PROCEDURE|Transumbilical incision|The incision for the repair of the umbilical hernia will be carried through the umbilicus itself.
57780537|NCT06498713|DRUG|Acetaminophen 650 mg Oral Tablet|650 mg pills
57780538|NCT06498713|DRUG|Acetaminophen 650mg Liquid|650 mg liquid
57780539|NCT06498713|DEVICE|CADD pump|Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.
57780540|NCT06643377|DRUG|Enlicitide|Oral tablet
57780541|NCT06741020|DRUG|Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin|Chemotherapy drugs including Oxaliplatin, Fluorouracil,Leucovorin and immunotherapy durgs Adebrelimab will infuse to liver by transarterial catheter toward to the lesion.
57780542|NCT06308081|OTHER|Tailored|Messages will be in the form of high-quality English-language anti-vaping messages comprising static text and imagery designed to resemble social media posts (e.g., image and a caption). We will create 24 messages based on the top-ranked tailoring features and belief themes tested in Aim 2 to comprise SGM-tailored messages. For the non-tailored message condition, we will create 24 anti-vaping social media messages that mirror the SGM-tailored messages but do not contain SGM identity cues. We will match the belief themes used in the tailored and non-tailored messages such that they represent a range of belief targets (e.g., addiction, physical health effects, mental health effects) as indicated in Aims 1 and 2. We do not utilize a social media platform for the delivery of the message to avoid potential contamination across randomized conditions.
57780543|NCT05781386|DRUG|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
57780544|NCT05560646|DRUG|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
57780545|NCT05560646|DRUG|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
57780546|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
57780547|NCT06738784|BEHAVIORAL|Perceive, Recall, Plan and Perform (PRPP) evaluation|Passing the PRPP for 2 activities
57780548|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
57780549|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
58136428|NCT02735122|DRUG|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
58136429|NCT02735122|DRUG|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
58481498|NCT00380783|DRUG|AGN 203818|
58481499|NCT06654570|DRUG|Intravaginal estrogen during adjuvant letrozole|Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
58481500|NCT04077879|DRUG|ASP1617|Oral
58481501|NCT04077879|DRUG|Placebo|Oral
58481502|NCT06170047|BEHAVIORAL|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
58481503|NCT06170047|OTHER|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
58481504|NCT00735436|DRUG|Gliadel/Avastin/CPT-11|
58481505|NCT03531112|BEHAVIORAL|Appetite Awareness Treatment + Lifestyle Modification|The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
58481506|NCT00029484|BEHAVIORAL|Tai chi chih|
58481507|NCT00043316|DRUG|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
58481508|NCT03769519|BEHAVIORAL|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
58481509|NCT06628830|DEVICE|VamosJuntxs App|"Psychoeducational materials (videos, information and interactive exercises) about depression, anxiety and social support~Skills training through information and activities based on the principles of cognitive behavioral therapy (cognitive restructuring, behavioral activation, emotional regulation, problem solving and exposure)"
58481510|NCT06628830|OTHER|Web Conciencia Saludable|mental health psychoeducational campaign (https://concienciasaludable.uchile.cl/)
58481511|NCT03244332|OTHER|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
58481512|NCT03244332|OTHER|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
58481513|NCT04221867|PROCEDURE|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
58481514|NCT04221867|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
58481515|NCT04308291|DEVICE|MiniMed™ 780G System|Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.
58481516|NCT01465919|DRUG|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
58481517|NCT01465919|OTHER|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
58481518|NCT02437344|DRUG|CI-581aa|92 minute infusion of CI-581aa
58481519|NCT02437344|DRUG|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
58481520|NCT05512156|OTHER|Supervised Toothbrushing|"* Recruitment, consent, and Questionnaires (Behaviors, Quality of Live, Cost Analysis) distribution.~* Inclusion \& Exclusion Criteria Applied~* Baseline Dental examination~* Toothbrushes \& Toothpastes Home and school use packs delivery-Colgate (six pack per child a year- child soft toothbrush with a1450ppm fluoridated toothpaste))~* Supervised teachers training~* Three months intervals monitoring visits~* 12months Follow up and Questionnaires (Behaviours) distribution~* Endpoint dental Examination and Questionnaires (Behaviours, Quality of Live, Cost Analysis) distribution"
58481521|NCT04277338|DRUG|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
58481522|NCT03533049|OTHER|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
58481523|NCT00651690|BIOLOGICAL|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
58481524|NCT00651690|BIOLOGICAL|Placebo|Saline injection on Day 0
58481525|NCT06128759|OTHER|Focusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
58481526|NCT03421483|DIETARY_SUPPLEMENT|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
58481527|NCT03421483|DIETARY_SUPPLEMENT|Adult Multivitamin|Participants will receive an adult multivitamin supplement
58481528|NCT05267613|DRUG|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
58481529|NCT05267613|DRUG|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
58481530|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
58481531|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
58481532|NCT02765750|BEHAVIORAL|No message|The headphones will be placed on patient's ears but no message will be played.
58481533|NCT06492642|OTHER|Patient Education for Chronic Low Back Pain|"Patient education on chronic low back pain (LBP), including:~Day 5: Basic LBP education, types of LBP, red flags; Day 8: LBP guideline recommendations re: imaging; Day 11: LBP guideline recommendations re: use of rehabilitation services, sitting and standing desks; Day 14: LBP guideline recommendations re:pharmacologic management; Day 17: LBP guideline recommendations re: injections and surgery."
58481534|NCT01001325|BIOLOGICAL|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
58481535|NCT01001325|BIOLOGICAL|Normal saline|0.5 mL intramuscular
58481536|NCT06322628|DRUG|VSA006|every 12 weeks, subcutaneous injections
58481537|NCT06322628|DRUG|Placebo|every 12 weeks, subcutaneous injections
58481538|NCT06096467|BEHAVIORAL|Comprehension Exercise Training|Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
58481539|NCT06096467|DIETARY_SUPPLEMENT|Placebo milk|Placebo milk: 8 g. protein for each serving and provided immediately after the CET session
58481540|NCT06096467|DIETARY_SUPPLEMENT|Protein Supplement|Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
58481541|NCT04554680|DRUG|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day \& oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- \& post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
58481542|NCT04963647|DIAGNOSTIC_TEST|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
58481543|NCT00823017|OTHER|Patient-preferred music|Music of patients' preference
58481544|NCT00823017|OTHER|Relaxation Music|Relaxation music compiled from results of first three stages of study
58481545|NCT00823017|OTHER|Standard Care Environment|Control, no interventions
58481546|NCT01980537|PROCEDURE|Magnetic wire navigation|
58481547|NCT01980537|PROCEDURE|Conventional wire navigation|
58481548|NCT00204178|BEHAVIORAL|Oxidative stress in kidney transplant recipients|
58481549|NCT01715740|DRUG|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
58481550|NCT01715740|DRUG|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
58481551|NCT00624598|BEHAVIORAL|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
58481552|NCT05556837|OTHER|Control Cereal|A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured
58481553|NCT05556837|OTHER|OBG Cereal|A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
58481554|NCT05556837|OTHER|BBG Cereal|A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
58481555|NCT05342077|BEHAVIORAL|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
58481556|NCT05342077|BEHAVIORAL|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
58481557|NCT03610269|DEVICE|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
58481558|NCT05033782|OTHER|questionnaire|"Each included patient will be given a paper questionnaire, with the following questions:~* Zip code of patient's iterative residences since 2018, as well as the zip code of residence at the time of the 2 confinements~* Occupational status~* Occurrence of COVID infection/date needed for hospitalization~* During the COVID-19 outbreak, did the patient: avoid seeing a doctor, avoid going to health care facilities, stop background treatment for MS. If yes to any of the questions, the reason, date and duration of the cessation will be asked.~Other sources of data will be used together:~Clinical data from the OFSEP registry Pollution data from approved air quality monitoring associations Data on the circulation of influenza and gastroenteritis, produced by Santé Publique France"
58481559|NCT00967070|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
58481560|NCT00967070|DRUG|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
58481561|NCT02885701|OTHER|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.
57785244|NCT02418299|DEVICE|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
58136430|NCT02735122|DRUG|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
57785245|NCT01667315|DRUG|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
58136431|NCT02735122|DRUG|Placebo Tablet|2 placebo tablets
58136432|NCT02735122|DRUG|Placebo Caplet|2 placebo caplets
58481562|NCT02885701|OTHER|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
58481563|NCT02885701|OTHER|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
58481564|NCT05079308|DEVICE|Peripheral sealing device for surgical mask or filtering face piece|The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
58481565|NCT05079308|DEVICE|IIR Surgical mask with Filtering face piece|The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
58481566|NCT01724099|DRUG|Euiiyin-tang|Korean medicinal herbal drug
58481567|NCT01724099|DRUG|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
58481568|NCT06176079|DRUG|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
58481569|NCT06176079|DRUG|Hyperpolarized 13C-Urea|Given intravenously (IV)
58481570|NCT06176079|PROCEDURE|Magnetic Resonance Imaging|Imaging procedure
58481571|NCT06176079|PROCEDURE|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
58481572|NCT01369888|DRUG|Cyclophosphamide|60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
58481573|NCT01369888|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
58481574|NCT01369888|BIOLOGICAL|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
58481575|NCT01369888|DRUG|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
58481576|NCT02989597|DRUG|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
58481577|NCT02989597|OTHER|Standard pain regimen|Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
58481578|NCT02989597|PROCEDURE|Spinal Fusion Surgery|Clinically-indicated spinal fusion surgery
58481579|NCT02989597|DRUG|Dexamethasone|Post operative swelling and pain control
58481580|NCT02989597|DRUG|Ketamine|Perioperative anesthesia medication
58481581|NCT02989597|DRUG|Remifentanil|Perioperative pain medication
58481582|NCT02989597|DRUG|Sufentanil|Perioperative pain medication
58481583|NCT04489836|DIETARY_SUPPLEMENT|Glutalytic®|Glutalytic® capsule
58481584|NCT04489836|DIETARY_SUPPLEMENT|DE111®|DE111® capsule
58481585|NCT04489836|OTHER|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
58481586|NCT01448980|PROCEDURE|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
58481587|NCT01448980|PROCEDURE|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
58481588|NCT06194331|BEHAVIORAL|iCHART/cASAP|When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.
58481589|NCT06194331|BEHAVIORAL|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
58481590|NCT00104286|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
58481591|NCT04396418|BEHAVIORAL|Education|Randomization between two groups at site level. One cluster with education and one without.
58481592|NCT01592357|BEHAVIORAL|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
58481593|NCT01592357|BEHAVIORAL|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
58481594|NCT02683577|DRUG|telotristat etiprate|
57780550|NCT06723899|OTHER|CanWork|CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.
57780551|NCT06739109|PROCEDURE|Therapy-guided internet-based treatment program|eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
57780552|NCT04879498|DRUG|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
57780553|NCT04879498|OTHER|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
57780554|NCT04879498|OTHER|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
57780555|NCT03314649|OTHER|Observational study|Lavage of the Peritoneal Cavity
57780556|NCT06487533|DEVICE|EmbracePlus Smartwatch|"The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
57780557|NCT06487533|DEVICE|Corti Sensor|"The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
57780558|NCT05009992|DRUG|ONC201|Given orally (PO)
57780559|NCT05009992|RADIATION|Radiation Therapy|Undergo radiation therapy
57780560|NCT05009992|DRUG|Paxalisib|Given PO
57780561|NCT05851690|PROCEDURE|Surgical treatment of pilonidal sinus disease|Advancement flap techniques in surgical treatment of pilonidal sinus disease.
57780562|NCT06736704|DRUG|SNV4818|SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
57780563|NCT06736704|DRUG|Fulvestrant|Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
57780564|NCT04215393|DRUG|Conbercept eye drop|In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
57780565|NCT04215393|DRUG|Placebo|In the second stage, subjects will be receive Conbercept eys drop or a placebo.
57780566|NCT06129695|PROCEDURE|Zygomatic implants|the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
57780567|NCT06739876|BEHAVIORAL|Wearable device-based intervention (with motivational support via social media)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.
57780568|NCT06739876|BEHAVIORAL|Wearable device-based intervention (without support)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.
57780569|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
58481595|NCT04441892|DEVICE|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
58481596|NCT06120985|DEVICE|Countertop pitcher water filter|Point-of-use drinking water filter
58481597|NCT00720915|OTHER|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
57780570|NCT04917549|OTHER|detection of oral lesions|oral lesions in patient diagnosed with COVID-19
57780571|NCT05099679|BEHAVIORAL|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
57780572|NCT05099679|BEHAVIORAL|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
57780573|NCT00002474|DRUG|carboplatin|
57780574|NCT00002474|DRUG|cyclophosphamide|
57780575|NCT00002474|DRUG|mitoxantrone hydrochloride|
57780576|NCT00002474|PROCEDURE|autologous bone marrow transplantation|
57780577|NCT00002474|PROCEDURE|bone marrow ablation with stem cell support|
57780578|NCT05580458|BIOLOGICAL|Shingrix|Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
57780579|NCT00253409|DRUG|chemotherapy|
57780580|NCT00253409|PROCEDURE|adjuvant therapy|
57780581|NCT00253409|PROCEDURE|conventional surgery|
57780582|NCT00253409|PROCEDURE|neoadjuvant therapy|
57780583|NCT00253409|RADIATION|radiation therapy|
57780584|NCT02336581|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
57780585|NCT02336581|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
57780586|NCT04127084|DRUG|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
57780587|NCT06692335|PROCEDURE|High-Intensity Focused Ultrasound (HIFU)|The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
57780588|NCT06692335|PROCEDURE|myomectomy|Laparoscopic or open or hysteroscopic myomectomy will be performed.
57780589|NCT05575115|BEHAVIORAL|Peer Comparison|"Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers."
57780590|NCT05443126|DRUG|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
57780591|NCT04317716|BEHAVIORAL|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
57780592|NCT04317716|OTHER|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
57780593|NCT04324463|DRUG|Colchicine|oral medication
57780594|NCT04324463|DRUG|Interferon-Beta|subcutaneous injection
57780595|NCT04324463|DRUG|Aspirin|oral medication
57780596|NCT04324463|DRUG|Rivaroxaban|oral medication
57780597|NCT02348320|BIOLOGICAL|Personalized polyepitope DNA vaccine|
57780598|NCT06038227|PROCEDURE|Robotic Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
57780599|NCT06038227|PROCEDURE|Video Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
57780600|NCT06585787|DRUG|KarXT|Specified dose on specified days
57780601|NCT06585787|DRUG|Placebo|Specified dose on specified days
57780602|NCT05955274|BEHAVIORAL|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
57780603|NCT05955274|BEHAVIORAL|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
57780604|NCT06740565|PROCEDURE|thoracic endovascular aortic repair|stent-graft implanted to seal the proximal entry tear of type B aortic dissection
57780605|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
57780606|NCT05966805|BEHAVIORAL|Exercise training group|12-Week Exercise intervention on mentaL, metabolic, physicaL, spiritual, social, and occupational well-being among shift-working acute care NURSE
57780607|NCT05966805|BEHAVIORAL|Wait-List Control Group|Control group
57780608|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
57780609|NCT00692055|DRUG|PN400|naproxen 375 mg / esomeprazole 20 mg
57780610|NCT00692055|DRUG|Naproxen|naproxen 375 mg
57780611|NCT06577935|DRUG|AGA2118|Subcutaneous injection
57780612|NCT06577935|OTHER|Placebo|Subcutaneous injection
57780613|NCT05295433|DRUG|mRNA-3705|A sterile liquid for injection
57780614|NCT06737029|DIAGNOSTIC_TEST|Enhanced diagnostic workup|"Patients will undergo review by a study physician, including a detailed history and physical examination, as well as review of additional investigations that have been performed thus far.~Based on the precise nature of the complaints, and additional findings, additional diagnostic testing may be requested, including, but not limited to: blood testing, spirometry, computed tomography of the chest, repeat chest X-ray, sputum investigations, or bronchoscopy."
57785246|NCT03358212|DRUG|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
58481598|NCT00720915|OTHER|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
58481599|NCT02266888|BIOLOGICAL|Rituximab (Rituxan®)|2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
58481600|NCT02266888|BIOLOGICAL|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
58481601|NCT05134428|DEVICE|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
58481602|NCT03127007|DRUG|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
58481603|NCT03127007|DRUG|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
57780615|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
57780616|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
57780617|NCT02653924|OTHER|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
57780618|NCT02653924|OTHER|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
57780619|NCT02653924|OTHER|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
57780620|NCT02653924|OTHER|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
57780621|NCT03620903|DRUG|Ibrutinib / Bortezomib / Rituximab|Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
57780622|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
57780623|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
57780624|NCT05066061|OTHER|control arm|usual process
57780625|NCT05066061|OTHER|anxiolytic and analgesic gas|add relaxing gas
57780626|NCT05066061|DEVICE|Virtual reality mask|use Virtual reality mask Oculus Quest with age-appropriate software
57780627|NCT05707650|PROCEDURE|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
57780628|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
57780629|NCT05623969|DIAGNOSTIC_TEST|Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)
57780630|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
57780631|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
57780632|NCT05953038|DRUG|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
57780633|NCT06739434|GENETIC|GCB-002|GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.
57780634|NCT06740331|BEHAVIORAL|Analysis of social cognition, memory functioning, and executive functioning processes|Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
57780635|NCT06740747|DEVICE|Intermittent theta-burst stimulation|Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
58481604|NCT02444767|DRUG|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
57780636|NCT06740747|DEVICE|Sham intermittent theta-burst stimulation|Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
57780637|NCT03109197|OTHER|Biospecimin Collection|
57780638|NCT05554341|PROCEDURE|Biopsy|Undergo biopsy
57780639|NCT05554341|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57780640|NCT05554341|PROCEDURE|Computed Tomography|Undergo CT
57780641|NCT05554341|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57780642|NCT05554341|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
57780643|NCT05554341|DRUG|Paclitaxel|Given IV
57780644|NCT06741189|OTHER|Home monitoring|"The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child.~An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home.~The response will be standardized on the basis of a protocol shared by the 4 investigating centers."
58481605|NCT03603353|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
58481606|NCT03603353|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
58481607|NCT06591078|OTHER|electropuncture|"The needle was retained for 30 minutes. During the retention period, the needle was lifted and twisted for 3 times with even small amplitude every 10 minutes, and the complement method was performed for 3 times. No manipulation before the needle, cotton ball press directly out of the needle.~④ Frequency, course and time: Start at the same time as immunotherapy, and complete 1-2 times of electroacupuncture treatment per week; Electroacupuncture was performed 4 times per 28 days. The number of electroacupuncture treatment cycles and the number of immunotherapy courses should be consistent."
58481608|NCT03891108|DRUG|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
58481609|NCT03891108|DRUG|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
58481610|NCT03891108|DRUG|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
58481611|NCT03891108|DRUG|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
58481612|NCT01193244|DRUG|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
58481613|NCT01193244|DRUG|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
58481614|NCT01193244|DRUG|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
58481615|NCT03486834|BIOLOGICAL|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
58481616|NCT03486834|DRUG|Placebo|Saline solution administered as a 0.5 mL IM injection
58481617|NCT03189004|BEHAVIORAL|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring"
58481618|NCT02097264|DRUG|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
58481619|NCT02097264|DRUG|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
58481620|NCT02097264|DRUG|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
58481621|NCT03155841|BEHAVIORAL|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
58481622|NCT03155841|BEHAVIORAL|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
57780645|NCT06741189|OTHER|usual medical monitoring|"During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures."
58481623|NCT03632473|DIAGNOSTIC_TEST|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
58481624|NCT04015544|DIETARY_SUPPLEMENT|Watermelon|Pureed whole (100%) watermelon
58481625|NCT04600596|BEHAVIORAL|Recording of food intake.|The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
58481626|NCT05777252|OTHER|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
57785247|NCT01686594|DRUG|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
58481627|NCT06055270|PROCEDURE|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
58481628|NCT06055270|OTHER|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
58481629|NCT01460693|DRUG|Imatinib|Oral Imatinib 100mg daily
58481630|NCT01460693|DRUG|Dasatinib|Oral Dasatinib 100mg daily
58481631|NCT05336162|OTHER|Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)|A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
58481632|NCT00004169|DRUG|carboplatin|
58481633|NCT00004169|DRUG|cyclophosphamide|
58481634|NCT00004169|DRUG|etoposide|
58481635|NCT00004169|PROCEDURE|peripheral blood stem cell transplantation|
58481636|NCT00004169|RADIATION|radiation therapy|
58481637|NCT04057417|OTHER|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
58481638|NCT03705338|DEVICE|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
58481639|NCT03705338|DRUG|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
58481640|NCT02024919|DRUG|intracoronary administration of diltiazem|
58481641|NCT02024919|DRUG|intracoronary injection of 5 mL saline|
58481642|NCT03278171|BEHAVIORAL|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
58481643|NCT04289935|PROCEDURE|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
58481644|NCT06274736|DEVICE|Motiva Sizer|No intervention will be made,
58481645|NCT00521404|DRUG|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
58481646|NCT00521404|DRUG|gemcitabine|Gemcitabine - 1000mg/meter sq
58481647|NCT04626908|DRUG|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
58481648|NCT01328132|DRUG|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
58481649|NCT01328132|DRUG|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
58481650|NCT02509442|PROCEDURE|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
57780646|NCT06560320|BEHAVIORAL|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
57780647|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
57780648|NCT02298205|OTHER|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
58481651|NCT00252096|DEVICE|Nucleic acid amplification test|
58481652|NCT01597804|PROCEDURE|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
58481653|NCT03520855|OTHER|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
58481654|NCT03520855|BEHAVIORAL|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
58481655|NCT01035086|DIETARY_SUPPLEMENT|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
58481656|NCT04449250|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
58481657|NCT01527097|DRUG|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
58481658|NCT01527097|DRUG|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
58481659|NCT02664896|OTHER|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
58481660|NCT02664896|OTHER|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
58481661|NCT04016935|OTHER|Observational|Observational
58481662|NCT05684172|DRUG|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
58481663|NCT05684172|OTHER|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
58481664|NCT00830440|DEVICE|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
58481665|NCT00830440|BEHAVIORAL|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
58481666|NCT05513404|DIETARY_SUPPLEMENT|Honeyberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
58481667|NCT05513404|DIETARY_SUPPLEMENT|Cherry|To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
58481668|NCT05513404|DIETARY_SUPPLEMENT|Raspberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
58481669|NCT02668653|DRUG|Chemotherapy|
58481670|NCT02668653|DRUG|Quizartinib|
58481671|NCT02668653|DRUG|Placebo|
58481672|NCT02877992|PROCEDURE|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
58481673|NCT02802540|DRUG|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
58481674|NCT02802540|DRUG|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
58481675|NCT05705453|DEVICE|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
58481676|NCT02947789|PROCEDURE|Emergency surgery|Patients undergoing emergency surgery
58481677|NCT04762589|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
58481678|NCT04762589|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
58481679|NCT04425109|BEHAVIORAL|meal test response|soy fermented versus non fermented meal test
58481680|NCT04427267|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
58481681|NCT03276624|PROCEDURE|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
58481682|NCT05704582|OTHER|Avatar Intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
58481683|NCT05704582|OTHER|Addiction supportive intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
58481684|NCT04572789|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
57780649|NCT02298205|OTHER|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
57780650|NCT01182168|DRUG|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
58481685|NCT04572789|DIETARY_SUPPLEMENT|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
58481686|NCT03041181|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
58481687|NCT03041181|DRUG|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
58481688|NCT03041181|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
58481689|NCT03041181|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
58481690|NCT05194644|OTHER|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
58481691|NCT05194644|OTHER|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
58481692|NCT04743843|DEVICE|Omnyx Dynamyx Software|Digital pathology image management and viewing software.
58481693|NCT05027555|OTHER|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
58481694|NCT05027555|OTHER|Conventional training|Conventional training included strengthening, balance training and gait training
58481695|NCT02850926|OTHER|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
58481696|NCT03921957|RADIATION|stereotactic radiotherapy|first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
58481697|NCT01323101|DRUG|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
58481698|NCT01323101|OTHER|No doxycycline|
58481699|NCT05348213|DRUG|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
58481700|NCT05348213|DRUG|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
58481701|NCT05348213|DRUG|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
58481702|NCT05348213|DRUG|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
58481703|NCT05348213|DRUG|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
58481704|NCT03511937|BEHAVIORAL|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
58481705|NCT03511937|OTHER|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
58481706|NCT00767988|DIETARY_SUPPLEMENT|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
58481707|NCT00767988|OTHER|Placebo|Capsule once daily at approximately the same time each day for 6 months.
58481708|NCT00168857|DRUG|telmisartan|
58481709|NCT00168857|DRUG|losartan|
58481710|NCT03488953|PROCEDURE|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
58481711|NCT01628640|OTHER|Laboratory Biomarker Analysis|Correlative studies
58481712|NCT01628640|OTHER|Pharmacological Study|Correlative studies
58481713|NCT01628640|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
58481714|NCT03312634|DRUG|Palovarotene|Palovarotene was taken orally once daily at approximately the same time each day following a meal.
58481715|NCT04698863|DEVICE|Oxygen reserve index|eveluating oxygen reserve in blood
58481716|NCT03690687|PROCEDURE|Primary anastomosis|
58481717|NCT03690687|PROCEDURE|Delayed anastomosis|
58481718|NCT03690687|PROCEDURE|Enterostomy|
58481719|NCT06351007|OTHER|Nutritional education and psychological intervention|"In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting"
57780651|NCT06375941|OTHER|Observational|Observational
57780652|NCT01139905|OTHER|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
58136433|NCT02735122|DRUG|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
58481720|NCT06351007|OTHER|Standard care|"The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml"
58481721|NCT06515730|DRUG|Apixaban|5 mg tablet twice a daily with dose reduction according to label
58481722|NCT06515730|DRUG|Warfarin|2.5 mg tablet once daily, with individual dosing according to coagulation tests
58481723|NCT00433420|BIOLOGICAL|pegfilgrastim|
58481724|NCT00433420|DRUG|cyclophosphamide|
58481725|NCT00433420|DRUG|epirubicin hydrochloride|
58481726|NCT00433420|DRUG|fluorouracil|
58481727|NCT00433420|DRUG|paclitaxel|
58481728|NCT00433420|PROCEDURE|adjuvant therapy|
58481729|NCT04490070|BEHAVIORAL|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
58481730|NCT06001203|PROCEDURE|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
58481731|NCT04457297|DRUG|trifluridine and tipiracil|Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
58481732|NCT04457297|DRUG|Placebo|Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
58481733|NCT04134208|PROCEDURE|Computed Tomography|Undergo PET-CT scan
58481734|NCT04134208|DRUG|Fluciclovine F18|Given IV
58481735|NCT04134208|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
58481736|NCT02859571|DRUG|Oxytocin|
58481737|NCT05975606|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied to primary motor cortex of the brain.
58481738|NCT05975606|DEVICE|functional electrical stimulation (FES) cycling|FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
58481739|NCT01173094|DEVICE|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
58481740|NCT01173094|DEVICE|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
58481741|NCT05821777|DRUG|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
58481742|NCT02531672|DRUG|11C-choline|
58481743|NCT02531672|DEVICE|PET/CT Scan|
58481744|NCT03597945|PROCEDURE|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
58481745|NCT03597945|PROCEDURE|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
58481746|NCT03597945|PROCEDURE|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
58481747|NCT02681029|PROCEDURE|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
58481748|NCT02681029|PROCEDURE|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
58481749|NCT01538095|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
58481750|NCT01538095|OTHER|Laboratory Biomarker Analysis|Correlative studies
58481751|NCT01538095|OTHER|Pharmacological Study|Correlative studies
58481752|NCT01538095|BIOLOGICAL|Trebananib|Given IV
58481753|NCT06312904|PROCEDURE|paravertebral block|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.
58481754|NCT06312904|PROCEDURE|Local infiltration anesthesia|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.
58481755|NCT04241419|BEHAVIORAL|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
57784589|NCT03406442|PROCEDURE|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
58481756|NCT05479019|BEHAVIORAL|Visual stimuli|Stimuli will be shown to participants and they will be asked to perform a visual task.
58481757|NCT04046120|OTHER|Heel-free bandage|The bandage is made by leaving the heel uncovered.
58481758|NCT04200846|BEHAVIORAL|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
58481759|NCT05053802|COMBINATION_PRODUCT|Microwave ablation plus Camrelizumab|Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
58481760|NCT05053802|DEVICE|Microwave ablation|Tumor received treatment of microwave ablation
58481761|NCT05458115|PROCEDURE|Liver resection|Patient underwent hepatic R0 resection within a week
58481762|NCT01136161|BIOLOGICAL|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
58481763|NCT01136161|BIOLOGICAL|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
58481764|NCT01136161|BIOLOGICAL|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
58481765|NCT01136161|BIOLOGICAL|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
58481766|NCT03614156|DRUG|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
58481767|NCT03614156|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
58481768|NCT01263197|DRUG|LY2216684|administered orally
58481769|NCT01263197|DRUG|albuterol|administered orally
58481770|NCT01263197|DRUG|propranolol|administered orally
58481771|NCT01263197|DRUG|placebo for LY2216684|administered orally
58481772|NCT01263197|DRUG|placebo for albuterol|administered orally
58481773|NCT01263197|DRUG|placebo for propranolol|administered orally
58481774|NCT02824341|DEVICE|fMRI|
58481775|NCT02109302|PROCEDURE|Blood sample|
58481776|NCT02109302|PROCEDURE|Skin biopsy|
58481777|NCT02109302|OTHER|Questionnaire|
58481778|NCT00318643|DRUG|Mitomycin C|intravesical administration
58481779|NCT00318643|DRUG|Chemophase|intravesical administration
58481780|NCT02061410|DEVICE|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
58481781|NCT01276210|DRUG|sorafenib tosylate|Given PO
58481782|NCT01276210|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
58481783|NCT01276210|OTHER|laboratory biomarker analysis|Correlative studies
58481784|NCT03681314|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
58481785|NCT03040544|PROCEDURE|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
58481786|NCT03040544|PROCEDURE|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
58481787|NCT05589467|OTHER|DASH-FP|Dash diet with only fried potatoes
58481788|NCT05589467|OTHER|DASH-NFP|Dash diet with only non-fried potatoes
58481789|NCT05589467|OTHER|Control|Dash diet with no potatoes
58481790|NCT06073301|DEVICE|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
58481791|NCT06073301|OTHER|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
58481792|NCT05217693|DRUG|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
58481793|NCT02222623|DRUG|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
58481794|NCT02222623|DRUG|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
58481795|NCT05378191|DRUG|COMIRNATY|One dose of COMIRNATY
58481796|NCT05429957|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~* MET of the Iliopsoas~* MET of Piriformis muscle~* MET of Quadratus Lumborum muscle~* MET of Erector Spinae muscle"
58481797|NCT05429957|OTHER|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~* Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~* Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~* Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
58481798|NCT03807206|BEHAVIORAL|Questionnaire|Patient questionnaire
58481799|NCT06405191|BEHAVIORAL|Web based education|The link to the web page was shared with the students in the experimental group (https://inonuhemsirelikesaslari.com, the expired page cannot be accessed at the moment). Theoretical training and application process steps video for IV catheterization and IM injection skills were taken to the students in the experimental group and uploaded to the web page. The students in the experimental group were given a username-password with which they could access the web page, and the access status of the students was followed by the researcher. The researcher was able to see the frequency of each student watching the videos and their scores in online tests. The student who did not watch the videos or did not take the test was interviewed and feedback was given about watching them. Students were able to access the web page as often as they wanted for two weeks.
58481800|NCT00760617|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
58481801|NCT00760617|BIOLOGICAL|Fluarix|Intramuscular (IM) administration, 1 dose
58481802|NCT05045495|DIAGNOSTIC_TEST|Sucrose Hydrogen Methane Breath Test|Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
58481803|NCT04911452|DEVICE|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
58481804|NCT02722993|DIETARY_SUPPLEMENT|Probiotics|
58481805|NCT02722993|DIETARY_SUPPLEMENT|Placebo|
58481806|NCT03705689|OTHER|validation of Bitts|No intervention, observation of photographs of stool
58481807|NCT05324059|DRUG|Pregabalin 75mg/ Tramadol 50 mg|Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
58481808|NCT05324059|DRUG|Pregabalin 75mg|Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
58481809|NCT02518438|DRUG|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
58481810|NCT02527811|DRUG|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
58481811|NCT00518765|DRUG|Aliskiren|
58481812|NCT00518765|DRUG|Aliskiren plus placebo|
58481813|NCT00518765|DRUG|Aliskiren|
58481814|NCT00518765|DRUG|Aliskiren plus placebo|
57780653|NCT01880060|BEHAVIORAL|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; \>20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
57780654|NCT01880060|BEHAVIORAL|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
57780655|NCT03763396|DRUG|Ketoconazole (KCZ)|Oral Tablet
58481815|NCT02896803|DRUG|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
58481816|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
58481817|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
58481818|NCT02837770|DRUG|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
58481819|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
58481820|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
58481821|NCT02837770|DRUG|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
58481822|NCT04951024|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
58481823|NCT04951024|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
57780656|NCT03763396|DRUG|Posaconazole (PCZ)|Delayed Release Oral Tablet
57780657|NCT02243631|DRUG|Probenecid|Treatment
57780658|NCT04679376|DRUG|Atorvastatin|40 mg daily administered orally in tablet or capsule form
57780659|NCT04679376|DRUG|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
57780660|NCT06738017|DRUG|BMN 349|250mg oral tablet
57780661|NCT06738017|DRUG|Placebo|250mg oral tablet
57780662|NCT06740786|DRUG|Dapagliflozin Treatment Group|"This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day)."
57780663|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
58481824|NCT05469659|DRUG|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
58481825|NCT05469659|DRUG|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
58481826|NCT01338740|DRUG|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
58481827|NCT00089752|DEVICE|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
58481828|NCT00089752|DEVICE|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
58481829|NCT05650385|DRUG|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
58481830|NCT04389281|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
58481831|NCT04431440|OTHER|silver nanoparticles|effect silver nanoparticles will be examined on multidrug resistant bacteria
58481832|NCT05880186|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
58481833|NCT06092593|DEVICE|Upper endoscopy|Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients
58481834|NCT03903406|DRUG|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
58481835|NCT00467116|BIOLOGICAL|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
58481836|NCT00467116|DRUG|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes"
58481837|NCT00467116|RADIATION|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions \> 3 days."
58481838|NCT01924338|DEVICE|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
58481839|NCT01924338|DEVICE|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
58481840|NCT01924338|PROCEDURE|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
58481841|NCT04214938|OTHER|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
58481842|NCT03879733|BEHAVIORAL|Thrive by Three|"The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no"
58481843|NCT03879733|BEHAVIORAL|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
58481844|NCT00336596|PROCEDURE|transcranial ultrasound in patients treated with iv t-PA|
58481845|NCT05851261|DRUG|PA3670|Placebo as control
58481846|NCT02601248|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
58481847|NCT01591525|BEHAVIORAL|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
58481848|NCT01591525|BEHAVIORAL|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
58481849|NCT01591525|BEHAVIORAL|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
58481850|NCT02615899|OTHER|Matched: Targeted (specific) balance exercise interventions|
58481851|NCT02615899|OTHER|Mismatched: Untargeted (non-specific) balance exercise interventions|
58481852|NCT00244569|DRUG|13C-Methacetin|
58481853|NCT00244569|DEVICE|Breath ID Machine|
58481854|NCT04455256|OTHER|x box binding protein|Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
58481855|NCT04343742|DRUG|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
58481856|NCT01753232|DEVICE|DALI-adsorber|Recording of treatment data. No extra interventional treatment
58481857|NCT01753232|DEVICE|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
58481858|NCT05680402|OTHER|Soft Tissue mobilization|mobilization of soft tissues of body
58481859|NCT05680402|OTHER|Piriformis Syndrome (Piriformis muscle stretching)|Stretching of Piriformis muscle
58481860|NCT04275362|DEVICE|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
58481861|NCT04275362|DEVICE|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
58481862|NCT04275362|DEVICE|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
58481863|NCT04275362|DEVICE|Control|No total knee replacement
58481864|NCT00148317|DRUG|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
58481865|NCT00148317|DRUG|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
58481866|NCT00148317|DRUG|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
58481867|NCT00148317|DRUG|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
58481868|NCT00148317|DRUG|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
58481869|NCT03307499|OTHER|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
58481870|NCT04193995|BEHAVIORAL|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
58481871|NCT01055431|OTHER|Control bread|Control bread
58481872|NCT01055431|OTHER|Teff Bread|Teff bread
58481873|NCT06119932|PROCEDURE|Evacuation for subdural hematoma by one burrhole|Evacuation for subdural hematoma by one burrhole
58481874|NCT05975684|DRUG|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
58481875|NCT05975684|DRUG|Placebo|Placebo three times a day for 4 weeks
58481876|NCT05164991|BEHAVIORAL|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
58481877|NCT03487237|BIOLOGICAL|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
58481878|NCT04207762|DIAGNOSTIC_TEST|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
58481879|NCT04207762|DIAGNOSTIC_TEST|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
58481880|NCT00408057|OTHER|no intervention|no intervenion
58481881|NCT00478543|DRUG|Furosemide|
58481882|NCT01925456|DRUG|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
58481883|NCT02439437|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
58481884|NCT03699514|DEVICE|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
58481885|NCT01104311|PROCEDURE|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
58481886|NCT01104311|PROCEDURE|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
58481887|NCT01528332|DEVICE|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
58481888|NCT01528332|DEVICE|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
58481889|NCT02085161|DRUG|placebo to tiotropium + olodaterol|comparator
58481890|NCT02085161|DRUG|tiotropium+olodaterol|tiotropium 5 mcg once daily
58481891|NCT02085161|DRUG|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
58481892|NCT02085161|DRUG|tiotropium|tiotropium 5 mcg once daily fixed dose combination
58481893|NCT00707889|DRUG|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
58481894|NCT00707889|DRUG|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
58481895|NCT00707889|DRUG|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
58481896|NCT00707889|DRUG|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
58481897|NCT00707889|DRUG|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
58481898|NCT00707889|DRUG|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
58481899|NCT04830332|DIAGNOSTIC_TEST|abdominal fluid CA-125 levels test|One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
58481900|NCT01654302|DRUG|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
58481901|NCT01654302|DRUG|Inactive patch|placebo patch applied once for 12 hours
58481902|NCT04058964|BIOLOGICAL|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
58481903|NCT04058964|BIOLOGICAL|Pembrolizumab|Given IV
58481904|NCT04976400|PROCEDURE|semi-individualized total knee replacement treatment with a gender-specific design|Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.
58481905|NCT04976400|PROCEDURE|Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)|Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
58481906|NCT01397214|DRUG|Megace F|Megace F oral suspension
58481907|NCT01397214|DRUG|Megace OS|Megace oral suspension
58481908|NCT03405597|DRUG|Commercial Hepatitis B vaccine|Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
58481909|NCT03405597|OTHER|Standard Treatment|HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
58481910|NCT01759446|DRUG|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
58481911|NCT01759446|DRUG|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
58481912|NCT01759446|DRUG|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
58481913|NCT01759446|DRUG|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
58481914|NCT01759446|DRUG|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
58481915|NCT01465555|BEHAVIORAL|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
58481916|NCT00996398|OTHER|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
58481917|NCT04843462|DEVICE|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time."
58481918|NCT04843462|DRUG|Esketamine nasal spray|All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
58481919|NCT06154213|BEHAVIORAL|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
58481920|NCT06154213|BEHAVIORAL|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
58481921|NCT00072839|DRUG|ALX-0600|teduglutide
58481922|NCT00072839|DRUG|placebo|placebo solution injected subcutaneously
58481923|NCT00072839|DRUG|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
58481924|NCT00072839|DRUG|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
58481925|NCT00072839|DRUG|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
58481926|NCT00072839|DRUG|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
58481927|NCT00454324|DRUG|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
58481928|NCT00454324|DRUG|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
58481929|NCT02693366|OTHER|Bone marrow stem cell|Endovascular infusion of bone marrow derived cells in both renal arteries.
58481930|NCT03819530|DIETARY_SUPPLEMENT|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
58481931|NCT00604799|DEVICE|Talent Thoracic Stent Graft|TEVAR
58481932|NCT03827096|DRUG|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
58481933|NCT02647996|PROCEDURE|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
58481934|NCT05463484|DRUG|Test composition Saliactive® (olive product, betaine and xylitol)|Fluoridated toothpaste with Saliactive®.
58481935|NCT05463484|DRUG|Placebo|Fluoridated toothpaste without Saliactive®.
58481936|NCT05463484|DRUG|Control|Commercial Fluoridated toothpaste for gingivitis with zinc citrate.
58481937|NCT04891068|DRUG|Azacitidine|5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
58481938|NCT00813202|DRUG|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
58481939|NCT00390143|BIOLOGICAL|Meningococcal vaccine 134612|One intramuscular dose during the primary study
58481940|NCT00390143|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose during the primary study
57780664|NCT01208415|DEVICE|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
58481941|NCT00335595|DRUG|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
58481942|NCT00335595|DRUG|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
58481943|NCT05790369|BEHAVIORAL|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
58481944|NCT05790369|BEHAVIORAL|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
58481945|NCT04302077|OTHER|virtual doctor visit|interactive live-video feed at home through EPIC
58481946|NCT04302077|OTHER|Standard care doctor's visit|In person visit as per standard of care
58481947|NCT01472289|OTHER|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
58481948|NCT02170077|DRUG|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
57780665|NCT06472128|BEHAVIORAL|DREAMLAND|Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
58481949|NCT02170077|DRUG|Placebo|Placebo tablets administered orally
58481950|NCT03611829|BEHAVIORAL|ACT Intervention|
58481951|NCT03611829|BEHAVIORAL|Standard Care|
58481952|NCT04286945|PROCEDURE|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
58481953|NCT05430399|DRUG|utidelone|Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
58481954|NCT05430399|DRUG|docetaxel|Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
58481955|NCT03405532|DIAGNOSTIC_TEST|DM-ECC|Diabetes mellitus CPB
58481956|NCT02873377|DRUG|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
58481957|NCT02873377|DRUG|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
58481958|NCT02873377|OTHER|Smoking Quitline Referral|Fax referral to the State smoking Quitline
58481959|NCT02873377|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
58481960|NCT01190462|BIOLOGICAL|cetuximab|
58481961|NCT01190462|DRUG|simvastatin|
58481962|NCT01190462|OTHER|laboratory biomarker analysis|
58481963|NCT04805034|OTHER|Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level|Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
58481964|NCT01544010|BEHAVIORAL|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
58481965|NCT01544010|BEHAVIORAL|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
58481966|NCT01544010|BEHAVIORAL|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
58481967|NCT01544010|BEHAVIORAL|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
58481968|NCT01544010|BEHAVIORAL|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
58481969|NCT04017663|OTHER|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
58481970|NCT03177655|OTHER|Guided Imagery|Guided Imagery meditation
58481971|NCT03177655|OTHER|Journaling|Keeping a journal
58481972|NCT01744977|BEHAVIORAL|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
58481973|NCT06447714|BEHAVIORAL|smoke|cotinine detection
58481974|NCT02315742|BEHAVIORAL|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
58481975|NCT03192735|DRUG|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
58481976|NCT02504151|DRUG|Cannabidiol|
58481977|NCT02504151|DRUG|Placebo|
58481978|NCT01896167|OTHER|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
58481979|NCT01896167|OTHER|Placebo|Inhalation of atmospheric air
58481980|NCT06125600|OTHER|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
58481981|NCT01736995|BEHAVIORAL|Functional Family Therapy|
58481982|NCT01736995|BEHAVIORAL|Motivational Enhancement Tx/Cognitive Behavioral Tx|
58481983|NCT01736995|BEHAVIORAL|Contingency Management|
58481984|NCT01588730|DEVICE|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
58481985|NCT01588730|PROCEDURE|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
58481986|NCT00899132|GENETIC|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
58481987|NCT00899132|GENETIC|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
58481988|NCT00899132|OTHER|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
58481989|NCT02052258|DRUG|Oxytocin|
58481990|NCT00248404|DRUG|NB1011|
58481991|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
58481992|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
58481993|NCT01635296|DRUG|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
58481994|NCT01635296|DRUG|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
58481995|NCT01551186|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
58481996|NCT00813241|DRUG|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
58481997|NCT00813241|DRUG|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
58481998|NCT00813241|DRUG|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
58481999|NCT00813241|DRUG|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
58482000|NCT04210531|DIETARY_SUPPLEMENT|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
58482001|NCT04210531|DIETARY_SUPPLEMENT|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
58482002|NCT01427153|PROCEDURE|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
58482003|NCT01427153|PROCEDURE|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
58482004|NCT02592798|DRUG|Abatacept|Abatacept IV administered on Day 1, 15, 29 and then every 28 days
58482005|NCT02592798|OTHER|Normal Saline|Normal Saline administer on Day 1, 15, 29 and then every 28 days
58482006|NCT02592798|OTHER|D5W|Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
58482007|NCT04035148|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
58482008|NCT00288132|BEHAVIORAL|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
58482009|NCT00288132|BEHAVIORAL|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
58482010|NCT05165940|BEHAVIORAL|Treatment As Usual|Care Coordination Treatment as usual with a VA mental health treatment coordinator
58482011|NCT05165940|BEHAVIORAL|New Health Services Intervention|The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
58482012|NCT00531544|DRUG|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
58482013|NCT05035381|DRUG|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
58482014|NCT02899468|DEVICE|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
58482015|NCT04961684|DEVICE|Solver Pen|One application per day for 3 months
58482016|NCT04961684|DRUG|Loceryl 5%|One application per week for 3 months
58136434|NCT02648347|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
58482017|NCT01424384|DRUG|Citalopram|Neurophysiological testing.
58482018|NCT01424384|DRUG|GSK424887|Neurophysiological testing
58482019|NCT01424384|DRUG|Plactebo To Match|Neurophysiological testing
58482020|NCT04706455|DEVICE|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
58482021|NCT04706455|DEVICE|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
58482022|NCT03241901|DRUG|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
58482023|NCT03241901|DRUG|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
58482024|NCT03241901|OTHER|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
58482025|NCT04128852|DEVICE|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
58482026|NCT05006963|OTHER|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
58482027|NCT04586439|DRUG|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
58482028|NCT03726580|DRUG|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
58482029|NCT06128954|DRUG|900mg TETA 4HCl Once Daily Formulation|3x300mg trientine base tablets as a single AM dose
58482030|NCT06128954|DRUG|900mg TETA 4HCl Cuprior®|6 x150mg trientine base tablets in two equally divided doses
58482031|NCT05044689|BEHAVIORAL|Questionnaire|Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
58482032|NCT05044689|DEVICE|Bioimpedance/Body Composition Unit|Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
58482033|NCT06081816|OTHER|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
58482034|NCT04640610|OTHER|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
58482035|NCT05410184|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
58482036|NCT05410184|OTHER|mural curtain group|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
58482037|NCT02846506|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
58482038|NCT02846506|DRUG|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58482039|NCT02846506|DRUG|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58482040|NCT02846506|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
58482041|NCT02538224|DRUG|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
58482042|NCT02538224|DRUG|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
58482043|NCT04859738|DRUG|Lidocaine Spray|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
58482044|NCT04859738|DRUG|Benzokain Sprey|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
58482045|NCT04859738|OTHER|Alcohol|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
58482046|NCT04273737|DRUG|Amantadine Hydrochloride|6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
58482047|NCT00414336|DRUG|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
58482048|NCT04324411|DRUG|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
58482049|NCT04627402|DRUG|Conbercept and TA|Intravitreous injection of Conbercept and TA
58482050|NCT04627402|DRUG|Conbercept|Intravitreous injection of Conbercept
58482051|NCT01293734|OTHER|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
58482052|NCT01293734|OTHER|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
58482053|NCT01293734|OTHER|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
58482054|NCT01293734|DRUG|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
58482055|NCT01447459|BEHAVIORAL|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
58482056|NCT05642052|DIETARY_SUPPLEMENT|low carb diet|low carb meals will be 50% less carbs than the regular meals
58482057|NCT05642052|DIETARY_SUPPLEMENT|Regular diet|Regular diet
58482058|NCT00926861|DEVICE|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
58482059|NCT00926861|DEVICE|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
58482060|NCT04583241|OTHER|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
58482061|NCT04583241|OTHER|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
58482062|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
58482063|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
58482064|NCT04583241|OTHER|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
58482065|NCT04263155|BEHAVIORAL|The Body Project|The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
58482066|NCT01809340|DRUG|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
58482067|NCT01809340|DRUG|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
58482068|NCT01809340|DRUG|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
57780666|NCT06472128|BEHAVIORAL|VITAL WELLNESS|Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
58482069|NCT06371781|DIAGNOSTIC_TEST|Serum Netrin-4, Resistin and Sfrp-5 level measurement|Measurements of the levels of these molecules in the serum samples of the study group will be done with the ELISA kit.
58482070|NCT00445926|DEVICE|deep TMS H-coil|
58482071|NCT00209612|DRUG|Taxol|Day1,15 X mg/m2, IV (in the vein)
58482072|NCT00209612|DRUG|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
58482073|NCT02850913|DRUG|Doxycycline|"* 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
57780667|NCT02378818|BEHAVIORAL|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
57780668|NCT01010217|DRUG|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
57780669|NCT01010217|DRUG|Fludarabine|40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
57780670|NCT01010217|DRUG|Melphalan|140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
57780671|NCT01010217|DRUG|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
58482074|NCT02850913|OTHER|Placebo|- Placebo (matching capsules containing no active ingredients)
58482075|NCT01957995|DRUG|nanosomal docetaxel lipid suspension|Given IV
58482076|NCT01957995|OTHER|pharmacological study|Correlative studies
58482077|NCT00843700|BEHAVIORAL|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
58482078|NCT00843700|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
58482079|NCT03690297|DEVICE|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
58482080|NCT04204525|DIAGNOSTIC_TEST|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
58482081|NCT04570137|DIETARY_SUPPLEMENT|Dietary fiber supplementation|"1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory"
58482082|NCT01598506|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
58482083|NCT03475095|OTHER|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
58482084|NCT06339801|DEVICE|MiVu|All patients will undergo mucosal impedance (MI) measurement using the MiVu™ Mucosal Integrity Testing System (Diversatek Healthcare, Inc.).
58482085|NCT03978546|DIAGNOSTIC_TEST|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
58482086|NCT03978546|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
58482087|NCT03978546|DIAGNOSTIC_TEST|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
58482088|NCT01100801|DRUG|TS-1 with cisplatin|
58482089|NCT01100801|DRUG|TS-1 with oxaliplatin|
58482090|NCT01216826|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
58482091|NCT06654206|OTHER|Exercise|"Supervised strength exercise sessions: There will be two sessions per week, each lasting 50 minutes. Each session will consist of three distinct parts:~Warm-up: 10 minutes of global strength and aerobic exercises at 60% of estimated VO2max, focusing on the areas that will primarily be worked on during that session.~Strength training: 6 strength exercises targeting the major muscle groups, lasting 30 minutes. The initial load will be set between 40-70% of the estimated 1-RM (assessed in the first session and based on the individual patient). When the participant is able to complete 3 sets of 12 repetitions with the established weight in two consecutive sessions, the weight will be increased by 10%. The exercises will be performed in a circuit format with 30 seconds of rest between exercises and 90 seconds of rest between sets.~Cool-down/stretching: 10 minutes of a combination of breathing exercises and stretching for the major muscle groups.~Promotion of physical activity: Participants"
58482092|NCT01302990|BIOLOGICAL|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
58482093|NCT02019095|OTHER|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
58482094|NCT04099199|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
58482095|NCT00309374|DRUG|LPS 2ng/kg intravenous bolus|
58482096|NCT00309374|DRUG|Simvastatin 80mg; administered daily p.o. over 5 days|
58482097|NCT00309374|DRUG|Rosuvastatin 40mg; administered daily p.o. over 5 days|
58482098|NCT00446849|DRUG|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
58482099|NCT01764906|DEVICE|Novosis|
58482100|NCT01764906|PROCEDURE|Iliac crest bone graft|
58482101|NCT06650878|PROCEDURE|Desarda|This technique prevent from using a mesh to surgical repair of a inguinal hernia
57780672|NCT01010217|DRUG|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
58482102|NCT06650878|PROCEDURE|Lichtenstein|This technique implies using a mesh to surgical repair of a inguinal hernia
58482103|NCT04580979|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
58482104|NCT03755258|DRUG|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
58482105|NCT03755258|DRUG|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
58482106|NCT03755258|DRUG|GCK 300 mg|GCK 300 mg, oral, 12 weeks
58482107|NCT03755258|DRUG|Placebo 300mg|Placebo 300mg, oral, 12 weeks
58482108|NCT03506152|DIAGNOSTIC_TEST|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
58482109|NCT04590521|BIOLOGICAL|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
57784590|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
58482110|NCT01055197|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
58482111|NCT01055197|RADIATION|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
58482112|NCT00751517|DRUG|Methotrexate|
58482113|NCT00751517|DRUG|Cyclophosphamide|
58482114|NCT01939613|DRUG|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
58482115|NCT05248152|COMBINATION_PRODUCT|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
58482116|NCT05248152|DRUG|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
58482117|NCT05248152|DRUG|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
58482118|NCT06490354|DEVICE|Lightback group|Use of the patented Lightback device to relax the gluteal musculature and prevent hamstring injuries.
58482119|NCT06490354|OTHER|Conventional treatment|Conventional treatment to relax the gluteal musculature and prevent hamstring injuries.
58482120|NCT03466814|OTHER|Non-Interventional|Non-Interventional
58482121|NCT03533504|OTHER|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
58482122|NCT06421532|DRUG|XYWAV|Daily before bedtime for 3 months
58482123|NCT06421532|DEVICE|gammaCore Sapphire|Twice daily for 3 months
58482124|NCT05281302|DEVICE|Neck muscle vibration|Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
58482125|NCT05281302|DEVICE|Neck muscle vibration + sham-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device."
58482126|NCT05281302|DEVICE|Neck muscle vibration + anodal-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy."
58482127|NCT02628873|DEVICE|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
58482128|NCT02572908|OTHER|Sourdough wheat bread|
58482129|NCT02572908|OTHER|Regular yeast baked toast bread|
58482130|NCT02572908|OTHER|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
57780673|NCT01010217|PROCEDURE|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
58482131|NCT00404144|DEVICE|Drug Eluting Balloon|PCI of small vessels single arm study
58482132|NCT01464437|DRUG|AMG 151|Drug: AMG 151 50 mg BID
58482133|NCT01464437|DRUG|Placebo|Placebo
58482134|NCT01464437|DRUG|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
58482135|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg BID
58482136|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg BID
58482137|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg QD
58482138|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg QD
58482139|NCT01464437|DRUG|AMG 151|Drug: AMG 151 400 mg QD
58482140|NCT02740452|DEVICE|ligamys technique|Ligamys technique (device) or standard technique
58482141|NCT02740452|OTHER|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
58482142|NCT00121615|DRUG|etanercept|
58482143|NCT05517252|OTHER|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
58482144|NCT05517252|OTHER|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
58482145|NCT01453218|DRUG|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
58482146|NCT00446004|DRUG|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
58482147|NCT00446004|DRUG|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
58482148|NCT01392105|DRUG|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
58482149|NCT01392105|DRUG|Control group|No additional treatment of mesenchymal stem cells
58482150|NCT01577992|DRUG|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
58482151|NCT01577992|PROCEDURE|determination of objective and subjective pain threshold|Test without levodopa intake
58482152|NCT00734500|DRUG|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
58482153|NCT03183297|DRUG|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
58482154|NCT03183297|DRUG|Naproxen|Naproxen sodium 220mg
58482155|NCT03183297|DRUG|Fexofenadine|Fexofenadine 60mg
58482156|NCT03183297|DRUG|placebo|placebo comparator
58482157|NCT00898417|BIOLOGICAL|bevacizumab|
58482158|NCT00898417|DRUG|carboplatin|
58482159|NCT00898417|DRUG|paclitaxel|
58482160|NCT00898417|GENETIC|proteomic profiling|
58482161|NCT00898417|OTHER|laboratory biomarker analysis|
58482162|NCT00898417|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
58482163|NCT04240496|OTHER|Determination of plasma concentration of clozapine/ Genotyping|Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
58482164|NCT00781703|OTHER|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
58482165|NCT00750438|DIETARY_SUPPLEMENT|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
58482166|NCT00750438|DIETARY_SUPPLEMENT|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
58482167|NCT00750438|DIETARY_SUPPLEMENT|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
58482168|NCT03311243|PROCEDURE|Non surgical periodontal therapy|
58482169|NCT03311243|DRUG|Chemical plaque control|
58482170|NCT04708561|BEHAVIORAL|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
58482171|NCT06038604|BEHAVIORAL|Psychosocial Support Intervention|Participants will receive six weekly 60-minute sessions conducted by videoconference.
58482172|NCT03498898|OTHER|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
58482173|NCT03054532|DRUG|Durvalumab|Durvalumab intravenous 1500 mg
58482174|NCT03054532|DRUG|Lenali|Lenalidomide oral 20 mg/day
58482175|NCT03288103|DRUG|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
57780674|NCT01010217|DRUG|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
57780675|NCT01010217|DRUG|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
58482176|NCT02650076|DRUG|SK-1405|
58482177|NCT04800809|OTHER|This study does not entail offering any intervention; all data collected will be based on standard of care.|This study does not entail offering any intervention; all data collected will be based on standard of care.
58482178|NCT01292629|DEVICE|iSert 251 intraocular lens|aphakic intraocular lens
58482179|NCT02298582|DRUG|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
58482180|NCT05910437|OTHER|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
58482181|NCT00600080|DEVICE|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
57780676|NCT01010217|DRUG|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
57780677|NCT01010217|DRUG|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
58482182|NCT00600080|DEVICE|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
58482183|NCT05165771|DRUG|GS-5718|Tablets administered orally
58482184|NCT05165771|DRUG|GS-5718|Tablets administered orally
58482185|NCT05165771|DRUG|Placebo to match GS-5718|Tablets administered orally
58482186|NCT05165771|DRUG|Tofacitinib 5 mg|Tablets administered orally
58482187|NCT05165771|DRUG|Placebo to match Tofacitinib|Tablets administered orally
58482188|NCT01912170|DIETARY_SUPPLEMENT|Fish oil|
58482189|NCT01912170|DIETARY_SUPPLEMENT|Flaxseed oil|
58482190|NCT02909400|DRUG|KH176|
58482191|NCT02909400|DRUG|placebo|
58482192|NCT00070967|PROCEDURE|Acupuncture|
58482193|NCT03550599|OTHER|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
58482194|NCT00643903|BEHAVIORAL|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
58482195|NCT00643903|BEHAVIORAL|Standard care|Participants will receive standard of care for HIV infections.
58482196|NCT00643903|BEHAVIORAL|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
58482197|NCT04226742|BEHAVIORAL|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
58482198|NCT04226742|BEHAVIORAL|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
58482199|NCT06655623|OTHER|Schema therapy|Schema therapy is a form of psychotherapy invented to address more complex clinical cases. It consists of elements from Cognitive Behavioral Therapy as well as psychodynamic, emotion-focused and gestalt therapies, with a distinct focus on experiential interventions. A therapy manual was developed for use in this study.
58482200|NCT03162263|DEVICE|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
58482201|NCT03420352|DIAGNOSTIC_TEST|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
58482202|NCT00936715|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
58482203|NCT01670487|DEVICE|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
58482204|NCT01670487|DEVICE|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
58482205|NCT01977989|DRUG|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
58482206|NCT03710499|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
58482207|NCT00002150|DRUG|Celgosivir hydrochloride|
58482208|NCT01567267|BEHAVIORAL|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
58482209|NCT01567267|BEHAVIORAL|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
58482210|NCT00600262|DRUG|intravitreal bevacizumab|
58482211|NCT01312740|OTHER|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
58482212|NCT01312740|OTHER|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
58482213|NCT05188833|DEVICE|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
58482214|NCT05188833|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
58482215|NCT00099333|DRUG|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
58482216|NCT00099333|DRUG|Insulin|Insulin will be taken according to the subject's current regimen
58482217|NCT00281242|OTHER|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
58482218|NCT04301154|BIOLOGICAL|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
57780678|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
57784591|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
58482219|NCT04301154|BIOLOGICAL|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
58482220|NCT04301154|BIOLOGICAL|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
58482221|NCT01743222|GENETIC|eASC|"* First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
58482222|NCT01743222|DRUG|Placebo|"* First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
58482223|NCT04648397|OTHER|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
58482224|NCT04648397|OTHER|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
58482225|NCT00163683|BEHAVIORAL|Dietary Therapy|
58482226|NCT04252534|COMBINATION_PRODUCT|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
57784592|NCT03824938|DRUG|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
58482227|NCT04252534|BIOLOGICAL|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
58482228|NCT03585751|PROCEDURE|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
58482229|NCT03585751|PROCEDURE|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
58482230|NCT03585751|PROCEDURE|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
58482231|NCT00378365|PROCEDURE|Arsenic trioxide|Arsenic trioxide
58482232|NCT00378365|PROCEDURE|ATRA|ATRA
58482233|NCT01147874|PROCEDURE|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
58482234|NCT05488041|PROCEDURE|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, ... AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
58482235|NCT02991040|DEVICE|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
58482236|NCT02991040|DEVICE|Revanesse Ultra|Comparator without lidocaine
58482237|NCT03561805|DEVICE|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
58482238|NCT03739203|DRUG|Cariprazine|Cariprazine supplied in capsules
58482239|NCT03739203|DRUG|Placebo|Placebo supplied in capsules
58482240|NCT03739203|DRUG|Antidepressant Therapy (ADT)|ADT as prescribed by the physician per standard of care in clinical practice.
58482241|NCT05764785|BEHAVIORAL|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
58482242|NCT01655732|PROCEDURE|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
58482243|NCT03527433|PROCEDURE|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
58482244|NCT06653387|DEVICE|CGuard Prime 80cm stent system|This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
58482245|NCT04515316|DEVICE|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
58482246|NCT04515316|DEVICE|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
57780679|NCT06738966|DRUG|BL0175|"BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue."
57780680|NCT06737042|DRUG|GZR18|GLP-1
57780681|NCT06737042|DRUG|Tirzepatide|Active Comparator
58482247|NCT04412629|DRUG|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
58482248|NCT04412629|PROCEDURE|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
58482249|NCT04412629|PROCEDURE|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
58482250|NCT05992753|OTHER|Questionnaire application|The research data were collected from 455 mothers admitted to the postpartum and lactation unit of a city hospital in Istanbul between September and November 2022. The mothers to be included in the study sample were determined according to the non-probability sampling method, considering the inclusion criteria of the study. The research data were collected by the researchers face-to-face through a questionnaire that lasted about 10-20 minutes.
58482251|NCT01672580|BEHAVIORAL|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
58482252|NCT01672580|BEHAVIORAL|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
58482253|NCT01672580|BEHAVIORAL|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
57784593|NCT03824938|DRUG|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
58482254|NCT01672580|BEHAVIORAL|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
58482255|NCT05089825|OTHER|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
58482256|NCT05089825|OTHER|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
58482257|NCT03386383|BEHAVIORAL|Intervention|Individual session, physical activity tracker, online intervention
58482258|NCT02932852|PROCEDURE|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
58482259|NCT02932852|PROCEDURE|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
58482260|NCT04320316|DRUG|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
58482261|NCT03250715|OTHER|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
58482262|NCT04809480|DIAGNOSTIC_TEST|Fungal rhinosinusitis|Pathology examination
58482263|NCT06112509|OTHER|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
58482264|NCT04377893|DEVICE|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
58482265|NCT06595394|OTHER|Exercise|Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.
58482266|NCT06595394|OTHER|Home program|The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
58482267|NCT04643613|DIETARY_SUPPLEMENT|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
58482268|NCT01534702|DRUG|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
58482269|NCT05338619|DRUG|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
58482270|NCT03183869|DRUG|Fecal microbiota|fecal microbial transplantation
58482271|NCT00080535|BIOLOGICAL|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
58482272|NCT02624076|OTHER|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
58482273|NCT02624076|OTHER|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
58482274|NCT04475796|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed after ERCP
58482275|NCT03629535|DEVICE|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
58136435|NCT02648347|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
58482276|NCT03629535|DEVICE|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
58482277|NCT03529669|DEVICE|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
58482278|NCT04675632|PROCEDURE|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
58482279|NCT04871646|DRUG|CKD-314+SOC|CKD-314 is administered intravenously and standard of care is also performed.
58482280|NCT04871646|DRUG|CKD-314 Placebo+SOC|CKD-314 placebo is administered intravenously and standard of care is also performed..
58482281|NCT05969158|DRUG|Hetrombopag|"After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT \< 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5)."
58482282|NCT01816035|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482283|NCT01816035|OTHER|Pharmacological Study|Correlative studies
58482284|NCT01816035|BIOLOGICAL|Trastuzumab Emtansine|Given IV
58482285|NCT04721886|PROCEDURE|Ultrasonsgraphy|Undergo ultrasonography
58482286|NCT04721886|DRUG|Perflutren Lipid Microcpheres|Given IV
58482287|NCT04721886|PROCEDURE|Contrast - Enhanced Ultrasound|Undergo CEUS
58482288|NCT03568227|PROCEDURE|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
58482289|NCT03568227|PROCEDURE|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
58482290|NCT04696965|OTHER|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
58482291|NCT04696965|OTHER|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
58482292|NCT05866315|DRUG|Remimazolam|Administer remimazolam
58482293|NCT05866315|DRUG|Desflurane|administer desflurane
58482294|NCT05866315|DRUG|Remifentanil|administer remifentanil
58482295|NCT03791814|DRUG|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
58482296|NCT00195104|DRUG|Arsenic Trioxide (Tricenox)|
58482297|NCT00195104|DRUG|Cytarabine|
58482298|NCT04546672|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
58482299|NCT04546672|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
58482300|NCT02172885|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
58482301|NCT05624970|BEHAVIORAL|aerobic training , tobacco cessation and nutritional advices|"1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months"
58482302|NCT05624970|BEHAVIORAL|tobacco cessation and nutritional advices|Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
58482303|NCT03252431|DRUG|F-627|single dose pre-filled syringe
58482304|NCT03252431|DRUG|Neulasta|single dose pre-filled syringe
58136436|NCT02335840|OTHER|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
58482305|NCT05876715|DRUG|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
58482306|NCT01870518|DEVICE|Bilateral GPi DBS|
58482307|NCT01870518|DEVICE|Bilateral STN DBS|
58482308|NCT02012413|DEVICE|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
58136437|NCT02335840|OTHER|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
58482309|NCT02012413|DEVICE|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
58482310|NCT05290714|BEHAVIORAL|Mentalization-Based Treatment for Children (MBT-C)|MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.
58482311|NCT05290714|BEHAVIORAL|Parenting and Social Skills Group|Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
58482312|NCT00509054|PROCEDURE|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
58482313|NCT02911584|PROCEDURE|Laparoscopic procedure|
58482314|NCT03646552|DRUG|THX-110|"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."
58482315|NCT03835806|OTHER|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
58482316|NCT03835806|OTHER|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
58482317|NCT06201780|DIAGNOSTIC_TEST|serum levels of Janus Kinase 1and 2|assessment of serum levels of Janus Kinase 1and 2 by ELISA
58482318|NCT05005117|PROCEDURE|Laparoscopic operation|Operation
58482319|NCT05005117|PROCEDURE|Open operation|Operation
58482320|NCT02600234|DEVICE|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
58482321|NCT02600234|OTHER|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
58482322|NCT00779350|DRUG|sertraline 100 mg tablets|
58482323|NCT02103387|BEHAVIORAL|Cognitive Behavioral Training|Cognitive Behavioral Training \[CBT\] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
58482324|NCT02103387|BEHAVIORAL|Relaxation Training|Relaxation Training \[RT\] (muscle relaxation, deep breathing, guided imagery, meditation)
58482325|NCT02103387|BEHAVIORAL|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
58482326|NCT04082793|COMBINATION_PRODUCT|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
58482327|NCT04082793|COMBINATION_PRODUCT|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
58482328|NCT03739723|OTHER|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
58482329|NCT04086901|RADIATION|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
58482330|NCT00753506|DIETARY_SUPPLEMENT|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
58482331|NCT00753506|DIETARY_SUPPLEMENT|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
58482332|NCT02124837|BEHAVIORAL|Park walk during lunch break|
58482333|NCT02124837|BEHAVIORAL|Relaxation during lunch break|
58482334|NCT06118632|OTHER|Observational|Observational
58482335|NCT02871934|GENETIC|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
58482336|NCT01208207|DRUG|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
58482337|NCT01208207|DRUG|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
58482338|NCT01208207|DRUG|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
58482339|NCT01208207|DRUG|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
58482340|NCT01208207|DRUG|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
58482341|NCT01208207|DRUG|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
58482342|NCT01208207|DRUG|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
58482343|NCT01208207|DRUG|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
58482344|NCT01208207|DRUG|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
58482345|NCT01208207|DRUG|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
58482346|NCT01208207|DRUG|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
58482347|NCT01208207|DRUG|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
58482348|NCT02379663|DRUG|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
58482349|NCT02379663|DRUG|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
58482350|NCT02379663|OTHER|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
58482351|NCT00461370|DRUG|SRX251|
58482352|NCT00002696|DRUG|CAF regimen|
58482353|NCT00002696|DRUG|CMF regimen|
58482354|NCT00002696|DRUG|cyclophosphamide|
58482355|NCT00002696|DRUG|doxorubicin hydrochloride|
58482356|NCT00002696|DRUG|fluorouracil|
58482357|NCT00002696|DRUG|methotrexate|
58482358|NCT00002696|PROCEDURE|adjuvant therapy|
58482359|NCT00002696|PROCEDURE|conventional surgery|
58482360|NCT00002696|PROCEDURE|neoadjuvant therapy|
58482361|NCT00002696|RADIATION|radiation therapy|
58482362|NCT02215252|DRUG|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
58482363|NCT02215252|DRUG|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
58482364|NCT02215252|DRUG|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
58482365|NCT02215252|DRUG|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
58482366|NCT06009133|PROCEDURE|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
58482367|NCT06009133|PROCEDURE|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
58482368|NCT04216056|BEHAVIORAL|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
58482369|NCT02077452|DRUG|HMS5552|
58482370|NCT02077452|DRUG|Placebo|
58482371|NCT04429256|OTHER|data collection|retrospective analysis of perioperative data collected from patient medical charts and from a telephone enquiry
58482372|NCT05063799|OTHER|pulmonary rehabilitation|pulmonary rehabilitation programs
58482373|NCT03367520|BEHAVIORAL|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
58482374|NCT03071926|DRUG|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
58482375|NCT00403520|DRUG|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
58482376|NCT00403520|DRUG|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
58482377|NCT04198688|BEHAVIORAL|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
58482378|NCT02453321|PROCEDURE|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
58482379|NCT02453321|PROCEDURE|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
58482380|NCT02453321|PROCEDURE|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
58482381|NCT02453321|DRUG|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
58136438|NCT02335840|OTHER|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
58136439|NCT02335840|OTHER|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
58136440|NCT05078138|DRUG|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
58136441|NCT06011538|OTHER|On-line, multi-media information on a specifically designed website for Same Day Discharge following Laparoscopic Hysterectomy|A patient educational website that provides clear, easily accessible, patient friendly information explaining what SDD after laparoscopic hysterectomy is, why SDD may be beneficial and what to expect from decision for surgery, through to the admission to hospital and immediate, short and long term recovery.
58136442|NCT02649803|BEHAVIORAL|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
58136443|NCT02502110|DRUG|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
58136444|NCT04236960|BIOLOGICAL|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
58136445|NCT00219323|DRUG|Omalizumab|
58136446|NCT03966365|DRUG|PRO-122|"* PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic."
58136447|NCT03966365|DRUG|Krytantek Ofteno®|"* - 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* - Route of administration: topical ophthalmic."
58136448|NCT05070676|DIAGNOSTIC_TEST|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
58136449|NCT01701024|DRUG|ACYC|ACYC active, topically applied to the face for 12 weeks
58136450|NCT01701024|DRUG|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
58136451|NCT00946166|DRUG|simvastatin|40 mg daily in the evening for a maximum of 14 days
58136452|NCT00946166|DRUG|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
58136453|NCT05440903|BEHAVIORAL|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
58136454|NCT05440903|BEHAVIORAL|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
58136455|NCT01497652|DRUG|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
58136456|NCT01497652|DRUG|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
58136457|NCT03336411|BEHAVIORAL|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
58136458|NCT03336411|BEHAVIORAL|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
58136459|NCT03611478|DIETARY_SUPPLEMENT|Probiotic formulation|Probiotic capsule
58136460|NCT03611478|DIETARY_SUPPLEMENT|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
58136461|NCT00819507|DRUG|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
58482382|NCT01116986|BEHAVIORAL|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
57784594|NCT03824938|OTHER|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
58136462|NCT02688257|OTHER|MRI|Functional magnetic resonance imaging
58136463|NCT02688257|OTHER|Ultrasound|Optoacoustic imaging
58136464|NCT01284439|DRUG|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
58136465|NCT01284439|DRUG|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
58136466|NCT05457101|OTHER|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
58136467|NCT03416777|BEHAVIORAL|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
58136468|NCT03416777|DIETARY_SUPPLEMENT|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
58136469|NCT03416777|BEHAVIORAL|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
58136470|NCT02932878|DRUG|DSXS topical|topical treatment
58136471|NCT01162226|BEHAVIORAL|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
58136472|NCT06121193|BEHAVIORAL|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
58136473|NCT06121193|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
58136474|NCT04548440|DRUG|Sintilimab|Route of administration: Intravenous
58136475|NCT04548440|DRUG|Nab paclitaxel|Route of administration: Intravenously over 30min
58136476|NCT04548440|DRUG|Cisplatin|Route of administration: Intravenous
58136477|NCT00840138|PROCEDURE|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
58136478|NCT03616106|OTHER|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
58136479|NCT01474668|DRUG|GDC-0941|Single oral dose\\n \\n\\n\\n\\n
58136480|NCT04712071|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
58136481|NCT06383962|DEVICE|Synergy cervical spine disc replacement|motion preservation disc
58136482|NCT01390844|DRUG|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
58136483|NCT01390844|DRUG|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
58136484|NCT01390844|DRUG|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
58136485|NCT01390844|DRUG|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
58136486|NCT01390844|DRUG|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
58136487|NCT00336479|DRUG|Telaprevir|tablet
58136488|NCT00336479|DRUG|Ribavirin|tablet
58136489|NCT00336479|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
58136490|NCT00336479|OTHER|Placebo|matching placebo tablet
58482383|NCT01116986|BEHAVIORAL|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
58482384|NCT01116986|BEHAVIORAL|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
58136491|NCT01870856|DEVICE|Spectacles|Per participant's habitual prescription
58136492|NCT01870856|DEVICE|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
58136493|NCT01870856|DEVICE|Etafilcon A contact lenses|Hydrogel single vision contact lenses
58136494|NCT01464970|PROCEDURE|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
58136495|NCT01464970|PROCEDURE|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
58136496|NCT01464970|PROCEDURE|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
58136497|NCT01464970|PROCEDURE|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
58136498|NCT02355431|DRUG|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
58136499|NCT02355431|DRUG|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
58136500|NCT02355431|DRUG|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
58136501|NCT02726581|BIOLOGICAL|Nivolumab|Specified dose on specified days, IV (intravenous)
58136502|NCT02726581|BIOLOGICAL|Elotuzumab|Specified dose on specified days, IV
58136503|NCT02726581|DRUG|Pomalidomide|Specified dose on specified days, PO (by mouth)
58136504|NCT02726581|DRUG|Dexamethasone|Specified dose on specified days, PO
58136505|NCT06061146|DRUG|Arm A|anti-PD-1 immunotherapy
58136506|NCT06061146|DRUG|Arm A|chemotherapy
58136507|NCT06061146|RADIATION|Arm A|Radiation Concurrent Radiation, 1.8Gy/f, 28f
58136508|NCT06061146|DRUG|Arm B|chemotherapy
58136509|NCT06061146|RADIATION|Arm B|Radiation Concurrent Radiation, 1.8Gy/f, 28f
58136510|NCT05405725|BIOLOGICAL|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
58136511|NCT05405725|BIOLOGICAL|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
58136512|NCT02472366|DRUG|ILUVIEN|
58136513|NCT01561274|DRUG|2 ml bupivacaine|2 ml bupivacaine
58136514|NCT01561274|DRUG|1.5 ml bupivicaine.|1.5 ml bupivicaine.
58136515|NCT06336291|DRUG|L19TNF|7 μg/kg
58136516|NCT06336291|DRUG|L19TNF|10 μg/kg
58136517|NCT06336291|DRUG|L19TNF|13 μg/kg
58136518|NCT06336291|DRUG|Lomustine|90 mg/m2
58136519|NCT06336291|DRUG|Lomustine|110 mg/m2
58136520|NCT00590408|DIETARY_SUPPLEMENT|coenzyme Q10|60mg capsule twice daily for 12 weeks
58136521|NCT00590408|DIETARY_SUPPLEMENT|matching placebo|matching placebo capsule twice daily for 12 weeks
58136522|NCT02605395|DRUG|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
58136523|NCT02605395|DRUG|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
58136524|NCT05372406|OTHER|• no intervention|• no intervention
58136525|NCT05741437|DRUG|CKD-378, QD, PO Drug: D745, D150, QD, PO|Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
58136526|NCT04361266|DEVICE|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
58136527|NCT04361266|PROCEDURE|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
58136528|NCT02131129|DEVICE|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
58136529|NCT02131129|DEVICE|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
58136530|NCT03773848|PROCEDURE|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
58136531|NCT06085300|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
58136532|NCT03965377|BEHAVIORAL|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
58136533|NCT05620225|DEVICE|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
58136534|NCT05620225|DEVICE|Sham and CMM|Sham and CMM
58136535|NCT04647266|PROCEDURE|endoscopic submucosal dissection|endoscopic submucosal dissection
58136536|NCT01213901|PROCEDURE|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
58136537|NCT03232437|DEVICE|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
58136538|NCT02307734|BEHAVIORAL|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
58136539|NCT02307734|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
58136540|NCT06433141|PROCEDURE|treatment option for primary second molar|final restoration for primary second molars
58482385|NCT01116986|BEHAVIORAL|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
58136541|NCT00014105|DRUG|carboplatin|
58136542|NCT00014105|DRUG|temozolomide|
58136543|NCT05119439|DRUG|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
58136544|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
58136545|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
58136546|NCT00216463|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
57780682|NCT06444048|BIOLOGICAL|EV68-228-N|EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.
57780683|NCT06444048|OTHER|Placebo for EV68-228-N|The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
57780684|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
58136547|NCT00216463|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
58136548|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
58136549|NCT01614730|DEVICE|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
58136550|NCT01614730|DEVICE|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
58136551|NCT06214208|OTHER|Transcutaneous Spinal Stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
58136552|NCT05567965|OTHER|Home care intervention|The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
58136553|NCT02804204|DRUG|Anti-TNF|
58136554|NCT02069665|OTHER|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
58136555|NCT02069665|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
58136556|NCT02069665|DRUG|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
58136557|NCT02069665|DRUG|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
58136558|NCT02069665|DRUG|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
58136559|NCT02069665|DRUG|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
58136560|NCT02069665|DRUG|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
58136561|NCT02069665|DRUG|Ibuprofen Suspension|taken under prescription
58136562|NCT02069665|DRUG|salbutamol|taken under prescription
58136563|NCT02904577|OTHER|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
58136564|NCT00595062|RADIATION|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
58136565|NCT01883271|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
58136566|NCT01883271|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
58136567|NCT05134792|DRUG|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
58136568|NCT03828058|DRUG|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
58136569|NCT03828058|DRUG|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
58136570|NCT05791032|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
58136571|NCT04503993|OTHER|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
58136572|NCT05067647|DEVICE|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
58136573|NCT03056937|OTHER|Bariatric surgery|evaluations pre and post bariatric surgery.
57780685|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
57780686|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
57780687|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
57780688|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
57780689|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
58136574|NCT03056937|OTHER|Control|without intervention, it will be performed only evaluations
58136575|NCT03769844|DRUG|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
58136576|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
58136577|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
58136578|NCT02457520|DRUG|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
58136579|NCT01113606|OTHER|Obagi New-Derm System|
58136580|NCT01113606|OTHER|Standard of Care|
58136581|NCT02019290|DRUG|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
58136582|NCT02019290|DRUG|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
58136583|NCT02612337|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
58136584|NCT02612337|DRUG|Placebo|Single intratympanic injection of placebo
58136585|NCT01202448|PROCEDURE|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
58136586|NCT04725708|PROCEDURE|procedure: cerebral oxygenation intervention|During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
58136587|NCT05292651|PROCEDURE|PCI|percutaneous coronary intervention
58136588|NCT04807270|OTHER|Intra-articular T-LAB / PRP KIT injection|Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
58136589|NCT04807270|OTHER|Intra-articular T-LAB / PRP INJECTION SYRINGE injection|Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
58136590|NCT04807270|OTHER|Intra-articular SALINE injection|Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
58136591|NCT03408119|DIETARY_SUPPLEMENT|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
58136592|NCT03408119|DIETARY_SUPPLEMENT|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
58136593|NCT02175238|DRUG|BI 691751 fasted|single dose BI 691751 in fasted state
58136594|NCT02175238|DRUG|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
58136595|NCT05437549|PROCEDURE|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
58136596|NCT05526573|DEVICE|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
58136597|NCT01748630|DRUG|dexmedetomidine|
58136598|NCT01748630|DRUG|Midazolam|
58136599|NCT01748630|DRUG|fentanyl|
58136600|NCT06146153|DIAGNOSTIC_TEST|digital impression|intra oral scanning
58136601|NCT00711464|DRUG|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
57780690|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
57780691|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
58136602|NCT02158182|DRUG|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
58136603|NCT02158182|DRUG|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
58136604|NCT02158182|DRUG|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
58136605|NCT02158182|DRUG|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
57780692|NCT05437575|DRUG|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
58136606|NCT06101225|OTHER|MindRegulation Intervention|The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
57780693|NCT05437575|DRUG|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
57780694|NCT05399485|DRUG|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
57780695|NCT05399485|DRUG|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
58136607|NCT06101225|OTHER|Relaxation|The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
58136608|NCT06101225|OTHER|Waiting List Control Group|No Intervention.
58136609|NCT01388270|DEVICE|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
58136610|NCT02501005|PROCEDURE|VT ablation|Catheter ablation of ventricular tachycardia
58136611|NCT01837654|BEHAVIORAL|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
58136612|NCT01837654|BEHAVIORAL|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
58136613|NCT03098108|RADIATION|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
58136614|NCT00594347|BIOLOGICAL|Pneumo 23|Vaccine (Pneumo 23)
58136615|NCT00594347|BIOLOGICAL|Prevnar|Vaccine (Prevnar)
58136616|NCT04773470|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
58136617|NCT01215266|DRUG|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
58136618|NCT01215266|DRUG|Placebo|Day 3-21 2x2 800 mg(milligram) daily
58136619|NCT00784823|DRUG|Bortezomib 1 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
58136620|NCT00784823|DRUG|Bortezomib 1.3 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
58136621|NCT00784823|DRUG|Bortezomib 1.6 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
58136622|NCT00784823|DRUG|Melphalan|"* Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight"
58136623|NCT01524653|DRUG|Rosuvastatin|20 mg po od
58136624|NCT01524653|DRUG|Placebo|20 mg po od
58136625|NCT01370408|DRUG|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
58136626|NCT01370408|DRUG|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
58136627|NCT01370408|DRUG|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
58136628|NCT05848245|DEVICE|Suction|Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.
58136629|NCT04274686|DEVICE|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
58136630|NCT04274686|OTHER|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
58136631|NCT04512547|DRUG|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
58136632|NCT01988909|DRUG|WR 279,396|Paromomycin + Gentamicin Topical Cream
58136633|NCT05342597|DRUG|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
58136634|NCT02770625|DRUG|ISU302|60 U/kg given intravenously
58136635|NCT05941481|COMBINATION_PRODUCT|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)|"1. Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid\*14d + oxaliplatin 130mg/m2, d1, q21d);~2. Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f."
58136636|NCT05724810|DEVICE|Active deep transcranial magnetic stimulation (dTMS)|"First, the investigators will find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
58136637|NCT05724810|DEVICE|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
57785248|NCT06455761|DRUG|68Ga-DOTA-NI-FAPI04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
58136638|NCT02628834|OTHER|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
58136639|NCT02628834|OTHER|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
58136640|NCT01157091|DRUG|pazopanib hydrochloride|Given orally
58136641|NCT01157091|OTHER|laboratory biomarker analysis|Correlative studies
58136642|NCT01157091|OTHER|immunologic technique|Correlative studies
58136643|NCT01311908|PROCEDURE|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
58136644|NCT01118247|PROCEDURE|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
58136645|NCT02620670|BEHAVIORAL|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
58136646|NCT01168557|DEVICE|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
58136647|NCT01589783|OTHER|completion of a questionnaire|Completion of a questionnaire
58136648|NCT01589783|OTHER|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
58136649|NCT02468778|DEVICE|HeartMate PHP|The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
58136650|NCT02468778|DEVICE|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
58136651|NCT01938547|DRUG|clevidipine|
58136652|NCT04829162|OTHER|Mother with obesity, daughter with obesity|Participants in this group were shown an image of a mother with obesity and a daughter with obesity.
58136653|NCT04829162|OTHER|Mother with obesity, daughter without obesity|Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
58136654|NCT04829162|OTHER|Mother without obesity, daughter with obesity|Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
58136655|NCT04829162|OTHER|Mother without obesity, daughter without obesity|Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
58136656|NCT04829162|OTHER|Mother with obesity, son with obesity|Participants in this group were shown an image of a mother with obesity and a son with obesity.
58136657|NCT04829162|OTHER|Mother with obesity, son without obesity|Participants in this group were shown an image of a mother with obesity and a son without obesity.
58136658|NCT04829162|OTHER|Mother without obesity, son with obesity|Participants in this group were shown an image of a mother without obesity and a son with obesity.
58136659|NCT04829162|OTHER|Mother without obesity, son without obesity|Participants in this group were shown an image of a mother without obesity and a son without obesity.
58136660|NCT04829162|OTHER|Father with obesity, daughter with obesity|Participants in this group were shown an image of a father with obesity and a daughter with obesity.
58136661|NCT04829162|OTHER|Father with obesity, daughter without obesity|Participants in this group were shown an image of a father with obesity and a daughter without obesity.
58136662|NCT04829162|OTHER|Father without obesity, daughter with obesity|Participants in this group were shown an image of a father without obesity and a daughter with obesity.
58136663|NCT04829162|OTHER|Father without obesity, daughter without obesity|Participants in this group were shown an image of a father without obesity and a daughter without obesity.
58136664|NCT04829162|OTHER|Father with obesity, son with obesity|Participants in this group were shown an image of a father with obesity and a son with obesity.
58136665|NCT04829162|OTHER|Father with obesity, son without obesity|Participants in this group were shown an image of a father with obesity and a son without obesity.
58136666|NCT04829162|OTHER|Father without obesity, son with obesity|Participants in this group were shown an image of a father without obesity and a son with obesity.
58136667|NCT04829162|OTHER|Father without obesity, son without obesity|Participants in this group were shown an image of a father without obesity and a son without obesity.
58136668|NCT01192230|DRUG|Endostatins|7.5mg/m2 qd \*14d,q3w
58136669|NCT01192230|DRUG|Docetaxel|75mg/m2 D1, q3w,4-6cycles
58136670|NCT01231490|DRUG|Placebo|Placebo
58136671|NCT01231490|DRUG|Naproxen|Capsule
58136672|NCT01732978|BEHAVIORAL|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
58136673|NCT03744715|DRUG|Poziotinib|Poziotinib
58136674|NCT05312697|BIOLOGICAL|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
58136675|NCT05606562|PROCEDURE|Dental care|Participants will be offered free dental care
58136676|NCT01609322|BEHAVIORAL|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
58136677|NCT01609322|BEHAVIORAL|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
58136678|NCT01450462|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
58136679|NCT01450462|DIETARY_SUPPLEMENT|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
58136680|NCT06151678|OTHER|Pain Education|Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
58136681|NCT03025945|DRUG|Nepafenac 0.3%|
58136682|NCT03025945|DRUG|Saline Solution|
58136683|NCT04437862|DEVICE|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
58136684|NCT03799029|OTHER|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
58136685|NCT03933748|DRUG|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
58136686|NCT01273337|BIOLOGICAL|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
58136687|NCT01273337|PROCEDURE|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
58136688|NCT03678038|DRUG|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
58136689|NCT03678038|DRUG|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
58136690|NCT04587778|DRUG|Ketamine Hydrochloride|intravenous infusion
58136691|NCT04587778|DRUG|Esketamine|intravenous infusion
58136692|NCT04587778|DRUG|Placebo|intravenous infusion
58136693|NCT04587778|DRUG|Pilot study II: Esketamine|intravenous infusion
58136694|NCT04587778|DRUG|Pilot study II: Placebo|intravenous infusion
58136695|NCT01194609|BIOLOGICAL|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
58136696|NCT01194609|RADIATION|Low dose radiation|20cGy whole body radiation every three weeks for three times
58136697|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
58136698|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
58136699|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
58136700|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
58136701|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
58482386|NCT01116986|BEHAVIORAL|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
58482387|NCT01116986|DRUG|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
57784595|NCT05244187|DEVICE|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
58136702|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
58136703|NCT02349893|DEVICE|RFA treatment|RFA treatment using CelonProSleep plus system
58136704|NCT03437304|BIOLOGICAL|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
58136705|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
58136706|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
57784596|NCT06529562|RADIATION|Surgery combined with Target-reduction intensity-modulated radiotherapy|in control arm
58136707|NCT03437304|BIOLOGICAL|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
58136708|NCT03437304|DRUG|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
58136709|NCT03437304|BIOLOGICAL|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
58136710|NCT04611789|DRUG|LY3832479|Administered subcutaneously
58136711|NCT04611789|DRUG|Placebo|Administered subcutaneously
58136712|NCT03222765|DRUG|Placebo, metformin, linagliptin, linagliptin + metformin|
58136713|NCT02152566|DEVICE|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
58136714|NCT02221765|DRUG|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
58136715|NCT02221765|DRUG|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
58136716|NCT03918486|DEVICE|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
58136717|NCT04874545|DRUG|Propofol|Total intravenous inhalational anesthesia
58136718|NCT00002905|DRUG|cyclophosphamide|
58136719|NCT00002905|DRUG|didanosine|
58136720|NCT00002905|DRUG|doxorubicin hydrochloride|
58136721|NCT00002905|DRUG|etoposide|
58136722|NCT00002905|DRUG|mitoxantrone hydrochloride|
58136723|NCT00002905|DRUG|prednimustine|
58136724|NCT00002905|DRUG|zidovudine|
58136725|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties|All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
58136726|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse|All children in the control group will consume on daily basis vegetable and fruit mousse for six months
58136727|NCT05140070|BEHAVIORAL|Dietary and physical activity counselling|All children in the study will obtain 4 dietary and physical activity advice during the course of the study
58136728|NCT04013425|PROCEDURE|Ice Cream Cone Technique|Guided bone regeneration
58136729|NCT02911662|DRUG|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
58136730|NCT02911662|DRUG|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
58136731|NCT02555111|DRUG|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
58136732|NCT02264106|DRUG|Lefradafiban tablet|
58136733|NCT02264106|DRUG|Lefradafiban double chamber sachet|
58136734|NCT02264106|DRUG|Pantoprazole|
58136735|NCT05245643|DEVICE|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
58136736|NCT01190163|DRUG|Dinoprostone|
58136737|NCT01190163|DRUG|Oxytocin|
58136738|NCT03165968|DEVICE|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
58136739|NCT04449666|DIAGNOSTIC_TEST|Neuropsychological assessment and structural MRI|Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
58136740|NCT05626894|COMBINATION_PRODUCT|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
57784597|NCT06529562|RADIATION|Surgery combined with Dose-reduction intensity-modulated radiotherapy|in experimental arm
58136741|NCT05626894|OTHER|Usual Care|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
58136742|NCT02155205|DRUG|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
58136743|NCT02155205|DRUG|Placebo|Matching placebo
58136744|NCT02155205|DRUG|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
57785249|NCT06455761|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
58136745|NCT02615847|DRUG|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
58136746|NCT00535860|DRUG|Teriparatide|Daily for 96 days
58136747|NCT00667862|DRUG|Panobinostat|
58136748|NCT02266264|DRUG|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
58136749|NCT04231838|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
58136750|NCT04231838|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
58136751|NCT03194412|DIETARY_SUPPLEMENT|Diet /nutritional|"• Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
58136752|NCT03194412|BEHAVIORAL|Physical activity|"* Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises."
58136753|NCT03194412|COMBINATION_PRODUCT|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
58482388|NCT01116986|DRUG|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
58482389|NCT01116986|DRUG|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
58482390|NCT01116986|DRUG|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
58482391|NCT01116986|DRUG|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
58482392|NCT01807988|BEHAVIORAL|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
58482393|NCT01684761|BIOLOGICAL|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
58482394|NCT01684761|BIOLOGICAL|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
58482395|NCT01393392|BEHAVIORAL|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
58482396|NCT01393392|BEHAVIORAL|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
58482397|NCT02786394|BEHAVIORAL|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
58482398|NCT05199077|DRUG|GM-XANTHO|a topical applied ointment
57780696|NCT06738667|OTHER|Acupuncture|Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19). Participants will lie supine, and the skin will be sterilized. Sterile stainless-steel needles (0.25 mm diameter, 40 mm length) will be inserted using a guide device and a self-adhesive pad. Needles will be manipulated for at least 10 seconds to induce Deqi. Participants will receive 30 minutes of acupuncture for twelve sessions (3 per week for 4 weeks).
58136754|NCT03194412|BEHAVIORAL|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
58136755|NCT06083389|BEHAVIORAL|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
58136756|NCT06083389|DEVICE|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
58482399|NCT05425472|DRUG|HR070803|HR070803
58482400|NCT04273776|DRUG|Suvorexant 10 mg|10 mg of suvorexant
58482401|NCT04273776|DRUG|Zolpidem|5 mg of zolpidem
58482402|NCT04273776|DRUG|Placebos|Avicel
58136757|NCT04029610|PROCEDURE|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
58136758|NCT04029610|DRUG|lidocaine and adrenalin|lidocaine and adrenalin
58136759|NCT04029610|DRUG|lidocaine and arterial blockage|lidocaine and arterial blockage
58136760|NCT00653471|DEVICE|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
58136761|NCT00653471|DEVICE|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
58136762|NCT00653471|DEVICE|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
58136763|NCT03204266|DRUG|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
58136764|NCT03204266|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
58136765|NCT00885456|BEHAVIORAL|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
58136766|NCT00885456|BEHAVIORAL|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
58136767|NCT02924883|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
58136768|NCT02924883|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
58136769|NCT02924883|OTHER|Placebo|Placebo matched to atezolizumab
58136770|NCT02648607|DEVICE|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
58136771|NCT06340139|OTHER|conventional treatment|conventional treatment with Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage
58482403|NCT02200406|DRUG|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
58136772|NCT06340139|OTHER|experimental treatment|1 being a fixation point and phase 2 including head and eye movements
58136773|NCT06266806|BEHAVIORAL|Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources|Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
58136774|NCT02679053|BEHAVIORAL|Aerobic exercise|
58136775|NCT02679053|BEHAVIORAL|Placebo control|
58136776|NCT00060307|DRUG|erlotinib hydrochloride|Given orally
58136777|NCT00060307|OTHER|laboratory biomarker analysis|Correlative studies
58136778|NCT00202319|PROCEDURE|Sedation management protocol|
58136779|NCT00913705|DRUG|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
58136780|NCT00913705|DRUG|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
58136781|NCT00913705|PROCEDURE|Surgery|Surgery
58136782|NCT01944930|DEVICE|Laparoscopic narrow band imaging|
58136783|NCT01944930|DEVICE|Standard white-light laparoscopy|
58136784|NCT00186706|DRUG|Selenium|
58136785|NCT00343278|DRUG|Valaciclovir Hydrochloride|
58482404|NCT01106690|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
58136786|NCT03514771|DEVICE|Fraxel DUAL 1550/1927|
58136787|NCT03514771|DRUG|oral isotretinoin|oral isotretinoin
58136788|NCT03514771|DRUG|oral valacyclovir|Oral valacyclovir
58136789|NCT03262012|DRUG|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
58136790|NCT03262012|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
58136791|NCT03262012|DRUG|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
58482405|NCT01106690|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
58482406|NCT01106690|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
58482407|NCT01106690|DRUG|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
58482408|NCT01106690|DRUG|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
58482409|NCT00157677|PROCEDURE|D-dimer testing|Uniform D-dimer use
57785250|NCT04729283|PROCEDURE|Sigmoidectomy|The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
58136792|NCT03262012|DRUG|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
58136793|NCT04874389|DIAGNOSTIC_TEST|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
58136794|NCT02134405|DRUG|Rebamipide|Rebamipide 100mg tid
58136795|NCT02134405|DRUG|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
58136796|NCT02134405|DRUG|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
58136797|NCT03827174|OTHER|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
58136798|NCT03827174|BEHAVIORAL|Behaviour Change Ability Program|"1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation and problem-solving.~3. Patient-specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work"
58136799|NCT01546766|DEVICE|Pupillometry testing.|
58482410|NCT00157677|PROCEDURE|D-dimer testing|Selective D-Dimer use
58482411|NCT04963010|DIAGNOSTIC_TEST|second forward view|second forward view examination of the proximal colon
58136800|NCT02799108|DEVICE|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
57780697|NCT06738667|OTHER|Sham treatment|The Park Sham device will be used for the sham acupuncture group. To maintain blinding, the acupuncture ritual will be identical in both groups, with the following exceptions: patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
57780698|NCT05135169|DRUG|Definity Suspension for Injection|Administration of Definity
57780699|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
57780700|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
57780701|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
57780702|NCT00696085|BEHAVIORAL|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
57780703|NCT06740162|BEHAVIORAL|PACE Program|The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
57780704|NCT01960205|DRUG|Saxagliptin|5mg a day for 6 months
57780705|NCT01960205|DRUG|saxagliptin|2.5 mg a day for 6 months
57780706|NCT01960205|DRUG|metformin|500mg three times a day for 6 months
57780707|NCT01960205|OTHER|lifestyle intervention|lifestyle intervention for 6 months
57780708|NCT02638610|DEVICE|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
57780709|NCT00488241|DEVICE|Zarzenda|Topically applied daily for 2 weeks
57780710|NCT01058330|OTHER|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
57780711|NCT05961813|BEHAVIORAL|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
57780712|NCT05961813|BEHAVIORAL|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
57780713|NCT06740214|DRUG|0.5% standard bupivacaine only|20ml 0.5% standard bupivacaine only
57780714|NCT06740214|DRUG|1.33% liposomal bupivacaine with 0.5% standard bupivacaine|10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
57780715|NCT06740214|DRUG|1.33% liposomal bupivacaine only|20ml 1.33% liposomal bupivacaine (266mg)
57780716|NCT01356173|DRUG|GDC-0349|Oral escalating dose
57780717|NCT03308578|DRUG|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
57780718|NCT03308578|DRUG|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
57780719|NCT01811017|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
57780720|NCT02502305|BEHAVIORAL|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
57780721|NCT06686797|DRUG|PF-08049820|Oral solution/suspension
57780722|NCT06686797|DRUG|Placebo|Oral solution/suspension
57780723|NCT05085288|DEVICE|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
57780724|NCT05085288|OTHER|Turning population every two hours|The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
57780725|NCT06738082|BIOLOGICAL|Influenza vaccine|Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.
57780726|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
57780727|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
57780728|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
57780729|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
57780730|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
57780731|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
57780732|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
57780733|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
57780734|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
58136801|NCT02799108|DEVICE|fMRI|fMRI acquisition under the same stimulation conditions
58482412|NCT01047488|DRUG|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
58482413|NCT01047488|DRUG|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
57780735|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
57780736|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
57780737|NCT06736613|DIAGNOSTIC_TEST|Cerebral Spinal Fluid ctDNA|MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
57780738|NCT06737523|DRUG|CVA|Chiglitazar Sodium in combination with Venetoclax and Azacitidine
58136802|NCT06364280|DEVICE|BVM|Bag-Valve-Mask Ventilation
58136803|NCT06364280|DEVICE|SGA|Supraglottic Airway
58136804|NCT06364280|DEVICE|ETI|Endotracheal Intubation
58136805|NCT05088005|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
58136806|NCT05554822|DRUG|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
58136807|NCT05554822|DRUG|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
58482414|NCT01047488|DRUG|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
57780739|NCT05552976|DRUG|Mezigdomide|Specified dose on specified days
58136808|NCT01351220|BEHAVIORAL|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
58136809|NCT01351220|BEHAVIORAL|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
58136810|NCT05100381|OTHER|dry needling|The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
58136811|NCT05100381|OTHER|sham (placebo) dry needling|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
58482415|NCT01047488|DRUG|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
58482416|NCT02999204|DRUG|Vitamin D3|Two different doses of Vitamin D3
58482417|NCT03131219|BIOLOGICAL|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
57780740|NCT05552976|DRUG|Carfilzomib|Specified dose on specified days
57780741|NCT05552976|DRUG|Dexamethasone|Specified dose on specified days
57780742|NCT06720168|DEVICE|Erythritol air polisher|Dental prophylaxis with erythritol air polisher in patients with dental black stain
57780743|NCT06720168|DEVICE|Dental prophylaxis with ultrasonic treatment|Dental prophylaxis with ultrasonic treatment in patients with dental black stain
58482418|NCT00387504|DRUG|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
58482419|NCT00387504|OTHER|pharmacological study|samples drawn per protocol
57780744|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
58482420|NCT01749332|OTHER|Perihepatic Phlebotomy|
58482421|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
58482422|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
58482423|NCT04569565|DEVICE|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
58482424|NCT02958917|DRUG|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
57780745|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
57780746|NCT06346067|DRUG|Naporafenib|Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
57780747|NCT06346067|DRUG|Dacarbazine|Dacarbazine IV - Day 1
57780748|NCT06346067|DRUG|Temozolomide|Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
58136812|NCT01269801|DRUG|onabotulinumtoxinA|"* Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
58136813|NCT01269801|DRUG|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
58136814|NCT00641394|BEHAVIORAL|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
58136815|NCT00641394|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
58136816|NCT02076022|DEVICE|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
58136817|NCT02076022|PROCEDURE|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
58136818|NCT02939729|OTHER|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
58136819|NCT02939729|DEVICE|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
58136820|NCT02939729|OTHER|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
58136821|NCT02563808|OTHER|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
58482425|NCT02958917|OTHER|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
57780749|NCT06346067|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
58136822|NCT02563808|OTHER|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
58136823|NCT04161365|PROCEDURE|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
58136824|NCT04161365|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
58136825|NCT05406791|DEVICE|VIRA App|Support from coach and using the VIRA app
58136826|NCT05406791|DEVICE|Mood Education App|Support from mood education app
58482426|NCT03483402|PROCEDURE|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
58482427|NCT02081781|PROCEDURE|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
58482428|NCT00304551|DRUG|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
58482429|NCT00304551|DRUG|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
58482430|NCT00304551|DRUG|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
58482431|NCT04098718|DRUG|Benralizumab|100mg sub cut once only
58482432|NCT04098718|DRUG|Prednisolone|30mg tablet daily for 5 days
58482433|NCT03449667|DEVICE|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
58482434|NCT03449667|DEVICE|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
58136827|NCT01695720|PROCEDURE|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
58136828|NCT06302530|PROCEDURE|Stayer|"In group A, the intervention involves using the Strayer technique, an echo-guided recession of the gastrocnemius tendon, with local anesthesia and sedation as needed. The patient can be in a prone or supine position. Ultrasound will identify the sural nerve and blood vessels to prevent damage. The entry point is 2-3 cm distal to the medial head of the gastrocnemius. Local anesthetic is infiltrated, and blunt dissection creates a working space. V-shaped curettes widen the entry point without harming noble structures.~Under direct ultrasound control, a curved scalpel is inserted until reaching the medial border of the gastrocnemius tendon. Transection occurs progressively from medial to lateral while flexing the foot. Verification of complete tendon transection is done with a blunt dissector. Finally, a dressing with adhesive strips and an elastic bandage is applied, eliminating the need for sutures."
58136829|NCT06302530|PROCEDURE|Plantar transection|In group B, an echo-guided transection of the plantar tendon will be performed. Local anesthesia and sedation will be used as needed. The patient will be in prone or supine position. The plantar tendon will be identified ultrasonographically on the medial aspect of the gastrocnemius distal to the myotendinous junction. Local anesthetic will be infiltrated at that point to isolate the plantar tendon. An ultrasound-guided retrograde hook is introduced until the plantar tendon is engaged. Then proceed to retrograde transection of the tendon from lateral to medial, verifying complete section. At the end, a dressing with adhesive strips and elastic bandage, without sutures, will be performed.
58136830|NCT05733884|OTHER|soft contact lens|soft contact lens
58136831|NCT04719949|BEHAVIORAL|Behavioral Activation (BA) Therapy|Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.
58136832|NCT04719949|BEHAVIORAL|Problem Solving Therapy (PST)|Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
58136833|NCT01263704|DRUG|Cyclophosphamide|150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
58136834|NCT01263704|DRUG|Fludarabine|12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
58136835|NCT01263704|DRUG|Rituximab|375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
58136836|NCT05320679|OTHER|Implementation of Questionnaire|Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
58136837|NCT01366079|PROCEDURE|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
58482435|NCT00613561|DRUG|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
58136838|NCT01366079|PROCEDURE|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
58136839|NCT05800652|BEHAVIORAL|Peer Mentoring Program|Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
58136840|NCT00006370|RADIATION|yttrium Y 90-edotreotide|
58482436|NCT03997344|BEHAVIORAL|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
58482437|NCT03997344|BEHAVIORAL|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
58482438|NCT00404469|PROCEDURE|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
58482439|NCT00404469|PROCEDURE|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
58482440|NCT00404469|PROCEDURE|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
58482441|NCT01125592|DEVICE|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
58482442|NCT03754777|PROCEDURE|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
58136841|NCT03496922|BEHAVIORAL|Experimental Tobacco Marketplace|See arm group description.
58136842|NCT00467220|BEHAVIORAL|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
58136843|NCT01700244|DEVICE|Pacemaker implant|
58136844|NCT06366477|DEVICE|Vibration stimulation combined with task-oriented training|Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
58136845|NCT03616990|BEHAVIORAL|TASC Service Linkages - Discharge Area Only|Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
58136846|NCT03616990|BEHAVIORAL|SRC Overnight Stay|Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
58482443|NCT04406857|DRUG|Capecitabine|Given PO
58136847|NCT03616990|BEHAVIORAL|TASC Services Linkages - SRC Onsite|While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
58136848|NCT03616990|BEHAVIORAL|APN Appointment|Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
58136849|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
58136850|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
58136851|NCT03026348|BIOLOGICAL|RSV F Vaccine with Aluminum Phosphate Adjuvant|
58136852|NCT03026348|BIOLOGICAL|RSV F Vaccine|
58136853|NCT03026348|BIOLOGICAL|Matrix-M1 Adjuvant|
58136854|NCT03026348|OTHER|Phosphate Buffer|
58136855|NCT00890526|OTHER|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from \~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
58482444|NCT04406857|RADIATION|Radiation Therapy|Undergo radiation therapy
58482445|NCT04406857|DRUG|Ropidoxuridine|Given PO
58136856|NCT00890526|OTHER|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
58136857|NCT00890526|OTHER|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
58136858|NCT00890526|OTHER|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
58482446|NCT02891577|PROCEDURE|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
58482447|NCT06212128|COMBINATION_PRODUCT|RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol (Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol)
58482448|NCT06212128|COMBINATION_PRODUCT|LCRT|LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine
58482449|NCT01987453|DRUG|LDV/SOF|Tablet(s) administered orally once daily
58136859|NCT05963321|DEVICE|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
58136860|NCT02461771|DRUG|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
58136861|NCT06327022|OTHER|Social media-based electronic bibliotherapy|Eight weekly sessions of bibliotherapy are delivered via their daily social media.
58136862|NCT06327022|OTHER|Usual care|The routine services provided by community centers
58136863|NCT01964092|BEHAVIORAL|Individual Placement and Support|
58136864|NCT01964092|BEHAVIORAL|Ordinary employment schemes|
58136865|NCT02828917|DEVICE|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
58136866|NCT03292653|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
58136867|NCT03292653|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
58136868|NCT03280394|DIAGNOSTIC_TEST|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
58136869|NCT04188106|DRUG|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
58136870|NCT04188106|DRUG|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
58136871|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
58136872|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
58136873|NCT01860105|DRUG|MDCO-157|intravenous administration
58136874|NCT01860105|DRUG|PLAVIX|oral administration
58136875|NCT02167165|DRUG|Digoxin Injection|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
58136876|NCT02747615|OTHER|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
58136877|NCT02747615|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
58136878|NCT02747615|OTHER|transfused only allogeneic blood.|
58136879|NCT06387186|DRUG|Leucine-Enriched Essential Amino Acid powder|Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
57780750|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
58136880|NCT00773422|DRUG|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
58136881|NCT00773422|DRUG|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
58136882|NCT00773422|DRUG|placebo|placebo
58136883|NCT00842595|DRUG|rituximab|6 courses every 28 days
58136884|NCT00842595|DRUG|vinorelbine|6 courses every 28 days
58136885|NCT00842595|DRUG|ifosfamide|6 courses every 28 days
58136886|NCT00842595|DRUG|Mitoxantrone|6 courses every 28 days
58136887|NCT00842595|DRUG|Prednisone|6 courses every 28 days
58136888|NCT02548403|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
58136889|NCT02548403|DRUG|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
58136890|NCT02493270|BEHAVIORAL|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
58136891|NCT02493270|PROCEDURE|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
58136892|NCT03884088|OTHER|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
58136893|NCT02088463|PROCEDURE|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
58136894|NCT02088463|PROCEDURE|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
58136895|NCT02088463|DEVICE|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
58136896|NCT02370719|BEHAVIORAL|Mobile application for diabetes self-management|
58136897|NCT05037760|DRUG|KER-050 monotherapy|KER-050 administered (SC) for up to 13 cycles
58136898|NCT05037760|DRUG|KER-050 in combination with ruxolitinib|KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib
58136899|NCT01427023|DEVICE|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
58136900|NCT01513486|BEHAVIORAL|immobilization|
58136901|NCT02171637|DRUG|BIBW 2992|escalating doses
58136902|NCT06449742|DIAGNOSTIC_TEST|IA Nanox AIHealthVCF|IA Nanox AIHealthVCF A(I software) will be used durint ct scan to identify vertebral fractures
58136903|NCT05761626|OTHER|MP < 17 J/min|assessment of the ventilatory variables according to the MP value (\< or \>= 17 J/min)
58136904|NCT03149653|DRUG|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
58136905|NCT03149653|DRUG|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
58136906|NCT03149653|DRUG|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
58482450|NCT01987453|DRUG|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
58136907|NCT03149653|DRUG|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
58136908|NCT03149653|DRUG|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
58136909|NCT03149653|DRUG|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
58136910|NCT04092647|DRUG|Ashwagandha|Ashwagandha 350 mg po BID
58136911|NCT04092647|DRUG|Placebo|Placebo 350 mg po BID
58136912|NCT03326271|PROCEDURE|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
58136913|NCT03326271|PROCEDURE|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
58136914|NCT04336696|PROCEDURE|Total thyroidectomy and central neck dissection|
58136915|NCT01581450|DRUG|Nitrous Oxide|35%
58136916|NCT01581450|DRUG|Nitrous Oxide|50%
58136917|NCT00685477|DRUG|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
58136918|NCT00685477|DRUG|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
58136919|NCT00685477|DRUG|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
58136920|NCT00685477|DRUG|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
58136921|NCT00685477|DRUG|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
58136922|NCT00685477|DRUG|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
58136923|NCT05059249|PROCEDURE|Hot Pack|Superficial Heating
58136924|NCT05059249|PROCEDURE|Manual Traction|Manual Traction for 10 minutes
58136925|NCT05059249|PROCEDURE|Mechanical Traction|Mechanical Traction for 10 minutes
58136926|NCT05059249|PROCEDURE|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
58136927|NCT05059249|PROCEDURE|TENS|TENS for 10 minutes with hot pack
58136928|NCT00213304|BIOLOGICAL|varicella vaccine (VARIVAX)|
58482451|NCT03228823|PROCEDURE|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
58482452|NCT03228823|DRUG|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
58136929|NCT04991090|RADIATION|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
58136930|NCT05106465|DEVICE|Konectom platform|Administered as specified in the treatment arm.
58136931|NCT05681247|DRUG|ezetimibe tablet|The subjects randomly received single oral administration of ezetimibe tablet 10 mg
58136932|NCT05681247|DRUG|ezetimibe tablet(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
58136933|NCT01194388|DEVICE|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
58136934|NCT06022237|DRUG|Ibandronate|Ibandronate 150 mg once monthly.
58136935|NCT06022237|DRUG|Calcium|Calcium 500 mg twice daily
58136936|NCT06022237|DRUG|Vitamin D3|Vitamin D3 - 1000 IU daily
58136937|NCT01642342|OTHER|laboratory biomarker analysis|Correlative studies
58136938|NCT01642342|OTHER|pharmacological study|Correlative studies
58136939|NCT01642342|BIOLOGICAL|recombinant albumin fusion protein sEphB4-HSA|Given IV
58136940|NCT04913376|DEVICE|Hilotherapy|Constant cooling device for hands and feet.
58136941|NCT00316745|DRUG|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
58136942|NCT00316745|DRUG|TS-1|S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)
58136943|NCT00316745|DRUG|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
58136944|NCT00316745|DRUG|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
58136945|NCT00316745|DRUG|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
58136946|NCT01785368|OTHER|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
58136947|NCT01785368|OTHER|Baseline observation|During this period of the study, baseline data will be collected.
58482453|NCT01773213|PROCEDURE|Ice-water-test|
58482454|NCT01006239|OTHER|No study intervention|The is no study related intervention.
58482455|NCT02396199|DEVICE|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
58482456|NCT00896896|OTHER|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
58482457|NCT00896896|OTHER|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
58482458|NCT00453219|PROCEDURE|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
58482459|NCT00453219|PROCEDURE|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
58482460|NCT00453219|GENETIC|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
58482461|NCT00453219|PROCEDURE|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
58482462|NCT00453219|PROCEDURE|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
58482463|NCT03279744|DRUG|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
58482464|NCT04780646|BEHAVIORAL|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
58482465|NCT04780646|BEHAVIORAL|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
58482466|NCT00615303|DRUG|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
58482467|NCT00615303|DRUG|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
58482468|NCT00871416|DEVICE|NovoFine® needle 6 mm|
58482469|NCT00871416|DEVICE|NovoFine® needle 12 mm|
58482470|NCT02631590|DRUG|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
58482471|NCT02631590|DRUG|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
58482472|NCT02631590|DRUG|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
58482473|NCT04434456|DEVICE|CGuard stent implantation|CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
58482474|NCT02986360|BEHAVIORAL|Vidscrip educational video|Vidscrip educational video provide to women
58482475|NCT00846976|DRUG|Bicalutamide|200mg daily
58482476|NCT03257059|OTHER|Breakfast|Glutinous rice (75 grams of available carbohydrate)
58482477|NCT03257059|OTHER|No Breakfast|No food to be served in the morning
58482478|NCT00067002|PROCEDURE|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
58482479|NCT00067002|PROCEDURE|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
58482480|NCT00067002|DRUG|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
58482481|NCT00067002|DRUG|Melphalan|140 mg/m2 by vein on Day -8.
58482482|NCT00067002|DRUG|Thiotepa|5 mg/Kg by vein on Day -7.
58482483|NCT00067002|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
58482484|NCT00067002|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6.
58482485|NCT00067002|DRUG|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
58482486|NCT00067002|RADIATION|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
58482487|NCT00354432|DIETARY_SUPPLEMENT|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
58482488|NCT00354432|DRUG|Venlafaxine|Patients receive oral venlafaxine 75mg.
58482489|NCT00354432|DIETARY_SUPPLEMENT|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
58482490|NCT00354432|DRUG|Placebo Pill|Patients receive oral placebo pill.
58482491|NCT01065883|BEHAVIORAL|community health worker|community health workers will provide education in the home
58482492|NCT01065883|BEHAVIORAL|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
58482493|NCT02497352|DIETARY_SUPPLEMENT|flaxseed|
58482494|NCT02497352|BEHAVIORAL|lifestyle modification|
58482495|NCT02331888|DEVICE|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
58482496|NCT03956654|DRUG|Ribociclib|combination of ribociclib and letrozole
58482497|NCT00798993|OTHER|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
58482498|NCT00798993|DRUG|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
58482499|NCT00798993|OTHER|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
58482500|NCT04558034|OTHER|cryotherapy|cryotherapy will be delivered
58482501|NCT03689621|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|
58482502|NCT04059159|DEVICE|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
58482503|NCT03762317|DRUG|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
58482504|NCT03762317|DRUG|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
58482505|NCT04214158|OTHER|Assessment|Assessment
58482506|NCT05024032|DRUG|Tirzepatide|Administered SC
58482507|NCT05024032|DRUG|Placebo|Administered SC
58482508|NCT02261701|OTHER|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
58482509|NCT02261701|OTHER|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
58482510|NCT02779946|DEVICE|Fibro Scan|
58482511|NCT02779946|GENETIC|PNPLA3|
58482512|NCT02275234|OTHER|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
58482513|NCT01649206|PROCEDURE|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
58482514|NCT00722943|OTHER|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
58482515|NCT00722943|OTHER|no intervention|The infant will not be touched by the therapist.
58482516|NCT00672321|GENETIC|gene expression analysis|
58482517|NCT00672321|GENETIC|mutation analysis|
58482518|NCT00672321|GENETIC|polymorphism analysis|
58482519|NCT00672321|OTHER|laboratory biomarker analysis|
58482520|NCT00672321|OTHER|questionnaire administration|
58482521|NCT00553891|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
57780751|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
58482522|NCT00553891|DRUG|placebo nasal spray|One spray in each nostril once daily for 3 months.
58482523|NCT01455701|DRUG|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
58482524|NCT03829644|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
58482525|NCT05959720|DRUG|Prednisone|60 mg/m2 D1 to D21
58482526|NCT05959720|DRUG|Vincristin|1.5 mg/m2 D1, D8, D15 and D22
58482527|NCT05959720|DRUG|Daunorubicin|40 mg/m2 D1, D8, D15 and D22
58482528|NCT05959720|DRUG|Peg-asparaginase|2000 UI/m2 D12 and D26
58482529|NCT05959720|DRUG|Intrathecal Suspension|MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
57780752|NCT02127905|BIOLOGICAL|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
58482530|NCT05959720|DRUG|Cyclophosphamide|1000 mg/m2 D36 and D64
58482531|NCT05959720|DRUG|Cytarabine|75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
58482532|NCT05959720|DRUG|Mercaptopurine|30 mg/m2 D36 to D63 and D1 to D56 of consolidation
58482533|NCT05959720|DRUG|Methotrexate|3.000 mg/m2 D8, D22, D36 and D50
58482534|NCT05959720|DRUG|Doxorubicin|30 mg/m2 D1 and D22
58482535|NCT03584789|OTHER|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
58482536|NCT03584789|OTHER|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
58482537|NCT04266145|DRUG|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
58482538|NCT04266145|DRUG|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
57780753|NCT06736964|DEVICE|Giomer|based on Pre-reacted glass ionomer (PRG)
58482539|NCT04030871|DEVICE|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
58482540|NCT04030871|DEVICE|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
58482541|NCT01230983|DRUG|asparaginase|Given IV
58482542|NCT01230983|DRUG|cytarabine|Given IV
58482543|NCT01230983|DRUG|dexrazoxane hydrochloride|Given IV
58482544|NCT01230983|DRUG|doxorubicin hydrochloride|Given IV
58482545|NCT01230983|DRUG|leucovorin calcium|Given IV
58482546|NCT01230983|DRUG|mercaptopurine|Given orally
58482547|NCT01230983|DRUG|methotrexate|Given IV
58482548|NCT01230983|DRUG|prednisone|Given orally
58482549|NCT01230983|DRUG|therapeutic hydrocortisone|Given IT
58482550|NCT01230983|DRUG|vincristine sulfate|Given IV
58482551|NCT01230983|RADIATION|radiation therapy|Radiation to cranium
58482552|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment."
58482553|NCT04195373|BIOLOGICAL|TMV-018 + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC."
58482554|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC."
58482555|NCT01573689|BEHAVIORAL|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
58482556|NCT02725918|DRUG|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
58482557|NCT02725918|DRUG|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
58482558|NCT02461134|DRUG|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
58482559|NCT05953623|BIOLOGICAL|Albumin|This is a 3 + 3 dose-escalation study with 5 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation.
58482560|NCT05996718|BEHAVIORAL|Training program pilot|This intervention for informal caregivers consists of training that will introduce participants to improvisational (improv) theatre and teach its core communication skills.
58482561|NCT03591211|BEHAVIORAL|Qigong Training|Eight-Section Brocades; participants were trained individually.
58482562|NCT03591211|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
58482563|NCT00807001|DRUG|IDX184|oral dose, active or placebo
58482564|NCT01871935|DRUG|Remifentanil|Anaesthesia with remifentanil/propofol.
58482565|NCT01871935|DRUG|Sufentanil|Anaesthesia with sufentanil/propofol
58482566|NCT01597596|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
58482567|NCT01597596|BIOLOGICAL|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
58482568|NCT01887483|DIETARY_SUPPLEMENT|Vetal Laban active|Dairy product with probiotic
58482569|NCT01887483|DIETARY_SUPPLEMENT|Placebo|Dairy product without probiotic
58482570|NCT03006003|DRUG|Raloxifene|Raloxifene tratment more than 4 weeks
58482571|NCT03006003|DRUG|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
58482572|NCT04592887|RADIATION|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
58482573|NCT02808117|DIETARY_SUPPLEMENT|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
58482574|NCT00420446|BEHAVIORAL|Adjusted diet|
58482575|NCT02566421|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482576|NCT02566421|OTHER|Quality-of-Life Assessment|Ancillary studies
58482577|NCT02566421|OTHER|Targeted Therapy|Receive treatment based on genomic sequencing
58482578|NCT02231359|DRUG|Berodual® Respimat® solution for inhalation|
58482579|NCT03980704|DRUG|IMPACT|Administration of oral immunostimulating oral supplement
58482580|NCT03980704|DRUG|resource protein|Administration of oral high-protein oral supplement
58482581|NCT00001027|DRUG|Pentamidine isethionate|
57780754|NCT05622201|DRUG|Rituximab|Infusion
58482582|NCT02766023|BIOLOGICAL|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
58482583|NCT02766023|DRUG|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
58482584|NCT02766023|OTHER|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
58482585|NCT05477667|DIAGNOSTIC_TEST|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
58482586|NCT02964182|DRUG|Cigarette|Smoke usual brand of cigarettes
58482587|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
58482588|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
58482589|NCT02964182|OTHER|Questionnaire Administration|Ancillary studies
58482590|NCT02964182|OTHER|Survey Administration|Ancillary studies
58482591|NCT02964182|DRUG|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
58482592|NCT02964182|DEVICE|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
58482593|NCT02964182|DEVICE|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
58482594|NCT01281904|BEHAVIORAL|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
58482595|NCT01281904|BEHAVIORAL|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
58482596|NCT06359353|DRUG|Pitavastatin|"Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision."
58482597|NCT03052062|DIETARY_SUPPLEMENT|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
58482598|NCT01734616|BEHAVIORAL|Old Exercise|
58482599|NCT01734616|DIETARY_SUPPLEMENT|Old Acute Cocoa|
58482600|NCT01734616|DIETARY_SUPPLEMENT|Old 7 Day Cocoa|
58482601|NCT04983446|DRUG|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
58482602|NCT04983446|OTHER|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
58482603|NCT02564835|OTHER|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
58482604|NCT02564835|OTHER|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
58482605|NCT02331212|OTHER|Cytology Specimen Collection Procedure|Correlative studies
58482606|NCT02331212|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482607|NCT05488444|BEHAVIORAL|Navigator Phone Calls|"The patient navigator will call you every week as described above in Study Groups. These phone calls will continue until you begin receiving chemotherapy."
58482608|NCT05488444|BEHAVIORAL|Exit Interview|Participants will be asked to complete an exit interview either in person or by phone
58482609|NCT00093626|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482610|NCT00093626|DRUG|Sorafenib Tosylate|Given orally
58482611|NCT06273215|DRUG|The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
58482612|NCT02000440|DRUG|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
58482613|NCT00483977|DRUG|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
58482614|NCT00483977|DRUG|Placebo|Placebo: oral for 2 weeks.
58482615|NCT00483977|DRUG|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
58482616|NCT04399785|OTHER|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
58482617|NCT01045837|DRUG|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
58482618|NCT01045837|BEHAVIORAL|Gluten free diet|Only gluten free diet will be given in this group
58482619|NCT00976560|DRUG|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
58482620|NCT00976560|OTHER|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
58482621|NCT00477386|DRUG|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
58482622|NCT01841411|DRUG|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
58482623|NCT01841411|DRUG|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
58482624|NCT01841411|DRUG|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
58482625|NCT00889720|DRUG|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
58482626|NCT03894683|DRUG|Melatonin 10 mg|Melatonin tablets (10 mg)
58482627|NCT03894683|DRUG|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
58482628|NCT01088867|OTHER|Acupuncture|Electroacupuncture
58482629|NCT03692624|BEHAVIORAL|Biofeedback|Heart Rate Variability Biofeedback
58482630|NCT00823693|DRUG|Bimosiamose Cream|
58482631|NCT00823693|DRUG|Placebo Cream|
58482632|NCT01569607|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
58482633|NCT01569607|DEVICE|Sham stimulation|Sham stimulation
58482634|NCT04581213|PROCEDURE|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
58482635|NCT02750917|DRUG|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
57780755|NCT05539963|DRUG|STIMULAN VG|Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
57780756|NCT05539963|DRUG|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements.
57780757|NCT06521463|DEVICE|WATCHMAN FLX Pro LAAC Device|WATCHMAN FLX Pro LAAC Device Implantation
58482636|NCT02750917|DRUG|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
58482637|NCT01539161|DEVICE|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
58482638|NCT01539161|PROCEDURE|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
58482639|NCT05481086|OTHER|No Interventions|There is no interventions in this study
58482640|NCT02382432|DRUG|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
58482641|NCT02382432|DRUG|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
58482642|NCT02500797|BIOLOGICAL|Ipilimumab|Given IV
58482643|NCT02500797|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482644|NCT02500797|BIOLOGICAL|Nivolumab|Given IV
58482645|NCT02500797|OTHER|Quality-of-Life Assessment|Ancillary studies
58482646|NCT01354314|DRUG|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
58482647|NCT01354314|DRUG|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
58482648|NCT01354314|DRUG|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
57780758|NCT02309606|OTHER|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
58482649|NCT01354314|DRUG|Placebo|One capsule in the morning, three capsules in the evening
58482650|NCT03517878|BEHAVIORAL|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
58482651|NCT04840693|BIOLOGICAL|Biological samples|blood, urine, saliva
58482652|NCT04840693|OTHER|Complications|bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
58482653|NCT04266717|BEHAVIORAL|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
58482654|NCT04266717|BEHAVIORAL|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
58482655|NCT00685191|DRUG|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
58482656|NCT03341702|OTHER|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
58482657|NCT04822116|OTHER|goal directed intraoperative haemodynamic optimization|all interventions that were pre-specified to be administered as part of the protocol
58482658|NCT06056518|OTHER|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
58482659|NCT02334904|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
58482660|NCT02334904|DRUG|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
58482661|NCT06452576|DEVICE|Vibration|Watch vibrates.
58482662|NCT06452576|BEHAVIORAL|constraint-induced movement therapy|A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.
58482663|NCT01539421|BEHAVIORAL|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
58482664|NCT05012917|OTHER|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
58482665|NCT05012917|OTHER|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
58482666|NCT02928965|DRUG|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
58482667|NCT02928965|DRUG|Placebo|Matching placebo with appearance of over - encapsulated minocycline
58482668|NCT02314559|DRUG|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
58482669|NCT02314559|DRUG|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
58482670|NCT06035913|DRUG|Dihydroergot mesylate|take medicine
58482671|NCT03798769|OTHER|Supportive Oncology Care at Home|"Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
58482672|NCT00809952|PROCEDURE|recombinant FSH|
58482673|NCT03450122|BIOLOGICAL|Aldesleukin|Given SC
58482674|NCT03450122|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
58482675|NCT03450122|DRUG|Cyclophosphamide|Given IV
58482676|NCT03450122|BIOLOGICAL|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
58482677|NCT02980393|BEHAVIORAL|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
58482678|NCT04112719|OTHER|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
58482679|NCT04112719|OTHER|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
58482680|NCT04112719|OTHER|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
58482681|NCT02405832|DIETARY_SUPPLEMENT|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
58482682|NCT02405832|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
58482683|NCT03537404|DRUG|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
58482684|NCT03537404|DRUG|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
58482685|NCT03537404|DRUG|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
58482686|NCT03537404|DRUG|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
57780759|NCT06738888|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
58482687|NCT01153932|DRUG|GSK2402968|Subcutaneous injection
58482688|NCT01153932|DRUG|matched placebo|Subcutaneous injection
58482689|NCT01213628|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
58482690|NCT00585026|DEVICE|D-28 bifocal lenses and frame|
58482691|NCT00585026|DEVICE|Progressive addition computer lenses and frame|
58482692|NCT03868657|DRUG|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
58482693|NCT03868657|DRUG|Placebo|Placebo
58482694|NCT05038982|DRUG|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
57780760|NCT01015014|DRUG|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
57780761|NCT01015014|DRUG|Placebo|0.9% sodium chloride for injection
58482695|NCT04567992|PROCEDURE|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
58482696|NCT02453308|DRUG|ACT|"1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days"
58482697|NCT02453308|DRUG|TACT|"1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
58482698|NCT05795608|DEVICE|respiratory exercise with incentive spirometry|Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
58482699|NCT05633758|DRUG|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
58482700|NCT05633758|DRUG|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
58482701|NCT04878718|BIOLOGICAL|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
58482702|NCT02682524|DRUG|Pelubiprofen CR 45mg tab.|
58482703|NCT02682524|DRUG|Aceclofenac 100mg tab.|
58482704|NCT00078546|BIOLOGICAL|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
58482705|NCT00078546|BIOLOGICAL|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
58482706|NCT03588585|PROCEDURE|Tension|Tension applied to catheter and taped firmly to leg.
58482707|NCT03588585|PROCEDURE|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
58482708|NCT01558804|OTHER|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
58482709|NCT02224560|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
58482710|NCT02224560|DRUG|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
58482711|NCT02051413|DRUG|Venlafaxine extended release|antidepressant drug
58482712|NCT00531661|DEVICE|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
58482713|NCT04230031|DRUG|Daratumumab|Experimental
58482714|NCT03548948|OTHER|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
58136948|NCT04346927|OTHER|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
58136949|NCT04346927|OTHER|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
58482715|NCT03548948|OTHER|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
58482716|NCT03548948|OTHER|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
58482717|NCT00210912|DRUG|topiramate|
58482718|NCT02168244|OTHER|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
58482719|NCT02168244|OTHER|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
58482720|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
58482721|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
58482722|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
58482723|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
58482724|NCT00616759|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy as usual
58482725|NCT00616759|PROCEDURE|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
58482726|NCT00616759|DRUG|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
58136950|NCT04469270|BIOLOGICAL|Engensis|Intramuscular injections
58136951|NCT04469270|OTHER|Placebo|Intramuscular injections
58136952|NCT00050778|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
58482727|NCT03992248|BEHAVIORAL|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
58482728|NCT03992248|BEHAVIORAL|Control|Eating for at least 14hrs per day.
58482729|NCT03708276|OTHER|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
58482730|NCT03537521|PROCEDURE|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
58482731|NCT01658319|DRUG|fludarabine phosphate|Given IV
58482732|NCT01658319|DRUG|methoxyamine|Given IV
58482733|NCT01658319|OTHER|laboratory biomarker analysis|Correlative studies
58482734|NCT01658319|OTHER|pharmacological study|Correlative studies
58482735|NCT01658319|GENETIC|western blotting|Correlative studies
58482736|NCT01658319|OTHER|mass spectrometry|Correlative studies
58482737|NCT01658319|GENETIC|DNA analysis|Correlative studies
58482738|NCT01523756|DEVICE|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
58482739|NCT01523756|DEVICE|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
58482740|NCT06229275|DEVICE|Pap smear collection using the Personal Pap Smear (PPS) Device|Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.
58482741|NCT06229275|DEVICE|Active Comparator: Pap smear collection using the Rovers Cervex-Brush|Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.
58482742|NCT00530972|DRUG|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)
58482743|NCT01876017|BIOLOGICAL|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
58482744|NCT02130843|DEVICE|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
58482745|NCT03672968|GENETIC|GS010|
58482746|NCT04664452|OTHER|Questionnaire|Participants will be asked to fill the questionnaire
58482747|NCT05824819|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
58482748|NCT02416206|DRUG|BeEAM|BeEAM
58482749|NCT01837121|OTHER|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
58482750|NCT04126941|OTHER|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
58482751|NCT00956319|DRUG|Zolpidem MR|oral
58482752|NCT00956319|DRUG|Estazolam|oral
58482753|NCT01935778|DRUG|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
58482754|NCT01935778|DRUG|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
58482755|NCT03082521|BEHAVIORAL|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
58482756|NCT01326949|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
58482757|NCT01326949|PROCEDURE|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
58482758|NCT00385359|PROCEDURE|aerosol drug deposition strategies|
58482759|NCT00385359|DRUG|Albuterol|
58482760|NCT01318460|DRUG|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
58482761|NCT01318460|DRUG|Placebo infusion|Twenty-four hour administration of placebo
58482762|NCT06295484|OTHER|Alternating traditional CPAP, NIPPV, and high CPAP|The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
58482763|NCT01129596|DRUG|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
58482764|NCT02751853|DEVICE|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
58482765|NCT04198558|DRUG|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
58482766|NCT04198558|DRUG|Placebo|Placebo
58482767|NCT01216553|OTHER|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
58482768|NCT01352000|BEHAVIORAL|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
58482769|NCT01887457|DRUG|VFEND|voriconazole will be administered in iv form
58482770|NCT03297112|DRUG|Perflutren Lipid Microspheres|Given IV
58482771|NCT03297112|PROCEDURE|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
58482772|NCT06519669|BIOLOGICAL|GT201 injection|GT201 injection to treat Advanced lung cancer
58482773|NCT02180100|DRUG|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
58482774|NCT02180100|DRUG|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
58482775|NCT05969834|DRUG|uHCG|Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
58482776|NCT05969834|DRUG|rHCG|Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
58482777|NCT05969834|DRUG|uHCG and GnRHa|Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
58482778|NCT04016623|DEVICE|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
58482779|NCT04016623|DEVICE|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
58482780|NCT03294252|DRUG|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
58482781|NCT03294252|DRUG|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
58482782|NCT03294252|DRUG|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
58482783|NCT06209307|BEHAVIORAL|Pelvic floor physical therapy|"Pelvic floor physical therapy (i.e., Kegel exercises):~* Finding the right muscles: To identify pelvic floor muscles, the patient should stop urination in midstream or tighten the muscles that keep from passing gas. These maneuvers use pelvic floor muscles. Once the pelvic floor muscles are identified, the patient can do the exercises in any position, although doing them lying down at first might be the easiest approach.~* Perfecting the technique: Tighten pelvic floor muscles, hold the contraction for three seconds, and then relax for three seconds. Try it a few times in a row. When muscles get stronger, try doing Kegel exercises while sitting, standing, or walking.~* Maintaining focus: For best results, focus on tightening only pelvic floor muscles. Be careful not to flex the muscles in the abdomen, thighs, or buttocks. Avoid breath-holding. Instead, breathe freely during the exercises.~* Repeat 3 times a day. Aim for three sets of 10 repetitions a day."
58482784|NCT05198596|BIOLOGICAL|MVC-COV1901|Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
58482785|NCT05198596|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
58482786|NCT05326490|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively
58482787|NCT05326490|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
58482788|NCT05326490|DRUG|Metformin hydrochloride|The dosage and administration of metformin hydrochloride remain unchanged before screening
58482789|NCT04852926|OTHER|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~* T0 (at inclusion) : before disease + since diagnosis~* C4 (chemotherapy course n°4)~* C6 (chemotherapy course n°6)~* M3 (3 months after chemotherapy)~* M6 (6 months after chemotherapy)~* A1 (1 year after chemotherapy)~* A2 (2 years after chemotherapy)"
58482790|NCT00933452|DRUG|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
58482791|NCT00933452|DRUG|duloxetine|15mg, oral administer
58482792|NCT00933452|DRUG|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
58482793|NCT05506033|PROCEDURE|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
58482794|NCT00867672|DRUG|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
58482795|NCT00867672|DRUG|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
58482796|NCT00867672|DRUG|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
58482797|NCT03698877|DIAGNOSTIC_TEST|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
58482798|NCT05069493|PROCEDURE|simple suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
58482799|NCT05069493|PROCEDURE|mesh|Hiatal hernia repair by tension-free mesh closure
58482800|NCT01376258|DRUG|5ARI|dutasteride or finasteride
58136953|NCT00050778|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).
58482801|NCT00071058|DRUG|XR9576 (Tariquidar)|
58482802|NCT00533676|DRUG|MK0524A, /Duration of Treatment : 8 Weeks|
58482803|NCT00533676|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
58482804|NCT04987333|DRUG|Efavaleukin alfa|Administered as a single dose SC injection.
58482805|NCT06480084|DIAGNOSTIC_TEST|Continuous Laryngoscopy during Exercise Test (CLE test)|A flexible fiberoptic laryngoscope (Olympus, Tokyo, Japan) is introduced directly through the nose or via a slightly modified Hans Rudolph facemask, and into the pharyngeal space. A modified Bruce protocol with a 60-second incremental intensity step is used (Appendix A) and heart rate is monitored. During the CLE test participants perform incremental exercise on a treadmill until symptom-limiting distress or exhaustion. Forced expiratory flow-volume loops are measured before, during and after the CLE test.
58482806|NCT03071107|BEHAVIORAL|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
58482807|NCT03254797|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
58482808|NCT03254797|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
58482809|NCT02374528|PROCEDURE|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
58482810|NCT02374528|PROCEDURE|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
58482811|NCT02717923|OTHER|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
58482812|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
58482813|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
58482814|NCT00286468|DRUG|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
58482815|NCT00545454|DRUG|SSR150106|
58482816|NCT00545454|DRUG|Placebos|
58482817|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
58482818|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
58482819|NCT01814267|OTHER|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed"
58482820|NCT01814267|OTHER|conventional|"conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed"
58482821|NCT01635439|DRUG|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
58482822|NCT01635439|DRUG|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
58482823|NCT04355169|DRUG|Naldemedine|Oral tablet
58482824|NCT04355169|DRUG|Placebo|Oral tablet
58482825|NCT01502774|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
58482826|NCT01502774|DRUG|Placebo|One single intravenous bolus injection of Placebo
58482827|NCT01502774|PROCEDURE|Echocardiography|1 year after AMI
58482828|NCT03767413|PROCEDURE|PNF|proprioceptive neuromuscular facilitation training
58482829|NCT03767413|PROCEDURE|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
58482830|NCT02270294|OTHER|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
58482831|NCT02270294|OTHER|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
58482832|NCT05386771|DIETARY_SUPPLEMENT|Whey/collagen protein blend|Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
58482833|NCT05386771|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
58482834|NCT01048619|DRUG|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
58482835|NCT02497170|BEHAVIORAL|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
58482836|NCT01035801|DRUG|IN-105|Prandial Oral Insulin
58482837|NCT01035801|DRUG|Insulin Lispro Injection|Insulin Lispro Injection
58482838|NCT05694416|DRUG|Etoposide Plus Cisplatin|Etoposide Plus Cisplatin ivdrip d1-5
58482839|NCT05744674|DRUG|HR18034|HR18034 228mg/342mg/456mg
58482840|NCT05744674|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
58482841|NCT01737437|DRUG|group C|0.9% normal saline was applied to trachea and laryngoscope blade
58482842|NCT01737437|DRUG|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
58482843|NCT01737437|DRUG|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
58482844|NCT01737437|DRUG|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
58482845|NCT06004427|OTHER|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
58482846|NCT06004427|OTHER|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
58482847|NCT00427765|DRUG|Busulfan|Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
58482848|NCT00427765|DRUG|Melphalan|70 mg/m\^2 IV for 2 Days
58482849|NCT01198977|BEHAVIORAL|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
58482850|NCT01198977|OTHER|Education counseling|Mailed informational video of exercise programs
58482851|NCT00897299|GENETIC|microarray analysis|
58482852|NCT00897299|GENETIC|protein expression analysis|
58482853|NCT00897299|OTHER|immunohistochemistry staining method|
58482854|NCT00897299|OTHER|laboratory biomarker analysis|
58482855|NCT01716234|DRUG|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
58482856|NCT01716234|DRUG|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
58482857|NCT01716234|DRUG|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
58482858|NCT01716234|DRUG|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
58482859|NCT00193661|DRUG|Testosterone Gel (1%)|
58482860|NCT02387502|DEVICE|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
58482861|NCT02387502|DEVICE|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
58482862|NCT02387502|DEVICE|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
58482863|NCT04002102|OTHER|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
58136954|NCT00050778|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
58136955|NCT02293083|DRUG|trigger point injection|
58482864|NCT04002102|OTHER|Usual care|Remain in standard care after randomization and educational materials.
58482865|NCT04002102|OTHER|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
58482866|NCT04205877|DEVICE|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
58482867|NCT06589089|DRUG|autologous hematopoietic stem cell|Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
58482868|NCT04248634|PROCEDURE|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
58482869|NCT00892476|DIETARY_SUPPLEMENT|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
58482870|NCT00892476|OTHER|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
58482871|NCT04601961|DRUG|Propofol|"Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1."
58482872|NCT04601961|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
57780762|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
58482873|NCT06473636|BEHAVIORAL|Mindfulness training|The mindfulness training program consisted of four 45-minute lessons, conducted once a week. After each lesson, participants were required to complete daily homework, which included the mindfulness exercises learned during that week for at least 30 minutes. The mindfulness training program was based on Kabat-Zinn's Mindfulness-Based Stress Reduction and Williams' Mindfulness-Based Cognitive Therapy. Additionally, specific contents of cancer-related mindfulness training were incorporated into this program, such as Anti-cancer Self-healing Power: 8 Lessons in Mindfulness-based Stress Reduction.
58482874|NCT02773810|OTHER|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
58482875|NCT06244160|OTHER|High flow oxygen therapy|High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
58482876|NCT00925457|OTHER|No Intervention|Neither current domperidone nor current PPI
58482877|NCT00925457|DRUG|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
58482878|NCT00925457|DRUG|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
58482879|NCT05077748|OTHER||
58482880|NCT05623917|BEHAVIORAL|Tele-supervised diaphragmatic respiratory exercise|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
58482881|NCT04686669|DRUG|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
58482882|NCT04686669|DRUG|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
58482883|NCT03308929|DEVICE|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
58482884|NCT00003278|DRUG|dexamethasone|
58482885|NCT00003278|RADIATION|radiation therapy|
58482886|NCT00044616|DRUG|Fluoxetine|
58482887|NCT00044616|DRUG|Lithium|
58482888|NCT00041561|DRUG|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
58482889|NCT00041561|DRUG|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
58482890|NCT02446574|DRUG|Paclitaxel|starting dose 20mg/m2 qw
58482891|NCT02446574|DRUG|Cisplatin|dose 25mg/m2 qw
58482892|NCT02446574|RADIATION|Radiation|60Gy/2Gy/30f
58482893|NCT00721383|BEHAVIORAL|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
58482894|NCT00721383|BEHAVIORAL|CSBI|Caregiver skill-building
58482895|NCT05336591|OTHER|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
58482896|NCT01052337|DRUG|anaesthetics: sevofluorane|0.5%of sevofluorane with air
58482897|NCT02775500|DRUG|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
58482898|NCT02740101|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
58482899|NCT02740101|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
58482900|NCT03008369|OTHER|Laboratory Biomarker Analysis|Correlative studies
58482901|NCT03008369|DRUG|Lenvatinib|Given PO
58482902|NCT03008369|OTHER|Quality-of-Life Assessment|Ancillary studies
58482903|NCT00045760|DRUG|Drotrecogin alfa (activated)|
58482904|NCT00675272|DRUG|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
58482905|NCT00675272|DRUG|sodium chloride|sodium chloride every 6 hours iv
58482906|NCT00636493|DEVICE|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
58482907|NCT04968275|BEHAVIORAL|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
58482908|NCT03584477|DEVICE|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
58482909|NCT03584477|OTHER|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
58482910|NCT00606606|OTHER|Clinical Decision Support|
58482911|NCT02196844|BEHAVIORAL|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
58482912|NCT02196844|BEHAVIORAL|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
58482913|NCT02196844|OTHER|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
58482914|NCT06655428|DEVICE|Endobronchial Therman Liquid Ablation (ETLA)|The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.
58482915|NCT03863769|OTHER|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
58482916|NCT00704236|DRUG|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
58482917|NCT00704236|DRUG|Placebo|
58482918|NCT02376153|DEVICE|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
58482919|NCT02376153|DEVICE|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
58482920|NCT01441076|DRUG|Anakinra|Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
58482921|NCT05995106|OTHER|Heart4U|Mobile app.
58482922|NCT03399552|DRUG|Avelumab|10mg/kg delivered by IV infusion
58482923|NCT03399552|RADIATION|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
58482924|NCT04349397|BEHAVIORAL|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
58482925|NCT06218966|DEVICE|intracochlear catheter|intracochlear administration of steroids through the intracochlear catheter INCAT
58482926|NCT06516978|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
58482927|NCT06516978|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
58482928|NCT06516978|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
58482929|NCT06516978|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
58482930|NCT06516978|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
58482931|NCT06516978|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
58482932|NCT06516978|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
58482933|NCT06516978|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
58482934|NCT06516978|DRUG|Chidamide|Chidamide PO will be administered as per the schedule specified in the respective arm.
58482935|NCT06516978|DRUG|Penpulimab|Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
58482936|NCT06516978|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
58482937|NCT02869464|OTHER|Imaging-Ultrasound|Abdominal Ultrasound
58482938|NCT02869464|OTHER|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
58482939|NCT02869464|GENETIC|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
58482940|NCT02734459|DRUG|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
58482941|NCT02797613|BEHAVIORAL|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
58482942|NCT05427188|BEHAVIORAL|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
58482943|NCT05427188|BEHAVIORAL|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
58482944|NCT04667221|DEVICE|Active transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.
58482945|NCT04667221|DEVICE|Sham transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
58482946|NCT06248996|RADIATION|Hyperfractionated radiotherpy|83.0 Gy in 68 fractions, 1.22 Gy per fraction, two daily fractions, five days per week to the primary tumour volume (GTVT_83.0). To the primary tumour with an added margin (PTVT_74.8) and to neck node metastases (PTVN_74.8) the prescribed dose will be 74.8 Gy in 68 fractions, 1.10 Gy per fraction twice daily. To elective neck nodes (PTV 54.4) the prescribed dose will be 54.4 Gy in 68 fractions, 0.80 Gy per fraction twice daily.
58482947|NCT06248996|RADIATION|Control group|68.0 Gy in 34 fractions, 2.00 Gy per fraction per day, five or six days per week to tumour volumes and 54.4 Gy in 34 fractions, 1.60 Gy per fraction to elective neck nodes.
58482948|NCT04452084|RADIATION|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
58482949|NCT04452084|RADIATION|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
58482950|NCT03237455|DIAGNOSTIC_TEST|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
58482951|NCT03237455|DIAGNOSTIC_TEST|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
58482952|NCT03237455|OTHER|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
58482953|NCT02546271|BEHAVIORAL|GPS|
58482954|NCT01526577|DRUG|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
58482955|NCT01526577|DRUG|placebo|LC23-1306 placebo
58482956|NCT01526577|DRUG|Ticagrelor|Ticagrelor 90mg
58482957|NCT06275516|DEVICE|multi-sensory stimulation immersive VR+ treadmill training|Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group
58482958|NCT06275516|DEVICE|treadmill training|Only treadmill training in treadmill training group
58482959|NCT00404612|DRUG|Placebo|PO BID
58482960|NCT00404612|DRUG|LX211|0.2 mg/kg, twice a day (BID)
58482961|NCT00404612|DRUG|LX211|0.4 mg/kg, twice a day (BID)
58482962|NCT00404612|DRUG|LX211|0.6 mg/kg, twice a day (BID)
58482963|NCT01070017|OTHER|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
58482964|NCT02853058|RADIATION|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
58482965|NCT02853058|RADIATION|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
58482966|NCT05486377|DRUG|Remimazolam besylate|Remimazolam besylate TIVA
58482967|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).
58482968|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
58482969|NCT00973804|DRUG|EPOCH-F/R|
58482970|NCT00973804|DRUG|FLAG|
58482971|NCT00973804|DRUG|Transplant Preparative Regimen (Flu/Cy/Mes)|
58482972|NCT00973804|DRUG|GVHD Prophylaxis (tacrolimus and sirolimus)|
58482973|NCT00973804|PROCEDURE|Double Cord Blood Transplantation|
58482974|NCT04045028|DRUG|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
58482975|NCT04045028|DRUG|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
58482976|NCT04045028|DRUG|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
58482977|NCT04045028|DRUG|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
58482978|NCT00194428|BEHAVIORAL|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
58482979|NCT00194428|BEHAVIORAL|Low fat caloric diet|Low fat caloric diet
58482980|NCT06188767|DRUG|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
58482981|NCT03266510|OTHER|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
58482982|NCT03266510|OTHER|Sham training|Subjects will perform sham training for 6 weeks.
58482983|NCT05681767|BEHAVIORAL|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
58482984|NCT05681767|OTHER|Treatment as usual|Treatment as usual
58482985|NCT05950074|BEHAVIORAL|"It´s Up To You program"|The main goal of this program is to prevent substance use and engagement in addictive behaviors through enabling teenagers to make informed and responsible decisions. It seeks to support students in the anticipation of realistic choice situations and problems typically affecting this age group. It is based on social influences, considering the peer group influences (peer pressure) and the affective and cognitive factors that intervene at the time of decision-making and problem-resolution. This program is intended to be delivered by trained teachers in six sessions through six different modules.
58482986|NCT01982097|DRUG|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
58482987|NCT02229669|PROCEDURE|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
58482988|NCT02229669|PROCEDURE|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
58482989|NCT02581410|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
58482990|NCT05677568|DEVICE|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
58482991|NCT04035460|DEVICE|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
58482992|NCT04035460|DEVICE|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
58482993|NCT02979496|DIETARY_SUPPLEMENT|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
58482994|NCT02979496|DIETARY_SUPPLEMENT|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
58482995|NCT02979496|DIETARY_SUPPLEMENT|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
58482996|NCT02979496|DIETARY_SUPPLEMENT|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
58482997|NCT00891904|BIOLOGICAL|cetuximab|Given IV
58482998|NCT00891904|RADIATION|stereotactic body radiation therapy|Undergoing Radiotherapy
58482999|NCT01931566|DRUG|Pioglitazone|Pioglitazone SR tablets
58483000|NCT01931566|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets
58483001|NCT00082225|BIOLOGICAL|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
58483002|NCT00082225|BIOLOGICAL|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
58483003|NCT02268175|DRUG|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
58483004|NCT02268175|DRUG|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
58483005|NCT02268175|DRUG|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
58483006|NCT02268175|DRUG|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
58483007|NCT02556840|OTHER|insulin therapy|
58483008|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
58483009|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
58483010|NCT03460249|OTHER|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
58483011|NCT00973635|OTHER|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
58483012|NCT05028543|PROCEDURE|Conventional TLH|"Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached."
58483013|NCT05028543|PROCEDURE|Clipping of utrine artery at its origin before bginning of TLH|"the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method."
58483014|NCT02395081|DIETARY_SUPPLEMENT|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
58483015|NCT02395081|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
58483016|NCT02395081|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
58483017|NCT00493129|DRUG|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
58483018|NCT06411080|DIAGNOSTIC_TEST|Ultrasound evaluation of fluid tolerance|Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.
58483019|NCT03388164|DRUG|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
58483020|NCT03388164|DRUG|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
58483021|NCT04198714|PROCEDURE|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
58483022|NCT03906448|COMBINATION_PRODUCT|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
58483023|NCT03881852|DRUG|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
58483024|NCT03881852|DRUG|Placebo|Dosed orally, twice daily for up to 3 weeks
58483025|NCT04292899|DRUG|Remdesivir|Administered as an intravenous infusion
58483026|NCT04292899|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
58483027|NCT05982418|DEVICE|3D Printed Models (3D printing facilities at GSTT)|3D patient-specific printed models are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D printing.
58483028|NCT05982418|DEVICE|3D Virtual Models (Innersight Labs)|3D patient-specific virtual models loaded into Innersight Labs platform are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D visualisation.
58483029|NCT00844961|BEHAVIORAL|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
58483030|NCT05119881|BEHAVIORAL|mirror therapy|a mirror box will be placed in front of the participants with the mirror reflection side toward the non-paretic limb. The paretic arm will be placed behind the mirror, and the mirror box will block the vision of the paretic limb. Through this method, the patients can only view the movement of the non-paretic limb and its mirror reflection from the mirror. The participants will be instructed to move or perform functional tasks with their non-paretic limb and look at the mirror reflection of the non-paretic limb and mentally imagine that it is the paretic arm moving. At the same time, the participants will be encouraged to move the paretic arm along with the mirror reflection of the non-paretic arm. Activities practice during MT will include gross motor movements, fine motor movements, and functional tasks.
57780763|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
57780764|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
57780765|NCT00865644|DRUG|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
57780766|NCT06649201|OTHER|Vulvovaginal Symptom Questionnaire|Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.
57780767|NCT06649201|DIAGNOSTIC_TEST|Vaginal Microbiome Evaluation|A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant.
57780768|NCT00210665|DRUG|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
57780769|NCT03496415|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
57780770|NCT03496415|DEVICE|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
57780771|NCT06728241|BEHAVIORAL|RecoVRy|A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
57780772|NCT06728241|BEHAVIORAL|VR Games|Patients randomized to this condition will receive a total of ten sessions of VR games.
57780773|NCT04983979|DRUG|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
57780774|NCT04983979|DRUG|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
57780775|NCT03847779|OTHER|"Rest"|Cutaneous perfusion and vasomotion assessment at rest in supoine position
57780776|NCT03847779|OTHER|"Exercise"|Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
57780777|NCT03847779|OTHER|"Foot lowering"|Cutaneous perfusion and vasomotion assessment after foot lowering
57780778|NCT03847779|OTHER|"Hyperthermia"|Cutaneous perfusion and vasomotion assessment during hyperthermia
57780779|NCT01132196|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
57780780|NCT06739031|DEVICE|PEF Treatment|PEF Energy ablation of lung tumors
57780781|NCT04165161|DIAGNOSTIC_TEST|search for a patent foramen ovale|Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
57780782|NCT03923296|DEVICE|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
57780783|NCT03923296|BEHAVIORAL|Interviews|Focus group interviews
57780784|NCT06728982|DRUG|Metformin|1000mg of metformin twice daily by mouth
57780785|NCT04065282|DRUG|Sintilimab|3 cycles before radical surgery
57780786|NCT04065282|DRUG|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
57780787|NCT04065282|DRUG|Capecitabine|1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
57780788|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
57780789|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
57780790|NCT04665297|BEHAVIORAL|International Guide for Monitoring Child Development|Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
57780791|NCT00709592|BIOLOGICAL|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
57780792|NCT00709592|RADIATION|Total-Body Irradiation|Undergo TBI
57780793|NCT00709592|PROCEDURE|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
57780794|NCT00709592|DRUG|Tacrolimus|Given PO
57780795|NCT00709592|DRUG|Mycophenolate Mofetil|Given PO
57780796|NCT06673095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57780797|NCT06673095|PROCEDURE|Excision|Undergo narrow margin excision
57780798|NCT06673095|PROCEDURE|Excision|Undergo wide margin excision
57780799|NCT06673095|OTHER|Survey Administration|Ancillary studies
57780800|NCT05656443|DRUG|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
57780801|NCT05656443|DRUG|Placebo|Placebo
57780802|NCT06435949|DRUG|Fentanyl (as Citrate)|intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
57780803|NCT06219343|DEVICE|Non-invasive vagus nerve stimulation|Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
57780804|NCT06527040|OTHER|Opioid Transitions Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
57780805|NCT06736678|DIETARY_SUPPLEMENT|Oral Immunonutrition|Patients receive enteral immunonutrition, Oral Impact® Nestle for 6 weeks from one week before radiotherapy;
57780806|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
58136956|NCT03117257|DRUG|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
57780807|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
58136957|NCT03117257|DRUG|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
57780808|NCT06008808|DRUG|Ruxolitinib|Ruxolitinib is provided by Incyte Corporation.
57780809|NCT05672082|DRUG|[18F]DPA-714|Participant received one injection of 200 MBq of \[18F\]DPA-714
57780810|NCT02874066|DRUG|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
57780811|NCT02475213|BIOLOGICAL|Enoblituzumab|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
57780812|NCT02475213|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
57780813|NCT02475213|BIOLOGICAL|MGA012|anti-PD-1 monoclonal antibody
57780814|NCT06541704|DRUG|Pozelimab|Subcutaneous (SC) injection
57780815|NCT06541704|DRUG|Cemdisiran|SC injection
57780816|NCT06541704|DRUG|Placebo|SC injection
57780817|NCT03557489|DEVICE|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
57780818|NCT06738212|OTHER|Group A aerobic exercises|"Group A will perform the aerobic exercises (such as bicycling, treadmill and running) Aerobic exercises 15min/session for each exercise, 2 times/week. Frequency: 2 times /week Intensity: Easy to moderate about 60 to 75% of maximum heart rate Type: treadmill, bicycling, running Time: 45min/session~Bicycling:~15~- Start with gentle, low-intensity cycling and gradually increase as comfort allows - Aim for regular, consistent cycling sessions (e.g., 2-3 times a week,15min/session) - Consider incorporating other exercises, like stretching or yoga, to complement cycling.~Running~To get started with running for dysmenorrhea:~1. Start with short distances and gradually increase as comfort allows~2. Aim for regular, consistent running sessions (e.g., 2-3 times a week,15 minute/session)~3. Consider incorporating other exercises, like stretching or yoga, to complement running."
57780819|NCT06738212|OTHER|Group B Aviva exercises|"Group B will perform the Aviva exercises in 18 different movements. Aviva exercise intervention method is based on a carefully structured, mild-to-moderate intensity series of 18 movement sequences and aerobic exercises 30min/session, 2 times/week (20)~Aviva Methods of exercises:~These exercises are a carefully structured, intense, and methodical series of movement sequences, including a 5 min warm-up exercise at the beginning and 5 min cooling-down exercises at the end of the session. These exercises are performed in Standing, Sitting, Supine lying, prone lying"
57780820|NCT05444673|DRUG|Paprizumab combined with cisplatin and 5-FU|Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
57780821|NCT03942874|BEHAVIORAL|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
57780822|NCT05585307|DRUG|bavtavirine|Administered orally
57780823|NCT05585307|DRUG|B/F/TAF|Administered orally
57780824|NCT05585307|DRUG|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
57780825|NCT05585307|DRUG|GS-1720|Administered orally
57780826|NCT05585307|DRUG|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
57780827|NCT05585307|DRUG|GS-6212|Administered orally
57780828|NCT05585307|DRUG|Standard of Care (Substudy 03)|Antiretroviral therapy, administered orally
57780829|NCT06739512|PROCEDURE|Extensive Electro-Anatomical Guided Ablation|Ablation using PFA. Combination of anatomical and electrogram-guided ablation techniques.
57780830|NCT06739512|PROCEDURE|Anatomical Guided Ablation|Ablation using PFA. Guided by anatomical landmarks without potential mapping
57780831|NCT06739512|PROCEDURE|Electrogram Guided Ablation|Ablation using PFA. Guided by real-time electrogram characteristics from a multi-electrode catheter.
57780832|NCT05437276|DEVICE|PoNS®|The PoNS device used in conjunction with rehabilitative physical therapy
57780833|NCT05521048|DRUG|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
57780834|NCT04019119|BEHAVIORAL|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
57780835|NCT02813460|DRUG|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
57780836|NCT02813460|DRUG|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
57780837|NCT02813460|DRUG|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
57780838|NCT02813460|DRUG|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
57780839|NCT02813460|DRUG|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
57780840|NCT02813460|DRUG|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
57780841|NCT02813460|DRUG|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
57780842|NCT02813460|DRUG|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
57780843|NCT02813460|DRUG|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
57780844|NCT02813460|DRUG|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
57780845|NCT02813460|DRUG|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
57780846|NCT02813460|DRUG|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
57780847|NCT06305962|DRUG|177Lu-RAD204|177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
57780848|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
57780849|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
57780850|NCT06738836|DRUG|[14C]-EDG-7500|Oral liquid suspension
57780851|NCT06738251|DRUG|SHR-A2102 for Injection|SHR-A2102 for Injection.
57780852|NCT06738251|DRUG|Docetaxel Injection|Docetaxel Injection.
57780853|NCT06738251|DRUG|Paclitaxel Injection|Paclitaxel Injection.
57780854|NCT06738251|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
57780855|NCT06738251|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection.
57780856|NCT04266171|BEHAVIORAL|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
57780857|NCT04266171|BEHAVIORAL|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
57780858|NCT06740318|OTHER|Motivational enhancement therapy|The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
57780859|NCT03377673|DIAGNOSTIC_TEST|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
57780860|NCT01681368|DRUG|Birinapant (TL32711)|47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
57780861|NCT05468125|PROCEDURE|guidance|either follow the care bundle or the best evidence practice
57780862|NCT06161753|BEHAVIORAL|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
57780863|NCT03763188|OTHER|Use of daily urinary urea excretion|Weaning dialysis catheter
57780864|NCT04773249|DEVICE|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
57780865|NCT04773249|DEVICE|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
57780866|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
57780867|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
57780868|NCT01186328|DRUG|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
57780869|NCT01186328|DRUG|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~1. - 1.99 years: 16 mg~2. - 2.99 years: 20 mg~3. - 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
57780870|NCT01186328|DRUG|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
57780871|NCT01186328|DRUG|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
57780872|NCT01186328|DRUG|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
57780873|NCT01186328|DRUG|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
58483031|NCT05119881|DEVICE|tDCS|The tDCS will be delivered by a DC-stimulator (Soterix Medical Inc, New York, USA) through 2 saline-soaked surface sponge electrodes (anodal electrode size: 25 cm2; cathode electrode size: 25 cm2). The anodal electrode will be placed over the ipsilesional M1 while the cathodal electrode will be placed over the contralesional M1. The stimulation intensity will be ramped up to 2mA in 15 seconds, and maintained at 2mA throughout the 20-minute stimulation for the MT+tDCS group.
58136958|NCT02346097|DEVICE|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
58136959|NCT00012948|PROCEDURE|Telephone Care|
58136960|NCT02064088|DRUG|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
57780874|NCT01186328|DRUG|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
57780875|NCT01186328|DRUG|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
57780876|NCT05482516|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
57780877|NCT05482516|DRUG|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
57780878|NCT06605599|DRUG|ABBV-932|Oral Capsule
57780879|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
57780880|NCT00564590|DRUG|Melatonin|4 mg of Melatonin once a day for 3 months
57780881|NCT00564590|OTHER|omeprazole|omeprazole 20 mg once a day
57780882|NCT00564590|DRUG|Placebo|Placebo once a day
57780883|NCT04232748|DRUG|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
57780884|NCT06736665|DEVICE|Orbital atherectomy|The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
57780885|NCT06736665|DEVICE|Intravascular lithotripsy|The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
57780886|NCT06736665|DEVICE|Optical Coherence Tomography (OCT)|"Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure.~These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment."
57780887|NCT06736665|DEVICE|Percutaneous coronary intervention with stent implantation|All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.
57780888|NCT06738511|DIAGNOSTIC_TEST|blood sampling|Molecular signature using plasma sample
57780889|NCT06738511|OTHER|stool sampling|Stool sampling (by the participant)
57780890|NCT06738511|OTHER|colonoscopy|Colonoscopy will be performed in the course of a screening programme
57780891|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
57780892|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
57780893|NCT06739759|DRUG|Antagonist protocol for IVF|antagonist protocol with triggering by Decapeptyl
57780894|NCT06739759|DRUG|Modified Agonist protocol for IVF with additive treatments as HCQ|giving additive drugs to agonist protocolas HCQ
57780895|NCT05730218|DRUG|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
57780896|NCT05730218|DRUG|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
57780897|NCT06738849|DEVICE|EkiYou V2|"Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment."
57780898|NCT05348889|DRUG|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
57780899|NCT06735040|OTHER|Photobiomodulation Therapy|Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
57780900|NCT06735040|OTHER|Sham|In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
57780901|NCT00003944|BIOLOGICAL|filgrastim|
57780902|NCT00003944|DRUG|carboplatin|
57780903|NCT00003944|DRUG|cyclophosphamide|
57780904|NCT00003944|DRUG|paclitaxel|
57780905|NCT00003944|DRUG|topotecan hydrochloride|
57780906|NCT00003944|PROCEDURE|peripheral blood stem cell transplantation|
57780907|NCT04037384|BEHAVIORAL|Eye yoga|Eye yoga exercises at home given by a trained instructor
57780908|NCT04037384|BEHAVIORAL|Passive Reading|Passive reading at home
57780909|NCT03084419|DRUG|Abatacept|"The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg \>100kg=1g~This equates to approximately 10mg/kg."
57780910|NCT03626974|BIOLOGICAL|Venipuncture|Venipuncture for blood collection
57780911|NCT03626974|DEVICE|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
57780912|NCT06685146|OTHER|Glucagon Infusion|A 240 minutes infusion of glucagon (10 ng/kg/min)
57780913|NCT06685146|OTHER|Glucose clamp|A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
58483032|NCT05119881|BEHAVIORAL|sham mirror therapy|For the sham MT (s-MT) condition, the same mirror box will be used except that the mirror side will be made blurred to view; thus, the participants will not be able to view the mirror reflection of the paretic limb. The participants will perform the same activities as the real MT condition.
58483033|NCT05119881|DEVICE|sham tDCS|For the sham tDCS group, the electrodes will be placed on the brain regions as the real tDCS group. The intensity will first be ramped up to 2mA within 15 seconds and then the stimulator will be turned off gradually within the next 30 seconds.
58483034|NCT00965172|OTHER|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
58483035|NCT00965172|OTHER|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
58483036|NCT02578706|DRUG|Clopidogrel|Clopidogrel 75mg
58483037|NCT02578706|DRUG|Aspirin|81 mg
58483038|NCT02578706|DRUG|Placebo|
58483039|NCT04264936|DRUG|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
58483040|NCT02410226|PROCEDURE|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
58483041|NCT02410226|RADIATION|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
58483042|NCT02410226|RADIATION|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
58483043|NCT06051149|PROCEDURE|caudal adhesolysis using RACZ Catheter|caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy
58483044|NCT06051149|PROCEDURE|caudal adhesiolysis using NAVI Catheter|caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
58483045|NCT06272396|DEVICE|Smart watch|ECG 1D/6D
58483046|NCT04057950|OTHER|cosmetic product|Disulfure de sélénium versus placebo formula
58483047|NCT03370978|BEHAVIORAL|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
58483048|NCT04765891|OTHER|Positional release therapy|Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
58483049|NCT04765891|OTHER|Therapeutic Massage|Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
57780914|NCT06737783|OTHER|Thoracic mobility exercises + Conventional therapy|mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) , Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.
58483050|NCT05950711|OTHER|Combination use of MBCT and IV Ketamine|Group with Major Depression who will receive a single dose of IV Ketamine embedded within a course of MBCT.
58483051|NCT02086253|DRUG|BQ-788 and/or BQ-123|
58483052|NCT04512157|BEHAVIORAL|Promoting Alternative Thinking Strategies (PATHS), Preschool Edition|PATHS® is a universal teacher implemented, and school-based intervention that aims to give preschool children a strategically timed boost in social emotional competence. Specifically, PATHS® encourages the use of interactive techniques to bolster children's ability to self-regulate, increase their adeptness at social cognitive problem solving, as well as to gain insight into their emotions and emotions of others.
58483053|NCT00811915|DRUG|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
58483054|NCT01418625|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
58483055|NCT04326803|BIOLOGICAL|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
58483056|NCT00694642|BIOLOGICAL|Selected CD 133+ cells|Endothelial progenitor cell CD 133
58483057|NCT04999540|DRUG|Tucidinostat|30 mg, administered orally twice per week (BIW)
58483058|NCT04999540|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
58483059|NCT03950297|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
58483060|NCT01042106|DRUG|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
58483061|NCT01042106|DRUG|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
58483062|NCT04803552|DEVICE|Overnight sleep study with Sleepiz One and a respiratory polygraphy|"Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~* Thoracic respiratory effort: respiration frequency (BR), respiration curve~* Airflow: respiration frequency (BR), respiration curve~* Body movement: body position~* Blood oxygen saturation (SpO2)~* Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions"
58483063|NCT00588016|DRUG|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
58483064|NCT01600716|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
58483065|NCT01600716|DRUG|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
58483066|NCT05400278|OTHER|No intervention|No intervention
58483067|NCT02321020|PROCEDURE|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
58483068|NCT02321020|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
58483069|NCT00279487|DRUG|Gabapentin|
58483070|NCT00279487|DRUG|Placebos|
58483071|NCT05971485|DRUG|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
58483072|NCT04856800|DIETARY_SUPPLEMENT|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
58483073|NCT04856800|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
58483074|NCT00831181|DRUG|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
58483075|NCT00831181|DRUG|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
58483076|NCT00831181|DRUG|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
58483077|NCT00831181|PROCEDURE|mesorectal excision|mesorectal excision
58483078|NCT05816447|BEHAVIORAL|interview|Interview patient's perception
58483079|NCT03570710|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
58483080|NCT03570710|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
58483081|NCT03570710|DRUG|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
58483082|NCT01875796|BEHAVIORAL|Cognitive-Behavioral Therapy|
58483083|NCT01875796|BEHAVIORAL|Motivation Enhancement Therapy|
58483084|NCT01875796|BEHAVIORAL|Integrated Cannabis and Anxiety Reduction Treatment|
58483085|NCT01875796|BEHAVIORAL|False Safety Behavior Elimination Therapy|
58483086|NCT03404700|BEHAVIORAL|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
58483087|NCT03404700|BEHAVIORAL|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
58483088|NCT03404700|BEHAVIORAL|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
58483089|NCT03404700|BEHAVIORAL|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
58483090|NCT02506244|DEVICE|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
58483091|NCT02506244|DEVICE|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
58483092|NCT02189317|DRUG|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
58483093|NCT03035357|DRUG|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
58483094|NCT00693771|DRUG|Insulin Glargine|Once daily and up-titrate accordingly
58483095|NCT04048356|DRUG|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
58483096|NCT00439517|DRUG|UFOX + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
58483097|NCT00439517|DRUG|FOLFOX4 + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16"
58483098|NCT05293223|BIOLOGICAL|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
58483099|NCT02419001|DRUG|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
58483100|NCT02419001|DRUG|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
58483101|NCT02419001|DRUG|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
58483102|NCT02419001|DRUG|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
58483103|NCT04444453|DEVICE|Wearable Pedometer|Pedometer worn on wrist
58483104|NCT04799912|PROCEDURE|Elective labor induction|Elective labor induction at 39 weeks of gestation
58483105|NCT06088784|DRUG|ATH-399A|Orally administered drug in capsule form.
58483106|NCT06088784|DRUG|Placebo|Orally administered drug in capsule form.
58483107|NCT03430102|DIAGNOSTIC_TEST|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
58483108|NCT02472470|DEVICE|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
58483109|NCT04012957|DRUG|Desidustat Oral Tablet|Desidustat tablet
58483110|NCT04012957|DRUG|Darbepoetin Alfa|Darbepoetin injection
58483111|NCT00874094|BIOLOGICAL|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
58483112|NCT00885170|DRUG|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
58483113|NCT00885170|DRUG|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
58483114|NCT00885170|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
58483115|NCT00885170|DIETARY_SUPPLEMENT|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
58483116|NCT02290249|DEVICE|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
58483117|NCT02290249|DEVICE|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
58483118|NCT01112839|BEHAVIORAL|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
58483119|NCT01112839|BEHAVIORAL|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
58483120|NCT02763670|OTHER|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
58483121|NCT02763670|OTHER|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
58483122|NCT03752437|DIAGNOSTIC_TEST|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
58483123|NCT03752437|DRUG|Heparin|300 IU of heparin
58483124|NCT04931706|OTHER|Magnetics Assisted by Singe port|Use of magnet for assistance through the surgery, and a novel approach as it is single port
58483125|NCT05067725|OTHER|CarePath|During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
58483126|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
58483127|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
58483128|NCT04168918|BEHAVIORAL|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
58483129|NCT00684918|DRUG|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
58483130|NCT02551887|BEHAVIORAL|Automated Reminder|Automated reminder shown to provider
58483131|NCT02551887|BEHAVIORAL|Automated Reminder Plus Script|Provider sees both reminder and script.
58483132|NCT00382759|PROCEDURE|stem cell transplant|
58483133|NCT02973750|PROCEDURE|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
58483134|NCT02973750|PROCEDURE|Tissue Collection|Tissue collection during debulking surgery.
58483135|NCT02973750|PROCEDURE|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
58483136|NCT00680108|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
58483137|NCT04459650|PROCEDURE|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
58483138|NCT01954446|DEVICE|3M|Conventional measuring of BP
58483139|NCT01954446|DEVICE|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
58483140|NCT01954446|DEVICE|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
58483141|NCT01206218|DRUG|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
58483142|NCT01206218|DRUG|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
58483143|NCT02643446|BIOLOGICAL|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
58483144|NCT02643446|BIOLOGICAL|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
58483145|NCT03812757|DIAGNOSTIC_TEST|Supraclavicular fossa US scanning|As previously stated.
58483146|NCT00445913|BIOLOGICAL|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
58483147|NCT00445913|BIOLOGICAL|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
58483148|NCT06390748|DRUG|esmolol|The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
58483149|NCT05106400|DRUG|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
58483150|NCT05106400|DRUG|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
58483151|NCT05106400|DRUG|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
58483152|NCT05106400|DRUG|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
58483153|NCT04612504|BIOLOGICAL|SynOV1.1|SynOV1.1 will be administered intratumorally.
58483154|NCT04671017|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
57780915|NCT06737783|OTHER|Self myofascial release with foam roller, T6- T7 Maitland mobilization + Conventional therapy|Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins. Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets).
57784361|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
57784362|NCT00039182|DRUG|erlotinib hydrochloride|Given orally
57784363|NCT00039182|OTHER|laboratory biomarker analysis|Correlative studies
57784364|NCT01236027|OTHER|no intervention|not applicable-no intervention
57784365|NCT03565770|OTHER|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
57784366|NCT03565770|OTHER|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
57784367|NCT02327910|OTHER|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
57784368|NCT02327910|OTHER|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
57784369|NCT00962663|DRUG|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
57784370|NCT00962663|DRUG|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
57784371|NCT00962663|DRUG|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
57784372|NCT01743274|PROCEDURE|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
57784373|NCT05604287|DRUG|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
57784374|NCT05604287|DRUG|Placebo|The participant will receive a oral dose of Placebo.
57784375|NCT00113698|DRUG|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
57784376|NCT00113698|OTHER|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
57784377|NCT04802642|OTHER|Survey|Survey
57784378|NCT02927821|BEHAVIORAL|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
57784379|NCT05978648|DRUG|Trilaciclib|240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
57784380|NCT05978648|DRUG|Epirubicin|90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
57784381|NCT05978648|DRUG|Cyclophosphamide|600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
57784382|NCT05978648|DRUG|Paclitaxel|80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.
57784383|NCT05978648|DRUG|Docetaxel|75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.
58483155|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
58483156|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
58136961|NCT02064088|DRUG|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
58483157|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
58483158|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
58483159|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
57784384|NCT05978648|DRUG|Carboplatin|area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.
57784385|NCT05978648|DRUG|Trastuzumab|8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
57780916|NCT06739317|RADIATION|Radiation|Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
57780917|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
57780918|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
57780919|NCT06739317|PROCEDURE|operation|If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
57780920|NCT02339649|PROCEDURE|Blood Sample|Blood Sample
57780921|NCT02339649|BEHAVIORAL|Neurocognitive Assessment|Neurocognitive Assessment
57780922|NCT02339649|OTHER|Resting State EEG|10-20 Minutes of Resting State EEG
57780923|NCT02339649|PROCEDURE|Lumbar Puncture|Lumbar Puncture
57780924|NCT02339649|OTHER|MRI|60 Minutes MRI
57780925|NCT03763162|DRUG|Bortezomib|Given SC
57780926|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
57780927|NCT03763162|DRUG|Dexamethasone|Given IV or PO
57780928|NCT03763162|DRUG|Ixazomib|Given PO
57780929|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
57780930|NCT06737835|DEVICE|18 FDG|18 flurodeoxy glucose PET/CT
57780931|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
57780932|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
57780933|NCT02981225|DIETARY_SUPPLEMENT|Phytostandard® Rhodiola-Saffron|
57780934|NCT06736925|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|DHA+EPA capsules contain purified deep-sea fish oil, made from 100% wild-caught sardines and anchovies with a 3-year shelf life. The capsule shell is made from bovine limed bone with a size of 20 oblongs. Each soft gel capsule contains 480 mg of DHA, 205 mg of EPA, 145 mg of other omega-3 FA, and 10 mg of vitamin E. Participants in the DHA+EPA group will ingest 5 capsules daily \[a total of 3.4 g/d: DHA (2.4 g), EPA (1.0 g)\].
57780935|NCT06736925|DIETARY_SUPPLEMENT|Organic soybean oil|We will use organic soybean oil pills ) as a placebo condition for the DHA+EPA group. One capsule contains 485 mg of organic soybean oil, including negligible amounts of DHA (1.1 mg), EPA (1.7 mg), and vitamin E (10 mg). Participants will ingest 5 capsules daily. Soybean oil is one of the most widely used vegetable oils in the world. Soybean oil contains polyunsaturated fats and 18-carbon omega-3 FA (total omega-3 FA of 73.9 mg per capsule), but very low levels of DHA and EPA, which makes it an excellent placebo counterpart when evaluating the effects of DHA/EPA. The placebo capsule's shelf life, composition, shape, size as the DHA+EPA active comparator.
57780936|NCT06736925|OTHER|Soccer Heading Model|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer (G-force tracker) embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 30 mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
57780937|NCT02215928|GENETIC|mutation analysis|Correlative studies
57780938|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
57780939|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
57780940|NCT03306407|OTHER|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
57780941|NCT06008756|DRUG|Enlicitide Decanoate|Enlicitide Decanoate 20 mg tablet taken by mouth.
57780942|NCT06008756|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth.
57780943|NCT04463784|DRUG|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
57780944|NCT04463784|DRUG|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
57780945|NCT04579120|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
57780946|NCT04579120|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
57780947|NCT06738641|BEHAVIORAL|Pro2col Health|The Pro2col Health application is a smartphone application that provides users with health behavior guidance, personalized feedback, and assessments designed to estimate their current healthspan and biological age.
57780948|NCT06738641|BEHAVIORAL|Control|The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
57780949|NCT02326844|DRUG|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
57780950|NCT02771210|BIOLOGICAL|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
57780951|NCT02771210|DRUG|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
57780952|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
57780953|NCT02749695|DRUG|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
57780954|NCT02749695|OTHER|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
57780955|NCT06475716|BEHAVIORAL|Internet-based guided programme Spring|Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
57780956|NCT01414530|DRUG|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
57780957|NCT01414530|DRUG|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
57780958|NCT00895973|OTHER|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
57780959|NCT03027713|PROCEDURE|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
57780960|NCT00324714|DRUG|risedronate sodium|
57780961|NCT00324714|OTHER|diagnostic laboratory biomarker analysis|
57780962|NCT06549595|DRUG|AZD0486|a fully human bispecific monoclonal IgG4 antibody
57780963|NCT06549595|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
57780964|NCT06549595|DRUG|R-CVP|Rituximab, Cyclophosphamide, Vincristine and Prednisone
57780965|NCT06549595|DRUG|BR|Bendamustine, Rituximab
57780966|NCT05111613|DEVICE|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
57780967|NCT05111613|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
57780968|NCT04814186|DRUG|Tafamidis|61 mg, once daily, oral administration, for 12 months.
57780969|NCT06615986|DIETARY_SUPPLEMENT|Cardiosyn|Two sachets by mouth daily. Each dose (sachet) is 8.1 grams. For 2 doses it will be 16.2 grams per person per day.
57780970|NCT00932490|BEHAVIORAL|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
57780971|NCT06738979|DRUG|TQF3510 (Semaglutide Injection)|Semaglutide injection is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist.
57780972|NCT06738979|DRUG|Wegovy®|Active Comparator
57780973|NCT06063746|DRUG|Vidutolimod|
57780974|NCT04676230|PROCEDURE|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
57780975|NCT04676230|PROCEDURE|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
57780976|NCT02690402|BEHAVIORAL|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
57780977|NCT04105920|DEVICE|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
57780978|NCT06739408|DIETARY_SUPPLEMENT|Lean red meat|30g of protein from lean beef.
57780979|NCT06739408|DIETARY_SUPPLEMENT|Whey protein|Whey protein to provide 30g protein
57780980|NCT06739408|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin, to provide 0g protein but matched isocalorically
57780981|NCT05423717|DRUG|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
57780982|NCT05423717|DRUG|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
57780983|NCT05423717|DRUG|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
57780984|NCT05423717|DRUG|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
57780985|NCT02506621|DEVICE|R test|
57780986|NCT02506621|DEVICE|Nuubo|
57780987|NCT02506621|DEVICE|TECHNOMED pocket ECG|
57780988|NCT02506621|DEVICE|ZIO xt patch|
57780989|NCT02506621|DEVICE|MoMe|
57780990|NCT06739577|DIAGNOSTIC_TEST|Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))|"To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task."
57780991|NCT06739577|DIAGNOSTIC_TEST|Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.|Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).
57780992|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
57780993|NCT06739174|DEVICE|Confidence Be 1-Piece Closed Bag|Active Chamber Filter - Circle Shape
57780994|NCT06739174|DEVICE|Confidence Natural 1-Piece Closed Bag|Protective Filter - Circle Shape
57780995|NCT06739174|DEVICE|Confidence Be go 1-Piece Closed Bag|Active Chamber Filter - Hexagon Shape
57780996|NCT05292391|BIOLOGICAL|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
57780997|NCT05292391|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
57780998|NCT01991444|OTHER|TAVI|no Intervention planned, Observation only
57780999|NCT01544491|DRUG|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
57781000|NCT01544491|DRUG|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
57781001|NCT06740604|DEVICE|BSD-10CH|The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
57781002|NCT06740604|DEVICE|Sham BSD-10CH|The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
57781003|NCT02522975|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
57781004|NCT02522975|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
57781005|NCT05586191|OTHER|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
57781006|NCT05586191|OTHER|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
57781007|NCT06739603|OTHER|pharmaceutical analysis|pharmaceutical analysis
57781008|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
58483160|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
58483161|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
57781009|NCT06736873|OTHER|Light intervention|Light intervention
57781010|NCT06736782|BEHAVIORAL|Self-Empowerment Care Intervention Group|"The intervention emphasizes four key principles: hydration, exercise, dietary support, and defecation care. Each component is designed to address fundamental needs and promote independence in activities of daily living (ADLs).~Individualized care plans will be developed in collaboration with healthcare professionals and caregivers to ensure alignment with participants' functional capabilities and personal goals."
57781011|NCT06736782|BEHAVIORAL|Control Group|"Standard caregiving practices without emphasis on structured hydration, exercise, or dietary programs.~General assistance with ADLs as per existing care routines in the respective facilities."
58483162|NCT00637455|DRUG|fexofenadine HCl|
58483163|NCT02874872|BEHAVIORAL|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
58483164|NCT06030024|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
58483165|NCT01501565|PROCEDURE|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
58483166|NCT03527459|BEHAVIORAL|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
58483167|NCT03527459|BEHAVIORAL|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
58483168|NCT02922647|DEVICE|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
58483169|NCT02922647|DEVICE|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
58483170|NCT05264922|DRUG|Tisseel Injectable Product|Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
58483171|NCT05264922|BIOLOGICAL|Stromal Vascular Fraction Cells|Stromal Vascular Fraction cells are autologously harvested, processed and reinjected into the affected shoulder.
58483172|NCT03146416|DRUG|Evinacumab|SC or IV administration of Evinacumab
58483173|NCT03146416|DRUG|Placebo|Matching placebo
58483174|NCT04204889|DRUG|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
58483175|NCT05945342|DRUG|Escitalopram|The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
58483176|NCT05945342|OTHER|Interpersonal Psychotherapy for Adolescent|Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
58483177|NCT05945342|OTHER|Escitalopram combined with psychotherapy|The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
58483178|NCT05945342|OTHER|Escitalopram combined with rTMS|The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
58483179|NCT05945342|DRUG|Escitalopram combined with sham rTMS|The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
58483180|NCT01291732|DRUG|Matching placebo|single dose of matching placebo
57781012|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
57781013|NCT06737328|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
57781014|NCT06720012|DEVICE|Patient specific instrumentation (PSI)|Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.
57781015|NCT06720012|DEVICE|Conventional instruments|Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.
57781016|NCT06720012|PROCEDURE|Cemented Total Knee Arthroplasty|A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
57781017|NCT03530046|COMBINATION_PRODUCT|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
57781018|NCT03530046|COMBINATION_PRODUCT|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
57781019|NCT03257592|DRUG|[11C]DPA-713|\[11C\]DPA-713 PET imaging
57781020|NCT00338767|BEHAVIORAL|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
57781021|NCT00338767|DRUG|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
57781022|NCT06734455|OTHER|Robot-Assisted Pyeloplasty|Pyeloplasty in Children using robotic surgery
57784386|NCT05978648|DRUG|Pertuzumab|840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
58483181|NCT01291732|DRUG|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
58483182|NCT04664699|DEVICE|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume"
58483183|NCT04664699|DEVICE|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
58483184|NCT03478709|OTHER|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
58483185|NCT03478709|OTHER|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
58483186|NCT03309735|DRUG|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
58136962|NCT04325100|BEHAVIORAL|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
58136963|NCT04325100|BEHAVIORAL|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
58136964|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
58136965|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
58136966|NCT00106548|DRUG|Placebo|iv / month
58136967|NCT00106548|DRUG|Methotrexate|10-25mg/week
58136968|NCT02401334|DEVICE|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
58136969|NCT00223197|DRUG|Pregnenolone|
58136970|NCT02146261|DRUG|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
58136971|NCT02146261|DRUG|Placebo|Subcutaneous administration of placebo
58136972|NCT01428830|PROCEDURE|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
58136973|NCT01428830|PROCEDURE|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
58136974|NCT00227136|DRUG|5-Hydroxy-Tryptamine|
58136975|NCT03415802|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
58136976|NCT04903600|DIETARY_SUPPLEMENT|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
58136977|NCT04903600|DIETARY_SUPPLEMENT|Placebo|Eat 16 g for once, and twice a day
58136978|NCT03955237|PROCEDURE|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
58136979|NCT03232372|DEVICE|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
58136980|NCT03232372|DEVICE|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
58136981|NCT03232372|DEVICE|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
58136982|NCT02865538|DRUG|BAY3427080|
58136983|NCT02865538|DRUG|Placebo (for BAY3427080)|
58136984|NCT06046846|DEVICE|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
58136985|NCT03875755|DIETARY_SUPPLEMENT|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
58136986|NCT03875755|OTHER|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
58136987|NCT01206153|DRUG|metformin|
58136988|NCT05737992|OTHER|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
58136989|NCT00041496|DRUG|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
58136990|NCT00041496|OTHER|Placebo|Placebo to match SB-207266
58136991|NCT03335761|DEVICE|InterStim Therapy|Device Programming
58483187|NCT03309735|DRUG|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
58483188|NCT03309735|DRUG|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
58136992|NCT05336708|OTHER|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
58136993|NCT05336708|OTHER|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
58136994|NCT03206619|OTHER|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
58136995|NCT03973983|PROCEDURE|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
58483189|NCT04672278|DIETARY_SUPPLEMENT|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
58483190|NCT00583076|DRUG|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
58136996|NCT03973983|PROCEDURE|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
58136997|NCT06062914|DRUG|oral nutritional supplements|Only ONS was used as enteral nutrition
58136998|NCT03426241|OTHER|no intervention|this is cross-sectional study
58136999|NCT03635125|DRUG|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
58137000|NCT03635125|DRUG|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
58137001|NCT03635125|OTHER|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
58483191|NCT05727124|DEVICE|Poul Gjessing|maxillary canine retraction
58483192|NCT05727124|DEVICE|T loops|T loops
58483193|NCT04000633|DRUG|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
58483194|NCT04000633|DRUG|Normal saline|Normal saline
58483195|NCT01725516|PROCEDURE|Myofascial release technique|
58483196|NCT00588107|OTHER|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
58137002|NCT03832257|OTHER|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
58137003|NCT03832257|OTHER|Matched Non-Participating Facilities|Matched Non-Participating Facilities
58483197|NCT00588107|BEHAVIORAL|print materials|tailored print materials designed to aid in smoking reduction and cessation
58483198|NCT04970225|OTHER|1 blood sample|4 tubes of 7 ml per sample (a single sample)
58483199|NCT04970225|OTHER|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
58483200|NCT00578149|DRUG|Bevacizumab|
58137004|NCT04121364|DEVICE|Tetranite|Dental Adhesive for increased implant stability
58483201|NCT00578149|DRUG|Carboplatin|
58483202|NCT00578149|DRUG|Paclitaxel|
58483203|NCT02407600|DRUG|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
58483204|NCT02407600|DRUG|Placebo|
58137005|NCT01683032|DRUG|MPH|a capsule containing 20 mg
58137006|NCT01500876|RADIATION|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
58137007|NCT05999669|OTHER|GLASS staging|use the Global Limb Anatomic Staging System (GLASS) to evaluate its correlation with clinical outcomes after revascularization
58483205|NCT03174730|BEHAVIORAL|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
58137008|NCT05454553|OTHER|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
58137009|NCT05086783|OTHER|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
58137010|NCT05086783|OTHER|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
58137011|NCT02109354|BIOLOGICAL|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
58137012|NCT02109354|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
58483206|NCT03174730|BEHAVIORAL|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
58483207|NCT02094157|DRUG|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
58483208|NCT02094157|DRUG|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
58483209|NCT06517420|OTHER|kefir consumption|Support and information was received from the Food Technology Department of a university's Experimental Medicine Application and Research Center. It was decided to choose the kefir to be used, which is produced from pasteurized cow's milk, lactase enzyme, probiotic culture (B. Lactis) and kefir culture, will meet the B12 need, contribute to increasing vitality and energy, and has the most suitable content in the market. Kefir, supplied by the researcher, was given to the patients at the end of each session in the amount that the patients should consume for a week, following the cold chain rule. While consuming kefir, it was recommended to gargle it in the mouth, hold it for a while, and then swallow. Patients were contacted for a week after the session to ensure that they applied kefir correctly.
58483210|NCT06589115|OTHER|Blood Flow Restriction Cuff|The standardized exercises will be performed while wearing a blood flow restriction cuff.
58483211|NCT06589115|OTHER|Physical Therapy|Standard physical therapy
58483212|NCT01807624|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
58483213|NCT03040336|BEHAVIORAL|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
58483214|NCT06188143|COMBINATION_PRODUCT|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
58483215|NCT03324087|DIAGNOSTIC_TEST|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
58483216|NCT05152394|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
58483217|NCT01935206|DRUG|Naloxone (2 mg/kg)|
58483218|NCT01935206|DRUG|Placebo|
58137013|NCT02109354|BIOLOGICAL|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
58137014|NCT02109354|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
58137015|NCT02109354|BIOLOGICAL|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
58137016|NCT02109354|BIOLOGICAL|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
58137017|NCT02109354|BIOLOGICAL|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
58137018|NCT02109354|BIOLOGICAL|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
58483219|NCT02894684|DRUG|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
58483220|NCT02894684|DRUG|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
58483221|NCT02863120|DRUG|liposomal bupivacaine|
58483222|NCT02863120|DRUG|bupivacaine HCl|
58483223|NCT02863120|DRUG|Ropivacaine|
58137019|NCT05110209|OTHER|Aflibercept|intravitreal injection
58137020|NCT05110209|OTHER|Ranibizumab|intravitreal injection
58137021|NCT05110209|OTHER|Bevacizumab|intravitreal injection
58137022|NCT00545545|BIOLOGICAL|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
58483224|NCT02863120|DRUG|Saline|
58483225|NCT01209416|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
58483226|NCT01209416|DRUG|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
58483227|NCT01209416|OTHER|Placebo|placebo tablets or saline infusion
58483228|NCT01249079|OTHER|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
58483229|NCT03847597|PROCEDURE|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
58137023|NCT00545545|BIOLOGICAL|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
58137024|NCT04487262|PROCEDURE|Cardiac surgery|Elective open heart surgery
58137025|NCT00881088|DRUG|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
58137026|NCT00881088|DRUG|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
58483230|NCT06204640|DRUG|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
58483231|NCT04926987|OTHER|brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders
58483232|NCT00088088|DRUG|Paclitaxel|
58137027|NCT03979703|OTHER|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
58137028|NCT06128811|DEVICE|Rubber Dam Isolation|Rubber dam isolation will be placed using a proper size dental clamp on the first permanent molar after topical anesthesia application.
58483233|NCT00088088|DRUG|Carboplatin|
58483234|NCT00088088|DRUG|STA 4783|
58137029|NCT06128811|DEVICE|DryShieled isolation|For the DryShieled isolation, a pedo-size mouthpiece will be utilized with all the participants.
58137030|NCT06128811|OTHER|fissure sealant|After proper isolation, fissure sealant (Conseal-F TM SDI) will be applied following the manufacturer's instructions, and the quality of the applied fissure sealant will be checked with an explorer. An additional layer will be applied if any deficiency is detected
58483235|NCT04883827|OTHER|Blood collection|20-40 mL of blood to extract cell free DNA
58483236|NCT04883827|OTHER|Urine collection|up to 15 mL of urine to extract cell free DNA
58483237|NCT06198582|OTHER|Virtual Reality Exercises|In addition to conventional treatment, patients in the study group underwent a virtual reality-based task-specific exercise program in a computer-based virtual reality station. Two different virtual reality games that fit the definition of task-specific exercise were selected for our study. In order for the patient to complete the task in the game, the patient was asked to extend the upper extremity and hand to touch the virtual object through the reflection on the screen and to first grasp the object in the virtual environment by making active flexion with all fingers and to move it from one place to another on a certain plane without disturbing the grasping posture of the hand. These virtual reality exercises selected in our study were practiced under the supervision of the researcher 3 days a week for 15 minutes each for a total of 4 weeks. These sessions consisted of three sets of 2.5 minutes each for each game, with 15-second breaks between sets.
58483238|NCT03387618|DIAGNOSTIC_TEST|Digital PET/CT imaging|Next generation PET/CT imaging
58483239|NCT05807620|OTHER|Gentle Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
58483240|NCT05807620|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen (morning and evening, 2x daily).
58483241|NCT05807620|OTHER|Sunscreen SPF 30|"Neutrogena Ultra Sheer Dry Touch SPF 30. Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an over the counter"
58137031|NCT02870920|DRUG|Tremelimumab|
58137032|NCT02870920|DRUG|Durvalumab|
58137033|NCT02870920|OTHER|Best Supportive Care|
58483242|NCT00045617|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
58483243|NCT00045617|BIOLOGICAL|monoclonal antibody GD2 anti-idiotype vaccine|
58483244|NCT00045617|DRUG|cisplatin|
58483245|NCT00045617|DRUG|etoposide|
58483246|NCT00045617|RADIATION|radiation therapy|
58483247|NCT03557034|DEVICE|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
58483248|NCT00628108|DRUG|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
58483249|NCT00628108|OTHER|Placebo|Placebo oral liquid once a day for two weeks
58483250|NCT03848832|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
58483251|NCT03848832|DRUG|Placebo|Matching placebo oral solution
58483252|NCT03333278|DRUG|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
58483253|NCT03333278|DRUG|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
58483254|NCT03333278|DRUG|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
58483255|NCT00783107|DRUG|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
58483256|NCT00783107|DRUG|Placebo|
58483257|NCT02779101|DRUG|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
58483258|NCT03495089|DIAGNOSTIC_TEST|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
58483259|NCT03495089|DIAGNOSTIC_TEST|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
58483260|NCT04906902|DRUG|Acalabrutinib|Tablet taken by mouth twice daily
58137034|NCT02987985|DRUG|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
58137035|NCT02987985|DRUG|Acetaminophen|acetaminophen 15 mg/kg
58137036|NCT02987985|DRUG|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
58137037|NCT02987985|DRUG|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
58483261|NCT02608684|DRUG|Pembrolizumab|Pembrolizumab IV solution
58483262|NCT02608684|DRUG|Gemcitabine|Gemcitabine IV solution
58137038|NCT02987985|DRUG|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
58483263|NCT02608684|DRUG|Cisplatin|Cisplatin IV solution
58483264|NCT02869568|OTHER|Data collection|
58483265|NCT03802292|BIOLOGICAL|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
58483266|NCT03802292|BIOLOGICAL|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
58483267|NCT05679869|OTHER|Masking Sound|Prerecorded environmental noise and masking sounds played from headphones
58483268|NCT05679869|OTHER|No masking sound|Prerecorded environmental noise but no masking sounds played from headphones
58483269|NCT02064777|DRUG|Tacrolimus|
58483270|NCT06151457|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
58483271|NCT06151457|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
58483272|NCT04783493|DEVICE|Non-invasive magnetic stimulation of the spinal cord|Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
58483273|NCT04783493|OTHER|Coil will not be connected to the stimulation device|coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
58483274|NCT02895893|BEHAVIORAL|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
58483275|NCT00406484|BEHAVIORAL|Standard drug counseling|Individual drug counseling
58483276|NCT00406484|BEHAVIORAL|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
58137039|NCT02987985|DRUG|Sevoflurane|Sevoflurane (dose titrated to effect)
58483277|NCT03854097|DEVICE|Active Intermittent Negative Pressure (INP)|Application of -40mmHg negative pressure on the lower limb
58483278|NCT03854097|DEVICE|Placebo Intermittent Negative Pressure (INP)|Application of -10mmHg negative pressure on the lower limb
58483279|NCT05301790|DEVICE|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
58483280|NCT04761328|BEHAVIORAL|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
58483281|NCT01707199|DRUG|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
58483282|NCT06472232|DRUG|Chloroprocaine|Selection of low concentration of chloroprocaine as local anesthetic for labor analgesia
58483283|NCT05324514|PROCEDURE|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
58483284|NCT05324514|DEVICE|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
58483285|NCT05324514|DEVICE|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
58483286|NCT04962308|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
58483287|NCT04962308|BIOLOGICAL|The SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
58137040|NCT02987985|DRUG|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
58137041|NCT02603224|DRUG|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
58137042|NCT02603224|DRUG|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
58483288|NCT03036202|DRUG|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
58483289|NCT02546206|DIETARY_SUPPLEMENT|Probiotic Yoghurt|Probiotic yoghurt consumption
58483290|NCT02546206|DIETARY_SUPPLEMENT|Natural Yoghurt|Natural yoghurt consumption
58483291|NCT02753504|DRUG|CKD-519|
58137043|NCT04517162|DRUG|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
58137044|NCT01469026|RADIATION|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
58483292|NCT02753504|DRUG|placebo|
58483293|NCT06442319|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction
58483294|NCT00369265|DRUG|Lansoprazole|Lansoprazole 30mg twice daily
58483295|NCT00369265|DIETARY_SUPPLEMENT|Sugar pill|placebo twice daily
58483296|NCT04442828|DIAGNOSTIC_TEST|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
58137045|NCT03866330|BIOLOGICAL|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
58137046|NCT00002166|DRUG|Nevirapine|
58137047|NCT04277026|BEHAVIORAL|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
58137048|NCT00171821|DRUG|Deferasirox|
58137049|NCT01908725|DRUG|Lamazym|ERT, i.v. infusions weekly
58137050|NCT06041061|BIOLOGICAL|Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
58137051|NCT06041061|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
58137052|NCT04000100|PROCEDURE|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
58137053|NCT05701215|DRUG|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
58137054|NCT04339894|OTHER|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
58137055|NCT00881556|DRUG|Palifermin|60 mcg/kg/day for 6 days
58137056|NCT00881556|DRUG|Fludarabine|30 mg/m2 IV x 1 for 6 days
58137057|NCT00881556|DRUG|Busulfan|4 mg/kg/day IV divided BID for 4 days
58137058|NCT00881556|DRUG|Lorazepam|0.02-0.05 mg/kg for 5 days
58137059|NCT00881556|DRUG|Alemtuzumab|20 mg/m2 IV for 5 days
58137060|NCT00881556|DRUG|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
58137061|NCT01184196|DRUG|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
58137062|NCT01184196|DRUG|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
58483297|NCT00078598|DRUG|Rituximab or Iodine I 131 Tositumomab Therapy|
58483298|NCT03075514|OTHER|MKD|Modified ketogenic diet
58483299|NCT03075514|OTHER|MCT|Medium chain triglyceride ketogenic diet
58483300|NCT05738642|DRUG|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
58483301|NCT03323424|RADIATION|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
58137063|NCT03432247|BEHAVIORAL|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
58137064|NCT03432247|BEHAVIORAL|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
58137065|NCT05326659|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
58137066|NCT05326659|DRUG|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
58137067|NCT02218905|BEHAVIORAL|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
58137068|NCT01064570|DRUG|all-trans retinoic acid (ATRA)|
58137069|NCT03004105|DRUG|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
58137070|NCT03004105|DRUG|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
58137071|NCT03004105|BEHAVIORAL|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
58137072|NCT04594278|BEHAVIORAL|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
58137073|NCT05037422|PROCEDURE|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
58137074|NCT03436225|DRUG|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
58137075|NCT03436225|DRUG|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
58137076|NCT03436225|DRUG|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
58137077|NCT03436225|DRUG|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
58137078|NCT03262688|DRUG|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
58137079|NCT03262688|DRUG|Bupivacaine HCl infiltration|Infiltration of the surgical site
58137080|NCT02243930|DEVICE|Disposable distal attachment|
58137081|NCT05031884|DEVICE|MGIR3-US|MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
58137082|NCT06351683|DRUG|MitoQ (mitoquinol mesylate)|MitoQ is an antioxidant molecule designed to target cell stress
58137083|NCT06351683|OTHER|Placebo|Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
58137084|NCT06185777|BEHAVIORAL|Exercise oncology counseling and referal|Identification \& brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
58137085|NCT02910037|DEVICE|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
58137086|NCT03962673|RADIATION|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
58137087|NCT05778448|DEVICE|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
58137088|NCT00430196|DRUG|BOTOX®|
58137089|NCT00430196|DRUG|Zanaflex®|
58137090|NCT00436553|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
58137091|NCT00436553|DRUG|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
58137092|NCT00436553|DRUG|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
58137093|NCT00436553|DRUG|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
58137094|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
58137095|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
58137096|NCT01318499|OTHER|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
58137097|NCT00731705|PROCEDURE|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
58137098|NCT01722474|DEVICE|ASI Device|
58137099|NCT04869787|DEVICE|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
58137100|NCT05594472|DRUG|Ozonated olive oil|Topical treatment will be applied for 5 consecutive days on the erosions.
58137101|NCT05594472|DRUG|Topical garamycin cream|Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
58137102|NCT06197529|OTHER|Homeostatic Plasticity|Anodal tDCS S1/M1
58137103|NCT06197529|DRUG|Topical alone (Capsaicin 8% Patch)|4x4 patch
58137104|NCT06197529|OTHER|Placebo Patch|4x4 patch
58137105|NCT06197529|OTHER|Homeostatic Plasticity (Sham)|sham Homeostatic Plasticity protocol over S1
58137106|NCT03248362|DEVICE|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
58137107|NCT03248362|DEVICE|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
58137108|NCT04336930|DIAGNOSTIC_TEST|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
58137109|NCT04499729|DEVICE|IntelliCare|IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
58137110|NCT04499729|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual in the Rush Collaborative Care service
58137111|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
58137112|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
58137113|NCT04470180|BEHAVIORAL|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
58137114|NCT04470180|BEHAVIORAL|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
58137115|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
58137116|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
58137117|NCT02549651|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
58137118|NCT02549651|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
58137119|NCT02549651|DRUG|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
58137120|NCT03236753|PROCEDURE|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
58137121|NCT03236753|PROCEDURE|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
58137122|NCT02726425|BEHAVIORAL|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
58137123|NCT06064136|PROCEDURE|Psoas tenotomy under ultrasound|Tenotomy of the ilio-psoas tendon under ultrasound is performed using an ultrasound machine, a 3 mm Acufex hook blade and a specific kit usually used for guided vertebroplasty and which allows the introduction of the Acufex hook blade atraumatically (foam end). The patient, under general anesthesia, is placed in supine position with the hip extending from 15 to 20°.
58137124|NCT05754632|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
58137125|NCT06048419|BEHAVIORAL|Home Program|Home program for 6 weeks (1 hr and 15 minutes per week)
58137126|NCT06091007|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
58137127|NCT03447717|DEVICE|ActiGait|implanted device for peroneal nerve stimulation
58137128|NCT01359566|DRUG|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
58137129|NCT01359566|DRUG|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
58137130|NCT01359566|DRUG|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
58137131|NCT01359566|DRUG|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
58137132|NCT01568476|PROCEDURE|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
58137133|NCT01568476|PROCEDURE|Interneural|Sciatic nerve blockade at the site of bifurcation
57781023|NCT06740968|DEVICE|transcranial alternating current stimulation (tACS)|During each of the 5 visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).
57781024|NCT04857372|DRUG|IAG933|Capsule
57781025|NCT06712719|OTHER|LP then HP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP"
57781026|NCT06712719|OTHER|HP then LP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP"
57781027|NCT00001416|DRUG|CEREDASE™|
57781028|NCT00239018|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
57781029|NCT06740695|BEHAVIORAL|Education group|"The training materials were prepared in line with the researchers and expert opinions were obtained. Trainings will be given for two weeks. After the trainings are completed, reminder information will be sent to the pregnant women via text messages every other day to inform them that the trainings are continuing. Reminder information prepared as text messages will be sent to the pregnant women's mobile phones. 4 weeks after the first training, the same training will be reminded again via WhatsApp as a summary training by emphasizing key points.~The trainings will be carried out by an expert researcher in the field. In the training content prepared in line with WhatsApp, the risks that may be seen during pregnancy and Gestational Diabetes Mellitus;~* Sensitivity perception and Seriousness perception, perceived risks that may be seen during pregnancy~* Health motivation perception, the pregnant woman's beliefs and practices regarding being healthy,~* Benefit perception, pregnancy follow"
57781030|NCT06525935|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
57781031|NCT06525935|DRUG|Placebo|Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
57781032|NCT05526235|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
57781033|NCT05526235|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
57781034|NCT05526235|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
57781035|NCT06739863|OTHER|healthcare waste management|"To evaluate and compare the healthcare waste management practices in primary and secondary hospital Mianwali.~Focuses on assessing the current methods of waste disposal, segregation, treatment, and overall management in healthcare settings at two different levels of care: primary and secondary hospitals."
57781036|NCT02885519|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
57784387|NCT01958177|BIOLOGICAL|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
57784388|NCT01757080|OTHER|Cardiorespiratory performance assessment with ergospirometry test|
57784389|NCT01757080|OTHER|Biochemical analysis|
57784390|NCT05456815|OTHER|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
58137134|NCT04000217|BEHAVIORAL|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
58137135|NCT04000217|BEHAVIORAL|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
58137136|NCT01077596|DRUG|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
58137137|NCT01077596|DRUG|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
58137138|NCT01077596|DRUG|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
58137139|NCT01077596|DRUG|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
58137140|NCT04459273|PROCEDURE|Computed Tomography|Undergo PET/CT
58137141|NCT04459273|DRUG|Gallium Ga 68 FAPi-46|Given IV
58137142|NCT04459273|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
58137143|NCT04459273|RADIATION|18F-FDG|Given IV
58137144|NCT04191993|DEVICE|Total hip arthroplasty|Surgical intervention designed to replace arthritic joint with artificial implant
58137145|NCT01536405|BIOLOGICAL|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
58137146|NCT01536405|BIOLOGICAL|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
58137147|NCT01958463|PROCEDURE|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
58137148|NCT02100228|DRUG|Apixaban|Oral, 2.5 or 5 mg BID
58137149|NCT02100228|DRUG|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
58137150|NCT03038048|PROCEDURE|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
58137151|NCT01866319|BIOLOGICAL|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
58137152|NCT01866319|BIOLOGICAL|Ipilimumab|3 mg/kg IV Q3W.
58137153|NCT04391062|DRUG|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
58137154|NCT04391062|DEVICE|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
58137155|NCT00148837|DRUG|Peg-interferon alpha 2b (drug)|
58137156|NCT00148837|DRUG|Ribavirin (drug)|
58137157|NCT00148837|DRUG|Prazosin (drug)|
58137158|NCT05188742|DRUG|mirabegron|mirabegron 50mg QD
58137159|NCT05188742|PROCEDURE|TTNS|transcutaneous tibial nerve stimulation
58137160|NCT00614952|DEVICE|PSG (polysomnography)|POLYSOMNOGRAPHY
58137161|NCT00614952|OTHER|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
58137162|NCT00533273|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
58137163|NCT06000709|DRUG|6% aqueous phenol|1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
58137164|NCT06000709|DRUG|MethylPREDNISolone 40 MG|40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance
57784391|NCT02767700|GENETIC|NGS|Next generation sequencing
58137165|NCT06000709|DRUG|Intraarticular Knee Placebo|Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
58137166|NCT06000709|DRUG|Genicular Nerve Placebo|1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
58137167|NCT02297932|BEHAVIORAL|Strength training|Participants will engage in a home-based strength training program.
58137168|NCT02297932|BEHAVIORAL|Stretching|Participants will engage in a home-based stretching training program
58137169|NCT00906165|DEVICE|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
58137170|NCT03621579|PROCEDURE|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
58137171|NCT03557762|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
58137172|NCT00167739|DRUG|Quinine plus sulfadoxine-pyrimethamine|
58137173|NCT03892694|DEVICE|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
58137174|NCT03892694|OTHER|Sham|Sham control procedure
58137175|NCT05851937|BEHAVIORAL|Written language intervention|Young adults with Intellectual and Developmental Disabilities (IDD) are taught reading comprehension strategies in three phases (before, during, after) using a graphic organizer as visual support. At the beginning of each phase, the interventionist: (a) defines the strategies, (b) describes and models how to use the strategies, and (c) answers questions about the strategies. Then the participant practices the strategies during 45-min sessions, two times per week, over 3 months. Each session follows the teach-model-coach-review format, the interventionist: (a) reviews the strategies (5 min), (b) models the strategies using a think-aloud (10 min), (c) prompts the participant to practice the strategies with support (15 min), (d) prompts the participant to use a think-aloud to practice the strategies independently using a functional literacy text (10 min), and (e) reviews and summarizes the session (review; 5 min).
58137176|NCT01245907|BEHAVIORAL|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
58483302|NCT03323424|OTHER|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
58483303|NCT04932486|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
58483304|NCT00506974|DRUG|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
58483305|NCT00210743|DRUG|epoetin alfa|
58483306|NCT03077841|OTHER|Laboratory Biomarker Analysis|Correlative studies
58483307|NCT03077841|RADIATION|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
58483308|NCT03077841|OTHER|Questionnaire Administration|Ancillary studies
58483309|NCT00002786|BIOLOGICAL|aldesleukin|
58483310|NCT00002786|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
58483311|NCT04467372|DIETARY_SUPPLEMENT|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
58483312|NCT04467372|DIETARY_SUPPLEMENT|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
58483313|NCT04467372|DIETARY_SUPPLEMENT|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
57781037|NCT02885519|BEHAVIORAL|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
57781038|NCT06475196|DRUG|Sintilimab (PD-1 inhibitor)|to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
57781039|NCT06739304|BEHAVIORAL|Mindfulness-based Relapse Prevention|250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists.
57781040|NCT06737185|OTHER|EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting|Comparison of FS4T and EAFS4T
57781041|NCT02942004|DRUG|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
57781042|NCT02942004|DRUG|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
57781043|NCT02942004|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
57781044|NCT01121640|PROCEDURE|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
57781045|NCT01121640|PROCEDURE|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
57781046|NCT01121640|PROCEDURE|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
57781047|NCT04708288|DEVICE|ARCHIMEDES Biodegradable Biliary and Pancreatic Stent|Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
57781048|NCT06739889|DIAGNOSTIC_TEST|Elongation longitudinaux articular vertebral and columnar decoaption osteo-articulaire also known as ELDOA|ELDOA targtes cervical and upper thoracic spine. ELDOA exercises involves spicific postural holds that improve forward neck posture.The goal of ELDOA is to help reduce stress and increase space in the vertebral joints so that muscles can move freely. The benefits of these stretches include joint mobility, increased fluid absorption in the discs of the spine, flexibility, improved muscle tone, postural alignment, body-mind connection, and coordination. The tension and release created by these stretches helps normalize the posture.
57781049|NCT06739889|DIAGNOSTIC_TEST|upper thoracic mobilization|Upper thoracic mobilization, often known as joint mobilization, is a common technique in manual therapy. In order to preserve or restore joint mobility, this approach glides and uses distraction on the joint surfaces.
58483314|NCT04467372|DIETARY_SUPPLEMENT|Capsule placebo|Two placebo capsules daily for 30 days
58483315|NCT01170169|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
58483316|NCT01170169|DRUG|Prilosec|Prilosec® 40 mg of Merck \& Co.Inc.
58483317|NCT00074048|DRUG|BL22|Dosing via IV on Days 1,3, and 5.
58483318|NCT03846206|DIETARY_SUPPLEMENT|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
58483319|NCT00880919|DRUG|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
58483320|NCT00880919|DRUG|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
58483321|NCT00055913|BIOLOGICAL|bevacizumab|Given IV
58483322|NCT00055913|DRUG|erlotinib hydrochloride|Given orally
58483323|NCT00055913|OTHER|laboratory biomarker analysis|Correlative studies
58483324|NCT03895749|DIETARY_SUPPLEMENT|NEO40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
58483325|NCT02397161|OTHER|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
58483326|NCT02397161|OTHER|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
58483327|NCT02397161|OTHER|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
58483328|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
58483329|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
58483330|NCT03705806|RADIATION|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
58483331|NCT05611320|OTHER|Awareness campaign - communications campaign|"How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well."
58483332|NCT05611320|OTHER|Online shopping|Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
58483333|NCT01471288|DRUG|Carum Cravi|40mg/kg of body weight
58483334|NCT01471288|DRUG|Placebo|Placebo
58483335|NCT05695508|DRUG|Teclistamab (Tec)|Subcutaneous administration of Teclistamab
58483336|NCT05695508|DRUG|Daratumumab|Subcutaneous administration of Daratumumab
58483337|NCT05695508|DRUG|Dexamethasone|administered i.v. or orally
58483338|NCT05695508|DRUG|Lenalidomide|Administration oral
58483339|NCT05695508|DRUG|Bortezomib|Subcutaneous administration
58483340|NCT05695508|DRUG|Talquetamab|Subcutaneous administration of Daratumumab
58483341|NCT05965544|DRUG|Bupivacain (preoperative)|After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
58483342|NCT05965544|DRUG|Bupivacaine-fentanyl|The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
58483343|NCT05965544|DRUG|Bupivacain (Postoperative)|After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
58483344|NCT03901872|DEVICE|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
58483345|NCT02641782|DRUG|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
58483346|NCT02641782|DRUG|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
58483347|NCT02641782|DRUG|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
58483348|NCT02641782|DRUG|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
58483349|NCT02641782|DRUG|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
58483350|NCT00003153|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58483351|NCT06109636|OTHER|Pentacam, Corvis ST and Casia2|scleral and ciliary muscle thickness were obtained by Casia2, biomechanical parameters were obtained by Pentacam and Corvis ST
58483352|NCT05858723|DIAGNOSTIC_TEST|ROAT|Repeated Open Application Test
58483353|NCT00350415|DRUG|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
58483354|NCT01318239|PROCEDURE|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
58483355|NCT02247986|DRUG|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
58483356|NCT02263027|BIOLOGICAL|Vaccine|Licensed trivalent inactivated influenza vaccine
58483357|NCT02536963|DEVICE|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
58483358|NCT02536963|OTHER|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
58483359|NCT01378585|DRUG|DLBS1033|3 x 490 mg DLBS1033 daily
58483360|NCT01378585|DRUG|Placebo|3 x 1 tablet daily
58483361|NCT03066947|BIOLOGICAL|SV-BR-1-GM|See above
58483362|NCT03066947|DRUG|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
57781050|NCT04838626|DRUG|[18F]CTT1057|PET/CT imaging with \[18F\]CTT1057
58483363|NCT03066947|BIOLOGICAL|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
58483364|NCT00649207|DRUG|ABT-888|Oral Capsules
58483365|NCT00649207|RADIATION|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
58483366|NCT03562377|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
58483367|NCT03562377|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
58483368|NCT03562377|BIOLOGICAL|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
58483369|NCT03562377|BIOLOGICAL|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
58483370|NCT00555698|DEVICE|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
58483371|NCT01406782|BIOLOGICAL|rituximab|
58483372|NCT01406782|GENETIC|DNA analysis|
58483373|NCT01406782|GENETIC|gene expression analysis|
58483374|NCT01406782|GENETIC|polymerase chain reaction|
58483375|NCT01406782|OTHER|laboratory biomarker analysis|
58483376|NCT03350672|DRUG|FTC/TAF|Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
58483377|NCT02778789|DRUG|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
58483378|NCT02778789|DRUG|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
58483379|NCT04963439|DRUG|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
58483380|NCT03666663|DRUG|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
58483381|NCT03666663|DRUG|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
58483382|NCT03666663|DRUG|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
58483383|NCT03666663|DRUG|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
58483384|NCT05295095|PROCEDURE|positive pressure during extubation procedure|positive pressure during extubation procedure
58483385|NCT03809104|OTHER|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
58483386|NCT06514014|DIETARY_SUPPLEMENT|Preterm Infant Formula|Transition from donor human milk to preterm infant formula
58483387|NCT06185543|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
58483388|NCT06185543|DRUG|Placebo|Placebo matches active drug in size, color and taste
58483389|NCT05660577|DEVICE|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
58483390|NCT06416384|OTHER|Hand Massage Group|The patients in the hand massage application group were asked by the researcher; Hand massage with olive oil was applied 12 times in total, three times a week for four weeks. No application was made to the side with fistula.
58483391|NCT06416384|OTHER|Control Group|Patients in the control group received routine nursing care in the clinic for four weeks.
58483392|NCT00719472|DRUG|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
58483393|NCT00719472|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
58483394|NCT00719472|DRUG|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
58483395|NCT00719472|DRUG|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
58483396|NCT01039740|DRUG|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
58483397|NCT04588571|PROCEDURE|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
57781051|NCT00272766|DRUG|pegaptanib sodium|
57784392|NCT06310590|DRUG|NRT6003 Injection|Selective internal radiation therapy (SIRT) with Yttrium-90 carbon microspheres
57784393|NCT04717063|DRUG|Peroxyl Oral Product|mouth wash
58483398|NCT04588571|PROCEDURE|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
58483399|NCT02964143|DEVICE|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
58483400|NCT02964143|DEVICE|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
58483401|NCT02964143|DEVICE|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
58483402|NCT00131248|DRUG|Metaclopramide|
58483403|NCT00131248|DRUG|Ranitidine|
58483404|NCT00131248|DRUG|placebo|
58483405|NCT05056389|DRUG|Oxaliplatin|Administration of oxaliplatin intraperitoneally
58483406|NCT06425900|DRUG|Winlevi (Clascoterone) cream 1%|Dosed twice daily (BID)
58483407|NCT01596010|DRUG|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
58483408|NCT05021978|DRUG|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
58483409|NCT05021978|DRUG|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
58483410|NCT05021978|DRUG|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
58483411|NCT01351181|BEHAVIORAL|Leaflet|Advice Leaflet
58483412|NCT01351181|BEHAVIORAL|Exercise Advice|Leaflet
58483413|NCT01351181|BEHAVIORAL|Normal Care|Normal Care
58483414|NCT01896219|DEVICE|Navigation station (IMACTIS-CT®)|
58483415|NCT01896219|DEVICE|CT|Reference method for gestures (carried out under CT) guidance
58483416|NCT04042948|DRUG|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
58483417|NCT06462599|GENETIC|Gene polymorphism from blood samples|"Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation"
58483418|NCT03780166|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
58483419|NCT00793897|DRUG|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
58483420|NCT00793897|DRUG|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
58483421|NCT00793897|DRUG|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
58483422|NCT01929746|BIOLOGICAL|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
58483423|NCT03758040|OTHER|Slips on Turns|Subjects will be administered a slip at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
58483424|NCT03758040|OTHER|Slips on Slopes|Slips will be administered at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the CAREN system treadmill.
58483425|NCT01327482|DRUG|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
58483426|NCT01582269|DRUG|LY2157299 monohydrate|Orally administered as tablets
58483427|NCT01582269|DRUG|Lomustine|Orally administered as capsules
58483428|NCT01582269|DRUG|Placebo|Orally administered as tablets
58483429|NCT03818321|DRUG|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
58483430|NCT03818321|DRUG|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
58483431|NCT02654769|DRUG|Ingenol Mebutate (Picato®)|Brand product
58483432|NCT02654769|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
58483433|NCT02654769|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
58483434|NCT00045318|DRUG|exatecan mesylate|
58483435|NCT02610114|OTHER|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
58483436|NCT02610114|OTHER|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
58483437|NCT03813927|DIETARY_SUPPLEMENT|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
58483438|NCT03813927|DIETARY_SUPPLEMENT|Placebo|Placebo with tablet 20 μg Vitamin each day.
58483439|NCT00692835|PROCEDURE|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
58483440|NCT00692835|PROCEDURE|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
58483441|NCT06120374|RADIATION|Radiotherapy|"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
58483442|NCT06120374|DRUG|Chemotherapy|For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
58483443|NCT06120374|DRUG|Immunotherapy|For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
58483444|NCT05403424|OTHER|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
58483445|NCT05403424|DIAGNOSTIC_TEST|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
58483446|NCT05403424|OTHER|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
58483447|NCT05403424|OTHER|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
58483448|NCT05204004|DEVICE|Sunrise|"Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test."
58483449|NCT05204004|DEVICE|Polygraphy|Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
58483450|NCT01577888|DEVICE|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
58483451|NCT03232697|DIAGNOSTIC_TEST|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
58483452|NCT03232697|DIAGNOSTIC_TEST|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
58483453|NCT01143246|DRUG|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
58483454|NCT01143246|DRUG|Placebo|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
58483455|NCT05546632|DIAGNOSTIC_TEST|Blood sampling|Patients will have one blood sampling using one EDTA tube and one Cyto-Chex BCT tube, one after the other
58483456|NCT04378543|BIOLOGICAL|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
58483457|NCT03986086|DRUG|MPH966|RP2D tablet
58483458|NCT03986086|DRUG|Placebo|MPH966 placebo table
58483459|NCT00297258|DRUG|pazopanib|oral tablet
58483460|NCT05897203|DRUG|TAZCOV|Herbal Syrup
58483461|NCT05897203|DRUG|Vidicine|Herbal Syrup
58483462|NCT03291496|OTHER|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
58483463|NCT03291496|OTHER|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is \>24 hours old.
58483464|NCT03291496|OTHER|Adult Blood collection|One Time 1 ml of whole blood collected
58483465|NCT02773316|DRUG|MR902|
58483466|NCT02773316|DRUG|IR morphine sulphate|
58483467|NCT00290316|PROCEDURE|Endoscopy ultrasound|
58483468|NCT02484118|PROCEDURE|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
58483469|NCT02528981|DRUG|Probiotic|Lactobacillus GR-1 and RC-14
58483470|NCT02528981|DRUG|Placebo|
58483471|NCT00485810|DRUG|Olanzapine Hydrochloride|
58483472|NCT00030914|DRUG|medroxyprogesterone|
58483473|NCT00030914|DRUG|venlafaxine|
58483474|NCT02503137|DRUG|Topical SM04554 solution|
58483475|NCT02503137|DRUG|Topical Vehicle solution|
58483476|NCT04772274|DRUG|Ustekinumab|45 mg, single-dose
58483477|NCT04295720|DEVICE|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
58483478|NCT03141138|BIOLOGICAL|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
58483479|NCT03141138|BIOLOGICAL|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
58483480|NCT01258686|DRUG|Silymarin|700mg thrice daily
58483481|NCT01258686|DRUG|Placebo|Placebo 700mg thrice daily
58483482|NCT06221306|PROCEDURE|Dental implant: NDI|Placement of narrow diameter implants (NDI) (3.3) in the dentoalveolar ridge
58483483|NCT06221306|PROCEDURE|Dental implant: SDI|Placement of standard diameter implants (SDI) (4.1) in the dentoalveolar ridge with simaltenous bone augmentation
58483484|NCT04330404|BEHAVIORAL|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
58483485|NCT04330404|BEHAVIORAL|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
58483486|NCT03498937|DEVICE|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
58483487|NCT03498937|DEVICE|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
58483488|NCT05429008|DRUG|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
58483489|NCT00118417|DRUG|Clonazepam|Participants will receive clonazepam.
58483490|NCT00118417|DRUG|Sertraline|Participants will receive sertraline.
58483491|NCT00118417|BEHAVIORAL|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
58483492|NCT04818788|DRUG|Biological Drug|we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
58483493|NCT05279677|DRUG|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
58483494|NCT04100252|OTHER|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
58483495|NCT02426203|PROCEDURE|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
58483496|NCT00102817|DRUG|somatropin|
58483497|NCT01916954|DRUG|3-day artemether-lumefantrine|
58483498|NCT01916954|DRUG|5-day artemether-lumefantrine|
58483499|NCT06383481|OTHER|Mobile based education|"Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided."
58483500|NCT05592717|DRUG|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
58483501|NCT01021891|DRUG|Technosphere®/Insulin|
58483502|NCT05586438|DRUG|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
58483503|NCT01562093|DRUG|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
58483504|NCT01562093|DRUG|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
58483505|NCT01129856|DRUG|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
58483506|NCT01129856|DRUG|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
58483507|NCT01321099|OTHER|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
58483508|NCT01321099|OTHER|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
58483509|NCT01321099|OTHER|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
58483510|NCT06595719|DIETARY_SUPPLEMENT|Multi-Strain Probiotics|Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120
58483511|NCT06595719|DIETARY_SUPPLEMENT|Placebo|Replicate for multi-strain probiotics without any active ingredients
58483512|NCT01408173|DRUG|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
58483513|NCT00065078|PROCEDURE|Home dispensing of contraception|
58483514|NCT06367140|DEVICE|EMG-triggered CIMCT device|The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.
58483515|NCT06367140|DEVICE|general cycling training|The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
58483516|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
58483517|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
58483518|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
58483519|NCT00801177|BIOLOGICAL|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
58483520|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
58483521|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
58483522|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
58483523|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
58483524|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
58483525|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 4~600 mg I.V."
58483526|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
58483527|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
58483528|NCT02688777|BEHAVIORAL|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
58483529|NCT02926885|DEVICE|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
58483530|NCT02926885|DEVICE|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
58483531|NCT02926885|PROCEDURE|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
58483532|NCT01740648|DRUG|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
58483533|NCT01740648|DRUG|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
58483534|NCT01740648|RADIATION|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
58483535|NCT01709084|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
58483536|NCT01709084|DRUG|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
58483537|NCT01709084|DRUG|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
58483538|NCT01709084|DRUG|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
58483539|NCT04396639|BIOLOGICAL|Moroctocog-alfa (AF-CC)|Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
58483540|NCT04078425|DRUG|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
58483541|NCT05109468|OTHER|Quality of life questionnaire|to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
58483542|NCT05614596|OTHER|CT guided and Flouroscopic guided injection of corticosteroid and local anathesia|Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
58483543|NCT01942837|DRUG|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
58483544|NCT06278714|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
58483545|NCT00981110|DEVICE|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
58483546|NCT00981110|DEVICE|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
58483547|NCT01385293|DRUG|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
58483548|NCT06373952|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
58483549|NCT03559374|OTHER|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
58483550|NCT05644158|PROCEDURE|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
58483551|NCT05644158|OTHER|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
58483552|NCT00002002|DRUG|Trimethoprim|
58483553|NCT00002002|DRUG|Sulfamethoxazole|
58483554|NCT00002002|DRUG|Leucovorin calcium|
58483555|NCT02399176|BEHAVIORAL|Yoga|Subjects assume 10 physical postures for 30 seconds each
58483556|NCT00694941|DRUG|ONO-2506PO|1200mg QD / 5 years
58483557|NCT06080841|DIETARY_SUPPLEMENT|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
58483558|NCT06080841|DIETARY_SUPPLEMENT|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
58483559|NCT04195841|PROCEDURE|Z shaped incision|"After local anaesthesia, a mucoperiosteal flap will be elevated at the edentulous ridge with two horizontal incisions placed with a no MB 69 blade, 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. The extend of the incisions should be up to the proximal line angles of the adjacent teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles. A periosteal elevator is used to elevate a full thickness mucoperiosteal flap buccally and lingually to the level of the mucogingival junction, exposing the alveolar ridge of the implant surgical sites.~Endosseous implant placement is done followed by simple interrupted resorbable sutures"
58483560|NCT04195841|PROCEDURE|H shaped incision|"After local anaesthesia, a mucoperiosteal flap is elelevated by placing sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles using a MB 69 blade.~Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth. A full thickness mucoperiosteal flap will be elevated buccally and lingually to the level of the mucogingival junction to expose the alveolar ridge of the implant surgical sites using a periosteal elevator.~Endosseous implant will be placed, followed by simple interrupted resorbable sutures."
58483561|NCT03286517|BIOLOGICAL|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
58483562|NCT05952882|DRUG|Liraglutide + Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks
58483563|NCT05952882|DRUG|Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
58483564|NCT04502082|BIOLOGICAL|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
58483565|NCT04786717|OTHER|core muscle training|The intervention of this group will focus on training the endurance of the core muscle.
58483566|NCT04786717|OTHER|movement control training|Based from the initial test, the subjects will receive either lumbar flexion control exercise or lumbar extension control exercise. They will perform each lumbar movement control exercise in different position. Starting from the lying position, then progressing to sitting, standing with support, and the last level will be standing without support. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
57781052|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
57781053|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
57784394|NCT04717063|DRUG|Placebo|placebo mouth wash
58483567|NCT04786717|OTHER|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, so the subjects will not have any real movement, and the last 7 times they will perform the lumbar motor control exercise literally. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
58483568|NCT00275509|DRUG|Thymoglobulin|
58483569|NCT00275509|DRUG|Daclizumab|
58483570|NCT00275509|OTHER|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
58483571|NCT00275509|DRUG|Mycophenolate mofetil|2 gm/day. Standard of care
58483572|NCT00275509|DRUG|Tacrolimus|To achieve serum level of 8-10 ng/ml.
58483573|NCT00275509|DRUG|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
58483574|NCT00275509|DRUG|Prednisone|Taper over three months to 5 mg daily
58483575|NCT00275509|DRUG|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
58483576|NCT03382353|DIETARY_SUPPLEMENT|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
58483577|NCT03382353|BEHAVIORAL|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
58483578|NCT03382353|BEHAVIORAL|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
58483579|NCT03382353|BEHAVIORAL|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
58483580|NCT03382353|BEHAVIORAL|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
58483581|NCT06601764|OTHER|Circuit Training|"1. Warm-up, balance~2. Aerobic, balance~3. Muscle strength Upper Limbs~4. Muscle strength Lower Limbs~5. Stretching both Upper Limb and Lower Limb"
58483582|NCT06601764|OTHER|Progressive Resistance|"1. Muscle habituation exercises~2. Hypertrophic phase 1 exercises~3. Hypertrophic phase 2 exercises"
58483583|NCT02978976|DRUG|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
58483584|NCT02978976|DRUG|saline|saline placebo injection in the same regimen.
58483585|NCT01120964|DRUG|Intravenous L-Citrulline|
58483586|NCT01120964|DRUG|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
58483587|NCT04577521|DEVICE|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
58483588|NCT01926457|OTHER|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
58483589|NCT00473564|PROCEDURE|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
58483590|NCT00489593|DRUG|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
58483591|NCT00000716|DRUG|Zidovudine|
58483592|NCT06591403|OTHER|the index and middle fingers of each participant&amp;#39;s active hand|A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
58483593|NCT00544297|DRUG|PEP005 gel|Two day application, 0.05%
58483594|NCT00000288|DRUG|Cotinine fumarate|
58483595|NCT05136014|OTHER|Collection of surgical waste|collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed
58483596|NCT04663282|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
58483597|NCT04663282|DRUG|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
58483598|NCT04089995|OTHER|data collection|No intervention
58483599|NCT00646880|DRUG|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
58483600|NCT00646880|DRUG|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
58483601|NCT05342714|DEVICE|Remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
58483602|NCT06238258|BEHAVIORAL|SPECTROM Training|Training regarding treatment of behavioral challenges in adults with intellectual disability
58483603|NCT00043979|DRUG|F-18 Fluorodeoxyglucose|
58483604|NCT00043979|BIOLOGICAL|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
57781054|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
57781055|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
57781056|NCT06737978|DEVICE|AngioSafe Peripheral-5 CTO Crossing System|AngioSafe Peripheral-5 CTO Crossing System is used to help the doctor to pass a guidewire through the blockage in blood vessels below the knee.
57781057|NCT01379820|DEVICE|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
57781058|NCT06682143|BEHAVIORAL|Virtual Reality (VR)|Participants will engage in a virtual reality greenspace activity for a period of 5 minutes
57781059|NCT06682143|BEHAVIORAL|Control|Participants will sit quietly for a period of 5 minutes
57781060|NCT03930186|DRUG|Apremilast|Tablets for oral administration
57781061|NCT03930186|DRUG|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
57781062|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
57781063|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 single dose as oral suspension.
57781064|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 multiple doses daily as oral suspension.
57781065|NCT06368440|DRUG|Placebo|Participants will receive matching doses of placebo as oral suspension.
57781066|NCT06173362|DRUG|Abiraterone|Given abiraterone
57781067|NCT06173362|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57781068|NCT06173362|DRUG|Darolutamide|Given darolutamide
57781069|NCT06173362|DRUG|Prednisone|Given prednisone
57781070|NCT06738563|OTHER|Collection breast milk|Collection of a milk sample taken as part of women's donation
57781071|NCT06737536|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
57781072|NCT06737536|OTHER|Placebo (NNC0662-0419)|Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
57781073|NCT01163149|DRUG|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
57781074|NCT01163149|DRUG|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
57781075|NCT03010735|DIETARY_SUPPLEMENT|probiotics|Daily take 4.0E+10 CFU of probiotics
57781076|NCT03010735|DIETARY_SUPPLEMENT|Placebo|
57781077|NCT06739902|DIAGNOSTIC_TEST|Traditional Physiotherapy Group|Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.
57781078|NCT06739902|COMBINATION_PRODUCT|VR + Traditional Physiotherapy Group|Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
57781079|NCT04299633|DRUG|Vadadustat|2 x 150 mg oral tablets
57781080|NCT04299633|DRUG|Sevelamer carbonate|2 x 800 mg oral tablets
57781081|NCT04299633|DRUG|Calcium acetate|2 x 667 mg oral gelcaps
57781082|NCT04299633|DRUG|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
57781083|NCT06723392|DRUG|Oral nitrofurantoin monohydrate/macrocrystals|7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)
57781084|NCT06723392|OTHER|Placebo|7-day course of oral placebo 100 mg twice daily (total of 14 doses)
57781085|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
57781086|NCT03879694|DRUG|Octreotide Acetate|Given IM
57781087|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
57781088|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
57781089|NCT06740266|BEHAVIORAL|Promoting First Relationships in Primary Care (PFR-PC)|"Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
57781090|NCT05457283|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
57781091|NCT00226564|DRUG|Alfentanil|
57781092|NCT06728449|DIETARY_SUPPLEMENT|Cumin tea|The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
57781093|NCT06728449|DIETARY_SUPPLEMENT|Ginger Tea|The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
57781094|NCT06728449|DIETARY_SUPPLEMENT|Lemon Peel Tea|The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
57781095|NCT06728449|DIETARY_SUPPLEMENT|Functional Tea|The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
57781096|NCT06728449|DIETARY_SUPPLEMENT|Conventional therapy|A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
57781097|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
57781098|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
57781099|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
57781100|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
57781101|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
57781102|NCT03122886|DIETARY_SUPPLEMENT|Fat Emulsion|Given IV
57781103|NCT03122886|OTHER|Placebo|Given IV
57781104|NCT05489705|DRUG|Mavacamten|As per product label
57781105|NCT05489705|DRUG|Non-mavacamten symptomatic oHCM therapy|Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
57781106|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
57781107|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
57781108|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
57781109|NCT06739447|OTHER|Consumer Wearable Device Vital Sign Measurement|Consumer Wearable Devices such as the Fitbit, are durable devices that can provide vital sign data.
57781110|NCT06739941|OTHER|Oat fiber (BG-OS)|Beta-glucan oligosaccharide (BG-OS) is beta-glucan predominant, dietary fiber obtained by extracting oat fiber from oat grain and applying a food-grade depolymerization process to shorten the polysaccharide chain length of the fiber. BG-OS retains the fiber structure of oat fiber but has a shorter chain length, which makes it water soluble and easily formulated into any food.
57781111|NCT05415137|DRUG|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
57781112|NCT05415137|DRUG|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
57781113|NCT05415137|DRUG|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
57781114|NCT06199076|DRUG|Oxytocin nasal spray|The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
57781115|NCT06719700|DRUG|Chemotherapy|Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
57781116|NCT06719700|DRUG|Immunotherapy|Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
57781117|NCT06719700|DRUG|Angio-immuno kinase inhibitor|Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
57781118|NCT06719700|RADIATION|radiotherapy|Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
57781119|NCT06719700|RADIATION|Prophylactic Cranial Irradiation|PCI is recommended after the completion of chemoradiotherapy.
57781120|NCT06719700|DRUG|Consolidation Therapy with Toripalimab and Surufatinib|Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
57781121|NCT06737003|DEVICE|Nasal high frequency oscillatory ventilation|NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
57781122|NCT06737003|DEVICE|Vapotherm Group|The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
57781123|NCT06737003|DEVICE|Nasal CPAP Group|CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
57781124|NCT00783120|OTHER|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
57781125|NCT00783120|OTHER|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
57781126|NCT06736769|DRUG|Ketamine infusion|Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
57781127|NCT03206060|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
57781128|NCT03206060|DRUG|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
57781129|NCT03206060|DRUG|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
57781130|NCT03206060|DRUG|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
57781131|NCT05375136|OTHER|Non-interventional|No intervention will be administered.
57781132|NCT06737900|OTHER|traditional physical therapy|"* Heating pad for 10 minutes~* Core stability exercises for 20 minutes with 10 seconds of rest intervals~* Patients were advised to stretch for 5 minutes then perform lumber stability exercises.~* These stability exercises included side bridges, supine extension bridge, straight leg raise in prone lying, alternate arm and leg raise from quadruped position and prone bridges.~Both groups took sessions thrice a week for a total of 4 weeks."
58483605|NCT00043979|DRUG|cyclophosphamide|"Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
58483606|NCT00043979|DRUG|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
58483607|NCT00043979|DRUG|doxorubicin hydrochloride|Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
58483608|NCT00043979|DRUG|etoposide|50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
58483609|NCT00043979|DRUG|fludarabine phosphate|"Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
58483610|NCT00043979|DRUG|melphalan|Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
58483611|NCT00043979|DRUG|prednisone|Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
58483612|NCT00043979|DRUG|sirolimus|Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
58483613|NCT00043979|DRUG|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
58483614|NCT00043979|DRUG|vincristine sulfate|Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
58483615|NCT00043979|PROCEDURE|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
57781133|NCT06737900|OTHER|jandas approach|"* Stretching exercise for erector spinae and back extensors muscles~* Stretching exercises for iliopsoas muscle and rectus femoris muscle~* Strengthening exercise for abdominal muscle and gluteal maximus muscle Stretching exercise was performed actively for 3 repetitions x 1 set and 4 days a week Strengthening exercise was performed for 10 second hold and 10 repetitions. All Exercises was performed 3 times per week for total of 4 weeks"
57781134|NCT05443620|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
57781135|NCT05443620|DEVICE|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
58483616|NCT00043979|DRUG|Filgrastim|
58483617|NCT00043979|PROCEDURE|Peripheral Blood Stem Cell donation|
57781136|NCT05125042|PROCEDURE|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
57781137|NCT05125042|DRUG|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
57781138|NCT01080963|DRUG|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
57781139|NCT01080963|DRUG|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
58483618|NCT06214065|DIAGNOSTIC_TEST|fMRI|fMRI will be performed pre- and post-rTMS
58483619|NCT06214065|DEVICE|rTMS|TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
58483620|NCT01955421|DRUG|Erlotinib 100mg qd|
58483621|NCT01955421|DRUG|Gefitinib 250mg qd|
58483622|NCT04593537|OTHER|No intervention|This is an observational study, no intervention is involved
58483623|NCT02036814|BEHAVIORAL|Program Health Education|
58483624|NCT05208099|BIOLOGICAL|Blood tests|"For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
58483625|NCT05208099|PROCEDURE|exeresis|"For patients, it will be performed:~- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
58483626|NCT05208099|PROCEDURE|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin"
58483627|NCT06141525|DEVICE|Remote ischemic conditioning|An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).
58483628|NCT01034332|PROCEDURE|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
58483629|NCT01749215|DRUG|Topiramate|Experimental study drug
58483630|NCT01749215|DRUG|placebo|Placebo comparator
58483631|NCT01749215|BEHAVIORAL|Medical Management|Brief alcohol counseling
57781140|NCT01005628|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
58483632|NCT00110448|DRUG|Aspirin|Aspirin 81 mg or 100 mg per day
58483633|NCT00110448|DRUG|No aspirin|No aspirin use
58483634|NCT06145620|OTHER|Physiotherapy|The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
58483635|NCT00658359|DRUG|Cyclosporine|Standard of care
58483636|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
58483637|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
58483638|NCT02551939|PROCEDURE|Autologous Fat Grafting|Autologous Fat Grafting
58483639|NCT02056587|DRUG|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
58483640|NCT01162642|DIETARY_SUPPLEMENT|Green Tea|Green Tea 4 cups daily
58483641|NCT01162642|OTHER|Placebo|4 cups placebo tea for 6 weeks
58483642|NCT06398756|OTHER|conventional rehabilitation|17 patients with cerebral palsy meeting the criteria will undergo conventional rehabilitation
58483643|NCT06398756|OTHER|aquatic therapy|17 patients with cerebral palsy meeting the criteria will undergo convertional rehabilitation and aquatic therapy
58483644|NCT00664625|DRUG|BMS-791325|Capsules, Oral, Once Daily, Single Dose
58483645|NCT00664625|DRUG|Placebo|Capsules, Oral, Once Daily, Single Dose
58483646|NCT02392624|DRUG|Omalizumab|Omalizumab 300 mg administered SC Q4W.
58483647|NCT02392624|DRUG|Placebo|Placebo matched to omalizumab administered SC Q4W.
58483648|NCT05275283|OTHER|PEEP|6 cmH2O of PEEP
58483649|NCT05889676|DIAGNOSTIC_TEST|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
58483650|NCT00006086|DRUG|BMS-188797|
58483651|NCT00006086|DRUG|carboplatin|
58483652|NCT04379895|DEVICE|Radiofrequency ablation|Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
58483653|NCT00757302|DEVICE|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
58483654|NCT04184089|DEVICE|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
58483655|NCT04184089|DEVICE|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
58483656|NCT04184089|DEVICE|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
57781141|NCT06699797|DEVICE|Acclaim Cochlear Implant|Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
58483657|NCT01339143|DRUG|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
58483658|NCT01339143|DRUG|pioglitazone|15mg, QD, PO, 16 weeks
58483659|NCT03652805|DRUG|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
58483660|NCT04400201|DRUG|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
58483661|NCT04400201|DRUG|Propofol|Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
58483662|NCT05932823|OTHER|Laminary airflow|A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
58483663|NCT02633306|DEVICE|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
58483664|NCT01206725|OTHER|Exercise|"1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
58483665|NCT01523106|DRUG|L-carnitine|dietary supplement
57781142|NCT06377761|DRUG|Qishen Granules|One package per time, twice a day, 90 days of treatment
57781143|NCT06377761|DRUG|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
58483666|NCT01523106|OTHER|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
58483667|NCT05940480|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
58483668|NCT05940480|BEHAVIORAL|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
58483669|NCT02318706|DRUG|DS-5565|
58483670|NCT02318706|DRUG|placebo|
58483671|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given weekly
58483672|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given monthly
58483673|NCT00892099|OTHER|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
58483674|NCT00759941|DRUG|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
58483675|NCT00759941|DRUG|Placebo eye drops|One drop three times a day in both eyes for 3 months
58483676|NCT00759941|DRUG|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
58483677|NCT04316013|DRUG|Sevoflurane|Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
58483678|NCT04316013|DRUG|Propofol|Intravenous anaesthetic used for induction and maintenance of anaesthesia
58483679|NCT04316013|DRUG|Lidocaine IV|1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
58483680|NCT00927953|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
58483681|NCT00927953|BIOLOGICAL|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
58483682|NCT02304367|BIOLOGICAL|Burosumab|Solution for subcutaneous injection
57781144|NCT04341350|DRUG|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
58483683|NCT00090207|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
58483684|NCT00090207|DRUG|Comparator: ondansetron / Duration of Treatment: 4 days|
58483685|NCT06067360|DEVICE|IFIS sleeve|IFIS sleeve will be inserted to prevent iris prolapse
58483686|NCT02819804|DRUG|Dasatinib|Given PO
57781145|NCT04341350|DRUG|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
57781146|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
57781147|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
57781148|NCT06737393|PROCEDURE|Backfill|Participants undergoing laparoscopic hysterectomy have the bladder filled with 200 mL saline prior to Foley removal at the end of surgery.
57781149|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
57781150|NCT06740513|PROCEDURE|Endovascular Treatment|Medical Therapy plus Stent/Balloon Angioplasty
57781151|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
57781152|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
57781153|NCT06736886|OTHER|Light application|Light application
57781154|NCT06170307|OTHER|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
57781155|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
57781156|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
57781157|NCT06050915|DRUG|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
57781158|NCT06050915|DRUG|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
58483687|NCT02819804|OTHER|Laboratory Biomarker Analysis|Correlative studies
58483688|NCT02819804|BIOLOGICAL|Nivolumab|Given IV
57781159|NCT05134389|PROCEDURE|One Anastomosis Gastric Bypass|Exposure to One Anastomosis Gastric Bypass
57781160|NCT05367440|DRUG|AZD5305|Patients will receive an oral dose of AZD5305 once daily
57781161|NCT05367440|DRUG|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
57781162|NCT05367440|DRUG|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
57781163|NCT05367440|DRUG|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
57781164|NCT05367440|DRUG|Apalutamide|Patients will receive an oral dose of Apalutamide once daily
58483689|NCT02819804|OTHER|Pharmacological Study|Correlative studies
58483690|NCT02785523|DRUG|Ganoderma Spore Lipids|
58483691|NCT02785523|DRUG|Placebo|
58483692|NCT02785523|DRUG|Chemotherapy|
58483693|NCT01790724|BEHAVIORAL|Walking exercise|
58483694|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
58483695|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
58483696|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
58483697|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
58483698|NCT02902562|PROCEDURE|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
58483699|NCT02902562|PROCEDURE|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
57781165|NCT06738732|DRUG|CBD: GT4 Transdermal Delivery System|CBD: GT4 Transdermal Delivery System
57781166|NCT06715241|COMBINATION_PRODUCT|combination of relatlimab and nivolumab wich are two immunotherapy treatments|Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks
57781167|NCT06715241|OTHER|Nivolumab alone|Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
57781168|NCT00816660|BIOLOGICAL|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
57781169|NCT00816660|BIOLOGICAL|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
57781170|NCT06183515|PROCEDURE|CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash|The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
57781171|NCT00165360|DRUG|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
57781172|NCT05880589|DIETARY_SUPPLEMENT|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
57781173|NCT05880589|DIETARY_SUPPLEMENT|Placebo group|Take 2 tablet 2 times per day for 14 days
57781174|NCT05683236|OTHER|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
57781175|NCT05683236|OTHER|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
57781176|NCT05683236|OTHER|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
57781177|NCT05683236|OTHER|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
57781178|NCT05683236|OTHER|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
57781179|NCT05683236|OTHER|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
57781180|NCT02833662|OTHER|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
57781181|NCT04840602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781182|NCT04840602|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
57781183|NCT04840602|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
57781184|NCT04840602|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
57781185|NCT04840602|DRUG|Ibrutinib|Given PO
57781186|NCT04840602|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57781187|NCT04840602|BIOLOGICAL|Rituximab|Given IV
57781188|NCT04840602|DRUG|Venetoclax|Given PO
57781189|NCT06740110|DEVICE|Bone replacement composite vs standard of care|"Bone replacement composite: Before application the Bone replacement composite (size 10 mm) will be mixed with autogenous blood or a saline solution and modelled. Next, the medical device will be applied to the place where teeth extraction is performed.~Standard of care: Before application standard of care (Bio-Oss) will be mixed with autogenous blood or a saline solution and modelled. Next, the standard of care will be applied to the place where teeth extraction is performed. Subsequent application of a collagen membrane (Bio-Gide) will be conducted."
57784642|NCT02619708|BEHAVIORAL|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
58483700|NCT06365632|DRUG|Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus|An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.
58483701|NCT06365632|PROCEDURE|antegrade appendectomy|An antegrade appendectomy is performed without using Antispike.
58483702|NCT03823742|OTHER|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
57781190|NCT03981445|BEHAVIORAL|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
57781191|NCT03981445|BEHAVIORAL|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
57781192|NCT02158624|DRUG|Intravitreal Lucentis 0.5mg|
57781193|NCT06740071|BEHAVIORAL|somatosensory interactive pelvic floor muscle training|synchronized PFMT guidance through a combination of audio and video
57781194|NCT06740071|PROCEDURE|pelvic floor magnetic stimulation therapy|stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions
57781195|NCT06740071|BEHAVIORAL|standard pelvic floor muscle training|"traditional verbal instructions and paper-based educational materials of PFMT are given to participants.~All patients would receive PFMT under the guidance of digital rectal examination by nurses, and their pelvic floor muscle function was graded according to the Oxford Grading System (grades 0-5), ensuring the correctness of subsequent PFMT."
57781196|NCT02202694|BEHAVIORAL|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
57781197|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
57781198|NCT03075293|OTHER|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
57781199|NCT01585922|PROCEDURE|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
57781200|NCT01585922|PROCEDURE|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
57781201|NCT05416775|DRUG|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
57781202|NCT05416775|DRUG|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
57781203|NCT05416775|DRUG|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
57781204|NCT02053779|DRUG|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
57781205|NCT06725212|DEVICE|Water Vapor Thermal Ablation|The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
57781206|NCT06725212|DEVICE|Cystoscopy|Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
57781207|NCT06740201|DRUG|Cipepofol|Adjust plasma target-controlled concentration
57781208|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
58483703|NCT03823742|OTHER|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
58483704|NCT05933850|BEHAVIORAL|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
58483705|NCT02868632|DRUG|MEDI4736|anti-PD-L1 human monoclonal antibody
57781209|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
57781210|NCT06741306|BEHAVIORAL|Group1|Current chemsex users Men who have sex with men, Aged 16-35 years (defined as last chemsex used within 3 months), Able to communicate in Thai fluently.
57781211|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
57781212|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
57781213|NCT06074900|OTHER|prospective cohort study|"This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient.~Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment."
57781214|NCT03464214|DEVICE|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
57781215|NCT03464214|BEHAVIORAL|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
57781216|NCT04873778|DEVICE|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
57781217|NCT04873778|DEVICE|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
57781218|NCT06442020|PROCEDURE|Tadalafil (PDE5i)|Tadalafil at a dose of 5mg/day
57781219|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
57781220|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
57781221|NCT05417789|DRUG|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
57781222|NCT05417789|DRUG|Placebo|Matching placebo administered once every 2 weeks (q2w)
58483706|NCT02868632|DRUG|Tremelimumab|anti-CTLA4 human monoclonal antibody
57781223|NCT05907928|OTHER|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
57781224|NCT05907928|OTHER|Single bond Universal|Radiolucent universal adhesive
57781225|NCT06441227|DRUG|HRS-5346 tablets|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
57781226|NCT06441227|DRUG|placebo|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
57781227|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
57781228|NCT05698654|BEHAVIORAL|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
57781229|NCT05698654|BEHAVIORAL|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI \>25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
57781230|NCT03821415|DRUG|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
57781231|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
57781232|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
58483707|NCT02868632|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
58483708|NCT05488535|DEVICE|cochlear implant headpiece|investigational cochlear implant headpiece
58483709|NCT01660724|PROCEDURE|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
57781233|NCT04082429|DRUG|Concizumab|When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
57781234|NCT06729112|DIAGNOSTIC_TEST|pan immune inflammation value|Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
57781235|NCT06738589|DEVICE|non-invasive ventilation|Non-invasive ventilation adds positive pressure to the upper airway via a mask on the face.
57781236|NCT05039229|OTHER|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
57781237|NCT05039229|OTHER|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
57781238|NCT06731699|DRUG|FD-001|"The initial dose was 0.4mg, and subsequent doses of 0.8mg, 1.6mg, 2.4mg, 3.2mg, and 4.0mg were proposed to be administered in a progressive manner using the rapid titration method combined with the traditional 3+3 experimental design. The trial process consists of three periods: screening period, treatment period, and follow-up period. The screening period lasted from D-28 to D-1 for treatment (DLT observation period): during this time frame, there was a single administration period (C0D1-C0D4) where oral administration occurred on day one followed by safety observations on days two to four; as well as multiple administration period one (C1D1-C1D28) where oral administration took place on days one to two and seven to nine with rest periods in between. The drug is available in capsule form."
57781239|NCT06730672|DRUG|Volonib combined with Everolimus Formation|Volonib 200mg once daily and Everolimus 5mg once daily
57781240|NCT05280548|DRUG|Venglustat (GZ402671)|Tablet; Oral
57781241|NCT05280548|DRUG|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
57781242|NCT05280548|DRUG|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
57781243|NCT05280548|DRUG|Migalastat|Hard capsules; Oral
57781244|NCT01315106|DEVICE|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
57781245|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
57781246|NCT03232138|DRUG|Placebo|Inactive ingredients
57781247|NCT04890834|OTHER|Best Practice|Receive standard care
57781248|NCT04890834|OTHER|Exercise Intervention|Participate in yoga sessions
57781249|NCT04890834|OTHER|Questionnaire Administration|Ancillary studies
57781250|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
57781251|NCT06602726|DRUG|REGN1908|Administered per the protocol
57781252|NCT06602726|DRUG|REGN1909|Administered per the protocol
57781253|NCT06602726|DRUG|Placebo|Administered per the protocol
57781254|NCT05671835|DRUG|TTI-101|Orally via a tablet.
57781255|NCT05671835|DRUG|Placebo|Orally via a tablet.
57781256|NCT04981509|BIOLOGICAL|Atezolizumab|Given PO
57781257|NCT04981509|BIOLOGICAL|Bevacizumab|Given IV
57781258|NCT04981509|PROCEDURE|Biopsy|Undergo biopsy
57781259|NCT04981509|PROCEDURE|Biospecimen Collection|Undergo blood collection
57781260|NCT04981509|PROCEDURE|Bone Scan|Undergo bone scan
57781261|NCT04981509|PROCEDURE|Computed Tomography|Undergo CT without contrast
57781262|NCT04981509|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
58483710|NCT01660724|PROCEDURE|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
57781263|NCT04981509|DRUG|Erlotinib|Given PO
57781264|NCT04981509|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57781265|NCT04981509|PROCEDURE|Positron Emission Tomography|Undergo PET
57781266|NCT04981509|DRUG|Sodium Fluoride F-18|Given F-18 sodium fluoride
57781267|NCT05443048|DEVICE|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
57781268|NCT06679270|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
57781269|NCT05971251|DRUG|Loncastuximab Tesirine and Acalabrutinib|Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
57781270|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
57781271|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
57781272|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
57781273|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
57781274|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
57781275|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
57781276|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
57781277|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
57781278|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
57781279|NCT06740669|BEHAVIORAL|Virtual reality glasses (VR) application|It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).
57781280|NCT06740669|BEHAVIORAL|Those who are applied expressive touch|Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
57781281|NCT06740669|BEHAVIORAL|Focus|. The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
57781282|NCT06720714|DRUG|Rozanolixizumab|Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
57781283|NCT06741072|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781284|NCT06741072|DRUG|Dulbecco''s Phosphate-Buffered Saline|Given SC
57781285|NCT06741072|BIOLOGICAL|Peptide Vaccine|Given OSU-2131 SC
57781286|NCT06741072|BIOLOGICAL|QS21|Given SC
57781287|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
57781288|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
57781289|NCT04418037|DEVICE|Digital Health Feedback System(DHFS)|We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
57781290|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
57781291|NCT06229080|DEVICE|NexGel|When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
57781292|NCT03815656|DEVICE|STN alone|DBS stimulation of STN alone
57781293|NCT03815656|DEVICE|GPi alone|DBS stimulation of GPi alone
57781294|NCT03815656|DEVICE|STN + GPi|cooperative DBS stimulation of STN and GPi sites
57781295|NCT03815656|DEVICE|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
57781296|NCT06741059|OTHER|Transkutanöz Elektriksel Sinir Stimülasyonu - TENS|Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option
57781297|NCT06271616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781298|NCT06271616|PROCEDURE|Echocardiography|Undergo echocardiography
57781299|NCT06271616|DRUG|Ibrutinib|Given PO
57781300|NCT05565560|DRUG|Apremilast|Oral tablets
57781301|NCT06739850|COMBINATION_PRODUCT|Identification of Risk Phenotypes of Sarcopenia|Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.
57781302|NCT06258837|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
57781303|NCT06258837|PROCEDURE|Adenotonsillectomy|Tonsil and/or adenoid removal
57781304|NCT04494113|PROCEDURE|Biopsy|Undergo biopsy
57781305|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
58137177|NCT04366401|BEHAVIORAL|Conventional Dietary Advice|"The education content in the control group will be centered on the acquisition of knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Culinary techniques: conservation of properties of the diet.~* - Feeding in particular situations."
57781306|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
57781307|NCT04494113|DRUG|Triapine|Given IV
57781308|NCT06595238|DRUG|AZD6234|IMP injected subcutaneously, once a week. Unit dose strength as per CSP
57781309|NCT06595238|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once a week.
57781310|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
57781311|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
57781312|NCT04605770|DRUG|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
57781313|NCT06235892|DRUG|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
57781314|NCT04729049|PROCEDURE|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
57781315|NCT04729049|DRUG|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
57781316|NCT06694584|BEHAVIORAL|Tea(m)Time|Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
57781317|NCT06097260|DRUG|PLN-74809|PLN-74809
57781318|NCT06097260|DRUG|Placebo|Placebo
57781319|NCT03971253|DRUG|Peficitinib|Oral
57781320|NCT06738108|DRUG|ECOS|The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE
57781321|NCT06738108|DRUG|Control group|Alteplase IV infusion
57781322|NCT00401674|DRUG|carboplatin|
57781323|NCT00401674|DRUG|paclitaxel|
57781324|NCT06561854|DRUG|Dexamethasone|"ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)"
57781325|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
57781326|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
57781327|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
57781328|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
57781329|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
57781330|NCT03701100|DEVICE|tDCS|tDCS
57781331|NCT05567796|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
57781332|NCT05567796|DRUG|Semaglutide|Participants will recieve semaglutide subcutaneously.
57781333|NCT05567796|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
57781334|NCT05567796|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
58483711|NCT00594841|PROCEDURE|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws"
58483712|NCT00594841|OTHER|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
58483713|NCT01083771|DIETARY_SUPPLEMENT|Olive Oil|Minimum of 3 tablespoon of olive oil per day
57781335|NCT04612049|DEVICE|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
57781336|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
57781337|NCT06739837|DIAGNOSTIC_TEST|traditional physiotherapy|Participants in this arm will undergo traditional physiotherapy exercises for managing tennis elbow.
57781338|NCT06739837|COMBINATION_PRODUCT|Non-immersive VR therapy|Participants undergo a VR-based rehabilitation program targeting tennis elbow symptoms. Sessions last 30 minutes, conducted 3 times per week for 6 weeks. Exercises focus on improving grip strength, wrist flexibility, and functional movement through interactive VR environments that visually engage the affected arm, promoting adherence and motivation without full immersion. The VR setup includes headsets or screens that enable visual interaction, enhancing the rehabilitation experience. The goal is to alleviate pain, increase range of motion, and restore muscle strength.
57781339|NCT06287463|DRUG|DCC-3084|Administered orally
57781340|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
57781341|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
57781342|NCT02523040|DRUG|Lenalidomide|
57781343|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
57781344|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
57781345|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
57781346|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
57781347|NCT04969835|DRUG|AVA6000|AVA6000 is a FAP-activated doxorubicin.
57781348|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
57781349|NCT06408298|DRUG|Placebo|Inactive tablet
57781350|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
57781351|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
57781352|NCT06461013|BEHAVIORAL|Blood flow restriction|A common clinical tourniquet (7cm \* 50cm in size) is placed in the middle section of the patient's thigh on the affected side, connected to a pressure gauge, observed and gradually pressurized to 160-170mmHg for about 10 minutes, then depressurized for 1 minute, and then re pressurized to 160-170mmHg. Each training session lasts for 20 minutes, once a day, five times a week, for a total of 8 weeks.
57781353|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
57781354|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
57781355|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
57781356|NCT06539741|DRUG|Ibuprofen 400 mg|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
57781357|NCT06539741|DRUG|Acetaminophen 500mg|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
57781358|NCT06539741|DRUG|OxyCODONE 5 mg Oral Tablet|5 mg by mouth every 6 hours as needed for pain
57781359|NCT05443347|BEHAVIORAL|Aerobic exercise|Supervised aerobic exercise
57781360|NCT05443347|BEHAVIORAL|Newsletter|Biweekly newsletter
57781361|NCT06610032|PROCEDURE|Mesotherapy|A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.
57781362|NCT06610032|PROCEDURE|Intra-articular steroid injection|Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
57781363|NCT05250804|OTHER|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
57781364|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
57781365|NCT04493034|BEHAVIORAL|Art Therapy|"The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health."
57785251|NCT05121675|BEHAVIORAL|Neuroflow app: Mental health and wellbeing resources for adults|"The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app."
57781366|NCT04493034|BEHAVIORAL|Music Therapy|"Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study."
57781367|NCT06734819|BEHAVIORAL|Storytelling Video|The Living Donation Storytelling Project (LDSP) is an online video library of living donation first-person narratives aiming to inspire more people to consider LDKT (https://livingdonationstories.org/).17 As of 2020, the library has 118 stories from living donors and kidney recipients sharing their experiences with the pursuit, challenges and outcomes of transplant.18,19 Four videos were selected from the LDSP and edited to standardized duration and thematic content. Videos were cut to three minutes in length and covered the topics of 1) challenges faced when seeking LDKT, 2) life after LDKT and 3) advice for other patients considering LDKT.
57781368|NCT06734819|BEHAVIORAL|Standard Patient Education|Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.
57781369|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
57781370|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
57781371|NCT06072807|DIAGNOSTIC_TEST|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
57781372|NCT06735079|DRUG|NMDA receptor antagonist (active drug)|"REL-1017 is an investigational drug administered as an oral tablet, providing a convenient option for daily treatment. The dosing regimen includes a 75 mg initiation dose on Day 1 under clinical supervision, followed by a 25 mg maintenance dose daily at home from Days 2 to 28, over a total 4-week treatment period, with regular safety, efficacy, and tolerability assessments.~REL-1017 stands out as a selective NMDAR antagonist, offering a rapid onset of action for faster relief of depressive symptoms compared to traditional antidepressants. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression.~With a favorable safety profile and minimal risk of psychotomimetic effects (e.g., hallucinations), REL-1017 is more accessible than intravenous treatments like ketamine. Its lower daily dose (25 mg) ensures sustained therapeutic effects while maintaining tolerability"
57781373|NCT06735079|DRUG|Placebo|"The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD)."
57781374|NCT06529094|BEHAVIORAL|Provider training|Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.
57781375|NCT06529094|BEHAVIORAL|CAPP-FIT intervention with RA facilitation|After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.
57781376|NCT06529094|BEHAVIORAL|CAPP-FIT implementation during maintenance phase|Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
57781377|NCT06740292|DEVICE|conventional miniplates|conventional miniplates in double configuration
57781378|NCT06740292|DEVICE|InterFlex plates|InterFlex plates in configuration
57781379|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
57781380|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
57781381|NCT05006716|DRUG|BGB-16673|Orally administered
57781382|NCT01807143|OTHER|laboratory biomarker analysis|Correlative studies
57781383|NCT04742205|DRUG|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
57781384|NCT06630325|DRUG|Abemaciclib|Given PO
57781385|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
57781386|NCT06630325|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781387|NCT06630325|PROCEDURE|Bone Scan|Undergo bone scan
57781388|NCT06630325|DRUG|Carboplatin|Given IV
57781389|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
57781390|NCT06630325|DRUG|Exemestane|Given PO
57781391|NCT06630325|DRUG|Fulvestrant|Given IM
57781392|NCT06630325|DRUG|Gefitinib|Given PO
57781393|NCT06630325|DRUG|Gemcitabine|Given IV
57781394|NCT06630325|DRUG|Letrozole|Given PO
57781395|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57781396|NCT06630325|DRUG|Olaparib|Given PO
57781397|NCT06630325|DRUG|Osimertinib|Given PO
57781398|NCT06630325|DRUG|Paclitaxel|Given IV
57781399|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
57781400|NCT06630325|DRUG|Pemetrexed|Given IV
57781401|NCT06630325|OTHER|Survey Administration|Ancillary studies
57781402|NCT06630325|DRUG|Tamoxifen|Given PO
57781403|NCT06630325|DRUG|Temozolomide|Given PO
57781404|NCT05780723|DRUG|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
57781405|NCT05780723|DRUG|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
57781406|NCT06373497|DIAGNOSTIC_TEST|18-F-NaF Cardiac PET/MRI and|All eligible subjects will receive 18-F-NaF Cardiac PET/MRI at baseline and 6 months after the completion of radiotherapy where the heart is in the treatment field
57781407|NCT06373497|DIAGNOSTIC_TEST|CT Angiogram|All eligible subjects will receive CT Angiogram at baselin
57781408|NCT06580587|DRUG|MK-8527|Oral administration
57781409|NCT05679921|DRUG|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
57781410|NCT06364319|DRUG|anti-CD25 rhMAb|1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
57781411|NCT06364319|DRUG|Prednisone|Maintain pre-screening dose
57781412|NCT06364319|DRUG|Ruxolitinib|10mg, BID PO
57781413|NCT06364319|DRUG|Cyclosporine|1.25mg/kg, BID PO/IV, target:150-250ng/ml
57781414|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
57781415|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
57781416|NCT03498079|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
57781417|NCT02021461|DRUG|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
57781418|NCT02021461|DRUG|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
57781419|NCT02021461|DRUG|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
57781420|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
57781421|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
57781422|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
57781423|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
57781424|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
57781425|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
57781426|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
57781427|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
57781428|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
57781429|NCT04842682|BIOLOGICAL|Late boost CD40 alone|CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
57781430|NCT04842682|BIOLOGICAL|Late boost CD40 adjuvanted|CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
57781431|NCT03869736|DRUG|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
57781432|NCT03869736|DRUG|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
57781433|NCT05499130|DRUG|TEV-48574|Subcutaneous infusion
57781434|NCT05499130|DRUG|Placebo|Matching Placebo
57781435|NCT05177523|DIAGNOSTIC_TEST|MRI|Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
57781436|NCT05177523|OTHER|Neurocognitive examination for healthy subjects|Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
57781437|NCT05177523|OTHER|blood sampling|Each enrolled subject will undergo a blood sampling (10 ml) at baseline
57781438|NCT06085625|BEHAVIORAL|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
57785252|NCT01720797|DEVICE|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
57781439|NCT06085625|BEHAVIORAL|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
57781440|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
57781441|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
57781442|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
57781443|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
57781444|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
57781445|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
57781446|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
57781447|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
57781448|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
57781449|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
57781450|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
57781451|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
57781452|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
57781453|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
57781454|NCT05082025|DRUG|Copanlisib|Given by IV
57781455|NCT05082025|DRUG|fulvestrant|Given by IM
57781456|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
57781457|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
57781458|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
57781459|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
57781460|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
57781461|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
58483714|NCT03461614|OTHER|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
57781462|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
57781463|NCT03817502|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
57781464|NCT03817502|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
57781465|NCT04495751|DIETARY_SUPPLEMENT|Muscadine grape extract|Four pills twice daily
57781466|NCT04495751|DRUG|Placebo|Four pills twice daily.
57781467|NCT04495751|OTHER|Quality of Life Assessment|Ancillary studies
57781468|NCT04495751|OTHER|Questionnaires|Ancillary studies
57781469|NCT04495751|OTHER|Participant Feedback|Ancillary studies
57781470|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
57781471|NCT05952024|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule of X.
57781472|NCT05952024|BIOLOGICAL|Rituximab|Patients will receive rituximab via IV infusion on Cycle 1 Day 15 and via SC injection on Day 1 of Cycle 2 through Cycle 8.
57781473|NCT06739980|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
57781474|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
57781475|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
57781476|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
57781477|NCT05229874|DRUG|carbon nanoparticles|Endoscopic injection
57781478|NCT05229874|DRUG|Indocyanine green|Endoscopic injection
57781479|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
57781480|NCT06726954|DEVICE|High-frequency real-time rTMS DLPF cortex protocol|It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
57781481|NCT06726954|DEVICE|High-frequency real-time rTMS M1 motor cortex protocol|It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
57781482|NCT06726954|DEVICE|Sham rTMS Protocol|It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
57781483|NCT05491343|DRUG|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
57781484|NCT05491343|DEVICE|Other|Follow up using US
57781485|NCT05658835|OTHER|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
57781486|NCT03418896|DRUG|human chorionic gonadotropin|a single injection of a standard dose
57781487|NCT06738823|PROCEDURE|INTERVENTION GROUP : TRAINING WITH WIIFIT|RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
57781488|NCT06738823|PROCEDURE|VESTIBULAR REHABILITATION TRAINING|WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
57781489|NCT02907554|DRUG|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
57781490|NCT02907554|DRUG|Placebo|control group receives a placebo
57781491|NCT06739590|BEHAVIORAL|Learning with CT scans|The average performance improvement in this group will serve as the baseline for learning achievable through conventional CT and MR imaging alone.
57781492|NCT06739590|BEHAVIORAL|Learning with 3D visualization models|Learning anatomical structures using three-dimensional visualization models displayed on a computer.
57781493|NCT06739590|RADIATION|Learning with 3D-MR visualization models|Viewing and manipulating 3D visualization models to learn anatomical structures using the MR headset.
57781494|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
57781495|NCT06739681|OTHER|Routine Intervention|These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.
57781496|NCT06739681|OTHER|Mental Imagery Intervention|Mental Imagination will be done with Recording Audio. An audio recording will last 5 minutes. The audio recording will be listened to 3 times in one session. The total visualization session will last 15 minutes in a dark and quiet room.
57781497|NCT06739681|OTHER|Breathing Exercise Intervention|Participants participating in Pranayama training will practice in a comfortable position in a quiet room at a temperature of 25 ± 2°C. The slow pranayama technique chosen is alternate nasal breathing (Nadishodhana Pranayama).
58483715|NCT03461614|OTHER|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
57781498|NCT06730958|DIAGNOSTIC_TEST|serum Follistatin-like protein 1|Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
57781499|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
57781500|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781501|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
57781502|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
57781503|NCT06249984|OTHER|Survey Administration|Ancillary studies
57781504|NCT04090398|PROCEDURE|Biospecimen Collection|Correlative studies
57781505|NCT04090398|PROCEDURE|Bone Scan|Undergo bone scan
57781506|NCT04090398|PROCEDURE|Computed Tomography|Undergo CT scan
57781507|NCT04090398|OTHER|Electronic Health Record Review|Ancillary studies
57781508|NCT04090398|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57781509|NCT04090398|DRUG|Paclitaxel|Given IV
57781510|NCT04090398|RADIATION|Radium Ra 223 Dichloride|Given IV
57781511|NCT04090398|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
57781512|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
57781513|NCT06736730|BEHAVIORAL|Hospital-Linked Violence Intervention Program|Activation of Operation Good, our community partner with a history of direct violence interruption in the streets and longitudinal health and wellness services to firearm injured patient (i.e. linking and aiding those who have suffered from violent injury to mental healthcare, job services, educational services)
57781514|NCT06736730|BEHAVIORAL|Mobile Community Event Support|A menu of services provided to the community in an activated cluster where funding will be provided to assist that community in holding events that support overall health and wellness (community clean-up, legal advisory services, pop-up clinic for blood pressure checks).
57781515|NCT06736730|BEHAVIORAL|Unrestricted Cash Assistance|A participant in an activated cluster after firearm injury will receive two disbursements of 500$. One at the time of initial hospital evaluation and a second disbursement \~1 month later to offset the financial burden associated with firearm injury on the individual.
57781516|NCT02928094|BIOLOGICAL|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
57781517|NCT02928094|BIOLOGICAL|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
57781518|NCT05656105|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
57781519|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
57781520|NCT02275416|DRUG|Ipilimumab|
57781521|NCT02275416|BIOLOGICAL|UV1 vaccine|
57781522|NCT02275416|BIOLOGICAL|GM-CSF|
57781523|NCT05876377|BIOLOGICAL|Pfizer-BioNTech COVID-19 mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
57781524|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
57781525|NCT06739382|COMBINATION_PRODUCT|extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.
57781526|NCT06739382|COMBINATION_PRODUCT|two β-lactam antibiotics plus a single non-β-lactam antibiotic|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients
57781527|NCT06739382|OTHER|Control group received standard therapy|Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
57781528|NCT06728085|BEHAVIORAL|Baseline Assessment For Mother-Daughter Day HPV Campaign|"Pre-Implementation:~Identify, screen, and enroll mother-daughter dyads in the study to participate in the upcoming Mother-Daughter Day event on HPV vaccination and screening.~Complete baseline surveys with enrolled participants. Distribute reminder cards and send text messages to mother-daughter dyads who agree to participate in the mother-daughter day campaign."
57781529|NCT06728085|BEHAVIORAL|Implement Mother-Daugther Day HPV Campaign|"Tailor and adapt to context: Mother-Daughter Day campaigns will be tailored and adapted to the local contexts within the 18 LGA.~Trained community health workers will implement the tailored Mother-Daughter Campaign by providing education on cervical cancer control and educational materials on HPV vaccination and HPV screening.~Engage mothers and daughters with on-site access to services: This includes offer of onsite vaccinations to girls by study nurse as well as offer of onsite self-collection screening kits to mothers and caregivers in a private area, along with instructions on how to use and return the sample.~Distribute gift bags with HPV vaccination cards, follow-up reminders, and linkage cards for participants with positive test results, as community health workers continue to provide onsite support and assistance."
57781530|NCT06728085|BEHAVIORAL|Post-Implementation Follow-Up|"A follow-up invitation will be sent to participate in a consultative phone call with study health workers to review self-collection results.~Participants with positive HPV test results will be linked to follow-up care and treatment."
57781531|NCT05325866|DRUG|Bemarituzumab|Intravenous (IV) infusion.
57781532|NCT05773781|OTHER|PuraBond|Application of PuraBond to surgical field
57781533|NCT03656549|DRUG|Pemetrexed + oral folinic acid rescue|3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
57781534|NCT05748600|DRUG|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
57781535|NCT05748600|DRUG|Placebo|administration of placebo tablet
57781536|NCT06062576|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
57781537|NCT00632710|OTHER|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
57781538|NCT00632710|OTHER|phototherapy placebo|disconnected laser (same device - experimental group)
57781539|NCT06649006|DRUG|Blinatumomab|IV infusion
57781540|NCT06184256|BEHAVIORAL|BfedBwell - Core Curriculum|12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
57781541|NCT06184256|BEHAVIORAL|BfedBwell - 1:1 Counseling|Individual 1:1 counseling sessions with a registered dietitian
57781542|NCT06184256|BEHAVIORAL|BfedBwell - Behavioral Skills|Group-based behavioral skills development sessions
57781543|NCT06184256|BEHAVIORAL|BfedBwell - Group Support|Structured group support sessions
57781544|NCT06184256|BEHAVIORAL|Program delivery|Delivery and evaluation of one or more intervention components
58483716|NCT03229785|BIOLOGICAL|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
57781545|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
57781546|NCT06319222|OTHER|DALC Digital Clinic|Providers randomized to the intervention arm will be able to refer their patients with ALD, to the DALC in addition to standard of care. Patients with providers randomized to the intervention arm will be consented by the study team. After appropriate consent, the referred patients will be instructed by our study team to download the RTP application in their smart devices (smartphones or tablets).
57781547|NCT05141487|DEVICE|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
57781548|NCT05141487|DEVICE|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
57781549|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
57781550|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
57781551|NCT06050252|PROCEDURE|Biopsy|Undergo tissue biopsy
57781552|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781553|NCT06050252|DRUG|Cisplatin|Given IV
57781554|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
57781555|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
57781556|NCT06050252|DRUG|Gemcitabine|Given IV
57781557|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
57781558|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
57781559|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
57781560|NCT05396625|BEHAVIORAL|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
57781561|NCT05396625|BEHAVIORAL|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention 'SAFE Children,' which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children (e.g., separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community). Each session lasts about one to one and a half hours and will be delivered by facilitator and co-facilitator at the SOS Child and Family Center.
57781562|NCT05396625|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
57781563|NCT05396625|OTHER|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
57781564|NCT05315167|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
57781565|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
57781566|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
58483717|NCT02154698|OTHER|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
58483718|NCT02154698|OTHER|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
57781567|NCT05519085|DRUG|mezigdomide|Specified dose on specified days
57781568|NCT05519085|DRUG|Pomalidomide|Specified dose on specified days
57781569|NCT05519085|DRUG|Bortezomib|Specified dose on specified days
57781570|NCT05519085|DRUG|Dexamethasone|Specified dose on specified days
58483719|NCT00735488|OTHER|Observational|Summary of data
58483720|NCT04773535|DEVICE|3D Motion analysis|Motion analysis using DyCare® Lynx system with inertial based sensors as well as an optoelectronic motion analysis system based on infrared cameras (11x Vicon infrared high speed cameras)
57781571|NCT05376267|DEVICE|Therapeutic Hypothermia|"Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours."
57781572|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
57781573|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
57781574|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
57781575|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
57781576|NCT06729775|OTHER|Data report back preference by life span|Data report back preference by life span.
57781577|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
57781578|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
57781579|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
57781580|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
57781581|NCT05918328|DRUG|Albumin paclitaxel+trastuzumab+pyrrolitinib|Albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (320mg, QD), one cycle every 21 days.
57781582|NCT05918328|DRUG|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
57781583|NCT06232902|DRUG|QL1101|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
57781584|NCT06232902|DRUG|Avastin®|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
57781585|NCT06738381|BEHAVIORAL|Digital intervention and motivational counselling|A single sesstion of motivational interviewing and access to a digital plattform for a six months period
57781586|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
57781587|NCT05268887|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
57781588|NCT05268887|DEVICE|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
57781589|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
57781590|NCT04772989|DRUG|AB308|Administered intravenously (IV) as specified in the treatment arm
57781591|NCT04772989|DRUG|Zimberelimab|Administered IV as specified in the treatment arm
57781592|NCT06720961|PROCEDURE|Collection of surgical specimen|Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
57781593|NCT06720961|PROCEDURE|Collection of stool sample|One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
57781594|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
57781595|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
57781596|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
57781597|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
57781598|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
57781599|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
57781600|NCT06083948|DRUG|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
57781601|NCT06083948|DRUG|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
57781602|NCT06257277|DRUG|GBCAs|GBCAs are given per routine clinical practice.
57781603|NCT06474182|PROCEDURE|Blood sampling|Blood sampling
57781604|NCT06474182|DRUG|Apixaban|Treatment by Apixaban
58483721|NCT06118398|DRUG|Intravenous methylprednisolone (IVMP) and Efgartigimod|IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
58483722|NCT06118398|DRUG|IVMP|IVMP 800-1000mg/day for 3-5 days.
57781605|NCT06737731|DRUG|SHR-1681|SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
57785253|NCT01720797|DRUG|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
57785254|NCT01720797|OTHER|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
58483723|NCT00722306|DRUG|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
57781606|NCT05039554|BEHAVIORAL|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
57781607|NCT05039554|OTHER|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
57781608|NCT05039554|OTHER|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
57781609|NCT04507841|DRUG|Niraparib|Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
57781610|NCT06736821|DIETARY_SUPPLEMENT|Open sinus augmentation with melatonin gel mixed with xenograft|"All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors"
57781611|NCT06736821|PROCEDURE|Open sinus augmentation with xenograft|All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
57781612|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
57781613|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
57781614|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
57781615|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
57781616|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
57781617|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
57781618|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
57781619|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
57781620|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
57781621|NCT05359731|DRUG|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
57781622|NCT05359731|DRUG|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
57781623|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
57781624|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
57781625|NCT04974099|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
57781626|NCT04974099|DRUG|Precision dosing with a dashboard|The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
57781627|NCT06739291|DRUG|SIGX1094R|Single drug treatment by SIGX1094R, orally administered once daily.
57781628|NCT02723591|DRUG|Tacrolimus|Oral Capsule
57781629|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
57781630|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
57781631|NCT06474169|OTHER|1 blood sample for each participant|"Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)"
57781632|NCT00170573|DRUG|Caelyx|40 mg/m² biweekly
57781633|NCT03677128|OTHER|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
57781634|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
58483724|NCT04259996|PROCEDURE|PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT|The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
58483725|NCT05019911|DEVICE|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
57781635|NCT06738992|DRUG|Aspirin|Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
57781636|NCT06738992|DRUG|Warfarin|Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
57781637|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
57781638|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
57781639|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
57781640|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
57781641|NCT06739954|COMBINATION_PRODUCT|Mulligan's Two Leg Rotation technique|The participants will undergo Mulligan's Two Leg Rotation technique, performing 10 repetitions with a 30-second hold for each repeat. There will be a 1-minute rest period between each stretch. The therapist positions themselves on the affected side of the supine patient lying on the treatment table and holds onto the side of the table with their hand on the opposite side. Both legs will be bent so that the feet are raised from the plinth. Maintaining the subject's shoulders on the bed, he gradually moves the subject's legs to the side, considering the restricted flexibility of the hamstring muscles. Once the patient reaches their maximum, the therapist applies extra pressure to sustain the posture for 30 seconds. Then, the legs are lowered to the plinth. A 1-minute interval was provided between each stretch, and the stretches were performed for a total of 10 repetitions. The identical technique is performed on the opposite side to address insufficient flexibility in the hamstrings.
57781642|NCT06739954|DIAGNOSTIC_TEST|Dry Needling|The DN technique, based on previous research, involved slowly inserting and removing the needle in the muscle or tendon to elicit a specific response. This response could be a local twitch, a dull ache, a feeling of heaviness or distension, or the reproduction of the participant's symptoms. The needle is manipulated in and out of the targeted tissue five times every five minutes for a total of fifteen minutes. After the treatment, sterile gauze is applied and pressed on the DN site, and sterile non-stick pads are used to cover the treated areas. The number of needles used varied depending on the participant's condition. The knee muscles that will be included in the dry needling intervention are the Quadriceps and Hamstrings .
57781643|NCT05226663|PROCEDURE|Computed Tomography|Undergo \[18F\]FFT PET/CT
57781644|NCT05226663|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
57781645|NCT05226663|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FFT PET/CT
57781646|NCT04551703|DRUG|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
57781647|NCT04953884|DRUG|wilate|wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
57781648|NCT04056728|BIOLOGICAL|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
57781649|NCT06734975|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
57781650|NCT06734975|DRUG|Superior laryngeal nerve block - Placebo (saline)|Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
57781651|NCT04447989|DRUG|Sildenafil|Sildenafil citrate injection or powder for suspension
57781652|NCT04447989|DRUG|Placebo|dextrose 5%
57781653|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
57781654|NCT05294731|DRUG|BGB-16673|Orally administered
57781655|NCT04716881|DRUG|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
57781656|NCT05211869|BEHAVIORAL|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
57781657|NCT06738550|DIETARY_SUPPLEMENT|inulin|In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided
57781658|NCT06738550|DRUG|Lactulose oral solution|In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
57781659|NCT05307900|OTHER|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
57784643|NCT04368195|PROCEDURE|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
58483726|NCT05019911|DEVICE|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
57781660|NCT06738290|BEHAVIORAL|Targeted home-based touchscreen training|Participants will practice the Swipe-Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants perform different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 min. per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. Feedback will be provided during the rest periods.
57781661|NCT06612268|DRUG|Etavopivat|Etavopivat will be administered orally.
57781662|NCT06612268|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
57781663|NCT05513001|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
57781664|NCT05513001|DRUG|Placebo|Placebo
57781665|NCT05513001|DRUG|LOU064 (open label)|LOU064 (open-label) active treatment
57781666|NCT06578455|DRUG|Cannabidiol (CBD) Powder|66.68 mg CBD per capsule for a total of 400 mg CBD per serving
57781667|NCT06578455|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|100 mg CBD/mL for a total of 400 mg CBD per serving
57781668|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
57781669|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
57781670|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
57781671|NCT05639348|OTHER|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
57781672|NCT06297265|OTHER|Lymphedema Management|Undergo MLD breast massage
57781673|NCT06297265|OTHER|Questionnaire Administration|Ancillary studies
57781674|NCT06297265|RADIATION|Adjuvant breast radiation therapy|Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.
57781675|NCT01351545|DRUG|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
57781676|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
57781677|NCT06232109|DRUG|Fluvoxamine|Oral
57781678|NCT06232109|DRUG|Itraconazole|Oral
57781679|NCT06232109|DRUG|Paroxetine|Oral
57781680|NCT06232109|DRUG|ASN51|Oral
57781681|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
57781682|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
57781683|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
57781684|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
57781685|NCT06716645|DRUG|Robitussin Maximum Strength Nighttime Cough DM|Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
57781686|NCT03806296|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning
57781687|NCT03806296|OTHER|Decrease evening blue light|Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
57781688|NCT03806296|BEHAVIORAL|Sleep scheduling|Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
57781689|NCT03806296|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
57781690|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
57781691|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
57781692|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
57784644|NCT00657111|DRUG|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
57781693|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
57781694|NCT05220033|OTHER|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
57781695|NCT05220033|OTHER|survey administration|Ancillary studies
57781696|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
57781697|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
57781698|NCT06740760|BEHAVIORAL|Genetic counselling|Behavioral: genetic counselling
57781699|NCT06740760|BEHAVIORAL|Leaflet|Genetic information as a form of a leaflet
57781700|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
57781701|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
57781702|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
57781703|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
57781704|NCT06400472|DRUG|LY4170156|Intravenous
57781705|NCT06183684|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
57781706|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
57781707|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
57781708|NCT03618550|DRUG|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
57781709|NCT03618550|DRUG|gemcitabine|1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
57781710|NCT03618550|DRUG|vinorelbine|20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
57781711|NCT03618550|DRUG|liposomal doxorubicin|15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
57781712|NCT03618550|PROCEDURE|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
57781713|NCT06737198|OTHER|without interventios.|without interventios.
57781714|NCT05252754|DRUG|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
57781715|NCT05252754|DRUG|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
57781716|NCT05252754|DRUG|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
57781717|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
57781718|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
57781719|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
57781720|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
57781721|NCT04478643|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus Reuteri|Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
57781722|NCT04478643|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
58483727|NCT05741671|OTHER|Questionnaire|Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
58483728|NCT02233361|BEHAVIORAL|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
57781723|NCT06696443|DRUG|Suzetrigine|Tablets for oral administration.
57781724|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
57781725|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
57781726|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
57781727|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
58483729|NCT00998296|DRUG|BIBW 2992|EGFR inhibitor
58483730|NCT00998296|DRUG|BIBF 1120|VEGF inhibitor
57781728|NCT03786016|BEHAVIORAL|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
57781729|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
57781730|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
57781731|NCT06740240|DRUG|68Ga-FAPI-Biotin|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
57781732|NCT06740240|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
57781733|NCT06738810|DIAGNOSTIC_TEST|Fibrotest-actitest/NASHtest|A blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest and to calculate the NAFLD fibrosis score
57781734|NCT04781231|DEVICE|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
57781735|NCT04781231|DEVICE|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
57781736|NCT04781231|OTHER|Usual management of anxiety|No specific intervention
57781737|NCT06526286|OTHER|Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)|Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.
57781738|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
57781739|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
57781740|NCT04158648|DRUG|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
57781741|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
57781742|NCT03770273|BIOLOGICAL|sarilumab|Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.
57781743|NCT03770273|OTHER|Placebo|Placebo
57781744|NCT06738654|PROCEDURE|robot-surgery|Breast-conserving surgery for breast cancer using single-port robotic surgery.
57781745|NCT06738654|PROCEDURE|traditional open surgry|Breast-conserving surgery for breast cancer using traditional open surgery.
57781746|NCT06739538|DIAGNOSTIC_TEST|Bobath exercises|Bobath concept, are therapeutic techniques designed to improve motor control and function in individuals with neurological conditions, particularly those with cerebral palsy. These exercises focus on facilitating normal movement patterns, enhancing postural stability, and reducing muscle spasticity. The approach emphasizes individualized treatment, utilizing hands-on techniques to promote movement awareness and encourage the development of functional skills. By reinforcing weak movements and inhibiting overactive ones, Bobath exercises aim to enhance overall motor abilities and improve the quality of life for affected individuals.
57781747|NCT06739538|COMBINATION_PRODUCT|Gasotransmitters|such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small gaseous signaling molecules that play key roles in various physiological functions, including the regulation of muscle tone and neuroinflammation. In the context of spastic diplegic cerebral palsy (CP), gasotransmitters may help reduce spasticity and pain. Gasotransmitters help reduce spasticity and pain in children with spastic diplegic cerebral palsy through multiple mechanisms: Muscle relaxation and improved blood flow reduce muscle tightness, Anti-inflammatory and neuroprotective properties help minimize the damage that exacerbates spasticity.They also modulate pain pathways, both centrally and peripherally, reducing pain perception.
57781748|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
57781749|NCT06214156|BIOLOGICAL|T3011|T3011 will be given intratumorally， Q2W；
57781750|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
57781751|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
57781752|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
57781753|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.
57781754|NCT06046222|DRUG|NS-229|Experimental
57781755|NCT06046222|DRUG|Placebo|Placebo comparator
57784645|NCT00657111|OTHER|Placebo|placebo capsules containing 25 mg lactose
58483731|NCT02831972|DRUG|AG120|
58483732|NCT02831972|DRUG|Itraconazole|
58483733|NCT00087841|BEHAVIORAL|Self-hypnotic relaxation|
57781756|NCT06462443|BEHAVIORAL|RISE for Physicians Program|RISE for Physicians Program. Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
57781757|NCT06534502|DRUG|Zonisamide Oral Product|Zonisamide oral suspension
57781758|NCT06494488|DRUG|EPA|Fish oil
57781759|NCT06494488|DRUG|DHA|Fish oil
57781760|NCT04853251|DEVICE|SUSVIMO PDS Implant|The ranibizumab 100 mg/mL will be delivered via PDS
57781761|NCT04853251|DRUG|LUCENTIS (ranibizumab injection)|Ranibizumab (intravitreal 0.5-mg intravitreal injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.
57781762|NCT06056830|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
57781763|NCT03883945|DRUG|AIV001|intradermal injection
57781764|NCT03883945|DRUG|Vehicle|intradermal injection
57781765|NCT00434837|PROCEDURE|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
57781766|NCT06738043|DRUG|Dexmedetomidine infusion|A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
57781767|NCT06738043|DRUG|Ketamine infusion|A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
57781768|NCT06738043|DRUG|Normal Saline Infusion (Placebo)|A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
57781769|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
57781770|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
57781771|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
57781772|NCT05632562|DRUG|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
57781773|NCT05130450|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
57781774|NCT06420518|OTHER|Ketogenic diets|During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.
57781775|NCT06420518|OTHER|8-hour insulin-suspension period|Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.
57781776|NCT05394519|DRUG|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
57781777|NCT05394519|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
57781778|NCT05394519|DRUG|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
57781779|NCT05394519|DRUG|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
57781780|NCT02964611|BEHAVIORAL|Observational Study|This is an observational study.
57781781|NCT05577702|DRUG|Tislelizumab|Administered as an intravenous infusion
57781782|NCT05577702|DRUG|Ociperlimab|Administered as an intravenous infusion
57781783|NCT05577702|DRUG|LBL-007|Administered as an intravenous infusion
57781784|NCT05577702|DRUG|Cisplatin|Administered as an intravenous infusion
57781785|NCT05577702|DRUG|Carboplatin|Administered as an intravenous infusion
57781786|NCT05577702|DRUG|Pemetrexed|Administered as an intravenous infusion
57781787|NCT05577702|DRUG|Paclitaxel|Administered as an intravenous infusion
57781788|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
57781789|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
57784646|NCT01966536|PROCEDURE|CD133+ cells transplantation into ovarian artery of one ovary|
57784647|NCT01064583|OTHER|cocoa|dissolved in water twice-daily intervention
57784648|NCT03174795|DRUG|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
57781790|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
57781791|NCT04214418|DRUG|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
57781792|NCT04214418|DRUG|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
57781793|NCT04214418|DRUG|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
57781794|NCT06664957|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.
57781795|NCT06664957|OTHER|Placebo|Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
57781796|NCT06737146|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
57781797|NCT06427941|DRUG|BGB-B2033|Administered by intravenous infusion
57781798|NCT06427941|DRUG|Tislelizumab|Administered by intravenous infusion
57781799|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
57781800|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
57781801|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
57781802|NCT06741267|DEVICE|RBS|physicians control RBS
57781803|NCT06741267|DEVICE|AB|physician control automatic bronchoscopy
57781804|NCT06741267|DEVICE|ENB|physicians control electromagnetic bronchoscopy
57781805|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
57781806|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
57781807|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
57781808|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
57781809|NCT02698254|BIOLOGICAL|Bevacizumab|
57781810|NCT02698254|OTHER|Quality-of-Life Assessment|Ancillary studies
57781811|NCT02698254|RADIATION|Radiation Therapy|Undergo radiation therapy with conventional fractionation
57781812|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
57781813|NCT05882877|OTHER|Placebo|SC injection
57781814|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
57781815|NCT04585815|DRUG|Encorafenib|capsules
57781816|NCT04585815|DRUG|Binimetinib|tablets
57781817|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
57781818|NCT04585815|DRUG|Axitinib|tablets
57781819|NCT04585815|DRUG|SEA-TGT|solution in vials
57781820|NCT06444880|DRUG|Ubamatamab|Given by IV
57781821|NCT06444880|DRUG|Cemiplimab|Given by IV
57781822|NCT03443323|BEHAVIORAL|Organizational Skills Training - Tier 2 (OST-T2)|OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
57781823|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
57781824|NCT06705192|DRUG|VES001|"VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg."
57781825|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
57784649|NCT03174795|DRUG|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
58137178|NCT04366401|BEHAVIORAL|Prebiotic/Probiotic Dietary Modulation|"The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* - Underlying mental pathology, lifestyles and associated comorbidities~* - Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* - Water requirements.~* - Foodstuffs.~* - Description and justification of prescribed prebiotic and probiotic diet.~* - Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* - Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* - Feeding in particular situations."
58137179|NCT03264898|DEVICE|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
58137180|NCT02982408|DIETARY_SUPPLEMENT|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
58137181|NCT02982408|BEHAVIORAL|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
58137182|NCT02982408|BEHAVIORAL|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
58137183|NCT03642548|DRUG|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
58137184|NCT03642548|DRUG|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
58137185|NCT05996510|DEVICE|ultrasound|Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
58137186|NCT05612724|DEVICE|Testing for SARS CoV2 Antigen|Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
58137187|NCT04018339|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
58137188|NCT04018339|DRUG|Placebo|Capsules containing an inert placebo
58137189|NCT05039190|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
58137190|NCT05039190|DRUG|Placebo|Placebo Injection
58137191|NCT04970992|DRUG|DZ-002|DZ-002 Injection
58137192|NCT05352360|DIAGNOSTIC_TEST|Pilates Exercises|Exercises with Kinesio Taping
58137193|NCT05352360|DIAGNOSTIC_TEST|Muscle Energy Technique|Exercises with Kinesio Taping
58137194|NCT00185705|DRUG|Telmisartan|
58137195|NCT02498847|BEHAVIORAL|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication"
58483734|NCT04775628|PROCEDURE|Inferior glide humerus in GH joint|Supine inferior glide GH joint
58483735|NCT02535806|DRUG|Velcade|4 doses of study drug will be given.
58483736|NCT02535806|DRUG|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
58483737|NCT02535806|DRUG|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
58483738|NCT02535806|DRUG|Dexamethasone|Days 1-5 and 15-19
58483739|NCT02535806|DRUG|Mitoxantrone|Days 1 and 2
58483740|NCT02535806|DRUG|Vincristine|Days 1, 8, 15, 22
58483741|NCT02535806|DRUG|Pegaspargase|Days 3 and 17
58483742|NCT00261820|DRUG|tacrolimus|
58483743|NCT00261820|DRUG|mycophenolate mofetil|
57781826|NCT05004233|BIOLOGICAL|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
58483744|NCT00261820|DRUG|methylprednisolone|
58483745|NCT00261820|DRUG|prednisolone|
58483746|NCT00261820|DRUG|sirolimus|
58483747|NCT00970996|DRUG|Temozolomide|250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
57781827|NCT05004233|BIOLOGICAL|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
57784650|NCT02636881|PROCEDURE|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
58137196|NCT04406753|OTHER|Manual therapy techniques in C0-1 and C2-3 with cervical exercise|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
58137197|NCT04406753|OTHER|Cervical Exercise|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
58137198|NCT00535951|DRUG|LBH589|
58137199|NCT00000229|DRUG|Buprenorphine|
58137200|NCT00233597|DRUG|ferumoxytol or oral iron|
58137201|NCT03659006|BIOLOGICAL|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
58137202|NCT03184480|DRUG|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
58137203|NCT06485999|PROCEDURE|Biologically Oriented Preparation Technique|It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
58137204|NCT00932880|DRUG|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
58137205|NCT00932880|DRUG|Norvasc|10 mg dose (Pfizer, USA)
58137206|NCT01421030|PROCEDURE|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
58137207|NCT00071591|BEHAVIORAL|Functional Adaptation Skills Training (FAST)|
58137208|NCT05083221|BEHAVIORAL|Hear-Talk-Activity audiological program|The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
58483748|NCT00970996|DRUG|Abraxane|100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
58137209|NCT00059865|DRUG|gemcitabine hydrochloride|
58137210|NCT00059865|DRUG|pemetrexed disodium|
58137211|NCT05237310|DEVICE|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
58137212|NCT05237310|DEVICE|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
58137213|NCT05237310|DEVICE|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
58137214|NCT01726205|DRUG|Pregabalin and normal saline infusion, PRG|
58137215|NCT01726205|DRUG|Pregabalin and ropivacaine 02% infusion|
58137216|NCT01726205|DRUG|Placebo drug, normal saline infusion|
57781828|NCT05990426|BEHAVIORAL|FAST Intervention|"Participants will alternate fasting days (FAST) with unrestricted eating (OFF, or Feast) days, for one week surrounding the start of each chemotherapy cycle. The participants will fast for two consecutive days in the middle of the ADF week - the day prior to chemotherapy start date, and chemotherapy day 1 for each cycle. Participants will consume regular diet (OFF/Feast) during other days 5-18 of each cycle."
57781829|NCT06470659|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW
57781830|NCT02988960|DRUG|ABBV-927|Intravenous
57781831|NCT02988960|DRUG|ABBV-927|Intratumoral
57781832|NCT02988960|DRUG|ABBV-181|Intravenous
57781833|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
57781834|NCT06648759|DEVICE|Vagal Nerve Stimulator|The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.
58137217|NCT00704821|DRUG|PTC299|Oral
58137218|NCT00704821|DRUG|Docetaxel|Intravenous infusion
58483749|NCT00970996|DRUG|Cisplatin|20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
58483750|NCT00970996|BIOLOGICAL|Interleukin-2|9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
58483751|NCT00970996|BIOLOGICAL|Interferon alpha 2b|5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
58483752|NCT05747794|BIOLOGICAL|eftilagimod alpha|APC activator, MHC II agonist
58483753|NCT05747794|DRUG|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
58483754|NCT05747794|OTHER|placebo|placebo matching eftilagimod alpha
58483755|NCT03906019|PROCEDURE|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
58483756|NCT03906019|DIAGNOSTIC_TEST|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
58483757|NCT03906019|DIAGNOSTIC_TEST|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
58483758|NCT03352037|DIAGNOSTIC_TEST|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
58137219|NCT04154579|BEHAVIORAL|HeRe We Arts|Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
58137220|NCT04154579|BEHAVIORAL|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
58483759|NCT05652439|OTHER|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
58483760|NCT01140126|DRUG|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
58483761|NCT01164709|DRUG|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
58483762|NCT01164709|DRUG|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
58483763|NCT00541385|DRUG|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
58483764|NCT00541385|DRUG|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
58483765|NCT01792895|PROCEDURE|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
58483766|NCT01792895|PROCEDURE|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
58483767|NCT01792895|PROCEDURE|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
58483768|NCT04913077|OTHER|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
58483769|NCT02941601|DRUG|Necitumumab|Administered IV
58483770|NCT02941601|DRUG|Gemcitabine|Administered IV
58483771|NCT02941601|DRUG|Carboplatin|Administered IV
58483772|NCT04030910|OTHER|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
58483773|NCT00560352|DRUG|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
58483774|NCT00560352|DRUG|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD
58483775|NCT00560352|DRUG|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
58483776|NCT03830541|OTHER|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
58483777|NCT05298956|OTHER|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
58483778|NCT05105204|DEVICE|ArteVu|The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
58483779|NCT04740372|OTHER|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
58483780|NCT01699438|DRUG|Mesalazine|2400 mg q.d. for 8 weeks
58483781|NCT01699438|DRUG|Placebo|3 tablets q.d. for 8 weeks
58483782|NCT01921309|DEVICE|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
58483783|NCT01921309|DEVICE|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
58483784|NCT00000670|DRUG|Probenecid|
57781835|NCT06648759|DEVICE|Placebo Vagal Nerve Stimulator|The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
57781836|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
57781837|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
57781838|NCT05601440|OTHER|Observation|Monitoring arm
58483785|NCT00000670|DRUG|Zidovudine|
58483786|NCT00929695|DRUG|prednisone|immunosuppressive drug
58483787|NCT00929695|DRUG|methylprednisolone|immunosuppressive drug
58483788|NCT00929695|OTHER|questionnaire administration|Ancillary studies
58483789|NCT00460083|DRUG|Elidel(R) (pimecrolimus 1%)|
58483790|NCT00460083|DEVICE|EpiCeram(R) -ceramide based barrier repair cream|
58483791|NCT02765516|OTHER|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
58483792|NCT02765516|OTHER|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
58483793|NCT00555516|OTHER|EW02|"1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
58483794|NCT02327832|PROCEDURE|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
58483795|NCT02327832|DRUG|bone marrow-derived mesenchymal stem cells|
58483796|NCT02851472|DRUG|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
58483797|NCT02851472|DRUG|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
57781839|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
57781840|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
57781841|NCT05601440|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
57781842|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
57781843|NCT06448026|DRUG|Cemiplimab|Given by IV
57781844|NCT06448026|DRUG|Cetuximab|Given by IV
57781845|NCT06191263|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
58483798|NCT00148083|DRUG|Risperdal Consta (drug)|
58483799|NCT00148083|BEHAVIORAL|Social Skills Training|
58483800|NCT01850654|GENETIC|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
58483801|NCT01850654|GENETIC|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~* CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~* CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~* CRC study participants diagnosed with CRC \<50 years, regardless of tumor studies or family history~* CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
58483802|NCT01850654|BEHAVIORAL|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
58483803|NCT01850654|OTHER|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
58483804|NCT01850654|BEHAVIORAL|Questionnaire|
58483805|NCT01635153|DIETARY_SUPPLEMENT|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
58483806|NCT01635153|DIETARY_SUPPLEMENT|Micronutrient|Dar-vite Multivitamin
58483807|NCT05744817|BEHAVIORAL|Inspiratory muscle strength training|30 breaths/day against a set resistance
58483808|NCT05788159|DRUG|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
57781846|NCT06191263|DRUG|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
57781847|NCT06740643|PROCEDURE|intracanal reinforcement using short composite post|after pupectomy is done flowable composite will be applied 3mm intacanal to make a short compsite post before zircon crown aplicaction
57781848|NCT06740643|PROCEDURE|no intracanal reinforcement|no intracanal reinforcement using resin modified glass ionmer before zircon crown application
57781849|NCT05774678|RADIATION|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
57781850|NCT05774678|OTHER|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
57781851|NCT05669664|PROCEDURE|Biopsy|Undergo biopsy
57781852|NCT05669664|PROCEDURE|Biospecimen Collection|Undergo collection of blood
57781853|NCT05669664|PROCEDURE|Computed Tomography|Undergo CT
57781854|NCT05669664|DRUG|Darolutamide|Given PO
57781855|NCT05669664|DRUG|Leuprolide Acetate|Given IM
57781856|NCT05669664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57784651|NCT02636881|PROCEDURE|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
58483809|NCT05788159|DRUG|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
58483810|NCT00624182|BIOLOGICAL|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
58483811|NCT00624182|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
58483812|NCT04864093|DIAGNOSTIC_TEST|muscular ultrasound|respiratroy and muscular ultrasound
58483813|NCT04342533|PROCEDURE|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
58483814|NCT04342533|PROCEDURE|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
58483815|NCT02757508|DIETARY_SUPPLEMENT|protein powder supplement|
58483816|NCT02757508|DIETARY_SUPPLEMENT|Vitamins/minerals|
58483817|NCT01483261|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
58483818|NCT04955691|OTHER|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
58483819|NCT04955691|OTHER|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
58483820|NCT02975375|PROCEDURE|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
58483821|NCT02975375|PROCEDURE|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
58483822|NCT00274729|BEHAVIORAL|Mono Unsaturated Fatty Acids in Obesity|
58483823|NCT05097963|DEVICE|Endoscopic Ultrasound Shear Wave Elastography|Software to determine stiffness of liver for evaluating liver fibrosis.
58483824|NCT02955173|PROCEDURE|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
58483825|NCT01635504|BIOLOGICAL|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
58483826|NCT02183649|DRUG|pentoxyverine citrate|
57781857|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
57781858|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
58483827|NCT02183649|DRUG|Placebo|
58483828|NCT01267500|PROCEDURE|Non surgical therapy|patching or fusion exercises
58483829|NCT04295447|OTHER|Standard of care|"1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
57781859|NCT03964571|DIAGNOSTIC_TEST|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
57781860|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
57781861|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
58483830|NCT04295447|DRUG|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
58483831|NCT03418714|DRUG|Salvinorin A|Salvinorin A, blinded doses
58483832|NCT04477096|DRUG|HS-10234|HS-10234
58483833|NCT04477096|DRUG|Emtricitabine|Emtricitabine
58483834|NCT04187781|DEVICE|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
58483835|NCT06069375|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day
58483836|NCT02283827|DRUG|BIA 2-093|
58483837|NCT02283827|DRUG|Phenytoin|
58483838|NCT02592590|BEHAVIORAL|Group A|"This condition receives three study components:~1. The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~2. The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~3. The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
58483839|NCT02592590|BEHAVIORAL|Group B|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
58483840|NCT02592590|BEHAVIORAL|Group C|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
58483841|NCT02592590|BEHAVIORAL|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
58483842|NCT01173367|OTHER|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
58483843|NCT01173367|OTHER|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
58483844|NCT01838096|DEVICE|THA using 4th generation CoC|
58483845|NCT03181932|DRUG|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
58483846|NCT03181932|DRUG|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
58483847|NCT03181932|DRUG|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
58483848|NCT04152941|DRUG|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
58483849|NCT06029829|DRUG|Sintilimab|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
58483850|NCT03770767|DRUG|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
58483851|NCT03770767|DRUG|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
58483852|NCT00256568|BEHAVIORAL|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
58137221|NCT03799653|OTHER|No intervention|This is a prospective observational study, and there is no intervention.
58483853|NCT00905866|OTHER|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
58483854|NCT05682196|DRUG|Rituximab added to standard of care treatment|Rituximab with standard of care treatment
58483855|NCT05682196|DRUG|standard of care treatment alone|Standard of care treatment alone
58483856|NCT03004937|OTHER|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
58483857|NCT02027441|OTHER|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
58483858|NCT03366077|DIETARY_SUPPLEMENT|Probiotic|Probiotic
58483859|NCT03449290|OTHER|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
58483860|NCT03449290|OTHER|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
58483861|NCT01976091|GENETIC|SRP-9004|Isolated Limb Infusion (ILI)
58483862|NCT01755182|DRUG|approved pharmacologic therapy|
58483863|NCT01755182|PROCEDURE|TAE|after randomization, and after 3 months
58483864|NCT01065987|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
58483865|NCT02178345|PROCEDURE|diffusion weighted (DW) MRI|
58483866|NCT02178345|PROCEDURE|dynamic contrast agent (DCE) MRI|
58483867|NCT02607709|PROCEDURE|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
58483868|NCT02607709|PROCEDURE|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
58483869|NCT00951340|OTHER|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
58483870|NCT00951340|BEHAVIORAL|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
58483871|NCT00951340|BEHAVIORAL|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
58483872|NCT04840823|DRUG|Enoxacin|Oral 200mg tablet
58483873|NCT04840823|DRUG|Placebo|Oral tablet
58483874|NCT02102178|OTHER|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
57781862|NCT06706739|OTHER|Online art game intervention group|The researchers conducted a prospective randomized controlled trial in which elderly patients with mild cognitive impairment combined with subthreshold depression who met the inclusion exclusion criteria were randomized into an online art game intervention group and a health education control group, with each group receiving an individualized intervention for 12 weeks. Participants in the experimental group created comic strips through an art game platform developed by the researchers' research team.
57781863|NCT05728944|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
57781864|NCT05728944|DRUG|Aceclidine|Aceclidine ophthalmic solution
57781865|NCT05728944|DRUG|Vehicle|Proprietary vehicle ophthalmic solution
57781866|NCT06737692|OTHER|Exercise|"Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises."
57781867|NCT06015282|BIOLOGICAL|Investigational aQIVc|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
57781868|NCT06015282|BIOLOGICAL|licensed QIV1|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
57781869|NCT06015282|BIOLOGICAL|licensed QIV2|Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
57781870|NCT03958565|BIOLOGICAL|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
57781871|NCT03958565|DRUG|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
57781872|NCT03958565|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
57781873|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
57781874|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
57781875|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
57781876|NCT05727670|PROCEDURE|exposure of the tooth crown|surgical exposure of the crown of a retentive tooth
57781877|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
57781878|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
57781879|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
57781880|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
57781881|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
57781882|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
57781883|NCT06739161|RADIATION|Sintilimab combined with chemotherapy and local treatment|"Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable."
57781884|NCT06739161|COMBINATION_PRODUCT|Sintilimab combined with chemotherapy only|"Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."
57781885|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
57781886|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
57781887|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
57781888|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
57781889|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
57781890|NCT05022485|DEVICE|ZNN Bactiguard tibia|Tibia fracture fixation
57781891|NCT04975230|BEHAVIORAL|Sleep Self-Management|Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
57781892|NCT06739720|DRUG|LingZhi capsule|Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
57781893|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
57781894|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
57781895|NCT06609590|PROCEDURE|Glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block|Ultrasound guided anterior glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
57781896|NCT06609590|PROCEDURE|Interscalene brachial plexus block|Ultrasound guided interscalene brachial plexus block
57781897|NCT06734728|DEVICE|Profilm Cold Sores|The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
57781898|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
57781899|NCT05772104|DRUG|Shugan Jieyu Capsules Placebo|"Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
57781900|NCT06522165|OTHER|Analysis|analysis and review of imaging and clinical data
57781901|NCT05652205|DRUG|Linaclotide|Capsule; oral
57781902|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
57781903|NCT06741241|BEHAVIORAL|eHealth Promotora|Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
57781904|NCT06741241|BEHAVIORAL|eHealth Healthy Nutrition|Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
57781905|NCT06407063|PROCEDURE|Micro-decompression alone|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
57781906|NCT06407063|PROCEDURE|Decompression and instrumented fusion|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
57781907|NCT06740825|DRUG|Quizartinib|Single oral dose of 60 mg
57781908|NCT06740825|DRUG|Rufinamide|Twice daily (BID) dose of 400 mg on Days 1 through 32
58483875|NCT02102178|OTHER|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
57781909|NCT06028529|DEVICE|Exoskeleton|lightweight ground exoskeleton
57781910|NCT06701617|BEHAVIORAL|restorative visual rehabitation|black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
57781911|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (low dose)|Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
57781912|NCT06740149|DRUG|Solvent of CG-BM1|Administered intravenously, once a week for a total of 4 doses.
57781913|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (medium dose)|Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
57781914|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (high dose)|Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
57781915|NCT06738797|DIAGNOSTIC_TEST|SPHERTEST test|The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.
57781916|NCT06581627|DRUG|Etavopivat|2 tablets of Etavopivat will be administered in fasted state via oral route
57781917|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
57781918|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
57781919|NCT00686335|DRUG|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
57781920|NCT00686335|DRUG|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
57781921|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
57781922|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
57781923|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
57781924|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
57781925|NCT05737940|DRUG|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
57781926|NCT05737940|DRUG|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
57781927|NCT06729424|DEVICE|Digital patient education program|The education consists of 8 modules including main themes within osteoporosis, with content aiming to promote behavioural changes including psychoeducation and behavioural activation.
57781928|NCT03625323|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
57781929|NCT03625323|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
57781930|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
57781931|NCT06644261|DRUG|Bupivacaine injection|"Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks"
57781932|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
57781933|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
57781934|NCT06275815|OTHER|Sit Together and Read (STAR)|Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.
57781935|NCT06275815|BEHAVIORAL|Monetary Reward|Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).
57781936|NCT06275815|BEHAVIORAL|Text Encouragement|Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
57781937|NCT06644157|DEVICE|Laser Néo Élite|One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
57781938|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
57781939|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
57781940|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
57781941|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
57781942|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
57781943|NCT05457998|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
57781944|NCT05457998|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
57781945|NCT05457998|DIAGNOSTIC_TEST|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
57781946|NCT06649149|OTHER|Genially|In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
57781947|NCT06649149|OTHER|Education|In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
57781948|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
57781949|NCT05271409|DRUG|Satralizumab|Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
57781950|NCT05271409|OTHER|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
57781951|NCT06483204|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|Medrol tapered dosepak given to experimental arm patients to determine if there is a significant difference in pain, nausea, edema and ecchymosis outcomes in the postoperative period after a functional rhinoplasty procedure.
57781952|NCT06630234|DRUG|DCC-3009|Administered orally
57781953|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
57781954|NCT06215586|DRUG|Tovinontrine (CRD-750|Tablets administered orally
57781955|NCT06215586|DRUG|Placebo|Tablets administered orally
57781956|NCT06738485|BIOLOGICAL|Recombinant single-chain factor VIII (rVIII-SingleChain)|Lyophilized powder for solution for intravenous injection
57781957|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
57781958|NCT06094010|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
57781959|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
57781960|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
57781961|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
57781962|NCT05554367|DRUG|Binimetinib|Given PO
57781963|NCT05554367|PROCEDURE|Biopsy|Undergo biopsy
57781964|NCT05554367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57781965|NCT05554367|PROCEDURE|Bone Scan|Undergo bone scan
57781966|NCT05554367|PROCEDURE|Computed Tomography|Undergo CT
57781967|NCT05554367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57781968|NCT05554367|DRUG|Palbociclib|Given PO
57781969|NCT04666129|DRUG|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
57781970|NCT04666129|DRUG|Abiraterone|Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
57781971|NCT04666129|DRUG|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
57781972|NCT04666129|DRUG|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
57781973|NCT04666129|DRUG|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
57781974|NCT04666129|DRUG|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
57781975|NCT06211036|DRUG|Tarlatamab|Intravenous (IV) infusion
57781976|NCT06211036|DRUG|Durvalumab|IV infusion
57781977|NCT06049797|DRUG|Fezolinetant|Oral
57781978|NCT06049797|DRUG|Paroxetine|Oral
57781979|NCT06049797|DRUG|Citalopram|Oral
57781980|NCT06049797|DRUG|Escitalopram|Oral
57781981|NCT06049797|DRUG|Desvenlafaxine|Oral
57781982|NCT06049797|DRUG|Venlafaxine|Oral
57781983|NCT06049797|DRUG|Gabapentin|Oral
57781984|NCT06049797|DRUG|Clonidine|Oral
57781985|NCT06049797|DRUG|Pregabalin|Oral
57781986|NCT06049797|DRUG|Oxybutynin|Oral
57781987|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
57781988|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
57781989|NCT06736912|DRUG|IN-114199 2.5mg or placebo|IN-114199 2.5mg or placebo (1 Tablet, QD)
57781990|NCT06736912|DRUG|IN-114199 10mg or placebo|IN-114199 10mg or placebo (1 Tablet, QD)
57781991|NCT06736912|DRUG|IN-114199 20mg or placebo|IN-114199 10mg or placebo (2 Tablets, QD)
57781992|NCT06736912|DRUG|IN-114199 40mg or placebo|IN-114199 10mg or placebo (4 Tablets, QD)
57781993|NCT06736912|DRUG|IN-114199 5mg or placebo|IN-114199 2.5mg or placebo (2 Tablets, QD)
57781994|NCT03604978|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57781995|NCT03604978|PROCEDURE|Echocardiography|Undergo ECHO
57781996|NCT03604978|BIOLOGICAL|Ipilimumab|Given IV
57781997|NCT03604978|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
57781998|NCT03604978|BIOLOGICAL|Nivolumab|Given IV
57781999|NCT03604978|RADIATION|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
57782000|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
57782001|NCT06097650|OTHER|cold snare polypectomy|Histological analyses suggest that cold snare polypectomy causes less damage to blood vessels in the submucosal layers, which results in a reduced incidence of hemorrhage
57782002|NCT06097650|OTHER|hot snare polypectomy|Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
57782003|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
57782004|NCT05784740|OTHER|12-week precision exercise training|The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
57782005|NCT06170671|DRUG|Non interventional study|CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection
57782006|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
58483876|NCT02102178|OTHER|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
58483877|NCT02102178|OTHER|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
58483878|NCT01582893|DEVICE|HCO1100|Dialysis
58483879|NCT01582893|DEVICE|P210H|Dialysis
58483880|NCT04254380|BIOLOGICAL|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
58483881|NCT04254380|BIOLOGICAL|Humalog|Route of administration: subcutaneous injection
58483882|NCT06204198|OTHER|No intervention|No intervention
58483883|NCT01764880|DRUG|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
58483884|NCT04315740|OTHER|Particles from candles|Generating fine and ultrafine particles from lit candles
58483885|NCT04315740|OTHER|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
58483886|NCT04315740|OTHER|Clean Air|Nothing but clean air
58483887|NCT04836780|DRUG|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
58483888|NCT02129127|DEVICE|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
58483889|NCT05740501|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
58483890|NCT05740501|OTHER|Electronic Health Record Review|Medical records are reviewed
58483891|NCT05740501|OTHER|Questionnaire Administration|Ancillary studies
58483892|NCT02640287|BIOLOGICAL|Blood or bone marrow samples|
58483893|NCT04941677|OTHER|no intervention|no intervention in this study
58483894|NCT03869047|DRUG|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
58483895|NCT03869047|DRUG|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
58483896|NCT04754048|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
58483897|NCT02660372|DRUG|Imonogas|Simethicone 120 mg in gel capsules
58483898|NCT02660372|DRUG|Espumisan|Simethicone 40 mg in gel capsules
58483899|NCT06002724|OTHER||
58483900|NCT02253862|DRUG|Tadalafil|administered days 1, 8 and 16
58483901|NCT02253862|DRUG|Tipranavir|administered days 8-18
58483902|NCT02253862|DRUG|Ritonavir|administered days 8-18
58483903|NCT02342028|BIOLOGICAL|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
58483904|NCT02461758|BIOLOGICAL|Standard dose Influenza vaccine (SDIV)|
58483905|NCT02461758|BIOLOGICAL|High dose influenza vaccine (HDIV)|
58483906|NCT06212726|BEHAVIORAL|InjureFree|The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
58483907|NCT04609176|DRUG|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
58483908|NCT04609176|DRUG|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
58483909|NCT06286488|DRUG|Vaxigrip|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
58483910|NCT00198822|DIETARY_SUPPLEMENT|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
58483911|NCT03370432|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
58483912|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
58483913|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
58483914|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
58483915|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
58483916|NCT00105781|BEHAVIORAL|Exercise counseling|
58137222|NCT04873310|OTHER|Triple P online with professional support|The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
58483917|NCT05174403|OTHER|Cerebral and spinal cord magnetic resonance imaging|"Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium).~Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331)."
58483918|NCT00132704|RADIATION|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
58483919|NCT00132704|RADIATION|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
58483920|NCT01904994|PROCEDURE|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
58483921|NCT01904994|PROCEDURE|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
58483922|NCT01904994|BEHAVIORAL|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
58483923|NCT01904994|BEHAVIORAL|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
58483924|NCT01904994|OTHER|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
58483925|NCT02642016|BIOLOGICAL|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
58483926|NCT03773276|DRUG|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses."
58483927|NCT05133141|DEVICE|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
58483928|NCT02350140|OTHER|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
58483929|NCT02350140|OTHER|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
58483930|NCT02306317|OTHER|Standard procedure|FiO2 manually controlled by nursing
58483931|NCT02306317|OTHER|Experimental procedure|FiO2 manually controlled by parents, after training.
57782007|NCT05522868|DRUG|SB17170|SB17170 capsules, Oral administration 21days/cycle
58483932|NCT05647148|BEHAVIORAL|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
58483933|NCT01829906|BEHAVIORAL|Multidisciplinary outpatient programme|
58483934|NCT01829906|BEHAVIORAL|Inpatient lifestyle programme|
58483935|NCT00752349|PROCEDURE|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
58483936|NCT01886066|BIOLOGICAL|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
58483937|NCT01902095|DEVICE|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
58483938|NCT01902095|DEVICE|Tooth paste (control)|Active Comparator
58483939|NCT03891849|DRUG|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
58483940|NCT03586154|COMBINATION_PRODUCT|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
58483941|NCT03586154|DRUG|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
58137223|NCT04873310|OTHER|Triple P online without professional support|The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
58137224|NCT05818709|DEVICE|HAC 22L|Subcutaneous and/or Supraperiosteal injection
58137225|NCT00558857|DEVICE|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
58137226|NCT01033305|DRUG|CyCol™|Orally, once per day for 4 weeks
58137227|NCT01033305|DRUG|Placebo|Orally, once per day for 4 weeks
58137228|NCT01097993|OTHER|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
58137229|NCT01097993|OTHER|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
58137230|NCT02775357|BEHAVIORAL|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
58137231|NCT02775357|BEHAVIORAL|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
58137232|NCT01314417|DRUG|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
58137233|NCT01603862|PROCEDURE|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
58137234|NCT05752994|OTHER|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
58137235|NCT05752994|OTHER|Home program|Home program
57782008|NCT05008042|DRUG|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
58483942|NCT03455595|PROCEDURE|Endoscopic exams|Coloscopy
58483943|NCT00930046|DEVICE|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
58483944|NCT00930046|DEVICE|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
58483945|NCT06523920|DEVICE|University of Wisconsin solution + cold storage|Preservation of the free flap with UW solution and cold storage during ischemia time
58483946|NCT06523920|OTHER|Unperfused free flap under warm ischemia|Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time
58483947|NCT01241201|DIETARY_SUPPLEMENT|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
58483948|NCT00988728|DRUG|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
58483949|NCT00988728|DRUG|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
58483950|NCT00988728|DRUG|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
58483951|NCT04615832|DEVICE|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
58483952|NCT02870907|OTHER|Observation|no post operative chemotherapy
58483953|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
58483954|NCT02870907|DRUG|Vincristine|1, 5 mg/m²/d, IV at D1.
58483955|NCT02870907|RADIATION|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
58483956|NCT02870907|DRUG|Carboplatin|160 mg/m²/d, IV from D1 to D5.
58483957|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d, IV at D22 and D26
57782009|NCT05008042|OTHER|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
57782010|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
58483958|NCT02870907|DRUG|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
58483959|NCT02870907|DRUG|Carboplatin|560 mg/m²/d, IV at D1.
58483960|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV from D1 to D5
58483961|NCT02870907|DRUG|Carboplatin|160 mg/m²/d,IV from D1 to D5
58483962|NCT02870907|DRUG|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
58483963|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d), IV at D22
58483964|NCT02870907|DRUG|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
58483965|NCT02870907|PROCEDURE|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
58483966|NCT02870907|DRUG|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
58483967|NCT02870907|DRUG|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
58483968|NCT02870907|DRUG|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
58483969|NCT02870907|PROCEDURE|Peripheral bood stem cell transplantation|at D0
58483970|NCT00713518|DRUG|0.5 mg ranibizumab|
58483971|NCT00713518|DRUG|3 mg PF-04523655|
58483972|NCT00713518|DRUG|1 mg PF-04523655|
58483973|NCT05854238|DEVICE|TIRA-VoM|"treat persistent atrial fibrillation~* The ablation temperature range is 50-60℃~* About 2 minutes per ablation"
58483974|NCT02565108|DRUG|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
58483975|NCT02565108|DRUG|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
58483976|NCT02565108|DRUG|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
58483977|NCT03490695|OTHER|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
58137236|NCT06179056|DIAGNOSTIC_TEST|assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.|"Microbiological samples were collected from all patients for:~1. Isolation of C. acnes~2. Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~3. Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine"
58137237|NCT02258620|DRUG|dinitrate isosorbide|dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat
58137238|NCT02258620|DRUG|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
58483978|NCT03490695|OTHER|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
58483979|NCT03513939|COMBINATION_PRODUCT|Sernova Cell Pouch|"The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass, \>3,000 islet equivalent (IEQ) numbers per kg of patient body weight (IEQ/kg), of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 3 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter)."
58483980|NCT03543878|DEVICE|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
58483981|NCT02740023|DEVICE|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
58483982|NCT02740023|DEVICE|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
58483983|NCT04529018|COMBINATION_PRODUCT|[18F]CETO|\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
58483984|NCT02881606|DEVICE|Naso-alveolar molding (NAM)|
58483985|NCT02881606|DEVICE|Computer aided design NAM (CAD/NAM)|
58483986|NCT04287582|OTHER|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
58483987|NCT02832115|DRUG|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
58483988|NCT02832115|DRUG|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
58483989|NCT04605809|DEVICE|combined motor and cognitive training|The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.
58483990|NCT04605809|DEVICE|motor training alone|The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
58483991|NCT04605809|DEVICE|cognitive training alone|The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
58483992|NCT00427453|BIOLOGICAL|MVA85A|
58483993|NCT05437406|BEHAVIORAL|Parent-based treatment- All caregivers (PBT-AC)|PBT-AC provides all the elements of FBT, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
58483994|NCT05437406|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
58483995|NCT01519921|DRUG|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
58137239|NCT02185872|OTHER|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
58483996|NCT02475694|OTHER|No intervention|No treatment
58137240|NCT02185872|OTHER|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
58137241|NCT04547517|OTHER|Evaluation of Counselling competencies|To complete a set of questionnaires
58137242|NCT00862979|DRUG|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
58137243|NCT00862979|DRUG|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
58483997|NCT00654771|OTHER|urine collection|clean catch urine collection and catheterized urine collection
58483998|NCT00264732|DRUG|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
58483999|NCT00264732|DRUG|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
58484000|NCT00264732|OTHER|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
58484001|NCT05182749|BIOLOGICAL|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
58484002|NCT05182749|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
58484003|NCT04230811|DIAGNOSTIC_TEST|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
58484004|NCT02791672|BEHAVIORAL|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
58137244|NCT00862979|DRUG|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
58484005|NCT02073058|DEVICE|No treatment|
58137245|NCT00862979|DRUG|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
58484006|NCT01637441|PROCEDURE|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
58137246|NCT00862979|DRUG|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
58137247|NCT00862979|DRUG|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
58137248|NCT00639028|OTHER|Ankle echography|Ankle echography
58137249|NCT00639028|OTHER|Ankle echography + stress radiography|Ankle echography + stress radiography
58137250|NCT00639028|OTHER|stress radiography|ankle stress radiography
58137251|NCT03687515|DRUG|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
58137252|NCT03687515|DRUG|budesonide|nasal spray 256μg BID
58484007|NCT01637441|PROCEDURE|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
58137253|NCT03687515|DRUG|Prednisone|oral prednisone 24mg QD
58484008|NCT04125472|DRUG|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
58484009|NCT05380817|OTHER|Remote Monitoring Program|Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
58484010|NCT01039519|DRUG|Ganetespib|Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
58484011|NCT02434406|BEHAVIORAL|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
58484012|NCT03461588|RADIATION|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
58484013|NCT03461588|RADIATION|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
58484014|NCT05811286|PROCEDURE|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
58484015|NCT03963258|DEVICE|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
58137254|NCT02818842|OTHER|Primary Health Insurance Fund data|"Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date"
58484016|NCT03963258|OTHER|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
58484017|NCT00803569|BIOLOGICAL|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
58484018|NCT00803569|BIOLOGICAL|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
58484019|NCT06003894|OTHER|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
58137255|NCT02818842|OTHER|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
58137256|NCT02818842|OTHER|Mother and child protection data collection|"Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)"
58484020|NCT06003894|OTHER|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
58484021|NCT04921072|BEHAVIORAL|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
58484022|NCT04921072|BEHAVIORAL|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
58484023|NCT00843219|PROCEDURE|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
58484024|NCT04995952|BEHAVIORAL|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
58484025|NCT04995952|BEHAVIORAL|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
58137257|NCT02818842|OTHER|Medicalisation Program of Information Systems data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)"
58484026|NCT04855526|DRUG|High THC/No CBD Marihuana|high THC (65 mg THC) and no CBD (0 mg CBD)
58484027|NCT04855526|DRUG|High THC/High CBD Marihuana|high THC (65 mg THC) and high CBD (50 mg CBD)
57782011|NCT04306367|DRUG|Olaparib|300 mg given orally.
57782012|NCT05324371|DEVICE|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
58484028|NCT04855526|DRUG|No THC/No CBD Marihuana|no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
58484029|NCT01817270|BIOLOGICAL|Live Attenuated Varicella Vaccine|
58484030|NCT00712439|DRUG|Gabapentin Extended Release tablets|
58484031|NCT00712439|DRUG|Placebo|
58484032|NCT03310918|OTHER|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
58484033|NCT03310918|OTHER|Standard Leukemia care|Standard care per the hospital guideline
58484034|NCT02393378|DRUG|Namilumab|Namilumab injection
58484035|NCT02393378|DRUG|Adalimumab|Adalimumab SC injection
58137258|NCT03638739|OTHER|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
58484036|NCT02393378|DRUG|Methotrexate|Methotrexate tablet
58484037|NCT02393378|DRUG|Folic Acid|Folic Acid Tablet
58484038|NCT01391546|BIOLOGICAL|ZOSTAVAX|1 dose 0.65 mL
58484039|NCT02677883|OTHER|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
58484040|NCT02677883|OTHER|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
58137259|NCT04971226|DRUG|Imatinib|Comes in 100 mg and 400 mg tablets and taken orally
58137260|NCT04971226|DRUG|Nilotinib|Comes in 150 mg capsules and taken orally
58484041|NCT00919321|BIOLOGICAL|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
58484042|NCT06190704|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
58484043|NCT05654818|DRUG|Vitamin D|100,000 UI
58484044|NCT05654818|DRUG|Placebo|The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
58484045|NCT01378871|DRUG|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
58484046|NCT03352609|DEVICE|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
58137261|NCT04971226|DRUG|Bosutinib|Comes in 100 mg and 400 mg tablets and taken orally
58137262|NCT04971226|DRUG|Dasatinib|Comes in 70 mg and 100 mg tablets and taken orally
58137263|NCT04971226|DRUG|Asciminib|Comes in 40 mg tablets and taken orally
58137264|NCT01805934|DRUG|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
58484047|NCT03352609|DEVICE|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
58484048|NCT04200599|OTHER|duration of initiation of oxytocin|mode of delivery
58484049|NCT04623632|DRUG|Transversus abdominus plane block|transversus abdominus plane block using 40 ml of bupivacaine 0.25%
58484050|NCT04623632|DRUG|Transversus abdominus plane placebo|injection of 40 ml of normal saline in the transversus abdominus plane
58484051|NCT05484895|BEHAVIORAL|WeTest-WeLink|"WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST."
58484052|NCT05484895|BEHAVIORAL|Control condition|Contact information of local NGO for emergency referrals; free additional HST.
58484053|NCT04468984|DRUG|Navitoclax|Tablet; Oral
58484054|NCT04468984|DRUG|Ruxolitinib|Tablet; Oral
58484055|NCT04468984|DRUG|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
58484056|NCT01046708|DRUG|micronized progesterone|600mg in 3 separate doses per day
58137265|NCT01805934|DRUG|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
58137266|NCT01248247|DRUG|Erlotinib|150 mg by mouth each day of a 28 day cycle.
58137267|NCT01248247|DRUG|AZD6244|100 mg by mouth daily of a 28 day cycle.
58137268|NCT01248247|DRUG|MK-2206|100 mg by mouth every week of a 28 day cycle.
58137269|NCT01248247|DRUG|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
58137270|NCT01248247|DRUG|Erlotinib|150 mg by mouth daily of a 28 day cycle.
58137271|NCT01248247|DRUG|MK-2206|135 mg by mouth every week of a 28 day cycle.
58484057|NCT02198378|DRUG|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
58484058|NCT02198378|DRUG|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
58484059|NCT04327804|DIAGNOSTIC_TEST|Odd/Even birth year intervention groups|The nostril used and order of testing will be different in each arm.
58484060|NCT05211843|OTHER|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
58137272|NCT05246462|OTHER|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
58137273|NCT01944332|PROCEDURE|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
58137274|NCT03770598|BEHAVIORAL|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
58137275|NCT03770598|BEHAVIORAL|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
58484061|NCT05211843|OTHER|Apple juice|apple juice
58484062|NCT01035125|BEHAVIORAL|Self-management program|Participants will receive a one week inpatient self-management program
58137276|NCT03770598|BEHAVIORAL|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
58137277|NCT03770598|BEHAVIORAL|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
58137278|NCT00443716|DRUG|estrogen|
58137279|NCT00667095|DRUG|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
58484063|NCT04562428|DRUG|Xiang Sha Liu Jun Zi Decoction dry powder|the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
58137280|NCT00667095|DRUG|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
58484064|NCT04562428|DRUG|XSLJZ Placebo|XSLJZ Placebo
58137281|NCT00534443|PROCEDURE|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
58137282|NCT05502978|BEHAVIORAL|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
58137283|NCT02758665|DRUG|ibrutinib|
58137284|NCT02758665|DRUG|obinutuzumab|
58137285|NCT02758665|DRUG|venetoclax|
58137286|NCT03435081|DRUG|Baricitinib|Administered orally
58137287|NCT03435081|DRUG|Placebo|Administered orally
58137288|NCT00874887|DRUG|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
58137289|NCT00874887|DRUG|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
58137290|NCT00709566|BEHAVIORAL|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
58137291|NCT00709566|BEHAVIORAL|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
58484065|NCT02196636|DRUG|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
58484066|NCT02196636|DRUG|RO6806127|Administered orally with approximately 240 mL of buffer
58484067|NCT01702649|DRUG|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
58484068|NCT01702649|DRUG|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
58137292|NCT04083846|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
58137293|NCT04083846|DRUG|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
58137294|NCT04083846|DRUG|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
58137295|NCT01895296|DRUG|Pasireotide|somatostatin analogue pasireotide
58484069|NCT03403283|OTHER|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
58484070|NCT03403283|OTHER|Healthy Controls 15 age matched control subjects|
58484071|NCT05903768|OTHER|Mobilization|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)"
58484072|NCT05903768|OTHER|Cyriax capsular stretching|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times."
58484073|NCT04823247|DRUG|Tildrakizumab|As provided in real world clinical practice.
58484074|NCT05104177|PROCEDURE|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~* Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~* Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~* Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~* Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~* A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
58484075|NCT01088724|DRUG|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
58484076|NCT04899986|OTHER|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
58484077|NCT04899986|OTHER|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
58137296|NCT01895296|DRUG|Placebo|placebo s.c.
58137297|NCT03874871|PROCEDURE|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
58137298|NCT03874871|PROCEDURE|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
58137299|NCT05843279|PROCEDURE|Myofunctional therapy|In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
58137300|NCT03065582|OTHER|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
58137301|NCT03065582|OTHER|Topical Product B|topical application of product A without topical antioxidants
58137302|NCT03065582|OTHER|Topical Product C|Topical application of antioxidants only
58137303|NCT03065582|OTHER|Control|No product applied
58137304|NCT03966560|DRUG|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
58137305|NCT03966560|DRUG|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
58137306|NCT03966560|DRUG|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
58137307|NCT03966560|DRUG|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
58484078|NCT00425776|DEVICE|acupuncture|
58484079|NCT00425776|DEVICE|Sham acupuncture|
58484080|NCT02767414|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
58137308|NCT03966560|DRUG|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
58137309|NCT03966560|DRUG|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
58137310|NCT01909076|BEHAVIORAL|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
58137311|NCT01909076|BEHAVIORAL|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
58137312|NCT01909076|BEHAVIORAL|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
58484081|NCT02767414|DEVICE|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
58137313|NCT01909076|BEHAVIORAL|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
58484082|NCT02767414|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
58484083|NCT01166282|BIOLOGICAL|adalimumab|Adalimumab solution for subcutaneous injection.
58137314|NCT01909076|BEHAVIORAL|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
58137315|NCT02987491|BEHAVIORAL|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
58137316|NCT02137993|DRUG|A-prexa|A-prexa 5-20 mg for 6 weeks
58137317|NCT02137993|DRUG|Zyprexa|Zyprexa 5-20 mg for 6 weeks
58137318|NCT01270919|DEVICE|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
58137319|NCT03549364|BEHAVIORAL|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
58137320|NCT00567177|DRUG|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
58137321|NCT02624557|DRUG|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
58484084|NCT01166282|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
58484085|NCT01462370|DRUG|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
58484086|NCT01462370|DRUG|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
58137322|NCT04753710|DRUG|Ocular gel|Instillation
58137323|NCT02210390|BEHAVIORAL|Psycho education|Psycho-education Sessions will be offered weekly basis
58137324|NCT03571880|DEVICE|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
58137325|NCT04785677|BEHAVIORAL|Resiliency in Stressful Experiences (RISE) Program|The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
58137326|NCT01520909|DRUG|Eltrombopag|Thrombopoietin receptor agonist
58137327|NCT01520909|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
58137328|NCT01345045|DRUG|ABT-639|ABT-639 Twice Daily for six weeks.
58137329|NCT01345045|DRUG|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
58137330|NCT01345045|DRUG|Placebo|Placebo twice daily for 6 weeks.
58137331|NCT01689792|DRUG|MOVIPREP|
58137332|NCT01689792|DRUG|CitraFleet|
58137333|NCT03138330|OTHER|this study is observational, it is not an intervention|
58484087|NCT01462370|DRUG|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
58484088|NCT01462370|DRUG|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
58484089|NCT01462370|DRUG|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
58484090|NCT00353483|PROCEDURE|Peripheral blood draw|
58484091|NCT00353483|PROCEDURE|Breast tissue collection|
58484092|NCT00353483|PROCEDURE|Bone marrow biopsy|
58484093|NCT02596932|OTHER|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60mg/dL
58484094|NCT02596932|OTHER|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60 mg/dL
58484095|NCT03365089|PROCEDURE|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
58484096|NCT00804921|DRUG|bevacizumab|
58137334|NCT00354198|DRUG|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
58137335|NCT00354198|DRUG|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
58137336|NCT02666300|OTHER|TaperGuard ETT|tracheal intubation with TaperGuard ETT
58137337|NCT05807932|DRUG|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
58137338|NCT05807932|DRUG|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
58484097|NCT00804921|PROCEDURE|anterior chamber paracentesis|
58484098|NCT00804921|DRUG|acetazolamide|
58484099|NCT00804921|DRUG|brimonidine|
58484100|NCT01525069|DRUG|Floxuridine|
58484101|NCT01525069|DRUG|Dexamethasone|
58137339|NCT05807932|DRUG|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
58484102|NCT01525069|DRUG|Gemcitabine|
58484103|NCT01525069|DRUG|Oxaliplatin|
58484104|NCT04773106|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally used implanted during routine local intraocular pressure lowering procedures in patients in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
58484105|NCT03903237|OTHER|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
58484106|NCT04569487|PROCEDURE|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
58484107|NCT02444078|OTHER|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
58484108|NCT02444078|OTHER|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
58484109|NCT03570099|DRUG|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
58137340|NCT05807932|DRUG|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
58137341|NCT05807932|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
58484110|NCT03570099|OTHER|Historical control cohort|Historical data will be retrieved from quality registries.
58484111|NCT04355039|DRUG|Pomalidomide|4 mg Days 1-21
58484112|NCT04355039|DRUG|Dexamethasone|40 mg Days 1, 8, 15 and 22
58484113|NCT04355039|DRUG|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
58484114|NCT04355039|DRUG|INCB053914 65 mg BID|Dose level 1: 65 mg BID
58484115|NCT04355039|DRUG|INCB053914 80 mg BID|Dose level 2: 80 mg BID
58484116|NCT05796934|BEHAVIORAL|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
58484117|NCT06255431|DRUG|Ezerra cream|"The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen."
58484118|NCT02192489|DRUG|CC-220 0.3 mg Daily|
58484119|NCT02192489|DRUG|CC-220 0.6mg Daily|
57785255|NCT01270763|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
58484120|NCT02192489|DRUG|Placebo|
58484121|NCT00018083|DRUG|rifabutin|
58484122|NCT00018083|DRUG|isoniazid|
58484123|NCT00018083|DRUG|efavirenz|
58484124|NCT02668978|DEVICE|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
58484125|NCT02668978|PROCEDURE|Standard surgical technique|Lung resuturing or restapling
58484126|NCT03170596|DRUG|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
58484127|NCT03170596|DEVICE|Microneedling|Microneedling is a method of percutaneous collagen induction
58484128|NCT04355143|DRUG|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
58484129|NCT04355143|OTHER|Current care per UCLA treating physicians|Current care
58137342|NCT01983761|DRUG|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
58484130|NCT00343460|DRUG|APF530|Given subcutanously
58137343|NCT01983761|DRUG|Fludarabine, Melphalan, ATG (Reduced Intensity)|
58137344|NCT03283943|RADIATION|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
58484131|NCT00343460|DRUG|dexamethasone|Given IV and orally
58484132|NCT00343460|DRUG|Palonosetron Hydrochloride|Given IV
58484133|NCT00343460|OTHER|placebo|Given subcutanously or IV
58484134|NCT05442476|OTHER|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
58484135|NCT05442476|OTHER|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
58484136|NCT05442476|OTHER|conventional physiotherapy|conventional physiotherapy
58484137|NCT00904137|PROCEDURE|Cast|
58484138|NCT00904137|PROCEDURE|Splint|
58484139|NCT00904137|PROCEDURE|Tape|
58484140|NCT02844868|DEVICE|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
58484141|NCT02844868|DEVICE|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
58484142|NCT04833218|DRUG|Propranolol|Test of catecholamines level in moderate traumatic brain injury
58484143|NCT06039111|PROCEDURE|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
58484144|NCT06117319|OTHER|Individual assistance Virtual reality training sessions|5 virtual reality training sessions where feedback will be provided to each individual by the research team
58484145|NCT06117319|OTHER|Collective assistance Virtual reality training sessions|4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual.
58484146|NCT02377817|DEVICE|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
58484147|NCT02377817|DEVICE|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
58484148|NCT00296621|DRUG|L-Glutamine|L-Glutamine
58484149|NCT00296621|DRUG|placebo|placebo
58484150|NCT00691834|BIOLOGICAL|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
57785256|NCT01270763|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
58137345|NCT03283943|DRUG|Durvalumab|Durvalumab 1500 mg IV every 28 days
58484151|NCT00691834|BIOLOGICAL|Placebo|Plasma and culture medium (10 ml)
58484152|NCT01436435|DEVICE|Jetstream Atherectomy System|Atherectomy
58484153|NCT04639258|DEVICE|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
58484154|NCT06054074|BEHAVIORAL|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
58484155|NCT06054074|BEHAVIORAL|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
58484156|NCT00120497|DRUG|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
58484157|NCT06239896|BEHAVIORAL|Facilitated Group ACP Session|Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
58484158|NCT06239896|BEHAVIORAL|Facilitated one-on-one ACP visits|Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
58484159|NCT00357006|DRUG|Estradiol|100 mcg adjunctive transdermal estradiol
58484160|NCT00357006|DRUG|Estradiol|200 mcg adjunctive transdermal estradiol
58484161|NCT00357006|OTHER|placebo|adjunctive transdermal placebo
58484162|NCT00938704|DRUG|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
58484163|NCT00938704|DRUG|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
58484164|NCT04057976|DIAGNOSTIC_TEST|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
58484165|NCT00733668|DRUG|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
58484166|NCT04606602|DRUG|SLN360|SLN360 for subcutaneous (s.c.) injection
58484167|NCT04606602|DRUG|Placebo|Sodium chloride for subcutaneous (s.c.) injection
58484168|NCT01024413|DRUG|erlotinib|study arm.erlotinib 150 mg oral till disease progression
58484169|NCT01024413|DRUG|gefitinib|study arm.gefitinib 250 mg oral till disease progression
58484170|NCT05847816|OTHER|Experimental group: infrared vascular imaging|"Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin."
58484171|NCT02212782|DRUG|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
58484172|NCT02212782|DRUG|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
58484173|NCT04114318|OTHER|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
58484174|NCT04033016|BEHAVIORAL|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
58484175|NCT04033016|BEHAVIORAL|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
58484176|NCT03703427|DRUG|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
58484177|NCT03703427|DRUG|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
58484178|NCT04560673|DRUG|Duloxetine|Given PO
58484179|NCT04560673|BEHAVIORAL|Neurofeedback|Receive neurofeedback training
58484180|NCT04560673|OTHER|Quality-of-Life Assessment|Ancillary studies
58484181|NCT04560673|OTHER|Questionnaire Administration|Ancillary studies
58484182|NCT03555448|DRUG|Once daily immunosuppression regimen|Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
58484183|NCT03555448|DRUG|Twice daily immunosuppression regimen|This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
58137346|NCT03027830|DEVICE|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
58484184|NCT00682123|DIETARY_SUPPLEMENT|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
58484185|NCT00200369|DEVICE|MEMS cap|
58484186|NCT04226755|DIETARY_SUPPLEMENT|Sodium chloride|1 gram tid (with every meal)
58484187|NCT04427813|BEHAVIORAL|questionaire to husband and wife|a form of questions will be asked to every partner
58484188|NCT02694016|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
58484189|NCT00482053|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
58484190|NCT00482053|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
58484191|NCT00482053|PROCEDURE|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
58484192|NCT00482053|DRUG|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
58484193|NCT00482053|DRUG|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
58484194|NCT00482053|DRUG|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
58484195|NCT00482053|DRUG|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
58484196|NCT00482053|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
58484197|NCT00482053|DRUG|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
58484198|NCT00482053|DRUG|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
58484199|NCT00482053|DRUG|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
58484200|NCT00482053|DRUG|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
58484201|NCT00482053|DRUG|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
58484202|NCT00482053|DRUG|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
58484203|NCT00482053|DRUG|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
58484204|NCT03937570|DEVICE|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
58484205|NCT05043662|DIAGNOSTIC_TEST|UroCAD assay, CTU examination and urine cytology|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
58484206|NCT02281916|DRUG|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
58484207|NCT01073111|DEVICE|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
58484208|NCT01073111|DEVICE|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
58484209|NCT01073111|DEVICE|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
58484210|NCT01856959|DRUG|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
58484211|NCT01856959|DRUG|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
58484212|NCT01856959|DRUG|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
58484213|NCT06521333|DRUG|Resveratrol-Based gel|The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
58484214|NCT06521333|DRUG|Hyaluronic acid gel 0.2%|The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
58484215|NCT06521333|DEVICE|Stent|The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
58484216|NCT05142501|OTHER|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
58484217|NCT01397968|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
58484218|NCT01397968|DRUG|Placebo|Placebo capsule Placebo tablet
58484219|NCT04607018|DEVICE|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
58484220|NCT01746901|DRUG|Placebo|Placebo solution + Placebo ALO-02 (intact)
58484221|NCT01746901|DRUG|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
58484222|NCT01746901|DRUG|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
58484223|NCT01746901|DRUG|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
58484224|NCT01746901|DRUG|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
58484225|NCT01746901|DRUG|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
58484226|NCT01374984|BIOLOGICAL|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
58484227|NCT04287790|BEHAVIORAL|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
58484228|NCT04287790|DRUG|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
58484229|NCT00766662|DRUG|Sulfadoxine pyrimethamine|
58484230|NCT02445898|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
58484231|NCT02445898|DRUG|Isotonic Sodium Chloride|Placebo
58484232|NCT05612620|DIAGNOSTIC_TEST|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
58484233|NCT03754998|BEHAVIORAL|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
58484234|NCT04148846|DRUG|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
58484235|NCT04148846|PROCEDURE|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
58484236|NCT04148846|DRUG|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
58484237|NCT04148846|DRUG|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
58484238|NCT04148846|DRUG|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
58484239|NCT04148846|DRUG|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
58484240|NCT04148846|DIETARY_SUPPLEMENT|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
58484241|NCT03143062|DIAGNOSTIC_TEST|NEWS|NEWS
58484242|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
58484243|NCT04922632|BEHAVIORAL|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
58484244|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
58484245|NCT04922632|BEHAVIORAL|Treatment As Usual (TAU)|TAU is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
58137347|NCT03027830|DEVICE|Conventional|Other diagnostic devices (including FFR and angiography)
58137348|NCT03601962|DIETARY_SUPPLEMENT|Aqualief|400mg oral mucoadesive tablets
58484246|NCT02733640|DRUG|Pantoprazole|pantoprazole 40 mg once-daily
58484247|NCT02733640|DRUG|Ranitidine|ranitidine 150 mg twice-daily
58484248|NCT05185869|DRUG|SHR6390|SHR6390, Oral Administration
58484249|NCT05185869|DRUG|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
58484250|NCT05185869|DRUG|Gemcitabine|Gemcitabine, Intravenous Injection
58484251|NCT01099462|DRUG|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
58484252|NCT00981448|DIETARY_SUPPLEMENT|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
58484253|NCT01821118|BIOLOGICAL|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
58484254|NCT01821118|OTHER|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
58484255|NCT03651414|OTHER|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
58484256|NCT06020820|OTHER|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
58484257|NCT06020820|OTHER|control group group B|"1. Relax shoulders and neck sufficiently~2. look down~3. turn face to the right~4. turn face to the left~5. incline head to the right~6. incline head to the left~7. turn shoulders round and round~8. slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
58484258|NCT04883372|OTHER|continuous glucose monitoring|a continuous glucose monitoring CGM system through the ETAPES telemedicine program
58484259|NCT01765257|DRUG|AZILECT®|
58484260|NCT01765257|DRUG|Placebo|
58484261|NCT06522100|DRUG|Intravenous administration of Methylprednisolone|Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
58484262|NCT06522100|DRUG|Oral Prednisone|After intravenous administration of Methylprednisolone patients will take by oral Prednisone 1mg/kg per day once a day (with a maximum dose of 90 mg per day for patients weighing \> 90kg) for 1 month, followed with a progressive decrease of 10 mg Prednisone every 15 days until a dose of 10mg per day during 15 days (= stop).
58484263|NCT06522100|DRUG|Perfusion of placebo|Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
58484264|NCT06522100|DRUG|Oral Prednisone placebo|After the perfusion of placebo, patients will take by oral Prednisone placebo once a day for the same duration as that required if the patient was in the investigational medicinal products group (1 month + progressive decrease).
58484265|NCT04846738|DEVICE|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
58484266|NCT04846738|DEVICE|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
58484267|NCT00225732|OTHER|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
58484268|NCT00225732|DRUG|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
58484269|NCT00993967|DRUG|idebenone|Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients \> 45 kg
58484270|NCT03874988|BEHAVIORAL|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
58484271|NCT03874988|BEHAVIORAL|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
58484272|NCT03874988|BEHAVIORAL|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
58484273|NCT03874988|BEHAVIORAL|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
58484274|NCT03168776|DEVICE|BuMA Supreme DES|Implant BuMA Supreme stent only
58484275|NCT03168776|DEVICE|Xience or Promus DES|Implant XIENCE family or Promus family only
58484276|NCT00089869|DRUG|olanzapine|
58484277|NCT00089869|DRUG|atomoxetine|
58484278|NCT00089869|DRUG|placebo|
58484279|NCT04475302|BIOLOGICAL|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
58484280|NCT04485390|OTHER|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
58484281|NCT05862649|OTHER|NeuraLight|NeuraLight software-based platform
58484282|NCT02689037|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
58484283|NCT02689037|DRUG|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
58484284|NCT02109497|DRUG|PBT2|PBT2 250 mg administered
58137349|NCT03601962|OTHER|Placebo|400mg Placebo oral mucoadesive tablets
58484285|NCT00557713|DRUG|bevacizumab|"1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
58484286|NCT04446104|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
58484287|NCT04446104|DRUG|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
58484288|NCT04446104|DRUG|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
58484289|NCT04446104|DRUG|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
58484290|NCT04446104|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 500mg daily for 42 days
58484291|NCT03943654|OTHER|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
58484292|NCT02754440|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
58484293|NCT00165477|DRUG|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
58484294|NCT00165477|RADIATION|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
58484295|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One Placebo capsule to be taken 30 minutes after sachet in the morning."
58484296|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~- One Placebo capsule to be taken 30 minutes after whey protein in the morning"
58484297|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning"
58484298|NCT05004441|DRUG|Fruquintinib Combined With mFOLFOX6/FOLFIRI|Fruquintinib (3mg) will be given p.o. daily
58484299|NCT06491485|DRUG|Group M (lidocaine with Magnesium sulfate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
58484300|NCT06491485|DRUG|Group B (lidocaine with Sodium bicarbonate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
58484301|NCT06491485|DRUG|Group C (lidocaine with saline)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
58484302|NCT04122716|DRUG|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
58484303|NCT04122716|BEHAVIORAL|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
58484304|NCT03452657|DRUG|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
58484305|NCT03452657|PROCEDURE|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
58484306|NCT05156034|DRUG|SRK-001|Participants will receive IV doses of SRK-001.
58484307|NCT05156034|DRUG|Placebo|Participants will receive IV doses of placebo.
58484308|NCT04540913|DEVICE|RHA 3|Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.
58484309|NCT04540913|DEVICE|Restylane-L|Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
58484310|NCT00345358|BIOLOGICAL|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
58484311|NCT00345358|BIOLOGICAL|Infanrix IPV/Hib|4 intramuscular injections
58484312|NCT02217358|DEVICE|NBI endoscopy|"see in detail description of the study part of the protocol"
58484313|NCT04961957|DEVICE|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
58484314|NCT04961957|DEVICE|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
58484315|NCT02853617|BIOLOGICAL|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
58484316|NCT02853617|BIOLOGICAL|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
58484317|NCT02853617|BIOLOGICAL|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
58484318|NCT02853617|BIOLOGICAL|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
58484319|NCT00911456|PROCEDURE|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
58484320|NCT00911456|PROCEDURE|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
58484321|NCT00911456|PROCEDURE|3 DUS|3 DUS
58484322|NCT02401789|DEVICE|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
58484323|NCT00195364|DRUG|Etanercept|
58484324|NCT02532803|OTHER|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
58484325|NCT04625504|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
58484326|NCT02494323|DEVICE|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
58484327|NCT02346162|BEHAVIORAL|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.
58484328|NCT02346162|OTHER|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
58484329|NCT03356041|OTHER|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
58484330|NCT05361707|DRUG|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
58484331|NCT00214890|DRUG|Tenofovir|300 mg once daily
58484332|NCT00214890|DRUG|Abacavir|600 mg once daily
58484333|NCT04764422|BIOLOGICAL|Normal Saline|0.9% normal saline for injection
58484334|NCT04764422|BIOLOGICAL|NDV-HXP-S vaccine|Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
58484335|NCT06410196|BEHAVIORAL|Mood modulation|Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events
58484336|NCT05569278|DRUG|GE200486 0.5M Injection|Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
58484337|NCT05524597|BEHAVIORAL|Writing Intervention|Participants will be asked to write about different kinds of experiences.
58484338|NCT02874989|DRUG|Dasatinib + Quercetin|
57782013|NCT06225297|COMBINATION_PRODUCT|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
58484339|NCT02874989|DRUG|Placebo|
58484340|NCT06517693|DRUG|PGT121.414.LS|Administered subcutaneously (SC) in the thigh
58484341|NCT06517693|DRUG|VRC07-523LS|Administered subcutaneously (SC) in the thigh
58484342|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
58484343|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
58484344|NCT00478023|DRUG|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
58484345|NCT00478023|DRUG|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
58484346|NCT00478023|DRUG|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
58484347|NCT00478023|DRUG|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
58484348|NCT00478023|DRUG|Placebo|4 - 6 hourly; Total 72 hours
58484349|NCT00396253|DRUG|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
57782014|NCT03759522|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
57782015|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
57782016|NCT06740994|PROCEDURE|conventional landmark paramedian technique|"a blind landmark scanning will be done and skin marking of the best palpable spinous process will be made.~the site of injection will be determined by palpation. continuous spinal anesthesia will be performed via paramedian approach."
58484350|NCT01054885|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
58484351|NCT01054885|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
58484352|NCT01054885|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
58484353|NCT01054885|DRUG|Placebo|Placebo
58484354|NCT02784899|DRUG|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
58484355|NCT02784899|DRUG|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
58484356|NCT03873792|DIAGNOSTIC_TEST|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
58484357|NCT04857320|COMBINATION_PRODUCT|Human insulin|Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
58484358|NCT05914337|BEHAVIORAL|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
58484359|NCT05914337|BIOLOGICAL|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
58484360|NCT02939443|RADIATION|supine- and prone-position Computed Tomography|
58484361|NCT06316050|PROCEDURE|humeral retroversion|REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
58484362|NCT03487432|DEVICE|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
58484363|NCT03487432|DEVICE|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
58484364|NCT01405144|DRUG|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
58484365|NCT01405144|PROCEDURE|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
58484366|NCT00218777|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|
58484367|NCT04496583|OTHER|Fluid depletion strategy|The fluid depletion strategy will be individualized depending on the response to the standardized furosemide test (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) with a urinary output (UO) cutoff of 200 ml at 2 hours. The desired depletion endpoint will be targeted by using diuretics (40 mg q6h iv initially, adjusting dose by UO) or ultrafiltration (UF) if UO \<200 ml/2h
58484368|NCT06071689|DEVICE|screw retained prosthesis|all-on-4 screw-retained prosthesis.
58484369|NCT06331143|DEVICE|Ultrasound-Guided Mid-Transverse Process to Pleura (MTP) Block|Patients will receive MTP block after induction of anesthesia.
58484370|NCT06331143|DRUG|Morphine|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
58484371|NCT05836896|GENETIC|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
58484372|NCT04904614|DRUG|Letermovir|Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
58484373|NCT05702606|OTHER|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
58484374|NCT04147663|OTHER|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
58484375|NCT01376934|PROCEDURE|procedure hysteroscopy|office hysteroscopy with gas or saline solution
58484376|NCT04595747|PROCEDURE|Biopsy|Undergo biopsy
58484377|NCT04595747|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
58484378|NCT04595747|PROCEDURE|Computed Tomography|Undergo CT scan and PET/CT scan
58484379|NCT04595747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
58484380|NCT04595747|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
58484381|NCT04595747|DRUG|Rogaratinib|Given PO
58484382|NCT04202107|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
58484383|NCT04202107|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
58484384|NCT00308490|DRUG|iron sucrose|
58484385|NCT04469335|DEVICE|mobile neurofeedback|"to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well."
58484386|NCT04469335|DEVICE|Sham mobile neurofeedback|"It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study."
58484387|NCT04469335|DEVICE|medication + mobile neurofeedback|The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
58484388|NCT04469335|DEVICE|medication + Sham mobile neurofeedback|The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
58484389|NCT04937218|BEHAVIORAL|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
58484390|NCT02579304|PROCEDURE|transbronchial lung cryobiopsy|bronchoscopic sampling
58484391|NCT04424719|OTHER|Blood test|"High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression)."
58484392|NCT06514768|BIOLOGICAL|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
58484393|NCT01003769|DRUG|Lenalidomide|Given PO
58484394|NCT01003769|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
58484395|NCT01003769|OTHER|Laboratory Biomarker Analysis|Correlative studies
58484396|NCT02105181|DEVICE|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
58484397|NCT00543413|DRUG|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
58484398|NCT00543413|DRUG|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
58484399|NCT00543413|DRUG|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
58484400|NCT04615377|BEHAVIORAL|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
58484401|NCT04615377|OTHER|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
58484402|NCT02390193|PROCEDURE|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
58484403|NCT03714672|DRUG|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
58484404|NCT03714672|DRUG|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
58484405|NCT03714672|DRUG|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
58484406|NCT03714672|DRUG|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
58484407|NCT01394003|DRUG|LY2584702|administered orally
58484408|NCT04913935|DIAGNOSTIC_TEST|Muscle-Skeleton Ultrasonography|postero-anterior radiography
58484409|NCT05185661|BEHAVIORAL|eHealth education|"eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education"
58484410|NCT04268381|OTHER|Biochemical analysis|aMMP-8 is measured by immunofluorometric assay (IFMA).
58484411|NCT00184301|BEHAVIORAL|inpatient treatment|inpatient treatment during 1 year
58484412|NCT00184301|BEHAVIORAL|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
58484413|NCT04238897|DEVICE|soft contact lens|
58484414|NCT03742323|DRUG|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
58484415|NCT05676619|DEVICE|3D foot scanner|Reliability of 3D foot scanner during repeated scans
58484416|NCT03637738|RADIATION|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
58484417|NCT03637738|RADIATION|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
58137350|NCT05426005|DRUG|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
58484418|NCT02858362|DRUG|Ezutromid|Administered orally.
58484419|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
58484420|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
58484421|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
58484422|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
58484423|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
58484424|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
58484425|NCT03071419|BEHAVIORAL|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
58484426|NCT05441748|OTHER|Walnuts|The intervention treatment will contain walnuts.
58484427|NCT05441748|OTHER|Walnut Oil|The intervention treatment will contain walnut oil.
58484428|NCT05441748|OTHER|Control|The control treatment will contain corn oil.
58484429|NCT00890123|DIETARY_SUPPLEMENT|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
58484430|NCT05422898|BEHAVIORAL|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
58484431|NCT05422898|BEHAVIORAL|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
58484432|NCT00598793|DRUG|biphasic insulin aspart|
58484433|NCT00598793|DRUG|insulin glargine|
58484434|NCT00598793|DRUG|metformin|
58484435|NCT00598793|DRUG|pioglitazone|
58484436|NCT04381754|DEVICE|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
58484437|NCT03859310|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
58484438|NCT01842217|PROCEDURE|FES-PET|
58484439|NCT05120401|DEVICE|presbyopia glasses|fogging for glasses for far and intermediate
58484440|NCT01666028|DEVICE|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
58484441|NCT01666028|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
58484442|NCT05178004|OTHER|Faecal and Urine sample collection|This is an observational study.
58484443|NCT04117516|PROCEDURE|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
58484444|NCT04117516|PROCEDURE|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
58484445|NCT02532881|OTHER|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
58484446|NCT02532881|OTHER|Treatment as usual|Treatment as usual
58484447|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
58484448|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
58484449|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region."
58484450|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region."
58484451|NCT00763880|DRUG|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
58484452|NCT00763880|DRUG|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
58484453|NCT05737953|DIAGNOSTIC_TEST|cfDNA methylation sequencing and proteome analysis|Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples
58484454|NCT05194735|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"
58484455|NCT05194735|BIOLOGICAL|Aldesleukin (IL-2)|To support growth and activation of TCR-T cell drug product
58484456|NCT06003049|DRUG|OnabotulinumtoxinA|BOTOX injection series
58484457|NCT06003049|OTHER|Placebo|Placebo injection series
58484458|NCT03224819|DRUG|Emerfetamab|Administered by intravenous (IV) infusion.
58484459|NCT05119361|OTHER|Early Dry protocol|"After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours."
58484460|NCT00811018|DRUG|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
58484461|NCT02177565|BIOLOGICAL|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
58484462|NCT05542719|OTHER|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
58484463|NCT01803607|DRUG|odanacatib|odanacatib 50 mg oral tablet
58484464|NCT01803607|OTHER|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
58484465|NCT04458870|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
58484466|NCT05928962|DRUG|Recombinant Human Adenovirus Type 5 Injection|"1. Recombinant Human Type 5 Adenovirus Injection:~   This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~2. PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
58484467|NCT05985252|PROCEDURE|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
58484468|NCT05985252|PROCEDURE|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
58484469|NCT01119378|OTHER|Dual isotope technique|Dual isotope technique using stable isotopes
58484470|NCT04342325|BIOLOGICAL|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
58484471|NCT03719859|OTHER|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
58484472|NCT03719859|OTHER|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
58484473|NCT05474157|OTHER|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
58484474|NCT04199988|DIAGNOSTIC_TEST|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
58484475|NCT02367833|DRUG|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
58484476|NCT02367833|DRUG|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
58484477|NCT02367833|DRUG|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
58484478|NCT02892448|OTHER|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
58484479|NCT02964091|DRUG|sofosbuvir/ledipasvir|
58484480|NCT04186143|OTHER|Closed Cinetic Chain Exercises|Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
58484481|NCT04186143|OTHER|Open Kinetic Chain Exercises|Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
58484482|NCT04186143|OTHER|Control Group|Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
58484483|NCT01686399|BEHAVIORAL|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
58484484|NCT03292367|PROCEDURE|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
58484485|NCT03186742|DRUG|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
58484486|NCT00475696|DRUG|Duloxetine|
58484487|NCT02289261|DRUG|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
58484488|NCT02289261|DRUG|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
58484489|NCT06523361|DEVICE|H'ability|H'ability is introduced depending the randomization result, during the baseline (before session 4, 5, 6 or 7 with occupational therapist
58484490|NCT04963868|PROCEDURE|Stent removed by the novel strategy|The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；
58484491|NCT04963868|PROCEDURE|Stent removed by the conventional strategy|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
58484492|NCT05848999|BIOLOGICAL|UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
58484493|NCT00787358|DRUG|ZT-031|80 ul subcutaneous injection per day
58484494|NCT00787358|OTHER|placebo|80 ul daily subcutaneous injection of vehicle only
58484495|NCT03417011|DEVICE|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
58484496|NCT05451901|PROCEDURE|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
58484497|NCT05451901|PROCEDURE|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
58484498|NCT04220541|BEHAVIORAL|Motor learning based exercise|Symptomatic exercise
58484499|NCT05108012|BIOLOGICAL|NK cell therapy|Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
58484500|NCT04938154|DEVICE|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
58484501|NCT04938154|DEVICE|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
58484502|NCT02284243|DRUG|Intranasal Dexmedetomidine|
58137351|NCT04921462|PROCEDURE|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
58484503|NCT02284243|DRUG|Intranasal Placebo|
58484504|NCT01239693|DIETARY_SUPPLEMENT|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
58484505|NCT01239693|DIETARY_SUPPLEMENT|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
58484506|NCT01239693|DIETARY_SUPPLEMENT|LNS|Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
58484507|NCT01110902|DRUG|Agomelatine (AGO178C)|
58484508|NCT01110902|DRUG|Placebo|
58484509|NCT03968562|DRUG|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
58484510|NCT01931293|DIETARY_SUPPLEMENT|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
58484511|NCT04109261|DRUG|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
58484512|NCT01586572|DRUG|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
58484513|NCT01586572|DRUG|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
58484514|NCT04543279|DRUG|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
58484515|NCT04543279|DRUG|Ruxolitinib|Ruxolitinib is commercially available.
58484516|NCT06517589|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|PBT (20 sessions), intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
58484517|NCT06517589|OTHER|Cognitive Behavioral Therapy (CBT)|CBT (20 sessions), intervention planning as usual based on manual.
58484518|NCT02030652|PROCEDURE|Intermittent nasal positive pressure positive ventilation.|
58484519|NCT02030652|PROCEDURE|CPAP|Nasal continuous positive airway pressure
58484520|NCT02084407|OTHER|Clinical examination, skin biopsy, blood and urine sampling|
58484521|NCT03916913|RADIATION|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
58484522|NCT01265537|DRUG|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
58484523|NCT01265537|DRUG|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
58484524|NCT01526733|DRUG|Sham Injection|
58484525|NCT01526733|DRUG|Recombinant human hyaluronidase PH20|
58484526|NCT01526733|DRUG|Insulin aspart|
58484527|NCT01526733|DRUG|Insulin lispro|
58484528|NCT04289974|DRUG|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
58484529|NCT03074240|PROCEDURE|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
58484530|NCT03074240|PROCEDURE|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
58484531|NCT03074240|PROCEDURE|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
58484532|NCT04767919|PROCEDURE|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
58484533|NCT04767919|PROCEDURE|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
58484534|NCT02788552|DRUG|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
58484535|NCT00402402|PROCEDURE|Tuberculin skin test|
58484536|NCT00402402|PROCEDURE|Quantiferon-TB Gold assay|
58484537|NCT01815697|DEVICE|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
58484538|NCT06379815|OTHER|Sodium Lactate|See arm/group description.
58484539|NCT06379815|OTHER|Sodium Chloride|See arm/group description.
58484540|NCT00741182|DRUG|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
58484541|NCT01715324|DRUG|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
58484542|NCT02841904|DEVICE|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
58484543|NCT06393699|PROCEDURE|NCCL restoration using resin composite materials|different types of resin composite restorations will be used to restore NCCL
58484544|NCT03788252|DRUG|Renamezin|7 capsules once, three times a day, for 48 weeks
58484545|NCT05288803|OTHER|Clinical decision support tool (CDS tool)|The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
58484546|NCT03930082|OTHER|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
58484547|NCT05724888|BEHAVIORAL|Peer mentorship and physical activity|Participants will be asked to participate for 12 weeks, attending 3 sessions per week (if in the intervention arm). Session 1 will be a group session that will be about 90 minutes, session 2 will be an individual session with a peer mentor for 20-30 minutes, and session 3 will be a virtual check in with the peer mentor about 15 minutes. The intervention will focus on increasing physical activity through the circle of courage.
58484548|NCT01630876|PROCEDURE|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
58484549|NCT01630876|PROCEDURE|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
58484550|NCT05779540|DEVICE|Safeback SBX|The intervention consists in the test of the active device.
58484551|NCT05779540|DEVICE|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
58484552|NCT04730232|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
58484553|NCT04730232|DRUG|Nab-paclitaxel|Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
58484554|NCT03327207|OTHER|Non Interventional|Non Interventional
58484555|NCT00840112|DIETARY_SUPPLEMENT|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
58484556|NCT02052518|BEHAVIORAL|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
58484557|NCT05370677|GENETIC|ARMS|amplification refractory mutation system
58484558|NCT06081270|OTHER|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
58484559|NCT03153943|DEVICE|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
58484560|NCT03153943|OTHER|Workbook support|Printed material support
58484561|NCT00589394|BIOLOGICAL|pneumococcal vaccination (Pneumovax)|pneumovax was given
58484562|NCT01662570|BEHAVIORAL|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
58484563|NCT01662570|OTHER|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
58484564|NCT02783807|DEVICE|Eyenez Retinal Camera v200|
58484565|NCT02783807|DEVICE|Volk Pictor Ret 1|
58484566|NCT02633202|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
58484567|NCT02633202|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
58137352|NCT05479110|BEHAVIORAL|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
58484568|NCT03829202|DEVICE|Own mechanical knee|Daily use of own mechanical knee
58484569|NCT03829202|DEVICE|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
58484570|NCT05372172|OTHER|none, observational study|none, observational study
58484571|NCT01696539|BEHAVIORAL|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
58484572|NCT01696539|OTHER|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
58484573|NCT00332176|DRUG|Celgosivir|400mg qd + standard of care for 12 weeks
58484574|NCT00332176|DRUG|Celgosivir|600mg qd + standard of care for 12 weeks
58484575|NCT00332176|DRUG|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
58484576|NCT02178150|DIETARY_SUPPLEMENT|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
58484577|NCT02178150|DIETARY_SUPPLEMENT|Placebo|
58484578|NCT03389958|OTHER|Counseling and provision of contraception|Provider training, availability of contraceptive methods
58484579|NCT05036733|DRUG|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
58484580|NCT01459497|RADIATION|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
58484581|NCT01459497|RADIATION|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
58484582|NCT01235078|DEVICE|EZ-IO|powered intraosseous vascular access system
58484583|NCT01907035|BEHAVIORAL|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
58484584|NCT01907035|OTHER|Usual care|
58137353|NCT05479110|OTHER|case studies|active control: case studies(text)
58137354|NCT01930227|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
58137355|NCT01930227|OTHER|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
58484585|NCT04430816|PROCEDURE|double mesh modification of chevrel's technique|repair of midline incisional hernia by double mesh modification of chevrel's technique
58484586|NCT04430816|PROCEDURE|on lay mesh hernioplasty|repair of midline incisional hernia by online mesh hernioplasty
58484587|NCT06522022|BEHAVIORAL|Culturally Responsive SBIRT for OB|"SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools"
58484588|NCT06522022|BEHAVIORAL|Brief Screening for PTSD|This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
58484589|NCT00892346|PROCEDURE|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
58484590|NCT03708614|OTHER|Controlled energy diet with elevated protein intake|Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
58484591|NCT04032093|BIOLOGICAL|RSV vaccine|RSV vaccine
58484592|NCT04032093|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
58484593|NCT01064947|DRUG|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
58484594|NCT05076162|DIAGNOSTIC_TEST|PAED|Delirium positive or negative
58484595|NCT06047418|PROCEDURE|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
58484596|NCT01751620|BEHAVIORAL|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
58484597|NCT01751620|BEHAVIORAL|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
58484598|NCT01017198|DRUG|BIIB021 and Food|Assessing the effect of food use on BIIB021
58484599|NCT01017198|DRUG|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
58484600|NCT05744934|DEVICE|LUX-Dx™|Placement of LUX-Dx at the time of stage 1 palliation
58484601|NCT00903188|DRUG|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
58484602|NCT00903188|DRUG|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
58484603|NCT03831750|OTHER|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
58484604|NCT05447884|OTHER|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
58484605|NCT05447884|OTHER|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
58484606|NCT05447884|OTHER|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
58484607|NCT02359097|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
58484608|NCT02359097|DRUG|Ferumoxytol|Given IV
58484609|NCT02359097|DRUG|Gadoteridol|Given IV
58484610|NCT02359097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
58484611|NCT02173899|BIOLOGICAL|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
58484612|NCT02173899|BIOLOGICAL|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
58484613|NCT02173899|BIOLOGICAL|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
58484614|NCT00976404|BIOLOGICAL|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
58484615|NCT00976404|DRUG|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
58484616|NCT00976404|DRUG|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
58484617|NCT04273035|DRUG|Midazolam oral solution|Oral Buccolam
58484618|NCT04273035|DEVICE|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
58484619|NCT03262844|BEHAVIORAL|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
58484620|NCT03262844|PROCEDURE|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
58484621|NCT04446884|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
58484622|NCT04446884|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
58484623|NCT04711226|DRUG|AT-1501|AT-1501 IV infusion
58484624|NCT04294680|DEVICE|Cryotherapy|see opiate sparing description
58484625|NCT05147259|DRUG|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
58484626|NCT00699114|DRUG|Placebo|Lactose as powder in gelatine capsules, single dose
58484627|NCT00699114|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
58484628|NCT00699114|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
58484629|NCT00699114|DRUG|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
58484630|NCT00699114|DRUG|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
58484631|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
58484632|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
58484633|NCT01601548|BEHAVIORAL|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
58484634|NCT03042819|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
58484635|NCT03042819|DRUG|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
58484636|NCT00737672|DEVICE|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
58484637|NCT00737672|PROCEDURE|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
58484638|NCT06025968|BEHAVIORAL|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
58484639|NCT06025968|BEHAVIORAL|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
58484640|NCT05653869|DRUG|APS03118|Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
58137356|NCT02728102|PROCEDURE|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
58137357|NCT02728102|PROCEDURE|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
58137358|NCT02728102|DRUG|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
58484641|NCT04778137|DRUG|Omalizumab|Biological: CMAB007 Biological: Xolair
58484642|NCT00463515|DRUG|carboplatin/gemcitabine|
58484643|NCT00463515|PROCEDURE|cisplatin/radiation therapy|
58484644|NCT01434199|PROCEDURE|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
58484645|NCT03378271|DEVICE|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
58484646|NCT00559819|DRUG|placebo|Placebo (orange juice), same volume as alcohol
58484647|NCT00559819|DRUG|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
58484648|NCT03854279|DEVICE|tonsillar dissection|The tonsils will be removed by bizact device
58484649|NCT06215261|DRUG|Methylone|Methylone capsules, given orally, once a week for 3 weeks
58484650|NCT06215261|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 3 weeks NOTE: Placebo is only in Part B
58484651|NCT03710161|DRUG|Vitamin D|Vitamin D taken in two different dosages daily for six months.
58484652|NCT06400043|OTHER|Cognitive dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.
58484653|NCT06400043|OTHER|Motor dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
58484654|NCT03626909|OTHER|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
58484655|NCT03626909|OTHER|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
58484656|NCT03626909|OTHER|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
58484657|NCT03626909|OTHER|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
58484658|NCT04242524|BEHAVIORAL|Circadian Clock Alignment|Use timed lights and meals to align the circadian clock
58484659|NCT04242524|BEHAVIORAL|Circadian Clock Control|No circadian clock alignment
58484660|NCT06071806|OTHER|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
58484661|NCT01077076|DRUG|Zegerid|Zegerid taken once daily for 11 days.
58484662|NCT01077076|DRUG|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
58484663|NCT01077076|OTHER|Placebo|Placebo taken once daily for 11 days.
58484664|NCT05641259|DRUG|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
58484665|NCT05641259|DRUG|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
58484666|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
58484667|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
58484668|NCT06094582|OTHER|questionnaire|Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.
58484669|NCT00193544|DRUG|Arsenic Trioxide|
58484670|NCT00193544|DRUG|Thalidomide|
58484671|NCT05552937|DRUG|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
58484672|NCT01671319|DRUG|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
58137359|NCT02728102|PROCEDURE|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
58484673|NCT03931369|DRUG|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
58484674|NCT02949791|PROCEDURE|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
58137360|NCT02728102|BIOLOGICAL|Myeloma vaccine|The target dose is 3 x 10\^6 fusion cells per vaccine. A minimum of 3 x 10\^6 total fusion cells will be required to proceed with vaccine administration. Patients who have \<3 x 10\^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
58484675|NCT02949791|OTHER|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
58484676|NCT02949791|OTHER|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
58484677|NCT05539898|DEVICE|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
58484678|NCT01859624|DRUG|Albuterol|Albuterol 4 mg
58484679|NCT05064137|DRUG|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
58484680|NCT05064137|DRUG|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
58484681|NCT05064137|DRUG|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
58484682|NCT03755349|DEVICE|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
58484683|NCT03755349|OTHER|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
58484684|NCT00450268|PROCEDURE|blood draw, skin shave biopsy|
58484685|NCT06023017|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
58484686|NCT06023017|BEHAVIORAL|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
58484687|NCT05366062|DRUG|ERC1671|ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
58484688|NCT05366062|DRUG|GM-CSF|Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
58484689|NCT05366062|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
58484690|NCT05366062|DRUG|Pembrolizumab|A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
58484691|NCT00598910|DRUG|Omacor|n-3 PUFA
58484692|NCT00598910|DRUG|Placebo|Placebo
58484693|NCT00337623|DRUG|Prednisolone|
58484694|NCT06169059|DRUG|JLP-2004|administration of JLP-2004(COX-2 inhibitor)
58484695|NCT06169059|DRUG|JC-013|administration of JC-013(COX-2 inhibitor))
58484696|NCT00359320|PROCEDURE|pancreaticojejunostomy|
58484697|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
58484698|NCT04055623|OTHER|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
58484699|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
58484700|NCT02820493|DRUG|vedolizumab|
58484701|NCT00084513|BIOLOGICAL|trastuzumab|
58484702|NCT00084513|DRUG|imatinib mesylate|
58484703|NCT00472030|DRUG|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
58484704|NCT00472030|DRUG|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
58137361|NCT02728102|DRUG|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
58137362|NCT02728102|DRUG|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
58484705|NCT01950130|PROCEDURE|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
58484706|NCT06361108|DRUG|YJ001 for Spray Use|Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
58484707|NCT06361108|DRUG|Placebo of YJ001 for Spray Use|Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
58484708|NCT05825378|DRUG|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
58137363|NCT01558141|OTHER|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
58484709|NCT05825378|DRUG|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
58484710|NCT00645346|BIOLOGICAL|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
58484711|NCT00645346|BIOLOGICAL|Placebo|Subjects will receive one dose of placebo
58484712|NCT05843396|BEHAVIORAL|Neonatal Massage|caregivers providing therapeutic touch techniques on their neonate
58484713|NCT03000660|DRUG|Venetoclax|Venetoclax at one of four escalating doses
58484714|NCT03000660|DRUG|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
58484715|NCT03292796|DRUG|Prostaglandins|
58484716|NCT05216354|DRUG|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
58484717|NCT00476853|DRUG|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
58484718|NCT00357903|BIOLOGICAL|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
58484719|NCT06174415|DEVICE|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
58484720|NCT02058303|DRUG|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
58484721|NCT02058303|DRUG|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
58484722|NCT05868616|DEVICE|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
58484723|NCT00397865|BEHAVIORAL|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
58484724|NCT00825487|DRUG|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
58484725|NCT06033404|PROCEDURE|Normal Clinical practice|Normal Clinical practice
58484726|NCT05459896|BEHAVIORAL|Physical Activity Training|Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
58484727|NCT05459896|OTHER|Mindfulness-based Intervention|Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
58484728|NCT05459896|OTHER|Energy Conservation Techniques|Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
58484729|NCT04006132|DEVICE|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
58492308|NCT03801044|RADIATION|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
58137364|NCT01558141|OTHER|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
58137365|NCT05614960|OTHER|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
58137366|NCT00566800|DRUG|erlotinib hydrochloride|
58137367|NCT00566800|OTHER|laboratory biomarker analysis|
58137368|NCT00566800|PROCEDURE|biopsy|
58484730|NCT05887388|BEHAVIORAL|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
58484731|NCT05599867|BEHAVIORAL|quality of life|to assess quality among patients with patients with IBD
58484732|NCT02566369|DRUG|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
58484733|NCT02566369|DRUG|Placebo cream|Placebo cream applied once daily for 12 weeks
58484734|NCT00967837|PROCEDURE|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
58484735|NCT02716480|BEHAVIORAL|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
58484736|NCT02716480|BEHAVIORAL|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
58484737|NCT02565368|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
58484738|NCT02565368|DRUG|CKD-395 0.5/1000mg|single oral administration
58484739|NCT03821727|PROCEDURE|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
58484740|NCT02001259|DRUG|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
58484741|NCT02001259|DRUG|epidural lidocaine|add into catheter at 48 hr after surgery
58484742|NCT06284135|OTHER|Michl-stitch|In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
58484743|NCT04767529|DRUG|EFX|Administered by subcutaneous injection
58484744|NCT04767529|DRUG|Placebo|Administered by subcutaneous injection
58484745|NCT06097715|DIAGNOSTIC_TEST|upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy to asses present of esophageal varices and will be done to all patient group
58484746|NCT06097715|DIAGNOSTIC_TEST|1- Complete blood count 2- Coagulation profile|cmplete blood count to detect thrombocytopenia, liver function test to detect if they are elevated,and any impaired coagulation profile
58484747|NCT00387985|DRUG|MOA-728|
58484748|NCT06233396|OTHER|Extra 4DCT scan|Extra 4DCT scan after routine simulation
58484749|NCT00946387|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
58484750|NCT00946387|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
58484751|NCT03651297|OTHER|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
58484752|NCT03651297|OTHER|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
58484753|NCT02106858|DRUG|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
58484754|NCT06147388|DIAGNOSTIC_TEST|Colposcopy|No surgery, observation
58484755|NCT05504785|DEVICE|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
58484756|NCT01093157|DRUG|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
58484757|NCT02745119|DRUG|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
58137369|NCT01550900|DRUG|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
58137370|NCT01550900|OTHER|Placebo|Placebo tablets by mouth 1 time a day.
58137371|NCT01868529|DRUG|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
58484758|NCT01216189|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
58484759|NCT05908019|OTHER|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
58484760|NCT03077412|DRUG|Filgotinib|Tablet(s) administered orally once daily
58484761|NCT03077412|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
58484762|NCT05098431|OTHER|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
58484763|NCT06410092|DRUG|FTL001|IV infusion every 2 weeks
58484764|NCT02639221|DRUG|PXT002331|
58484765|NCT02396121|DIETARY_SUPPLEMENT|Oral nutritional supplement : Renutryl® Booster|
58484766|NCT04207788|OTHER|HIP-REP|HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.
58484767|NCT04207788|OTHER|Usual care|The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
58484768|NCT05969652|OTHER|Heavy slow resistance training|"Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets\*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3\*15 2-3.week 3\*12 4th-5th week 3\*10 6th week 3\*8"
58484769|NCT05969652|OTHER|Eccentric exercise training|"Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week."
58484770|NCT00905801|OTHER|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
58484771|NCT02281513|OTHER|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
58484772|NCT02281513|OTHER|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
58484773|NCT02281513|OTHER|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
58484774|NCT02415478|OTHER|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
58484775|NCT01232023|DRUG|Indobufen|Single Oral Dose of
58484776|NCT00516360|DEVICE|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
58484777|NCT06125717|BIOLOGICAL|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
58484778|NCT06383533|DRUG|Disitamab Vedotin Plus Cadonilimab|Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
58484779|NCT04161157|BEHAVIORAL|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
58484780|NCT00487656|DRUG|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
58137372|NCT01868529|DRUG|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
58137373|NCT06316921|PROCEDURE|Epidural patient-controlled analgesia|Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery
58484781|NCT00487656|DRUG|placebo|6 mg/ml ampule solution for injection at .01mg/kg
58484782|NCT00622440|DRUG|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
58484783|NCT00622440|DRUG|Placebo|Placebo twice daily for 48 weeks.
58484784|NCT01554241|DIETARY_SUPPLEMENT|D3 2000 IU/day|2000 IU/day D3
58484785|NCT01554241|DIETARY_SUPPLEMENT|D3 4000 IU/day|vitamin D3 4000 IU/day
58484786|NCT01554241|DIETARY_SUPPLEMENT|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
58484787|NCT01554241|DIETARY_SUPPLEMENT|vitamin D3 800 IU/day|vitamin D3 800 IU/day
58484788|NCT02963285|OTHER|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
58484789|NCT02961829|DRUG|Maraviroc|antiretroviral intensification
58484790|NCT02961829|DRUG|Dolutegravir|antiretroviral intensification
58484791|NCT02961829|BIOLOGICAL|Dendritic Cell Vaccine|Therapeutic vaccination
58484792|NCT02961829|DRUG|Auranofin|purging
58484793|NCT02961829|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
58484794|NCT04691076|DRUG|Propofol|Propofol is administered by target-controlled infusion
58484795|NCT04691076|DRUG|Esketamine|Esketamine is intravenously administrated
58484796|NCT04691076|DRUG|Fentanyl|Fentanyl is intravenously administrated
58484797|NCT00355966|DRUG|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
58484798|NCT00355966|DRUG|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
58484799|NCT03501108|OTHER|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
58484800|NCT04816552|BEHAVIORAL|CHoBI7 mHealth program Arm|We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
58484801|NCT04816552|BEHAVIORAL|general message on oral rehydration solution (ORS)|general message on oral rehydration solution (ORS)
58484802|NCT04257929|DRUG|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
58484803|NCT04257929|DRUG|Placebo oral tablet|Matching placebo tablets
58484804|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
58484805|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
58484806|NCT00516516|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 1g orally, twice daily
58484807|NCT00516516|DIETARY_SUPPLEMENT|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
58484808|NCT06214234|PROCEDURE|Band ligation|Band ligation in variceal bleeding
58484809|NCT02035267|DRUG|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
58484810|NCT02035267|DRUG|Placebo|Phosphate buffered saline placebo for injection.
58484811|NCT00426413|DRUG|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
58484812|NCT00986856|DRUG|Fucidin® cream|
58484813|NCT04041414|OTHER|Proud & Empowered!|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
58484814|NCT06515600|DEVICE|Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.|"All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min."
58484815|NCT04298242|DEVICE|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
58484816|NCT00417417|DRUG|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
58484817|NCT00417417|DRUG|Placebo|Normal saline subcutaneously at each treatment visit.
58484818|NCT00670748|BIOLOGICAL|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
58484819|NCT00670748|DRUG|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
58484820|NCT00670748|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
58484821|NCT00670748|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
58484822|NCT00670748|BIOLOGICAL|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
58484823|NCT00002330|DRUG|Ganciclovir|
58484824|NCT02324192|OTHER|Ultrasonography|imaging findings
58484825|NCT02022124|DRUG|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
58484826|NCT03566134|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
58484827|NCT03566134|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
58484828|NCT03566134|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
58484829|NCT03566134|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
58484830|NCT03566134|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
58484831|NCT00985361|DIETARY_SUPPLEMENT|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
58484832|NCT00985361|DIETARY_SUPPLEMENT|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
58484833|NCT04291898|DEVICE|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
58484834|NCT04291898|DEVICE|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
58484835|NCT04291898|DEVICE|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
58484836|NCT04103749|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
58484837|NCT01907711|DEVICE|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
58484838|NCT00002630|BIOLOGICAL|filgrastim|
58484839|NCT00002630|DRUG|cyclophosphamide|
58484840|NCT00002630|DRUG|melphalan|
58484841|NCT00002630|PROCEDURE|peripheral blood stem cell transplantation|
58484842|NCT00002630|RADIATION|low-LET cobalt-60 gamma ray therapy|
58484843|NCT00002630|RADIATION|low-LET photon therapy|
58484844|NCT02170103|PROCEDURE|percutaneous intervention (PCI)|Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
58484845|NCT02170103|DRUG|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
58484846|NCT02170103|PROCEDURE|Ultrasound|Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
58484847|NCT05724095|OTHER|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
58484848|NCT05724095|OTHER|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
58484849|NCT05724095|OTHER|electrodes attached|electrodes are attached to area of acupoints
58484850|NCT04922385|OTHER|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
58137374|NCT06316921|PROCEDURE|Standard postoperative pain management|Standard of care for postoperative pain after lumber spine surgery
58484851|NCT02037399|DRUG|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
58484852|NCT02037399|DRUG|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
58484853|NCT00072709|DRUG|TCH346|
58484854|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
58484855|NCT03604406|OTHER|Placebo Injection|Saline solution injection
58484856|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
58484857|NCT02911168|PROCEDURE|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
58484858|NCT02911168|PROCEDURE|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
58484859|NCT03678519|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
58484860|NCT00891943|OTHER|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
58484861|NCT05659186|DRUG|Tislelizumab|200mg IV Q3W
58484862|NCT05659186|DRUG|Anlotinib|12mg PO QD
58484863|NCT05659186|RADIATION|Radiotherapy|Multimodal Radiotherapy
58484864|NCT00996333|DRUG|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
58484865|NCT01103752|OTHER|no intervention, descriptive study|no intervention, descriptive study
58484866|NCT01523093|DRUG|Ondansetron|Orally Disintegrating Tablets 8mg
58484867|NCT05073146|OTHER|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
58484868|NCT01647347|DRUG|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
58484869|NCT01647347|OTHER|Water|
58484870|NCT03651401|DEVICE|Scapular muscle endurance test|The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
58484871|NCT03651401|OTHER|Pain intensity|"Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20."
58484872|NCT03651401|DEVICE|Upper Limb Functional Performance|The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
58484873|NCT01926561|OTHER|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
58484874|NCT00553878|DRUG|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
58484875|NCT03762993|BEHAVIORAL|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
58484876|NCT04178603|OTHER|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
58484877|NCT06518408|DRUG|Cabotegravir Injectable Product|long-acting regimen dosed every 2-months
58484878|NCT06518408|DRUG|Rilpivirine Injectable Product|long-acting regimen dosed every 2-months
58484879|NCT01167413|DEVICE|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
58484880|NCT01167413|OTHER|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
58484881|NCT02982980|PROCEDURE|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
58492309|NCT03801044|DIAGNOSTIC_TEST|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
58484882|NCT02982980|PROCEDURE|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
58484883|NCT05779189|BEHAVIORAL|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
58484884|NCT05779189|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
58484885|NCT05127863|BEHAVIORAL|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
58484886|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
58484887|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
58484888|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
58484889|NCT03530124|BIOLOGICAL|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
58484890|NCT03530124|BIOLOGICAL|DTaP|ACIP Recommended vaccine
58484891|NCT03530124|BIOLOGICAL|HBV|ACIP Recommended vaccine
58484892|NCT03530124|BIOLOGICAL|IPV|ACIP Recommended vaccine
58484893|NCT03530124|BIOLOGICAL|Hib|ACIP Recommended vaccine
58484894|NCT03120897|DEVICE|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
58484895|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
58484896|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
58484897|NCT00738933|DIETARY_SUPPLEMENT|placebo|Margarine product without plant stanol or sterol esters
58484898|NCT04029285|OTHER|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
58484899|NCT01718405|OTHER|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
58484900|NCT01718405|GENETIC|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
58484901|NCT04596384|OTHER|Best Practice|Participate in a surgeon-only perioperative care program
58484902|NCT04596384|PROCEDURE|Functional Assessment|Complete a functional assessment
58484903|NCT04596384|OTHER|Medical Device Usage and Evaluation|Wear an actigraph
58484904|NCT04596384|PROCEDURE|Nutritional Assessment|Complete a nutritional assessment
58484905|NCT04596384|OTHER|Quality-of-Life Assessment|Ancillary studies
58484906|NCT04596384|OTHER|Questionnaire Administration|Ancillary studies
58484907|NCT04596384|OTHER|TapCloud|Use TapCloud app
58484908|NCT01422343|PROCEDURE|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
58484909|NCT02861885|OTHER|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
58484910|NCT03008057|DIETARY_SUPPLEMENT|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
58484911|NCT03008057|DIETARY_SUPPLEMENT|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
58484912|NCT02572102|DIETARY_SUPPLEMENT|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
58484913|NCT02572102|DIETARY_SUPPLEMENT|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
58484914|NCT02572102|OTHER|Placebo|Lime juice, water and cherry flavoring
58484915|NCT03895840|DRUG|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
58484916|NCT04731545|DEVICE|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
58484917|NCT02910531|DIETARY_SUPPLEMENT|Alpha lipoic acid|Already mentioned in arm/group descriptions.
58484918|NCT02910531|DRUG|Placebo|Already mentioned in arm/group descriptions.
58484919|NCT01020240|BEHAVIORAL|Avolition|- avolition for cesarean discomforts
58137375|NCT01390493|BEHAVIORAL|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
58484920|NCT01020240|BEHAVIORAL|Orientation|"* avolition of cesarean discomfort~* physiotherapy orientation"
58484921|NCT01020240|BEHAVIORAL|Guide|"* avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation"
58484922|NCT01147510|DRUG|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
58484923|NCT01147510|DRUG|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
58484924|NCT01931319|DRUG|Intravenous baclofen|
58484925|NCT02769585|BEHAVIORAL|Self-hypnosis|Self-hypnosis
58484926|NCT02769585|BEHAVIORAL|CDE training|standard CDE training for an obese diabetic
58484927|NCT01082068|DRUG|XL147 (SAR245408)|given orally once daily as tablets
58484928|NCT01082068|DRUG|XL765 (SAR245409)|given orally twice daily as capsules
58484929|NCT01082068|DRUG|letrozole (Femara)|given orally once daily as tablets
58484930|NCT03328091|OTHER|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
58484931|NCT03328091|OTHER|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
58484932|NCT01096355|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
58484933|NCT01096355|OTHER|diagnostic laboratory biomarker analysis|
58484934|NCT01096355|OTHER|pharmacogenomic studies|
58484935|NCT01096355|OTHER|pharmacological study|
58484936|NCT04298671|BEHAVIORAL|Yoga-Pilates|As above
58484937|NCT01308177|DRUG|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
58484938|NCT00000426|DRUG|Calcium supplement|
58484939|NCT02484885|OTHER|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
58484940|NCT05938400|DEVICE|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
58484941|NCT04411667|DRUG|Octagam|Standard of Care plus Octagam infusion for 3 days.
58484942|NCT05240391|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
58484943|NCT05240391|DRUG|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
58484944|NCT03275649|OTHER|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
58484945|NCT02559999|OTHER|Painful tonic stimuli|
58484946|NCT02559999|OTHER|non-painful stimuli|
58484947|NCT00790842|DRUG|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
58484948|NCT00790842|DRUG|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
58484949|NCT00790842|DRUG|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
58484950|NCT05234697|DRUG|Remifentanil|Remifentanil was used for maintenance of anesthesia.
58484951|NCT05945537|DRUG|INI-822 (A)|Different dose levels of INI-822
58484952|NCT05945537|OTHER|Placebo (B)|Matching placebo to INI-822
58484953|NCT02352389|OTHER|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
58484954|NCT02352389|OTHER|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
58484955|NCT02352389|OTHER|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
58484956|NCT02352389|OTHER|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
58484957|NCT02352389|OTHER|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
58484958|NCT03193593|DRUG|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
58484959|NCT03193593|DRUG|EB-001|Single injection of EB-001 into Pectoralis Muscle
58484960|NCT02713464|BEHAVIORAL|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
58484961|NCT02064257|BEHAVIORAL|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
58484962|NCT01131689|DRUG|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
58484963|NCT05220072|DRUG|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
58484964|NCT04685044|DEVICE|IH 1Tx32Rx Head Array|BrainPET insert
58484965|NCT06415136|DEVICE|SeaSpine Shoreline|The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
58484966|NCT05552989|OTHER|this is a non-interventional study|this is a non-interventional study
58484967|NCT02145377|BIOLOGICAL|PXVX0200 10E8|Oral dose of PXVX0200 10E8
58484968|NCT02145377|BIOLOGICAL|PXVX0200 10E9|Oral dose of PXVX0200 10E9
58484969|NCT02145377|BIOLOGICAL|Placebo|Oral dose of sodium bicarbonate buffer
58484970|NCT02145377|BIOLOGICAL|Shanchol|Licensed comparator
58484971|NCT03710577|BEHAVIORAL|Yoga|1 session
58484972|NCT03710577|BEHAVIORAL|Quiet Rest|1 session
58484973|NCT04254172|DEVICE|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
58484974|NCT05510596|OTHER|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
58484975|NCT05510596|OTHER|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
58484976|NCT05510596|OTHER|Neuropsychological tests|Neuropsychological tests
57782017|NCT06740994|PROCEDURE|preprocedural ultrasound guided midline technique|"a preprocedural ultrasound scanning will be done, and skin marking of the best quality space will be made.~the site of injection and the insertion angle of the needle will be determined by ultrasound.~continuous spinal anesthesia will be performed via midline approach."
57782018|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
57782019|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
57782020|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
57782021|NCT01265641|DRUG|AZD1981, 2000mg|Single oral dose, tablets
57782022|NCT01265641|DRUG|AZD1981, 200mg|Single oral dose, tablets
57782023|NCT01265641|DRUG|Moxifloxacin, 400mg|Single oral dose, capsule
57782024|NCT01265641|DRUG|Placebo|Single oral dose, tablets
57782025|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
57782026|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
57782027|NCT05918913|DRUG|Revumenib|Revumenib administered orally every 12 hours.
57782028|NCT04922736|DEVICE|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
57782029|NCT06362967|COMBINATION_PRODUCT|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG|For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
57782030|NCT06738537|OTHER|Focus Groups/Quantitative Survey for Patients|5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.
57782031|NCT06738537|OTHER|Focus Group/Quantitative Survey for HCPs|5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.
57782032|NCT06738537|OTHER|Qualitative Focus Group|Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.
57782033|NCT05975099|BIOLOGICAL|mRNA-1975|Dispersion delivered IM
57782034|NCT05975099|BIOLOGICAL|mRNA-1982|Dispersion delivered IM
57782035|NCT05975099|BIOLOGICAL|Placebo|Solution delivered IM
57782036|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
57782037|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
57782038|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
57782039|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
57782040|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
57782041|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
57782042|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
58484977|NCT01287741|DRUG|Rituximab|Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
58484978|NCT01287741|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
58484979|NCT01287741|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
57782043|NCT06731062|DEVICE|EF192A|EF192A will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. EF192A will be reapplied to the participants' back in a naive area and removed after 48 hours.
57782044|NCT06731062|DEVICE|Saline solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back in a naive area and removed after 48 hours.
57782045|NCT06734962|PROCEDURE|Apical surgery procedure using A-PRF|Participants will undergo an apical surgery procedure using A-PRF. Before the surgery and at follow-ups, patients will undergo comprehensive evaluation using clinical, radiological, and ultrasonographic techniques.
57782046|NCT06734962|PROCEDURE|Apical surgery without using A-PRF|Participants will undergo an apical surgery procedure without using A-PRF. Patients will undergo comprehensive evaluation before the surgery and at follow-ups using clinical, radiological, and ultrasonographic techniques.
57782047|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
57782048|NCT04699188|DRUG|JDQ443|KRAS G12C inhibitor
57782049|NCT04699188|DRUG|TNO155|SHP2 inhibitor
57782050|NCT04699188|BIOLOGICAL|tislelizumab|Anti PD1 antibody
57782051|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
57782052|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
57782053|NCT03493113|DIAGNOSTIC_TEST|EEG|
57784652|NCT02358460|DEVICE|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
57782054|NCT04876053|BEHAVIORAL|Healthy Food Delivery Intervention|Each weekly food box will include \~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
57782055|NCT06666764|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
57782056|NCT06666764|OTHER|Control|Best medical care
57782057|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
57782058|NCT04910087|DIAGNOSTIC_TEST|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
57782059|NCT05992896|DRUG|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
57782060|NCT05992896|DRUG|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
57782061|NCT01375114|DRUG|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
57782062|NCT01375114|DIETARY_SUPPLEMENT|Placebo|Placebo by mouth twice daily for 4 weeks.
57782063|NCT01375114|BEHAVIORAL|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
57782064|NCT06473779|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
57782065|NCT06473779|COMBINATION_PRODUCT|Budesonide/formoterol|AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
57782066|NCT06473779|COMBINATION_PRODUCT|Albuterol/budesonide (AIRSUPRA®)|AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
57782067|NCT06473779|COMBINATION_PRODUCT|Mannitol|NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
57782068|NCT06473779|COMBINATION_PRODUCT|Salbutamol|AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
57782069|NCT04193293|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
57782070|NCT04193293|BIOLOGICAL|Pembrolizumab|Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
57782071|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.
57782072|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
57782073|NCT06713304|BEHAVIORAL|A community-based Protective Behavioral Strategies program|"A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking."
57782074|NCT06188208|DRUG|VVD-130850|Oral tablets
57782075|NCT06188208|DRUG|Pembrolizumab|IV infusion
57782076|NCT06739733|DIAGNOSTIC_TEST|SRG|Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.
57784653|NCT00671684|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
57784654|NCT01913964|DRUG|Acetylcarnitine|
57784655|NCT01913964|DRUG|Placebo|(sugar pill)
58484980|NCT01287741|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
58484981|NCT01287741|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
58484982|NCT01287741|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
57782077|NCT06739733|DIAGNOSTIC_TEST|EMS|"Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals."
57782078|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
57782079|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
57782080|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
57782081|NCT03141528|OTHER|Self-learning|Training without supervision
57782082|NCT03141528|OTHER|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
57782083|NCT00614198|OTHER|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
57782084|NCT05956938|DEVICE|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
57782085|NCT05956938|DEVICE|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
57782086|NCT06329518|DRUG|Rezafungin|After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
57782087|NCT03866772|DRUG|Misoprostol Oral Tablet|50 mcg oral consumption
57782088|NCT03866772|DEVICE|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
57782089|NCT03027505|DRUG|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day"
57782090|NCT06741007|PROCEDURE|Retroperitoneal pelvic lymphatic and uterine vessel dissection|ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.
57782091|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
57782092|NCT06736938|DRUG|Propofol 1%|Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
57782093|NCT06736938|DRUG|Midazolam|Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
57782094|NCT06736938|DRUG|Pethidine|Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
57782095|NCT05107401|BEHAVIORAL|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
57782096|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
57782097|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
57782098|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
57782099|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
57782100|NCT05105009|DRUG|Furosemide Injection|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
57782101|NCT05105009|DRUG|Creatinine Powder|5g of creatinine (Sigma) in 250 ml of water was taken orally
57782102|NCT05105009|DRUG|Iohexol|5 ml iohexol (Omnipaque) intravenously
57782103|NCT06385210|OTHER|Semi structured interviews|Participants will be interviewed concerning perceived barriers to routine surgical video recording
57782104|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
57782105|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
57782106|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
57782107|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
57782108|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
57782109|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
57782110|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
57782111|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
57782112|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
57782113|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
57782114|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
57782115|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
57782116|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
57782117|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
57782118|NCT03935750|PROCEDURE|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
57782119|NCT03935750|PROCEDURE|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
57782120|NCT06364163|DIETARY_SUPPLEMENT|Herring oil concentrate|Capsules containing herring oil concentrate, taken daily for 8 weeks.
57782121|NCT06364163|DIETARY_SUPPLEMENT|Control|Capsules containing control oil, taken daily for 8 weeks.
57782122|NCT06215911|DRUG|Tovinontrine (CRD-750)|Tablets administered orally
57782123|NCT06215911|DRUG|Placebo|Tablets administered orally
57782124|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
57782125|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
57782126|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
57782127|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
57782128|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
57782129|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
57782130|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
57782131|NCT04843813|DIETARY_SUPPLEMENT|Lutein|Participants will consume daily soft gels containing the lutein supplement.
57782132|NCT04843813|DIETARY_SUPPLEMENT|Placebo|Participants will consume daily soft gels containing the safflower oil.
57782133|NCT06738355|BEHAVIORAL|PREVENT|The proposed study will assess the effectiveness of clinic-based outreach to increase vaccination rates for HPV at community clinics in rural counties. The study includes the following: (1) Boot camp translation to tailor messaging based on patient and provider input; (2) PREVENT randomized controlled trial (RCT) that will assign adult parent/caregiver participants to a timeline for receiving the vaccination messaging intervention; and (3) qualitative interviews with parents/caregivers, providers, and other healthcare team members and development of best practices, implementation guides and dissemination of findings for other clinics to implement the program on a broader scale. The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).
57782134|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
57782135|NCT04622020|PROCEDURE|Cervical Plexus Block with Local Anaesthesia|Ultrasound guided intermediate cervical plexus block
57782136|NCT04622020|PROCEDURE|Cervical Plexus Block with Depot Steroids|Ultrasound guided intermediate cervical plexus block
57782137|NCT05879068|DRUG|PM8002|IV infusion
57782138|NCT05879068|DRUG|Paclitaxel|IV infusion
57782139|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
57782140|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
57782141|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
57782142|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
57784656|NCT00042393|DRUG|Adefovir Dipivoxil|
57784657|NCT01016990|DRUG|valproic acid|
57784658|NCT01016990|GENETIC|western blotting|
57784659|NCT01016990|OTHER|laboratory biomarker analysis|
58484983|NCT02538978|BIOLOGICAL|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
57782143|NCT06740708|BEHAVIORAL|SCALE-NCD|"1. FCHV home visits every three months, including~   * For hypertension i. Blood pressure measurement with digital BP devices ii. Lifestyle counseling iii. Referral if uncontrolled BP (≥140/90 mmHg) for 3 months~  * For type 2 diabetes i. Fasting blood glucose measurement with glucometer ii. Lifestyle counseling focusing on diabetes management iii. Referral if uncontrolled diabetes (≥126mg/dl) for 3 months~  * For current smokers i. Smoking cessation counseling ii. Referral for nicotine replacement therapy if request by participants~2. Mobile phone messages, including~   * Lifestyle modification~  * Conveyed as voice or text messages, depending on participant preference"
57782144|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
57782145|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
57782146|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
57782147|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
57782148|NCT05009979|DRUG|F18-FDG|Within approximately 2 weeks of each 18F-DCFPyL PET/CT scan, participants will be scanned with a 18F-FDG PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.
57782149|NCT05009979|DEVICE|MRI|A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.
57782150|NCT05009979|DEVICE|CT|A standard of care CT and/or MRI will be performed within 2 months of each 18F-DCFPyL PET/CT.
57782151|NCT05009979|DRUG|F18-DCFPyL|Each subject will receive a single IV dose of 18F-DCFPyL by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL PET/CT imaging will consist of the 18F-DCFPyL injection, followed by a approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/- 10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.
57782152|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
57782153|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
57782154|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
57782155|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
57782156|NCT02724878|DRUG|Bevacizumab|
57782157|NCT02724878|DRUG|Atezolizumab|
57782158|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
57782159|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
57782160|NCT06727721|BIOLOGICAL|mesenchymal stem cells with OCN-19|The patient received mesenchymal stem cells with OCN-19 three times
57782161|NCT06727721|BIOLOGICAL|Mesenchymal stem cells|Ordinary mesenchymal stem cells were given
57782162|NCT06727721|BIOLOGICAL|albumin injection|Placebo
57782163|NCT06578728|DRUG|Methotrexate|25mg/mL intralesional injection into nail bed/nail matrix
57782164|NCT06578728|DRUG|Triamcinolone Acetonide 10mg/mL|10mg/mL intralesional injection into nail bed/nail matrix
57782165|NCT06578728|DRUG|Saline|saline intralesional injection into nail bed/nail matrix
57782166|NCT05274347|OTHER|Muti-faceted virtual, remote intervention|Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
57782167|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
57782168|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
57782169|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
57782170|NCT06738745|DRUG|HRS-2189|HRS-2189
57782171|NCT06738745|DRUG|HRS-5041|HRS-5041
57782172|NCT05520567|DRUG|Gilteritinib|Oral
57782173|NCT05520567|DRUG|Venetoclax|Oral
57782174|NCT05520567|DRUG|Azacitidine|Subcutaneous injection or intravenous infusion
57784660|NCT01016990|OTHER|pharmacological study|
57784661|NCT00131560|GENETIC|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
57782175|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
57782176|NCT04488055|BEHAVIORAL|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
57782177|NCT04488055|BEHAVIORAL|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
57782178|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
57782179|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
57782180|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction|"The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment"
57782181|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction plus inertial exercises|"The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group."
57782182|NCT04590326|DRUG|REGN5668|REGN5668 will be administered by once weekly intravenous (IV) infusion.
57782183|NCT04590326|DRUG|Cemiplimab|For Module 1, after a minimum of a 3-week monotherapy lead-in of REGN5668, cemiplimab will be administered concomitantly every 3 weeks (Q3W) by IV infusion.
57782184|NCT04590326|DRUG|REGN4018|For Module 2, a 4-5 week monotherapy lead-in of REGN4018 will be administered by once weekly IV infusion. After lead-in, REGN5668 and REGN4018 will be administered concomitantly.
57782185|NCT04590326|DRUG|Sarilumab|Administered by IV infusion as prophylaxis for mitigating potential CRS in patients receiving REGN4018
57782186|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
57782187|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
57782188|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
57782189|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
57782190|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
57782191|NCT06586606|DRUG|MK-1708|Oral administration
57782192|NCT06586606|DRUG|Itraconazole|Oral administration
57782193|NCT04875078|DEVICE|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
57782194|NCT06348719|PROCEDURE|Robot-assisted laparoscopy|The experimental procedure corresponds to robot-assisted laparoscopy.
57782195|NCT06348719|PROCEDURE|conventional laparoscopy|"The control procedure corresponds to conventional laparoscopy."
57782196|NCT06348719|OTHER|Prospective cohort study|A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
58484984|NCT02538978|BIOLOGICAL|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
57782197|NCT06348719|OTHER|Retrospective cohort study|Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.
57782198|NCT06348719|OTHER|information and consent|information and consent
57782199|NCT06348719|OTHER|randomization|Randomization
57782200|NCT06348719|OTHER|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
57782201|NCT06348719|OTHER|Surgical data collection|Surgical data collection at Day 0
57782202|NCT06348719|OTHER|Biological data collection|Biological data collection at Day 1
57782203|NCT06348719|OTHER|Collection of histological data from the surgical specimen|Collection of histological data from the surgical specimen et Day 42
57782204|NCT06348719|OTHER|Phone calls|Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
57782205|NCT06348719|OTHER|Pain assessment|Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
57782206|NCT06348719|OTHER|Collect of data on non-reimbursed transport|Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
57782207|NCT06348719|OTHER|Collect of everyday help|Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
57782208|NCT06348719|OTHER|Collection of the business resumption date|Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
57782209|NCT06348719|OTHER|SF36 questionnaire|SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
57782210|NCT06348719|OTHER|Questionnaire EQ5D-5L|Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
57782211|NCT06348719|OTHER|FIGO Stadium|FIGO Stadium at inclusion and Day 42
57782212|NCT06348719|OTHER|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
57782213|NCT06348719|OTHER|Collection of adjuvant treatments|Collection of adjuvant treatments at month 6
57782214|NCT06348719|OTHER|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
57782215|NCT06348719|OTHER|Collection of data|Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used
57782216|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
57782217|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
57782218|NCT04970901|DRUG|Glofitamab|IV infusion
57782219|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
57782220|NCT04970901|DRUG|Obinutuzumab|IV infusion
57782221|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
57782222|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
57782223|NCT06312020|DRUG|HZN-1116|Subcutaneous Administration
57782224|NCT06312020|DRUG|Placebo|Subcutaneous Administration
57782225|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
57782226|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
57782227|NCT04143724|DRUG|ACE-536|Specified dose on specified days
57782228|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
57782229|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
57782230|NCT05627856|DRUG|GNC-038|Administration by intravenous infusion
57782231|NCT05616013|BIOLOGICAL|Bimagrumab|Human monoclonal antibody to the activin receptor type II
57782232|NCT05616013|DRUG|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
58484985|NCT03913507|DEVICE|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
58484986|NCT00636298|DRUG|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
57782233|NCT05616013|OTHER|Bimagrumab Placebo|Placebo
57782234|NCT00650078|DRUG|MR prednisone|1 x 5 mg daily
57782235|NCT00650078|DRUG|Placebo|1x daily
57782236|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
58137376|NCT04993664|DRUG|Pelacarsen (TQJ230)|The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
57782237|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
57782238|NCT06075095|DRUG|BGF MDI HFO 320/14.4/9.6μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
57782239|NCT06075095|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
57782240|NCT06075095|DRUG|Placebo MDI HFA|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
57782241|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
57782242|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
57782243|NCT06739421|PROCEDURE|NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
57782244|NCT06739421|PROCEDURE|NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
57782245|NCT05252962|DIETARY_SUPPLEMENT|Collagen Peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
57782246|NCT03270111|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
57782247|NCT03270111|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
57782248|NCT03270111|BEHAVIORAL|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
57782249|NCT03270111|BEHAVIORAL|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
57782250|NCT05444504|DEVICE|Cup|an insertable vaginal cup ('cup')
57782251|NCT05444504|DEVICE|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
57782252|NCT06740955|RADIATION|hypofractionated postoperative radiotherapy|hypofractionated radiotherapy with a total dose of 52.5Gy, 3.5 Gy/ fraction, 15 fractions, 5 fractions per week,
57782253|NCT06740955|RADIATION|Conventionally fractionated postoperative radiotherapy|Conventionally fractionated radiotherapy with a total dose of 60 Gy, 2 Gy/ fraction, 30 fractions, 5 fractions per week,
57782254|NCT02422147|PROCEDURE|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
57782255|NCT04306315|BIOLOGICAL|Brodalumab|Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
57782256|NCT05673304|RADIATION|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
57782257|NCT06568458|DRUG|Nintedanib|Specified Dose on specified days
57782258|NCT06568458|DRUG|BMS 986278|Specified dose on specified days
57782259|NCT04899310|BIOLOGICAL|mRNA-3705|A sterile liquid for injection
57782260|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
57782261|NCT05990335|BEHAVIORAL|mHealth application (custom)|Smartphone based application designed to engage user executive functions
57782262|NCT05378347|DEVICE|Medtronic Endurant II or Endurant IIs Stent Graft System|EVAR treatment with Medtronic Endurant II/IIs Stent Graft System
57782263|NCT05378347|DEVICE|Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis|EVAR treatment with Excluder / Excluder Conformable Stent Graft System
57782264|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57782265|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
57782266|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
57782267|NCT04963153|PROCEDURE|Echocardiography|Undergo echocardiography
58492310|NCT03801044|DIAGNOSTIC_TEST|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
58492311|NCT02249832|DEVICE|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
57782268|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
57782269|NCT04963153|DRUG|Erdafitinib|Given PO
57782270|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
57782271|NCT05475171|DRUG|Lorigerlimab|Given by vein (IV)
57782272|NCT06060665|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for up to 52 weeks
57782273|NCT06060665|DRUG|Placebo|One capsule daily for up to 52 weeks
57782274|NCT06542588|COMBINATION_PRODUCT|HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)|Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
57782275|NCT05245513|BEHAVIORAL|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
57782276|NCT05245513|BEHAVIORAL|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
57782277|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
57782278|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
57782279|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
57782280|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
57782281|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
57782282|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
57782283|NCT06730074|DEVICE|Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)|This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
57782284|NCT05678998|DRUG|WTX-330|Investigation Product
57782285|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
57782286|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
57782287|NCT01518114|BEHAVIORAL|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
57782288|NCT04656652|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
57782289|NCT04656652|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
57782290|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
57782291|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
57782292|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
57782293|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
57782294|NCT06641232|PROCEDURE|Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.|"The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block."
57782295|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
58484987|NCT03613519|BEHAVIORAL|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
58492312|NCT03311698|BEHAVIORAL|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
57782296|NCT04493853|DRUG|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
57782297|NCT04493853|OTHER|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
57782298|NCT04493853|DRUG|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
57784662|NCT04488172|DIETARY_SUPPLEMENT|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
57784663|NCT02912429|DEVICE|Patellofemoral Arthroplasty|
58484988|NCT03613519|BEHAVIORAL|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
58484989|NCT03613519|BEHAVIORAL|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
57782299|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
57782300|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
57782301|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
57782302|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
57782303|NCT06178354|OTHER|Survey Administration|Ancillary studies
57782304|NCT06740539|PROCEDURE|Catheter ablation of atrial fibrillation|Catheter ablation of atrial fibrillation
57782305|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
57782306|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
57782307|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
57782308|NCT04120805|DEVICE|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
57782309|NCT04120805|OTHER|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
57782310|NCT03519581|DEVICE|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
57782311|NCT03519581|DEVICE|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
57782312|NCT04219709|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
57782313|NCT04219709|OTHER|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
57782314|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
57782315|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
57782316|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
57782317|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
57782318|NCT01658930|PROCEDURE|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
57784664|NCT04271384|COMBINATION_PRODUCT|nivolumab|Combined neoadjuvant therapy consisting of nivolumab + SABR
57782319|NCT01658930|PROCEDURE|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
57782320|NCT05073679|DRUG|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
57782321|NCT05073679|OTHER|Control|Methylcellulose and gelatin capsule only
57782322|NCT04024761|BIOLOGICAL|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
57782323|NCT04024761|DRUG|Fludarabine|Fludarabine is a chemotherapy agent
57782324|NCT04024761|DRUG|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
57782325|NCT06740084|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the EUC plus the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised Guidance and Counselling Coordinators (GCC) at schools in 6 sessions. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the GCC helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
57782326|NCT06740084|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC): Guidance and counselling coordinators in the schools provide some counselling to students who need it. Building on the existing structure, enhanced usual care in the Y-mind programme, will be enhanced in three ways: 1) Teaching staff will receive basic training on common mental health conditions affecting youth in Ghana with an emphasis on depression and suicidal symptoms and treatment. The WHO guidelines for school health services will form the basis for the training for teachers. 2) Nurses in all schools and other relevant local health care professionals will be trained in mental health, substance-use and self-harm including guidelines on when and where to refer young people for psychiatric care. The World Health Organization (WHO) Mental Health Gap intervention guide (mhGAP) will be used for training of nurses and other health care professionals . 3) The study team will provide a letter for the Guidance and Counselling Coordinators for the participant.
57782327|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
57782328|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
57782329|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
57782330|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
57782331|NCT06719635|PROCEDURE|Laparoscopic Presacral Neurectomy|Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.
57782332|NCT06719635|PROCEDURE|Fluoroscopically guided Superior Hypogastric Plexus Neurolysis|The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
57782333|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
57782334|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
57782335|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
57782336|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
57782337|NCT03941730|PROCEDURE|Biopsy|Undergo tissue biopsy
57782338|NCT03941730|PROCEDURE|Computed Tomography|Undergo CT
57782339|NCT03941730|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
57782340|NCT03941730|PROCEDURE|Positron Emission Tomography|Undergo PET
57782341|NCT03941730|BIOLOGICAL|Therapeutic Estradiol|Given PO
57782342|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
57782343|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
57782344|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
57782345|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
57782346|NCT05919264|DRUG|mFOLFOX-6|mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
57782347|NCT05919264|DRUG|Nivolumab|Nivolumab will be administered per the prescribing information in combination with FOG-001
57782348|NCT05919264|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
57782349|NCT05919264|DRUG|Bevacizumab|Bevacizumab will be administered per the prescribing information in combination with FOG-001
58484990|NCT00513916|DIETARY_SUPPLEMENT|soy isoflavones|High or low dose of soy isoflavones in the diet.
58484991|NCT03641586|DRUG|BGB-283|
58484992|NCT02622282|OTHER|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
58484993|NCT02622282|OTHER|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
58484994|NCT02622282|OTHER|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
58484995|NCT02297594|DRUG|AK0529|AK0529 capsule for oral administration
58484996|NCT02297594|DRUG|Placebo|Sugar placebo capsule for oral administration
58484997|NCT04129008|DRUG|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
58484998|NCT04129008|DRUG|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
58484999|NCT03983811|DRUG|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
58485000|NCT03983811|DRUG|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
58485001|NCT03983811|OTHER|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
58485002|NCT05251324|OTHER|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
58485003|NCT02581241|DEVICE|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
58485004|NCT06344221|DEVICE|Dextrain Manipulandum and haptic feedback device|Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.
58485005|NCT04179669|DRUG|IBI306|Administered by subcutaneous injection
58485006|NCT04179669|DRUG|placebo|Administered by subcutaneous injection
58485007|NCT00179192|PROCEDURE|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
58485008|NCT00179192|PROCEDURE|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
58485009|NCT00328107|BIOLOGICAL|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
58485010|NCT02289157|DEVICE|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
58485011|NCT02991976|PROCEDURE|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
58485012|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
58485013|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
58485014|NCT05740540|DEVICE|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
58485015|NCT05740540|DEVICE|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
58485016|NCT06395337|DRUG|[111In]In-DOTA-ANTI-CEA antibody injection|tracer injection
58485017|NCT06395337|RADIATION|SPECT/CT scan|abdominal and thoracic SPECT/CT scan
58485018|NCT06395337|PROCEDURE|Resection surgery|oncological resection surgery will be performed extended with the use of dual-modality imaging.
58485019|NCT03976219|OTHER|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
58485020|NCT05254704|OTHER|TEX-Q-F before scheduled surgery|"The TEX-Q-F questionnaire (French version of the breif version of the TEX-Q) contains 15 questions to assess the patient's overall expectations concerning the surgery.~The first 11 questions concern the patient's expectations regarding the postoperative period: pain and functional recovery. The last 4 questions focus on the patient's hopes for the outcome of the surgery. Each item is scored from 0 to 10, according to the intensity of the level of expectation."
58485021|NCT00753649|BIOLOGICAL|Infanrix™ hexa|Intramuscular, three doses
58492313|NCT00463567|DRUG|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
57782350|NCT06737263|DEVICE|BioHPP abutment|Patients in the test group receive abutments made of BioHPP
57782351|NCT06737263|DEVICE|Titanium abutment|Patients in the control group receive abutments made of titanium
58485022|NCT05684393|OTHER|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
58485023|NCT01342016|DRUG|tacrolimus capsule|oral
58485024|NCT01342016|DRUG|tacrolimus placebo|oral
58485025|NCT01342016|DRUG|leflunomide tablet|oral
58485026|NCT01342016|DRUG|leflunomide placebo|oral
58485027|NCT01342016|DRUG|prednisone|oral
58485028|NCT03330301|OTHER|D-tect|"1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
58485029|NCT04312724|DEVICE|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
58485030|NCT02224001|PROCEDURE|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
58485031|NCT03515330|OTHER|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
58485032|NCT06172309|DRUG|NTQ1062|tablet(s) PO
58485033|NCT05915910|DIAGNOSTIC_TEST|Specimen Donation|blood donation
58485034|NCT01165216|DRUG|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
58485035|NCT01165216|DRUG|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
58485036|NCT01165216|DRUG|Paclitaxel|IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles
58485037|NCT01165216|DRUG|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
58485038|NCT02268357|DRUG|Propranolol|Oral propranolol capsules
58485039|NCT04129463|DEVICE|Subscleral Trabeculectomy (SST) with Iris incarceration|Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
58485040|NCT04129463|DEVICE|Conventional trabeculotomy|Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
58485041|NCT04665167|BEHAVIORAL|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
58485042|NCT04665167|BEHAVIORAL|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
58485043|NCT05086107|DRUG|BV100|Rifabutin for infusion
58485044|NCT01463644|DRUG|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
58485045|NCT01463644|DRUG|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
58485046|NCT03318302|OTHER|Survey|Survey of the adult population in Israel
58485047|NCT04653077|OTHER|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
58485048|NCT00560001|BEHAVIORAL|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
58485049|NCT02812342|DRUG|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
58485050|NCT03937934|BEHAVIORAL|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
58485051|NCT00972062|OTHER|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
58485052|NCT00972062|OTHER|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
58485053|NCT06347120|PROCEDURE|nasogastric tube|nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.
58485054|NCT06347120|OTHER|NOM without NGT insertion|intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h
58485055|NCT00776074|DRUG|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58485056|NCT00776074|DRUG|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
58485057|NCT06324513|DIETARY_SUPPLEMENT|Mediterranean Crohn's Disease Exclusion Diet (Med-CDED)|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
58485058|NCT06324513|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease.
58485059|NCT00256997|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
58485060|NCT00256997|DRUG|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
58485061|NCT04490876|PROCEDURE|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
58485062|NCT01647217|DRUG|Terpinen-4-ol|Lid scrub once or twice per day for one month.
58485063|NCT01647217|OTHER|Placebo|Lid scrub once or twice per day for one month
58485064|NCT02886455|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
58485065|NCT02886455|OTHER|New adhesive strip|This a newly developed adhesive strip.
58485066|NCT05039892|DRUG|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
58485067|NCT02106390|BIOLOGICAL|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
58485068|NCT02106390|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
58485069|NCT03599739|BIOLOGICAL|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
58485070|NCT00829504|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
58485071|NCT00829504|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg
58485072|NCT01999257|OTHER|Online pre-test genetic education tool|See Arm Descriptions above.
58485073|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
58485074|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
58485075|NCT01840982|DIETARY_SUPPLEMENT|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
58485076|NCT01840982|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
58485077|NCT02424877|PROCEDURE|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
58485078|NCT01559857|DRUG|Pioglitazone|30mg once daily for 12 weeks
58485079|NCT01559857|DRUG|Sugar Pill|Placebo
58485080|NCT02772367|PROCEDURE|skin punch biopsy|
58485081|NCT00578825|DRUG|Lopinavir / Ritonavir plus Ribavirin|
58485082|NCT00217607|DRUG|paclitaxel|
58485083|NCT05498714|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
58485084|NCT05498714|DRUG|CSP＋lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
58485085|NCT02718144|DRUG|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
58485086|NCT01678404|DRUG|131I-rituximab|
58492314|NCT00463567|DRUG|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
58485087|NCT03089281|DEVICE|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
58485088|NCT05255315|BEHAVIORAL|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
58485089|NCT02217202|DEVICE|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
58485090|NCT03317184|PROCEDURE|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
58485091|NCT03317184|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
58485092|NCT00541541|PROCEDURE|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
58485093|NCT03677557|DRUG|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
58485094|NCT02645669|PROCEDURE|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
58485095|NCT02645669|PROCEDURE|Control site|Only Scaling and Root planing was done.
58485096|NCT02185482|BEHAVIORAL|Physician Supported Care|
58485097|NCT02185482|OTHER|Usual care|
58485098|NCT03522896|OTHER|control|balancing sugars and organic acids
58485099|NCT03522896|OTHER|test meal 1|orange juice plus hesperidin low dose
58485100|NCT03522896|OTHER|test meal 2|orange juice plus hesperidin higher dose
58485101|NCT03522896|OTHER|test meal 3|diluted orange juice plus hesperidin low dose
58485102|NCT00040989|DRUG|BAY 56-3722|
58485103|NCT00040989|PROCEDURE|enzyme inhibitor therapy|
58485104|NCT05509140|OTHER|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
58485105|NCT05846854|OTHER|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
58485106|NCT03946475|OTHER|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
58485107|NCT04630496|BEHAVIORAL|Fitbit|Electronic activity tracker
58485108|NCT05285046|OTHER|No intervention|No intervention
58485109|NCT00005618|DRUG|arsenic trioxide|
58485110|NCT05805917|DEVICE|Neoviderm Skin Emulsion medical device|Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
58485111|NCT05805917|DRUG|Connettivina 0.2% Cream|Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
58485112|NCT01965574|PROCEDURE|Trendelenburg position|
58485113|NCT02495519|DRUG|Imatinib|Imatinib 400 mg/day until disease progression
58485114|NCT03423784|DEVICE|HA BPX V3.3|medical device containing HA
58485115|NCT03423784|OTHER|Dentinox-Gel N|Anaesthetic gel
58485116|NCT02395471|DEVICE|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
58485117|NCT05542030|DIAGNOSTIC_TEST|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
58485118|NCT05542030|DIAGNOSTIC_TEST|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
58485119|NCT05542030|DIAGNOSTIC_TEST|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
58485120|NCT00983658|DRUG|huMAb OX40L|Intravenous repeating dose
58485121|NCT00983658|DRUG|placebo|Intravenous repeating dose
58485122|NCT05465577|OTHER|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
58485123|NCT02369796|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
58485124|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q14 day schedule
58485125|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q21 day schedule
58485126|NCT00604487|DEVICE|ARD (Atad Ripener Device)|Atad double balloon ripener device
58485127|NCT00604487|DEVICE|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
58485128|NCT00604487|DEVICE|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
58485129|NCT04506138|DRUG|Camrelizumab|Camrelizumab 200mg D1, D22
58485130|NCT04506138|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
58485131|NCT04506138|DRUG|Carboplatin|Carboplatin AUC5 D1, D22
58485132|NCT01442103|DEVICE|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
58485133|NCT00087867|DRUG|SCIO-469|two 30-mg capsules three times daily
58485134|NCT00087867|DRUG|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
58485135|NCT06514560|DRUG|Miltefosine|Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
58485136|NCT01010646|DRUG|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
58485137|NCT01010646|DRUG|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
58485138|NCT01010646|DRUG|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
58485139|NCT05585450|DEVICE|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
58485140|NCT05585450|DEVICE|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
58485141|NCT01209533|DRUG|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
58485142|NCT06226493|DEVICE|Transcutaneous vagus nerve stimulation|The Parasym Plus device (https://parasym.io) is a transcutaneous auricular vagus nerve stimulator that has been deemed non-significant risk (NSR) by the FDA. Transcutaneous auricular vagus nerve stimulator is a non-significant risk device, as it involves electrical stimulation of the external ear using an ear clip, with no invasive components. The stimulation parameters will be limited to the confines of existing published data. tVNS is safe and well tolerated at doses tested in research studies. The Parasym device is considered low risk when used in accordance with the instructions for use. Participants will be properly trained to use the device, and those with contraindications will be excluded for extra precaution. A low incidence of skin irritation has been reported. No serious adverse events have been reported.
58485143|NCT02873351|DRUG|carbidopa-levodopa 25-100 mg|included in arm description
58485144|NCT02873351|DRUG|placebo for carbidopa-levodopa 25-100 mg|included in arm description
58485145|NCT04336878|BEHAVIORAL|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
58485146|NCT01512238|OTHER|Pharmaceutical care|Information about medicine, sideeffect, adherence
58485147|NCT00663091|DRUG|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
58492315|NCT00463567|DRUG|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
58492316|NCT00463567|DRUG|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
58492317|NCT00463567|DRUG|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
57782352|NCT06737263|DEVICE|Zirconia abutment|Patients in the control group receive abutments made of zirconia
58485148|NCT00663091|DRUG|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
58485149|NCT00663091|DRUG|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
58485150|NCT03498404|RADIATION|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
58485151|NCT03498404|OTHER|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
58485152|NCT05611190|DIAGNOSTIC_TEST|CT-FFR|CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
58485153|NCT05611190|DIAGNOSTIC_TEST|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice.
58485154|NCT04147780|PROCEDURE|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
58485155|NCT02949284|DRUG|Abiraterone Acetate|Given PO
58485156|NCT02949284|DRUG|Androgen Receptor Antagonist ARN-509|Given PO
58485157|NCT02949284|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC
58485158|NCT02949284|DRUG|Prednisone|Given PO
58485159|NCT02949284|OTHER|Quality-of-Life Assessment|Ancillary studies
58485160|NCT02949284|OTHER|Questionnaire Administration|Ancillary studies
58485161|NCT02949284|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
58485162|NCT02684825|DEVICE|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
58485163|NCT04601649|BEHAVIORAL|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
58485164|NCT03549767|DEVICE|Springfusor|Springfusor for administration of magnesium sulphate
58485165|NCT03549767|PROCEDURE|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
58485166|NCT03725891|DRUG|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
58485167|NCT03725891|DRUG|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58485168|NCT03725891|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58485169|NCT03811704|DEVICE|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
58485170|NCT03811704|DRUG|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
58485171|NCT01290770|OTHER|blood sample|blood sample at inclusion and 1 month after inclusion
58485172|NCT02840461|DRUG|Ivermectin Cream, 1%|
58485173|NCT02840461|DRUG|Placebo/Vehicle cream|
58485174|NCT02079961|DIETARY_SUPPLEMENT|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
58485175|NCT02079961|BEHAVIORAL|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
58485176|NCT00854399|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
58485177|NCT03384862|DIETARY_SUPPLEMENT|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
58485178|NCT03384862|DIETARY_SUPPLEMENT|Placebo|Placebo pills, with same appearance as intervention pills.
58485179|NCT03384862|DIETARY_SUPPLEMENT|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
58485180|NCT04550884|DIAGNOSTIC_TEST|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
58485181|NCT03949803|BEHAVIORAL|Morning Chocolate Timing|During two consecutive weeks volunteers will eat chocolate within 1 hour of their habitual wake-time (100g).
58485182|NCT03949803|BEHAVIORAL|Evening Chocolate Timing|During two consecutive weeks volunteers will eat chocolate within 1 hours of habitual bedtime (100g).
58485183|NCT03949803|BEHAVIORAL|No Chocolate Timing|During two consecutive weeks volunteers will not eat chocolate.
58485184|NCT04085289|DRUG|Galcanezumab|Administered SC
58485185|NCT04085289|DRUG|Placebo|Administered SC
58485186|NCT03370900|OTHER|Testing|Participants either received 20 case testing with or without feedback
58485187|NCT02503761|DRUG|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
58485188|NCT00156468|BEHAVIORAL|Provider Prompt|
58485189|NCT00273494|PROCEDURE|Surgery|
58485190|NCT05173753|OTHER|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
58485191|NCT02945488|OTHER|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
58485192|NCT02945488|OTHER|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
58485193|NCT02945488|OTHER|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
58485194|NCT01834911|DRUG|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
58485195|NCT04563143|OTHER|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
58485196|NCT05394155|DIETARY_SUPPLEMENT|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
58485197|NCT04306341|BEHAVIORAL|real time fMRI neurofeedback|Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
58485198|NCT04530084|DEVICE|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
58485199|NCT03326336|COMBINATION_PRODUCT|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
58485200|NCT00104923|DRUG|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
58485201|NCT02955849|DEVICE|SLT laser|Patients will be offered initial SLT laser by doctors
58485202|NCT00501917|DRUG|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
58485203|NCT02586740|PROCEDURE|Pulmonary artery rehabilitation|
58485204|NCT02675634|DEVICE|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
58485205|NCT02675634|DEVICE|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
58485206|NCT02675634|DEVICE|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
58485207|NCT00721968|DEVICE|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
58485208|NCT00721968|PROCEDURE|cataract surgery alone|Cataract surgery alone
58485209|NCT02039141|OTHER|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
58485210|NCT01543048|OTHER|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
58485211|NCT03657082|DEVICE|PEP-10|Bottle PEP with a water level of 10 cmH2O
58485212|NCT03657082|DEVICE|PEP-1|Bottle PEP with a water level of 1 cmH2O
58485213|NCT02462135|BEHAVIORAL|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
58485214|NCT02462135|BEHAVIORAL|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
58485215|NCT03335670|DRUG|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
58485216|NCT00201110|BEHAVIORAL|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
58485217|NCT00201110|BEHAVIORAL|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
58485218|NCT01852409|DRUG|bevacizumab|
58485219|NCT00206817|DEVICE|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
57784665|NCT01196104|DRUG|Technosphere® Insulin Inhalation Powder|
58485220|NCT05153096|DRUG|NBL-015|NBL-015 by intravenous infusion
58485221|NCT03516968|DRUG|Monthly bolus of cholecalciferol per os|Bolus therapy (100'000 - 200'000 IU/month depending on age: \< or ≥ 9 years old) for 3 months
58485222|NCT03516968|DRUG|Daily dose of cholecalciferol per os|Daily substitution (3'500 to 6'500 IU/day depending on age: \< or ≥ 9 years old) for 3 months
58485223|NCT03516968|OTHER|Control|no cholecalciferol therapy
58485224|NCT01088698|RADIATION|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
58485225|NCT00002496|DRUG|chemotherapy|
58485226|NCT00002496|DRUG|cisplatin|
58485227|NCT00002496|DRUG|fluorouracil|
58485228|NCT00002496|PROCEDURE|conventional surgery|
58485229|NCT00002496|RADIATION|low-LET cobalt-60 gamma ray therapy|
58485230|NCT00002496|RADIATION|low-LET electron therapy|
58485231|NCT00002496|RADIATION|low-LET photon therapy|
58485232|NCT01497223|DRUG|MGCD290|1 Oral Dose Administration
58485233|NCT03236636|DRUG|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
58485234|NCT03236636|DRUG|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
58485235|NCT01012440|DEVICE|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
58485236|NCT01012440|DEVICE|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
58485237|NCT02181088|BIOLOGICAL|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10\^9 vp
58485238|NCT02181088|BIOLOGICAL|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10\^10 vp
58485239|NCT02181088|BIOLOGICAL|MVA RH5 low dose|MVA RH5 at 1 x 10\^8 pfu
58485240|NCT02181088|BIOLOGICAL|MVA RH5 full dose|MVA RH5 at 2 x 10\^8 pfu
58485241|NCT00633113|PROCEDURE|MPPA|- Medial Parapatellar Arthrotomy
58485242|NCT00633113|PROCEDURE|SV|- Subvastus Technique
58485243|NCT02379091|DRUG|Namilumab|Namilumab subcutaneous injection
58485244|NCT02379091|DRUG|Placebo|Namilumab placebo-matching subcutaneous injection
58485245|NCT02379091|DRUG|Methotrexate|Methotrexate tablets
58485246|NCT02379091|DRUG|Folic/folinic acid|Folic/folinic acid tablets
58485247|NCT03636516|DEVICE|SWL|extracorporeal shockwave lithotripsy apply
58485248|NCT04145518|DRUG|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
58485249|NCT04561765|DEVICE|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
58485250|NCT04561765|DEVICE|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
58485251|NCT02302339|DRUG|glembatumumab vedotin|
58485252|NCT02302339|DRUG|glembatumumab vedotin and varlilumab|
58485253|NCT02302339|DRUG|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
58485254|NCT02302339|DRUG|glembatumumab vedotin and CDX-301|
58485255|NCT05419778|DEVICE|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
58485256|NCT05419778|DEVICE|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
58485257|NCT03060096|OTHER|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
58485258|NCT03060096|OTHER|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
58485259|NCT03060096|OTHER|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
58485260|NCT06096961|BEHAVIORAL|Baby smell|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process.
57784666|NCT01196104|DRUG|Insulin Aspart|Usual Care
58485261|NCT04799093|DIAGNOSTIC_TEST|EyeBOX|Eye-Tracking based diagnostic
58485262|NCT06152393|DIAGNOSTIC_TEST|Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.|"Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118)."
58485263|NCT05486806|DRUG|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
58485264|NCT05486806|RADIATION|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
58485265|NCT00624169|PROCEDURE|An optimized perioperative course|A number of interventions before, during and after surgery
58485266|NCT01628666|DRUG|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
58485267|NCT01628666|DRUG|Conventional|Cefazolin preoperative
58492318|NCT04949321|OTHER|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
58492319|NCT02469870|BEHAVIORAL|Autism Parent Trainer (APT)|Experimental condition
58485268|NCT02282514|BIOLOGICAL|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
58485269|NCT02282514|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
58485270|NCT02282514|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
58485271|NCT02282514|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
58485272|NCT02282514|DRUG|Methylprednisolone|Steroid
58485273|NCT02282514|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
58485274|NCT02282514|DRUG|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
58485275|NCT02460419|DRUG|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
58485276|NCT02460419|OTHER|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
58485277|NCT06450483|DEVICE|Auricular vagus nerve stimulation|"Auricular vagal nerve stimulation using TPN dual channel TENS will be used for the study.The device used to stimulate is a conventional TENS. The stimulation is by applying a clip electrode placed on the tragus of the left ear and a second electrode applied on the left upper trapezius of the participant which will then stimulate the vagus nerve.Auricular vagus nerve stimulation session will be applied for 15 minutes. Participant is seated and relaxed.After the first session ended; heart rate will be measured and recorded once again to see the effect of the VNS.~Before the last AVNS session started; heart rate will be measured and recorded. The participants' vagus nerve is then stimulated for 15 minutes."
58485278|NCT01550224|DRUG|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
58485279|NCT01550224|DRUG|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
58485280|NCT02869880|OTHER|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
58485281|NCT02869880|OTHER|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
58485282|NCT02739061|BEHAVIORAL|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
58485283|NCT02739061|DRUG|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
58485284|NCT02739061|OTHER|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
58485285|NCT06214273|DEVICE|Low level diode laser|diode laser with a wave length range of 800-980 n m and power less than 500 ml
58485286|NCT06214273|DRUG|Chamomile|Chamomile 3% mucoadhesive gel
58485287|NCT06214273|DRUG|Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel|Topical anti-inflammatory, topical analgesic and topical antifungal
58485288|NCT03805282|DRUG|Lidocaine|Continuous infusion, variable dose of lidocaine.
58485289|NCT03783832|OTHER|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
58485290|NCT05176405|BEHAVIORAL|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
58485291|NCT05176405|BEHAVIORAL|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
58485292|NCT04961411|PROCEDURE|operation or non-operative treatment|type of operation or if possible non-operative treatment
58485293|NCT00904592|DRUG|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
58485294|NCT00904592|DRUG|Placebo Comparator|"Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid"
57782353|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
58485295|NCT04948359|OTHER|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
58492320|NCT02469870|BEHAVIORAL|Teaching Routines (Control)|Content comparison group.
57784667|NCT01196104|DRUG|Insulin Glargine|
58485296|NCT04948359|OTHER|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
58485297|NCT04948359|OTHER|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
58485298|NCT00060840|DRUG|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
58485299|NCT00060840|DRUG|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
58485300|NCT01695304|OTHER|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
58485301|NCT00865566|BIOLOGICAL|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
58485302|NCT00865566|BIOLOGICAL|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
58485303|NCT00865566|BIOLOGICAL|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
58485304|NCT00865566|BIOLOGICAL|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
58485305|NCT04139213|DRUG|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
58485306|NCT04139213|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
58485307|NCT04139213|OTHER|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
58485308|NCT04139213|DRUG|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
58485309|NCT02944487|DRUG|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
58485310|NCT02944487|DRUG|Placebo|Matching placebo capsules
58485311|NCT05991297|OTHER|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
58485312|NCT05991297|OTHER|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
58485313|NCT06250348|OTHER|Non invasive measure of endogenous exhaled Nitric Oxyde in exhaled gaz, by a laser spectrometer|A sample of exhaled gases is taken from the expiratory part of the respirator circuit (same way as a capnometry measurement). A laser spectrometer continuously and non-invasively monitors online the concentrations of endogenous NO exhaled by patients.
58485314|NCT01641185|PROCEDURE|radiation|radiation with protons or carbon ions
58485315|NCT03088956|OTHER|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
58485316|NCT01424072|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
58485317|NCT01424072|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
58485318|NCT05716282|OTHER|Accuracy of neuromuscular recovery estimation|"Accuracy of the estimation of neuromuscular recovery will be measured as:~* Correct attribution of the patients to the groups slow, intermediate or fast recovery~* Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery"
58485319|NCT01174719|DRUG|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
58485320|NCT01174719|DRUG|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
58485321|NCT01174719|DRUG|volume replacement|up 10 50mL/kg/24 hours
58485322|NCT02927561|OTHER|Diabetic Retinopathy screening|Diabetic Retinopathy screening
58485323|NCT04674761|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
58485324|NCT04674761|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
58485325|NCT01441232|DRUG|LX4211|400 mg of LX4211 administered as two 200 mg tablets
58485326|NCT01441232|DRUG|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
58485327|NCT02640534|DRUG|Enzalutamide|Enzalutamide 160 mg od until disease progression
58485328|NCT02640534|DRUG|Metformin|850 mg bid until disease progression
58485329|NCT04347876|DIAGNOSTIC_TEST|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
58485330|NCT04749992|PROCEDURE|Polysomnographic examination in sleep laboratory (PSG measurement)|Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
58485331|NCT04843657|BEHAVIORAL|Observation for symptom distress|Observation for symptom distress
58485332|NCT02224807|BEHAVIORAL|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
58485333|NCT02224807|BEHAVIORAL|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
58485334|NCT00101673|DRUG|vildagliptin|
58485335|NCT03937622|OTHER|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
58485336|NCT04944004|OTHER|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
58485337|NCT04944004|OTHER|Training As Usual (TAU)|Training As Usual (TAU)
58485338|NCT04981483|PROCEDURE|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
58485339|NCT00069615|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
58485340|NCT00069615|DEVICE|Continuous Glucose Monitoring System™ (CGMS)|
58485341|NCT06256796|OTHER|fresh frozen plasma|repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
58485342|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
58485343|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2.5mg po daily
58485344|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
58485345|NCT01688349|OTHER|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
58485346|NCT01070485|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
58485347|NCT01342211|BIOLOGICAL|Placebo|Intravenous placebo monthly during treatment phase.
58485348|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
58485349|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
58485350|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
58485351|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
58485352|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
58485353|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
58485354|NCT01342211|DRUG|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
58485355|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
58485356|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
58485357|NCT02309242|BEHAVIORAL|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
58485358|NCT04791332|DRUG|JNJ-67953964|JNJ-67953964 capsule will be administered orally.
58485359|NCT04791332|DRUG|Placebo|Matching placebo will be administered orally.
58485360|NCT00538018|DRUG|Telithromycin|
58485361|NCT02321709|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58485362|NCT02321709|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
58485363|NCT05378750|OTHER|Diuretic algorithm|Implementing diuretic algorithm
58485364|NCT05341141|DEVICE|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
58485365|NCT05341141|DRUG|ddEC-ddT|Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
58485366|NCT05513794|DEVICE|MRI Imaging|Neuromelanin sequence imaging
58485367|NCT01786577|OTHER|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
58485368|NCT01786577|BEHAVIORAL|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
58485369|NCT02018718|DEVICE|Magnetic Resonance Imaging (MRI)|
58485370|NCT02282098|DRUG|Colchicine|Colchicine 0.6mg twice daily
58485371|NCT02282098|DRUG|Placebo|Placebo Colchicine
58485372|NCT00346697|DRUG|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
58485373|NCT00346697|DRUG|Placebo|Corn-oil placebo
58485374|NCT04454918|DRUG|TAK-906 Oral Capsule|TAK-906 capsule.
58485375|NCT04454918|DRUG|[14C]-TAK-906 Intravenous Infusion|\[14C\]-TAK-906 intravenous infusion.
58485376|NCT04454918|DRUG|[14C]-TAK-906 Oral Solution|\[14C\]-TAK-906 oral solution.
57782354|NCT06501729|OTHER|Kiss|Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.
57782355|NCT06737068|PROCEDURE|Low pressure pneumoperitoneum (8-10mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with low pressure pneumoperitoneum (8-10mmHg) with AirSeal device
58485377|NCT03727256|OTHER|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
58485378|NCT03727256|OTHER|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
58485379|NCT05576454|DRUG|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
58485380|NCT05576454|DRUG|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
58485381|NCT05576454|DRUG|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
58485382|NCT05151276|BEHAVIORAL|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
58485383|NCT05793268|OTHER|Nuc Discontinuation|Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.
58485384|NCT05793268|DRUG|Entecavir or Tenofovir|Continuation of either entecavir or tenofovir treatment for 3 years
58485385|NCT02406508|DEVICE|Melphalan/HDS|
58485386|NCT02406508|DRUG|Sorafenib|
58485387|NCT00649038|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
58485388|NCT00649038|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
58485389|NCT00171561|DRUG|valsartan/hydrochlorothiazide|
57782356|NCT06737068|PROCEDURE|Standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
58485390|NCT00888732|DRUG|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
58485391|NCT02131506|DRUG|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
58485392|NCT02844309|DRUG|Thalidomide|thalidomide 50-150 mg per night
58485393|NCT04289064|DEVICE|Taking a fundus image|The participant only needs to take a fundus image as usual.
58485394|NCT03941288|DRUG|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
58485395|NCT03941288|OTHER|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
58485396|NCT05374512|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
57782357|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
57782358|NCT06409663|BIOLOGICAL|NVX-CoV2705 Vaccine|All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.
58485397|NCT05374512|DRUG|Paclitaxel|IV Infusion. Active comparator
58485398|NCT05374512|DRUG|Nab-paclitaxel|IV infusion. Active comparator
58485399|NCT05374512|DRUG|Carboplatin|IV infusion. Active comparator
58485400|NCT05374512|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
58485401|NCT05374512|DRUG|Eribulin mesylate|IV infusion. Active comparator
58485402|NCT05593978|BEHAVIORAL|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
58485403|NCT05593978|BEHAVIORAL|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
58485404|NCT04982263|DIAGNOSTIC_TEST|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
58485405|NCT03798353|COMBINATION_PRODUCT|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
58485406|NCT03798353|PROCEDURE|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
58485407|NCT03254758|BIOLOGICAL|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
58485408|NCT03083834|DIAGNOSTIC_TEST|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
58485409|NCT01004991|BIOLOGICAL|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
57782359|NCT03829631|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
58137377|NCT04993664|DRUG|Placebo|The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
58485410|NCT01004991|DRUG|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
58485411|NCT01004991|DRUG|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
58485412|NCT01004991|DRUG|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
58485413|NCT01004991|DRUG|prednisone|100 mg PO days 8-12 of each of 6 cycles
58485414|NCT01004991|DRUG|azacytidine|Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
58485415|NCT03154411|DRUG|ABY-029|A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
58485416|NCT01175577|DIETARY_SUPPLEMENT|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
58485417|NCT01175577|DIETARY_SUPPLEMENT|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
58485418|NCT01175577|OTHER|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
58485419|NCT01175577|OTHER|Placebo|Safflower oil-filled capsules, one twice daily with meals
58137378|NCT03343795|DRUG|oral progesterone|daily
58137379|NCT03343795|DRUG|intramuscular progesterone|every week
58485420|NCT00909298|DRUG|TTP889|300 mg
58485421|NCT00909298|DRUG|Placebo|Placebo
58485422|NCT02357368|DRUG|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
58485423|NCT02357368|DEVICE|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
58485424|NCT02357368|DEVICE|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
58485425|NCT02357368|DEVICE|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
58485426|NCT02038933|DRUG|Nivolumab|
58485427|NCT03441815|DRUG|XC8|
58485428|NCT03441815|DRUG|Placebo|
58485429|NCT00331097|DRUG|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
58485430|NCT00331097|DRUG|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
58485431|NCT00331097|DRUG|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
58485432|NCT00331097|DRUG|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
58485433|NCT02357771|DRUG|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
58485434|NCT02357771|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
58485435|NCT00298558|BEHAVIORAL|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
58485436|NCT03611153|DRUG|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
58485437|NCT03611153|DRUG|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
58485438|NCT01301027|DRUG|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
58485439|NCT01301027|DRUG|Placebo|1 pill a day for 26 weeks
58485440|NCT05736068|PROCEDURE|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
58485441|NCT05736068|PROCEDURE|Surgical treatment|Closed reduction with or without fixation
58485442|NCT00000285|DRUG|Phenytoin|
58485443|NCT04075032|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
58485444|NCT04075032|OTHER|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
58485445|NCT05408442|OTHER|No intervention|No intervention
58485446|NCT02351856|DRUG|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
58485447|NCT01377103|DRUG|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
58485448|NCT01377103|DRUG|Placebo|
58485449|NCT00584636|DRUG|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
58485450|NCT03952975|OTHER|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
58485451|NCT01885741|DEVICE|IPBS|
58485452|NCT05271877|PROCEDURE|Laparoscopy|Diagnostic/operative laparoscopic procedure
58485453|NCT04980703|DEVICE|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
58485454|NCT04980703|DEVICE|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
58485455|NCT04980703|OTHER|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
58485456|NCT06492746|DEVICE|HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring|The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
58485457|NCT04843007|DRUG|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
58485458|NCT00852852|BEHAVIORAL|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
58485459|NCT01072643|DRUG|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
58485460|NCT00001209|DRUG|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
58485461|NCT02099955|DRUG|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
58485462|NCT02999672|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
57784668|NCT01521949|DRUG|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
58485463|NCT00912795|BEHAVIORAL|SMS Turkey|"6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
58485464|NCT00997308|DRUG|AZD1446|Solution, oral, for 4 weeks
58485465|NCT00997308|DRUG|Placebo|
58485466|NCT05654532|DRUG|AC699|Participants will receive AC699 orally daily in 28-day cycles.
58485467|NCT06374628|PROCEDURE|breast reconstruction|breast reconstruction in two-stages using tissue expander entirely wrapped by acellular dermal matrix
58485468|NCT03553303|DRUG|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
58485469|NCT03705143|BEHAVIORAL|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
58485470|NCT03705143|BEHAVIORAL|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
58485471|NCT01947140|DRUG|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
58485472|NCT01947140|DRUG|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
58485473|NCT04539795|DRUG|Alvelestat|oral tablet
58485474|NCT04539795|DRUG|Placebo|oral tablet
58485475|NCT03630445|OTHER|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
58485476|NCT03630445|OTHER|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
58485477|NCT03630445|OTHER|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
58485478|NCT03630445|OTHER|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
58485479|NCT03630445|OTHER|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
58485480|NCT04814004|DRUG|hCD19.IL15.CAR-iNKT|Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
58485481|NCT00942227|OTHER|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
58485482|NCT00942227|OTHER|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
58485483|NCT03400839|DIAGNOSTIC_TEST|Daily physical activity levels|Objectively measured physical activity using activity monitors.
58485484|NCT03400839|DIAGNOSTIC_TEST|6-minute walk test|Assessment of functional exercise capacity.
58485485|NCT03400839|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Assessment of maximal exercise capacity.
58485486|NCT03400839|DIAGNOSTIC_TEST|Muscle Function|Assessment of muscle force, muscle endurance and muscle fatigability
58485487|NCT03400839|DIAGNOSTIC_TEST|Lung Function|Assessment of whole-body plethysmography and spirometry.
58485488|NCT03400839|DIAGNOSTIC_TEST|Body composition|Assessment of bioelectrical impedance.
58485489|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SGRQ-I|"Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)"
58485490|NCT03400839|DIAGNOSTIC_TEST|Symptoms - UCSD/SOBQ|"Assessment of symptoms by the UCSD Short of breath questionnaire"
58485491|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SF36|"Assessment of Health-related quality of life by the SF-36 questionnaire"
58485492|NCT03400839|DIAGNOSTIC_TEST|Anxiety and depression|"Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale"
58485493|NCT03400839|DIAGNOSTIC_TEST|Symptoms - mMRC|"Assessment of symptoms by the modified Medical Research Council (mMRC) scale"
58485494|NCT03400839|DIAGNOSTIC_TEST|Sleep quality|"Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)"
58485495|NCT03400839|DIAGNOSTIC_TEST|Sleepiness|"Assessment of sleepiness by the Epworth Sleepiness Scale"
58485496|NCT03400839|DIAGNOSTIC_TEST|Inflammatory markers and oxidative stress|"blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP."
58485497|NCT03400839|DIAGNOSTIC_TEST|Functional performance tests|Timed-up-and-go at usual pace (TUGu) and at a fast pace (TUGf), four-metre gait speed test (4MGS), sit-to-stand test using three protocols: 30 seconds (30sec-STS), one minute (1min-STS) and five-repetition (5rep-STS) and Short Physical Performance Balance (SPPB).
58485498|NCT06212336|DRUG|Favipiravir|Interventional Medicinal Product (IMP)
58485499|NCT06212336|DRUG|Ribavirin|Control arm
58485500|NCT06212336|DRUG|Dexamethasone|Interventional Medicinal Product (IMP)
58485501|NCT04805398|BIOLOGICAL|CM310|300 mg every two weeks
58485502|NCT04805398|BIOLOGICAL|Placebo|300 mg every two weeks
58485503|NCT05145101|BIOLOGICAL|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
58485504|NCT05635253|OTHER|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
58485505|NCT05635253|OTHER|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
58485506|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
58485507|NCT00953056|BIOLOGICAL|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
58485508|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
58485509|NCT00953056|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
58485510|NCT00515762|DEVICE|elasto-gel cap|scalp cooling cap
58485511|NCT01411046|DIAGNOSTIC_TEST|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
58485512|NCT06516016|RADIATION|PET|\[18F\]DPA-714 will be injected intravenously as a 1 minute intravenous bolus injection and dynamic PET acquisition will last 90 min. The aim is the quantification of the neuroimmune reaction during neuroinflammation process.
58485513|NCT06516016|OTHER|MRI 3T|Brain MRI will aim at providing imaging biomarkers which will allow evaluating brain structure, microstructure, iron load, myelin, neurodegeneration of the substantia nigra and locus coeruleus, functional connectivity, brain perfusion and the glymphatic system.
58485514|NCT06516016|OTHER|Oculomotricity assessment|Recording eye movements in a controlled environment (requiring no specific room or area) in binocular vision at a frequency \> 500Hz, while retaining infrared video footage of eye movements for high-quality clinical monitoring.
58485515|NCT06516016|OTHER|Magnetoencephalography assessment|Recording brain magnetic activity using the Elekta Neuromag® TRIUX Magnetoencephalograph ; The participant will be comfortably seated in an adjustable-height chair. The device is enclosed in a shielded room isolated from external electric and magnetic fields to measure the extremely weak magnetic activities produced by the brain.
58485516|NCT06516016|OTHER|Body posture and gait assessment|The acquisition of kinematic gait parameters will be achieved ; markers are positioned on the different segments of members, recognized by a camera system positioned on the walls. Neurophysiologic muscular activity of the lower limbs will also be recorded.
58485517|NCT06516016|OTHER|Voice recording|Participants will be recorded during a single session at every visit upon baseline with a professional quality head mounted microphone.
58485518|NCT06516016|OTHER|Video-polysomnography|Participants will complete standard sleep questionnaires before the visit and perform neurophysiological tests including cognitive tasks before and after the sleep recording.
58485519|NCT06516016|BIOLOGICAL|Blood sampling, skin biopsy, excreta sampling, lumbar puncture|Experimental analyses, genetic and multi-OMIC analyses for biomarker research.
58485520|NCT01537705|DRUG|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
58485521|NCT02124785|PROCEDURE|Blood sampling|At Years 21 to 25 after their second vaccine dose.
58485522|NCT05322382|PROCEDURE|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
58485523|NCT00659789|DRUG|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
58485524|NCT00659789|DRUG|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
58485525|NCT04838470|OTHER|cardiac rehabilitation|multidisciplinary disease management program
58485526|NCT04093102|DIAGNOSTIC_TEST|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
58485527|NCT06147791|DEVICE|External scrotal drainage|Application of external scrotal drainage during three-component penile prosthesis placement
58485528|NCT04376866|DRUG|Toripalimab|anti-PD-1 antibody
58485529|NCT04001322|OTHER|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
58485530|NCT04001322|OTHER|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
58485531|NCT04001322|OTHER|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
58485532|NCT04001322|OTHER|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
58485533|NCT04001322|OTHER|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
58485534|NCT04001322|OTHER|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
58485535|NCT04001322|OTHER|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
58485536|NCT05699928|DIAGNOSTIC_TEST|General pediatrician autism diagnostic assessment|General pediatricians will assess children for possible autism spectrum disorder diagnosis as they usually would (i.e. no specific tests will be required).
58485537|NCT05699928|DIAGNOSTIC_TEST|Multidisciplinary team diagnostic assessment|The multidisciplinary team will assess children for possible autism spectrum disorder diagnosis. The team consists of a developmental pediatrician, a psychologist, and a psychometrist. Administered tests include the Autism Diagnostic Interview - Revised (ADI-R; a developmental history will be substituted for children with a developmental age of \<18 months), the Autism Diagnostic Observation Schedule (ADOS), and the Mullen Scales of Early Learning. When needed and available, the team will call a preschool or school teacher to gather more information about the child.
58485538|NCT05699928|DIAGNOSTIC_TEST|Autism Assessment for Preschoolers with Language Element Sequence|The AAPLES was developed at the Glenrose/Holland Bloorview and is designed for children who have flexible phrase speech. The assessment will be conducted virtually over Zoom Health by a trained clinician. This tool involves coaching the caregiver to interact with the child in specific ways to allow a trained professional to observe for features of ASD while watching remotely. It should take about 30-45 minutes. The individual who conducts the assessment will be blinded to the results of the other assessments. This virtual assessment will occur after the other assessments have been completed so as to not delay the child receiving a potential diagnosis.
58485539|NCT00404196|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
58485540|NCT01886053|DRUG|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
58485541|NCT01886053|DRUG|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
58485542|NCT01886053|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
58485543|NCT03586466|DEVICE|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
58485544|NCT03586466|DRUG|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
58485545|NCT03586466|OTHER|MEMS|Subjects will receive their medication in a MEMS pill bottle.
58485546|NCT00140608|DEVICE|Seprapack Sinus Dressing|
58485547|NCT01282762|BIOLOGICAL|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
58485548|NCT01282762|BIOLOGICAL|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
58485549|NCT05676177|DIAGNOSTIC_TEST|Ultra Low Dose CT|"* Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)\>30), that is 5 or 10 mAs~* Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI\>30), that is 10 or 20 mAs"
58137380|NCT03104166|DEVICE|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
58137381|NCT03104166|DEVICE|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
58485550|NCT05676177|DIAGNOSTIC_TEST|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
58485551|NCT02206633|DEVICE|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
58485552|NCT04067817|DRUG|norepinephrine|patient who was received the treatment of norepinephrine
58485553|NCT04067817|DRUG|Phenylephrine|patient who was received the treatment of phenylephrine
58485554|NCT05482100|DIAGNOSTIC_TEST|Patients monitored with OmniGraf testing|This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
58485555|NCT00689858|DRUG|Cilostazol, Ginkgo biloba and placebo|dosing time
58485556|NCT00207480|BEHAVIORAL|Brief, motivational interviewing intervention|
58485557|NCT03822845|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
58485558|NCT01483521|OTHER|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
58485559|NCT01578369|OTHER|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
58485560|NCT00052117|DRUG|capravirine|
58485561|NCT00052117|DRUG|Kaletra|
58485562|NCT00052117|DRUG|2 NRTIs|
58485563|NCT06289907|DIETARY_SUPPLEMENT|Bonafide-HF3.0|Take 2 capsules once daily in the mornings with food
58485564|NCT06289907|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
58485565|NCT04371159|DEVICE|Velieve U.S.|The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
58485566|NCT04382352|BIOLOGICAL|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
58485567|NCT02884713|DRUG|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
58485568|NCT02884713|DRUG|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
58485569|NCT02884713|DRUG|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
58485570|NCT03419559|BIOLOGICAL|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
58485571|NCT03419559|DRUG|Durvalumab|PD-L1 antagonist monoclonal antibody
58485572|NCT04558294|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
58485573|NCT04558294|DRUG|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
58485574|NCT04558294|DRUG|Ketanserin|A dose of 40 mg Ketanserin will be administered.
58485575|NCT04539132|BEHAVIORAL|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
58485576|NCT04235621|OTHER|FSGS/TR-MCD|This is a non-interventional study
58485577|NCT04235621|OTHER|Diabetic Nephropathy (DN)|This is a non-interventional study
58485578|NCT03032978|OTHER|Calcium hydroxide|Pulp capping material
58485579|NCT03032978|OTHER|Calcium silicate|Pulp capping material
58485580|NCT04766840|DRUG|CAR-T cells|Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
58485581|NCT06001073|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
58485582|NCT00569959|OTHER|fasting 12+ hours|fasting 12+ hours
58485583|NCT00569959|OTHER|Non-fasting|Non-fasting
58485584|NCT00322660|DRUG|Adrenaline|
58485585|NCT06282978|DRUG|Elranatamab (PF-06863135)|The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
58485586|NCT02350296|DRUG|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
57784669|NCT02447679|DRUG|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
58485587|NCT02350296|DRUG|OKi® 80 mg|"OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight)."
58485588|NCT01470326|DRUG|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
58485589|NCT04782583|OTHER|Questionnaire|questionnaire for the patients and the volontaire
58485590|NCT04258800|DEVICE|Music during colonoscopy|Music during colonoscopy
58485591|NCT04563949|OTHER|Repeat Testing|Repeat Testing with the PLA will be conducted
58485592|NCT04777175|DRUG|immunity therapy|The patient receives immunotherapy
58485593|NCT03739125|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
58485594|NCT03739125|DRUG|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
58485595|NCT04588584|OTHER|Survey and Interviews|Survey and Interviews
58485596|NCT03193502|DRUG|rivaroxaban|rivaroxaban
58485597|NCT06119139|DRUG|3.6 ml 4% Articaine hydrochloride|3.6 ml 4% articaine buccal infiltration
58485598|NCT06119139|DRUG|1.8 ml 4% Articaine hydrochloride|1.8 ml 4% articaine buccal infiltration
58485599|NCT03729700|OTHER|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
58485600|NCT04071288|PROCEDURE|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
58485601|NCT03644004|OTHER|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
58485602|NCT04249986|BEHAVIORAL|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
58485603|NCT02194478|BEHAVIORAL|Meditation|30 minute, 8 week meditation
58485604|NCT05377255|COMBINATION_PRODUCT|16 mg naloxone AP003|4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
58485605|NCT05377255|COMBINATION_PRODUCT|8 mg naloxone NARCAN Nasal Spray|2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
58485606|NCT01092546|DRUG|[18F]Flutemetamol|All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
58485607|NCT00634777|OTHER|pet scan|pet scan
58485608|NCT05103046|DRUG|UCT-03-008|Orally available kinase inhibitor
58485609|NCT05345899|DIAGNOSTIC_TEST|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
58485610|NCT05345899|OTHER|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
58485611|NCT05579613|DEVICE|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
58485612|NCT02461641|OTHER|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
58485613|NCT02461641|OTHER|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
57784670|NCT02447679|DRUG|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
58485614|NCT02461641|OTHER|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
58485615|NCT03721003|DEVICE|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
58485616|NCT02230033|DRUG|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
58485617|NCT02230033|DRUG|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
58485618|NCT02230033|DRUG|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
58485619|NCT04442802|PROCEDURE|Percutaneous transluminal angioplasty|Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
58485620|NCT02760953|PROCEDURE|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
58485621|NCT02760953|DRUG|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
58485622|NCT01897688|BIOLOGICAL|Islet Cell Transplant|
58485623|NCT05379998|OTHER|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
58485624|NCT05379998|OTHER|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
58485625|NCT00327600|DRUG|imexon|
58485626|NCT00327600|DRUG|DTIC|
58485627|NCT01683357|PROCEDURE|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
58485628|NCT00257985|DRUG|GTN|
58485629|NCT04818372|DRUG|CM313-Dose escalation|Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
58485630|NCT04818372|DRUG|CM313|Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
58485631|NCT04818372|DRUG|Dexamethasone|dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
58485632|NCT04818372|DRUG|Lenalidomide|25 mg/day lenalidomide 21 of 28 days cycle
58485633|NCT02804113|DEVICE|Supera Peripheral Stent System|
58485634|NCT06339372|DIETARY_SUPPLEMENT|Standard feeding|Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20_35% from fats and 10-35% from protein)
58485635|NCT06339372|DIETARY_SUPPLEMENT|Omega 3 and dipeptiven|Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
58485636|NCT00515619|DRUG|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
58485637|NCT02910882|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
58485638|NCT02910882|DRUG|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
58485639|NCT02910882|RADIATION|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
58485640|NCT05569083|GENETIC|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
58485641|NCT05569083|DIAGNOSTIC_TEST|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
58485642|NCT05569083|DIAGNOSTIC_TEST|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
58485643|NCT05569083|DIAGNOSTIC_TEST|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
58485644|NCT05569083|DIAGNOSTIC_TEST|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
58485645|NCT05569083|DIAGNOSTIC_TEST|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
58485646|NCT05569083|DIAGNOSTIC_TEST|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
58485647|NCT00714870|BEHAVIORAL|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
58485648|NCT02620748|DRUG|Tranexamic Acid|
58485649|NCT02620748|OTHER|Saline Solution|
58485650|NCT02202941|OTHER|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
58485651|NCT02202941|OTHER|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
58485652|NCT01259414|OTHER|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
58485653|NCT01259414|OTHER|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
58485654|NCT00337480|BEHAVIORAL|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
58485655|NCT02932241|BEHAVIORAL|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
58485656|NCT05335226|PROCEDURE|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation|Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation. (HLA 6-10/10, TNC≥1-3×10-7/Kg)
58485657|NCT05335226|PROCEDURE|haploidentical hematopoietic stem cell transplantation|Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
58485658|NCT00072319|BIOLOGICAL|filgrastim|
58485659|NCT00072319|DRUG|cyclophosphamide|
58485660|NCT00072319|DRUG|epirubicin hydrochloride|
58485661|NCT00072319|DRUG|paclitaxel|
58485662|NCT00072319|PROCEDURE|adjuvant therapy|
58485663|NCT00072319|PROCEDURE|neoadjuvant therapy|
58485664|NCT05717543|DEVICE|Retro-illuminator|The device Retro-illuminator will be used to photograph the eyes.
58485665|NCT06384014|DEVICE|retrograde and orthograde root canal filling|Apical resection application after root canal filling
58485666|NCT00996853|OTHER|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
58485667|NCT00203099|DRUG|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
58485668|NCT06116370|PROCEDURE|Rezum procedure|In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.
58485669|NCT06116370|PROCEDURE|B-TURP procedure|In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
58485670|NCT04188561|DRUG|Intra articular injection Group|"Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average."
58485671|NCT04188561|DEVICE|Radiofrequency Group|Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
58485672|NCT06654531|DRUG|Dexmedetomidine|"Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2"
58485673|NCT02362282|BEHAVIORAL|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
58485674|NCT02362282|BEHAVIORAL|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
58485675|NCT02362282|BEHAVIORAL|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
58485676|NCT00588835|DRUG|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
58485677|NCT00588835|DRUG|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
58485678|NCT00998361|PROCEDURE|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
58485679|NCT00131261|DRUG|PXD101|
58485680|NCT00131261|DRUG|Dexamethasone|
58485681|NCT03018652|DRUG|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
58485682|NCT03018652|DRUG|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
58485683|NCT00770172|BIOLOGICAL|filgrastim|Given subcutaneously
58485684|NCT02606513|OTHER|MR Urography; CT Urography|
58485685|NCT00885534|DRUG|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
58485686|NCT03995602|DIETARY_SUPPLEMENT|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
58485687|NCT03995602|DIETARY_SUPPLEMENT|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
58485688|NCT00137072|DRUG|Viagra (Sildenafil Citrate) 100 mg|
58485689|NCT05838898|DEVICE|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
58485690|NCT05103137|OTHER|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
58485691|NCT04798404|OTHER|Multimodal exercise intervention|The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
58485692|NCT02849899|DRUG|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
58485693|NCT02849899|DRUG|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
58485694|NCT03440164|OTHER|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
58485695|NCT01237197|DRUG|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
58485696|NCT01237197|DRUG|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
58485697|NCT00995800|DRUG|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
58485698|NCT00706238|BIOLOGICAL|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
58485699|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
58485700|NCT04423302|DIETARY_SUPPLEMENT|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
58485701|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
58485702|NCT00522808|DRUG|A-831|
58485703|NCT04226196|DEVICE|Implantation of an intraocular lens|Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
58485704|NCT03193099|OTHER|Brain imaging|Volume, DWS and DTI
58485705|NCT03193099|OTHER|Neurological assessments|UHDRS
58485706|NCT03193099|BEHAVIORAL|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
58485707|NCT03193099|BEHAVIORAL|Behavioural assessments|Computerized game
58485708|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
58485709|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO|Slow-release CHO, alginate encapsulated
58485710|NCT06165393|DIETARY_SUPPLEMENT|CHO|Carbohydrate-only, control
58485711|NCT05360680|DRUG|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
58485712|NCT00213434|DEVICE|Herbst oral appliance|
58485713|NCT03422094|BIOLOGICAL|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
58485714|NCT03422094|BIOLOGICAL|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
58485715|NCT03422094|BIOLOGICAL|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
58485716|NCT03422094|PROCEDURE|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
58485717|NCT03422094|PROCEDURE|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
58485718|NCT04522544|DRUG|Tremelimumab|300 mg Tremelimumab C1D1
58485719|NCT04522544|DRUG|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
58485720|NCT04522544|PROCEDURE|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
58485721|NCT04522544|PROCEDURE|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
58485722|NCT06170294|DRUG|TCR-MAGE-A4 T-Cells|"* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells"
58485723|NCT03349034|DRUG|Ropivicaine|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
58485724|NCT03349034|DRUG|Local Saline Infusion|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
58485725|NCT02203968|DRUG|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
58485726|NCT02203968|DRUG|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
58485727|NCT02248246|DEVICE|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)"
58485728|NCT06472843|BEHAVIORAL|Exercise Intervention|The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).
58485729|NCT02132429|DRUG|AMG 333|Oral administration available in varying dose strength.
58485730|NCT02132429|DRUG|Placebo|Placebo containing no active drug
58485731|NCT04379622|OTHER|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
58485732|NCT05224999|DRUG|nivolumab|nivolumab 3mg/kg (every 2 weeks)
58485733|NCT00055757|DRUG|tipifarnib|Given orally
58485734|NCT00055757|DRUG|cisplatin|Given IV
58485735|NCT00055757|DRUG|gemcitabine hydrochloride|Given IV
58485736|NCT00055757|OTHER|laboratory biomarker analysis|Correlative studies
58485737|NCT03080896|DEVICE|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
58485738|NCT03080896|DEVICE|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
58485739|NCT03108469|DRUG|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
58485740|NCT03108469|OTHER|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
58485741|NCT05651061|BIOLOGICAL|SS109|27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
58485742|NCT00714727|PROCEDURE|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
58485743|NCT00500513|PROCEDURE|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
58485744|NCT00500513|PROCEDURE|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
58485745|NCT00500513|RADIATION|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
58485746|NCT02334462|BIOLOGICAL|Pfs230D1M-EPA/Alhydrogel|
58485747|NCT02334462|BIOLOGICAL|Pfs25M-EPA/Alhydrogel|
58485748|NCT02334462|DRUG|TWINRIX|
58485749|NCT02334462|DRUG|Menactra|
58485750|NCT02295618|DEVICE|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
58485751|NCT02295618|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
58485752|NCT02421835|DIETARY_SUPPLEMENT|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
58485753|NCT02421835|DIETARY_SUPPLEMENT|Placebo|700 mg Maltodextrin per day
58485754|NCT04573582|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
58485755|NCT01469611|BIOLOGICAL|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
58485756|NCT05368246|DEVICE|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
58485757|NCT05571332|DRUG|Avatrombopag 20 MG Oral Tablet|p-ATG and CsA in combination with Avatrombopag to treat
58485758|NCT05434416|OTHER|mobile app|mobile app self-guided psychological interventions
58485759|NCT00194506|BEHAVIORAL|Internet co-management module|
58485760|NCT03345784|DRUG|Adavosertib|Given PO
58485761|NCT03345784|DRUG|Cisplatin|Given IV
58485762|NCT03345784|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
58485763|NCT06458881|COMBINATION_PRODUCT|Mixture of Simethicone and Tyndallized Bacillus Coagulans|. Enrolled infants were treated for 28 days with a mixture of Tyndallized B. Coagulans and Simethicone: 20 drops, four times a day. At enrolment, clinical and dietary history, obstetrical data and anthropometry were recorded. The subjects were classified as having IC based on their parents' responses to the validated questionnaires regarding IC according to Rome IV criteria.
58485764|NCT01271985|DRUG|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
58485765|NCT01271985|OTHER|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
58485766|NCT06367530|DIAGNOSTIC_TEST|Incidence and survival of trilateral retinoblastoma and the differences globally|The detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.
58485767|NCT02763501|PROCEDURE|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
58485768|NCT02763501|PROCEDURE|non-closure of mesenteric defects|Mesenteric defects are left open
58485769|NCT02724618|DRUG|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
58485770|NCT02724618|RADIATION|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
58485771|NCT02724618|DRUG|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
58485772|NCT06009848|DRUG|Cadonilimab|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
58485773|NCT03473509|OTHER|CKD Registry|Health Service intervention
58485774|NCT01771289|DRUG|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
58485775|NCT01771289|RADIATION|Radiation|chemoradiation
58485776|NCT00658125|PROCEDURE|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
58485777|NCT02182752|DRUG|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
58485778|NCT02182752|DRUG|Ropivacaine|Interscalene block using ropivacaine
58485779|NCT01117363|OTHER|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
58485780|NCT00107913|DRUG|Doxil|
58485781|NCT00642083|DEVICE|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
58485782|NCT01584440|DRUG|AVP-923-20|AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
58485783|NCT01584440|DRUG|Placebo|Placebo capsule
58485784|NCT01584440|DRUG|AVP-923-30|AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
58485785|NCT00000258|DRUG|Nitrous oxide 10% & placebo|
58485786|NCT00000258|DRUG|Nitrous oxide 20% & placebo|
58485787|NCT00000258|DRUG|Nitrous oxide 30% & placebo|
58485788|NCT00000258|DRUG|Nitrous oxide 40% and placebo|
58485789|NCT01774396|DRUG|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
58485790|NCT01774396|DRUG|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
58485791|NCT01982656|OTHER|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
58485792|NCT05000255|BEHAVIORAL|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
58485793|NCT05000255|BEHAVIORAL|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
58485794|NCT02970162|DRUG|Amifampridine Phosphate|
58485795|NCT02970162|DRUG|Placebo Oral Tablet|
58485796|NCT05526482|DEVICE|mobile app|preoperative respiratory exercises and thoracic surgery with a mobile application
58485797|NCT01421719|DRUG|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
58485798|NCT01492335|BEHAVIORAL|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
58485799|NCT01492335|BEHAVIORAL|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
58485800|NCT06437041|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days.
58485801|NCT06437041|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
58485802|NCT04359316|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
58485803|NCT04359316|DRUG|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
58485804|NCT02902861|DRUG|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
58485805|NCT02902861|DRUG|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
58485806|NCT02912689|DEVICE|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
58485807|NCT02912689|DEVICE|Pressure support ventilation|PS during Non-invasive ventilation
58485808|NCT03554564|BEHAVIORAL|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
58485809|NCT03554564|OTHER|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
58485810|NCT02145013|PROCEDURE|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
58485811|NCT04847336|OTHER|No intervention is planned|No intervention is planned
58485812|NCT02453711|DRUG|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
58485813|NCT02453711|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
58485814|NCT02453711|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
58485815|NCT05666310|DRUG|Denosumab|Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
58485816|NCT05666310|DRUG|Zoledronic Acid|Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
57782360|NCT05398770|DIETARY_SUPPLEMENT|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
57782361|NCT05681442|DRUG|continuous pivotal βL-AB|continuous pivotal βL-AB
57782362|NCT05681442|DRUG|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
57782363|NCT05681442|DRUG|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
57782364|NCT05681442|DRUG|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
58485817|NCT05666310|OTHER|Denosumab Placebo|Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
58485818|NCT05666310|OTHER|Zoledronic Acid Placebo|Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
57782365|NCT04867278|PROCEDURE|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
57782366|NCT04867278|PROCEDURE|Debridement|Gluteus minimus debridement in the OR
57782367|NCT05109494|RADIATION|Conventional Fractionated|50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive \> 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
58485819|NCT06522139|PROCEDURE|Implantation of Episealer Talus Implant|Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
58485820|NCT05510232|DEVICE|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
58485821|NCT05510232|DEVICE|A treatment group that will have headset on and will watch a non-VR video|"Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver non VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
58485822|NCT05510232|DEVICE|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR reality Samsung Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities. iPad will be set up and held for patients in the iPad group.
58485823|NCT04441918|COMBINATION_PRODUCT|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
58485824|NCT05756959|DEVICE|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
58485825|NCT05756959|DEVICE|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
58485826|NCT05756959|DEVICE|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
58485827|NCT05808829|OTHER|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
58485828|NCT05302726|DRUG|Estrogen|Transdermal and oral estrogen both as substitution therapy
57782368|NCT05109494|RADIATION|Hypofractionated|27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive \> 97% of the prescribed dose
58485829|NCT03507569|DRUG|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
58485830|NCT03507569|OTHER|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
58485831|NCT01234389|DEVICE|Electrochemical H. pylori detection method|Determination of H. pylori infection.
58485832|NCT01234389|DEVICE|IHC|Determination of H. pylori infection.
58485833|NCT01234389|DEVICE|C13-urea breath test|Determination of H. pylori infection.
58485834|NCT01234389|DEVICE|HUT|Determination of H. pylori infection.
58485835|NCT03229980|DRUG|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
58485836|NCT03229980|DRUG|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
58485837|NCT04517175|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
58485838|NCT00512915|DEVICE|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
58485839|NCT00455182|PROCEDURE|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
58485840|NCT00455182|PROCEDURE|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
58485841|NCT00455182|PROCEDURE|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
58485842|NCT00277732|PROCEDURE|Pharmaceutical care at baseline and follow-up visits over 6 months|
58485843|NCT03139591|DRUG|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
58485844|NCT00254384|DRUG|Cisplatin|Given IV
58485845|NCT00254384|DRUG|Docetaxel|Given IV
58485846|NCT00254384|DRUG|Erlotinib|Given PO
58485847|NCT00254384|DRUG|Erlotinib Hydrochloride|Given PO
58485848|NCT00254384|OTHER|Laboratory Biomarker Analysis|Correlative studies
58485849|NCT05637580|DRUG|Timing of drug administration|The effect of drug administration timing on tumor and lymph node responses was observed.
58485850|NCT02644421|DRUG|VVZ-149|
58485851|NCT02644421|DRUG|Lidocaine|
58485852|NCT02644421|DRUG|Placebo|
57782369|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
58485853|NCT04040387|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
58485854|NCT04040387|DEVICE|Sham NightWare|NightWare device not providing interventions
58485855|NCT02449148|OTHER|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
58485856|NCT00378157|BEHAVIORAL|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
58485857|NCT01771224|DIETARY_SUPPLEMENT|Palmitoleic acid|Palmitoleic acid and 5-ASA
58485858|NCT04313062|BEHAVIORAL|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
58485859|NCT02356861|DEVICE|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
58485860|NCT02506413|OTHER|MamaToto Package|"The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers."
57782370|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
57782371|NCT03899103|DRUG|Rituximab|First course Course Rituximab at Randomization.
57782372|NCT03899103|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
57782373|NCT05431010|DEVICE|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
57782374|NCT05431010|BEHAVIORAL|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
57782375|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
57782376|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
57782377|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
57782378|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
57782379|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
57785257|NCT06320275|BEHAVIORAL|Storytelling Intervention|A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.
58485861|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with external ureteral catheter|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.
58492321|NCT03241511|OTHER|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
57785258|NCT02451423|DRUG|Atezolizumab|1200 mg Given IV
58485862|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with double J internal ureteral stent|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
58485863|NCT02549872|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
58485864|NCT00248040|DRUG|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
58485865|NCT00248040|DRUG|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
58485866|NCT00248040|OTHER|placebo infusion|placebo was volume/schedule matched saline
58485867|NCT04784572|OTHER|first injection delay and second injection delay|"During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance."
58485868|NCT04402567|OTHER|No Intervention|Not Apply
58485869|NCT05268913|DIAGNOSTIC_TEST|MRI scan|Participants will undertake a magnetic resonance imaging scan.
58485870|NCT05268913|BIOLOGICAL|Blood test|Participants will undertake a fasting blood test.
58485871|NCT01941186|OTHER|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
58485872|NCT00380367|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
58485873|NCT05235269|DRUG|I124-AT01 only|Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
58485874|NCT06383728|DRUG|Osimertinib|Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
57782380|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
57782381|NCT06360354|DRUG|AMG 193|Administered Orally
58485875|NCT01939418|DRUG|RAD001|Afinitor 5mg qd. po.
58485876|NCT01939418|DRUG|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
58485877|NCT01939418|DRUG|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
57782382|NCT06360354|DRUG|Gemcitabine|Administered IV
57782383|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
57782384|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
57782385|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
57782386|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
57782387|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
58485878|NCT06416124|DIAGNOSTIC_TEST|Anthropometric assessment|A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
58485879|NCT05876000|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for mechanical circulatory support
58485880|NCT04495920|DRUG|CGB-S-100|Alcohol and choline geranate
58485881|NCT02542319|DIETARY_SUPPLEMENT|Mablet 360 mg|
58485882|NCT02542319|DIETARY_SUPPLEMENT|Placebo|
58485883|NCT04632836|OTHER|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
58485884|NCT02510508|BEHAVIORAL|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
58485885|NCT02510508|BEHAVIORAL|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
58485886|NCT02510508|OTHER|Non-intervention|Non-intervention
58485887|NCT03593746|OTHER|Physical training|Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
58485888|NCT03593746|OTHER|Light-Emitting Diode (LED) therapy|Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
58485889|NCT04666220|OTHER|VETC evaluation|We will evaluate VETC presence on tissue specimens
58485890|NCT01685502|DRUG|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
58485891|NCT04863469|BEHAVIORAL|B-POC high load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
58485892|NCT04863469|BEHAVIORAL|B-POC low load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
58485893|NCT03830307|DEVICE|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
58485894|NCT01850758|PROCEDURE|Regenexx SD|stem cell treatment
58485895|NCT01850758|OTHER|Exercise Therapy|exercise therapy control
58485896|NCT05808543|OTHER|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
58485897|NCT05808543|OTHER|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
58485898|NCT01450332|DEVICE|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
58485899|NCT02196662|DRUG|IBD98-M:|single adiministration
58485900|NCT02196662|DRUG|IBD98-M without HA|single adiministration
58485901|NCT02196662|DRUG|Delzicol|single adiministration
58485902|NCT02668562|PROCEDURE|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
58485903|NCT02668562|PROCEDURE|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
58485904|NCT00943618|DRUG|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
58485905|NCT00943618|DRUG|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
58485906|NCT00943618|OTHER|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
58485907|NCT00943618|BEHAVIORAL|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
58485908|NCT05479357|DRUG|Oxytocin|10 iu will be given intravenously.
58485909|NCT05479357|DRUG|Carbetocin|100 micrograms will be given intravenously.
58485910|NCT06271746|DEVICE|FibroNova (Active mode)|FibroNova neurostimulator of conditional pain modulation (CPM)
58485911|NCT06271746|DEVICE|FibroNova (Sham mode)|FibroNova neurostimulator with an electrical output not intended for neurostimulation
58485912|NCT05107726|BEHAVIORAL|TRE Group|This group will practice time-restricted eating
58485913|NCT01672671|DRUG|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
58485914|NCT01551511|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
58485915|NCT01551511|DRUG|Placebo|Identical step-up approach to the Namisol arm.
58485916|NCT05885399|DRUG|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
58485917|NCT02780752|DRUG|hymecromone|Oral Hymecromone
58485918|NCT02447302|DRUG|Etrasimod|
58485919|NCT02447302|DRUG|Placebo|
58485920|NCT01240824|DRUG|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
58485921|NCT02042274|DIETARY_SUPPLEMENT|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
58485922|NCT00193271|DRUG|Docetaxel|
58485923|NCT00193271|DRUG|Estramustine|
58485924|NCT00159887|DRUG|Sildenafil citrate|
58485925|NCT04749004|BEHAVIORAL|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
58485926|NCT06305832|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
58485927|NCT06305832|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
58485928|NCT06305832|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
58485929|NCT05283941|DIETARY_SUPPLEMENT|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
58485930|NCT02728687|DRUG|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
57782388|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
57782389|NCT06737276|OTHER|Interactive fiction activities|The case studies were prepared using interactive fiction through Twine. Each case simulated a nursing consultation with a patient requiring dietary advice, and the patient's evolution depended on the students' choices. All cases created had similar structures, durations, and difficulties to avoid complexity-related bias. For each circumstance, three possible dietary advice options were offered to the patient: one option that would be ideal, one suitable option, and one unsuitable option.
57782390|NCT06737276|OTHER|Role-play simulation|Role-play activity of the nursing consultation on dietary advice according to Nemec et al. (2021) recommendations. Ten case studies of a nursing consultation on dietary advice involving a nurse and a patient were designed with the consensus of a group of nursing professionals with expertise in food and nutrition, health literacy, and communication. Each student was assigned a role and provided with the necessary information to play their character or understand their patient's context. The information provided was different according to the role assigned. They had to perform a simulation of eight minutes, similar to the time available in the student's primary care consultations in the referral health system. Thus, the patient and the family member had to explain the situation or health problem, the professional would analyse it, and together, they would try to reach a therapeutic agreement. After the consultation, a debriefing was carried out.
57782391|NCT06155279|DRUG|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
57782392|NCT03630562|PROCEDURE|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
57782393|NCT05683418|DRUG|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
57782394|NCT03653676|OTHER|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
57782395|NCT06183892|DRUG|Tacrolimus Sustained-release Capsules|"Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)"
57782396|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
57782397|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
57782398|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
57782399|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
57782400|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
57782401|NCT06736587|DRUG|DWP212525 10mg|DWP212525 10mg
57782402|NCT06736587|DRUG|DWP212525 30mg|DWP212525 30mg
57782403|NCT06736587|DRUG|DWP212525 50mg|DWP212525 50mg
57782404|NCT06736587|DRUG|DWP212525 100mg|DWP212525 100mg
57782405|NCT06736587|DRUG|DWP212525 200mg|DWP212525 200mg
57782406|NCT06736587|DRUG|DWP212525 400mg|DWP212525 400mg
57782407|NCT06736587|DRUG|DWP212525 placebo|DWP212525 placebo
57782408|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
57782409|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
57782410|NCT06381492|DEVICE|MRI|MRI using DTI technology
57782411|NCT06381492|DEVICE|Ultrasound (US)|Standard US
58485931|NCT02728687|DRUG|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
57782412|NCT06381492|DEVICE|Neuromuscular electric stimulation (NMES)|Standard NMES
57782413|NCT01812343|OTHER|Exercise test|
57782414|NCT06632496|DEVICE|BD Prevue(TM) II|Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
57782415|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
57782416|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
57782417|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
57782418|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
57782419|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
57782420|NCT02654379|BIOLOGICAL|Rituximab|Rituximab use in non-oncology indications
57782421|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
57782422|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
57782423|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
57782424|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
57782425|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
57782426|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
57782427|NCT06410391|RADIATION|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
57782428|NCT04755140|BEHAVIORAL|Questionnaires|The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.
57782429|NCT04755140|BEHAVIORAL|Interviews|Cognition and memory interviews will take place with the patient.
57782430|NCT04755140|DIAGNOSTIC_TEST|Blood Test|Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.
57782431|NCT04755140|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
57782432|NCT06738953|BEHAVIORAL|Cognitive-Behavioral Intervention to increase Self Efficacy|Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
57782433|NCT06738953|BEHAVIORAL|Placebo: Weekly Recap and Group Discussion on Psychological Experiments|Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
57782434|NCT01508299|PROCEDURE|skin test|skin test with the Suspected raw food
57782435|NCT06720311|PROCEDURE|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
57782436|NCT06720311|PROCEDURE|Flexible Ureterorenoscopy|Flexible Ureterorenoscopy
57782437|NCT06720311|PROCEDURE|Shockwave Lithotripsy|Shockwave Lithotripsy
57782438|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
57782439|NCT05620914|DRUG|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
57782440|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
57782441|NCT05753189|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
57782442|NCT05753189|DRUG|Placebo|Placebo: Proprietary Vehicle Solution
57782443|NCT05753189|DRUG|Aceclidine Ophthalmic Solution|Aceclidine
57782444|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
57782445|NCT05331729|RADIATION|FMISO-PET Protocol|"* injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT"
57782446|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
57782447|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
57782448|NCT06739993|BEHAVIORAL|Resonance frequency breathing with heart rate variability biofeedback training|During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds. When the participants achieved the specified breathing frequency, resulting in an increased sinus arrhythmia, the symbols appearing on the smartphone display were green. When the participants did not achieve the specified breathing frequency, the symbols appeared in yellow (non-significant deviation), orange (significant deviation), or red (very significant deviation). The participants were instructed to adjust their breathing frequency to reach emergence of as many green symbols as possible for the entire training session.
57782449|NCT06739993|BEHAVIORAL|Anti-Stress program|The mobile system eSense Pulse from Mindfield Biosystems is used for the digital anti-stress program. To do this, the participants put on a chest strap with a sensor and can start training via the eSense app. The anti-stress program is carried out using a procedure generated for the study. During the anti-stress program units, the participants receive application-related information and tips to better understand the topic of stress, identify stressors in their own lives and reduce stress. The active control intervention of the anti-stress program was selected to investigate the effect of a specific stress level reduction without the direct modulation of physiological mechanisms of action as with HRV-BF-RFA.
57782450|NCT06397313|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
57782451|NCT06397313|DRUG|Ruxolitinib|Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
57782452|NCT05656027|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
57782453|NCT05656027|DRUG|Aceclidine|LNZ100 Aceclidine ophthalmic solution
57782454|NCT05656027|DRUG|Brimonidine|Brimonidine ophthalmic solution
57782455|NCT06718803|BEHAVIORAL|Hypnosis|"The Evia program includes three mayor components, 1. A hypnotherapy program for the reduction of hot flashes, 2. Educational readings on hot flashes and menopausal-related topics, 3. Daily hot flash tracker.~The hypnotherapy is delivered in short, daily 10-20 minute audio recordings that involve numerous suggestions for coolness and relaxation (i.e., cool breeze, snowy mountain, deep lake) for a period of five weeks. The hypnotherapy program is based on previous randomized controlled trials for the reduction of hot flashes (Elkins et al., 2008; Elkins et al., 2013)."
57782456|NCT06718803|OTHER|Structured Attention|Data collection of hot flash severity and frequency will mirror the hot flashes daily tracker offered by the intervention group (Evia app), and account for time and structured attention control while removing any potential therapeutic effects.
58485932|NCT00809718|DRUG|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
57782457|NCT05906303|DRUG|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
57782458|NCT05906303|DRUG|Normal Saline|Provide normal saline to serve as a placebo
57782459|NCT06340503|DEVICE|Research-grade accelerometer|Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit. Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
57782460|NCT06340503|OTHER|National Comprehensive Cancer Network (NCCN) Education Materials|The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
57782461|NCT06340503|DEVICE|Garmin Vivofit activity tracker|This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
57782462|NCT06340503|OTHER|Exercise Consultation Calls|The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
57782463|NCT06340503|OTHER|Interview|The interviews will be conducted by a trained Q-PRO interviewer and audio recorded. Interviews are expected to last approximately 30 minutes. Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
57782464|NCT06340503|OTHER|Physical Activity Index Assessment (Intervention Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 1, 3, 6, 9 and 12 while on study
57785259|NCT05543421|DEVICE|TMS|rTMS (30sessions) or iTBS (40sessions)
58485933|NCT02298010|DRUG|Capecitabine, oxaliplatin|
58485934|NCT00299169|BEHAVIORAL|N of 1 Trials|N of 1 Trials of statin therapy
58485935|NCT03239106|DRUG|Apremilast|Apremilast 30 mg BID daily
58485936|NCT04084691|OTHER|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
57782465|NCT06340503|OTHER|Physical Activity Index Assessment (Control Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.
57782466|NCT06340503|OTHER|Health Surveys|Various health surveys will be completed to assess participant health and physical activities.
57782467|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
57782468|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
57782469|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
57782470|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
57782471|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
57782472|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
57782473|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
57782474|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
57782475|NCT04134858|OTHER|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
57782476|NCT06740591|DEVICE|HD-tDCS|The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
57782477|NCT06740591|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation(sham HD-tDCS)|The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
57782478|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
57782479|NCT06737770|PROCEDURE|osseointegrated surgery for transfemoral amputation|osseointegrated surgery for transfemoral amputation
57782480|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
57782481|NCT03729349|BIOLOGICAL|Golimumab|Participants will receive golimumab as a part of clinical practice.
57782482|NCT05939518|OTHER|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
57782483|NCT05939518|OTHER|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
57782484|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
57782485|NCT06555822|DRUG|AZD5004|Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
58485937|NCT04084691|OTHER|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
57782486|NCT06555822|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
57782487|NCT04574024|DRUG|NBT-NM108|MS Patients received NBT-NM108 at 60 g/day.
57782488|NCT05544058|OTHER|Retrospective study|Retrospective study
57782489|NCT06738329|OTHER|Carrageenan gummy sweet|Gummy sweet containing carrageenan and agar as the gelling agents.
57782490|NCT06738329|OTHER|Carrageenan and inulin gummy sweet|Gummy sweet containing agar and carrageenan as gelling agents, with added inulin.
57782491|NCT06738329|OTHER|Placebo agar agar gummy|Gummy sweet containing agar as gelling agents.
57782492|NCT00570258|DRUG|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
57782493|NCT00570258|DRUG|erlotinib|150 mg PO QD
57782494|NCT00570258|DRUG|Fulvestrant|250 mg IM Q 4 weeks
57782495|NCT00570258|DRUG|Placebo|Placebo 150 mg PO QD
57782496|NCT05138796|DRUG|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
57782497|NCT05138796|DRUG|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
57782498|NCT03888170|OTHER|No intervention|No intervention
57782499|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
57782500|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
57782501|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
57782502|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
57782503|NCT05800366|DRUG|Glofitamab|human IgG1-bispecific antibody, via IV infusion
57782504|NCT05800366|DRUG|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
57782505|NCT05800366|DRUG|Rituximab|Per standard care, via IV infusion
57782506|NCT05800366|DRUG|Doxorubicin Hydrochloride|Per standard care, via IV infusion
57782507|NCT05800366|DRUG|Cyclophosphamide|Per standard care, via IV infusion
57782508|NCT05800366|DRUG|Prednisone|Per standard care, orally
57782509|NCT04008030|BIOLOGICAL|Ipilimumab|Specified dose on specified days
57782510|NCT04008030|DRUG|Oxaliplatin|Specified dose on specified days
57782511|NCT04008030|DRUG|Leucovorin|Specified dose on specified days
57782512|NCT04008030|DRUG|Fluorouracil|Specified dose on specified days
57782513|NCT04008030|DRUG|Irinotecan|Specified dose on specified days
57782514|NCT04008030|DRUG|Bevacizumab|Specified dose on specified days
57782515|NCT04008030|DRUG|Cetuximab|Specified dose on specified days
57782516|NCT04008030|BIOLOGICAL|Nivolumab|Specified dose on specified days
57782517|NCT06345729|DRUG|MK-1084|Oral tablets
57782518|NCT06345729|OTHER|Placebo|Oral tablets
57782519|NCT06345729|BIOLOGICAL|Pembrolizumab|IV infusion
57782520|NCT05247502|BIOLOGICAL|Data observation|At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
57782521|NCT01196130|BEHAVIORAL|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
57782522|NCT01196130|OTHER|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
57782523|NCT06688578|DEVICE|Subperceptual Stimulus|For each test participants will be stimulated using a subperceptual electric signal that is optimized to improve their gait.
57782524|NCT06688578|DEVICE|Sham Comparator|During intervention trial, sham comparator will consist of same stimulation device but no actual electrical stimulation will be provided by device during intervention trial.
57782525|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
57782526|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
58485938|NCT04084691|OTHER|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
57782527|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
57782528|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
57782529|NCT06737510|BEHAVIORAL|Informational brochure on household emergency preparedness|"An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones ."
57782530|NCT06737510|BEHAVIORAL|Phone-based household emergency preparedness|A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
57782531|NCT01307280|BEHAVIORAL|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
57782532|NCT01307280|BEHAVIORAL|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
57782533|NCT01307280|BEHAVIORAL|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
57782534|NCT05313893|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
57782535|NCT04283045|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
57782536|NCT04283045|BEHAVIORAL|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
57782537|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
57782538|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
57782539|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
57782540|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
57782541|NCT02321085|PROCEDURE|Sinus Rhythm control|
57782542|NCT02321085|PROCEDURE|Pulse Rate control|
57782543|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
57782544|NCT06730360|PROCEDURE|MTA Pulpotomy without photobiomodulation|This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.
57782545|NCT06730360|PROCEDURE|MTA Pulpotomy with Photobiomodulation (LLLT)|This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
57782546|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
57782547|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
57782548|NCT06738719|BIOLOGICAL|CT-P13 SC Auto-Injector|Subcutaneous(SC) Injection
57782549|NCT06738719|BIOLOGICAL|Placebo Auto-Injector|Subcutaneous(SC) Injection
57782550|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
57782551|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
57782552|NCT06524804|RADIATION|palliative radiotherapy|Undergo palliative radiotherapy
57782553|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
57782554|NCT06524804|RADIATION|curative radiotherapy|Undergo curative radiotherapy
57782555|NCT05546411|DRUG|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
57782556|NCT05546411|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
57782557|NCT05546411|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
57782558|NCT05546411|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
57782559|NCT05546411|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
57782560|NCT05546411|DRUG|NIS793|Given by intravenous infusion
57782561|NCT05546411|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
57782562|NCT05546411|PROCEDURE|Surgery|Surgical removal of tumor
57782563|NCT02631603|DRUG|Placebo|Administer Placebo as anti-inflammatory
57782564|NCT02631603|DRUG|Prednisolone|Administer Prednisolone as anti-inflammatory
57782565|NCT06737744|OTHER|Active Games for Change (AG4C)|This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.
58485939|NCT04084691|OTHER|Normal meal|- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
57782566|NCT06737744|BEHAVIORAL|Active Games for Change Group Working|The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.
57782567|NCT04982653|OTHER|Quality-of-Life Assessment|Ancillary studies
57782568|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
57782569|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
57782570|NCT01565018|DRUG|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
57782571|NCT01565018|DRUG|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
57782572|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
57782573|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
57782574|NCT06719661|DRUG|Dapagliflozin 10mg|Uncontrolled type 2 diabetic patients receive dapagliflozin 10 mg tablet once daily. They are asked to take it for 3 months, then return for their final assessment after 3 months
57782575|NCT06719661|OTHER|Clinical Pharmacist-led Intervention|Patients with uncontrolled type 2 diabetes will undergo dosage intensification of their dual or triple oral hypoglycemic medicines up to maximum daily doses. Further, they will be advised on specific dietary modification, education on the importance of adherence, strategies to improve adherence, including giving pill boxes, and regular follow-up every month via telephone-based communication.
57782576|NCT06719661|OTHER|Standard therapy group|Patients are receiving their standard dual or triple oral hypoglycemic therapy only.
57782577|NCT06330961|OTHER|Isometric exercise|Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.
57782578|NCT06330961|OTHER|Aerobic exercise|After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.
57782579|NCT06330961|OTHER|Placebo intervention|A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
57782580|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57782581|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
57782582|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
57782583|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
57782584|NCT06639958|OTHER|Media Intervention|View MIPE program videos
57782585|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
57782586|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
57782587|NCT06639958|DRUG|Mercaptopurine|Given PO
57782588|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
58485940|NCT04084691|OTHER|Normalized meal|"- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
57782589|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
57782590|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminder
57782591|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
57782592|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
57782593|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
57782594|NCT02928497|DEVICE|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
57782595|NCT02928497|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
57782596|NCT06727526|OTHER|Acupressure|The literature found that acupressure positively affects child health, but no study was found to determine the effect of acupressure on pain and physiological parameters in children undergoing cardiac catheterization. Therefore, this study was designed to determine the effect of acupressure applied before and after cardiac catheterization on infants' pain levels and physiological parameters.
57784671|NCT05040061|BEHAVIORAL|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
57784672|NCT05040061|BEHAVIORAL|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
58485941|NCT04084691|OTHER|Fasting|non meal in the hour before exercise
58485942|NCT00077415|DRUG|gemcitabine hydrochloride|
58485943|NCT00077415|DRUG|triapine|
57782597|NCT06727526|OTHER|Placebo acupressure|In health sciences, placebo refers to an inactive intervention used to relax the patient and assess treatment efficacy. It may involve inert substances (e.g., sugar tablets, saline) or non-therapeutic interventions (e.g., artificial electrical stimulation or conversations). Expectancy theory often explains The placebo effect, which suggests that treatment expectations can induce physiological changes. Factors like age, cognitive development, and previous pain experiences influence children's responses to placebo. Parental belief in an intervention's efficacy can reduce a child's pain expectations and positively influence their perception of pain. Although the sample included young children, our study incorporated the placebo group to account for this effect, especially since the parents evaluated pain scores.
57782598|NCT06735924|DIETARY_SUPPLEMENT|Low-oxalate fixed diet|Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
57782599|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
57782600|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
57782601|NCT04028843|BEHAVIORAL|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
57782602|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
57782603|NCT03441074|BEHAVIORAL|enhanced olfactory stimuli|Patients in intervention group will get enhanced olfactory stimuli during perioperative period (2 to 3 days before the surgery and 7 days after the surgery), by using portable scented sachets.
57782604|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
57782605|NCT06498128|DRUG|Daridorexant|Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
57782606|NCT06498128|DRUG|Non-orexin receptor antagonist medications for insomnia|Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
57782607|NCT06498128|OTHER|No insomnia medication|No insomnia medication was administered.
57782608|NCT06735859|BEHAVIORAL|Comparison of eating windows intervention|Participants will be randomized into two groups to follow either eating window for 12 months, with normocaloric meal plans based on the Mediterranean diet adapted to Brazilian culture. After 12 months, a 3-month washout period will follow, during which participants return to their usual eating patterns. The groups will then be swapped to follow the opposite eating window for another 12 months. Finally, a new data collection will be conducted 3 months post-intervention to analyze the stability of behavior.
57782609|NCT06720610|DRUG|Vonoprazan 20 mg|Vonoprazan PO, 20mg, once a day, 14 days.
57782610|NCT06720610|DRUG|Esomeprazole|Esomeprazole PO, 40mg, once a day, 14 days
57782611|NCT01650675|BEHAVIORAL|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
57782612|NCT01650675|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
57782613|NCT03482674|BEHAVIORAL|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
57782614|NCT05345912|DRUG|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
57782615|NCT05345912|DRUG|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
57782616|NCT05345912|OTHER|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
57782617|NCT05345912|OTHER|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
57782618|NCT06393998|DEVICE|Breathing with CO2 during daytime and night at high altitude|Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.
57782619|NCT06393998|DEVICE|Sleep and doing exercise test under inhalation of air|Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
57782620|NCT06739473|BEHAVIORAL|Movies|Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.
57782621|NCT06739473|BEHAVIORAL|Cold|Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.
57782622|NCT06739473|DRUG|Hyperinsulinemic euglycemic clamp|Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.
57782623|NCT06739473|RADIATION|H2[15O]O PET/CT|H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.
57782624|NCT06739473|RADIATION|[18F]FDG PET/CT|Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq
57782625|NCT06739473|DRUG|CEUS or Contrast enhanced Ultrasound|Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
57782626|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
57782627|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
57782628|NCT00033956|DRUG|M40403|
57782629|NCT05309928|DRUG|Amoxicillin|medication administration
57782630|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
57782631|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
57782632|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
57782633|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
57782634|NCT05088694|BEHAVIORAL|Peaceful Coexistence|"The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior."
57782635|NCT06741033|DIAGNOSTIC_TEST|Conventional physiotherapy|Conventional physiotherapy of medial knee osteoarthritis patients: Isometric exercises, strengthening exercises, stretching exercises and electrotherapy.
57782636|NCT06741033|COMBINATION_PRODUCT|Toe-in gait modification|A specific alteration in walking pattern where the toes are directed inward during walking. This modification should be clearly defined, including the degree of inward rotation of the foot and how it is taught and monitored in participants. Toe-in gait modification basically includes decrease foot progression angle from baseline through internal foot rotation. Participants are instructed to increase the Toe-in angle of their study limb by 5 degree and walk at least 5-10 minutes (progressed to 15-20 min after 4 week) with this progression angle.
57782637|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
57782638|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
57782639|NCT03092674|DRUG|Azacitidine|Given SC or IV
57782640|NCT03092674|DRUG|Cytarabine|Given IV
57782641|NCT03092674|DRUG|Decitabine|Given IV
57782642|NCT03092674|OTHER|Laboratory Biomarker Analysis|Correlative studies
57782643|NCT03092674|DRUG|Midostaurin|Given PO
57782644|NCT03092674|BIOLOGICAL|Nivolumab|Given IV
57782645|NCT04832412|DIETARY_SUPPLEMENT|BrainPhyt|BrainPhyt low dose supplementation during 6 months
57782646|NCT04832412|DIETARY_SUPPLEMENT|100 % Maltodextrin|100 % Maltodextrin
57782647|NCT02531880|DRUG|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
57782648|NCT00669747|DRUG|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
57782649|NCT00669747|DRUG|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
57782650|NCT00669747|DRUG|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
57782651|NCT02343575|DRUG|Valproic Acid|"1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
57782652|NCT02343575|DRUG|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
57782653|NCT02343575|DRUG|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
57782654|NCT02742506|OTHER|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
57782655|NCT04963764|DRUG|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
58485944|NCT00880243|DRUG|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
58485945|NCT02564003|DRUG|Oxycodone|oxycodone 0,1 mg/kg iv
57782656|NCT04963764|DRUG|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
57782657|NCT05834582|DRUG|Fluzoparib+Paclitaxel|Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
57782658|NCT05834582|DRUG|Epirubicin+Cyclophosphamide|Epirubicin+Cyclophosphamide
57782659|NCT03562169|DRUG|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
57782660|NCT03562169|DRUG|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
57782661|NCT03562169|DRUG|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
57782662|NCT03562169|DRUG|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
57782663|NCT00747383|DRUG|Glimepiride|3mg oral tablet.
57782664|NCT00747383|DRUG|Sitagliptin|100mg oral tablet.
57782665|NCT05297903|DRUG|XmAb20717|10mg/kg IV
57782666|NCT06737991|OTHER|Range of motion exercises|Range of motion Exercises, soft tissue massage, positioning to prevent pressure sores, stretch pole for 20 minutes
57782667|NCT05992909|PROCEDURE|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
57782668|NCT05175105|DRUG|Mitapivat|Tablets or granules
57782669|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
57782670|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
57782671|NCT06736808|OTHER|Handout Written at Below a Sixth Grade Reading Level|Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.
57782672|NCT06736808|OTHER|Handout Written at Above a Sixth Grade Reading Level|Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
57782673|NCT06188468|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
57782674|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
57782675|NCT06737549|DRUG|Nerver growth factor (NGF) injection|The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
57782676|NCT06737549|DRUG|Placebo injection|Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
57782677|NCT06737549|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of patient can tolerate, targeting a current strength of 3.0mA, for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
57782678|NCT06737549|DEVICE|Acupuncture intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are connected to an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) without closed circuit, with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
57782679|NCT05074693|OTHER|EASE app|EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
57782680|NCT05074693|OTHER|INSIGHT (Control) App|"A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos."
57782681|NCT06663020|BEHAVIORAL|Smoking Cessation Duration|Participants are categorized based on their smoking status and the duration since they quit smoking prior to lung cancer surgery. This observational study focuses on evaluating the relationship between the duration of smoking cessation (measured in days or weeks) and the incidence of postoperative complications. Smoking cessation duration is recorded for each participant to determine its impact on surgical outcomes.
57782682|NCT06728761|BEHAVIORAL|Standardised test meal|"Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant."
57782683|NCT06728761|BEHAVIORAL|Ingestion of test drink|Ingestion of 2,5 cl Calvados 40° at the 70th min of the meal (before cheese and dessert)
57782684|NCT06728761|BEHAVIORAL|Ingestion of Control drink|Ingestion of 2,5 cl water at the 70th min of the meal (before cheese and dessert)
57782685|NCT06728761|DIAGNOSTIC_TEST|Ultrasound measurement of the antral area|Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
57782686|NCT06728761|DIAGNOSTIC_TEST|Breathalyser for measurement of the level of exhaled ethanol|Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
57782687|NCT06728761|BEHAVIORAL|Discomfort|discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
57782688|NCT06728761|BEHAVIORAL|Appetite|Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
57782689|NCT06728761|DIAGNOSTIC_TEST|Pregnancy urine test carried out during the intake visit on the day of the protocol|Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
57782690|NCT06716957|OTHER|Schroth exercise|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
57782691|NCT06716957|OTHER|Dynamic Stabilization exercises|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 12 weeks
57782692|NCT02035787|DRUG|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
57782693|NCT04915612|DRUG|Gemtuzumab Ozogamicin|Given IV
57782694|NCT04915612|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
57782695|NCT06209606|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
57782696|NCT06209606|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
57782697|NCT06209606|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
57782698|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
57782699|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
57782700|NCT05603819|DEVICE|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
57782701|NCT01579019|DRUG|RO5024048|1500 mg po bid, 24 or 26 weeks
57782702|NCT01579019|DRUG|RO5024048|1000 mg po bid, 24 or 26 weeks
57782703|NCT01579019|DRUG|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
58485946|NCT00026169|DRUG|imatinib mesylate|Given orally
58485947|NCT00026169|OTHER|laboratory biomarker analysis|Correlative studies
57782704|NCT01579019|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
57782705|NCT01579019|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
57782706|NCT01579019|DRUG|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
57782707|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
57782708|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
58485948|NCT00026169|OTHER|pharmacological study|Correlative studies
58485949|NCT04151303|PROCEDURE|Cervical cerclage|Cervical cerclage and cervical cerclage removal
58485950|NCT02731105|DRUG|Acnatac® Gel left face|topical application
57782709|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
57782710|NCT02453087|DRUG|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
57782711|NCT02453087|DRUG|Rituximab|Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
57782712|NCT02453087|DRUG|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
57782713|NCT03851874|PROCEDURE|Bariatric surgery|Bariatric surgery
57782714|NCT01941992|DRUG|SAMITAL®|
57782715|NCT01941992|DRUG|Placebo sachets|
57782716|NCT03231449|OTHER|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
57782717|NCT01021163|DRUG|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
57782718|NCT03944980|DRUG|Docetaxel|Docetaxel injection
57782719|NCT03944980|BIOLOGICAL|PD1-T cells|PD1-T cells injection
57782720|NCT04314063|OTHER|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
57782721|NCT01783093|OTHER|Data Collection|Collection of data from existing medical records
57782722|NCT05797519|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
57782723|NCT06738446|DIETARY_SUPPLEMENT|Multicomponent dietary supplement group|Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks
57782724|NCT02674243|DRUG|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
57782725|NCT02674243|DRUG|Talc|In this group, Talc will be used as pleurodesis substance
57782726|NCT05327010|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
57782727|NCT05327010|PROCEDURE|Biopsy|Undergo tumor biopsy
57782728|NCT05327010|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57782729|NCT05327010|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
57782730|NCT05327010|DRUG|Talazoparib|Given PO
57782731|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
57782732|NCT04234048|DRUG|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
57782733|NCT06467357|DRUG|Gemcitabine|Standard of care chemotherapy by intravenous infusion
57782734|NCT06467357|DRUG|Cisplatin|Standard of care chemotherapy by intravenous infusion
57782735|NCT06467357|DRUG|Durvalumab|Standard of care immunotherapy by intravenous infusion
57782736|NCT06467357|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
57782737|NCT06467357|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
57782738|NCT06467357|DIAGNOSTIC_TEST|Agilent HercepTest™ mAb pharmDx|"A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis)."
57782739|NCT06467357|DIAGNOSTIC_TEST|Ventana PD-L1 SP263 assay|A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
57782740|NCT05035654|DRUG|LYR-220 Design 1 (Part 1 only)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
57782741|NCT05035654|DRUG|LYR-220 Design 2 (Part 1 and Part 2)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
57782742|NCT05035654|DRUG|Bilateral sham procedure control (Part 2)|Bilateral sham procedure control
57782743|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
57782744|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
57782745|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
57782746|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
57782747|NCT06738433|DIETARY_SUPPLEMENT|ABB i5|Prebiotic ABB i5 (NextDext®, 5g)
57782748|NCT06738433|DIETARY_SUPPLEMENT|ABB C24|ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
57782749|NCT04260126|COMBINATION_PRODUCT|Pembrolizumab (KEYTRUDA®) and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
57782750|NCT03237013|BEHAVIORAL|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
57782751|NCT03237013|BEHAVIORAL|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
57784709|NCT04207684|DRUG|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
57784710|NCT00145717|DRUG|Plant sterol enriched milk tea|
57784711|NCT04288973|DIAGNOSTIC_TEST|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
58485951|NCT02731105|DRUG|Epiduo® Gel right face|topical application
57782752|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
57782753|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
57782754|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
57782755|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
57782756|NCT01190176|PROCEDURE|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
57782757|NCT01190176|BIOLOGICAL|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
57782758|NCT01190176|BIOLOGICAL|Placebo control|Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
57782759|NCT05561244|DEVICE|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
57782760|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
57782761|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
57782762|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
57782763|NCT04543591|OTHER|Placebo|Matching placebo
57782764|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
57782765|NCT01902589|OTHER|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
57782766|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
57782767|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
57782768|NCT06442761|DRUG|Motixafortide|Given Subcutaneously (under the skin).
57782769|NCT06739746|OTHER|No intervention measures|No intervention measures
57782770|NCT06602193|DRUG|BIIB122 225 mg|Administered as specified in the treatment arm
57782771|NCT06602193|OTHER|BIIB122-Matching Placebo|Administered as specified in the treatment arm
57782772|NCT05723614|BEHAVIORAL|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
57782773|NCT06737120|PROCEDURE|Mod-fgg|"Following an intrasulcular incision, 2 mm long horizontal incisions will be made on each side at the level of the gum line. From these incisions, divergent vertical release incisions will be made extending towards the alveolar mucosa. To prepare the recipient area, a thin partial thickness flap will be lifted and then removed. A foil template will be obtained by measuring the dimensions of the resulting area.~A horizontal incision will be made apical to the exposed root area of the target teeth at a distance corresponding to the height of the exposed root surface. Starting from the endpoints of this incision, two more slightly divergent incisions will be made in the coronal direction. Thus, a connective tissue pedicle flap will be formed and carefully separated from the periosteum. The pedicle graft will be turned over the exposed root surface and fixed with bioabsorbable sutures. The palatal graft will be sutured to cover the connective tissue."
57782774|NCT06737120|PROCEDURE|Fgg|The surgical procedures to be performed in this group will be the same as in the modified free gingival graft group, but no connective tissue pedicle flap will be performed.
58485952|NCT02731105|DRUG|Acnatac® Gel right face|topical application
57782775|NCT06737939|OTHER|intravenous ibuprofen|A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.
57782776|NCT06737939|OTHER|periprostatic nerve block|A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
57782777|NCT05501704|DRUG|Tamoxifen|Taken orally
57782778|NCT05501704|DRUG|Anastrozole|Taken orally
57782779|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
57782780|NCT05501704|DRUG|Abemaciclib|Taken orally
57782781|NCT06736951|OTHER|MMSH (Multi-Modal Sleep Hygiene) Bundle|Focus on Noise Reduce Noise Perception, Reduce Hallway Noise, Reduce Noise in Rooms Focus on Light Reduce Lights at Night, Increase Light in Day, Reduce Light Perception Focus on Staff-Patient Interactions Delirium Screening, Avoid Care Procedures at Night, Z-time Plan \&amp; Prep Focus on Daytime Activity Increased Mobility, Increase Patient Engagement Focus on Medications Pain Management, Medication Monitoring, Continue pharmacy protocols, Timing of Medications/Monitoring Labs
57782782|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
57782783|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
57782784|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
57782785|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H1coil|Participants will receive dTMS treatment with H1 coil
57782786|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H7 coil|Participants will receive dTMS treatment with H7 coil
57782787|NCT01400464|DRUG|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
57782788|NCT02919956|OTHER|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
57782789|NCT02919956|OTHER|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
57782790|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
57782791|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
57782792|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
57782793|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
57782794|NCT06728254|DEVICE|medication management|"The test system consists of:~* Linked care platform (backend) which provides a new possibility of data exchange for IT systems of caregivers, pharmacies, and GPs~* User interfaces for caregivers as well as for the systems myneva.carecenter and mynevaTOgo~* An extension of the user interface for GPs in their IT system (in the test only for the physician software PCPO by CompoGroup Medical )~* An extension of the user interface for pharmacists in their IT system (in the test only for pharmacies with software from Apothekerverlag)~Functionally, the solution should, coordinate the medication requirements between pharmacies, GPs, and caregivers (subarea medication)."
57782795|NCT06728254|OTHER|Usual Care Group|Usual care.
57782796|NCT06741280|DEVICE|Profilm Aftas Bucales|The treatment will consist of daily applications of the product as soon as an oral ulcer appears, until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
57782797|NCT03442023|DRUG|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
57782798|NCT03442023|DRUG|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
57782799|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
57784712|NCT00977028|DRUG|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
58485953|NCT02731105|DRUG|Epiduo® Gel left face|topical application
57782800|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
57782801|NCT06447805|DEVICE|Double Sequential Defibrillation (DSD)|The second defibrillator will be applyed with electrodes placed in the A-P position
57782802|NCT06447805|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
57782803|NCT04927364|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
57782804|NCT06713239|DEVICE|Cleerly Labs and Cleerly ISCHEMIA|Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
57782805|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
57782806|NCT04436107|DRUG|Lenalidomide|Administered as specified in the treatment arm
57782807|NCT05795842|DEVICE|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
57782808|NCT05795842|OTHER|Samsung Galaxy Watch 6|"The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development."
57782809|NCT05795842|DEVICE|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
57782810|NCT06729762|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation, microwave ablation, laser ablation
57782811|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
57782812|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
57782813|NCT05482932|DIAGNOSTIC_TEST|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
57782814|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
57782815|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
57782816|NCT00422721|PROCEDURE|realization of a family tree|
57782817|NCT00422721|PROCEDURE|refractometry|
57782818|NCT00422721|PROCEDURE|evaluation of the presence of a nystagmus|
57782819|NCT00422721|PROCEDURE|ocular behavior|
57782820|NCT00422721|PROCEDURE|test of baby vision|
57782821|NCT00422721|PROCEDURE|test of keenness|
57782822|NCT00422721|PROCEDURE|reading test|
57782823|NCT00422721|PROCEDURE|visual field|
57782824|NCT00422721|PROCEDURE|color vision|
57782825|NCT00422721|PROCEDURE|electroretinographical activity|
57782826|NCT00422721|PROCEDURE|biomicroscopical test|
57782827|NCT00422721|PROCEDURE|retinal imaging|
57782828|NCT00422721|PROCEDURE|retinal autofluorescence|
57782829|NCT00422721|PROCEDURE|genotyping|
57782830|NCT06739148|DEVICE|Low Level Laser Therapy|Low-level laser therapy can increase cellular energy production, making it useful as a pre-conditioning treatment to prevent muscle contraction fatigue or as a post-contraction therapy to accelerate fatigue recovery.
57782831|NCT06739148|DEVICE|blood flow restriction|Its advantage is that during training, it can surpass the \&#34;overload principle,\&#34; allowing for effective muscle cross-sectional area growth with relatively light weight training (20%-50% of 1RM or 20%-40% of MVC).
57782832|NCT06739148|DEVICE|Neuromuscular Electrical Stimulation|It is a strength training method that uses electrical currents to stimulate nerve and muscle activation, helping to maintain muscle mass, increase blood flow, and slow down or prevent muscle atrophy.
57782833|NCT06631417|DRUG|BI 1291583|formulation 1
57782834|NCT06631417|DRUG|BI 1291583|formulation 2
57782835|NCT06631417|DRUG|BI 1291583|formulation 3
57782836|NCT02398747|DRUG|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
57782837|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
57782838|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
58485954|NCT02645019|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
57782839|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
57782840|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
57782841|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
57782842|NCT02807805|DRUG|Abiraterone Acetate|Given PO
57782843|NCT02807805|DRUG|Niclosamide|Given PO
57782844|NCT02807805|DRUG|Prednisone|Given PO
57782845|NCT06738901|BIOLOGICAL|SKP-0141|Human plasma-derived coagulation factor VIII concentrate
57782846|NCT05234177|OTHER|Observation|No intervention
57782847|NCT06714578|OTHER|Questionnaire and Physical Exam|The investigators use questionnaire to assess biological factors (sleep quality, externalizing problem behavior, prosocial tendencies, sensation seeking, and hedonic hunger), psychological factors (risk awareness of drug misusing, indulgence of drug misusing, self-efficacy of drug misusing, and ACEs), and social factors (whether work in a special place, whether have drug-addicts around, cognition of traditional drug types, and cognition of NPS types) and demographic data
57782848|NCT02712840|PROCEDURE|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
57782849|NCT02712840|PROCEDURE|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
57782850|NCT06357182|DRUG|Azacitidine|Given SC
57782851|NCT06357182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
57782852|NCT06357182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
57782853|NCT06357182|PROCEDURE|Echocardiography|Undergo ECHO
57782854|NCT06357182|DRUG|Iadademstat|Given PO
57782855|NCT06357182|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
57782856|NCT06357182|OTHER|Questionnaire Administration|Ancillary study
57782857|NCT06357182|DRUG|Venetoclax|Given PO
57782858|NCT03308903|DIAGNOSTIC_TEST|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
57782859|NCT03863899|PROCEDURE|Nerve block|drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
57782860|NCT03863899|PROCEDURE|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
57782861|NCT03863899|PROCEDURE|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
57782862|NCT03863899|DRUG|Additional intraoperative analgesia|Administration of any analgesics during the operation
57782863|NCT03863899|DRUG|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
57782864|NCT01398501|DRUG|Sorafenib|Oral, 200 to 400 mg QD or BID
57782865|NCT06719778|OTHER|Two-stage nutritional therapy concept|"1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect."
57782866|NCT00075803|DRUG|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.
57782867|NCT00075803|DRUG|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
57782868|NCT05257551|OTHER|Observation|No intervention
57782869|NCT06739772|BEHAVIORAL|HPV Self-Sampling and Behavior Intervention|Participants in the intervention group will receive HPV self sampling and behavioral intervention
57782870|NCT06739772|BEHAVIORAL|Participants in the intervention group will receive HPV self sampling and behavioral intervention|Received enhance standard care
57782871|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
58137382|NCT01288352|OTHER|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
57782872|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
58137383|NCT03212222|OTHER|Peek Acuity|Cell phone application for visual acuity screening
57782873|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
57782874|NCT05723575|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
57782875|NCT05723575|BEHAVIORAL|somatosensory acuity measurement|Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
57782876|NCT06739525|COMBINATION_PRODUCT|Blue Light-Blocking Glasses (Intervention Group)|Participants in this arm wore blue light-blocking glasses designed to filter out a portion of short-wavelength blue light. These lenses were intended to reduce eye strain and protect against blue light exposure, especially during prolonged screen time. Participants used blue light-blocking glasses consistently throughout the study period to assess their effect on contrast sensitivity and visual fatigue.
57782877|NCT06739525|DIAGNOSTIC_TEST|Standard Lenses (Control Group)|Participants in this arm wore standard lenses without any blue light-blocking properties. These lenses allow the full spectrum of visible light to pass through and serve as a baseline control to measure against the blue light-blocking glasses. Participants used these lenses under the same conditions to assess contrast sensitivity and visual fatigue without blue light filtration.
57782878|NCT04607421|DRUG|Encorafenib|75 mg capsules
57782879|NCT04607421|DRUG|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
57782880|NCT04607421|DRUG|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
57782881|NCT04607421|DRUG|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
57782882|NCT04607421|DRUG|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
57782883|NCT04607421|DRUG|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
57782884|NCT04607421|DRUG|Capecitabine|150 mg or 500 mg Tablet
57782885|NCT04607421|DRUG|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
57782886|NCT01117597|RADIATION|low RF exposure level|Exposure with 1.5 W/kg
57782887|NCT01117597|RADIATION|sham exposure|intervention with sham RF exposure
57782888|NCT01117597|RADIATION|high RF exposure|intervention with high RF exposure
57782889|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
57782890|NCT03857711|PROCEDURE|Conventional CABG|Coronary artery bypass grafting
57782891|NCT03857711|PROCEDURE|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
57782892|NCT03857711|PROCEDURE|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
57782893|NCT03857711|PROCEDURE|CABG+amiodarone|
57782894|NCT06042257|DRUG|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
57782895|NCT06042257|DRUG|Placebo|Matching placebo capsule
57782896|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
57782897|NCT05144256|DRUG|Mitapivat|Tablets or granules
57782898|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
57782899|NCT06137183|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
57782900|NCT06137183|DRUG|Placebo|Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
57782901|NCT05785624|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
57782902|NCT05785624|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
57782903|NCT05195710|DRUG|Yttrium-90 (Y-90) resin microspheres|Given by scan
58137384|NCT03212222|OTHER|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
57782904|NCT06739343|PROCEDURE|PHACO-Trabeculectomy|Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.
57784713|NCT00977028|PROCEDURE|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
58485955|NCT02645019|DEVICE|Cuffed LMA|Cuffed laryngeal mask airway.
58485956|NCT00509613|DRUG|Sorafenib|
57782905|NCT06739343|PROCEDURE|MSICS-Trabeculectomy|Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.
57782906|NCT05601726|DRUG|ABD-3001|"Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m²."
57782907|NCT05601726|DRUG|ABD-3001|"For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days."
57782908|NCT06740682|BEHAVIORAL|Podcast olumlu doğum hikayeler|"ositive birth stories were listened to by women who gave birth in the hospital included in the study and created with their permission. The podcast recording was done in a single session. These positive birth stories were expertly reviewed by 3 obstetricians and 3 academics. Each podcast content is 10 to 20 minutes (Cai et al., 2023). A WhatsApp reminder msg will be sent so that the stories are not forgotten.~In addition, the pregnant woman will be contacted by phone and trained to listen (Cai et al., 2023).~Participants will be allowed to listen to the podcasts as much as they want (Cai et al., 2023). After listening to each story, their feedback will be received and the participants' doubts will be clarified. (Cai et al., 2023; Çankaya and Şimşek, 2021; Mousavi et al., 2022).~Based on multimedia principles, podcast positive birth experiences will be prepared (Clark and Mayer, 2023). Week 24, Week 30-32, Week 36-38 First story"
57782909|NCT02367014|DRUG|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
57782910|NCT02367014|DRUG|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
57782911|NCT02367014|DRUG|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
57782912|NCT02367014|DRUG|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
57782913|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
57782914|NCT05471843|DRUG|BGB-11417|Administered orally
57782915|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
57782916|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
57782917|NCT05540665|DRUG|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
57782918|NCT01155726|DEVICE|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
57782919|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
58485957|NCT00509613|DRUG|Sirolimus|
57782920|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
57782921|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
57782922|NCT01155726|DEVICE|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
57782923|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
57782924|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
57782925|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
57782926|NCT06724432|DRUG|oral melatonin|Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
57782927|NCT06724432|DRUG|Placebo|Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
57782928|NCT05157204|PROCEDURE|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
58485958|NCT06161389|DEVICE|Partially inflated mask|Manikin ventilation with a partially inflated mask
58485959|NCT06161389|DEVICE|Fully inflated mask|Manikin ventilation with a fully inflated mask
58485960|NCT06142929|PROCEDURE|Microfasciectomy|Using the microscope in Dupuytren's surgery
58485961|NCT01193504|DRUG|Pred Forte|Pred Forte BID for 4 weeks postop
57782929|NCT06276140|DIAGNOSTIC_TEST|Laboratory analyses for the detection of iron deficiency anaemia|"Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected."
57782930|NCT05644561|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
57782931|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
57782932|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
57782933|NCT06525220|DRUG|Petosemtamab|MCLA-158
57782934|NCT06525220|DRUG|Pembrolizumab|Humanized Antibody
57782935|NCT00811148|PROCEDURE|Tissue Bank|Collection of clinical data and tumor tissue.
57782936|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
57782937|NCT06425029|OTHER|Experimental Intervention (Music A)|Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.
57782938|NCT06425029|OTHER|Active Comparator Intervention (Music B)|Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.
57782939|NCT06425029|OTHER|Active Comparator Intervention (Music C)|Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
57782940|NCT06163547|RADIATION|MMA embolization|Middle meningeal artery embolization
57782941|NCT01925781|DRUG|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
57782942|NCT01925781|OTHER|STAM 1100mAh CE4 eGo Clearomizer|
57782943|NCT05980949|DRUG|KarXT|KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
57782944|NCT00737061|DEVICE|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
57782945|NCT05561764|DRUG|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
57782946|NCT06737822|COMBINATION_PRODUCT|TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment|"TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment."
57782947|NCT06737822|COMBINATION_PRODUCT|Surgery and Adjuvant Treatment|Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
57782948|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
57782949|NCT00186147|PROCEDURE|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
57782950|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
57782951|NCT04421014|DIETARY_SUPPLEMENT|Ketone Ester drink|The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
57782952|NCT04421014|DIETARY_SUPPLEMENT|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
57782953|NCT06738056|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
57782954|NCT06728462|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
57782955|NCT06197295|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
57782956|NCT06197295|DRUG|Combination pharmacotherapy|Solifenacin 5mg and Mirabegron 25mg
57782957|NCT06740422|DRUG|Xuanhuang Runtong Tablet|A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
57782958|NCT06740422|DRUG|Xuanhuang Runtong Tablet Simulator|Xuanhuang Runtong Tablet Simulator
57782959|NCT04221542|DRUG|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
57782960|NCT04221542|DRUG|Abiraterone|Abiraterone administered as oral tablets.
57782961|NCT04221542|DRUG|Enzalutamide|Enzalutamide administered as oral tablets.
57782962|NCT04698889|DIETARY_SUPPLEMENT|natural cow|
57782963|NCT04698889|DIETARY_SUPPLEMENT|high protein cow milk|
57782964|NCT04698889|DIETARY_SUPPLEMENT|natural human|
57782965|NCT04698889|DIETARY_SUPPLEMENT|low protein cow milk|
57782966|NCT06290206|BEHAVIORAL|PREVENT - BCT|"Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings)."
57782967|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
57782968|NCT03749902|DRUG|Oral misoprostol|"* An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
57782969|NCT03749902|DRUG|Oxytocin|"* Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured."
57782970|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
57782971|NCT06641089|DRUG|Sonelokimab|Sonelokimab
57782972|NCT06641089|DRUG|Placebo|Placebo
57782973|NCT06641089|DRUG|Risankizumab|Active comparator
57782974|NCT04708691|OTHER|Aerobic exercise|aerobic exercise
57782975|NCT05345093|DEVICE|Ialuxid gel|"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."
57782976|NCT03746756|BEHAVIORAL|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
57782977|NCT03746756|BEHAVIORAL|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
57782978|NCT06136832|BEHAVIORAL|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
57782979|NCT03877263|DIAGNOSTIC_TEST|Endocervical swab for detection of STI|After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
57782980|NCT03877263|DIAGNOSTIC_TEST|Vaginal swab for detection of STI|"After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups"
57782981|NCT00369811|DRUG|Oxycodone, fentanyl|
57782982|NCT05048238|DRUG|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
57782983|NCT04157790|OTHER|CARE score|CARE score calculation
57782984|NCT00810641|PROCEDURE|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
57782985|NCT00810641|PROCEDURE|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
57782986|NCT00810641|PROCEDURE|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
58485962|NCT01193504|DRUG|Lotemax|Lotemax BID for 4 weeks postop.
57782987|NCT02854215|OTHER|Collection of additional data with questionnaires|"* questionnaires for quality of life measurements: QLQC30; QLQ-OV28~* questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
57782988|NCT03093844|DEVICE|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
57782989|NCT05630989|OTHER|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
57782990|NCT05630989|DRUG|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
57782991|NCT05630989|DRUG|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
57782992|NCT05630989|DRUG|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
57782993|NCT03756454|BIOLOGICAL|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
57782994|NCT03756454|OTHER|Normal Saline|Placebo
57782995|NCT02498743|PROCEDURE|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
57782996|NCT02498743|BEHAVIORAL|Watching Animated cartoons|
57782997|NCT04509830|OTHER|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
57782998|NCT04509830|OTHER|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
57782999|NCT06423599|DRUG|Semaglutide Injectable Product|Weight loss using Semaglutide
57783000|NCT06423599|DIETARY_SUPPLEMENT|Calorie-restricted diet|Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
57783001|NCT05445687|BEHAVIORAL|Narrative language intervention program|"Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program"
57783002|NCT05445687|BEHAVIORAL|Conventional language intervention|Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
57783003|NCT04253704|COMBINATION_PRODUCT|IDL lotion|IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
57783004|NCT04253704|COMBINATION_PRODUCT|Control lotion|Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
57783005|NCT00519246|DRUG|Saline|Saline 5 ml administrated intravenously
58485963|NCT01185080|DRUG|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
57783006|NCT00519246|DRUG|Opioid|Butorphanol tartrate 1 mg i.v.
57783007|NCT00519246|DRUG|Opioid|Butorphanol Tartrate 2 mg i.v.
57783008|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 50 mg i.v.
57783009|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 100 mg i.v.
57783010|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 10 mg i.v.
57783011|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 20 mg i.v.
57783012|NCT03627988|OTHER|Patients with invasive breast cancer will receive:|"* Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
57783013|NCT04763135|DRUG|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
57783014|NCT04763135|DRUG|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
57783015|NCT05553574|BEHAVIORAL|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
57783016|NCT03477461|DRUG|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
57783017|NCT01704885|BEHAVIORAL|Play Intervention|
57783018|NCT01704885|OTHER|Questionnaires|
58137385|NCT00765648|DRUG|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
58137386|NCT00765648|DRUG|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
58485964|NCT01185080|DRUG|Placebo|Nasal spray solution, intranasal, three times weekly for one month
58485965|NCT01185080|DRUG|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
58485966|NCT03806764|DIAGNOSTIC_TEST|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
58485967|NCT00329355|DRUG|sumatriptan succinate/naproxen sodium|
58485968|NCT03669341|OTHER|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
58485969|NCT03669341|OTHER|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
57783019|NCT00180518|DEVICE|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
57783020|NCT00006085|DRUG|CP-609,754|
57783021|NCT00533247|DRUG|Celecoxib|
57783022|NCT03035071|PROCEDURE|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
57783023|NCT03035071|PROCEDURE|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
57783024|NCT01055106|DRUG|GW05|vaginal gel once daily regimen A
57783025|NCT01055106|DRUG|GW05|vaginal gel once daily regimen B
57783026|NCT01055106|DRUG|GW05|vaginal gel once daily regimen C
57783027|NCT01055106|DRUG|Metronidazole|vaginal gel 0.75% once daily for 5 days
57783028|NCT06228729|PROCEDURE|Endotracheal intubation|Inserting endotracheal tube into the trachea
57783029|NCT06575192|DEVICE|ARTIA Reconstructive Tissue Matrix|Surgical Implant
57783030|NCT06575192|OTHER|No Intervention|No ADM
57783031|NCT06198660|OTHER|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
57783032|NCT06198660|OTHER|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
57783033|NCT06198660|OTHER|conventional therapy only|conventional therapy two sessions for 6 weeks
57783034|NCT05679700|OTHER|Rigid Taping|Rigid taping was applied to stroke patients with knee hyperextension.
57783035|NCT03251404|OTHER|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
57783036|NCT02026713|OTHER|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
57783037|NCT03072082|DRUG|Danlou Tablet|Conventional western medicine \& Danlou Tablet
57783038|NCT03072082|DRUG|DanLou Tablet placebo|Conventional western medicine \& placebo (for Danlou Tablet)
57783039|NCT03072082|DRUG|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
57783040|NCT03072082|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
57783041|NCT03072082|DRUG|Atorvastatin calcium|10 mg tablet, two tablets each night.
57783042|NCT03072082|DRUG|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
57783043|NCT03072082|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
57783044|NCT03072082|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
57783045|NCT02380521|DRUG|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
57783046|NCT05124249|DIAGNOSTIC_TEST|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
57783047|NCT05124249|PROCEDURE|PCI|Patients who undergoing PCI
57783048|NCT00553020|DRUG|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
57783049|NCT00610675|DRUG|Org 50081|One tablet daily
57783050|NCT05906537|DRUG|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
57783051|NCT02580773|DRUG|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
57783052|NCT02580773|DRUG|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
57783053|NCT00074763|BIOLOGICAL|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
57783054|NCT00802841|DRUG|nilotinib|Supplied as 200 mg tablets
57783055|NCT00802841|DRUG|imatinib|Supplied as 100 mg and 400 mg tablets
57783056|NCT02546687|OTHER|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
57783057|NCT01994720|DRUG|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
58485970|NCT00529867|DRUG|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
58485971|NCT00529867|DRUG|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
58485972|NCT06041607|BEHAVIORAL|Shared meditation|"Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
58485973|NCT06041607|BEHAVIORAL|Meditation with patients oly|"Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
58485974|NCT00067730|DRUG|Drotrecogin Alfa (activated)|
58485975|NCT05438303|DRUG|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
58485976|NCT05438303|DRUG|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
58485977|NCT05438303|DRUG|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
58485978|NCT05438303|DRUG|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
58485979|NCT05438303|DRUG|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
58485980|NCT02141828|DRUG|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
58485981|NCT04106752|DIETARY_SUPPLEMENT|Caffeine|Provide caffeine supplements with or without meal before exercise
58485982|NCT05606432|OTHER|Instructor-led, one-on-one M2M exercise group|Participants will attend 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. Each session will last from 25 to 50 minutes by increasing 5 to 10 minutes each week. The exercise program will focus on improving cardiorespiratory fitness using a series of movement patterns accompanied by music. The program will be tailored to individuals' abilities (e.g., use of arms only vs. truck movement together; slow vs. fast tempo music). The exercise will be prescribed at a moderate intensity level (working somewhat hard with increased heart rate and breathing rate). For the follow-up phase (weeks 25-36), participants will receive the recorded M2M exercise sessions between the M2M instructors and themselves to continue to exercise for the remaining 12 weeks.
58485983|NCT05606432|OTHER|Self-guided control with pre-recorded standard exercise videos|Participants will exercise for 36 weeks using pre-recorded exercise videos. The videos include warm-up, flexibility, muscular strength, aerobic endurance, balance, and cool-down.
58485984|NCT03135964|DEVICE|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
58485985|NCT02345993|DRUG|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
58485986|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
58485987|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
58485988|NCT03057483|BIOLOGICAL|Seasonal Influenza vaccine|Seasonal Influenza vaccine
58485989|NCT01388335|DRUG|warfarin|Administered orally
58485990|NCT01388335|DRUG|enzastaurin|Administered orally
58485991|NCT01516021|DIETARY_SUPPLEMENT|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
58485992|NCT05812872|DRUG|Toothgraft|Particulate dentin
58485993|NCT05812872|DRUG|Allograft|Mineralized corticocancellous allograft
58485994|NCT05812872|DRUG|Alloplast|Beta tri-calcuim phosphate
58485995|NCT02758184|DEVICE|ROTEM-based coagulation monitoring|
58485996|NCT02758184|PROCEDURE|Spine surgery|
58485997|NCT05821062|OTHER|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
58485998|NCT05821062|OTHER|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
58485999|NCT05821062|OTHER|standard ASA therapy|ASA 100 mg daily
58486000|NCT01297829|DRUG|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
58486001|NCT01297829|OTHER|IV Placebo|IV normal saline
58486002|NCT01776216|OTHER|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
58486003|NCT01776216|OTHER|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
58486004|NCT00180336|DEVICE|CRT-D|
58486005|NCT02245217|DEVICE|PET/CT scan to assess treatment efficacy|
58486006|NCT00357552|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
58486007|NCT00357552|DRUG|Lopinavir/Ritonavir|Twice daily
58486008|NCT05442788|BIOLOGICAL|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
58486009|NCT05442788|BIOLOGICAL|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
58486010|NCT05442788|BIOLOGICAL|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
57783058|NCT01994720|DRUG|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
58486011|NCT00457457|DRUG|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
58486012|NCT00457457|DRUG|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
58486013|NCT00214201|DRUG|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
58486014|NCT04295278|DIAGNOSTIC_TEST|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
58486015|NCT03494998|DIAGNOSTIC_TEST|PAT-POPS|Emergency Department-specific screening tool
58486016|NCT02983552|OTHER|iPad®|Binocular therapy using a Dig Rush application on an iPad®
58486017|NCT02983552|OTHER|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
58486018|NCT04371458|DRUG|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
58486019|NCT04256083|BIOLOGICAL|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
58486020|NCT03171571|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
58486021|NCT02196948|OTHER|Electrolysis Percutaneous Therapeutic (EPTE)|
58486022|NCT02196948|OTHER|Eccentric exercise|
58137387|NCT01798732|PROCEDURE|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
58486023|NCT03182569|DEVICE|FLEXIBLE CATHETER|
58486024|NCT03182569|DEVICE|hourly rigid needle puncture|
58486025|NCT04652037|DEVICE|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
58486026|NCT00641667|DRUG|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
58486027|NCT05902806|DIETARY_SUPPLEMENT|Upgraded tube feed|Total duration of study: 4 weeks; 1 week on current tube feed followed by 2 weeks on upgraded tube feed comparable in energy density and fiber content as their current tube feed. The tube feeding regimen is similar to pre study feeding regimen. There will then be a one week follow up period.
58486028|NCT04724993|OTHER|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
58486029|NCT04724993|OTHER|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
58486030|NCT05196295|DRUG|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
58486031|NCT04587427|DRUG|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
58486032|NCT02641288|DRUG|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
58486033|NCT02641288|DRUG|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
58486034|NCT03038880|DRUG|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
58486035|NCT03038880|DRUG|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
58486036|NCT03038880|DRUG|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
58486037|NCT02809001|PROCEDURE|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
58486038|NCT03187392|DRUG|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
58486039|NCT03187392|DRUG|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
58486040|NCT01536886|DRUG|LEO 90100|
58486041|NCT01536886|DRUG|Betamethasone plus calcipotriol|
58486042|NCT01536886|DRUG|Ointment vehicle|
58486043|NCT01536886|DRUG|LEO 90100 vehicle|
58486044|NCT03619720|OTHER|Records|Respiratory records, Vocal records Video records Questionnaires
58486045|NCT02360878|DEVICE|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
58486046|NCT00272311|DRUG|Aspirin|Dosage
58486047|NCT03028519|DRUG|Vitamin D3|Vitamin D3
58486048|NCT05765578|BIOLOGICAL|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
58486049|NCT05765578|BIOLOGICAL|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
57783059|NCT01662427|OTHER|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
58486050|NCT05765578|BIOLOGICAL|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
58486051|NCT05765578|BIOLOGICAL|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
58486052|NCT05765578|BIOLOGICAL|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
58486053|NCT06067152|DEVICE|EIT measurement|Evaluation of mechanical ventilation and ventilation distribution through EIT. Mechanical ventilation is set by the physician according to clinical protocolized criteria
58486054|NCT06067152|DEVICE|Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial|"SRMs will be performed with a standardized ventilation protocol. Patient will be sedated, paralyzed and ventilated in pressure controlled mode, FIO2 to obtain SPO2\> 92%, RR 25, I:E =1:1.5. Alarm of pressure limit will be set at 35 cmH2O. The ventilator will be equipped with inspiratory and expiratory hold taste. Inspiratory and expiratory occlusion will be held for 5 seconds, data will be stored and analyzed with the ventilator own tool.~Decremental PEEP trial will start if plateau pressure 30 cmH2O will be reached or end inspiratory transpulmonary pressure will exceed 28 cmH2O value. Once reached this level of plateau or transpulmonary pressure, PEEP will be reduced in three steps from 12, 10 and finally to 8 cmH2O every 20 minutes"
58486055|NCT06067152|DEVICE|Setting of EIT-guided mechanical ventilation|Mechanical ventilation is set according to EIT measurement
58486056|NCT06067152|DEVICE|Reevaluation after 24 h|Evaluation of mechanical ventilation and ventilation distribution through EIT after 24h of ventilation EIT-guided
58486057|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
58486058|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
58486059|NCT03847896|DRUG|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
58486060|NCT03847896|DRUG|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
58486061|NCT03847896|OTHER|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
58486062|NCT04163952|BIOLOGICAL|Panitumumab|Given IV
58486063|NCT04163952|BIOLOGICAL|Talimogene Laherparepvec|Given IM
58486064|NCT05497999|OTHER|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
58486065|NCT05497999|OTHER|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
58486066|NCT06519708|DRUG|Erector Spinae Plane Block|Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
58486067|NCT06519708|DRUG|External Oblique Intercostal Plane Block|Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
58486068|NCT01481818|DRUG|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
58486069|NCT01288261|DRUG|paclitaxel|Given IV
58486070|NCT01288261|BIOLOGICAL|bavituximab|Given IV
58486071|NCT01288261|OTHER|laboratory biomarker analysis|Correlative studies
58486072|NCT01288261|OTHER|pharmacological study|Correlative study
58486073|NCT02986295|DEVICE|BioMimeTM Stent, Ultimaster® Stent|
58486074|NCT03106311|DIAGNOSTIC_TEST|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
58486075|NCT02231905|DRUG|BI-Sifrol®|
58486076|NCT03715049|PROCEDURE|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
58486077|NCT01315639|BIOLOGICAL|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
58137388|NCT02215083|DIETARY_SUPPLEMENT|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
58486078|NCT04230278|BEHAVIORAL|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
58486079|NCT04230278|BEHAVIORAL|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
58486080|NCT03734380|BEHAVIORAL|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
58486081|NCT03734380|BEHAVIORAL|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
58486082|NCT03734380|BEHAVIORAL|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
58486083|NCT02492763|DRUG|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
58486084|NCT02492763|DRUG|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
58486085|NCT02492763|DRUG|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
58486086|NCT02492763|DRUG|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
58486087|NCT05459883|PROCEDURE|splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation
58486088|NCT05349071|DRUG|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
58486089|NCT05349071|DRUG|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
58486090|NCT02256709|DRUG|BIBP 5371 CL tablet|single rising daily doses
58486091|NCT02256709|DRUG|BIBP 5371 CL solution|
58486092|NCT02256709|OTHER|High fat, high caloric breakfast|
58486093|NCT02256709|DRUG|Placebo tablet|
58486094|NCT02256709|DRUG|BIBP 5371 CL tablet high dose|
58486095|NCT02256709|DRUG|Placebo drinking solution|
58486096|NCT02256709|DRUG|BIBP 5371 CL tablet low dose|
58486097|NCT03638037|DIAGNOSTIC_TEST|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
58486098|NCT04585126|DRUG|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
58486099|NCT04422158|DIETARY_SUPPLEMENT|Nuun electrolyte tablet|Each table contains 2 grams of carbohydrate and a combination of electrolytes. calcium (13mg, 1%DV), sodium (300mg, 13%DV), potassium (150mg, 3%DV), magnesium (25mg, 6%DV), and chloride (40mg, 2%DV).
58486100|NCT04422158|OTHER|water|water
58486101|NCT00705952|OTHER|Lifestyle intervention|Diet, exercise and behavioural change intervention.
58486102|NCT01173237|PROCEDURE|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
58486103|NCT01173237|PROCEDURE|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
58486104|NCT05267522|OTHER|Egg diet|30% fat \[6% saturated fat\], 20% protein, 40% carbohydrate, 600 mg cholesterol
58486105|NCT05267522|OTHER|Egg-free Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 300 mg cholesterol
58137389|NCT06078878|DEVICE|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
58137390|NCT04095247|DEVICE|Vagus nerv stimulator|pulse triggered autostimulation
58137391|NCT00909493|OTHER|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
58486106|NCT05267522|OTHER|Control Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 600 mg cholesterol
58486107|NCT00670306|DRUG|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
58486108|NCT04258267|PROCEDURE|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
58486109|NCT04258267|PROCEDURE|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
58486110|NCT03682770|DRUG|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
58486111|NCT03682770|DRUG|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
58486112|NCT03682770|DRUG|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
58486113|NCT01413204|DRUG|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
58486114|NCT01413204|DRUG|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
58486115|NCT01413204|DRUG|Placebo|The patients will receive Placebo orally for 24 weeks.
58486116|NCT01981018|OTHER|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
58486117|NCT03846908|OTHER|MCT|patients will receive fat load with MCT
58486118|NCT03846908|OTHER|SFA|patients will receive fat load with SFA
58486119|NCT03846908|OTHER|MUFA|patients will receive fat load with MUFA
58486120|NCT02052388|DRUG|Daptomycin|Active Comparator
58486121|NCT02052388|DRUG|Brilacidin|Experimental Drug
58486122|NCT01698580|OTHER|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
58486123|NCT01698580|OTHER|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
58486124|NCT01698580|OTHER|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
58486125|NCT01698580|OTHER|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
58486126|NCT01698580|OTHER|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
58486127|NCT00510822|DRUG|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
58486128|NCT00510822|DRUG|Placebo|tablet
58486129|NCT02653599|DRUG|TTP273|
58486130|NCT02653599|DRUG|Placebo|
58486131|NCT01432730|DRUG|Gefapixant|Oral tablets, BID
58486132|NCT01432730|DRUG|Placebo|Oral tablets, BID
58486133|NCT03236376|OTHER|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
58486134|NCT03236376|OTHER|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
58486135|NCT05304533|DRUG|MYK-224|Specified dose on specified days
58486136|NCT05304533|DRUG|Itraconazole|Specified dose on specified days
58486137|NCT05304533|DRUG|Verapamil|Specified dose on specified days
58486138|NCT03417154|DRUG|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
58486139|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
58486140|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
58486141|NCT04765319|BEHAVIORAL|CPT for PTSD|Evidence based psychotherapy for PTSD
58486142|NCT00936923|DRUG|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
58486143|NCT03714958|DRUG|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
58486144|NCT03714958|DRUG|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
58486145|NCT01472718|DEVICE|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
58486146|NCT01472718|DEVICE|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
58486147|NCT04416841|BEHAVIORAL|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
58486148|NCT04416841|BEHAVIORAL|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
58486149|NCT04416841|BEHAVIORAL|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
58486150|NCT05131737|PROCEDURE|High altitude exposure|Exposure to 2500m of altitude
58486151|NCT05131737|PROCEDURE|Low altitude exposure|Exposure to 490 m
58486152|NCT02598583|BIOLOGICAL|ALXN1210|Participants were administered ravulizumab as an IV infusion every 4 weeks.
58486153|NCT04618107|PROCEDURE|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
58486154|NCT04618107|PROCEDURE|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
58486155|NCT02217826|DRUG|DG3173|
58486156|NCT02217826|DRUG|Saline|
58486157|NCT02217826|DRUG|Octreotide|
58486158|NCT04259099|OTHER|Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)|Administer the questionnaires to 150 participants to classify their status of quality of life.
58486159|NCT05014087|DRUG|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
58486160|NCT06139367|DRUG|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
58486161|NCT06132867|DRUG|Brigatinib|Brigatinib oral solution
58486162|NCT06132867|DRUG|Brigatinib|Brigatinib tablet
58486163|NCT00598676|DEVICE|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
58486164|NCT00598676|DEVICE|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
58486165|NCT00598676|DEVICE|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
58486166|NCT00606593|DRUG|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486167|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486168|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486169|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486170|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486171|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486172|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486173|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486174|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486175|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
58486176|NCT05411315|OTHER|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
58486177|NCT05411315|OTHER|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
58486178|NCT02695563|DRUG|Lactoferrin|
58486179|NCT02026531|OTHER|3-Helium gas|3-Helium gas for MRI contrast
58486180|NCT05062499|DEVICE|Active TENS|electrical stimulation
58486181|NCT05062499|DEVICE|Sham TENS|no stimulation
58486182|NCT03527732|DRUG|Albendazole|Monotherapy of albendazole (400 mg)
58486183|NCT03527732|DRUG|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
58490990|NCT05345340|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
58137392|NCT02701114|PROCEDURE|Proximal Adductor Canal Block|Continuous Nerve Block
58137393|NCT02701114|PROCEDURE|Distal Adductor Canal Block|Continuous Nerve Block
58486184|NCT01298986|PROCEDURE|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
58486185|NCT01298986|PROCEDURE|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
58486186|NCT01298986|PROCEDURE|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
58486187|NCT01298986|PROCEDURE|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
58486188|NCT02658396|DRUG|GO-203-2C|
58486189|NCT02658396|DRUG|Bortezomib|
58486190|NCT06021704|BEHAVIORAL|Enhanced home health aide training in dementia and dementia-related behaviors|8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
58486191|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
58486192|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) Dim light-therapy|\<100 lux for 30 minutes
58486193|NCT03782506|BEHAVIORAL|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
58486194|NCT03782506|BEHAVIORAL|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
58486195|NCT04616989|BEHAVIORAL|Psycho-education|Provide psycho-education to members of the community
58486196|NCT04616989|BEHAVIORAL|Comparator|Distribution of COVID-19 leaflets to members of the community
58486197|NCT00619710|DRUG|Meropenem|Intravenous
58486198|NCT00619710|DRUG|Imipenem-cilastatin|Intravenous
58486199|NCT01615536|PROCEDURE|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
58486200|NCT01615536|PROCEDURE|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
58486201|NCT01210404|DRUG|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
58486202|NCT04493788|OTHER|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
58486203|NCT00474591|DRUG|Fondaparinux|
58486204|NCT03622476|DRUG|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
58486205|NCT03244839|PROCEDURE|bariatric surgery|bariatric surgery
58486206|NCT03761368|PROCEDURE|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
58486207|NCT03761368|PROCEDURE|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
58486208|NCT05844007|BEHAVIORAL|Trauma-Informed Yoga|Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
58486209|NCT00487461|DRUG|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
58486210|NCT00487461|DRUG|Placebo|Placebo tablet
58486211|NCT00487461|DRUG|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
58486212|NCT05824104|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
58486213|NCT05109143|DRUG|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
58486214|NCT05109143|OTHER|Standard Medical Treatment|Standard Medical Treatment
58486215|NCT03174600|OTHER|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
58486216|NCT05766696|PROCEDURE|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
58486217|NCT05766696|PROCEDURE|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
58486218|NCT04445896|OTHER|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
58486219|NCT00560170|DRUG|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
58486220|NCT00560170|DRUG|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
58486221|NCT01663103|DRUG|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
58486222|NCT01663103|DRUG|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
58486223|NCT00575731|BEHAVIORAL|Weight management strategies|
58486224|NCT06091683|PROCEDURE|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
58486225|NCT01167504|OTHER|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
58486226|NCT04512612|DIAGNOSTIC_TEST|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
58486227|NCT04512612|DIAGNOSTIC_TEST|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
58486228|NCT06519474|DEVICE|Theraband chest compression|Chest compression applicated via a Red Theraband over the upper or lower chest region
58486229|NCT02124317|DRUG|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
58486230|NCT02124317|DRUG|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
58486231|NCT02282605|DRUG|XF-73 nasal gel|
58486232|NCT02282605|DRUG|Placebo nasal gel|
58486233|NCT02282605|OTHER|Chlorhexidine gluconate 2% topical cloths|
58486234|NCT00241436|DRUG|Anastrozole (ARIMIDEX™)|
58486235|NCT02570048|DEVICE|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
58486236|NCT02044640|PROCEDURE|Appendectomy|
58486237|NCT06440681|OTHER|Providing nutritional counselling|"Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks."
58486238|NCT06440681|OTHER|counseling on physical activity|"Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)"
58486239|NCT03714880|DRUG|Mifepristone 200 MG|Ingestion of study medication vs placebo
58486240|NCT03714880|DRUG|Placebo Oral Tablet|Ingestion of study medication vs placebo
58486241|NCT04995224|OTHER|Assessment of Psychophysiological factors|Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
58486242|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
58486243|NCT04995224|GENETIC|Assessment of Genetics|Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
58486244|NCT04995224|BEHAVIORAL|Assessment of Quality of Life|Investigating QOL by questionnaires.
58486245|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
58486246|NCT02876549|DRUG|Chloroquine|10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
58486247|NCT02876549|DRUG|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
58486248|NCT02876549|DRUG|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
58486249|NCT06520774|DEVICE|Concave Supra-arch Branched Stent-Graft System|To evaluate the efficacy and safety of Concave Supra-arch Branched Stent-Graft System for endovascular treatment of Aortic Arch Diseases
58486250|NCT02567578|DRUG|YH12852 0.1 mg|
58486251|NCT02567578|DRUG|YH12852 0.25 mg|
58486252|NCT02567578|DRUG|YH12852 0.5 mg|
58486253|NCT02567578|DRUG|Placebo|
58486254|NCT05755321|OTHER|Skin biopsy|Skin biopsy performed during surgery.
58486255|NCT02259088|DRUG|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
58486256|NCT02259088|PROCEDURE|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
58486257|NCT02259088|DRUG|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
58486258|NCT02259088|PROCEDURE|Sham laser|Imitation of an active laser
58137394|NCT00005025|BIOLOGICAL|herpes simplex thymidine kinase|
58137395|NCT00005025|DRUG|ganciclovir|
58486259|NCT04518358|BEHAVIORAL|Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges|During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
58486260|NCT02189733|BIOLOGICAL|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
58486261|NCT02117661|DIETARY_SUPPLEMENT|L-carnitine capsules|Oral
58486262|NCT02117661|DIETARY_SUPPLEMENT|Cellulose capsules|oral
58486263|NCT03524118|DRUG|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
58486264|NCT03524118|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
58486265|NCT02577718|DRUG|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
58137396|NCT05026671|PROCEDURE|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
58486266|NCT05727852|DIAGNOSTIC_TEST|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
58486267|NCT05727852|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
58486268|NCT05727852|DIAGNOSTIC_TEST|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
57783060|NCT02148718|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
57783061|NCT06378502|DRUG|Amoxicillin Short|Short Span
58486269|NCT02114073|DRUG|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
58486270|NCT02114073|DRUG|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
58486271|NCT05726708|BEHAVIORAL|E-Learning|On line modules of coaching for parents
58486272|NCT02149043|DEVICE|Thermography|Thermographic imaging of the patient's abdomen surface
58486273|NCT02149043|PROCEDURE|Colonoscopy|Endoscopic examination of the colon
58486274|NCT02447523|PROCEDURE|Elective abdominal surgery|
58486275|NCT02694289|DRUG|Metformin|Treatment/continuation of metformin therapy during admission
58486276|NCT02694289|DRUG|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
58486277|NCT01419288|OTHER|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
58486278|NCT01678235|DRUG|Insulin glulisine|
58486279|NCT01678235|DRUG|Insulin aspart|
58486280|NCT00196313|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
58486281|NCT00196313|DRUG|Placebo tablet|1 tablet daily by mouth
58486282|NCT02292589|DEVICE|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
58486283|NCT02292589|DEVICE|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
58486284|NCT02292589|DEVICE|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
58486285|NCT01898559|OTHER|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
58486286|NCT06045702|PROCEDURE|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
58486287|NCT00433082|BEHAVIORAL|Ramadan Fasting|
58486288|NCT03532204|RADIATION|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
58486289|NCT03532204|DRUG|Chemotherapy|At investigator's discretion
58486290|NCT04300166|DEVICE|Telemedicine & Humidification|Wireless control of CPAP usage, adherence, leakage and humidifier usage
58486291|NCT06001957|DIAGNOSTIC_TEST|Whole exome sequencing|"Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described.~Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer."
58486292|NCT02340364|BEHAVIORAL|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
58486293|NCT02340364|BEHAVIORAL|Self-care Education|208 patients randomized to self-care education alone.
58486294|NCT02842489|PROCEDURE|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
58486295|NCT02842489|PROCEDURE|left lateral horizontal position|patients will be horizontally positioned on their left side
58486296|NCT02354053|DRUG|Switch to Triumeq|
58486297|NCT02354053|BEHAVIORAL|Adherence support + current ART|
58486298|NCT01587924|DRUG|GSK1278863|tablet
58486299|NCT01587924|DRUG|rhEPO|injection
58486300|NCT03590821|DRUG|Aspirin 81 mg|timed administration of aspirin in the evening
58486301|NCT03590821|DRUG|Celecoxib 200mg capsule|daily administration of celecoxib
58486302|NCT05605886|DRUG|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
58486303|NCT05605886|DRUG|placebo|placebo
57783062|NCT06378502|DRUG|Amoxicillin Long|Long span
57783063|NCT05555095|BEHAVIORAL|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
57783064|NCT00457613|DRUG|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
58137397|NCT05026671|PROCEDURE|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
58137398|NCT05026671|PROCEDURE|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
58486304|NCT01288885|DRUG|ASP1941|Oral
58486305|NCT01288885|DRUG|Placebo|Oral
58486306|NCT05842096|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
58486307|NCT05842096|DIAGNOSTIC_TEST|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
58486308|NCT05842096|DIAGNOSTIC_TEST|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
58486309|NCT05291312|PROCEDURE|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
58486310|NCT03807856|DRUG|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
58486311|NCT03807856|OTHER|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
58486312|NCT04727307|DRUG|Atezolizumab (neoadjuvant)|Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
58486313|NCT04727307|PROCEDURE|Percutaneous Radiofrequency|Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
58486314|NCT04727307|DRUG|Bevacizumab (adjuvant)|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
58486315|NCT04727307|DRUG|Atezolizumab (adjuvant)|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
58486316|NCT02905890|DRUG|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
58486317|NCT02905890|DEVICE|Condoms|Latex male condoms
58486318|NCT05237076|DIAGNOSTIC_TEST|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
58486319|NCT03983356|OTHER|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
58486320|NCT01052701|DRUG|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)"
58486321|NCT01052701|DRUG|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
58486322|NCT01168986|OTHER|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
58486323|NCT01168986|OTHER|Exercise|Participants perform an exercise to strengthen the deep neck flexors
58486324|NCT02461277|OTHER|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
58486325|NCT04782479|PROCEDURE|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
58486326|NCT06385626|DIETARY_SUPPLEMENT|Raspberry leaf tea|10 g of raspberry leaf tea
58486327|NCT03248206|BEHAVIORAL|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
58486328|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
58486329|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
58486330|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
58486331|NCT01708902|DRUG|Metformin 500mg|Metformin 500mg BID
58486332|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
58486333|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
58486334|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
58486335|NCT01708902|DRUG|Metformin 1000mg|Metformin 1000mg BID
58486336|NCT05853991|OTHER|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
58486337|NCT05853991|OTHER|Active comparator|Application of affective touch
58486338|NCT05853991|OTHER|Placebo|Application of static touch
58486339|NCT03475836|DIETARY_SUPPLEMENT|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
58486340|NCT03475836|DIETARY_SUPPLEMENT|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
58486341|NCT00872443|OTHER|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
58486342|NCT00602472|DRUG|linagliptin|active
58486343|NCT00602472|DRUG|placebo|placebo to linagliptin 5 mg
58486344|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
58486345|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
58486346|NCT02210039|DEVICE|SECM Probe|Imaging of the esophagus using SECM probe and system.
58486347|NCT00888940|DRUG|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
58486348|NCT00888940|DRUG|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
58486349|NCT06216509|DEVICE|Endoscopic ultrasound pressure measurement|all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
58490991|NCT03181529|DRUG|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
58486350|NCT00792220|PROCEDURE|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
58486351|NCT00792220|PROCEDURE|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
58486352|NCT02796183|DRUG|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
58486353|NCT00515268|DRUG|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
58486354|NCT00515268|DRUG|Placebo|Subjects will receive placebo inhaler.
58486355|NCT00693901|BEHAVIORAL|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
58486356|NCT00693901|BEHAVIORAL|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
58486357|NCT04070872|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
58486358|NCT04070872|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
58486359|NCT04251403|DIAGNOSTIC_TEST|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
58486360|NCT02633020|BIOLOGICAL|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
58486361|NCT02633020|BIOLOGICAL|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
58486362|NCT03233581|BEHAVIORAL|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
58486363|NCT03233581|BEHAVIORAL|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
58486364|NCT03061396|OTHER|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
58486365|NCT03061396|OTHER|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
58486366|NCT01202032|DRUG|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
58486367|NCT04420104|PROCEDURE|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
58486368|NCT04420104|DRUG|iv analgesia|iv contromal
57783065|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
58486369|NCT04695808|BEHAVIORAL|yoga|Yoga practice will be done two days a week for 10 weeks.
58486370|NCT03792906|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
58486371|NCT03792906|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
58486372|NCT03792906|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
58486373|NCT03792906|DRUG|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
58486374|NCT00655200|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
58486375|NCT03585738|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
58486376|NCT03585738|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
58486377|NCT04433988|DRUG|Pentoxifylline|Pentoxifylline 400 mg SR tablet
58486378|NCT04433988|DRUG|Placebo|Placebo tablet
58486379|NCT00126334|PROCEDURE|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
58486380|NCT01145976|DRUG|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
58486381|NCT01145976|DRUG|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
58486382|NCT02094924|DRUG|GSK587323|Single dose of FDC tablet formulation to be taken orally.
58486383|NCT02094924|DRUG|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
58486384|NCT00125177|BEHAVIORAL|Knack therapy|
58486385|NCT05002296|PROCEDURE|upper cervical manipulation|rotatory upper cervical manipulation to both sides. The treatment program was conducted for twelve sessions (three sessions per week). Assessment procedures were performed before and after treatment through visual analogue scale (VAS)
58486386|NCT03298035|DEVICE|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
58486387|NCT03298035|DEVICE|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
58486388|NCT01847326|DRUG|carboplatin|Given IV
58486389|NCT01847326|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
58486390|NCT01847326|DRUG|fluorouracil|Given IV
58486391|NCT01847326|DRUG|hydroxyurea|Given PO
58486392|NCT01847326|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
58486393|NCT01847326|RADIATION|radiation therapy|Undergo radiation therapy
58486394|NCT01847326|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
58486395|NCT01847326|OTHER|laboratory biomarker analysis|Correlative studies
58486396|NCT03137199|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
58486397|NCT00684541|BEHAVIORAL|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
58486398|NCT00684541|BEHAVIORAL|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
57783066|NCT01339611|BEHAVIORAL|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
58486399|NCT02457143|BEHAVIORAL|Letter|
58486400|NCT02457143|BEHAVIORAL|Phone call|
58486401|NCT04341870|DRUG|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
58486402|NCT04341870|DRUG|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
58486403|NCT04341870|DRUG|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
58486404|NCT05303311|DRUG|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
58486405|NCT05303311|DRUG|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
58486406|NCT04319588|PROCEDURE|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
58486407|NCT04319588|PROCEDURE|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
58486408|NCT05346419|DRUG|Risedronate|Participants received risedronate 35 mg once a week for 6 months.
58486409|NCT05346419|DRUG|Vitamin D|Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
58486410|NCT03889522|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition \[47, 49\]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
58486411|NCT03889522|DIAGNOSTIC_TEST|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
58486412|NCT03889522|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
58486413|NCT03172416|DRUG|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
58486414|NCT03172416|DRUG|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
58486415|NCT04879251|OTHER|No intervention|No intervention
58486416|NCT03281200|DRUG|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
58486417|NCT03281200|DRUG|L01 - Antineoplastic agents|L01 - Antineoplastic agents
58486418|NCT03281200|DRUG|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
58486419|NCT03281200|DRUG|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
58486420|NCT03281200|DRUG|L01XE31 - Nintedanib|L01XE31 - Nintedanib
58486421|NCT03521440|BEHAVIORAL|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
58486422|NCT03521440|BEHAVIORAL|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
58486423|NCT06246461|DRUG|capecitabine|The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
58486424|NCT04823013|OTHER|high power pain threshold ultrasound which the dose was kept constant|Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
58486425|NCT04823013|OTHER|high power pain threshold ultrasound which the dose reduced to one half|Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
58486426|NCT04823013|OTHER|ischemic compression|Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
58486427|NCT03636100|DEVICE|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
58486428|NCT01099332|OTHER|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
58486429|NCT01099332|OTHER|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
58486430|NCT02415413|DRUG|carfilzomib|
58486431|NCT02415413|DRUG|Lenalidomide|
58486432|NCT02415413|DRUG|Dexamethasone|
58486433|NCT02415413|DRUG|Melphalan|
58486434|NCT00110747|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
58486435|NCT00110747|DRUG|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
58486436|NCT02198118|OTHER|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
58486437|NCT01967576|DRUG|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
58486438|NCT04986267|OTHER|ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
58486439|NCT00082797|DRUG|leucovorin calcium|
58486440|NCT00082797|DRUG|methotrexate|
58486441|NCT04174326|BEHAVIORAL|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
58486442|NCT04531930|PROCEDURE|surgery|Colorectal surgery, mainly total proctocolectomy.
58486443|NCT04531930|PROCEDURE|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
58486444|NCT04531930|OTHER|self choosed methods|A patient chooses a method for himself other than surgery.
58486445|NCT05155267|OTHER|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
58486446|NCT06103786|BEHAVIORAL|Assigned Interventions|"Ice hockey players did 12 weeks of on-ice high-intensity interval training. Their training included:~Repetitive sprint training Sprint interval training Long-pass tracking drills Chase-the-rabbit tracking drills High-intensity interval training in four types improved college ice hockey players' sports performance in 12 weeks."
58486447|NCT06103786|BEHAVIORAL|Random Interventions|"Ice hockey players did 12 weeks of traditional on-ice training. Their training included:~Varied pacing skating Dribbling and shooting Passing and catching drills 2-on-1 offensive tactics Traditional training in four types improved college ice hockey players' sports performance in 12 weeks.~A 12-week on-ice training program was conducted on college players to observe its effects on their physical fitness, skills, and tactical performance compared to an experimental and control group."
58486448|NCT00505349|BEHAVIORAL|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
58486449|NCT01254422|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
58486450|NCT01254422|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
58486451|NCT02281383|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|
58486452|NCT04651062|DEVICE|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
58486453|NCT04651062|PROCEDURE|no endocuff|colonoscopy is performed without endocuff.
58486454|NCT01391078|DEVICE|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
58486455|NCT01391078|DEVICE|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
58486456|NCT00046462|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
58486457|NCT00046462|DRUG|Metformin|
58486458|NCT00046462|DRUG|Glyburide|
58486459|NCT00046462|DRUG|Thiazolidinedione|
58486460|NCT01574092|DRUG|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
58486461|NCT00005080|DRUG|nelarabine|Given IV
58486462|NCT00225485|DRUG|Effexor XR|
58486463|NCT03332706|OTHER|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
58486464|NCT04646044|DRUG|Bempegaldesleukin|Administered as an intravenous infusion
58486465|NCT04646044|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
58486466|NCT04646044|OTHER|Placebo|Administered as an intravenous infusion
58486467|NCT01134055|DRUG|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
58486468|NCT01134055|DRUG|placebo|placebo eye drops
58486469|NCT01134055|BIOLOGICAL|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
58486470|NCT00768456|DRUG|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
58486471|NCT00768456|DRUG|Isotonic NaCl|Local Infiltration with NaCl
58486472|NCT00828204|DEVICE|single-use autoinjector with a prefilled liquid Avonex syringe|
58486473|NCT00828204|DEVICE|Avonex prefilled syringe via manual IM injection|
58486474|NCT00828204|DRUG|BG9418 (interferon beta-1a)|
58486475|NCT05510349|OTHER|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
58486476|NCT04028219|DIAGNOSTIC_TEST|Online surveys|Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
58486477|NCT00614731|BIOLOGICAL|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
58137399|NCT05026671|PROCEDURE|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
58486478|NCT01209013|DEVICE|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
58486479|NCT01209013|PROCEDURE|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
58486480|NCT01209013|PROCEDURE|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
58486481|NCT01209013|PROCEDURE|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
58486482|NCT01209013|PROCEDURE|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
58486483|NCT01209013|PROCEDURE|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
58486484|NCT01209013|PROCEDURE|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
58486485|NCT00356304|BEHAVIORAL|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
58486486|NCT00356304|BEHAVIORAL|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
58486487|NCT02698553|DRUG|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
58486488|NCT02698553|DRUG|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
58486489|NCT01333930|OTHER|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
58486490|NCT01333930|OTHER|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
58486491|NCT03598686|DIAGNOSTIC_TEST|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
58486492|NCT01956838|DIETARY_SUPPLEMENT|umami|intraduodenal infusion of umami tastant
58486493|NCT01956838|DIETARY_SUPPLEMENT|bitter|intraduodenal infusion of bitter tastant
58486494|NCT01956838|DIETARY_SUPPLEMENT|sweet|intraduodenal infusion of sweet tastant
58486495|NCT05017272|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
58486496|NCT06137417|DEVICE|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
58486497|NCT03903588|DEVICE|Optical Coherence Tomography|Imaging of the Retina
58486498|NCT06048978|OTHER|Commercial native starch without processing|A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
58486499|NCT06048978|OTHER|Modified starch with extrusion processing|A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
58486500|NCT00888719|DRUG|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
58486501|NCT00888719|DRUG|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
58486502|NCT00888719|DRUG|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
58486503|NCT06093841|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
58486504|NCT06093841|DRUG|Fludarabine|Administered according to package insert
58486505|NCT06093841|DRUG|Cyclophosphamide|Administered according to package insert
58486506|NCT03616028|DEVICE|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
58486507|NCT00160901|DRUG|two complex naturopathic add-on therapies, leaflet 5-a-day|
58486508|NCT02141204|BIOLOGICAL|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
58486509|NCT02141204|BIOLOGICAL|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
58486510|NCT04976543|DRUG|nadroparin calcium-warfarin sequential anticoagulation|The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
58486511|NCT05757544|DRUG|IV Ganaxolone|IV Ganaxolone will be administered.
58486512|NCT05757544|DRUG|IV Placebo|IV Placebo will be administered
58486513|NCT01744106|DRUG|pseudoephedrine hydrochloride 30 mg tablets|
58486514|NCT01744106|DRUG|Placebo tablets|
58486515|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
58486516|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
58486517|NCT04349332|DEVICE|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate \<30breaths/min and PaO2 \>75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
58486518|NCT00412919|DRUG|Azacitidine|
58486519|NCT01730482|DRUG|[14C] AT1001|150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
58486520|NCT02321176|DRUG|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
58486521|NCT01995188|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
58486522|NCT01995188|DRUG|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
58486523|NCT01995188|DRUG|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
58486524|NCT04421027|DRUG|Baricitinib|Given orally
58486525|NCT04421027|DRUG|Placebo|Given orally
58486526|NCT05530564|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
58486527|NCT05530564|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
58486528|NCT01032252|OTHER|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
58486529|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel for lip augmentation
58486530|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
58486531|NCT00749853|DRUG|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
58486532|NCT00749853|DRUG|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
58486533|NCT00520806|DRUG|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
58486534|NCT00520806|DRUG|Placebo|Intravenous infusion for 48 h
58486535|NCT03227120|OTHER|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
58486536|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
58486537|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
58486538|NCT02625909|DRUG|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
58486539|NCT02625909|DRUG|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
58486540|NCT05190497|DEVICE|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
58486541|NCT05305404|DRUG|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
58486542|NCT05305404|DRUG|Placebo|oral placebo to be administered once at 11:00PM
58486543|NCT01412684|PROCEDURE|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
58486544|NCT02752282|OTHER|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
58486545|NCT02752282|OTHER|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
58486546|NCT05415917|DRUG|Gemcitabine and Capecitabine|"A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."
58486547|NCT01387997|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
58486548|NCT00157989|PROCEDURE|Controlled tidal volume resuscitation|
58486549|NCT03304158|BEHAVIORAL|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
58486550|NCT03488017|DEVICE|Ocular Coil|Non-invasive ocular device
58486551|NCT05505617|OTHER|Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.|"Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)"
58486552|NCT05971082|OTHER|Follow-up|Follow-up study of progression/remission of liver disease
58486553|NCT02743104|DRUG|Ketamine|
58486554|NCT02743104|DRUG|Propofol|
58486555|NCT02743104|DRUG|midazolam and atropine|
58486556|NCT02743104|DRUG|Lidocaine|
58486557|NCT05791604|DIETARY_SUPPLEMENT|probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG|Take probiotics, 2g each time, twice a day, for 12 weeks
58486558|NCT05791604|DIETARY_SUPPLEMENT|Prebiotics with galactomannan and oligofructose|Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
58486559|NCT03970317|DEVICE|Broad Band Light|Broad Band Light Device
58486560|NCT04437134|OTHER|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
58486561|NCT04437134|OTHER|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
58486562|NCT01376804|DRUG|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
58486563|NCT02055118|BIOLOGICAL|idursulfase-IT|10mg
58486564|NCT02055118|OTHER|No IT treatment|Standard of Care
58486565|NCT01081106|PROCEDURE|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
58486566|NCT05083286|DRUG|OnabotulinumtoxinA|Injection of glabellar rhytids
58486567|NCT02454842|DRUG|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
58486568|NCT06328335|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
58486569|NCT06328335|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
58486570|NCT04282330|DIAGNOSTIC_TEST|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
58486571|NCT04791163|DEVICE|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
58486572|NCT05247047|DEVICE|TENA SmartCare Change Indicator|The intervention is a medical device system that consists of a reusable electronic sensor and an application installed on one or more smart phones. The device estimates the saturation level of an absorbing incontinence product used by a study subject. The device is non-invasive and does not have any effect on the function of the absorbing incontinence product.
58486573|NCT05825573|DRUG|Vitamin K antagonist|VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
58486574|NCT05825573|DRUG|Direct oral anticoagulant|DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
58486575|NCT01642589|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
58486576|NCT01642589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
58486577|NCT03933085|BEHAVIORAL|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
58486578|NCT06073561|OTHER|learning curve of Underwater mucosectomy|Patients will be submitted to underwater mucosectomy (U-EMR)
58486579|NCT01811966|OTHER|Volume|
58486580|NCT01811966|OTHER|Control|
58486581|NCT01177397|DRUG|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
58486582|NCT04780997|OTHER|Virtual Reality|Microsoft Xbox Kinect® was used for virtual reality exercises
58486583|NCT05452343|BIOLOGICAL|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
58486584|NCT03487705|OTHER|electromyographic essential tremor|"* Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
58486585|NCT06428292|DEVICE|Virtual reality device branded ''Meta Quest 2''|Combining different exercise equipment with a virtual reality device and using them in a virtual environment can be used to decide which one is more effective.
58486586|NCT00433134|BEHAVIORAL|Adherence|
58486587|NCT02877589|OTHER|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
58486588|NCT04129996|DRUG|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
58486589|NCT05459818|DEVICE|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
58486590|NCT01963078|DRUG|Oxytocin|
58486591|NCT01963078|DRUG|Placebo|
58486592|NCT00183482|BEHAVIORAL|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
58486593|NCT00183482|BEHAVIORAL|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
58486594|NCT05078840|OTHER|Evaluation of first line treatment in patients with stage I and II LBCL|Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
58486595|NCT02447003|BIOLOGICAL|Pembrolizumab|IV infusion of 200 mg.
58486596|NCT05868122|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
58486597|NCT05868122|DRUG|Placebo|Placebo will be administered orally.
58486598|NCT06193668|BEHAVIORAL|High-fat overnutrition|Overnutrition: 40% higher lipid consumption per day than required
58486599|NCT06193668|BEHAVIORAL|Normocaloric macronutrient-balanced nutrition|"Normocaloric, macronutrient-balanced nutrition:~Calories requirement for weight maintenance \[(kcal/d) 55% carbohydrates, 15% proteins, 30% fat\]"
58486600|NCT05653076|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract|Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
58486601|NCT03216226|DRUG|dasiglucagon|Glucagon Analog
58486602|NCT03216226|DRUG|GlucaGen|Native Glucagon
58486603|NCT04841083|DEVICE|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
58486604|NCT04296838|DRUG|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
58486605|NCT00967421|DRUG|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
58486606|NCT00967421|DRUG|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
58486607|NCT00967421|OTHER|Placebo drink|Placebo drink containing no alcohol + placebo pill
58486608|NCT00399906|DRUG|BMS-582949|Tablets, Oral, Once daily, 12 weeks
58486609|NCT00399906|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks
58486610|NCT03317015|DRUG|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
58486611|NCT03317015|DRUG|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
58486612|NCT04422483|OTHER|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
58486613|NCT06223984|DRUG|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
58486614|NCT02512029|DRUG|18F-AV-1451|
58486615|NCT02271672|DEVICE|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
58486616|NCT02271672|DEVICE|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
58486617|NCT03823209|BEHAVIORAL|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
58486618|NCT03823209|BEHAVIORAL|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
58486619|NCT04737304|DRUG|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
58486620|NCT05812911|PROCEDURE|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
58486621|NCT05812911|PROCEDURE|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
58486622|NCT05812911|PROCEDURE|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
58486623|NCT06418256|OTHER|Spleen, blood and plasma collection|Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
58486624|NCT01223781|BEHAVIORAL|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
58486625|NCT02559024|DRUG|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
58486626|NCT00000596|DRUG|prednisone|
58486627|NCT00000596|DRUG|cyclophosphamide|
58486628|NCT00000596|DRUG|dapsone|
58486629|NCT05777356|DIAGNOSTIC_TEST|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
58486630|NCT05597488|DEVICE|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
58486631|NCT00938067|BEHAVIORAL|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
58486632|NCT01209689|DRUG|Tocilizumab|
58486633|NCT01209689|DRUG|Placebo|
58486634|NCT00499148|OTHER|herbal extract; root of woody shrub grown in India/Sri-Lanka|
58486635|NCT03990727|DIAGNOSTIC_TEST|Retina Analysis-mosaic|Fundus retina pattern study
58486636|NCT03990727|DIAGNOSTIC_TEST|Autofluorescence|Fundus reflectance-functionality
58486637|NCT03990727|DIAGNOSTIC_TEST|OCT- 1 micra|Fine tomography fundus retina
58486638|NCT03990727|PROCEDURE|Genotype analysis|Molecular target retina dystrophy analysis
58486639|NCT06320262|PROCEDURE|Wet cupping therapy (WCT)|"Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking.~Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas.~After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done."
58486640|NCT00025519|BIOLOGICAL|therapeutic allogeneic lymphocytes|
58486641|NCT00025519|DRUG|fludarabine phosphate|
58486642|NCT00025519|DRUG|mycophenolate mofetil|
58486643|NCT00025519|DRUG|tacrolimus|
58486644|NCT00025519|DRUG|thalidomide|
58486645|NCT00025519|PROCEDURE|peripheral blood stem cell transplantation|
58486646|NCT00025519|RADIATION|radiation therapy|
58486647|NCT06521931|DRUG|PN20|Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
58486648|NCT00971815|DRUG|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
58486649|NCT00971815|DRUG|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
58486650|NCT04613037|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
58486651|NCT05221957|DRUG|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
58486652|NCT00408200|DRUG|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
58486653|NCT00408200|DEVICE|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
58486654|NCT05601895|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
58486655|NCT00711191|BIOLOGICAL|monoclonal antibody|CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles
58486656|NCT00711191|DRUG|chemotherapy|gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
58486657|NCT04217304|DRUG|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
58486658|NCT00002999|DRUG|cisplatin|
58486659|NCT00002999|DRUG|fluorouracil|
58486660|NCT00002999|RADIATION|radiation therapy|
58486661|NCT05022732|DIETARY_SUPPLEMENT|Polyglucosamine L112|750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients
58486662|NCT05022732|COMBINATION_PRODUCT|Placebo|excipients and gum arabic
58486663|NCT00946283|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
58486664|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
58486665|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
58486666|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
58486667|NCT04923282|BIOLOGICAL|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
58486668|NCT04923282|BIOLOGICAL|Placebo|Intravenous infusion
58486669|NCT01443052|OTHER|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
58486670|NCT03369262|DRUG|OBE022|Oral
58486671|NCT03369262|DRUG|Placebos|Oral
58486672|NCT03369262|DRUG|Atosiban|I.V.
58486673|NCT05669911|DEVICE|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
58486674|NCT06072664|BEHAVIORAL|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
58486675|NCT02797938|DEVICE|Taper guard tube|Taper guard tube was intubated
58486676|NCT02797938|DEVICE|Cylindrical tube|Cylindrical tube was intubated
58486677|NCT03501719|DRUG|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
58486678|NCT04667130|BEHAVIORAL|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
58486679|NCT00030732|DRUG|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
58486680|NCT00030732|DRUG|Gemcitabine alone|Gemcitabine alone
58486681|NCT03638765|BIOLOGICAL|DCVax-Direct|activated, autologous dendritic cells
58486682|NCT01312103|BEHAVIORAL|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
58486683|NCT01312103|BEHAVIORAL|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
58486684|NCT00275912|DRUG|Oxcarbazepine|
58486685|NCT06442878|OTHER|Belly Dance Program|All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
58486686|NCT04129567|OTHER|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
58486687|NCT04129567|OTHER|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
58486688|NCT04129567|OTHER|Humidified air|Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
58486689|NCT04129567|OTHER|Dry air|Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
58486690|NCT02738385|BEHAVIORAL|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
58486691|NCT02738385|BEHAVIORAL|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
58486692|NCT03860259|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
58486693|NCT03860259|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
58486694|NCT03176706|OTHER|no intervention|this is a completely observational study, NO INTERVENTION
58486695|NCT01707732|DRUG|Enoxaparin|Administration of Enoxaparin
58486696|NCT01157403|BIOLOGICAL|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
58486697|NCT00882557|DRUG|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
58486698|NCT00882557|DRUG|daptomycin|6 mg/kg administered after a hemodialysis session
58486699|NCT00452972|DRUG|Spinal Anesthesia|
58486700|NCT01637129|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
58486701|NCT01637129|DEVICE|Sham Magnetic Stimulation|Sham Magnetic Stimulation
58486702|NCT03172988|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
58486703|NCT03172988|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
58486704|NCT03172988|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
58486705|NCT03172988|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
58486706|NCT02354430|BEHAVIORAL|Water-exercise|"1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises."
58486707|NCT01281800|PROCEDURE|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
58486708|NCT02560558|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
58486709|NCT01009216|DRUG|ABT-384|Doses will be administered daily for 5 days.
58486710|NCT00804908|DRUG|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
58486711|NCT00804908|DRUG|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
58486712|NCT00804908|OTHER|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
58486713|NCT06208280|DRUG|After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.|"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)"
58486714|NCT05171556|OTHER|Cosmetic product|RV4942A is a face balm product
58486715|NCT04276948|DIETARY_SUPPLEMENT|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
58486716|NCT05401097|DRUG|Azacitidine|Given IV or SC
58486717|NCT05401097|PROCEDURE|Biopsy|Undergo biopsy of the bone marrow
58486718|NCT05401097|DRUG|Enasidenib|Given PO
58486719|NCT05401097|DRUG|Ivosidenib|Given PO
58486720|NCT05401097|DRUG|Venetoclax|Given PO
58486721|NCT00526071|DRUG|migalastat HCl|
58486722|NCT01130480|DEVICE|Accu-Chek Integra Glucometer|
58486723|NCT06432218|OTHER|video education|A re-watchable video provided before pessary fitting which mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy.
58486724|NCT06432218|OTHER|conventional education|Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.
58486725|NCT03553693|OTHER|RAPID-VL study intervention|"* Viral load (VL) ordering flowsheet with periodic health facility performance feedback~* Rapid near-point-of-care VL testing and telephone delivery of results~* Structured VL counseling package"
58486726|NCT02824653|BIOLOGICAL|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
58486727|NCT04876469|PROCEDURE|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
58486728|NCT05256199|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
58486729|NCT04510961|OTHER|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
58486730|NCT02348099|OTHER|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
58486731|NCT01723319|DEVICE|HBLPADD coil deep TMS|20 daily deep TMS treatment
58486732|NCT01723319|DEVICE|Sham|inactive treatment
58486733|NCT02324348|PROCEDURE|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
58486734|NCT02324348|PROCEDURE|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
58486735|NCT05034939|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
58486736|NCT05034939|DEVICE|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
58486737|NCT06292208|BIOLOGICAL|IBD0333|This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
58486738|NCT03163303|BEHAVIORAL|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
58486739|NCT03163303|BEHAVIORAL|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
58486740|NCT03163303|DRUG|nicotine patch|14-day supply of nicotine patch
58486741|NCT03622788|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
58486742|NCT03622788|DRUG|Cyclophosphamide|Given IV
58486743|NCT03622788|BIOLOGICAL|Cytokine-treated Veto Cells|Given IV
58486744|NCT03622788|DRUG|Fludarabine|Given IV
58486745|NCT03622788|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
58486746|NCT03622788|RADIATION|Total-Body Irradiation|Undergo TBI
58486747|NCT04555616|BEHAVIORAL|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
58486748|NCT04555616|BEHAVIORAL|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
58486749|NCT04555616|BEHAVIORAL|Placebo|Participants' caregivers will receive a set script of placebo modifications.
58486750|NCT01684293|BEHAVIORAL|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
58486751|NCT01684293|BEHAVIORAL|Psychoeducation/games|Psychoeducation/games
58486752|NCT03702153|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
58486753|NCT00306826|DRUG|pioglitazone|
58486754|NCT00306826|DRUG|simvastatin|
58486755|NCT00306826|DRUG|pioglitazone + simvastatin|
58491036|NCT03348228|DIETARY_SUPPLEMENT|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
58486756|NCT01579929|DRUG|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
58486757|NCT02136069|DRUG|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
58486758|NCT02136069|DRUG|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
58486759|NCT02136069|OTHER|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
58486760|NCT02136069|OTHER|Placebo (Injection)|Administered by SC injection Q4W until Week 52
58486761|NCT01180582|DEVICE|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
58486762|NCT03008434|OTHER|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
58486763|NCT01308437|BIOLOGICAL|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
58486764|NCT01308437|BIOLOGICAL|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
58486765|NCT04945928|PROCEDURE|Surgery|Participants having been evaluated as operable after receiving first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) will receive surgery.
58486766|NCT03247946|BEHAVIORAL|upright head position|Bottle feeding of infants with their head in upward and not supine head position
58486767|NCT02376699|DRUG|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
58486768|NCT02376699|DRUG|Pembrolizumab|Given intravenously; schedule is cohort-specific.
58486769|NCT02376699|DRUG|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
58486770|NCT02376699|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
58486771|NCT02376699|DRUG|Nab-paclitaxel|125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
58486772|NCT01804127|DRUG|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
58486773|NCT02792530|OTHER|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
58486774|NCT01038843|DRUG|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
58486775|NCT04334967|DRUG|Hydroxychloroquine|Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.
58486776|NCT04334967|DIETARY_SUPPLEMENT|Vitamin C|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
58486777|NCT05053646|PROCEDURE|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
58486778|NCT05053646|PROCEDURE|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
58486779|NCT03074838|PROCEDURE|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
58486780|NCT03074838|PROCEDURE|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
58486781|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
58486782|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
58486783|NCT00991016|DRUG|PF-04805712|ascending single and multiple doses starting at 30 mg
58486784|NCT02047032|PROCEDURE|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
58486785|NCT02047032|DRUG|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
58486786|NCT02047032|PROCEDURE|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
58486787|NCT04887129|DIAGNOSTIC_TEST|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
58486788|NCT04887129|OTHER|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
58486789|NCT02248519|PROCEDURE|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
58486790|NCT02248519|PROCEDURE|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
58486791|NCT02817464|DRUG|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
58486792|NCT02817464|DRUG|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
58486793|NCT04299789|OTHER|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
58486794|NCT00004114|BIOLOGICAL|filgrastim|
58486795|NCT00004114|DRUG|cyclophosphamide|
58486796|NCT00004114|DRUG|cytarabine|
58486797|NCT00004114|DRUG|fludarabine phosphate|
58486798|NCT00004114|PROCEDURE|peripheral blood stem cell transplantation|
58486799|NCT02389153|BEHAVIORAL|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
58486800|NCT00623142|DRUG|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
58486801|NCT05029778|DIETARY_SUPPLEMENT|L-arginine 3g + L-Citruline 2 g|receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
58486802|NCT05029778|DRUG|Placebo|receive placebo 3g PO, for 24 h, until birth.
58486803|NCT05619172|DRUG|Nanrilkefusp alfa|Subcutaneous (SC) injection
58486804|NCT05619172|DRUG|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
58486805|NCT06012552|DRUG|Tianeptine|Tianesal 12,5mg
58486806|NCT06012552|DRUG|Placebo|application as in the control group
58486807|NCT03543917|COMBINATION_PRODUCT|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
58486808|NCT04607538|OTHER|No intervention is made|No intervention is made. This i an observational study.
58486809|NCT04619771|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
58486810|NCT02193503|OTHER|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
58486811|NCT00379691|DRUG|phenylephrine|
58486812|NCT02111304|DRUG|iOWH032|
58486813|NCT01399372|BIOLOGICAL|Rituximab|One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
58486814|NCT01399372|DRUG|Cytarabine|One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
58486815|NCT01399372|DRUG|Methotrexate|One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
58486816|NCT01399372|DRUG|Procarbazine|One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
58486817|NCT01399372|DRUG|Vincristine|One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
58486818|NCT01399372|RADIATION|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
58486819|NCT03192553|BEHAVIORAL|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
58486820|NCT03192553|BEHAVIORAL|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
58486821|NCT03192553|BEHAVIORAL|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
58486822|NCT03192553|BEHAVIORAL|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
58486823|NCT03688594|DIAGNOSTIC_TEST|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
58491037|NCT05615519|DIAGNOSTIC_TEST|A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.|Digital ruler of strabismus
58491038|NCT00010829|BEHAVIORAL|American Heart Association Step 1 diet|
58491039|NCT00010829|BEHAVIORAL|American Heart Association Step 2 diet + 10 g/day flax seed|
58486824|NCT05198440|DEVICE|non-invasive neuromodulation|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
58486825|NCT05198440|DEVICE|electroencephalography|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
58486826|NCT05198440|DEVICE|anatomical MRI|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
58486827|NCT04282603|COMBINATION_PRODUCT|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
58486828|NCT00002013|DRUG|Zidovudine|
58486829|NCT00002013|DRUG|AS-101|
58486830|NCT03900091|DIAGNOSTIC_TEST|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
58486831|NCT03900091|DIAGNOSTIC_TEST|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
58486832|NCT03900091|DIAGNOSTIC_TEST|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
58486833|NCT03900091|OTHER|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
58486834|NCT02207452|DEVICE|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
58486835|NCT02207452|DRUG|Salbutamol|Salbutamol 5mg nebulised single dose
58486836|NCT02207452|DRUG|Ipratropium|Ipratropium 500mcg nebulised single dose
58486837|NCT02207452|DEVICE|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
58486838|NCT01673737|DRUG|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
58486839|NCT01673737|DRUG|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
58486840|NCT05556044|DRUG|Empagliflozin 10 MG|This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
58486841|NCT02192411|DRUG|Lidocaine|1/4 dose lidocaine
58486842|NCT01908062|DRUG|Extended Release Naltrexone|
58486843|NCT01908062|OTHER|Treatment As usual|
58486844|NCT04989335|DRUG|Bisantrene|Combined escalated dose chemotherapy
58486845|NCT04989335|DRUG|Fludarabine|Combined escalated dose chemotherapy
58486846|NCT04989335|DRUG|Clofarabine|Combined escalated dose chemotherapy
58486847|NCT03557060|DRUG|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
58486848|NCT05684211|DRUG|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
58486849|NCT05684211|DRUG|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
58486850|NCT05684211|DRUG|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
58486851|NCT05684211|DRUG|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
58486852|NCT03743636|DRUG|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
58486853|NCT03743636|DRUG|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
58486854|NCT03743636|OTHER|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
58486855|NCT01877395|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
58486856|NCT01877395|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
58486857|NCT01680471|DRUG|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
58486858|NCT01680471|DRUG|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
58486859|NCT01680471|DRUG|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
58486860|NCT05666167|BEHAVIORAL|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
58486861|NCT03458819|DIAGNOSTIC_TEST|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
58486862|NCT01189409|DRUG|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
58486863|NCT01189409|DRUG|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
58486864|NCT05766046|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with LDCT at one or two years interval
58486865|NCT05766046|OTHER|blood test|blood analysis for microRNA and other biomarkers detection
58486866|NCT03214848|BEHAVIORAL|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
58486867|NCT02790190|OTHER|Radiotherapy dose|
58486868|NCT04315064|DRUG|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
58486869|NCT03088735|PROCEDURE|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
58486870|NCT03088735|PROCEDURE|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
58486871|NCT03644511|DRUG|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
58486872|NCT03644511|DRUG|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
58486873|NCT04178785|DRUG|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
58486874|NCT03917953|DEVICE|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3)."
58486875|NCT04048772|BEHAVIORAL|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
58486876|NCT04048772|OTHER|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
58486877|NCT01993797|OTHER|Lung US|
58486878|NCT04087850|BEHAVIORAL|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
58486879|NCT05071248|DEVICE|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
58486880|NCT03881215|PROCEDURE|Platelet Rich Plasma|Platelet Rich Plasma
58486881|NCT03881215|PROCEDURE|intra-uterine balloon|intra-uterine balloon
58486882|NCT03899922|DRUG|Drugs inducing uveitis|Drugs susceptible to induce uveitis
58486883|NCT02403648|DRUG|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
58486884|NCT02403648|DRUG|Lilly Glucagon|
58486885|NCT02403648|DRUG|Novo Glucagon|
58486886|NCT06330558|PROCEDURE|laparoscopic right adrenalectomy|adrenalectomy
58491040|NCT00010829|BEHAVIORAL|Macrobiotic dietary intervention|
57783067|NCT02763891|OTHER|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
57783068|NCT02763891|OTHER|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
57783069|NCT03366883|COMBINATION_PRODUCT|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
57783070|NCT03366883|RADIATION|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
57783071|NCT05620017|DRUG|BAT8008 for Injection|Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
57783072|NCT00232934|DRUG|Thalidomide|
57783073|NCT01615991|DRUG|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
57783074|NCT04313348|BEHAVIORAL|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
57783075|NCT05675917|DEVICE|MacuTest platform|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
57783076|NCT04530474|DRUG|Ivermectin Pill|Ivermecin as a one-time dose
57783077|NCT04530474|DRUG|Placebo|Inactive medication as a one time dose
57783078|NCT04064554|DEVICE|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
57783079|NCT04064554|DEVICE|BCG vaccination with conventional needle|BCG vaccination with conventional needle
57783080|NCT01500226|DRUG|Rolapitant|(4 X 50 mg capsule) 200 mg PO
57783081|NCT01500226|DRUG|Granisetron|2 mg PO
57783082|NCT01500226|DRUG|Dexamethasone|20 mg PO
57783083|NCT01500226|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
57783084|NCT06008691|DRUG|"novel MAB (alone or in combination)"|"novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy"
57783085|NCT04504084|OTHER|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
57783086|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
57783087|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
57783088|NCT01054911|DRUG|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
57783089|NCT01054911|PROCEDURE|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
57783090|NCT01286974|DRUG|[14C]linifanib|\[14C\]linifanib, single administration, oral liquid
57783091|NCT01286974|DRUG|ABT-869, linifanib|linifanib once a day (QD), oral tablet
57783092|NCT03985163|OTHER|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
57783093|NCT00003175|DRUG|fluorouracil|
57783094|NCT06363435|DEVICE|AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans|Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients
57783095|NCT00872469|DRUG|Tranexamic acid|1-2 grams by intravenous injection
57783096|NCT00872469|DRUG|Placebo [Saline]|Matched to active comparator
57783097|NCT02338713|DRUG|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
57783098|NCT02338713|DRUG|Noncarbonated Water|Noncarbonated water 200 mL
57783099|NCT04994574|DRUG|tiotropium/olodaterol|From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.
57783100|NCT04890522|DRUG|Triprilimab(JS001)|Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
57783101|NCT04890522|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
57783102|NCT04890522|DRUG|5-Fluorouracil|Maximum 6 cycles for combined therapy.
57783103|NCT04890522|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
57783104|NCT00019890|DRUG|dendritic cell-gp100-MART-1 antigen vaccine|
57783105|NCT00019890|DRUG|sargramostim|
57783106|NCT03856021|PROCEDURE|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
57783107|NCT03856021|PROCEDURE|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
57783108|NCT05719285|DRUG|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
57783109|NCT05719285|DRUG|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
57783110|NCT04028115|DRUG|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
57783111|NCT00000719|DRUG|Zidovudine|
57783112|NCT00000719|DRUG|Zalcitabine|
57783113|NCT02249871|DRUG|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
57783114|NCT02249871|DRUG|Omeprazole|Will be given daily with oral semaglutide.
57783115|NCT06416618|PROCEDURE|Surgical|Surgical group: After osteosynthesis, they will be provided with a sling and swathe immediately after the surgery. From the first postoperative day, only the sling will be used. Two weeks postoperatively, patients will undergo clinical and radiological follow-up in the outpatient clinic. They will be referred to post-operative rehabilitation in the municipalities. At 12 weeks postoperatively, patients will have another clinical and radiological follow-up. This is the current standard care for surgical treatment with a plate or intramedullary nail.
57783116|NCT06416618|PROCEDURE|Non surgical|Non-surgical group: Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit, 10-14 days post-injury. Patients will be referred to rehabilitation in the municipalities. At week 6 post-injury, all patients will undergo clinical and radiological follow-up. This represents the current standard care for non-surgical treatment of displaced PHF at the departments.
57783117|NCT00554983|BIOLOGICAL|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
57783118|NCT00554983|BIOLOGICAL|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
57783119|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
57783120|NCT04491643|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
57783121|NCT04491643|DRUG|Rosuvastatin|At a dosage of 10 mg/day
57783122|NCT05197075|DRUG|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
57783123|NCT06493838|DRUG|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
57783124|NCT06493838|DRUG|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
57783125|NCT01589302|DRUG|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
57783126|NCT01589302|OTHER|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
57783127|NCT01589302|OTHER|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
57783128|NCT03753971|OTHER|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
58491041|NCT05219370|DRUG|Cannabis oil|administration of different cannabis oil types as compared with placebo
57783129|NCT04730934|OTHER|Perceived stress scale|Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
57783130|NCT04730934|OTHER|Fibromyalgia impact questionnaire|Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
57783131|NCT04730934|OTHER|The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status|"Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better."
57783132|NCT03978754|DIAGNOSTIC_TEST|ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report|All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
57783133|NCT03978754|DIAGNOSTIC_TEST|Bioelectrical impedance technology、CM|These two methods are routine evaluation methods for breast cancer patients before surgery
57783134|NCT04833309|PROCEDURE|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
57783135|NCT04833309|PROCEDURE|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
57783136|NCT00994136|DRUG|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
57783137|NCT01259336|DRUG|Itraconazole|Tablet 200 mg twice daily for 6 months
57783138|NCT01259336|DRUG|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
57783139|NCT04052971|DRUG|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
57783140|NCT04052971|DRUG|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
57783141|NCT01702428|BIOLOGICAL|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
57783142|NCT01702428|BIOLOGICAL|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
57783143|NCT01702428|BIOLOGICAL|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
57783144|NCT01702428|BIOLOGICAL|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
57783145|NCT01702428|BIOLOGICAL|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
57783146|NCT04507672|DRUG|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
57783147|NCT02254096|DRUG|BIRT 1696 BS|
57783148|NCT02254096|DRUG|Placebo|
57783149|NCT02254096|OTHER|Grapefruit juice (GFJ)|
57783150|NCT02254096|OTHER|High fat meal (HFM)|
57783151|NCT04946305|OTHER|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
57783152|NCT00600743|DRUG|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
57783153|NCT00600743|BEHAVIORAL|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
58486887|NCT03468140|DRUG|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
58486888|NCT03468140|OTHER|No intervention|Historical control arm
58486889|NCT02067481|BEHAVIORAL|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
58486890|NCT02979548|DRUG|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
57783154|NCT00600743|BEHAVIORAL|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
57783155|NCT00600743|DRUG|Placebo|Drug one trial vs placebo
57783156|NCT00951561|DEVICE|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
57783157|NCT00951561|DRUG|Ibuprofen|400 mg daily
57783158|NCT00730990|OTHER|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
57783159|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
57783160|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
57783161|NCT00730990|DRUG|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
57783162|NCT05881083|BEHAVIORAL|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
57783163|NCT05881083|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
57783164|NCT01080196|BEHAVIORAL|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
57783165|NCT00334425|DRUG|MENOPUR; GONAL-F|
57783166|NCT02909101|DEVICE|Active Cognitive Training (ACT)|Cognitive training games
57783167|NCT02909101|DEVICE|Control Training (CON)|Cognitive training games
57783168|NCT01811563|DEVICE|Zimmer|
57783169|NCT01811563|DEVICE|Stryker|
57783170|NCT01615588|DIETARY_SUPPLEMENT|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
57783171|NCT00014339|DRUG|Wobe-Mugos E|
57783172|NCT00014339|DRUG|melphalan|
57783173|NCT00014339|DRUG|prednisone|
57783174|NCT00014339|PROCEDURE|quality-of-life assessment|
57783175|NCT00772798|DRUG|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
57783176|NCT01570179|DRUG|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
57783177|NCT01570179|DRUG|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
57783178|NCT01570179|DRUG|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
57783179|NCT01570179|DRUG|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
57783180|NCT02234310|BIOLOGICAL|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
57783181|NCT02117674|PROCEDURE|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
57783182|NCT02117674|PROCEDURE|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
57783183|NCT02117674|PROCEDURE|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
57783184|NCT02378064|DRUG|6-month treatment|
57783185|NCT04668664|DEVICE|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
57783186|NCT01971320|DEVICE|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
57783187|NCT00734890|BIOLOGICAL|bevacizumab|
57783188|NCT00734890|DRUG|vandetanib|
57783189|NCT00734890|OTHER|laboratory biomarker analysis|
57783190|NCT00734890|OTHER|pharmacological study|
57783191|NCT04477850|DRUG|Luspatercept|Specified dose on specified days
57783192|NCT04033224|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
57783193|NCT03841825|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions and motivation
57783194|NCT01877096|BEHAVIORAL|Motivational Interviewing|A brief motivational interviewing session
57783195|NCT01877096|BEHAVIORAL|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
57783196|NCT01554254|DRUG|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
58486891|NCT02979548|DRUG|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
57783197|NCT04201522|OTHER|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
57783198|NCT04201522|OTHER|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
57783199|NCT06313983|DRUG|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
57783200|NCT06313983|DRUG|Lapatinib+Capecitabine|Take the pills according to the instructions
57783201|NCT02726178|DRUG|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
58486892|NCT02979548|DRUG|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
58486893|NCT00565292|DRUG|MK0859|
58486894|NCT04440904|DEVICE|CT workstation (Syngo Via VB10B, Siemens, Germany)|Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
57783202|NCT02726178|DRUG|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
57783203|NCT06480643|OTHER|High load exercise type|Heavier load, fewer reps
57783204|NCT06480643|BEHAVIORAL|Low load exercise type|Lighter load, more reps
57783205|NCT03340155|OTHER|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
57783206|NCT05800119|BEHAVIORAL|Brain-level condition|Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
57783207|NCT05800119|OTHER|Mind-level condition|Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
57783208|NCT00041795|DRUG|leteprinim potassium (Neotrofin)|
57783209|NCT05697432|DIAGNOSTIC_TEST|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
57783210|NCT05697432|DIAGNOSTIC_TEST|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
57783211|NCT05697432|DIAGNOSTIC_TEST|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
57783212|NCT05697432|DIAGNOSTIC_TEST|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
57783213|NCT05697432|BEHAVIORAL|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
57783214|NCT02391038|DRUG|MLN0264|MLN0264 IV.
57783215|NCT02729636|DEVICE|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
57783216|NCT02729636|OTHER|Conventional therapy|2. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
57783217|NCT00134524|PROCEDURE|MME procedure|
57783218|NCT02622971|OTHER|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
57783219|NCT02622971|OTHER|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
57783220|NCT05760430|COMBINATION_PRODUCT|PVE+cTACE+Camrelizumab+Apatinib|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
57783221|NCT05760430|COMBINATION_PRODUCT|cTACE+Atirizumab+Bevacizumab|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
58486895|NCT01107158|BIOLOGICAL|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
57783222|NCT04916899|DRUG|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
57783223|NCT01253382|BIOLOGICAL|ecallantide|10 - 30mg subcutaneous injection.
57783224|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
57783225|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
57783226|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
57783227|NCT03342781|DEVICE|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
57783228|NCT03342781|DEVICE|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
57783229|NCT02171364|PROCEDURE|Virtual ablation in based 3D CT of patient who diagnosed AF|
57783230|NCT02171364|PROCEDURE|conventional ablation based on physician's personal experience|
57783231|NCT01817543|DEVICE|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
57783232|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
57783233|NCT02163447|DRUG|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
57783234|NCT02163447|DRUG|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
57783235|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for infants|
57783236|NCT02163447|DRUG|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
57783237|NCT00000692|DRUG|Butyldeoxynojirimycin|
57783238|NCT02505139|OTHER|the number of circulating tumor cells|
58486896|NCT03615443|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
58491042|NCT05181293|BEHAVIORAL|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
57783239|NCT01315743|BEHAVIORAL|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
57783240|NCT05909787|OTHER|Auto-questionnaire|MCH (Montreal Children's Hospital) self questionnaire completed by the parents
57783241|NCT02425475|DEVICE|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
57783242|NCT02189863|DEVICE|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
57783243|NCT02189863|DEVICE|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
57783244|NCT02189863|DEVICE|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
57783245|NCT02189863|DEVICE|Comfilcon A MF|Multifocal contact lenses worn in both eyes
57783246|NCT02189863|DEVICE|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
57783247|NCT01169259|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
57783248|NCT01169259|DRUG|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
57783249|NCT01169259|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
57783250|NCT01169259|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
57783251|NCT03350477|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
57783252|NCT03350477|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
57783253|NCT00030654|DRUG|bicalutamide|
57783254|NCT00030654|DRUG|docetaxel|
57783255|NCT00030654|DRUG|doxorubicin hydrochloride|
57783256|NCT00030654|DRUG|estramustine phosphate sodium|
57783257|NCT00030654|DRUG|flutamide|
57783258|NCT00030654|DRUG|ketoconazole|
57783259|NCT00030654|DRUG|paclitaxel|
57783260|NCT00030654|DRUG|releasing hormone agonist therapy|
58491043|NCT02583737|PROCEDURE|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
57783261|NCT00030654|DRUG|vinblastine sulfate|
57783262|NCT02933463|OTHER|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
57783263|NCT02933463|OTHER|Clinpro sealant|
57783264|NCT04895020|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
57783265|NCT06530524|DRUG|OnabotulinumtoxinA|Injection of onabotulinumtoxinA into the at-risk major salivary glands
57783266|NCT06530524|DRUG|Placebo|Injection of normal saline into the at-risk major salivary glands
57783267|NCT05040490|DRUG|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
57783268|NCT06385470|BEHAVIORAL|Dynamic Temporal and Tactile Cueing treatment|"DTTC is a motor-based treatment designed for children with CAS who may have limited verbal output. It applies the principles of motor learning and focuses on speech movement gestures in the context of functional words and phrases.~The participants will receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]), where probe data will be collected before, during, between and after the treatment intervention."
57783269|NCT03693599|DRUG|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
57783270|NCT03693599|DRUG|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
57783271|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
57783272|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
57783273|NCT00524238|DRUG|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
57783274|NCT00894751|DRUG|dexmedetomidine|dexmedetomidine general anesthesia for MRI
57783275|NCT00894751|DRUG|propofol|propofol general anesthesia for MRI
57783276|NCT02765243|BIOLOGICAL|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
57783277|NCT03113760|DRUG|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
57783278|NCT03113760|OTHER|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
57783279|NCT02638064|PROCEDURE|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
57783280|NCT06236581|BEHAVIORAL|GEM Intervention|Lifestyle coaching
57783281|NCT01699893|OTHER|unique arm|blood, nasal swab, skin biopsy, stool samples
57783282|NCT02563834|DRUG|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
57783283|NCT02563834|DRUG|Saline|Saline infusion for control
58491044|NCT02583737|PROCEDURE|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
57783284|NCT02563834|DRUG|Insulin|Insulin infusion for insulin/glucose clamp procedure
57783285|NCT05472220|DRUG|Alpelisib|Given orally
57783286|NCT05472220|DRUG|Carboplatin|Given IV during imaging
57783287|NCT05472220|DRUG|Hyperpolarized Carbon-13 (13C) Pyruvate|Given IV
57783288|NCT05472220|DEVICE|Continuous Glucose Monitor (CGM)|Self-applied devices that sit partially beneath the skin
57783289|NCT03988374|DRUG|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
57783290|NCT05208281|DRUG|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
57783291|NCT05208281|DRUG|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
57783292|NCT05208281|DRUG|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
57783293|NCT06073028|OTHER|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
57783294|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
57783295|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
57783296|NCT05902130|OTHER|symptoms of a myocardial infarction|Analysis of the differences in symptoms of a myocardial infarction between a man and a woman
57783297|NCT03260361|OTHER|Hypnosis, kinesitherapy, MEOPA|classical intervention
57783298|NCT03260361|OTHER|Usual practice|Usual practice with treatments and physio
57783299|NCT03527693|DEVICE|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
57783300|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
57783301|NCT02717013|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
57783302|NCT02717013|DIETARY_SUPPLEMENT|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
57783303|NCT00999401|DRUG|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
58486897|NCT01681719|DEVICE|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
58486898|NCT01681719|DEVICE|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
58486899|NCT01681719|DEVICE|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
57783304|NCT02986737|DEVICE|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
57783305|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read positive messages
57783306|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about positive experiences
57783307|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about neutral topics
57783308|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read neutral messages
57783309|NCT04776941|OTHER|Quality-of-Life Assessment|Ancillary studies
57783310|NCT04776941|OTHER|Questionnaire Administration|Complete questionnaires
57783311|NCT06373588|BEHAVIORAL|Patient Navigator|The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
57783312|NCT04149262|DRUG|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
57783313|NCT04149262|DRUG|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
57783314|NCT04149262|DEVICE|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
57783315|NCT02005614|PROCEDURE|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
57783316|NCT04686643|DRUG|AGSAVI|S-amlodipine, Valsartan, Indapamide
57783317|NCT04686643|DRUG|AGLS|S-amlodipine, Valsartan
57783318|NCT04934319|BEHAVIORAL|Balance and Proprioceptive Training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks"
57783319|NCT04218370|PROCEDURE|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
57783320|NCT05912530|OTHER|no intervention|there is no intervention will done
57783321|NCT06063369|DRUG|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
57783322|NCT06449235|DRUG|Omarigliptin|"Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing."
57783323|NCT06449235|DRUG|Sulphonylureas|"Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs."
57783324|NCT06449235|DRUG|Metformin|"Chemical Name: Metformin Class: Biguanide~Mechanism of Action:~Decreases hepatic glucose production. Improves insulin sensitivity in peripheral tissues. Enhances peripheral glucose uptake and utilization. Reduces intestinal absorption of glucose. Administration: Administered orally, usually once or twice daily with meals."
57783325|NCT06449235|DRUG|Other DPP4-i|"Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs."
57783326|NCT06449235|DRUG|Thiazolidinediones|"Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
57783327|NCT06449235|DRUG|Alpha-Glucosidase Inhibitor|"Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response."
57783328|NCT06449235|DRUG|Glucagon-Like Peptide-1|"Chemical Name: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: GLP-1 Receptor Agonists~Mechanism of Action:~Mimics the action of endogenous GLP-1. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
57783329|NCT06449235|DRUG|Receptor Agonists (GLP1RA)|"Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
57783330|NCT06449235|DRUG|SGLT2 inhibitors|"Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors~Mechanism of Action:~Inhibits SGLT2 in the proximal renal tubules. Reduces reabsorption of filtered glucose from the renal tubules. Increases urinary glucose excretion. Lowers blood glucose levels independently of insulin. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
57783331|NCT01062906|DRUG|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
57783332|NCT01062906|DRUG|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
57783333|NCT04770818|DEVICE|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
57783334|NCT04770818|DEVICE|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
57783335|NCT01221181|DRUG|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
57783336|NCT01843452|RADIATION|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
57783337|NCT01843452|BIOLOGICAL|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
57783338|NCT01843452|DRUG|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
57783339|NCT01843452|DRUG|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
58491045|NCT00042003|DRUG|decitabine (5-aza-2'deoxycytidine)|
57783340|NCT06004752|DRUG|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
57783341|NCT06004752|DRUG|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
57783342|NCT04288362|OTHER|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
57783343|NCT04288362|OTHER|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
57783344|NCT02011958|DRUG|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
57783345|NCT02011958|DRUG|Miltefosine|"Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
57783346|NCT03293485|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
57783347|NCT04104672|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
57783348|NCT04104672|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
57783349|NCT04104672|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
57783350|NCT04104672|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
57783351|NCT00003288|BIOLOGICAL|filgrastim|
57783352|NCT00003288|DRUG|cyclophosphamide|
57783353|NCT00003288|DRUG|tirapazamine|
57783354|NCT01125774|DRUG|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
57783355|NCT01125774|DRUG|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
57783356|NCT05970289|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
57783357|NCT05970289|DRUG|BRII-835|BRII-835 will be given via subcutaneous injection
57783358|NCT02585791|OTHER|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
57783359|NCT02585791|OTHER|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
57783360|NCT02585791|OTHER|PG+VG|inhaled PG+VG by vaporing
57783361|NCT06203444|DRUG|Tenapanor|The study drug will be administered in dose of 50 mg bid
57783362|NCT03531463|PROCEDURE|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
57783363|NCT01940653|DRUG|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
57783364|NCT00003509|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
57783365|NCT03524274|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
57783366|NCT03524274|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
57783367|NCT05597683|PROCEDURE|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
57783368|NCT00744081|DRUG|Glivec|
57783369|NCT00744081|DRUG|Mitoxantrone|
57783370|NCT00744081|DRUG|Topotecan|
57783371|NCT00744081|DRUG|AraC|
57783372|NCT00507026|DRUG|IV Diclofenac|IV Diclofenac q6h
57783373|NCT00507026|DRUG|IV ketorolac|IV ketorolac q6h
57783374|NCT00507026|DRUG|Placebo|Placebo q6h
57783375|NCT05631990|DRUG|AD-209|PO, Once daily(QD), 8weeks
57783376|NCT05631990|DRUG|AD-209-1A|PO, Once daily(QD), 8weeks
57783377|NCT05631990|DRUG|AD-209-1B|PO, Once daily(QD), 8weeks
57783378|NCT05631990|DRUG|AD-209-1C|PO, Once daily(QD), 8weeks
57783379|NCT05631990|DRUG|AD-209 placebo|PO, Once daily(QD), 8weeks
57783380|NCT05631990|DRUG|AD-209-1 placebo|PO, Once daily(QD), 8weeks
57783381|NCT00268229|DRUG|cytarabine|300 mg/m2/day
58486900|NCT05862168|DRUG|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
57783382|NCT00268229|DRUG|daunorubicin hydrochloride|45 mg/m2/day
57783383|NCT00268229|DRUG|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
57783384|NCT01107730|DRUG|Vitamin C|VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
57783385|NCT01107730|DRUG|L-Carnitine|L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
57783386|NCT01107730|DRUG|Placebo|Placebo
57783387|NCT04377022|OTHER|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~1. Combined therapy~2. Conventional Therapy"
57783388|NCT03095599|BIOLOGICAL|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
57783389|NCT03095599|OTHER|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
57783390|NCT06504576|DRUG|Cilostazol 50 MG Oral Tablet|Two consecutive weeks of Cilostazol (50mg BID) two days after admission
57783391|NCT06504576|PROCEDURE|Conventional internal medicine treatment|Receives only conventional internal medicine treatment
57783392|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
57783393|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
57783394|NCT00721331|DRUG|nortriptyline HCl|Topical
57783395|NCT00721331|DRUG|mometasone furoate|Topical
57783396|NCT00721331|DRUG|Active ingredient free vehicle cream of CRx-197|Topical
57783397|NCT06048731|DEVICE|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
57783398|NCT03450421|DEVICE|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
57783399|NCT02945293|OTHER|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
58486901|NCT05862168|DRUG|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
58486902|NCT05862168|DRUG|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
58486903|NCT05862168|DRUG|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
58486904|NCT00882817|OTHER|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
58486905|NCT03855059|DRUG|Placebos|This will be a saline solution of given IV or perineural.
58486906|NCT03855059|DRUG|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
58486907|NCT01573052|DRUG|Chlordiazepoxide|25mg four times daily x 3 days then tapered over 3 days
58486908|NCT01573052|DRUG|Gabapentin|300mg four times daily x 3 days then tapered over 3 days
58486909|NCT02219425|PROCEDURE|endometrial biopsy|
58486910|NCT03135496|OTHER|Study of endothelial function biological markers|Study of endothelial function biological markers
57783400|NCT04173663|BEHAVIORAL|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
57783401|NCT05136196|PROCEDURE|Biopsy|Undergo tumor biopsies
57783402|NCT05136196|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
57783403|NCT05136196|DRUG|Cabozantinib S-malate|Given PO
57783404|NCT05136196|PROCEDURE|Computed Tomography|Undergo CT scans
57783405|NCT05136196|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
57783406|NCT05136196|BIOLOGICAL|Nivolumab|Given IV
57783407|NCT04592614|BEHAVIORAL|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
57783408|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
57783409|NCT00320879|DRUG|irbesartan|
57783410|NCT01567163|BIOLOGICAL|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
57783411|NCT01567163|DRUG|Docetaxel|docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
58486911|NCT03805152|DRUG|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
58486912|NCT03805152|DRUG|Dysport (R)|Intramuscular injection
58486913|NCT02458326|OTHER|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
58486914|NCT02458326|OTHER|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
58491046|NCT06451198|DRUG|Indobufen|Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
58486915|NCT02682043|DEVICE|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
58486916|NCT03097809|OTHER|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
58486917|NCT02622178|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
58486918|NCT02622178|DIAGNOSTIC_TEST|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
58486919|NCT02644499|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
58486920|NCT02644499|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
58486921|NCT02644499|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
58486922|NCT02644499|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
58486923|NCT02644499|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
58486924|NCT06274918|DEVICE|Personalized Body-Worn Alcohol Dispenser|This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
58486925|NCT06317740|OTHER|green management intervention program|The program activities focused on integrating green management concepts into both theory and practice learning
58486926|NCT00343096|DRUG|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
58486927|NCT06131736|OTHER|Tabata Training|This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
58486928|NCT06131736|OTHER|Cluster Training|The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
58486929|NCT01917630|DRUG|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
58486930|NCT01917630|DRUG|placebo|
58486931|NCT00577798|PROCEDURE|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
58486932|NCT04867304|OTHER|Patient education about chronic pancreatitis.|"Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters."
58486933|NCT05402488|BEHAVIORAL|Auditory stimulation|Auditory stimulation during sleep
58486934|NCT02200640|DRUG|High dose of Micardis®, once daily|
58486935|NCT02200640|DRUG|Low dose of Micardis®, once daily|
58486936|NCT02200640|DRUG|Low dose of COZAAR®, once daily|
58486937|NCT02200640|DRUG|High dose of COZAAR®, once daily|
58486938|NCT02200640|DRUG|Placebo|
58486939|NCT03208647|OTHER|AA or not|to study their risk factors
58486940|NCT05445791|DRUG|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
58486941|NCT05445791|OTHER|Placebo|Placebo 500 mg twice daily until disease progression
58486942|NCT05391490|GENETIC|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
58486943|NCT00782847|BEHAVIORAL|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
58486944|NCT01318980|DRUG|GSK2190915 100mg milled tablet|Taken orally
58486945|NCT01318980|DRUG|[14C] radiolabelled GSK2190915 solution|Microtracer solution
58486946|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
58486947|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
58486948|NCT01318980|DRUG|GSK2190915 100mg enteric-coated tablet.|Taken orally
58486949|NCT00986011|OTHER|questionnaire administration|
58486950|NCT00986011|OTHER|study of socioeconomic and demographic variables|
58486951|NCT00986011|OTHER|survey administration|
58486952|NCT00986011|PROCEDURE|study of high risk factors|
58486953|NCT00485784|OTHER|Blood test|Blood test
58486954|NCT02864056|OTHER|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
58486955|NCT02096640|PROCEDURE|Type of surgical teqnique for tracheostomy|
58486956|NCT01564576|DRUG|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
58486957|NCT06403969|BEHAVIORAL|Applied Behavior Analysis|Applied Behavior Analysis focusing on nocturnal awakenings. It starts with identification of target behaviors and goals. A functional analysis is conducted to analyze the underlying function of a behavior in connection to the problem. A treatment plan is formulated, including strategies to achieve the goals, and methods to evaluate. Families receive education sleep hygiene. Adaptations focus on antecedents and consequences, with an emphasis on positive reinforcement of favorable behaviors. Various components of Cognitive Behavioral Therapy may be applicable. These include changes in sleep environment, stimulus control, bedtime routines with visual support and prompting. Sleep restriction and bedtime fading are included. Modified extinction techniques with parental presence can be applied, gradually phasing out parental immediate presence. The intervention continues until goals are achieved or for a maximum of 8 sessions (each lasting up to 60 minutes) spread over 8 weeks.
58486958|NCT01320917|DEVICE|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
58486959|NCT01320917|DEVICE|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
58486960|NCT04641208|DEVICE|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
58486961|NCT05414058|DRUG|Apo-Methylphenidate ER|For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
58486962|NCT01106248|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
58486963|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
58486964|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
58486965|NCT01111799|PROCEDURE|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
58486966|NCT02486185|OTHER|SCREENING TEST|"* Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
58486967|NCT00508196|OTHER|RVP-min|DDD pacing with long AV delay
58486968|NCT00508196|OTHER|RVP-max|DDD pacing with short AV delay
58486969|NCT03695367|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
58486970|NCT03695367|DEVICE|Luer lock applicator|Applicator for instillation.
58486971|NCT03695367|DEVICE|Vial access device|Device for withdrawal of drug product.
58486972|NCT03695367|DRUG|Ibuprofen|Ibuprofen, 600 mg.
58486973|NCT03695367|DRUG|Acetaminophen|Acetaminophen, 1 g.
58486974|NCT03695367|DRUG|Ketorolac|Intraoperative IV ketorolac.
58486975|NCT02629900|BEHAVIORAL|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
58486976|NCT04794569|DRUG|tinzaparin|low molecular weight heparin
58486977|NCT04794569|DRUG|Rivaroxaban|direct oral anticoagulant
58486978|NCT01921595|OTHER|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
58486979|NCT01921595|OTHER|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
58486980|NCT01342159|PROCEDURE|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
58486981|NCT02013271|DEVICE|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
58486982|NCT04287517|DEVICE|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
58486983|NCT03522311|PROCEDURE|Vitrectomy|
58486984|NCT00232752|DEVICE|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
58486985|NCT04655989|DEVICE|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
58486986|NCT02748083|DEVICE|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
58491047|NCT06451198|DRUG|Aspirin|Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
58491048|NCT06451198|DRUG|Ticagrelor|All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
58491049|NCT06444191|DRUG|Rilzabrutinib|Rilzabrutinib tablet(s) administered orally
58486987|NCT02748083|DEVICE|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
58486988|NCT06517355|OTHER|In this research, the procedure under study is represented:|"* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.~* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation."
58486989|NCT05803733|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
58486990|NCT05803733|OTHER|Routine strength training|range of motion exercises and strength training
58486991|NCT06067217|DRUG|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
58486992|NCT06067217|DRUG|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
58486993|NCT02629263|DIETARY_SUPPLEMENT|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
58486994|NCT04292418|DRUG|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
58486995|NCT00997776|OTHER|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
58486996|NCT00997776|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
58486997|NCT02774629|OTHER|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
58486998|NCT04917016|DIAGNOSTIC_TEST|Plasma B-HCG levels|Blood sample
58486999|NCT05321277|DIETARY_SUPPLEMENT|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
58487000|NCT05321277|DIETARY_SUPPLEMENT|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
58487001|NCT06202820|BEHAVIORAL|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
58487002|NCT04944199|OTHER|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
58487003|NCT00753181|OTHER|Nutritional Formula|nutritional shake daily
58487004|NCT00753181|OTHER|Usual diet|usual dietary habits
58487005|NCT00753181|OTHER|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
58487006|NCT01119209|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
58487007|NCT01119209|DRUG|Saline|Approved by the Danish Medicines Agency
58487008|NCT00302367|DRUG|OROS methylphenidate hydrochloride|
58487009|NCT00302367|DRUG|immediate release methylphenidate hydrochloride|
58487010|NCT01862237|OTHER|Intervention|"* blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery."
58487011|NCT05136924|DRUG|OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo|OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo
58487012|NCT05136924|OTHER|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
58487013|NCT02490865|DRUG|RNS60|RNS60, 4 ml dose nebulized twice daily
58487014|NCT02490865|DRUG|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
58487015|NCT01760252|DRUG|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
58487016|NCT01574729|DRUG|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
58487017|NCT01574729|PROCEDURE|Surgery|Surgery plus post-surgery chemotherapy
58487018|NCT03390283|OTHER|Survey Administration|Complete online survey
58487019|NCT03363490|BEHAVIORAL|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
58487020|NCT03363490|BEHAVIORAL|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
58487021|NCT03363490|BEHAVIORAL|Health education|All four groups of patient will receive two times of health education in the first week.
58487022|NCT04556799|PROCEDURE|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
58487023|NCT04556799|PROCEDURE|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
58487024|NCT06003270|DRUG|Quercetin 1000 mg|Active comparator
58487025|NCT06003270|DRUG|Quercetin 500 MG|Active comparator
58487026|NCT06003270|DRUG|Placebo|Placebo comparator
58487027|NCT02422667|OTHER|Patient Registry|Orthopedic Data Registry
58487028|NCT04526769|DIAGNOSTIC_TEST|Tear Collection|"A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored."
58487029|NCT01260402|DEVICE|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
58487030|NCT01260402|DEVICE|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
58487031|NCT04398927|DRUG|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
58487032|NCT04398927|DRUG|Sintilimab|Sintilimab
58487033|NCT04844398|OTHER|Clown visits by RED NOSES Clowndoctors Austria|Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
58487034|NCT00309348|OTHER|Weekly measurement of graft flow|
58487035|NCT05949801|DRUG|Neucardin|10 days IV infusion of 0.6 ug/kg/day
58487036|NCT05949801|DRUG|Placebo|10 days IV infusion of 0 ug/kg/day
58487037|NCT05298553|DEVICE|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
58487038|NCT05298553|DEVICE|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
58487039|NCT00031317|DRUG|Paroxetine|
58487040|NCT00031317|DRUG|Clozapine|
58487041|NCT05021861|DRUG|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
58487042|NCT05021861|DIAGNOSTIC_TEST|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
58487043|NCT05021861|DIAGNOSTIC_TEST|Control group|SYSTEMICALLY HEALTHY FEMALES
58487044|NCT03399188|PROCEDURE|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
58487045|NCT04527770|DRUG|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
58487046|NCT04527770|DRUG|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
58487047|NCT00580307|PROCEDURE|Septoplasty|Surgical straightening of nasal septum
58487048|NCT00580307|PROCEDURE|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
58487049|NCT00695097|DRUG|Rituximab|Rituximab infusion on Day 1 and Day 15
58487050|NCT00695097|DRUG|No Rituximab|No Rituximab
58487051|NCT02595489|DIETARY_SUPPLEMENT|vitamin D3|Daily oral supplement provided by study investigators
58487052|NCT03085264|BEHAVIORAL|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
58487053|NCT03669783|DRUG|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
58487054|NCT03669783|DRUG|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
58487055|NCT03669783|DRUG|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
58487056|NCT03669783|DRUG|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
58487057|NCT03669783|DRUG|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
58487058|NCT05819151|DIAGNOSTIC_TEST|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
58487059|NCT05240027|BEHAVIORAL|Vape use survey|pre \& post test surveys
58487060|NCT01652534|DRUG|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
58487061|NCT01652534|DRUG|Placebo|Sugar Pill
58487062|NCT04724109|DRUG|Equfina|Equfina oral tablets.
58487063|NCT03752567|OTHER|Follow up|like group descriptions
58487064|NCT04285970|OTHER|cycle detection|6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
58487065|NCT04285970|OTHER|detection of effort intensity|6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
58487066|NCT03766737|DEVICE|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
58487067|NCT01364844|DRUG|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
58487068|NCT03238430|DRUG|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
58487069|NCT03238430|DRUG|Morphine PCA|a postoperative Morphine PCA
58487070|NCT03238430|DRUG|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
58487071|NCT04063007|OTHER|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
58487072|NCT04182828|DRUG|Lidocaine|both the drugs will be prepared in same volume, color, consistency and appearance
58487073|NCT03520504|RADIATION|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
58487074|NCT03835364|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
58487075|NCT02528552|DEVICE|LH80 PRO|
58487076|NCT02528552|DEVICE|Sham Device|
58487077|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
58487078|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
58487079|NCT01056016|OTHER|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
58487080|NCT03284580|OTHER|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
58487081|NCT03284580|OTHER|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
58487082|NCT03284580|OTHER|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
58487083|NCT05002712|OTHER|Heavy resistance training|Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
58487084|NCT05002712|OTHER|Contrast strength training|Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
58487085|NCT05002712|OTHER|Elastic resistance training|During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
58487086|NCT04259814|BEHAVIORAL|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
58487087|NCT04259814|BEHAVIORAL|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
58487088|NCT05115149|DEVICE|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
58487089|NCT05115149|PROCEDURE|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
58487090|NCT05115149|PROCEDURE|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
58491050|NCT04267484|DEVICE|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
58487091|NCT05115149|DEVICE|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
58487092|NCT05115149|PROCEDURE|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
58487093|NCT03646097|PROCEDURE|Angio-PCI|PCI only with angiography and without OCT findings
58487094|NCT03646097|PROCEDURE|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
58487095|NCT03646097|PROCEDURE|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
58487096|NCT04061330|DRUG|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
58487097|NCT04061330|DRUG|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
58487098|NCT01515553|DRUG|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
58487099|NCT06176235|DRUG|Teriflunomide|Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.
58487100|NCT06176235|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
58487101|NCT06064916|DIAGNOSTIC_TEST|Visual Acuity|Monocular and binocular measurement of distance, intermediate, and near visual acuity
58487102|NCT06064916|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
58487103|NCT06064916|OTHER|Intraocular Lens Satisfaction (IOLSAT) Questionnaire|Self-reported post-operative patient satisfaction with vision after surgery
58487104|NCT06064916|OTHER|Quality of Vision After Surgery (QUVID) Questionnaire|Self-reported post-operative patient vision quality after surgery
58487105|NCT06064916|OTHER|Visual Disturbance Questionnaire|Questionnaire of self-reported visual disturbances of patients
58487106|NCT06064916|DIAGNOSTIC_TEST|Topography and Tomography|Topography and tomography measurements with Atlas, iTrace, and/or Pentacam
58487107|NCT04598802|DEVICE|covered stent|atherosclerotic aorto-iliac aneurysm
58487108|NCT01915589|DRUG|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
58487109|NCT05612828|BEHAVIORAL|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
58487110|NCT02336217|OTHER|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
58487111|NCT02336217|OTHER|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
58487112|NCT05824780|OTHER|Exercise training|4-week weightlifting strength training
58487113|NCT04609670|DRUG|[14C]-ALXN2050|A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
58487114|NCT02207088|DRUG|ombitasvir/paritaprevir/ritonavir|tablet
58487115|NCT02207088|DRUG|dasabuvir|tablet
58487116|NCT02207088|DRUG|Ribavirin|tablet
58487117|NCT02462096|DEVICE|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
58487118|NCT01022528|DRUG|Dexamethasone (0.1 mg/kg)|
58487119|NCT01022528|DRUG|Dexamethasone (0.2 mg/kg)|
58487120|NCT01022528|OTHER|Saline|
58487121|NCT02062840|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
58487122|NCT02062840|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
58487123|NCT02062840|DEVICE|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
58487124|NCT02062840|OTHER|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
58487125|NCT04441086|BEHAVIORAL|eMotion|Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
58487126|NCT04441086|BEHAVIORAL|Healthy Living Active Control|The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
58491051|NCT04267484|OTHER|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
58491052|NCT04155580|DRUG|ASTX660|Capsule for oral administration
58491053|NCT04155580|DRUG|ASTX727|Tablet for oral administration
58487127|NCT05242380|OTHER|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
58487128|NCT06259370|BEHAVIORAL|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
58487129|NCT00125164|DRUG|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
58487130|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
58487131|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
58487132|NCT00940953|DRUG|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
58487133|NCT00470275|DRUG|cytarabine|Given IV
58487134|NCT02172690|PROCEDURE|Laparoscopic Staging|Laparoscopic Staging
58487135|NCT05711212|DIETARY_SUPPLEMENT|micellar solubilized Xanthohumol|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
58487136|NCT05711212|DIETARY_SUPPLEMENT|Placebo|single administration of 4 soft gelatine capsules containing only micelles
58487137|NCT04631250|DRUG|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
58487138|NCT02373683|DEVICE|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
58487139|NCT05169489|BIOLOGICAL|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
58487140|NCT02442388|PROCEDURE|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
58487141|NCT02442388|PROCEDURE|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
58487142|NCT02442388|PROCEDURE|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
58487143|NCT02230995|DRUG|metformin|single dose of metformin given as tablets
58487144|NCT02230995|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
58487145|NCT02230995|DRUG|empagliflozin|single dose of empagliflozin given as tablet
58487146|NCT00589199|PROCEDURE|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
58487147|NCT00690781|DIETARY_SUPPLEMENT|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
58487148|NCT00690781|DIETARY_SUPPLEMENT|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
58487149|NCT00690781|DIETARY_SUPPLEMENT|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
58487150|NCT00690781|DIETARY_SUPPLEMENT|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
58487151|NCT01121770|DRUG|fondaparinux sodium injection|1.5mg subcutaneously every day
58487152|NCT03009396|DRUG|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
58487153|NCT04558840|PROCEDURE|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
58487154|NCT02827929|BEHAVIORAL|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
58487155|NCT05042414|BEHAVIORAL|High intensity interval training|Four times four minutes treadmill interval training
58487156|NCT05042414|BEHAVIORAL|Moderate intensity training|Moderate intensity treadmill training
58487157|NCT05042414|BEHAVIORAL|Resting|No training
58487158|NCT03517397|BEHAVIORAL|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
58487159|NCT02562677|DEVICE|Transcutaneous Trigeminal Nerve Stimulation|
58487160|NCT06138496|DRUG|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
58487161|NCT06313918|OTHER|High intensity training (HIT)|Please see information already included in the arm descriptions.
58487162|NCT04413461|OTHER|TENS|Transcutaneous Electro Neuro Stimulation
58487163|NCT04413461|OTHER|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
58487164|NCT02668393|DRUG|Docetaxel|
58487165|NCT02668393|DRUG|Nintedanib|Low Dose
58487166|NCT02668393|DRUG|Nintedanib|Medium dose
58487167|NCT02668393|DRUG|Nintedanib|High dose
58487168|NCT02668393|DRUG|Nintedanib|Continuous high dose
58487169|NCT01570946|BEHAVIORAL|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
58487170|NCT03669497|RADIATION|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
58487171|NCT03437616|BEHAVIORAL|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
58487172|NCT02765646|DEVICE|Coronary stent procedure (CSP)|
58487173|NCT05367596|BEHAVIORAL|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
58487174|NCT05367596|BEHAVIORAL|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
58487175|NCT05367596|BEHAVIORAL|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
58487176|NCT05367596|BEHAVIORAL|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
58487177|NCT05367596|BEHAVIORAL|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
58487178|NCT05367596|BEHAVIORAL|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
58487179|NCT05367596|BEHAVIORAL|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
58487180|NCT04189887|BEHAVIORAL|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
58487181|NCT04189887|BEHAVIORAL|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
58487182|NCT03085602|BEHAVIORAL|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
58487183|NCT03085602|BEHAVIORAL|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
58487184|NCT05440552|DIAGNOSTIC_TEST|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
58487185|NCT05440552|DIAGNOSTIC_TEST|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
58487186|NCT05169008|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular injection
58487187|NCT05169008|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
58487188|NCT04004195|DRUG|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
58487189|NCT00775190|DRUG|ortho tricyclen|brand name oral contraceptive
58487190|NCT00775190|DRUG|Trinessa|generic oral contraceptive
58487191|NCT02987790|OTHER|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak\> 100mg / L), with a limit of seven days, if there is clinical improvement.
58487192|NCT04494802|BEHAVIORAL|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
58487193|NCT04494802|BEHAVIORAL|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
58487194|NCT00831480|DRUG|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
58487195|NCT02864459|OTHER|Muscular ultrasound|Muscular ultrasound is done before extubation
58487196|NCT00473239|DRUG|cholecalciferol.|100,000 IU of Vitamin D
58487197|NCT06195514|DRUG|TAK-113|Description: TAK-113 5 mg capsules, orally, once daily, in a 3 weeks on/1 week off schedule for each 4-week cycle per treatment guidelines.
58487198|NCT03329638|DRUG|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
58487199|NCT03329638|DRUG|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
58487200|NCT03329638|DRUG|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
58487201|NCT03329638|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
58487202|NCT00218842|BEHAVIORAL|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
58487203|NCT05503823|DEVICE|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
58487204|NCT01059435|DRUG|Romosozumab|Administered subcutaneously or intravenously
58487205|NCT01059435|DRUG|Placebo|Administered subcutaneously or intravenously
58487206|NCT05060029|DRUG|Lactobacillus Species|Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
58487207|NCT05060029|OTHER|Placebo|Coconut Oil Fatty Acids
58487208|NCT02561832|DRUG|Olaparib|tablets taken orally twice daily
58487209|NCT02561832|DRUG|Carboplatin|intravenous injections on day one of each cycle
58487210|NCT02561832|DRUG|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
58487211|NCT02561832|DRUG|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
58487212|NCT00002080|DRUG|Rifabutin|
58487213|NCT04514653|BIOLOGICAL|Ranibizumab|Ranibizumab (anti-VEGF agent)
58487214|NCT04514653|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
58487215|NCT04514653|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
58487216|NCT04514653|GENETIC|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
58487217|NCT04514653|DRUG|Local Steroid|Local steroid
58487218|NCT04514653|DRUG|Topical Steroid|Topical steroid
58487219|NCT01936870|DRUG|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
58487220|NCT01310075|DEVICE|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
58487221|NCT01310075|DEVICE|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
58487222|NCT04988243|OTHER|All aortic valve products on the market|"1. Subjects with severe aortic valve stenosis~2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~4. Be able to contact the subjects or their legal guardians / relatives;~5. The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
58487223|NCT04016662|DEVICE|Tandem t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
58487224|NCT05907057|DRUG|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
58487225|NCT05907057|DRUG|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
58487226|NCT00000921|DRUG|Prednisone|
58487227|NCT00686686|BIOLOGICAL|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
58487228|NCT04478006|GENETIC|RNA-seq|Gene expression and fusion transcripts analysis
58487229|NCT04478006|GENETIC|whole exon sequencing|Genetic alternation analysis
58487230|NCT04478006|OTHER|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
58487231|NCT02776397|DIETARY_SUPPLEMENT|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
58487232|NCT02776397|OTHER|Placebo|Placebo arm
58487233|NCT06219408|BEHAVIORAL|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
58487234|NCT00329589|DRUG|Velcade (bortezomib)|
58487235|NCT03270501|DRUG|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
58487236|NCT04515238|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
58487237|NCT04515238|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
58487238|NCT04515238|BIOLOGICAL|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
58487239|NCT04515238|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
58487240|NCT04957875|DEVICE|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
58487241|NCT00166777|PROCEDURE|exercise training|
58487242|NCT00212368|DRUG|Zinc acetate|
58487243|NCT00842491|DRUG|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
58487244|NCT00842491|DRUG|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
58487245|NCT00842491|DRUG|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
58487246|NCT02232906|DRUG|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
58487247|NCT02125669|PROCEDURE|Laser treatment|Pulsed dye laser 595nm
58487248|NCT02125669|DEVICE|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
58487249|NCT04993157|DRUG|FIA586|FIA586 capsule
58487250|NCT02731235|OTHER|High-intensity training|high intensity training 5 days a week for 12 weeks
58487251|NCT02731235|DRUG|prophylactic stroke medication|Usual care medication for stroke prophylaxis
58487252|NCT02731235|BEHAVIORAL|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
58487253|NCT02633709|DRUG|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
58487254|NCT02633709|OTHER|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
58487255|NCT02633709|DRUG|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
58487256|NCT04830319|OTHER|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
58487257|NCT04830319|OTHER|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
58487258|NCT05413317|OTHER|Color Doppler Ultrasound|Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
58487259|NCT05353153|OTHER|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
58487260|NCT05353153|OTHER|standart care|no intervention no hypnosis
58487261|NCT03046862|DRUG|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
58487262|NCT03046862|DRUG|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
58487263|NCT03046862|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks
57784782|NCT03405662|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
58487264|NCT03046862|DRUG|Cisplatin|Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
58487265|NCT04943653|DRUG|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
58487266|NCT02575690|DIETARY_SUPPLEMENT|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
58487267|NCT02575690|OTHER|Placebo|Individuals receive a placebo daily, for 3 months.
58487268|NCT01247272|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
58487269|NCT01247272|DRUG|PROZAC WEEKLY®|90 mg Capsules
58487270|NCT02253446|DRUG|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
58487271|NCT02253446|DRUG|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
58487272|NCT00110721|DRUG|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
58487273|NCT02856672|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
58487274|NCT02856672|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
58487275|NCT01823016|DRUG|Placebo|Placebo tablet, taken once daily
58487276|NCT01823016|DRUG|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
58487277|NCT01872390|OTHER|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
58487278|NCT01872390|OTHER|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
58487279|NCT04688008|DRUG|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
58487280|NCT03722004|BIOLOGICAL|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
58487281|NCT03722004|BIOLOGICAL|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
58487282|NCT03722004|BIOLOGICAL|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
58487283|NCT04751006|OTHER|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
58487284|NCT04751006|OTHER|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
58487285|NCT03415542|BEHAVIORAL|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
58487286|NCT00065572|DRUG|ZD6126|
58487287|NCT00065572|DRUG|Placebo|
58487288|NCT01444040|DEVICE|iStent inject|Implantation of two iStent inject devices
58487289|NCT01444040|DRUG|Travoprost|Travoprost drops
58487290|NCT03200288|DEVICE|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
58487291|NCT03200288|DEVICE|Placebo|2 ml intra-articular single injection
58487292|NCT05679258|DRUG|HLX15|A single dose (8 mg/kg) of HLX15 via intravenous infusion.
58487293|NCT05679258|DRUG|US-sourced DARZALEX®|A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
58487294|NCT05679258|DRUG|CN-sourced DARZALEX®|A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
58487295|NCT05679258|DRUG|EU-sourced DARZALEX®|A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
58487296|NCT03651570|DEVICE|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
58487297|NCT03651570|BEHAVIORAL|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
58487298|NCT01486095|DEVICE|AXXESS + Biomatrix Biolimus Eluting stent|NAP
58487299|NCT01486095|DEVICE|Culotte technique with Xience V or Xience Prime stents|NAP
58487300|NCT04016766|BEHAVIORAL|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
58487301|NCT00232427|PROCEDURE|Hemodynamic monitoring system PiCCO|
58487302|NCT03238495|DRUG|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
58487303|NCT03238495|DRUG|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
58487304|NCT02900040|OTHER|kidney transplantation|
58487305|NCT00145808|DEVICE|Given® Diagnostic System|
58487306|NCT00662441|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
58487307|NCT05400382|BEHAVIORAL|Mindfulness|Meditation training to help reduce stress and reactivity to pain and other stressors.
58487308|NCT02157883|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
58487309|NCT02157883|DRUG|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
58487310|NCT02157883|DRUG|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
58487311|NCT01879098|DIETARY_SUPPLEMENT|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
58487312|NCT01879098|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
58487313|NCT01879098|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
58487314|NCT01879098|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
58487315|NCT04545580|DRUG|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
58487316|NCT04545580|DRUG|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
58487317|NCT04079140|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
58487318|NCT04079140|DRUG|placebo|one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
58487319|NCT01463449|PROCEDURE|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
58487320|NCT00779155|DEVICE|The Resonator|active magnetic field therapy
58487321|NCT00779155|DEVICE|The Resonator control|inactive magnetic field therapy with placebo fields
58487322|NCT05927155|DRUG|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
58487323|NCT05927155|DRUG|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
58487324|NCT02790411|DEVICE|Imaging devices|technological adjustment tests
58487325|NCT02790411|DEVICE|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
58487326|NCT02062619|BEHAVIORAL|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
58487327|NCT02062619|OTHER|Real tDCS|Real tDCS 20 minutes per session, three times per week
58487328|NCT02062619|OTHER|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
58487329|NCT00668889|DRUG|Lactic acid (Dermacid)|
58487330|NCT01420952|DRUG|[11C]LY2428703|
58487331|NCT05761548|DIAGNOSTIC_TEST|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
58487332|NCT01398306|OTHER|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
58487333|NCT04867096|OTHER|Physical activity|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
58487334|NCT02481661|PROCEDURE|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
57784783|NCT03405662|OTHER|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
57784784|NCT00347867|DRUG|Viagra administration in IUGR/PET pregnancies|
58487335|NCT02640456|BIOLOGICAL|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
58487336|NCT02640456|PROCEDURE|Type of surgery|Surgical approach and complications.
58487337|NCT02640456|BIOLOGICAL|Biochemistry|Amylase concentration i pus aspirates.
58487338|NCT02640456|BIOLOGICAL|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
58487339|NCT00772317|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
58487340|NCT01796366|DRUG|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
58487341|NCT01796366|DRUG|placebo|S.c placebo administered in combination with insulin 338
58487342|NCT01796366|DRUG|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
58487343|NCT01796366|DRUG|placebo|Oral placebo administered in combination with s.c. insulin glargine
58487344|NCT01253577|DEVICE|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
58487345|NCT01253577|DEVICE|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
58487346|NCT05046561|DRUG|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
58487347|NCT05046561|DRUG|Placebo|Placebo oral capsule
58487348|NCT05275504|DRUG|TT-01488|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
58487349|NCT06232824|BEHAVIORAL|Tele-rehabilitation|The whole program is constituted of preoperative education and postoperative rehabilitation (in hospital and out of hospital). All the participants received the same preoperative education through the mobile phone application and oral communication. Participants in the intervention group get the multicomponent supervised tele-rehabilitation, while participants in the control group get the home-based self-rehabilitation. All the postoperative rehabilitation programs are presented and executed through the mobile phone application.
58487350|NCT00248768|DEVICE|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
58487351|NCT03470298|PROCEDURE|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
58487352|NCT06441240|DIAGNOSTIC_TEST|MRI|Breast MRI
58487353|NCT04366817|BEHAVIORAL|psychological assessment|psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
58487354|NCT04664127|DRUG|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
58487355|NCT04664127|DRUG|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
58487356|NCT04560699|OTHER|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
58487357|NCT04560699|OTHER|medical care|medical care three times during the study period; baseline, week 13 and week 26
58487358|NCT01356277|BEHAVIORAL|Action-focused problem-solving|"* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
58487359|NCT01356277|DEVICE|Electronic pillbox monitoring, dose reminders, and feedback|"* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders"
58487360|NCT02346721|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
58487361|NCT03252925|DRUG|N-Acetylcysteine|50mg/Kg.d, oral
58487362|NCT03252925|DRUG|Placebo Oral Tablet|50mg/Kg.d, oral
58487363|NCT02256280|DRUG|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
58487364|NCT02256280|DRUG|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
58487365|NCT03751917|DRUG|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
58487366|NCT01415414|DRUG|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
58487367|NCT01075542|DEVICE|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
58487368|NCT01075542|DEVICE|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
58487369|NCT01340846|DRUG|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
58487370|NCT01340846|DRUG|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
58487371|NCT01340846|DRUG|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
58487372|NCT01340846|DRUG|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
58487373|NCT01340846|DRUG|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
57784785|NCT02372175|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
57784786|NCT06048874|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
57784787|NCT06048874|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
57784788|NCT06048874|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
58487374|NCT01752777|BEHAVIORAL|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
58487375|NCT01752777|BEHAVIORAL|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
58487376|NCT01704209|DRUG|Fibroblast Treatment|
58487377|NCT01704209|PROCEDURE|Vehicle|
58487378|NCT01357525|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
58487379|NCT00755183|DRUG|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
58487380|NCT00755183|DRUG|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
58487381|NCT00354978|DRUG|5-Fluorouracil|"400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection."
58487382|NCT00354978|DRUG|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
58487383|NCT00354978|DRUG|Leucovorin|400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
58487384|NCT00354978|DRUG|Irinotecan|180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
58487385|NCT02736578|DRUG|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
58487386|NCT02736578|DRUG|Cetuximab|Administered as a 100 mg IV loading dose
58487387|NCT03858309|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
58487388|NCT03858309|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
58487389|NCT03636893|DRUG|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
58487390|NCT03636893|DRUG|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
58487391|NCT03103334|OTHER|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
58487392|NCT03103334|DRUG|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
58487393|NCT02708186|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
58487394|NCT02708186|DRUG|Placebo|once daily, oral, matching tablets
58487395|NCT03072108|DIETARY_SUPPLEMENT|Bonolive|2 caps per day of Bonolive
58487396|NCT03072108|DIETARY_SUPPLEMENT|Placebo|2 caps per day of Placebo
57783412|NCT05825729|DIAGNOSTIC_TEST|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
57784789|NCT03437434|OTHER|Visual Acuity|Ocular Examination
57784790|NCT00747981|PROCEDURE|Thoracic CT Scan|Perform a CT Scan and an endoscopy
58487397|NCT05338814|OTHER|scapular corrective exercises|40 minutes each, three times a week for six weeks
58487398|NCT05338814|OTHER|conventional neck exercises|40 minutes each, three times a week for six weeks
58487399|NCT02451709|DEVICE|Activated Smartinhaler or Smartturbo|Medication reminder alarms
58487400|NCT02451709|OTHER|Feedback of adherence data|Review of adherence data with action planning
58487401|NCT02451709|DEVICE|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
58487402|NCT05295069|BEHAVIORAL|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
58487403|NCT05228951|DRUG|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
58487404|NCT04845503|RADIATION|MR-guided Radiotherapy|Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
58487405|NCT02003599|DEVICE|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
58487406|NCT02003599|DEVICE|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
58487407|NCT03108326|BIOLOGICAL|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
58487408|NCT01547078|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
58487409|NCT01547078|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
58487410|NCT02753452|BEHAVIORAL|Residential Immersive Life Skills programming|
58487411|NCT02753452|BEHAVIORAL|Non-residential life skills programming|
58487412|NCT02501577|DEVICE|SAD 1|Placement and fiberoptic control
58487413|NCT02501577|DEVICE|SAD 2|Placement and fiberoptic control
58487414|NCT01565824|OTHER|web-based support|
58487415|NCT03346980|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
58487416|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
58487417|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
58487418|NCT01918306|DRUG|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------"
58487419|NCT01918306|OTHER|laboratory biomarker analysis|correlative studies
58487420|NCT01918306|OTHER|pharmacological study|correlative studies
58487421|NCT01918306|PROCEDURE|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
58487422|NCT01918306|DRUG|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
58487423|NCT01526681|OTHER|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
58487424|NCT01526681|OTHER|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
58487425|NCT01526681|OTHER|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
58487426|NCT01526681|DEVICE|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
58487427|NCT01526681|PROCEDURE|Autologous Breast Reconstruction with Neurotization|
58487428|NCT01526681|PROCEDURE|Autologous Breast Reconstruction without Neurotization|
58487429|NCT02259335|DEVICE|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
58487430|NCT04176471|OTHER|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
58487431|NCT04176471|OTHER|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
58487432|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
58487433|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
58487434|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
58487435|NCT05961007|DRUG|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
58487436|NCT00507143|DRUG|irinotecan|
58487437|NCT00802256|PROCEDURE|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
58487438|NCT05865119|DEVICE|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
58487439|NCT05865119|PROCEDURE|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
58487440|NCT02280343|OTHER|evaluated lung function|lung function tests
58487441|NCT03485378|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
58487442|NCT01626872|DRUG|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
58487443|NCT01626872|DRUG|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
57783413|NCT05825729|DIAGNOSTIC_TEST|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
58487444|NCT01626872|DRUG|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
58487445|NCT01626872|DRUG|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
58487446|NCT00663182|DRUG|Entecavir|Entecavir 0.5 mg/d
58487447|NCT01474252|DRUG|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
58487448|NCT02476461|DRUG|xiapex|
58487449|NCT02476461|PROCEDURE|percutaneous needle fasciotomy|
58487450|NCT01473901|DRUG|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
58487451|NCT01473901|DRUG|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
58487452|NCT04551209|PROCEDURE|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
58487453|NCT00430404|OTHER|Collaborative care (Intervention)|Structured shared care with treatment protocol \& support
58487454|NCT01605799|BEHAVIORAL|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
58487455|NCT01605799|BEHAVIORAL|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
58487456|NCT00420771|DRUG|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
58487457|NCT00420771|DRUG|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
58487458|NCT05959356|DRUG|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
58487459|NCT05959356|DRUG|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
58487460|NCT02214134|GENETIC|Tumour markers testing|
58487461|NCT05796375|PROCEDURE|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
58487462|NCT05796375|DIAGNOSTIC_TEST|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
58487463|NCT05796375|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
58487464|NCT05210777|DEVICE|observation|no intervention
58487465|NCT03241368|DEVICE|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
58487466|NCT00379964|DRUG|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC\>500/mm3), and for up to 72 hours later.
58487467|NCT00573300|PROCEDURE|Phlebotomy|Single blood draw
58487468|NCT00857714|DRUG|lapatinib|1500 mg lapatinib for 14-21 days
58487469|NCT00561509|DRUG|SSRIs|Use within normal clinical practice
58487470|NCT00561509|DRUG|Dual antidepressants|Use within clinical practice
57784791|NCT04675242|DRUG|NCX 4251|NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily
57784792|NCT04675242|DRUG|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
57784793|NCT00403988|DRUG|Oxaliplatin|
57784794|NCT00403988|DRUG|vinorelbine|
57784795|NCT06190574|OTHER|Telephone follow-up|Telephone follow-up
58487471|NCT03854877|BEHAVIORAL|Health behaviour intervention|The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
58487472|NCT04154813|DRUG|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
58487473|NCT04154813|DRUG|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
58487474|NCT04154813|BEHAVIORAL|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
58487475|NCT04154813|BEHAVIORAL|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
58487476|NCT00080444|DRUG|aprepitant|aprepitant capsules
58487477|NCT00080444|DRUG|ondansetron|ondansetron IV preparation
58487478|NCT00080444|DRUG|dexamethasone|dexamethasone tablets
58487479|NCT00080444|DRUG|placebo to aprepitant|Matching placebo to aprepitant capsules
58487480|NCT00080444|DRUG|placebo to dexamethasone|Matching placebo to dexamethasone tablets
58487481|NCT00080444|DRUG|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
58487482|NCT04717219|OTHER|Blood drawing|Blood will be drawn after inclusion of the participants.
58487483|NCT05494424|BEHAVIORAL|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
58487484|NCT06464978|DEVICE|Stapler Reinforcement Patch|Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
58487485|NCT06464978|DEVICE|Standard Stapler|Participants in this group will receive gastrojejunostomy with the use of Standard Stapler
58487486|NCT03453138|DEVICE|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
58487487|NCT03453138|DEVICE|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
58487488|NCT01885130|OTHER|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
58487489|NCT05733117|DRUG|Vitamin D|cholecalciferol
58487490|NCT03828578|PROCEDURE|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
58487491|NCT04873219|DEVICE|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
58487492|NCT00731302|DRUG|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
58487493|NCT03336112|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
58487494|NCT03336112|OTHER|Information program|Information program delivered by the Internet during 5 weeks.
58487495|NCT00434785|DRUG|AGG-523|
58487496|NCT04043858|DRUG|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
58487497|NCT05079243|BIOLOGICAL|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
58487498|NCT05418205|OTHER|Families with FGP support|Non-randomized controlled trial with four points of measurement ( in 18 months)
58487499|NCT06356896|BEHAVIORAL|diaphragmatic breathing exercise|Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
57784796|NCT01426620|DIETARY_SUPPLEMENT|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
58487500|NCT00659737|DRUG|Aprepitant|40mg tablet
58487501|NCT00659737|DRUG|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
58487502|NCT00464191|DRUG|escitalopram|
57784797|NCT03927872|OTHER|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
58487503|NCT02328638|BEHAVIORAL|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
58487504|NCT02328638|BEHAVIORAL|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
58487505|NCT02117297|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
58487506|NCT02681978|DRUG|Ivabradine|Ivabradine 5 mg twice daily
58487507|NCT02681978|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
58487508|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
58487509|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
58487510|NCT01528969|DIETARY_SUPPLEMENT|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
58487511|NCT01528969|DIETARY_SUPPLEMENT|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
58487512|NCT00689507|BIOLOGICAL|LY2127399|monoclonal antibody
58487513|NCT06315816|BEHAVIORAL|virtual reality glasses used during tooth extraction and extirpation treatment|The effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in 7-10 years old children
58487514|NCT02135926|DEVICE|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
58487515|NCT02135926|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
58487516|NCT00897819|GENETIC|DNA methylation analysis|
58487517|NCT00897819|GENETIC|loss of heterozygosity analysis|
58487518|NCT00897819|GENETIC|microsatellite instability analysis|
58487519|NCT00897819|OTHER|laboratory biomarker analysis|
58487520|NCT01276054|RADIATION|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
58487521|NCT01276054|DRUG|methylene blue|Given subcutaneously
58487522|NCT01276054|DRUG|indocyanine green solution|Given subcutaneously
58487523|NCT01276054|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
58487524|NCT01276054|PROCEDURE|axillary lymph node biopsy|Undergo axillary lymph node biopsy
58487525|NCT01276054|PROCEDURE|bioimpedance spectroscopy|Correlative studies
58487526|NCT01276054|PROCEDURE|quality-of-life assessment|Ancillary studies
58487527|NCT01276054|OTHER|lymphedema management|Undergo axillary reverse mapping
58487528|NCT05324852|DRUG|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
58487529|NCT05324852|DRUG|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
58487530|NCT00629343|DRUG|Azacitidine In Combination With Temozolomide|mg, oral
58487531|NCT00993148|DRUG|maraviroc|150 mg tab by mouth once daily for 96 weeks
58487532|NCT00993148|DRUG|darunavir|800 mg tab by mouth once daily for 96 weeks
58487533|NCT00993148|DRUG|ritonavir|100 mg capsule by mouth once daily for 96 weeks
58487534|NCT04338802|DRUG|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
58487535|NCT04338802|OTHER|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
58487536|NCT04250909|DEVICE|Passeo-18|POBA
58487537|NCT04250909|DEVICE|Passeo-18 Lux|DCB
58487538|NCT05701501|DRUG|Vitamin B5 Tablets|The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.
58487539|NCT05701501|DRUG|placebo|The control group was given placebo tablets of the same type based on the standard IBD treatment.
58487540|NCT03639909|PROCEDURE|sweating function|Sweating dysfunction by Sudoscan
58487541|NCT03639909|PROCEDURE|Cardiovascular function|Cardiovascular (CV) tests
58487542|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
58487543|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
58487544|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
58487545|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
58487546|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
58487547|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
58487548|NCT05626868|DEVICE|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
58487549|NCT00846092|DEVICE|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
58487550|NCT00846092|DEVICE|Near-infrared light (NIR)|"* Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily."
58487551|NCT00523302|DEVICE|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
58487552|NCT00523302|DEVICE|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
58487553|NCT04581694|DIAGNOSTIC_TEST|TAVI without contrast|TAVI without contrast
58487554|NCT01956929|DRUG|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
58487555|NCT01956929|DRUG|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
58487556|NCT02784691|DEVICE|Feeligreen patch|
58487557|NCT04660916|DRUG|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
58487558|NCT04583163|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
58487559|NCT00140582|DRUG|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
58487560|NCT04903613|DRUG|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
58487561|NCT04375085|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
58487562|NCT06225713|DEVICE|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
58487563|NCT06225713|DEVICE|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
58487564|NCT00946621|DRUG|Ramipril 10 mg Capsule (Sandoz)|
58487565|NCT00946621|DRUG|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
58487566|NCT05676840|PROCEDURE|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
58487567|NCT00073476|DRUG|traxiprodil (CP-101,606)|
58487568|NCT01716052|DRUG|placebo|Lactulose
58487569|NCT01716052|DRUG|Ibuprofen|
58487570|NCT05008406|OTHER|Satisfaction|Students Satisfaction
58487571|NCT03207061|DIAGNOSTIC_TEST|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
58487572|NCT00158418|PROCEDURE|Cemented Humeral Stem|
58487573|NCT00158418|PROCEDURE|Uncemented Humeral Stem|
58487574|NCT02814994|BEHAVIORAL|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
58487575|NCT02814994|BEHAVIORAL|low tidal volume|ventilation ventilated with low tidal volume
58487576|NCT00004554|DRUG|naltrexone (Revia)|100mg/day
58487577|NCT00004554|DRUG|sertraline (Zoloft)|200mg/day
58487578|NCT00004554|DRUG|Placebo|Placebo
58487579|NCT05322473|DRUG|Sonelokimab (M1095)|randomized treatment; parallel-group
58487580|NCT05322473|DRUG|Adalimumab|randomized treatment; parallel-group
58487581|NCT05322473|OTHER|Placebo|randomized treatment; parallel-group
58487582|NCT04615026|DIAGNOSTIC_TEST|duplex sonography|all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
57784798|NCT00906295|OTHER|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
58487583|NCT02897440|PROCEDURE|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
58487584|NCT02897440|PROCEDURE|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
58487585|NCT00051532|DRUG|Seocalcitol|
58487586|NCT04073979|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
58487587|NCT05631613|PROCEDURE|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
58487588|NCT04565639|DEVICE|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
58487589|NCT05724537|PROCEDURE|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
58487590|NCT03810924|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
58487591|NCT03810924|BEHAVIORAL|Ergometer|Riding ergometer
58487592|NCT03810924|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
58487593|NCT03810924|BEHAVIORAL|Reading Newspaper|Participants read newspaper
58487594|NCT04978298|OTHER|Placebo|Placebo
58487595|NCT04978298|DRUG|Rasigiline|Rasigiline
58487596|NCT04978298|DRUG|Phenelzine|Phenelzine
58487597|NCT04978298|DRUG|Ozanimod|Ozanimod
58487598|NCT06009211|OTHER|QueaseEase|Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
58487599|NCT02816385|PROCEDURE|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
58487600|NCT02816385|PROCEDURE|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
58487601|NCT02223858|BEHAVIORAL|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
58487602|NCT02223858|BEHAVIORAL|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
58487603|NCT02394587|BEHAVIORAL|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
58487604|NCT04029077|OTHER|NA: intervention is not part of the study|NA: it is not an interventional study
58487605|NCT05824195|OTHER|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
58487606|NCT05573997|DIAGNOSTIC_TEST|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
58487607|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)|Comparison of these micro RNAs with the micro RNAs extracted from oral swabs (in Fetal Alcohol Spectrum Disorder group)
58487608|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from bucal swabs (act added for research).|Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group
58487609|NCT03529591|DEVICE|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
58487610|NCT03529591|PROCEDURE|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
58487611|NCT04473677|DIAGNOSTIC_TEST|The new qFIT and colonoscopy with pathological examination|Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
58487612|NCT02534740|DRUG|tafamidis|relative bioavailability
58487613|NCT02534740|DRUG|tafamidis|fasted
58487614|NCT02534740|DRUG|tafamidis|fed
58487615|NCT01029106|PROCEDURE|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
58487616|NCT01093235|BIOLOGICAL|bevacizumab|
58487617|NCT01093235|DRUG|cyclophosphamide|
58487618|NCT01093235|DRUG|docetaxel|
58487619|NCT01093235|DRUG|epirubicin hydrochloride|
58487620|NCT01093235|DRUG|fluorouracil|
58487621|NCT01093235|PROCEDURE|assessment of therapy complications|
58487622|NCT01093235|PROCEDURE|neoadjuvant therapy|
58487623|NCT01093235|PROCEDURE|quality-of-life assessment|
57784799|NCT00906295|OTHER|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
58487624|NCT01093235|PROCEDURE|therapeutic conventional surgery|
58487625|NCT02379637|DRUG|N-acetylcysteine|
58487626|NCT02379637|DRUG|Placebo|
58487627|NCT01962740|DEVICE|Drug-eluting stent implantation|
58487628|NCT01263847|DIETARY_SUPPLEMENT|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
58487629|NCT04617704|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
58487630|NCT05263778|DRUG|Bempedoic Acid / Ezetimibe Oral Tablet|Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
58487631|NCT05263778|DRUG|Placebo|Matching placebo by mouth once daily for 12 weeks
58487632|NCT00075257|DRUG|DVS-233 SR|
58487633|NCT00645996|DIETARY_SUPPLEMENT|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
58487634|NCT00645996|DIETARY_SUPPLEMENT|Cornflor|Cornflour 2 gram daily
58487635|NCT04372940|DRUG|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
58487636|NCT04372940|OTHER|Saline Irrigation|Saline will serve as the control.
58487637|NCT05111730|DEVICE|The Shock wave Therapy.|Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
58487638|NCT03599089|DRUG|CA-008|single-dose wound infiltration prior to surgical incision closure
58487639|NCT03599089|DRUG|Placebo|single-dose wound infiltration prior to surgical incision closure
58487640|NCT03599089|DRUG|Ketorolac|30mg IV administered intraoperatively
58487641|NCT03599089|DRUG|Acetaminophen|1000mg IV administered intraoperatively
58487642|NCT03599089|DRUG|Oxycodone|5mg PO prn post-surgery
58487643|NCT03599089|DRUG|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
58487644|NCT02156934|BIOLOGICAL|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
58487645|NCT03731676|DEVICE|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
58487646|NCT03731676|DEVICE|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
58487647|NCT03993106|DRUG|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
58487648|NCT05668052|OTHER|questionnaire|This survey was conducted in Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 2022 to December 2023. The research objects were patients with COVID-19.
58487649|NCT05269667|DRUG|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
58487650|NCT01011309|BIOLOGICAL|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
58487651|NCT01011309|DRUG|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
58487652|NCT02812862|DRUG|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
58487653|NCT03683459|DEVICE|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
58487654|NCT03279562|DRUG|Nalmefene|Educational and behaviorally oriented drug counseling
58487655|NCT04837378|OTHER|Abdominal Massage|The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
58487656|NCT04837378|OTHER|In-bed Exercise|In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
58487657|NCT03470844|BEHAVIORAL|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
58487658|NCT03470844|BEHAVIORAL|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
58487659|NCT03470844|OTHER|fMRI|Brain volume, chemical markers, functional outcome
58487660|NCT03470844|BEHAVIORAL|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
58487661|NCT04065672|DRUG|Low-dose IL-2|After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
58487662|NCT04065672|DRUG|Placebo|After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
58487663|NCT03005158|OTHER|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
58487664|NCT03005158|OTHER|Randomization Phase|Standard care or HighSTEACS pathway.
58487665|NCT03005158|OTHER|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
58487666|NCT02186418|GENETIC|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
58487667|NCT02904954|DRUG|Durvalumab|Intravenously
58487668|NCT02904954|OTHER|Durvalumab plus SBRT|Intravenously plus radiotherapy
58487669|NCT06252688|BEHAVIORAL|Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.|"All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
58487670|NCT03775135|OTHER|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
58487671|NCT03249116|OTHER|animal-assisted intervention|Interaction with a therapy dog
58487672|NCT03249116|OTHER|active control|Interaction with a stuffed dog
58487673|NCT06035757|DRUG|Bridion 200 MG in 2 ML Injection|Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
58487674|NCT06035757|DRUG|Pyridostigmine Bromide 5 MG/ML|Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
58487675|NCT01614392|BEHAVIORAL|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
58487676|NCT01614392|BEHAVIORAL|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
58487677|NCT04769388|DRUG|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
58487678|NCT04769388|DRUG|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
58487679|NCT00296699|DRUG|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~\* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
58487680|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
58487681|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
58487682|NCT01523041|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
58487683|NCT06227104|DEVICE|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
58487684|NCT03418818|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
58487685|NCT03418818|DRUG|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
58487686|NCT03519295|DRUG|MPDL3280A|MPDL3280A administered every 2 weeks at 800 mg for 12 months.
58487687|NCT03519295|DRUG|mDCF|8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
58487688|NCT02998268|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
58487689|NCT02998268|DRUG|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
58487690|NCT02998268|DRUG|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
58487691|NCT05244252|DRUG|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
58487692|NCT05244252|DRUG|Bupivacaine|bupivacaine
58487693|NCT02505919|DEVICE|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
58487694|NCT02505919|PROCEDURE|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
58487695|NCT02481128|PROCEDURE|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
58487696|NCT05700019|BEHAVIORAL|Pinkwashed Advertisements|Real advertisements from alcoholic beverage companies' social media accounts that contain messaging or other features that associate the alcohol company with breast cancer awareness or research.
58487697|NCT05700019|BEHAVIORAL|Control - Standard Advertisements|Real advertisements from the same alcoholic beverage companies' social media accounts that do not contain messaging or other features associated with breast cancer awareness or research.
58487698|NCT00948441|DRUG|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
58487699|NCT00948441|OTHER|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
58487700|NCT06492525|DRUG|Ensartinib|225 mg oral dose on day 1 in period 1 and on day 18 in period 2
58487701|NCT06492525|DRUG|Rifampicin|600 mg QD from day 9 to day 22 in period 2
58487702|NCT06492525|DRUG|Itraconazole|200 mg QD from day 9 to day 19 in period 2
58487703|NCT06492525|DRUG|Ensartinib|100 mg oral dose on day 1 in period 1 and on day 12 in period 2
58487704|NCT06403332|BEHAVIORAL|brief intervention|The intervention for cohort A (intervention arm) based on brief intervention on alcohol consumption performed by a psycologist, medical visit peformed by an hepatologist including assessment of underlying liver disease with non invasive test (i.e Fibroscan and lab work).
58487705|NCT01955330|PROCEDURE|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
58487706|NCT05974124|DEVICE|Povidone-Iodine 0.66%|Povidone-iodine 0.66% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
58487707|NCT05974124|DEVICE|Chlorhexidine 0.02%|Chlorhexidine 0.02% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
58487708|NCT02876562|PROCEDURE|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
58487709|NCT03620461|DRUG|Gemcitabine - nabpaclitaxel|efficacy and safety
58487710|NCT00108199|BEHAVIORAL|Problem-Solving Training|
58487711|NCT00108199|BEHAVIORAL|Work-Related Social Skills Training|
58487712|NCT03849508|DRUG|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
58487713|NCT03849508|DRUG|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
58487714|NCT05242120|OTHER|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
58487715|NCT03519711|DRUG|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
58487716|NCT05821881|OTHER|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
58487717|NCT05529797|OTHER|Veovita-VR|Veovita-VR is a VR intervention with positive emotional stimuli and positive behavioral activation designed to reduce depressive symptoms in people with at least moderate depressive symptoms. In the VR session, the participants stay in a beautiful environment (island, sandy beach, beautiful scenery). They can engage in activities that are perceived as positive (climbing, treasure hunting, listening to music, building sandcastles). The session has a length of approx. 30 minutes. Participants are free to continue to engage with any treatment they require during the duration of the study.
58487718|NCT02792829|DRUG|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
58487719|NCT06518746|OTHER|Cryopreservation of gonadal tissue|Patients at risk for primary gonadal tumors will undergo unilateral or bilateral gonadectomy for clinical purposes as a standard of care, and a portion of the surgically removed tissue will be cryopreserved for fertility preservation. The pathologist will assess the tissue using sterile technique and every other section will undergo histologic analysis, including evaluation for the presence of tumor or viable germ cell elements. The sections of the tissue for fertility preservation will be refrigerated and held until a final diagnosis is made on the tissue sections that are being processed for histologic analysis. If no tumor is identified and viable germ cell elements are identified, the tissue sections allotted for preservation will be sent in holding media for processing and cryopreservation.
58487720|NCT03310853|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
58487721|NCT03310853|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
58487722|NCT03339752|DRUG|Rosuvastatin|10 mg tablet
58487723|NCT03339752|DRUG|ACT-541468|25 mg hard capsule
58487724|NCT05216809|BEHAVIORAL|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.
58487725|NCT05216809|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
58487726|NCT04969302|DIAGNOSTIC_TEST|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
58487727|NCT00565084|DRUG|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
58487728|NCT00565084|DRUG|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
58487729|NCT05335278|DRUG|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
58487730|NCT01339052|DRUG|BKM120|
58487731|NCT01339052|PROCEDURE|Surgery|Surgery
57784800|NCT03187561|BEHAVIORAL|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
58487732|NCT05840757|DEVICE|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
58487733|NCT00004428|DRUG|CPX|
58487734|NCT05860309|OTHER|quadratous lumborum block|The patient will be placed in the lateral position, after sterilization.. QLB will be done using ultrasound, The probe will be positioned superior to the iliac crest, in the transverse orientation, at the posterior axillary line. The Shamrock sign will be identified at the L4 level, and the insulated nerve block needle will be advanced from posterior to anterior, through the QL muscle, until the needle tip is visualized in the interfascial plane between the QL muscle and psoas muscle. As the correct needle placement is confirmed with 2-3 mL of saline, 20 mL of 0.25% bupivacaine will be injected ensuring that the psoas muscle will be pushed deeply.
58487735|NCT05940090|DEVICE|SkinIO|The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
58487736|NCT05055206|DIAGNOSTIC_TEST|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
58487737|NCT03760861|DEVICE|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
58487738|NCT02441595|BEHAVIORAL|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
58487739|NCT02441595|BEHAVIORAL|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
58487740|NCT00915616|DRUG|Melatonin|
58487741|NCT03995953|BEHAVIORAL|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for family members to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
58487742|NCT03995953|OTHER|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
58487743|NCT00528593|DRUG|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
58487744|NCT00451347|DEVICE|Quadriceps strength training|
58487745|NCT00451347|DEVICE|Taping|
58487746|NCT00451347|DEVICE|Home exercise|
58487747|NCT03972943|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP treatment
58487748|NCT03972943|OTHER|Patient Observation|Undergo observation
58487749|NCT03972943|OTHER|Questionnaire Administration|Ancillary studies
58487750|NCT04733859|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
58487751|NCT04733859|DIETARY_SUPPLEMENT|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
58487752|NCT04578236|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
58487753|NCT04578236|DRUG|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
58487754|NCT01470950|PROCEDURE|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
58487755|NCT04037696|BEHAVIORAL|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
58487756|NCT04037696|BEHAVIORAL|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
58487757|NCT05536596|PROCEDURE|Orthognathic Surgery|Prognathism/Retrognathism correction through surgical procedures
58487758|NCT05536596|DRUG|Melatonin 10 MG Oral Tablet|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
58487759|NCT05536596|DRUG|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
58487760|NCT05536596|DRUG|Centrum|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneuron). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
58487761|NCT00156676|DEVICE|Body-weight supported treadmill|
58487762|NCT00156676|DEVICE|Lokomat|
58487763|NCT00156676|DEVICE|Body-weight supported treadmill|
58487764|NCT00156676|DEVICE|Lokomat|
58487765|NCT03819114|DRUG|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
58487766|NCT04827680|DEVICE|Venus Viva MD|The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
58487767|NCT03216824|OTHER|Dressing|A dressing is maintained on the CVAD exit site.
58487768|NCT03216824|OTHER|No-Dressing|The CVAD exit site is not covered with a dressing.
58487769|NCT05373914|DRUG|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
58487770|NCT05373914|DRUG|Control: Matching Placebo|Placebo - 250mg tablets (orally)
58487771|NCT00842296|DEVICE|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
58487772|NCT04113421|DIAGNOSTIC_TEST|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
58487773|NCT03656380|DRUG|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
58487774|NCT03656380|DRUG|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
58487775|NCT03656380|OTHER|Placebo|Saline subcutaneous injection
58487776|NCT02177149|DEVICE|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
58487777|NCT02177149|DEVICE|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
58487778|NCT00240396|DRUG|Narcotics alone|
58487779|NCT00240396|DRUG|Narcotics and NSAIDS|
58487780|NCT00563472|DRUG|estetrol|10 mg orally per day for 28 days
58487781|NCT00563472|DRUG|estetrol|20 mg orally per day for 28 days
58487782|NCT00563472|DRUG|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
58487783|NCT00563472|DRUG|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
58487784|NCT02789293|DEVICE|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
58487785|NCT04395742|OTHER|Data collection|Only data collection
58487786|NCT03436082|DEVICE|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
58487787|NCT03668899|PROCEDURE|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
58487788|NCT06083740|DEVICE|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
58487789|NCT06326567|OTHER|C4 Program|C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
58487790|NCT06255613|DEVICE|Belun Ring|The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.
58487791|NCT06255613|DEVICE|Belun Cor|"The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts."
58487792|NCT04549129|BEHAVIORAL|Breastfeeding education video|"An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes)."
58487793|NCT04549129|BEHAVIORAL|Breastfeeding website|"The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby)."
58487794|NCT04549129|BEHAVIORAL|Usual breastfeed education|The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
58487795|NCT02696967|DRUG|CLR325|CLR325 Concentrate for solution for infusion
58487796|NCT02696967|OTHER|Placebo|Normal saline
58487797|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
58487798|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
58487799|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
58487800|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
58487801|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
58487802|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
58487803|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
58487804|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
58487805|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
58487806|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
58487807|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
58487808|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
58487809|NCT01328067|DEVICE|Exablate 2100|MRgFUS
58487810|NCT01328067|PROCEDURE|Myomectomy|Non-Hysteroscopic Myomectomy
58487811|NCT02702791|BEHAVIORAL|Telecoaching|Pedeometer based goals and telecoaching support
58487812|NCT02702791|OTHER|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
58487813|NCT05576636|BEHAVIORAL|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
58487814|NCT05576636|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
58487815|NCT02153749|BEHAVIORAL|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
58487816|NCT02153749|BEHAVIORAL|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
58487817|NCT01096459|PROCEDURE|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
58487818|NCT01267214|DRUG|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
58487819|NCT01267214|PROCEDURE|Osteotomy alone|no injection
58487820|NCT02354196|PROCEDURE|CCTA|CT of heart to assess coronary disease
58487821|NCT02252796|RADIATION|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
58487822|NCT02252796|DRUG|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
58487823|NCT02252796|DRUG|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
58487824|NCT02252796|RADIATION|Image-guided IMRT|Given during chemo-radiation phase
58487825|NCT06005207|DRUG|progesterone vaginal sustained-release gel|90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
58487826|NCT02948634|DEVICE|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
58487827|NCT02948634|DEVICE|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
58487828|NCT02211170|DRUG|BIBR 796 BS, low dose|
58487829|NCT02211170|DRUG|BIBR 796 BS, high dose|
58487830|NCT02211170|DRUG|Placebo|
58487831|NCT02211170|DRUG|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
58487832|NCT00726011|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
58487833|NCT04240548|RADIATION|Regional Nodal Irradiation|
58487834|NCT05272501|BEHAVIORAL|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
58487835|NCT00238641|DRUG|Botulinum Toxin type B|
58487836|NCT02611583|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation
58487837|NCT02612519|DEVICE|Alfapump|Implantation of Alfapump
58487838|NCT02612519|DEVICE|TIPS|Implantation of TIPS
58487839|NCT02469311|OTHER|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
58487840|NCT02469311|OTHER|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
58487841|NCT03888417|DEVICE|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
58487842|NCT01424215|DRUG|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
58487843|NCT02885025|DIETARY_SUPPLEMENT|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
58487844|NCT02885025|DRUG|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
58487845|NCT02885025|DIETARY_SUPPLEMENT|broccoli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
58487846|NCT02885025|DRUG|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
58487847|NCT05067699|DIAGNOSTIC_TEST|Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)|The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
58487848|NCT05243732|BEHAVIORAL|Mindful Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness."
58487849|NCT05243732|BEHAVIORAL|Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given"
58487850|NCT04808661|PROCEDURE|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
58487851|NCT04808661|DRUG|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
58487852|NCT03256916|DRUG|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
58487853|NCT03256916|DRUG|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
58487854|NCT03256916|RADIATION|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
58487855|NCT05982405|OTHER|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
58487856|NCT05982405|OTHER|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
58487857|NCT02446119|DEVICE|EndoFLIP|Measurement of pyloric resistance and compliance
58487858|NCT00740311|DEVICE|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
58487859|NCT04858022|BEHAVIORAL|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
58487860|NCT04858022|OTHER|No treatment - waitlist|10-week period of no treatment
58487861|NCT04788706|OTHER|Low level Laser Therapy and Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
58487862|NCT04788706|OTHER|Placebo Laser and Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
58487863|NCT04788706|OTHER|Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
58487864|NCT04788706|OTHER|Placebo Laser and Placebo Laser plus Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
58487865|NCT02722083|DRUG|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
58487866|NCT02722083|DRUG|Placebo|placebo tablet, single dose, orally
58487867|NCT02602210|DRUG|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
58487868|NCT02602210|DRUG|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
58487869|NCT01993121|OTHER|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
58487870|NCT00540085|DRUG|Rocuronium|0.6 mg/kg given intravenously before intubation
58487871|NCT05139004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
58487872|NCT05139004|BIOLOGICAL|Basiliximab|Given IV
58487873|NCT05139004|DRUG|Fludarabine Phosphate|Given IV
58487874|NCT05139004|DRUG|Indium In 111-DOTA-Basiliximab|Given IV
58487875|NCT05139004|DRUG|Melphalan|Given IV
58487876|NCT05139004|BIOLOGICAL|Palifermin|Given IV
58487877|NCT05139004|RADIATION|Total Lymphoid Irradiation|Undergo TMLI
58487878|NCT05139004|RADIATION|Total Marrow Irradiation|Undergo TMLI
58487879|NCT05139004|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
58487880|NCT04670367|BEHAVIORAL|Walk 30mins|aerobic exercise
58487881|NCT04670367|BEHAVIORAL|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
58487882|NCT04670367|OTHER|usual care|routine care
58487883|NCT04670367|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
58487884|NCT05322395|DIAGNOSTIC_TEST|ESC 0/1 hour troponin pathway|randomisation to 0/1 versus 0/3 hour pathway
58487885|NCT05243511|DEVICE|Digital ACT|Participants in this arm receive Digital ACT as well as standard of care.
58487886|NCT05243511|OTHER|Digital Symptom Tracker|Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
58487887|NCT01583296|BEHAVIORAL|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
58487888|NCT01583296|BEHAVIORAL|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
58487889|NCT05417919|OTHER|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
58487890|NCT02897856|DRUG|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
58487891|NCT02897856|DRUG|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
58487892|NCT04591353|DRUG|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
58487893|NCT04591353|DRUG|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
58487894|NCT02991872|PROCEDURE|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
58487895|NCT05751603|DRUG|sugammadex|sugammadex is administered just after extubation
58487896|NCT02470650|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
58487897|NCT02470650|DRUG|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
58487898|NCT02470650|DRUG|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
58487899|NCT02470650|DRUG|Ritonavir|Ritonavir 100 mg recovered tablet once a day
58487900|NCT02470650|DRUG|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
58487901|NCT02470650|DRUG|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
58487902|NCT00534482|BEHAVIORAL|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
58487903|NCT00534482|BEHAVIORAL|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
58487904|NCT00534482|BEHAVIORAL|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
58487905|NCT00534482|BEHAVIORAL|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
58487906|NCT01940796|DRUG|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
58487907|NCT01469715|DEVICE|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
58487908|NCT00241839|DRUG|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
58487909|NCT00241839|DRUG|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
58487910|NCT00241839|DRUG|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
58487911|NCT00241839|DRUG|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
58487912|NCT01033448|DRUG|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
58487913|NCT01033448|DRUG|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
58487914|NCT02127697|DRUG|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
58487915|NCT02127697|DRUG|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
58487916|NCT02127697|DRUG|salbutamol/ albuterol|Taken as rescue medication
58487917|NCT01538758|OTHER|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
58487918|NCT01538758|OTHER|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
58487919|NCT00675610|BEHAVIORAL|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
58487920|NCT03860493|PROCEDURE|Perfusion evaluation with indocyanine green|"1. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs."
58487921|NCT05675969|OTHER|Blood sample|Collection of 2 additional tubes of 4.5mL of citrate blood
58487922|NCT00558649|BIOLOGICAL|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
58487923|NCT05829226|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
58487924|NCT05829226|DRUG|Venetoclax|Bcl-2 inhibitor
58487925|NCT05829226|DRUG|Azacitidine|Hypomethylating agent
58487926|NCT05829226|DRUG|Decitabine|Hypomethylating agent
58487927|NCT04510441|OTHER|Nil intervention|Nil intervention; retrospective cohort study
58487928|NCT01000792|DRUG|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
58487929|NCT01000792|DRUG|Levocetirizine|Levocetirizine
58487930|NCT00041743|BEHAVIORAL|Group Cognitive Behavioral Therapy|
58487931|NCT04690452|BEHAVIORAL|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
58487932|NCT03071042|DRUG|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
58487933|NCT03071042|DRUG|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
58491088|NCT00498771|BEHAVIORAL|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
58491089|NCT01719497|DRUG|[C-11]OMAR|PET radioligand
58487934|NCT04822506|PROCEDURE|Routine perioperative management and PEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Preoperation:RN 6 + RN 4 +ST30 + ST 36+ Hegu (bilateral),De qi, electroacupuncture, continuous wave, 5Hz, 30min before surgery at 19:00 PM Inoperatively: LI 4+ PC 6 + ST36 + GB 34 (bilateral) ,Deqi, electroacupuncture with density wave, 2/100Hz, 30 minutes before operation to the end of the operation Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
58487935|NCT04822506|PROCEDURE|Routine perioperative management and postEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
58487936|NCT06290570|DIAGNOSTIC_TEST|12-Lead ECG|A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.
58487937|NCT06290570|DIAGNOSTIC_TEST|Apple Smart Watch Single Lead ECG|A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.
58487938|NCT06290570|DIAGNOSTIC_TEST|AliveCor KardiaMobile 6-Lead ECG|A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
58487939|NCT04919200|DIAGNOSTIC_TEST|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
58487940|NCT04670471|DRUG|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
58487941|NCT04670471|DRUG|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
58487942|NCT02676141|OTHER|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
58487943|NCT03956446|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
58487944|NCT03956446|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
58487945|NCT03956446|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
58487946|NCT05895812|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
58487947|NCT05467969|BEHAVIORAL|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
58487948|NCT02019797|DRUG|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
58487949|NCT01506804|OTHER|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
58487950|NCT02550834|OTHER|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
58487951|NCT03016052|BEHAVIORAL|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
57785260|NCT05350085|DRUG|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
58487952|NCT01576900|BEHAVIORAL|SyBeMeP (Systemized Behavioural Modification education Program)|"* Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
58487953|NCT03254589|DRUG|Methotrexate|See arm descriptions
58487954|NCT03254589|DRUG|Sulfasalazine|See arm description
58487955|NCT03254589|DRUG|Other DMARDs|See arm
58487956|NCT02131649|DEVICE|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
58487957|NCT01818011|DRUG|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
58487958|NCT01818011|DRUG|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
58487959|NCT01818011|DRUG|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
58487960|NCT01818011|DRUG|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
58487961|NCT01818011|DRUG|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
58487962|NCT01818011|DRUG|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
58487963|NCT01818011|DRUG|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
58487964|NCT04433416|DIAGNOSTIC_TEST|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
58487965|NCT02353624|BEHAVIORAL|Cycling|Cycling distance of 2880 km in 14 days
58487966|NCT00221117|DEVICE|Neuroprosthesis-FES Therapy|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
58487967|NCT00221117|OTHER|Conventional Ocupational Therapy (COT)|Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
58487968|NCT05219552|BEHAVIORAL|personalized lactation support|Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
58487969|NCT04350762|DIETARY_SUPPLEMENT|Protein shake + Fish Oil|2 shakes of protein as well as 1 fish oil daily.
58487970|NCT06411314|COMBINATION_PRODUCT|Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
58487971|NCT06411314|DRUG|Lactulose 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
58487972|NCT06411314|DRUG|Pimafucin® (natamycin) 100 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
58487973|NCT02560545|DRUG|Cannabis oil|Cannabis oil 20% THC
58487974|NCT01792752|BEHAVIORAL|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
58487975|NCT01792752|BEHAVIORAL|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
58487976|NCT01792752|BEHAVIORAL|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
58487977|NCT01792752|BEHAVIORAL|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
58491090|NCT01684813|DRUG|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
58487978|NCT01792752|BEHAVIORAL|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
58487979|NCT02605460|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
58487980|NCT02605460|DRUG|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
58487981|NCT02605460|DRUG|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
58487982|NCT02605460|PROCEDURE|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
58487983|NCT01651637|DRUG|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
58487984|NCT06400381|BEHAVIORAL|Mindfulness|There are many mindfulness-based interventions protocol that can be implemented and practice by healthcare organization. In the current study, the intervention protocol the investigators will use is based on Smiths version of mindfulness meditation (Smith, 2005). This version is compromised of several components includes being mindful of breathing, thought, sounds, taste, body scan, and sitting. The initial educational session by power point presentation will be given to the participant to explain the intervention rationale and procedure of mindfulness in daily life. In addition to giving opportunity for the participant to ask questions during the educational session.
58487985|NCT00834093|BIOLOGICAL|Epstein-Barr Virus Specific Immunotherapy|
58487986|NCT03574012|DEVICE|Monitoring Device|Use Fitbit tracker
58487987|NCT03574012|OTHER|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
58487988|NCT03574012|OTHER|Informational Intervention|Receive general health and fitness information from clinician
58487989|NCT03574012|OTHER|Questionnaire Administration|Ancillary studies
58487990|NCT01817803|DRUG|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
58487991|NCT01817803|DRUG|metolazone/no spironolactone|metolazone (add 2.5mg qod)
58487992|NCT01817803|DRUG|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
58487993|NCT01817803|DRUG|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
58487994|NCT01748513|OTHER|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
58487995|NCT02338271|OTHER|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
58487996|NCT00705549|DRUG|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
58487997|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
58487998|NCT00705549|DRUG|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
58487999|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
58488000|NCT00705549|DRUG|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
58488001|NCT00705549|DRUG|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
58488002|NCT01615913|DRUG|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
58488003|NCT01615913|DRUG|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
58488004|NCT01615913|DRUG|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
58488005|NCT04469764|DRUG|Abemaciclib|Given PO
58488006|NCT04469764|DRUG|Anastrozole|Given PO
58488007|NCT04469764|DRUG|Letrozole|Given PO
58488008|NCT01791712|PROCEDURE|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
58488009|NCT01791712|PROCEDURE|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
58488010|NCT04723277|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf)|Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
58488011|NCT04723277|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
58488012|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
58488013|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
58488014|NCT02584010|OTHER|Silicon-based aerosol|Apply twice a day over the postoperative scar
58488015|NCT02584010|OTHER|Silicon-based gel|Apply twice a day over the postoperative scar
58488016|NCT03385980|OTHER|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
58488017|NCT05080335|OTHER|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~1. TRANS- vs CIS-gender female instructors~2. With or without short videos of transgender youth embedded into the didactic \[TV or CV\]; for the group with no embedded videos \[NV\], the same videos will be shown AFTER completion of the post measures)~3. No-intervention control, in which TV will be delivered \*after\* collection of pre/post measures."
58488018|NCT01227993|DRUG|Finasteride|
58488019|NCT03862911|RADIATION|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
58488020|NCT03862911|RADIATION|Stereotactic ablative radiotherapy|"Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily"
58488021|NCT06107881|BEHAVIORAL|Low Vision Rehabilitation|Evaluation and training with magnification or visual assistive devices for visually-impaired adults
58488022|NCT06042062|DEVICE|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
58488023|NCT06042062|DEVICE|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
58488024|NCT04926389|OTHER|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
58488025|NCT04926389|OTHER|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
58488026|NCT05172908|DRUG|Dexamethasone|"5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes.~The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
58488027|NCT05172908|DRUG|Saline|"A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
58488028|NCT01103193|DRUG|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
58488029|NCT01103193|DRUG|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
58488030|NCT01524796|OTHER|No intervention. Non-interventional study|No intervention. Non-interventional study
58488031|NCT04952948|OTHER|PILATES Training|During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
58488032|NCT00594815|DRUG|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
58488033|NCT04793737|RADIATION|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
58488034|NCT04919798|DEVICE|Non-invasive bladder emptying device|The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
58488035|NCT03869697|DRUG|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
58488036|NCT04553380|DRUG|basic insulin|"1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night."
58488037|NCT01463085|OTHER|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
58488038|NCT03179319|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
58488039|NCT03749837|DEVICE|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
58488040|NCT03749837|DEVICE|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
58488041|NCT04455815|DRUG|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
58488042|NCT02293317|BIOLOGICAL|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
58488043|NCT02293317|DRUG|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
58488044|NCT02293317|OTHER|Saline|Placebo
58488045|NCT05136950|PROCEDURE|Secondary in-the-bag IOL fixation|The experimental group with secondary IOL fixated in the capsular bag
58488046|NCT05136950|PROCEDURE|Secondary ciliary sulcus IOL fixation|The control group with secondary IOL fixated in the ciliary sulcus
58488047|NCT02052999|DRUG|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
58488048|NCT02052999|OTHER|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
58488049|NCT02052999|DRUG|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
58488050|NCT00750503|BEHAVIORAL|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
58488051|NCT06405724|DRUG|Liposomal bupivacaine|133mg LB 20mL thoracic paravertebral nerve block
58488052|NCT06405724|DRUG|Ropivacaine|0.5% ropivacaine 20mL thoracic paravertebral nerve block
58488053|NCT01262196|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
58488054|NCT01262196|DRUG|Saline|Normal saline (0.9%) solution
58488055|NCT01755819|DEVICE|Biocomposite interference screw|
58488056|NCT01755819|DEVICE|Extracortical ACL Tightrope fixation|
58488057|NCT01449968|OTHER|home visit|home visit of UMG
58488058|NCT01449968|OTHER|telephone management|telephone management of the situation reported by the patient's GP
58488059|NCT03339219|DRUG|Cabozantinib|Cabozantinib tablets
58488060|NCT00404222|DRUG|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
58488061|NCT00404222|DRUG|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
58488062|NCT00404222|DRUG|Placebo|q 4 hours x 3
58488063|NCT03212144|OTHER|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
58488064|NCT03212144|OTHER|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
58488065|NCT02185495|BEHAVIORAL|Observer nodule detection|Radiologists will detect the nodules.
58488066|NCT02185495|DEVICE|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
58488067|NCT04922567|DRUG|Lenalidomide|25mg po on day 1-10
58488068|NCT04922567|DRUG|Cyclophosphamide|750mg/m² iv on day1
58488069|NCT04922567|DRUG|Doxorubicin|50mg/m² iv on day 1
58488070|NCT04922567|DRUG|Vincristine|1.4mg/m² iv on day 1
58488071|NCT04922567|DRUG|Prednisone|100mg po on day1-5
58488072|NCT02721966|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
58488073|NCT02721966|DRUG|Secukinumab and Placebo|Placebo matching AIN457
58488074|NCT05641480|DEVICE|Transcutaneous electrical acupoint stimulation&Music therapy|"Procedure: electro-acupuncture;Points: Shenting（DU24）, Benshen（BG13）, Tou Wei （ST8）.The specially-made pad is stick on pierced acupoints, until local sour and heavy feeling coming. The electric stimulator is applied to bilateral BG13 and ST8, with dilatational wave,10/50 Hz and electric current 1-5mA(milliampere).Every session lasts for 30 min per day. The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each participants in all.~Selecting the participants' music of memory and music of favourite(Music is purchased and downloaded from music stores), forming a personalized music playlist, and the decibel level is suitable for participants.~The treatment is designed based on recent literature research in 10 years, former result and expert consensus.~Other Names:~* JS-502-A Intelligent and portable electroacupuncture~* apparatus(Han's low frequency neuromodulator, made in China)"
58488075|NCT05641480|DRUG|Donepezil hydrochloride tablets or carpalatine bitartrate tablets|"① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months."
58488076|NCT03678220|DEVICE|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
58488077|NCT00643721|OTHER|dehydration|dehydration to 3% and 5% loss of total body water
58488078|NCT04509219|DRUG|Methylprednisolone Injection|methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
58488079|NCT03765034|BEHAVIORAL|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
58488080|NCT03765034|BEHAVIORAL|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
58488081|NCT03212781|DRUG|Iron dextran|total dose infusion
58488082|NCT03212781|DRUG|Ferrous Fumarate|oral tablets
58488083|NCT04682054|PROCEDURE|ocular surgery|surgery to remove the pathological eye tissue
58488084|NCT00035932|DRUG|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
58488085|NCT00035932|DRUG|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
58488086|NCT00035932|DRUG|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
58488087|NCT05741749|DEVICE|Socket Seal Abutment|Customized Healing Abutment
58488088|NCT03117140|DRUG|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
58488089|NCT03117140|DRUG|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
58488090|NCT03117140|DRUG|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
58488091|NCT03117140|DRUG|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
58488092|NCT04216264|BEHAVIORAL|Standard response|Parents pick from a menu of behavior changes
58488093|NCT04216264|BEHAVIORAL|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
58488094|NCT00183313|BEHAVIORAL|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
58488095|NCT00183313|BEHAVIORAL|Usual care|Usual care includes standard mental health services.
58488096|NCT01436929|DRUG|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
57785261|NCT05350085|DRUG|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
58488097|NCT01436929|DRUG|Placebo|Placebo 1tab bid
58488098|NCT00916331|PROCEDURE|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
58488099|NCT00916331|PROCEDURE|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
58488100|NCT01432483|DRUG|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
58488101|NCT01567540|DRUG|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
58488102|NCT00528034|PROCEDURE|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
58488103|NCT04115865|DEVICE|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
58488104|NCT05808361|OTHER|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
58488105|NCT05808361|OTHER|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
58488106|NCT01763840|DRUG|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
58488107|NCT01710319|OTHER|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
58488108|NCT02670096|DRUG|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
58488109|NCT06112886|OTHER|There was no intervention in this study|There was no intervention in this study
58488110|NCT00006206|DRUG|naltrexone (Revia)|
58488111|NCT00006206|DRUG|acamprosate (Campral)|
58488112|NCT02902146|DEVICE|Bougie|
58488113|NCT02902146|DEVICE|Endotracheal tube|
58488114|NCT00851058|BEHAVIORAL|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
58488115|NCT00851058|BEHAVIORAL|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
58488116|NCT00851058|BEHAVIORAL|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
58488117|NCT00851058|BEHAVIORAL|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
58488118|NCT04433676|OTHER|no intervention|
58488119|NCT02541604|DRUG|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
58488120|NCT00005062|RADIATION|radiation therapy|
58488121|NCT03067714|OTHER|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
58488122|NCT03067714|OTHER|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
58488123|NCT02699424|RADIATION|External radiation therapy|
58488124|NCT00002127|DRUG|Thalidomide|
58488125|NCT02350478|DRUG|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
58488126|NCT02350478|DRUG|Placebo|The subject will receive placebo orally once daily for 12 weeks.
58488127|NCT04859933|PROCEDURE|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
58488128|NCT04859933|PROCEDURE|AV-node ablation|Right sided ablation of the AV-node
58488129|NCT04628325|DRUG|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
58488130|NCT02901392|PROCEDURE|AMS-800|Artificial urianry sphincter
58488131|NCT02901392|PROCEDURE|ADVANCE/ADVANCEXP|Male sling
58488132|NCT02901392|PROCEDURE|VIRTUE|Male sling
58488133|NCT02901392|PROCEDURE|INVANCE|Male sling
58488134|NCT06170099|RADIATION|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
58488135|NCT06170099|DEVICE|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
58488136|NCT03108443|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
58488137|NCT01470118|DRUG|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
58488138|NCT01470118|DRUG|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
58488139|NCT01470118|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
58488140|NCT00158496|DRUG|pegylated interferon alpha2a|
58488141|NCT00158496|DRUG|ribavirin|
58488142|NCT05675488|DIAGNOSTIC_TEST|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
58488143|NCT05246358|DEVICE|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
58488144|NCT01869764|DRUG|omega-3 fatty acid|Given PO
58488145|NCT01869764|OTHER|placebo|Given PO
58488146|NCT01869764|OTHER|laboratory biomarker analysis|Correlative studies
58488147|NCT02009280|DRUG|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
58488148|NCT02009280|DRUG|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
58488149|NCT04976101|DEVICE|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
58488150|NCT04976101|DEVICE|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
58488151|NCT01851759|DRUG|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
58488152|NCT01851759|DRUG|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
58488153|NCT02162199|DRUG|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
58488154|NCT02162199|DRUG|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
58488155|NCT04365608|PROCEDURE|Direct laryngoscopy|standard laryngoscope with Macintosh blade
58488156|NCT04365608|PROCEDURE|Vie Scope laryngoscopy|Vie Scope with dedicated bougie stylet
58488157|NCT02483962|OTHER|Gelatine capsule|Gelatine capsules containing no active ingredients.
58488158|NCT02483962|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
58488159|NCT06344962|DEVICE|Absorbable Suture|3-0 V-Loc
58488160|NCT06344962|DEVICE|Non-absorbable Suture|3-0 Prolene
58488161|NCT01576068|OTHER|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
58488162|NCT06434142|PROCEDURE|implant overdenture|Following the two-stage surgical protocol, two dental implant fixtures with a length of 10 mm and a diameter of 3.7 mm were inserted at the canine area of the mandibular alveolar ridge.
58488163|NCT06519721|DRUG|Lenvatinib Combined with VIC-1911|"Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months."
58488164|NCT00078897|DRUG|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
58488165|NCT05318352|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
58488166|NCT06456502|DEVICE|Non-invasive neuromodulation|The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
58488167|NCT06456502|OTHER|Placebo|The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
58488168|NCT06519071|OTHER|Tryptophan Intake|Each hourly meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 Resting Energy Expenditure and adequate protein (at 1.5 g.kg.d), to maintain a metabolic steady state. The liquid shake contains protein-free powder orange-flavored drink crystals, corn oil, and water.
58488169|NCT03960996|PROCEDURE|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
58488170|NCT02903329|OTHER|Detoxification|Two ways of composing the detoxification protocol
58488171|NCT05259280|OTHER|Wellinks|Digital health and virtual care program for COPD management.
58488172|NCT00785642|DRUG|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
58488173|NCT01295164|DEVICE|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
58488174|NCT01295164|DEVICE|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
58488175|NCT06521307|DIETARY_SUPPLEMENT|Nicotinamide riboside|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
58488176|NCT06521307|OTHER|Placebo|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
58488177|NCT04421703|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
57783414|NCT05825729|DIAGNOSTIC_TEST|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
57783415|NCT02153021|RADIATION|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
57783416|NCT00004189|BIOLOGICAL|filgrastim|
57783417|NCT00004189|DRUG|becatecarin|
57783418|NCT00004189|DRUG|cisplatin|
57783419|NCT01349010|DRUG|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
57783420|NCT01349010|DRUG|Placebo|1 tablet bid. p.o for 8 weeks
57783421|NCT03692988|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
57785262|NCT05902403|OTHER|invasive mechanical ventilation|Invasive mechanical ventilation for patients admitted to the ICU
57785263|NCT00305201|DRUG|pravastatin|
57783422|NCT04133428|DRUG|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
57783423|NCT04261361|BEHAVIORAL|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
57783424|NCT04261361|BEHAVIORAL|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
57783425|NCT04261361|BEHAVIORAL|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
57783426|NCT05539391|OTHER|Data patient|Medical History and characteristic of patient
57783427|NCT05539391|OTHER|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
57783428|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
57783429|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
57783430|NCT02333929|DEVICE|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
57783431|NCT03416504|BEHAVIORAL|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
57783432|NCT03416504|BEHAVIORAL|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
57783433|NCT01988519|PROCEDURE|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
57783434|NCT01988519|PROCEDURE|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
57783435|NCT00102193|DEVICE|Adacolumn Apheresis System|
57783436|NCT00104182|DRUG|insulin detemir|
57783437|NCT00104182|DRUG|insulin NPH|
57783438|NCT00131911|DRUG|sorafenib tosylate|400 mg given orally
57783439|NCT01112150|DEVICE|NormaTec Pump|Normatec Pump
57783440|NCT03092960|BEHAVIORAL|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
57783441|NCT03092960|BEHAVIORAL|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
57783442|NCT06425705|DRUG|Silymarin|140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
57783443|NCT06425705|DRUG|Placebo|placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
57783444|NCT05486208|DRUG|LY3844583|Administered SC and/or IV.
57783445|NCT05486208|DRUG|Placebo|Administered SC and/or IV.
57783446|NCT04039802|PROCEDURE|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
57783447|NCT04039802|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
57783448|NCT00492804|PROCEDURE|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
57783449|NCT00492804|PROCEDURE|Neurectomy|Neurectomy
57783450|NCT00585559|DRUG|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
57783451|NCT00585559|DRUG|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
57783452|NCT00585559|DRUG|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
57783453|NCT00585559|DRUG|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
57783454|NCT00585559|DRUG|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
57783455|NCT05551429|BEHAVIORAL|Invitation to the CR|"1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later."
57783456|NCT05810948|BIOLOGICAL|efgartigimod IV|Intravenous (IV) infusion of efgartigimod
57783457|NCT05810948|OTHER|Placebo|Intravenous (IV) infusion of placebo
57783458|NCT00884520|DRUG|[F-18] VM4-037|"The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
57783459|NCT03347864|DRUG|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
57785264|NCT02958761|BIOLOGICAL|intraarticular injections of platelet lysate|
58488178|NCT03050385|DEVICE|transcranial direct current stimulation|
57783460|NCT01694992|OTHER|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
57783461|NCT03646045|OTHER|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
57783462|NCT04632290|DEVICE|STIMO-BSI system implantation|Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
57783463|NCT02005003|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
57783464|NCT02005003|PROCEDURE|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
57783465|NCT02005003|BIOLOGICAL|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
57783466|NCT02005003|PROCEDURE|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
57783467|NCT02005003|BEHAVIORAL|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
57783468|NCT02005003|BEHAVIORAL|Memory task|Participants perform short memory tasks on each visit
57783469|NCT02005003|BEHAVIORAL|Food consumption task|Participants are given a selection of food items to consume on each visit
57783470|NCT02027363|DRUG|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
57783471|NCT02027363|OTHER|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
57783472|NCT02175160|OTHER|Braking and functionality|
57783473|NCT03629873|DRUG|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2
57783474|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
57783475|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
57783476|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
57783477|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
57783478|NCT00401921|DRUG|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
57783479|NCT00401921|DRUG|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
57783480|NCT05259943|DRUG|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
57783481|NCT05259943|DRUG|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
57783482|NCT03862989|PROCEDURE|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
57783483|NCT02802683|DRUG|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
57783484|NCT02802683|DRUG|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
57783485|NCT02802683|DRUG|Phenylephrine|continous infusion of phenylephrine
57783486|NCT02802683|DRUG|normal saline|continous infusion of normal saline
57783487|NCT01238783|DRUG|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
57783488|NCT01238783|DRUG|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
57783489|NCT01238783|DRUG|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
57783490|NCT01238783|DRUG|Vehicle|Topical ocular dosed 3 times per day for 3 days
57783491|NCT00288873|DRUG|Ergocalciferol|
57783492|NCT00288873|DRUG|Cholecalciferol|
57783493|NCT01645332|DRUG|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
57783494|NCT01645332|DRUG|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
57783495|NCT01645332|OTHER|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
57783496|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
57783497|NCT04395768|DIETARY_SUPPLEMENT|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
57783498|NCT04395768|DRUG|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
58488179|NCT01453985|PROCEDURE|Full-Thickness-Gastroplication|
57783499|NCT04395768|DRUG|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
57783500|NCT04395768|DIETARY_SUPPLEMENT|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
57783501|NCT04395768|DIETARY_SUPPLEMENT|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
57783502|NCT04395768|DIETARY_SUPPLEMENT|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
57783503|NCT02589925|DEVICE|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
58488180|NCT03055130|OTHER|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
57783504|NCT02589925|PROCEDURE|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
57783505|NCT02589925|PROCEDURE|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
57783506|NCT02589925|PROCEDURE|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
57783507|NCT03684187|BEHAVIORAL|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
57783508|NCT05562843|BIOLOGICAL|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
57783509|NCT00141687|PROCEDURE|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
57783510|NCT00141687|PROCEDURE|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
57783511|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（Low Dose）
57783512|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（High Dose）
57783513|NCT05459220|DRUG|Placebo|Placebo for SHR0410 Injection.
57783514|NCT02985333|DRUG|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
57783515|NCT02985333|DRUG|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
57783516|NCT02985333|DRUG|Dexamethasone|Dexamethasone 20mg iv d1-4
57783517|NCT00832143|BEHAVIORAL|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
57783518|NCT02702258|BEHAVIORAL|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
57783519|NCT03013361|DRUG|Bupivacaine|Post operative pain control
57783520|NCT03013361|DRUG|Ropivacaine|Post operative pain control
57783521|NCT03013361|OTHER|Normal Saline|Acts as comparator
57783522|NCT04957940|DRUG|SMOFlipid|Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
57783523|NCT04957940|OTHER|0.9% saline|Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
57783524|NCT00663117|DRUG|Naltrexone-HCl|naltrexone 4.5 mg
57783525|NCT00663117|DRUG|Placebo|Placebo
57783526|NCT05929456|DRUG|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
57783527|NCT01238796|DRUG|telavancin|Intravenous
57783528|NCT03661229|DEVICE|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
57783529|NCT06497660|DRUG|Deoxyadrenaline|Deoxyadrenaline is a vasoactive drug
57783530|NCT06497660|DRUG|normal saline|Deoxyadrenaline is a vasoactive drug
57783531|NCT02465333|PROCEDURE|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
57783532|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
57783533|NCT00435903|DEVICE|Palm Pilot|
57783534|NCT01728038|BEHAVIORAL|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
57783535|NCT04861207|DRUG|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
57783536|NCT04311242|OTHER|Diet|Ketogenic diet
57783537|NCT03295006|DEVICE|TheraSphere|Patients who had received TheraSphere
57783538|NCT04102540|OTHER|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
57783539|NCT06047873|DEVICE|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
57783540|NCT02448836|DEVICE|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
57783541|NCT02448836|DEVICE|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
57785265|NCT02958761|DRUG|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
57783542|NCT01708187|BIOLOGICAL|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
57783543|NCT01862211|OTHER|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
57783544|NCT02266329|DRUG|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
57783545|NCT02266329|DRUG|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
57783546|NCT06054620|DIETARY_SUPPLEMENT|Collagen and Vitamin C|Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
57783547|NCT06054620|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Iso-caloric Placebo (30g maltodextrin).
57783548|NCT01734382|DRUG|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
57783549|NCT03242044|PROCEDURE|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
57783550|NCT00684983|DRUG|Capecitabine|Given PO
57783551|NCT00684983|BIOLOGICAL|Cixutumumab|Given IV
57783552|NCT00684983|DRUG|Lapatinib Ditosylate|Given PO
57783553|NCT00684983|OTHER|Quality-of-Life Assessment|Ancillary studies
57783554|NCT00394875|PROCEDURE|Treated and educated by nurses specialized in diabetes.|
57783555|NCT05139979|BEHAVIORAL|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
57783556|NCT05139979|OTHER|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
57783557|NCT04499742|RADIATION|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
57783558|NCT01426906|DRUG|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
57783559|NCT01426906|DRUG|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
57783560|NCT06304311|PROCEDURE|Routine Obstetrics care & Lamaze breathing techniques and backside massage|"Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist."
57783561|NCT01103986|BEHAVIORAL|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
57783562|NCT06476587|OTHER|Assessment of postural stability and active motion perception|"This assessment, designed to evaluate the impact of the vestibular deficit on everyday tasks, will include questionnaires and standardised clinical tests.~The questionnaires are the Fall Efficacy Scale; the Dizziness Handicap Inventory; the Oscillopsia Severity Questionnaire; the Hospital Anxiety and Depression Scale; the Hamilton Anxiety Scale; the Global Physical Activity Questionnaire; the Motion Sickness Susceptibility Questionnaire part B; and the Cambridge Depersonalization Scale.~In addition, three standardised clinical tests will be carried out: Five Times Sit to Stand Test; Tandem walking test; and Fukuda step test (50 steps).~Five specific clinical tests will also be carried out: Sit-to-stand-with-walk-and-turn; Perception of active body rotation; Perception of walking distance; Triangle Completion Task; and Gait assessment."
57783563|NCT06476587|OTHER|Cognitive tests|Four cognitive tests from the French Focus Group on Executive Functions Assessment (GREFEX) battery will be carried out: the Stroop test; the Trail Making Test; the Baddeley's dual task; and a test of Corsi's Blocks.
57783564|NCT06476587|OTHER|Eccentric axis rotation|This test, also known as the unilateral centrifugation test, provides a quantitative assessment of unilateral utricular otolith function, whereas the tests currently used (vestibular evoked myogenic potential, VEMP) only provide a qualitative assessment.
57783565|NCT06476587|OTHER|Osteodensitometry|To assess the participants' bone mineral density, the reference technique of densitometry using two-photon absorptiometry will be used.
57783566|NCT06476587|OTHER|Posturography|Participants' ability to maintain their balance will be assessed using measurements taken on the Synapsys platform. To standardise their position, they will have to stand on the platform with their feet apart, arms at their sides and look straight ahead. Volunteers will be asked to sit down between each trial. The surface area and length of the centre of pressure will be measured under open-eye balance conditions with and without image reading/exploration and dynamics. During this test, 9 balance assessment situations lasting approximately 1 minute each will be performed.
57785266|NCT03124680|COMBINATION_PRODUCT|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
57785267|NCT03124680|COMBINATION_PRODUCT|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
57785268|NCT04027335|DEVICE|leva|Vaginal device used for pelvic floor muscle exercises
57783567|NCT06476587|OTHER|Vestibulo-sympathetic regulation test|"Participants will be seated on a rotating chair in the dark. Using a virtual reality headset, three visual stimuli will be presented: (A) no visual stimulus (darkness), (B) visual stimulus corresponding to a displacement of the participant along a cylindrical trajectory, (C) visual stimulus corresponding to a displacement of the participant along a conical trajectory. These 3 types of visual stimuli will be presented alone or during an Off-Vertical Axis Rotation (OVAR) with the chair axis inclined at an angle of 10° to the vertical and a rotation speed of 60°/s.~During each sequence, blood pressure, heart rate and end-tidal carbon dioxide (CO2) will be continuously recorded using standard medical equipment."
57783568|NCT06476587|OTHER|Sleep quality assessment|"Participants will have to complete five standardised clinical questionnaires: Pittsburgh Sleep Quality Index; Spiegel questionnaire assessing sleep quality; Morningness-Eveningness questionnaire; Insomnia Severity Scale; and Epworth Sleepiness Scale.~Moreover, the activity/rest rhythm will be measured continuously by actimetry over a period of 11 days.~The volunteer will also have to wear a Somno-Art® bracelet all night long during the eleven days of monitoring to collect the volunteer's actimetry and heart rate in order to specify which sleep stage the volunteer is in and thus monitor changes in sleep stages over the course of the night.~Finally, participants will have to complete a sleep diary."
57783569|NCT06476587|OTHER|Representation of space and time assessment|"* Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity."
57783570|NCT06476587|OTHER|Influence of vestibular information on the bodily self-consciousness|"Participants will wear a virtual reality headset which allows them to be immersed in a virtual room similar in appearance to the one they are in. They will sit on a stool and hold a joystick in their hand. An avatar seen from behind, also sitting on a stool, will be presented in the centre of the virtual room approximately 2 m from them. The experimenter will touch several areas of the participant's back, over his clothes, with the end of the joystick. This movement will be reproduced by the virtual joystick in contact with the avatar's back, in two conditions: the synchronous condition, and the asynchronous condition.~After 2 min of stimulation, participants will perform a mental imagery task: a ball in the background of the virtual scene will roll towards them. After 3'', a black screen will appear and participants will have to imagine that the ball keeps moving towards them at the same speed. They will have to press the trigger when they think the ball has reached their level."
57783571|NCT06476587|OTHER|3 Tesla MRI|"The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal."
57783572|NCT06441019|DRUG|HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab|The patient will receive combined treatment with HAIC, TQB2868, and Ramucirumab. After enrollment, the patient will undergo routine hepatic artery angiography via femoral artery catheterization and placement of a hepatic artery catheter，they will then receive 150ml of 5% sodium bicarbonate + Oxaliplatin (85mg/m2) for 4-6 hours + Raltitrexed (2mg/m2) for 2-4 hours . This will be done every 3-4 weeks for at least 2 cycles. Systemic treatment will be administered every 21 days, with TQB2868 injection given on the first day of each cycle (1-7 days after HAIC). The fixed dose of TQB2868 will be 300mg, and Ramucirumab will be given at a dose of 500mg (initial intravenous infusion for 60 minutes, followed by 30 minutes if tolerated).
57783573|NCT01175538|DRUG|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
57783574|NCT01175538|DRUG|Lactulose|lactulose will be used in 30-60ml/day
57783575|NCT01144221|PROCEDURE|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
57783576|NCT00315224|BEHAVIORAL|heart-rate controlled 12 week exercise program|
57783577|NCT05594355|DRUG|TEBOFORTAN|TEBOFORTAN 240 mg is administrated 1 tablet per day
57783578|NCT05802550|OTHER|Ocular Surface Disease Index|Questionnaire on ocular surface disorders
57783579|NCT05802550|OTHER|Interferometry|Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
57783580|NCT05802550|OTHER|Oxford score|Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
57783581|NCT05802550|OTHER|Conjunctival collection|Two conjunctival prints: one for metabolomic and one for lipidomic
57783582|NCT05802550|OTHER|Aqueous humor collection|Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
57783583|NCT05802550|OTHER|Quantification of Tyndall and flare|Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
57783584|NCT01959945|BIOLOGICAL|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
57783585|NCT01959945|BIOLOGICAL|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
57783586|NCT01284777|GENETIC|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
57783587|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
57783588|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
57783589|NCT00413608|DRUG|Clopidogrel|Clopidogrel
57783590|NCT00559910|DRUG|PH-797804|PH-797804 at four dose levels
57783591|NCT00559910|DRUG|Placebo|Placebo
57783592|NCT04344834|DIAGNOSTIC_TEST|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
57783593|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
57783594|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
57783595|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
57783596|NCT05538299|BEHAVIORAL|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
57783597|NCT00099216|DRUG|Rivastigmine|
57783598|NCT00949962|DRUG|antiandrogen therapy|Given systemically
57783599|NCT00949962|DRUG|leuprolide acetate|Given subcutaneously
57783600|NCT00949962|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
57783601|NCT01799772|BEHAVIORAL|Comprehensive Behavioral Intervention|"1. Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~2. Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~3. Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~4. Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
57783602|NCT01799772|OTHER|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
57783603|NCT03587987|DEVICE|Neopff|manual ventilation
57783604|NCT03587987|DEVICE|rPap|Manual ventilation
57783605|NCT04239365|DIAGNOSTIC_TEST|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
57783606|NCT02492217|DRUG|Adalimumab|
57783607|NCT05783674|OTHER|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
57783608|NCT05783674|OTHER|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
57783609|NCT01820468|BEHAVIORAL|Adapted critical time intervention team|
57783610|NCT04082182|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
57783611|NCT04082182|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
57783612|NCT04082182|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
57783613|NCT00463541|DRUG|solifenacin succinate|oral
57783614|NCT02514564|BEHAVIORAL|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
57783615|NCT05540691|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
57783616|NCT02415218|BIOLOGICAL|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
57783617|NCT06083103|DIAGNOSTIC_TEST|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
57783618|NCT04047069|BEHAVIORAL|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
57783619|NCT04047069|BEHAVIORAL|Awareness Training|"Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)"
57783620|NCT01914367|BIOLOGICAL|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
57783621|NCT01914367|BIOLOGICAL|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
57783622|NCT04253197|DEVICE|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
57783623|NCT00553111|OTHER|educational video|educational video
57783624|NCT06352515|DIAGNOSTIC_TEST|Flow cytometry|flow cytometry to study distribution of T lymphocyte subsets in ulcerative colitis patients
57783625|NCT00000582|DRUG|factor ix|
57783626|NCT00508339|BEHAVIORAL|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
57783627|NCT06292624|DEVICE|Intermittent vacuum therapy (Weyergans High Care® Medial, Germany)|The participants' lower limb will be placed in the vacuum chamber and sealed with a cuff. The maximum negative pressure applied in the experimental group would be -40mmHg (negative pressure/ambient pressure phase: 9s / 7s). The parameters are selected based on the manufacturer's recommendations.
57783628|NCT06292624|BEHAVIORAL|Cycling exercise|The participant will perform 20 minutes of cycling exercise. Aiming at reaching a moderate exercise intensity (50% - 70%) of maximal heart rate on a gym bike.
57783629|NCT00004928|DIETARY_SUPPLEMENT|calcitriol|
57783630|NCT00004928|DRUG|zoledronic acid|
57783631|NCT00002750|DRUG|melphalan|
57783632|NCT00479596|DRUG|Botox|
57783633|NCT00001084|DRUG|Indinavir sulfate|
57783634|NCT00001084|DRUG|Lamivudine|
57783635|NCT00001084|DRUG|Stavudine|
57783636|NCT00001084|DRUG|Zidovudine|
57783637|NCT02739243|BEHAVIORAL|Tailored group intervention (PREPARE)|
57783638|NCT02739243|BEHAVIORAL|Individual treatment as usual|
57783639|NCT05884021|OTHER|Postoperative analgesia|In patients who used intravenous PCA after surgery
57783640|NCT05552690|PROCEDURE|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
57783641|NCT01314781|DRUG|solifenacin|solifenacin 5mg tablet once daily
57783642|NCT01314781|PROCEDURE|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
57783643|NCT04079283|DIAGNOSTIC_TEST|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
57783644|NCT04079283|DIAGNOSTIC_TEST|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
57783645|NCT04079283|DIAGNOSTIC_TEST|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
57783646|NCT02033460|OTHER|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
57783647|NCT02033460|OTHER|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
57783648|NCT02033460|OTHER|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
57783649|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
57783650|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
57783651|NCT06375629|DEVICE|FocalOne|The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device. This study is a non-interventional study. All the data will be collected from routine care. Data as indicated in the table below will be systematically recorded on the e-CRF to coincide with the scheduled follow-up visits at 3, 6 and 12 months.
57783652|NCT03740074|BEHAVIORAL|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
57783653|NCT01835561|DRUG|Pomalidomide|Single oral dose of 4-mg capsule
57783654|NCT01835561|DRUG|Pomalidomide|4-mg capsule
57783655|NCT05700799|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
57783656|NCT04015882|OTHER|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
57783657|NCT05398497|DEVICE|Cryoablation|Cryoablation will be performed under ultrasound guidance.
57783658|NCT00026637|DRUG|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
57783659|NCT00026637|BEHAVIORAL|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
57783660|NCT06318780|OTHER|three-phase CT angiography|three-phase CT angiography
57783661|NCT06318780|OTHER|CEUS ultrasound|CEUS ultrasound
57783662|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
57783663|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
57783664|NCT04323644|PROCEDURE|Surgery|Emergency or elective surgery
57783665|NCT04968028|PROCEDURE|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
57783666|NCT04968028|PROCEDURE|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
57783667|NCT00995358|BIOLOGICAL|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
57783668|NCT00931203|DRUG|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
57783669|NCT02899598|BIOLOGICAL|Extra blood draw samples|NEVER STARTED
57783670|NCT02899598|BIOLOGICAL|extra amniotic fluid samples|NEVER STARTED
57783671|NCT02210910|DEVICE|InSpace™ system over repair|
57783672|NCT02210910|PROCEDURE|Best Repair of torn Rotator Cuff|
57783673|NCT04421378|DRUG|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
57783674|NCT04421378|DRUG|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
57783675|NCT04421378|DRUG|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
57783676|NCT04421378|RADIATION|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
57783677|NCT04421378|DRUG|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
57783678|NCT04421378|DEVICE|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
57783679|NCT04421378|DRUG|Carmustine|Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
57783680|NCT01451060|DRUG|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
57783681|NCT01451060|DRUG|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
57783682|NCT00743743|DIETARY_SUPPLEMENT|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
57783683|NCT00743743|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo daily for 52 weeks
57783684|NCT00530192|OTHER|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
57783685|NCT05924490|BEHAVIORAL|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
57783686|NCT05924490|BEHAVIORAL|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
57783687|NCT00219141|DRUG|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
57783688|NCT00219141|DRUG|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
57783689|NCT00219141|DRUG|Aliskiren placebo|Aliskiren 150 mg placebo tablet
57783690|NCT00219141|DRUG|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
57783691|NCT06268639|PROCEDURE|Osseodensification|The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
57783692|NCT03391713|BEHAVIORAL|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
57783693|NCT01327937|DEVICE|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
57783694|NCT01327937|OTHER|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
57783695|NCT00232843|DEVICE|stent|Cordis SMART™ nitinol self-expanding stent.
57783696|NCT00232843|DEVICE|angioplasty|balloon angioplasty
57783697|NCT01007552|DRUG|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
57783698|NCT04118985|BEHAVIORAL|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
57783699|NCT04118985|BEHAVIORAL|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
57783700|NCT04531072|DRUG|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
57783701|NCT04531072|DRUG|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
57783702|NCT04537338|GENETIC|1. Characterize the immune response after infection with SARS-CoV-2|1. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
57783703|NCT03133468|DRUG|AJM347|Oral administration
57783704|NCT03133468|DRUG|Placebo|Oral administration
57783705|NCT03439696|PROCEDURE|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
57783706|NCT02026973|DRUG|Fulvestrant|
57783707|NCT02026973|DRUG|Anastrozole|
57783708|NCT02026973|DRUG|Placebo|
57783709|NCT02026973|DRUG|Somatostatin|
57783710|NCT01339494|DIETARY_SUPPLEMENT|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
57783711|NCT02487446|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
57783712|NCT02487446|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
57783713|NCT02487446|DRUG|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
57783714|NCT02487446|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
57783715|NCT04974879|DRUG|Osimertinib Oral Tablet|Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
57783716|NCT05557383|BEHAVIORAL|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
57783717|NCT01934699|DEVICE|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
57783718|NCT01934699|DEVICE|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
57783719|NCT01403389|DRUG|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
57783720|NCT01403389|DRUG|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
57783721|NCT05187598|OTHER|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
57783722|NCT05162807|BEHAVIORAL|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
57783723|NCT05162807|BEHAVIORAL|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
57783724|NCT01599416|DIETARY_SUPPLEMENT|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
57783725|NCT05266196|DRUG|Seclidemstat|Treatment assigned as per parent protocol
57783726|NCT05711238|OTHER|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
57783727|NCT05711238|OTHER|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
57783728|NCT01581879|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
57783729|NCT03048110|DRUG|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
57783730|NCT03048110|DRUG|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
58488181|NCT01809743|DRUG|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
57783731|NCT03048110|DRUG|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
57783732|NCT03472287|DRUG|Diacerein 1% Ointment|Diacerein 1% Ointment administered topically
57783733|NCT05835193|OTHER|Diagnostic Test: Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
57783734|NCT00725010|DRUG|Temozolomide|Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
57783735|NCT00725010|RADIATION|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
57783736|NCT04996069|DEVICE|Crest Whitening Emulsions|Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
57783737|NCT01691443|PROCEDURE|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
57783738|NCT05767047|DRUG|Apremilast|Oral tablets or liquid suspension
57783739|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
57783740|NCT01648179|DRUG|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
58488182|NCT01809743|DRUG|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
57783741|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
57783742|NCT01648179|DRUG|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
57783743|NCT06423586|DIETARY_SUPPLEMENT|Curcuma longa and Boswellia serrata extracts|Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
57783744|NCT04745858|OTHER|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
57783745|NCT04745858|OTHER|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
57783746|NCT02832765|RADIATION|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
57783747|NCT02832765|RADIATION|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
57783748|NCT02832765|RADIATION|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
57783749|NCT02832765|RADIATION|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
57783750|NCT00925028|DRUG|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
57783751|NCT00925028|DRUG|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
57783752|NCT00002708|PROCEDURE|surgical procedure|
57783753|NCT00002708|RADIATION|radiation therapy|
57783754|NCT00002708|RADIATION|stereotactic radiosurgery|
57783755|NCT02438462|OTHER|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
57783756|NCT00918749|DRUG|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
57783757|NCT00918749|DRUG|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
57783758|NCT00918749|DRUG|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
57783759|NCT00301002|DRUG|Alefacept|
57783760|NCT00003928|DRUG|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
57783761|NCT00003928|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
57783762|NCT01919463|BEHAVIORAL|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
57783763|NCT01919463|DEVICE|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
57783764|NCT03029780|BIOLOGICAL|Opdivo|Specified dose on specified days
57783765|NCT03029780|BIOLOGICAL|Yervoy|Specified dose on specified days
57783766|NCT03772743|OTHER|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
57783767|NCT03772743|OTHER|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
57783768|NCT00804869|DEVICE|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
57783769|NCT00804869|DEVICE|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
57783770|NCT01621282|OTHER|Education|A 6-month interactive course on critical appraisal
57783771|NCT01621282|OTHER|Conventional|Conventional method/no intervention
57783772|NCT03506217|DEVICE|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
57783773|NCT04814485|DRUG|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
57783774|NCT00351221|DRUG|rhIGF-1/rhIGFBP-3|
57783775|NCT03208400|BEHAVIORAL|virtual reality exposure|one-session exposure conveyed via virtual reality technology
57783776|NCT06451744|OTHER|Blood samples collection|50 mL blood sample
58488183|NCT01809743|DRUG|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
58488184|NCT01809743|DRUG|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
58488185|NCT01809743|DRUG|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
58488186|NCT03308370|BIOLOGICAL|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
58488187|NCT03459885|DEVICE|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
58488188|NCT03966638|PROCEDURE|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
58488189|NCT00614068|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
58488190|NCT00614068|BEHAVIORAL|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
58488191|NCT05457010|BIOLOGICAL|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
58488192|NCT05457010|BIOLOGICAL|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
58488193|NCT01607684|DEVICE|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
58488194|NCT03079843|OTHER|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
58488195|NCT03079843|OTHER|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
58488196|NCT03416543|OTHER|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
58488197|NCT01967329|DRUG|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
58488198|NCT01967329|DRUG|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
58488199|NCT01967329|DRUG|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
58488200|NCT04165694|PROCEDURE|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
58488201|NCT01655004|DRUG|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
58488202|NCT03994848|BEHAVIORAL|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
58488203|NCT05398913|DRUG|Rimonabant|Rimonabant
58488204|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|"Group A:~1. Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~2. Treatment will focus on the patient's needs and in accordance with the physicians requests.~3. Three months post initial treatment re-assessment will be conducted."
58488205|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
58488206|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
58488207|NCT03045796|DEVICE|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
58488208|NCT02795403|OTHER|blood draw of 150ml, twice|
58488209|NCT02945904|PROCEDURE|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
58488210|NCT06296329|OTHER|Rubber Hand Illusion|The traditional behavioural illusion of the Rubber Hand will be applied
57783777|NCT06451744|OTHER|Skin or mucous membrane brushing|brushing on skin or mucous membrane lesions
58488211|NCT01077050|DEVICE|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
58488212|NCT04712630|PROCEDURE|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
58488213|NCT04712630|PROCEDURE|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
58488214|NCT05368012|DRUG|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
58488215|NCT04236609|DEVICE|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
58488216|NCT04236609|DEVICE|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
58488217|NCT01079299|DEVICE|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
58488218|NCT04960657|DRUG|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
58488219|NCT04960657|DRUG|PACAP38|PACAP38 infusion
58488220|NCT04910997|OTHER|Aerobic exercise training|Combination of supervised and home-based aerobic exercise training
58488221|NCT01809119|PROCEDURE|Partial nephrectomy|
58488222|NCT00092443|BIOLOGICAL|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
58488223|NCT00092443|BIOLOGICAL|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
58488224|NCT03082625|DRUG|Transdermal Magnesium|Magnesium
58488225|NCT03082625|DRUG|Placebo|
58488226|NCT05494164|OTHER|Nigella sativa nasal oil drops|in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
58488227|NCT05494164|DRUG|standard treatment|intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
58488228|NCT01684865|DRUG|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
58488229|NCT05820191|DRUG|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
58488230|NCT04759326|OTHER|Hippotherapy|Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
58488231|NCT04759326|OTHER|Conventional Neurorehabilitation|The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
58488232|NCT03623529|DRUG|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
58488233|NCT03623529|DRUG|Placebo|Placebo Arm
58488234|NCT01212341|BIOLOGICAL|Allogeneic NK cells|
58488235|NCT02876601|DRUG|Defibrotide|6.25mg/kg bodyweight over 2h infusion
58488236|NCT02876601|DRUG|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
58488237|NCT02876601|DRUG|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
58488238|NCT02876601|DRUG|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
58488239|NCT00111852|DRUG|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
58488240|NCT00111852|DRUG|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
58488241|NCT00111852|DRUG|Placebo|Dose-Match Placebo, intravenous administration.
58488242|NCT00891670|DRUG|cilostazol|100mg twice daily for at least 1 month
58488243|NCT00891670|DRUG|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
58488244|NCT00891670|DRUG|aspirin|aspirin 100mg
58488245|NCT06369727|DRUG|MOB015B|Topcal formulation
58488246|NCT06369727|DRUG|MOB015B vehicle|Topcal formulation
58488247|NCT06369727|DRUG|Negative irritant solution of 0.9% saline|Negative control
58488248|NCT04449263|DEVICE|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
58488249|NCT04449263|DEVICE|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
58488250|NCT04449263|DEVICE|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
58488251|NCT04655352|DIETARY_SUPPLEMENT|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
58488252|NCT02149901|DRUG|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
58488253|NCT02149901|DRUG|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
58488254|NCT02149901|OTHER|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
58488255|NCT02149901|OTHER|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
58488256|NCT04021641|DIAGNOSTIC_TEST|Speech recognition in noise|Measurement of speech recognition performance in noise
58488257|NCT05060601|PROCEDURE|Gracey micro-curettes|Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
58488258|NCT05060601|PROCEDURE|Standard Gracey curettes|After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
58488259|NCT03358264|DIETARY_SUPPLEMENT|L-citrulline|Amino acid supplement
58488260|NCT04367818|PROCEDURE|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
58488261|NCT04367818|PROCEDURE|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
58488262|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
58488263|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
58488264|NCT05411952|OTHER|No intervention|Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
58488265|NCT04265105|DRUG|fluticasone-vilanterol|LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
58488266|NCT04265105|DRUG|Standard Preparation|inhaled SABA or Inhaled corticosteroid
58488267|NCT02223845|OTHER|Music|Self-selected music played via headphones
58488268|NCT04350957|DIAGNOSTIC_TEST|Low-dose Imaging|"We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations."
58488269|NCT02747498|PROCEDURE|Procedure with circumferential pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
58488270|NCT02747498|PROCEDURE|Procedure with linear ablation in addiction to pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
58488271|NCT03414931|DRUG|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
58488272|NCT03414931|DRUG|Sertraline|Use of SSRI as an active comparator
58488273|NCT03414931|DRUG|Placebo - Cap|Use of placebo as a comparator
58488274|NCT01696188|DEVICE|interscalene nerve catheter|
58488275|NCT00034268|DRUG|LY900003|
58488276|NCT04922541|DRUG|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
58488277|NCT02559804|OTHER|survival and late effects|survival and late effects
58488278|NCT04781959|DRUG|Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
58488279|NCT04781959|DRUG|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
58488280|NCT01694797|DRUG|Metoprolol Succinate|
58488281|NCT01531569|OTHER|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
58488282|NCT02668536|DRUG|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
58488283|NCT02668536|DEVICE|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
58488284|NCT01724632|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
58488285|NCT05828485|DRUG|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
57783778|NCT06451744|OTHER|Skin or mucous membrane biopsy|6 mm biopsy
58491091|NCT01684813|DRUG|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
58488286|NCT03959267|BEHAVIORAL|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
58488287|NCT03171467|PROCEDURE|Salpingectomy|
58488288|NCT05785442|DRUG|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
58488289|NCT05785442|DRUG|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
58488290|NCT03714152|DRUG|ABI-H2158|5 mg or 25 mg tablets
58488291|NCT03714152|DRUG|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
58488292|NCT04339452|DEVICE|Impella 5.0 and Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.0 Device or Impella 5.5 with SmartAssist, followed by Impella supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
58488293|NCT03644472|DRUG|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
58488294|NCT03644472|DRUG|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
58488295|NCT04145232|BIOLOGICAL|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
58488296|NCT05328349|BEHAVIORAL|Education Program|After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
58488297|NCT06248749|DRUG|IV iron|Intravenous Iron supplement
58488298|NCT05461534|BEHAVIORAL|mindfulness yoga|Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
58488299|NCT04038021|BEHAVIORAL|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
58488300|NCT04038021|BEHAVIORAL|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
58488301|NCT06256380|BEHAVIORAL|Enhanced Cognitive-behavior therapy for adolescents with an eating disorder|Psychotherapy
58488302|NCT06256380|BEHAVIORAL|Family-based therapy for adolescents with an eating disorder|Psychotherapy
58488303|NCT00088764|BEHAVIORAL|Coping skills training|8 sessions of pain and stress coping skills training
58488304|NCT00088764|BEHAVIORAL|Written emotional disclosure|4 sessions of writing about stress
58488305|NCT00088764|BEHAVIORAL|Arthritis education|8 sessions of learning about rheumatoid arthritis
58488306|NCT00088764|BEHAVIORAL|Health behavior writing|4 sessions of writing about various health behaviors
58488307|NCT00566696|DEVICE|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
58488308|NCT00566696|PROCEDURE|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
58488309|NCT00566696|DRUG|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488310|NCT00566696|DRUG|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488311|NCT00566696|DRUG|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488312|NCT00566696|DRUG|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488313|NCT00566696|DRUG|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488314|NCT00566696|DRUG|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
58488315|NCT00566696|DRUG|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488316|NCT00566696|DRUG|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488317|NCT00566696|DRUG|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
58488318|NCT00566696|DRUG|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
58488319|NCT00684008|DRUG|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
58488320|NCT00684008|DRUG|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
58488321|NCT04154189|DRUG|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
58488322|NCT04154189|DRUG|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
58488323|NCT04154189|DRUG|Etoposide|Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
58488324|NCT04154189|DRUG|Lenvatinib|Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
58488325|NCT01610934|DRUG|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
58488326|NCT01610934|DRUG|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
58488327|NCT02213861|DRUG|SHAPE|topical gel
58488328|NCT01938716|DRUG|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
58488329|NCT02411097|PROCEDURE|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
58488330|NCT01006993|DEVICE|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
58488331|NCT00056069|OTHER|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
58488332|NCT05009004|BEHAVIORAL|text messages to support medication adherence|text messages to support medication adherence
58488333|NCT06422897|OTHER|anterior segment optical coherence tomography|surgically treated corneal perforation by amniotic membrane graft and platelet rich plasma clot is assessed by anterior segment optical coherence tomography 1 month postoperative
58488334|NCT00042315|PROCEDURE|Chemotherapy|
58488335|NCT00042315|DRUG|tariquidar + vinorelbine|
58488336|NCT00042315|DRUG|placebo + vinorelbine|
58488337|NCT03454360|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
58488338|NCT01497561|DRUG|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
58488339|NCT01497561|DRUG|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
58488340|NCT03001817|DRUG|K-877|
58488341|NCT03001817|DRUG|Fenofibrate|
58488342|NCT03001817|DRUG|Placebo (for K-877)|
58488343|NCT03001817|DRUG|Placebo (for Fenofibrate)|
58488344|NCT03841201|DRUG|Lenvatinib|oral
58488345|NCT03841201|DRUG|Nivolumab|iv infusion
58488346|NCT01614483|OTHER|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
58488347|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
58488348|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
58488349|NCT00068419|DRUG|tamoxifen citrate|Given orally
58488350|NCT00068419|DRUG|sulindac|Given orally
58488351|NCT00068419|OTHER|laboratory biomarker analysis|Correlative studies
58488352|NCT02670811|DIETARY_SUPPLEMENT|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
58488353|NCT02670811|DIETARY_SUPPLEMENT|Acidified milk|150 mL daily of artificially acidified milk
58488354|NCT04316988|DIAGNOSTIC_TEST|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
58488355|NCT04101942|BEHAVIORAL|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
58488356|NCT02970903|DEVICE|VitalPAD|VitalPAD prototype device
58488357|NCT02970903|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
58488358|NCT01933685|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
58488359|NCT01933685|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
58488360|NCT06532149|DRUG|Alectinib|Alectinib 600 mg/BID
58488361|NCT06532149|DRUG|Brigatinib|180 mg/daily
58488362|NCT06532149|DRUG|Lorlatinib 100 mg|100 mg/daily
58488363|NCT06532149|DRUG|Osimertinib|80 mg/daily
58488364|NCT06532149|DRUG|Sotorasib|960 mg/daily
58488365|NCT06532149|DRUG|Dabrafenib|150 mg/BID
58488366|NCT06532149|DRUG|Trametinib|2 mg/daily
58488367|NCT06532149|DRUG|Selpercatinib|160 mg/BID
58488368|NCT06532149|DRUG|Pembrolizumab|200 mg intravenous every 21 days
58488369|NCT06532149|DRUG|Cemiplimab|350 mg intravenous every 21 days
58488370|NCT06532149|DRUG|Nivolumab|240 mg intravenous every 14 days
58488371|NCT06532149|DRUG|Carboplatin|AUC4/AU5 intravenous every 21 days
58488372|NCT06532149|DRUG|Pemetrexed|500 mg/mq intravenous every 21 days
58488373|NCT06532149|DRUG|Paclitaxel|175 mg/mq intravenous every 21 days
58488374|NCT03812276|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
58488375|NCT06453889|DEVICE|Multimode thermal therapy|The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
58488376|NCT02283762|DRUG|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
58488377|NCT02283762|DRUG|Placebo|Sham-titration
58488378|NCT01036048|DEVICE|drug eluting stent|pts with cabg disease treated with drug eluting stent
58488379|NCT01036048|DEVICE|bare metal stent|pts with cabg disease treated with bare metal stent
58488380|NCT04411732|DEVICE|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
58488381|NCT04411732|DIAGNOSTIC_TEST|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
58488382|NCT04411732|DIAGNOSTIC_TEST|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
58488383|NCT04411732|DIAGNOSTIC_TEST|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
58488384|NCT06444841|BEHAVIORAL|Digital - Google Calendar|"Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm)."
58488385|NCT06444841|BEHAVIORAL|Paper-based - Memory Support System|The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
58488386|NCT04466670|DRUG|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
58488387|NCT04466670|DRUG|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
58488388|NCT03126513|PROCEDURE|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
58488389|NCT03590041|BEHAVIORAL|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
58491092|NCT04297527|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
58488390|NCT03590041|BEHAVIORAL|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
58488391|NCT04417699|DRUG|TAS 102|Oral medication over Days 1-5
58488392|NCT04417699|DRUG|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
58488393|NCT04473287|OTHER|reflexology practice|Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
58488394|NCT02061371|OTHER|virtual therapy|
58488395|NCT02061371|OTHER|conventional physiotherapy|
58488396|NCT05330299|BEHAVIORAL|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
58488397|NCT06165289|OTHER|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
58488398|NCT02433470|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
58488399|NCT01966848|DEVICE|Wich prosthesis is used|
58488400|NCT04460001|DRUG|Ranibizumab|Intravitreal
58488401|NCT04460001|DRUG|Ranibizumab|Intravitreal
58488402|NCT04460001|DRUG|triamcinolone acetate|intravitreal
58488403|NCT03078218|DIAGNOSTIC_TEST|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
58488404|NCT04326283|DRUG|Trametinib (0.5 mg)|0.5 mg/day
58488405|NCT04326283|DRUG|Trametinib (1 mg)|1 mg/day
58488406|NCT04326283|DRUG|Riluzole (100 mg)|100 mg/day (50 mg twice)
58488407|NCT02400385|DRUG|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
58488408|NCT02400385|DRUG|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
58488409|NCT00654550|DRUG|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
58488410|NCT04014517|OTHER|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
58488411|NCT04014517|DIETARY_SUPPLEMENT|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
58488412|NCT04160754|BEHAVIORAL|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
58488413|NCT04160754|BEHAVIORAL|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
58488414|NCT04049149|OTHER|Biogenetic explanation and endocrinologist intensive managment|"* JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires"
58488415|NCT04049149|OTHER|Usual care management|"* JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires"
58488416|NCT04328077|DRUG|TERN-101|Investigational drug
58488417|NCT04328077|OTHER|Placebo|Matching placebo
58488418|NCT03944317|DRUG|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
58488419|NCT03944317|DRUG|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
58488420|NCT06437743|DEVICE|Nociception Level (NoL) Monitor|The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.
58488421|NCT04989868|PROCEDURE|Trans-Nasal Afferent Loop Decompression|A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (\<3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
58488422|NCT04989868|PROCEDURE|Without Trans-Nasal Afferent Loop Decompression|No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
58488423|NCT03124004|PROCEDURE|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
58488424|NCT00387790|DRUG|motexafin gadolinium|Given IV
58488425|NCT00387790|RADIATION|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
58488426|NCT02941718|BEHAVIORAL|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
58488427|NCT02941718|BEHAVIORAL|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
58488428|NCT00229567|DRUG|Lidocaine infusion plus ketamine injection|
58488429|NCT04002492|BEHAVIORAL|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
58488430|NCT03070964|DRUG|plitidepsin|
58488431|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 1g|Ginseng extract 1g, parallel design
58488432|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 3g|Ginseng extract 3g, parallel design
58488433|NCT02763280|DIETARY_SUPPLEMENT|Placebo|placebo, parallel design
58488434|NCT02510560|DRUG|NTRA-2112|
58488435|NCT02510560|DRUG|Placebo|
58488436|NCT00239330|DRUG|Rosuvastatin|
58488437|NCT00239330|DRUG|Atorvastatin|
58488438|NCT03951662|OTHER|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level \>3mg/dL and AST level\>50U/L
58488439|NCT03951662|OTHER|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
58488440|NCT02781259|PROCEDURE|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
58488441|NCT02781259|DRUG|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
58488442|NCT02781259|DEVICE|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
58488443|NCT02087696|DRUG|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
58488444|NCT00392769|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
58488445|NCT01160822|BIOLOGICAL|Canakinumab|Intra-articular injection
58488446|NCT01160822|DRUG|Placebo to canakinumab|Intra-articular injection
58488447|NCT01160822|DRUG|Naproxen|Tablets for oral administration
58488448|NCT01160822|DRUG|Placebo to Naproxen|Tablets for oral administration
58488449|NCT05775276|PROCEDURE|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
58488450|NCT03419923|DRUG|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
58488451|NCT03419923|DRUG|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
58488452|NCT03212313|DRUG|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
58488453|NCT03031015|DEVICE|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
58488454|NCT03031015|DEVICE|Plating|Fractures were reduced and then fixed with Plate.
58488455|NCT05384431|DIETARY_SUPPLEMENT|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
58488456|NCT05384431|OTHER|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
58488457|NCT04000854|DRUG|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
58488458|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
58488459|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
58488460|NCT06143904|DRUG|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
58488461|NCT02891135|OTHER|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
58488462|NCT00986037|DRUG|ABT-308|Single IV doses
58488463|NCT00986037|DRUG|ABT-308|Multiple SC doses x 3
58488464|NCT00986037|DRUG|Placebo|Single IV dose
58488465|NCT00986037|DRUG|Placebo|Multiple SC doses x 3
58488466|NCT00751608|DRUG|APL180|
58488467|NCT00751608|DRUG|APL180|
58488468|NCT00751608|DRUG|Placebo|
58488469|NCT04885777|DRUG|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
58491093|NCT04297527|PROCEDURE|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
58488470|NCT04885777|OTHER|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
58488471|NCT02052492|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
58488472|NCT06013046|BEHAVIORAL|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
58488473|NCT06013046|BEHAVIORAL|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
58488474|NCT01607255|DRUG|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
58488475|NCT01607255|PROCEDURE|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
58488476|NCT01607255|PROCEDURE|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
58488477|NCT01607255|PROCEDURE|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
58488478|NCT03605485|DEVICE|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
58488479|NCT06062342|BEHAVIORAL|FPI|The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
58488480|NCT03319758|PROCEDURE|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
58488481|NCT05346666|DRUG|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
58488482|NCT00805337|DEVICE|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
58488483|NCT00351429|DEVICE|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
58488484|NCT00123422|BEHAVIORAL|Breathing retraining|exercise training with computerized training program
58488485|NCT00123422|BEHAVIORAL|Heliox|exercise training with a helium oxygen combination
58488486|NCT00123422|BEHAVIORAL|Exercise|exercise training
58488487|NCT02616796|BEHAVIORAL|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
58488488|NCT06015152|DRUG|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|\[ARAZLO\]
58488489|NCT05270252|OTHER|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright \& Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
58488490|NCT04207632|DRUG|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
58488491|NCT03931252|DIETARY_SUPPLEMENT|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
58488492|NCT03931252|DIETARY_SUPPLEMENT|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
58488493|NCT03131609|OTHER|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
58488494|NCT03131609|OTHER|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
58488495|NCT03131609|OTHER|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
58488496|NCT03131609|OTHER|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
58488497|NCT01047553|DRUG|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
58488498|NCT01623050|DEVICE|SinuSys Dilation System|Sinuplasty
58488499|NCT04141436|BEHAVIORAL|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
58488500|NCT04141436|OTHER|Routine clinical procedure|Routine clinical procedure
58488501|NCT02425943|DEVICE|injectable poly-L-lactic acid Sculptra Aesthetic|
58488502|NCT05053204|OTHER||
58488503|NCT02518295|OTHER|Positive control|200ml milk containing 18g lactose
58488504|NCT02518295|OTHER|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
58488505|NCT02518295|OTHER|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
58488506|NCT02518295|OTHER|Negative control|200 ml of UHT Lactose free milk
58488507|NCT03766152|DEVICE|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
58488508|NCT02745080|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
58488509|NCT02745080|BIOLOGICAL|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
58488510|NCT00235365|BEHAVIORAL|meta-cognitive therapy|Meta-cognitive therapy
58488511|NCT00235365|OTHER|waiting list|waiting list control
58488512|NCT00215839|DRUG|Peginterferon a-2a plus Ribavirin|
58488513|NCT06016777|PROCEDURE|Ultrasound-guided paraspinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided paraspinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
58488514|NCT06016777|PROCEDURE|Ultrasound-guided erector spinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided erector spinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
58488515|NCT06016777|PROCEDURE|Patient-controlled intravenous analgesia pump|Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
58488516|NCT01694407|DRUG|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
58488517|NCT01694407|DRUG|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
58488518|NCT01694407|DRUG|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
58488519|NCT01694407|DRUG|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
58488520|NCT05785676|DEVICE|Filter implantation|Implantation of OATF ALN vena cava filter
58488521|NCT01039883|DRUG|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
58488522|NCT01039883|DRUG|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
58488523|NCT06140862|OTHER|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
58488524|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
58488525|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
58488526|NCT01976741|DRUG|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
58488527|NCT05699694|DIETARY_SUPPLEMENT|StemRegen product|"Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible:~Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance."
58488528|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL|One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
58488529|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL|One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
58488530|NCT03433040|DRUG|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
58488531|NCT03064061|DEVICE|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
58488532|NCT04730219|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
58488533|NCT04730219|DRUG|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
58488534|NCT02167139|DRUG|Humira (adalimumab)|
58488535|NCT02167139|DRUG|SB5 (proposed biosimilar to adalimumab)|
58488536|NCT00850239|DRUG|dutogliptin|400 mg
58488537|NCT00850239|DRUG|placebo|
58488538|NCT05985369|OTHER|Controlled diet and resistance exercise|Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
58488539|NCT03048578|DRUG|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
58488540|NCT03048578|DRUG|Placebo|Subcutaneous Saline Solution
58488541|NCT06413849|OTHER|Telephone coached graphic narrative bibliotherapy|Eight weekly sessions of telephone coached graphic narrative bibliotherapy
58488542|NCT06413849|OTHER|Control group|Reading educational booklet
58488543|NCT01994096|DRUG|Caspofungin|
58488544|NCT05997303|OTHER|Continuous norepinephrine infusion via an infusion pump|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
58488545|NCT05997303|OTHER|Manual bolus norepinephrine administration|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
58488546|NCT04722419|OTHER|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
58488547|NCT05613465|DRUG|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
58488548|NCT05613465|DRUG|Placebo|Placebo is packaged in the same package as the drug
58488549|NCT00254696|DRUG|Extended-Spectrum-Lactamases (ESBLs)|
58488550|NCT05475080|DRUG|Antiplatelet Drug|Any antiplatelet drug or combination
58488551|NCT05475080|DRUG|Anticoagulant|Any anticoagulante
58488552|NCT05475080|PROCEDURE|Endovascular|Angioplasty +- stent
58488553|NCT05475080|PROCEDURE|Surgery|Endarterectomy
58488554|NCT01636518|PROCEDURE|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
58488555|NCT01280708|OTHER|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
58488556|NCT05039983|OTHER|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 30 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
58488557|NCT04968769|OTHER|ischemic compression|manual therapy
58488558|NCT04968769|OTHER|kinesio taping|elastic therapeutic taping
58488559|NCT04968769|OTHER|exercise|posture exercises
58488560|NCT04282408|DEVICE|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
58488561|NCT03658681|OTHER|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
58488562|NCT03658681|OTHER|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
58488563|NCT04600661|OTHER|Traditional exercise therapy|Neuromuscular training
58488564|NCT01963416|DIETARY_SUPPLEMENT|macro- and micro-nutrient matched control (240 ml)|
58488565|NCT01963416|DIETARY_SUPPLEMENT|Orange juice|
58488566|NCT01963416|DIETARY_SUPPLEMENT|whole orange fruit|
58488567|NCT01963416|DIETARY_SUPPLEMENT|Processed whole orange|
58488568|NCT02554461|OTHER|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
58488569|NCT04462627|DIAGNOSTIC_TEST|Blood group determination|Determination of the blood group (ABO/LE)
58488570|NCT04462627|DIAGNOSTIC_TEST|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
58488571|NCT04462627|DIETARY_SUPPLEMENT|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
58488572|NCT04857164|DRUG|Pembrolizumab combined with Chemotherapy|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
58488573|NCT01168037|DEVICE|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
58488574|NCT01168037|PROCEDURE|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
58488575|NCT00574522|RADIATION|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
58488576|NCT06237504|DEVICE|SaCoVLM™|Patients will receive general anesthesia with their airways maintained with the SaCoVLM, which is a newer supraglottic airway device with a video port to directly visualize the upper airway.
58488577|NCT06237504|DEVICE|Ambu®Auragain™|Patients will receive general anesthesia with their airways maintained with the Ambu Auragain, which is a conventional 2nd generation supraglottic airway device.
58488578|NCT04195893|DEVICE|somofilcon A|Contact Lens
58488579|NCT04195893|DEVICE|etafilcon A|Contact Lens
58491094|NCT00410098|BEHAVIORAL|Bikram Yoga|
58488580|NCT01010867|DRUG|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10\^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
58488581|NCT06378216|DIAGNOSTIC_TEST|neurocognitive evaluations|clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
58488582|NCT00395668|DEVICE|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
58488583|NCT04946981|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
58488584|NCT04946981|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
58488585|NCT06266832|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
58488586|NCT06266832|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1, Q3W
58488587|NCT06266832|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W
58488588|NCT06266832|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
58488589|NCT06266832|PROCEDURE|Biopsy|local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
58488590|NCT02502617|DIETARY_SUPPLEMENT|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
58488591|NCT05326269|DRUG|Terbutaline|Subcutaneous injection
58488592|NCT06208943|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
58488593|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
58488594|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
58488595|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
58488596|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
58488597|NCT05577117|DRUG|Dexmedetomidine|drugs are injected with induction of general anesthesia
58488598|NCT01630538|DRUG|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
58488599|NCT01493076|DEVICE|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
58488600|NCT04287270|OTHER|Assesment|Evaluations which explained in the arms section will be made as described.
58488601|NCT04133688|DEVICE|ASC|mobile app
58488602|NCT06288100|OTHER|Observation|"1. Measure changes in tibial slope after medial opening wedge High tibial osteotomy in Skeletally mature patient with unicompartmental osteoarthitis and genuvarus knee~2. Evaluate the effect of tibial slope angle change on the clinical outcome at 1 year ."
58488603|NCT04953728|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
58488604|NCT02231931|DRUG|Digoxin|single dose, fasted
58488605|NCT02231931|DRUG|Rosuvastatin|single dose, fasted
58488606|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
58488607|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
58488608|NCT02231931|DRUG|Metformin hydrochloride|single dose, fasted
58488609|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
58488610|NCT02231931|DRUG|Furosemide|single dose, fasted
58488611|NCT05404932|DRUG|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
58488612|NCT00267566|BEHAVIORAL|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
58488613|NCT03164239|BEHAVIORAL|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
58488614|NCT04080167|BEHAVIORAL|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
58491095|NCT00357669|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
58491096|NCT00357669|DRUG|Brivaracetam 50 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
58488615|NCT04080167|BEHAVIORAL|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
58488616|NCT00568386|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
58488617|NCT00568386|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
58488618|NCT05343624|DEVICE|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
58488619|NCT00124514|DRUG|Triptorelin pamoate|IM injection given monthly
58488620|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
58488621|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
58488622|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
58488623|NCT00124514|OTHER|placebo|placebo 0.9% normal saline IM injection
58488624|NCT01539460|PROCEDURE|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
58488625|NCT05225805|DRUG|Lefamulin|Antibiotic
58488626|NCT00851227|DRUG|conivaptan hydrochloride|intravenous
58488627|NCT06364488|DEVICE|TrueBlue App|The use of the TrueBlue App, to generate automated measures of mood that can be assessed for agreement with validated clinical scales eg. PHQ9.
58488628|NCT02597478|DRUG|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
58488629|NCT02597478|PROCEDURE|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
58488630|NCT02597478|BEHAVIORAL|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
58488631|NCT02597478|BEHAVIORAL|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
58488632|NCT02597478|BEHAVIORAL|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
58488633|NCT00839319|DRUG|Acyline|300 ug/kg subcutaneous injections on Day 1.
58488634|NCT00839319|OTHER|placebo hCG (no active ingredient)|placebo hCG
58488635|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
58488636|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
58488637|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
58488638|NCT00839319|DRUG|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
58488639|NCT06230211|OTHER|Music Therapy|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
58488640|NCT06230211|OTHER|Maternal Voice|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
58488641|NCT03838432|DEVICE|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
58488642|NCT03959176|DRUG|Brimonidine|2 drops administered once in the left eye in both study arms
58488643|NCT03959176|DRUG|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
58488644|NCT03959176|DRUG|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
58488645|NCT04153396|DRUG|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
58488646|NCT04153396|DRUG|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
58488647|NCT03820895|DIAGNOSTIC_TEST|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
58488648|NCT02795702|DEVICE|tDCS|Transcranial direct current stimulation
58488649|NCT02795702|BEHAVIORAL|training|Cognitive training
58488650|NCT03261752|DIAGNOSTIC_TEST|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
58488651|NCT02694692|PROCEDURE|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
58488652|NCT02694692|BEHAVIORAL|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
58488653|NCT03221153|PROCEDURE|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
58488654|NCT00863226|DEVICE|Resonator Device|Application of Magnetic Fields Using the Resonator Device
58488655|NCT00345748|DRUG|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
58488656|NCT00345748|DRUG|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
58488657|NCT04182646|DEVICE|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
58488658|NCT02519985|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
58488659|NCT04723797|OTHER|Physical activity|Physical activity program consisting of running and/or cycling
58488660|NCT00597324|PROCEDURE|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
58488661|NCT00004366|PROCEDURE|Physical therapy|
58488662|NCT02693132|BEHAVIORAL|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
58488663|NCT02693132|BEHAVIORAL|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
58488664|NCT02693132|BEHAVIORAL|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
58488665|NCT04539769|PROCEDURE|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
58488666|NCT04539769|PROCEDURE|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
58488667|NCT04539769|PROCEDURE|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
58488668|NCT05155514|PROCEDURE|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
58488669|NCT02118441|DEVICE|Ultrasound-guided Radial Artery Catheter Insertion|
58488670|NCT02118441|DEVICE|Direct Palpation-guided Radial Artery Catheter insertion|
58488671|NCT06310941|DEVICE|Mechanical insufflation-exsufflation|Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection
58488672|NCT06310941|OTHER|Standard of Care|systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines
58488673|NCT06310941|OTHER|Hypertonic saline with hyaluronic acid|Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
58488674|NCT01339572|DRUG|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~1. Pre-apheresis peripheral blood CD34+ count \<20 cells/μL on day 5.~2. Estimated CD34+ cell collection is \< 25% of target cell dose after 1 day of apheresis.~3. Estimated CD34+ cell collection is \< 50% of target cell dose after 2 days of apheresis."
58488675|NCT01339572|DRUG|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID."
58488676|NCT01341613|DIETARY_SUPPLEMENT|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
58488677|NCT01341613|DIETARY_SUPPLEMENT|Placebo capsule|Twice per day (BID), 9 weeks
58488678|NCT04151576|OTHER|aromatherapy massage|aromatherapy massage
58488679|NCT02118961|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
58488680|NCT02118961|BIOLOGICAL|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
58488681|NCT05475756|DEVICE|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
58488682|NCT05475756|DEVICE|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
58488683|NCT03339843|DRUG|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
58488684|NCT05791019|OTHER|Paleolithic diet effect on patients|Efficacy of paleolithic diet in control of blood level of glucose in type 2 DM patients
58488685|NCT04482452|PROCEDURE|Colonoscopy|Diagnostic colonoscopy will be performed
58488686|NCT00224991|PROCEDURE|Intensive systematic information (osteoporosis school)|
58488687|NCT00343941|DRUG|Tucaresol tablets 25 mg|
58488688|NCT03053167|DRUG|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
58488689|NCT03053167|DRUG|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
58488690|NCT00647959|DRUG|Doxycycline Tablets, 150mg|150mg, single dose fasting
58488691|NCT00647959|DRUG|Adoxa Tablets 150 mg|150mg, single dose fasting
58488692|NCT03401814|OTHER|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
58488693|NCT03446404|DIAGNOSTIC_TEST|Standing Computed Tomography|Provides weight bearing 3D view of knees.
58488694|NCT01781299|DEVICE|AlloDerm RTU|
58488695|NCT01781299|DEVICE|SurgiMend PRS|
58488696|NCT00557856|DRUG|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
58488697|NCT05357248|DEVICE|BT-NCBT-00X|the intervention group will consist of 20 patients to receive the BT-NCBT-00X treatment for 90 days. They will receive a baseline MRI-PDFF, Fibroscan and have the tests repeated at 90 days.
58488698|NCT01571518|DRUG|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
58488699|NCT01571518|DRUG|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
58488700|NCT00556504|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
58488701|NCT00556504|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
58488702|NCT00556504|DRUG|Ribavirin|conventional treatment of Hepatitis C
58488703|NCT00556504|DRUG|Placebo|Placebo, without acting ingredient.
58488704|NCT03478098|OTHER|Low GI mealtest|Meal with low glycaemic index (GI) is consumed over 20 min
58488705|NCT03478098|OTHER|Low GI mealtest and subsequent exercise|Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
58488706|NCT03478098|OTHER|High GI mealtest|Meal with high glycaemic index (GI) is consumed over 20 min
58488707|NCT03478098|OTHER|High GI mealtest and subsequent exercise|Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
58488708|NCT05731063|PROCEDURE|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
58488709|NCT03551561|DRUG|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
58488710|NCT03551561|DRUG|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
58488711|NCT03713346|OTHER|Lactose free milk|Single dose of lactose free milk
58488712|NCT03713346|OTHER|Jersey milk|Single dose of jersey milk
58488713|NCT03713346|OTHER|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
58488714|NCT03713346|OTHER|High A2 β-casein milk|Single dose of A2 β-casein milk
58488715|NCT03393988|DRUG|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
57783779|NCT04326985|BIOLOGICAL|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
58488716|NCT03393988|PROCEDURE|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
58488717|NCT03393988|DRUG|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
58488718|NCT05446064|BEHAVIORAL|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
58491097|NCT00357669|OTHER|Placebo|"* Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use"
58491098|NCT05942495|BEHAVIORAL|short-term schema focused group therapy|There are two intervention phases. The first concerns the pre-treatment phase, which consists of five online sessions and three face-to-face sessions. The second intervention phase is the short-term SFGT. The SFGT consists of 17 weekly group sessions.
58488719|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
58488720|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
58488721|NCT02225691|DEVICE|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
58488722|NCT01867177|OTHER|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
58488723|NCT01867177|OTHER|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
58488724|NCT01867177|BEHAVIORAL|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
58488725|NCT04775940|PROCEDURE|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
58488726|NCT04775940|PROCEDURE|Occlusive collagen membrane|Occlusive collagen membrane
58488727|NCT00742144|DRUG|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
58488728|NCT00419952|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
58488729|NCT00419952|DRUG|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
58488730|NCT05949437|OTHER|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
58488731|NCT05949437|OTHER|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
58488732|NCT00679796|PROCEDURE|Varicella (chickenpox) lesion sampling|
58488733|NCT02392819|DIETARY_SUPPLEMENT|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
58488734|NCT02392819|DIETARY_SUPPLEMENT|Placebo|
58488735|NCT01906606|BEHAVIORAL|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
58488736|NCT01875406|OTHER|diagnostic exercises|
58488737|NCT01255436|OTHER|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
58488738|NCT01255436|OTHER|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
58488739|NCT00990197|DRUG|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
58488740|NCT00613275|OTHER|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
58488741|NCT02930018|DRUG|Nerinetide (NA-1), 2.6 mg/kg|Single intravenous infusion of nerinetide over 10 ± 1 minutes
58488742|NCT02930018|DRUG|Placebo|Placebo Comparator: Placebo
58491099|NCT01534897|DRUG|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
57783780|NCT04326985|DRUG|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
58488743|NCT04610593|BEHAVIORAL|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
58488744|NCT03702283|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
58488745|NCT06414993|BEHAVIORAL|Contingency Management for Emerging Adults (CM-EA)|After CM-EA is introduced, a contingency contract is developed between a parent and emerging adult (EA) that provides EAs with rewards for negative drug screens and completion of developmentally appropriate goals to build recovery capital, along with disincentives for positive screens or engaging in inappropriate behaviors. Concurrently, parents are taught to conduct random urine drug screens. Additionally, parents are trained to complete functional analyses in collaboration with their EA to identify the EA's triggers for poly-substance use and negative behaviors. Individualized triggers are targeted via self-management planning and drug refusal skills training. At the end of CM-EA, plans are made with the family for sustaining abstinence and improvements in other behaviors.
58488746|NCT06414993|BEHAVIORAL|Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services|Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation, employment). After needs are identified, a peer worker addresses needs through informational resources and community referrals and engages clients in positive recreational activities offering advice, hope and empowerment to encourage steps toward a reduction in substance use and eventual abstinence. When desired, peer workers also link clients to a broader recovery peer community. In addition, the peer worker will dedicate time to increasing recovery capital via improving skills related to V/E advancement using a workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health Providers, for which peer workers will be trained.
58488747|NCT00511368|DRUG|matching placebo|
58488748|NCT00511368|DRUG|Bevirimat|
58488749|NCT01926262|BEHAVIORAL|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
58488750|NCT05226637|DEVICE|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
58488751|NCT05226637|DEVICE|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
58488752|NCT06516536|OTHER|MBI (Mindfulness-Based Intervention)|"Breath-Focused Meditation Approach (5-7 minutes):~They will be guided to observe the flow of air in and out of the nose, noting sensations in the abdomen or chest.~Body scan (7-8 minutes):~Students will be guided through a careful exploration of their body. You'll start with your toes and slowly work your way toward your head, paying attention to the physical sensations in each part of your body.~Simple yoga poses (5-7 minutes):~Students will stand and follow instructions to perform a series of simple poses, such as mountain pose, tree pose, and cat-cow pose."
58488753|NCT02425852|DRUG|Azathioprine|Azathioprine alone versus Azathioprine and IFX
58488754|NCT02425852|DRUG|Infliximab|
58488755|NCT02425852|DRUG|Prednisolone|
58488756|NCT02425852|DRUG|Hydrocortisone|
58488757|NCT04413617|DRUG|PF-06650833|400 mg
58488758|NCT04413617|DRUG|PF-06651600|100 mg
58488759|NCT04413617|DRUG|Tofacitinib|11 mg
58488760|NCT00965861|OTHER|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
58488761|NCT05569070|OTHER|Guided Young United Parents! Website Intervention|Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.
58488762|NCT05569070|OTHER|Nutrition Website|Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
58488763|NCT02433808|DRUG|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
58488764|NCT02433808|OTHER|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
58488765|NCT00734877|DRUG|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
58488766|NCT00734877|DRUG|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
58488767|NCT05548322|DEVICE|Different surfaces to be touched|The participant will touch various different surfaces and textures, including ones of different temperature and including solids and liquids.
58488768|NCT05548322|BEHAVIORAL|Emotional state change|The emotional state of the participant will be modulated by listening to music.
58488769|NCT05548322|DEVICE|Electrical stimulation|The participant will receive electrical stimulation of single nerve fibers (a few microamps) to artificially excite an individual afferent.
58488770|NCT04660565|DRUG|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
58488771|NCT04660565|DRUG|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
58488772|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^11 DRP/mL
58488773|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
58488774|NCT00126724|GENETIC|tgAAC94 placebo|placebo
58488775|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^12 DRP/mL tgAAC94
58488776|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
58488777|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^13 DRP/mL tgAAC94
58488778|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
58488779|NCT04683614|DRUG|Norepinephrine|5 mic/kg/hr norepinephrine
58488780|NCT04683614|BIOLOGICAL|Fresh frozen plasma|early administration of fresh frozen plasma
58488781|NCT00845117|PROCEDURE|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
58488782|NCT02747836|OTHER|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
58488783|NCT01964820|BEHAVIORAL|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
58488784|NCT05669261|PROCEDURE|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
58488785|NCT05669261|BIOLOGICAL|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
58488786|NCT03929380|OTHER|Squat protocol|60% of 1RM weight for 100 squat reps
58488787|NCT05453591|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
58488788|NCT02817568|OTHER|Drawing Blood|Drawing Blood for genetic analysis
58488789|NCT02050893|DRUG|sedatives(Midazolam and Propofol)|
58488790|NCT02025413|DEVICE|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
58488791|NCT04239014|DRUG|Olaparib|Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
58488792|NCT04239014|DRUG|Ceralasertib|Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
58488793|NCT04239014|DRUG|Placebo to match olaparib|Per olaparib
58488794|NCT01847027|DRUG|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
58488795|NCT01847027|DRUG|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
58488796|NCT03898557|BEHAVIORAL|Provision of HIV self-test with Commitment and planning prompts|The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
58488797|NCT03898557|BEHAVIORAL|Provision of HIV self-test|This arm will receive a HIV self-test
58488798|NCT06355232|BIOLOGICAL|Covid-19 vaccine|Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant
58488799|NCT06355232|BIOLOGICAL|Influenza vaccine|Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
58488800|NCT05410873|DRUG|MitoQ Compound|Mitoquinol mesylate
58488801|NCT05410873|DRUG|Placebo|Placebo
58488802|NCT00297518|DEVICE|PerioWave|
58488803|NCT00297518|PROCEDURE|Scaling and Root Planing|
58488804|NCT05266170|DEVICE|aerobic and anaerobic exercises|"\[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1. Fitness exercise program with EX1"
58488805|NCT04759443|OTHER|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
58488806|NCT00000903|DRUG|Indinavir sulfate|
58488807|NCT00000903|DRUG|Lamivudine/Zidovudine|
58488808|NCT00000903|DRUG|Nelfinavir mesylate|
58488809|NCT00000903|DRUG|Efavirenz|
58488810|NCT00372593|DRUG|asparaginase|Given intramuscularly
58488811|NCT00372593|DRUG|cytarabine|Given IV
58488812|NCT00372593|DRUG|daunorubicin hydrochloride|Given IV over 6 hours
58488813|NCT00372593|DRUG|etoposide|Given IV over 1-4 hours
58488814|NCT00372593|DRUG|gemtuzumab ozogamicin|Given IV over 2 hours
58488815|NCT00372593|DRUG|mitoxantrone hydrochloride|Given IV over 1 hour
58488816|NCT01568242|DEVICE|Phacoemlsification|Transurgical measurement of temperature
58488817|NCT01898260|DEVICE|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
58488818|NCT01898260|DEVICE|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
58488819|NCT01638871|BEHAVIORAL|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
58488820|NCT01521403|DRUG|Metronidazole|3x500 mg/day for 10 days
58488821|NCT01521403|DRUG|Placebo|3x1 tablet per day for 10 days
58488822|NCT04587661|BEHAVIORAL|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
58488823|NCT04587661|BEHAVIORAL|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
58488824|NCT00000369|BEHAVIORAL|Individual psychotherapy|
58488825|NCT00000369|DRUG|Lithium carbonate|
58488826|NCT02222948|DRUG|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58488827|NCT02222948|DRUG|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
58488828|NCT02817009|BEHAVIORAL|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
58488829|NCT02817009|BEHAVIORAL|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
58488830|NCT02817009|BEHAVIORAL|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
58488831|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
58488832|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
58488833|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
58488834|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
58488835|NCT04752904|DEVICE|ClearSight System|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem
58488836|NCT06445985|OTHER|Hydrotherapy|Physiotherapy led pool session
58488837|NCT02386644|OTHER|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
58488838|NCT02386644|DEVICE|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
58488839|NCT02386644|DEVICE|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
58488840|NCT02386644|OTHER|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
58488841|NCT02386644|OTHER|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
58488842|NCT05480267|PROCEDURE|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
58488843|NCT02112071|BEHAVIORAL|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
58488844|NCT05631483|DEVICE|DAISe|Use of the DAISe Thrombectomy Device
58488845|NCT01576809|DRUG|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
58488846|NCT00170859|DRUG|Everolimus|
58488847|NCT03674905|PROCEDURE|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
58488848|NCT03674905|PROCEDURE|Peripheral nerve block|Pre-operative peripheral nerve block.
58488849|NCT05021068|OTHER|Postural Assessment|Spinal mouse measurement
58488850|NCT03646461|DRUG|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
58488851|NCT03646461|DRUG|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
58488852|NCT03646461|DRUG|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
58488853|NCT03692299|DRUG|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
58488854|NCT03692299|DRUG|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
58488855|NCT00522769|BEHAVIORAL|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
58491135|NCT04894331|OTHER|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris \& Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
58488856|NCT04988581|OTHER|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
58488857|NCT04244916|BIOLOGICAL|AUC of MPA measure|"Plasmatic AUC determination of MPA requires 3 blood punctures at H0, H30 and H2.~These punctures will be made at inclusion after 6 weeks, 12 weeks, 6 months and one year."
58488858|NCT04669444|DEVICE|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
58488859|NCT02386540|BEHAVIORAL|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
58488860|NCT06516094|DRUG|Celecoxib+Pregabalin+Vitamin B fixed dose|One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
58488861|NCT06516094|DRUG|Celecoxib + Vitamin B fixed dose|One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
58488862|NCT06516094|DRUG|Pregabalin + Vitamin B fixed dose|One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
58488863|NCT05677113|DRUG|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
58488864|NCT05677113|DRUG|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
58488865|NCT00773214|BEHAVIORAL|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
58488866|NCT03307876|OTHER|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
58488867|NCT01750229|DEVICE|Sham|Frequency Setting - Sham
58488868|NCT01750229|DEVICE|1200 Hz|Frequency Setting - 1200 Hz
58488869|NCT01750229|DEVICE|3030 Hz|Frequency Setting - 3030 Hz
58488870|NCT01750229|DEVICE|5882 Hz|Frequency Setting - 5882 Hz
58488871|NCT02124993|OTHER|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
58488872|NCT01885598|DRUG|Apixaban|
58488873|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
58488874|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
58488875|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
58488876|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
58488877|NCT05317741|DRUG|IA-14069|Subjects received IA-14069 tablet orally on Day 1.
58488878|NCT05317741|DRUG|Placebo|Subjects received matching placebo tablet orally on Day 1.
58488879|NCT05166200|OTHER|Experimental Formula|Diabetes-specific study formula
58488880|NCT05166200|OTHER|Test Meal|Instant oatmeal
58488881|NCT05644522|DEVICE|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
58488882|NCT04673019|BEHAVIORAL|Nurse AMIE (Addressing Metastatic Individuals Every day)|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
58488883|NCT02964169|BEHAVIORAL|Family Planning Support|
58488884|NCT03751930|OTHER|Samples|Urinary and faecal samples
58488885|NCT06146361|BEHAVIORAL|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
57783781|NCT02786043|DRUG|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
57783782|NCT06196645|BEHAVIORAL|Physical Activity Intervention Based on Theory of Planned Behavior|The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in.
57783783|NCT06196645|BEHAVIORAL|Physical Activity Intervention Based on Theory of Planned Behavior with Parental Participation|The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in. In this group, at least one parent will also be involved.
57783784|NCT02262611|DRUG|Micardis®|
57783785|NCT02262611|DRUG|MicardisPlus®|
57783786|NCT05449574|DIAGNOSTIC_TEST|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
57783787|NCT03020095|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
57783788|NCT03020095|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
57783789|NCT03020095|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
57783790|NCT03020095|DRUG|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally
57783791|NCT04130906|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
57783792|NCT04130906|DEVICE|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
57783793|NCT00955903|BEHAVIORAL|Exercise|Participants will participate in supervised exercise sessions
57783794|NCT00955903|BEHAVIORAL|Reduced Calorie Diet|Participants will follow a reduced calorie diet
57783795|NCT00955903|BEHAVIORAL|Weight Maintenance Diet|Participants will follow a weight maintenance diet
57783796|NCT06442813|BEHAVIORAL|EFT GROUP|One times one pregnancy
57783797|NCT00778063|DRUG|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
57783798|NCT00778063|DRUG|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
57783799|NCT04602494|DRUG|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
57783800|NCT04602494|DRUG|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
57783801|NCT03654053|DRUG|Placebo Oral Tablet|Placebo taken once nightly at bed time.
57783802|NCT03654053|DRUG|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
57783803|NCT02544737|DRUG|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
57783804|NCT01984710|DEVICE|Medtronic Activa PC+S System|
57783805|NCT01844193|DEVICE|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
57783806|NCT00900627|DRUG|AZD8931|Tablet Oral bid
57783807|NCT00900627|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
57783808|NCT00900627|DRUG|Placebo|Oral bid (twice daily)
57783809|NCT04141579|DRUG|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
57783810|NCT04141579|DRUG|Placebo|Matching placebo
57783811|NCT04707391|COMBINATION_PRODUCT|MenABCWY vaccine|2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
57783812|NCT04707391|COMBINATION_PRODUCT|Placebo|1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
57783813|NCT04707391|BIOLOGICAL|MenACWY vaccine|1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
57783814|NCT04707391|COMBINATION_PRODUCT|MenB vaccine|2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
57783815|NCT06058871|BEHAVIORAL|Regular messages|The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
58488886|NCT06146361|BEHAVIORAL|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
57783816|NCT06058871|BEHAVIORAL|Nurse-led real-time support messages (chat type)|The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
57783817|NCT00007930|PROCEDURE|conventional surgery|
57783818|NCT00007930|PROCEDURE|laparoscopic surgery|
57783819|NCT00399425|DRUG|bemiparin (low molecular weight heparin)|
57783820|NCT00069719|DRUG|Glaucoma therapy|
57783821|NCT03757169|OTHER|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
57783822|NCT03757169|OTHER|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
57783823|NCT05280470|DRUG|Ifinatamab Deruxtecan (I-DXd)|I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
57783824|NCT00824174|BEHAVIORAL|Questionnaire|1 questionnaire, about 15-20 minutes.
57783825|NCT02911337|DIETARY_SUPPLEMENT|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
57783826|NCT00763932|BIOLOGICAL|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
57783827|NCT01190033|DEVICE|Neurotome OFF|In this intervention the neurotome will be unconnected.
57783828|NCT01190033|PROCEDURE|neurolysis|In this procedure the neurotome will be connected
57783829|NCT06261944|DEVICE|Near-infrared (NIR)|Near-infrared assessment of glycated keratin in middle fingernail
57783830|NCT01443429|DRUG|beraprost sodium(BPS)|
57783831|NCT04814017|PROCEDURE|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
57783832|NCT04814017|PROCEDURE|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
57783833|NCT01591161|DRUG|Mapracorat|1 drop of study medication into the study eye QID for 14 days
57783834|NCT01591161|DRUG|Placebo|1 drop of vehicle into the study eye QID for 14 days.
57783835|NCT04276818|PROCEDURE|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
57783836|NCT04276818|PROCEDURE|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
57783837|NCT01773538|DRUG|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
57783838|NCT01773538|DIETARY_SUPPLEMENT|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
57783839|NCT01773538|OTHER|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
57783840|NCT04381702|PROCEDURE|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
57783841|NCT00598481|GENETIC|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
57783842|NCT00598481|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
57783843|NCT04932720|BEHAVIORAL|chıld yoga programme|"Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes."
57783844|NCT01093300|DEVICE|Paclitaxel-eluting balloon catheter|
58491136|NCT04894331|OTHER|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
57783845|NCT01093300|DEVICE|Everolimus-eluting stent|
57783846|NCT02206152|DRUG|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
57783847|NCT02206152|DRUG|Placebo|
57783848|NCT03962452|GENETIC|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
57783849|NCT00003639|BIOLOGICAL|recombinant interferon alfa|
57783850|NCT00003639|DRUG|chlorambucil|
57783851|NCT00003639|DRUG|dexamethasone|
57783852|NCT00003639|DRUG|idarubicin|
57783853|NCT04033211|DEVICE|Novosyn® CHD for fascia and skin closure|Experimental
57783854|NCT04033211|DEVICE|Novosyn® for fascia and skin closure|Comparator
57783855|NCT01490515|PROCEDURE|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
57783856|NCT01490515|OTHER|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
57783857|NCT00747773|DEVICE|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
57783858|NCT05552729|DRUG|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
57783859|NCT05445596|BEHAVIORAL|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
57783860|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
57783861|NCT06250166|BEHAVIORAL|iPLANT diet plan and diet counselling|A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).
57783862|NCT06250166|BEHAVIORAL|Usual diet counselling|General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
57783863|NCT06463457|DRUG|Darolutamide|Androgen receptor antagonist, tablet taken orally per protocol.
57783864|NCT06463457|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.
57783865|NCT01138319|GENETIC|DNA analysis|
57783866|NCT01138319|GENETIC|mutation analysis|
57783867|NCT01138319|GENETIC|polymerase chain reaction|
57783868|NCT01138319|OTHER|laboratory biomarker analysis|
57783869|NCT05531903|DEVICE|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
57783870|NCT05771194|DRUG|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
57783871|NCT05771194|DRUG|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
57783872|NCT05771194|PROCEDURE|Cleaning, hot compresses and massage of the meibomian gland|Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
57783873|NCT00322374|DRUG|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
57783874|NCT00322374|DRUG|Epirubicin|Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
57783875|NCT03259971|DIETARY_SUPPLEMENT|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
57783876|NCT03259971|DIETARY_SUPPLEMENT|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
57783877|NCT05474443|OTHER|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
57783878|NCT05474443|OTHER|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
57783879|NCT01924403|PROCEDURE|Staple Closure|
58491137|NCT04580992|DRUG|Ajmaline|Ajmaline administration
57783880|NCT01924403|PROCEDURE|Vertical Mattress Closure|
57783881|NCT01924403|PROCEDURE|Running Subcuticular Closure|
57783882|NCT02451904|OTHER|Observation|
57783883|NCT04537949|BIOLOGICAL|BNT162b3|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
57783884|NCT00280423|DRUG|GW679769|
57783885|NCT01615861|PROCEDURE|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
58491138|NCT03759353|DIAGNOSTIC_TEST|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
57783886|NCT01615861|DEVICE|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
57783887|NCT03069794|DIAGNOSTIC_TEST|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
57783888|NCT06328920|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
57783889|NCT06328920|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
57783890|NCT04899505|OTHER|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
57783891|NCT00890643|DRUG|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
57783892|NCT00890643|DRUG|placebo|placebo
57783893|NCT00792428|DEVICE|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
57783894|NCT00792428|DEVICE|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
57783895|NCT03268590|DRUG|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
57783896|NCT04071470|BEHAVIORAL|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
57783897|NCT04071470|DRUG|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
57783898|NCT03732703|DRUG|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57783899|NCT03732703|DRUG|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57783900|NCT03732703|DRUG|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57783901|NCT03732703|DRUG|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57783902|NCT03732703|DRUG|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57783903|NCT03732703|DRUG|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57783904|NCT03732703|DRUG|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57783905|NCT03732703|DRUG|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57783906|NCT00399282|DRUG|Omega-3 and Vitamin E supplementation|
57783907|NCT03682822|PROCEDURE|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
57783908|NCT03682822|PROCEDURE|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
57783909|NCT01632332|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
57783910|NCT01632332|OTHER|laboratory biomarker analysis|Correlative studies
57783911|NCT06062823|DRUG|Afatinib 40 MG|Afatinib 40mg administered orally daily.
57783912|NCT04054895|DEVICE|Lead placed in the His-Purkinje system in order to achieve QRS shortening.|Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
57783913|NCT04054895|DEVICE|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
57783914|NCT06615141|DEVICE|Oculus Quest 3|Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.
57783915|NCT06615141|DEVICE|Neofect Smartboard and Tyromotion Myro|"Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills."
57783916|NCT01950260|DRUG|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
57783917|NCT01950260|OTHER|Placebo|Placebo to start at 4 weeks after RAI
58137400|NCT04022798|OTHER|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
58137401|NCT02373319|BEHAVIORAL|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
58137402|NCT02373319|BEHAVIORAL|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
58137403|NCT02373319|BEHAVIORAL|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
58137404|NCT02373319|BEHAVIORAL|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
58137405|NCT05856604|BEHAVIORAL|Music Therapy|"Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017)."
58137406|NCT05856604|BEHAVIORAL|Storytelling|"Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation."
58137407|NCT04258982|OTHER|no intervention|no intervention
58137408|NCT06391983|OTHER|resistance training (elastic band)|The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.
58137409|NCT05983562|DIETARY_SUPPLEMENT|Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
58137410|NCT05983562|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
58137411|NCT04511273|DRUG|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
57783918|NCT02936154|DRUG|PF-06650833|
58137412|NCT03744364|DRUG|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
58137413|NCT03744364|DRUG|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
58137414|NCT03044171|DEVICE|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
58137415|NCT03044171|DRUG|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
58137416|NCT03044171|DRUG|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
58137417|NCT01691508|DRUG|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
57783919|NCT02936154|DRUG|placebo|
58137418|NCT01691508|DRUG|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
57783920|NCT01620359|DEVICE|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
58137419|NCT01691508|DRUG|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
58137420|NCT04211493|BEHAVIORAL|whole-body-workout|20 minutes whole-body-workout
57783921|NCT01560377|DEVICE|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
58137421|NCT04211493|DEVICE|EMS|Electromyostimulation-intensity 5 (muscle stimulation)
58137422|NCT04211493|DEVICE|EMS-Placebo|Electromyostimulation-intensity 1 (no muscle stimulation)
57783922|NCT04641624|OTHER|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
57783923|NCT02718352|OTHER|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
58137423|NCT02019940|DRUG|Riluzole|
58137424|NCT00938171|PROCEDURE|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
58137425|NCT00938171|PROCEDURE|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
58137426|NCT04287322|BEHAVIORAL|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
58137427|NCT04287322|BEHAVIORAL|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
58137428|NCT01027143|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
58137429|NCT01027143|DRUG|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
58137430|NCT06222645|DEVICE|ICG fluorescence imaging technology|Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
58137431|NCT06222645|DEVICE|Imaging photoplethysmography|Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
58137432|NCT04364568|RADIATION|Magnetic Resonance Imaging|IRM Sequences T1, T2, FLAIR, T2\*, Cerebral Blood Flow (CBF) et mean diffusivity (MD)
58137433|NCT04203030|BEHAVIORAL|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
58137434|NCT03687736|BIOLOGICAL|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
58137435|NCT00128154|DRUG|Chromium picolinate|
58137436|NCT04548453|DEVICE|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
58137437|NCT01258725|PROCEDURE|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI\<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
58137438|NCT00563264|BEHAVIORAL|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
58137439|NCT02405325|BEHAVIORAL|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
58137440|NCT00006264|BIOLOGICAL|aldesleukin|
58137441|NCT00006264|DRUG|ganciclovir|
58137442|NCT00006264|DRUG|zidovudine|
58137443|NCT03583593|DIETARY_SUPPLEMENT|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
58137444|NCT03583593|DIETARY_SUPPLEMENT|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
58137445|NCT06215352|OTHER|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
58137446|NCT01037283|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
58137447|NCT06394505|OTHER|Data Collection Tools|"Safety Climate Scale: Since a customized safety climate perception measurement tool for nurses could not be found in the literature, the Safety Climate Scale (SAS), developed by Choudry et al. in 2009 and adapted to Turkish by Türen et al. in 2014, was used on healthcare workers and electronics industry workers. The scale consists of two subscales: 10 items evaluating the management's perspective and rules (YÖBAK) and 4 items evaluating colleagues and safety training (İAGE). Participants rate the statements in the scale between strongly agree (five points) and strongly disagree (one point). The total score of the scale is calculated by taking the average of the item scores, and as the average gets closer to five, the safety climate improves, and as it gets closer to one, it gets worse. The Cronbach Alpha reliability coefficient of the scale was determined as 0.93 in the study conducted by Türen et al., and in this study it was calculated as 0.82."
58137448|NCT00162669|DRUG|bevacizumab|
58137449|NCT02713022|DEVICE|DEXA Scan|
58137450|NCT02713022|BEHAVIORAL|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
58491139|NCT03759353|DRUG|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
58137451|NCT05133778|DIETARY_SUPPLEMENT|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
58137452|NCT05133778|OTHER|Maltodextrin control|Supplementation with 760 mg maltodextrin
58137453|NCT01393288|DRUG|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
58137454|NCT01393288|DRUG|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
58137455|NCT01393288|DRUG|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
58137456|NCT01026623|BIOLOGICAL|Cixutumumab|Given IV
58137457|NCT01026623|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
58137458|NCT01026623|DRUG|Temsirolimus|Given IV
58137459|NCT03047265|DRUG|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
58137460|NCT03047265|DRUG|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
58137461|NCT01853553|DRUG|Spironolactone|Blood pressure medication.
58137462|NCT01853553|DRUG|Sugar pill|Placebo.
58137463|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Pomegranate extract|Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period
58137464|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Microcrystalline cellulose|Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period
58137465|NCT05909579|BEHAVIORAL|PelvicSense (R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
58137466|NCT03146247|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
58137467|NCT06254677|OTHER|Retrospective review of histological features|Correlate histopathology characteristics of acute kidney injury with molecular signatures, kidney function and aetiology of acute kidney injury to derive clinically validated scoring system for acute kidney injury and acute tubular injury
58137468|NCT03827044|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
58137469|NCT05711771|BEHAVIORAL|medication therapy management|Patients receive medication therapy management within the primary care office
58137470|NCT01652794|RADIATION|stereotactic body radiation therapy|Undergo SBRT
58137471|NCT01652794|DRUG|carboplatin|Given IV
58137472|NCT01652794|DRUG|gemcitabine hydrochloride|Given IV
58137473|NCT01652794|OTHER|laboratory biomarker analysis|Optional correlative studies
58488887|NCT06146361|BEHAVIORAL|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
58488888|NCT04163211|PROCEDURE|Abdominal drain|A latex-free drain (size 20F)
58137474|NCT01652794|OTHER|pharmacogenomic studies|Optional correlative studies
58137475|NCT05983874|BIOLOGICAL|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|100µg Month 0 and Month 3
58137476|NCT05774860|OTHER|No intervention|No intervention
58137477|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58137478|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58137479|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
58137480|NCT03106610|DRUG|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
58137481|NCT03106610|BEHAVIORAL|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
58137482|NCT00791947|DRUG|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
58137483|NCT04832399|DRUG|Natalizumab|As described in the treatment arm.
58137484|NCT02884232|PROCEDURE|Nasofibroscopy|
58488889|NCT01469377|DRUG|Placebo|Placebo was supplied in capsules
58137485|NCT03067207|BEHAVIORAL|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
58137486|NCT05034653|OTHER|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
58137487|NCT05034653|OTHER|Healthy Plate|Quarter-quarter-half meal concept
58137488|NCT03453125|BEHAVIORAL|Spanish modified Story Memory Technique (mSMT)|
58137489|NCT01123265|DRUG|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
58137490|NCT01123265|DRUG|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
58137491|NCT01759901|PROCEDURE|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
58137492|NCT02947230|OTHER|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
58137493|NCT04567186|DEVICE|Investigational senofilcon A C3 Multifocal Lens|TEST
58137494|NCT04567186|DEVICE|delefilcon A Multifocal Lens|Dailies Total 1® Multifocal Contact Lens
58137495|NCT00353353|PROCEDURE|consumption of fortified bread|
58137496|NCT01768858|DRUG|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
58137497|NCT00279357|PROCEDURE|Narrow Band Imaging|
58137498|NCT02601482|BEHAVIORAL|CON|
58137499|NCT02601482|BEHAVIORAL|IW-60|
58137500|NCT02601482|BEHAVIORAL|IW-45|
58137501|NCT05789602|DRUG|BPI-460372|Subjects will receive BPI-460372 until disease progression
58137502|NCT02883335|OTHER|Observational registry|
58137503|NCT05009225|OTHER|Comprehensive ED AF management tool|Managing atrial fibrillation (AF) patients in the emergency department (ED) is complex, often requiring many separate decisions: How to best reduce the heart rate? Should emergency physicians attempt cardioversion? If so, how? Does this patient need stroke prevention? The investigators' CDSS provides emergency physicians with a one-stop, evidence-based resource that addresses all aspects of ED AF management.
58137504|NCT01988974|BEHAVIORAL|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
58137505|NCT01988974|BEHAVIORAL|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
58137506|NCT00535054|DRUG|Tears Again|Liposome Eye Spray
58137507|NCT03164889|DRUG|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
58137508|NCT03164889|DRUG|Entecavir|Antiviral drug for hepatitis b virus (HBV)
58137509|NCT04584268|BEHAVIORAL|mindfulness|in person and smart phone application mindfulness practice
58137510|NCT04584268|OTHER|standard medical education|standard medical education / control
58137511|NCT05343143|DEVICE|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
58137512|NCT02898545|DEVICE|SEEQ monitor|An external cardiac rhythm monitor
58137513|NCT06373705|DEVICE|Cardiac simulator|A computer software cardiac simulator for surgical planning in complex Congenital Heart Disease (CHD) pediatric patients.
58137514|NCT03916094|DRUG|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
58137515|NCT00827853|PROCEDURE|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
58137516|NCT00827853|PROCEDURE|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
58137517|NCT03734497|OTHER|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
58137518|NCT03734497|OTHER|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
58137519|NCT03734497|OTHER|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
58137520|NCT00803478|PROCEDURE|LASIK|
58137521|NCT00824148|DEVICE|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
58137522|NCT00824148|OTHER|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
58137523|NCT02172105|DRUG|BI 1744 CL|
58137524|NCT02172105|DRUG|Placebo|
58137525|NCT00183807|DRUG|irinotecan, cisplatin, celecoxib|
58137526|NCT01297348|DRUG|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
58137527|NCT01297348|DRUG|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
58137528|NCT00119379|DRUG|NucleomaxX|NucleomaxX 36 grams TID every other day
58137529|NCT00119379|DRUG|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
58137530|NCT04691830|BEHAVIORAL|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
58137531|NCT04691830|BEHAVIORAL|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
58137532|NCT00830401|PROCEDURE|Treatment of predefined abnormality by hysteroscopic surgery|"* Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint"
58137533|NCT00830401|DRUG|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
58137534|NCT03343730|DIAGNOSTIC_TEST|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
58137535|NCT03343730|DIAGNOSTIC_TEST|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
58137536|NCT01621165|DRUG|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
58137537|NCT01621165|DRUG|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
58137538|NCT00380445|DRUG|Vildagliptin|
58137539|NCT00994253|DRUG|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
58137540|NCT00994253|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
58137541|NCT05218798|DIAGNOSTIC_TEST|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial"
58137542|NCT02956772|DRUG|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
58137543|NCT02956772|DRUG|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
58137544|NCT04497181|DEVICE|Coil embolization surgery|Embolization of aneurysms with various coils system
58137545|NCT00939003|BIOLOGICAL|Adalimumab|40 mg every other week up to Week 12
58137546|NCT00939003|BIOLOGICAL|Placebo|Placebo every other week up to Week 12
58137547|NCT00939003|BIOLOGICAL|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
58137548|NCT00464048|PROCEDURE|controlled physical exercise|
58137549|NCT03685565|PROCEDURE|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
58137550|NCT03685565|PROCEDURE|Dermabond|Laceration repaired with Dermabond
57783924|NCT02696226|DRUG|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
57783925|NCT02696226|DRUG|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
57783926|NCT02696226|DRUG|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
57783927|NCT02696226|DRUG|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
57783928|NCT00114153|DRUG|capecitabine|
57783929|NCT00114153|DRUG|carboplatin|
57783930|NCT00114153|PROCEDURE|conventional surgery|
57783931|NCT00114153|RADIATION|radiation therapy|
57783932|NCT04079374|DRUG|Etanercept|Subcutaneous injections
58137551|NCT00278980|DRUG|C-peptide|
57783933|NCT04079374|DRUG|Enbrel|Subcutaneous injections
57783934|NCT05232149|DRUG|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
57783935|NCT05232149|DRUG|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
57783936|NCT01828307|BEHAVIORAL|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
57783937|NCT01828307|BEHAVIORAL|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
57783938|NCT01828307|BEHAVIORAL|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
57783939|NCT00892268|PROCEDURE|acupuncture therapy|Undergo acupuncture
57783940|NCT00892268|PROCEDURE|pain therapy|Receive standard care
58488890|NCT01469377|DRUG|Cariprazine|Cariprazine was supplied in capsules.
57783941|NCT01670227|BEHAVIORAL|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
57783942|NCT04112264|PROCEDURE|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
57783943|NCT04112264|PROCEDURE|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
57783944|NCT01668433|DRUG|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
57783945|NCT04974125|PROCEDURE|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
57783946|NCT04974125|PROCEDURE|Manual exsufflation|Exsufflation through the trocar opening.
57783947|NCT05471193|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
57783948|NCT01555021|GENETIC|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
57783949|NCT06234137|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
57783950|NCT06234137|DRUG|Carboplatin|AUC=6 min/mL iv 3-weekly
57783951|NCT06234137|DRUG|Inetetamab|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
57783952|NCT06234137|DRUG|Pyrotinib|400mg orally daily
57783953|NCT02107443|BEHAVIORAL|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
57783954|NCT02107443|BEHAVIORAL|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
57783955|NCT02107443|BEHAVIORAL|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
57783956|NCT04622644|DEVICE|Device: clinical investigation microwave device class IIa not marked CE for stroke detection|Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
57783957|NCT03213015|DIAGNOSTIC_TEST|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
57783958|NCT03447379|DRUG|P2Y12 antagonist monotherapy|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
57783959|NCT03447379|DRUG|Aspirin plus P2Y12 antagonist|DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
57783960|NCT02543723|BEHAVIORAL|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
57783961|NCT02668406|OTHER|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
57783962|NCT02668406|OTHER|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
57783963|NCT02668406|OTHER|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
57783964|NCT02668406|OTHER|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
57783965|NCT03619174|DEVICE|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
57783966|NCT03273803|DIAGNOSTIC_TEST|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
57783967|NCT05812703|BEHAVIORAL|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR \> 50% HRmax.
57783968|NCT05812703|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
57783969|NCT05812703|BEHAVIORAL|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
57783970|NCT02253524|DRUG|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
57783971|NCT02253524|DRUG|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
57783972|NCT01046747|PROCEDURE|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
57783973|NCT00230815|DEVICE|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
57783974|NCT00230815|DEVICE|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (\>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
57783975|NCT04633083|OTHER|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
57783976|NCT04424290|DRUG|BI 764524|BI 764524
57783977|NCT04424290|DRUG|Sham control of BI 764524|Sham control of BI 764524
57783978|NCT01616290|DRUG|PRT-201|0.03, 1, or 3 mg single adventitial administration
57783979|NCT05355753|DRUG|CFT8634|Oral dose of CFT8634
57783980|NCT03855111|OTHER|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
57783981|NCT03855111|OTHER|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
57783982|NCT01703533|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
57783983|NCT01703533|DRUG|Placebo|Strawberry flavored solution and Water for Injection
57783984|NCT03979950|BEHAVIORAL|Survey|Solid Organ Transplant patients will be recruited via social media. Co-investigators will reach out to the administrators of various social media networks to share information regarding the study with their networks on our behalf. Potential participants who are interested in participating, can then follow the link to the online survey tool, which includes the participant demographic information (age, ethnicity and highest level of education) and questionnaire. The questionnaire is 30 questions long and takes approximately 15 minutes to complete. This questionnaire will be a single, cross-sectional survey. No personal information will be documented on the questionnaire. All responses will be anonymous. Participants will be recruited for 6 months.
57783985|NCT01024751|DEVICE|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
57783986|NCT01024751|DEVICE|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
57783987|NCT03376555|DRUG|Acetylcholine (ACh) Dose Response|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin
57783988|NCT03376555|DRUG|Local Heating (LH)|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
57783989|NCT03376555|DRUG|Flow Mediated Dilation with nitroglycerin|"BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration."
57783990|NCT01012973|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
57783991|NCT01012973|OTHER|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
57783992|NCT00231894|DRUG|Pioglitazone|pioglitazone 30-45 mg/day
57783993|NCT00231894|BEHAVIORAL|Life style diet group|life style diet education group 1x/week
57783994|NCT00231894|OTHER|Placebo|placebo comparator capsules
57783995|NCT05832580|DRUG|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
57783996|NCT05832580|DRUG|Placebo|Placebo in similar capsules
57783997|NCT01722136|BEHAVIORAL|Low Dosage|Exercise dose of 8kcal/kg/week
57783998|NCT01722136|BEHAVIORAL|High Dosage|Exercise dose of 14kcal/kg/week
57783999|NCT00006040|BIOLOGICAL|filgrastim|
57784000|NCT00006040|DRUG|etoposide|
57784001|NCT00006040|PROCEDURE|autologous bone marrow transplantation|
57784002|NCT00006040|PROCEDURE|peripheral blood stem cell transplantation|
57784003|NCT00006040|RADIATION|yttrium Y 90 monoclonal antibody M195|
57784004|NCT01508143|DRUG|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
57784005|NCT01508143|DRUG|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
57784006|NCT04016051|DRUG|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
57784007|NCT04016051|DRUG|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
57784008|NCT04016051|DRUG|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
57784009|NCT04016051|DRUG|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
57784010|NCT04016051|DRUG|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
57784011|NCT04016051|DRUG|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
57784012|NCT01120171|DRUG|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
57784013|NCT01120171|DRUG|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
57784014|NCT05335772|BEHAVIORAL|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
57784015|NCT05335772|BEHAVIORAL|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
57784016|NCT02391285|DEVICE|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
57784017|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release oral tablet
57784018|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release tablet
57784019|NCT01050075|OTHER|acupuncture therapy|acupuncture therapy
57784020|NCT01050075|OTHER|questionnaire administration|Ancillary study
57784021|NCT01050075|OTHER|management of therapy complications|To be determined by the treating physician
57784022|NCT05175482|OTHER|Virtual Education|health belief model based virtual education
57784023|NCT01549691|DRUG|Zopiclone|7.5 mg before sleep, the evening before surgery
57784024|NCT01549691|DRUG|Alprazolam|0.5 mg at awakening, the day of surgery
57784025|NCT01549691|DRUG|placebo|given night before surgery and at awakening, the day of surgery
57784026|NCT00857376|DIETARY_SUPPLEMENT|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
57784027|NCT01340482|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
57784028|NCT00136812|BEHAVIORAL|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
57784029|NCT04184024|OTHER|Massage|"Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist."
57784030|NCT04184024|OTHER|Kinesio tape|Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
57784031|NCT04184024|OTHER|Neck stabilization exercise|Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
57784032|NCT04394546|DEVICE|WATCHMAN FLX LAAC Device|WATCHMAN FLX LAAC Device Implantation
57784033|NCT04394546|DRUG|Non-Vitamin K Oral Anticoagulant|Initiation or continuation of a NOAC drug
57784034|NCT02370290|OTHER|Medical Chart Review|Clinical and imaging information collected
57784035|NCT02370290|OTHER|Informational Intervention|Clinical and imaging data collected
57784036|NCT05181943|DEVICE|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
57784037|NCT05181943|DRUG|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
57784038|NCT06052033|PROCEDURE|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
57784039|NCT02971891|DRUG|CLS006 (Furosemide) Topical Gel|
57784040|NCT02971891|DRUG|Vehicle Topical Gel|
57784041|NCT05018429|PROCEDURE|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
57784042|NCT01629654|BEHAVIORAL|Health promotion program|"A 13 weeks organized program:~* One group session about poststroke fatigue involving both patient and relatives~* Two personal meetings, involving both patient and relatives~* Three telephone meetings, involving only patient"
57784043|NCT05794919|DRUG|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
57784044|NCT05794919|DRUG|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
57784045|NCT04537104|DEVICE|Coala Heart Monitor|ECG monitoring
57784046|NCT05753449|DEVICE|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
57784047|NCT05753449|DEVICE|Standard of care DBS programming|Standard of care DBS stimulation programming
57784048|NCT05872828|OTHER|No intervention|Observational study. No intervention will be adopted.
57784049|NCT06275932|OTHER|Interventional group|Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.
57784050|NCT06275932|OTHER|Standard of care group|Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
57784051|NCT02168920|DRUG|2 mg/day|Once daily for 10 weeks
57784052|NCT02168920|DRUG|3 mg/day|Once daily for 10 weeks
57784053|NCT02168920|DRUG|6 mg/day|Once daily for 10 weeks
57784054|NCT02168920|DRUG|Placebo (0 mg/day)|Once daily for 10 weeks
57784055|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
57784056|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
57784057|NCT04128033|OTHER|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
57784058|NCT04128033|OTHER|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
57784059|NCT02643979|DRUG|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
57784060|NCT02643979|DRUG|Propofol|100mg of Propofol
57784061|NCT02643979|DRUG|Saline|1mL of saline
57784062|NCT01037205|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
57784063|NCT01037205|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
57784064|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
57784065|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
58137552|NCT02304809|DRUG|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
57784066|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
57784067|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
57784068|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
58137553|NCT00721747|DRUG|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
57784069|NCT05278923|DEVICE|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
57784070|NCT06257264|DRUG|BG-68501|Planned doses administered orally.
57784071|NCT06257264|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
57784072|NCT06257264|DRUG|BGB-43395|Planned doses administered orally.
57784073|NCT01683994|DRUG|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
57784074|NCT01683994|DRUG|Docetaxel|75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
57784075|NCT01683994|DRUG|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
57784076|NCT00771875|DRUG|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
57784077|NCT00771875|DRUG|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
57784078|NCT00771875|DRUG|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
57784079|NCT00771875|DRUG|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
57784080|NCT00771875|DRUG|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
57784081|NCT00771875|DRUG|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
57784082|NCT02320721|DRUG|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
57784083|NCT02320721|DRUG|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
57784084|NCT02320721|DRUG|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
57784085|NCT03055832|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
57784086|NCT03055832|DEVICE|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
57784087|NCT02564055|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
57784088|NCT02564055|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
57784089|NCT02564055|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
57784090|NCT05482880|OTHER|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~\*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
57784091|NCT01300559|DEVICE|Tissuelink device|Tissuelink device plus Unipolar electrocautery
57784092|NCT03868319|PROCEDURE|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
57784093|NCT03868319|PROCEDURE|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
57784094|NCT04672746|BEHAVIORAL|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
57784095|NCT04672746|BEHAVIORAL|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
57784096|NCT05737667|BEHAVIORAL|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
58137554|NCT04886973|OTHER|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
58137555|NCT02711852|DRUG|Duvelisib|Administered as oral capsules
57784097|NCT03950219|OTHER|Group course|Education and support
57784098|NCT02774343|DRUG|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
57784099|NCT02774343|DRUG|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
57784100|NCT02774343|BEHAVIORAL|Therapy|Cognitive-behavioral therapy 1 hour per week
57784101|NCT02774343|BEHAVIORAL|Contingency Management|Prize-based contingency management for attendance
57784102|NCT00354367|DRUG|Certolizumab pegol|
57784103|NCT05194917|OTHER|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
57784104|NCT05194917|OTHER|Control Motivational Message|"One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code."
57784105|NCT01866241|DRUG|Misoprostol|Is a prostaglandin
57784106|NCT01140022|OTHER|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
57784107|NCT01189253|DRUG|doxorubicin hydrochloride|
57784108|NCT01189253|DRUG|trabectedin|
57784109|NCT01189253|OTHER|laboratory biomarker analysis|
57784110|NCT01189253|PROCEDURE|quality-of-life assessment|
57784111|NCT05181813|PROCEDURE|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
57784112|NCT05181813|PROCEDURE|Metapex|Fill the infected root canal of of primary teeth with Metapex
57784113|NCT04616274|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
57784114|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
57784115|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
57784116|NCT04506580|PROCEDURE|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
57784117|NCT04845438|DIAGNOSTIC_TEST|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
57784118|NCT00988585|DIETARY_SUPPLEMENT|EPA 600|EPA 600 mg/day for 6 weeks
57784119|NCT00988585|DIETARY_SUPPLEMENT|EPA 1800|1800 mg/day for 6 weeks
57784120|NCT00988585|DIETARY_SUPPLEMENT|Olive Oil|600 mg/day for 6 weeks
57784121|NCT00988585|DIETARY_SUPPLEMENT|DHA|600 mg/day for 6 weeks
57784122|NCT03518164|PROCEDURE|Allograft|Bone graft
57784123|NCT00737984|PROCEDURE|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
57784124|NCT00416923|BIOLOGICAL|rituximab|
57784125|NCT03717259|PROCEDURE|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
57784126|NCT03717259|PROCEDURE|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
57784127|NCT03717259|PROCEDURE|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
57784128|NCT06411288|DRUG|AOC 1001 (del-desiran)|Del-desiran will be administered by intravenous (IV) infusion.
57784129|NCT06411288|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
57784130|NCT00927628|PROCEDURE|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
57784131|NCT02209636|DRUG|Lanthanum carbonate|Non-calcium containing phosphorus binder
57784132|NCT02209636|DRUG|placebo|Table identical to lanthanum carbonate but with no active ingredient
57784133|NCT02209636|DRUG|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
57784134|NCT02209636|DRUG|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
57784135|NCT02209636|PROCEDURE|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
57784136|NCT02209636|PROCEDURE|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
57784137|NCT02209636|PROCEDURE|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
57784138|NCT05905471|OTHER|Interview|Interview study
57784139|NCT03508128|OTHER|surgical procedure|Surgical procedure
57785269|NCT05507489|DRUG|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
57784140|NCT06218836|OTHER|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
57784141|NCT06218836|OTHER|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
57784142|NCT06439290|PROCEDURE|Phonosurgery|Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
57784143|NCT06439290|PROCEDURE|Mastectomy/breast augmentation|Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
57784144|NCT05967260|DEVICE|DailyDose Smart Snack app|A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
57784145|NCT05967260|DEVICE|Dexcom G6 CGM|A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
57784146|NCT04823897|DRUG|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
57784147|NCT02642718|DRUG|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
57784148|NCT02642718|OTHER|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
57784149|NCT01011790|BEHAVIORAL|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
57784150|NCT04376411|DIAGNOSTIC_TEST|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
57784151|NCT04376411|DIAGNOSTIC_TEST|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
57784152|NCT04376411|DIAGNOSTIC_TEST|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
57784153|NCT03785340|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
57784154|NCT03785340|DRUG|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
57784155|NCT01716208|DRUG|Ofatumumab + Fresh Frozen Plasma|
57784156|NCT04454762|DRUG|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
57784157|NCT01874574|DRUG|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
57784158|NCT01874574|DRUG|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
57784159|NCT04408001|OTHER|Clinical interview|At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
57784160|NCT04408001|BIOLOGICAL|Blood collection|"At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected."
57784161|NCT04408001|BIOLOGICAL|Saliva collection|At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
57784162|NCT01608438|DEVICE|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
57784163|NCT06220201|DRUG|CC-97540|Specified dose on specified days
57784164|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
57784165|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
57784166|NCT06126822|DRUG|Zabdeno® booster|A single Zabdeno® booster vaccination
57784167|NCT06126822|DRUG|Ervebo® booster|A single Ervebo® booster vaccination
57784168|NCT02347449|OTHER|Questionnaires, Oncotype Dx Assay|"1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire"
57784169|NCT03781011|BEHAVIORAL|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
57784170|NCT00003238|DRUG|perillyl alcohol|
57784171|NCT00337116|DRUG|iso sorbide dinitrate iv bolus or s/l|
57784172|NCT03423459|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
57784173|NCT00605371|DRUG|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
57784174|NCT00605371|DRUG|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
57784175|NCT05948462|DRUG|Lorlatinib|Participants will receive assigned dose of daily oral lorlatinib continuously for each cycle. Each cycle is 3 weeks.
57784176|NCT05948462|DRUG|Cisplatin or Carboplatin|Participants will receive standard of care intravenous Cisplatin or Carboplatin, both chemotherapy medications, on day 1 of each cycle every 3 weeks, for Cycles 1-4. Each cycle is 3 weeks.
57784177|NCT05948462|DRUG|Pemetrexed|Participants will receive intravenous Pemetrexed, a chemotherapy medication, on day 1 of each cycle. Each cycle is 3 weeks.
57784178|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
57784179|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
57784180|NCT04971616|OTHER|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
57784181|NCT03513198|DIAGNOSTIC_TEST|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes."
57784182|NCT03513198|OTHER|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
57784183|NCT03513198|OTHER|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
57784184|NCT03513198|DIAGNOSTIC_TEST|Contrast-enhanced computed tomography (CT)|"* Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
57784185|NCT02682498|DRUG|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
57784186|NCT02682498|DRUG|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
57784187|NCT02965209|PROCEDURE|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
57784188|NCT00165269|PROCEDURE|Mantle irradiation|Limited to above the diaphragm
57784189|NCT04731103|DRUG|Abacavir (ABC)|Tablets or oral solution
57784190|NCT04731103|DRUG|Lamivudine (3TC)|Tablet or oral solution
57784191|NCT04731103|DRUG|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
57784192|NCT01396928|PROCEDURE|Colonic reservoir|Type of reservoir to be performed
58491140|NCT03759353|DRUG|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
57784193|NCT03395938|BEHAVIORAL|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
57785270|NCT05655481|OTHER|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
57785271|NCT05655481|OTHER|Health education|Telehealth and guidelines for the practice of physical activity and health education
57784194|NCT03395938|BEHAVIORAL|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
57784195|NCT05773040|DRUG|JV-213|Given by (IV) vein
57784196|NCT05773040|PROCEDURE|Leukapheresis|Given by IV (vein)
57784197|NCT05321914|BEHAVIORAL|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
57784198|NCT01242943|DRUG|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
57784199|NCT00580229|DRUG|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
57784200|NCT00338715|DEVICE|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
57784201|NCT01210235|BEHAVIORAL|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
57784202|NCT04227340|DEVICE|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
57784203|NCT04227340|OTHER|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
57784204|NCT04227340|OTHER|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
57784205|NCT01719146|OTHER|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
57784206|NCT02626403|DEVICE|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
57784207|NCT02626403|DEVICE|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
57784208|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 7 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
57784209|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 14 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
57784210|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 6 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
57784211|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 12 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
57784212|NCT06071975|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
57784213|NCT06071975|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
57784214|NCT03949751|DRUG|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
57784215|NCT05447247|OTHER|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
57784216|NCT03390036|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
57784217|NCT03390036|DEVICE|Monovisc|Hyaluronic Acid
57784218|NCT03390036|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
57784219|NCT06191731|OTHER|biological samples collection|Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
57784220|NCT06354621|DIETARY_SUPPLEMENT|Vitamin-D supplementation|Participants receiving a daily dose of vitamin D supplementation
58491141|NCT03759353|DIAGNOSTIC_TEST|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
57784221|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57784222|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57784223|NCT05887804|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
57784224|NCT05212493|DRUG|Cannabis oil|Cannabis oil 20:1 CBD:THC ratio
57784225|NCT01510613|DRUG|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
57784226|NCT04131868|BEHAVIORAL|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
57784227|NCT04131868|BEHAVIORAL|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
57784228|NCT02451813|PROCEDURE|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
57784229|NCT00086086|DRUG|Darbepoetin Alfa|
57784230|NCT01857323|DRUG|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
57784231|NCT05748782|OTHER|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
57784232|NCT05748782|DEVICE|Endotracheal tube|BASKA Mask
57784233|NCT01553786|DRUG|Lenalidomide|Lenalidomide
57784234|NCT01628510|DEVICE|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
57784235|NCT01628510|OTHER|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
57784236|NCT06386146|DRUG|JAB-30355|Oral administration
57784237|NCT06386146|DRUG|JAB-30355|Oral administration
57784238|NCT01531140|DRUG|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
57784239|NCT01531140|DRUG|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
57784240|NCT01531140|DRUG|Sennosides|Sennosides 1tbl/8kg for 2 days
57784241|NCT00047710|DRUG|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
57784242|NCT00047710|DRUG|Capecitabine|650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
57784243|NCT00047710|RADIATION|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
57784244|NCT00959803|DRUG|PF-04447943|3 mg solution, oral single dose.
57784245|NCT00959803|DRUG|PF-04447943|10 mg solution, oral single dose.
57784246|NCT00959803|DRUG|PF-04447943|25 mg solution, oral single dose.
57784247|NCT00959803|DRUG|Placebo|Solution, oral single dose.
57784248|NCT00959803|DRUG|PF-04447943|25 mg solution, oral twice daily for 7 days.
57784249|NCT00959803|DRUG|Placebo|Solution, oral twice daily for 7 days.
57784250|NCT00726336|DRUG|GSK1349572 and tenofovir|
57784251|NCT05107778|DRUG|ASC42 10mg|ASC42 10mg orally once daily;
57784252|NCT05107778|DRUG|ASC42 15mg|ASC42 15mg orally once daily.
57784253|NCT05107778|DRUG|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
57784254|NCT05107778|DRUG|Entecavir|Entecavir 0.5 mg orally once daily.
57784255|NCT05107778|DRUG|Placebo|Placebo orally once daily.
57784256|NCT00027768|PROCEDURE|adjuvant therapy|
57784257|NCT00027768|RADIATION|iodine I 131 ethiodized oil|
57784258|NCT02929342|DRUG|Pitolisant|
57784259|NCT02929342|RADIATION|[14C]-Pitolisant|
57784260|NCT01041508|DRUG|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
57784261|NCT01041508|RADIATION|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
57784262|NCT01041508|OTHER|Stem Cell Transplantation|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
57784263|NCT01041508|DRUG|Cyclosporine|"Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age \> 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml."
57784264|NCT01041508|DRUG|Mycophenolate Mofetil|MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
57785272|NCT04728711|DRUG|ADX-629|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
57785273|NCT04728711|DRUG|Placebo|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
57784265|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
57784266|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
57784267|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
57784268|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup|Source of polyphenols
57784269|NCT03577145|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
57784270|NCT02444143|DRUG|tacrolimus extended release|
57784271|NCT04019561|DRUG|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
57784272|NCT04019561|DRUG|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
57784273|NCT04019561|DRUG|MEDI0382 low dose|MEDI0382 low dose administered subcutaneously
57784274|NCT04019561|DRUG|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
57784275|NCT03334760|OTHER|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
57784276|NCT05323214|DRUG|Control Analgesic regimen|testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
57784277|NCT05323214|DRUG|Fentanyl Analgesic regimen|testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
57784278|NCT05323214|DRUG|Dexmedetomidine Analgesic regimen|testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
57784279|NCT01160991|PROCEDURE|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
57784280|NCT01160991|DRUG|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
57784281|NCT01160991|DRUG|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
57784282|NCT01160991|DRUG|Placebo|Placebo capsules are given at 8:00 a.m.
57784283|NCT02500511|BIOLOGICAL|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
57784284|NCT02431728|DIETARY_SUPPLEMENT|Melatonin|5 mg capsule p.o. at bedtime daily
57784285|NCT02431728|DIETARY_SUPPLEMENT|Matched Placebo|5 mg capsule p.o. at bedtime daily
57784286|NCT03496025|DEVICE|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
57784287|NCT00928460|PROCEDURE|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
57784288|NCT00311428|BIOLOGICAL|Influenza|
57784289|NCT01345643|OTHER|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
57784290|NCT01345643|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
57784291|NCT03412981|OTHER|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
57784292|NCT00432575|DRUG|surinabant (SR147778)|oral administration
57784293|NCT00432575|DRUG|placebo|oral administration
57784294|NCT00029627|DRUG|Yohimbine|
57784295|NCT01043536|RADIATION|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
57784296|NCT01043536|DRUG|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
57784297|NCT04791228|DEVICE|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
57784298|NCT04791228|DRUG|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
57784299|NCT03864133|DRUG|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
57784300|NCT01424163|DRUG|Single dose reduced|Treatment 1 (Part A)
58137556|NCT03060694|OTHER|diabetes|"1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
57784301|NCT01424163|DRUG|Single dose standard|Treatment 2 (Part A)
57784302|NCT01424163|DRUG|Multiple Dose|Treatment 3 (Part A)
57784303|NCT01424163|DRUG|Multiple Dose|Part B
57784304|NCT00126685|BIOLOGICAL|autologous tumor cell vaccine|
57784305|NCT00126685|BIOLOGICAL|therapeutic autologous dendritic cells|
58488891|NCT03532867|OTHER|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
58488892|NCT03532867|OTHER|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
58488893|NCT03532867|OTHER|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
58137557|NCT00860405|DRUG|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
58137558|NCT00860405|DRUG|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
58137559|NCT02435225|BEHAVIORAL|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
58488894|NCT04056390|PROCEDURE|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
58488895|NCT01662609|PROCEDURE|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
58488896|NCT02342236|DEVICE|cemented or cementless type of hip prothesis|
58488897|NCT03868813|BEHAVIORAL|Semi-structured Interview|One-on-one semi-structured interviews
58488898|NCT00702299|DRUG|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
58488899|NCT00702299|DRUG|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
58488900|NCT00702299|DRUG|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
58488901|NCT00702299|OTHER|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
58488902|NCT05593068|PROCEDURE|MRI|Pancreatic MRI
58137560|NCT01841866|OTHER|LMA removal|
58137561|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose
58488903|NCT00746057|BIOLOGICAL|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
58488904|NCT00101452|DRUG|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
58488905|NCT00101452|DRUG|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
58488906|NCT00101452|DRUG|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
58488907|NCT03881527|DEVICE|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
58488908|NCT03881527|PROCEDURE|aortic valve replacement|Aortic valve replacement in a standard fashion
58137562|NCT00936871|DRUG|Placebo|Placebo single dose
58137563|NCT00936871|DRUG|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
58488909|NCT05178797|OTHER|Kinesiology taping technique with exercise therapy|Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
57785274|NCT00608361|DRUG|Dasatinib|Given PO
57785275|NCT00608361|OTHER|Pharmacological Study|Correlative studies
58137564|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
58137565|NCT00936871|DRUG|Placebo|Placebo single dose
58137566|NCT00936871|DRUG|Moxifloxacin|Moxifloxacin 400 mg single dose
58137567|NCT01095692|PROCEDURE|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
58137568|NCT01095692|PROCEDURE|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
58137569|NCT01185821|DRUG|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
58488910|NCT05178797|OTHER|Compression decongestive therapy|"It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma."
58488911|NCT04241562|OTHER|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
58488912|NCT03078140|DIETARY_SUPPLEMENT|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
58488913|NCT03078140|DIETARY_SUPPLEMENT|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
58488914|NCT04436848|OTHER|This is a non-interventional study|This is a non-interventional study
58488915|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
58488916|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
58488917|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
58488918|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
58488919|NCT03458104|OTHER|Cone Beam Computed Tomography|Cone Beam CT of the larynx
58488920|NCT03458104|DIAGNOSTIC_TEST|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
58488921|NCT03458104|DIAGNOSTIC_TEST|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
58488922|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
58488923|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
58488924|NCT00728403|DIETARY_SUPPLEMENT|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
58488925|NCT00135499|DRUG|Rituximab|375 mg/m², D1, 4 cycles
58488926|NCT00135499|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
58488927|NCT00135499|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
58488928|NCT00135499|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
58488929|NCT00135499|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
58488930|NCT00135499|DRUG|Prednisone|60 mg, D1-D5, 4 cycles
58488931|NCT00135499|DRUG|Prednisone|40 mg, D1-D5, 4 cycles
58488932|NCT00135499|DRUG|Doxorubicin|50 mg/m², D1, 4 cycles
58488933|NCT00135499|DRUG|Cyclophosphamide|750 mg/m², D1, 4 cycles
58488934|NCT00135499|DRUG|Vincristine|1.4 mg/m², D1, 4 cycles
58488935|NCT02336529|DRUG|Bupivacaine|
58488936|NCT02336529|DRUG|NaCl|
58488937|NCT00351052|DRUG|Pimecrolimus|Pimecroliums cream 1 % bid.
58488938|NCT00351052|DRUG|Placebo|Vehicle control (placebo) bid.
58488939|NCT05939843|BEHAVIORAL|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
58488940|NCT05939843|BEHAVIORAL|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
58488941|NCT05939843|BEHAVIORAL|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
57785276|NCT00238043|DRUG|Biogeneric Epoetin|
58488942|NCT05939843|BEHAVIORAL|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
58488943|NCT00774566|PROCEDURE|PV-Isolation RF|Radiofrequency
58488944|NCT00774566|PROCEDURE|PV-Isolation Cryo|Cryo-Balloon
58488945|NCT02335788|DEVICE|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
58488946|NCT02974543|DEVICE|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
58488947|NCT02974543|DEVICE|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
58488948|NCT03855488|BEHAVIORAL|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
58488949|NCT03855488|BEHAVIORAL|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
58488950|NCT03855488|BEHAVIORAL|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
58488951|NCT03007225|DRUG|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
58488952|NCT03007225|DRUG|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
58488953|NCT06245980|DRUG|SGLT2 inhibitor|According to whether SGLT2i was used
58488954|NCT02728167|DEVICE|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
58488955|NCT00865280|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
58488956|NCT00865280|DRUG|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
58488957|NCT00865280|DRUG|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
58488958|NCT03358524|DRUG|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
58488959|NCT03358524|DRUG|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
58488960|NCT05346068|DEVICE|OPN™ NCB Super High Pressure PCI Balloon|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
58488961|NCT05346068|DEVICE|Shockwave™ C2 IVL Catheter|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
58488962|NCT04485351|OTHER|no intervention|no intervention
58488963|NCT06254885|PROCEDURE|Equi-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.
58488964|NCT06254885|PROCEDURE|Sub-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
58488965|NCT05102032|PROCEDURE|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
58488966|NCT05102032|PROCEDURE|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
58488967|NCT00273793|BEHAVIORAL|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
58488968|NCT01574183|DRUG|Vilazodone|up to 40 mg capsule daily
58488969|NCT01574183|DRUG|Placebo|up to 40 mg capsule daily
58488970|NCT00276341|DRUG|EGb 761® (Tanakan®)|
58488971|NCT00299390|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
58488972|NCT03816293|DEVICE|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
58488973|NCT05741619|OTHER|Long-term outcome|Autonomy, physical examination, behavioural disorders
58488974|NCT02232568|BEHAVIORAL|Feedback|
58488975|NCT06251882|OTHER|injection|10ml D5W injection for MP patients
58488976|NCT01614691|DRUG|SPARC1203|Active
58488977|NCT01614691|DRUG|Placebo|Placebo
58491173|NCT05828056|DEVICE|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
57785277|NCT02013687|BIOLOGICAL|Pfs25 VLP- FhCMB|
57785278|NCT01946243|DRUG|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
58488978|NCT01411891|DEVICE|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
58488979|NCT02515721|DEVICE|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
58488980|NCT02515721|DEVICE|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
58488981|NCT03666364|OTHER|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
58488982|NCT00085176|PROCEDURE|management of therapy complications|
58488983|NCT00085176|PROCEDURE|psychosocial assessment and care|
58488984|NCT02790892|BEHAVIORAL|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
58488985|NCT01600144|OTHER|digital mammography|data collection
58488986|NCT05933382|OTHER|Corticosteroid Group|Conventional exercise and corticosteroid injection
58488987|NCT05933382|OTHER|Mulligan Group|Conventional exercise and mulligan mobilization
58488988|NCT03313037|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
58488989|NCT03313037|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
58488990|NCT03313037|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
58488991|NCT03313037|OTHER|Saline|Placebo
58488992|NCT03463928|BIOLOGICAL|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
58488993|NCT02214394|OTHER|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
58488994|NCT02214394|DEVICE|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
58488995|NCT01646489|DRUG|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
58488996|NCT01646489|DRUG|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
58488997|NCT00975780|OTHER|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
58488998|NCT00975780|OTHER|Usual oral care|Usual oral care and feeding positioning
58488999|NCT04704596|DEVICE|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
58489000|NCT04704596|DEVICE|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
58489001|NCT05814172|OTHER|no intervention|no intervention
58489002|NCT03105752|OTHER|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
58489003|NCT04618848|DIAGNOSTIC_TEST|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
58489004|NCT00470886|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
58489005|NCT01147913|BEHAVIORAL|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
58489006|NCT01147913|BEHAVIORAL|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
58489007|NCT03843554|OTHER|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
58489008|NCT03843554|PROCEDURE|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
58489009|NCT03544177|OTHER|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
58489010|NCT03544177|OTHER|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
58489011|NCT06406296|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
58489012|NCT00923572|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
58489013|NCT00212589|DRUG|Capecitabine|
58489014|NCT00212589|DRUG|Fluorouracil + folinic acid|
58489015|NCT00644800|DRUG|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
58489016|NCT00276523|BIOLOGICAL|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
58489017|NCT00276523|PROCEDURE|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
58489018|NCT00276523|PROCEDURE|Neoadjuvant therapy|
58489019|NCT03646396|DRUG|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
58489020|NCT06156748|PROCEDURE|postoperative adjuvant transarterial chemoembolization|HCC patients received hepatectomy and PA-TACE.
58489021|NCT01500720|DRUG|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
58489022|NCT01500720|DRUG|Topotecan|Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
58489023|NCT02223377|DRUG|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
58489024|NCT02223377|DRUG|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
58489025|NCT02794532|PROCEDURE|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
58489026|NCT05133310|DRUG|Simvastatin|Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
58489027|NCT04271397|OTHER|Multiple blood samples|Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
58489028|NCT04271397|OTHER|Single blood sample|Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
58489029|NCT02314819|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
58489030|NCT02314819|DRUG|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
58489031|NCT04499924|DRUG|tucatinib|300 mg given twice daily orally
58489032|NCT04499924|DRUG|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
58489033|NCT04499924|DRUG|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
58489034|NCT04499924|DRUG|paclitaxel|60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
58489035|NCT04499924|OTHER|tucatinib placebo|Given twice daily orally
58489036|NCT04499924|OTHER|trastuzumab placebo|IV on Days 1 and 15 of each cycle
58489037|NCT06213103|PROCEDURE|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
58489038|NCT06213103|PROCEDURE|Control cohort|Collection of 6 blood tubes at the inclusion visit.
58489039|NCT01043367|DIETARY_SUPPLEMENT|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
58489040|NCT01043367|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
58489041|NCT04621149|OTHER|chlorine dioxide|chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
58489042|NCT04621149|DIETARY_SUPPLEMENT|zinc acetate|zinc acetate lozenges have been suggested to have antiviral properties
58489043|NCT04621149|DRUG|Famotidine|famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
58489044|NCT04621149|OTHER|placebo|filtered water
58489045|NCT04621149|DIETARY_SUPPLEMENT|lactoferrin, green tea extract|lactoferrin and green tea extract are dietary supplements
58489046|NCT06186843|BEHAVIORAL|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
58489047|NCT00976924|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
58491174|NCT05770089|OTHER|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
58491175|NCT02436837|OTHER|sessions with virtual reality|sessions with virtual reality to improve the balance
58491176|NCT03465969|DRUG|tacrolimus|oral
58491177|NCT00002771|BIOLOGICAL|recombinant interferon alfa|
58491178|NCT00002771|DRUG|busulfan|
58489048|NCT06265662|BEHAVIORAL|A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand|The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
58489049|NCT01635426|DRUG|Aspirin|Aspirin 75 mg daily for 2 months after meals
58489050|NCT01635426|DRUG|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
58489051|NCT03037580|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
58489052|NCT03037580|DRUG|Placebo|Placebo (sugar pill) for TID oral administration
58489053|NCT05036421|DRUG|Empagliflozin 10 milligram|antihyperglycemic medication
58489054|NCT02689362|DRUG|Evogliptin|1 tablet per day
58489055|NCT02689362|DRUG|Sitagliptin|1 tablet per day
58489056|NCT02689362|DRUG|Placebo Evogliptin|1 tablet per day
58489057|NCT02689362|DRUG|Placebo Sitagliptin|1 tablet per day
58489058|NCT03083873|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
58489059|NCT03083873|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
58489060|NCT01691222|DEVICE|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
58489061|NCT05998057|OTHER|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~* Standing Hip Out 3 sets of 30sec~* 90-90 Hip Stretch 3 sets of 30 seconds~* World's Greatest Stretch 3 sets of 30 seconds~* Star Excursion 3 sets of 5 reps~* Side Jumps+ Balance 3 sets of 10 reps~* Forward Hops + Balance 3 sets of 10 reps~* Squat 3 sets of 10 reps~* Squat Jump 3 sets of 10 reps~* Jumping Spider Push-up 3 sets of 10 reps~* Double Leg Vertical Jump 3 sets of 10 reps~* Broad Jumps 3 sets of 10 reps~* Lateral Box Shuffles 3 sets of 10 reps~* Plank 3 sets of 30 seconds~* Side Plank 3 sets of 30 seconds~* Bird Dog 3 sets of 10 reps~* Glute Bridge 3 sets of 10 reps~* Single Leg Glute Bridge 3 sets of 10 reps~* Single Toe Raises 3 sets of 30sec~* Nordic Hamstrings 3 sets of 10 reps~* Monster Walk 3 sets of 10 reps"
58489062|NCT05998057|OTHER|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
58489063|NCT05862103|OTHER|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
58489064|NCT02431962|PROCEDURE|Computed Tomography|Low dose chest CT screening annually x 3
58489065|NCT02431962|BEHAVIORAL|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
58489066|NCT02431962|BEHAVIORAL|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
58489067|NCT04149756|OTHER|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
58489068|NCT04565704|DEVICE|Biopsy imaged by Optical imaging device.|
58489069|NCT02280408|OTHER|Placebo|Normal saline placebo.
58489070|NCT02280408|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
58489071|NCT04041167|DRUG|alpha lipoic acid|alpha lipoic acid treatment
58489072|NCT04041167|DRUG|Saline|No alpha lipoic acid treatment
58489073|NCT05201300|DRUG|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
58489074|NCT05201300|DRUG|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
58489075|NCT05201300|DRUG|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
58489076|NCT01957306|DIETARY_SUPPLEMENT|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
58489077|NCT00552435|DEVICE|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
58489078|NCT01153334|DRUG|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
58489079|NCT02506348|DRUG|Diclofenac|
58489080|NCT02506348|DRUG|Nepafenac|
58489081|NCT02835079|DRUG|Tamoxifen|
58489082|NCT02533453|BIOLOGICAL|Bydureon|exenatide once weekly
58489083|NCT03830619|DIAGNOSTIC_TEST|collect samples|collect serum samples and clinical features
58489084|NCT02838394|PROCEDURE|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
58489085|NCT02838394|OTHER|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
58489086|NCT03348059|DRUG|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
58491179|NCT00002771|DRUG|cytarabine|
58491180|NCT00002771|DRUG|hydroxyurea|
58491181|NCT00002771|DRUG|idarubicin|
58491182|NCT00002771|PROCEDURE|allogeneic bone marrow transplantation|
58491183|NCT00002771|PROCEDURE|autologous bone marrow transplantation|
58491184|NCT00002771|PROCEDURE|peripheral blood stem cell transplantation|
58491185|NCT00002771|RADIATION|radiation therapy|
58489087|NCT00606437|PROCEDURE|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
58489088|NCT02369172|DRUG|Bupropion|
58489089|NCT02369172|DRUG|ASP2151|
58489090|NCT01348516|DRUG|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
58489091|NCT01348516|DRUG|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
58489092|NCT04052152|DRUG|Anlotinib and Sintilimab injection|Patients will be treated with Anlotinib and Sintilimab injection
58489093|NCT01025518|OTHER|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
58489094|NCT01025518|DIETARY_SUPPLEMENT|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
58489095|NCT01025518|DIETARY_SUPPLEMENT|Placebo|Maltodextrine
58489096|NCT00882297|PROCEDURE|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
58489097|NCT02911831|DRUG|Tranexamic Acid|
58489098|NCT02911831|DRUG|Sodium Chloride|
58489099|NCT05978843|BEHAVIORAL|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
58489100|NCT03180918|PROCEDURE|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
58489101|NCT03439384|DEVICE|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
58489102|NCT05083117|DRUG|XW001|It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
58489103|NCT05083117|DRUG|Placebo|It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
58489104|NCT01032122|DRUG|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
58489105|NCT06090136|DRUG|TPN171H|5 mg TPN171H tablets，single dose,oral
58489106|NCT04911608|OTHER|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
58489107|NCT04911608|OTHER|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
58489108|NCT05013541|OTHER|No intervention|Observational study, standard record of need to void during cystometry
58489109|NCT01873534|DRUG|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
58489110|NCT00989872|DRUG|EDP-322|
58489111|NCT00074490|DRUG|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
58489112|NCT00074490|DRUG|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
58489113|NCT00074490|DRUG|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
58489114|NCT00074490|DRUG|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
58489115|NCT00074490|DRUG|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
58489116|NCT00074490|DRUG|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
58489117|NCT00074490|PROCEDURE|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
58489118|NCT00074490|GENETIC|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
58489119|NCT00074490|DRUG|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
58489120|NCT00074490|PROCEDURE|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
58489121|NCT00074490|DRUG|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
58489122|NCT00074490|GENETIC|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
58489123|NCT04650529|DEVICE|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
58489124|NCT00787267|DRUG|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
58489125|NCT02236936|DIETARY_SUPPLEMENT|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
58489126|NCT02236936|DIETARY_SUPPLEMENT|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
58489127|NCT02236936|BIOLOGICAL|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
58489128|NCT02236936|DRUG|Cisplatin|Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
58489129|NCT02236936|RADIATION|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
58489130|NCT04286048|OTHER|Weight implement|"The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement."
58489131|NCT03915093|OTHER|Educational nursing protocol|It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
58489132|NCT03915093|OTHER|Routine hospital care|The routine care given by physicians and nurses after thoracoscopic surgery
58489133|NCT02479646|BIOLOGICAL|MYL-1401H|
58489134|NCT02479646|BIOLOGICAL|EU-Neulasta|
58489135|NCT02479646|BIOLOGICAL|US-Neulasta|
58489136|NCT05438472|OTHER|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
58489137|NCT04405453|PROCEDURE|trapezius muscle injection|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
58489138|NCT04405453|PROCEDURE|erector spina plane block|1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
58489139|NCT02888119|DEVICE|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
58489140|NCT06057467|DRUG|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
58489141|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
58489142|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
58489143|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
58489144|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
58489145|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
58489146|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
58489147|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
58489148|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
58489149|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
58489150|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
58489151|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
58489152|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
58489153|NCT06521762|DRUG|Etrasimod|2 mg/day oral tablet
58489154|NCT06521762|DRUG|Placebo|matching placebo oral tablet
58489155|NCT06521762|DRUG|Corticosteroids|Corticosteroids will be given in conjunction with study drug or placebo
58489156|NCT04987788|BEHAVIORAL|Motívate|The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.
58489157|NCT04987788|BEHAVIORAL|Video link|General health information video link
58489158|NCT05465252|DIETARY_SUPPLEMENT|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
58489159|NCT05465252|DIETARY_SUPPLEMENT|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
58489160|NCT04502680|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
58489161|NCT04828317|OTHER|Pork Challenge|Double blind oral challenges comparing wild-type and alpha-gal free pork.
58489162|NCT04150861|DRUG|Follitropin Delta|Solution for Injection, subcutaneous administration
58489163|NCT02591225|DRUG|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
58489164|NCT02591225|DRUG|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
58489165|NCT04306861|DIAGNOSTIC_TEST|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
58489166|NCT06322654|PROCEDURE|Robotically Assisted Locomotion|"* Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy"
58489167|NCT06322654|PROCEDURE|Robotically Assisted Verticalization|"* Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy"
58489168|NCT00607490|BEHAVIORAL|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
58489169|NCT00607490|BEHAVIORAL|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
58489170|NCT06425692|BEHAVIORAL|Education|Education on basic palliative care via e-learning + webinar to deepen knowledge.
58489171|NCT01621802|BIOLOGICAL|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
58489172|NCT01621802|BIOLOGICAL|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
58489173|NCT01621802|BIOLOGICAL|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
58489174|NCT01621802|BIOLOGICAL|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
58489175|NCT00999778|BEHAVIORAL|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
58489176|NCT00999778|BEHAVIORAL|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
58489177|NCT03894813|DRUG|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
58489178|NCT03894813|DRUG|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
58489179|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
58489180|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
58489181|NCT03257449|DIETARY_SUPPLEMENT|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
58489182|NCT02922049|OTHER|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
58489183|NCT04277923|DRUG|SMOFlipid|the lipid of all-in-one is less than 4g/kg.d
58489184|NCT04277923|DRUG|Lipofundin|the lipid of all-in-one is less than 4g/kg.d
58489185|NCT02399163|DRUG|Fluoride free toothpaste|Brushing with fluoride free toothpaste
58489186|NCT02399163|DRUG|Fluoride toothpaste|Brushing with fluoride containing toothpaste
58489187|NCT02399163|DRUG|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
58489188|NCT02559375|OTHER|Survey|
58489189|NCT02509026|BIOLOGICAL|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
58489190|NCT04785469|OTHER|Low-load eccentric training|"* Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
58489191|NCT04785469|OTHER|Usual care|"* Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + \[0.002x6-Minute walk work (6MWW)\]. \[Sex: female = 0; male:1\] \[6MWW = 6-Minute walk distance x weight in kg\].~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
58489192|NCT01794767|DRUG|0,9% NaCl flush|Normal Saline solution
58489193|NCT01794767|DRUG|Heparin 50U/ml|Heparin solution
58489194|NCT00458978|DRUG|Cediranib Maleate|Given orally
58489195|NCT00458978|OTHER|Laboratory Biomarker Analysis|Correlative studies
58489196|NCT00176917|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
58489197|NCT00176917|DRUG|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
58489198|NCT02532738|DRUG|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
58489199|NCT02532738|BIOLOGICAL|MSC treatment 01|Injection of 3×10E6/kg of MSC
58489200|NCT02532738|BIOLOGICAL|MSC treatment 02|Injection of 6×10E6/kg of MSC
58489201|NCT02532738|OTHER|NS|Injection of NS
58489202|NCT05459857|OTHER|Heated tobacco device Intense (Product A)|Heated Tobacco device Intense, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
58489203|NCT05459857|OTHER|Heated tobacco device Regular (Product B)|Heated Tobacco device Regular, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
58489204|NCT05459857|OTHER|Heated tobacco device Menthol (Product C)|Heated Tobacco device Menthol, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
58489205|NCT05459857|OTHER|Combustible cigarette (Product D)|Subject's own brand combustible cigarette, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
58489206|NCT00473096|BEHAVIORAL|Informed breast cancer surgical treatment|
58489207|NCT02170415|DRUG|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
58489208|NCT02170415|OTHER|Pain education|Participant will receive a pain education leaflet
58489209|NCT02170415|BEHAVIORAL|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
58489210|NCT02170415|PROCEDURE|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
58489211|NCT02170415|OTHER|Daily visits from pain team whilst in hospital|
58489212|NCT02302014|OTHER|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
58489213|NCT00285623|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
58489214|NCT04678219|OTHER|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
58489215|NCT03839797|BEHAVIORAL|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
58489216|NCT03839797|BEHAVIORAL|Standard Health Education|Standard Health Education
58489217|NCT06287099|DRUG|BRL-101|Subjects will receive a single infusion of BRL-101.
58489218|NCT00845897|DRUG|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
58489219|NCT00845897|DRUG|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
58489220|NCT02905227|DRUG|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
58489221|NCT02225002|DRUG|CP-870,893|
58489222|NCT01149018|DRUG|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
58489223|NCT01149018|DRUG|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
58489224|NCT00452816|BEHAVIORAL|Workplace Solutions Consulting approach|"Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation"
58489225|NCT00452816|BEHAVIORAL|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
58489226|NCT04475887|DRUG|Iron Carboxymaltose|see above
58489227|NCT04475887|DRUG|Placebo|see above
58489228|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
58489229|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
58489230|NCT00364104|DRUG|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
58489231|NCT00364104|DRUG|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
58489232|NCT00226759|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
58489233|NCT00226759|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
58489234|NCT05242198|PROCEDURE|Robotic prostatectomy|patients who will undergo robotic prostatectomy
58489235|NCT00005035|DRUG|oxaliplatin|
58489236|NCT03429270|DEVICE|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
58489237|NCT04542018|OTHER|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
58489238|NCT00010699|DRUG|Vitamin E|
58489239|NCT05271435|DEVICE|PAMSys Activity Monitoring System|This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
58489240|NCT05271435|BEHAVIORAL|Motor, Speech, and Handwriting Assessment|"These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).~* 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.~* Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.~* Handwriting Assessment Battery (HAB) (15 minutes) \[Faddy2008\] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.~* Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room."
58489241|NCT05063448|BEHAVIORAL|DadSpace|A group educational support and mentoring program for perinatal fathers.
58489242|NCT03586557|DEVICE|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
58489243|NCT03586557|DRUG|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
58489244|NCT02829567|BEHAVIORAL|Motivational interviewing|
58489245|NCT00934362|DRUG|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
58489246|NCT00934362|DRUG|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
58489247|NCT05461508|BIOLOGICAL|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
58489248|NCT05461508|OTHER|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
58489249|NCT04279626|PROCEDURE|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
58489250|NCT05163899|PROCEDURE|Release of filum terminale|Surgery will be offered to section the filum terminale
58489251|NCT03763877|DRUG|PXL770|Oral capsule
58489252|NCT03763877|DRUG|Placebo Oral Capsule|Oral capsule
58489253|NCT02110043|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
58489254|NCT02110043|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
58489255|NCT00451633|DRUG|E2007|
58489256|NCT00462397|DRUG|carboplatin|
58489257|NCT00462397|DRUG|cisplatin|
58489258|NCT00462397|DRUG|paclitaxel|
58489259|NCT00462397|PROCEDURE|neoadjuvant therapy|
58489260|NCT00462397|RADIATION|brachytherapy|
58489261|NCT00462397|RADIATION|radiation therapy|
58489262|NCT04812717|DEVICE|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
58489263|NCT01053780|OTHER|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
58489264|NCT01053780|BEHAVIORAL|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
58489265|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
58489266|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
58489267|NCT02640508|DRUG|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
58489268|NCT02640508|DRUG|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
58489269|NCT04658199|DRUG|UCB0107 (bepranemab)|UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
58489270|NCT03293368|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
58489271|NCT03293368|DRUG|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
58489272|NCT03098004|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
58489273|NCT02611089|PROCEDURE|Tissue biopsy|Sampling of tissue as described.
58489274|NCT05119634|OTHER|whole body vibration training|participants will receive whole body vibration training 3 days in a week and for 8 weeks
58489275|NCT05119634|OTHER|home based exercises|participants will receive a home based exercise program for 8 weeks
58489276|NCT02279706|OTHER|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
58489277|NCT02586649|DRUG|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
58489278|NCT02586649|DRUG|Placebo|Placebo is a non-active inhalation capsule .
58489279|NCT03208985|DRUG|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
58489280|NCT02921841|BEHAVIORAL|D*STAR|
58489281|NCT02921841|BEHAVIORAL|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
58489282|NCT01733680|DRUG|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
58489283|NCT01733680|BEHAVIORAL|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
58489284|NCT01347619|OTHER|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
58489285|NCT01347619|OTHER|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
58489286|NCT01347619|OTHER|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
58489287|NCT05890716|DIAGNOSTIC_TEST|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
58489288|NCT03959397|DRUG|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
58489289|NCT00161343|BEHAVIORAL|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
58489290|NCT01773759|BEHAVIORAL|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
58489291|NCT02516969|RADIATION|Stereotactic Body Radiotherapy|Radiation
58489292|NCT04754659|DEVICE|Stentgraft|Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
58489293|NCT04571567|DRUG|Secukinumab|Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
58489294|NCT05454917|DEVICE|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
58489295|NCT06079970|DEVICE|Neelde Based Confocal Laser Endomicroscopy|Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
58489296|NCT06079970|PROCEDURE|Conventional diagnostic bronchoscopy|Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
58489297|NCT04861168|PROCEDURE|driving pressure guided ventilation|driving pressure guided ventilation
58489298|NCT04861168|PROCEDURE|Conventional protective lung strategy|Conventional protective lung strategy
58489299|NCT04323657|DRUG|TC-110 T Cells|TC-110 T Cells
58489300|NCT04323657|DRUG|Fludarabine|Flu/Cy Lymphodepletion
58489301|NCT04323657|DRUG|Cyclophosphamide|Flu/Cy Lymphodepletion
58489302|NCT02037230|DRUG|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
58489303|NCT02037230|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
58489304|NCT02037230|RADIATION|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
58489305|NCT04986319|DIAGNOSTIC_TEST|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
58489306|NCT04805099|DRUG|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
58489307|NCT04200352|DRUG|TEV-50717|Oral tablets are 6, 9, and 12 mg.
58489308|NCT00385437|BEHAVIORAL|Driving Simulator Testing|
58489309|NCT00385437|DRUG|Mirtazapine Treatment|
58489310|NCT00004101|BIOLOGICAL|apolizumab|
58489311|NCT02569788|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
58489312|NCT03367637|OTHER|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
58489313|NCT03367637|OTHER|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
58489314|NCT05181436|DIAGNOSTIC_TEST|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
58489315|NCT03748004|BEHAVIORAL|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
58489316|NCT03748004|BEHAVIORAL|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
58489317|NCT03391921|BIOLOGICAL|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
58489318|NCT02537015|DRUG|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
58489319|NCT04516889|PROCEDURE|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
58489320|NCT02146534|DRUG|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
58489321|NCT02146534|DRUG|Placebo|placebo will be taken PO BID
58489322|NCT02896413|DRUG|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
58489323|NCT02896413|DRUG|Control group|0.9% saline infusion
58489324|NCT01545505|BEHAVIORAL|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
58489325|NCT06029855|OTHER|Kabat Therapy|The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.
58489326|NCT06029855|OTHER|Mime Therapy|The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.
58489327|NCT03021343|DRUG|Colchicine|colchicine given as per trial protocol
58489328|NCT00201188|BEHAVIORAL|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
58489329|NCT04183426|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
58489330|NCT04183426|DIAGNOSTIC_TEST|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
57784306|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
58489331|NCT06172062|OTHER|laparoscopic pancreaticoduodenectomy|we recorded the surgical videos of laparoscopic pancreaticoduodenectomy, and labeled the information in the video to build and test the algorithms.
58489332|NCT01085006|DRUG|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
58489333|NCT01085006|DRUG|Normal saline|Tranexamic acid in cases, normal saline in controls
58489334|NCT01742117|DRUG|Clopidogrel|One 75 mg tablet per day by mouth for one year
58489335|NCT01742117|DRUG|Ticagrelor|One 90 mg tablet twice per day by mouth for one year
58489336|NCT03018262|DEVICE|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
58489337|NCT03018262|DEVICE|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
58489338|NCT03018262|DEVICE|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
58489339|NCT04310189|PROCEDURE|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
58489340|NCT01262989|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
58489341|NCT01262989|DRUG|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
58489342|NCT01766258|DRUG|ODM-101 65mg Carbidopa|
58489343|NCT01766258|DRUG|ODM-101 105mg Carbidopa|
58489344|NCT01766258|DRUG|Stalevo|
58489345|NCT04490096|DRUG|[11C]-PBR28|"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."
58489346|NCT01970098|DRUG|KPS-0373, High dose|28 weeks
58489347|NCT01970098|DRUG|KPS-0373, Low dose|28 weeks
58489348|NCT01970098|DRUG|Placebo|28 weeks
58489349|NCT00895206|DRUG|individual adapted immunosuppression|individual adapted immunosuppression
58489350|NCT00895206|DRUG|golden standard therapy|golden standard therapy
58489351|NCT04791306|OTHER|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
58489352|NCT04791306|OTHER|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
58489353|NCT01926496|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
58489354|NCT01926496|DRUG|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
58489355|NCT04656327|OTHER|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
58489356|NCT01855646|OTHER|Structured Sign Out Form|
58489357|NCT03870243|DEVICE|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
58489358|NCT03870243|DEVICE|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
58489359|NCT06456996|COMBINATION_PRODUCT|Multi-component intervention package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
58489360|NCT04427982|BEHAVIORAL|dance|Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
58489361|NCT04427982|BEHAVIORAL|diabetes education|The dance classes will be followed by a brief diabetes education and discussion session.
58489362|NCT05538715|PROCEDURE|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
58489363|NCT05538715|PROCEDURE|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
58489364|NCT02074683|PROCEDURE|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
58489365|NCT02074683|PROCEDURE|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
58489366|NCT02459483|BEHAVIORAL|Nurse phone call|
58489367|NCT01924949|DRUG|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
58489368|NCT02722304|BIOLOGICAL|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
58489369|NCT02722304|BIOLOGICAL|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
58489370|NCT02722304|BIOLOGICAL|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
58489371|NCT02722304|BIOLOGICAL|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
58489372|NCT02722304|BIOLOGICAL|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
58489373|NCT04924881|DRUG|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
58489374|NCT04924881|OTHER|Placebo granules|Placebo granules once daily for 8 weeks
58489375|NCT04203186|DRUG|atovaquone-proguanil|Malaria standard treatment regimen
58489376|NCT06380413|OTHER|Tai Chi Chuan Plus Walking|Participants perform a 12-week program with two weekly sessions on non-consecutive days. The sessions last 75 min (5 min of warm-up, 45 min of Tai Chi Chuan (TCC), 20 min of walking, and 5 min of cool-down). The intervention occurs at the School of Physical Education, Federal University of Pelotas. The TCC section occurs in a mirrored dance studio, while walking occurs on an indoor sports court. The TCC sections are based on the simplified Yang 16-movement form. Over the 12 weeks, participants learn the fundamentals and basic principles of TCC and practice the 16 movements. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
58489377|NCT06380413|OTHER|Walking|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. The sessions last 30 minutes (5 minutes of warm-up, 20 minutes of walking, and 5 minutes of cool-down) throughout the intervention period. The intervention occurs in an indoor sports court at the School of Physical Education, Federal University of Pelotas. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
58489378|NCT03962504|BEHAVIORAL|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
58489379|NCT06521905|DEVICE|intravascular lithotripsy|The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.
58489380|NCT06521905|DEVICE|high-pressure ballon|High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
58489381|NCT03690752|DEVICE|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
58489382|NCT03690752|DEVICE|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
58489383|NCT00132470|DRUG|AX200 (G-CSF)|
58489384|NCT03920319|DRUG|Bupropion|Bupropion 150 mg sustained release
58489385|NCT03920319|OTHER|Placebo|
58489386|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
58489387|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
58489388|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
58489389|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
58489390|NCT05711563|OTHER|Observational study|Observational study
58489391|NCT02970942|DRUG|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
58489392|NCT02970942|DRUG|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
58489393|NCT00162019|DRUG|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
58489394|NCT01377337|DRUG|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
58489395|NCT04036396|BEHAVIORAL|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
58489396|NCT04036396|BEHAVIORAL|Usual Care plus Customized Referrals|Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
58489397|NCT04442061|DEVICE|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
58489398|NCT04442061|DEVICE|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
58489399|NCT04442061|DEVICE|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
58489400|NCT04442061|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
58489401|NCT04442061|GENETIC|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
58489402|NCT04442061|OTHER|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
58489403|NCT03725618|BIOLOGICAL|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
58489404|NCT02344524|DEVICE|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
58489405|NCT06193226|OTHER|Cryotherapy|"Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure.~The spray's nozzle of the Cryogun spray -50 ◦C was situated 1 cm away from the skin's surface and applied on the oral lesion for 30 seconds. Each freezing cycle lasted 10 to 30 seconds, with the subsequent 60-second thaw interval lasting twice as long as the freezing time. The ice ball that formed during freezing was totally melted before the subsequent freezing process could begin.~The application process should went from the core out to the edges. The management of lesions that are too big to be frozen by a single spray requires many overlapping treatments of liquid nitrogen. Mucoceles and erosive lichen planus took 30 to 50 seconds to freeze, whereas fibromas and leukoplakia took 60 to 70 seconds."
58489406|NCT04187183|OTHER|Fresh Platelet Rich Plasma with leukocyte|autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
58489407|NCT04187183|OTHER|Fresh Platelet Rich Plasma without leukocyte|autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
58489408|NCT04579939|DIAGNOSTIC_TEST|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
58489409|NCT06307197|DEVICE|HAAL platform|"The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices.~The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors."
58489410|NCT06248723|OTHER|Nutritional intervention|"The objectives of the dietary intervention will be in accordance with the principles of the Mediterranean diet. Weekly menus will be provided that ensure a balanced intake of the various nutrients, according to the objectives outlined in the study protocol, including a reduction in saturated fatty acids (with proportionately more mono- and polyunsaturated fatty acids), promotion of fiber sources and reduction of sugars, adequate protein and micronutrient intake. They will be accompanied by specific dietary patterns that can be individualized based on weight, comorbidities and personal preferences.~The need for weight loss or gain will be assessed on an individual basis. Dietary interventions will include group and individual sessions, and will be conducted by dietitians and nutritionists in a harmonized manner among the centers. The first meeting will be in-person and will be held at the subject's clinical center of enrollment. Follow-up will be conducted through online meetings."
58489411|NCT06248723|OTHER|Physical exercise|The physical activity protocol will be geared to the principles of progressive and individualized loading, in group sessions supervised by a physical therapist within gyms for the strength and balance training portion, and in moderate to intense aerobic activities based on individual preferences and characteristics. The physiotherapist will conduct an individual assessment and develop personalized programs for all participants. Exercise sessions will be held 2-3 times a week.
58489412|NCT06248723|OTHER|Cognitive training|Participants will be evaluated through a Cognitive and Psychological Assessment, which will allow measurement of each participant's cognitive functioning and well-being. Computerized cognitive training (CCT) using Brain HeadQuarter (BrainHQ) or similar software will be used as a cognitive intervention. The CCT includes game-based adaptive exercises that target attention, intelligence, memory, navigation, processing speed and social skills. The training will consist of 72 sessions for 24 weeks (about six months), at least three times a week.
58489413|NCT06248723|OTHER|Oral hygiene|"Participants will be referred for evaluation at dental hygiene offices. As part of the study, participants will also undergo anticholinergic burden calculation, screening for risk factors for oral diseases (smoking, alcohol), and reduction in the frequency of sugar intake through dietary intervention will be sought.~Participants will also undergo the Oral Health Assessment Tool rating scale."
58489414|NCT06248723|OTHER|Sleep quality|"During the visits, participants' sleep will be assessed, either by clinical interview or by scales. Participants will also have the opportunity to assess their own sleep via wearable devices.~If sleep hygiene issues are detected, advice based on currently available scientific evidence will be provided. If, on the other hand, a suspicion of sleep disorders, including, for example, obstructive sleep apnea syndrome, restless legs syndrome, insomnia, or Rapid Eye Movement (REM) sleep disorder, is raised from the medical history, participants will be referred to the relevant specialists for diagnosis and treatment of such problems."
58489415|NCT06248723|OTHER|Control of cardiovascular, metabolic, and infectious risk factors|Measurements of blood pressure, weight, BMI, abdominal circumference, and advice on health promotion and healthy lifestyle will be provided. Recommendations on adherence to the Piano Nazionale di Prevenzione Vaccinale (PNPV) will also be provided.
58489416|NCT06248723|OTHER|Pharmacological evaluation|Evaluation of prescriptive appropriateness (STOP\&START and Beers criteria) and calculation of anticholinergic burden (ACB calculator) will be carried out by a geriatrician, with rationalization of therapy and, where possible, de-prescribing.
58489417|NCT06248723|BEHAVIORAL|Socializing|"To encourage socialization, proposed activities will be carried out as much as possible in groups of 10-12 people, and outdoor group activities will be suggested on a biweekly basis (e.g., walks in parks). On a monthly basis, the nurse and psychologist will organize motivational and check-up meetings (in recreation centers/via telematics) in order to promote adherence to the protocol, collect questions and stimulate participants.~Social activity will also be implemented in the context of all interventions, for example through:~* Physical activity in groups or pairs, including dance or choir activities where possible~* Opportunities for further cognitive stimulation in groups through games (e.g., chess, cards, etc.)~* Proposal to cook, eat or shop together~* Group sessions with dietitian"
58491186|NCT02714322|BIOLOGICAL|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
58491187|NCT02714322|BIOLOGICAL|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
58489418|NCT06248723|OTHER|Self-administered interventions|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website. Such advice and information will be timed to encourage adherence. In addition, participants randomized to the self-guided intervention will receive an initial counseling session of 30-60 minutes on all domains covered by the study, where guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
58489419|NCT05397158|PROCEDURE|single administration of low dose polyethylene glycol|"Patients in single administration of low dose polyethylene glycol (PEG) group: Take 30ml lactulose and 2L PEG.~Patients in control group: Take 4L PEG."
58489420|NCT05762068|OTHER|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
58489421|NCT01497288|DRUG|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
58489422|NCT03346694|DEVICE|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
58489423|NCT03346694|DEVICE|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
58489424|NCT03346694|DEVICE|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
58489425|NCT00533936|BIOLOGICAL|trastuzumab|
58489426|NCT00533936|DRUG|cyclophosphamide|
58489427|NCT00533936|DRUG|doxorubicin hydrochloride|
58489428|NCT00533936|DRUG|fluorouracil|
58489429|NCT00533936|DRUG|paclitaxel|
58489430|NCT00533936|PROCEDURE|adjuvant therapy|
58489431|NCT00533936|PROCEDURE|conventional surgery|
58489432|NCT00533936|PROCEDURE|neoadjuvant therapy|
58489433|NCT01794286|OTHER|Provider bulletins|
58489434|NCT01794286|OTHER|Trigger alerts|
58489435|NCT06205368|BEHAVIORAL|Combine mobile app|"* HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~* Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~* Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~* Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~* Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
58489436|NCT06205368|BEHAVIORAL|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
58489437|NCT06205368|BEHAVIORAL|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
58489438|NCT02499757|DEVICE|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
58489439|NCT02499757|DEVICE|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
58489440|NCT02499757|DEVICE|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
58489441|NCT02499757|DEVICE|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
58489442|NCT00245752|DEVICE|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
58489443|NCT00981058|BIOLOGICAL|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
58489444|NCT00981058|DRUG|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles."
58489445|NCT00981058|DRUG|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles."
58489446|NCT03965390|BEHAVIORAL|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
58489447|NCT00518089|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
58489448|NCT00518089|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
58489449|NCT01572285|PROCEDURE|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
58489450|NCT01572285|PROCEDURE|Sham|Sham procedure using a non-penetrating needle
58489451|NCT06262126|OTHER|Virtual Reality|Virtual Reality therapy
57784307|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
57784308|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
58489452|NCT06297811|DRUG|Trilaciclib Injection|Experimental: trilaciclib group Intervention: Drug: Trilaciclib Injection \[Cosela\] 240 mg/m\^2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
58489453|NCT06297811|DRUG|Paclitaxel|Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.
58489454|NCT06297811|DRUG|Carboplatin|area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.
58489455|NCT02578303|OTHER|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
58489456|NCT02382380|DRUG|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
58489457|NCT02382380|OTHER|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
58489458|NCT02608671|PROCEDURE|Skin adhesive tape|
58489459|NCT03304938|DRUG|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
58489460|NCT03304938|DRUG|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
58489461|NCT04947085|DRUG|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
58489462|NCT04947085|DRUG|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
58489463|NCT01146795|DRUG|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
58489464|NCT01146795|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
58489465|NCT01146795|DRUG|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
58489466|NCT02925299|DEVICE|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
58489467|NCT02925299|DEVICE|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
58489468|NCT05968729|OTHER|Active Comparator: 0.25 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.
58489469|NCT05968729|OTHER|Active Comparator: 0.50 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
58489470|NCT00409734|BEHAVIORAL|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
58489471|NCT00409734|BEHAVIORAL|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
58489472|NCT02988895|RADIATION|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
58489473|NCT01744080|OTHER|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
58489474|NCT01744080|OTHER|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
58489475|NCT02188888|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
58489476|NCT05773170|DRUG|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
58489477|NCT02590224|DRUG|Ferrous bis-glycinate|
58489478|NCT02590224|DRUG|Ferrous glycine sulphate|
58489479|NCT04199130|BEHAVIORAL|BrainHQ|"BrainHQ is a web-based brain-training program. The investigators will assign participants to attention specific modules that they will complete at home with the goal of restoring attentional functions lost through injury via repetitive tasks of graded difficulty."
58489480|NCT04199130|BEHAVIORAL|Goal Management Training|"This is a manualized, interactive, metacognitive-strategy training designed to promote a mindful approach to complex real-life tasks and reduce lapses in attention via implementation of compensatory mechanisms for monitoring tasks."
58489481|NCT05648032|COMBINATION_PRODUCT|lyophilized platelet (30ng) and triamcinolone acetonide 10mg|Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
58489482|NCT05648032|OTHER|lyophilized platelet (30ng)|Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
58489483|NCT05648032|DRUG|triamcinolone acetonide 10mg|Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
58489484|NCT03534180|OTHER|Laboratory Biomarker Analysis|Correlative studies
58489485|NCT03534180|DRUG|Romidepsin|Given IV
58489486|NCT03534180|DRUG|Venetoclax|Given PO
58489487|NCT04673396|DRUG|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
58489488|NCT04673396|DRUG|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
58489489|NCT02765581|DEVICE|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
58489490|NCT02765581|DEVICE|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
58489491|NCT02765581|BEHAVIORAL|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
58489492|NCT01594216|DRUG|Ruxolitinib|
58489493|NCT01594216|DRUG|Exemestane|
58489494|NCT03612752|DIETARY_SUPPLEMENT|CMI-168|Dietary supplement
58489495|NCT03612752|OTHER|Placebo|Placebo
58489496|NCT03160235|RADIATION|Magnetic resonance imaging|
58489497|NCT03160235|DEVICE|EEG|
58489498|NCT03160235|DEVICE|NIRS|
58489499|NCT03746158|DIETARY_SUPPLEMENT|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
58489500|NCT01266187|PROCEDURE|adjuvant surgery + FOLFOX + cetuximab|surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab
58489501|NCT01266187|PROCEDURE|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab"
58489502|NCT04522700|PROCEDURE|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
58489503|NCT00456170|PROCEDURE|Performing Vaginal hysterectomy with Harmonic Scalpel|
58489504|NCT05252091|DRUG|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
58489505|NCT04112381|DEVICE|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
58489506|NCT01855061|PROCEDURE|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
58489507|NCT01855061|PROCEDURE|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
58489508|NCT01855061|PROCEDURE|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
58489509|NCT01855061|PROCEDURE|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
58489510|NCT01988285|OTHER|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
58489511|NCT01988285|OTHER|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
58489512|NCT04066231|DEVICE|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
58489513|NCT04066231|DRUG|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
58489514|NCT00295373|DRUG|Rosuvastatin|
58489515|NCT00295373|BEHAVIORAL|Exercise Training|
58489516|NCT02053376|DRUG|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
58489517|NCT04761224|DEVICE|Fluido® Irrigation Fluid Heater System|"Patients in the Heated group will benefit from intraoperative warming by means of NaCl bags instilled using the Fluido® Irrigation warming cassette and with the use of specific instillation tubing (SEBAC laboratory, Set URO Fluido® Irrigation): this device allows continuous and precise heating of the solution with an instillation temperature of 38-39°C."
58489518|NCT02721472|PROCEDURE|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
58489519|NCT02721472|PROCEDURE|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
58489520|NCT00842751|DRUG|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
58489521|NCT00842751|OTHER|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
58489522|NCT00842751|DRUG|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
58489523|NCT00842751|DRUG|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
58489524|NCT00842751|OTHER|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
58489525|NCT05291715|DEVICE|Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)|Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
58489526|NCT03101332|BEHAVIORAL|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
58489527|NCT00482248|DRUG|Omalizumab|
58489528|NCT05306756|DIAGNOSTIC_TEST|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
58489529|NCT05306756|DIAGNOSTIC_TEST|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
58489530|NCT06168916|DIAGNOSTIC_TEST|PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.
58489531|NCT05353504|DIETARY_SUPPLEMENT|Inulin|28g/day delivered in 2 sachets throughout the day with main meals
58489532|NCT05353504|BEHAVIORAL|Lifestyle intervention|weekly educational sessions to improve individual's eating behaviour
58489533|NCT05353504|DIETARY_SUPPLEMENT|Placebo|equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
58489534|NCT00583895|DRUG|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
58489535|NCT00583895|DRUG|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
58489536|NCT01802138|BIOLOGICAL|Activated T lymphocyte|intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
58489537|NCT00409552|BEHAVIORAL|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
58489538|NCT00409552|BEHAVIORAL|VR with flat projection display|VR with flat projection display
58489539|NCT00409552|BEHAVIORAL|non-interactive video with head display|non-interactive video with head display
58489540|NCT00409552|BEHAVIORAL|non-interactive video with with flat projection display|non-interactive video with with flat projection display
58489541|NCT03464175|DEVICE|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
58489542|NCT03464175|DEVICE|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
58489543|NCT03464175|DEVICE|Heated-humidified circuit|It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
58489544|NCT03464175|DEVICE|Dry ventilator circuit specific for aerosol therapy|Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
58489545|NCT03464175|DEVICE|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
58489546|NCT02757417|DRUG|sodium fluorescein|
58489547|NCT02757417|DRUG|phenazopyridine|
58489548|NCT03320577|BEHAVIORAL|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
58489549|NCT03320577|BEHAVIORAL|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
58489550|NCT03320577|BEHAVIORAL|Control|Log dinner times
58489551|NCT01163227|DRUG|Placebo (single and multiple doses)|
58489552|NCT01163227|DRUG|AQW051 2 mg (single and multiple doses)|
58489553|NCT01163227|DRUG|AQW051 15mg (single and multiple doses)|
58489554|NCT01163227|DRUG|AQW051 100mg (single dose), and 50mg (multiple doses)|
58489555|NCT02751489|OTHER|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
58489556|NCT04212962|BEHAVIORAL|Transitional care model (TCM)|Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient
58489557|NCT04212962|BEHAVIORAL|Usual care|usual hospital discharge and post-discharge care
58489558|NCT04239612|BEHAVIORAL|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
58489559|NCT00071630|BEHAVIORAL|Cognitive Behavioral Therapy|
58489560|NCT00942526|DRUG|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
58489561|NCT00942526|OTHER|Water|perioperative gargling with water
58489562|NCT05179356|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg given once daily for three months
58489563|NCT05179356|DRUG|Placebo|Matching placebo
58489564|NCT05545540|OTHER|Musical Neurostimulation|Daily exposure to musical composition found to have antiseizure properties
58489565|NCT05545540|OTHER|Placebo Musical Neurostimuloation|Daily exposure to musical composition found NOT to have antiseizure properties
58489566|NCT02127957|OTHER|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
58489567|NCT02921178|OTHER|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
58489568|NCT01544335|OTHER|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
58489569|NCT00932178|BEHAVIORAL|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
58489570|NCT04980092|OTHER|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
58489571|NCT05213767|DRUG|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
58489572|NCT03474419|PROCEDURE|laser surgery|laser surgery
58489573|NCT00503815|DRUG|BLI-800|
58489574|NCT00503815|DRUG|Polyethylene glycol 3350 based bowel preparation|
58489575|NCT02714972|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
58489576|NCT00272103|DRUG|Itopride (drug)|
58489577|NCT00611026|DRUG|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
58489578|NCT00611026|DRUG|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
58489579|NCT00611026|DRUG|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
58489580|NCT00342108|BEHAVIORAL|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
58489581|NCT02023697|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
58489582|NCT00554632|DRUG|Ethinyl estradiol and norgestimate|Oral contraceptive
58489583|NCT00554632|DRUG|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
58489584|NCT02549365|DRUG|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
58489585|NCT02549365|PROCEDURE|Surveillance (nasal swabbing) during influenza season|
58489586|NCT02358941|BEHAVIORAL|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
58489587|NCT02358941|BEHAVIORAL|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
58489588|NCT04509661|DRUG|LABA/LAMA or Placebo inhalation|Inhaled LABA/LAMA for one year.
58489589|NCT01519869|DRUG|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
58489590|NCT02295670|DEVICE|Vividtrac|video-laryngoscopy
58489591|NCT02295670|DEVICE|MIL|direct-laryngoscopy
57784309|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
57784310|NCT01233635|OTHER|no drug|none, no drug
57784311|NCT01233635|DRUG|start cozaar|start cozaar
58489592|NCT02592096|DRUG|0.1% Pazufloxacin Mesilate Ear Drops|
58489593|NCT02592096|DRUG|0.3% Pazufloxacin Mesilate Ear Drops|
58489594|NCT02592096|DRUG|0.5% Pazufloxacin Mesilate Ear Drops|
58489595|NCT02592096|DRUG|Pazufloxacin mesilate injection|
58489596|NCT01685515|DRUG|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
58489597|NCT01685515|DRUG|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
58489598|NCT00002751|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
58489599|NCT05593562|DRUG|SPH3127|Oral 100 mg \[14 c\] SPH3127 mixed suspension
58489600|NCT00607373|DRUG|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
58489601|NCT00607373|DRUG|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
58489602|NCT04640220|PROCEDURE|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
58489603|NCT06311097|OTHER|Fermented dairy|Participants will consume 300g of yogurt daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
58489604|NCT06311097|OTHER|Non-fermented dairy|Participants will consume 300g of milk daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
58489605|NCT03111186|DRUG|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
58489606|NCT03111186|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
58489607|NCT03111186|DRUG|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
58489608|NCT02212951|DRUG|BIOD-531|
58489609|NCT02212951|DRUG|Humalog Mix 75/25|
58489610|NCT02212951|DRUG|Humulin R U-500|
58489611|NCT00141791|DRUG|Etanercept|
58489612|NCT02967783|DEVICE|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
58489613|NCT02967783|DEVICE|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
58489614|NCT02967783|DEVICE|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
58489615|NCT02422459|BEHAVIORAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
58489616|NCT01151904|DRUG|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
58489617|NCT01151904|DRUG|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
58489618|NCT03810105|DRUG|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
58489619|NCT03810105|DRUG|Durvalumab|Durvalumab 1500mg IV monthly
58489620|NCT05242627|BEHAVIORAL|Clinical Firearm Safety Counseling Module|"The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program."
58489621|NCT04301804|DRUG|SHR6390|a selective small-molecule CDK4/6 inhibitor
58489622|NCT00373997|PROCEDURE|Esophageal and Laryngeal biopsies|one day procedure
58489623|NCT00373997|PROCEDURE|egd with biopsy|standard of care procedure with biopsy
58489624|NCT00334113|BEHAVIORAL|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
58489625|NCT00867815|DRUG|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
58489626|NCT02138448|BEHAVIORAL|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
58489627|NCT03048006|PROCEDURE|MRI with Dotarem|
58489628|NCT00692263|DRUG|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
58489629|NCT00692263|DRUG|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
58489630|NCT00692263|DRUG|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
58489631|NCT02872935|DRUG|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
58489632|NCT02872935|DRUG|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
58489633|NCT03103477|OTHER|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
58489634|NCT02692638|PROCEDURE|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
58489635|NCT02692638|PROCEDURE|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
58489636|NCT03578783|DRUG|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
58489637|NCT03578783|DRUG|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
58489638|NCT00006289|DRUG|Placebo|4 tabs b.i.d.
58489639|NCT00006289|DRUG|Neurotropin|4 tabs b.i.d.
58489640|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
58491188|NCT03100552|DIAGNOSTIC_TEST|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
57784312|NCT01233635|DRUG|continue cozaar|continue cozaar
57784313|NCT01474408|BEHAVIORAL|interval training day 1|
57784314|NCT01474408|BEHAVIORAL|Moderate exercise day 2|
57784315|NCT01474408|BEHAVIORAL|Control day 3|
58491189|NCT00038818|BIOLOGICAL|CD8 Depleted Donor Lymphocyte|
58489641|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
58489642|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
58489643|NCT01091220|BIOLOGICAL|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
58489644|NCT01091220|BIOLOGICAL|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
58489645|NCT01880138|OTHER|watching animated cartoon before general anesthesia|
58489646|NCT01880138|OTHER|not watching animated cartoon beofre general anaesthesia|
58489647|NCT02309905|DEVICE|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
58489648|NCT02744404|DEVICE|POC EID|
58489649|NCT02417506|OTHER|E-OA-07 (Lanconone)|
58489650|NCT02417506|DRUG|Ibuprofen|
58489651|NCT02410564|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
58489652|NCT02410564|BEHAVIORAL|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
58489653|NCT06276504|DRUG|Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection|Pembrolizumab administration at D0, M1 and M2
58489654|NCT04638361|OTHER|Questionnaires|To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
58489655|NCT02950467|DRUG|Psilocybin|One individual oral psilocybin treatment session
58489656|NCT02950467|BEHAVIORAL|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
58489657|NCT03313167|OTHER|Non-interventional|Non-interventional
58489658|NCT00424541|DRUG|SPP100 (aliskiren)|
58489659|NCT00464776|DRUG|Aliskiren|
58489660|NCT00464776|DRUG|Aliskiren|
58489661|NCT00464776|DRUG|Aliskiren|
58489662|NCT00464776|DRUG|Aliskiren|
58489663|NCT00003439|BIOLOGICAL|recombinant interleukin-12|
58489664|NCT03692104|DIAGNOSTIC_TEST|transrectal ultrasound|Use of US for post implant quality assessment
58489665|NCT03365349|OTHER|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
58489666|NCT03365349|OTHER|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
58489667|NCT05932667|DRUG|Milademetan|The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
58489668|NCT05932667|BEHAVIORAL|Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)|Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
58489669|NCT02918513|BEHAVIORAL|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
58489670|NCT02918513|BEHAVIORAL|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
58489671|NCT02918513|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
58489672|NCT02918513|BEHAVIORAL|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
58489673|NCT02918513|BEHAVIORAL|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
58489674|NCT02918513|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
58489675|NCT02918513|BEHAVIORAL|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
58489676|NCT01229267|BIOLOGICAL|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
58489677|NCT01229267|BIOLOGICAL|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
58489678|NCT02901704|DEVICE|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
58489679|NCT02901704|PROCEDURE|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
58489680|NCT05739201|PROCEDURE|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
58489681|NCT05739201|PROCEDURE|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
58489682|NCT05739201|PROCEDURE|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
58489683|NCT05674305|DRUG|Radiotherapy|IMRT for primary and regional field
58489684|NCT05674305|DRUG|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
58489685|NCT02064101|PROCEDURE|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
58489686|NCT06462105|DRUG|Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection|"Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable."
58489687|NCT01608945|DRUG|Hydrocortisone sodium succinate|100mg/day
58489688|NCT00899431|DRUG|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
58489689|NCT00899431|DRUG|Fludarabine|30 mg/m\^2 intravenously daily on days -5, -4, -3.
58489690|NCT00899431|DRUG|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
58489691|NCT00899431|DRUG|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
58489692|NCT00899431|PROCEDURE|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
58489693|NCT00899431|DRUG|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
58489694|NCT00899431|DRUG|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
58489695|NCT02967224|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58489696|NCT02967224|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58489697|NCT02967224|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58489698|NCT02967224|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58489699|NCT02967224|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
58489700|NCT00632606|DRUG|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
58489701|NCT00632606|DRUG|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
58489702|NCT06020989|DRUG|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
58489703|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
58489704|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
58489705|NCT02544516|OTHER|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
58489706|NCT02544516|OTHER|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
58489707|NCT05936697|DEVICE|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
58491190|NCT05586269|BEHAVIORAL|Meal Kit Delivery|Families receive 6 weeks of healthy meal kit delivery. Meal kits come with embedded nutrition education and access to online cooking demonstrations.
58489708|NCT05936697|DEVICE|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
58489709|NCT05936697|OTHER|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
58489710|NCT05008965|BIOLOGICAL|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
58489711|NCT05008965|OTHER|Placebo|Formulation buffer
58489712|NCT04635540|BEHAVIORAL|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
58489713|NCT03061006|DRUG|Dabigatran Etexilate|150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.
58489714|NCT03061006|DRUG|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
58489715|NCT03396263|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
58489716|NCT03396263|BEHAVIORAL|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
58489717|NCT03396263|BEHAVIORAL|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
58489718|NCT05360121|OTHER|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
58489719|NCT05360121|OTHER|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
58489720|NCT05360121|OTHER|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
58489721|NCT05360121|OTHER|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
58489722|NCT05360121|OTHER|Back strengthening exercises|"1. Supine Abdominal Draw In~2. Supine Butt Lift with Arms at Side~3. Abdominal Draw In with Heel Slide~4. Abdominal Draw In with Knee to Chest~5. Abdominal Draw In with feet on the ball~6. Abdominal Draw In with feet on the ball- add movement"
58489723|NCT05360121|OTHER|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
58489724|NCT01359085|DRUG|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
58489725|NCT01359085|PROCEDURE|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
58489726|NCT00992797|DRUG|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.
58489727|NCT00992797|OTHER|Orange juice|Orange juice at randomization day and at week 5.
58489728|NCT00617968|DRUG|DOCETAXEL|
58489729|NCT04743986|BIOLOGICAL|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
58489730|NCT04743986|DRUG|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
58489731|NCT02751190|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
58489732|NCT02751190|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
58489733|NCT02751190|PROCEDURE|Open anterior mesh repair|
58489734|NCT02751190|PROCEDURE|Open Anterior Non Mesh|
58489735|NCT02751190|PROCEDURE|Combined anterior and posterior repair|
58489736|NCT02751190|PROCEDURE|Open preperitoneal mesh repair|
58489737|NCT02644603|PROCEDURE|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
58489738|NCT05389904|OTHER|Arm 1: Routine care|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.
58491191|NCT04549298|OTHER|No interventions|No interventions - observational study
58491192|NCT03152929|DRUG|Paravertebral Block|20-30 mL 0.5% Ropivacaine
57784316|NCT03606096|BIOLOGICAL|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
57784317|NCT03606096|BIOLOGICAL|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
57784318|NCT03606096|BIOLOGICAL|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
57784319|NCT03606096|BIOLOGICAL|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
57784320|NCT00168051|DRUG|ReFacto|
57784321|NCT00168051|DRUG|Advante|
57784322|NCT03826433|BIOLOGICAL|Peripheral iv|6\*10\^7 cells
57784323|NCT03867474|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
57784324|NCT04351750|OTHER|general exercise|The participants will receive training sessions twice a week for 8 weeks. General exercise includes aerobic exercise (stationary bike) and resistance training (thera-band, sandbags, dumbbell and swiss ball), and the intensity and progression of both aerobic and resistance exercises will be provided as recommended by the ACSM, and the exercise will individualized based on participant's HRR, 1 RM weight and Borg Scale of Perceived Exertion Scale (Borg RPE scale). An oximeter will be utilized to monitor the heart rate and SPO2 of the participants to ensure safety during the training session.
57784325|NCT04351750|OTHER|pelvic floor muscle training|Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
57784326|NCT00980109|DRUG|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
57784327|NCT00980109|DRUG|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
57784328|NCT00980109|DRUG|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
57784329|NCT00980109|DRUG|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
57784330|NCT06228664|OTHER|foam rolling|Foam Rolling Technique on trapezius and suboccipital muscles.conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range). Patients will be treated 3 times per week for 6 consecutive weeks
58137570|NCT00336622|DEVICE|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
58137571|NCT04510077|BEHAVIORAL|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
58137572|NCT04510077|OTHER|Survey Administration|Ancillary studies
58137573|NCT00488774|OTHER|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
58137574|NCT00488774|DRUG|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
58137575|NCT00488774|DRUG|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
58137576|NCT00488774|DRUG|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
58137577|NCT05123495|BEHAVIORAL|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
58137578|NCT05123495|BEHAVIORAL|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
58137579|NCT01758627|DRUG|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
58137580|NCT03726866|DRUG|Sequence 1|D326, D337 or CKD-828 for 9 days
58137581|NCT03726866|DRUG|Sequence 2|D326, D337 or CKD-828 for 9 days
58137582|NCT03726866|DRUG|Sequence 3|D326, D337 or CKD-828 for 9 days
58137583|NCT03726866|DRUG|Sequence 4|D326, D337 or CKD-828 for 9 days
58137584|NCT03726866|DRUG|Sequence 5|D326, D337 or CKD-828 for 9 days
58137585|NCT03726866|DRUG|Sequence 6|D326, D337 or CKD-828 for 9 days
58137586|NCT02455492|OTHER|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
58137587|NCT02763865|DEVICE|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
58137588|NCT02763865|DEVICE|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
58137589|NCT01110005|OTHER|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
58137590|NCT01110005|OTHER|Lactated Ringer's Solution (LR)|LR IV fluid
58491193|NCT03152929|DRUG|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
58491194|NCT06517004|BIOLOGICAL|JWCAR201|Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
58491195|NCT00002271|DRUG|Alovudine|
58491196|NCT06318013|DIAGNOSTIC_TEST|vitality test|A vitality test will be performed using a vitalometer to check if the drowsiness is gone
58137591|NCT05101044|BEHAVIORAL|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
58137592|NCT06364709|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
58137593|NCT05448430|DEVICE|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
58137594|NCT01386294|DRUG|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
58137595|NCT01386294|DRUG|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
58137596|NCT05478395|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
58137597|NCT06181071|OTHER|Distal Muscle Fatigue Protocol|Initially, sociodemographic data, muscle viscoelastic properties, foot plantar pressure, and static and dynamic balance are assessed. Additionally, the strengths of the plantar flexor and dorsiflexor muscles are evaluated. After these assessments, the heel raise exercise will be implemented in this protocol. Firstly, dominant leg, the heel raise exercise will be performed for 3 sets with the knees in full extension until the individual reaches fatigue. Subsequently, the heel raise exercise will be conducted for another 3 sets with the knee in flexion until the individual reaches fatigue. Following these exercises, Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
58137598|NCT06181071|OTHER|Proximal Muscle Fatigue Protocol|One week after the application of the distal muscle fatigue protocol, the same individuals will undergo the proximal fatigue protocol. In this protocol, individuals will perform, dominant leg, a single-leg squat exercise targeting the fatigue of the hip flexor and extensor muscles. Prior to this exercise, the viscoelastic properties of the muscles, foot plantar pressure, static and dynamic balances, as well as the strengths of the hip flexor and extensor muscles will be assessed. Then, individuals will perform the single-leg squat exercise, 3 sets. When the individual indicates fatigue, the set will conclude, allowing a 30-second rest between sets. Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
58137599|NCT03481998|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
58137600|NCT03481998|DRUG|Letrozole or anastrozole or Fulvestrant|Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
58137601|NCT04249271|OTHER|serum sampling|repeated serum sampling during pregnancy and thereafter
58137602|NCT05782647|DEVICE|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
58137603|NCT02104960|OTHER|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
58137604|NCT02104960|OTHER|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
58137605|NCT02104960|OTHER|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
58137606|NCT04181853|OTHER|exercise|aerobic exercise
58137607|NCT02024646|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
58137608|NCT02024646|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
58137609|NCT02024646|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
58137610|NCT01530880|DRUG|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
58137611|NCT01530880|DRUG|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
58137612|NCT02830516|OTHER|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
58137613|NCT03027115|DRUG|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
58137614|NCT00487669|DRUG|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
58137615|NCT03192696|DEVICE|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
58137616|NCT00620022|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
58137617|NCT00620022|DRUG|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
58137618|NCT05275205|DRUG|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
58137619|NCT05275205|DRUG|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
58137620|NCT02881255|DEVICE|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
58137621|NCT05487274|PROCEDURE|Total Shoulder Arthroplasty + augmented glenoid component|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components. A prosthetic component is also implanted to correct for the amount of bone loss in the shoulder and restore stability.
58137622|NCT05487274|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
58137623|NCT02939092|DRUG|Pomegranates peel extract|Pomegranate is antimicrobial
58137624|NCT02939092|DRUG|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
58137625|NCT00234078|DRUG|0.5% OPC-12759|
58137626|NCT00234078|DRUG|1% OPC-12759|
58137627|NCT00234078|DRUG|2% OPC-12759|
58137628|NCT00234078|DRUG|placebo|
58137629|NCT00516880|DRUG|rosiglitazone|
58137630|NCT01828697|DRUG|Low dose nadroparin|"Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily"
58137631|NCT01828697|DRUG|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily."
58137632|NCT01828697|DRUG|Low dose enoxaparin|"Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily"
58137633|NCT01828697|DRUG|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily."
58137634|NCT01828697|DRUG|Low dose dalteparin|"Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily"
58137635|NCT01828697|DRUG|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily."
58137636|NCT01828697|DRUG|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily"
58137637|NCT01828697|DRUG|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily."
58137638|NCT03314688|BEHAVIORAL|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
58137639|NCT03314688|BEHAVIORAL|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
58137640|NCT00856388|DRUG|fludarabine phosphate|Given IV
58137641|NCT00856388|DRUG|melphalan|Given IV
58137642|NCT00856388|RADIATION|total-body irradiation|Undergo total-body irradiation
58137643|NCT00856388|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
58137644|NCT00856388|BIOLOGICAL|anti-thymocyte globulin|Given IV
58137645|NCT06022302|DRUG|Diet + laxative|The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.
58137646|NCT06022302|OTHER|Diet only|This is only a control and participants will not receive Movicol.
58137647|NCT00096265|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
58137648|NCT00096265|DRUG|Erlotinib Hydrochloride|Given orally
58137649|NCT00096265|RADIATION|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
58137650|NCT00096265|DRUG|Temozolomide|Given orally
58137651|NCT00057239|DRUG|Radafaxine|
58137652|NCT03423056|OTHER|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
58137653|NCT00022386|BIOLOGICAL|epoetin alfa|
58137654|NCT00022386|PROCEDURE|quality-of-life assessment|
58137655|NCT06064799|DIAGNOSTIC_TEST|miRNA-223 & -214 detection|miRNA-223 \& -214 detection in GCF samples by PCR kits
58137656|NCT00431600|OTHER|100% Oxygen|100% Oxygen- breathing over 30 minutes
58137657|NCT03929393|BEHAVIORAL|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
58137658|NCT03929393|OTHER|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
58137659|NCT05335863|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
58137660|NCT05335863|DIETARY_SUPPLEMENT|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
58137661|NCT02867930|DRUG|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
58137662|NCT02867930|DRUG|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
58137663|NCT06372457|DRUG|Approved Hypertrophic Cardiomyopathy drug treatments|As per product label
58137664|NCT06372457|DRUG|Mavacamten|As per product label
58137665|NCT04776525|DRUG|Ifosfamide|3 g/m2 each day for three days
58137666|NCT04776525|DRUG|Doxorubicin|80 mg/m2 over four hours day 1
58137667|NCT03274830|DEVICE|aneXys|150 patients with the aneXys cup
58137668|NCT02866422|OTHER|No Intervention|Observational Study: No intervention
58137669|NCT03902028|OTHER|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
58137670|NCT01591447|DRUG|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
58137671|NCT01591447|DRUG|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
58137672|NCT04589091|OTHER|Refractive surgery|Refractive surgery for correction of error of refraction
58137673|NCT02516657|DRUG|Liraglutide|Liraglutide 0.6 mg
58137674|NCT04455581|DRUG|SHR-1209|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
58137675|NCT02648334|DEVICE|IN.PACT drug coated balloon|
58137676|NCT02648334|DEVICE|Lutonix drug coated balloon|
58137677|NCT00998556|DRUG|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
58137678|NCT02072486|OTHER|Laboratory Biomarker Analysis|Correlative studies
58137679|NCT02072486|DRUG|Sorafenib Tosylate|Given PO
58137680|NCT05332925|DRUG|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
58137681|NCT00996788|DRUG|Rebamipide|Rebamipide 100 mg tid for 28 days
58137682|NCT05113966|DRUG|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 mL of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
58137683|NCT05113966|DRUG|Sacituzumab Govitecan-hziy|10 mg/kg reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
57784331|NCT06228664|OTHER|bowen therapy|Bowen Therapy. conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range) will be given to both groups. Patients will be treated 3 times per week for 6 consecutive weeks
57784332|NCT02809274|OTHER|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
58137684|NCT00413764|DRUG|tibolone|tibolone (2.5 mg) over 24 weeks
57784333|NCT00588003|DRUG|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
57784334|NCT00588003|OTHER|Placebo|No medication before surgery
57784335|NCT03728153|DRUG|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
57784336|NCT01935960|OTHER|Laboratory Biomarker Analysis|Correlative studies
57784337|NCT01935960|OTHER|Pharmacological Study|Correlative studies
57784338|NCT01935960|OTHER|Placebo|Given PO
57784339|NCT01935960|DRUG|Retinoid 9cUAB30|Given PO
57784340|NCT00333788|BIOLOGICAL|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
58137685|NCT00413764|DRUG|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
58137686|NCT06111703|BEHAVIORAL|Knowledge assessment|Knowledge, Attitude and Practice Survey
58137687|NCT00804063|PROCEDURE|drawing blood sample|fasting blood sample
58137688|NCT01371162|DRUG|RO5428029|Multiple ascending doses
58137689|NCT01371162|DRUG|placebo|multiple doses
58137690|NCT05341622|BEHAVIORAL|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
58137691|NCT05341622|BEHAVIORAL|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
58137692|NCT05341622|BEHAVIORAL|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
58137693|NCT05341622|BEHAVIORAL|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
58137694|NCT05341622|BEHAVIORAL|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
58137695|NCT05341622|BEHAVIORAL|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
58137696|NCT02214264|BEHAVIORAL|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
58137697|NCT02214264|BEHAVIORAL|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
58137698|NCT02214264|BEHAVIORAL|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
58137699|NCT02214264|BEHAVIORAL|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
58137700|NCT03488186|DRUG|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
58137701|NCT00229645|DRUG|Quetiapine Fumarate (Seroquel®)|
58137702|NCT02327130|DEVICE|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
58137703|NCT04795609|OTHER|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening."
58137704|NCT05165537|DEVICE|NIMM_MRS|evaluation of new MRS methods
58137705|NCT01678638|PROCEDURE|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
58137706|NCT01678638|PROCEDURE|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
58137707|NCT02417805|PROCEDURE|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
58137708|NCT01604694|PROCEDURE|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
58137709|NCT04132778|DEVICE|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
58137710|NCT02409693|PROCEDURE|Myringotomy with tube insertion|
58137711|NCT00445003|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
58137712|NCT00445003|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
58137713|NCT00445003|BEHAVIORAL|Sham injection|Sham injection at baseline and 4 weeks
58137714|NCT00445003|PROCEDURE|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
58137715|NCT03603314|DRUG|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
58137716|NCT03603314|OTHER|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
58137717|NCT03603314|DRUG|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
58137718|NCT02566278|OTHER|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
58137719|NCT00649025|DRUG|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
58137720|NCT00649025|DRUG|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
58137721|NCT00649025|DRUG|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
58137722|NCT00020826|OTHER|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
58137723|NCT05921955|DEVICE|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
58137724|NCT05430698|DRUG|PD-1antibody plus GEMOX|"1. PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~3. Three weeks is a course of treatment,a total of 6-8 courses."
58137725|NCT03804762|PROCEDURE|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
58137726|NCT02934347|PROCEDURE|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
58137727|NCT05381766|OTHER|CSA Model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
58137728|NCT05070286|BEHAVIORAL|Observational Study.|Semi-structured interviews.
58137729|NCT06086951|BEHAVIORAL|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
58137730|NCT06086951|OTHER|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
58137731|NCT05814926|DRUG|GP681|GP681, tablet, oral
58137732|NCT05932095|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
58137733|NCT05932095|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
58137734|NCT02819934|DRUG|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
58137735|NCT04661384|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
58137736|NCT02381210|DEVICE|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
58137737|NCT05833581|OTHER|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
58137738|NCT03518281|DIETARY_SUPPLEMENT|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing \>50% Beta Glucan
58137739|NCT03518281|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
58137740|NCT03239509|PROCEDURE|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
58137741|NCT03239509|PROCEDURE|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
58137742|NCT02312700|BEHAVIORAL|Interactive empowerment tool|
58137743|NCT03681145|BEHAVIORAL|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
58137744|NCT02602041|OTHER|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
58137745|NCT01739101|BEHAVIORAL|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
58137746|NCT00560443|DRUG|ketorolac|0,5 mg/kg per os one time
58137747|NCT00560443|DRUG|tramadol|2,5 mg/ kg per os in one dose
58137748|NCT03329326|OTHER|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
58137749|NCT03006445|DRUG|FYU-981|
58137750|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
58137751|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (40 mg/ml) with needles|Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
58137752|NCT03613922|OTHER|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
58137753|NCT03613922|OTHER|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
58137754|NCT00401947|DRUG|ACH-0137171|
58137755|NCT01636609|DRUG|Azacitidine|Given IV or SC
58137756|NCT01636609|DRUG|Cytarabine|Given SC
58137757|NCT01636609|DRUG|Tosedostat|Given PO
58137758|NCT04881903|BEHAVIORAL|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
58137759|NCT04881903|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
58137760|NCT05962879|BEHAVIORAL|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
58137761|NCT01346163|DRUG|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
58137762|NCT01346163|OTHER|Placebo|Placebo will be used as a comparator to the active arm.
58491197|NCT04995367|DEVICE|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
58137763|NCT02512393|DEVICE|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
58137764|NCT02512393|DEVICE|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
58137765|NCT01256892|PROCEDURE|induction of labour|
58137766|NCT00911898|DRUG|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
58137767|NCT02412215|PROCEDURE|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
58137768|NCT02412215|DEVICE|NanoFlex toric Intraocular Lens|
58137769|NCT00720330|DRUG|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
58137770|NCT00720330|DRUG|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
58137771|NCT00720330|OTHER|placebo|placebo
58137772|NCT01582126|OTHER|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
58137773|NCT05300139|OTHER|Color Doppler Ultrasound|Comparison between D90±5 and baseline CDUS
58137774|NCT06341322|BEHAVIORAL|Standard letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, based on the current invite letter.
58137775|NCT06341322|BEHAVIORAL|Behaviorally informed letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, with incorporates severally behaviorally informed components, including an active choice prompt, social norm, call to action, chunking and simplification.
58137776|NCT06341322|BEHAVIORAL|Home testing colorectal cancer kit|The home testing kit is included with the reminder letter, instead of the usual process of responding to the letter to order the kit
58137777|NCT00528606|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
58137778|NCT00528606|BIOLOGICAL|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
58137779|NCT03366805|BEHAVIORAL|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
58137780|NCT03366805|BEHAVIORAL|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
58137781|NCT03233646|DEVICE|Retinal and Choroidal Imaging|Non-invasive OCT, OCTA, and UWF fundus photography of retina
58137782|NCT00841178|PROCEDURE|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
58137783|NCT00841178|PROCEDURE|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
58137784|NCT05636241|OTHER|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
58491198|NCT00344578|DEVICE|Restor IOL|
57784341|NCT00318825|DRUG|Nitrous oxide|
57784342|NCT04006366|BEHAVIORAL|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
57784343|NCT03085121|PROCEDURE|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
57784344|NCT00001955|DRUG|Etanercept|
57784345|NCT00001955|DRUG|Celecoxib|
57784346|NCT02561715|BEHAVIORAL|Questionnaires|Pre and post deep brain surgery questionnaires
57784347|NCT03658811|DEVICE|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
57784348|NCT00187317|BEHAVIORAL|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
57784349|NCT00187317|OTHER|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
57784350|NCT04961216|BEHAVIORAL|OPTIMISE|Self-regulation intervention
57784351|NCT01114620|BIOLOGICAL|Arepanrix™|Intramuscular administration, one dose
57784352|NCT00339625|OTHER|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
57784353|NCT05075655|DEVICE|Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration|"Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance."
57784354|NCT00157742|PROCEDURE|Spinal Cord Stimulation (SCS)|
57784355|NCT00157742|PROCEDURE|Percutaneous Myocardial Laser Revascularisation (PMR)|
57784356|NCT04496414|DEVICE|Bactiseal Catheter|Bactiseal Catheter manufactured by Codman \& Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.
58137785|NCT05636241|OTHER|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
58137786|NCT01067885|DEVICE|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
58137787|NCT01772537|DRUG|Propofol|Intravenous anesthetic
58137788|NCT01772537|DRUG|isoflurane|
58137789|NCT02325141|PROCEDURE|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
58137790|NCT00584922|PROCEDURE|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
58137791|NCT01381705|BIOLOGICAL|rituximab|
58137792|NCT01381705|GENETIC|DNA analysis|
58137793|NCT01381705|GENETIC|gene expression analysis|
58137794|NCT01381705|GENETIC|polymorphism analysis|
58137795|NCT01381705|OTHER|laboratory biomarker analysis|
58137796|NCT01381705|OTHER|medical chart review|
58137797|NCT00724477|DRUG|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
58137798|NCT00377390|BIOLOGICAL|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
58137799|NCT00408070|DRUG|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
58137800|NCT00408070|DRUG|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
58137801|NCT00408070|DRUG|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
58137802|NCT02400957|OTHER|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
58137803|NCT02400957|OTHER|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
58137804|NCT01658228|DRUG|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
58137805|NCT01658228|DRUG|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
58137806|NCT01658228|DRUG|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
58137807|NCT01658228|DRUG|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
58137808|NCT04097730|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
58137809|NCT04097730|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
58137810|NCT04097730|DRUG|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
58137811|NCT04097730|OTHER|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
58137812|NCT02670057|PROCEDURE|Transnasal SPG block|
58137813|NCT04484493|DRUG|mometasone furoate nasal spray|dose of 2 puff in each nostril (100 µg once daily each nostril).
58137814|NCT04444557|OTHER|Beck Depression Inventory (BDI)|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
58138168|NCT04700774|BEHAVIORAL|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
58138169|NCT01770938|DEVICE|Effective light-emitting diode therapy|
58138170|NCT01770938|DEVICE|Placebo light-emitting diode therapy|
58138171|NCT04225663|BEHAVIORAL|Guided Meditation|Participants will meditate in response to the guidance provided by a trained meditation coach in person.
58491199|NCT05345652|PROCEDURE|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
58137815|NCT05525871|DIETARY_SUPPLEMENT|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
58137816|NCT05525871|DIETARY_SUPPLEMENT|Control product|Fruit puree
58137817|NCT01746329|OTHER|Tea|Oral intake of tea containing 75 grams of glucose
58137818|NCT01746329|OTHER|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
58137819|NCT01746329|OTHER|Placebo|Oral intake of 75 grams of glucose in water
58137820|NCT00280553|DRUG|bupivicaine|PCA and bupivicaine infusion for up to five days
58137821|NCT00280553|OTHER|Saline infusion|PCA and pump with saline infusion for up to five days
58137822|NCT01612520|BEHAVIORAL|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
58137823|NCT04572386|OTHER|light cure 3m single bond universal bond|light -cure universal bond
58137824|NCT04572386|OTHER|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
58137825|NCT00189293|DRUG|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
58137826|NCT00189293|OTHER|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
58137827|NCT02613000|OTHER|No intervention|
58137828|NCT05561335|DEVICE|hearing aid -novel program|novel microphone configuration
58137829|NCT05561335|DEVICE|hearing aid - standard program|standard microphone configuration
58137830|NCT02731365|DEVICE|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
58137831|NCT02535494|OTHER|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
58137832|NCT06124235|COMBINATION_PRODUCT|Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles|"insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position."
58137833|NCT06124235|COMBINATION_PRODUCT|Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles|Non-coated orthodontic miniscrews
58137834|NCT02566928|DRUG|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
58137835|NCT02566928|OTHER|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
58137836|NCT02566928|BEHAVIORAL|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
58137837|NCT05189405|DEVICE|INVOcell IVC|Embryo development in intravaginal incubation
58137838|NCT03968718|BEHAVIORAL|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
58137839|NCT03239990|BEHAVIORAL|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
58137840|NCT06061471|DRUG|AK111|AK111 regimen 1-subcutaneous injection,until week 24.
58137841|NCT06061471|DRUG|AK111|AK111 regimen 2-subcutaneous injection,until week 24.
58137842|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK|horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror
58137843|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK|horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
58137844|NCT02646397|DRUG|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
58137845|NCT02646397|DRUG|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
58137846|NCT02646397|DRUG|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
58137847|NCT03071029|BEHAVIORAL|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
58137848|NCT01719731|BEHAVIORAL|Education|This group will receive the psychoeducation
58137849|NCT01719731|BEHAVIORAL|Non-Education|This group will not receive the psychoeducation
58137850|NCT04646213|BEHAVIORAL|Managing Cancer and Living Meaningfully (CALM) Therapy|6 sessions of individualized CALM therapy
58137851|NCT00816569|DEVICE|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
58137852|NCT05717257|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
58137853|NCT00914420|DEVICE|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
58137854|NCT00914420|DEVICE|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
58137855|NCT05528263|DEVICE|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
58137856|NCT05528263|OTHER|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
58137857|NCT04075461|PROCEDURE|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
58137858|NCT04075461|PROCEDURE|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
58137859|NCT02466594|DEVICE|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
58137860|NCT03136380|DRUG|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
58137861|NCT03136380|DRUG|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
58137862|NCT04970368|PROCEDURE|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
58137863|NCT04970368|PROCEDURE|Selective staging|Intraoperative consultation (IOC)
58137864|NCT05192850|DRUG|Metformin use|As an observational study, this is past exposure to metformin that occurred during the study period
58137865|NCT01947218|PROCEDURE|bronchial biopsies|
58137866|NCT01947218|OTHER|Determination of CO in exhaled air|
58137867|NCT00626184|DRUG|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
58137868|NCT03686033|DRUG|Placebo|Participants will receive E2082-matched placebo tablets orally.
58137869|NCT03686033|DRUG|E2082|Participants will receive E2082 tablets orally.
58137870|NCT03225456|DRUG|Syntocinon|Intra-nasal oxytocin
58137871|NCT03225456|DRUG|Placebos|Intra-nasal placebo
58137872|NCT01900964|PROCEDURE|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
58137873|NCT01900964|PROCEDURE|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
58137874|NCT01789385|DRUG|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
58137875|NCT02419937|DRUG|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
58137876|NCT02419937|DRUG|Placebo|Saline injection
58137877|NCT03354221|DEVICE|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
58137878|NCT03354221|OTHER|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
58137879|NCT03354221|OTHER|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
58137880|NCT03354221|OTHER|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
58137881|NCT03800251|DIETARY_SUPPLEMENT|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
58137882|NCT00614471|DRUG|Entecavir|0.5mg po daily for 24 weeks
58137883|NCT00614471|DRUG|Entecavir|0.5mg po daily from week 13 to week 36
58137884|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
58137885|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
58137886|NCT03872505|DRUG|Durvalumab|IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
58137887|NCT03872505|RADIATION|Radiation Therapy|The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
58137888|NCT03872505|DRUG|Carboplatin|IV administration weekly for 12 weeks
58137889|NCT03872505|DRUG|Paclitaxel|IV administration every week for 12 weeks
58137890|NCT05178095|DEVICE|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
58137891|NCT05178095|DEVICE|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
58491200|NCT06254365|BIOLOGICAL|Exogenous LEAP2 hormone|This intervention has never been examined in this type of study before.
58491201|NCT00012844|DEVICE|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
58491202|NCT00012844|PROCEDURE|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
58137892|NCT06213506|BIOLOGICAL|Measles and Rubella vaccine|Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
58137893|NCT06213506|BIOLOGICAL|Yellow Fever vaccine|Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
58137894|NCT06213506|BIOLOGICAL|Pentavalent vaccine|Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
58137895|NCT06213506|BIOLOGICAL|Pneumococcal vaccine|Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
58137896|NCT06213506|BIOLOGICAL|Inactivated polio vaccine|Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
58137897|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose C|-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults_Dose C and Children_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Dose C and Infants_6W_Dose C_2 groups.
58137898|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose B|-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose B and Infants_6W_Dose B_2 groups.
58137899|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose A|3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose A and Infants_6W_Dose A_2 groups.
58137900|NCT06213506|BIOLOGICAL|MenACWY|-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children_Control B and Children_Control C groups, and at Day 1 and Day 85 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Control A, Infants_6W_Control B, Infants_6W_Control C and Infants_6W_Control_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
58137901|NCT06213506|COMBINATION_PRODUCT|DTPa-HBV-IPV+Hib|1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants_9M_Control A, Infants_9M_Control B and Infants_9M_Control C groups.
58137902|NCT06213506|DRUG|Placebo|1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults_Control group.
58137903|NCT00378131|DRUG|RC-1291|
58137904|NCT00378131|DRUG|placebo|
58137905|NCT01313949|OTHER|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
58137906|NCT03048812|DEVICE|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
58137907|NCT03048812|DEVICE|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
58137908|NCT01903317|OTHER|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
58137909|NCT01903317|OTHER|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
58137910|NCT01903317|OTHER|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
58491203|NCT05313334|BEHAVIORAL|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
58491204|NCT05249517|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a patient education approach that explains in detail the neurobiology, neurophysiology of pain, and the processing of pain by the nervous system in the management of chronic pain.
58137911|NCT05801497|PROCEDURE|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
58137912|NCT01423760|BIOLOGICAL|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
58137913|NCT01423760|OTHER|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
58137914|NCT00158171|DRUG|Nicotine Replacement Therapies|Nicotine gum 2 \& 4 mg dependent on baseline smoking rate
58137915|NCT00158171|DRUG|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
58137916|NCT00158171|DIETARY_SUPPLEMENT|Folic Acid|400 mg
58137917|NCT05857098|OTHER|Local Field potential recording|Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
58137918|NCT05313425|OTHER|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
58137919|NCT05599295|DRUG|Oritavancin|Oritavancin for IV infusion
58137920|NCT01474798|DRUG|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
58137921|NCT02794974|OTHER|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
58137922|NCT02794974|OTHER|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
58137923|NCT02794974|OTHER|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
58137924|NCT05151588|DRUG|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
58137925|NCT05151588|DRUG|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
58137926|NCT05151588|DRUG|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
58137927|NCT05151588|DRUG|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
58137928|NCT05151588|PROCEDURE|Surgery|Radical surgery
58137929|NCT05151588|OTHER|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
58137930|NCT04641130|OTHER|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
58137931|NCT05708105|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C or 7100 Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
58137932|NCT05708105|DIAGNOSTIC_TEST|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and \< 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
58137933|NCT05708105|DIAGNOSTIC_TEST|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
58137934|NCT04350580|DRUG|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
58137935|NCT04350580|DRUG|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
58137936|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
58137937|NCT04591405|BIOLOGICAL|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
58137938|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
58137939|NCT04591405|BIOLOGICAL|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
58137940|NCT00122577|DRUG|Tenofovir|
58137941|NCT00122577|DRUG|Atazanavir|
58137942|NCT00122577|DRUG|Ritonavir|
58137943|NCT02758691|DRUG|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
58137944|NCT02758691|DRUG|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
58137945|NCT05130554|PROCEDURE|XEN45 gel stent implantation|The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
58137946|NCT02605148|DIETARY_SUPPLEMENT|Gluten free diet|Gluten free diet during 18 months.
58137947|NCT02605148|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Omega 3 fatty acid
58137948|NCT02605148|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 800 U/day
58137949|NCT02605148|DIETARY_SUPPLEMENT|Probiotics|Probiotics
58137950|NCT00914394|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
58137951|NCT00914394|DRUG|Phenylephrine|1µg/kg/min, infusion period 20 minutes
58137952|NCT00914394|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
58137953|NCT00914394|DEVICE|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
58137954|NCT00914394|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
58137955|NCT00914394|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
58137956|NCT03365297|DRUG|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
58137957|NCT00063856|BIOLOGICAL|Wetvax (APSV)|
58137958|NCT05662163|PROCEDURE|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
58137959|NCT05662163|PROCEDURE|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
58137960|NCT03850639|BEHAVIORAL|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
58137961|NCT03751605|PROCEDURE|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
58137962|NCT06284538|DEVICE|NOVA.EMOSTOP RE-EPITHELIZING|RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
58137963|NCT04455126|DRUG|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
58137964|NCT02865122|DRUG|NTRA-9620|Oral daily dose
58137965|NCT02865122|DRUG|Placebo|Oral daily dose
58137966|NCT02142556|DRUG|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
58137967|NCT06123533|OTHER|No intervention|There is no intervention.
58137968|NCT03736382|OTHER|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
58137969|NCT03736382|OTHER|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
58137970|NCT03736382|OTHER|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
58137971|NCT00322803|DRUG|ELB139|
58137972|NCT05275179|OTHER|Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
58137973|NCT03139019|BEHAVIORAL|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
58137974|NCT03139019|BEHAVIORAL|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
58137975|NCT03139019|BEHAVIORAL|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
58137976|NCT01386593|DRUG|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
58137977|NCT01386593|DRUG|"Basel Cocktail"|
58137978|NCT01386593|DRUG|Basel cocktail + Rifampicin|
58137979|NCT02006173|DRUG|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
58137980|NCT02006173|DRUG|Normal Saline|
58137981|NCT05099822|DRUG|CC-97489|Specified dose on specified days
58137982|NCT05099822|OTHER|Placebo|Specified dose on specified days
58137983|NCT06203522|PROCEDURE|Data collection of successful completion of MRI|age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
58137984|NCT00858923|DEVICE|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
58137985|NCT05883956|DRUG|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
58137986|NCT05883956|DRUG|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
58137987|NCT02623543|DEVICE|OrthoK|
58137988|NCT03488667|DRUG|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
58137989|NCT03488667|DRUG|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
58137990|NCT03927066|OTHER|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
58137991|NCT03806062|DRUG|domperidone|10 mg domperidone 3 times a day after meals
58137992|NCT03806062|DEVICE|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
58137993|NCT03806062|DEVICE|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
58137994|NCT02393157|DRUG|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
58137995|NCT02393157|DRUG|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
58137996|NCT02393157|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
58137997|NCT02393157|DRUG|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
58137998|NCT02393157|DRUG|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
58137999|NCT01316549|DRUG|Fludarabine|Given as injection
58138000|NCT01576042|DRUG|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
58138001|NCT01576042|DRUG|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
58138002|NCT01576042|DEVICE|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
58138003|NCT05257746|PROCEDURE|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
58138004|NCT05910632|BEHAVIORAL|Eccentrically strengthened resistance exercise|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with high intensity (ever 10 on the OMNI-RES Scale).
58138005|NCT05910632|BEHAVIORAL|Traditional resistance training|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8-12 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with moderate and high intensities (6 to 10 on the OMNI-RES scale).
58138006|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
58138007|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
58138008|NCT01745783|OTHER|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
58138009|NCT01745783|OTHER|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
58138010|NCT02337218|DEVICE|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
58138011|NCT06370780|OTHER|EPI LOVE|Observational cohort only
58138012|NCT00161564|DRUG|Rituximab|
58138013|NCT02874300|OTHER|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
58138014|NCT02874300|OTHER|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
58138015|NCT03739749|PROCEDURE|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
58138016|NCT05634772|DEVICE|dormia basket|Use of dormia basket in management of proximal stent migration
58138017|NCT05634772|DEVICE|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
58138018|NCT01003002|DRUG|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
58138019|NCT01793194|OTHER|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
58138020|NCT00004359|DRUG|methoxsalen|
58138021|NCT02219945|OTHER|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
58138022|NCT05693597|DRUG|Imtenan Oil|Cold Press Oil
58138023|NCT05693597|DRUG|Baraka Capsules|Soft Gelatin Capsules
58138024|NCT01138436|DRUG|MEBO Wound Ointment (MEBO)|Topical application once a day
58138025|NCT01138436|PROCEDURE|Standard of Care|Application of Profore multilayer compression bandage system
58138026|NCT06149130|DRUG|Adebrelimab|adebrelimab:1200mg intravenously, Q3W.
58138027|NCT06149130|DRUG|dalpiciclib|dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
58138028|NCT03962348|BEHAVIORAL|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
58138029|NCT00585689|DRUG|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
58138030|NCT00585689|DRUG|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
58138031|NCT00585689|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
58138032|NCT00585689|PROCEDURE|Radical Cystectomy|
58138033|NCT02068105|DRUG|ALKS 5461|Sublingual tablet
58138034|NCT02068105|DRUG|Placebo|Sublingual tablet
58138035|NCT02550678|BIOLOGICAL|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
58138036|NCT02550678|DRUG|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
58138037|NCT00010647|PROCEDURE|Acupuncture|
58138038|NCT02126137|DRUG|Ezetimibe|
58138039|NCT05298267|DEVICE|Do Not Disturb While Driving|Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
58138040|NCT05165381|DEVICE|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
58138041|NCT01482377|DRUG|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
58138042|NCT01482377|DRUG|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.
58138043|NCT01482377|DRUG|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
58138044|NCT01482377|DRUG|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
58138045|NCT05136183|DEVICE|HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)|"* If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization."
58138046|NCT03593980|DIETARY_SUPPLEMENT|Cranberry juice|400ml cranberry juice
58138047|NCT04738084|BEHAVIORAL|Meru Health Program|Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
58138048|NCT01641380|BEHAVIORAL|Text Messaging Intervention|"1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
58138049|NCT01544361|OTHER|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
58138050|NCT01544361|BIOLOGICAL|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
58138051|NCT01544361|BIOLOGICAL|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
58138052|NCT01544361|BIOLOGICAL|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
58138053|NCT01544361|BIOLOGICAL|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
58138054|NCT02975141|DRUG|Afatinib 30Mg Tab|Study Drug
58138055|NCT02975141|DRUG|Afatinib 40Mg Tab|Study Drug
58138056|NCT02975141|DRUG|Gemzar|Chemotherapy Backbone
58138057|NCT02975141|DRUG|Abraxane|Chemotherapy Backbone
58138058|NCT04000815|DIAGNOSTIC_TEST|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
58138059|NCT05240495|BEHAVIORAL|Internet-based Cognitive-behavioural therapy|Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.
58138060|NCT05240495|BEHAVIORAL|Work-focused Cognitive-behavioural therapy|The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
58138061|NCT01292720|DRUG|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
58138062|NCT01292720|DRUG|Placebo|Placebo in matching volumes
58138063|NCT05651230|DIETARY_SUPPLEMENT|Rhamnan sulfate|A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
58138064|NCT00086996|DRUG|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
58138065|NCT00086996|DRUG|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
58138066|NCT00086996|PROCEDURE|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
58138067|NCT00086996|RADIATION|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
58138068|NCT01591785|DRUG|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
58138069|NCT01591785|DRUG|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
58138070|NCT02616809|OTHER|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
58138071|NCT02616809|OTHER|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
58138072|NCT02616809|OTHER|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
58489739|NCT05389904|OTHER|Arm 2: Preemptive C. difficile infection prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
58489740|NCT05915481|DRUG|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
58489741|NCT05915481|RADIATION|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
58489742|NCT04348916|BIOLOGICAL|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
58489743|NCT04348916|BIOLOGICAL|pembrolizumab|Anti-PD-1 monoclonal antibody
58489744|NCT04743778|BEHAVIORAL|Virtual Diabetes Self-Management Education and Support|Diabetes self-management education and support delivered through Zoom for health.
58489745|NCT06278441|OTHER|Kangaroo care and White noise|CG newborns underwent routine heel lancing, and no intervention was performed.
58489746|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
58489747|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
58489748|NCT02004678|DRUG|DS-1150b|
58489749|NCT02004678|OTHER|Placebo|
58489750|NCT04550429|DEVICE|MyoSure Hysteroscopic Morcellator Device|This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
58489751|NCT05938205|DIETARY_SUPPLEMENT|AA-1|low dose aminoacids
58489752|NCT05938205|DIETARY_SUPPLEMENT|AA-2|high dose aminoacids
58489753|NCT05938205|BEHAVIORAL|Placebo|Nutritional Placebo
58489754|NCT05938205|BEHAVIORAL|Exe-H|high intensity physical exercise
58489755|NCT04003948|DRUG|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
58489756|NCT02877771|DEVICE|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
58489757|NCT03452163|DEVICE|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
58489758|NCT03452163|DEVICE|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
58489759|NCT03034070|DIAGNOSTIC_TEST|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
58489760|NCT00199303|DRUG|pre-operatively followed by 30 mg three times per day after surgery|
58489761|NCT03915652|BEHAVIORAL|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
58489762|NCT00423917|BIOLOGICAL|bevacizumab|
58489763|NCT00423917|DRUG|fulvestrant|
58489764|NCT02406534|BEHAVIORAL|HRQoL surveys|
58489765|NCT03124342|OTHER|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals"
58489766|NCT04239391|DRUG|Triferic|Ferric Pyrophosphate Citrate
58489767|NCT02726854|DRUG|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
58489768|NCT04916691|PROCEDURE|EPSB for rib fractures|EPSB for rib fractures
58489769|NCT04916691|DRUG|Ropivacaine|Standard of care weight-based optimal Ropivacaine dosing for ESPB
58489770|NCT02985528|OTHER|further diagnostic|further diagnostic procedures - mainly CHEST CT -
58489771|NCT02861001|DEVICE|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
58489772|NCT02861001|DEVICE|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
58489773|NCT05241548|PROCEDURE|BMAC on PCL Scaffold|Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
58489774|NCT00249899|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
58489775|NCT00249899|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
58489776|NCT01305993|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
58489777|NCT00610480|DRUG|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
58489778|NCT00610480|DRUG|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
58489779|NCT06005064|DIETARY_SUPPLEMENT|Krill oil|Superba krill oil
58489780|NCT06005064|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
58489781|NCT01179113|DRUG|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
58489782|NCT01179113|DRUG|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
58489783|NCT03024099|OTHER|Hippotherapy once a week|Hippotherapy once a week
58489784|NCT03024099|OTHER|Hippotherapy twice a week|Hippotherapy twice a week
58489785|NCT01650597|DRUG|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
58489786|NCT01650597|DRUG|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
58489787|NCT01650597|DRUG|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
58489788|NCT01079052|DRUG|Famotidine|Tablets
58489789|NCT02086500|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
58489790|NCT02086500|OTHER|Saline control|Saline Control
58489791|NCT00338585|DRUG|alfimeprase|
58489792|NCT02352155|PROCEDURE|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
58489793|NCT02352155|OTHER|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
58489794|NCT02198404|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
58489795|NCT05750446|DRUG|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
58489796|NCT05750446|OTHER|Placebo|Placebo
58489797|NCT03677453|OTHER|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
58489798|NCT01039376|BIOLOGICAL|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
58489799|NCT01039376|OTHER|Observation|Observation/Safety Evaluation
58489800|NCT04816669|BIOLOGICAL|BNT162b2|Intramuscular injection
58489801|NCT01732237|DRUG|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
58138073|NCT02616809|OTHER|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
58138074|NCT02678286|DRUG|N1539|
58138075|NCT02678286|DRUG|Intravenous Placebo|
58489802|NCT01732237|DRUG|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
58489803|NCT01732237|DRUG|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
58489804|NCT02395159|DEVICE|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
58489805|NCT02395159|OTHER|sterile plaster dressings|standard wound management method of sterile plaster dressings
58489806|NCT04240834|DRUG|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
58489807|NCT04240834|DRUG|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
58489808|NCT03843840|DEVICE|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
58489809|NCT00388817|BEHAVIORAL|Pharmacist intervention|
58489810|NCT05676021|BEHAVIORAL|motivational interview|motivational interview-based health education
58489811|NCT02347137|OTHER|step-reduction|reduce daily physical activity to less than 1500 steps per day
58489812|NCT02347137|OTHER|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
58489813|NCT01610778|DIETARY_SUPPLEMENT|Placebo|
58489814|NCT01610778|DIETARY_SUPPLEMENT|5-aminolevulinic acid phosphate|
58489815|NCT04981990|PROCEDURE|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
58489816|NCT04981990|PROCEDURE|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
58491205|NCT05249517|OTHER|Progressive submaximal exercise program|It has been shown that the long-term results of the use of PNE in addition to physiotherapy are more effective in reducing pain and disability. It has been reported that progressive submaximal exercise program including cervicothoracic strengthening, endurance, flexibility, and coordination exercises has positive effects on chronic neck pain, related disability, quality of life and mood.
58489817|NCT06246045|DIAGNOSTIC_TEST|Walking test|"PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy."
58489818|NCT05743959|PROCEDURE|No intervention|No intervention
58489819|NCT00459732|DIETARY_SUPPLEMENT|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
58489820|NCT00459732|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
58489821|NCT00485095|BEHAVIORAL|Intake of plant sterols|
58489822|NCT01438736|DRUG|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
58489823|NCT01438736|DRUG|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
58489824|NCT06517628|OTHER|Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.|The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.
58489825|NCT04173494|DRUG|Momelotinib|Momelotinib tablets will be self-administered orally once daily
58489826|NCT04173494|DRUG|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
58489827|NCT04173494|DRUG|Danazol|Danazol capsules will be self-administered orally twice daily
58489828|NCT04173494|DRUG|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
58489829|NCT04510818|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
58489830|NCT02398435|BIOLOGICAL|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
58489831|NCT01810536|DEVICE|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
58489832|NCT01810536|DEVICE|Venturi mask|
58489833|NCT02925884|DEVICE|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
58489834|NCT06343519|DEVICE|Echocardiography|Measuring echocardiographic parameters (cardiac index, speckle tracking, tissue Doppler indices)
58489835|NCT05196321|OTHER|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
58489836|NCT02065258|OTHER|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
58489837|NCT02065258|OTHER|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
58489838|NCT00619814|PROCEDURE|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
58489839|NCT00732537|DRUG|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
58491206|NCT06117046|DRUG|Cardiopeptides|Cardiopeptide was administered intravenously once a day with 60mg of cardiopeptide for 3 days
58491207|NCT00006340|DRUG|arginine butyrate|
58491208|NCT00006340|DRUG|ganciclovir|
58491209|NCT02209532|DEVICE|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
58138076|NCT00359905|DRUG|Silodosin|8 mg daily for 12 weeks
58138077|NCT00359905|DRUG|Tamsulosin|0.4 mg daily for 12 weeks
58138078|NCT00359905|DRUG|Placebo|once daily for 12 weeks
58489840|NCT00732537|DRUG|Oxygen (>90% by hood) - standard therapy|"Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
58489841|NCT00002317|DRUG|Trimetrexate glucuronate|
58489842|NCT00002317|DRUG|Leucovorin calcium|
58489843|NCT00351871|DRUG|PEG-Intron Plus REBETOL|
58489844|NCT01798108|RADIATION|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
58489845|NCT01526759|DIETARY_SUPPLEMENT|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
58489846|NCT01526759|DIETARY_SUPPLEMENT|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
58489847|NCT00990704|DRUG|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
58489848|NCT00990704|DRUG|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
58489849|NCT01777113|OTHER|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
58489850|NCT01777113|OTHER|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
58489851|NCT01777113|OTHER|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
58489852|NCT01437566|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
58489853|NCT01437566|DRUG|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
58489854|NCT01437566|DRUG|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
58489855|NCT01437566|DRUG|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
58489856|NCT01437566|DRUG|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
58489857|NCT04440527|DEVICE|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
58489858|NCT04440527|OTHER|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
58489859|NCT03704896|OTHER|Lung function measurement|Spirometry-derived lung function measurements
58489860|NCT02301416|DRUG|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
58489861|NCT02301416|OTHER|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
58489862|NCT03145870|OTHER|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
58489863|NCT04772612|DRUG|sitravatinib|sitravatinib
58489864|NCT06045156|DRUG|Tirofiban|Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
58489865|NCT06045156|DRUG|Tirofiban simulant|Tirofiban simulant is placebo packed the same style as tirofiban
58489866|NCT06268977|DRUG|SGLT2 inhibitor|a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
58489867|NCT01915836|OTHER|web-based video game (Quit IT)|
58489868|NCT01915836|BEHAVIORAL|Questionnaires|
58489869|NCT01915836|BEHAVIORAL|Evaluation Interview|
58489870|NCT00504972|DRUG|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
58489871|NCT01785485|OTHER|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
58489872|NCT03111641|DIAGNOSTIC_TEST|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
58489873|NCT05513209|PROCEDURE|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
58489874|NCT05513209|PROCEDURE|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
58489875|NCT04470076|DRUG|Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin|"① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy."
58489876|NCT04470076|PROCEDURE|Surgical treatment|The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
58489877|NCT04470076|DRUG|Adjuvant treatment:afatinib|The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
58489878|NCT01122121|DRUG|Leuprorelin SR|Leuprorelin SR injection
58489879|NCT01122121|RADIATION|Radiotherapy|Radiotherapy 70 +/- 4 Gy
58489880|NCT01122121|DRUG|Flutamide|Flutamide tablets
58489881|NCT02759367|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
58489882|NCT00673738|DRUG|Cetuximab|"* Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
58489883|NCT00673738|RADIATION|Conformal Thoracic Radiotherapy (CTRT)|"* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \>1,000 and platelets \>75,000) required. Patient may be delayed for a max. of 2 weeks. If \> 2 week delay occurs, patient will come off study."
58489884|NCT00629889|DRUG|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
58489885|NCT00629889|DRUG|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
58489886|NCT02299843|PROCEDURE|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
58489887|NCT02299843|PROCEDURE|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
58489888|NCT02859870|DEVICE|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
58489889|NCT01632618|BEHAVIORAL|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
58489890|NCT01632618|BEHAVIORAL|Passive control intervention|Passive physical therapy approach to low back pain
58489891|NCT05428397|DIAGNOSTIC_TEST|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
58489892|NCT03711695|DEVICE|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
58489893|NCT05185713|OTHER|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
58489894|NCT02405377|PROCEDURE|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
58489895|NCT02405377|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
58489896|NCT02405377|DRUG|0.9% sodium chloride ﬂuid administration|
58489897|NCT02405377|DEVICE|5-French catheter|
58489898|NCT02835976|DRUG|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
58491210|NCT00493051|BIOLOGICAL|GAM501|Ad5PDGF-B formulated in a collagen gel
58491211|NCT00493051|BIOLOGICAL|Placebo|Collagen gel
58489899|NCT04413006|BEHAVIORAL|Self-Compassion for Chronic Pain Virtual Group Treatment Program|6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
58489900|NCT01586130|OTHER|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
58489901|NCT04607317|BEHAVIORAL|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
58489902|NCT04607317|BEHAVIORAL|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
58489903|NCT04607317|BEHAVIORAL|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
58489904|NCT02652858|PROCEDURE|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
58489905|NCT01255683|DRUG|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
58489906|NCT02685137|DRUG|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
58489907|NCT02685137|OTHER|Sham Injection|nothing
58489908|NCT00808080|BIOLOGICAL|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
58489909|NCT02139007|DRUG|Alendronate|
58489910|NCT03617224|RADIATION|TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
58489911|NCT03617224|DRUG|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
58489912|NCT05289895|OTHER|No intervention|This study was an observational trial without any intervention
58489913|NCT01171482|DRUG|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
58489914|NCT01171482|DRUG|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
58489915|NCT01171482|DRUG|sorafenib|400 mg BID every 28 days
58489916|NCT02780128|PROCEDURE|Biopsy|Needle or incisional tumor biopsy
58489917|NCT02780128|GENETIC|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
58489918|NCT02780128|PROCEDURE|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
58489919|NCT02780128|PROCEDURE|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
58489920|NCT02780128|OTHER|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
58489921|NCT02780128|OTHER|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
58489922|NCT02780128|OTHER|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
58489923|NCT02780128|OTHER|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
58489924|NCT02780128|BEHAVIORAL|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
58489925|NCT02780128|OTHER|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
58489926|NCT02780128|OTHER|Echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
58489927|NCT02780128|DRUG|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
58489928|NCT02780128|DRUG|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
58489929|NCT03210337|DRUG|A-101 Topical Solution|A-101 Topical Solution
58489930|NCT03210337|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
58489931|NCT02296645|DRUG|ZuraPrep|Apply topically.
58489932|NCT02296645|DRUG|ChloraPrep|Apply topically.
58489933|NCT05434780|OTHER|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
58489934|NCT05779618|OTHER|no intervention|observational study, all data collected are binary
58489935|NCT05927649|DRUG|Omaveloxolone|Omaveloxolone capsules
58489936|NCT05927649|DRUG|Moxifloxacin|Moxifloxacin capsules
58489937|NCT02660983|DRUG|Donepezil hydrochloride|
58489938|NCT02660983|DRUG|Donepezil matching placebo|
58489939|NCT02660983|DRUG|Donepezil hydrochloride|
58489940|NCT00694148|DRUG|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
58489941|NCT01829152|DEVICE|CHM|
58489942|NCT04388254|DRUG|Simufilam 100 mg oral tablet|Simufilam 100 mg oral tablet for b.i.d. administration
58489943|NCT04388254|DRUG|Placebo|Matching placebo oral tablets
58489944|NCT05170880|PROCEDURE|Primary endodontic treatment|Primary non surgical endodontic treatment will be provided to patients in treatment group.
58489945|NCT01162837|DEVICE|BEAM device|A red/blue LED device for the treatment of acne
58489946|NCT00351858|DRUG|ertumaxomab|
58489947|NCT00641368|BEHAVIORAL|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
58489948|NCT00641368|OTHER|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
58489949|NCT00701883|DRUG|Placebo|2 capsules, once a day for 8 weeks
58489950|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
58489951|NCT00701883|DRUG|MBX-8025|2 capsule, once daily for 8 weeks
58489952|NCT00701883|DRUG|Atorvastatin|2 capsules, once daily for 8 weeks
58489953|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
58489954|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
58489955|NCT01075685|BEHAVIORAL|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
58489956|NCT01075685|BEHAVIORAL|Minimum information|"This intervention includes:~* information about hazardous drinking~* an alcohol diary"
58489957|NCT02527421|DRUG|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
58489958|NCT00114517|DRUG|17B-estradiol|Oral 17B-estradiol 1 mg daily
58489959|NCT00114517|OTHER|Placebo|Matching oral 17B-estradiol placebo daily
58489960|NCT02510677|OTHER|myocardial perfusion scintigraphy|
58489961|NCT03052426|DEVICE|Ergotron WorkFit - TL|A sit to stand work station.
58489962|NCT04013659|OTHER|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
58489963|NCT03736642|BIOLOGICAL|blood sampling|12 ml sample
58489964|NCT03736642|OTHER|stool sampling|20 g sample
58138079|NCT02696694|OTHER|Progesterone 25-75|Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
58489965|NCT03736642|OTHER|urine sampling|18 ml sample
58489966|NCT03736642|DIAGNOSTIC_TEST|neuropsychological tests|"* Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale"
58489967|NCT00475956|DRUG|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
58489968|NCT00475956|DRUG|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
58489969|NCT01666041|DRUG|placebo|
58489970|NCT01666041|DRUG|fenofibrate/omega|
58489971|NCT01666041|DRUG|fenofibrate|
58489972|NCT05429385|DRUG|HLX70|Single-dose, intravenous infusion
58489973|NCT05429385|DRUG|Placebo|Single-dose, intravenous infusion
58489974|NCT00363480|DRUG|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
58489975|NCT00363480|DRUG|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
58489976|NCT00363480|DEVICE|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
58489977|NCT00517088|DRUG|IPAQ|
58489978|NCT05986396|DEVICE|INSPIRIS Resilia (model 11500A)|Aortic Valve
58489979|NCT01569893|OTHER|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
58489980|NCT05688475|DRUG|CC-122|Specified dose on specified days
58489981|NCT05688475|DRUG|Dexamethasone|Specified dose on specified days
58489982|NCT00253162|DRUG|risperidone|
58489983|NCT05430997|DEVICE|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
58489984|NCT05430997|DEVICE|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
58489985|NCT00644982|DRUG|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
58489986|NCT00644982|DRUG|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
58489987|NCT04429477|DEVICE|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
58491212|NCT00493051|OTHER|Standard of care|moist dressing changes daily
58489988|NCT03214666|DRUG|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day"
58489989|NCT03214666|DRUG|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
58489990|NCT04858048|PROCEDURE|Anesthesia|2 types of anesthesia (general and WALANT) performed during the surgery
58489991|NCT04454853|OTHER|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
58489992|NCT04454853|OTHER|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
58489993|NCT04454853|OTHER|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
58489994|NCT01150188|DIETARY_SUPPLEMENT|Amino acids|11 g amino acids two times per day for eight weeks
58489995|NCT01150188|DIETARY_SUPPLEMENT|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
58489996|NCT01949818|DRUG|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
58489997|NCT01949818|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
58489998|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (LAX)
58489999|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (SAX)
58490000|NCT02657603|PROCEDURE|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
58490001|NCT02657603|PROCEDURE|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
58490002|NCT04059588|DRUG|2141 V-11|intratumoral injection of 2141-V11
58490003|NCT06048640|DIETARY_SUPPLEMENT|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
58490004|NCT03756324|DRUG|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
58490005|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
58490006|NCT03756324|BEHAVIORAL|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
58490007|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
58490008|NCT06394141|BEHAVIORAL|Real-time triggers|The first intervention group (n= 30 professional drivers) will receive real-time triggers related to acute stress and sleepiness/fatigue. The real-time feedback involves giving relevant triggers when exceeding some critical stress values or detecting events of \&#39;energy-takers\&#39; based on accurate measurements of mental energy in a fully automated way. The selected triggers will be based on the co-creation workshops with drivers (e.g., auditive, visual) in order to select the most efficient (type or combination of) trigger(s) for the real-time feedback. The warning messages will be tailored to the preferences of the driver (e.g., personalized comfort- and safety-related settings) and aim to generate a warning message/signal meant to alert drivers and prevent they might end up with high stress levels
58490009|NCT06394141|BEHAVIORAL|Personalized tailored feedback|The second intervention group (n= 30 professional drivers) will receive personalized tailored feedback to reduce chronic stress and sleepiness/fatigue. The advice involves personalized (semi-)automatic feedback to drivers about a reduced stress level via the mobile app with automatic reports, as well as post-intervention during the next work break or at the end of the workday, based on the preferences of the driver. The (semi-)automatic feedback is based on the theory of Stages of Change, by which a driver will only receive relevant feedback based on their attitude and willingness during daily life.
58490010|NCT06394141|BEHAVIORAL|Real-time triggers + Personalized tailored feedback|The third intervention group (n= 30 professional drivers) will receive both real-time feedback related to acute stress and sleepiness/fatigue, as well as personalized tailored feedback related to chronic stress and sleepiness/fatigue, similar as in the first and second intervention groups.
58490011|NCT06394141|BEHAVIORAL|App-supported exercise therapy|The fourth intervention group (n= 30 professional drivers) will receive app-supported exercise therapy. The intervention will be based on principles of high-intensity training exercises that focus on the improvement of cardiorespiratory exercise capacity, as well as on the reduction of stress levels during work. Participants will receive instructions via the app to do some short, vigorous exercises adapted to their work environment at regular intervals, e.g., bending-and-stretching exercises with a weight in their hands, walking up and down the stairs of their vehicle for a few minutes, etc.
58490012|NCT06394141|BEHAVIORAL|Conventional intervention|The active control group (n= 20 professional drivers) will get a conventional intervention to reduce stress, e.g., mindfulness.
58490013|NCT00029770|PROCEDURE|Chiropractic spinal manipulation|
58490014|NCT00029770|DRUG|Acetaminophen|
58490015|NCT00029770|BEHAVIORAL|Self-care|
58490016|NCT00029770|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
58490017|NCT00029770|DRUG|Tylenol with codeine|
58490018|NCT05205889|BEHAVIORAL|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
58490019|NCT01136980|DEVICE|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
58490020|NCT01136980|OTHER|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
58490021|NCT00326859|DRUG|remifentanil|
58490022|NCT01939769|OTHER|Exercise - Low-intensity exercise|
58490023|NCT01939769|OTHER|Exercise - High-intensity exercise|
58490024|NCT03967353|BEHAVIORAL|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
58490025|NCT01657240|DRUG|PRO-118|instill one drop in each eye once a day for 21 days
58490026|NCT01657240|DRUG|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
58490027|NCT05753696|DRUG|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
58490028|NCT05753696|DRUG|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
58490029|NCT04693624|OTHER|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
58490030|NCT01965678|OTHER|Osteopathic Manipulative Treatment|
58490031|NCT03544762|DRUG|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
58490032|NCT06458478|OTHER|Hyper-oxygenated gel|Novox drop is a medical device (CE certified, class II b, non-invasive) based on oxygen-enriched olive oil (Excipients: Mint essential oil (2%), Stevia extract (1%)). Mechanism of action: facilitate the healing process by creating, thanks to the release of reactive oxygen species (ROS), a microenvironment favorable to the activation of the microcirculation and at the same time unfavorable to the proliferation of pathogens. Furthermore, it has a film-forming, protective, barrier and soothing action thanks to its oily nature.
58490033|NCT06458478|OTHER|glycerin based gel|The placebo consists of a viscous, colorless and transparent gel, based on glycerin (Conformity:FUI).
58490034|NCT03371043|OTHER|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
58490035|NCT04106076|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
58490036|NCT06268756|OTHER|Data collection|Data collection
58490037|NCT04146636|DIAGNOSTIC_TEST|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
58490038|NCT05425940|DRUG|XL092|Supplied as tablets; administered orally daily
58490039|NCT05425940|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
58490040|NCT05425940|DRUG|Regorafenib|Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
58490041|NCT03347955|PROCEDURE|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
58490042|NCT03347955|PROCEDURE|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
58490043|NCT04651842|DEVICE|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
58490044|NCT03497312|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
58490045|NCT04338776|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
58491240|NCT03314922|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
58491241|NCT03027882|OTHER|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
58491242|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
58490046|NCT04338776|DEVICE|Rezum|"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
58490047|NCT02981615|DRUG|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
58490048|NCT02981615|DRUG|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
58490049|NCT06032325|DIAGNOSTIC_TEST|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
58490050|NCT03134703|DRUG|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
58490051|NCT03134703|DRUG|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
58490052|NCT02110836|DIETARY_SUPPLEMENT|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
58490053|NCT02110836|DIETARY_SUPPLEMENT|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
58490054|NCT01398709|OTHER|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
58490055|NCT01398709|OTHER|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
58490056|NCT03500224|DRUG|[14C]-TAK-954|\[14C\]-TAK-954 intravenous infusion.
58490057|NCT03893942|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
58490058|NCT03893942|OTHER|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
58490059|NCT03893942|OTHER|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
58490060|NCT03893942|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
58490061|NCT03893942|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
58490062|NCT03893942|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
58490063|NCT03893942|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
58490064|NCT03893942|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
58490065|NCT03831906|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
58490066|NCT00858104|PROCEDURE|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
58490067|NCT00770159|DRUG|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
58490068|NCT00770159|DRUG|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
58490069|NCT05406635|DIAGNOSTIC_TEST|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
58490070|NCT05925868|BEHAVIORAL|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
58490071|NCT06445114|DRUG|Cisplatin|"Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation."
58490072|NCT03331640|DRUG|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
58490073|NCT03331640|DRUG|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
58491243|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
58491244|NCT05543993|DRUG|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
58490074|NCT00633204|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
58490075|NCT02901678|DEVICE|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
58490076|NCT04121663|DEVICE|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
58490077|NCT03222999|OTHER|No intervention planned|No intervention planned
58490078|NCT00400972|DEVICE|GlideScope videolaryngoscope|
58490079|NCT03443570|DRUG|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
58490080|NCT03443570|DRUG|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
58490081|NCT00268853|DRUG|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
58490082|NCT00268853|DRUG|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
58490083|NCT00357682|DRUG|Esomeprazole|20mg per day
58490084|NCT00357682|DRUG|Esomeprazole|80mg per day
58490085|NCT00357682|DRUG|Aspirin|300mg per day
58490086|NCT05875506|DRUG|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
58490087|NCT05875506|DRUG|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
58490088|NCT02969148|PROCEDURE|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
58490089|NCT02969148|PROCEDURE|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
58490090|NCT03561467|OTHER|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
58490091|NCT01580215|DEVICE|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
58490092|NCT01043913|DRUG|Guarana extract|Guarana extract 50mg q12 hours for 21 days
58490093|NCT04150848|BEHAVIORAL|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
58490094|NCT04150848|BEHAVIORAL|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
58490095|NCT01957046|DRUG|Laxative|
58490096|NCT00746512|DRUG|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
58490097|NCT00746512|DRUG|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
58490098|NCT00746512|DRUG|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
58490099|NCT00746512|DRUG|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
58490100|NCT01823913|DRUG|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
58490101|NCT01823913|DRUG|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
58490102|NCT03944252|DRUG|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
58490103|NCT03944252|DRUG|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
58490104|NCT00706342|DRUG|Fostamatinib Disodium / R935788|R935788 tablets
58490105|NCT03655249|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
58490106|NCT03655249|DRUG|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
58490107|NCT03925779|DRUG|Dexmedetomidine|dexmedetomidine sedation
58490108|NCT03925779|DRUG|Propofol|propofol sedation
58490109|NCT03925779|DRUG|Remifentanil|Remifentanil sedation
58490110|NCT06182956|DEVICE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
58490111|NCT06182956|DEVICE|Nasal high-flow oxygen therapy|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
58490112|NCT06182956|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
58490113|NCT02865213|DEVICE|OBA|"The intrusion of posterior teeth using removable appliance OBA."
58490114|NCT02865213|DEVICE|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
58490115|NCT02865213|DEVICE|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
58490116|NCT06342505|PROCEDURE|Venipunctures|Extra venipunctures
58490117|NCT02181244|OTHER|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
58491245|NCT00528450|DRUG|arsenic trioxide|
58491246|NCT00528450|DRUG|idarubicin|
58491247|NCT00528450|DRUG|tretinoin|
58491248|NCT02665832|DRUG|DWJ1351|
58490118|NCT02181244|OTHER|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
58490119|NCT03916900|PROCEDURE|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
58490120|NCT03916900|PROCEDURE|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
58490121|NCT05226494|DRUG|fb-PMT|Daily dosing based on patient weight
58490122|NCT05418543|PROCEDURE|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
58490123|NCT01033799|OTHER|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
58490124|NCT01033799|OTHER|Non fermented dairy product (control)|
58490125|NCT04106206|DRUG|LY3372689|Administered orally
58490126|NCT04106206|DRUG|Placebo|Administered orally
58490127|NCT00643162|DRUG|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
58490128|NCT00643162|BEHAVIORAL|Light touch|Light touch twice a week, for 8 weeks
58490129|NCT00643162|BEHAVIORAL|Massage|Massage twice a week, for 8 weeks.
58490130|NCT00773604|DEVICE|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
58490131|NCT04233723|OTHER|peripheral blood samples|venous puncture
58490132|NCT01286051|DRUG|Follistim administration|adminstation of FSH for ovulation induction
58490133|NCT01286051|DRUG|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
58490134|NCT05475730|PROCEDURE|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
58490135|NCT06248775|BEHAVIORAL|Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)|During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
58490136|NCT01694498|DRUG|A: Desmopressin 25 µg|
58490137|NCT01694498|DRUG|B. Desmopressin 50 µg|
58490138|NCT01694498|DRUG|Placebo|
58490139|NCT04354636|DRUG|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
58490140|NCT04354636|OTHER|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
58490141|NCT01344525|PROCEDURE|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
58490142|NCT01344525|PROCEDURE|Gastric Banding|Gastric Banding
58490143|NCT01344525|PROCEDURE|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
58490144|NCT01344525|PROCEDURE|Roux-en-Y Bypass|Roux-en-Y Bypass
58490145|NCT03068585|DRUG|Neovasculgen (Cambiogeneplasmid)|treatment
58490146|NCT05829369|OTHER|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
58490147|NCT05829369|OTHER|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
58490148|NCT05829369|OTHER|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
58490149|NCT04986514|OTHER|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
58490150|NCT06423274|DIAGNOSTIC_TEST|fundus photography|using artificial intelligence to identify diabetic retinopathy using fundus photography
58490151|NCT06423274|DIAGNOSTIC_TEST|optical coherence tomography|detect diabetic retinopathy and diabetic macular edema by optical coherence tomography
58490152|NCT06423274|DIAGNOSTIC_TEST|fundus fluorescence angiography|detect diabetic retinopathy by fundus fluorescence angiography
58490153|NCT04028401|DRUG|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
58490154|NCT01169818|DRUG|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
58490155|NCT03620877|BEHAVIORAL|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
58491249|NCT02665832|DRUG|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
57784599|NCT03510858|OTHER|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
57784600|NCT04565314|DIETARY_SUPPLEMENT|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
57784601|NCT00972543|BIOLOGICAL|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
57784602|NCT00972543|BIOLOGICAL|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
57784603|NCT04716140|PROCEDURE|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
57784604|NCT04126525|DRUG|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
57784605|NCT04456738|BEHAVIORAL|Parent Training|16 weeks of of parent training led by a trained group facilitator
57784606|NCT01220141|DRUG|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
57784607|NCT06418035|BEHAVIORAL|Video modeling by scanning Qr code|The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.
57784608|NCT06418035|BEHAVIORAL|Modeling traditional method|The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
57784609|NCT00451815|DRUG|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
57784610|NCT00451815|DRUG|placebo|
57784611|NCT05255263|OTHER|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
57784612|NCT05255263|OTHER|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
57784613|NCT02541539|DIETARY_SUPPLEMENT|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
57784614|NCT02541539|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
57784615|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
57784616|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
57784617|NCT00061360|DRUG|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
57784618|NCT00061360|DRUG|ATG+cyclosporine|ATG+cyclosporine
57784619|NCT03323151|DRUG|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
57784620|NCT03323151|DRUG|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
57784621|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
57784622|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
57784623|NCT00896454|DRUG|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
57784624|NCT05843175|OTHER|Exercise and meal testing (acute stimuli)|"Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake"
57784625|NCT01577030|DIETARY_SUPPLEMENT|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
57784626|NCT01577030|DIETARY_SUPPLEMENT|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
57784627|NCT03976310|DRUG|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
57784628|NCT03976310|OTHER|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
57784629|NCT00649480|DRUG|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
57784630|NCT00649480|DRUG|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
57784631|NCT05476211|DEVICE|BTL-785F|Radiofrequency
57784632|NCT00255567|DRUG|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
57784633|NCT00255567|DRUG|Paromomycin sulphate|Paromomycin sulphate
57784634|NCT00255567|DRUG|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
57784635|NCT04436081|DRUG|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
57784636|NCT04436081|DRUG|Placebo|Placebo Gelcaps
57784637|NCT00237562|PROCEDURE|Large loop electrosurgical excision|
57784638|NCT05076370|DRUG|CBD Day 1|CBD 400mg
57784639|NCT05076370|DRUG|CBD Day 2|CBD 800mg
57784640|NCT05076370|DRUG|CBD Day 3|CBD 1200mg
57784641|NCT01015573|DEVICE|magnetic sensor system to measure the movements of finger tapping|
57784673|NCT04141111|DEVICE|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
57784674|NCT01418092|DRUG|ALKS 37|Capsules for oral administration
57784675|NCT01418092|DRUG|Placebo|Capsules for oral administration
57784676|NCT03930966|DIAGNOSTIC_TEST|PDEQ, PCL-5 and demographic survey|Questionnaires
57784677|NCT05084261|DRUG|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
57784678|NCT05084261|DRUG|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
57784679|NCT05084261|DRUG|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
57784680|NCT05084261|DRUG|Matching Placebo|Placebo Matching BT051
57784681|NCT06396962|OTHER|WANG DAORONG|surgery
57784682|NCT02359968|DRUG|FOLFOX|radiochemotherapy before surgery
57784683|NCT02359968|DRUG|CarboP-pacliT|radiochemotherapy before surgery
57784684|NCT01513967|DRUG|RPh201, botanical drug product|SC administration at varying doses
57784685|NCT01513967|DRUG|Placebo|SC administration at varying doses
57784686|NCT06318390|DIETARY_SUPPLEMENT|XO Genius|This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health
57784687|NCT01850966|DRUG|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
57784688|NCT06109259|DRUG|DWJ1567|One tablet of DWJ1567
57784689|NCT06109259|DRUG|DWC202312|One tablet of DWC202312
57784690|NCT05608733|DRUG|Epidural catheter|Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.
57784691|NCT05608733|DRUG|Continuous sciatic nerve block|The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
57784692|NCT05023317|BEHAVIORAL|Strengths-based linkage to alcohol care|SLAC is a behavioral intervention designed to link persons with substance use/misuse to care
57784693|NCT05023317|BEHAVIORAL|Usual care|Usual care consists of brief screening and intervention and/or standard referral to alcohol care
57784694|NCT02263144|PROCEDURE|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
57784695|NCT00236821|DRUG|levofloxacin|
57784696|NCT01134211|DEVICE|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
57784697|NCT01134211|DEVICE|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
57784698|NCT04033991|DRUG|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
57784699|NCT04033991|DRUG|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
57784700|NCT05128292|DIETARY_SUPPLEMENT|CoQ10 plus Selenium|400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
57784701|NCT02400307|DRUG|Bictegravir|75 mg tablet administered orally
57784702|NCT05493904|PROCEDURE|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~1. By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane \[EEL\] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex\> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~2. By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex\> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
57784703|NCT05493904|PROCEDURE|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
57784704|NCT05493904|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
57784705|NCT04746430|DRUG|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
57784706|NCT00279994|PROCEDURE|Exercise therapy|
57784707|NCT00279994|DEVICE|Accelerometer (PAM; Personal Activity Monitor)|
57784708|NCT00279994|PROCEDURE|Oral Exercise Therapy advise|
57784762|NCT01151982|BEHAVIORAL|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
57784763|NCT03351361|DRUG|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
57784764|NCT03351361|DRUG|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
57784765|NCT05397938|DRUG|JMT103|JMT103, subcutaneous injection, once every 6 months (Q6M)
57784766|NCT05397938|DRUG|Alendronate sodium|Alendronate sodium tablet, once every week (QW)
57784767|NCT05397938|DRUG|JMT103 placebo|JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
57784768|NCT05397938|DRUG|Alendronate sodium placebo|Alendronate sodium tablet placebo, once every week (QW)
57784769|NCT03389893|DRUG|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
57784770|NCT03389893|DRUG|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
57784771|NCT04142463|OTHER|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
57784772|NCT03157102|DEVICE|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 \>92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
57784773|NCT03157102|DEVICE|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
57784774|NCT00294996|DRUG|Myocet|
57784775|NCT01959880|DEVICE|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
57784776|NCT05993871|DIAGNOSTIC_TEST|Clinical Evaluation/Questionnaires|Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
57784777|NCT05993871|DIAGNOSTIC_TEST|Nerve Conduction Study|Routine Nerve Conduction Study.
57784778|NCT05993871|DIAGNOSTIC_TEST|Small fiber electrodiagnostic tests|R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
57784779|NCT05993871|DIAGNOSTIC_TEST|Nerve Ultrasound|Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
57784780|NCT05993871|DIAGNOSTIC_TEST|Skin Biopsy|distal leg 3mm punch skin biopsy
57784781|NCT00365495|PROCEDURE|Physical training (aerobic training)|
58138080|NCT02696694|OTHER|Progesterone <25, >75|Impact of serum progesterone concentrations (\<25, \>75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
57784807|NCT06082128|BEHAVIORAL|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
57784808|NCT00510796|BEHAVIORAL|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
57784809|NCT05188365|OTHER|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
57784810|NCT05188365|OTHER|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
57784811|NCT06314191|OTHER|blood sampling|blood sampling with analyses
57784812|NCT06314191|OTHER|knee radiography|radiography of both knees in Schuss
57784813|NCT04669080|BEHAVIORAL|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
57784814|NCT00876122|DRUG|GDC-0941|Escalating oral dose
57784815|NCT05062629|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing
57784816|NCT04179994|OTHER|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
57784817|NCT04179994|OTHER|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
57784818|NCT04179994|OTHER|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
57784819|NCT06008535|PROCEDURE|Open inguinal hernia repair|Lichtenstein hernioplasty or open inguinal hernia repair with self-gripping mesh
57784820|NCT03890120|DRUG|Cilofexor|100 mg tablet administered orally once daily
57784821|NCT03890120|DRUG|Placebo|Tablet administered orally once daily
57784822|NCT03699046|PROCEDURE|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
57784823|NCT03699046|PROCEDURE|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
57784824|NCT03699046|BIOLOGICAL|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
57784825|NCT05373602|DIAGNOSTIC_TEST|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
57784826|NCT02145481|BEHAVIORAL|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
57784827|NCT02145481|BEHAVIORAL|CAD Education|Education for patients with coronary artery disease
57784828|NCT03386760|DEVICE|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
57784829|NCT03386760|DEVICE|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
57784830|NCT01203241|PROCEDURE|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
57784831|NCT01203241|PROCEDURE|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
57784832|NCT03688789|OTHER|Hydrocortisone supplementation|"* Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30"
58138081|NCT03020641|PROCEDURE|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
58138082|NCT03020641|PROCEDURE|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
57784878|NCT03903146|BEHAVIORAL|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
57784879|NCT01307852|DEVICE|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
57784880|NCT04179461|DRUG|Cholecalciferol|Oral administration
57784881|NCT04179461|DRUG|antihistamine|Oral administration
57784882|NCT04179461|DRUG|Azithromycin|Oral administration
57784883|NCT04179461|DRUG|emollient cream|Topical
57784884|NCT04179461|DRUG|Fluticasone Propionate|Nasal spray
57784885|NCT04179461|DRUG|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
57784886|NCT04437771|OTHER|Safety and efficacy assessments|Long term disease and gene therapy specific safety evaluations and efficacy assessments
57784887|NCT00531011|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
57784888|NCT00531011|DEVICE|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
57784889|NCT04822636|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
57784890|NCT01667120|DRUG|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
57784891|NCT01667120|DRUG|placebo|0.9% normal saline 1ml/kg
57784892|NCT00029809|BEHAVIORAL|Chinese exercise modalities|
57784893|NCT00951860|OTHER|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
57784894|NCT02781506|DRUG|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
57784895|NCT02781506|RADIATION|SAbR|SAbR (1-3 lesions)
57784896|NCT05122754|DRUG|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
57784897|NCT05122754|DRUG|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
57784898|NCT03169179|BEHAVIORAL|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
57784899|NCT01207934|DIETARY_SUPPLEMENT|placebo|saline placebo
57784900|NCT01207934|DRUG|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
57784901|NCT01207934|DRUG|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
57784902|NCT05125692|PROCEDURE|vaginal surgical repair of isthmocele|after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
57784903|NCT05500027|DIAGNOSTIC_TEST|serum test|serum test of sCD58 and TGFbeta1
57784904|NCT03772106|DRUG|Propofol Fresenius|Propolipid 1% : IV
57784905|NCT03772106|DRUG|sevorane|sevorane Quick fill (sevoflurane) : inhalation
57784906|NCT01800344|DEVICE|LMA|
57784907|NCT01800344|DEVICE|Ultra|Ultra
57784908|NCT03164733|OTHER|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
57784909|NCT03666065|DRUG|Aspart insulin|Standard insulin
57784910|NCT05312619|OTHER|Cross sectional survey|A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19
57784911|NCT03427086|DRUG|Biotin|High dose biotin
57784912|NCT03427086|DRUG|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
57784913|NCT00421694|DRUG|Bicalutamide|
57784914|NCT00321256|PROCEDURE|human pancreatic islet transplantation|
57784915|NCT02774213|OTHER|Questionnaires completion|
57784916|NCT02774213|OTHER|Clinical Pain Assessments|
57784917|NCT05441358|PROCEDURE|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
57784918|NCT05573919|DEVICE|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
57784919|NCT01822028|DRUG|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
57784920|NCT01822028|DRUG|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
57784921|NCT03908281|BEHAVIORAL|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
58138083|NCT02722980|DIETARY_SUPPLEMENT|Placebo|The intervention consists of capsules containing placebo.
57785165|NCT05791461|BEHAVIORAL|MARS (Measures Against Work-related Stress)|"The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended."
57785166|NCT03613779|COMBINATION_PRODUCT|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
57785167|NCT03613779|OTHER|Standard of Care|Standard of care will be provided.
57785168|NCT04777188|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
57785169|NCT04607915|BEHAVIORAL|Intervention for TECC Model|The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
57785170|NCT00649129|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
57785171|NCT00649129|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
57785172|NCT04746274|BEHAVIORAL|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
57785173|NCT04746274|BEHAVIORAL|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
57785174|NCT05127161|BEHAVIORAL|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
57785175|NCT00918216|GENETIC|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
57785176|NCT00918216|OTHER|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
57785177|NCT00918216|OTHER|medical chart review|Patients' medical charts are reviewed to obtain clinical information
57785178|NCT00918216|PROCEDURE|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
57785179|NCT00918216|PROCEDURE|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
57785180|NCT00918216|PROCEDURE|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
57785181|NCT02359253|OTHER|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
57785182|NCT02359253|OTHER|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
57785183|NCT02359253|OTHER|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
57785184|NCT02359253|OTHER|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
57785185|NCT00429793|DRUG|temsirolimus|Given IV
57785186|NCT00590070|DRUG|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
57785187|NCT00590070|DRUG|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
57785188|NCT00590070|DRUG|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
57785189|NCT00043095|DRUG|gemcitabine hydrochloride|
57785190|NCT00043095|DRUG|ixabepilone|
57785497|NCT06500520|OTHER|Resisted Exercise group|The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.
57785498|NCT06500520|OTHER|Stretching Exercise group|The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
57785499|NCT03706729|DEVICE|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
57785500|NCT03271619|OTHER|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
57785501|NCT06285760|DRUG|Standarized diuretic therapy|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.
57785502|NCT03299374|OTHER|Pilates Intervention|Intervention based on Pilates principles
57785503|NCT03299374|OTHER|Fall prevention intervention|Intervention based on principles to prevent falls
57785504|NCT01859650|OTHER|MR and CT imaging|
57785505|NCT03079115|DRUG|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
57785506|NCT03079115|DRUG|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
57785507|NCT00401817|DRUG|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
57785508|NCT00401817|DRUG|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
57785509|NCT00401817|DRUG|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
57785510|NCT02784652|DRUG|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
57785511|NCT02784652|RADIATION|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
57785512|NCT03544528|PROCEDURE|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
57785513|NCT00092170|DRUG|MK0826, ertapenem sodium|
57785514|NCT00092170|DRUG|Comparator: Ticarcillin/Clavulanate|
57785515|NCT06500182|OTHER|hippotherapy sessions|Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
57785516|NCT03662893|BEHAVIORAL|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
57785517|NCT03662893|DRUG|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
57785518|NCT03662893|BEHAVIORAL|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
57785519|NCT01071889|DRUG|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
57785520|NCT01071889|DRUG|Placebo|Placebo - only excipients with no API
57785521|NCT04778384|BEHAVIORAL|Micro-training to promote self-management in pain therapy|Micro-training according to the checklist \& targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire) In this discussion, the nurses give their opinion on any patient-related barriers that become apparent after completing the second part of the questionnaire. This is not done according to a fixed template, but with the specialist knowledge and everyday experience of the nurse.
57785522|NCT04778384|OTHER|Sham intervention|An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
57785523|NCT03202875|DRUG|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57785524|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57785525|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
57785526|NCT04946448|OTHER|FIT diet|Dietary intervention as add-on therapy to biologicals
58138084|NCT02722980|DIETARY_SUPPLEMENT|: Probiotic capsules|The intervention consists of capsules containing probiotics.
58138085|NCT00003528|DRUG|raltitrexed|Given IV
58138086|NCT04836078|PROCEDURE|open flap subgingival debridement|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
58138087|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly
57785540|NCT04068727|OTHER|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
57785541|NCT01639261|DRUG|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever \>38,5 dose increase: 50µg/m² BSA three times/week
57785542|NCT03184714|DEVICE|NIPPV|BiPAP treatment for 3 years
57785543|NCT01653847|DRUG|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
57785544|NCT01653847|DRUG|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
57785545|NCT05814874|DIETARY_SUPPLEMENT|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
57785546|NCT05814874|DIETARY_SUPPLEMENT|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
57785547|NCT05814874|OTHER|Placebo|Placebo pill
57785548|NCT05125120|OTHER|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
57785549|NCT01457040|DRUG|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
57785550|NCT01457040|DRUG|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
57785551|NCT02703961|DRUG|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
57785552|NCT02703961|DRUG|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
57785553|NCT02703961|RADIATION|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
57785554|NCT02703961|RADIATION|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
57785555|NCT02703961|DRUG|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
57785556|NCT00605319|DRUG|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
57785557|NCT02675140|DRUG|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
57785558|NCT02675140|DRUG|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
57785559|NCT02173535|DEVICE|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
57785560|NCT02173535|DEVICE|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
57785561|NCT02173535|DEVICE|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
57785562|NCT02173535|DEVICE|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
57785563|NCT02173535|DEVICE|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
57785564|NCT01807078|DRUG|Ezetimibe|10 mg p.d. of ezetimibe
57785565|NCT01807078|DIETARY_SUPPLEMENT|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
57785566|NCT06179589|DIETARY_SUPPLEMENT|VS002A|Amino acid based, glucose free ORS
57785567|NCT05188391|DIAGNOSTIC_TEST|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
57785568|NCT05919667|DIETARY_SUPPLEMENT|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
57785569|NCT06220786|DEVICE|Low-level laser therapy|Low-level laser therapy ca. 72 Joules per cm2
57786005|NCT06167382|OTHER|Device: Arm Ergometer|Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
57786006|NCT03810079|DEVICE|Anodal transcranial direct current stimulation|Neuromodulation of bilateral prefrontal areas using 2 mA tDCS delivered during 20 minutes via sponge electrodes on the scalp
58138088|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly
58138089|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (III); injected subgingivally with placebo chitosan 2% gel weekly
58138090|NCT02263092|BEHAVIORAL|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
58138091|NCT02263092|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
58138092|NCT02263092|BEHAVIORAL|Rest|15 or 30 minutes seat without move the legs
58138093|NCT03123471|DRUG|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
58138094|NCT03123471|OTHER|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
58138095|NCT02778165|OTHER|MyCaRe (my cardiac recovery Android application)|Android application \& Fitbit Inspire 2 activity monitor
58138096|NCT03101995|DRUG|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
58138097|NCT04769648|DRUG|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
58138098|NCT04769648|DRUG|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
58138099|NCT01333332|DRUG|Capecitabine|Capecitabine
58138100|NCT01333332|RADIATION|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
58138101|NCT01807793|BEHAVIORAL|Psychoeducation|
58138102|NCT00857623|DRUG|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
58138103|NCT00857623|DRUG|Placebo|Capsule, once daily
58138104|NCT04857697|PROCEDURE|Biopsy|Undergo biopsy
58138105|NCT04857697|PROCEDURE|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
58138106|NCT04857697|DRUG|Probiotic|Given PO
58138107|NCT04857697|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
58138108|NCT01979341|PROCEDURE|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
58138109|NCT02865356|DRUG|Cyclosporine 5% solution|topical solution
58138110|NCT02865356|DRUG|Placebo|topical vehicle solution
58138111|NCT03410862|DRUG|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
58138112|NCT03410862|DRUG|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
58138113|NCT01423526|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
58138114|NCT01423526|DRUG|Placebo|Placebo tablets, oral administration, single administrations
58138115|NCT04697017|OTHER|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
58138116|NCT00416520|DRUG|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
58138117|NCT00416520|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
58138118|NCT00416520|DRUG|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
58138119|NCT01415557|OTHER|Non-Fortified Control Product|Non-Fortified Control Beverage
58138120|NCT01415557|OTHER|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
58138121|NCT05310097|BEHAVIORAL|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
58138122|NCT05310097|BEHAVIORAL|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
58138897|NCT05647031|OTHER|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
58138898|NCT05689762|BEHAVIORAL|Healthy lifestyle counseling and E-health support|Promotion of healthy lifestyle behaviors through counseling and access to E-health platform
58138899|NCT06327243|OTHER|Elastic tape ( kinesio tape)|This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.
58138900|NCT06327243|OTHER|Sham Taping|Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
58138901|NCT03538405|OTHER|Supporting cushions|Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
58138902|NCT03538405|OTHER|Harmonic techniques|Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
58138903|NCT04384978|BEHAVIORAL|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
58138904|NCT04384978|BEHAVIORAL|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
58138905|NCT01327690|BEHAVIORAL|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
58138906|NCT01327690|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
58138907|NCT02461823|DEVICE|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
58138908|NCT02461823|DEVICE|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
58138909|NCT01488786|DEVICE|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
58138910|NCT00818545|DRUG|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
58138911|NCT00818545|DRUG|placebo|
58138912|NCT05859841|OTHER|Music listening|Music listening under instruction by music therapist, min 3 hours daily
58138913|NCT05859841|OTHER|Control|Standard treatment, care and rehabilitation
58138914|NCT00723476|BEHAVIORAL|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
58138915|NCT00723476|BEHAVIORAL|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
58138916|NCT01835093|DRUG|Tipepidine Hibenzate|
58138917|NCT05789238|BEHAVIORAL|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
58138918|NCT05789238|BEHAVIORAL|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
58138919|NCT04624412|OTHER|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down"
58138920|NCT04624412|OTHER|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down"
58138921|NCT03061526|OTHER|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
58138922|NCT04004091|BIOLOGICAL|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
58138923|NCT03195491|BIOLOGICAL|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
58138924|NCT01944800|DRUG|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
58138925|NCT01944800|DRUG|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg
58138926|NCT02404662|OTHER|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
58490563|NCT03282214|BEHAVIORAL|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
58490564|NCT06445270|BEHAVIORAL|GDM Prevention Program|Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
58490565|NCT00922012|DEVICE|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
58490566|NCT03275350|DRUG|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
58490567|NCT03275350|OTHER|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
58490568|NCT03858816|OTHER|Mixture probiotics|The mixture probiotics capsule
58490569|NCT03858816|OTHER|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
58490570|NCT05463848|DRUG|Pembrolizumab|Intravenous infusion
58490571|NCT05463848|DRUG|Olaparib|Pill taken by mouth
58490572|NCT05463848|DRUG|Temozolomide|Pill taken by mouth
58490573|NCT01185665|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulator
58490574|NCT01185665|DEVICE|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
58490575|NCT01347411|PROCEDURE|CPAP|Treatment with CPAP
58490576|NCT04896515|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
58490577|NCT02557880|BEHAVIORAL|Sleep Application Diary|Tool used to document sleep hygiene.
58490578|NCT02557880|BEHAVIORAL|Treatment As Usual|Sleep hygiene counseling
58490579|NCT04119466|BEHAVIORAL|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
58490580|NCT04609462|PROCEDURE|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
58490581|NCT04609462|PROCEDURE|High flow nasal cannula|Breathing support with High-flow nasal cannula
58490582|NCT03188497|DRUG|Lobaplatin|Lobaplatin for Injection
58490583|NCT03188497|DEVICE|linear accelerator|Medical linear accelerator
58490584|NCT00233064|BIOLOGICAL|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
58490585|NCT00233064|BIOLOGICAL|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
58490586|NCT01578876|DEVICE|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
58490587|NCT06359444|OTHER|Combined aerobic + strength training|"Participants will follow a combination of endurance and strength training for 14 weeks.~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
58490588|NCT06359444|OTHER|Combined strength + HIIT training|"6 weeks of endurance training and strength training, 8 weeks of strength training and HIIT.~Participants will follow the same combination of endurance and strength training for the first six weeks, to build up to a baseline level of physical fitness. They will then switch to eight weeks of a combination of strength training and High Intensity Interval Training (HIIT).~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
58490589|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
58490590|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
58490591|NCT00806819|DRUG|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
58490592|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
58490593|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
58490594|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
58490595|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
58490596|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
58490597|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
58490598|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
58490620|NCT05911685|DEVICE|SeaLA™ left atrial appendage occluder|"1. Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~2. Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~3. Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~4. Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
58490621|NCT02722018|DRUG|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
58490622|NCT02722018|DRUG|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
58490623|NCT02796313|BEHAVIORAL|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
58490624|NCT02796313|BEHAVIORAL|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
58490625|NCT02459834|OTHER|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
58490626|NCT02459834|OTHER|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
58490627|NCT02459834|OTHER|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
58490628|NCT02014337|DRUG|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
58490629|NCT02411890|PROCEDURE|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
58490630|NCT02411890|PROCEDURE|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
58490631|NCT02411890|PROCEDURE|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
58490632|NCT02411890|PROCEDURE|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
58490633|NCT05581524|DEVICE|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
58490634|NCT02164708|BEHAVIORAL|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
58490635|NCT02223494|DRUG|Terbogrel|
58490636|NCT04298476|PROCEDURE|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
58490637|NCT00992472|DRUG|Prochlorperazine suppositories, 25mg|
58490638|NCT00992472|DRUG|Compazine® suppositories, 25mg|
58490639|NCT02015962|DRUG|Intravenous potassium chloride|
58490640|NCT02015962|DRUG|Oral potassium chloride|
58490641|NCT02543957|PROCEDURE|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
58490642|NCT06101589|DIETARY_SUPPLEMENT|25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.|5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
58490643|NCT06101589|DIETARY_SUPPLEMENT|Placebo|Olive oil in 1 ml ethyl oleate with no vitamin D3 content
58490644|NCT05525481|DRUG|Tamoxifen|Hormone therapy
58490645|NCT00309491|DRUG|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
58490646|NCT00309491|DRUG|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
58490647|NCT02163941|BEHAVIORAL|Compassion Training|
58490648|NCT00380653|DRUG|sapacitabine|
58490649|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
58490650|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
58490651|NCT01019083|OTHER|Control|Control will be selected from the Arsenic non contaminated Area
58490838|NCT04223219|DRUG|Fentanyl|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
58490839|NCT04223219|DRUG|Fentanyl, Propofol|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
58490840|NCT04223219|DRUG|Dexmedetomidine, Ketamine, Magnesium sulfate|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
58490841|NCT02728492|DRUG|Quisinostat|
58490842|NCT02728492|DRUG|Paclitaxel|
58490843|NCT02728492|DRUG|Carboplatin|
58490844|NCT02728492|DRUG|Gemcitabine|
58490845|NCT02728492|DRUG|Cisplatin|
58490846|NCT05358769|DIETARY_SUPPLEMENT|Incoxil food supplement and pelvic floor muscle exercise|"Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.~Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity."
58490847|NCT05358769|OTHER|Pelvic floor muscle exercise|Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
58490848|NCT05048966|BEHAVIORAL|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
58490849|NCT05048966|BEHAVIORAL|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
58490850|NCT05298449|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
58490851|NCT05298449|DRUG|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
58490852|NCT03462693|OTHER|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
58490853|NCT04499352|DRUG|BI 754091|BI 754091
58490854|NCT04499352|DRUG|BI 836880|BI 836880
58490855|NCT02098668|OTHER|Fertility treatment|Fertility treatment
58490856|NCT02331277|DRUG|BI 655064|subcutaneous injection
58490857|NCT02331277|DRUG|Placebo|Placebo
58490858|NCT03755804|DRUG|bendamustine|Given intravenously (IV)
58490859|NCT03755804|DRUG|Etoposide|Given intravenously (IV)
58490860|NCT03755804|DRUG|Doxorubicin|Given intravenously (IV)
58490861|NCT03755804|DRUG|Bleomycin|Given intravenously (IV)
58490862|NCT03755804|DRUG|Vincristine|Given intravenously (IV)
58490863|NCT03755804|DRUG|Vinblastine|Given intravenously (IV)
58490864|NCT03755804|DRUG|Prednisone|Given orally (PO)
58490865|NCT03755804|DRUG|Filgrastim|Given subcutaneously (SQ) or IV
58490866|NCT03755804|DRUG|Brentuximab Vedotin|Given intravenously (IV)
58490867|NCT03755804|DRUG|Cyclophosphamide|Given intravenously (IV)
58490868|NCT03755804|DRUG|DTIC|Given intravenously (IV)
58490869|NCT03755804|OTHER|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
58491004|NCT04564157|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
58491005|NCT06341920|BEHAVIORAL|Experimental: BoneFit intervention|Exercise, nutrition and psychological support provided in 8 weeks prior to surgery
58491006|NCT06341920|BEHAVIORAL|Placebo Comparator: Control|Control group receive usual care (zero intervention)
58491007|NCT02029248|OTHER|Quality of life questionnaire|
58491008|NCT01774409|GENETIC|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
58491009|NCT06067672|OTHER|Observations to investigate the current practices of communication and decision-making during Nurse-patient consultations|No intervention
58491010|NCT05868434|PROCEDURE|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
58491011|NCT04440865|OTHER|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
58491012|NCT04440865|OTHER|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
58491013|NCT00737815|DIETARY_SUPPLEMENT|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
58491014|NCT00737815|OTHER|Placebo|Inactive placebo pill
58491015|NCT03650283|OTHER|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of \>0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
58491016|NCT00272532|DRUG|Thiocolchicoside|
58491017|NCT06338969|OTHER|Carbohydrate Restriction after a Gastric Bypass|"All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates."
58491018|NCT02476539|DRUG|Hemay022|
58491019|NCT02453672|BIOLOGICAL|SB8|SB8, proposed bevacizumab biosimilar
58491020|NCT02453672|BIOLOGICAL|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
58491021|NCT02453672|BIOLOGICAL|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
58491022|NCT04776655|DRUG|Bevacizumab|"This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
58491023|NCT04776655|DRUG|Cetuximab|"This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
58491024|NCT04776655|DRUG|5-FU|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
58491025|NCT04776655|DRUG|Irinotecan|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
58491026|NCT04776655|DRUG|Calcium levofolinate|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
58491027|NCT01311141|DRUG|doripenem|doripenem once i.v.500mg
58491028|NCT00968513|BEHAVIORAL|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
58491029|NCT00968513|BEHAVIORAL|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
58491030|NCT00968513|BEHAVIORAL|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
58491031|NCT01585506|OTHER|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
58491032|NCT01585506|OTHER|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
58491033|NCT04535778|BEHAVIORAL|COMPASS|An 11 module, therapist-supported online CBT program.
58491034|NCT04535778|BEHAVIORAL|Standard charity resources|Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
58491035|NCT00124436|DRUG|alitretinoin|
58491054|NCT03892304|OTHER|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
58491055|NCT02670148|PROCEDURE|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
58491056|NCT02252939|RADIATION|X-Ray|X-ray as part of standard care
58491057|NCT02569749|OTHER|Berlin and Epworth questionaries|
58491058|NCT02569749|OTHER|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
58491059|NCT02569749|OTHER|Night polygraph / Polysomnography|
58491060|NCT01575626|DRUG|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
58491061|NCT04024189|OTHER|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
58491062|NCT03770988|DRUG|Treatment with Poziotinib|Treatment with Poziotinib
58491063|NCT05942235|OTHER|Education|Education
58491064|NCT03099278|DRUG|Ezetimibe|Ezetimibe 20 mg oral daily
58491065|NCT00233883|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
58491066|NCT00233883|DRUG|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
58491067|NCT00710580|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
58491068|NCT00710580|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
58491069|NCT00710580|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
58491070|NCT05380401|DIETARY_SUPPLEMENT|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
58491071|NCT00768313|DEVICE|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
58491072|NCT00768313|DEVICE|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
58491073|NCT02969655|DRUG|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
58491074|NCT02969655|DRUG|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
58491075|NCT02969655|DRUG|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
58491076|NCT02969655|DRUG|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
58491077|NCT02969655|DRUG|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
58491078|NCT02969655|DRUG|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
58491079|NCT00887211|DEVICE|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
58491080|NCT00887211|DEVICE|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
58491081|NCT04951635|DRUG|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
58491082|NCT04951635|DRUG|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
58491083|NCT02961101|DRUG|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
58491084|NCT02961101|DRUG|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
58491085|NCT02961101|DRUG|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
58491086|NCT03158285|DRUG|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
58491087|NCT03158285|DRUG|Placebo|Participants will receive matching placebo as SC injection.
58491250|NCT01349400|OTHER|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
58491100|NCT06400758|OTHER|questionary|"A questionnaire, based on the main sexual health topics frequently discussed, was given to students by the school management prior to an intervention.~The preventive intervention consisted of comprehensive prevention on the emotional and sexual lives of adolescents. It was carried out by health professionals and was based on questions from the students, who were able to leave their questions anonymously in a box in the school infirmary for several months.~These questions were collected and used to identify several themes for discussion:~emotional life, with notions of affection, love, friendship and the notion of normality, as well as consent and sexual violence physical and sexual aspects, with reminders of the menstrual cycle, contraception, sexually transmitted infections, pregnancy and abortion.~The same questionnaire was given to students after the intervention, to check whether the prevention intervention had improved their general knowledge."
58491101|NCT05388292|OTHER|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
58491102|NCT02586558|OTHER|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
58491103|NCT02586558|OTHER|Reference group|Ready-to-feed infant formula to be fed ad libitum
58491104|NCT04128813|DEVICE|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
58491105|NCT05987995|PROCEDURE|Endometrial injury|A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
58491106|NCT04587765|BEHAVIORAL|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
58491107|NCT03817697|OTHER|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
58491108|NCT01740453|DRUG|ropivacaine 2 mg/ml|single
58491109|NCT04146428|BEHAVIORAL|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
58491110|NCT04146428|BEHAVIORAL|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
58491111|NCT02679118|DEVICE|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
58491112|NCT00312195|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
58491113|NCT00312195|DRUG|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
58491114|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
58491115|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
58491116|NCT04303039|DRUG|ABP-671|ABP-671 Tablet 1.0 mg
58491117|NCT00916929|DEVICE|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
58491118|NCT03970915|DEVICE|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
58491119|NCT03970915|DEVICE|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
58491120|NCT03220321|OTHER|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
58491121|NCT03220321|OTHER|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
58491122|NCT02879188|OTHER|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
58491123|NCT02879188|OTHER|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
58491124|NCT02757716|OTHER|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
58491125|NCT04473469|DEVICE|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
58491126|NCT01196403|OTHER|questionnaire administration|
58491127|NCT01196403|PROCEDURE|quality-of-life assessment|
58491128|NCT01196403|PROCEDURE|robot-assisted laparoscopic surgery|
58491129|NCT01196403|PROCEDURE|therapeutic conventional surgery|
58491130|NCT01196403|PROCEDURE|therapeutic laparoscopic surgery|
58491131|NCT00473733|PROCEDURE|GLP receptors expression|
58491132|NCT00473733|PROCEDURE|ESOPHAGOGASTRODUODENOSCOPY|
58491133|NCT01273753|OTHER|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
58491134|NCT01500681|PROCEDURE|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
58491143|NCT05904418|OTHER|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
58491144|NCT05904418|RADIATION|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
58491145|NCT05755243|DEVICE|glucose sensor|skin biopsy (punch)
58491146|NCT04014868|DEVICE|Nasal high-flow|See arm description.
58491147|NCT04014868|OTHER|Sham nasal high-flow|See arm description.
58491148|NCT01732718|DRUG|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
58491149|NCT01732718|DRUG|Placebo|Matching placebo tablet by mouth daily for 6 weeks
58491150|NCT01890603|OTHER|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
58491151|NCT01890603|OTHER|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
58491152|NCT05066932|OTHER|Additionnal blood samples|Additionnal blood samples
58491153|NCT01512511|PROCEDURE|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
58491154|NCT00433043|DRUG|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
58491155|NCT00433043|PROCEDURE|CRT (cardiac resynchronization therapy)|Both arms
58491156|NCT02427464|BIOLOGICAL|Engensis (VM202)|gene therapy
58491157|NCT02427464|OTHER|placebo|
58491158|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
58491159|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
58491160|NCT02578758|OTHER|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
58491161|NCT03723304|PROCEDURE|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
58491162|NCT03723304|PROCEDURE|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
58491163|NCT02615639|BIOLOGICAL|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
58491164|NCT02615639|DRUG|Entecavir|0.5mg tablet every night by mouth
58491165|NCT02615639|DRUG|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
58491166|NCT02615639|DRUG|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
58491167|NCT02615639|DRUG|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
58491168|NCT02615639|DRUG|Telbivudine|Telbivudine 600mg tablet every day by mouth
58491169|NCT00089401|DRUG|isolated perfusion|
58491170|NCT00089401|DRUG|melphalan|
58491171|NCT00089401|PROCEDURE|conventional surgery|
58491172|NCT03565419|DEVICE|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
58491213|NCT03882268|BEHAVIORAL|MIYCN interventions|"1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
58491214|NCT02139592|DRUG|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
58491215|NCT02852616|BEHAVIORAL|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
58491216|NCT04276376|DRUG|Atezolizumab|Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
58491217|NCT04276376|DRUG|Rucaparib|Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
58491218|NCT00416221|DRUG|Lexapro, an antidepressant medicine|
58491219|NCT00416221|BEHAVIORAL|Physical Activity|
58491220|NCT00416221|BEHAVIORAL|Mood Management Skills|
58491221|NCT00416221|BEHAVIORAL|Personalized support from a Family Nurse Practitioner|
58491222|NCT03360318|DEVICE|elbow cast|elbow cast
58491223|NCT03360318|DEVICE|Removable elbow brace|Removable elbow brace
58491224|NCT00388193|DRUG|RITUXIMAB|375 mg/m2/d day 1
58491225|NCT02269267|DRUG|Imatinib (Stopping their TKI)|Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
58491226|NCT02269267|DRUG|Dasatinib (Stopping their TKI)|Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
58491227|NCT02269267|DRUG|Nilotinib (Stopping their TKI)|Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
58491228|NCT02269267|DRUG|Bosutinib (Stopping their TKI)|Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
58491229|NCT03056508|BEHAVIORAL|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
58491230|NCT03056508|BEHAVIORAL|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
58491231|NCT02940314|DRUG|HIP1503|
58491232|NCT02940314|DRUG|HGP1103|
58491233|NCT00426452|DRUG|Vatalinib|
58491234|NCT01612806|DEVICE|PriMatrix|fetal bovine dermal scaffold
58491235|NCT01612806|DEVICE|PriMatrix Ag|fetal bovine dermal scaffold with Ag
58491236|NCT01612806|PROCEDURE|moist wound therapy|standard of care moist wound therapy
58491237|NCT02453347|DEVICE|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
58491238|NCT06520644|DEVICE|Wii-based interactive training program|include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension
58491239|NCT06520644|OTHER|Traditional physical therapy program|Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
58491263|NCT00499083|OTHER|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
58491264|NCT00499083|OTHER|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
58491265|NCT00499083|PROCEDURE|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
58491266|NCT00499083|PROCEDURE|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
58491267|NCT00499083|PROCEDURE|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
58491268|NCT00499083|PROCEDURE|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
58491269|NCT00499083|RADIATION|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
58491270|NCT04211909|DRUG|SOF/VEL|400/100 mg FDC tablet orally once daily.
58491271|NCT04211909|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
58491272|NCT05446818|DIETARY_SUPPLEMENT|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
58491273|NCT05446818|OTHER|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
58491274|NCT00651729|BIOLOGICAL|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
58491275|NCT03588884|DRUG|Calcifediol Oral Capsule|Capsule, daily
58491276|NCT03588884|DRUG|Calcifediol Oral Product|Capsule, once a month
58491277|NCT03588884|DRUG|Cholecalciferol|Capsule, once a month
58491278|NCT03588884|DRUG|Paricalcitol Oral Capsule|Capsule, daily
58491279|NCT01179685|PROCEDURE|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
58491280|NCT03031080|DEVICE|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
58491281|NCT05852613|DEVICE|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
58491282|NCT05852613|COMBINATION_PRODUCT|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
58491283|NCT03401619|COMBINATION_PRODUCT|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
58491477|NCT06416579|OTHER|Schroth Method Based Virtual Reality Group|During Schroth method-based virtual reality exercises, continuity in stabilization will be ensured by using external focus and muscular activation in positions appropriate to the Schroth method and in corrected posture. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Warm-up and cool-down will consist of aerobic games available in Nitendo wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis and Baseball will be included in the program. Progression will be made by difficulty level and positional in all games. The exercises will be made more difficult by side sitting, side sitting on a stool, sitting position, knight position, standing, sitting on a balance ball, standing on a soft floor, on a bosu ball and moving towards the balance board.
58491478|NCT06416579|OTHER|Control Group|Participants in the control group will be placed on a waiting list for 24 weeks. Participants will not receive any exercise intervention for 24 weeks and will be able to continue their routine physical activities.
58491479|NCT06085885|DEVICE|Cochlear implant|Cochlear implant
58491480|NCT00232726|DRUG|CP-4055 (ELACYT)|
58491481|NCT01897818|DEVICE|communication system P300 Speller|
58491482|NCT01821560|DRUG|Baclofen|
58491483|NCT01821560|DRUG|placebo|
58491484|NCT01628185|PROCEDURE|Repositioning|pain assessment at baseline then following routine care repositioning in bed
58491485|NCT03807921|DRUG|Warfarin|Oral anticoagulation
58491486|NCT03807921|DRUG|Aspirin|Antiplatelet treatment
58491487|NCT03675906|OTHER|hypoalbuminemia|hypoalbuminemia and acute kidney injury
58491488|NCT04083768|DEVICE|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
58491489|NCT03924830|PROCEDURE|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
58491490|NCT03924830|PROCEDURE|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
58491491|NCT03924830|PROCEDURE|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
58491492|NCT01643096|OTHER|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
58491493|NCT01643096|OTHER|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
58491494|NCT05568303|BEHAVIORAL|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
58491495|NCT03783624|BEHAVIORAL|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
58491496|NCT03783624|BEHAVIORAL|Open label placebo|Ritual intake of 2 placebo capsules twice a day
58491497|NCT03227640|PROCEDURE|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
58491498|NCT03227640|DEVICE|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
58491499|NCT05420259|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
58491500|NCT05420259|BEHAVIORAL|Standard Care|Standard Care
58491501|NCT00861562|DRUG|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
58491502|NCT00861562|DRUG|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
58491503|NCT04176848|DRUG|CFI-400945|CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
58491504|NCT04176848|DRUG|Durvalumab|Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
58491505|NCT01646125|DRUG|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
58491506|NCT01646125|DRUG|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
58491507|NCT01646125|DRUG|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
58491508|NCT00853567|DRUG|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
58491509|NCT00853567|OTHER|placebo|Placebo
58491510|NCT04518267|BEHAVIORAL|Structured clinical interview|A structured clinical interview will be performed at enrollment.
58491511|NCT04518267|BEHAVIORAL|Psychological questionnaires|Several psychological questionnaires will be performed at enrollment.
58491512|NCT05491668|DIAGNOSTIC_TEST|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
58491513|NCT00936780|DEVICE|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
58491832|NCT06211959|BEHAVIORAL|Approach Bias Modification with Implementation Intentions|Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
58491833|NCT01281332|DEVICE|Menopod|The mechanism of action of the device will not be revealed in advance.
58491834|NCT01281332|DEVICE|Inactive device|
58491835|NCT05526404|OTHER|Dieta mobile application|Mobile application that functions on mobile phones and allows for tracking of symptoms, dietary intake, and stool characteristics using logs and pictures. Users of the application track symptoms by completing questionnaires regarding stool frequency, consistency, and mental status changes. Users can track dietary intake and stool characteristics by taking time-stamped photos of all dietary intake and bowel movements.
58491836|NCT05860972|DEVICE|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
58491837|NCT00870519|DRUG|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
58491838|NCT00870519|DRUG|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
58491839|NCT06413082|DRUG|Torasemide|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
58491840|NCT06413082|DRUG|Spironolactone|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
58491841|NCT04056832|PROCEDURE|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
58491842|NCT04056832|PROCEDURE|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
58491843|NCT04514952|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
58491844|NCT02752581|DEVICE|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
58491845|NCT02752581|DEVICE|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
58491846|NCT00569517|BEHAVIORAL|CBT|6-CBT based sesions
58491847|NCT00569517|OTHER|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
58491848|NCT03227419|DRUG|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
58491849|NCT03227419|DRUG|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection."
58491850|NCT02174822|DRUG|AVP-786|
58491851|NCT02174822|DRUG|Paroxetine|
58491852|NCT02174822|DRUG|Duloxetine|
58491853|NCT03279640|DEVICE|rTMS on ipsilesional M1|
58491854|NCT03279640|DEVICE|tDCS on contralesional M1|
58491855|NCT05658315|OTHER|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
58491856|NCT04768608|DRUG|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
58491857|NCT01279785|DRUG|123I-MIP-1072|Single IV dose
58491858|NCT03110770|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
58491859|NCT03110770|OTHER|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
58491860|NCT04287296|BEHAVIORAL|Wakey!|Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
58491861|NCT04309097|BEHAVIORAL|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
58491862|NCT04309097|BEHAVIORAL|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
58491863|NCT04936087|OTHER|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
58491864|NCT04464018|OTHER|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
58491865|NCT02642315|DRUG|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
58491866|NCT05063773|DEVICE|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
58491867|NCT00610454|DRUG|Levetiracetam|
58491868|NCT05054387|DRUG|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
58491869|NCT03727724|DRUG|Afatinib|Tablet
58491870|NCT03727724|DRUG|Cetuximab|Injection
58491871|NCT06327880|DRUG|PF-07054894 or placebo|multiple oral doses of PF-07054894 for 14 days
58491872|NCT06520085|OTHER|interactive mHealth application for patients undergoing RSA|Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
58491873|NCT04980144|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
58491874|NCT04980144|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
58491875|NCT05585606|DRUG|Placebo|Volume Matched Placebo
58491876|NCT05585606|DRUG|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg"
58491877|NCT05585606|DRUG|scp776 (3.8 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 3.8 mg/kg"
58491878|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
58491879|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
58491880|NCT00505401|BIOLOGICAL|recombinant HIV-1 Tat protein|
58491881|NCT01278212|RADIATION|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
58491882|NCT04043156|RADIATION|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
58491883|NCT06176911|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
58491884|NCT06176911|DRUG|Danazol|200 mg twice daily.
58491885|NCT00925925|OTHER|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
58491886|NCT01996761|DRUG|porcine brain peptide (Cerebrolysin)|
58491887|NCT01996761|DRUG|Placebo|
58491888|NCT04599413|OTHER|SURVEY|Pain survey on pianists
58491889|NCT02966444|OTHER|MUFA-rich HF Meal|
58491890|NCT02966444|OTHER|PUFA-rich HF Meal|
58491891|NCT02966444|OTHER|SFA-rich HF Meal|
58491906|NCT06159426|OTHER|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
58491907|NCT04179292|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
58491908|NCT04179292|OTHER|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
58491909|NCT00492128|DRUG|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
58491910|NCT00703248|PROCEDURE|Osteopathic Manipulative Treatments|"1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
58491911|NCT04950478|OTHER|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
58491912|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
58491913|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
58491914|NCT00707941|DRUG|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
58491915|NCT00707941|DRUG|Placebo|"Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
58491916|NCT05339997|OTHER|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
58491917|NCT04251026|DRUG|tividenofusp alfa|Intravenous repeating dose
58491918|NCT00538668|DRUG|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
58491919|NCT00479687|DEVICE|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
58491920|NCT00479687|DEVICE|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
58491921|NCT03651024|DEVICE|ED surgery|The surgical implant for ED treatment
58491922|NCT06326333|PROCEDURE|Combined parasternal block and serratus anterior plane block|"The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally."
58491923|NCT05721599|BEHAVIORAL|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
58491924|NCT02653417|DRUG|RAD1901|RAD1901
58491925|NCT02653417|OTHER|Placebo|Placebo
58491926|NCT03652285|DEVICE|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
58492256|NCT01783704|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
58492257|NCT01783704|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
58492258|NCT01783704|BEHAVIORAL|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
58492259|NCT04551534|DRUG|DNL201|Oral dose(s)
58492260|NCT04551534|DRUG|Placebo|Oral dose(s)
58492261|NCT04518579|PROCEDURE|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
58492262|NCT02550405|BEHAVIORAL|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
58492263|NCT03825861|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
58492264|NCT06159218|DEVICE|CEST - coiled oesophageal string test|All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
58492265|NCT02049593|DRUG|PARP inhibitor BMN-673|Given PO
58492266|NCT02049593|DRUG|temozolomide|Given PO
58492267|NCT02049593|DRUG|irinotecan hydrochloride|Given IV
58492268|NCT02049593|OTHER|pharmacological study|Correlative studies
58492269|NCT02049593|OTHER|laboratory biomarker analysis|Correlative studies
58492270|NCT02039024|DRUG|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
58492271|NCT04494997|OTHER|Survey Questionnaire|"This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent."
58492272|NCT02004041|DRUG|VLY-686|
58492273|NCT02004041|DRUG|Placebo|
58492274|NCT00283335|DRUG|gemfibrozil|
58492275|NCT00283335|OTHER|Placebo|Matching placebo tablets taken once per day
58492276|NCT00332722|PROCEDURE|Cervical facet joint nerve blocks|
58492277|NCT05355883|BEHAVIORAL|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
58492278|NCT05355883|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
58492279|NCT05355883|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
